trial_id,number_of_countries,min_end_date,max_end_date,comp_date,has_results,includes_pip,exempt,single_blind,rare_disease,phase,bioequivalence_study,health_volunteers,trial_status,any_terminated,all_terminated,results_expected,all_completed_no_comp_date,sponsor_status,name_of_sponsor,trial_title,trial_url,comp_date_while_ongoing,contains_non_eu,only_non_eu 2004-000007-18,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,GlaxoSmithKline AB,"A Multicentre, Randomised, Double-Blind, Parallel Group, 24 Week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE) 50/250mcg with Salmeterol 50mcg Bot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000007-18,0,0,0 2004-000012-13,3,2005-08-31,2005-08-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,WYETH LEDERLE,"A Double-Blind, Placebo-Controlled, Parallel, Randomized Study To Evaluate The Efficacy And Safety Of 3 Oral Dose Levels Of TMI-005 In Subjects With Active Rheumatoid Arthritis On A Background Of Meth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000012-13,0,0,0 2004-000012-13,3,2005-08-31,2005-08-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A Double-Blind, Placebo-Controlled, Parallel, Randomized Study To Evaluate The Efficacy And Safety Of 3 Oral Dose Levels Of TMI-005 In Subjects With Active Rheumatoid Arthritis On A Background Of Meth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000012-13,0,0,0 2004-000015-25,4,2006-03-30,2006-09-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,"A phase 3 randomized, placebo-controlled, double-blind study of oral CCI-779 administered in combination with letrozole vs. letrozole alone as first line hormonal therapy in postmenopausal women with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000015-25,0,0,0 2004-000016-10,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A 3-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF SRA-333 IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE WITH DON...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000016-10,0,0,0 2004-000020-32,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Bristol Myers Squibb International Corporation,The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Severe Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000020-32,0,0,0 2004-000022-75,4,2005-11-09,2005-11-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000022-75,0,0,0 2004-000022-75,4,2005-11-09,2005-11-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000022-75,0,0,0 2004-000023-15,14,2007-07-13,2007-07-22,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000023-15,0,0,0 2004-000023-15,14,2007-07-13,2007-07-22,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000023-15,0,0,0 2004-000023-15,14,2007-07-13,2007-07-22,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000023-15,0,0,0 2004-000025-29,3,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Novartis Sweden AB,"A randomized, double-blind, placebo-controlled, parallel group, multi-center, multiple dose (7 days) dose-ranging study, to assess the efficacy and safety of 4 doses of QAB149 (50, 100, 200 & 400 µg)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000025-29,0,0,0 2004-000025-29,3,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, parallel group, multi-center, multiple dose (7 days) dose-ranging study, to assess the efficacy and safety of 4 doses of QAB149 (50, 100, 200 & 400 µg)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000025-29,0,0,0 2004-000025-29,3,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Novartis Healthcare A/S,"A randomized, double-blind, placebo-controlled, parallel group, multi-center, multiple dose (7 days) dose-ranging study, to assess the efficacy and safety of 4 doses of QAB149 (50, 100, 200 & 400 µg)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000025-29,0,0,0 2004-000028-34,4,2008-03-10,2008-03-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,A randomised Phase 3 Trial of ALIMTA and Cisplatin versus GEMZAR and Cisplatin in Patients with locally advanced or metastatic Non-Small-Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000028-34,0,0,0 2004-000028-34,4,2008-03-10,2008-03-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A,A randomised Phase 3 Trial of ALIMTA and Cisplatin versus GEMZAR and Cisplatin in Patients with locally advanced or metastatic Non-Small-Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000028-34,0,0,0 2004-000029-31,1,,,0,0,0,0,0,3,3,0,0,1,0,0,0,1,1,InterMune,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000029-31,0,0,0 2004-000033-11,1,2005-06-30,2005-06-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,The Efficacy and Safety of Irbesartan/HCTZ Combination Therapy as First Line Treatment for Patients with Moderate Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000033-11,0,0,0 2004-000035-28,1,2004-12-01,2004-12-01,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Wyeth Consumer Healthcare,TDS-943 MAXIMUM USE TOLERANCE STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000035-28,0,0,0 2004-000039-27,8,2006-05-12,2006-05-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"MedImmune, Inc.","A Pivotal Phase 3 Study of MEDI-524 (Numax??), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000039-27,0,0,0 2004-000039-27,8,2006-05-12,2006-05-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,MEDIMMUNE ONCOLOGY INC,"A Pivotal Phase 3 Study of MEDI-524 (Numax??), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000039-27,0,0,0 2004-000046-21,5,2007-07-17,2007-07-17,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,CENTOCOR,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000046-21,0,0,0 2004-000046-21,5,2007-07-17,2007-07-17,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Centocor BV,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000046-21,0,0,0 2004-000047-18,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Biogen Idec Ltd.,"An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000047-18,0,0,0 2004-000050-23,2,2006-06-15,2006-07-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NV Organon,"Prospective, double-blind, randomized, placebo-controlled dose finding study of the efficacy and safety of 2 target doses of Org 34517 used as adjunctive therapy in subjects with psychotic major depre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000050-23,0,0,0 2004-000053-34,1,2005-11-22,2005-11-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Orion Corporation, Orion Pharma, Orionintie,","Comparison of continuous combined estrogen-progestin regimen in alleviation of estrogen deficiency symptoms of postmenopausal women. A randomized, double-blind, fixed dose, multicentre phase IIIb stu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000053-34,0,0,0 2004-000060-27,1,2007-11-27,2007-11-27,1,1,0,0,0,3,3,0,0,1,0,0,1,0,1,GLAXO SMITHKLINE,"A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 700mg BID plus ritonavir 100mg BID Versus Lopinavir/ritonavir 400mg/100mg BID when Administered in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000060-27,0,0,0 2004-000063-10,1,2006-11-16,2006-11-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Galderma R&D,A comparison of Metvix PDT with simple excision surgery in subjects with superficial Basal cell Carcinoma (sBCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000063-10,0,0,0 2004-000073-64,1,2006-01-06,2006-01-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck & Co., Inc./Suomen MSD Oy","A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Effects of L-000124467 on Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis as Measured by MR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000073-64,0,0,0 2004-000074-31,2,2005-05-09,2005-05-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme BV,"A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of L-000124467 in Rheumatoid Arthritis Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000074-31,0,0,0 2004-000074-31,2,2005-05-09,2005-05-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of L-000124467 in Rheumatoid Arthritis Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000074-31,0,0,0 2004-000081-13,1,2006-01-10,2006-01-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F Hoffmann-La Roche Ltd,"A randomized, controlled, open-label, multi-center, parallel group study to demonstrate efficacy and safety of RO0503821 when administered with pre-filled syringes for the maintenance treatment of ane...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000081-13,0,0,0 2004-000083-27,5,2009-09-30,2009-11-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-Abelló A/S,"A randomised, parallel-group, double-blind, placebo-controlled Phase III trial assessing the efficacy and safety of ALK Grass Tablet Phleum pratense in subjects with seasonal grass pollen induced rhin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000083-27,0,0,0 2004-000083-27,5,2009-09-30,2009-11-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-Abello A/S,"A randomised, parallel-group, double-blind, placebo-controlled Phase III trial assessing the efficacy and safety of ALK Grass Tablet Phleum pratense in subjects with seasonal grass pollen induced rhin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000083-27,0,0,0 2004-000083-27,5,2009-09-30,2009-11-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-ABELLO',"A randomised, parallel-group, double-blind, placebo-controlled Phase III trial assessing the efficacy and safety of ALK Grass Tablet Phleum pratense in subjects with seasonal grass pollen induced rhin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000083-27,0,0,0 2004-000086-35,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novo Nordisk Scandinavia AB,"A one-year, multi-national, open-labelled, parallel-group, 2:1 randomised treat-to-target trial comparing efficacy and safety of insulin detemir with insulin glargine using a basal-bolus regimen with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000086-35,0,0,0 2004-000086-35,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novo Nordisk Farma Oy,"A one-year, multi-national, open-labelled, parallel-group, 2:1 randomised treat-to-target trial comparing efficacy and safety of insulin detemir with insulin glargine using a basal-bolus regimen with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000086-35,0,0,0 2004-000087-27,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novo Nordisk Scandinavia AB,"A one-year, multi-national, open-labelled, parallel-group, 2:1 randomised treat-to-target trial comparing efficacy and safety of insulin detemir with insulin glargine using a basal-bolus regimen with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000087-27,0,0,0 2004-000087-27,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novo Nordisk Farma Oy,"A one-year, multi-national, open-labelled, parallel-group, 2:1 randomised treat-to-target trial comparing efficacy and safety of insulin detemir with insulin glargine using a basal-bolus regimen with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000087-27,0,0,0 2004-000088-92,3,2006-04-27,2006-05-12,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Recombinant Factor VIIa (NovoSeven®/Niastase®) with Brain Contusi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000088-92,0,0,0 2004-000088-92,3,2006-04-27,2006-05-12,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,NOVO NORDISK,"A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Recombinant Factor VIIa (NovoSeven®/Niastase®) with Brain Contusi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000088-92,0,0,0 2004-000089-11,2,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Axonyx Inc,"A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer’s disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000089-11,0,0,0 2004-000091-14,5,2005-12-07,2005-12-07,1,1,0,0,0,2,3,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000091-14,0,0,0 2004-000091-14,5,2005-12-07,2005-12-07,1,1,0,0,0,2,3,0,0,1,0,0,1,0,1,GlaxoSmithKline AB,"A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000091-14,0,0,0 2004-000091-14,5,2005-12-07,2005-12-07,1,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A","A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000091-14,0,0,0 2004-000091-14,5,2005-12-07,2005-12-07,1,1,0,0,0,2,3,0,0,1,0,0,1,0,1,GLAXO SMITHKLINE,"A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000091-14,0,0,0 2004-000091-14,5,2005-12-07,2005-12-07,1,1,0,0,0,2,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Latvia SIA,"A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000091-14,0,0,0 2004-000100-40,5,2007-11-29,2007-11-29,4,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Novo Nordisk A/S,"A Multicentre, randomised, double-blind, placebo controlled, dose escalation trial on safety and efficacy of activated recombinant factor VII (rFVIIa/NovoSeven) in the treatment of post-operative blee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000100-40,0,0,0 2004-000100-40,5,2007-11-29,2007-11-29,4,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Novo Nordisk AS,"A Multicentre, randomised, double-blind, placebo controlled, dose escalation trial on safety and efficacy of activated recombinant factor VII (rFVIIa/NovoSeven) in the treatment of post-operative blee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000100-40,0,0,0 2004-000100-40,5,2007-11-29,2007-11-29,4,1,0,0,0,2,2,0,0,1,1,0,1,0,1,NOVO NORDISK,"A Multicentre, randomised, double-blind, placebo controlled, dose escalation trial on safety and efficacy of activated recombinant factor VII (rFVIIa/NovoSeven) in the treatment of post-operative blee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000100-40,0,0,0 2004-000106-41,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GlaxoSmithKline Research & Development Ltd,A study to investigate the effect of GW406381 on methotrexate pharmacokinetics in patients treated with methotrexate for rheumatoid arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000106-41,0,0,0 2004-000107-18,1,2007-03-02,2007-03-02,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Alliance Pharmaceuticals,A RANDOMISED OPEN COMPARISON OF INTRAVAGINAL APL202 (25 or 50μg) FOLLOWED BY 25μg AFTER 4 AND 8 HOURS VERSUS 3mg OF DINOPROSTONE AS A VAGINAL TABLET FOLLOWED BY 3mg AFTER 6 HOURS IN THE INDUCTION OF ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000107-18,0,0,0 2004-000108-42,1,2007-03-11,2007-03-11,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Alliance Pharmaceuticals,A RANDOMISED OPEN COMPARISON OF INTRAVAGINAL APL202 (25μg) FOLLOWED BY 25μg AFTER 4 AND 8 HOURS VERSUS 3mg of DINOPROSTONE AS A VAGINAL TABLET FOLLOWED BY 3mg AFTER 6 HOURS IN THE INDUCTION OF LABOUR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000108-42,0,0,0 2004-000113-18,3,,,0,1,0,0,0,0,3,0,0,1,1,0,0,1,2,Novartis Hungaria Kft.,"A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2000 mg/d as adjunctive therapy to an atypical antipsychotic in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000113-18,0,0,0 2004-000113-18,3,,,0,1,0,0,0,0,3,0,0,1,1,0,0,1,2,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2000 mg/d as adjunctive therapy to an atypical antipsychotic in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000113-18,0,0,0 2004-000113-18,3,,,0,1,0,0,0,0,3,0,0,1,1,0,0,1,2,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2000 mg/d as adjunctive therapy to an atypical antipsychotic in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000113-18,0,0,0 2004-000114-40,3,2007-06-29,2007-06-29,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2000 mg/d as adjunctive therapy to lithium or valproate in the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000114-40,0,0,0 2004-000119-24,2,2006-03-29,2006-03-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Protocol CA165020: A Randomized, Two -Cohort Phase II Study of Two Doses of BMS-275183 Given On a Weekly Schedule in Patients with Pre-Treated Non- Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000119-24,0,0,0 2004-000120-32,11,2008-11-18,2009-08-28,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Schering-Plough Research Institute,"""Inhibición precoz de la glucoproteina IIb/IIIa en el síndrome coronario agudo sin elevación del segmento ST: ensayo aleatorizado y controlado con placebo para evaluar los efectos clínicos beneficioso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000120-32,0,0,0 2004-000120-32,11,2008-11-18,2009-08-28,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Schering-Plough A/S,"""Inhibición precoz de la glucoproteina IIb/IIIa en el síndrome coronario agudo sin elevación del segmento ST: ensayo aleatorizado y controlado con placebo para evaluar los efectos clínicos beneficioso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000120-32,0,0,0 2004-000120-32,11,2008-11-18,2009-08-28,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHERING-PLOUGH,"""Inhibición precoz de la glucoproteina IIb/IIIa en el síndrome coronario agudo sin elevación del segmento ST: ensayo aleatorizado y controlado con placebo para evaluar los efectos clínicos beneficioso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000120-32,0,0,0 2004-000134-37,8,2009-03-28,2009-07-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,Trial to Reduce Cardiovascular Events with Aranesp Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000134-37,0,0,0 2004-000134-37,8,2009-03-28,2009-07-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,Trial to Reduce Cardiovascular Events with Aranesp Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000134-37,0,0,0 2004-000137-11,10,2007-11-30,2011-03-24,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck KGaA,"Open, randomized, controlled, multicenter phase III study comparing 5-FU/FA plus irinotecan plus cetuximab versus 5-FU/FA plus irinotecan as first-line treatment for epidermal growth factor receptor-e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000137-11,0,0,0 2004-000137-11,10,2007-11-30,2011-03-24,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK S.P.A.,"Open, randomized, controlled, multicenter phase III study comparing 5-FU/FA plus irinotecan plus cetuximab versus 5-FU/FA plus irinotecan as first-line treatment for epidermal growth factor receptor-e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000137-11,0,0,0 2004-000138-35,13,2008-05-30,2008-10-14,11,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Amgen Inc,A Study to Evaluate AMG 162 in the Treatment of Postmenopausal Osteoporosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000138-35,0,0,0 2004-000138-35,13,2008-05-30,2008-10-14,11,1,0,0,0,2,3,0,0,1,0,0,1,0,1,AMGEN,A Study to Evaluate AMG 162 in the Treatment of Postmenopausal Osteoporosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000138-35,0,0,0 2004-000139-27,1,2006-07-31,2006-07-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer AB,"A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study of the Efficacy, Safety, and Tolerability of Fixed Combination Torcetrapib/Atorvastatin Administered Orally, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000139-27,0,0,0 2004-000140-25,1,2006-02-01,2006-02-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Procter & Gamble Pharmaceuticals,"A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of 2 mg/kg Bolus Plus 24-hour 0.05 mg/kg/hr Infusion Pexelizumab in Patients Undergoing Coronary Artery Bypass Graftin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000140-25,0,0,0 2004-000142-20,5,2006-08-08,2006-08-08,3,0,0,0,0,2,3,0,0,1,1,0,1,0,1,PROCTER & GAMBLE,"A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (PC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000142-20,0,0,0 2004-000142-20,5,2006-08-08,2006-08-08,3,0,0,0,0,2,3,0,0,1,1,0,1,0,1,Procter & Gamble Pharmaceuticals,"A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (PC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000142-20,0,0,0 2004-000145-38,3,2006-08-28,2006-11-03,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Centocor B.V.,"A Phase 2, Double-blind, Placebo-controlled, Randomized, Dose-ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects with Relapsing-remittin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000145-38,0,0,0 2004-000148-26,7,2008-12-19,2008-12-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ PHARMA,"A multi-center, multinational, phase 3, open-label extension trial to assess the safety of long term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinsons disease who ar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000148-26,0,0,0 2004-000148-26,7,2008-12-19,2008-12-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Schwarz BioSciences Inc.,"A multi-center, multinational, phase 3, open-label extension trial to assess the safety of long term treatment of rotigotine patch in subjects with advanced stage, idiopathic Parkinsons disease who ar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000148-26,0,0,0 2004-000149-39,1,2010-06-18,2010-06-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme Corporation,"'Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-line Therapy with Fludara plus Alentuzumab (CAMPATH, MabCampth) versus Fludara Alone in patients with B-Cell Chronic Lymphocyt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000149-39,0,0,0 2004-000152-16,7,2010-08-05,2010-08-05,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ BIOSCIENCES GmbH,An international open-label extension trial to determine safety and efficacy of long-term oral SPM 927 in patients with partial seizures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000152-16,0,0,0 2004-000152-16,7,2010-08-05,2010-08-05,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ BIOSCIENCES GmbH; A member of the UCB group,An international open-label extension trial to determine safety and efficacy of long-term oral SPM 927 in patients with partial seizures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000152-16,0,0,0 2004-000156-16,3,2006-12-02,2007-04-29,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer SA,"Phase 3 multi center, double blind, randomized, parallel group evaluation of the fixed combination torcetrapib/atorvastatin, administered orally, once daily (QD), compared with atorvastatin alone, on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000156-16,0,0,0 2004-000156-16,3,2006-12-02,2007-04-29,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer AB,"Phase 3 multi center, double blind, randomized, parallel group evaluation of the fixed combination torcetrapib/atorvastatin, administered orally, once daily (QD), compared with atorvastatin alone, on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000156-16,0,0,0 2004-000156-16,3,2006-12-02,2007-04-29,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Ltd (PGRD),"Phase 3 multi center, double blind, randomized, parallel group evaluation of the fixed combination torcetrapib/atorvastatin, administered orally, once daily (QD), compared with atorvastatin alone, on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000156-16,0,0,0 2004-000160-28,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Department of Health,Ibuprofen and paracetamol in combination and separately for fever in pre-school children presenting to primary care: a randomised controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000160-28,0,0,0 2004-000166-13,6,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,2,International Breast Cancer Study Group (IBCSG),A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000166-13,0,0,0 2004-000166-13,6,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,2,GBG Forschungs GmbH,A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000166-13,0,0,0 2004-000167-95,3,2008-01-23,2008-01-23,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000167-95,0,0,0 2004-000167-95,3,2008-01-23,2008-01-23,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000167-95,0,0,0 2004-000168-28,3,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,2,International Breast Cancer Study Group (IBCSG),A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000168-28,0,0,0 2004-000168-28,3,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,2,GBG Forschungs GmbH,A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000168-28,0,0,0 2004-000172-13,6,2010-01-08,2010-01-26,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Amgen Inc.,AN OPEN LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF LONG-TERM DOSING OF AMG 531 IN THROMBOCYTOPENIC SUBJECTS WITH IMMUNE (IDIOPATHIC) THROMBOCITOPENIC PURPURA Studio in aperto per valutare la...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000172-13,0,0,0 2004-000172-13,6,2010-01-08,2010-01-26,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,AMGEN S.P.A.,AN OPEN LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF LONG-TERM DOSING OF AMG 531 IN THROMBOCYTOPENIC SUBJECTS WITH IMMUNE (IDIOPATHIC) THROMBOCITOPENIC PURPURA Studio in aperto per valutare la...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000172-13,0,0,0 2004-000173-65,2,2006-12-21,2006-12-27,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000173-65,0,0,0 2004-000174-31,2,2006-09-05,2006-11-01,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Placebo Controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splene...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000174-31,0,0,0 2004-000185-12,5,2008-11-11,2008-11-11,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo in patients with Parkinson's disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000185-12,0,0,0 2004-000185-12,5,2008-11-11,2008-11-11,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Orion Corporation, ORION PHARMA, 02200 Espoo, Finland","A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo in patients with Parkinson's disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000185-12,0,0,0 2004-000185-12,5,2008-11-11,2008-11-11,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Orion Corporation, ORION PHARMA","A long term, double-blind, randomized, parallel-group, carbidopa/levodopa controlled, multi-center study to evaluate the effect of Stalevo in patients with Parkinson's disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000185-12,0,0,0 2004-000186-35,1,2007-05-31,2007-05-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, double blind, active controlled, parallel group study to evaluate the effectiveness of valsartan 320 mg in combination with lisinopril 20 mg versus monotherapy with lisinopril 40 mg or v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000186-35,0,0,0 2004-000193-31,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000193-31,0,0,0 2004-000195-13,1,2006-10-02,2006-10-02,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics,"A Phase II, Randomized, Open label, Controlled, Multicenter Study to Evaluate the Safety, Immunogenicity and Induction of Immunological Memory after Two or Three Doses of Novartis Meningococcal ACWY C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000195-13,0,0,0 2004-000199-14,5,2006-03-22,2007-03-22,3,1,0,0,0,2,3,0,0,1,0,0,1,0,1,UCB PHARMA,"A Double-Blind, Randomized, Multicenter, Placebo-Controlled, In-Patient, Maximum 24 Day Study of Levetiracetam Oral Solution 20-50 mg/kg/day as Adjunctive Treatment of Refractory Partial Onset Se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000199-14,0,0,0 2004-000199-14,5,2006-03-22,2007-03-22,3,1,0,0,0,2,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"A Double-Blind, Randomized, Multicenter, Placebo-Controlled, In-Patient, Maximum 24 Day Study of Levetiracetam Oral Solution 20-50 mg/kg/day as Adjunctive Treatment of Refractory Partial Onset Se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000199-14,0,0,0 2004-000199-14,5,2006-03-22,2007-03-22,3,1,0,0,0,2,3,0,0,1,0,0,1,0,1,UCB Pharma Inc.,"A Double-Blind, Randomized, Multicenter, Placebo-Controlled, In-Patient, Maximum 24 Day Study of Levetiracetam Oral Solution 20-50 mg/kg/day as Adjunctive Treatment of Refractory Partial Onset Se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000199-14,0,0,0 2004-000199-14,5,2006-03-22,2007-03-22,3,1,0,0,0,2,3,0,0,1,0,0,1,0,1,UCB S.A. Pharma Sector,"A Double-Blind, Randomized, Multicenter, Placebo-Controlled, In-Patient, Maximum 24 Day Study of Levetiracetam Oral Solution 20-50 mg/kg/day as Adjunctive Treatment of Refractory Partial Onset Se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000199-14,0,0,0 2004-000200-40,5,2008-05-01,2008-06-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB S.A.,"A Multi-Center, Open-Label, Long Term, Follow-Up Study of the Safety and Efficacy of Levetiracetam in Children with Partial Onset Seizures.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000200-40,0,0,0 2004-000200-40,5,2008-05-01,2008-06-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma Inc.,"A Multi-Center, Open-Label, Long Term, Follow-Up Study of the Safety and Efficacy of Levetiracetam in Children with Partial Onset Seizures.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000200-40,0,0,0 2004-000200-40,5,2008-05-01,2008-06-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB PHARMA,"A Multi-Center, Open-Label, Long Term, Follow-Up Study of the Safety and Efficacy of Levetiracetam in Children with Partial Onset Seizures.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000200-40,0,0,0 2004-000200-40,5,2008-05-01,2008-06-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB S.A. Pharma Sector,"A Multi-Center, Open-Label, Long Term, Follow-Up Study of the Safety and Efficacy of Levetiracetam in Children with Partial Onset Seizures.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000200-40,0,0,0 2004-000200-40,5,2008-05-01,2008-06-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"A Multi-Center, Open-Label, Long Term, Follow-Up Study of the Safety and Efficacy of Levetiracetam in Children with Partial Onset Seizures.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000200-40,0,0,0 2004-000202-49,4,2007-01-30,2007-12-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,Efficacy of Aripiprazole in Combination with Valproate or Lithium in the Treatment of Mania in Patients with Bipolar I Disorder Partially Nonresponsive to Valproate or Lithium Monotherapy Revised Pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000202-49,0,0,0 2004-000202-49,4,2007-01-30,2007-12-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,Efficacy of Aripiprazole in Combination with Valproate or Lithium in the Treatment of Mania in Patients with Bipolar I Disorder Partially Nonresponsive to Valproate or Lithium Monotherapy Revised Pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000202-49,0,0,0 2004-000211-26,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,AstraZeneca AB,"A comperative, placebo-controlled, doubleblind, double dummy, cross over, single center phase IIIb study between formoterol alone and the fixed combination of formoterol and budesonide on airway respo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000211-26,0,0,0 2004-000213-19,2,2008-01-21,2008-01-21,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Lundbeck SA,"Sertindole versus Risperidone safety outcome study: a randomised, partially-blinded, parallel-group, active-controlled, post-marketing study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000213-19,0,0,0 2004-000219-24,5,2005-04-28,2007-11-08,3,1,0,0,0,2,4,0,0,1,1,0,1,0,1,Wyeth Pharmaceuticals,A multicenter study to describe the immunogenic epitope(s) of factor VIII in previously treated patients with congenital hemophilia A who develop de novo factor VIII inhibitors while receiving factor ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000219-24,0,0,0 2004-000219-24,5,2005-04-28,2007-11-08,3,1,0,0,0,2,4,0,0,1,1,0,1,0,1,WYETH LEDERLE,A multicenter study to describe the immunogenic epitope(s) of factor VIII in previously treated patients with congenital hemophilia A who develop de novo factor VIII inhibitors while receiving factor ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000219-24,0,0,0 2004-000231-29,2,2005-05-13,2005-05-15,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Roche Products Ltd,Safety and pharmacokinetics of valganciclovir syrup formulation in paediatric solid organ transplant recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000231-29,0,0,0 2004-000232-91,3,2015-02-26,2015-02-26,2,0,0,0,0,0,3,0,0,1,0,0,1,0,2,Fresenius Biotech GmbH,EICH Profilaxis con ATeGe-FRESENIUS en trasplante alogénico de progenitores hematopoyéticos procedente de donantes no emparentados,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000232-91,0,0,0 2004-000232-91,3,2015-02-26,2015-02-26,2,0,0,0,0,0,3,0,0,1,0,0,1,0,2,FRESENIUS BIOTECH GMBH,EICH Profilaxis con ATeGe-FRESENIUS en trasplante alogénico de progenitores hematopoyéticos procedente de donantes no emparentados,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000232-91,0,0,0 2004-000235-28,1,2006-06-09,2006-06-09,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Sepracor Inc.,The effects of a single evening dose of 3mg eszopiclone on next day driving ability and psychomotor/memory function in patients with primary insomnia compared to placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000235-28,0,0,0 2004-000238-36,2,2011-07-11,2012-04-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,The University of Edinburgh & Lothian Health Board,Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000238-36,0,0,0 2004-000240-25,4,2005-06-27,2006-06-08,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An 8 week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000240-25,0,0,0 2004-000240-25,4,2005-06-27,2006-06-08,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis Sverige AB,"An 8 week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000240-25,0,0,0 2004-000240-25,4,2005-06-27,2006-06-08,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis s.r.o.,"An 8 week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000240-25,0,0,0 2004-000240-25,4,2005-06-27,2006-06-08,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis Finland OY,"An 8 week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with hy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000240-25,0,0,0 2004-000242-20,7,2013-06-17,2018-12-31,5,1,0,0,2,2,3,0,0,1,0,0,1,0,0,Medical Research Council,A randomised trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000242-20,0,0,0 2004-000242-20,7,2013-06-17,2018-12-31,5,1,0,0,2,2,3,0,0,1,0,0,1,0,0,"MRC Clinical Trials Unit, Cancer Division",A randomised trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000242-20,0,0,0 2004-000242-20,7,2013-06-17,2018-12-31,5,1,0,0,2,2,3,0,0,1,0,0,1,0,0,,A randomised trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000242-20,0,0,0 2004-000242-20,7,2013-06-17,2018-12-31,5,1,0,0,2,2,3,0,0,1,0,0,1,0,0,University Hospital Ghent,A randomised trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000242-20,0,0,0 2004-000242-20,7,2013-06-17,2018-12-31,5,1,0,0,2,2,3,0,0,1,0,0,1,0,0,Norwegian Radium Hospital,A randomised trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000242-20,0,0,0 2004-000242-20,7,2013-06-17,2018-12-31,5,1,0,0,2,2,3,0,0,1,0,0,1,0,0,SSG,A randomised trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000242-20,0,0,0 2004-000243-23,2,2007-01-25,2007-05-09,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Genmab A/S,"An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with refractory or relapsed Non-Cutaneous CD4+ T-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000243-23,0,0,0 2004-000244-24,5,2005-06-03,2005-06-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Pfizer Ltd.,"A Phase 2b, multi-center, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000244-24,0,0,0 2004-000244-24,5,2005-06-03,2005-06-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Pfizer, S.A.","A Phase 2b, multi-center, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000244-24,0,0,0 2004-000244-24,5,2005-06-03,2005-06-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Pfizer AB,"A Phase 2b, multi-center, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000244-24,0,0,0 2004-000244-24,5,2005-06-03,2005-06-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Pfizer Kft,"A Phase 2b, multi-center, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000244-24,0,0,0 2004-000244-24,5,2005-06-03,2005-06-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,2,PFIZER,"A Phase 2b, multi-center, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000244-24,0,0,0 2004-000245-38,1,2016-11-10,2016-11-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),A randomised trial to compare ASPIRIN versus HYDROXYUREA/ASPIRIN in 'intermediate risk' primary thrombocythaemia and ASPIRIN only with observation in 'Low risk' primary thrombocythaemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000245-38,0,0,0 2004-000248-25,3,2007-04-04,2007-04-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A multinational, multicenter, randomized, double-blind, double-dummy, stratified, active controlled parallel group study comparing the efficacy and safety of intravenous zoledronic acid, 5 mg once yea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000248-25,0,0,0 2004-000254-23,4,2005-10-31,2005-11-24,2,0,0,0,0,3,2,0,0,1,0,0,1,0,1,Alizyme Therapeutics Limited,"A Phase II Multicentre, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study of ATL 962 to Assess Weight Loss, Safety and Tolerability in Obese Patients with Type II Diabetes being tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000254-23,0,0,0 2004-000280-99,2,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,"Ark Therapeutics, Ltd.","A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Dose-Titration Study of Imidapril Hydrochloride (EG006) in the Treatment of Cancer Cachexia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000280-99,0,0,0 2004-000282-35,3,2011-06-27,2011-06-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000282-35,0,0,0 2004-000282-35,3,2011-06-27,2011-06-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A randomised, double-blind phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000282-35,0,0,0 2004-000283-27,1,2005-06-13,2005-06-13,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Pilot Open-Label Study to Investigate the Safety and Anti-inflammatory Effects of VX-765, an Orally Administered Interleukin-1β Converting Enzyme Inhibitor, in Patients with Muckle-Wells Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000283-27,0,0,0 2004-000288-89,1,2005-11-08,2005-11-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA Pharma AG,"A 24 week, double blind, randomized study to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo on parameters indicative of hyperinflation in patients with chronic obstruct...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000288-89,0,0,0 2004-000290-58,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,SCHWARZ BIOSCIENCES GmbH,"Estudio multicéntrico, doble ciego, aleatorizado, controlado con placebo, en grupos paralelos, para investigar la eficacia y la seguridad de SPM927 (200 mg y 400 mg/día)como tratamiento complementario...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000290-58,0,0,0 2004-000299-15,2,2009-10-06,2009-10-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Algeta ASA, Oslo, Norway","A double-blind dose-response phase II, multicentre study of radium-223 (Alpharadrin ™) for the palliation of painful bone metastases in hormone refractory prostate cancer patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000299-15,0,0,0 2004-000299-15,2,2009-10-06,2009-10-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Algeta AS,"A double-blind dose-response phase II, multicentre study of radium-223 (Alpharadrin ™) for the palliation of painful bone metastases in hormone refractory prostate cancer patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000299-15,0,0,0 2004-000304-41,6,2006-12-28,2006-12-28,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,FUJISAWA,"A MULTICENTRE, 1:1 RANDOMISED, DOUBLE BLIND, TWO ARM PARALLEL GROUP STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF MODIFIED RELEASE TACROLIMUS FK506E (MR4) VERSUS TACROLIMUS FK506 IN COMBINA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000304-41,0,0,0 2004-000304-41,6,2006-12-28,2006-12-28,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Astellas Pharma GmbH,"A MULTICENTRE, 1:1 RANDOMISED, DOUBLE BLIND, TWO ARM PARALLEL GROUP STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF MODIFIED RELEASE TACROLIMUS FK506E (MR4) VERSUS TACROLIMUS FK506 IN COMBINA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000304-41,0,0,0 2004-000305-21,7,2006-08-28,2006-09-05,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Solvay Pharmaceuticals,"A randomized, placebo-controlled, double-blind, six-arm, dose escalation, multi-center study to evaluate the efficacy and safety of SLV306: 150, 300, 600 mg once daily, 150-300 mg twice daily and amlo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000305-21,0,0,0 2004-000306-46,3,2006-02-27,2006-02-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma GmbH,"A MULTICENTRE, 1:1 RANDOMISED, DOUBLE BLIND, TWO ARM PARALLEL GROUP STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF MODIFIED RELEASE TACROLIMUS FK506E (MR4) VERSUS TACROLIMUS FK506 IN COMBINA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000306-46,0,0,0 2004-000306-46,3,2006-02-27,2006-02-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Fujisawa GmbH,"A MULTICENTRE, 1:1 RANDOMISED, DOUBLE BLIND, TWO ARM PARALLEL GROUP STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF MODIFIED RELEASE TACROLIMUS FK506E (MR4) VERSUS TACROLIMUS FK506 IN COMBINA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000306-46,0,0,0 2004-000306-46,3,2006-02-27,2006-02-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FUJISAWA,"A MULTICENTRE, 1:1 RANDOMISED, DOUBLE BLIND, TWO ARM PARALLEL GROUP STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF MODIFIED RELEASE TACROLIMUS FK506E (MR4) VERSUS TACROLIMUS FK506 IN COMBINA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000306-46,0,0,0 2004-000311-26,5,2005-11-10,2005-11-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitaz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000311-26,0,0,0 2004-000311-26,5,2005-11-10,2005-11-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitaz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000311-26,0,0,0 2004-000311-26,5,2005-11-10,2005-11-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"UAB ""Merck Sharp & Dohme""","A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitaz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000311-26,0,0,0 2004-000311-26,5,2005-11-10,2005-11-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck, Sharp & Dohme","A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitaz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000311-26,0,0,0 2004-000311-26,5,2005-11-10,2005-11-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitaz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000311-26,0,0,0 2004-000312-93,5,2007-01-31,2007-03-09,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000312-93,0,0,0 2004-000312-93,5,2007-01-31,2007-03-09,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme BV,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000312-93,0,0,0 2004-000312-93,5,2007-01-31,2007-03-09,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000312-93,0,0,0 2004-000312-93,5,2007-01-31,2007-03-09,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 to Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000312-93,0,0,0 2004-000313-19,2,2007-02-16,2007-03-09,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Limited,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of MK-0431 Monotherapy in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000313-19,0,0,0 2004-000313-19,2,2007-02-16,2007-03-09,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of MK-0431 Monotherapy in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000313-19,0,0,0 2004-000315-26,4,2007-07-31,2007-10-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche Ltd.,"First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. Estudio abierto, no comparativo, multicéntrico de bevacizumab más quimioterapia en el tratamiento de primera lín...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000315-26,0,0,0 2004-000315-26,4,2007-07-31,2007-10-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. Estudio abierto, no comparativo, multicéntrico de bevacizumab más quimioterapia en el tratamiento de primera lín...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000315-26,0,0,0 2004-000315-26,4,2007-07-31,2007-10-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. Estudio abierto, no comparativo, multicéntrico de bevacizumab más quimioterapia en el tratamiento de primera lín...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000315-26,0,0,0 2004-000320-32,4,2005-10-12,2010-04-16,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,H. Lundbeck A/S,"A double-blind, randomised, multicenter, fixed-dose study comparing the efficacy of escitalopram (20mg/day) with that of citalopram (40mg/day) in patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000320-32,0,0,0 2004-000326-70,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Janssen-Cilag, Johnson & Johnson spol. s.r.o.","A Randomized, 6-Week Double-Blind, Placebo-Controlled Study With an Optional 24-Week Open-Label Extension to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliperido...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000326-70,0,0,0 2004-000327-15,4,2006-11-29,2006-12-06,2,1,0,0,2,2,3,0,0,1,1,0,1,0,1,"Exelixis, Inc.","A Phase 3 Multicenter, Open-label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) plus Leucovorin (LV) in Subjects with Advanced Biliary Tumors Not Amenable to Conventional Surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000327-15,0,0,0 2004-000327-15,4,2006-11-29,2006-12-06,2,1,0,0,2,2,3,0,0,1,1,0,1,0,1,Helsinn Healthcare SA,"A Phase 3 Multicenter, Open-label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) plus Leucovorin (LV) in Subjects with Advanced Biliary Tumors Not Amenable to Conventional Surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000327-15,0,0,0 2004-000327-15,4,2006-11-29,2006-12-06,2,1,0,0,2,2,3,0,0,1,1,0,1,0,1,HELSINN HEALTHCARE SA,"A Phase 3 Multicenter, Open-label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) plus Leucovorin (LV) in Subjects with Advanced Biliary Tumors Not Amenable to Conventional Surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000327-15,0,0,0 2004-000329-31,1,2008-10-03,2008-10-03,1,1,0,0,0,3,3,0,0,1,0,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Continuous fluorouracil plus mitomycin C versus mitomycin C plus Cisplatin as chemotherapy combination in combined radiochemotherapy for locally advanced anal cancer. A phase II-III study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000329-31,0,0,0 2004-000330-36,2,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,"Telik, Inc.","Phase 3 Randomized Study of TLK286 (Telcyta?) versus Gefitinib (Iressa®) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Ensayo fase III, aleatorizado, de TLK286 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000330-36,0,0,0 2004-000330-36,2,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,"TELIK, INC.","Phase 3 Randomized Study of TLK286 (Telcyta?) versus Gefitinib (Iressa®) as Third-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Ensayo fase III, aleatorizado, de TLK286 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000330-36,0,0,0 2004-000333-10,1,2006-03-01,2006-03-01,1,1,0,0,0,3,4,0,1,1,0,0,1,0,0,"Research & Innovation Services, University of Dundee",The inhibitory effect of local anaesthetics on the G-protein-mediated vascular flare response to bradykinin and substance P,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000333-10,0,0,0 2004-000335-28,5,2006-03-20,2006-03-20,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Serono International SA,"A phase IIIB/IV, open label study to assess the efficacy and safety of a pre-defined, fixed dose of Gonal-f Filled-by-Mass in a Prefilled Pen based on subject baseline characteristics, for ovarian s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000335-28,0,0,0 2004-000335-28,5,2006-03-20,2006-03-20,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,SERONO INTERNATIONAL SA,"A phase IIIB/IV, open label study to assess the efficacy and safety of a pre-defined, fixed dose of Gonal-f Filled-by-Mass in a Prefilled Pen based on subject baseline characteristics, for ovarian s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000335-28,0,0,0 2004-000335-28,5,2006-03-20,2006-03-20,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Serono International S.A.,"A phase IIIB/IV, open label study to assess the efficacy and safety of a pre-defined, fixed dose of Gonal-f Filled-by-Mass in a Prefilled Pen based on subject baseline characteristics, for ovarian s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000335-28,0,0,0 2004-000336-81,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,GLAXO SMITHKLINE,GW433908 Expanded Access Program for HIV infected subjects non responding or intolerant to the previous antiretroviral treatments,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000336-81,0,0,0 2004-000337-12,1,2006-01-31,2006-01-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Serono International SA,"A multicentre, single arm, open-label, phase IV study to evaluate the immunogenicity and safety of subcutaneously administered r-hIFN beta-1a (Rebif) using clone 484-39 in the treatment of subjects wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000337-12,0,0,0 2004-000344-24,4,2009-02-06,2009-02-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A phase II, randomised, double-blind, parallel-group, placebo-controlled, multi-centre study to assess the efficacy and safety of once-daily orally administered ZD4054 15 mg and 10 mg doses in pain-fr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000344-24,0,0,0 2004-000345-38,5,2007-09-13,2007-09-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Basilea Pharmaceutica Ltd,EFFICACY AND SAFETY OF BAL4079 IN THE TREATMENT OF SEVERE REFRACTORY CHRONIC HAND DERMATITIS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000345-38,0,0,0 2004-000345-38,5,2007-09-13,2007-09-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Basilea Pharmaceutica Ltd.,EFFICACY AND SAFETY OF BAL4079 IN THE TREATMENT OF SEVERE REFRACTORY CHRONIC HAND DERMATITIS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000345-38,0,0,0 2004-000346-21,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,SOLVAY PHARMACEUTICALS GMBH,"A Multi-center, Double-Blind,Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000346-21,0,0,0 2004-000346-21,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Solvay Pharmaceuticals GmbH,"A Multi-center, Double-Blind,Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000346-21,0,0,0 2004-000347-14,4,2006-12-14,2008-05-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A 52-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Administered to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000347-14,0,0,0 2004-000347-14,4,2006-12-14,2008-05-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca Sverige,"A 52-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Administered to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000347-14,0,0,0 2004-000348-25,1,2006-03-03,2006-03-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"GALLANT 8 - A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Added to the Thera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000348-25,0,0,0 2004-000349-40,1,2005-10-18,2005-10-18,1,1,0,0,0,3,3,0,0,1,0,0,1,0,1,ELI LILLY,Efficacy of Exenatide Compared with Insulin Glargine in Patients with Type 2 Diabetes Using Metformin or Sulfonylurea for Whom Insulin is the Next Appropriate Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000349-40,0,0,0 2004-000350-24,2,2006-03-14,2006-07-31,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,ASTRAZENECA,"A 16-Week Randomized, Double-blind, Parallel-group, Multicentre, Placebo- and Active- Metformin Controlled Study to Evaluate the Effect on Whole Body Insulin Sensitivity of Tesaglitazar Therapy when...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000350-24,0,0,0 2004-000350-24,2,2006-03-14,2006-07-31,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 16-Week Randomized, Double-blind, Parallel-group, Multicentre, Placebo- and Active- Metformin Controlled Study to Evaluate the Effect on Whole Body Insulin Sensitivity of Tesaglitazar Therapy when...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000350-24,0,0,0 2004-000352-16,6,2005-06-03,2005-06-03,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca R&D,"A Double-blind, Double-dummy, Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000352-16,0,0,0 2004-000352-16,6,2005-06-03,2005-06-03,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Double-blind, Double-dummy, Parallel Group Randomised Dose Confirmation and Feasibility Study of AZD6140 + Acetyl Salicylic Acid (ASA) Compared with Clopidogrel + ASA in Patients with Non-ST Segment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000352-16,0,0,0 2004-000353-38,5,2012-10-31,2012-10-31,1,0,0,0,0,2,3,0,0,2,1,0,0,0,1,Wilex AG,A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with clear cell RCC and high risk of recurrence,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000353-38,1,0,0 2004-000354-22,5,2006-09-19,2006-09-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,,"An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine –Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL II Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000354-22,0,0,0 2004-000354-22,5,2006-09-19,2006-09-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Pfizer Corporation Austria GmbH,"An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine –Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL II Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000354-22,0,0,0 2004-000354-22,5,2006-09-19,2006-09-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Pfizer Healthcare Ireland,"An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine –Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL II Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000354-22,0,0,0 2004-000354-22,5,2006-09-19,2006-09-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Pfizer S.A.,"An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine –Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL II Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000354-22,0,0,0 2004-000354-22,5,2006-09-19,2006-09-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Pfizer,"An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine –Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL II Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000354-22,0,0,0 2004-000356-17,6,2008-07-22,2008-10-22,4,1,0,0,0,2,0,0,0,2,0,0,0,0,1,Ipsen Scandinavia,"PHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQ USING A NOVEL CAPILLARY BLOOD COLLECTION METHOD (OPTIMA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000356-17,1,0,0 2004-000356-17,6,2008-07-22,2008-10-22,4,1,0,0,0,2,0,0,0,2,0,0,0,0,1,Beaufour Ipsen Pharma,"PHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQ USING A NOVEL CAPILLARY BLOOD COLLECTION METHOD (OPTIMA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000356-17,1,0,0 2004-000356-17,6,2008-07-22,2008-10-22,4,1,0,0,0,2,0,0,0,2,0,0,0,0,1,IPSEN,"PHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQ USING A NOVEL CAPILLARY BLOOD COLLECTION METHOD (OPTIMA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000356-17,1,0,0 2004-000358-21,2,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,AstraZeneca AB,"A Phase II Randomised, Double-blind, Placebo-controlled, Multicentre Comparative study of ZD1839 250 mg or 500 mg (Iressatm) given either continuously or concomitantly with cisplatin plus radiotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000358-21,0,0,0 2004-000359-41,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,AstraZeneca AB,"A Controlled, Randomised, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837 in the Prevention of Stroke and other Thromboembolic Complications...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000359-41,0,0,0 2004-000361-35,2,2008-04-10,2008-04-10,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Eisai Limited,"A 12-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON'S DISEASE WITH ""WEARING OFF"" MOTOR FLUCTUATIONS AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000361-35,0,0,0 2004-000361-35,2,2008-04-10,2008-04-10,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,EISAI LTD UK,"A 12-MONTH OPEN LABEL MULTI-CENTERED EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF E2007 IN PATIENTS WITH PARKINSON'S DISEASE WITH ""WEARING OFF"" MOTOR FLUCTUATIONS AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000361-35,0,0,0 2004-000362-12,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Kowa Research Europe Ltd,"A Double-Blind, Randomised, Dose-Ranging Study to Compare K-832 with Placebo in the treatment of Patients with Active Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000362-12,0,0,0 2004-000363-10,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Wyeth Pharmaceuticals,A Randomized Open Label Study to compare the Safety and Efficacy of Two Different Sirolimus Regimens with a Tacrolimus + Mycophenolate Mofetil Regimen in de novo Renal Allograft Recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000363-10,0,0,0 2004-000365-35,2,2008-04-04,2008-04-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Limited,"Prospective, Open-label, Non-comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) with Voriconazole in Patients with Allogeneic Stem Cell Transplants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000365-35,0,0,0 2004-000365-35,2,2008-04-04,2008-04-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer S.A,"Prospective, Open-label, Non-comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) with Voriconazole in Patients with Allogeneic Stem Cell Transplants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000365-35,0,0,0 2004-000367-98,8,2007-01-17,2007-01-31,5,1,0,0,0,2,0,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A double-blind, randomised, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin receptor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000367-98,0,0,0 2004-000368-28,7,2007-02-28,2007-02-28,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Group of Companies,"A Double-blind, Randomised, Multicentre, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (SB-4971...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000368-28,0,0,0 2004-000368-28,7,2007-02-28,2007-02-28,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXO SMITHKLINE,"A Double-blind, Randomised, Multicentre, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (SB-4971...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000368-28,0,0,0 2004-000369-37,4,2005-08-23,2005-12-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Group of Companies,"A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjuncti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000369-37,0,0,0 2004-000370-31,4,2005-08-04,2005-08-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Group of Companies,"A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antago...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000370-31,0,0,0 2004-000371-34,5,2005-12-09,2006-01-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Group of Companies,"A Phase II Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769 Wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000371-34,0,0,0 2004-000371-34,5,2005-12-09,2006-01-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXO SMITHKLINE,"A Phase II Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769 Wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000371-34,0,0,0 2004-000374-31,1,2006-07-21,2006-07-21,1,1,0,0,0,3,2,0,0,1,0,0,1,0,1,GLAXO SMITHKLINE,"A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-Ranging Study to Investigate the Efficacy and Safety of Three Months administration of SB 683699 (150 - 1200mg twice daily) in Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000374-31,0,0,0 2004-000376-14,1,,,0,1,0,0,0,3,3,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED STUDY TO COMPARE THE EFFECT OF 52 WEEKS TREATMENT WITH LAF237 50 MG BID TO METFORMIN UP TO 1000 MG BID IN DRUG NAIVE PATIENTS WITH TYPE 2 DIA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000376-14,0,0,0 2004-000379-32,3,2007-03-23,2007-10-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,AstraZeneca AB,"A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000379-32,0,0,0 2004-000379-32,3,2007-03-23,2007-10-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,ASTRAZENECA,"A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000379-32,0,0,0 2004-000383-27,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,AstraZeneca AB,"A double-blind randomized placebo controlled crossover study of AZD7371 ER 5 mg bid, 20 mg bid and placebo treatment for one week on visceral perception and symptoms in patients with Irritable Bowel S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000383-27,0,0,0 2004-000384-10,2,2017-12-06,2017-12-06,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"An Open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocious ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000384-10,0,0,0 2004-000390-59,2,2005-12-01,2005-12-01,1,1,0,0,0,2,2,0,0,1,1,0,1,0,1,SCHERING-PLOUGH,Safety and Efficacy of SCH-417690 in HIV-infected Treatment-Naive Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000390-59,0,0,0 2004-000390-59,2,2005-12-01,2005-12-01,1,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Schering Plough Research Institute,Safety and Efficacy of SCH-417690 in HIV-infected Treatment-Naive Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000390-59,0,0,0 2004-000394-60,2,,,0,0,0,0,0,1,2,0,0,1,1,0,0,1,1,A. Carlsson Research AB,"A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000394-60,0,0,0 2004-000397-31,1,2006-12-11,2006-12-11,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Wyeth Vaccines Research,A Randomized Controlled Open-Label Phase IV Multi Center Study to Assess the Effect of Antipyretic Prophylactic Treatment on the Rate of Febrile Reactions Following Concomitant Contralateral Administr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000397-31,0,0,0 2004-000398-76,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"MADAUS, S.A.","Ensayo clínico aleatorizado, paralelo de dos vías, doble ciego, para evaluar la influencia del ácido acetilsalicílico de liberación sostenida sobre parámetros plaquetarios y del estado oxidativo en pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000398-76,0,0,0 2004-000404-40,3,2007-01-10,2007-01-10,1,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Bayer plc,"A double blind, randomised, placebo-controlled study to investigate chronic intermittent ''pulse'' therapy of moxifloxacin as a prevention of acute exacerbation in out-patients with chronic bronchitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000404-40,0,0,0 2004-000404-40,3,2007-01-10,2007-01-10,1,1,0,0,0,2,3,0,0,1,0,0,1,0,1,BAYER,"A double blind, randomised, placebo-controlled study to investigate chronic intermittent ''pulse'' therapy of moxifloxacin as a prevention of acute exacerbation in out-patients with chronic bronchitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000404-40,0,0,0 2004-000405-22,1,2010-11-25,2010-11-25,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Medical Research Council,TE23: Randomised Phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP chemotherapy in poor prognosis male germ cell tumours.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000405-22,0,0,0 2004-000406-51,7,2007-05-31,2007-05-31,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"GlaxoSmithKline,s.r.o.","A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000406-51,0,0,0 2004-000406-51,7,2007-05-31,2007-05-31,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,,"A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000406-51,0,0,0 2004-000406-51,7,2007-05-31,2007-05-31,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Sepsicure LLC,"A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000406-51,0,0,0 2004-000406-51,7,2007-05-31,2007-05-31,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,GlaxoSmithKline SIA Latvia,"A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000406-51,0,0,0 2004-000406-51,7,2007-05-31,2007-05-31,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"GlaxoSmithkline, S.A.","A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000406-51,0,0,0 2004-000406-51,7,2007-05-31,2007-05-31,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,GlaxoSmithKline,"A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000406-51,0,0,0 2004-000408-41,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,RIBAPHARM,"RANDOMIZED, DOUBLE–BLIND, MULTICENTER STUDY TO COMPARE THE SAFETY AND EFFICACY OF VIRAMIDINE TO RIBAVIRIN IN TREATMENT–NAïVE PATIENTS WITH CHRONIC HEPATITIS C",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000408-41,0,0,0 2004-000408-41,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Ribapharm, Inc.","RANDOMIZED, DOUBLE–BLIND, MULTICENTER STUDY TO COMPARE THE SAFETY AND EFFICACY OF VIRAMIDINE TO RIBAVIRIN IN TREATMENT–NAïVE PATIENTS WITH CHRONIC HEPATITIS C",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000408-41,0,0,0 2004-000411-25,1,,,0,0,0,0,0,3,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST,"A phase II trial and ""scheduling finding"" of cetuximab in combination with rapidly alternating chemo-radiation in unresectable,locally advanced, squamous cell carcinoma of the head and neck (HNC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000411-25,0,0,0 2004-000414-39,2,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Mundipharma AB,"A randomised, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the long-term efficacy and safety of Norspan® versus placebo Norspan in subjects with chronic, moderate to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000414-39,0,0,0 2004-000414-39,2,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Mundipharma OY,"A randomised, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the long-term efficacy and safety of Norspan® versus placebo Norspan in subjects with chronic, moderate to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000414-39,0,0,0 2004-000415-26,5,2006-10-10,2007-12-31,3,0,0,0,0,2,2,0,0,1,1,0,1,0,1,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,"A DOUBLE-BLIND, DOSE-RANGE, PLACEBO CONTROLLED STUDY OF THE EFFECTS OF PST2238 VS. PLACEBO IN PATIENTS WITH STABLE, UNCOMPLICATED, ESSENTIAL HYPERTENSION.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000415-26,0,0,0 2004-000415-26,5,2006-10-10,2007-12-31,3,0,0,0,0,2,2,0,0,1,1,0,1,0,1,SIGMA-TAU,"A DOUBLE-BLIND, DOSE-RANGE, PLACEBO CONTROLLED STUDY OF THE EFFECTS OF PST2238 VS. PLACEBO IN PATIENTS WITH STABLE, UNCOMPLICATED, ESSENTIAL HYPERTENSION.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000415-26,0,0,0 2004-000415-26,5,2006-10-10,2007-12-31,3,0,0,0,0,2,2,0,0,1,1,0,1,0,1,Sigma-Tau,"A DOUBLE-BLIND, DOSE-RANGE, PLACEBO CONTROLLED STUDY OF THE EFFECTS OF PST2238 VS. PLACEBO IN PATIENTS WITH STABLE, UNCOMPLICATED, ESSENTIAL HYPERTENSION.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000415-26,0,0,0 2004-000417-18,1,2010-12-01,2010-12-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Southampton University Hospitals NHS Trust,"A phase III, randomised, mulicentre dose escalation, efficacy and safety study examining the effects of treatment with peginterferon alfa-2a in patients with Child's A or B cirrhosis in chronic hepati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000417-18,0,0,0 2004-000422-73,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,FARMACEUTICI DAMOR,"OPEN-LABEL, CONTROLLED, RANDOMISED, MULTICENTRE, PARALLEL GROUP CLINICAL TRIAL OF EFFICACY AND TOLERABILITY OF FITOSTIMOLINE ANTIBIOTICO SOAKED GAUZES AND CITRIZAN GEL ANTIBIOTIC IN THE TOPICAL TREATM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000422-73,0,0,0 2004-000424-32,1,2006-02-10,2006-02-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme BV,"A Multicenter, Open, Noncomparative Study to Estimate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in the Treatment of Adults with Invasive Candida Infections (Excluding Patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000424-32,0,0,0 2004-000432-85,4,2007-02-01,2007-05-21,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Basilea Pharmaceutica Ltd,Follow up Efficacy and safety Study of BAL4079 in the Treatment of Chronic Hand Dermatitis Refractory to Topical Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000432-85,0,0,0 2004-000438-35,1,2007-07-06,2007-07-06,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NPS Allelix Corporation,A study of the Efficacy and Safety of Teduglutide in subjects with Parenteral Nutritional Dependant Short Bowel Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000438-35,0,0,0 2004-000439-27,1,2008-01-24,2008-01-24,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NPS Allelix Corporation,A Study of the Safety and Efficacy of Teduglutide in Subjects with Parenteral Nutrition-Dependant Short Bowel Syndrome Who Completed Protocol CL0600-004,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000439-27,0,0,0 2004-000440-24,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Cephalon UK Limited,"A Randomized, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-etodolac) in Combination with Chlorambucil, and that of Chlorambucil alone, in Patients with Chronic Lym...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000440-24,0,0,0 2004-000441-38,3,2007-07-11,2007-07-11,1,0,0,0,0,0,3,0,0,1,1,0,1,0,0,"National Institute of Allergy and Infectious Diseases, National Institutes of Health","A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000441-38,0,0,0 2004-000441-38,3,2007-07-11,2007-07-11,1,0,0,0,0,0,3,0,0,1,1,0,1,0,0,COMMUNITY PROGRAMS FOR CLINICAL RESEARCH ON AIDS,"A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000441-38,0,0,0 2004-000442-21,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Solvay Pharmaceuticals GmbH,"A randomized, placebo-controlled, double-blind, multi-center, parallel group, single dose study to evaluate cardiac hemodynamics and safety during right heart catheterization of three iv doses of SLV3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000442-21,0,0,0 2004-000443-17,2,2009-12-08,2009-12-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Idenix Pharmaceuticals, Inc.","A Randomized, Double-Blind Trial of Telbivudine (LdT) versus Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of Cirrhosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000443-17,0,0,0 2004-000446-20,2,2011-01-30,2011-01-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Imperial College,A multi-centre randomised trial of therapeutic intervention at primary HIV-1 infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000446-20,0,0,0 2004-000448-26,1,2005-12-15,2005-12-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Axcan Pharma Inc. (Axcan Pharma International BV is subsidiary of Axcan Pharma Inc.),"A multicentre, randomized, double-blind, placebo-controlled study of the efficacy and safety of Itopride HCl in patients suffering from functional dyspepsia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000448-26,0,0,0 2004-000450-23,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",A 10-MONTH OPEN-LABEL EVALUATION OF THE LONG-TERM SAFETY OF DVS-233 SR IN OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000450-23,0,0,0 2004-000452-16,4,2009-10-27,2009-10-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,2,OTSUKA MARYLAND RESEARCH INSTITUTE,"International, Multi-Centre, Study of One year, Open Label, Titrated Oral Tolvaptan Tablet Administration in Patients with Chronic Hyponatraemia: Extension to Studies 156-02-235 and 156-03-238 to asse...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000452-16,0,0,0 2004-000452-16,4,2009-10-27,2009-10-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Otsuka Maryland Research Institute,"International, Multi-Centre, Study of One year, Open Label, Titrated Oral Tolvaptan Tablet Administration in Patients with Chronic Hyponatraemia: Extension to Studies 156-02-235 and 156-03-238 to asse...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000452-16,0,0,0 2004-000452-16,4,2009-10-27,2009-10-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Otsuka Pharmaceutical Development & Commercialization, Inc.","International, Multi-Centre, Study of One year, Open Label, Titrated Oral Tolvaptan Tablet Administration in Patients with Chronic Hyponatraemia: Extension to Studies 156-02-235 and 156-03-238 to asse...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000452-16,0,0,0 2004-000457-34,5,2006-07-31,2006-08-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FUJISAWA,"A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION THERAPY OF TACROLIMUS WITH SIROLIMUS VERSUS TACROLIMUS WITH MYCOPHENOLATE MOFETIL IN KIDNEY TRANSPLAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000457-34,0,0,0 2004-000457-34,5,2006-07-31,2006-08-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma GmbH,"A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION THERAPY OF TACROLIMUS WITH SIROLIMUS VERSUS TACROLIMUS WITH MYCOPHENOLATE MOFETIL IN KIDNEY TRANSPLAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000457-34,0,0,0 2004-000457-34,5,2006-07-31,2006-08-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Fujisawa GmbH,"A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION THERAPY OF TACROLIMUS WITH SIROLIMUS VERSUS TACROLIMUS WITH MYCOPHENOLATE MOFETIL IN KIDNEY TRANSPLAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000457-34,0,0,0 2004-000462-13,2,,,0,1,0,0,0,2,2,0,0,1,0,0,0,1,1,TEVA,"A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000462-13,0,0,0 2004-000462-13,2,,,0,1,0,0,0,2,2,0,0,1,0,0,0,1,1,TEVA Pharmaceutical Industries Ltd.,"A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 300mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000462-13,0,0,0 2004-000463-94,2,,,0,1,0,0,0,2,2,0,0,1,0,0,0,1,1,TEVA,"A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 600mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000463-94,0,0,0 2004-000463-94,2,,,0,1,0,0,0,2,2,0,0,1,0,0,0,1,1,TEVA Pharmaceutical Industries Ltd.,"A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of an oral once-daily 600mg dose of glatiramer acetate (GA) in subjects with Relapsing Remitting...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000463-94,0,0,0 2004-000464-28,4,2008-06-10,2008-06-10,3,0,0,0,0,1,3,0,0,1,0,0,1,0,1,Ark Therapeutics Limited,"A Controlled, Randomised, Parallel Group, Multicentre Study of the Efficacy and Safety of Herpes Simplex Virus-Thymidine Kinase Gene Therapy (CereproTM), with Subsequent Ganciclovir, for the Treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000464-28,0,0,0 2004-000469-36,3,2006-01-15,2009-01-15,3,1,0,0,0,0,2,0,2,1,0,0,1,0,1,ORGANON ITALIA,"A multicenter, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the efficacy and safety of four different doses of Org 50081 in the treatment of moderate to severe vasomo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000469-36,0,0,0 2004-000469-36,3,2006-01-15,2009-01-15,3,1,0,0,0,0,2,0,2,1,0,0,1,0,1,NV Organon,"A multicenter, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the efficacy and safety of four different doses of Org 50081 in the treatment of moderate to severe vasomo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000469-36,0,0,0 2004-000472-14,5,2006-01-15,2006-01-15,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NV Organon,"A multicenter, randomized, parallel-group, double- blind, placebo-controlled trial to evaluate the efficacy and safety of four different doses of Org 50081 in the treatment of moderate to severe vasom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000472-14,0,0,0 2004-000472-14,5,2006-01-15,2006-01-15,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Organon Hungary Ltd.,"A multicenter, randomized, parallel-group, double- blind, placebo-controlled trial to evaluate the efficacy and safety of four different doses of Org 50081 in the treatment of moderate to severe vasom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000472-14,0,0,0 2004-000476-13,2,2007-07-11,2007-07-11,1,1,0,0,0,2,3,0,0,1,0,0,1,0,1,SCHWARZ PHARMA,LONG-TERM OPEN-LABEL EXTENSION TRIAL FOR SUBJECTS COMPLETING THE PHASE 3 TRIAL OF FESOTERODINE (SP583) FOR THE TREATMENT OF OVERACTIVE BLADDER SYNDROME,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000476-13,0,0,0 2004-000476-13,2,2007-07-11,2007-07-11,1,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Schwarz Biosciences GmbH,LONG-TERM OPEN-LABEL EXTENSION TRIAL FOR SUBJECTS COMPLETING THE PHASE 3 TRIAL OF FESOTERODINE (SP583) FOR THE TREATMENT OF OVERACTIVE BLADDER SYNDROME,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000476-13,0,0,0 2004-000478-30,8,2006-11-09,2011-02-11,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of bosentan in patients with mildly symptomatic pulmonary arterial hypertension. S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000478-30,0,0,0 2004-000478-30,8,2006-11-09,2011-02-11,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of bosentan in patients with mildly symptomatic pulmonary arterial hypertension. S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000478-30,0,0,0 2004-000480-10,5,2008-08-28,2010-01-14,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,CELL THERAPEUTICS INC. (EUROPE)-SEDE SECONDARIA,"Pixantrone (BBR 2778) versus Other Chemotherapeutic Agents for Third-line Single Agent Treatment of Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma: A Randomized, Controlled, Phase III Compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000480-10,1,0,0 2004-000480-10,5,2008-08-28,2010-01-14,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,CELL THERAPEUTICS EUROPE S.r.l.,"Pixantrone (BBR 2778) versus Other Chemotherapeutic Agents for Third-line Single Agent Treatment of Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma: A Randomized, Controlled, Phase III Compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000480-10,1,0,0 2004-000480-10,5,2008-08-28,2010-01-14,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Cell Therapeutics, Inc. Sede Secondaria","Pixantrone (BBR 2778) versus Other Chemotherapeutic Agents for Third-line Single Agent Treatment of Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma: A Randomized, Controlled, Phase III Compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000480-10,1,0,0 2004-000482-35,2,2006-12-08,2006-12-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd.,"A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthrit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000482-35,0,0,0 2004-000483-27,3,2008-01-28,2008-01-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"BIAL - Portela & Ca, S.A.","Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000483-27,0,0,0 2004-000483-27,3,2008-01-28,2008-01-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bial – Portela & Cª S.A.,"Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000483-27,0,0,0 2004-000485-13,6,2010-03-19,2010-09-19,4,0,0,0,0,1,3,0,0,1,0,0,1,0,1,Procter & Gamble Ltd,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study of One-year Duration Followed by 2 Years of Open-label Treatment to Determine the Safety and Efficacy of Orally Admini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000485-13,0,0,0 2004-000486-35,1,2007-02-28,2007-02-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Procter & Gamble Pharmaceuticals,"A multicentre, double-blind, randomised, active controlled, parallel group, noninferiority study comparing 75mg risedronate dosed on two consecutive days monthly with 5mg daily risedronate in the trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000486-35,0,0,0 2004-000487-27,3,2005-03-15,2005-03-15,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Double-Blind, Parallel-Group, 4-week Trial to Assess the Efficacy and Safety of Etoricoxib 60mg and Diclofenac 150mg in Patients with Chronic Low Back Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000487-27,0,0,0 2004-000487-27,3,2005-03-15,2005-03-15,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Double-Blind, Parallel-Group, 4-week Trial to Assess the Efficacy and Safety of Etoricoxib 60mg and Diclofenac 150mg in Patients with Chronic Low Back Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000487-27,0,0,0 2004-000487-27,3,2005-03-15,2005-03-15,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Double-Blind, Parallel-Group, 4-week Trial to Assess the Efficacy and Safety of Etoricoxib 60mg and Diclofenac 150mg in Patients with Chronic Low Back Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000487-27,0,0,0 2004-000488-83,10,2008-05-15,2008-05-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Integrated Therapeutics Group, Incorporated-a subsidiary of Schering Plough",A Study to Assess Treatment with PEG-Intron® and Rebetol® in Naïve Patients with Genotype 1 Chronic Hepatitis C and Slow Virological Response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000488-83,0,0,0 2004-000488-83,10,2008-05-15,2008-05-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Intergrated Therapeutics Group, Incorporated-a subsidiary of Schering Plough",A Study to Assess Treatment with PEG-Intron® and Rebetol® in Naïve Patients with Genotype 1 Chronic Hepatitis C and Slow Virological Response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000488-83,0,0,0 2004-000488-83,10,2008-05-15,2008-05-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation",A Study to Assess Treatment with PEG-Intron® and Rebetol® in Naïve Patients with Genotype 1 Chronic Hepatitis C and Slow Virological Response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000488-83,0,0,0 2004-000488-83,10,2008-05-15,2008-05-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering Plough Research Institute, a Division of Schering Corporation",A Study to Assess Treatment with PEG-Intron® and Rebetol® in Naïve Patients with Genotype 1 Chronic Hepatitis C and Slow Virological Response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000488-83,0,0,0 2004-000488-83,10,2008-05-15,2008-05-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHERING-PLOUGH,A Study to Assess Treatment with PEG-Intron® and Rebetol® in Naïve Patients with Genotype 1 Chronic Hepatitis C and Slow Virological Response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000488-83,0,0,0 2004-000488-83,10,2008-05-15,2008-05-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Schering Plough Research Institute,A Study to Assess Treatment with PEG-Intron® and Rebetol® in Naïve Patients with Genotype 1 Chronic Hepatitis C and Slow Virological Response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000488-83,0,0,0 2004-000492-33,3,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ALTANA Pharma AG,Healing of patients suffering from gastroesophageal reflux esophagitis grade C-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparison ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000492-33,0,0,0 2004-000493-32,3,2005-02-01,2005-02-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA Pharma AG,Healing of patients suffering from gastroesophageal reflux esophagitis grade A-D according to Los Angeles classification after treatment with pantoprazole-magnesium dihydrate 80 mg o.d. in comparison ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000493-32,0,0,0 2004-000495-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,ASTRAZENECA,"A PHASE II, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF ZD1839 (IRESSA?) IN COMBINATION WITH CASODEX? IN PATIENTS WITH OPERABLE PROSTATE CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000495-14,0,0,0 2004-000499-16,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Novatreat Ltd,"A controlled, randomised, double-blind, parallel-group, phase II study to investigate clostridium difficile-immune whey (CDIW) concentrate in the treatment of recurrent clostridium difficile-associate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000499-16,0,0,0 2004-000501-21,1,2005-08-30,2005-08-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,XTL Biopharmaceuticals,"A Phase II, Multicenter, Randomized, Open-Label, Dose-Ranging, Parallel Group Study to Compare the Anti-Viral Effects, Pharmacokinetics and Safety of HepeX-B, a Mixture of Two Monoclonal Antibodies, a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000501-21,0,0,0 2004-000502-40,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Southampton University Hospitals Trust,"A thematic analysis of semi-structured interviews using a phenomenological approach into palliative care patients experiences of change in ""fatigue"" following treatment with methylphenidate – an explo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000502-40,0,0,0 2004-000506-52,9,2009-06-02,2009-06-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Daiichi Sankyo Europe GmbH,Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000506-52,0,0,0 2004-000506-52,9,2009-06-02,2009-06-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Sankyo Pharma GmbH,Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000506-52,0,0,0 2004-000506-52,9,2009-06-02,2009-06-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,2,DAIICHI SANKYO EUROPE GMBH,Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000506-52,0,0,0 2004-000506-52,9,2009-06-02,2009-06-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Daiichi Sankyo Pharma GmbH,Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000506-52,0,0,0 2004-000507-17,1,,,0,0,0,0,0,3,2,0,0,0,0,0,0,0,0,FONDAZIONE SANTA LUCIA,Effectiveness of rivastigmine treatment in post-stroke patients with right brain damage and unilateral spatial neglect,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000507-17,0,0,0 2004-000509-24,4,2006-06-15,2006-06-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AMGEN,A randomised active controlled study of AMG 162 in breast cancer subjects with bone metastases who have not previously been treated with bisphosphonate therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000509-24,0,0,0 2004-000509-24,4,2006-06-15,2006-06-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,A randomised active controlled study of AMG 162 in breast cancer subjects with bone metastases who have not previously been treated with bisphosphonate therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000509-24,0,0,0 2004-000511-25,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Amgen Inc,"A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects with Advanced Cancer Currently Being Treated with Intravenous Bisphosphonates",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000511-25,0,0,0 2004-000512-17,3,2008-05-14,2008-05-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Double-Blind, Placebo-controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000512-17,0,0,0 2004-000514-38,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novo Nordisk Pharmaceuticals Ltd,"4T study Treating to Target in Type 2 Diabetes A 36-month, Multi-centre, Open-label, Randomised, Parallel-group Trial Comparing the Safety, Efficacy and Durability of Adding a Basal Insulin versus a T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000514-38,0,0,0 2004-000517-19,1,,,0,0,0,0,1,0,4,0,0,3,0,0,0,0,0,Blackpool Fylde & Wyre Healthcare NHS Trust,PRETREATMENT WITH HIGH DOSE CLOPIDOGREL FOR REDUCTION OF THROMBOTIC EVENTS AFTER ELECTIVE CORONARY TERRITORY STENTING WITH DRUG ELUTING STENTS: ThePROTECTED Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000517-19,0,0,0 2004-000518-37,2,2009-01-20,2009-01-20,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline AS,"A phase III, double-blind, randomized, controlled study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals? HPV-16/18 VLP/AS04 vaccine administered intramuscularly according to a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000518-37,0,0,0 2004-000518-37,2,2009-01-20,2009-01-20,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline SA,"A phase III, double-blind, randomized, controlled study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals? HPV-16/18 VLP/AS04 vaccine administered intramuscularly according to a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000518-37,0,0,0 2004-000520-32,1,2006-08-01,2006-08-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Fujisawa GmbH,"A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION OF TACROLIMUS AND MYCOPHENOLATE MOFETIL BASED REGIMEN WITH OR WITHOUT INDUCTION IN ELDERLY RECIPIENTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000520-32,0,0,0 2004-000526-75,1,2008-10-17,2008-10-17,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Aspreva pharmaceuticals Corporation,"Estudio multicéntrico, prospectivo, aleatorizado, con doble enmascaramiento, controlado con placebo, de grupos paralelos y 52 semanas de duración para evaluar la eficacia y la seguridad del micofenola...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000526-75,0,0,0 2004-000530-37,3,2005-04-05,2005-04-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Serono International S.A.,"A multicentre, randomised, double blind, placebo controlled phase III study of subcutaneously administered onercept in the initial treatment and continued treatment after extended therapy in subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000530-37,0,0,0 2004-000532-85,1,2007-12-13,2007-12-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Penine Acute NHS Trust, North Manchester General Hospital",Enfuvirtide induction in heavily drug experienced patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000532-85,0,0,0 2004-000534-36,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Laboratoires Expanscience,Efficacy and Safety of Piascledine 300 versus Chondroitin Sulfate in a 6 Months Treatment plus 2 Months Observation in Patients with Osteoarthritis of the Knee,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000534-36,0,0,0 2004-000535-29,6,2005-06-01,2005-06-01,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Serono International S.A.,"A multicentre, open label and subsequent randomised, double blind, placebo controlled phase III study to assess the safethy and efficacy of maintenance and extended therapy with subcutaneously adminis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000535-29,0,0,0 2004-000535-29,6,2005-06-01,2005-06-01,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SERONO INTERNATIONAL SA,"A multicentre, open label and subsequent randomised, double blind, placebo controlled phase III study to assess the safethy and efficacy of maintenance and extended therapy with subcutaneously adminis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000535-29,0,0,0 2004-000537-11,2,2006-03-28,2006-03-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ZLB BEHRING,"An open label, multi-center study on the efficacy and safety of IgPro10 in patients with chronic immune thrombocytopenic purpura ITP",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000537-11,0,0,0 2004-000537-11,2,2006-03-28,2006-03-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ZLB Behring AG,"An open label, multi-center study on the efficacy and safety of IgPro10 in patients with chronic immune thrombocytopenic purpura ITP",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000537-11,0,0,0 2004-000539-27,3,2007-07-11,2007-07-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg qd to Placebo in Drug-Naïve Patients with Type 2 Diabetes and Mild Hyperglyc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000539-27,0,0,0 2004-000539-27,3,2007-07-11,2007-07-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Finland Oy,"A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg qd to Placebo in Drug-Naïve Patients with Type 2 Diabetes and Mild Hyperglyc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000539-27,0,0,0 2004-000539-27,3,2007-07-11,2007-07-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Sverige AB,"A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg qd to Placebo in Drug-Naïve Patients with Type 2 Diabetes and Mild Hyperglyc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000539-27,0,0,0 2004-000540-24,6,2008-03-03,2008-04-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Multicenter, Double-Blind,Randomized, Active Controlled Study to Compare the Effect of Long Term Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily in Drug Na?ve Patients with Type 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000540-24,0,0,0 2004-000540-24,6,2008-03-03,2008-04-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma CH,"A Multicenter, Double-Blind,Randomized, Active Controlled Study to Compare the Effect of Long Term Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily in Drug Na?ve Patients with Type 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000540-24,0,0,0 2004-000540-24,6,2008-03-03,2008-04-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A Multicenter, Double-Blind,Randomized, Active Controlled Study to Compare the Effect of Long Term Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily in Drug Na?ve Patients with Type 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000540-24,0,0,0 2004-000540-24,6,2008-03-03,2008-04-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A","A Multicenter, Double-Blind,Randomized, Active Controlled Study to Compare the Effect of Long Term Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily in Drug Na?ve Patients with Type 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000540-24,0,0,0 2004-000541-38,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"A Six-month, Multicenter, Randomized, Open-label Study of the Safety, Tolerability and Efficacy of Two Neoral Doses in addition to Certican 61668; and Steroids in de novo Heart Transplant Recipients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000541-38,0,0,0 2004-000542-20,7,2006-01-24,2009-03-02,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Novartis Pharma CH,"A Multicenter, Double-Blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily as Add-On Therapy in Patients with T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000542-20,0,0,0 2004-000542-20,7,2006-01-24,2009-03-02,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,NOVARTIS FARMA,"A Multicenter, Double-Blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily as Add-On Therapy in Patients with T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000542-20,0,0,0 2004-000542-20,7,2006-01-24,2009-03-02,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Novartis Pharmaceuticals UK Limited,"A Multicenter, Double-Blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily as Add-On Therapy in Patients with T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000542-20,0,0,0 2004-000542-20,7,2006-01-24,2009-03-02,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Novartis Farmacéutica S.A.,"A Multicenter, Double-Blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily as Add-On Therapy in Patients with T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000542-20,0,0,0 2004-000542-20,7,2006-01-24,2009-03-02,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Novartis Pharma Services AG,"A Multicenter, Double-Blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg bid to Gliclazide up to 320 mg Daily as Add-On Therapy in Patients with T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000542-20,0,0,0 2004-000551-42,4,2011-01-05,2011-01-05,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ PHARMA,"A MULTI-CENTER, OPEN-LABEL, FOLLOW-ON TRIAL TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF LACOSAMIDE IN SUBJECTS WITH PAINFUL DISTAL DIABETIC NEUROPATHY INCLUDING A DOUBLE-BLIND, RANDOMIZED TIME POIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000551-42,0,0,0 2004-000551-42,4,2011-01-05,2011-01-05,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ BIOSCIENCES GmbH,"A MULTI-CENTER, OPEN-LABEL, FOLLOW-ON TRIAL TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF LACOSAMIDE IN SUBJECTS WITH PAINFUL DISTAL DIABETIC NEUROPATHY INCLUDING A DOUBLE-BLIND, RANDOMIZED TIME POIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000551-42,0,0,0 2004-000555-42,9,2010-09-01,2010-09-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Sanofi-aventis US, Inc","A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000555-42,0,0,0 2004-000555-42,9,2010-09-01,2010-09-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis U.S Inc,"A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000555-42,0,0,0 2004-000555-42,9,2010-09-01,2010-09-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Recherche & De`veloppement,"A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000555-42,0,0,0 2004-000555-42,9,2010-09-01,2010-09-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis U.S. Inc,"A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000555-42,0,0,0 2004-000555-42,9,2010-09-01,2010-09-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Aventis Pharmaceuticals Inc.,"A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000555-42,0,0,0 2004-000555-42,9,2010-09-01,2010-09-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Sanofi-Aventis US, Inc.","A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000555-42,0,0,0 2004-000557-35,1,2007-04-27,2007-04-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Newron Pharmaceuticals SpA,"A phase II, multi centre, pilot, randomised, ascending dose, double -blind, placebo controlled, dose titration study to determine the safety, maximum tolerated dose and preliminary evidence of efficac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000557-35,0,0,0 2004-000558-22,3,2013-01-10,2013-01-10,2,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.","Assessment of the Safety, Efficacy, Tolerability and Pharmacokinetics of PEG-Intron Plus REBETOL for Pediatric Patients with Chronic Hepatitis C",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000558-22,1,1,0 2004-000558-22,3,2013-01-10,2013-01-10,2,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Schering-Plough Research Insitute,"Assessment of the Safety, Efficacy, Tolerability and Pharmacokinetics of PEG-Intron Plus REBETOL for Pediatric Patients with Chronic Hepatitis C",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000558-22,1,1,0 2004-000558-22,3,2013-01-10,2013-01-10,2,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","Assessment of the Safety, Efficacy, Tolerability and Pharmacokinetics of PEG-Intron Plus REBETOL for Pediatric Patients with Chronic Hepatitis C",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000558-22,1,1,0 2004-000562-13,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, FLEXIBLE-DOSE STUDY OF DVS-233 SR AND VENLAFAXINE ER IN ADULT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000562-13,0,0,0 2004-000563-96,9,2008-03-11,2008-06-25,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals,"A 24-MONTH, RANDOMIZED, DOUBLE-BLIND, TWO PERIOD STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE COMBINATION OF ETANERCEPT AND METHOTREXATE AND METHOTREXATE ALONE IN SUBJECTS WITH ACTIVE EARLY RHEUMA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000563-96,0,0,0 2004-000563-96,9,2008-03-11,2008-06-25,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,WYETH LEDERLE,"A 24-MONTH, RANDOMIZED, DOUBLE-BLIND, TWO PERIOD STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE COMBINATION OF ETANERCEPT AND METHOTREXATE AND METHOTREXATE ALONE IN SUBJECTS WITH ACTIVE EARLY RHEUMA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000563-96,0,0,0 2004-000564-28,11,2008-09-30,2009-04-17,2,1,0,0,0,0,0,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,AN EXPANDED ACCESS PROGRAM OF TARCEVA (ERLOTINIB) IN PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000564-28,0,0,0 2004-000564-28,11,2008-09-30,2009-04-17,2,1,0,0,0,0,0,0,0,1,1,0,1,0,1,ROCHE,AN EXPANDED ACCESS PROGRAM OF TARCEVA (ERLOTINIB) IN PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000564-28,0,0,0 2004-000565-34,1,,,0,0,0,0,0,3,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""","A PHASE II, MULTI-CENTRE, OPEN LABEL STUDY OF MELPHALAN, PREDNISONE, THALIDOMIDE AND BORTEZOMIB IN ADVANCED AND REFRACTORY MULTIPLE MYELOMA PATIENTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000565-34,0,0,0 2004-000566-12,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,AstraZeneca AB,"CHANT (Cerebral Hemorrhage And NXY Treatment) A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase IIb study to assess the safety and tolerability of 72 hours intravenous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000566-12,0,0,0 2004-000572-14,4,2009-04-17,2009-04-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Aventis Pharmaceuticals, Inc. (a subsidiary of sanofi-aventis group)","PHASE II MULTICENTER, OPEN LABEL, NON RANDOMIZED STUDY OF INTRAVENOUS RPR109881 Q 3 WEEKS IN PATIENTS WITH METASTATIC BREAST CANCER PROGRESSING AFTER THERAPY WITH ANTHRACYCLINES, TAXANES AND CAPECITAB...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000572-14,0,0,0 2004-000572-14,4,2009-04-17,2009-04-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AVENTIS PHARMA S.P.A.,"PHASE II MULTICENTER, OPEN LABEL, NON RANDOMIZED STUDY OF INTRAVENOUS RPR109881 Q 3 WEEKS IN PATIENTS WITH METASTATIC BREAST CANCER PROGRESSING AFTER THERAPY WITH ANTHRACYCLINES, TAXANES AND CAPECITAB...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000572-14,0,0,0 2004-000572-14,4,2009-04-17,2009-04-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Aventis Pharmaceuticals, Inc.","PHASE II MULTICENTER, OPEN LABEL, NON RANDOMIZED STUDY OF INTRAVENOUS RPR109881 Q 3 WEEKS IN PATIENTS WITH METASTATIC BREAST CANCER PROGRESSING AFTER THERAPY WITH ANTHRACYCLINES, TAXANES AND CAPECITAB...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000572-14,0,0,0 2004-000573-54,3,2007-10-16,2009-04-07,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients with Type 2 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000573-54,0,0,0 2004-000573-54,3,2007-10-16,2009-04-07,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Ltd,An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients with Type 2 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000573-54,0,0,0 2004-000573-54,3,2007-10-16,2009-04-07,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients with Type 2 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000573-54,0,0,0 2004-000576-13,1,2005-10-28,2005-10-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A two-centre, randomised, double-blind, double-dummy, placebo-controlled, 3-period cross-over study to evaluate the effect of treatment with repeat doses of GW274150 on the allergen-induced late asthm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000576-13,0,0,0 2004-000577-65,1,2009-12-03,2009-12-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Phase 3, randomized, open label, comparator-controlled, parallel-group, multicentre study to compare the effects of exenatide and insulin glargine on beta cell function and cardiovascular risk marke...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000577-65,0,0,0 2004-000580-10,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Oy Eli Lilly Finland Ab,Effect of Tadalafil on the Quality of Life and Sexual Life Satisfaction in Erectile Dysfunction (ED) Patients Previously Treated with other Oral ED therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000580-10,0,0,0 2004-000585-13,8,2005-08-31,2005-08-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"MedImmune Vaccines, Inc.","A RANDOMIZED, DOUBLE-BLIND TRIAL TO ASSESS THE SAFETY AND RELATIVE EFFICACY OF CAIV-T AGAINST INACTIVATED INFLUENZA VACCINE IN CHILDREN 659 MONTHS OF AGE.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000585-13,0,0,0 2004-000585-13,8,2005-08-31,2005-08-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MEDIMMUNE ONCOLOGY INC,"A RANDOMIZED, DOUBLE-BLIND TRIAL TO ASSESS THE SAFETY AND RELATIVE EFFICACY OF CAIV-T AGAINST INACTIVATED INFLUENZA VACCINE IN CHILDREN 659 MONTHS OF AGE.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000585-13,0,0,0 2004-000587-26,3,2005-09-17,2005-09-17,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 24-month Extension to a one-year, multicentre, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral and steroids v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000587-26,0,0,0 2004-000587-26,3,2005-09-17,2005-09-17,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 24-month Extension to a one-year, multicentre, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral and steroids v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000587-26,0,0,0 2004-000589-11,1,2006-06-28,2006-06-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ELI LILLY and COMPANY,Protocol F1D-MC-HGKR. Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated with Bipolar I Disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000589-11,0,0,0 2004-000592-33,6,2009-07-29,2009-07-29,5,0,0,0,0,1,3,0,0,1,0,0,1,0,2,Gentium S.p.A,"Prospective Study of the Incidence and Outcome of Venoocclusive Disease (VOD) with the Prophylactic Use of Defibrotide (DF, Gentium, Italy) in Pediatric Stem Cell Transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000592-33,0,0,0 2004-000592-33,6,2009-07-29,2009-07-29,5,0,0,0,0,1,3,0,0,1,0,0,1,0,2,EBMT Central Office,"Prospective Study of the Incidence and Outcome of Venoocclusive Disease (VOD) with the Prophylactic Use of Defibrotide (DF, Gentium, Italy) in Pediatric Stem Cell Transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000592-33,0,0,0 2004-000592-33,6,2009-07-29,2009-07-29,5,0,0,0,0,1,3,0,0,1,0,0,1,0,2,EBMT Trial Office,"Prospective Study of the Incidence and Outcome of Venoocclusive Disease (VOD) with the Prophylactic Use of Defibrotide (DF, Gentium, Italy) in Pediatric Stem Cell Transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000592-33,0,0,0 2004-000592-33,6,2009-07-29,2009-07-29,5,0,0,0,0,1,3,0,0,1,0,0,1,0,2,GENTIUM,"Prospective Study of the Incidence and Outcome of Venoocclusive Disease (VOD) with the Prophylactic Use of Defibrotide (DF, Gentium, Italy) in Pediatric Stem Cell Transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000592-33,0,0,0 2004-000592-33,6,2009-07-29,2009-07-29,5,0,0,0,0,1,3,0,0,1,0,0,1,0,2,EBMT,"Prospective Study of the Incidence and Outcome of Venoocclusive Disease (VOD) with the Prophylactic Use of Defibrotide (DF, Gentium, Italy) in Pediatric Stem Cell Transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000592-33,0,0,0 2004-000592-33,6,2009-07-29,2009-07-29,5,0,0,0,0,1,3,0,0,1,0,0,1,0,2,Gentium S.p.A.,"Prospective Study of the Incidence and Outcome of Venoocclusive Disease (VOD) with the Prophylactic Use of Defibrotide (DF, Gentium, Italy) in Pediatric Stem Cell Transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000592-33,0,0,0 2004-000593-32,5,2005-09-12,2005-09-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,A 6-week open label cross-over study with 2 different daily doses of Minirin oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin tablet (0.2 mg and 2 x 0.2 mg) in children and...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000593-32,0,0,0 2004-000593-32,5,2005-09-12,2005-09-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Arzneimittel GmbH,A 6-week open label cross-over study with 2 different daily doses of Minirin oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin tablet (0.2 mg and 2 x 0.2 mg) in children and...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000593-32,0,0,0 2004-000596-34,4,2006-08-15,2006-09-04,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or improve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000596-34,0,0,0 2004-000596-34,4,2006-08-15,2006-09-04,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ASPREVA PHARMACEUTICALS CORPORATION,"A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or improve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000596-34,0,0,0 2004-000596-34,4,2006-08-15,2006-09-04,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd as part of the Aspreva Rare Disease Program,"A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or improve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000596-34,0,0,0 2004-000596-34,4,2006-08-15,2006-09-04,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche Ltd.,"A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or improve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000596-34,0,0,0 2004-000597-31,2,2009-07-31,2009-07-31,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A one year open label, non comparative extension to a randomised, multicentre, phase II study to evaluate the asfety, tolerability, pharmacokinetics and effects on iron concentration of repeated doses...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000597-31,0,0,0 2004-000597-31,2,2009-07-31,2009-07-31,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"A one year open label, non comparative extension to a randomised, multicentre, phase II study to evaluate the asfety, tolerability, pharmacokinetics and effects on iron concentration of repeated doses...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000597-31,0,0,0 2004-000602-44,1,2009-10-14,2009-10-14,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Pierre Fabre Ibérica, S.A.",Ensayo clínico en fase I-II de vinorelbina oral (Navelbine) en combinación con capecitabina en tratamiento de primera línea en pacientes con cáncer de mama avanzado,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000602-44,0,0,0 2004-000603-18,1,,,0,0,0,0,0,3,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA UMBERTO I,ubiquinone in Down syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000603-18,0,0,0 2004-000607-17,4,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,"Seattle Genetics, Inc.",A Phase II Multi-Dose Study of SGN-30 (anti-CD30 mAb) in Patients with Refractory or Recurrent Hodgkin’s Disease or Anaplastic Large Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000607-17,0,0,0 2004-000607-17,4,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,SEATTLE GENETICS INC.,A Phase II Multi-Dose Study of SGN-30 (anti-CD30 mAb) in Patients with Refractory or Recurrent Hodgkin’s Disease or Anaplastic Large Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000607-17,0,0,0 2004-000608-42,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,University of Sheffield,A randomised study to determine whether zoledronic acid adds to the benefits of chemotherapy and/or hormone therapy in the treatment of women with breast cancer. –AZURE STUDY–,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000608-42,0,0,0 2004-000609-23,1,,,0,0,0,0,0,3,2,0,0,1,0,0,0,1,1,BIOXELL SPA,"A randomized, double blind, placebo controlled, parallel-group study to determine the effect of BXL-628 in post-menopausal women with Overactive Bladder (OAB)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000609-23,0,0,0 2004-000610-39,3,2006-09-15,2006-09-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd.,"A Dose Ranging Trial for the Evaluation of the Safety, Tolerability and Efficacy of Odiparcil in the Prevention of Venous Thromboembolism following Total Knee Replacement Surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000610-39,0,0,0 2004-000611-25,2,2007-01-17,2007-03-04,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Otsuka Maryland Research Institute, Inc.","A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, 52-Week Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC-6535 Oral Tablets and 800 mg BID of Asacol® in th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000611-25,0,0,0 2004-000612-54,1,2004-11-04,2004-11-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Multicenter, Randomized, Parallel-Group, Active-Controlled Double-Blind Study Conducted Under In-House Blinding Conditions to Determine the Incidence of Gastroduodenal Ulcers in Patients With Osteoa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000612-54,0,0,0 2004-000614-39,2,2007-03-12,2007-05-10,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme,"A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast With Placebo in Patients With Acute Asthma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000614-39,0,0,0 2004-000614-39,2,2007-03-12,2007-05-10,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Multicenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast With Placebo in Patients With Acute Asthma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000614-39,0,0,0 2004-000616-70,8,2006-11-03,2007-02-05,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Aventis Pharmaceuticals, Inc.","Efficacy and safety of insulin glulisine compared with insulin lispro in children and adolescents with type 1 diabetes mellitus: a 26-week, multicenter, open, parallel clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000616-70,0,0,0 2004-000616-70,8,2006-11-03,2007-02-05,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Aventis Pharma Finland,"Efficacy and safety of insulin glulisine compared with insulin lispro in children and adolescents with type 1 diabetes mellitus: a 26-week, multicenter, open, parallel clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000616-70,0,0,0 2004-000617-19,9,2008-12-18,2008-12-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG,A Randomized Controlled Study of Docetaxel Monotherapy or DOXIL/CAELYX and Docetaxel for the Treatment of Advanced Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000617-19,0,0,0 2004-000617-19,9,2008-12-18,2008-12-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,A Randomized Controlled Study of Docetaxel Monotherapy or DOXIL/CAELYX and Docetaxel for the Treatment of Advanced Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000617-19,0,0,0 2004-000617-19,9,2008-12-18,2008-12-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Johnson & Johnson, Pharmaceutical Research and Development",A Randomized Controlled Study of Docetaxel Monotherapy or DOXIL/CAELYX and Docetaxel for the Treatment of Advanced Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000617-19,0,0,0 2004-000617-19,9,2008-12-18,2008-12-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag Limited,A Randomized Controlled Study of Docetaxel Monotherapy or DOXIL/CAELYX and Docetaxel for the Treatment of Advanced Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000617-19,0,0,0 2004-000617-19,9,2008-12-18,2008-12-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"J&JPRD, a division of Janssen-Cilag",A Randomized Controlled Study of Docetaxel Monotherapy or DOXIL/CAELYX and Docetaxel for the Treatment of Advanced Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000617-19,0,0,0 2004-000617-19,9,2008-12-18,2008-12-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Johnson & Johnson Pharmaceutical Research and Development,A Randomized Controlled Study of Docetaxel Monotherapy or DOXIL/CAELYX and Docetaxel for the Treatment of Advanced Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000617-19,0,0,0 2004-000618-38,1,2010-05-10,2010-05-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Aventis Pharmaceuticals Inc.,"A randomized, open-label, phase III study of RPR109881 IV every 3 weeks versus capecitabine (Xeloda®) tablets twice daily for 2 weeks in 3-week cycles in patients with metastatic breast cancer progres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000618-38,0,0,0 2004-000622-67,1,2007-01-31,2007-01-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Dose, Safety Study of MYO-029 Administered to Adult Patients with Becker, Facioscapulohumeral and Limb-Girdle Muscular Dystrophy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000622-67,0,0,0 2004-000623-16,2,2005-12-15,2005-12-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,n.v. Boehringer Ingelheim s.a.,A retrospective study to compare the 3-year antiviral efficacy of nevirapine and efavirenz in combination with D4T and 3TC in 2NN patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000623-16,0,0,0 2004-000623-16,2,2005-12-15,2005-12-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd,A retrospective study to compare the 3-year antiviral efficacy of nevirapine and efavirenz in combination with D4T and 3TC in 2NN patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000623-16,0,0,0 2004-000625-30,2,2009-01-22,2010-02-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INO Therapeutics,Comparison of Supplemental Oxygen and Nitric Oxide for Inhalation Plus Oxygen in the Evaluation of the Reactivity of the Pulmonary Vasculature During Acute Pulmonary Vasodilator Testing,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000625-30,0,0,0 2004-000629-32,3,2010-10-22,2014-03-31,3,1,0,0,0,0,3,0,0,1,1,0,1,0,0,University of Oxford,Multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000629-32,0,0,0 2004-000630-37,5,2007-02-15,2007-02-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCHERING AG,"A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the safety, tolerability and efficacy of the CCR1 antagonist ZK 811752, given orally in a dose of 600 mg t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000630-37,0,0,0 2004-000630-37,5,2007-02-15,2007-02-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Schering Nordiska AB,"A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the safety, tolerability and efficacy of the CCR1 antagonist ZK 811752, given orally in a dose of 600 mg t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000630-37,0,0,0 2004-000630-37,5,2007-02-15,2007-02-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Schering AG,"A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the safety, tolerability and efficacy of the CCR1 antagonist ZK 811752, given orally in a dose of 600 mg t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000630-37,0,0,0 2004-000631-28,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,ACTELION PHARMACEUTICALS ITALIA,Bosentan use in interstitial lung disease (open label). Long-term open-label study in patients with interstitial lung disease associated with systemic sclerosis who completed the protocol AC-052-330/B...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000631-28,0,0,0 2004-000632-82,2,2009-01-16,2009-01-26,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ACTELION PHARMACEUTICALS ITALIA,Long term bosentan open label extension of the RAPIDS-2 study in Systemic Sclerosis patients with ischemic digital ulcers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000632-82,0,0,0 2004-000632-82,2,2009-01-16,2009-01-26,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,Long term bosentan open label extension of the RAPIDS-2 study in Systemic Sclerosis patients with ischemic digital ulcers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000632-82,0,0,0 2004-000638-35,2,2008-01-23,2008-01-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals Corporation,"A 2-year randomized, multicenter, double-blind, placebocontrolled study to determine the efficacy and safety of intravenous zoledronic acid 5 mg administered either annually at randomization and 12 mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000638-35,0,0,0 2004-000638-35,2,2008-01-23,2008-01-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Sverige AB,"A 2-year randomized, multicenter, double-blind, placebocontrolled study to determine the efficacy and safety of intravenous zoledronic acid 5 mg administered either annually at randomization and 12 mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000638-35,0,0,0 2004-000642-21,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,BioMarin Pharmaceutical Inc.,"A Multicenter, Multinational, Open-Label Extension Study of Recombinant Human N-acetylgalactosamine 4-sulfatase (rhASB) in Patients with Mucopolysaccharidosis VI",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000642-21,0,0,0 2004-000644-25,2,,,0,0,0,0,0,2,0,0,0,2,1,0,0,0,1,Insmed Incorporated,"A Phase II/III, Open-Label, Multi-Center Clinical Trial to Evaluate the Safety and Efficacy of Insulin-Like Growth Factor I/ Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3), Administe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000644-25,0,0,0 2004-000644-25,2,,,0,0,0,0,0,2,0,0,0,2,1,0,0,0,1,INSMED INCORPORATED,"A Phase II/III, Open-Label, Multi-Center Clinical Trial to Evaluate the Safety and Efficacy of Insulin-Like Growth Factor I/ Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3), Administe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000644-25,0,0,0 2004-000645-37,4,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Amgen Inc,"A Randomised, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Finding Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-myeloid Malignancies...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000645-37,0,0,0 2004-000646-20,4,2005-12-27,2005-12-27,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ALEXION PHARMACEUTICALS INC,"A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal He...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000646-20,0,0,0 2004-000646-20,4,2005-12-27,2005-12-27,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Hemoglobin Stabilization and Transfusion Reduction Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal He...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000646-20,0,0,0 2004-000647-24,1,,,0,0,0,0,1,3,2,0,0,0,0,0,0,0,0,"Dept. Oncology, Aarhus University Hospital",Fase II undersøgelse af kemo-embolisering af lokal avancerede primære hepatocellulære carcinomer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000647-24,0,0,0 2004-000649-39,3,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Merck KGaA,"A randomized, controlled, multicenter, phase I/II study of cetuximab plus irinotecan investigating the pharmacodynamics, genomics and -genetics as well as the safety and efficacy of a dose escalation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000649-39,0,0,0 2004-000649-39,3,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,MERCK S.P.A.,"A randomized, controlled, multicenter, phase I/II study of cetuximab plus irinotecan investigating the pharmacodynamics, genomics and -genetics as well as the safety and efficacy of a dose escalation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000649-39,0,0,0 2004-000651-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ProstaLundOperations AB,Efficacy and Safety of Intraprostatic Injection of Mepivacaine Adrenaline prior to ProstaLund Feedback Treatment in Patients with Symptomatic Benign Prostatic Hyperplasia (BPH).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000651-42,0,0,0 2004-000654-23,3,2009-01-31,2011-03-30,2,1,0,0,0,0,3,0,0,1,1,0,1,0,0,EORTC,"Extended schedule, escalated dose Temozolomide versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000654-23,0,0,0 2004-000655-41,1,2005-03-10,2005-03-10,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients maintaine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000655-41,0,0,0 2004-000658-22,1,2009-12-22,2009-12-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"University of Oxford, NDM","The Second Multi-Centre Intra-Pleural Sepsis Trial (MIST2), to assess whether DNase or Alteplase improves pleural fluid drainage in pleural infection.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000658-22,0,0,0 2004-000663-99,3,2006-03-31,2006-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec Inc.,"Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000663-99,0,0,0 2004-000663-99,3,2006-03-31,2006-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec Ltd,"Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000663-99,0,0,0 2004-000664-27,1,2004-01-03,2004-01-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmaceutica S.A.,"A 34 week, open label, single cohort, exploratory study to evaluate the effect of FTY720 on chronic Hepatitis C in patients who are non-responsive to, or intolerant of Interferon-based antiviral thera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000664-27,0,0,0 2004-000665-35,1,2007-12-19,2007-12-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Medicament,Phase II study of oral vinorelbine in combination with capecitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes Estudio en fase II de vinorelbina oral en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000665-35,0,0,0 2004-000669-36,1,,,0,0,0,0,0,3,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""","A MULTICENTER, OPEN LABEL STUDY OF ORAL MELPHALAN, PREDNISONE AND CC-5013 (REVLIMID) (MPR) AS INDUCTION THERAPY IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000669-36,0,0,0 2004-000671-34,4,2005-06-27,2005-06-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/5 mg or 160/10 mg versus valsartan ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000671-34,0,0,0 2004-000671-34,4,2005-06-27,2005-06-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/5 mg or 160/10 mg versus valsartan ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000671-34,0,0,0 2004-000673-57,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Baxter Healthcare S.A.,"Efficacy and Safety of Epoetin-Omega i.v. for Treatment of Anemia in Hemodialyzed Patients Hyporesponsive to a Previous Epoetin Beta i.v. Treatment: a Randomized, Parallel Group Trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000673-57,0,0,0 2004-000675-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Utrecht,"A Prospective, Randomized, Controlled, Multi-center, (Pilot) Study of Osigraft® in Instrumented Posterolateral Fusions",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000675-34,0,0,0 2004-000676-13,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Baxter Healthcare S.A.,An Evaluation of the Efficacy of Epo-Omega in The Treatment of Anaemia in Chronic Kidney Disease (CKD) Patients When Administered by Once Weekly Subcutaneous Injection: A Dose Dependency Evaluation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000676-13,0,0,0 2004-000677-62,4,2005-06-28,2005-06-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/10 mg versus amlodipine 10 mg alo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000677-62,0,0,0 2004-000677-62,4,2005-06-28,2005-06-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, multicenter, active-controlled, parallel design trial to evaluate the safety and efficacy of the combination of valsartan/amlodipine 160/10 mg versus amlodipine 10 mg alo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000677-62,0,0,0 2004-000678-30,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Baxter Healthcare S.A.,An Evaluation of the Efficacy of Epo-Omega in Treatment of Anaemia in ESRD Patients When Administered by Thrice Weekly Intravenous Injection: A Dose Dependency Evaluation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000678-30,0,0,0 2004-000679-32,1,2006-12-19,2006-12-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca Oy,"A comparison of the efficacy of Symbicort Single inhaler Therapy (Symbicort Turbuhaler 160/4.5 microg, one inhalation twice a day plus as-needed) and conventional best standard treatment for the treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000679-32,0,0,0 2004-000683-27,1,2006-08-30,2006-08-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Research and Innovation Services,A Placebo Controlled Trial to Evaluate The Effects of Levocetirizine on Nasal Allergen Challenge And Adenosine Monophosphate Challenge In Patients with Intermittent and Persistent Allergic Rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000683-27,0,0,0 2004-000684-10,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"Meiji Seika Kaisha, Ltd.","A randomised, double-blind, placebo-controlled crossover study to investigate the efficacy and safety of three doses of ME3301 in patients with seasonal allergic rhinitis during allergen challenge in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000684-10,0,0,0 2004-000686-35,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Novartis Pharma AG,A 52-week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2000 mg/d in the treatment of manic episodes of bipolar I disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000686-35,0,0,0 2004-000687-27,3,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Pharma AG,A 52 week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2500 mg/d in the treatment of manic episodes of bipolar I disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000687-27,0,0,0 2004-000690-63,1,,,0,0,0,0,0,3,4,0,0,1,1,1,0,1,1,CRINOS S.P.A.,"An Italian randomised, multicentre, double blind study to assess the efficacy and tolerability of defibrotide (Prociclide) versus placebo in the treatment of acute phase of haemorrhoids with thrombosi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000690-63,0,0,0 2004-000691-13,1,2007-09-24,2007-09-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,A phase 2 study of ALIMTA plus doxorubicin administered every 21 days in patients with advanced breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000691-13,0,0,0 2004-000693-31,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,Colotech A/S,"An international, multi centre, randomised, parallel group, prospective, double blind, placebo controlled clinical trial evaluating the efficacy and safety of a combination treatment administered over...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000693-31,0,0,0 2004-000696-34,1,2005-10-17,2005-10-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Daiichi Pharmaceutical Co., Ltd",A Phase II study of DJ-927 administered orally once every three weeks as second line therapy to subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of a plati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000696-34,0,0,0 2004-000700-41,3,2006-02-06,2006-02-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GALDERMA R&D,Comparison of Metvix® PDT with Cryotherapy in Subjects with Actinic Keratoses on locations other than the face and scalp,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000700-41,0,0,0 2004-000700-41,3,2006-02-06,2006-02-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Galderma R&D,Comparison of Metvix® PDT with Cryotherapy in Subjects with Actinic Keratoses on locations other than the face and scalp,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000700-41,0,0,0 2004-000701-21,5,2007-04-04,2007-11-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to letrozole Femara as preoperative therapy of primary breast cancer in postmenopaus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000701-21,0,0,0 2004-000701-21,5,2007-04-04,2007-11-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to letrozole Femara as preoperative therapy of primary breast cancer in postmenopaus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000701-21,0,0,0 2004-000701-21,5,2007-04-04,2007-11-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmaceutica, S.A","A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to letrozole Femara as preoperative therapy of primary breast cancer in postmenopaus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000701-21,0,0,0 2004-000701-21,5,2007-04-04,2007-11-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Services AG,"A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to letrozole Femara as preoperative therapy of primary breast cancer in postmenopaus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000701-21,0,0,0 2004-000703-18,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,SOLVAY PHARMACEUTICALS GMBH,"A multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan respectively Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure level...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000703-18,0,0,0 2004-000703-18,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,SOLVAY PHARMA,"A multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan respectively Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure level...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000703-18,0,0,0 2004-000707-18,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,LUNDBECK ITALIA,"A 40-week open, flexible dose, extension study of bifeprunox in patients with schizophrenia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000707-18,0,0,0 2004-000711-26,4,2006-11-02,2008-09-26,2,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Bracco Imaging S.p.A.,ABDOMINAL COMPUTED TOMOGRAPHY IOMERON 400 VS VISIPAQUE 320 ENHANCEMENT ACTIVE.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000711-26,0,0,0 2004-000711-26,4,2006-11-02,2008-09-26,2,1,0,0,0,0,4,0,0,1,1,0,1,0,1,BRACCO IMAGING,ABDOMINAL COMPUTED TOMOGRAPHY IOMERON 400 VS VISIPAQUE 320 ENHANCEMENT ACTIVE.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000711-26,0,0,0 2004-000712-42,4,2005-12-15,2005-12-15,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Bracco Imaging S.p.A.,ENHANCEMENT OF THE LOWER EXTREMITIES COMPUTED TOMOGRAPHY: IOMERON-400 VS VISIPAQUE™-320 (ELECTIV),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000712-42,0,0,0 2004-000712-42,4,2005-12-15,2005-12-15,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,BRACCO IMAGING,ENHANCEMENT OF THE LOWER EXTREMITIES COMPUTED TOMOGRAPHY: IOMERON-400 VS VISIPAQUE™-320 (ELECTIV),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000712-42,0,0,0 2004-000715-26,8,2012-06-29,2012-11-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/ Leuco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000715-26,0,0,0 2004-000715-26,8,2012-06-29,2012-11-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"F. Hoffmann - La Roche Ltd. - Pharmaceuticals Division, PDR","A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/ Leuco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000715-26,0,0,0 2004-000718-37,2,2005-02-17,2005-02-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"Double blind, double dummy, multinational, multicenter, parallel- group design clinical trial of superiority of CHF 1535 1 puff in b.i.d. regimen administered via an HFA-propellant-pMDI versus a doub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000718-37,0,0,0 2004-000722-69,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Cáncer de Ovario (GEICO),"A PHASE II, RANDOMIZED STUDY OF CARBOPLATIN-GEMCITABINE PLUS CARBOPLATIN-PACLITAXEL VERSUS CARBOPLATIN-PACLITAXEL IN PLATINUM-SENSITIVE PATIENTS WITH RECURRENT OVARIAN CARCINOMA, PRIMARY PERITONEAL CA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000722-69,0,0,0 2004-000723-15,6,2006-11-02,2006-11-02,6,0,0,0,0,1,3,0,0,1,0,0,1,0,1,Fresenius Biotech GmbH,"Two-arm, randomized (2:1), open-label phase II/III study in EpCAM positive cancer patients with symptomatic malignant ascites using paracentesis plus the tri-functional antibody removab (anti-EpCAM x ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000723-15,0,0,0 2004-000725-30,1,2008-06-13,2008-06-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A phase II, multi-centre, open-label, uncontrolled study to evaluate the efficacy and safety of BAY 43-9006 given daily in combination with repeated 21-day cycles of dacarbazine (DTIC) chemotherapy in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000725-30,0,0,0 2004-000726-78,1,2005-07-04,2005-07-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Shire Pharmaceuticals Group plc,A 24 Week Randomised Double Blind Placebo Controlled Study to Evaluate the Atrophogenic Potential of Eflornithine in the Treatment of Women with Excessive Facial Hair,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000726-78,0,0,0 2004-000727-15,1,2014-09-04,2014-09-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) vs. Exemestane (AROMASIN™) in Postmenopausal Women with Hormone Receptor Positive Adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000727-15,0,0,0 2004-000730-37,4,2006-06-09,2006-10-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Janssen-Cilag A/S,"A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose-response phase III A study to evaluate safety and efficacy of Prolonged Release (PR) OROS methylphenidate (18, 36 and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000730-37,0,0,0 2004-000730-37,4,2006-06-09,2006-10-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Janssen-Cilag Medical Affairs EMEA,"A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose-response phase III A study to evaluate safety and efficacy of Prolonged Release (PR) OROS methylphenidate (18, 36 and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000730-37,0,0,0 2004-000731-28,1,2009-08-25,2009-08-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,EORTC,A Randomised Phase II/III Study of Taxol-BEP Versus BEP in Patients with Intermediate Prognosis Germ Cell Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000731-28,0,0,0 2004-000733-12,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Shire Pharmaceutical Development Inc,"A phase III, randomized, multi-center, double-blind, parallel-group, placebo controlled study to evaluate the safety and efficacy of SPD476 (mesalazine) given twice daily (2.4g/day) versus SPD476 give...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000733-12,0,0,0 2004-000734-36,1,2006-03-13,2006-03-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shire Pharmaceutical Development Inc.,"A phase III, randomized, multi-center, open-label, 12 to 14 months extension study to evaluate the safety and tolerability of SPD476 (mesalazine) give once daily vs. twice daily for the maintenance of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000734-36,0,0,0 2004-000738-34,1,2007-09-03,2007-09-03,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Aventis Pharmaceuticals, Inc.","Multinational, randomized, double-blind, double-dummy, comparative study to evaluate the efficacy and safety of telithromycin 25 mg/kg given once daily for 5 or 10 days depending on age and previous t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000738-34,0,0,0 2004-000742-21,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,AMERSHAM HEALTH,"OPEN-LABEL, MULTICENTRE, PHASE 2 STUDY EVALUATING THE UTILITY OF 123I-nIBG SCINTIGRAPHYFOR ASSESSING ARRHYTHMIC RISK AS COMPARED TO ELECTROPHYSIOLOGY TESTING IN SUBJECTS WITH LEFT VENTRICULAR DYSFUNCT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000742-21,0,0,0 2004-000745-37,3,2006-09-28,2006-09-28,2,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,Uncontrolled extension trial to protocol AC-052-406 to evaluate the long term effect of bosentan therapy in patient with pulmonary arterial hypertension related to connective tissue disease (TRUST-ext...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000745-37,0,0,0 2004-000745-37,3,2006-09-28,2006-09-28,2,1,0,0,0,1,4,0,0,1,0,0,1,0,1,ACTELION PHARMACEUTICALS ITALIA,Uncontrolled extension trial to protocol AC-052-406 to evaluate the long term effect of bosentan therapy in patient with pulmonary arterial hypertension related to connective tissue disease (TRUST-ext...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000745-37,0,0,0 2004-000746-20,2,2007-12-27,2007-12-31,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Menarini Benelux S.A/N.V.,"Effects Of The Long-Term Administration Of Nebivolol On The Clinical Symptoms, Exercise Capacity And Left Ventricular Function Of The Patients With Diastolic Dysfunction (ELANDD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000746-20,0,0,0 2004-000746-20,2,2007-12-27,2007-12-31,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Menarini Benelux SA/NV,"Effects Of The Long-Term Administration Of Nebivolol On The Clinical Symptoms, Exercise Capacity And Left Ventricular Function Of The Patients With Diastolic Dysfunction (ELANDD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000746-20,0,0,0 2004-000748-26,1,2019-05-21,2019-05-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pierre Fabre Ibérica, S.A. en representación de Pierre Fabre Mèdicament",Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000748-26,0,0,0 2004-000750-22,1,2007-08-28,2007-08-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase IIIb Study of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Immediate-release Tabl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000750-22,0,0,0 2004-000751-42,1,2008-05-11,2008-05-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Chi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000751-42,0,0,0 2004-000752-17,4,2012-06-21,2012-06-21,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ROCHE,"Phase II study of Herceptin, alone or in combination with a taxane, as a first-line treatment for patients with metastatic breast cancer, who have relapsed after receiving Herceptin in the djuvant set...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000752-17,0,0,0 2004-000752-17,4,2012-06-21,2012-06-21,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Hoffmann-La Roche Ltd/Inc/AG/Roche Global Development,"Phase II study of Herceptin, alone or in combination with a taxane, as a first-line treatment for patients with metastatic breast cancer, who have relapsed after receiving Herceptin in the djuvant set...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000752-17,0,0,0 2004-000753-30,1,2007-11-03,2007-11-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Ibérica S.A. as legal representative of Pierr Fabre Mèdicament,Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000753-30,0,0,0 2004-000754-24,1,2006-05-22,2006-05-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D UK Ltd,"An open-label, two-period, crossover, pharmacokinetic study of abacavir and its intracellular anabolite carbovir triphosphate following once-daily and twice-daily administration of abacavir in HIV-inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000754-24,0,0,0 2004-000755-41,1,2005-06-06,2005-06-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceurtici S.p.A,"A three-month, double-blind, double dummy, parallel group, controlled study comparing the efficacy and safety between 12 µg twice daily of Formoterol-HFA and 12 µg twice daily of Formoterol-DPI (Forad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000755-41,0,0,0 2004-000759-40,1,2006-06-28,2006-06-28,1,1,0,0,0,3,2,0,0,1,0,0,1,0,1,TEVA,"A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 15 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000759-40,0,0,0 2004-000762-13,1,2006-01-03,2006-01-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TEVA ITALIA srl,"A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 30 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000762-13,0,0,0 2004-000763-98,2,2005-12-31,2005-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Aventis Pharmaceuticals Inc.,"A phase II, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HP184 at 100, 200 and 400 mg doses administered orally once daily for twenty-four weeks in adult su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000763-98,0,0,0 2004-000766-12,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"BIAL Portela & Companhia, S.A.","Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomised, placebo-controlled, parallel-group, multicentre clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000766-12,0,0,0 2004-000767-10,1,,,0,1,0,0,0,3,2,0,1,1,0,0,0,1,1,CHIRON,"A Phase I/II, Single Center, Partially Observer-Blind, Controlled, Randomized Study to Explore Safety and Immunogenicity in Healthy Adult Subjects who Receive Either One Dose of Chiron Combined MenC-H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000767-10,0,0,0 2004-000771-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"J. Uriach y Compañía, S.A.","A 6-week multicentre, double-blind, randomised, placebo-controlled, parallel-group study to assess the efficacy and safety of rupatadine 10 and 20 mg in the treatment of Chronic Idiopathic Urticaria ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000771-34,0,0,0 2004-000772-14,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,TKT Inc,A Phase I-II Pharmacokinetic/Pharmacodynamic Study of Replagal to Assess the Effects of Alternative Dose and Regimen in Patients with Fabry Disease (TKT027),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000772-14,0,0,0 2004-000773-60,1,2006-10-31,2006-10-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Healthcare & Pharma Consulting AG (Europe),"52 week multicenter, randomized, double-blind placebo-controlled trial evaluating the efficacy and safety of SNMC in patients with chronic hepatitis C",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000773-60,0,0,0 2004-000774-31,3,2005-06-24,2006-09-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Limited,"An open-label, randomized phase II study of the efficacy and safety of indisulam (E7070) in combination with capecitabine versus capecitabine monotherapy for the treatment of metastatic breast cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000774-31,0,0,0 2004-000775-34,7,2007-04-24,2007-05-15,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Europe R&D Centre Ltd,"A double-blind, randomised, parallel group study to evaluate the safety, tolerability and efficacy of TAK-475 alone or co-administered with atorvastatin in patients with primary dyslipidemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000775-34,0,0,0 2004-000782-35,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,NOVARTIS FARMA,EVALUATION OF THE QUALITY OF LIFE AND GASTROINTESTINAL SYMPTOMS AFTER CONVERSION TO MYFORTIC (ERL080) and CELLCEPT WITHDRAWAL IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS TREATED WITH TACROLIMUS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000782-35,0,0,0 2004-000784-97,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Double-blind, Double-Dummy, Multicenter, Non-inferiority Phase III Study to Assess the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily, versus Oral Cephalexin, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000784-97,0,0,0 2004-000784-97,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,GLAXO SMITHKLINE,"A Randomized, Double-blind, Double-Dummy, Multicenter, Non-inferiority Phase III Study to Assess the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily, versus Oral Cephalexin, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000784-97,0,0,0 2004-000786-35,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ABBOTT,"A phase III, open-label, randomized, comparative study of the antiviral efficacy of ARV therapy with Lopinavir/Ritonavir (LPV/r - Kaletra) in combination with Tenofovir versus SOC (Kaletra in combinat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000786-35,0,0,0 2004-000789-11,4,2005-09-15,2005-09-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A 12-week, randomised, double-blind, placebo-controlled, parallel-group multicentre study to evaluate the anti-inflammatory activity of GW842470 4mg twice daily on pulmonary hyperinflation in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000789-11,0,0,0 2004-000789-11,4,2005-09-15,2005-09-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline SA,"A 12-week, randomised, double-blind, placebo-controlled, parallel-group multicentre study to evaluate the anti-inflammatory activity of GW842470 4mg twice daily on pulmonary hyperinflation in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000789-11,0,0,0 2004-000795-14,2,2005-03-14,2005-03-14,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,AstraZeneca,"A Multicentre, Randomised, Double-blind, Placebo-controlled, Study on the Use of Prophylactic Meropenem Therapy in Subjects with Severe Acute Necrotizing Pancreatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000795-14,0,0,0 2004-000798-71,1,2005-12-20,2005-12-20,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Imperial College London,"Efficacy of Levetiracetam in Pendular Nystagmus: A Randomized, Double-blind, Placebo-controlled trial with crossover",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000798-71,0,0,0 2004-000799-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Aker University Hospital,DOES BENFOTIAMINE SUPPLEMENTATION REDUCE SERUM LEVELS OF ADVANCED GLYCATION END PRODUCTS AND BIOCHEMICAL MARKERS OF VASCULAR DYSFUNCTION IN TYPE 1 DIABETES?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000799-15,0,0,0 2004-000803-17,1,2007-07-11,2007-07-11,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,The SAVE trial group,"Prospective, controlled clinical study on the effect of 120 mg depot-methyl-prednisolone compared to placebo on the course of recent onset arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000803-17,0,0,0 2004-000804-41,1,2006-12-20,2006-12-20,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,CECOG,Phase II Trial of Dose-Dense Paclitaxel and Cisplatin as Neo-Adjuvant Chemotherapy for Operable Stage II and IIIA Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000804-41,0,0,0 2004-000805-23,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,GLAXO SMITHKLINE,"A national, multicentric, randomised, controlled trial. Applications of a critical pathway using LEVOFLOXACIN for the management of patients with abnormal PSA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000805-23,0,0,0 2004-000806-39,2,2006-11-09,2006-12-04,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CECOG,Randomized Phase II Study of Dose-Dense Fluorouracil Plus Epirubicin75 Plus Cyclophosphamide (FEC75) and Fluorouracil Plus Epirubicin90 Plus Cyclophosphamide (FEC90) as Adjuvant Therapy for Early Brea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000806-39,0,0,0 2004-000808-40,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Hexal AG,"Randomized, open label, multi-center, phase III study on pharmacokinetics, pharmacodynamics, efficacy and safety of Goserelin 1M Implant HEXAL in patients with advanced prostatic cancer in comparison ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000808-40,0,0,0 2004-000811-24,2,2005-01-06,2005-01-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Schering AG,"Multicenter, double-blind, randomized, pleacebo-controlled study to evaluate the oral low-dose estradiol preparations SH T 04170 E (100 µg estradiol) and SH T 04170 F (190 µg estradiol) in postmenopau...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000811-24,0,0,0 2004-000815-25,2,2006-12-31,2008-04-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,A randomized phase 3 study of two doses of ALIMTA in patients with locally advanced or metastatic Non-Small Cell Lung Cancer who have failed a prior platinum-containing chemotherapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000815-25,0,0,0 2004-000816-24,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ABBOTT,"A Pilot, Open-Label, Randomized, Comparative Study of the Antiviral Efficacy of Lopinavir/Ritonavir Single-Drug Regimen versus Lopinavir/Ritonavir in Combination with Lamivudine/Zidovudine in Antiretr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000816-24,0,0,0 2004-000816-24,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Abbott France,"A Pilot, Open-Label, Randomized, Comparative Study of the Antiviral Efficacy of Lopinavir/Ritonavir Single-Drug Regimen versus Lopinavir/Ritonavir in Combination with Lamivudine/Zidovudine in Antiretr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000816-24,0,0,0 2004-000817-20,6,2005-10-03,2005-10-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Kyowa Hakko U.K. Limited,"A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (Istradefylline) and that of Entacapo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000817-20,0,0,0 2004-000817-20,6,2005-10-03,2005-10-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,KYOWA HAKKO UK LTD,"A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/day KW-6002 (Istradefylline) and that of Entacapo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000817-20,0,0,0 2004-000820-34,1,2008-03-31,2008-03-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Integrated Therapeutics Group, Incorporated-a subsidiary of Schering Plough","Comparison of Three Regimens of PEG-Intron plus Ribavirin in the Treatment of Chronic Hepatitis C, Genotype 2 or 3, in Previously Untreated Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000820-34,0,0,0 2004-000821-31,3,2006-04-19,2006-04-20,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Schering AG,"Multi-center, open, randomized, parallel group comparison of cycle control for seven cycles and endometrial safety in a subgroup for thirteen cycles of contraceptive patch SH P00331F (0.9 mg ethinyles...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000821-31,0,0,0 2004-000822-58,6,2006-08-24,2009-08-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"A double blind randomized study of Clopidogrel 75 mg/d versus placebo on a background of ASA 75-100 mg/d, in peripheral arterial disease (PAD) patients receiving a unilateral below knee by-pass graft",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000822-58,0,0,0 2004-000822-58,6,2006-08-24,2009-08-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-SYNTHELABO,"A double blind randomized study of Clopidogrel 75 mg/d versus placebo on a background of ASA 75-100 mg/d, in peripheral arterial disease (PAD) patients receiving a unilateral below knee by-pass graft",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000822-58,0,0,0 2004-000822-58,6,2006-08-24,2009-08-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-synthelabo groupe,"A double blind randomized study of Clopidogrel 75 mg/d versus placebo on a background of ASA 75-100 mg/d, in peripheral arterial disease (PAD) patients receiving a unilateral below knee by-pass graft",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000822-58,0,0,0 2004-000822-58,6,2006-08-24,2009-08-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Groupe,"A double blind randomized study of Clopidogrel 75 mg/d versus placebo on a background of ASA 75-100 mg/d, in peripheral arterial disease (PAD) patients receiving a unilateral below knee by-pass graft",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000822-58,0,0,0 2004-000825-31,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ALTANA Pharma AG,Comparison of ciclesonide (80 µg or 160 µg once daily in the evening) and fluticasone propionate (100 µg twice daily in the morning and evening) in pediatric asthma patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000825-31,0,0,0 2004-000827-13,5,2008-10-13,2010-07-08,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Pfizer, S.A.",LINEZOLID IN THE TREATMENT OF SUBJECTS WITH NOSOCOMIAL PNEUMONIA PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000827-13,0,0,0 2004-000827-13,5,2008-10-13,2010-07-08,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Pfizer Global Pharmaceutical Group,LINEZOLID IN THE TREATMENT OF SUBJECTS WITH NOSOCOMIAL PNEUMONIA PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000827-13,0,0,0 2004-000827-13,5,2008-10-13,2010-07-08,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Pfizer Pharmaceutical Group,LINEZOLID IN THE TREATMENT OF SUBJECTS WITH NOSOCOMIAL PNEUMONIA PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000827-13,0,0,0 2004-000827-13,5,2008-10-13,2010-07-08,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,PFIZER,LINEZOLID IN THE TREATMENT OF SUBJECTS WITH NOSOCOMIAL PNEUMONIA PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000827-13,0,0,0 2004-000827-13,5,2008-10-13,2010-07-08,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Pfizer Inc.,LINEZOLID IN THE TREATMENT OF SUBJECTS WITH NOSOCOMIAL PNEUMONIA PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000827-13,0,0,0 2004-000829-30,1,2007-07-24,2007-07-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,NOVARTIS FARMA,Project on the promotion of cardiovascular risk evaluation in clinical practice and the assessment of cardiovascular risk evolution after the introduction of a preventive multifactorial strategy aimed...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000829-30,0,0,0 2004-000830-35,1,,,0,1,0,0,0,3,3,0,0,1,0,0,0,1,1,JANSSEN-CILAG,Maintenance of the clinical response with long-acting injectable Risperidone in patients with Schizophrenia or schizoaffective disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000830-35,0,0,0 2004-000833-12,2,2006-01-23,2006-01-23,1,1,0,0,0,2,3,0,0,1,0,0,1,0,1,NEWRON PHARMACEUTICALS,"A Phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000833-12,0,0,0 2004-000833-12,2,2006-01-23,2006-01-23,1,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Newron Pharmaceuticals S.p.A.,"A Phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000833-12,0,0,0 2004-000835-27,2,2007-01-29,2007-01-29,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,NEWRON PHARMACEUTICALS,"A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A DOSE RANGE OF SAFINAMIDE OF 50-200 MG/DAY, AS ADD-ON THERAPY IN PATIENTS WITH EARLY ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000835-27,0,0,0 2004-000835-27,2,2007-01-29,2007-01-29,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Newron Pharmaceuticals S.P.A,"A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF A DOSE RANGE OF SAFINAMIDE OF 50-200 MG/DAY, AS ADD-ON THERAPY IN PATIENTS WITH EARLY ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000835-27,0,0,0 2004-000838-36,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Pharmexa A/S,A Phase II trial evaluating the immunological and clinical efficay and safety of HER-2 Protein Autovac(TM) monotherapy in patients with metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000838-36,0,0,0 2004-000843-61,1,,,0,1,0,0,0,3,3,0,0,1,0,0,0,1,1,ZAMBON GROUP,Efficacy and tolerability of topical Ketoprofen TDS patch KEOFIX in the treatment of traumatic painful soft-tissue injuries,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000843-61,0,0,0 2004-000848-24,4,2005-07-11,2005-07-21,2,1,0,0,0,0,2,0,0,1,1,0,1,0,2,GlaxoSmithKline Research & Development Limited,"An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects with Irritable Bowel Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000848-24,0,0,0 2004-000848-24,4,2005-07-11,2005-07-21,2,1,0,0,0,0,2,0,0,1,1,0,1,0,2,GlaxoSmithKline S.A.,"An Eight-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Talnetant in Subjects with Irritable Bowel Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000848-24,0,0,0 2004-000849-38,1,2011-03-23,2011-03-23,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A Phase 3, randomized, double-blind, placebo-controlled multi-center study of RAD001 in combination with letrozole (Femara®) to investigate the value of adding RAD001 to letrozole as a first-line ther...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000849-38,0,0,0 2004-000850-22,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ANGELINI,"Evaluation of tolerability and analgesic activity of paracetamol 1000 mg+caffeine 130 mg in the treatment of tension-type headache. Randomized, double blind, double-dummy, cross-over study vs. naproxe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000850-22,0,0,0 2004-000851-41,2,2005-11-15,2005-11-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter study evaluating the efficacy and safety of four doses of SR147778 in obese patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000851-41,0,0,0 2004-000851-41,2,2005-11-15,2005-11-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Synthelabo AB,"A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter study evaluating the efficacy and safety of four doses of SR147778 in obese patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000851-41,0,0,0 2004-000860-28,2,2008-06-12,2008-06-12,1,0,0,0,0,2,3,0,0,2,0,0,0,0,1,ribosepharm GmbH,"PHASE III, OPEN-LABEL, RANDOMIZED, MULTICENTER EFFICACY AND SAFETY STUDY OF BENDAMUSTINE HYDROCHLORIDE VERSUS CHLORAMBUCIL IN TREATMENT-NAÏVE PATIENTS WITH (BINET STAGE B/C) B-CLL REQUIRING THERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000860-28,1,0,0 2004-000860-28,2,2008-06-12,2008-06-12,1,0,0,0,0,2,3,0,0,2,0,0,0,0,1,RIBOSEPHARM,"PHASE III, OPEN-LABEL, RANDOMIZED, MULTICENTER EFFICACY AND SAFETY STUDY OF BENDAMUSTINE HYDROCHLORIDE VERSUS CHLORAMBUCIL IN TREATMENT-NAÏVE PATIENTS WITH (BINET STAGE B/C) B-CLL REQUIRING THERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000860-28,1,0,0 2004-000864-29,6,2007-11-30,2016-06-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A randomized, double-blind multicenter 2-stage phase III study of bevacizumab in combination with cisplatin and gemcitabine versus placebo, cisplatin and gemcitabine in patients with advanced or recur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000864-29,0,0,0 2004-000864-29,6,2007-11-30,2016-06-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomized, double-blind multicenter 2-stage phase III study of bevacizumab in combination with cisplatin and gemcitabine versus placebo, cisplatin and gemcitabine in patients with advanced or recur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000864-29,0,0,0 2004-000866-11,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ZAMBON GROUP,"A multicenter, randomized, parallel group, controlled, double-blind study to evaluate efficacy and safety of pholcodine as antitussive agent vs dextrometorphan in non-productive cough",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000866-11,0,0,0 2004-000867-92,4,2006-04-26,2006-05-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Limited,"A Multicenter, Randomized, Double-Blind Study of MK-0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000867-92,0,0,0 2004-000867-92,4,2006-04-26,2006-05-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind Study of MK-0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000867-92,0,0,0 2004-000867-92,4,2006-04-26,2006-05-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"UAB ""Merck Sharp & Dohme""","A Multicenter, Randomized, Double-Blind Study of MK-0431 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000867-92,0,0,0 2004-000870-29,7,2007-11-07,2007-12-18,5,1,0,0,0,0,0,0,0,1,0,0,1,0,2,Janssen-Cilag Medical Affairs EMEA,CONSTATRE Risperdal Consta Trial of Relapse Prevention and Effectiveness,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000870-29,0,0,0 2004-000870-29,7,2007-11-07,2007-12-18,5,1,0,0,0,0,0,0,0,1,0,0,1,0,2,JANSSEN-CILAG,CONSTATRE Risperdal Consta Trial of Relapse Prevention and Effectiveness,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000870-29,0,0,0 2004-000870-29,7,2007-11-07,2007-12-18,5,1,0,0,0,0,0,0,0,1,0,0,1,0,2,"Janssen-Cilag,S.A.",CONSTATRE Risperdal Consta Trial of Relapse Prevention and Effectiveness,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000870-29,0,0,0 2004-000871-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Apogepha Arzneimittel GmbH,"Propiverine hydrochloride extended release (ER): Tolerability in patients with LUTS and BPS/BPH A randomised, double-blind, placebo-controlled, multi-centre clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000871-33,0,0,0 2004-000874-30,1,2007-01-26,2007-01-26,1,1,0,0,1,3,3,0,0,1,0,0,1,0,1,AOP ORPHAN PHARMACEUTICALS,"A SINGLE BLIND, MULTI-CENTE, RANDOMIZED MULTINATIONAL PHASE III STUDY TO COMPARE THE EFFICACY AND TOLERABILITY OF ANAGRELIDE VS HYDROXYUREA IN PATIENTS WITH ESSENTIAL THROMBOCYTHAEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000874-30,0,0,0 2004-000876-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"FERRER INTERNACIONAL, S.A.","A multicentre, multinational, parallel, randomised, double blind clinical trial, to evaluate the non-inferiority of Prolonged Release Torasemide (PR) versus Immediate Release Torasemide (IR) in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000876-14,0,0,0 2004-000877-80,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,S&K Pharma Schumann und Kohl GmbH,"Efficacy and Safety of Corti Biciron N versus Dexa-Gentamicinin the treatment of external ocular inflammation in which the application of antibiotics is advisableA multicentre, randomised, single-blin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000877-80,0,0,0 2004-000881-10,1,2008-12-31,2008-12-31,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,CELSG (Central European Leukemia Study Group),"International, multicenter, randomised, open-labeled, 2-arm - Phase III Study comparing Imatinib (STI571, Glivec®) Standard Dose (400 mg/day) with Imatinib High Dose Induction (800 mg/day) followed by...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000881-10,0,0,0 2004-000882-36,4,2006-06-20,2006-07-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKine Research & Development Limited,"A multi-centre, two-staged with interim analysis, parallel, randomised, double blind, placebo-controlled, dose ranging study of the safety, tolerability, and effects on plasma high-density lipoprotein...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000882-36,0,0,0 2004-000894-67,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Lilly S.A,The Effect of Teriparatide on Distal Radius Fracture Healing,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000894-67,0,0,0 2004-000894-67,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Eli Lilly and Company,The Effect of Teriparatide on Distal Radius Fracture Healing,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000894-67,0,0,0 2004-000895-16,6,2007-04-04,2007-04-04,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of aliskiren on proteinuria when added to standardized losartan therapy and optimal antihypert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000895-16,0,0,0 2004-000895-16,6,2007-04-04,2007-04-04,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of aliskiren on proteinuria when added to standardized losartan therapy and optimal antihypert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000895-16,0,0,0 2004-000895-16,6,2007-04-04,2007-04-04,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis s.r.o. org zlozka,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of aliskiren on proteinuria when added to standardized losartan therapy and optimal antihypert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000895-16,0,0,0 2004-000895-16,6,2007-04-04,2007-04-04,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Ireland Ltd,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of aliskiren on proteinuria when added to standardized losartan therapy and optimal antihypert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000895-16,0,0,0 2004-000895-16,6,2007-04-04,2007-04-04,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of aliskiren on proteinuria when added to standardized losartan therapy and optimal antihypert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000895-16,0,0,0 2004-000895-16,6,2007-04-04,2007-04-04,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of aliskiren on proteinuria when added to standardized losartan therapy and optimal antihypert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000895-16,0,0,0 2004-000903-17,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Bristol-Myers Squibb International Corporation,"A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Functioning of a Treatment with Aripiprazole in a Broad Range of Schizophrenic Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000903-17,0,0,0 2004-000904-41,3,2005-10-19,2005-10-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Aventis Pharmaceuticals Inc.,"A multinational, randomized, double-blind, double-dummy, exploratory, parallel-group, dose-ranging phase II study to evaluate the pharmacodynamics, the safety and tolerability, and the pharmacokinetic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000904-41,0,0,0 2004-000905-24,2,2010-08-03,2010-08-03,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of York,Cryotherapy versus salicylic acid for the treatment of verrucae: a randomised controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000905-24,0,0,0 2004-000907-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Bonaventura Clotet/Ramón Planas/Ricard Solá,"Open, multicenter and randomized phase IV trial to evaluate the viral kinetic during 12 first weeks of patients with chronic hepatitis C genotype 1 and 4 coinfected with HIV treated with induction dos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000907-16,0,0,0 2004-000909-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MDS Pharma Services,Comparative efficacy and tolerability of a topical ketoprofen TDS patch vs ketoprofen gel in the treatment of acute pain in soft-tissue injuries,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000909-22,0,0,0 2004-000912-13,7,2006-03-09,2006-03-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA AB,"A 6-WEEK INTERNATIONAL, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE FEASIBILITY OF SWITCHING FROM IMMEDIATE-REALESE QUETIAPINE FUMARATE SEROQUEL TM TO SUST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000912-13,0,0,0 2004-000912-13,7,2006-03-09,2006-03-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca R&D Södertälje,"A 6-WEEK INTERNATIONAL, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE FEASIBILITY OF SWITCHING FROM IMMEDIATE-REALESE QUETIAPINE FUMARATE SEROQUEL TM TO SUST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000912-13,0,0,0 2004-000913-21,4,2006-09-25,2006-12-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca R&D Södertälje,"A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL) in Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000913-21,0,0,0 2004-000914-37,1,2005-03-29,2005-03-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Neurim Pharmaceuticals (1991) Ltd,"A DOUBLE-BLIND, PARALLEL GROUP, RANDOMISED, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF CIRCADIN® 2MG IN THE IMPROVEMENT OF SLEEP QUALITY IN PATIENTS WITH INSOMNIA AGED 55-80 YEARS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000914-37,0,0,0 2004-000915-25,1,2007-06-05,2007-06-05,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,AstraZeneca R&D Sodertalje,"Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate and Lithium as Monotherapy for up to 104 weeks Maintenance T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000915-25,0,0,0 2004-000916-25,1,,,0,1,0,0,0,3,3,0,0,1,0,0,0,1,1,GIULIANI,"A PHASE III PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUPS, STUDY, TO ASSESS THE EFFECT OF 5-ASA MMx 1.2 g Tablets IN MAINTENANCE OF REMISSION OF LEFT-SIDED ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000916-25,0,0,0 2004-000919-26,2,2008-08-21,2008-08-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Trust,"Phase II, randomized, pharmokinetic, dose finding, and dose frequency determination using rt-PA in intraventricular hemorrhage",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000919-26,0,0,0 2004-000919-26,2,2008-08-21,2008-08-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Johns Hopkins University,"Phase II, randomized, pharmokinetic, dose finding, and dose frequency determination using rt-PA in intraventricular hemorrhage",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000919-26,0,0,0 2004-000922-59,4,2009-07-03,2009-07-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination with Methotrexate in Controlling Disease Activity in Subjects with R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000922-59,0,0,0 2004-000929-30,1,,,0,1,0,0,0,3,3,0,0,1,0,0,0,1,1,GLAXO SMITHKLINE,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase III Study to Evaluate Corticosteroid-reduction and -sparing Effects of Mepolizumab 750 mg Intravenous in Subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000929-30,0,0,0 2004-000930-35,2,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,SmithKline Beecham plc,"An open-label extension study to Study 100185 to evaluate long-term saftey, efficacy and optimal dosing frequency of 750mg intravenous mepolizumab in subjects with hypereosinophilic syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000930-35,0,0,0 2004-000930-35,2,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,GLAXO SMITHKLINE,"An open-label extension study to Study 100185 to evaluate long-term saftey, efficacy and optimal dosing frequency of 750mg intravenous mepolizumab in subjects with hypereosinophilic syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000930-35,0,0,0 2004-000933-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Axonyx Inc,"A randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of two different doses of phenserine-tartrate in patients with probable mild to moderate Alzheimer’s disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000933-12,0,0,0 2004-000935-27,1,2008-08-23,2008-08-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.Clinical Research & Development Department,"A Randomized, Open-label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000935-27,0,0,0 2004-000940-26,3,2005-09-04,2005-10-14,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"A 22-week randomized, multicenter, parallel-group, double-blind study to compare a pimecrolimus 1 % (Elidel) twice daily (b.i.d.) maintenance dosing regimen to a once daily (o.d.) maintenance dosing r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000940-26,0,0,0 2004-000940-26,3,2005-09-04,2005-10-14,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma,"A 22-week randomized, multicenter, parallel-group, double-blind study to compare a pimecrolimus 1 % (Elidel) twice daily (b.i.d.) maintenance dosing regimen to a once daily (o.d.) maintenance dosing r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000940-26,0,0,0 2004-000944-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HOVON foundation,"A randomized phase III study on the effect of Bortezomib combined with Adriamycin, Dexamethasone (AD) for induction treatment, followed by High Dose Melphalan and Bortezomib alone during maintenance i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000944-26,0,0,0 2004-000948-25,1,2005-09-07,2005-09-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació de Lluita Contra la Sida,Determinación de niveles plasmáticos e intracelulares de los inhibidores de la transcriptasa inversa análogos a nucleósidos (NRTI) y del análogo a nucleótido tenofovir disoproxil fumarato (TDF) en pac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000948-25,0,0,0 2004-000953-46,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Amersham plc,"A Multicentre, Phase 3, Open-Label, Controlled Study Evaluating the Efficacy and Safety of 0.1 mmol/kg Omniscan (Gadodiamide Injection) in Magnetic Resonance Angiography (MRA) of the Renal Arteries",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000953-46,0,0,0 2004-000954-22,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Pfizer Global Research & Development,A 1-Year Open-Label Safety Extension Study of Pregabalin (CI-1008) in Patients With Anxiety Disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000954-22,0,0,0 2004-000955-40,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Pfizer Global Research & Development,A Placebo-Controlled Study of Pregabalin in Elderly Patients With Generalized Anxiety Disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000955-40,0,0,0 2004-000957-47,1,2008-07-31,2008-07-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Charité,Comparison of Bisoprolol and Carvedilol in elderly patients with heart failure. A randomised doubleblind multicenter trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000957-47,0,0,0 2004-000959-42,1,2005-06-23,2005-06-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Integrated Therapeutics Group, Inc./Schering-Plough Oy","Avoin, randomis., rinnakkaisryhmillä tehtävä monikeskustutk., jossa tutk. tehoa ja turvallisuutta vertailtaessa lääkityksen vaihtamista rosuvastatiiniin 10 mg päivässä verrattuna atorvastatiiniin 10...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000959-42,0,0,0 2004-000960-28,6,2007-10-31,2007-10-31,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ PHARMA,"A multi-center, open-label trial to assess the long-term safety and efficacy of SPM 927 in subjects with painful diabetic neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000960-28,0,0,0 2004-000960-28,6,2007-10-31,2007-10-31,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ BIOSCIENCES GmbH,"A multi-center, open-label trial to assess the long-term safety and efficacy of SPM 927 in subjects with painful diabetic neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000960-28,0,0,0 2004-000962-11,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Pierre Fabre Medicament represented by IRPF,Phase II Study of Navelbine oral and Arimidex as neo-adjuvant treatment in post-menopausal women with locally advanced breast carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000962-11,0,0,0 2004-000963-81,2,2006-10-31,2006-10-31,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Robapharm AG,A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000963-81,0,0,0 2004-000963-81,2,2006-10-31,2006-10-31,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pierre Fabre Medicament,A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000963-81,0,0,0 2004-000966-10,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,na,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000966-10,0,0,0 2004-000971-33,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,PFIZER,"Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study of AG-013736 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Metastatic Breast Cancer Preceded by a Phase 1 Evaluation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000971-33,0,0,0 2004-000971-33,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Pifzer Limited,"Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study of AG-013736 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Metastatic Breast Cancer Preceded by a Phase 1 Evaluation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000971-33,0,0,0 2004-000972-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Michael Larsen,DIAMETIB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000972-15,0,0,0 2004-000973-69,7,2006-06-07,2006-06-28,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,WYETH LEDERLE,"A RANDOMIZED, OPEN-LABEL, COMPARATIVE EVALUATION OF THE SAFETY AND EFFICACY OF SIROLIMUS VERSUS CYCLOSPORINE WHEN COMBINED IN A REGIMEN CONTAINING BASILIXIMAB, MYCOPHENOLATE MOFETIL, AND CORTICOSTEROI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000973-69,0,0,0 2004-000973-69,7,2006-06-07,2006-06-28,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc,"A RANDOMIZED, OPEN-LABEL, COMPARATIVE EVALUATION OF THE SAFETY AND EFFICACY OF SIROLIMUS VERSUS CYCLOSPORINE WHEN COMBINED IN A REGIMEN CONTAINING BASILIXIMAB, MYCOPHENOLATE MOFETIL, AND CORTICOSTEROI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000973-69,0,0,0 2004-000975-32,3,2006-01-05,2006-03-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB S.A. Pharma Sector,"An exploratory, double blind, randomized, placebo-controlled, parallel group, multicenter study, for the assessment of efficacy, safety and tolerability of ucb 34714 50 mg oral capsules in b.i.d. admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000975-32,0,0,0 2004-000975-32,3,2006-01-05,2006-03-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB S.A. - Pharma Sector,"An exploratory, double blind, randomized, placebo-controlled, parallel group, multicenter study, for the assessment of efficacy, safety and tolerability of ucb 34714 50 mg oral capsules in b.i.d. admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000975-32,0,0,0 2004-000979-33,1,2006-11-29,2006-11-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LABORATOIRES EXPANSCIENCE,A multinational multicentre randomised paralle group study on therapeutic efficacy and tolerability of PIASCLEDINE capsules 300 mg in comparison with placebo in the treatment of hip osteoarthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000979-33,0,0,0 2004-000980-93,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,CRINOS S.P.A.,"A randomised, double blind, multicentre Italian study, to assess the efficacy and tolerability of octatropine methilbromide in combination with diazepam(Valpinax) compared versus placebo in the treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000980-93,0,0,0 2004-000983-29,2,2006-11-27,2006-11-27,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,Effectiveness of a once weekly subcutaneous sc epoetin beta treatment in hemodialysis patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000983-29,0,0,0 2004-000983-29,2,2006-11-27,2006-11-27,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,ROCHE,Effectiveness of a once weekly subcutaneous sc epoetin beta treatment in hemodialysis patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000983-29,0,0,0 2004-000984-81,2,2005-07-30,2005-07-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Astellas Pharma US, Inc.","A PHASE III PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, TOLERANCE AND EFFICACY STUDY OF RSD1235 IN SUBJECTS WITH ATRIAL FIBRILLATION OR ATRIAL FLUTTER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000984-81,0,0,0 2004-000984-81,2,2005-07-30,2005-07-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Cardiome Pharma Corp,"A PHASE III PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, TOLERANCE AND EFFICACY STUDY OF RSD1235 IN SUBJECTS WITH ATRIAL FIBRILLATION OR ATRIAL FLUTTER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000984-81,0,0,0 2004-000985-12,2,2006-04-10,2006-04-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000985-12,0,0,0 2004-000985-12,2,2006-04-10,2006-04-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Limited,"An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000985-12,0,0,0 2004-000986-37,6,2010-12-31,2010-12-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000986-37,0,0,0 2004-000986-37,6,2010-12-31,2010-12-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000986-37,0,0,0 2004-000986-37,6,2010-12-31,2010-12-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000986-37,0,0,0 2004-000990-78,3,2005-06-03,2005-06-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"H. Lundbeck A/S, Lundbeck Austria GmbH","A Double-Blind, Multicentre, Randomised, Parallel-group, Placebo-controlled Study Assessing the Efficacy and Safety of Escitalopram in Post-Myocardial Infarction Patients Suffering from Depressive Sym...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000990-78,0,0,0 2004-000990-78,3,2005-06-03,2005-06-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A Double-Blind, Multicentre, Randomised, Parallel-group, Placebo-controlled Study Assessing the Efficacy and Safety of Escitalopram in Post-Myocardial Infarction Patients Suffering from Depressive Sym...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000990-78,0,0,0 2004-000994-69,3,2006-02-28,2006-02-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amersham Health,"A multicentre, phase 3, open label study to assess the efficacy and safety of 0.1 mmol/kg Omniscan™ (gadodiamide injection) for Magnetic Resonance Angiography (MRA) of the aorto-iliac arteries",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000994-69,0,0,0 2004-000994-69,3,2006-02-28,2006-02-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amersham Health AB,"A multicentre, phase 3, open label study to assess the efficacy and safety of 0.1 mmol/kg Omniscan™ (gadodiamide injection) for Magnetic Resonance Angiography (MRA) of the aorto-iliac arteries",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000994-69,0,0,0 2004-000994-69,3,2006-02-28,2006-02-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amersham Buchler GmbH & Co KG an affiliate of GE Healthcare Bio-Sciences,"A multicentre, phase 3, open label study to assess the efficacy and safety of 0.1 mmol/kg Omniscan™ (gadodiamide injection) for Magnetic Resonance Angiography (MRA) of the aorto-iliac arteries",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000994-69,0,0,0 2004-000996-33,4,2005-03-10,2005-10-07,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,PFIZER,"A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate the Effectiveness of Detrusitol SR 4mg on Patient`s Perception of Bladder Condition (PPBC).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000996-33,0,0,0 2004-000996-33,4,2005-03-10,2005-10-07,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Global Pharmaceuticals, Pfizer Inc.","A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate the Effectiveness of Detrusitol SR 4mg on Patient`s Perception of Bladder Condition (PPBC).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000996-33,0,0,0 2004-000996-33,4,2005-03-10,2005-10-07,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer ApS,"A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate the Effectiveness of Detrusitol SR 4mg on Patient`s Perception of Bladder Condition (PPBC).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000996-33,0,0,0 2004-000996-33,4,2005-03-10,2005-10-07,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer AB,"A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate the Effectiveness of Detrusitol SR 4mg on Patient`s Perception of Bladder Condition (PPBC).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000996-33,0,0,0 2004-001000-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"AlgoRx Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Phase II, Exploratory Evaluation of a Single Dose of ALGRX 4975 in Subjects with Acute Lateral Epicondylitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001000-12,0,0,0 2004-001010-13,1,2007-05-11,2007-05-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Dept. of Neurology, Odense University Hospital","Escitalopram til behandling af smerter ved polyneuropati En dobbeltblind, randomiseret, placebokontrolleret undersøgelse (Escitalopram as a treatment for painful polyneuropathy: A double-blind, rand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001010-13,0,0,0 2004-001012-32,3,2008-03-12,2008-03-12,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Gloucester Pharmaceuticals Inc.,A single agent Phase II study of depsipeptide (FK228) in the treatment of Cutaneous T-cell lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001012-32,0,0,0 2004-001020-20,8,2005-11-21,2006-01-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Group of Companies,"A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose ranging, Parallel Group Study of the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antogonist, GW679769, when adminis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001020-20,0,0,0 2004-001020-20,8,2005-11-21,2006-01-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd.,"A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Dose ranging, Parallel Group Study of the Safety and Efficacy of the Oral Neurokinin-1 Receptor Antogonist, GW679769, when adminis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001020-20,0,0,0 2004-001021-22,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GlaxoSmithKline Group of Companies,"A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 mg a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001021-22,0,0,0 2004-001021-22,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GlaxoSmithKline Research and Development Limited,"A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 mg a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001021-22,0,0,0 2004-001033-41,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ELI LILLY,"A Randomized, Double-Blind, Parallel-Design, Placebo-Controlled Study to Evluate the Efficacy and Safety of Tadalafil (2.5 mg e 5 mg) administered once daily to men with diabetes mellitus and erectile...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001033-41,0,0,0 2004-001035-32,1,,,0,0,0,0,0,3,2,0,0,1,1,1,0,1,0,ITALIAN SARCOMA GROUP,NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FROM HLA IDENTICAL SIBLING FOR METASTATIC SOFT TISSUE SARCOMAS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001035-32,0,0,0 2004-001036-23,2,2005-07-18,2005-07-18,1,1,0,0,0,0,0,0,0,1,0,0,1,0,2,NOVARTIS FARMA,"A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the safety and efficacy of Elid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001036-23,0,0,0 2004-001036-23,2,2005-07-18,2005-07-18,1,1,0,0,0,0,0,0,0,1,0,0,1,0,2,Novartis Sverige AB,"A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the safety and efficacy of Elid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001036-23,0,0,0 2004-001041-15,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Neuro3d,"MULTICENTRE, DOUBLE-BLIND, RISING DOSE PARALLEL GROUP STUDY OF THE EFFICACY AND TOLERABILITY OF OCAPERIDONE VERSUS OLANZAPINE IN SCHIZOPHRENIC PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001041-15,0,0,0 2004-001043-30,1,,,0,0,0,0,0,3,2,0,0,1,1,1,0,1,1,SIGMA-TAU,"A non-comparative, randomized phase II study of two different oral schedules of gimatecan (ST1481) as second line therapy for patients with advanced Non Small Cell Lung Cancer (NSCLC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001043-30,0,0,0 2004-001044-72,1,,,0,1,0,0,0,3,2,0,0,1,0,0,0,1,1,AVENTIS PHARMA S.P.A.,Randomized phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001044-72,0,0,0 2004-001052-36,3,2007-05-30,2007-05-30,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A 12-month, multi-center, randomized, open-label non-inferiority study of renal function and efficacy comparing concentration-controlled Certican® (1.5 mg/day starting dose) with reduced Neoral® dose ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001052-36,0,0,0 2004-001052-36,3,2007-05-30,2007-05-30,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-month, multi-center, randomized, open-label non-inferiority study of renal function and efficacy comparing concentration-controlled Certican® (1.5 mg/day starting dose) with reduced Neoral® dose ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001052-36,0,0,0 2004-001052-36,3,2007-05-30,2007-05-30,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 12-month, multi-center, randomized, open-label non-inferiority study of renal function and efficacy comparing concentration-controlled Certican® (1.5 mg/day starting dose) with reduced Neoral® dose ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001052-36,0,0,0 2004-001054-84,1,2009-03-01,2009-03-01,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,NHS Lothian- University Hospitals Division,A comparison of the efficacy of dietary hydroxypropylcellulose and questran as therapeutic agents in bile acid induced diarrhoea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001054-84,0,0,0 2004-001056-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut de Recerca,Ensayo clínico con Ziprasidona para el tratamiento de la psicopatología no constituyente de un trastorno mental grave en la dependencia del alcohol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001056-36,0,0,0 2004-001060-50,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Farmacéutica S.A.,"An eight-week, randomized, double-blind, multi-center, active-controlled, parallel group study to evaluate the safety and efficacy of an aliskiren based regimen compared to a lisinopril based regimen ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001060-50,0,0,0 2004-001060-50,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"An eight-week, randomized, double-blind, multi-center, active-controlled, parallel group study to evaluate the safety and efficacy of an aliskiren based regimen compared to a lisinopril based regimen ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001060-50,0,0,0 2004-001061-17,5,2006-03-08,2006-03-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 26 week, double-blind, randomized, multicenter, parallel group, active-controlled study comparing aliskiren to ramipril with optional addition of hydrochlorothiazide (HCTZ), followed by a 4 week dou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001061-17,0,0,0 2004-001061-17,5,2006-03-08,2006-03-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A 26 week, double-blind, randomized, multicenter, parallel group, active-controlled study comparing aliskiren to ramipril with optional addition of hydrochlorothiazide (HCTZ), followed by a 4 week dou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001061-17,0,0,0 2004-001062-40,5,2005-08-30,2005-08-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma CH,"An eight-week, randomized, double-blind, parallel group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with ramipril in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001062-40,0,0,0 2004-001062-40,5,2005-08-30,2005-08-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An eight-week, randomized, double-blind, parallel group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with ramipril in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001062-40,0,0,0 2004-001062-40,5,2005-08-30,2005-08-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"An eight-week, randomized, double-blind, parallel group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with ramipril in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001062-40,0,0,0 2004-001062-40,5,2005-08-30,2005-08-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An eight-week, randomized, double-blind, parallel group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with ramipril in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001062-40,0,0,0 2004-001065-18,1,2005-07-07,2005-07-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA Pharma AG,Morning versus evening administration of 500µg Roflumilast once dailyfor 6 weeks in patients with asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001065-18,0,0,0 2004-001069-17,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Novartis Pharma GmbH,"A double-blind, active-controlled, randomized, multicenter, parallel-group 2 day comparison of 1000 mg propyphenazone / 80 mg codeine (applied as two suppositories) combination therapy versus a 1000 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001069-17,0,0,0 2004-001072-39,2,2006-01-09,2006-01-09,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA Pharma AG,Comparison of Ciclesonide (80 µg Once Daily in the Evening) and Fluticasone propionate (100 µg Twice Daily) in Patients with Mild to Moderate Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001072-39,0,0,0 2004-001075-20,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Fujisawa GmbH,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, DOUBLE-DUMMY PLACEBO- CONTROLLED PARALLEL-GROUP MULTIPLE DOSE STUDY OF THE EFFICACY AND SAFETY OF TACROLIMUS INHALATION AEROSOL IN PATIENTS WITH MODERATE PERS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001075-20,0,0,0 2004-001083-43,2,2005-07-26,2005-10-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis ODIXa-DVT A prospective, randomized, multinational, multicenter, partially blinded, parallel-group, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001083-43,0,0,0 2004-001086-17,1,2006-05-01,2006-05-01,1,0,0,0,0,3,4,0,0,1,1,1,1,0,1,Medi-Flex,Prospective randomised clinical trial to assess the efficacy of 70% v/v isopropyl alcohol and 2% w/v chlorhexidine in 70% v/v isopyl alcohol for the disinfection of skin prior to peripheral venous cat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001086-17,0,0,0 2004-001090-25,7,2007-01-30,2007-02-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,QUADRAMED,"METABOLIC EFFICIENCY WITH RANOLAZINE FOR LESS ISCHEMIA IN NON-ST ELEVATION ACUTE CORONARY SYNDROMES A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, MULTINATIONAL, CLINICAL TRIAL TO EV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001090-25,0,0,0 2004-001090-25,7,2007-01-30,2007-02-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CV THERAPEUTICS INC,"METABOLIC EFFICIENCY WITH RANOLAZINE FOR LESS ISCHEMIA IN NON-ST ELEVATION ACUTE CORONARY SYNDROMES A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, MULTINATIONAL, CLINICAL TRIAL TO EV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001090-25,0,0,0 2004-001091-40,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,Beaufour Ipsen Pharma,"A Phase III, Prospective, Multicentre, Randomised, Open, Parallel Group Comparison of Lanreotide Autogel (90 and 120mg) Administered by Deep Subcutaneous Injection Every Four Weeks, with Sandostatin L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001091-40,0,0,0 2004-001093-11,6,2007-10-22,2011-12-13,3,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Pfizer Hellas A.E.,A Treatment Protocol for Patients Continuing from Prior SU0011248 Protocol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001093-11,0,0,0 2004-001093-11,6,2007-10-22,2011-12-13,3,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Pfizer Ltd,A Treatment Protocol for Patients Continuing from Prior SU0011248 Protocol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001093-11,0,0,0 2004-001093-11,6,2007-10-22,2011-12-13,3,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Pfizer,A Treatment Protocol for Patients Continuing from Prior SU0011248 Protocol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001093-11,0,0,0 2004-001093-11,6,2007-10-22,2011-12-13,3,1,0,0,0,0,3,0,0,1,1,0,1,0,2,PFIZER,A Treatment Protocol for Patients Continuing from Prior SU0011248 Protocol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001093-11,0,0,0 2004-001093-11,6,2007-10-22,2011-12-13,3,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Pfizer SA,A Treatment Protocol for Patients Continuing from Prior SU0011248 Protocol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001093-11,0,0,0 2004-001093-11,6,2007-10-22,2011-12-13,3,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Pfizer Global Research and Development,A Treatment Protocol for Patients Continuing from Prior SU0011248 Protocol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001093-11,0,0,0 2004-001098-25,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Zambon SA,N-Acetylcisteine (NAC) effect on the inmunologycal system,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001098-25,0,0,0 2004-001100-12,3,2005-03-18,2005-03-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH&Co.KG,"A multi-centre, double-blind, parallel-group, randomised, placebo-controlled study to investigate the safety and tolerability of 0.25, 0.5 and 1.0 mg NS 2330 orally and once daily during a 14-week tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001100-12,0,0,0 2004-001100-12,3,2005-03-18,2005-03-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A multi-centre, double-blind, parallel-group, randomised, placebo-controlled study to investigate the safety and tolerability of 0.25, 0.5 and 1.0 mg NS 2330 orally and once daily during a 14-week tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001100-12,0,0,0 2004-001100-12,3,2005-03-18,2005-03-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,"A multi-centre, double-blind, parallel-group, randomised, placebo-controlled study to investigate the safety and tolerability of 0.25, 0.5 and 1.0 mg NS 2330 orally and once daily during a 14-week tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001100-12,0,0,0 2004-001101-10,6,2010-05-12,2010-05-12,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A","A prospective, multicenter, randomized phase III study to evaluate the efficacy of ZOMETA (zoledronic acid) in preventing or delaying of bone metastasis in patients with Stage III non-small cell lung...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001101-10,0,0,0 2004-001101-10,6,2010-05-12,2010-05-12,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A prospective, multicenter, randomized phase III study to evaluate the efficacy of ZOMETA (zoledronic acid) in preventing or delaying of bone metastasis in patients with Stage III non-small cell lung...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001101-10,0,0,0 2004-001101-10,6,2010-05-12,2010-05-12,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A prospective, multicenter, randomized phase III study to evaluate the efficacy of ZOMETA (zoledronic acid) in preventing or delaying of bone metastasis in patients with Stage III non-small cell lung...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001101-10,0,0,0 2004-001101-10,6,2010-05-12,2010-05-12,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"A prospective, multicenter, randomized phase III study to evaluate the efficacy of ZOMETA (zoledronic acid) in preventing or delaying of bone metastasis in patients with Stage III non-small cell lung...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001101-10,0,0,0 2004-001103-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Nordic Society for Gynecologic Oncology,Exemestane in Advanced or Recurrent Endometrial Carcinoma. A multicentre non-randomized Phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001103-35,0,0,0 2004-001105-96,8,2012-04-19,2012-04-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck KGaA,"''Open, randomized, controlled, multicenter phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vinorelbine as first-line treatment for patients with EGFR-expressing advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001105-96,0,0,0 2004-001105-96,8,2012-04-19,2012-04-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK S.P.A.,"''Open, randomized, controlled, multicenter phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vinorelbine as first-line treatment for patients with EGFR-expressing advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001105-96,0,0,0 2004-001107-36,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,AstraZeneca NV/SA,"A comparison of Symbicort Single inhaler Therapy (Symbicort Turbohaler 160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolesce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001107-36,0,0,0 2004-001108-11,1,2021-01-13,2021-01-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,European Organisation for the Research and Treatment of Cancer,"A phase II study of intravenous TZT-1027, administered weekly times two, every three weeks, to patients with advanced or metastatic soft tissue sarcomas (STS) with prior exposure to doxorubicin-based ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001108-11,0,0,0 2004-001109-81,1,2007-02-12,2007-02-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici SpA,"A randomised, controlled with placebo, double blind, double dummy, parallel group study on the therapeutic efficacy and safety of Beclomethasone dipropionate (BDP) in the treatment of patients with po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001109-81,0,0,0 2004-001113-33,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,University Hospital Ghent,"Effect of TNFalpha blockade on the induction of specific B cell responses in vivo, using human spondyloarthropathy as model.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001113-33,0,0,0 2004-001114-14,1,,,0,1,0,1,0,0,1,1,1,1,0,0,0,1,1,SIGMA-TAU,"BIOAVAILABILITY AND BIOEQUIVALENCE OF TWO ORAL FORMULATION OF L-PROPIONYLCARNITINE TABLET VS SACHET IN HEALTHY VOLUNTEERS AT THE DOSE OF 2 G OPEN, RANDOMISED, TWO-WAYS CROSS-OVER, SINGLE DOSE STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001114-14,0,0,0 2004-001116-31,2,2004-12-21,2004-12-21,2,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Laboratorios Dr. Esteve S.A.,"Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001116-31,0,0,0 2004-001117-34,2,2010-06-16,2010-06-16,1,1,0,0,0,2,2,0,0,1,0,0,1,0,1,PHARMA MAR,"A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin’s Lymphoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001117-34,0,0,0 2004-001117-34,2,2010-06-16,2010-06-16,1,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Pharma Mar S.A.,"A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin’s Lymphoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001117-34,0,0,0 2004-001118-15,1,2007-03-20,2007-03-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pharma Mar, S.A","Phase II multicenter,open-label, clinical and pharmacokinetic study of Aplidin® as a 3-hour infusion every 2 weeks, in patients with advanced or metastatic transitional cell carcinoma of the urotheli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001118-15,0,0,0 2004-001119-69,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Laboratorios Dr. Esteve, SA","An evaluation of the dose-response relationship of Cizolirtine citrate 300 mg, twice daily, and 400 mg, twice daily, versus placebo in subjects with urge urinary incontinence. A 12-week, randomised, d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001119-69,0,0,0 2004-001124-20,4,2010-03-30,2010-03-30,2,0,0,0,0,0,4,0,0,1,1,0,1,0,0,Sigrun Kjøtrød,"Metformin treatment before IVF/ICSI in non obese women with polycystic ovarian syndrome . A European, prospective, randomised, double-blind, multicenter study. (MET-AR study )",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001124-20,0,0,0 2004-001124-20,4,2010-03-30,2010-03-30,2,0,0,0,0,0,4,0,0,1,1,0,1,0,0,Sigrun Kjotrod,"Metformin treatment before IVF/ICSI in non obese women with polycystic ovarian syndrome . A European, prospective, randomised, double-blind, multicenter study. (MET-AR study )",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001124-20,0,0,0 2004-001125-20,1,,,0,0,0,0,0,3,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA S. LUIGI GONZAGA,"First International Randomized trial in Metastatic Adrenocortical Cancer Treatment FIRM-ACT Etoposide, Doxorubicin, Cisplatin and Mitotane vs. Streptozotocin and Mitotane",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001125-20,0,0,0 2004-001126-24,1,2006-10-09,2006-10-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Ghent,Feasibility of radiotherapy and concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001126-24,0,0,0 2004-001128-19,1,2005-11-24,2005-11-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2 Randomized, Double Blinded (BMS-562247 and enoxaparin), Active-Controlled (enoxaparin and warfarin), Parallel-Arm, Dose Response Study of the Oral Factor Xa Inhibitor BMS-562247 in Subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001128-19,0,0,0 2004-001130-16,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,1,J. URIACH & COMPAÑIA,12 months long term safety and tolerability of Rupatadine 10 mg in the treatment of moderate-severe persistent allergic rhinitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001130-16,0,0,0 2004-001132-23,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"A 52-week, international, multicenter, randomized, double-blind, double-dummy, parallel-group clinical trial to compare retention on treatment, safety, tolerability and efficacy of lumiracoxib 100mg o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001132-23,0,0,0 2004-001144-71,1,2007-03-14,2007-03-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Added to the Therapy of Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001144-71,0,0,0 2004-001149-14,3,2008-09-19,2008-09-19,3,1,0,0,0,2,3,0,0,1,0,0,1,0,2,"Pfizer, S.A.","A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001149-14,0,0,0 2004-001149-14,3,2008-09-19,2008-09-19,3,1,0,0,0,2,3,0,0,1,0,0,1,0,2,Pfizer Inc. - 235 East 42nd Street - New York - 10017,"A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001149-14,0,0,0 2004-001149-14,3,2008-09-19,2008-09-19,3,1,0,0,0,2,3,0,0,1,0,0,1,0,2,PFIZER,"A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001149-14,0,0,0 2004-001150-88,2,2009-07-22,2009-07-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Menarini International Operation Luxembourg -SA,Comparison between zofenopril and ramipril in combination with ASA on the extent of cardiovascular risk in patients with systolic left ventricular dysfunction after acute myocardial infarction (SMILE ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001150-88,0,0,0 2004-001154-86,1,2007-01-17,2007-01-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,"A Multicenter, Double-blind, Placebo-controlled Roll-over Study to Protocol 20010103 of Darbepoetin Alfa for the Treatment of Anemia of Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001154-86,0,0,0 2004-001155-11,1,,,0,1,0,0,0,3,2,0,0,1,0,0,0,1,1,"OSI Pharmaceuticals, Inc.","A Randomized, Open Label, Phase II Study of OSI-7904L versus 5-FU/LV as First-Line Treatment in Patients with Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001155-11,0,0,0 2004-001156-37,2,2010-09-02,2010-09-02,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,University of Oxford,Study of Heart and Renal Protection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001156-37,0,0,0 2004-001159-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. CARLO,A randomized phase II study of oxaliplatin and capecitabine combination vs irinotecan and capecitabine combination for the treatment of elderly patients with advanced colorectal cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001159-12,0,0,0 2004-001162-40,6,2006-10-20,2006-10-20,4,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Eisai Ltd,"An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001162-40,0,0,0 2004-001162-40,6,2006-10-20,2006-10-20,4,1,0,0,0,2,2,0,0,1,0,0,1,0,1,EISAI LTD UK,"An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001162-40,0,0,0 2004-001164-41,1,2006-07-24,2006-07-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Beaufour Ipsen Pharma,"AN EXPLORATORY, OPEN, TWO-ARM, MATCH-CONTROL, RANDOMISED AND STRATIFIED PILOT PHASE II STUDY ASSESSING THE PREVENTION OF THE ADVERSE EFFECTS OF LONG-TERM HIGH-DOSE GLUCOCORTICOID THERAPY BY GROWTH HOR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001164-41,0,0,0 2004-001168-28,4,2007-11-20,2007-11-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 12-month, double-blind, double-dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2x160/4.5μg bid and 2x80/4.5 μg bid compared to Formoterol TBH 2x4.5μg bid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001168-28,0,0,0 2004-001173-26,2,2009-01-06,2009-01-06,2,1,0,0,1,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, double-blind, randomized study to assess the consistency of the immunogenicity of three consecutive production lots of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine administered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001173-26,0,0,0 2004-001174-25,1,2010-11-16,2010-11-16,1,0,0,0,0,3,2,0,1,1,0,0,1,0,1,Neurocure Ltd,"A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF A COMBINATION OF GALANTAMINE (AN ACETYLCHOLINESTERASE INHIBITOR) PLUS TRIMIPRAMINE IN SMOKING CESSATION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001174-25,0,0,0 2004-001175-19,4,2006-08-10,2006-10-08,3,1,0,0,0,0,3,0,1,1,0,0,1,0,2,GLAXO SMITHKLINE,"A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals' oral live attenuated...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001175-19,0,0,0 2004-001175-19,4,2006-08-10,2006-10-08,3,1,0,0,0,0,3,0,1,1,0,0,1,0,2,GlaxoSmithKline,"A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals' oral live attenuated...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001175-19,0,0,0 2004-001175-19,4,2006-08-10,2006-10-08,3,1,0,0,0,0,3,0,1,1,0,0,1,0,2,GlaxoSmithKline S.A.,"A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals' oral live attenuated...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001175-19,0,0,0 2004-001177-25,1,2006-08-28,2006-08-28,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Schering-Plough CE AG Hungarian Commercial Representative Office,Cardiac safety profile of Caelyx therapy in anthracyclin pretreated metastatic breast cancer patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001177-25,0,0,0 2004-001178-13,3,2006-04-20,2006-10-18,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Janssen-Cilag, div.Johnson and Johnson s.r.o.",An International Single-Arm Protocol to Provide Expanded Access to VELCADE(TM) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and are Refractory to or Have...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001178-13,0,0,0 2004-001178-13,3,2006-04-20,2006-10-18,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Janssen Cilag International NV,An International Single-Arm Protocol to Provide Expanded Access to VELCADE(TM) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and are Refractory to or Have...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001178-13,0,0,0 2004-001178-13,3,2006-04-20,2006-10-18,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Janssen Cilag International N.V.,An International Single-Arm Protocol to Provide Expanded Access to VELCADE(TM) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and are Refractory to or Have...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001178-13,0,0,0 2004-001179-21,2,2008-02-29,2008-02-29,2,0,0,0,0,0,2,0,0,1,1,0,1,0,1,MannKind Corporation,"A Four Year, Safety and Tolerability, Open-Label, 'Follow On' Trial Evaluating Technosphere®/Insulin in Subjects with Type 2 Diabetes Mellitus.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001179-21,0,0,0 2004-001181-41,4,2007-02-07,2007-02-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Prospective, Multicenter, Open-Label Study of Aripiprazole in the Management of Patients with Schizophrenia in General Psychiatric Practices",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001181-41,0,0,0 2004-001182-18,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GlaxoSmithKline R & D Limited,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunct...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001182-18,0,0,0 2004-001183-41,1,2007-01-03,2007-01-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 6-month, double-blind, double-dummy, randomised, parallel group, multicenter, efficacy and safety study of Symbicort® pMDI 2x160/4.5μg and 2x80/4.5μg bid compared to Formoterol Turbuhaler, Budesoni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001183-41,0,0,0 2004-001186-17,6,2007-12-13,2008-05-16,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,CSL Behring GmbH,Human pasteurized C1 esterase inhibitor concentrate (CE1145) in subjects with congenital C1-INH deficiency and acute abdominal or facial HAE attacks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001186-17,0,0,0 2004-001186-17,6,2007-12-13,2008-05-16,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ZLB Behring GmbH,Human pasteurized C1 esterase inhibitor concentrate (CE1145) in subjects with congenital C1-INH deficiency and acute abdominal or facial HAE attacks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001186-17,0,0,0 2004-001187-52,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,3,Axonyx Corporation,"A Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Two Different Dosages of Phenserine-tartrate in Patients with Mild to Moderate Probable Alzheimer’s Disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001187-52,0,0,0 2004-001190-25,6,2006-02-09,2006-03-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Pfizer Ltd.,"A Double-blind, Proof of Concept Trial of the Use of Pegvisomant to Reduce Urinary Albumin Excretion in Type 1 and Type 2 Diabetic Patients Treated with Angiotensin Convertase Inhibitors/Angiotensin R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001190-25,0,0,0 2004-001190-25,6,2006-02-09,2006-03-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Pfizer, S.A.","A Double-blind, Proof of Concept Trial of the Use of Pegvisomant to Reduce Urinary Albumin Excretion in Type 1 and Type 2 Diabetic Patients Treated with Angiotensin Convertase Inhibitors/Angiotensin R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001190-25,0,0,0 2004-001190-25,6,2006-02-09,2006-03-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Pfizer Ltd,"A Double-blind, Proof of Concept Trial of the Use of Pegvisomant to Reduce Urinary Albumin Excretion in Type 1 and Type 2 Diabetic Patients Treated with Angiotensin Convertase Inhibitors/Angiotensin R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001190-25,0,0,0 2004-001190-25,6,2006-02-09,2006-03-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Pfizer ApS,"A Double-blind, Proof of Concept Trial of the Use of Pegvisomant to Reduce Urinary Albumin Excretion in Type 1 and Type 2 Diabetic Patients Treated with Angiotensin Convertase Inhibitors/Angiotensin R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001190-25,0,0,0 2004-001190-25,6,2006-02-09,2006-03-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Pfizer Pharma GmbH,"A Double-blind, Proof of Concept Trial of the Use of Pegvisomant to Reduce Urinary Albumin Excretion in Type 1 and Type 2 Diabetic Patients Treated with Angiotensin Convertase Inhibitors/Angiotensin R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001190-25,0,0,0 2004-001197-10,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharmaceuticals Corporation,"A double-blind, randomized, multi-center active-controlled, parallel-group study comparing the combination of valsartan 320 mg plus hydrochlorothiazide 12.5 mg and valsartan 320 mg plus hydrochloroth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001197-10,0,0,0 2004-001199-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,(GOTEL) Grupo Oncológico para el tratamiento y estudio de los linfomas,"A Phase II, Single Arm, Open label Study of Cyclophosphamide, Vincristine, Liposomal Doxorubicine (Myocet™) and Prednisone plus Rituximab in Fortnightly Regimen (R-COMP-14), as First Line of therapy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001199-37,0,0,0 2004-001200-12,5,2007-07-23,2007-07-24,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer,S.A.",LINEZOLID IN THE TREATMENT OF SUBJECTS WITH COMPLICATED SKIN AND SOFT TISSUE INFECTIONS PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001200-12,0,0,0 2004-001200-12,5,2007-07-23,2007-07-24,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Limited,LINEZOLID IN THE TREATMENT OF SUBJECTS WITH COMPLICATED SKIN AND SOFT TISSUE INFECTIONS PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001200-12,0,0,0 2004-001200-12,5,2007-07-23,2007-07-24,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Global Research and Development,LINEZOLID IN THE TREATMENT OF SUBJECTS WITH COMPLICATED SKIN AND SOFT TISSUE INFECTIONS PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001200-12,0,0,0 2004-001200-12,5,2007-07-23,2007-07-24,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,PFIZER,LINEZOLID IN THE TREATMENT OF SUBJECTS WITH COMPLICATED SKIN AND SOFT TISSUE INFECTIONS PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001200-12,0,0,0 2004-001201-10,2,2005-04-24,2005-04-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG,Comparison of transdermal fentanyl PCA and IV morphine PCA in the management of post-operative pain control.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001201-10,0,0,0 2004-001201-10,2,2005-04-24,2005-04-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag EMEA Medical Affairs,Comparison of transdermal fentanyl PCA and IV morphine PCA in the management of post-operative pain control.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001201-10,0,0,0 2004-001205-99,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,3,FUJISAWA,"AN OPEN, MULTICENTRE, RANDOMISED, PARALLEL GROUP STUDY TO COMPARE IN MARGINAL OLD-FOR-OLD RENAL TRANSPLANT PATIENTS THE SAFETY AND EFFICACY OF TWO TREATMENTS: SEQUENTIAL MYCOPHENOLATE MOFETIL / DELAY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001205-99,0,0,0 2004-001210-13,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Bracco Imaging S.p.A,MS-CTA IN PULMONARY ARTERIES FOR THE DETECTION OF PULMONARY EMBOLI AND SUBSEQUENT FOLLOW-UP MS-CTP OF THE LOWER EXTREMITY VEINS FOR THE DETECTION OF DEEP VENOUS THROMBOSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001210-13,0,0,0 2004-001213-34,3,2008-05-08,2008-05-08,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, double-dummy, randomized, multicentre study to compare the efficacy and safety of oral budesonide (9 mg) and oral mesalazine (4.5 g) in moderately active Crohn’s disease patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001213-34,0,0,0 2004-001216-31,8,2006-06-15,2006-06-15,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, double-dummy, randomised, multicentre, comparative study of the efficacy and tolerability of once daily 3.0 g mesalazine granules versus three times daily 1.0 g mesalazine granules in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001216-31,0,0,0 2004-001218-15,7,2007-04-27,2007-04-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, double-dummy, randomised, multicentre, 12-months, comparative study of the efficacy and tolerability of once daily 3.0 g mesalazine granules versus once daily 1.5 g mesalazine granules v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001218-15,0,0,0 2004-001220-20,5,2008-06-23,2008-06-23,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Integrated Therapeutics Group, Incorporated - a subsidiary of Schering-Plough",Efficacy and Safety of PEG-Intron plus Rebetol in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001220-20,0,0,0 2004-001220-20,5,2008-06-23,2008-06-23,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SCHERING-PLOUGH,Efficacy and Safety of PEG-Intron plus Rebetol in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001220-20,0,0,0 2004-001220-20,5,2008-06-23,2008-06-23,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Integrated Therapeutics Group, Incorporated- a subsidiary of Schering Plough",Efficacy and Safety of PEG-Intron plus Rebetol in Subjects with Chronic Hepatitis C Genotype 1 Non Responder to Pegasys,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001220-20,0,0,0 2004-001222-25,1,2007-01-09,2007-01-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Procter and Gamble Pharmaceuticals,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, 52-week Study to Evaluate the Efficacy ans Safety of Transdermal Patches Delivering 150 or 300 microgram/day Testosterone i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001222-25,0,0,0 2004-001223-37,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,GlaxoSmithKline S.A.,"Ensayo clínico abierto en fase IV, para evaluar la inmunogenicidad y reactogenicidad de la vacuna combinada DTPa (Infanrix) de GlaxoSmithKline Biologicals administrada como dosis de recuerdo a los 4 a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001223-37,0,0,0 2004-001224-21,3,2006-10-23,2006-10-23,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A 24 week, open label single arm study to evaluate the safety and efficacy of switching a toxicity causing antiretroviral ARV to enfuvirtide ENF and to assess resolution or improvement of ARV toxic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001224-21,0,0,0 2004-001224-21,3,2006-10-23,2006-10-23,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ROCHE,"A 24 week, open label single arm study to evaluate the safety and efficacy of switching a toxicity causing antiretroviral ARV to enfuvirtide ENF and to assess resolution or improvement of ARV toxic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001224-21,0,0,0 2004-001225-16,1,2005-08-11,2005-08-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Orion Pharma,"Survival of patients with acute heart failure in need of intravenous inotropic support; a multicentre parallel- group, randomised, double- blind, double- dummy study of levosimendan versus dobutamine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001225-16,0,0,0 2004-001234-17,12,2009-04-28,2009-05-11,10,1,0,0,0,0,4,0,0,2,0,0,0,0,2,,"Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001234-17,1,0,0 2004-001234-17,12,2009-04-28,2009-05-11,10,1,0,0,0,0,4,0,0,2,0,0,0,0,2,Pfizer Healthcare Ireland,"Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001234-17,1,0,0 2004-001234-17,12,2009-04-28,2009-05-11,10,1,0,0,0,0,4,0,0,2,0,0,0,0,2,Pfizer Hellas,"Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001234-17,1,0,0 2004-001234-17,12,2009-04-28,2009-05-11,10,1,0,0,0,0,4,0,0,2,0,0,0,0,2,Pfizer Inc.,"Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001234-17,1,0,0 2004-001234-17,12,2009-04-28,2009-05-11,10,1,0,0,0,0,4,0,0,2,0,0,0,0,2,Pfizer Limited,"Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001234-17,1,0,0 2004-001234-17,12,2009-04-28,2009-05-11,10,1,0,0,0,0,4,0,0,2,0,0,0,0,2,Pfizer AB,"Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001234-17,1,0,0 2004-001234-17,12,2009-04-28,2009-05-11,10,1,0,0,0,0,4,0,0,2,0,0,0,0,2,Pfizer SA/NV,"Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001234-17,1,0,0 2004-001234-17,12,2009-04-28,2009-05-11,10,1,0,0,0,0,4,0,0,2,0,0,0,0,2,"Laboratórios Pfizer, Lda","Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001234-17,1,0,0 2004-001234-17,12,2009-04-28,2009-05-11,10,1,0,0,0,0,4,0,0,2,0,0,0,0,2,Pfizer Inc. New York,"Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001234-17,1,0,0 2004-001234-17,12,2009-04-28,2009-05-11,10,1,0,0,0,0,4,0,0,2,0,0,0,0,2,Pfizer Pharma GmbH,"Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001234-17,1,0,0 2004-001234-17,12,2009-04-28,2009-05-11,10,1,0,0,0,0,4,0,0,2,0,0,0,0,2,"Pfizer, S.A.","Double-blind, triple dummy, parallel-group, randomized, six-month study to compare celecoxib (200 mg BID) with diclofenac SR (75 mg BID) plus omeprazole (20 mg QD) for gastrointestinal events in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001234-17,1,0,0 2004-001236-23,12,2007-04-30,2007-04-30,9,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Serono International S.A.,"A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001236-23,0,0,0 2004-001236-23,12,2007-04-30,2007-04-30,9,1,0,0,0,0,0,0,0,1,0,0,1,0,1,SERONO INTERNATIONAL SA,"A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001236-23,0,0,0 2004-001237-42,1,2006-08-25,2006-08-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,Open-Label Duloxetine Extension phase in Patients Who Have Completed the F1J-MC-HMDG Clinical Trial Fase de extensión abierta con duloxetina en aquellos pacientes que hayan finalizado el ensayo clíni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001237-42,0,0,0 2004-001239-42,1,2007-03-30,2007-03-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"RE&D VÚFB, s.r.o.",Evaluation of tolerance of preparation KETOPROFEN HBF GEL 2.5% (Herbacos-bofarma) and its comparison with preparation PROFENID GEL (Laboratoires Aventis) in patients with benign joint injury.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001239-42,0,0,0 2004-001241-14,4,2006-02-14,2006-03-14,4,1,0,0,2,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Dermatologie,Efficacy of the topic RV3131A-HC3221 IN THE PREVENTION OF POLYMORPHIC LIGHT ERUPTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001241-14,0,0,0 2004-001241-14,4,2006-02-14,2006-03-14,4,1,0,0,2,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE DERMATOLOGIE,Efficacy of the topic RV3131A-HC3221 IN THE PREVENTION OF POLYMORPHIC LIGHT ERUPTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001241-14,0,0,0 2004-001241-14,4,2006-02-14,2006-03-14,4,1,0,0,2,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Dermatologie represented by Institut de Recherche Pierre Fabre,Efficacy of the topic RV3131A-HC3221 IN THE PREVENTION OF POLYMORPHIC LIGHT ERUPTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001241-14,0,0,0 2004-001243-30,5,2006-11-30,2006-12-13,4,0,0,0,0,0,0,0,0,1,0,0,1,0,1,Apogepha Arzneimittel GmbH,"Propiverine hydrochloride in children suffering from overactive bladder and urinary incontinence A randomised, double-blind, placebo-controlled, parallel grouped, multicentre clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001243-30,0,0,0 2004-001243-30,5,2006-11-30,2006-12-13,4,0,0,0,0,0,0,0,0,1,0,0,1,0,1,APOGEPHA Arzneimittel GmbH,"Propiverine hydrochloride in children suffering from overactive bladder and urinary incontinence A randomised, double-blind, placebo-controlled, parallel grouped, multicentre clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001243-30,0,0,0 2004-001246-33,4,2007-10-16,2009-03-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Limited Ireland,An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201 or TMC114-C207.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001246-33,0,0,0 2004-001246-33,4,2007-10-16,2009-03-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Ltd. Ireland,An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201 or TMC114-C207.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001246-33,0,0,0 2004-001246-33,4,2007-10-16,2009-03-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,An open label trial of TMC114/RTV in HIV-1 infected subjects who were randomized in the trials TMC114-C201 or TMC114-C207.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001246-33,0,0,0 2004-001249-14,1,2005-03-17,2005-03-17,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline,"A Phase III open, multicentre, booster vaccination study to assess the immunogenicity, safety and reactogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals’ Haemophilus influenzae type b-m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001249-14,0,0,0 2004-001250-91,5,2006-05-09,2007-04-17,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"GenVec, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of BIOBYPASS® (ADGVVEGF121.10NH) Delivered by NOGA-Guided/MYOSTAR Catheter in ""No Option"" Patients with Class ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001250-91,0,0,0 2004-001252-36,3,2006-06-16,2007-03-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmazeutici SpA,"DOUBLE BLIND, PARALLEL GROUP, MULTICENTRE STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF CHF 1521 (FIXED COMBINATION OF MANIDIPINE AND DELAPRIL) VS LOSARTAN 50 MG AND HYDROCHLOROTHIAZIDE 12.5 MG I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001252-36,0,0,0 2004-001252-36,3,2006-06-16,2007-03-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici SpA,"DOUBLE BLIND, PARALLEL GROUP, MULTICENTRE STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF CHF 1521 (FIXED COMBINATION OF MANIDIPINE AND DELAPRIL) VS LOSARTAN 50 MG AND HYDROCHLOROTHIAZIDE 12.5 MG I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001252-36,0,0,0 2004-001252-36,3,2006-06-16,2007-03-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CHIESI,"DOUBLE BLIND, PARALLEL GROUP, MULTICENTRE STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF CHF 1521 (FIXED COMBINATION OF MANIDIPINE AND DELAPRIL) VS LOSARTAN 50 MG AND HYDROCHLOROTHIAZIDE 12.5 MG I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001252-36,0,0,0 2004-001253-29,1,2007-03-16,2007-03-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PharmaMar SAU,"Clinical and pharmacokinetic phase II study of one hour infusion of kahalalide F administered every week to patients with Non Small Cell Lung Cancer Stage IIIB with pleural effusion and stage IV, afte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001253-29,0,0,0 2004-001258-94,4,2007-05-11,2007-05-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Ltd,"A One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin Exubera on Glycemic Control in Patients with Type 2 Diabetes Mellitus Who Are Poor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001258-94,0,0,0 2004-001258-94,4,2007-05-11,2007-05-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin Exubera on Glycemic Control in Patients with Type 2 Diabetes Mellitus Who Are Poor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001258-94,0,0,0 2004-001258-94,4,2007-05-11,2007-05-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER,"A One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin Exubera on Glycemic Control in Patients with Type 2 Diabetes Mellitus Who Are Poor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001258-94,0,0,0 2004-001258-94,4,2007-05-11,2007-05-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"PFIZER, S.A.","A One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin Exubera on Glycemic Control in Patients with Type 2 Diabetes Mellitus Who Are Poor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001258-94,0,0,0 2004-001261-17,1,,,0,0,0,0,0,3,3,0,0,1,0,0,0,1,1,InterMune,An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001261-17,0,0,0 2004-001262-40,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Investigador del estudio: Dr. Agustín Alomar Muntañola,Tratamiento de los hemangiomas de la infancia con imiquimod tópico al 5%,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001262-40,0,0,0 2004-001263-22,1,2007-04-30,2007-04-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,YM Biosciences Inc,A Phase III study of DPPE (Temilifene) combined with Epirubicin and Cyclophosphamide versus Epirubicin and Cyclophosphamide alone as First – line Treatment in Metastatic/Recurrent Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001263-22,0,0,0 2004-001264-45,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,H. Lundbeck A/S,"Protocol title study No. 10402: A 12-month Phase III safety study of gaboxadol 10 mg daily consisting of a 6-month double-blind, randomised, placebo-controlled, parallel-group periodfollowed by a 6-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001264-45,0,0,0 2004-001265-18,1,,,0,1,0,0,1,0,3,0,0,1,0,0,0,1,1,H. Lundbeck A/S,"Protocol title No.10403: A double-blind, randomised, placebo-controlled, parallel-group, Phase III study evaluating the efficacy and safety of gaboxadol 5 mg and 10 mg daily in elderly outpatients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001265-18,0,0,0 2004-001270-77,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Equipo de doctores: Dr. Amado Andrés y Dr. Manuel Praga,Estudio piloto para evaluar la eficacia y seguridad de Valsartán para el control de la progresión de la insuficiencia renal y la morbimortalidad cardiovascular en pacientes con trasplante renal funcio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001270-77,0,0,0 2004-001272-39,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,"GP-PHARM, S.A.","Estudio multicéntrico, prospectivo, abierto, no controlado en pacientes con edad igual o superior a 65 años para evaluar la eficacia y seguridad de Doxorubicina liposomal (Doxorubicina GP-Pharm) en pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001272-39,0,0,0 2004-001273-26,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,"NOVARTIS FARMACEUTICA, S.A","A 3 weeks study randomized, multicenter, double blind, vehicle controlled , parallel-group to evaluate the efficacy and safety of Pimecrolimus cream 1% in children between 2 – 11 years with mild to mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001273-26,0,0,0 2004-001277-25,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,"A Phase III, Multicentre, Double Blinded Study In Patients With Chronic Hepatitis C Who Are Non-Responders To Prior Peginterferon Alpha + Ribavirin Therapy Comparing Treatment With Thymosin Alpha 1 + ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001277-25,0,0,0 2004-001277-25,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SIGMA-TAU,"A Phase III, Multicentre, Double Blinded Study In Patients With Chronic Hepatitis C Who Are Non-Responders To Prior Peginterferon Alpha + Ribavirin Therapy Comparing Treatment With Thymosin Alpha 1 + ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001277-25,0,0,0 2004-001281-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Gottfries Clinic,Long-term study with the staphylococcus vaccine Staphypan in treatment of patients with fibromyalgia and chronic fatigue syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001281-40,0,0,0 2004-001285-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Ghent,"Wat is de ideale concentratie van Ropivacaine bij Sufenta 0,75 microgram/ml voor Thoracale Epidurale?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001285-40,0,0,0 2004-001286-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Española de Esclerosis Múltiple (FEDEM),Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantrone in patients under treatment with high dose interferon-beta-1a for relapsing-remitting or relapsing secondary progresive ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001286-17,0,0,0 2004-001287-49,6,2007-10-25,2008-01-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AVENTIS PHARMA S.P.A.,"52-week, open, randomized, multinational, multicenter clinical trial comparing insulin glulisine in combination with insulin glargine in an intensified insulin regimen to a two-injection conventional ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001287-49,0,0,0 2004-001287-49,6,2007-10-25,2008-01-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Deutschland GmbH,"52-week, open, randomized, multinational, multicenter clinical trial comparing insulin glulisine in combination with insulin glargine in an intensified insulin regimen to a two-injection conventional ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001287-49,0,0,0 2004-001287-49,6,2007-10-25,2008-01-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Aventis Pharma Deutschland GmbH,"52-week, open, randomized, multinational, multicenter clinical trial comparing insulin glulisine in combination with insulin glargine in an intensified insulin regimen to a two-injection conventional ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001287-49,0,0,0 2004-001287-49,6,2007-10-25,2008-01-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi Aventis Deutschland GmbH,"52-week, open, randomized, multinational, multicenter clinical trial comparing insulin glulisine in combination with insulin glargine in an intensified insulin regimen to a two-injection conventional ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001287-49,0,0,0 2004-001290-25,4,2011-12-31,2011-12-31,4,0,0,0,0,1,3,0,0,1,0,0,1,0,0,"Prof Allan Glanville, St Vincents Hospital",": Estudio multicéntrico, abierto, aleatorizado, de 3 años de seguimiento, que compara micofenolato sódico con recubrimiento entérico de novo con everolimus de inicio retrasado, ambos grupos en combina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001290-25,0,0,0 2004-001290-25,4,2011-12-31,2011-12-31,4,0,0,0,0,1,3,0,0,1,0,0,1,0,0,Hospital Vall d Hebron,": Estudio multicéntrico, abierto, aleatorizado, de 3 años de seguimiento, que compara micofenolato sódico con recubrimiento entérico de novo con everolimus de inicio retrasado, ambos grupos en combina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001290-25,0,0,0 2004-001290-25,4,2011-12-31,2011-12-31,4,0,0,0,0,1,3,0,0,1,0,0,1,0,0,St Vincent's Hospital,": Estudio multicéntrico, abierto, aleatorizado, de 3 años de seguimiento, que compara micofenolato sódico con recubrimiento entérico de novo con everolimus de inicio retrasado, ambos grupos en combina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001290-25,0,0,0 2004-001290-25,4,2011-12-31,2011-12-31,4,0,0,0,0,1,3,0,0,1,0,0,1,0,0,"St Vincent’s Hospital, Sydney, Australia",": Estudio multicéntrico, abierto, aleatorizado, de 3 años de seguimiento, que compara micofenolato sódico con recubrimiento entérico de novo con everolimus de inicio retrasado, ambos grupos en combina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001290-25,0,0,0 2004-001298-24,1,2005-12-08,2005-12-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001298-24,0,0,0 2004-001299-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Metabolism and Nutrition Group of the SEMICYUC,"Study prospective, multicenter, randomized, comparative, double blind, to evaluate two different lipidic emulsions in the total parenteral nutrition of the critic patient and their influence in the no...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001299-38,0,0,0 2004-001301-10,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,PFIZER,"A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED, DOSE-RANGING, MULTI-CENTER TRIAL TO ASSESS THE EFFECT OF PEGAPTANIB SODIUM ON FOVEAL THICKENING IN PATIENTS WITH EXUDATIVE SUBFOVEAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001301-10,0,0,0 2004-001302-27,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,UCB S.A. Pharma Sector,"An 8-week exploratory, double-blind, placebo controlled, randomized trial : Evaluation of the efficacy and safety of levetiracetam up to 3000 mg/day (250-500 mg oral tablets in b.i.d. administration) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001302-27,0,0,0 2004-001307-35,1,2009-05-12,2009-05-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Ferring Arzneimittel GmbH,"A prospective, open label, randomised, parallel group, comparative pilot study to study the efficacy and safety of highly purified Menotrophin versus recombinant FSH (Follitropin alfa) administered su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001307-35,0,0,0 2004-001308-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Lilly.S.A.,"Optimal Treatment Duration with Olanzapine following Remission of Manic or Mixed Episode. An Open-Label, Randomized Trial Comparing Two Treatment Strategies ?Duración óptima del tratamiento con O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001308-11,0,0,0 2004-001316-31,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,"ALK-ABELLO, S.A.",TOLERABILIDAD DE LAS VACUNAS ALERGÉNICAS VALORADAS EN UNIDADES DE MASA Y ADMINISTRADAS POR VÍA SUBLINGUAL. ESTUDIO RANDOMIZADO DOBLE CIEGO CONTROLADO CON PLACEBO EN PACIENTES CON ENFERMEDAD ALÉRGICA R...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001316-31,0,0,0 2004-001317-34,9,2006-05-12,2006-06-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001317-34,0,0,0 2004-001317-34,9,2006-05-12,2006-06-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001317-34,0,0,0 2004-001317-34,9,2006-05-12,2006-06-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Denmark A/S,"A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001317-34,0,0,0 2004-001317-34,9,2006-05-12,2006-06-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,"A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001317-34,0,0,0 2004-001317-34,9,2006-05-12,2006-06-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Austria GmbH,"A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001317-34,0,0,0 2004-001317-34,9,2006-05-12,2006-06-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer-Ingelheim AB,"A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001317-34,0,0,0 2004-001317-34,9,2006-05-12,2006-06-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001317-34,0,0,0 2004-001317-34,9,2006-05-12,2006-06-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001317-34,0,0,0 2004-001319-71,1,2007-05-08,2007-05-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,A Phase IIIb Study to Determine Efficacy and Safety of Extended Drotrecogin Alfa (Activated) Therapy in Patients With Persistent Requirement for Vasopressor Support After 96-Hour Infusion With Commerc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001319-71,0,0,0 2004-001321-25,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,WYETH LEDERLE,"A prospective, open label, monocenter trial to evaluate the interaction between the Platelia Aspergillus ELISA test and the administration of piperacillin/tazobactam.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001321-25,0,0,0 2004-001323-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,H. 12 de Octubre,"Phase IV-III, open-label, randomized, comparative study, to evaluate the safety and efficacy of the nucleoside supression of a triple therapy based on lopinavir-ritonavir vs. continuous triple therapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001323-37,0,0,0 2004-001323-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,H. La Paz.,"Phase IV-III, open-label, randomized, comparative study, to evaluate the safety and efficacy of the nucleoside supression of a triple therapy based on lopinavir-ritonavir vs. continuous triple therapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001323-37,0,0,0 2004-001325-14,1,2009-11-26,2009-11-26,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline SA,"Estudio en fase III, doble ciego, aleatorizado, controlado, multicéntrico para evaluar la eficacia de la vacuna HPV-16/18 VLP/AS04 de GlaxoSmithKline Biologicals comparada con la vacuna antihepatitis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001325-14,0,0,0 2004-001330-16,1,2007-03-05,2007-03-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,3,Sanofi-Synthélabo Recherche,"Estudio de Fase II, aleatorizado, multicéntrico, doble ciego y controlado con placebo, del efecto de SR57667B sobre la función dopaminérgica nigro-estriada, evaluado mediante imágenes PET 18F-Dopa en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001330-16,0,0,0 2004-001331-36,2,2009-12-02,2009-12-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,A randomized phase III study of follow up with or without adjuvant Gefitinib (IressaTM) following chemotherapy in patients with advanced non-small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001331-36,0,0,0 2004-001331-36,2,2009-12-02,2009-12-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,A randomized phase III study of follow up with or without adjuvant Gefitinib (IressaTM) following chemotherapy in patients with advanced non-small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001331-36,0,0,0 2004-001332-23,1,2005-11-04,2005-11-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,Phase II Study with Gefitinib (sequentially) following Gemcitabine/Cisplatin as induction regimen for patients with stage IIIA N2 NSCLC.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001332-23,0,0,0 2004-001336-22,1,2006-11-08,2006-11-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Axonyx Inc.,"Effect of Phenserine Treatment on Amyloid in Brains of Patients with Mild Probable Alzheimer’s Disease as studied by Positron Emission Tomography (PET). A Randomised, three Months Double-Blind, Placeb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001336-22,0,0,0 2004-001339-41,14,2007-10-13,2007-10-31,9,1,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB S.A. Pharma Sector,"A therapeutic confirmatory, open-label, multi-center, randomized 2 parallel groups, community-based trial studying the efficacy and safety of levetiracetam 1000 to 3000 mg/day oral tablets 250-500 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001339-41,1,0,0 2004-001339-41,14,2007-10-13,2007-10-31,9,1,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB S.A. (Pharma Sector),"A therapeutic confirmatory, open-label, multi-center, randomized 2 parallel groups, community-based trial studying the efficacy and safety of levetiracetam 1000 to 3000 mg/day oral tablets 250-500 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001339-41,1,0,0 2004-001339-41,14,2007-10-13,2007-10-31,9,1,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB Pharma S.A.,"A therapeutic confirmatory, open-label, multi-center, randomized 2 parallel groups, community-based trial studying the efficacy and safety of levetiracetam 1000 to 3000 mg/day oral tablets 250-500 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001339-41,1,0,0 2004-001339-41,14,2007-10-13,2007-10-31,9,1,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB PHARMA,"A therapeutic confirmatory, open-label, multi-center, randomized 2 parallel groups, community-based trial studying the efficacy and safety of levetiracetam 1000 to 3000 mg/day oral tablets 250-500 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001339-41,1,0,0 2004-001341-14,6,2005-07-18,2005-07-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Controlled, Double-Blind, Randomized, Dose-ranging Study of once-daily regimen of BAY59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement-ODIXa-OD.HIP Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001341-14,0,0,0 2004-001341-14,6,2005-07-18,2005-07-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BAYER,"Controlled, Double-Blind, Randomized, Dose-ranging Study of once-daily regimen of BAY59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement-ODIXa-OD.HIP Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001341-14,0,0,0 2004-001346-33,2,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Gilead Sciences Inc.,"A Phase 3 Double-Blind Randomised, Placebo-Controlled Study of the safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents (Age 2to <18) with Chronic Hepatitis B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001346-33,0,1,0 2004-001346-33,2,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Gilead Sciences Inc,"A Phase 3 Double-Blind Randomised, Placebo-Controlled Study of the safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents (Age 2to <18) with Chronic Hepatitis B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001346-33,0,1,0 2004-001347-29,1,2009-05-07,2009-05-07,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,Odense University Hospital,"Treatment of patients with locally advanced rectal cancer. TEGAFOX (UFT/leukovorin og Oxaliplatin) before, during and after curatively intended radiotherapy. A Danish phase I/II trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001347-29,0,0,0 2004-001349-14,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"NeoPharm, Inc.",A Study Extension to Evaluate the Safety and Tolerability of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients that Completed Study LEP-ETU-102A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001349-14,0,0,0 2004-001356-37,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,Nordic Society for Gynecological Cancer,Phase I-II-III studies of Cisplatin and Combretastatin (CA4P) in recurrent or advanced servical cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001356-37,0,0,0 2004-001361-18,1,2006-08-22,2006-08-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma N.V.,Conversion trial from Cellcept® (MMF) to myfortic® (enteric-coated MPA) in stable transplanted patients suffering from GI adverse events while on Cellcept® therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001361-18,0,0,0 2004-001362-40,1,2008-05-05,2008-05-05,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,PHASE II STUDY OF IMATINIB MESYLATE IN CHORDOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001362-40,0,0,0 2004-001363-22,1,2007-08-10,2007-08-10,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Threshold Pharmaceuticals,A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001363-22,0,0,0 2004-001369-17,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Novartis Farmacéutica S.A.,"An open-label, randomized, multicenter study to evaluate the use of Zoledronic Acid in the prevention of cancer treatment-related bone loss in postmenopausal women with ER+ and/or PgR+ breast cancer r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001369-17,0,0,0 2004-001373-26,1,2007-10-16,2007-10-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Laboratorios Menarini, S.A","Multicentre clinical trial to evaluate the efficacy and safety of dexketoprofen trometamol (50 mg t.i.d.) versus ketorolac (30 mg t.i.d.) and placebo by intravenous route, as part of balanced analgesi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001373-26,0,0,0 2004-001374-34,2,2005-06-08,2005-06-08,1,1,0,0,1,0,3,0,1,1,1,0,1,0,1,Baxter Vaccine AG,SINGLE-BLIND RANDOMIZED CONTROLLED PHASE II/III STUDY TO INVESTIGATE THE IMMUNOGENICITY AND SAFETY AFTER A SINGLE VACCINATION WITH ONE OF THREE DIFFERENT LOTS OF AN INACTIVATED INFLUENZA VACCINE (WHOL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001374-34,0,0,0 2004-001376-39,3,2006-10-06,2006-10-15,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NV Organon,"Long-term efficacy and safety evaluation of asenapine (10-20 mg/day) in subjects with schizophrenia or schizoaffective disorder, in a multicenter trial using olanzapine (10-20 mg/day) as a control.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001376-39,0,0,0 2004-001378-19,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Pfizer AB,A two part study to a) investigate the reproducilibility of the vaginal photoplethysmograhpy (VPP) teqnique in healthy pre-menopausal volunteers and subjects suffering from Female Sexual Arousal Disor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001378-19,0,0,0 2004-001379-20,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Pfizer AB,A two part study to a) investigate the reproducibility of the vaginal photoplethysmography (VPP) technique in healthy post-menopausal volunteers and subjects suffering from Female Sexual Arousal Disor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001379-20,0,0,0 2004-001383-46,1,2007-07-31,2007-07-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Karolinska University Hospital, Huddinge",Swdeish Exelon Titration study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001383-46,0,0,0 2004-001388-23,4,2006-03-28,2006-05-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Baxter R&D Europe SCRL,A Study to Evaluate the Efficacy and Safety of Extraneal Physiological pH Compared with Current Extraneal in Patients Receiving Continuous Ambulatory Peritoneal Dialysis (CAPD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001388-23,0,0,0 2004-001390-26,4,2006-07-12,2006-08-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Baxter R&D Europe SCRL,A Subjective Evaluation of Inflow Pain: Comparison of Extraneal to Extraneal Physiological pH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001390-26,0,0,0 2004-001396-19,1,2008-10-23,2008-10-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"An extension to a phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive leukemia including acute lymphoblastic leukaemia, acute m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001396-19,0,0,0 2004-001397-92,1,2013-11-29,2013-11-29,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,An extension to a phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001397-92,0,0,0 2004-001403-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Doctor Pere Domingo,"Estudio abierto, multicéntrico y aleatorizado sobre la eficacia y seguridad de la reducción de dosis de estavudina en pacientes en tratamiento antirretroviral que incluye estavudina a dosis estándar c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001403-35,0,0,0 2004-001404-12,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,"Laboratorios Rubió, S.A.","Estudio prospectivo, aleatorizado, doble ciego, para la evaluación de la eficacia y seguridad del metilfenidato de liberación prolongada con respecto al metilfenidato de liberación inmediata y placebo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001404-12,0,0,0 2004-001405-10,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Lybar a.s.,"Randomized,double-blind, placebo- controlled trial Phase III to discover efficacy and safety of Diffusil H Forte spray containing carbaryl in patients with pediculosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001405-10,0,0,0 2004-001412-30,1,2006-05-20,2006-05-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Laboratoire Aventis,"An open-label, randomized, multicenter, clinical study to compare the effects of telithromycin, azithromycin and cefuroxime axetil on the penicillin or macrolide resistance of Streptococcus pneumoniae...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001412-30,0,0,0 2004-001413-34,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Bonaventura Clotet Sala,ESTUDIO DE UNA DOBLE ESTRATEGIA PARA INDUCIR Y EXPANDIR EL REPERTORIO DE CÉLULAS T BASADA EN LA ADMINISTRACIÓN DE HORMONA DE CRECIMIENTO Y VACUNA EN PACIENTES CON INFECCIÓN POR EL VIH 1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001413-34,0,0,0 2004-001417-33,8,2006-06-16,2006-08-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001417-33,0,0,0 2004-001417-33,8,2006-06-16,2006-08-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN,A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001417-33,0,0,0 2004-001426-24,1,2009-08-30,2009-08-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Prof. Heinz Ludwig, MD, Wilhelminenspital, First Department of Medicine and Medical Oncology","Multicenter, open, randomized study for first-line treatment of multiple myeloma: thalidomide/dexamethasone vs. MP for induction therapy and thalidomide/Intron A vs. Intron A for maintenance therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001426-24,0,0,0 2004-001430-16,6,2009-12-25,2011-01-04,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Wyeth Research, Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development","An Open-Label, Randomized, Phase 3 Trial of Intravenous Temsirolimus (CCI-779) at Two Dose Levels Compared to Investigator's Choice Therapy in Relapsed, Refractory Subjects with Mantle Cell Lymphoma (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001430-16,0,0,0 2004-001430-16,6,2009-12-25,2011-01-04,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Wyeth Research, Division of Wyeth Pharmaceuticals, Inc. (A Pfizer Company)","An Open-Label, Randomized, Phase 3 Trial of Intravenous Temsirolimus (CCI-779) at Two Dose Levels Compared to Investigator's Choice Therapy in Relapsed, Refractory Subjects with Mantle Cell Lymphoma (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001430-16,0,0,0 2004-001430-16,6,2009-12-25,2011-01-04,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,WYETH LEDERLE,"An Open-Label, Randomized, Phase 3 Trial of Intravenous Temsirolimus (CCI-779) at Two Dose Levels Compared to Investigator's Choice Therapy in Relapsed, Refractory Subjects with Mantle Cell Lymphoma (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001430-16,0,0,0 2004-001443-29,1,2006-02-02,2006-02-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Ipsen Pharma, S.A.","A multicentre, randomized, double-blind, parallel and controlled with placebo pilot study to evaluate the efficacy and safety of a single dose of botulinum toxin Type A (Dysport®) associated with reha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001443-29,0,0,0 2004-001449-13,2,2006-03-27,2006-05-31,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,BioGeneriX AG,Safety and Efficacy of XM 02 in patients with Non-Hodgkin-Lymphoma receiving chemotherapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001449-13,0,0,0 2004-001450-84,2,2006-04-19,2006-04-19,1,0,0,0,0,3,3,0,0,1,0,0,1,0,1,BioGeneriX,"Safety and Efficacy of XM 02 in patients with small cell or non small cell lung cancer receiving platinum-based chemotherapy. Multinational, multicentre, randomised, controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001450-84,0,0,0 2004-001452-36,2,2006-04-19,2006-04-19,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,BioGeneriX,"Efficacy and Safety of XM 02 compared to Filgrastim in patients with breast cancer receiving chemotherapy. Multinational, multicentre, randomised, controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001452-36,0,0,0 2004-001453-28,1,2007-10-15,2007-10-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"Open-label, Multicenter, Phase II Study Assessing the Safety of Lucentis (ranibizumab) Administered in Conjunction with Photodynamic Therapy with Visudyne in Patients with Occult or Predominantly Clas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001453-28,0,0,0 2004-001455-11,1,2008-11-26,2008-11-26,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Renovo Ltd,"A single centre, placebo and standard care controlled, double blind, randomised, trial to investigate the efficacy of eight doses of RN1003 in the reduction of scarring from approximated wound margins...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001455-11,0,0,0 2004-001456-36,1,2010-02-18,2010-02-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GLAXO SMITHKLINE,"A phase III, randomized, open-label, multicenter study comparing GW572016 and Capecitabile (Xeloda) versus Capecitabile in women with refractory advanced or metastatic breast cancer. Studio di fase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001456-36,0,0,0 2004-001457-28,2,2006-07-19,2006-07-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,2,Cell Therapeutics Europe S.r.l,Phase II open label study of CT-2106 as a single agent in patients with advanced metastatic ovarian cancer who have failed one prior platinum and taxane based regimen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001457-28,0,0,0 2004-001457-28,2,2006-07-19,2006-07-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,2,CELL THERAPEUTICS EUROPE,Phase II open label study of CT-2106 as a single agent in patients with advanced metastatic ovarian cancer who have failed one prior platinum and taxane based regimen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001457-28,0,0,0 2004-001458-10,1,2005-04-25,2005-04-25,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Renovo Ltd,"A single site, placebo and standard-care controlled, double blind, randomised trial to investigate the efficacy of four doses of RN1002 in accelerating early wound healing of punch biopsy wounds",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001458-10,0,0,0 2004-001460-42,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Aventis Intercontinental - Sanofi-aventis,"A prospective, randomized, open-label, active-controlled study in adult subjects with acute bacterial sinusitis comparing the clinical efficacy of telithromycin (KETEK®) 800 mg once a day for 5 days ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001460-42,0,0,0 2004-001461-18,2,2006-03-01,2006-03-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"A 20 week multi-national, open-labelled, randomised, three-group parallel trial comparing administration of insulin detemir morning, insulin detemir evening and NPH insulin evening as add-on to oral a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001461-18,0,0,0 2004-001461-18,2,2006-03-01,2006-03-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk AS,"A 20 week multi-national, open-labelled, randomised, three-group parallel trial comparing administration of insulin detemir morning, insulin detemir evening and NPH insulin evening as add-on to oral a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001461-18,0,0,0 2004-001467-22,2,2007-03-19,2007-03-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001467-22,0,0,0 2004-001467-22,2,2007-03-19,2007-03-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer S.A.,A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001467-22,0,0,0 2004-001469-16,3,2006-10-20,2006-10-20,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A double-blind, randomized, placebo-controlled, multi-centre, dose-ranging, parallel group, phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a thrombopoietin receptor ag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001469-16,0,0,0 2004-001469-16,3,2006-10-20,2006-10-20,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"GlaxoSmithKline,S.A.","A double-blind, randomized, placebo-controlled, multi-centre, dose-ranging, parallel group, phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a thrombopoietin receptor ag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001469-16,0,0,0 2004-001473-25,2,2014-02-14,2014-02-24,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals Corporation,A facilitated access program to provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001473-25,0,0,0 2004-001473-25,2,2014-02-14,2014-02-24,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A facilitated access program to provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001473-25,0,0,0 2004-001474-12,1,2008-02-27,2008-02-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Research and Innovation Services,"A Proof Of Concept Study to Investigate the Clinical, Histological And Molecular Predictors of Response to Oral and Intranasal Corticosteroid in Nasal Polyposis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001474-12,0,0,0 2004-001482-17,1,2006-12-13,2006-12-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company,Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar I disorder.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001482-17,0,0,0 2004-001483-51,7,2011-09-20,2012-09-20,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant CML in accelerated phase or blast crisis, rela...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001483-51,0,0,0 2004-001483-51,7,2011-09-20,2012-09-20,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant CML in accelerated phase or blast crisis, rela...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001483-51,0,0,0 2004-001483-51,7,2011-09-20,2012-09-20,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant CML in accelerated phase or blast crisis, rela...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001483-51,0,0,0 2004-001483-51,7,2011-09-20,2012-09-20,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant CML in accelerated phase or blast crisis, rela...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001483-51,0,0,0 2004-001485-41,3,,,0,0,0,0,0,3,4,0,0,2,1,0,0,0,0,Institute for Neurodegenerative Disorders,A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001485-41,0,0,0 2004-001487-43,1,2006-05-10,2006-05-10,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Norgine Ltd.,"A randomised, single-centre, single-blind,parallel group, pilot study to assess the efficacy, safety and patient acceptability of a new 2-litre bowel preparation agent (Moviprep) compared to a standar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001487-43,0,0,0 2004-001490-26,2,2007-03-30,2007-04-30,2,0,0,0,1,0,2,0,0,1,0,0,1,0,1,"CombinatoRx, Inc","A MULTI-CENTER, RANDOMIZED, BLINDED STUDY COMPARING THE EFFECT OF CRx-150 PLUS DMARD THERAPY TO THAT OF PLACEBO PLUS DMARD THERAPY ON SERUM C-REACTIVE PROTEIN (CRP) AND CYTOKINES IN SUBJECTS WITH RHEU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001490-26,0,0,0 2004-001491-39,5,2005-12-20,2006-04-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Fujisawa Healthcare, Inc","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN AS ANTIFUNGAL TREATMENT IN PATIENTS WITH INVASIVE CANDIDIASIS OR CANDIDEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001491-39,0,0,0 2004-001491-39,5,2005-12-20,2006-04-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Astellas Pharma US, Inc.","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN AS ANTIFUNGAL TREATMENT IN PATIENTS WITH INVASIVE CANDIDIASIS OR CANDIDEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001491-39,0,0,0 2004-001496-20,4,2010-04-01,2010-04-01,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,University College London,A randomised phase II pilot trial of carboplatin compared to docetaxel for patients with metastatic genetic breast cancer. Ensayo piloto randomizado en fase II que compara carboplatino y docetaxel en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001496-20,1,0,0 2004-001496-20,4,2010-04-01,2010-04-01,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,"University College London, UK",A randomised phase II pilot trial of carboplatin compared to docetaxel for patients with metastatic genetic breast cancer. Ensayo piloto randomizado en fase II que compara carboplatino y docetaxel en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001496-20,1,0,0 2004-001497-13,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,PFIZER,"A RANDOMIZED, OPEN LABEL, TRIAL OF THE PHARMACOKINETICS OF AZITHROMYCIN IN SERUM, BRONCHIAL WASHINGS AND LUNG TISSUE FOLLOWING A SINGLE DOSE OF NEW FORMULATION AZITHROMYCIN MICROSPHERES (2 GRAM) OR CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001497-13,0,0,0 2004-001500-13,5,2005-11-14,2006-11-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Ltd.,"An 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the Acute Treatment of DSM-IV Generalize...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001500-13,0,0,0 2004-001500-13,5,2005-11-14,2006-11-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer AB,"An 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the Acute Treatment of DSM-IV Generalize...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001500-13,0,0,0 2004-001500-13,5,2005-11-14,2006-11-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER,"An 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the Acute Treatment of DSM-IV Generalize...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001500-13,0,0,0 2004-001500-13,5,2005-11-14,2006-11-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer, S.A.","An 8-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the Acute Treatment of DSM-IV Generalize...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001500-13,0,0,0 2004-001503-36,1,2006-11-15,2006-11-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"SERONO ESPAÑA, S.A.","Lutropin alfa (Luveris) in mid follicular phase for controlled ovarian stimulation (COS) in ovarian ageing: a randomised, comparative with parallel control group, phase II clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001503-36,0,0,0 2004-001507-35,2,2007-07-24,2007-07-24,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharmion Corporation,"A Multicenter, Randomized, Open-Label, Parallel-Group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001507-35,0,0,0 2004-001511-54,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Pfizer Global Research and Development,Linezolid vs. Vancomycin/Oxacillin/Dicloxacillin in the Treatment of Catheter-Related Gram Positive Bloodstream Infections.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001511-54,0,0,0 2004-001512-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Industial Farmacéutica Cantabria S. A.,Evaluación del efecto de AM3 en el tratamiento de la cistitis recidivante de la mujer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001512-31,0,0,0 2004-001518-15,1,2008-07-08,2008-07-08,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Hvidovre Hospital,Effekten af lavdosis væksthormonbehandling hos HIV positive patienter i højaktiv antiretroviral behandling (HAART),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001518-15,0,0,0 2004-001521-19,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,SEVAPHARMA a.s.,An open clinical trial on teh efficacy of H-AL pollens (Grass mixture I) administered orally and sublingually in patients with indicated allergen immunotherapy (AIT) with Type I allergy mediated by Ig...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001521-19,0,0,0 2004-001525-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"ORVACS, Objectif Recherche Vaccin SIDA","Estudio clínico controlado con placebo, aleatorizado, de fase II, para evaluar la inmunogenicidad y la toxicidad de dos patrones de inducción-refuerzo complementarios con el ALVAC-VIH vCP1452 en pacie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001525-21,0,0,0 2004-001529-88,1,2006-12-31,2006-12-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Medical University of Vienna,"Dose efficacy relation of inhalative prostaglandin I2 vs. inhalative prostaglandin E1 in patients with ARDS: comparison of efficacy with respect to paO2/FiO2 ratio, Qs/Qt and PAP.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001529-88,0,0,0 2004-001538-18,1,2006-08-24,2006-08-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LETI Pharma GmbH,"A randomised, double blinded, placebo controlled multicentre study for the efficacy and safety of Depigoid birch pollen",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001538-18,0,0,0 2004-001540-71,8,2007-04-20,2008-03-31,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Jerini AG,"Randomised, double blind, controlled, parallel group, multicentre study of a subcutaneous formulation of Icatibant vs. oral Tranexamic acid for the treatment of hereditary angioedema (HAE).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001540-71,0,0,0 2004-001540-71,8,2007-04-20,2008-03-31,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,JERINI AG,"Randomised, double blind, controlled, parallel group, multicentre study of a subcutaneous formulation of Icatibant vs. oral Tranexamic acid for the treatment of hereditary angioedema (HAE).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001540-71,0,0,0 2004-001545-15,2,2007-10-10,2007-10-10,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Schering AG,"Estudio multicéntrico, doble ciego, aleatorizado, controlado con placebo de Testogel® (testosterona 50–100mg) para evaluar su eficacia y seguridad en hombres que presentan síntomas típicos de deficit ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001545-15,0,0,0 2004-001546-32,3,2005-10-19,2006-04-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Sverige AB,"A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50 mg qd or bid) to placebo as add-on therapy to glimepiride in patients with typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001546-32,0,0,0 2004-001546-32,3,2005-10-19,2006-04-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50 mg qd or bid) to placebo as add-on therapy to glimepiride in patients with typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001546-32,0,0,0 2004-001546-32,3,2005-10-19,2006-04-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Finland Oy,"A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment with LAF237 (50 mg qd or bid) to placebo as add-on therapy to glimepiride in patients with typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001546-32,0,0,0 2004-001548-60,1,2008-05-20,2008-05-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"Double-blind, partially randomized, parallel group, multicenter study to assess the efficacy and safety of 100 mg and 150 mg monthly oral ibandronate in women with postmenopausal osteoporosis having c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001548-60,0,0,0 2004-001549-13,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,GLAXO SMITHKLINE,"A pilot, randomized, double-blind, placebo-controlled, crossover study evaluating the efficacy and safety of Vardenafil versus placebo administered 12, 18 and 24 hours prior to initiation of sexual in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001549-13,0,0,0 2004-001551-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Lund University Hospital,Behandling av förhöjt pulmonellt arteriellt tryck med inhalerad iloprost,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001551-11,0,0,0 2004-001552-37,1,2015-06-15,2015-06-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Birmingham,Effectiveness and Cost-effectiveness of Levonorgestrel containing Intrauterine system in Primary care against Standard Treatment for menorrhagia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001552-37,0,0,0 2004-001557-29,11,2008-05-12,2009-05-12,9,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Pfizer Inc.,"A 52-WEEK MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL, TWO - ARM STUDY COMPARING EXUBERA® (INHALED HUMAN INSULIN) VS. HUMALOG® (INSULIN LISPRO), BOTH IN COMBINATION WITH INSULIN GLARGINE IN SUBJECTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001557-29,0,0,0 2004-001557-29,11,2008-05-12,2009-05-12,9,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Pfizer Inc,"A 52-WEEK MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL, TWO - ARM STUDY COMPARING EXUBERA® (INHALED HUMAN INSULIN) VS. HUMALOG® (INSULIN LISPRO), BOTH IN COMBINATION WITH INSULIN GLARGINE IN SUBJECTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001557-29,0,0,0 2004-001557-29,11,2008-05-12,2009-05-12,9,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Pfizer bv,"A 52-WEEK MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL, TWO - ARM STUDY COMPARING EXUBERA® (INHALED HUMAN INSULIN) VS. HUMALOG® (INSULIN LISPRO), BOTH IN COMBINATION WITH INSULIN GLARGINE IN SUBJECTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001557-29,0,0,0 2004-001557-29,11,2008-05-12,2009-05-12,9,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Pfizer Oy,"A 52-WEEK MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL, TWO - ARM STUDY COMPARING EXUBERA® (INHALED HUMAN INSULIN) VS. HUMALOG® (INSULIN LISPRO), BOTH IN COMBINATION WITH INSULIN GLARGINE IN SUBJECTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001557-29,0,0,0 2004-001557-29,11,2008-05-12,2009-05-12,9,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Pfizer Ltd.,"A 52-WEEK MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL, TWO - ARM STUDY COMPARING EXUBERA® (INHALED HUMAN INSULIN) VS. HUMALOG® (INSULIN LISPRO), BOTH IN COMBINATION WITH INSULIN GLARGINE IN SUBJECTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001557-29,0,0,0 2004-001557-29,11,2008-05-12,2009-05-12,9,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Pfizer Limited,"A 52-WEEK MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL, TWO - ARM STUDY COMPARING EXUBERA® (INHALED HUMAN INSULIN) VS. HUMALOG® (INSULIN LISPRO), BOTH IN COMBINATION WITH INSULIN GLARGINE IN SUBJECTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001557-29,0,0,0 2004-001557-29,11,2008-05-12,2009-05-12,9,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Pfizer Pharma GmbH,"A 52-WEEK MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL, TWO - ARM STUDY COMPARING EXUBERA® (INHALED HUMAN INSULIN) VS. HUMALOG® (INSULIN LISPRO), BOTH IN COMBINATION WITH INSULIN GLARGINE IN SUBJECTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001557-29,0,0,0 2004-001558-10,3,2012-08-31,2012-08-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,BEACOPP (4 ciclos escalado + 4 ciclos basal) vs ABDV (8 ciclos) en el linfoma de Hodgkin en estadios III-IV.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001558-10,0,0,0 2004-001558-10,3,2012-08-31,2012-08-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,HOSPITAL DE LA SANTA CREU I SANT PAU,BEACOPP (4 ciclos escalado + 4 ciclos basal) vs ABDV (8 ciclos) en el linfoma de Hodgkin en estadios III-IV.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001558-10,0,0,0 2004-001559-12,1,2006-06-07,2006-06-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer,"Measurement of Urethral Function in Women with Stress Urinary Incontinence - Evaluation of the Sensitivity of Urethral Reflectometry compared to Urethral Pressure Profilometry, using [S,S]-Reboxetine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001559-12,0,0,0 2004-001562-41,1,2009-11-30,2009-11-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly SA,Efectos del Arzoxifeno en la incidencia de fracturas vertebrales y en la incidencia de cáncer de mama invasivo en las mujeres posmenopáusicas con osteoporosis o con baja densidad ósea Effects of Arz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001562-41,0,0,0 2004-001563-21,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Immunomedics, Inc.","A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001563-21,0,0,0 2004-001569-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,BAXTER SAS R&D Parenteral Nutrition,EFFICIENCY AND SAFETY OF CLINAVIT PAEDIATRIC AT A WEIGHT DEPENDANT DOSE ADMINISTERED DAILY FOR 5 CONTINUOUS DAYS ON 4 VITAMINS BLOOD LEVEL IN NEONATES AND CHILDREN UP TO 11 YEARS OF AGE RECEIVING PARE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001569-16,0,0,0 2004-001580-22,2,2005-09-30,2005-10-01,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Ltd,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitoste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001580-22,0,0,0 2004-001580-22,2,2005-09-30,2005-10-01,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,MSD SHARP & DOHME GMBH,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitoste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001580-22,0,0,0 2004-001583-52,1,2010-02-01,2010-02-01,1,1,0,0,1,0,4,1,0,1,0,0,1,0,0,Lund University Hospital,Balanced anestesia for intubation of newborn premature infants – a randomized intervention study Balanserad anestesi för intubation av nyfödda prematura barn – en randomiserad interventionsstudie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001583-52,0,0,0 2004-001586-18,1,2005-05-19,2005-05-19,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Wyeth Consumer Healthcare,A Safety Study of TDS-943,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001586-18,0,0,0 2004-001588-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""","PHARMACOKINETIC/PHARMACODINAMIC STUDY OF TRANSDERMAL BUPRENORPHINE FOR TREATMENT OF CHRONIC, MEDIUM-SEVERE, NON-ONCOLOGIC PAIN.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001588-22,0,0,0 2004-001589-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NeuroBiotec GmbH,Transdermal lisuride: Phase II/III study (efficacy and tolerance) of transdermal lisuride (patches) in patients with Restless Legs Syndrome (RLS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001589-42,0,0,0 2004-001590-26,1,2006-02-24,2006-02-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,"NATIONAL, MULTICENTER, RANDOMIZED,OPEN STUDY TO EVALUATE EFFICACY AND SAFETY OF LAMIVUDINE (300 MG QD) MONOTHERAPY AS AN ALTERNATIVE TO THERAPEUTIC INTERRUPTION IN PAZIENTS AFFECTED BY HIV-1, IN VIRAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001590-26,0,0,0 2004-001593-10,2,2006-02-10,2006-02-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Merck KGaA,"A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001593-10,0,0,0 2004-001593-10,2,2006-02-10,2006-02-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,2,MERCK S.P.A.,"A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001593-10,0,0,0 2004-001594-25,3,2006-03-22,2006-03-22,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck KGaA,"A double-blind, placebo controlled, multicenter, multinational, phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d in patients with Parkinson' s disease suffering from tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001594-25,0,0,0 2004-001594-25,3,2006-03-22,2006-03-22,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK KGaA,"A double-blind, placebo controlled, multicenter, multinational, phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d in patients with Parkinson' s disease suffering from tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001594-25,0,0,0 2004-001600-12,1,2004-10-15,2004-10-15,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,OMNINVEST Kft.,Fluval AB Vaccine Serologic Clinical Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001600-12,0,0,0 2004-001601-10,2,,,0,0,0,0,1,0,3,0,0,2,0,0,0,0,0,CHRU Rennes,"Evaluation d’une nouvelle stratégie thérapeutique chez des patients à fort risque évolutif, à la phase initiale de la sclérose en plaques : traitement séquentiel par mitoxantrone (Elsep 10mg/m² par mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001601-10,0,0,0 2004-001601-10,2,,,0,0,0,0,1,0,3,0,0,2,0,0,0,0,0,OSPEDALE S. RAFFAELE,"Evaluation d’une nouvelle stratégie thérapeutique chez des patients à fort risque évolutif, à la phase initiale de la sclérose en plaques : traitement séquentiel par mitoxantrone (Elsep 10mg/m² par mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001601-10,0,0,0 2004-001605-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,"A Phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors GISTs resistant to imatinib mesylate",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001605-10,0,0,0 2004-001607-35,1,2006-06-28,2006-06-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Ltd.,"AN OPEN-LABEL, MULTICENTER STUDY WITH FOLLOW-UP EVALUATING THE SAFETY AND EFFICACY OF VARENICLINE TARTRATE IN COMPARISON TO TRANSDERMAL NICOTINE PATCH FOR SMOKING CESSATION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001607-35,0,0,0 2004-001608-11,1,2005-08-22,2005-08-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shire Pharmaceutical Development Ltd,"A Multi-centre, Open Label, Randomised, Parallel Group Pilot Study to assess the Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001608-11,0,0,0 2004-001609-89,2,2007-03-01,2007-03-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Peninsula Pharmaceuticals, Inc","A Multicenter, Randomized, Open-Label Phase 3 Study to Compare the Safety and Efficacy of Intravenous Doripenem with that of Intravenous Imipenem in Ventilator-Associated Pneumonia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001609-89,0,0,0 2004-001610-14,1,2007-04-24,2007-04-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Univ. hospital, Dpt. of anaesthesia",Effects of colloids on hemostasis in paediatric anaesthesia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001610-14,0,0,0 2004-001611-58,2,2009-03-09,2009-03-09,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JSC Grindeks,Mildronate-efficacy and safety in treatment for chronic coronary heart Disease (stable angina) II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001611-58,0,0,0 2004-001611-58,2,2009-03-09,2009-03-09,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"JSC ""Grindeks""",Mildronate-efficacy and safety in treatment for chronic coronary heart Disease (stable angina) II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001611-58,0,0,0 2004-001613-34,2,2006-09-05,2006-09-05,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Schering AG,"A multi-center, double-blind, double-dummy, controlled, randomized study to evaluate cycle control and safety of a four-phasic oral contraceptive containing estradiol valerate and dienogest (SH T00658...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001613-34,0,0,0 2004-001614-13,1,2006-03-24,2006-03-24,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Schering AG,"A single-center, open-label, controlled, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) as compared to a sequen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001614-13,0,0,0 2004-001616-31,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,LUSOFARMACO,EFFICACY AND SAFETY OF OLMESARTAN IN ELDERLY PATIENTS WITH MILD TO MODERATE HYPERTENSION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001616-31,0,0,0 2004-001616-31,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,GUIDOTTI,EFFICACY AND SAFETY OF OLMESARTAN IN ELDERLY PATIENTS WITH MILD TO MODERATE HYPERTENSION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001616-31,0,0,0 2004-001617-34,8,2007-06-22,2008-09-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Fujisawa GmbH,"AN OPEN, RANDOMISED, MULTICENTRE, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS AND MINIMAL STEROIDS IN COMBINATION WITH EITHER A MONOCLONAL ANTI-IL2R ANTIBODY (DACLIZUMAB) OR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001617-34,0,0,0 2004-001617-34,8,2007-06-22,2008-09-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma GmbH,"AN OPEN, RANDOMISED, MULTICENTRE, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS AND MINIMAL STEROIDS IN COMBINATION WITH EITHER A MONOCLONAL ANTI-IL2R ANTIBODY (DACLIZUMAB) OR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001617-34,0,0,0 2004-001617-34,8,2007-06-22,2008-09-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd,"AN OPEN, RANDOMISED, MULTICENTRE, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS AND MINIMAL STEROIDS IN COMBINATION WITH EITHER A MONOCLONAL ANTI-IL2R ANTIBODY (DACLIZUMAB) OR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001617-34,0,0,0 2004-001617-34,8,2007-06-22,2008-09-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FUJISAWA,"AN OPEN, RANDOMISED, MULTICENTRE, CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS AND MINIMAL STEROIDS IN COMBINATION WITH EITHER A MONOCLONAL ANTI-IL2R ANTIBODY (DACLIZUMAB) OR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001617-34,0,0,0 2004-001620-21,4,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,LAB Pharma Ltd,"A Multicentre, Multinational, Randomised, Double Blind, Single Dummy, Parallel Group, Placebo-Controlled Trial To Investigate The Dose-Response And Safety Of Fentanyl TAIFUN R 100 microgrammi, 200 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001620-21,0,0,0 2004-001620-21,4,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,LAB PHARMA LTD,"A Multicentre, Multinational, Randomised, Double Blind, Single Dummy, Parallel Group, Placebo-Controlled Trial To Investigate The Dose-Response And Safety Of Fentanyl TAIFUN R 100 microgrammi, 200 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001620-21,0,0,0 2004-001621-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University College London (UCL),"An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with advanced stage, asymptomatic, non-bulky fillicular lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001621-16,0,0,0 2004-001622-24,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,0,Newcastle Hospital Trust,"Phase III,multicentre,open-label,prospective randomised trial comparing Imatinib alone at 400mg versus 800mg daily versus Imatinib 400mg daily plus PEG Interferon-alpha with newly diagnosed chronic my...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001622-24,0,0,0 2004-001623-38,1,2009-09-11,2009-09-11,1,1,0,0,0,3,0,0,0,1,0,0,1,0,3,Baxter AG,"Phase 3B Recombinant Antihemophilic Factor Manufactured and Formulated without added Human or Animal Proteins (rAHF-PFM): Evaluation of Immunogenicity, Efficacy, and Safety in Previously Untreated Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001623-38,0,0,0 2004-001633-42,1,2005-01-01,2005-01-01,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,NHS GRAMPIAN,Is there a role for Helicobacter pylori eradication in the treatment of laryngopharyngeal reflux? : A double blinded randomised case controlled clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001633-42,0,0,0 2004-001637-41,1,2008-03-25,2008-03-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Consumer Healthcare cva/sca,A community pharmacy based investigation in the self-medication area Efficacy and safety of Sinutab® (Paracetamol (500mg)/Pseudoephedrine (30mg)) on subjects with nasal congestion accompanied by head...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001637-41,0,0,0 2004-001644-80,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Fujisawa GmbH,Clinical study on tacrolimus ointment over the long-term “Control Study - Children” Revised version of FG-506-06-39,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001644-80,0,0,0 2004-001646-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. DANIEL PODZAMCZER PALTER,"ESTUDIO PILOTO PARA EVALUAR LA EFICACIA Y TOLERANCIA DE LA COMBINACION DE TRIZIVIR Y TENOFOVIR EN PACIENTES INFECTADOS POR EL VIH, SIN TRATAMENTO ANTIRRETROVIRAL PREVIO (NAÏVES)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001646-32,0,0,0 2004-001647-30,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA,An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL) studio clinico per valutare la si...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001647-30,0,0,0 2004-001648-64,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,ardana LTD,"A Phase II multicentre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix 90 mg, long-acting form...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001648-64,0,0,0 2004-001653-28,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,The Leeds teaching Hospitals NHS trust,A comparison of the effects on prostaglandin synthesis and cytokine production of an olive-oil based lipid emulsion (Clinoloeic) with a soya based emulsion (Intralipid) in newborn infnats receiving pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001653-28,0,0,0 2004-001657-29,2,2006-07-11,2006-07-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Limited,"A Phase II, randomized, active controlled, open label trial to investigate the efficacy and tolerability of TMC125 in HIV-1 infected subjects, who are PI-naïve and with documented genotypic evidence o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001657-29,0,0,0 2004-001658-10,5,2007-03-20,2007-03-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Limited,An open-label trial of TMC125 in HIV-1 infected subjects who were randomized in any sponsor selected TMC125 trial to an active control arm and either virologically failed or completed the entire treat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001658-10,0,0,0 2004-001658-10,5,2007-03-20,2007-03-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,An open-label trial of TMC125 in HIV-1 infected subjects who were randomized in any sponsor selected TMC125 trial to an active control arm and either virologically failed or completed the entire treat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001658-10,0,0,0 2004-001662-41,4,2006-02-22,2006-02-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Basilea Pharmaceutica Ltd,"A Phase III, Randomized, Double-Blind Study of Ceftobiprole versus Vancomycin in the Treatment of Complicated Skin and Skin Structure Infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001662-41,0,0,0 2004-001662-41,4,2006-02-22,2006-02-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,2,BASILEA PHARMACEUTICA,"A Phase III, Randomized, Double-Blind Study of Ceftobiprole versus Vancomycin in the Treatment of Complicated Skin and Skin Structure Infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001662-41,0,0,0 2004-001664-50,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,ITALFARMACO,"An open label, phase II multicentre evaluation of the activity and safety of fotemustine administered to patients with recurrent or progressive glioblastoma multiforme.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001664-50,0,0,0 2004-001666-40,3,2007-05-01,2007-05-01,1,1,0,0,0,3,2,0,0,1,1,0,1,0,1,Novartis Pharma AG,"An international, multicenter, randomized, open-label, safety and efficacy trial of intravenous zoledronic acid administered either once or twice yearly in children with severe osteogenesis imperfecta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001666-40,0,0,0 2004-001667-22,8,2011-01-05,2011-01-05,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK S.P.A.,Cetuximab (ERBITUX) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and nec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001667-22,0,0,0 2004-001667-22,8,2011-01-05,2011-01-05,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck KGaA,Cetuximab (ERBITUX) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and nec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001667-22,0,0,0 2004-001672-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr Moya Mur,EFECTO PROTECTOR DE LA ATORVASTATINA SOBRE LA FUNCION MICROVASCULAR CORONARIA Y FUNCION COGNITIVA CEREBRAL EN PACIENTES SOMETIDOS A REVASCULARIZACION CORONARIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001672-39,0,0,0 2004-001673-25,1,2011-12-16,2011-12-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,EFFECTS OF ANGIOTENSIN RECEPTOR ANTAGONIST ON CHRONIC NEPHROPATY IN KIDNEY TRANSPLANTED PATIENTS. A PILOT STUDY.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001673-25,0,0,0 2004-001674-80,2,2006-10-04,2006-10-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mitsubishi Pharma Corporation,"A Randomised, Open, Parallel Group, Multicentre Study to Examine the Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Combination with Clopidogrel and Aspirin in Patients unde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001674-80,0,0,0 2004-001677-26,6,2006-09-21,2006-09-21,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"Nolpitantium Besylate In patients with mild to moderate Ulcerative Colitis: a double-blind, placebo-controlled Efficacy and safety, 8-week study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001677-26,0,0,0 2004-001677-26,6,2006-09-21,2006-09-21,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SANOFI-SYNTHELABO,"Nolpitantium Besylate In patients with mild to moderate Ulcerative Colitis: a double-blind, placebo-controlled Efficacy and safety, 8-week study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001677-26,0,0,0 2004-001677-26,6,2006-09-21,2006-09-21,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & developpement,"Nolpitantium Besylate In patients with mild to moderate Ulcerative Colitis: a double-blind, placebo-controlled Efficacy and safety, 8-week study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001677-26,0,0,0 2004-001680-22,6,2005-07-01,2005-07-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd.,"A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety and efficacy of controlled-release ropinirole CR 1-24mg administered once daily for 12 weeks in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001680-22,0,0,0 2004-001680-22,6,2005-07-01,2005-07-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXO SMITHKLINE,"A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety and efficacy of controlled-release ropinirole CR 1-24mg administered once daily for 12 weeks in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001680-22,0,0,0 2004-001681-40,2,2005-11-30,2005-11-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA PHARMA,Comparison of inhaled ciclesonide (640 g/day) and fluticasone propionate (1000 g/day) in patients with moderate and severe persistent asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001681-40,0,0,0 2004-001681-40,2,2005-11-30,2005-11-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA Pharma AG,Comparison of inhaled ciclesonide (640 g/day) and fluticasone propionate (1000 g/day) in patients with moderate and severe persistent asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001681-40,0,0,0 2004-001682-17,1,2007-05-21,2007-05-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Synthelabo-Recherche,"A Randomized Dose Ranging Study of Hexadecasaccharide including Active Control, in Patients with Unstable Angina or Non-ST-segment Elevation Myocardial Infarction Scheduled to Undergo Percutaneous Cor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001682-17,0,0,0 2004-001685-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Hoffmann-La Roche Inc,An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) (“XELOX”) versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001685-40,0,0,0 2004-001685-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Roche Polska, Sp.z.o",An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) (“XELOX”) versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001685-40,0,0,0 2004-001688-23,3,2008-05-27,2008-05-27,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A multicentre, double-blind, placebo-controlled randomized trial of the efficacy, safety and tolerability of 12 months of once daily treatment with 1 mg of RO3300074 in patients with symptomatic emphy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001688-23,0,0,0 2004-001690-26,1,2006-12-15,2006-12-15,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Craigavon Area Hospital Group Trust,The Low HDL On six Weeks statin therapy (LOW) study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001690-26,0,0,0 2004-001692-19,1,2005-10-09,2005-10-09,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novo Nordisk AS,"A single-centre, randomised, double-blind, cross-over trial comparing the within-subject variability of the pharmacokinetic profiles of insulin detemir and insulin glargine in children and adolescents...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001692-19,0,0,0 2004-001696-19,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Spanish Cooperative Group for Gastrointestinal Tomour therapy,"Open-label, phase II, multicentre study on cetuximab treatment as first-line monotherapy in elderly patients with metastatic colorectal cancer expressing EGFR",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001696-19,0,0,0 2004-001700-12,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Spanish Cooperative Group for Gastrointestinal Tomour therapy,"Open-label, phase II, ramdomised, pilot study to evaluate the safety and efficacy of combination therapy with cetuximab and FOLFOX4 or FOLFOX4 alone in patients with EGFR-pos. colorectal cancer and in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001700-12,0,0,0 2004-001701-97,1,2004-11-08,2004-11-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Berkshire and Battle Hospitals NHS Trust,Prospective randomised controlled trial of: MRSA Prophylaxis for lower limb amputation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001701-97,0,0,0 2004-001712-31,1,2007-07-31,2007-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Lothian Health - University Hospitals Division,A study to evaluate the biological effects of RAD001 on invasive breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001712-31,0,0,0 2004-001713-34,1,2005-03-01,2005-03-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Pfizer Limited,"RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF THE EFFICACY, TOLERABILITY AND SAFETY OF VALDECOXIB (BEXTRA®)10 MG OD VS. DICLOFENAC SODIUM 50 MG TDS FOR 6 WEEKS IN SUBJECTS WITH OSTEOARTHRITIS OF THE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001713-34,0,0,0 2004-001716-31,1,2007-05-25,2007-05-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Swedish Orphan Biovitrum AB (publ.),"A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001716-31,0,0,0 2004-001718-15,3,2011-09-26,2011-09-26,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"An open-label, multicenter protocol providing pegylated interferon alfa 2-a PEGASYS as monotherapy or in combination with ribavirin COPEGUS for patients with chronic hepatitis C who have partecipat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001718-15,0,0,0 2004-001718-15,3,2011-09-26,2011-09-26,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ROCHE,"An open-label, multicenter protocol providing pegylated interferon alfa 2-a PEGASYS as monotherapy or in combination with ribavirin COPEGUS for patients with chronic hepatitis C who have partecipat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001718-15,0,0,0 2004-001719-77,10,2007-10-05,2007-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,JANSSEN-CILAG,A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or older.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001719-77,0,0,0 2004-001719-77,10,2007-10-05,2007-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Janssen-Cilag International N.V.,A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or older.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001719-77,0,0,0 2004-001719-77,10,2007-10-05,2007-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Janssen-Cilag International NV,A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or older.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001719-77,0,0,0 2004-001719-77,10,2007-10-05,2007-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Johnson&Johnson Pharmaceutical Research and Development, Division de Janssen-Cilag",A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or older.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001719-77,0,0,0 2004-001719-77,10,2007-10-05,2007-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Janssen-Cilag Limited,A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or older.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001719-77,0,0,0 2004-001719-77,10,2007-10-05,2007-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Janssen-Cilag International,A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or older.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001719-77,0,0,0 2004-001719-77,10,2007-10-05,2007-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Johnson&Johnson Pharmaceutical Research and Development,A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or older.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001719-77,0,0,0 2004-001719-77,10,2007-10-05,2007-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Johnson & Johnson Pharmaceutical Research and Development,A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or older.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001719-77,0,0,0 2004-001720-21,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,Takeda Europe R&D Centre Ltd,"A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001720-21,0,0,0 2004-001721-13,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,Takeda Europe R&D Center Ltd,"A Phase III, multi-center, randomized, double-blind study to evaluate the efficacy and safety of 50 mg and 100 mg of sufugolix (TAK-013) tablets administered twice daily versus placebo for 12 weeks in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001721-13,0,0,0 2004-001724-20,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,AstraZeneca AB,"A randomised, placebo-controlled, double-blind, double-dummy, crossover study to assess the onset of action of two inhalations of Symbicort 160/4.5μg compared with two inhalations of Seretide 25/250μ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001724-20,0,0,0 2004-001729-11,4,2008-03-07,2008-07-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,EBEWE Pharma GesmbH Nfg.KG,"A prospective, randomised, placebo controlled, double blind trial about safety and efficacy of combined treatment with Alteplase (rt-PA) and Cerebrolysin in acute ischemic hemispheric stroke",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001729-11,0,0,0 2004-001729-11,4,2008-03-07,2008-07-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,EBEWE Pharma Ges.m.b.H Nfg.KG,"A prospective, randomised, placebo controlled, double blind trial about safety and efficacy of combined treatment with Alteplase (rt-PA) and Cerebrolysin in acute ischemic hemispheric stroke",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001729-11,0,0,0 2004-001730-17,5,2007-05-18,2007-05-29,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF CEFTOBIPROLE VERSUS LINEZOLID PLUS CEFTAZIDIME IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001730-17,0,0,0 2004-001730-17,5,2007-05-18,2007-05-29,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Basilea Pharmaceutica Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF CEFTOBIPROLE VERSUS LINEZOLID PLUS CEFTAZIDIME IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001730-17,0,0,0 2004-001731-28,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,FOURNIER Laboratories Ireland,"A double-blind, 3-arm study on weight loss with combination of micronised fenofibrate 267 mg and metformin 1700 mg per day compared to metformin 1700 mg and placebo, at 6 months, in obese patients, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001731-28,0,0,0 2004-001735-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FERRING ARZNEIMITTEL Ges.m.b.h. CEE AUSTRIA,AN OPEN LABEL STUDY OF ORAL DESMOPRESSIN IN CHILDREN AGED 5 TO 15 YEARS WITH PRIMARY NOCTURAL ENURESIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001735-37,0,0,0 2004-001737-41,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,1,Mekos Laboratories AS,"Clinical evaluation of 3 allergens for ""TRUE Test Panel 3"" - A phase III study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001737-41,0,0,0 2004-001738-17,1,2014-04-02,2014-04-02,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,Evaluation of the intensification of post-remissional therapy in the treatment of high-risks adult Acute Lymphoblastic Leukemia and monitoring of the minimal residual disease Ruolo della intensific...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001738-17,0,0,0 2004-001739-53,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,"Therapy with Alemtuzumab (Mabcampath) in patients with acute Lymphoblastic leukemia either refractoy or in relapse. Phase II, multicentric, not randomized study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001739-53,0,0,0 2004-001746-32,1,2010-06-25,2010-06-25,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,"Phase II clinical trial with Caelyx mono-chemotherapy in patients with advanced Mycosis fungoides stage IIb, IVa and IVb with or without previous chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001746-32,0,0,0 2004-001748-66,1,2008-01-22,2008-01-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bial – Portela & Cª S.A,"Ensayo clínico multicéntrico, doble ciego, aleatorizado, controlado con placebo, en grupos paralelos, de la eficacia y seguridad de BIA 2-093 como tratamiento complementario en las crisis parciales re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001748-66,0,0,0 2004-001749-13,1,2008-08-28,2008-08-28,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,AESCA Pharma GesmbH,Randomized Phase II Study: Temozolomide (TMZ) Concomitant to Radiotherapy followed by sequential TMZ in Advanced NSCLC Patients with CNS Metastasis versus Radiotherapy alone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001749-13,0,0,0 2004-001750-81,2,2005-06-13,2005-06-13,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Merck & Co. Inc.,"A randomized, double-blind, placebo-controlled study to evaluate the persistence of the effect of oral monthly ibandronate on bone resorption in postmenopausal women with osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001750-81,0,0,0 2004-001750-81,2,2005-06-13,2005-06-13,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Limited,"A randomized, double-blind, placebo-controlled study to evaluate the persistence of the effect of oral monthly ibandronate on bone resorption in postmenopausal women with osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001750-81,0,0,0 2004-001754-92,2,2006-07-27,2006-07-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A phase II, 12-month, double-blind, placebo-controlled, dose-finding, multicenter study to evaluate the safety, tolerability, and disease modifying efficacy of daily oral AAE581 (10, 25 and 50 mg tabl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001754-92,0,0,0 2004-001754-92,2,2006-07-27,2006-07-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase II, 12-month, double-blind, placebo-controlled, dose-finding, multicenter study to evaluate the safety, tolerability, and disease modifying efficacy of daily oral AAE581 (10, 25 and 50 mg tabl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001754-92,0,0,0 2004-001756-36,7,2016-12-31,2017-12-31,5,1,0,0,0,0,3,0,0,1,0,0,1,0,0,LYSA (The Lymphoma Study Association),"A multicentre, phase III, open-label, randomised study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera®) after induction of respons...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001756-36,0,0,0 2004-001756-36,7,2016-12-31,2017-12-31,5,1,0,0,0,0,3,0,0,1,0,0,1,0,0,GELA (Groupe d'Etude du Lymphome de l'Adulte),"A multicentre, phase III, open-label, randomised study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera®) after induction of respons...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001756-36,0,0,0 2004-001756-36,7,2016-12-31,2017-12-31,5,1,0,0,0,0,3,0,0,1,0,0,1,0,0,LYSARC,"A multicentre, phase III, open-label, randomised study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera®) after induction of respons...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001756-36,0,0,0 2004-001756-36,7,2016-12-31,2017-12-31,5,1,0,0,0,0,3,0,0,1,0,0,1,0,0,GELA(RC),"A multicentre, phase III, open-label, randomised study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera®) after induction of respons...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001756-36,0,0,0 2004-001766-40,6,2006-05-11,2006-05-11,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SANOFI-SYNTHELABO,"Placebo controlled double blind dose ranging study of the efficacy and safety of SSR149744C 50, 100, 200 or 300 mg OD, with amiodarone as calibrator for the maintenance of sinus rhythm in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001766-40,0,0,0 2004-001766-40,6,2006-05-11,2006-05-11,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"Placebo controlled double blind dose ranging study of the efficacy and safety of SSR149744C 50, 100, 200 or 300 mg OD, with amiodarone as calibrator for the maintenance of sinus rhythm in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001766-40,0,0,0 2004-001770-40,1,2008-04-11,2008-04-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,A randomized controlled study of BAY 43-9006 in combination with doxorubicin versus doxorubicin in patients with advanced hepatocellular carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001770-40,0,0,0 2004-001773-26,5,2008-11-19,2008-11-21,4,1,0,0,0,2,3,0,0,1,0,0,1,0,1,BAYER,"A Phase III randomised, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001773-26,0,0,0 2004-001773-26,5,2008-11-19,2008-11-21,4,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Bayer HealthCare AG, D-51368 Leverkusen Germany","A Phase III randomised, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001773-26,0,0,0 2004-001773-26,5,2008-11-19,2008-11-21,4,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A Phase III randomised, placebo-controlled study of sorafenib in patients with advanced hepatocellular carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001773-26,0,0,0 2004-001778-21,5,2011-04-19,2011-04-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, KENT. CT13 9NJ","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001778-21,0,0,0 2004-001778-21,5,2011-04-19,2011-04-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer S.A,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001778-21,0,0,0 2004-001778-21,5,2011-04-19,2011-04-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ViiV Healthcare UK Limited,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001778-21,0,0,0 2004-001778-21,5,2011-04-19,2011-04-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001778-21,0,0,0 2004-001778-21,5,2011-04-19,2011-04-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER LTD,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001778-21,0,0,0 2004-001779-20,5,2009-04-07,2009-04-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Limited,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A NOVEL CCR5 ANTAGONIST, UK-427,857, IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY VERSUS OPTIMIZED BACKGROUND THERAPY ALONE FOR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001779-20,0,0,0 2004-001779-20,5,2009-04-07,2009-04-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer S.A,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A NOVEL CCR5 ANTAGONIST, UK-427,857, IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY VERSUS OPTIMIZED BACKGROUND THERAPY ALONE FOR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001779-20,0,0,0 2004-001782-18,1,2006-06-30,2006-06-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"Saftey and efficacy of two different doses of Neramexane mesylate as preemptive analgesic and add-on therapy to opioids in the management of postoperative pain. A randomised, double-blind, placebo-con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001782-18,0,0,0 2004-001786-18,1,2014-03-25,2014-03-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,EAU EUROPEAN ASSOCIATION OF UROLOGY,"Effectiveness of Zometa treatment for the prevention of bone metastases in high risk prostate cancer patients. A randomized, open-label, multicenter study of the European Association of Urology (EAU) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001786-18,0,0,0 2004-001789-42,1,2007-01-23,2007-01-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Laboratorios Menarini, S.A.",A MULTICENTRE CLINICAL TRIAL EVALUATING THE ANALGESIC EFFICACY AND SAFETY OF DEXKETOPROFEN TROMETAMOL (50 mg i.v. FOLLOWED BY AN ORAL DOSAGE OF 25 mg t.i.d.) VERSUS METAMIZOL (2 g i.v. and 575 mg t.i....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001789-42,0,0,0 2004-001805-90,1,2007-05-25,2007-05-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Fresenius Kabi,"Efficacy and security of glutamine dipeptide (Dipeptiven®) - Supplemented parenteral nutrition in critic patients. Double blind, randomized, multicenter study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001805-90,0,0,0 2004-001806-29,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Arakis Ltd,"A multi-center, randomized, double-blind, parallel group, placebo controlled study, including an additional open label tiotropium group, to assess the efficacy, safety and tolerability of different d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001806-29,0,0,0 2004-001810-16,6,2017-07-12,2017-07-12,5,1,0,0,0,2,3,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,"Intermediate and high risk localized , completely resected, gastrointestinal stromal tumors ( GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate ( Glivec) versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001810-16,0,0,0 2004-001810-16,6,2017-07-12,2017-07-12,5,1,0,0,0,2,3,0,0,1,0,0,1,0,0,EORTC,"Intermediate and high risk localized , completely resected, gastrointestinal stromal tumors ( GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate ( Glivec) versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001810-16,0,0,0 2004-001810-16,6,2017-07-12,2017-07-12,5,1,0,0,0,2,3,0,0,1,0,0,1,0,0,ITALIAN SARCOMA GROUP,"Intermediate and high risk localized , completely resected, gastrointestinal stromal tumors ( GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate ( Glivec) versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001810-16,0,0,0 2004-001814-14,5,2006-05-09,2007-04-09,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline R&D Limited,"A Double-Blind, Placebo-Controlled, Multicenter Phase IIb Extension Study to Evaluate the Safety and Efficacy of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunctio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001814-14,0,0,0 2004-001814-14,5,2006-05-09,2007-04-09,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline R & D Limited,"A Double-Blind, Placebo-Controlled, Multicenter Phase IIb Extension Study to Evaluate the Safety and Efficacy of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunctio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001814-14,0,0,0 2004-001823-39,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"An open, randomized, controlled, phase II study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ 11-valent pneumococcal conjugate vaccine, when administered intramuscularly as...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001823-39,0,0,0 2004-001825-69,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,THERAKOS,"A Multi Center, Open label, Extension study of RA 1 using Extracoproreal photoimmune therapy with Uvadex",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001825-69,0,0,0 2004-001827-39,1,2006-04-10,2006-04-10,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,"NATIONAL, MULTICENTER, RANDOMISED, OPEN STUDY TO VALUATE THE EFFICACY OF DIFFERENT THERAPEUTIC STRATEGIES TO AVOID THE IMMUNOLOGIC FAILURE IN MULTIRESISTENT HIV-1 INFECTED PATIENTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001827-39,0,0,0 2004-001838-16,2,2005-06-28,2005-06-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALTANA Pharma AG,"Efficacy and safety of a fixed combination of ciclesonide and formoterol once or twice daily in the treatment of persistent asthma A randomized, double-blind, placebo-controlled, parallel-group, multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001838-16,0,0,0 2004-001841-14,3,,,0,1,1,0,0,0,2,0,0,2,0,0,0,0,2,Sanofi-Synthelabo Recherche,Dose-ranging pharmacodynamic assessment of platelet aggregation inhibition with clopidogrel in children of Blalock-Taussig shunt age categories (neonates and infants/toddlers),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001841-14,0,1,0 2004-001841-14,3,,,0,1,1,0,0,0,2,0,0,2,0,0,0,0,2,SANOFI-SYNTHELABO,Dose-ranging pharmacodynamic assessment of platelet aggregation inhibition with clopidogrel in children of Blalock-Taussig shunt age categories (neonates and infants/toddlers),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001841-14,0,1,0 2004-001842-34,5,2014-05-30,2014-06-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG,A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001842-34,0,0,0 2004-001842-34,5,2014-05-30,2014-06-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Johnson&Johnson Pharmaceutical Research and Development, Division de Janssen-Cilag",A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001842-34,0,0,0 2004-001842-34,5,2014-05-30,2014-06-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Cilag International NV,A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001842-34,0,0,0 2004-001842-34,5,2014-05-30,2014-06-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JJANSSEN-CILAG; JOHNSON & JOHNSON spol. s r.o.,A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001842-34,0,0,0 2004-001842-34,5,2014-05-30,2014-06-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Johnson & Johnson Pharmaceutical Research and Development,A Randomized Controlled Study of DOXIL/CAELYX (doxorubicin HCL liposome injection) and VELCADE (bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001842-34,0,0,0 2004-001845-13,4,2006-05-18,2006-05-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Beaufour Ipsen Pharma S.A.S.,"A Phase II, multicentre, multinational, prospective, randomised, double-blind, placebo controlled study assessing the efficacy and safety of a single application of three doses of Dysport in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001845-13,0,0,0 2004-001845-13,4,2006-05-18,2006-05-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,IPSEN LIMITED,"A Phase II, multicentre, multinational, prospective, randomised, double-blind, placebo controlled study assessing the efficacy and safety of a single application of three doses of Dysport in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001845-13,0,0,0 2004-001853-27,2,2007-07-25,2007-07-25,1,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Bioenvision Limited,"A Phase II, Open-Label Study of Clofarabine in Paediatric Patients with Refractory / Relapsed Acute Lymphoblastic Leukaemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001853-27,0,0,0 2004-001853-27,2,2007-07-25,2007-07-25,1,1,0,0,0,2,2,0,0,1,0,0,1,0,1,BIOENVISION,"A Phase II, Open-Label Study of Clofarabine in Paediatric Patients with Refractory / Relapsed Acute Lymphoblastic Leukaemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001853-27,0,0,0 2004-001854-10,4,2007-02-06,2007-02-06,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"Randomized, two arm, placebo controlled double dummy study to compare the efficacy of intravenous loading doses followed by maintenance treatment with oral ibandronic acid versus zoledronic acid in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001854-10,0,0,0 2004-001854-10,4,2007-02-06,2007-02-06,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ROCHE,"Randomized, two arm, placebo controlled double dummy study to compare the efficacy of intravenous loading doses followed by maintenance treatment with oral ibandronic acid versus zoledronic acid in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001854-10,0,0,0 2004-001855-12,4,2007-02-02,2007-02-06,3,1,0,0,2,0,3,0,0,1,1,0,1,0,1,ROCHE,"Randomized, two arm, placebo controlled study to compare the efficacy of IV loading doses followed by maintenance treatment with IV ibandronic acid versus zoledronic acid in patients with skeletal met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001855-12,0,0,0 2004-001855-12,4,2007-02-02,2007-02-06,3,1,0,0,2,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"Randomized, two arm, placebo controlled study to compare the efficacy of IV loading doses followed by maintenance treatment with IV ibandronic acid versus zoledronic acid in patients with skeletal met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001855-12,0,0,0 2004-001856-35,6,2006-03-28,2006-04-28,4,1,0,0,0,0,0,0,0,2,0,0,0,0,1,UCB S.A. Pharma Sector,"A multicenter, double-blind, randomized, placebo-controlled, 3 parallel groups, dose-ranging trial evaluating the efficacy and safety of ucb 34714 used as adjunctive treatment at doses of 50 and 150 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001856-35,1,0,0 2004-001858-90,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,EORTC,Randomised Phase III Intergroup Trial in Resected Stage 2 (Dukes B) Colon Cancer : 6-month Infusional 5FU-CPT11 (+/- Folinic Acid) versus Observation. Determination of Biologic Predictive and Response...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001858-90,0,0,0 2004-001860-27,10,2006-04-28,2011-10-05,4,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Pfizer Hellas A.E.,A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001860-27,0,0,0 2004-001860-27,10,2006-04-28,2011-10-05,4,1,0,0,0,0,3,0,0,1,1,0,1,0,2,PFIZER,A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001860-27,0,0,0 2004-001860-27,10,2006-04-28,2011-10-05,4,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Pfizer Kft.,A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001860-27,0,0,0 2004-001860-27,10,2006-04-28,2011-10-05,4,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Pfizer Global research Development,A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001860-27,0,0,0 2004-001860-27,10,2006-04-28,2011-10-05,4,1,0,0,0,0,3,0,0,1,1,0,1,0,2,"Pfizer Inc., Clinical Development, Pfizer Global Research & Development, La Jolla Laboratories",A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001860-27,0,0,0 2004-001860-27,10,2006-04-28,2011-10-05,4,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Pfizer SA,A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001860-27,0,0,0 2004-001860-27,10,2006-04-28,2011-10-05,4,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Pfizer Global Research Development,A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001860-27,0,0,0 2004-001860-27,10,2006-04-28,2011-10-05,4,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Pfizer Corporation Austria Ges.m.b.H.,A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001860-27,0,0,0 2004-001860-27,10,2006-04-28,2011-10-05,4,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Pfizer Oy,A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001860-27,0,0,0 2004-001860-27,10,2006-04-28,2011-10-05,4,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Pfizer Limited,A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001860-27,0,0,0 2004-001861-17,4,2008-06-27,2008-06-27,2,1,0,0,0,2,0,0,0,2,1,0,0,0,0,University Hospital of Northern Norway. Department of Pediatrics,EURO-LB-02. Treatment Protocol for Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001861-17,1,0,0 2004-001861-17,4,2008-06-27,2008-06-27,2,1,0,0,0,2,0,0,0,2,1,0,0,0,0,NOPHO-NHL GRUPP,EURO-LB-02. Treatment Protocol for Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001861-17,1,0,0 2004-001861-17,4,2008-06-27,2008-06-27,2,1,0,0,0,2,0,0,0,2,1,0,0,0,0,A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA,EURO-LB-02. Treatment Protocol for Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001861-17,1,0,0 2004-001862-42,1,2007-06-21,2007-06-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Clinical Research Facilities,"A multicenter, double-blind, randomized 2x2 factorial design study to compare the efficacy of early (<6 hours) versus late (24-48 hours) ACE-inhibition and to compare the efficacy of Zofenopril and L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001862-42,0,0,0 2004-001876-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Centre,BENEFIT-study: A randomized placebo controlled trial of anti-TNF-alpha chimeric monoclonal antibody ( infliximab) in idiopathic pulmonary fibrosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001876-37,0,0,0 2004-001883-39,1,2005-01-14,2005-01-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Schering Plough Reserach Institute,Study to Evaluate the Effect of the Coadministration of SCH 497079 (a Histamine 3 [H3] Receptor Antagonist) Plus Desloratadine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis Who Have ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001883-39,0,0,0 2004-001888-21,1,2007-11-15,2007-11-15,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Pharmaxis Ltd,"A cross-over comparative study of inhaled mannitol, alone and in combination with daily rhDNase, in children with cystic fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001888-21,0,0,0 2004-001894-24,2,2005-09-19,2005-09-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine combination or Paroxetine monotherapy to Placebo in Patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001894-24,0,0,0 2004-001896-21,1,2006-10-12,2006-10-12,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Chiron S.r.l.,"A Phase II, Randomized, Observer Blind, Multi-Center, Active Controlled Study to Evaluate the Safety and Immunogenicity of Chiron Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001896-21,0,0,0 2004-001900-12,1,,,0,0,0,0,0,3,2,0,1,0,0,0,0,0,0,SERVICIO DE PSIQUIATRIA. HOSPITAL UNIVERSITARI VALL D'HEBRON,"ENSAYO CLINICA DOBLE CIEGO, ALEATORIZADO Y PARALELO SOBRE EL EFECTO DE ESCITALOPRAM vs REBOXETINA EN LA SENSIBILIDAD SOMATICA Y VISCERAL EN PACIENTES CON TRASTORNO DEPRESIVO MAYOR",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001900-12,0,0,0 2004-001901-81,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AISAR ASSOCIAZIONE ITALIANA PER LO STUDIO DEGLI ANTIMICROBICI E DELLE RESISTENZE,"Efficacy and tollerability of thiamphenicol glycinate acetylcysteinate, given in sequential therapy sistematic and aerosol or by aerosol in the treatment of hight respiratory tract acute infection a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001901-81,0,0,0 2004-001904-10,2,2006-05-31,2006-05-31,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pierre Fabre Medicament represented by IRPF,Prospective randomised clinical phase III trial of (alternating IV and oral) vinorelbine plus cisplatin versus docetaxel plus cisplatin in first line chemotherapy of locally advanced or metastatic non...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001904-10,0,0,0 2004-001904-10,2,2006-05-31,2006-05-31,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pierre Fabre Médicament represented by IRPF,Prospective randomised clinical phase III trial of (alternating IV and oral) vinorelbine plus cisplatin versus docetaxel plus cisplatin in first line chemotherapy of locally advanced or metastatic non...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001904-10,0,0,0 2004-001905-93,2,2006-11-01,2006-11-01,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Ltd,"A Phase II study to evaluate the efficacy, safety and pharmacodynamics of lapatinib in combination with paclitaxel as neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001905-93,0,0,0 2004-001906-29,3,2008-03-28,2010-05-31,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Ltd,"Phase II study to evaluate the efficacy, safety and pharmacodynamics of lapatinib in patients with relapsed or refractory inflammatory breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001906-29,0,0,0 2004-001907-36,1,2006-07-31,2006-07-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Limited,A Phase II Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (L-001079038) in Patients with Relapsed Diffuse Large B-Cell Lymphoma (DLBCL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001907-36,0,0,0 2004-001909-10,1,2008-01-31,2008-01-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,Effect of Rosuvastatin on surrogate markers for cardiovascular events and joint disease progression in patients with rheumatoid arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001909-10,0,0,0 2004-001910-15,8,2006-03-29,2006-03-29,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,STALLERGENES,"RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL, MULTI-CENTRE, PHASE IIB/III STUDY OF THE EFFICACY AND SAFETY OF THREE DOSES OF SLIT ADMINISTERED AS TABLETS ONCE DAILY TO PATIENTS SUFFERIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001910-15,0,0,0 2004-001910-15,8,2006-03-29,2006-03-29,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Stallergenes S.A.,"RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL, MULTI-CENTRE, PHASE IIB/III STUDY OF THE EFFICACY AND SAFETY OF THREE DOSES OF SLIT ADMINISTERED AS TABLETS ONCE DAILY TO PATIENTS SUFFERIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001910-15,0,0,0 2004-001914-15,3,2012-12-12,2012-12-13,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer LTD, Pfizer Global RD-Sandwich Laboratories-I.P.C. 582","A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001914-15,0,0,0 2004-001914-15,3,2012-12-12,2012-12-13,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer S.A,"A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001914-15,0,0,0 2004-001914-15,3,2012-12-12,2012-12-13,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ViiV Healthcare UK Limited,"A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001914-15,0,0,0 2004-001915-78,1,2006-09-27,2006-09-27,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Institut Pasteur,"A Comparative Double Blind Placebo-Controlled Study of Immunogenicity and Safety of two doses 10 ^5 and 10^7 CFU of SC599 oral vaccine, a Live Attenuated Shigella dysenteriae 1 vaccine strain in Hea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001915-78,0,0,0 2004-001918-13,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Wales College of Medicine,"Randomised induction and post induction therapy in older patients (>=61 years of age) with acute myeloid leukaemia (AML) and refractory anaemia with excess blasts (RAEB, RAEB-t)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001918-13,0,0,0 2004-001922-26,2,2007-08-03,2007-08-23,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Bioheart,"A Phase II, Open-label, Randomized, Multicenter Study to Assess the Safety and Cardiovascular Effects of MyoCell™ Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001922-26,0,0,0 2004-001922-26,2,2007-08-03,2007-08-23,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Bioheart, Inc","A Phase II, Open-label, Randomized, Multicenter Study to Assess the Safety and Cardiovascular Effects of MyoCell™ Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001922-26,0,0,0 2004-001926-26,1,2015-11-25,2015-11-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,XERXES: Examining the role of early neoadjuvant and synchronous Erbitux in pre-operative chemo-radiotherapy using Xeloda followed by excisional surgery. A phase I/II dose escalation study of intrave...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001926-26,0,0,0 2004-001927-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SIGMA-TAU,"A PHASE II, MULTICENTER, UNCONTROLLED, OPEN STUDY IN PATIENTS WITH CHRONIC HEPATITIS C WHO ARE INTOLERANT TO INTERFERONS THERAPY TO EVALUATE THE SAFETY AND EFFICACY OF A TREATMENT WITH THYMOSIN ALPHA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001927-39,0,0,0 2004-001928-20,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,1,UCB Pharma Belgium,"Open-label, multi-centre study to compare the effectiveness of QvarTM Autohaler therapy with conventional therapy (similar doses) in children with stable asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001928-20,0,0,0 2004-001929-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Servicio de Psiquiatría. Hospital Universitari Vall d’Hebron,EL TEST DE APOMORFINA COMO MARCADOR BIOLÓGICO DE LAS RECAÍDAS EN PACIENTES DEPENDIENTES DE SUSTANCIAS PSICOTROPAS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001929-20,0,0,0 2004-001930-18,1,2006-08-10,2006-08-10,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,"CombinatoRx, Inc","A MULTI-CENTER, RANDOMIZED, BLINDED STUDY COMPARING THE EFFECT OF CRx-102 PLUS DMARD THERAPY TO THAT OF PLACEBO PLUS DMARD THERAPY ON SERUM C-REACTIVE PROTEIN (CRP) AND CYTOKINES IN SUBJECTS WITH RHEU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001930-18,0,0,0 2004-001937-40,2,2010-05-31,2010-05-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,"Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001937-40,0,0,0 2004-001937-40,2,2010-05-31,2010-05-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,"Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001937-40,0,0,0 2004-001941-14,1,2007-11-02,2007-11-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS TAYSIDE,MECHANISMS OF IMIQUIMOD INDUCED REGESSION IN LENTIGO MALIGNA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001941-14,0,0,0 2004-001943-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sociedad Española de Cardiología,ESTUDIO ALEATORIZADO PARA COMPARAR LA EFICACIA Y SEGURIDAD DE LA FIBRINOLISIS O LA ANGIOPLASTIA PRIMARIA COMO TRATAMIENTO INICIAL DE REPERFUSIÓN EN LOS PACIENTES DE EDAD AVANZADA (>/=75 AÑOS) CON INFA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001943-31,0,0,0 2004-001949-15,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,1,photonamic GmbH & Co. KG,"PD P 506 A applied for 0.5, 1, 2 or 4 hours in combination with red light for photodynamic therapy of mild to moderate actinic keratosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001949-15,0,0,0 2004-001952-35,1,2005-09-15,2005-09-15,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Chiron S.r.l.,"A Phase IV, Observer-Blind, Randomized, Parallel Groups, Single-Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of Two 0.25 mL Intramuscular Doses of Agrippal™ S1, Influva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001952-35,0,0,0 2004-001953-27,1,2010-01-15,2010-01-15,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University Hospitals of Leicester NHS Trust,The Pharmacokinetics of Systemic Corticosteriods in Refractory Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001953-27,0,0,0 2004-001955-12,4,2005-06-24,2005-06-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,pfizer s.a,"A double blind, placebo controlled, parallel group, multicenter study to assess the duration of action, safety and toleration of differing doses and combinations of immediate and modified release form...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001955-12,0,0,0 2004-001955-12,4,2005-06-24,2005-06-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer S.A. Belgium,"A double blind, placebo controlled, parallel group, multicenter study to assess the duration of action, safety and toleration of differing doses and combinations of immediate and modified release form...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001955-12,0,0,0 2004-001955-12,4,2005-06-24,2005-06-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A double blind, placebo controlled, parallel group, multicenter study to assess the duration of action, safety and toleration of differing doses and combinations of immediate and modified release form...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001955-12,0,0,0 2004-001955-12,4,2005-06-24,2005-06-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Limited,"A double blind, placebo controlled, parallel group, multicenter study to assess the duration of action, safety and toleration of differing doses and combinations of immediate and modified release form...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001955-12,0,0,0 2004-001959-11,15,2007-12-13,2008-07-28,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales,Effects of ivabradine on cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled intern...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001959-11,0,0,0 2004-001959-11,15,2007-12-13,2008-07-28,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Servier Research and Development Ltd,Effects of ivabradine on cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled intern...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001959-11,0,0,0 2004-001959-11,15,2007-12-13,2008-07-28,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Effects of ivabradine on cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled intern...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001959-11,0,0,0 2004-001959-11,15,2007-12-13,2008-07-28,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Effects of ivabradine on cardiovascular events in patients with stable coronary artery disease and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled intern...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001959-11,0,0,0 2004-001960-30,9,2007-10-17,2007-10-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradina compared to placebo on top of a background therapy with atenolol in patients with stable angina pectoris. A 4-mo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001960-30,0,0,0 2004-001960-30,9,2007-10-17,2007-10-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradina compared to placebo on top of a background therapy with atenolol in patients with stable angina pectoris. A 4-mo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001960-30,0,0,0 2004-001960-30,9,2007-10-17,2007-10-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratorios Servier S.L. (For Spain only),Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradina compared to placebo on top of a background therapy with atenolol in patients with stable angina pectoris. A 4-mo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001960-30,0,0,0 2004-001965-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,LABORATORIOS LETI,"ENSAYO CLÍNICO, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO CONTROLADO CON PLACEBO, DE INMUNOTERAPIA SUBLINGUAL CON EXTRACTO ALERGÉNICO DE DERMATOPHAGOIDES PTERONYSSINUS EN PACIENTES CON ASMA, DE INTENSI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001965-16,0,0,0 2004-001966-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,LABORATORIOS LETI,"ENSAYO CLÍNICO, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO CONTROLADO CON PLACEBO, DE INMUNOTERAPIA SUBLINGUAL CON EXTRACTO DE POLEN DE PHLEUM PRATENSE EN PACIENTES CON HIPERSENSIBILIDAD AL POLEN DE GRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001966-41,0,0,0 2004-001967-24,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Sanofi-Synthelabo Rt.,Kiegészítő zolpidem kezelés friss antidepresszáns kezelés alatt álló disztimiás vagy depressziós betegek alvászavarának kezelésében,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001967-24,0,0,0 2004-001969-17,5,2006-06-16,2006-06-16,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Vernalis Development Limited,"A double-blind, placebo-controlled, parallel group study with an open label extension phase, to assess the efficacy, tolerability and safety of oral frovatriptan in the prevention of menstrually-relat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001969-17,0,0,0 2004-001969-17,5,2006-06-16,2006-06-16,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,VERNALIS DEVELOPMENT LIMITED,"A double-blind, placebo-controlled, parallel group study with an open label extension phase, to assess the efficacy, tolerability and safety of oral frovatriptan in the prevention of menstrually-relat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001969-17,0,0,0 2004-001979-18,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Novartis Farmacéutica, S.A.","Extensión de 28 semanas de duración del estudio multicéntrico, doble ciego, aleatorizado, de grupos paralelos que compara el efecto de 24 semanas de tratamiento con 50 mg bid de LAF237 frente a placeb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001979-18,0,0,0 2004-001981-41,1,2008-06-30,2008-06-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,UNIVERSITY OF OXFORD,Bipolar Affective disorder: Lithium/ANti-Convulsant Evaluation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001981-41,0,0,0 2004-001984-22,1,,,0,1,0,0,0,0,3,0,0,0,0,0,0,0,0,Fédération Nationale des Centres de Lutte Contre le Cancer,Essai randomisé de phase III comparant l’association traitement hormonal + docétaxel au traitement hormonal seul dans les cancers de la prostate métastatiques,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001984-22,0,0,0 2004-001988-21,9,2006-07-19,2006-08-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A phase II trial randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate cap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001988-21,0,0,0 2004-001988-21,9,2006-07-19,2006-08-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,"A phase II trial randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate cap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001988-21,0,0,0 2004-001988-21,9,2006-07-19,2006-08-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer-Ingelheim Denmark A/S,"A phase II trial randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate cap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001988-21,0,0,0 2004-001988-21,9,2006-07-19,2006-08-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase II trial randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate cap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001988-21,0,0,0 2004-001988-21,9,2006-07-19,2006-08-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A phase II trial randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate cap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001988-21,0,0,0 2004-001988-21,9,2006-07-19,2006-08-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer-Ingelheim AB,"A phase II trial randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate cap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001988-21,0,0,0 2004-001988-21,9,2006-07-19,2006-08-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A phase II trial randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate cap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001988-21,0,0,0 2004-001988-21,9,2006-07-19,2006-08-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Austria GmbH,"A phase II trial randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens of orally administered dabigatran etexilate cap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001988-21,0,0,0 2004-001989-41,10,2011-04-19,2011-11-08,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen - Cilag , Johnson & Johnson s.r.o.","An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects with Previously Untreated Multiple Myeloma An Open-Label, Randomized Study of VELCADE/Melphal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001989-41,0,0,0 2004-001989-41,10,2011-04-19,2011-11-08,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag Oy,"An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects with Previously Untreated Multiple Myeloma An Open-Label, Randomized Study of VELCADE/Melphal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001989-41,0,0,0 2004-001989-41,10,2011-04-19,2011-11-08,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag Kft.,"An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects with Previously Untreated Multiple Myeloma An Open-Label, Randomized Study of VELCADE/Melphal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001989-41,0,0,0 2004-001989-41,10,2011-04-19,2011-11-08,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag S.A.,"An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects with Previously Untreated Multiple Myeloma An Open-Label, Randomized Study of VELCADE/Melphal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001989-41,0,0,0 2004-001989-41,10,2011-04-19,2011-11-08,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"J&J PRD, a division of Janssen-Cilag NV","An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects with Previously Untreated Multiple Myeloma An Open-Label, Randomized Study of VELCADE/Melphal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001989-41,0,0,0 2004-001989-41,10,2011-04-19,2011-11-08,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG,"An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects with Previously Untreated Multiple Myeloma An Open-Label, Randomized Study of VELCADE/Melphal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001989-41,0,0,0 2004-001989-41,10,2011-04-19,2011-11-08,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag Limited,"An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects with Previously Untreated Multiple Myeloma An Open-Label, Randomized Study of VELCADE/Melphal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001989-41,0,0,0 2004-001989-41,10,2011-04-19,2011-11-08,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Cilag Limited,"An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects with Previously Untreated Multiple Myeloma An Open-Label, Randomized Study of VELCADE/Melphal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001989-41,0,0,0 2004-001989-41,10,2011-04-19,2011-11-08,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag Intrenational N.V.,"An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects with Previously Untreated Multiple Myeloma An Open-Label, Randomized Study of VELCADE/Melphal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001989-41,0,0,0 2004-001989-41,10,2011-04-19,2011-11-08,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Cilag Pharma GmbH,"An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects with Previously Untreated Multiple Myeloma An Open-Label, Randomized Study of VELCADE/Melphal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001989-41,0,0,0 2004-001990-25,1,2006-07-20,2006-07-20,1,0,0,0,0,3,2,0,1,1,0,0,1,0,0,Bo Söderpalm,Hur påverkar Remeron alkoholkonsumtionen? How will Remeron influence alcohol consumption in high consumers?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001990-25,0,0,0 2004-001991-37,1,2007-11-01,2007-11-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Moorfields Eye Hospital,A pilot study investigating the effects of a combination of local and systemic anti-inflammatory adjuncts in patients undergoing vitrectomy and silicone oil for established Proliferative Vitreoretinop...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001991-37,0,0,0 2004-001994-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Institute Danderyd Hospital,Effects of atorvastatin on plasma fibrin gel structure and skin microvascular reactivity in patients with type 1 diabetes and dyslipidemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001994-24,0,0,0 2004-001997-13,2,2007-07-10,2007-09-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB SA Pharma Sector,"An open-label, multicenter, follow-up study to evaluate the safety and efficacy of levetiracetam (LEV) (oral tablets of 166, 250 or 500 mg b.i.d.), at individualized doses up to a maximum of 4000 mg/d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001997-13,0,0,0 2004-001997-13,2,2007-07-10,2007-09-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB S.A. Pharma Sector,"An open-label, multicenter, follow-up study to evaluate the safety and efficacy of levetiracetam (LEV) (oral tablets of 166, 250 or 500 mg b.i.d.), at individualized doses up to a maximum of 4000 mg/d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001997-13,0,0,0 2004-001998-25,1,2008-04-14,2008-04-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Diamyd Therapeutics AB,A placebo-controlled study to investigate the impact of DiamydTM on the diabetic status of patients with LADA (Latent Autoimmune Diabetes in Adult).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001998-25,0,0,0 2004-001999-40,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,GlaxoSmithKline R&D Ltd,"A randomised, multicentre, double-blind, placebo-controlled, 2-arm, Phase III study of oral GW572016 in combination with paclitaxel in subjects previously untreated for advanced or metastatic breast c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001999-40,0,0,0 2004-002006-30,1,2006-06-06,2006-06-06,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,North Glasgow NHS Trust,Triple therapy in early active rheumatoid arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002006-30,0,0,0 2004-002007-33,1,2007-07-11,2007-07-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"An 80-week, randomized, multi center, parallel group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhibito...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002007-33,0,0,0 2004-002013-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CONCEPCION MORO SERRANO,"A PROSPECTIVE DOUBLE BLIND AND RANDOMIZED STUDY ON THE EFFECT OF TRANDOLAPRIL, IN MAINTAINING SINUS RHYTHM IN PATIENTS WITH LONG-LASTING PERSISTENT ATRIAL FIBRILLATION. ESTUDIO PROSPECTIVO, DOBLE CIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002013-36,0,0,0 2004-002015-86,4,2005-09-08,2005-09-08,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S),"Calcipotriol plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle and the Gel Vehicle alone in Scalp Psoriasis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002015-86,0,0,0 2004-002015-86,4,2005-09-08,2005-09-08,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FARMACUSI S.A. (filial of LEO Pharma),"Calcipotriol plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle and the Gel Vehicle alone in Scalp Psoriasis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002015-86,0,0,0 2004-002015-86,4,2005-09-08,2005-09-08,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharma A/S,"Calcipotriol plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle and the Gel Vehicle alone in Scalp Psoriasis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002015-86,0,0,0 2004-002016-28,5,2007-10-17,2016-07-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Ltd,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002016-28,0,0,0 2004-002016-28,5,2007-10-17,2016-07-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002016-28,0,0,0 2004-002016-28,5,2007-10-17,2016-07-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002016-28,0,0,0 2004-002017-37,5,2007-08-31,2008-01-16,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SANOFI-SYNTHELABO,"Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002017-37,0,0,0 2004-002017-37,5,2007-08-31,2008-01-16,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-Synthelabo Research,"Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002017-37,0,0,0 2004-002019-97,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"FARMACUSI, S.A.","Long term subcutaneous tinzaparin compared with tinzaparin and oral anticoagulants in the treatment of acute pulmonary embolism. A multicentre, prospective, randomised, open, parallel group clinical t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002019-97,0,0,0 2004-002020-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Catalan Society of Family Medicine, represented by Dr Mariano de la Figuera Von Wichman and Gabriel",ESTRATEGIAS PARA EL TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL. EVALUACIÓN DE UNA TERAPIA COMBINADA A DOSIS FIJAS (LOSARTÁN/HIDROCLOROTIAZIDA) vs MONOTERAPIA (ESTRATAAR). (STRATEGIES FOR THE TREATMENT OF...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002020-17,0,0,0 2004-002022-22,1,2005-04-08,2005-04-08,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,SSL International plc,"A phase II randomised, controlled, assessor-blind, parallel group clinical trial to demonstrate the proof of concept of an experimental pediculicide rinse and Lyclear Creme Rinse in the treatment of h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002022-22,0,0,0 2004-002030-19,1,2011-11-22,2011-11-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,AUSTRIAN BREAST CANCER STUDY GROUP,"A randomized phase III study comparing epirubicin, docetaxel and capecitabine + G-CSF to epirubicin and docetaxel + G-CSF as neoadjuvant treatment for early HER-2 negative breast cancer and comparing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002030-19,0,0,0 2004-002032-26,11,2008-06-04,2010-01-22,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002032-26,0,0,0 2004-002032-26,11,2008-06-04,2010-01-22,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002032-26,0,0,0 2004-002033-39,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SAN GERARDO DI MONZA,STUDY OF PREOPERATIVE AND POSTOPERATIVE IL-2 IMMUNOTHERAPY IN PANCREATIC CANCER SURGERY - RANDOMIZED PHASE 2 STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002033-39,0,0,0 2004-002036-25,8,2008-12-01,2008-12-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LABORATOIRE AVENTIS,Comparison of three therapeutic strategies for treating type 2 diabetes mellitus patients poorly controlled with basal insulin associated with oral antidiabetic drugs OSIRIS STUDY: Opposing Step-by-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002036-25,0,0,0 2004-002036-25,8,2008-12-01,2008-12-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi aventis groupe,Comparison of three therapeutic strategies for treating type 2 diabetes mellitus patients poorly controlled with basal insulin associated with oral antidiabetic drugs OSIRIS STUDY: Opposing Step-by-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002036-25,0,0,0 2004-002036-25,8,2008-12-01,2008-12-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AVENTIS PHARMA S.P.A.,Comparison of three therapeutic strategies for treating type 2 diabetes mellitus patients poorly controlled with basal insulin associated with oral antidiabetic drugs OSIRIS STUDY: Opposing Step-by-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002036-25,0,0,0 2004-002041-12,2,2006-04-26,2006-04-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gambro Lundia AB, Corporate Research",Is it possible to increase free sodium removal by the use of low sodium peritoneal dialysis solution?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002041-12,0,0,0 2004-002050-66,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,PENTA,INTERRUPCIÓN DEL TRATAMIENTO EN NIÑOS CON INFECCIÓN CRÓNICA POR VIH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002050-66,0,0,0 2004-002050-66,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,PENTA Foundation,INTERRUPCIÓN DEL TRATAMIENTO EN NIÑOS CON INFECCIÓN CRÓNICA POR VIH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002050-66,0,0,0 2004-002051-13,1,,,0,1,0,0,0,0,4,0,0,3,0,0,0,0,0,"Imperial College, London",A randomised double-blind placebo-controlled trial of oral misoprostol for cervical priming before outpatient hysteroscopy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002051-13,0,0,0 2004-002053-31,1,2010-03-26,2010-03-26,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Hammersmith Hospital,To determine the diagnostic accuracy of MRI in detecting lymph node metastases using USPIO (Ultra small super-paramagnetic iron oxide particles) in patients with gynecological malignancy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002053-31,0,0,0 2004-002054-55,2,2007-01-02,2007-01-02,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Topotarget A/S,A phase II Clinical Trial of PXD101 in Patients with Advanced Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002054-55,0,0,0 2004-002056-34,1,2007-11-13,2007-11-13,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,Bradford Teaching Hospitals NHS Foundation Trust,Glucocorticosteroid replacement therapy and fibrinolysis in hypopituitarism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002056-34,0,0,0 2004-002058-69,1,2009-05-01,2009-05-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals of Leicester NHS Trust,The use of nicotine patches for the treatment of psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002058-69,0,0,0 2004-002065-20,1,2010-05-25,2010-05-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Derbyshire NHS Trust,Single site randomised trial of fibrin tissue glue versus surgery in the treatment of pilonidal sinus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002065-20,0,0,0 2004-002069-19,3,2010-06-17,2010-06-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Refractory Partial Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002069-19,0,0,0 2004-002070-36,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Metcon Medicin AB,"Efficacy of MM005-Granulae as prophylaxis for nocturnal hypoglycemia in insulin treated Type 1 diabetic subjects. A double-blind, randomized, placebo-controlled phase II multi-center study in three pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002070-36,0,0,0 2004-002071-16,4,2005-11-12,2005-11-12,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,BIOMARIN,"A Phase 2, Multicenter, Open-Label Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin Treatment in Subjects with Phenylketonuria Who Have Elevated Phenylalanine Levels",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002071-16,0,0,0 2004-002071-16,4,2005-11-12,2005-11-12,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc.,"A Phase 2, Multicenter, Open-Label Study to Evaluate the Response to and Safety of an 8-Day Course of Phenoptin Treatment in Subjects with Phenylketonuria Who Have Elevated Phenylalanine Levels",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002071-16,0,0,0 2004-002076-42,2,2006-02-09,2006-02-09,2,0,0,0,0,0,3,0,1,1,1,0,1,0,1,Grünenthal GmbH,"Safety, hemostatic and metabolic effects and contraceptive efficacy of an oral monophasic contraceptive containing 0.03 mg ethinylestradiol and 2 mg chlormadinone acetate (CG5025) used in two differen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002076-42,0,0,0 2004-002076-42,2,2006-02-09,2006-02-09,2,0,0,0,0,0,3,0,1,1,1,0,1,0,1,Laboratorios Andrómaco S.A. (co-sponsor Spain),"Safety, hemostatic and metabolic effects and contraceptive efficacy of an oral monophasic contraceptive containing 0.03 mg ethinylestradiol and 2 mg chlormadinone acetate (CG5025) used in two differen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002076-42,0,0,0 2004-002076-42,2,2006-02-09,2006-02-09,2,0,0,0,0,0,3,0,1,1,1,0,1,0,1,Laboratorios Andrómaco S.A.,"Safety, hemostatic and metabolic effects and contraceptive efficacy of an oral monophasic contraceptive containing 0.03 mg ethinylestradiol and 2 mg chlormadinone acetate (CG5025) used in two differen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002076-42,0,0,0 2004-002077-23,4,2009-03-17,2009-03-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.,Efficacy and safety of Olmesartan medoxomil in elderly patients with mild to moderate hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002077-23,0,0,0 2004-002078-45,2,2005-07-28,2005-07-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Fujisawa GmbH,"A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TACROLIMUS MDI AS ADD-ON THERAPY TO ICS AND LABA IN MODERATE TO SEVERE PERSISTENT ASTHMATIC PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002078-45,0,0,0 2004-002079-18,2,2005-08-26,2005-08-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Fujisawa GmbH,"A MULTICENTRE, RANDOMISED, DOUBLE BLIND, DOUBLE- DUMMY PARALLEL-GROUP STUDY INVESTIGATING THE EFFICACY AND SAFETY OF THREE DIFFERENT DOSES OF TACROLIMUS INHALATION AEROSOL AND A STANDARD DOSE OF INH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002079-18,0,0,0 2004-002086-20,1,2008-04-30,2008-04-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Ipsen Pharma GmbH,"Open, multicentre study on the equivalent efficacy and safety of Botulinum toxin A (500 Units Dysport®) in the treatment of heterogeneous forms of cervical dystonia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002086-20,0,0,0 2004-002089-39,4,2005-11-30,2005-11-30,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, multi-center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10 mcg b.i.d., tiotropium HandiHaler mcg 18 mcg o.d. and tiotropium HandiHaler ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002089-39,0,0,0 2004-002089-39,4,2005-11-30,2005-11-30,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, multi-center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10 mcg b.i.d., tiotropium HandiHaler mcg 18 mcg o.d. and tiotropium HandiHaler ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002089-39,0,0,0 2004-002089-39,4,2005-11-30,2005-11-30,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, multi-center, placebo controlled 24 week study to compare the efficacy and safety of formoterol Certihaler 10 mcg b.i.d., tiotropium HandiHaler mcg 18 mcg o.d. and tiotropium HandiHaler ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002089-39,0,0,0 2004-002090-23,2,2005-10-17,2005-10-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Kowa Research Europe Ltd.,"A phase IIa multicentre randomised double-blind, double-dummy study to evaluate the efficacy and safety of K-111 versus Fenofibrate in patients with hyperlipidaemia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002090-23,0,0,0 2004-002093-30,1,2008-01-01,2008-01-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"Extension protocol for patients with Chronic Myelogenous Leukemia (CML), Malignant Melanoma (MM) or Renal Cell Carcinoma (RCC) that have responded to treatment with Pegylated-interferon α-2a (PEG-IFN)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002093-30,0,0,0 2004-002094-23,4,2006-09-29,2006-09-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,0,EORTC,Estudio aleatorizado de fase II de docetaxel (Taxotere) y oblimersén (oligonucleótido antisentido dirigido frente a bcl-2) vs. Taxotere solo en pacientes con cáncer de próstata refractario a la hormon...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002094-23,0,0,0 2004-002096-16,1,2005-12-31,2005-12-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Universitätskinderklinik Innsbruck,Effect of plasma volume expansion with hydroxy-ethyl-starch (HES) 130/0.4 or crystalloids on interstitial fluid accumulation and blood pressure in newborn infants with arterial hypotension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002096-16,0,0,0 2004-002099-40,3,2005-08-23,2006-08-23,3,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Schering AG,"Double-blind, randomized, reference-controlled, multicenter, parallel-group study to compare the efficacy and safety of Advantan ointment once daily with Protopic 0.03% ointment twice daily over max. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002099-40,0,0,0 2004-002099-40,3,2005-08-23,2006-08-23,3,1,0,0,0,0,4,0,0,1,0,0,1,0,2,SCHERING,"Double-blind, randomized, reference-controlled, multicenter, parallel-group study to compare the efficacy and safety of Advantan ointment once daily with Protopic 0.03% ointment twice daily over max. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002099-40,0,0,0 2004-002102-30,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,CELGENE EUROPE LIMITED,"OPEN-LABEL, SINGLE-ARM STUDY OF THE SAFETY AND EFFICACY OF CC-5013 MONOTHERAPY FOR SUBJECTS WITH MULTIPLE MYELOMA A COMPANION STUDY FOR STUDIES THAL-MM-003, CC-5013-MM-009, AND CC-5013-MM-010",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002102-30,0,0,0 2004-002103-32,1,2014-01-16,2014-01-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,GELA-Recherche Clinique,"Phase III multicentre open-label randomised study of ICE plus Rituximab (R-ICE) versus DHAP plus Rituximab (R-DHAP) in previously treated patients with CD 20 positive diffuse large B-cell lymphoma, el...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002103-32,0,0,0 2004-002106-29,3,2005-05-11,2008-05-05,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Pharma Mar SA Unipersonal,"A Randomized, Multicenter, Open-label Study of YONDELIS ™ (ET-743 ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002106-29,0,0,0 2004-002106-29,3,2005-05-11,2008-05-05,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,PHARMA MAR,"A Randomized, Multicenter, Open-label Study of YONDELIS ™ (ET-743 ecteinascidin) Administered by 2 Different Schedules (Weekly for 3 of 4 weeks vs. q3 Weeks) in Subjects With Locally Advanced or Metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002106-29,0,0,0 2004-002108-14,1,2006-05-15,2006-05-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Fresenius Medical Care Deutschland GmbH.,Multizentrische Studie mit einer Niedrig-Natrium Peritonealdialyse-Lösung bei hypertensiven od. antihypertensiv behandelten CAPD Patienten auf balance Lösung,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002108-14,0,0,0 2004-002109-58,6,2007-01-19,2007-06-19,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"ALLOS Therapeutics, Inc.","A Phase 3 Randomized, Open-label Comparative Study of Standard Whole Brain Radiation Therapy with Supplemental Oxygen, with or without Concurrent RSR13 efaproxiral , in Women with Brain Metasta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002109-58,1,0,0 2004-002109-58,6,2007-01-19,2007-06-19,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ALLOS,"A Phase 3 Randomized, Open-label Comparative Study of Standard Whole Brain Radiation Therapy with Supplemental Oxygen, with or without Concurrent RSR13 efaproxiral , in Women with Brain Metasta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002109-58,1,0,0 2004-002113-36,1,2012-07-05,2012-07-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,European Organisation for the Research and Treatment of Cancer,Randomised trial of single agent doxorubicin versus doxorubicin plus ifosfamide in the first line treatment of advanced or metastatic soft tissue sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002113-36,0,0,0 2004-002114-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Infociencia Clinical Research,"A double blind, randomized, placebo-controlled, cross-over study to evaluate the effects of Levetiracetam on membrane excitability properties of afferent myelinated and unmyelinated fibers and change ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002114-11,0,0,0 2004-002116-28,1,2009-03-03,2009-03-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,"Does Vitamin D supplementation improve function and quality of life in older heart failure patients - A double blind, placebo controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002116-28,0,0,0 2004-002122-22,1,2009-03-19,2009-03-19,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Intercytex Limited,"A prospective, multi-centre, double blind, randomized, placebo controlled trial to evaluate the safety and efficacy of ICXP007 in a phase III trial with four-layer therapeutic compression, for treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002122-22,0,0,0 2004-002125-42,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",EFFECT OF PROLONGED TREATMENT WITH TH9507 ON IGF-I LEVELS IN ADOLESCENTS WITH ISOLATED GH DEFICIENCY DUE TO HYPOTHALAMIC PATHOGENESIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002125-42,0,0,0 2004-002130-18,3,2009-02-06,2009-02-06,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Centocor B.V.,"A Phase 1/2 , Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human av Integrins (CNTO 95), Alone and in Combination with Dacarbazine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002130-18,0,0,0 2004-002131-12,1,2007-03-29,2007-03-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,Evaluation of efficacy and safety of ibandronate as treatment of metastatic bone pain in patients with different tumor types. A randomised phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002131-12,0,0,0 2004-002132-26,2,2013-02-06,2013-02-06,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F Hoffmann-La Roche Limited,"A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMAb 2H7) in patients with moderate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002132-26,0,0,0 2004-002132-26,2,2013-02-06,2013-02-06,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F. Hoffmann-La Roche Limited,"A randomized placebo-controlled, multicenter, blinded Phase I/II study of the safety of escalating single intravenous doses of ocrelizumab (Ro 496-4913, PRO70769, rhuMAb 2H7) in patients with moderate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002132-26,0,0,0 2004-002136-25,2,2006-08-02,2006-08-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma S.A,"A 52-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to metformin up to 1000 mg bid in drug naïve p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002136-25,0,0,0 2004-002136-25,2,2006-08-02,2006-08-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"A 52-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to metformin up to 1000 mg bid in drug naïve p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002136-25,0,0,0 2004-002137-39,1,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,3,,A randomised controlled trial of the combined use of paracetamol and ibuprofen to treat febrile children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002137-39,0,0,0 2004-002140-10,10,2019-05-28,2019-05-28,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"An open-label, multi-center, follow-up trial to evaluate long-term safety and efficacy of brivaracetam (ucb 34714) used as adjunctive treatment at a flexible dose up to a maximum of 200 mg/day in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002140-10,0,0,0 2004-002140-10,10,2019-05-28,2019-05-28,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB S.A. Casa Madre,"An open-label, multi-center, follow-up trial to evaluate long-term safety and efficacy of brivaracetam (ucb 34714) used as adjunctive treatment at a flexible dose up to a maximum of 200 mg/day in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002140-10,0,0,0 2004-002140-10,10,2019-05-28,2019-05-28,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB S.A. Pharma Sector,"An open-label, multi-center, follow-up trial to evaluate long-term safety and efficacy of brivaracetam (ucb 34714) used as adjunctive treatment at a flexible dose up to a maximum of 200 mg/day in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002140-10,0,0,0 2004-002140-10,10,2019-05-28,2019-05-28,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB S.A.,"An open-label, multi-center, follow-up trial to evaluate long-term safety and efficacy of brivaracetam (ucb 34714) used as adjunctive treatment at a flexible dose up to a maximum of 200 mg/day in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002140-10,0,0,0 2004-002143-27,4,2005-12-17,2005-12-17,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim AB,"A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002143-27,0,0,0 2004-002143-27,4,2005-12-17,2005-12-17,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim GmbH,"A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002143-27,0,0,0 2004-002143-27,4,2005-12-17,2005-12-17,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Austria GmbH,"A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to compare the efficacy and safety of duloxetine hydrochloride (40mg twice a day) and tolterodine tartrate (XL)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002143-27,0,0,0 2004-002147-27,1,,,0,1,0,0,0,3,4,0,1,1,0,0,0,1,0,Department of General Psychiatry,Influence of treatment of olanzapine and ziprasidone on transcapillary glucose transport in human skeletal muscle,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002147-27,0,0,0 2004-002150-64,1,2011-06-30,2011-06-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medical University Vienna, Dept. of Medicine I, Clinical Division of Oncology","Bortezomib, Rituximab, and Dexamethasone (BORID), followed by Rituximab maintenance, for patients with relapsed/refractory mantle cell lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002150-64,0,0,0 2004-002152-33,4,2005-08-30,2015-07-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharma A/S,Calcipotriol plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle and Calcipotriol in the Gel Vehicle in Scalp Psoriasis. A phase III study comparing a gel con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002152-33,0,0,0 2004-002152-33,4,2005-08-30,2015-07-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S),Calcipotriol plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle and Calcipotriol in the Gel Vehicle in Scalp Psoriasis. A phase III study comparing a gel con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002152-33,0,0,0 2004-002156-34,1,2006-06-09,2006-06-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NV Organon,"Double-blind, placebo-controlled trial investigating the safety of re-exposure to 900 mg of Org 34517, used as adjunctive therapy in subjects with psychotic major depression (major depressive episode,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002156-34,0,0,0 2004-002157-30,3,2005-11-14,2006-09-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Europe R&D Centre Ltd. (TEuR&D),"A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Oral TAK-715 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002157-30,0,0,0 2004-002159-16,12,2006-06-08,2007-06-08,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck & Co Inc.,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002159-16,0,0,0 2004-002159-16,12,2006-06-08,2007-06-08,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme BV,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002159-16,0,0,0 2004-002159-16,12,2006-06-08,2007-06-08,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002159-16,0,0,0 2004-002159-16,12,2006-06-08,2007-06-08,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck, Sharp & Dohme","A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002159-16,0,0,0 2004-002159-16,12,2006-06-08,2007-06-08,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Limited,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002159-16,0,0,0 2004-002159-16,12,2006-06-08,2007-06-08,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"UAB ""Merck Sharp & Dohme""","A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002159-16,0,0,0 2004-002159-16,12,2006-06-08,2007-06-08,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002159-16,0,0,0 2004-002159-16,12,2006-06-08,2007-06-08,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002159-16,0,0,0 2004-002159-16,12,2006-06-08,2007-06-08,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002159-16,0,0,0 2004-002159-16,12,2006-06-08,2007-06-08,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Suomen MSD Oy,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002159-16,0,0,0 2004-002160-22,2,2006-07-27,2006-07-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431 Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002160-22,0,0,0 2004-002160-22,2,2006-07-27,2006-07-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck & Co. Inc.,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431 Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002160-22,0,0,0 2004-002163-24,8,2009-02-04,2009-02-24,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn'...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002163-24,0,0,0 2004-002163-24,8,2009-02-04,2009-02-24,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & co. KG,"A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn'...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002163-24,0,0,0 2004-002163-24,8,2009-02-04,2009-02-24,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmBH Co KG,"A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn'...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002163-24,0,0,0 2004-002163-24,8,2009-02-04,2009-02-24,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott Laboratories,"A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn'...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002163-24,0,0,0 2004-002165-20,3,2006-07-03,2007-03-07,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Amgen Inc,An Open Label Study of AMG 706 in Subjects with Advanced Gastrointestinal Stromal Tumors (GISTs) who Developed Progressive Disease or Relapsed While on Imatinib Mesylate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002165-20,0,0,0 2004-002165-20,3,2006-07-03,2007-03-07,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,AMGEN,An Open Label Study of AMG 706 in Subjects with Advanced Gastrointestinal Stromal Tumors (GISTs) who Developed Progressive Disease or Relapsed While on Imatinib Mesylate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002165-20,0,0,0 2004-002166-38,3,2006-04-11,2006-10-27,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A 12-week randomised, double blind, placebo controlled, parallel group trial evaluating the efficacy and safety of inhaled tiotropium 18µg q.d. in patients with CIOD and a concomitant diagnosis of ast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002166-38,0,0,0 2004-002166-38,3,2006-04-11,2006-10-27,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A 12-week randomised, double blind, placebo controlled, parallel group trial evaluating the efficacy and safety of inhaled tiotropium 18µg q.d. in patients with CIOD and a concomitant diagnosis of ast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002166-38,0,0,0 2004-002168-59,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,3,GENZYME,"An Open-Label, Multicenter, Multinational, Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Acid alpha- Glucosidase (rhGAA) Treatment in Patients > 6 and <= 3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002168-59,0,0,0 2004-002170-34,1,2010-02-15,2010-02-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cambridge University Hospital (Addenbrookes Hospital),"""Ensayo clínico controlado randomizado sobre el tratamiento precoz con insulina en recién nacidos de muy bajo peso""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002170-34,0,0,0 2004-002171-16,4,2005-12-07,2005-12-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BAYER,Once-daily oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. The Einstein-DVT dose-finding study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002171-16,0,0,0 2004-002171-16,4,2005-12-07,2005-12-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,Once-daily oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with acute symptomatic Deep Vein Thrombosis. The Einstein-DVT dose-finding study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002171-16,0,0,0 2004-002172-42,7,2007-09-26,2007-12-17,7,1,0,0,2,0,0,0,0,1,0,0,1,0,1,BAYER,"A randomized, double-blind, double-dummy, multi-center, parallel group study to compare the tolerability and efficacy of once daily vardenafil versus vardenafil PRN versus placebo in men immediately a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002172-42,0,0,0 2004-002172-42,7,2007-09-26,2007-12-17,7,1,0,0,2,0,0,0,0,1,0,0,1,0,1,Bayer Healthcare AG,"A randomized, double-blind, double-dummy, multi-center, parallel group study to compare the tolerability and efficacy of once daily vardenafil versus vardenafil PRN versus placebo in men immediately a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002172-42,0,0,0 2004-002172-42,7,2007-09-26,2007-12-17,7,1,0,0,2,0,0,0,0,1,0,0,1,0,1,Bayer Oy,"A randomized, double-blind, double-dummy, multi-center, parallel group study to compare the tolerability and efficacy of once daily vardenafil versus vardenafil PRN versus placebo in men immediately a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002172-42,0,0,0 2004-002173-23,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,GENZYME,PHASE 2 CLINICAL STUDY PROTOCOL: SAFETY AND EFFICACY OF RISING DOSES OF DEFERITRIN IN BETA-THALASSEMIA PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002173-23,0,0,0 2004-002174-32,4,2006-03-06,2006-04-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GENZYME,"An Open Label, Randomized, Parallel Design Study to Investigate the Efficacy and Safety of Sevelamer Hydrochloride Renagel Compared with Calcium Acetate in Peritoneal Dialysis Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002174-32,0,0,0 2004-002174-32,4,2006-03-06,2006-04-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme Europe BV,"An Open Label, Randomized, Parallel Design Study to Investigate the Efficacy and Safety of Sevelamer Hydrochloride Renagel Compared with Calcium Acetate in Peritoneal Dialysis Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002174-32,0,0,0 2004-002176-42,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,DOMPE' BIOTEC,"Open randomized study to evaluate the efficacy of i.v. iron support (ferrum gluconate, 125 mg i.v. infusion weekly for 6 weeks) in primary solid tumour patients (breast, lung, colon-rectum and gynecol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002176-42,0,0,0 2004-002180-24,1,2009-04-30,2009-04-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Swindon & Marlborough NHS Trust,Prospective randomised double blind comparative study of cinnarizine versus placebo as prophylactic anti-travel sickness therapy in patients undergoing dy-case gynaecological surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002180-24,0,0,0 2004-002181-38,3,2011-07-19,2011-07-19,3,0,0,0,0,0,0,0,0,1,0,0,1,0,0,NIH-National Institut of Health - NINDS-National Institut of Neurogical Disorders and Stroke,WARFARIN VERSUS ASPIRIN IN REDUCED CARDIAC EJECTION FRACTION (WARCEF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002181-38,0,0,0 2004-002181-38,3,2011-07-19,2011-07-19,3,0,0,0,0,0,0,0,0,1,0,0,1,0,0,Columbia University Medical Center of New York,WARFARIN VERSUS ASPIRIN IN REDUCED CARDIAC EJECTION FRACTION (WARCEF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002181-38,0,0,0 2004-002181-38,3,2011-07-19,2011-07-19,3,0,0,0,0,0,0,0,0,1,0,0,1,0,0,Sandwell & West Birmingham Hospitals NHS Trust,WARFARIN VERSUS ASPIRIN IN REDUCED CARDIAC EJECTION FRACTION (WARCEF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002181-38,0,0,0 2004-002181-38,3,2011-07-19,2011-07-19,3,0,0,0,0,0,0,0,0,1,0,0,1,0,0,"Warcef Clinical Coordinating Center, Department of Neuroscience, University of Medicine and Dentistr",WARFARIN VERSUS ASPIRIN IN REDUCED CARDIAC EJECTION FRACTION (WARCEF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002181-38,0,0,0 2004-002183-18,1,,,0,0,0,0,0,3,2,0,0,0,0,0,0,0,0,Institut Gustav Roussy,ESOPE (QLK3-2002-02003) European Standard Operating Procedures for Electrochemotherapy and Electrogenetherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002183-18,0,0,0 2004-002184-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"MADAUS, S.A.","Ensayo clínico multicéntrico, comparativo, doble ciego, paralelo de dos vías, de los efectos del tratamiento con cutículas de semillas de Plantago Ovata sobre el perfil lipídico de pacientes afectos d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002184-24,0,0,0 2004-002185-38,1,2006-03-24,2006-03-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H.Lundbeck A/S,"A 6 months double-blind, risperidone-referenced, flexible dose, parallel-group extension study of bifeprunox in patients with schizophrenia Estudio de extensión de 6 meses con bifeprunox, doble cie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002185-38,0,0,0 2004-002187-22,7,2010-09-15,2010-09-15,5,0,0,0,0,0,3,0,0,1,1,0,1,0,0,Ullevål University Hospital,Scandinavian Candesartan Acute Stroke Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002187-22,0,0,0 2004-002197-34,1,2017-04-03,2017-04-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University College London,A phase III multicentre randomised clinical trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diff...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002197-34,0,0,0 2004-002200-14,1,2008-08-21,2008-08-21,1,0,0,0,0,1,3,0,0,1,0,0,1,0,1,ReceptoPharm Inc.,Randomised Placebo Controlled Trial of a Parenteral Modified Cobratoxin in Adrenomyeloneuropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002200-14,0,0,0 2004-002202-30,1,2006-02-01,2006-02-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Ltd.,"An open label study to evaluate the effects on Mycobacterium tuberculosis, safety, tolerability and pharmacokinetics of single doses of R207910, in treatment naive patients with mycobacterium tubercul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002202-30,0,0,0 2004-002203-32,6,2010-12-17,2010-12-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis group,"A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III TRIAL COMPARING IMMEDIATE ADJUVANT HORMONAL THERAPY ELIGARD LEURPOLIDE ACETATE IN COMBINATION WITH TAXOTERE DOCETAXEL ADMINISTERED EVERY THREE WE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002203-32,0,0,0 2004-002203-32,6,2010-12-17,2010-12-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Groupe,"A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III TRIAL COMPARING IMMEDIATE ADJUVANT HORMONAL THERAPY ELIGARD LEURPOLIDE ACETATE IN COMBINATION WITH TAXOTERE DOCETAXEL ADMINISTERED EVERY THREE WE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002203-32,0,0,0 2004-002203-32,6,2010-12-17,2010-12-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AVENTIS PHARMA S.P.A.,"A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III TRIAL COMPARING IMMEDIATE ADJUVANT HORMONAL THERAPY ELIGARD LEURPOLIDE ACETATE IN COMBINATION WITH TAXOTERE DOCETAXEL ADMINISTERED EVERY THREE WE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002203-32,0,0,0 2004-002205-69,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Organisation name was not entered,Investigation of Hepatic Tumors with Positron Emission Tomography Using [11C]-Metomidate and [11C]-Acetate Tracers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002205-69,0,0,0 2004-002208-14,1,2008-06-24,2008-06-24,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Cardiff and Vale NHS Trust,Duration of Amiodarone therapy required for new post cardiac surgery atrial fibrillation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002208-14,0,0,0 2004-002211-92,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Efficacy and safety of subsequent treatment with 90Y-Zevalin in patients with stage II to IV follicular non-Hodgkin?s lymphoma in partial or complete remission after oral fludarabine and mitoxantrone ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002211-92,0,0,0 2004-002215-80,1,2013-01-01,2013-01-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A Double-Blind, Parallel, Randomized Extension Trial to Evaluate Safety and Efficacy of TMI-005 (Apratastat) in Subjects with Rheumatoid Arthritis on Methotrexate Who Have Completed Protocol 3140A1-20...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002215-80,0,0,0 2004-002216-28,3,2005-12-15,2005-12-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Limited,"A multi-center, multinational, randomized, double-blind, placebo-controlled, proof of concept trial to assess the effects of a subject-optimized dose of UK-369,003 Modified Release on exercise capacit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002216-28,0,0,0 2004-002218-13,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,INDUSTRIA FARMACEUTICA SERONO,"A phase III, multicenter, randomized, open, comparative study to evaluate if the addition of r-hLH (Luveris) ti FSH from day 8 of ovarian stimulation is able to decrease total FSH dose and to improve ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002218-13,0,0,0 2004-002225-45,3,,,0,1,0,0,2,0,3,2,1,1,0,0,0,1,1,Solvay Pharmaceuticals B.V.,"Randomized, endpoint-blind, parallel group study to demonstrate the serological non-inferiority of the virosomal influenza vaccine Invivac® to the conventional subunit influenza vaccine Influvac® and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002225-45,0,0,0 2004-002228-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Danderyds Sjukhus,Blödningsmönster och klinisk uppföljning av kvinnor som genomgått medicinsk abort och som har fått Implanon insatt i samband med aborten eller vid den första menstruationen efter aborten.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002228-17,0,0,0 2004-002231-92,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,"ARIAD Pharmaceuticals, Inc.","A Phase II Study of AP23573, an mTOR Inhibitor, in Patients with Advanced Sarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002231-92,0,0,0 2004-002232-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL 12 OCTUBRE,CHANGES IN GLOMERULAR HEMODINAMICS PARAMETERS IN HIPERTENSIVE PATIENTS AFTER TREATMENT WITH LERCANIDIPINE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002232-26,0,0,0 2004-002236-26,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,SCHERING-PLOUGH,"A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo Controlled Study Comparing The Efficacy, Safety, And Tolerability Of Co-administration Of Ezetimibe 10 Mg With Ongoing Treatment with S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002236-26,0,0,0 2004-002241-12,1,2006-04-22,2006-04-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim España S.A,"Ensayo clínico de fase IIIb - IV, aleatorizado y abierto, para evaluar la eficacia y seguridad de tenecteplasa junto con heparina no fraccionada administrada previo a la realización de PCI primaria, e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002241-12,0,0,0 2004-002243-27,1,2005-04-22,2005-04-22,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Clinical Pharmacology,Vascular effects of peroxisome proliferator–activated receptor gamma stimulation with rosiglitazone during exogenousely elevated free fatty acid concentrations in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002243-27,0,0,0 2004-002245-12,3,2011-06-08,2011-06-08,3,1,0,0,0,0,3,0,0,1,1,0,1,0,0,European Organisation for the Research and Treatment of Cancer,Intravenous versus intra-arterial fotemustine chemotherapy in patients with liver metastases from uveal melanoma: a randomized phase III study of the EORTC Melanoma Group.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002245-12,0,0,0 2004-002245-12,3,2011-06-08,2011-06-08,3,1,0,0,0,0,3,0,0,1,1,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Intravenous versus intra-arterial fotemustine chemotherapy in patients with liver metastases from uveal melanoma: a randomized phase III study of the EORTC Melanoma Group.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002245-12,0,0,0 2004-002249-11,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,BAUSCH&LOMB - IOM S.P.A.,"Double blind, randomized, multicenter, placebo-controlled, parallel-group design clinical trial of the efficacy and tolerability of cloriclomene hydrochloride capsules 100 mg TID in diabetic patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002249-11,0,0,0 2004-002252-33,2,2006-08-16,2006-08-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002252-33,0,0,0 2004-002252-33,2,2006-08-16,2006-08-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A twelve-week, randomized, double-blind, parallel-group, multicenter, dose escalation study to evaluate the efficacy and safety of aliskiren administered alone and in combination with atenolol in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002252-33,0,0,0 2004-002254-59,2,2007-06-25,2007-06-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Limited,"A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002254-59,0,0,0 2004-002255-14,6,2006-11-14,2007-06-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"Randomized, double-blind, double-dummy, parallel group, multicenter study to compare the efficacy and safety of once-monthly oral administration of 150 mg ibandronate with once-weekly oral administrat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002255-14,0,0,0 2004-002259-15,1,2008-09-26,2008-09-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Photocure ASA,"A RANDOMIZED, COMPARATIVE,CONTROLLED PHASE III, MULTICENTER STUDY OF HEXVIX FLUORESCENCE CYSTOSCOPY ANDWHITE LIGHT CYSTOSCOPY IN THE DETECTION OF PAPILLARY BLADDER CANCER AND THE EARLYRECURRENCE RATE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002259-15,0,0,0 2004-002260-25,1,2005-10-01,2005-10-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Desitin Arzneimittel GmbH,"A randomized, phase III, double blind, active-controlled, two-armed, multi-center study on efficacy and safety of once-daily oxcarbazepine (-modified release formulation) versus twice-daily oxcarbazep...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002260-25,0,0,0 2004-002262-37,1,2005-10-31,2005-10-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Newcastle Hospitals Trust,Adenosine testing in the diagnosis of unexplained syncope: A pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002262-37,0,0,0 2004-002267-24,7,2009-07-28,2009-10-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,Assessment of Everolimus in addition to Calcineurin Inhibitors Reduction in Mainteinance Renal Transplant Recipients ? ASCERTAIN Valutazione di Everolimus in associazione agli Inibitori della Calci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002267-24,0,0,0 2004-002267-24,7,2009-07-28,2009-10-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma AG,Assessment of Everolimus in addition to Calcineurin Inhibitors Reduction in Mainteinance Renal Transplant Recipients ? ASCERTAIN Valutazione di Everolimus in associazione agli Inibitori della Calci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002267-24,0,0,0 2004-002267-24,7,2009-07-28,2009-10-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,Assessment of Everolimus in addition to Calcineurin Inhibitors Reduction in Mainteinance Renal Transplant Recipients ? ASCERTAIN Valutazione di Everolimus in associazione agli Inibitori della Calci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002267-24,0,0,0 2004-002267-24,7,2009-07-28,2009-10-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,Assessment of Everolimus in addition to Calcineurin Inhibitors Reduction in Mainteinance Renal Transplant Recipients ? ASCERTAIN Valutazione di Everolimus in associazione agli Inibitori della Calci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002267-24,0,0,0 2004-002267-24,7,2009-07-28,2009-10-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma AG,Assessment of Everolimus in addition to Calcineurin Inhibitors Reduction in Mainteinance Renal Transplant Recipients ? ASCERTAIN Valutazione di Everolimus in associazione agli Inibitori della Calci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002267-24,0,0,0 2004-002272-41,1,2005-08-09,2005-08-09,1,0,0,0,1,0,4,0,0,1,0,0,1,0,1,Stiefel Laboratories International Division,"A Multi-Centre, Single-Blind, Parallel Group, Clinical Evaluation of the Efficacy and Safety of Duac Gel (A Gel containing Clindamycin Phosphate [Equivalent to 1% Clindamycin] and 5% Benzoyl Peroxide)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002272-41,0,0,0 2004-002273-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,A phase 2 trial of CHOP chemotherapy followed by Zevalin for untreated elderly diffuse large b-cell lymphoma DLBCL patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002273-24,0,0,0 2004-002276-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,IVAX Pharmaceuticals s.r.o.,Tolerability and safety of Oxamet® in patients with acute rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002276-42,0,0,0 2004-002280-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)","THERAPEUTIC AND BIOLOGICAL EFFECTS OF IMATINIB MESYLATE (STI571) IN PRIMARY HYPERESINOPHILIC SYNDROME (HES), CHRONIC EOSINOPHILIC LEUKEMIA (CEL) AND CHRONIC IDIOPHATIC HYPEREOSINOPHILIA (CIH): A STUDY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002280-24,0,0,0 2004-002290-22,1,2008-07-17,2008-07-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Schering AG,Phase II open-label study to investigate the efficacy and safety of PTK787/ZK222584 orally administered once daily or twice daily at a total daily dose of 1250 mg as second-line monotherapy in patient...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002290-22,0,0,0 2004-002291-42,4,2008-12-09,2008-12-09,4,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Bayer Schering Pharma AG,"Multi-center, open, randomized, dose finding phase II study to investigate for a maximum of three years ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) releasing in vitro 12 µg/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002291-42,0,0,0 2004-002291-42,4,2008-12-09,2008-12-09,4,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Schering AG,"Multi-center, open, randomized, dose finding phase II study to investigate for a maximum of three years ultra low dose levonorgestrel contraceptive intrauterine systems (LCS) releasing in vitro 12 µg/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002291-42,0,0,0 2004-002295-41,1,2016-03-01,2016-03-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The University of Birmingham,A randomised phase II/III study of Docetaxel plus Prednisolone vs. Docetaxel plus Prednisolone plus Zoledronic acid vs. Docetaxel plus Prednisolone plus Strontium-89 vs. Docetaxel plus Prednisolone ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002295-41,0,0,0 2004-002296-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Antonio Antela López,"Ensayo para evaluar la eficacia, seguridad y tolerabilidad, de una estrategia de simplificacion temprana a Trizivir, en pacientes con supresion virologica tras tratamiento antiretroviral con Combivir ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002296-16,0,0,0 2004-002302-30,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"FMZ Fludarabine, Mitoxantrone, Zevalin regimen a phase II study as front-line treatment in indolent non-follicular non-Hodgkins lymphoma patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002302-30,0,0,0 2004-002304-16,1,2012-10-19,2012-10-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,South Tees Hospitals NHS Foundation Trust,The STARS (STeroids Against Re-Stenosis) Trial [THE USE OF Peri-PROCEDURAL ORAL CORTICOSTERIODS TO PREVENT IN-SEGMENT RESTENOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION.],https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002304-16,0,0,0 2004-002306-29,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Royal Liverpool and Broadgreen University Hospitals NHS Trust,"Psoriasis, Folic Acid Supplementation and Plasma Homocysteine Levels",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002306-29,0,0,0 2004-002310-10,1,2005-11-10,2005-11-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Development Europe,Study to Investigate Cinacalcet Treatment in Haemodialysis Patients with Secondary Hyperparathyroidism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002310-10,0,0,0 2004-002311-91,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,University Hospital Ghent,"A randomised, controlled, 4-week, cross-over study assessing the efficacy and safety of adding oral morphine IR 10mg or sublingual buprenorphine 0.2mg on demand to a treatment with transdermal bupreno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002311-91,0,0,0 2004-002312-29,7,2015-06-23,2015-07-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INO Therapeutics,The Effects of Nitric Oxide for Inhalation on the Development of Chronic Lung Disease in Pre-term Infants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002312-29,0,0,0 2004-002312-29,7,2015-06-23,2015-07-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INO THERAPEUTICS,The Effects of Nitric Oxide for Inhalation on the Development of Chronic Lung Disease in Pre-term Infants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002312-29,0,0,0 2004-002317-37,1,2007-04-17,2007-04-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Aventis Inc.,OPEN-LABEL STUDY TO DETERMINE HOW PRIOR THERAPY WITH ALENDRONATE OR RISEDRONATE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS INFLUENCES THE CLINICAL EFFECTIVENESS OF TERIPARATIDE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002317-37,0,0,0 2004-002322-22,4,2006-05-10,2006-05-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ BIOSCIENCES Inc.,"A multi-center, open-label trial to investigate the safety and tolerability of intravenous SPM 927 as replacement for oral SPM 927 in subjects with partial seizures with or without secondary generaliz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002322-22,0,0,0 2004-002322-22,4,2006-05-10,2006-05-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"SCHWARZ BIOSCIENCES, Inc.","A multi-center, open-label trial to investigate the safety and tolerability of intravenous SPM 927 as replacement for oral SPM 927 in subjects with partial seizures with or without secondary generaliz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002322-22,0,0,0 2004-002327-41,2,2006-12-29,2006-12-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"an eight-week, multicenter, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of one fixed 100 mg dose of Saredutant in patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002327-41,0,0,0 2004-002327-41,2,2006-12-29,2006-12-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & developpement,"an eight-week, multicenter, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of one fixed 100 mg dose of Saredutant in patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002327-41,0,0,0 2004-002328-16,2,2006-12-26,2006-12-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"An eight-week, multicenter, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of one fixed 100 mg dose of Saredutant in patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002328-16,0,0,0 2004-002328-16,2,2006-12-26,2006-12-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis recherche and developpement,"An eight-week, multicenter, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of one fixed 100 mg dose of Saredutant in patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002328-16,0,0,0 2004-002329-32,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Karolinska Institutet Danderyds Sjukhus,Effekt av tilläggsbehandling med insulinet Lantus på tidsförloppet vid ketosutveckling vid tillfälligt uppehåll med insulinpumpbehandling.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002329-32,0,0,0 2004-002337-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Gabinete Berthier y Martínez, S.L.","Estudio piloto de 24 semanas, doble-ciego aleatorizado, paralelo, controlado con placebo de memantina y terapia del lenguaje restringida en las afasias post-ictus: correlación de los cambios neurofisi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002337-39,0,0,0 2004-002341-12,4,2005-12-21,2006-01-04,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Debiopharm SA,"Multicenter, 8-week, Randomised, Double-Blind, Placebo Controlled Study of Two Doses of Depelestat in Cystic Fibrosis Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002341-12,0,0,0 2004-002341-12,4,2005-12-21,2006-01-04,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,DEBIOPHARM S.A.,"Multicenter, 8-week, Randomised, Double-Blind, Placebo Controlled Study of Two Doses of Depelestat in Cystic Fibrosis Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002341-12,0,0,0 2004-002342-35,1,2006-01-11,2006-01-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"SkyePharma, Inc.","A Phase 2, Multicenter, Randomized, Double-Blind, Dose-Escalating/De-Escalating Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of a Single Dose of Sustained-Release Encapsulated Bupivaca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002342-35,0,0,0 2004-002344-99,1,2006-03-03,2006-03-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"SkyePharma, Inc.","A Phase 2, Multicenter, Randomized, Double-Blind, Dose-Escalating/De-Escalating Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sustained-Release Encapsulated Bupivacaine (SKY0402) Adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002344-99,0,0,0 2004-002345-12,4,2007-06-07,2009-02-22,3,1,0,0,0,2,0,0,0,1,0,0,1,0,2,MERCK SHARP DOHME,"An Open-Label, Multicenter Study to Assess the Efficacy of Switching to a Combination tablet Ezetimibe/Simvastatin 10mg/40mg, Compared to Doubling the Dose of Statin in Patients Hospitalized With a Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002345-12,0,0,0 2004-002345-12,4,2007-06-07,2009-02-22,3,1,0,0,0,2,0,0,0,1,0,0,1,0,2,,"An Open-Label, Multicenter Study to Assess the Efficacy of Switching to a Combination tablet Ezetimibe/Simvastatin 10mg/40mg, Compared to Doubling the Dose of Statin in Patients Hospitalized With a Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002345-12,0,0,0 2004-002345-12,4,2007-06-07,2009-02-22,3,1,0,0,0,2,0,0,0,1,0,0,1,0,2,Merck Sharp & Dohme Gesellschaft m.b.H.,"An Open-Label, Multicenter Study to Assess the Efficacy of Switching to a Combination tablet Ezetimibe/Simvastatin 10mg/40mg, Compared to Doubling the Dose of Statin in Patients Hospitalized With a Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002345-12,0,0,0 2004-002345-12,4,2007-06-07,2009-02-22,3,1,0,0,0,2,0,0,0,1,0,0,1,0,2,Merck & Co. Inc.,"An Open-Label, Multicenter Study to Assess the Efficacy of Switching to a Combination tablet Ezetimibe/Simvastatin 10mg/40mg, Compared to Doubling the Dose of Statin in Patients Hospitalized With a Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002345-12,0,0,0 2004-002349-11,1,2007-09-27,2007-09-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Research,"A randomisation, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of SR121463B in patients with syndrome of inappropriate antidiuretic hormone sec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002349-11,0,0,0 2004-002350-63,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Stallergenes GmbH & Co.KG,"Efficacy and Safety of Sublingual Immunotherapy with Ultra-Rush Titration in Children with Allergic Rhinoconjunctivitis to Tree Pollen, a Multicentre DBPC Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002350-63,0,0,0 2004-002353-31,1,2008-09-02,2008-09-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Organisation name was not entered,A fase I/II trial with docetaxel and gemcitabine in hormone refractory prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002353-31,0,0,0 2004-002355-14,2,2013-12-13,2013-12-13,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,GBG Forschungsgesellschaft mbH,"A randomized, multicenter, open phase III study comparing the postoperative use of zoledronic acid versus no treatment in patients with histological tumor residuals after preoperative anthracycline a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002355-14,0,0,0 2004-002358-72,1,2013-12-19,2013-12-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Austrian Breast and Colorectal Cancer Study Group (ABCSG),"Preoperative combined radiochemotherapy for patients with newly diagnosed, primary operable and locally advanced rectal carcinoma (cT3, Nx, M0) of the lower and middle rectum",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002358-72,0,0,0 2004-002362-37,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GlaxoSmithKline Research & Development Limited,"A multicentre, randomised, double-blind, placebo-controlled, dose ascending, four way crossover study to examine efficacy (FEV1),safety, tolerability, pharmacodynamics and pharmacokinetics of single ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002362-37,0,0,0 2004-002365-21,1,2007-08-24,2007-08-24,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,John F. Kennedy Institute,"Trial with BH4, a new and simple treatment of phenylketonuria, PKU",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002365-21,0,0,0 2004-002366-38,1,2005-11-21,2005-11-21,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,GABA GmbH,Fluoride uptake and remineralisation of incipient carious lesions following the application of fluoride fluids with different fluoride concentrations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002366-38,0,0,0 2004-002367-24,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,PhotoCure ASA,"A blinded, prospective, randomised, placebo-controlled, multi-centre, split-face study of photodynamic therapy with Metvix 160 mg/g cream in subjects with acne vulgaris.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002367-24,0,0,0 2004-002369-19,1,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Hvidovre Hospital,Behandling af savlen hos børn med cerebral parese ved anvendelse af botulinum toksin i spytkirtler,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002369-19,0,0,0 2004-002370-39,2,,,0,1,1,0,0,0,3,0,0,2,0,0,0,0,1,ASTRAZENECA,"A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease GER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002370-39,0,1,0 2004-002370-39,2,,,0,1,1,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease GER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002370-39,0,1,0 2004-002371-16,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ASTRAZENECA,"A RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTRE, PHASE III STUDYCOMPARING THE EFFICACY AND TOLERABILITY OF FULVESTRANT (FASLODEX?) 500 MG WITH FULVESTRANT (FASLODEX?) 250 MG IN POSTMENOPAUSAL ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002371-16,0,0,0 2004-002371-16,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTRE, PHASE III STUDYCOMPARING THE EFFICACY AND TOLERABILITY OF FULVESTRANT (FASLODEX?) 500 MG WITH FULVESTRANT (FASLODEX?) 250 MG IN POSTMENOPAUSAL ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002371-16,0,0,0 2004-002376-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST,PHASE II TRIAL OF SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH CAPECITABINE PLUS INTERFERON ALPHA2a FOLLOWED BY IL-2 IN PATIENTS WITH METASTATIC KIDNEY CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002376-42,0,0,0 2004-002378-42,1,2007-11-07,2007-11-07,1,1,0,0,0,3,3,0,0,1,0,0,1,0,0,Dept of ped hem/onc,"RCT of oral midazolam for procedural anxiety, distress and pain in children with cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002378-42,0,0,0 2004-002380-24,7,2007-03-19,2008-03-31,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Nycomed Danmark ApS, International Medical Affairs","An open randomised, prospective, multi-centre, parallel-group trial to compare efficacy and safety of TachoSil versus standard surgical treatment in patients undergoing pulmonary lobectomy for lung ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002380-24,0,0,0 2004-002380-24,7,2007-03-19,2008-03-31,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NYCOMED HEADQUARTER,"An open randomised, prospective, multi-centre, parallel-group trial to compare efficacy and safety of TachoSil versus standard surgical treatment in patients undergoing pulmonary lobectomy for lung ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002380-24,0,0,0 2004-002390-23,1,,,0,1,0,0,0,1,4,0,1,1,0,0,0,1,1,Aventis Pharma Ltd.,Evaluation of the pharmacokinetic profile of Riluzole (XRP4274) and RPR112512 following multiple oral administrations of XRP4274 for 8 days in healthy Japanese and Caucasian male subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002390-23,0,0,0 2004-002391-42,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,CECOG (Central European Cooperative Oncology Group),"A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX6 + Cetuximab versus FOLFIRI + Cetuximab as first-line therapy in patients with metastatic colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002391-42,0,0,0 2004-002395-41,1,2006-07-27,2006-07-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Schering AG,"Phase II study of MS-275, a histone deacetylase inhibitor, comparing 2 dosage schedules in patients with metastatic melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002395-41,0,0,0 2004-002397-38,8,2009-12-09,2009-12-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et développement,"12-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy, pharmacodynamic and safety of two doses of alfuzosin (0.1 mg/kg/day; 0.2 mg/kg/day...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002397-38,0,0,0 2004-002398-22,1,2005-11-23,2005-11-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,IDEA AG,"Double-blind, placebo-controlled study to investigate the efficacy and safety of IDEA-070 (ketoprofen in Transfersome®) in different dermatological diseases",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002398-22,0,0,0 2004-002399-40,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Rigshospitalet,Carboplatin + paclitaxel vs carboplatin + stealth liposomal doxorubicin. A randomised multicentre trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002399-40,0,0,0 2004-002406-30,1,2005-11-27,2005-11-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Conwy and Denbighshire NHS Trust,Estimating glomerular filtration rate using measured muscle mass,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002406-30,0,0,0 2004-002406-30,1,2005-11-27,2005-11-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,North West Wales NHS Trust,Estimating glomerular filtration rate using measured muscle mass,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002406-30,0,0,0 2004-002407-32,2,2013-07-08,2013-07-08,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"Extension to a multicenter, open label study to assess the safety and efficacy of 600 micrograms SOM230, administered subcutaneously, b.i.d. in patients with Cushing's disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002407-32,0,0,0 2004-002407-32,2,2013-07-08,2013-07-08,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"Extension to a multicenter, open label study to assess the safety and efficacy of 600 micrograms SOM230, administered subcutaneously, b.i.d. in patients with Cushing's disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002407-32,0,0,0 2004-002408-13,2,2006-04-07,2006-04-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FOURNIER Laboratories Ireland Ltd,"A randomised, double-blind study comparing the efficacy and safety of 145mg NanoCrystal® fenofibrate, 10mg ezetimibe and their combination in patients with type IIb dyslipidemia and features of the me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002408-13,0,0,0 2004-002410-11,3,2005-10-24,2005-10-24,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A six-week, randomized, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of the combination of aliskiren 150 mg and amlodipine 5 mg compared to amlodipine 5 mg and 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002410-11,0,0,0 2004-002416-29,1,2007-03-01,2007-03-01,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Akademische Eigenstudie, Sektion für Hygiene und Medizinische Mikrobiologie",Verträglichkeit von N-Chlortaurin bei infektiöser Kolpitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002416-29,0,0,0 2004-002418-12,2,2011-03-17,2011-03-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label, randomised, multicentre safety study to evaluate the skeletal and lipid profile effects of letrozole and tamoxifen in postmenopausal women with resected, receptor positive early breast ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002418-12,0,0,0 2004-002418-12,2,2011-03-17,2011-03-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label, randomised, multicentre safety study to evaluate the skeletal and lipid profile effects of letrozole and tamoxifen in postmenopausal women with resected, receptor positive early breast ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002418-12,0,0,0 2004-002420-18,2,2005-04-29,2005-04-29,1,1,0,0,0,1,2,0,0,2,0,0,0,0,0,"Prof. B. Wiedenmann, Klinik für Gastroenterologie, Charité, Campus Virchow","A prospective, non-randomised, non-controlled, open label, multicentre phase II study: PTK 787/ZK222584 in patients with advanced neuroendocrine tumours",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002420-18,1,0,0 2004-002420-18,2,2005-04-29,2005-04-29,1,1,0,0,0,1,2,0,0,2,0,0,0,0,0,CHARITE Universitätsmedizin Berlin Campus Virchow-Klinikum,"A prospective, non-randomised, non-controlled, open label, multicentre phase II study: PTK 787/ZK222584 in patients with advanced neuroendocrine tumours",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002420-18,1,0,0 2004-002425-52,6,2008-12-18,2013-12-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,A Phase 3 Study of Pemetrexed Plus Best Supportive Care versus Best Supportive Care As Maintenance Therapy Immediately Following Induction Treatment For Advanced Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002425-52,0,0,0 2004-002425-52,6,2008-12-18,2013-12-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,A Phase 3 Study of Pemetrexed Plus Best Supportive Care versus Best Supportive Care As Maintenance Therapy Immediately Following Induction Treatment For Advanced Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002425-52,0,0,0 2004-002425-52,6,2008-12-18,2013-12-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,A Phase 3 Study of Pemetrexed Plus Best Supportive Care versus Best Supportive Care As Maintenance Therapy Immediately Following Induction Treatment For Advanced Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002425-52,0,0,0 2004-002427-40,1,2008-10-10,2008-10-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Newcastle Upon Tyne Hospitals NHS Foundation Trust,What is the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002427-40,0,0,0 2004-002429-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Nordic Society for Gynecologic Oncology,A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma NSGO-EC-9501 Amendment 2.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002429-37,0,0,0 2004-002437-39,3,2006-10-24,2006-10-24,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Daiichi Asubio Pharmaceuticals Inc.,"A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan)Administered for 72 Hours by Continuous ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002437-39,0,0,0 2004-002440-96,1,2006-12-22,2006-12-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,South Manchester University Hospitals NHS Trust,A randomised placebo controlled trial of itraconazole in the treatment of fungal-sensitised patients with severe asthma and without ABPA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002440-96,0,0,0 2004-002440-96,1,2006-12-22,2006-12-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Manchester,A randomised placebo controlled trial of itraconazole in the treatment of fungal-sensitised patients with severe asthma and without ABPA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002440-96,0,0,0 2004-002453-31,6,2006-03-20,2006-03-20,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,ACTELION PHARMACEUTICALS ITALIA,"A Phase IIb, multi-center, international, double-blind, randomized, placebo-controlled, parallel-group, dose-finding study for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002453-31,0,0,0 2004-002453-31,6,2006-03-20,2006-03-20,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"A Phase IIb, multi-center, international, double-blind, randomized, placebo-controlled, parallel-group, dose-finding study for the prevention of cerebral vasospasm after aneurysmal subarachnoid hemorr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002453-31,0,0,0 2004-002455-13,1,2015-05-01,2015-05-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Dept. of Internal Medicine,Vergleich der Effektivität von Insulin Aspart und Normalinsulin bei Typ 2 Diabetikern hinsichtlich des postprandialen Stoffwechsels während zwei aufeinanderfolgender Mahlzeiten. Die Huckepack Studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002455-13,0,0,0 2004-002466-38,1,2006-06-21,2006-06-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002466-38,0,0,0 2004-002468-89,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Axcan Pharma S.A.,"A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PANCREATIN VS. PLACEBO FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EXOCRINE INSU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002468-89,0,0,0 2004-002470-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitario Gregorio Marañón,"Ensayo Clínico en fase III, abierto, multicéntrico, para valorar el efecto del sistema renina-angiotensina con inhibidores de la enzima de conversión de la angiotensina (IECA) (lisinopril), bloqueante...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002470-31,0,0,0 2004-002473-23,1,2011-03-09,2011-03-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Dr. Amalia Velasco,PHASE II TRIAL OF THE SEQUENTIAL ADMINISTRATION OF COMBINATIONS OF GEMCITABINE-CISPLATIN AND CARBOPLATIN-PACLITAXEL FOR THE TREATMENT OF PATIENTS WITH ADVANCED CARCINOMA OF THE OVARY WITH SUB-OPTIMA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002473-23,0,0,0 2004-002474-36,1,2006-03-17,2006-03-17,1,1,0,0,1,0,3,0,1,1,0,0,1,0,1,Intercell AG,"Observer blinded, randomized Phase III study to investigate the non-inferiority of IC51 (JE-PIV) vs. JE-VAX as vaccines for japanese encephalitis in healthy volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002474-36,0,0,0 2004-002477-23,2,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,Fujisawa GmbH,"Comparative, multicentre, randomised, double-blind study to assess the efficacy of tacrolimus 0.1% ointment versus fluticasone 0.005% ointment in adult patients suffering from moderate to severe atopi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002477-23,0,0,0 2004-002478-47,2,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,Fujisawa GmbH,"Comparative, multicentre, randomised, double-blind study to assess the efficacy of tacrolimus 0.03% ointment versus fluticasone 0.005% ointment in children aged 2 years or over suffering from moderate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002478-47,0,0,0 2004-002482-20,1,2007-10-16,2007-10-16,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Newcastle upon Tyne Hospitals NHS Trust,A Pilot Study to Test the Effect of Treating Depression Associated with Rueumatoid Arthritis (RA) using Venlaflaxine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002482-20,0,0,0 2004-002496-17,3,2008-09-16,2008-09-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,"A Six-Month Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002496-17,0,0,0 2004-002501-72,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,3,,Studie zur neoadjuvanten Therapie bei Hochrisikopatienten mit Weichteilsarkom (STS) im Erwachsenenalter,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002501-72,0,0,0 2004-002502-29,3,2008-06-17,2008-09-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALLERGAN,"A Six-Month Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002502-29,0,0,0 2004-002502-29,3,2008-06-17,2008-09-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,"A Six-Month Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002502-29,0,0,0 2004-002503-33,1,2016-03-08,2016-03-08,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,Our Lady's Hospital for Sick Children,PROTOCOL FOR THE TREATMENT OF EXTRACRANIAL GERM CELL TUMOURS IN CHILDREN AND ADOLESCENTS (GC III),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002503-33,0,0,0 2004-002504-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,The Nordic CML Study Group,A RANDOMIZED PHASE II STUDY COMPARING IMATINIB AND THE COMBINATION OF IMATINIB AND PEGYLATED INTERFERON ALPHA-2B IN NEWLY DIAGNOSED NON-HIGH RISK CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE HEMATOLO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002504-15,0,0,0 2004-002505-74,5,2005-12-06,2005-12-06,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cephalon Europe, A Division of Cephalon UK Limited","A 6 month open-label, flexible-dosage study to assess the safety and effectiveness of PROVIGIL® (Modafinil) treatment in children and adolescents with excessive sleepiness associated with narcolepsy o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002505-74,0,0,0 2004-002505-74,5,2005-12-06,2005-12-06,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,CEPHALON EUROPE,"A 6 month open-label, flexible-dosage study to assess the safety and effectiveness of PROVIGIL® (Modafinil) treatment in children and adolescents with excessive sleepiness associated with narcolepsy o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002505-74,0,0,0 2004-002507-32,1,2011-02-28,2011-02-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Royal Hospital For Sick Children, Yorkhill Division",Effect of recombinant growth hormone on growth and chondrocyte dynamics in children with Inflammatory bowel disease (IBD) and growth failure.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002507-32,0,0,0 2004-002508-13,2,2010-02-08,2010-03-11,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Genzyme Europe BV,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-Selection Study of Ad2/Hypoxia Inducible Factor HIF-1alfa/VP16 in Patients with Intermittent Claudication.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002508-13,0,0,0 2004-002509-63,2,2005-11-23,2005-12-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GW Pharma Ltd,"A double blind, randomised, placebo controlled, parallel group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002509-63,0,0,0 2004-002510-11,1,2006-01-11,2006-01-11,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Cyclacel Ltd,Protocol for the Extended Use of CYC202 for Patients who have previously been enrolled in a Clinical Trial with CYC202,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002510-11,0,0,0 2004-002511-83,3,2006-03-13,2006-06-24,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,TransTech Pharma,"A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Weeks Extended VTE Prophylaxis with Daily Oral Doses of TTP889 After One Week of Standard Prophylactic Treatment Follo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002511-83,0,0,0 2004-002515-89,8,2008-04-09,2008-04-09,7,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002515-89,0,0,0 2004-002515-89,8,2008-04-09,2008-04-09,7,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002515-89,0,0,0 2004-002515-89,8,2008-04-09,2008-04-09,7,1,0,0,0,2,2,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,A Phase II Study of BMS-354825 in Subjects with Accelerated Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002515-89,0,0,0 2004-002516-28,7,2007-04-19,2008-03-26,5,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,A Phase II Study of BMS-354825 in Subjects with Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002516-28,0,0,0 2004-002516-28,7,2007-04-19,2008-03-26,5,1,0,0,0,2,2,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,A Phase II Study of BMS-354825 in Subjects with Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002516-28,0,0,0 2004-002516-28,7,2007-04-19,2008-03-26,5,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Phase II Study of BMS-354825 in Subjects with Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002516-28,0,0,0 2004-002517-36,7,2005-11-28,2007-12-07,4,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002517-36,0,0,0 2004-002517-36,7,2005-11-28,2007-12-07,4,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002517-36,0,0,0 2004-002517-36,7,2005-11-28,2007-12-07,4,1,0,0,0,2,2,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002517-36,0,0,0 2004-002520-18,2,2006-07-11,2006-07-11,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Merz Pharmaceuticals GmbH,"Safety and efficacy of Neramexane mesylate as add-on therapy to opioids in cancer patients for the management of chronic pain attributable to skeletal metastases: A randomised, double-blind, placebo-c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002520-18,0,0,0 2004-002526-22,1,2007-07-31,2007-07-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Instituto Cientí­fico y Tecnológico de Navarra, S.A.","Estudio piloto, fase IV(II), abierto, no controlado, unicéntrico con escalada de dosis, para evaluar la eficacia y seguridad de Imiquimod en pacientes con hemangioma infantil",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002526-22,0,0,0 2004-002530-20,2,2006-06-07,2006-06-08,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GW Pharma Ltd,"A double blind, randomised, placebo controlled, parallel group study of Sativex in the treatment of subjects with pain due to diabetic neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002530-20,0,0,0 2004-002531-32,4,2006-10-18,2006-10-18,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GW Pharma Ltd,"A double blind, randomised, placebo controlled, parallel group study of Sativex, in the treatment of subjects with peripheral neuropathic pain associated with allodynia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002531-32,0,0,0 2004-002534-18,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma GmbH,"An open, multicenter study to evaluate the efficacy and safety of a 4 week therapy with CoDiovan 160/25 (fixed dose combination of valsartan 160 mg plus HCTZ 25 mg) in patients not adequately respondi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002534-18,0,0,0 2004-002535-12,1,2008-01-31,2008-01-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Clinical Institute of Medical and Chemical Laboratory Diagnostics Graz,Fluvastatin 80 mg ret. vs combination with ezetimib 10 mg,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002535-12,0,0,0 2004-002536-26,1,2009-07-14,2009-07-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Dr Ken O'Byrne,"Open, non-randomized phase II pilot study of neoadjuvant cetuximab in combination with cisplatin and gemcitabine, to evaluate their efficacy, safety and biological pharmacodynamic effects in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002536-26,0,0,0 2004-002537-39,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,ELI LILLY,Phase II Trial of Neoadjuvant ALIMTA plus Cisplatin followed by Surgery and Radiation in the Treatment of Pleural Mesothelioma Studio di Fase II con ALIMTA piu` Cisplatino in Neoadiuvante seguiti ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002537-39,0,0,0 2004-002538-20,1,2008-12-18,2008-12-18,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,Phase 2 study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcomas expressing the t(17;22)(q22;q13) translocation resulting in a COL1A1/PDGF rearrangement i.e. DermatoFibroS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002538-20,0,0,0 2004-002539-25,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,UNIVERSITA' DEGLI STUDI DI UDINE,Randomized phase II trial of second-line chemotherapy with oxaliplatin and docetaxel vs. docetaxel in patients with advanced non-small cell lung cancer (NSCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002539-25,0,0,0 2004-002540-94,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Norrlands university hospital,"Effects of allopregnanolone in women with PMDD, depression, PCOS och oral contraceptives",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002540-94,0,0,0 2004-002547-27,1,2017-12-31,2017-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Bristol,Combined Immunosuppression and Radiotherapy in Thyroid Eye Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002547-27,0,0,0 2004-002549-11,8,2007-02-28,2007-02-28,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca AB,"An Open, Multi-Centre and Long-Term Extension Study to Evaluate the Safety and Tolerability of oral Tesaglitazar therapy 1 mg in patients with Type 2 Diabetes Mellitus. (Protocol Amendment Nr.1, dat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002549-11,0,0,0 2004-002550-56,4,2007-02-23,2007-12-16,4,1,0,0,1,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 24-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined with Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Glycaemic Effects,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002550-56,0,0,0 2004-002560-17,9,2007-06-20,2007-08-02,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NV Organon,"A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002560-17,0,0,0 2004-002560-17,9,2007-06-20,2007-08-02,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Limited,"A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002560-17,0,0,0 2004-002560-17,9,2007-06-20,2007-08-02,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ORGANON ITALIA,"A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and Safety of Asenapine With Olanzapine in Stable Subjects With Predominant, Persistent Negative Symptoms of Schizophre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002560-17,0,0,0 2004-002563-24,3,2006-06-28,2006-06-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER,A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE TIME TO ONSET OF MEANINGFUL PAIN RELIEF IN SUBJECTS WITH POSTHERPETIC NEURALGIA (PHN) TREATED WITH PREGABALIN (150 - 600 MG/DAY FLEXIBLE OP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002563-24,0,0,0 2004-002563-24,3,2006-06-28,2006-06-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Ltd,A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE TIME TO ONSET OF MEANINGFUL PAIN RELIEF IN SUBJECTS WITH POSTHERPETIC NEURALGIA (PHN) TREATED WITH PREGABALIN (150 - 600 MG/DAY FLEXIBLE OP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002563-24,0,0,0 2004-002563-24,3,2006-06-28,2006-06-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"PFIZER, S.A.",A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE TIME TO ONSET OF MEANINGFUL PAIN RELIEF IN SUBJECTS WITH POSTHERPETIC NEURALGIA (PHN) TREATED WITH PREGABALIN (150 - 600 MG/DAY FLEXIBLE OP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002563-24,0,0,0 2004-002565-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Asociación para el estudio de enfermedades infecciosas,Food effect on antiviral activity of videx enteric-coated capsules,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002565-20,0,0,0 2004-002567-24,3,2007-04-04,2007-04-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc.",A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002567-24,0,0,0 2004-002569-19,1,2008-08-01,2008-08-01,1,1,0,0,0,3,2,0,1,1,0,0,1,0,0,"Department of Asthma, Allergy and Respiratory Science, GKT School of Medicine, King's College London",The effects of systemic vitamin D administration on production of interleukin-10 by peripheral blood T cells in asthmatics and controls.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002569-19,0,0,0 2004-002570-32,7,2008-04-14,2010-11-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"Open label, parallel group, multicenter study of two IV ibandronate dose regimens (2 mg every 2 months and 3 mg every 3 months) in women with postmenopausal osteoporosis who completed trial BM 16550.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002570-32,0,0,0 2004-002570-32,7,2008-04-14,2010-11-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"Open label, parallel group, multicenter study of two IV ibandronate dose regimens (2 mg every 2 months and 3 mg every 3 months) in women with postmenopausal osteoporosis who completed trial BM 16550.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002570-32,0,0,0 2004-002570-32,7,2008-04-14,2010-11-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"Open label, parallel group, multicenter study of two IV ibandronate dose regimens (2 mg every 2 months and 3 mg every 3 months) in women with postmenopausal osteoporosis who completed trial BM 16550.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002570-32,0,0,0 2004-002571-16,9,2009-05-22,2009-05-22,9,0,0,0,0,0,2,0,0,1,1,0,1,0,1,BioMS Technology Corp,"A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002571-16,0,0,0 2004-002577-23,1,2006-01-09,2006-01-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Efficacy and safety of Agomelatine (25 mg with potential adjustment at 50 mg) given orally once a day for 12 weeks in out-patients with Generalised Anxiety Disorder. A randomised flexible dose double-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002577-23,0,0,0 2004-002579-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medizinische Klinik B, Herzzentrum Ludwigshafen","A double-blind, randomised placebo controlled study of the effects of Acarbose on endothelial function, hemostatic and fibrinolytic plasmatic factors in patients with stable coronary artery disease an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002579-17,0,0,0 2004-002586-21,1,,,0,1,0,0,0,3,3,0,1,1,0,0,0,1,1,Aventis Pasteur MSD SNC,"An open, randomised, comparative, multicentre study of the immunogenicity and safety of M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX® when administered concomitantly by intra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002586-21,0,0,0 2004-002591-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,H.Lundbeck A/S,"A pharmacoeconomic study conducted in parallel with clinical trial 10200, a 24-week double-blind, risperidone-referenced, flexible dose, parallel-group extension study of bifeprunox in patients with s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002591-42,0,0,0 2004-002594-23,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Weber & Weber GmbH & Co.KG,"A randomized, double-blind, vehicle-controlled, half-side comparison, monocenter, clinical study evaluating the efficacy and safety of a herbal dermatitis ointment for the treatment of mild to moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002594-23,0,0,0 2004-002597-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Eisai Ltd,An open label dose adjustment and phase II study of E7070 in combination with capecitabine: Part 1: to determine the recommended dose of the combination Part 2: to determine the efficacy of the comb...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002597-33,0,0,0 2004-002598-21,2,2005-07-21,2005-07-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Schwarz Biosciences GmbH,"A phase 3b, open-label, multicenter, multinational trial to evaluate the effects of rotigotine transdermal patch on early morning motor impairment and sleep disorders in patients with idiopathic Parki...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002598-21,0,0,0 2004-002601-69,10,2007-07-07,2008-04-07,8,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,A Phase II Study to Determine the Activity of BMS-354825 in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease that is Resistant to High Dose Imatin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002601-69,0,0,0 2004-002601-69,10,2007-07-07,2008-04-07,8,1,0,0,0,2,2,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,A Phase II Study to Determine the Activity of BMS-354825 in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease that is Resistant to High Dose Imatin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002601-69,0,0,0 2004-002605-77,1,2005-05-16,2005-05-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare,A Proof-of-Principle Study to Evaluate a Combination Therapy for the Treatment of Migraine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002605-77,0,0,0 2004-002608-13,1,2007-05-21,2007-05-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King’s College London & King’s College Hospital,Pragmatic Randomised Control Trial of Quetiapine for psychosis in Parkinson’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002608-13,0,0,0 2004-002609-66,2,2005-10-25,2005-10-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Schwarz Biosciences GmbH,"A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impair...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002609-66,0,0,0 2004-002609-66,2,2005-10-25,2005-10-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ PHARMA,"A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impair...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002609-66,0,0,0 2004-002612-28,1,2006-08-04,2006-08-04,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"A one year, open label, multi-center, extension study to CHTF919D2301 to assess the long term safety of tegaserod 6 mg bid given orally in female patients with symptoms of dyspepsia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002612-28,0,0,0 2004-002614-10,2,2009-02-12,2009-02-12,2,1,0,0,0,0,4,0,2,1,0,0,1,0,1,H. Lundbeck A/s,"A 1-Year Randomised, Double-Blind Placebo-Controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients with Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002614-10,0,0,0 2004-002614-10,2,2009-02-12,2009-02-12,2,1,0,0,0,0,4,0,2,1,0,0,1,0,1,Lundbeck Limited,"A 1-Year Randomised, Double-Blind Placebo-Controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients with Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002614-10,0,0,0 2004-002619-10,2,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Oscient Pharmaceuticals,"A Phase IIIb, Randomized, Double-Blind, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Oral Gemifloxacin 320 mg Once Daily for 5 Days Versus Oral Gemifloxacin 320 mg Once Daily...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002619-10,0,0,0 2004-002620-18,5,2008-02-04,2008-04-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multi-National Randomized, Double-Blind, Exploratory Study of Abatacept versus Placebo in Preventing the Development of Rheumatoid Arthritis in Adult Subjects with Undifferentiated Inflammatory Arth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002620-18,0,0,0 2004-002620-18,5,2008-02-04,2008-04-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"A Multi-National Randomized, Double-Blind, Exploratory Study of Abatacept versus Placebo in Preventing the Development of Rheumatoid Arthritis in Adult Subjects with Undifferentiated Inflammatory Arth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002620-18,0,0,0 2004-002621-46,1,2012-12-14,2012-12-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Nottingham,"Double-blind, randomised, placebo-controlled trial of nicotine replacement therapy in pregnancy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002621-46,0,0,0 2004-002623-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Anders Nyboe Andersen, klinikchef, dr. med., Fertilitetsklinikken afsnit 4071, Rigshospitalet",Anvendelse af aromatase-inhibitor (Arimidex) i kombination med GnRH agonist (Zoladex) som forbehandling til IVF hos patienter med ovariel endometriose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002623-41,0,0,0 2004-002626-22,2,2007-03-14,2007-03-14,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,Duloxetine 60 to 120 mg Once Daily Compared with Placebo in the Prevention of Relapse in Generalized Anxiety Disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002626-22,0,0,0 2004-002627-40,6,2007-06-25,2007-06-28,4,1,1,0,0,2,3,0,0,2,0,0,0,0,1,Schering-Plough Research Institute,"Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002627-40,1,1,0 2004-002627-40,6,2007-06-25,2007-06-28,4,1,1,0,0,2,3,0,0,2,0,0,0,0,1,"Schering-Plough Research Institute, a division of Schering Corporation","Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002627-40,1,1,0 2004-002627-40,6,2007-06-25,2007-06-28,4,1,1,0,0,2,3,0,0,2,0,0,0,0,1,SCHERING-PLOUGH,"Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002627-40,1,1,0 2004-002627-40,6,2007-06-25,2007-06-28,4,1,1,0,0,2,3,0,0,2,0,0,0,0,1,"Schering-Plough Research Institute on behalf of MSP Singapore Company, LLC","Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002627-40,1,1,0 2004-002629-36,12,2007-02-12,2007-02-12,9,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals, Global Medical Affairs Department","A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects with Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002629-36,0,0,0 2004-002629-36,12,2007-02-12,2007-02-12,9,1,0,0,0,0,0,0,0,1,0,0,1,0,1,WYETH LEDERLE,"A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects with Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002629-36,0,0,0 2004-002633-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Prof. Dr. med. Milos Opravil, Universitätsspital Zürich",Prospective study of switch to 3TC monotherapy with evaluation of replication capacity in patients with virologic failure and 3TC resistance (a multicenter prospective clinical study within the SHCS)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002633-39,0,0,0 2004-002640-97,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Pfizer,Time to onset of action of tolterodine using force fill cystometry in SPINAL CORD INJURY PATIENTS WITH neurogenic detrusor overactivity.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002640-97,0,0,0 2004-002641-12,4,2008-12-11,2008-12-16,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Schwarz Biosciences GmbH,"A multicenter, multinational, phase 3B, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson s disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002641-12,0,0,0 2004-002641-12,4,2008-12-11,2008-12-16,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ PHARMA,"A multicenter, multinational, phase 3B, open-label extension trial to assess the safety and tolerability of long-term treatment of rotigotine patch in subjects with idiopathic Parkinson s disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002641-12,0,0,0 2004-002642-35,1,2007-12-14,2007-12-14,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Green Medicine AB,A randomized double-blind placebo-controlled parallel group study of SHR -5 extract of Rhodiola Rosea as adjuvant therapy in patients with stress related fatigue.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002642-35,0,0,0 2004-002643-27,1,2005-06-14,2005-06-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Orion Pharma GmbH,Efficacy and tolerability of Comtess® versus Cabaseril® as add-on to levodopa in the treatment of Parkinsonian patients suffering from wearing- off phenomenon,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002643-27,0,0,0 2004-002644-10,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Farmaceutica S.A.,"A 28-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug naïve patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002644-10,0,0,0 2004-002646-35,1,2008-10-31,2008-10-31,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,"Franz Volhard Clinic, Charite Campus Buch",Pilot study for evaluation of growth factor erythropoietin beta for improvement of left ventricular function after coronary interventions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002646-35,0,0,0 2004-002647-27,1,2010-06-30,2010-06-30,1,1,0,0,1,1,4,0,1,1,0,0,1,0,0,Universitätsklinik für Kinder-und Jugendheilkunde,FSME (human tick-borne encephalitis) - vaccination in children after thymectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002647-27,0,0,0 2004-002648-88,3,2010-01-06,2010-01-06,1,0,0,0,0,1,0,0,0,2,0,0,0,0,1,Wyeth Pharmaceuticals,In vitro evaluation of allergic reactions in hemophilia B subjects who have exhibited a systemic allergic response after exposure to BeneFIX (Nonacog Alfa; recombinant Factor IX),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002648-88,1,0,0 2004-002650-59,1,2005-07-06,2005-07-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ BIOSCIENCES,"A phase 3b, open-label, multicentre, multinational trial to assess the tolerability of switching subjects from ropinerole, pramipexole or cabergoline to the rotigotine transdermal system and its effec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002650-59,0,0,0 2004-002653-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Odense University hospital,CAPHI. Profylactic effect of Ca2+ sensitizer versus phosphodiesterase inhibitor infusion at CAGB patients with preoperative low ejection fraction. A prospective randomised clinical trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002653-31,0,0,0 2004-002661-21,1,2006-10-02,2006-10-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmaceutica S. A.,"A multicenter, randomized, double-blind active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to acarbose up to 100 mg tid in drug naïve patients with type 2 diabet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002661-21,0,0,0 2004-002662-38,3,2006-10-05,2007-03-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A PHASE III RANDOMISED, STRATIFIED, PARALLEL-GROUP, MULTI-CENTRE, COMPARATIVE STUDY OF ZD1839 (IRESSA®) 250 MG AND 500 MG VERSUS METHOTREXATE FOR PREVIOUSLY TREATED PATIENTS WITH SQUAMOUS CELL CARCINO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002662-38,0,0,0 2004-002669-19,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,AVENTIS PASTEUR MSD S.P.A.,"A double-blind, randomised, controlled, multi-centre safety study of a refrigerator-stable formulation of VARIVAX® in healthy 12 to 15 month-old infants.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002669-19,0,0,0 2004-002673-22,3,2006-06-13,2006-06-13,3,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Schering AG,"Double-blind, placebo controlled, randomized, multicenter, parallel-group study to compare the efficacy and safety of Advantan cream twice weekly with Advabas cream during a maintenance phase of 16 we...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002673-22,0,0,0 2004-002673-22,3,2006-06-13,2006-06-13,3,1,0,0,0,0,4,0,0,1,0,0,1,0,2,SCHERING,"Double-blind, placebo controlled, randomized, multicenter, parallel-group study to compare the efficacy and safety of Advantan cream twice weekly with Advabas cream during a maintenance phase of 16 we...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002673-22,0,0,0 2004-002676-41,5,2016-12-15,2016-12-15,4,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"Blinded, randomised, controlled, multicenter study to evaluate the clinical efficacy against varicella disease of GlaxoSmithKline Biologicals live attenuated varicella vaccine (VarilrixTM) given on a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002676-41,0,0,0 2004-002677-24,1,2011-12-22,2011-12-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Karolinska Institutet, Institutionen för klinisik neurovetenskap, sektion för psykiatri",Hormonersättningseffekt på serotoninåterupptag hos ooforektomerade kvinnor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002677-24,0,0,0 2004-002685-38,1,2011-06-14,2011-06-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Yakult Honsha Co,Randomised controlled trial of metronidazole and probiotic preparation versus placebo in the treatment of irritable bowel syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002685-38,0,0,0 2004-002686-21,1,2007-06-30,2007-06-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Dept of Dermatology,Efficacy of Endothelin 1 receptor antagonist Bosentan in secondary Raynauds Syndrom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002686-21,0,0,0 2004-002687-14,1,2005-03-11,2005-03-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S),Fucidin® Cream in the Treatment of Impetigo A phase IV study comparing clinical and bacteriological efficacy of Fucidin® cream with Fucidin® cream vehicle in the treatment of impetigo in paediatric pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002687-14,0,0,0 2004-002688-25,1,2006-01-03,2006-01-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"A 4-week, randomized, multicenter, parallel-group, placebo-controlled study to investigate the effect of Elidel (pimecrolimus) cream 1% on the Quality of Life (QoL) of patients with moderate facial At...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002688-25,0,0,0 2004-002692-16,1,2007-11-20,2007-11-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PharmaMar SA unipersonal,"A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory Indolent Non-Hodgkin’s Lymphoid Neoplasms.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002692-16,0,0,0 2004-002693-37,2,2006-09-13,2006-09-13,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Therakos,"A MULTICENTER, OPEN-LABEL, STUDY OF EXTRACORPOREAL PHOTOIMMUNE THERAPY WITH UVADEX IN THE TREATMENT OF PATIENTS WITH MODERATELY ACTIVE CROHN’S DISEASE WHO ARE REFRACTORY OR INTOLERANT TO IMMUNOSUPPRES...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002693-37,0,0,0 2004-002694-22,8,2006-12-27,2007-10-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double Blind, Parallel-Group Comparative Study of Flexibly Dosed Paliperidone Palmitate(25, 50, 75, 100 mg eq) Administered Every 4 Weeks and Flexibly Dosed Risperdal Consta (25, 37.5, o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002694-22,0,0,0 2004-002694-22,8,2006-12-27,2007-10-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen-Cilag, S.A.","A Randomized, Double Blind, Parallel-Group Comparative Study of Flexibly Dosed Paliperidone Palmitate(25, 50, 75, 100 mg eq) Administered Every 4 Weeks and Flexibly Dosed Risperdal Consta (25, 37.5, o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002694-22,0,0,0 2004-002694-22,8,2006-12-27,2007-10-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG International N.V.,"A Randomized, Double Blind, Parallel-Group Comparative Study of Flexibly Dosed Paliperidone Palmitate(25, 50, 75, 100 mg eq) Administered Every 4 Weeks and Flexibly Dosed Risperdal Consta (25, 37.5, o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002694-22,0,0,0 2004-002694-22,8,2006-12-27,2007-10-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Double Blind, Parallel-Group Comparative Study of Flexibly Dosed Paliperidone Palmitate(25, 50, 75, 100 mg eq) Administered Every 4 Weeks and Flexibly Dosed Risperdal Consta (25, 37.5, o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002694-22,0,0,0 2004-002694-22,8,2006-12-27,2007-10-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V,"A Randomized, Double Blind, Parallel-Group Comparative Study of Flexibly Dosed Paliperidone Palmitate(25, 50, 75, 100 mg eq) Administered Every 4 Weeks and Flexibly Dosed Risperdal Consta (25, 37.5, o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002694-22,0,0,0 2004-002700-16,9,2006-10-17,2006-10-31,4,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Janssen-Cilag International N.V.,"A Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study of the Efficacy and Safety of Dapoxetine in the Treatment of Subjects With Premature Ejaculation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002700-16,0,0,0 2004-002700-16,9,2006-10-17,2006-10-31,4,1,0,0,0,2,3,0,0,1,1,0,1,0,1,JANSSEN-CILAG,"A Placebo-Controlled, Double-Blind, Randomized, Parallel-Group Study of the Efficacy and Safety of Dapoxetine in the Treatment of Subjects With Premature Ejaculation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002700-16,0,0,0 2004-002701-68,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Prosidion Ltd.,"A randomised, double-blind, placebo-controlled, multiple dose, time-lagged parallel groups trial, investigating the pharmacodynamics, the safety and tolerability and the pharmacokinetics of PSN9301 in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002701-68,0,0,0 2004-002707-32,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,SERVIER s.r.o.,"HEMODEX study- Detralex* versus placebo in the treatment of acute hemorrhoids in patients with acute hemorrhoidal attack. One week, double-blind, randomized, placebo controlled, multicentre study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002707-32,0,0,0 2004-002708-13,1,,,0,0,0,0,1,0,2,0,0,1,0,0,0,1,1,"Synergia Pharma, Inc.","A RANDOMIZED, BLINDED, CROSSOVER TRIAL OF A SINGLE DOSE OF ORAL L-DOPS 300 MG IN AN ENVIRONMENTAL EXPOSURE UNIT IN SUBJECTS WITH SEASONAL ALLERGIC RHINITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002708-13,0,0,0 2004-002711-83,1,2013-11-30,2013-11-30,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,HELIXOR Heilmittel GmbH & Co.KG,Evaluation of anthroposophic supportive medicine on treatment-related toxicity in children receiving cancer therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002711-83,0,0,0 2004-002712-28,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,1,ITALFARMACO,"Chronic iloprost administration in scleroderma patients effect on disease progression, as assessed by skin fibrosis evaluation. A randomized, controlled, blind-observer, multicenter phase III study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002712-28,0,0,0 2004-002714-11,11,2014-05-01,2014-05-14,9,1,0,0,0,0,3,0,0,1,1,0,1,0,0,European Organisation for Research and Treatment of Cancer,"Estudio de fase III para evaluar la quimioterapia primaria con temozolomida frente a la radioterapia en pacientes con gliomas de bajo grado, con estratificación por pérdida del 1p",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002714-11,0,0,0 2004-002714-11,11,2014-05-01,2014-05-14,9,1,0,0,0,0,3,0,0,1,1,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,"Estudio de fase III para evaluar la quimioterapia primaria con temozolomida frente a la radioterapia en pacientes con gliomas de bajo grado, con estratificación por pérdida del 1p",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002714-11,0,0,0 2004-002715-92,1,2007-01-31,2007-01-31,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,Royal Group Hospitals,"A randomised, control, assessor blinded, dose escalating study to compare high dose rocuronium and suxamethonium for use in rapid sequence induction of anaesthesia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002715-92,0,0,0 2004-002724-17,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Fresenius Kabi Deutschland GmbH,Efficacy of Neodolpasse™ in the treatment of postoperative pain: Morphine sparing effect during the first 24 hours postoperatively after unilateral total hip arthroplasty.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002724-17,0,0,0 2004-002729-34,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,AVENTIS PHARMA S.P.A.,"PILOT STUDY FOR THE EVALUATION OF THE EFFECTS OF INSULIN TREATMENT ON MYOCARDIAL FUNCTION, PERFUSION, AND GLUCOSE METABOLISM IN PATIENTS WITH PRIMARY LEFT VENTRICULAR DYSFUNCTION AND TYPE 2 DIABETES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002729-34,0,0,0 2004-002730-19,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,AVENTIS PHARMA S.P.A.,see above,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002730-19,0,0,0 2004-002731-62,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,AVENTIS PHARMA S.P.A.,OPTIMISATION OF INSULIN TREATMENT OF TYPE 2 DIABETES MELLITUS BY TELECARE ASSISTANCE FOR SELF MONITORING OF BLOOD GLUCOSE ELEONOR STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002731-62,0,0,0 2004-002732-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Geir Øystein Andersen, Department of Cardiology, Ulleval University Hospital",Safety and efficacy of levosimendan in patients with acute myocardial infarction complicated by symptomatic left ventricular failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002732-25,0,0,0 2004-002733-39,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ROCHE,FC + rituximab followed by rituximab maintenance treatment in patients with advanced untreated Indolent B-cell Non follicular Lymphomas: phase II study. FC + rituximab seguito da terapia di manteni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002733-39,0,0,0 2004-002734-19,1,2007-01-25,2007-01-25,1,1,0,0,0,3,4,0,0,1,0,0,1,0,0,South Tees Acute Hospitals NHS Trust,Do the drugs that are normally used to treat low blood pressure during Caesarean section affect spread of spinal anaesthesia?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002734-19,0,0,0 2004-002737-39,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,National Headache Institute,"Prophylactic treatment of episodic cluster headache with an angiotensin II receptor blocker (candesartan cilexetil); a randomized, placebo controlled parallel study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002737-39,0,0,0 2004-002740-10,4,2008-05-07,2008-06-25,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME. Pharmacogenetics Blood Sample Amendment 01, versio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002740-10,0,0,0 2004-002740-10,4,2008-05-07,2008-06-25,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"A PHASE IV, OPEN-LABEL, RANDOMIZED, MULTICENTER TRIAL ASSESSING A REYATAZ-BASED SUBSTITUTION APPROACH IN THE MANAGEMENT OF LIPODYSTROPHY SYNDROME. Pharmacogenetics Blood Sample Amendment 01, versio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002740-10,0,0,0 2004-002743-27,5,2007-05-31,2008-01-31,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,TKT Inc.,An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002743-27,0,0,0 2004-002743-27,5,2007-05-31,2008-01-31,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,TKT INC,An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002743-27,0,0,0 2004-002743-27,5,2007-05-31,2008-01-31,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Shire Human Genetic Therapies INC.,An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002743-27,0,0,0 2004-002746-35,8,2006-08-01,2006-08-29,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca AB,"The ""EXTEND"" study: A randomized, double-blind, parallel-group, phase IIIb, multi-centre study evaluating extended prophylactic treatment with melagatran/ximelagatran versus enoxaparin for the prevent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002746-35,0,0,0 2004-002752-34,2,2005-06-06,2005-06-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,AGI Therapeutics Limited,"A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF AGI 003 IN THE TREATMENT OF NON-CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002752-34,0,0,0 2004-002754-62,1,2007-04-15,2007-04-15,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Göttingen; Dep. of Clinical Pharmacology,Development of CYP2D6 genotype based dosage guidelines for the beta-blockers metoprolol and carvedilol based on hepatic clearance and resting and exercise heart rate reduction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002754-62,0,0,0 2004-002757-31,1,2006-03-29,2006-03-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Sverige AB,"A 28-Week Extension to a Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy in Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002757-31,0,0,0 2004-002759-15,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Dr. Miguel Martín,Randommized Phase II study of the continuous treatment vs. standard treatment with capecitabine in metastatic breast cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002759-15,0,0,0 2004-002760-16,1,2011-06-10,2011-06-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's and St Thomas' NHS Foundation Trust,A randomised Study of “bluelight” hexyl amino levulinic acid (HAL) photodynamic assisted resection of bladder tumours versus conventional “white light” transurethral resection of newly diagnosed bladd...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002760-16,0,0,0 2004-002761-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center,"RANDOMIZED, MULTICENTRE OPEN LABEL STUDY TO COMPARE THE EFFICACY AND TOLERABILITY OF SOLARAZE® FOR 3 MONTHS VERSUS 6 MONTHS IN PATIENTS WITH MILD TO MODERATE ACTINIC KERATOSIS LOCATED AT THE FACE AND ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002761-21,0,0,0 2004-002762-38,2,2004-02-11,2004-02-11,1,0,0,0,0,0,2,0,0,1,1,0,1,0,1,AGI Therapeutics Limited,"A randomised, double-blind, placebo-controlled study of AGI 001 in the treatment of functional dyspepsia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002762-38,0,0,0 2004-002766-37,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,HEXAL AG (Project Management on behalf of the Sponsor: HEXAL Pharmaforschung GmbH,"Open-label, multi-center, non-controlled follow-up study over 3-months on the safety of Formoterol Easyhaler® in approximately 35 asthmatic pediatric patients initially treated in study 2003-51-DPI-2",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002766-37,0,0,0 2004-002767-25,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,WALA Heilmittel GmbH,"Clinical trial on the efficacy of Calendula-Echinacea Ointment in sodium lauryl sulphate irritation test. A monocentric, randomised, placebo-controlled double blind clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002767-25,0,0,0 2004-002769-18,4,2006-03-02,2006-03-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development,"A 28-day, randomised, double-blind, placebo-controlled study to assess the safety, tolerability, anti-inflammatory effect and steadystate pharmacokinetics of SB-681323 7.5 mg per day in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002769-18,0,0,0 2004-002769-18,4,2006-03-02,2006-03-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D,"A 28-day, randomised, double-blind, placebo-controlled study to assess the safety, tolerability, anti-inflammatory effect and steadystate pharmacokinetics of SB-681323 7.5 mg per day in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002769-18,0,0,0 2004-002778-50,8,2006-03-24,2006-03-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A multi-national, open labelled, randomised, stratified, parallel group 36 week comparison of twice daily Biphasic Insulin Aspart 30 versus thrice daily Biphasic Insulin Aspart 50 and 70 all in combin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002778-50,0,0,0 2004-002778-50,8,2006-03-24,2006-03-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"A multi-national, open labelled, randomised, stratified, parallel group 36 week comparison of twice daily Biphasic Insulin Aspart 30 versus thrice daily Biphasic Insulin Aspart 50 and 70 all in combin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002778-50,0,0,0 2004-002782-20,2,2010-02-23,2010-02-23,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Eli Lilly and Company Limited,A Phase 1 and 2 Clinical Trial of ALIMTA (Pemetrexed) in Combination with Carboplatin in Patients with Recurrent Ovarian or Primary Peritoneal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002782-20,0,0,0 2004-002783-24,1,2008-12-01,2008-12-01,1,0,0,0,0,1,4,0,0,1,1,1,1,0,0,AMC Medical research BV,Prednisolone versus Dexamethasone in Chronic inflammatory demyelinating polyradiculoneuropathy Trial; PREDICT-trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002783-24,0,0,0 2004-002784-24,3,2007-03-06,2007-04-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Lilly S.A.,"A Randomized, Double-Blind, Phase 2 Study of Two Doses of Pemetrexed in the Treatment of Platinum-Resistant, Epithelial Ovarian or Primary Peritoneal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002784-24,0,0,0 2004-002784-24,3,2007-03-06,2007-04-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Eli Lilly and Company Limited,"A Randomized, Double-Blind, Phase 2 Study of Two Doses of Pemetrexed in the Treatment of Platinum-Resistant, Epithelial Ovarian or Primary Peritoneal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002784-24,0,0,0 2004-002787-15,4,2011-12-12,2011-12-12,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FC-R) versus chemotherapy with Fludarabine and Cyclophosophamide (FC) alone in patients with previously...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002787-15,1,0,0 2004-002787-15,4,2011-12-12,2011-12-12,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ROCHE,"Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FC-R) versus chemotherapy with Fludarabine and Cyclophosophamide (FC) alone in patients with previously...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002787-15,1,0,0 2004-002788-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg",Hippocampal volume in young adults with moderate to severe depression before and after combined antidepressant therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002788-25,0,0,0 2004-002795-42,6,2006-08-31,2006-10-18,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ALEXION PHARMACEUTICALS INCORPORATED,SHEPHERD: Safety in hemolytic PNH patients treated with Eculizumab: a multi-center open label research design study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002795-42,0,0,0 2004-002795-42,6,2006-08-31,2006-10-18,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ALEXION PHARMACEUTICALS INC,SHEPHERD: Safety in hemolytic PNH patients treated with Eculizumab: a multi-center open label research design study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002795-42,0,0,0 2004-002798-21,4,2006-07-10,2006-08-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche Ltd,"A Phase II, prospective, randomized, double-blind, active-controlled, parallel group, multi-center 'proof of concept' trial in adult patients with community-acquired pneumonia requiring hospitalizatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002798-21,0,0,0 2004-002799-41,1,2010-03-24,2010-03-24,1,1,0,0,0,1,2,0,0,1,0,0,1,0,2,Salford Royal Hospitals Trust,Iontophoresis as a possible therapy for digital ischaemia - preliminary studies in patients with scleroderma spectrum disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002799-41,0,0,0 2004-002799-41,1,2010-03-24,2010-03-24,1,1,0,0,0,1,2,0,0,1,0,0,1,0,2,UNIVERSITY OF MANCHESTER,Iontophoresis as a possible therapy for digital ischaemia - preliminary studies in patients with scleroderma spectrum disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002799-41,0,0,0 2004-002802-31,1,2006-02-10,2006-02-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Ferring-Leciva, a.s.","Multicentre, Controlled, Randomised, Open, Cross-over Study Comparing the Acceptability of Pentasa® Sachets versus Pentasa® tbl. 500mg in Children with Crohn´s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002802-31,0,0,0 2004-002803-34,1,2009-11-01,2009-11-01,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,"Klinik und Poliklinik fuer Strahlentherapie, Universität Erlangen-Nürnberg",Phase I/II-Studie Praeoperative Radiochemotherapie mit Capecitabin plus Oxaliplatin und Cetuximab beim lokal fortgeschrittenen Rektumkarzinom im UICC-Stadium II und III,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002803-34,0,0,0 2004-002807-33,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,1,Biolipox AB,"A double blind, randomized, cross-over, placebo controlled study, evaluating the time-to-onset of action of BLX000441-002 nasal spray in healthy volunteers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002807-33,0,0,0 2004-002811-98,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE,"Randomised phase II study of cetuximab in combination with gemcitabine or gemcitabine followed by cetuximab in patients with advanced non-small-cell lung cancer, not suitable for standard platin-based...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002811-98,0,0,0 2004-002812-27,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,deCODE genetics ehf.,"A prospective, randomised, double-blind, placebo-controlled, parallel group dose ranging study in asthma patients in Iceland to assess the safety, tolerability and efficacy of the MLK inhibitor, CEP-1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002812-27,0,0,0 2004-002815-10,6,2009-01-18,2009-12-11,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Centocor B.V.,"Multicenter, Randomized, Double-Blind, Active-Controlled Trial Comparing REMICADE® (infliximab) and REMICADE® plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn’s Disease Naive ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002815-10,0,0,0 2004-002818-11,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Heart of England NHS Foundation Trust,Magnesium Sulphate for the Prevention of Super Ventricular Dysrrhythmias following Non-Cardiac Thoracic Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002818-11,0,0,0 2004-002821-30,1,2009-04-16,2009-04-16,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Institute of Oncology, Vilnius University",Study of the efficacy of intravesical instillations of interleukin-2 in treatment of superficial bladder cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002821-30,0,0,0 2004-002823-42,2,2005-12-09,2005-12-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,UCB PHARMA,"A multicentre, double-blind, parallel, randomized, placebo-controlled study Evaluation of the efficacy and safety of Levocetirizine 5 mg and Desloratadine 5 mg administered orally as capsules once da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002823-42,0,0,0 2004-002823-42,2,2005-12-09,2005-12-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,UCB S.A. Pharma Sector,"A multicentre, double-blind, parallel, randomized, placebo-controlled study Evaluation of the efficacy and safety of Levocetirizine 5 mg and Desloratadine 5 mg administered orally as capsules once da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002823-42,0,0,0 2004-002824-16,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,Karolinska Universitetssjukhuset,Spinalt klonidin och baklofen som adjuvans till ryggmärgsstimulering vid terapiresistent smärta. (Möjlighet att förstärka den smärtlindrande effekten av alektrisk tyggmärgsstimulering med läkemedel so...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002824-16,0,0,0 2004-002825-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Tays/ anestesiayksikkö,Levosimendaanin vaikutus systeemiseen ja splanknikusalueen verenkiertoon vatsa-aortan anyrysman vuoksi leikattavilla potilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002825-37,0,0,0 2004-002831-14,1,2013-12-02,2013-12-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor negative breast cancer and adjuvant chemotherapeutic treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002831-14,0,0,0 2004-002832-24,1,2014-05-19,2014-05-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine or...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002832-24,0,0,0 2004-002834-20,1,2007-08-31,2007-08-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Universitätsklinik für Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie",Behandlung des fortgeschrittenen hepatozellulären Karzinoms mit dem mTOR-Inhibitor Rapamycin (HCC-Rap-001) Treatment of advanced hepatocellular carcinoma with the mTOR-inhibitor rapamycin (HCC-Rap-0...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002834-20,0,0,0 2004-002836-25,1,2005-05-19,2005-05-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Aerovance Inc.,A Phase IIa Study To Investigate The Effects of AER 001on Antigen Challenge In Atopic Asthmatic Subjects Following Repeated Administration.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002836-25,0,0,0 2004-002837-37,1,2006-02-14,2006-02-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Farma y Química, S.A.",An exploratory pharmacogenomic study of cetuximab monotherapy in patients with metastatic EGFR-Positive colorectal carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002837-37,0,0,0 2004-002839-10,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Fédération Nationale des Centres de Lutte Contre le Cancer,Phase II trial assessing the impact on instrumental and daily living autonomy of a chemotherapy regimen with bi-weekly docetaxel in the treatment of metastatic breast cancer in patients over the age o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002839-10,0,0,0 2004-002842-37,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Fujisawa GmbH,"A randomised, double-blind, vehicle-controlled, parallel group, multicentre, proof of concept, phase II clinical study to investigate the efficacy and safety of 1 % FR260500 gel in patients with facia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002842-37,0,0,0 2004-002844-93,7,2007-03-01,2007-03-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,KYOWA HAKKO UK LTD,"A Long-Term, Multicenter, Open-Label Safety Study with Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002844-93,0,0,0 2004-002844-93,7,2007-03-01,2007-03-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Kyowa Hakko U.K. Limited,"A Long-Term, Multicenter, Open-Label Safety Study with Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002844-93,0,0,0 2004-002846-36,5,2006-06-20,2006-06-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Corporation Austria Ges.m.b.H.,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP-690,550 VERSUS PLACEBO, ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATMEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002846-36,0,0,0 2004-002846-36,5,2006-06-20,2006-06-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP-690,550 VERSUS PLACEBO, ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATMEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002846-36,0,0,0 2004-002846-36,5,2006-06-20,2006-06-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP-690,550 VERSUS PLACEBO, ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATMEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002846-36,0,0,0 2004-002846-36,5,2006-06-20,2006-06-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Global & Developement, Pfizer Limited","A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP-690,550 VERSUS PLACEBO, ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATMEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002846-36,0,0,0 2004-002846-36,5,2006-06-20,2006-06-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO COMPARE 3 DOSE LEVELS OF CP-690,550 VERSUS PLACEBO, ADMINISTERED ORALLY TWICE DAILY (BID) FOR 6 WEEKS, IN THE TREATMEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002846-36,0,0,0 2004-002849-12,3,2013-12-06,2013-12-06,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"Extension to a multicenter, randomized, crossover, open label, dose finding study to compare the safety, efficacy and PK/PD relationship of multiple doses of SOM230 (200, 400 and 600 µg b.i.d.) and do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002849-12,0,0,0 2004-002849-12,3,2013-12-06,2013-12-06,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Farmaceutica S.A.,"Extension to a multicenter, randomized, crossover, open label, dose finding study to compare the safety, efficacy and PK/PD relationship of multiple doses of SOM230 (200, 400 and 600 µg b.i.d.) and do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002849-12,0,0,0 2004-002849-12,3,2013-12-06,2013-12-06,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"Extension to a multicenter, randomized, crossover, open label, dose finding study to compare the safety, efficacy and PK/PD relationship of multiple doses of SOM230 (200, 400 and 600 µg b.i.d.) and do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002849-12,0,0,0 2004-002850-69,1,2011-09-02,2011-09-02,1,0,0,0,1,3,4,0,0,1,1,1,1,0,0,Swansea NHS Trust,Role of High dose insulin and glucose-potassium-magnesium (HDI-GKM) for Myocardial protection in cardiac surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002850-69,0,0,0 2004-002852-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Jose Vicente Torregrosa Prats (fundacio clinic),"a randomised, open clinical trial to study the efficacy of risedronate 35 mg/week in prevention of bone mass loss and vascular calcifications after kidney transplantation Ensayo aleatorio, abierto par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002852-33,0,0,0 2004-002854-78,8,2008-03-19,2008-03-26,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomised, double blind, placebo controlled, multicentre phase III trial to evaluate the efficacy and safety of adding bevacizumab to gemcitabine and erlotinib in patients with metastatic pancreati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002854-78,0,0,0 2004-002854-78,8,2008-03-19,2008-03-26,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A randomised, double blind, placebo controlled, multicentre phase III trial to evaluate the efficacy and safety of adding bevacizumab to gemcitabine and erlotinib in patients with metastatic pancreati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002854-78,0,0,0 2004-002855-15,3,2005-01-11,2005-01-11,1,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A long term extension to a randomised, double-blind, placebo-controlled, stratified, paralle-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 1.0, 2.5, 7.5 and 15 mg admin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002855-15,0,0,0 2004-002855-15,3,2005-01-11,2005-01-11,1,1,0,0,0,1,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A long term extension to a randomised, double-blind, placebo-controlled, stratified, paralle-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 1.0, 2.5, 7.5 and 15 mg admin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002855-15,0,0,0 2004-002856-32,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ZAMBON GROUP,"Ketoprofen TDS patch Keofix in the treatment of flare-ups of non articular rheumatisms. A double blind, double dummy study vs oral ketoprofen retard 200 mg capsules",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002856-32,0,0,0 2004-002859-13,2,2017-12-19,2017-12-19,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,SIAK,"A randomized phase III trial comparing two schedules of rituximab maintenance in rituximab-responding patients with untreated, chemotherapy resistant or relapsed follicular lymphoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002859-13,0,0,0 2004-002860-43,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SIAK,"Master protocol for mantle cell lymphoma A multicenter phase II trial testing Gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002860-43,0,0,0 2004-002861-19,3,2006-07-06,2006-09-22,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S),Long-term treatment of Scalp Psoriasis with Calciptriol plus Betamethasone dipropionate gel. A phase III safety study of a new gel containing calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as dipro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002861-19,0,0,0 2004-002861-19,3,2006-07-06,2006-09-22,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharma A/S,Long-term treatment of Scalp Psoriasis with Calciptriol plus Betamethasone dipropionate gel. A phase III safety study of a new gel containing calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as dipro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002861-19,0,0,0 2004-002871-18,1,2009-11-02,2009-11-02,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"IPSEN PHARMA, S.A.","Phase II, open, single group,multicentre study to evaluate the efficacy and safety of Somatuline Autogel® (120 mg) administered every 4 weeks by deep subcutaneous injection in the tumour´s growth stab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002871-18,0,0,0 2004-002872-41,1,2007-05-06,2007-05-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,A Study to Validate Key Therapeutic Targets and Biomarkers during Allergen Exposure in Subjects with Allergic Rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002872-41,0,0,0 2004-002873-21,1,2012-05-21,2012-05-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,A study to assess disease pathology and key therapeutic targets in severe asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002873-21,0,0,0 2004-002880-26,3,2009-03-31,2009-03-31,2,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase IV, Multi-center, Cross-sectional study to evaluate the I50L substitution among subjects experiencing virologic failure on a HAART regimen containing atazanavir (ATV) Protocol: version 2.0, 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002880-26,0,0,0 2004-002880-26,3,2009-03-31,2009-03-31,2,1,0,0,0,0,4,0,0,1,1,0,1,0,1,BRISTOL-M.SQUIBB,"A Phase IV, Multi-center, Cross-sectional study to evaluate the I50L substitution among subjects experiencing virologic failure on a HAART regimen containing atazanavir (ATV) Protocol: version 2.0, 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002880-26,0,0,0 2004-002882-19,1,2010-04-29,2010-04-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Mid Cheshire Hospitals NHS Trust,"A controlled trial into the benefit of topical perianal glyceryl trinitrate (GTN) as a sphincter relaxant, pre-insertion of ultrasound probe for trans rectal ultrasound (TRUS) guided biopsy of the pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002882-19,0,0,0 2004-002887-41,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,1,OmniVision GmbH,"Randomisierte, kontrollierte, für den Prüfer verblindete klinische Prüfung (Pilotstudie) zur Untersuchung der Wirksamkeit von Spersadex® Augentropfen im Vergleich zu Isopto®-Dex Augentropfen bei Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002887-41,0,0,0 2004-002888-24,1,2006-08-14,2006-08-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"An open-label, multi-center trial to evaluate the feasibility and safety of short-term treatment with subcutaneously injected certoparin (8000 U anti-Xa twice daily) in patients with persistent nonval...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002888-24,0,0,0 2004-002889-38,1,,,0,1,0,0,0,3,3,0,0,1,0,0,0,1,1,OmniVision GmbH,"Randomisierte, kontrollierte, doppelblinde klinische Prüfung zur Untersuchung der Wirksamkeit und Verträglichkeit von Novesine® 0,4% Augentropfen im Vergleich zur Augentropfengrundlage bei zur Tonomet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002889-38,0,0,0 2004-002894-21,4,2006-06-22,2006-08-23,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-week, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety and tolerability of darifenacin (7.5 mg o.d. with voluntary up-titration to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002894-21,0,0,0 2004-002899-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dept of Paediatric Anaesthesia, Karolinska University Hospital-Solna",Etomidate-Lipuro vs. Diprivan-Propofol with added lignocaine: incidence of injection pain in association with induction of anaesthesia in children.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002899-42,0,0,0 2004-002901-57,2,2007-03-07,2007-03-07,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pharmazeutische Fabrik Evers & Co. GmbH,"“Randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of a herbal combination product, Eviprostat N, in the treatment of moderate LUTS associated with benign prost...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002901-57,0,0,0 2004-002902-31,7,2007-07-11,2007-07-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,THERAVANCE,"A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Methicillin Resistant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002902-31,0,0,0 2004-002902-31,7,2007-07-11,2007-07-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Theravance, Inc.","A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Methicillin Resistant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002902-31,0,0,0 2004-002903-34,1,,,0,1,0,0,0,3,4,0,1,0,0,0,0,0,0,"University of Frankfurt, Institute of Clinical Pharmacology",Phänotypisierung und Genotypisierung von Cytochrom P450-Enzymen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002903-34,0,0,0 2004-002904-13,7,2007-03-31,2007-10-20,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Theravance, Inc.","A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infectio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002904-13,0,0,0 2004-002908-15,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Carlos Gómez Martín,"ENSAYO FASE I/II, MULTICENTRICO DE LA COMBINACIÓN DE CARBOPLATINO Y GEMCITABINA EN EL TRATAMIENTO DE PACIENTES CON CARCINOMA DE OVARIO EN 1ª RECIDIVA TRAS QUIMIOTERAPIA SENSIBLES A PLATINO",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002908-15,0,0,0 2004-002910-12,1,2006-06-12,2006-06-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Theravance Inc.,"A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram-Positive Skin and Skin Structure Infections with a focus on Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002910-12,0,0,0 2004-002912-27,1,2005-03-16,2005-03-16,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ONO PHARMA UK LTD,Open-Label Extension Study to Investigate the Continued Safety and Effect of ONO 2506PO (1200 mg OD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002912-27,0,0,0 2004-002914-12,3,2006-06-15,2006-06-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Theravance Inc.,"A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram-positive Skin and Skin Structure Infections with a Focus on Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002914-12,0,0,0 2004-002914-12,3,2006-06-15,2006-06-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,THERAVANCE,"A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram-positive Skin and Skin Structure Infections with a Focus on Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002914-12,0,0,0 2004-002920-17,1,2008-06-11,2008-06-11,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Department of Health,A randomised preference trial of medical versus surgical termination of pregnancy less that 14 weeks' gestation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002920-17,0,0,0 2004-002924-16,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,FUJISAWA,"AN OPEN, MULTICENTRE, RANDOMISED PARALLEL GROUP CLINICAL STUDY TO COMPARE SAFETY AND EFFICACY OF TACROLIMUS FK506 WITH MONOCLONAL ANTI-IL2R ANTIBODIES DACLIZUMAB VS TACROLIMUS FK506 WITH STEROID...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002924-16,0,0,0 2004-002925-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Kliniken för onkologi, Karolinska Universitetssjukhuset, Solna",A Phase II study of Temozolomide (Temodal) Given Continously 100mg/m2 for 21 Days in 28 Day cycles in Patients with Metastatic Melanoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002925-39,0,0,0 2004-002926-23,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,INSTITUT DE RECHERCHE PIERRE FABRE,"Evaluation of the impact of the moisturizing milk RV2478B on the use of corticoids and on quality of life, in a population of children with atopic dermatitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002926-23,0,0,0 2004-002930-21,4,2009-10-23,2009-11-09,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Schering-Plough Research Institute,"Comparative Study of the Effect of Two Doses of Mometasone Furoate Dry Powder Inhaler 200 mcg and 400 mcg QD PM, Fluticasone Propionate 250 mcg BID, and Montelukast 10 mg QD PM, on Bone Mineral Densit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002930-21,0,0,0 2004-002934-20,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Abbott GmbH & Co. KG,"A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Moderate to Severe Croh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002934-20,0,0,0 2004-002935-23,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL ADULTO,Phase II study of PS341 VELCADE in myelodysplastic syndromes MDS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002935-23,0,0,0 2004-002937-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Dr. Angel Chamorro Sánchez. Servicio de Neurología, Hospital Clinic",Estudio farmacocinético del ácido úrico administrado por vía intravenosa en el ictus isquémico de menos de 12 horas de evolución.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002937-37,0,0,0 2004-002940-82,4,2006-01-06,2006-02-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Combination Therapy of LAF237 and Pioglitazone to LAF237 Monotherapy or Pioglitazone M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002940-82,0,0,0 2004-002940-82,4,2006-01-06,2006-02-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Combination Therapy of LAF237 and Pioglitazone to LAF237 Monotherapy or Pioglitazone M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002940-82,0,0,0 2004-002941-11,1,2006-04-03,2006-04-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Debiopharm SA,"A multicentre, 3-month, randomised, double blind, placebo and active controlled study on the tolerability and efficacy of ZT-1 for the symptomatic treatment of mild to moderate Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002941-11,0,0,0 2004-002943-28,2,2007-03-07,2007-07-19,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomized, Open Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002943-28,0,0,0 2004-002944-90,6,2008-07-01,2008-07-01,5,1,0,0,0,0,2,0,0,1,0,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,"A Multicenter, Open, Phase II Study to Estimate the activity and safety of Caspofungin CASP in the Firstline Treatment of probable and proven Invasive Aspergillosis IA in Patients with Hematolo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002944-90,0,0,0 2004-002944-90,6,2008-07-01,2008-07-01,5,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA S. CROCE E CARLE,"A Multicenter, Open, Phase II Study to Estimate the activity and safety of Caspofungin CASP in the Firstline Treatment of probable and proven Invasive Aspergillosis IA in Patients with Hematolo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002944-90,0,0,0 2004-002944-90,6,2008-07-01,2008-07-01,5,1,0,0,0,0,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,"A Multicenter, Open, Phase II Study to Estimate the activity and safety of Caspofungin CASP in the Firstline Treatment of probable and proven Invasive Aspergillosis IA in Patients with Hematolo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002944-90,0,0,0 2004-002945-10,5,2017-08-22,2017-08-22,3,1,0,0,0,0,3,0,1,2,0,0,0,0,2,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.","A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the Inci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002945-10,1,1,0 2004-002945-10,5,2017-08-22,2017-08-22,3,1,0,0,0,0,3,0,1,2,0,0,0,0,2,Merck & Co. Inc.,"A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the Inci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002945-10,1,1,0 2004-002945-10,5,2017-08-22,2017-08-22,3,1,0,0,0,0,3,0,1,2,0,0,0,0,2,"Merck & Co., Inc","A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the Inci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002945-10,1,1,0 2004-002945-10,5,2017-08-22,2017-08-22,3,1,0,0,0,0,3,0,1,2,0,0,0,0,2,Suomen MSD OY,"A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the Inci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002945-10,1,1,0 2004-002945-10,5,2017-08-22,2017-08-22,3,1,0,0,0,0,3,0,1,2,0,0,0,0,2,Merck Sharp & Dohme (Sweden) AB,"A Study to Evaluate the Efficacy of Quadrivalent HPV (Types 6, 11, 16, and 18) L1 Virus-Like Particle (VLP) in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related Anogenital Warts, and the Inci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002945-10,1,1,0 2004-002948-10,4,2007-06-19,2007-06-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer, S.A.",A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF PREGABALIN IN THE TREATMENT OF SUBJECTS WITH NEUROPATHIC PAIN ASSOCIATED WITH LUMBO-SACRAL RADICULOPATHY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002948-10,0,0,0 2004-002948-10,4,2007-06-19,2007-06-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer AB,A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF PREGABALIN IN THE TREATMENT OF SUBJECTS WITH NEUROPATHIC PAIN ASSOCIATED WITH LUMBO-SACRAL RADICULOPATHY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002948-10,0,0,0 2004-002948-10,4,2007-06-19,2007-06-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF PREGABALIN IN THE TREATMENT OF SUBJECTS WITH NEUROPATHIC PAIN ASSOCIATED WITH LUMBO-SACRAL RADICULOPATHY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002948-10,0,0,0 2004-002948-10,4,2007-06-19,2007-06-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER,A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF PREGABALIN IN THE TREATMENT OF SUBJECTS WITH NEUROPATHIC PAIN ASSOCIATED WITH LUMBO-SACRAL RADICULOPATHY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002948-10,0,0,0 2004-002950-67,6,2007-02-27,2007-03-07,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,NUVELO,"Phase 3, Multi-center, Multi-National, Randomized, partial double-blind, Placebo controlled study to evaluate the efficacy and safety of Alfimeprase in subjects with acute peripheral arterial occlusio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002950-67,0,0,0 2004-002950-67,6,2007-02-27,2007-03-07,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Nuvelo, Inc.","Phase 3, Multi-center, Multi-National, Randomized, partial double-blind, Placebo controlled study to evaluate the efficacy and safety of Alfimeprase in subjects with acute peripheral arterial occlusio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002950-67,0,0,0 2004-002951-16,1,2012-08-01,2012-08-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Medical Research Council,COIN A three-arm randomised controlled trial comparing either COntinous chemotherapy plus cetuximab or INtermittent chemotherapy with standard coninuous palliative combination chemotherapy with oxalip...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002951-16,0,0,0 2004-002952-33,4,2006-05-03,2006-05-17,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmaceútica S.A.,"A 2-year extension to study 2203, partially randomized, double-blind, placebo-controlled in the first year and open label in the second year, to assess the safety of the dose of AAE581 selected for p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002952-33,0,0,0 2004-002952-33,4,2006-05-03,2006-05-17,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 2-year extension to study 2203, partially randomized, double-blind, placebo-controlled in the first year and open label in the second year, to assess the safety of the dose of AAE581 selected for p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002952-33,0,0,0 2004-002952-33,4,2006-05-03,2006-05-17,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 2-year extension to study 2203, partially randomized, double-blind, placebo-controlled in the first year and open label in the second year, to assess the safety of the dose of AAE581 selected for p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002952-33,0,0,0 2004-002955-14,5,2010-03-09,2010-03-17,2,1,0,0,0,0,0,0,0,2,0,0,0,0,0,London School of Hygiene and Tropical Medicine,"A large randomised placebo controlled trial among trauma patients with or at risk of significant haemorrhage, of the effects of antifibrinolytic treatment on death and transfusion requirement",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002955-14,1,0,0 2004-002955-14,5,2010-03-09,2010-03-17,2,1,0,0,0,0,0,0,0,2,0,0,0,0,0,World Health Organisation,"A large randomised placebo controlled trial among trauma patients with or at risk of significant haemorrhage, of the effects of antifibrinolytic treatment on death and transfusion requirement",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002955-14,1,0,0 2004-002963-25,1,2008-06-26,2008-06-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Genetronics, Inc.",An Open-Label Study using the MedPulser Electroporation System To Treat Head and Neck Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002963-25,0,0,0 2004-002965-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Orthopaedic department, Karolinska Institutet, Danderyd's Hospital","Can risedronate prevent periprosthetic bone loss after hip arthroplasty? A randomized, double-blind, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002965-19,0,0,0 2004-002966-39,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Sheffield Teaching Hospitals NHS Foundation Trust,A Double-blind randomised controlled trial to compare buscopan versus placebo as an adjunct to colonoscopy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002966-39,0,0,0 2004-002971-18,1,2005-09-22,2005-09-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,UCB S.A. Pharma Sector,"A monocenter, double-blind, randomized trial, with two parallel groups comparing the clinical efficacy of levocetirizine 5 mg capsules and desloratadine 5 mg capsules taken once a day over 3 weeks of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002971-18,0,0,0 2004-002973-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA OSPEDALE POLICLINICO UMBERTO I,Epidemiological open-label study to evaluate the frequency of helicobacter Pylori infections prior to and after equimolar switch from therapy with MMF to enteric-coated Mycophenolic Acid (MYFORTIC-ERL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002973-22,0,0,0 2004-002973-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA POLICLINICO UMBERTO I,Epidemiological open-label study to evaluate the frequency of helicobacter Pylori infections prior to and after equimolar switch from therapy with MMF to enteric-coated Mycophenolic Acid (MYFORTIC-ERL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002973-22,0,0,0 2004-002974-48,10,2010-04-01,2014-09-30,7,1,0,0,2,0,3,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - EXTended Criteria Donors (BENEFIT-EXT) Amendment 1 and Revised protocol Number:01 (Incorporates Amendment...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002974-48,0,0,0 2004-002975-17,1,2006-12-01,2006-12-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Epsom & St Helier University Hospitals NHS Trust,A pilot study to examine the effect of vitamin C on bone turnover and antioxidant levels in postmenopausal women with low bone density,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002975-17,0,0,0 2004-002977-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,A PHASE II STUDY OF VELCADE BORTEZOMIB - PS341 IN THE TREATMENT OF PATIENTS OVER 18 YEARS WITH Ph LEUKEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002977-22,0,0,0 2004-002979-16,1,2006-08-08,2006-08-08,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,CARDIFF UNIVERSITY,"A Six-Week/Six-Week, Prospective, Randomised, Masked, Cross over, Primary Therapy Study comparing IOP Lowering Effects of Lumigan® and Xalatan® in Subjects with Primary Open Angle Glaucoma, Ocular Hy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002979-16,0,0,0 2004-002980-26,5,2008-07-17,2008-07-17,2,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"An open-label, phase II dose titration study of ACZ885 (human anti-IL-1beta monoclonal antibody) to assess the clinical efficacy, safety, pharmacokinetics and pharmacodynamics in patients with NALP3 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002980-26,1,1,0 2004-002980-26,5,2008-07-17,2008-07-17,2,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Farmacéutica,"An open-label, phase II dose titration study of ACZ885 (human anti-IL-1beta monoclonal antibody) to assess the clinical efficacy, safety, pharmacokinetics and pharmacodynamics in patients with NALP3 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002980-26,1,1,0 2004-002981-39,1,2015-05-03,2015-05-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals of Leicester NHS Trust,Randomised trial of detrusor botulinum toxin injection (BOTOX®) compared to placebo in women with idiopathic detrusor overactivity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002981-39,0,0,0 2004-002983-80,2,2005-07-06,2005-08-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALTANA Pharma AG,Comparison of the Efficacy of a Fixed Combination of Ciclesonide and Formoterol versus a Fixed Combination of Fluticasone and Salmeterol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002983-80,0,0,0 2004-002985-39,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ROCHE,"A multicenter, randomized, controlled study comparing the efficacy and safety of 48 weeks of 40kD branched pegylated interferon alfa-2a (PEGASYS, Ro 25-8310) versus 96 weeks of PEGASYS, alone or in co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002985-39,0,0,0 2004-002988-24,1,2007-05-25,2007-05-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp and Dohme de España,"A prospective, multicenter, randomized, double-blind, pilot study to evaluate the safety, the efficacy, the tolerability, and the emergence of resistant gram-negative microorganisms in the bowel in e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002988-24,0,0,0 2004-002991-40,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc,Evolution of Growth Rate in Children Suffering From a Disease Associated With Growth Retardation and Treated by Genotonorm. A Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002991-40,0,1,1 2004-002992-17,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,"Pfizer, Inc.",EVOLUTION OF GROWTH RATE IN CHILDREN WITH GROWTH RETARDATION RELATED TO LONG-TERM GLUCOCORTICOSTEROID THERAPY AND TREATED BY GENOTONORM®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002992-17,0,1,1 2004-002993-49,9,2006-09-01,2006-10-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Celltech R&D Ltd,"A Phase III multicentre, double blind, placebo-controlled, parallel group 52-week study to assess the efficacy and safety of 2 dose regimens of lyophilised CDP870 given subcutaneously as additional me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002993-49,0,0,0 2004-002993-49,9,2006-09-01,2006-10-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Celltech,"A Phase III multicentre, double blind, placebo-controlled, parallel group 52-week study to assess the efficacy and safety of 2 dose regimens of lyophilised CDP870 given subcutaneously as additional me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002993-49,0,0,0 2004-002993-49,9,2006-09-01,2006-10-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"A Phase III multicentre, double blind, placebo-controlled, parallel group 52-week study to assess the efficacy and safety of 2 dose regimens of lyophilised CDP870 given subcutaneously as additional me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002993-49,0,0,0 2004-002996-18,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,ARYx Therapeutics Limited,A Phase 2 Pilot Study of the Efficacy of ATI-2042 in subjects with Paroxysmal Atrial Fibrillation and Pacemakers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-002996-18,0,0,0 2004-003000-37,5,2005-10-14,2005-10-28,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination tablets Ezetimibe/Simvastatin 10mg/20mg and Ezetimibe/Simvastatin 10mg/40mg compared to Atorvastatin 20mg in Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003000-37,0,0,0 2004-003000-37,5,2005-10-14,2005-10-28,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Merck & Co. Inc.,"A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination tablets Ezetimibe/Simvastatin 10mg/20mg and Ezetimibe/Simvastatin 10mg/40mg compared to Atorvastatin 20mg in Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003000-37,0,0,0 2004-003000-37,5,2005-10-14,2005-10-28,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Merck Sharp & Dohme BV,"A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination tablets Ezetimibe/Simvastatin 10mg/20mg and Ezetimibe/Simvastatin 10mg/40mg compared to Atorvastatin 20mg in Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003000-37,0,0,0 2004-003000-37,5,2005-10-14,2005-10-28,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination tablets Ezetimibe/Simvastatin 10mg/20mg and Ezetimibe/Simvastatin 10mg/40mg compared to Atorvastatin 20mg in Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003000-37,0,0,0 2004-003015-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Laboratorios Galderma S.A.,Estudio de la eficacia y seguridad de la Terapia Fotodinámica con Metil Aminolevulinato en crema (Metvix®) en pacientes de alto riesgo con Carcinoma Basocelular Superficial (CBCs).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003015-23,0,0,0 2004-003016-30,1,,,0,1,0,1,0,0,1,0,1,1,0,0,0,1,1,Pfizer Health AB,"PHARMACOKINETICS OF NICOTINE FILM FOR USE IN THE MOUTH. A RANDOMIZED, CROSSOVER, PHASE-I, COMPARATIVE STUDY IN HEALTHY SMOKERS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003016-30,0,0,0 2004-003017-16,2,2011-03-30,2011-03-30,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,A combined phase 1 and 2 study investigating the combination of RAD001 and erlotinib in patients with advanced NSCLC previously treated only with chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003017-16,0,0,0 2004-003018-41,2,2007-10-24,2007-10-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"Open label, non-randomized, phase 2 Study investigating the effect of RAD001 monotherapy in patients with advanced NSCLC previously treated with either chemotherapy only or with chemotherapy and EGFR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003018-41,0,0,0 2004-003018-41,2,2007-10-24,2007-10-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"Open label, non-randomized, phase 2 Study investigating the effect of RAD001 monotherapy in patients with advanced NSCLC previously treated with either chemotherapy only or with chemotherapy and EGFR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003018-41,0,0,0 2004-003035-31,3,2006-08-17,2016-07-21,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,FORMENTI,Safety of the oral monophasic contraceptive GRT4248 (0.02 mg ethinylestradiol/2 mg chlormadinone acetate) in comparison to 0.02 mg ethinylestradiol/0.15 mg desogestrel given for 6 medication cycles Ra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003035-31,0,0,0 2004-003035-31,3,2006-08-17,2016-07-21,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Laboratorios Andrómaco S.A.,Safety of the oral monophasic contraceptive GRT4248 (0.02 mg ethinylestradiol/2 mg chlormadinone acetate) in comparison to 0.02 mg ethinylestradiol/0.15 mg desogestrel given for 6 medication cycles Ra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003035-31,0,0,0 2004-003035-31,3,2006-08-17,2016-07-21,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Grünenthal GmbH,Safety of the oral monophasic contraceptive GRT4248 (0.02 mg ethinylestradiol/2 mg chlormadinone acetate) in comparison to 0.02 mg ethinylestradiol/0.15 mg desogestrel given for 6 medication cycles Ra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003035-31,0,0,0 2004-003035-31,3,2006-08-17,2016-07-21,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Laboratorios Andrómaco S.A. (Co-sponsor Spanien),Safety of the oral monophasic contraceptive GRT4248 (0.02 mg ethinylestradiol/2 mg chlormadinone acetate) in comparison to 0.02 mg ethinylestradiol/0.15 mg desogestrel given for 6 medication cycles Ra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003035-31,0,0,0 2004-003036-53,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,A. N. M. C. O. - FONDAZIONE ITALIANA LOTTA MALATTIE CARDIOVASCOLARI,"GISSI AF Randomized, prospective, parallel group, placebo-controlled, multi-center study on the use of valsartan an angiotensin II AT1-receptor blocker in the prevention of Atrial Fibrillation recurr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003036-53,0,0,0 2004-003055-40,2,2007-09-30,2007-09-30,1,0,0,0,0,0,2,0,0,2,0,0,0,0,2,SONUS Pharmaceuticals Inc.,"A PHASE 2 MULTICENTER EVALUATION OF THE SAFETY AND EFFICACY OF TOCOSOL ® PACLITAXEL (S-8184 PACLITAXEL INJECTABLE EMULSION) IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED, UNRESECTABLE TRANSITIONAL C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003055-40,1,0,0 2004-003075-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Nordic Lymphoma Group,"CHOEP-14 + rituximab with CNS prophylaxis in patients less than 65 years with Diffuse Large B-Cell Lymphoma/Follicular Lymphoma grade III, stage II-IV with risk factors (age adjusted IPI) ≥ 2. A phase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003075-37,0,0,0 2004-003116-33,1,2007-12-20,2007-12-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Swedish Orphan Biovitrum (Sobi) AB (publ),A Phase 2 Study to Evaluate the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) in the Reduction of Dysphagia in Patients Receiving Concurrent Chemoradiotherapy follow...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003116-33,0,0,0 2004-003175-36,1,2011-09-30,2011-09-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Kings College London/South London and Maudsley NHS Foundation Trust,Randomised controlled trial of injectable opioid treatment for heroin dependence (RIOTT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003175-36,0,0,0 2004-003195-11,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Sankyo Pharma GmbH,"The effect of the co-administration of multiple oral doses of the fructose-1,6-bisphosphatase (FBPase) inhibitor CS-917 and glibenclamide on pharmacokinetics, safety and tolerability in diabetic patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003195-11,0,0,0 2004-003215-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Antonio Noda Cabrera,"Ensayo clínico piloto, unicéntrico, aleatorizado, doble ciego, con dos grupos paralelos sobre el efecto del Tacalcitol en pacientes afectos de vitíligo.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003215-22,0,0,0 2004-003235-31,1,2006-01-31,2006-01-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Div. of Cardiology, Innsbruck Medical University",Effect of pravastatin or fluvastatin and add-on valsartan on inflammatory markers and peripheral endothelial function in patients with acute coronary syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003235-31,0,0,0 2004-003236-59,7,2011-07-20,2011-07-20,6,1,0,0,0,1,0,0,0,1,0,0,1,0,1,United Therapeutics Corporation,Double Blind Placebo Controlled Clinical Investigation into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients with Severe Pulmonary Arterial Hypertension Double Blind Placebo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003236-59,0,0,0 2004-003236-59,7,2011-07-20,2011-07-20,6,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Lung Rx Inc.,Double Blind Placebo Controlled Clinical Investigation into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients with Severe Pulmonary Arterial Hypertension Double Blind Placebo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003236-59,0,0,0 2004-003238-32,1,2009-06-19,2009-06-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Dept. of Clinical Pharmacology,Effect of pioglitazone on portal and systemic hemodynamics in patients with advanced cirrhosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003238-32,0,0,0 2004-003255-39,1,,,0,0,0,0,0,1,4,0,0,1,0,0,0,1,0,The Finnish Lymphoma group,Treatment protocol for elderly patients with mantle cell lymphoma (MCL). A phase II study of the Finnish Lymphoma Group.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003255-39,0,0,0 2004-003295-10,5,2010-12-14,2012-06-06,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CENTOCOR,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNF 945; Monoclonal Antibody, Administered Subcutaneously, in Methotrexatena ve Subjects with Activ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003295-10,0,0,0 2004-003295-10,5,2010-12-14,2012-06-06,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Centocor BV,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNF 945; Monoclonal Antibody, Administered Subcutaneously, in Methotrexatena ve Subjects with Activ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003295-10,0,0,0 2004-003296-36,2,2012-05-17,2012-05-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Centocor B.V.,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthriti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003296-36,0,0,0 2004-003298-10,5,2012-01-10,2012-01-13,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Centocor BV,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003298-10,0,0,0 2004-003299-12,4,2007-01-31,2012-01-18,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Biologics B.V.,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Ankylosing Spondyli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003299-12,0,0,0 2004-003299-12,4,2007-01-31,2012-01-18,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Centocor BV,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Ankylosing Spondyli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003299-12,0,0,0 2004-003340-22,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Pfizer Luxembourg SARL Latvia Branch,"A randomised, placebo controlled, double blind trial of asenapine in the prevention of relapse after long term treatment of schizophrenia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003340-22,0,0,0 2004-003341-40,1,2010-04-27,2010-04-27,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Oxford,PRE-EMPT: Prevention of Mood Disorders by Folic Acid Supplement.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003341-40,0,0,0 2004-003355-39,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Eisai Limited,"A 52-week, multicentre, open label extension study of the safety, tolerability and efficacy of donepezil (Aricept) in Parkinson's disease patients with dementia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003355-39,0,0,0 2004-003435-31,5,2007-11-14,2007-12-19,4,0,0,0,0,0,3,0,0,1,1,0,1,0,1,NEUROCHEM INC.,A Phase III Study of the Efficacy and Safety of AlzhemedTM as Add-on Therapy in Mild to Moderate Alzheimer s Disease Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003435-31,0,0,0 2004-003435-31,5,2007-11-14,2007-12-19,4,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Neurochem Inc.,A Phase III Study of the Efficacy and Safety of AlzhemedTM as Add-on Therapy in Mild to Moderate Alzheimer s Disease Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003435-31,0,0,0 2004-003479-35,1,2007-01-20,2007-01-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Internal Medicine IV, Mecdical University of Vienna",PHARMACOKINETICS OF VORICONAZOLE DURING CONTINUOUS VENOVENOUS HEMODIAFILTRATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003479-35,0,0,0 2004-003495-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO,PHASE III STUDY OF CHEMOHORMONAL THERAPY WITH TO DIFFERENT MODALITIES CONCOMITANT OR ALTERNATE VERSUS HORMONAL THERAPY ALONE IN ADVANCED PROSTATE CANCER PATIENTS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003495-11,0,0,0 2004-003516-35,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA UMBERTO I,Proposal of pilot study for evaluation of Campath-1h activity as second line therapy of mantle cell lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003516-35,0,0,0 2004-003595-11,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Asociación Colaboración Cochrane Iberoamericana (ACCIb),PeriOperative ISchemic Evaluation study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003595-11,0,0,0 2004-003595-11,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Canadian Cardiovascular Collaboration, Population Health Research Institute, McMaster University",PeriOperative ISchemic Evaluation study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003595-11,0,0,0 2004-003616-37,1,2006-07-19,2006-07-19,1,1,0,0,1,0,4,0,1,1,0,0,1,0,1,Chiron Behring GmbH & Co KG,"M48P3: A phase IV, randomized, controlled, single-blind, multi-center study in children to evaluate the safety, tolerability and immunogenicity of two TBE vaccines administered according to two differ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003616-37,0,0,0 2004-003617-16,3,2007-07-09,2007-07-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomized, Open-label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg with Fulvestrant (FASLODEX™) 250 mg whe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003617-16,0,0,0 2004-003617-16,3,2007-07-09,2007-07-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca Österreich GmbH,"A Randomized, Open-label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg with Fulvestrant (FASLODEX™) 250 mg whe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003617-16,0,0,0 2004-003619-22,1,2005-06-23,2005-06-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare,A placebo-controlled study to investigate the efficacy of a combination analgesic treatment compared to its individual components in primary dysmenorrhoea.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003619-22,0,0,0 2004-003635-31,10,2014-01-09,2015-11-18,8,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT). Revised Protocol 05 incorporating Protocol Amendments 13 (dated 10-Feb-2011),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003635-31,0,0,0 2004-003635-31,10,2014-01-09,2015-11-18,8,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT). Revised Protocol 05 incorporating Protocol Amendments 13 (dated 10-Feb-2011),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003635-31,0,0,0 2004-003657-99,2,2006-07-24,2006-07-24,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Arrow Therapeutics Ltd,"A double-blind, randomised, placebo controlled study to evaluate the safety and efficacy of A-60444 in adults with RSV infection following stem cell transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003657-99,0,0,0 2004-003661-33,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"Sepracor, Inc.",A Pilot Study of the Safety and Efficacy of SEP-226330 in Subjects with Restless Legs Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003661-33,0,0,0 2004-003675-36,3,2007-08-14,2007-08-14,2,0,0,0,0,1,3,0,0,1,0,0,1,0,1,Forest Laboratories UK Ltd,"A randomised, open label study to compare the efficacy and safety of a dry powder formulation of inhaled Colistimethate Sodium and nebulised TNSFI (Tobramycin nebuliser solution for inhalation, TOBI®)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003675-36,0,0,0 2004-003699-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,INMUNO DESIGNED MOLECULES (IDM),"Phase II/III, Multicenter, Open-label, Randomized Study Comparing Autologous Intravesical Macrophage Cell Therapy (“Bexidem”) to Intravesical BCG-Therapy in Patients With Superficial Papillary Bladder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003699-13,0,0,0 2004-003700-38,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,Profil Institut fuer Stoffwechselforschung GmbH,Einfluß einer supplementären Therapie mit postprandial injiziertem Insulin Lispro (Huma-log®) auf diabetesbezogene Komplikationen und Lebensqualität bei geriatrischen Patienten mit Typ 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003700-38,0,0,0 2004-003701-24,2,2010-05-31,2010-05-31,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,"A RANDOMISED, OPEN-LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEXAROTENE (TARGRETIN) CAPSULES COMBINED WITH PUVA, COMPARED TO PUVA TREATMENT ALONE IN PATIENTS WITH MYCOSIS FUNGOIDES.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003701-24,0,0,0 2004-003701-24,2,2010-05-31,2010-05-31,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer (EORTC),"A RANDOMISED, OPEN-LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEXAROTENE (TARGRETIN) CAPSULES COMBINED WITH PUVA, COMPARED TO PUVA TREATMENT ALONE IN PATIENTS WITH MYCOSIS FUNGOIDES.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003701-24,0,0,0 2004-003703-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Semmelweis University,The role of hyperhomocysteinemia in the genesis of atherothrombotic vascular disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003703-21,0,0,0 2004-003727-12,3,2005-11-23,2005-11-23,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals, Global Medical Affairs","A Single Dose, Randomized, 2-Period Crossover Study in Patients with Hemophilia A to Evaluate the Pharmacokinetics of Refacto(B-domain deleted recombinant human factor VIII (BDDrFVIII) and Advate (a f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003727-12,0,0,0 2004-003727-12,3,2005-11-23,2005-11-23,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,WYETH LEDERLE,"A Single Dose, Randomized, 2-Period Crossover Study in Patients with Hemophilia A to Evaluate the Pharmacokinetics of Refacto(B-domain deleted recombinant human factor VIII (BDDrFVIII) and Advate (a f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003727-12,0,0,0 2004-003728-36,1,2010-06-25,2010-06-25,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,"PHASE II CLINICAL TRIAL WITH CAELYX MONO-CHEMOTHERAPY IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES STAGE IIb, IVa AND IVb WITH OR WITHOUT PREVIOUS CHEMOTHERAPY.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003728-36,0,0,0 2004-003731-31,1,2011-11-01,2011-11-01,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,University Hospitals of Leiceter NHS Trust,Pharmacogenetics and metabolism of cyclophosphamide in paediatric non-Hodgkin’s Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003731-31,0,0,0 2004-003733-14,4,2012-02-24,2012-02-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann La-Roche AG,"A randomized, double-blind, parallel group study of the safety and prevention of structural joint damage during treatment with MRA versus placebo, in combination with methotrexate, in patients with mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003733-14,0,0,0 2004-003733-14,4,2012-02-24,2012-02-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann La-Roche Ltd.,"A randomized, double-blind, parallel group study of the safety and prevention of structural joint damage during treatment with MRA versus placebo, in combination with methotrexate, in patients with mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003733-14,0,0,0 2004-003733-14,4,2012-02-24,2012-02-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F Hoffmann La-Roche Ltd.,"A randomized, double-blind, parallel group study of the safety and prevention of structural joint damage during treatment with MRA versus placebo, in combination with methotrexate, in patients with mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003733-14,0,0,0 2004-003733-14,4,2012-02-24,2012-02-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A randomized, double-blind, parallel group study of the safety and prevention of structural joint damage during treatment with MRA versus placebo, in combination with methotrexate, in patients with mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003733-14,0,0,0 2004-003734-34,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Barrier Therapeutics nv,"A one-week, randomized, double-blind, placebo-controlled pilot trial to evaluate oral R129160 (60 mg b.i.d.) on the alleviation of itch in atopic dermatitis patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003734-34,0,0,0 2004-003735-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Gedeon Richter LTD,"Randomizált, kettős vak, multicentrikus vizsgálat disztális, szenzomotoros típusú diabéteszes neuropátiás fájdalomban az együttesen adott emelkedő dózisú 150 mg-os tolperisone filmtabletta és 30 mg-os...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003735-31,0,0,0 2004-003737-13,6,2006-03-08,2006-09-28,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,PFIZER,"A Phase 2 multi-center, open label, long-term extension trial to assess the safety and sustained efficacy of oral UK-390,957 administered as required in adult men with premature ejaculation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003737-13,0,0,0 2004-003737-13,6,2006-03-08,2006-09-28,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Ltd.,"A Phase 2 multi-center, open label, long-term extension trial to assess the safety and sustained efficacy of oral UK-390,957 administered as required in adult men with premature ejaculation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003737-13,0,0,0 2004-003737-13,6,2006-03-08,2006-09-28,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Limited,"A Phase 2 multi-center, open label, long-term extension trial to assess the safety and sustained efficacy of oral UK-390,957 administered as required in adult men with premature ejaculation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003737-13,0,0,0 2004-003737-13,6,2006-03-08,2006-09-28,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Corporation Austria Ges.m.b.H., Clinical Research","A Phase 2 multi-center, open label, long-term extension trial to assess the safety and sustained efficacy of oral UK-390,957 administered as required in adult men with premature ejaculation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003737-13,0,0,0 2004-003737-13,6,2006-03-08,2006-09-28,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer,"A Phase 2 multi-center, open label, long-term extension trial to assess the safety and sustained efficacy of oral UK-390,957 administered as required in adult men with premature ejaculation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003737-13,0,0,0 2004-003737-13,6,2006-03-08,2006-09-28,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Pharma GmbH,"A Phase 2 multi-center, open label, long-term extension trial to assess the safety and sustained efficacy of oral UK-390,957 administered as required in adult men with premature ejaculation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003737-13,0,0,0 2004-003739-30,1,2007-06-12,2007-06-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Ulm / University Clinical Center Ulm,"Phase II Study on Gemtuzumab Ozogamicin in Combination with All-trans-Retinoic Acid, high-dose Cytarabine and Mitoxantrone in Patients with primary refractory acute myeloid leukemia [GO-A-HAM]",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003739-30,0,0,0 2004-003740-22,1,,,0,0,0,0,0,0,3,0,1,1,0,0,0,1,1,PKH-Pharmazeutische Kontroll- und Herstellungslabor GmbH,"Doppelblinder, randomisierter, vehikel- und referenzkontrollierter Nachweis der antibakteriellen Wirksamkeit von Kaliumpermanganat(0,001%)-enthaltenden topischen Präparationen zur epikutanen Applikati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003740-22,0,0,0 2004-003741-40,5,2006-11-20,2007-01-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann La-Roche AG,"A randomized, double-blind, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate, in patients with moderate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003741-40,0,0,0 2004-003741-40,5,2006-11-20,2007-01-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A randomized, double-blind, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate, in patients with moderate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003741-40,0,0,0 2004-003742-18,4,2006-05-02,2006-05-02,1,1,0,0,0,3,0,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A ten-week, randomized, double-blind study evaluating the efficacy of Duloxetine 60 mg once daily versus placebo in outpatients with major depressive disorder and pain (EU-Pain enriched study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003742-18,0,0,0 2004-003742-18,4,2006-05-02,2006-05-02,1,1,0,0,0,3,0,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co KG,"A ten-week, randomized, double-blind study evaluating the efficacy of Duloxetine 60 mg once daily versus placebo in outpatients with major depressive disorder and pain (EU-Pain enriched study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003742-18,0,0,0 2004-003742-18,4,2006-05-02,2006-05-02,1,1,0,0,0,3,0,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A ten-week, randomized, double-blind study evaluating the efficacy of Duloxetine 60 mg once daily versus placebo in outpatients with major depressive disorder and pain (EU-Pain enriched study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003742-18,0,0,0 2004-003745-40,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GILEAD SCIENCES S.R.L.,Phase II pilot study on safety of administration of 3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment ( day 50-8th W...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003745-40,0,0,0 2004-003749-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Enric Pedrol Clotet. Unidad Enfermedades Infecciosas.Hospital de Granollers,ESTUDIO DE LOS CAMBIOS EN EL RECUENTO DE LINFOCITOS CD4 TRAS LA SUSTITUCIÓN DE TENOFOVIR POR ABACAVIR EN PACIENTES CON UNA PAUTA HAART QUE INCLUYA DDI + TENOFOVIR Y CON SUPRESIÓN VIRAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003749-42,0,0,0 2004-003750-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Anestesiología. Hospital Universitario Germans Trias i Pujol. Badalona,Título completo del ensayo: Efecto del remifentanilo en perfusión continua comparado con dosis discontinuas de fentanilo en cirugía torácica con resección pulmonar,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003750-25,0,0,0 2004-003752-19,6,2007-04-27,2007-07-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"A Randomized, Double-blind, Placebo- and Active-controlled, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged-release Tablets in Subjects with Mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003752-19,0,0,0 2004-003752-19,6,2007-04-27,2007-07-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co.KG,"A Randomized, Double-blind, Placebo- and Active-controlled, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged-release Tablets in Subjects with Mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003752-19,0,0,0 2004-003753-56,1,2014-03-25,2014-03-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,Randomised double blind control trial of single dose methotrexate versus expectant management in women with tubal ectopic pregnancy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003753-56,0,0,0 2004-003754-26,4,2006-08-28,2006-12-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Idenix Pharmaceuticals, Inc.",A Randomized Trial of Switching Antiviral Therapy from Lamivudine to Telbivudine (LdT) vs. Continued Lamivudine Treatment in Adults with Chronic Hepatitis B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003754-26,0,0,0 2004-003754-26,4,2006-08-28,2006-12-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,IDENIX,A Randomized Trial of Switching Antiviral Therapy from Lamivudine to Telbivudine (LdT) vs. Continued Lamivudine Treatment in Adults with Chronic Hepatitis B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003754-26,0,0,0 2004-003755-39,1,2005-11-14,2005-11-14,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,"CombinatoRx, Inc","A SINGLE CENTER, SINGLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF THE EFFECT OF CRx-102 COMPARED TO PLACEBO ON SERUM C-REACTIVE PROTEIN (CRP) AND INFLAMMATORY CYTOKINES IN SUBJECTS WITH SEVERE AD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003755-39,0,0,0 2004-003761-33,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Unidad de Neuroinmunología,"Unicenter double-blind, cross-over, randomised, placebo controlled clinical trial to evaluate efficacy of vardenafil in subjects with E.D. and multiple sclerosis (M.S.)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003761-33,0,0,0 2004-003764-30,1,2007-10-03,2007-10-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Diamyd Therapeutics AB,"A Phase II, Randomised, Double-Blind, Placebo-controlled, Multi-centre Study to Investigate the Impact of Diamyd on the Progression of diabetes in Patients Newly Diagnosed with Type 1 Diabetes Mellitu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003764-30,0,0,0 2004-003768-32,1,2006-03-03,2006-03-03,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of four different formulations of GlaxoSmithKline (GSK) Bio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003768-32,0,0,0 2004-003769-33,1,2006-07-13,2006-07-13,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III open (partially double-blind), controlled, multicenter, multicountry primary & booster vaccination study to demonstrate the non-inferiority of the meningococcal serogroup C response of Gla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003769-33,0,0,0 2004-003771-37,1,2007-04-04,2007-04-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Genmab A/S,"A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthritis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003771-37,0,0,0 2004-003774-29,5,2007-09-04,2007-09-04,3,0,0,0,0,2,3,0,0,1,1,0,1,0,1,THERAKOS,"A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy with THERAKOS* UVADEX* for the Treatment of Patients with Newly Diagnosed Acute Graft-versus-Host Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003774-29,0,0,0 2004-003774-29,5,2007-09-04,2007-09-04,3,0,0,0,0,2,3,0,0,1,1,0,1,0,1,"Therakos, Inc.","A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy with THERAKOS* UVADEX* for the Treatment of Patients with Newly Diagnosed Acute Graft-versus-Host Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003774-29,0,0,0 2004-003776-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Neuro3d,"Safety amd tolerability of ocaperidone in the continuation treatment of patients with schizophrenia: a double-blind, parallel group, multicentre, fixed dose, follow-up study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003776-10,0,0,0 2004-003777-90,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Organisation name was not entered,Har magnesiumsulfat (MgSO4) en smertelindrende effekt ved total hoftealloplastik?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003777-90,0,0,0 2004-003777-90,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Anæstesiklinikken, Frederiksberg Hospital",Har magnesiumsulfat (MgSO4) en smertelindrende effekt ved total hoftealloplastik?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003777-90,0,0,0 2004-003778-27,3,2006-07-06,2006-07-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development,A Randomized Double-Blind Placebo Controlled Trial Evaluating the Safety and Efficacy of Etanercept 25 mg Twice Weekly in Subjects with Moderate to Severe Persistent Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003778-27,0,0,0 2004-003781-14,3,2007-12-20,2008-02-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Johnson & Johnson Pharmaceutical Research and Development,"A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar I Disorder, wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003781-14,0,0,0 2004-003781-14,3,2007-12-20,2008-02-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Janssen Cilag International,"A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar I Disorder, wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003781-14,0,0,0 2004-003781-14,3,2007-12-20,2008-02-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Johnson and Johnson Pharmaceutical Research and Development, una división de Janssen-Cilag, S.A","A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar I Disorder, wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003781-14,0,0,0 2004-003783-30,1,2006-10-15,2006-10-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Technical Unversity of Munich,Application of Aprepitant as salvage prophylaxis after failure of a conventional antiemetic therapy during moderately emetogenic chemotherapy in gastrointestinal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003783-30,0,0,0 2004-003784-68,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Bern,Subcutanoeus Delivery of Filgrastim (rG-CSF) for the Promotion of Collateral Growth in Patients with Coroanry Artery Disease (FILCAD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003784-68,0,0,0 2004-003786-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GON-North Oncology Group,"A multicenter, phase II clinical trial comparing Vinorelbine and Epirubicine versus Epirubicine and docetaxel in First Line of treatment for women with breast cancer Estudio fase II, abierto, multicén...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003786-33,0,0,0 2004-003793-29,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Ste-Justine Hospital - Montréal in the name of Canadian Institute of Health Research (Canada),INternational Trial of Antioxidants for the Prevention of Preeclampsia (INTAPP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003793-29,0,0,0 2004-003796-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Dept. of surg.gastroent., Gentofte University Hospital, Copenhagen",Effekt af melatonin på forekomsten af postoperativ træthed og søvnforstyrrelser efter laparoskopisk kolecystektomi. En randomiseret dobbelt-blindet placebo kontrolleret undersøgelse.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003796-37,0,0,0 2004-003797-28,1,2006-11-01,2006-11-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Hammersmith Hospitals NHS Trust,A comparison of the effectiveness of prostaglandin gel and tablet preparations in induction of labour at term.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003797-28,0,0,0 2004-003798-94,1,2006-04-15,2006-04-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, open-label, parallel-group study to investigate blood concentrations, safety and tolerability of 2 ointment formulations of ASM981 in adult patients with atopic dermatitis treated topica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003798-94,0,0,0 2004-003799-13,6,2007-06-26,2007-06-29,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Serono International SA,"A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003799-13,0,0,0 2004-003801-26,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Institut für anwendungsorientierte Forschung und klinische Studien gGmbH der UMG Göttingen,"Offene, multizentrische, nicht-randomisierte Phase II Studie:Dosiseskalation von Zevalin und zeitnahe Applikation der Hochdosischemotherapie BEAM gefolgt von autologer Stammzelltransplantation zur Beh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003801-26,0,0,0 2004-003803-19,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,GlaxoSmithKline Research & Development,"A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo- and Active- Controlled, Flexible Dose Study Evaluating the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochlor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003803-19,0,0,0 2004-003807-19,4,2005-09-29,2005-09-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Ltd,A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003807-19,0,0,0 2004-003807-19,4,2005-09-29,2005-09-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck & Co Inc.,A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003807-19,0,0,0 2004-003807-19,4,2005-09-29,2005-09-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck, Sharp & Dohme",A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003807-19,0,0,0 2004-003807-19,4,2005-09-29,2005-09-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.",A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003807-19,0,0,0 2004-003809-25,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,Sanofi-Synthelabo Co. Ltd.,Comparison of the efficacy and tolerability of drotaverine 80 mg or ibuprofen 400 mg administered alone with their combination for the treatment of primary and secondary dysmenorrhea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003809-25,0,0,0 2004-003810-41,1,2005-12-02,2005-12-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,biosyn Arzneimittel GmbH,"Einfluss von Selen auf die endotheliale Dysfunktion bei Patienten mit kardiovaskulären Erkrankungen: prospektive, randomisierte, dreiarmige, doppelblinde, monozentrische klinische Prüfung der Phase II",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003810-41,0,0,0 2004-003813-18,1,2007-06-14,2007-06-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc,A continuation study of CPG 7909 Injection in patients with matastatic or recurrent malignancies who have stable disease or who have responded to CPG 7909 Injection therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003813-18,0,0,0 2004-003814-40,2,2009-10-13,2009-10-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"An open-label, multi-centre, extension study evaluation the long-term safety and tolerability of Degarelix one-month depots in patients with prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003814-40,0,0,0 2004-003815-22,2,2006-11-08,2006-11-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"An Open-Label, Multi-Centre, Randomised Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens of 240 mg (40 mg/mL) and 240 mg (60 mg/mL) in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003815-22,0,0,0 2004-003816-47,1,2007-08-01,2007-08-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Pädiatrische Endokrinologie, Universitätsmedizin Berlin, Charité",Clinical pilot study on the effect of Metformin in adipose children and adolescents with insulin-resistance Klinische Pilotstudie zur Untersuchung der Wirkung von Metformin bei adipösen Kindern und J...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003816-47,0,0,0 2004-003819-23,3,2006-06-02,2006-06-02,3,1,0,0,1,3,3,0,0,1,0,0,1,0,1,NV Organon,"A multi-center, randomized, parallel dose-finding, safety-assessor blinded trial to explore the efficacy, safety and pharmacokinetics of four doses of Org 25969 and placebo in pediatric and adult subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003819-23,0,0,0 2004-003820-37,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,2,BRACCO IMAGING,A multicentre study to evaluate the Contibution of SonoVue® and CnTI technology (Contrast Tuned Imaging) to a correct classification of Adnexal Masses as benign or malignant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003820-37,0,0,0 2004-003820-37,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,2,Bracco Imaging Spa,A multicentre study to evaluate the Contibution of SonoVue® and CnTI technology (Contrast Tuned Imaging) to a correct classification of Adnexal Masses as benign or malignant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003820-37,0,0,0 2004-003822-80,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,The Leeds Teaching Hospitals NHS Trust,Modulation of Sympathetic Nerve Activity By Pioglitazone In Type 2 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003822-80,0,0,0 2004-003824-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundació Institut Català de Farmacologia,"Randomized, double blind, parallel groups, placebo controlled pivotal clinical trial to asses preliminary efficacy and security of a sublingual Cannabis Standardized Extract (Sativex) added to referen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003824-36,0,0,0 2004-003825-29,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,Cardiff and Vale NHS Trust,MAGNET - a randomised placebo controlled trial of the use of nebulised magnesium sulphate in moderate/severe acute asthma in childhood,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003825-29,0,0,0 2004-003826-92,1,2006-02-27,2006-02-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"AstraZeneca Farmacéutica Spain, S.A.","""A Randomized, Parallel Group, Open Trial Examining the Safety, Efficacy and Tolerability of Fast Titration, 800mg/day by day 4, of Quetiapine Fumarate Compared to Standard Titration, 400mg/day by day...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003826-92,0,0,0 2004-003827-10,4,2007-04-27,2007-04-30,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline R&D,"A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopinav...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003827-10,0,0,0 2004-003827-10,4,2007-04-27,2007-04-30,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.","A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopinav...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003827-10,0,0,0 2004-003827-10,4,2007-04-27,2007-04-30,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GLAXO SMITHKLINE,"A Phase III, Randomized, Controlled, Open-label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-boosted HIV-1 Protease Inhibitor (PI) regimen of Fosamprenavir (FPV)/ Lopinav...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003827-10,0,0,0 2004-003829-28,2,2005-08-31,2005-08-31,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Takeda Europe R&D Centre Ltd,"An open-label investigation into the tolerability and pharmacokinetic / pharmacodynamic effects of sufugolix (TAK-013), at a dosage of 100mg twice-daily, during six months treatment of pre-menopausal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003829-28,0,0,0 2004-003833-15,1,2007-08-01,2007-08-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,South Manchester University NHS Trust,A randomised parallel group study to investigate the effect of Seretide withdrawal in COPD using non-invasive biomarkers and physiological measurements,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003833-15,0,0,0 2004-003833-15,1,2007-08-01,2007-08-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medicines Evaluation Unit,A randomised parallel group study to investigate the effect of Seretide withdrawal in COPD using non-invasive biomarkers and physiological measurements,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003833-15,0,0,0 2004-003833-15,1,2007-08-01,2007-08-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Manchester,A randomised parallel group study to investigate the effect of Seretide withdrawal in COPD using non-invasive biomarkers and physiological measurements,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003833-15,0,0,0 2004-003835-30,1,2007-06-01,2007-06-01,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Belfast City Hospital,"An open label, single centre, assessor blind pilot study comparing topical tacrolimus 0.1% and hydrocortisone ointment 1% in the treatment of flexural psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003835-30,0,0,0 2004-003836-77,1,2017-05-31,2017-05-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Oxford,"AspECT - A phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia & oesophagitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003836-77,0,0,0 2004-003839-31,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Elan Pharma Ltd.,"A Phase III, Multicenter, Open-Label, Long-Term Study of the Tolerability of Intravenous Natalizumab in Crohn's Disease Subjects Who Have Previously Participated in Natalizumab Crohn's Disease Study C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003839-31,0,0,0 2004-003840-22,2,2007-02-06,2007-02-06,2,1,0,0,0,0,3,0,0,1,0,0,1,0,2,AstraZeneca AB,"A Double-blind, Multi-centre, Active-Controlled (15, 30, and 45mg Pioglitazone) Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar (0.5 and 1 mg) in Patients with T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003840-22,0,0,0 2004-003841-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Servicio de Infecciones. Hospital Clínic de Barcelona,Título completo del ensayo: Estudio fase II de utilización de células dendríticas mieloides autólogas como adyuvante celular para una vacuna terapéutica contra el virus de la inmunodeficiencia tipo 1 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003841-42,0,0,0 2004-003843-28,1,2009-09-01,2009-09-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,The acute effects of testosterone administration in patients with pulmonary hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003843-28,0,0,0 2004-003844-24,1,2006-04-11,2006-04-11,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,The effects of testosterone therapy in men with pulmonary hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003844-24,0,0,0 2004-003845-41,1,2020-04-01,2020-04-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,Transplantation of umbilical cord blood (UCB) from unrelated donors (URD) in patients with haematological diseases using a reduced intensity conditioning regimen.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003845-41,0,0,0 2004-003847-37,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,BIOPROJET,An Open label uncontrolled study of the safety and efficacy of chronic intravenous Remodulin in patients with pulmonary Arterial Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003847-37,0,0,0 2004-003851-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. César Sánchez Sánchez,"Ensayo clínico fase IV-IV, unicéntrico, prospectivo, aleatorizado, abierto y paralelo, para evaluar la eficacia del tratamiento combinado de sueroterapia oral y racecadotrilo frente a monoterapia de s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003851-38,0,0,0 2004-003853-13,1,2007-06-12,2007-06-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Hela Pharma AB,"Placebo controlled, randomised, double-blind, multicentre study of PlusEPA (a PUFA, Polyunsaturated Fatty Acids, supplement) as treatment for ADHD (combined type) with co-morbidity in Swedish children...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003853-13,0,0,0 2004-003854-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Interní grantová agentura, Ministerstvo zdravotnictví ČR",Individuální úprava dávkového režimu vysokodávkového busulfanu (HD-BUSU) u nemocných před transplantací krvetvorných buněk jako prevence toxicity.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003854-25,0,0,0 2004-003858-26,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,UCB PHARMA,"A pilot, open, monocenter, randomized two parallel groups, clinical efficacy trial: Comparison continuous versus on demand regimen of treatment with Levocetirizine 5 mg oral tablets, once a day, in ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003858-26,0,0,0 2004-003861-34,1,2006-06-03,2006-06-03,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Department of Nuclear Medicine,Influence of the PPAR gamma -agonist Pioglitazone on endothelial function in the peripheral and myocardial vascular territories and on myocardial efficiency in obese subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003861-34,0,0,0 2004-003865-33,4,2006-01-12,2007-09-16,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regimens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003865-33,0,0,0 2004-003865-33,4,2006-01-12,2007-09-16,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline S.A.,"A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regimens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003865-33,0,0,0 2004-003865-33,4,2006-01-12,2007-09-16,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GLAXO SMITHKLINE,"A Phase IIb, 96 week, randomized, open-label, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of different doses and regimens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003865-33,0,0,0 2004-003866-13,5,2006-01-19,2006-07-23,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GLAXO SMITHKLINE,"A Phase IIb, 96 week, randomised, partially double-blinded, multicentre, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003866-13,0,0,0 2004-003866-13,5,2006-01-19,2006-07-23,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Phase IIb, 96 week, randomised, partially double-blinded, multicentre, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003866-13,0,0,0 2004-003866-13,5,2006-01-19,2006-07-23,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline S.A.,"A Phase IIb, 96 week, randomised, partially double-blinded, multicentre, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003866-13,0,0,0 2004-003868-30,2,2011-04-01,2011-04-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Birmingham,BTOG2: A British Thoracic Oncology Group phase III trial of gemcitabine plus cisplatin at 80 mg/m2 versus gemcitabine plus cisplatin at 50 mg/m2 versus gemcitabine plus carboplatin AUC 6 in stage IIIB...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003868-30,0,0,0 2004-003868-30,2,2011-04-01,2011-04-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Royal Wolverhampton Hospitals NHS Trust,BTOG2: A British Thoracic Oncology Group phase III trial of gemcitabine plus cisplatin at 80 mg/m2 versus gemcitabine plus cisplatin at 50 mg/m2 versus gemcitabine plus carboplatin AUC 6 in stage IIIB...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003868-30,0,0,0 2004-003870-27,4,2013-10-15,2014-10-22,4,1,0,0,1,0,3,0,0,1,0,0,1,0,0,"University of Nottingham, ResearchHead of research grants and contractsInnovation Services","A prospective, collaborative, international, multicentre, randomised, parallel-group, single and outcome blinded, controlled, factorial trial to investigate the safety and efficacy of treatment with t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003870-27,0,0,0 2004-003870-27,4,2013-10-15,2014-10-22,4,1,0,0,1,0,3,0,0,1,0,0,1,0,0,"University of Nottingham, Research Innovation Services","A prospective, collaborative, international, multicentre, randomised, parallel-group, single and outcome blinded, controlled, factorial trial to investigate the safety and efficacy of treatment with t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003870-27,0,0,0 2004-003870-27,4,2013-10-15,2014-10-22,4,1,0,0,1,0,3,0,0,1,0,0,1,0,0,University of Nottingham,"A prospective, collaborative, international, multicentre, randomised, parallel-group, single and outcome blinded, controlled, factorial trial to investigate the safety and efficacy of treatment with t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003870-27,0,0,0 2004-003880-61,3,2005-12-19,2005-12-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Yamanouchi Europe B.V.,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE POTENTIAL EFFICACY, SAFETY AND TOLERABILITY OF DIFFERENT ORAL DOSES OF YM060 IN PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOW...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003880-61,0,0,0 2004-003885-14,1,2009-07-18,2009-07-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Aventis Pharma, S.A.","Multidisciplinar, multicenter, randomized phase III clinical trial comparing taxotere plus estramustine phosphate plus prednisone, versus taxotere prednisone, in advanced prostate carcinoma patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003885-14,0,0,0 2004-003886-34,1,2010-05-14,2010-05-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,Phase II study on letrozole in patients with advanced or recurrent hormone receptor positive endometrial cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003886-34,0,0,0 2004-003887-31,1,,,0,0,0,0,0,3,4,0,1,0,0,0,0,0,0,"Klinisk Farmakologisk Center og Med. Afd. M, Århus Sygehus, NBG","""Farmakodynamiske egenskaber af to langtidsvirkende insulinanaloger i sammenligning med NPH insulin""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003887-31,0,0,0 2004-003888-71,1,2010-08-19,2010-08-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,An open phase III trial with Letrozole (Femara®) alone or in combination with Zoledronic acid (Zometa®) as extended adjuvant treatment of postmenopausal patients with primary breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003888-71,0,0,0 2004-003889-15,1,2010-07-15,2010-07-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,An open phase III trial with Letrozole (Femara®) as Early Adjuvant treatment of postmenopausal patients with primary breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003889-15,0,0,0 2004-003892-35,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ALLERGOPHARMA JOACHIM GANZER KG,A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed Allergoid Preparation of Ho...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003892-35,0,0,0 2004-003896-35,5,2008-09-15,2008-09-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003896-35,0,0,0 2004-003896-35,5,2008-09-15,2008-09-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,0,European Organisation for Research and Treatment of Cancer,Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003896-35,0,0,0 2004-003901-25,1,2008-03-26,2008-03-26,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Thornton & Ross Ltd,"A multi-centre, double-blind, vehicle-controlled, randomised group comparative trial to evaluate the efficacy, steroid sparing properties, safety and acceptability of a topically applied sodium cromog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003901-25,0,0,0 2004-003905-26,3,2006-03-27,2006-03-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma S.A,"A 12-week, double-blind, parallel group study to evaluate the efficacy and safety of the combination of aliskiren with HCTZ compared to irbesartan or amlodipine with HCTZ or HCTZ alone in hypertensive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003905-26,0,0,0 2004-003905-26,3,2006-03-27,2006-03-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-week, double-blind, parallel group study to evaluate the efficacy and safety of the combination of aliskiren with HCTZ compared to irbesartan or amlodipine with HCTZ or HCTZ alone in hypertensive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003905-26,0,0,0 2004-003906-81,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oncology Institute of Vilnius University,Chemoradiation with once weekly gemcitabine for invasive bladder cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003906-81,0,0,0 2004-003910-41,1,2006-08-10,2006-08-10,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,3M Health Care Limited,"Pilot Phase II, Open Label, Multicenter, Efficacy and Safety Study of 852A Administered Intravenously to Subjects with Unresectable Metastatic Cutaneous Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003910-41,0,0,0 2004-003913-18,3,2006-06-05,2006-06-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the safety and efficacy of SAB378 (15 mg t.i.d.) administered orally for 4 weeks to patients with postherp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003913-18,0,0,0 2004-003917-17,1,2007-04-01,2007-04-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Birken GmbH,"Treatment of actinic keratoses with Birken-Oleogel in comparison to cryotherapy and the combination of cryotherapy plus Birken-Oleogel: a randomized, monocenter study. Behandlung aktinischer Keratose...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003917-17,0,0,0 2004-003927-11,1,2007-03-22,2007-03-22,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,NV Organon,"A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Continuing Lithium or ValproicAcid/Divalproex Sodium for the Treatment of an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003927-11,0,0,0 2004-003928-35,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,GLAXO SMITH KLINE RESEARCH & DEVELOPMENT LTD,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole versus Letrozole in Subjects with Estrogen/Progesterone Receptor-Positive Advanced or Meta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003928-35,0,0,0 2004-003929-27,2,2007-10-11,2007-10-19,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo-Recherche,"Randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20-mg od, for inhibition of astherosclerosis progression assessed by IVUS (IntraVascular UltraSoun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003929-27,0,0,0 2004-003929-27,2,2007-10-11,2007-10-19,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-SYNTHELABO,"Randomized, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20-mg od, for inhibition of astherosclerosis progression assessed by IVUS (IntraVascular UltraSoun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003929-27,0,0,0 2004-003934-32,1,2007-08-29,2007-08-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Isis Pharmaceuticals Inc.,"A Phase II, Randomized, Double Blind, Placebo-Controlled Study to assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Varying Loading and Maintenance Dosing Regimens of ISIS 3010...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003934-32,0,0,0 2004-003937-14,1,2006-10-27,2006-10-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"IPSEN PHARMA, S.A","A phase II, unicentre, randomized, double-blind, parallel and placebo-controlled, pilot study to evaluate the efficacy and safety of Somatuline Autogel (60 mg) in patients with active thyroid-associat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003937-14,0,0,0 2004-003939-32,1,2006-11-24,2006-11-24,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Alliance Pharmaceuticals Ltd,A double-blind placebo controlled cross-over study to determine if 1.5 and 3mg of APL510 can normalise sleep patterns in elderly subjects with difficulty in maintenance of sleep and/or initiating slee...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003939-32,0,0,0 2004-003941-42,1,2006-08-21,2006-08-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Eli Lilly Sweden AB,"A Randomised, Double Blind Placebo Controlled Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Swedish Children and Ado...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003941-42,0,0,0 2004-003943-28,6,2006-06-28,2006-06-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Teva Pharmaceutical Industries Ltd,"A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the efficacy, tolerability and safety of two doses of laquinimod orally administered in re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003943-28,0,0,0 2004-003943-28,6,2006-06-28,2006-06-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TEVA,"A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the efficacy, tolerability and safety of two doses of laquinimod orally administered in re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003943-28,0,0,0 2004-003944-23,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Medical University of Vienna,Acetyl salicylic acid in the treatment of patients with positive margins after surgery for cervical dysplasia grade II-III: A phase II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003944-23,0,0,0 2004-003945-41,1,2012-09-30,2012-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,liverpool university,Pharmacogenetics of GABAergic mechanisms of benefit and harm in epilepsy: : A prospective cohort study to determine the enviromental and genetic factors associated with response to clobazam.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003945-41,0,0,0 2004-003953-16,8,2008-06-17,2010-06-22,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients diagnosed with transfusion-dependent iron overload",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003953-16,0,0,0 2004-003953-16,8,2008-06-17,2010-06-22,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients diagnosed with transfusion-dependent iron overload",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003953-16,0,0,0 2004-003953-16,8,2008-06-17,2010-06-22,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients diagnosed with transfusion-dependent iron overload",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003953-16,0,0,0 2004-003955-37,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Efficacy of perindopril/indapamide combination on coronary Pet Scan parameters. A 6 month, open non controlled stydy in hypertensive patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003955-37,0,0,0 2004-003956-20,3,2005-09-26,2005-09-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,HEXAL AG,"Multi-center, double-blind, double-dummy, controlled, randomized phase III study on the tolerability and efficacy of Diclofenac Sodium 150 mg o.d. in comparison to Voltaren® 50 t.i.d. and Voltaren® Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003956-20,0,0,0 2004-003962-14,1,2006-08-24,2006-08-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Pharma GmbH,"Candesartan ""added"" Treatment for Optimisation of Heart Failure (HF) Therapy - Effects on BNP and other HF associated Parameters. An open, non-controlled and multicentre trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003962-14,0,0,0 2004-003963-58,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA S. LUIGI GONZAGA,CONTINOUS INFUSION OF 5-FLUORURACIL PLUS OCTREOTIDE LONG ACTING IN PATIENTS WITH NEUROENDOCRINE ADVANCED NOT SMALL CELL TUMORS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003963-58,0,0,0 2004-003972-12,2,2006-12-04,2007-02-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 2 week multiple ascending dose, double-blind placebo controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of twice daily administration of oral AEB071 and to explore the p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003972-12,0,0,0 2004-003973-10,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"Capnia, Inc.","Multi-Center, Randomized Double-Blind Study to Evaluate the Efficacy and Safety of CAP3 in the Treatment of Acute Migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003973-10,0,0,0 2004-003975-35,1,2006-06-23,2006-06-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,"Multi-center, double-blind, placebo-controlled, randomized phase III study to prove the efficacy, safety and tolerability of Lavender oil WS 1265 (Lavandula angustifolia) in patients with restlessness...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003975-35,0,0,0 2004-003977-10,2,2008-06-05,2008-06-05,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Genetronics Biomedical Corporation,A Randomized Trial Comparing Preservation of Function Status After Either MedPulser Electroporation With Intratumoral Bleomycin Therapy of Surgery in Patients With Locally Recurrent or Second Primar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003977-10,0,0,0 2004-003977-10,2,2008-06-05,2008-06-05,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Genetronics / inovio Biomedical,A Randomized Trial Comparing Preservation of Function Status After Either MedPulser Electroporation With Intratumoral Bleomycin Therapy of Surgery in Patients With Locally Recurrent or Second Primar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003977-10,0,0,0 2004-003980-62,1,2010-03-30,2010-03-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GBG Forschungs GmbH,Prospective randomized multicenter study to prevent chemotherapy induced ovarian failure with the GnRH-Agonist Goserelin in young hormone insensitive breast cancer patients receiving anthracycline con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003980-62,0,0,0 2004-003981-13,2,2007-07-11,2007-07-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,A study to determine the maintenance of efficacy of agomelatine (25 mg to 50 mg) to prevent relapse in out-patients with Major Depressive Disorder. A 8 to 10 weeks open period treatment with agomelat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003981-13,0,0,0 2004-003981-13,2,2007-07-11,2007-07-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Servier Research and Development Ltd (for UK only),A study to determine the maintenance of efficacy of agomelatine (25 mg to 50 mg) to prevent relapse in out-patients with Major Depressive Disorder. A 8 to 10 weeks open period treatment with agomelat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003981-13,0,0,0 2004-003985-14,4,2007-07-18,2007-07-18,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of Two Doses of a Vasopressin V2 Receptor Antagonist (SR121463B) on Serum Sodium in Patients with Dilutional Hyp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003985-14,0,0,0 2004-003985-14,4,2007-07-18,2007-07-18,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Research,"A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of Two Doses of a Vasopressin V2 Receptor Antagonist (SR121463B) on Serum Sodium in Patients with Dilutional Hyp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003985-14,0,0,0 2004-003986-34,3,2005-10-14,2005-10-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A randomised, double-blind, placebo-controlled, parallel group, 16-week MICARDIS (160 mg) tablets, proof-of-concept study, evaluating insulin sensitivity in overweight or obese, non-diabetic, normot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003986-34,0,0,0 2004-003986-34,3,2005-10-14,2005-10-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Danmark A/S,"A randomised, double-blind, placebo-controlled, parallel group, 16-week MICARDIS (160 mg) tablets, proof-of-concept study, evaluating insulin sensitivity in overweight or obese, non-diabetic, normot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003986-34,0,0,0 2004-003986-34,3,2005-10-14,2005-10-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, placebo-controlled, parallel group, 16-week MICARDIS (160 mg) tablets, proof-of-concept study, evaluating insulin sensitivity in overweight or obese, non-diabetic, normot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003986-34,0,0,0 2004-003989-15,1,2008-10-24,2008-10-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,SCHERING-PLOUGH,"Pegylated Liposomal Doxorubicin (Caleyx) in combination with Herceptin and Taxotere as first-line chemotherapy in metastatic breast cancer patients: A 2 stage Phase II, open label, Multicenter study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003989-15,0,0,0 2004-003990-10,2,2006-04-06,2006-04-06,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Axcan Pharma Inc. (Axcan Pharma International B.V. is a subsidiary of Axcan Pharma Inc.),"Multicenter, open-label, randomised, controlled phase III clinical study of the efficacy and safety of photodynamic therapy using porfimer sodium for injection as palliative treatment for unresectable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003990-10,0,0,0 2004-003990-10,2,2006-04-06,2006-04-06,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Axcan Pharma Inc.,"Multicenter, open-label, randomised, controlled phase III clinical study of the efficacy and safety of photodynamic therapy using porfimer sodium for injection as palliative treatment for unresectable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003990-10,0,0,0 2004-003992-35,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Queen Mary University of London,International Breast Cancer Intervention Study II (DCIS). An international multi-centre trial of tamoxifen v anastrozole in post-menopausal women with ductal carcinoma in situ.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003992-35,0,0,0 2004-003996-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA DEGLI STUDI DI UDINE,"randomized,double blind, placebo-controlled trial of the effect of treatment with 3 hypertonic salin solution on bronchiolitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003996-35,0,0,0 2004-003999-11,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTI FISIOTERAPICI OSPITALIERI,GEMZAR AS PROLONGED INFUSION IN COMBINATION WITH PACLITAXEL IN ANTHRACYCLINE PRETREATED METASATTIC BREAST CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-003999-11,0,0,0 2004-004003-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Vakcina Kft,"Kettos vak, randomizalt komparativ vizsgalat a Gynevac lactobacillus vakcinaval vegzett kezeles hatekonysaganak es biztonsaganak osszehasonlitasara a hagyomanyos antibiotikus (ofloxacin) kezelessel ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004003-38,0,0,0 2004-004004-20,1,2007-06-20,2007-06-20,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Leeds,"A Randomised, Double-blind, Placebo Controlled trial to test the efficacy of St John's Wort (Hypericum Perforatum) for Premenstrual Syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004004-20,0,0,0 2004-004007-37,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Novartis Pharma GmbH,Neoadjuvant therapy for postmenopausal women with ER and/or PgR positive breast cancer. A randomized open phase II trial evaluating the efficacy of a 6 months preoperative treatment with Letrozole ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004007-37,0,0,0 2004-004008-19,3,2008-03-14,2008-03-14,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"EFFICACY AND SAFETY OF AGOMELATINE (25 MG/DAY WITH POTENTIAL ADJUSTMENT TO 50 MG) GIVEN ORALLY FOR 8 WEEKS IN OUT-PATIENTS WITH SEVERE MAJOR DEPRESSIVE DISORDER. A RANDOMISED DOUBLE-BLIND, PARALLEL G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004008-19,0,0,0 2004-004008-19,3,2008-03-14,2008-03-14,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratorios Servier S.L. (For Spain only),"EFFICACY AND SAFETY OF AGOMELATINE (25 MG/DAY WITH POTENTIAL ADJUSTMENT TO 50 MG) GIVEN ORALLY FOR 8 WEEKS IN OUT-PATIENTS WITH SEVERE MAJOR DEPRESSIVE DISORDER. A RANDOMISED DOUBLE-BLIND, PARALLEL G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004008-19,0,0,0 2004-004008-19,3,2008-03-14,2008-03-14,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"EFFICACY AND SAFETY OF AGOMELATINE (25 MG/DAY WITH POTENTIAL ADJUSTMENT TO 50 MG) GIVEN ORALLY FOR 8 WEEKS IN OUT-PATIENTS WITH SEVERE MAJOR DEPRESSIVE DISORDER. A RANDOMISED DOUBLE-BLIND, PARALLEL G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004008-19,0,0,0 2004-004008-19,3,2008-03-14,2008-03-14,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SERVIER Research and Development ICTR (For United Kingdom only),"EFFICACY AND SAFETY OF AGOMELATINE (25 MG/DAY WITH POTENTIAL ADJUSTMENT TO 50 MG) GIVEN ORALLY FOR 8 WEEKS IN OUT-PATIENTS WITH SEVERE MAJOR DEPRESSIVE DISORDER. A RANDOMISED DOUBLE-BLIND, PARALLEL G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004008-19,0,0,0 2004-004009-10,4,2007-01-30,2007-03-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Efficacy of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally on rest/activity circadian rhythms in outpatients with Major Depressive Disorder. A randomized, double-blind interna...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004009-10,0,0,0 2004-004009-10,4,2007-01-30,2007-03-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratorios Servier S.L. (For Spain only),"Efficacy of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally on rest/activity circadian rhythms in outpatients with Major Depressive Disorder. A randomized, double-blind interna...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004009-10,0,0,0 2004-004009-10,4,2007-01-30,2007-03-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Efficacy of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally on rest/activity circadian rhythms in outpatients with Major Depressive Disorder. A randomized, double-blind interna...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004009-10,0,0,0 2004-004010-17,4,2006-01-22,2006-01-22,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Amersham Health, S.A.","An open-label, multi-centre, phase 2a study to assess the feasibility and safety of intravenous bolus administration of 99mTc-NC100692 Injection in imaging metastases in late stage cancer patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004010-17,0,0,0 2004-004010-17,4,2006-01-22,2006-01-22,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Amersham plc and its Amersham Health affiliates, trading as GE Healthcare","An open-label, multi-centre, phase 2a study to assess the feasibility and safety of intravenous bolus administration of 99mTc-NC100692 Injection in imaging metastases in late stage cancer patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004010-17,0,0,0 2004-004010-17,4,2006-01-22,2006-01-22,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GE Healthcare Limited (previously known as Amersham plc) and its Amersham Health affiliates.,"An open-label, multi-centre, phase 2a study to assess the feasibility and safety of intravenous bolus administration of 99mTc-NC100692 Injection in imaging metastases in late stage cancer patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004010-17,0,0,0 2004-004014-16,4,2007-01-19,2007-03-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A twelve-week, randomized, double-blind, multi-center, placebo controlled, parallel group study to evaluate the safety and efficacy of aliskiren 150 mg when added to standard therapy in hypertensive p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004014-16,0,0,0 2004-004014-16,4,2007-01-19,2007-03-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A twelve-week, randomized, double-blind, multi-center, placebo controlled, parallel group study to evaluate the safety and efficacy of aliskiren 150 mg when added to standard therapy in hypertensive p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004014-16,0,0,0 2004-004015-38,4,2006-01-27,2006-07-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A twenty six-week, randomized, double-blind, parallel group, multicenter, active controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004015-38,0,0,0 2004-004015-38,4,2006-01-27,2006-07-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A twenty six-week, randomized, double-blind, parallel group, multicenter, active controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004015-38,0,0,0 2004-004015-38,4,2006-01-27,2006-07-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A twenty six-week, randomized, double-blind, parallel group, multicenter, active controlled, dose titration study to evaluate the efficacy and safety of aliskiren compared to HCTZ with the optional ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004015-38,0,0,0 2004-004021-98,2,2007-10-10,2007-10-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,A single arm Phase IV study to assess efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-fluorouracil/folinic acid regimens as first line treatment for patients with me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004021-98,0,0,0 2004-004021-98,2,2007-10-10,2007-10-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ROCHE,A single arm Phase IV study to assess efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-fluorouracil/folinic acid regimens as first line treatment for patients with me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004021-98,0,0,0 2004-004022-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F.Hoffmann - La Roche Ltd,"Phase IIa, multicenter, randomised, double-blind, placebo controlled study of the efficacy and safety of RO0506997, an α4 integrin antagonist, in combination with methotrexate, versus methotrexate alo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004022-27,0,0,0 2004-004024-12,2,2009-12-31,2009-12-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Technical University of Munich,Efficacy of the EGFR antibody Cetuximab in combination with weekly Oxaliplatin/5FU/Folinsäure (AIO-FUFOX) in advanced gastro-oesophageal adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004024-12,0,0,0 2004-004024-12,2,2009-12-31,2009-12-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Verein für Tumorforschung,Efficacy of the EGFR antibody Cetuximab in combination with weekly Oxaliplatin/5FU/Folinsäure (AIO-FUFOX) in advanced gastro-oesophageal adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004024-12,0,0,0 2004-004028-11,1,2007-05-22,2007-05-22,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Bioenvision Limited,"A Phase II, Non-randomised, Study of Modrenal (Trilostane) in Pre-menopausal Women with Oestrogen Receptor Positive Breast Cancer who have Relapsed or are Refractory to Hormone Therapies of Tamoxifen,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004028-11,0,0,0 2004-004029-87,1,2007-08-20,2007-08-20,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Institute of Psychiatry,Pillot randomised controlled trial of antidepressant switching for treatmetn-refractory depression in primary care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004029-87,0,0,0 2004-004031-59,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,Weekly maintainance therapy with Paclitaxel vs control arm after first line chemotherapy in patients with metastatic breast carcinoma. Phase III multicentric clinical trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004031-59,0,0,0 2004-004042-41,5,2007-03-17,2007-10-26,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,A comparison of the inflammatory control of asthma provided by one inhalation of Symbicort® Turbuhaler® 160/4.5 µg/inhalation b.i.d. plus as-needed versus one inhalation of Symbicort® Turbuhaler® 320/...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004042-41,0,0,0 2004-004042-41,5,2007-03-17,2007-10-26,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca Sweden,A comparison of the inflammatory control of asthma provided by one inhalation of Symbicort® Turbuhaler® 160/4.5 µg/inhalation b.i.d. plus as-needed versus one inhalation of Symbicort® Turbuhaler® 320/...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004042-41,0,0,0 2004-004051-19,6,2008-07-08,2008-10-31,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Glucoco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004051-19,0,0,0 2004-004051-19,6,2008-07-08,2008-10-31,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol Myers Squibb International Corporation,"A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Glucoco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004051-19,0,0,0 2004-004052-39,1,2005-06-07,2005-06-07,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,BørneklinikkenRanders,Korttidsvækst hos børn med atopisk dermatitis behandlet med tacrolimus og hydrokortison-17-butyrat,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004052-39,0,0,0 2004-004053-26,2,2007-10-24,2008-11-06,2,0,0,0,0,0,2,0,0,1,1,0,1,0,0,Birthe Pedersen,"An explorative use open-label, multi-center, randomized trial studying the safety and efficacy of levetiracetam (500 mg/day to 3000 mg/day) and valproate (600 mg/day to 3000 mg/day) as monotherapy in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004053-26,0,0,0 2004-004055-19,3,2011-12-15,2011-12-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Limited,"A Phase IIb randomized, partially blinded, dose-finding trial of TMC278 in antiretroviral naive HIV-1 infected subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004055-19,0,0,0 2004-004055-19,3,2011-12-15,2011-12-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"A Phase IIb randomized, partially blinded, dose-finding trial of TMC278 in antiretroviral naive HIV-1 infected subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004055-19,0,0,0 2004-004058-20,4,2008-01-22,2008-04-03,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Shire Pharmaceutical Development Limited,"A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamic and safety study of anagrelide hydrochloride in young (18-50 years) and elderly (≥ 65 years) patients with essential thrombocythae...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004058-20,0,0,0 2004-004060-70,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Juan Gonzalez García,Pilot study randomised and open to compare the switch to trizivir against the previous treatment in chronic HIV-1 infected patients with liver cirrhosis secondary to Hepatitis C coinfection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004060-70,0,0,0 2004-004061-15,9,2015-12-15,2015-12-15,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Shire Pharmaceutical Development Ltd.,"A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004061-15,0,0,0 2004-004061-15,9,2015-12-15,2015-12-15,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Shire Pharmaceutical Development Ltd,"A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004061-15,0,0,0 2004-004061-15,9,2015-12-15,2015-12-15,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,SHIRE PHARMACEUTICALS LTD,"A Phase IIIb, randomised, open label study to compare the safety, efficacy and tolerability of anagrelide hydrochloride versus hydroxyurea in high-risk essential thrombocythaemia patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004061-15,0,0,0 2004-004063-29,1,2008-08-26,2008-08-26,1,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,Glivec (imatinib mesylate) in combination with hydroxyurea or hydroxyurea alone as an oral therapy in temozolomide resistant progressive glioblastoma patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004063-29,0,0,0 2004-004066-32,1,2010-12-30,2010-12-30,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Silvia Delgado Aros,Reducción de la Ingesta Calórica en la Obesidad Mediante Modulación Farmacológica del Vaciamiento Gástrico Reduction of Caloric Intake in Obesity through Pharmacological Modulation of Gastric Emptyin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004066-32,0,0,0 2004-004072-37,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,CETUXIMAB AND FOLFIRI AS FIRST-LINE TREATMENT OF LOCALLY ADVANCED AND METASTATIC GASTRIC CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004072-37,0,0,0 2004-004074-93,2,2005-09-01,2005-09-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,EpiTan Limited,"A Pilot, Phase II, Open, Controlled Study to Evaluate the Safety, Tolerability and Efficacy of a Subcutaneous Implant of Melanotan in Patients Suffering from Recurrent Polymorphous Light Eruption.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004074-93,0,0,0 2004-004077-29,5,2005-11-18,2005-11-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Procter & Gamble Technical Centres Ltd,"A Double-blind, Randomized, Multicenter, Active-control, 56-day Study with a 28-day Follow-up to Assess the Efficacy and Safety of RDP58 200 mg/day plus Mesalazine 2.4 g/day and RDP58 600 mg/day plus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004077-29,0,0,0 2004-004077-29,5,2005-11-18,2005-11-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Procter & Gamble Pharmaceuticals,"A Double-blind, Randomized, Multicenter, Active-control, 56-day Study with a 28-day Follow-up to Assess the Efficacy and Safety of RDP58 200 mg/day plus Mesalazine 2.4 g/day and RDP58 600 mg/day plus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004077-29,0,0,0 2004-004082-15,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)",A PHASE II CLINICAL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DEPOCITE (CITARABINE LIPOSOMIALE INJECTON) FOR THE TREATMENT OF CNS RELAPSE IN ADULT PATIENTS WITH ACUTE LYMPOBLASTIC LEUKEMIA OR VERY...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004082-15,0,0,0 2004-004083-77,2,2008-07-10,2008-07-10,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Disphar International B.V.,"A Randomised, International, Multicenter Study to assess the Efficacy and Safety of Mesalazine EC tablets 500 mg (4.5g/daily) and Salofalk® tablets 500 mg (4.5 g/daily) in the Treatment of Moderate Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004083-77,0,0,0 2004-004084-29,1,,,0,1,0,0,0,3,3,0,0,1,0,0,0,1,1,Bracco ALTANA Pharma GmbH,Intraindividual cross-over study to compare 1.5-tesla and 3.0-tesla MRI with 0.05+0.05 mmol/kgbw MultiHance® in patients with Myocardial Infarction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004084-29,0,0,0 2004-004086-15,1,2006-12-31,2006-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"University Hospital of Frankfurt, Department of Cardiology","Comparison of nephrotoxic effects of the contrast dyes iodixanol (iso-osmolar, non-ionic, dimer) and ioversol (low-osmolar, non-ionic, monomer) in patients with impaired renal function and severe hear...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004086-15,0,0,0 2004-004088-31,1,2008-02-06,2008-02-06,1,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 weeks in Newly Diagnosed Children and Adolescents Outpatients with Attention-Deficit/Hypera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004088-31,0,0,0 2004-004090-29,7,2008-08-08,2008-08-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"GlaxoSmithKline, S.A.","A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004090-29,0,0,0 2004-004090-29,7,2008-08-08,2008-08-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,GlaxoSmithKline Research & Development Ltd,"A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004090-29,0,0,0 2004-004090-29,7,2008-08-08,2008-08-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,GlaxoSmithKline R&D,"A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004090-29,0,0,0 2004-004090-29,7,2008-08-08,2008-08-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,GLAXO SMITHKLINE,"A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone versus Glipizide on the Progression of Atherosclerosis in Subjects with Type 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004090-29,0,0,0 2004-004094-28,5,2008-10-01,2008-10-01,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase III Study of Rosuvastatin (CRESTOR) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL Ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004094-28,0,0,0 2004-004095-37,3,2005-04-30,2005-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services,"An exploratory, multi-center, randomized, open-label, single dose, crossover study to assess the safety and tolerability of 200µg of QAB149, delivered via a MDDPI, with or without the co-administratio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004095-37,0,0,0 2004-004106-25,2,2005-09-13,2006-09-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"(OSI) Eyetech, Inc","A Phase II randomised, dose-ranging, double-masked, multi-center trial, in parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreous injections of pegaptanib sodium comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004106-25,0,0,0 2004-004106-25,2,2005-09-13,2006-09-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Eyetech Pharamceuticals, Inc","A Phase II randomised, dose-ranging, double-masked, multi-center trial, in parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreous injections of pegaptanib sodium comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004106-25,0,0,0 2004-004107-37,2,2008-06-05,2008-06-05,1,1,0,0,2,0,3,0,0,1,1,0,1,0,1,Genetronics Biomedical Corporation,A Randomized Trial Comparing Preservation of Function Status After Either MedPulser® Electroporation with Intraumoral Bleomycin Therapy or Surgery in Patients with Locally Recurrent or Second Primary ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004107-37,0,0,0 2004-004107-37,2,2008-06-05,2008-06-05,1,1,0,0,2,0,3,0,0,1,1,0,1,0,1,Genetronics / inovio Biomedical,A Randomized Trial Comparing Preservation of Function Status After Either MedPulser® Electroporation with Intraumoral Bleomycin Therapy or Surgery in Patients with Locally Recurrent or Second Primary ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004107-37,0,0,0 2004-004110-17,1,2008-01-21,2008-01-21,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Roche Products Limited,"Full title of the trial : An open-label, multicentre, dose-escalating phase I/II trial of 3-weekly rhuMAb 2H7 in patients with follicular non Hodgkin’s lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004110-17,0,0,0 2004-004113-42,1,2007-04-02,2007-04-02,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Schering Plough Research Institute,SCH 486757 vs Codeine and Placebo in Subjects with Persistent Postviral Cough,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004113-42,0,0,0 2004-004115-38,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,University Hospital Antwerp,"Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A prospective, randomised trial of Sirolimus versus Cyclosporine.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004115-38,0,0,0 2004-004120-12,2,2009-11-12,2009-11-12,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Elan Pharma Ltd,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, and Amyloid-Imaging Positron Emission Tomography (PET) Trial of AAB-001 (ELN115727) in Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004120-12,0,0,0 2004-004120-12,2,2009-11-12,2009-11-12,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Elan Regulatory Holdings Ltd,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, and Amyloid-Imaging Positron Emission Tomography (PET) Trial of AAB-001 (ELN115727) in Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004120-12,0,0,0 2004-004124-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA O.I.R.M. - S. ANNA,LACTOBACILLUS REUTERI REUTERIN AS A THERAPEUTIC AGENT IN INFANTILE COLIC A PROSPECTIVE STUDY.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004124-12,0,0,0 2004-004129-89,1,2013-01-16,2013-01-16,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,Universitätsklinikum Münster,Potentiation of procedural motor learning by pharmacological neuromodulation and brain stimulation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004129-89,0,0,0 2004-004130-14,1,,,0,1,0,0,1,0,3,0,0,1,0,0,0,1,0,Biogen Idec GmbH,"A multicenter, randomized, rater-blind study to compare the efficacy and safety of natalizumab (300 mg IV every four weeks) with Interferon beta-1a (44 mcg SC three times a week) in subjects with rela...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004130-14,0,0,0 2004-004131-57,13,2010-10-06,2010-11-23,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A two year multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the fracture efficacy and safety of intravenous zoledronic acid 5 mg annually for the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004131-57,0,0,0 2004-004131-57,13,2010-10-06,2010-11-23,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A two year multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the fracture efficacy and safety of intravenous zoledronic acid 5 mg annually for the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004131-57,0,0,0 2004-004131-57,13,2010-10-06,2010-11-23,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis CPO to fill,"A two year multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the fracture efficacy and safety of intravenous zoledronic acid 5 mg annually for the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004131-57,0,0,0 2004-004136-31,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,3,"Laboratorios Effik, S.A.",Ensayo clínico para evaluar la eficacia de los suplementos de progesterona natural en la prevención del parto pretérmino gemelar,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004136-31,0,0,0 2004-004139-74,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Neurologisk afdeling F,"Parkinson’s Disease: PET scan and evaluation of memantines pharmacological effect. (Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004139-74,0,0,0 2004-004141-18,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE,"STUDY RANDOMIZED, CONTROLLED, DOUBLE BLIND, PHASE III, TO CONFRONTED LEVOBUPIVACAINA 0.2 , LEVOBUPIVACAINE 0.15 KETAMINE S 0.5 MG/KG AND LEVOBUPIVACAINA 0.125 KETAMINE S 0.5 MG/KG",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004141-18,0,0,0 2004-004146-40,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTI FISIOTERAPICI OSPITALIERI,"pILOT STUDY TO EVALUATE QUALITY OF LIFE, SEIZURES CONTROL AND SIDE EFFECTS IN PATIENTS WITH BRAIN TUMORS AND EPILEPSY TREATED WITH LEVETIRACETAM IN MONOTHERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004146-40,0,0,0 2004-004148-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dr. José Ignacio Chacón López-Muñiz,ENSAYO EN FASE I/II DE LA COMBINACIÓN DE GEMCITABINA EN INFUSIÓN PROLONGADA Y PACLITAXEL ADMINISTRADOS DE FORMA QUINCENAL EN EL TRATAMIENTO DE PRIMERA LÍNEA DE PACIENTES CON CÁNCER DE MAMA AVANZADO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004148-34,0,0,0 2004-004149-16,1,2008-04-30,2008-04-30,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Lilly S.A.,"Phase 1/2 Study of Biweekly ALIMTA plus Cisplatin in patients with Locally Advanced, non-Resectable or Metastatic Urothelial Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004149-16,0,0,0 2004-004150-51,1,2005-07-28,2005-07-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Limited,"A Phase 2 multi centre, double blind, placebo controlled flexible dose study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004150-51,0,0,0 2004-004153-25,1,2007-07-01,2007-07-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Royal Hospital For Sick Children, Yorkhill Division",Effect of recombinant growth hormone on growth and chondrocyte dynamics in children with juvenile idiopathic arthritis (JIA) and growth failure.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004153-25,0,0,0 2004-004156-39,1,2010-02-01,2010-02-01,1,1,0,0,0,3,3,0,0,1,0,0,1,0,0,Dept. of Neurology Vienna,Brain serotonin 5-HT1A receptor binding in human mesial temporal lobe epilepsy measured by positron emission tomography and [11C]WAY-100635,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004156-39,0,0,0 2004-004158-23,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL ON THE USE OF ACETYL-L-CARNITINE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004158-23,0,0,0 2004-004160-67,2,2006-03-21,2008-07-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,Effect of Duloxetine on Valsalva Leak Point Pressure and Quantitative Rhabdosphincter Electromyography Measures in Women with Stress Urinary Incontinence,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004160-67,0,0,0 2004-004162-33,1,2006-02-06,2006-02-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Multicenter Study of the Efficacy of RWJ-333369 in the Prophylaxis of Migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004162-33,0,0,0 2004-004169-13,1,2006-12-19,2006-12-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,south manchester university hospital nhs trust,A Pilot study to assess the effects of beta-blockade on exercise capacity and BNP levels in patients with predominantly diastolic heart failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004169-13,0,0,0 2004-004178-10,6,2006-05-24,2006-05-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Limited,"A Randomized, Double-Blind, Equivalence Study of the Efficacy of Darbepoetin Alfa Manufactured by Serum Free Bioreactor Technology and Darbepoetin Alfa Manufactured by Roller-Bottle Technology for the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004178-10,0,0,0 2004-004180-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Clínic de Barcelona,"Ensayo clínico multicéntrico, fase IV, abierto y aleatorizado para evaluar la eficacia de proteinsuccinilato de hierro, frente a sulfato ferroso sesquihidratado, en el tratamiento de la anemia en muje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004180-30,0,0,0 2004-004181-32,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE ONCOLOGICO DI BARI,FOLFOX 4 + CETUXIMAB IN UNTREATED PATIENTS WITH ADVANCED COLO-RECTAL TUMOUR. A PHASE II MULTICENTER STUDY OF THE GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004181-32,0,0,0 2004-004184-29,9,2009-09-07,2009-10-05,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shire Pharmaceutical Development Ltd,"A phase III, randomised, multi-centre, double blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily (qd) versus Asacol® 1.6g/day ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004184-29,0,0,0 2004-004193-91,5,2006-07-21,2006-07-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of GW823093 (2.5mg, 7.5mg, 15mg, 30mg and 45m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004193-91,0,0,0 2004-004201-18,3,2006-12-28,2006-12-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Lederle Nordiska AB,"A multicenter, open-label, randomized, pilot study to evaluate the efficacy and safety of the combination of etanercept (ETN) and methotrexate and of etanercept (ETN) alone in patients with active pla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004201-18,0,0,0 2004-004202-24,10,2006-01-24,2007-01-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Hae...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004202-24,0,0,0 2004-004202-24,10,2006-01-24,2007-01-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Hae...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004202-24,0,0,0 2004-004203-38,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO,ADMINISTRATION S EFFECTS OF L-ARGININE AND N-ACETYLCYSTEINE ON NITRIC OXIDE S PRODUCTION AND ON BLOOD PRESSURE IN DIABETIC AND HYPERTENSIVE PATIENTS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004203-38,0,0,0 2004-004206-25,2,2007-02-22,2016-04-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A PHASE II MULTICENTRE RANDOMISED, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ZD1839 (IRESSA TM) (250MG TABLET) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN CHEMOTHERAPY-N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004206-25,0,0,0 2004-004208-19,2,2005-12-23,2006-01-19,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-week multicentre, double blind, double dummy, randomized, parallel group, active controlled study to evaluate the efficacy and tolerability of fluvastatin extended release (Lescol XL® 80 mg) alon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004208-19,0,0,0 2004-004209-98,1,2009-09-01,2009-09-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical University Vienna, Department of Medicine III",The Vienna Prograf and Endothelial Progenitor Cell Study (Vienna PEP Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004209-98,0,0,0 2004-004212-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"Unidad Integral de Investigación en Oncología, S.L.","Randomized study with oral tegafur versus capecitabina in the treatment of advanced politreated breast cancer and refractory, resistant or in progression to the standard chemotherapeutic treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004212-23,0,0,0 2004-004214-16,1,2007-04-10,2007-04-10,1,0,0,0,1,0,3,0,0,1,0,0,1,0,0,"Committee of Management, Common Services Agency T/A Scottish National Blood Transfusion Service",A randomised control clinical study to determine whether SNBTS Fibrin Sealant promotes wound healing in patients undergoing cardiac surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004214-16,0,0,0 2004-004215-35,1,,,0,0,0,0,0,3,2,0,1,0,0,0,0,0,0,Turku PET Centre,Influence of muscle specific activation on regional glucose uptake in the human Achilles tendon,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004215-35,0,0,0 2004-004217-42,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,AKH Wien,Injektion von Botulinum Toxin in den Pylorus zur Behandlung von Chronic Upper Gastrointestinal Symptoms bei Diabetic Patients mit verzögerter Gastric Emptying,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004217-42,0,0,0 2004-004220-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Q-Develop AB/co Freddie Norberg,"Treatment of vulvar vestibulitis by an antioxidant cream: a double-blind, placebo-controlled, parallel group multi-center study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004220-13,0,0,0 2004-004223-36,1,2008-10-01,2008-10-01,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,South Manchester University Hospital,Short term biological study effects of Zoledronate and Letrozole on invasive breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004223-36,0,0,0 2004-004225-10,4,2006-03-14,2006-03-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Orion Pharma,"Effects of peroral levosimendan in the prevention of further hospitalisations in patients with chronic heart failure. A randomised, double-blind, placebo-controlled, multi-centre, parallel-group study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004225-10,0,0,0 2004-004226-28,1,2006-11-21,2006-11-21,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Takeda Pharma GmbH,Effects of Pioglitazone in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease at High Risk for Cardiovascular Complications,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004226-28,0,0,0 2004-004229-93,2,2017-10-02,2017-10-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"Multicentre, open label, extension study of treatment with gefitinib (IRESSA™) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004229-93,0,0,0 2004-004230-14,1,2020-12-06,2020-12-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,AGI Therapeutics Limited,"A randomised, double-blind, placebo-controlled study of AGI 001 in the treatment of irritable bowel syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004230-14,0,0,0 2004-004231-53,1,2010-05-30,2010-05-30,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Royal Devon and Exeter NHS Foundation Trust,The Effect Of Antihypertensive Treatment With Lisinopril and Labetalol on Baroreflex Sensitivity in Stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004231-53,0,0,0 2004-004232-31,1,2005-03-29,2005-03-29,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Pfizer Ltd,"A double-blind (third party open), placebo-controlled, parallel group, multiple dose study to investigate the safety, toleration and pharmacokinetics of [S,S]-Reboxetine in young and elderly healthy v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004232-31,0,0,0 2004-004239-78,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Göteborgs Universitet, Institutionen för Invärtesmedicin",Förekomst av syrarelaterade besvär efter utsättning av protonpumpshämmare hos friska frivilliga.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004239-78,0,0,0 2004-004243-21,1,2008-06-24,2008-06-24,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"PDL BioPharma, Inc.",Phase 2 Open-Label Study of Volociximab (M200) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Cancer Not Previously Treated with Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004243-21,0,0,0 2004-004247-22,1,2007-06-06,2007-06-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A 28-day, Randomised, Double-Blind, Active Comparator, Controlled Study to Assess the Effects of Rosiglitazone, Inhaled Corticosteroid, Theophylline and Theophylline Plus Inhaled Corticosteroid on Inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004247-22,0,0,0 2004-004248-37,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase II open (partially double-blind), randomized, controlled, primary vaccination study to assess the immunogenicity, safety and reactogenicity of one intramuscular dose of four different formulat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004248-37,0,0,0 2004-004249-16,3,2007-04-26,2007-04-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,THE EFFECT OF MILNACIPRAN 100MG BID ON SENSITIVITY TO STIMULUS-EVOKED PAIN IN PATIENTS WITH FIBROMYALGIA: A FMRI NEUROIMAGING STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004249-16,0,0,0 2004-004252-40,1,,,0,1,0,0,0,3,2,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"An open-label, Phase I/II, dose escalating study evaluating the safety and efficacy of EPO906, q3w, in patients with non-small cell lung cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004252-40,0,0,0 2004-004255-18,3,2006-02-21,2006-02-21,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An 8-week, randomized, double-blind, parallel-group, multicenter study assessing the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in patients 65 years of age with essential hypertens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004255-18,0,0,0 2004-004255-18,3,2006-02-21,2006-02-21,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An 8-week, randomized, double-blind, parallel-group, multicenter study assessing the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in patients 65 years of age with essential hypertens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004255-18,0,0,0 2004-004257-26,1,2006-08-01,2006-08-01,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Organisation name was not entered,A randomised study of the effect of metformin and exercise in overweight women with polycystic ovary syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004257-26,0,0,0 2004-004258-26,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,University Clinic of Dermatology Division of Special and Enviromental Dermatology,Photodynamic Therapy (PDT) vs Chemopeeling for the treatment of multiple actinic keratoses on the underarms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004258-26,0,0,0 2004-004260-71,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Medizinische Universität Wien Univ.Klinik f.Innere Medizin I/Hämatologie,Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism and cardiovascular events in patients with idiopathic venous thromboembolism. The WAR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004260-71,0,0,0 2004-004263-30,1,2009-12-31,2009-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Univ.-Prof. Dr. Oliver Findl Med. Univ. Wien,Effect of topical prednisolone and diclofenac on the morphology of Posterior Capsule Opacification,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004263-30,0,0,0 2004-004264-75,5,2008-08-07,2008-09-16,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ASTRAZENECA,"A Dose-ranging, Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less Than 6 Years of Age: A 4-week, Multicenter, Randomized, Double-Blind Study with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004264-75,0,0,0 2004-004264-75,5,2008-08-07,2008-09-16,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca Pharmaceuticals,"A Dose-ranging, Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less Than 6 Years of Age: A 4-week, Multicenter, Randomized, Double-Blind Study with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004264-75,0,0,0 2004-004264-75,5,2008-08-07,2008-09-16,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Dose-ranging, Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less Than 6 Years of Age: A 4-week, Multicenter, Randomized, Double-Blind Study with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004264-75,0,0,0 2004-004266-32,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,THE USE OF CASPOFUNGIN(CANCIDAS) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCES AND CONCOMITANT CANDIDEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004266-32,0,0,0 2004-004267-30,1,2008-02-11,2008-02-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gebro Pharma GmbH,Efficacy and Tolerability of Dexibuprofen Film coated tablets in Comparison to Ibuprofen in Children and Adolescents with Tonsillopharyngitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004267-30,0,0,0 2004-004269-14,3,2006-03-03,2006-03-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer,"Phase 3, Multi-center, double-blind, randomized, parallel group study of the efficacy, safety, and tolerability of fixed combination torcetrapib (CP-529,414)/Atorvastatin administered orally, once dai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004269-14,0,0,0 2004-004269-14,3,2006-03-03,2006-03-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer AB,"Phase 3, Multi-center, double-blind, randomized, parallel group study of the efficacy, safety, and tolerability of fixed combination torcetrapib (CP-529,414)/Atorvastatin administered orally, once dai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004269-14,0,0,0 2004-004269-14,3,2006-03-03,2006-03-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,,"Phase 3, Multi-center, double-blind, randomized, parallel group study of the efficacy, safety, and tolerability of fixed combination torcetrapib (CP-529,414)/Atorvastatin administered orally, once dai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004269-14,0,0,0 2004-004269-14,3,2006-03-03,2006-03-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Denmark,"Phase 3, Multi-center, double-blind, randomized, parallel group study of the efficacy, safety, and tolerability of fixed combination torcetrapib (CP-529,414)/Atorvastatin administered orally, once dai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004269-14,0,0,0 2004-004273-28,2,2008-12-02,2008-12-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,A phase II feasibility trial of induction chemotherapy followed by extrapleural pneumonectomy and postoperative radiotherapy in patients with malignant pleural mesothelioma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004273-28,0,0,0 2004-004273-28,2,2008-12-02,2008-12-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,A phase II feasibility trial of induction chemotherapy followed by extrapleural pneumonectomy and postoperative radiotherapy in patients with malignant pleural mesothelioma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004273-28,0,0,0 2004-004274-87,5,2008-09-01,2010-05-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004274-87,0,0,0 2004-004274-87,5,2008-09-01,2010-05-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS PHARMA AG,An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004274-87,0,0,0 2004-004274-87,5,2008-09-01,2010-05-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Idenix Pharmaceuticals, Inc",An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004274-87,0,0,0 2004-004275-11,1,2006-05-18,2006-05-18,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Novartis Pharma Services AG,"An open-label study to investigate blood concentrations, safety, tolerability and efficacy of Elidel® Cream 1% in patients with moderate or severe seborrheic dermatitis treated topically for 3 weeks.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004275-11,0,0,0 2004-004278-10,1,2008-08-04,2008-08-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Lothian Health Board- University Hospitals Division,Determination of the subarachnoid ED50 and ED95 of hyperbaric 0.5% bupivacaine when co-administered with diamorphine hydrochloride for caesarean section,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004278-10,0,0,0 2004-004278-10,1,2008-08-04,2008-08-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Lothian Health Board University Hospitals Division,Determination of the subarachnoid ED50 and ED95 of hyperbaric 0.5% bupivacaine when co-administered with diamorphine hydrochloride for caesarean section,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004278-10,0,0,0 2004-004280-30,1,2010-02-28,2010-02-28,1,0,0,0,0,3,2,0,0,1,0,0,1,0,0,Landstinget Dalarna,"Injestion of the steroid betamethasone during operation for inguinal hernia repair for purpose to optimize treatment of postoperative pain, reduction of postoperative discomfort like nausea and possib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004280-30,0,0,0 2004-004281-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,San Joan de Déu. Serveis de Salut Mental,"“Double blind, placebo-controlled study of efficacy, safety and tolerance of raloxifene as an adjuvant treatment for negative symptoms of schizophrenia in postmenopausal women” Estudio doble ciego co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004281-32,0,0,0 2004-004282-15,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,PHARMING TECHNOLOGIES B.V.,"A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004282-15,0,0,0 2004-004286-15,3,2007-03-27,2007-03-27,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,BIOCRYST PHARMACEUTICALS INC.,"A Phase II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride (BCX-1777) Infusion in Patients with Advanced T-Cell Leukemia with an Option of Long-Term Forodesine Hydrochloride (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004286-15,0,0,0 2004-004286-15,3,2007-03-27,2007-03-27,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,BioCryst Pharmaceuticals Inc.,"A Phase II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride (BCX-1777) Infusion in Patients with Advanced T-Cell Leukemia with an Option of Long-Term Forodesine Hydrochloride (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004286-15,0,0,0 2004-004287-71,1,2005-09-01,2005-09-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,THE EFFECT OF REMIFENTANIL ON DESFLURANE REQUIREMENTS FOR SYMPATHETIC RESPONSES TO SURGICAL INCISION.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004287-71,0,0,0 2004-004288-31,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTI FISIOTERAPICI OSPITALIERI,Phase II parallel studies on the use of 3D-radiotherapy plus Amifostine or IMRT to evaluate xerostomia reduction in patients with head and neck cancer treated in definitve or postoperative setting.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004288-31,0,0,0 2004-004290-29,1,2006-04-30,2006-04-30,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,University of Oxford,Randomised controlled trial of effect of antibiotic dose on antibiotic resistance in young children with otitis media,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004290-29,0,0,0 2004-004292-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Endocrine Department, Sahlgrenska University Hospital","Discontinuation of long-term GH replacement therapy - a randomised, placebo controlled trial in adult GH deficiency.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004292-11,0,0,0 2004-004295-37,2,2010-04-01,2010-12-21,2,0,0,0,0,0,3,0,0,1,0,0,1,0,2,All-Ireland Cooperative Oncology Research Group,A Phase III Trial Comparing Docetaxel Every Third Week to Biweekly Docetaxel Monotherapy in Metastatic Hormone Refractory Prostate Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004295-37,0,0,0 2004-004295-37,2,2010-04-01,2010-12-21,2,0,0,0,0,0,3,0,0,1,0,0,1,0,2,Finnish Uro-Oncological Group,A Phase III Trial Comparing Docetaxel Every Third Week to Biweekly Docetaxel Monotherapy in Metastatic Hormone Refractory Prostate Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004295-37,0,0,0 2004-004296-11,3,2008-03-31,2008-03-31,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,(OSI) Eyetech Pharamceuticals Inc,"An open label, non-comparative protocol for the use of pegaptanib sodium injection every 6 weeks in patients with exudative age-related macular degeneration (AMD).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004296-11,1,0,0 2004-004296-11,3,2008-03-31,2008-03-31,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Eyetech Pharamceuticals Inc,"An open label, non-comparative protocol for the use of pegaptanib sodium injection every 6 weeks in patients with exudative age-related macular degeneration (AMD).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004296-11,1,0,0 2004-004296-11,3,2008-03-31,2008-03-31,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,(OSI) Eyetech Inc,"An open label, non-comparative protocol for the use of pegaptanib sodium injection every 6 weeks in patients with exudative age-related macular degeneration (AMD).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004296-11,1,0,0 2004-004302-24,5,2005-11-21,2005-11-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Merck & Co. Inc.,"A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety and Tolerability of L-000883191 in Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004302-24,0,0,0 2004-004302-24,5,2005-11-21,2005-11-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Merck & Co., Inc.","A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety and Tolerability of L-000883191 in Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004302-24,0,0,0 2004-004302-24,5,2005-11-21,2005-11-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Suomen MSD Oy,"A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety and Tolerability of L-000883191 in Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004302-24,0,0,0 2004-004302-24,5,2005-11-21,2005-11-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,MERCK SHARP DOHME,"A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety and Tolerability of L-000883191 in Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004302-24,0,0,0 2004-004308-19,2,2006-09-22,2006-09-29,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AXCAN PHARMA Inc.,"A multicentre, open-label study to evaluate the long-term safety and efficacy of itopride HCl in patients suffering from functional dyspepsia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004308-19,0,0,0 2004-004309-69,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,GISCAD,A randomized phase II study of gemcitabine/cisplatin with or without Cetuximab to evaluate the efficacy in patients with locally advanced or metastatic EGFR-positive pancreatic cancer. SpaCe TRIAL.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004309-69,0,0,0 2004-004314-16,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,3,NINDS,Ensayo multicéntrico de tratamiento de la hipotiroxinemia transitoria en los niños <= 1000 gr de peso al nacimiento o <= 28 semanas de gestación y seguimiento del desarrollo psicomotor hasta los 5 año...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004314-16,0,0,0 2004-004316-23,1,2005-05-10,2005-05-10,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,"Randomised, controlled , double blind trial on emodinamic, analgesic, pharmacoeconomic effects of clonidine and magnesium in premedication of laparoscopic surgery for colecitis ablation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004316-23,0,0,0 2004-004317-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Bial Industrial Farmacéutica S.A.,"Ensayo clínico aleatorizado, doble ciego, doble dummy, controlado con placebo, para valorar la eficacia y seguridad de diferentes presentaciones de inmunoterapia subcutánea en pacientes asmáticos sens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004317-42,0,0,0 2004-004320-13,1,2010-06-05,2010-06-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Universitätsklinikum Ulm / University Clinical Center Ulm,"RANDOMIZED PHASE III-STUDY ON VALPROIC ACID IN COMBINATION WITH ALL-TRANS RETINOIC ACID, STANDARD INDUCTION- AND CONSOLIDATION THERAPY IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004320-13,0,0,0 2004-004321-95,1,2011-08-12,2011-08-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Ulm,"RANDOMIZED PHASE II-STUDY ON VALPROIC ACID, ALL-TRANS RETINOIC ACID AND THEIR COMBINATION IN INDUCTION AND CONSOLIDATION THERAPY AS WELL AS PEGFILGRASTIM AFTER CONSOLIDATION THERAPY IN YOUNGER PATIENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004321-95,0,0,0 2004-004325-10,1,2007-09-30,2007-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,United Bristol Healthcare Trust,Evaluate Whether A Short Course Of Once Weekly Risedronate Prevents Bone Loss Following High-Dose Steroid Therapy For An Acute Exacerbation Of Inflammatory Bowel Disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004325-10,0,0,0 2004-004327-35,3,2006-03-29,2006-03-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild Cognitive Impairment patients treated over a 12-month oral administration period. An international multicentre, 3 parallel groups,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004327-35,0,0,0 2004-004329-90,1,2010-11-17,2010-11-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,CAMBRIDGE UNIVERSITY HOSPITALS FOUNDATION NHS TRUST,EARLY METABOLIC CHANGES WITH THIAZIDE OR BETA BLOCKER THERAPY FOR ESSENTIAL HYPERTENSION (MAIN STUDY).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004329-90,0,0,0 2004-004333-34,5,2012-03-06,2012-10-31,5,1,0,0,0,0,3,0,0,1,0,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,"A randomized, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004333-34,0,0,0 2004-004333-34,5,2012-03-06,2012-10-31,5,1,0,0,0,0,3,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,"A randomized, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004333-34,0,0,0 2004-004334-13,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,1,Genaera Corporation,"A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Talniflumate in Cystic Fibrosis Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004334-13,0,0,0 2004-004337-33,1,2006-11-26,2006-11-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,RANDOMIZED COMPARISON OF CIRCUMFERENTIAL PULMONARY VEIN ABLATION VERSUS ANTIARRHYTHMIC THERAPY FOR CURING PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION. (APAF STUDY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004337-33,0,0,0 2004-004339-78,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,FOLFOX6 TRIAL: TREATMENT OF THE FIRST LINE OF LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER. CLINICAL TRIAL ABOUT BIOMOLECULAR PREDICTIVE FACTORS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004339-78,0,0,0 2004-004340-42,1,2007-07-18,2007-07-18,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Antisoma Research Ltd,"An Open Label, Randomized, Phase I/II Study of DMXAA in Combination with Carboplatin and Paclitaxel in Patients with Locally Advanced and Metastatic Non-Small Cell Lung Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004340-42,0,0,0 2004-004342-41,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,GlaxoSmithKline Research and Development Ltd,"A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Partial Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004342-41,0,0,0 2004-004343-21,1,2008-05-13,2008-05-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004343-21,0,0,0 2004-004346-40,1,2012-09-12,2012-09-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"Full title of the trial : Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic® and Certican® in comparison to standard therapy with M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004346-40,0,0,0 2004-004348-39,1,2008-07-04,2008-07-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Brompton & Harefield NHS Trust,Effect of Strict Control of Blood Sugar with Insulin Regimen on Prevention of Atrial Fibrillation after Coronary Artery Bypass Grafting.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004348-39,0,0,0 2004-004349-16,1,2009-03-01,2009-03-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GELA Group,Targeted Intensification by a new preparative regimen for patients with Low-Grade B-Cell Lymphoma utilizing standard dose Ytrium 90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy (RIT) combined wit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004349-16,0,0,0 2004-004350-91,5,2006-09-25,2006-10-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global R&D Centre (Europe),"A multicentre, randomised, double-blind, double-dummy, placebo-controlled study to evaluate the safety and efficacy of ramelteon compared to placebo with zopiclone as a reference arm in adults with ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004350-91,0,0,0 2004-004350-91,5,2006-09-25,2006-10-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TAKEDA EUROPE RESEARCH DEVELOPMENT CENTRE LTD,"A multicentre, randomised, double-blind, double-dummy, placebo-controlled study to evaluate the safety and efficacy of ramelteon compared to placebo with zopiclone as a reference arm in adults with ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004350-91,0,0,0 2004-004350-91,5,2006-09-25,2006-10-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Europe R&D Centre Ltd,"A multicentre, randomised, double-blind, double-dummy, placebo-controlled study to evaluate the safety and efficacy of ramelteon compared to placebo with zopiclone as a reference arm in adults with ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004350-91,0,0,0 2004-004351-20,4,2006-12-15,2006-12-15,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global R&D Centre (Europe),"A randomised, double-blind, placebo-controlled study to determine the long-term efficacy and safety of ramelteon in adults with chronic insomnia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004351-20,0,0,0 2004-004351-20,4,2006-12-15,2006-12-15,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Europe R&D Centre Ltd,"A randomised, double-blind, placebo-controlled study to determine the long-term efficacy and safety of ramelteon in adults with chronic insomnia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004351-20,0,0,0 2004-004352-40,1,2009-07-13,2009-07-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Kliniken für Anästhesiologie und op. Intensivmedizin, Charité – Universitätsmedizin Berlin, CVK/CCM",Einfluss einer präoperativen Vakzinierung auf das Immunsystem und die postoperative Infektionsrate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004352-40,0,0,0 2004-004356-39,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Gemtuzumab Ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy: a randomized phase II/III trial...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004356-39,0,0,0 2004-004358-24,3,2007-11-05,2008-04-28,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A phase IIIb/IV randomised, controlled study evaluating an intensification treatment strategy of adding enfuvirtide (ENF) to an oral Highly Active AntiRetroviral Therapy (HAART) in treatment experienc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004358-24,0,0,0 2004-004358-24,3,2007-11-05,2008-04-28,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,ROCHE,"A phase IIIb/IV randomised, controlled study evaluating an intensification treatment strategy of adding enfuvirtide (ENF) to an oral Highly Active AntiRetroviral Therapy (HAART) in treatment experienc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004358-24,0,0,0 2004-004370-85,1,2005-04-18,2005-04-18,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, multicentric open study to evaluate the immunological memory induced by a 3-dose primary vaccination followed by a booster dose with GSK Biologicals’ 11-valent conjugate pneumococcal vacc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004370-85,0,0,0 2004-004371-11,2,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase IIIB, partially blind, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella vaccine (MeMuRu-OKA) given to healthy children...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004371-11,0,0,0 2004-004374-90,6,2007-02-01,2007-02-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Administered as Monotherapy to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004374-90,0,0,0 2004-004375-11,3,2008-05-16,2008-05-16,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Antisoma Research Limited,"AN OPEN LABEL, RANDOMISED, PHASE II STUDY OF AS1404 IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN EPITHELIAL CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004375-11,1,0,0 2004-004377-28,1,2006-05-27,2006-05-27,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A two-year extension to a one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral and cort...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004377-28,0,0,0 2004-004378-10,3,2009-06-30,2014-02-11,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"Multi-center, open-label, non-randomised phase II study to evaluate the activity and tolerability of GW786034 in patients with advanced and/or metastatic soft tissue sarcoma who have relapsed followin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004378-10,0,0,0 2004-004384-29,1,2010-09-29,2010-09-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Dr GED DEMPSEY, University Hospital Aintree",Double blind randomised controlled trial of Levosimendan versus Dopexamine in septic shock,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004384-29,0,0,0 2004-004386-15,4,2006-09-27,2006-10-27,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,AMERSHAM HEALTH,"An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004386-15,0,0,0 2004-004386-15,4,2006-09-27,2006-10-27,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Amersham Health, S.A. como filial de GE Healthcare Limited","An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004386-15,0,0,0 2004-004386-15,4,2006-09-27,2006-10-27,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,GE Healthcare Limited and its affiliates,"An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004386-15,0,0,0 2004-004387-72,2,2007-05-04,2007-05-04,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"PDL BioPharma, Inc.","A Phase IIa, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients with Crohn’s Disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004387-72,0,0,0 2004-004387-72,2,2007-05-04,2007-05-04,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Protein Design Labs, Inc.","A Phase IIa, Open-label Study of Visilizumab for Treatment of Perianal Fistulas in Patients with Crohn’s Disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004387-72,0,0,0 2004-004388-31,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"PDL BioPharma, Inc","A Phase IIa, Open-label Study of Visilizumab in Patients with Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004388-31,0,0,0 2004-004390-28,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Univ.-Kl.f.Nuklearmedizin Wien,11C-Acetate PET and 18F-Choline PET in Bladder Carcinoma: Prospective Validation for the Preoperative Staging,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004390-28,0,0,0 2004-004391-36,2,2007-02-21,2007-02-21,2,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"A multicenter, open-label, single-arm safety study to investigate the effects of chronic TRACLEER® treatment on testicular function in male patients with pulmonary arterial hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004391-36,0,0,0 2004-004392-11,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Liege,Human phase 1/2 clinical study of the safety and efficacy of sulfasalazine as a therapy for recurrent or progressing high grade gliomas.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004392-11,0,0,0 2004-004394-28,1,2008-08-20,2008-08-20,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Guy's & St Thomas' NHS Foundation Trust,The use of local anasthesia for pain control in children undergoing dental general anaesthesia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004394-28,0,0,0 2004-004395-36,3,2007-07-29,2007-08-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GW Pharma Ltd,"A Multi-Centre, Open Label, Follow-on Study to Assess the Maintenance of Effect, Tolerance and Safety of Sativex in the Treatment of Subjects with Neuropathic Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004395-36,0,0,0 2004-004399-35,1,2006-11-13,2006-11-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,North Glasgow Trust,The effects of eplerenone on left ventricular remodelling post-acute myocardial infarction: a double-blind placebo-controlled cardiac MR-based study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004399-35,0,0,0 2004-004401-26,1,2008-01-11,2008-01-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,STADA R&D GmbH,Evaluation of the Safety of a Formulation Containing Epoetin (Epoetin STADA) Administered Intravenously for the Maintenance Treatment of Renal Anemia: an Open Follow-up Trial. Study code (CRO) 411-54-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004401-26,0,0,0 2004-004403-37,1,2011-03-31,2011-03-31,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Universitätsklinikum Heidelberg,"Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zur S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004403-37,0,0,0 2004-004404-21,1,2007-02-01,2007-02-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,GreenPark Healthcare Trust,Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004404-21,0,0,0 2004-004404-21,1,2007-02-01,2007-02-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Queens University Belfast,Omega-3-Polyunsaturated Fatty Acids and Atherosclerosis in Systemic Lupus Erythematosus: Cellular Mechanisms and Functional Consequences,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004404-21,0,0,0 2004-004406-24,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,GLAXO SMITHKLINE,"A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1 SB-275833 Ointment versus Placebo Ointment Applied Twice Daily ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004406-24,0,0,0 2004-004409-24,2,2005-10-20,2005-10-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,"A Multi-Centre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, Flexible Dose Study to Evaluate the Efficacy, Safety and Tolerability of Extended-Release Bupropion Hydrochloride (150mg-3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004409-24,0,0,0 2004-004414-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Pethema,"Ensayo clínico multicéntrico, prospectivo, abierto, no controlado para determinar la eficacia y seguridad de DepoCyte (citarabina liposómica inyectable) para el tratamiento de la recidiva de SNC en pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004414-17,0,0,0 2004-004415-29,2,2005-10-19,2005-10-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Daiichi Medical Research Inc,"A Phase IIa, multi-center, multi-national, open-label, dose ranging study of the efficacy, safety, and tolerability of oral DU-176b administered once or twice daily in the treatment of adult patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004415-29,0,0,0 2004-004416-22,1,2012-06-13,2012-06-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Karolinska Institutet, Dept of Medicine, Clinical Pharmacology Unit","Platelet function in diabetic patients without and with renal impairment, and the effects of lipid-lowering treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004416-22,0,0,0 2004-004434-14,4,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double-blind, placebo controlled, parallel group, multicentre two week study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aquenous nasal spra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004434-14,0,0,0 2004-004434-14,4,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,GlaxoSmithKline Research & Development Limited,"A randomised, double-blind, placebo controlled, parallel group, multicentre two week study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aquenous nasal spra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004434-14,0,0,0 2004-004439-70,2,2005-09-09,2005-09-09,1,1,0,0,2,0,3,0,0,1,1,0,1,0,1,GLAXO SMITHKLINE,"A Randomised, Observer-blind, Multicentre, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, versus Topical 2% Sodium Fusi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004439-70,0,0,0 2004-004439-70,2,2005-09-09,2005-09-09,1,1,0,0,2,0,3,0,0,1,1,0,1,0,1,GlaxSmithKline Research & Development,"A Randomised, Observer-blind, Multicentre, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, versus Topical 2% Sodium Fusi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004439-70,0,0,0 2004-004442-40,3,2005-06-10,2005-06-15,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA Pharma AG,500µg roflumilast once daily in combination with 50µg salmeterol twice daily versus 50µg salmeterol twice daily alone over 52 weeks in patients with COPD.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004442-40,0,0,0 2004-004443-22,1,2006-03-23,2006-03-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Spirig Pharma AG,"Untersuchung der Wirksamkeit einer glycerinhaltigen Creme bei der Behandlung von Atopischer Dermatitis. Kontrolliert, randomisierte Doppel-Blind-Studie.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004443-22,0,0,0 2004-004448-30,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"METRONOMIC THERAPY ,ORAL SOMMINISTRATION OF LOW DOSES OF CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE CARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004448-30,0,0,0 2004-004450-96,11,2006-02-27,2008-03-31,8,1,0,0,0,2,2,0,2,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,A Randomized Multi-center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Dise...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004450-96,0,0,0 2004-004450-96,11,2006-02-27,2008-03-31,8,1,0,0,0,2,2,0,2,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Randomized Multi-center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Dise...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004450-96,0,0,0 2004-004452-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Christel B. Lajer, Dep. of Otolaryngology head and neck surgery, Rigshospitalet",Photodynamic therapy as palliative treatment for recurrent squamous cell carcinom of the head and neck region,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004452-39,0,0,0 2004-004456-39,11,2009-05-08,2012-06-01,8,0,0,0,0,0,3,0,0,2,1,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""","A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004456-39,1,0,0 2004-004456-39,11,2009-05-08,2012-06-01,8,0,0,0,0,0,3,0,0,2,1,0,0,0,0,ARCAGY,"A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004456-39,1,0,0 2004-004456-39,11,2009-05-08,2012-06-01,8,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Studienzentrale AGO Austria,"A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004456-39,1,0,0 2004-004456-39,11,2009-05-08,2012-06-01,8,0,0,0,0,0,3,0,0,2,1,0,0,0,0,EORTC (European Organization for Research and Treatment of Cancer),"A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004456-39,1,0,0 2004-004461-15,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,SANOFI-SYNTHELABO,SOLIAN solution in the acute setting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004461-15,0,0,0 2004-004463-30,1,2006-10-23,2006-10-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Pharma GmbH,Effects of Pioglitazone in Combination with Atorvastatin in Comparison to Atorvastatin treatment alone on Intima-Media Thickness in patients at Risk for Vascular Complications,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004463-30,0,0,0 2004-004464-69,1,2006-05-03,2006-05-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,vectura group plc,"A Home Based Phase IIb, Multi-centre, Randomised, Double-Blind, Placebo Controlled, Dose Finding Parallel Group Study to explore the Optimal Dose of Inhaled VR004 in Patients with Erectile Dysfunction...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004464-69,0,0,0 2004-004465-15,2,2008-04-30,2008-04-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biotest AG,"A multicentre, open, prospective study investigating clinical efficacy, safety, and pharmacokinetic properties of the human normal immunoglobulin for intravenous administration BT681 in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004465-15,0,0,0 2004-004466-33,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Dr. Theiss Naturwaren GmbH,"doubleblind (observer blind), placebo-controlled, clinical-experimental study phase II in order to examine the local compatibility of Dr. Theiss Ringelblumen Salbe N by the duhring-chamber-test and in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004466-33,0,0,0 2004-004467-29,1,2009-07-15,2009-07-15,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Craigavon Area Hospital Group Trust,An open label pilot study to evaluate the efficacy and safety of topical tacrolimus 0l1% (Protopic) in the treatment of varicose eczema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004467-29,0,0,0 2004-004475-12,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo de Tratamiento de los Tumores Digestivos,Phase II Clinical Trial ok weekly administration of oxaliplatin plus capecitabine and radioteraphy followed by surgery in patients with resectable locally advanced rectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004475-12,0,0,0 2004-004481-33,1,2007-03-29,2007-03-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,Vorionazole for IFI prophilaxis in oncoematologic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004481-33,0,0,0 2004-004482-15,1,2006-12-01,2006-12-01,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,"Universitätsklinikum Aachen, Klinik f. Psychiatrie und Psychotherapie",Hirnaktivierung während Gedächtnisaufgaben bei Patienten mit Schizophrenie unter Behandlung von Ziprasidon oder Risperidon. Eine FMRT-Untersuchung.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004482-15,0,0,0 2004-004488-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Rikshospitalet University Hospital, University of Oslo",Does cyclosporine A reduce the insulin secretion from the pancreas?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004488-31,0,0,0 2004-004496-10,1,2005-09-24,2005-09-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Norgine International Limited,"A Phase 2a double blind, randomised, placebo controlled, two dose study to determine the effect of orally administered methylnaltrexone (MNTX) in preventing post-operative opiate induced constipation ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004496-10,0,0,0 2004-004499-35,2,2006-10-05,2006-10-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Limited,A Study to Evaluate the Efficacy of Converting from Intravenous or Subcutaneous rHuEPO to Intravenous Darbepoetin Alfa (Aranesp®) in Subjects with Chronic Kidney Disease Receiving Haemodialysis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004499-35,0,0,0 2004-004509-11,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,University hospital of the University of Ulm,Efficiency and tolerability of L-Dopa in patients with Hereditary Spastic Paraplegia (HSP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004509-11,0,0,0 2004-004511-39,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,1,Dr. Theiss Naturwaren GmbH,"Double blind (observer Blind) Placebo controlled, clinical-experimental Study of the Phase II for the examination of the local tolerance by Duhring-Chamber-Test as well as open user trial of the produ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004511-39,0,0,0 2004-004512-23,4,2006-02-15,2006-02-15,2,0,0,0,0,1,3,0,0,1,0,0,1,0,1,BIOMARIN,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Phenoptin in Subjects with Phenylketonuria Who Have Elevated Phenylalanine Levels",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004512-23,0,0,0 2004-004512-23,4,2006-02-15,2006-02-15,2,0,0,0,0,1,3,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Phenoptin in Subjects with Phenylketonuria Who Have Elevated Phenylalanine Levels",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004512-23,0,0,0 2004-004513-41,4,2006-10-10,2006-10-10,2,0,0,0,0,1,3,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc.,"A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects with Phenylketonuria Who Have Elevated Phenylalanine Levels",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004513-41,0,0,0 2004-004513-41,4,2006-10-10,2006-10-10,2,0,0,0,0,1,3,0,0,1,0,0,1,0,1,BIOMARIN,"A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects with Phenylketonuria Who Have Elevated Phenylalanine Levels",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004513-41,0,0,0 2004-004514-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Beroendcentrum Stockholm,Does Acamprosate Decrease Cue-induced Alcohol Craving?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004514-17,0,0,0 2004-004515-26,1,2010-12-07,2010-12-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GYN Research GmbH,"An open-label, multicenter, randomized phase II study to compare the effects of Paclitaxel/Carboplatin and Lonafarnib to those of Paclitaxel/Carboplatin for 1st line treatment of patients with epithel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004515-26,0,0,0 2004-004516-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,Uppsala University,The impact of steroid hormones on symptom provocation in patients with premenstrual dysphoric disorder.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004516-22,0,0,0 2004-004519-43,5,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"Estudio de Fase 2, Multicéntrico, Aleatorizado, Doble Ciego, Controlado con Placebo, de Grupos Paralelos y de Escalada de Dosis para determinar el Efecto del RO0506997 sobre las lesiones en Imagen de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004519-43,0,0,0 2004-004525-99,1,2007-06-21,2007-06-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"A randomized, prospective, double-blind study to evaluate the effects on lipid profile of combined Ezetimibe and Simvastatin therapy as compared to Simvastatin alone in people with type 2 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004525-99,0,0,0 2004-004527-35,2,2008-12-16,2008-12-16,1,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Bioenvision Limited,A PHASE II TRIAL OF CLOFARABINE IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA FOR WHOM INTENSIVE CHEMOTHERAPY IS NOT CONSIDERED SUITABLE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004527-35,0,0,0 2004-004528-11,3,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,F. Hoffmann-La Roche Ltd,"Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPPIV inhibitor RO0730699 in patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004528-11,0,0,0 2004-004529-84,2,2006-06-19,2006-06-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"Multicenter, double-blind, randomized, placebo controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPP-IV inhibitor RO0730699 in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004529-84,0,0,0 2004-004529-84,2,2006-06-19,2006-06-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"Multicenter, double-blind, randomized, placebo controlled, dose ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of the DPP-IV inhibitor RO0730699 in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004529-84,0,0,0 2004-004533-34,1,2008-02-08,2008-02-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bioenvision,"A Phase IV Non-randomised Study of Modrenal® (Trilostane) in Post-menopausal Women with Advanced, Oestrogen Receptor Positive Breast Cancer for whom Prior Endocrine Therapies have Failed, One of whic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004533-34,0,0,0 2004-004545-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU Sart Tilman,Cell therapy for cardiac repair through mobilization of hematopoietic stem cells and endothelial progenitors in patients with chronic ischemic cardiomyopathy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004545-18,0,0,0 2004-004546-41,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Helsinki University Central Hospital,A phase II trial assessing bevacizumab in the treatment of advanced or metastatic angiosarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004546-41,0,0,0 2004-004557-25,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,NERVIANO MEDICAL SCIENCE,Phase II study of Brostallicin a(PNU- 166196) and Cisplatin (CDDP) in Adult Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)preceded by a dose-escalation component,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004557-25,0,0,0 2004-004558-18,5,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Amgen Inc,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects with Secondary Hyperparathyroidism Not Receiving Dialysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004558-18,0,0,0 2004-004558-18,5,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AMGEN,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects with Secondary Hyperparathyroidism Not Receiving Dialysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004558-18,0,0,0 2004-004559-21,9,2008-05-07,2008-07-22,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Novartis Pharma Services AG,"A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Long-Term Effect (up to 5 Years) of Treatment with LAF237 50 mg bid to Glimepiride up to 6 mg Daily as Add-On Therapy i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004559-21,0,0,0 2004-004559-21,9,2008-05-07,2008-07-22,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,NOVARTIS FARMA,"A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Long-Term Effect (up to 5 Years) of Treatment with LAF237 50 mg bid to Glimepiride up to 6 mg Daily as Add-On Therapy i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004559-21,0,0,0 2004-004559-21,9,2008-05-07,2008-07-22,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Novartis Farmacéutica S.A.,"A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Long-Term Effect (up to 5 Years) of Treatment with LAF237 50 mg bid to Glimepiride up to 6 mg Daily as Add-On Therapy i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004559-21,0,0,0 2004-004561-14,7,2008-06-12,2008-06-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Fujisawa GmbH,"AN OPEN, RANDOMISED, MULTICENTRE, EXPLORATORY CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS IN COMBINATION WITH MONOCLONAL ANTI-IL2R ANTIBODIES OR STEROIDS IN HCV POSITIVE PATIENTS U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004561-14,0,0,0 2004-004561-14,7,2008-06-12,2008-06-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma GmbH,"AN OPEN, RANDOMISED, MULTICENTRE, EXPLORATORY CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS IN COMBINATION WITH MONOCLONAL ANTI-IL2R ANTIBODIES OR STEROIDS IN HCV POSITIVE PATIENTS U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004561-14,0,0,0 2004-004561-14,7,2008-06-12,2008-06-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd,"AN OPEN, RANDOMISED, MULTICENTRE, EXPLORATORY CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS IN COMBINATION WITH MONOCLONAL ANTI-IL2R ANTIBODIES OR STEROIDS IN HCV POSITIVE PATIENTS U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004561-14,0,0,0 2004-004561-14,7,2008-06-12,2008-06-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,FUJISAWA,"AN OPEN, RANDOMISED, MULTICENTRE, EXPLORATORY CLINICAL STUDY TO COMPARE THE SAFETY AND EFFICACY OF TACROLIMUS IN COMBINATION WITH MONOCLONAL ANTI-IL2R ANTIBODIES OR STEROIDS IN HCV POSITIVE PATIENTS U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004561-14,0,0,0 2004-004565-15,6,2007-05-16,2007-06-15,6,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Ferring BV,Pentasa® Once Daily In Ulcerative colitis for Maintenance of remission: PODIUM An International multi-centre investigator blinded randomised controlled study of Pentasa ® Sachet comparing one gram t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004565-15,0,0,0 2004-004567-29,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO,Pelvic lymph node metastases from bladder and prostate cancer magnetic resonance imaging with ultrasmall superparamagnetic iron oxyde sinerem.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004567-29,0,0,0 2004-004572-36,2,2006-04-03,2006-04-03,1,0,0,0,0,1,3,0,0,1,0,0,1,0,1,Antigenics Inc,"A Multi-Center, Randomized, Phase 3 Study of Adjuvant Oncophage versus Observation in Patients with High Risk of Recurrence after Surgical Treatment of Renal Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004572-36,0,0,0 2004-004573-29,1,2010-06-16,2010-06-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Peninsula Pharmaceuticals, Inc.","A Multicenter, Phase 3 Study to Confirm the Safety and Efficacy of Intravenous Doripenem in Complicated Lower Urinary Tract Infection or Pyelonephritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004573-29,0,0,0 2004-004575-11,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Pfizer Health AB,"PERCEPTION AND TOLERABILITY OF NICOTINE FILMS FOR USE IN THE MOUTH. A RANDOMIZED, CROSSOVER, PHASE-II, STUDY IN HEALTHY SMOKERS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004575-11,0,0,0 2004-004577-28,4,2005-12-01,2005-12-13,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,FARMACUSI S.A.,Different treatment regimens of calcipotriol cream and combination (calcipotiol/betamethasone dipropionate) ointment in psoriasis vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004577-28,0,0,0 2004-004577-28,4,2005-12-01,2005-12-13,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,LEO Pharma A/S,Different treatment regimens of calcipotriol cream and combination (calcipotiol/betamethasone dipropionate) ointment in psoriasis vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004577-28,0,0,0 2004-004577-28,4,2005-12-01,2005-12-13,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S ),Different treatment regimens of calcipotriol cream and combination (calcipotiol/betamethasone dipropionate) ointment in psoriasis vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004577-28,0,0,0 2004-004586-14,4,2005-08-19,2005-08-19,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,FAES FARMA S.A.,"Double-blind, randomised, placebo-controlled, phase III study comparing the efficacy and safety of bilastine 20 mg once daily and cetirizine 10 mg for the treatment of allergic allergic rhinitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004586-14,0,0,0 2004-004589-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rehabilitation Department. Hospital mútua de Terrassa,"Tratamiento del dolor cervical crónico secundario a síndrome del latigazo cervical con toxina botulínica tipo A: estudio piloto. Estudio de fase IV, randomizado, a doble ciego y controlado con placebo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004589-33,0,0,0 2004-004590-28,1,2005-06-30,2005-06-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"Efficacy and safety of 40 mg, 80 mg and 160 mg KUC 7483 BS administered twice daily and 160 mg administered once a day over 8 weeks in patients with overactive bladder syndrome (a double-blind, placeb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004590-28,0,0,0 2004-004591-37,1,2007-07-01,2007-07-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Leeds teaching Hospitals,Efficacy of intrarticular steroid injection in osteoarthritis of the first carpometacarpal joint (CMCJ).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004591-37,0,0,0 2004-004592-11,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,IGENEON,Vaccination with IGN101 in patients with non-small-cell-lung-cancer (NSCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004592-11,0,0,0 2004-004594-29,2,2009-10-01,2009-10-01,2,1,0,0,2,0,2,0,0,1,0,0,1,0,0,INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG),Phase II Study of VELCADETM in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with one prior systemic therapy regimen (X05142),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004594-29,0,0,0 2004-004594-29,2,2009-10-01,2009-10-01,2,1,0,0,2,0,2,0,0,1,0,0,1,0,0,International Extranodal Lymphoma Study Group,Phase II Study of VELCADETM in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with one prior systemic therapy regimen (X05142),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004594-29,0,0,0 2004-004596-11,2,2008-02-22,2008-02-22,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG),Phase II Study of VELCADETM in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with more than one prior systemic therapy regimen (X05142),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004596-11,1,0,0 2004-004596-11,2,2008-02-22,2008-02-22,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,International Extranodal Lymphoma Study Group,Phase II Study of VELCADETM in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with more than one prior systemic therapy regimen (X05142),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004596-11,1,0,0 2004-004602-25,4,2006-05-17,2006-05-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Phase 3, Multicenter, Randomized, Double-Blind,Double-Dummy, Placebo-Controlled StudyComparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects withModerate to Severe Ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004602-25,0,0,0 2004-004604-20,2,2008-06-23,2008-06-23,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"An Open-Label, Two-Stage, Fixed-Dose, Multicenter Phase II Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004604-20,0,0,0 2004-004604-20,2,2008-06-23,2008-06-23,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Medarex, Inc.","An Open-Label, Two-Stage, Fixed-Dose, Multicenter Phase II Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004604-20,0,0,0 2004-004606-24,1,,,0,0,0,1,0,3,1,0,1,1,0,0,0,1,1,Fujisawa GmbH,"A randomized, open-label, monocentric clinical phase I/IV study in healthy human volunteers to evaluate the skin tolerability and cosmetic acceptance of three marketed anti-acne drugs (Differin® Creme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004606-24,0,0,0 2004-004612-23,2,2007-03-05,2007-03-05,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Teva Pharmaceutical Industries Ltd,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort Designed, Escalating Dose Study to Assess the Tolerability, Safety and Maximal Tolerated Dose MTD of Ladostigil in Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004612-23,0,0,0 2004-004612-23,2,2007-03-05,2007-03-05,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,TEVA,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort Designed, Escalating Dose Study to Assess the Tolerability, Safety and Maximal Tolerated Dose MTD of Ladostigil in Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004612-23,0,0,0 2004-004614-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,DIATER LABORATORIES S.A.,Alternaria alternata inmunotherapy effects on AMP and methacholine bronchial answer and on inflammation markers in exhaled air (nitric oxide) and in condensated air (pH and hydrogen peroxide) in asth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004614-16,0,0,0 2004-004617-42,1,2007-04-03,2007-04-03,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Icagen Inc,"A Phase III, Multicenter, 52-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Efficacy and Safety of ICA-17043 with or without Hydroxyurea Therapy in Patients with Sickle Cell ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004617-42,0,0,0 2004-004618-18,2,2006-06-26,2006-06-26,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,HAL Allergy BV,SUBLIVAC® study on the safety of an initial phase rush-in with the use of a compliance friendly one bottle concept.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004618-18,0,0,0 2004-004620-12,1,2006-12-07,2006-12-07,1,0,0,0,0,0,2,0,0,1,1,1,1,0,3,Royal Marsden Hospital,Assessment of normal release morphine in the management of dyspnoea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004620-12,0,0,0 2004-004624-13,3,2007-11-09,2007-11-09,2,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Barts and The London NHS Trust,"A prospective, multi-centre, multinational, open-label study to investigate the equipotent dose ratio after switching from strong opioids to Transtec® in subjects with pain due to cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004624-13,0,0,0 2004-004625-96,1,2014-03-20,2014-03-20,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Group for the Study of Resistant Depression (GSRD), Head: Prof. Julien Mendlewicz",A naturalistic study of the efficacy and safety of escitalopram in treatment resistant depression.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004625-96,0,0,0 2004-004633-33,1,2008-09-05,2008-09-05,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Sexological Clinic, Rigshospitalet",local botox administration on patients with vulvar vestbulitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004633-33,0,0,0 2004-004648-29,2,2008-07-16,2008-07-16,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,"Janssen Cilag International, N.V. (Sponsor in European Union)","A Multicenter, Open-label, Phase 2 Study of VELCADE bortezomib for Injection in Previously treated Patients with Stage IIIB an IV Bronchioloalveolar Carcinoma and Adenocarcinoma with Bronchioloalveol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004648-29,0,0,0 2004-004648-29,2,2008-07-16,2008-07-16,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,JANSSEN-CILAG,"A Multicenter, Open-label, Phase 2 Study of VELCADE bortezomib for Injection in Previously treated Patients with Stage IIIB an IV Bronchioloalveolar Carcinoma and Adenocarcinoma with Bronchioloalveol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004648-29,0,0,0 2004-004654-19,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,3M ITALIA,"Multicenter, randomized, double-blind, vehicle-controlled study comparing recurrence rate following imiquimod 5% cream or vehicle 3 times per week for 4 weeks prior to ablative therapy in subjects suf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004654-19,0,0,0 2004-004661-15,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Vion Pharmaceuticals, Inc.",A Phase III Randomized Study of CLORETAZINE™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients with Acute Myeloid Leukemia in First Relapse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004661-15,0,0,0 2004-004670-88,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"AlgoRx Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Analgesic Efficacy, Safety and Tolerability of ALGRX 4975 in Subjects after Inguinal Hernia Repair",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004670-88,0,0,0 2004-004675-11,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Clinical trial of phase II for the a front line treatment of the non-Hodgkin lymphomas of derivation lymphocyte T Gemcitabine and Oxaliplatin GEMOX,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004675-11,0,0,0 2004-004676-37,7,2007-08-08,2007-08-08,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme Europe BV,"A randomized, double-blind study of GT267-004 versus vancomycin, and GT267-004 versus metronidazole, in patients with C.difficile-associated diarrhea",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004676-37,0,0,0 2004-004681-33,4,2007-05-26,2007-06-26,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"An International, Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™, single oral 300 mg or 600 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004681-33,0,0,0 2004-004684-30,1,,,0,1,0,1,0,3,1,0,0,1,0,0,0,1,0,Ludwig Institute for Cancer Research,Phase I/II Studie zur Immunisierung mit dem Peptid MAGE-3.A1 gemischt mit der immunologischen Adjuvans CpG 7909 bei Patienten mit metastasiertem Melanom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004684-30,0,0,0 2004-004685-32,5,2008-05-13,2008-08-27,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,SCHERING-PLOUGH,A Pivotal Randomized Study of Lonafarnib (SCH66336) Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004685-32,0,0,0 2004-004685-32,5,2008-05-13,2008-08-27,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Schering-Plough Research Institute,A Pivotal Randomized Study of Lonafarnib (SCH66336) Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who Are Platelet Transfusi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004685-32,0,0,0 2004-004686-15,1,,,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,Ludwig Institute For Cancer Research,Phase I/II study of immunization with multiple peptides mixed with the immunological adjuvant CpG 7909 in HLA-A2 patients with metastatic melanoma ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004686-15,0,0,0 2004-004691-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St Vincents University Hospital,"Etanercept in Psoriasis and Psoriatic Arthritis: a single center, open-label study in 15 patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004691-37,0,0,0 2004-004693-87,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,OSPEDALE SACRO CUORE-DON CALABRIA,Randomized study on therapy of Strongyloides stercoralis invasion: ivermectine VS thiabendazole,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004693-87,0,0,0 2004-004695-36,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SAN GERARDO DI MONZA,SEVOFLURANE SOMMINISTRED THROGH ANACONDA VERSUS PROPOFOL + REMIFENTANIL DURING THE SEDATION OF THE CRITICAL PATIENT INTUBATED AND VENTILATED IN THE INTENSIVE CARE UNIT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004695-36,0,0,0 2004-004696-11,9,2006-03-16,2007-11-26,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,A open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004696-11,0,0,0 2004-004696-11,9,2006-03-16,2007-11-26,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.",A open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004696-11,0,0,0 2004-004696-11,9,2006-03-16,2007-11-26,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,A open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004696-11,0,0,0 2004-004700-20,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"Epix Pharmaceuticals, Inc.",Phase II Feasibility study of safety and efficacy of Magnetic Resonance Imaging of Thrombi with EP-2104R in the detection in Venous Thromboembolism (VTE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004700-20,0,0,0 2004-004701-23,2,2008-04-07,2008-04-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Epix Pharmaceuticals, Inc.",Phase II feasibility study to evaluate the safety and efficacy of EP-2104R for Magnetic Resonance Imaging of thrombi in the arterial vasculature and cardiac chambers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004701-23,0,0,0 2004-004707-38,3,2016-07-20,2016-07-20,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Prof David Cunningham,"A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004707-38,1,0,0 2004-004707-38,3,2016-07-20,2016-07-20,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Royal Marsden NHS Trust,"A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004707-38,1,0,0 2004-004708-19,2,2006-01-04,2006-01-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALTANA Pharma AG,A dose range finding study of formoterol administered once daily in the evening in combination with ciclesonide using the UltrahalerTM versus monotherapy of each drug in asthmatic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004708-19,0,0,0 2004-004709-53,4,2008-11-14,2008-11-14,3,1,0,0,0,0,4,0,0,2,0,0,0,0,1,"Merck & Co., Inc.","A Multicenter, Double-Blind, Randomized, Cross-Over Design Study to Evaluate the Effect of Montelukast vs. Salmeterol on the Inhibition of Excercise-Induced Bronchoconstriction in Asthmatic Patients A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004709-53,1,1,0 2004-004709-53,4,2008-11-14,2008-11-14,3,1,0,0,0,0,4,0,0,2,0,0,0,0,1,Merck Sharp & Dohme OÜ,"A Multicenter, Double-Blind, Randomized, Cross-Over Design Study to Evaluate the Effect of Montelukast vs. Salmeterol on the Inhibition of Excercise-Induced Bronchoconstriction in Asthmatic Patients A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004709-53,1,1,0 2004-004709-53,4,2008-11-14,2008-11-14,3,1,0,0,0,0,4,0,0,2,0,0,0,0,1,MERCK SHARP DOHME,"A Multicenter, Double-Blind, Randomized, Cross-Over Design Study to Evaluate the Effect of Montelukast vs. Salmeterol on the Inhibition of Excercise-Induced Bronchoconstriction in Asthmatic Patients A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004709-53,1,1,0 2004-004709-53,4,2008-11-14,2008-11-14,3,1,0,0,0,0,4,0,0,2,0,0,0,0,1,Merck & Co. Inc.,"A Multicenter, Double-Blind, Randomized, Cross-Over Design Study to Evaluate the Effect of Montelukast vs. Salmeterol on the Inhibition of Excercise-Induced Bronchoconstriction in Asthmatic Patients A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004709-53,1,1,0 2004-004710-16,8,2010-04-23,2017-04-03,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Taiho Pharma USA, Inc.","An Open-Label, Multicenter, randomized, Phase 3 Study of S-1 in combination with cisplatin compared against 5-FU in combination with cisplatin in patients with advanced gastric cancer previously untre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004710-16,0,0,0 2004-004710-16,8,2010-04-23,2017-04-03,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"TAIHO PHARMA USA, INC","An Open-Label, Multicenter, randomized, Phase 3 Study of S-1 in combination with cisplatin compared against 5-FU in combination with cisplatin in patients with advanced gastric cancer previously untre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004710-16,0,0,0 2004-004719-43,1,2008-07-18,2008-07-18,1,1,0,0,0,1,4,0,1,1,1,1,1,0,0,University of Cambridge,"The Effects of 6-Month Administration of a Low Growth Hormone Dose on Insulin Sensitivity, Postload Glucose Tolerance and Cardiovascular Disease Risk Markers in Subjects with Impaired Glucose Toleranc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004719-43,0,0,0 2004-004721-10,1,2006-07-21,2006-07-21,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Sussex NHS Research Consortium, Research Department, Worthing Hospital",None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004721-10,0,0,0 2004-004722-27,1,2010-10-14,2010-10-14,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Instituto Científico y Tecnológico de Navarra, S.A.","Randomised, open, multicenter, sequential trial assessing the safety and efficacy of bemiparin on the response to the treatment in patients diagnosed with localized small cell carcinoma of the lung.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004722-27,0,0,0 2004-004723-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE DI MILANO,PRECONDITIONING EFFECT OF INALATORY ANESTHETICS EFFETTO DI PRECONDIZIONAMENTO DEGLI ANESTETICI INALATORI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004723-35,0,0,0 2004-004727-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Charles University, 3rd Faculty of Medicine",Influence of low-dose i.v. growth hormone treatment together with glutamine supplementation in late-phase critically ill patient after multiple injury. A pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004727-36,0,0,0 2004-004728-11,3,2005-12-13,2006-04-24,2,0,0,0,1,0,2,0,0,1,0,0,1,0,1,Avera Pharmaceuticals Inc.,"A Multicenter, Randomized, Controlled, Observer-Blinded, Dose-Response Study to Evaluate The Efficacy in Tracheal Intubation and Safety of Gantacurium Chloride for Injection in Healthy Adult Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004728-11,0,0,0 2004-004736-30,2,2009-10-15,2009-10-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Foundation of Liver research,Peginterferon alfa-2a and Ribavirin Combination Therapy in Patients with HBeAg-negative Chronic HBV Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004736-30,0,0,0 2004-004736-30,2,2009-10-15,2009-10-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Erasmus MC,Peginterferon alfa-2a and Ribavirin Combination Therapy in Patients with HBeAg-negative Chronic HBV Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004736-30,0,0,0 2004-004738-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Karolinska University Hospital, Huddinge",Intermittent intravenous adenosine with prolonged pain in the back of the neck with allodynia/dysaesthesia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004738-15,0,0,0 2004-004740-51,1,,,0,0,0,0,1,0,2,0,0,1,0,0,0,1,1,Agis Industries (1983) ltd.,Determination of antipsoriatic efficacy of topical paroxetine hydrochloride ointments in a psoriasis plaque test,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004740-51,0,0,0 2004-004741-17,2,2007-12-20,2007-12-20,2,0,0,1,0,0,1,0,0,1,1,1,0,0,1,Santaris Pharma,"SPC2996 in Chronic Lymphocytic Leukaemia An open-labelled, international multicenter dose escalating, phase I/II study of SPC2996, an LNA antisense molecule against Bcl-2, in patients with relapsed or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004741-17,0,0,0 2004-004743-22,3,2006-01-16,2006-01-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004743-22,0,0,0 2004-004744-43,3,2005-12-30,2005-12-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004744-43,0,0,0 2004-004745-18,3,2005-11-23,2005-11-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004745-18,0,0,0 2004-004745-18,3,2005-11-23,2005-11-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GLAXO SMITHKLINE,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004745-18,0,0,0 2004-004748-27,1,2007-08-31,2007-08-31,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,"Hull and east Yorkshire Hospitals Trust, Research and Deveopment, admin porta cabin","An 8 week, double-blind, randomised, parallel group study to investigate the effect of 20 mg Esomeprazole (Nexium) tablets Twice daily versus placebo on symptoms associated with chronic cough due to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004748-27,0,0,0 2004-004749-17,1,2006-01-31,2006-01-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomized, double-blind, placebo-controlled, 2-week crossover, knemometric assessment of the effect of once daily GW685698X Aqueous Nasal Spray 100 mcg on short term growth in children ages 6 - 11 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004749-17,0,0,0 2004-004761-15,1,2008-06-17,2008-06-17,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,City University,Rapid Ejaculation: An exploration of the pharmacological and behavioural therapies in men living in East London and a preliminary trial of these treatment modalities,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004761-15,0,0,0 2004-004771-11,8,2007-11-29,2008-11-29,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,"A phase III, randomized, double-blind, active-controlled, non-inferiority clinical trial to investigate the efficacy and safety of a single injection of Org 36286 (corifollitropin alfa) to induce mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004771-11,0,0,0 2004-004772-36,6,2009-03-15,2009-04-16,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,Pregnancy and neonatal follow-up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 38819 for Org 36286 (corifollitropin alfa),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004772-36,0,0,0 2004-004773-28,6,2009-05-07,2009-05-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,Follow-up protocol to collect the outcome of frozen-thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004773-28,0,0,0 2004-004774-85,6,2007-03-05,2007-06-13,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Biogen Idec Inc,"A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004774-85,0,0,0 2004-004776-37,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Consumer Health S.A.,"An 8-week, multi-center, randomized, double-blind, placebo-controlled, parallel group trial of Diclofenac Sodium Gel 1% in patients with primary osteoarthritis of the hand",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004776-37,0,0,0 2004-004778-99,1,2013-03-31,2013-03-31,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,"Pediatric Unit, Hillerød Hospital",The growth of the internal genitalia and the bone mineralization during hormonal replacement therapy and the presence of aortic root dilatation in girls with Turner Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004778-99,0,0,0 2004-004781-33,1,2010-03-24,2010-03-24,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"Somatropin Therapy for Short Children Born of Premature Gestation: A Controlled, Prospective Randomized, Multicenter Study with an Untreated Control Group",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004781-33,0,0,0 2004-004787-74,1,2008-12-01,2008-12-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Group of Hospitals Trust,"A double blind, prospective, randomised, controlled clinical trial to evaluate the effect of topical phenytoin, on healing, in diabetic foot ulcers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004787-74,0,0,0 2004-004794-28,2,2007-05-07,2007-05-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-week, randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy and safety of aliskiren in patients with diabetes and hypertension not adequately responsive to th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004794-28,0,0,0 2004-004794-28,2,2007-05-07,2007-05-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A 12-week, randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy and safety of aliskiren in patients with diabetes and hypertension not adequately responsive to th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004794-28,0,0,0 2004-004796-11,1,2008-12-16,2008-12-16,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Klinikum Augsburg,"An Open-Label, Non-Randomized, Single center Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PgR+ Breast Ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004796-11,0,0,0 2004-004799-35,3,2007-02-23,2007-02-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Sanofi-aventis recherche and developpement,Double blind placebo controlled dose ranging study of the efficacy and safety of SSR149744C 100 or 300 mg for the prevention of ventricular arrhythmia-triggered ICD interventions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004799-35,0,0,0 2004-004799-35,3,2007-02-23,2007-02-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,2,SANOFI-SYNTHELABO,Double blind placebo controlled dose ranging study of the efficacy and safety of SSR149744C 100 or 300 mg for the prevention of ventricular arrhythmia-triggered ICD interventions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004799-35,0,0,0 2004-004799-35,3,2007-02-23,2007-02-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Sanofi-Synthelabo-Recherche,Double blind placebo controlled dose ranging study of the efficacy and safety of SSR149744C 100 or 300 mg for the prevention of ventricular arrhythmia-triggered ICD interventions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004799-35,0,0,0 2004-004801-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Zealand Pharma A/S,"A Phase II, Multicenter, Double-Blind, Efficacy, Safety, and Tolerability Study of ZP120 Administered as Short Term I.V. Infusion as Add-On Therapy in Patients with Subacute Decompensated Chronic Hear...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004801-11,0,0,0 2004-004802-26,1,2005-12-31,2005-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Lluita contra la SIDA,ESTUDIO DE LA INFLUENCIA DE LAS ESTATINAS EN LA REPLICACIÓN PLASMÁTICA DEL VIH EN PACIENTES CON INFECCION POR EL VIH-1 QUE INTERRUMPEN EL TRATAMIENTO ANTIRRETROVIRAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004802-26,0,0,0 2004-004803-39,6,2006-09-19,2006-10-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"SAINT II (Stroke - Acute Ischemic - NXY Treatment) A double blind, randomized, placebo controlled, parallel group, multicenter, phase IIb/III study to assess the efficacy and safety of intravenous NXY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004803-39,0,0,0 2004-004806-25,3,2006-03-21,2007-04-13,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA Pharma AG,Evaluation of the complete remission rates in patients with symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD) treated with pantoprazole 40 mg o.d. over 4...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004806-25,0,0,0 2004-004811-53,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,PIERRE FABRE PHARMA,Ex-vivo study regarding the effects of Serenoa r. on the expression of VEGF vascular endothelial growth factor and microvessel density in patients with benign prostatic hypertrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004811-53,0,0,0 2004-004819-29,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,UNIVERSITA' DEGLI STUDI DI UDINE,Use of Rituximab in the treatment of extensive chronic graft versus host disease after allogenic stem cells transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004819-29,0,0,0 2004-004822-29,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,SINTETICA SA,"Spinal anaesthesia with 2 -chlopoprocaine 1% for lower limb procedures of short duration: a prospective randomized, blind, dose-finding study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004822-29,0,0,0 2004-004823-36,1,,,0,1,0,0,0,3,4,0,1,1,0,0,0,1,1,daacro - diagnostic assessment and clinical research organization,"Effects of Alprazolam and Flupentixol on endocrine, autonomic and psychological parameters in the Trier Social Stress Test (TSST)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004823-36,0,0,0 2004-004824-11,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Universitätshautklinik Kiel,"Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, intra-patient, double-blind (right/left arm) stu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004824-11,0,0,0 2004-004825-87,3,2005-05-08,2006-05-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Dermatologie represented by Institut de Recherche Pierre Fabre,"Efficacy and safety of 0,1%, 0,5% and 1% TAZAROTENE nail lacquer formulation versus vehicle in nail psoriasis. International, multicenter, double-blind, randomized study of four parallel groups.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004825-87,0,0,0 2004-004826-28,1,2010-06-30,2010-06-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Instituto Científico y Tecnológico de Navarra,Multicenter double-blind placebo controlled aleatorized study to evaluate the efficacy and safety of bemiparin (3500 IU/day) in thromboprophylaxis in cancer paients with central vein catheter,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004826-28,0,0,0 2004-004829-97,1,2005-02-11,2005-02-11,1,0,0,1,1,3,1,0,1,1,0,0,0,0,1,Stiefel Laboratories Maidenhead Ltd (commonly known as Stiefel International R&D),96 HOUR HUMAN PATCH TEST FOR ASSESSMENT OF PRIMARY SKIN IRRITATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004829-97,0,0,0 2004-004830-15,1,2005-02-11,2005-02-11,1,0,0,1,0,3,1,0,1,1,0,0,0,0,1,Stiefel Laboratories Maidenhead Ltd (commonly known as Stiefel International R&D),Human Repeat Insult Patch Test with Challenge,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004830-15,0,0,0 2004-004831-76,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,non disponibile,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004831-76,0,0,0 2004-004835-72,1,2013-10-23,2013-10-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Birmingham,A study to determine the effects of growth hormone (GH) replacement therapy on quality of life and cardiovascualr risk in GH deficient adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004835-72,0,0,0 2004-004835-72,1,2013-10-23,2013-10-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital Birmingham Foundation NHS Trust,A study to determine the effects of growth hormone (GH) replacement therapy on quality of life and cardiovascualr risk in GH deficient adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004835-72,0,0,0 2004-004837-33,1,2005-10-05,2005-10-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,3,Pfizer Ltd,"A randomised, double-blind, parallel group trial to assess the variability and treatment effect size for a Neuropathic Pain offset design",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004837-33,0,0,0 2004-004845-17,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,PHASE II STUDY ON PACLITAXEL-GEMCITABINE IN RECURRENT OVARIAN CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004845-17,0,0,0 2004-004848-45,1,2012-12-01,2012-12-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Medizinische Universität Wien,HCV/HIV Coinfection- STUDY: MULTICENTER STUDY TO EVALUATE THE EFFICACY OF 48 WEEKS COMBINATION-THERAPY WITH PEGYLATED INTERFERON ALFA 2A (PEG-IFN ALFA 2A) AND DIFFERENT DOSES OF RIBAVIRIN IN PATIENT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004848-45,0,0,0 2004-004849-18,2,2012-01-31,2012-01-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Merck KGaA,"Cilengitide (EMD121974) and temozolomide with concomitant radiation therapy, followed by cilengitide and temozolomide maintenance therapy in subjects with newly diagnosed glioblastoma multiforme – a m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004849-18,0,0,0 2004-004852-38,1,2008-12-17,2008-12-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A randomized, open label, multicenter, parallel group study evaluating the efficacy and safety of 135 mcg and 90 mcg of Pegasys given as monotherapy to patients with chronic hepatitis C and end-stage ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004852-38,0,0,0 2004-004854-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Italfarmaco S.p.A.,"A randomized, double-blind, placebo-controlled, parallel group multicenter study to investigate efficacy and safety of ITF 2357 in the management of patients with active moderate to severe Crohn’s dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004854-19,0,0,0 2004-004857-24,1,2006-06-13,2006-06-13,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Pfizer Global Research and Development,"A Phase 1/2, Randomized, Masked, Single and Multiple-Dose, Sequential Dose-Escalation Study of the Safety and Efficacy of AG-013958 in Subjects with Subfoveal Choroidal Neovascularization Associated w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004857-24,0,0,0 2004-004862-33,1,2007-12-31,2007-12-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Berlin-Chemie Menarini,"INFLUENCE OF NEBIVOLOL ON OCULAR PERFUSION IN PATIENTS WITH ARTERIAL HYPERTENSION AND GLAUCOMA A mono-center, active-substance controlled, randomized, double-blind, prospective phase IV parallel-grou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004862-33,0,0,0 2004-004863-32,2,2009-03-31,2009-03-31,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Berlin-Chemie Menarini,EFFECTS OF NEBIVOLOL ON THE WALKING ABILITY IN PATIENTS WITH ESSENTIAL HYPERTENSION AND PERIPHERAL ARTERIAL DISEASE INTERMITTENT CLAUDICATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004863-32,0,0,0 2004-004864-54,1,2007-12-31,2007-12-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Berlin-Chemie Menarini,COMPARISON OF THE EFFECTS OF COMBINED RATE- AND RHYTHM-CONTROL TREATMENT WITH NEBIVOLOL AND ELECTRIC CARDIOVERSION TO RATE-CONTROL TREATMENT WITH NEBIVOLOL ALONE ON CLINICAL AND ECHOCARDIOGRAPHIC PARA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004864-54,0,0,0 2004-004865-14,1,2006-03-16,2006-03-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 2 x 5 weeks open label, multicenter, randomized cross-over study to compare the reduction of predialysis systolic blood pressure with valsartan (Diovan) 80 mg compared to irbesartan150 mg in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004865-14,0,0,0 2004-004867-31,6,2006-10-11,2008-03-31,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Eyetech Pharmaceuticals, Inc","A Phase 3B/4, randomized, active controlled, double-masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macugen®...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004867-31,0,0,0 2004-004867-31,6,2006-10-11,2008-03-31,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"(OSI) Eyetech Pharmaceuticals, Inc","A Phase 3B/4, randomized, active controlled, double-masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macugen®...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004867-31,0,0,0 2004-004867-31,6,2006-10-11,2008-03-31,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"A Phase 3B/4, randomized, active controlled, double-masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macugen®...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004867-31,0,0,0 2004-004868-69,2,2006-01-31,2006-01-31,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,ZLB Behring LLC,Study of Safety and Efficacy of Antihemophilic Factor / von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects with von Willebrand’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004868-69,0,0,0 2004-004874-96,1,2010-08-20,2010-08-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Newcastle Upon Tyne Hospitals NHS Trust,"Protocol: HL/IDP/PTS/001 Tumour Profiling In An Open-Labelled, 2-Arm Study Investigating The Tolerability And Efficacy Of Taxotere In Patients With High Risk Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004874-96,0,0,0 2004-004876-36,1,2008-06-01,2008-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Addenbrookes Hospital NHS Trust,AN INVESTIGATION INTO THE ROLE OF MATRIX METALLOPROTEINASES (MMP’s) IN LOWER LIMB VASCULAR RESTENOSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004876-36,0,0,0 2004-004880-31,1,2011-05-05,2011-05-05,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,German Breast Group Forschungs GmbH,A multicentre phase I-II study to investigate the combination of bendamustine with weekly paclitaxel as first or second line therapy in patients with metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004880-31,0,0,0 2004-004881-34,2,2005-05-20,2006-06-09,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo-Recherche,"A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve patients with type 2 dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004881-34,0,0,0 2004-004881-34,2,2005-05-20,2006-06-09,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve patients with type 2 dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004881-34,0,0,0 2004-004884-31,1,2007-07-01,2007-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Trust,"An open label, randomized pilot study evaluating the early conversion from calcineurin inhibitors to Rapamune in patients with impaired renal function following kidney transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004884-31,0,0,0 2004-004885-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Bio Minerals n.v.,Topical treatment of hand osteoarthritis with glucosamine cream.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004885-33,0,0,0 2004-004890-26,1,2006-04-26,2006-04-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,HULL AND EAST YORKSHIRE NHS TRUST,RANDOMISED CONTROLLED TRIAL OF SEDATION FOR COLONOSCOPY-ENTONOX VERSUS MIDAZOLAM/ FENTANYL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004890-26,0,0,0 2004-004891-36,1,2005-09-19,2005-09-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"CROSS-OVER COMPARISON OF TESTOSTERONE SERUM LEVELS IN HYPOGONADAL MEN TREATED WITH L0074 TESTOSTERONE PATCH 60CM2 (2 patches/48H) AND ORAL TESTOSTERONE UNDECANOATE -PANTESTONE® 40mg- (2 caps, bid)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004891-36,0,0,0 2004-004893-96,1,2010-10-01,2010-10-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Hammersmith Hospitals NHS trust,Randomised double-blind trial of combination antibiotic therapy in rheumatoid arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004893-96,0,0,0 2004-004899-36,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Mekos Laboratories,"Clinical evaluation of the 3 allergens: Methyldibromoglutharonitrile, Parthenolide and Goldsodiumthiosulphate for ""TRUE Test Panel 3"" - a phase II, dose-response study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004899-36,0,0,0 2004-004901-12,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,TEVA Pharma Belgium,Phase II randomized study of Combined Infusional Leucovorin Sodium and 5-FU Versus the Classical Sequential administration of Leucovorin Calcium followed by 5-FU both in combination with standard Iri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004901-12,0,0,0 2004-004903-39,1,2011-12-01,2011-12-01,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,The Walton Centre for Neurology and Neurosurgery,A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004903-39,0,0,0 2004-004904-19,1,2011-05-26,2011-05-26,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Christie Hospital,"A two-centre, open label study of weekly pegvisomant treatment for patients with acromegaly",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004904-19,0,0,0 2004-004905-11,2,2006-06-16,2006-10-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"Efficacy and safety of Symbicort® Turbuhaler® 160/4.5 µg/inhalation, two inhalations twice daily plus as-needed compared with Seretide™ Diskus™ 50/500 µg/inhalation, one inhalation twice daily plus te...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004905-11,0,0,0 2004-004907-39,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,AstraZeneca AB,"A Phase II, double-blind, randomized, cross-over, international, multicentre study to evaluate the analgesic efficacy of 3 weeks oral administration of AZD4282 300 mg b.i.d. compared with placebo in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004907-39,0,0,0 2004-004908-21,1,,,0,0,0,0,0,3,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase II, double-blind, randomized, cross-over, international, multicentre study to evaluate the analgesic efficacy of 3 weeks oral administration of AZD4282 300 mg b.i.d. compared with placebo in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004908-21,0,0,0 2004-004909-16,1,2007-05-31,2007-05-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"An International, Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™, single oral 300 mg or 600 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004909-16,0,0,0 2004-004914-18,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,A pilot multicentric study for the use of the anti-TNF alfa in patients with: 1) Fanconi Anemia with marrow failure with no bone marrow compatible donor 2) In patients with acquired aplastic anemia ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004914-18,0,0,0 2004-004917-41,9,2007-03-16,2010-03-25,6,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Aspreva Pharmaceuticals Corporation as part of the Roche-Aspreva Collaboration Agreement,"A prospective, randomized, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004917-41,0,0,0 2004-004917-41,9,2007-03-16,2010-03-25,6,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Aspreva International Ltd.,"A prospective, randomized, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004917-41,0,0,0 2004-004917-41,9,2007-03-16,2010-03-25,6,1,0,0,0,2,3,0,0,1,1,0,1,0,1,ASPREVA PHARMACEUTICALS CORPORATION,"A prospective, randomized, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004917-41,0,0,0 2004-004918-17,4,2006-07-17,2006-07-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004918-17,0,0,0 2004-004918-17,4,2006-07-17,2006-07-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc,"A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004918-17,0,0,0 2004-004918-17,4,2006-07-17,2006-07-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Limited,"A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004918-17,0,0,0 2004-004918-17,4,2006-07-17,2006-07-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004918-17,0,0,0 2004-004921-89,1,2006-04-06,2006-04-06,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,North Bristol NHS Trust,Improving diagnosis and treatment of attention deficits in head injured patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004921-89,0,0,0 2004-004924-11,1,2006-08-30,2006-08-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-Abelló A/S,"A multicentre, randomised, double-blind, placebo-controlled parallel group clinical trial to investigate the efficacy and safety of specific sublingual immunotherapy with SLIT One birch in patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004924-11,0,0,0 2004-004928-12,1,2008-06-02,2008-06-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INO Therapeutics AB,"A pilot, unicenter, prospective, aleatorized, with parallel groups, controlled and open to evaluate the efficacy of the Nitric Oxide for Inhalation in the prevention of reperfusion in pulmonary donor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004928-12,0,0,0 2004-004929-99,1,,,0,1,0,0,0,1,4,0,0,1,0,0,0,1,0,"Department of women's and Children's health, Uppsala University.","Cardiac effects of oxytocin administrated during cesarean section, signs of myocardial ischaemia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004929-99,0,0,0 2004-004933-32,1,,,0,1,0,0,0,3,4,0,0,1,0,0,0,1,1,"KRKA, d. d., Novo mesto",Efficacy and safety of Lorista and Lorista H in the treatment of mild to moderate arterial hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004933-32,0,0,0 2004-004947-23,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Efficacité de la rapamycine dans la prévention secondaire des cancers cutanés chez les transplantés rénaux. Etude ouverte randomisée Rapamycine vs anticalcineurines,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004947-23,0,0,0 2004-004947-23,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UF de méthodologie en recherche clinique,Efficacité de la rapamycine dans la prévention secondaire des cancers cutanés chez les transplantés rénaux. Etude ouverte randomisée Rapamycine vs anticalcineurines,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004947-23,0,0,0 2004-004948-45,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,José Hernández-Quero. Hospital Clínico San Cecilio,"Open, multicenter and randomized study phase IV to evaluate the efficacy and safety of 24 weeks more of treatment in patients with chronic hepatitis C genotype 1 and/or 4 co-infected with human inmmun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004948-45,0,0,0 2004-004952-38,1,2008-12-31,2008-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Prof John Yarnold, Institute of Cancer Research",Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for early breast cancer (HOT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004952-38,0,0,0 2004-004953-24,1,2005-11-15,2005-11-15,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Department of Anesthesiology, University Hospital Erlangen",A double-blind placebo-controlled two period crossover study of pregabalin and aprepitant in the electrical hyperalgesia model of central sensitisation in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004953-24,0,0,0 2004-004956-38,1,2012-01-19,2012-01-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Gerlinde Egerer (MD); Internal Medicine, Department V","Randomised, placebo controlled, single-center, double-blind clinical trial to investigate efficacy and safety of Aprepitant combined with Kevatril and Dexamethasone versus Placebo combined with Kevatr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004956-38,0,0,0 2004-004957-24,4,2008-12-18,2008-12-18,3,0,0,0,0,0,2,0,0,2,1,0,0,0,0,Fondazione Michelangelo,EUROPEAN COOPERATIVE STUDY OF PRIMARY SYSTEMIC THERAPY IN WOMEN WITH OPERABLE BREAST CANCER AND T < 2 CM STUDIO COOPERATIVO EUROPEO DI TERAPIA SISTEMICA PRIMARIA IN PAZIENTI CON CARCINOMA MAMMAR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004957-24,1,0,0 2004-004957-24,4,2008-12-18,2008-12-18,3,0,0,0,0,0,2,0,0,2,1,0,0,0,0,FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI,EUROPEAN COOPERATIVE STUDY OF PRIMARY SYSTEMIC THERAPY IN WOMEN WITH OPERABLE BREAST CANCER AND T < 2 CM STUDIO COOPERATIVO EUROPEO DI TERAPIA SISTEMICA PRIMARIA IN PAZIENTI CON CARCINOMA MAMMAR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004957-24,1,0,0 2004-004958-63,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"A two years extension to a one year multicenter, partially blinded double dummy randomized study to evaluate the efficacy and safety of FTY720 combined with reduced dose or full dose Neoral and cortic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004958-63,0,0,0 2004-004958-63,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"A two years extension to a one year multicenter, partially blinded double dummy randomized study to evaluate the efficacy and safety of FTY720 combined with reduced dose or full dose Neoral and cortic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004958-63,0,0,0 2004-004960-64,2,2007-01-24,2007-01-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,"A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004960-64,0,0,0 2004-004962-33,1,2005-11-15,2005-11-15,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Chiron S.r.l.,"A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization with Chiron Meningococcal C Conjugate Vaccine Menjugate® Administ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004962-33,0,0,0 2004-004963-32,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Univ. Prof. Dr. Markus Peck-Radosavljevic,Bevacizumab (Avastin®) as inhibitor of collateral tumor vessel growth during transarterial chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC): a pilot trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004963-32,0,0,0 2004-004966-34,5,2009-04-08,2009-04-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ORGANON ITALIA,"A Phase III, open-label trial to assess the non-immunogenicity and safety of Org 36286 in patients undergoing repeated controlled ovarian stimulation cycles using either a multiple dose GnRH antagonis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004966-34,0,0,0 2004-004966-34,5,2009-04-08,2009-04-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,"A Phase III, open-label trial to assess the non-immunogenicity and safety of Org 36286 in patients undergoing repeated controlled ovarian stimulation cycles using either a multiple dose GnRH antagonis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004966-34,0,0,0 2004-004967-30,4,2010-01-21,2010-01-21,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,Pregnancy and neonatal follow-up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 38825 for Org 36286 (corifollitropin alfa),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004967-30,0,0,0 2004-004974-94,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Santen Oy,"Efficacy and safety of tafluprost 0.0015% eye drops as adjunctive therapy with timolol 0.5% eye drops. A randomised, placebo-controlled, phase III study in patients with open-angle glaucoma or ocular ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004974-94,0,0,0 2004-004976-35,1,2006-08-29,2006-08-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"CV Therapeutics, Inc.","A Phase III, Randomized, Double-Blind Study of Intravenous CVT 3146 vs. Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004976-35,0,0,0 2004-004980-30,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,deCODE genetics ehf.,"A single-site, open-label, randomised dose finding study to examine safety, tolerability and dose-related effects of DG-031 on inflammatory biomarkers in serum of FLAP and/or LTA4 hydrolase haplotype ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004980-30,0,0,0 2004-004983-56,1,2008-07-08,2008-07-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hull and East Yorkshire Hospitals NHS Trust,A randomised placebo controlled trial of pre-operative statin use in elective abdominal aortic aneurysm repair to determine the effect on systemic and cellular responses of ischaemia reperfusion injur...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004983-56,0,0,0 2004-004983-56,1,2008-07-08,2008-07-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Hull,A randomised placebo controlled trial of pre-operative statin use in elective abdominal aortic aneurysm repair to determine the effect on systemic and cellular responses of ischaemia reperfusion injur...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004983-56,0,0,0 2004-004984-32,5,2006-08-16,2006-09-27,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major Depressiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004984-32,0,0,0 2004-004984-32,5,2006-08-16,2006-09-27,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXO SMITHKLINE,"A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major Depressiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004984-32,0,0,0 2004-004984-32,5,2006-08-16,2006-09-27,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects with Major Depressiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004984-32,0,0,0 2004-004988-30,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,Mater Misercordiae Hospital - Department of Anaesthesia,"PHARMACOKINETICS AND ANALGESIC EFFICACY OF LAEVOBUPIVACAINE, FENTANYL AND CLONIDINE FOR POSTOPERATIVE PARAVERTEBRAL ANAESTHESIA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004988-30,0,0,0 2004-004990-27,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,TIBOTEC PHARMACEUTICALS LTD.,"The pharmacokinetic interaction between TMC114, lopinavir and ritonavir, in HIV-1 infected subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004990-27,0,0,0 2004-004993-95,1,2005-11-01,2005-11-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,IDEA AG,"A double blind, placebo-controlled evaluation of dose realted safety and efficacy of epicutaneously applied IDEA-033 for 3 months treatment of osteoarthritis of the knee",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004993-95,0,0,0 2004-004995-35,6,2006-12-04,2007-01-18,6,0,0,0,2,0,2,0,0,1,0,0,1,0,1,"CombinatoRx, Inc.","A PHASE II MULTI-CENTER, RANDOMIZED, BLINDED STUDY OF 14 WEEKS DURATION COMPARING THE EFFECT OF CRx-139 PLUS DMARD THERAPY TO THAT OF STEROID PLUS DMARD THERAPY USING ACR-20 IN SUBJECTS WITH ACTIVE RH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004995-35,0,0,0 2004-004995-35,6,2006-12-04,2007-01-18,6,0,0,0,2,0,2,0,0,1,0,0,1,0,1,"COMBINATORX, INC","A PHASE II MULTI-CENTER, RANDOMIZED, BLINDED STUDY OF 14 WEEKS DURATION COMPARING THE EFFECT OF CRx-139 PLUS DMARD THERAPY TO THAT OF STEROID PLUS DMARD THERAPY USING ACR-20 IN SUBJECTS WITH ACTIVE RH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004995-35,0,0,0 2004-004996-12,6,2012-06-01,2012-06-01,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Allergan Limited,"A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Appli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004996-12,0,0,0 2004-004997-10,3,2012-05-29,2012-05-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALLERGAN Limited,"A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Appli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004997-10,0,0,0 2004-004997-10,3,2012-05-29,2012-05-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,"A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Appli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004997-10,0,0,0 2004-004999-36,1,2007-12-31,2007-12-31,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Berlin-Chemie AG,"Effects of Frovatriptan as Prophylactic Treatment of Cluster Headache, a Multi-Center, Placebo Controlled, Randomized, Double-Blind Prospective Phase III Parallel-Group Trial Comparing Frovatriptan wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-004999-36,0,0,0 2004-005001-29,1,2007-12-17,2007-12-17,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Zentaris GmbH,"Efficacy and safety of ozarelix acetate, a new GnRH antagonist in male patients with mild to moderate Alzheimer’s Disease (Regimen: 130 mg q4w, x3)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005001-29,0,0,0 2004-005002-68,2,2007-02-26,2007-02-26,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Amersham Health SA (Parte de GE Healthcare Ltd. y sus filiales),"A multicentre, randomised, double-blind, parallel group, phase IV study to compare the renal effects of the non-ionic iso-osmolar contrast medium iodixanol 320 mgI/mL Visipaque with the non-ionic lo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005002-68,0,0,0 2004-005002-68,2,2007-02-26,2007-02-26,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AMERSHAM HEALTH,"A multicentre, randomised, double-blind, parallel group, phase IV study to compare the renal effects of the non-ionic iso-osmolar contrast medium iodixanol 320 mgI/mL Visipaque with the non-ionic lo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005002-68,0,0,0 2004-005007-14,3,2014-03-31,2014-03-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Ltd,"A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) for Reduction of Oral Mucositis in Subjects With St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005007-14,0,0,0 2004-005007-14,3,2014-03-31,2014-03-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) for Reduction of Oral Mucositis in Subjects With St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005007-14,0,0,0 2004-005010-37,1,2008-08-18,2008-08-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Suffolk Mental Health Partnerships Trust,Enhancing cognition in bipolar disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005010-37,0,0,0 2004-005012-80,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Solvay Pharmaceuticals GmbH,"Double-blind, multicenter, randomized, placebo-controlled, parallel-group study to investigate the effect of Creon 25 000 Minimicrospheres on body mass index (BMI) in patients after gastrectomy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005012-80,0,0,0 2004-005013-11,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Umeå University Hospital,"A 36 wk three-center double-blind randomized three-way cross-over trial comparing metabolic effects of candesartan, hydrochlorothiazide and placebo. The MEDICA study Mechanisms for the diabetes-prev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005013-11,0,0,0 2004-005014-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,TOLLERANZA ED EFFICACIA DELL?a-TOCOFEROLO SUCCINATO NEL TRATTAMENTO DI PAZIENTI IN ETA? PEDIATRICA AFFETTI DA EPATITE CRONICA HBsAg POSITIVA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005014-36,0,0,0 2004-005015-29,1,2014-09-15,2014-09-15,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Les Laboratoires CTRS,"A multicenter double-blind randomized study to investigate the efficacy and tolerability of three doses of GS-101 eye drops, an antisense oligonucleotide, versus placebo on inhibition of corneal neova...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005015-29,0,0,0 2004-005016-93,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Vrinnevi Hospital,Oral immunoglobulin - a novel treatment of children with Crohn´s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005016-93,0,0,0 2004-005018-35,1,2007-06-06,2007-06-06,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Randomized, single-blind, multicentre study to compare the efficacy and safety of once daily 1 g mesalazine suppositories versus three times daily 0.5 g mesalazine suppositories in patients with acute...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005018-35,0,0,0 2004-005019-28,1,2007-09-28,2007-09-28,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,Papworth Hospital NHS Foundation Trust,Diabetes therapy to improve body mass index pulmoanry function in cystic fibrosis subjects with abnormal blood glucose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005019-28,0,0,0 2004-005020-41,1,2008-06-30,2008-06-30,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Heinrich Heine Universität Düsseldorf,Topische Anwendung von Tacrolimus (Protopic) bei verschiedenen Formen des kutanen Lupus erythe-matodes im Rahmen einer klinischen Untersuchung an mehreren nationalen Zentren,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005020-41,0,0,0 2004-005022-45,6,2006-02-03,2006-02-08,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,"A Multicenter, Randomized, Double-Blind, Placebo- And Active-Controlled Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated with Menopause",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005022-45,0,0,0 2004-005023-18,2,2006-04-30,2006-05-10,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Merck & Co., Inc","Study in Healthy Young Adults to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured by a Process Upgrade",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005023-18,0,0,0 2004-005023-18,2,2006-04-30,2006-05-10,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Suomen MSD Oy,"Study in Healthy Young Adults to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured by a Process Upgrade",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005023-18,0,0,0 2004-005023-18,2,2006-04-30,2006-05-10,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"Study in Healthy Young Adults to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured by a Process Upgrade",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005023-18,0,0,0 2004-005024-40,2,2005-02-17,2005-02-17,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LAMOTRIGINE 200-400MG/DAY COMPARED WITH PLACEBO IN SUBJECTS WITH PAINFUL DIABET...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005024-40,0,0,0 2004-005024-40,2,2005-02-17,2005-02-17,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LAMOTRIGINE 200-400MG/DAY COMPARED WITH PLACEBO IN SUBJECTS WITH PAINFUL DIABET...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005024-40,0,0,0 2004-005027-18,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,CONCURRENT RADIOCHEMIOTHERAPHY AND SURGERY IN NSCLC . A PHASE II MULTICENTRIC STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005027-18,0,0,0 2004-005028-42,1,,,0,1,0,0,0,1,3,0,0,1,1,1,0,1,1,Nycomed Danmark ApS,"A prospective, multi-centre, phase III-b study of TachoSil in paediatric patients scheduled for resection of the liver with or without segmental liver transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005028-42,0,0,0 2004-005032-35,8,2008-04-01,2008-04-01,6,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Alizyme Therapeutics Limited,"A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005032-35,1,0,0 2004-005032-35,8,2008-04-01,2008-04-01,6,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ALIZYME,"A Multicentre, Randomised, Double-Blind, Double-Dummy, Active Comparator Controlled, Parallel Group Study of COLAL PRED® in the Treatment of Moderate Acute Ulcerative Colitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005032-35,1,0,0 2004-005034-39,1,,,0,0,0,0,0,0,4,0,1,3,0,0,0,0,0,Queen Elizabeth Hospital,"Nicotinamide,vitamin B3, metabolic pathways in patients with early idiopathic parkinson's disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005034-39,0,0,0 2004-005035-26,1,2009-10-29,2009-10-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Anesthesiology Clinic,Akademiska Sjukhuset, Uppsala",Methadone in chronic non-cancer pain: rotation from other opioids and choice of dose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005035-26,0,0,0 2004-005037-19,5,2009-07-16,2009-07-17,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck & Co. Inc.,"Multicenter, Double Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of L-000900612 in Combination With an Optimized Back...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005037-19,0,0,0 2004-005037-19,5,2009-07-16,2009-07-17,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme,"Multicenter, Double Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of L-000900612 in Combination With an Optimized Back...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005037-19,0,0,0 2004-005037-19,5,2009-07-16,2009-07-17,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MSD ITALIA S.R.L.,"Multicenter, Double Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of L-000900612 in Combination With an Optimized Back...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005037-19,0,0,0 2004-005037-19,5,2009-07-16,2009-07-17,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Limited,"Multicenter, Double Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Antiretroviral Activity of L-000900612 in Combination With an Optimized Back...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005037-19,0,0,0 2004-005040-27,2,2007-07-25,2007-07-25,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Medarex, Inc.","An Open-Label, Phase II Extension Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease Previously Treated in Protocol MDX060-03",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005040-27,0,0,0 2004-005040-27,2,2007-07-25,2007-07-25,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb Company,"An Open-Label, Phase II Extension Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease Previously Treated in Protocol MDX060-03",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005040-27,0,0,0 2004-005041-35,1,2008-06-02,2008-06-02,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"University Hospital Basel, Dept. of Angiology","The effects of physical training, Aspirin, and Clopidogrel on the walking capacity of patients with stage II peripheral arterial disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005041-35,0,0,0 2004-005043-97,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,St Mary's NHS Trust,A Pilot study investigating the use of Intravitreal Triamcinolone prior to macular laser for Clinically Significant Diabetic Macular Oedema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005043-97,0,0,0 2004-005044-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Luis Miguel Ruilope Urioste,"COMPARATIVE, RANDOMIZED, OPEN, MULTICENTER TRIAL ASSESING THE EFFECT ON ALBUMIN EXCRETION RATE OF 320 MG. VALSARTAN (WITH OR WITHOUT HYDROCHLOROTHIAZIDE) vs. 40 MG. LISINOPRIL (WITH OR WITHOUT HYDROC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005044-27,0,0,0 2004-005045-35,1,2005-09-28,2005-09-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Sverige AB,"A multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug naïve patients with type 2 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005045-35,0,0,0 2004-005046-12,1,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,Ulster Community & Hospitals Trust,A double blind prospective randomised controlled trial to evaluate the effect of topical phenytoin on the healing of venous leg ulcers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005046-12,0,0,0 2004-005049-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",CAMPATH-1H MONOCLONAL ANTIBODY AS MANTEINANCE THERAPY AFTER FLUDARABINE AND CYCLOPHOSPHAMIDE COMBINATION REGIMEN AS 2ND LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005049-36,0,0,0 2004-005050-31,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,THE IMMUNE RESPONSE CORPORATION,A safety and Immunogenicity Study of IR103 HIV-1 Antigen plus Amplivax TM in IFA Comapared to Remune R HIV-1 antigen in IFA in Antiretroviral Naive HIV-1 Infected Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005050-31,0,0,0 2004-005051-34,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,LFB BIOTECHNOLOGIES,Efficacy and safety study of vWF SD-35-DH (WILFACTIN) in children under 6 years of age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005051-34,0,0,0 2004-005054-31,7,2007-09-12,2007-09-17,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Serono International S.A.,A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome pre-pubertal children treated with SAIZEN.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005054-31,0,0,0 2004-005054-31,7,2007-09-12,2007-09-17,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,INDUSTRIA FARMACEUTICA SERONO,A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome pre-pubertal children treated with SAIZEN.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005054-31,0,0,0 2004-005054-31,7,2007-09-12,2007-09-17,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SERONO INTERNATIONAL SA,A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome pre-pubertal children treated with SAIZEN.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005054-31,0,0,0 2004-005054-31,7,2007-09-12,2007-09-17,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Merck Serono International S.A.,A phase IV open-label study of predictive markers in Growth Hormone Deficient and Turner Syndrome pre-pubertal children treated with SAIZEN.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005054-31,0,0,0 2004-005055-33,1,2005-02-10,2005-02-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Barts and the London NHS Trust,"Evaluating the safety and efficacy of mycophenolate mofetil, daclizumab and a single, initial week of corticosteroids in combination with tacrolimus or sirolimus with continued steroid as mainstay imm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005055-33,0,0,0 2004-005058-30,2,2006-04-06,2006-04-06,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline R&D,"A randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 500µg of GW799943X administered once-daily in the morning, 500µg of GW799943X administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005058-30,0,0,0 2004-005058-30,2,2006-04-06,2006-04-06,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline R&D Limited,"A randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 500µg of GW799943X administered once-daily in the morning, 500µg of GW799943X administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005058-30,0,0,0 2004-005059-32,4,2009-08-27,2009-08-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Peptide Vaccine Monotherapy in HLA-A*0201-Positive Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005059-32,0,0,0 2004-005059-32,4,2009-08-27,2009-08-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Medarex, Inc.","A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Peptide Vaccine Monotherapy in HLA-A*0201-Positive Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005059-32,0,0,0 2004-005060-24,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Klinikum Leverkusen gGmbH,Comparison of Levobupivacaine and Ropivacaine for epidural application in obstetric gynaecology,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005060-24,0,0,0 2004-005068-26,2,2008-03-06,2008-03-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company limited,A Phase 2 Study of Oral Enzastaurin HCl in Patients with Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005068-26,0,0,0 2004-005069-39,6,2006-09-12,2006-11-10,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A double blind, randomised, multicenter, comparative study of escitalopram and duloxetine in outpatients with Major Depressive Dissorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005069-39,0,0,0 2004-005069-39,6,2006-09-12,2006-11-10,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,LUNDBECK ITALIA,"A double blind, randomised, multicenter, comparative study of escitalopram and duloxetine in outpatients with Major Depressive Dissorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005069-39,0,0,0 2004-005069-39,6,2006-09-12,2006-11-10,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,H.Lundbeck A/S,"A double blind, randomised, multicenter, comparative study of escitalopram and duloxetine in outpatients with Major Depressive Dissorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005069-39,0,0,0 2004-005071-42,2,2008-03-25,2008-03-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Limited,A study of the effect of conversion to Myfortic on quality of life in patients with gastrointestinal (GI) symptoms related to MMF therapy after renal transplantation (MYQOL).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005071-42,0,0,0 2004-005072-17,2,2006-02-06,2006-02-06,1,1,0,0,1,0,3,0,1,1,0,0,1,0,1,Intercell AG,PHASE 3 STUDY TO COMPARE A RAPID IMMUNIZATION REGIME WITH THE STANDARD REGIME FOR IC51 (JE-PIV) AS VACCINE FOR JAPANESE ENCEPHALITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005072-17,0,0,0 2004-005074-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Febena Pharma GmbH,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF AN OINTMENT FORMULATION CONTAINING DEXAMETHASONE IN PATIENTS WITH RHINOSINUSITIS A CLINICAL PHASE IV STU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005074-24,0,0,0 2004-005078-22,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Medical School of Hannover,"Quetiapin: Zur Sicherheit, Verträglichkeit und zum Einfluss auf kognitive Funktionen bei Patienten/innen mit einer schizophrenen Psychose Quetiapine: safety and influence on cognitive functions in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005078-22,0,0,0 2004-005079-40,2,2006-12-19,2006-12-19,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Bayer Consumer Care, Research & Development","Placebo and active controlled, double dummy phase II study to prove efficacy of Aspirin (1000 mg solid dose) in treatment of acute low back pain.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005079-40,0,0,0 2004-005083-25,1,2007-11-09,2007-11-09,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Gilead Sciences Incorporated,"A Phase IV, Randomized, Double-Blind, Placebo-Controlled Two-Phase Crossover Study of the Metabolic Impact of Tenofovir Disoproxil Fumarate on HIV 1 Seronegative Healthy Adult Males",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005083-25,0,0,0 2004-005085-21,1,2009-11-03,2009-11-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dermal Laboratories Limited,Scalp lotion for the treatment of pityriasis capitis (severe dandruff) and seborrhoeic dermatitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005085-21,0,0,0 2004-005087-24,1,2012-06-20,2012-06-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals of Leicester NHS Trust,CIMETIDINE IN THE TREATMENT OF CALCIFIC SUPRASPINATUS TENDINITIS- A TRIAL OF CIMETIDINE 200mg B.D IN THE RESOLUTION OF CALCIFICATION IN THE SUPRASINATUS TENDON.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005087-24,0,0,0 2004-005088-17,1,2008-04-30,2008-04-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Hungária Ltd.,"A multicenter, Open-label Study to Determine the Effect of I.V. Zometa on Pain and Quality of Life in Patients with Bone Metastases with or without Skeletal Related Events (SREs) Resulting from Breast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005088-17,0,0,0 2004-005091-16,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Helsinki University Hospital,"Comparison of vascular findings between symptomatic and asymptomatic postmenopausal women before and during hormone therapy: randomized, placebo-controlled prospective study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005091-16,0,0,0 2004-005093-24,4,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"Multicentre, open label, extension study of treatment with gefitinib (IRESSA) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005093-24,0,0,0 2004-005093-24,4,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,AstraZeneca Österreich GmbH,"Multicentre, open label, extension study of treatment with gefitinib (IRESSA) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005093-24,0,0,0 2004-005094-29,1,2010-01-15,2010-01-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ARIAD PHARMACEUTICALS,INC.","A Phase II Study of AP23573, a mTOR Inhibitor, in Female Adult Patients with Recurrent or Persistent Endometrial Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005094-29,0,0,0 2004-005095-17,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Engelhard Arzneimittel GmbH & Co. KG,"Randomised, double-blind, placebo-controlled, monocentric phase III study on the efficacy and safety of Lidocaine 8 mg Sore Throat Lozenges in patients with moderate to severe acute sore throat not ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005095-17,0,0,0 2004-005096-42,6,2006-06-08,2009-06-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,A phase II marker identification trial for Tarceva in second line NSCLC patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005096-42,0,0,0 2004-005096-42,6,2006-06-08,2009-06-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,A phase II marker identification trial for Tarceva in second line NSCLC patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005096-42,0,0,0 2004-005101-29,1,2016-05-23,2016-05-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,THE EFFICACY AND SAFETY OF LENALIDOMIDE (Revlimid®) MONOTHERAPY IN RED BLOOD CELL TRANSFUSION DEPENDENT SUBJECTS WITH MYELODYSPLASTIC SYNDROME ASSOCIATED WITH A DEL (5q) CYTOGENETIC ABNORMALITY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005101-29,0,0,0 2004-005101-29,1,2016-05-23,2016-05-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,King's College London,THE EFFICACY AND SAFETY OF LENALIDOMIDE (Revlimid®) MONOTHERAPY IN RED BLOOD CELL TRANSFUSION DEPENDENT SUBJECTS WITH MYELODYSPLASTIC SYNDROME ASSOCIATED WITH A DEL (5q) CYTOGENETIC ABNORMALITY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005101-29,0,0,0 2004-005102-68,7,2007-06-19,2009-08-11,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects with Active Rheumatoid Arthritis on Background Non-Biologic DMARDs W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005102-68,0,0,0 2004-005102-68,7,2007-06-19,2009-08-11,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects with Active Rheumatoid Arthritis on Background Non-Biologic DMARDs W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005102-68,0,0,0 2004-005103-16,1,,,0,0,0,0,0,3,4,0,1,0,0,0,0,0,0,Estonian Science Foundation,"Central serotonergic activity measured by citalopram challenge test and platelet monoamine oxidase activity, associations with gene polymorphism (5-HTTLPR) and impulsivity",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005103-16,0,0,0 2004-005106-79,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sigma Tau industrie Farmaceutiche Riunite Spa,Phase II study of gimatecan (ST 1481) as salvage treatment in patients with advanced breast cancer after anthracycline /taxanes-based chemotherapy regimen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005106-79,0,0,0 2004-005108-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO,RANDOMISED CONTROLLED STUDY ON EARLY RENSPONSE TO COMBINED ANTIVIRAL THERAPY IN CHRONIC H EPATITIS C PATIENTS GENOTIPE 2 AND 3 WITH HCV-RNA NEGATIVE WEEK 4,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005108-33,0,0,0 2004-005112-83,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO,RANDOMISED CONTROLLED STUDY ON EARLY RESPONSE TO COMBINED ANTIVIRAL THERAPY IN CHRONIC EPATITES C PATIENT GENOTIPE 1 AND 4 WITH HCV RNA NEGATIVE WEEK 6,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005112-83,0,0,0 2004-005115-29,2,2006-08-03,2006-08-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Ltd,"A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005115-29,0,0,0 2004-005115-29,2,2006-08-03,2006-08-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, placebo-controlled, parallel group single dose study of SB681323 in patients with active RA to investigate the CRP dose response relationship",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005115-29,0,0,0 2004-005118-35,1,2008-07-10,2008-07-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Ludwig Institute for Cancer Research,Randomized double-blind phase II trial of NY-ESO-1 ISCOMATRIX and ISCOMATRIXadjuvant alone in patients with resected stage III or IV malignant melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005118-35,0,0,0 2004-005119-27,5,2016-01-18,2016-01-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Inc.,"A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of Presumed Pre-core Mutant Chronic Hepatitis B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005119-27,0,0,0 2004-005119-27,5,2016-01-18,2016-01-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Incorporated,"A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of Presumed Pre-core Mutant Chronic Hepatitis B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005119-27,0,0,0 2004-005120-41,5,2016-01-28,2016-01-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Incorporated,"A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005120-41,0,0,0 2004-005120-41,5,2016-01-28,2016-01-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Inc.,"A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005120-41,0,0,0 2004-005122-45,1,2006-09-13,2006-09-13,1,1,0,0,0,3,2,0,0,1,0,0,1,0,1,AstraZeneca GmbH,"RACE : Rapid Dose Escalation of Quetiapine versus Conventional Escalation in the Treatment of Patients with Acute Schizophrenia – a Multicentre, Double-blind, Parallel group, Randomized Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005122-45,0,0,0 2004-005123-18,2,2005-11-22,2005-11-22,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline,"A phase III, partially blind, randomised, primary vaccination study to assess the immunogenicity and safety of three different lots of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005123-18,0,0,0 2004-005123-18,2,2005-11-22,2005-11-22,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, partially blind, randomised, primary vaccination study to assess the immunogenicity and safety of three different lots of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005123-18,0,0,0 2004-005124-40,1,2007-07-23,2007-07-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Leicester R&D,Efficacy of a short course of oral steroids for hospitalised preschool children with viral-induced wheeze; a randomised double-blind placebo-controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005124-40,0,0,0 2004-005127-17,1,,,0,0,0,0,0,3,2,0,1,1,0,0,0,1,1,pharmed holding GmbH,Potentiation of the antihyperalgesic effects of topically applied diclofenac by concomitant use of topical lidocaine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005127-17,0,0,0 2004-005135-26,1,2012-05-09,2012-05-09,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Pierre Fabre Médicament,ORAL VINORELBINE AND CISPLATIN WITH CONCOMITANT RADIOTHERAPY FOLLOWED BY EITHER CONSOLIDATION THERAPY WITH ORAL VINORELBINE AND CISPLATIN PLUS BEST SUPPORTIVE CARE OR BEST SUPPORTIVE CARE ALONE IN STA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005135-26,0,0,0 2004-005136-76,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Professor Christina Eintrei,Institution of Medical & Health, Section of Anesthesiology",Aspirin in noncardiac surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005136-76,0,0,0 2004-005138-38,1,2007-08-17,2007-08-17,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Hvidovre Hospital,Antibiotikaprofylakse ved vaginalplastik,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005138-38,0,0,0 2004-005142-12,1,2006-02-01,2006-02-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Limited,"An open-label study to evaluate the extended early bactericidal activity, safety, tolerability and pharmacokinetics of multiple doses (m.d.) of TMC207 oral solution (os) and isoniazid (JH), m.d. of TM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005142-12,0,0,0 2004-005147-10,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,KORPO S.R.L.,"Randomised controlled clinical trial to evaluate the efficacy of a sodium salicylate hydroglyceric solution used at different concentrations in the aesthetic and functional sclerotherapy of veins, ven...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005147-10,0,0,0 2004-005148-28,12,2008-11-12,2008-12-19,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Serono International S.A.,"A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005148-28,0,0,0 2004-005148-28,12,2008-11-12,2008-12-19,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Serono International, a branch of Laboratories Serono S.A.","A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005148-28,0,0,0 2004-005148-28,12,2008-11-12,2008-12-19,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Serono International S.A.,"A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005148-28,0,0,0 2004-005148-28,12,2008-11-12,2008-12-19,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Serono International, a branch of Laboratoires Serono S.A.","A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005148-28,0,0,0 2004-005148-28,12,2008-11-12,2008-12-19,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SERONO SA,"A phase III, randomised, double-blind, three-arm, placebo-controlled, multi-center study to evaluate the safety and efficacy of oral Cladribine in subjects with relapsing remitting multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005148-28,0,0,0 2004-005149-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Fundacion General Universidad de Valladolid,Estudio aleatorizado del efecto de la terapia con células madre hematopoyéticas sobre la neoangiogénesis y neomiogénesis del infarto agudo de miocardio reperfundido y la re-endotelización del stent co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005149-36,0,0,0 2004-005150-31,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,Chiron Behring GmbH & Co. KG,"A Phase IV, Multi-Center, Controlled, Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of Chiron Meningococcal C Conjugate Vaccine Menjugate® when Given as First, Third or Four...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005150-31,0,0,0 2004-005157-63,2,2006-02-09,2006-02-09,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ACTELION PHARMACEUTICALS ITALIA,"An open label multicenter study to assess the pharmacokinetic, tolerability and safety of a pediatric formulation of bosentan in children with idiopathic or familial pulmonary arterial hypertension i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005157-63,0,0,0 2004-005157-63,2,2006-02-09,2006-02-09,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"An open label multicenter study to assess the pharmacokinetic, tolerability and safety of a pediatric formulation of bosentan in children with idiopathic or familial pulmonary arterial hypertension i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005157-63,0,0,0 2004-005159-32,4,2006-09-18,2007-04-06,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Pharma GmbH,LINEZOLID VS VANCOMYCIN/CEFAZOLIN IN THE TREATMENT OF HEMODIALYSIS PATIENTS WITH CATHETER-RELATED GRAM-POSITIVE BLOODSTREAM INFECTIONS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005159-32,0,0,0 2004-005159-32,4,2006-09-18,2007-04-06,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Limited,LINEZOLID VS VANCOMYCIN/CEFAZOLIN IN THE TREATMENT OF HEMODIALYSIS PATIENTS WITH CATHETER-RELATED GRAM-POSITIVE BLOODSTREAM INFECTIONS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005159-32,0,0,0 2004-005159-32,4,2006-09-18,2007-04-06,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer, S.A",LINEZOLID VS VANCOMYCIN/CEFAZOLIN IN THE TREATMENT OF HEMODIALYSIS PATIENTS WITH CATHETER-RELATED GRAM-POSITIVE BLOODSTREAM INFECTIONS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005159-32,0,0,0 2004-005159-32,4,2006-09-18,2007-04-06,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PHARMACIA UPJOHN,LINEZOLID VS VANCOMYCIN/CEFAZOLIN IN THE TREATMENT OF HEMODIALYSIS PATIENTS WITH CATHETER-RELATED GRAM-POSITIVE BLOODSTREAM INFECTIONS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005159-32,0,0,0 2004-005164-25,1,2007-12-04,2007-12-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Odense University Hospital,Phase II study of thalidomide in combination with temozolomide in metastatic malignant melanoma with brain metastases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005164-25,0,0,0 2004-005166-20,1,2008-01-02,2008-01-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Odense University Hospital,Phase II study of first-line therapy with Thalidomide in combination with Peg-introna and decrescendo IL-2 in patients with metastatic malignant melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005166-20,0,0,0 2004-005169-39,4,2007-02-22,2007-02-22,3,1,0,0,1,0,4,0,0,1,0,0,1,0,1,AstraZeneca AB,A single-blind single arm study to validate the Reflux Disease Questionnaire (RDQ) for the diagnosis of reflux disease in primary care in patients treated with esomeprazole 40 mg o.d.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005169-39,0,0,0 2004-005172-17,1,2008-07-16,2008-07-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Charité/Campus Virchow-Klinikum, Medizinische Klinik m. S. Kardiologie",Renal haemodynamics during application of contrast media in patients undergoing cardiac catheterisation with high risk of acute renal failure: randomized comparison of different contrast media,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005172-17,0,0,0 2004-005173-27,5,2006-06-16,2007-12-05,3,1,0,0,1,0,3,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF A COMBINATION OF LEVONORGESTREL AND ETHINYL ESTRADIOL IN A CONTINUOUS DAILY REGIMEN IN SUBJECTS WITH PREMENSTRUAL DYSPHORIC DISORDE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005173-27,0,0,0 2004-005174-23,1,2006-11-20,2006-11-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Grampian,Is smooth muscle mitogenesis down regulated by platelet inactivation with combination antiplatelet therapy after angioplasty for claudication?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005174-23,0,0,0 2004-005181-20,8,2010-02-26,2010-03-02,8,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/resi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005181-20,0,0,0 2004-005181-20,8,2010-02-26,2010-03-02,8,1,0,0,0,2,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/resi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005181-20,0,0,0 2004-005181-20,8,2010-02-26,2010-03-02,8,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A","A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/resi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005181-20,0,0,0 2004-005181-20,8,2010-02-26,2010-03-02,8,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals Corporation,"A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/resi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005181-20,0,0,0 2004-005182-37,1,2006-10-20,2006-10-20,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Curatis Pharma GmbH,"A double-blind, randomized, placebo-controlled, multicenter phase III study of intravenous terlipressin in patients with hepatorenal syndrome type 1",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005182-37,0,0,0 2004-005184-15,1,2011-03-23,2011-03-23,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Christie Hospital NHS Trust,Central Hypothyroidism and Adjusted Thyroxine dose Study (CHATS): impact of increasing free thyroxine levels in patients with hypopituitarism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005184-15,0,0,0 2004-005187-24,4,2008-04-30,2008-04-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag Medical Affaires EMEA,"Randomized, open label, comparative parallel group study to assess efficacy and safety of flexible dosages of OROS hydromorphone once-daily compared to sustained release oxycodone twice-daily in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005187-24,0,0,0 2004-005187-24,4,2008-04-30,2008-04-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Cilag Medical Affairs EMEA,"Randomized, open label, comparative parallel group study to assess efficacy and safety of flexible dosages of OROS hydromorphone once-daily compared to sustained release oxycodone twice-daily in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005187-24,0,0,0 2004-005187-24,4,2008-04-30,2008-04-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG,"Randomized, open label, comparative parallel group study to assess efficacy and safety of flexible dosages of OROS hydromorphone once-daily compared to sustained release oxycodone twice-daily in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005187-24,0,0,0 2004-005188-12,1,2009-12-09,2009-12-09,1,1,0,0,0,3,4,0,0,1,0,0,1,0,0,University of Leeds,DENTAL TRAUMA: The effectiveness of an internet based computer database for data collection in a randomised controlled trail to evaluate immediate extirpation of necrotic pulp tissue and placement of ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005188-12,0,0,0 2004-005194-27,1,,,0,1,0,0,0,3,4,0,1,0,0,0,0,0,0,"Department of Neurology, Medical University of Vienna","Anti-inflammatory and/or antinociceptive effects of botulinum toxin A in an experimental inflammatory human skin pain model: a randomised, double blinded, placebo controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005194-27,0,0,0 2004-005197-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Klinik und Poliklinik für Augenheilkunde der Universität Regensburg,Funktionelle Ergebnisse der intravitrealen Injektion von Triamcinolonacetonid im Vergleich zur konventionellen Lasertherapie bei diabetischem Makulaödem.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005197-23,0,0,0 2004-005205-30,2,2010-12-09,2010-12-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Médicament,Randomised phase II study of the combination of oral vinorelbine with capecitabine versus a sequential regimen of oral vinorelbine and capecitabine versus the combination of docetaxel and capecitabine...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005205-30,0,0,0 2004-005205-30,2,2010-12-09,2010-12-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Medicament,Randomised phase II study of the combination of oral vinorelbine with capecitabine versus a sequential regimen of oral vinorelbine and capecitabine versus the combination of docetaxel and capecitabine...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005205-30,0,0,0 2004-005207-15,1,,,0,0,0,0,0,3,0,0,0,4,0,0,0,0,0,Region Skåne,Low dose muscle relaxant in intubation in children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005207-15,0,0,0 2004-005210-37,5,2007-01-31,2007-05-02,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann La-Roche AG,"A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005210-37,0,0,0 2004-005211-28,1,2006-08-12,2006-08-12,1,1,0,0,0,3,4,0,1,1,0,0,1,0,0,"Department of Anesthesiology, University Hospital of Erlangen",A double-blind placebo-controlled four period crossover study of paracetamol and tramadol in the electrical hyperalgesia model of central sensitisation in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005211-28,0,0,0 2004-005213-11,13,2005-02-07,2006-06-01,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A multi-centre, randomised, double-blind, parallel group study assessing the efficacy and safety of IV nesiritide versus placebo, in addition to background care, in the treatment of subjects with acut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005213-11,0,0,0 2004-005213-11,13,2005-02-07,2006-06-01,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"A multi-centre, randomised, double-blind, parallel group study assessing the efficacy and safety of IV nesiritide versus placebo, in addition to background care, in the treatment of subjects with acut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005213-11,0,0,0 2004-005213-11,13,2005-02-07,2006-06-01,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International,"A multi-centre, randomised, double-blind, parallel group study assessing the efficacy and safety of IV nesiritide versus placebo, in addition to background care, in the treatment of subjects with acut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005213-11,0,0,0 2004-005215-29,1,2008-06-04,2008-06-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,ADVENTRX Pharmaceuticals Inc,"A Multi-Center, Open Label, Parallel Group, Randomised, Phase IIB Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-FU versus Leucovorin and 5-FU in Subjects with Metastatic Colorec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005215-29,0,0,0 2004-005218-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Nordic Society of Gynecological Oncology (NSGO),A phase II study of management of the patients with locally advanced (FIGO III & IVa or stage II unfavorably located lesion) or relapsed vulvar carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005218-35,0,0,0 2004-005222-41,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,UHCW NHS Trust,Intrathecal Morphine for pain management in patients undergoing major abdominal surgery: The optimal dose?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005222-41,0,0,0 2004-005223-18,1,2011-02-17,2011-02-17,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Childrens´ Hospital Erlangen,"Evaluation of growth response in short children suffering from a disease with growth retardation and treated with Somatropin: A prospective, longitudinal non-randomised, open, phase II study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005223-18,0,0,0 2004-005234-39,8,2009-03-31,2009-03-31,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Orion Corporation, ORION PHARMA, 02200 Espoo, Finland","Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005234-39,0,0,0 2004-005234-39,8,2009-03-31,2009-03-31,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Orion Corporation, ORION PHARMA","Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005234-39,0,0,0 2004-005234-39,8,2009-03-31,2009-03-31,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Orion Corporation, ORION PHARMA, Finland","Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005234-39,0,0,0 2004-005238-37,1,2006-02-16,2006-02-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A single dose, placebo-controlled, randomized, double-blind, double-dummy, crossover efficacy, pharmacokinetics and safety comparison of salmeterol inhalation powder (25 µg salmeterol), administered a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005238-37,0,0,0 2004-005239-25,3,2007-08-28,2007-08-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Research,"An open-label, multicenter study evaluating the long-term safety and efficacy of SR121463B in patients with Syndrome of Inappropriate Antidiuretic Hormone Secretion.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005239-25,0,0,0 2004-005241-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ACROSS Group,"Phase II clinical trial of Cisplatin, Gemcitabine and Trastuzumab (Herceptin®) as first line treatment of advanced irresectable transitional-cell urothelial carcinoma with overexpression of C-erbB-2",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005241-36,0,0,0 2004-005243-97,3,2007-02-16,2007-02-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Long Term Extension Study to Evaluate the Safety and Tolerability of oral Tesaglitazar Therapy in Patients with Type 2 Diabetes Mellit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005243-97,0,0,0 2004-005244-28,1,2013-08-31,2013-08-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Universität Leipzig,Pilotstudie zur Therapieoptimierungsstudie für den Morbus Hodgkin bei Kindern und Jugendlichen Prüfung der Verträglichkeit der Chemotherapiekombination VECOPA bei Patienten der Therapiegruppen 2 und...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005244-28,0,0,0 2004-005247-10,2,2008-11-25,2008-12-03,2,0,0,1,0,2,1,0,0,1,0,0,0,0,0,FONDAZIONE SENDO,"PHASE I STUDIES OF TARCEVATM (ERLOTINIB HYDROCHLORIDE, OSI-774) AS SINGLE AGENT IN CHILDREN WITH REFRACTORY AND RELAPSED MALIGNANT BRAIN TUMORS AND IN COMBINATION WITH IRRADIATION IN NEWLY DIAGNOSED M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005247-10,0,0,0 2004-005247-10,2,2008-11-25,2008-12-03,2,0,0,1,0,2,1,0,0,1,0,0,0,0,0,The University Hospitals of Leicester NHS Trust,"PHASE I STUDIES OF TARCEVATM (ERLOTINIB HYDROCHLORIDE, OSI-774) AS SINGLE AGENT IN CHILDREN WITH REFRACTORY AND RELAPSED MALIGNANT BRAIN TUMORS AND IN COMBINATION WITH IRRADIATION IN NEWLY DIAGNOSED M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005247-10,0,0,0 2004-005250-31,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA PER I SERVIZI SANITARI 1 TRIESTINA,Oxaliplatin and vinorelbine in metastatic mammary carcinoma phase II trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005250-31,0,0,0 2004-005252-14,3,2006-11-28,2006-11-28,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,KAI Pharmaceuticals Incorporated,Direct Inhibition of δ Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI): Intracoronary KAI-9803 for Injection as an Adjunct to Primary Percutaneous Coronar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005252-14,0,0,0 2004-005259-32,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,Imperial College Heathcare NHS Trust,A phase 2 randomised trial to investigate the effects of recombinant human erythropoietin on infarct size in patients undergoing primary percutaneous coronary angiography for ST-segment elevation myoc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005259-32,0,0,0 2004-005261-38,1,2007-09-19,2007-09-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Genzyme Europe BV,"A Multicenter, Parallel, Double-Blind, Blinded Evaluator, Randomized Comparison of the Efficacy and Safety of an Alternate Viscosupplement (AVS-beta) to Methylprednisolone Acetate in Patients with Sym...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005261-38,0,0,0 2004-005262-20,1,,,0,1,0,0,1,0,4,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase IV, single-blinded, randomized, single centre study to demonstrate the non-inferiority of immunogenicity elicited by GSK Biologicals’ hepatitis B vaccine, Engerix-B in multidose presentation t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005262-20,0,0,0 2004-005263-19,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GSK Biologicals,"A phase III, blinded, randomised, controlled study to evaluate the immunogenicity and safety of three production lots of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella (MeMuRu-O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005263-19,0,0,0 2004-005267-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,A RANDOMIZED PHASE II PREVENTION TRIAL IN SUBJECTS AT HIGH RISK FOR HORMONE NON RESPONSIVE BREAST CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005267-21,0,0,0 2004-005271-42,1,2007-11-22,2007-11-22,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Dept. of Anaestesiology, University hospital in Glostrup",Effect of paracetamol versus paracetamol combined with pregabalin versus paracetamol combined with pregabalin and dexamethason on pain and opioid requirements in patients scheduled for abdominal hystr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005271-42,0,0,0 2004-005275-42,1,,,0,0,0,0,0,1,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA,Study on the effect of r-hGH in combination with bisphosphonate treatment on bone metabolism in Osteogenesis Imperfecta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005275-42,0,0,0 2004-005276-16,6,2010-11-12,2010-11-12,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Pharma Mar S.A.,An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL/CAELYX and YONDELIS with DOXIL/CAELYX alone in subjects with advanced relapsed ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005276-16,0,0,0 2004-005276-16,6,2010-11-12,2010-11-12,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,PHARMA MAR,An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL/CAELYX and YONDELIS with DOXIL/CAELYX alone in subjects with advanced relapsed ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005276-16,0,0,0 2004-005276-16,6,2010-11-12,2010-11-12,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Pharma Mar S.A. Sociedad Unipersonal,An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL/CAELYX and YONDELIS with DOXIL/CAELYX alone in subjects with advanced relapsed ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005276-16,0,0,0 2004-005282-37,1,2007-02-13,2007-02-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"QUIMICA FARMACEUTICA BAYER, S.A.","Double-blind, cross-over, placebo-controlled pilot study to characterize the profile of those patients with traumatic spinal cord injury diagnosed by electrophysiological, urodynamic and clinical (ASI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005282-37,0,0,0 2004-005285-20,3,2006-05-09,2006-05-09,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Almirall Prodesfarma, S.A.","Treatment of Acute Migraine when Pain is Mild versus when Pain is Moderate to Severe an Almotriptan Parallel, Placebo Controlled Clinical Trial. Act when mild",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005285-20,0,0,0 2004-005285-20,3,2006-05-09,2006-05-09,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ALMIRALL PRODESFARMA,"Treatment of Acute Migraine when Pain is Mild versus when Pain is Moderate to Severe an Almotriptan Parallel, Placebo Controlled Clinical Trial. Act when mild",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005285-20,0,0,0 2004-005287-24,1,2007-02-13,2007-02-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Univ.-Kl. f.Augenheilkunde und Optometrie Wien,"Effect of diclofenac-sodium, unpreserved diclofenac-sodium or ketorolac on the inflammatory response after cataract surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-005287-24,0,0,0 2005-000004-13,2,2008-09-02,2008-09-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SIGMA-TAU,EVALUATION OF ACETYL -L-CARNITINE ST 200 TO REDUCE INTENSITY OF TAXANES- OR PLATINUM-INDUCED SENSORY NEUROPATHY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000004-13,0,0,0 2005-000004-13,2,2008-09-02,2008-09-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sigma-Tau i.f.r. S.p.A.,EVALUATION OF ACETYL -L-CARNITINE ST 200 TO REDUCE INTENSITY OF TAXANES- OR PLATINUM-INDUCED SENSORY NEUROPATHY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000004-13,0,0,0 2005-000005-65,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Servicio de Infecciones. Hospital Clínic de Barcelona,"Comparación de dos alternativas de combinación de nucleósidos, en pacientes infectados por el HIV-1 con supresión virológica mantenida y en tratamiento con lamivudina (3TC). Estudio aleatorizado, mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000005-65,0,0,0 2005-000006-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"IVAX RESEARCH, INC.","A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, DOSE RANGING STUDY TO DETERMINE THE EFFICACY AND SAFETY OF AN INVESTIGATIONAL INTRANASAL CORTICOSTEROID COMPARED TO PLACEBO AND OPEN-LABEL FLUTICASONE PROPI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000006-32,0,0,0 2005-000012-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Department of Nephrology and Renal Transplantation,Pharmacokinetic interactions between probenecid and the combination mycophenolate mofetil - cyclosporine/tacrolimus in stable renal allograft recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000012-27,0,0,0 2005-000013-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Dr. Olivier F. Bertrand , Laval Hospital",A Multicenter Randomized Double-Blind Trial Comparing Rosiglitazone to Placebo for the Prevention of Atherosclerosis Progression after Coronary Bypass Surgery in Diabetic Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000013-36,0,0,0 2005-000015-10,1,2006-05-10,2006-05-10,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Discovery Laboratoryies, INC","A Randomized, Double-blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of Surfaxinâ (lucinactant), in Very Low Birth Weight (VLBW) Infants at Risk for Developing Bronchopulmonary Dyspl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000015-10,0,0,0 2005-000016-27,5,2006-10-06,2006-10-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Safety an efficacy of S 33138 versus risperidone in schizophrenic patients with predominant positive symptoms: A pilot phase IIa, international, multicentre, randomised, double-blind, parallel-group, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000016-27,0,0,0 2005-000016-27,5,2006-10-06,2006-10-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratorios Servier S.L. (For Spain only),"Safety an efficacy of S 33138 versus risperidone in schizophrenic patients with predominant positive symptoms: A pilot phase IIa, international, multicentre, randomised, double-blind, parallel-group, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000016-27,0,0,0 2005-000016-27,5,2006-10-06,2006-10-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Safety an efficacy of S 33138 versus risperidone in schizophrenic patients with predominant positive symptoms: A pilot phase IIa, international, multicentre, randomised, double-blind, parallel-group, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000016-27,0,0,0 2005-000016-27,5,2006-10-06,2006-10-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SERVIER Research and Development ICTR (For United Kingdom only),"Safety an efficacy of S 33138 versus risperidone in schizophrenic patients with predominant positive symptoms: A pilot phase IIa, international, multicentre, randomised, double-blind, parallel-group, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000016-27,0,0,0 2005-000021-32,3,2011-03-17,2011-03-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ELI LILLY,"A Randomized Phase 2 Trial of Doxorubicin plus Pemetrexed followed by Docetaxel, versus Doxorubicin plus Cyclophosphamide followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000021-32,0,0,0 2005-000021-32,3,2011-03-17,2011-03-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized Phase 2 Trial of Doxorubicin plus Pemetrexed followed by Docetaxel, versus Doxorubicin plus Cyclophosphamide followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000021-32,0,0,0 2005-000021-32,3,2011-03-17,2011-03-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,"A Randomized Phase 2 Trial of Doxorubicin plus Pemetrexed followed by Docetaxel, versus Doxorubicin plus Cyclophosphamide followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000021-32,0,0,0 2005-000025-35,3,2010-08-18,2010-08-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergopharma Joachim Ganzer KG,A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation of bi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000025-35,0,0,0 2005-000027-42,1,2008-05-20,2008-05-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,The effect of testosterone therapy on angina threshold and atheroma in patients with stable angina,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000027-42,0,0,0 2005-000028-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,DAVID DALMAU,"Eficacia virológica, inmunológica y trascendencia clínica del efecto de la lamivudina en pacientes portadores de la mutación M184V/I con fracaso terapéutico.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000028-17,0,0,0 2005-000039-73,2,2006-09-05,2006-09-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"An 8-week randomized, double-blind, parallel group, multi-center, placebo and active controlled dose escalation study to evaluate the efficacy and safety of aliskiren (150 mg and 300 mg) administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000039-73,0,0,0 2005-000039-73,2,2006-09-05,2006-09-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An 8-week randomized, double-blind, parallel group, multi-center, placebo and active controlled dose escalation study to evaluate the efficacy and safety of aliskiren (150 mg and 300 mg) administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000039-73,0,0,0 2005-000040-85,1,2008-01-31,2008-01-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Medical School Hannover,Erbitux Monotherapie bei Patienten mit lokoregional nicht behandelbarem Hepatozellulären Karzinom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000040-85,0,0,0 2005-000042-37,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,Novo Nordisk A/S,Norditropin Treatment in Subjects with Noonan Syndrome. Effects on Linear Growth and Final Height - Data Collection and Follow-up Visit,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000042-37,0,0,0 2005-000043-28,6,2008-09-12,2008-09-12,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase III Open label extension study of Eculizumab in patients with transfusion dependent hemolytic paroxysmal nocturnal hemoglobinuria PNH who have participated in Triumph C04-001 , Shepherd C0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000043-28,0,0,0 2005-000043-28,6,2008-09-12,2008-09-12,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ALEXION PHARMACEUTICALS INC,"A Phase III Open label extension study of Eculizumab in patients with transfusion dependent hemolytic paroxysmal nocturnal hemoglobinuria PNH who have participated in Triumph C04-001 , Shepherd C0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000043-28,0,0,0 2005-000048-10,1,2010-03-03,2010-03-03,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A 52-week, multi-center, randomized, double-blind, placebo-controlled, time-lagged, parallel group study in patients with mild to moderate Alzheimer's Disease (AD) to investigate the safety, tolerabil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000048-10,0,0,0 2005-000049-12,1,2006-07-20,2006-07-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Sheffield teaching Hospitals NHS Foundation Trust,The effects of testosterone therapy in men with pulmonary hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000049-12,0,0,0 2005-000051-15,4,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Streeet, New York, NY 10017","CONTINUING ACCESS TO THE TYROSINE KINASE INHIBITOR OF VEGFR-2, AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 IN CLINICAL TRIALS ACCESSO CONTINUO ALL'INIBITORE DELLA TIROSIN-CHINASI D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000051-15,0,0,0 2005-000051-15,4,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,PFIZER INC.,"CONTINUING ACCESS TO THE TYROSINE KINASE INHIBITOR OF VEGFR-2, AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 IN CLINICAL TRIALS ACCESSO CONTINUO ALL'INIBITORE DELLA TIROSIN-CHINASI D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000051-15,0,0,0 2005-000051-15,4,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,Pfizer Pharma GmbH,"CONTINUING ACCESS TO THE TYROSINE KINASE INHIBITOR OF VEGFR-2, AG-013736 (A406) FOR PATIENTS PREVIOUSLY RECEIVING AG-013736 IN CLINICAL TRIALS ACCESSO CONTINUO ALL'INIBITORE DELLA TIROSIN-CHINASI D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000051-15,0,0,0 2005-000053-30,5,2008-03-14,2008-03-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.",A RANDOMIZED PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH CHEMOTHERAPY-NAIVE ADVANCED PANCREATIC CANCER PRECEDED BY A PHASE 1 PORTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000053-30,0,0,0 2005-000053-30,5,2008-03-14,2008-03-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,A RANDOMIZED PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH CHEMOTHERAPY-NAIVE ADVANCED PANCREATIC CANCER PRECEDED BY A PHASE 1 PORTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000053-30,0,0,0 2005-000053-30,5,2008-03-14,2008-03-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc. - La Jolla laboratories,A RANDOMIZED PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH CHEMOTHERAPY-NAIVE ADVANCED PANCREATIC CANCER PRECEDED BY A PHASE 1 PORTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000053-30,0,0,0 2005-000053-30,5,2008-03-14,2008-03-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,A RANDOMIZED PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH CHEMOTHERAPY-NAIVE ADVANCED PANCREATIC CANCER PRECEDED BY A PHASE 1 PORTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000053-30,0,0,0 2005-000060-16,1,2006-07-15,2006-07-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Aerogen, Inc.","A Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Dose-Ranging Study of Nebulized Amikacin Delivered Via the Pulmonary Drug Delivery System (PDDS) in Patients With Ventilator-Associated Pneum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000060-16,0,0,0 2005-000063-25,1,2005-04-05,2005-04-05,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Axonyx Inc,"A 26 week double-blind extension to a 26 week randomised, double-blind placebo-controlled study that evaluated the safety and efficacy of two different doses of phenserine-tartrate in patients with pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000063-25,0,0,0 2005-000071-18,1,2006-05-02,2006-05-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical University, Dpt. Internal Medicin, Division of General Inteal Medicine",Pharmakokinetik von Teicoplanin bei kritisch Kranken während kontinuierlicher veno-venöser Hämofiltration und während Albumindialyse (Pharmacokinetics of teicoplanin in critically ill durining veno-v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000071-18,0,0,0 2005-000074-51,1,2009-06-25,2009-06-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GBG Forschungs GmbH,"A multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000074-51,0,0,0 2005-000077-22,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Institut de Recherches Internationales Servier,"Acceptability, safety, pharmacokinetics and effects on blood pressure of a daily dose of 0.025 to 0.135 milligram per kilogram of S 90652, a paediatric formulation of perindopril, in 2-16 years old hy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000077-22,0,0,0 2005-000077-22,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Acceptability, safety, pharmacokinetics and effects on blood pressure of a daily dose of 0.025 to 0.135 milligram per kilogram of S 90652, a paediatric formulation of perindopril, in 2-16 years old hy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000077-22,0,0,0 2005-000085-39,11,2008-05-28,2008-06-19,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Schering-Plough Research Institute,"An Open-Label, Randomized Efficacy and Safety Study of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000085-39,0,0,0 2005-000085-39,11,2008-05-28,2008-06-19,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHERING-PLOUGH,"An Open-Label, Randomized Efficacy and Safety Study of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000085-39,0,0,0 2005-000086-19,6,2008-10-19,2008-10-19,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Alcon Research, Ltd.",''An Open Label Evaluation of Long Term Efficacy and Safety of Posterior Justascleral Injections of Anecortave Acetate 15 mg in Patients with Subfoveal Exudative Age-Related Macular Degeneration (AMD)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000086-19,0,0,0 2005-000086-19,6,2008-10-19,2008-10-19,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Alcon Sverige AB,''An Open Label Evaluation of Long Term Efficacy and Safety of Posterior Justascleral Injections of Anecortave Acetate 15 mg in Patients with Subfoveal Exudative Age-Related Macular Degeneration (AMD)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000086-19,0,0,0 2005-000086-19,6,2008-10-19,2008-10-19,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Alcon Research Limited,''An Open Label Evaluation of Long Term Efficacy and Safety of Posterior Justascleral Injections of Anecortave Acetate 15 mg in Patients with Subfoveal Exudative Age-Related Macular Degeneration (AMD)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000086-19,0,0,0 2005-000086-19,6,2008-10-19,2008-10-19,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Alcon Research, Ltd",''An Open Label Evaluation of Long Term Efficacy and Safety of Posterior Justascleral Injections of Anecortave Acetate 15 mg in Patients with Subfoveal Exudative Age-Related Macular Degeneration (AMD)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000086-19,0,0,0 2005-000086-19,6,2008-10-19,2008-10-19,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Alcon Research LTD.,''An Open Label Evaluation of Long Term Efficacy and Safety of Posterior Justascleral Injections of Anecortave Acetate 15 mg in Patients with Subfoveal Exudative Age-Related Macular Degeneration (AMD)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000086-19,0,0,0 2005-000086-19,6,2008-10-19,2008-10-19,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ALCON ITALIA,''An Open Label Evaluation of Long Term Efficacy and Safety of Posterior Justascleral Injections of Anecortave Acetate 15 mg in Patients with Subfoveal Exudative Age-Related Macular Degeneration (AMD)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000086-19,0,0,0 2005-000087-12,2,2009-04-15,2011-07-15,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AMERSHAM HEALTH,"A multicentre, randomised, double-blind, parallel group, phase IV study to compare the renal effects of the non-ionic iso-osmolar contrast medium, iodixanol 320 mg I/mL VisipaqueTM , with the non-ion...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000087-12,0,0,0 2005-000087-12,2,2009-04-15,2011-07-15,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Amersham Health S.A. (parte de GE Healthcare Ltd y sus filiales),"A multicentre, randomised, double-blind, parallel group, phase IV study to compare the renal effects of the non-ionic iso-osmolar contrast medium, iodixanol 320 mg I/mL VisipaqueTM , with the non-ion...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000087-12,0,0,0 2005-000091-40,1,2007-11-02,2007-11-02,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,ApoPharma Inc.,Pivotal Study to Evaluate the Efficacy and Safety of Dermal - Living Skin Replacement (Dermal – LSR) in the Treatment of Chronic Diabetic Foot Ulcers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000091-40,0,0,0 2005-000093-50,7,2007-01-09,2007-01-25,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp and Dohme de España,"A Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000093-50,0,0,0 2005-000093-50,7,2007-01-09,2007-01-25,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000093-50,0,0,0 2005-000093-50,7,2007-01-09,2007-01-25,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000093-50,0,0,0 2005-000093-50,7,2007-01-09,2007-01-25,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000093-50,0,0,0 2005-000093-50,7,2007-01-09,2007-01-25,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme,"A Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000093-50,0,0,0 2005-000093-50,7,2007-01-09,2007-01-25,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme GesmbH,"A Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of the Addition of MK-0431 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000093-50,0,0,0 2005-000095-41,4,2009-10-20,2009-10-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co KG,A Multi-Centre Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Clinical Study with Adalimumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000095-41,0,0,0 2005-000100-14,3,2006-03-07,2006-03-07,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Intercell AG,"Safety and tolerability of the Japanese encephalitis vaccine IC51 (JE-PIV). Double blind, randomized, placebo controlled phase 3 study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000100-14,0,0,0 2005-000101-54,1,2008-12-31,2008-12-31,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,"University Hospitals Leicester, Leicester General Hospital","A randomized, observer-blind, dose-ranging, single-centre, study to evaluate the safety, tolerability and immunogenicity of adjuvanted and non-adjuvanted influenza A/Hong Kong/1073/99 (H9N2) vaccines,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000101-54,0,0,0 2005-000103-34,2,2007-01-31,2007-01-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Evaluation of the effects of 3 succesive oral dosages (2.5; 5; 7.5 mg b.i.d.) of ivabradine in patients with stable moderate to severe systolic chronic heart failure treated with beta-blockers A 9 we...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000103-34,0,0,0 2005-000103-34,2,2007-01-31,2007-01-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratorios Servier S.L. (For Spain only),Evaluation of the effects of 3 succesive oral dosages (2.5; 5; 7.5 mg b.i.d.) of ivabradine in patients with stable moderate to severe systolic chronic heart failure treated with beta-blockers A 9 we...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000103-34,0,0,0 2005-000103-34,2,2007-01-31,2007-01-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Evaluation of the effects of 3 succesive oral dosages (2.5; 5; 7.5 mg b.i.d.) of ivabradine in patients with stable moderate to severe systolic chronic heart failure treated with beta-blockers A 9 we...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000103-34,0,0,0 2005-000104-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Translational Oncology Research International,"A multicenter, placebo-controlled, double-blind randomised phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by six cycles of docetaxel, doxorubucin, and cyclo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000104-13,0,0,0 2005-000105-65,1,,,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,"Medical University of Vienna, Department of Internal Med. I, Division of Infectious Diseases",Comparative study of the efficacy and tolerance of intravenously administered azithromycin (1.5 g) given either as a single dose or over a 3 day period in patients with community-acquired pneumonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000105-65,0,0,0 2005-000106-31,1,2007-12-20,2007-12-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Liverpool University Hospital Clinical Trials 4th floor Linda McCartney Centre,"IMPACT OF CYP2D6, SEROTONIN TRANSPORTER, 5HT1, 5HT2 AND 5HT3 RECEPTOR AND MU RECEPTOR GENE POLYMORPHISMS ON EFFICACY AND TOXICITY OF TRAMADOL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000106-31,0,0,0 2005-000107-33,4,2006-03-23,2006-03-23,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios Dr. Esteve, S.A.","A 12-week multicentre, randomised, double-blind, parallel group, Phase II pilot study to evaluate the efficacy and safety of cizolirtine citrate 200 mg bid (400 mg/d), cizolirtine citrate 300 mg bid (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000107-33,0,0,0 2005-000108-15,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,"Institute of Psychiatry, Kings College London & South London and Maudsley NHS Trust","Pharmacokinetic and pharmacodynamic properties of oral, intramuscular and intravenous methadone in methadone maintenance patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000108-15,0,0,0 2005-000115-10,1,2008-01-09,2008-01-09,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Cardiff University,"A randomised, double blind, placebo-controlled, cross-over study of the effects of dehydroepiandrosterone replacement on vascular function in patients with primary and secondary adrenal insufficiency.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000115-10,0,0,0 2005-000117-34,4,2009-04-30,2009-04-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,The Nordic Colorectal Cancer Biomodulation Group,"5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin®) (FLOX regimen) given Continuously or intermittently in combination with cetuximab (Erbitux®), in First-Line Treatment of Metastatic Colorectal Cancer. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000117-34,0,0,0 2005-000120-17,1,2006-04-19,2006-04-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Alliance Pharmaceuticals Ltd,A double-blind placebo-controlled cross-over study to determine if melatonin can improve the length of day time sleep in subjects with transient misalignment of the sleep-wake cycle as a result of wor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000120-17,0,0,0 2005-000121-30,1,2013-08-02,2013-08-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE),"An Open Label Pilot study with oral fludarabine, oral cyclophosphamide and CAMPATH 1H (FCC) for patients with refractory or Relapsed B cells Chronic Lynphocytic Leukaemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000121-30,0,0,0 2005-000127-42,1,2009-12-31,2009-12-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Medical University of Vienna,Non Responder- STUDY: MULTICENTER STUDY TO EVALUATE THE EFFICACY OF SILYMARIN IN ADDITION TO COMBINATION-THERAPY WITH PEGYLATED INTERFERON ALFA 2A (PEG-IFN ALFA 2A) AND RIBAVIRIN IN PATIENTS WITH ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000127-42,0,0,0 2005-000129-47,1,2007-02-07,2007-02-07,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Dept. of Rhematology UMAS,The effect of Adalimumab (Humira) on vascular abnormalities in rheumatoid arthritis. A pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000129-47,0,0,0 2005-000137-37,1,2006-08-31,2006-08-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Helsinn Healthcare SA,"Single Dose, Randomized, Double-Blind, Parallel Group, Multicenter Study of Palonosetron 0.25 mg, 0.50 mg and 0.75 mg Administered by the Oral Route versus Palonosetron 0.25 mg IV for the Prevention o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000137-37,0,0,0 2005-000140-85,1,2007-03-20,2007-03-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BioGeneriX AG,"Efficacy and Safety of subcutaneous administration of XM01 and Epoetin beta for treatment of anaemia in chronic renal failure patients not yet receiving dialysis. A multinational, multicentre, randomi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000140-85,0,0,0 2005-000142-37,1,2007-05-10,2007-05-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BioGeneriX AG,Efficacy and Safety of subcutaneous administration of XM01 compared to Epoetin beta in anaemic chronic renal failure patients not yet receiving dialysis and in maintenance phase treatment with Epoetin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000142-37,0,0,0 2005-000144-87,1,2008-01-21,2008-01-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BioGeneriX AG,"Long-term efficacy and safety of subcutaneous administration of XM01 in chronic renal failure patients and comparison of once-weekly with three-times weekly administration of XM01 - A multinational, m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000144-87,0,0,0 2005-000146-36,3,2008-08-01,2008-08-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,Randomized Phase II open-label controlled study of EMD 72000 (matuzumab) in combination with the chemotherapy regimen ECX or the chemotherapy regimen ECX alone as first-line treatment in subjects with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000146-36,0,0,0 2005-000149-12,5,2005-12-01,2005-12-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Phase III, 12-week, Multicentre, Double-blind, Double-dummy, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group study to investigate the Efficacy and Safety of GW406381 1mg, 5mg, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000149-12,0,0,0 2005-000154-76,2,2007-06-25,2007-06-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,BioXell S.p.A.,"A randomized, double blind, double dummy, placebo controlled, parallel group study to determine the effect of BXL628 in monotherapy 75 mcg and 150 mcg and in combination 150 mcg with tamsulosin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000154-76,0,0,0 2005-000154-76,2,2007-06-25,2007-06-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,BIOXELL SPA,"A randomized, double blind, double dummy, placebo controlled, parallel group study to determine the effect of BXL628 in monotherapy 75 mcg and 150 mcg and in combination 150 mcg with tamsulosin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000154-76,0,0,0 2005-000158-61,12,2006-09-14,2006-09-14,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GLAXO SMITHKLINE,"A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000158-61,0,0,0 2005-000158-61,12,2006-09-14,2006-09-14,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000158-61,0,0,0 2005-000158-61,12,2006-09-14,2006-09-14,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline s.a.,"A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000158-61,0,0,0 2005-000162-40,2,2010-03-08,2010-03-08,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Helix Product Development (Ireland) Limited,"Treatment of genital warts with Interferon alpha-2b Cream: a randomized, double blind, placebo-controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000162-40,0,0,0 2005-000163-25,1,2011-07-11,2011-07-11,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Research and Enterprise, University of Birmingham",Proteomics and Pharmacokinetics of Adriamycin Following Different Techniques for Chemoembolisation of Hepatocellular Carcinoma (PPATCH) Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000163-25,0,0,0 2005-000170-40,1,2007-01-31,2007-01-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,EFFECT OF AN ORAL DOSE OF FERROUS SULFATE ON URINARY ESCRETION OF EPCIDINA IN PATIENTS AFFECTED BY EMOCROMATOSI.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000170-40,0,0,0 2005-000171-18,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,"A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000171-18,0,0,0 2005-000173-21,1,2007-06-30,2007-06-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Dieter Hoelzer, MD,PhD",A PHASE II CLINICAL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF DEPOCYTE® (CYTARABINE LIPOSOME INJECTION) FOR THE TREATMENT OF CNS RELAPSE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA OR HIGH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000173-21,0,0,0 2005-000174-52,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,ASSOCIAZIONE MALATTIE SANGUE,"Phase II multicenter study of immuno-chemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for symptomatic Waldenstrom's macroglobulinemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000174-52,0,0,0 2005-000175-17,1,2006-06-01,2006-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.",A pharmacokinetic study to assess Nevirapine levels in HIV-infected patients with impaired hepatic function.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000175-17,0,0,0 2005-000177-22,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,TRIGEN,"An open-label, multi-centre, Phase IIa study to evaluate the safety, tolerability, pharmacodynamic efficacy and dose-related pharmacokinetics of titrated doses of the intravenous thrombin inhibitor TR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000177-22,0,0,0 2005-000181-39,1,2007-06-19,2007-06-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Med. Universitaetsklinik Graz, ao Univ. Professor Dr. med. Thomas C. Wascher","A Prospective Trial of Anti-TNF-a Chimeric Monoclonal Antibody (infliximab, Remicade®) on Insulin Sensitivity, Beta Cell Function and Cardiovascular Risk Profile in Insulin Resistant Human Obesity",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000181-39,0,0,0 2005-000182-19,1,2008-06-04,2008-06-04,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Phönix Laboratorium GmbH,"Wirksamkeit und Verträglichkeit von Cholincitrat bei postoperativer Darmatonie nach laparotomischer linksseitiger Hemikolektomie, Sigmaresektion oder Rektumresektion ohne endständiges oder protektives...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000182-19,0,0,0 2005-000183-11,1,2006-03-31,2006-03-31,1,0,0,0,0,3,4,0,1,1,0,0,1,0,0,Medizinische Universitätsklinik,None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000183-11,0,0,0 2005-000184-25,8,2006-12-13,2006-12-15,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GLAXO SMITHKLINE,"A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release XR Tablets Compared with Ropinirole Immediate R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000184-25,0,0,0 2005-000184-25,8,2006-12-13,2006-12-15,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release XR Tablets Compared with Ropinirole Immediate R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000184-25,0,0,0 2005-000184-25,8,2006-12-13,2006-12-15,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A,"A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release XR Tablets Compared with Ropinirole Immediate R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000184-25,0,0,0 2005-000186-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION PETHEMA,"Estudio nacional, multicéntrico, abierto, de tratamiento de inducción con VELCADE y Dexametasona (VELCADEXA) en régimen alternante, previo a trasplante en pacientes menores de 65 años con mieloma múlt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000186-19,0,0,0 2005-000188-24,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Ichthyol-Gesellschaft Cordes, Hermanni & Co. (GmbH & Co.) KG","Multizentrische, prospektive, randomisierte, kontrollierte Observerblind-Studie zum Nachweis der Wirksamkeit und Verträglichkeit von 2 % Natriumbituminosulfonat, hell in einer auswaschbaren Creme-Grun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000188-24,0,0,0 2005-000192-17,1,2012-02-01,2012-02-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Barts & The London NHS Trust,Gemcitabine and Oxaliplatin in the treatment of locally advanced or metastatic transitional cell carcinoma of the urinary tract in patients with impaired renal function and patients who have progress...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000192-17,0,0,0 2005-000194-21,1,2010-05-04,2010-05-04,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,Effetti della L-argina nella profilassi della ipertensione cronica dal secondo trimestre di gravidanza,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000194-21,0,0,0 2005-000195-41,1,2006-07-04,2006-07-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Leeds Teaching Hospitals NHS Trust,To investigate the effect of methylprednisolone on inflammatory cytokines and urinary N-acetyl-beta-D-glucosaminidase/creatinine ratio in elective aortic aneurysm repair.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000195-41,0,0,0 2005-000200-14,1,2006-01-31,2006-01-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,North Bristol NHS Trust,"A randomised, double-blinded comparison of the effectiveness of intravenously administered Ketoralac versus Dexamethasone in the treatment of pain following surgical removal of third molar teeth under...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000200-14,0,0,0 2005-000203-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Enrique Ortega González,"Open, multicenter and randomized study phase IV to evaluate the efficacy and safety of 24 weeks versus 48 weeks of treatment in patients with chronic hepatitis C genotype II and/or III coinfected with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000203-34,0,0,0 2005-000204-13,5,2006-03-31,2006-05-09,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A double-blind, randomised, placebo-controlled, parallel-group, multicentre, phase II study to assess the efficacy of AZD7009 (AR-H065522XX) given intravenously (infusion for 15 or 30 minutes) to pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000204-13,0,0,0 2005-000206-31,3,2007-11-13,2009-10-13,3,1,0,0,0,1,3,0,0,1,0,0,1,0,2,"Laboratorios Dr. Esteve, S.A.","A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000206-31,0,0,0 2005-000206-31,3,2007-11-13,2009-10-13,3,1,0,0,0,1,3,0,0,1,0,0,1,0,2,Pharming Tecnologies B.V.,"A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000206-31,0,0,0 2005-000206-31,3,2007-11-13,2009-10-13,3,1,0,0,0,1,3,0,0,1,0,0,1,0,2,Pharming Technologies B.V.,"A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000206-31,0,0,0 2005-000206-31,3,2007-11-13,2009-10-13,3,1,0,0,0,1,3,0,0,1,0,0,1,0,2,PHARMING TECHNOLOGIES B.V.,"A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000206-31,0,0,0 2005-000211-99,1,2006-10-05,2006-10-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca A/S,Acutely Manic Patients Insufficiently Responding After 2 Weeks Continued Quetiapine Monotherapy: Continued Quetiapine Versus Sodium Valproate Add-on.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000211-99,0,0,0 2005-000213-35,5,2007-09-11,2017-07-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Swedish Orphan Biovitrum AB (publ.),"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000213-35,0,0,0 2005-000213-35,5,2007-09-11,2017-07-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN S.P.A.,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000213-35,0,0,0 2005-000213-35,5,2007-09-11,2017-07-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biovitrum AB (publ),"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000213-35,0,0,0 2005-000217-35,7,2016-12-31,2016-12-31,1,0,0,0,0,2,0,0,0,2,0,0,0,0,0,University of Birmingham,EpSSG RMS 2005 a protocol for non metastatic rhabdomyosarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000217-35,1,0,0 2005-000217-35,7,2016-12-31,2016-12-31,1,0,0,0,0,2,0,0,0,2,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,EpSSG RMS 2005 a protocol for non metastatic rhabdomyosarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000217-35,1,0,0 2005-000217-35,7,2016-12-31,2016-12-31,1,0,0,0,0,2,0,0,0,2,0,0,0,0,0,Academic Medical Center,EpSSG RMS 2005 a protocol for non metastatic rhabdomyosarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000217-35,1,0,0 2005-000217-35,7,2016-12-31,2016-12-31,1,0,0,0,0,2,0,0,0,2,0,0,0,0,0,Dr Jose Sanchez de Toledo Codina,EpSSG RMS 2005 a protocol for non metastatic rhabdomyosarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000217-35,1,0,0 2005-000217-35,7,2016-12-31,2016-12-31,1,0,0,0,0,2,0,0,0,2,0,0,0,0,0,Rikshospitalet-Radiumhospitalet HF,EpSSG RMS 2005 a protocol for non metastatic rhabdomyosarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000217-35,1,0,0 2005-000217-35,7,2016-12-31,2016-12-31,1,0,0,0,0,2,0,0,0,2,0,0,0,0,0,Hôpital Universitaire Des Enfants Reine Fabiola (H.U.D.E.R.F.),EpSSG RMS 2005 a protocol for non metastatic rhabdomyosarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000217-35,1,0,0 2005-000217-35,7,2016-12-31,2016-12-31,1,0,0,0,0,2,0,0,0,2,0,0,0,0,0,Children's Health Ireland at Crumlin,EpSSG RMS 2005 a protocol for non metastatic rhabdomyosarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000217-35,1,0,0 2005-000222-22,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,OLV-ziekenhuis,Prospective Open Single-Centre Study on the Effect of Initiation of RAD and CNI minimalisation on renal function in heart transplant patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000222-22,0,0,0 2005-000223-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University Hospital Hamburg-Eppendorf, Psychiatry",Effects of ziprasidone vs. placebo during the first four weeks of eight weeks sertraline treatment in patients with posttraumatic stress disorder (PTSD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000223-42,0,0,0 2005-000229-51,1,2005-11-11,2005-11-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 1-week, multi-center, randomized, double-blind, double-dummy, active-controlled, parallel trial of lumiracoxib (400 mg od) in patients with acute flares of gout, using indomethacin (50 mg tid) as a ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000229-51,0,0,0 2005-000240-82,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,AESCA Pharma GesmbH,"Randomized, controlled Study of Methadone and Buprenrphine in Hepatitis C patients in need of treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000240-82,0,0,0 2005-000244-90,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,ALMIRALL PRODESFARMA,"A randomized, prospective, cross-over, double blind, placebo-controlled multicentre study to assess the efficacy and tolerability of almotriptan 12.5 mg in the mild pain phase of Mestrual Migraine fol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000244-90,0,0,0 2005-000253-29,3,2006-03-07,2011-03-25,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Intercell AG,LONG TERM IMMUNOGENICITY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (JE-PIV). AN UNCONTROLLED PHASE 3 FOLLOW-UP STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000253-29,0,0,0 2005-000258-64,1,2008-02-13,2008-02-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca AB,"SCORE An open, randomised, parallel, three treatment groups, multicentre, phase IV study - in real life - to compare the change in social outcome of quetiapine fumarate (Seroquel®) combined with Cogni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000258-64,0,0,0 2005-000260-57,1,2008-02-27,2008-02-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai GmbH,Randomized trial to assess efficacy and safety of an add-on treatment with zonisamide in adults with focal epileptic seizures with or without secondary generalization,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000260-57,0,0,0 2005-000267-26,1,,,0,0,0,0,1,3,4,0,0,0,0,0,0,0,1,"LABORATORIOS CASEN-FLEET,S.L.",ESTUDIO COMPARATIVO DE EFICACIA Y SEGURIDAD DE FOSFOSODA R FRENTE A SOLUCIÓN EVACUANTE BOHM R COMO TRATAMIENTO EVACUANTE PREVIO A CIRUGÍA DIGESTIVA O EXPLORACIÓN COLÓNICA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000267-26,0,0,0 2005-000276-40,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,GENERICS [UK] Ltd.,"A RANDOMISED, OPEN TWO WAY CROSS-OVER STUDY TO ASSESS THE BRONCHODILATING PROPERTIES OF A NEW SALBUTAMOL-HFA 134a FORMULATION GIVEN AS CUMULATIVE DOSES AND A REFERENCE SALBUTAMOL-HFA 134a FORMULATION...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000276-40,0,0,0 2005-000279-16,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Sahlgrenska University Hospital,Phase III Clinical Study of Allogeneic Stem Cell Transplantation with Reduced Conditioning (RICT) versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000279-16,0,0,0 2005-000285-39,1,2012-11-02,2012-11-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"Randomized Phase II Trial Testing the Efficacy of Three Bevacizumab-Containing First-Line Regimens for Metastatic Colorectal Cancer. Studio multicentrico, randomizzato di fase II, di valutazione de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000285-39,0,0,0 2005-000286-19,1,2008-04-22,2008-04-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000286-19,0,0,0 2005-000289-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Organisation name was not entered,N-acetylcystein til gravide med præeklampsi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000289-38,0,0,0 2005-000290-22,1,,,0,0,0,0,0,3,4,0,1,0,0,0,0,0,0,TÜ Kardioloogiakliinik,"Endoteeli funktsiooni hindamiskompleksi (pulsilaine analüüs, koronarograafia, immunohistokeemilised meetodid, biomarkerid) teaduslik väljatöötamine ja juurutamine kliinilises praktikas",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000290-22,0,0,0 2005-000292-17,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,OSPEDALE POLICLINICO S. MATTEO,A randomized study on the use of thalidomide administered either in a continually route or in cycles in association with high dose dexamethasone in patients with refractory or relapsed multiple myelom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000292-17,0,0,0 2005-000295-41,1,2010-04-07,2010-04-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Universität zu Köln,"Double-blind,placebo-controlled cross-over study for evaluation of the efficacy of the PDE-5-inhibitor vardenafil on the peripheral perfusion and the clinical symptomatology of patients with Raynaud´s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000295-41,0,0,0 2005-000298-23,2,2006-05-03,2006-05-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Helsinn Healthcare SA,"A Randomized, Double-blind, Multicenter, Parallel Group, Balanced, Stratified Phase 3 Study to Evaluate the Efficacy and the Safety of Single IV Doses of Palonosetron 0.025 mg, 0.050 mg, and 0.075 mg ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000298-23,0,0,0 2005-000302-31,1,2008-02-02,2008-02-02,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,"NHS Lanarkshire, Primary Care Operating Division","TOLERANCE OF MILK FEEDS IN PRETERM, VERY LOW BIRTH WEIGHT BABIES: THE USE OF GLYCERINE SUPPOSITORIES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000302-31,0,0,0 2005-000307-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sogaisida,Control y seguimiento de pacientes infectados por VIH-1 en tratamiento antirretroviral y en programa de mantenimiento con metadona,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000307-33,0,0,0 2005-000309-75,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,"Christian Geisler, Righospitalet, dept. Haematology 4042",A randomized phase III study in previously untreated patients with biological high-risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000309-75,0,0,0 2005-000309-75,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,HOVON CLL Group,A randomized phase III study in previously untreated patients with biological high-risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000309-75,0,0,0 2005-000309-75,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,"Christian Geisler, Rigshospitalet, dept. Haematology 4042",A randomized phase III study in previously untreated patients with biological high-risk CLL: Fludarabine + cyclophosphamide (FC) versus FC + low-dose alemtuzumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000309-75,0,0,0 2005-000311-98,1,2007-12-01,2007-12-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Nottingham,A randomised controlled trial (pilot study) of the use of macerated garlic oil in patients with cystic fibrosis who have pulmonary infection with Pseudomonas aeruginosa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000311-98,0,0,0 2005-000313-35,1,2007-01-08,2007-01-08,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Aerovance Inc,"A Phase I/II Study to Investigate the Efficacy and Safety of AER 002 in Cystic Fibrosis Given at 3 mg, 10 mg, and 30 mg Doses in Single then Multiple Ascending Doses and to Determine Efficacy of the H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000313-35,0,0,0 2005-000314-12,2,2005-05-30,2007-07-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Effect of 3 doses ( 20, 40 and 60 mg) of a sublingual formulation of piribedil ( S 90049) in combination with levodopa on end-of-dose fluctuations in advanced Parkinson's disease patients after a 14 d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000314-12,0,0,0 2005-000317-35,1,2007-01-02,2007-01-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A double-blind, randomized Phase II study to determine efficacy and safety of oral treatment with BIBF 1120 ES 250 mg twice daily versus 150 mg twice daily in patients suffering from advanced non-smal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000317-35,0,0,0 2005-000319-87,1,2006-11-20,2006-11-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novo Nordisk Pharma GmbH,"A 52 week, Open Labelled, Randomised multi-centre 2 Arm Parallel Group Trial comparing Efficacy and Safety of Insulin Aspart, given in a Fixed Dose Regimen or in a Flexible Regimen, with or without In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000319-87,0,0,0 2005-000326-24,2,2008-04-08,2008-04-08,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,INO Therapeutics,The Effects of Nitric Oxide for Inhalation during Left Ventricular Assist Device (LVAD) Implantation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000326-24,0,0,0 2005-000329-52,1,2012-06-27,2012-06-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's & St Thomas' NHS Foundation Trust,Safety Study of Sequential and Synchronous ChemoRadiation and Cetuximab (Erbitux) in Patients with Stage III Non Small Cell Lung Cancer. SCRATCH Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000329-52,0,0,0 2005-000331-14,1,2012-12-31,2012-12-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,All Ireland Cooperative Oncology Research Group,"A phase III clinical trial comparing infusional 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (mFOLFOX -6) every 2 weeks with Bevacizumab to the same regimen without Bevacizumab for the treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000331-14,0,0,0 2005-000333-38,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Organisation name was not entered,A randomized placebo-controlled trial to investigate blood pressure lowering effects of folic acid in patients with borderline hypertension.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000333-38,0,0,0 2005-000336-25,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ROCHE,"Longitudinal analysis of HBV-specific T cell responses in patients with HBeAg-negative chronic hepatitis B (CHB) treated with pegylated interferon alfa-2a (40 KD) (PEGASYS, Ro 25-8310). Immunolog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000336-25,0,0,0 2005-000341-11,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Solvay Pharmaceuticqals B.V.,"Immunogenicity and reactogenicity of the trivalent virosomal influenza vaccine Invivac® for the season 2005/2006. An open, baseline controlled study in two groups of healthy subjects: adult subjects a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000341-11,0,0,0 2005-000343-28,4,2006-11-01,2006-11-26,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Aspreva Pharmaceutical Corporation,"An optional continuation of double-blind treatment for subjects who have achieved good symptom control with stable prednisone dosing and who have completed Protocol WX17798 A prospective, randomized,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000343-28,0,0,0 2005-000343-28,4,2006-11-01,2006-11-26,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Aspreva Pharmaceuticals Corporation,"An optional continuation of double-blind treatment for subjects who have achieved good symptom control with stable prednisone dosing and who have completed Protocol WX17798 A prospective, randomized,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000343-28,0,0,0 2005-000343-28,4,2006-11-01,2006-11-26,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ASPREVA PHARMACEUTICALS CORPORATION,"An optional continuation of double-blind treatment for subjects who have achieved good symptom control with stable prednisone dosing and who have completed Protocol WX17798 A prospective, randomized,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000343-28,0,0,0 2005-000343-28,4,2006-11-01,2006-11-26,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"An optional continuation of double-blind treatment for subjects who have achieved good symptom control with stable prednisone dosing and who have completed Protocol WX17798 A prospective, randomized,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000343-28,0,0,0 2005-000346-36,11,2009-06-07,2010-06-07,2,0,0,0,0,1,3,0,0,1,1,0,1,0,1,BioPartners GmbH,"A Phase III, Multi-centre, Randomised, Parallel Group Study of Safety and Efficacy of LB03002, a New Sustained Release Formulation of Human Recombinant Growth Hormone as Compared to Standard Daily The...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000346-36,0,0,0 2005-000346-36,11,2009-06-07,2010-06-07,2,0,0,0,0,1,3,0,0,1,1,0,1,0,1,LG Life Science Ltd.,"A Phase III, Multi-centre, Randomised, Parallel Group Study of Safety and Efficacy of LB03002, a New Sustained Release Formulation of Human Recombinant Growth Hormone as Compared to Standard Daily The...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000346-36,0,0,0 2005-000346-36,11,2009-06-07,2010-06-07,2,0,0,0,0,1,3,0,0,1,1,0,1,0,1,BIOPARTNERS GMBH,"A Phase III, Multi-centre, Randomised, Parallel Group Study of Safety and Efficacy of LB03002, a New Sustained Release Formulation of Human Recombinant Growth Hormone as Compared to Standard Daily The...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000346-36,0,0,0 2005-000347-29,6,2010-06-16,2010-06-16,3,1,0,0,0,1,4,0,0,1,0,0,1,0,1,BAXTER AG,"ADVATE ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN FREE METHOD (ADVATE rAHF PFM): A PHASE 4 STUDY COMPARING TWO PROPHYLACTIC REGIMENS IN SUBJECTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000347-29,0,0,0 2005-000347-29,6,2010-06-16,2010-06-16,3,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Baxter AG,"ADVATE ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN FREE METHOD (ADVATE rAHF PFM): A PHASE 4 STUDY COMPARING TWO PROPHYLACTIC REGIMENS IN SUBJECTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000347-29,0,0,0 2005-000347-29,6,2010-06-16,2010-06-16,3,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,"ADVATE ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN FREE METHOD (ADVATE rAHF PFM): A PHASE 4 STUDY COMPARING TWO PROPHYLACTIC REGIMENS IN SUBJECTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000347-29,0,0,0 2005-000350-69,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Novartis Pharma Services AG,"A two-year extension to a one-year, multicenter, open-label, randomized study to evaluate the safety and efficacy of FTY720 combined with tacrolimus and steroids versus MMF (Cellcept) combined with ta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000350-69,0,0,0 2005-000355-15,1,2016-03-10,2016-03-10,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Martin-Luther-Universität Halle-Wittenberg,Phase I/II-study of hyperfractionated-accelerated radiation therapy (HART) plus cetuximab (CET) plus cisplatin (CIS) chemotherapy in locally advanced inoperable squamous cell cancers of head and neck.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000355-15,0,0,0 2005-000358-65,5,2007-01-03,2007-01-03,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,UCB PHARMA,"A multicentre, double-blind, two parallel groups, randomized trial over four weeks of treatment to compare the clinical efficacy and safety of Levocetirizine 5 mg oral capsules once daily in the morn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000358-65,0,0,0 2005-000358-65,5,2007-01-03,2007-01-03,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"A multicentre, double-blind, two parallel groups, randomized trial over four weeks of treatment to compare the clinical efficacy and safety of Levocetirizine 5 mg oral capsules once daily in the morn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000358-65,0,0,0 2005-000358-65,5,2007-01-03,2007-01-03,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,UCB S.A. Pharma Sector,"A multicentre, double-blind, two parallel groups, randomized trial over four weeks of treatment to compare the clinical efficacy and safety of Levocetirizine 5 mg oral capsules once daily in the morn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000358-65,0,0,0 2005-000358-65,5,2007-01-03,2007-01-03,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,UCB S.A.,"A multicentre, double-blind, two parallel groups, randomized trial over four weeks of treatment to compare the clinical efficacy and safety of Levocetirizine 5 mg oral capsules once daily in the morn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000358-65,0,0,0 2005-000359-13,1,2013-08-12,2013-08-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche (Magyarország) Kft,"Hungarian Study of Maintenance after Rituximab Pretreatment. A multicentre, phase III, open-label study evaluating the benefit of a long-term MabThera® (rituximab) maintenance therapy in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000359-13,0,0,0 2005-000360-45,2,2006-01-31,2006-01-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,PFIZER,"A MULTICENTER, PARALLEL GROUP FLEXIBLE DOSE STUDY WITH A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED PHASE AND AN OPEN-LABEL PHASE TO EVALUATE THE QUALITY OF ERECTIONS IN MEN WITH ERECTILE DYSFUNCT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000360-45,0,0,0 2005-000360-45,2,2006-01-31,2006-01-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A MULTICENTER, PARALLEL GROUP FLEXIBLE DOSE STUDY WITH A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED PHASE AND AN OPEN-LABEL PHASE TO EVALUATE THE QUALITY OF ERECTIONS IN MEN WITH ERECTILE DYSFUNCT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000360-45,0,0,0 2005-000361-19,1,2006-11-16,2006-11-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label, one-period, one-treatment study which objective is to evaluate the time course of the antiproteinuric and blood pressure lowering effect of renin inhibition with Aliskiren in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000361-19,0,0,0 2005-000362-39,1,2008-03-06,2008-03-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, parallel-group, cross-over, 4-period, 4 treatment, within-subject placebo-controlled study to assess the renoprotective effect of renin inhibition with Aliskiren as an alte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000362-39,0,0,0 2005-000365-19,11,2009-07-29,2009-07-29,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000365-19,0,0,0 2005-000365-19,11,2009-07-29,2009-07-29,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000365-19,0,0,0 2005-000365-19,11,2009-07-29,2009-07-29,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NovartisPharma Services AG,"A 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 1.25 mg and 0.5 mg administered orally once daily versus placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000365-19,0,0,0 2005-000366-39,1,2006-04-21,2006-04-21,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Inamed Research GmbH & Co. KG,Effect of Oxis on the Efficacy of Mucociliary Clearance in Patients with COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000366-39,0,0,0 2005-000371-18,1,2011-03-28,2011-03-28,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Portsmouth Hospitals Trust,"The use of Thalidomide as a treatment for the cachexia of incurable upper gastrointestinal adenocarcinomas:a randomised, double-blinded, placebo controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000371-18,0,0,0 2005-000372-41,1,2007-01-31,2007-01-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca UK Limited,Real life effectiveness in asthma of Symbicort® Single Inhaler Therapy (RELEASE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000372-41,0,0,0 2005-000374-48,1,2007-05-29,2007-05-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Pharma A/S,"A randomized, open label comparative study to determine the proportion of asthma patients on Seretide Diskus 50/250 mcg b.i.d. achieving total control when given medication and compli-ance enhancement...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000374-48,0,0,0 2005-000380-26,1,2008-07-21,2008-07-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3 mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000380-26,0,0,0 2005-000381-39,1,2009-02-09,2009-02-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,"Efficacy and Safety of Memantine Hydrochloride, a low affinity antagonist to N-Methyl-D-Aspartate (NMDA) type receptors, in the prevention of cognitive decline and disease progression in older people ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000381-39,0,0,0 2005-000382-19,4,2006-10-26,2007-02-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ZLB Behring GmbH,"Efficacy and tolerance of BERIPLEX® P/N in subjects with acquired deficiency of coagulation factors II, VII, IX and X due to oral anticoagulation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000382-19,0,0,0 2005-000384-26,8,2007-10-23,2008-03-04,7,0,0,0,0,2,3,0,0,2,0,0,0,0,1,BioPartners GmbH,"A phase III, double-blind, randomized, placebo-controlled, parallel-group, multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000384-26,1,0,0 2005-000384-26,8,2007-10-23,2008-03-04,7,0,0,0,0,2,3,0,0,2,0,0,0,0,1,LG Life Science Ltd.,"A phase III, double-blind, randomized, placebo-controlled, parallel-group, multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000384-26,1,0,0 2005-000384-26,8,2007-10-23,2008-03-04,7,0,0,0,0,2,3,0,0,2,0,0,0,0,1,BioPartners,"A phase III, double-blind, randomized, placebo-controlled, parallel-group, multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000384-26,1,0,0 2005-000387-39,8,2009-12-28,2010-07-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"F. Hoffmann - La Roche Ltd. Pharmaceuticals Division, PDR",An open-label randomized multicentre phase III study of trastuzumab in combination with a fluoropyrimidine and cisplatin versus chemotherapy alone as first-line therapy in patients with HER2 positive ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000387-39,0,0,0 2005-000387-39,8,2009-12-28,2010-07-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Hoffmann-La Roche Ltd/Inc/AG/Roche Global Development,An open-label randomized multicentre phase III study of trastuzumab in combination with a fluoropyrimidine and cisplatin versus chemotherapy alone as first-line therapy in patients with HER2 positive ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000387-39,0,0,0 2005-000387-39,8,2009-12-28,2010-07-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,An open-label randomized multicentre phase III study of trastuzumab in combination with a fluoropyrimidine and cisplatin versus chemotherapy alone as first-line therapy in patients with HER2 positive ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000387-39,0,0,0 2005-000390-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,Antikoagulanttihoito varfariinilla sydäntahdistimen asennuksen yhteydessä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000390-22,0,0,0 2005-000393-47,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,"Effect of Cannabis Based Medicine Extract Sativex on brain function as assessed by fMRI and neurophysiologic evaluation in patients with Multiple Sclerosis a double blind, randomised, placebo-contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000393-47,0,0,0 2005-000394-21,1,2006-10-26,2006-10-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Heidelberg Pharma,A Double-Blind Phase II Study of HDP 99.0006 in Patients with Actinic Keratosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000394-21,0,0,0 2005-000395-41,2,2016-05-31,2016-05-31,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,All Ireland co-operative Oncology Research Group,"Phase II Study to Assess the Safety, Efficacy, and Tolerability of Combination Therapy with Velcade (Bortezomib), Adriamycin, and Dexamethasone (PAD) as Therapy for Patients with relapsed or refracto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000395-41,1,0,0 2005-000397-45,1,2006-11-28,2006-11-28,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Queen's Medical centre,Randomised Controlled Trial Of Intravitreal Triamcinolone In Patients With Diabetic Macular Oedema Refractory To Laser Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000397-45,0,0,0 2005-000402-32,1,2008-06-24,2008-06-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Genetronics Biomedical Corporation,An open-label study using the MedPulser Elektroporation System to treat cutaneous & subcutaneous foci of cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000402-32,0,0,0 2005-000403-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GRUPO ESPAÑOL DE INVESTIGACIÓN EN CÁNCER DE MAMA (GEICAM),Randomized clinical trial to evaluate the predictive accuracy of a gene expression profile-based test to select patients for preoperative taxane/anthracycline chemotherapy for stage I-III breast cance...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000403-33,0,0,0 2005-000405-56,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GRUPO ESPAÑOL DE INVETIGACION EN CANCER DE MAMA (GEICAM),RANDOMIZED CLINICAL TRIAL TO COMPARE THE BENEFIT OF ADDING HERCEPTIN TO CAPECITABINE PLUS VINORELBINE AS SECOND LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED NON OPERABLE OR METASTATIC BREAST CAN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000405-56,0,0,0 2005-000407-34,4,2008-02-21,2008-02-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A 50 Week Extension to: A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK-0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000407-34,0,0,0 2005-000407-34,4,2008-02-21,2008-02-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Limited,"A 50 Week Extension to: A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK-0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000407-34,0,0,0 2005-000407-34,4,2008-02-21,2008-02-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MSD (Norge) AS,"A 50 Week Extension to: A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK-0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000407-34,0,0,0 2005-000408-16,1,,,0,0,0,1,0,3,1,0,1,0,0,0,0,0,0,"Karolinska University Hospital, Huddinge",Caffeine-mediated modulation of human experimental pain models,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000408-16,0,0,0 2005-000409-67,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,NON FORNITO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000409-67,0,0,0 2005-000411-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"BG-Kliniken Bergmannsheil, Dept. of Pain Management",Effects of Pregabalin on mechanical hyperalgesia - EPOM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000411-10,0,0,0 2005-000412-27,5,2006-08-02,2006-08-02,3,0,0,0,0,1,3,0,0,1,1,0,1,0,1,"Arginox Pharmaceuticals, Inc.","A Phase III International Multi-center, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Nitric Oxide Synthase Inhibition with Tilarginine Acetate I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000412-27,0,0,0 2005-000417-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dra. Almudena Zapatero Laborda,"""PHASE III RANDOMISED AND MULTICENTRE TRIAL OF ADJUVANT ANDROGEN DEPRIVATION COMBINED WITH HIGH-DOSE THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY IN INTERMEDIATE-OR HIGH-RISK LOCALIZED PROSTATE CANCER"" “...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000417-36,0,0,0 2005-000421-34,4,2009-04-06,2009-04-06,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,PAION Deutschland GmbH,"DESMOTEPLASE (INN) IN ACUTE ISCHAEMIC STROKE: PHASE III; A prospective, randomised, double-blind, placebo-controlled, single bolus, multinational, multi-centre, parallel group, dose ranging study of d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000421-34,0,0,0 2005-000427-42,1,2009-04-23,2009-04-23,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,UK Children’s Cancer Study Group,SIOPEL 5 (HCC-1) trial on the hepatocellular carcinoma family of tumours in children/adolescents and young adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000427-42,0,0,0 2005-000428-18,7,2006-08-23,2006-08-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Schwarz Biosciences GmbH,"A mulit-center, randomized, double-blind, placebo-controlled, four-arm parallel group trial to investigate the efficacy and safety of three different transdermal doses of rotigotine in subjects with i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000428-18,0,0,0 2005-000428-18,7,2006-08-23,2006-08-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ PHARMA,"A mulit-center, randomized, double-blind, placebo-controlled, four-arm parallel group trial to investigate the efficacy and safety of three different transdermal doses of rotigotine in subjects with i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000428-18,0,0,0 2005-000430-20,1,2005-06-02,2005-06-02,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Chiron Behring GmbH & Co KG,"A phase III, multicenter, uncontrolled, open label study to demonstrate safety, tolerability and immunogenicity of the Chiron Behring preservative free inactivated split influenza vaccine using the st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000430-20,0,0,0 2005-000431-22,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",VALUTATION OF PLACEBO EFFECT AFTER CONDITIONING WITH APOMORPHINE AND WITHOUT PHARMACOLOGICAL CONDITIONING ON THE RIGIDITY AND ELECTRICAL ACTIVITY OF NEURONS OF SUBTHALAMIC NUCLEUS IN PARKINSON PATIENT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000431-22,0,0,0 2005-000434-21,1,,,0,0,0,0,1,3,2,0,1,0,0,0,0,0,0,"Kognitive Neurologie, Institut für Medizin, Forschungszentrum Jülich",Neurochemische Modulation von Exekutiv- und Gedächtnisfunktionen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000434-21,0,0,0 2005-000435-18,1,2009-09-17,2009-09-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Hull,"Study to Determine if The Cardiovascular risk indices in Impaired Glucose Tolerance are similar for Polycystic Ovarian Syndrome, and whether they may be modified by Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000435-18,0,0,0 2005-000436-24,3,2006-10-09,2006-10-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,AGI Therapeutics Limited,"A randomised, double-blind, placebo-controlled study of AGI 006 in the treatment of functional dyspepsia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000436-24,0,0,0 2005-000436-24,3,2006-10-09,2006-10-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,AGI Therapeutics Limtied,"A randomised, double-blind, placebo-controlled study of AGI 006 in the treatment of functional dyspepsia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000436-24,0,0,0 2005-000438-19,5,2013-04-18,2013-04-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Medicament,Randomised phase II study of the combination of oral vinorelbine with capecitabine versus gemcitabine in combination with paclitaxel versus gemcitabine in combination with docetaxel as first line chem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000438-19,0,0,0 2005-000438-19,5,2013-04-18,2013-04-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Médicament,Randomised phase II study of the combination of oral vinorelbine with capecitabine versus gemcitabine in combination with paclitaxel versus gemcitabine in combination with docetaxel as first line chem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000438-19,0,0,0 2005-000443-28,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Bristol Myers Squibb International Corporation,"A Phase III, Multi-Center, Multi-National, Randomized, Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents with Active Polyarticular Juvenile Rheumatoid Arth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000443-28,0,1,1 2005-000444-84,5,2006-07-04,2006-10-23,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck KGaA,"An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson s disease suffering from tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000444-84,0,0,0 2005-000444-84,5,2006-07-04,2006-10-23,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MERCK S.P.A.,"An open-label, multicenter, multinational Phase III follow-up study to investigate the long-term safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson s disease suffering from tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000444-84,0,0,0 2005-000447-28,2,2006-11-22,2006-12-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sankyo Pharma GmbH,EFFICACY AND SAFETY OF AMLODIPINE USED AS ADD-ON THERAPY IN MODERATELY TO SEVERELY HYPERTENSIVE PATIENTS NOT ADEQUATELY CONTROLLED BY OLMESARTAN MEDOXOMIL 20 MG MONOTHERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000447-28,0,0,0 2005-000448-99,8,2008-09-03,2008-09-03,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,WYETH LEDERLE,"A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000448-99,0,0,0 2005-000448-99,8,2008-09-03,2008-09-03,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals, Inc., Global Medical Affairs","A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000448-99,0,0,0 2005-000449-12,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,GlaxoSmithKline,"A phase II, double-blind, randomized, placebo controlled study to compare the immunogenicity, reactogenicity and safety of two different formulations of GlaxoSmithKline (GSK) Biologicals’ live attennu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000449-12,0,0,0 2005-000450-75,5,2006-11-03,2007-05-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANKYO EUROPE,Add-on Study of Olmesartan Medoxomil in Patients with Moderate to Severe Hypertension not Achieving Target Blood Pressure on Amlodipine 5 mg Alone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000450-75,0,0,0 2005-000450-75,5,2006-11-03,2007-05-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sankyo Pharma GmbH,Add-on Study of Olmesartan Medoxomil in Patients with Moderate to Severe Hypertension not Achieving Target Blood Pressure on Amlodipine 5 mg Alone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000450-75,0,0,0 2005-000450-75,5,2006-11-03,2007-05-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Daiichi Sankyo Europe GmbH,Add-on Study of Olmesartan Medoxomil in Patients with Moderate to Severe Hypertension not Achieving Target Blood Pressure on Amlodipine 5 mg Alone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000450-75,0,0,0 2005-000452-32,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTI FISIOTERAPICI OSPITALIERI,DOCETAXEL AND GEMCITABINE IN THE TREATMENT OF UNKNOWN PRIMARY TUMORS - A PHASE II STUDY -,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000452-32,0,0,0 2005-000454-73,6,2014-05-20,2014-06-24,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Celgene Europe Limited,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000454-73,0,0,0 2005-000454-73,6,2014-05-20,2014-06-24,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000454-73,0,0,0 2005-000458-57,1,2007-02-20,2007-02-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomised, open, phase IV, parallel group multicentre study to evaluate a change of management in Gastroesophageal Reflux Disease (GERD) patients by treatment with esomeprazole 40 mg or any other P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000458-57,0,0,0 2005-000459-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Oncologisch Centrum, Academisch Ziekenhuis Vrije Universiteit Brussel",A Stratified Phase II Study of Cetuximab (ErbituxTM) for the Treatment of Recurrent Glioblastoma Multiforme / Estudio de fase II estratificado de cetuximab para el tratamiento del glioblastoma multifo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000459-14,0,0,0 2005-000461-18,1,2006-07-17,2006-07-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Hull,"Study to Determine if The Cardiovascular risk indices in Type 2 diabetes are similar for Polycystic Ovarian Syndrome, and whether they may be modified by Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000461-18,0,0,0 2005-000464-95,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Inotek Pharmaceuticals Corporation,"A phase II randomized, double-blind, placebo-controlled, multi-center study to evaluate tolerability, safety pharmacokinetics and efficacy of intravenous INO-1001 in high-risk subjects undergoing card...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000464-95,0,0,0 2005-000472-40,8,2007-04-06,2007-04-06,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are Experiencing Insufficient Efficacy with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000472-40,0,0,0 2005-000472-40,8,2007-04-06,2007-04-06,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Comparative, Randomized, Open -Label, Multicenter Study on the Efficacy and Safety of Switch Treatment with Aripiprazole in Schizophrenic Out-patients who are Experiencing Insufficient Efficacy with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000472-40,0,0,0 2005-000473-22,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind study to compare the effects of 24 weeks treatment with LAF237 (50 mg qd, 50 mg bid or 100 mg qd) to placebo in drug naïve patients with type 2 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000473-22,0,0,0 2005-000474-42,1,2010-04-27,2010-04-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Safety and effects on blood pressure of a daily dose of 0.025 to 0.135 milligram per kilogram of S 90652, a paediatric formulation of perindopril, in hypertensive children having received S 90652 - an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000474-42,0,0,0 2005-000480-25,1,2009-02-23,2009-02-23,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Investigator Trondheim Hudlegesenter AS,Classification and characterization of patient suffering from moderate to severe plaque psoriasis responding to subcutaneous administered efalizumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000480-25,0,0,0 2005-000483-77,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,"Lund University, Malmö University Hospital",Inverkan av fraktionerad tillförsel av propofol med eller utan samtidig venstas på intensitet av lokal smärta utlöst av efterföljande intravenös injektion av propofol.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000483-77,0,0,0 2005-000487-11,7,2008-02-08,2008-07-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000487-11,0,0,0 2005-000487-11,7,2008-02-08,2008-07-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000487-11,0,0,0 2005-000487-11,7,2008-02-08,2008-07-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Service AG,"A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000487-11,0,0,0 2005-000487-11,7,2008-02-08,2008-07-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000487-11,0,0,0 2005-000489-37,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Nektar Therapeutics,"An open label, randomized, controlled study to evaluate the safety and efficacy of aerosolized surfactant, Curosurf®, delivered via nasal continuous positive airway pressure pulmonary drug delivery sy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000489-37,0,0,0 2005-000490-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,1. Frauenklinik der LMU- Innenstadt,"Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance-Trial SUCCESS-Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000490-21,0,0,0 2005-000492-18,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Insulin resistance and endothelial dysfunction TNF-Alpha dependent in patients with rheumatoid arthritis or metabolic syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000492-18,0,0,0 2005-000494-22,1,2011-03-16,2011-03-16,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Obstetrics and Gynecolog, Randers Centralsygehusy",Ny behandling af bartholins cyste/abscess med sølvnitrat,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000494-22,0,0,0 2005-000496-17,1,2007-09-04,2007-09-04,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,Region Skåne,Atorvastatin in moderat active Crohns disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000496-17,0,0,0 2005-000497-50,1,2008-07-21,2008-07-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"An open-label safety study of bifeprunox investigating flexible doses of 20, 30, or 40mg/day in patients with schizophrenia who have completed studies 10206 or 10265",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000497-50,0,0,0 2005-000499-41,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,mechanisms of endothelial disfunction in patients with les: role of TNF- Alpha,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000499-41,0,0,0 2005-000500-13,1,2008-07-01,2008-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford- Research Services,"Metformin treatment before IVF in women with ultrasound evidence of polycystic ovaries; a prospective, randomised, double blind, placebo controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000500-13,0,0,0 2005-000503-33,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,"Department Integrative Medicine, Kliniken Essen Mitte",Effectiveness of leech therapy in osteoarthritis of the thumb joint (rhizarthrosis) - a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000503-33,0,0,0 2005-000508-15,2,2006-11-07,2006-11-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,Efficacy and safety assessment of 6 months (24 weeks) treatment with Structum® 500 mg capsule bid in hip osteoarthritis: multicenter randomised double blind parallel group and placebo controlled study...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000508-15,0,0,0 2005-000515-95,3,2006-01-24,2006-01-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women with Osteoporosis: A Histomorphometric Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000515-95,0,0,0 2005-000515-95,3,2006-01-24,2006-01-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Lilly S.A.,Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women with Osteoporosis: A Histomorphometric Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000515-95,0,0,0 2005-000517-36,6,2007-04-25,2007-11-09,4,1,0,0,0,2,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","RESCUE Study (Certican in Liver Transplant Recipients with Renal Insufficiency) A 6-month, multicenter, randomized, open-label study of safety and efficacy of Certican-based regimen versus CNI-base...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000517-36,0,0,0 2005-000517-36,6,2007-04-25,2007-11-09,4,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"RESCUE Study (Certican in Liver Transplant Recipients with Renal Insufficiency) A 6-month, multicenter, randomized, open-label study of safety and efficacy of Certican-based regimen versus CNI-base...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000517-36,0,0,0 2005-000517-36,6,2007-04-25,2007-11-09,4,1,0,0,0,2,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"RESCUE Study (Certican in Liver Transplant Recipients with Renal Insufficiency) A 6-month, multicenter, randomized, open-label study of safety and efficacy of Certican-based regimen versus CNI-base...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000517-36,0,0,0 2005-000524-16,2,2008-05-27,2008-06-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,AN OPEN LABEL INTERNATIONAL MULTI-CENTER PHASE 2 ACTIVITY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH ADVANCED / METASTATIC GASTRIC CANCER PROGRESSING OR RECURRING AFTER ONE PRIOR CHEMOTHERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000524-16,0,0,0 2005-000524-16,2,2008-05-27,2008-06-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios Pfizer, Lda",AN OPEN LABEL INTERNATIONAL MULTI-CENTER PHASE 2 ACTIVITY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH ADVANCED / METASTATIC GASTRIC CANCER PROGRESSING OR RECURRING AFTER ONE PRIOR CHEMOTHERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000524-16,0,0,0 2005-000525-30,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Pfizer Hellas A.E.,AN OPEN LABEL INTERNATIONAL MULTI-CENTER PHASE 2 ACTIVITY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000525-30,0,0,0 2005-000526-23,1,2008-09-15,2008-09-15,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Pfizer Inc.,"A PHASE 1 STUDY OF SU011248 IN COMBINATION WITH FOLFIRI (IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN) IN PATIENTS WITH METASTATIC COLORECTAL CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000526-23,0,0,0 2005-000532-25,5,2006-09-04,2008-06-06,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,AstraZeneca AB,"A comparison of Symbicort Single inhaler Therapy (Symbicort Turbuhaler 160/4.5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolesc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000532-25,0,0,0 2005-000532-25,5,2006-09-04,2008-06-06,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,AstraZeneca Portugal,"A comparison of Symbicort Single inhaler Therapy (Symbicort Turbuhaler 160/4.5 mcg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adolesc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000532-25,0,0,0 2005-000534-20,1,2005-04-01,2005-04-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Addenbrooke's Hospital NHS Foundation Trust,Influence of brain tissue pH regulation on cerebral oxygenation and metabolism in patients with severe traumatic brain injury.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000534-20,0,0,0 2005-000535-18,1,2006-05-31,2006-05-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche Pharma (Schweiz) AG,"Prospective, multicenter study to evaluate the renal safety of 6 mg ibandronic acid infusions over 15 min or 60 min in patients with metastatic bone disease due to breast cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000535-18,0,0,0 2005-000537-38,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Centre Hospitalier Universitaire de Nantes,Etude multicentrique randomisée de phase III en ouvert comparant l'association Velcade Dexamethasone à la chimiothérapie de type VAD pour le traitement des patients porteurs de myélome multiple de nov...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000537-38,0,0,0 2005-000538-19,1,2007-11-27,2007-11-27,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,DURECT Corporation,"Protocol CLIN004−0009 (February 02, 2005): A Pharmacodynamic/Pharmacokinetic Study of SABER−Bupivacaine and/or Bupivacaine HCl Administered Intra−operatively During Open Inguinal Hernia Repair under L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000538-19,0,0,0 2005-000541-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Slidgigtinstituttet A/S,Glukosaminsulfat og hyperkolesterolæmi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000541-11,0,0,0 2005-000544-86,2,2010-06-23,2010-06-23,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomised, open-label, multi-center phase II study of first-line treatment with BAY 43-9006 (Sorafenib) versus standard treatment with Interferon alpha-2a in patients with unresectable and/or metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000544-86,0,0,0 2005-000544-86,2,2010-06-23,2010-06-23,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG; D-51368 Leverkusen,"A randomised, open-label, multi-center phase II study of first-line treatment with BAY 43-9006 (Sorafenib) versus standard treatment with Interferon alpha-2a in patients with unresectable and/or metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000544-86,0,0,0 2005-000546-37,1,2008-09-26,2008-09-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals of Leicester NHS Trust,An investigation of the effect of Vitamin D Receptor genotypes on clinical response to treatment of psoriasis with a topical vitamin D analogue and molecular mechanisms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000546-37,0,0,0 2005-000547-28,1,2009-09-21,2009-09-21,1,1,0,0,0,3,4,0,0,1,0,0,1,0,0,Department of Psychiatry; Section of Sleep Research and Pharmacopsychiatry,"EEG and ERP tomography by means of LORETA (Low-Resolution Brain Electromagnetic Tomography) identifying essential brain regions for vigilance and cognition in narcolepsy: double-blind, placebo-control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000547-28,0,0,0 2005-000549-13,2,2006-02-20,2006-02-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000549-13,0,0,0 2005-000550-75,1,2014-03-19,2014-03-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Birmingham,Phase II Study of the Tolerability and Efficacy of the Histone Deacetylase Inhibitor Sodium Valproate given in Conjunction with 5-azacytidine and ATRA (all trans retinoic acid ) in Patients with Acute...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000550-75,0,0,0 2005-000551-15,1,2008-03-14,2008-03-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,Effect of folic acid supplementation and allopurinol on endothelial function in patients with rheumatoid arthritis treated with methotrexate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000551-15,0,0,0 2005-000557-30,5,2008-09-15,2011-03-04,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A phase II, open- label, controlled, randomized, multicenter study to evaluate the efficacy and safety of pertuzumab (Omnitarg™), a recombinant humanized antibody against HER2, in combination with ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000557-30,0,0,0 2005-000557-30,5,2008-09-15,2011-03-04,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"A phase II, open- label, controlled, randomized, multicenter study to evaluate the efficacy and safety of pertuzumab (Omnitarg™), a recombinant humanized antibody against HER2, in combination with ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000557-30,0,0,0 2005-000558-60,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Pharmexa A/S,A Phase II trial evaluating the immunological and clinical efficacy and safety of HER-2 Protein AutoVac(TM) and Stimulon® Adjuvant QS-21 monotherapy in patients with metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000558-60,0,0,0 2005-000561-18,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,NOVARTIS FARMA,A phaseI dose escalation study of AMN107 in combination with Imatinib on a continous daily dosing schedule in adult patients with Imatinib-resistent gastrointestinal stromal tumours (GIST).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000561-18,0,0,0 2005-000562-38,1,2005-10-31,2005-10-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Berlin-Chemie AG,"RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A GASTRO-RESISTANT FILM-COATED PANCREATIN TABLET FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000562-38,0,0,0 2005-000566-40,1,2008-05-28,2008-05-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly Company,"A Pivotal Long-Term, Open-Label, Parallel Study of the Efficacy and Safety of Human Insulin Inhalation Powder in Patients with Type 1 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000566-40,0,0,0 2005-000567-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,NUMICO RESEARCH BV,Tolerance and immunological response in HIV seropositive individuals after NR100063 supplementation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000567-25,0,0,0 2005-000570-52,1,2007-03-31,2007-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"CRC, Medical Department IV, University Erlangen-Nuremberg",Einfluss von Pioglitazon auf den 24-Stunden-Blutdruck,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000570-52,0,0,0 2005-000574-40,1,2007-02-01,2007-02-01,1,1,0,0,0,1,2,0,1,1,0,0,1,0,0,Kompetenznetz Parkinson e.V.,Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000574-40,0,0,0 2005-000577-21,1,2007-07-18,2007-07-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"Estudio abierto y multicéntrico, de cincuenta y dos semanas de duración, para evaluar la seguridad y tolerabilidad a largo plazo de SR58611A 350 mg cada 12 horas en pacientes con trastorno depresivo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000577-21,0,0,0 2005-000583-28,2,2007-01-07,2007-01-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,HELSINN HEALTHCARE SA,"EFFICACY AND TOLERABILITY OF NIMESULIDE FOR THE TREATMENT OF MIGRAINE TTACKS: A RANDOMISED, MULTICOUNTRY, DOUBLE BLIND, PLACEBO CONTROLLED, CROSS-OVER TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000583-28,0,0,0 2005-000586-19,1,2009-04-15,2009-04-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Bayer Schering Pharma AG,Phase-II study to investigate the efficacy and safety of ZK 219477 as second-line therapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000586-19,0,0,0 2005-000590-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Faustus Forschung Compagnie, Translational Cancer Research GmbH",A Phase II Study of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)-urea (HECNU) in pancreatic cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000590-21,0,0,0 2005-000593-41,2,2007-11-26,2007-11-26,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Intercell AG,Long term persistence and effect of a booster dose of the Japanese encephalitis vaccine IC51 (JE-PIV).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000593-41,0,0,0 2005-000594-22,8,2008-01-11,2011-10-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,"A radomized, controlled, open-label trial to compare the efficacy, safety, and tolerability of TMC114/RTV versus LPV/RTV in treatmet- experienced HIV-1 infected subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000594-22,0,0,0 2005-000594-22,8,2008-01-11,2011-10-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Limited,"A radomized, controlled, open-label trial to compare the efficacy, safety, and tolerability of TMC114/RTV versus LPV/RTV in treatmet- experienced HIV-1 infected subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000594-22,0,0,0 2005-000595-40,3,2006-12-15,2006-12-15,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,SIGMA-TAU,"A Phase II study of oral gimatecan ST 1481 in progressing or recurring patients with advanced epithelial ovarian, fallopian or peritoneal cancer, previously treated with platinum and taxanes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000595-40,1,0,0 2005-000595-40,3,2006-12-15,2006-12-15,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.,"A Phase II study of oral gimatecan ST 1481 in progressing or recurring patients with advanced epithelial ovarian, fallopian or peritoneal cancer, previously treated with platinum and taxanes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000595-40,1,0,0 2005-000595-40,3,2006-12-15,2006-12-15,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Sigma Tau Industrie Farmaceutiche Riunite S.p.A.,"A Phase II study of oral gimatecan ST 1481 in progressing or recurring patients with advanced epithelial ovarian, fallopian or peritoneal cancer, previously treated with platinum and taxanes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000595-40,1,0,0 2005-000596-17,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,University Hospital Ghent,Dubbel blind gerandomiseerde studie waar metformine versus placebo toegediend worden in de behandeling van NASH bij patiënten die omwille van obesitas bariatrische chirurgie ondergaan.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000596-17,0,0,0 2005-000597-53,1,2007-04-17,2007-04-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Schering AG,Phase II study to investigate the efficacy and safety of ZK 219477 as first-line therapy in chemotherapy naive patients with extensive disease (ED) stage small cell lung cancer (SCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000597-53,0,0,0 2005-000604-14,12,2006-12-18,2006-12-18,9,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Speedel Pharma Ltd.,"A randomised, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000604-14,1,0,0 2005-000604-14,12,2006-12-18,2006-12-18,9,0,0,0,0,0,3,0,0,2,1,0,0,0,1,SPEEDEL,"A randomised, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000604-14,1,0,0 2005-000606-31,1,2007-09-30,2007-09-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,NHS Lothian - University Hospitals Division,Does tacrolimus ointment modify patch test responses?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000606-31,0,0,0 2005-000613-35,2,2006-12-21,2006-12-21,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVOSIS AG,"A double-blind, multi - centre, reference-controlled, randomised phase III study to compare the analgesic efficacy and tolerability of two buprenorphine transdermal systems using three different dosag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000613-35,0,0,0 2005-000613-35,2,2006-12-21,2006-12-21,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Novosis AG,"A double-blind, multi - centre, reference-controlled, randomised phase III study to compare the analgesic efficacy and tolerability of two buprenorphine transdermal systems using three different dosag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000613-35,0,0,0 2005-000614-12,3,2007-02-01,2007-02-22,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,Irbesartan in the treatment of Hypertensive Patients with Metabolic Syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000614-12,0,0,0 2005-000614-12,3,2007-02-01,2007-02-22,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,Irbesartan in the treatment of Hypertensive Patients with Metabolic Syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000614-12,0,0,0 2005-000615-99,1,2015-03-02,2015-03-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Medical Center Freiburg,Freiburger ZNS-NHL Studie Therapie für Patienten mit primären Non-Hodgkin Lymphomen des ZNS – Sequentielle Hochdosis-Chemotherapie mit autologer peripherer Blutstammzelltransplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000615-99,0,0,0 2005-000619-85,1,2009-05-01,2009-05-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The University of Liverpool,The relationship between genetic polymorphisms in the organic cation transporter genes and the pharmacokinetics and pharmacodynamics of metformin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000619-85,0,0,0 2005-000619-85,1,2009-05-01,2009-05-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Royal Liverpool and Broadgreen University Hospitals NHS Trust,The relationship between genetic polymorphisms in the organic cation transporter genes and the pharmacokinetics and pharmacodynamics of metformin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000619-85,0,0,0 2005-000621-38,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,CHIRON,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD? Surface Antigen, Inactivated, (Adjuvanted with MF59C.1) Influenza Vaccine, Formulation 2005-200...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000621-38,0,0,0 2005-000622-23,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,CHIRON,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL? S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2005-2006, when Administered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000622-23,0,0,0 2005-000627-42,1,2007-03-27,2007-03-27,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,BioCryst Pharmaceuticals Inc.,"A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydroch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000627-42,0,0,0 2005-000635-15,1,2007-06-26,2007-06-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Schering AG,"Randomized, multicentre, prospective, two-arm, open-label Phase II study to investigate the efficacy and safety of two ZK219477 i.v. infusions (3-hour infusion of 16mg/m2 versus 0.5-hour infusion of 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000635-15,0,0,0 2005-000639-13,3,2006-05-30,2006-05-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Pfizer Pharma GmbH,"An open-label, multi-center trial of azithromycin pharmacokinetics in sinus aspirate and serum following oral administration of either a 500 mg immediate-release (IR) once-daily 3 day regimen or a sin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000639-13,0,0,0 2005-000639-13,3,2006-05-30,2006-05-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Pfizer Ltd,"An open-label, multi-center trial of azithromycin pharmacokinetics in sinus aspirate and serum following oral administration of either a 500 mg immediate-release (IR) once-daily 3 day regimen or a sin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000639-13,0,0,0 2005-000640-91,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut de Recerca Hospital Sta. Creu i St. Pau,Treatment for acute myeloid leukemia (AML) during its first complete remision with the monoclonal antibody Mylotarg ® (anti-CD33/calicheamicina) pre- and post- autologous transplant of hematopoietic s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000640-91,0,0,0 2005-000650-79,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Boehringer Ingelheim Coordination Centre Belgium,"A Randomized, Multiple-dose, Double-Blind, Placebo- and Active-Controlled, Parallel Group Efficacy and Safety Study to determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat Inhaler in Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000650-79,0,0,0 2005-000651-14,1,2005-06-25,2005-06-25,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,CSL Limited,"A Single Site, Open-Label Study to Evaluate the Immunogenicity and Safety of Influenza Vaccine, CSL Limited in Healthy 'Adults' aged >18 to <60 years and in Healthy 'Older Adults' aged >60 years for t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000651-14,0,0,0 2005-000654-67,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Uppsala University/Uppsala County Council,"Can patients with fibromyalgia be improved by subcutaneous injections of sterile water in tenderpoints? A randomised, controlled, tripple masked clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000654-67,0,0,0 2005-000656-33,1,2009-06-10,2009-06-10,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Devon and Exeter NHS Foundation Trust,A Phase I/II Study of Sirolimus (Rapamune TM) in Combination with Cyclophosphamide and Dexamethasone in Relapsed Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000656-33,0,0,0 2005-000657-29,4,2010-11-05,2010-11-05,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized open label study of 400 mg versus 800 mg of Gleevec/glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) us...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000657-29,0,0,0 2005-000657-29,4,2010-11-05,2010-11-05,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A randomized open label study of 400 mg versus 800 mg of Gleevec/glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) us...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000657-29,0,0,0 2005-000657-29,4,2010-11-05,2010-11-05,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized open label study of 400 mg versus 800 mg of Gleevec/glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) us...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000657-29,0,0,0 2005-000658-56,1,2008-07-01,2008-07-01,1,0,0,0,0,1,4,0,0,1,1,1,1,0,0,"Deparment of pediatrics, Skejby Hospital, Denmark",PEG-asparaginase during two treatment courses in the treatment of childhood acute lymphoblastic leukemia (Användande av PEG-asparaginase under två behandlingsomgångar vid behandling av akut lymfatisk ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000658-56,0,0,0 2005-000659-14,1,2005-05-09,2005-05-09,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Chiron Vaccines Limited,"A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of FLUVIRIN® Surface Antigen, Inactivated Influenza Vaccine, Formulation 2005-2006, when administered to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000659-14,0,0,0 2005-000660-74,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Tuomo Nieminen,Tamsulosiinin ja sildenafiilin sydän- ja verenkiertoelinvaikutukset BPH-potilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000660-74,0,0,0 2005-000661-19,1,2010-10-31,2010-10-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Novartis Pharmaceuticals UK Ltd,Neoadjuvant hormone therapy for postmenopausal women with ER and/or PgR positive primary breast cancer: A multi-center study to determine the optimum length of treatment with Femara (letrozole 2.5mg d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000661-19,0,0,0 2005-000662-39,1,2008-11-15,2008-11-15,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Oxford Brookes University,A 2x2 phase II randomized controlled trial to investigate the efficacy of NRT plus St John's wort versus NRT plus placebo in smoking cessation and to examine the efficacy of chromium nicotinate versu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000662-39,0,0,0 2005-000663-26,1,2008-04-30,2008-04-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Universitätsklinik Freiburg,Immunsuppressive Therapy in Duchenne Muscular Dystrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000663-26,0,0,0 2005-000664-51,2,2009-04-24,2009-04-24,1,1,0,0,0,0,4,0,0,2,0,0,0,0,1,GUERBET,A RANDOMIZED DOUBLE-BLIND PARALLELL GROUP CLINICAL STUDY OF XENETIX 300 VERSUS VISIPAQUE 270 IN MULTISLICE CT PEDIATRIC INDICATIONS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000664-51,1,0,0 2005-000666-39,4,2008-10-24,2008-10-24,3,0,0,0,0,1,2,0,0,1,0,0,1,0,1,MediGene AG,"A Controlled, Randomized, Open label Phase II Trial to Evaluate Safety and Efficacy of a 1st line Combination Treatment with Weekly Infusion of Gemcitabine and Twice Weekly Administration of Lipid Com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000666-39,0,0,0 2005-000668-17,7,2006-06-15,2009-11-27,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Novartis Pharma Services AG,"A 3 year, double-blind extension to CZOL446H2301 to evaluate the long term safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000668-17,0,0,0 2005-000668-17,7,2006-06-15,2009-11-27,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,NOVARTIS FARMA,"A 3 year, double-blind extension to CZOL446H2301 to evaluate the long term safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000668-17,0,0,0 2005-000669-21,1,2008-08-28,2008-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,Pilot study of HIV Viral slope in naive patients treated with Enfuvirtide (ENF) based therapy compared to current standard treatment.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000669-21,0,0,0 2005-000671-17,5,2006-10-16,2006-10-16,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,WYETH LEDERLE,A Safety and Efficacy Dose-Ranging Study of GAP-486 in Subjects With Nonsustained Ventricular Tachycardia and Acute Ischemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000671-17,0,0,0 2005-000671-17,5,2006-10-16,2006-10-16,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development",A Safety and Efficacy Dose-Ranging Study of GAP-486 in Subjects With Nonsustained Ventricular Tachycardia and Acute Ischemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000671-17,0,0,0 2005-000674-43,1,2009-09-01,2009-09-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leeds,"AN OPEN LABEL STUDY OF THE EFFECT OF TREATMENT WITH RITUXIMAB ON RESISTANT RHEUMATOID ARTHRITIS: Clinical, radiological, synovial and immunological outcomes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000674-43,0,0,0 2005-000677-21,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,CMC Contrast AB,Evaluation of the diagnostic quality of CMC-001 (manganese chloride tetrahydrate) in liver MR-imaging in patients with liver metastases in comparison to Gadolinium BOPTA. A randomised cross-over Phase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000677-21,0,0,0 2005-000679-16,1,2006-12-14,2006-12-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,Randomized phase II trial with infliximab (Remicade) in patients with myelodysplastic syndrome and a relatively low risk of developing acute leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000679-16,0,0,0 2005-000680-26,1,2010-01-27,2010-01-27,1,0,0,0,0,1,4,0,1,1,0,0,1,0,0,North west London Hospital Trust,A randomised double blind controlled crossover trial of intravenous taurine supplementation in parenteral nutrition as an effective treatment for reducing hepatobiliary complications in chronic intest...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000680-26,0,0,0 2005-000682-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"FARMALIDER, S.A.","ENSAYO CLÍNICO ALEATORIZADO, DOBLE-CIEGO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS PARA EVALUAR LA EFICACIA, TOLERABILIDAD Y NIVELES PLASMÁTICOS DE UNA FORMULACIÓN DE DICLOFENACO 2% SPRAY EN EL TR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000682-19,0,0,0 2005-000684-26,7,2007-01-04,2007-04-18,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double blind, parallel group, active-controlled, multi-center, 14 week study to evaluate the effectiveness of a valsartan versus an amlodipine treatment strategy in achieving blood press...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000684-26,0,0,0 2005-000684-26,7,2007-01-04,2007-04-18,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double blind, parallel group, active-controlled, multi-center, 14 week study to evaluate the effectiveness of a valsartan versus an amlodipine treatment strategy in achieving blood press...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000684-26,0,0,0 2005-000684-26,7,2007-01-04,2007-04-18,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A randomized, double blind, parallel group, active-controlled, multi-center, 14 week study to evaluate the effectiveness of a valsartan versus an amlodipine treatment strategy in achieving blood press...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000684-26,0,0,0 2005-000685-39,1,2007-09-17,2007-09-17,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Universitetssjukhuset Örebro,"Postoperativ smärtlindring och mobilisering efter per- och postoperativ injektion av ropivakin, ketorolak och adrenalin givet i operationsområdet, infiltrativt och i knäleden, vid enkammarknäplastikop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000685-39,0,0,0 2005-000686-19,1,2006-07-17,2006-07-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Leeds,PACT (Patient Preferences in Adjuvant Colorectal Cancer Therapy) - A randomised crossover clinical trial comparing Bolus Fluorouracil/Leucovorin to Capecitabine as treatment for moderate to high risk ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000686-19,0,0,0 2005-000687-77,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Uni-Zentrum naturheilkunde,Pilotstudie zur Verträglichkeit und Effektivität eines Artischockenpräparates bei Patienten mit chronischer Hepatitis C,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000687-77,0,0,0 2005-000689-38,1,,,0,0,0,0,0,3,3,0,0,0,0,0,0,0,0,Institut Català d’Oncologia,"ESTUDIO FASE III, ALEATORIZADO, DOBLE CIEGO DE TRATAMIENTO DE LA MUCOSITIS ORAL CON COCIMIENTO DE LLANTÉN VS CLORHEXIDINA AL 0,12% VS DISOLUCIÓN ACUOSA DE BICARBONATO AL 5% EN PACIENTES ONCOLÓGICOS QU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000689-38,0,0,0 2005-000690-22,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Clavis Pharma as,A phase II Clinical Study of CP-4055 in patients with metastatic melanoma not previous treated with chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000690-22,0,0,0 2005-000691-41,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,"Greater Glasgow Health Board, North Glasgow University Hospitals Division",Randomised controlled trial to evaluate the effect of statins on asthma control of patients with chronic asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000691-41,0,0,0 2005-000693-45,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI,"A phase II study for the treatment of patients with splenic marginal lymphoma with the combination of Cyclophosfamide, Vincristine, Liposomal Doxorubicin, Predinisone and Rituximab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000693-45,0,0,0 2005-000694-22,1,2008-05-05,2008-05-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Prof. Dr.Christian Werner,„Levobupivacaine for postoperative pain control in patients with knee arthroplasty – a comparison with ropivacaine“,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000694-22,0,0,0 2005-000695-40,1,2008-10-15,2008-10-15,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Nottingham,A randomised trial of aminosalicylate withdrawal in patients with ulcerative colitis in established remission on combination treatment of azathioprine (or 6−mercaptopurine) and an aminosalicylate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000695-40,0,0,0 2005-000699-41,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE,Multicentric Pilot Phase II Study for use of Fludarabine plus Cyclophosphamide Followed by 90 Y-Ibritumomab Tiuxetan Zevalin in the Treatment of non-Follicular Indolent Lymphomas Refractory or Relap...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000699-41,0,0,0 2005-000700-14,1,2013-07-29,2013-07-29,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE,"MULTI-CENTRE, RANDOMISED, PHASE III TRIAL COMPARING HIGH DOSE SEQUENTIAL CHEMOTHERAPY hds WITH RITUXIMAB AND AUTOLOGOUS PERIPHERAL BLOOD PROGENITUR ALL TRANSPLANTION VERSUS 2- WEEKLY CHOP WITH RITUX...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000700-14,0,0,0 2005-000701-61,1,2008-04-03,2008-04-03,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University College London,An open label trial of the dual specificity endothelin receptor antagonist bosentan in established scleroderma renal crisis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000701-61,0,0,0 2005-000703-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación PETHEMA,Ensayo Clínico de Tolerancia y Seguridad de Anfotericina B liposómica (AMBISOME) Nebulizada en la Profilaxis de la Aspergilosis Pulmonar Invasora en la Leucemia Mieloide Aguda (LMA) y en el Trasplante...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000703-34,0,0,0 2005-000704-14,1,,,0,0,0,1,1,3,1,0,1,4,0,0,0,0,1,Stiefel Laboratories International Division,Human 96 Hour Repeat Open Application Test for Assessment of Skin Irritation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000704-14,0,0,0 2005-000705-59,6,2007-03-08,2007-03-08,2,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Immunomedics, Inc.","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurologic Systems",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000705-59,1,0,0 2005-000705-59,6,2007-03-08,2007-03-08,2,1,0,0,0,0,3,0,0,2,1,0,0,0,1,IMMUNOMEDICS,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurologic Systems",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000705-59,1,0,0 2005-000705-59,6,2007-03-08,2007-03-08,2,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"UCB Pharma, Inc","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurologic Systems",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000705-59,1,0,0 2005-000706-31,5,2007-02-16,2007-02-16,1,1,0,0,0,0,3,0,0,2,1,0,0,0,1,IMMUNOMEDICS,"A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi- Center Study of Epratuzumab in Patients with Active Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000706-31,1,0,0 2005-000706-31,5,2007-02-16,2007-02-16,1,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Immunomedics, Inc.","A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi- Center Study of Epratuzumab in Patients with Active Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000706-31,1,0,0 2005-000706-31,5,2007-02-16,2007-02-16,1,1,0,0,0,0,3,0,0,2,1,0,0,0,1,UCB Pharma Inc.,"A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi- Center Study of Epratuzumab in Patients with Active Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000706-31,1,0,0 2005-000707-34,1,2013-12-30,2013-12-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Newcastle upon Tyne Hospitals NHS Trust,The induction of apoptosis by anti-psoriatic treatments,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000707-34,0,0,0 2005-000709-70,1,2006-09-07,2006-09-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ipsen Ltd,"A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000709-70,0,0,0 2005-000710-12,1,2006-01-31,2006-01-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Aalborg Sygehus,Smertebehandling af børn i skadestuen med Actiq,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000710-12,0,0,0 2005-000711-10,1,2006-03-31,2006-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ALTANA Pharma Ltd.,Determination of the performance characteristics of ReQuestTM in Practice in the stepped down management of GORD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000711-10,0,0,0 2005-000712-27,5,2008-08-29,2008-08-30,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Limited,"An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000712-27,0,0,0 2005-000712-27,5,2008-08-29,2008-08-30,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,"An open-label trial with TMC125 in HIV-1 infected subjects, who were randomized to a TMC125 treatment arm in a sponsor-selected TMC125 trial and were treated for at least 48 weeks.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000712-27,0,0,0 2005-000713-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AVI BioPharma Inc.,A Phase IIA Study to Evaluate the Safety and Preliminary Efficacy of Resten-MP when used in Conjunction with a Bare Metal Stent in de novo Native Coronary Artery Lesions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000713-35,0,0,0 2005-000715-98,11,2008-01-18,2008-04-21,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"A placebo-controlled, double blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with At...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000715-98,0,0,0 2005-000715-98,11,2008-01-18,2008-04-21,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-SYNTHELABO,"A placebo-controlled, double blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with At...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000715-98,0,0,0 2005-000715-98,11,2008-01-18,2008-04-21,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A placebo-controlled, double blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with At...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000715-98,0,0,0 2005-000717-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Lungmedicinska kliniken,"COX-2-hämmare och kemoterapi vid avancerad icke småcellig lungcancer. En prospektiv randomiserad dubbel-blind studie. Key elements: CYclooxygenase-2 inhibitor, Chemotherapy, LUng cancer, Survival (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000717-35,0,0,0 2005-000720-16,7,2006-10-05,2006-11-17,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals, Inc.","A Randomised, Two-way, Blinded, Crossover-Design Study to Establish the Bioequivalence of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) with a Full-Length Recombinant Factor VIII Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000720-16,0,0,0 2005-000720-16,7,2006-10-05,2006-11-17,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals, Inc. Clinical Research & Development","A Randomised, Two-way, Blinded, Crossover-Design Study to Establish the Bioequivalence of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) with a Full-Length Recombinant Factor VIII Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000720-16,0,0,0 2005-000720-16,7,2006-10-05,2006-11-17,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,WYETH LEDERLE,"A Randomised, Two-way, Blinded, Crossover-Design Study to Establish the Bioequivalence of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) with a Full-Length Recombinant Factor VIII Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000720-16,0,0,0 2005-000722-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,"PHASE II STUDY WITH CETUXIMAB SINGLE AGENT FOLLOWED BY 5-FU, CETUXIMAB AND PELVIC RADIOTHERAPY AS NEO-ADJUVANT TREATMENT FOR OPERABLE, LOCALLY ADVANCED RECTAL CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000722-24,0,0,0 2005-000727-42,1,2007-06-15,2007-06-15,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,Cytos Biotechnology AG,"A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A-VLP Vaccine in HLA-A2 Positive Patients with stage III/IV Malignant Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000727-42,0,0,0 2005-000728-18,1,2005-12-19,2005-12-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,AISAR ASSOCIAZIONE ITALIANA PER LO STUDIO DEGLI ANTIMICROBICI E DELLE RESISTENZE,An experiment of phase II open label about safety and Mifepristone vgx-410 anti-HIV activity on patients affected by HIV-1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000728-18,0,0,0 2005-000730-20,6,2011-01-14,2011-01-14,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nycomed Denmark Aps,"An open label, international, multi centre, parallel group, phase III b, randomised trial, investigating lumbar spine Bone Mineral Density (BMD) changes in postmenopausal women with primary osteoporos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000730-20,0,0,0 2005-000730-20,6,2011-01-14,2011-01-14,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nycomed Danmark Aps,"An open label, international, multi centre, parallel group, phase III b, randomised trial, investigating lumbar spine Bone Mineral Density (BMD) changes in postmenopausal women with primary osteoporos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000730-20,0,0,0 2005-000730-20,6,2011-01-14,2011-01-14,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TAKEDA PHARMA A/S,"An open label, international, multi centre, parallel group, phase III b, randomised trial, investigating lumbar spine Bone Mineral Density (BMD) changes in postmenopausal women with primary osteoporos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000730-20,0,0,0 2005-000731-26,4,2012-04-19,2012-04-19,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Nerviano Medical Sciences S.r.l.,Nemorubicin hydrochloride (PNU-152243A) administered via intra-hepatic artery in combination with cisplatin in adult patients with unresectable hepatocellular carcinoma: phase II study preceeded by a ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000731-26,0,0,0 2005-000731-26,4,2012-04-19,2012-04-19,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NERVIANO MEDICAL SCIENCES,Nemorubicin hydrochloride (PNU-152243A) administered via intra-hepatic artery in combination with cisplatin in adult patients with unresectable hepatocellular carcinoma: phase II study preceeded by a ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000731-26,0,0,0 2005-000733-37,2,2006-04-01,2006-04-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NV Organon,"A randomized, double-blind, placebo-controlled, multicenter parallel-group dose ranging clinical trial to assess the efficacy and safety of Org 4419-2 in the treatment of obstructive sleep apnea/hypop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000733-37,0,0,0 2005-000734-21,1,2011-04-18,2011-04-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Groupe d'Etude des Lymphomes de l'Adulte (GELA),A Phase 2 Study of VELCADE™ in Subjects with Relapsed or Refractory follicular B-cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000734-21,0,0,0 2005-000736-24,1,2005-10-31,2005-10-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Berlin-Chemie AG,"RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE IV TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AN ENTERIC-COATED PANCREATIN TABLET FOR LIPID DIGESTION AND ABSORPTION IN PATIENTS WITH PANCREATIC EX...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000736-24,0,0,0 2005-000737-38,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,RAFAEL GARCIA LOPEZ,NUEVOS ENFOQUES TERAPEUTICOS PARA EL SINDROME DE TOURETTE EN NIÑOS: Estudio fase II para conocer la eficacia y la seguridad del Magnesio y Vitamina B6 para el tratamiento del Síndrome de Tourette en ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000737-38,0,0,0 2005-000743-29,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Heads Study Group,"Treatment of patients with post-transplant lymphoproliferative disorder (PILD) with a sequential treatment consisting of anti-CD20 antibody rituximab and CHOP + GCSF chemotherapy (including first, sec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000743-29,0,0,0 2005-000744-82,1,2006-05-16,2006-05-16,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Medical University Vienna, Dept. of Clinical Pharmacology",Impact of rhCu/Zn SOD on inflammation-induced impairment of vascular reactivity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000744-82,0,0,0 2005-000749-13,1,2009-01-29,2009-01-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cardiff University,A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000749-13,0,0,0 2005-000751-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,"CLINICAL STUDY OF APPRAISAL OF THE EFFECTIVENESS OF 1,25 (OH)2D3 (CALCITRIOL) TOWARDS PLACEBO IN THE DIABETES OF TYPE 1 OF RECENET INSORGENCE (IMDIAB XIII)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000751-15,0,0,0 2005-000752-32,1,2013-11-05,2013-11-05,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Klinikum Grosshadern,"Medical treatment of Menière’s disease with betahistine: a placebo-controlled, dose-finding study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000752-32,0,0,0 2005-000755-15,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University Hospital of Birmingham Foundation Trust,Perhexiline therapy in patients with Hypertrophic Cardiomyopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000755-15,0,0,0 2005-000767-26,2,2008-07-25,2008-07-25,2,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Baxter Vaccine AG,Open-label follow-up study to investigate the seropersistence of TBE antibodies and the booster response to a tick-borne encephalitis vaccine in children and adolescents aged 3 - 18 years.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000767-26,0,0,0 2005-000767-26,2,2008-07-25,2008-07-25,2,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Baxter AG,Open-label follow-up study to investigate the seropersistence of TBE antibodies and the booster response to a tick-borne encephalitis vaccine in children and adolescents aged 3 - 18 years.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000767-26,0,0,0 2005-000768-19,1,2006-07-05,2006-07-05,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Baxter Vaccine AG,Multicenter Phase IV Study to Investigate the Seropersistence of TBE Virus Antibodies Approximately 3 Years after a Booster Vaccination with FSME-IMMUN 0.25 ml Junior in Children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000768-19,0,0,0 2005-000771-18,1,2011-01-31,2011-01-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Universitätsklinikum Ulm,"Prospective, doubleblind, randomized multicenter study to proof the clinical and bacteriological non-inferiority of amoxicillin versus moxifloxacin in hospitalized patients with non-severe community-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000771-18,0,0,0 2005-000774-46,1,2016-06-24,2016-06-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medical School, Dept. of Cardiology and Angiology",BOne marrOw transfer to enhance ST-elevation infarct regeneration-2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000774-46,0,0,0 2005-000776-41,1,2008-01-30,2008-01-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Department of Ophthalmology,"Comparison of reduced fluence versus standard photodynamic therapy (in combination with intravitreal triamcinolone acetonide): A prospective, randomized, comparative study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000776-41,0,0,0 2005-000777-21,1,2008-07-28,2008-07-28,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,BioVex Ltd,AN EXPLORATORY STUDY OF THE SAFETY AND BIOLOGICAL ACTIVITY OF ONCOVEXGM-CSF IN COMBINATION WITH RADIOTHERAPY AND CISPLATIN IN THE TREATMENT OF LOCALLY ADVANCED EPITHELIAL CANCER OF THE HEAD AND NECK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000777-21,0,0,0 2005-000778-31,1,,,0,1,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dept. of Cardiology, Medical University of Vienna","OMEGA-3-POLYUNSATURATED FATTY-ACIDS (n3-PUFA) IN PATIENTS WITH SEVERE CHRONIC HEART FAILURE: EFFECTS ON ENDOTHELIAL FUNCTION, LEFT VENTRICULAR REMODELLING, NATRIURETIC PEPTIDE LEVELS, AND EXERCISE CAP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000778-31,0,0,0 2005-000784-26,8,2009-02-04,2009-10-13,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bristol Myers Squibb International Corporation,"A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated with Abatacept plus Methotrexate Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000784-26,0,0,0 2005-000784-26,8,2009-02-04,2009-10-13,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated with Abatacept plus Methotrexate Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000784-26,0,0,0 2005-000785-39,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,MIPHARM,"Efficacy and Tolerability of Ketomousse, Ketoconazole 1 , Salicilic Acid and Zinc phyritione thermolabile foam in the treatment of Pityriasis Versicolor in comparison with Ketoconazole 2 cream Niz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000785-39,0,0,0 2005-000786-19,1,2009-05-14,2009-05-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Instituto Científico y Tecnológico de Navarra S.A.,"Estudio abierto, aleatorizado, multicéntrico, nacional para comparar el riesgo de enfermedad cardiovascular en pacientes adultos receptorea de un primer aloinjerto hepático, tratados con un régimen li...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000786-19,0,0,0 2005-000787-90,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hellmuth Ulrici Kliniken,Wirksamkeit periduraler Steroidinjektionen im Rahmen eines multimodelen Behandlungskonzeptes in der Therapie von nicht radikulären chronischen Rückenschmerzen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000787-90,0,0,0 2005-000793-45,2,2007-06-06,2007-06-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,Open-label safety study of TMC114 in combination with low dose RTV and other ARVs in highly experienced HIV-1 infected patients with limited or no treatment options,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000793-45,0,0,0 2005-000793-45,2,2007-06-06,2007-06-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Ltd.,Open-label safety study of TMC114 in combination with low dose RTV and other ARVs in highly experienced HIV-1 infected patients with limited or no treatment options,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000793-45,0,0,0 2005-000799-42,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Mepha Ltd.,"Randomised, double-blind, active-controlled, parallel-group, multicentre study comparing two slow release formulations of 100 mg diclofenac in patients with primary symptomatic osteoarthritis of the h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000799-42,0,0,0 2005-000802-30,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ROCHE,Phase II study of the combination of Bevacizumab (rhuMab VEGF) plus Capecitabine with pre-operative standard radiotherapy in patients with locally advanced rectal cancer. Studio di fase II sulla co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000802-30,0,0,0 2005-000803-32,1,2009-05-16,2009-05-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Leeds Teaching Hospitals NHS Trust,Does the infiltration of Levobupivacaine into the rectus abdominus muscle ( Rectus Sheath Block) improve post-operative analgesia following open gastric bypass for morbid obesity?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000803-32,0,0,0 2005-000805-68,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE,A RANDOMISED STUDY TO COMPARE THE REDUCED INTENSIVE REGIMEN CONTAINING ALEMTUZUMAB VERSUS ATG IN ALLOGENIC TRAPIANTS FROM MUD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000805-68,0,0,0 2005-000807-33,3,2007-02-22,2007-04-19,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A randomized, double blind, two-arms placebo-controlled, parallel group, multicenter study of rimonabant 20 mg once daily in the treatment of atherogenic dyslipidemia in abdominally obese patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000807-33,0,0,0 2005-000807-33,3,2007-02-22,2007-04-19,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-SYNTHELABO,"A randomized, double blind, two-arms placebo-controlled, parallel group, multicenter study of rimonabant 20 mg once daily in the treatment of atherogenic dyslipidemia in abdominally obese patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000807-33,0,0,0 2005-000808-14,1,2007-11-27,2007-11-27,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Ambria Dermatology,"A randomized, double-blind, parallell-group, controlled study of topical pentane-1,5-diol hydrogel in patients with impetigo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000808-14,0,0,0 2005-000812-29,6,2006-02-21,2006-02-21,3,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Myogen, Inc","ARIES-1 “Ambrisentan in PAH − A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension”",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000812-29,0,0,0 2005-000812-29,6,2006-02-21,2006-02-21,3,1,0,0,0,1,3,0,0,1,1,0,1,0,1,MYOGEN INC.,"ARIES-1 “Ambrisentan in PAH − A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension”",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000812-29,0,0,0 2005-000812-29,6,2006-02-21,2006-02-21,3,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Myogen, Inc.","ARIES-1 “Ambrisentan in PAH − A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension”",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000812-29,0,0,0 2005-000813-36,1,2007-10-01,2007-10-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,STRAGEN France,"A phase II, multicentre, single-arm, open-label study of subcutaneous homoharringtonine (HHT) alone in patients with accelerated phase chronic myeloid leukemia (CML) who are refractory to, or have rel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000813-36,0,0,0 2005-000813-36,1,2007-10-01,2007-10-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ChemGenex Pharmaceuticals Ltd.,"A phase II, multicentre, single-arm, open-label study of subcutaneous homoharringtonine (HHT) alone in patients with accelerated phase chronic myeloid leukemia (CML) who are refractory to, or have rel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000813-36,0,0,0 2005-000814-11,1,2007-10-01,2007-10-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,STRAGEN France,"A phase II, multicentre, open-label, single arm, extension study of maintenance treatment with subcutaneous homoharringtonine (HHT) as a single agent in patients with chronic myeloid leukemia (CML) wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000814-11,0,0,0 2005-000814-11,1,2007-10-01,2007-10-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ChemGenex Pharmaceuticals Ltd.,"A phase II, multicentre, open-label, single arm, extension study of maintenance treatment with subcutaneous homoharringtonine (HHT) as a single agent in patients with chronic myeloid leukemia (CML) wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000814-11,0,0,0 2005-000817-37,1,2008-03-07,2008-03-07,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Cardiff University,A Study On The Efficacy Of Delta-9-Tetrahydrocannabinol (Dronabinol) In Renal Itch,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000817-37,0,0,0 2005-000823-40,4,2006-04-21,2006-04-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Synthelabo-Recherche,Double blind placebo controlled dose ranging study of the efficacy and safety of SSR149744C 300 or 600 mg for the conversion of atrial fibrillation/flutter,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000823-40,0,0,0 2005-000823-40,4,2006-04-21,2006-04-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SANOFI-SYNTHELABO,Double blind placebo controlled dose ranging study of the efficacy and safety of SSR149744C 300 or 600 mg for the conversion of atrial fibrillation/flutter,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000823-40,0,0,0 2005-000826-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Psychiatric Centre Prague,"4 - weeks, double blind, parallel, randomized study: Comparison of repetitive transcranial magnetic stimulation (rTMS) and venlafaxine (Effectin ER) in the treatment of resistant depressive disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000826-22,0,0,0 2005-000829-32,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Folktandvården,Fluorkoncentrationer i saliv och approximal vätska efter olika sätt att tillföra fluor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000829-32,0,0,0 2005-000832-26,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Department of Endocrinology,Adjuvant treatment of Graves´ ophthalmopathy with NSAID (aGO study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000832-26,0,0,0 2005-000833-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,RANDOMIZED STUDY WITH POSTOPERATIVE RADIOTHERAPY AND CONCURRENT LOW DOSE CISPLATIN VS RADIOTHERAPY AND CONCURRENT CISPLATIN + FLUOROURACIL IN OPERATED HIGH RISK SQUAMOUS CELL CARCINOMA OF THE ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000833-39,0,0,0 2005-000836-25,1,2007-07-29,2007-07-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline AB,Seretide vs Flixotide in mild persistent asthma (GINAII),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000836-25,0,0,0 2005-000837-39,3,2009-02-09,2009-02-09,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Cytonet GmbH & Co. KG,"Open, randomized, prospective, controlled, multicentre study to evaluate the efficacy and safety of multiple intraportal applications of liver cell suspension in patients with acute liver failure not ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000837-39,1,0,0 2005-000838-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,RANDOMIZED STUDY OF RADIOTHERAPY WITH CONCOMITANT BOOST (RTcb) AND CONCURRENT LOW DOSE CISPLATIN VS RTcb AND CISPLATIN + FLUOROURACIL IN ADVANCED HNSCC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000838-21,0,0,0 2005-000839-17,2,2007-01-24,2007-01-24,2,1,0,0,2,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 16-week, randomized, multi-center, parallel-group, pimecrolimus-blinded, controlled study (4-week treatment period followed by 12-week observational period) to evaluate the safety of concomitant use...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000839-17,0,0,0 2005-000839-17,2,2007-01-24,2007-01-24,2,1,0,0,2,0,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 16-week, randomized, multi-center, parallel-group, pimecrolimus-blinded, controlled study (4-week treatment period followed by 12-week observational period) to evaluate the safety of concomitant use...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000839-17,0,0,0 2005-000840-10,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,KEDRION,Open Label Phase II Multicenter Study for the Evaluation of Pharmacokinetics of VENBIG (Human Immunoglobulin anti-Hepatitis B for Intravenous Use) and IMMUNOHBS (Human Immunoglobulin anti Hepatitis B ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000840-10,0,0,0 2005-000841-12,1,2005-12-07,2005-12-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised open label, six way, cross-over scintigraphic evaluation of the effect of inspiratory flow rate on lung and oropharyngeal deposition with the Respimat(R) inhaler vs a Metered Dose Inhaler...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000841-12,0,0,0 2005-000842-35,4,2007-04-26,2007-04-26,1,0,0,0,0,2,2,0,0,1,0,0,1,0,1,"Barrier Therapeutics, Inc.","A Randomised, Double-Blind, Multinational, Multicenter, Placebo-controlled Parallel Phase II/III Trial to Evaluate the Efficacy and Safety of 2 Doses of Oral Liarozole (75 mg o.d. and 150 mg o.d.) Gi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000842-35,0,0,0 2005-000842-35,4,2007-04-26,2007-04-26,1,0,0,0,0,2,2,0,0,1,0,0,1,0,1,"BARRIER THERAPEUTICS, INC.","A Randomised, Double-Blind, Multinational, Multicenter, Placebo-controlled Parallel Phase II/III Trial to Evaluate the Efficacy and Safety of 2 Doses of Oral Liarozole (75 mg o.d. and 150 mg o.d.) Gi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000842-35,0,0,0 2005-000846-35,1,2022-06-22,2022-06-22,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,GlaxoSmithKline,"GlaxoSmithKline Study EGF100161 – An open-label, multicenter, 2 Part, Phase I/II dose escalation study of oral lapatinib in combination with docetaxel (Taxotere) plus trastuzumab (Herceptin) in subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000846-35,0,0,0 2005-000848-83,1,2009-10-28,2009-10-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline Consumer Healthcare GmbH & Co KG, 77815 Bühl","Teilverblindete, randomisierte, Placebo-kontrollierte, multizentrische Studie zur Wirksamkeit von Dickextrakt aus Kürbissamen (Kürbissamen-Extrakt) und Kürbissamen bei Patienten mit benigner Prostatah...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000848-83,0,0,0 2005-000852-34,6,2007-07-27,2007-07-27,5,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CETPARP,"Double blind, placebo controlled randomized study of the effects of co-administering testosterone with PDE V inhibitor in ED patients non responders to PDE V inhibitors alone",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000852-34,0,0,0 2005-000852-34,6,2007-07-27,2007-07-27,5,0,0,0,0,0,3,0,0,1,0,0,1,0,0,SELARL du Docteur Jacques Buvat,"Double blind, placebo controlled randomized study of the effects of co-administering testosterone with PDE V inhibitor in ED patients non responders to PDE V inhibitors alone",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000852-34,0,0,0 2005-000852-34,6,2007-07-27,2007-07-27,5,0,0,0,0,0,3,0,0,1,0,0,1,0,0,SELARL du Dr Jacques BUVAT,"Double blind, placebo controlled randomized study of the effects of co-administering testosterone with PDE V inhibitor in ED patients non responders to PDE V inhibitors alone",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000852-34,0,0,0 2005-000852-34,6,2007-07-27,2007-07-27,5,0,0,0,0,0,3,0,0,1,0,0,1,0,0,SELARL du Docteur Jacques BUVAT,"Double blind, placebo controlled randomized study of the effects of co-administering testosterone with PDE V inhibitor in ED patients non responders to PDE V inhibitors alone",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000852-34,0,0,0 2005-000855-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,"Multicenter, not controlled, prospectic clinical phase IV study: safety and efficacy of an immunosuppressive regimen with Thymoglobuline and Rapamune in patients receiving a renal transplantation from...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000855-14,0,0,0 2005-000856-34,5,2007-11-28,2007-11-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 36 week, randomized, double-blind, multi-center, parallel group study comparing the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of left ventr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000856-34,0,0,0 2005-000856-34,5,2007-11-28,2007-11-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 36 week, randomized, double-blind, multi-center, parallel group study comparing the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of left ventr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000856-34,0,0,0 2005-000856-34,5,2007-11-28,2007-11-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A 36 week, randomized, double-blind, multi-center, parallel group study comparing the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of left ventr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000856-34,0,0,0 2005-000859-15,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ROCHE,Randomized prospective study comparing dexamethasone and dexamethasone plus rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP) in adults.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000859-15,0,0,0 2005-000860-24,1,2008-10-01,2008-10-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,IBI,"A randomized, double-blind, placebo-controlled trial on the efficacy of 12 months of treatment with Realsil in subjects with hipertransaminasemia and steatosis or non-alcoholic steatohepatitis with or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000860-24,0,0,0 2005-000864-16,1,2007-07-24,2007-07-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"Multicenter, randomized, open-label trial to evaluate the safety, tolerability and efficacy of two regimens of Everolimus plus Neoral, given according different blood target levels, in de novo renal t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000864-16,0,0,0 2005-000865-21,7,2008-01-30,2008-01-31,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase with Unboosted vs. Boosted Reyataz After an Induction Phase with Reyataz and Ritonavir in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000865-21,0,0,0 2005-000865-21,7,2008-01-30,2008-01-31,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase with Unboosted vs. Boosted Reyataz After an Induction Phase with Reyataz and Ritonavir in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000865-21,0,0,0 2005-000866-38,1,2008-11-06,2008-11-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,A. MENARINI I.F.R.,DEXKETOPROFEN TROMETAMOL IN ATTACK THERAPY OF MIGRAINE.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000866-38,0,0,0 2005-000867-24,2,2007-05-10,2007-05-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Human Genome Sciences, Inc.","A PHASE 2b, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALBUFERON (RECOMBINANT HUMAN ALBUMIN-INTERFERON ALFA FUSION PROTEIN) IN COMBINATION WI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000867-24,0,0,0 2005-000869-20,3,2006-06-03,2006-06-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pierre Fabre Médicament,"Post-operative care by chlorhexidine mouthwash after periodontal surgery. Randomised, parallel groups; blind study, DC071BB versus placebo, in patients presenting with periodontal surgery with suture.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000869-20,0,0,0 2005-000871-16,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Dr John Berth-Jones,"Methotrexate in adults with severe atopic dermatitis: a double-blind, randomised, parallel-group, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000871-16,0,0,0 2005-000872-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,N-Gene Research & Development Ltd.,"RANDOMIZED DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO-CONTROLLED STUDY TO DETERMINE THE INSULIN SENSITIZING EFFECT OF BGP-15 IN PATIENTS WITH INSULIN RESISTANCE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000872-41,0,0,0 2005-000877-23,1,2005-06-28,2005-06-28,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Oxford Radcliffe Hospitals NHS trust,Is Remifentanil better than Propofol in providing optimal conditions for an awake fibreoptic intubation?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000877-23,0,0,0 2005-000878-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Sanitari Terrassa,Ensayo clínico de la eficacia de dos estrategias terapéuticas en el tratamiento de la diverticulitis aguda no complicada,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000878-42,0,0,0 2005-000884-25,5,2007-04-23,2007-04-23,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche AG,"A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000884-25,0,0,0 2005-000884-25,5,2007-04-23,2007-04-23,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000884-25,0,0,0 2005-000888-26,1,2006-05-29,2006-05-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ratiopharm GmbH,"Randomised, double-blind, multi-centre, placebo-controlled clinical dose finding study in four parallel groups comparing Diclofenac Gel 1 %, Diclofenac Gel 3 %, Diclofenac Gel 5 % and placebo Gel in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000888-26,0,0,0 2005-000889-39,1,2006-03-29,2006-03-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,OMRIX biopharmaceuticals Ltd,"A Prospective, Randomized Controlled Study to Compare the Effects of a Fibrin Sealant(FS2) Versus Manual Compression on Haemostatic Efficacy During Vascular Surgical Procedures Utilising Polytetrafluo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000889-39,0,0,0 2005-000890-23,1,2008-01-16,2008-01-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Ingrid Ehrén,NO as an objective marker for inflammation in patients with interstitial cystitis treated with cyclosporine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000890-23,0,0,0 2005-000891-42,1,2006-05-16,2006-05-16,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novo Nordisk A/S,"A randomised, open-label, multi-centre trial investigating the intra-subject variability of ROTEM® and TEG® parameters following two intravenous administrations of the same dose of activated recombina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000891-42,0,0,0 2005-000893-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Prof. Gustav Dobos, Kliniken Essen Mitte",Effectiveness of leech therapy in epicondylitis humeroradialis - a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000893-27,0,0,0 2005-000895-41,1,,,0,0,0,0,0,0,4,0,1,1,1,1,0,1,0,Hospital Clinic,Obtención de una base de datos de estudios de SPECT con DaTSCAN® correspondiente a una población de sujetos normales,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000895-41,0,0,0 2005-000897-38,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,FARMACEUTICI DAMOR,"Open-label, controlled, randomised, multicentre, parallel group clinical trial of efficacy and tolerability of Fitostimoline soaked gauzes, Fitostimoline cream and Citrizan gel in the topical tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000897-38,0,0,0 2005-000899-40,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,GUIDOTTI,ASSESSMENT OF EFFECTS OF A 12-MONTH TREATMENT WITH METFORMIN ON INSULIN ACTION AND SECRETION IN WOMEN WITH PRIOR GESTATIONAL DIABETES MELLITUS (GDM) ASSESSMENT OF EFFECTS OF A 12-MONTH TREATMENT WI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000899-40,0,0,0 2005-000900-15,5,2011-07-14,2011-07-14,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Eli Lilly and Company,"The effect of Ruboxistaurin on Clinically Significant Macular Edema in Patients with Diabetes Mellitus, as assessed by Optical Coherence Tomography",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000900-15,0,0,0 2005-000901-77,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Treatment of sialorrhoea with botulinum toxin in patients with neurodegenerative diseases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000901-77,0,0,0 2005-000902-30,1,2006-12-04,2006-12-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,A Study of the Pharmacodynamic Effects of Prednisolone on Whole Blood Protein and Gene Expression in Rheumatoid Arthritis Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000902-30,0,0,0 2005-000904-15,2,2008-10-24,2008-11-04,2,1,0,0,0,0,0,0,0,1,1,0,1,0,0,George Washington University Biostatistics Center,Intervention with mycophenolate mofetil and daclizumab in patients with recently diagnosed type 1 diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000904-15,0,0,0 2005-000904-15,2,2008-10-24,2008-11-04,2,1,0,0,0,0,0,0,0,1,1,0,1,0,0,NIDDK TYPE 1 DIABETES TRIALNET,Intervention with mycophenolate mofetil and daclizumab in patients with recently diagnosed type 1 diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000904-15,0,0,0 2005-000914-11,3,2006-08-14,2007-04-11,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V. by August 2005),"A Phase II, Multicenter, Open-Label Study of YM155 in Patients With Advanced Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) Who Have Failed One or Two Prior Lines of Therapy, at Least One of Whi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000914-11,0,0,0 2005-000915-80,2,2009-10-30,2010-03-31,2,1,0,0,0,2,2,0,0,1,0,0,1,0,0,ISTITUTO GIANNINA GASLINI,A phase II study of Topotecan-Vincristine-Doxorubicin (TVD) in children with stage 4 neuroblastoma failing to respond to COJEC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000915-80,0,0,0 2005-000915-80,2,2009-10-30,2010-03-31,2,1,0,0,0,2,2,0,0,1,0,0,1,0,0,University of Birmingham,A phase II study of Topotecan-Vincristine-Doxorubicin (TVD) in children with stage 4 neuroblastoma failing to respond to COJEC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000915-80,0,0,0 2005-000917-37,1,,,0,1,0,1,0,0,1,0,1,1,0,0,0,1,1,Pfizer Health AB,Comparision of single-dose nicotine pharmacokinetics of three variants of nicotine oral drops 2 mg and of Nicorette Gum 2 mg in healthy smokers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000917-37,0,0,0 2005-000918-13,1,2006-02-07,2006-02-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A single dose, placebo-controlled, randomized, double-blind, double-dummy, crossover efficacy, pharmacokinetics and safety comparison of salmeterol inhalation powder (12.5 µg, 25 µg and 50 µg salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000918-13,0,0,0 2005-000922-22,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Xenova Ltd,"A phase II double blind, randomised, placebo controlled, multicentre study to assess the efficacy and safety of TA-NIC in maintaining smoking cessation when given in conjunction with Nicotine Replacem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000922-22,0,0,0 2005-000924-18,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase III, Multi-Center, Open-Label, Controlled, Randomized Study to Evaluate the Immunogenicity, Safety, Tolerability and the Ability to Prime for Memory of Chiron Meningococcal C Conjugate Vaccine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000924-18,0,0,0 2005-000927-41,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Surgery plus intraperitoneal Hypertermic chemotherapy in platinum-sensitive patients with ovarian cancer recurrence after 12 months. Phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000927-41,0,0,0 2005-000928-17,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Hyperthermic intra-arterial chemotherapy with oxaliplatin in total hepatic vascular exclusion. A Phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000928-17,0,0,0 2005-000929-31,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Surgery plus intraperitoneal hyperthermic chemoterapy in platinum-resistant patients with ovarian cancer reccurrence. A Phase II study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000929-31,0,0,0 2005-000933-39,1,2011-04-29,2011-04-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,Randomised phase II/III study comparing gemcitabine followed by gemcitabine plus concomitant radiation (50.4 Gy) versus gemcitabine alone after curative pancreaticoduodenectomy for pancreatic head can...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000933-39,0,0,0 2005-000934-19,1,2008-02-25,2008-02-25,1,0,0,0,1,1,2,0,1,1,0,0,1,0,0,Neurologisk Afdeling Århus Universitetshospital,Undersøgelse af subcutan immunglobulin behandling af patienter med multifokal motorisk neuropati,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000934-19,0,0,0 2005-000936-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"Wyeth Farma, S.A.",Sirolimus en el tratamiento de la nefropatía crónica del injerto demostrada histológicamente,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000936-26,0,0,0 2005-000940-10,1,2007-01-02,2007-01-02,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"RE&D VÚFB, s.r.o.",Evaluation of tolerance and efficacy of preparation TERBINAFIN HBF CREAM (Herbacos-Bofarma) and its comparison with preparation LAMISIL CREAM (Novartis) in patients with interdigital form of tinea ped...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000940-10,0,0,0 2005-000941-12,2,2009-01-08,2009-01-08,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Onyx Pharmaceuticals, Inc.","Phase III randomised, placebo controlled study of sorafenib in repeated cycles of 21 days in combination with paclitaxel/carboplatin chemotherapy in subjects with unresectable stage III or stage IV me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000941-12,0,0,0 2005-000944-98,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,Norlands University Hospital,FARMAKOKINETISKA EGENSKAPER HOS ISOALLOPREGNANOLON OCH ANTAGONISM AV ALLOPREGNANOLONS SEDERINGS EFFEKT HOS KVINNOR. Pharmacokinetic properties of isoallopregnanolone and antagonism of allopregnanolon...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000944-98,0,0,0 2005-000949-11,8,2011-10-04,2011-11-21,6,1,0,0,0,2,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized, Double-blind Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Advanced, Malignant Pleural Mesothelioma Refractory to Systemic Chemotherapy Studio clinico...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000949-11,0,0,0 2005-000949-11,8,2011-10-04,2011-11-21,6,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Phase 3, Randomized, Double-blind Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Advanced, Malignant Pleural Mesothelioma Refractory to Systemic Chemotherapy Studio clinico...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000949-11,0,0,0 2005-000949-11,8,2011-10-04,2011-11-21,6,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Merck Sharp and Dohme de España,"A Phase 3, Randomized, Double-blind Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Advanced, Malignant Pleural Mesothelioma Refractory to Systemic Chemotherapy Studio clinico...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000949-11,0,0,0 2005-000949-11,8,2011-10-04,2011-11-21,6,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Merck & Co. Inc,"A Phase 3, Randomized, Double-blind Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Advanced, Malignant Pleural Mesothelioma Refractory to Systemic Chemotherapy Studio clinico...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000949-11,0,0,0 2005-000949-11,8,2011-10-04,2011-11-21,6,1,0,0,0,2,3,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","A Phase 3, Randomized, Double-blind Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Advanced, Malignant Pleural Mesothelioma Refractory to Systemic Chemotherapy Studio clinico...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000949-11,0,0,0 2005-000949-11,8,2011-10-04,2011-11-21,6,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme BV,"A Phase 3, Randomized, Double-blind Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Advanced, Malignant Pleural Mesothelioma Refractory to Systemic Chemotherapy Studio clinico...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000949-11,0,0,0 2005-000949-11,8,2011-10-04,2011-11-21,6,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase 3, Randomized, Double-blind Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Advanced, Malignant Pleural Mesothelioma Refractory to Systemic Chemotherapy Studio clinico...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000949-11,0,0,0 2005-000958-71,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,ABOCA,Randomised parallel study against placebo for the determination of efficacy of liophilised Salvia Officinalis and Helichrysum italicum in pain treatment from post-surgery pain in 45 male or female pat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000958-71,0,0,0 2005-000959-15,1,2008-06-26,2008-06-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,sanofi-aventis,A multicenter clinical trial to evaluate quality of life in patients with Type 2 diabetes before and after changing therapy to a combination of insulin glargine and oral antidiabetic drugs in a real l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000959-15,0,0,0 2005-000960-25,1,2009-07-16,2009-07-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Lothian NHS trust,Role of Inflammation and Platelet Activation in the adverse Cardiovascular Outcomes of Patients with Critical Limb Ischaemia - a double-blind randomised trial of Clopidogrel.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000960-25,0,0,0 2005-000963-25,5,2006-07-20,2012-12-24,2,1,1,0,0,1,3,0,0,2,1,0,0,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent, UK","A Multicenter, Long-Term Extension Study to Assess Safety of Oral Sildenafil in the Treatment of Subjects Who Have Completed Study A1481131",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000963-25,1,1,0 2005-000965-21,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase II open (partially double-blind), randomized, controlled, primary vaccination study to assess the immunogenicity, safety and reactogenicity of one intramuscular dose of four different formulat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000965-21,0,0,0 2005-000967-24,1,2014-05-07,2014-05-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Technical University of Munich,"Evaluation of Response Rate to Pre-operative Docetaxel + Herceptin study part A and Docetaxel study part B In Locally Advanced Breast Cancer Patients, Stratified by HER2-Status, Trial Phase II",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000967-24,0,0,0 2005-000968-33,1,2010-03-31,2010-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Klinik III, Kardiologie, Universität Frankfurt","Doppel-blinde, randomisierte, kontrollierte Studie zur intraarteriellen Transplantation von Knochenmarks-Progenitorzellen bei Patienten mit chronischer Ischämie bei pAVK (Intraarterial Progenitor Ce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000968-33,0,0,0 2005-000969-19,1,2010-04-28,2010-04-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Klinik III, Kardiologie",Klinische Studie zur intraarteriellen Transplantation von Knochenmarks-Progenitorzellen bei Patienten mit Diabetischer Neuropathie (Restoration of Nerve functions by Intra-arterial Tra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000969-19,0,0,0 2005-000970-37,5,2010-09-09,2010-09-09,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MERCK S.P.A.,"Open, randomized, controlled, multicenter phase II study comparing 5-FU/FA plus oxaliplatin FOLFOX-4 plus cetuximab versus 5-FU/FA plus oxaliplatin as first-line treatment for epidermal growth facto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000970-37,0,0,0 2005-000970-37,5,2010-09-09,2010-09-09,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"Open, randomized, controlled, multicenter phase II study comparing 5-FU/FA plus oxaliplatin FOLFOX-4 plus cetuximab versus 5-FU/FA plus oxaliplatin as first-line treatment for epidermal growth facto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000970-37,0,0,0 2005-000973-24,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ERREKAPPA EUROTERAPICI,"Nimesulide spray in the treatment of simpthomatic inflammation with pain of the oral cavity (faringitis, stomatitis, pharyngitis) pre e post dental extraction. Randomised controlled vs active drug (F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000973-24,0,0,0 2005-000974-29,1,2005-04-08,2005-04-08,1,0,0,0,0,0,4,0,1,1,0,0,1,0,1,Boots Healthcare International Limited,"An open label, oral bioavailability study to determine the levels of Amylmetacresol BP (AMC) and 2,4-dichlorobenzyl alcohol (DCBA) in the saliva of healthy volunteers after a single oral dose of Stre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000974-29,0,0,0 2005-000976-42,1,2006-12-21,2006-12-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk Pharma S.A.,"A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000976-42,0,0,0 2005-000979-18,4,2006-12-11,2006-12-11,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A phase IIa/b double-blind, randomised, placebo-controlled, linear trend design dose-ranging study to investigate the effects of 24 weeks of monotherapy with SB-742457 on cognition in subjects with mi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000979-18,0,0,0 2005-000986-20,1,2007-07-31,2007-07-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Technical University of Munich,The CORE Study (Chemotherapy or Endocrine Treatment first?),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000986-20,0,0,0 2005-000988-26,1,2011-03-07,2011-03-07,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Portsmouth Hospitals NHS Trust,Cyclooxygenase inhibitor therapy in patients with oesophageal adenocarcinoma: A pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000988-26,0,0,0 2005-000989-39,1,2019-01-31,2019-01-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Guy's & St Thomas NHS foundation Trust,"A Single Centre, double blind, placebo controlled, randomised trial to evaluate the efficacy and safety of Simvastatin in the treatment of Psoriasis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000989-39,0,0,0 2005-000990-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Exxentia Grupo Fitoterapéutico, S.A",BÚSQUEDA DE DOSIS EN LA EFICACIA DE EXXENTEROL EN LA REDUCCIÓN DEL COLESTEROL SÉRICO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000990-22,0,0,0 2005-000993-29,1,,,0,1,0,0,1,0,3,0,0,1,0,0,0,1,1,IBSA,"A prospective, randomized, investigator-blind, controlled, clinical study of phase III on the clinical efficacy and tolerability of hMG-IBSA IBSA Institut Biochimique sa versus Menopur Ferring adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000993-29,0,0,0 2005-000995-41,2,2008-02-29,2008-02-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D,"A double-blind, randomized, placebo-controlled multi-centre, phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 in chronic hepatitis C subjects with hepatic fibrosis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000995-41,0,0,0 2005-000996-16,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I,Silence Study - Longitudinal study on the use of aspirin versus placebo in patients with silent cerebral infarcts,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-000996-16,0,0,0 2005-001000-39,2,2006-11-08,2006-11-08,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Kowa Research Europe Ltd.,STUDY OF PITAVASTATIN 2 MG vs. ATORVASTATIN 10 MG AND PITAVASTATIN 4 MG vs. ATORVASTATIN 20 MG (FOLLOWING UP-TITRATION) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001000-39,0,0,0 2005-001004-39,1,2009-04-06,2009-04-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Edinburgh,Investigation of combined phosphodiesterase 5 inhibitor and isosorbide mononitrate for the treatment of resistant hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001004-39,0,0,0 2005-001005-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Spanish Lung Cancer Group,"A single-arm phase II study of dose-dense gemcitabine and carboplatin as neoadyuvant chemotherapy, with pegfilgrastim support for subjects with operable stage IIIA NSCLC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001005-26,0,0,0 2005-001006-12,4,2009-12-15,2009-12-15,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,AXXONIS PHARMA GMBH,"Continuous Application of Lisparin in Parkinson s Disease by Subcutaneous Infusion Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001006-12,0,0,0 2005-001006-12,4,2009-12-15,2009-12-15,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Axxonis Pharma GmbH,"Continuous Application of Lisparin in Parkinson s Disease by Subcutaneous Infusion Double-blind, placebo-controlled, randomized, multicentre Phase II / III study to evaluate the efficacy and safe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001006-12,0,0,0 2005-001007-18,1,2009-03-15,2009-03-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Victoria Infirmary,Reversal of warfarin anticoagulation with oral vitamin K: towards a better management of over-anticoagulation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001007-18,0,0,0 2005-001008-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sahlgrenska University Hospital,Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001008-37,0,0,0 2005-001009-25,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,DR DIMENSIONE RICERCA,"Efficacy, safety and tolerability of Atorvastatin 40 mg in patients with Relapsing-remitting multIple sclerosis in treAtment with INterferoN-betA. Efficacia, sicurezza e tollerabilita` dell`Atorvas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001009-25,0,0,0 2005-001010-41,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,GLAXO SMITHKLINE,"An outpatient, randomised, double-blind, placebo controlled, parallel group exploratory study to evaluate safety, tolerability and efficacy of GW679769 in patients with Fibromyalgia syndrome comorbid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001010-41,0,0,0 2005-001012-41,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ROCHE,Phase II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Oxaliplatin plus Capecitabine (XELOX) in Patients with Advanced Colorectal Cancer Studio di fase II sulla combinazione di bevacizu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001012-41,0,0,0 2005-001013-18,1,2013-03-25,2013-03-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"Multi-center, open-label, prospective, randomized, parallel group study investigating a CNI-free regimen with Myfortic® and Certican® in comparison to standard therapy with Myfortic® and a calcineurin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001013-18,0,0,0 2005-001015-22,3,2010-03-03,2010-03-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TRANSGENE,A Phase IIb Multicentric Controlled Study Evaluating the Therapeutic Vaccine TG4010 (MVA-MUC1-IL2) as an Adjunct to Standard Chemotherapy in Advanced Non Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001015-22,0,0,0 2005-001016-51,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Karolinska Hospital,In vivo effects of transdermal Estradiol+ oral Progesterone vs oral Conjugated Equine Estrogens + MedroxyProgesteroneAcetate on normal human breast cells proliferation: a randomized comparative study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001016-51,0,0,0 2005-001017-17,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University of Aachen,µ-Opiatrezeptorvermittelte Dopaminfreisetzung bei Alkoholabhängigkeit: PET-Studien mit [18F]Fallypride,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001017-17,0,0,0 2005-001019-23,1,2006-02-07,2006-02-07,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,BioInvent International AB,"A double blind, phase I/II, randomized, single and repeat dose, dose escalation study of the antibody BI-201 directed against Tat, given IV, versus Placebo in asymptomatic HIV-1 patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001019-23,0,0,0 2005-001021-28,3,2007-01-11,2007-01-11,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.",".A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to assess the efficacy and safety of duloxetine (20 mg bid for 2 weeks escalating to 40 mg bid) for up to 12 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001021-28,0,0,0 2005-001021-28,3,2007-01-11,2007-01-11,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,".A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to assess the efficacy and safety of duloxetine (20 mg bid for 2 weeks escalating to 40 mg bid) for up to 12 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001021-28,0,0,0 2005-001021-28,3,2007-01-11,2007-01-11,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim GmbH,".A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to assess the efficacy and safety of duloxetine (20 mg bid for 2 weeks escalating to 40 mg bid) for up to 12 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001021-28,0,0,0 2005-001024-36,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,FONDAZIONE MONZINO CENTRO CARDIOLOGICO,ALTERED ENFOTHELIAL FUNCTION AS A CARDIOVASCULAR RISK INDEX IN PATIENTS WITH METABOLIC SYNDROME,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001024-36,0,0,0 2005-001026-89,1,2010-01-26,2010-01-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Serono GmbH,"Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple scleros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001026-89,0,0,0 2005-001027-11,1,2009-08-05,2009-08-05,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospitals Coventry and Warwickshire NHS Trust,Diabetes in the Very Elderly Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001027-11,0,0,0 2005-001030-33,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,PATCH Prostate Adenocarcinoma: TransCutaneous Hormones A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH agonists in prostate cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001030-33,0,0,0 2005-001031-29,1,2006-08-01,2006-08-01,1,1,0,0,0,3,4,0,1,1,0,0,1,0,1,Bioforce GmbH,Wirkung einer einmaligen Einnahme eines alkoholischen Baldrian/Hopfen Flüssigextraktes (Dormeasan® -Tropfen) im Vergleich zu Placebo auf das Schlafverhalten von Patienten mit Ein- bzw. Durchschlafstör...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001031-29,0,0,0 2005-001032-72,3,2007-09-25,2007-09-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 t.i.d. vs. immediate release carbidopa/levodopa t.i.d. in Parkinsons disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001032-72,0,0,0 2005-001032-72,3,2007-09-25,2007-09-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 39-week randomized, double-blind, parallel group, multicenter study to evaluate the effect of fixed dose Stalevo 100 t.i.d. vs. immediate release carbidopa/levodopa t.i.d. in Parkinsons disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001032-72,0,0,0 2005-001033-15,3,2006-09-29,2006-09-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,KOWA RESEARCH EUROPE LTD,STUDY OF PITAVASTATIN 2 MG vs. SIMVASTATIN 20 MG AND PITAVASTATIN 4 MG vs. SIMVASTATIN 40 MG FOLLOWING UP-TITRATION IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001033-15,0,0,0 2005-001033-15,3,2006-09-29,2006-09-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Kowa Research Europe Ltd.,STUDY OF PITAVASTATIN 2 MG vs. SIMVASTATIN 20 MG AND PITAVASTATIN 4 MG vs. SIMVASTATIN 40 MG FOLLOWING UP-TITRATION IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001033-15,0,0,0 2005-001034-32,1,2010-06-01,2010-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"NHS Greater Glasgow, Yorkhill",Does pre-operative Sildenafil protect against pulmonary related complications following cardiopulmonary bypass? A randomised trial in children undergoing cardiac surgical repair,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001034-32,0,0,0 2005-001037-15,4,2006-10-02,2006-10-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Kowa Research Europe Ltd.,STUDY OF PITAVASTATIN 4 MG vs. SIMVASTATIN 40 MG (FOLLOWING UP- TITRATION) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA AND 2 OR MORE RISK FACTORS FOR CORONARY HEART DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001037-15,0,0,0 2005-001038-34,3,2007-06-26,2007-09-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Kowa Research Europe Ltd.,STUDY OF PITAVASTATIN 4 MG vs. ATORVASTATIN 20 MG (FOLLOWING UP-TITRATION) IN PATIENTS WITH TYPE II DIABETES MELLITUS AND COMBINED DYSLIPIDEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001038-34,0,0,0 2005-001039-31,3,2006-05-12,2006-05-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Kowa Research Europe Ltd.,"STUDY OF PITAVASTATIN 1 MG vs. PRAVASTATIN 10 MG, PITAVASTATIN 2 MG vs. PRAVASTATIN 20 MG AND PITAVASTATIN 4 MG vs. PRAVASTATIN 40 MG (FOLLOWING UP-TITRATION) IN ELDERLY PATIENTS WITH PRIMARY HYPERCHO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001039-31,0,0,0 2005-001040-23,1,2005-11-10,2005-11-10,1,1,0,0,1,0,4,0,1,1,0,0,1,0,1,"Pfizer Consumer Healthcare, Pfizer Health AB","AN EVALUATOR-BLINDED, OPEN, RANDOMIZED, PARALLEL CONTROLLED STUDY ON NICORETTE® FRESHMINT GUM VS NICORETTE® MICROTAB IN HEALTHY SMOKERS MOTIVATED TO QUIT SMOKING AND WITH VISIBLE STAINING OF TEETH",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001040-23,0,0,0 2005-001041-42,1,2006-02-22,2006-02-22,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,University of Oxford,Assessment of protection against malaria by sporozoite challenge of healthy adults vaccinated with the virosomal vaccine PEV3A and FP9-MVA ME-TRAP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001041-42,0,0,0 2005-001043-32,1,2008-11-14,2008-11-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,A PROOF OF CONCEPT STUDY TO EVALUATE THE DOSE RESPONSE FOR THE SYSTEMIC BENEFIT RISK RATIO OF INHALED FLUTICASONE PROPIONATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001043-32,0,0,0 2005-001048-22,1,2011-03-02,2011-03-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Göteborg University, Institute for Internal Medicine","Rosuvastatin in Visceral Adiposity. A 26-week, single center, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the effect of rosuvastatin on visceral adipose tissue in ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001048-22,0,0,0 2005-001055-38,1,2011-12-17,2011-12-17,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP IELSG,"RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE, ALONE OR ASSOCIATED WITH HIGHDOSE CYTARABINE, FOLLOWED BY RESPONSE- AND AGE-TAILORED RADIOTHERAPY FOR IMMUNOCOMPETENT PAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001055-38,0,0,0 2005-001057-21,4,2006-04-18,2011-03-17,2,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Schering-Plough Research Insititute, a division of Schering Corporation",VICRIVIROC SCH 417690 in combination treatment with optimized ART regimen in experienced subjects VICTOR-E1 .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001057-21,0,0,0 2005-001057-21,4,2006-04-18,2011-03-17,2,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Schering-Plough Research Institute,VICRIVIROC SCH 417690 in combination treatment with optimized ART regimen in experienced subjects VICTOR-E1 .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001057-21,0,0,0 2005-001057-21,4,2006-04-18,2011-03-17,2,1,0,0,0,0,0,0,0,1,1,0,1,0,1,SCHERING-PLOUGH,VICRIVIROC SCH 417690 in combination treatment with optimized ART regimen in experienced subjects VICTOR-E1 .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001057-21,0,0,0 2005-001058-26,4,2006-10-04,2006-10-04,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,SCHERING-PLOUGH,VICRIVIROC SCH 417690 in combination treatment with optimized ART regimen in Experienced subjects VICTOR E2 .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001058-26,0,0,0 2005-001058-26,4,2006-10-04,2006-10-04,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Schering-Plough Research Institute,VICRIVIROC SCH 417690 in combination treatment with optimized ART regimen in Experienced subjects VICTOR E2 .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001058-26,0,0,0 2005-001059-39,13,2014-09-18,2014-09-18,13,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Schering-Plough Research Institute,"A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001059-39,0,0,0 2005-001059-39,13,2014-09-18,2014-09-18,13,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp. a Subsidiary of Merck & Co.,Inc.","A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001059-39,0,0,0 2005-001059-39,13,2014-09-18,2014-09-18,13,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc","A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001059-39,0,0,0 2005-001059-39,13,2014-09-18,2014-09-18,13,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001059-39,0,0,0 2005-001059-39,13,2014-09-18,2014-09-18,13,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001059-39,0,0,0 2005-001059-39,13,2014-09-18,2014-09-18,13,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001059-39,0,0,0 2005-001062-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"prof W.J. Fokkens, academic medical center","MACS Macrolides in chronic rhinosinusitis Double-blind, randomized, placebo-controlled, multinational, multicenter-trial on prolonged macrolide treatment in patients with moderate/ severe chronic rh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001062-14,0,0,0 2005-001067-64,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,PETHEMA Foundation,Multicentre study of optimization of therapy in mature B-cell acute lymphoblastic leukemia and Burkitt's lymphoma in adults (over 15 years),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001067-64,0,0,0 2005-001069-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Psychosis Early Detection and Intervention Centre, Department for Psychiatry, UKE Hamburg","A prospective 8 weeks acute phase-IV study investigating efficacy, safety and tolerability of Quetiapine fumarate in 60 drug-naïve first-episode psychosis patients aged 18 to 35 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001069-32,0,0,0 2005-001070-27,1,2010-02-09,2010-02-09,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Division of Angiology Graz,"Open, randomised, monosite pilot trial for comparison of thrombolytic efficacy of tenecteplase and alteplase in patients with acute pulmonary embolism",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001070-27,0,0,0 2005-001072-13,2,2012-05-14,2021-05-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,FNCLCC,A risk-adapted strategy of the use of dose-dense chemotherapy in patient with poor-prognosis dissemined non-seminomatous germ cell tumors. GETUG 13 / 0206,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001072-13,0,0,0 2005-001072-13,2,2012-05-14,2021-05-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,UNICANCER,A risk-adapted strategy of the use of dose-dense chemotherapy in patient with poor-prognosis dissemined non-seminomatous germ cell tumors. GETUG 13 / 0206,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001072-13,0,0,0 2005-001073-94,3,2006-07-17,2006-07-17,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Threshold Pharmaceuticals, Inc","A Randomised Phase 3, Double Blind, Placebo-Controlled Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001073-94,1,0,0 2005-001073-94,3,2006-07-17,2006-07-17,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,THRESHOLD PHARMACEUTICALS INC.,"A Randomised Phase 3, Double Blind, Placebo-Controlled Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001073-94,1,0,0 2005-001073-94,3,2006-07-17,2006-07-17,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Threshold Pharmaceuticals Inc,"A Randomised Phase 3, Double Blind, Placebo-Controlled Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001073-94,1,0,0 2005-001074-27,4,2008-05-05,2008-05-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ThromboGenics Ltd.,"A MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING DOSE, CLINICAL TRIAL OF INTRA-VENOUS MICROPLASMIN ADMINISTRATION IN PATIENTS WITH ACUTE ISCHEMIC STROKE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001074-27,0,0,0 2005-001075-35,1,2008-09-16,2008-09-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,ThromboGenics Ltd.,AN OPEN-LABEL CLINICAL TRIAL OF INTRA-ARTERIAL MICROPLASMIN ADMINISTRATION IN PATIENTS WITH ACUTE INTRACRANIAL VERTEBROBASILAR ARTERY OCCLUSION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001075-35,0,0,0 2005-001078-29,1,2010-01-25,2010-01-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Odense University Hospital, afd.M","Effekten af forbehandling med 0.1 mg rekombinant human TSH (rhTSH) på glandula thyreoidea’s 131I-optagelse og graden af strumareduktion efter 131I-behandling, hos patienter med atoksisk multinodøs str...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001078-29,0,0,0 2005-001084-56,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,ITALFARMACO,Phase II Multiple-Dose Clinical Trial of Oral ITF 2357 In Patients with Advanced Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001084-56,0,0,0 2005-001086-34,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,ISTITUTO GIANNINA GASLINI-PRINTO,A randomised Phase III trial of 6 months versus 12 months withdrawal of methotrexate in patients with juvenile idiopathic arthritis in clinical remission,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001086-34,0,0,0 2005-001086-34,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,A randomised Phase III trial of 6 months versus 12 months withdrawal of methotrexate in patients with juvenile idiopathic arthritis in clinical remission,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001086-34,0,0,0 2005-001086-34,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Istituto Giannina Gaslini-PRINTO,A randomised Phase III trial of 6 months versus 12 months withdrawal of methotrexate in patients with juvenile idiopathic arthritis in clinical remission,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001086-34,0,0,0 2005-001090-10,4,2007-09-07,2007-09-07,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"AstraZeneca AB, AstraZeneca Sverige","A randomised, double blind, double dummy, multicentre phase III study comparing the efficacy of budesonide/formoterol (Symbicort® forte Turbuhaler®) and oral prednisolone + formoterol (Oxis® Turbuhale...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001090-10,0,0,0 2005-001090-10,4,2007-09-07,2007-09-07,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca Oy,"A randomised, double blind, double dummy, multicentre phase III study comparing the efficacy of budesonide/formoterol (Symbicort® forte Turbuhaler®) and oral prednisolone + formoterol (Oxis® Turbuhale...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001090-10,0,0,0 2005-001092-35,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,3,,Adoptive Immuntherapie der akuten ADV-Infektion nach allogener Knochenmark- oder peripherer Blutstammzelltransplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001092-35,0,0,0 2005-001094-95,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,MELORA PORTUGUESA. LDA.,"ESTUDIO DE LOS BENEFICIOS DE LAS ISOFLAVONAS DE SOJA, GENISTEÍNA, DAIDZEÍNA Y GLICITEÍNA EN LA MUJER POSTMENOPÁUSICA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001094-95,0,0,0 2005-001095-13,1,2017-03-31,2017-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical University Innsbruck,Intragastrale Injektion von Botulinum Toxin A zur Behandlung der Adipositas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001095-13,0,0,0 2005-001097-27,1,2007-05-01,2007-05-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Bio-Gels Pharmaceuticals,A Study of the Clinical Activity of Monocaprin/Doxycycline Gel on Cold Sores,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001097-27,0,0,0 2005-001099-11,12,2008-09-22,2008-09-25,7,1,0,0,0,0,0,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,"A randomized, open label, parallel-group, international, multicenter study evaluating persistency of response to omalizumab during 32 weeks treatment given as add on to optimized asthma therapy in adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001099-11,1,0,0 2005-001099-11,12,2008-09-22,2008-09-25,7,1,0,0,0,0,0,0,0,2,1,0,0,0,1,Novartis Farmaceutica S.A.,"A randomized, open label, parallel-group, international, multicenter study evaluating persistency of response to omalizumab during 32 weeks treatment given as add on to optimized asthma therapy in adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001099-11,1,0,0 2005-001099-11,12,2008-09-22,2008-09-25,7,1,0,0,0,0,0,0,0,2,1,0,0,0,1,NOVARTIS FARMA,"A randomized, open label, parallel-group, international, multicenter study evaluating persistency of response to omalizumab during 32 weeks treatment given as add on to optimized asthma therapy in adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001099-11,1,0,0 2005-001100-40,2,2011-08-09,2011-08-09,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Cell Therapeutics Europe S.r.l.,"Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone plus Rituximab (CPOP-R) in Patients with Diffuse Large-B-cell L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001100-40,0,0,0 2005-001100-40,2,2011-08-09,2011-08-09,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,CELL THERAPEUTICS INC. SEDE SECONDARIA,"Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone plus Rituximab (CPOP-R) in Patients with Diffuse Large-B-cell L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001100-40,0,0,0 2005-001102-31,2,2007-07-31,2007-07-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma GmbH,"A phase II, open-label, multi-centre study to assess the effect of single and multiple oral doses (1 mg, 2 mg, and 3 mg) of everolimus on the pharmacokinetics of tacrolimus in stable renal transplant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001102-31,0,0,0 2005-001102-31,2,2007-07-31,2007-07-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd,"A phase II, open-label, multi-centre study to assess the effect of single and multiple oral doses (1 mg, 2 mg, and 3 mg) of everolimus on the pharmacokinetics of tacrolimus in stable renal transplant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001102-31,0,0,0 2005-001110-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FUNDACION PETHEMA,"Estudio Fase III Nacional, Abierto, Multicéntrico, Randomizado, Comparativo de VBMCP-VBAD/Velcade versus Talidomida/Dexametasona versus Velcade/Talidomida/Dexametasona como terapia de inducción seguid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001110-41,0,0,0 2005-001111-21,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Fundación PETHEMA,"Estudio Fase III Nacional, Abierto, Multicéntrico, Randomizado, Comparativo de tratamiento de inducción con Melfalán/Prednisona/VelcadeÒ versus Talidomida/Prednisona/VelcadeÒ seguido de tratamiento de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001111-21,0,0,0 2005-001112-41,4,2007-09-27,2007-11-26,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Kowa Research Europe Ltd.,"OPEN-LABEL, LONG TERM 1 YEAR EXTENSION STUDY OF PITAVASTATIN 4MG QD IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001112-41,0,0,0 2005-001112-41,4,2007-09-27,2007-11-26,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,KOWA RESEARCH EUROPE LTD,"OPEN-LABEL, LONG TERM 1 YEAR EXTENSION STUDY OF PITAVASTATIN 4MG QD IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001112-41,0,0,0 2005-001113-18,1,2008-09-17,2008-09-17,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Universitätsklinikum Münster,Beeinflussung assoziativen Lernens und motorischer Fähigkeiten durch G-CSF und EPO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001113-18,0,0,0 2005-001117-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GEICAM (GRUPO ESPAÑOL DE INVESTIGACION EN CANCER DE MAMA),"PHASE IV.II, CLINICAL TRIAL, WITH THE COMBINATION OF PEGYLATED LIPOSOMAL DOXORUBICIN (CAELYX), CYCLOPHOSPHAMIDE AND TRASTUZUMAB (HERCEPTIN) IN PATIENTS WITH METASTATIC BREAST CANCER WITH OVEREXPRESSIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001117-17,0,0,0 2005-001122-87,2,2006-01-13,2006-01-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline Research and Development,"A Randomized Double-Blind Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 200mcg, 400mcg, 600mcg and 800mcg Administered Once ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001122-87,0,0,0 2005-001123-11,3,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GlaxoSmithKline Research and Development Ltd,"A Randomized Double-Blind Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 25mcg, 50mcg, 100mcg, and 200mcg Administered Once D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001123-11,0,0,0 2005-001124-36,4,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,GlaxoSmithKline Research and Development,"A Randomized Double-Blind Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 100mcg, 200mcg, 300mcg and 400mcg Administered Once ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001124-36,0,0,0 2005-001128-35,3,2006-07-25,2006-07-25,2,1,0,0,1,0,0,0,0,1,0,0,1,0,1,PHARMACIA UPJOHN,"A 12-week randomised, evaluator-masked, parallel-group, multinational, multi-centre study comparing the efficacy and safety of the fixed combination of latanoprost and timolol (XalacomTM) with the fix...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001128-35,0,0,0 2005-001128-35,3,2006-07-25,2006-07-25,2,1,0,0,1,0,0,0,0,1,0,0,1,0,1,Pfizer AB,"A 12-week randomised, evaluator-masked, parallel-group, multinational, multi-centre study comparing the efficacy and safety of the fixed combination of latanoprost and timolol (XalacomTM) with the fix...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001128-35,0,0,0 2005-001128-35,3,2006-07-25,2006-07-25,2,1,0,0,1,0,0,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A 12-week randomised, evaluator-masked, parallel-group, multinational, multi-centre study comparing the efficacy and safety of the fixed combination of latanoprost and timolol (XalacomTM) with the fix...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001128-35,0,0,0 2005-001131-30,1,2011-01-25,2011-01-25,1,0,0,0,0,1,3,0,0,1,0,0,1,0,1,Fresenius Biotech North America,"A Double-Blind, Placebo-Controlled, Multicenter, Dose-ranging Study of an Anti-T-lymphocyte Immunglobuline (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001131-30,0,0,0 2005-001132-72,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO EUROPEO DI ONCOLOGIA,A Phase 2 Study of combined modality treatment with primary chemotherapy followed by endoscopic laser resection in intermediate stage laryngeal squamous cell carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001132-72,0,0,0 2005-001133-15,3,2006-03-06,2006-03-06,1,1,0,0,0,3,2,0,0,1,0,0,1,0,1,NV Organon,"A multi-center, randomized, open-label, prospective bridging, parallel dosefinding trial comparing efficacy, safety and pharmacokinetics of 4 doses of Org 25969 and placebo administered at reappearanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001133-15,0,0,0 2005-001134-32,1,2006-04-11,2006-04-11,1,1,0,0,0,3,2,0,0,1,0,0,1,0,1,NV Organon,"A multi-center, randomized, open-label, prospective bridging, parallel dosefinding trial comparing efficacy and safety of 5 doses of Org 25969 administered at 1-2 PTC after rocuronium or vecuronium in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001134-32,0,0,0 2005-001135-30,7,2006-03-06,2006-03-06,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,NV Organon,"A multi-center, randomized, parallel group, comparative, active controlled, safety-assessor blinded, phase IIIa, pivotal trial, in adult subjects comparing Org 25969 with neostigmine as reversal agent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001135-30,0,0,0 2005-001135-30,7,2006-03-06,2006-03-06,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,ORGANON ITALIA,"A multi-center, randomized, parallel group, comparative, active controlled, safety-assessor blinded, phase IIIa, pivotal trial, in adult subjects comparing Org 25969 with neostigmine as reversal agent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001135-30,0,0,0 2005-001136-76,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,KEDRION,Double blind Randomized Controlled trial of prolonged treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)with high dose intravenous immunoglobulins (IVIg) or intravenous meti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001136-76,0,0,0 2005-001138-33,7,2007-04-23,2007-12-19,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann La-Roche AG,"A randomized, double-blind, double-dummy, parallel group study of the safety and efficacy of MRA monotherapy, versus methotrexate MTX monotherapy, in patients with active rheumatoid arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001138-33,0,0,0 2005-001138-33,7,2007-04-23,2007-12-19,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A randomized, double-blind, double-dummy, parallel group study of the safety and efficacy of MRA monotherapy, versus methotrexate MTX monotherapy, in patients with active rheumatoid arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001138-33,0,0,0 2005-001139-31,4,2019-03-11,2019-03-11,1,0,0,0,0,1,0,0,0,2,0,0,0,0,0,CHC-Clinique Espérance,"A protocol for localized non rhabdomyosarcoma Soft Tissue Sarcomas, in paediatric age protocollo di studio per sarcomi dei tessuti molli localizzati, non rabdomiosarcomi, in eta' pediatrica",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001139-31,1,0,0 2005-001139-31,4,2019-03-11,2019-03-11,1,0,0,0,0,1,0,0,0,2,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,"A protocol for localized non rhabdomyosarcoma Soft Tissue Sarcomas, in paediatric age protocollo di studio per sarcomi dei tessuti molli localizzati, non rabdomiosarcomi, in eta' pediatrica",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001139-31,1,0,0 2005-001139-31,4,2019-03-11,2019-03-11,1,0,0,0,0,1,0,0,0,2,0,0,0,0,0,Our Lady's Children's Hospital,"A protocol for localized non rhabdomyosarcoma Soft Tissue Sarcomas, in paediatric age protocollo di studio per sarcomi dei tessuti molli localizzati, non rabdomiosarcomi, in eta' pediatrica",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001139-31,1,0,0 2005-001139-31,4,2019-03-11,2019-03-11,1,0,0,0,0,1,0,0,0,2,0,0,0,0,0,"Research and Development Directorate, University Hospitals of Leicester NMS Trust","A protocol for localized non rhabdomyosarcoma Soft Tissue Sarcomas, in paediatric age protocollo di studio per sarcomi dei tessuti molli localizzati, non rabdomiosarcomi, in eta' pediatrica",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001139-31,1,0,0 2005-001143-31,1,2006-02-03,2006-02-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Nippon Suisan Kaisha, Ltd","A Phase II, Multicentre, Double-blind, Parallel Group 8 Week Study to Assess the Efficacy and Safety of Two Doses of CNS-242 in Lowering Serum Uric Acid (SUA) and Preventing Gout Attacks in Gout Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001143-31,0,0,0 2005-001144-23,1,2008-01-23,2008-01-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Simultaneous Pancreas-Kidney Transplant Recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001144-23,0,0,0 2005-001148-22,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"A 12-Months, Randomized, Double-Blind, Parallel-Group, Multicenter, Proof of Concept Study of the Efficacy of Oral RAD001 (6 mg/day) versus Azathioprine and Placebo in Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001148-22,0,0,0 2005-001150-24,4,2007-07-30,2007-09-11,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GLAXO SMITHKLINE,"A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, Pharmacokinetics and Antiviral Activity of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy Comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001150-24,0,0,0 2005-001150-24,4,2007-07-30,2007-09-11,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd.,"A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, Pharmacokinetics and Antiviral Activity of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy Comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001150-24,0,0,0 2005-001161-34,2,2010-01-14,2010-10-19,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Pharma Mar SA, sociedad unipersonal","Phase I-II multicenter, randomized, open-label, clinical and pharmacokinetic study of plitidepsin, administered alone or in combination with dacarbazine, as front-line therapy to subjects with unresec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001161-34,0,0,0 2005-001161-34,2,2010-01-14,2010-10-19,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Pharma Mar SA,"Phase I-II multicenter, randomized, open-label, clinical and pharmacokinetic study of plitidepsin, administered alone or in combination with dacarbazine, as front-line therapy to subjects with unresec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001161-34,0,0,0 2005-001164-32,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)","A RANDOMIZED STUDY, POSPECTIVE, ON THREE DIFFERENT STRATEGY OF HIV POSITIVE NAIVE FOR THE ANTIRETROVIRAL THERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001164-32,0,0,0 2005-001165-33,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Bart Morlion,"A prospective, open randomized, parallel group trial to compare the efficacy and safety of transdermal buprenorphine (Transtec) with gabapentin (Neurontin) in patients with neuropatic pain syndromes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001165-33,0,0,0 2005-001166-13,1,2008-11-20,2008-11-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Cougar Biotechnology, Inc","A Phase I/II Open Label Study of the 17α-hydroxylase/ C17,20 lyase inhibitor, Abiraterone acetate, in Patients with Prostate Cancer who have failed hormone therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001166-13,0,0,0 2005-001169-32,12,2008-03-24,2013-06-30,11,1,0,0,0,2,0,0,2,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized Two-Arm, Multicenter, Open-Label Phase II Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001169-32,0,0,0 2005-001169-32,12,2008-03-24,2013-06-30,11,1,0,0,0,2,0,0,2,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"A Randomized Two-Arm, Multicenter, Open-Label Phase II Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001169-32,0,0,0 2005-001171-36,2,2007-07-18,2007-07-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ThromboGenics Ltd.,A Dose-Escalation Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy for Vitreomacular Traction Maculopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001171-36,0,0,0 2005-001173-96,1,2011-07-26,2011-07-26,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,University College London,"Porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with advanced or metastatic cholangiocarcinomas and other biliary tract tumours: a multicentre, randomised, phase l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001173-96,0,0,0 2005-001176-12,1,2007-05-11,2007-05-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, double-dummy, parallel-group study to compare the effects of multiple dose administration of aliskiren and irbesartan on biomarkers of inflammation and cardiovascular risk ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001176-12,0,0,0 2005-001179-36,1,2007-06-08,2007-06-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Alcon Pharma GmbH,"Efficacy and safety of Dexa-Polyspectran® drops, preserved with benzalkonium chloride, vs. Dexa-Polyspectran® drops without dexamethasone phosphate, preserved with benzalkonium chloride, in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001179-36,0,0,0 2005-001180-65,1,2007-07-06,2007-07-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Alcon Pharma GmbH,"Efficacy and safety of Polyspectran® drops, preserved with benzalkonium chloride vs. glycerol ear drops in patients with acute bacterial otitis externa – A double-blind, multicenter, prospective, ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001180-65,0,0,0 2005-001183-31,5,2006-03-10,2006-06-01,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A prospective, open label, randomized, multicenter, multinational study evaluating the overall efficacy and safety including the effect on renal function of sirolimus (Rapamune) replacing CNI in a sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001183-31,0,0,0 2005-001185-14,7,2006-08-21,2006-10-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"Safety and Efficacy of Adalimumab in Patients with Psoriatic Arthritis (PsA)- An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Stan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001185-14,0,0,0 2005-001186-34,1,2010-02-02,2010-02-02,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Julian Panés,Utilidad del tratamiento precoz con azatioprina en la enfermedad de Crohn (EC). Impacto en el mantenimiento de la remisión de la EC y en la prevención del desarrollo de un fenotipo fistulizante.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001186-34,0,0,0 2005-001187-31,8,2007-01-19,2007-01-30,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,TAP Pharmaceutical Products Inc.,"A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mgQD) on Healing of Erosive Esophagitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001187-31,0,0,0 2005-001188-70,6,2007-01-22,2007-01-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TAP Pharmaceutical Products Inc.,"A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mgQD) on Healing of Erosive Esophagitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001188-70,0,0,0 2005-001189-15,5,2006-03-09,2006-03-09,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,TAP Pharmaceutical Products Inc.,A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001189-15,0,0,0 2005-001190-10,5,,,0,1,0,0,0,0,3,0,0,1,1,0,0,1,1,TAP Pharmaceutical Products Inc.,A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001190-10,0,0,0 2005-001191-12,1,2008-01-01,2008-01-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Odense Universitetshospital,Forebyggelse af inkompenseret levercirrose med Losartan Et prospektivt randomiseret dobbeltblindet lantidsstudie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001191-12,0,0,0 2005-001192-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Vicente Soriano-Hospital Carlos III. Madrid,Open pilot study phase IV to treat co infected HCV-HIV patients after their relapse with interferon therapy. Tratamiento de los pacientes con hepatitis crónica C infectados por el VIH que han recaído ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001192-34,0,0,0 2005-001193-28,1,2009-04-01,2009-04-01,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Myogen, Inc","ARIES-320/321-E “A Long-Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 or AMB-321""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001193-28,0,0,0 2005-001194-96,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Laboratorios LETI, S.L. Unipersonal",Extracto alergénico de Chortoglyphus arcuatus. Determinación de la potencia alergénica in vivo en unidades equivalentes de histamina (HEP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001194-96,0,0,0 2005-001195-13,1,2010-11-01,2010-11-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leeds,The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) Prisons Project: An open label pragmatic randomised control trial comparing the efficacy of differing therapeutic agents for prison pri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001195-13,0,0,0 2005-001201-25,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,Gedeon Richter Ltd,"Phase II placebo-controlled study to evaluate the efficacy, safety and tolerability of RGH-896 in patients with pain due to diabetic sensorimotor peripheral neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001201-25,0,0,0 2005-001202-60,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Organisation name was not entered,Metotreksaatti aksiaalisen spondyloartropatian hoidossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001202-60,0,0,0 2005-001203-19,1,2006-02-23,2006-02-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of research & development, TheLeeds teaching hospitals NHS trust",Does Hyaluronidase permit volume reduction in sub-Tenon anaestehesia?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001203-19,0,0,0 2005-001207-19,1,2008-12-16,2008-12-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Universitaetsklinikum Hamburg,Randomized multicenter open label trial comparing the efficacy and safety of 48 versus 72 weeks of Peginterferon-alfa-2a plus daily Ribavirin and Amantadinsulfat in patients with chronic Hepatitis C i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001207-19,0,0,0 2005-001209-24,1,2009-02-27,2009-02-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Bristol,"A double-blind, placebo controlled parallel group pilot study of the effectiveness of D-cycloserine in reducing craving during cue-exposure therapy in abstinent alcohol dependent subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001209-24,0,0,0 2005-001212-44,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CONSORZIO ONCOTECH,Letrozole adjuvant therapy duration (LEAD)study: standard versus long treatment. A phase III study in postmenopausal women with early breast cancer Terapia ormonale adiuvante con letrozolo: terapia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001212-44,0,0,0 2005-001213-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CONSORZIO ONCOTECH,Letrozole adjuvant therapy after tamoxifen. Study of gene CYP19 correlation with letrozole efficacy in postmenopausal early breast cancer patients Terapia adiuvante con Letrozolo dopo Tamoxifene. S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001213-18,0,0,0 2005-001214-40,1,2009-01-21,2009-01-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London,A trial to compare the effects of nebivolol versus atenolol on various cardiovascular measurements including insulin sensitivity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001214-40,0,0,0 2005-001217-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Max-Planck-Institute of Psychiatry,"Comparison of venlafaxine augmentation with lamotrigine, quetiapine, or placebo in treatment resistant depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001217-17,0,0,0 2005-001218-42,1,,,0,1,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Clinical role of PPAR gamma activator (pioglitazone) in reducing the gastric phlogosis in patiens with istological gastritis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001218-42,0,0,0 2005-001220-37,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Hoffmann-La Roche AG,A pilot study of trastuzumab monotherapy in patients who progressed under a previous platinum-based or 5-fluoropyrimidin-based chemotherapy in metastatic or locally advanced gastric cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001220-37,0,0,0 2005-001221-28,7,2010-06-24,2010-09-17,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, open label study to compare the development of liver fibrosis after transplantation for hepatitis C cirrhosis in patients receiving either Neoral or tacrolimus.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001221-28,0,0,0 2005-001221-28,7,2010-06-24,2010-09-17,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A multicenter, randomized, open label study to compare the development of liver fibrosis after transplantation for hepatitis C cirrhosis in patients receiving either Neoral or tacrolimus.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001221-28,0,0,0 2005-001221-28,7,2010-06-24,2010-09-17,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Novartis S.A.,"A multicenter, randomized, open label study to compare the development of liver fibrosis after transplantation for hepatitis C cirrhosis in patients receiving either Neoral or tacrolimus.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001221-28,0,0,0 2005-001222-83,1,2015-09-01,2015-09-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London,A phase I/II safety and tolerability dose escalation study following the autologous infusion of expanded adult haemopoietic stem cells to patients with liver insufficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001222-83,0,0,0 2005-001224-36,1,2012-10-26,2012-10-26,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Pfizer Inc. - Research & Development,"Phase 1, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CP-751,871 in Patients with Advanced Solid Tumours",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001224-36,0,0,0 2005-001228-35,1,,,0,1,0,0,1,0,3,0,0,3,0,0,0,0,1,Bio Products Laboratory,"A randomized, single-blind, parallel-group, multi-center comparative study to assess the efficacy and safety of an application of Fybex (fibrin sealant) to the operative field, for the reduction of po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001228-35,0,0,0 2005-001229-27,1,2006-12-04,2006-12-04,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Bio Products Laboratory,"A randomized, sigle-blind, parallel group, multicentre comparative study to assess the efficacy and safety of an application of Fybex (fibrin sealant) to the operative field, for the reduction of post...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001229-27,0,0,0 2005-001231-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Dept of Transplantation Surgery B 56, Karolinska University Hospital, Huddinge","A PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED, MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF RITUXIMAB AS INDUCTION THERAPY TOGETHER WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS FOR PATIENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001231-29,0,0,0 2005-001233-16,1,,,0,1,0,0,1,0,3,0,0,1,0,0,0,1,1,Bristol-Myers Squibb International Corporation,Efficacy of Aripiprazole in Combination with Lithium or Valproate in the Long Term Treatment of Mania in Patients with Bipolar I Disorder Partially Nonresponsive to Lithium or Valproate Monotherapy R...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001233-16,0,0,0 2005-001234-32,4,2006-11-29,2006-11-29,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Janssen Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for the Prophylaxis of Migraine in Pediatric Subjects 12 to 17 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001234-32,1,0,0 2005-001234-32,4,2006-11-29,2006-11-29,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Jansen-Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for the Prophylaxis of Migraine in Pediatric Subjects 12 to 17 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001234-32,1,0,0 2005-001234-32,4,2006-11-29,2006-11-29,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for the Prophylaxis of Migraine in Pediatric Subjects 12 to 17 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001234-32,1,0,0 2005-001235-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Genaera Corporation,"A Phase 3 Multicenter, Randomized, Double-Masked, Controlled Study of Squalamine Lactate (MSI-1256F) for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Relat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001235-30,0,0,0 2005-001239-32,1,2008-07-16,2008-07-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Laboratorios SALVAT, S.A.","Ensayo clínico multicéntrico, aleatorizado, paralelo, doble ciego, para evaluar la eficacia y seguridad de eberconazol solución 1% frente a placebo en el tratamiento de las dermatofitosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001239-32,0,0,0 2005-001242-17,3,2006-11-23,2007-05-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA Pharma AG,Efficacy and Safety – Study by ALTANA on Ciclesonide in Pre-school Asthma Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001242-17,0,0,0 2005-001243-28,1,2006-09-08,2006-09-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,essex pharma GmbH,Study to determine the non inferiority of GROUP I (“high need”) compared to GROUP II (“low need”) concerning the efficacy of infliximab with respect to safety and tolerability in patients suffering fr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001243-28,0,0,0 2005-001245-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Department of Dermatology, Hospital of the Medical University Graz","A single-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Dapsone in adult patients with cutaneous leukocytoclastic vasculitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001245-41,0,0,0 2005-001246-16,6,2005-09-14,2007-06-27,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development,"A Phase III, randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001246-16,0,0,0 2005-001247-39,6,2007-08-08,2007-10-23,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Phase III, randomised, double-blind, placebo-controlled, multicentre, parallel group study to compare the efficacy and safety of GW873140 400mg BID in combination with a ritonavir-containing optimis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001247-39,0,0,0 2005-001248-22,2,2010-01-07,2010-01-26,2,0,0,0,0,0,0,0,0,1,1,0,1,0,0,Fertilitetsklinikken Nordica,A prospective randomized multicentre study to compare Crinone 8% once daily versus other vaginal progesterone.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001248-22,0,0,0 2005-001248-22,2,2010-01-07,2010-01-26,2,0,0,0,0,0,0,0,0,1,1,0,1,0,0,Fertilitetsklinikken Herlev Hospital,A prospective randomized multicentre study to compare Crinone 8% once daily versus other vaginal progesterone.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001248-22,0,0,0 2005-001250-24,1,2006-04-05,2006-04-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,APOGEPHA Arzneimittel GmbH,Proof-of-Concept Trial of NS-8 in 3 doses: Comparison of efficacy and tolerability in patients with overactive bladder.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001250-24,0,0,0 2005-001252-21,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Novartis Pharma Services AG,"An open-label, multiple-dose study to evaluate the pharmacokinetics, safety and tolerability of SPP100 (Aliskiren) and Atenolol (Tenormin®) administered alone and in combination in healthy subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001252-21,0,0,0 2005-001254-25,1,2010-05-28,2010-05-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,CMC Contrast AB,"Evaluation of the diagnostic efficacy of CMC-001 (manganese chloride tetrahydrate) in liver MR-imaging in patients with liver metastases. A randomised, parallel group, open-label Phase II trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001254-25,0,0,0 2005-001256-20,9,2006-11-09,2006-12-28,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd.,"A randomized, double blind, double dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 250mg, 375mg an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001256-20,0,0,0 2005-001256-20,9,2006-11-09,2006-12-28,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXO SMITHKLINE,"A randomized, double blind, double dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 250mg, 375mg an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001256-20,0,0,0 2005-001256-20,9,2006-11-09,2006-12-28,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A randomized, double blind, double dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 250mg, 375mg an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001256-20,0,0,0 2005-001258-26,7,2007-03-14,2008-10-08,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An 8 week extension to a randomized, double-blind, parallel group, active-controlled, multi-center, 14 week study to evaluate the effectiveness of a valsartan versus anamlodipine treatment strategy i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001258-26,0,0,0 2005-001258-26,7,2007-03-14,2008-10-08,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Faarmacéutica S.A,"An 8 week extension to a randomized, double-blind, parallel group, active-controlled, multi-center, 14 week study to evaluate the effectiveness of a valsartan versus anamlodipine treatment strategy i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001258-26,0,0,0 2005-001258-26,7,2007-03-14,2008-10-08,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An 8 week extension to a randomized, double-blind, parallel group, active-controlled, multi-center, 14 week study to evaluate the effectiveness of a valsartan versus anamlodipine treatment strategy i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001258-26,0,0,0 2005-001259-39,1,2006-07-01,2006-07-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,West Herts NHS Trust,An investigation into a novel clinical use of a single low dose of insulin in the prevention of excessive cutaneous scarring,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001259-39,0,0,0 2005-001260-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA USL 6 LIVORNO ZONA LIVORNESE,PHASE II MULTICENTRIC STUDY OF SEQUENTIAL CHEMOTHERAPY WITH GEMCITABINE FOLLOWED FROM DOCETAXEL IN ELDERLY PATIENTS WITH NOT SMALL CELLS LUNG CANCER NSCLC ADVANCED,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001260-31,0,0,0 2005-001264-31,2,2007-06-20,2007-06-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCHERING-PLOUGH,PEG-Intron/Rebetol vs PEG-Intron/ SCH 503034 With and Without Ribavirin in Chronic Hepatitis C HCV 1 Peginterferon alfa/Ribavirin Nonresponders: A SCH 503034 Dose Finding Phase 2 Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001264-31,0,0,0 2005-001264-31,2,2007-06-20,2007-06-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Schering-Plough Research Institute,PEG-Intron/Rebetol vs PEG-Intron/ SCH 503034 With and Without Ribavirin in Chronic Hepatitis C HCV 1 Peginterferon alfa/Ribavirin Nonresponders: A SCH 503034 Dose Finding Phase 2 Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001264-31,0,0,0 2005-001267-63,2,2006-02-01,2006-02-01,1,1,0,0,0,2,0,0,0,1,0,0,1,0,0,ISTITUTO GIANNINA GASLINI,A PHASE I BRIDGING STUDY USING CH14.18/CHO ANTIBODY IN CHILDREN WITH REFRACTORY NEUROBLASTOMA (NB),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001267-63,0,0,0 2005-001267-63,2,2006-02-01,2006-02-01,1,1,0,0,0,2,0,0,0,1,0,0,1,0,0,St. Anna Kinderspital,A PHASE I BRIDGING STUDY USING CH14.18/CHO ANTIBODY IN CHILDREN WITH REFRACTORY NEUROBLASTOMA (NB),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001267-63,0,0,0 2005-001268-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SOFAR SPA,Not applicable,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001268-30,0,0,0 2005-001269-32,1,2007-02-28,2007-02-28,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Universitätskinderklinik Innsbruck,Clinical trial on skin care in Neonatology. A comparison between two skin care products and no skin care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001269-32,0,0,0 2005-001270-27,2,2008-04-09,2008-05-15,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,PFIZER LTD,A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 ADMINISTERED IN A CONTINUOUS DAILY REGIMEN IN PATIENTS WITH CYTOKINE-REFRACTORY METASTATIC RENAL CELL CARCINOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001270-27,0,0,0 2005-001270-27,2,2008-04-09,2008-05-15,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 ADMINISTERED IN A CONTINUOUS DAILY REGIMEN IN PATIENTS WITH CYTOKINE-REFRACTORY METASTATIC RENAL CELL CARCINOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001270-27,0,0,0 2005-001271-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA USL 6 LIVORNO ZONA LIVORNESE,ASSOCIATION OF CAPECITABINA And GEMCITABIN In METASTATIC MAMMARY CARCINOMA CLINICAL STUDY of Dose-finding and Activity Of the ASSOCIATION PHASE I-II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001271-35,0,0,0 2005-001278-28,1,2006-10-20,2006-10-20,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Technical University of Munich,Untersuchungen über die Wirkung der gestörten Glucosetoleranz auf die renale und systemische Hämodynamik und das renin-Angiotensin-System sowie deren pharmakologische Beeinflussung mittels AT1-Rezepto...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001278-28,0,0,0 2005-001279-36,1,2006-09-05,2006-09-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Hexal AG,"RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE II STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF GOSERELIN 3M IMPLANT HEXAL IN PATIENTS WITH ADVANCED PROSTATIC CANCER IN COMPARISON TO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001279-36,0,0,0 2005-001281-13,1,2014-01-16,2014-01-16,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,"DSC Services, s.r.o.",Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001281-13,0,0,0 2005-001282-34,2,2006-03-16,2006-03-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AXCAN PHARMA Inc.,"A multicentre, randomized, double-blind, placebo-controlled study of the efficacy and safety of itopride HCl in patients suffering from functional dyspepsia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001282-34,0,0,0 2005-001288-73,2,2007-09-06,2008-02-13,2,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of four different formulations of GlaxoSmithKline (GSK) Bio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001288-73,0,0,0 2005-001290-10,7,2008-04-11,2008-10-08,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,A study to provide expanded access of EXJADE (deferasirox) to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated w...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001290-10,0,0,0 2005-001290-10,7,2008-04-11,2008-10-08,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,A study to provide expanded access of EXJADE (deferasirox) to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated w...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001290-10,0,0,0 2005-001290-10,7,2008-04-11,2008-10-08,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Novartis Farmaceútica, S.A.",A study to provide expanded access of EXJADE (deferasirox) to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated w...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001290-10,0,0,0 2005-001291-12,1,2009-06-12,2009-06-12,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Cardiff University,Histamine Release and Implications of H1- and H2- Blockade in Adult Cardiac Surgery - A Randomised Controlled Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001291-12,0,0,0 2005-001294-99,13,2014-07-14,2014-07-14,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001294-99,0,0,0 2005-001297-27,1,2006-12-21,2006-12-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Neolab td,Comparative Efficacy & Safety of Two Intranasal Fluticasone Propionate Formulations in Persistent Allergic Rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001297-27,0,0,0 2005-001300-39,2,2007-07-17,2008-06-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dompé s.p.a.,"A phase 2, multi-centre, randomized, double-blind, placebo-controlled, parallel-group 3 arms pilot study to assess the efficacy, the safety and the pharmacokinetics of two treatment schedules of rep...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001300-39,0,0,0 2005-001300-39,2,2007-07-17,2008-06-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,DOMPE s.p.a.,"A phase 2, multi-centre, randomized, double-blind, placebo-controlled, parallel-group 3 arms pilot study to assess the efficacy, the safety and the pharmacokinetics of two treatment schedules of rep...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001300-39,0,0,0 2005-001303-19,1,2008-04-10,2008-04-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 ADMINISTERED IN A CONTINUOUS DAILY REGIMEN IN PATIENTS WITH ADVANCED GASTRO INTESTINAL STROMAL TUMOR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001303-19,0,0,0 2005-001306-87,1,2008-05-27,2008-05-27,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,TAKEDA,EFFECTS OF CANDESARTAN CILEXETIL VS STANDARD THERAPY ON SERUM LEVELS OF BRAIN NATRIURETIC PEPTIDE IN PATIENTS SUFFERING FROM CHRONIC HEART FAILURE WITH DEPRESSED AND PRESERVED SYSTOLIC FUNCTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001306-87,0,0,0 2005-001315-22,1,2009-07-31,2009-07-31,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Ludwig Boltzmann Gesellschaft,The effect of the cholinesterase inhibitor donepezil on organic and functional deficits related to growth hormone deficiency in old age.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001315-22,0,0,0 2005-001316-47,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Turku University Central Hospital,"Bevacizumab (Avastin™), dacarbazine and interferon α-2a (Roferon-A; IFN α-2a ) combination as a first-line therapy in patients with locally advancing or metastatic melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001316-47,0,0,0 2005-001319-23,3,2000-10-20,2006-10-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,WYETH LEDERLE,"A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Ther...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001319-23,0,0,0 2005-001319-23,3,2000-10-20,2006-10-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development,"A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Ther...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001319-23,0,0,0 2005-001321-28,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AISSM ONLUS,Phase II multicenter study of association of arsenic trioxide (ATO) and ascorbic acid in myelodisplastic syndromes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001321-28,0,0,0 2005-001324-36,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Instituto Oftalmológico de Alicante (VISSUM),"ENSAIO CLÍNICO DE FASE IIIB, PROSPECTIVO, CONTROLADO, COM OCULTAÇÃO DUPLA, ALEATÓRIO COM GRUPOS PARALELOS E MULTICÊNTRICO PARA COMPARAR A SEGURANÇA E A EFICÁCIA DA TERAPIA FOTODINÂMICA COM VERTEPORFIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001324-36,0,0,0 2005-001332-69,1,2007-07-01,2007-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Aberdeen,A randomised control trial of omega-3 fatty acid on platelet and endothelial function in patients with peripheral arterial disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001332-69,0,0,0 2005-001335-30,6,2007-08-21,2007-09-11,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithkline S.A.,"A Multicentre, Two-Part, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Tolerability and Pharmacokinetics of the iNOS Inhibitor GW274150 Administered up t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001335-30,0,0,0 2005-001335-30,6,2007-08-21,2007-09-11,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D,"A Multicentre, Two-Part, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Tolerability and Pharmacokinetics of the iNOS Inhibitor GW274150 Administered up t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001335-30,0,0,0 2005-001335-30,6,2007-08-21,2007-09-11,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R D,"A Multicentre, Two-Part, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Tolerability and Pharmacokinetics of the iNOS Inhibitor GW274150 Administered up t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001335-30,0,0,0 2005-001338-33,8,2006-07-27,2007-11-05,6,1,0,0,0,2,3,0,0,2,1,0,0,0,1,JANSSEN-CILAG,"A Randomized, Double-Blind, Placebo Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurren...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001338-33,1,0,0 2005-001338-33,8,2006-07-27,2007-11-05,6,1,0,0,0,2,3,0,0,2,1,0,0,0,1,Janssen-Cilag International N.V.,"A Randomized, Double-Blind, Placebo Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurren...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001338-33,1,0,0 2005-001339-31,1,2007-10-31,2007-10-31,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Jansenn Cilag International N.V.,"Estudio abierto, aleatorizado, multicéntrico con extensión abierta para evaluar la farmacocinética y seguridad de la solución oral líquida y de la formulación dispersable de topiramato como terapia a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001339-31,0,0,0 2005-001340-22,4,2008-07-03,2008-07-03,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Bayhill Therapeutics,BHT-3009 IMMUNOTHERAPY IN RELAPSING REMITTING MULTIPLE SCLEROSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001340-22,1,0,0 2005-001341-42,1,2012-04-20,2012-04-20,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Rigshospitalet,Treatment strategy in adrenocortical carcinomas Fase II trial with docetaxel and cisplatin in patients with locally advanced or disseminated adrenocortical carcinomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001341-42,0,0,0 2005-001347-37,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,Gemtuzumab ozogamicin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61-75 years old with previously untreate...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001347-37,0,0,0 2005-001348-22,7,2007-08-31,2008-02-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma GmbH,"AN OPEN, RANDOMISED, MULTICENTRE CLINICAL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF STEROID WITHDRAWAL WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND DACLIZUMAB AGAINST TACROLIMUS, MYCOPHENOLATE MOF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001348-22,0,0,0 2005-001348-22,7,2007-08-31,2008-02-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd,"AN OPEN, RANDOMISED, MULTICENTRE CLINICAL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF STEROID WITHDRAWAL WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND DACLIZUMAB AGAINST TACROLIMUS, MYCOPHENOLATE MOF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001348-22,0,0,0 2005-001349-40,3,2008-05-06,2008-05-06,3,1,0,0,1,0,3,0,0,1,1,0,1,0,1,Chiron Corporation Limited,"A Multicentre, Randomised, Assessor-Blind Study to Evaluate Efficacy and Safety of Daptomycin versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (cSSTI)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001349-40,0,0,0 2005-001349-40,3,2008-05-06,2008-05-06,3,1,0,0,1,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A Multicentre, Randomised, Assessor-Blind Study to Evaluate Efficacy and Safety of Daptomycin versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections (cSSTI)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001349-40,0,0,0 2005-001350-24,7,2012-02-06,2012-02-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Celltech,"A Phase III multi-centre, open-label, follow-on study to CDP870-027, to assess the efficacy and safety of lyophilised CDP870 an engineered human anti-TNF PEG conjugate, as additional medication to met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001350-24,0,0,0 2005-001350-24,7,2012-02-06,2012-02-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Inc.,"A Phase III multi-centre, open-label, follow-on study to CDP870-027, to assess the efficacy and safety of lyophilised CDP870 an engineered human anti-TNF PEG conjugate, as additional medication to met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001350-24,0,0,0 2005-001354-25,1,2009-04-01,2009-04-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Dundee,Use of Omega-3 poyunsaturated Fatty Acid Supplements to Maintain Sinus Rhythm in Persistent Atrial Fibrillation:a prospective and randomised study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001354-25,0,0,0 2005-001356-20,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Reckitt Benckiser (UK) Limited,"A preliminary single dose, three-way, double-blind, placebo-controlled crossover study of intravenous buprenorphine/naloxone in the treatment of neuropathic pain of diabetic neuropathy origin.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001356-20,0,0,0 2005-001360-31,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ABIOGEN PHARMA,"A multicenter, randomised, double- blind, between-patient, dose finding study to assess the safety, tolerability and efficacy of three different dosages (500, 1000 and 2000 mcg/g) of ABIO 12/01 gel, i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001360-31,0,0,0 2005-001361-34,1,2006-09-30,2006-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,A randomised controlled trial of oxytocin 5 IU versus oxytocin 5 IU and 30 IU infusion for the control of blood loss at elective caesarean section - pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001361-34,0,0,0 2005-001362-14,3,2007-10-30,2007-10-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"Open-label, single-arm, multicenter phase II study of matuzumab in combination with irinotecan background chemotherapy in subjects with epidermal growth factor receptor (EGFR)-expressing metastatic co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001362-14,0,0,0 2005-001363-58,1,2007-03-12,2007-03-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Photopharmica Ltd,"Phase IIa randomised, placebo controlled trial to investiagte antimicrobial photodynamic therapy in chronic leg ulcers and diabetic foot ulcers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001363-58,0,0,0 2005-001371-35,1,2005-05-26,2005-05-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Stiefel Laboratories Maidenhead Ltd (commonly known as Stiefel Laboratories International Division),"A Double-Blind, Placebo Controlled, Half-Head Design, CPO Solution Dose Ranging-Finding Study in Patients with Seborrhoeic Dermatitis of the Scalp",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001371-35,0,0,0 2005-001372-12,1,2007-11-23,2007-11-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Netherlands B.V.,"An open-label, non-randomized, single arm study, to investigate the mechanism(s) by which nevirapine increases plasma high density lipoproteins concentration in HIV + subjects treated with Viramune ta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001372-12,0,0,0 2005-001373-97,9,2007-01-02,2007-02-01,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Long-Term, Post treatment, Safety Follow-up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLEX or ARMOR Studies, G-PLUS (GALLANT, GALLEX and ARMOR - Post treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001373-97,0,0,0 2005-001376-12,1,2011-08-04,2011-08-04,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Sheffield,Cost-effective use of BISphonphonates in metastatic bone disease - a comparison of bone MARKer directed zoledronic acid therapy to a standard schedule.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001376-12,0,0,0 2005-001378-29,1,2009-11-04,2009-11-04,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Bradford Teaching Hospitals NHS Foundation Trust,A double blinded randomised controlled trial of injection of botulinum toxin versus normal saline into the puborectalis muscle in patients with pelvic floor dyssynergia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001378-29,0,0,0 2005-001380-61,1,2013-04-22,2013-04-22,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,An extension to a phase II open label study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast cris...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001380-61,0,0,0 2005-001381-14,1,2013-09-23,2013-09-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,An extension to a phase II study to determine the safety and the anti- leukemic effects of STI571 in adults patients with Philadelphia chromosome positive leukemia including acute lymphoblastic leuke...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001381-14,0,0,0 2005-001382-33,1,2013-11-29,2013-11-29,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,An extension to a phase II study to determine the efficacy and the safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha estensione dell...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001382-33,0,0,0 2005-001384-60,1,2005-11-29,2005-11-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare,"An exploratory, observational cohort study investigating commercially available treatments which may reduce the scab stage of recurrent herpes labialis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001384-60,0,0,0 2005-001385-14,1,,,0,1,0,0,1,0,3,0,0,1,0,0,0,1,0,IOBA. FACULTAD DE MEDICINA,Evaluacion de la eficacia y seguridad de la inyección intravítrea de triamcinolona en el tratamiento del edema difuso del diabético,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001385-14,0,0,0 2005-001386-34,1,2006-06-21,2006-06-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA Pharma AG,Effect of Ciclesonide (320 µg/day) vs. Fluticasone Propionate (375 µg/day) vs. Placebo on Short-term Linear Growth Rate and HPA-axis Function in Prepubertal Children with Mild Asthma A double-blind...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001386-34,0,0,0 2005-001388-71,4,2007-03-27,2007-03-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Dee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001388-71,0,0,0 2005-001388-71,4,2007-03-27,2007-03-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Dee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001388-71,0,0,0 2005-001391-12,5,2007-02-15,2007-02-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TEVA,"A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Three Doses of Edratide TV-4710 f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001391-12,0,0,0 2005-001391-12,5,2007-02-15,2007-02-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"TEVA Pharmaceutical Industries, Ltd.","A Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel Group Study to Assess the Efficacy, Tolerability and Safety of Three Doses of Edratide TV-4710 f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001391-12,0,0,0 2005-001396-35,1,2008-01-03,2008-01-03,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,SLA Pharma (UK) Ltd,Evaluation of Topical 10% Metronidazole Ointment for the Reduction of Pain after Haemorrhoidectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001396-35,0,0,0 2005-001398-86,1,2008-09-17,2008-09-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,POSTOPERATIVE RADIOCHEMIOTHERAPY WITH SIB IN NEOPLASTIC DISEASE OF CERVICO-FACIAL DISTRICT IN LOCALLY ADVANCED STATUS : PHASE I-II STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001398-86,0,0,0 2005-001404-40,2,2006-08-09,2006-08-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Grünenthal GmbH,Cross-over multiple dose study assessing the analgesic efficacy and safety of oral GRT9906 PR compared to active comparator and placebo in subjects with painful polyneuropathy of mixed origin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001404-40,0,0,0 2005-001411-22,1,2013-07-31,2013-07-31,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,"University School of Medicine Hannover (MHH), represented by the chairmanship",Serotonin-Transporter Binding in Tourette-Syndrome and Obsessive-Compulsive Disorder before and during Treatment with SRI: a I-123-ADAM-SPECT-Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001411-22,0,0,0 2005-001412-50,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,J. Uriach & Compañía SA,"Randomised, parallel clinical trial, to compare efficacy and safety of sucrose intravenous iron versus oral ferrous sulfate for the treatment of perioperative lack of iron in patients with colorrectal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001412-50,0,0,0 2005-001415-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Röntgendiagnostik der Technischen Universität München,Phase II Studie zur Evaluierung der SH U 555 C unterstützten Magnetresonanztomographie der arteriosklerotischen Karotisstenose bei Patienten vor Thrombendarteriektomie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001415-21,0,0,0 2005-001416-42,7,2008-05-21,2008-11-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Teva Pharmaceuticals Industries LtD,"A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001416-42,0,0,0 2005-001416-42,7,2008-05-21,2008-11-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TEVA,"A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001416-42,0,0,0 2005-001417-18,2,2007-02-26,2007-02-26,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,DIATOS S.A.,A Phase II Clinical Trial to Evaluate Intratumoral Injection of a Depot Formulation of Paclitaxel (DTS-301) as Neoadjuvant Therapy of Patients with Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001417-18,0,0,0 2005-001426-84,3,2009-08-01,2009-10-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,OCTAPHARMA AG,"CLINICAL STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND IMMUNOGENICITY OF WILATE IN CHILDREN < 6 YEARS OF AGE WITH INHERITED VON WILLEBRAND DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001426-84,0,0,0 2005-001426-84,3,2009-08-01,2009-10-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Octapharma AG,"CLINICAL STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND IMMUNOGENICITY OF WILATE IN CHILDREN < 6 YEARS OF AGE WITH INHERITED VON WILLEBRAND DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001426-84,0,0,0 2005-001430-32,8,2008-07-15,2008-07-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral Naïv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001430-32,0,0,0 2005-001430-32,8,2008-07-15,2008-07-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmBH Co KG,"A Phase 3, Randomized, Open-label, Study of Lopinavir/ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, when Coadministered with NRTIs in Antiretroviral Naïv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001430-32,0,0,0 2005-001431-30,2,2013-07-05,2013-07-05,1,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Abbott GmbH & Co. KG,"A Randomized, Open Label Study Assessing Safety, Tolerability, and Efficacy of an Induction/Maintenance Treatment Strategy Including Lopinavir/ritonavir (LPV/r) plus Tenofovir Disoproxil Fumarate (TDF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001431-30,0,0,0 2005-001436-72,3,2008-10-11,2008-10-11,3,0,0,0,0,0,3,0,1,1,0,0,1,0,1,MannKind Corporation,Pulmonary Outcomes within a 2-year Period in Subjects with Diabetes Mellitus Treated with Technosphere®/Insulin or Antidiabetic Treatment and in Subjects without Abnormalities in Glucose Control,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001436-72,0,0,0 2005-001438-34,1,,,0,1,0,0,1,0,2,0,0,4,0,0,0,0,1,McNeil Consumer and Specialty Pharmaceuticals,"A Phase II, Randomized, Investigator-Blinded, Parallel-Group, Pilot Study Evaluating the Safety, Palatability and Efficacy of Four Doses of Pancrelipase Microtablets in the Treatment of Infants and To...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001438-34,0,0,0 2005-001440-23,1,2006-07-10,2006-07-10,1,0,0,0,1,0,2,0,0,1,1,1,1,0,1,"CombinatoRx, Inc.","A SINGLE CENTER, BLINDED, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF THE EFFECT OF CRx-139 ON POCKET DEPTH AND INFLAMMATORY CYTOKINES COMPARED TO PLACEBO IN SUBJECTS WITH SEVERE ADULT PERIODONTITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001440-23,0,0,0 2005-001446-16,1,2008-01-16,2008-01-16,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD,"Comparison of the immunogenicity and safety of a combined adsorbed low dose diphtheria, tetanus and inactivated poliomyelitis vaccine (REVAXIS®) with a combined diphtheria, tetanus and inactivated pol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001446-16,0,0,0 2005-001453-22,1,2007-02-23,2007-02-23,1,0,0,0,0,3,3,0,1,1,0,0,1,0,0,"German Sport University Cologne, Institute of CArdiology and Sports Medicine",Endocrine study on the effects of testosterone gel application in male athletes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001453-22,0,0,0 2005-001454-24,1,2008-08-14,2008-08-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,RIEMSER Arzneimittel AG,"An Open Labelled, Clinical Phase II Study With Oral Cis-U-Hydroxy-L-Proline (CHP) in 45 Patients With: - Chronic viral hepatitis - Chronic alcoholic liver diseases without cirrhosis - Compensate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001454-24,0,0,0 2005-001456-20,1,2008-07-10,2008-07-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,„Pilotstudie zum Einfluss selektiver neurogener Blockaden auf die perioperative Immunreaktion bei Lungen-resezierten Patienten.“,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001456-20,0,0,0 2005-001457-16,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,UNIVERSITA' DEGLI STUDI DI UDINE,"RANDOMIZED, DOUBLE BLIND TRIAL MONTELUKAST VERSUS LEVOCETIRIZINE IN THE TREATMENT OF SEASONAL RHINITIS AND CONJUNCTIVITIS IN CHILDREN 6-14 YEARS OLD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001457-16,0,0,0 2005-001459-39,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,SOFAR SPA,"Efficacy of mesalazine in the long term prevention of diverticulitis relapses. Randomised study, double blind, controlled vs placebo. Valutazione dell'efficacia della mesalazina nella prevenzione a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001459-39,0,0,0 2005-001460-32,10,2011-07-15,2011-07-15,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc 235 East 42nd Street New York, NY 10017","A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3, 0.03 or 0.00...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001460-32,0,0,0 2005-001460-32,10,2011-07-15,2011-07-15,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"(OSI) Eyetech Pharmaceuticals, Inc.","A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3, 0.03 or 0.00...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001460-32,0,0,0 2005-001460-32,10,2011-07-15,2011-07-15,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eyetech Pharmaceuticals Inc,"A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3, 0.03 or 0.00...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001460-32,0,0,0 2005-001460-32,10,2011-07-15,2011-07-15,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc 235 East 42nd Street New York, NY 10017, USA","A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3, 0.03 or 0.00...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001460-32,0,0,0 2005-001460-32,10,2011-07-15,2011-07-15,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc,"A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3, 0.03 or 0.00...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001460-32,0,0,0 2005-001463-64,4,2007-04-10,2007-11-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"A Phase II Study of Intravenous (IV) Vinflunine in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium Revised Protocol #01, version 2.0 incorporating Pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001463-64,0,0,0 2005-001463-64,4,2007-04-10,2007-11-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase II Study of Intravenous (IV) Vinflunine in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium Revised Protocol #01, version 2.0 incorporating Pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001463-64,0,0,0 2005-001464-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut Universitari de Neurorehabiltació Guttmann,"""Evaluación clínica de los efectos de un agonista colinérgico (Donezepilo) en la rehabilitación de la memoria en pacientes con traumatismo craneoencefálico""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001464-30,0,0,0 2005-001466-14,1,2006-04-27,2006-04-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,A Proof of Concept Study to Investigate the use of Simvastatin as a Putative Anti-inflammatory Agent in Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001466-14,0,0,0 2005-001472-12,1,2007-12-11,2007-12-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,N V Organon,"A Phase 3, Placebo-Controlled, Double-Blinded Continuation Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Completing Trial A7501008 and Continuing Lithium or Valproic Acid/Divalproe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001472-12,0,0,0 2005-001474-27,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,TopoTarget A/S,"A randomised, double-blinded parallel group study to compare efficacy and tolerability of topically applied Baceca and Tazarotene against placebo and Tazarotene in patients with basal cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001474-27,0,0,0 2005-001475-35,4,2007-06-01,2007-06-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A 3-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF LECOZOTAN (SRA-333) SR IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001475-35,0,0,0 2005-001475-35,4,2007-06-01,2007-06-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,WYETH LEDERLE,"A 3-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF LECOZOTAN (SRA-333) SR IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001475-35,0,0,0 2005-001476-13,5,2008-03-14,2008-03-18,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, LONG-TERM EXTENSION STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY LONG TERM EFFICACY OF LECOZOTAN SRA-333 SR IN PATIENTS WITH MILD TO MODERATE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001476-13,0,0,0 2005-001476-13,5,2008-03-14,2008-03-18,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, LONG-TERM EXTENSION STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY LONG TERM EFFICACY OF LECOZOTAN SRA-333 SR IN PATIENTS WITH MILD TO MODERATE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001476-13,0,0,0 2005-001477-94,4,2007-10-11,2007-11-22,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Reserach and Development","A 6-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF LECOZOTAN (SRA-333) SR IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S DI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001477-94,0,0,0 2005-001477-94,4,2007-10-11,2007-11-22,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A 6-MONTH, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, SAFETY, TOLERABILITY, AND EFFICACY STUDY OF 3 DOSES OF LECOZOTAN (SRA-333) SR IN OUTPATIENTS WITH MILD TO MODERATE ALZHEIMER’S DI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001477-94,0,0,0 2005-001478-28,5,2008-06-11,2008-06-11,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, LONG-TERM EXTENSION STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY LONG TERM EFFICACY OF LECOZOTAN SRA-333 SR IN PATIENTS WITH MILD TO MODERATE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001478-28,0,0,0 2005-001481-14,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,University Hospital Tübingen,LOCAL-TAX Trial: Local intracoronary administration of Paclitaxel after stent implantation for prevention of restenosis in comparison with stent implantation alone and with implantation of a Paclitaxe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001481-14,0,0,0 2005-001484-64,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,International Breast Cancer Study Group (IBCSG),Chemotherapy for Radically Resected Loco-regional Relapse A randomized clinical trial of adjuvant chemotherapy for radically resected loco-regional relapse of breast cancer Chemotherapy vs. Observatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001484-64,0,0,0 2005-001486-33,1,2008-06-18,2008-06-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Charité Campus Mitte, Klinik für Psychiatrie und Psychotherapie",Efficacy and safety of levetiracetam in the inpatient treatment of alcohol withdrawal syndrome [Sicherheit und Wirksamkeit von Levetiracetam (Keppra) für die Behandlung des stationären Alkoholentzugsy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001486-33,0,0,0 2005-001487-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Linköping University,Evaluation of Corticosteroids on Idiopathic Sudden Sensorineural Hearing Loss,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001487-32,0,0,0 2005-001488-79,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Healthcare Product Development,HCP 20A for the treament of atopic eczema: A pilot study to investigate the clinical efficacy of a novel treatment for eczema incorporating anti-inflammatory and antibacterial agents.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001488-79,0,0,0 2005-001490-95,5,2008-02-28,2011-02-28,5,1,0,0,0,0,0,0,0,1,0,0,1,0,0,National Institute of Allergy and Infectious Diseases (NIAID),"A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 (rIL-2, Aldesleukin) with and without Concomitant Antiretroviral Therapy in Patients with HIV-1 Infection and CD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001490-95,0,0,0 2005-001490-95,5,2008-02-28,2011-02-28,5,1,0,0,0,0,0,0,0,1,0,0,1,0,0,National Institute of Allergy and Infectious Diseases,"A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 (rIL-2, Aldesleukin) with and without Concomitant Antiretroviral Therapy in Patients with HIV-1 Infection and CD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001490-95,0,0,0 2005-001491-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Combustin Pharmazeutische Präparate GmbH,"Klinische Prüfung von Acoin im Vergleich zu Tetracain bei Patienten, die sich einer Bronchoskopie unterziehen müssen (Clinical trial with Acoin as compared with tetracaine in patients who have to unde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001491-13,0,0,0 2005-001496-35,1,2008-09-10,2008-09-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust,"A single centre, randomised controlled, open label study of rituximab as induction therapy in kidney transplantation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001496-35,0,0,0 2005-001497-27,1,2007-01-24,2007-01-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALTANA Pharma AG,Effect of pantoprazole on sleep-related breathing disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001497-27,0,0,0 2005-001499-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,Dr. José Ramón Mel Lorenzo,'Pilot trial of Pegilated Liposomal Doxorrubicin (Caelyx) in combination with Docetaxel (Taxotere) in advanced breast cancer patients' Estudio Piloto de Doxorrubicina Liposomal Pegilada (Caelyx) en co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001499-10,0,0,0 2005-001500-39,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI,A phase II GISL study of R-HyperCVAD in the treatment of patients with Mantle cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001500-39,0,0,0 2005-001501-26,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""","A randomized, double-blind pilot study vs placebo for the evaluation of the therapeutic effect of erythropoietin administered by iv route in patients whith diabetic neuropathy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001501-26,0,0,0 2005-001502-11,1,2012-09-24,2012-09-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche Austria GmbH,“CHAIROS” – Early brief intensification by chemoimmunotherapy with FCR followed by FR and Rituximab maintenance in chemonaive patients with B-CLL – A phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001502-11,0,0,0 2005-001503-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,CLINICAL AND BIOLOGICAL STUDY ON THE ADMINISTRATION OF THALIDOMIDE IN PATIENTS WITH PRIMARY CANCER OF THE LIVER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001503-19,0,0,0 2005-001505-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FUNDACIÓN GREGORIO MARAÑÓN,Estudio comparativo de amiodarona intravenosa y procainamida intravenosa para tratamiento de la taquicardia regular de QRS ancho (probablemente ventricular ) con aceptable tolerancia clínica.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001505-25,0,0,0 2005-001506-29,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,Group of Clinical Investigation in Radiotherapy Oncology (GICOR),"PHASE I/II TRIAL OF ERLOTINIB, RADIATIONTHERAPY, AND CISPLATIN IN PATIENTS WITH COMPLETE RESECTED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK Ensayo Fase I/II de Erlotinib en combinación con radioter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001506-29,0,0,0 2005-001507-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,National Children's Hospital & Trinity College Dublin,Treatment with recombinant Growth Hormone in Children born Small for Gestational Age (SGA) without Catch-up Growth.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001507-19,0,0,0 2005-001508-38,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,SIGMA-TAU,Phase II Explorative Study of Acetyl-L-Carnitine (ST 200) for Vincristine-Induced Neurotoxicity in Patients With Acute Lymphoblastic Leukemia (ALL).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001508-38,0,0,0 2005-001510-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"TEDEC MEIJI FARMA, S.A.",Prospective randomized study to assess the efficacy and tolerability of ferrimannitol ovoalbumin compared to ferrous sulphate in the treatment of iron deficiency anaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001510-40,0,0,0 2005-001511-22,3,2016-01-20,2016-01-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,","A 24-Month Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Postmenopausal Wom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001511-22,0,0,0 2005-001511-22,3,2016-01-20,2016-01-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A 24-Month Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Postmenopausal Wom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001511-22,0,0,0 2005-001511-22,3,2016-01-20,2016-01-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A 24-Month Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Postmenopausal Wom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001511-22,0,0,0 2005-001514-41,6,2010-11-04,2010-11-04,4,0,0,0,1,2,3,0,0,2,1,0,0,0,0,The Cardiovascular Research Foundation,A dual arm factorial randomized trial in patients with ST segment elevation AMI to compare the results of using anticoagulation with either unfractionated heparin plus routine GP IIb/IIIa inhibition w...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001514-41,1,0,0 2005-001516-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Clínica Plató Fundació Privada,Efficacy and safety of Levetiracetam treatment in patients suffering from Restless Legs Syndrome Eficacia y seguridad de un tratamiento con levetiracetam en pacientes con síndrome idiopático de pierna...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001516-41,0,0,0 2005-001518-42,3,2007-03-26,2007-03-26,2,1,0,0,0,2,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A six-month, prospective, multicenter, open label, parallel, randomized study of the safety, tolerability and efficacy of myfortic® (ERL080) with Simulect®, corticosteroids and two different levels of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001518-42,0,0,0 2005-001518-42,3,2007-03-26,2007-03-26,2,1,0,0,0,2,0,0,0,1,0,0,1,0,1,Novartis Farmaceútica S.A,"A six-month, prospective, multicenter, open label, parallel, randomized study of the safety, tolerability and efficacy of myfortic® (ERL080) with Simulect®, corticosteroids and two different levels of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001518-42,0,0,0 2005-001518-42,3,2007-03-26,2007-03-26,2,1,0,0,0,2,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A six-month, prospective, multicenter, open label, parallel, randomized study of the safety, tolerability and efficacy of myfortic® (ERL080) with Simulect®, corticosteroids and two different levels of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001518-42,0,0,0 2005-001522-88,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,sa Novo Nordisk Pharma nv,A four-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once or twice daily in a basal-bolus regimen with insulin aspart in subjects wit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001522-88,0,0,0 2005-001524-37,4,2007-06-27,2007-06-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,Duloxetine 60/120 mg Versus Placebo in the Treatment of Fibromyalgia Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001524-37,0,0,0 2005-001524-37,4,2007-06-27,2007-06-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,Duloxetine 60/120 mg Versus Placebo in the Treatment of Fibromyalgia Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001524-37,0,0,0 2005-001525-28,1,2007-01-01,2007-01-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Imperial College London,INFLUENCE OF THE ANTIOXIDANT N-ACETYLCYSTEINE ON INHALED NITRIC OXIDE INDUCED PULMONARY RESPONSES FOLLOWING HUMAN LUNG ISCHAEMIA-REPERFUSION INJURY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001525-28,0,0,0 2005-001527-11,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Eli Lilly and Company,"A Pivotal, Open-Label, Parallel Study to Evaluate the Safety and Efficacy of Human Insulin Inhalation Powder (HIIP) Compared to Injectable Insulin in Patients With Diabetes and COPD or Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001527-11,0,0,0 2005-001529-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Jan Engvall,Effect of reperfusion on infarct size and cardiac function evaluated with MRI and echocardiography/Effekt av reperfusion på infarktstorlek och hjärtfunktion utvärderat med MR och ultraljud,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001529-27,0,0,0 2005-001530-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Jan Engvall,Can pharmacological stress test at MRI of the heart improve the detection of coronary stenoses/Kan belastningsprov i magnetkamera ge förbättrad diagnostik av kranskärlsförträngningar?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001530-32,0,0,0 2005-001533-15,13,2008-03-28,2008-03-29,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Global Medical Affairs, Wyeth Research Division of Wyeth Pharmaceuticals Inc","A Randomised, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects with Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001533-15,0,0,0 2005-001533-15,13,2008-03-28,2008-03-29,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc,"A Randomised, Double-Blind, Two-Period Study to Evaluate the Safety and Efficacy of Etanercept on Skin and Joint Disease in Psoriasis Subjects with Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001533-15,0,0,0 2005-001537-15,1,2012-07-05,2012-07-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"Open-label trial of imatinib mesylate (Glivec, formerly known as STI571) in combination with vinorelbine (Navelbine) for patients with advanced breast carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001537-15,0,0,0 2005-001539-31,1,2006-11-10,2006-11-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"An Open-label, Multi-centre, Phase III Study of Local Tolerability of Zomacton 10 mg (Recombinant Somatropin) administered by ZomaJet Vision X",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001539-31,0,0,0 2005-001540-23,2,2006-11-15,2006-12-05,2,1,0,0,1,0,3,0,0,1,1,0,1,0,1,Schering Nordiska AB,"A Scandinavian, randomized, rater-blinded study of single and double-dose (2x250 mcg e.o.d.) Betaferon in patients with early secondary progressive multiple sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001540-23,0,0,0 2005-001543-36,1,2010-09-29,2010-09-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Lothian,The effects of lipoic acid on glycaemic control in type 2 diabetes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001543-36,0,0,0 2005-001544-23,1,2008-11-01,2008-11-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Max Zeller Söhne AG,Hypericum-Extrakt Ze 117 (Zeller AG): Klinische Studie zur Verminderung von Rückfällen bei Patienten mit Depression nach DSM-IV (Mittelschwere Major Depression: einzeln/rezi- divierend),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001544-23,0,0,0 2005-001545-42,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,ELI LILLY,A Randomized Phase III Trial of Gemcitabine and Docetaxel versus Gemcitabine and Paclitaxel in Patients with Metastatic Breast Cancer: a comparison of different schedules STUDIO RANDOMIZZATO DI FAS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001545-42,0,0,0 2005-001546-17,1,2012-08-01,2012-08-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,German Breast Group,GeparQuattro: A randomized phase III study exploring the efficacy of Capecitabine given concomitantly or in sequence to EC - Doc with or without Trastuzumab as neoadjuvant treatment of primary breast ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001546-17,0,0,0 2005-001548-21,1,2006-08-21,2006-08-21,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Arpida AG,"Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim versus Intravenous Linezolid in Complicated Skin and Skin Structure Infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001548-21,0,0,0 2005-001549-41,13,2008-01-23,2008-02-01,11,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc,"A Randomised, Double-Blind Study Comparing the Safety and Efficacy of Etanercept with Sulphasalazine in Subjects with Ankylosing Spondylitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001549-41,0,0,0 2005-001549-41,13,2008-01-23,2008-02-01,11,1,0,0,0,0,0,0,0,1,0,0,1,0,1,WYETH LEDERLE,"A Randomised, Double-Blind Study Comparing the Safety and Efficacy of Etanercept with Sulphasalazine in Subjects with Ankylosing Spondylitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001549-41,0,0,0 2005-001551-38,1,2007-11-01,2007-11-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Gloucestershire Hospitals NHS Foundation Trust,A study to research if foam sclerotherapy of saphenous trunks can speed up the healing of chronic venous leg ulcers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001551-38,0,0,0 2005-001554-24,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,CHU de TOULOUSE,"INTERET D’UN TRAITEMENT D’ENTRETIEN PAR REVLIMID APRES AUTOGREFFE DE CELLULES SOUCHES CHEZ LES PATIENTS DE MOINS DE 65 ANS ATTEINTS DE MYELOME (Essai de phase III, multicentrique, randomisé, double av...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001554-24,0,0,0 2005-001555-38,1,2005-08-08,2005-08-08,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,Open Immunization Study to Determine the Reactogenicity and Immunogenicity of Fluarix/ Influsplit SSW 2005/2006 in Persons as of 18 Years of Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001555-38,0,0,0 2005-001556-20,6,2005-11-05,2007-08-28,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.",Integrated Biomarker and Imaging Study – 2 (IBIS-2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001556-20,0,0,0 2005-001556-20,6,2005-11-05,2007-08-28,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,Integrated Biomarker and Imaging Study – 2 (IBIS-2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001556-20,0,0,0 2005-001558-26,3,2007-06-25,2007-06-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, MULTICENTRE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ORAL GW677954 CAPSULES 2.5mg, 5mg, 10mg AND 20mg A DAY FOR 24 WEE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001558-26,0,0,0 2005-001558-26,3,2007-06-25,2007-06-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, MULTICENTRE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ORAL GW677954 CAPSULES 2.5mg, 5mg, 10mg AND 20mg A DAY FOR 24 WEE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001558-26,0,0,0 2005-001559-39,1,2013-01-10,2013-01-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité-Campus Mitte und Campus Virchow-Klinikum,Randomisierte Phase II Studie zum Vergleich einer wöchentlichen Topotecangabe mit der Topotecangabe an fünf aufeinander folgenden Tagen bei Patientinnen mit platinresistentem rezidiviertem epitheliale...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001559-39,0,0,0 2005-001562-13,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI,OXCARBAZEPINE VS PHENYTOIN IN THE TREATMENT OF SEIZURES IN PATIENTS WITH BRAIN TUMORS UNDERGOING NEUROSURGICAL PROCEDURES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001562-13,0,0,0 2005-001564-31,2,2009-03-30,2009-03-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Myogen Inc.,"A phase 2, Open-label, Multicenter Study Evaluating Ambrisentan in Subjects with Pulmonary Arterial Hypertension Who Have Previously Discontinued Endothelin Receptor Antagonist Therapy Due to Serum Am...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001564-31,0,0,0 2005-001567-55,4,2006-03-06,2006-03-06,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Protein Design Labs, Inc.","A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001567-55,0,0,0 2005-001568-29,1,2009-09-30,2009-09-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Dept. of Nephrology,Pulsbølgehastighed og pulsbølgemorfologi hos patienter med kronisk nyreinsufficiens: Effekten af blokade af renin-angiotensinsystemet.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001568-29,0,0,0 2005-001569-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Dept. Hematology, Hospital Clinic","First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia. Tratamiento...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001569-33,0,0,0 2005-001573-10,1,2009-03-02,2009-03-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"ALK-Abello, S.A.",ESTUDIO DOBLE CIEGO CONTROLADO CON PLACEBO DE INMUNOTERAPIA CON UN EXTRACTO DE Dermatophagoides MEZCLA COMO TRATAMIENTO DEL ASMA PERSISTENTE LEVE-MODERADO Y SU PAPEL AHORRADOR DE MEDICACIÓN DE FONDO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001573-10,0,0,0 2005-001574-27,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PERUGIA,Sevoflurane on cardiac surgery: vantage to use during CEC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001574-27,0,0,0 2005-001576-13,1,2006-06-01,2006-06-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gloucester Pharmaceuticals Inc.,"An exploratory Phase II, multicenter, open-label trial evaluating the activity and tolerability of of FK228 in androgen independent metastatic prostate cancer patients with a rising PSA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001576-13,0,0,0 2005-001577-97,1,2010-02-25,2010-02-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Gunnar Hillerdal,Treatment of locally advanced or metastatic non-small cell lung cancer with Pemetrexed (Alimta) and Gemcitabine or Gemcitabine and Carboplatin: The PAGe study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001577-97,0,0,0 2005-001578-28,1,2008-12-09,2008-12-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Berlin-Chemie AG Menarini Group,"Comparison the effects of Nebivolol versus Metoprolol succinate on endothelial function and large artery stiffness. A parallel group, randomized, double-blind, active control phase IV clinical trial N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001578-28,0,0,0 2005-001579-37,3,2008-06-12,2008-06-12,3,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals, Inc. Clinical Research and Development","An Open Label Multi-center Study to Assess the Efficacy and Safety of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001579-37,0,0,0 2005-001584-66,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,LETI Pharma GmbH,A randomised controlled multicentre study for the safety of Depigoid(R) rush schedule,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001584-66,0,0,0 2005-001587-31,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,SantoSolve AS,None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001587-31,0,0,0 2005-001588-78,1,2006-12-04,2006-12-04,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Cardiff University,AML16 Pilot Trial: A Phase1/2 Trial to assess the feasibility of combining Clofarabine with daunorubicin and Daunorubicin + Clofarabine with Mylotarg in older patients with Acute Myeloid Leukaemia and...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001588-78,0,0,0 2005-001589-15,1,2006-01-13,2006-01-13,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,Bausch & Lomb Incorporated,A multi-center study evaluating the safety of a replacement intravitreal fluocinolone acetonide (FA) (0.59 mg) implant in patients with non-infectious posterior uveitis who were previously treated wit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001589-15,0,0,0 2005-001592-36,2,2007-03-08,2007-03-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"A Randomised, Double-Blind, Placebo-Controlled, Clinical Dose-Ranging Trial to Evaluate Efficacy and Safety of a NMDA antagonist for Oral Administration in Patients with Subjective Tinnitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001592-36,0,0,0 2005-001593-26,1,2006-12-01,2006-12-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,HERMAL Kurt Herrmann GmbH & Co OHG,"Topical treatment of verrucae vulgares with Verrumal® in organtransplant recipients (OTR) – prospective, double-blind, placebo-controlled randomised trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001593-26,0,0,0 2005-001596-34,1,2012-07-11,2012-07-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universität zu Köln,Multicentre phase II trial of Bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001596-34,0,0,0 2005-001598-93,2,2009-11-13,2009-11-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Alcon Research Limited,An Evaluation of Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) versus Sham Administration in Patients (Enrolled in Study “A”...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001598-93,0,0,0 2005-001602-76,1,2010-08-03,2010-08-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,Phase III clinical trial comparing treatments of hormone-refractory prostate cancer (HRPC) with Docetaxel: continuous treatment vs. intermittent repetition of treatment after progression.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001602-76,0,0,0 2005-001606-66,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",OLANZAPINE VS LAMOTRIGINE ADD-ON TO LITHIUM:EFFICACY ON ANXIETY SYMPTOMS IN REMITTING BIPOLAR PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001606-66,0,0,0 2005-001612-49,2,2008-11-05,2009-04-27,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-Synthelabo Recherche,"Ensayo aleatorizado, multicéntrico, doble ciego, controlado con placebo y con dos grupos paralelos, de rimonabant 20 mg od, para la inhibición de la progresión de la aterosclerosis evaluada mediante e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001612-49,0,0,0 2005-001613-17,3,2007-06-19,2007-07-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Fixed- Dose Study Evaluating the Effect of One Dose of Rimonabant 20 mg/day on Glycemic Control in Type 2 Diabetic Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001613-17,0,0,0 2005-001613-17,3,2007-06-19,2007-07-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et développement,"A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Fixed- Dose Study Evaluating the Effect of One Dose of Rimonabant 20 mg/day on Glycemic Control in Type 2 Diabetic Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001613-17,0,0,0 2005-001614-41,1,2009-06-23,2009-06-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,OPEN-LABEL TRIAL OF GLIVEC IMATINIB MESYLATE IN PATIENTS WITH REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMORS DSRCT EXPRESSING A MOLECULAR TARGET OF GLIVEC PDGF-R AND/OR C-KIT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001614-41,0,0,0 2005-001616-45,1,,,0,1,0,0,0,3,4,0,0,1,0,0,0,1,1,Instituto Grifols S.A.,"ESTUDIO PILOTO PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL RECAMBIO PLASMÁTICO CON ALBÚMINA HUMANA 5% EN EL ACLARAMIENTO PERIFÉRICO DEL PEPTIDO BETA-AMILOIDE, Y SUS EFECTOS EN PACIENTES CON ENFERMEDAD DE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001616-45,0,0,0 2005-001618-42,6,2007-03-09,2007-03-13,5,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Amgen Inc.,A Phase 2 Open-Label Study of AMG 706 to Treat Subjects with Locally Advanced or Metastatic Thyroid Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001618-42,0,0,0 2005-001618-42,6,2007-03-09,2007-03-13,5,1,0,0,0,2,2,0,0,1,0,0,1,0,1,AMGEN,A Phase 2 Open-Label Study of AMG 706 to Treat Subjects with Locally Advanced or Metastatic Thyroid Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001618-42,0,0,0 2005-001621-29,3,2013-09-15,2013-09-15,3,0,0,0,0,0,2,0,2,1,0,0,1,0,0,Dresden University of Technology,A dose finding safety and immune efficacy study for primary mucosal insulin therapy in islet autoantibody negative children at high genetic risk for type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001621-29,0,0,0 2005-001621-29,3,2013-09-15,2013-09-15,3,0,0,0,0,0,2,0,2,1,0,0,1,0,0,"Faculty of Medicine Carl Gustav Carus, University of Technology, Dresden",A dose finding safety and immune efficacy study for primary mucosal insulin therapy in islet autoantibody negative children at high genetic risk for type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001621-29,0,0,0 2005-001622-91,1,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,0,Royal Group Hospitals,A randomised assessor blinded study to examine the role of skin testing in the prediction of peri-operative anaphylaxis and its correlation with mast cell tryptase and total IgE.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001622-91,0,0,0 2005-001623-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,National Institute of Oncology,Docetaxellel bövített standard 5-fluorouracil plusz ciszplatin alapú neoadjuváns kemoterápia plusz ciszplatin alapú radiokemoterápia összehasonlítása a standard ciszplatin alapú radiokemoterápiával l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001623-11,0,0,0 2005-001627-11,10,2006-10-02,2007-04-10,8,1,0,0,0,0,0,0,0,1,0,0,1,0,1,YAMANOUCHI PHARMA,"A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001627-11,0,0,0 2005-001627-11,10,2006-10-02,2007-04-10,8,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)","A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001627-11,0,0,0 2005-001627-11,10,2006-10-02,2007-04-10,8,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Yamanouchi Europe B.V. (en trámite de cambio de nombre a Astellas Pharma Europe, B.V.)","A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract symptoms ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001627-11,0,0,0 2005-001628-35,6,2013-08-26,2013-08-28,6,0,0,0,0,0,3,0,0,1,0,0,1,0,0,European Group for Blood and Marrow Transplantation (EBMT),A Randomized controlled study of Velcade (Bortezomib) plus Thalidomide plus Dexamethasone compared to Thalidomide plus Dexamethasone for the treatment of myeloma patients progressing or relapsing afte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001628-35,0,0,0 2005-001628-35,6,2013-08-26,2013-08-28,6,0,0,0,0,0,3,0,0,1,0,0,1,0,0,The European group for Blood and Marrow Transplantation (EBMT),A Randomized controlled study of Velcade (Bortezomib) plus Thalidomide plus Dexamethasone compared to Thalidomide plus Dexamethasone for the treatment of myeloma patients progressing or relapsing afte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001628-35,0,0,0 2005-001628-35,6,2013-08-26,2013-08-28,6,0,0,0,0,0,3,0,0,1,0,0,1,0,0,EBMT Clinical Trial Office,A Randomized controlled study of Velcade (Bortezomib) plus Thalidomide plus Dexamethasone compared to Thalidomide plus Dexamethasone for the treatment of myeloma patients progressing or relapsing afte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001628-35,0,0,0 2005-001628-35,6,2013-08-26,2013-08-28,6,0,0,0,0,0,3,0,0,1,0,0,1,0,0,EBMT - CLWP,A Randomized controlled study of Velcade (Bortezomib) plus Thalidomide plus Dexamethasone compared to Thalidomide plus Dexamethasone for the treatment of myeloma patients progressing or relapsing afte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001628-35,0,0,0 2005-001629-27,2,2006-06-12,2006-06-12,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GENZYME,A Long-term Continuation Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001629-27,0,0,0 2005-001629-27,2,2006-06-12,2006-06-12,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Genzyme Europe BV,A Long-term Continuation Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001629-27,0,0,0 2005-001633-14,2,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,0,"Hvidovre Hospital, Dept. Rheumatology","Randomised, multi-center, open-label, parallel-group study comparing adalimumab (Humira[R]) 40 mg s.c. eow versus infliximab (Remicade[R]) 3 mg/kg i.v. every 6. week in RA patients with unsustainable ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001633-14,0,0,0 2005-001635-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Daniel Schmidt,Kontrollerad utsättning av långvarig behandling med protonpumpshämmare.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001635-29,0,0,0 2005-001638-34,1,2007-02-28,2007-02-28,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,Health Protection Agency,"A phase IV, single group study to evaluate the magnitude of antibody response, its persistence and avidity maturation following meningococcal serogroup C conjugate booster vaccination in older childre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001638-34,0,0,0 2005-001639-30,1,2007-08-30,2007-08-30,1,1,0,0,0,3,4,0,1,1,0,0,1,0,0,"Department of Anaesthesia&Intensive Care B, Vienna Medical University",Investigation of the antihyperalgesic effect of a combination of tramadol and paracetamol on primary and secondary hyperalgesia in an UV-B induced inflammatory skin pain model in healthy volunteers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001639-30,0,0,0 2005-001650-25,2,2006-08-25,2006-08-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the efficacy and safety of Elide...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001650-25,0,0,0 2005-001651-37,6,2010-06-22,2010-06-22,6,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"A phase IV, open label, non comparative, multicenter study to evaluate the long term efficacy and safety and tolerability of oral miglustat as a maintenance after a switch form enzyme replacement ther...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001651-37,0,0,0 2005-001651-37,6,2010-06-22,2010-06-22,6,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Actelion Registration Ltd,"A phase IV, open label, non comparative, multicenter study to evaluate the long term efficacy and safety and tolerability of oral miglustat as a maintenance after a switch form enzyme replacement ther...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001651-37,0,0,0 2005-001655-38,4,2008-11-21,2008-11-21,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Menarini IFR - International Division,"Bromuro de Otilonio en el Síndrome de Colon Irritable-(OBIS) Estudio doble ciego, aleatorizado, de grupos paralelos y controlado con placebo para evaluar el efecto del bromuro de otilonio en el dolor ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001655-38,0,0,0 2005-001655-38,4,2008-11-21,2008-11-21,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Menarini IFR – International Division,"Bromuro de Otilonio en el Síndrome de Colon Irritable-(OBIS) Estudio doble ciego, aleatorizado, de grupos paralelos y controlado con placebo para evaluar el efecto del bromuro de otilonio en el dolor ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001655-38,0,0,0 2005-001656-21,4,2006-02-17,2006-02-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Grünenthal GmbH,"A randomized, multi-center, double-blind, parallel-group, multiple-dose study assessing the analgesic efficacy and safety of 3 different doses of GRT0151Y compared to placebo and an active comparator ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001656-21,0,0,0 2005-001658-25,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Pfizer Global Research and Development,"An open label, two period crossover study to explore the safety, pharmacokinetics and pharmacodynamics of PHA-794428 after single subcutaneous injections in adult male patients with growth hormone def...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001658-25,0,0,0 2005-001659-39,2,2007-02-07,2007-02-07,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"ZERIA Pharmaceutical Co., Ltd.","A Phase Ib/IIa, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of Z-360 in Subjects with Unresectable Advanced Pancreatic C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001659-39,0,0,0 2005-001660-31,1,2012-02-07,2012-02-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Royal Marsden Hospital NHS Foundation Trust,A Prospective Randomized Controlled Trial of Morphine versus Oxycodone for Cancer Pain: Genetic Determinants of Response to Opioids.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001660-31,0,0,0 2005-001661-34,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,IBSA,Effects of Lidocaine patch application of pain s subjective and objective components in patients with Myofascial Pain Syndrome MPS .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001661-34,0,0,0 2005-001667-58,2,2007-03-01,2007-03-01,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, double-blind, randomized study to assess the consistency of the immunogenicity of three consecutive production lots of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001667-58,0,0,0 2005-001669-33,1,2008-09-09,2008-09-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Greater Glasgow NHS Health Board / University of Glasgow co-sponsorship,New therapeutic targets in stroke prevention: the effect of allopurinol on the cerebral vasculature of patients with subcortical stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001669-33,0,0,0 2005-001670-27,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Greater Glasgow NHS Health Board / University of Glasgow co-sponsorship,Reversibility of cerebrovascular endothelial dysfunction in diabetes: the role of allopurinol.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001670-27,0,0,0 2005-001671-35,10,2006-05-16,2008-06-26,4,1,1,0,0,0,2,0,0,2,1,0,0,0,1,"MedImmune, Inc.","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001671-35,1,1,0 2005-001671-35,10,2006-05-16,2008-06-26,4,1,1,0,0,0,2,0,0,2,1,0,0,0,1,"MedImmune, LLC","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001671-35,1,1,0 2005-001678-28,1,2007-03-20,2007-03-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer Healthcare AG,"A randomized, explorative, double-blind, double-dummy, multi-center, parallel group study to assess sustainable efficacy of once daily vardenafil (10 mg) for 12 and 24 weeks versus vardenafil PRN in m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001678-28,0,0,0 2005-001679-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,3,Kožní ordinace,"Prospektivní, otevřená, randomizovaná multicentrická studie hodnotící účinnost a bezpečnost kombinace isotretinoinu (Roaccutane® tobolky) a interferonu alfa 2a oproti samotnému interferonu alfa 2a v a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001679-36,0,0,0 2005-001680-57,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Heidelberg Pharma GmbH,Phase II study of fosfluridine tidoxil in an oral multiple dose schedule given once-a-day for 7 consecutive days every 2 weeks in patients with advanced breast and colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001680-57,0,0,0 2005-001688-74,1,2007-10-10,2007-10-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's & St Thomas' NHS Foundation Trust,"A prospective, randomized, double-blind, placebo controlled trial evaluating the effects of Mycophenolate Mofetil (MMF) on 'surrogate markers' for atherosclerosis in female patients with systemic lupu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001688-74,0,0,0 2005-001690-99,5,2006-11-22,2006-11-22,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,CeNeS Ltd,"A RANDOMISED, DOUBLE BLIND STUDY TO COMPARE THE ANALGESIC EFFICACY AND SAFETY PROFILES OF MORPHINE-6-GLUCURONIDE AND MORPHINE SULPHATE, GIVEN AS A LOADING DOSE FOLLOWED BY PATIENT-CONTROLLED ANALGESIA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001690-99,0,0,0 2005-001693-27,1,2007-06-30,2007-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Oxford Radcliffe Hospitals NHS Trust,Pilot Effectiveness of Randomised Mandatory Insulin Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001693-27,0,0,0 2005-001698-89,1,2014-07-22,2014-07-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust,Molecular profiling of postmenopausal women with breast cancer on neoadjuvant exemestane or tamoxifen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001698-89,0,0,0 2005-001700-39,1,2006-11-07,2006-11-07,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Fresenius Biotech GmbH,Determination of systemic exposure and characterization of pharmacokinetics of the tri-functional antibody catumaxomab (anti-EpCAM X anti-CD3) administered intraperitoneally in EpCAM positive cancer p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001700-39,0,0,0 2005-001701-26,5,2008-02-14,2008-02-28,3,1,0,0,0,0,3,0,0,1,1,0,1,0,0,CESAR Central European Society for,"First- Line Treatment of Postmenopausal Patients with Endocrine Responsive Metastatic Breast Cancer. A Randomized, Multicenter Study Comparing Letrozole Combined with Standard Chemotherapy Vs Letrozol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001701-26,0,0,0 2005-001705-26,1,2007-01-26,2007-01-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Spirig Pharma AG,"Efficacy and safety of topically applied cyclodextrin gel (Spirig Pharma) in the treatment of recurrent genital herpes simplex virus infections: a randomised, double-blind, placebo-controlled, multice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001705-26,0,0,0 2005-001709-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Sarcomas (GEIS),"Estudio en fase II, abierto, multicéntrico, prospectivo y aleatorizado, con DTIC o la combinación de Gemcitabina y DTIC en sarcomas de partes blandas avanzados del adulto",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001709-24,0,0,0 2005-001714-41,4,2008-12-23,2008-12-23,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A twelve-month, prospective, multicenter, open-label, randomized study of the safety, tolerability and efficacy of Certican™ with an IL-2 receptor antagonist, corticosteroids and two different exposur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001714-41,0,0,0 2005-001714-41,4,2008-12-23,2008-12-23,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A twelve-month, prospective, multicenter, open-label, randomized study of the safety, tolerability and efficacy of Certican™ with an IL-2 receptor antagonist, corticosteroids and two different exposur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001714-41,0,0,0 2005-001720-36,1,2007-05-14,2007-05-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER,"A pivotal, placebo controlled, phaseIII study to compare efficacy and tollerability of a fixed combination, containing 500 mg ASA and 30 mg Pseudoephedrine, in comparison to its single components in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001720-36,0,0,0 2005-001721-29,2,2007-02-19,2007-02-19,1,0,0,0,0,2,2,0,0,1,1,0,1,0,1,STRUCTURAL GENOMIX,"An Open-Label, Single-Arm, Multi-Center, Phase 2 Study of Troxatyl troxacitabine Administered by Continuous Infusion in Patients with Acute Myeloid Leukemia AML in Second Salvage",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001721-29,0,0,0 2005-001721-29,2,2007-02-19,2007-02-19,1,0,0,0,0,2,2,0,0,1,1,0,1,0,1,"SGX Pharmaceuticals, Inc.","An Open-Label, Single-Arm, Multi-Center, Phase 2 Study of Troxatyl troxacitabine Administered by Continuous Infusion in Patients with Acute Myeloid Leukemia AML in Second Salvage",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001721-29,0,0,0 2005-001722-92,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery,Systemic Bevacizumab (Avastin®) Therapy for Exudative Neovascular Age-Related Macular Degeneration (BEAT-AMD-Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001722-92,0,0,0 2005-001723-10,7,2006-05-18,2006-05-26,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline R & D Limited,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001723-10,0,0,0 2005-001724-37,3,2006-06-29,2006-06-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001724-37,0,0,0 2005-001724-37,3,2006-06-29,2006-06-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline R & D Limited,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001724-37,0,0,0 2005-001725-28,9,2007-02-08,2007-02-16,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001725-28,0,0,0 2005-001725-28,9,2007-02-08,2007-02-16,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline R & D Limited,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-Induced Bowel Dysfun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001725-28,0,0,0 2005-001726-80,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Karolinska University Hospital, Stockholms Läns Landsting","Effects of new longacting insulin analogs on metabolic control, endogenous insulin production, GH/IGF-I axis and quality of life – comparison of NPH, glargine och detemir insulin from the debut of T1D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001726-80,0,0,0 2005-001727-11,11,2008-12-05,2008-12-05,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Schering Lusitana,"A phase III, open-label, prospective, two armed multicenter, randomized, group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001727-11,0,0,0 2005-001727-11,11,2008-12-05,2008-12-05,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer Schering Pharma AG,"A phase III, open-label, prospective, two armed multicenter, randomized, group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001727-11,0,0,0 2005-001727-11,11,2008-12-05,2008-12-05,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biogen Idec,"A phase III, open-label, prospective, two armed multicenter, randomized, group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001727-11,0,0,0 2005-001727-11,11,2008-12-05,2008-12-05,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Bayer AB, Bayer Health Care, Bayer Schering Pharma","A phase III, open-label, prospective, two armed multicenter, randomized, group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001727-11,0,0,0 2005-001727-11,11,2008-12-05,2008-12-05,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schering AG, Global Medical Development","A phase III, open-label, prospective, two armed multicenter, randomized, group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001727-11,0,0,0 2005-001727-11,11,2008-12-05,2008-12-05,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Schering AG,"A phase III, open-label, prospective, two armed multicenter, randomized, group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001727-11,0,0,0 2005-001727-11,11,2008-12-05,2008-12-05,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SCHERING,"A phase III, open-label, prospective, two armed multicenter, randomized, group sequential study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001727-11,0,0,0 2005-001729-26,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,VIATRIS GmbH & Co. KG,Clinical trial to show equivalent efficacy and safety of fluticasone propionate (FP) delivered either through the Novolizer or through the Diskus in patients with mild to moderate persistent asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001729-26,0,0,0 2005-001730-32,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,VIATRIS GmbH & Co. KG,Clinical trial to show equivalent efficacy and safety of fluticasone propionate (FP) delivered either through the Novolizer or through the Diskus in patients with moderate to severe asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001730-32,0,0,0 2005-001731-30,1,2009-06-25,2009-06-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Celltech,"A Two-Part, Open Label Phase II Trial: Part One, Dose Escalation Safety; Part Two, Randomized/Comparing CDP791 (10 or 20 mg/kg) Plus Carboplatin/Paclitaxel With Carboplatin/Paclitaxel Alone in Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001731-30,0,0,0 2005-001737-15,1,2007-11-01,2007-11-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NV AstraZeneca SA,"An open-label, non-comparative, multi-centre, phase II prospective trial to assess the efficacy of Quetiapine fumarate augmentation of selective serotonin reuptake inhibitors (SSRIs) in SSRI-resistant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001737-15,0,0,0 2005-001738-34,1,2006-04-28,2006-04-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Medivir AB,Phase 2 open-label study of MIV-210 in antiretroviral treatment experienced HIV-1 infected subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001738-34,0,0,0 2005-001740-24,1,2006-02-03,2006-02-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,ALTANA Pharma AG,A Dose Range Finding Study of Formoterol Fumarate administered twice daily using the Ultrahaler™ in Patients with Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001740-24,0,0,0 2005-001742-16,6,2012-05-22,2012-05-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Biologics B.V.,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthritis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001742-16,0,0,0 2005-001742-16,6,2012-05-22,2012-05-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Centocor B.V.,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthritis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001742-16,0,0,0 2005-001745-42,1,2009-12-31,2009-12-31,1,1,0,1,0,3,1,1,1,1,0,0,0,0,0,University of Liverpool and Royal Liverpool University Hospital,"BCR-ABL Peptide Vaccination in Normal Subjects.An investigation in normal subjects with HLA-A3 and HLA-B8, as an extension of an identical study in patients with Chronic Myeloid Leukaemia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001745-42,0,0,0 2005-001746-17,2,2012-07-17,2012-07-17,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,LFB BIOTECHNOLOGIES,EFFICACY AND SAFETY STUDY OF vWF SD-35-DH (WILFACTIN) IN PATIENTS UNDER LONG TERM PROPHYLAXIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001746-17,0,0,0 2005-001747-29,10,2014-06-25,2014-06-25,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"OSI PHARMACEUTICALS, LLC","A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001747-29,0,0,0 2005-001747-29,10,2014-06-25,2014-06-25,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"OSI Pharmaceuticals, LLC","A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001747-29,0,0,0 2005-001747-29,10,2014-06-25,2014-06-25,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"OSI Pharmaceuticals, Inc.","A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva (erlotinib) Following Complete Tumor Resection and with or without Adjuvant Chemotherapy in Patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001747-29,0,0,0 2005-001750-25,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,LILLY FRANCE,Efficacy and Safety of Somatropin in Combination with Leuprorelin Compared to Somatropin Alone and to an Untreated Control Group in Pubertal Children with Idiopathic Short Stature,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001750-25,0,0,0 2005-001755-38,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Fundación Teknon,"Clinical Trial phase I-II, Multicentic of the Application of TRC in the Surgical Treatment of Non-Hypertrophic Pseudoarthrosis and Complex Fractures of Long Bones Ensayo Clínico Fase I-II, multicéntri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001755-38,0,0,0 2005-001762-13,1,2005-07-07,2005-07-07,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Universitätskinderklinik Heidelberg,Energy metabolism of critically ill children treated with lipid emulsion and carnitine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001762-13,0,0,0 2005-001763-60,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dra. Nuria Mañes Bonet. Sección de Cirugía Torácica. Hospital Universitario de Canarias,"Ensayo clínico aleatorizado de dos grupos de tratamiento del empiema en fase II o fibrinopurulenta, videotoracoscopia asistida vs fibrinolisis intrapleural",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001763-60,0,0,0 2005-001768-30,1,,,0,0,0,0,1,1,4,0,0,0,0,0,0,0,0,EM-kliniken,Comparison of 2 and 4 doses hydrocortison substitution with regard to plasma concentration and quality of life.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001768-30,0,0,0 2005-001771-35,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Research & Development,"Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Centre, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001771-35,0,0,0 2005-001774-27,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AISSM ONLUS,CAMPATH-1H AS IMMUNOSUPPRESSIVE AGENT IN MDS PATIENTS MULTICENTRIC PILOT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001774-27,0,0,0 2005-001775-35,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,medac GmbH,Intravesical instillation of BCG strain RIVM versus TICE for prevention of recurrenec in patients with high-risk papillary superficial carcinomas of the urinary bladder. A randomised phase II clinical...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001775-35,0,0,0 2005-001776-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Organisation name was not entered,Efficacy of Levetiracetam in the treatment of spasticity in MS: a ranomized double blind cross over study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001776-13,0,0,0 2005-001781-14,1,2007-08-27,2007-08-27,1,1,0,0,0,1,2,0,1,1,0,0,1,0,1,Bavarian Nordic A/S,"A partially randomized, partially double-blind, placebo-controlled Phase II non-inferiority study to evaluate immunogenicity and safety of one and two doses of MVA-BN (IMVAMUNE™) smallpox vaccine in 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001781-14,0,0,0 2005-001786-34,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,ALCON ITALIA,"Hypotonic efficacy and tollerability of Travoprost in patient with open angle primary glaucoma and/or ocular hypertension, not controlled with dorzolamide + timolol treatment in fixed association, o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001786-34,0,0,0 2005-001791-13,1,2007-07-03,2007-07-03,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Mundipharma GmbH,"An open-label, randomized, parallel-group, monocenter study to evaluate safety and efficacy of Oxycodone Hydrochloride administered orally (CR) and intravenously in patients with total hip endoprosthe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001791-13,0,0,0 2005-001792-35,2,2006-05-25,2006-05-25,1,1,0,0,0,2,3,0,0,1,0,0,1,0,1,ORGANON ITALIA,Comparison of rocuronium and Org 25969 with cis-atracurium and neostigmine when neuromuscular block is reversed at reappearance of T2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001792-35,0,0,0 2005-001792-35,2,2006-05-25,2006-05-25,1,1,0,0,0,2,3,0,0,1,0,0,1,0,1,NV Organon,Comparison of rocuronium and Org 25969 with cis-atracurium and neostigmine when neuromuscular block is reversed at reappearance of T2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001792-35,0,0,0 2005-001794-10,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,Ipsen Ltd,"A Phase IV, Randomised, Double-blind, Dose-ranging, Study in Children and Young People to determine the Optimal Dose of Botulinum Toxin Type-A (Dysport®) in Managing the Symptoms of Hip Muscle Spastic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001794-10,0,0,0 2005-001797-27,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,University Hospital Ghent,Accuracy of the Kataria model for propofol anesthesia in children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001797-27,0,0,0 2005-001808-40,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,MEDESTEA RESEARCH & PRODUCTION,EFFICACY And TOLLERABILITY Of TREATMENT for inhalation WITH L-ASA IN PATIENTS WITH MILD Or MODERATED ASTHMA IN COMPARISON WITH CORTICOSTEROID for inhalation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001808-40,0,0,0 2005-001809-25,7,2007-09-27,2007-09-27,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment with Aripiprazole in Patients with Schizophrenia + Pharmacogenetics Bloo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001809-25,0,0,0 2005-001816-27,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Clinical Data Care Spain S.L.,"Open label randomized phase II, multicentre, pilot study to evaluate safety and efficacy of the combination of cetuximab and concomitant-boost accelerated radiotherapy followed or not by a complementa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001816-27,0,0,0 2005-001818-41,14,2008-10-15,2008-11-12,9,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An open label multicenter expanded access study of oral AMN107 in adult patients with imatinib Glivec/Gleevec resistant or intolerant chronic myeloid leukemia in blast crisis, accelerated phase or ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001818-41,0,0,0 2005-001818-41,14,2008-10-15,2008-11-12,9,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Novartis Pharma Services,"An open label multicenter expanded access study of oral AMN107 in adult patients with imatinib Glivec/Gleevec resistant or intolerant chronic myeloid leukemia in blast crisis, accelerated phase or ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001818-41,0,0,0 2005-001818-41,14,2008-10-15,2008-11-12,9,1,0,0,0,2,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","An open label multicenter expanded access study of oral AMN107 in adult patients with imatinib Glivec/Gleevec resistant or intolerant chronic myeloid leukemia in blast crisis, accelerated phase or ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001818-41,0,0,0 2005-001818-41,14,2008-10-15,2008-11-12,9,1,0,0,0,2,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"An open label multicenter expanded access study of oral AMN107 in adult patients with imatinib Glivec/Gleevec resistant or intolerant chronic myeloid leukemia in blast crisis, accelerated phase or ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001818-41,0,0,0 2005-001824-35,1,2008-05-16,2008-05-16,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Manchester,Non-randomised phase II trial of Sequential Therapy of Imiquimod followed by Vaccination with TA CIN for High Grade VIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001824-35,0,0,0 2005-001824-35,1,2008-05-16,2008-05-16,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Central Manchester and Manchester Childrens University Hospitals NHS Trust,Non-randomised phase II trial of Sequential Therapy of Imiquimod followed by Vaccination with TA CIN for High Grade VIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001824-35,0,0,0 2005-001826-99,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,"Hvidovre Hospital, Dept. of Rheumatology",DANISH – a DANish multicenter study of new Imaging- and bio-markers for improved assessment of disease activity and progression and prediction of therapeutic outcome in Spondyloarthritis patients rece...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001826-99,0,0,0 2005-001827-12,1,2020-03-10,2020-03-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Georg-August-Universität Göttingen, Bereich Humanmedizin",Myfortic ® zur Therapie des Bullösen Pemphigoids. Eine offene monozentrische proof-of-concept Studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001827-12,0,0,0 2005-001830-34,1,2007-10-31,2007-10-31,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,King's College Hospital,The use of Myfortic in paediatric patients after liver transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001830-34,0,0,0 2005-001834-34,1,2010-02-15,2010-02-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Oxford Radcliffe Hospitals NHS Trust,Phase 2 trial of neo-adjuvant Oxaliplatin and 5-fluorouracil in oesophageal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001834-34,0,0,0 2005-001841-40,3,2012-11-27,2012-11-27,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research And Development Ltd,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 200mcg Twice-Daily, GW685698X Inhalation Powder 200...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001841-40,0,0,0 2005-001843-49,1,2005-11-15,2005-11-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Schering Plough Research Institute,Vicriviroc (SCH 417690) Treatment Protocol in HIV-Infected Subjects: A Substudy of P03802,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001843-49,0,0,0 2005-001845-40,3,2006-11-21,2007-01-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Subjects With Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001845-40,0,0,0 2005-001849-42,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,BIOXELL SPA,"A randomized, double blind, placebo controlled, parallel group study to determine the effect of BXL628 in patients with Chronic Non-Bacterial Prostatitis category III Chronic Pelvic Pain Syndrome, CP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001849-42,0,0,0 2005-001854-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sociedad Andaluza de Trasplante de Órganos y Tejidos,"Estudio comparativo de tacrolimus y rapamicina para evaluar la función renal en pacientes mayores de 50 años, receptores de un riñón de donante mayor de 55 años, en un régimen inmunosupresor de dacliz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001854-25,0,0,0 2005-001855-39,1,2009-03-17,2009-03-17,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Psychiatric Research Unit, Frederiksborg General Hospital",Chronos: Can the antidepressive response induced by sleep deprivation (wake-therapy) be sustained through continuous stabilisation of the diurnal rhythm and long term light treatment in patients with ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001855-39,0,0,0 2005-001856-19,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,"Miravant Pharmaceuticals, Inc.","A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex™ (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal Ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001856-19,0,0,0 2005-001866-15,7,2008-06-17,2008-09-26,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Boehringer Ingelheim France SAS,"A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista (Darunavir, DRV/r) in three-class (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001866-15,0,0,0 2005-001866-15,7,2008-06-17,2008-09-26,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Boehringer Ingelheim Ellas AE,"A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista (Darunavir, DRV/r) in three-class (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001866-15,0,0,0 2005-001866-15,7,2008-06-17,2008-09-26,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Boehringer Ingelheim España, S.A.","A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista (Darunavir, DRV/r) in three-class (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001866-15,0,0,0 2005-001866-15,7,2008-06-17,2008-09-26,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista (Darunavir, DRV/r) in three-class (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001866-15,0,0,0 2005-001866-15,7,2008-06-17,2008-09-26,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,BOEHRINGER ING.,"A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista (Darunavir, DRV/r) in three-class (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001866-15,0,0,0 2005-001866-15,7,2008-06-17,2008-09-26,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Boehringer Ingelheim, Canada Ltd.","A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista (Darunavir, DRV/r) in three-class (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001866-15,0,0,0 2005-001866-15,7,2008-06-17,2008-09-26,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A prospective randomized, open-labelled, multi-centre trial comparing the safety and efficacy of Ritonavir-boosted Aptivus (Tipranavir, TPV/r) to that of Prezista (Darunavir, DRV/r) in three-class (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001866-15,0,0,0 2005-001870-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospital Clínic de Barcelona,EFECTOS DE UN ANTICOLINÉRGICO DE ACCIÓN PROLONGADA (BROMURO DE TIOTROPIO) SOBRE EL DESEQUILIBRIO DE LAS RELACIONES VENTILACIÓN-PERFUSIÓN (VA/Q) EN LA ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA ESTABLE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001870-29,0,0,0 2005-001873-91,1,2007-11-15,2007-11-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Aventis Pharma,Docetaxel (Taxotere) v léčbě hormonálně independentního karcinomu prostaty.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001873-91,0,0,0 2005-001875-37,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Warwick,Neo-ESCAPE (Neoadjuvant Extended Sequential Chemotherapy with Adjuvant Postoperative treatment for Epithelial non-mucinous advanced inoperable peritoneal malignancy): a randomised feasibility study of...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001875-37,0,0,0 2005-001876-11,1,2017-08-17,2017-08-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UZLeuven,"A randomized phase II trial exploring feasibility of densification and optimal sequencing of postoperative adjuvant Fluorouracil, Epirubicin plus Cyclophosphamide (FEC) and Docetaxel chemotherapy in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001876-11,0,0,0 2005-001880-68,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,LETI Pharma GmbH,Standardization of Latex allergenic extract. Determination of biological activity in HEP units,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001880-68,0,0,0 2005-001884-80,1,2006-10-27,2006-10-27,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Mannkind Corporation,"A Parallel, Open-label, Single Dose of Inhaled Technosphere®/Insulin Pulmonary Lung Function Study Followed by a Parallel Prospective, Controlled, Two-center, Euglycemic Clamp Procedure Before and Aft...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001884-80,0,0,0 2005-001885-14,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Henogen s.a.,"A phase II, randomised, double blind, matched pair, controlled study to assess the safety and efficacy of Henogen recombinant soluble human tissue factor (rshTF) on the mandible bone consolidation an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001885-14,0,0,0 2005-001889-13,9,2008-05-01,2008-10-29,7,1,0,0,2,0,3,0,0,1,1,0,1,0,1,"Integrated Therapeutics Group, Inc. - A subsidiary of Schering-Plough Corp.",Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001889-13,0,0,0 2005-001889-13,9,2008-05-01,2008-10-29,7,1,0,0,2,0,3,0,0,1,1,0,1,0,1,Schering-Plough Research Institute (SPRI),Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001889-13,0,0,0 2005-001889-13,9,2008-05-01,2008-10-29,7,1,0,0,2,0,3,0,0,1,1,0,1,0,1,"Schering Plough Research Institute, a Division of Schering Corporation",Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001889-13,0,0,0 2005-001889-13,9,2008-05-01,2008-10-29,7,1,0,0,2,0,3,0,0,1,1,0,1,0,1,"Schering-Plough Research Institute, a division of Schering Corporation",Randomised controlled trial evaluating strategies to optimize disease activity control in RA patients treated with infliximab in clinical practice.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001889-13,0,0,0 2005-001890-83,4,2006-01-28,2006-09-21,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SCHERING-PLOUGH,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Thrombin Receptor AntagoN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001890-83,0,0,0 2005-001890-83,4,2006-01-28,2006-09-21,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Schering-Plough Research Institute,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Thrombin Receptor AntagoN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001890-83,0,0,0 2005-001893-28,3,2013-10-31,2013-10-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,IBCSG,A RANDOMIZED PHASE III TRIAL OF EXEMESTANE VERSUS ANASTROZOLE IN POSTMENOPAUSAL WOMEN WITH RECEPTOR POSITIVE PRIMARY BREAST CANCER Studio randomizzato di fase III per valutare il ruolo dell'Exeme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001893-28,0,0,0 2005-001893-28,3,2013-10-31,2013-10-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,International Breast Cancer Study Group (IBCSG),A RANDOMIZED PHASE III TRIAL OF EXEMESTANE VERSUS ANASTROZOLE IN POSTMENOPAUSAL WOMEN WITH RECEPTOR POSITIVE PRIMARY BREAST CANCER Studio randomizzato di fase III per valutare il ruolo dell'Exeme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001893-28,0,0,0 2005-001895-11,8,2008-10-28,2008-10-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A 96 Week Phase IIIB Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir ATV/RTV with Lopinavir/ritonavir LPV/RTV , Each in Combination with Fixed Dose Tenofovir-Emtricitabin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001895-11,0,0,0 2005-001895-11,8,2008-10-28,2008-10-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"A 96 Week Phase IIIB Study Comparing the Antiviral Efficacy and Safety of Atazanavir/ritonavir ATV/RTV with Lopinavir/ritonavir LPV/RTV , Each in Combination with Fixed Dose Tenofovir-Emtricitabin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001895-11,0,0,0 2005-001907-21,1,2009-06-05,2009-06-05,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Klinik für Anästhesiologie und operative Intensivmedizin, Charité – Universitätsmedizin Berlin","A randomised, double-blinded, multicenter, parallel group study comparing a remifentanil-regimen with a fentanyl-regimen for analgesia in mechanically ventilated patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001907-21,0,0,0 2005-001909-25,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,3,,Effekter av behandling med atomoxetine ved komorbid ADHD hos pasienter med Pervasive Developmental Disorders (Effects of treatment with atomoxetine in children with Pervasive Developmental Disorder an...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001909-25,0,0,0 2005-001912-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ACROSS,PHASE II TRIAL OF THE COMBINATION OF GEMCITABINE AND OXALIPLATIN IN THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF UNKNOWN PRIMARY SITE Estudio fase II de la combinación de gemcitabina y ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001912-38,0,0,0 2005-001919-21,1,2010-03-03,2010-03-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Martin-Luther-Universität Halle-Wittenberg, Medizinische Fakultät, endvertreten durch den Dekan",Phase II-Studie: Standardchemotherapie Capecitabin in Kombination mit Bevacizumab in der Erstlinientherapie beim metastasierten kolorektalen Karzinom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001919-21,0,0,0 2005-001925-27,1,2013-01-10,2013-01-10,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Great Ormond Street Hospital For Children NHS Trust,Phase I/II clinical trial of T cell suicide gene therapy following haploidentical stem cell transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001925-27,0,0,0 2005-001928-37,1,,,0,1,0,1,0,0,1,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase I/II, open, controlled study in order to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals influenza candidate vaccine containing the adjuvant AS25 (FluAS25) in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001928-37,0,0,0 2005-001930-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Department of Cardiology, Odense University Hospital",Left ventricular reverse remodelling after aortic valve replacement in severe valvular aortic stenosis - effect of blockade of the angiotensin-II receptor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001930-34,0,0,0 2005-001932-61,1,2008-08-20,2008-08-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospitals of Leicester,"Mepolizumab and exacerbation frequency in refractory eosinophilic asthma. A randomised, double blind, placebo controlled, parallel group trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001932-61,0,0,0 2005-001936-59,3,2008-06-26,2008-06-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALLERGAN LTD,"A multicenter, double-blind, randomized, placebo-controlled, parallel-group, dose-response study of the safety and efficacy of a single treatment of BOTOX® (botulinum toxin type A) purified neurotoxin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001936-59,0,0,0 2005-001938-32,1,2014-01-15,2014-01-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,B.Braun Melsungen AG,"EFFICACY, SAFETY, AND QUALITY OF LIFE OF A LONG-TERM HOME PARENTERAL NUTRITION REGIMEN WITH EITHER LIPIDEM® OR LIPOFUNDIN® MCT A MONO-CENTER, RANDOMIZED, DOUBLE BLIND STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001938-32,0,0,0 2005-001942-18,1,2008-05-16,2008-05-16,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Organisation name was not entered,Peroraalinen pregabaliini tähystyksen avulla tehtävän kohdunpoiston jälkeisen kivunhoidon hallinnassa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001942-18,0,0,0 2005-001944-21,1,2006-04-27,2006-04-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Helsinn Healthcare SA,"Multicenter, Phase III, Open-Label, Uncontrolled Study to Assess the Safety and Efficacy of a Single Oral Dose of Palonosetron 0.75 mg in the Prevention of Chemotherapy Induced Nausea and Vomiting in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001944-21,0,0,0 2005-001949-42,1,2008-12-29,2008-12-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,A randomised controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001949-42,0,0,0 2005-001951-39,3,2007-10-04,2007-10-04,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Sigma Tau Industrie Farmaceutiche Riunite S.p.A.,"""Estudio fase II de Gimatecan (ST1481) como tratamiento de rescate en pacientes con sarcoma de partes blandas avanzado o metastático y recidivados después de un régimen de quimioterapia basado en antr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001951-39,1,0,0 2005-001951-39,3,2007-10-04,2007-10-04,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,SIGMA-TAU,"""Estudio fase II de Gimatecan (ST1481) como tratamiento de rescate en pacientes con sarcoma de partes blandas avanzado o metastático y recidivados después de un régimen de quimioterapia basado en antr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001951-39,1,0,0 2005-001951-39,3,2007-10-04,2007-10-04,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.,"""Estudio fase II de Gimatecan (ST1481) como tratamiento de rescate en pacientes con sarcoma de partes blandas avanzado o metastático y recidivados después de un régimen de quimioterapia basado en antr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001951-39,1,0,0 2005-001958-24,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,SOFAR SPA,"Efficacy and tolerability of Diltiazem cream in the treatment of chronic anal fissure: a prospective,randomized, double blind study versus glyceryl trinitrate.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001958-24,0,0,0 2005-001959-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Gedske Daugaard,Fase II trial with gemcitabine and oxaliplatin in patients with unknown primary tumours,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001959-38,0,0,0 2005-001965-33,6,2007-02-07,2007-02-07,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"Estudio prospectivo, aleatorizado, controlado con placebo, doble-ciego, multicéntrico, en grupos paralelos, para evaluar la eficacia, seguridad y tolerabilidad de bosentan en pacientes con hipertensió...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001965-33,0,0,0 2005-001965-33,6,2007-02-07,2007-02-07,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ACTELION PHARMACEUTICALS ITALIA,"Estudio prospectivo, aleatorizado, controlado con placebo, doble-ciego, multicéntrico, en grupos paralelos, para evaluar la eficacia, seguridad y tolerabilidad de bosentan en pacientes con hipertensió...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001965-33,0,0,0 2005-001967-70,3,2011-10-28,2011-10-28,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,An open label long term safety and tolerability extension study using the pediatric formulation of bosentan in the treatment of children with idiopathic or familial pulmonary arterial hypertension who...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001967-70,0,0,0 2005-001967-70,3,2011-10-28,2011-10-28,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,An open label long term safety and tolerability extension study using the pediatric formulation of bosentan in the treatment of children with idiopathic or familial pulmonary arterial hypertension who...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001967-70,0,0,0 2005-001970-29,1,2013-07-30,2013-07-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Schwarz Pharma Deutschland GmbH,"Multinational, prospective, randomized, double-blind, placebo-controlled, parallel groups study to assess the efficacy and safety of Prostaglandin E1 in subjects with circulatory disturbance of a limb",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001970-29,0,0,0 2005-001971-36,1,2007-07-31,2007-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,"PILOT, OPEN NON COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICAY AND SAFETY OF RETAANE (ANECORTAVE ACETATO 15 MG, 0.5 ML DI 30 MG/ML ANECORTAVE ACETATO STERILE SUSPENSION) IN PATIENTS WITH COROIDEAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001971-36,0,0,0 2005-001974-28,6,2006-05-09,2006-05-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Limited,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunct...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001974-28,0,0,0 2005-001975-37,1,2011-10-27,2011-10-27,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,North West London NHS Trust,A pilot study to examine the efficacy of vaginally administered oestradiol in the treatment of faecal incontinence in post menopausal women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001975-37,0,0,0 2005-001976-12,1,2007-04-10,2007-04-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Dr. Winzer Pharma,"12-monatige, prospektive klinische Phase IV-Prüfung zur Untersuchung der lokalen und systemischen Verträglichkeit von Clonid-Ophtal® 1/8% AT versus Tim-Ophtal® 0,5% AT bei Patienten mit okulärer Hyper...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001976-12,0,0,0 2005-001977-82,1,2007-12-19,2007-12-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A randomised, double-blind, placebo-controlled, parallel group study to investigate the safety, tolerability, pharmacokinetics and effect on synovial thickness and vascularity of 28 days repeat dosing...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001977-82,0,0,0 2005-001982-33,7,2007-08-03,2007-08-03,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,EISAI LTD UK,An Open Label Study of ZONEGRANTM Zonisamide in patients with partial onset seizures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001982-33,0,0,0 2005-001982-33,7,2007-08-03,2007-08-03,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Eisai Limited,An Open Label Study of ZONEGRANTM Zonisamide in patients with partial onset seizures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001982-33,0,0,0 2005-001986-32,1,2006-09-27,2006-09-27,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,NHS Tayside,Comparison of 2 contrast agents in preventing acute renal failure after angiography,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001986-32,0,0,0 2005-001991-11,1,,,0,1,0,0,0,3,4,0,1,1,0,0,0,1,0,University of Aachen,Effekte von Escitalopram auf Aufmerksamkeit und kognitive Funktionen bei gesunden Probanden,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001991-11,0,0,0 2005-001997-29,1,2006-09-29,2006-09-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,A Proof of Concept Study into the Effects on Inhlaed Extra-Fine and Standard Formulations of Beclomethasone Dipropionate and Oral Montelukast on Surrogate Markers of Small and Large Airway Inflammatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001997-29,0,0,0 2005-001998-10,1,2006-06-26,2006-06-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd.,"A phase III, randomized, parallel-group, double-blind, active controlled study to investigate the efficacy and safety of two different dose regimens (75mg day 1 followed by 150 mg day 2-completion, an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001998-10,0,0,0 2005-001999-12,13,2009-05-11,2009-07-21,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma Ges mbH,"'A phase III, randomised, double-blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg b.i.d.) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001999-12,0,0,0 2005-001999-12,13,2009-05-11,2009-07-21,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim AB,"'A phase III, randomised, double-blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg b.i.d.) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001999-12,0,0,0 2005-001999-12,13,2009-05-11,2009-07-21,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim,"'A phase III, randomised, double-blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg b.i.d.) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001999-12,0,0,0 2005-001999-12,13,2009-05-11,2009-07-21,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Austria GmbH,"'A phase III, randomised, double-blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg b.i.d.) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001999-12,0,0,0 2005-001999-12,13,2009-05-11,2009-07-21,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim BV,"'A phase III, randomised, double-blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg b.i.d.) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001999-12,0,0,0 2005-001999-12,13,2009-05-11,2009-07-21,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,BOEHRINGER ING.,"'A phase III, randomised, double-blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg b.i.d.) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001999-12,0,0,0 2005-001999-12,13,2009-05-11,2009-07-21,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A.","'A phase III, randomised, double-blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg b.i.d.) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001999-12,0,0,0 2005-001999-12,13,2009-05-11,2009-07-21,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Finland Ky,"'A phase III, randomised, double-blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg b.i.d.) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001999-12,0,0,0 2005-001999-12,13,2009-05-11,2009-07-21,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Ltd.,"'A phase III, randomised, double-blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg b.i.d.) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001999-12,0,0,0 2005-001999-12,13,2009-05-11,2009-07-21,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Ellas A.E,"'A phase III, randomised, double-blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg b.i.d.) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001999-12,0,0,0 2005-001999-12,13,2009-05-11,2009-07-21,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"'A phase III, randomised, double-blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg b.i.d.) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001999-12,0,0,0 2005-002000-42,2,2006-08-01,2006-08-01,1,1,0,0,0,3,3,0,0,1,0,0,1,0,1,NV Organon,"A multi-center, randomized, parallel-group, placebo-controlled, safety-assessor blinded trial, evaluating the safety and efficacy of Org 25969 in cardiac patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002000-42,0,0,0 2005-002003-17,4,2015-04-13,2015-04-13,2,0,0,0,0,1,2,0,0,2,0,0,0,0,0,Rikshospitalet-Radiumhospitalet HF,High-dose therapy with autologous stem cell support in first line treatment of mantle cell lymphoma - Yttrium-90-ibritumomab tiuxetan in combination with BEAM or BEAC to improve outcome for patients n...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002003-17,1,0,0 2005-002003-17,4,2015-04-13,2015-04-13,2,0,0,0,0,1,2,0,0,2,0,0,0,0,0,Uppsala University Hospital,High-dose therapy with autologous stem cell support in first line treatment of mantle cell lymphoma - Yttrium-90-ibritumomab tiuxetan in combination with BEAM or BEAC to improve outcome for patients n...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002003-17,1,0,0 2005-002004-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Oncopaz y Hospitales Asociados,"""Phase IV-II safety protocol, open-label , not randomized, of Myocet® in combination with Taxotere® as first line antineoplasic treatment in patients with advanced breast cancer”Protocolo de tratamie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002004-42,0,0,0 2005-002009-22,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,VALEAS,CTi-Inoc Study. Compliance to the Inhalatory Therapy - Inoc . Nitric oxide in exhaled air as a marker for monitoring the compliance of therapy with steroid inhalers in asthmatic patients Pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002009-22,0,0,0 2005-002010-38,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Institut de Recherches Internationales Servier (I.R.I.S.),"Assessment of the acceptability of a sublingual formulation of piribedil (S90049), 10 to 30 mg on request (maximum 5 times a day) on the top of L-dopa and a dopamine agonist in advanced Parkinson Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002010-38,0,0,0 2005-002011-24,3,2011-12-09,2015-01-03,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,European Group for Blood and Marrow Transplantation,Dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation in patients with MDS or sAML: A randomised phase III study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002011-24,0,0,0 2005-002011-24,3,2011-12-09,2015-01-03,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,European Group for Blood and Marrow Transplantation (EBMT),Dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation in patients with MDS or sAML: A randomised phase III study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002011-24,0,0,0 2005-002014-38,6,2008-05-16,2008-05-16,6,0,0,0,0,1,3,0,0,1,0,0,1,0,1,GTC BIOTHERAPEUTICS,"A Multicenter, Multinational Study to Assess the Safety and Efficacy of Antithrombin alfa in Hereditary Antithrombin AT Deficient Patients in High-Risk Situations for Thrombosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002014-38,0,0,0 2005-002014-38,6,2008-05-16,2008-05-16,6,0,0,0,0,1,3,0,0,1,0,0,1,0,1,GTC Biotherapeutics Inc.,"A Multicenter, Multinational Study to Assess the Safety and Efficacy of Antithrombin alfa in Hereditary Antithrombin AT Deficient Patients in High-Risk Situations for Thrombosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002014-38,0,0,0 2005-002027-13,1,2007-08-17,2007-08-17,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,Royal Marsden NHS FOundation Trust,A phase I/II study of docetaxel plus prednisolone plus diethylstilbestrol plus aspirin in androgen-independent prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002027-13,0,0,0 2005-002028-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Clínic-Maternitat,BENEFICIOS DEL HIERRO ENDOVENOSO FRENTE A LA ADMINISTRACIÓN DE HIERRO POR VÍA ORAL EXCLUSIVAMENTE COMO TRATAMIENTO DE LA ANEMIA SEVERA POSTPARTO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002028-32,0,0,0 2005-002035-28,1,2007-02-28,2007-02-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Trial to Assess the Efficacy and Safety of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis (CF) Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002035-28,0,0,0 2005-002038-36,7,2008-12-22,2009-01-29,6,1,0,0,0,0,0,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson s disease dementia or dementia with Lewy Bodies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002038-36,0,0,0 2005-002041-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Sant Joan de Déu,"Double-blind, placebo controlled cross-over study to assess efficacy of Levetiracetam in paediatric and childhood Tourette syndrome. Estudio cruzado, aleatorizado, doble ciego controlado con placebo, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002041-40,0,0,0 2005-002042-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Sant Joan de Déu,"Double-blind, placebo controlled cross-over study to assess the efficacy of Levetiracetam in paediatric and childhood non-epileptic myoclonus Estudio cruzado, aleatorizado, doble ciego controlado con ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002042-19,0,0,0 2005-002044-26,1,2006-05-31,2006-05-31,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A randomized, double-blind, placebo-controlled, post-marketing phase III Study to evaluate the efficacy of GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscularly in adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002044-26,0,0,0 2005-002048-25,1,2006-12-07,2006-12-07,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,SBL Vaccin AB,A pilot study to investigate the use of recombinant cholera toxin B subunit in the treatment of active Crohn’s disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002048-25,0,0,0 2005-002051-41,6,2007-07-18,2007-07-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma Revised Protocol 01, incorporating Amendment 02...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002051-41,0,0,0 2005-002051-41,6,2007-07-18,2007-07-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"A Multi-Center Single Arm Phase II Study of MDX-010 (BMS-734016) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma Revised Protocol 01, incorporating Amendment 02...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002051-41,0,0,0 2005-002058-23,1,2006-07-06,2006-07-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 4 week, randomized, vehicle-controlled, multicenter evaluation of the efficacy and safety of 1% pimecrolimus cream in adult patients with perioral dermatitis followed by a 8 week treatment free obse...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002058-23,0,0,0 2005-002059-41,13,2008-09-04,2008-11-09,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novo Nordisk A/S,"A multi-center, randomized, double-blind, parallel group, placebo controlled trial to evaluate the efficacy and safety of activated recombinant factor VII rFVIIa/NovoSeven/NiaStase in severely injur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002059-41,0,0,0 2005-002059-41,13,2008-09-04,2008-11-09,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVO NORDISK,"A multi-center, randomized, double-blind, parallel group, placebo controlled trial to evaluate the efficacy and safety of activated recombinant factor VII rFVIIa/NovoSeven/NiaStase in severely injur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002059-41,0,0,0 2005-002060-28,2,2010-02-26,2010-02-26,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Novartis Nordic Countries, Business Unit Transplantation","Nordic Certican trial in heart and lung transplantation (""NOCTET"")",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002060-28,0,0,0 2005-002060-28,2,2010-02-26,2010-02-26,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Healthcare A/S,"Nordic Certican trial in heart and lung transplantation (""NOCTET"")",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002060-28,0,0,0 2005-002063-87,6,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"Protein Design Labs, Inc.","A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002063-87,0,0,0 2005-002063-87,6,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"PDL BioPharma, Inc","A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002063-87,0,0,0 2005-002063-87,6,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"PDL BioPharma, Inc.","A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002063-87,0,0,0 2005-002068-27,1,2008-05-31,2008-05-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical University of Vienna,"Prevention of venous thrombosis in cancer patients: A prospective, randomized, double-blind study comparing two different dosages of low-molecular weight heparin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002068-27,0,0,0 2005-002072-15,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",EFFECTS OF TREATMENT WITH L-ARGININE ASSOCIATED TO N-ACETILCYSTEINE IN PATIENTS WITH CORONARY ISCHEMIC CARDIOPATHY EVALUATED WITH MYOCARDIAL SPECT (TC99) WITH EXERCISE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002072-15,0,0,0 2005-002077-76,1,2006-07-31,2006-07-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Aerovance Inc,A Phase 2a Study To Investigate The Effects of Repeated Administration of AeroDerm in subjects with Atopic Eczema.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002077-76,0,0,0 2005-002080-88,1,2006-05-01,2006-05-01,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Aintree Hospitals NHS Trust and University of Liverpool,"A double−blind, placebo−controlled crossover trial to quantify the effects of sibutramine on energy intake and energy expenditure in obese subjects during a test meal",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002080-88,0,0,0 2005-002084-85,3,2009-01-07,2009-01-07,1,0,0,0,0,0,3,0,0,2,1,0,0,0,0,GBG Forchungs GmBH,A multicenter randomized phase III study to compare capecitabine alone or in combination with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous treatme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002084-85,1,0,0 2005-002084-85,3,2009-01-07,2009-01-07,1,0,0,0,0,0,3,0,0,2,1,0,0,0,0,GBG Forschungs GmbH,A multicenter randomized phase III study to compare capecitabine alone or in combination with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous treatme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002084-85,1,0,0 2005-002088-98,6,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Amarin Neuroscience Ltd,"A multicentre, multinational, double-blind, randomised, parallel group, placebo controlled trial of ethyl-EPA ethyl-Icosapent in patients with Huntington s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002088-98,0,0,0 2005-002088-98,6,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,AMARIN NEUROSCIENCE LTD,"A multicentre, multinational, double-blind, randomised, parallel group, placebo controlled trial of ethyl-EPA ethyl-Icosapent in patients with Huntington s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002088-98,0,0,0 2005-002089-13,1,2004-12-31,2004-12-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Hospitals of Leicester NHS Trust,International Phase II Studies of 131I-mIBG in combination with topotecan and peripheral blood stem cell rescue for (A) primary resistant high risk neuroblastoma and (B) relapsed stage 4 neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002089-13,0,0,0 2005-002090-76,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,SERVICIO DE PSIQUIATRIA. HOSPITAL UNIVERSITARI VALL DE HEBRON,Estudio de la eficacia de la cafeína en el tratamiento de mantenimiento de pacientes con dependencia de cocaína,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002090-76,0,0,0 2005-002091-15,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",POLICYSTIC OVARIAN SYNDROME AND NITRIC OXIDE. EFFECTS OF TREATMENT WITH N-ACETYLCYSTEINE AND ARGININE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002091-15,0,0,0 2005-002095-15,9,2008-03-21,2008-03-21,7,0,0,0,0,0,3,0,0,1,1,0,1,0,1,"Keryx Biopharmaceuticals, Inc.",The Collaborative Study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002095-15,0,0,0 2005-002095-15,9,2008-03-21,2008-03-21,7,0,0,0,0,0,3,0,0,1,1,0,1,0,1,KERYX BIOPHARMACEUTICALS INC.,The Collaborative Study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002095-15,0,0,0 2005-002096-32,1,2007-12-08,2007-12-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,A randomised controlled clinical trial of metformin versus orlistat for the management of obses anovulatory women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002096-32,0,0,0 2005-002097-30,12,2007-12-08,2011-11-29,8,1,0,0,0,2,0,0,0,1,1,0,1,0,2,Pfizer Inc.,A SU011248 EXPANDED ACCESS PROTOCOL FOR SYSTEMIC THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS BUT MAY DERIVE BENEFIT FRO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002097-30,0,0,0 2005-002097-30,12,2007-12-08,2011-11-29,8,1,0,0,0,2,0,0,0,1,1,0,1,0,2,"PFIZER Inc 235 East 42nd Street, New York, NY, 10017",A SU011248 EXPANDED ACCESS PROTOCOL FOR SYSTEMIC THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS BUT MAY DERIVE BENEFIT FRO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002097-30,0,0,0 2005-002097-30,12,2007-12-08,2011-11-29,8,1,0,0,0,2,0,0,0,1,1,0,1,0,2,Pfizer Corporation Austria Ges.m.b.H.,A SU011248 EXPANDED ACCESS PROTOCOL FOR SYSTEMIC THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS BUT MAY DERIVE BENEFIT FRO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002097-30,0,0,0 2005-002097-30,12,2007-12-08,2011-11-29,8,1,0,0,0,2,0,0,0,1,1,0,1,0,2,Pfizer Inc,A SU011248 EXPANDED ACCESS PROTOCOL FOR SYSTEMIC THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS BUT MAY DERIVE BENEFIT FRO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002097-30,0,0,0 2005-002097-30,12,2007-12-08,2011-11-29,8,1,0,0,0,2,0,0,0,1,1,0,1,0,2,Pfizer Pharma GmbH,A SU011248 EXPANDED ACCESS PROTOCOL FOR SYSTEMIC THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS BUT MAY DERIVE BENEFIT FRO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002097-30,0,0,0 2005-002097-30,12,2007-12-08,2011-11-29,8,1,0,0,0,2,0,0,0,1,1,0,1,0,2,"Pfizer, S.A.",A SU011248 EXPANDED ACCESS PROTOCOL FOR SYSTEMIC THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS BUT MAY DERIVE BENEFIT FRO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002097-30,0,0,0 2005-002097-30,12,2007-12-08,2011-11-29,8,1,0,0,0,2,0,0,0,1,1,0,1,0,2,PFIZER,A SU011248 EXPANDED ACCESS PROTOCOL FOR SYSTEMIC THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS BUT MAY DERIVE BENEFIT FRO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002097-30,0,0,0 2005-002097-30,12,2007-12-08,2011-11-29,8,1,0,0,0,2,0,0,0,1,1,0,1,0,2,Pfizer Kft.,A SU011248 EXPANDED ACCESS PROTOCOL FOR SYSTEMIC THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS BUT MAY DERIVE BENEFIT FRO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002097-30,0,0,0 2005-002100-42,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Ardana Bioscience Ltd,"A Phase II single centre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix, long-acting formulat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002100-42,0,0,0 2005-002101-23,1,2009-03-31,2009-03-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"North West London Hospitals NHS Trust, R&D Office","Do Steroids Provide Additional Benefit Over Pressure Alone In Reducing Oedema And Ecchymosis Following Rhinoplasty? A Randomised, Prospective, Double Blind, Placebo Controlled Clinical Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002101-23,0,0,0 2005-002109-22,1,2008-09-30,2008-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical University of Vienna,Comparative Effects of Telmisartan and Candesartan on glucose metabolism in patients with chronic heart failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002109-22,0,0,0 2005-002110-38,1,2010-12-29,2010-12-29,1,1,0,0,0,3,3,0,0,1,0,0,1,0,0,Dept of ped hem/onc,"RCT of oral paracetamol for procedural anxiety, distress and pain in children with cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002110-38,0,0,0 2005-002112-17,1,2008-11-27,2008-11-27,1,1,0,0,0,3,3,0,0,1,0,0,1,0,0,Dept of ped hem/onc,"RCT of oral morphine for procedural anxiety, distress and pain in children with cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002112-17,0,0,0 2005-002113-21,1,2006-07-18,2006-07-18,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Merck & Co. Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter 16 Week Study to Assess the Effect of Vitamin D3 8400 IU Once Weekly on Body Sway and Neuromuscular Function in Men and Women Over 70 Years ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002113-21,0,0,0 2005-002114-38,1,2008-03-07,2008-03-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Medical Research Council Clinical Trials Unit,Ensayo randomizado para determinar el tratamiento óptimo de pacientes con infección por VIH en quienes la terapia con TARGA de primera y segunda línea ha fracasado,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002114-38,0,0,0 2005-002115-24,2,2006-04-26,2006-04-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,Complaints Associated with Use of the Prefilled Pen B When Used by Patients with Type 2 Diabetes on Twice-Daily Insulin Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002115-24,0,0,0 2005-002115-24,2,2006-04-26,2006-04-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Ltd.,Complaints Associated with Use of the Prefilled Pen B When Used by Patients with Type 2 Diabetes on Twice-Daily Insulin Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002115-24,0,0,0 2005-002118-39,1,2007-02-28,2007-02-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Merck & Co., Inc.",RECAP-DM (Real-life Effectiveness and Care Patterns of Diabetes Management),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002118-39,0,0,0 2005-002125-32,1,2008-10-28,2008-10-28,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Bayer Schering Pharma AG,"A multicenter, open, randomized, parallel-group comparison to assess the safety and efficacy of the oral contraceptive SH T 00186 D (0.02 mg ethinylestradiol as betadex clathrate and 3 mg drospirenone...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002125-32,0,0,0 2005-002126-64,4,2007-10-11,2008-02-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Randomized Phase II Study to Determine Potential Predictive Markers of Response to MDX-010 BMS-734016 in Patients with Unresectable Stage III or IV Malignant Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002126-64,0,0,0 2005-002126-64,4,2007-10-11,2008-02-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,A Randomized Phase II Study to Determine Potential Predictive Markers of Response to MDX-010 BMS-734016 in Patients with Unresectable Stage III or IV Malignant Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002126-64,0,0,0 2005-002128-32,1,2012-02-03,2012-02-03,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Abteilung für Anaesthesiologie und Intensivmedizin,Serum concentrations and concentrations in epithelial lining fluid of antibiotics under continious infusion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002128-32,0,0,0 2005-002130-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,INSTITUTO DE ESTUDIOS DEL SISTEMA NERVIOSO,"A Multicenter, Randomized, Parallel groups, Double-Blind, Placebo-controlled and 12 weeks follow-up Study to Evaluate the Safety, Tolerability and Efficacy of Pregabalin in Idiopathic Restless Legs Sy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002130-35,0,0,0 2005-002131-27,5,2006-11-23,2007-01-12,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Bial - Portela & Cª, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN A DOUBLE-BLIND, RANDOMISED, DOSE-TITRATION, PLACEBO-CONTROLLED, MULTICENTRE CLI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002131-27,0,0,0 2005-002131-27,5,2006-11-23,2007-01-12,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BIAL - Portela & Cª, SA","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN A DOUBLE-BLIND, RANDOMISED, DOSE-TITRATION, PLACEBO-CONTROLLED, MULTICENTRE CLI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002131-27,0,0,0 2005-002131-27,5,2006-11-23,2007-01-12,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BIAL - Portela & Ca, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN A DOUBLE-BLIND, RANDOMISED, DOSE-TITRATION, PLACEBO-CONTROLLED, MULTICENTRE CLI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002131-27,0,0,0 2005-002132-94,1,2009-07-20,2009-07-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"„Effect of intravenous Zoledronic Acid on Bone Metabolism given over 4 month in patients with prostate cancer or breast cancer and bone metastasis. A prospective, single-arm multicenter study” (ZoTe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002132-94,0,0,0 2005-002133-13,1,2006-11-13,2006-11-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BIAL - Portela & Ca, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN A DOUBLE-BLIND, FIXED MULTIPLE DOSE, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002133-13,0,0,0 2005-002134-35,6,2007-06-15,2007-07-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Bial - Portela & Cª, S.A.","EXTENSION STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN THE RECURRENCE PREVENTION OF BIPOLAR I DISORDER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002134-35,0,0,0 2005-002134-35,6,2007-06-15,2007-07-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BIAL - Portela & Cª, SA","EXTENSION STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN THE RECURRENCE PREVENTION OF BIPOLAR I DISORDER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002134-35,0,0,0 2005-002134-35,6,2007-06-15,2007-07-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BIAL - Portela & Ca, S.A.","EXTENSION STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (BIA 2-093) IN THE RECURRENCE PREVENTION OF BIPOLAR I DISORDER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002134-35,0,0,0 2005-002135-27,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,ISTITUTO GIANNINA GASLINI,"""Glargine insulin efficacy in Cystic Fibrosis patients with glucose intolerance and clinical deterioration""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002135-27,0,0,0 2005-002136-10,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,ISTITUTO GIANNINA GASLINI,Comparison between once-per-cycle peg-Filgrastim and daily injection r-Hu-G-CSF in chemotherapy-induced neutropenia treatment and peripheral blood progenitor cells mobilization in childhood.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002136-10,0,0,0 2005-002138-36,1,2008-02-18,2008-02-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital of Leicester NHS Trust,Randomised placebo controlled trial of low dose prednisolone for 3-years in subjects with chronic obstructive pulmonary disease with a sputum eosinophilia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002138-36,0,0,0 2005-002141-39,1,2007-01-11,2007-01-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"Multicenter, dose response, randomized, double blin, parallel, 3 arms, placebo controlled clinical trial to evaluate the efficacy and the safety of subcutaneous CDP870 (certolizumab pegol) at 2 differ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002141-39,0,0,0 2005-002145-39,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,deCODE genetics ehf.,"An open-label, randomised dose finding study to examine safety, tolerability and dose-related effects of DG-031 on inflammatory biomarkers in serum of patients with history of myocardial infarction (p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002145-39,0,0,0 2005-002148-25,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Great Ormond Street Hospital,A double blind randomised control trial of perioperative glutamine administration: a potential therapy for preventing post-operative immune hypo-responsiveness.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002148-25,0,0,0 2005-002152-18,1,,,0,0,0,0,0,3,2,0,1,0,0,0,0,0,0,Prof. Dr. H. Lode,Untersuchung über die Empfindlichkeitsveränderungen oraler Mundstreptokokken gegenüber Makrolidantibiotika nach Gabe von AzithromycinSR versus ClarithromycinXL bei freiwilligen gesunden Probanden,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002152-18,0,0,0 2005-002156-17,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,''Geriatric assessment adapted'' therapy for the treatment of Ph-negative Acute lymphoblastic Leukemia in elder patients. Terapia ''geriatric assessment adapted'' per il trattamento della Leucemia ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002156-17,0,0,0 2005-002157-51,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,1,Antares Pharma AG,"A Phase II, Single-Center, Open-Label, Parallel, Three-Treatment, Single-Period, Randomized, Single and Multiple-Dose Pharmacokinetic Study of Oxybutynin Gel in Healthy Volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002157-51,0,0,0 2005-002159-41,1,,,0,1,0,0,0,3,4,0,1,1,0,0,0,1,0,Department of Anaesthesia & General Intensive Care Medicine,Investigation of the antihyperalgesic effect of topical buprenorphine in an UV-B induced inflammatory skin pain model in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002159-41,0,0,0 2005-002160-28,1,2007-11-21,2007-11-21,1,1,0,0,1,1,3,0,0,1,0,0,1,0,0,"Medical University Graz,Department of Internal Medicine, Division of Gastroenterology and Hepatology",Safety and efficacy of long-term treatment with atorvastatin in patients with primary biliary cirrhosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002160-28,0,0,0 2005-002161-36,5,2007-03-23,2007-03-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Groupe,RANDOMIZED COMPARISON OF A TWO-MONTH REGIMEN OF IRBESARTAN VERSUS ENALAPRIL ON CARDIOVASCULAR MARKERS IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002161-36,0,0,0 2005-002161-36,5,2007-03-23,2007-03-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Groupe,RANDOMIZED COMPARISON OF A TWO-MONTH REGIMEN OF IRBESARTAN VERSUS ENALAPRIL ON CARDIOVASCULAR MARKERS IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT ST SEGMENT ELEVATION.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002161-36,0,0,0 2005-002163-84,3,2006-05-10,2006-05-10,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ALTANA PHARMA,Comparison of the Efficacy and Safety of 160 mcg Ciclesonide Administered Once Daily in the Evening with ot without Different Spacer Types in Patients with Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002163-84,0,0,0 2005-002163-84,3,2006-05-10,2006-05-10,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ALTANA Pharma AG,Comparison of the Efficacy and Safety of 160 mcg Ciclesonide Administered Once Daily in the Evening with ot without Different Spacer Types in Patients with Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002163-84,0,0,0 2005-002169-35,8,2008-01-16,2008-01-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,"A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the safety and Efficacy of Asenapine With Olanzapine in Subjects who Completed Protocol 25543",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002169-35,0,0,0 2005-002169-35,8,2008-01-16,2008-01-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Limited,"A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the safety and Efficacy of Asenapine With Olanzapine in Subjects who Completed Protocol 25543",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002169-35,0,0,0 2005-002169-35,8,2008-01-16,2008-01-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ORGANON ITALIA,"A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the safety and Efficacy of Asenapine With Olanzapine in Subjects who Completed Protocol 25543",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002169-35,0,0,0 2005-002169-35,8,2008-01-16,2008-01-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER,"A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the safety and Efficacy of Asenapine With Olanzapine in Subjects who Completed Protocol 25543",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002169-35,0,0,0 2005-002171-33,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Aalborg Sygehus Syd,Hepatitis vaccination til patienter med HIV infektion. Betydning af adjuverende interleukin-2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002171-33,0,0,0 2005-002174-30,1,2009-09-25,2009-09-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company,The Use of Nuclear Scintigraphy to Evaluate the Anabolic Effects of Teriparatide on the Skeleton in Postmenopausal Women in Osteoporosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002174-30,0,0,0 2005-002175-32,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Sanofi Pasteur SA,Take evaluation and safety of smallpox vaccine (LISTER strain) in naïve healthy adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002175-32,0,0,0 2005-002179-34,1,2008-01-29,2008-01-29,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,Euro Nippon Kayaku GmbH,SAFETY AND EFFICACY STUDY ON DEOXYSPERGUALIN (NKT-01) IN PATIENTS WITH UNCONTROLLED LUPUS NEPHRITIS RECEIVING ORAL CORTICOSTEROIDS AND PRIOR TREATMENT OF STANDARD IMMUNOSUPPRESSIVE THERAPY - a prospec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002179-34,0,0,0 2005-002180-90,1,2008-04-01,2008-04-01,1,0,0,1,0,1,1,0,0,1,1,1,0,0,0,Neurologische Uniklinik Regensburg,Lókoregionale Tiefenhyperthermie begleitend zu ACNU in der Rezidivtherapie von Patienten mit malignen Gliomen (WHO°III/IV)- Phase I/II-Studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002180-90,0,0,0 2005-002181-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE ONCOLOGICO DI BARI,FOLFIRI vs XELIRI in the treatment of advanced colo-rectal untreated carcinoma: a phase II randomized study of the Gruppo Oncologico dell'Italia Meridionale,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002181-11,0,0,0 2005-002182-36,5,2008-04-09,2008-04-29,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Valeant Research & Development,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP PHASE 3 STUDY TO DETERMINE THE EFFICACY AND SAFETY OF TWO DOSES OF RETIGABINE (900 MG/DAY AND 600 MG/DAY) USED AS ADJUNCTIVE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002182-36,0,0,0 2005-002189-12,6,2008-02-29,2008-03-20,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Integrated Therapeutics Group, Inc. - A subsidiary of Schering-Plough Corp.","A randomized, multicenter, international, open-label study of infliximab plus methotrexate versus methotrexate (MTX) alone for the treatment of MTX naïve subjects with Active Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002189-12,0,0,0 2005-002189-12,6,2008-02-29,2008-03-20,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Schering Plough Research Institute,"A randomized, multicenter, international, open-label study of infliximab plus methotrexate versus methotrexate (MTX) alone for the treatment of MTX naïve subjects with Active Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002189-12,0,0,0 2005-002192-32,1,2008-10-31,2008-10-31,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Univeristy Hospital Schleswig-Holstein,"Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002192-32,0,0,0 2005-002195-15,1,2005-11-05,2005-11-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"EVALUATION OF THE 24-HOUR TROUGH FEV1 FOLLOWING 7 DAYS OF DOSING WITH CHF4226 2µg ONCE DAILY. A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL GROUP, PLACEBO AND ACTIVE (FORMOTEROL 12µg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002195-15,0,0,0 2005-002199-14,5,2007-09-12,2007-10-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis S.A.,"A Multicenter, Double-blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with Vidagliptin 50 mg bid to Pioglitazone 30 mg Daily as Add-On Therapy in Patients with T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002199-14,0,0,0 2005-002199-14,5,2007-09-12,2007-10-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Multicenter, Double-blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with Vidagliptin 50 mg bid to Pioglitazone 30 mg Daily as Add-On Therapy in Patients with T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002199-14,0,0,0 2005-002199-14,5,2007-09-12,2007-10-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A Multicenter, Double-blind, Randomized, Active Controlled Study to Compare the Effect of 52 Weeks Treatment with Vidagliptin 50 mg bid to Pioglitazone 30 mg Daily as Add-On Therapy in Patients with T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002199-14,0,0,0 2005-002202-28,1,2008-05-01,2008-05-01,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,Rigshospitalet,Hepatitis C virusdynamik og immunaktivering hos HCV/HIV-koinficerede patienter under behandling med pegyleret interferon a-2a og ribavirin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002202-28,0,0,0 2005-002203-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació de Lluita Contra la Sida,"Estudio piloto unicéntrico, abierto, aleatorizado para evaluar la evolución inmuno-virológica y clínica de una combinación con análogos a nucleósidos/nucléotidos (TrizivirÒ +Tenofovir) en pacientes mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002203-17,0,0,0 2005-002206-37,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Medizinische Universitätsklinik II , Abteilung Hämatologie, Onkologie, Immunologie und Rheumatologie",Multicenter phase I/II study of radioimmunotherapy with 90Y-ibritumomab tiuxetan in a nonmyeloablative conditioning regimen for allogeneic hematopoietic cell transplantation from HLA-identical donors ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002206-37,0,0,0 2005-002207-16,1,2007-10-20,2007-10-20,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust,A randomised controlled trial of Myfortic versus Mycophenolate Mofetil in the treatment of multi-system autoimmune disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002207-16,0,0,0 2005-002208-40,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"Levetiracetam Keppra in the dyskinesias induced from levodopa in patients with disease of Parkinson. Clinical study pilot in open, with farmacokinetic-farmacodynamic monitoring of the effects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002208-40,0,0,0 2005-002209-22,1,2010-01-15,2010-01-15,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,University Hospitals of Leicester NHS Trust,"A randomised, placebo-controlled, rising-dose crossover study to evaluate the effectiveness of modafinil in the management of fatigue in fibromyalgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002209-22,0,0,0 2005-002211-24,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,FAZ - Floridsdorf Allergy Center,Wirksamkeit von oralem Vitamin C bei der Seekrankheit,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002211-24,0,0,0 2005-002212-13,3,2006-09-18,2013-09-10,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,A Phase II Study of GW786034 Using a Randomized Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002212-13,0,0,0 2005-002216-25,3,2011-01-03,2011-01-03,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,GE Healthcare Ltd and its affliates,"A multicentre, randomised, open label, comparative Phase 4 trial to assess changes in clinical management after DaTSCAN imaging of subjects with clinically uncertain parkinsonism in a general neurolog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002216-25,0,0,0 2005-002216-25,3,2011-01-03,2011-01-03,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,GE Healthcare Ltd e le sue filiali,"A multicentre, randomised, open label, comparative Phase 4 trial to assess changes in clinical management after DaTSCAN imaging of subjects with clinically uncertain parkinsonism in a general neurolog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002216-25,0,0,0 2005-002216-25,3,2011-01-03,2011-01-03,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Amersham Health, S.A. (filial de GE Healthcare Ltd)","A multicentre, randomised, open label, comparative Phase 4 trial to assess changes in clinical management after DaTSCAN imaging of subjects with clinically uncertain parkinsonism in a general neurolog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002216-25,0,0,0 2005-002218-39,1,2007-11-08,2007-11-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Affymax, Inc.","A Phase 2, Open-label, Multi-center, Sequential Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Multiple Doses of AF37702 Injection (HematideTM) in Chronic Kidney Disease P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002218-39,0,0,0 2005-002219-26,8,2006-10-18,2006-10-19,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002219-26,0,0,0 2005-002219-26,8,2006-10-18,2006-10-19,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline S.A.,"A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002219-26,0,0,0 2005-002219-26,8,2006-10-18,2006-10-19,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline R&D Ltd,"A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002219-26,0,0,0 2005-002219-26,8,2006-10-18,2006-10-19,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GLAXO SMITHKLINE,"A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002219-26,0,0,0 2005-002219-26,8,2006-10-18,2006-10-19,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline,"A randomised, parallel group, placebo-controlled, double blind study to assess the safety and tolerability of SB-681323 at 7.5mg daily dose for 28 days and its effect on the levels of serum C-reactive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002219-26,0,0,0 2005-002220-34,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,"Fundación Investigación y Desarrollo Área Cardiovascular & Dr. Javier Segovia, Unidad de Trasplante",Estudio prospectivo y aleatorizado para la evaluación del efecto del everolimus en la progresión clínica y por ecografía intracoronaria de la enfermedad vascular del injerto cardíaco (EVI) establecida...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002220-34,0,0,0 2005-002221-31,1,2006-08-31,2006-08-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Clinic for Nephrology,Efficacy of niacin on phosphatic metabolism in patients with renal insufficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002221-31,0,0,0 2005-002223-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Rigshospitalet,Fase II study of carboplatin and vinorelbine in malignant pleural mesothelioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002223-14,0,0,0 2005-002229-30,1,2007-01-30,2007-01-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Serono España, S.A.",Lutropin alfa in mid follicular phase in women at risk of poor response suppresed with cetrorelix: an exploratory trial.Lutropina alfa en mitad de la fase folicular en mujeres con riesgo de pobre resp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002229-30,0,0,0 2005-002231-27,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,Clínica del Dr. Lobatón,"Estudio prospectivo, in vivo, aleatorizado, controlado, abierto, de fase IV, en grupos paralelos para medir el efecto de los antihistamínicos (levocetirizina 5 mg/día y ebastina 20 mg/día, vía oral) s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002231-27,0,0,0 2005-002233-12,1,2009-06-02,2009-06-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,Measurement and Analysis of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Patients with Autoimmune Diseases treated with Mycophenolic Acid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002233-12,0,0,0 2005-002234-35,1,2008-09-19,2008-09-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002234-35,0,0,0 2005-002239-29,6,2007-02-16,2007-02-16,5,1,0,0,0,3,2,0,0,1,0,0,1,0,1,F. Hoffmann - La Roche AG,"A phase II prospective, open label, randomized, active-controlled, parallel group, multi-center ‘proof of concept’ trial in adult patients with complicated skin and skin structure infections requiring...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002239-29,0,0,0 2005-002241-39,13,2009-09-04,2011-11-09,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A multicentre, double blind randomised, phase III study to evaluate the efficacy of Tarceva or placebo following 4 cycles of platinum-based chemotherapy in patients with histologically documented, adv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002241-39,0,0,0 2005-002241-39,13,2009-09-04,2011-11-09,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann- La Roche Ltd,"A multicentre, double blind randomised, phase III study to evaluate the efficacy of Tarceva or placebo following 4 cycles of platinum-based chemotherapy in patients with histologically documented, adv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002241-39,0,0,0 2005-002247-86,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Royal Devon and Exeter NHS Foundation Trust,Peripheral Blood Stem Cell Mobilisation with Cyclophosphamide and Methylprednisolone in Patients with Myeloma and Indolent Lymphoma– a prospective single arm study with historical controls,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002247-86,0,0,0 2005-002249-38,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Pfizer S.A.,"A PHASE 1B DOSE ESCALATION/PHASE 2 RANDOMIZED, NON-COMPARATIVE, MULTIPLE CENTER, OPEN LABEL STUDY OF CP-751,871 IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN AND OF PACLITAXEL AND CARBOPLATIN ALONE A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002249-38,0,0,0 2005-002250-21,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ANGELINI,"EVALUATION OF ANTALGIC EFFECT AND TOLERABILITY OF A NEW PARACETAMOL SYRUP DOSAGE IN PHARINGOTONSILLYTIS IN PEDIATRY. DOUBLE-BLIND VS PLACEBO STUDY, CONTROLLED VS KETOPROFEN LYSINA SALT.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002250-21,0,0,0 2005-002251-41,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA,"ASTRA STUDY (Angioplasty, Stent X-ray Intensive Antithrombotic Therapy) A PHASE III, PROSPECTIVE AND RANDOMIZED, MULTICENTER STUDY, OPEN LABEL, PARALLEL-GROUP, BLINDED ADJUDICATION, TO INVESTIGATE THE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002251-41,0,0,0 2005-002252-18,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,ALCON ITALIA,"Hypotonic efficacy and tollerability of Travoprost in patient with glaucoma or ocular hypertension, monotherapy or fixed association beta-blocking not controlled or intollerant.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002252-18,0,0,0 2005-002256-17,9,2007-02-08,2007-04-23,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-Center Dose Ranging Study with the Beta-3 AGONist YM178 in Patients with Symptomatic Overactive Bladder (DRAGON)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002256-17,0,0,0 2005-002257-47,1,2006-04-18,2006-04-18,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Chiron S.r.l.,"A Phase III, Randomized, Controlled, Observer-Blind, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity of a Single Intramuscular Dose of Three Lots of Trivalent Subunit Influenza ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002257-47,0,0,0 2005-002258-23,4,2009-03-05,2010-01-13,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Cephalon, Inc.","A Randomized, Open Label Study of Oral CEP 701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT 3 Activating Mutations.Estudio ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002258-23,0,0,0 2005-002258-23,4,2009-03-05,2010-01-13,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,CEPHALON EUROPE,"A Randomized, Open Label Study of Oral CEP 701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT 3 Activating Mutations.Estudio ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002258-23,0,0,0 2005-002258-23,4,2009-03-05,2010-01-13,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Cephalon Inc.,"A Randomized, Open Label Study of Oral CEP 701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT 3 Activating Mutations.Estudio ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002258-23,0,0,0 2005-002261-37,2,,,0,1,0,0,1,0,2,0,0,1,1,0,0,1,1,GlaxoSmithKline Research & Development Ltd,"A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of Radafaxine Extended-Release (100-140mg/day) Compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002261-37,0,0,0 2005-002266-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Evaristo Varo Pérez,Estudio para comparar la evolución de la hepatitis C con ciclosporina C2 frente a tacrolimus en receptores de trasplante hepático de novo virus C positivos. Study to compare hepatitis C evolution wit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002266-10,0,0,0 2005-002269-35,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,Phase II trial to evaluate the combination of FOLFOX6 + Bevacizumab in initially unresectable liver metastases from colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002269-35,0,0,0 2005-002270-29,6,2008-04-08,2008-05-26,5,1,0,0,0,0,0,0,0,1,1,0,1,0,1,LEO Pharma A/S,Safety profile of innohep versus subcutaneous unfractionated Heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002270-29,0,0,0 2005-002270-29,6,2008-04-08,2008-05-26,5,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"FARMACUSI, S.A.",Safety profile of innohep versus subcutaneous unfractionated Heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002270-29,0,0,0 2005-002274-30,1,2010-02-04,2010-02-04,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University College London,"A Study to assess the safety, efficacy and tolerability of Rituximab(Mabthera) in combination with Plasma Exchange in patients with Acute Thrombotic Thrombocytopenia Purpura.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002274-30,0,0,0 2005-002279-33,1,2007-12-20,2007-12-20,1,1,0,0,0,3,2,0,0,1,0,0,1,0,1,Lilly S.A.,Tratamiento con Alimta (Pemetrexed) y cisplatino como tratamiento neoadyuvante en el cancer no microcitico de pulmon,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002279-33,0,0,0 2005-002301-23,5,2006-01-31,2007-01-31,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","A Phase 3, Randomized, Double-Blind Study Of Ceftobiprole Medocaril Versus Vancomycin With Ceftazidime in The Treatment Of Complicated Skin And Skin Structure Infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002301-23,0,0,0 2005-002304-41,6,2009-12-29,2009-12-29,4,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Janssen-Cilag Medical Affairs EMEA,Early versus late initiation of treatment with Risperdal Consta in subjects with schizophrenia after an acute episode,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002304-41,0,0,0 2005-002304-41,6,2009-12-29,2009-12-29,4,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Janssen-Cilag EMEA Medical Affairs,Early versus late initiation of treatment with Risperdal Consta in subjects with schizophrenia after an acute episode,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002304-41,0,0,0 2005-002304-41,6,2009-12-29,2009-12-29,4,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Janssen-Cilag EMEA,Early versus late initiation of treatment with Risperdal Consta in subjects with schizophrenia after an acute episode,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002304-41,0,0,0 2005-002304-41,6,2009-12-29,2009-12-29,4,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Janssen Cilag EMEA Medical Affairs,Early versus late initiation of treatment with Risperdal Consta in subjects with schizophrenia after an acute episode,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002304-41,0,0,0 2005-002305-23,1,2009-10-10,2009-10-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,R&D Addenbrookes Hospital,"A pilot study of combination monoclonal antibody treatment in early active relapsing-remitting multiple sclerosis using Campath-1H and its non-binding form, SM3.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002305-23,0,0,0 2005-002306-39,1,2006-07-05,2006-07-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Maryland Research Institute, Inc.","Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002306-39,0,0,0 2005-002308-40,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Plymouth,Evaluation of Intranasal (IN) Morphine Sulphate as a Paramedic Administered Analgesic for Children in the Pre-Hospital Environment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002308-40,0,0,0 2005-002313-21,6,2007-03-01,2007-03-02,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Europe R&D Centre Limited,"A placebo-controlled, double-blind, randomized study to evaluate the efficacy and safety of TAK-475 50mg and 100mg versus placebo, when co-administered with simvastatin 20mg or 40mg in subjects with p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002313-21,0,0,0 2005-002313-21,6,2007-03-01,2007-03-02,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Europe Research & Development Limited,"A placebo-controlled, double-blind, randomized study to evaluate the efficacy and safety of TAK-475 50mg and 100mg versus placebo, when co-administered with simvastatin 20mg or 40mg in subjects with p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002313-21,0,0,0 2005-002315-25,7,2006-12-20,2008-01-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Europe R&D Centre Ltd,"A double-blind, double dummy, randomized, parallel group, multi-centre Phase III study to evaluate the efficacy and safety of TAK-475 100 mg and TAK-475 100 mg administered in combination with ezetimi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002315-25,0,0,0 2005-002315-25,7,2006-12-20,2008-01-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global Research &Development Centre (Europe) Ltd,"A double-blind, double dummy, randomized, parallel group, multi-centre Phase III study to evaluate the efficacy and safety of TAK-475 100 mg and TAK-475 100 mg administered in combination with ezetimi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002315-25,0,0,0 2005-002315-25,7,2006-12-20,2008-01-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A double-blind, double dummy, randomized, parallel group, multi-centre Phase III study to evaluate the efficacy and safety of TAK-475 100 mg and TAK-475 100 mg administered in combination with ezetimi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002315-25,0,0,0 2005-002316-24,8,2007-04-30,2007-05-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Europe R &D Centre Ltd,"A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002316-24,0,0,0 2005-002316-24,8,2007-04-30,2007-05-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global R &D Centre (Europe),"A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002316-24,0,0,0 2005-002319-26,4,2007-05-25,2007-05-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"Efficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, four week, parallel-group, multicentre, phase II study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002319-26,0,0,0 2005-002320-34,1,2018-02-01,2018-02-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité Universitätsmedizin Berlin,Randomized controlled 12 months trial with etanercept (enbrel ®) vs. sulfasalazine followed by an open-label extension with etanercept up to week 540 in early axial spondyloarthritis with focus on imp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002320-34,0,0,0 2005-002323-14,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Landspítali Háskólasjúkrahús,Samanburður á þremur meðferðum við áreynsluþvagleka.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002323-14,0,0,0 2005-002325-31,1,2007-05-14,2007-05-14,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Taunton & Somerset NHS Trust,"Two parallel trials to compare the effectiveness, and potential adverse side-effects, of four routinely used topical therapies to prolong breastfeeding, by either (1) preventing or (2) treating nipple...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002325-31,0,0,0 2005-002326-63,5,2006-09-19,2006-09-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Celltech,"A Phase III Multi–center, Double–blind, Placebo–controlled, Parallel Group 24–Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002326-63,0,0,0 2005-002326-63,5,2006-09-19,2006-09-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"A Phase III Multi–center, Double–blind, Placebo–controlled, Parallel Group 24–Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002326-63,0,0,0 2005-002327-13,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Heart of England NHS Foundation Trust,Mild to moderate intermittent claudication: the clinical and cost-effectiveness of supervised exercise programmes and Cilostazol therapy in patient management,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002327-13,0,0,0 2005-002329-30,1,2010-05-31,2010-05-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"CELLERIX, S.A.","ENSAYO CLINICO COMPARATIVO, ABIERTO, MULTICENTRICO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE UNA NUEVA TERAPIA CON PIEL QUIMÉRICA CULTIVADA PARA EL TRATAMIENTO DE LAS LESIONES CUTÁNEAS DE LOS PACIENTES...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002329-30,0,0,0 2005-002335-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,Botulin Toxin injection for the treatment of Internal Anal Sphincter Achalasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002335-27,0,0,0 2005-002338-36,1,2008-09-15,2008-09-15,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,TopoTarget A/S,"A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients with Advanced Solid Tumours",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002338-36,0,0,0 2005-002342-19,1,2007-06-20,2007-06-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Zentiva, a.s.","A multicentre, open label study to evaluate the safety and efficacy of Alendros 70 therapy administered 70mg once a week in women with postmenopausal osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002342-19,0,0,0 2005-002344-26,1,2011-04-29,2011-04-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GELA,"GEMCITABINE-OXALIPLATINE PLUS RITUXIMAB (R-GEMOX) IN REFRACTORY/RELAPSED PATIENTS WITH CD20 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NON ELIGIBLE FOR HIGH-DOSE CHEMOTHERAPY FOLLOWED BY AUTOTRANSPLANTAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002344-26,0,0,0 2005-002345-39,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,NOPHO NHL-group,B-NHL BFM 04,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002345-39,0,0,0 2005-002347-82,4,2007-05-11,2007-05-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nycomed Danmark ApS,"Intranasal fentanyl for the treatment of breakthrough pain in cancer patients: A randomised, double-blind, placebo-controlled, cross-over confirmatory trial testing the doses 50, 100 and 200 µg fentan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002347-82,0,0,0 2005-002347-82,4,2007-05-11,2007-05-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NYCOMED HEADQUARTER,"Intranasal fentanyl for the treatment of breakthrough pain in cancer patients: A randomised, double-blind, placebo-controlled, cross-over confirmatory trial testing the doses 50, 100 and 200 µg fentan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002347-82,0,0,0 2005-002348-24,5,2008-08-29,2008-08-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nycomed Danmark ApS,"A double-blind, randomised, placebo-controlled trial confirming the efficacy of intranasal fentanyl titrated to 50, 100 or 200 µg with an open long-term safety follow-up in cancer patients with breakt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002348-24,0,0,0 2005-002348-24,5,2008-08-29,2008-08-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NYCOMED (HEADQUARTER),"A double-blind, randomised, placebo-controlled trial confirming the efficacy of intranasal fentanyl titrated to 50, 100 or 200 µg with an open long-term safety follow-up in cancer patients with breakt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002348-24,0,0,0 2005-002349-38,1,2008-10-01,2008-10-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Beaufour Ipsen Pharma-Ipsen Biotech Department,"Phase III multicentre, Randomised, Double Blind, Comparative study to assess the efficacy and safety of lanreotide 30mg versus placebo as a palliative treatment of clinical symptoms associated with in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002349-38,0,0,0 2005-002352-18,1,,,0,1,0,0,0,1,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, randomized, multinational study, double-blinded for the immunogenicity and consistency evaluation of 3 Hib-MenCY-TT vaccine lots and single-blinded and controlled for the evaluation of sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002352-18,0,1,1 2005-002355-40,4,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Scandinavian prostate cancer group,An open randomized phase III trial of six cycles of docetaxel versus surveillance after radical prostatectomy in prostate cancer patients with high grade pT3 or margin positive pT2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002355-40,0,0,0 2005-002360-28,1,,,0,1,0,1,0,0,1,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"An open, randomized phase I/II study to demonstrate the non inferiority in term of cellular mediated immune response between GlaxoSmithKline Biologicals influenza candidate vaccines containing various...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002360-28,0,0,0 2005-002364-29,7,2008-10-02,2008-10-02,7,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Merck Sharp & Dohme GesmbH,"A Two Year Study to Assess the Efficacy, Safety, and Tolerability of L-000899055 in Obese Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002364-29,0,0,0 2005-002364-29,7,2008-10-02,2008-10-02,7,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Merck & Co. Inc.,"A Two Year Study to Assess the Efficacy, Safety, and Tolerability of L-000899055 in Obese Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002364-29,0,0,0 2005-002364-29,7,2008-10-02,2008-10-02,7,1,0,0,0,0,3,0,0,1,1,0,1,0,2,,"A Two Year Study to Assess the Efficacy, Safety, and Tolerability of L-000899055 in Obese Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002364-29,0,0,0 2005-002364-29,7,2008-10-02,2008-10-02,7,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Merck Sharp and Dohme de España,"A Two Year Study to Assess the Efficacy, Safety, and Tolerability of L-000899055 in Obese Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002364-29,0,0,0 2005-002364-29,7,2008-10-02,2008-10-02,7,1,0,0,0,0,3,0,0,1,1,0,1,0,2,"Merck & Co., Inc.","A Two Year Study to Assess the Efficacy, Safety, and Tolerability of L-000899055 in Obese Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002364-29,0,0,0 2005-002364-29,7,2008-10-02,2008-10-02,7,1,0,0,0,0,3,0,0,1,1,0,1,0,2,MSD (Norge) AS,"A Two Year Study to Assess the Efficacy, Safety, and Tolerability of L-000899055 in Obese Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002364-29,0,0,0 2005-002368-27,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",EFFECT OF AN ANTI-OXIDANT TREATMENT ON RESISTIN SERUM LEVELS. A RANDOMISED STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002368-27,0,0,0 2005-002369-35,1,2006-07-13,2006-07-13,1,1,0,0,0,3,3,0,1,1,0,0,1,0,1,Ursapharm Arzneimittel GmbH&Co. KG,Reduction of pain under pressure of an experimentally induced hematoma in healthy volunteers by two Bromelain preparations (Bromelain-POS(R) and Traumanase(R) forte).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002369-35,0,0,0 2005-002371-33,1,2007-08-16,2007-08-16,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Urologische Partnerschaft,Finasterid-unterstützte Diagnostik des Prostatakarzinoms bei Patienten mit BPH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002371-33,0,0,0 2005-002372-16,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Novartis Farmaceútica S.A,"Multicenter, open-label, single-arm, safety, tolerability, efficacy and pharmacokinetic study of RAD001 in pediatric de novo renal transplant patients Estudio multicéntrico, abierto, con un grupo de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002372-16,0,0,0 2005-002380-90,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,"Nyremedicinsk afdeling, Aalborg Sygehus",Effekten af intravenøs infusion af n-3 polyumættede fedtsyrer på risikomarkører for pludselig hjertedød hos hæmodialysepatienter,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002380-90,0,0,0 2005-002381-10,1,2009-03-31,2009-03-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Dept anaesthesiology and intensive care,Evaluation of the optimal dose of prophylactic anticoagulation with low-molecular-weight heparine administered subcutaneously to critically ill patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002381-10,0,0,0 2005-002382-36,2,2006-08-31,2006-09-07,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-week treatment, randomized, double-blind, parallel group, multicenter study to evaluate the efficacy of the valsartan/simvastatin combinations 160/20mg up titrated to 320/20mg versus 160/40mg up ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002382-36,0,0,0 2005-002385-11,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,F. HOFFMANN - LA ROCHE LTD.,- STUDIO MULTICENTRICO DI FASE III IN APERTO RANDOMIZZATO A TRE BRACCI DI CONFRONTO TRA 1 ANNO E 2 ANNI DI TRATTAMENTO CON HERCEPTIN VERSO NESSUN TRATTAMENTO CON HERCEPTIN IN DONNE AFFETTE DA TUMOR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002385-11,0,0,0 2005-002386-37,1,2008-06-02,2008-06-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Cardiology, Aalborg Hospital",Intravenous infusion of n-3 polyunsaturated fatty acids and ventricular tackycardi in patients with implantable cardioverter defibrillator (ICD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002386-37,0,0,0 2005-002388-95,6,2008-01-21,2008-01-21,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"EFFICACY OF AGOMELATINE 25 TO 50 MG/DAY GIVEN ORALLY ON QUALITY OF REMISSION IN ELDERLY DEPRESSED PATIENTS, AFTER A 12-WEEK TREATMENT PERIOD. A RANDOMISED, DOUBLE-BLIND, FLEXIBLE-DOSE INTERNATIONAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002388-95,0,0,0 2005-002388-95,6,2008-01-21,2008-01-21,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratorios Servier S.L. (For Spain only),"EFFICACY OF AGOMELATINE 25 TO 50 MG/DAY GIVEN ORALLY ON QUALITY OF REMISSION IN ELDERLY DEPRESSED PATIENTS, AFTER A 12-WEEK TREATMENT PERIOD. A RANDOMISED, DOUBLE-BLIND, FLEXIBLE-DOSE INTERNATIONAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002388-95,0,0,0 2005-002388-95,6,2008-01-21,2008-01-21,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"EFFICACY OF AGOMELATINE 25 TO 50 MG/DAY GIVEN ORALLY ON QUALITY OF REMISSION IN ELDERLY DEPRESSED PATIENTS, AFTER A 12-WEEK TREATMENT PERIOD. A RANDOMISED, DOUBLE-BLIND, FLEXIBLE-DOSE INTERNATIONAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002388-95,0,0,0 2005-002389-13,1,2007-02-09,2007-02-09,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,Moorfields Eye Hospital,Endothelial Lamellar Keratoplasty (ELK) with Tisseel adhesive.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002389-13,0,0,0 2005-002391-14,1,,,0,1,0,0,1,1,4,0,0,1,0,0,0,1,0,Moorfields Eye Hospital NHS Foundation Trust,Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002391-14,0,0,0 2005-002392-32,5,2013-02-28,2013-07-23,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomised, placebo controlled, double-blind, parallel group, international study to evaluate the safety and efficacy of rituximab (MabThera/Rituxan) in combination with methotrexate, compared to me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002392-32,0,0,0 2005-002395-15,9,2013-07-22,2013-07-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomized, phase 3, controlled, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX alone, in met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002395-15,0,0,0 2005-002395-15,9,2013-07-22,2013-07-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann - La Roche Ltd.,"A randomized, phase 3, controlled, double-blind, parallel-group, multicenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate (MTX) compared to MTX alone, in met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002395-15,0,0,0 2005-002396-33,8,2012-06-30,2013-03-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomised, double-blind, international study to evaluate the efficacy and safety of various re-treatment regimens of rituximab in combination with methotrexate in RA patients with an inadequate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002396-33,0,0,0 2005-002396-33,8,2012-06-30,2013-03-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann- La Roche Ltd.,"A randomised, double-blind, international study to evaluate the efficacy and safety of various re-treatment regimens of rituximab in combination with methotrexate in RA patients with an inadequate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002396-33,0,0,0 2005-002398-57,5,2008-04-25,2008-04-25,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"A randomized, double-blind, parallel-group, multicenter study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of lt; 20 mg/day ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002398-57,0,0,0 2005-002398-57,5,2008-04-25,2008-04-25,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MUNDIPHARMA RESEARCH GMBH CO. KG,"A randomized, double-blind, parallel-group, multicenter study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of lt; 20 mg/day ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002398-57,0,0,0 2005-002401-23,2,2008-07-02,2008-07-02,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Immunogenicity of the Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with Intramuscular Vaccination with Vaxigrip® in Adults.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002401-23,0,0,0 2005-002402-36,1,2007-03-20,2007-03-20,1,0,0,0,0,1,3,0,0,1,0,0,1,0,1,Talecris Biotherapeutics,"Multi-center, open-label trial to evaluate the safety and tolerability of Alpha-1 MP in subjects with Alpha-1-antitrypsin (α1AT) deficiency. STAMP: Safety and Tolerability of Alpha-1 MP",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002402-36,0,0,0 2005-002404-42,1,2010-09-06,2010-09-06,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,University of Dundee,A pilot study to inform a randomised controlled trial of iodine supplementation in preterm infants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002404-42,0,0,0 2005-002407-17,1,2010-11-30,2010-11-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Technical University Dresden,Effects of rosiglitazone on renal hemodynamics and proteinuria of type 2 diabetic patients with renal insufficiency due to overt diabetic nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002407-17,0,0,0 2005-002409-21,1,2007-10-24,2007-10-24,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,Population Council - Center for Biomedical Research,A dose-finding randomized clinical trial to evaluate the differential impact of four progestins for their use as male contraceptives in healthy men.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002409-21,0,0,0 2005-002411-25,3,2006-07-07,2006-07-07,2,1,0,0,2,0,4,0,0,1,0,0,1,0,1,PFIZER,"A prospective multicenter, parallel group study with a single blind phase and a double blind randomised phase, to evaluate the efficacy and satisfaction of Viagra® (Sildenafil Citrate) high dose (100m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002411-25,0,0,0 2005-002411-25,3,2006-07-07,2006-07-07,2,1,0,0,2,0,4,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A prospective multicenter, parallel group study with a single blind phase and a double blind randomised phase, to evaluate the efficacy and satisfaction of Viagra® (Sildenafil Citrate) high dose (100m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002411-25,0,0,0 2005-002411-25,3,2006-07-07,2006-07-07,2,1,0,0,2,0,4,0,0,1,0,0,1,0,1,"Pfizer Global Pharamceuticals, EuCAn, Pfizer Inc","A prospective multicenter, parallel group study with a single blind phase and a double blind randomised phase, to evaluate the efficacy and satisfaction of Viagra® (Sildenafil Citrate) high dose (100m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002411-25,0,0,0 2005-002414-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Española de Hematología y Hemoterapia.,"Estudio prospectivo, multicéntrico, abierto, de un único brazo de darbepoetin alfa en sujetos anémicos con síndrome mielodisplásico",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002414-38,0,0,0 2005-002418-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SOFAR SPA,"Valutation of the efficacy of Lactobacillus casei subspeciae casei DG in prevention of Crohn s disease relapse after induction of clinical remission by antibiotics a multicentric, randomised, double-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002418-39,0,0,0 2005-002421-31,2,2006-08-29,2006-08-29,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Arakis Ltd.,"A phase II randomised, double-blind, multicenter, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of 3 strengths of AD 452 in adult subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002421-31,1,0,0 2005-002421-31,2,2006-08-29,2006-08-29,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Arakis Ltd,"A phase II randomised, double-blind, multicenter, placebo-controlled, dose-ranging, parallel group study to compare the efficacy, safety and tolerability of 3 strengths of AD 452 in adult subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002421-31,1,0,0 2005-002423-13,6,2011-10-06,2012-05-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann La-Roche Ltd,Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in WA 17822 Studio di estensione sulla sicurezza a lungo termine del trattamento con MR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002423-13,0,0,0 2005-002423-13,6,2011-10-06,2012-05-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F.Hoffmann La Roche Ltd,Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in WA 17822 Studio di estensione sulla sicurezza a lungo termine del trattamento con MR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002423-13,0,0,0 2005-002423-13,6,2011-10-06,2012-05-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in WA 17822 Studio di estensione sulla sicurezza a lungo termine del trattamento con MR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002423-13,0,0,0 2005-002425-31,3,2008-10-23,2008-10-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Fresenius Kabi Deutschland GmbH,"A double-blind, randomised study comparing the safety and tolerance of SMOFlipid 20% and Intralipid 20% in long-term treatment with parenteral nutrition",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002425-31,0,0,0 2005-002427-14,1,2008-11-12,2008-11-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd,A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment with BIBF 1120 Following Chemotherapy in Patients with Relapsed Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002427-14,0,0,0 2005-002428-33,6,2007-09-24,2007-09-24,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"SONUS PHARMACEUTICALS, INC.","A MULTICENTER PHASE 3, RANDOMIZED COMPARISON OF THE SAFETY AND EFFICACY OF WEEKLY TOCOSOL® PACLITAXEL VS. WEEKLY PACLITAXEL INJECTION IN THE TREATMENT OF METASTATIC BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002428-33,1,0,0 2005-002428-33,6,2007-09-24,2007-09-24,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"SONUS Pharmaceuticals, Inc","A MULTICENTER PHASE 3, RANDOMIZED COMPARISON OF THE SAFETY AND EFFICACY OF WEEKLY TOCOSOL® PACLITAXEL VS. WEEKLY PACLITAXEL INJECTION IN THE TREATMENT OF METASTATIC BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002428-33,1,0,0 2005-002430-34,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Eli Lilly & Company Limited,Efectos del bloqueo 5HT2A en pacientes deprimidos con respuesta inadecuada al tratamiento antidepresivo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002430-34,0,0,0 2005-002430-34,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Lilly S.A.,Efectos del bloqueo 5HT2A en pacientes deprimidos con respuesta inadecuada al tratamiento antidepresivo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002430-34,0,0,0 2005-002432-10,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,Solvay Pharmaceuticals,"A multicenter, randomized, double-blind, placebo-controlled, ascending dose, parallel group study exploring effects of SLV308 up to 42 mg/day administered as an adjunctive therapy to l-dopa in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002432-10,0,0,0 2005-002437-13,2,2009-09-29,2009-09-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002437-13,0,0,0 2005-002437-13,2,2009-09-29,2009-09-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Ltd.,Early access of TMC114 in combination with low-dose ritonavir (RTV) and other antiretrovirals (ARVs) in highly treatment experienced HIV-1 infected subjects with limited to no treatment options.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002437-13,0,0,0 2005-002438-37,1,2012-06-08,2012-06-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Velindre NHS Trust,A randomised phase III clinical trial investigating the effect of FRAGMin® Added to standard Therapy In patients with lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002438-37,0,0,0 2005-002441-39,8,2007-01-04,2008-01-04,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomised, double-blind, parallel-group, placebo controlled study of esomeprazole i.v. (bolus infusion of 80 mg followed by a continuous infusion of 8 mg per hour) administered for 72 hours to asse...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002441-39,0,0,0 2005-002442-19,7,2006-08-03,2006-08-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ireland Ltd.,A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002442-19,0,0,0 2005-002442-19,7,2006-08-03,2006-08-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd.,A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002442-19,0,0,0 2005-002442-19,7,2006-08-03,2006-08-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002442-19,0,0,0 2005-002442-19,7,2006-08-03,2006-08-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002442-19,0,0,0 2005-002442-19,7,2006-08-03,2006-08-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.",A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002442-19,0,0,0 2005-002442-19,7,2006-08-03,2006-08-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002442-19,0,0,0 2005-002442-19,7,2006-08-03,2006-08-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,A prospective randomised study to compare a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg with a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002442-19,0,0,0 2005-002445-40,1,2008-06-30,2008-06-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Neurologische Klinik Bad Neustadt,Efficacy of Levetiracetam in early post-stroke seizures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002445-40,0,0,0 2005-002446-19,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Hospital de Valme,Insuline resistance treatment effect in patients with genotype 1 hepatitis C treated with peginterferon alfa-2a plus ribavirin in usual clinical practice Efecto del tratamiento de la resistencia a ins...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002446-19,0,0,0 2005-002452-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitario de Valme,"Pilot, open, multicenter, phase IV Clinical Trial to evaluate safety and efficacy in treatment with peginterferon alfa-2a plus ribavirin in VIH patients with advanced immunosupression and chronic hepa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002452-17,0,0,0 2005-002454-21,5,2008-10-02,2009-02-10,4,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Merck Sharp and Dohme Ltd,"A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of L-000899055 in Obese Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002454-21,0,0,0 2005-002454-21,5,2008-10-02,2009-02-10,4,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of L-000899055 in Obese Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002454-21,0,0,0 2005-002454-21,5,2008-10-02,2009-02-10,4,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of L-000899055 in Obese Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002454-21,0,0,0 2005-002454-21,5,2008-10-02,2009-02-10,4,1,0,0,0,0,0,0,0,1,1,0,1,0,1,MERCK SHARP DOHME,"A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of L-000899055 in Obese Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002454-21,0,0,0 2005-002455-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska Institutet,"Clinical, morphological and biochemical effects of antioxidant treatment of patients with chronic hepatitis C.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002455-41,0,0,0 2005-002456-18,1,2006-12-01,2006-12-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF A FOUR-WEEK TREATMENT WITH YM758 IN SUBJECTS WITH STABLE ANGINA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002456-18,0,0,0 2005-002457-41,13,2007-05-07,2007-10-19,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Astellas Pharma Europe B.V.,"Direct Factor Xa inhibitor YM150 for prevention of venous thromboembolism in patients undergoing elective total hip replacement. A double blind, parallel, dose-finding study in comparison with open la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002457-41,0,0,0 2005-002457-41,13,2007-05-07,2007-10-19,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ASTELLAS PHARMA,"Direct Factor Xa inhibitor YM150 for prevention of venous thromboembolism in patients undergoing elective total hip replacement. A double blind, parallel, dose-finding study in comparison with open la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002457-41,0,0,0 2005-002460-29,4,2011-09-15,2011-09-15,4,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Rheumazentrum Ruhrgebiet.,"An Open Extension, Investigator Initiated Trial, to Examine Radiographic Progression, Efficacy and Safety, of Long-Term Treatment with Infliximab in Patients with Ankylosing Spondylitis EASIC (E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002460-29,0,0,0 2005-002462-11,1,2007-01-07,2007-01-07,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Pulmonary Research Institute GmbH an der Asklepiosklinik Barmbek. Niederlassung Hamburg.,Clinical efficacy of different inhalation sequences of Formoterol and Budesonide in asthmatic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002462-11,0,0,0 2005-002463-88,5,2011-09-06,2011-09-06,3,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Orfagen,"Efficacy and safety of a human normal immunoglobulin product for intravenous administration (IVIg) in the treatment of dermatomyositis (DM) and polymyositis (PM): prospective, randomised, double-blind...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002463-88,0,0,0 2005-002463-88,5,2011-09-06,2011-09-06,3,1,1,0,0,1,3,0,0,1,0,0,1,0,1,ORFAGEN,"Efficacy and safety of a human normal immunoglobulin product for intravenous administration (IVIg) in the treatment of dermatomyositis (DM) and polymyositis (PM): prospective, randomised, double-blind...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002463-88,0,0,0 2005-002466-11,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,King's College Hospital,"A Pilot Study to Examine the Safety and Efficacy of Posterior Juxtascleral Triamcinolone acetonide administration, in addition to Visudyne photoynamic therapy for predominantly Classic Choroidal Neov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002466-11,0,0,0 2005-002467-86,1,2008-10-27,2008-10-27,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Liisa Elomaa,A Randomised Multicenter Trial Comparing Docetaxel q2w and Docetaxel q3w in the Treatment of Patients with Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002467-86,0,0,0 2005-002471-32,1,,,0,0,0,0,1,0,2,0,0,4,0,0,0,0,1,Stiefel Laboratories Maidenhead Ltd (commonly known as Stiefel International R&D),"A PHASE II, SINGLE-CENTRE, INVESTIGATOR-BLIND, PARALLEL GROUP CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF 1% CICLOPIROX OLAMINE (BATRAFEN® CREAM), COMPARED TO 1% HYDROCORTISONE ACETATE (H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002471-32,0,0,0 2005-002472-15,1,2009-07-31,2009-07-31,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Ferring Laegemidler A/S,"The effect on mucosal healing with Pentasa® Sachet 4 g in mild to moderate active small bowel Crohn's disease, evaluated with video capsule endoscopy after 6 and 12 weeks treatment. A pilot study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002472-15,0,0,0 2005-002474-30,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Hospital Ruber Internacional,Influence of levetiracetam on gamma band activity in a group of epilepsy patients Estudio sobre la influencia de levetiracetam en la actividad de las ondas gamma en pacientes con epilepsia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002474-30,0,0,0 2005-002475-32,1,2011-11-21,2011-11-21,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Charitè Universitätmeditin Berlin,"Pilotstudy about endocrinilogical, peripherphysilogical and painreducing effects of Gamma-hydroxybutyrate in combination with operant-behaviour-therapeutic paintherapy with patients in Fibromyalgia-Sy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002475-32,0,0,0 2005-002476-15,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,Phase II pilot trial to evaluate the efficacy and safety of a first-line combined therapeutic approach for young (> = 60 years old) CLL patients with advanced and progressive disease stratified...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002476-15,0,0,0 2005-002483-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Dept. of Anaestesiology, University hospital in Glostrup",Effect of paracetamol versus paracetamol combined with pregabalin versus paracetamol combined with pregabalin and dexamethason on pain and opioid requirements in patients scheduled for a primary total...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002483-28,0,0,0 2005-002484-87,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Raija Ristamäki,Biweekly Taxotere in combination with Xeloda as first-line treatment in patients with advanced gastric cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002484-87,0,0,0 2005-002485-11,3,2007-12-27,2007-12-27,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd.,"A Randomized, Single Blind, Placebo-controlled, Multi-centre, Phase II Study of Lapatinib in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002485-11,0,0,0 2005-002485-11,3,2007-12-27,2007-12-27,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A Randomized, Single Blind, Placebo-controlled, Multi-centre, Phase II Study of Lapatinib in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002485-11,0,0,0 2005-002486-36,10,2012-05-08,2012-05-08,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Limited,"A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002486-36,0,0,0 2005-002486-36,10,2012-05-08,2012-05-08,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Ltd,"A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002486-36,0,0,0 2005-002486-36,10,2012-05-08,2012-05-08,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN R&D IRELAND,"A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002486-36,0,0,0 2005-002493-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació de Lluita contra la Sida,"ENSAYO CLÍNICO PILOTO, ABIERTO, PARALELO Y ALEATORIZADO PARA EVALUAR LA UTILIDAD DE LA MONITORIZACIÓN TERAPEUTICA DE LOS NIVELES PLASMÁTICOS DE EFAVIRENZ EN PACIENTES INFECTADOS POR EL VIH QUE INICIA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002493-30,0,0,0 2005-002494-75,11,2011-02-17,2011-02-17,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"The efficacy and safety of two doses of strontium ranelate (1g and 2g per day) versus placebo administered orally for 2 years in the treatment of knee osteoarthritis. A prospective multicentre, intern...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002494-75,0,0,0 2005-002494-75,11,2011-02-17,2011-02-17,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Servier S.L.,"The efficacy and safety of two doses of strontium ranelate (1g and 2g per day) versus placebo administered orally for 2 years in the treatment of knee osteoarthritis. A prospective multicentre, intern...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002494-75,0,0,0 2005-002494-75,11,2011-02-17,2011-02-17,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"The efficacy and safety of two doses of strontium ranelate (1g and 2g per day) versus placebo administered orally for 2 years in the treatment of knee osteoarthritis. A prospective multicentre, intern...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002494-75,0,0,0 2005-002494-75,11,2011-02-17,2011-02-17,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Servier Research and Development Ltd. (S.R.D.L) (for UK only),"The efficacy and safety of two doses of strontium ranelate (1g and 2g per day) versus placebo administered orally for 2 years in the treatment of knee osteoarthritis. A prospective multicentre, intern...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002494-75,0,0,0 2005-002495-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Cáncer de Ovario (GEICO),"""Estudio exploratorio fase II para evaluar la eficacia y seguridad de topotecan semanal en el tratamiento de cáncer de cérvix persistente o recidivante tras fracaso de tratamiento de primera línea con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002495-15,0,0,0 2005-002499-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Neurooncología Médica (GENOM),"""Protocolo fase II de tratamiento con Topotecan e irradiación holocraneal en metástasis cerebrales"".",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002499-14,0,0,0 2005-002501-23,7,2006-01-16,2006-01-16,5,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Stallergenes S.A,"A randomised, double-blind, placebo-controlled, multi-national, multi-centre, phase III extension study to assess the long term efficacy, safety and carry-over effect of one dose of sublingual immuno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002501-23,0,0,0 2005-002501-23,7,2006-01-16,2006-01-16,5,0,0,0,0,0,3,0,0,1,1,0,1,0,1,STALLERGENES,"A randomised, double-blind, placebo-controlled, multi-national, multi-centre, phase III extension study to assess the long term efficacy, safety and carry-over effect of one dose of sublingual immuno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002501-23,0,0,0 2005-002502-34,4,2006-01-12,2006-01-12,2,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Stallergenes S.A.,"A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of one dose of sublingual immunotherapy (SLIT) administered as aller...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002502-34,0,0,0 2005-002502-34,4,2006-01-12,2006-01-12,2,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Stallergenes SA,"A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of one dose of sublingual immunotherapy (SLIT) administered as aller...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002502-34,0,0,0 2005-002508-41,4,2009-06-29,2009-06-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Double-Blind, 52-week, Parallel-Group, Multicentre, Phase IIb Study to Evaluate the Effects of Rosuvastatin 10 mg, Rosuvastatin 40 mg and Atorvastatin 80 mg on Urinary Protein Excretio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002508-41,0,0,0 2005-002508-41,4,2009-06-29,2009-06-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Randomised, Double-Blind, 52-week, Parallel-Group, Multicentre, Phase IIb Study to Evaluate the Effects of Rosuvastatin 10 mg, Rosuvastatin 40 mg and Atorvastatin 80 mg on Urinary Protein Excretio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002508-41,0,0,0 2005-002509-22,5,2007-06-29,2007-08-22,5,1,0,0,0,0,2,0,0,1,1,1,1,0,2,Merck Sharp and Dohme de España,"A 24-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of MK-0677 for the Treatment of Sarcopenia in Patients Recovering From Hip Fracture",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002509-22,0,0,0 2005-002509-22,5,2007-06-29,2007-08-22,5,1,0,0,0,0,2,0,0,1,1,1,1,0,2,Merck & Co,"A 24-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of MK-0677 for the Treatment of Sarcopenia in Patients Recovering From Hip Fracture",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002509-22,0,0,0 2005-002509-22,5,2007-06-29,2007-08-22,5,1,0,0,0,0,2,0,0,1,1,1,1,0,2,Merck Sharp & Dohme (Sweden) AB,"A 24-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of MK-0677 for the Treatment of Sarcopenia in Patients Recovering From Hip Fracture",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002509-22,0,0,0 2005-002509-22,5,2007-06-29,2007-08-22,5,1,0,0,0,0,2,0,0,1,1,1,1,0,2,Merck Sharp & Dohme Ltd.,"A 24-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of MK-0677 for the Treatment of Sarcopenia in Patients Recovering From Hip Fracture",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002509-22,0,0,0 2005-002509-22,5,2007-06-29,2007-08-22,5,1,0,0,0,0,2,0,0,1,1,1,1,0,2,Merck Sharp & Dohme,"A 24-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of MK-0677 for the Treatment of Sarcopenia in Patients Recovering From Hip Fracture",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002509-22,0,0,0 2005-002510-38,3,2009-03-04,2009-03-04,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Double-Blind, 52-Week, Parallel-Group, Multicentre, Phase IIb Study to Evaluate the Effects of Rosuvastatin 10 mg, Rosuvastatin 40 mg and Atorvastatin 80 mg on Urinary Protein Excretion ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002510-38,0,0,0 2005-002510-38,3,2009-03-04,2009-03-04,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Randomised, Double-Blind, 52-Week, Parallel-Group, Multicentre, Phase IIb Study to Evaluate the Effects of Rosuvastatin 10 mg, Rosuvastatin 40 mg and Atorvastatin 80 mg on Urinary Protein Excretion ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002510-38,0,0,0 2005-002517-20,1,2008-05-05,2008-05-05,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Dept. of Anaestesiology, University hospital in Glostrup","Effect of paracetamol, low dose Ketamin, paracetamol, NSaid and dexametason on pain and opioid requirements in patients scheduled for primary total hip replacement",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002517-20,0,0,0 2005-002520-33,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Santhera Pharmaceuticals LLC,"A Phase IIa double blind, randomised, placebo controlled, single centre study at the university of Leuven to assess the efficacy and tolerability of idebenone in 10 - 16 year old males with cardiac dy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002520-33,0,0,0 2005-002524-34,9,2008-11-05,2008-11-05,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,BAYER Healthcare AG,"An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002524-34,0,0,0 2005-002524-34,9,2008-11-05,2008-11-05,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,BAYER,"An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients with Advanced Renal Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002524-34,0,0,0 2005-002527-14,1,2009-10-06,2009-10-06,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,PREDICTIVE PERFORMANCE OF ''TARGET CONTROLLED INFUSION'' OF PROPOFOL ASSOCIATED WITH NEUROPHISIOLOGIC MONITORING WITH BISPECTRAL INDEX AND CEREBRAL STATE INDEX IN PATIENT WITH ELEVATED ANESTESIOLOGIC ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002527-14,0,0,0 2005-002531-27,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Ferring Pharmaceuticals A/S,"The PEACE Study: Investigating the Pharmacodynamics and Pharmacokinetics of FE 106483 Tablets in a Single Dose Study in Children with Nocturnal Enuresis. A Randomised, Double-Blind and Placebo-Control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002531-27,0,0,0 2005-002534-35,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Coombe Women's Hospital,Determination of plasma concentration of levobupivicaine following low concentration epidural infusion of levobupivicaine in pre-eclamptic and non pre-eclamptic nulliparous women.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002534-35,0,0,0 2005-002536-94,15,2010-08-30,2011-08-19,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Austria GmbH,"'A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002536-94,0,0,0 2005-002536-94,15,2010-08-30,2011-08-19,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"'A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002536-94,0,0,0 2005-002536-94,15,2010-08-30,2011-08-19,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","'A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002536-94,0,0,0 2005-002536-94,15,2010-08-30,2011-08-19,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,"'A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002536-94,0,0,0 2005-002536-94,15,2010-08-30,2011-08-19,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"'A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002536-94,0,0,0 2005-002536-94,15,2010-08-30,2011-08-19,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"'A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002536-94,0,0,0 2005-002536-94,15,2010-08-30,2011-08-19,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"'A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002536-94,0,0,0 2005-002536-94,15,2010-08-30,2011-08-19,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas AE,"'A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002536-94,0,0,0 2005-002536-94,15,2010-08-30,2011-08-19,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"'A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002536-94,0,0,0 2005-002536-94,15,2010-08-30,2011-08-19,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"'A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002536-94,0,0,0 2005-002536-94,15,2010-08-30,2011-08-19,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"'A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002536-94,0,0,0 2005-002538-37,1,2005-12-12,2005-12-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Pharmachemie B.V.,"Randomised, double-blind study to demonstrate therapeutic equivalence of formoterol fumarate 12µg capsules delivered by Cyclohaler with Foradil in mild to moderate reversible obstructive airways dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002538-37,0,0,0 2005-002540-26,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Evalutation of the effects of non pegylated liposomial doxorubicin MYOCET on the reduction of skin and cardiac toxicity in platinum resistant ovarian and endometrial cancer patients . A phase II s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002540-26,0,0,0 2005-002541-39,2,2006-07-22,2006-11-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Orion Corporation,"A Prospective, Multi-Centre, Randomised, Double-Blind Comparison of intravenous Dexmedetomidine with Propofol/Midazolam for continous sedation (24 hours to 14 days) of ventilated Patients in Intensive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002541-39,0,0,0 2005-002544-25,1,2007-08-08,2007-08-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,LAB Pharma Ltd,"A Multicentre, Multinational, Open-Label Trial (including Double-Blind, Placebo-Controlled Cross-Over Extension Part) to Evaluate the Time to Significant Pain Relief with Fentanyl TAIFUN® in the Treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002544-25,0,0,0 2005-002546-20,2,2014-01-29,2014-01-29,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ HPV 16/18 L1/AS04 vaccine administered intramuscularly accor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002546-20,0,0,0 2005-002547-66,2,2007-02-01,2007-02-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Schering AG,Intra-individual open-label multicenter comparison study of magnetic resonance angiography (MRA) with the blood pool contrast agent Vasovist® and a conventional extracellular contrast agent with intra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002547-66,0,0,0 2005-002552-17,2,2008-05-15,2008-05-15,2,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Sosei R&D Ltd,"A Multicentre, Randomised, Double-Blind, Double-Dummy, Crossover Study to Evaluate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) in Comparison to Morphine Sulphate Immediate Release (MSIR) f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002552-17,0,0,0 2005-002553-50,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,non disponibile,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002553-50,0,0,0 2005-002568-27,5,2007-12-13,2008-07-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Groupe,"A randomized, double blind, two-arm placebo controlled, 12-Month study of the effects of rimonabant 20mg once daily on the amount and the activity of visceral fat in abdominally obese patients with me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002568-27,0,0,0 2005-002568-27,5,2007-12-13,2008-07-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-SYNTHELABO,"A randomized, double blind, two-arm placebo controlled, 12-Month study of the effects of rimonabant 20mg once daily on the amount and the activity of visceral fat in abdominally obese patients with me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002568-27,0,0,0 2005-002568-27,5,2007-12-13,2008-07-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Groupe,"A randomized, double blind, two-arm placebo controlled, 12-Month study of the effects of rimonabant 20mg once daily on the amount and the activity of visceral fat in abdominally obese patients with me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002568-27,0,0,0 2005-002570-30,6,2009-10-12,2009-10-30,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,"A multicenter randomized, double-blind placebo controlled phase III study of the efficacy of Xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002570-30,0,0,0 2005-002570-30,6,2009-10-12,2009-10-30,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-Synthelabo Recherche,"A multicenter randomized, double-blind placebo controlled phase III study of the efficacy of Xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002570-30,0,0,0 2005-002570-30,6,2009-10-12,2009-10-30,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SANOFI-SYNTHELABO,"A multicenter randomized, double-blind placebo controlled phase III study of the efficacy of Xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002570-30,0,0,0 2005-002574-29,2,2006-04-05,2006-04-05,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Santen Oy,Pharmacodynamics of tafluprost 0.0015% eye drops: a comparison between the preserved and unpreserved formulation in patients with open-angle glaucoma or ocular hypertension.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002574-29,0,0,0 2005-002578-31,2,2005-09-20,2005-09-20,1,0,0,0,0,0,3,0,1,2,1,0,0,0,1,Sanofi Pasteur MSD S.N.C.,"A controlled, double-blind and randomized study, to compare the immunogenicity and safety of HEXAVAC manufactured by an upgraded process to HEXAVAC manufactured by the current process when given to he...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002578-31,1,0,0 2005-002580-85,1,2010-12-31,2010-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,Acute haemodynanic effects of Treatment with ACE inhibitores in patients with severe Aortic Stenosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002580-85,0,0,0 2005-002582-37,1,2006-04-21,2006-04-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Allergie-Centrum-Charité Universitätsmedizin Berlin,"Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002582-37,0,0,0 2005-002584-90,1,2006-04-06,2006-04-06,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD8309 on Airway Inflammation as Assessed in Induced Sputum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002584-90,0,0,0 2005-002585-11,1,2007-03-01,2007-03-01,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Imperial College,CPAP;Heliox Effects on Stability and Therapeutics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002585-11,0,0,0 2005-002586-36,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE S. RAFFAELE,"PEXG VERSUS PDXG IN LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA : RANDOMIZED, PHASE II STUDY.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002586-36,0,0,0 2005-002590-73,8,2011-08-31,2011-08-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Andromeda Biotech Ltd.,"A PHASE III, MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF DIAPEP277™ IN NEWLY DIAGNOSED TYPE I PATIENTS A PHA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002590-73,0,0,0 2005-002590-73,8,2011-08-31,2011-08-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ANDROMEDA BIOTECH LTD.,"A PHASE III, MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF DIAPEP277™ IN NEWLY DIAGNOSED TYPE I PATIENTS A PHA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002590-73,0,0,0 2005-002590-73,8,2011-08-31,2011-08-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Andromeda Biotec Ltd,"A PHASE III, MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF DIAPEP277™ IN NEWLY DIAGNOSED TYPE I PATIENTS A PHA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002590-73,0,0,0 2005-002590-73,8,2011-08-31,2011-08-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,DeveloGen Autoimmune GmbH,"A PHASE III, MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF DIAPEP277™ IN NEWLY DIAGNOSED TYPE I PATIENTS A PHA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002590-73,0,0,0 2005-002590-73,8,2011-08-31,2011-08-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Andromeda Biotech Ltd,"A PHASE III, MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF DIAPEP277™ IN NEWLY DIAGNOSED TYPE I PATIENTS A PHA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002590-73,0,0,0 2005-002597-30,1,2008-10-20,2008-10-20,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Gesellschaft für Wissens- und Technologietransfer der TU Dresden mbH,Placebokontrollierte Untersuchung zur Wirkung von Nikotinsäure auf die Dyslipidämie bei Metabolischem Syndrom und das Arterioskleroserisiko,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002597-30,0,0,0 2005-002600-41,5,2008-07-11,2008-07-24,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A phase II, open-label, multi-centre, single-arm study, evaluating the efficacy of Glivec® plus Hydroxyurea (HU) in patients with progressive glioblastoma multiforme (GBM), not receiving enzyme induc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002600-41,0,0,0 2005-002600-41,5,2008-07-11,2008-07-24,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A phase II, open-label, multi-centre, single-arm study, evaluating the efficacy of Glivec® plus Hydroxyurea (HU) in patients with progressive glioblastoma multiforme (GBM), not receiving enzyme induc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002600-41,0,0,0 2005-002603-16,5,2008-06-24,2008-08-19,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A phase II, open-label, multi-centre, single-arm study, evaluating the efficacy of Glivec® plus Hydroxyurea (HU) in patients with progressive glioblastoma multiforme (GBM), receiving enzyme inducing a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002603-16,0,0,0 2005-002603-16,5,2008-06-24,2008-08-19,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A phase II, open-label, multi-centre, single-arm study, evaluating the efficacy of Glivec® plus Hydroxyurea (HU) in patients with progressive glioblastoma multiforme (GBM), receiving enzyme inducing a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002603-16,0,0,0 2005-002607-17,6,2008-06-20,2008-06-20,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,STRAKAN PHARMACEUTICALS LIMITED,Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002607-17,0,0,0 2005-002607-17,6,2008-06-20,2008-06-20,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Prostrakan Pharmaceuticals Ltd,Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002607-17,0,0,0 2005-002607-17,6,2008-06-20,2008-06-20,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Strakan Pharmaceuticals Ltd,Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002607-17,0,0,0 2005-002607-17,6,2008-06-20,2008-06-20,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,ProStrakan Ltd,Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002607-17,0,0,0 2005-002610-37,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,NEPHROLOGY DEPARTMENT (HOSPITAL UNIVERSITARY OF BELLVITGE),PILOT TRIAL OF TREATMENT OF POOR-PROGNOSIS IgA NEPHROPATHY WITH LOW EXPOSURE TO SIROLIMUS. Ensayo clínico piloto de tratamiento de la nefropatía IgA con factores de mal pronóstico con dosis bajas de s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002610-37,0,0,0 2005-002611-25,7,2005-09-30,2007-09-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ BIOSCIENCES GmBH,An open label extension trial to investigate the safety and tolerability of long-term treatment with transdermal rotigotine in subjects with idiopathic restless legs syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002611-25,0,0,0 2005-002611-25,7,2005-09-30,2007-09-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ PHARMA,An open label extension trial to investigate the safety and tolerability of long-term treatment with transdermal rotigotine in subjects with idiopathic restless legs syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002611-25,0,0,0 2005-002611-25,7,2005-09-30,2007-09-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Schwarz Biosciences GmbH,An open label extension trial to investigate the safety and tolerability of long-term treatment with transdermal rotigotine in subjects with idiopathic restless legs syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002611-25,0,0,0 2005-002614-38,1,2008-08-20,2008-08-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SANOFI AVENTIS GROUPE,COMPARISON OF TWO THERAPEUTIC STRATEGIES FOR TREATING TYPE 2 DIABETIC PATIENTS POORLY CONTROLLED WITH BASAL INSULIN ASSOCIATED WITH ORAL ANTIDIABETIC DRUGS: 6-MONTH PROOF OF CONCEPT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002614-38,0,0,0 2005-002618-40,1,2016-01-31,2016-01-31,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,"Rheinische Friedrich-Wilhelms-University of Bonn, University Hospital","HIT-REZ 2005 - A multicentre clinical trial and phase II study for the treatment of refractory and relapsed primitive neuroectodermal tumours (medulloblastomas, supratentorial PNETs) and ependymomas i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002618-40,0,0,0 2005-002625-31,7,2020-02-26,2020-02-26,5,0,0,0,0,0,3,0,0,2,0,0,0,0,0,European Organisation for Research and Treatment of Cancer,"MINDACT (El uso de microarray en la enfermedad con ganglios negativos y de 1 a 3 ganglios positivos puede evitar la quimioterapia). Estudio prospectivo, aleatorizado que compara la firma de expresión ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002625-31,1,0,0 2005-002625-31,7,2020-02-26,2020-02-26,5,0,0,0,0,0,3,0,0,2,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),"MINDACT (El uso de microarray en la enfermedad con ganglios negativos y de 1 a 3 ganglios positivos puede evitar la quimioterapia). Estudio prospectivo, aleatorizado que compara la firma de expresión ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002625-31,1,0,0 2005-002626-59,2,2006-12-31,2006-12-31,1,0,0,0,0,0,3,0,0,1,1,0,1,0,0,International Breast Cancer Study Group (IBCSG),A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002626-59,0,0,0 2005-002626-59,2,2006-12-31,2006-12-31,1,0,0,0,0,0,3,0,0,1,1,0,1,0,0,GBG Forschung GmbH,A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002626-59,0,0,0 2005-002629-30,5,2012-02-06,2012-02-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Celltech,"A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002629-30,0,0,0 2005-002629-30,5,2012-02-06,2012-02-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Inc,"A Phase III Multi-center, Open-label, Follow-up Study, to Assess the Safety and Efficacy of Liquid Certolizumab Pegol as Additional Medication to Methotrexate, in the Treatment of Signs and Symptoms a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002629-30,0,0,0 2005-002634-35,1,2012-07-07,2012-07-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Medizinische Hochschule Hannover","Single centre, prospective, comparative, open-label, randomised study to evaluate the efficacy and tolerability of the combination of Moxifloxacin plus Metronidazole versus Piperacillin/Tazobactam for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002634-35,0,0,0 2005-002635-27,2,2007-01-11,2007-01-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An eight week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / valsartan / HCTZ (300/320/25 mg), compared to the combi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002635-27,0,0,0 2005-002635-27,2,2007-01-11,2007-01-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutuca, S.A.","An eight week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / valsartan / HCTZ (300/320/25 mg), compared to the combi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002635-27,0,0,0 2005-002636-97,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Immuno-Designed Molecules,"An open-label, phase II study of matured dendritic cells pulsed ex vivo with 3 melanoma cell line lysates (IDD-3) with or without peginterferon alpha-2b (PegIFN-a 2b) in patients with resected stage ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002636-97,0,0,0 2005-002641-39,1,2007-02-19,2007-02-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Helsinn Healthcare SA,Open-Label Pilot Study to Evaluate the Efficacy of Palonosetron Associated with Aprepitant (Emend) and Dexamethasone in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy (HEC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002641-39,0,0,0 2005-002643-89,4,2007-11-29,2008-04-01,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,HELSINN HEALTHCARE SA,"Double-blind Study to Compare the Efficacy of Palonosetron with or without the use of Dexamethasone on Days 2 and 3, in the Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemother...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002643-89,0,0,0 2005-002643-89,4,2007-11-29,2008-04-01,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Helsinn Healthcare SA,"Double-blind Study to Compare the Efficacy of Palonosetron with or without the use of Dexamethasone on Days 2 and 3, in the Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemother...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002643-89,0,0,0 2005-002647-35,5,2006-07-25,2006-10-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alcon Research, Ltd","Nepafenac 0.1 Eye Drops, Suspension compared to Ketorolac Trometamol 0.5 Eye Drops, Solution and Placebo Nepafenac Vehicle for the Prevention and Treatment of Ocular Inflammation and Ocular pain a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002647-35,0,0,0 2005-002647-35,5,2006-07-25,2006-10-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALCON ITALIA,"Nepafenac 0.1 Eye Drops, Suspension compared to Ketorolac Trometamol 0.5 Eye Drops, Solution and Placebo Nepafenac Vehicle for the Prevention and Treatment of Ocular Inflammation and Ocular pain a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002647-35,0,0,0 2005-002650-22,1,2008-04-16,2008-04-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Mulitcenter, Randomized, Double-Blind Study Comparing the Clinical Effects of Intravenous Montelukast With Placebo in Pediatric Patients (Ages 6 to 14 Years) With Acute Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002650-22,0,0,0 2005-002654-21,2,2011-04-21,2011-04-21,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Solvay Pharmaceuticals GmbH,A long-term health economics study of intraduodenal levodopa (Duodopa®) in routine care for patients with advanced idiopathic Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002654-21,0,0,0 2005-002655-41,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Hospital Universitario La Paz,IMPACTO DE UN PROGRAMA DE TRATAMIENTO PSIQUIÁTRICO COMBINADO SOBRE LA SINTOMATOLOGÍA ANSIOSA Y DEPRESIVA DE UN GRUPO DE PACIENTES ONCOLÓGICOS Y SUS CUIDADORES PRNCIPALES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002655-41,0,0,0 2005-002657-45,1,2012-04-18,2012-04-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Cardiovascular laboratory 2014, Rigshospitalet",Mesenchymal stem cell therapy in patients with severe myocardial ischemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002657-45,0,0,0 2005-002660-29,2,2007-11-19,2007-11-19,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Eli Lilly and Company Limited,A Phase 1b/2 Multiple-Dose Safety and Pharmacokinetic/Pharmacodynamic Study of LY2189102 in Patients with Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002660-29,0,0,0 2005-002660-29,2,2007-11-19,2007-11-19,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Lilly S.A.,A Phase 1b/2 Multiple-Dose Safety and Pharmacokinetic/Pharmacodynamic Study of LY2189102 in Patients with Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002660-29,0,0,0 2005-002666-11,1,2006-11-28,2006-11-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Cassella-med,"Randomisierter,doppelblinder, Verum-kontrollierter Parallelgruppenvergleich zur Wirksamkeit und Unbedenklichkeit von Cineol bei Patienten mit akuten Sinusitiden im Vergleich zum Phytopharmakon mit den...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002666-11,0,0,0 2005-002678-31,2,2007-08-01,2007-08-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"Randomized, Double-Blind, Placebo-Controlled Phase II Study Comparing the Safety of Ipilimumab Administered With or Without Prophylactic Oral Budesonide (Entocort EC) in Patients with Unresectable Sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002678-31,0,0,0 2005-002678-31,2,2007-08-01,2007-08-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Randomized, Double-Blind, Placebo-Controlled Phase II Study Comparing the Safety of Ipilimumab Administered With or Without Prophylactic Oral Budesonide (Entocort EC) in Patients with Unresectable Sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002678-31,0,0,0 2005-002679-34,1,2008-11-30,2008-11-30,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,"The Fertility Clinic, Sygehus Viborg (Skive)",The effect of LH priming in early follicular phase on the endocrinological function of the ovary and pregnancy rate in GnRh downregulated women stimulated by exogen gonadotophins in IVF-treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002679-34,0,0,0 2005-002686-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Všeobecná fakultní nemocnice v Praze,"Developmental pharmacokinetics and pharmacogenetics aspects of analgosedation by tramadol of newborns, infants and older children treated at the intensive care unit",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002686-36,0,0,0 2005-002687-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,XAVIER CARBONELL ESTRANY,Single-dose dexamethasone and/or bronchoalveolar lavage with diluted surfactant in the treatment of severe meconium aspiration syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002687-29,0,0,0 2005-002688-10,1,2008-08-21,2008-08-21,1,1,0,0,0,3,4,0,0,1,0,0,1,0,0,University of Dundee,The Effect of omega-3 polyunsaturated Fatty Acid Supplements on Microvolt T-Alternans in Patients with Ventricular Arrythmia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002688-10,0,0,0 2005-002691-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Ferrosan A/S,"Ginger, ginger-avokado-soy, glucosamine sulfate and ginger-ibuprofen in relation to chronic low back pain - a randomised double-blind, placebo-controlled clinical trial with parallel groups for 3 mont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002691-15,0,0,0 2005-002692-33,6,2007-08-16,2008-08-16,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ELI LILLY,"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002692-33,0,0,0 2005-002692-33,6,2007-08-16,2008-08-16,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Lilly ICOS LLC,"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002692-33,0,0,0 2005-002696-32,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FAZ - Floridsdorf Allergy Center,DIE WIRKUNG VON INTRAVENÖSEM VITAMIN C AUF HISTAMINSPIEGEL UND DIAMINOXIDASEAKTIVITÄT IM BLUT BEI MASTOZYTOSEPATIENTEN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002696-32,0,0,0 2005-002698-65,1,2009-11-30,2009-11-30,1,1,0,0,1,0,2,0,0,1,1,1,1,0,0,Christie Hospital NHS Trust,A randomised clinical trial comparing safety and efficacy of topical preparations for the eradication of methicillin resistant staphylococcus aureus (MRSA) compared with a novel preparation based on a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002698-65,0,0,0 2005-002699-13,1,2007-12-31,2007-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Palliative Medicine, RWTH Aachen",Modafinil in der Behandlung von Müdigkeit bei Tumorpatienten - eine randomisierte doppelblinde N=1 Studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002699-13,0,0,0 2005-002701-23,1,2006-12-19,2006-12-19,1,1,0,0,0,3,4,0,1,1,0,0,1,0,0,"Siegfried Kasper, O.Univ.Prof.Dr.Dr.h.c.",Escitalopram versus Citalopram Treatment effects on cortical and subcortical activity assessed by pharmacological fMRI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002701-23,0,0,0 2005-002705-23,1,2005-10-20,2005-10-20,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,OMNINVEST Kft.,FluvalAB Influenza Vaccine Serologic Clinical Trial for 2005-2006 Influenza Season,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002705-23,0,0,0 2005-002706-27,1,2015-04-08,2015-04-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Barts and the London NHS Trust, Department of Cardiology",Randomised Control Trial To Compare The Effects Of G-CSF And Autologous Bone Marrow Progenitor Cells Infusion On Quality Of Life And Left Ventricular Function In Patients With Heart Failure Secondary ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002706-27,0,0,0 2005-002711-25,3,2010-03-04,2010-03-04,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ACRAF S.p.A.,DOSE-FINDING STUDY OF TRAZODONE IN THE TREATMENT OF PATIENTS WITH PRIMARY INSOMNIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002711-25,0,0,0 2005-002711-25,3,2010-03-04,2010-03-04,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ANGELINI,DOSE-FINDING STUDY OF TRAZODONE IN THE TREATMENT OF PATIENTS WITH PRIMARY INSOMNIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002711-25,0,0,0 2005-002715-24,1,2011-09-01,2011-09-01,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Royal Marsden Hospital,"TARGET Trial: A Phase I-II dose finding and early efficacy study of combination therapy with erlotinib (tarceva), gemcitabine, bevacizumab (avastin) and capecitabine in advanced pancreatic cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002715-24,0,0,0 2005-002716-16,1,2008-04-30,2008-04-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,PHILOGEN S.P.A.,A DOSE FINDING PHARMACOKINETIC STUDY OF THE TUMOUR TARGETING HUMAN L19IL2 MONOCLONAL ANTIBODY CYTOKINE FUSION PROTEIN IN PATIENTS WITH ADVANCED SOLID TUMOURS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002716-16,0,0,0 2005-002717-21,4,2011-09-20,2011-12-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017, USA","A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRAC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002717-21,0,0,0 2005-002717-21,4,2011-09-20,2011-12-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc,235 East 42nd Street, New York,NY 10017","A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRAC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002717-21,0,0,0 2005-002717-21,4,2011-09-20,2011-12-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRAC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002717-21,0,0,0 2005-002717-21,4,2011-09-20,2011-12-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, NON-COMPARATIVE, TWO-ARM OPEN LABEL, MULTIPLE-CENTER STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL/PREDNISONE IN CHEMOTHERAPY- NAÏVE (ARM A) AND DOCETAXEL/PREDNISONE REFRAC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002717-21,0,0,0 2005-002723-13,1,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"Univerzita Karlova v Praze, Lékařská fakulta v Hradci Králové","Farmakokinetika gentamicinu, predikce dávkování u nedonošených a donošených novorozenců. (Pharmacokinetics of gentamicin, dosage prediction in term and preterm neonates.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002723-13,0,0,0 2005-002728-33,1,2012-01-09,2012-01-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Plymouth Hospitals NHS Trust,Cannabinoid Use in Progressive Inflammatory brain Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002728-33,0,0,0 2005-002735-27,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Fidia Farmaceutici SpA,A multicentre study to assess the safety and efficacy of sodium hyaluronate (Hyalgan-F) produced by fermentation in knee psteoarthritis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002735-27,0,0,0 2005-002736-10,1,2012-11-09,2012-11-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Royal Marsden Hospital,"Open, Randomised Phase II Study Assessing The Toxicity And Efficacy Of Platinum-Based Chemotherapy With Vitamin Supplementation In The Treatment Of Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002736-10,0,0,0 2005-002738-36,5,2008-10-16,2008-10-16,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"CELL GENESYS, LTD.","A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naïve",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002738-36,1,0,0 2005-002738-36,5,2008-10-16,2008-10-16,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Cell Genesys Inc,"A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naïve",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002738-36,1,0,0 2005-002740-26,1,2007-07-03,2007-07-03,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Ester Neuroscience Ltd,"A Phase II Double Blind, Cross-Over Study to Compare the Safety and Efficacy of 10, 20 and 40 mg Monarsen (EN101) administered to Patients with Myasthenia Gravis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002740-26,0,0,0 2005-002741-39,5,2008-05-06,2008-05-26,5,0,0,0,2,0,0,0,0,1,0,0,1,0,0,"Università di Milano, Dipartimento di Scienze Chirurgiche, Ospedale Maggiore Policlinico, Padiglione","A PROSPECTIVE, CONTROLLED, RANDOMIZED, PATIENT AND EVALUATOR BLINDED STUDY TO EVALUATE PAIN AND FURTHER DISABLING COMPLICATIONS IN PATIENTS UNDERGOING LICHTENSTEIN TECHNIQUE FOR PRIMARY INGUINAL HER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002741-39,0,0,0 2005-002741-39,5,2008-05-06,2008-05-26,5,0,0,0,2,0,0,0,0,1,0,0,1,0,0,OSPEDALE MAGGIORE DI MILANO IRCCS,"A PROSPECTIVE, CONTROLLED, RANDOMIZED, PATIENT AND EVALUATOR BLINDED STUDY TO EVALUATE PAIN AND FURTHER DISABLING COMPLICATIONS IN PATIENTS UNDERGOING LICHTENSTEIN TECHNIQUE FOR PRIMARY INGUINAL HER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002741-39,0,0,0 2005-002741-39,5,2008-05-06,2008-05-26,5,0,0,0,2,0,0,0,0,1,0,0,1,0,0,"Pr Giampiero CAMPANELLI Università di Milano, Dipartimento di Scienze Chirurgiche, Ospedale Maggior","A PROSPECTIVE, CONTROLLED, RANDOMIZED, PATIENT AND EVALUATOR BLINDED STUDY TO EVALUATE PAIN AND FURTHER DISABLING COMPLICATIONS IN PATIENTS UNDERGOING LICHTENSTEIN TECHNIQUE FOR PRIMARY INGUINAL HER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002741-39,0,0,0 2005-002741-39,5,2008-05-06,2008-05-26,5,0,0,0,2,0,0,0,0,1,0,0,1,0,0,"Pr Giampiero CAMPANELLI - Ospedale Maggiore Policlinico, Padiglione Beretta Est","A PROSPECTIVE, CONTROLLED, RANDOMIZED, PATIENT AND EVALUATOR BLINDED STUDY TO EVALUATE PAIN AND FURTHER DISABLING COMPLICATIONS IN PATIENTS UNDERGOING LICHTENSTEIN TECHNIQUE FOR PRIMARY INGUINAL HER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002741-39,0,0,0 2005-002741-39,5,2008-05-06,2008-05-26,5,0,0,0,2,0,0,0,0,1,0,0,1,0,0,Prof. Giampiero CAMPANELLI,"A PROSPECTIVE, CONTROLLED, RANDOMIZED, PATIENT AND EVALUATOR BLINDED STUDY TO EVALUATE PAIN AND FURTHER DISABLING COMPLICATIONS IN PATIENTS UNDERGOING LICHTENSTEIN TECHNIQUE FOR PRIMARY INGUINAL HER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002741-39,0,0,0 2005-002742-19,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Neolab Limited,Comparative efficacy and safety of two intranasal Triamcinolone Acetonide formulations in persistent allergic rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002742-19,0,0,0 2005-002744-25,1,2009-03-03,2009-03-03,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Roskamp Institute,An open label evaluation of the safety and efficacy of nilvadipine in mild to moderate Alzheimer's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002744-25,0,0,0 2005-002748-24,1,2006-04-10,2006-04-10,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Pharma Stulln GmbH,"Randomisierte, kontrollierte, doppelblinde klinische Prüfung zur Untersuchung der Verträglichkeit von Keto-Stulln® UD im Vergleich zu physiologischer Kochsalzlösung am Auge in einem intraindividuellen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002748-24,0,0,0 2005-002749-38,3,2007-12-12,2007-12-12,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Barrier Therapeutics nv,"A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002749-38,0,0,0 2005-002754-22,1,2010-04-22,2010-04-22,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"An open, randomized, multicentre phase II pilot study to evaluate the efficacy of budesonide 3 mg effervescent tablet in patients with resistant oral chronic GvHD using different application durations...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002754-22,0,0,0 2005-002756-18,5,2010-04-30,2010-05-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Nordic Myeloma Study Group,Bortezomib consolidation in patients with myeloma following treatment with high-dose melphalan and autologous stem cell support. A randomised NMSG trial (15/05),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002756-18,0,0,0 2005-002756-18,5,2010-04-30,2010-05-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Sahlgrenska Universitetssjukhus,Bortezomib consolidation in patients with myeloma following treatment with high-dose melphalan and autologous stem cell support. A randomised NMSG trial (15/05),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002756-18,0,0,0 2005-002757-45,2,2008-03-25,2008-03-25,2,1,0,0,0,2,4,0,0,1,0,0,1,0,1,BAYER,A prospective controlled study on the effect on bleeding events and joint function in young adults with severe hemophilia A after a 6 month prophylaxis treatment compared to on demand treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002757-45,0,0,0 2005-002757-45,2,2008-03-25,2008-03-25,2,1,0,0,0,2,4,0,0,1,0,0,1,0,1,Bayer HealthCare LLC/Biological Products,A prospective controlled study on the effect on bleeding events and joint function in young adults with severe hemophilia A after a 6 month prophylaxis treatment compared to on demand treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002757-45,0,0,0 2005-002759-42,1,2007-08-29,2007-08-29,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Genzyme Europe BV,"A Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Myozyme, Recombinant Human Acid alpha-Glucosidase (rhGAA), Treatment i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002759-42,0,0,0 2005-002765-37,6,2015-01-09,2015-01-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Euopean Organisation of Research and Treatment of Cancer,The H10 EORTC/GELA randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's ly...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002765-37,0,0,0 2005-002765-37,6,2015-01-09,2015-01-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,EORTC Lymphoma Group,The H10 EORTC/GELA randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's ly...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002765-37,0,0,0 2005-002765-37,6,2015-01-09,2015-01-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),The H10 EORTC/GELA randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's ly...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002765-37,0,0,0 2005-002772-14,3,2006-10-13,2006-10-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial of lumiracoxib COX189 100 mg o.d. in patients with primary hip osteoarthritis using celecoxib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002772-14,0,0,0 2005-002772-14,3,2006-10-13,2006-10-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial of lumiracoxib COX189 100 mg o.d. in patients with primary hip osteoarthritis using celecoxib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002772-14,0,0,0 2005-002777-68,1,2007-05-21,2007-05-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cardiff and Vale NHS Trust,The effects of rosuvastatin therapy on glucose metabolism in non-diabetic renal transplant recipients with a focus on insulin sensitivity and pancreatic beta islet cell function,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002777-68,0,0,0 2005-002778-30,5,2006-07-05,2006-07-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of 12 Week Treatment with Vildagliptin (LAF237) 50 mg QD in Subjects with Impaired G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002778-30,0,0,0 2005-002778-30,5,2006-07-05,2006-07-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of 12 Week Treatment with Vildagliptin (LAF237) 50 mg QD in Subjects with Impaired G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002778-30,0,0,0 2005-002779-34,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,BAYER,"Prospective, multicenter, randomized, double blind, parallel arm study to evaluate the efficacy and safety of Moxifloxacin 400 mg OD for 7 days versus amoxicillin clavulanate/claritromycin for 10 days...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002779-34,0,0,0 2005-002780-82,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Richter Gedeon Rt,"Alendronat (Sedron 70 mg) hatékonyságának és biztonságosságának nyílt, multicentrikus, fázis IV vizsgálata osteoporosisban szenvedő veseköves férfibetegekben",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002780-82,0,0,0 2005-002782-37,1,2007-06-08,2007-06-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Heart of England NHS Foundation Trust,A Randomised Trial of Inhaled Entonox Plus Local Anaesthesia Versus Intravenous Midazolam Plus Local Anaesthesia To Improve Pain Control During Bone Marrow Biopsy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002782-37,0,0,0 2005-002784-91,1,2010-07-01,2010-07-01,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,Cardiff and Vale NHS Trust,"A Randomized, Multicentre, Parallel Group Single-Blind Study to Assess the Efficacy and Safety of Dosing Mesalazine 800 mg Tablets (Asacol®) at 2.4 g Once Daily versus Divided Doses Three Times Daily ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002784-91,0,0,0 2005-002785-10,5,2008-03-18,2008-03-18,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Procter & Gamble Pharmaceuticals Inc,"A Phase III, Multicenter, Double-Blind, Randomized, Active-controlled, Parallel Group, Non-inferiority Study Comparing 150 mg Risedronate Monthly with 5 mg Risedronate Daily in the Treatment of Postme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002785-10,1,0,0 2005-002789-12,1,2006-02-27,2006-02-27,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD S.N.C,"A double blind comparative and randomised study in healthy adults of the safety, tolerability, and immunogenicity of PNEUMOVAX®II formulated with either all new process polysaccharides or all current ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002789-12,0,0,0 2005-002794-79,1,2009-06-30,2009-06-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Swansea NHS Trust,Effect of Intravenous Adenosine on neuro-psychological dysfunction post coronary artery bypass surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002794-79,0,0,0 2005-002796-32,1,2006-06-19,2006-06-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer Healthcare AG,"A randomized, double-blind, placebo-controlled, multi-center, parallel group study to assess the efficacy of vardenafil in the treatment of symtomatic Benign Prostatic Hyperplasia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002796-32,0,0,0 2005-002800-40,5,2009-01-27,2009-02-10,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,,"Prospective, Open-label, Comparative, Multicenter Study of Voriconazole Compared to Itraconazole for the Primary Prophylaxis of Invasive Fungal Infections (IFI) in Subjects with Allogeneic Hematopoiet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002800-40,0,0,0 2005-002800-40,5,2009-01-27,2009-02-10,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratorios Pfizer S.A,"Prospective, Open-label, Comparative, Multicenter Study of Voriconazole Compared to Itraconazole for the Primary Prophylaxis of Invasive Fungal Infections (IFI) in Subjects with Allogeneic Hematopoiet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002800-40,0,0,0 2005-002800-40,5,2009-01-27,2009-02-10,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Ltd,"Prospective, Open-label, Comparative, Multicenter Study of Voriconazole Compared to Itraconazole for the Primary Prophylaxis of Invasive Fungal Infections (IFI) in Subjects with Allogeneic Hematopoiet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002800-40,0,0,0 2005-002800-40,5,2009-01-27,2009-02-10,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Ltd.,"Prospective, Open-label, Comparative, Multicenter Study of Voriconazole Compared to Itraconazole for the Primary Prophylaxis of Invasive Fungal Infections (IFI) in Subjects with Allogeneic Hematopoiet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002800-40,0,0,0 2005-002800-40,5,2009-01-27,2009-02-10,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Laboratórios Pfizer, Lda.","Prospective, Open-label, Comparative, Multicenter Study of Voriconazole Compared to Itraconazole for the Primary Prophylaxis of Invasive Fungal Infections (IFI) in Subjects with Allogeneic Hematopoiet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002800-40,0,0,0 2005-002801-22,1,2010-04-23,2010-04-23,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,The Royal Marsden NHSF Trust,Carboplatin Plus Xeloda Followed By Maintenance Xeloda (CARBOX),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002801-22,0,0,0 2005-002802-48,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,ROCHE,Evaluation of efficacy and safety of i.v. and oral ibandronate in elderly patients with bone metastases from solid tumors. A randomised phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002802-48,0,0,0 2005-002803-18,5,2006-06-02,2006-06-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND EFFICACY STUDY OF THE EMOLLIENT V0034CR IN ADDITION TO A MODERATELY POTENT CORTICOSTEROID IN THE ACUTE PHASE OF TREATMENT OF ATOPIC DERMATITIS IN INFANTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002803-18,0,0,0 2005-002803-18,5,2006-06-02,2006-06-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pierre Fabre Medicament,"RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND EFFICACY STUDY OF THE EMOLLIENT V0034CR IN ADDITION TO A MODERATELY POTENT CORTICOSTEROID IN THE ACUTE PHASE OF TREATMENT OF ATOPIC DERMATITIS IN INFANTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002803-18,0,0,0 2005-002805-21,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,AstraZeneca AB,"A randomized, double-blind, placebo controlled, three-way crossover study exploring the efficacy of AZD3778 compared with placebo and an oral antihistamine (loratadine) in a model of seasonal allergic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002805-21,0,0,0 2005-002808-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPO ONCOPAZ,"Estudio abierto, no controlado, multicéntrico, de fase II para estudiar la eficacia y seguridad de una combinación de Capecitabina + Bevacizumab, en 1ª línea de tratamiento, en pacientes ancianos no s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002808-42,0,0,0 2005-002809-23,1,2007-06-28,2007-06-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb SL,Electrophysiological effects of Irbesartan in patients with paroxysmal AF Efectos electrofisiológicos del Irbesartán en sujetos con FA paroxística,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002809-23,0,0,0 2005-002812-94,1,2007-07-31,2007-07-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,North Bristol NHS Trust,Randomised trial of carbetocin versus oxytocin for the prevention of postpartum haemorrhage after caesarean section,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002812-94,0,0,0 2005-002813-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Pethema,"“Estudio en fase II, multicentrico, prospectivo, abierto, de tratamiento anticipado con valganciclovir de la infección por citomegalovirus en el transplante alogénico de progenitores hematopoyético ”.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002813-19,0,0,0 2005-002814-39,5,2006-07-21,2006-07-21,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ PHARMA,"A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TWO-ARM, PARALLEL-GROUP, SLEEP LAB TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF TRANSDERMAL ROTIGOTINE IN SUBJECTS WITH IDIOPATHIC RESTL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002814-39,0,0,0 2005-002814-39,5,2006-07-21,2006-07-21,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Schwarz Biosciences GmbH,"A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TWO-ARM, PARALLEL-GROUP, SLEEP LAB TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF TRANSDERMAL ROTIGOTINE IN SUBJECTS WITH IDIOPATHIC RESTL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002814-39,0,0,0 2005-002817-19,5,2009-08-13,2009-08-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F Hoffmann-La Roche Ltd,"A Randomized, Double-Blind, Placebo Controlled Multi-Center Study of the Efficacy and Safety of up to 100 days of Valganciclovir vs. up to 200 days of Valganciclovir for Prevention of Cytomegalovirus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002817-19,0,0,0 2005-002817-19,5,2009-08-13,2009-08-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Randomized, Double-Blind, Placebo Controlled Multi-Center Study of the Efficacy and Safety of up to 100 days of Valganciclovir vs. up to 200 days of Valganciclovir for Prevention of Cytomegalovirus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002817-19,0,0,0 2005-002817-19,5,2009-08-13,2009-08-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A Randomized, Double-Blind, Placebo Controlled Multi-Center Study of the Efficacy and Safety of up to 100 days of Valganciclovir vs. up to 200 days of Valganciclovir for Prevention of Cytomegalovirus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002817-19,0,0,0 2005-002818-38,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ROCHE,ESPrES 500 - Evaluation of the safety profile of the new 500 mg film-coated tablet (FCT) formulation of boosted saquinavir (Invirase 500 mg) in HIV-1 infected patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002818-38,0,0,0 2005-002820-32,1,2006-12-16,2006-12-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dow Pharmaceutical Sciences Inc.,"A Multi-Center, Double-Blind, Randomized, Dose-Ranging Study of the Safety and Efficacy of IDP-102 Gel 5 %, and 15 % Compared with Vehicle in the Treatment of Common Warts.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002820-32,0,0,0 2005-002822-78,1,2010-03-16,2010-03-16,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Klinik Neuropädiatrie und Muskelkrankheiten,Can treatment with human growth hormone increase strength in spinal muscular atrophy type II and III?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002822-78,0,0,0 2005-002823-15,1,2009-09-21,2009-09-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Nottingham University Hospitals NHS Trust,A PHASE I/II TRIAL OF THE USE OF SIROLIMUS (RAPAMUNE) AND LOW DOSE ARA-C IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002823-15,0,0,0 2005-002825-29,6,2011-09-28,2011-09-28,6,1,0,0,0,0,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,Randomized phase II trial evaluating the feasibility and tolerance of the combination of FOLFOX with cetuximab and the combination of FOLFOX with cetuximab and bevacizumab as perioperative treatment i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002825-29,0,0,0 2005-002826-70,4,2009-05-14,2010-02-19,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,PFIZER,"A PHASE 2, OPEN LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TICILIMUMAB IN PATIENTS WITH ADVANCED REFRACTORY AND/OR RELAPSED MELANOMA STUDIO DI FA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002826-70,0,0,0 2005-002826-70,4,2009-05-14,2010-02-19,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer, S.A.","A PHASE 2, OPEN LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TICILIMUMAB IN PATIENTS WITH ADVANCED REFRACTORY AND/OR RELAPSED MELANOMA STUDIO DI FA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002826-70,0,0,0 2005-002826-70,4,2009-05-14,2010-02-19,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, 10017, USA","A PHASE 2, OPEN LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TICILIMUMAB IN PATIENTS WITH ADVANCED REFRACTORY AND/OR RELAPSED MELANOMA STUDIO DI FA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002826-70,0,0,0 2005-002826-70,4,2009-05-14,2010-02-19,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Pharma GmbH,"A PHASE 2, OPEN LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TICILIMUMAB IN PATIENTS WITH ADVANCED REFRACTORY AND/OR RELAPSED MELANOMA STUDIO DI FA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002826-70,0,0,0 2005-002827-15,10,2010-05-27,2010-08-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Hellas SA,"A PHASE 3, OPEN LABEL, RANDOMIZED, COMPARATIVE STUDY OF TICILIMUMAB AND EITHER DACARBAZINE OR TEMOZOLOMIDE IN PATIENTS WITH ADVANCED MELANOMA STUDIO DI FASE 3, APERTO, RANDOMIZZATO, COMPARATO SU TI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002827-15,0,0,0 2005-002827-15,10,2010-05-27,2010-08-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 3, OPEN LABEL, RANDOMIZED, COMPARATIVE STUDY OF TICILIMUMAB AND EITHER DACARBAZINE OR TEMOZOLOMIDE IN PATIENTS WITH ADVANCED MELANOMA STUDIO DI FASE 3, APERTO, RANDOMIZZATO, COMPARATO SU TI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002827-15,0,0,0 2005-002827-15,10,2010-05-27,2010-08-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A PHASE 3, OPEN LABEL, RANDOMIZED, COMPARATIVE STUDY OF TICILIMUMAB AND EITHER DACARBAZINE OR TEMOZOLOMIDE IN PATIENTS WITH ADVANCED MELANOMA STUDIO DI FASE 3, APERTO, RANDOMIZZATO, COMPARATO SU TI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002827-15,0,0,0 2005-002827-15,10,2010-05-27,2010-08-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A PHASE 3, OPEN LABEL, RANDOMIZED, COMPARATIVE STUDY OF TICILIMUMAB AND EITHER DACARBAZINE OR TEMOZOLOMIDE IN PATIENTS WITH ADVANCED MELANOMA STUDIO DI FASE 3, APERTO, RANDOMIZZATO, COMPARATO SU TI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002827-15,0,0,0 2005-002827-15,10,2010-05-27,2010-08-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc. Research & Developent Unit,"A PHASE 3, OPEN LABEL, RANDOMIZED, COMPARATIVE STUDY OF TICILIMUMAB AND EITHER DACARBAZINE OR TEMOZOLOMIDE IN PATIENTS WITH ADVANCED MELANOMA STUDIO DI FASE 3, APERTO, RANDOMIZZATO, COMPARATO SU TI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002827-15,0,0,0 2005-002827-15,10,2010-05-27,2010-08-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, OPEN LABEL, RANDOMIZED, COMPARATIVE STUDY OF TICILIMUMAB AND EITHER DACARBAZINE OR TEMOZOLOMIDE IN PATIENTS WITH ADVANCED MELANOMA STUDIO DI FASE 3, APERTO, RANDOMIZZATO, COMPARATO SU TI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002827-15,0,0,0 2005-002827-15,10,2010-05-27,2010-08-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Ltd.,"A PHASE 3, OPEN LABEL, RANDOMIZED, COMPARATIVE STUDY OF TICILIMUMAB AND EITHER DACARBAZINE OR TEMOZOLOMIDE IN PATIENTS WITH ADVANCED MELANOMA STUDIO DI FASE 3, APERTO, RANDOMIZZATO, COMPARATO SU TI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002827-15,0,0,0 2005-002827-15,10,2010-05-27,2010-08-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER,"A PHASE 3, OPEN LABEL, RANDOMIZED, COMPARATIVE STUDY OF TICILIMUMAB AND EITHER DACARBAZINE OR TEMOZOLOMIDE IN PATIENTS WITH ADVANCED MELANOMA STUDIO DI FASE 3, APERTO, RANDOMIZZATO, COMPARATO SU TI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002827-15,0,0,0 2005-002827-15,10,2010-05-27,2010-08-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Ltd,"A PHASE 3, OPEN LABEL, RANDOMIZED, COMPARATIVE STUDY OF TICILIMUMAB AND EITHER DACARBAZINE OR TEMOZOLOMIDE IN PATIENTS WITH ADVANCED MELANOMA STUDIO DI FASE 3, APERTO, RANDOMIZZATO, COMPARATO SU TI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002827-15,0,0,0 2005-002829-31,2,2006-07-13,2006-07-13,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Genzyme Europe BV,"Full title of the trial : A Single Centre, Open-Label, Bridging Study of the Safety, Pharmacokinetics and Efficacy of Recombinant Human Acid Alpha-Glucosidase (rhGAA) Treatment in Patients with Late-O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002829-31,0,0,0 2005-002830-36,1,2008-06-04,2008-06-04,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,"Intravenous low-dose decitabine versus supportive care in elderly patients with primary Myelodysplastic Syndrome (MDS) (>10 % blasts or high-risk cytogenetics), secondary MDS or Chronic Myelomonocytic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002830-36,0,0,0 2005-002832-93,1,2009-06-09,2009-06-09,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Städt. Krankenhaus Martha Maria Halle,"Phase I/II-Studie Kombinationschemotherapie mit Docetaxel und Pemetrexed in der 2nd line-Therapie bei Patienten mit NSCLC, Stadium IIIB und IV",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002832-93,0,0,0 2005-002833-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,German Competence network “Acute and Chronic Leukemias” sponsored by Federal Ministry of Education a,Curative and palliative treatment of adults aged > 60 years with AML.A randomised trial by OSHO on the role of (1) early intensification {OSHO protocol} vs. common standard arm of German AML Intergrou...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002833-10,0,0,0 2005-002838-36,1,2018-04-11,2018-04-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,COALICIÓN IBEROAMERICANA DE INVESTIGACIÓN EN ONCOLOGÍA MAMARIA (CIBOMA),"PHASE IV.III, MULTICENTER, OPEN, RANDOMIZED TREATMENT STUDY TO EVALUATE THE EFFICACY OF MAINTENANCE THERAPY WITH CAPECITABINE (X) AFTER STANDARD ADJUVANT CHEMOTHERAPY IN PATIENTS WITH OPERABLE, HORMON...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002838-36,0,0,0 2005-002842-20,1,2006-12-12,2006-12-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,York Pharma GmbH,Phase II dose ranging study to evaluate the anti-mycotic efficacy of topical Abafungin formulations in patients with tinea pedis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002842-20,0,0,0 2005-002844-24,6,2012-02-27,2012-02-27,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ELI LILLY,- Estudio doble ciego de extensión para evaluar la seguridad y eficacia a largo plazo del inhibidor de la fosfodiesterasa tipo 5 (PDE5) tadalafilo en el tratamiento de pacientes con hipertensión arter...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002844-24,0,0,0 2005-002844-24,6,2012-02-27,2012-02-27,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Lilly ICOS LLC,- Estudio doble ciego de extensión para evaluar la seguridad y eficacia a largo plazo del inhibidor de la fosfodiesterasa tipo 5 (PDE5) tadalafilo en el tratamiento de pacientes con hipertensión arter...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002844-24,0,0,0 2005-002844-24,6,2012-02-27,2012-02-27,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,- Estudio doble ciego de extensión para evaluar la seguridad y eficacia a largo plazo del inhibidor de la fosfodiesterasa tipo 5 (PDE5) tadalafilo en el tratamiento de pacientes con hipertensión arter...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002844-24,0,0,0 2005-002844-24,6,2012-02-27,2012-02-27,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,- Estudio doble ciego de extensión para evaluar la seguridad y eficacia a largo plazo del inhibidor de la fosfodiesterasa tipo 5 (PDE5) tadalafilo en el tratamiento de pacientes con hipertensión arter...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002844-24,0,0,0 2005-002847-14,2,2017-04-03,2017-04-03,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Cardiff University,AML16; A National Cancer Research Institute Trial in Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndromes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002847-14,0,0,0 2005-002848-25,1,2008-02-08,2008-02-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bristol-Myers Squibb SL,"Protocol Title: A Phase IV, Multi-Center, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate The Analgesic Efficacy And Safety of IV Paracetamol Versus Placebo in subjects with postoperat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002848-25,0,0,0 2005-002849-40,1,2009-12-01,2009-12-01,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Swedish Institute for Infectious Disease Control,"Active immunotherapy against HIV during highly active anti-retroviral therapy followed by repeated treatment interruptions, VAC 09.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002849-40,0,0,0 2005-002851-41,4,2007-08-10,2007-08-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim s.r.o.,"Reduced factorial design, randomized, double blind trial comparing combinations of telmisartan 20 or 80 mg and simvastatin 20 or 40 mg with single component therapies in the treatment of hypertension ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002851-41,0,0,0 2005-002851-41,4,2007-08-10,2007-08-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Reduced factorial design, randomized, double blind trial comparing combinations of telmisartan 20 or 80 mg and simvastatin 20 or 40 mg with single component therapies in the treatment of hypertension ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002851-41,0,0,0 2005-002851-41,4,2007-08-10,2007-08-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"Reduced factorial design, randomized, double blind trial comparing combinations of telmisartan 20 or 80 mg and simvastatin 20 or 40 mg with single component therapies in the treatment of hypertension ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002851-41,0,0,0 2005-002851-41,4,2007-08-10,2007-08-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,"Reduced factorial design, randomized, double blind trial comparing combinations of telmisartan 20 or 80 mg and simvastatin 20 or 40 mg with single component therapies in the treatment of hypertension ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002851-41,0,0,0 2005-002854-22,4,2009-08-01,2009-08-18,4,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 24-month, multicenter, randomized, open label non inferiority study of efficay and safety comparing concentration- controlled Certican in two doses (1.5 and 3.0 mg/day starting doses) with reduced N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002854-22,0,0,0 2005-002854-22,4,2009-08-01,2009-08-18,4,1,0,0,0,2,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 24-month, multicenter, randomized, open label non inferiority study of efficay and safety comparing concentration- controlled Certican in two doses (1.5 and 3.0 mg/day starting doses) with reduced N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002854-22,0,0,0 2005-002856-17,1,2009-04-14,2009-04-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hammersmith Hospital NHS Trust,A randomised controlled comparison of Campath−Tacrolimus vs IL2R MoAb −Tacrolimus / Mycophenolate as Induction−Maintenance immunosuppression in kidney transplantation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002856-17,0,0,0 2005-002857-29,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Synta Pharmaceutical Corporation,"A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 mesylate, for the Induction of Clinical Response in Patients with Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002857-29,0,0,0 2005-002859-41,1,2008-12-11,2008-12-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,HAL Allergy B.V.,"Open-label, blinded endpoint, randomized, parallel treatment study to compare the clinical efficacy of PURETHAL® Bee and Alutard SQ Bee.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002859-41,0,0,0 2005-002864-27,3,2005-05-17,2006-05-17,2,1,0,0,1,0,3,0,0,1,0,0,1,0,1,LEO Pharma A/S,Calcipotriol plus Betamethasone Dipropionate Gel Compared to DAIVONEX/DOVONEX Scalp Solution in Patients with Scalp Psoriasis. A phase III study comparing a gel containing calcipotriol 50 mcg/g plus b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002864-27,0,0,0 2005-002868-28,4,2014-07-28,2017-01-13,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Randomised, Open-Label, Parallel-Group, Multi-centre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as First Line Horm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002868-28,0,0,0 2005-002868-28,4,2014-07-28,2017-01-13,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Open-Label, Parallel-Group, Multi-centre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as First Line Horm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002868-28,0,0,0 2005-002873-62,1,2006-10-17,2006-10-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,HEXAL AG,"RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE II STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF BUSERELIN 3M IMPLANT HEXAL IN PATIENTS WITH ADVANCED PROSTATIC CANCER IN COMPARISON TO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002873-62,0,0,0 2005-002875-34,1,2006-09-07,2006-09-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,IDEA AG,Safety and efficacy of IDEA-070 for the treatment of pain and inflammation induced by photodynamic therapy of actinic keratosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002875-34,0,0,0 2005-002880-98,8,2007-10-02,2007-10-02,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GP-Pharm s.a,"Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002880-98,1,0,0 2005-002880-98,8,2007-10-02,2007-10-02,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GP-Pharm s.a.,"Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002880-98,1,0,0 2005-002880-98,8,2007-10-02,2007-10-02,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GP-PHARM S.A.,"Efficacy and safety of a new Leuprolide acetate 3.75 mg depot formulation, GP-Pharm s.a., when given as palliative treatment to prostate cancer patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002880-98,1,0,0 2005-002882-35,5,2019-05-22,2019-05-22,3,1,1,0,0,2,1,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"Phase I study of Src/Abl tyrosine kinase inhibitor dasatinib [BMS-354825] in children and adolescents with relapsed or refractory leukemia, Protocol ITCC 005. Decision number of Paediatric Investigat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002882-35,0,0,0 2005-002882-35,5,2019-05-22,2019-05-22,3,1,1,0,0,2,1,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Phase I study of Src/Abl tyrosine kinase inhibitor dasatinib [BMS-354825] in children and adolescents with relapsed or refractory leukemia, Protocol ITCC 005. Decision number of Paediatric Investigat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002882-35,0,0,0 2005-002883-27,1,2008-06-28,2008-06-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A multi-centre, double blind, double-dummy, placebo-controlled, randomised, adaptive, dose-range study to evaluate the dafety and efficacy of SB-773812 administered once daily for 12 weeks in adults w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002883-27,0,0,0 2005-002888-88,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,ANGELINI,"A randomised, ciprofloxacin-controlled study of two prulifloxacin regimens in antibiotic prophylaxis for transrectal prostatic biopsy TPB .",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002888-88,0,0,0 2005-002889-11,1,2007-02-15,2007-02-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"An 18-Week, Randomized, Multicenter, Phase IIIb, Double-Blind, Crossover Study, Followed by an 18-Week Open-Label Period to Evaluate the Efficacy and Safety of the Lipid-Regulating Agents, Rosuvastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002889-11,0,0,0 2005-002892-34,7,2007-10-06,2007-11-22,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca SAS,Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002892-34,0,0,0 2005-002892-34,7,2007-10-06,2007-11-22,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002892-34,0,0,0 2005-002897-31,1,2006-10-31,2006-10-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,North Bristol NHS Trust,Objective assessment of attention difficulties in adults with Attention-Deficit Hyperactivity Disorder (ADHD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002897-31,0,0,0 2005-002900-40,7,2009-02-13,2009-02-23,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ACTELION PHARMACEUTICALS ITALIA,BENEFIT-OL / Estudio abierto de extensión a largo plazo en pacientes con hipertensión pulmonar tromboembólica crónica (HPTC) inoperable que hayan completado el protocolo AC-052-366/BENEFIT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002900-40,0,0,0 2005-002900-40,7,2009-02-13,2009-02-23,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,BENEFIT-OL / Estudio abierto de extensión a largo plazo en pacientes con hipertensión pulmonar tromboembólica crónica (HPTC) inoperable que hayan completado el protocolo AC-052-366/BENEFIT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002900-40,0,0,0 2005-002901-22,1,2011-09-23,2011-09-23,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Oncopeptides AB,"A phase I-IIa clinical study on the investigational anticancer drug J1 in patients with advanced cancer. A prospective, single armed, open label, dose-finding phase I-IIa study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002901-22,0,0,0 2005-002907-18,1,2007-01-17,2007-01-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A multi-center phase 2 randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of RO4389620 in patients with type 2 diabete...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002907-18,0,0,0 2005-002908-42,3,2006-11-09,2006-11-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A multi-center, double-blind, randomized, placebo-controlled dose-ranging phase 2 study to investigate efficacy, safety, tolerability and pharmacokinetics of RO4389620 in patients with type 2 diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002908-42,0,0,0 2005-002909-23,13,2013-04-24,2013-04-24,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F Hoffmann La-Roche AG,Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002909-23,0,0,0 2005-002909-23,13,2013-04-24,2013-04-24,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann - La Roche Ltd,Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002909-23,0,0,0 2005-002909-23,13,2013-04-24,2013-04-24,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F Hoffmann La-Roche Ltd.,Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002909-23,0,0,0 2005-002909-23,13,2013-04-24,2013-04-24,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F Hoffmann-La Roche AG,Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002909-23,0,0,0 2005-002910-39,1,2007-08-28,2007-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 over a 24-week period in Patients with CHD or a CHD Risk Equivalent",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002910-39,0,0,0 2005-002911-26,2,2013-07-30,2013-07-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,A Randomized Phase 2 Study of Pemetrexed in Combination with Cisplatin or Carboplatin as Adjuvant Chemotherapy in Patients with Completely Resected Stage Ib or II Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002911-26,0,0,0 2005-002911-26,2,2013-07-30,2013-07-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,A Randomized Phase 2 Study of Pemetrexed in Combination with Cisplatin or Carboplatin as Adjuvant Chemotherapy in Patients with Completely Resected Stage Ib or II Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002911-26,0,0,0 2005-002912-73,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Hospitals Leuven,An Open Label Evaluation of Efficacy and Safety of Posterior Juxtascleral Administrations of 15 mg Anecortave Acetate for Depot Suspension Combined with Verteporfin Therapy in Patients with Exudative ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002912-73,0,0,0 2005-002919-24,1,2010-01-12,2010-01-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A multicenter, single arm, proof of concept study to investigate in a first stage the efficacy of a combination therapy of Sandostatin® LAR® and Cabergoline, optionally followed by a combination of Sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002919-24,0,0,0 2005-002920-32,3,2010-12-17,2013-01-22,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"PRESERVATION OF RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS WITH CERTICAN THERAPY: PROTECT Study A twelve-month, multicenter, randomized, open-label study of safety, tolerability and efficacy of Cer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002920-32,0,0,0 2005-002922-79,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Avemedica, s.r.o.",Investigation of 0.1% tacrolimus ointment for the treatment of vitiligo patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002922-79,0,0,0 2005-002925-29,1,2005-12-31,2005-12-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Childrens Hospital,Irinotecan singele drug treatment for children with refractory or relapsed hepatoblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002925-29,0,0,0 2005-002926-67,1,2007-07-16,2007-07-16,1,1,0,0,0,3,3,0,0,1,0,0,1,0,1,NV Organon,"An open-label, randomized, phase IIIB, multicenter trial to evaluate the pharmacodynamic parameters of intubation bolus, and bolus and infusion maintenance doses of Zemuron® in pediatric and adolescen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002926-67,0,0,0 2005-002928-34,2,2007-07-26,2007-07-26,1,1,0,0,2,2,3,0,0,2,0,0,0,0,1,Organon,"A randomized, assessor-blind, dose-ranging, phase IIIB, multicenter trial comparing the intubating conditions and time course of block of three different intubating doses (0.45 mg/kg, 0.6 mg/kg, and 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002928-34,1,1,0 2005-002928-34,2,2007-07-26,2007-07-26,1,1,0,0,2,2,3,0,0,2,0,0,0,0,1,NV Organon,"A randomized, assessor-blind, dose-ranging, phase IIIB, multicenter trial comparing the intubating conditions and time course of block of three different intubating doses (0.45 mg/kg, 0.6 mg/kg, and 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002928-34,1,1,0 2005-002935-28,1,2006-07-10,2006-07-10,1,1,0,0,0,0,2,1,1,1,0,0,1,0,1,Bertek Pharmaceuticals International Limited,"Single-Dose, Two Treatment, Four-Way Crossover Replicate Design to Assess the Bioequivalence of two Fentanyl Transdermal Delivery Systems MYLAN (25ug/h) and Durogesic Dtrans (25ug/h) in Healthy Volunt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002935-28,0,0,0 2005-002937-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ANRS (Agence Nationale de Recherche sur le SIDA et les hépatites virales),"Etude randomisée, en double insu et multicentrique de l'association Interferon pégylé alpha 2b-Ribavirine versus l'association Interferon pégylé alpha 2b-placebo dans le traitement au long cours (3 an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002937-11,0,0,0 2005-002942-20,14,2008-11-06,2009-04-29,11,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Sanofi-Synthelabo Recherche,"Ensayo aleatorizado, multinacional, multicéntrico, doble ciego, controlado con placebo, con dos grupos paralelos, de rimonabant 20 mg od, para la reducción del riesgo de acontecimientos cardiovascular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002942-20,1,0,0 2005-002942-20,14,2008-11-06,2009-04-29,11,1,0,0,0,0,3,0,0,2,1,0,0,0,1,sanofi-aventis recherche et developpement,"Ensayo aleatorizado, multinacional, multicéntrico, doble ciego, controlado con placebo, con dos grupos paralelos, de rimonabant 20 mg od, para la reducción del riesgo de acontecimientos cardiovascular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002942-20,1,0,0 2005-002942-20,14,2008-11-06,2009-04-29,11,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Sanofi-aventis recherche and developpement,"Ensayo aleatorizado, multinacional, multicéntrico, doble ciego, controlado con placebo, con dos grupos paralelos, de rimonabant 20 mg od, para la reducción del riesgo de acontecimientos cardiovascular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002942-20,1,0,0 2005-002942-20,14,2008-11-06,2009-04-29,11,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Sanofi-Aventis Recherche & Développement,"Ensayo aleatorizado, multinacional, multicéntrico, doble ciego, controlado con placebo, con dos grupos paralelos, de rimonabant 20 mg od, para la reducción del riesgo de acontecimientos cardiovascular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002942-20,1,0,0 2005-002943-23,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,TopoTarget A/S,"Ensayo clínico en fase I-II de Topotect (dexrazoxano) y dosis altas de etopósido en el tratamiento de pacientes adultos con tumores cerebrales sólidos, primarios o secundarios.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002943-23,0,0,0 2005-002949-40,8,2006-10-26,2006-10-27,6,1,0,0,0,0,0,0,0,1,0,0,1,0,1,GLAXO SMITHKLINE,"A multicentre, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination SERETIDE at a dose of 50/100mcg twice daily and fluticasone ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002949-40,0,0,0 2005-002949-40,8,2006-10-26,2006-10-27,6,1,0,0,0,0,0,0,0,1,0,0,1,0,1,GlaxoSmithKline Centre of Excellence,"A multicentre, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination SERETIDE at a dose of 50/100mcg twice daily and fluticasone ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002949-40,0,0,0 2005-002949-40,8,2006-10-26,2006-10-27,6,1,0,0,0,0,0,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A multicentre, randomised, double-blind, double dummy, parallel group study to compare the salmeterol/fluticasone propionate combination SERETIDE at a dose of 50/100mcg twice daily and fluticasone ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002949-40,0,0,0 2005-002950-23,8,2007-07-06,2007-08-27,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GLAXO SMITHKLINE,"A multi-centre, randomised, double blind, stratified, and parallel group study to evaluate whether a treatment strategy based on aiming for ‘Total control’ results in better airway hyper-responsivenes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002950-23,0,0,0 2005-002950-23,8,2007-07-06,2007-08-27,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline SA,"A multi-centre, randomised, double blind, stratified, and parallel group study to evaluate whether a treatment strategy based on aiming for ‘Total control’ results in better airway hyper-responsivenes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002950-23,0,0,0 2005-002950-23,8,2007-07-06,2007-08-27,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Centre of Excellence,"A multi-centre, randomised, double blind, stratified, and parallel group study to evaluate whether a treatment strategy based on aiming for ‘Total control’ results in better airway hyper-responsivenes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002950-23,0,0,0 2005-002950-23,8,2007-07-06,2007-08-27,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,"A multi-centre, randomised, double blind, stratified, and parallel group study to evaluate whether a treatment strategy based on aiming for ‘Total control’ results in better airway hyper-responsivenes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002950-23,0,0,0 2005-002958-21,1,2008-06-20,2008-06-20,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Sanofi-Synthelabo Rt.,The determination of the exact time of administration of Lantus basal insulin for treating type 2 diabetes mellitus patients poorly controlled with basal insulin associated with oral antidiabetic drug...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002958-21,0,0,0 2005-002959-41,1,2006-11-15,2006-11-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,AWD.pharma GmbH & Co. KG; Medical Development,"A multicentre, double-blind, randomised, placebo-controlled clinical trial to investigate pain relieving effects of the modified release (MR) formulation of flupirtine in patients suffering from moder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002959-41,0,0,0 2005-002960-27,1,2012-12-20,2012-12-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharma Nord ApS,"Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on Symptoms, Biomarker status (BNP) and long-term Outcome (hospitalisation/mortali...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002960-27,0,0,0 2005-002961-35,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"AS ""GRINDEKS""",MILDRONĀTA PIELIETOŠANAS EFEKTIVITĀTE UN DROŠĪBA SLIMNIEKIEM AR MIJKLIBOŠANU (CLAUDICATIO INTERMITTENS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002961-35,0,0,0 2005-002965-35,1,,,0,1,0,1,0,0,1,0,1,1,0,0,0,1,1,Sanofi Pasteur SA,"Safety of the Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Healthy Children",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002965-35,0,0,0 2005-002966-12,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,TRASTEC,PHYSIOPATHOLOGY OF NONALCOHOLIC HEPATIC STEATOSIS AND EFFICACY OF SILYMARIN IN THE THERAPY OF NONALCOHOLIC HEPATIC STEATOSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002966-12,0,0,0 2005-002969-37,3,2006-11-18,2006-11-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A randomised, placebo-controlled, parallel group single dose study of GW856553 in patients with active RA to investigate the CRP dose response relationship.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002969-37,0,0,0 2005-002969-37,3,2006-11-18,2006-11-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, placebo-controlled, parallel group single dose study of GW856553 in patients with active RA to investigate the CRP dose response relationship.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002969-37,0,0,0 2005-002976-14,1,2007-10-15,2007-10-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A phase IIa, single-centre, randomised, placebo-controlled, double-blind, three-period crossover exploratory study investigating the effects on gut autonomic responses of single administrations of eit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002976-14,0,0,0 2005-002978-30,1,2006-05-24,2006-05-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKlin Research and Development Ltd,"A double-blind, randomized, placebo-controlled, repeat dose study to compare the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK189075 with GW869682 in subjects with type 2 diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002978-30,0,0,0 2005-002979-33,1,2006-12-20,2006-12-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,Estudio de la eficacia y seguridad de risperidona en el tratamiento de adolescentes con esquizofrenia: Estudio abierto de seis meses.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002979-33,0,0,0 2005-002982-35,1,2010-06-30,2010-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Barts and The London NHS Trust,"The effect of Niaspan (slow release nicotinic acid) on plasma phosphate, and renal phosphate handling in patents with severe chronic kidney disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002982-35,0,0,0 2005-002983-27,1,2008-02-27,2008-02-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsklinikum der RWTH Aachen - Ärztlicher Direktor Univ.-Prof. Dr. H. Sass,Prospektive randomisierte Studie zur Untersuchung der Wirksamkeit der Photodynamischen Therapie bei aktinischen Keratosen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002983-27,0,0,0 2005-002984-10,6,2011-08-01,2011-08-09,5,1,0,0,0,0,3,0,2,1,0,0,1,0,2,Nordic Bioscience,"A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Calcitonin in the Treatment of Postmenopausal Women Taking Calcium and Vitamin D.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002984-10,0,0,0 2005-002984-10,6,2011-08-01,2011-08-09,5,1,0,0,0,0,3,0,2,1,0,0,1,0,2,NORDIC BIOSCIENCE,"A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Calcitonin in the Treatment of Postmenopausal Women Taking Calcium and Vitamin D.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002984-10,0,0,0 2005-002987-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Mekos Laboratories,An open single centre evaluation of the reactivity of the T.R.U.E TestTM Quaternium-15 patch and a real use exposure in subjects known to be allergic to Quaternium-15.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002987-27,0,0,0 2005-002989-11,1,2009-02-11,2009-02-11,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,IIT : University Hospital - Medical Clinic II (Director: Prof. Dr. med. J. Floege - Sponsor),Treatment of chronic glomerulonephritis with low molecular weight heparin (ClexaneR),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002989-11,0,0,0 2005-002992-34,1,2010-12-01,2010-12-01,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Deutsches Herzzentrum Berlin,"Monocenter, double blinded, prospective, randomized, placebo controlled study investigating prevention of Major Adverse Cardiac Events (MACE) after 6 months by systemic treatment with Everolimus after...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002992-34,0,0,0 2005-002995-13,1,2009-12-31,2009-12-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,UZLeuven,An open label Phase II trial to investigate the cardiac effects of pegylated liposomal doxorubicine (Caelyx) in elderly breast cancer patients with new imaging and biochemical techniques.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002995-13,0,0,0 2005-002996-34,1,2013-11-01,2013-11-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Hospitals of Leicester NHS Trust,Pharmacokinetics of actinomycin D in children with cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002996-34,0,0,0 2005-002997-31,1,2010-01-11,2010-01-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Sheffield Children's NHS Trust,A multi-centre randomised trial of insulin detemir in pre-diabetes associated with cystic fibrosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-002997-31,0,0,0 2005-003000-11,8,2007-01-30,2007-01-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.",An open-label follow-up trial of the efficacy and safety of chronic administration of the fixed dose combination of telmisartan 80 mg hydrochlorothiazide 25 mg tablets alone or in combination with o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003000-11,0,0,0 2005-003000-11,8,2007-01-30,2007-01-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,An open-label follow-up trial of the efficacy and safety of chronic administration of the fixed dose combination of telmisartan 80 mg hydrochlorothiazide 25 mg tablets alone or in combination with o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003000-11,0,0,0 2005-003000-11,8,2007-01-30,2007-01-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,An open-label follow-up trial of the efficacy and safety of chronic administration of the fixed dose combination of telmisartan 80 mg hydrochlorothiazide 25 mg tablets alone or in combination with o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003000-11,0,0,0 2005-003000-11,8,2007-01-30,2007-01-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ireland Ltd.,An open-label follow-up trial of the efficacy and safety of chronic administration of the fixed dose combination of telmisartan 80 mg hydrochlorothiazide 25 mg tablets alone or in combination with o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003000-11,0,0,0 2005-003000-11,8,2007-01-30,2007-01-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd.,An open-label follow-up trial of the efficacy and safety of chronic administration of the fixed dose combination of telmisartan 80 mg hydrochlorothiazide 25 mg tablets alone or in combination with o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003000-11,0,0,0 2005-003000-11,8,2007-01-30,2007-01-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co.KG,An open-label follow-up trial of the efficacy and safety of chronic administration of the fixed dose combination of telmisartan 80 mg hydrochlorothiazide 25 mg tablets alone or in combination with o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003000-11,0,0,0 2005-003000-11,8,2007-01-30,2007-01-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,An open-label follow-up trial of the efficacy and safety of chronic administration of the fixed dose combination of telmisartan 80 mg hydrochlorothiazide 25 mg tablets alone or in combination with o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003000-11,0,0,0 2005-003000-11,8,2007-01-30,2007-01-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim GmbH,An open-label follow-up trial of the efficacy and safety of chronic administration of the fixed dose combination of telmisartan 80 mg hydrochlorothiazide 25 mg tablets alone or in combination with o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003000-11,0,0,0 2005-003001-85,4,2009-11-30,2009-11-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Austrian Forum against Cancer,Bortezomib-Doxorubicin-Dexamethasone (BDD) as Treatment for Patients with Multiple Myeloma Presenting with Acute Renal Failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003001-85,0,0,0 2005-003002-28,1,2006-02-04,2006-02-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 7 week multicenter, double-blind, randomized, placebo-controlled cross-over evaluation of the efficacy and safety of a modified-release oral dosage form of methylphenidate-HCl, Ritalin LA® (20 mg, q...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003002-28,0,0,0 2005-003006-29,2,2006-10-27,2006-10-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of the Anxiolytic Efficacy of Pregabalin and Alprazolam IR in Subjects with Anxiety prior to Dental Procedure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003006-29,0,0,0 2005-003006-29,2,2006-10-27,2006-10-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Limited,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of the Anxiolytic Efficacy of Pregabalin and Alprazolam IR in Subjects with Anxiety prior to Dental Procedure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003006-29,0,0,0 2005-003007-36,1,2008-02-09,2008-02-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Imperial College London,"B.R.E.A.T.H.E. Bronchiolitis RCT: Emergency Assisted Therapy with Heliox - an Evaluation. A Prospective, Double-Blinded, Randomised, Controlled Clinical Trial to assess the effect of helium-oxygen gas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003007-36,0,0,0 2005-003007-36,1,2008-02-09,2008-02-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,2,BOC Ltd.,"B.R.E.A.T.H.E. Bronchiolitis RCT: Emergency Assisted Therapy with Heliox - an Evaluation. A Prospective, Double-Blinded, Randomised, Controlled Clinical Trial to assess the effect of helium-oxygen gas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003007-36,0,0,0 2005-003008-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,STALLERGENES,"Prospective trial to evaluate the safety of one cluster regimen in patients with allergic rhinitis/ rhinoconjunctivitis and/or mild or moderate allergic asthma to grass polen, tree pollen or mites.b E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003008-12,0,0,0 2005-003009-10,1,2006-06-09,2006-06-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Barts and The London NHS Trust,"A randomized, open label pilot study to investigate the effect of chronic administration of buprenorphine prior to arthroplasty on the opioid requirements of patients intraoperatively and postoperativ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003009-10,0,0,0 2005-003010-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC),"Estudio piloto fase II abierto, no controlado y multicéntrico para evaluar la eficacia y seguridad de cetuximab (Erbitux) en combinación con paclitaxel semanal en primera linea de tratamiento de pacie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003010-15,0,0,0 2005-003013-32,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Deutsches Herzzentrum München,"PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED; MULTICENTER TRIAL OF BIVALIRUDIN AND UN-FRACTIONATED HEPARIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003013-32,0,0,0 2005-003018-14,2,2015-04-21,2015-04-21,1,1,0,0,0,0,3,0,0,1,1,0,1,0,0,AKH Vienna,"Randomized phase III trial comparing early treatment with fludarabine, cyclophosphamide + rituximab versus deferred treatment in untreated Binet Stage A patients with high risk of progression.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003018-14,0,0,0 2005-003018-14,2,2015-04-21,2015-04-21,1,1,0,0,0,0,3,0,0,1,1,0,1,0,0,"Deutsche CLL-Studiengruppe, Klinik fur Innere Medizin","Randomized phase III trial comparing early treatment with fludarabine, cyclophosphamide + rituximab versus deferred treatment in untreated Binet Stage A patients with high risk of progression.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003018-14,0,0,0 2005-003021-19,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University Of Birmingham,The use of selenium and vitamin E supplementation to prevent recurrence and progression of non-muscle-invasive bladder cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003021-19,0,0,0 2005-003023-40,1,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,Food Standards Agency,The role of peanut specific T cell responses in children with peanut allergy and in children who are tolerant to peanuts,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003023-40,0,0,0 2005-003026-26,1,,,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,University Medical Center Hamburg-Eppendorf,High-dose chemotherapy with transplantation of gene-modified haematopoietic stem cells for HIV-positive patients with malignant diseases indicating an HSCT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003026-26,0,0,0 2005-003033-41,2,2009-09-22,2009-09-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Procter & Gamble Technical Centres Limited,"A Non-invasive Evaluation of Bone Microarchitecture Modification in Osteopenic Postmenopausal Women by 3D Peripheral Quantitative Computed Tomography: A 12 Month, Multicenter, Double-blind, Randomized...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003033-41,0,0,0 2005-003035-52,3,2006-03-08,2006-03-08,2,1,0,0,0,0,3,0,2,1,0,0,1,0,1,Merck & Co. Inc.,"A Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly with Influenza Virus Vaccine (Ina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003035-52,0,0,0 2005-003035-52,3,2006-03-08,2006-03-08,2,1,0,0,0,0,3,0,2,1,0,0,1,0,1,Merck Sharp & Dohme Ltd.,"A Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly with Influenza Virus Vaccine (Ina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003035-52,0,0,0 2005-003035-52,3,2006-03-08,2006-03-08,2,1,0,0,0,0,3,0,2,1,0,0,1,0,1,MERCK SHARP DOHME,"A Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly with Influenza Virus Vaccine (Ina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003035-52,0,0,0 2005-003041-14,1,2006-07-31,2006-07-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Department of Clinical Pharmacology, Medical University of Vienna",Anti-inflammatory effect of statins in the human endotoxin model,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003041-14,0,0,0 2005-003046-33,1,2008-10-02,2008-10-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Søren H. Sindrup, Department of Neurology, Odense University Hospital","Double-bllind, randomised, placebo-controlled trial of levetiracetam in painful polyneuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003046-33,0,0,0 2005-003048-78,6,2008-02-27,2008-05-27,6,1,0,0,2,0,4,0,0,1,0,0,1,0,1,Pfizer Limited,"A 9 Week, Randomized, Double-Blind, placebo-controlled, Multicenter, Study of Pregabalin (BID) in subjects with posttraumatic peripheral neuropathic pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003048-78,0,0,0 2005-003048-78,6,2008-02-27,2008-05-27,6,1,0,0,2,0,4,0,0,1,0,0,1,0,1,"Laboratórios Pfizer,Lda","A 9 Week, Randomized, Double-Blind, placebo-controlled, Multicenter, Study of Pregabalin (BID) in subjects with posttraumatic peripheral neuropathic pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003048-78,0,0,0 2005-003048-78,6,2008-02-27,2008-05-27,6,1,0,0,2,0,4,0,0,1,0,0,1,0,1,PFIZER,"A 9 Week, Randomized, Double-Blind, placebo-controlled, Multicenter, Study of Pregabalin (BID) in subjects with posttraumatic peripheral neuropathic pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003048-78,0,0,0 2005-003048-78,6,2008-02-27,2008-05-27,6,1,0,0,2,0,4,0,0,1,0,0,1,0,1,Pfizer Oy,"A 9 Week, Randomized, Double-Blind, placebo-controlled, Multicenter, Study of Pregabalin (BID) in subjects with posttraumatic peripheral neuropathic pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003048-78,0,0,0 2005-003048-78,6,2008-02-27,2008-05-27,6,1,0,0,2,0,4,0,0,1,0,0,1,0,1,Pfizer Limited. Pfizer Global Research and Development,"A 9 Week, Randomized, Double-Blind, placebo-controlled, Multicenter, Study of Pregabalin (BID) in subjects with posttraumatic peripheral neuropathic pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003048-78,0,0,0 2005-003048-78,6,2008-02-27,2008-05-27,6,1,0,0,2,0,4,0,0,1,0,0,1,0,1,Pfizer AB,"A 9 Week, Randomized, Double-Blind, placebo-controlled, Multicenter, Study of Pregabalin (BID) in subjects with posttraumatic peripheral neuropathic pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003048-78,0,0,0 2005-003050-96,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,IBSA,"Multicentre, prospective, assessor-blind, in parallel groups randomised and vs reference marketed product controlled confirmatory trial of the efficacy and safety of IBSA BMV medicated plaster for the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003050-96,0,0,0 2005-003052-36,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase II, multicentre booster study to evaluate booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or to evaluate the immune memory following the administration of a ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003052-36,0,0,0 2005-003053-26,1,2007-06-22,2007-06-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,The Medicines Company UK Ltd,The ZBMUF trial: an open-label randomised study of the effects of ultra-filtration and high dose aprotinin on bivalirudin pharmacokinetics during and/or after cardiopulmonary bypass surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003053-26,0,0,0 2005-003057-28,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University Hospital Aintree NHS Trust,"An Investigation Into the Prevalence, Cause and treatment of Unexplained Anamia in Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003057-28,0,0,0 2005-003068-47,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"Region Skåne, Universitetssjukhuset i Lund, Urologiska kliniken",Behandling med botulinumtoxin vid neurogen blåsfunktionsstörning,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003068-47,0,0,0 2005-003069-18,1,2006-09-21,2006-09-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Anders Nyboe Andersen, klinikchef dr.med., Fertilitetsklinikken 4071, Rigshospitalet",Nedregulering og androgen priming i kort protokol ved reagensglasbefrugtning,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003069-18,0,0,0 2005-003070-19,1,2007-03-28,2007-03-28,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, multicenter, parallel-group, open-label study to assess the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic®) versus continuation of previous therapy in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003070-19,0,0,0 2005-003071-20,1,,,0,0,0,0,1,0,2,0,0,1,0,0,0,1,1,FIT Biotech Oyj Plc,"Immunogenicity and therapeutic effects of GTU-MultiHIV B clade DNA vaccine. A randomized, controlled, phase II clinical trial in treatment-naive HIV-positive subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003071-20,0,0,0 2005-003074-20,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,University of Dundee,Use Of Oral Montelukast As Adjuvant Therapy In The Treatment Of Acute Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003074-20,0,0,0 2005-003076-37,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Sanos Bioscience A/S,"GLP-2 and Bone Resorption A double-blind, randomized, placebo-controlled, dose ranging, safety, tolerability and pharmacokinetic/dynamic efficacy study with multiple subcutaneous injections of GLP-2 i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003076-37,0,0,0 2005-003077-25,1,2008-04-15,2008-04-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AKH Vienna,PHASE II TRIAL OF BORTEZOMIB (VELCADE®) IN PATIENTS WITH ADVANCED OR RELAPSED LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003077-25,0,0,0 2005-003080-23,5,2008-01-03,2008-01-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI SYNTHELABO RECHERCHE,"Efficacy and safety of eplivanserin 5mg/day on sleep maintenance insomnia: a 12-week multicenter, randomized, double-blind, placebo-controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003080-23,0,0,0 2005-003080-23,5,2008-01-03,2008-01-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT,"Efficacy and safety of eplivanserin 5mg/day on sleep maintenance insomnia: a 12-week multicenter, randomized, double-blind, placebo-controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003080-23,0,0,0 2005-003080-23,5,2008-01-03,2008-01-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis recherche et développement,"Efficacy and safety of eplivanserin 5mg/day on sleep maintenance insomnia: a 12-week multicenter, randomized, double-blind, placebo-controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003080-23,0,0,0 2005-003081-42,1,2009-02-26,2009-02-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of DUndee,EXPLORING THE THERAPEUTIC POTENTIAL OF XANTHINE OXIDASE INHIBITORS IN CORONARY ARTERY DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003081-42,0,0,0 2005-003082-16,7,2008-09-10,2008-09-10,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-SYNTHELABO RECHERCHE,"Efficacy and safety of eplivanserin 5mg/day on Sleep Maintenance Insomnia : a 12-week multicenter, randomized, double-blind, placebo-controlled study followed by an open treatment phase extension wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003082-16,0,0,0 2005-003082-16,7,2008-09-10,2008-09-10,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT,"Efficacy and safety of eplivanserin 5mg/day on Sleep Maintenance Insomnia : a 12-week multicenter, randomized, double-blind, placebo-controlled study followed by an open treatment phase extension wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003082-16,0,0,0 2005-003082-16,7,2008-09-10,2008-09-10,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"Efficacy and safety of eplivanserin 5mg/day on Sleep Maintenance Insomnia : a 12-week multicenter, randomized, double-blind, placebo-controlled study followed by an open treatment phase extension wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003082-16,0,0,0 2005-003082-16,7,2008-09-10,2008-09-10,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,anofi-aventis recherche et développement,"Efficacy and safety of eplivanserin 5mg/day on Sleep Maintenance Insomnia : a 12-week multicenter, randomized, double-blind, placebo-controlled study followed by an open treatment phase extension wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003082-16,0,0,0 2005-003082-16,7,2008-09-10,2008-09-10,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis recherche et développement,"Efficacy and safety of eplivanserin 5mg/day on Sleep Maintenance Insomnia : a 12-week multicenter, randomized, double-blind, placebo-controlled study followed by an open treatment phase extension wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003082-16,0,0,0 2005-003083-36,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,"Efficacy and safety of factor VIIa eptacog alfa, Novoseven on rebleeding after surgery for spontaneous supratentorial intracerebral, hemorrhage. A randomized, controlled, open-label, investigator-bl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003083-36,0,0,0 2005-003092-20,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Liposomial doxorubicin Investigational chemotherapy - Tissue doppler imaging -Evaluation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003092-20,0,0,0 2005-003093-21,1,2010-10-01,2010-10-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical Department I,Influence of combined therapy of niacin and statins on stem cell mobilization and inflammatory parameters in patients suffering from coronary artery disease – randomized clinical study -,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003093-21,0,0,0 2005-003096-20,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,Use of peg-filgrastim in severe chronic neutropenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003096-20,0,0,0 2005-003097-19,2,2009-01-14,2009-01-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,A Phase 2 Study of HKI-272 in Subjects with Advanced Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003097-19,0,0,0 2005-003098-26,2,2018-04-20,2018-04-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Phase 2 Study of HKI-272 in Subjects with Advanced Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003098-26,0,0,0 2005-003099-39,1,2009-07-28,2009-07-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Liverpool Women's NHS Foundation Trust Hospital,A Randomised Controlled Trial of Thyroxine in Preterm Infants Under 28 weeks' Gestation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003099-39,0,0,0 2005-003100-11,2,2007-05-29,2008-06-08,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Oncoscience AG,Phase III Study on the effectiveness of OSAG 101 (Theraloc) in newly diagnosed intrinsic pontine gliomas of children and adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003100-11,0,0,0 2005-003100-11,2,2007-05-29,2008-06-08,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ONCOSCIENCE AG,Phase III Study on the effectiveness of OSAG 101 (Theraloc) in newly diagnosed intrinsic pontine gliomas of children and adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003100-11,0,0,0 2005-003101-85,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,Oncoscience AG,Phase-III study of standard radiotherapy plus concomitant and adjuvant OSAG 101 (Theraloc®) plus Temozolomide vs. standard radiotherapy plus concomitant and adjuvant Temozolomide in patient with newly...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003101-85,0,0,0 2005-003104-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fertility clinic Odense University Hospital,Androgen priming in the late luteal phase as a mean to improve the outcome of ovarian stimulation for IVF in normogonadotrophic women with a previously proven poor response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003104-11,0,0,0 2005-003107-36,1,2005-12-31,2005-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Thoracic and Hyperbaric Surgery, University Medical School Graz","Pharmacokinetic of Amoxicillin and Clavulanacid in pneumonic, interstitial lung tissue measured by in vivo microdialysis, in patients with pleural empyema treated by decortication.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003107-36,0,0,0 2005-003115-74,1,2009-12-30,2009-12-30,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,"Dept. of Anaestesiology, University hospital in Glostrup",Effect of paracetamol versus paracetamol combined with pregabalin versus paracetamol combined with pregabalin and dexamethason on pain and opiod requirements in patient sheduled for tonsilectomie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003115-74,0,0,0 2005-003119-62,4,2008-12-03,2008-12-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"Double-blind, double-dummy, randomized, parallel group trial of SL650472 (three dose regimens versus placebo and cilostazol), for 24-week improvement of walking distance in patients with stage II peri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003119-62,0,0,0 2005-003122-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ANGEL LANAS,EFECTO DEL ÁCIDO ACETILSALICÍLICO EN LA PROLIFERACIÓN Y APOPTOSIS CELULAR DEL EPITELIO METAPLÁSICO DEL ESÓFAGO DE BARRETT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003122-25,0,0,0 2005-003129-23,1,2015-02-27,2015-02-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Belfast Health and Social Care Trust, Musgrave Park Hospital",Prevention and Treatment of Steroid-Induced Osteopenia in children and adolescents with rheumatic diseases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003129-23,0,0,0 2005-003132-21,1,2007-10-10,2007-10-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Dept. of Ophthalmology, Medical University of Vienna",European Intravitreal Avastin® Trial 1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003132-21,0,0,0 2005-003136-22,2,2010-05-27,2010-10-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gilead Sciences Incorporated,"A Phase 2, Randomized, Double-Blind Study Exploring the Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combinatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003136-22,0,0,0 2005-003137-40,10,2007-06-07,2007-09-04,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pierre Fabre Medicament,"A EUROPEAN PHASE III, MULTICENTRE, DOUBLE-BLIND,RANDOMISED,PLACEBO-CONTROLLED, MONOTHERAPY STUDY OF MILNACIPRAN FOR THE TREATMENT OF THE FIBROMYALGIA SYNDROME.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003137-40,0,0,0 2005-003137-40,10,2007-06-07,2007-09-04,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"A EUROPEAN PHASE III, MULTICENTRE, DOUBLE-BLIND,RANDOMISED,PLACEBO-CONTROLLED, MONOTHERAPY STUDY OF MILNACIPRAN FOR THE TREATMENT OF THE FIBROMYALGIA SYNDROME.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003137-40,0,0,0 2005-003138-16,1,2009-07-24,2009-07-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"R+ D department, Hull and East Yorkshire NHS Hospital Trust",A clinical observational study to assess the effectiveness of Strontium Ranelate on bone protection in osteoporotic patients pre-treated with bisphosphonates.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003138-16,0,0,0 2005-003139-38,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,ZLB Behring GmbH,Open-label extension study of CE1145 (Human pasteurized C1 esterase inhibitor concentrate) in subjects with congenital C1-INH deficiency and acute HAE attacks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003139-38,0,1,1 2005-003140-56,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"Department of Human Nutrition, The Royal Veterinary and Agricultural University","Probiotics to infants with atopic dermatitis; an investigation of the effect on eczema, immune system and intestinal microflora, inflammation and permeability. DK-titel Probiotiske bakterier til bør...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003140-56,0,0,0 2005-003142-34,1,2008-10-27,2008-10-27,1,0,0,0,0,0,4,0,1,1,1,1,1,0,0,Respiratory and Allergy Research Unit,Elite sport and development of asthma: Airway inflammation and treatment.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003142-34,0,0,0 2005-003144-65,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Merck Selbstmedikation GmbH,"Doubleblind, randomized, placebo controlled clinical trial to proof the efficacy of a comfrey extract in subjects with painfull gonarthrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003144-65,0,0,0 2005-003145-13,2,2008-08-13,2008-08-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Limited,"A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003145-13,0,0,0 2005-003146-33,1,,,0,0,0,0,0,3,3,0,0,1,1,1,0,1,1,Pfizer AB,"INDIVIDUALIZED DOSE OF GENOTROPIN® (SOMATROPIN) TO SHORT PREPUBERTAL CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA): COMPARISON WITH FIXED DOSE TREATMENT IN EVALUATION OF GROWTH AND SAFETY IN AN OPEN, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003146-33,0,0,0 2005-003148-79,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Wirral Hospitals NHS Trust,Role of antibiotic line locks in the prevention of tunnelled haemodialysis catheter infection: a double blind randomised controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003148-79,0,0,0 2005-003156-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Department of Psychiatry and Psychotherapy (Cologne),Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003156-35,0,0,0 2005-003158-91,8,2008-01-31,2008-02-28,7,0,0,0,0,0,3,0,0,1,0,0,1,0,1,KERYX BIOPHARMACEUTICALS INC.,THE COLLABORATIVE STUDY GROUP TRIAL THE EFFECT OF SULODEXIDE IN PATIENTS WITH TYPE 2 DIABETES AND MICROALBUMINURIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003158-91,0,0,0 2005-003158-91,8,2008-01-31,2008-02-28,7,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Keryx Biopharmaceuticals, Inc.",THE COLLABORATIVE STUDY GROUP TRIAL THE EFFECT OF SULODEXIDE IN PATIENTS WITH TYPE 2 DIABETES AND MICROALBUMINURIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003158-91,0,0,0 2005-003160-32,6,2008-08-01,2008-08-12,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Limited,"A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003160-32,0,0,0 2005-003160-32,6,2008-08-01,2008-08-12,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,"A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003160-32,0,0,0 2005-003162-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Almirall Prodesfarma S.A.,"A double-blind, randomized, parallel, multicenter, vehicle-controlled, left/right paired comparison to study the efficacy, safety and tolerability of 1% LAS 37779 cream administered once and twice dai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003162-42,0,0,0 2005-003164-35,3,2010-10-28,2010-10-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,essex pharma GmbH,"A multinational, Subsidiary Sponsored, Randomized, Open-Label Study Comparing Treatment with Either Pegylated Liposomal Doxorubicin or Capecitabine as First Line Chemotherapy for Metastatic Breast Can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003164-35,0,0,0 2005-003164-35,3,2010-10-28,2010-10-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Essex Pharma GmbH,"A multinational, Subsidiary Sponsored, Randomized, Open-Label Study Comparing Treatment with Either Pegylated Liposomal Doxorubicin or Capecitabine as First Line Chemotherapy for Metastatic Breast Can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003164-35,0,0,0 2005-003166-42,1,2009-08-31,2009-08-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Leipzig,Palliative Chemotherapy (2nd line) with Imatinib (GlivecTM) in Patients with Bile Duct Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003166-42,0,0,0 2005-003171-21,1,2008-06-10,2008-06-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Danish Pain Research Center,"Effect of levetiracetam in spinal cord injury pain: a randomized, double-blind, placebo-controlled crossover study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003171-21,0,0,0 2005-003173-24,3,2020-10-08,2020-10-08,1,0,0,0,0,1,2,0,0,2,0,0,0,0,0,Sydvestjysk Sygehus,"An open, randomized study treating refractory adult-onset Still's disease (AOSD) with interleukin-1 receptor antagonist anakinra (KineretR), compared to an established, single anti-rheumatic drug trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003173-24,1,0,0 2005-003173-24,3,2020-10-08,2020-10-08,1,0,0,0,0,1,2,0,0,2,0,0,0,0,0,Landstinget i Uppsala län,"An open, randomized study treating refractory adult-onset Still's disease (AOSD) with interleukin-1 receptor antagonist anakinra (KineretR), compared to an established, single anti-rheumatic drug trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003173-24,1,0,0 2005-003173-24,3,2020-10-08,2020-10-08,1,0,0,0,0,1,2,0,0,2,0,0,0,0,0,Helsinki University Central Hospital,"An open, randomized study treating refractory adult-onset Still's disease (AOSD) with interleukin-1 receptor antagonist anakinra (KineretR), compared to an established, single anti-rheumatic drug trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003173-24,1,0,0 2005-003176-38,3,2008-02-11,2008-02-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,A placebo controlled trial of alteplase (rt-PA) in acute ischemic hemispheric stroke where thrombolysis is initiated between 3 and 4 hours 30 minutes after stroke onset,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003176-38,0,0,0 2005-003176-38,3,2008-02-11,2008-02-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,A placebo controlled trial of alteplase (rt-PA) in acute ischemic hemispheric stroke where thrombolysis is initiated between 3 and 4 hours 30 minutes after stroke onset,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003176-38,0,0,0 2005-003177-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dr. José García-Arumí,Estudio Multicéntrico para el tratamiento quirúrgico de la Oclusión de la Vena Central de la Retina. Neurotomía Óptica Radial para la Oclusión de la Vena Central de la Retina. (Estudio ROVO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003177-24,0,0,0 2005-003180-23,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,sanofi-aventis recherche & développement,"An 8-week, double blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy and safety of 2 fixed doses of SR58611A (175 mg q12 and 350 mg q...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003180-23,0,0,0 2005-003181-41,3,2007-01-18,2007-01-18,3,1,0,0,0,3,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"An eight-week, double-blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy, safety and tolerability of a fixed dose of SR58611A (350 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003181-41,0,0,0 2005-003181-41,3,2007-01-18,2007-01-18,3,1,0,0,0,3,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"An eight-week, double-blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy, safety and tolerability of a fixed dose of SR58611A (350 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003181-41,0,0,0 2005-003182-16,1,2008-10-21,2008-10-21,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Addenbrooke's Hospital Trust,Blood Pressure Optimisation In Patients With Polycystic Kidney Disease And Hypertension By Rotation Through The Main Therapeutic Classes Of Antihypertensive Drugs.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003182-16,0,0,0 2005-003184-23,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,"Klinik for Klinisk Fysiologi, Nuklearmedicin og PET, Rigshospitalet",Effekt af statiner på koronar endothelfunktion hos HIV-positive i antiretroviral behandling,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003184-23,0,0,0 2005-003187-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Oncology, Rigshospitalet","A phase II study of etoposide, oxaliplatin and capecitabine in patients with advanced hepatocellular carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003187-32,0,0,0 2005-003194-24,2,2008-05-25,2008-06-23,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cadence Pharmaceuticals, Inc.","A Phase 3, Multicenter, Randomized, Evaluation Committee-Blinded Study to Assess the Efficacy of Topical Administration of Omiganan 1.0% Gel in Preventing Local Catheter Site Infections and Catheter C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003194-24,0,0,0 2005-003195-38,1,2007-10-11,2007-10-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Center for Muscle and Bone Research of the Charité Universitaetsmedizin Berlin,Randomized double-blind placebo-controlled and parallel group study to evaluate the impact of one year therapy with monthly oral ibandronate 150 mg on structural properties of bone in postmenopausal ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003195-38,0,0,0 2005-003196-21,1,2011-07-05,2011-07-05,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Technische Universität München,"Enhancing the Therapeutic Efficacy of Sleep Deprivation by Modafinil - a double blind, randomized, placebo-controlled, monocentric phase II study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003196-21,0,0,0 2005-003197-17,1,2008-03-07,2008-03-07,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Cardiff and Vale NHS Trust,"The Metabolic,Vascular and Inflammatory effects of Conjugated Linoleic acid in patients with the Metabolic Syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003197-17,0,0,0 2005-003201-81,1,2012-12-31,2012-12-31,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Universitätsklinikum Heidelberg,"GACHE: German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis. A multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003201-81,0,0,0 2005-003209-10,1,2009-09-17,2009-09-17,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Tampere University Hospital,"VEGF, VEGFR1 and VEGFR2 expression in serous epithelial ovarian carcinoma, and its association to the efficacy of bevacizumab combined with paclitaxel and carboplatin as first line treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003209-10,0,0,0 2005-003211-69,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Medical University of Vienna,Anticoagulation with Prostaglandin E1 and unfractioned Heparin versus Placebo and unfractioned Heparin during continuous venovenous hemofiltration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003211-69,0,0,0 2005-003214-15,5,2006-10-23,2006-10-23,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Voyager Pharmaceutical Corporation,A DOUBLE-BLIND PLACEBO- CONTROLLED STUDY OF VP4896 FOR THE TREATMENT OF MILD-TO-MODERATE ALZHEIMER'S DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003214-15,1,0,0 2005-003215-78,4,2006-05-03,2006-05-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharma A/S,"Calcipotriol plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle and the Gel Vehicle alone in Psoriasis Vulgaris.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003215-78,0,0,0 2005-003215-78,4,2006-05-03,2006-05-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S),"Calcipotriol plus Betamethasone Dipropionate Gel Compared to Betamethasone Dipropionate in the Gel Vehicle, Calcipotriol in the Gel Vehicle and the Gel Vehicle alone in Psoriasis Vulgaris.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003215-78,0,0,0 2005-003216-30,7,2008-07-04,2009-01-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Schering AG,"Ensayo clínico de fase II prospectivo, multicéntrico, aleatorizado de grupos paralelos, abierto, para estudiar la eficacia, seguridad y tolerabilidad de 2 dosis de ZK 219477 (16 y 12 mg/m2 de área de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003216-30,0,0,0 2005-003216-30,7,2008-07-04,2009-01-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCHERING,"Ensayo clínico de fase II prospectivo, multicéntrico, aleatorizado de grupos paralelos, abierto, para estudiar la eficacia, seguridad y tolerabilidad de 2 dosis de ZK 219477 (16 y 12 mg/m2 de área de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003216-30,0,0,0 2005-003216-30,7,2008-07-04,2009-01-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer Schering Pharma AG,"Ensayo clínico de fase II prospectivo, multicéntrico, aleatorizado de grupos paralelos, abierto, para estudiar la eficacia, seguridad y tolerabilidad de 2 dosis de ZK 219477 (16 y 12 mg/m2 de área de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003216-30,0,0,0 2005-003217-32,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA USL DI FORLI,PHASE-II STUDY TO EVALUATE ACTIVITY OF DEXRAZOXANE CARDIOXANE IN ORDER TO PREVENT CARDIAC TOXICITY IN PATIENTS WITH BREAST CANCER AND TREATED WITH ANTHRACYCLINE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003217-32,0,0,0 2005-003219-66,1,2015-01-06,2015-01-06,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,university Hospitals of Leicester NHS Trust,Allopurinol in the prevention of superficial bladder tumour recurrence,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003219-66,0,0,0 2005-003220-19,14,2012-06-22,2012-06-22,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A multicentre, open-label, randomized, phase III study to evaluate the efficacy of Tarceva or comparator Alimta (pemetrexed) or Taxotere (docetaxel) in patients with histologically documented, advance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003220-19,0,0,0 2005-003220-19,14,2012-06-22,2012-06-22,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F Hoffmann - La Roche Ltd,"A multicentre, open-label, randomized, phase III study to evaluate the efficacy of Tarceva or comparator Alimta (pemetrexed) or Taxotere (docetaxel) in patients with histologically documented, advance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003220-19,0,0,0 2005-003228-20,2,2007-01-26,2007-03-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V,"A PHASE II, MULTI-CENTER, OPEN-LABEL STUDY OF YM155 IN SUBJECTS WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) PREVIOUSLY TREATED WITH AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003228-20,0,0,0 2005-003228-20,2,2007-01-26,2007-03-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V by August 2005),"A PHASE II, MULTI-CENTER, OPEN-LABEL STUDY OF YM155 IN SUBJECTS WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) PREVIOUSLY TREATED WITH AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003228-20,0,0,0 2005-003230-18,1,2006-01-21,2006-01-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Barts and The London NHS Trust,"A prospective double-blind, randomised, cross-over trial to compare the effects of adding buprenorphine or morphine to Transtec for 'breakthrough' pain in patients with severe pain due to osteoarthrit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003230-18,0,0,0 2005-003231-46,1,2015-05-19,2015-05-19,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Dept of Internal Medicine IV, Med Uni Vienna",Changes in hepatic lipid content assessed by MR Spectroscopy in patients with non-alcoholic fatty liver disease (NAFLD) under standard therapy (reduction diet and regular aerobic exercise) with and wi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003231-46,0,0,0 2005-003232-21,5,2009-09-26,2009-09-26,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Centocor B.V.,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Intravenously, in Subjects with Active Rheumatoid Arthritis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003232-21,0,0,0 2005-003233-41,3,2007-01-23,2007-03-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme Europe BV,"An open label, dose titration study of sevelamer carbonate tablets dosed three times a day in hyperphosphatemic chronic kidney disease patients not on dialysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003233-41,0,0,0 2005-003242-34,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,National Institutes of Neurological Disorders: Stroke,Secondary Prevention of Small Subcortical Strokes Prevención secundaria de infartos subcorticales de pequeño tamaño,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003242-34,0,0,0 2005-003243-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Luis Fernando López Cortés,"Randomized, double-blind, study to compare the incidence and intensity lf neurologic and pschiatic adverse events of efavirenz when given as a stepped dosage (200 mg qd for 6 days, 400 mg qd for 7 day...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003243-31,0,0,0 2005-003245-14,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Aachen",Neuronale Korrelate von dysfunktionellen Aufmerksamkeitskomponenten bei Patienten mit Schizophrenie: cholinerge Rezeptorsysteme und pharmakologische Therapie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003245-14,0,0,0 2005-003248-75,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",PILOT STUDY ON SAFETY AND TOLERABILITY OF REPEATED MOBILIZATION PROCEDURES OF OSTEO-MEDULLARY DERIVED CELLS IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003248-75,0,0,0 2005-003249-15,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,BIONORICA AG,"Efficacy and tolerability of Bronchipret® Saft for the treatment of acute bronchitis in adults A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase IV study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003249-15,0,0,0 2005-003250-98,1,2007-05-11,2007-05-11,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,UZ LEUVEN,Sandostatine LAR in Dumping syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003250-98,0,0,0 2005-003251-13,1,2007-08-30,2007-08-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca UK Ltd,Quetiapine Augmentation In Treatment-Resistant Depression – An Open Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003251-13,0,0,0 2005-003254-10,1,2013-05-21,2013-05-21,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University College London,A Phase II Study to determine the efficacy and safety of conventional dose oral Treosulfan in patients with advanced pre-treated Ewing’s Sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003254-10,0,0,0 2005-003258-87,6,2007-07-31,2007-07-31,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Aventis Pharma Deutschland GmbH,"Efficacy and safety of intra-articular multiple doses of 500 mcg icatibant including 40 mg triamcinolone as calibrator in a randomized, double-blind, parallel-group, placebo-controlled 13-week multi-c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003258-87,0,0,0 2005-003258-87,6,2007-07-31,2007-07-31,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi Aventis Deutschland GmbH,"Efficacy and safety of intra-articular multiple doses of 500 mcg icatibant including 40 mg triamcinolone as calibrator in a randomized, double-blind, parallel-group, placebo-controlled 13-week multi-c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003258-87,0,0,0 2005-003264-38,1,2009-04-03,2009-04-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche Pharma AG,COMPARE: Comparison Ibandronate - Zoledronate regarding nephrotoxicity in patients with multiple myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003264-38,0,0,0 2005-003265-16,4,2007-07-31,2009-05-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Double-Blind, Multi-center, Phase II Fixed Dose Study of Multiple Doses of Ipilimumab (MDX-010) Monotherapy in Patients with Previously Treated Unresectable Stage III or IV Melanoma Rev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003265-16,0,0,0 2005-003269-17,1,2008-12-31,2008-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,manchester mental health and social care trust,Aromatherapy in Alzheimer's disease: a randomised controlled trial in comparison with Aricept,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003269-17,0,0,0 2005-003270-14,4,2008-09-30,2008-09-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FOURNIER Laboratories Ireland Ltd,"A multicenter, double-blind, randomized, active comparator, forced-titration study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 20 or 40 mg simvastatin with 40 mg si...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003270-14,0,0,0 2005-003271-21,1,2008-12-17,2008-12-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Universität zu Köln,"Doppelblinde, prospektive, randomisierte, monozentrische, placebo-kontrollierte Pilotstudie zur Wirksamkeit und Sicherheit von Moxifloxacin in der Prophylaxe der Bakteriämie nach Hochdosis-Chemotherap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003271-21,0,0,0 2005-003272-38,1,2008-07-08,2008-07-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Taiho Pharma USA, Inc","AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, TWO-STAGE, PHASE 2 STUDY OF S-1 IN CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003272-38,0,0,0 2005-003275-20,6,2008-10-16,2008-10-16,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Cell Genesys Inc.,"A Phase 3 Randomized, Open-Label Study of Docetaxel in Combination with CG1940 and CG8711 versus Docetaxel and Prednisone in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003275-20,1,0,0 2005-003275-20,6,2008-10-16,2008-10-16,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Cell Genesys Ltd,"A Phase 3 Randomized, Open-Label Study of Docetaxel in Combination with CG1940 and CG8711 versus Docetaxel and Prednisone in Taxane-Naïve Patients with Metastatic Hormone-Refractory Prostate Cancer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003275-20,1,0,0 2005-003279-18,1,,,0,0,0,0,0,1,4,0,0,4,0,0,0,0,0,"Barncancerforskningsenheten, Astrid Lindgrens Barnsjukhus",HLH-2004. Hemophagocytic Lymphohistiocytosis Study Group. Treatment Protocol of the Second International HLH Study 2004.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003279-18,0,0,0 2005-003281-41,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,2,Institut de Recherches Internationales Servier,A factorial randomised trial of blood pressure lowering with a fixed low-dose perindopril-indapamide combination and intensive glucose control with a modified-release gliclazide-based regimen for the ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003281-41,0,0,0 2005-003281-41,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,2,Institute for International Health,A factorial randomised trial of blood pressure lowering with a fixed low-dose perindopril-indapamide combination and intensive glucose control with a modified-release gliclazide-based regimen for the ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003281-41,0,0,0 2005-003282-16,2,2006-10-17,2006-10-17,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Nuvelo, Inc.","PHASE 3, MULTICENTER, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALFIMEPRASE IN SUBJECTS WITH OCCLUDED CENTRAL VENOUS ACCESS DEVICES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003282-16,0,0,0 2005-003284-22,7,2016-09-08,2016-10-26,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Randomized, Observational Study of Entecavir to Assess Long-term Outcomes Associated with Nucleoside/Nucleotide Monotherapy for Patients with Chronic HBV Infection: The REALM Study Revised Protocol 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003284-22,0,0,0 2005-003285-42,1,2006-12-13,2006-12-13,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Portsmouth Institution Medicine, Health & Social Care, Portsmouth University",A RCT to test the analgesic efficacy of topical morphine on minor and partial thickness burns in A&E,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003285-42,0,0,0 2005-003285-42,1,2006-12-13,2006-12-13,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Research & Development Unit, Queen Alexandra Hospital",A RCT to test the analgesic efficacy of topical morphine on minor and partial thickness burns in A&E,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003285-42,0,0,0 2005-003286-17,5,2006-09-21,2006-09-29,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 4-week, multicentre, randomized, double-blind, double-dummy, parallel group ambulatory blood pressure monitoring study to demonstrate that treatment with lumiracoxib 100 mg o.d. results in a 24-hour...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003286-17,0,0,0 2005-003287-28,1,,,0,0,0,0,0,3,2,0,0,4,0,0,0,0,0,Queen Silvia's Childrens hospital,Nitrous oxide for analgesia and sedation during procedural pain in children -Efficacy ina short and long perspective regarding joint injections,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003287-28,0,0,0 2005-003288-21,1,2008-12-31,2008-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Dept. of Ophthalmology, Medical University of Vienna",INTRAOCULAR BEVACIZUMAB (AVASTIN™) FOR CENTRAL AND BRANCH RETINAL VEIN OCCLUSION STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003288-21,0,0,0 2005-003290-25,2,2006-09-01,2006-09-01,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A multicenter, double-blind placebo controlled, fixed dose study with an open-label, flexible dose phase to assess the efficacy of Sildenafil Citrate in providing a better sexual experience including ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003290-25,0,0,0 2005-003290-25,2,2006-09-01,2006-09-01,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer AB,"A multicenter, double-blind placebo controlled, fixed dose study with an open-label, flexible dose phase to assess the efficacy of Sildenafil Citrate in providing a better sexual experience including ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003290-25,0,0,0 2005-003293-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""","A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF MELPHALAN, PREDNISONE, THALIDOMIDE AND DEFIBROTIDE IN ADVANCED AND REFRACTORY MULTIPLE MYELOMA PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003293-25,0,0,0 2005-003295-38,1,2009-04-30,2009-04-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Medice Arzneimittel Pütter GmbH & Co. KG,Vergleich der Wirksamkeit von Medikinet retard mit Concerta bei Kindern mit ADHS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003295-38,0,0,0 2005-003297-13,1,2007-06-01,2007-06-01,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,Imperial College,"A randomised, double-blind, placebo-controlled, parallel-group study to investigate the effect of Symbicort® and Pulmicort® on HAT and HDAC expression and activity in induced sputum cells obtained fro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003297-13,0,0,0 2005-003299-40,1,,,0,1,0,0,1,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase IIIa randomized, controlled study to assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine, when administered as a 3-dose primary immunizatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003299-40,0,0,0 2005-003300-11,1,2006-06-28,2006-06-28,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III randomised, controlled study to assess in a double blind manner the lot-to-lot consistency of three consecutive production lots of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003300-11,0,0,0 2005-003302-28,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,PLIVA Research and Development Ltd.,“MAINTENANCE PHASE STUDY” A THERAPEUTIC EQUIVALENCE STUDY COMPARING THE EFFICACY AND SAFETY OF INTRAVENOUS EPOETIN (PLIVA) AND EPOETIN ALFA (JANSSEN CILAG) IN PATIENTS WITH CHRONIC RENAL FAILURE REQU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003302-28,0,0,0 2005-003305-90,2,2014-12-31,2014-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Fred Hutchinson Cancer Research Center,A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003305-90,0,0,0 2005-003305-90,2,2014-12-31,2014-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Tübingen,A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003305-90,0,0,0 2005-003307-36,1,2010-12-31,2010-12-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Liverpool/Liverpool Women's Hospital,A randomised controlled trial of prednisolone for women with recurrent miscarriage and high levels of uNK cells in the endometrium,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003307-36,0,0,0 2005-003312-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,TB Investigation Unit of Barcelona,"Evaluation of a Moxifloxacin-Based, Isoniazid-Sparing Regimen for Tuberculosis Treatment TBTC/UITB Study 28",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003312-29,0,0,0 2005-003318-13,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,The University of Southampton,A randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003318-13,0,0,0 2005-003319-64,1,2007-12-18,2007-12-18,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A randomised, placebo-controlled, crossover study to measure the effect of alosetron on mucosal blood flow in female healthy volunteers and diarrhea-predominant IBS subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003319-64,0,0,0 2005-003321-57,1,2009-09-23,2009-09-23,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,UHL NHL Trust,Treatment protocol for relapsed anaplastic large cell lymphoma of childhood and adolescence,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003321-57,0,0,0 2005-003324-19,2,2011-08-31,2011-08-31,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Mainz,"STEP ONE –trial (Study on the Treatment of Elderly Patients with Older and Newer antiepileptic drugs) - trial: A multicentre, double-blind, randomized, phase IV clinical trial comparing the safety, t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003324-19,0,0,0 2005-003325-67,1,2008-08-08,2008-08-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Grupo para el Tratamiento de Tumores Digestivos,"Estudio aleatorizado, multicéntrico, fase III, para estudiar la eficacia y seguridad de bevacizumab solo o en combinación con capecitabina y oxaliplatino, como terapia de mantenimiento, tras tratamien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003325-67,0,0,0 2005-003327-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Martin-Luther-University,"Integration of 3D-conformal, local radiotherapy (3DCRT) to metastatic sites in a paclitaxel weekly chemotherapy regimen in oligometastatic breast cancer patients: a phase I- and randomised phase II-st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003327-39,0,0,0 2005-003331-44,1,2005-11-17,2005-11-17,1,1,0,0,1,0,4,0,1,1,0,0,1,0,1,CSL Limited,"A Randomized, Observer-Blind, Single-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of Enzira 2005/2006 compared to Mutagrip 2005/2006 in Healthy 'Adults@ aged >18 to <60 years a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003331-44,0,0,0 2005-003337-40,3,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,2,,"A multicentre, prospective, randomised phase III study conducted by the European Crohn's and Colitis Organisation (ECCO), sponsored by the Autoimmune Disease Working Party of the European Group for Bl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003337-40,0,0,0 2005-003337-40,3,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,2,European Group for Blood and Marrow Transplantation (EMBT),"A multicentre, prospective, randomised phase III study conducted by the European Crohn's and Colitis Organisation (ECCO), sponsored by the Autoimmune Disease Working Party of the European Group for Bl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003337-40,0,0,0 2005-003337-40,3,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,2,WOLFSON DIGESTIVE DISEASES CENTRE,"A multicentre, prospective, randomised phase III study conducted by the European Crohn's and Colitis Organisation (ECCO), sponsored by the Autoimmune Disease Working Party of the European Group for Bl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003337-40,0,0,0 2005-003344-62,1,2007-08-29,2007-08-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College,Effect of theophylline on histone deacetylase activity: enhancement of in-vitro glucocorticoid function in patients with COPD.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003344-62,0,0,0 2005-003347-31,1,2007-07-17,2007-07-17,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,FOURNIER Laboratories Ireland Ltd,"Assessment of insulin sensitivity in type 2 diabetics treated with metformin, fenofibrate and their combination",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003347-31,0,0,0 2005-003349-15,2,2008-07-16,2008-11-05,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Ariston Pharmaceuticals, Inc","Intranasal Hydroxocobalamin (AST-726) Treatment for Prohylaxis of Migraine: a Placebo-Controlled, Clinical Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003349-15,0,0,0 2005-003350-99,1,,,0,0,0,0,1,3,4,0,1,0,0,0,0,0,1,B. Braun Medical s.r.o.,METABOLIC EFFECT OF RINGERFUNCIN B. BRAUN IN HEALTHY VOLUNTEERS AND COMPARISON WITH IONIC SOLUTION PLASMA-LYTE BAXTER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003350-99,0,0,0 2005-003351-12,11,2012-01-24,2012-01-24,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Ltd,THE EFFECT OF EPLERENONE VERSUS PLACEBO ON CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALISATION IN SUBJECTS WITH NYHA CLASS II CHRONIC SYSTOLIC HEART FAILURE (EMPHASIS-HF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003351-12,0,0,0 2005-003351-12,11,2012-01-24,2012-01-24,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc.,THE EFFECT OF EPLERENONE VERSUS PLACEBO ON CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALISATION IN SUBJECTS WITH NYHA CLASS II CHRONIC SYSTOLIC HEART FAILURE (EMPHASIS-HF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003351-12,0,0,0 2005-003351-12,11,2012-01-24,2012-01-24,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Hellas AE,THE EFFECT OF EPLERENONE VERSUS PLACEBO ON CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALISATION IN SUBJECTS WITH NYHA CLASS II CHRONIC SYSTOLIC HEART FAILURE (EMPHASIS-HF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003351-12,0,0,0 2005-003351-12,11,2012-01-24,2012-01-24,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,THE EFFECT OF EPLERENONE VERSUS PLACEBO ON CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALISATION IN SUBJECTS WITH NYHA CLASS II CHRONIC SYSTOLIC HEART FAILURE (EMPHASIS-HF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003351-12,0,0,0 2005-003351-12,11,2012-01-24,2012-01-24,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Kft.,THE EFFECT OF EPLERENONE VERSUS PLACEBO ON CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALISATION IN SUBJECTS WITH NYHA CLASS II CHRONIC SYSTOLIC HEART FAILURE (EMPHASIS-HF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003351-12,0,0,0 2005-003351-12,11,2012-01-24,2012-01-24,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Limited,THE EFFECT OF EPLERENONE VERSUS PLACEBO ON CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALISATION IN SUBJECTS WITH NYHA CLASS II CHRONIC SYSTOLIC HEART FAILURE (EMPHASIS-HF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003351-12,0,0,0 2005-003351-12,11,2012-01-24,2012-01-24,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer AB,THE EFFECT OF EPLERENONE VERSUS PLACEBO ON CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALISATION IN SUBJECTS WITH NYHA CLASS II CHRONIC SYSTOLIC HEART FAILURE (EMPHASIS-HF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003351-12,0,0,0 2005-003351-12,11,2012-01-24,2012-01-24,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Laboratórios Pfizer, Lda",THE EFFECT OF EPLERENONE VERSUS PLACEBO ON CARDIOVASCULAR MORTALITY AND HEART FAILURE HOSPITALISATION IN SUBJECTS WITH NYHA CLASS II CHRONIC SYSTOLIC HEART FAILURE (EMPHASIS-HF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003351-12,0,0,0 2005-003354-10,2,2007-06-18,2007-06-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Affymax, Inc.","A Phase 2, Open-Label, Multi-Center Dose Escalation Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Subcutaneously Administered AF37702 Injection (HematideTM) in Anemic Cancer Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003354-10,0,0,0 2005-003355-12,1,2009-11-04,2009-11-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University hospitals of Leicester NHS Trust,A prospective randomised trial in order to determine the benefit of preoperative oral iron supplementation for patients undergoing elective colorectal cancer resection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003355-12,0,0,0 2005-003357-27,2,2008-01-01,2008-01-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Multicenter, Open-Label, Study of Alimta® (pemetrexed) plus VELCADE® (bortezomib) or Alimta Alone or VELCADE alone in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003357-27,0,0,0 2005-003357-27,2,2008-01-01,2008-01-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL NV,"A Randomized, Multicenter, Open-Label, Study of Alimta® (pemetrexed) plus VELCADE® (bortezomib) or Alimta Alone or VELCADE alone in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003357-27,0,0,0 2005-003360-26,2,2006-08-11,2006-08-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Grünenthal GmbH,"A randomized, multi-centre, double blind, parallel-group study assessing the analgesic efficacy and safety of different dosages of GRT0151Y bid compared to active comparator bid and placebo bid in sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003360-26,0,0,0 2005-003360-26,2,2006-08-11,2006-08-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios Andromaco, S.A.","A randomized, multi-centre, double blind, parallel-group study assessing the analgesic efficacy and safety of different dosages of GRT0151Y bid compared to active comparator bid and placebo bid in sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003360-26,0,0,0 2005-003367-23,3,2007-04-23,2007-04-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of YM672 in the Treatment of Painful Bladder Syndrome/Interstitial Cystitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003367-23,0,0,0 2005-003369-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,A phase II Multi-Dose Study of SGN-30 anti-CD30 mAb in Patients with Refractory or Recurrent Hodgkin s Disease or Anaplstic Large Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003369-17,0,0,0 2005-003370-15,3,2006-10-31,2006-10-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Teikoku Pharma USA, Inc.","Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Teikoku Tulobuterol Tape in Adults with Bronchial Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003370-15,0,0,0 2005-003374-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,OPOCRIN S.P.A.,"A phase 2, controlled, multi-center pilot study to evaluate the efficacy and safety of Deligoparin in subjects with retinal vein occlusion of recent onset.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003374-24,0,0,0 2005-003376-37,2,2006-08-04,2006-08-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 6-week, multicenter, randomized, double-blind, parallel-group study to evaluate the combination of valsartan/HCTZ (160/12.5 mg with forced titration to a maximum dose of 320/25 mg) compared to valsa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003376-37,0,0,0 2005-003381-41,1,2006-11-28,2006-11-28,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Pharma Stulln GmbH,"Innerhalb der Strata randomisierte, kontrollierte, für den Prüfarzt verblindete klinische Prüfung zur Untersuchung der Wirksamkeit von Keto-Stulln® UD im Vergleich zu Zaditen® ophtha sine am Auge in e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003381-41,0,0,0 2005-003382-16,3,2008-02-28,2008-03-04,3,1,0,0,0,1,0,0,0,1,0,0,1,0,0,Guy's & St Thomas's NHS Foundation Trust,Pilot randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003382-16,0,0,0 2005-003382-16,3,2008-02-28,2008-03-04,3,1,0,0,0,1,0,0,0,1,0,0,1,0,0,King's College London,Pilot randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003382-16,0,0,0 2005-003382-16,3,2008-02-28,2008-03-04,3,1,0,0,0,1,0,0,0,1,0,0,1,0,0,ISTITUTO CLINICO HUMANITAS,Pilot randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003382-16,0,0,0 2005-003383-39,1,2006-07-11,2006-07-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Roche Farma S.A.,"A randomized, open-label, multi-center study comparing a steroid sparing regimen versus standard steroid regimen in combination with daclizumab, mycophenolate mofetil and sirolimus in the prevention o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003383-39,0,0,0 2005-003387-28,1,2008-02-27,2008-02-27,1,0,0,0,1,0,4,0,0,1,1,1,1,0,1,Medice Arzneimittel Pütter GmbH & Co. KG,Multizentrische Studie zur Optimierung der Methylphenidat-Therapie bei Kindern mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003387-28,0,0,0 2005-003391-37,1,2008-03-04,2008-03-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Scil Technology GmbH,Pilot Study on Safety and explorative Efficacy of MD05 in Comparison with the Medical Device Beta-TCP Mixed with Autogenous Bone Material in Patients Undergoing Two-Stage Unilateral Maxillary Sinus Fl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003391-37,0,0,0 2005-003396-21,5,2006-09-07,2006-11-07,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"LONG-TERM MANAGEMENT OF ATOPIC DERMATITIS WITH THE EMOLLIENT V0034 CR. A RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUPS, DOUBLE-BLIND STUDY IN INFANTS AND CHILDREN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003396-21,0,0,0 2005-003396-21,5,2006-09-07,2006-11-07,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pierre Fabre Medicament,"LONG-TERM MANAGEMENT OF ATOPIC DERMATITIS WITH THE EMOLLIENT V0034 CR. A RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUPS, DOUBLE-BLIND STUDY IN INFANTS AND CHILDREN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003396-21,0,0,0 2005-003400-11,4,2008-06-24,2008-06-24,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 or Paroxetine Comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003400-11,0,0,0 2005-003400-11,4,2008-06-24,2008-06-24,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research Development Ltd,"A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 or Paroxetine Comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003400-11,0,0,0 2005-003400-11,4,2008-06-24,2008-06-24,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 or Paroxetine Comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003400-11,0,0,0 2005-003401-87,6,2008-11-28,2008-12-03,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,"A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/day to 2.0 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003401-87,0,0,0 2005-003402-29,1,2009-12-22,2009-12-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Greater Glasgow NHS Board, Yorkhill Division",Does additional vitamin A supplementation improve retinal function and conjunctival health in very low birth weight infants?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003402-29,0,0,0 2005-003403-36,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,Trattamento con Capecitabina e Gemcitabina in pazienti con carcinoma della mammella metastatico pretrattati con Taxani ed Antracicline. Studio di fase II.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003403-36,0,0,0 2005-003406-28,1,2007-07-08,2007-07-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical University, Dpt. Internal Medicin, Division of General Inteal Medicine",Pharmakokinetik von lipid-formuliertem Amphotericin B unter Albumindialyse (Pharmacokinetics of lipid-formulated amphotericin B during albumin dialysis),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003406-28,0,0,0 2005-003409-98,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Hôpital Erasme, Cliniques Universitaires de Bruxelles",Enhancement by tacrolimus of nerve regeneration after peripheral nerve repair.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003409-98,0,0,0 2005-003410-15,1,2010-12-28,2010-12-28,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,Neurology Unit,A twelve-month double-blind placebo-controlled cross-over study of the effect ofAricept treatment on cognitive dysfunction in multiple sclerosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003410-15,0,0,0 2005-003411-75,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Clínico de San Carlos,Estudio sobre la utilización de levetiracetam en monoterapia en pacientes HIV-positivos con epilepsia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003411-75,0,0,0 2005-003413-32,7,2011-07-01,2011-07-11,7,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 24-month, multi-center, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0 g MMF with sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003413-32,0,0,0 2005-003413-32,7,2011-07-01,2011-07-11,7,1,0,0,0,2,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 24-month, multi-center, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0 g MMF with sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003413-32,0,0,0 2005-003413-32,7,2011-07-01,2011-07-11,7,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Novartis Farmaceútica S.A,"A 24-month, multi-center, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0 g MMF with sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003413-32,0,0,0 2005-003414-15,3,2007-05-07,2007-06-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,Liraglutide Effect and Action in Diabetes LEAD-1 Effect on glycaemic control after once daily administration of liraglutide in combination with glimepiride versus glimepiride monotherapy versus ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003414-15,0,0,0 2005-003414-15,3,2007-05-07,2007-06-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Liraglutide Effect and Action in Diabetes LEAD-1 Effect on glycaemic control after once daily administration of liraglutide in combination with glimepiride versus glimepiride monotherapy versus ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003414-15,0,0,0 2005-003415-71,6,2007-04-16,2007-05-31,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Liraglutide Effect and Action in Diabetes (LEAD-5): Effects on glycaemic control after once daily administration of liraglutide in combination with glimepiride and metformin versus glimepiride and met...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003415-71,0,0,0 2005-003415-71,6,2007-04-16,2007-05-31,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,Liraglutide Effect and Action in Diabetes (LEAD-5): Effects on glycaemic control after once daily administration of liraglutide in combination with glimepiride and metformin versus glimepiride and met...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003415-71,0,0,0 2005-003416-30,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ROCHE,Phase II study of Dacarbazine with the anti-vascular endothelial growth factor antibody (Bevacizumab) in patients with unresectable/metastatic melanoma. Studio di fase II sull`associazione di Daca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003416-30,0,0,0 2005-003417-32,10,2008-11-11,2009-02-13,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efecto y acción de liraglutida en diabetes (LEAD-2): Efecto sobre el control glucémico tras la administración una vez al día de liraglutida en combinación con metformina frente a metformina en monoter...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003417-32,0,0,0 2005-003417-32,10,2008-11-11,2009-02-13,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,Efecto y acción de liraglutida en diabetes (LEAD-2): Efecto sobre el control glucémico tras la administración una vez al día de liraglutida en combinación con metformina frente a metformina en monoter...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003417-32,0,0,0 2005-003422-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Göteborg University,Immunological and virological effects of high dose intravenous immunoglobulin (IVIG) treatment added to antiretroviral therapy against HIV,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003422-26,0,0,0 2005-003432-22,1,2019-10-21,2019-10-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Glaxo SmithKline Research and Development Limited,"A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003432-22,0,0,0 2005-003434-18,6,2011-12-31,2011-12-31,5,1,0,0,0,0,3,0,0,1,1,0,1,0,0,International Breast Cancer Study Group (IBCSG),"Phase III Trial Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin PLD, Caelyx, Doxil for Women age 66 years or older with Endocrine Nonresponsive Breast Cancer Who Are NOT Suitable f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003434-18,0,0,0 2005-003434-18,6,2011-12-31,2011-12-31,5,1,0,0,0,0,3,0,0,1,1,0,1,0,0,IBCSG,"Phase III Trial Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin PLD, Caelyx, Doxil for Women age 66 years or older with Endocrine Nonresponsive Breast Cancer Who Are NOT Suitable f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003434-18,0,0,0 2005-003435-40,1,2007-03-28,2007-03-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Department of Health,A Randomised Controlled Trial to Investigate the effectiveness of the Healthy Sexual Functioning (HSF) Module and Selective Serotonin Reuptake Inhibitor (SSRI) Medication to treat Deviant Sexual Arous...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003435-40,0,0,0 2005-003436-21,4,2008-04-30,2008-04-30,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Dainippon Sumitomo Pharma Europe Ltd.,"A phase 2, multi-centre, randomised, double blind, placebo controlled study evaluating the efficacy, safety and pharmacokinetics of two doses of a candidate Disease Modifying Anti-Rheumatic Drug (DMAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003436-21,0,0,0 2005-003436-21,4,2008-04-30,2008-04-30,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Dainippon Sumitomo Pharma Europe Ltd,"A phase 2, multi-centre, randomised, double blind, placebo controlled study evaluating the efficacy, safety and pharmacokinetics of two doses of a candidate Disease Modifying Anti-Rheumatic Drug (DMAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003436-21,0,0,0 2005-003436-21,4,2008-04-30,2008-04-30,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Sumitomo Pharmaceuticals Europe Limited,"A phase 2, multi-centre, randomised, double blind, placebo controlled study evaluating the efficacy, safety and pharmacokinetics of two doses of a candidate Disease Modifying Anti-Rheumatic Drug (DMAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003436-21,0,0,0 2005-003437-41,3,2007-01-17,2007-01-17,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"An open, randomized, phase IIIa study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ 10-valent pneumococcal conjugate vaccine, when administered intramuscularly according to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003437-41,0,0,0 2005-003438-17,1,2008-01-31,2008-01-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Oxford Radcliffe Hospitals NHS Trust,SimSepT: Simvastatin and severe sepsis in the ICU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003438-17,0,0,0 2005-003440-66,11,2015-08-19,2015-08-19,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003440-66,0,0,0 2005-003440-66,11,2015-08-19,2015-08-19,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003440-66,0,0,0 2005-003441-13,1,2008-09-03,2008-09-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Two-part, Open-label, Multi-centre, Phase II Study in Patients with Advanced Solid Tumours, Consisting of a Randomised 2-period Crossover Protocol to Determine the Effect of Food upon the Pharmacoki...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003441-13,0,0,0 2005-003442-33,2,2011-04-26,2011-04-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Randomised, Factorial, Double-blind Study to Investigate the Management of AZD2171-induced Hypertension and Efficacy of AZD2171 at Doses of 30 mg and 45 mg in Patients with Advanced Solid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003442-33,0,0,0 2005-003443-31,7,2009-10-01,2009-10-30,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Double-blind, Randomized Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003443-31,0,0,0 2005-003444-53,1,2007-10-23,2007-10-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomised, open label, multicenter study comparing the efficacy and safety of medical treatment with Sandostatin LAR 30 mg administered every 21 days for 6 months with that of Sandostatin LAR 60 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003444-53,0,0,0 2005-003449-15,1,2009-03-20,2009-03-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme Europe B.V.,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ISIS 301012 as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003449-15,0,0,0 2005-003450-10,1,2009-12-17,2009-12-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme Europe B.V.,An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 301012 in Patients with Familial Hypercholesterolemia or Severe Hypercholesterolemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003450-10,0,0,0 2005-003458-81,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SENESE,A randomized phase III trial on first line metastatic colorectal carcinoma GOLFIG gemcitabine FOLFOX-4 GM-CSF and interleukin 2 chemo-immunotherapy vs standard FOLFOX-4 chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003458-81,0,0,0 2005-003459-12,8,2012-09-26,2013-03-14,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,CSL Behring GmbH,"A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to compare the Efficacy and Safety of 60 mg/kg body weight of Zemaira® weekly i.v. administration with Placebo weekly i.v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003459-12,0,0,0 2005-003460-35,1,2006-07-13,2006-07-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"ALK-Abelló, S.A.",Evaluación de los cambios inmunológicos tras la inmunoterapia subcutánea con un extracto de Phleum pratense,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003460-35,0,0,0 2005-003463-23,8,2016-10-15,2016-10-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Fédération Francophone de Cancérologie Digestive (FFCD),ADJUVANT TREATMENT OF FULLY RESECTED STAGE III COLON CANCER WITH FOLFOX-4 VERSUS FOLFOX-4 PLUS CETUXIMAB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003463-23,0,0,0 2005-003463-23,8,2016-10-15,2016-10-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,0,FFCD,ADJUVANT TREATMENT OF FULLY RESECTED STAGE III COLON CANCER WITH FOLFOX-4 VERSUS FOLFOX-4 PLUS CETUXIMAB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003463-23,0,0,0 2005-003464-30,1,2009-04-20,2009-04-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Queen Mary, University of London",Double blind randomised cross-over trial to assess the value of screening an adult population for hypothyroidism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003464-30,0,0,0 2005-003469-18,5,2007-03-13,2007-03-13,3,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Toray Industries, Inc.","A randomised, double-blind, placebo-controlled study of TRK-820 in haemodyalisis patients with uremic pruritus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003469-18,1,0,0 2005-003469-18,5,2007-03-13,2007-03-13,3,0,0,0,0,1,3,0,0,2,0,0,0,0,1,TORAY,"A randomised, double-blind, placebo-controlled study of TRK-820 in haemodyalisis patients with uremic pruritus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003469-18,1,0,0 2005-003471-20,2,2009-06-18,2009-06-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SIGMA-TAU,"Phase II, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter Study to investigate the efficacy of Two Dosages of Propionyl-L-carnitine ST 261 Colon Release Tablets in Patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003471-20,0,0,0 2005-003475-20,2,2008-02-25,2008-02-25,2,0,0,0,0,0,3,0,0,1,1,1,1,0,1,"Solvay Pharmaceuticals, Inc","A Randomized, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects with Psychosis and Behavioural Disturbances Associated with D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003475-20,0,0,0 2005-003479-19,1,2016-04-02,2016-04-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,A Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt's Lymphoma (BL) of Internation...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003479-19,0,0,0 2005-003481-42,8,2007-08-28,2007-08-28,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"PDL BioPharma, Inc.","A Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003481-42,1,0,0 2005-003481-42,8,2007-08-28,2007-08-28,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"PDL BioPharma, Inc","A Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003481-42,1,0,0 2005-003481-42,8,2007-08-28,2007-08-28,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"Protein Design Labs, Inc","A Randomized, Double-blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003481-42,1,0,0 2005-003482-17,5,,,0,0,0,0,0,2,2,0,0,2,1,0,0,0,1,"PDL BioPharma, Inc.","A Phase 2, Randomized, Double-Blind, Multicenter, Dose-Exploration Study of Visilizumab in Subjects with Intraveneous Steroid-Refractory Ulcerative Colitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003482-17,0,0,0 2005-003482-17,5,,,0,0,0,0,0,2,2,0,0,2,1,0,0,0,1,"PDL BioPharma , Inc.","A Phase 2, Randomized, Double-Blind, Multicenter, Dose-Exploration Study of Visilizumab in Subjects with Intraveneous Steroid-Refractory Ulcerative Colitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003482-17,0,0,0 2005-003483-31,1,2007-02-01,2007-02-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AXCAN PHARMA Inc.,Eficacia y tolerabilidad preliminar del NCX-1000 oral después de repetidas administraciones a pacientes con hipertensión portal. Estudio a doble ciego con dosis creciente,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003483-31,0,0,0 2005-003484-23,1,2019-03-20,2019-03-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Universitätsklinikum Erlangen, Strahlenklinik insoweit handelnd für den Freistaat Bayern",Randomised phase-III-trial of simultaneous radiochemotherapy (RCT) of locally advanced head and neck cancer in the stages III and IV A-B: Comparing dose reduced RCT (63.6 Gy) with Paclitaxel/Cisplatin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003484-23,0,0,0 2005-003485-42,6,2007-08-14,2007-08-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA Pharma AG,Treatment response in patients with symptoms due to gastroesophageal reflux disease either with or without esophagitis treated with pantoprazole sodium 40 mg o.d. over 8 weeks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003485-42,0,0,0 2005-003485-42,6,2007-08-14,2007-08-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nycomed GmbH,Treatment response in patients with symptoms due to gastroesophageal reflux disease either with or without esophagitis treated with pantoprazole sodium 40 mg o.d. over 8 weeks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003485-42,0,0,0 2005-003488-22,1,2007-05-31,2007-05-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Charité CBF, Endokrinologie",Regulation des Antidiuretisches Hormons (ADH) und der antidiuretischen Wirkung unter Glucocorticoid - Therapie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003488-22,0,0,0 2005-003492-20,1,2014-03-17,2014-03-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Leeds,A randomised clinical trial of treatment for fluorouracil-resistant advanced colorectal cancer comparing standard single-agent irinotecan versus irinotecan plus panitumumab and versus irinotecan plus ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003492-20,0,0,0 2005-003493-19,3,2015-07-28,2015-09-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"An exploratory phase II, single arm, multicenter study to evaluate the efficacy and safety of the combination of pertuzumab and Herceptin (trastuzumab) in patients with HER2-positive metastatic breast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003493-19,0,0,0 2005-003493-19,3,2015-07-28,2015-09-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche Ltd,"An exploratory phase II, single arm, multicenter study to evaluate the efficacy and safety of the combination of pertuzumab and Herceptin (trastuzumab) in patients with HER2-positive metastatic breast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003493-19,0,0,0 2005-003494-25,4,2008-05-20,2008-05-20,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic after 3 months), vs. myfortic plus tacrolimus i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003494-25,0,0,0 2005-003494-25,4,2008-05-20,2008-05-20,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic after 3 months), vs. myfortic plus tacrolimus i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003494-25,0,0,0 2005-003494-25,4,2008-05-20,2008-05-20,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmaceútica S.A,"12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic after 3 months), vs. myfortic plus tacrolimus i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003494-25,0,0,0 2005-003495-38,6,2007-07-02,2007-11-23,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of 5 dose regimens of RO4402257 in patients with active rheumatoid arthritis (RA) on stable methotrexate (MTX)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003495-38,0,0,0 2005-003496-20,1,2010-11-15,2010-11-15,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Oxford Radcliffe Hospitals NHS trust,"The effect of pre-operative Octreotide LAR treatment on surgical cure rates of subjects with Acromegaly, and post-operative responsiveness to somatostatin analogue treatment in patients not cured surg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003496-20,0,0,0 2005-003501-90,1,2007-07-11,2007-07-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 as Second- or Later-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003501-90,0,0,0 2005-003504-11,4,2007-10-26,2008-02-19,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Hellas AE,"A six-month, open-label outpatient, parallel group trial assessing the impact of inhaled insulin (Exubera®) on glycemic control in patients with type 2 diabetes mellitus who are poorly controlled on t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003504-11,0,0,0 2005-003504-11,4,2007-10-26,2008-02-19,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer, Inc.","A six-month, open-label outpatient, parallel group trial assessing the impact of inhaled insulin (Exubera®) on glycemic control in patients with type 2 diabetes mellitus who are poorly controlled on t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003504-11,0,0,0 2005-003504-11,4,2007-10-26,2008-02-19,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer AB,"A six-month, open-label outpatient, parallel group trial assessing the impact of inhaled insulin (Exubera®) on glycemic control in patients with type 2 diabetes mellitus who are poorly controlled on t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003504-11,0,0,0 2005-003504-11,4,2007-10-26,2008-02-19,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"PFIZER,S.A.","A six-month, open-label outpatient, parallel group trial assessing the impact of inhaled insulin (Exubera®) on glycemic control in patients with type 2 diabetes mellitus who are poorly controlled on t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003504-11,0,0,0 2005-003505-85,1,2006-02-28,2006-02-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Dermal Laboratories Limited,4head User Evaluation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003505-85,0,0,0 2005-003508-12,3,2006-11-30,2007-06-14,2,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Merck Sharp & Dohme BV,Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003508-12,0,0,0 2005-003508-12,3,2006-11-30,2007-06-14,2,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Merck Sharp & Dohme GesmbH,Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003508-12,0,0,0 2005-003508-12,3,2006-11-30,2007-06-14,2,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"Merck and Co., Inc.",Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003508-12,0,0,0 2005-003510-15,6,2008-07-14,2008-07-14,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"A randomised, double-blind, double-dummy, parallel-group multicenter study to demonstrate improvement in symptoms of constipation in subjects with non-malignant pain taking oxycodone equivalent of 60 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003510-15,0,0,0 2005-003511-75,5,2007-12-18,2007-12-18,4,1,0,0,0,0,4,0,0,2,0,0,0,0,1,Sankyo Pharma Development (SPhD),"Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Colesevelam HCl Administered to Pediatric Patients with Heterozygous Familial Hypercholesterolemia on a Stable Dose of Statins...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003511-75,1,0,0 2005-003511-75,5,2007-12-18,2007-12-18,4,1,0,0,0,0,4,0,0,2,0,0,0,0,1,Daiichi Sankyo Pharma Development,"Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Colesevelam HCl Administered to Pediatric Patients with Heterozygous Familial Hypercholesterolemia on a Stable Dose of Statins...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003511-75,1,0,0 2005-003512-30,2,2009-04-30,2009-05-27,2,1,0,0,0,1,4,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc,"A Phase 4 Multi-center, Multi-national, Open-label, Randomized, Two Dose Level Study of Naglazyme (galsulfase) in Infants with Maroteaux-Lamy Syndrome (MPS VI)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003512-30,0,0,0 2005-003512-30,2,2009-04-30,2009-05-27,2,1,0,0,0,1,4,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc.,"A Phase 4 Multi-center, Multi-national, Open-label, Randomized, Two Dose Level Study of Naglazyme (galsulfase) in Infants with Maroteaux-Lamy Syndrome (MPS VI)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003512-30,0,0,0 2005-003513-32,1,2006-03-31,2006-03-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,South Tees Hospitals NHS Trust,A Randomised controlled trial to compare the efficacy of two types of local anaesthetic blocks in carpal tunnel decompression surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003513-32,0,0,0 2005-003514-15,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,BRACCO,CLINICAL EVALUATION OF EFFICACY AND TOLERABILITY OF ANTROLIN RETTAL CREME IN THE TREATMENT OF POSTHEMORROIDECTOMY PAIN. DUOBLE BLIND STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003514-15,0,0,0 2005-003516-29,1,2010-04-11,2010-04-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Universität zu Köln,"Prospective, randomized, double-blinded clinical trial on remifentanil for analgesia and sedation of ventilated neonates and infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003516-29,0,0,0 2005-003517-33,12,2008-01-09,2008-03-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Service AG,"A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety of ranibizumab (0.3 mg and 0.5 mg) administered as two dosing regimens in patients with subfoveal ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003517-33,0,0,0 2005-003517-33,12,2008-01-09,2008-03-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety of ranibizumab (0.3 mg and 0.5 mg) administered as two dosing regimens in patients with subfoveal ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003517-33,0,0,0 2005-003517-33,12,2008-01-09,2008-03-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety of ranibizumab (0.3 mg and 0.5 mg) administered as two dosing regimens in patients with subfoveal ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003517-33,0,0,0 2005-003517-33,12,2008-01-09,2008-03-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety of ranibizumab (0.3 mg and 0.5 mg) administered as two dosing regimens in patients with subfoveal ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003517-33,0,0,0 2005-003518-14,3,2007-07-20,2007-07-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Skyepharma AG,Long-term Open-label Safety Study with SKP Flutiform HFA pMDI (100/10μg and 250/10μg) in Adult and Adolescent Patients with Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003518-14,0,0,0 2005-003520-18,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,ISTITUTO C. MONDINO,"Multicenter, double-blind placebo controlled study of levetiracetam in the treatment of childhood and juvenile absence epilepsy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003520-18,0,0,0 2005-003521-13,4,2008-03-20,2008-04-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Aventis Pharmaceuticals Inc.,"Double-blind, randomized, parallel-group, dose ranging, multi-center study to evaluate the efficacy and safety of 2.5, 10, 35 and 50 mg AVE7688 once daily, using 100 mg losartan-potassium once daily a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003521-13,0,0,0 2005-003521-13,4,2008-03-20,2008-04-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Aventis Pharma Recherche De ve loppement,"Double-blind, randomized, parallel-group, dose ranging, multi-center study to evaluate the efficacy and safety of 2.5, 10, 35 and 50 mg AVE7688 once daily, using 100 mg losartan-potassium once daily a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003521-13,0,0,0 2005-003522-26,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,ISTITUTO C. MONDINO,"Open label, multicenter study of levetiracetam in the treatment of childhood and juvenile absence epilepsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003522-26,0,0,0 2005-003525-92,2,2007-12-20,2007-12-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Centocor B.V.,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo controlled Trial of CNTO 1275, a Fully Human Anti IL 12 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Ar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003525-92,0,0,0 2005-003526-25,1,,,0,1,0,0,1,3,3,0,1,1,0,0,0,1,1,Intercell AG,"Safety and immunogenicity of concomitant vaccination with IC51 and Havrix 1440 in healthy subjects. A single-blind randomised, controlled phase 3 study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003526-25,0,0,0 2005-003530-17,3,2011-10-07,2011-10-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Centocor B.V.,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003530-17,0,0,0 2005-003530-17,3,2011-10-07,2011-10-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Biologics B.V.,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003530-17,0,0,0 2005-003537-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,TRICHOLOG GmbH,"Efficacy of the treatment with VANIQA 11,5% creme in patients suffering from hirsutism of the upper lip",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003537-41,0,0,0 2005-003542-33,1,2011-09-13,2011-09-13,1,0,0,0,0,0,4,0,0,1,1,1,1,0,1,B Braun Medical S.A.,"Estudio prospectivo, multicéntrico, aleatorizado, comparativo, doble ciego, para evaluar dos emulsiones lipídicas diferentes en la nutrición parenteral total del enfermo crítico y su influencia en la ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003542-33,0,0,0 2005-003549-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NeuroBiotec GmbH,"Transdermal Lisuride: A double-blind, randomized, active- and placebo-controlled multi-centre phase III efficacy trial for the treatment of patients with Restless Legs Syndrome (RLS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003549-16,0,0,0 2005-003552-35,4,2008-09-15,2008-09-15,4,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Octapharma AG,Clinical study to evaluate the efficacity and safety of octagam®10% in idiopathic thrombocytopenic purpura in adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003552-35,0,0,0 2005-003553-27,1,2008-12-15,2008-12-15,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,DIMETHAID AG,"A SINGLE CENTRE, OPEN LABEL, PHASE II CLINICAL STUDY OF THE ADJUNCTIVE BENEFIT OF WF10 TO STANDARD CAPECITABINE CHEMOTHERAPY IN SUBJECTS WITH UNRESECTABLE PANCREATIC CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003553-27,0,0,0 2005-003555-13,1,2007-08-01,2007-08-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,photonamic GmbH & Co. KG,PD P 506 A or its placebo in combination with red light for photodynamic therapy of mild to moderate actinic keratosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003555-13,0,0,0 2005-003556-36,1,2007-05-31,2007-05-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,photonamic GmbH & Co. KG,Photodynamic Therapy with PD P 506 A or its placebo compared with cryosurgery for the treatment of mild to moderate actinic keratosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003556-36,0,0,0 2005-003557-27,1,2013-08-29,2013-08-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Dean of the Medical Faculty (University of Bonn),Covered Transjugular Intrahepatic Portosystemic Stent Shunt versus Optimized medical Treatment for the Secondary Prevention of Variceal Bleeding in Cirrhosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003557-27,0,0,0 2005-003558-83,12,2007-10-15,2008-02-06,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003558-83,0,0,0 2005-003558-83,12,2007-10-15,2008-02-06,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AMGEN S.P.A.,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous AMG 108 in Subjects with Rheumatoid Arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003558-83,0,0,0 2005-003561-16,11,2007-02-01,2021-03-01,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Europe R&D Centre Ltd,"A Pivotal, Multicentre, Multinational, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Severe Sepsis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003561-16,0,0,0 2005-003561-16,11,2007-02-01,2021-03-01,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Takeda Global R&D Centre (Europe) Ltd.,","A Pivotal, Multicentre, Multinational, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Severe Sepsis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003561-16,0,0,0 2005-003561-16,11,2007-02-01,2021-03-01,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,TAKEDA EUROPE RESEARCH DEVELOPMENT CENTRE LTD,"A Pivotal, Multicentre, Multinational, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Severe Sepsis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003561-16,0,0,0 2005-003562-42,1,2009-08-25,2009-08-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Queen Mary, University of London",Trial of Adjunctive Vitamin D in Tuberculosis Treatment (AdjuVIT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003562-42,0,0,0 2005-003570-22,1,2007-03-29,2007-03-29,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Health Protection Agency,"A PHASE II, OPEN LABEL, RANDOMISED, SINGLE CENTRE STUDY TO EVALUATE THE SAFETY, REACTOGENICITY AND IMMUNOGENICITY OF THREE OR FOUR DOSES OF MENINGOCOCCAL SEROGROUP B OUTER MEMBRANE VESICLE (OMV) VACCI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003570-22,0,0,0 2005-003572-38,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Plethora Solutions Limited,"A PHASE II, MULTI-CENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-WAY CROSS-OVER STUDY TO EVALUATE EFFICACY, PLASMA CONCENTRATIONS AND SAFETY OF 0.25ML OF 20%W/W PSD503 FOR TOPICAL APPLICATION IN FEMALE V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003572-38,0,0,0 2005-003577-24,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,remifentanil in continuos infusion as a labour analgesic,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003577-24,0,0,0 2005-003578-55,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,remifentanil and neuroendocrin effect in stress by cesarean section,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003578-55,0,0,0 2005-003581-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amtssygehuset i Roskilde,Randomiseret undersøgelse af sutureringsteknikkens betydning for myometriets tykkelse efter sectio bedømt ved ultralyd post partum.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003581-42,0,0,0 2005-003582-16,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,"Dose-dense treatment with gemcitabine, epirubicin and paclitaxel GET combination in advanced breast cancer a phase II parallel study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003582-16,0,0,0 2005-003583-31,1,2010-06-09,2010-06-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Berlin-Chemie AG,"NEBIVOLOL OR METOPROLOL IN ARTERIAL OCCLUSIVE DISEASE A DOUBLE-BLIND, RANDOMISED CLINICAL Deutscher Titel: Nebivolol im Vergleich zu Metoprolol bei peripherer arterieller Verschlusskrankheit Eine ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003583-31,0,0,0 2005-003587-34,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,MolMed,"A phase I-II study: infusion of donor lymphocytes transduced with the suicide gene HSV TK, after transplantation of allogeneic T-depleted stem cells from a haploidentical donor in patients with haemat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003587-34,0,0,0 2005-003588-22,1,2006-02-24,2006-02-24,1,0,0,0,1,0,4,0,0,1,0,0,1,0,1,Boots Healthcare International Limited,"A single centre, randomised, single (patient) blind, single dose, parallel group exploratory study to compare the efficacy of an 8.75mg flurbiprofen lozenge (Strefen) with a 3mg benzydamine lozenge (D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003588-22,0,0,0 2005-003590-24,6,2006-03-24,2007-09-27,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, de determinación de dosis óptima de SB-480848, un inhibidor de la fosfolipasa A2 asociada a lipoproteínas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003590-24,0,0,0 2005-003590-24,6,2006-03-24,2007-09-27,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.","Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, de determinación de dosis óptima de SB-480848, un inhibidor de la fosfolipasa A2 asociada a lipoproteínas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003590-24,0,0,0 2005-003591-38,3,2006-07-31,2006-08-30,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AstraZeneca AB,"A phase II, double-blind, placebo controlled, randomised study to assess the efficacy and safety of ZD6474 in combination with Arimidex vs. Arimidex alone in patients with hormone sensitive (ER+ve and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003591-38,0,0,0 2005-003592-20,3,2007-07-13,2009-01-02,3,1,0,0,0,3,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A phase II, double-blind, placebo controlled, randomised study to assess the efficacy and safety of ZD6474 in combination with docetaxel (Taxotere) vs docetaxel alone as 2nd line treatment for advance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003592-20,0,0,0 2005-003593-16,3,2007-08-10,2008-09-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A phase II, double-blind, placebo-controleed, randomised study to assess the efficacy and safety of docetaxel (Taxotere)/ prednisolone/ ZD6474 vs. docetaxel/ prednisolone/ placebo in patients with hor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003593-16,0,0,0 2005-003595-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dept of Anaesthesiology 530,Optimeret multimodal analgesi ved abdominal hysterectomi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003595-38,0,0,0 2005-003599-39,1,2008-01-08,2008-01-08,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,AnorMED Corp.,"A randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (240 mcg/kg) plus G-CSF (10 mcg/kg) versus G-CSF (10 mcg/kg) plus placebo to mobilize and collect greater than or equal to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003599-39,0,0,0 2005-003601-93,1,2008-09-03,2008-09-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Asklepios Krankenhaus Weißenfels,Neoadjuvante Chemotherapie mit 3x Epirubicin / Docetaxel gefolgt von 3x Carboplatin / Docetaxel beim primären Mammakarzinom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003601-93,0,0,0 2005-003605-82,1,2007-06-01,2007-06-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, open-label, multicentric parallel group study to assess the impact of supportive measures on the drug adherence of patients with essential hypertension treated with Valsartan or Valsarta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003605-82,0,0,0 2005-003606-28,1,2007-06-18,2007-06-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 12 week treatment, open-label, multicenter study to investigate the efficacy and safety of valsartan 160-320 mg with regard to effects on lipid subfractions in hypertensive patients with metabolic s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003606-28,0,0,0 2005-003608-13,1,2008-08-12,2008-08-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Plymouth Hospitals NHS Trust,A Prospective Double-blind Placebo Controlled Randomised Trial of Intravenous Iron Supplementation in Patients Undergoing Colorectal Cancer Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003608-13,0,0,0 2005-003609-96,1,2009-06-10,2009-06-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical University, Dpt. Internal Medicin, Division of General Internal Medicine",Amphotericin B Spiegel in bronchoalveolären Lavagen (Epithelial Lining Fluid) unter Behandlung mit lipidformuliertem Amphotericin B (Amphotericin B levels in broncho-alveolar lavage [epithelial lining...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003609-96,0,0,0 2005-003610-15,3,2009-07-08,2010-04-12,2,1,0,0,0,2,0,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust,"An International, randomised, open trial comapring a rituximab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of 'generalised' ANCA associated vasculitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003610-15,0,0,0 2005-003610-15,3,2009-07-08,2010-04-12,2,1,0,0,0,2,0,0,0,1,0,0,1,0,0,"Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust","An International, randomised, open trial comapring a rituximab based regimen with a standard cyclophosphamide/azathioprine regimen in the treatment of 'generalised' ANCA associated vasculitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003610-15,0,0,0 2005-003612-30,1,2008-03-04,2008-03-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Barts and the London NHS Trust,A comparison of Helium-oxygen mixture (Heliox) with an oxygen-air mixture in reducing the work of breathing during weaning from mechanical ventilation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003612-30,0,0,0 2005-003615-70,1,2006-05-18,2006-05-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,Does vitamin D improve markers of vascular health in type 2 diabetes?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003615-70,0,0,0 2005-003617-33,1,2006-12-31,2006-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Charité,A Randomised Cross-Over Study to Explore the Pathophysiological Mechanisms Involved in the Treatment of Actinic Keratoses with Solaraze,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003617-33,0,0,0 2005-003625-46,4,2012-12-01,2013-01-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Italchimici S.p.A.,"EFFICACY OF ORAL SODIUM CROMOGLICATE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: A MULTI-CENTRE, RANDOMIZED, GROUP COMPARATIVE, DOUBLE -BLIND, PLACEBO CONTROLLED STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003625-46,0,0,0 2005-003625-46,4,2012-12-01,2013-01-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ITALCHIMICI SPA,"EFFICACY OF ORAL SODIUM CROMOGLICATE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: A MULTI-CENTRE, RANDOMIZED, GROUP COMPARATIVE, DOUBLE -BLIND, PLACEBO CONTROLLED STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003625-46,0,0,0 2005-003626-26,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Takeda Europe R&D Centre Ltd,"A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous fami...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003626-26,0,0,0 2005-003628-20,1,2009-09-12,2009-09-12,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,West Yorkshire Primary Care R&D Unit,The Shoulder Window of Opportunity Study (SWOP) - A pragmatic randomised trial comparing corticosteroid injection with timely physiotherapy with physiotherapy alone for older subjects with subacromial...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003628-20,0,0,0 2005-003630-18,4,2007-04-10,2007-09-07,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Arpida AG,"Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Intravenous Linezolid in Complicated Skin and Skin Structure Infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003630-18,0,0,0 2005-003632-22,1,2012-05-10,2012-05-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"An open-label, exploratory study of the pharmacokinetic and pharmacodynamic activity of rituximab in combination with methotrexate (MTX) in synovial tissue and in peripheral blood of patients with act...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003632-22,0,0,0 2005-003635-46,1,2008-09-10,2008-09-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"NHS Lothian University, Research & Development",Do Anti-Oxidants Modulate the Outcome of Fractures? The Effect of Vitamin C on Functional Outcome Following Fracture of Distal Radius: A Prospective randomised controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003635-46,0,0,0 2005-003637-41,1,2009-07-16,2009-07-16,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,Biopure Corporation,"A Phase II, Multi-Center, Single-Blinded, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Hemoglobin-Based Oxygen Carrier-201 (HBOC-201, hemoglobin-glutamer-250 (bovine)]) on Wound...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003637-41,0,0,0 2005-003639-30,1,2009-07-16,2009-07-16,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,Biopure Corporation,Enhancement of Tissue Preservation During Cardiopulmonary Bypass with HemoPure®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003639-30,0,0,0 2005-003644-59,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,University of Heidelberg,A two months study of the utility of Elidel cream 1% (pimecrolimus) in the long term management of atopic hand eczema.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003644-59,0,0,0 2005-003646-34,1,2008-04-10,2008-04-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Klaipeda hospital,COX-2 alteration in advanced colon cancer treated with capecitabine versus 5-fluorouracil and calcium folinate (Mayo regimen) combination,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003646-34,0,0,0 2005-003648-70,1,2011-10-04,2011-10-04,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Charité Universitätsmedizin Berlin,"Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003648-70,0,0,0 2005-003651-12,1,2007-08-14,2007-08-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ZAMBON, S.A.",NAC EFFECT ON OXIDATIVE STRESS AND MUSCLE FUNCTION IN COPD PATIENTS. Efecto de NAC en estrés oxidativo y función muscular en pacientes con EPOC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003651-12,0,0,0 2005-003652-35,1,2006-06-01,2006-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Barnsley Hospital NHS Foundation Trust,"A randomised, double blind, placebo controlled study to assess the effect of testosterone treatment on arterial stiffness in patients with type 2 diabetes, peripheral vascular disease and hypogonadism...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003652-35,0,0,0 2005-003656-35,5,2007-07-24,2009-10-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Limited,"A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer, previously treated with anthracycline, taxane, and capecitabine therapy, refractory to th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003656-35,0,0,0 2005-003660-38,1,2006-11-30,2006-11-30,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Medizinische Universitätsklinik,Effects of urapidil and doxazosin on heart rate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003660-38,0,0,0 2005-003662-41,6,2010-01-29,2010-04-06,4,0,0,0,0,0,3,0,0,2,1,0,0,0,1,MediWound Ltd,Enzymatic Debridement in Burns Patients (Children & Adults): A Comparison to Standard of Care (Protocol MW 2004-11-02),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003662-41,1,0,0 2005-003662-41,6,2010-01-29,2010-04-06,4,0,0,0,0,0,3,0,0,2,1,0,0,0,1,MEDIWOUND,Enzymatic Debridement in Burns Patients (Children & Adults): A Comparison to Standard of Care (Protocol MW 2004-11-02),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003662-41,1,0,0 2005-003666-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Castellano-Leonesa de Cardiología (FUCALEC),"ENSAYO CLÍNICO DE FASE IV / III, DOBLE CIEGO, ALEATORIZADO, PROSPECTIVO, PARA EVALUAR LA EFICACIA DE FLUVASTATINA SOBRE LOS MARCADORES INFLAMATORIOS EN LA PROGRESIÓN HEMODINÁMICA DE LA ESTENOSIS AÓRTI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003666-42,0,0,0 2005-003669-18,1,2008-01-03,2008-01-03,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Seven Seas Limited,Efficacy an tolerability of a combinatzion of glucosamine sulphate and the tw omega-3 unsaturated fatty acids EPA and DHA in comparison to glucosamine sulphate in patients with ostearthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003669-18,0,0,0 2005-003670-26,1,2009-12-02,2009-12-02,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A phase IA/II, two-arm, multi-center, open-label, dose-escalation study of LBH589 administered orally via different dosing schedules in adult patients with advanced hematological malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003670-26,0,0,0 2005-003674-14,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Mª Consuelo del Cañizo Fernández-Roldán,Ensayo clínico en fase I/II de tratamiento de EICH refractaria mediante la infusión de células mesenquimales alogénicas expandidas in vitro / A Phase I/II clinical trial for the treatment of refractor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003674-14,0,0,0 2005-003676-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,CAPECITABINE TIME TABLE AND RADIOTHERAPY AS ADJUVANT THERAPY IN RECTAL CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003676-38,0,0,0 2005-003680-22,3,2009-12-02,2009-12-04,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Algeta ASA,"A double blind, randomised, dose finding, repeat dose, phase II, multicentre study of Alpharadin TM for the treatment of patients with hormone refractory prostate cancer and skeletal metastases.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003680-22,0,0,0 2005-003681-42,1,2007-07-05,2007-07-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cardiff University,The effects of Acacia (sen) SUPERGUM (Gum Arabic) on renal physiology and arterial function in type II diabetic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003681-42,0,0,0 2005-003687-37,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,University College London,"HiLo: Multicentre randomised phase III clinical trial of high versus low dose radioiodine, with or without recombinant human thyroid stimulating hormone (rhTSH), for remnant ablation following surgery...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003687-37,0,0,0 2005-003693-14,1,2006-05-12,2006-05-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi farmaceutici S.p.A.,"In-vivo deposition of formoterol after inhalation of a single dose of Formoterol HFA- MDI (Chiesi), and Foradil P inhalation powder (Novartis) in COPD patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003693-14,0,0,0 2005-003694-25,3,2007-06-21,2007-06-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, double-blind, double-dummy, parallel group study to determine the efficacy and safety of RO4402257 monotherapy in comparison to methotrexate monotherapy in patients with active rheumatoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003694-25,0,0,0 2005-003694-25,3,2007-06-21,2007-06-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"A randomized, double-blind, double-dummy, parallel group study to determine the efficacy and safety of RO4402257 monotherapy in comparison to methotrexate monotherapy in patients with active rheumatoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003694-25,0,0,0 2005-003696-20,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Donau-universität Krems,"""TCM- Phythotherapie bei Osteoarthrose von Knie und Hüfte"" (TCM-Phythotherapy in the Osteoarthrosis of the knee and hip)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003696-20,0,0,0 2005-003697-25,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Institut de Recerca del Hospital de la Santa Creu i Sant Pau,Ensayo clínico de Fase II para la evaluación del tratamiento secuencial de Interleukina 2 e Interferón alfa subcutáneo seguido de Sorafenib (BAY 43-9006) en pacientes con carcinoma de células renales ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003697-25,0,0,0 2005-003700-10,16,2010-03-10,2011-03-30,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack. The PERFORM Study. An internat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003700-10,0,0,0 2005-003700-10,16,2010-03-10,2011-03-30,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Laboratorios Servier S.L.,Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack. The PERFORM Study. An internat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003700-10,0,0,0 2005-003700-10,16,2010-03-10,2011-03-30,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack. The PERFORM Study. An internat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003700-10,0,0,0 2005-003700-10,16,2010-03-10,2011-03-30,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Servier Research and Development Ltd,Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack. The PERFORM Study. An internat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003700-10,0,0,0 2005-003701-91,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,ONCE WEEKLY DOSING OF DARBEPOETIN ALPHA AS PROPHYLACTIC TREATMENT FOR ANEMIA IN ELDERLY CANCER PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003701-91,0,0,0 2005-003703-36,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,OSPEDALE FATEBENEFRATELLI E OFTALMICO DI MILANO,Open clinical study on the efficacy and tolerability of buprenorfina tds transtec as first line opioid W.H.O. ladder s 3rd step for the medium-long term pain treatment in patients with solid advan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003703-36,0,0,0 2005-003707-37,2,,,0,0,0,0,0,1,3,0,0,1,1,0,0,1,1,"PDL BioPharma, Inc","A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003707-37,0,0,0 2005-003710-14,1,2006-06-22,2006-06-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Nottingham,A randomised controlled study of the effect of dietary sodium modification on asthma control,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003710-14,0,0,0 2005-003713-32,4,2006-07-10,2006-09-01,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Ltd,"A phase II, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of UK-500,001 Dry Powder for Inhalation (DPI) in adults with moderate to severe Chron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003713-32,0,0,0 2005-003713-32,4,2006-07-10,2006-09-01,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Kft.,"A phase II, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of UK-500,001 Dry Powder for Inhalation (DPI) in adults with moderate to severe Chron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003713-32,0,0,0 2005-003713-32,4,2006-07-10,2006-09-01,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer SA,"A phase II, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of UK-500,001 Dry Powder for Inhalation (DPI) in adults with moderate to severe Chron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003713-32,0,0,0 2005-003714-15,1,2012-06-01,2012-06-01,1,1,0,0,1,0,3,0,1,1,0,0,1,0,0,"Charite CBF, Endokrinologie",Mechanismen der Glukagon-induzierten Stimulation des Wachstumshormons; die Rolle des Glukagons in der Ghrelin-Regulation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003714-15,0,0,0 2005-003717-33,1,2007-03-08,2007-03-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHERING-PLOUGH,"Open-Label, limited access protocol of Posaconazole in invasive fungal infections.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003717-33,0,0,0 2005-003718-14,1,2010-08-06,2010-08-06,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Lilly S.A.,Estudio fase I/II de quimioterapia con la combinación de Pemetrexed y Cisplatino concomitante con radioterapia seguida de quimioterapia de consolidación con Pemetrexed en pacientes con cáncer de pulmó...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003718-14,0,0,0 2005-003722-26,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,Barts and the London NHS Trust,"A prospective, single centre, randomised, double-blind, placebo controlled trial to assess the analgesic effects of one week treatment with anti-TNF in patients with lower back and leg pain.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003722-26,0,0,0 2005-003723-39,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"A phase 3, prospective, randomized clinical study with Velcade-Thalidomide- Dexamethasone versus Thalidomide-Dexamethasone for previously untreated patients with symptomatic multiple myeloma who are...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003723-39,0,0,0 2005-003724-19,2,2006-07-04,2006-08-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Maryland Research Institute, Inc.","A Phase 3, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Efficacy and Safety of OPC-6535 Tablets in the Treatment of Subjects with Active Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003724-19,0,0,0 2005-003732-22,1,2014-10-22,2014-10-22,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Kings College London,Pilot study of 5 Azacitidine in the treatment of MDS/AML with high risk (chromosome 7 and/or complex cytogenetic abnormality),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003732-22,0,0,0 2005-003733-40,7,2008-01-18,2008-07-30,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma TCC of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003733-40,0,0,0 2005-003737-40,2,2008-03-03,2008-03-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BIOTEST AG,"An open, prospective, randomised parallel study investigating efficacy and safety of the human hepatitis B immunoglobulin BT088 after subcutaneous or intramuscular application in liver transplanted pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003737-40,0,0,0 2005-003737-40,2,2008-03-03,2008-03-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biotest AG,"An open, prospective, randomised parallel study investigating efficacy and safety of the human hepatitis B immunoglobulin BT088 after subcutaneous or intramuscular application in liver transplanted pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003737-40,0,0,0 2005-003739-32,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Santosolve A/S,"A double-blind, placebo-controlled, enriched enrolment, randomised withdrawal study to evaluate the efficacy and safety of 2PX in patients with neuropathic pain due to post-herpetic neuralgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003739-32,0,0,0 2005-003740-62,1,2011-11-09,2011-11-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ABCSG (Austrian Breast & Colorectal Cancer Study Group),Preoperative chemoradiation with capecitabine and cetuximab within a multidisciplinary therapeutic approach in patients with operable T3-T4 rectal cancer: a phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003740-62,0,0,0 2005-003745-14,4,2007-09-12,2007-09-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multi-centre, Double-blind, Randomised Withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR®) as Monotherap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003745-14,0,0,0 2005-003747-31,1,2007-02-14,2007-02-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,"Randomised, Double-Blind, Placebo-Controlled, Parallel Group Trial to Confirm the Efficacy, Safety and Tolerability of Ginkgo biloba Special Extract EGb 761® in Patients Suffering from Mild Mental Imp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003747-31,0,0,0 2005-003749-15,1,2006-12-18,2006-12-18,1,1,0,0,0,3,4,0,0,1,1,1,1,0,1,"Merck, Sharp & Dohme-Clinical Pharmacology,Europe",Investigation of the effectiveness of oral lorazepam in managing preoperative dental anxiety in phobic dental patients-A pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003749-15,0,0,0 2005-003750-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VästraGötaland,Growth hormone and androgens in the treatment of glucocorticoid induced protein catabolism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003750-10,0,0,0 2005-003755-12,1,2017-04-12,2017-04-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hull & East Yorkshire NHS Trust,A Randomised Phase III Study in Advanced Oesophageal Cancer to compare Quality of Life and Palliation of Dysphagia in Patients Treated with Radiotherapy versus Chemo-radiotherapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003755-12,0,0,0 2005-003759-11,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,BKH Schwaz,Autologous myoblasts for treatment of anal incontinence due to anal sphincter defects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003759-11,0,0,0 2005-003760-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Sten Madsbad,Effect of three doses of nasal glp-1 versus placebo on postprandial hyperglycaemia in type 2 diabetes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003760-38,0,0,0 2005-003761-16,1,2008-07-08,2008-07-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of R & D, Central Manchester and Manchester Children's Hospital NHS Trust",Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003761-16,0,0,0 2005-003762-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Psychiatry, Ludwig-Maximilian University Munich",Diffusionstensorgewichtete MRT bei der Alzheimer Krankheit: Prädiktion und Darstellung von symptomatischen und krankheitsmodifizierenden Behandlungseffekten von Galantamin (Reminyl®),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003762-41,0,0,0 2005-003765-17,1,2007-10-01,2007-10-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Sanofi Pasteur Inc.,Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses Of BIKEN Acellular Pertussis Vaccine in Combination with Diphtheria and Tetanus Toxoids (Tripedia®)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003765-17,0,0,0 2005-003767-23,4,2014-01-21,2014-01-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A Randomized, Double-Blind, Placebo-Controlled, Multicentre, Phase II Study of Oral Lapatinib in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003767-23,0,0,0 2005-003767-23,4,2014-01-21,2014-01-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Randomized, Double-Blind, Placebo-Controlled, Multicentre, Phase II Study of Oral Lapatinib in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003767-23,0,0,0 2005-003770-23,8,2006-05-31,2006-05-31,5,1,0,0,0,2,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,Comparative Trial inMultiple Myeloma Patients of Oral Ibandronic Acid versus Intravenous Zoledronate: a phase III study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003770-23,0,0,0 2005-003771-20,3,2006-10-12,2006-10-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim GmbH,"A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 360 mg/day orally, in male and female patients suffer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003771-20,0,0,0 2005-003772-37,7,2009-03-12,2009-03-12,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003772-37,0,0,0 2005-003772-37,7,2009-03-12,2009-03-12,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,CHIRON CORPORATION LIMITED,"A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003772-37,0,0,0 2005-003772-37,7,2009-03-12,2009-03-12,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Chiron Corporation Ltd,"A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to TOBI® in Cystic Fibrosis Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003772-37,0,0,0 2005-003773-25,2,2010-07-20,2010-07-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER S.A,A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN COMBINATION WITH TRASTUZUMAB AS TREATMENT FOR METASTATIC DISEASE IN PATIENTS WITH BREAST CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003773-25,0,0,0 2005-003773-25,2,2010-07-20,2010-07-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER s.a.,A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN COMBINATION WITH TRASTUZUMAB AS TREATMENT FOR METASTATIC DISEASE IN PATIENTS WITH BREAST CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003773-25,0,0,0 2005-003774-15,7,2010-04-12,2011-04-26,4,1,0,0,0,0,2,0,0,1,1,0,1,0,2,"Pfizer, S.A.","A RANDOMIZED PHASE 2 STUDY OF SU011248 VERSUS STANDARD-OF-CARE FOR PATIENTS WITH PREVIOUSLY TREATED, ADVANCED, TRIPLE RECEPTOR NEGATIVE (ER, PR, AND HER2) BREAST CANCER STUDIO RANDOMIZZATO DI FAS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003774-15,0,0,0 2005-003774-15,7,2010-04-12,2011-04-26,4,1,0,0,0,0,2,0,0,1,1,0,1,0,2,PFIZER,"A RANDOMIZED PHASE 2 STUDY OF SU011248 VERSUS STANDARD-OF-CARE FOR PATIENTS WITH PREVIOUSLY TREATED, ADVANCED, TRIPLE RECEPTOR NEGATIVE (ER, PR, AND HER2) BREAST CANCER STUDIO RANDOMIZZATO DI FAS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003774-15,0,0,0 2005-003774-15,7,2010-04-12,2011-04-26,4,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Pfizer Inc. - 235 East 42nd Street - New York - 10017,"A RANDOMIZED PHASE 2 STUDY OF SU011248 VERSUS STANDARD-OF-CARE FOR PATIENTS WITH PREVIOUSLY TREATED, ADVANCED, TRIPLE RECEPTOR NEGATIVE (ER, PR, AND HER2) BREAST CANCER STUDIO RANDOMIZZATO DI FAS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003774-15,0,0,0 2005-003774-15,7,2010-04-12,2011-04-26,4,1,0,0,0,0,2,0,0,1,1,0,1,0,2,"Pfizer Inc., 235 East 42nd Street, New York, 10017, United States","A RANDOMIZED PHASE 2 STUDY OF SU011248 VERSUS STANDARD-OF-CARE FOR PATIENTS WITH PREVIOUSLY TREATED, ADVANCED, TRIPLE RECEPTOR NEGATIVE (ER, PR, AND HER2) BREAST CANCER STUDIO RANDOMIZZATO DI FAS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003774-15,0,0,0 2005-003774-15,7,2010-04-12,2011-04-26,4,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Pfizer Pharma GmbH,"A RANDOMIZED PHASE 2 STUDY OF SU011248 VERSUS STANDARD-OF-CARE FOR PATIENTS WITH PREVIOUSLY TREATED, ADVANCED, TRIPLE RECEPTOR NEGATIVE (ER, PR, AND HER2) BREAST CANCER STUDIO RANDOMIZZATO DI FAS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003774-15,0,0,0 2005-003775-21,1,2008-11-24,2008-11-24,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Salford Royal Hospitals NHS Trust,Effects of atorvastatin on microcirculatory endothelial function in patients with systemic sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003775-21,0,0,0 2005-003775-21,1,2008-11-24,2008-11-24,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,University of Manchester,Effects of atorvastatin on microcirculatory endothelial function in patients with systemic sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003775-21,0,0,0 2005-003777-24,3,2006-11-06,2006-11-06,3,0,0,0,0,1,3,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc.,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin 20 mg/kg/day to Increase Phenylalanine Tolerance in Phenylketonuric Children...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003777-24,0,0,0 2005-003778-13,1,2009-06-10,2009-06-10,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc,"A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Phenoptin in Subjects with Hyperphenylalaninemia Due to Primary BH4 Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003778-13,0,0,0 2005-003781-42,1,2008-04-04,2008-04-04,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,University of Dundee,None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003781-42,0,0,0 2005-003783-27,3,2008-04-10,2008-04-10,2,0,0,0,0,0,2,0,0,1,1,0,1,0,1,PAION Deutschland GmbH,"TOLERABILITY OF ENECADIN (INN) IN ACUTE ISCHEMIC STROKE TRIAL - TEST- PHASE IIA : A multicentre, double-blind, randomised, placebo-controlled, dose-escalating parallel- group study to investigate the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003783-27,0,0,0 2005-003788-22,7,2006-12-20,2008-07-11,6,1,0,0,0,0,4,0,0,1,0,0,1,0,2,BOEHRINGER ING.,"A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson s disease patients with stable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003788-22,0,0,0 2005-003788-22,7,2006-12-20,2008-07-11,6,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Boehringer Ingelheim AB,"A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson s disease patients with stable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003788-22,0,0,0 2005-003788-22,7,2006-12-20,2008-07-11,6,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Boehringer Ingelheim Austria GmbH,"A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson s disease patients with stable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003788-22,0,0,0 2005-003788-22,7,2006-12-20,2008-07-11,6,1,0,0,0,0,4,0,0,1,0,0,1,0,2,,"A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson s disease patients with stable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003788-22,0,0,0 2005-003788-22,7,2006-12-20,2008-07-11,6,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Boehringer Ingelheim Finland Ky,"A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson s disease patients with stable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003788-22,0,0,0 2005-003788-22,7,2006-12-20,2008-07-11,6,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Boehringer Ingelheim Limited,"A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson s disease patients with stable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003788-22,0,0,0 2005-003788-22,7,2006-12-20,2008-07-11,6,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Boehringer Ingelheim España S.A.,"A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson s disease patients with stable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003788-22,0,0,0 2005-003788-22,7,2006-12-20,2008-07-11,6,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomized, double-blind, placebo-controlled, parallel group, efficacy study of pramipexole and placebo administered orally over a 12-week treatment phase in Parkinson s disease patients with stable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003788-22,0,0,0 2005-003789-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Pharmapnea AB,"A randomized, four-way cross-over, double-blind, controlled study of oral donepezil (2, 5, 10 mg) in patients with moderate to severe obstructive sleep apnea.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003789-40,0,0,0 2005-003791-38,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Solvay Pharmaceuticals B.V.,"Immunogenicity and reactogenicity of the trivalent virosomal influenza vaccine Invivac® for the season 2005/2006. An open, baseline controlled study in two groups of healthy subjects: adult subjects a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003791-38,0,0,0 2005-003795-37,1,2009-03-01,2009-03-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,The Royal Marsden NHS Foundation Trust,Response to Parenteral Morphine and Oxycodone in Acute Pain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003795-37,0,0,0 2005-003796-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,"Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan (""Zevalin"") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission foll...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003796-20,0,0,0 2005-003797-25,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,"ConjuChem, Inc.","A Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study to Evaluate the Efficacy and Safety of CJC-1295 administered for 12 weeks in HIV-Infected Patients with HIV-associated Viscera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003797-25,0,0,0 2005-003800-12,4,2006-05-04,2006-05-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"PDL BioPharm, Inc.","A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study Of Ularitide In The Treatment Of Subjects With Acute Decompensated Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003800-12,0,0,0 2005-003800-12,4,2006-05-04,2006-05-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"PDL BioPharma, Inc.","A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study Of Ularitide In The Treatment Of Subjects With Acute Decompensated Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003800-12,0,0,0 2005-003806-27,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Princess Alexandra Hospital,Is potent topical corticosteroid ointment covered by a plastic film dressing more effective than using potent corticosteroid ointment alone in children with atopic dermatitis?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003806-27,0,0,0 2005-003809-86,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Arbeitskreis für urologische Onkologie der österr. Gesellschaft für Urologie und Andrologie (AUO),Phase II-Studie über die Ablative Wirkung von Immucothel 20mg beim oberflächlichen papillären Harnblasenkarzinom pTa /pT1 mit einer Markerläsion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003809-86,0,0,0 2005-003812-31,1,2009-02-27,2009-02-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Abteilung Klinische Chemie, UKL Freiburg",Niaspan in combination with fluvastatin compared to fluvastatin-monotherapy fpr patients with metabolic syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003812-31,0,0,0 2005-003813-33,1,2007-03-26,2007-03-26,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,The Cardiothoracic Centre Liverpool NHS Trust,Effects of Adrenaline on gastric tube blood flow in patients having thoracic epidural for Oesophagogastrectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003813-33,0,0,0 2005-003814-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Unidad Integral de Investigación en Oncología, S.L.",Pharmacodynamic study of Erlotinib (Tarceva) in patients with mestastatic or locally advanced Epidermoid carcinoma of the head and neck,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003814-14,0,0,0 2005-003819-71,3,2007-09-21,2007-09-21,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Dyax Corp,"A double-blind, placebo-controlled study followed by a repeat dosing phase to assess the efficacy and safety of DX-88 recombinant plasma kallikrein inhibitor for the treatment of acute attacks of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003819-71,0,0,0 2005-003819-71,3,2007-09-21,2007-09-21,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GENZYME,"A double-blind, placebo-controlled study followed by a repeat dosing phase to assess the efficacy and safety of DX-88 recombinant plasma kallikrein inhibitor for the treatment of acute attacks of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003819-71,0,0,0 2005-003821-25,1,2007-02-01,2007-02-01,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Psychiatric Hospital,"A 12 week multi-centre, randomized, double-blind, placebo controlled evaluation of the most efficacious and tolerable dose of escitalopram in the treatment of elderly patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003821-25,0,0,0 2005-003822-25,2,2019-02-19,2019-02-19,1,1,0,0,0,0,2,0,0,1,1,0,1,0,0,European Organisation for Research and Treatment of Cancer,Randomized Phase II Study Of Pemetrexed And Cisplatin As Either Induction or Adjuvant Chemotherapy In Stage IB-II Non-Small Cell Lung Cancer (NSCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003822-25,0,0,0 2005-003824-21,1,2011-01-25,2011-01-25,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Royal Liverpool University Hospital,"Effects and comparisons of once & twice daily insulin’s in combination with oral hypoglycaemic agents on glycaemic control, hypoglycaemia and weight in type 2 Diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003824-21,0,0,0 2005-003826-24,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,Andi - Ventis,"A RANDOMISED, FOUR WAY CROSS-OVER STUDY TO ASSESS THE BRONCHODILATING PROPERTIES OF A NEW GENERIC DRY POWDER FORMOTEROL FORMULATION GIVEN AS CUMULATIVE DOSES FROM A NOVEL DRY POWDER INHALER AND TWO RE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003826-24,0,0,0 2005-003827-38,10,2007-06-24,2009-06-24,8,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"ChemoCentryx, Inc","A Multinational Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects with Moderate to Severe Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003827-38,1,0,0 2005-003829-31,2,2007-05-30,2007-05-30,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"IBSA, Institut Biochimique S.A.","A multicentre, prospective, double-blind, in parallel groups randomised, versus placebo and versus reference product controlled, confirmatory clinical trial of the efficacy and tolerance of Flector Ti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003829-31,0,0,0 2005-003829-31,2,2007-05-30,2007-05-30,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,IBSA Institut Biochimique S.A.,"A multicentre, prospective, double-blind, in parallel groups randomised, versus placebo and versus reference product controlled, confirmatory clinical trial of the efficacy and tolerance of Flector Ti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003829-31,0,0,0 2005-003832-24,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Deutsches Herzzentrum München,"An open, prospective, randomized, comparative study to evaluate the effect of Iodixanol 320 compared to Iomeprol 350 on contrast medium induced nephropathy in patients with impaired renal function und...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003832-24,0,0,0 2005-003836-22,11,2009-10-14,2010-01-08,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biogen Idec Ltd.,"A Phase III, Randomized, Double-Blind Study of Galiximab in Combination with Rituximab Compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003836-22,0,0,0 2005-003837-42,1,2007-06-30,2007-06-30,1,1,0,0,1,0,4,0,1,1,1,1,1,0,0,Belfast City Hospital Trust,CIPROFLOXACIN-INDUCED PHOTOTOXICITY IN PATIENTS WITH CYSTIC FIBROSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003837-42,0,0,0 2005-003839-41,1,2013-10-01,2013-10-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,HOVON Foundation,Imatinib in combination with Cytarabine as compared to Imatinib alone in patients with first chronic phase Chronic Myeloid Leukemia. A prospective randomized phase III study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003839-41,0,0,0 2005-003841-14,1,2006-11-28,2006-11-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,St Stephens AIDS Trust,A pilot evaluation of the pharmacokinetic and safety characteristics of TMC114/ritonavir and TMC125 co-administered to HIV-1-infected subjects with limited treatment options,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003841-14,0,0,0 2005-003843-30,1,2006-08-14,2006-08-14,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,"ORTHO BIOTECH, Division of JANSSEN-CILAG GmbH",Bortezomib and Bendamustine in the Treatment of Refractory/Relapsed Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003843-30,0,0,0 2005-003845-15,1,2009-04-03,2009-04-03,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,University of Manchester,A cluster randomised control trial to measure the benefit of fluoride varnish in preventing dental decay when applied to the permanent teeth of children for three years in the school setting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003845-15,0,0,0 2005-003846-33,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Dr. Narcís Cardoner,Efecto de la duloxetina en la respuesta nociceptiva cerebral en el trastorno depresivo mayor. Estudio mediante resonancia magnética funcional (RMf),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003846-33,0,0,0 2005-003853-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""","A randomized, controlled, multicenter clinical trial comparing the efficacy of Peginterferon alfa-2a and ribavirin and metformin versus Peginterferon alfa-2a and ribavirin for the treatment of naïve p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003853-29,0,0,0 2005-003854-80,1,2010-12-15,2010-12-15,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-University",Modulation of the Surgical Inflammatory Response by Etoricoxib: Peripheral versus Central,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003854-80,0,0,0 2005-003855-11,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Klinikum Großhadern, University of Munich / Medical Director: Prof. Dr. med. Burkhard Götze",Gemcitabine and cisplatin in combination with hyperthermia in patients with locally advanced or metastatic pancreatic cancer as second-line therapy after adjuvant or first-line chemotherapy with Gemci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003855-11,0,0,0 2005-003860-47,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma GmbH,"A randomized, 20 week, double-blind, placebo-controlled, parallel-group, multiple-dose, multicenter study to assess the efficacy and safety of Omalizumab in combination with Depigoid, versus Depigoid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003860-47,0,0,0 2005-003862-40,9,2012-02-03,2013-10-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Limited,"A randomised, double blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of bevacizumab in combination with docetaxel compared with docetaxel plus placebo, as first line ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003862-40,0,0,0 2005-003862-40,9,2012-02-03,2013-10-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomised, double blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of bevacizumab in combination with docetaxel compared with docetaxel plus placebo, as first line ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003862-40,0,0,0 2005-003862-40,9,2012-02-03,2013-10-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"F. Hoffmann-La Roche Limited, Pharmaceuticals Division, PDR","A randomised, double blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of bevacizumab in combination with docetaxel compared with docetaxel plus placebo, as first line ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003862-40,0,0,0 2005-003862-40,9,2012-02-03,2013-10-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann - La Roche Ltd,"A randomised, double blind, placebo-controlled, multi-centre study to evaluate the efficacy and safety of bevacizumab in combination with docetaxel compared with docetaxel plus placebo, as first line ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003862-40,0,0,0 2005-003867-21,1,2007-08-11,2007-08-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Sahlgrenska University Hospital,"Induction chemotherapy with docetaxel and cisplatin followed by radiotherapy concomitant with cetuximab for locally advanced stage III non-small cell lung cancer- amulticentre, open label non-randomis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003867-21,0,0,0 2005-003869-17,1,2007-02-07,2007-02-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multi-center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability, and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Melli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003869-17,0,0,0 2005-003870-88,1,2010-05-19,2010-05-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Mukoviszidose Institut gGmbH i. G.,"Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-week inhalation treatment with glutathione in cystic fibrosis patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003870-88,0,0,0 2005-003871-19,1,2009-07-01,2009-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Salford Royal Hospital,A randomised control trial to identify the effects of cinacalcet on bone and cardiovascular health in end-stage renal disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003871-19,0,0,0 2005-003876-39,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,"Integrated Therapeutics Group, Incorporated-a subsidiary of Schering Plough","A Randomized, Open-label, Multi-center, Phase 3, 2-arm Study Evaluating the Efficacy and Safety of Peg interferon Alfa-2b Low-dose Maintenance Monotherapy Versus Standard Supportive Care in Patients W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003876-39,0,0,0 2005-003877-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"National Centre for Diabetes Care, 1st Dept. Medicine, Diabetes Unit","Comparison of the effect of insulin detemir and NPH insulin on dawn phenomenon in patients with Type 1 diabetes An open-labelled, randomised, cross-over, multi-center trial comparing the effect of in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003877-26,0,0,0 2005-003884-22,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,"Columbia Laboratories, Inc","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Prochieve® 8% Progesterone Gel in Preventing Preterm Delivery in Pregna...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003884-22,0,0,0 2005-003885-40,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA PROVINCIALE DI LECCO,ACE-inhibitors and Angiotensin two receptor antagonists in IgA nephropathy with mild proteinuria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003885-40,0,0,0 2005-003887-48,1,2006-11-15,2006-11-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,HULL AND EAST YORKSHIRE NHS TRUST,Randomised Controlled Trial of patient-controlled sedation for colonoscopy: Entonox versus target-controlled infusion of propofol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003887-48,0,0,0 2005-003888-23,1,2011-07-11,2011-07-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,"A phase II multicentre trial of CVP, rituximab and gemcitabine for the treatment of patients with newly diagnosed diffuse large b-cell lymphoma considered unsuitable for r-chop chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003888-23,0,0,0 2005-003889-42,1,2011-03-03,2011-03-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Renovo,"A double blind, placebo controlled, randomised trial to investigate the efficacy of Juvista in the prevention or improvement of scar appearance when administered intradermally to approximated wound ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003889-42,0,0,0 2005-003891-39,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,HOVON Foundation,Lenalidomide maintenance following tandem autologous stem cell and non myeloablative allogeneic transplantation for patients with multiple myeloma <= 66 years who have been treated in or according to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003891-39,0,0,0 2005-003893-46,1,2010-12-28,2010-12-28,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group),AZITHROMYCIN IN BRONCHIOLITIS OBLITERANS SYNDROME,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003893-46,0,0,0 2005-003894-26,13,2009-03-15,2009-04-01,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co KG,Evaluación aleatorizada del tratamiento anticoagulante a largo plazo comparando la eficacia y la seguridad de dos dosis de dabigatran etexilato administradas en condiciones de ciego con warfarina abie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003894-26,0,0,0 2005-003894-26,13,2009-03-15,2009-04-01,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,BOEHRINGER INGELHEIM ELLAS,Evaluación aleatorizada del tratamiento anticoagulante a largo plazo comparando la eficacia y la seguridad de dos dosis de dabigatran etexilato administradas en condiciones de ciego con warfarina abie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003894-26,0,0,0 2005-003894-26,13,2009-03-15,2009-04-01,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Ltd.,Evaluación aleatorizada del tratamiento anticoagulante a largo plazo comparando la eficacia y la seguridad de dos dosis de dabigatran etexilato administradas en condiciones de ciego con warfarina abie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003894-26,0,0,0 2005-003894-26,13,2009-03-15,2009-04-01,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A.",Evaluación aleatorizada del tratamiento anticoagulante a largo plazo comparando la eficacia y la seguridad de dos dosis de dabigatran etexilato administradas en condiciones de ciego con warfarina abie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003894-26,0,0,0 2005-003894-26,13,2009-03-15,2009-04-01,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GesmbH,Evaluación aleatorizada del tratamiento anticoagulante a largo plazo comparando la eficacia y la seguridad de dos dosis de dabigatran etexilato administradas en condiciones de ciego con warfarina abie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003894-26,0,0,0 2005-003894-26,13,2009-03-15,2009-04-01,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,BOEHRINGER ING.,Evaluación aleatorizada del tratamiento anticoagulante a largo plazo comparando la eficacia y la seguridad de dos dosis de dabigatran etexilato administradas en condiciones de ciego con warfarina abie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003894-26,0,0,0 2005-003894-26,13,2009-03-15,2009-04-01,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,Evaluación aleatorizada del tratamiento anticoagulante a largo plazo comparando la eficacia y la seguridad de dos dosis de dabigatran etexilato administradas en condiciones de ciego con warfarina abie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003894-26,0,0,0 2005-003894-26,13,2009-03-15,2009-04-01,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boegringer Ingelheim Finland Ky,Evaluación aleatorizada del tratamiento anticoagulante a largo plazo comparando la eficacia y la seguridad de dos dosis de dabigatran etexilato administradas en condiciones de ciego con warfarina abie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003894-26,0,0,0 2005-003894-26,13,2009-03-15,2009-04-01,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Austria GmbH,Evaluación aleatorizada del tratamiento anticoagulante a largo plazo comparando la eficacia y la seguridad de dos dosis de dabigatran etexilato administradas en condiciones de ciego con warfarina abie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003894-26,0,0,0 2005-003894-26,13,2009-03-15,2009-04-01,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim AB,Evaluación aleatorizada del tratamiento anticoagulante a largo plazo comparando la eficacia y la seguridad de dos dosis de dabigatran etexilato administradas en condiciones de ciego con warfarina abie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003894-26,0,0,0 2005-003901-10,1,2006-08-18,2006-08-18,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Neosil Inc.,"A randomized, placebo controlled, double-blind study to evaluate the efficacy of topical formulations in male subjects with androgenetic alopecia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003901-10,0,0,0 2005-003902-27,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"ORTHO BIOTECH, Division of JANSSEN-CILAG GmbH","Clinical trial on induction of remission with bortezomib (Vel), cyclophosphamide (C) and dexamethasone (D) in patients until the age of 60 with untreated multiple myeloma and planned high dosage chemo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003902-27,0,0,0 2005-003903-35,1,2009-07-31,2009-07-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Newcastle-upon-Tyne Hospitals NHS Trust,: The Role of Keppra in the Treatment of Tremor in Multiple Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003903-35,0,0,0 2005-003906-27,1,2014-11-14,2014-11-14,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University College London,A PHASE II EVALUATION OF HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR INTESTINAL AND OTHER DEFINED HISTOLOGICAL SUBTYPES OF AGGRESSIVE T-CELL LYMPHOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003906-27,0,0,0 2005-003910-13,1,2008-06-05,2008-06-05,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,"Martin Luther Universität Halle-Wittenberg, Klinikum der Medizinischen Fakultät",Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Cetuximab und Bevacizumab in der Erstlinientherapie von Patienten mit fortgeschrittenem kolorektalem Karzinom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003910-13,0,0,0 2005-003911-63,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University of Heidelberg, Frau I. Gürkan, Kaufmännische Direktorin",Combined Radiochemotherapy with Erbitux (Cetuximab) plus Temozolomide in the primary therapy of Glioblastoma Multiforme (GBM) - Phase I/II Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003911-63,0,0,0 2005-003924-21,1,2006-04-08,2006-04-08,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,University of Nottingham,"A Randomised, Single-Blind Study to Evaluate Upper Gastrointestinal Handling of Branded versus Generic Alendronate Tablets",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003924-21,0,0,0 2005-003926-24,9,2008-09-18,2010-10-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Ltd,"""Estudio fase 3, aleatorizado, abierto, multicéntrico, de lapatinib en combinación con trastuzumab vs lapatinib en monoterapia en sujetos con cáncer de mama metastásico cuyo tumor ha progresado durant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003926-24,0,0,0 2005-003926-24,9,2008-09-18,2010-10-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","""Estudio fase 3, aleatorizado, abierto, multicéntrico, de lapatinib en combinación con trastuzumab vs lapatinib en monoterapia en sujetos con cáncer de mama metastásico cuyo tumor ha progresado durant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003926-24,0,0,0 2005-003926-24,9,2008-09-18,2010-10-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"""Estudio fase 3, aleatorizado, abierto, multicéntrico, de lapatinib en combinación con trastuzumab vs lapatinib en monoterapia en sujetos con cáncer de mama metastásico cuyo tumor ha progresado durant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003926-24,0,0,0 2005-003927-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Per Whiss, Faculty of Health Sciences",Platelet adhesion assay for evaluation of anti-platelet treatment in coronary heart disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003927-38,0,0,0 2005-003929-22,7,2013-03-31,2013-06-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Medical Research Council,"Estudio aleatorizado del “Gynaecologic Cancer InterGroup”, de dos grupos, multicéntrico para añadir bevacizumab a la quimioterapia estándar (carboplatino y paclitaxel) en pacientes que sufren cáncer e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003929-22,0,0,0 2005-003929-22,7,2013-03-31,2013-06-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,0,GRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER DE OVARIO (GEICO),"Estudio aleatorizado del “Gynaecologic Cancer InterGroup”, de dos grupos, multicéntrico para añadir bevacizumab a la quimioterapia estándar (carboplatino y paclitaxel) en pacientes que sufren cáncer e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003929-22,0,0,0 2005-003930-16,3,2010-04-29,2010-04-29,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Biogen Idec A/S,"A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003930-16,0,0,0 2005-003931-40,1,2014-01-08,2014-01-08,1,1,0,0,0,3,2,0,0,1,0,0,1,0,0,University College London,Phase ll Trial of Fludarabine & Cyclophosphamide followed by Thalidomide for Angioimmunoblastic Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003931-40,0,0,0 2005-003932-23,2,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Roche spol. s r.o.,"An Open-Label, Multicenter Phase IV Study assessing safety and efficacy of ribavirin (Copegus®) as part of combination therapy with peginterferon alfa-2a (Pegasys®) in selected groups of patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003932-23,0,0,0 2005-003937-42,4,2008-09-18,2008-09-25,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nycomed GmbH,"Effect of roflumilast on exacerbation rate in patients with COPD A 52 weeks, double-blind study with 500 mcg roflumilast once daily versus placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003937-42,0,0,0 2005-003937-42,4,2008-09-18,2008-09-25,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA Pharma AG,"Effect of roflumilast on exacerbation rate in patients with COPD A 52 weeks, double-blind study with 500 mcg roflumilast once daily versus placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003937-42,0,0,0 2005-003938-18,3,2008-04-29,2008-08-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA Pharma AG,"Effect of roflumilast on exacerbation rate in patients with COPD. A 52 weeks, double-blind study with 500 mcg roflumilast once daily versus placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003938-18,0,0,0 2005-003938-18,3,2008-04-29,2008-08-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nycomed GmbH,"Effect of roflumilast on exacerbation rate in patients with COPD. A 52 weeks, double-blind study with 500 mcg roflumilast once daily versus placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003938-18,0,0,0 2005-003942-32,1,2006-07-12,2006-07-12,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Biologische Heilmittel Heel GmbH,None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003942-32,0,0,0 2005-003943-30,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,University of Leipzig,Doubleblind randomized multicenter trial to investigate the influence of dimenhydrinate suppositories vs. placebo on oral rehydration in infants and children with infectious enteritis and vomiting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003943-30,0,0,0 2005-003944-68,8,2018-03-15,2018-03-15,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab based Systemic Therapy and Cranial Radiotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003944-68,0,0,0 2005-003944-68,8,2018-03-15,2018-03-15,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.",A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab based Systemic Therapy and Cranial Radiotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003944-68,0,0,0 2005-003944-68,8,2018-03-15,2018-03-15,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline R&D Ltd,A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab based Systemic Therapy and Cranial Radiotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003944-68,0,0,0 2005-003944-68,8,2018-03-15,2018-03-15,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GLAXO SMITH KLINE RESEARCH & DEVELOPMENT LTD,A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab based Systemic Therapy and Cranial Radiotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003944-68,0,0,0 2005-003945-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GlaxoSmithKline R&D Ltd,"An open-label, single-arm, multicentre, Phase II study of oral lapatinib in combination with paclitaxel as first-line treatment for ErbB2-amplified metastatic breast cancer patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003945-16,0,0,0 2005-003949-14,1,2008-12-01,2008-12-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ORTHO BIOTECH, Geschäftsbereich der JANSSEN-CILAG GmbH",Pilot study of bortezomib under rituximab standard therapy in patients with relapsed or refractory follicular lymphoma and at least 2 prior therapies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003949-14,0,0,0 2005-003951-11,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Merz Pharmaceuticals GmbH,"Prospective, double-blind, placebo-controlled, randomized, multi-center trial with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of post-stroke spast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003951-11,0,0,0 2005-003956-37,6,,,0,0,0,0,1,2,3,0,0,3,0,0,0,0,0,University Hospital Gent,"FIVE-YEAR SINGLE-BLIND, PHASE III EFFECTIVENESS RANDOMIZED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE DERMATOMYOSITIS PREDNISONE VERSUS PREDNISONE PLUS CYCLOSPORINE A VERSUS PREDNISONE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003956-37,0,0,0 2005-003956-37,6,,,0,0,0,0,1,2,3,0,0,3,0,0,0,0,0,Istituto Giannina Gaslini,"FIVE-YEAR SINGLE-BLIND, PHASE III EFFECTIVENESS RANDOMIZED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE DERMATOMYOSITIS PREDNISONE VERSUS PREDNISONE PLUS CYCLOSPORINE A VERSUS PREDNISONE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003956-37,0,0,0 2005-003956-37,6,,,0,0,0,0,1,2,3,0,0,3,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,"FIVE-YEAR SINGLE-BLIND, PHASE III EFFECTIVENESS RANDOMIZED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE DERMATOMYOSITIS PREDNISONE VERSUS PREDNISONE PLUS CYCLOSPORINE A VERSUS PREDNISONE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003956-37,0,0,0 2005-003957-28,3,2007-06-25,2007-06-25,2,0,0,0,1,0,3,0,0,2,0,0,0,0,0,Istituto Giannina Gaslini,"FIVE-YEAR SINGLE-BLIND, PHASE II EFFECTIVENESS RANDOMISED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS NEPHTRITIS ORAL CYCLOPHOSPHAMIDE VERSUS HIGH DOSE INTRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003957-28,1,0,0 2005-003957-28,3,2007-06-25,2007-06-25,2,0,0,0,1,0,3,0,0,2,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,"FIVE-YEAR SINGLE-BLIND, PHASE II EFFECTIVENESS RANDOMISED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS NEPHTRITIS ORAL CYCLOPHOSPHAMIDE VERSUS HIGH DOSE INTRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003957-28,1,0,0 2005-003957-28,3,2007-06-25,2007-06-25,2,0,0,0,1,0,3,0,0,2,0,0,0,0,0,University Hospital Gent,"FIVE-YEAR SINGLE-BLIND, PHASE II EFFECTIVENESS RANDOMISED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS NEPHTRITIS ORAL CYCLOPHOSPHAMIDE VERSUS HIGH DOSE INTRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003957-28,1,0,0 2005-003958-94,1,2007-12-24,2007-12-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Phama GmbH,"A randomized, open-label, multicenter, cross-over trial to evaluate the efficacy of a 20 week treatment of Valsartan 320 mg (Diovan) versus Atenolol 100 mg in combination with Hydrochlorothiazide on m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003958-94,0,0,0 2005-003962-40,1,2009-07-07,2009-07-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,FONDAZIONE SENDO,"An open label, Phase II study of biweekly VELCADETM and intermittent CAELIXTM in patients with ovarian cancer failing platinum containing regimens",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003962-40,0,0,0 2005-003971-19,2,2008-08-18,2008-08-18,2,1,0,0,0,0,4,0,0,1,1,0,1,0,1,MEDA AB,"Clinical study to evaluate the ability of MUSE to increase erectile function in post-radical prostatectomy patients - Randomised, controlled, open study with two parallel groups comparing MUSE 250 µg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003971-19,0,0,0 2005-003971-19,2,2008-08-18,2008-08-18,2,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Meda AB,"Clinical study to evaluate the ability of MUSE to increase erectile function in post-radical prostatectomy patients - Randomised, controlled, open study with two parallel groups comparing MUSE 250 µg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003971-19,0,0,0 2005-003976-39,1,2006-07-07,2006-07-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"An open-label, multicenter study to evaluate the efficacy and safety of a 5 week therapy with the combination of valsartan 160 mg plus amlodipine 10 mg in hypertensive patients not adequately respondi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003976-39,0,0,0 2005-003977-25,2,2010-03-31,2010-03-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma S.A,"A phase III B multicentre open label 54 weeks clinical trial evaluating certolizumab pegol, a PEGylated Fab fragment of humanized antibody to tumor necrosis factor alpha (TNF alpha) on endoscopic and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003977-25,0,0,0 2005-003977-25,2,2010-03-31,2010-03-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB S.A,"A phase III B multicentre open label 54 weeks clinical trial evaluating certolizumab pegol, a PEGylated Fab fragment of humanized antibody to tumor necrosis factor alpha (TNF alpha) on endoscopic and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003977-25,0,0,0 2005-003980-21,2,2006-11-06,2006-11-06,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novo Nordisk Ltd,"A Multinational, Open Label, Randomised, Three Period, Cross Over Trial Investigating The Impact Of Exercise And Type Of Basal Insulin Used On Blood Glucose Levels In Subjects With Type 1 Diabetes Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003980-21,0,0,0 2005-003985-40,4,2008-11-28,2008-11-28,3,1,0,0,0,2,2,0,0,1,0,0,1,0,0,University Hospital Leuven. Dept Hemaetology,A prospective multicentre phase II trial of zoledronic acid in patients with myelofibrosis with myeloid metaplasia (MMM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003985-40,0,0,0 2005-003985-40,4,2008-11-28,2008-11-28,3,1,0,0,0,2,2,0,0,1,0,0,1,0,0,"Department of Internal Medicine, University Hospital Gasthuisberg",A prospective multicentre phase II trial of zoledronic acid in patients with myelofibrosis with myeloid metaplasia (MMM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003985-40,0,0,0 2005-003985-40,4,2008-11-28,2008-11-28,3,1,0,0,0,2,2,0,0,1,0,0,1,0,0,University Hospital Leuven - Department of Haematology,A prospective multicentre phase II trial of zoledronic acid in patients with myelofibrosis with myeloid metaplasia (MMM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003985-40,0,0,0 2005-003985-40,4,2008-11-28,2008-11-28,3,1,0,0,0,2,2,0,0,1,0,0,1,0,0,University Hospital Gasthuisberg,A prospective multicentre phase II trial of zoledronic acid in patients with myelofibrosis with myeloid metaplasia (MMM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003985-40,0,0,0 2005-003991-39,1,2007-05-10,2007-05-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"insaf, Institut für Atemwegsforschung GmbH","RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL CROSSOVER TRIAL IN ADULT ASTHMATICS EVALUATING THE EFFECT OF CONCOMITANT TWO WEEKS TREATMENT WITH MONTELUKAST (SINGULAIR™) 10 MG ONCE DAILY OR MAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003991-39,0,0,0 2005-003997-74,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,Rigshospitalet,Depletion of regulatory T-lymphocytes by intratumoral injection of antibodies.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003997-74,0,0,0 2005-003999-38,2,2007-01-25,2007-01-25,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer Pharmaceuticals Corporation,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Elective Spinal Fus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003999-38,0,0,0 2005-004001-29,2,2009-11-18,2009-11-18,1,1,0,0,0,0,3,0,2,1,0,0,1,0,1,ASTRAZENECA,"An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX™ 10.8 mg Given Every 12 Weeks with ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women with Oestrogen Receptor Po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004001-29,0,0,0 2005-004001-29,2,2009-11-18,2009-11-18,1,1,0,0,0,0,3,0,2,1,0,0,1,0,1,AstraZeneca AB,"An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX™ 10.8 mg Given Every 12 Weeks with ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women with Oestrogen Receptor Po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004001-29,0,0,0 2005-004005-28,1,2008-03-25,2008-03-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An open, randomised clinical Phase II trial to investigate the efficacy, safety and pharmacokinetics of a single dose of 200 mg of i.v. BI 2536 in comparison to 50 mg of i.v. BI 2536 administered on d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004005-28,0,0,0 2005-004006-81,3,2008-02-01,2008-02-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche&developpement,"A double-blind, 6 to 12-month, multicenter, multinational, randomized study evaluating the efficacy and safety of SR58611A (350 mg q12) versus placebo in the prevention of relapse / recurrence of depr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004006-81,0,0,0 2005-004006-81,3,2008-02-01,2008-02-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A double-blind, 6 to 12-month, multicenter, multinational, randomized study evaluating the efficacy and safety of SR58611A (350 mg q12) versus placebo in the prevention of relapse / recurrence of depr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004006-81,0,0,0 2005-004006-81,3,2008-02-01,2008-02-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"A double-blind, 6 to 12-month, multicenter, multinational, randomized study evaluating the efficacy and safety of SR58611A (350 mg q12) versus placebo in the prevention of relapse / recurrence of depr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004006-81,0,0,0 2005-004008-36,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,ISTITUTO GIANNINA GASLINI,Efficacy and safety of treatment with Anakinra in patients with CINCA/MUCKLE-WELLS syndrome and systemic juvenile idiopathic arthritis Efficacia e sicurezza del trattamento con Anakinra nei pazient...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004008-36,0,0,0 2005-004009-26,10,2017-12-11,2018-01-16,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,EISAI Limited,"A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004009-26,0,0,0 2005-004009-26,10,2017-12-11,2018-01-16,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eisai Limited,"A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004009-26,0,0,0 2005-004009-26,10,2017-12-11,2018-01-16,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Eisai Limited, European Knowledge Centre","A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004009-26,0,0,0 2005-004009-26,10,2017-12-11,2018-01-16,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,EISAI LTD UK,"A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 versus Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004009-26,0,0,0 2005-004011-30,1,2010-06-01,2010-06-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Gwent Healthcare NHS Trust,A prospective open study evaluating the use of botulinum toxin in patients with overactive bladder as an alternative to other conservative treatments.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004011-30,0,0,0 2005-004012-78,1,2007-11-15,2007-11-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical University of Graz,"Effects of acarbose on endothelial function, platelet activity, insulin sensitivity and glucose control in subjects with coronary artery disease and new onset type-II diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004012-78,0,0,0 2005-004013-15,1,2006-03-31,2006-03-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Bioforce AG,Effects of Echinaforce®-treatment on the response of ex vivo stimulated blood cells,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004013-15,0,0,0 2005-004021-26,1,2011-05-31,2011-05-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Birmingham,Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comparison between Efavirenz (Sustiva) plus AZT/3TC (Combivir) and a less mitochrondial DNA-toxic regime...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004021-26,0,0,0 2005-004023-19,16,2010-04-01,2010-04-09,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer AB, Vetenskapsvagen 10, 191 90 Sollentuna, Sweden","A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN LYRICA AND LAMOTRIGINE LAMICTAL IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004023-19,0,0,0 2005-004023-19,16,2010-04-01,2010-04-09,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,,"A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN LYRICA AND LAMOTRIGINE LAMICTAL IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004023-19,0,0,0 2005-004023-19,16,2010-04-01,2010-04-09,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Oy,"A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN LYRICA AND LAMOTRIGINE LAMICTAL IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004023-19,0,0,0 2005-004023-19,16,2010-04-01,2010-04-09,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer,"A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN LYRICA AND LAMOTRIGINE LAMICTAL IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004023-19,0,0,0 2005-004023-19,16,2010-04-01,2010-04-09,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer S.A.,"A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN LYRICA AND LAMOTRIGINE LAMICTAL IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004023-19,0,0,0 2005-004023-19,16,2010-04-01,2010-04-09,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc,"A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN LYRICA AND LAMOTRIGINE LAMICTAL IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004023-19,0,0,0 2005-004023-19,16,2010-04-01,2010-04-09,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER,"A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN LYRICA AND LAMOTRIGINE LAMICTAL IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004023-19,0,0,0 2005-004023-19,16,2010-04-01,2010-04-09,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Ltd,"A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN LYRICA AND LAMOTRIGINE LAMICTAL IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004023-19,0,0,0 2005-004023-19,16,2010-04-01,2010-04-09,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Ltd, Ramsgate Rd, Sandwich, Kent, United Kingdom","A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN LYRICA AND LAMOTRIGINE LAMICTAL IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004023-19,0,0,0 2005-004023-19,16,2010-04-01,2010-04-09,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Luxembourg SARL Branch Office in Lithuania,"A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN LYRICA AND LAMOTRIGINE LAMICTAL IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004023-19,0,0,0 2005-004023-19,16,2010-04-01,2010-04-09,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN LYRICA AND LAMOTRIGINE LAMICTAL IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004023-19,0,0,0 2005-004023-19,16,2010-04-01,2010-04-09,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Limited,"A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN LYRICA AND LAMOTRIGINE LAMICTAL IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004023-19,0,0,0 2005-004023-19,16,2010-04-01,2010-04-09,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A RANDOMIZED, COMPARATIVE, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER, MONOTHERAPY, STUDY OF PREGABALIN LYRICA AND LAMOTRIGINE LAMICTAL IN PATIENTS WITH NEWLY DIAGNOSED PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004023-19,0,0,0 2005-004024-39,2,2008-09-30,2008-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","Ensaio clínico multicêntrico, randomizado, aberto, de 12 semanas, para determinar o efeito do tratamento com Myfortic® (micofenolato de sódio) em termos de qualidade de vida em doentes com sintomas ga...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004024-39,0,0,0 2005-004025-26,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)","THERAPEUTIC SIMPLIFICATION WITH THYMIDINE ANALOGUR SPARING REGIMENS IN PATIENTS ON EFFECTIVE HAART: A CONTROLLED, RANDOMIZED STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004025-26,0,0,0 2005-004029-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Thoracale Oncologie Groep Antwerpen TOGA,Randomized Phase II Study Evaluating The Tolerability Of Adjuvant Docetaxel-based Chemotherapy For Completely Resected Stage IB-II Non-Small Cell Lumg Cancer (NSCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004029-24,0,0,0 2005-004030-40,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Thoracale Oncologie Groep Antwerpen,A RANDOMIZED MULTICENTER PHASE II STUY OF INDUCTION THERAPY WITH PEMETREXED AND CISPLATIN FOLLOWED BY CHEMORADIATION WITH PEMETREXED VERSUS CHEMORADIATION WITH PEMETREXED FOLLOWED BY CONSOLIDATION THE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004030-40,0,0,0 2005-004032-48,1,2007-01-09,2007-01-09,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AstraZeneca AB,"A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Effect of Tesaglitazar 1 mg once daily on the Pharmacokinetics of Metformin Following Addition of Tesaglitazar to Metfo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004032-48,0,0,0 2005-004034-41,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Genzyme Europe B.V.,Evaluation of Skeletal Myoblast Transplant for Treating Ischemic Heart Failure Phase 2 Study Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004034-41,0,0,0 2005-004037-18,3,2008-07-10,2008-07-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag EMEA,"An Open Label, Multicenter Study to Evaluate the Long Term Safety of Prolonged Release (PR) OROS Methylphenidate (18, 36, 54, 72 and 90 mg/day) in Adults with Attention Deficit/Hyperactivity Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004037-18,0,0,0 2005-004037-18,3,2008-07-10,2008-07-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag Medical Affairs EMEA,"An Open Label, Multicenter Study to Evaluate the Long Term Safety of Prolonged Release (PR) OROS Methylphenidate (18, 36, 54, 72 and 90 mg/day) in Adults with Attention Deficit/Hyperactivity Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004037-18,0,0,0 2005-004048-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku Univeristy Hospital,Raskausdiabeteksen lääkehoito,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004048-30,0,0,0 2005-004051-35,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,University Hospital Düsseldorf,Intramyocardial Application of Stem Cells in combination with transmyocardial Laser Revascularisation (TMLR) in CABG Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004051-35,0,0,0 2005-004052-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Asociación Científica para la investigación Nefrológica (ACINEF),"Estudio abierto, aleatorizado y controlado sobre las propiedades antiinflamatorias de sevelamer (Renagel®) en pacientes sometidos a hemodiálisis crónica",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004052-12,0,0,0 2005-004053-10,3,2007-02-26,2007-02-26,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Henogen,"A phase III, multicentric, multinational, controlled, randomised, open study comparing the immunogenicity, reactogenicity and safety of Henogen’s new adjuvanted hepatitis B vaccine, HB-AS02V, administ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004053-10,0,0,0 2005-004055-35,4,2007-01-25,2007-01-25,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"A multi-center, randomized, double blind, placebo controlled study to investigate the efficacy and safety of Aprotinin on transfusion requirements in patients with bladder cancer undergoing radical or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004055-35,0,0,0 2005-004056-13,2,2009-07-15,2009-07-15,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Henogen,"A phase III, multicentric, multinational, long-term follow-up study to evaluate the persistence of anti-HBs antibodies at Months 12, 24 and 36 in pre-dialysis / peritoneal dialysis or haemodialysis pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004056-13,1,0,0 2005-004057-98,1,2008-04-07,2008-04-07,1,0,0,0,0,0,3,0,1,1,0,0,1,0,1,Henogen,"A phase III, single centre, double blind, randomised study evaluating the consistency of three lots of Henogen’s new adjuvanted hepatitis B vaccine HB-AS02V, when administered according to a 0, 1 mont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004057-98,0,0,0 2005-004058-28,4,2007-10-15,2007-10-15,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Henogen,"A phase III multicentric, multinational, controlled, randomised, open study comparing the immunogenicity, reactogenicity and safety of Henogen’s new adjuvanted hepatitis B vaccine, HB-AS02V, to that ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004058-28,0,0,0 2005-004059-37,3,2007-10-23,2007-10-23,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Henogen,"A phase III, multicentric, multinational, controlled, randomised, open study comparing the immunogenicity, reactogenicity and safety of Henogen’s new adjuvanted hepatitis B vaccine, HB-AS02V, to that ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004059-37,0,0,0 2005-004060-24,1,2011-08-12,2011-08-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Department of Clinical Pharmacology,A double-masked randomized cross-over study comparing the effect of Xalacom (latanoprost/timolol) and Combigan (brimonidine/timolol) fixed combination on intraocular pressure and ocular blood flow in ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004060-24,0,0,0 2005-004061-41,13,2014-04-30,2014-04-30,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BIOGEN IDEC LTD,"An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 or C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004061-41,0,0,0 2005-004065-42,1,2007-03-15,2007-03-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vectura Group plc,"Phase II, double blind, intermittent dose, placebo controlled, randomised, two period crossover study to investigate the effect of inhaled doses of VR776 administered via Aspirair inhaler on IVELT (in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004065-42,0,0,0 2005-004067-30,3,2009-05-31,2009-05-31,2,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Department of Rheumatology, Internal Medicine III, Medical University of Vienna","A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFafa Chimeric Monoclonal Antibody (Infliximab, Remicade®) and Azathioprine in Patients Suffering from Systemic Lupus Erythe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004067-30,0,0,0 2005-004068-21,1,2009-04-30,2009-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Genzyme Europe BV,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study of Ad2/Hypoxia Inducible Factor (HIF)-1alfa/VP16 Administered by Intramuscular Injection to Patients with No ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004068-21,0,0,0 2005-004074-24,1,2008-10-24,2008-10-24,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Gesellschaft für Epilepsieforschung e.V.,Effectiveness and safety of pregabalin in patients with epilepsy and anxiety disorder.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004074-24,0,0,0 2005-004076-21,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,ESTHER URIARTE ITZAZELAIA,A randomized clinical trial to investigate the efficacy and safety of the combination of intra-articular hyaluronan and corticosteroids for osteoarthritis of the knee Ensayo clínico aleatorizado para ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004076-21,0,0,0 2005-004078-25,11,2014-12-29,2014-12-29,7,1,0,0,0,1,3,0,2,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or Me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004078-25,0,0,0 2005-004078-25,11,2014-12-29,2014-12-29,7,1,0,0,0,1,3,0,2,1,1,0,1,0,1,GLAXO SMITH KLINE RESEARCH & DEVELOPMENT LTD,"A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients with Locally Advanced and/or Me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004078-25,0,0,0 2005-004080-28,1,2006-02-08,2006-02-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Sandwell Medical Research Unit,Efficacy and Safety of Niaspan in South Asian Stroke Survivors: NIASTAR TRIAL (Niaspan: Indo-Asian Stroke patienT Atherosclerotic Regression trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004080-28,0,0,0 2005-004082-42,1,2008-11-18,2008-11-18,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Søren Sindrup, Dept. of Neurology, University Hospital of Odense",The Pharmacogenetics of Oxycodone analgesia in human experimental pain models,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004082-42,0,0,0 2005-004083-22,5,2010-01-29,2010-01-29,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Santhera Pharmaceuticals (Switzerland) Ltd,"A Phase III double blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of idebenone in the treatment of Friedreich's Ataxia patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004083-22,0,0,0 2005-004083-22,5,2010-01-29,2010-01-29,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Santhera Pharmaceuticals (Switzerland) Limited,"A Phase III double blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of idebenone in the treatment of Friedreich's Ataxia patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004083-22,0,0,0 2005-004084-37,1,2006-03-07,2006-03-07,1,0,0,0,1,0,3,0,0,1,0,0,1,0,1,SSL International plc,"A phase III, randomised, controlled, assessor-blind, parallel group clinical trial to confirm the safety and efficacy of an experimental pediculicide rinse and Lyclear Creme Rinse in the treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004084-37,0,0,0 2005-004087-24,1,2008-09-26,2008-09-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,JANSSEN-CILAG GmbH,"Global assessment of treatment with IONSYS and its handling by patients, doctors and nursing staff in the management of acute moderate to severe post-surgery pain in hospitalised patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004087-24,0,0,0 2005-004094-25,15,2011-06-07,2013-05-09,13,1,0,0,0,0,0,0,0,1,1,0,1,0,1,ASTELLAS PHARMA,A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing and locally advanced prostate cancer who...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004094-25,0,0,0 2005-004094-25,15,2011-06-07,2013-05-09,13,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Astellas Pharma Europe B.V.,A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing and locally advanced prostate cancer who...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004094-25,0,0,0 2005-004094-25,15,2011-06-07,2013-05-09,13,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Astellas Pharma Europe B.V,A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing and locally advanced prostate cancer who...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004094-25,0,0,0 2005-004096-37,6,2007-11-14,2012-04-12,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gilead Sciences Incorporated,"A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004096-37,0,0,0 2005-004096-37,6,2007-11-14,2012-04-12,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gilead Sciences Inc,"A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004096-37,0,0,0 2005-004102-90,1,2001-02-27,2001-02-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Oxford Radcliffe Hospitals NHS Trust,Efficacy and safety of amiodarone 100mg versus 200mg for the maintenance of sinus rhythm after cardioversion of atrial fibrillation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004102-90,0,0,0 2005-004103-10,2,2008-01-07,2008-01-07,1,0,0,1,0,2,1,2,0,2,0,0,0,0,2,PARI GmbH,"Randomized, open labeled, multi center, active controlled, parallel 28 days safety and bioavailability study of Tobramycin 100 PARI nebulized with eFlow® versus TOBI® nebulized with PARI LC PLUS in cy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004103-10,1,0,0 2005-004103-10,2,2008-01-07,2008-01-07,1,0,0,1,0,2,1,2,0,2,0,0,0,0,2,PARI Pharma GmbH,"Randomized, open labeled, multi center, active controlled, parallel 28 days safety and bioavailability study of Tobramycin 100 PARI nebulized with eFlow® versus TOBI® nebulized with PARI LC PLUS in cy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004103-10,1,0,0 2005-004104-37,8,2008-04-02,2008-08-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB PHARMA,"A Phase IIIb multicentre, open label induction and double blind comparison of two maintenance schedules evaluating clinical benefit and tolerability of certolizumab pegol, a PEGylated Fab' fragment of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004104-37,0,0,0 2005-004104-37,8,2008-04-02,2008-08-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB S.A.,"A Phase IIIb multicentre, open label induction and double blind comparison of two maintenance schedules evaluating clinical benefit and tolerability of certolizumab pegol, a PEGylated Fab' fragment of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004104-37,0,0,0 2005-004104-37,8,2008-04-02,2008-08-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"A Phase IIIb multicentre, open label induction and double blind comparison of two maintenance schedules evaluating clinical benefit and tolerability of certolizumab pegol, a PEGylated Fab' fragment of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004104-37,0,0,0 2005-004105-28,7,2007-08-28,2007-08-28,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"PDL BioPharma, Inc.",An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004105-28,1,0,0 2005-004105-28,7,2007-08-28,2007-08-28,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"PDL BioPharma, Inc",An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004105-28,1,0,0 2005-004109-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Neuropsychiatric clinic,"A double-blind, placebo-controlled multi-centre trial of memantine in patients with Parkinsons’ disease dementia or dementia with Lewy bodies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004109-27,0,0,0 2005-004110-32,4,2006-11-16,2006-11-16,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients with M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004110-32,0,0,0 2005-004115-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Research Institute for the prevention of allergy and airway diseases in childhood,Investigation to identify predictors of response to a treatment with montelukast,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004115-29,0,0,0 2005-004120-39,1,2007-02-19,2007-02-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A randomised, double blind, placebo-controlled, multicentre study in asymptomatic HIV infected patients to investigate pharmacodynamics, pharmacokinetics, safety and toleration of UK-453,061",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004120-39,0,0,0 2005-004122-70,1,2008-03-27,2008-03-27,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Great Ormond Street Hospital,Immunogenicity of conjugate pneumococcal vaccine (Prevenar) in patients with ataxia -telangiectasia (AT) including a randomised study of one versus two doses of vaccine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004122-70,0,0,0 2005-004123-19,1,2014-04-17,2014-04-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Klinikum rechts der Isar der Technischen Universitaet Muenchen,Metabolic Response Evaluation for an Individualization of Neoadjuvant Chemo- and Radiotherapy in Esophageal Adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004123-19,0,0,0 2005-004124-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dr. Enrique Martínez López,Ensayo clínico fase II randomizado de radioterapia torácica 3D frente a la combinación de radioterapia torácica 3D y erlotinib (Tarceva®) en pacientes con carcinoma no microcítico de pulmón localizado...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004124-39,0,0,0 2005-004126-56,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Newcastle upon Tyne Hospitals NHS Trust,Observational pharmacokinetic study of doxorubicin and cyclophosphamide in patients with early breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004126-56,0,0,0 2005-004128-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,Pregabalin for pain reduction in Critical Limb Ischemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004128-38,0,0,0 2005-004133-17,2,2007-05-08,2007-05-28,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur Incorporated,"A randomised, controlled, double blind study of the immunogenicity and safety of PEDIACEL®, a combined diphtheria, tetanus, five component acellular pertussis, inactivated poliomyelitis and Haemophilu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004133-17,0,0,0 2005-004135-22,1,2008-08-31,2008-08-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Krankenhaus Nordwest,"Multicenter phase II study with docetaxel, 5-FU, leucovorin, and oxaliplatin in patients with metastatic or locally advanced gastric cancer or cancer of the esophagogastric junction- FLOT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004135-22,0,0,0 2005-004137-18,2,2010-12-10,2014-01-02,2,1,0,0,0,2,0,0,0,1,0,0,1,0,0,Britt Skogseid,FIRM-ACT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004137-18,0,0,0 2005-004137-18,2,2010-12-10,2014-01-02,2,1,0,0,0,2,0,0,0,1,0,0,1,0,0,Collaborative group for Adrenocortical Carcinoma Therapy (COAT),FIRM-ACT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004137-18,0,0,0 2005-004137-18,2,2010-12-10,2014-01-02,2,1,0,0,0,2,0,0,0,1,0,0,1,0,0,"University of Würzburg, Internat. study-Coordinator",FIRM-ACT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004137-18,0,0,0 2005-004138-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BRAINSGATE LTD,A multicenter prospective study Safety and feasibility of NeuropathTM Activation during chemiotherapy on Inoperable and Recurrent Glioblastoma Multiforme Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004138-42,0,0,0 2005-004139-23,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,0,University of Cologne,"An open-label, non-randomized phase I/II trial of neoadjuvant radio-immunochemotherapy with cetuximab and 5-FU for advanced rectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004139-23,0,0,0 2005-004145-34,3,2010-09-14,2010-09-14,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nordic Bioscience A/S,"A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects with Knee Osteoarthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004145-34,0,0,0 2005-004148-29,1,,,0,1,0,0,0,0,4,0,0,0,0,0,0,0,0,"MUW, Division of nephrology",Cinacalcet: Eine Pilotstudie bei therapierefraktärem Hyperparathyroidismus niereninsuffizienter Patienten.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004148-29,0,0,0 2005-004149-33,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,"Stryker Biotech, LLC","A randomized, controlled trial of the effect of Osigraft when used in the treatment of displaced femoral neck fractures – a pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004149-33,0,0,0 2005-004150-27,1,2009-12-01,2009-12-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Universitätsklinik für Kinder- und Jugendheilkunde,RANDOMIZED CONTROLLED TRIAL COMPARING TWO HEPARINIZATION PROTOCOLS FOR PROPHYLAXIS OF SHORT- AND LONG-TERM THROMBOTIC COMPLICATIONS OF PEDIATRIC CARDIAC CATHETERIZATION The HEARTCAT – Study (HEparin ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004150-27,0,0,0 2005-004151-35,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,Universität Heidelberg,Pharmacokinetics of oral cefuroxime-axetil compared to intravenous cefuroxime in term neonates and possible adjustment of the oral therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004151-35,0,0,0 2005-004153-10,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,OTH - Chief Medical Officer's Office,Safety and immunogenecity of NIBRG-14 H5N1 01-2005 mock-up vaccine for potencial pandemic vaccine producers in Hungary,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004153-10,0,0,0 2005-004155-35,2,2007-01-20,2007-01-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Global Research & Development,"A randomized, double blind, parallel group study to examine the effect of multiple doses of CJ-040,714 on distal esophageal acid exposure an patients with erosive gastro-esophageal reflux disease (GER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004155-35,0,0,0 2005-004155-35,2,2007-01-20,2007-01-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Limited,"A randomized, double blind, parallel group study to examine the effect of multiple doses of CJ-040,714 on distal esophageal acid exposure an patients with erosive gastro-esophageal reflux disease (GER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004155-35,0,0,0 2005-004157-99,3,2009-09-29,2009-09-29,2,1,0,0,0,2,3,0,0,1,0,0,1,0,2,Eli Lilly and Company Limited,"A Randomized, Open-Label Study Comparing the Effects of Olanzapine Pamoate Depot with Oral Olanzapine on Treatment Outcomes in Outpatients with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004157-99,0,0,0 2005-004157-99,3,2009-09-29,2009-09-29,2,1,0,0,0,2,3,0,0,1,0,0,1,0,2,Lilly S.A.,"A Randomized, Open-Label Study Comparing the Effects of Olanzapine Pamoate Depot with Oral Olanzapine on Treatment Outcomes in Outpatients with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004157-99,0,0,0 2005-004161-41,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Idea AG,Efficacy and Safety of IDEA-068 in Plaque Psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004161-41,0,0,0 2005-004163-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospital Sant Joan de Déu,Effects on Endocrine-Metabolic Parameters and Body Composition of the Addition of Low-Dose Pioglitazone to Flutamide-Metformin Therapy in Young Women with Hyperinsulinemic Ovarian Hyperandrogenism and...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004163-39,0,0,0 2005-004164-23,2,2006-10-02,2006-10-02,2,1,0,1,1,0,1,0,1,1,0,0,0,0,1,Baxter AG,"Single-blind, Randomized, Controlled Phase I/II Study to Compare the Safety and Immunogenicity of an Inactivated Influenza Vaccine (Whole Virion, Vero cell derived) with a Licensed Egg derived Influen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004164-23,0,0,0 2005-004167-27,4,2008-05-23,2008-05-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A PHASE 3, RANDOMIZED, 6-MONTH, DOUBLE BLIND TRIAL IN SUBJECTS WITH BIPOLAR I DISORDER TO EVALUATE THE CONTINUED SAFETY AND MAINTENANCE OF EFFECT OF ZIPRASIDONE PLUS A MOOD STABILIZER VS PLACEBO P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004167-27,0,0,0 2005-004167-27,4,2008-05-23,2008-05-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer AB,"A PHASE 3, RANDOMIZED, 6-MONTH, DOUBLE BLIND TRIAL IN SUBJECTS WITH BIPOLAR I DISORDER TO EVALUATE THE CONTINUED SAFETY AND MAINTENANCE OF EFFECT OF ZIPRASIDONE PLUS A MOOD STABILIZER VS PLACEBO P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004167-27,0,0,0 2005-004167-27,4,2008-05-23,2008-05-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER,"A PHASE 3, RANDOMIZED, 6-MONTH, DOUBLE BLIND TRIAL IN SUBJECTS WITH BIPOLAR I DISORDER TO EVALUATE THE CONTINUED SAFETY AND MAINTENANCE OF EFFECT OF ZIPRASIDONE PLUS A MOOD STABILIZER VS PLACEBO P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004167-27,0,0,0 2005-004167-27,4,2008-05-23,2008-05-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A PHASE 3, RANDOMIZED, 6-MONTH, DOUBLE BLIND TRIAL IN SUBJECTS WITH BIPOLAR I DISORDER TO EVALUATE THE CONTINUED SAFETY AND MAINTENANCE OF EFFECT OF ZIPRASIDONE PLUS A MOOD STABILIZER VS PLACEBO P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004167-27,0,0,0 2005-004168-21,3,2006-01-23,2008-01-31,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 & 400 µg o.d.) in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004168-21,0,0,0 2005-004169-41,2,2006-01-31,2006-01-31,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 52-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 & 400 µg o.d) in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004169-41,0,0,0 2005-004170-25,3,2008-09-26,2008-09-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRACCO IMAGING,"A PHASE III, MULTI-CENTER, OPEN-LABEL STUDY TO EVALUATE SAFETY AND EFFICACY OF MULTIHANCE® AT THE DOSE OF 0.10 mmol/kg IN MAGNETIC RESONANCE IMAGING OF THE CENTRAL NERVOUS SYSTEM IN PEDIATRIC PATIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004170-25,0,0,0 2005-004170-25,3,2008-09-26,2008-09-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bracco Imaging S.p.A.,"A PHASE III, MULTI-CENTER, OPEN-LABEL STUDY TO EVALUATE SAFETY AND EFFICACY OF MULTIHANCE® AT THE DOSE OF 0.10 mmol/kg IN MAGNETIC RESONANCE IMAGING OF THE CENTRAL NERVOUS SYSTEM IN PEDIATRIC PATIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004170-25,0,0,0 2005-004171-37,1,2007-06-28,2007-06-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,United Bristol Healthcare Trust,Oxidative Stress in children undergoing cardiopulmonary bypass: A trial of Sildenafil therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004171-37,0,0,0 2005-004174-24,1,2007-05-17,2007-05-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Johnson&Johnson Pharmaceutical Research&Development, L.L.C.","A Phase 3 Randomized, Double-Blind Study of Ceftobiprole Medocaril versus Linezolid Plus Ceftazidime in the Treatment of Nosocomial Pneumonia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004174-24,0,0,0 2005-004176-21,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,CMC Contrast AB c/o Öresund Health Care Management,"Evaluation of the diagnostic efficacy of CMC-001 (MnCl2 tetrahydrate) in MR cholangiography in patients with suspected liver lesions. A randomised, parallel group, open-label Phase II trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004176-21,0,0,0 2005-004180-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Brystkirurgisk afd. F Amtsygehuset i Herlev 18 sal,Kan en enkelt dosis steroid nedsætte mængeden af serom efter mastektomi? et randomiseret pilotstudie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004180-28,0,0,0 2005-004186-41,1,2010-06-09,2010-06-09,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,University of Aachen,Cholinerg/dopaminerge Kontrolle von Aufmerksamkeitsprozessen bei schizophrenen Störungen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004186-41,0,0,0 2005-004188-50,2,2007-10-30,2007-10-30,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Eli Lilly and Company,Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004188-50,0,0,0 2005-004188-50,2,2007-10-30,2007-10-30,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,ELI LILLY,Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004188-50,0,0,0 2005-004189-17,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,N.V. Roche S.A.,"An open-label, single arm, multicenter study to assess the safety and efficacy of once-weekly administration of NeoRecormon using the 30.000 IU prefilled syringe in anaemic adult patients with solid t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004189-17,0,0,0 2005-004195-20,2,2007-01-03,2007-01-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Cardiome Pharma Corp,"A Phase 3, Multi-Center, Open Label Safety Study of RSD1235 in Subjects with Atrial Fibrillation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004195-20,0,0,0 2005-004195-20,2,2007-01-03,2007-01-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Astellas Pharma US, Inc.","A Phase 3, Multi-Center, Open Label Safety Study of RSD1235 in Subjects with Atrial Fibrillation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004195-20,0,0,0 2005-004196-37,1,2014-08-21,2014-08-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"University of Birmingham, Research & Enterprise Services",Taurine and Painful Diabetic Neuropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004196-37,0,0,0 2005-004196-37,1,2014-08-21,2014-08-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Heart of England NHS Foundation Trust Birmingham Heartlands Hospital,Taurine and Painful Diabetic Neuropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004196-37,0,0,0 2005-004199-18,6,2007-02-06,2007-02-06,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Limited,"A Double-blind, Placebo-controlled, Dose-escalation, Parallel Group Study of E2007 given as Adjunctive Therapy in Patients with Refractory Partial Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004199-18,0,0,0 2005-004200-36,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,NERVIANO MEDICAL SCIENCES,Phase II exploratory study of brostallicin PNU-166196A as third/fourth line chemoterapy in adult patients with advanced/metastatic colorectal cancer CRC .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004200-36,0,0,0 2005-004201-29,1,,,0,1,0,0,0,3,4,0,0,1,1,1,0,1,1,Alcon Hungarian ltd,THE EFFICACY AND SAFETY OF TIMOLOL MALEATE 0.5% COMPARED TO BRINZOLAMIDE 1% EACH GIVEN TWICE DAILY WHEN ADDED TO TRAVOPROST 0.004% GIVEN EACH EVENING IN PRIMARY OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004201-29,0,0,0 2005-004207-11,1,,,0,1,0,0,1,0,4,0,0,1,1,1,0,1,0,"Malmö University Hospital, Dep of Radiology",Single blind study comparing nephrotoxicity in patients with decreased renal function after intravenous gadodiamide(Omniscan) or gadopenteate (Magnevist) injection in routine clinical Magnetic Resonan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004207-11,0,0,0 2005-004209-27,1,,,0,1,0,0,0,0,4,0,0,3,0,0,0,0,0,Oxford Radcliffe Hospitals NHS Trust,Effect of altering inspired oxygen concentrations on cerebral oxygenation during awake carotid surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004209-27,0,0,0 2005-004211-30,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,The Norwegian Radium Hospital,Penicillin G and an aminoglycoside versus meropenem as initial empiric antibiotic therapy in lymphoma and leukemia patients with febrile neutropenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004211-30,0,0,0 2005-004215-30,1,2010-01-14,2010-01-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Joint Sponsorship: University College London (UCL) & University College London Hospitals (UCLH),"Imaging the neural correlates of cholinergic and behaviour driven rehabilitation in patients with Wernicke’s aphasia: a double-blinded, cross-over, randomised controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004215-30,0,0,0 2005-004216-70,2,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,ROCHE,"A randomized, double-blind, parallel group, placebo-controlled with open-label active comparator arm , dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of RO07...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004216-70,0,0,0 2005-004216-70,2,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,F.Hoffmann-La Roche Ltd.,"A randomized, double-blind, parallel group, placebo-controlled with open-label active comparator arm , dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of RO07...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004216-70,0,0,0 2005-004218-34,1,2009-06-05,2009-06-05,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"Department of Cardiology, UK Aachen",Effect of extended-release niacin on myocardial blood flow and flow reserve in patients with coronary artery disease treated with statins,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004218-34,0,0,0 2005-004222-10,1,2007-12-01,2007-12-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,AKH Wien,Does Dexamethasone Improve Perioperative Outcomes?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004222-10,0,0,0 2005-004227-19,2,2007-02-08,2007-02-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A 4-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE PRELIMINARY EFFICACY, SAFETY, AND PHARMACOKINETICS OF PPM-204 ADMINISTERED ORALLY TO TREATMENT-NAÏVE SUBJECTS W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004227-19,0,0,0 2005-004230-40,7,2015-07-30,2015-07-30,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., a Pfizer Company",A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004230-40,0,0,0 2005-004230-40,7,2015-07-30,2015-07-30,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004230-40,0,0,0 2005-004230-40,7,2015-07-30,2015-07-30,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc., a wholly owned subsidary of Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA",A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004230-40,0,0,0 2005-004230-40,7,2015-07-30,2015-07-30,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc., a wholly owned subsidiary of Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA",A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004230-40,0,0,0 2005-004234-41,1,2014-03-31,2014-03-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Otto-von-Guericke Universität Magdeburg,Dosisdichte 1st-line Therapie des metastasierten Mammakarzinoms mit Paclitaxel und liposomalem Doxorubicin (Myocet®),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004234-41,0,0,0 2005-004235-21,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA,CALF VEIN THROMBOSIS 6 WEEKS-TREATMENT WITH LMWH vs WARFARIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004235-21,0,0,0 2005-004236-40,1,2013-04-18,2013-04-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Ulm,Phase II study: Docetaxel plus Oxaliplatin as second-line therapy in patients with advanced metastatic pancreatic cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004236-40,0,0,0 2005-004247-54,3,2019-03-13,2019-03-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Double-blind, Parallel-group, Multicentre, Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 250 mg, Fulvestrant (FASLODEX™) 250 mg (plus 250 mg Loading...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004247-54,0,0,0 2005-004249-33,5,2006-11-17,2006-11-17,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Ltd.,"A phase 2, 26 week, multicenter, randomized double blind, placebo controlled, crossover study evaluating the efficacy and safety of tolterodine, pregabalin and a tolterodine-pregabalin combination for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004249-33,0,0,0 2005-004249-33,5,2006-11-17,2006-11-17,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,,"A phase 2, 26 week, multicenter, randomized double blind, placebo controlled, crossover study evaluating the efficacy and safety of tolterodine, pregabalin and a tolterodine-pregabalin combination for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004249-33,0,0,0 2005-004249-33,5,2006-11-17,2006-11-17,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer AB,"A phase 2, 26 week, multicenter, randomized double blind, placebo controlled, crossover study evaluating the efficacy and safety of tolterodine, pregabalin and a tolterodine-pregabalin combination for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004249-33,0,0,0 2005-004249-33,5,2006-11-17,2006-11-17,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A phase 2, 26 week, multicenter, randomized double blind, placebo controlled, crossover study evaluating the efficacy and safety of tolterodine, pregabalin and a tolterodine-pregabalin combination for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004249-33,0,0,0 2005-004249-33,5,2006-11-17,2006-11-17,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Limited,"A phase 2, 26 week, multicenter, randomized double blind, placebo controlled, crossover study evaluating the efficacy and safety of tolterodine, pregabalin and a tolterodine-pregabalin combination for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004249-33,0,0,0 2005-004250-28,6,2008-09-22,2008-09-22,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals, Inc.","A MULTICENTER, RANDOMIZED, OPEN-LABEL COMPARISON OF THE SAFETY AND EFFICACY OF TIGECYCLINE WITH THAT OF AMPICILLIN-SULBACTAM OR AMOXICILLIN-CLAVULANATE TO TREAT COMPLICATED SKIN AND SKIN STRUCTURE INF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004250-28,0,0,0 2005-004253-10,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,Helena Isoniemi,viite: EudraCT-numero 2005-004253-10 Tyypin 2 diabetesta sairastavien maksansiirtopotilaiden rasvamaksan hoito insuliiniherkistäjällä (rosiglitatsoni),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004253-10,0,0,0 2005-004254-26,1,2006-10-10,2006-10-10,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Santosolve A/S,"A double-blind, placebo-controlled, enriched enrolment, randomized-withdrawal study to evaluate the efficacy and safety of 2PX in patients with pain due to osteoarthritis of the knee",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004254-26,0,0,0 2005-004257-96,1,2007-09-12,2007-09-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Xanthus Pharmaceuticals Inc,Phase II Study with Symadex (C-1311) in Women with Metastatic Breast Cancer after Anthracycline and Taxane Failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004257-96,0,0,0 2005-004258-28,1,2007-04-26,2007-04-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Xanthus Pharmaceuticals, Inc",Phase II Study with Symadex (C-1311) in Patients with Metastatic Colorectal Cancer after Oxaliplatin and/or Irinotecan Failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004258-28,0,0,0 2005-004259-37,1,2007-12-20,2007-12-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"An uncontrolled, multicenter 12 month long term study on skin reconstitution with Elidel® (pimecrolimus) 1% cream in adult patients with atopic eczema and corticosteroid induced skin damage",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004259-37,0,0,0 2005-004262-16,1,2011-05-16,2011-05-16,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Guy's & St Thomas' NHS Foundation Trust,A trial comparing Metvix® photodynamic therapy (PDT) followed by Mohs micrographic surgery with Mohs micrographic surgery alone for the treatment of basal cell carcinoma (BCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004262-16,0,0,0 2005-004263-35,10,2014-09-08,2014-09-08,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharrna Services AG,"A randomised multi-center Phase IIIb, open label, study of letrozole vs anastrazole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004263-35,0,0,0 2005-004263-35,10,2014-09-08,2014-09-08,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomised multi-center Phase IIIb, open label, study of letrozole vs anastrazole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004263-35,0,0,0 2005-004263-35,10,2014-09-08,2014-09-08,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Farmacéutica SA,"A randomised multi-center Phase IIIb, open label, study of letrozole vs anastrazole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004263-35,0,0,0 2005-004263-35,10,2014-09-08,2014-09-08,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A randomised multi-center Phase IIIb, open label, study of letrozole vs anastrazole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004263-35,0,0,0 2005-004264-23,1,2006-10-01,2006-10-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Gastrotech Pharma A/S,"A randomized, double-blind, placebo controlled, cross-over, multi-center study to assess the effect of the GLP-1 analogue LY307161 in patients suffering from Irritable Bowel Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004264-23,0,0,0 2005-004265-42,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Renovo,"A double blind, placebo controlled, randomised trial to investigate the efficacy of Juvista in the improvement of scar appearance in patients undergoing bilateral reduction mammaplasty.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004265-42,0,0,0 2005-004268-21,3,2007-06-01,2007-07-02,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,F. Hoffmann-La Roche Ltd,"A multicenter, open label, extension study to evaluate the long-term safety and tolerability of RO4389620 in type 2 diabetic patients from studies BM18248 or BM18249.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004268-21,0,0,0 2005-004270-25,2,2008-02-21,2008-02-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer S.A.,"Double-blind, parallel-group, randomized, study of the efficacy and safety of continuous use of celecoxib vs the “usual use” of celecoxib in the treatment of subjects with chronicosteoarthritis of the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004270-25,0,0,0 2005-004270-25,2,2008-02-21,2008-02-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Ltd,"Double-blind, parallel-group, randomized, study of the efficacy and safety of continuous use of celecoxib vs the “usual use” of celecoxib in the treatment of subjects with chronicosteoarthritis of the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004270-25,0,0,0 2005-004271-37,3,2008-02-18,2010-02-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Limited,"A Phase II Multicenter, Open Label, Two-Stage Design Study Evaluating E7389 in Patients with Hormone Refractory Prostate Cancer with Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004271-37,0,0,0 2005-004272-20,4,2012-06-28,2012-06-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Limited,Phase II Study of E7389 Administered as an IV Infusion Day 1 and 8 every 3 Weeks in Pretreated Patients with Advanced and/or Metastatic Soft Tissue Sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004272-20,0,0,0 2005-004279-39,1,2007-08-21,2007-08-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Napp Pharmaceuticals Limited,"An open, randomised, multicentre study to compare buprenorphine transdermal delivery system (BTDS) with standard treatment in elderly subjects with OA of the hip and/or knee.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004279-39,0,0,0 2005-004280-31,1,2009-04-30,2009-04-30,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,University of Dundee,Hyperthermic Intraperitoneal Chemotherapy - Gastric Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004280-31,0,0,0 2005-004281-17,7,2010-04-27,2010-05-27,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergan Inc.,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Efficacy of a Single Treatment of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Comple...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004281-17,0,0,0 2005-004281-17,7,2010-04-27,2010-05-27,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALLERGAN,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Efficacy of a Single Treatment of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Comple...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004281-17,0,0,0 2005-004283-23,1,2011-07-01,2011-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,South Manchester University Hospital,An evaluation of potential therapies to inhibit cerebral emboli in dementia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004283-23,0,0,0 2005-004285-16,3,2007-08-03,2007-08-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A 28-day, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, anti-inflammatory effect and steady-state pharmacokinetics of SB-681323 (7.5 mg) in subjects with coron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004285-16,0,0,0 2005-004285-16,3,2007-08-03,2007-08-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A 28-day, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, anti-inflammatory effect and steady-state pharmacokinetics of SB-681323 (7.5 mg) in subjects with coron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004285-16,0,0,0 2005-004287-23,1,2008-10-29,2008-10-29,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Schering Plough Research Institute, a division of Schering Corporation",Safety and Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004287-23,0,0,0 2005-004288-47,1,,,0,1,0,0,0,0,4,0,1,0,0,0,0,0,0,Hôpital Erasme,Etude des effets d'un antagoniste calcique(la barnidipine) sur la sensibilité des chémorécepteurs et l'activité orthosympathique.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004288-47,0,0,0 2005-004289-18,3,2011-04-07,2011-04-07,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,E. Merck AB,"A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 4...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004289-18,0,0,0 2005-004289-18,3,2011-04-07,2011-04-07,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Merck AB,"A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline versus placebo as add-on therapy in patients who are on treatment with Interferon-beta-1a 4...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004289-18,0,0,0 2005-004290-19,4,2006-06-23,2006-06-23,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Schwarz Biosciences GmbH,"A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004290-19,0,0,0 2005-004291-20,1,2009-04-30,2009-04-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Prof.Dr.Hartmut ZWICK,Studie zur Wirksamkeit von hyperkalorischer Ernährung und Androgengabe auf die körperliche Leistungsfähigkeit und Lebensqualität von Patienten mit schwerer COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004291-20,0,0,0 2005-004293-24,12,2014-06-06,2014-07-01,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Limited,"A 14-Month Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 as an Adjunctive Therapy in Patients With Refractory Partial Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004293-24,0,0,0 2005-004294-21,4,2009-02-03,2009-02-03,1,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Fresenius Biotech GmbH,Estudio de fase II del anticuerpo trifuncional anti-HER-2/neu x anti-CD3 ertumaxomab en pacientes con cáncer de mama avanzado o metastásico resistente al tratamiento hormonal que expresa HER­2/neu 1+ ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004294-21,0,0,0 2005-004294-21,4,2009-02-03,2009-02-03,1,0,0,0,0,0,2,0,0,1,1,0,1,0,1,FRESENIUS BIOTECH GMBH,Estudio de fase II del anticuerpo trifuncional anti-HER-2/neu x anti-CD3 ertumaxomab en pacientes con cáncer de mama avanzado o metastásico resistente al tratamiento hormonal que expresa HER­2/neu 1+ ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004294-21,0,0,0 2005-004299-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Ostrava,New Possibilities of TDM of Cyclosporine A and its metabolites after kidney transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004299-19,0,0,0 2005-004300-36,1,2010-06-01,2010-06-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Plymouth Hospital NHS Trust, R&D dept",Use of somatostatin analogue therapy as primary medical treatment of acromegaly,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004300-36,0,0,0 2005-004301-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,KAS Glostrup,Treatment of painful knee osteoarthrosis with adalimumab (Humira (R)): Open-label study to evaluate safety and efficacy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004301-28,0,0,0 2005-004309-27,1,2006-02-01,2006-02-01,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Schering Plough Research Institute,Cross-Over Study of the Decongestant Effect of Phenylephrine Compared With Placebo and Pseudoephedrine as Active Control in SAR Subjects Exposed to Pollen in the Vienna Challenge Chamber,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004309-27,0,0,0 2005-004313-15,2,2006-12-10,2006-12-10,2,0,0,1,0,0,1,0,0,1,0,0,0,0,1,NovImmune S.A.,"A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-Escalation Study of NI-0401 in Patients with Moderate to Severe Active Crohn´s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004313-15,0,0,0 2005-004314-33,12,2007-08-23,2007-08-23,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Limited,"A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctua...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004314-33,0,0,0 2005-004314-33,12,2007-08-23,2007-08-23,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,EISAI LTD UK,"A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients with Motor Fluctua...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004314-33,0,0,0 2005-004316-73,1,2012-09-25,2012-09-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Liverpool University hospital,"The effects of growth hormone, strontium ranelate and phosphate on PTH circadian rhythm, PTH target organ sensitivity, bone turnover markers, phospho-calcium metabolism and bone mineral density. A pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004316-73,0,0,0 2005-004321-26,2,2008-09-03,2008-09-18,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,A Case-Control Toxicogenomics Study to identify Unique Genetic Polymorphisms in Patients who have experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity within the First 8 weeks of Nevira...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004321-26,0,0,0 2005-004321-26,2,2008-09-03,2008-09-18,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd.,A Case-Control Toxicogenomics Study to identify Unique Genetic Polymorphisms in Patients who have experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity within the First 8 weeks of Nevira...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004321-26,0,0,0 2005-004323-18,8,2010-02-15,2012-07-16,5,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Amgen Inc.,An Open Label Study Treatment Extension Study of AMG 706 Studio in aperto di estensione del trattamento con AMG706,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004323-18,0,0,0 2005-004325-25,1,2007-09-18,2007-09-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Administration management, Ludwig-Maximilians-University of Munich",Comprehensive whole-body 3T MRA of Patients with Low or Moderate Clinical Probability for Pulmonary Embolism using an Intravascular MR Contrast Agent Vasovist®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004325-25,0,0,0 2005-004330-40,5,2011-02-08,2011-02-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"- Ensayo clínico abierto y randomizado, para comparar la seguridad y eficacia virológica de Atazanavir/ritonavir versus Nevirapina con un régimen de base que incluya Tenofovir y Emtricitabina, en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004330-40,0,0,0 2005-004330-40,5,2011-02-08,2011-02-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","- Ensayo clínico abierto y randomizado, para comparar la seguridad y eficacia virológica de Atazanavir/ritonavir versus Nevirapina con un régimen de base que incluya Tenofovir y Emtricitabina, en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004330-40,0,0,0 2005-004330-40,5,2011-02-08,2011-02-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"- Ensayo clínico abierto y randomizado, para comparar la seguridad y eficacia virológica de Atazanavir/ritonavir versus Nevirapina con un régimen de base que incluya Tenofovir y Emtricitabina, en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004330-40,0,0,0 2005-004330-40,5,2011-02-08,2011-02-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"- Ensayo clínico abierto y randomizado, para comparar la seguridad y eficacia virológica de Atazanavir/ritonavir versus Nevirapina con un régimen de base que incluya Tenofovir y Emtricitabina, en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004330-40,0,0,0 2005-004334-41,6,2017-05-09,2017-07-23,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Teva Pharmaceutical Industries Ltd,"An active extension of LAQ/5062 study. A multinational, multi-center, randomized, double-blind, parallel-group study, to evaluate the safety, tolerability and efficacy of two doses (0.3mg and 0.6mg) o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004334-41,0,0,0 2005-004334-41,6,2017-05-09,2017-07-23,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Teva Pharmaceutical Industries Ldt,"An active extension of LAQ/5062 study. A multinational, multi-center, randomized, double-blind, parallel-group study, to evaluate the safety, tolerability and efficacy of two doses (0.3mg and 0.6mg) o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004334-41,0,0,0 2005-004337-18,1,2006-09-12,2006-09-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,OSI-prosidion Ltd.,"A randomised, double-blind, placebo-controlled, multiple dose, time-lagged cohort, dose-escalation trial, investigating the pharmacodynamics, safety and tolerability, and the pharmacokinetics of PSN35...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004337-18,0,0,0 2005-004338-42,9,2008-05-01,2008-05-27,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"A Phase 2, Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban In Patients with a Recent Acute Coronary Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004338-42,0,0,0 2005-004339-23,1,2006-06-06,2006-06-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Gedeon Richter Co.,Cink-hyaluronát (Curiosin®) gél és adapalen (Differin®) gél kezelés hatása az életminőség alakulására és a két gyógyszerkészítmény összehasonlító tolerabilitási vizsgálata acnes betegeken.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004339-23,0,0,0 2005-004340-32,6,2008-05-27,2008-05-27,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Schering AG,"A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004340-32,0,0,0 2005-004340-32,6,2008-05-27,2008-05-27,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Schering Pharma AG,"A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004340-32,0,0,0 2005-004344-30,2,2006-11-06,2006-11-20,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,AOP Orphan Pharmaceuticals AG,An Evaluation of the Safety and Tolerability of Multiple Dose Regimens of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis and Stable Lung Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004344-30,0,0,0 2005-004350-28,2,2013-05-17,2015-03-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination with Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects with Advanced or Me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004350-28,0,0,0 2005-004351-35,13,2007-03-13,2007-03-13,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Ensayo clínico controlado, doble ciego y aleatorizado de BAY 59-7939 en la prevención del tromboembolismo venoso en pacientes con cirugía electiva de sustitución total de cadera. Estudio RECORD 1 REC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004351-35,0,0,0 2005-004351-35,13,2007-03-13,2007-03-13,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER,"Ensayo clínico controlado, doble ciego y aleatorizado de BAY 59-7939 en la prevención del tromboembolismo venoso en pacientes con cirugía electiva de sustitución total de cadera. Estudio RECORD 1 REC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004351-35,0,0,0 2005-004354-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. LUIGI GONZAGA,STREPTOZOTOCINE + MITOTANE IN THE TREATMENT OF ADRENO-CORTICAL CANCER PATIENTS PROGRESSED AFTER CHEMOTHERAPY WITH CISPLATIN CONTAINING SCHEME,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004354-27,0,0,0 2005-004357-94,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Nordfjord Psychiatric Centre,Escitalopram in bipolar depression: a placebo-controlled study of acute and maintenance treatment.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004357-94,0,0,0 2005-004360-23,1,2008-09-17,2008-09-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Barts and The London NHS Trust,Randomised controlled study of “physiological” peritoneal dialysis solutions.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004360-23,0,0,0 2005-004363-34,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,VALEAS,Antibiotic therapy in children for the upper respiratory tract infections. Study of the ''tollerability profile'' of cefaclor and amoxicillin-clavulanate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004363-34,0,0,0 2005-004370-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dr. Jesús San Miguel Izquierdo,"Estudio Fase II Nacional, Abierto, Multicéntrico de Bortezomib (Velcade) y FLAG-IDA (V-FLAG-IDA) en pacientes con Leucemia Mieloblástica Aguda (LMA) refractaria o en recaída.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004370-24,0,0,0 2005-004372-20,1,2011-11-11,2011-11-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Oxford Radcliffe Hospitals NHS Trust,"A randomised, prospective,open-label, multi-centre study comparing the efficacy and safety of conversion to Sirolimus in stable renal transplant recipients with a cutaneous squamous cell carcinoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004372-20,0,0,0 2005-004373-23,1,2010-05-21,2010-05-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"LABORATORIOS FARMACEUTICOS ROVI, S.A.","MULTICENTRIC, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND THE SAFETY OF THE PROPHYLAXIS WITH BEMIPARIN 3,500 IU/day FOR 28 DAYS COMPARED TO 8 DAYS, IN VENO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004373-23,0,0,0 2005-004378-25,1,2009-05-11,2009-05-11,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Urologische Klinik und Poliklinik, Klinikum Großhadern der LMU München","A randomized, double-blinded, multicentric phase II trial to optimize the treatment of the hormon refractory prostatic carcinoma in patients without preceding chemotherapy with Sorafenib + Docetaxel +...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004378-25,0,0,0 2005-004380-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA DEGLI STUDI DI PAVIA,"RANDOMISED, CONTROLLED STUDY WITH A BLINDED END-POINT TO EVALUATE BY MEANS OF 24-HOUR AMBULATORY BLOOD PRESSURE MONITORING THE ANTIHYPERTENSIVE ACTIVITY OF OLMESARTAN 20 MG IN COMPARISON WITH THAT O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004380-32,0,0,0 2005-004383-23,2,2009-03-31,2009-03-31,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Janssen Cilag Ltd,Pragmatic randomized trial of Risperdal Consta versus oral atypical antipsychotics in poorly aderant subjects with schizophrenia ina routine care setting. Protocol RISSCH4055; Phase IV (risperidone m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004383-23,0,0,0 2005-004383-23,2,2009-03-31,2009-03-31,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Janssen-Cilag Ltd,Pragmatic randomized trial of Risperdal Consta versus oral atypical antipsychotics in poorly aderant subjects with schizophrenia ina routine care setting. Protocol RISSCH4055; Phase IV (risperidone m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004383-23,0,0,0 2005-004384-33,1,2008-03-13,2008-03-13,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Amicus Therapeutics,"A Phase 2, Open-Label, Single Dose Level, 24-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Patients with Fabry Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004384-33,0,0,0 2005-004385-16,1,2008-02-13,2008-02-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,United Bristol Healthcare NHS Trust,CIRCADIAN VARIATIONS IN CYTOKINES AND THE EFFECT OF TIMED RELEASE TABLET PREDNISONE IN RHEUMATOID ARTHRITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004385-16,0,0,0 2005-004389-17,1,2006-09-18,2006-09-18,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Transave, Inc",SAFETY AND TOLERABILITY STUDY OF SLIT AMIKACIN 500 MG ONCE DAILY FOR 14 DAYS BY INHALATION IN CYSTIC FIBROSIS STUDY SUBJECTS CHRONICALLY INFECTED WITH PSEUDOMONAS AERUGINOSA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004389-17,0,0,0 2005-004391-21,5,2007-01-10,2008-01-10,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer S.A.,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, COMPARING THE EFFICACY AND TOLERABILITY OF ZIPRASIDONE (ZELDOX®, GEODON®) VS OLANZAPINE (ZYPREXA®) IN THE TREATMENT AND MAINTENANCE OF RE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004391-21,0,0,0 2005-004391-21,5,2007-01-10,2008-01-10,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Ltd - Sandwich Laboratories,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, COMPARING THE EFFICACY AND TOLERABILITY OF ZIPRASIDONE (ZELDOX®, GEODON®) VS OLANZAPINE (ZYPREXA®) IN THE TREATMENT AND MAINTENANCE OF RE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004391-21,0,0,0 2005-004391-21,5,2007-01-10,2008-01-10,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Pharma GmbH,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, COMPARING THE EFFICACY AND TOLERABILITY OF ZIPRASIDONE (ZELDOX®, GEODON®) VS OLANZAPINE (ZYPREXA®) IN THE TREATMENT AND MAINTENANCE OF RE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004391-21,0,0,0 2005-004391-21,5,2007-01-10,2008-01-10,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Ltd.,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, COMPARING THE EFFICACY AND TOLERABILITY OF ZIPRASIDONE (ZELDOX®, GEODON®) VS OLANZAPINE (ZYPREXA®) IN THE TREATMENT AND MAINTENANCE OF RE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004391-21,0,0,0 2005-004391-21,5,2007-01-10,2008-01-10,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, COMPARING THE EFFICACY AND TOLERABILITY OF ZIPRASIDONE (ZELDOX®, GEODON®) VS OLANZAPINE (ZYPREXA®) IN THE TREATMENT AND MAINTENANCE OF RE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004391-21,0,0,0 2005-004392-38,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,NHS Greater Glasgow/Glasgow University,The feasibility of using Bone Morphogenetic Protein (rhBMP-7) for reconstruction of alveolar cleft,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004392-38,0,0,0 2005-004398-76,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Golden Jubilee National Hospital,A comparison of Myocardial Protection Using Preconditioning with Sevoflurane Against High Thoracic Epidural Analgesia for CABG Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004398-76,0,0,0 2005-004400-37,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,GRUPO ESPAÑOL DE LINFOMAS Y TRANSPLANTES AUTOLOGO DE MEDULA OSEA (GELTAMO),TRATAMIENTO DE INDUCCIÓN CON RITUXIMAB + HYPER-CVAD Y ALTAS DOSIS DE METROTREXATO/CITARABINA Y CONSOLIDACIÓN CON Y90-IBRITUMOMAB TIUXETAN EN PACIENTES CON LINFOMA DE CELULAS DEL MANTO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004400-37,0,0,0 2005-004406-93,1,2008-07-31,2008-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Klinikum der Universität München,Photodynamische Diagnostik mit 5-Aminolävulinsäure zur Beurteilung der intraoperativen Absetzungsränder im Rahmen der radikalen Prostatovesikulektomie bei Patienten mit einem Prostatakarzinom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004406-93,0,0,0 2005-004411-29,5,2008-08-18,2009-03-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Limited,"A 12-week, double-blind, placebo-controlled, multicenter study with a 40 week follow-up evaluating the safety and efficacy of Varenicline tartrate 1 mg BID for smoking cessation in subjects with cardi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004411-29,0,0,0 2005-004411-29,5,2008-08-18,2009-03-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd street, New York, NY 10017","A 12-week, double-blind, placebo-controlled, multicenter study with a 40 week follow-up evaluating the safety and efficacy of Varenicline tartrate 1 mg BID for smoking cessation in subjects with cardi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004411-29,0,0,0 2005-004411-29,5,2008-08-18,2009-03-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A 12-week, double-blind, placebo-controlled, multicenter study with a 40 week follow-up evaluating the safety and efficacy of Varenicline tartrate 1 mg BID for smoking cessation in subjects with cardi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004411-29,0,0,0 2005-004411-29,5,2008-08-18,2009-03-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,,"A 12-week, double-blind, placebo-controlled, multicenter study with a 40 week follow-up evaluating the safety and efficacy of Varenicline tartrate 1 mg BID for smoking cessation in subjects with cardi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004411-29,0,0,0 2005-004411-29,5,2008-08-18,2009-03-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc,"A 12-week, double-blind, placebo-controlled, multicenter study with a 40 week follow-up evaluating the safety and efficacy of Varenicline tartrate 1 mg BID for smoking cessation in subjects with cardi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004411-29,0,0,0 2005-004412-70,1,2009-04-30,2009-04-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER,"A 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL WITH 40-WEEK FOLLOW-UP EVALUATING THE SAFETY AND EFFICACY OF VARENICLINE TARTRATE FOR SMOKING CESSATION IN PATIENTS WITH M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004412-70,0,0,0 2005-004413-15,1,2009-12-17,2009-12-17,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Cedars Sinai Medical Center,Effectiveness of SOM230 In Treating Non-Functioning Pituitary Adenomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004413-15,0,0,0 2005-004416-78,1,2007-11-29,2007-11-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"A prospective, randomized, double-blind, placebo-controlled, multicenter trial with an open-label extension period to investigate the efficacy and safety of NT 201, free of complexing proteins, in the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004416-78,0,0,0 2005-004417-15,1,,,0,1,0,0,0,1,4,0,0,1,0,0,0,1,1,UCB Pharma Ltd,"Single center, therapeutic exploratory clinical trial to evaluate the safety of sodium oxybate (Xyrem) 500 mg/mL oral solution on potential endocrine changes at currently labeled therapeutic dose regi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004417-15,0,0,0 2005-004419-31,3,2007-01-10,2007-01-11,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004419-31,0,0,0 2005-004420-39,4,2009-12-04,2009-12-04,1,0,0,0,0,1,2,0,0,2,1,0,0,0,0,All-Ireland Co-operative Oncology Research Group (ICORG),An Open Label Phase II Multicentre Clinical Trial of Single Agent VELCADE (Bortezomib) in Patients with Malignant Pleural Mesothelioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004420-39,1,0,0 2005-004420-39,4,2009-12-04,2009-12-04,1,0,0,0,0,1,2,0,0,2,1,0,0,0,0,University Hospital Gent,An Open Label Phase II Multicentre Clinical Trial of Single Agent VELCADE (Bortezomib) in Patients with Malignant Pleural Mesothelioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004420-39,1,0,0 2005-004421-26,1,2006-09-01,2006-09-01,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Institut fuer Gesundheits- und Praxismanagement GmbH,"Effect of Pioglitazone on Intima Media Thickness, Endothelial Function and Heart Rate Variability in Patients with Impaired Glucose Tolerance",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004421-26,0,0,0 2005-004422-50,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,"J.Uriach y Compania S.A.,","A placebo-controlled, double-blind, cross-over study with rupatadine 10 mg in 30 mosquito-bite allergic adult subjects Rupatadiini-antihistamiini hyttyspistoallergiassa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004422-50,0,0,0 2005-004423-19,1,2007-09-01,2007-09-01,1,0,0,0,1,3,4,0,0,1,0,0,1,0,0,"The North West London Hospitals NHS Trust, Northwick Park Hospital",A randomised study of the optimal bowel preparation for routine Capsule endoscopy using Citramag and Senna or Metoclopramide.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004423-19,0,0,0 2005-004426-93,1,,,0,1,0,0,0,3,4,0,1,1,0,0,0,1,0,Department of Anaesthesia and General Intensive Care Medicine,Investigation of antihyperalgesic effect...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004426-93,0,0,0 2005-004427-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ludwig-Maximilians-Universitaet Muenchen,Health-related quality of life (QoL) and psychological well-being after withdrawal from hormone therapy (HT). A randomised double-blind placebo-controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004427-19,0,0,0 2005-004429-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Viborg Sygehus,"A single cohort, open trial to evaluate the efficacy and safety of TachoSil in prevention of seroma formation following axillary lymph node dissection in women following surgery for breast cancer. A p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004429-25,0,0,0 2005-004430-41,1,2006-03-13,2006-03-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,St Stephen's AIDS Trust,Effect of food on the pharmacokinetic profile of saquinavir at steady state in HIV-infected patients treated with saquinavir/ritonavir 1000/100 mg b.i.d.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004430-41,0,0,0 2005-004431-21,2,2010-04-29,2010-04-29,2,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Fresenius Biotech GmbH,"Estudio abierto, multicéntrico, aleatorio, con el objetivo de evaluar la eficacia y la seguridad de la inmunosupresión tras un primer trasplante renal cadavérico a corazón latiente basado la utilizaci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004431-21,0,0,0 2005-004433-18,2,2009-05-12,2009-05-12,1,0,0,0,0,0,4,1,0,2,0,0,0,0,0,Fondazione P E N T A,PLASMA PHARMACOKINETIC STUDY OF ONCE VERSUS TWICE DAILY ABACAVIR AS PART OF COMBINATION ANTIRETROVIRAL THERAPY IN CHILDREN WITH HIV-1 INFECTION AGED 3 MONTHS TO < 36 MONTHS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004433-18,1,0,0 2005-004433-18,2,2009-05-12,2009-05-12,1,0,0,0,0,0,4,1,0,2,0,0,0,0,0,PENTA,PLASMA PHARMACOKINETIC STUDY OF ONCE VERSUS TWICE DAILY ABACAVIR AS PART OF COMBINATION ANTIRETROVIRAL THERAPY IN CHILDREN WITH HIV-1 INFECTION AGED 3 MONTHS TO < 36 MONTHS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004433-18,1,0,0 2005-004434-40,2,2006-08-18,2006-08-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A randomised, double-blind, double dummy, 3 way cross-over study evaluating the effects of Seretide 50/500mcg twice daily plus tiotropium bromide 18mcg once daily compared with the individual treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004434-40,0,0,0 2005-004435-22,2,,,0,1,0,0,0,0,0,0,0,2,0,0,0,0,1,OCTAPHARMA AG,INCIDENCE OF INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEAMOPHILIA A TREATED WITH OCTANATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004435-22,0,0,0 2005-004437-18,1,2013-01-19,2013-01-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Otolaryngology, Head and Neck Surgery Johannes Gutenberg-Universität Mainz",Placebo-controlled double-blind study about the effectiveness of longtime acetylsalicylic acid desactivation therapy as prevention of recurrens of poyposis nasi in case of acetylsalicylic acid intole...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004437-18,0,0,0 2005-004442-14,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,UNIVERSITA' DEGLI STUDI DI UDINE,A pilot clinical trial to evaluate the ability of pegylate r-metHg-CSF (Pegilgrastim) to accelerate haematology recovery of patients with Non-Hodgkins Lymphoma after High-dose chemiotherapy and autolo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004442-14,0,0,0 2005-004448-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Barrier Therapeutics nv,"A double-blind, placebo-controlled, randomized, multicenter, parallel-group phase IIa trial to assess the efficacy, safety and tolerability of topical 0.35% R115866 gel applied during 12 consecutive w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004448-30,0,0,0 2005-004449-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE,EFFECTIVENESS OF THE LEVOSIMENDAN IN THE THERAPY OF DIASTOLIC DYSFUNCTION OF CARDIAC SURGERY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004449-32,0,0,0 2005-004450-27,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,GENZYME,Follow-up of Thyroid Cancer Patients from Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004450-27,0,0,0 2005-004451-35,5,2011-07-29,2011-07-29,4,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Genzyme Europe BV,"Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004451-35,0,0,0 2005-004452-13,7,2007-04-14,2007-07-13,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Inc,"A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED DETROL LA ADD-ON TO ALPHA-BLOCKER STUDY IN MEN WITH PERSISTENT OVERACTIVE BLADDER SYMPTOMS OF URINARY FREQUENCY AND URGENCY WITH/WITHOUT URGENCY INCO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004452-13,0,0,0 2005-004452-13,7,2007-04-14,2007-07-13,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,PFIZER,"A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED DETROL LA ADD-ON TO ALPHA-BLOCKER STUDY IN MEN WITH PERSISTENT OVERACTIVE BLADDER SYMPTOMS OF URINARY FREQUENCY AND URGENCY WITH/WITHOUT URGENCY INCO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004452-13,0,0,0 2005-004452-13,7,2007-04-14,2007-07-13,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED DETROL LA ADD-ON TO ALPHA-BLOCKER STUDY IN MEN WITH PERSISTENT OVERACTIVE BLADDER SYMPTOMS OF URINARY FREQUENCY AND URGENCY WITH/WITHOUT URGENCY INCO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004452-13,0,0,0 2005-004452-13,7,2007-04-14,2007-07-13,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer AB,"A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED DETROL LA ADD-ON TO ALPHA-BLOCKER STUDY IN MEN WITH PERSISTENT OVERACTIVE BLADDER SYMPTOMS OF URINARY FREQUENCY AND URGENCY WITH/WITHOUT URGENCY INCO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004452-13,0,0,0 2005-004452-13,7,2007-04-14,2007-07-13,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Ltd,"A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED DETROL LA ADD-ON TO ALPHA-BLOCKER STUDY IN MEN WITH PERSISTENT OVERACTIVE BLADDER SYMPTOMS OF URINARY FREQUENCY AND URGENCY WITH/WITHOUT URGENCY INCO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004452-13,0,0,0 2005-004452-13,7,2007-04-14,2007-07-13,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED DETROL LA ADD-ON TO ALPHA-BLOCKER STUDY IN MEN WITH PERSISTENT OVERACTIVE BLADDER SYMPTOMS OF URINARY FREQUENCY AND URGENCY WITH/WITHOUT URGENCY INCO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004452-13,0,0,0 2005-004452-13,7,2007-04-14,2007-07-13,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Inc.,"A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED DETROL LA ADD-ON TO ALPHA-BLOCKER STUDY IN MEN WITH PERSISTENT OVERACTIVE BLADDER SYMPTOMS OF URINARY FREQUENCY AND URGENCY WITH/WITHOUT URGENCY INCO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004452-13,0,0,0 2005-004454-27,1,2009-07-31,2009-07-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Heinrich-Heine-Universität,"Klinische Phase II-Prüfung zur Bestimmung von Wirksamkeit und Verträglichkeit der Kombination von 5-Azacytidin und Valproinsäure bei Personen mit MDS und anderen myeloischen Neoplasien, bei denen eine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004454-27,0,0,0 2005-004455-35,1,2008-06-11,2008-06-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Clinical Pharmacology, Medical University of Vienna",Plasma and abscess fluid pharmacokinetics of cefpirome and moxifloxacin after single dose and multiple dose administration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004455-35,0,0,0 2005-004457-10,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Laboratoires Expanscience,Clinical and biological activity of Piascledine® 300 in patients with chronic periodontitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004457-10,0,0,0 2005-004459-36,1,2006-09-05,2006-09-05,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Chiron Behring GmbH & Co KG,"A phase IV, randomized, open-label, multi-center study in adults: Evaluation of long-term immunogenicity in subjects boosted with a new TBE vaccine for adults (free of protein-derived stabilizer) in s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004459-36,0,0,0 2005-004460-22,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Hopital Erasme,"Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo neph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004460-22,0,0,0 2005-004464-24,6,2006-10-30,2006-12-12,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Integrated Therapeutics Group, Inc","A Double-blind, Placebo-controlled, Randomized, Parallel-group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects with Symptomatic Seasonal Al...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004464-24,0,0,0 2005-004464-24,6,2006-10-30,2006-12-12,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SCHERING-PLOUGH,"A Double-blind, Placebo-controlled, Randomized, Parallel-group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects with Symptomatic Seasonal Al...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004464-24,0,0,0 2005-004465-41,1,2009-05-25,2009-05-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHERING-PLOUGH,"A multi-center, open-label trial evaluating the Efficacy, Safety and the Impact on Quality of Life of Infliximab Therapy in patients with moderate to severe psoriasis not responding and/or intolerant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004465-41,0,0,0 2005-004468-22,1,2008-07-01,2008-07-01,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"Klinikum der Universität München, Kinderklinik und Poliklinik im Dr. von Haunerschen Kinderspital","HEAD-TO-HEAD evaluation of the antiepileptic drugs Levetiracetam (LEV) vs. Sulthiame (STM) in a German multi-centre, doubleblind controlled trial in children with benign epilepsy with centro-temporal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004468-22,0,0,0 2005-004469-40,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Hopital Erasme,"Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndrome ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004469-40,0,0,0 2005-004473-14,1,2007-05-21,2007-05-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,Proof of concept study to investigate the impact of BAY 58-2667 given intravenously in patients with acute decompensated chronic congestive heart failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004473-14,0,0,0 2005-004474-25,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Dr. Willmar Schwabe GmbH & Co. KG,"Multi-center, double-blind, placebo-controlled, randomized dose-finding study on Lavender oil WS 1265 (Lavandula angustifolia) in patients with generalized anxiety disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004474-25,0,0,0 2005-004475-37,1,2007-04-20,2007-04-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee ( Research & Innovation Services),Comparative study of the bioactivity of the HFA Fluticasone Dipropionate via current delivery devices,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004475-37,0,0,0 2005-004476-20,1,2006-03-11,2006-03-11,1,1,0,0,0,3,3,0,1,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,"Randomisierte, doppelblinde, placebokontrollierte Studie im Parallelgruppen-Design zur Untersuchung der Wirkung von Ginkgo-Spezialextrakt EGb 761® auf Lernprozesse bei gesunden Probanden",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004476-20,0,0,0 2005-004478-26,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Karolinska universitetssjukhuset,"Effects of growth hormone treatment to patients with partial growth hormone deficiency, with special emphasis on acute phase proteins and pro-inflammatory cytokines.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004478-26,0,0,0 2005-004479-38,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)",Effects of the association remifentanil-propofol in TCI on the respiratory exchanges: comparison between controlled and spontaneous ventilation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004479-38,0,0,0 2005-004480-37,1,2006-08-22,2006-08-22,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A single blind, placebo controlled, multi-centre study to investigate the pharmacokinetics, safety, tolerability and pharmacodynamics of the TRPV1 antagonist SB-705498 against the pain of acute migrai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004480-37,0,0,0 2005-004481-16,2,2007-10-02,2007-10-02,1,1,0,0,1,0,2,0,2,1,0,0,1,0,1,GLAXOSMITHKLINE,"A multi-centre, randomised, single blind, placebo controlled, parallel group study to examine the effect of single doses of SB-705498, a TRPV1 receptor antagonist, on pain following third molar tooth ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004481-16,0,0,0 2005-004481-16,2,2007-10-02,2007-10-02,1,1,0,0,1,0,2,0,2,1,0,0,1,0,1,GlaxoSmithKline Research and Development,"A multi-centre, randomised, single blind, placebo controlled, parallel group study to examine the effect of single doses of SB-705498, a TRPV1 receptor antagonist, on pain following third molar tooth ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004481-16,0,0,0 2005-004482-41,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Napp Pharmaceuticals Research Limited,"A randomised, double blind, double-dummy, parallel group study to compare the efficacy and tolerability of morphine sulphate prolonged release capsules and methadone oral solution in once per day admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004482-41,0,0,0 2005-004486-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Eastern Norway Regional Health Authority,"Catheter-directed Venous Thrombolysis (CaVenT) in Acute Iliofemoral Vein Thrombosis - an open Randomized, Controlled, Clinical Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004486-42,0,0,0 2005-004486-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ullevaal University Hospital,"Catheter-directed Venous Thrombolysis (CaVenT) in Acute Iliofemoral Vein Thrombosis - an open Randomized, Controlled, Clinical Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004486-42,0,0,0 2005-004487-22,2,2007-07-17,2007-07-21,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Bio-Medisinsk Innovasjon AS,A Proof of Biological Efficacy Study Assessing the Potential of Piboserod a Specific 5-HT4 Antagonist for the Treatment of Symptomatic Congestive Heart Failure in stable outpatients NYHA class II-III ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004487-22,0,0,0 2005-004492-37,1,2007-07-24,2007-07-24,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Klinik für Anästhesiologie; Johannes Gutenberg Universität,Untersuchung über den Einfluss einer Omega-3 reichen parenteralen Ernährung auf die zelluläre Abwehr an postoperativen Patienten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004492-37,0,0,0 2005-004493-25,4,2006-06-23,2006-06-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004493-25,0,0,0 2005-004495-21,1,2007-08-17,2007-08-17,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Gilead Sciences GmbH,Pilot study on safety of four weekly administrations of 7 mg/kg of liposomal amphotericin B (AmBisome®) in antifungal primary prophylaxis treatment of elderly patients with acute lymphoblastic leukemi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004495-21,0,0,0 2005-004496-38,1,2009-06-12,2009-06-12,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,"Rigshospitalet, Copenhagen",Desmopressin in the management of von Willebrand disease; Biological versus clinical efficacy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004496-38,0,0,0 2005-004497-24,1,,,0,1,0,1,0,0,1,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"Observer-blinded, randomised, controlled, phase I/II study, to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ candidate tuberculosis vaccines M72/AS01B and M72/AS02A when ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004497-24,0,0,0 2005-004498-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE SANTA LUCIA,Behaviour and cognition in Alzheimer s disease patients treated with the NMDA receptor antagonist memantine collelation with the apoptotic mechanisms.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004498-31,0,0,0 2005-004499-19,2,2006-10-06,2006-10-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Limited,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of L-000796568 in Postmenopausal Women With Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004499-19,0,0,0 2005-004499-19,2,2006-10-06,2006-10-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Ireland (Human Health) Limited,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of L-000796568 in Postmenopausal Women With Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004499-19,0,0,0 2005-004500-37,1,2009-03-12,2009-03-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,SIGMA-TAU,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients with Venous Stasis Ulcers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004500-37,0,0,0 2005-004501-28,1,2013-02-22,2013-02-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Psychiatry, Ludwig-Maximilians-University Munich",Study to compare the efficacy of ziprasidone (Zeldox) and aripiprazole (Abilify) on cognitive functioning and quality of sleep in the treatment of schizophrenic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004501-28,0,0,0 2005-004502-82,1,2015-12-22,2015-12-22,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,A Phase II Study of Neoadjuvant Sunitinib in Metastatic Renal Cell Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004502-82,0,0,0 2005-004503-11,3,2013-05-27,2013-05-27,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Eisai Inc.,Randomized Phase 3 Trial of Decitabine Versus Patient's Choice with Physician's Advice of Either Supportive Care or Low-dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute M...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004503-11,0,0,0 2005-004503-11,3,2013-05-27,2013-05-27,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,MGI Pharma Inc.,Randomized Phase 3 Trial of Decitabine Versus Patient's Choice with Physician's Advice of Either Supportive Care or Low-dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute M...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004503-11,0,0,0 2005-004503-11,3,2013-05-27,2013-05-27,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Eisai Medical Research Inc.,Randomized Phase 3 Trial of Decitabine Versus Patient's Choice with Physician's Advice of Either Supportive Care or Low-dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute M...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004503-11,0,0,0 2005-004504-36,6,2008-03-13,2008-04-28,6,1,0,0,0,2,3,0,0,1,0,0,1,0,2,Merck & Co. Inc.,"A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004504-36,0,0,0 2005-004504-36,6,2008-03-13,2008-04-28,6,1,0,0,0,2,3,0,0,1,0,0,1,0,2,MERCK SHARP DOHME,"A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004504-36,0,0,0 2005-004504-36,6,2008-03-13,2008-04-28,6,1,0,0,0,2,3,0,0,1,0,0,1,0,2,Merck & Co. Inc,"A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004504-36,0,0,0 2005-004504-36,6,2008-03-13,2008-04-28,6,1,0,0,0,2,3,0,0,1,0,0,1,0,2,"Merck sharp & Dohme, Lda.","A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004504-36,0,0,0 2005-004504-36,6,2008-03-13,2008-04-28,6,1,0,0,0,2,3,0,0,1,0,0,1,0,2,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004504-36,0,0,0 2005-004504-36,6,2008-03-13,2008-04-28,6,1,0,0,0,2,3,0,0,1,0,0,1,0,2,Merck Sharp & Dohme BV,"A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004504-36,0,0,0 2005-004505-29,1,2015-02-10,2015-02-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Marsden NHS Trust,Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004505-29,0,0,0 2005-004508-35,1,2008-05-30,2008-05-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Marsden Hospital,THE USE OF PET/CT SCANNING TO ASSESS EARLY RESPONDERS TO TARCEVA (ERLOTINIB): A PHASE II STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004508-35,0,0,0 2005-004509-27,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Cliniques Hopitaux Universitaires NANTES,Intérêt de la rapamicine (Rapamune(R)) pour la prévention secondaire des cancers cutanés chez les transplantés rénaux ayant présentant plus d'un Carcinome Spinocellaire.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004509-27,0,0,0 2005-004509-27,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Intérêt de la rapamicine (Rapamune(R)) pour la prévention secondaire des cancers cutanés chez les transplantés rénaux ayant présentant plus d'un Carcinome Spinocellaire.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004509-27,0,0,0 2005-004510-33,10,2008-11-27,2008-11-27,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, controlled, open-label, multi-center, parallel-group study to compare the efficacy and safety of RO0503821 with that of darbepoetin alfa administered intravenously at extended dosing int...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004510-33,0,0,0 2005-004510-33,10,2008-11-27,2008-11-27,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A randomized, controlled, open-label, multi-center, parallel-group study to compare the efficacy and safety of RO0503821 with that of darbepoetin alfa administered intravenously at extended dosing int...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004510-33,0,0,0 2005-004511-29,1,2007-07-07,2007-07-07,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Barnsley Hospital NHS Foundation Trust,Pilot Study of Homeopathic Treatment of Fibromyalgia Syndrome (HOFS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004511-29,0,0,0 2005-004513-15,1,2006-12-13,2006-12-13,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Univ. Prof. Dr. Christoph Zielinski,ASSESSMENT OF BIOCHEMICAL MARKERS OF BONE TURNOVER IN PATIENTS WITH METASTATIC BREAST CANCER SWITCHED FROM INTRAVENOUS ZOLEDRONIC ACID THERAPY TO ORAL IBANDRONATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004513-15,0,0,0 2005-004514-32,12,2009-06-01,2009-08-07,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Pfizer Inc.,"A 102-WEEK, OPEN LABEL, MULTICENTER TRIAL TO INVESTIGATE THE EFFICACY OF MACUGEN FOR THE PRESERVATION OF VISUAL FUNCTION IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMD AND TO A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004514-32,0,0,0 2005-004514-32,12,2009-06-01,2009-08-07,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Pfizer Inc,"A 102-WEEK, OPEN LABEL, MULTICENTER TRIAL TO INVESTIGATE THE EFFICACY OF MACUGEN FOR THE PRESERVATION OF VISUAL FUNCTION IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMD AND TO A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004514-32,0,0,0 2005-004514-32,12,2009-06-01,2009-08-07,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Pfizer AB,"A 102-WEEK, OPEN LABEL, MULTICENTER TRIAL TO INVESTIGATE THE EFFICACY OF MACUGEN FOR THE PRESERVATION OF VISUAL FUNCTION IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMD AND TO A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004514-32,0,0,0 2005-004514-32,12,2009-06-01,2009-08-07,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Pfizer Corporation Austria Ges.m.b.H.,"A 102-WEEK, OPEN LABEL, MULTICENTER TRIAL TO INVESTIGATE THE EFFICACY OF MACUGEN FOR THE PRESERVATION OF VISUAL FUNCTION IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMD AND TO A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004514-32,0,0,0 2005-004514-32,12,2009-06-01,2009-08-07,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Pfizer Ltd,"A 102-WEEK, OPEN LABEL, MULTICENTER TRIAL TO INVESTIGATE THE EFFICACY OF MACUGEN FOR THE PRESERVATION OF VISUAL FUNCTION IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMD AND TO A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004514-32,0,0,0 2005-004514-32,12,2009-06-01,2009-08-07,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,PFIZER,"A 102-WEEK, OPEN LABEL, MULTICENTER TRIAL TO INVESTIGATE THE EFFICACY OF MACUGEN FOR THE PRESERVATION OF VISUAL FUNCTION IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMD AND TO A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004514-32,0,0,0 2005-004514-32,12,2009-06-01,2009-08-07,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Pfizer S.A. Belgium,"A 102-WEEK, OPEN LABEL, MULTICENTER TRIAL TO INVESTIGATE THE EFFICACY OF MACUGEN FOR THE PRESERVATION OF VISUAL FUNCTION IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMD AND TO A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004514-32,0,0,0 2005-004514-32,12,2009-06-01,2009-08-07,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Pfizer Limited,"A 102-WEEK, OPEN LABEL, MULTICENTER TRIAL TO INVESTIGATE THE EFFICACY OF MACUGEN FOR THE PRESERVATION OF VISUAL FUNCTION IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMD AND TO A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004514-32,0,0,0 2005-004514-32,12,2009-06-01,2009-08-07,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Pfizer, S.A.","A 102-WEEK, OPEN LABEL, MULTICENTER TRIAL TO INVESTIGATE THE EFFICACY OF MACUGEN FOR THE PRESERVATION OF VISUAL FUNCTION IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMD AND TO A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004514-32,0,0,0 2005-004514-32,12,2009-06-01,2009-08-07,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,,"A 102-WEEK, OPEN LABEL, MULTICENTER TRIAL TO INVESTIGATE THE EFFICACY OF MACUGEN FOR THE PRESERVATION OF VISUAL FUNCTION IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMD AND TO A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004514-32,0,0,0 2005-004514-32,12,2009-06-01,2009-08-07,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Pfizer Hellas AE,"A 102-WEEK, OPEN LABEL, MULTICENTER TRIAL TO INVESTIGATE THE EFFICACY OF MACUGEN FOR THE PRESERVATION OF VISUAL FUNCTION IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMD AND TO A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004514-32,0,0,0 2005-004514-32,12,2009-06-01,2009-08-07,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Pfizer Pharma GmbH,"A 102-WEEK, OPEN LABEL, MULTICENTER TRIAL TO INVESTIGATE THE EFFICACY OF MACUGEN FOR THE PRESERVATION OF VISUAL FUNCTION IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AMD AND TO A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004514-32,0,0,0 2005-004517-14,1,2006-04-20,2006-04-20,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,Open study to determine the immunogenicity and reactogenicity of Influsplit SSW 2005/2006 in children from 6 years until 13 years of age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004517-14,0,0,0 2005-004519-32,1,2010-11-30,2010-11-30,1,1,0,0,1,3,2,0,0,1,0,0,1,0,0,"Medical University Vienna, Dept. of surgery",A randomised controlled pilot study of the efficacy of adding bevacizumab to gemcitabine as neoadjuvant treatment for locally advanced non metastatic pancreatic cancer - Neo-Avastin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004519-32,0,0,0 2005-004523-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Área de Trasplante y Terapia Celular - Hospital Central de Asturias,Phase II clinical trial to evaluate the efficacy and safety in the use of pancreatic islets cells from cadaver donors for the treatment of Type-I Diabetes Mellitus in renal transplant patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004523-19,0,0,0 2005-004525-26,1,2010-09-17,2010-09-17,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Ruhr Universität Bochum,Cognitive behavioural therapy vs. sertraline in patients with depression and poorly controlled diabetes mellitus: A randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004525-26,0,0,0 2005-004526-72,1,2006-11-03,2006-11-03,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Addenbrooke's NHS Trust,A randomised controlled study of continuous subcutaneous insulin infusion (CSII) therapy compared to conventional bolus insulin treatment in preschool aged children with Type 1 diabetes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004526-72,0,0,0 2005-004527-19,1,2007-08-30,2007-08-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,MRC Health Services Research Collaboration,Joint pain personalised treatment assessment to investigate the acceptability of modified release oxycontin for managing chronic pain in patients with osteoarthritis of the hip,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004527-19,0,0,0 2005-004530-40,1,2008-04-23,2008-04-23,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,AESCA Pharma Ges.m.b.H,Induction of remission in RA patients at low disease activity by additional Infliximab-therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004530-40,0,0,0 2005-004531-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Májbetegekért Alapítvány,Efficacy and Safety of Continuing for a Total of 48 or Prolonging for a Total of 72 weeks of Combined Treatment of Patients Receiving Pegasys and Copegus who are Biochemical Responders but Virologic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004531-22,0,0,0 2005-004532-43,1,2007-11-26,2007-11-26,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,"Klinikum Großhadern, ENT-Department","Treatment of extraesophageal manifestations of laryngopharyngeal reflux with Nexium (esomeprazole) 20mg bid, a doubleblind placebo controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004532-43,0,0,0 2005-004534-40,4,2009-11-26,2020-11-26,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development","A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT-WITHDRAWAL STUDY OF THE EFFICACY AND SAFETY OF PANTOPRAZOLE SODIUM ENTERIC-COATED GRANULES IN INFANTS (1 THROUGH 11 MONTHS) WITH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004534-40,0,0,0 2005-004540-31,1,2009-12-15,2009-12-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Universitätsklinikum Tübingen,"Monozentrische, randomisierte, placebo-kontrollierte Studie zur Evaluation der Nephroprotektion durch Theophyllin unter Cisplatin-haltiger Chemotherapie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004540-31,0,0,0 2005-004541-34,1,2008-10-02,2008-10-02,1,1,0,0,0,1,4,0,0,1,1,1,1,0,0,South Manchester University Healthcare Trust,The Effect of Enteral Administration of Synbiotics Upon Infection Rates in Major Burns,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004541-34,0,0,0 2005-004543-57,6,2008-04-23,2008-05-21,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA,"A 6-month randomized, double-blind, parallel-group, multicentre, placebo-controlled Phase II study to compare anti-asthmatic effect and safety of esomeprazole NexiumTR 40 mg twice daily or 40 mg onc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004543-57,0,0,0 2005-004543-57,6,2008-04-23,2008-05-21,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 6-month randomized, double-blind, parallel-group, multicentre, placebo-controlled Phase II study to compare anti-asthmatic effect and safety of esomeprazole NexiumTR 40 mg twice daily or 40 mg onc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004543-57,0,0,0 2005-004545-34,1,2008-10-31,2008-10-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Unit of Esophageal and Gastric Research Dep. of Molecular Medicine and Surgery Karolinska Institutet,Can Angiotensin II type 1 Receptor Inhibitor Be Used to Lower the Amount of Lipase and Amylase Level after Endoscopic Retrograde Cholangio-Pancreatography?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004545-34,0,0,0 2005-004548-30,1,2015-06-26,2015-06-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II randomised, double-blind, stratified, multi-centre trial comparing the Nolvadex 20 mg and placebo combination to the Nolvadex 20 mg and ZD1839 (IRESSA™) 250 mg combination in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004548-30,0,0,0 2005-004555-35,10,2006-06-21,2008-07-17,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Pharma GmbH,"INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF PACLITAXEL/CARBOPLATIN PLUS PF-3512676 VERSUS PACLITAXEL/CARBOPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004555-35,0,0,0 2005-004555-35,10,2006-06-21,2008-07-17,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Ltd,"INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF PACLITAXEL/CARBOPLATIN PLUS PF-3512676 VERSUS PACLITAXEL/CARBOPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004555-35,0,0,0 2005-004555-35,10,2006-06-21,2008-07-17,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF PACLITAXEL/CARBOPLATIN PLUS PF-3512676 VERSUS PACLITAXEL/CARBOPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004555-35,0,0,0 2005-004555-35,10,2006-06-21,2008-07-17,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc,"INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF PACLITAXEL/CARBOPLATIN PLUS PF-3512676 VERSUS PACLITAXEL/CARBOPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004555-35,0,0,0 2005-004555-35,10,2006-06-21,2008-07-17,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer S.A,"INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF PACLITAXEL/CARBOPLATIN PLUS PF-3512676 VERSUS PACLITAXEL/CARBOPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004555-35,0,0,0 2005-004555-35,10,2006-06-21,2008-07-17,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Hellas A.E.,"INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF PACLITAXEL/CARBOPLATIN PLUS PF-3512676 VERSUS PACLITAXEL/CARBOPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004555-35,0,0,0 2005-004555-35,10,2006-06-21,2008-07-17,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer,"INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF PACLITAXEL/CARBOPLATIN PLUS PF-3512676 VERSUS PACLITAXEL/CARBOPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004555-35,0,0,0 2005-004555-35,10,2006-06-21,2008-07-17,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer S.A.,"INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF PACLITAXEL/CARBOPLATIN PLUS PF-3512676 VERSUS PACLITAXEL/CARBOPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004555-35,0,0,0 2005-004557-10,10,2006-06-21,2008-06-25,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF GEMCITABINE/CISPLATIN PLUS PF-3512676 VERSUS GEMCITABINE/CISPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004557-10,0,0,0 2005-004557-10,10,2006-06-21,2008-06-25,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc,"INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF GEMCITABINE/CISPLATIN PLUS PF-3512676 VERSUS GEMCITABINE/CISPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004557-10,0,0,0 2005-004557-10,10,2006-06-21,2008-06-25,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Corporation Austria Ges.m.b.H,"INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF GEMCITABINE/CISPLATIN PLUS PF-3512676 VERSUS GEMCITABINE/CISPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004557-10,0,0,0 2005-004557-10,10,2006-06-21,2008-06-25,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Ltd,"INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF GEMCITABINE/CISPLATIN PLUS PF-3512676 VERSUS GEMCITABINE/CISPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004557-10,0,0,0 2005-004557-10,10,2006-06-21,2008-06-25,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Kft.,"INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF GEMCITABINE/CISPLATIN PLUS PF-3512676 VERSUS GEMCITABINE/CISPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004557-10,0,0,0 2005-004557-10,10,2006-06-21,2008-06-25,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer, S.A.","INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF GEMCITABINE/CISPLATIN PLUS PF-3512676 VERSUS GEMCITABINE/CISPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004557-10,0,0,0 2005-004557-10,10,2006-06-21,2008-06-25,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Pharma GmbH,"INTERNATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF GEMCITABINE/CISPLATIN PLUS PF-3512676 VERSUS GEMCITABINE/CISPLATIN ALONE AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004557-10,0,0,0 2005-004559-36,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Abteilung für Herz-Thorax-Gefäß Anästhesie & Intensivmedizin (HTG),Desmopressin in Acquired von Willebrand Syndrome caused by Aortic Valve Stenosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004559-36,0,0,0 2005-004566-16,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Novartis Pharma Services AG,Part 1: An open Label Pilot Study to Determine Interstitial and Tissue Concentrations of Aliskiren and Effects on the Renin-Angiotensin System (RAS) in Fat and Skeletal Muscle of Hypertensive Patients...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004566-16,0,0,0 2005-004569-40,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO CLINICO HUMANITAS,Phase I and II perspective study with Citrate in Liposoma not Pegilate Doxorubicine TLC D-99 in association to Ifosfamide in patients with metastatic soft tissue sarcoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004569-40,0,0,0 2005-004575-37,3,2009-09-07,2011-08-02,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocortic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004575-37,0,0,0 2005-004577-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitetet i Bergen,Remifentanil as pain relief during labour,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004577-23,0,0,0 2005-004579-39,2,2007-06-03,2007-07-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An eight-week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in comparison with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004579-39,0,0,0 2005-004579-39,2,2007-06-03,2007-07-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An eight-week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in comparison with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004579-39,0,0,0 2005-004580-40,7,2007-08-09,2007-08-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An eight-week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / HCTZ (150/25 mg and 300/25 mg) in comparison with HCTZ ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004580-40,0,0,0 2005-004582-41,1,2009-09-01,2009-09-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leeds,Safety and efficacy of combination treatment with rituximab and leflunomide in patients with active rheumatoid arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004582-41,0,0,0 2005-004587-23,1,2009-11-25,2009-11-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UZ Leuven,A belgian multicenter phase II randomized trial in her2 negative metastatic breast cancer evaluating consolidation antiangiogenic therapy with SU11248 after response to taxane chemotherapy induction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004587-23,0,0,0 2005-004589-18,3,2008-03-06,2008-03-26,3,0,0,0,0,0,3,0,0,1,1,0,1,0,1,MannKind Corporation,"A Phase 3, 12-Month Treatment, Multicenter, Randomized, Open-Label, Parallel Group Clinical Trial Comparing Prandial Subcutaneous Insulin with Prandial Inhaled Technosphere®/Insulin in Subjects with D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004589-18,0,0,0 2005-004590-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO,PHASE II PILOT PROTOCOL OF BONEMARROW STAM CELLS MOBILIZATION BY CYTOCHINE STIMULATION IN PATIENTS WITH COMPLEX ANAL FISTULAS AND/OR RECURRENCES AND/OR ANAL-PERIANAL LOCALIZATIONS OF IBD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004590-24,0,0,0 2005-004596-38,1,2016-08-29,2016-08-29,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,Eskelinen Matti/KYS,Oksikodonin analgeettinen pitoisuus plasmassa avo-ja laparoskooppisesti sappileikatuilla aikuispotilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004596-38,0,0,0 2005-004597-24,4,2007-08-15,2007-08-21,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A randomised, double-blind, placebo-controlled, five parallel groups efficacy and safety exploratory study comparing BI 1356 BS (1mg, 5mg and 10mg) to open label glimepiride each administered orally o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004597-24,0,0,0 2005-004597-24,4,2007-08-15,2007-08-21,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, placebo-controlled, five parallel groups efficacy and safety exploratory study comparing BI 1356 BS (1mg, 5mg and 10mg) to open label glimepiride each administered orally o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004597-24,0,0,0 2005-004597-24,4,2007-08-15,2007-08-21,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A randomised, double-blind, placebo-controlled, five parallel groups efficacy and safety exploratory study comparing BI 1356 BS (1mg, 5mg and 10mg) to open label glimepiride each administered orally o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004597-24,0,0,0 2005-004598-20,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,Clinical study of the association between n-3 PUFA and statin effects on inflammation and lipids.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004598-20,0,0,0 2005-004599-19,9,2020-08-17,2020-08-17,1,0,1,0,0,1,3,0,0,2,0,0,0,0,0,Dutch Childhood Oncology Group,INTERFANT 06 INTERFANT 06 - International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004599-19,1,0,0 2005-004599-19,9,2020-08-17,2020-08-17,1,0,1,0,0,1,3,0,0,2,0,0,0,0,0,DCOG,INTERFANT 06 INTERFANT 06 - International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004599-19,1,0,0 2005-004599-19,9,2020-08-17,2020-08-17,1,0,1,0,0,1,3,0,0,2,0,0,0,0,0,St. Anna Kinderkrebsforschung,INTERFANT 06 INTERFANT 06 - International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004599-19,1,0,0 2005-004599-19,9,2020-08-17,2020-08-17,1,0,1,0,0,1,3,0,0,2,0,0,0,0,0,University of Birmingham,INTERFANT 06 INTERFANT 06 - International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004599-19,1,0,0 2005-004599-19,9,2020-08-17,2020-08-17,1,0,1,0,0,1,3,0,0,2,0,0,0,0,0,A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA,INTERFANT 06 INTERFANT 06 - International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004599-19,1,0,0 2005-004599-19,9,2020-08-17,2020-08-17,1,0,1,0,0,1,3,0,0,2,0,0,0,0,0,Dutch Childhood Oncology Group (DCOG),INTERFANT 06 INTERFANT 06 - International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004599-19,1,0,0 2005-004602-86,1,2016-12-31,2016-12-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Medical University of Vienna,A comparison of crystalloids vs. colloids for intraoperative goal-directed fluid management,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004602-86,0,0,0 2005-004604-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Gallego de Cáncer de Pulmón (GGCP),"Ensayo clínico fase II, abierto, no aleatorizado, de erlotinib (Tarceva®) como tratamiento de mantenimiento en pacientes con cáncer de pulmón no microcítico en estadio III tras tratamiento con quimiot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004604-36,0,0,0 2005-004605-29,1,2011-04-27,2011-04-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A Phase IIIb Study of Tarceva (Erlotinib) in patients with locally advanced, unresectable or metastatic pancreatic cancer Studio Clinico di Fase IIIb in pazienti con carcinoma del pancreas ad uno ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004605-29,0,0,0 2005-004607-11,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Hopital Erasme,"Prospective, randomized, long-term study compairing a Neoral (C-0h monitoring)-based steroid-free to an everolimus-myfortic based, calcineurin-inhibitor-free immunosuppressive treatment on graft funct...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004607-11,0,0,0 2005-004611-30,2,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Barrier Therapeutics nv,An open label phase IIa trial to assess efficacy and tolerability of a once a week oral dose of 200 mg R126638 in disto-lateral toenail onychomycosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004611-30,0,0,0 2005-004614-32,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,0,ISTITUTO EUROPEO DI ONCOLOGIA,Randomized phase II trial of Budesonide Turbuhaler 800 micrograms/twice daily versus placebo in high-risk population with undetermined lung nodules detected at screening low dose CT scan,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004614-32,0,0,0 2005-004617-15,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Klinik für Anästhesiologie und Operative Intensivmedizin Klinikum Ludwigshafen,„Einsatz des Beta-Blockers Esmolol in Kombination mit dem Phosphodiesterase-III-Hemmer Enoximon im Vergleich zur alleinigen Gabe von Esmolol zur Optimierung der Hämodynamik bei Patienten mit koronarer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004617-15,0,0,0 2005-004620-40,8,2007-01-18,2007-04-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Ensayo clínico controlado, doble ciego y aleatorizado de BAY 59-7939 en la prevención del tromboembolismo venoso en sujetos con cirugía electiva de sustitución total de rodilla. Estudio RECORD 3 RECO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004620-40,0,0,0 2005-004620-40,8,2007-01-18,2007-04-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER,"Ensayo clínico controlado, doble ciego y aleatorizado de BAY 59-7939 en la prevención del tromboembolismo venoso en sujetos con cirugía electiva de sustitución total de rodilla. Estudio RECORD 3 RECO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004620-40,0,0,0 2005-004620-40,8,2007-01-18,2007-04-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AS,"Ensayo clínico controlado, doble ciego y aleatorizado de BAY 59-7939 en la prevención del tromboembolismo venoso en sujetos con cirugía electiva de sustitución total de rodilla. Estudio RECORD 3 RECO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004620-40,0,0,0 2005-004621-25,7,2007-10-27,2008-03-14,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004621-25,0,0,0 2005-004621-25,7,2007-10-27,2008-03-14,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Janssen-Cilag Medical Affairs EMEA,Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004621-25,0,0,0 2005-004621-25,7,2007-10-27,2008-03-14,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,JANSSEN-CILAG EMEA,Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004621-25,0,0,0 2005-004621-25,7,2007-10-27,2008-03-14,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Janssen-Cilag Ltd,Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004621-25,0,0,0 2005-004621-25,7,2007-10-27,2008-03-14,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Janssen Cilag EMEA,Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004621-25,0,0,0 2005-004621-25,7,2007-10-27,2008-03-14,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Janssen-Cilag EMEA,Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004621-25,0,0,0 2005-004621-25,7,2007-10-27,2008-03-14,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Janssen-Cilag B.V.,Is premorbid functioning a predictor of outcome in patients with early onset psychosis treated with Risperdal Consta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004621-25,0,0,0 2005-004623-19,3,2007-05-18,2008-05-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Barrier Therapeutics, Inc.","A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Exploratory Study of the Safety and Efficacy of Oral R115866 vs. R115866 Placebo in the Treatment of Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004623-19,0,0,0 2005-004624-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen-Cilag EMEA Medical Affairs,"A Phase II, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade® added to Thalidomide-Dexamethasone Standard Treatment in Subjects with Multiple My...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004624-38,0,0,0 2005-004626-10,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Pulmonary Department, Gentofte Hospital","Smoking cessation by nurses with smokelesstobacco buccal tabltes, nicotine buccal tablets, nicotine patches with repeated thearapy every 6 months for 2 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004626-10,0,0,0 2005-004627-18,6,2014-05-23,2014-08-19,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Eli Lilly and Company Limited,"A Randomized Phase 3 Study of Enzastaurin versus Lomustine in the Treatment of Recurrent, Intracranial Glioblastoma Multiforme",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004627-18,0,0,0 2005-004627-18,6,2014-05-23,2014-08-19,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,ELI LILLY,"A Randomized Phase 3 Study of Enzastaurin versus Lomustine in the Treatment of Recurrent, Intracranial Glioblastoma Multiforme",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004627-18,0,0,0 2005-004627-18,6,2014-05-23,2014-08-19,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Eli Lilly and Company limited,"A Randomized Phase 3 Study of Enzastaurin versus Lomustine in the Treatment of Recurrent, Intracranial Glioblastoma Multiforme",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004627-18,0,0,0 2005-004627-18,6,2014-05-23,2014-08-19,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Lilly S.A.,"A Randomized Phase 3 Study of Enzastaurin versus Lomustine in the Treatment of Recurrent, Intracranial Glioblastoma Multiforme",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004627-18,0,0,0 2005-004630-41,12,2013-05-16,2013-07-31,7,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004630-41,0,0,0 2005-004630-41,12,2013-05-16,2013-07-31,7,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Eli Lilly and Company Limited,A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004630-41,0,0,0 2005-004630-41,12,2013-05-16,2013-07-31,7,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Eli Lilly and Company limited,A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004630-41,0,0,0 2005-004630-41,12,2013-05-16,2013-07-31,7,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Lilly S.A.,A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004630-41,0,0,0 2005-004630-41,12,2013-05-16,2013-07-31,7,1,0,0,0,2,3,0,0,1,1,0,1,0,1,ELI LILLY,A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004630-41,0,0,0 2005-004632-40,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,University Hospital Ghent,Study on the pharmacodynamic interactions between propofol and sevoflurane during induction of anesthesia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004632-40,0,0,0 2005-004636-52,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Heart of England NHS Foundation Trust,Randomised Double-Blind Placebo Controlled Trial of 40mg/day of Atorvastatin on Reduction in Severity of Sepsis in Ward Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004636-52,0,0,0 2005-004637-17,2,2008-08-11,2008-08-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALLERGAN LTD,A Multicenter Study Evaluating the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-W...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004637-17,0,0,0 2005-004639-24,1,2009-09-05,2009-09-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,Pharmacological intervention study with L-arginin in prevention of diabete type II in patients affected by metabolic syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004639-24,0,0,0 2005-004640-31,1,,,0,1,0,0,0,0,4,0,0,0,0,0,0,0,0,Technische Universität Dresden,Control of therapy of acne papulopustulosa by visible light with waterfiltered infrared and / or Adapalen (Differin Gel),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004640-31,0,0,0 2005-004641-34,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Matrixx Initiatives Inc,Human Clinical Study: Assessment of Zicam Cold Remedy RapidMelts,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004641-34,0,0,0 2005-004642-14,1,2007-04-26,2007-04-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen S.A.,"Estudio abierto, de un solo grupo, de palifermin para la reducción de la mucositis en sujetos con linfoma no Hodgkin (LNH) o mieloma múltiple (MM) sometidos a quimioterapia a altas dosis y trasplante ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004642-14,0,0,0 2005-004643-53,7,2011-05-13,2011-05-13,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,Bone Histomorphometry Assessment For Dialysis Patients with Secondary Hyperparathyroidism of End Stage Renal Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004643-53,0,0,0 2005-004643-53,7,2011-05-13,2011-05-13,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AMGEN S.P.A.,Bone Histomorphometry Assessment For Dialysis Patients with Secondary Hyperparathyroidism of End Stage Renal Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004643-53,0,0,0 2005-004645-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,SOFAR SPA,Valutation of the action of red chili Capsicum Annuum on the irritable colon symptomatology. A double blind placebo controlled study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004645-33,0,0,0 2005-004646-13,1,2013-06-04,2013-06-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"PEG-Filgrastim versus Filgrastim as an adjunct to therapy CHOP-14 Rituximab in elderly patients 60-75 years old with B cell non-Hodgkin s High/intermediate grade lymphoma. A randomized, prospecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004646-13,0,0,0 2005-004648-30,1,2006-06-29,2006-06-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Limited,"A randomized double blind, placebo controlled balanced 4-way crossover study to assess the efficacy of single oral doses of PF-00592379 on erectile function, using 100mg sildenafil as a positive contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004648-30,0,0,0 2005-004652-13,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,PLETHORA SOLUTIONS LIMITED,"Phase II, multi centre, randomised, double blind, placebo controlled, pilot study to determine efficacy, safety, tolerability and preliminary pharmacokinetics of PSD502 in the management of pain from ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004652-13,0,0,0 2005-004653-96,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Plethora Solutions Limited,"Phase II, single centre, randomised, double-blind, placebo-controlled study to determine the efficacy, safety and tolerability of PSD502 in the management of pain in subjects undergoing treatment for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004653-96,0,0,0 2005-004654-28,1,2008-12-03,2008-12-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Gilead Sciences, S.L.","Phase IV, multicenter, randomized, open-label pilot study of Truvada or Emtricitabine alone versus HAART interruption in HIV-infected patients who need to interrupt HAART and who are infected with HIV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004654-28,0,0,0 2005-004659-36,5,2008-04-07,2008-04-08,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Daiichi Sankyo Europe GmbH,Treat-to-target study of olmesartan medoxomil and an add-on treatment algorithm consisting of hydrochlorothiazide and amlodipine besylate in patients with mild to moderate hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004659-36,0,0,0 2005-004659-36,5,2008-04-07,2008-04-08,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Sankyo Pharma GmbH,Treat-to-target study of olmesartan medoxomil and an add-on treatment algorithm consisting of hydrochlorothiazide and amlodipine besylate in patients with mild to moderate hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004659-36,0,0,0 2005-004659-36,5,2008-04-07,2008-04-08,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Daiichi SankyoGmbH,Treat-to-target study of olmesartan medoxomil and an add-on treatment algorithm consisting of hydrochlorothiazide and amlodipine besylate in patients with mild to moderate hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004659-36,0,0,0 2005-004662-16,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,"Roche Farma, S.A.","Estudio fase I/II de la adición de erlotinib a la combinación de bevacizumab, capecitabina y oxaliplatino a dosis fijas, como terapia de primera línea en pacientes con adenocarcinoma colorrectal metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004662-16,0,0,0 2005-004664-23,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,SIGMA-TAU,The role of Acetyl-L-Carnitine in Reflex Sympathetic Dystrophy RDS and in Complex Regional Pain Syndrome CRPS .Pilot clinical trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004664-23,0,0,0 2005-004665-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,SIGMA-TAU,"Evaluation of the efficacy and tollerability of long-term somministration of Acetyl-l-carnitine in the treatment of HIV related lipodystrophy.Parallel group, randomized, double blind, controlled versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004665-42,0,0,0 2005-004667-36,2,2007-05-10,2007-06-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Takeda Global Research & Development Center, Inc.,","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with a Sulfonylurea in Subjects with Type 2 Diabe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004667-36,0,0,0 2005-004667-36,2,2007-05-10,2007-06-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Takeda Global Research & Development Center, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with a Sulfonylurea in Subjects with Type 2 Diabe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004667-36,0,0,0 2005-004668-22,5,2007-06-12,2007-07-30,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Takeda Global Research & Development Center, Inc.,","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with Metformin in Subjects with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004668-22,0,0,0 2005-004668-22,5,2007-06-12,2007-07-30,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Takeda Global Research & Development Center, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with Metformin in Subjects with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004668-22,0,0,0 2005-004669-40,5,2007-08-02,2007-08-02,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Takeda Global Research & Development Center, Inc.,","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with Pioglitazone in Subjects with Type 2 Diabete...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004669-40,0,0,0 2005-004670-24,2,2007-07-05,2007-07-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Takeda Global Research & Development Center, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) Compared with Placebo in Subjects with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004670-24,0,0,0 2005-004670-24,2,2007-07-05,2007-07-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Takeda Global Research & Development Centre, Inc.,","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) Compared with Placebo in Subjects with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004670-24,0,0,0 2005-004671-38,4,2007-05-17,2007-05-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Takeda Global Research & Development Center, Inc.,","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with Insulin in Subjects with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004671-38,0,0,0 2005-004672-20,4,2011-11-15,2011-11-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Takeda Global Research & Development Center, Inc.","A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004672-20,0,0,0 2005-004672-20,4,2011-11-15,2011-11-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Takeda Global Research & Development Center, Inc.,","A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004672-20,0,0,0 2005-004675-37,1,2009-05-28,2009-05-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-SCHERAX Arzneimittel GmbH,"Multicenter, randomized, double-blind, placebo-controlled parallel group study to demonstrate the efficacy of a 12-month subcutaneous specific immunotherapy with ALK-depot SQ Milbenmischung in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004675-37,0,0,0 2005-004676-20,14,2010-09-13,2010-09-13,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN S.P.A.,"""A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004676-20,0,0,0 2005-004676-20,14,2010-09-13,2010-09-13,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Limited,"""A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004676-20,0,0,0 2005-004676-20,14,2010-09-13,2010-09-13,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"""A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004676-20,0,0,0 2005-004676-20,14,2010-09-13,2010-09-13,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,"""A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Chemotherapy to the Efficacy of Chemotherapy Alone in Patients with Previously Treated Metastatic Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004676-20,0,0,0 2005-004677-20,2,2013-03-02,2013-09-25,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"University of Heidelberg, Klinikum Mannheim, Dep Surgery/Thoracical Oncology","Randomised Phase II/III Study on Sectional Single Agent Gemcitabine and Docetaxel Versus Carboplatine / Gemcitabine Doublet Therapy, both combined Cetuximab in the Treatment of Advanced NSCLC (Stage I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004677-20,0,0,0 2005-004681-16,2,2008-12-16,2008-12-16,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Neurobiological Technologies Inc,"ASP I (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment within 6 Hours o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004681-16,0,0,0 2005-004684-31,1,2007-02-28,2007-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Barts and the London NHS Trust,Does Selenium Supplementation reduce Oxidative Stress associated with Subarachnoid Haemorrhage?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004684-31,0,0,0 2005-004685-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CUB - Hôpital Erasme,A prospective placebo controlled study of botulilium toxin (BOTOX) on gait disorder induced by spastic equinovarus foot.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004685-17,0,0,0 2005-004689-18,4,2007-01-25,2007-03-13,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Bayer HealthCare,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Surgical Procedures...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004689-18,0,0,0 2005-004689-18,4,2007-01-25,2007-03-13,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Bayer Inc.,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Surgical Procedures...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004689-18,0,0,0 2005-004691-20,7,2007-05-07,2007-05-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"RECORD 2 Study: REgulation of Coagulation in ORthopedic Surgery to prevent DVT and PE, controlled, Double-Blind, Randomized Study of BAY59-7939 in the Extended Prevention of VTE in Patients Undergoing...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004691-20,0,0,0 2005-004691-20,7,2007-05-07,2007-05-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare A/S,"RECORD 2 Study: REgulation of Coagulation in ORthopedic Surgery to prevent DVT and PE, controlled, Double-Blind, Randomized Study of BAY59-7939 in the Extended Prevention of VTE in Patients Undergoing...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004691-20,0,0,0 2005-004695-20,2,2015-10-26,2015-10-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche Pharma AG,Randomized multicenter trial comparing Valganciclovir CMV prophylaxis versus pre-emptive therapy after renal transplantation using proteomics for monitoring of graft alteration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004695-20,0,0,0 2005-004698-39,1,2007-09-12,2007-09-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Randomized, double-blind, placebo-controlled 7 day monotherapy Phase IIa study to evaluate the antiviral activity and safety of oral administered RTV-boosted BILR 355 (75 mg and 150 mg twice daily) i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004698-39,0,0,0 2005-004699-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Dr. V. Soriano,"“Estudio piloto, abierto, comparativo y multicéntrico de 2 brazos para evaluar la eficacia y seguridad de un período de extensión de 12 semanas con peginterferon α-2b y ribavirina versus un brazo de d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004699-19,0,0,0 2005-004706-90,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PROVINCIALE DI LECCO,A pilot study of G-CSF in patient with anterior acute MI undergoing primary coronary angioplasty,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004706-90,0,0,0 2005-004708-35,1,,,0,0,0,0,1,0,4,0,0,3,0,0,0,0,1,"Laboratorios Stiefel (España), S.A.","A Multi-Centre, Comparative, Randomized, Single-Blind, Parallel Group, Clinical Trial in Phase IV for the Evaluation of the Subjects Quality of Life, the Efficacy and the Tolerance of Duac® Gel (a Gel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004708-35,0,0,0 2005-004710-33,1,2009-04-30,2009-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust,A PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PTK787 IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004710-33,0,0,0 2005-004712-73,2,2008-03-27,2008-03-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a division of Schering Corporation","A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose Finding Study to Determine the Safety and Efficacy of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomitin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004712-73,0,0,0 2005-004713-15,3,2006-08-17,2007-07-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cardiome Pharma Corp.,"A Pilot Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centred Safety, Tolerability and Preliminary Efficacy Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004713-15,0,0,0 2005-004714-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,"A PHASE II, MULTI-CENTER STUDY OF BORTEZOMIB, ADRIAMYCIN, DEXAMETHASONE (PAD) as induction and MELPHALAN 100 mg/m2 (MEL 100) as transplant, IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004714-32,0,0,0 2005-004716-75,1,2009-02-28,2009-02-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Swansea NHS Trust,"A double blind, randomised, placebo controlled crossover study of intra-trigonal injections of Botulinum toxin type B for treating patients with idiopathic detrusor overactivity refractory to other co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004716-75,0,0,0 2005-004724-39,4,2007-11-21,2007-11-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-Abelló A/S,"A randomised, parallel-group, open, controlled Phase III trial assessing the treatment compliance with GRAZAX in subjects with seasonal grass pollen induced rhinoconjunctiviits",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004724-39,0,0,0 2005-004727-18,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,THERABEL PHARMACEUTICAL Ltd,"EFFECT OF MOLSIDOMINE 16 MG ADMINISTERED ONCE-DAILY AS A LONG-TERM ADD-ON TREATMENT, ON ATHEROSCLEROSIS PROGRESSION AND INFLAMMATORY BIOMARKERS IN PATIENTS HOSPITALIZED FOR ACUTE CORONARY SYNDROME.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004727-18,0,0,0 2005-004729-25,1,2008-01-15,2008-01-15,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,"R & D Directorate,Central Manchester and Manchester Children's University Hospitals NHS Trust",A pilot randomised controlled trial to determine if vitamin D treatment will result in a greater bone mass acquisition in pubertal girls,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004729-25,0,0,0 2005-004730-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,"A PHASE II, MULTI-CENTER STUDY OF MELPHALAN 100 mg/m2 (MEL 100) as transplant, REVLIMID and PREDNISONE (RP) as consolidation and REVLIMID ALONE as maintenance IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYEL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004730-41,0,0,0 2005-004731-21,1,2008-12-26,2008-12-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"ALK-Abelló, S.A.","Estudio doble ciego controlado con placebo para evaluar la eficacia de SLITone en pacientes alérgicos a ácaros de polvo de casa. A randomised, double-blind, placebo-controlled trial assessing the ef...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004731-21,0,0,0 2005-004736-51,1,2007-12-01,2007-12-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Prof V Lund,"Double-blind randomized placebo-controlled multinational, multicentre-trial on prolonged macrolide treatment in patients with moderate/severe chronic rhinosinusitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004736-51,0,0,0 2005-004737-17,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA BIANCHI-MELACRINO-MORELLI,Evaluation of the Efficacy of Darbepoetin Alfa for the Treatment of Anemia in Patients with Myelodysplastic Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004737-17,0,0,0 2005-004740-31,1,2010-12-31,2010-12-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Copenhagen,"Efficacy of B-cell depletion with rituximab on oral, ocular and general disease manifestations in patients with primary Sjögren disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004740-31,0,0,0 2005-004744-32,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,Merck Generics UK Ltd.,A CUMULATIVE DOSE RESPONSE STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE OF A NEW SALMETEROL INHALATION AEROSOL CONTAINING A REPLACEMENT HFA PROPELLANT IN A PRESSURISED METERED DOSE INHALER AND EXIST...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004744-32,0,0,0 2005-004745-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,"A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE V-MPT Versus VELCADE, MELPHALAN, PREDNISONE V-MP IN ELDERLY UNTREATED MULTIPLE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004745-33,0,0,0 2005-004747-64,4,2008-05-28,2008-06-03,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,ELI LILLY,"A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder HIIP Compared to Preprandial Injectable Insulin in Insulin-Na ve Patients with Type...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004747-64,0,0,0 2005-004747-64,4,2008-05-28,2008-06-03,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Eli Lilly and Company Ltd,"A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder HIIP Compared to Preprandial Injectable Insulin in Insulin-Na ve Patients with Type...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004747-64,0,0,0 2005-004748-30,1,2007-08-03,2007-08-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Victoria Hospital Belfast,Therapeutic implications of the effects of oral hypoglycaemic therapy on the enteroinsular axis in type 2 diabetes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004748-30,0,0,0 2005-004749-32,8,2012-11-09,2013-02-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Phase III, Randomized, Double-Blinded, Multi-Center Study to Assess the Efficacy of Docetaxel TAXOTERE in Combination with ZD6474 ZACTIMA versus Docetaxel TAXOTERE in combination with Placebo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004749-32,0,0,0 2005-004749-32,8,2012-11-09,2013-02-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase III, Randomized, Double-Blinded, Multi-Center Study to Assess the Efficacy of Docetaxel TAXOTERE in Combination with ZD6474 ZACTIMA versus Docetaxel TAXOTERE in combination with Placebo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004749-32,0,0,0 2005-004752-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,H. Universitari Germans Trias i Pujol,"Comparación cruzada, a doble ciego, aleatoria, de dosis única, de levocetirizina con desloratadina, rupatadina, ebastina y placebo: supresión de la respuesta de pápula y eritema inducida por histamina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004752-13,0,0,0 2005-004753-95,1,2006-11-27,2006-11-27,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Diabetology Ltd,"A Phase II, Dose Ranging Single Centre, Single Blind, Parallel-group, Controlled Study of the Safety, Tolerability and Effects on Metabolic Control of an Oral Insulin Formulation in a Type II Diabetic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004753-95,0,0,0 2005-004754-27,1,2009-09-03,2009-09-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cardiff University,Comparison of insulin detemir and insulin glargine in patients with Type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004754-27,0,0,0 2005-004755-35,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Hospital Ramón y Cajal,Profilaxis del fracaso renal agudo perioperatorio. Un Proyecto del Hospital Ramón y Cajal de Madrid.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004755-35,0,0,0 2005-004760-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Roche Farma, S.A.","“Estudio abierto, aleatorizado y comparativo, para establecer la seguridad y eficacia de Bondronat i.v. (6 mg) en pacientes con cáncer de mama y metástasis óseas, que presentan dolor de moderado a gra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004760-23,0,0,0 2005-004761-42,1,2017-01-11,2017-01-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Fundacion Leucemia y Linfoma,First line treatment with Rituximab asociated to CVP plus Interferon in Follicular Lymphoma. Phase II study. Asociación de Rituximab al esquema CVP + Interferón en el tratamiento de primera línea del ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004761-42,0,0,0 2005-004765-42,1,2007-04-03,2007-04-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"An Open label Randomised, multicentre study to evaluate the efficacy of two Zometa (Zoledronic acid) schedules on bone mineral density in prostrate cancer patients undergoing Androgen deprivation Ther...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004765-42,0,0,0 2005-004766-16,6,2007-08-30,2007-08-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALCON ITALIA,Comparison of Safety and Efficacy of Brinzolamide/Timolol Fixed Combination vs COSOPT in Patients with Open-Angle Glaucoma or Ocular Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004766-16,0,0,0 2005-004766-16,6,2007-08-30,2007-08-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.",Comparison of Safety and Efficacy of Brinzolamide/Timolol Fixed Combination vs COSOPT in Patients with Open-Angle Glaucoma or Ocular Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004766-16,0,0,0 2005-004767-34,6,2007-01-26,2007-05-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.","A Six-Week, Multicenter, Randomized, Double-Masked Study to Evaluate the Efficacy and Safety of Two Dosing Regimens of Travoprost 0.004 /Timolol 0.5 Once-Daily Morning Dosing and Once-Daily Evening ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004767-34,0,0,0 2005-004767-34,6,2007-01-26,2007-05-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Alcon Research Ltd,"A Six-Week, Multicenter, Randomized, Double-Masked Study to Evaluate the Efficacy and Safety of Two Dosing Regimens of Travoprost 0.004 /Timolol 0.5 Once-Daily Morning Dosing and Once-Daily Evening ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004767-34,0,0,0 2005-004768-22,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,ALCON ITALIA,Clinical study of the mast-cell stabilizing effects of the Olopatadine using the Conjunctival Allergen Challeenge model,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004768-22,0,0,0 2005-004770-24,1,2008-08-26,2008-08-26,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc,"A Phase 3, Randomized, Active-controlled, Double-Blind Trial of the Safety, Tolerability and Immunologic Noninferiority of a 13-valent Pneumococcal Conjugate Vaccine Compared to a 7-valent Pneumococca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004770-24,0,0,0 2005-004771-38,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A phase 3, randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healhy Infants Given With Routine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004771-38,0,0,0 2005-004772-21,1,2008-07-28,2008-07-28,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc,"A Phase 3, Randomized, Active-Controlled, Double-Blind, Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004772-21,0,0,0 2005-004774-24,1,2009-01-21,2009-01-21,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Novartis Pharma GmbH,An open-label multicenter phase II study of Imatinib mesylate (Glivec) treatment of patients with malignant peripheral nerve sheath tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004774-24,0,0,0 2005-004775-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Medicinsk Afd. M, Århus Sygehus, Nørrebrogade","A comparison of pharmacodynamics and pharmacokinetics of Insulin Aspart and Biphasic Insulin Aspart 30, 50 og 70. A quadruple cross-over trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004775-38,0,0,0 2005-004776-20,1,2007-05-09,2007-05-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Basilea Pharmaceutica Ltd,Safety and Efficacy of Alitretinoin in the Treatment of Severe Refractory Chronic Hand Dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004776-20,0,0,0 2005-004780-34,1,2007-07-17,2007-07-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Ltd, Sandwich, UK","An eight-week, double-blind, group sequential design, placebo controlled trial to evaluate the safety and efficacy of the co-administration of sertraline and elzasonan (CP-448,187) in outpatients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004780-34,0,0,0 2005-004782-41,5,2008-11-11,2009-11-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,A parallel phase II study of Tarceva (Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) non pre-treated by chemotherapy including dose escalation to toxicity in current a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004782-41,0,0,0 2005-004782-41,5,2008-11-11,2009-11-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,A parallel phase II study of Tarceva (Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) non pre-treated by chemotherapy including dose escalation to toxicity in current a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004782-41,0,0,0 2005-004798-60,2,2009-01-15,2009-01-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,I.R.I.S. Institut de Recherches Internationales Servier,"A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex (150 mg od to 150 mg tid) versus pioglitazone (30 mg od to 45 mg od) in combination with sulfonylure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004798-60,0,0,0 2005-004809-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)",The steady state pharmacokinetics (PK) of atazanavir boosted with ritonavir during pregnancy and postpartum in HIV-1 infected pregnant women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004809-29,0,0,0 2005-004810-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ville Artto,"PITKITTYNEEN PÄÄNSÄRKYKOHTAUKSEN HOITO HYDROKORTISONILLA, RANDOMOITU JA KAKSOISSOKKOUTETTU TUTKIMUS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004810-34,0,0,0 2005-004811-31,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL ADULTO,"An open label, phase II, non randomized, clinical trial of chemotherapy treatment with 5-Azacytidine plus valproic acid and eventually atra for patients diagnosed with Intermediate II and high risk My...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004811-31,0,0,0 2005-004814-33,1,2009-12-31,2009-12-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Gesellschaft für Wissens- und Technologietransfer,Metabolic optimized fast track concept in general surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004814-33,0,0,0 2005-004822-19,1,2016-06-30,2016-06-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ICORG the all Ireland Co-operative Oncology Research Group,"A Phase III, adjuvant trial comparing three chemotherapy regimens in women with node positive breast cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004822-19,0,0,0 2005-004824-38,1,2006-08-29,2006-08-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,UZ Leuven,Een gecombineerde spinale epidurale anesthesie (CSE) bij arbeid : nood aan een fluid load ?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004824-38,0,0,0 2005-004825-25,3,2012-01-25,2012-05-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferrer Grupo S.A.,CITICOLINE IN THE TREATMENT OF ACUTE ISCHEMIC STROKE. AN INTERNATIONAL RANDOMIZED MULTICENTER PLACEBO-CONTROLLED STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004825-25,0,0,0 2005-004825-25,3,2012-01-25,2012-05-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferrer Internacional,CITICOLINE IN THE TREATMENT OF ACUTE ISCHEMIC STROKE. AN INTERNATIONAL RANDOMIZED MULTICENTER PLACEBO-CONTROLLED STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004825-25,0,0,0 2005-004826-21,12,2007-05-29,2007-05-29,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004826-21,0,0,0 2005-004826-21,12,2007-05-29,2007-05-29,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ABBOTT,Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004826-21,0,0,0 2005-004826-21,12,2007-05-29,2007-05-29,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott Laboratories,Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004826-21,0,0,0 2005-004827-20,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,1,"NanoCarrier Co., Ltd.",Phase I Study to Determine the Maximum Tolerated Dose of NC-6004 in Patients with Solid Tumours,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004827-20,0,0,0 2005-004830-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Instituto Grifols, S.A.","""Ensayo clínico piloto, unicéntrico, controlado con placebo, a doble-ciego, aleatorio y cruzado con alfa-1-antitripsina humana en sujetos con fibromialgia"". ""A single-centre, randomised, double-blind...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004830-42,0,0,0 2005-004831-23,1,2011-02-21,2011-02-21,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Sankt Lukas Hospice,"Effekten af ""røde dråber"" på åndenød hos terminale patienter med primær lungecancer eller lungemetastaser - et pilotprojekt",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004831-23,0,0,0 2005-004833-17,1,2013-07-01,2013-07-01,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Dstl,Assessment of the effect of prior anthrax vaccine precipitated (AVP) vaccination on the immune response to booster AVP vaccination.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004833-17,0,0,0 2005-004834-42,2,2009-08-28,2009-08-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergan,"A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Safety Study of Pulmonary Function in Patients with Reduced Lung Function Treated with BOTOX® (Botulinum Toxin Type A) Purified Neuroto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004834-42,0,0,0 2005-004835-23,3,2006-10-19,2006-10-20,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Minster Pharmaceuticals Ltd,"Multi-centre, parallel group, double-blind, placebo controlled study of the efficacy and tolerability of TONABERSAT in prophylaxis of migraine headache",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004835-23,1,0,0 2005-004837-16,1,2012-11-28,2012-11-28,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"Multicenter, single-arm, two-stage phase II trial of RAD001 (everolismus) with Glivec® in Glivec®-resistant patients with progressive GIST",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004837-16,0,0,0 2005-004838-40,1,2009-06-02,2009-06-02,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Glostrup Amtssygehuset,Behandling af akut opticus neuritis med simvastatin. Et dobbeltblind randomiseret placebokontrolleret fase III forsøg.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004838-40,0,0,0 2005-004840-30,2,2014-04-14,2014-04-14,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Thoraxklinik Heidelberg,"ADJUVANT CHEMOTHERAPY WITH PEMETREXED AND CISPLATIN vs. VINORELBINE AND CISPLATIN IN NSCLC IB, IIA, IIB, T3N1: A RANDOMIZED PHASE II STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004840-30,0,0,0 2005-004845-32,1,,,0,0,0,0,1,0,2,0,1,0,0,0,0,0,1,"Soria Natural, S.A.","ESTUDIO FASE II ABIERTO, COMPARATIVO, CRUZADO, SOBRE EFECTO ANTIAGREGANTE PLAQUETARIO DE CRATAESOR® Y ASPIRINA EN VOLUNTARIOS SANOS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004845-32,0,0,0 2005-004848-31,1,2007-03-27,2007-03-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SCHERING-PLOUGH,"A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo Controlled Study Comparing The Efficacy, Safety, And Tolerability Of Administration Of Ezetimibe/Simvastatin tablet 10/20 Mg Versus Dou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004848-31,0,0,0 2005-004849-33,1,2008-03-09,2008-03-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Greater Glasgow,"Prevention of oesophagitis, gastric and duodenal lesions in patients taking antithrombotic low-dose aspirin with famotidine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004849-33,0,0,0 2005-004850-28,1,2014-05-14,2014-05-14,1,0,0,0,0,3,2,0,0,1,0,0,1,0,0,Hospital for Children and Adolescents,ANGIOCOMB Antiangiogenetic therapy for pediatric patients with brain stem tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004850-28,0,0,0 2005-004851-37,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,"Freistaat Bayern, vertreten durch die Universität Regensburg, Klinikum","Doppelblinde, randomisierte, prospektive multizentrische klinische Studie zur Definition der optimalen antibiotischen Therapiedauer bei Patienten mit unkomplizierter akuter Cholangitis: Moxifloxacin o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004851-37,0,0,0 2005-004852-11,1,2007-03-01,2007-03-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Barrier Therapeutics Inc.,"A double-blind, randomized, placebo-controlled, dose finding study of R126638 given as a single or repeat dose in oral solution vs placebo in the treatment of pityriasis versicolor.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004852-11,0,0,0 2005-004853-86,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Erythropoietin and ischaemic heart disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004853-86,0,0,0 2005-004854-29,4,2011-07-01,2011-07-01,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Solvay Pharmaceuticals GmbH,"One week double-blind, randomized, placebo-controlled, parallel-group, multi-center study with Creon 25.000 Minimicrospheres in subject with pancreatic exocrine insufficiency after pancreatic surgery,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004854-29,0,0,0 2005-004854-29,4,2011-07-01,2011-07-01,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Solvay Pharmaceuticals, GmbH","One week double-blind, randomized, placebo-controlled, parallel-group, multi-center study with Creon 25.000 Minimicrospheres in subject with pancreatic exocrine insufficiency after pancreatic surgery,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004854-29,0,0,0 2005-004854-29,4,2011-07-01,2011-07-01,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Abbott Products GmbH,"One week double-blind, randomized, placebo-controlled, parallel-group, multi-center study with Creon 25.000 Minimicrospheres in subject with pancreatic exocrine insufficiency after pancreatic surgery,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004854-29,0,0,0 2005-004856-11,1,2007-06-29,2007-06-29,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,ALTANA Pharma AG,Symptom reduction in hospitalized patients suffering from symptomatic non-erosive or erosive gastroesophageal reflux disease treated with pantoprazole 20 or 40 mg o.d. for 7 days,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004856-11,0,0,0 2005-004858-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,José Antonio Pérez Simón,"Estudio Fase II Nacional, Abierto, Multicéntrico, no controlado de pacientes con mieloma múltiple tratados con Bortezomib (Velcade) pre y post trasplante alogénico de progenitores hematopoyéticos con ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004858-27,0,0,0 2005-004859-35,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"G&W Laboratories, Inc.",Determination of antipsoriatic efficacy of topical formulations and comparison to a brand medication and placebo in a psoriasis plaque test,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004859-35,0,0,0 2005-004863-41,1,2009-01-31,2009-01-31,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,"Dept. of Internal Medicine II, University Hospital Giessen","Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension (Shorttitle: SIPHT) Double-blind, randomized, prospecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004863-41,0,0,0 2005-004866-17,2,2012-12-31,2012-12-31,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Paracelsus Medical University,"An Open-label, single arm Phase II Trial of Photodynamic Therapy using Foscan for non-curatively-resectable bile duct carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004866-17,0,0,0 2005-004866-17,2,2012-12-31,2012-12-31,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Dept Medicine I, Paracelsus Med. Univ. Landeskrankenanstalten Salzburg / SALK","An Open-label, single arm Phase II Trial of Photodynamic Therapy using Foscan for non-curatively-resectable bile duct carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-004866-17,0,0,0 2005-004874-26,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,An open label study on the use of Velcade in combination with high-dose dexamethasone as first line therapy in multiple myeloma patients aged /= 10 to 65 J.) und jüngeren Patienten, die nicht für eine Hochdosistherapie mit autologer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005473-29,0,0,0 2005-005474-77,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,University Hospital Ghent,Validation of a pharmacologic profile of propofol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005474-77,0,0,0 2005-005475-14,1,2013-10-31,2013-10-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,INTEnsification Radiotherapy with Accelerated fractionation or ChemoTherapy And Local Excision After 3D External Radio-chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005475-14,0,0,0 2005-005476-32,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Vectura Group plc,"A Phase IIb, Randomised, Double-Blind, Placebo Controlled, Dose Finding Study Assessing the Haemodynamic Safety and ""At Home"" Efficacy of Inhaled VR004 in patients with Erectile Dysfunction (ED).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005476-32,0,0,0 2005-005478-66,1,2006-08-10,2006-08-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,Effect of a single oral 120 µg dose of SSR150106XB compared to placebo on the assessment of post dental surgical pain after extraction of an impacted or partially impacted third molar in 90 male and f...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005478-66,0,0,0 2005-005481-36,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,"Sanofi-Synthelabo Produtos Farmaceuticos, S.A.",Alfuzosin in Uretheric Stones,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005481-36,0,0,0 2005-005482-10,4,2009-01-27,2009-04-02,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Renovo,"A double blind, placebo controlled, randomised dose response trial to investigate the efficacy of Juvista in the improvement of scar appearance when applied to approximated wound margins following bil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005482-10,0,0,0 2005-005484-28,10,2009-06-22,2011-11-14,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Multicenter, Open Label, Randomized Study of AMG 951 in Subjects with Previously Untreated Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Treated with Chemotherapy with or without Bevacizumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005484-28,0,0,0 2005-005485-37,14,2014-04-09,2014-04-09,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN S.P.A.,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone-refractory Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005485-37,0,0,0 2005-005485-37,14,2014-04-09,2014-04-09,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men with Hormone-refractory Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005485-37,0,0,0 2005-005494-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ullevål University Hospital,Rifampin combination therapy versus monotherapy in early staphylococcal infections after total hip and knee arthroplasty,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005494-29,0,0,0 2005-005499-34,1,2007-05-04,2007-05-04,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,H. Lundbeck A/S,"A double-blind, randomised, placebo-controlled, quetiapine-referenced, multicentre study of the long-term bifeprunox efficacy, safety and tolerability in patiens with stable schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005499-34,0,0,0 2005-005500-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,The Back Research center,Antibiotic treatment of patients with low back pain and Modic changes after a lumbar disc herniation. A randomized clinical controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005500-17,0,0,0 2005-005501-28,2,2009-03-24,2009-03-24,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Pfizer Pharma GmbH,"Six week, double-blind, placebo controlled Phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005501-28,0,0,0 2005-005501-28,2,2009-03-24,2009-03-24,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Pfizer AB,"Six week, double-blind, placebo controlled Phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005501-28,0,0,0 2005-005502-23,2,2009-03-24,2009-03-24,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Pfizer Pharma GmbH,26-week open-label extension study evaluating the safety and tolerability of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005502-23,0,0,0 2005-005502-23,2,2009-03-24,2009-03-24,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Pfizer AB,26-week open-label extension study evaluating the safety and tolerability of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005502-23,0,0,0 2005-005506-23,2,2009-04-07,2009-04-30,2,1,0,0,0,3,4,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Randomized, Multicenter, Double Blinded, Phase IV Study Comparing the Safety and Efficacy of Pegasys 180 µg plus Copegus 1000 or 1200 mg to the Currently Approved Combination of Pegasys 180 µg plus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005506-23,0,0,0 2005-005507-41,8,2009-03-13,2009-04-22,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Hig...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005507-41,0,0,0 2005-005510-21,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,"Medical Department M, Aarhus Sygehus",GH treatment of women with Turner syndrome. Body composition and heart function.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005510-21,0,0,0 2005-005512-24,1,2008-08-06,2008-08-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,EctoPharma Limited,A phase IIa clinical trial to demonstrate the proof of concept of an experimental pediculicide lotion for the treatment of head lice,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005512-24,0,0,0 2005-005519-12,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,CHIRON,"A Phase 3, Multi-Center, Observer Blind, Controlled, Randomized Study to Compare the Immunogenicity and Safety of the Concomitant Administration of a Combined Tetanus, Reduced Diphtheria, and Acellula...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005519-12,0,0,0 2005-005523-34,1,2010-09-14,2010-09-14,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Dundee (Research & Innovation Services),A PROOF OF CONCEPT STUDY TO EVALAUTE EFFECTS INTRANASAL SALMETEROL AND FLUTICASONE GIVEN ALONE AND IN COMBINATION IN ALLERGIC RHINITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005523-34,0,0,0 2005-005524-13,1,2006-09-21,2006-09-21,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,CRINOS S.p.A.,"Defibrotide in the prevention of recurrences in venous thrombosis: DEPRIVE. A randomised, multicentre, European, double blind, parallel group study, to assess the efficacy and tolerability of defibrot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005524-13,0,0,0 2005-005525-63,1,2007-06-11,2007-06-11,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"Follow-up of study C87040 : Multicenter, single blind study to describe the efficacy and safety of re-treatment with CDP870 (certolizumab pegol) subcutaneous at 2 different dose regimens (400 mg init...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005525-63,0,0,0 2005-005528-15,1,2015-04-30,2015-04-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University College London,A RANDOMISED CONTROLLED TRIAL TO STUDY THE SIDE EFFECT PROFILE AND TO ESTABLISH MEASURES OF EFFICACY USING PHOTOFRIN OR 5 AMINOLAEVULINIC ACID PHOTODYNAMIC THERAPY IN THE ERADICATION OF DYSPLASIA IN B...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005528-15,0,0,0 2005-005529-74,3,2008-01-22,2008-01-22,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Roche (Hungary) Ltd.,"A randomised, open-label, multi-national, multi-center study to investigate the impact of bone-marker feedback (at 3 months) on adherence to once monthly ibandronate treatment of patients with post-me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005529-74,0,0,0 2005-005531-99,1,2008-08-06,2008-08-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee(Research & Innovation Services),A PROOF OF CONCEPT STUDY TO ASSESS THE STEROID SPARING EFFECT OF COMBINED NASAL AND INHALED CORTICOSTEROID IN PATIENTS WITH ASTHMA AND PERSISTENT RHINITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005531-99,0,0,0 2005-005532-27,1,2006-10-31,2006-10-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Sanofi Pasteur Inc.,Comparison of Pertussis Specific Cellular and Humoral Immunity Before and After a Acellular Pertussis Booster-Vaccineation in Combination With a Diphtheria-Tetanus-Polio-Vaccine Between Three Groups o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005532-27,0,0,0 2005-005533-35,4,2007-07-16,2007-07-16,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F. Hoffmann La-Roche Ltd,"An open-label, non-controlled study of bevacizumab in combination with cisplatin-gembitabine or carboplatin-paclitaxel, as first line treatment for patients with advanced or recurrent squamous non-sma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005533-35,0,0,0 2005-005534-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,The Symbio Herborn Group GmbH,randomized double blind placebo controlled study on the efficacy of autologous autovaccine in house dust mite allergy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005534-12,0,0,0 2005-005535-10,3,2009-03-11,2009-03-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A,A Phase 2 study of ALIMTA in solid tumor patients with stable third-space fluid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005535-10,0,0,0 2005-005535-10,3,2009-03-11,2009-03-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,A Phase 2 study of ALIMTA in solid tumor patients with stable third-space fluid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005535-10,0,0,0 2005-005537-35,9,2010-10-28,2010-10-28,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,EISAI LTD UK,A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005537-35,0,0,0 2005-005537-35,9,2010-10-28,2010-10-28,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eisai Limited,A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005537-35,0,0,0 2005-005542-39,4,2009-04-04,2009-11-11,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cephalon Inc.,An Open-Label Extended-Use Study of Oral CEP-701 in Patients With Hematologic Malignancies Who Have Participated in a Clinical Study of CEP-701,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005542-39,0,0,0 2005-005542-39,4,2009-04-04,2009-11-11,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CEPHALON EUROPE,An Open-Label Extended-Use Study of Oral CEP-701 in Patients With Hematologic Malignancies Who Have Participated in a Clinical Study of CEP-701,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005542-39,0,0,0 2005-005543-25,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Wyeth Research Division,Phase II Study of SKI-606 in Subjects with Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005543-25,0,0,0 2005-005544-79,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"The Clinical Research Centre, RCSI Education and Research Centre",Adalimumab (Humira) as add-on therapy in the treatment of patients with severe persistent therapy resistant asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005544-79,0,0,0 2005-005546-39,9,2007-05-17,2007-06-06,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ASTELLAS PHARMA,"SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN WITH SIMPLIFIED BLADDER TRAINING VERSUS SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN ALONE IN A PROSPECTIVE, RANDOMIZED, PARALLEL GROUP, OVERACTIVE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005546-39,0,0,0 2005-005546-39,9,2007-05-17,2007-06-06,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Astellas Pharma Europe BV,"SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN WITH SIMPLIFIED BLADDER TRAINING VERSUS SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN ALONE IN A PROSPECTIVE, RANDOMIZED, PARALLEL GROUP, OVERACTIVE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005546-39,0,0,0 2005-005546-39,9,2007-05-17,2007-06-06,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd,"SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN WITH SIMPLIFIED BLADDER TRAINING VERSUS SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN ALONE IN A PROSPECTIVE, RANDOMIZED, PARALLEL GROUP, OVERACTIVE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005546-39,0,0,0 2005-005546-39,9,2007-05-17,2007-06-06,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN WITH SIMPLIFIED BLADDER TRAINING VERSUS SOLIFENACIN SUCCINATE IN A FLEXIBLE DOSE REGIMEN ALONE IN A PROSPECTIVE, RANDOMIZED, PARALLEL GROUP, OVERACTIVE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005546-39,0,0,0 2005-005547-26,2,2007-05-24,2007-05-24,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Medarex, Inc.","An Open-label, Fixed-dose, Multicenter, Phase II Study of MDX-060 in Patients with Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005547-26,0,0,0 2005-005548-21,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,CONSORZIO ONCOTECH,Phase I-II Study of the Combination of Bevacizumab (rhuMAb VEGF) and Erlotinib (EGFR TKI) plus Oxaliplatin and Capecitabine (XELOX) in Patients with Metastatic Colorectal Cancer: XELOX-TARAV study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005548-21,0,0,0 2005-005552-41,1,2012-01-26,2012-01-26,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,Effect of long-acting somatostatin on disease progression in nephropathy due to autosomal dominant polycystic disease a long-term three year follow-up study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005552-41,0,0,0 2005-005555-17,9,2007-10-11,2007-10-15,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Ltd,"S,S -REBOXETINE ADD-ON TRIAL A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL OF S,S -REBOXETINE IN PATIENTS WITH POSTHERPETIC NEURALGIA PHN CONCOMITANTLY TREATED WITH PREGABA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005555-17,0,0,0 2005-005555-17,9,2007-10-11,2007-10-15,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer, S.A.","S,S -REBOXETINE ADD-ON TRIAL A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL OF S,S -REBOXETINE IN PATIENTS WITH POSTHERPETIC NEURALGIA PHN CONCOMITANTLY TREATED WITH PREGABA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005555-17,0,0,0 2005-005555-17,9,2007-10-11,2007-10-15,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Global Research & Development Ltd, Clinical R & D, IPC 137","S,S -REBOXETINE ADD-ON TRIAL A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL OF S,S -REBOXETINE IN PATIENTS WITH POSTHERPETIC NEURALGIA PHN CONCOMITANTLY TREATED WITH PREGABA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005555-17,0,0,0 2005-005555-17,9,2007-10-11,2007-10-15,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,PFIZER,"S,S -REBOXETINE ADD-ON TRIAL A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL OF S,S -REBOXETINE IN PATIENTS WITH POSTHERPETIC NEURALGIA PHN CONCOMITANTLY TREATED WITH PREGABA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005555-17,0,0,0 2005-005555-17,9,2007-10-11,2007-10-15,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer AB,"S,S -REBOXETINE ADD-ON TRIAL A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL OF S,S -REBOXETINE IN PATIENTS WITH POSTHERPETIC NEURALGIA PHN CONCOMITANTLY TREATED WITH PREGABA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005555-17,0,0,0 2005-005555-17,9,2007-10-11,2007-10-15,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Pharma GmbH,"S,S -REBOXETINE ADD-ON TRIAL A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL OF S,S -REBOXETINE IN PATIENTS WITH POSTHERPETIC NEURALGIA PHN CONCOMITANTLY TREATED WITH PREGABA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005555-17,0,0,0 2005-005557-22,1,2007-05-29,2007-05-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee (Research & Innovation),COMPARATIVE STUDY OF THE SYSTEMIC BIOACTIVITY OF HFA FLUTICASONE PROPIONATE VIA ANTI-STATIC SPACER DEVICES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005557-22,0,0,0 2005-005563-28,1,2010-07-19,2010-07-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Clinic Essen,PRevention of Atherosclerosis In High-Risk Patients: Aggressive Risk Modification including NiAspan,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005563-28,0,0,0 2005-005565-10,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Uppsala University,Allopregnanolone effects on short term memory,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005565-10,0,0,0 2005-005569-12,3,2014-01-31,2014-01-31,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of six months treatment with the tyrosine kinase inhibitor of STI571 for the treatment of pulmonary arterial hy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005569-12,0,0,0 2005-005575-14,1,2007-10-01,2007-10-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Baxter R&D Europe S.C.R.L,"A randomized, double-blind, placebo-controlled, single-dose, parallel-group comparison of the analgesic efficacy, safety and local tolerability of intravenous paracetamol 1% solution Bioren (test), Pe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005575-14,0,0,0 2005-005576-32,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,BRACCO,TOLERABILITY OF A NEW FORMULATION OF ARGOTONE IN HEALTH VOLONTEERS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005576-32,0,0,0 2005-005581-36,7,2010-01-29,2011-03-21,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer Schering Pharma AG,"Estudio fase II aleatorizado para investigar la eficacia, seguridad y tolerabilidad de ZK 230211 (100 mg frente a 25 mg) como tratamiento endocrino de segunda línea en mujeres posmenopáusicas con cánc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005581-36,0,0,0 2005-005581-36,7,2010-01-29,2011-03-21,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Schering AG,"Estudio fase II aleatorizado para investigar la eficacia, seguridad y tolerabilidad de ZK 230211 (100 mg frente a 25 mg) como tratamiento endocrino de segunda línea en mujeres posmenopáusicas con cánc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005581-36,0,0,0 2005-005581-36,7,2010-01-29,2011-03-21,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SCHERING,"Estudio fase II aleatorizado para investigar la eficacia, seguridad y tolerabilidad de ZK 230211 (100 mg frente a 25 mg) como tratamiento endocrino de segunda línea en mujeres posmenopáusicas con cánc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005581-36,0,0,0 2005-005584-28,1,2006-06-30,2006-06-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Pediatric Cardiology,Tracleer - Therapie bei Patienten mit Downsyndrom und Eisenmengerreaktion: Verträglichkeit und hämodynamische Wirkungen.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005584-28,0,0,0 2005-005587-82,10,2007-11-29,2008-03-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,PFIZER,A DOUBLE BLIND PARALLEL GROUP RANDOMISED MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMIC RESPONSE AND SAFETY OF PHA-794428 IN ADULT GROWTH HORMONE DEFICIENT PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005587-82,0,0,0 2005-005587-82,10,2007-11-29,2008-03-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Limited,A DOUBLE BLIND PARALLEL GROUP RANDOMISED MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMIC RESPONSE AND SAFETY OF PHA-794428 IN ADULT GROWTH HORMONE DEFICIENT PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005587-82,0,0,0 2005-005587-82,10,2007-11-29,2008-03-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer NV/SA,A DOUBLE BLIND PARALLEL GROUP RANDOMISED MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMIC RESPONSE AND SAFETY OF PHA-794428 IN ADULT GROWTH HORMONE DEFICIENT PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005587-82,0,0,0 2005-005587-82,10,2007-11-29,2008-03-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Pharma GmbH,A DOUBLE BLIND PARALLEL GROUP RANDOMISED MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMIC RESPONSE AND SAFETY OF PHA-794428 IN ADULT GROWTH HORMONE DEFICIENT PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005587-82,0,0,0 2005-005587-82,10,2007-11-29,2008-03-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,,A DOUBLE BLIND PARALLEL GROUP RANDOMISED MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMIC RESPONSE AND SAFETY OF PHA-794428 IN ADULT GROWTH HORMONE DEFICIENT PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005587-82,0,0,0 2005-005587-82,10,2007-11-29,2008-03-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer AB,A DOUBLE BLIND PARALLEL GROUP RANDOMISED MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMIC RESPONSE AND SAFETY OF PHA-794428 IN ADULT GROWTH HORMONE DEFICIENT PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005587-82,0,0,0 2005-005587-82,10,2007-11-29,2008-03-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Ltd,A DOUBLE BLIND PARALLEL GROUP RANDOMISED MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMIC RESPONSE AND SAFETY OF PHA-794428 IN ADULT GROWTH HORMONE DEFICIENT PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005587-82,0,0,0 2005-005587-82,10,2007-11-29,2008-03-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer,A DOUBLE BLIND PARALLEL GROUP RANDOMISED MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMIC RESPONSE AND SAFETY OF PHA-794428 IN ADULT GROWTH HORMONE DEFICIENT PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005587-82,0,0,0 2005-005591-32,1,2008-03-26,2008-03-26,1,1,0,0,0,0,0,0,0,1,1,1,1,0,0,Derby Hospitals NHS Foundation Trust,A prospective study to assess the effectiveness of lignocaine versus normal saline in the reduction of pain associated with dressing removal in finger tip injuries,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005591-32,0,0,0 2005-005592-14,1,2011-06-30,2011-06-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"IFSgGmbH, Institute for clinical research","Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PROTEC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005592-14,0,0,0 2005-005593-79,4,2007-11-28,2007-11-29,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer SA,"A Double blind, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005593-79,0,0,0 2005-005593-79,4,2007-11-28,2007-11-29,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer N.V./S.A.,"A Double blind, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005593-79,0,0,0 2005-005593-79,4,2007-11-28,2007-11-29,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Pharma GmbH,"A Double blind, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005593-79,0,0,0 2005-005593-79,4,2007-11-28,2007-11-29,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Limited,"A Double blind, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005593-79,0,0,0 2005-005594-29,3,2021-04-23,2021-04-23,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,AOP Orphan Pharmaceuticals AG,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005594-29,0,0,0 2005-005595-33,5,2007-10-08,2007-10-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005595-33,0,0,0 2005-005597-67,2,2007-08-21,2007-08-21,2,1,0,0,1,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche&developpement,"An eight-week, double-blind placebo controlled, multicenter study evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A (350 mg q12) in elderly patients with Major Depressive Disor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005597-67,0,0,0 2005-005597-67,2,2007-08-21,2007-08-21,2,1,0,0,1,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"An eight-week, double-blind placebo controlled, multicenter study evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A (350 mg q12) in elderly patients with Major Depressive Disor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005597-67,0,0,0 2005-005598-30,1,2009-06-22,2009-06-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Groupe,"A NON-INVASIVE EVALUATION OF BONE MICROARCHITECTURE MODIFICATION IN OSTEOPENIC POSTMENOPAUSAL WOMEN BY 3D-PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY : A 24-MONTH, MONOCENTER, DOUBLE-BLIND, RANDOMIZED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005598-30,0,0,0 2005-005602-23,1,2007-02-13,2007-02-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,"Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease (COPD) in a Randomized, Double-Blind, Placebo-Controlled Study of Treatment with Fluticasone Propionate/Salmeterol ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005602-23,0,0,0 2005-005606-23,4,2007-08-03,2007-09-24,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Merck &Co.Inc.,"A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005606-23,0,0,0 2005-005606-23,4,2007-08-03,2007-09-24,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005606-23,0,0,0 2005-005606-23,4,2007-08-03,2007-09-24,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Merck Sharp and Dohme de España,"A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005606-23,0,0,0 2005-005606-23,4,2007-08-03,2007-09-24,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Merck & Co. Inc.,"A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005606-23,0,0,0 2005-005612-24,1,2010-06-26,2010-06-26,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,University of Cologne,PHASE II STUDY OF CETUXIMAB FOR THE TREATMENT OF REFRACTORY OR RELAPSED MULTIPLE MYELOMA EMMA-1 (ERBITUX FOR MULTIPLE MYELOMA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005612-24,0,0,0 2005-005613-38,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Dr. Chris Thompson,Assessment of platelet function in the hypopituitary population. Does hormone replacement therapy alter thrombotic risk?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005613-38,0,0,0 2005-005615-21,3,2007-11-08,2008-02-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Randomised, Double-Blind, Placebo-Controlled, Crossover Efficacy and Safety Evaluation of 8-Week Treatment Periods of Two Doses [5 µg (2 actuations of 2.5 µg) and µg (2 actuations of 5 µg)] of Tiotr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005615-21,0,0,0 2005-005615-21,3,2007-11-08,2008-02-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A Randomised, Double-Blind, Placebo-Controlled, Crossover Efficacy and Safety Evaluation of 8-Week Treatment Periods of Two Doses [5 µg (2 actuations of 2.5 µg) and µg (2 actuations of 5 µg)] of Tiotr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005615-21,0,0,0 2005-005616-25,10,2008-08-09,2008-10-13,8,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A 16-week random., placebo-contr., db, double-dummy, parallel-group efficacy and safety study comparing the efficacy and safety of tiotropium inhalation solution (2 actuations of 2.5 µg once daily) de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005616-25,0,0,0 2005-005616-25,10,2008-08-09,2008-10-13,8,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Ellas A.E,"A 16-week random., placebo-contr., db, double-dummy, parallel-group efficacy and safety study comparing the efficacy and safety of tiotropium inhalation solution (2 actuations of 2.5 µg once daily) de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005616-25,0,0,0 2005-005616-25,10,2008-08-09,2008-10-13,8,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Austria GmbH,"A 16-week random., placebo-contr., db, double-dummy, parallel-group efficacy and safety study comparing the efficacy and safety of tiotropium inhalation solution (2 actuations of 2.5 µg once daily) de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005616-25,0,0,0 2005-005616-25,10,2008-08-09,2008-10-13,8,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co.KG,"A 16-week random., placebo-contr., db, double-dummy, parallel-group efficacy and safety study comparing the efficacy and safety of tiotropium inhalation solution (2 actuations of 2.5 µg once daily) de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005616-25,0,0,0 2005-005616-25,10,2008-08-09,2008-10-13,8,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Finland Ky,"A 16-week random., placebo-contr., db, double-dummy, parallel-group efficacy and safety study comparing the efficacy and safety of tiotropium inhalation solution (2 actuations of 2.5 µg once daily) de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005616-25,0,0,0 2005-005616-25,10,2008-08-09,2008-10-13,8,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim,"A 16-week random., placebo-contr., db, double-dummy, parallel-group efficacy and safety study comparing the efficacy and safety of tiotropium inhalation solution (2 actuations of 2.5 µg once daily) de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005616-25,0,0,0 2005-005616-25,10,2008-08-09,2008-10-13,8,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A.","A 16-week random., placebo-contr., db, double-dummy, parallel-group efficacy and safety study comparing the efficacy and safety of tiotropium inhalation solution (2 actuations of 2.5 µg once daily) de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005616-25,0,0,0 2005-005616-25,10,2008-08-09,2008-10-13,8,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Ltd.,"A 16-week random., placebo-contr., db, double-dummy, parallel-group efficacy and safety study comparing the efficacy and safety of tiotropium inhalation solution (2 actuations of 2.5 µg once daily) de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005616-25,0,0,0 2005-005616-25,10,2008-08-09,2008-10-13,8,1,0,0,0,0,2,0,0,1,0,0,1,0,2,BOEHRINGER ING.,"A 16-week random., placebo-contr., db, double-dummy, parallel-group efficacy and safety study comparing the efficacy and safety of tiotropium inhalation solution (2 actuations of 2.5 µg once daily) de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005616-25,0,0,0 2005-005621-55,6,2008-11-05,2008-11-05,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Zeria Pharmaceutical Co., Ltd.","Z-338: A Phase IIb, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety in Subjects with Functional Dyspepsia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005621-55,0,0,0 2005-005622-31,1,2007-05-25,2007-05-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,A Proof Of Concept Study To Investigate The Potential Role Of Acetylsalicyclic Acid (Aspirin) As An Anti-Inflammatory Agent For The Treatment Of Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005622-31,0,0,0 2005-005624-13,1,2006-11-20,2006-11-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,Investigation on treatment effect and safety of Hametum® Wund- und Heilsalbe in patients with drug induced skin symptoms. An open phase IV trial [Untersuchung zu Behandlungseffekt und Verträglichkeit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005624-13,0,0,0 2005-005631-97,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005631-97,0,0,0 2005-005634-12,2,2008-02-26,2008-02-26,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,S.L.A. PHARMA UK LTD,The effect of two dose levels of eicosapentaenoic acid EPA on apoptosis and cell proliferation in the colonic mucosa in patients with a history of colonic polyps.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005634-12,0,0,0 2005-005634-12,2,2008-02-26,2008-02-26,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,S.L.A. Pharma (UK) Ltd,The effect of two dose levels of eicosapentaenoic acid EPA on apoptosis and cell proliferation in the colonic mucosa in patients with a history of colonic polyps.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005634-12,0,0,0 2005-005635-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Liver Unit, ICMD, Hospital Clinic Barcelona",INDUCTION TREATMENT FOLLOWED BY IMMUNOSUPPRESSION WITHDRAWAL IN LIVER TRANSPLANTATION: A COMPARATIVE TRIAL. Tratamiento de inducción y retirada de la inmunosupresión en el trasplante hepático. Estudio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005635-10,0,0,0 2005-005636-28,1,2008-05-13,2008-05-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"ALK-ABELLÓ, S.A.","Valoración de la eficacia a corto plazo de un extracto de Dermatophagoides pteronyssinus, valorado en unidades de masa y administrado por vía subcutánea, en el tratamiento del asma alérgico. Estudio r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005636-28,0,0,0 2005-005638-10,1,2009-12-04,2009-12-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Münster,Evaluation of the antipruritic effect of Elidel (pimecrolimus) in non-atopic pruritic disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005638-10,0,0,0 2005-005641-19,1,2008-12-19,2008-12-19,1,1,0,0,0,0,2,1,0,1,0,0,1,0,1,Takeda Pharma GmbH,"3 Months, Open-Label, Parallel-Group Study of the Pharmacodynamics, Pharmacokinetics and Safety of TAP-144SR 1-month Depot Gelatin-Free vs. Gelatin-Containing Formulation in Female Patients with Uteri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005641-19,0,0,0 2005-005644-11,1,2010-10-27,2010-10-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BEAUFOUR IPSEN PHARMA,"Phase III, multicentre, non comparative, open and single stage study to assess the efficacy and safety of pamoate of triptorelin 11.25 mg in children with precocious puberty",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005644-11,0,0,0 2005-005645-19,1,,,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,Dept of ped hem/onc,"RCT of oral ibuprofen for procedural anxiety, distress and pain in children with cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005645-19,0,0,0 2005-005646-39,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,NERVIANO MEDICAL SCIENCES,Phase II exploratory study of brostallicin PNU-166196A in patients with ovarian cancer resistant/refractory to platinum based chemotherapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005646-39,0,0,0 2005-005650-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,SESP,"A Comparative, Randomized, Open-label, Multicenter Study, of Directly Observed Treatment of Chronic Hepatitis C (DOT) and auto administrated treatment with Copegus® (Ro 20-9963) and Pegasys® (Ro 25-83...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005650-41,0,0,0 2005-005654-53,1,2007-09-04,2007-09-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ursapharm Arzneimittel GmbH & Co. KG,"""Explorative triple-arm dosis-finding study for examination about the effectivity and tolerance of Bromelain by acute sinusitis""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005654-53,0,0,0 2005-005658-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dpt. of Urology -K. Aarhus University Hospital,"A randomized, multi-center study to assess the effect of Darbepoetin alfa (Aranesp®) for the treatment of anemia in patients with advanced hormone independent prostate cancer and anaemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005658-37,0,0,0 2005-005660-86,1,2013-08-05,2013-08-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Christie Hospital NHS Trust,"A Phase II, open label, single arm study to evaluate Ticilimumab in Advanced Gastric/Oesophageal Adenocarcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005660-86,0,0,0 2005-005661-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",PHASE II STUDY OF NEOADJUVANT CHEMORADIOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005661-11,0,0,0 2005-005664-88,1,2006-07-14,2006-07-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Oxford,Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A Pot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005664-88,0,0,0 2005-005665-11,4,2007-05-10,2008-01-04,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Recordati S.p.A,"EVALUATION OF THE EFFICACY AND SAFETY OF SILODOSIN vs. TAMSULOSIN AND PLACEBO IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA. MULTICENTRE, RANDOMISED, DOUBLE-BLIND, CONTRO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005665-11,0,0,0 2005-005665-11,4,2007-05-10,2008-01-04,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,RECORDATI,"EVALUATION OF THE EFFICACY AND SAFETY OF SILODOSIN vs. TAMSULOSIN AND PLACEBO IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA. MULTICENTRE, RANDOMISED, DOUBLE-BLIND, CONTRO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005665-11,0,0,0 2005-005666-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,International Breast Cancer Study Group,Low-dose Cytotoxics as “Anti-angiogenesis Treatment” following Adjuvant Induction Chemotherapy for Patients with ER-negative and PgR-negative Breast Cancer Maintenance Chemotherapy in Hormone Non- Re...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005666-36,0,0,0 2005-005669-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. FILIPPO NERI,A dose-finding study of PTK787/ZK 222584 in combination with weekly vinorelbine and trastuzumab as treatment of patients with metastatic breast cancer overexpressing HER-2/neu pre-treated withy at lea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005669-12,0,0,0 2005-005670-71,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA,Dose-finding and Phase II study of the Combination of Bevacizumab rhuMAb VEGF plus low- dose Immunotherapy and Chemotherapy in patients with metastatic Renal Cell Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005670-71,0,0,0 2005-005672-33,3,2008-01-17,2008-01-17,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,IATEC B.V.,"A Randomized, Controlled, Open-Label, 48-Week Study of Continuing Successfully Suppressive Treatment in HIV-1 Infected Adults with First-Line Twice-Daily Zidovudine and Lamivudine-Based Regimens versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005672-33,1,0,0 2005-005675-15,3,2014-04-24,2014-04-24,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,"Tecnimede, Sociedade Técnico-Medicinal S.A.","Randomized, multicenter, placebo-controlled, single blind study to assess the efficacy and tolerability of a combination of a cream containing ubidecarenone, dexpanthenol and chlorohexidine and a past...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005675-15,0,0,0 2005-005677-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"J. Uriach y Compañia, S. A.","Evaluación de la eficacia clinica, seguridad y actividad farmacologica de UR-1505 en voluntarios con alergia a niquel: estudio aleatorizado, doble ciego, cruzado y con control activo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005677-30,0,0,0 2005-005678-61,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,University Hospital Tuebingen,Entwicklung einer Untersuchungsmethode zur Bestimmung des NO-Transferfaktors der Lunge Evaluierung der Methode und Normwerterhebung an gesunden Probanden (Development of a new method for steady-state ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005678-61,0,0,0 2005-005679-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,"An open-label, prospective, multicentric pilot study evaluating safety and symptomatics effects of low dose Naltrexone in patients with primary progressive multiple sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005679-13,0,0,0 2005-005680-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. LUIGI GONZAGA,VINORELBINE AND CAPECITABINE as first line treatment in advanced breast cancer patients with non measurable lesions for RECIST criteria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005680-29,0,0,0 2005-005681-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. LUIGI GONZAGA,VINORELBINE CAPECITABINE EPIRUBICINE AS FIRST LINE THERAPY IN ADVANCED BREAST CANCER PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005681-36,0,0,0 2005-005682-11,3,2006-03-16,2007-09-18,2,1,0,1,0,0,1,0,1,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase I/II, randomized, observer blinded study to evaluate and compare the safety, reactogenicity and immunogenicity of various formulations of the GlaxoSmithKline Biologicals’ adjuvanted 11-valent ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005682-11,0,0,0 2005-005683-87,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. LUIGI GONZAGA,VINORELBINA CAPECITABIME PACLITAXEL AS FIRST LINE THERAPY IN ADVANCED BREAST CANCER PATIENTS PRETREATED WITH ADJUVANT ANTHRACYCLINES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005683-87,0,0,0 2005-005686-11,2,2010-02-25,2010-06-30,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,SCHWARZ PHARMA Deutschland GmbH,"CONFIRMATORY, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUPS STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROSTAGLANDIN E1 IN SUBJECTS WITH DRY AGE-RELATED MACULAR DEGENERATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005686-11,0,0,0 2005-005692-15,1,2018-02-15,2018-02-15,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,"Evaluation of bio-clinician plus of perisurgery administration of Metilprednisolone MP in high doses in short term in laparotomy and laparoscopic colic surgeryfor neoplastic patology. Prospective, c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005692-15,0,0,0 2005-005695-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Renal Iñigo Álvarez de Toledo,"Ensayo clínico aleatorizado, controlado y abierto, para evaluar la eficacia (biocompatibilidad peritoneal) de la adición de bemiparina a la solución de icodextrina, en pacientes en diálisis peritoneal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005695-32,0,0,0 2005-005697-71,10,2015-12-09,2015-12-09,9,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Baxter AG,"Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method (rAHF PFM): A Phase 3/4, Prospective, Controlled, Randomized, Multi-Center Study to Compare the Efficacy and Safety of Continuous Infusio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005697-71,0,0,0 2005-005697-71,10,2015-12-09,2015-12-09,9,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Baxalta Innovations GmbH,"Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method (rAHF PFM): A Phase 3/4, Prospective, Controlled, Randomized, Multi-Center Study to Compare the Efficacy and Safety of Continuous Infusio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005697-71,0,0,0 2005-005697-71,10,2015-12-09,2015-12-09,9,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,"Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method (rAHF PFM): A Phase 3/4, Prospective, Controlled, Randomized, Multi-Center Study to Compare the Efficacy and Safety of Continuous Infusio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005697-71,0,0,0 2005-005698-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,National Medical Center (Országos Gyógyintézeti Központ),Efficacy of fenofibrate treatment on the insulin sensitivity and pancreas ß-cell function in obese patients with hypertriglyceridemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005698-31,0,0,0 2005-005701-32,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ELI LILLY,An Open-Label Study of the Efficacy of Atomoxetine Hydrochloride on Quality of Life of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without comorbid conditions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005701-32,0,0,0 2005-005702-23,1,2008-01-29,2008-01-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Nycomed GmbH,"Efficacy of 500µg roflumilast once daily versus placebo over 12 weeks in patients with diabetes mellitus type 2. A double blind, parallel group, phase IIb, proof of concept clinical study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005702-23,0,0,0 2005-005703-42,1,2007-08-28,2007-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A 12 week, randomised, double blind study evaluating the effects of low dose (10mg) and high dose (80mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by Ultra smal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005703-42,0,0,0 2005-005707-42,1,2011-12-27,2011-12-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,A single centre phase II study of Interleukin 1 receptor antagonist in the treatment of severe Traumatic Brain Injury,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005707-42,0,0,0 2005-005708-17,1,2006-08-28,2006-08-28,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,elbion AG,"International, multicenter, randomized, double-blind, placebo controlled, two-period, cross-over study to demonstrate safety, tolerability and anxiolytic effects of 600 mg ELB139 given orally t.i.d. t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005708-17,0,0,0 2005-005709-50,1,2011-05-31,2011-05-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Cardiology, University of Frankfurt",Extracorporal shock wave therapy for induction of therapeutic neovascularization and homing of bone marrow progenitor cells in patients with chronic ischemic heart disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005709-50,0,0,0 2005-005711-17,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,St. Jude Children’s Research Hospital,AN OPEN LABEL DOSE-ESCALATION STUDY OF A SELF COMPLEMENTARY ADENO-ASSOCIATED VIRAL VECTOR (scAAV2/8-LP1-hFIXco) FOR GENE TRANSFER IN SUBJECTS WITH HEMOPHILIA B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005711-17,0,0,0 2005-005714-20,2,2009-10-07,2009-10-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma GmbH,"A LONG-TERM FOLLOW UP STUDY TO EVALUATE THE SAFETY AND EFFICACY IN TRANSPLANT RECIPIENTS TREATED WITH MODIFIED RELEASE TACROLIMUS, FK506E (MR4); BASED IMMUNOSUPPRESSION REGIMEN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005714-20,0,0,0 2005-005714-20,2,2009-10-07,2009-10-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd,"A LONG-TERM FOLLOW UP STUDY TO EVALUATE THE SAFETY AND EFFICACY IN TRANSPLANT RECIPIENTS TREATED WITH MODIFIED RELEASE TACROLIMUS, FK506E (MR4); BASED IMMUNOSUPPRESSION REGIMEN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005714-20,0,0,0 2005-005715-22,3,2007-10-22,2009-01-15,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AstraZeneca AB,A randomised Phase II Study comparing anastrozole and fulvestrant to an-astrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005715-22,0,0,0 2005-005717-38,1,2009-12-21,2009-12-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"An Open-Label, Phase II Study to Evaluate the Biological Activity of AZD2171, as Measured by FDG-PET Response, in Patients with Metastatic Gastro-Intestinal Stromal Tumours (GIST) Resistant or Intoler...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005717-38,0,0,0 2005-005718-19,7,2007-08-17,2007-10-24,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Double Blind, Randomised, 3-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil/Hydrochlorothiazid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005718-19,0,0,0 2005-005719-83,3,2014-01-13,2014-02-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Universitary Hospital Hamburg,Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-T-lymphocyte-globulin (ATG Fresenius) prior allogeneic peripheral stem cell transplantation from HLA-identical siblings af...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005719-83,0,0,0 2005-005719-83,3,2014-01-13,2014-02-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Hamburg-Eppendorf,Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-T-lymphocyte-globulin (ATG Fresenius) prior allogeneic peripheral stem cell transplantation from HLA-identical siblings af...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005719-83,0,0,0 2005-005719-83,3,2014-01-13,2014-02-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-T-lymphocyte-globulin (ATG Fresenius) prior allogeneic peripheral stem cell transplantation from HLA-identical siblings af...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005719-83,0,0,0 2005-005721-55,1,2008-11-24,2008-11-24,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Imperial College Healthcare NHS Trust,Adjuvant Cytotoxic Chemotherapy in Older Women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005721-55,0,0,0 2005-005721-55,1,2008-11-24,2008-11-24,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Institute of Cancer Research,Adjuvant Cytotoxic Chemotherapy in Older Women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005721-55,0,0,0 2005-005723-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dept of Medicine,"Studies on the effect of hyperglycemia on the structure of the fibrin-gel and on the glycosylation of fibrin , and in what way the use of acetylsalicylic acid may interfere with this effect.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005723-34,0,0,0 2005-005725-64,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO,PHASE II CLINICAL AND PHARMACOKINETIC STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN ADVANCED OVARIAN CARCINOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005725-64,0,0,0 2005-005732-27,2,,,0,0,0,0,0,0,2,0,0,1,1,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,EFFICACY AND SAFETY OF THE MULTITARGET INHIBITOR AGENT SU11248 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005732-27,0,0,0 2005-005732-27,2,,,0,0,0,0,0,0,2,0,0,1,1,0,0,1,0,Policlinico Universitario Agustino Gemelli,EFFICACY AND SAFETY OF THE MULTITARGET INHIBITOR AGENT SU11248 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005732-27,0,0,0 2005-005733-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Ghent,Invloed van corticoïden op de nierfunctie postoperatief na cardiochirurgie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005733-35,0,0,0 2005-005734-12,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,GEICAM (GRUPO ESPAÑOL DE INVESTIGACIÓN EN CÁNCER DE MAMA),"ENSAYO CLÍNICO FASE IV.II, MULTICÉNTRICO, PARA LA ADMINISTRACIÓN DE CAPECITABINA SIMULTÁNEA A RADIOTERAPIA EN PACIENTES CON RECICIVA LOCAL DE CÁNCER DE MAMA Y TUMORES HER2 NEGATIVOS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005734-12,0,0,0 2005-005738-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Unidad integral de investigación en oncologia,Phase II Study of Single Agent RAD001 in Patients with Colon Cancer and Activating Mutations in the PI3KCA gene.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005738-11,0,0,0 2005-005739-91,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,University Hospital Ghent,"Functional Neuroimaging in depression: longitudinal study of PET metabolism in correlation with changes in attentional bias, autobiographical memory, future fluency and facial recognition in depressed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005739-91,0,0,0 2005-005742-39,1,2006-07-17,2006-07-17,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Ardana Bioscience Ltd,"A Phase II single centre, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of a loading dose regimen of a new GnRH antagonist, Teverelix, long-acting formulat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005742-39,0,0,0 2005-005745-18,2,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,0,Emma Children's Hospital-AMC,"Levamisole treatment for children with steroid sensitive nephrotic syndrome. A multi-centre, double-blind, placebo-controlled, randomised trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005745-18,0,0,0 2005-005745-18,2,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Levamisole treatment for children with steroid sensitive nephrotic syndrome. A multi-centre, double-blind, placebo-controlled, randomised trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005745-18,0,0,0 2005-005746-39,1,2007-06-26,2007-06-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Ineos Healthcare Ltd,"A multicentre Phase II study with Alpharen™: an open-label, dose-ranging phase followed by a placebo-controlled, double-blind, parallel-group comparison in haemodialysis subjects with hyperphosphataem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005746-39,0,0,0 2005-005749-20,1,2007-08-28,2007-08-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Richter Gedeon Vegyészeti Gyár Rt,Amlodipint és lisinoprilt tartalmazó fix gyógyszerkombináció (Lisonorm®) hatásosságának és biztonságosságának vizsgálata essentialis hypertoniás betegeken (ALFESS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005749-20,0,0,0 2005-005751-18,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,UCL Biomedicine R&D Unit,A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies (NA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005751-18,0,0,0 2005-005754-50,1,2009-08-05,2009-08-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Biotec Pharmacon ASA,"A randomised, double-blind, placebo-controlled study to determine the efficacy of soluble beta-1,3/1,6-glucan in chronic foot ulcers in diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005754-50,0,0,0 2005-005757-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut de Recerca / Hospital de la Santa Creu i Sant Pau,"Estudio sobre la utilidad de la Escala de Craving (EMCA), de la Escala de Deterioro del Autocontrol (EDACA) y del SPECT con yodobenzamida-I-123, como posibles predictores de la evolución del paciente ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005757-22,0,0,0 2005-005758-39,1,2011-02-11,2011-02-11,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Greater Glasgow Health Board,"Effect site controlled, reaction time safeguarded, patient maintained sedation with Propofol A) in oral surgery patients B) in general dentistry patients C) in colonoscopy patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005758-39,0,0,0 2005-005761-11,1,2009-12-31,2009-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Australasian Gastro−Intestinal Trials Group,"The MAX study: A randomised phase II/III study to evaluate the role of Mitomycin C, Avastin and Xeloda in patients with untreated metastatic colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005761-11,0,0,0 2005-005763-28,6,2006-11-08,2013-07-20,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-Aventis Groupe,"Estudio aleatorizado, doble ciego, en el que se comparan los efectos de un régimen de clopidogrel durante 3 meses en combinación con AAS durante el primer mes, frente a AAS en monoterapia, para el tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005763-28,0,0,0 2005-005765-11,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Dr. Willmar Schwabe GmbH & Co. KG,"Randomised, double-blind, placebo-controlled, parallel group trial to confirm the efficacy, safety and tolerability of Ginkgo biloba Special Extract EGb 761® in patients suffering from Mild Mental Imp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005765-11,0,0,0 2005-005766-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Sofamor - Danek,A Randomized Prospective Study of Instrumented Posterior Lumbar Interbody Fusion: Autologous Iliac Crest Bone Graft vs. Inductos™,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005766-36,0,0,0 2005-005769-12,1,2007-03-26,2007-03-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Galderma R&D,FLUORESCENT DETECTION WITH METHYL AMINOLEVULINATE OF BASAL CELL CARCINOMA: TO ASSESS THE ACCURACY OF THIS TECHNIQUE BY COMPARISON WITH RESECTION MARGIN LEFT BY MOH’S MICROGRAPHIC SURGERY AFTER DIFFER...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005769-12,0,0,0 2005-005770-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA,"RAPSODY - RANDOMIZED, PROSPECTIVE TRIAL OF TWO SCHEDULES OF SORAFENIB 800 mg DAILY AND INTERFERON ALPHA IN METASTATIC RENAL CELL CARCINOMA MRCC A GOIRC PHASE II STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005770-72,0,0,0 2005-005775-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Pilot phase II study of a combined immunotherapy protocol based on oral vaccination and direct intratumoral injection of Salmonella Typhi Ty21a Vivotif in metastatic cutaneous melanoma patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005775-15,0,0,0 2005-005777-30,7,2010-06-25,2010-07-02,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Open Label, Multicenter Study of VELCADE with Rituximab or Rituximab Alone in Subjects with Relapsed or Refractory, Rituximab Naive or Sensitive Follicular Non-Hodgkin s B-cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005777-30,0,0,0 2005-005777-30,7,2010-06-25,2010-07-02,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL NV,"A Randomized, Open Label, Multicenter Study of VELCADE with Rituximab or Rituximab Alone in Subjects with Relapsed or Refractory, Rituximab Naive or Sensitive Follicular Non-Hodgkin s B-cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005777-30,0,0,0 2005-005778-63,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO GIANNINA GASLINI,Phase II study of Glivec (imatinib mesylate) in patients with advanced neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005778-63,0,0,0 2005-005786-11,1,2008-09-16,2008-09-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Gilead Sciences S.L.,"Pilot phase IV, multicenter, randomized, open-label and controlled study to assess the evolution of peripheral body fat distribution after switching from AZT containing backbone to Truvada in HIV-1-in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005786-11,0,0,0 2005-005788-27,8,2007-06-04,2008-06-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ BIOSCIENCES GmbH,"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF 400MG/DAY LACOSAMIDE IN SUBJECTS WITH PAINFUL DISTAL DIABETIC NEUROPATHY USING TWO DIFFERENT T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005788-27,0,0,0 2005-005788-27,8,2007-06-04,2008-06-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHWARZ PHARMA,"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF 400MG/DAY LACOSAMIDE IN SUBJECTS WITH PAINFUL DISTAL DIABETIC NEUROPATHY USING TWO DIFFERENT T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005788-27,0,0,0 2005-005791-32,2,2008-08-11,2008-08-11,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Hunter-Fleming Ltd,Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005791-32,0,0,0 2005-005792-15,1,2006-06-23,2006-06-23,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Astion Danmark A/S,Evaluation of the efficacy of topical formulations containing ASF-1075 in the prevention and treatment of contact dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005792-15,0,0,0 2005-005793-75,2,2007-06-07,2007-06-07,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Astion Danmark A/S,Evaluation of the efficacy of a topical formulation containing ASF-1075 in the treatment of chronic hand dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005793-75,0,0,0 2005-005794-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Groupe français des Myélodysplasies,Traitement des syndromes myélodysplasiques par l'association aracytine et bortezomib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005794-29,0,0,0 2005-005804-17,3,2007-08-10,2007-08-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Laboratorios Almirall, S.A.","A Single Dose, Double-Blind, Double-Dummy, 3 Period Cross-Over, Placebo Controlled Clinical Trial To Assess the Rate of Onset of Action of Inhaled LAS 34273 200µg Compared To Placebo and Tiotropium 18...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005804-17,0,0,0 2005-005804-17,3,2007-08-10,2007-08-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Almirall Prodesfarma, S.A.","A Single Dose, Double-Blind, Double-Dummy, 3 Period Cross-Over, Placebo Controlled Clinical Trial To Assess the Rate of Onset of Action of Inhaled LAS 34273 200µg Compared To Placebo and Tiotropium 18...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005804-17,0,0,0 2005-005809-38,1,2008-04-01,2008-04-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Research & Development Department, Addenbrookes Hospital",Does prophylactic N acetylcysteine reduce the incidence of contrast nephropathy in patients undergoing peripheral angiography,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005809-38,0,0,0 2005-005812-25,2,2007-11-16,2007-11-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone Compared with Flexibly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005812-25,0,0,0 2005-005816-26,3,2017-09-04,2017-09-04,2,1,1,0,0,0,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV) in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-Positive. Revised Protocol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005816-26,1,1,0 2005-005819-26,6,2010-01-08,2010-02-02,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag EMEA Medical Affairs,"A Phase II, Open-Label Trial Using VELCADE for Re-Treatment of Multiple Myeloma Subjects Following an Initial Response to VELCADE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005819-26,0,0,0 2005-005819-26,6,2010-01-08,2010-02-02,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International,"A Phase II, Open-Label Trial Using VELCADE for Re-Treatment of Multiple Myeloma Subjects Following an Initial Response to VELCADE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005819-26,0,0,0 2005-005819-26,6,2010-01-08,2010-02-02,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase II, Open-Label Trial Using VELCADE for Re-Treatment of Multiple Myeloma Subjects Following an Initial Response to VELCADE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005819-26,0,0,0 2005-005820-15,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Servicio de Neumologia. Hospital Universitario Vall d'Hebron,"Ensayo clínico piloto, aleatorizado, controlado con placebo, paralelo, para evaluar la eficacia y seguridad de la tobramicina inhalada, en el paciente afecto de bronquiectasias, sin fibrosis quística ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005820-15,0,0,0 2005-005821-71,1,2013-11-13,2013-11-13,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University College London,A multicentre phase III randomised double blind placebo controlled trial of pravastatin added to first-line chemotherapy in patients with small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005821-71,0,0,0 2005-005825-75,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,GLAXO SMITHKLINE,"A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline s GSK Biologicals measles-mumps-rubella-varicella candidate vaccine MeMuRu-OKA and GSK...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005825-75,0,0,0 2005-005827-32,1,2009-12-31,2009-12-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Verein zur Förderung der Pneumologie am Krankenhaus Großhansdorf e.V.,"Offene, randomisierte, multizentrische Phase-II-Studie zum Vergleich der Wirksamkeit und Verträglichkeit von Erlotinib vs Carboplatin/Vinorelbin bei Patienten mit unvorbehandeltem nicht-kleinzelligen ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005827-32,0,0,0 2005-005828-14,1,2006-12-19,2006-12-19,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Neolab Ltd,"A phase III, Randomised, Double-blind, Double-dummy, placebo controlled crossover study to compare the systemic effects of inhaled combination Fluticasone propionate 250ug and Salmeterol xinafoate 50 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005828-14,0,0,0 2005-005835-87,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,GermanBreastGroup,A randomized discontinuation phase II study to determine the efficacy of RAD001 in breast cancer patients with bone metastases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005835-87,0,0,0 2005-005838-12,1,2007-10-26,2007-10-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Oxagen Ltd,"A PHASE II STUDY OF THE EFFICACY (AS ASSESSED BY BRONCHIAL ALLERGEN CHALLENGE) AND SAFETY OF OC000459 DOSED ORALLY (200mg BID WITH FOOD) IN SUBJECTS WITH ALLERGIC ASTHMA; IN A RANDOMISED, DOUBLE BLIND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005838-12,0,0,0 2005-005839-10,1,2011-04-30,2011-04-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Georg-August-University Göttingen,Efficacy and safety of quetiapine in treating affective symptoms of patients with first-episode psychosis - a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005839-10,0,0,0 2005-005843-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hanns-Ulrich Marschall,Studie på effekten av rifampicin och ursodeoxycholsyra på gallipider och deras transport och avgiftning hos patienter med kolesterolgallstenar.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005843-24,0,0,0 2005-005846-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.O.N.O. Gruppo Oncologico del Nord Ovest,"STUDY MULTICENTRIC PILOT OF CHEMOTHERAPY WITH CAPECITABINE, OXALIPLATIN LOHP IRINOTECAN Cpt-11 IN PATIENTS WITH Colorectal METASTATIC cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005846-37,0,0,0 2005-005849-19,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Southampton University Hospitals NHS Trust,Finite duration treatment in pre-cirrhotic chronic hepatitis B virus (HBV) infection: Phase IV study of Lamivudine priming of Pegasys treatment in HBeAg positive patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005849-19,0,0,0 2005-005850-30,1,2010-11-19,2010-11-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Medical University Vienna,"Low molecular weight heparin (Fragmin) in pregnant women with a history of uteroplacental insufficiency and thrombophilia, a randomized trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005850-30,0,0,0 2005-005852-42,3,2007-01-05,2010-01-28,3,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label, two-step, multicenter European study to evaluate the efficacy and safety of Sandostatin LAR at High Dose or in combination either with GH-receptor antagonist or dopamine-agonist in a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005852-42,0,0,0 2005-005852-42,3,2007-01-05,2010-01-28,3,1,0,0,0,1,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An open-label, two-step, multicenter European study to evaluate the efficacy and safety of Sandostatin LAR at High Dose or in combination either with GH-receptor antagonist or dopamine-agonist in a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005852-42,0,0,0 2005-005855-16,5,2006-07-06,2006-07-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005855-16,0,0,0 2005-005855-16,5,2006-07-06,2006-07-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005855-16,0,0,0 2005-005856-42,4,2006-07-11,2006-07-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50 mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005856-42,0,0,0 2005-005857-23,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,CHIESI,"DOUBLE BLIND, DOUBLE DUMMY, RANDOMISED, PARALLEL GROUP, MONOCENTRIC CLINICAL TRIAL ON THE EFFECTS OF CHF 1535 MDI OR SERETIDE DPI ON LUNG HYPERINFLATION AND EXERCISE TOLERANCE IN PATIENTS WITH COPD A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005857-23,0,0,0 2005-005859-18,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,FONDAZIONE SANTA LUCIA,EFFECT OF MEMANTINE TREATMENT ON BRAIN FUNCTION AND MORPHOLOGICAL STRUCTURE IN PATIENTS WITH MODERATE TO SEVERE PATIENTS WITH ALZHEIMER S DISEASE A STRUCTURAL MR AND FMRI STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005859-18,0,0,0 2005-005862-36,1,2013-12-31,2013-12-31,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,"Klinikum der Universität München Innenstadt, I. Frauenklinik",Prospectively Randomized Phase I/II Trial of Liposomal-encapsulated Doxorubicin and Cisplatin +/- Locoregional Hyperthermia in patients with Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005862-36,0,0,0 2005-005863-26,4,2008-02-05,2008-02-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Europe R&D Centre Ltd,"A Phase 2, double blind, placebo controlled, dose-ranging study in subjects with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005863-26,0,0,0 2005-005863-26,4,2008-02-05,2008-02-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd,"A Phase 2, double blind, placebo controlled, dose-ranging study in subjects with post herpetic neuralgia (PHN) to evaluate the efficacy, safety, tolerability and pharmacokinetics of four doses of TAK-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005863-26,0,0,0 2005-005868-93,2,2007-06-18,2007-06-18,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,AVERA PHARMACEUTICALS INC.,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects with Idiopathic Detrusor Overactivity",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005868-93,0,0,0 2005-005871-14,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,CHIRON,"A Phase II, Randomized, Controlled, Observer-blind, Multi-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two FLUAD-like Surface Antigen Adjuvanted...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005871-14,0,0,0 2005-005873-31,1,2008-05-08,2008-05-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ISTITUTO NEUROLOGICO CARLO BESTA,"A randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of Erytropoietin administered by iv route as add-on treatment in patients affected by Amyotrophic Late...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005873-31,0,0,0 2005-005874-65,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Antwerp,Non-invasive monitoring of airway inflammation in asthmatic patients during adaptation of inhaled steroid therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005874-65,0,0,0 2005-005876-33,1,2007-01-29,2007-01-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Zentiva a.s.,"A Randomised, Double Blind, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of nasal spray ANTIRIN® and NASIC® in the Treatment of Acute Viral Rhinitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005876-33,0,0,0 2005-005877-31,1,2008-03-05,2008-03-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ISTITUTO NEUROLOGICO CARLO BESTA,Phase II study Systemic treatment with ZK219477 EPOTHILONE in recurrent Glioblastoma patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005877-31,0,0,0 2005-005883-10,1,2007-09-25,2007-09-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche Austria GmbH,A phase II study of Bevacizumab with Docetaxel and Capecitabine in the neoadjuvant setting for breast cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005883-10,0,0,0 2005-005885-36,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA USL DI FORLI,Dose finding study of Liposomal Doxorubicin Myocet in combination with Capecitabine Xeloda in the treatment of metastatic breast cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005885-36,0,0,0 2005-005887-97,18,2009-06-30,2009-11-09,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"Estudio abierto sobre bevacizumab(AVASTIN®) en combinación con quimioterapia basada en platino como tratamiento de primera línea de pacientes con carcinoma de pulmón no microcítico, no epidermoide, av...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005887-97,0,0,0 2005-005887-97,18,2009-06-30,2009-11-09,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"Estudio abierto sobre bevacizumab(AVASTIN®) en combinación con quimioterapia basada en platino como tratamiento de primera línea de pacientes con carcinoma de pulmón no microcítico, no epidermoide, av...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005887-97,0,0,0 2005-005895-34,1,,,0,1,0,0,0,3,4,0,1,1,1,1,0,1,0,"Department of Clinical Pharmacology, Medical University of Vienna",Effects of common topical glaucoma therapy on optic nerve head blood flow autoregulation during increased arterial blood pressure and artificially elevated intraocular pressure in healthy humans,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005895-34,0,0,0 2005-005896-14,1,2008-03-05,2008-03-05,1,1,0,0,0,3,2,0,1,1,1,1,1,0,0,Department of Clinical Pharmacology,Role of endothelin- and nitric oxide-system in the regulation of optic nerve head blood flow during changes in ocular perfusion pressure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005896-14,0,0,0 2005-005897-54,1,2006-02-10,2006-02-10,1,0,0,1,1,3,1,0,1,1,0,0,0,0,1,Stiefel Laboratories Maidenhead Ltd,"A Phase 1, Single-Centre, Single-blind, CPO Solution Human Patch Test in Healthy Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005897-54,0,0,0 2005-005898-29,1,2010-12-01,2010-12-01,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,University Hospital Birmingham,"The effect of bosentan, a selective endothelin antagonist, on cardiovascular performance in patients with a Fontan circulation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005898-29,0,0,0 2005-005905-51,1,2006-10-19,2006-10-19,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,Stiefel Laboratories (Maidenhead) Limited trading as Stiefel International Research and Development,"A PHASE II, SINGLE CENTRE, RANDOMISED, PARALLEL GROUP, CLINICAL STUDY TO INVESTIGATE THE TOLERABILITY OF DOUBLE BLIND CICLOPIROX NAIL PRODUCT COMPARED TO DOUBLE BLIND PLACEBO NAIL PRODUCT COMPARED TO ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005905-51,0,0,0 2005-005910-20,2,2008-01-30,2008-01-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a division of Schering Corporation","A 12-Week Efficacy and Safety Study of Two Doses of Mometasone Furoate/Formoterol Combination Formulation Compared With Mometasone Furoate Monotherapy, in Persistent Asthmatics Previously treated With...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005910-20,0,0,0 2005-005913-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE POLICLINICO S. MATTEO,"A phase II, multicentre, clinical study evaluating the safety and efficacy of Treosulfan-based conditioning of allogenic transplantation of haemopoietic stem-cells in patients affected by Thalassemia ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005913-40,0,0,0 2005-005914-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Diabetes-Centre Quakenbrueck,Effect of Insulin Glulisin on postprandial plasma glucose levels in obese subjectts with type 2 diabetes after a standard meal in comparison to Insulin Lispro,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005914-18,0,0,0 2005-005915-13,1,2007-07-24,2007-07-24,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,TauRx Therapeutics PTE Ltd,An Open Pilot Study of Methlythioninium Chloride (MTC) in Frontotemporal Dementia and Related Dementia Syndromes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005915-13,0,0,0 2005-005916-26,1,2006-04-07,2006-04-07,1,0,0,1,1,3,1,0,1,1,0,0,0,0,1,Stiefel Laboratories Maidenhead Ltd,"A phase I, single-blind, CPO solution human repeat insult patch test in healthy subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005916-26,0,0,0 2005-005918-20,3,2011-07-14,2013-01-15,3,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Rikshospitalet,"Rituximab as second line treatment for ITP. A Multicentre, Randomized, Double blind, Placebo-controlled, Phase III study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005918-20,0,0,0 2005-005918-20,3,2011-07-14,2013-01-15,3,1,0,0,0,1,3,0,0,1,0,0,1,0,0,"Sykehuset Østfold, Fredrikstad","Rituximab as second line treatment for ITP. A Multicentre, Randomized, Double blind, Placebo-controlled, Phase III study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005918-20,0,0,0 2005-005919-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Dr. Falk Pharma Portugal,"Randomized, multicenter, double blind, placebo controlled trial, for the evaluation of the efficacy and tolerability of ursodeoxycholic acid on the dissolution of cholesterol gallstones (<15mm) after ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005919-24,0,0,0 2005-005921-73,9,2008-04-18,2008-04-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Service AG,"""Estudio de fase IIIB, multicéntrico, abierto, de 12 meses de duración para evaluar la seguridad, tolerabilidad y eficacia de ranibizumab (0.3 mg) en pacientes con neovascularización coroidea subfovea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005921-73,0,0,0 2005-005921-73,9,2008-04-18,2008-04-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"""Estudio de fase IIIB, multicéntrico, abierto, de 12 meses de duración para evaluar la seguridad, tolerabilidad y eficacia de ranibizumab (0.3 mg) en pacientes con neovascularización coroidea subfovea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005921-73,0,0,0 2005-005921-73,9,2008-04-18,2008-04-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"""Estudio de fase IIIB, multicéntrico, abierto, de 12 meses de duración para evaluar la seguridad, tolerabilidad y eficacia de ranibizumab (0.3 mg) en pacientes con neovascularización coroidea subfovea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005921-73,0,0,0 2005-005921-73,9,2008-04-18,2008-04-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","""Estudio de fase IIIB, multicéntrico, abierto, de 12 meses de duración para evaluar la seguridad, tolerabilidad y eficacia de ranibizumab (0.3 mg) en pacientes con neovascularización coroidea subfovea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005921-73,0,0,0 2005-005922-29,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Anæstesisektor Nordjylland,Præhospital smertebehandling med Actiq®-slikkepind (Fentanyl 400 µg/dosis) af patienter visiteret præhospitalt med akut STEMI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005922-29,0,0,0 2005-005928-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Landspitali-University Hospital,Prospective randomized double blind trial on the use of Scopoderm patch for control of post-operative nausea and vomitting in patients undergoing gynecologic laparoscopic procedures.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005928-13,0,0,0 2005-005929-62,1,2009-06-05,2009-06-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,A Feasibility study of Pemetrexed single agent and folic acid given as neoadjuvant treatment in patients with resectable rectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005929-62,0,0,0 2005-005930-11,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Augenklinik des Universitätsklinikums Erlangen,"Einfach maskierte, randomisierte , cross over Studie zur Bestimmung der Wirkung von COSOPT® (Dorzolamid/ Timolol, MSD) auf die Perfusion und Sauerstoffsättigung der retinalen Gefäße bei Glaukompatient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005930-11,0,0,0 2005-005934-11,1,2009-09-01,2009-09-01,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Cornwall College Camborne,Investigating the possible Therapeutic Effects of the Homoeopathic Remedy Apis Mellifica on Weaver Fish Stings using a Double Blind Randomised Control Trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005934-11,0,0,0 2005-005934-11,1,2009-09-01,2009-09-01,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Royal National Lifeboat Institution,Investigating the possible Therapeutic Effects of the Homoeopathic Remedy Apis Mellifica on Weaver Fish Stings using a Double Blind Randomised Control Trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005934-11,0,0,0 2005-005936-29,6,2007-05-07,2007-05-07,4,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical research and Development,"A Multicenter, Parallel, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005936-29,0,0,0 2005-005936-29,6,2007-05-07,2007-05-07,4,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Wyeth Pharmaceuticals France, Wyeth Research Division","A Multicenter, Parallel, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005936-29,0,0,0 2005-005936-29,6,2007-05-07,2007-05-07,4,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,"A Multicenter, Parallel, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005936-29,0,0,0 2005-005938-12,1,2007-11-01,2007-11-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Dr. Sylvia Boesch,"Eine offene, nicht randomisierte, einarmige Pilotstudie zur Beurteilung der Wirksamkeit von Erythropoetin bei Friedreich Ataxie.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005938-12,0,0,0 2005-005939-10,1,2007-05-10,2007-05-10,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Merck & Co. Inc.,"A study in healthy, young adults and healthy infants of the safety, tolerability, and immunogenicity of an investigational manufacturing process for the recombinant hepatitis B vaccine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005939-10,0,0,0 2005-005943-24,1,2007-06-19,2007-06-19,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase I/II, observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005943-24,0,0,0 2005-005944-22,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline GmbH & Co. KG,"Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus intramuscular administration of GlaxoSmithKline Biologicals’ combined measles...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005944-22,0,0,0 2005-005945-20,1,2009-06-22,2009-06-22,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Fresenius Biotech GmbH,"Multicenter, open-label and randomized phase II study to evaluate safety and efficacy of the tri-functional bispecific antibody catumaxomab(anti-EpCAM x anti-CD3) in patients after curative resection ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005945-20,0,0,0 2005-005946-38,1,2007-05-25,2007-05-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bracco ALTANA Pharma GmbH,A DOUBLE-BLIND INTER-INDIVIDUAL COMPARISON OF IOMEPROL 300 AND IOMEPROL 400 IN MULTI-DETECTOR CT ANGIOGRAPHY (MDCTA) OF PERIPHERAL ARTERIES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005946-38,0,0,0 2005-005949-19,1,2006-12-15,2006-12-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, placebo controlled, parallel group study to compare efficacy of a single dose of lumiracoxib 400 mg given preemptively versus post-operatively, in reducing pai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005949-19,0,0,0 2005-005950-33,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset,Studie av Domperidon och barn med kongenitalt centralt hypoventilationssyndrom.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005950-33,0,0,0 2005-005951-16,1,2006-12-31,2006-12-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Dr. Joan Ramon Masclans. Servicio de Medicina Intensiva. Hospital Universitario Vall d'Hebron,"Ensayo clínico piloto, aleatorizado, controlado con placebo, paralelo, doble ciego, para evaluar el efecto de salbutamol intravenoso sobre marcadores de inflamación en pacientes con síndrome de distré...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005951-16,0,0,0 2005-005957-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,RANDOMIZED CLINICAL STUDY OF DIFFERENT DOSES And DURATION OF PARNAPARINA In the TREATMENT Of SUPERFICIAL VENOUS THROMBOSIS - STEFLUX STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005957-23,0,0,0 2005-005960-95,1,2012-05-14,2012-05-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Enturia, Inc.","Prospective, randomised clinical trial to compare the efficacy of 0.5% (w/v) chlorhexidine gluconate in 70% (v/v) isopropyl alcohol with 2% (w/v) chlorhexidine gluconate in 70% (v/v) isopropyl alcohol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005960-95,0,0,0 2005-005964-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aino Ruohola,Äkillisen välikorvatulehduksen hoito -tutkimus.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005964-10,0,0,0 2005-005966-35,1,2009-07-07,2009-07-07,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Universitätsklinikum Münster,"A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in elderly patients with newly diagnosed AML",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005966-35,0,0,0 2005-005967-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA USL 6 LIVORNO ZONA LIVORNESE,"Study pilot of metronomic chemotherapy with ciclofosfamide, celecoxib and desametasone in patients with diagnosis of carcinoma of the refractory ormon prostate in advanced stage appraisal pharmacody...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005967-27,0,0,0 2005-005968-90,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE,An international multicenter randomized phase III study of first-line Erlotinib followed by second-line Cisplatin Gemcitabine versus first-line Cisplatin Gemcitabine followed by second-line Erlot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005968-90,0,0,0 2005-005972-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fredericia Hospital,Retrograd intrarenal stenkirurgi. En metode til behandling af den ESWL-resistente nyresten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005972-34,0,0,0 2005-005974-64,1,2008-10-15,2008-10-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"AstraZeneca Farmacéutica Spain, S.A.","Comparación del tratamiento con un único inhalador de Symbicort (Symbicort Turbuhaler 160/4,5 mg, 1 inhalación 2 veces/día como dosis de mantenimiento, y a demanda para el alivio de los síntomas, SM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005974-64,0,0,0 2005-005975-13,3,2006-08-14,2006-08-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005975-13,0,0,0 2005-005978-79,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,MCM Klosterfrau GmbH,Proof of the noninferiority of a benzocain containing lozenge compared to Anaesthesin pastilles on patients with acute pharyngitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005978-79,0,0,0 2005-005980-27,3,2007-12-19,2007-12-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Kowa Research Europe Ltd.,"OPEN-LABEL, LONG-TERM ( ≥ 1 YEAR) EXTENSION STUDY OF PITAVASTATIN 2 MG AND 4 MG QD IN ELDERLY PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005980-27,0,0,0 2005-005981-35,4,2007-08-07,2007-08-14,4,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Kowa Research Europe Ltd.,"DOUBLE-BLIND FOLLOW-ON STUDY OF PITAVASTATIN (4 MG) VERSUS SIMVASTATIN (40 MG AND 80 MG), WITH A SINGLE-BLIND EXTENSION OF TREATMENT, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPID...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005981-35,0,0,0 2005-005984-27,10,2010-04-12,2010-04-16,9,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients with Chronic Asthma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005984-27,0,0,0 2005-005984-27,10,2010-04-12,2010-04-16,9,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Merck Sharp & Dohme oü,"A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients with Chronic Asthma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005984-27,0,0,0 2005-005984-27,10,2010-04-12,2010-04-16,9,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Suomen MSD Oy,"A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients with Chronic Asthma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005984-27,0,0,0 2005-005984-27,10,2010-04-12,2010-04-16,9,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Merck Sharp and Dohme de España,"A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients with Chronic Asthma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005984-27,0,0,0 2005-005984-27,10,2010-04-12,2010-04-16,9,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Merck Sharp & Dohme GesmbH,"A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients with Chronic Asthma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005984-27,0,0,0 2005-005984-27,10,2010-04-12,2010-04-16,9,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"MERCK & Co, Inc","A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients with Chronic Asthma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005984-27,0,0,0 2005-005984-27,10,2010-04-12,2010-04-16,9,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme, Lda.","A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients with Chronic Asthma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005984-27,0,0,0 2005-005984-27,10,2010-04-12,2010-04-16,9,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Merck Sharp & Dohme BV,"A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients with Chronic Asthma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005984-27,0,0,0 2005-005984-27,10,2010-04-12,2010-04-16,9,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Merck & Co., Inc","A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients with Chronic Asthma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005984-27,0,0,0 2005-005984-27,10,2010-04-12,2010-04-16,9,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Merck & Co, Inc.","A Multicenter, Randomized, Double-Blind, Parallel-Group 6-Month Study to Evaluate the Efficacy and Safety of Oral Montelukast Sodium, Fluticasone Propionate and Placebo in Patients with Chronic Asthma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005984-27,0,0,0 2005-005985-35,2,2007-02-09,2007-02-09,1,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Boehringer Ingelheim Ltd,"A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300 an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005985-35,0,0,0 2005-005985-35,2,2007-02-09,2007-02-09,1,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Boehringer Ingelheim,"A 24 week, MRI based, double-blind, randomised, placebo-controlled, modified dose-escalation trial to evaluate the safety, efficacy and pharmacokinetics of BIRT 2584 XX tablets at doses of 100, 300 an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005985-35,0,0,0 2005-005987-94,1,2009-12-08,2009-12-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Leipzig,Double-blind placebo-controlled randomised trial of lamivudine in the treatment of acute hepatitis B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005987-94,0,0,0 2005-005989-37,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,Schering Oy,CogniMS: observational study to assess cognition in patients with early Multiple Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005989-37,0,0,0 2005-005998-29,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SENESE,FIVE- VERSUS SEVEN-DAY SUBCUTANEOUS ADMINISTRATION OF CLADRIBINE IN HAIRY CELL LEUKEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005998-29,0,0,0 2005-006005-61,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Pharmaceutical Research Network, LLC",A COMPARISON OF THE EFFICACY AND SAFETY OF THE DORZOLAMIDE/TIMOLOL FIXED COMBINATION GIVEN TWICE DAILY VERSUS THE LATANOPROST/TIMOLOL FIXED COMBINATION GIVEN ONCE EVERY MORNING FOLLOWING A RUN-IN PE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006005-61,0,0,0 2005-006014-18,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Macular structure and function after intravitreal injection of bevacizumab for wet macular degeneration a interventional study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006014-18,0,0,0 2005-006017-41,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Calabar AB,"A single-centre, placebo-controlled, cross-over, double blind study of the effects on salivation by increasing doses of physostigmine applied to the labial mucosa of subjects with chronic dry mouth sy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006017-41,0,0,0 2005-006018-16,1,2011-05-26,2011-05-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Royal Marsden Hospital,A Randomised Phase III Trial Of Low Dose DailyDexamethasone Versus Intermittent Dexamethasone Versus Prednisolone In Hormone Refractory Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006018-16,0,0,0 2005-006022-29,3,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,Pfizer Inc. - 235 East 42nd Street - New York - 10017,"RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF ERLOTINIB WITH OR WITHOUT SU011248 IN THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006022-29,0,0,0 2005-006022-29,3,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,"Pfizer, S.A.","RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF ERLOTINIB WITH OR WITHOUT SU011248 IN THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006022-29,0,0,0 2005-006022-29,3,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,PFIZER,"RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF ERLOTINIB WITH OR WITHOUT SU011248 IN THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006022-29,0,0,0 2005-006024-11,1,2008-08-01,2008-08-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University hospital of Bonn,"Prospective, open label, multi center phase II clinical trial of oral BAY 43-9006 (Sorafenib) in patients with relapsed or refractory multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006024-11,0,0,0 2005-006026-28,1,2010-09-24,2010-09-24,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Pfizer Pharma GmbH,"Randomized, Double-Blind Study of the morphine-sparing efficacy and safety of Parecoxib sodium 40 mg i.v. followed by 20 mg i.v. every 12 hours in the treatment of pain following radical prostatectomy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006026-28,0,0,0 2005-006029-94,6,2009-04-02,2009-08-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Limited,"A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006029-94,0,0,0 2005-006033-32,3,2007-12-15,2007-12-15,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Solvay Pharmaceuticals,"A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006033-32,0,0,0 2005-006037-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Universitätsklinikum Bonn; Klinik und Poliklinik für Psychiatrie und Psychotherapie,Überwachung einer Therapie mit Bromocriptin bei Patienten mit klinisch relevanter Risperidon-induzierter Hyperprolaktinämie. Eine psychiatrisch-endokrinologische Ver-laufsbeobachtung.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006037-33,0,0,0 2005-006041-16,3,2008-04-29,2008-04-29,3,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Kowa Research Europe Ltd.,"DOUBLE-BLIND FOLLOW-ON STUDY OF PITAVASTATIN (4 MG) VERSUS ATORVASTATIN (20 MG AND 40 MG), WITH A SINGLE BLIND EXTENSION OF TREATMENT IN PATIENTS WITH TYPE II DIABETES MELLITUS AND COMBINED DYSLIPIDEM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006041-16,0,0,0 2005-006042-41,1,2015-12-31,2015-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Karolinska Institutet,Local treatment of craniomandibular myofascial pain with the 5-HT3 receptor antagonist granisetron. A randomized and double-blind study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006042-41,0,0,0 2005-006048-42,1,2008-03-06,2008-03-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Schering-Plough Research Institute,"A Phase 2a, Multiple-Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti-Psychotic-Induced Extra-Pyramidal Symptoms Among Subjects With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006048-42,0,0,0 2005-006052-37,1,2007-05-25,2007-05-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bracco ALTANA Pharma GmbH,COMPARISON OF IOMEPROL 300 AND IOMEPROL 400 FOR THE EFFICIENCY OF AUTOSEGMENTATION IN 64-ROW MULTI-DETECTOR CTA OF THE CORONARY ARTERIES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006052-37,0,0,0 2005-006053-25,1,2008-07-10,2008-07-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bracco ALTANA Pharma GmbH,PET/CT WITH IOMERON® 400 IN PATIENTS WITH SUSPECTED MALIGNANT LIVER LESIONS - A FEASIBILITY STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006053-25,0,0,0 2005-006060-63,3,2007-04-01,2007-09-18,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,FOURNIER Laboratories Ireland Ltd,"A randomized, double-blind trial comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006060-63,0,0,0 2005-006065-14,2,2006-11-24,2006-11-24,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, open, randomised, comparative study to evaluate the immunogenicity and safety of GlaxoSmithKline GSK Biologicals measles-mumps-rubella-varicella candidate vaccine MeMuRu-OKA and GSK B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006065-14,0,0,0 2005-006066-34,1,,,0,1,0,0,1,1,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, single-blind, randomized, controlled, multinational study for the evaluation of safety of GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-teta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006066-34,0,1,1 2005-006067-31,3,2008-12-16,2008-12-16,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Neurobiological Technologies Inc.,"ASP II (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment within 6 Hours ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006067-31,0,0,0 2005-006067-31,3,2008-12-16,2008-12-16,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Neurobiological Technologies Inc,"ASP II (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment within 6 Hours ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006067-31,0,0,0 2005-006069-15,1,2010-10-08,2010-10-08,1,1,0,0,0,0,3,1,0,1,0,0,1,0,1,Gebro Pharma GmbH,Population pharmacokinetic/pharmacodynamic and tolerability clinical trial in patients suffering from acute post-operative pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006069-15,0,0,0 2005-006071-12,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SAN CAMILLO FORLANINI,"Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine Vitamin B12 plus Calcium levofolinate in relapsing-remitting multiple sclerosis patients Already in treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006071-12,0,0,0 2005-006074-10,1,2008-11-25,2008-11-25,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd.,"A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/kg) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006074-10,0,0,0 2005-006076-35,3,2007-07-19,2007-07-19,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Generics,"A MULTICENTRE, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL-GROUP STUDY TO DETERMINE THE THERAPEUTIC EQUIVALENCE BETWEEN FLUTICASONE PROPIONATE, 125 OR 250 µg TWICE DAILY DELIVERED VIA pMDI (MERCK...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006076-35,0,0,0 2005-006077-27,4,2007-07-02,2007-07-02,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Generics,"A MULTICENTRE, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL-GROUP STUDY TO DETERMINE THE THERAPEUTIC EQUIVALENCE BETWEEN FLUTICASONE PROPIONATE, 100 µg TWICE DAILY DELIVERED VIA A PRESSURISED METE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006077-27,0,0,0 2005-006078-84,1,2008-07-29,2008-07-29,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Generics [UK] Ltd trading as Merck Generics,"A two-way crossover, sequential-dose, double-blinded, double-dummy, multiple dose, pharmacodynamic, comparative study of fluticasone propionate, 500 μg and 1000 μg twice daily delivered via pressuriz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006078-84,0,0,0 2005-006082-14,12,2013-10-10,2013-11-14,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients with Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs. Da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006082-14,0,0,0 2005-006082-14,12,2013-10-10,2013-11-14,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb S.r.L.,"A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients with Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs. Da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006082-14,0,0,0 2005-006083-57,11,2009-02-12,2014-03-18,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol Myers Squibb International Corporation,"A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010) Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006083-57,0,0,0 2005-006083-57,11,2009-02-12,2014-03-18,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010) Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006083-57,0,0,0 2005-006089-32,1,2008-08-01,2008-08-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Greater Glasgow - Yorkhill Division,A prospective randomised controlled trial of management of recurrent nosebleeds in children: antiseptic cream alone versus antiseptic cream with nasal cautery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006089-32,0,0,0 2005-006096-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Karolinska University Hospital, Huddinge","Can peroperative subcutaneous, injection of bupivacaine with adrenaline decrease the postoperative need or opiates after cesarean section?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006096-12,0,0,0 2005-006097-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitätsklinikum Essen,Pilot study of dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esoph...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006097-10,0,0,0 2005-006098-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitätsklinikum Essen,"Prospektiv, randomisierte, doppelblinde, multizentrische Phase-II- Studie zum Vergleich der Wirksamkeit einer Chemotherapie mit Gemcitabin plus Cisplatin und Sorafenib (BAY 43-9006) versus Gemcitabin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006098-29,0,0,0 2005-006105-40,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI,TREATMENT OF IDIOPATHIC ASTHENOZOOSPERMIE WITH COENZYME Q10. A DOUBLE BLIND CONTROLLED STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006105-40,0,0,0 2005-006109-19,5,2013-02-28,2013-02-28,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Sopherion Therapeutics, Inc.","A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel versus Trastuzumab and Paclitaxel for First line Therapy of Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006109-19,1,0,0 2005-006109-19,5,2013-02-28,2013-02-28,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"SOPHERION THERAPEUTICS, INC.","A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel versus Trastuzumab and Paclitaxel for First line Therapy of Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006109-19,1,0,0 2005-006111-47,1,2006-07-10,2006-07-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,McNeil Ltd,"A double-blind, randomised, parallel group pilot study to compare macrogol 3350 + electrolytes versus placebo in the overnight relief of constipation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006111-47,0,0,0 2005-006113-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Universitäres Herzzentrum Hamburg,Untersuchung der Modulation der Endothelfunktion durch Enoxaparin bei Patienten mit Koronarkrankheit. Bedeutung der Enoxaparin-vermittelten Dissoziation endothelial gebundener Oxidasen für die Regulat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006113-40,0,0,0 2005-006118-17,1,2007-06-14,2007-06-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the beta3-Adrenergic Receptor Agonist Solabegron in Subjects with Irritable Bowel Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006118-17,0,0,0 2005-006128-13,7,2007-06-23,2007-06-23,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A phase IV randomised, double-blind, placebo-controlled, dose titration trial with 0.125-0.75 mg/day pramipexole Sifrol, Mirapexin orally for 12 weeks to investigate the safety and efficacy in out-p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006128-13,0,0,0 2005-006128-13,7,2007-06-23,2007-06-23,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A phase IV randomised, double-blind, placebo-controlled, dose titration trial with 0.125-0.75 mg/day pramipexole Sifrol, Mirapexin orally for 12 weeks to investigate the safety and efficacy in out-p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006128-13,0,0,0 2005-006128-13,7,2007-06-23,2007-06-23,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A phase IV randomised, double-blind, placebo-controlled, dose titration trial with 0.125-0.75 mg/day pramipexole Sifrol, Mirapexin orally for 12 weeks to investigate the safety and efficacy in out-p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006128-13,0,0,0 2005-006128-13,7,2007-06-23,2007-06-23,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Boehringer Ingeleim España, S.A.","A phase IV randomised, double-blind, placebo-controlled, dose titration trial with 0.125-0.75 mg/day pramipexole Sifrol, Mirapexin orally for 12 weeks to investigate the safety and efficacy in out-p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006128-13,0,0,0 2005-006128-13,7,2007-06-23,2007-06-23,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A phase IV randomised, double-blind, placebo-controlled, dose titration trial with 0.125-0.75 mg/day pramipexole Sifrol, Mirapexin orally for 12 weeks to investigate the safety and efficacy in out-p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006128-13,0,0,0 2005-006128-13,7,2007-06-23,2007-06-23,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase IV randomised, double-blind, placebo-controlled, dose titration trial with 0.125-0.75 mg/day pramipexole Sifrol, Mirapexin orally for 12 weeks to investigate the safety and efficacy in out-p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006128-13,0,0,0 2005-006133-32,1,2006-05-11,2006-05-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Allergie-Centrum-Charité,"An exploratory phase IV, randomised, double-blind, placebo controlled crossover study to assess and compare the effects of 5 mg vs. 20 mg Desloratadine on the development of experimentally induced urt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006133-32,0,0,0 2005-006136-29,1,2007-08-31,2007-08-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Peter Wolf MD, Department of Dermatology, Medical University of Graz",Mikroperfusions-Pilotstudie zur Korrelation von Schmerzreaktion und neurogener Entzündung bei photodynamischer Therapie superfizieller Basaliome (English: Microperfusion-pilotstudy to correlate pain ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006136-29,0,0,0 2005-006138-14,1,2008-05-29,2008-05-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"Multi-center, open-label, prospective, randomized, parallel group study investigating an intensified Myfortic® dosing regimen in comparison to a standard dosing regimen of Myfortic® in combination wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006138-14,0,0,0 2005-006140-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Effectiveness of the Fentanyl in continuous infusion in the newborns in mechanical ventilation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006140-37,0,0,0 2005-006141-16,1,2009-06-09,2009-06-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Oxford,"A Randomised, Placebo-Controlled Study of Two Doses of Oral 6R-BH4 on Vascular Function in Subjects with Coronary Artery Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006141-16,0,0,0 2005-006150-25,1,2007-06-18,2007-06-18,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,University Hospital,Kan risikoen for RD og hypoglykæmi efter elektivt sectio reduceres ved indgift af adrenalin.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006150-25,0,0,0 2005-006151-20,1,2008-07-08,2008-07-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Erlangen-Nuremberg,Quetiapine and the dopaminergic epigenetic control – a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006151-20,0,0,0 2005-006157-24,2,2011-09-22,2011-09-22,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,TopoTarget A/S,A multicenter open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006157-24,0,0,0 2005-006161-13,1,2010-01-21,2010-01-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche Pharma AG,A single arm Phase II study to assess efficacy and safety of bevacizumab in combination with the standard therapy (interferon alfa-2a and vinblastine) as first-line treatment for patients with metasta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006161-13,0,0,0 2005-006162-33,1,2008-09-09,2008-09-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,Relationships between pharmacokinetic and pharmacodynamic strategies for assessment of the risks for acute rejection and side effects of mofetil mycophenolate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006162-33,0,0,0 2005-006163-31,10,2012-04-17,2012-06-06,8,1,0,0,0,2,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with B-cell Chronic Lymphocytic Leukemia who have failed fludarabine and alemtuz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006163-31,0,0,0 2005-006163-31,10,2012-04-17,2012-06-06,8,1,0,0,0,2,3,0,0,1,1,0,1,0,1,GENMAB,"A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with B-cell Chronic Lymphocytic Leukemia who have failed fludarabine and alemtuz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006163-31,0,0,0 2005-006163-31,10,2012-04-17,2012-06-06,8,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Genmab A/S,"A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with B-cell Chronic Lymphocytic Leukemia who have failed fludarabine and alemtuz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006163-31,0,0,0 2005-006163-31,10,2012-04-17,2012-06-06,8,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Glaxo SmithKline Research and Development Limited,"A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with B-cell Chronic Lymphocytic Leukemia who have failed fludarabine and alemtuz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006163-31,0,0,0 2005-006163-31,10,2012-04-17,2012-06-06,8,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Glaxo SmithKine Research and Development Limited,"A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with B-cell Chronic Lymphocytic Leukemia who have failed fludarabine and alemtuz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006163-31,0,0,0 2005-006164-59,1,2008-04-16,2008-04-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,"An Open Label Study Comparing Exenatide with Basal Insulin in Achieving an HbA1c of <_7.4% with Minimum Weight Gain, in Type 2 Diabetes Patients who are not Achieving Adequate HbA1c Control on Oral An...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006164-59,0,0,0 2005-006165-14,3,2007-08-21,2007-09-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals Inc,","A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study of the Efficacy, Safety, and Pharmacokinetics of MLN3897 in Patients with Rheumatoid Arthritis Taking Methotrexate",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006165-14,0,0,0 2005-006168-71,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,A.S.L. 2,Phase II study with gemcitabine/docetaxel first line in women with metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006168-71,0,0,0 2005-006169-15,1,2007-09-09,2007-09-09,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Allergan Limited,"A Double-Blind, Randomised, Cross-over, Safety and Efficacy Pilot Study Comparing Two Botulinum Toxin Type-A Products in the Treatment of Moderate to Severe Cervical Dystonia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006169-15,0,0,0 2005-006170-10,1,2008-01-29,2008-01-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Allergan Limited,"A Double-Blind, Randomised, Parallel group, Safety and Efficacy Pilot Study Comparing Two Botulinum Toxin Type-A Products in the Treatment of Blepharospasm",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006170-10,0,0,0 2005-006171-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Unidad Integral de Investigación en Oncología S.L.,"Estudio del tratamiento combinado, en primera línea, de capecitabina administrada de forma continua, oxaliplatino y bevacizumab administrado bisemanalmente en pacientes con adenocarcinoma colorrectal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006171-12,0,0,0 2005-006172-35,1,2009-06-19,2009-06-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,North Hampshire Hospital NHS Trust,"A Randomised, Prospective, Double Blinded, Placebo Controlled Trial to Determine the Efficacy of Continuous Infusion Ankle Block Compared to Standard Single Bolus Block in the Management of Postoperat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006172-35,0,0,0 2005-006173-27,4,2011-01-31,2011-01-31,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,MARSHALL EDWARDS PTY LTD,"Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol (Oral Dosage Form) in Combination with Carboplatin versus Carboplatin with Placebo in Patients with Platinum-Resi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006173-27,0,0,0 2005-006173-27,4,2011-01-31,2011-01-31,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Marshall Edwards Pty Limited,"Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol (Oral Dosage Form) in Combination with Carboplatin versus Carboplatin with Placebo in Patients with Platinum-Resi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006173-27,0,0,0 2005-006174-97,2,2010-12-24,2010-12-24,2,1,0,0,0,0,4,0,0,1,1,0,1,0,0,"University of Oxford, Research Governance & Clinical Trials Office",Which oxygen saturation level should we use for very premature infants? A randomised controlled trial (BOOST-II UK),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006174-97,0,0,0 2005-006178-86,4,2008-11-12,2008-11-12,2,0,0,0,0,0,3,0,0,2,1,0,0,0,0,European group for Blood and Marrow Transplantation,A randomized placebo-controlled trial comparing cyclosporine plus steroids with or without Myfortic® as primary treatment for extensive chronic graft-versus host disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006178-86,1,0,0 2005-006179-11,4,2007-03-19,2007-03-19,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,Tibotec Pharmaceuticals,"A Phase II, open-label trial, to investigate pharmacokinetics, safety, tolerability and antiviral activity of TMC114/rtv b.i.d. in treatmentexperienced HIV-1 infected children and adolescents.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006179-11,1,1,0 2005-006179-11,4,2007-03-19,2007-03-19,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,TIBOTEC PHARMACEUTICALS LTD.,"A Phase II, open-label trial, to investigate pharmacokinetics, safety, tolerability and antiviral activity of TMC114/rtv b.i.d. in treatmentexperienced HIV-1 infected children and adolescents.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006179-11,1,1,0 2005-006179-11,4,2007-03-19,2007-03-19,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,Tibotec Pharmaceuticals Ltd.,"A Phase II, open-label trial, to investigate pharmacokinetics, safety, tolerability and antiviral activity of TMC114/rtv b.i.d. in treatmentexperienced HIV-1 infected children and adolescents.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006179-11,1,1,0 2005-006182-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITA DEGLI STUDI DI UDINE,"Intravitreal Bevacizumab Avastin, Roche, United Kingdom for exudative maculopathies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006182-14,0,0,0 2005-006186-14,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,KEDRION,"Open Label Phase II Evaluation of Pharmacokinetics, Efficacy, and Safety of Kedrion Human Plasma-derived Antihaemophilic Double Virus inactivated and Nanofiltered Factor IX Administered to Previously ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006186-14,0,0,0 2005-006189-32,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,Steiermärkische Gebietskrankenkasse,"Clinical evaluation study: ""Bupropion versus Psychodynamic mental training according to Dr. Grohs for smoke withdrawal"" (Klinische Evaluierungsstudie: ""Bupropion versus Psychodynamisches Mentaltraini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006189-32,0,0,0 2005-006191-35,1,2010-07-16,2010-07-16,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,"HSK, Dr. Horst Schmidt Kliniken GmbH","Tumorfreies Überleben nach Ablation von Barrett-Schleimhaut Plus Esomeprazol versus tumorfreies Überleben unter Esomeprazol ohne Ablation von Barrett-Schleimhaut bei Patienten, die von einem „Barrett-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006191-35,0,0,0 2005-006192-13,6,2008-06-30,2008-07-17,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"COTHERIX, INC.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ADDITION OF INHALED ILOPROST IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) RECEIVING ORAL SILDE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006192-13,0,0,0 2005-006192-13,6,2008-06-30,2008-07-17,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"CoTherix, Inc","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ADDITION OF INHALED ILOPROST IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) RECEIVING ORAL SILDE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006192-13,0,0,0 2005-006192-13,6,2008-06-30,2008-07-17,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Actelion Pharmaceuticals US, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ADDITION OF INHALED ILOPROST IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) RECEIVING ORAL SILDE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006192-13,0,0,0 2005-006195-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut de Recerca / Hospital de Sant Pau,"Estudio clínico con Escitalopram para el tratamiento de la depresión, la ansiedad y el craving, asociados al alcoholismo.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006195-35,0,0,0 2005-006196-12,1,2008-06-02,2008-06-02,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Nottingham City Hospital NHS Trust,"Epidural steroid injection in chronic, lumbar back pain; a cross-over, single-blinded study of Methyl-prednisolone 80mg versus Methyl-prednisolone 40mg.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006196-12,0,0,0 2005-006201-12,1,2007-09-24,2007-09-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,MERCK SHARP DOHME,"A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006201-12,0,0,0 2005-006202-26,6,2007-05-08,2007-06-18,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel group, Dose Response Study of subcutaneous AVE5026 with an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006202-26,0,0,0 2005-006202-26,6,2007-05-08,2007-06-18,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche et Développement,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel group, Dose Response Study of subcutaneous AVE5026 with an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006202-26,0,0,0 2005-006203-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Efficacy of Patient Controlled Paravertebral Analgesia for postoperative analgesia: a comparison of two regimens.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006203-39,0,0,0 2005-006205-28,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTI FISIOTERAPICI OSPITALIERI,Role of Erbitux plus a combination of CPT-11/5-fluorouracil/leucovorin/oxaliplatin as neoadjuvant chemotherapy in patients with colorectal liver metastases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006205-28,0,0,0 2005-006208-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Department of Dermatology, University of Kiel","Clinical Efficacy of Pimecrolimus Cream in Seborrheic Dermatitis. Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and differe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006208-21,0,0,0 2005-006209-16,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Evaluation of the role of 18F-di-idrossi-fenil-alanina 18F-DOPA in images diagnostic by Positron Emission Tomography PET in study of human neuroendocrin neoplasia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-006209-16,0,0,0 2006-000001-27,1,2009-03-31,2009-03-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Universitäres Herzzentrum, Klinik für Kardiologie und Angiologie",Untersuchung der antiinflammatorischen Eigenschaften von Clopidogrel im Vergleich zu Acetylsalicylsäure bei Patienten mit chronischer ischämischer Kardiomyopathie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000001-27,0,0,0 2006-000004-16,1,2011-04-05,2011-04-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Hvidovre Hospital, Dept. of Rheumatology",HUmira treatment in PSoriatic Arthritis (HUPSA) - a danish multicenter study of new imaging- and bio-markers for improved assessment of disease activity and progression and prediction of therapeutic o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000004-16,0,0,0 2006-000006-23,3,2008-12-09,2008-12-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin IR as Initial Therapy Compared to Saxaglipt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000006-23,0,0,0 2006-000006-23,3,2008-12-09,2008-12-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin IR as Initial Therapy Compared to Saxaglipt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000006-23,0,0,0 2006-000009-51,4,2012-01-20,2012-01-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,EORTC-European Organisation for the Research and Treatment of Cancer,Phase II study of Bortezomib (VELCADE) with cisplatin as first line treatment of malignant mesothelioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000009-51,0,0,0 2006-000009-51,4,2012-01-20,2012-01-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Phase II study of Bortezomib (VELCADE) with cisplatin as first line treatment of malignant mesothelioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000009-51,0,0,0 2006-000011-15,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Roche Oy,"A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of once monthly inbandronate in the prevention of glucocorticoid-induced osteoporosis in postmenopausal wome...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000011-15,0,0,0 2006-000012-24,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,OSPEDALE POLICLINICO S. MATTEO,A phase II study of the safety and efficacy of doxycycline administered cyclically in patients suffering from Transthyretin Amiloidosis ATTR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000012-24,0,0,0 2006-000014-20,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,CYTOCHEMIA AG,"Prospective, double-blind, randomized, placebo-controlled, parallel group, multi-centre phase III study to evaluate the efficacy and safety of a human leukocytic ultrafiltrate (Leukonorm Cytochemia®) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000014-20,0,0,0 2006-000021-57,1,2008-01-22,2008-01-22,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Rigshospitalet,Bosentan and Sildenfil for patients with Eisenmenger syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000021-57,0,0,0 2006-000024-13,1,2009-03-03,2009-03-03,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Cardiff and Vale NHS Trust,Does Aggressive management with early high dose aspirin reduce the hypercoagulability of platelets following coronary artery bypass grafting?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000024-13,0,0,0 2006-000026-31,1,2008-07-31,2008-07-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Roche Austria GmbH,Bevacizumab as treatment for patients with relapsed/refractory multiple myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000026-31,0,0,0 2006-000028-15,5,2007-08-31,2007-12-17,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,NYCOMED HEADQUARTER,"A randomised, open label, parallel-group, multi-centre trial to compare the efficacy and safety of TachoSil versus standard haemostatic treatment in cardiovascular surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000028-15,0,0,0 2006-000028-15,5,2007-08-31,2007-12-17,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Nycomed Danmark ApS,"A randomised, open label, parallel-group, multi-centre trial to compare the efficacy and safety of TachoSil versus standard haemostatic treatment in cardiovascular surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000028-15,0,0,0 2006-000032-27,1,2010-04-30,2010-04-30,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,ISTITUTO NEUROLOGICO CARLO BESTA,MULTICENTRE RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF LONG-TERM ASCORBIC ACID TREATMENT IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A CMT-TRIAAL CMT-TRial Italian with Ascorbic Acid Long term,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000032-27,0,0,0 2006-000038-11,1,2007-02-28,2007-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CHIESI Farmaceutici S.p.A,"EVALUATION OF THE EFFICACY, SAFETY AND TOLERABILITY OF THE CONCURRENT ADMINISTRATION OF CHF 4226 HFA pMDI AND EXTRAFINE BUDESONIDE HFA pMDI, BOTH GIVEN ONCE OR TWICE DAILY (2μg + 200μg qd or 1μg + 100...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000038-11,0,0,0 2006-000044-71,1,2009-10-02,2009-10-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospitals of Leicester NHS Trust Research & Development Department,Randomised controlled trial of the effects of fish oil emulsion in total parenteral nutrition upon tumour vascularity in patients with hepatic colorectal metastases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000044-71,0,0,0 2006-000047-26,1,,,0,0,0,0,1,0,4,0,1,3,0,0,0,0,0,Leeds Teaching Hospitals NHS Trust,"A randomized controlled trial of caudal epidural or intravenous fentanyl on the post-operative analgesia requirements after transurethral endoscopic resection of prostate, bladder neck or bladder tumo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000047-26,0,0,0 2006-000051-18,6,2008-09-03,2009-04-01,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 52-Week, Multinational, Multi-Centre, Open-Labelled, Randomised, Parallel, Efficacy and Safety Comparison of Insulin Detemir and NPH Insulin in Children and Adolescents 2-16 years with Type 1 Diabet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000051-18,0,0,0 2006-000053-22,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Leeds Teaching Hospitals NHS Trust,Eradication of Minimal Residual Disease (MRD) in patients with Chronic Lymphocytic Leukaemia (CLL) with Alemtuzumab: A Phase II Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000053-22,0,0,0 2006-000057-22,2,2007-02-07,2007-02-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Celgene Corporation, Inc.","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Comparison Study of CC-10004 in Subjects with Moderate-to-severe Plaque-Type Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000057-22,0,0,0 2006-000058-35,1,2008-03-25,2008-03-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Consumer Healthcare Comm. VA/SCA,A community pharmacy based investigation in the self-medication area Efficacy and safety of Sinutab® [Paracetamol (500mg) and Pseudoephedrine (30mg)] on subjects with nasal congestion accompanied by ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000058-35,0,0,0 2006-000060-82,1,2007-08-22,2007-08-22,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Dansk Hovedpinecenter,Forbyggende effekt af memantin ved kronisk hovedpine af spændningstype.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000060-82,0,0,0 2006-000061-11,1,2007-08-13,2007-08-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BODE Chemie GmbH & Co,Prospective randomized controlled double-blind multicentric phase III study to evaluate antiseptic efficacy and local tolerability of Stellisept mucosa in patients with chronic wounds,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000061-11,0,0,0 2006-000062-37,1,2006-06-19,2006-06-19,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,BODE Chemie GmbH & Co.,"A 14 day monocentric, double-blind, randomized phase III clinical study to investigate the antimicrobial efficacy and local tolerability of an antiseptic mouth rinse solution (Stellisept mucosa, conta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000062-37,0,0,0 2006-000063-28,1,2006-06-21,2006-06-21,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,BODE Chemie GmbH,"A monocentric, double-blind, randomized phase III clinical study to investigate the antimicrobial efficacy and local tolerability of an antiseptic (Stellisept mucosa, containing 0.1 % octenidine dihyd...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000063-28,0,0,0 2006-000067-29,1,2009-08-17,2009-08-17,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bayer Schering Pharma AG,"Phase I/II study to investigate the safety, tolerability, efficacy and pharmacokinetics of ZK 219477 in combination with cisplatin as first-line therapy in chemotherapy-naive patients with extensive-d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000067-29,0,0,0 2006-000068-10,2,,,0,1,0,0,0,2,2,0,0,1,1,0,0,1,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 75 MG AND 150 MG DOSES OF ERB-041 ON THE REDUCTION OF SYMPTOMS ASSOCIATED WITH ENDOMETRIOSIS DURING TREATMEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000068-10,0,0,0 2006-000071-15,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,Alcon Laboratories Inc.,Study of the Efficacy and Safety of Travatan Therapy compared with Cosopt Therapy in Patients with Open-Angle Glaucoma or Ocular Hypertension.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000071-15,0,0,0 2006-000073-29,1,2008-07-02,2008-07-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"Prospective, randomised, double-blind, placebo-controlled multicentre pilot trial to investigate the impact of an early use of NT 201 in patients with an acute cerebrovascular event on the development...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000073-29,0,0,0 2006-000074-79,3,2007-06-05,2007-06-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Ltd,"A Multicenter, Single Arm Study Evaluating The Extension From Weekly To Once Every Other Week Darbepoetin Alfa Administration In Subjects With Chronic Kidney Disease Receiving Dialysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000074-79,0,0,0 2006-000074-79,3,2007-06-05,2007-06-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN S.P.A.,"A Multicenter, Single Arm Study Evaluating The Extension From Weekly To Once Every Other Week Darbepoetin Alfa Administration In Subjects With Chronic Kidney Disease Receiving Dialysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000074-79,0,0,0 2006-000078-65,3,2009-09-01,2011-04-03,2,0,0,0,0,1,2,0,0,2,0,0,0,0,0,Karolinska University Hospital,Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000078-65,1,0,0 2006-000081-36,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,GPC Biotech AG,Ensayo en Fase I-II para evaluar la administración de radioterapia concomitante prequirúrgica y quimioterapia con satraplatin más capecitabina en el tratamiento del adenocarcinoma rectal localmente a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000081-36,0,0,0 2006-000082-10,1,2008-05-01,2008-05-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Aintree University Hospitals NHS Trust,The efficacy of oral transmucosal fentanyl as an analgesic agent during pan retinal photocoagulation (Pilot Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000082-10,0,0,0 2006-000087-83,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Liverpool,EUROPAC2 trial to investigate the efficacy of ANTOX(vers) 1.2 and MGCT (magnesiocard) for the treatment of hereditary pancreatitis and idiopathic chronic pancreatitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000087-83,0,0,0 2006-000087-83,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,The Royal Liverpool and Broadgreen University Hospitals NHS Trust,EUROPAC2 trial to investigate the efficacy of ANTOX(vers) 1.2 and MGCT (magnesiocard) for the treatment of hereditary pancreatitis and idiopathic chronic pancreatitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000087-83,0,0,0 2006-000089-35,1,2008-08-25,2008-08-25,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ITALFARMACO,"Phase II, open label, international, multicentre clinical trial to investigate safety and efficacy of oral ITF 2357 in patients with active systemic onset juvenile idiopathic arthritis SOJIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000089-35,0,0,0 2006-000091-32,4,2012-05-30,2012-05-30,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Amgen Inc.,"A Randomized Phase 2 Trial of Double- Blind, Placebo Controlled AMG 706 in Combination with Paclitaxel, or Open- Label Bevacizumab in Combination with Paclitaxel, as First Line Therapy in Women with H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000091-32,0,0,0 2006-000096-16,1,2006-03-22,2006-03-22,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Incyte Corporation,"A Randomized, Double-Blind, Phase II Study Comparing the Anti-Retroviral Safety and Efficacy of Dexelvucitabine (DFC) 200 mg Once Daily to Lamivudine (3TC) 300 mg Once Daily in Addition to Optimized B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000096-16,0,0,0 2006-000105-38,1,2010-10-07,2010-10-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London (IOP),A definitive multi-centre pragmatic randomised controlled double-blind trial of the clinical and cost effectiveness of mirtazapine and sertraline versus placebo for the treatment of depression in deme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000105-38,0,0,0 2006-000106-24,1,2008-10-09,2008-10-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Kings College London (IOP),Using genotype to tailor prescribing of nicotine replacement therapy: a randomised controlled trial assessing impact upon adherence,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000106-24,0,0,0 2006-000110-21,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Biotest AG,"An open, randomised parallel study investigating efficacy and safety of the human hepatitis B immunoglobulin BT088 after subcutaneous or intramuscular application for perinatal prophylaxis in infants ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000110-21,0,0,0 2006-000113-38,1,2010-11-11,2010-11-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,"A randomised phase II double blind placebo controlled trial of Whole Brain Radiotherapy (WBRT) and Tarceva (OSI-774, erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) with multip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000113-38,0,0,0 2006-000120-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA USL 6 LIVORNO ZONA LIVORNESE,Study of the association of docetaxel and liposomial doxorubicin Myocet in metastatic breast cancer phase II clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000120-14,0,0,0 2006-000122-31,1,2007-11-27,2007-11-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Aventis Pharma s.r.o.,Srovnání fluktuací glykemií při bazální substituci humánním inzulínem NPH a inzulínovým analogem glargine (kontinuální měření glykemií),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000122-31,0,0,0 2006-000126-31,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"A phase II trial of carboplatin and paclitaxel compared with carboplatin or gemcitabine paclitaxel ""induction"" followed by carboplatin/paclitaxel/gemcitabine in patients with suboptimally resected sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000126-31,0,0,0 2006-000129-76,1,2010-06-07,2010-06-07,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Guy's & St Thomas' NHS Foundation Trust,Botulinum toxin-A in Sensory Urgency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000129-76,0,0,0 2006-000132-27,9,2008-12-30,2008-12-30,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis R&D,"Estudio de Satavaptan en el Tratamiento de Ascitis Cirrótica: comparación doble ciego, aleatorizada, y con grupos paralelos del tratamiento con satavaptan de 5 a 10 mg diarios frente a placebo añadido...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000132-27,0,0,0 2006-000132-27,9,2008-12-30,2008-12-30,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"Estudio de Satavaptan en el Tratamiento de Ascitis Cirrótica: comparación doble ciego, aleatorizada, y con grupos paralelos del tratamiento con satavaptan de 5 a 10 mg diarios frente a placebo añadido...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000132-27,0,0,0 2006-000132-27,9,2008-12-30,2008-12-30,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis R&D,"Estudio de Satavaptan en el Tratamiento de Ascitis Cirrótica: comparación doble ciego, aleatorizada, y con grupos paralelos del tratamiento con satavaptan de 5 a 10 mg diarios frente a placebo añadido...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000132-27,0,0,0 2006-000132-27,9,2008-12-30,2008-12-30,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & developpement,"Estudio de Satavaptan en el Tratamiento de Ascitis Cirrótica: comparación doble ciego, aleatorizada, y con grupos paralelos del tratamiento con satavaptan de 5 a 10 mg diarios frente a placebo añadido...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000132-27,0,0,0 2006-000134-12,9,2008-09-11,2008-10-09,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis R&D,"Satavaptan en la Prevención de la Recurrencia de Ascitis: comparación doble ciego, aleatorizada, y con grupos paralelos de satavaptan de 5 a 10 mg diarios frente a placebo con diuréticos concomitantes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000134-12,0,0,0 2006-000134-12,9,2008-09-11,2008-10-09,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi- aventis R&D,"Satavaptan en la Prevención de la Recurrencia de Ascitis: comparación doble ciego, aleatorizada, y con grupos paralelos de satavaptan de 5 a 10 mg diarios frente a placebo con diuréticos concomitantes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000134-12,0,0,0 2006-000134-12,9,2008-09-11,2008-10-09,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-Synthelabo Recherche,"Satavaptan en la Prevención de la Recurrencia de Ascitis: comparación doble ciego, aleatorizada, y con grupos paralelos de satavaptan de 5 a 10 mg diarios frente a placebo con diuréticos concomitantes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000134-12,0,0,0 2006-000134-12,9,2008-09-11,2008-10-09,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-Aventis Recherche & Devéloppement,"Satavaptan en la Prevención de la Recurrencia de Ascitis: comparación doble ciego, aleatorizada, y con grupos paralelos de satavaptan de 5 a 10 mg diarios frente a placebo con diuréticos concomitantes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000134-12,0,0,0 2006-000135-10,6,2008-11-10,2009-03-03,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis R&D,"Satavaptan en la Prevención de la Recurrencia de Ascitis: comparación doble ciego, aleatorizada, y con grupos paralelos de satavaptan de 5 a 10 mg diarios frente a placebo en asuncia de diuréticos en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000135-10,0,0,0 2006-000135-10,6,2008-11-10,2009-03-03,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-Aventis Recherche & Devéloppement,"Satavaptan en la Prevención de la Recurrencia de Ascitis: comparación doble ciego, aleatorizada, y con grupos paralelos de satavaptan de 5 a 10 mg diarios frente a placebo en asuncia de diuréticos en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000135-10,0,0,0 2006-000135-10,6,2008-11-10,2009-03-03,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis R & D,"Satavaptan en la Prevención de la Recurrencia de Ascitis: comparación doble ciego, aleatorizada, y con grupos paralelos de satavaptan de 5 a 10 mg diarios frente a placebo en asuncia de diuréticos en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000135-10,0,0,0 2006-000135-10,6,2008-11-10,2009-03-03,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-Synthelabo Recherche,"Satavaptan en la Prevención de la Recurrencia de Ascitis: comparación doble ciego, aleatorizada, y con grupos paralelos de satavaptan de 5 a 10 mg diarios frente a placebo en asuncia de diuréticos en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000135-10,0,0,0 2006-000135-10,6,2008-11-10,2009-03-03,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-aventis R&D,"Satavaptan en la Prevención de la Recurrencia de Ascitis: comparación doble ciego, aleatorizada, y con grupos paralelos de satavaptan de 5 a 10 mg diarios frente a placebo en asuncia de diuréticos en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000135-10,0,0,0 2006-000136-27,1,2015-11-23,2015-11-23,1,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Cytonet GmbH & Co KG,"Open, Prospective, Uncontrolled, Multicentre Study to Evaluate The Safety and Efficacy of Multiple Applications of Liver Cell Suspension Into The Portal Vein in Children with Urea Cycle Disorders (UCD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000136-27,0,0,0 2006-000137-35,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,"UAB ""Roche Lietuva""",Prospective controlled clinical trial of metastatic breast cancer treatment with capecitabine/docetaxel in combination with beta epoetin as compared with sole capecitabine/docetaxel treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000137-35,0,0,0 2006-000138-11,5,2008-10-31,2008-11-28,3,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"InterMune, Inc.","A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000138-11,0,0,0 2006-000143-26,2,2008-04-07,2008-04-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A Phase II, Non-randomized, Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib GW786034 as Pre-Surgical Therapy in Treatment-Na ve Subjects with Stage IA or IB, Resectable Non Small ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000143-26,0,0,0 2006-000143-26,2,2008-04-07,2008-04-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithkline S.A.,"A Phase II, Non-randomized, Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib GW786034 as Pre-Surgical Therapy in Treatment-Na ve Subjects with Stage IA or IB, Resectable Non Small ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000143-26,0,0,0 2006-000144-92,3,2008-05-21,2008-06-10,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Amgen Inc,"An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000144-92,0,0,0 2006-000152-41,4,2000-05-02,2007-05-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche développement,"A multicenter, Randomized, Double Blind, Double Dummy, Parallel Group, Dose Ranging Study of subcutaneous SR123781A with an Enoxaparin calibrator arm in the Prevention of Venous Thromboembolism in Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000152-41,0,0,0 2006-000152-41,4,2000-05-02,2007-05-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & developpement,"A multicenter, Randomized, Double Blind, Double Dummy, Parallel Group, Dose Ranging Study of subcutaneous SR123781A with an Enoxaparin calibrator arm in the Prevention of Venous Thromboembolism in Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000152-41,0,0,0 2006-000152-41,4,2000-05-02,2007-05-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi Synthelabo Recherche,"A multicenter, Randomized, Double Blind, Double Dummy, Parallel Group, Dose Ranging Study of subcutaneous SR123781A with an Enoxaparin calibrator arm in the Prevention of Venous Thromboembolism in Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000152-41,0,0,0 2006-000156-40,10,2011-01-14,2011-01-14,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,EISAI LTD UK,"""Estudio aleatorizado, multicéntrico, doble ciego, para comparar la eficacia y seguridad de zonisamida y carbamazepina como monoterapia en pacientes con epilepsia parcial recién diagnosticada"" (A ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000156-40,0,0,0 2006-000156-40,10,2011-01-14,2011-01-14,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eisai Limited,"""Estudio aleatorizado, multicéntrico, doble ciego, para comparar la eficacia y seguridad de zonisamida y carbamazepina como monoterapia en pacientes con epilepsia parcial recién diagnosticada"" (A ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000156-40,0,0,0 2006-000164-93,1,,,0,0,0,0,1,0,3,0,1,0,0,0,0,0,0,Department of Anesthesiology University Hospital Center,Effect of Nutritional Support on Liver Integrity during General Anesthesia for Laparoscopic Cholecystectomy. A Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000164-93,0,0,0 2006-000165-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,A.S.L. 2 SAVONA,Phase II study with gemcitabine/docetaxel fist line in women with metastatic breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000165-10,0,0,0 2006-000168-10,1,2007-12-06,2007-12-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Biovitrum AB,"A 4-week, double-masked, parallel-group, randomized , multicenter, proof of concept study comparing the efficacy and safety of two dose levels of BVT.28949 with placebo in patients with ocular hyperte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000168-10,0,0,0 2006-000169-12,5,2007-10-10,2007-10-15,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,UCB S.A.,"A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000169-12,0,0,0 2006-000169-12,5,2007-10-10,2007-10-15,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,UCB S.A. Casa Madre,"A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000169-12,0,0,0 2006-000169-12,5,2007-10-10,2007-10-15,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000169-12,0,0,0 2006-000170-70,8,2013-01-10,2013-01-24,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc,"A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Oxaliplatin/ 5-fluorouracil/ leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ leucovorin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000170-70,0,0,0 2006-000170-70,8,2013-01-10,2013-01-24,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AMGEN S.P.A.,"A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination with Oxaliplatin/ 5-fluorouracil/ leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ leucovorin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000170-70,0,0,0 2006-000171-15,1,2010-09-10,2010-09-10,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital of Ulm,"Randomized, placebo-controlled, double-blinded study evaluating the effects of Pioglitazone on intima-media-thickness (IMT) of the carotid arteries measured by MRI in non-diabetic patients with confir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000171-15,0,0,0 2006-000173-29,2,2008-04-30,2008-04-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB S.A. (Global Medical Affairs),"A multicenter, open-label single-arm follow-up trial evaluating the long-term safety of levetiracetam, for patients suffering from epilepsy and coming from the study N01175.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000173-29,0,0,0 2006-000176-32,4,2011-03-07,2013-08-05,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Stragen France,A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000176-32,0,0,0 2006-000176-32,4,2011-03-07,2013-08-05,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,STRAGEN FRANCE SAS,A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000176-32,0,0,0 2006-000179-13,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,University Hospital Ghent,Validation of the methodology of serum creatinine measurement and the estimated glomular filtration ratio,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000179-13,0,0,0 2006-000180-29,1,2009-02-03,2009-02-03,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,H:S Hvidovre hospital,Virkningen af postoperativ laksans på tarmfunktionen efter kolonkirurgi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000180-29,0,0,0 2006-000181-36,1,2008-05-09,2008-05-09,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Amicus Therapeutics, Inc.","A Phase 2, Open-Label, Multiple Dose Level, 12-Week Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AT1001 in Female Patients with Fabry Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000181-36,0,0,0 2006-000182-10,1,2009-06-15,2009-06-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Rigshospitalet, Finsen Center","A phase II trial with cetuximab, bevacizumab and irinotecan for patients with malignant glioblastomas and progression after radiation therapy and temozolamid",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000182-10,0,0,0 2006-000185-37,1,2010-10-20,2010-10-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Vienna University Medical School,Ampicillin plus Clarithromycin versus Ampicillin allein beim frühen vorzeitigen Blasensprung,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000185-37,0,0,0 2006-000186-11,1,2011-06-30,2011-06-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Med. Klinik / Kardiologie der Med. Fakultät Carl Gustav Carus an der Technischen Unversität Dresden,Double blind randomized placebo controlled study by virtual histology on the influence of oral pioglitazone for 9 month on the development of coronary plaques in non-diabetic patients with coronary he...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000186-11,0,0,0 2006-000191-32,1,2008-05-28,2008-05-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ZAMBON GROUP,"A multicenter, multinational, randomized, parallel group, placebo-controlled, double-blind study to evaluate efficacy and safety of a food supplement containing 80 mg soy isoflavones ZAVITAL in the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000191-32,0,0,0 2006-000192-14,5,2007-06-08,2011-01-17,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,The Medicines Company,A Clinical Trial Comparing Cangrelor To Clopidogrel In Subjects Who Require Percutaneous Coronary Intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000192-14,0,0,0 2006-000192-14,5,2007-06-08,2011-01-17,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,THE MEDICINES COMPANY UK,A Clinical Trial Comparing Cangrelor To Clopidogrel In Subjects Who Require Percutaneous Coronary Intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000192-14,0,0,0 2006-000193-77,1,2007-12-31,2007-12-31,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,The University of Manchester,Protective analgesia using bupivacaine and conventional release ibuprofen versus bupivacaine and sustained release ibuprofen for postoperative pain relief in patients undergoing third molar surgery: a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000193-77,0,0,0 2006-000194-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Fertility Clinic, dept. of Obstetrics and gynecology, OUH.",In Vitro Maturation (IVM) as part of the treatment of infertility in women with polycystic ovaries (PCO). Is priming with hCG favourable? A prospective randomized study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000194-29,0,0,0 2006-000197-69,2,2006-10-15,2006-10-15,1,0,0,0,0,0,2,0,0,2,0,0,0,0,2,AM PHARMA B.V.,"A pilot, open-label, multi-center clinical trial to investigate the safety and efficacy of Bovine-Calf Intestinal Alkaline Phosphatase in patients with moderate to severe ulcerative colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000197-69,1,0,0 2006-000197-69,2,2006-10-15,2006-10-15,1,0,0,0,0,0,2,0,0,2,0,0,0,0,2,AM-Pharma B.V.,"A pilot, open-label, multi-center clinical trial to investigate the safety and efficacy of Bovine-Calf Intestinal Alkaline Phosphatase in patients with moderate to severe ulcerative colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000197-69,1,0,0 2006-000205-34,3,2022-10-13,2022-10-13,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,University College London,Radiotherapy and Androgen Deprivation in Combination After Local Surgery. A randomised controlled trial for patients with prostate cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000205-34,1,0,0 2006-000206-23,2,2010-12-01,2011-04-19,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BRACCO IMAGING,"PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF MULTIHANCE WITH 0.1 mmol/kg OF GADOVIST IN MAGNETIC RESONANCE IMAGING (MRI) OF THE BRAIN (MERIT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000206-23,0,0,0 2006-000206-23,2,2010-12-01,2011-04-19,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bracco Imaging S.p.A.,"PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF MULTIHANCE WITH 0.1 mmol/kg OF GADOVIST IN MAGNETIC RESONANCE IMAGING (MRI) OF THE BRAIN (MERIT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000206-23,0,0,0 2006-000207-42,1,2007-11-14,2007-11-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 24-weeks , national, multicenter, double blind controlled vs placebo trial to evaluate the efficacy of Neoral ciclosporine 5mg/kg/day , twice a week administered in reduction of the rate of relaps...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000207-42,0,0,0 2006-000208-17,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"University hospital Mainz, I. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität","An open-label, non-randomized phase II trial of cetuximab in combination with irinotecan and 5-FU/FA for patients with metastatic gastric cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000208-17,0,0,0 2006-000210-21,1,2008-07-17,2008-07-17,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Prof Jes Olesen,"A single centre, double-blind, randomised, placebo controlled cross-over study to evaluate the efficacy and tolerability of tonabersat in the prophylaxis of migraine in patients presenting with migrai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000210-21,0,0,0 2006-000215-22,1,2006-11-20,2006-11-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double blind, placebo controlled, two-way crossover, three phase, study, to investigate the trial models, Vienna Challenge Chamber, in and out of season, and Park Study in season and the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000215-22,0,0,0 2006-000216-24,1,2009-01-05,2009-01-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Bristol,Serotonin sensitivity in insomnia: a placebo-controlled crossover study of sleep after 5HT2 blockade in primary insomnia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000216-24,0,0,0 2006-000218-19,1,2015-06-01,2015-06-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A single stage phase II, multi-centre, open label study of Glivec in combination with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfane for anti-inflammatory and angiostatic treatment i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000218-19,0,0,0 2006-000220-14,1,2007-05-30,2007-05-30,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,TopoTarget A/S,A therapeutic and pharmacokinetic study of Savene (dexrazoxane) in the treatment of accidental anthracycline extravasation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000220-14,0,0,0 2006-000222-31,1,2013-03-07,2013-03-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,UNIVERSITÄTSKLINIKUM DER MEDIZINISCHEN FAKULTÄT FREIBURG,Vergleich einer strukturierten störungsspezifischen Gruppenpsychotherapie plus Placebo oder Methylphenidat versus einer psychiatrischen Beratung plus Placebo oder Methylphenidat bei ADHS im Erwachsen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000222-31,0,0,0 2006-000224-13,3,2009-02-16,2009-02-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER S.A.,AN EXPLORATIVE STUDY OF TOLERABILITY AND PHARMACOKINETICS OF SU011248 IN COMBINATION WITH DOCETAXEL AS FIRST-LINE TREATMENT IN PATIENTS WITH BREAST CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000224-13,0,0,0 2006-000224-13,3,2009-02-16,2009-02-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER AB,AN EXPLORATIVE STUDY OF TOLERABILITY AND PHARMACOKINETICS OF SU011248 IN COMBINATION WITH DOCETAXEL AS FIRST-LINE TREATMENT IN PATIENTS WITH BREAST CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000224-13,0,0,0 2006-000224-13,3,2009-02-16,2009-02-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,AN EXPLORATIVE STUDY OF TOLERABILITY AND PHARMACOKINETICS OF SU011248 IN COMBINATION WITH DOCETAXEL AS FIRST-LINE TREATMENT IN PATIENTS WITH BREAST CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000224-13,0,0,0 2006-000228-14,1,,,0,0,0,0,0,3,2,0,0,0,0,0,0,0,0,Cliniques Universitaires Saint-Luc,Immunization of disease-free melanoma patients with different HLA-A2 peptides.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000228-14,0,0,0 2006-000231-95,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO,A PHASE II STUDY OF BAY 43-9006 IN COMBINATION WITH WEEKLY GEMCITABINE FOR THE TREATMENT OF METASTATIC RCC EITHER UNSUITABLE FOR OR REFRACTORY TO PRIOR TREATMENT WITH CYTOKINES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000231-95,0,0,0 2006-000236-27,7,2011-07-21,2011-07-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects with FIGO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000236-27,0,0,0 2006-000236-27,7,2011-07-21,2011-07-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects with FIGO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000236-27,0,0,0 2006-000236-27,7,2011-07-21,2011-07-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Ltd,"A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects with FIGO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000236-27,0,0,0 2006-000247-26,3,2008-05-30,2008-11-24,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Lilly S.A.,"A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients with Type 2 Diabetes Treated with Once-Daily Insulin Glargin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000247-26,0,0,0 2006-000247-26,3,2008-05-30,2008-11-24,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company Ltd,"A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients with Type 2 Diabetes Treated with Once-Daily Insulin Glargin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000247-26,0,0,0 2006-000251-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dr. Llombart Cussac,Phase II Cardiac Safety trial of liposomal pegillated doxorrubicine in patients with breast cancer with non evidence of disease and previous exposition to Antraciclines. Estudio Fase II de Seguridad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000251-18,0,0,0 2006-000252-41,2,2008-11-10,2008-11-10,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,INTERMUNE,"A Randomized, Double-Blind, Placebo Controlled, Phase 3 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000252-41,0,0,0 2006-000252-41,2,2008-11-10,2008-11-10,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"InterMune, Inc.","A Randomized, Double-Blind, Placebo Controlled, Phase 3 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000252-41,0,0,0 2006-000253-21,1,2007-09-14,2007-09-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline GmbH & Co KG,Reaching asthma control with salmeterol/fluticasone 50 / 250µg bd combination in steroid naive or low dose JCS patients by using the asthma control test (ACT) as measurement.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000253-21,0,0,0 2006-000254-51,2,2007-04-26,2007-04-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A phase 2, multicenter, open label, titration study to assess the efficacy, safety and tolerability of RO4389620 in doses up to 200 mg BID in patients with type 2 diabetes mellitus not optimally contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000254-51,0,0,0 2006-000257-22,1,2007-06-11,2007-06-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca UK Ltd,A study to assess the effectiveness of esomeprazole 40 mg once daily in subjects with continuing gastroesophageal reflux disease (GORD) symptoms following treatment with a previous full dose proton pu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000257-22,0,0,0 2006-000259-16,7,2009-10-16,2016-11-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase III, Randomised, Double-Blind, Multi-Centre Parallel-Group Study to Assess the Efficacy of ZD6474 (ZACTIMA™ ) Versus Erlotinib (TARCEVA®) in Patients With Locally Advanced or Metastatic (Stage...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000259-16,0,0,0 2006-000259-16,7,2009-10-16,2016-11-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Phase III, Randomised, Double-Blind, Multi-Centre Parallel-Group Study to Assess the Efficacy of ZD6474 (ZACTIMA™ ) Versus Erlotinib (TARCEVA®) in Patients With Locally Advanced or Metastatic (Stage...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000259-16,0,0,0 2006-000267-29,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Centro sociale oncologico,Adjuvant chemotherapy in stage III colon carcinoma in patients age or 70 years. Feasibility of CAPOX scheme oxaliplatin 70 mg/mq days 1-8 and capecitabine 1000 mg/mq X 2 die days 1-14 every 21 days ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000267-29,0,0,0 2006-000269-12,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Sociedad Madrileña de Nefrología (SOMANE),"Estudio multicéntrico, aleatorizado, abierto, de 2 años de seguimiento para evaluar el efecto de la retirada de inhibidores de la calcineurina y la introdicción temprana de everolimus, sobre la funció...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000269-12,0,0,0 2006-000277-30,2,2013-08-29,2014-01-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust,Simvastatin in Aneurysmal Subarachnoidal Haemorrhage (STASH): a multicentre randomized controlled clinical phase III study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000277-30,0,0,0 2006-000277-30,2,2013-08-29,2014-01-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Cambridge University,Simvastatin in Aneurysmal Subarachnoidal Haemorrhage (STASH): a multicentre randomized controlled clinical phase III study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000277-30,0,0,0 2006-000280-28,1,2014-08-21,2014-08-21,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Imperial College London,A Phase I/II safety and tolerability dose escalation study following the autologous infusion of expanded adult haematopoietic stem cells to patients with established myocardial ischaemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000280-28,0,0,0 2006-000281-36,1,2013-07-31,2013-07-31,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Imperial College London,A Phase I/II safety and tolerability study following autologous infusion of adult haematopoietic cells to patients with acute total anterior circulation ischaemic stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000281-36,0,0,0 2006-000282-11,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Universitätsklinikum Hamburg-Eppendorf,Clinical trial for the research into changes in renal function of adolescent and adult patients with Glycogen storage disease type Ia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000282-11,0,0,0 2006-000284-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Universitätsklinikum des Saarlandes,Einfluss einer Behandlung mit dem HMG-CoA Reduktasehemmer Fluvastatin auf die Erektionsfähigkeit bei Patienten mit kardiovaskulären Risikofaktoren und erektiler Dysfunktion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000284-28,0,0,0 2006-000285-36,1,,,0,0,0,0,0,0,3,0,1,1,1,1,0,1,0,ISTITUTI FISIOTERAPICI OSPITALIERI,Protocol for a pilot study examining the impact of Metformin use on serum testosterone levels in postmenopausal women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000285-36,0,0,0 2006-000287-84,1,2007-09-04,2007-09-04,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Sykehuset Innlandet HF,Seponering av antipsykotika og antidepressiva hos demente pasienter med APSD i sykehjem - en åpen studie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000287-84,0,0,0 2006-000292-15,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Stiefel Laboratories Maidenhead Ltd.,"A Phase II, Single-Centre, Randomised,Double-Blind, Parallel Group, CPO Solution, Dose Range Finding Study in Subjects with Seborrhoeic Dermatitis of the Scalp",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000292-15,0,0,0 2006-000294-29,1,2007-04-04,2007-04-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Dermatology, medical University of Graz",Die Bedeutung des sensorischen Nervensystems der Haut bei polymorpher Lichtdermatose English title: The role of the cutaneous sensory nervous system in polymorphic light eruption (PLE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000294-29,0,0,0 2006-000296-15,12,2009-06-09,2009-06-09,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Limited,"A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Clinical Events and Biomarkers in Patients with Non-ST-Segment Elevation Acute Coronary...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000296-15,0,0,0 2006-000296-15,12,2009-06-09,2009-06-09,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,EISAI LTD UK,"A Randomised, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Clinical Events and Biomarkers in Patients with Non-ST-Segment Elevation Acute Coronary...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000296-15,0,0,0 2006-000297-72,7,2008-10-27,2009-10-13,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,BEAUFOUR IPSEN Pharma,"PHASE III, MULTICENTRE, OPEN STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILES OF THE CO-ADMINISTRATION OF LANREOTIDE AUTOGEL 120 MG (ADMINISTERED VIA DEEP SUBCUTANEOUS INJECTIONS EVERY 28 DAYS) AND PE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000297-72,0,0,0 2006-000297-72,7,2008-10-27,2009-10-13,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,BEAUFOUR IPSEN PHARMA,"PHASE III, MULTICENTRE, OPEN STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILES OF THE CO-ADMINISTRATION OF LANREOTIDE AUTOGEL 120 MG (ADMINISTERED VIA DEEP SUBCUTANEOUS INJECTIONS EVERY 28 DAYS) AND PE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000297-72,0,0,0 2006-000303-42,2,2008-12-19,2008-12-19,2,0,0,0,0,0,0,0,0,1,0,0,1,0,0,ISALA KLINIEKEN,"A randomized, double blind controlled trial evaluating the benefits of early up-front-loaded high dose Tirofiban in the treatment of patients with ST-segment elevation myocardial infarction, who are c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000303-42,0,0,0 2006-000303-42,2,2008-12-19,2008-12-19,2,0,0,0,0,0,0,0,0,1,0,0,1,0,0,Diagram B.V.,"A randomized, double blind controlled trial evaluating the benefits of early up-front-loaded high dose Tirofiban in the treatment of patients with ST-segment elevation myocardial infarction, who are c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000303-42,0,0,0 2006-000304-16,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000304-16,0,1,1 2006-000305-35,2,2008-09-08,2008-09-08,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,MannKind Corporation,"A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000305-35,0,0,0 2006-000306-23,2,2008-06-26,2008-06-26,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,MannKind Corporation,"A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000306-23,0,0,0 2006-000310-20,1,2010-09-22,2010-09-22,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Hannu Kokki,NAPROKSEENIN JA FLURBIPROFEENIN AIVO-SELKÄYDINNESTEPITOISUUDET LAPSILLA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000310-20,0,0,0 2006-000313-38,18,2009-07-16,2010-12-31,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & Développement,"Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or myocardial infarction managed with an early...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000313-38,0,0,0 2006-000313-38,18,2009-07-16,2010-12-31,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis Recherche & Développement,"Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or myocardial infarction managed with an early...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000313-38,0,0,0 2006-000313-38,18,2009-07-16,2010-12-31,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Recherche & Développement,"Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or myocardial infarction managed with an early...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000313-38,0,0,0 2006-000313-38,18,2009-07-16,2010-12-31,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or myocardial infarction managed with an early...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000313-38,0,0,0 2006-000313-38,18,2009-07-16,2010-12-31,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Recherche & Developpement,"Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or myocardial infarction managed with an early...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000313-38,0,0,0 2006-000313-38,18,2009-07-16,2010-12-31,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche&de'veloppement,"Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or myocardial infarction managed with an early...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000313-38,0,0,0 2006-000313-38,18,2009-07-16,2010-12-31,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis Recherche & Developpement,"Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or myocardial infarction managed with an early...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000313-38,0,0,0 2006-000313-38,18,2009-07-16,2010-12-31,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & Dev.,"Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or myocardial infarction managed with an early...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000313-38,0,0,0 2006-000313-38,18,2009-07-16,2010-12-31,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis Recherche Développement,"Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or myocardial infarction managed with an early...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000313-38,0,0,0 2006-000313-38,18,2009-07-16,2010-12-31,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or myocardial infarction managed with an early...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000313-38,0,0,0 2006-000313-38,18,2009-07-16,2010-12-31,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche and developpement,"Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or myocardial infarction managed with an early...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000313-38,0,0,0 2006-000313-38,18,2009-07-16,2010-12-31,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et développement,"Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or myocardial infarction managed with an early...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000313-38,0,0,0 2006-000314-20,1,2007-03-12,2007-03-12,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Biofrontera Bioscience GmbH,A randomized placebo-controlled clinical trial of topical photodynamic therapy with a nanoemulsion formulation of 5-aminolevulinic acid for the treatment of actinic keratosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000314-20,0,0,0 2006-000319-96,1,2007-07-12,2007-07-12,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novagali Pharma SA,"“Estudio de fase II/III, Multicéntrico, doble enmascarado, Aleatorizado, de Grupos paralelos, Con variacion de dósis, controlado para valorar la eficacia y seguridad de NOVA22007 (emulsión ocular cati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000319-96,0,0,0 2006-000320-14,5,2012-02-01,2012-02-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca,"Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant combination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000320-14,0,0,0 2006-000320-14,5,2012-02-01,2012-02-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant combination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000320-14,0,0,0 2006-000320-14,5,2012-02-01,2012-02-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca Produtos Farmacêuticos Lda,"Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant combination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000320-14,0,0,0 2006-000320-14,5,2012-02-01,2012-02-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca oy,"Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant combination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000320-14,0,0,0 2006-000320-14,5,2012-02-01,2012-02-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"Anastrozole monotherapy versus maximal oestrogen blockage with anastrozole and fulvestrant combination therapy: An open, randomised, comparative, phase III multicentre study in postmenopausal women wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000320-14,0,0,0 2006-000324-13,9,2008-06-06,2008-06-12,8,1,0,0,0,0,4,0,0,1,0,0,1,0,2,sanofi-aventis groupe,"ESTUDIO MULTICÉNTRICO, INTERNACIONAL, ALEATORIZADO, ABIERTO, COMPARATIVO Y DE GRUPOS PARALELOS: OBJETIVOS DEL CONTROL GLUCÉMICO E INCIDENCIA DE HIPOGLUCEMIA SINTOMÁTICA COMPROBADA EN PACIENTES CON DIA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000324-13,0,0,0 2006-000329-78,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,1,PROMEFARM,"Naburen enema for prevention of radiation proctitis. A multicentre randomised placebo-controlled dose-finding phase II study to evaluate efficacy, tolerability, acceptability and compliance with enema...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000329-78,0,0,0 2006-000330-13,1,2007-02-06,2007-02-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bionorica AG,Efficacy and tolerability of Bronchipret® TP film coated tablets for the treatment of acute bronchitis in adults.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000330-13,0,0,0 2006-000333-36,1,2007-01-22,2007-01-22,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Hull & East Yorkhire NHS Hospitals Trust,A randomised comparison of 0.5% levobupivacaine with a lidocaine/epinephrine/ fentanyl mixture for epidural top up for emergency caesarean section after “low dose” epidural for labour,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000333-36,0,0,0 2006-000334-12,1,2006-06-14,2006-06-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Almirall Prodesfarma,"A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND, CROSS-OVER, MONOCENTER STUDY TO EVALUATE THE EFFECT OF A 7-DAY MONTELUKAST TREATMENT ON AIRWAY INFLAMMATION AND FUNCTION BY MEANS OF BRONCHOPROVOCATION ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000334-12,0,0,0 2006-000335-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Specialisttandvården/Bettfysiologi, Folktandvården Södra Bohslän",Utvärdering av glukosamin för artrosbehandling i käkleden,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000335-10,0,0,0 2006-000336-28,1,2018-03-03,2018-03-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 52-week open-label, single-arm, multi-center study to evaluate the long term safety of pimecrolimus 1% cream intermittent treatment of seborrhoeic dermatitis in patients 12 years of age and older",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000336-28,0,0,0 2006-000338-10,1,2009-07-31,2009-07-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,NHS Lothian Health Board,"Can long term nebulised gentamicin reduce the bacterial burden, break the vicious cycle of inflammation and improve quality of life in patients with bronchiectasis?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000338-10,0,0,0 2006-000338-10,1,2009-07-31,2009-07-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Edinburgh Research and Innovation,"Can long term nebulised gentamicin reduce the bacterial burden, break the vicious cycle of inflammation and improve quality of life in patients with bronchiectasis?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000338-10,0,0,0 2006-000339-93,15,2009-09-22,2012-04-04,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid Zometa in the Treatment of Bone Metastases in Subjects with Advanced Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000339-93,0,0,0 2006-000339-93,15,2009-09-22,2012-04-04,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,"A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid Zometa in the Treatment of Bone Metastases in Subjects with Advanced Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000339-93,0,0,0 2006-000341-19,17,2010-03-30,2012-02-27,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Double-Blind, Multicenter Study of Denosumab Compared with Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Men with Hormone-Refractory Prostate Cancer Studio M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000341-19,0,0,0 2006-000344-10,2,2010-06-01,2010-06-01,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Christie Hospital,Multi-centre study of cabergoline alone and in combination with pegvisomant in the management of active acromegaly,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000344-10,0,0,0 2006-000348-26,1,2010-07-31,2010-07-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Guy's & St Thomas' NHS Foundation Trust,A randomised prospective study to investigate the efficacy of corneal collagen cross-linkage with riboflavin (vitamin B2) and ultraviolet A light (UVA) (370nm) to halt the progression of keratoconus.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000348-26,0,0,0 2006-000349-20,3,2012-06-18,2014-04-02,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Institut fuer Frauengesundheit GmbH,Prospective Randomized Phase-III-Trial of Paclitaxel plus Topotecan versus Topotecan plus Cisplatin in Recurrent or Persistent Cervical Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000349-20,0,0,0 2006-000353-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Cliniques Universitaire St Luc,Comparison of the vasoreactivity and endogenous NO production between the left and right internal mammary 6 months after bypass surgery with the injection of substance P and exogenous nitric oxide.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000353-21,0,0,0 2006-000357-22,3,2008-12-31,2008-12-31,2,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Bracco ALTANA Pharma GmbH,ASSESSMENT OF GLOBAL AND REGIONAL LEFT VENTRICULAR FUNCTION AT REST AND DURING DOBUTAMINE STRESS WITH SONOVUE®-ENHANCED REALTIME 3D-ECHOCARDIOGRAPHY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000357-22,0,0,0 2006-000357-22,3,2008-12-31,2008-12-31,2,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Bracco Imaging Deutschland GmbH,ASSESSMENT OF GLOBAL AND REGIONAL LEFT VENTRICULAR FUNCTION AT REST AND DURING DOBUTAMINE STRESS WITH SONOVUE®-ENHANCED REALTIME 3D-ECHOCARDIOGRAPHY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000357-22,0,0,0 2006-000358-38,1,2010-01-08,2010-01-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Klinikum der J. W. Goethe-Universität Frankfurt - Medizinische Klinik I,Individually adapted therapy duration from 24 to 72 weeks for the treatment of patients with a chronic hepatitis C genotype 1 infection with Peginterferon alfa-2b plus Ribavirin in dependence of the i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000358-38,0,0,0 2006-000359-16,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Ove Bäck, Dept Dermatology, University Hospital, Lund, Sweden",Vitamin D and atopic allergy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000359-16,0,0,0 2006-000361-11,1,2007-04-02,2007-04-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Fujimoto Pharmaceutical Corporation,A Proof of Concept Study to Determine the Minimum Effective Dose and to Assess the Efficacy and Safety of Subcutaneous Injections of FPFS-1169 in Parkinson's Disease Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000361-11,0,0,0 2006-000363-28,1,2009-09-14,2009-09-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Greater Glasgow Health Board,DIFFERENTIATING THE MECHANISM OF ACTION OF ANTI TNF-alpha AGENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000363-28,0,0,0 2006-000363-28,1,2009-09-14,2009-09-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Glasgow University,DIFFERENTIATING THE MECHANISM OF ACTION OF ANTI TNF-alpha AGENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000363-28,0,0,0 2006-000366-36,2,2008-06-30,2008-06-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Telik, Inc.",Phase 3 randomized study of TLK286 (Telcyta™) in combination with liposomal doxorubicin (Doxil®/Caelyx®) versus liposomal doxorubicin (Doxil®/Caelyx®) as second-line therapy in platinum refractory or ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000366-36,0,0,0 2006-000368-10,1,2008-10-11,2008-10-11,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Tecnical University of Munich,High-dose therapy with Esomeprazol in combination with Baclofen therapy for symptomatic therapy-resistant gastrooesophageal reflux disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000368-10,0,0,0 2006-000369-12,1,2011-03-16,2011-03-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Institute of Anaesthesiology, German Heart Centre","An open, randomized, single-center study assessing the serum time-concentration curves and the effect of prophylactic moxifloxacin (in comparison with cefuroxime) on the early inflammatory response to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000369-12,0,0,0 2006-000371-15,1,2007-11-26,2007-11-26,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,no sponsor for this trial,Intraläsionelle Phospatidylcholin-Injektionen zur Reduktion von Körperfett: Halbseitenvergleichsstudie: Messung der subkutanen Fettschichtdicke mit dem Lipometer (Pilotstudie),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000371-15,0,0,0 2006-000374-75,2,2007-04-04,2020-08-28,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"Long-term, open-label, multicenter extension study of bosentan in patients with pulmonary hypertension associated with sickle cell disease completing a double-blind ASSET study (AC-052-368 or AC-052-3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000374-75,0,0,0 2006-000378-61,5,2015-01-08,2016-01-08,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genentech Inc.,"A MULTICENTER, PHASE III, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY REGIMENS IN SUBJECTS WITH PREVIOUSLY UNTREATED METASTA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000378-61,0,0,0 2006-000378-61,5,2015-01-08,2016-01-08,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genentech,"A MULTICENTER, PHASE III, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY REGIMENS IN SUBJECTS WITH PREVIOUSLY UNTREATED METASTA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000378-61,0,0,0 2006-000379-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Alimentary Health Ltd,A double-blind randomised placebo controlled feeding study to establish the effect of a probiotic strain on the course of Clostridium difficile carriage in humans.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000379-14,0,0,0 2006-000381-36,2,2011-02-28,2011-02-28,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Nottingham,Randomised controlled trials to investigate whether prophylactic antibiotics can prevent further episodes of cellulitis (erysipelas) of the leg (PATCH I & PATCH II),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000381-36,0,0,0 2006-000383-88,2,2007-08-07,2007-08-07,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,CSC Pharmaceuticals Handels GmbH,"A Multicenter, Parallel-group, Double-blind, Placebo Controlled and Randomized Clinical Study to Assess the Efficacy and Safety of Ketoprofen 10% Cutaneous Spray versus Placebo in Patients with Acute ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000383-88,0,0,0 2006-000389-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Nordic Lymphoma Group,A Nordic phase II study of peripheral T-cell lymphomas based on dose-intensive induction and high-dose consolidation with autologous stem cell rescue,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000389-35,0,0,0 2006-000390-30,1,2007-06-28,2007-06-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Helsinki University Central Hospital, Skin and Allergy Hospital",A phase II trial assessing dapsone topical gel in the prevention and treatment of erlotinib associated rash,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000390-30,0,0,0 2006-000391-32,3,2007-07-02,2007-08-01,3,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Britannia Pharmaceuticals Limited,"A 2 Treatment Period Study with Period 1 Comprising a 3-Week Randomised, Double-Blind, Crossover Comparison of Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Combination with a 12-Week Open, Act...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000391-32,0,0,0 2006-000393-76,1,,,0,1,0,0,0,3,2,0,0,1,1,1,0,1,0,Johann Wolfgang Goethe-Universität Frankfurt am Main,Allogenic stem cell transplantation with CD3/CD19 depleted stem cells from haploidentical related and non-related donators in pediatric patients with and without malignant systemic diseases.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000393-76,0,0,0 2006-000394-30,3,2012-08-08,2012-10-18,2,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Schering AG,Multicenter study to investigate the bleeding profile and the insertion easiness in women inserted with a second consecutive MIRENA for contraception or menorrhagia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000394-30,0,0,0 2006-000394-30,3,2012-08-08,2012-10-18,2,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"Bayer AB, Bayer Health Care, Bayer Schering Pharma",Multicenter study to investigate the bleeding profile and the insertion easiness in women inserted with a second consecutive MIRENA for contraception or menorrhagia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000394-30,0,0,0 2006-000394-30,3,2012-08-08,2012-10-18,2,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Schering Oy,Multicenter study to investigate the bleeding profile and the insertion easiness in women inserted with a second consecutive MIRENA for contraception or menorrhagia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000394-30,0,0,0 2006-000395-32,1,2011-03-29,2011-03-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,The effect of COX-2 Inhibition on Reducing Central Sensitisation of Pain in Osteoarthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000395-32,0,0,0 2006-000397-71,1,2009-01-12,2009-01-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Søren H. Sindrup, Department of Neurology, Odense University Hospital","Double-blind, randomised, placebo-controlled trial of levetiracetam for central neuropathic pain in patients with multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000397-71,0,0,0 2006-000405-27,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Greenpark Health Care Trust,Postoperative pain and mobility outcomes after primary hip and knee arthroplasty. A comparison of intravenous morphine with local wound infiltration.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000405-27,0,0,0 2006-000410-20,4,2010-06-24,2010-06-24,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CENTOCOR,"A Phase 3, Randomized, Open-label, Parallel-group, Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (REMICADE) in Pediatric Subjects with Moderately to Severely Active Ulcerative...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000410-20,0,0,0 2006-000410-20,4,2010-06-24,2010-06-24,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Centocor BV,"A Phase 3, Randomized, Open-label, Parallel-group, Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (REMICADE) in Pediatric Subjects with Moderately to Severely Active Ulcerative...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000410-20,0,0,0 2006-000413-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA UNITA SANITARIA LOCALE N 12 DI VIAREGGIO,"trastuzumab, docetaxel and oxaliplatino association in metastatic breast cancer with her2 receptor overexepression Phase II clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000413-37,0,0,0 2006-000415-15,1,2007-08-11,2007-08-11,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"EQUIPO (Efecto de Quinagolida en la Prevención de OHSS) Estudio de prueba de hipótesis, aleatorizado, doble ciego, de grupos paralelos, en búsqueda de dosis, controlado con placebo, multicéntrico, pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000415-15,0,0,0 2006-000418-20,4,2006-12-15,2006-12-15,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AstraZeneca AB,"A 4-week randomized, double-blind, placebo controlled, parallel group, phase II study to assess the efficacy and safety of gefitinib tablets, 250 mg once daily (OD), in adult patients with moderate ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000418-20,0,0,0 2006-000419-90,6,2007-04-23,2007-05-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TAP Pharmaceutical Products Inc.,A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000419-90,0,0,0 2006-000421-62,3,2011-03-11,2011-03-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Comparative Study of Chronic Hepatitis B Subjects Treated with Entecavir Plus Tenofovir Combination Therapy vs Entecavir Monotherapy in Adults who are Treatment-Naïve to Nucleosides and Nucleotides:...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000421-62,0,0,0 2006-000422-31,2,2012-06-04,2012-06-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Comparative Study of Entecavir vs Adefovir Plus Lamivudine vs Combination Entecavir plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Subjects: The DEFINE Study Revised Protocol 02, incorpo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000422-31,0,0,0 2006-000425-57,9,2007-11-08,2008-02-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer,"A 14 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PREGABALIN TWICE DAILY IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000425-57,0,0,0 2006-000425-57,9,2007-11-08,2008-02-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER,"A 14 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PREGABALIN TWICE DAILY IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000425-57,0,0,0 2006-000425-57,9,2007-11-08,2008-02-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc,"A 14 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PREGABALIN TWICE DAILY IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000425-57,0,0,0 2006-000425-57,9,2007-11-08,2008-02-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer España,"A 14 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PREGABALIN TWICE DAILY IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000425-57,0,0,0 2006-000425-57,9,2007-11-08,2008-02-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Ltd.,"A 14 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PREGABALIN TWICE DAILY IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000425-57,0,0,0 2006-000425-57,9,2007-11-08,2008-02-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer AB,"A 14 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PREGABALIN TWICE DAILY IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000425-57,0,0,0 2006-000425-57,9,2007-11-08,2008-02-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A 14 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PREGABALIN TWICE DAILY IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000425-57,0,0,0 2006-000425-57,9,2007-11-08,2008-02-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc./ Ann Arbor,"A 14 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PREGABALIN TWICE DAILY IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000425-57,0,0,0 2006-000426-31,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",STUDIO DI FASE I DELLA COMBINAZIONE FARMACOLOGICA TRA ACIDO ZOLEDRONICO E DOCETAXEL IN PAZIENTI CON CARCINOMA PROSTATICO METASTATICO ORMONO - REFRATTARIO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000426-31,0,0,0 2006-000428-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HANNA THORÉN,INFLUENCE OF DEKSAMETASONE ON POST-OPERATIVE RECOVERY AFTER OPERATIVE TREATMENT OF FACIAL FRACTURES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000428-15,0,0,0 2006-000432-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Epidural analgesia vs systemic intravenous analgesia in the major gynecological surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000432-27,0,0,0 2006-000435-99,1,2006-11-01,2006-11-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Zentiva a.s.,"A Randomized, Double Blind, Placebo Controlled Multicenter Study to Assess the Efficacy and Safety of nasal spray ANTIRIN® and NASIC® in the Treatment of Allergic Rhinitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000435-99,0,0,0 2006-000436-27,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Birmingham,Neoadjuvant trial of pre-operative exemestane or letrozole +/-celecoxib in the treatment of ER positive postmenopausal early breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000436-27,0,0,0 2006-000436-27,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,0,University Hospital Birmingham NHS Foundation Trust,Neoadjuvant trial of pre-operative exemestane or letrozole +/-celecoxib in the treatment of ER positive postmenopausal early breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000436-27,0,0,0 2006-000438-11,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Chiron Behring GmbH & Co KG,"A Phase III, Multicenter, Uncontrolled, Open-label study to evaluate Safety and Immunogenicity of Begrivac, preservative free inactivated Split Influenza Vaccine, using the Strain Composition 2006/200...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000438-11,0,0,0 2006-000441-19,3,2010-08-24,2010-08-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ELI LILLY,"A Randomized Phase II Study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxane Pretreated Advanced Breast Cancer Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000441-19,0,0,0 2006-000441-19,3,2010-08-24,2010-08-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized Phase II Study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxane Pretreated Advanced Breast Cancer Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000441-19,0,0,0 2006-000441-19,3,2010-08-24,2010-08-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli lilly and Company Limited,"A Randomized Phase II Study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxane Pretreated Advanced Breast Cancer Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000441-19,0,0,0 2006-000442-39,1,2006-10-06,2006-10-06,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"An open, phase I/II study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ 11PCV combined with adjuvant AS02V given as a 2-dose vaccination in adults aged 18-40 years old.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000442-39,0,0,0 2006-000445-19,2,2018-08-13,2018-08-13,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Swiss Group for Clinical Cancer Research,Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy. A randomized multicenter phase II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000445-19,1,0,0 2006-000445-19,2,2018-08-13,2018-08-13,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Swiss group for clinical cancer research,Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy. A randomized multicenter phase II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000445-19,1,0,0 2006-000450-49,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,Helsinki University Central Hospital,Pharmacokinetics of transdermal fentanyl in normal weight and cachectic patients with cancer related pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000450-49,0,0,0 2006-000451-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Marienkrankenhaus Soest,Etoricoxib als präemptives Analgetikum bei therapeutischen Arthroskopien,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000451-17,0,0,0 2006-000453-22,3,2011-03-10,2011-03-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,Study of the Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000453-22,0,0,0 2006-000453-22,3,2011-03-10,2011-03-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol_myers Squibb International Corporation,Study of the Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000453-22,0,0,0 2006-000454-44,2,2017-03-16,2017-03-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The lymphoma Study Association (LYSA),Etude prospective multicentrique de phase II évaluant l’adjonction du rituximab et du DepoCyte® en intrathécal au protocole de chimiothérapie C5R chez les patients âgés de 18 à 60 ans porteurs de lymp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000454-44,0,0,0 2006-000454-44,2,2017-03-16,2017-03-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Groupe d’Etude des Lymphomes de l’Adulte (GELA),Etude prospective multicentrique de phase II évaluant l’adjonction du rituximab et du DepoCyte® en intrathécal au protocole de chimiothérapie C5R chez les patients âgés de 18 à 60 ans porteurs de lymp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000454-44,0,0,0 2006-000460-90,1,2009-04-06,2009-04-06,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Ghent,Echocardiographic study of the haemodynamic effects of remifentanil with and without glycopyrrolate in healthy children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000460-90,0,0,0 2006-000461-10,1,2016-06-29,2016-06-29,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,The Royal Liverpool University Hospital NHS Trust,"A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination gemcitabine and capecitabine therapy with concurrent and sequential chemoimmunotherapy using a telome...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000461-10,0,0,0 2006-000463-29,1,2007-09-06,2007-09-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer Healthcare AG,Evaluation of vardenafil for the treatment of subjective tinnitus: A controlled pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000463-29,0,0,0 2006-000468-95,6,2007-06-12,2007-06-12,6,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A double-blind, randomised, placebo-controlled, parallel group study to investigate the effects of SB-742457, donepezil and placebo on cognition in subjects with mild to moderate Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000468-95,0,0,0 2006-000469-13,1,2007-06-12,2007-06-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gloucester Pharmaceuticals Inc.,"A MULTICENTER, OPEN-LABEL CONTINUATION TRIAL EVALUATING THE TOLERABILITY AND ACTIVITY OF DEPSIPEPTIDE (FK228) IN PATIENTS THAT HAVE COMPLETED A PRIOR CLINICAL STUDY WITH DEPSIPEPTIDE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000469-13,0,0,0 2006-000470-78,12,2008-07-18,2008-07-18,10,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000470-78,0,0,0 2006-000470-78,12,2008-07-18,2008-07-18,10,1,0,0,0,2,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000470-78,0,0,0 2006-000471-14,15,2015-07-06,2015-07-06,13,1,0,0,0,2,0,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"EXTEND (Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000471-14,0,0,0 2006-000471-14,15,2015-07-06,2015-07-06,13,1,0,0,0,2,0,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE R&D LTD,"EXTEND (Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000471-14,0,0,0 2006-000471-14,15,2015-07-06,2015-07-06,13,1,0,0,0,2,0,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"EXTEND (Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopag s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000471-14,0,0,0 2006-000475-16,1,2009-02-17,2009-02-17,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Johannes Gutenberg-Universität Mainz, Urologische Klinik (ausführende Stelle), Prof. Dr. med. Thürof","Prospective, randomized, open, crossover, patient preference study comparing oral immediate release and transdermal oxybutynin in overactive bladder patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000475-16,0,0,0 2006-000476-33,1,2009-08-20,2009-08-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Johannes-Gutenberg-Universität Mainz, I. Medizinische Klinik und Poliklinik","An open-label, multicenter phase II trial of Sunitinib for patients with chemo-refractory metastatic gastric cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000476-33,0,0,0 2006-000477-29,2,2008-12-23,2008-12-23,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Safety and immunogenicity of an intramuscular, inactivated, split-virion, pandemic influenza A/H5N1 vaccine in adults and the elderly.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000477-29,0,0,0 2006-000477-29,2,2008-12-23,2008-12-23,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,sanofi pasteur SA,"Safety and immunogenicity of an intramuscular, inactivated, split-virion, pandemic influenza A/H5N1 vaccine in adults and the elderly.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000477-29,0,0,0 2006-000481-37,4,2007-07-24,2008-07-24,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,NV Organon,"A randomized, open-label clinical trial to identify predictive factors for controlled ovarian stimulation using a fixed daily dose of 200 IU of recombinant FSH in a GnRH antagonist regimen with or wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000481-37,0,0,0 2006-000485-36,1,2011-03-31,2011-03-31,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Trust,"A randomised, double blind, placebo controlled study to Assess The Effect of Antibiotic Therapy on Chronic Rejection in Human Lung Transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000485-36,0,0,0 2006-000487-92,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Royal College of Surgeon's Ireland,"A Phase II, Randomised, Double Blind, Placebo Controlled Study examining the suitability of Phenytoin Sodium Topical Gel in the treatement of Venous Ulcers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000487-92,0,0,0 2006-000490-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Insitute for Clinical and Experimental Medicine,Effect of 3-week AT-1 receptor blockade on insulin resistance in relation to endocrine activity of adipose tissue in patients with insulin resistance,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000490-29,0,0,0 2006-000492-16,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,Royal Marsden Foundation Hospital,"A Phase II, Single-Centre, Randomised, Controlled, Open-Label Clinical Trial to Compare the Efficacy and Safety of Three Therapeutic Interventions on the Treatment of Hypothalamic Obesity due to Child...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000492-16,0,0,0 2006-000497-80,3,2008-05-27,2008-05-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Ltd,"A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder HIIP Compared to Preprandial Injectable Insulin in Patients with Type 1 Diabetes M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000497-80,0,0,0 2006-000497-80,3,2008-05-27,2008-05-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,"A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder HIIP Compared to Preprandial Injectable Insulin in Patients with Type 1 Diabetes M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000497-80,0,0,0 2006-000499-33,1,2010-04-16,2010-04-16,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Queen Mary, University of London","Effects of Pregabalin on acid-induced oesophageal pain hypersensitivity in male and female healthy adult volunteers, as investigated in a single centre, placebo-controlled, double-blind, randomised, t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000499-33,0,0,0 2006-000500-16,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Ardeypharm GmbH,E. coli Stamm Nissle 1917 zur Behandlung des postinfektiösen/Antibiotika-assoziierten Reizdarmsyndroms mit Diarrhö E. coli strain Nissle 1917 for the treatment of post-infectious/antibiotic-associate...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000500-16,0,0,0 2006-000501-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Technical University Carl-Gustav-Carus,"Monozentrische, offene Therapiestudie zur Behandlung von Psoriasis-Patienten ab vollendetem 18. Lebensjahr mit Fumaderm® in Kombination mit einer UVB-Therapie (311 nm) im intraindividuellen Halbseiten...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000501-37,0,0,0 2006-000503-41,2,2010-10-22,2010-10-22,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Rigshospitalet, Ultralydklinikken 4002",The PREDICT Study: The PREterm Delivery In Twins Study Effectiveness of vaginally administered progesterone to prevent preterm delivery in twin pregnancies – A multicentre randomized trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000503-41,0,0,0 2006-000503-41,2,2010-10-22,2010-10-22,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Rigshospitalet, Ultrasound Clinic 4023",The PREDICT Study: The PREterm Delivery In Twins Study Effectiveness of vaginally administered progesterone to prevent preterm delivery in twin pregnancies – A multicentre randomized trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000503-41,0,0,0 2006-000504-17,1,2010-09-06,2010-09-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Heinrich-Heine-Universität Düsseldorf,Konsekutive Aderlass- und Peginterferon alfa-2a -Ribavirin-Standardtherapie im Vergleich zu einer Peginterferon alfa-2a-Ribavirin-Standardtherapie bei naiven Patienten mit HCV Genotyp 1 und Ferritin >...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000504-17,0,0,0 2006-000506-22,11,2009-02-16,2009-03-01,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Sanofi Synthelabo Recherche,"A randomized, double-blind, triple-dummy, dose-ranging study, including an active control of unfractionated heparin and eptifibatide, to evaluate the clinical efficacy and safety of otamixaban, in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000506-22,0,0,0 2006-000506-22,11,2009-02-16,2009-03-01,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Sanofi aventis recherche & développement,"A randomized, double-blind, triple-dummy, dose-ranging study, including an active control of unfractionated heparin and eptifibatide, to evaluate the clinical efficacy and safety of otamixaban, in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000506-22,0,0,0 2006-000506-22,11,2009-02-16,2009-03-01,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A randomized, double-blind, triple-dummy, dose-ranging study, including an active control of unfractionated heparin and eptifibatide, to evaluate the clinical efficacy and safety of otamixaban, in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000506-22,0,0,0 2006-000506-22,11,2009-02-16,2009-03-01,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,sanofi-aventis recherche&developpement,"A randomized, double-blind, triple-dummy, dose-ranging study, including an active control of unfractionated heparin and eptifibatide, to evaluate the clinical efficacy and safety of otamixaban, in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000506-22,0,0,0 2006-000509-40,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Gebro Pharma,"Estudio piloto unicéntrico, aleatorizado, abierto, de grupos paralelos, controlado con metotrexato oral, para evaluar la eficacia y seguridad del tratamiento de la psoriasis en placas con metotrexato ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000509-40,0,0,0 2006-000511-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitätsklinik Mainz Pneumologie,Change of the inspiratory peak flow after bronchial dilatation on patients with median to severe chronic obstruktiv lung disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000511-26,0,0,0 2006-000512-25,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,CHIESI,"DOUBLE BLIND, DOUBLE DUMMY, RANDOMISED, PARALLEL GROUP, MONOCENTRIC CLINICAL TRIAL ON THE EFFECTS OF CHF 1535 MDI OR SERETIDE DPI ON BIOLOGICAL AND FUNCTIONAL MARKERS OF SMALL AIRWAYS IN PATIENTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000512-25,0,0,0 2006-000513-37,1,2019-11-27,2019-11-27,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ACOSOG,"A Randomised Phase III Trial comparing 16 to 18 weeks of neoadjuvant Exemestane (25mg daily), Letrozole (2.5mg), or Anastrozole(1mg) in postmenopausal Women with Clinical Stage II and III Estrogen Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000513-37,0,0,0 2006-000514-21,4,2007-12-18,2008-01-05,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CIS bio International,"Multicenter, randomized, open-label, clinical study on the agreement of Scintimun® Granulocyte and labeled 99mTc-White Blood Cells in diagnosing infection/ inflammation by immunoscintigraphy in periph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000514-21,0,0,0 2006-000514-21,4,2007-12-18,2008-01-05,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CISbio International,"Multicenter, randomized, open-label, clinical study on the agreement of Scintimun® Granulocyte and labeled 99mTc-White Blood Cells in diagnosing infection/ inflammation by immunoscintigraphy in periph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000514-21,0,0,0 2006-000515-15,1,2008-09-11,2008-09-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FOURNIER LABORATORIES IRELAND Ltd,"A multicenter, double-blind, randomized, forced-titration study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 20 or 40 mg simvastatin with 40 mg pravastatin monothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000515-15,0,0,0 2006-000516-24,2,2010-07-13,2010-07-13,1,0,0,0,0,0,3,0,0,1,1,0,1,0,0,Stiftung Institut für Herzinfarktforschung,CIPAMI-Study: Clopidogrel administered prehospital to improve primary PCI in Patients with Acute Myocardial Infarction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000516-24,0,0,0 2006-000518-19,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A Phase III, open, multicentre study to assess the long-term persistence of a booster dose of GSK Biologicals? Hib-MenC conjugate vaccine compared to a booster dose of Infanrix? hexa (combined diphthe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000518-19,0,0,0 2006-000519-21,3,2008-09-02,2008-09-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FOURNIER LABORATORIES IRELAND Ltd,"A multicenter, double-blind, randomized, forced-titration study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 20 or 40 mg simvastatin with atorvastatin monotherapy in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000519-21,0,0,0 2006-000520-14,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO EUROPEO DI ONCOLOGIA,A PHASE II STUDY OF GW572016 LAPATINIBTM ON CELL PROLIFERATION IN HER-2/neu ErbB2 POSITIVE BREAST CANCER BEFORE SURGERY.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000520-14,0,0,0 2006-000521-61,1,2011-04-13,2011-04-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,"Multi-center, double-blind, randomized, reference-controlled study to prove the efficacy, safety and tolerability of Lavender oil WS 1265 (Lavandula angustifolia) in patients with generalized anxiety ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000521-61,0,0,0 2006-000523-34,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Århus Sygehus,Intensiv ikke-sympatikus aktiverende vasodilaterende behandling hos patienter med mikrovaskulær angina pectoris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000523-34,0,0,0 2006-000524-14,1,2006-07-07,2006-07-07,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,ViraNative AB,Comparison of virological response during high and low-dose regimen with natural IFN α in combination with ribavirin in patients with genotype 1 chronic hepatitis C who have experienced an incomplete ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000524-14,0,0,0 2006-000525-60,1,2008-03-27,2008-03-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,"Multi-center, double-blind, placebo-controlled, randomized phase III study to demonstrate the efficacy and investigate the safety of Hypericum extract WS® 5570 in patients with a Major Depressive Epis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000525-60,0,0,0 2006-000526-31,1,2007-12-18,2007-12-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Section of Clinical Pain Research, Department of Molecular Medicine and Surgery Karolinska Institute","Brush-evoked allodynia in patients with peripheral neuropathy before and following intravenous infusion of ondansetron. A randomised, double-blind, placebo controlled, cross-over study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000526-31,0,0,0 2006-000531-10,2,2007-06-26,2007-06-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Pharmaceuticals Inc.,"A Randomized, Controlled, 14-Treatment Day, Multicenter Study to Determine the Optimal Efficacious and Safe Dose of CHF 4226 in a Metered Dose Inhaler in Treating Patients With Chronic Obstuctive Pulm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000531-10,0,0,0 2006-000537-35,1,2010-08-25,2010-08-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Portuguese Lung Cancer Study Group,"Open-label, Uncontrolled, Multicenter, Phase II study evaluating the efficacy and safety of Cetuximab in combination with Cisplatin & Gemcitabine as first-line therapy in patients with advanced non sm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000537-35,0,0,0 2006-000540-98,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,Substudie Bröstmärta provocerad med iv bolus adenosin injektion i huvudstudie: Jämförelse mellan aktiv och passiv fysisk träning för behandling av persisterande angina pectoris - en randomiserad studi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000540-98,0,0,0 2006-000545-19,3,2008-04-29,2008-04-29,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,"Nuvelo, Inc.","Phase 3, Multicenter, Multi-National, Open-Label Study to Evaluate the Safety and Efficacy of Alfimeprase in Subjects with Occluded Central Venous Access Devices",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000545-19,0,0,0 2006-000549-20,1,2006-12-14,2006-12-14,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"An open, phase IV, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in healthy children 7 to 9 years o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000549-20,0,0,0 2006-000553-22,1,2006-11-27,2006-11-27,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"An open, phase IV, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in healthy children 4-6 years old,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000553-22,0,0,0 2006-000554-46,1,2007-05-31,2007-05-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, observer-blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DSSITGDPa-HBV-IPV/Hib vaccine containing diphtheri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000554-46,0,0,0 2006-000556-41,1,2007-05-14,2007-05-14,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"An open, phase IV, single-group multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in children at 4-5 ye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000556-41,0,0,0 2006-000557-21,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IIIb randomized, double-blind, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000557-21,0,1,1 2006-000558-30,2,2007-10-24,2007-10-24,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A phase IIIb randomised, open, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine when co-administe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000558-30,0,0,0 2006-000558-30,2,2007-10-24,2007-10-24,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIb randomised, open, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine when co-administe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000558-30,0,0,0 2006-000559-16,1,2007-04-10,2007-04-10,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIb randomized, open, controlled study to assess the effect of prophylactic antipyretic treatment on the rate of febrile reactions following concomitant administration of GlaxoSmithKline (GS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000559-16,0,0,0 2006-000560-93,1,2006-12-08,2006-12-08,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIa, open, multicentre study to evaluate the immunological memory induced in healthy children following a 3-dose primary vaccination with either GSK Biologicals’ 10-valent pneumococcal conjug...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000560-93,0,0,0 2006-000562-36,17,2016-04-26,2021-07-01,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"''A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer''",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000562-36,0,0,0 2006-000562-36,17,2016-04-26,2021-07-01,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd.,"''A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer''",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000562-36,0,0,0 2006-000562-36,17,2016-04-26,2021-07-01,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Ltd.,"''A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer''",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000562-36,0,0,0 2006-000562-36,17,2016-04-26,2021-07-01,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"''A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer''",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000562-36,0,0,0 2006-000564-81,10,2019-12-23,2019-12-23,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A randomised, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000564-81,0,0,0 2006-000564-81,10,2019-12-23,2019-12-23,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithkline R&D Ltd,"A randomised, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000564-81,0,0,0 2006-000564-81,10,2019-12-23,2019-12-23,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomised, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000564-81,0,0,0 2006-000564-81,10,2019-12-23,2019-12-23,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline S.A.,"A randomised, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000564-81,0,0,0 2006-000567-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Clínic Recerca Biomédica,Eficacia de tungstato sódico por vía oral a una dosis fija de 200 mg por día sobre la pérdida de peso en pacientes con obesidad grado I y grado II.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000567-28,0,0,0 2006-000568-95,2,2009-02-06,2010-02-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc. Laboratoires,Phase 2 randomized non-comparative study of Ticilimumab or Best Supportive Care (BSC) immediately following first-line platinum-based therapy in patients with stage IIIB (with effusion) or stage IV no...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000568-95,0,0,0 2006-000568-95,2,2009-02-06,2010-02-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Limited,Phase 2 randomized non-comparative study of Ticilimumab or Best Supportive Care (BSC) immediately following first-line platinum-based therapy in patients with stage IIIB (with effusion) or stage IV no...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000568-95,0,0,0 2006-000569-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Cardioangiologisches Centrum Bethanien,Influence on the coronary Microcirculation and on myocArdial perfusion Reserve of Niaspan given IN addition to simvastatin in diabEtic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000569-13,0,0,0 2006-000570-78,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"PHASE I/II STUDY OF TEMOZOLOMIDE COMBINED WITH ORAL ETOPOSIDE IN CHILDREN AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SUPRATENTORIAL PNET/MEDULLOBLASTOMA COHORT A , AND MALIGNANT GLIAL TUMOUR COHO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000570-78,0,0,0 2006-000571-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Laboratorios LETI S.L.,Extracto alergénico despigmentado polimerizado de Dermatophagoides pteronyssinus como tratamiento antiasmático en niños con asma leve alérgicos a ácaros.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000571-15,0,0,0 2006-000574-69,1,2007-03-12,2007-03-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca A/S,Development of an algorithm for identification of responders to short term treatment with esomeprazol (Nexium) in primary care.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000574-69,0,0,0 2006-000576-33,1,2008-10-01,2008-10-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,St Helens & Knowsley Hospitals NHS Trust,Pilot Study to investigate the role of Glutamine in the early protective stress response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000576-33,0,0,0 2006-000576-33,1,2008-10-01,2008-10-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Universtiy of Liverpool,Pilot Study to investigate the role of Glutamine in the early protective stress response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000576-33,0,0,0 2006-000577-29,1,2011-09-20,2011-09-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)","A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Subjects Receiving Optimized Treatments with Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000577-29,0,0,0 2006-000578-53,1,2012-10-25,2012-10-25,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Abbott Laboratories,"Open-Label, 12-Month Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000578-53,0,0,0 2006-000579-14,16,2015-09-08,2015-09-09,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck KGaA,"START – Stimulating Targeted Antigenic Responses To NSCLC. A multi-center phase III randomized, double-blind placebo-controlled study of the cancer vaccine Stimuvax(L-BLP25 or BLP25 liposome vaccine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000579-14,0,0,0 2006-000579-14,16,2015-09-08,2015-09-09,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck KGaA and EMD Serono, Inc","START – Stimulating Targeted Antigenic Responses To NSCLC. A multi-center phase III randomized, double-blind placebo-controlled study of the cancer vaccine Stimuvax(L-BLP25 or BLP25 liposome vaccine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000579-14,0,0,0 2006-000579-14,16,2015-09-08,2015-09-09,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck KGaA and EMD Serono, Inc.","START – Stimulating Targeted Antigenic Responses To NSCLC. A multi-center phase III randomized, double-blind placebo-controlled study of the cancer vaccine Stimuvax(L-BLP25 or BLP25 liposome vaccine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000579-14,0,0,0 2006-000579-14,16,2015-09-08,2015-09-09,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck KgAa,"START – Stimulating Targeted Antigenic Responses To NSCLC. A multi-center phase III randomized, double-blind placebo-controlled study of the cancer vaccine Stimuvax(L-BLP25 or BLP25 liposome vaccine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000579-14,0,0,0 2006-000582-11,1,2006-11-03,2006-11-03,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,ALTANA Inc,Determination of anti-inflammatory efficacy of topical formulations in a UV erythema test,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000582-11,0,0,0 2006-000585-36,1,2010-02-01,2010-02-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MEDICE Arzneimittel Pütter GmbH & Co. KG,Placebokontrollierte multizentrische Doppelblindstudie bei Erwachsenen mit Methylphenidat retard bei tumorbedingter Fatigue,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000585-36,0,0,0 2006-000591-33,1,2014-01-23,2014-01-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University College London,A Phase II study of Gemcitabine and Bexarotene (GemBex) in the treatment of cutaneous T-cell lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000591-33,0,0,0 2006-000595-32,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO GIANNINA GASLINI,Rescue therapy for indwelling central venous Hickmann-Broviac catheter related infections with antibiotic lock technique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000595-32,0,0,0 2006-000598-31,1,2015-11-06,2015-11-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Christie Hospital NHS Trust,Phase II Study of Fractionated 90Y Ibritumomab tiuxetan (ZevalinTM) as initial therapy of Follicular Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000598-31,0,0,0 2006-000599-33,1,2013-01-30,2013-01-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Liverpool Women's NHS Foundation Trust,Duration of luteal phase support with progesterone pessaries to improve the success rate in assisted reproduction cycles. A prospective randomised control trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000599-33,0,0,0 2006-000602-23,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Laboratorios LETI S.L.,"A randomized double blind, placebo controlled study to evaluate the efficacy and security of immunotherapy with a depigmented and polymerized allergen extract of Dermatophagoides pteronyssinus in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000602-23,0,0,0 2006-000604-16,2,2008-11-06,2008-11-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A Multicenter, Open-Label, Single-Arm Study of Intravenous AVE0005 VEGF Trap Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000604-16,0,0,0 2006-000604-16,2,2008-11-06,2008-11-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Sanofi-Synthelabo Recherche, a subsidiary of sanofi-aventis group","A Multicenter, Open-Label, Single-Arm Study of Intravenous AVE0005 VEGF Trap Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000604-16,0,0,0 2006-000606-23,1,2010-11-15,2010-11-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Merck, S.L.",Post-authorization safety study to check the potential association between the safety profile of beta interferon 1a and the body mass index or pharmacodynamics during the titration phase Estudio po...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000606-23,0,0,0 2006-000607-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institute for clinical and experimental Medicine,Treatment of borderline changesin protocol biopsy 3 months after renal transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000607-42,0,0,0 2006-000608-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Roche Farma, S.A.","Estudio abierto y aleatorizado, comparativo de la tolerabilidad renal de Bondronat® 6 mg I.V. en perfusión de 15 minutos frente a 60 minutos en pacientes con metástasis óseas",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000608-18,0,0,0 2006-000609-43,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,CHIRON,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2006-2007, when Administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000609-43,0,0,0 2006-000610-20,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,CHIRON,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, (Adjuvanted with MF59C.1) Influenza Vaccine, Formulation 2006-2007...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000610-20,0,0,0 2006-000612-24,1,2010-05-12,2010-05-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Greater Glasgow Health Board (North Glasgow University Hospitals Division),Trial of Aciclovir Prophylaxis of Herpes Infections in Critical Care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000612-24,0,0,0 2006-000613-38,2,2009-10-27,2009-10-27,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Boehringer Ingelheim Austria GmbH,"An open, randomised clinical Phase I/IIa trial to investigate the maximum tolerated dose, efficacy, safety and pharmacokinetics of repeated three-week courses of a single dose i.v. BI 2536 on day 1 in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000613-38,0,0,0 2006-000613-38,2,2009-10-27,2009-10-27,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An open, randomised clinical Phase I/IIa trial to investigate the maximum tolerated dose, efficacy, safety and pharmacokinetics of repeated three-week courses of a single dose i.v. BI 2536 on day 1 in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000613-38,0,0,0 2006-000614-21,4,2007-05-30,2007-06-07,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Zambon Group S.p.A,"A multicentre, open-label study to evaluate the efficacy and safety of 5-MTHF administration, added on to the individual established therapy, on plasma homocysteine levels in patients with congenital ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000614-21,0,0,0 2006-000619-51,8,2008-03-27,2008-03-27,7,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Fibrex Medical Research & Development GmbH,"A Multicenter, Double-blind, Randomized, Placebo-Controlled Study to Measure the Effect of FX06 (a fibrin derived peptide Bβ15-42) on Ischemia-Reperfusion Injury in Patients Undergoing Primary Percuta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000619-51,0,0,0 2006-000635-94,1,2006-06-15,2006-06-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,"A Phase II, randomized, double-blind, parallel group study to examine bone quality and bone mineral density changes following treatment with SB-462795 (40mg, 80mg, 120mg or 160mg), alendronate or plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000635-94,0,0,0 2006-000637-35,1,2008-02-19,2008-02-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Addenbrookes Hospital Cambridge University Hospitals NHS Foundation Trust,double blind crossover compariosn of diuretics in young patients with low-renin hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000637-35,0,0,0 2006-000644-13,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY,"Multicenter, randomized, controlled study to compare palonosetron plus dexamethasone before chemotherapy administration versus the same regimen with dexamethasone continuing on Days 2 and 3 in prevent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000644-13,0,0,0 2006-000648-15,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,ORPHANETICS Pharma Entwicklungs- GmbH,"A double-blind, placebo-controlled, multicentre study with an open-label extension to evaluate the efficacy and safety of tetrahydrobiopterin (BH4) in children and adolescents with hyperphenylalaninem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000648-15,0,0,0 2006-000653-22,1,2011-07-19,2011-07-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Moorfields Eye Hospital,The UK Glaucoma Treatment Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000653-22,0,0,0 2006-000654-43,8,2008-07-11,2008-09-11,3,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Myriad Pharmaceuticals Inc,"Estudio en fase 3 multinacional, aleatorizado, doble ciego, controlado con placebo del efecto del tratamiento diario con MPC-7869 en las variables capacidad cognitiva, actividades cotidianas y función...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000654-43,0,0,0 2006-000654-43,8,2008-07-11,2008-09-11,3,0,0,0,0,0,3,0,0,1,1,0,1,0,1,"Myriad Pharmaceuticals, Inc","Estudio en fase 3 multinacional, aleatorizado, doble ciego, controlado con placebo del efecto del tratamiento diario con MPC-7869 en las variables capacidad cognitiva, actividades cotidianas y función...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000654-43,0,0,0 2006-000658-27,16,2009-03-01,2009-05-20,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000658-27,0,0,0 2006-000658-27,16,2009-03-01,2009-05-20,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000658-27,0,0,0 2006-000658-27,16,2009-03-01,2009-05-20,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"AstraZeneca AB, European Regulatory Affairs","A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000658-27,0,0,0 2006-000660-89,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,Timo Iirola,The effect of dexmedetomidine sedation on intracranial and cerebral perfusion pressures in patients with acute severe brain injury,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000660-89,0,0,0 2006-000663-28,2,2008-09-04,2008-09-04,1,1,0,0,0,1,3,0,0,2,0,0,0,0,2,Bio Products Laboratory,"An open multi-centre study in patients with von Willebrand Disease to investigate the pharmacokinetics, efficacy and safety of Optivate, a high purity, dual inactivated Factor VIII and Von Willebrand ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000663-28,1,0,0 2006-000664-85,2,2008-09-04,2008-09-04,1,1,0,0,0,2,3,0,0,2,0,0,0,0,1,Bio Products Laboratory,"An Open Multi-centre Study to Investigate the Safety and Efficacy of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and von Willebrand Factor Concentrate, in Patients with von Willebrand Disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000664-85,1,0,0 2006-000666-37,2,2008-07-01,2008-08-31,2,0,0,0,0,0,4,0,0,1,0,0,1,0,2,IATEC B.V.,"A Randomised, Controlled, Open-Label, 48-Week, Study To Asses Differences in Changes In Plasma Lipid Profile Between Patients On Saquinavir/Ritonavir Or Atazanavir/Ritonavir In Combination With Tenofo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000666-37,0,0,0 2006-000671-15,1,2006-08-09,2006-08-09,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2006-2007 Formulation (Intramuscular Route)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000671-15,0,0,0 2006-000673-30,1,2016-01-20,2016-01-20,1,0,0,0,1,1,2,0,0,1,0,0,1,0,0,Medizinische Hochschule Hannover,Placebo kontrollierte Phase II Studie zur Therapie des fortgeschrittenen HCC mit Viscum fraxini,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000673-30,0,0,0 2006-000674-73,8,2009-02-13,2009-02-13,3,0,0,0,0,1,3,0,0,2,1,0,0,0,1,LA JOLLA PHARMACEUTICAL COMPANY,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-ARM, PARALLEL-GROUP, MULTICENTER, MULTINATIONAL SAFETY AND EFFICACY TRIAL OF 300 MG AND 900 MG OF ABETIMUS SODIUM IN SYSTEMIC LUPUS ERYTHEMATOSUS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000674-73,1,0,0 2006-000674-73,8,2009-02-13,2009-02-13,3,0,0,0,0,1,3,0,0,2,1,0,0,0,1,La Jolla Pharmaceutical Company,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-ARM, PARALLEL-GROUP, MULTICENTER, MULTINATIONAL SAFETY AND EFFICACY TRIAL OF 300 MG AND 900 MG OF ABETIMUS SODIUM IN SYSTEMIC LUPUS ERYTHEMATOSUS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000674-73,1,0,0 2006-000675-15,1,2007-10-18,2007-10-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Great Ormond Street Hospital for Children NHS Trust,Open label Randomised Controlled Trial comparing povidone-iodine 10% with alcohol and 0.5% chlorhexidine with alcohol for prevention of early infection associated with insertion of central venous acce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000675-15,0,0,0 2006-000676-33,1,2008-01-21,2008-01-21,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,NV Organon,"A randomized, open-label, comparative, multi-center trial to evaluate the effects on hemostasis, lipids and carbohydrate metabolism, and on adrenal and thyroid function of a monophasic COC containing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000676-33,0,0,0 2006-000678-57,9,2008-02-13,2008-03-14,9,1,0,0,2,0,3,0,0,1,0,0,1,0,1,SOLVAY PHARMACEUTICALS B.V.,"A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parki...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000678-57,0,0,0 2006-000678-57,9,2008-02-13,2008-03-14,9,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Solvay pharmaceuticals,"A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parki...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000678-57,0,0,0 2006-000678-57,9,2008-02-13,2008-03-14,9,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Solvay pharmaceuticals B.V.,"A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Parki...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000678-57,0,0,0 2006-000679-14,1,2012-06-19,2012-06-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"INSTITUTO CIENTÍFICO Y TECNOLÓGICO (ICT )DE NAVARRA, S.A.","ESTUDIO DE FASE II CIEGO, CONTROLADO Y ALEATORIZADO DE EFICACIA DEL IMPLANTE PERCUTÁNEO DE MIOBLASTOS AUTÓLOGOS EN PACIENTES CON INFARTO ANTIGUO. (STUDY PHASE II BLINDED, CONTROLATED AND RANDOMIZED TO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000679-14,0,0,0 2006-000680-28,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,"NOVARTIS FARMACEUTICA, S.A","Estudio multicéntrico, doble ciego, aleatorizado y de tres meses de seguimiento para evaluar la eficacia de levodopa/carbidopa/entacapona frente a levodopa/carbidopa en pacientes con enfermedad de Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000680-28,0,0,0 2006-000683-84,2,2007-11-07,2007-11-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Andi-Ventis Ltd.,"A DOUBLE BLIND, DOUBLE DUMMY, GROUP COMPARATIVE STUDY TO ASSESS THERAPEUTIC EQUIVALENCE OF A NEW GENERIC FORMOTEROL 12 uG DRY POWDER FORMULATION WITH OXIS 12uG TURBUHALER IN ADOLESCENT AND ADULT ASTHM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000683-84,0,0,0 2006-000685-36,6,2012-05-15,2012-05-15,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX-4 plus cetuximab versus UFOX plus cetuximab as first-line therapy in subjects with metastatic colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000685-36,0,0,0 2006-000687-89,1,2020-11-02,2020-11-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Institute of Cancer Research,A randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000687-89,0,0,0 2006-000692-15,1,2008-03-20,2008-03-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Intercytex,"A prospective single centre, open label, pilot study to evaluate the safety of ICXP007 plus standard of care, for the treatment of lower extremity chronic, neuropathic diabetic foot ulcers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000692-15,0,0,0 2006-000694-30,2,2008-03-17,2008-03-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Takeda Europe Research & Development Centre Ltd.,","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS) in Subjects with Type 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000694-30,0,0,0 2006-000694-30,2,2008-03-17,2008-03-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Takeda Europe Research & Development Centre Ltd,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of the Combination of SYR-322 (SYR110322) and Pioglitazone HCl (ACTOS) in Subjects with Type 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000694-30,0,0,0 2006-000697-74,1,2008-08-14,2008-08-14,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,The BONiFIN study group,"A phase II, open label study to establish the safety and efficacy of intravenous loading dose of 3 x Bondronat 6 mg in 3 consecutive days in patients with breast cancer and skeletal metastases experie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000697-74,0,0,0 2006-000701-35,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Erasmus Hospital,Chemoreflex sensitivity during exercise with beta blockers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000701-35,0,0,0 2006-000703-42,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,ROCHE,A phase III randomized trial of trastuzumab continuation vs discontinuation in combination with 2nd-line chemotherapy after progression on a 1st-line trastuzumab-chemotherapy combination for HER2 ove...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000703-42,0,0,0 2006-000704-17,9,2008-12-15,2011-07-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ver...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000704-17,0,0,0 2006-000704-17,9,2008-12-15,2011-07-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ver...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000704-17,0,0,0 2006-000704-17,9,2008-12-15,2011-07-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A 12-month double-blind, randomized, multicenter, active controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ver...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000704-17,0,0,0 2006-000708-18,21,2010-04-19,2010-04-19,20,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Effects of Ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double blind placebo contr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000708-18,0,0,0 2006-000708-18,21,2010-04-19,2010-04-19,20,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Effects of Ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double blind placebo contr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000708-18,0,0,0 2006-000713-37,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Intervention Baclofen Intervention Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000713-37,0,0,0 2006-000714-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dr. Wolfgang Jaksch,Klinische Studie zum Einfluss einer postoperativen Verabreichung von (S)-(+)-Ketamin auf das Schmerzempfinden nach großen chirurgischen Eingriffen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000714-20,0,0,0 2006-000715-19,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Sanofi Pasteur SA,A Long-Term Safety and Immunogenicity Follow-up of Healthy Adults Vaccinated with One Dose of Smallpox Vaccine (LISTER Strain).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000715-19,0,0,0 2006-000720-13,4,2014-01-21,2014-02-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomised, placebo-controlled, multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000720-13,0,0,0 2006-000722-31,2,2006-11-28,2006-11-28,2,0,0,0,0,0,3,0,0,1,1,0,1,0,1,"(OSI) Eyetech, Inc","An Exploratory randomized, double-masked, multi-center, multi-dose comparative trial, in parallel groups, to explore the safety and efficacy of three different doses of intravitreous injections of peg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000722-31,0,0,0 2006-000725-54,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,TAKEDA,"Double-blind, randomized, multicenter, parallel-group study to evaluate the effects of pioglitazone on metabolic syndrome in patients with type 2 diabetes treated with metformin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000725-54,0,0,0 2006-000729-70,1,2007-12-20,2007-12-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development,"A randomised, double-blind, placebo-controlled parallel study to assess the safety, tolerability, pharmacodynamics and steady-state pharmacokinetics of repeated doses of GW856553 in patients with COPD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000729-70,0,0,0 2006-000732-28,1,2006-08-10,2006-08-10,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Chiron S.r.l.,"A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C saccharide component of Chiron’s Meningococcal C Conjugate Vaccine (Menjugate®) Administered to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000732-28,0,0,0 2006-000734-13,1,2006-07-25,2006-07-25,1,1,0,0,0,3,2,0,1,1,1,1,1,0,0,Department of Clinical Pharmacology,Effect of L-NMMA on retinal and choroidal blood flow in smokers compared to non-smokers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000734-13,0,0,0 2006-000736-26,9,2009-04-28,2009-04-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,"An 8-Week, Multicenter, Masked, Randomized Trial with an 18-Week Masked Extension to Assess the Safety and Efficacy of 700 g and 350 g Dexamethasone Posterior Segment Drug Delivery System DEX PS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000736-26,0,0,0 2006-000736-26,9,2009-04-28,2009-04-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALLERGAN Limited,"An 8-Week, Multicenter, Masked, Randomized Trial with an 18-Week Masked Extension to Assess the Safety and Efficacy of 700 g and 350 g Dexamethasone Posterior Segment Drug Delivery System DEX PS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000736-26,0,0,0 2006-000737-36,5,2007-03-15,2007-03-15,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Allergan Limited,"A 6-Week, Multicenter, Masked, Randomized Trial (with a 20-Week Masked Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000737-36,0,0,0 2006-000741-19,1,2009-08-05,2009-08-05,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,UHL NHS Trust,A phase I study of subcutaneous alemtuzumab in combination with oral fludarabine in previously untreated patients with chronic lymphocytic leukaemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000741-19,0,0,0 2006-000744-17,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,University Hospital Ghent,A randomised phase II study evaluating two schedules of the 21-day regimen of Gemcitabine and Carboplatin in advanced NSCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000744-17,0,0,0 2006-000748-14,9,2008-11-10,2008-11-10,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmBH Co,"A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhibito...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000748-14,0,0,0 2006-000748-14,9,2008-11-10,2008-11-10,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhibito...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000748-14,0,0,0 2006-000753-22,1,2007-09-27,2007-09-27,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Oxford MioMedica UK Ltd.,"A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000753-22,0,0,0 2006-000754-40,1,2008-07-01,2008-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Dresden University of Technology,Interaktion von Statinen mit Clopidogrel als Sekundärprophylaxe bei der akuten zerebralen Ischämie - CLOPISTAT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000754-40,0,0,0 2006-000755-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación PETHEMA,"Estudio Fase IV, Nacional, Multicéntrico, competitivo, aleatorizado, doble ciego, controlado de grupos paralelos, para determinar la seguridad, tolerabilidad, y eficacia de aprepitant, más palonosetró...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000755-18,0,0,0 2006-000756-41,3,2007-07-30,2007-07-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,DEBIOPHARM S.A.,"Estudio multicéntrico Fase IIa, aleatorizado, doble ciego, controlado con placebo de una semana de tratamiento con Depelestat en pacientes con síndrome de distrés respiratorio agudo Phase IIa multice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000756-41,0,0,0 2006-000756-41,3,2007-07-30,2007-07-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Debiopharm SA,"Estudio multicéntrico Fase IIa, aleatorizado, doble ciego, controlado con placebo de una semana de tratamiento con Depelestat en pacientes con síndrome de distrés respiratorio agudo Phase IIa multice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000756-41,0,0,0 2006-000757-21,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,AESCA Pharma GmbH,Study to evaluate Response Rates in CHC Patients genotype 1 with Insulin Resistance and to assess prolonged Treatment Duration in late virological Responders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000757-21,0,0,0 2006-000758-29,3,2007-06-09,2007-06-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Daiichi Sankyo Pharma Development,"A PHASE IIB, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, DOUBLE-DUMMY, MULTI-CENTER, MULTI NATIONAL, MULTI-DOSE STUDY OF DU-176b COMPARED TO DALTEPARIN IN PATIENTS UNDERGOING ELECTIVE UNILATERAL TOTAL H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000758-29,0,0,0 2006-000763-29,1,2006-10-31,2006-10-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Aventis Deutschland GmbH,"Pharmacokinetics, pharmacodynamics and safety of intra-articular multiple doses of 500 mcg icatibant in an uncontrolled 13-week multi-center study in patients with symptomatic knee osteoarthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000763-29,0,0,0 2006-000764-85,4,2007-05-24,2008-02-21,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Merck Sharp & Dohme BV,"A Open-label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of GARDASIL™ Given Concomitantly with REPEVAX™ in Healthy Adolescents 11-17 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000764-85,0,0,0 2006-000764-85,4,2007-05-24,2008-02-21,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Merck & Co., Inc","A Open-label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of GARDASIL™ Given Concomitantly with REPEVAX™ in Healthy Adolescents 11-17 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000764-85,0,0,0 2006-000764-85,4,2007-05-24,2008-02-21,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Merck & Co. Inc.,"A Open-label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of GARDASIL™ Given Concomitantly with REPEVAX™ in Healthy Adolescents 11-17 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000764-85,0,0,0 2006-000767-28,1,2008-03-18,2008-03-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Vienna Medical University,Standardisierte Verlaufsbeobachtung von Patienten mit intrathekalem S(+)-Ketamin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000767-28,0,0,0 2006-000769-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AM-Pharma,"A double-blind, randomized, placebo-controlled study to investigate the clinical efficacy and safety of two doses of Alkaline Phosphatase administered for three days in patients with severe sepsis a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000769-13,0,0,0 2006-000770-75,1,2009-10-11,2009-10-11,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA,Cortisone Eliminates Restenosis as Effectively As DES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000770-75,0,0,0 2006-000774-70,5,2006-04-14,2007-08-02,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An 8-week, multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the combination of valsartan/HCTZ/amlodipine compared to valsartan/HCTZ, valsartan/amlodip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000774-70,0,0,0 2006-000775-15,1,2008-01-09,2008-01-09,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,PLIVA - ISTRAŽIVANJE I RAZVOJ d.o.o.,"Double blind, comparative, randomized, placebo controlled, clinical study of therapeutic equivalence and tolerability of the topical preparation Terbinafine cream 1% (Pliva Croatia) with the medical p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000775-15,0,0,0 2006-000781-37,15,2007-08-08,2017-08-24,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000781-37,0,0,0 2006-000781-37,15,2007-08-08,2017-08-24,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000781-37,0,0,0 2006-000781-37,15,2007-08-08,2017-08-24,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithkline Research Development Ltd,"A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000781-37,0,0,0 2006-000785-36,5,2008-10-24,2008-10-28,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Menarini International Operations Luxembourg S.A., Avenue de la Gare, 1611 Luxembourg, Luxembourg","A double-blind, cross-over patient preference study of frovatriptan versus rizatriptan for the acute treatment of migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000785-36,0,0,0 2006-000787-88,1,2006-11-16,2006-11-16,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Chiron Vaccines Limited,"A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of FLUVIRIN® Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, when Administered to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000787-88,0,0,0 2006-000788-27,2,2017-12-31,2017-12-31,2,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Royal United Hospital Bath NHS Trust,International Collaborative Infantile Spasms Study (ICISS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000788-27,0,0,0 2006-000789-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,INFAI GmbH,Two-way Crossover Comparison of the Sensitivity and Specificity of the Modified Helicobacter Test INFAI Using New Test Meal vs. Standard 13C-Urea Breath Test in Helicobacter Pylori Positive and Negati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000789-35,0,0,0 2006-000796-15,7,2008-03-03,2008-03-05,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novo Nordisk A/S,"Inhaled pre-prandial human insulin with the AERx® iDMS plus metformin versus rosiglitazone plus metformin in type 2 diabetes: a 26-week, open-label, multicentre, randomised, parallel trial to investig...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000796-15,0,0,0 2006-000798-31,2,2007-05-16,2007-05-16,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,Nerviano Medical Sciences S.r.l.,Phase II randomized study of nemorubicin hydrochloride (PNU-152243A) or doxorubicin administered in adult patients with unresectable hepatocellular carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000798-31,0,0,0 2006-000798-31,2,2007-05-16,2007-05-16,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,NERVIANO MEDICAL SCIENCES,Phase II randomized study of nemorubicin hydrochloride (PNU-152243A) or doxorubicin administered in adult patients with unresectable hepatocellular carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000798-31,0,0,0 2006-000799-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitätsklinikum Essen,A Study of the efficacy and safety of Rizatriptan 10 mg PRD in the treatment of acute migraine in patients with non satisfactory response to previous pharmacologic treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000799-33,0,0,0 2006-000800-17,9,2008-09-17,2008-09-29,8,1,0,0,0,2,3,0,0,1,0,0,1,0,1,United Therapeutics Corporation,"A 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000800-17,0,0,0 2006-000800-17,9,2008-09-17,2008-09-29,8,1,0,0,0,2,3,0,0,1,0,0,1,0,1,UNITED THERAPEUTICS,"A 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000800-17,0,0,0 2006-000801-50,5,2010-04-29,2011-04-29,4,1,0,0,0,2,3,0,0,1,0,0,1,0,1,UNITED THERAPEUTICS,"A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000801-50,0,0,0 2006-000801-50,5,2010-04-29,2011-04-29,4,1,0,0,0,2,3,0,0,1,0,0,1,0,1,United Therapeutics Corporation,"A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000801-50,0,0,0 2006-000803-40,3,2007-08-17,2007-11-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA Pharma AG,A comparative study of inhaled ciclesonide versus placebo in children with asthma (RAINBOW),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000803-40,0,0,0 2006-000803-40,3,2007-08-17,2007-11-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nycomed GmbH,A comparative study of inhaled ciclesonide versus placebo in children with asthma (RAINBOW),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000803-40,0,0,0 2006-000804-18,11,2019-07-24,2020-02-12,8,1,0,0,0,2,3,0,0,1,0,0,1,0,1,United Therapeutics Corporation,An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000804-18,0,0,0 2006-000804-18,11,2019-07-24,2020-02-12,8,1,0,0,0,2,3,0,0,1,0,0,1,0,1,UNITED THERAPEUTICS,An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000804-18,0,0,0 2006-000805-42,4,2008-11-03,2008-11-03,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Menarini International Operations Luxembourg S.A.,","A double-blind, cross-over patient preference study of frovatriptan versus zolmitriptan for the acute treatment of migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000805-42,0,0,0 2006-000805-42,4,2008-11-03,2008-11-03,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Menarini International Operations Luxembourg S.A., Avenue de la Gare, 1611 Luxembourg, Luxembourg","A double-blind, cross-over patient preference study of frovatriptan versus zolmitriptan for the acute treatment of migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000805-42,0,0,0 2006-000810-18,1,2014-03-06,2014-03-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Marsden Hospital,A Randomised Study to Investigate the Effectiveness of Acupuncture for the Relief of Dyspnoea in Patients with Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000810-18,0,0,0 2006-000811-12,2,2018-11-30,2018-11-30,2,1,0,0,0,0,2,0,0,1,1,0,1,0,0,Medizinische Fakultät der Technischen Universität München,A Randomised Phase II/III trial of peri-operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000811-12,0,0,0 2006-000811-12,2,2018-11-30,2018-11-30,2,1,0,0,0,0,2,0,0,1,1,0,1,0,0,Medical Research Council Clinical Trials Unit,A Randomised Phase II/III trial of peri-operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000811-12,0,0,0 2006-000813-39,2,2007-06-20,2007-06-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,Prasugrel in comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation (PRINCIPLE) - TIMI 44,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000813-39,0,0,0 2006-000815-24,1,2006-10-31,2006-10-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Charité,A randomized study of topical 3% Diclofenac in a 2.5% Hyaluronate base (Solaraze® 3% Gel) versus topical 5% 5-Fluorouracil (Efudix® Cream) versus liquid nitrogen spray cryotherapy in immunosufficient ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000815-24,0,0,0 2006-000819-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"HYKS, sisätautien toimiala, diabetesklinikka",RIMONABANT-LÄÄKEHOIDON JA LAIHDUTUKSEN VAIKUTUKSET MAKSAN RASVAPITOISUUTEEN JA RASVAKUDOKSEN AINEENVAIHDUNTAAN METABOLISTA OIREYHTYMÄÄ SAIRASTAVILLA POTILAILLA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000819-16,0,0,0 2006-000821-74,1,2007-12-20,2007-12-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital of Muenster,"A randomized. double-blind, placebo-controlled, phase III trial for the efficacy of Traumeel S in the prevention and treatment of chemotherapie-induced Mucositis in Patients undergoing allogeneic stem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000821-74,0,0,0 2006-000822-30,3,2007-10-08,2007-11-19,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH,"A randomized, double-blind, double-dummy, parallel group trial comparing 12 weeks treatment with tiotropium inhalation capsules 18 mcg via the HandiHaler® once daily to Combivent® Inhalation Aerosol C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000822-30,0,0,0 2006-000822-30,3,2007-10-08,2007-11-19,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd.,"A randomized, double-blind, double-dummy, parallel group trial comparing 12 weeks treatment with tiotropium inhalation capsules 18 mcg via the HandiHaler® once daily to Combivent® Inhalation Aerosol C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000822-30,0,0,0 2006-000828-14,3,2008-05-20,2008-06-03,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With and Without Ribavirin (Copegus®) in Subjects with Hepatitis C",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000828-14,0,0,0 2006-000830-11,1,2010-11-24,2010-11-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Leeds Teaching Hospitals NHS Trust,"A randomised prospective trial of tacrolimus-based steroid avoidance in renal transplantation with either alemtuzumab induction or, basiliximab induction and mycophenolate mofetil maintenance therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000830-11,0,0,0 2006-000832-28,1,2008-10-14,2008-10-14,1,1,0,0,0,3,0,0,0,1,0,0,1,0,0,Liverpool Women's NHS Foundation Trust,Dopamine pharmacokinetics in extremely premature infants: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000832-28,0,0,0 2006-000833-36,1,2011-07-01,2011-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,The Action of Botox® on Urgency – A precise evaluation of its impact on urodynamic parameters during bladder filling in patients with non-neurogenic Overactive Bladder (OAB).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000833-36,0,0,0 2006-000834-11,1,2007-07-31,2007-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),"Estudio multicéntrico fase II, abierto, de tratamiento con cetuximab y capecitabina en primera línea de tratamiento en pacientes ancianos con un cáncer colorrectal metastático",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000834-11,0,0,0 2006-000835-84,4,2007-07-19,2007-07-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Jansen-Cilag International N.V.,"Randomized, Double-Blind, Multicenter Study of Ceftobiprole Medocaril Versus Ceftriaxone with/without Linezolid in Treatment of Subjects Hospitalized With Community-Acquired Pneumonia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000835-84,0,0,0 2006-000837-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Beroendecentrum Stockholm,Effect of Naltrexone on cue-induced craving for Amphetamine in amphetamine dependent individuals,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000837-36,0,0,0 2006-000838-12,1,2008-03-31,2008-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Peter Wolf MD, Department of Dermatology, Medical University of Graz",Die Bedeutung des sensorischen Nervensystems für die Repigmentierung der Haut bei Vitiligo (engl.: The role of the sensory nervous system for repigmentation in vitiligo),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000838-12,0,0,0 2006-000839-10,5,2009-04-23,2009-08-24,3,0,0,0,0,1,3,0,0,2,0,0,0,0,1,BIOMARIN,"A Phase 3b, Multicenter, Open-Label Extension Study of Phenoptin in Subjects with Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000839-10,1,0,0 2006-000839-10,5,2009-04-23,2009-08-24,3,0,0,0,0,1,3,0,0,2,0,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Phase 3b, Multicenter, Open-Label Extension Study of Phenoptin in Subjects with Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000839-10,1,0,0 2006-000844-17,2,2010-05-01,2010-06-29,2,1,0,0,0,0,0,0,0,1,0,0,1,0,0,Vienna Medical University,A multi-centre pilot study of Rituximab in patients with active PsA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000844-17,0,0,0 2006-000845-21,2,2011-02-04,2011-02-04,2,1,0,0,0,1,3,0,0,1,0,0,1,0,0,University Hospital Innsbruck,AN OPEN-LABEL; RANDOMIZED; PROSPECTIVE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CAMPATH-1H AS AN INDUCTION AGENT IN COMBIANTION IWTH TACROLIMUS MONOTHERAPY COMPARED TO SHORT-COURSE ATG-INDUCTIO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000845-21,0,0,0 2006-000846-38,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Janssen-Cilag International N.V.,"A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an Acu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000846-38,0,0,0 2006-000848-65,15,2009-10-05,2011-08-24,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid Zometa 63720; in the Treatment of Bone Metastases in Subjects with Advanced Cancer Excluding Breast and Pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000848-65,0,0,0 2006-000849-19,3,2008-03-18,2008-03-18,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AMGEN S.P.A.,A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women with Low Bone Mineral Density,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000849-19,0,0,0 2006-000849-19,3,2008-03-18,2008-03-18,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc,A Randomized Study to Evaluate Safety and Efficacy of Transitioning Therapy From Alendronate to Denosumab (AMG 162) in Postmenopausal Women with Low Bone Mineral Density,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000849-19,0,0,0 2006-000850-33,5,2007-04-10,2007-04-24,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A double-blind, randomized, multicenter 8 weeks study to evaluate the efficacy and safety of of valsartan / amlodipine combination based therapy versus amlodipine monotherapy based therapy in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000850-33,0,0,0 2006-000850-33,5,2007-04-10,2007-04-24,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Farmaceútica S.A.,"A double-blind, randomized, multicenter 8 weeks study to evaluate the efficacy and safety of of valsartan / amlodipine combination based therapy versus amlodipine monotherapy based therapy in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000850-33,0,0,0 2006-000850-33,5,2007-04-10,2007-04-24,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A double-blind, randomized, multicenter 8 weeks study to evaluate the efficacy and safety of of valsartan / amlodipine combination based therapy versus amlodipine monotherapy based therapy in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000850-33,0,0,0 2006-000853-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,3,Kožní ordinace,"Prospektivní, otevřená, randomizovaná multicentrická studie hodnotící účinnost a bezpečnost pegylovaného interferonu alfa 2a (Pegasys) v adjuvantní léčbě rizikového primárního kožního melanomu",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000853-23,0,0,0 2006-000854-32,1,2009-02-27,2009-02-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Vienna Medical University,Rituximab in Rheumatoid Arthritis in Patients Who Failed Therapy With TNF-Blockers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000854-32,0,0,0 2006-000858-45,3,2008-07-07,2008-07-07,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Solvay Pharmaceuticals,An open label SLV308 safety extension to study S308.3.001 in early PD patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000858-45,0,0,0 2006-000859-18,7,2008-10-12,2008-10-12,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SOLVAY PHARMACEUTICALS B.V.,An open label SLV308 safety extension to study S.308.3.003 in early PD patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000859-18,0,0,0 2006-000859-18,7,2008-10-12,2008-10-12,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Solvay Pharmaceuticals,An open label SLV308 safety extension to study S.308.3.003 in early PD patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000859-18,0,0,0 2006-000859-18,7,2008-10-12,2008-10-12,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Solvay pharmaceuticals,An open label SLV308 safety extension to study S.308.3.003 in early PD patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000859-18,0,0,0 2006-000860-10,3,2006-09-04,2006-09-04,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,H. Lundbeck A/S,An Open-Label Study Investigating the Specific Effects of Memantine in Institutionalised Patients with Alzheimer’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000860-10,1,0,0 2006-000861-12,2,2009-02-02,2009-02-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A one-year partial double-blinded, randomized, multi-center, multi-national study to assess the effects of combination therapy of annual zoledronic acid (5 mg) and daily subcutaneous teriparatide (20 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000861-12,0,0,0 2006-000864-94,4,2014-04-22,2015-04-22,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer (EORTC),A Phase I-II Study of Lapatinib and docetaxel as neoadjuvant treatment for HER-2 positive locally advanced/inflammatory or large operable breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000864-94,0,0,0 2006-000864-94,4,2014-04-22,2015-04-22,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,A Phase I-II Study of Lapatinib and docetaxel as neoadjuvant treatment for HER-2 positive locally advanced/inflammatory or large operable breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000864-94,0,0,0 2006-000865-13,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,0,Univ.Clinic of Dermatology,"Evaluation of the impact from Polypodium leukotomos Extract on the Prophylaxis of Polymorphic Light Eruption (PMLE) An investigator initiated, prospective, open label study with an in Austria regist...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000865-13,0,0,0 2006-000867-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,"Gated 13N-NH3 PET before and during hemodialysis for the assessment of changes in myocardial perfusion, volumes and output of the left ventricle",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000867-27,0,0,0 2006-000868-83,2,2009-07-02,2009-07-02,2,0,0,1,0,1,1,0,0,1,0,0,0,0,1,Clavis Pharma ASA,A Phase I/II Study of CP-4055 in Patients with Refractory/Relapsed Hematologic Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000868-83,0,0,0 2006-000869-11,1,2008-08-28,2008-08-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Neuro-Consil GmbH,Comparison of efficacy and tolerability of rapid intravenous infusion of levetiracetam and sodium valproat.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000869-11,0,0,0 2006-000870-63,2,2010-04-16,2010-06-30,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche Ltd,"A phase IV, 2x2 factorial, double blind study of 24 versus 48 weeks and 90 versus 180 mcg doses of pegylated interferon alfa 2a 40KD (PEG IFN, Ro 25-8310) in adult patients with HBeAg positive chronic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000870-63,0,0,0 2006-000870-63,2,2010-04-16,2010-06-30,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A phase IV, 2x2 factorial, double blind study of 24 versus 48 weeks and 90 versus 180 mcg doses of pegylated interferon alfa 2a 40KD (PEG IFN, Ro 25-8310) in adult patients with HBeAg positive chronic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000870-63,0,0,0 2006-000871-13,1,2006-10-30,2006-10-30,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Merck KGaA,"A Phase I/II, Open Label, Dose-Escalating Study Evaluating the Safety and Efficacy of the Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody EMD 72000 (Matuzumab) in Combination with the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000871-13,0,0,0 2006-000873-32,1,2008-07-30,2008-07-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Royal Group of Hospitals Trust,Effect of statin therapy on monocyte function in the metabolic syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000873-32,0,0,0 2006-000874-56,7,2009-03-25,2009-03-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A prospective, randomized, double dummy, double blind, multi-center trial comparing the safety and efficacy of moxifloxacin 400 mg IV QD 24 hours to that of ertapenem 1.0 g IV QD 24 hours for 5 to 14 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000874-56,0,0,0 2006-000875-14,2,2008-06-17,2008-06-17,1,0,0,0,0,0,4,0,0,2,0,0,0,0,1,AIR LIQUIDE SANTE INTERNATIONAL,"Short-, and long-term effects of the intra-operative nitrous oxide administration on the remifentanil-induced post-operative hyperalgesia, morphine consumption and long-term quality of life",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000875-14,1,0,0 2006-000877-30,1,2007-02-16,2007-02-16,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare International,"A 6 week, multi centre study to evaluate the efficacy and safety of E45 complete emollient therapy and E45 itch relief cream in the treatment of mild to moderate atopic eczema compared to a patients n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000877-30,0,0,0 2006-000880-27,7,2013-06-24,2013-06-24,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000880-27,0,0,0 2006-000880-27,7,2013-06-24,2013-06-24,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.",A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000880-27,0,0,0 2006-000880-27,7,2013-06-24,2013-06-24,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000880-27,0,0,0 2006-000881-35,7,2008-04-25,2008-07-08,4,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000881-35,0,0,0 2006-000881-35,7,2008-04-25,2008-07-08,4,1,0,0,0,2,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A phase II, multicentre study of oral LBH589 in patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000881-35,0,0,0 2006-000889-36,4,2011-01-10,2011-02-01,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly and Company limited,"A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000889-36,0,0,0 2006-000889-36,4,2011-01-10,2011-02-01,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000889-36,0,0,0 2006-000891-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hôpital Ambroise Paré,"A randomized, international, open-label, phase II study of peripheral blood progenitor cell (PBPC) mobilization and engraftment with pegfilgrastim or filgrastim for autologous transplantation in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000891-34,0,0,0 2006-000897-65,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA,Therapy of tumors SSTR2 expressing using somatostatine analogs labeled with 90Y and 177 Lu.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000897-65,0,0,0 2006-000898-30,1,2007-09-17,2007-09-17,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur Incorporated,"Safety and Immunogenicity of Booster Vaccination with PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjuga...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000898-30,0,0,0 2006-000899-32,2,2009-05-05,2009-06-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"EMD Pharmaceuticals, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany","Randomized, phase II, open-label controlled study of two different doses and schedules of EMD 72000 (matuzumab) in combination with pemetrexed, or pemetrexed alone, as second-line treatment in subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000899-32,0,0,0 2006-000899-32,2,2009-05-05,2009-06-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"EMD Pharmaceuticals, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany)","Randomized, phase II, open-label controlled study of two different doses and schedules of EMD 72000 (matuzumab) in combination with pemetrexed, or pemetrexed alone, as second-line treatment in subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000899-32,0,0,0 2006-000900-17,1,2010-12-06,2010-12-06,1,1,0,0,0,1,4,0,0,1,1,1,1,0,0,The University of Manchester,"A randomised double-blind placebo controlled trial of the oral bisphosphonate, Alendronate, plus intravenous pamidronate, in active diabetic Charcot neuroarthropathy (CN).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000900-17,0,0,0 2006-000900-17,1,2010-12-06,2010-12-06,1,1,0,0,0,1,4,0,0,1,1,1,1,0,0,Central Manchester and Manchester Children's University NHS trust,"A randomised double-blind placebo controlled trial of the oral bisphosphonate, Alendronate, plus intravenous pamidronate, in active diabetic Charcot neuroarthropathy (CN).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000900-17,0,0,0 2006-000905-41,1,2006-11-30,2006-11-30,1,0,0,0,1,1,4,0,0,1,0,0,1,0,0,ao. Univ. Prof. Dr. Elisabeth Aberer,"Offene, monozentrische, randomisierte, placebo-kontrollierte, einfach blinde und Observer-blinde klinische Studie bei PatientInnen mit Raynaud Syndrom mit / ohne progressiver systemischer Sklerodermie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000905-41,0,0,0 2006-000907-41,1,2006-11-29,2006-11-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A single dose, randomised, double blind, double dummy, placebo-controlled, three-period crossover clinical study, comparing the efficacy, safety and tolerability of Formoterol-HFA pMDI 12 microgram p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000907-41,0,0,0 2006-000908-17,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SENESE,Medical therapy of keratoconus with Riboflavin/Ultraviolet-A collagen Cross-Linking and investigation of the corneal stromal and Keratocytes modifications apoptosis and stromal repopulation with con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000908-17,0,0,0 2006-000910-19,2,2009-03-24,2011-03-24,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,TopoTarget A/S,"A multi-centre, two-stage, open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with advanced melanoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000910-19,0,0,0 2006-000910-19,2,2009-03-24,2011-03-24,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Apoxis SA,"A multi-centre, two-stage, open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with advanced melanoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000910-19,0,0,0 2006-000914-19,6,2008-10-19,2009-09-10,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,JANSSEN-CILAG INTERNATIONAL NV,"A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000914-19,0,0,0 2006-000914-19,6,2008-10-19,2009-09-10,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000914-19,0,0,0 2006-000914-19,6,2008-10-19,2009-09-10,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Johnson & Johnson Pharmaceutical Research & Development,"A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000914-19,0,0,0 2006-000914-19,6,2008-10-19,2009-09-10,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Janssen-Cilag International N.V.,"A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000914-19,0,0,0 2006-000914-19,6,2008-10-19,2009-09-10,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Janssen-Cilag International N.V., Turnhoutseweg 30, 2340 Beerse, Belgium","A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000914-19,0,0,0 2006-000923-32,1,2009-10-29,2009-10-29,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double-blind, placebo-controlled, Bayesian adaptive dose finding study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat intravenous inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000923-32,0,0,0 2006-000924-15,5,2008-12-08,2008-12-08,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,FOURNIER Laboratories Ireland Ltd,"A randomized, double-blind study comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs metformin alone in patients with type 2 diabetes mellitus and dyslipidemia not...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000924-15,0,0,0 2006-000925-71,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,University Hospital Ghent,"TNF-blockade for the treatment of erosive osteoarthritis (OA) of interphalangeal finger joints. Randomized, double blind, placebo-controlled study to evaluate the efficacy of adalimumab 40 mg sc every...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000925-71,0,0,0 2006-000926-30,3,2007-03-29,2007-03-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA Pharma AG,Investigation of clinical endpoints for treatment-induced gastroesophageal reflux disease (GERD) symptom changes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000926-30,0,0,0 2006-000927-33,1,2007-10-11,2007-10-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Nycomed GmbH,Confirmation of superiority of complete remission concept vs classical healing concept for treatment of patients with erosive GERD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000927-33,0,0,0 2006-000929-59,1,2009-09-30,2009-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bracco ALTANA Pharma GmbH,INTRAINDIVIDUAL CROSS-OVER STUDY TO COMPARE MULTIHANCE® AND MAGNEVIST® AT A DOSE OF 0.1 MMOL/KGBW IN CERVICO-CEREBRAL MR ANGIOGRAPHY AND CEREBRAL MR PERFUSION IMAGING AT 3 TESLA IN PATIENTS WITH CAROT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000929-59,0,0,0 2006-000934-11,1,2011-02-23,2011-02-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Alllergopharma Joachim Ganzer KG,A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacacy of a specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000934-11,0,0,0 2006-000935-86,1,2010-05-24,2010-05-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche Pharma AG,"Randomized, multicentric, partially double blind placebo-controlled phase II study for examining the influence of Ribavirin on the initial virological response in previous untreated patients with chro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000935-86,0,0,0 2006-000936-28,6,2007-10-31,2007-11-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Astellas Pharma GmbH,"A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE LIVER TRANSPLANT PATIEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000936-28,0,0,0 2006-000936-28,6,2007-10-31,2007-11-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Astellas Pharma Europe Ltd,"A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE LIVER TRANSPLANT PATIEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000936-28,0,0,0 2006-000936-28,6,2007-10-31,2007-11-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Astellas Pharma Europe Limited,"A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE LIVER TRANSPLANT PATIEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000936-28,0,0,0 2006-000937-37,4,2007-07-11,2007-07-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma GmbH,"A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE KIDNEY TRANSPLANT PATIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000937-37,0,0,0 2006-000937-37,4,2007-07-11,2007-07-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd,"A MULTICENTER, OPEN, SINGLE SEQUENCE CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF A TACROLIMUS MODIFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN STABLE KIDNEY TRANSPLANT PATIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000937-37,0,0,0 2006-000939-97,2,2006-12-19,2006-12-19,2,1,0,0,1,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIb, controlled, randomised, multicenter, single blind study to demonstrate the Non-Inferiority of the low dose influenza vaccine with or without adjuvant AS03 compared with Fluarix™ (GlaxoSmi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000939-97,0,0,0 2006-000945-20,1,2009-02-10,2009-02-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Barts and the London NHS Trust,To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000945-20,0,0,0 2006-000946-38,12,2010-02-01,2010-02-01,10,1,1,0,0,0,3,0,0,2,0,0,0,0,1,sanofi-aventis recherche & développement,International randomized double blind clinical study evaluating the efficacy and safety of clopidogrel 0.2mg/kg once daily versus placebo in neonates and infants with cyanotic congenital heart disea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000946-38,1,1,0 2006-000946-38,12,2010-02-01,2010-02-01,10,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Sanofi-Aventis recherche de veloppement,International randomized double blind clinical study evaluating the efficacy and safety of clopidogrel 0.2mg/kg once daily versus placebo in neonates and infants with cyanotic congenital heart disea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000946-38,1,1,0 2006-000947-24,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Peterborough and Stamford Hospitals NHS Foundation Trust,Evaluating the efficacy of acupuncture versus beconase in the treatment of allergic rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000947-24,0,0,0 2006-000954-31,1,2007-03-22,2007-03-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca Oy,Centralised Pan-European Survey on the Undertreatment of Hyperchlesterolemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000954-31,0,0,0 2006-000955-17,1,2011-11-30,2011-11-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ICT de Navarra S.A.,Estudio Fase II aleatorizado y controlado de tratamiento con cirugía de revascularización con o sin inyección de mioblastos esqueléticos autólogos en pacientes con Infarto de Miocardio Antiguo.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000955-17,0,0,0 2006-000956-42,5,2016-12-05,2018-06-21,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Valeant Research & Development,"A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of Study VRX-RET-E22-302)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000956-42,0,0,0 2006-000956-42,5,2016-12-05,2018-06-21,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline LLC,"A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of Study VRX-RET-E22-302)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000956-42,0,0,0 2006-000956-42,5,2016-12-05,2018-06-21,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Valeant Pharmaceuticals, North America","A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of Study VRX-RET-E22-302)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000956-42,0,0,0 2006-000956-42,5,2016-12-05,2018-06-21,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithkline LLC,"A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of Study VRX-RET-E22-302)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000956-42,0,0,0 2006-000961-12,1,2007-10-31,2007-10-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Roche Pharma AG,Prospective study to investigate if patients on reduced-dose EC-MPS treatment due to gastrointestinal problems can be switched to a higher than the equimolar dose of MMF,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000961-12,0,0,0 2006-000974-54,3,2008-05-15,2008-05-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GALDERMA Research & Development,"A multi-centre, randomized, parallel groups, vehicle and active controlled study of amorolfine 4% and 10% nail lacquer new formulation in the topical treatment of distal and lateral subungual toenail ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000974-54,0,0,0 2006-000977-31,4,2013-09-04,2020-01-29,3,1,1,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000977-31,0,0,0 2006-000977-31,4,2013-09-04,2020-01-29,3,1,1,0,0,0,3,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC HE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000977-31,0,0,0 2006-000978-68,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,AstraZeneca,Treatment of systemic effects in patients with COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000978-68,0,0,0 2006-000980-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación biomedica del Hospital Gregorio Marañon,"""Estudio comparativo, randomizado y de grupos paralelos con PET en pacientes esquizofrénicos de nuevo diagnóstico en tratamiento con Aripiprazol y Risperidona""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000980-26,0,0,0 2006-000985-34,1,2009-09-30,2009-09-30,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Clinical Immunology Division,A Phase I-IIa Study of Dose escalating Intravesical AdCD40L instillation in Urinary Bladder Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000985-34,0,0,0 2006-000987-10,1,2007-07-19,2007-07-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB S.A.,"A double-blind, placebo-controlled, randomized efficacy and safety study of levetiracetam extended release formulation (LEV XR), administered as 2 x 500 mg LEV XR tablets once daily as add-on therapy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000987-10,0,0,0 2006-000987-10,1,2007-07-19,2007-07-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Inc.,"A double-blind, placebo-controlled, randomized efficacy and safety study of levetiracetam extended release formulation (LEV XR), administered as 2 x 500 mg LEV XR tablets once daily as add-on therapy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000987-10,0,0,0 2006-000991-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"Dr. Gerhard Mann, Chem-pharm. Fabrik GmbH","A randomized, double-blind, monocentric phase IV clinical study on the ocular tolerability of a topical ophthalmic product containing Retinolpalmitat 1000 I.U. in comparison to a reference product con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000991-34,0,0,0 2006-000995-33,13,2018-01-30,2018-11-14,11,1,0,0,0,2,0,0,0,1,0,0,1,0,0,Martin Luther University of Halle-Wittemberg,EuroNet-Paediatric Hodgkin's Lymphoma Group / First International inter-group study for classical Hodgkin’s lymphoma in children and adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000995-33,0,0,0 2006-000995-33,13,2018-01-30,2018-11-14,11,1,0,0,0,2,0,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),EuroNet-Paediatric Hodgkin's Lymphoma Group / First International inter-group study for classical Hodgkin’s lymphoma in children and adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000995-33,0,0,0 2006-000995-33,13,2018-01-30,2018-11-14,11,1,0,0,0,2,0,0,0,1,0,0,1,0,0,Martin-Luther-University Halle-Wittenberg,EuroNet-Paediatric Hodgkin's Lymphoma Group / First International inter-group study for classical Hodgkin’s lymphoma in children and adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000995-33,0,0,0 2006-000995-33,13,2018-01-30,2018-11-14,11,1,0,0,0,2,0,0,0,1,0,0,1,0,0,Martin Luther University of Hallle/Wittenburg,EuroNet-Paediatric Hodgkin's Lymphoma Group / First International inter-group study for classical Hodgkin’s lymphoma in children and adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000995-33,0,0,0 2006-000995-33,13,2018-01-30,2018-11-14,11,1,0,0,0,2,0,0,0,1,0,0,1,0,0,Our Lady's Children's Hospital,EuroNet-Paediatric Hodgkin's Lymphoma Group / First International inter-group study for classical Hodgkin’s lymphoma in children and adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000995-33,0,0,0 2006-000995-33,13,2018-01-30,2018-11-14,11,1,0,0,0,2,0,0,0,1,0,0,1,0,0,Martin Luther University of Halle/Wittenberg,EuroNet-Paediatric Hodgkin's Lymphoma Group / First International inter-group study for classical Hodgkin’s lymphoma in children and adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000995-33,0,0,0 2006-000995-33,13,2018-01-30,2018-11-14,11,1,0,0,0,2,0,0,0,1,0,0,1,0,0,"Martin Luther University of Halle/Wittenberg, Medizinische Fakultät, Prodekanat Forschung",EuroNet-Paediatric Hodgkin's Lymphoma Group / First International inter-group study for classical Hodgkin’s lymphoma in children and adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000995-33,0,0,0 2006-001000-37,1,2010-11-18,2010-11-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche Pharma AG,Efficacy and safety of rituximab in patients with rheumatoid arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001000-37,0,0,0 2006-001001-28,2,2006-10-18,2006-11-15,2,0,0,0,0,2,2,0,1,1,0,0,1,0,1,GTx Inc,"Double-blind, placebo controlled, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of GTx-024 in Postmenopausal Females and Elderly Males",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001001-28,0,0,0 2006-001002-83,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Hospital Clinico San Carlos, Unidad de Investigacion Cardiovascular",Pilot study to evaluate the effect of vardenafil treatment on the proteomic pattern of mononuclear cells and serum proteins in patients with erectile dysfunction and mellitus diabetes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001002-83,0,0,0 2006-001007-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST,"OPEN-LABEL, MULTICENTER, PHASE II STUDY OF FIRST- LINE BI-WEEKLY IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV (FOLFOXIRI) IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001007-11,0,0,0 2006-001009-27,13,2009-01-13,2009-02-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001009-27,0,0,0 2006-001009-27,13,2009-01-13,2009-02-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer-Ingelheim AB,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001009-27,0,0,0 2006-001009-27,13,2009-01-13,2009-02-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001009-27,0,0,0 2006-001009-27,13,2009-01-13,2009-02-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001009-27,0,0,0 2006-001009-27,13,2009-01-13,2009-02-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim UK Ltd,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001009-27,0,0,0 2006-001009-27,13,2009-01-13,2009-02-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001009-27,0,0,0 2006-001009-27,13,2009-01-13,2009-02-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim (UK), Ltd","A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001009-27,0,0,0 2006-001009-27,13,2009-01-13,2009-02-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim (UK) Ltd.,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001009-27,0,0,0 2006-001009-27,13,2009-01-13,2009-02-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GesmbH,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001009-27,0,0,0 2006-001009-27,13,2009-01-13,2009-02-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas A.E.,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001009-27,0,0,0 2006-001009-27,13,2009-01-13,2009-02-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001009-27,0,0,0 2006-001009-27,13,2009-01-13,2009-02-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer-Ingelheim,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Long Term (one year) Efficacy and Safety Study of Tiotropium Inhalation Solution 5µg (2 puffs of 2.5µg) Delivered by th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001009-27,0,0,0 2006-001011-29,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Roche (Hellas) S.A.,A phase II study to assess the efficacy of intravenous loading doses of Bondronat 6 mg on metastatic bone pain in patients with breast cancer and skeletal metastases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001011-29,0,0,0 2006-001012-68,2,2010-04-16,2010-04-16,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized 2-Arm, Open Label, Phase II Study of BMS-582664, Administered Orally At A Dose of 800 mg Daily or Doxorubicin Administered Intravenously At A Dose of 60 mg/m2 Every 3 Weeks In Patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001012-68,0,0,0 2006-001014-32,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,PHASE II STUDY OF BAY 43-9006 IN PATIENTS WITH ADVANCED CHOLANGIOCELLULAR CARCINOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001014-32,0,0,0 2006-001031-22,1,2011-03-29,2011-03-29,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,Institute of Cancer Research,The Potentiation of Efficacy of Radiotherapy in Non-Small-Cell Lung Cancer (NSCLC) by Inhibition of Akt Activation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001031-22,0,0,0 2006-001033-18,1,2007-05-25,2007-05-25,1,1,0,0,0,3,4,0,0,1,0,0,1,0,0,Chelsea and Westminster Hospital,Extending low-dose epidural for emergency Caesarean section - a comparison of bicarbonated lidocaine with 0.5% levobupivacaine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001033-18,0,0,0 2006-001035-22,4,2010-09-16,2011-03-04,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Alimera Sciences Inc,"A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 µg/day and ASI-001B 0.2 µg/day Fluocinolone Acetonide Intravitreal Inserts...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001035-22,1,0,0 2006-001035-22,4,2010-09-16,2011-03-04,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Alimera Science Inc,"A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 µg/day and ASI-001B 0.2 µg/day Fluocinolone Acetonide Intravitreal Inserts...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001035-22,1,0,0 2006-001035-22,4,2010-09-16,2011-03-04,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ALIMERA SCIENCES INC,"A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 µg/day and ASI-001B 0.2 µg/day Fluocinolone Acetonide Intravitreal Inserts...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001035-22,1,0,0 2006-001039-23,1,2008-06-30,2008-06-30,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""",A Pilot Phase II Study for the evaluation of efficacy and tolerability of Gammaidroxybutyrate (ALCOVER) administered by oral route as add on treatmant in patients affected by DYT 11 Myoclonic Dystonia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001039-23,0,0,0 2006-001040-31,1,2011-09-28,2011-09-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Technology Dresden,"Treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with 5-Azacytidin (Vidaza®) after hematopoietic stem cell transplantation ""RELAZA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001040-31,0,0,0 2006-001045-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA USL 6 LIVORNO ZONA LIVORNESE,Metronomic chemiotherapic treatment WITH IRINOTECAN Cpt-11 IN PATIENTS WITH metastatic colon-rectal cancer PHARMACODYNAMIC And PHARMACOKINETIC evaluation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001045-34,0,0,0 2006-001046-13,1,,,0,0,0,1,0,3,1,0,1,0,0,0,0,0,1,Dr. Falk Pharma GmbH,Pharmacokinetic interaction study between budesonide and metronidazole in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001046-13,0,0,0 2006-001055-35,1,2010-10-13,2010-10-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Imperial College London,Lapatinib Pre-Surgical Phase 2 Study in Patients with Primary Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001055-35,0,0,0 2006-001061-42,4,2008-10-07,2008-10-07,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals France, Wyeth Research Division","An open-label, multicentre, supplementary and extension study of Etanercept in subjects with Ankylosing Spondylitis (AS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001061-42,0,0,0 2006-001062-17,2,2007-07-27,2007-07-27,2,0,0,0,0,2,2,0,0,1,1,0,1,0,1,Astion Danmark A/S,"Efficacy and safety of ASF-1096 Cream 0.5% in the treatment of patients with newly developed discoid lupus erythematosus (DLE) lesions. A multi centre clinical phase 2, placebo controlled and double ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001062-17,0,0,0 2006-001065-41,4,2009-04-20,2009-04-20,3,0,0,0,0,2,2,0,0,2,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Phase 2 single-arm studies of Gemcitabine in combination with Oxaliplatin in refractory and relapsed pediatric solid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001065-41,1,0,0 2006-001065-41,4,2009-04-20,2009-04-20,3,0,0,0,0,2,2,0,0,2,0,0,0,0,0,Institut Gustave Roussy,Phase 2 single-arm studies of Gemcitabine in combination with Oxaliplatin in refractory and relapsed pediatric solid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001065-41,1,0,0 2006-001065-41,4,2009-04-20,2009-04-20,3,0,0,0,0,2,2,0,0,2,0,0,0,0,0,"University Hospitals of Leicester NHS Trust, Research and Development Directorate",Phase 2 single-arm studies of Gemcitabine in combination with Oxaliplatin in refractory and relapsed pediatric solid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001065-41,1,0,0 2006-001066-16,3,2012-12-15,2012-12-15,1,0,0,0,0,2,2,0,0,2,0,0,0,0,2,John L. Berk,"A randomized, double-blind, placebo-controlled, international multi-center trial of diflunisal on neurologic disease progression in 200 familial amyloid subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001066-16,1,0,0 2006-001066-16,3,2012-12-15,2012-12-15,1,0,0,0,0,2,2,0,0,2,0,0,0,0,2,Boston University- The Amyloid Treatment and Research Program,"A randomized, double-blind, placebo-controlled, international multi-center trial of diflunisal on neurologic disease progression in 200 familial amyloid subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001066-16,1,0,0 2006-001066-16,3,2012-12-15,2012-12-15,1,0,0,0,0,2,2,0,0,2,0,0,0,0,2,"John L. Berk, M.D.","A randomized, double-blind, placebo-controlled, international multi-center trial of diflunisal on neurologic disease progression in 200 familial amyloid subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001066-16,1,0,0 2006-001067-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Gustave Roussy,Etude de phase II de l'association 5-fluoro-uracile - acide folinique (schéma LV5FU2 simplifié) et cetuximab en intraveineux avec une chimiothérapie intra-artérielle hépatique par Oxaliplatine dans le...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001067-39,0,0,0 2006-001072-21,2,2008-04-23,2008-08-11,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,A double-blind placebo-controlled study of the efficacy and safety of the P38 Map Kinase inhibitor SB681323 in patients with neuropathic pain following nerve trauma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001072-21,0,0,0 2006-001075-37,1,2013-11-21,2013-11-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Technology Dresden,A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplantation in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001075-37,0,0,0 2006-001079-39,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Universitätsklinikum Bonn; Klinik und Poliklinik für Psychiatrie und Psychotherapie,"Interozeptive Aufmerksamkeit, Hitze-Schwelle und körperliche Symptome bei Patienten mit einer depressiven Episode, vor und nach Behandlung mit Duloxetin. Eine Pilotstudie mittels funktioneller Magnet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001079-39,0,0,0 2006-001080-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Klinik für Anästhesiologie und Operative Intensivmedizin Klinikum Ludwigshafen,"Einfluss einer fischölhaltigen Fettemulsion (SMOF®) auf die systemische immunologische Antwort, die Leberfunktion und die Utilisation bei parenteral ernährten Patienten auf einer chirurgischen Intensi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001080-38,0,0,0 2006-001081-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Victor Martínez Taboada,Infliximab en pacientes con polimialgia reumática refractaria a corticoides. Ensayo doble ciego controlado con placebo. (Infliximab in patients with rheumatic polymyalgia refractory to corticosteroids...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001081-16,0,0,0 2006-001084-27,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALI GALLIERA,Phase I/II study of prevention of Colorectal Cancer CRC with Allopurinol in High-Risk Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001084-27,0,0,0 2006-001085-17,1,2008-08-29,2008-08-29,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Bristol,Further development of a new model of GAD: The effect of a clinically effective and non−effective dose of lorazepam on CO2 induced anxiety,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001085-17,0,0,0 2006-001090-23,1,2009-12-18,2009-12-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,"Testosterone therapy as an adjunct to exercise rehabilitation: effects on exercise capacity, inflammatory markers and quality of life in hypogonadal males with chronic heart failure.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001090-23,0,0,0 2006-001094-15,1,2008-03-26,2008-03-26,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Oxford Radcliffe Hospitals NHS Trust (Cancer Research UK Medical Oncology Unit, Churchill Hospital)",Dose-banding of carboplatin: Effect on area under the plasma concentration - time curve (AUC) compared with individualised dosing,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001094-15,0,0,0 2006-001095-21,1,,,0,1,0,0,1,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc.,"Immunogenicity and Safety of PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed), Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001095-21,0,1,1 2006-001097-24,1,2015-08-13,2015-08-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Technische Universitaet Muenchen, Medizinische Fakultaet",Phase I/II study of continous infusion with 5-FU and weekly Oxaliplatin / Cetuximab combined with concurrent radiation as neoadjuvant treatment in locally advanced oesophageal squamous cell carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001097-24,0,0,0 2006-001099-20,5,2007-06-05,2007-10-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"An international, seven-week, double blind, placebo-controlled, two parallel group study to assess the efficacy of dianicline 40 mg bid as an aid to smoking cessation in cigarette smokers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001099-20,0,0,0 2006-001099-20,5,2007-06-05,2007-10-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"An international, seven-week, double blind, placebo-controlled, two parallel group study to assess the efficacy of dianicline 40 mg bid as an aid to smoking cessation in cigarette smokers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001099-20,0,0,0 2006-001104-36,1,2007-11-28,2007-11-28,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Dundee (Research & Innovation Services),COMPARATIVE LUNG BIOAVAILABILITY OF HFA-SERETIDE VIA SPACER DEVICES IN HEALTHY VOLUNTEERS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001104-36,0,0,0 2006-001107-10,1,2007-02-01,2007-02-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Heidelberg Pharma GmbH,"A randomized, double-blind, placebo-controlled, phase II, dose finding, multicenter study to explore the safety, tolerability, efficacy, and pharmacokinetics of fosalvudine tidoxil capsules in antiret...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001107-10,0,0,0 2006-001108-35,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Clinic of University of Wuerzburg,"CHANGES OF LEFT VENTRICULAR MASS AND CARDIAC FUNCTION IN PATIENTS WITH ACTIVE ACROMEGALY DURING TREATMENT WITH THE GROWTH HORMONE RECEPTOR ANTAGONIST PEGVISOMANT: AN OPEN-LABELLED, PROSPECTIVE STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001108-35,0,0,0 2006-001109-28,1,2011-06-06,2011-06-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Aberdeen,Perhexiline therapy in patients with heart failure with preserved left ventricular ejection fraction(HFpEF syndrome),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001109-28,0,0,0 2006-001125-26,1,2011-05-25,2011-05-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Aberdeen,A randomised controlled trial of oral l-arginine supplementation on platelet and endothelial function and walking distance in patients with peripheral arterial disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001125-26,0,0,0 2006-001126-90,1,2007-06-08,2007-06-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Hermal Kurt Herrmann GmbH & Co. OHG,Evaluation of safety and efficacy of Curatoderm® Emulsion in the treatment of patients with mild to moderate plaque psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001126-90,0,0,0 2006-001128-38,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Uppsala University Hospital,DNA Vaccine Coding for the Rhesus Prostate Specific Antigen (rhPSA) and Electroporation in Patients with Relapsed Prostate Cancer. A Phase I/II Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001128-38,0,0,0 2006-001130-41,1,2009-09-30,2009-09-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Laboratorios LETI, S.L. Unipersonal","Ensayo clínico prospectivo, randomizado, doble ciego, paralelo, controlado frente a placebo de inmunoterapia sublingual con extracto alergénico despigmentado y polimerizado con glutaraldehído de Olea ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001130-41,0,0,0 2006-001132-45,4,2008-01-29,2008-01-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development","A MULTICENTER, RANDOMIZED, OPEN LABEL, SINGLE AND MULTIPLE DOSE STUDY OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 DOSE LEVELS OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001132-45,0,0,0 2006-001132-45,4,2008-01-29,2008-01-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc., Wyeth Research Div., Clinical research and Development","A MULTICENTER, RANDOMIZED, OPEN LABEL, SINGLE AND MULTIPLE DOSE STUDY OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 DOSE LEVELS OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001132-45,0,0,0 2006-001133-18,1,2007-03-16,2007-03-16,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Pharmos Corp.,CANNABINOR DENTAL IMPACTION PAIN STUDY PROOF-OF-CONCEPT DOSE-RANGING STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001133-18,0,0,0 2006-001136-47,1,2008-05-14,2008-05-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació de Lluita contra la SIDA,"ESTUDIO PILOTO, ABIERTO, COMPARATIVO Y RANDOMIZADO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE SAQUINAVIR/RITONAVIR EN MONOTERAPIA vs TERAPIA HAART ESTÁNDAR COMO TERAPIA DE MANTENIMIENTO",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001136-47,0,0,0 2006-001138-42,3,2007-11-20,2007-11-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001138-42,0,0,0 2006-001138-42,3,2007-11-20,2007-11-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001138-42,0,0,0 2006-001139-23,9,2006-04-28,2011-06-30,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PIERRE FABRE MEDICAMENT,"Ensayo en fase III de vinflunina más gemcitabina frente a paclitaxel más gemcitabina en pacientes con cáncer de mama irresecable, localmente recurrente o metastásico, tras quimioterapia adyuvante pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001139-23,0,0,0 2006-001139-23,9,2006-04-28,2011-06-30,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PIERRE FABRE Ltd,"Ensayo en fase III de vinflunina más gemcitabina frente a paclitaxel más gemcitabina en pacientes con cáncer de mama irresecable, localmente recurrente o metastásico, tras quimioterapia adyuvante pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001139-23,0,0,0 2006-001139-23,9,2006-04-28,2011-06-30,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pierre Fabre Médicament,"Ensayo en fase III de vinflunina más gemcitabina frente a paclitaxel más gemcitabina en pacientes con cáncer de mama irresecable, localmente recurrente o metastásico, tras quimioterapia adyuvante pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001139-23,0,0,0 2006-001139-23,9,2006-04-28,2011-06-30,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PIERRE FABRE PHARMA,"Ensayo en fase III de vinflunina más gemcitabina frente a paclitaxel más gemcitabina en pacientes con cáncer de mama irresecable, localmente recurrente o metastásico, tras quimioterapia adyuvante pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001139-23,0,0,0 2006-001141-34,1,2007-07-23,2007-07-23,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,LABOpoint GmbH,"Randomised, double-blind, double-dummy, cross-over trial comparing a novel DPI with formoterol versus Oxis Turbohaler 12 µg in patients with stable persistent asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001141-34,0,0,0 2006-001143-59,1,2008-05-31,2008-05-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,School of Human Development,"A prospective, randomised study comparing two fixed daily doses (150 IU versus 225 IU) of recombinant FSH for ovarian stimulation during in-vitro fertilisation treatment in predicted low and intermedi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001143-59,0,0,0 2006-001146-13,1,2006-08-14,2006-08-14,1,1,0,0,0,0,4,0,0,1,1,1,1,0,3,University Hospital of Heidelberg,"""Investigation of Caspofungin Plasma Concentration and Pharmacokinetic for the Improvement of the Antifungal Therapy in Patients of Surgical Intensive Care Unit""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001146-13,0,0,0 2006-001150-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Gent,Sandostatin LAR in prevention of Chemotherapy Induced Diarrhea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001150-27,0,0,0 2006-001151-35,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,PFIZER,AN EXPLORATIVE STUDY OF THE TOLERABILITY OF SU011248 IN COMBINATION WITH DOCETAXEL AND TRASTUZUMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH BREAST CANCER OVER-EXPRESSING HER-2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001151-35,0,0,0 2006-001151-35,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Pfizer Global Research & Development, La Jolla Laboratories",AN EXPLORATIVE STUDY OF THE TOLERABILITY OF SU011248 IN COMBINATION WITH DOCETAXEL AND TRASTUZUMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH BREAST CANCER OVER-EXPRESSING HER-2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001151-35,0,0,0 2006-001152-12,12,2016-02-05,2017-02-07,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & développement,"An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001152-12,0,0,0 2006-001152-12,12,2016-02-05,2017-02-07,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"An international, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two year treatment with teriflunomide 7 mg once daily and 14 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001152-12,0,0,0 2006-001156-12,1,2006-11-28,2006-11-28,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,Santen Oy,Corneal penetration of timolol into the human aqueous humor after administration of 0.1% Timosan eye gel or 0.5% timolol eye drops,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001156-12,0,0,0 2006-001161-42,5,2011-08-30,2011-08-30,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Biogen Idec Ltd.,"Multicentre, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects with Relapsing-Remitting Multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001161-42,0,0,0 2006-001161-42,5,2011-08-30,2011-08-30,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Biogen Idec Ltd,"Multicentre, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects with Relapsing-Remitting Multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001161-42,0,0,0 2006-001163-29,1,2008-12-15,2008-12-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,RESCUE CHEMIOTERAPY WITH MI Mitomicina e Isofosfamide in pancreatic adenocarcinoma with metastasis a phase II study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001163-29,0,0,0 2006-001164-24,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI,MAINTENANCE TREATMENT WITH ALEMTUZUMAB Campath AS AN ALTERNATIVE TO ALLOGENIC TRANSPLANTATION IN PATIENTS WITHOUT COMPATIBLE DONOR IN PATIENTS WITH PERIPHERAL T CELL LYMPHOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001164-24,0,0,0 2006-001168-22,2,2007-07-10,2009-12-04,2,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A phase II, randomized, open, partially controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001168-22,0,0,0 2006-001168-22,2,2007-07-10,2009-12-04,2,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, randomized, open, partially controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001168-22,0,0,0 2006-001169-40,4,2006-12-18,2006-12-18,4,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIb, controlled, randomised, multicenter, observer blinded study to demonstrate the lot-to-lot consistency of three consecutive production lots of low dose of influenza vaccine adjuvanted with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001169-40,0,0,0 2006-001173-14,10,2007-12-20,2008-06-06,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ELI LILLY,A Randomised Phase 3 Trial of Alimta (pemetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001173-14,0,0,0 2006-001173-14,10,2007-12-20,2008-06-06,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company Limited,A Randomised Phase 3 Trial of Alimta (pemetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001173-14,0,0,0 2006-001173-14,10,2007-12-20,2008-06-06,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Lilly S.A.,A Randomised Phase 3 Trial of Alimta (pemetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001173-14,0,0,0 2006-001174-25,1,2007-10-30,2007-10-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,EFFECT OF REMIFENTANIL AND PRPOPOFOL TIMING ADMINISTRATION ON THE DEEPNESS OF HYPNOSIS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001174-25,0,0,0 2006-001179-39,2,2008-06-24,2008-06-24,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Procter & Gamble Pharmaceuticals,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-group, Multicentre, 24 week Study to Evaluate the Efficacy and Safety of Transdermal Testosterone (300 mcg/day) in Naturally Menopausal Women w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001179-39,0,0,0 2006-001182-41,1,2009-10-09,2009-10-09,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Ass.Prof. Petros Sfikakis,"Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: a Randomized, Double-Masked, Placebo-Controlled, Cross-over, 32 Weeks Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001182-41,0,0,0 2006-001183-24,12,2010-02-11,2010-04-29,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ACTELION PHARMACEUTICALS LTD,"Efectos de Bosentan sobre la morbilidad y mortalidad en pacientes con Fibrosis Pulmonar Idiopática- Estudio fase III, multicéntrico, randomizado, de grupos paralelos, doble ciego, controlado con plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001183-24,0,0,0 2006-001183-24,12,2010-02-11,2010-04-29,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals LTD,"Efectos de Bosentan sobre la morbilidad y mortalidad en pacientes con Fibrosis Pulmonar Idiopática- Estudio fase III, multicéntrico, randomizado, de grupos paralelos, doble ciego, controlado con plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001183-24,0,0,0 2006-001184-29,1,2009-03-11,2009-03-11,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Spirig Pharma AG,"A controlled, randomized, evaluator-blinded study for the assessment of efficacy and safety of Imazol® Paste and Multilind® Heilsalbe in infants with diaper dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001184-29,0,0,0 2006-001185-17,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Ineos Healthcare Ltd,"A long-term, open-label continuation study to assess the safety of Alpharen™ in haemodialysis subjects with hyperphosphataemia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001185-17,0,0,0 2006-001186-42,1,2006-08-28,2006-08-28,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,Astion Danmark A/S,Determination of antipsoriatic efficacy of topical formulations in a psoriasis plaque test,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001186-42,0,0,0 2006-001193-25,4,2007-08-28,2007-08-28,4,1,0,0,0,2,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 4 week randomised, double blind, placebo controlled, parallel group, phase II, PoP study to assess the efficacy and safety of AZD1981 in adult patients with asthma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001193-25,0,0,0 2006-001194-14,4,2013-08-30,2016-08-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Double-blind, Phase III Study to Compare the Efficacy and Safety of AZD2171 when added to 5 fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001194-14,0,0,0 2006-001195-21,1,2008-05-22,2008-05-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Double-blind, Randomised, Parallel Group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Mono-therapy in the Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001195-21,0,0,0 2006-001196-38,2,2008-02-04,2008-02-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) as Mono-Therapy in the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001196-38,0,0,0 2006-001197-24,4,2007-09-18,2007-09-18,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase II, Double-blind, Randomised, Parallel Group, Multi-centre Study Comparing gefitinib 250 mg (IRESSA™) with erlotinib 150 mg (Tarceva®) in Previously Treated Patients with Locally Advanced or M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001197-24,1,0,0 2006-001198-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Sligo General Hospital,Improving Tolerability of Statins,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001198-18,0,0,0 2006-001200-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,St. Eriks Eye Hospital,"A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin) versus verteporfin photodynamic therapy (PDT) in patients with neovascular age-related macular degeneratio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001200-36,0,0,0 2006-001201-28,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,"Department of Gynaecology, Helse Finnmark, Klinikk Hammerfest",Self-administered vaginal misoprostol at home for cervical ripening prior to outpatient hysteroscopy: a randomised placebo-controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001201-28,0,0,0 2006-001202-84,1,2013-01-01,2013-01-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001202-84,0,0,0 2006-001204-36,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO NEUROLOGICO CARLO BESTA,Open pilot study for the evaluation of the analgesic effect of buprenorphine TDS administered as add-on treatment in patients with chronic neuropathic pain inadequately controlled by conventional ther...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001204-36,0,0,0 2006-001208-35,1,2009-09-07,2009-09-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Esteban Ribera Pascuet,"A multicentre, randomised study comparing the starting treatment with full dose or dose escalation of nevirapine in patients needing efavirenz withdrawal due to adverse reactions. Estudio multicéntric...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001208-35,0,0,0 2006-001210-33,1,2008-07-15,2008-07-15,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospitals of Leicester NHS Trust,A cohort study of anticholinergic drugs in South Asian women with detrusor overactivity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001210-33,0,0,0 2006-001212-72,1,2013-04-10,2013-04-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital of Heidelberg,Therapie des nodalen Follikulären Non-Hodgkin-Lymphoms (WHO Grad I/II) im klinischen Stadium I / II mittels involved-field Bestrahlung in Kombination mit Rituximab (Mabthera Involved-field Radiotherap...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001212-72,0,0,0 2006-001217-15,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,1,Lassila Riitta,"PRO-FEIBA. Asetelma on selkeä etenevä satunnaistettu kaksisuuntainen tutkimus aktivoitujen hyytymistekijöiden (aPCC, activated prothrombin complex concentrate) vaikutuksesta vaikeaa A hemofiliaa saira...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001217-15,0,0,0 2006-001218-34,1,2007-11-20,2007-11-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on glucagon counterregulatory response during hypoglycemia in patients with type 2 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001218-34,0,0,0 2006-001219-31,1,2007-10-02,2007-10-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A single-center, double-blind, randomized, placebo-controlled, cross-over study to assess the effect of vildagliptin on the incretin effect in patients with type 2 diabetes treated with metformin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001219-31,0,0,0 2006-001222-46,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,Klaus Olkkola,Interaction of rocuronium with nitrous oxide as quantified by closed-loop feedback control / Typpioksiduulin vaikutus rokuronin annostarpeeseen käytettäessä rokuronin tietokoneohjattua annostelua,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001222-46,0,0,0 2006-001228-37,4,2007-08-03,2007-08-03,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Bayer HealthCare AG, D-51368 Leverkusen","A randomized, double blind, parallel group study of vardenafil flexible dose versus placebo in males with erectile dysfunction and their female partners’ sexual quality of life. PARTNER II",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001228-37,0,0,0 2006-001230-41,8,2008-10-02,2008-10-10,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PIERRE FABRE MEDICAMENT,"A EUROPEAN PHASE III, MULTICENTRE, DOUBLE-BLIND, RANDOMISED, MONOTHERAPY, 12-MONTH STUDY OF MILNACIPRAN FOR THE TREATMENT OF THE FIBROMYALGIA SYNDROME",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001230-41,0,0,0 2006-001232-42,1,2009-08-01,2009-08-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Royal Group of Hospitals Trust,The Pharmacogenetics of Aspirin Resistance,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001232-42,0,0,0 2006-001234-40,1,2008-01-21,2008-01-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"Estudio aleatorizado, doble ciego, controlado con placebo para investigar la seguridad, tolerabilidad y actividad clínica de dosis orales repetidas de 7,5 mg de GW856553 dos veces al día durante 28 d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001234-40,0,0,0 2006-001237-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Raitakari Olli,Imaging the vulnerable carotid artery atherosclerotic plaque,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001237-17,0,0,0 2006-001238-41,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,Phase II trial of Erlotinib in combination with increasing dose of gemcitabine given as fixed dose rate infusion in advanced pancreatic cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001238-41,0,0,0 2006-001240-30,13,2006-11-10,2008-03-12,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,Long term double blind comparison of gliclazide MR (30 to 120 mg daily per os) and rosiglitazone (4 to 8 mg daily per os) given in combination with metformin in type 2 diabetic patients. A 2-year inte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001240-30,0,0,0 2006-001243-55,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Miguel Santin Cerezales,"Open, multicenter, phase IV study to evaluate the safety and effectiveness of peginterferon alfa-2a (40 KD) associated with ribavirin for the treatment chronic hepatitis C with persistent normal ALT i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001243-55,0,0,0 2006-001245-33,3,2007-08-07,2007-08-07,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,FAES FARMA S.A.,"Double-blind, randomised, placebo-controlled, phase III study comparing the efficacy and safety of bilastine 20 mg once daily and levocetirizine 5 mg for the treatment of chronic idiopathic urticaria.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001245-33,0,0,0 2006-001246-13,3,2009-12-23,2009-12-23,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Oxford BioMedica UK Ltd.,"An international, randomised, double blind, placebo controlled, parallel group study to investigate whether TroVax®, added to first-line standard of care therapy, prolongs the survival of patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001246-13,0,0,0 2006-001247-64,6,2012-04-13,2012-04-13,4,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy Studio in aperto, stratificat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001247-64,0,0,0 2006-001247-64,6,2012-04-13,2012-04-13,4,1,0,0,0,2,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy Studio in aperto, stratificat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001247-64,0,0,0 2006-001247-64,6,2012-04-13,2012-04-13,4,1,0,0,0,2,2,0,0,1,0,0,1,0,1,"Novartis Farmaceutica, S.A","An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy Studio in aperto, stratificat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001247-64,0,0,0 2006-001248-30,2,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Sanofi-Aventis U.S. Inc.,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 μg administered either in a once-dai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001248-30,0,0,0 2006-001251-35,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Aalborg University,TO STUDY THE PERIPHERAL EFFECT OF BOTULINUM TOXIN-A (BOTOX-A) ON EXPERIMENTALLY INDUCED CUTANEOUS PAIN IN HEALTHY SUBJECTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001251-35,0,0,0 2006-001254-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001254-27,0,0,0 2006-001259-36,1,2009-01-16,2009-01-16,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomised, parallel group, single blind, multicentre, 9-month, phase IV study in a primary care setting, comparing treatment guided by clinical symptoms and signs and NT-proBNP vs treatment guided ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001259-36,0,0,0 2006-001261-42,1,2006-09-15,2006-09-15,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Evotec NeuroSciences GmbH,Assessment of Inhibition of Brain MAO-B by EVT 301 after Repeated Dosing to Steady-state in Patients with Alzheimer’s Disease and in Elderly Control Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001261-42,0,0,0 2006-001263-32,3,2007-08-14,2007-08-14,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,York Pharma GmbH,Phase III study to evaluate the anti-mycotic efficacy of a topical Abafungin formulation in patients with tinea pedis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001263-32,0,0,0 2006-001265-41,1,2010-03-31,2010-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Trust,A comparison of Sirolimus versus Tacrolimus as a delayed treatment of recipients of non heart beating donor kidneys after anti-IL2 monoclonal antibody,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001265-41,0,0,0 2006-001267-33,6,2008-04-28,2011-06-15,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","PHASE 3 RANDOMIZED, MULTI CENTER STUDY OF SUNITINIB MALATE (SU 011248) OR CAPECITABINE IN SUBJECTS WITH ADVANCED BREAST CANCER WHO FAILED BOTH A TAXANE AND AN ANTHRACYCLINE CHEMOTHERAPY REGIMEN OR FAI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001267-33,0,0,0 2006-001267-33,6,2008-04-28,2011-06-15,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer, S.A","PHASE 3 RANDOMIZED, MULTI CENTER STUDY OF SUNITINIB MALATE (SU 011248) OR CAPECITABINE IN SUBJECTS WITH ADVANCED BREAST CANCER WHO FAILED BOTH A TAXANE AND AN ANTHRACYCLINE CHEMOTHERAPY REGIMEN OR FAI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001267-33,0,0,0 2006-001267-33,6,2008-04-28,2011-06-15,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Pharma GmbH,"PHASE 3 RANDOMIZED, MULTI CENTER STUDY OF SUNITINIB MALATE (SU 011248) OR CAPECITABINE IN SUBJECTS WITH ADVANCED BREAST CANCER WHO FAILED BOTH A TAXANE AND AN ANTHRACYCLINE CHEMOTHERAPY REGIMEN OR FAI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001267-33,0,0,0 2006-001267-33,6,2008-04-28,2011-06-15,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"PHASE 3 RANDOMIZED, MULTI CENTER STUDY OF SUNITINIB MALATE (SU 011248) OR CAPECITABINE IN SUBJECTS WITH ADVANCED BREAST CANCER WHO FAILED BOTH A TAXANE AND AN ANTHRACYCLINE CHEMOTHERAPY REGIMEN OR FAI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001267-33,0,0,0 2006-001269-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Charité University Medicine,Induction of Tolerance with Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Severe Systemic Lupus Erythematosus (SLE) Refractory to Standard Immunosuppressive Thera...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001269-40,0,0,0 2006-001270-24,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Pfizer Pharma GmbH,"Phase 2, single arm study of ticilimumab in patients with refractory metastatic adenocarcinoma of the colon or rectum",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001270-24,0,0,0 2006-001271-38,2,2009-08-20,2009-08-20,1,0,0,0,0,2,2,0,0,2,0,0,0,0,0,Our Lady's Hospital for Sick Children,Intensified pre-operative chemotherapy and radical surgery for HIGH RISK HEPATOBLASTOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001271-38,1,0,0 2006-001271-38,2,2009-08-20,2009-08-20,1,0,0,0,0,2,2,0,0,2,0,0,0,0,0,SIOP,Intensified pre-operative chemotherapy and radical surgery for HIGH RISK HEPATOBLASTOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001271-38,1,0,0 2006-001272-21,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERO-UNIVERSITARIA S. MARIA DELLA MISERICORDIA DI UDINE,"Phase II trial of second line therapy with Oxaliplatin and Pemetrexed in patients with advanced pancreatic cancer Trattamento di seconda linea nell'adenocarcinoma del pancreas metastatico, in progr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001272-21,0,0,0 2006-001275-38,2,2006-10-20,2007-04-27,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline R&D,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Study To Evaluate Efficacy, Safety And Tolerability Of Oral GW677954 Capsules (2.5, 5, 10, 15 And 20 Mg Once ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001275-38,0,0,0 2006-001276-20,1,2007-06-14,2007-06-14,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,GlaxoSmithKline GmbH & Co. KG,"A randomized, open-label, multicenter, parallel-group study to compare the efficacy, safety and resource utilization of a remifentanil/propofol analgosedation regimen versus a sufentanyl/propofol anal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001276-20,0,0,0 2006-001278-26,1,2010-07-05,2010-07-05,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001278-26,0,0,0 2006-001279-39,2,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,Bristol-Myers Squibb International Corporation,A Phase II Study of Dasatinib (BMS-354825) in Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001279-39,0,0,0 2006-001281-16,4,2006-10-25,2007-07-31,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, observer-blind, randomised study to evaluate the safety and immunogenicity of one and two administrations of pandemic monovalent (H5N1) influenza vaccine (split virus formulation containi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001281-16,0,0,0 2006-001281-16,4,2006-10-25,2007-07-31,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A phase III, observer-blind, randomised study to evaluate the safety and immunogenicity of one and two administrations of pandemic monovalent (H5N1) influenza vaccine (split virus formulation containi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001281-16,0,0,0 2006-001284-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,air liquide sante international,"pain relief management by kalinox 170 bar for short-time painful procedure in paediatric patients ""alivio del dolor con kalinox 170 bar en pacientes pediatricos sometidos a procedimientos dolorosos d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001284-33,0,0,0 2006-001286-42,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Aastrom Biosciences, Inc","Multi-center, Multi-national Clinical Trial of the Application of Tissue Repair Cell (TRC) Therapy of Osteonecrosis in the Femur Head",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001286-42,0,0,0 2006-001287-23,6,2012-01-24,2012-01-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Limited,An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator selected OBR in HIV-1 infected subjects who participated in a DUET trial TMC125-C206 or TMC125-C216,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001287-23,0,0,0 2006-001287-23,6,2012-01-24,2012-01-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,An open-label trial with TMC125 as part of an ART including TMC114/rtv and an investigator selected OBR in HIV-1 infected subjects who participated in a DUET trial TMC125-C206 or TMC125-C216,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001287-23,0,0,0 2006-001294-18,3,2012-07-03,2012-07-03,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Kuros Biosurgery AG,"A phase 2 randomised, open-label, multi-centre ascending dose study of the efficacy, safety and tolerability of I-040302 versus control injection (bone marrow aspirate or steroids) in children and you...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001294-18,0,0,0 2006-001298-57,4,2008-02-28,2008-02-28,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GUERBET,"Comparison of the diagnostic efficacy of Xenetix 350 and Iomeron 400, for visualisation of the aorta and abdominal vascular tree with 64-slices computed tomography",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001298-57,0,0,0 2006-001299-19,1,2008-04-17,2008-04-17,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Golden Jubilee National Hospital,Prospective randomised trial comparing intraoperative topical Quixil and intravenous tranexamic acid in reduction of blood loss following primary hip and knee joint replacement surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001299-19,0,0,0 2006-001300-37,2,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Solvay Pharmaceuticals B.V.,"Immunogenicity and reactogenicity of the trivalent influenza subunit vaccine Influvac® for the season 2006/2007. An open, baseline-controlled study in two groups of healthy subjects: adult subjects gr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001300-37,0,0,0 2006-001301-28,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Solvay Pharmaceuticals B.V.,"Immunogenicity and reactogenicity of the trivalent virosomal influenza vaccine Invivac® for the season 2006/2007. An open, baseline-controlled study in two groups of healthy subjects: adult subjects g...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001301-28,0,0,0 2006-001307-11,5,2008-08-04,2008-08-04,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Pfizer Ltd,"A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATHY (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001307-11,0,0,0 2006-001307-11,5,2008-08-04,2008-08-04,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Pfizer Pharma GmbH,"A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATHY (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001307-11,0,0,0 2006-001307-11,5,2008-08-04,2008-08-04,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Pfizer Luxembourg SARL Branch Office Estonia,"A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATHY (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001307-11,0,0,0 2006-001308-35,1,2009-05-25,2009-05-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"The Finsen Center, Rigshospitalet","A phase II study of erlotinib and bevacizumab in patients with advanced upper gastrointestinal carcinomas, refractory or intolerable to standard systemic therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001308-35,0,0,0 2006-001310-32,5,2007-06-25,2007-06-25,5,1,0,0,0,2,3,0,0,1,0,0,1,0,2,Procter & Gamble Technical Centres Limited,"A double-blind, randomized, 6-week, parallel-group clinical trial to assess the safety and efficacy of Asacol 4.8 g/day (800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mg mesalamine tablet) fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001310-32,0,0,0 2006-001311-30,1,2006-12-27,2006-12-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of valsartan 160 mg plus HCTZ 25 mg in hypertensive patients not adequate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001311-30,0,0,0 2006-001313-15,1,2008-07-24,2008-07-24,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,University of Dundee,Cranberry product versus low dose trimethoprim in the prevention of recurrent urinary infections in older women: a double blind randomised trial of effectiveness and acceptability,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001313-15,0,0,0 2006-001316-76,1,2007-10-22,2007-10-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca GmbH,"A randomized, open, parallel-group, multi-centre, phase IV study to evaluate the efficacy of three different patient management strategies with and without esomeprazole 20 mg during a 3 months mainten...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001316-76,0,0,0 2006-001317-15,1,2006-09-15,2006-09-15,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Oxford,BALANCE 2: Bipolar disorder:Antidepressant/Lamotrigine/ANtipsychotic Comparative Evaluation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001317-15,0,0,0 2006-001321-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset,Prövning av hypotesen att lågdosinfusion av adenosin hos patienter med ischemisk hjärtsjukdom har en prekonditionerande effekt. En placebokontrollerad crossover-studie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001321-25,0,0,0 2006-001322-25,1,2007-07-11,2007-07-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A PHASE 2b MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001322-25,0,0,0 2006-001334-40,2,2009-09-24,2009-09-24,1,0,0,0,0,0,2,0,0,1,1,0,1,0,1,PLETHORA SOLUTIONS LIMITED,"A double-blind, placebo controlled study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients symptoms of overactive bladder (OAB)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001334-40,0,0,0 2006-001335-22,2,2007-03-02,2007-03-16,2,1,0,0,2,0,3,0,0,1,0,0,1,0,2,MERCK SHARP DOHME,"A Multicenter, Double-Blind, Placebo and Active Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100mg Once Daily in Patients with Type 2 Diabetes With I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001335-22,0,0,0 2006-001335-22,2,2007-03-02,2007-03-16,2,1,0,0,2,0,3,0,0,1,0,0,1,0,2,Merck Sharp & Dohme (Sweden) AB,"A Multicenter, Double-Blind, Placebo and Active Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100mg Once Daily in Patients with Type 2 Diabetes With I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001335-22,0,0,0 2006-001337-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Max-Planck-Institute of Psychiatry,Characterisation of multiple sclerosis pathology by “ultra small particles of iron oxide (USPIO)” in comparison with conventional and advanced MRI imaging techniques [Charakterisierung der Multiple S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001337-17,0,0,0 2006-001341-34,2,2011-01-24,2011-01-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & developpement,"Open label, uncontrolled study of XRP9881 in combination with trastuzumab (Herceptin®) in patients with HER2 positive metastatic breast cancer (MBC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001341-34,0,0,0 2006-001341-34,2,2011-01-24,2011-01-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"Open label, uncontrolled study of XRP9881 in combination with trastuzumab (Herceptin®) in patients with HER2 positive metastatic breast cancer (MBC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001341-34,0,0,0 2006-001343-55,4,2007-09-21,2007-10-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer, S.A.","A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001343-55,0,0,0 2006-001343-55,4,2007-09-21,2007-10-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Ltd,"A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001343-55,0,0,0 2006-001343-55,4,2007-09-21,2007-10-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Luxembourg SARL Branch Office in Lithuania,"A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001343-55,0,0,0 2006-001347-66,3,2008-08-14,2008-08-14,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,PFIZER,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER GAD SWITCHING FROM BENZODIAZEPINE THERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001347-66,0,0,0 2006-001347-66,3,2008-08-14,2008-08-14,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Pfizer España,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER GAD SWITCHING FROM BENZODIAZEPINE THERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001347-66,0,0,0 2006-001347-66,3,2008-08-14,2008-08-14,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER GAD SWITCHING FROM BENZODIAZEPINE THERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001347-66,0,0,0 2006-001352-13,1,2008-12-17,2008-12-17,1,0,0,0,1,0,3,0,0,1,0,0,1,0,1,Isotechnika Inc,"A PHASE III, RANDOMIZED, MULTICENTRE, DOUBLE-BLIND, PLACEBO AND CYCLOSPORINE CONTROLLED STUDY OF ISA247 IN PLAQUE PSORIASIS PATIENTS (ISA05-25)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001352-13,0,0,0 2006-001353-96,1,2012-05-31,2012-05-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Universitätsklinikum Würzburg,Wirksamkeit eines Elterntrainings zur Behandlung der Aufmerksamkeitsdefizit- und Hyperaktivitätsstörung (ADHS) bei Kindern in Abhängigkeit von der Behandlung ihrer ebenfalls betroffenen Mütter mit ent...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001353-96,0,0,0 2006-001354-28,3,2014-05-20,2014-05-30,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer Not...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001354-28,0,0,0 2006-001354-28,3,2014-05-20,2014-05-30,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer Not...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001354-28,0,0,0 2006-001358-29,1,2008-08-15,2008-08-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ARQule Inc.,"A Phase 2 Study of ARQ 501 in Combination with Gemcitabine in Adult Patients with Treatment Naive, Unresectable Pancreatic Adenocarcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001358-29,0,0,0 2006-001359-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Leiden University Medical Center,Effects of low-dose aspirin taken at bedtime on pathophysiologic mechanisms underlying hypertension in subjects with grade 1 essential hypertension: the Aspirin In Reduction of Tension (ASPIRETENSION)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001359-36,0,0,0 2006-001363-31,6,2009-03-23,2009-05-26,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co KG,"Estudio VITAL- Estudio del activador del receptor de la vitamina D selectivo (Paricalcitol) para la reducción de la albúmina: Estudio multicéntrico de fase II, prospectivo aleatorizado, a doble ciego ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001363-31,0,0,0 2006-001365-42,5,2015-01-08,2015-01-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, open-label, 2-arm, multicentre, phase III study to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab / docetaxel compared with trastuzumab / docetaxel alone...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001365-42,0,0,0 2006-001365-42,5,2015-01-08,2015-01-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A randomized, open-label, 2-arm, multicentre, phase III study to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab / docetaxel compared with trastuzumab / docetaxel alone...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001365-42,0,0,0 2006-001367-36,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Prof. Dr. Peter Eickholz,Benefit of adjunctive systemic postsurgical doxycycline in regenerative periodontal surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001367-36,0,0,0 2006-001368-22,1,2006-12-18,2006-12-18,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,deCODE genetics ehf.,"A randomized, double blind, placebo controlled phase II evaluation of the pharmacokinetics, pharmacodynamics and safety of DG-041 in PAD patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001368-22,0,0,0 2006-001371-38,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Institute of Oncology Ljubljana,"Cetuximab (Erbitux®), capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer: A phase II Pilot Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001371-38,0,0,0 2006-001375-38,1,2008-03-01,2008-03-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Klinik und Poliklinik für Neurologie der Universität Regensburg am Bezirksklinikum,Temozolomide and pegylated (PEG)-liposomal Doxorubicin in first line treatment of patients with Glioblastoma WHO Grad IV,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001375-38,0,0,0 2006-001378-26,5,2007-09-11,2007-09-12,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios SALVAT, S.A.","A Multicentre, Placebo Controlled, Randomised, Double-blind, Dose Ranging Study of SVT-40776 0.05 mg, 0.1 mg, 0.2 mg, Tolterodine 4 mg and Placebo Daily Doses for 4 Weeks in Patients Suffering from Ov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001378-26,0,0,0 2006-001383-23,4,2012-03-26,2016-08-24,3,1,0,0,0,2,3,0,0,1,0,0,1,0,0,Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico,"Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inher...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001383-23,0,0,0 2006-001383-23,4,2012-03-26,2016-08-24,3,1,0,0,0,2,3,0,0,1,0,0,1,0,0,Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico,"Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inher...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001383-23,0,0,0 2006-001383-23,4,2012-03-26,2016-08-24,3,1,0,0,0,2,3,0,0,1,0,0,1,0,0,"Prof Flora Peyvandi, MD","Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inher...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001383-23,0,0,0 2006-001383-23,4,2012-03-26,2016-08-24,3,1,0,0,0,2,3,0,0,1,0,0,1,0,0,FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI,"Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inher...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001383-23,0,0,0 2006-001384-30,1,2007-03-31,2007-03-31,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Brighton and Sussex Universities Hospitals Trust Research and Development Directorate,Standard vs reduced dose naloxone for the reversal of opiate overdose. Does dose modification increase the likelihood of reaching hospital and entering a substance misuse programme?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001384-30,0,0,0 2006-001385-16,1,2012-02-08,2012-02-08,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery, Rudolf Foundation Clinic",Rheohemapheresis and Lutein Supplementation (xantophyll carotenoid) in the Non-Exsudative Form of Age-Related Macular Degeneration. (ReLux-AMD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001385-16,0,0,0 2006-001386-42,1,2008-06-02,2008-06-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College,"The timing of intra-vitreal (4mg) triamcinolone acetonide, in addition to verteporfin photodynamic therapy for choroidal neovascularisation, in age-related macular degeneration: a prospective randomis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001386-42,0,0,0 2006-001389-18,1,2008-03-31,2008-03-31,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,Ludwig Boltzmann Institute forRetinology and Biomicroscopic Laser Surgery,Comparison of Combined Therapy of Intravitreal Injection of Bevacizumab and Pegaptanib versus Mono-therapy (The MAAM Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001389-18,0,0,0 2006-001392-37,1,2007-08-15,2007-08-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme GesmbH,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metfo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001392-37,0,0,0 2006-001398-44,1,2015-11-24,2015-11-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Barts and The London NHS Trust,The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001398-44,0,0,0 2006-001402-92,10,2009-03-02,2009-03-24,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Limited,"A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001402-92,0,0,0 2006-001402-92,10,2009-03-02,2009-03-24,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A,"A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001402-92,0,0,0 2006-001403-11,8,2009-01-28,2009-01-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Limited,"A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone extended release tablets as adjunctive therapy to donepezil on cognition and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001403-11,0,0,0 2006-001403-11,8,2009-01-28,2009-01-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research Development,"A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone extended release tablets as adjunctive therapy to donepezil on cognition and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001403-11,0,0,0 2006-001403-11,8,2009-01-28,2009-01-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A,"A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone extended release tablets as adjunctive therapy to donepezil on cognition and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001403-11,0,0,0 2006-001404-37,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Maastricht University,Cardiometabolic risk reduction by Rimonabant: the effectiveness in daily practice and its use,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001404-37,0,0,0 2006-001406-83,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Effet d'une supplémentation en acides biliaires par de l'acide ursodesoxycholique sur la synthèse endogène du cholestérol et des triglycérides chez les patients ayant un grêle court,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001406-83,0,0,0 2006-001407-11,1,2010-05-18,2010-05-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Medizinische Hochschule Hannover,A single center study investigating ciclosporine A microemulsion in combination with basiliximab and prednisolon and switch to low-dose ciclosporine A and everolimus without steroids in the prevention...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001407-11,0,0,0 2006-001409-27,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO CLINICO HUMANITAS,"Pegfilgrastim versus filgrastim after high-dose chemotherapy followed by autologous peripheral blood stem cell, in patients with hematologic and solid tumors a randomized phase II study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001409-27,0,0,0 2006-001414-33,1,2013-07-01,2013-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Royal Group Hospitals Trust,The effect of hydroxyl-methyl coenzyme A reductase inhibition (statins) in patients with acute lung injury(ALI) and the acute respiratory distress syndrome(ARDS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001414-33,0,0,0 2006-001415-29,1,2009-02-11,2009-02-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Intercytex,A phase IIa uncontrolled study to evaluate hair growth in subjects with male-pattern baldness using a cell suspension of expanded autologous dermal papilla cells (ICX-TRC).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001415-29,0,0,0 2006-001417-16,4,2008-01-25,2008-01-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A randomized, double-blind, double-dummy, parallel group study evaluating the safety of fluticasone propionate/salmeterol 100/50mcg HFA (2 inhalations of 50/25mcg) twice daily compared with fluticason...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001417-16,0,0,0 2006-001417-16,4,2008-01-25,2008-01-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A randomized, double-blind, double-dummy, parallel group study evaluating the safety of fluticasone propionate/salmeterol 100/50mcg HFA (2 inhalations of 50/25mcg) twice daily compared with fluticason...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001417-16,0,0,0 2006-001419-30,2,2007-04-03,2007-04-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A randomised, double-blind, placebo-controlled, dose ascending, 3 period crossover study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of GSK233705...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001419-30,0,0,0 2006-001425-25,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTI FISIOTERAPICI OSPITALIERI,Neoadjuvant treatment in high risk superficial soft tissue sarcomas of limbs and soft tissue of the trunk phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001425-25,0,0,0 2006-001428-38,1,2010-05-30,2010-05-30,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,University Hospitals Birmingham NHS Foundation Trust,Remission Induction in Very Early Rheumatoid Arthritis (RIVERA): a comparison of etanercept plus methotrexate plus steroid with standard therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001428-38,0,0,0 2006-001430-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Department of Cardiology,Tiral of Invasive versus Medical therapy of Early coronary artery disease in Diabetes (TIME-DM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001430-40,0,0,0 2006-001433-17,8,2013-05-23,2013-05-23,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Glaxo SmithKline Research and Development Limited,"A double-blind, randomized, two-dose-arm, parallel group, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are ref...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001433-17,0,0,0 2006-001433-17,8,2013-05-23,2013-05-23,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,GLAXO SMITH KLINE RESEARCH & DEVELOPMENT LTD,"A double-blind, randomized, two-dose-arm, parallel group, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are ref...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001433-17,0,0,0 2006-001433-17,8,2013-05-23,2013-05-23,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Genmab A/S,"A double-blind, randomized, two-dose-arm, parallel group, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are ref...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001433-17,0,0,0 2006-001433-17,8,2013-05-23,2013-05-23,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A double-blind, randomized, two-dose-arm, parallel group, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are ref...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001433-17,0,0,0 2006-001434-41,8,2009-10-07,2009-10-07,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using once monthly subcutaneous injections of RO0503821 in patients with chronic kidney disease who a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001434-41,0,0,0 2006-001434-41,8,2009-10-07,2009-10-07,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ROCHE,"An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using once monthly subcutaneous injections of RO0503821 in patients with chronic kidney disease who a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001434-41,0,0,0 2006-001434-41,8,2009-10-07,2009-10-07,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"F. Hoffmann-La Roche Ltd, Pharmaceuticals Division, PDR","An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using once monthly subcutaneous injections of RO0503821 in patients with chronic kidney disease who a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001434-41,0,0,0 2006-001437-18,1,2009-09-24,2009-09-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios LETI, S.L. Unipersonal","Inmunoterapia con extracto alergénico despigmentado y polimerizado con glutaraldehído de Phleum pratense, en pacientes afectos de rinoconjuntivitis y/o asma alérgicos",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001437-18,0,0,0 2006-001443-63,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,European Lung Cancer Working Party,A phase II study assessing the activity of valproate acid plus doxorubicin in refractory or recurrent malignant mesothelioma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001443-63,0,0,0 2006-001446-14,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,"NOVAG S.A., FERRER GRUPO","Multicenter parallel-group, concealed and randomized allocation and blinded-endpoint study, to evaluate the effects of Torasemide PR versus furosemide on a biochemical marker of collagen synthesis and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001446-14,0,0,0 2006-001448-29,1,2008-06-25,2008-06-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,St Georges Healthcare NHS trust,A prospective observational cohort study of intra-articular Infliximab in knee mono-arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001448-29,0,0,0 2006-001449-33,7,2009-04-03,2009-04-04,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Integrated Therapeutics Group Incorporated (ITGI),"A study of efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with Aerius tablets (5 mg, 10 mg or 20 mg once daily).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001449-33,0,0,0 2006-001449-33,7,2009-04-03,2009-04-04,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Schering Plough Research Institute, A Division of Schering Corporation","A study of efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with Aerius tablets (5 mg, 10 mg or 20 mg once daily).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001449-33,0,0,0 2006-001449-33,7,2009-04-03,2009-04-04,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Schering Plough Institute, A Division of Schering Corporation","A study of efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with Aerius tablets (5 mg, 10 mg or 20 mg once daily).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001449-33,0,0,0 2006-001449-33,7,2009-04-03,2009-04-04,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, A Division of Schering Corporation","A study of efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with Aerius tablets (5 mg, 10 mg or 20 mg once daily).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001449-33,0,0,0 2006-001449-33,7,2009-04-03,2009-04-04,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Schering Plough Research Institute (SPRI), A Division of Schering Corporation","A study of efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with Aerius tablets (5 mg, 10 mg or 20 mg once daily).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001449-33,0,0,0 2006-001449-33,7,2009-04-03,2009-04-04,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SCHERING-PLOUGH,"A study of efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with Aerius tablets (5 mg, 10 mg or 20 mg once daily).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001449-33,0,0,0 2006-001451-35,1,2009-02-11,2009-02-11,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,South Manchester University NHS Trust,How does fish oil supplementation protect against atrial fibrillation following coronary artery by-pass surgery? - A cellular study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001451-35,0,0,0 2006-001452-12,4,2010-10-20,2010-10-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,"An open-label, non-controlled multicentre trial to evaluate the insertion characteristics of the radiopaque etonogestrel implant using a next generation applicator",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001452-12,0,0,0 2006-001453-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hans-Henrik Parving,Autoregulation af den glomerulære filtrations rate (GFR) under spironolacton behandling hos type 1 diabetikere.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001453-10,0,0,0 2006-001455-35,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Intérêt de l'association du midazolam par voie sublinguale à la morphine par voie orale dans l'analgésie des fractures déplacées de l'enfant aux urgences,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001455-35,0,0,0 2006-001456-12,4,2013-07-24,2013-07-24,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients with Unresectable AJCC Stage 3 or 4 Malignant Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001456-12,0,0,0 2006-001457-10,4,2007-07-20,2008-07-01,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs capecitabine (Xeloda) in Patients with Colorectal Cancer who have Failed One Or Two Prior Chemotherapeutic Regimens.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001457-10,0,0,0 2006-001458-28,1,2011-12-31,2011-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Lennart Andren,Do treatment with glucosamine interfere with the lipid lowering effects of simvastatin and atorvastatin?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001458-28,0,0,0 2006-001462-16,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,"A phase II Study of Bortezomib (Velcade), a proteasome Inhibitor, in treating patients with idiopathic Myelofibrosis (IM) randomized to receive new investigational drugs.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001462-16,0,0,0 2006-001464-23,5,2013-08-20,2013-08-20,5,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Pfizer Ltd,"A MULTINATIONAL, MULTICENTRE, RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL SILDENAFIL 20MG TID OR PLACEBO WHEN ADDED TO BOSENTAN IN THE TREATMENT OF SUBJECTS, AGED 18 YEARS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001464-23,0,0,0 2006-001464-23,5,2013-08-20,2013-08-20,5,1,0,0,0,1,4,0,0,1,0,0,1,0,1,"Pfizer Ltd,Ramsgate Road,Sandwich CT13 9NJ","A MULTINATIONAL, MULTICENTRE, RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL SILDENAFIL 20MG TID OR PLACEBO WHEN ADDED TO BOSENTAN IN THE TREATMENT OF SUBJECTS, AGED 18 YEARS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001464-23,0,0,0 2006-001464-23,5,2013-08-20,2013-08-20,5,1,0,0,0,1,4,0,0,1,0,0,1,0,1,PFIZER,"A MULTINATIONAL, MULTICENTRE, RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL SILDENAFIL 20MG TID OR PLACEBO WHEN ADDED TO BOSENTAN IN THE TREATMENT OF SUBJECTS, AGED 18 YEARS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001464-23,0,0,0 2006-001464-23,5,2013-08-20,2013-08-20,5,1,0,0,0,1,4,0,0,1,0,0,1,0,1,"Pfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK","A MULTINATIONAL, MULTICENTRE, RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL SILDENAFIL 20MG TID OR PLACEBO WHEN ADDED TO BOSENTAN IN THE TREATMENT OF SUBJECTS, AGED 18 YEARS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001464-23,0,0,0 2006-001468-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Karolinska Institutet,Sympthomatic and prophylactic treatment of drug induced oral dryness in elderly patients with high drug consumption.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001468-21,0,0,0 2006-001469-41,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,ISTITUTO AUXOLOGICO ITALIANO,"Randomized, open label, multicenter ABPM study to evaluate the effects of barnidipine as add-on therapy in patients with hypertension not adequately controlled on therapy with losartan",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001469-41,0,0,0 2006-001470-25,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,"Lilly Deutschland GmbH, Teichweg 3, 35396 Gießen","Randomisierte, doppelblinde Studie zum Vergleich neuropsychologischer Effekte von Atomoxetin gegen Placebo im Tagesverlauf bei Kindern mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung unter Anwendun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001470-25,0,0,0 2006-001471-37,1,2009-01-23,2009-01-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Lilly Deutschland GmbH, Teichweg 3, 35396 Gießen","A Randomized, Double-Blind Comparison of Atomoxetine versus Placebo in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001471-37,0,0,0 2006-001472-20,3,2007-07-04,2007-08-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharmaceutical Products Ltd A/S (LEO Pharma A/S),"LEO19123 Cream in the Treatment of Atopic Dermatitis A Phase II, proof of concept study, testing once daily use of two dose-combinations of LEO19123 cream (calcipotriol and LEO80122) in the treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001472-20,0,0,0 2006-001472-20,3,2007-07-04,2007-08-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharma A/S,"LEO19123 Cream in the Treatment of Atopic Dermatitis A Phase II, proof of concept study, testing once daily use of two dose-combinations of LEO19123 cream (calcipotriol and LEO80122) in the treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001472-20,0,0,0 2006-001473-24,4,2007-12-20,2007-12-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Research, Clinical Research and Development, Division of Wyeth Pharmaceuticals Inc.","A MULTICENTER, OPEN-LABEL PHARMACOKINETIC, PHARMACODYNAMIC, CLINICAL SYMPTOMS, AND SAFETY STUDY OF PANTOPRAZOLE DELAYED-RELEASED GRANULES ADMINISTERED AS A SUSPENSION IN NEONATES AND PRETERM INFANTS W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001473-24,0,0,0 2006-001473-24,4,2007-12-20,2007-12-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc., Wyeth Research, Clinical Research and Development Division","A MULTICENTER, OPEN-LABEL PHARMACOKINETIC, PHARMACODYNAMIC, CLINICAL SYMPTOMS, AND SAFETY STUDY OF PANTOPRAZOLE DELAYED-RELEASED GRANULES ADMINISTERED AS A SUSPENSION IN NEONATES AND PRETERM INFANTS W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001473-24,0,0,0 2006-001474-24,4,2008-03-25,2008-03-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A MULTICENTER, OPEN LABEL SAFETY STUDY OF 2 DOSES OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANTS AGED LESS THAN 12 MONTHS WITH PRESUMED GERD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001474-24,0,0,0 2006-001474-24,4,2008-03-25,2008-03-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development","A MULTICENTER, OPEN LABEL SAFETY STUDY OF 2 DOSES OF PANTOPRAZOLE SODIUM ENTERIC-COATED SPHEROID SUSPENSION IN INFANTS AGED LESS THAN 12 MONTHS WITH PRESUMED GERD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001474-24,0,0,0 2006-001475-38,1,2007-02-27,2007-02-27,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Janssen Cliag Ltd. C/O Johnson & Johnson PRD,"A DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED, SEQUENTIAL GROUP, MULTIPLE DOSE STUDY OF THE EFFICACY OF THE CRF1-RECEPTOR ANTAGONIST R317573 ON CCK-4 INDUCED ANXIETY IN HEALTHY MALE SUBJECTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001475-38,0,0,0 2006-001478-25,1,2008-11-30,2008-11-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Bristol NHS Foundation Trust,"Analgesia provided by intravenous paracetamol compared with intravenous morphine, for pain secondary to islolated limb trauma, in the emergency department: a pilot randomised controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001478-25,0,0,0 2006-001481-17,1,2009-02-17,2009-02-17,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, open, controlled study to assess the effect of prophylactic antipyretic treatment on the rate of febrile reactions following concomitant booster administration of GlaxoSmithKline (GSK) B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001481-17,0,0,0 2006-001482-42,1,2008-08-27,2008-08-27,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIb open, controlled study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine when given as a catch-up im...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001482-42,0,0,0 2006-001484-39,1,2007-02-22,2007-02-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the combination of valsartan 160 mg plus amlodipine 5 mg in hypertensive patients not adequately res...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001484-39,0,0,0 2006-001485-16,3,2013-10-11,2013-10-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001485-16,0,0,0 2006-001486-41,1,2010-11-30,2010-11-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Oogziekenhuis Rotterdam,Effects of post-operative topical steroid versus intraoperative subconjunctival steroid injection and postoperative miotic on intraocular inflammation following cataract extraction.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001486-41,0,0,0 2006-001487-23,1,2008-09-11,2008-09-11,1,0,0,0,0,3,2,0,0,1,1,1,1,0,1,"Teikoku Pharma USA, Inc.",A Double Blind Randomized Controlled Study of the Effiacy and Safety of Topical Sterile 5% Lidocaine Patch in the Treatment of Postoperative Pain Due to Plastic Surgery of the Breast,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001487-23,0,0,0 2006-001488-51,2,2006-12-20,2006-12-20,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Addex Pharmaceuticals S.A.,"A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF THE MGLUR5 NEGATIVE ALLOSTERIC MODULATOR ADX10059 IN THE ACUTE TREATMENT OF MIGRAINE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001488-51,0,0,0 2006-001489-17,11,2017-06-08,2017-06-08,1,0,0,0,0,2,3,0,0,2,0,0,0,0,0,ST. ANNA KINDERKREBSFORSCHUNG e.V.,Anticuerpo monoclonal recombinante antiGDch14.18. Estudio 1 de Neuroblastoma de Alto Riesgo de la SIOP-Europa. Recombination Chimeric Monoclonal Antibody CH.14.18,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001489-17,1,0,0 2006-001489-17,11,2017-06-08,2017-06-08,1,0,0,0,0,2,3,0,0,2,0,0,0,0,0,St. Anna Kinderkrebsforschung e.V.,Anticuerpo monoclonal recombinante antiGDch14.18. Estudio 1 de Neuroblastoma de Alto Riesgo de la SIOP-Europa. Recombination Chimeric Monoclonal Antibody CH.14.18,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001489-17,1,0,0 2006-001489-17,11,2017-06-08,2017-06-08,1,0,0,0,0,2,3,0,0,2,0,0,0,0,0,Jagiellonian University Medical College,Anticuerpo monoclonal recombinante antiGDch14.18. Estudio 1 de Neuroblastoma de Alto Riesgo de la SIOP-Europa. Recombination Chimeric Monoclonal Antibody CH.14.18,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001489-17,1,0,0 2006-001489-17,11,2017-06-08,2017-06-08,1,0,0,0,0,2,3,0,0,2,0,0,0,0,0,University medical center Ljubljana,Anticuerpo monoclonal recombinante antiGDch14.18. Estudio 1 de Neuroblastoma de Alto Riesgo de la SIOP-Europa. Recombination Chimeric Monoclonal Antibody CH.14.18,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001489-17,1,0,0 2006-001489-17,11,2017-06-08,2017-06-08,1,0,0,0,0,2,3,0,0,2,0,0,0,0,0,Victoria Castel Sánchez,Anticuerpo monoclonal recombinante antiGDch14.18. Estudio 1 de Neuroblastoma de Alto Riesgo de la SIOP-Europa. Recombination Chimeric Monoclonal Antibody CH.14.18,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001489-17,1,0,0 2006-001489-17,11,2017-06-08,2017-06-08,1,0,0,0,0,2,3,0,0,2,0,0,0,0,0,University of Birmingham,Anticuerpo monoclonal recombinante antiGDch14.18. Estudio 1 de Neuroblastoma de Alto Riesgo de la SIOP-Europa. Recombination Chimeric Monoclonal Antibody CH.14.18,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001489-17,1,0,0 2006-001490-15,2,2009-04-06,2009-04-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V,"A randomized, double-blind, placebo- and active-controlled, parallel-group study to evaluate the efficacy and safety of risperidone long-acting injectable for the prevention of mood episodes in the tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001490-15,0,0,0 2006-001491-21,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Max Planck Institute of Psychiatry,Studies on Permeability of the Blood-Brain-Barrier for Escitaloprame related to various Genotypes of the ABCB1-Gene: Effects on Sleep and Motoric Learning,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001491-21,0,0,0 2006-001498-13,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Effetti della iniezione endovitreale di Avastin per il trattamento delle maculopatie essudative,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001498-13,0,0,0 2006-001499-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Radio-controlled Surgery RGS in the cancer of the rectum clinical study of feasibility to improve the treatment and prognosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001499-18,0,0,0 2006-001500-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Radio-controlled surgery RGS in the gastric carcinoma locally advanced subordinate to neoadiuvante medical therapy. Clinical study of feasibilities and correlation with the traditional methodical o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001500-36,0,0,0 2006-001503-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Technology of the radioisotopes for the intra-operative identification of the sentinel node in the premature gastric cancer. Clinical study of feasibility in order to improve the treatment and prognos...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001503-10,0,0,0 2006-001504-37,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,SUBCUTANEOUS INOCULATION OF ALLOGENEIC GENE-MODIFIED TUMOR CELLS ACHN-IL2 MIXED TO AUTOLOGOUS TUMOR CELLS CT-AUT IN PATIENTS WITH METASTATIC RENAL CARCINOMA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001504-37,0,0,0 2006-001505-28,1,2008-07-30,2008-07-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI,"Randomised, parallel phase IV study on the safety of hymenoptera venom immunotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001505-28,0,0,0 2006-001506-81,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,SPINAL ANESTHESIA IN THE CAESAREAN CUT LEVOBUPIVACAINE VERSUS ROPIVACAINE VERSUS HYPERBARIC BUPIVACAINE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001506-81,0,0,0 2006-001509-26,1,2007-10-05,2007-10-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Dermal Laboratories Limited,An open evaluation of an emollient shower gel for dry skin conditions.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001509-26,0,0,0 2006-001510-32,2,2007-12-28,2007-12-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MedPointe Pharmaceuticals,Active-Controlled Trial of the Safety and Tolerability of MP03-33 in Patients with Chronic Allergic or Nonallergic Rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001510-32,0,0,0 2006-001510-32,2,2007-12-28,2007-12-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Meda Pharmaceuticals,Active-Controlled Trial of the Safety and Tolerability of MP03-33 in Patients with Chronic Allergic or Nonallergic Rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001510-32,0,0,0 2006-001511-30,6,2007-10-11,2007-10-11,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Beaufour Ipsen Pharma,"A phase III, single arm, multicentre study to evaluate the efficacy and safety of a subcutaneous four-month sustained-release formulation of triptorelin, a gonadotrophin releasing hormone analogue in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001511-30,0,0,0 2006-001511-30,6,2007-10-11,2007-10-11,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Beafour Ipsen Pharma,"A phase III, single arm, multicentre study to evaluate the efficacy and safety of a subcutaneous four-month sustained-release formulation of triptorelin, a gonadotrophin releasing hormone analogue in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001511-30,0,0,0 2006-001514-33,2,2008-03-14,2008-03-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratoires SMB S.A,"A phase III, randomized, parallel group study to compare the therapeutic efficacy of SMB BUDESONIDE-SALMETEROL DPI capsule 300/25µg BID delivered by the AXAHALER® versus SERETIDE® DISKUS® 500/50µg (Fl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001514-33,0,0,0 2006-001514-33,2,2008-03-14,2008-03-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratories SMB S.A.,"A phase III, randomized, parallel group study to compare the therapeutic efficacy of SMB BUDESONIDE-SALMETEROL DPI capsule 300/25µg BID delivered by the AXAHALER® versus SERETIDE® DISKUS® 500/50µg (Fl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001514-33,0,0,0 2006-001515-29,7,2007-08-10,2008-10-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Double-blind, randomised, placebo-controlled study comparing the efficacy and safety of two fixed dosages of a novel antidepressant compound to that of placebo in patients with Major Depressive Disor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001515-29,0,0,0 2006-001517-15,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ROCHE,Italian multicenter phase II trial using Fotemustine plus Bevacizumab as first-line therapy in metastatic melanoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001517-15,0,0,0 2006-001518-34,1,2010-03-23,2010-03-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farma, S.A.","Estudio fase II abierto, no aleatorizado, de erlotinib en combinación con gemcitabina en pacientes con adenocarcinoma de páncreas avanzado irresecable o metastásico: relación entre rash cutáneo y sup...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001518-34,0,0,0 2006-001522-84,1,2008-08-15,2008-08-15,1,1,0,0,0,1,0,0,1,1,0,0,1,0,0,Novartis Vaccines and Diagnostics Srl.,"A Phase 2, Open Label, Multi-Center, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, when Administered to Healthy I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001522-84,0,0,0 2006-001524-39,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Menarini Ricerche S.p.A.,"Pilot study to evaluate the intestinal absorption, safety, tolerability, and efficacy of nepadutant administered as single oral doses in infantile colic patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001524-39,0,0,0 2006-001527-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitario de Canarias,ENSAYO CLÍNICO ALEATORIZADO FASE IV PARA EVALUAR LA EFICACIA COMPARATIVA DEL TRATAMIENTO CON AMOXICILINA-CLAVULÁNICO O LEVOFLOXACINO EN PACIENTES CON NEUMONÍA ADQUIRIDA EN LA COMUNIDAD (NAC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001527-19,0,0,0 2006-001528-38,1,2011-04-19,2011-04-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Charité Universitätsmedizin Berlin,Prevention of skin cancer in high risk patients after conversion a to Sirolimus-based immunosuppressive,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001528-38,0,0,0 2006-001529-24,5,2009-03-31,2009-07-30,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Sepracor NV in care of Sepracor Inc.,"Adults administered Venlafaxine and Eszopiclone Response to Treatment (AVERT): A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-administered with Venlafaxine in Subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001529-24,0,0,0 2006-001530-40,1,2008-10-17,2008-10-17,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,STEBA FRANCE,"Vascular targeted photodynamic therapy using WST09 for patients with untreated localised prostate cancer - Repeat procedure – Phase IIa, Single centre, open-label study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001530-40,0,0,0 2006-001533-17,8,2018-08-02,2018-08-02,3,1,0,0,0,0,3,0,0,2,0,0,0,0,0,EORTC European Organisation for research and treatment of cancer,Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001533-17,1,0,0 2006-001533-17,8,2018-08-02,2018-08-02,3,1,0,0,0,0,3,0,0,2,0,0,0,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001533-17,1,0,0 2006-001533-17,8,2018-08-02,2018-08-02,3,1,0,0,0,0,3,0,0,2,0,0,0,0,0,EORTC,Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001533-17,1,0,0 2006-001536-46,2,2008-01-08,2008-01-08,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,UCB S.A.,"A multicenter, randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of brivaracetam used as adjunctive treatment for 12 weeks in adolescent and adult patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001536-46,0,0,0 2006-001539-23,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,department of clinical pharmacology,Does imatinib therapy lead to an increased uptake of low molecular weight substances into solid tumor metastasis in patients with hormone refractory prostate cancer?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001539-23,0,0,0 2006-001540-31,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,BIOSENSORS EUROPE SA,LIMUS ELUTED FROM A DURABLE VERSUS ERODABLE STENT COATING,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001540-31,0,0,0 2006-001543-60,1,2007-01-08,2007-01-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Sahlgrenska Akademin vid Göteborgs Universitet,FIBRINOGEN OCH BLÖDNING EFTER HJÄRTKIRURGI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001543-60,0,0,0 2006-001544-31,1,2008-12-02,2008-12-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Moorfields Eye Hospital,"A randomised, double-masked, phase 3 study of the efficacy and safety of Avastin® (bevacizumab) intravitreal injections compared to best available therapy in subjects with choroidal neovascularizatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001544-31,0,0,0 2006-001545-34,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTI FISIOTERAPICI OSPITALIERI,Evaluating primary chemotherapy with temozolomide continuative low dose in patients with low grade gliomas grade II WHO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001545-34,0,0,0 2006-001546-14,1,2008-01-29,2008-01-29,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,NV Organon,"A randomized, open-label, comparative trial to evaluate the effects on ovarian function of a monophasic combined oral contraceptive (COC) containing 2.5 mg nomegestrol acetate (NOMAC) and 1.5 mg estra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001546-14,0,0,0 2006-001547-59,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA SENESE,Clinical study on the efficacy and safety of extracorporeal blood oxygenation and ozonation in ischemic cardiovascular patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001547-59,0,0,0 2006-001548-30,6,2007-10-28,2007-10-31,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Artu Biologicals Europe B.V.,"A randomised, double-blind, placebo-controlled, multi-centre, multi-national Phase II / III study to assess the efficacy and safety of three different dose regimens of Oralgen® Grass Pollen in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001548-30,0,0,0 2006-001549-32,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA,"Prospectic, multicentric, randomized, controlled trial for the evaluation of efficacy of Caspofungin vs Amfotericina B liposomiale for the empirical treatment of the FUO in children neutropenic for an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001549-32,0,0,0 2006-001550-27,5,2008-09-23,2008-09-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmaceútica,"A 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1 beta monoclonal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001550-27,0,0,0 2006-001550-27,5,2008-09-23,2008-09-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1 beta monoclonal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001550-27,0,0,0 2006-001552-12,1,2010-06-08,2010-06-08,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Kliniken Essen Mitte,Taxotere-Mono Studie: 1st-Line Docetaxel versus Gemcitabin Monotherapie mit festgelegter platinhaltiger 2nd-Line bei PD bei Patienten mit metastasiertem nicht-kleinzelligem Bronchial-Karzinom; eine r...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001552-12,0,0,0 2006-001553-10,4,2008-12-19,2008-12-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 26-week, phase II, multi-center, randomized, double-blind, placebo-controlled study to assess the response to treatment (ACR50) and to determine a biomarker profile in responders to ACZ885 (anti-int...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001553-10,0,0,0 2006-001553-10,4,2008-12-19,2008-12-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 26-week, phase II, multi-center, randomized, double-blind, placebo-controlled study to assess the response to treatment (ACR50) and to determine a biomarker profile in responders to ACZ885 (anti-int...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001553-10,0,0,0 2006-001556-12,1,2011-03-24,2011-03-24,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Derby Hospitals NHS Foundation Trust,Hamstrings Graft Donor Site Infiltration with Bupivacaine for Pain Relief after Arthroscopically Assisted Anterior Cruciate Ligament Reconstruction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001556-12,0,0,0 2006-001559-37,1,2007-12-31,2007-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Aberdeen,A study to observe the effects of one month’s supplementation with forceval junior on asthma control in children aged 7-12 years with asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001559-37,0,0,0 2006-001562-16,1,2009-05-01,2009-05-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Group of Hospitals Trust,Studies of insulin action in patients at increased vascular risk. Modulation by antihypertensive and endocrine replacement therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001562-16,0,0,0 2006-001563-37,2,2011-07-30,2011-07-30,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,Department of Pediatrics Holbaek Hospital,"Tidlig selektiv behandling med Curosurf. Behandling af RDS efter bestemmelse af lamellar body counts på ventrikelaspirat sammenholdt med behandling ved a/APO2 <0,36 En randomiseret kontrolleret multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001563-37,1,0,0 2006-001564-22,1,2007-08-06,2007-08-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Maruho Co, Ltd. Kyoto R&D Center","A Phase IIa Multiple-Centre Randomized, Double-Blind, Placebo- Controlled, Parallel Group Study To Investigate The Efficacy Of M5161 In Relieving Pruritus Associated With Atopic Dermatitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001564-22,0,0,0 2006-001571-37,1,2014-07-24,2014-07-24,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University College London,AN OPEN-LABEL DOSE ESCALATION STUDY OF AN ADENO-ASSOCIATED VIRUS VECTOR (AAV2/2-hRPE65p-hRPE65) FOR GENE THERAPY OF SEVERE EARLY-ONSET RETINAL DEGENERATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001571-37,0,0,0 2006-001574-24,1,2013-01-01,2013-01-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Radboud University Nijmegen Medical Centre, Department of Endocrinology",Visualisation of coronary arteries for the analysis of premature atherosclerosis in patients with adult-onset GH deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001574-24,0,0,0 2006-001577-13,3,2008-08-31,2008-08-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a division of Schering Corporation",A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects with Pe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001577-13,0,0,0 2006-001578-25,3,2008-09-23,2008-09-23,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a division of Schering Corporation",A 26-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate/Formoterol Fumarate Combination Formulation Compared With Mometasone Furoate and Formoterol Monotherapy in Subjects with Pe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001578-25,0,0,0 2006-001579-40,4,2008-11-26,2008-11-26,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Schering-Plough France,Study of peripheral enthesitis with ultrasonography doppler in spondyloarthropathies treated with infliximab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001579-40,0,0,0 2006-001580-30,1,2011-08-05,2011-08-05,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Cornwall Hospitals NHS Trust,Investigation into the effects of steroid and local anaesthetic infiltration into soft tissues in total hip replacement wounds on post-operative pain relief.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001580-30,0,0,0 2006-001588-52,2,2007-06-21,2008-01-31,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,PFIZER,A RANDOMIZED PHASE II TRIAL OF PEMETREXED WITH OR WITHOUT PF- 3512676 FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF ONE PRIOR CHEMOTH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001588-52,0,0,0 2006-001588-52,2,2007-06-21,2008-01-31,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Pfizer Pharma GmbH,A RANDOMIZED PHASE II TRIAL OF PEMETREXED WITH OR WITHOUT PF- 3512676 FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF ONE PRIOR CHEMOTH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001588-52,0,0,0 2006-001589-17,3,2009-05-05,2009-05-08,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,KeyNeurotek Pharmaceuticals AG,"A doubel-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic brai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001589-17,0,0,0 2006-001595-20,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,NOVARTIS FARMA,A phase Ib study investigating the combination of RAD001 with trastuzumab and vinorelbine in patients with HER2- overexpressing metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001595-20,0,0,0 2006-001596-37,1,2014-03-20,2014-03-20,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,A phase Ib/II study investigating the combination of RAD001 with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001596-37,0,0,0 2006-001598-10,1,2008-10-07,2008-10-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GW Pharma Ltd,"A double blind, randomised, placebo controlled, parallel group study of Sativex® in the treatment of subjects with pain due to diabetic neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001598-10,0,0,0 2006-001599-18,13,2008-06-12,2018-06-12,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"A prospective, randomized, double dummy, double blind, multinational, multicenter trial comparing the safety and efficacy of sequential intravenous/oral moxifloxacin 400 mg once daily to intravenous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001599-18,0,0,0 2006-001599-18,13,2008-06-12,2018-06-12,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BAYER,"A prospective, randomized, double dummy, double blind, multinational, multicenter trial comparing the safety and efficacy of sequential intravenous/oral moxifloxacin 400 mg once daily to intravenous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001599-18,0,0,0 2006-001608-35,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Dr. Valérie gangji,"TREATMENT OF SCIATICA BY ADALIMUMAB INJECTION : A RANDOMIZED, DOUBLE BLIND CONTROLLED TRIAL.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001608-35,0,0,0 2006-001611-30,1,,,0,1,0,0,0,0,0,0,0,3,0,0,0,0,0,Hammersmith Hospital NHS Trust,Clinical trial comparing the effect of Acetaminophen and Ibuprofen on the duration of influenza viral shedding in young children (Pilot study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001611-30,0,0,0 2006-001614-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Appraisal of the role of the 68Ga-DOTANOC in the diagnostic by Positron emission tomography (PET) in the study of human tumors of neuroendocrine derivation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001614-33,0,0,0 2006-001618-34,2,2008-08-26,2008-08-26,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"An eight-week, randomized, double-blind, two parallel groups, study to assess clinical response of Duloxetine 60 mg and 120 mg per day in patients hospitalized for severe depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001618-34,0,0,0 2006-001618-34,2,2008-08-26,2008-08-26,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"An eight-week, randomized, double-blind, two parallel groups, study to assess clinical response of Duloxetine 60 mg and 120 mg per day in patients hospitalized for severe depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001618-34,0,0,0 2006-001619-31,5,2009-04-24,2009-05-05,4,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Onyvax Limited,A PHASE IIB TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF ONY-P VACCINES IN THE MANAGEMENT OF PROSTATE CANCER WITHOUT DETECTABLE METASTASES FOLLOWING INITIAL ESCAPE FROM HORMONE TREATMENT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001619-31,0,0,0 2006-001621-26,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,A.U.S.L. RIMINI,"A RANDOMIZED, MULTICENTER STUDY OF USE INTERMITTENT HAART HIGHLY ACTIVE ANTIRETROVIRAL THERAPY THERAPY VERSUS CONTINUATIVE HAART THERAPY IN HIV PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001621-26,0,0,0 2006-001623-18,13,2013-11-07,2013-11-15,10,1,0,0,0,2,3,0,0,1,1,0,1,0,2,GlaxoSmithKline Research & Development Limited,"A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001623-18,0,0,0 2006-001623-18,13,2013-11-07,2013-11-15,10,1,0,0,0,2,3,0,0,1,1,0,1,0,2,GLAXO SMITHKLINE,"A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001623-18,0,0,0 2006-001628-38,2,2007-11-06,2007-11-06,2,1,0,0,1,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIa single-blind, controlled multicentre study to assess the safety, reactogenicity and immunogenicity of GSK Biologicals 10-valent pneumococcal conjugate vaccine or Prevenar when given as a ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001628-38,0,0,0 2006-001629-24,6,2008-11-12,2008-11-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 12 month, open-label, multi-center trial to investigate the endometrial safety of Vagifem Low Dose (10ug 17beta-estradiol vaginal tablet) in postmenopausal women with atrophic vaginitis symptoms. Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001629-24,0,0,0 2006-001635-21,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"VIA PHARMACEUTICALS, INC.","A Phase 2 Randomised, Double-blind, Placebo-controlled Study of the Effects of VIA-2291, a 5-lipoxygenase Inhibitor, on Atherosclerotic Plaque and Biomarkers of Vascular Inflammation in Patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001635-21,0,0,0 2006-001637-18,10,2009-04-06,2009-07-30,10,1,0,0,0,0,3,0,0,1,1,0,1,0,2,NovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc),"A multicenter,randomized,doubleblind, placebo-controlled study of the effects of KW-3902 injectable emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001637-18,0,0,0 2006-001637-18,10,2009-04-06,2009-07-30,10,1,0,0,0,0,3,0,0,1,1,0,1,0,2,FGK Representative Service GmbH,"A multicenter,randomized,doubleblind, placebo-controlled study of the effects of KW-3902 injectable emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001637-18,0,0,0 2006-001637-18,10,2009-04-06,2009-07-30,10,1,0,0,0,0,3,0,0,1,1,0,1,0,2,NovaCardia Inc,"A multicenter,randomized,doubleblind, placebo-controlled study of the effects of KW-3902 injectable emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001637-18,0,0,0 2006-001638-42,2,2007-10-24,2007-10-24,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Merck & Co. Inc.,"Study to Assess the Safety, Tolerability, and Immunogenicity of 2 Antigen Doses of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process Administered to Healthy Infants at 2, 4, and 6 M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001638-42,0,0,0 2006-001638-42,2,2007-10-24,2007-10-24,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,MSD (Norge) AS,"Study to Assess the Safety, Tolerability, and Immunogenicity of 2 Antigen Doses of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process Administered to Healthy Infants at 2, 4, and 6 M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001638-42,0,0,0 2006-001639-23,1,2008-06-23,2008-06-23,1,1,0,0,1,0,3,0,1,1,0,0,1,0,1,Merck SHARP & DOHME DE ESPAÑA,A Study to Assess the Anamnestic Immune Response 4 to 6 Years After a Primary Vaccination Series With HBVAXPRO™ Estudio para evaluar la respuesta inmune anamnésica 4 a 6 años después de una pauta de v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001639-23,0,0,0 2006-001641-33,1,2018-03-31,2018-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsklinikum Essen,Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (Positron emission tomography guided therapy of aggressive non-Hodgkin's lymphomas),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001641-33,0,0,0 2006-001643-63,1,,,0,0,0,0,0,3,3,0,0,0,0,0,0,0,0,GERENCIA DE ATENCIÓN PRIMARIA,PREVENCIÓN DE CAÍDAS EN ANCIANOS MEDIANTE LA ADMINISTRACIÓN DE CALCIO Y VITAMINA D. ESTUDIO DE INTERVENCIÓN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001643-63,0,0,0 2006-001652-12,2,2007-04-03,2007-04-03,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Icagen Inc.,An Open-Label Extension Study Evaluating the Long-Term Safety of ICA 17043 with or without Hydroxyurea Therapy in Subjects with Sickle Cell Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001652-12,1,0,0 2006-001656-13,1,2009-01-28,2009-01-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Cassella-med,"Multizentrischer, randomisierter, doppelblinder, Placebo-kontrollierter Parallelgruppenvergleich zum Nachweis der Wirksamkeit und Unbedenklichkeit von Cineol im Rahmen der Langzeittherapie bei Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001656-13,0,0,0 2006-001657-94,3,,,0,0,0,0,0,0,3,2,0,2,0,0,0,0,0,Scandinavian prostate cancer group,A randomised adjuvant Phase III Trial of six cycles of docetaxel and hormonal treatment versus hormonal treatment in patients with intermediate or high-risk prostate cancer treated with radical radiot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001657-94,0,0,0 2006-001657-94,3,,,0,0,0,0,0,0,3,2,0,2,0,0,0,0,0,"ICORG, All-Ireland Cooperative Oncology Research Group",A randomised adjuvant Phase III Trial of six cycles of docetaxel and hormonal treatment versus hormonal treatment in patients with intermediate or high-risk prostate cancer treated with radical radiot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001657-94,0,0,0 2006-001657-94,3,,,0,0,0,0,0,0,3,2,0,2,0,0,0,0,0,,A randomised adjuvant Phase III Trial of six cycles of docetaxel and hormonal treatment versus hormonal treatment in patients with intermediate or high-risk prostate cancer treated with radical radiot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001657-94,0,0,0 2006-001657-94,3,,,0,0,0,0,0,0,3,2,0,2,0,0,0,0,0,Scandinavian Prostate Cancer Group/ P.O. Hedlund,A randomised adjuvant Phase III Trial of six cycles of docetaxel and hormonal treatment versus hormonal treatment in patients with intermediate or high-risk prostate cancer treated with radical radiot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001657-94,0,0,0 2006-001659-37,5,2008-04-30,2008-06-16,5,1,0,0,0,0,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,Phase II Study of ZK 219 477 in patients with recurrent glioblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001659-37,0,0,0 2006-001659-37,5,2008-04-30,2008-06-16,5,1,0,0,0,0,2,0,0,1,0,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Phase II Study of ZK 219 477 in patients with recurrent glioblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001659-37,0,0,0 2006-001660-23,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,CENTRO STUDI FADOI,"Optimized treatment of patients with severe peripheral arterial disease (Leriche-Fontaine stage IIb), when open or endovascular intervention is possible or not, in terms of measurement of pain free wa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001660-23,0,0,0 2006-001661-41,1,2008-05-09,2008-05-09,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Karolinska University Hospital,Body Composition and Metabolic Changes During Antipsychotic Treatment. A Randomized Trial Comparing Sertindole and Olanzapine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001661-41,0,0,0 2006-001663-33,8,2013-02-14,2013-02-14,6,1,0,0,0,2,0,0,0,2,0,0,0,0,0,Vasculitis and Lupus Clinic,A randomised clinical trial of mycophenolat mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001663-33,1,0,0 2006-001663-33,8,2013-02-14,2013-02-14,6,1,0,0,0,2,0,0,0,2,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),A randomised clinical trial of mycophenolat mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001663-33,1,0,0 2006-001663-33,8,2013-02-14,2013-02-14,6,1,0,0,0,2,0,0,0,2,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust,A randomised clinical trial of mycophenolat mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001663-33,1,0,0 2006-001663-33,8,2013-02-14,2013-02-14,6,1,0,0,0,2,0,0,0,2,0,0,0,0,0,Vasculitis Clinical Trial Office,A randomised clinical trial of mycophenolat mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001663-33,1,0,0 2006-001669-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Thessaloniki's Aristoteleio University,PROJECT TITLE: EFFECTS OF ATORVASTATIN ON BLOOD PRESSURE AND URINARY ALBUMIN EXCRETION IN PATIENTS WITH ESSENTIAL HYPERTENSION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001669-41,0,0,0 2006-001671-38,6,2008-06-16,2008-11-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Centocor B.V.,"A Phase 2 Multicenter, Open-label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refractory Prostate Cancer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001671-38,0,0,0 2006-001676-21,1,2011-10-07,2011-10-07,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics GmbH & Co. KG,"A phase IV, open-label, single-center study in adolescents and adults: Evaluation of immunogenicity and safety of the first booster immunization with Chiron’s TBE vaccine for adults in participants of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001676-21,0,0,0 2006-001678-25,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Macular structure and function after intravitreal injection of bevacizumab for vascular retinopathy a interventional study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001678-25,0,0,0 2006-001679-39,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,efficacy and safety evaluation of transtec for pain therapy such as first line opioid in patients afected by solid tumors with CT treatment . Fase IV study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001679-39,0,0,0 2006-001680-33,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,BRACCO IMAGING,"Phase IV, Double-blind, Multi-center, Randomized, Cross-over Study to Compare 0.10 mmol/kg of MultiHance R with 0.10 mmol/kg of Omniscan R in Magnetic Resonance Imaging MRI of the Brain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001680-33,0,0,0 2006-001681-16,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,FONDAZIONE NADIR ONLUS,"A pilot, open label, randomised clinical trial assessing the 12 week immunological response in HIV-1 failing subjects receiving monotherapy with emtricitabine 200 mg once a day or emtricitabine 200 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001681-16,0,0,0 2006-001682-42,1,2009-05-01,2009-05-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche AB,"Rituximab phase IIIb open-label, multi-centre assessment of safety and effectiveness in patients with RA following inadequate response to one prior anti-TNF inhibitor (RESET).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001682-42,0,0,0 2006-001684-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Knud Kragballe, Dermatological Department, Århus Sygehus (Hospital)",Adalimumab clinical trial in plaque psoriasis – effect on expression of TNF-a and MAP-kinases in psoriatic skin – ACTION An open-label trial investigating adalimumab (HUMIRA) 80 mg s.c. at week 0 foll...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001684-34,0,0,0 2006-001685-16,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Wyeth Research Division of Wyeth Pharmceuticals Inc.,"A Phase 3, Randomized, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Manufactured With and Without Polysorbate 80 in Healthy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001685-16,0,1,1 2006-001688-49,4,2008-06-17,2008-06-17,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,TEVA Pharmaceutical Industries. Ltd.,"A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate for Injection in Subjects w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001688-49,0,0,0 2006-001688-49,4,2008-06-17,2008-06-17,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Teva Pharmaceutical Industries Ltd.,"A Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of 40 mg Glatiramer Acetate for Injection in Subjects w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001688-49,0,0,0 2006-001694-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,National Institute of Oncology,Efficacy of cetuximab in locally advanced or metastatic adenoid cystic carcinoma. Phase II.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001694-23,0,0,0 2006-001702-88,4,2007-11-02,2007-11-02,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Novacea, Inc.","A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination with Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001702-88,1,0,0 2006-001703-11,1,2008-11-26,2008-11-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A multi-center, randomized, open-label, controlled, one-year trial to measure the effect of zoledronic acid and alendronate on bone metabolism in post menopausal women with osteopenia and osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001703-11,0,0,0 2006-001704-37,10,2009-03-19,2009-11-19,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 36 week, multicenter, randomized, double-blind, placebo- controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high ri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001704-37,0,0,0 2006-001704-37,10,2009-03-19,2009-11-19,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 36 week, multicenter, randomized, double-blind, placebo- controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high ri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001704-37,0,0,0 2006-001707-11,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,NKI-AvL,"Prospective, randomized, pharmacological intervention study; evaluating the effect of the angiotensin II-receptor (AT1) blocker candesartan versus placebo in prevention of trastuzumab-associated cardi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001707-11,0,0,0 2006-001709-27,3,2008-01-18,2008-02-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade® when added to Adriamycin-Dexamethasone Treatment versus Vincristine-Adriamycin-Dexa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001709-27,0,0,0 2006-001709-27,3,2008-01-18,2008-02-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade® when added to Adriamycin-Dexamethasone Treatment versus Vincristine-Adriamycin-Dexa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001709-27,0,0,0 2006-001710-32,1,2008-12-15,2008-12-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Dept. of Anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital Rigshospitalet",PeRioperative OXygen fraction – effect on surgical site Infection and pulmonary complications after abdominal surgery. (The PROXI-study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001710-32,0,0,0 2006-001711-30,19,2008-10-24,2009-04-02,11,1,0,0,2,0,0,0,0,1,1,0,1,0,1,Sanofi Aventis Groupe,"A Pan-European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with impaired fasting...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001711-30,0,0,0 2006-001711-30,19,2008-10-24,2009-04-02,11,1,0,0,2,0,0,0,0,1,1,0,1,0,1,SANOFI-AVENTIS S.P.A,"A Pan-European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with impaired fasting...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001711-30,0,0,0 2006-001711-30,19,2008-10-24,2009-04-02,11,1,0,0,2,0,0,0,0,1,1,0,1,0,1,sanofi aventis Groupe,"A Pan-European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with impaired fasting...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001711-30,0,0,0 2006-001711-30,19,2008-10-24,2009-04-02,11,1,0,0,2,0,0,0,0,1,1,0,1,0,1,sanofi aventis groupe,"A Pan-European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with impaired fasting...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001711-30,0,0,0 2006-001715-30,12,2008-10-24,2009-01-30,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,sanofi-aventis Oy,"A European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with dyslipidemia with or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001715-30,0,0,0 2006-001715-30,12,2008-10-24,2009-01-30,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,sanofi aventis Groupe,"A European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with dyslipidemia with or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001715-30,0,0,0 2006-001715-30,12,2008-10-24,2009-01-30,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,SANOFI-AVENTIS S.P.A,"A European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with dyslipidemia with or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001715-30,0,0,0 2006-001716-71,3,2008-12-18,2008-12-18,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi aventis Groupe,"A RANDOMIZED, DOUBLE BLIND, TWO ARM, PARALLEL, PLACEBO CONTROLLED STUDY OF RIMONABANT 20MG EFFECT ON HIGH DENSITY LIPOPROTEIN KINETICS IN PATIENTS WITH ABDOMINAL OBESITY AND ADDITIONAL CARDIOMETABOLIC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001716-71,0,0,0 2006-001721-26,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,UAB “Eli Lilly Lietuva”,The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001721-26,0,0,0 2006-001723-19,1,2007-04-30,2007-04-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Bristol,"AN OPEN LABEL, SINGLE CENTRE PILOT STUDY TO EVALUATE THE KINETICS OF THE SYSTEMIC B-CELL IMMUNE RESPONSE TO A MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE IN HEALTHY ADULTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001723-19,0,0,0 2006-001724-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE,Phase II study with capecitabine as monotherapy in the treatment of platinum resistant or refractory ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001724-40,0,0,0 2006-001725-25,1,2007-08-06,2007-08-06,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,GREATER GLASGOW HEALTH BOARD,REVISION HP REPLACEMENT - ACETABULAR IMPACTION GRAFTING - A RADIOSTEREOMETRIC COMPARISON BETWEEN FRESH FROZEN ALLOGRAFT AND MARROW-DEPLETED BONE WITH CALCIUM PHOSPHATE PLUS OR MINUS BONE MORPHOGENIC P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001725-25,0,0,0 2006-001727-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Triamcinolone Acetonide Intravitreal Injection for the treatment for exudative maculopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001727-19,0,0,0 2006-001729-24,9,2010-02-17,2010-11-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB PHARMA,"Ensayo clínico abierto a largo plazo para evaluar la eficacia y seguridad del tratamiento crónico con certolizumab pegol, un fragmento Fab pegilado del anticuerpo humanizado dirigido al factor de necr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001729-24,0,0,0 2006-001729-24,9,2010-02-17,2010-11-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB S.A.,"Ensayo clínico abierto a largo plazo para evaluar la eficacia y seguridad del tratamiento crónico con certolizumab pegol, un fragmento Fab pegilado del anticuerpo humanizado dirigido al factor de necr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001729-24,0,0,0 2006-001729-24,9,2010-02-17,2010-11-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB S.A,"Ensayo clínico abierto a largo plazo para evaluar la eficacia y seguridad del tratamiento crónico con certolizumab pegol, un fragmento Fab pegilado del anticuerpo humanizado dirigido al factor de necr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001729-24,0,0,0 2006-001729-24,9,2010-02-17,2010-11-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma SA,"Ensayo clínico abierto a largo plazo para evaluar la eficacia y seguridad del tratamiento crónico con certolizumab pegol, un fragmento Fab pegilado del anticuerpo humanizado dirigido al factor de necr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001729-24,0,0,0 2006-001729-24,9,2010-02-17,2010-11-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"Ensayo clínico abierto a largo plazo para evaluar la eficacia y seguridad del tratamiento crónico con certolizumab pegol, un fragmento Fab pegilado del anticuerpo humanizado dirigido al factor de necr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001729-24,0,0,0 2006-001732-53,1,2013-01-08,2013-01-08,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,University Hospital of Heidelberg,"Eine multizentrische, randomisierte, kontrollierte Studie zur Untersuchung von Adalimumab bei der Behandlung verschiedener Formen von refraktärer Uveitis im Vergleich zur Standardtherapie Randomized ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001732-53,0,0,0 2006-001742-13,1,2010-09-15,2010-09-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Christie Hospital NHS Trust,Locally Advanced Pancreatic Cancer: Phase II study of cetuximab and 3-D conformal image-guided radiotherapy (PACER Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001742-13,0,0,0 2006-001743-66,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,"INSTITUT PASTEUR, Biomedical Parasitology Unit","Phase I and IIa trial to assess the safety, immunogenicity and protective efficacy against sporozoite challenge of the candidate malaria vaccine pfLSA-3 vaccine.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001743-66,0,0,0 2006-001750-28,1,2009-06-24,2009-06-24,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,"Rigshospitalet, Psykiatrisk Klinik","Associationer mellem genpolymorfier, endofænotyper for depression og antidepressiv behandling",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001750-28,0,0,0 2006-001754-26,2,2010-05-14,2010-05-14,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cardiokine Biopharma, LLC","Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subjects with Euvolemic Hyponatremia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001754-26,0,0,0 2006-001755-36,3,2007-08-23,2007-08-23,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Orion Corporation Orion Pharma, FI-02200 Espoo, Finland","Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001755-36,0,0,0 2006-001755-36,3,2007-08-23,2007-08-23,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Orion Corporation Orion Pharma,"Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001755-36,0,0,0 2006-001756-13,1,2007-09-10,2007-09-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,"Multi-center, double-blind, placebo-controlled, four-arm, randomized phase II dose finding study with Sokatin® (WS® 1261) in patients with a Major Depressive Episode",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001756-13,0,0,0 2006-001761-42,2,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Merck Sharp & Dohme GesmbH,"A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001761-42,0,0,0 2006-001761-42,2,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,"Merck & Co., Inc","A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001761-42,0,0,0 2006-001763-36,6,2009-04-30,2009-06-11,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, parallel-group, placebo-controlled, multinational clinical trial to evaluate the efficacy of Aliskiren and valsartan versus placebo in lowering levels on NT-proBNP in stabi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001763-36,0,0,0 2006-001765-42,2,2015-04-17,2015-04-17,2,0,0,0,0,0,4,0,0,1,0,0,1,0,0,ULB Erasme,A prospective and randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation (REVERSE study...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001765-42,0,0,0 2006-001765-42,2,2015-04-17,2015-04-17,2,0,0,0,0,0,4,0,0,1,0,0,1,0,0,UZ Brussel,A prospective and randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation (REVERSE study...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001765-42,0,0,0 2006-001767-31,1,2010-04-15,2010-04-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Sheffield,Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001767-31,0,0,0 2006-001770-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dr Antoni Gual, Hospital Clínic de Barcelona, Unitat d'Alcohologia de la Generalitat de Catalunya","Ensayo clínico unicéntrico, cruzado, aleatorizado, doble ciego, controlado con placebo, para evaluar la calidad de la vida sexual en pacientes alcohólicos afectados de DE tras un tratamiento con varde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001770-25,0,0,0 2006-001772-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Clinica Rotger,Effect of intracoronary injection of autologous stemm cells on left ventricular ejection fraction and volumes one year after an acute myocardial infarction. Efecto de la inyección intracoronaria de c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001772-20,0,0,0 2006-001774-24,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,Newcastle u Tyne Hospitals NHS Trust,INTESTINAL MICRO-ORGANISMS IN THE PATHOGENESIS OF NASH AND THE ROLE OF MODULATION OF ENTERIC BACTERIA IN TREATMENT.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001774-24,0,0,0 2006-001777-19,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON foundation,A Phase II multicenter study to assess the tolerability and efficacy of the addition of Bevacizumab to standard induction therapy in AML and high risk MDS above 60 years.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001777-19,0,0,0 2006-001779-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Azienda Ospedaliera Universitaria S.Martino - U.O. Oncologia Medica - Genova,"Phase II trial FOLFOX combined with Bevacizumab, Cetuximab and Imatinib in patients with advanced untreated colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001779-39,0,0,0 2006-001780-30,2,2010-03-02,2010-03-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cliniques Universiatires St Luc- Centre du Cancer,A PHASE II STUDY OF SU011248 IN PATIENTS WITH RECURRENT AND/OR METASTATIC SQUAMOUS HEAD AND NECK CARCINOMA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001780-30,0,0,0 2006-001780-30,2,2010-03-02,2010-03-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UCL Saint Luc 1200 Bruxelles,A PHASE II STUDY OF SU011248 IN PATIENTS WITH RECURRENT AND/OR METASTATIC SQUAMOUS HEAD AND NECK CARCINOMA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001780-30,0,0,0 2006-001782-42,3,2007-11-09,2007-12-19,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Cosmo Technologies Ltd,"Efficacy and tolerability of a new oral extended-release formulation containing Low Molecular Weight Heparin CB-01-05-MMXTM , administered as add-on therapy to oral mesalazine or other 5-ASA derivati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001782-42,0,0,0 2006-001782-42,3,2007-11-09,2007-12-19,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,COSMO TECHNOLOGIES LTD,"Efficacy and tolerability of a new oral extended-release formulation containing Low Molecular Weight Heparin CB-01-05-MMXTM , administered as add-on therapy to oral mesalazine or other 5-ASA derivati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001782-42,0,0,0 2006-001783-23,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,URSAPHARM Arzneimittel GmbH & Co. KG,"A randomized, double-masked, placebo-controlled two cross-over study comparing the effects of moxaverine and placebo on ocular blood flow",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001783-23,0,0,0 2006-001784-35,1,,,0,0,0,0,0,3,4,0,1,1,0,0,0,1,0,Nuvo research Inc,Validation of the microdialysis technique as a tool to assess local delivery of topical drugs used in the treatment of osteoarthritis of superficial joints,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001784-35,0,0,0 2006-001785-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Karolinska universitetssjukhuset,Neo-adjuvant behandling av esofagus-cardia cancer inför kurativt syftande resektion. Jämförande studie mellan kemo- och radiokemobehandling.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001785-16,0,0,0 2006-001786-42,14,2009-01-19,2010-11-10,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,sanofi-aventis recherche et développement,"An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E 3.0 mg s.c. once weekly versus oral INR-adjusted warfarin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001786-42,0,0,0 2006-001786-42,14,2009-01-19,2010-11-10,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,sanofi-synthelabo recherche,"An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E 3.0 mg s.c. once weekly versus oral INR-adjusted warfarin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001786-42,0,0,0 2006-001786-42,14,2009-01-19,2010-11-10,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,sanofi-Aventis recherche & developpement,"An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E 3.0 mg s.c. once weekly versus oral INR-adjusted warfarin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001786-42,0,0,0 2006-001786-42,14,2009-01-19,2010-11-10,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,sanofi-aventis recherche & développement,"An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3-month or 6-month treatment with SSR126517E 3.0 mg s.c. once weekly versus oral INR-adjusted warfarin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001786-42,0,0,0 2006-001787-23,11,2010-08-16,2010-08-27,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A,"A 12-week, open label, multicenter, titration study, with a 9- month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001787-23,0,0,0 2006-001787-23,11,2010-08-16,2010-08-27,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 12-week, open label, multicenter, titration study, with a 9- month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001787-23,0,0,0 2006-001787-23,11,2010-08-16,2010-08-27,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 12-week, open label, multicenter, titration study, with a 9- month maintenance treatment extension, to demonstrate efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001787-23,0,0,0 2006-001791-20,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"University Hospital of Schleswig-Holstein (UKSH), Campus Lübeck","A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001791-20,0,0,0 2006-001793-24,2,2007-09-21,2007-09-21,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,"BIAL - Portela & Cª, SA","A MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF NEBICAPONE IN PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001793-24,0,0,0 2006-001795-20,6,2008-01-30,2008-07-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-Abelló A/S,A phase II-III trial assessing the efficacy and safety of three doses of the ALK HDM tablet in house dust mite allergic subjects.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001795-20,0,0,0 2006-001795-20,6,2008-01-30,2008-07-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-ABELLO,A phase II-III trial assessing the efficacy and safety of three doses of the ALK HDM tablet in house dust mite allergic subjects.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001795-20,0,0,0 2006-001796-37,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO,Effect of alendronate on spontaneous osteoclastogenesis in postmenopausal osteoporosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001796-37,0,0,0 2006-001798-95,1,2007-08-14,2007-08-14,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Jari Tiihonen,"Ketamiini hoitoresistentin depression hoidossa. Satunnaistettu, placebokontrolloitu rinnakkaisryhmätutkimus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001798-95,0,0,0 2006-001806-94,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hôpital Erasme,Comparison of the efficacy of pneumococcal and tetanus vaccination between hemodialysis patients and renal tranpslant recipients treated with Mycophenolic acid(VACC-IR) study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001806-94,0,0,0 2006-001808-37,1,2009-05-30,2009-05-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Devon and Exeter NHS Foundation Trust,A randomised controlled trial of fentanyl versus morphine following lower limb arthroplasty,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001808-37,0,0,0 2006-001810-33,1,2012-05-07,2012-05-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"A Phase II study with Stimuvax® (L-BLP25 liposome vaccine) in subjects with either chemotherapy-naive, slowly progressive asymptomatic multiple myeloma or with stage II/ III multiple myeloma following...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001810-33,0,0,0 2006-001812-65,1,2006-10-04,2006-10-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the effect of valsartan on proteinuria and glomerular filtration rate in children with Chronic Kidney Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001812-65,0,0,0 2006-001814-34,1,2010-09-24,2010-09-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Norwegian University of Science and Technology,"Effects of hypothermia on the disposition of morphine, fentanyl, midazolam and propofol in intensive care unit patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001814-34,0,0,0 2006-001815-30,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,"St George's, University of London (SGUL)",Prevention Of Endometrial Tumours (POET),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001815-30,0,0,0 2006-001815-30,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,"Queen Mary and Westfield College, University of London (QMUL)",Prevention Of Endometrial Tumours (POET),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001815-30,0,0,0 2006-001816-56,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Rigshospitalet,Can PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001816-56,0,0,0 2006-001822-23,4,2012-09-26,2012-09-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,A Randomized Multicenter Phase II Trial of Patupilone (EPO906) plus Prednisone versus Docetaxel (Taxotere) plus Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001822-23,0,0,0 2006-001822-23,4,2012-09-26,2012-09-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.",A Randomized Multicenter Phase II Trial of Patupilone (EPO906) plus Prednisone versus Docetaxel (Taxotere) plus Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001822-23,0,0,0 2006-001822-23,4,2012-09-26,2012-09-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A Randomized Multicenter Phase II Trial of Patupilone (EPO906) plus Prednisone versus Docetaxel (Taxotere) plus Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001822-23,0,0,0 2006-001823-20,1,2007-12-13,2007-12-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,CHIESI,"A twelve-week, multicentre, double blind, randomised, parallel group, clinical study to assess the antihypertensive efficacy of delapril 15 mg b.i.d. and 30 mg b.i.d. versus lisinopril and placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001823-20,0,0,0 2006-001827-21,1,2013-08-27,2013-08-27,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,"Glostrup Hospital, Dep. of Neurology","A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in patients treated with Copaxone fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001827-21,0,0,0 2006-001831-23,8,2009-06-17,2010-03-30,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Wyeth Pharmaceuticals Inc.,"A Phase 2/3, Multicenter, Double-Blind, Randomized, Controlled Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP 2)/Calcium Phosphate Matrix (CPM) in Closed Diaphyseal Tibial Fractures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001831-23,0,0,0 2006-001832-34,6,2010-04-28,2010-06-22,5,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals Inc.,"A Phase 2, Multicenter, Single-Blind, Randomized, Stratified, Standard-of-Care Controlled, Feasibility and Safety Study of rhBMP-2/CPM as an Adjuvant Therapy for Fractures of the Proximal Femur",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001832-34,0,0,0 2006-001833-16,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"Multicentric, no-profit, open, controlled randomized clinical study to evaluate comparable tolerability and efficacy of two pharmacological treatments for persistent, non oncological pain in the elder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001833-16,0,0,0 2006-001834-42,3,2010-03-09,2010-03-09,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Multi-Center, Open label, Repeated Dose Range Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Efficacy of an Anti-IL-1 946; Monoclonal Antibody ACZ885 Gi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001834-42,0,0,0 2006-001834-42,3,2010-03-09,2010-03-09,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,NOVARTIS PHARMA AG,"A Multi-Center, Open label, Repeated Dose Range Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Efficacy of an Anti-IL-1 946; Monoclonal Antibody ACZ885 Gi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001834-42,0,0,0 2006-001836-32,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ELI LILLY,Pemetrexed monochemotherapy in patients with locally advanced or metastatic Non Small Cell Lung Cancer. A pilot study to define the best dosing schedule for a planned phase II randomized trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001836-32,0,0,0 2006-001837-16,5,2008-06-17,2008-07-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ACRAF S.p.A.,PRULIFLOXACIN VERSUS LEVOFLOXACIN IN PATIENTS WITH ACUTE BACTERIAL RHINOSINUSITIS ABRS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001837-16,0,0,0 2006-001837-16,5,2008-06-17,2008-07-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Angelini Farmaceutici,PRULIFLOXACIN VERSUS LEVOFLOXACIN IN PATIENTS WITH ACUTE BACTERIAL RHINOSINUSITIS ABRS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001837-16,0,0,0 2006-001837-16,5,2008-06-17,2008-07-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ANGELINI,PRULIFLOXACIN VERSUS LEVOFLOXACIN IN PATIENTS WITH ACUTE BACTERIAL RHINOSINUSITIS ABRS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001837-16,0,0,0 2006-001837-16,5,2008-06-17,2008-07-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ACRAF SpA,PRULIFLOXACIN VERSUS LEVOFLOXACIN IN PATIENTS WITH ACUTE BACTERIAL RHINOSINUSITIS ABRS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001837-16,0,0,0 2006-001839-21,3,2011-06-21,2012-06-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,2,GLAXO SMITH KLINE,CHEMOTHERAPY PLUS LAPATINIB OR TRASTUZUMAB OR BOTH IN HER2 PRIMARY BREAST CANCER. A RANDOMIZED PHASE IIb STUDY WITH BIOMARKER EVALUATION.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001839-21,0,0,0 2006-001839-21,3,2011-06-21,2012-06-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,2,GlaxoSmithKline Reseacrh and Development Limited,CHEMOTHERAPY PLUS LAPATINIB OR TRASTUZUMAB OR BOTH IN HER2 PRIMARY BREAST CANCER. A RANDOMIZED PHASE IIb STUDY WITH BIOMARKER EVALUATION.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001839-21,0,0,0 2006-001839-21,3,2011-06-21,2012-06-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,2,GlaxoSmithKline Research and Development Limited,CHEMOTHERAPY PLUS LAPATINIB OR TRASTUZUMAB OR BOTH IN HER2 PRIMARY BREAST CANCER. A RANDOMIZED PHASE IIb STUDY WITH BIOMARKER EVALUATION.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001839-21,0,0,0 2006-001840-30,8,2008-02-01,2008-02-13,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer bv,"A 12-WEEK, OPEN-LABEL, SAFETY TRIAL OF PREGABALIN IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001840-30,0,0,0 2006-001840-30,8,2008-02-01,2008-02-13,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Ltd,"A 12-WEEK, OPEN-LABEL, SAFETY TRIAL OF PREGABALIN IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001840-30,0,0,0 2006-001840-30,8,2008-02-01,2008-02-13,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER,"A 12-WEEK, OPEN-LABEL, SAFETY TRIAL OF PREGABALIN IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001840-30,0,0,0 2006-001840-30,8,2008-02-01,2008-02-13,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Ltd/Ann Arbor,"A 12-WEEK, OPEN-LABEL, SAFETY TRIAL OF PREGABALIN IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001840-30,0,0,0 2006-001840-30,8,2008-02-01,2008-02-13,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A 12-WEEK, OPEN-LABEL, SAFETY TRIAL OF PREGABALIN IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001840-30,0,0,0 2006-001840-30,8,2008-02-01,2008-02-13,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer,"A 12-WEEK, OPEN-LABEL, SAFETY TRIAL OF PREGABALIN IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001840-30,0,0,0 2006-001841-32,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,TRBChemedica,"Eficacia y Seguridad de SVS20 en pacientes con síndrome de ojo seco moderado bilateral: Estudio Piloto de 3 meses, fase II, aleatorio de pares correspondientes, controlado y enmascarado para el evalua...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001841-32,0,0,0 2006-001843-74,5,2008-01-07,2008-01-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A randomized, double-blind, parallel-group, placebo-controlled, dose-response, multicentre, multinational study evaluating the efficacy and safety of AVE2268 administered either twice daily breakfast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001843-74,0,0,0 2006-001843-74,5,2008-01-07,2008-01-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Synthelabo Recherche,"A randomized, double-blind, parallel-group, placebo-controlled, dose-response, multicentre, multinational study evaluating the efficacy and safety of AVE2268 administered either twice daily breakfast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001843-74,0,0,0 2006-001845-33,1,2009-12-18,2009-12-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Roche Farma, S.A.","Estudio fase III randomizado, controlado de erlotinib (Tarceva®) como tratamiento de mantenimiento en pacientes con carcinoma epidermoide de cabeza y cuello resecado y tratado con radioterapia con o ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001845-33,0,0,0 2006-001846-15,1,2009-04-15,2009-04-15,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,InDex Pharmaceuticals AB,"A placebo-controlled, randomised, double-blind, single dose proof of concept study of Kappaproct, in steroid resistant or steroid dependent patients with ulcerative colitis of mild to moderate degree",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001846-15,0,0,0 2006-001852-11,1,,,0,1,0,0,1,0,4,0,0,1,0,0,0,1,0,Medical University of Vienna,Influence of L-Arginine on perfusion in patients receiving peripheral bypass surgery (Einfluss von L-Arginin auf die Perfusion bei Patienten mit peripheren Bypassoperationen),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001852-11,0,0,0 2006-001853-89,2,2007-12-19,2009-11-27,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Vion Pharmaceuticals, Inc",A phase II study of Cloretazine for elderly patients with de novo poor risk acute myelogenous leukemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001853-89,0,0,0 2006-001855-37,4,2008-12-09,2009-03-03,3,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Schülke & Mayr GmbH,"Effect of an octenidine-based topical antimicrobial agent (Octenisept) on wound healing of chronic venous leg ulcers: a prospective, twelve week comparison versus local treatment with Ringer solution....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001855-37,0,0,0 2006-001858-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NEUROLOGICO CARLO BESTA,"A randomized, double-blind pilot study vs placebo for the evaluation of efficacy and tolerability of doxycline administered by oral route in patients affected by Creutzfeldt-Jakob disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001858-27,0,0,0 2006-001859-35,3,2009-03-25,2009-03-25,3,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Imperial College London,Abatacept in ANCA associated vasculitis: ABAVAS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001859-35,0,0,0 2006-001860-22,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,3,Karl Andersen,CREATE. Cardiovascular Risk Evaluation and Attenuation of inflammation by early rosuvastatin TrEatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001860-22,0,0,0 2006-001861-40,4,2009-12-08,2009-12-08,3,0,0,0,0,1,2,0,0,1,0,0,1,0,1,"SYSTEMS MEDICINE, LLC",Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001861-40,0,0,0 2006-001861-40,4,2009-12-08,2009-12-08,3,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Nerviano Medical Sciences S.r.l.,Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001861-40,0,0,0 2006-001862-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,"Ensayo clínico, multicéntrico, aleatorizado, controlado y doble ciego, para el estudio de la terapia puente con bemiparina sódica frente a heparina cálcica no fraccionada en procedimientos invasivos a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001862-17,0,0,0 2006-001865-41,13,2016-04-13,2016-04-13,12,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Celgene International Sàrl,"A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001865-41,0,0,0 2006-001865-41,13,2016-04-13,2016-04-13,12,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Celgene,"A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001865-41,0,0,0 2006-001866-18,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperact...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001866-18,0,1,1 2006-001871-39,1,2009-02-12,2009-02-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Cytokinetics, Inc","A PHASE II, MULTI CENTRE, DOUBLE-BLIND, RANDOMISED, PLACEBO CONTROLLED, DOSE-ESCALATION, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF CK-1827452 IN PATIENTS WITH STABLE HEART FAILURE.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001871-39,0,0,0 2006-001877-13,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double-blind, double-dummy, parallel-group, placebo-controlled study comparing correlates of brain functional activation before and after treatment with placebo, active comparator paroxe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001877-13,0,0,0 2006-001879-38,1,2010-08-25,2010-08-25,1,1,0,0,1,0,4,0,0,1,1,1,1,0,1,B. Braun Melsungen AG,"Prospective, controlled, single-blind, bicentric, randomized study on the safety of HES 130/0.42 combined with a balanced electrolyte solution vs. 5% Albumin combined with an unbalanced electrolyte so...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001879-38,0,0,0 2006-001880-42,1,2009-04-28,2009-04-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo de Tratamiento de los Tumores Digestivos,"Estudio piloto fase II abierto, no controlado y multicéntrico para evaluar la eficacia y seguridad de la combinación de cetuximab y quimioterapia (docetaxel, cisplatin, 5-fluorouracilo) como tratamien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001880-42,0,0,0 2006-001881-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación General Universidad Autónoma de Madrid,Estudio piloto fase II no controlado y multicéntrico para evaluar la eficacia y seguridad de la combinación de cetuximab (Erbitux®) y temozolamida como tratamiento de inducción seguido de radioterapia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001881-18,0,0,0 2006-001885-17,4,2012-10-24,2012-11-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Oxford,HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): A randomized trial of the long-term clinical effects of raising HDL cholesterol with MK 524A (ER niacin and laropipirant).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001885-17,0,0,0 2006-001885-17,4,2012-10-24,2012-11-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"CTSU, University of Oxford",HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events): A randomized trial of the long-term clinical effects of raising HDL cholesterol with MK 524A (ER niacin and laropipirant).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001885-17,0,0,0 2006-001886-40,1,2008-09-16,2008-09-16,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,TopoTarget Germany AG,"A randomized, double-blind, placebo-controlled parallel group study to assess the safety and efficacy of a new oral formulation of 2-propyl pentanoic acid (2-PPA, PEAC minitablets) for the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001886-40,0,0,0 2006-001888-40,2,2008-02-01,2008-02-01,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Mundipharma Research Ltd.,A phase II prospective non-comparative multicenter clinical trial to determine the efficacy and safety of intrathecal liposomal cytarabine (DepoCyte®) in preventing CNS-relapse in patients with aggres...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001888-40,0,0,0 2006-001889-16,1,,,0,0,0,0,1,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SENESE,Use of clembuterol in patients affected by valvular hearth disease and dilated cardiomyopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001889-16,0,0,0 2006-001891-19,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,GlaxoSmithKline Research & Development Limited,"A multi-centre, randomised, dose-ascending, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001891-19,0,0,0 2006-001896-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SOFAR SPA,"Evaluation of symbiotic effect on the intestinal function in idiopathic chronic constipation. Multicenter, randomised, cross-over, double-blind, placebo-controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001896-39,0,0,0 2006-001897-26,1,2010-03-03,2010-03-03,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Centocor B.V.,A Phase 2 Multicenter Study of CNTO 328 (Anti Interleukin 6 Monoclonal Antibody) in Subjects with Relapsed or Refractory Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001897-26,0,0,0 2006-001898-25,6,2009-01-16,2009-01-16,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Myogen, Inc.","DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001898-25,0,0,0 2006-001898-25,6,2009-01-16,2009-01-16,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001898-25,0,0,0 2006-001898-25,6,2009-01-16,2009-01-16,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Colorado, Inc.","DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001898-25,0,0,0 2006-001898-25,6,2009-01-16,2009-01-16,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc","DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001898-25,0,0,0 2006-001898-25,6,2009-01-16,2009-01-16,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Inc.,"DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001898-25,0,0,0 2006-001899-20,7,2010-01-14,2010-02-18,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Gilead Sciences Inc.,"DORADO-EX – A Dose-Blinded, Long Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001899-20,0,0,0 2006-001899-20,7,2010-01-14,2010-02-18,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Gilead Colorado, Inc.","DORADO-EX – A Dose-Blinded, Long Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001899-20,0,0,0 2006-001899-20,7,2010-01-14,2010-02-18,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.","DORADO-EX – A Dose-Blinded, Long Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001899-20,0,0,0 2006-001902-10,1,2009-05-01,2009-05-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Kirurgisk Forskningsafsnit, Herning Sygehus","Effects of caffeine on people suffering from intermittens claudication. Three double blinded, placebo-controlled cross-over studies and a follow-up study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001902-10,0,0,0 2006-001904-36,11,2011-12-01,2019-09-24,10,1,0,0,0,1,2,0,0,1,0,0,1,0,2,Centocor B.V.,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study Comparing the Combination of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and Velcade® versus Velcade alone in Subjects with Relapsed or Refra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001904-36,0,0,0 2006-001904-36,11,2011-12-01,2019-09-24,10,1,0,0,0,1,2,0,0,1,0,0,1,0,2,Janssen-Cilag International,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study Comparing the Combination of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and Velcade® versus Velcade alone in Subjects with Relapsed or Refra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001904-36,0,0,0 2006-001904-36,11,2011-12-01,2019-09-24,10,1,0,0,0,1,2,0,0,1,0,0,1,0,2,Janssen Biologics B.V.,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study Comparing the Combination of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and Velcade® versus Velcade alone in Subjects with Relapsed or Refra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001904-36,0,0,0 2006-001907-13,3,2011-04-09,2011-04-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"LETROZOLE versus LETROZOLE PLUS LAPATINIB GW572016 IN HORMONE-SENSITIVE, HER-2 NEGATIVE OPERABLE BREAST CANCER. A DOUBLE BLIND RANDOMIZED PHASE II STUDY WITH BIOMARKER EVALUATION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001907-13,0,0,0 2006-001907-13,3,2011-04-09,2011-04-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXO SMITH KLINE RESEARCH DEVELOPMENT LTD,"LETROZOLE versus LETROZOLE PLUS LAPATINIB GW572016 IN HORMONE-SENSITIVE, HER-2 NEGATIVE OPERABLE BREAST CANCER. A DOUBLE BLIND RANDOMIZED PHASE II STUDY WITH BIOMARKER EVALUATION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001907-13,0,0,0 2006-001909-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Grupo GICOR,"Ensayo clínico fase IV-III multicéntrico, prospectivo, aleatorizado, abierto y paralelo de 36 meses para evaluar la eficacia del bloqueo androgénico intermitente versus continuo en el tratamiento de l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001909-28,0,0,0 2006-001910-33,2,,,0,0,0,0,0,1,4,0,1,3,0,0,0,0,1,Genzyme Europe BV,"A Multicenter, Multinational Study of the Effects of Fabrazyme® (agalsidase beta) Treatment on Lactation and Infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001910-33,0,0,0 2006-001911-31,1,2008-10-01,2008-10-01,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Universitätsfrauenklinik Innsbruck,Metformin-Wirkung am Ovar bei PCOS (MAO-Studie) - eine Pilotstudie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001911-31,0,0,0 2006-001913-13,4,2008-05-20,2008-05-20,4,1,0,0,2,0,3,0,0,1,1,1,1,0,1,Merck Sharp & Dohme Limited,"A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK-0524A 2g Coadministered with Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001913-13,0,0,0 2006-001913-13,4,2008-05-20,2008-05-20,4,1,0,0,2,0,3,0,0,1,1,1,1,0,1,"Merck & Co., Inc","A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK-0524A 2g Coadministered with Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001913-13,0,0,0 2006-001913-13,4,2008-05-20,2008-05-20,4,1,0,0,2,0,3,0,0,1,1,1,1,0,1,Laboratoires Merck Sharp & Dohme - Chibret,"A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK-0524A 2g Coadministered with Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001913-13,0,0,0 2006-001913-13,4,2008-05-20,2008-05-20,4,1,0,0,2,0,3,0,0,1,1,1,1,0,1,"Merck & Co., Inc.","A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK-0524A 2g Coadministered with Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001913-13,0,0,0 2006-001914-34,1,2008-07-31,2008-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Bert Mueller, Dep. Ophthalmology",Treatment of neovascular age related macular degeneration with intravitreal Bevacizumab (Avastin),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001914-34,0,0,0 2006-001916-54,4,2010-02-22,2010-02-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals Inc.,"A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of rhBMP-2/CPM as an Adjuvant Therapy in Closed Fractures of the Humerus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001916-54,0,0,0 2006-001918-33,1,2006-08-28,2006-08-28,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,A Phase III study for evaluation of immunogenicity and reactogenicity of Fluarix™ (Influspit SSW®) 2006/2007 in people aged 18 years or above,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001918-33,0,0,0 2006-001921-25,4,2009-11-02,2009-11-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as first Line Therapy for Locally Recurrent or Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001921-25,0,0,0 2006-001921-25,4,2009-11-02,2009-11-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as first Line Therapy for Locally Recurrent or Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001921-25,0,0,0 2006-001923-20,1,2006-07-20,2006-07-20,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,"Palifermin use in patients , out of clinical investigation, which are receiving chemioterapic therapy with staminal cells to reduce severuty and incidence of mucositis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001923-20,0,0,0 2006-001927-20,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO GIANNINA GASLINI,Treatment with Anakinra in TRAPS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001927-20,0,0,0 2006-001933-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Christos N. Papandreou,"""A Phase II, Open-Label study of Velcade(Bortezomib)for patients with Androgen-Independent Prostate Carcinoma who progressed on or after prior chemotherapy""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001933-16,0,0,0 2006-001934-42,1,2007-08-13,2007-08-13,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIa open, randomised, controlled study to assess the safety, reactogenicity and immunogenicity induced by a booster dose of GlaxoSmithKline (GSK) Biologicals 10-valent pneumococcal conjugate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001934-42,0,0,0 2006-001935-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Heidelberg,Real-time contrast-enhanced sonography of renal transplant recipients accurately predicts vascular allograft nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001935-23,0,0,0 2006-001936-30,1,2009-10-26,2009-10-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universität zu Köln,A phase II dose escalation study of caspofungin in patients with invasive aspergillosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001936-30,0,0,0 2006-001937-17,1,2006-11-29,2006-11-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Schwarz Biosciences GmbH,"A randomized, double-blind, placebo-controlled, parallel-group proof-of-concept trial to assess the efficacy, safety and tolerability of ascending doses of rotigotine nasal spray for the acute treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001937-17,0,0,0 2006-001938-41,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Lilly Deutschland GmbH,Effect of Exenatide plus Metformin vs. Premixed Human Insulin Aspart plus Metformin on Glycemic Control and Hypoglycemia in Patients with Inadequate Control of Type 2 Diabetes on Oral Antidiabetic Tre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001938-41,0,0,0 2006-001942-15,1,2008-05-05,2008-05-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ARQule Inc.,"A Phase 2 Study of ARQ 501 in Patients with Locally Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001942-15,0,0,0 2006-001945-32,1,2008-02-29,2008-02-29,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,ULB Erasme,Introduction of everolimus is associated with a reduction in the dosage of calcineurine-inhibitors in patients with a pulmonary graft who suffer from a notable chronic renal insuffisance.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001945-32,0,0,0 2006-001947-70,1,2009-09-25,2009-09-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,BioMS Technology Corp.,"A Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001947-70,0,0,0 2006-001949-34,8,2013-05-11,2013-05-31,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Limited,"A Phase III Open Label, Randomized Parallel Two-Arm Multi Center Study of E7389 versus ‘Treatment of Physician's Choice' in Patients with Locally Recurrent or Metastatic Breast Cancer, Previously Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001949-34,0,0,0 2006-001949-34,8,2013-05-11,2013-05-31,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,EISAI LIMITED,"A Phase III Open Label, Randomized Parallel Two-Arm Multi Center Study of E7389 versus ‘Treatment of Physician's Choice' in Patients with Locally Recurrent or Metastatic Breast Cancer, Previously Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001949-34,0,0,0 2006-001951-36,1,2008-04-30,2008-04-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Medical University of Vienna,Perioperative Analgesie in der Gefäßchirurgie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001951-36,0,0,0 2006-001954-28,13,2008-07-21,2008-07-22,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (300 & 600 µg o.d.) in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001954-28,0,0,0 2006-001954-28,13,2008-07-21,2008-07-22,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NovartisPharma Services AG,"A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (300 & 600 µg o.d.) in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001954-28,0,0,0 2006-001954-28,13,2008-07-21,2008-07-22,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (300 & 600 µg o.d.) in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001954-28,0,0,0 2006-001955-37,4,2008-08-22,2008-08-23,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 26-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (7...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001955-37,0,0,0 2006-001955-37,4,2008-08-22,2008-08-23,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 26-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (7...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001955-37,0,0,0 2006-001955-37,4,2008-08-22,2008-08-23,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A 26-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (7...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001955-37,0,0,0 2006-001956-11,4,2009-12-14,2010-09-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cabrellis Pharmaceuticals Corporation,Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001956-11,0,0,0 2006-001956-11,4,2009-12-14,2010-09-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Celgene International SARL,Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001956-11,0,0,0 2006-001956-11,4,2009-12-14,2010-09-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CABRELLIS PHARMACEUTICALS CORPORATION,Randomized Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin versus Etoposide-Cisplatin as first-Line Treatment in Patients with Extensive Stage SCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001956-11,0,0,0 2006-001958-27,5,2007-10-17,2009-05-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly ICOS LLC,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001958-27,0,0,0 2006-001958-27,5,2007-10-17,2009-05-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001958-27,0,0,0 2006-001958-27,5,2007-10-17,2009-05-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001958-27,0,0,0 2006-001961-40,1,2011-05-27,2011-05-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Oncology, University Hospital Herlev",Phase II study of therapy with Cetuximab and Irinotecan every second week to Irinotecan resistant patients with metastatic colorectal cancer-effect and biological markers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001961-40,0,0,0 2006-001963-52,1,2014-01-17,2014-01-17,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Queen Mary University London,GAMEC-SHORT (S) & GAMEC-ANTHRACYCLINE (A) RISK-ADAPTED PROTOCOL FOR RELAPSED GERM CELL TUMOURS (GCT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001963-52,0,0,0 2006-001965-41,1,2015-04-22,2015-04-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University College London,"Phase III, multicentre, randomised study of fludarabine/cyclophosphamide combination with or without Rituximab in patients with untreated mantle cell lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001965-41,0,0,0 2006-001971-38,1,,,0,1,0,0,1,0,3,0,0,1,0,0,0,1,1,HARRAS-PHARMA-CURARINA GmbH,"Comparative Study with a Propolis Cream vs. Aciclovir Cream in Patients with Herpes labialis A single-blind, randomised, two-arm study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001971-38,0,0,0 2006-001972-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hanns-Ulrich Marschall,Study of atorvastatin and fenofibrate mediated effects on the metabolism and hepatic excretion of biliary compounds in gallstone patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001972-19,0,0,0 2006-001973-10,2,2009-03-26,2009-03-26,1,0,0,0,0,0,2,0,0,1,1,0,1,0,1,GPC Biotech AG,A Phase 2 Study comparing sequential satraplatin and erlotinib to single-agent erlotinib in patients >70 years of age with unresectable stage 3 or 4 Non-small Cell Lung Cancer as 1st-line therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001973-10,0,0,0 2006-001973-10,2,2009-03-26,2009-03-26,1,0,0,0,0,0,2,0,0,1,1,0,1,0,1,GPC BIOTECH,A Phase 2 Study comparing sequential satraplatin and erlotinib to single-agent erlotinib in patients >70 years of age with unresectable stage 3 or 4 Non-small Cell Lung Cancer as 1st-line therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001973-10,0,0,0 2006-001975-40,2,2008-07-09,2008-07-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effects of a 4-week treatment of 15 mg b.i.d BIBW 2948 BS (inhalation powder, hard capsule for HandiHaler®) on epit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001975-40,0,0,0 2006-001975-40,2,2008-07-09,2008-07-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effects of a 4-week treatment of 15 mg b.i.d BIBW 2948 BS (inhalation powder, hard capsule for HandiHaler®) on epit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001975-40,0,0,0 2006-001976-19,1,2007-10-22,2007-10-22,1,1,0,0,0,3,4,0,1,1,0,0,1,0,0,"Institut for Sundhedstjenesteforskning, Klinisk Farmakologi, Syddansk Universitet","“Betydningen af CYP2C19 polymorfi for escitaloprams farmakokinetik og farmakodynamik, målt som ændringer i pupildiameter”",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001976-19,0,0,0 2006-001977-17,1,2010-03-29,2010-03-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"An open-label, randomized, parallel group study comparing the efficacy and safety of Amlodipine in combination with Valsartan compared to Losartan in combination with Hydrochlorothiazide given for 52 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001977-17,0,0,0 2006-001979-38,2,2010-01-28,2010-01-28,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bracco Imaging Deutschland GmbH,INTRAINDIVIDUAL CROSS-OVER STUDY TO COMPARE MULTIHANCE AND OMNISCAN AT A DOSE OF 0.1 MMOL/KGBW IN THE DIFFERENTIAL DIAGNOSIS OF DISC HERNIATION VS. SCAR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001979-38,0,0,0 2006-001980-41,1,2008-04-03,2008-04-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,Glivec® (imatinib mesylate)/Litalir® (hydroxyurea) plus initial radiotherapy after surgery in patients with newly diagnosed glioblastoma multiforme followed by Glivec® and Litalir® – A phase I/II safe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001980-41,0,0,0 2006-001982-41,1,2010-02-01,2010-02-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Bradford Teaching Hospitals NHS Foundation Trust,An evaluation of the safety and effectiveness of combination therapy using the thiazolidinedione pioglitazone alongside insulin in type 2 diabetes mellitus.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001982-41,0,0,0 2006-001984-53,2,2013-05-06,2013-05-06,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Friedrich-Schiller-Universität Jena,Effectiveness of Dalteparin Therapy as Intervention in recurrent pregnancy loss,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001984-53,0,0,0 2006-001985-17,2,2012-11-05,2012-11-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company limited,"An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine, and Oxaliplatin plus Oral Enzastaurin as Treatment for Patients with Relapsed Diffuse Large B-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001985-17,0,0,0 2006-001987-22,2,2008-07-01,2008-07-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,The Comparison of the Efficacy and Safety of Arzoxifene versus Raloxifene in Postmenopausal Women with Osteoporosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001987-22,0,0,0 2006-001987-22,2,2008-07-01,2008-07-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,The Comparison of the Efficacy and Safety of Arzoxifene versus Raloxifene in Postmenopausal Women with Osteoporosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001987-22,0,0,0 2006-001989-16,1,2009-11-01,2009-11-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AGMT,Phase II study of Oxaliplatin / Irinotecan / Cetuximab as first line therapy in locally advanced or metastatic gastric cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001989-16,0,0,0 2006-001990-32,2,2010-01-07,2010-02-01,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVELOS THERAPEUTICS INC.,"A Randomized, Open-Label, Phase 3 Trial of NOV-002 in Combination with Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001990-32,0,0,0 2006-001990-32,2,2010-01-07,2010-02-01,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novelos Therapeutics, Inc.","A Randomized, Open-Label, Phase 3 Trial of NOV-002 in Combination with Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001990-32,0,0,0 2006-001996-39,3,2009-04-29,2009-04-29,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"AN INTERNATIONAL, MULTICENTER, LARGE SIMPLE TRIAL (LST) TO EVALUATE THE LONG-TERM PULMONARY AND CARDIOVASCULAR SAFETY OF EXUBERA® IN PATIENTS WITH DIABETES MELLITUS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001996-39,0,0,0 2006-001996-39,3,2009-04-29,2009-04-29,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Inc,"AN INTERNATIONAL, MULTICENTER, LARGE SIMPLE TRIAL (LST) TO EVALUATE THE LONG-TERM PULMONARY AND CARDIOVASCULAR SAFETY OF EXUBERA® IN PATIENTS WITH DIABETES MELLITUS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001996-39,0,0,0 2006-001996-39,3,2009-04-29,2009-04-29,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Limited,"AN INTERNATIONAL, MULTICENTER, LARGE SIMPLE TRIAL (LST) TO EVALUATE THE LONG-TERM PULMONARY AND CARDIOVASCULAR SAFETY OF EXUBERA® IN PATIENTS WITH DIABETES MELLITUS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001996-39,0,0,0 2006-001998-25,1,2008-09-24,2008-09-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Takeda Pharma GmbH,"Double-blind, randomised trial to investigate the antihypertensive and metabolic effects of candesartan in insulin-resistant obese patients with a hypertension not adequately controlled by previous be...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001998-25,0,0,0 2006-001999-20,3,2007-06-18,2007-06-18,3,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Galderma Research & Development SNC,"ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001999-20,0,0,0 2006-002000-34,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Fundación Cerebro y Mente,CLOZAPINA EN PRIMEROS BROTES DE ESQUIZOFRENIA COMO POSIBLE TRATAMIENTO PREVENTIVO DEL DETERIORO CEREBRAL Y CLINICO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002000-34,0,0,0 2006-002001-31,3,2009-04-14,2009-04-19,2,1,1,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of esomeprazole once daily for the treatment of gastroesophageal reflux disease (GERD) in neonatal patients, in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002001-31,1,1,0 2006-002003-14,1,2007-08-22,2007-08-22,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Winthrop Arzneimittel GmbH,Efficacy and tolerability of Triamcinolonacetonide crystalline solution for local treatment of keloids: clinical verum-controlled study in parallel groups with Triam 10 mg Lichtenstein versus Volon A ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002003-14,0,0,0 2006-002004-33,1,2009-03-06,2009-03-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Encysive Pharmaceuticals Inc,"The effects of sitaxsentan once daily dosing on proteinuria, 24 hour systemic blood pressure and arterial stiffness in subjects with chronic kidney disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002004-33,0,0,0 2006-002006-60,1,2022-06-09,2022-06-09,1,1,0,0,0,0,4,0,1,1,1,1,0,0,0,Otto-von-Guericke University,Functional neuroanatomy and regional metabolism in depressed patients with quetiapin: An fMRI-guided MRS study on a 7 Tesla scanner,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002006-60,0,0,0 2006-002007-13,1,2007-03-21,2007-03-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, active-controlled, open-label, multicenter cross-over study with two 6-week treatment periods to investigate the effect of the combination of Lescol XL (fluvastatin) 80 mg and fenofibrat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002007-13,0,0,0 2006-002010-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Prof. Herta Flor, Head of the Institute of Clinical and Cognitive Neuroscience",An Extinction Training in Tinnitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002010-35,0,0,0 2006-002011-27,6,2008-01-29,2008-08-26,4,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A phase II, multicentre study of oral LBH589 in patients with accelerated phase or blast phase (blast crisis) chronic myeloid leukemia with resistant disease following treatment with at least two B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002011-27,0,0,0 2006-002011-27,6,2008-01-29,2008-08-26,4,1,0,0,0,2,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A phase II, multicentre study of oral LBH589 in patients with accelerated phase or blast phase (blast crisis) chronic myeloid leukemia with resistant disease following treatment with at least two B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002011-27,0,0,0 2006-002018-36,2,2009-06-16,2009-06-16,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm.V,An open label phase II trial to assess the efficacy and safety of a once daily oral dose of 50 mg BIBW 2992 in two cohorts of patients with HER2-negative metastatic breast cancer after failure of no...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002018-36,0,0,0 2006-002018-36,2,2009-06-16,2009-06-16,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,An open label phase II trial to assess the efficacy and safety of a once daily oral dose of 50 mg BIBW 2992 in two cohorts of patients with HER2-negative metastatic breast cancer after failure of no...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002018-36,0,0,0 2006-002022-29,1,2008-06-06,2008-06-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Karolinska Institutet, Center for Molecular medicine, L8:03 L8:03",A randomized double blind controlled proof of concept study of the efficacy and safety of Valcyte® as an add-on therapy in patients with malignant glioblastoma with successful surgical resection of at...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002022-29,0,0,0 2006-002024-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude de l'efficacité de la kétamine à faibles doses analgésiques, en association avec les morphiniques, dans le traitement de la douleur cancéreuse rebelle",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002024-41,0,0,0 2006-002027-16,1,2008-08-02,2008-08-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB AE,"Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002027-16,0,0,0 2006-002031-24,1,2009-10-20,2009-10-20,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Imperial College,The HAM Ciclosporin Study: An observational trial of therapy in early or progressing HAM/TSP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002031-24,0,0,0 2006-002033-21,9,2007-10-09,2017-10-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002033-21,0,0,0 2006-002033-21,9,2007-10-09,2017-10-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002033-21,0,0,0 2006-002033-21,9,2007-10-09,2017-10-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GLAXOSMITKKLINE R&D LTD,"A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002033-21,0,0,0 2006-002034-37,1,2009-02-28,2009-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Intercell AG,"OPEN-LABEL, MULTICENTER TRIAL WITH IC41, A THERAPEUTIC HCV VACCINE IN PATIENTS WITH CHRONIC HCV",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002034-37,0,0,0 2006-002036-25,1,2008-06-21,2008-06-21,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University Hospitals of Leicester NHS Trust,Epidermal growth factor enemas versus mesalazine enemas for the treatment of mild-to-moderate active left-sided ulcerative colitis or proctitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002036-25,0,0,0 2006-002037-20,11,2008-07-21,2019-07-21,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Teva Pharmaceutical Industries, Ltd.","A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind, Study, to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002037-20,0,0,0 2006-002037-20,11,2008-07-21,2019-07-21,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Teva Pharmaceuticals Industries Ltd.,"A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind, Study, to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002037-20,0,0,0 2006-002038-39,7,2008-05-29,2008-10-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Ltd,"A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002038-39,0,0,0 2006-002042-11,1,2007-02-02,2007-02-02,1,1,0,0,0,3,4,0,1,1,0,0,1,0,0,Newcastle Upon Tyne Hospitals NHS Trust,“The efficacy of inferior alveolar nerve block and buccal infiltration for pulp anaesthesia in mandibular teeth”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002042-11,0,0,0 2006-002045-36,3,2008-09-09,2008-09-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,Phase II Study of Dasatinib BMS-354825 for Advanced Triple-negative Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002045-36,0,0,0 2006-002045-36,3,2008-09-09,2008-09-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,Phase II Study of Dasatinib BMS-354825 for Advanced Triple-negative Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002045-36,0,0,0 2006-002047-92,1,2010-04-28,2010-04-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Newcastle Primary Care Trust,"A multicentre, open-label, randomized comparison of once daily insulin detemir given pre-breakfast or bedtime, according to need, with bedtime insulin glargine in people with type 2 diabetes character...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002047-92,0,0,0 2006-002049-35,1,2008-02-22,2008-02-22,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"""Estudio unicéntrico, a doble ciego, aleatorizado y controlado con placebo, cruzado de 2 brazos, para investigar el efecto de miglustat sobre la diferencia de potencial nasal en pacientes con fibrosi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002049-35,0,0,0 2006-002052-15,9,2008-07-30,2008-09-30,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Shire,"An Open-Label, Phase IIIb, Multi-Centre, Randomised, Parallel-Group Study to Investigate the Efficacy and Safety of Four Dosing Schedules of Subcutaneous Dynepo in Adult Patients with Anaemia Associat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002052-15,0,0,0 2006-002052-15,9,2008-07-30,2008-09-30,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Shire Pharmaceutical Ltd,"An Open-Label, Phase IIIb, Multi-Centre, Randomised, Parallel-Group Study to Investigate the Efficacy and Safety of Four Dosing Schedules of Subcutaneous Dynepo in Adult Patients with Anaemia Associat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002052-15,0,0,0 2006-002053-69,2,2010-09-30,2010-09-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,FRACTURE INCIDENCE REDUCTION AND SAFETY OF TSE-424 (BAZEDOXIFENE ACETATE) COMPARED TO PLACEBO AND RALOXIFENE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002053-69,0,0,0 2006-002055-32,3,2007-11-01,2007-11-01,1,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Plethora Solutions Limited,"A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruction...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002055-32,0,0,0 2006-002056-14,1,2010-11-28,2010-11-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Universitätsklinikum Heidelberg,Akute Cholezystitis – Frühe laparoskopische Operation versus antibiotischer Therapie mit elektiver Cholezystektomie im Intervall (ACDC-Studie) (Acute cholecystitis – early laparoscopic surgery versus ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002056-14,0,0,0 2006-002060-26,1,2007-03-29,2007-03-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Intendis GmbH,"A double-blind, randomized, vehicle-controlled, 6-week exploratory multicenter pilot study of the efficacy and safety of Azelaic Acid (AzA) 15% gel in the topical treatment of mild to moderate seborr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002060-26,0,0,0 2006-002061-39,3,2013-01-16,2013-02-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Adjuvant and Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, and Immunogenicity Trial of ACC-001 and QS-21 Adjuvant in S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002061-39,0,0,0 2006-002061-39,3,2013-01-16,2013-02-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA","A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Adjuvant and Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, and Immunogenicity Trial of ACC-001 and QS-21 Adjuvant in S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002061-39,0,0,0 2006-002065-39,1,,,0,0,0,0,0,3,4,0,1,0,0,0,0,0,0,Ilkka Pörsti ja tutkimusryhmä,Primaarin ja sekundaarisen hypertension hemodynamiikka: DYNAMIC–tutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002065-39,0,0,0 2006-002068-25,1,2006-06-23,2006-06-23,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,CSL Limited,"A Single Site, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira in Healthy 'Adults' aged >18 to <60 years and in Healthy 'Older Adults' aged >60 years for the 2006/2007 Northern He...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002068-25,0,0,0 2006-002070-21,5,2011-10-27,2011-10-27,2,1,0,0,0,2,3,0,0,1,0,0,1,0,2,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled, multicenter phase III study to compare the safety and efficacy of RAD001 plus Best Supportive Care (BSC) versus BSC plus Placebo in patients with met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002070-21,0,0,0 2006-002070-21,5,2011-10-27,2011-10-27,2,1,0,0,0,2,3,0,0,1,0,0,1,0,2,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, multicenter phase III study to compare the safety and efficacy of RAD001 plus Best Supportive Care (BSC) versus BSC plus Placebo in patients with met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002070-21,0,0,0 2006-002072-18,14,2007-09-06,2007-10-25,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTELLAS PHARMA,"A randomized, double-blind, parallel group, placebo controlled, multi center dose ranging study of solifenacin succinate 3 mg, 6 mg and 9 mg in combination with tamsulosin OCAS 0.4 mg compared with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002072-18,0,0,0 2006-002072-18,14,2007-09-06,2007-10-25,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A randomized, double-blind, parallel group, placebo controlled, multi center dose ranging study of solifenacin succinate 3 mg, 6 mg and 9 mg in combination with tamsulosin OCAS 0.4 mg compared with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002072-18,0,0,0 2006-002074-22,2,2013-09-18,2013-09-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002074-22,0,0,0 2006-002075-40,12,2012-02-24,2012-03-21,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,EVOLVE Evaluation of Cinacalcet HCI Therapy to lower CardioVascular events.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002075-40,0,0,0 2006-002075-40,12,2012-02-24,2012-03-21,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN S.P.A.,EVOLVE Evaluation of Cinacalcet HCI Therapy to lower CardioVascular events.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002075-40,0,0,0 2006-002076-18,2,2007-04-20,2007-04-20,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Intercell AG,"COMPARISON OF THREE BATCHES OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (JE-PIV). DOUBLE BLIND, RANDOMIZED, CONTROLLED PHASE 3 STUDY.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002076-18,0,0,0 2006-002078-23,17,2008-07-28,2008-09-05,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG (Abbott),"A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderate to Severe Crohn s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002078-23,0,0,0 2006-002078-23,17,2008-07-28,2008-09-05,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH Co. KG,"A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderate to Severe Crohn s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002078-23,0,0,0 2006-002078-23,17,2008-07-28,2008-09-05,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderate to Severe Crohn s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002078-23,0,0,0 2006-002080-93,20,2015-03-31,2015-05-31,14,0,0,0,0,0,0,0,0,2,1,0,0,0,1,Glaxo SmithKline Research and Development Limited,An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002080-93,1,0,0 2006-002080-93,20,2015-03-31,2015-05-31,14,0,0,0,0,0,0,0,0,2,1,0,0,0,1,GlaxoSmithKline,An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002080-93,1,0,0 2006-002081-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,VU University Medical Centre,The Effects of EGFR Inhibition on Pulmonary Arterial Hypertension Associated with Systemic Sclerosis A phase II open-label safety and efficacy study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002081-19,0,0,0 2006-002084-49,1,2008-02-01,2008-02-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Belfast City Hospital Trust,Vascular function in impaired glucose tolerance - effect of pioglitazone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002084-49,0,0,0 2006-002085-19,1,2012-04-24,2012-04-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München","PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER TRIAL OF ABCIXIMAB AND BIVALIRUDIN IN PATIENTS WITH NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002085-19,0,0,0 2006-002087-26,6,2008-07-25,2008-09-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NYCOMED (HEADQUARTER),"An open label, comparative, randomised, balanced crossover trial comparing nasal fentanyl and oral transmucosal fentanyl (Actiq) in breakthrough pain in patients with cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002087-26,0,0,0 2006-002087-26,6,2008-07-25,2008-09-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nycomed Danmark ApS,"An open label, comparative, randomised, balanced crossover trial comparing nasal fentanyl and oral transmucosal fentanyl (Actiq) in breakthrough pain in patients with cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002087-26,0,0,0 2006-002088-18,6,2007-12-10,2008-01-02,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"An open label, dose escalation study with a double blind randomised placebo controlled withdrawal to examine the effects of the histamine H3 antagonist GSK189254 in patients with narcolepsy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002088-18,0,0,0 2006-002088-18,6,2007-12-10,2008-01-02,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline,"An open label, dose escalation study with a double blind randomised placebo controlled withdrawal to examine the effects of the histamine H3 antagonist GSK189254 in patients with narcolepsy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002088-18,0,0,0 2006-002090-47,4,2007-10-19,2007-10-24,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,MERCK SHARP DOHME,An Efficacy and Tolerability Study of MK-0533 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002090-47,0,0,0 2006-002090-47,4,2007-10-19,2007-10-24,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merck & Co., Inc.",An Efficacy and Tolerability Study of MK-0533 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002090-47,0,0,0 2006-002090-47,4,2007-10-19,2007-10-24,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Merck & Co. Inc.,An Efficacy and Tolerability Study of MK-0533 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002090-47,0,0,0 2006-002094-46,1,,,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,Chiesi Farmaceutici S.p.A.,"Single blind, randomized, crossover, repeated dose, pharmacokinetic and pharmacodynamic interaction study of CHF 4226 HFA and Extra-fine BUD HFA in asthmatic patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002094-46,0,0,0 2006-002095-18,1,2007-07-13,2007-07-13,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II randomized, double-blind (observer blind), adjuvant justification study of RTS,S/AS01B and RTS,S/AS02A, candidate malaria vaccines, administered according to a 0, 1, 2 months schedule in ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002095-18,0,0,0 2006-002098-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Erasmus Medical Centre Rotterdam,Efficacy of Inhaled RhDNase in Mechanically Ventilated Pediatric Patients with an Atelectasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002098-30,0,0,0 2006-002099-16,1,2006-10-16,2006-10-16,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,King's College London,The effect of milk thistle extract (Legalon) versus tea on serum iron increase after a meal containing non-haem iron in hereditary haemochromatosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002099-16,0,0,0 2006-002102-57,3,2009-03-19,2009-03-19,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002102-57,0,0,0 2006-002102-57,3,2009-03-19,2009-03-19,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002102-57,0,0,0 2006-002107-13,7,2009-03-13,2009-11-18,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, multicenter, open-label, 6-month study to explore the efficacy and safety of enteric coated mycophenolate sodium (Myfortic) in combination with two corticosteroid regimens for the treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002107-13,0,0,0 2006-002107-13,7,2009-03-13,2009-11-18,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Arzneimittel GmbH,"A randomized, multicenter, open-label, 6-month study to explore the efficacy and safety of enteric coated mycophenolate sodium (Myfortic) in combination with two corticosteroid regimens for the treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002107-13,0,0,0 2006-002107-13,7,2009-03-13,2009-11-18,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, multicenter, open-label, 6-month study to explore the efficacy and safety of enteric coated mycophenolate sodium (Myfortic) in combination with two corticosteroid regimens for the treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002107-13,0,0,0 2006-002107-13,7,2009-03-13,2009-11-18,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A randomized, multicenter, open-label, 6-month study to explore the efficacy and safety of enteric coated mycophenolate sodium (Myfortic) in combination with two corticosteroid regimens for the treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002107-13,0,0,0 2006-002110-35,4,2007-05-09,2007-05-09,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Advanced Life Sciences,"A Double-Blinded, Randomized, Parallel group, Multi-Centre, Multi-National Comparative Study of the Safety and Efficacy of Cethromycin 300mg QD to Clarithromycin (KLACID®) 250mg BID for the treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002110-35,0,0,0 2006-002112-99,8,2009-06-03,2009-09-30,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly & Company Limited,A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002112-99,0,0,0 2006-002112-99,8,2009-06-03,2009-09-30,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Lilly S.A,A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002112-99,0,0,0 2006-002112-99,8,2009-06-03,2009-09-30,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly UK,A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002112-99,0,0,0 2006-002113-12,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,ITALFARMACO,"Open label, uncontrolled, pilot, phase II study of histone-deacetylase inhibitor ITF2357 administered orally to subjects aged over 60 years with primary or secondary DLBCL refractory/ relapsed after c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002113-12,0,0,0 2006-002116-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Carboplatin Gemcitabine as second line treatment in platinum sensitive advanced ovarian cancer phase II study on a new schedule.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002116-10,0,0,0 2006-002119-28,7,2006-11-21,2006-11-21,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,"Open label, randomized, multicenter study to investigate the efficacy and safety of once-weekly (reduced administration frequency) NeoRecormon® (Epoetin beta) therapy versus thrice weekly NeoRecormon®...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002119-28,0,0,0 2006-002123-17,1,2008-01-01,2008-01-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London,Mechanistic study assessing the immunological response of subjects after treatment with different formulations of sublingual immunotherapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002123-17,0,0,0 2006-002139-26,1,2006-12-12,2006-12-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"An open label, repeat dose, dose escalation study conducted in RLS patients to characterize pharmacokinetics and food effect of ropinirole controlled release for RLS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002139-26,0,0,0 2006-002141-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON foundation,"Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002141-37,0,0,0 2006-002143-83,6,2010-03-05,2010-05-04,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment with Two Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified Neur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002143-83,0,0,0 2006-002146-10,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO GIANNINA GASLINI,Rescue therapy of tunnel/pocket infections of Hickman-Broviac/Port indwelling central venous catheters with antibiotic continuous infusion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002146-10,0,0,0 2006-002147-91,14,2011-05-25,2011-05-25,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol_myers Squibb International Corporation,"""Estudio BMS CV185030- Estudio fase III, controlado con Warfarina, aleatorizado, doble ciego y de brazos paralelos, para evaluar la seguridad y la eficacia de Apixaban en la prevención de accidente ce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002147-91,0,0,0 2006-002147-91,14,2011-05-25,2011-05-25,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"""Estudio BMS CV185030- Estudio fase III, controlado con Warfarina, aleatorizado, doble ciego y de brazos paralelos, para evaluar la seguridad y la eficacia de Apixaban en la prevención de accidente ce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002147-91,0,0,0 2006-002152-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Phase II randomized study of intravenous bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine in patients with locally advanced or recurrent breast cancer with lymphangitic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002152-16,0,0,0 2006-002157-79,1,2006-12-18,2006-12-18,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline,"“A Multi-Center, Double-Blind, Parallel-Group, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Denagliptin in Subjects With Type 2 Diabetes Mellitus”",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002157-79,0,0,0 2006-002161-39,3,2008-05-08,2008-05-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3 Randomized, Double-Blind, Active-Controlled (Enoxaparin), Parallel Group, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Apixaban in Subjects Undergoing Elective Total Knee R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002161-39,0,0,0 2006-002164-26,1,2007-10-22,2007-10-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Schering Plough Research Institute, a division of Schering Corporation",Study of the Efficacy and Safety of SCH619734 in Subjects with Chronic Idiopathic Cough,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002164-26,0,0,0 2006-002165-39,1,2007-11-29,2007-11-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Schering Plough Research Institute, a division of Schering Corporation",Study of the Efficacy and Safety of SCH486757 in Subjects With Chronic Idiopathic Cough,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002165-39,0,0,0 2006-002168-24,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO EUROPEO DI ONCOLOGIA,O6-alkylguanine-DNA-alkyltransferase modulation study Fotemustine plus Temozolomide phase I/II .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002168-24,0,0,0 2006-002174-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Mondobiotech Laboratories Anstalt,Influence of inhaled Aviptadil on CCL18 serum concentrations in patients with pulmonary fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002174-22,0,0,0 2006-002175-40,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,3,,Effect of Botulinum Toxin A Injections and Specific Intensive Rehabilitation Therapy in Children with Hemiparetic Cerebral Palsy on Upper Limb Functions and Skills,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002175-40,0,0,0 2006-002178-23,3,2009-05-06,2009-05-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,Phase II Study of Dasatinib BMS-354825 for Advanced Estrogen/Progesterone Receptor-Positive or Her2/neu-Positive Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002178-23,0,0,0 2006-002178-23,3,2009-05-06,2009-05-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,Phase II Study of Dasatinib BMS-354825 for Advanced Estrogen/Progesterone Receptor-Positive or Her2/neu-Positive Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002178-23,0,0,0 2006-002179-41,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,"Studio aperto, randomizzato, controllato per valutare gli effetti di nuove soluzioni biocompatibili per Dialisi Peritoneale(poliglucosio, aminoacidi, bicarbonato/lattato)rispetto alle soluzioni standa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002179-41,0,0,0 2006-002180-72,1,2009-01-12,2009-01-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche (Hungary) Ltd.,"Open Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6mg in Patients with Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, within ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002180-72,0,0,0 2006-002182-39,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Hilkka Soininen/Kuopio University Hospital,"Rivastigmiinin vaikutus lievässä Alzheimerin taudissa, toiminnallinen magneettikuvantamistutkimus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002182-39,0,0,0 2006-002183-26,2,2008-02-27,2008-02-27,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Tibotec Pharmaceuticals Ltd,"A Phase I, open-label trial to investigate pharmacokinetics, safety and tolerability of TMC125 at steady-state in treatment-experienced HIV-1 infected children.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002183-26,0,0,0 2006-002185-19,1,2007-12-07,2007-12-07,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,NeurogesX Incorporated,"A MULTICENTER RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF NGX-4010 FOR THE TREATMENT OF PAINFUL HIV-ASSOCIATED NEUROPATHY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002185-19,0,0,0 2006-002187-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Radiumhemmet, Karolinska University Hospital","A multicenter, open label, non-randomised phase II study with induction chemotherapy with Cisplatin and 5-fluorouracil as combined with accelerated radiotherapy and Erbitux for locally advanced unrese...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002187-25,0,0,0 2006-002190-49,1,2009-02-02,2009-02-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Oncolytics Biotech Inc,A Multi-Centre Single-Arm Phase II Study To Evaluate The Biological Effects Of Intratumoral Administration of Wild-Type Reovirus (REOLYSIN®) in Combination with Low Dose Radiation in Patients With Adv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002190-49,0,0,0 2006-002192-40,1,,,0,0,0,0,0,3,2,0,1,0,0,0,0,0,0,Zsolt Lohinai DMD PhD,New treatment of periodontitis by inhibition of lysine decarboxilase enzyme,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002192-40,0,0,0 2006-002198-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Biomet NL,Prospective randomized study of the effect of autologous concentrated thrombocytes versus corticosteroid injections in lateral epicondylitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002198-32,0,0,0 2006-002201-31,5,2009-03-16,2009-03-16,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ORFAGEN,Long-term efficacy and safety of V0034 CR 01B cream in patients with moderate-to-severe uremic xerosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002201-31,0,0,0 2006-002202-54,1,2010-07-01,2010-07-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Dandrit Biotech A/S,Vaccination med autologe dendritiske celler pulset med allogent tumorlysat (MelCancerVac) til behandling af patienter med avanceret eller metastatisk ikke-småcellet lungecancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002202-54,0,0,0 2006-002204-33,9,2009-07-10,2010-07-28,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,UCB Pharma S.A.,"Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two doses o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002204-33,0,0,0 2006-002204-33,9,2009-07-10,2010-07-28,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,UCB Pharma,"Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two doses o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002204-33,0,0,0 2006-002205-31,2,2009-02-19,2010-10-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,Phase II Study of Dasatinib BMS-354825 for Androgen-Deprived Progressive Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002205-31,0,0,0 2006-002205-31,2,2009-02-19,2010-10-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,Phase II Study of Dasatinib BMS-354825 for Androgen-Deprived Progressive Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002205-31,0,0,0 2006-002207-13,1,2009-12-21,2009-12-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Dept. Child & Adolescent Psychiatry Univ. Freiburg,"Ziprasidone for severe conduct and other disruptive behavior disorders in children and adolescents – a placebo controlled, randomized, double blind clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002207-13,0,0,0 2006-002208-32,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,York Hospital NHS Trust,A comparison of the analgesic efficacy of oral and intravenous paracetamol (perfalgan) in a day case setting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002208-32,0,0,0 2006-002210-36,1,2012-11-02,2012-11-02,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Queen Mary University of London,A Phase II study evaluating intravenous Melphalan with autologous whole blood stem cell transplantation (PBSCT) in patients with Androgen –Independent Prostate Cancer (AIPC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002210-36,0,0,0 2006-002211-26,2,2008-04-29,2008-04-29,1,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Pharmexa A/S,"Heptovax - A Phase II, Open-label trial evaluating the safety and efficacy of GV1001 in advanced hepatocellular carcinoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002211-26,1,0,0 2006-002213-13,1,2007-12-03,2007-12-03,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Menarini Ricerche S.p.A.,"A Phase I/II, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Systemic Absorption and Dihydropyrimidine Dehydrogenase (DPD) Enzyme Activity Following Repea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002213-13,0,0,0 2006-002214-35,1,2006-08-16,2006-08-16,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,ALTANA Pharma AG,"Free, not protein-bound concentrations of budesonide in subcutaneous adipose tissue, muscle tissue, and serum after oral inhalation via Turbohaler®",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002214-35,0,0,0 2006-002216-10,4,2007-12-20,2007-12-20,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Procter & Gamble Pharmaceuticals,"A Multicenter, Double-blind, Randomized, Parallel, Placebo-controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG 7605...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002216-10,0,0,0 2006-002221-23,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,MediGene AG,"An open-label, randomized, controlled Phase-II trial evaluating the efficacy and safety of EndoTAG-1 in triple receptor negative breast cancer patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002221-23,0,0,0 2006-002228-40,10,2013-07-19,2013-10-29,6,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Pfizer Inc,A PHASE III PLACEBO-CONTROLLED TRIAL OF CELECOXIB IN GENOTYPE POSITIVE SUBJECTS WITH FAMILIAL ADENOMATOUS POLYPOSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002228-40,1,0,0 2006-002228-40,10,2013-07-19,2013-10-29,6,1,0,0,0,1,3,0,0,2,1,0,0,0,1,PFIZER,A PHASE III PLACEBO-CONTROLLED TRIAL OF CELECOXIB IN GENOTYPE POSITIVE SUBJECTS WITH FAMILIAL ADENOMATOUS POLYPOSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002228-40,1,0,0 2006-002235-25,4,2008-06-05,2008-06-05,1,1,1,0,0,1,3,0,0,2,1,0,0,0,1,"Pfizer Ltd, Ramsgate Rd, Sandwich, Kent, United Kingdom","A Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Parallel Group Study of Oral Sildenafil in the Treatment of Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002235-25,1,1,0 2006-002237-20,1,2010-01-25,2010-01-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Pharma GmbH,Pilot trial studying the Effects of Pioglitazone in Comparison to Placebo on Myocardial Function and Oxidative Stress in Patients with Type II Diabetes and Insulin Resistance undergoing elective PTCA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002237-20,0,0,0 2006-002241-37,1,2012-08-15,2012-08-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Velindre NHS Trust,"A randomised phase II/III multi-centre clinical trial of definitive chemo-radiaiton, with or without cetuximab, in carcinoma of the oesophagus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002241-37,0,0,0 2006-002245-36,2,2008-02-04,2008-02-04,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,MannKind Corporation,"A Phase 3, 24-Week, Multi-Center, Open-Label, Randomized, Controlled Trial Comparing the Efficacy and Safety of Prandial Inhalation of Technosphere®/Insulin in Combination with Metformin or Technosphe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002245-36,0,0,0 2006-002249-35,1,2011-03-10,2011-03-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Addiction Center Stockholm,Clinical trial of sustained release methylphenidate for Attention-Deficit-Hyperactivity-Disorder (ADHD) in adult criminal offenders with amphetamine addiction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002249-35,0,0,0 2006-002251-33,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,University of Vienna,Hypoxia Imaging with the novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic impact in Cervical Cancer .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002251-33,0,0,0 2006-002253-71,4,2007-09-19,2007-12-09,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche de veloppement,"A double-blind, multi-center, randomized withdrawal study evaluating the efficacy and safety of Amibegron 350 mg twice a day versus placebo in the prevention of relapse of anxiety up to 1 year in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002253-71,0,0,0 2006-002253-71,4,2007-09-19,2007-12-09,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-Aventis recherche & développement,"A double-blind, multi-center, randomized withdrawal study evaluating the efficacy and safety of Amibegron 350 mg twice a day versus placebo in the prevention of relapse of anxiety up to 1 year in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002253-71,0,0,0 2006-002253-71,4,2007-09-19,2007-12-09,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,"A double-blind, multi-center, randomized withdrawal study evaluating the efficacy and safety of Amibegron 350 mg twice a day versus placebo in the prevention of relapse of anxiety up to 1 year in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002253-71,0,0,0 2006-002253-71,4,2007-09-19,2007-12-09,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-Aventis Recherche & Développement,"A double-blind, multi-center, randomized withdrawal study evaluating the efficacy and safety of Amibegron 350 mg twice a day versus placebo in the prevention of relapse of anxiety up to 1 year in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002253-71,0,0,0 2006-002257-76,16,2009-03-01,2009-03-18,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once Daily Dose of Tigecycline versus Ertapenem for the Treatment of Foot Infections in Subjects with Diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002257-76,0,0,0 2006-002259-33,1,2007-07-31,2007-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Paediatrisches Sekretariat fuer Klinische Studien,"Protocol for a Phase II-study Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - a randomised, double-blinded, placebo-controlled, cross over study -",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002259-33,0,0,0 2006-002262-19,1,2006-09-02,2006-09-02,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Novartis Pharma B.V.,Angiotensin II receptor blockers in patients with systemic right ventricle.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002262-19,0,0,0 2006-002267-11,7,2008-11-13,2011-06-20,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A","A randomized, open-label, multi-center study to evaluate the efficacy of nilotinib versus imatinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and resistant/intoler...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002267-11,0,0,0 2006-002267-11,7,2008-11-13,2011-06-20,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services,"A randomized, open-label, multi-center study to evaluate the efficacy of nilotinib versus imatinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and resistant/intoler...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002267-11,0,0,0 2006-002267-11,7,2008-11-13,2011-06-20,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, open-label, multi-center study to evaluate the efficacy of nilotinib versus imatinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and resistant/intoler...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002267-11,0,0,0 2006-002267-11,7,2008-11-13,2011-06-20,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, open-label, multi-center study to evaluate the efficacy of nilotinib versus imatinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and resistant/intoler...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002267-11,0,0,0 2006-002270-21,1,2013-09-10,2013-09-10,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Odense University Hospital,"Phase I/II study of Taxotere® (docetaxel), Eloxatin® (oxaliplatin) and Xeloda® (capecitabine) as first line treatment to patients with non-resectable ventricular cancer and/or distal esophageal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002270-21,0,0,0 2006-002271-41,1,2008-12-16,2008-12-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Pharma GmbH,Effects of Pioglitazone in Combination with Glimepiride in Comparison to Glimepiride Monotherapy on Metabolic Control in Patients with Type 2 Diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002271-41,0,0,0 2006-002273-41,1,2007-12-28,2007-12-28,1,1,0,0,0,3,4,0,1,1,0,0,1,0,0,Medical University of Vienna; Clinical Pharmacology,"Effect of antioxidants on ocular blood flow, endothelial function, and cytokine levels in LPS induced inflammatory model in humans.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002273-41,0,0,0 2006-002274-22,2,2008-02-21,2013-01-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bracco Imaging S.p.A.,"A PHASE IIIB, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, CROSS-OVER STUDY TO COMPARE 0.1 MMOL/KG OF MULTIHANCE® WITH 0.1 MMOL/KG OF MAGNEVIST® FOR CONTRAST-ENHANCED MAGNETIC RESONANCE ANGIOGRAPHY (CE-MRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002274-22,0,0,0 2006-002275-40,2,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"Uppsala University Hospital, Dept. of Medical Sciences",Prospective study of patients treated with pegylated interferon-alpha 2b (PegIntron) for metastasizing ileal/coecal carcinoids,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002275-40,0,0,0 2006-002276-17,1,2008-11-10,2008-11-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pharma Mar SA, Sociedad Unipersonal",Phase II Study of Yondelis® in Men with Advanced Prostate Carcinoma Estudio fase II con Yondelis en hombres con cáncer de próstata avanzado,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002276-17,0,0,0 2006-002278-24,8,2008-09-05,2008-09-05,5,0,0,0,0,2,3,0,0,2,0,0,0,0,1,BioPartners GmbH,"A phase III, open-label, uncontrolled, multicentre, rollover study to assess safety and efficacy of LB03002 administered weekly in adults with growth hormone deficiency.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002278-24,1,0,0 2006-002278-24,8,2008-09-05,2008-09-05,5,0,0,0,0,2,3,0,0,2,0,0,0,0,1,LG Life Sciences Ltd.,"A phase III, open-label, uncontrolled, multicentre, rollover study to assess safety and efficacy of LB03002 administered weekly in adults with growth hormone deficiency.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002278-24,1,0,0 2006-002283-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University of Oslo, Institute of General Practice and Community Medicine","Physiotherapy alone, in combination with corticosteroid injection or wait-and-see for acute lateral epicondylitis in general practice: a randomised, placebo-controlled study with 12 months follow-up.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002283-26,0,0,0 2006-002286-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Pfizer bv,Chronic Pain Management after Herniorraphy Pregabaline versus Placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002286-40,0,0,0 2006-002289-21,1,2006-12-08,2006-12-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open label study to assess the utility of measuring markers of inflammation, to detect transition from optimal to sub-optimal Inhaled corticosteroid therapy in moderatesevere bronchial asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002289-21,0,0,0 2006-002290-52,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University Clinic Erlangen, Medical Clinic II",Telmisartan und systemische Inflammationsparameter bei Patienten mit arterieller Hypertonie und asymtomatischer Koronarer Herzkrankheit,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002290-52,0,0,0 2006-002292-40,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Fundación para la Investigación y Desarrollo en el Área Cardiovascular (FIC),Análisis proteómico del plasma y plaquetas de pacientes con Diabetes tipo II con enfermedad arterial coronaria estabilizada. Modificación por el tratamiento con clopidogrel. Estudio piloto.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002292-40,0,0,0 2006-002295-18,2,2012-08-17,2012-08-17,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"University Hospital, Dept of Oncology, clinical trial unit",ACT: Avastin and Chemoterapy followed by Avastin alone or in combination with Tarceva for the treatment of metatstatic colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002295-18,0,0,0 2006-002295-18,2,2012-08-17,2012-08-17,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"University Hospital Lund, Dept of Oncology, Clinical Trial Unit",ACT: Avastin and Chemoterapy followed by Avastin alone or in combination with Tarceva for the treatment of metatstatic colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002295-18,0,0,0 2006-002303-14,2,2014-01-02,2014-01-02,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,PFIZER,PROSPECTIVE STUDY OF OPHTHALMOLOGIC FUNCTION IN PATIENTS RECEIVING LINEZOLID FOR TWO MONTHS OR GREATER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002303-14,0,0,0 2006-002303-14,2,2014-01-02,2014-01-02,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY10017, USA",PROSPECTIVE STUDY OF OPHTHALMOLOGIC FUNCTION IN PATIENTS RECEIVING LINEZOLID FOR TWO MONTHS OR GREATER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002303-14,0,0,0 2006-002304-33,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Rijnstate Hospital,Letrozole Treatment to Normalize Serum Testosterone in Men with Hypogonadotropic Hypogonadism due to Pituitary Damage.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002304-33,0,0,0 2006-002306-64,1,2007-07-10,2007-07-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité Universitaetsmedizin,Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002306-64,0,0,0 2006-002308-32,4,2010-07-08,2011-02-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a division of Schering Corporation",A Randomized Placebo-Controlled Efficacy and Safety Study of 1-Year Duration with High and Medium Dose Inhaled Mometasone Furoate/Formoterol Combination Formulation Compared With Formoterol and High D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002308-32,0,0,0 2006-002309-30,5,2010-07-27,2010-07-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a division of Schering Corporation",A Randomized Placebo-Controlled Efficacy and Safety Study of 1-Year Duration with High and Medium Dose Inhaled Mometasone Furoate/Formoterol Combination Formulation Compared With Formoterol and High D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002309-30,0,0,0 2006-002311-27,1,2007-09-28,2007-09-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim Pharmaceuticals, Inc.","A randomized, double-blind, placebo-controlled, five parallel group study investigating the efficacy and safety of BI 1356 BS (0.5 mg, 2.5 mg and 5.0 mg administered orally once daily) over 12 weeks i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002311-27,0,0,0 2006-002316-10,3,2012-07-11,2012-07-11,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company limited,"A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatment i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002316-10,0,0,0 2006-002316-10,3,2012-07-11,2012-07-11,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatment i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002316-10,0,0,0 2006-002317-12,3,2007-07-12,2007-07-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis,A double-blind placebo-controlled study of the activity of AVE1625 at doses of 10 mg and 40mg for 12 weeks in patients with mild to moderate Alzheimer s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002317-12,0,0,0 2006-002321-23,2,2008-10-13,2008-10-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ELI LILLY,"A Phase 2 Study of LY573636 Administered a san Intravenous Infusion on Day 1 of a 21-Day cycle as third-line Treatment in patients with unresectable, metastatic non-Small Cell lung cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002321-23,0,0,0 2006-002321-23,2,2008-10-13,2008-10-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,"A Phase 2 Study of LY573636 Administered a san Intravenous Infusion on Day 1 of a 21-Day cycle as third-line Treatment in patients with unresectable, metastatic non-Small Cell lung cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002321-23,0,0,0 2006-002324-41,1,2008-12-17,2008-12-17,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cancer Research UK,"A Cancer Research UK Randomised Multicentre Phase II Trial of the DNA-hypomethylating Agent, 5-Aza-2'-deoxycytidine(Decitabine) given intravenously in Combination with Carboplatin, versus Carboplatin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002324-41,0,0,0 2006-002328-40,1,2013-05-31,2013-05-31,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Imperial College London,A phase I safety and tolerability study of infusing the autologous progeny of an adult CD34+ subset into patients with type I diabetes mellitus and a successful renal transplant.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002328-40,0,0,0 2006-002330-38,1,2017-03-09,2017-03-09,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,King's College London,Randomised Trial of Anti-CD20 in C4d+ Chronic Allograft Nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002330-38,0,0,0 2006-002332-17,1,2011-12-22,2011-12-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Leeds Teaching Hospitals NHS Trust,"Prospective, randomised trial comparing the use of Tisseel versus no fibrin sealant in preventing postoperative fluid complications following liver resection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002332-17,0,0,0 2006-002333-21,1,2012-08-30,2012-08-30,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Allgemeines Krankenhaus Wien, Medizinische Un iversität Wien",Intraoperative Goal-Directed Fluid Therapy in Lean and Obese Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002333-21,0,0,0 2006-002333-21,1,2012-08-30,2012-08-30,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Allgemeines Krankenhaus Wien, Medizinische Universität Wien",Intraoperative Goal-Directed Fluid Therapy in Lean and Obese Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002333-21,0,0,0 2006-002335-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University of Chicago,A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients with N2/N3 Locally Advanced Head and Neck Cancer Estudio de fase III randomizado de una quimioterapia de inducción ba...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002335-24,0,0,0 2006-002337-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Erasmus Medical Centre Rotterdam,Efficacy of peripherally targeted inhaled rhDNase for persistent obstructive asthma in childhood,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002337-20,0,0,0 2006-002338-39,1,2008-04-13,2008-04-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsklinikum Heidelberg,Pharmakokinetik von Linezolid bei Dialyse (pharmacokinetics of linezolid under dialysis),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002338-39,0,0,0 2006-002339-26,12,2008-06-22,2008-07-30,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,EISAI LTD UK,"A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Flu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002339-26,0,0,0 2006-002339-26,12,2008-06-22,2008-07-30,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eisai Limited,"A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Flu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002339-26,0,0,0 2006-002342-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Klinikum Fulda gAG,"Multicenter study of neurotransmitters and neuropeptides in schizophrenia: A multidisciplinary study of biological, pharmacokinetic, receptor occupancy and clinical relationships in patients suffering...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002342-11,0,0,0 2006-002346-11,1,2007-10-01,2007-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical Faculty, Otto-von-Guericke University",Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of an omeprazole therapy in patients with GERD -- a pilot study (phase IV-study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002346-11,0,0,0 2006-002348-27,1,2015-01-22,2015-01-22,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cancer Research UK,"A Cancer Research UK Phase II Proof of Principle Trial of the activity of the PARP-1 inhibitor, AG-014699, in known carriers of a BRCA 1 or BRCA 2 mutation with locally advanced or metastatic breast o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002348-27,0,0,0 2006-002349-35,1,2008-08-06,2008-08-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Farma S.A.,"Estudio piloto randomizado, doble ciego, multicéntrico a 12 semanas para evaluar el efecto de etanercept 100mg y 50mg semanales en sujetos con espondilitis anquilosante. A 12-week randomized, doubl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002349-35,0,0,0 2006-002351-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA,"Evaluation of safety and efficacy of intravitreal bevacizumab for macular edema, retinal or choroidal neovascularization or neovascular glaucoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002351-33,0,0,0 2006-002354-30,1,2007-01-23,2007-01-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Pharma GmbH,Effect of Acute Insulin Intervention followed by Pioglitazone and Metformin Treatment on Metabolic Parameters in Type 2 Diabetic Patients with inadequate Metabolic Control,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002354-30,0,0,0 2006-002358-31,1,2007-12-31,2007-12-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,RIVM,Specific B-cell Memory After a Single Dose or Booster MenC Conjugate Vaccination: a Pilot Study in Adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002358-31,0,0,0 2006-002361-39,1,2007-09-21,2007-09-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Bayer Vital GmbH,"A 4-week, open-label, multicenter, urodynamic pilot study to explore the efficacy, tolerability and safety of darifenacin (7.5 mg with up-titration to 15 mg) in patients with multiple sclerosis and ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002361-39,0,0,0 2006-002366-18,3,2009-06-16,2009-06-16,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Immunogenicity of the Investigational Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip in the Elderl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002366-18,0,0,0 2006-002366-18,3,2009-06-16,2009-06-16,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,SANOFI PASTEUR,"Immunogenicity of the Investigational Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip in the Elderl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002366-18,0,0,0 2006-002369-37,3,2007-06-06,2007-06-06,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,Estudio sobre la consistencia lote a lote de la vacuna en investigación contra la gripe de virión fraccionado inactivado administrada por vía intradérmica en adultos,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002369-37,0,0,0 2006-002370-21,1,2009-12-04,2009-12-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,North Bristol NHS Trust,Comparison of oral and intravenous paracetamol plasma levels when given as premedication for perioperative analgesia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002370-21,0,0,0 2006-002372-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Spectrum Pharmaceuticals, Inc.",Pilot Study of the Intravesical Administration of EOquin Immediately Following Transurethral Resection in Patients with Superficial Bladder Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002372-18,0,0,0 2006-002381-18,10,2009-07-23,2013-12-20,5,1,0,0,0,2,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,An Open-Label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects with Renal Cell Carcinoma previously enrolled on Protocol VEG105192,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002381-18,0,0,0 2006-002381-18,10,2009-07-23,2013-12-20,5,1,0,0,0,2,3,0,0,1,1,0,1,0,1,GlaxoSmithKline R D Ltd,An Open-Label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects with Renal Cell Carcinoma previously enrolled on Protocol VEG105192,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002381-18,0,0,0 2006-002384-12,8,2014-11-30,2014-11-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase III, International, Randomised, Double-Blind, Parallel-Group, Multi-Centre Study to Assess the Efficacy of ZD6474(ZACTIMA™) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002384-12,0,0,0 2006-002384-12,8,2014-11-30,2014-11-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Phase III, International, Randomised, Double-Blind, Parallel-Group, Multi-Centre Study to Assess the Efficacy of ZD6474(ZACTIMA™) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002384-12,0,0,0 2006-002384-12,8,2014-11-30,2014-11-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca,"A Phase III, International, Randomised, Double-Blind, Parallel-Group, Multi-Centre Study to Assess the Efficacy of ZD6474(ZACTIMA™) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002384-12,0,0,0 2006-002385-20,1,2017-06-30,2017-06-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Strahlenklinik, Universitätsklinikum Erlangen, insoweit handelnd für den Freistaat Bayern",Prospective randomised multicenter phase-III-study: Preoperative radiochemotherapy and adjuvant chemotherapy with 5-Fluorouracil plus oxaliplatin versus preoperative radiochemotherapy and adjuvant ch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002385-20,0,0,0 2006-002388-15,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"AZIENDA DI RILIEVO NAZIONALE E DI ALTA SPECIALIZZAZIONE OSPEDALE CIVICO E BENFRATELLI, G.DI CRISTINA E M.ASCOLI",LCH-III Treatment Protocol of the Third International Study for LANGERHANS CELL HISTIOCYTOSIS Protocollo di trattamento per la Istiocitosi a cellule di Langerhans nel bambino,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002388-15,0,0,0 2006-002389-21,1,2013-06-10,2013-06-10,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,North Wales NHS Trust,"A phase I/II study of Docetaxel (Taxotere, TM), Cisplatinum and Capecitabine (Xeloda, TM) (TCX) in patients with advanced oesophago-gastric cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002389-21,0,0,0 2006-002391-17,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"AZIENDA DI RILIEVO NAZIONALE E DI ALTA SPECIALIZZAZIONE OSPEDALE CIVICO E BENFRATELLI, G.DI CRISTINA E M.ASCOLI",Treatment protocol of the second international study for hemophagoocytic lymphohistiocytosis (HLH) Protocollo di diagnosi e cura per la Lnfoistiocitosi Emofagocitica (LEF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002391-17,0,0,0 2006-002392-40,2,,,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,"AZ. DI RILIEVO NAZ. E DI ALTA SPECIALIZZAZIONE OSP. CIVICO E BENFRATELLI, G.DI CRISTINA E M.ASCOLI",First international trial for diagnosia nd treatment of langerhans cell histiocytosis in adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002392-40,0,0,0 2006-002392-40,2,,,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,VU University Medical Center,First international trial for diagnosia nd treatment of langerhans cell histiocytosis in adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002392-40,0,0,0 2006-002395-18,1,2020-11-06,2020-11-06,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,"Aarhus Universitetshospital, Aarhus Sygehus THG",Intervention studier med steviol til belysning af dosis respons forhold samt langtidseffekt hos personer med type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002395-18,0,0,0 2006-002399-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Jorge Alonso Zafra,Eficacia de la administración postoperatoria prolongada de agonistas de la hormona hipotalámica liberadora de gonadotropinas (triptorelina) previa a fecundación vitro en el tratamiento de la esterilid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002399-17,0,0,0 2006-002402-60,4,2007-11-22,2008-05-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Pharmaceutical Corporation,"RECORD 4 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a controlled, double-blind, randomized study of BAY 59-7939 in the prevention of VTE in subjects undergoing elect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002402-60,0,0,0 2006-002402-60,4,2007-11-22,2008-05-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Pharmaceutical,"RECORD 4 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a controlled, double-blind, randomized study of BAY 59-7939 in the prevention of VTE in subjects undergoing elect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002402-60,0,0,0 2006-002403-13,3,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,PDL BioPharma Inc,"A Phase 3, Randomized, Double-blinded, Placebo-controlled Study of Ularitide in the Treatment of Subjects with Acute Decompensated Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002403-13,0,0,0 2006-002404-34,7,2007-10-22,2007-10-22,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Médicament,"A DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, PLACEBO-CONTROLLED 10-WEEK STUDY ASSESSING THE EFFICACY AND SAFETY OF F2695 SR FLEXIBLE DOSE (75,100 MG /DAY) IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRES...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002404-34,0,0,0 2006-002407-14,1,2007-12-04,2007-12-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline Research, European Medical Governance",Eptifibatide Versus Abciximab in primary PCI for Acute ST elevation Myocardial Infarction (EVA-AMI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002407-14,0,0,0 2006-002408-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut de Recerca del Hospital de la Santa Creu i Sant Pau,Modulación dopaminérgica de las funciones cognitivas y afectivas por el tratamiento con diferentes métodos de estimulación dopaminérgica en la enfermedad de Parkinson . Implicaciones para el tratamien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002408-32,0,0,0 2006-002410-35,1,2008-07-31,2008-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,"Double-blind, double-dummy, randomized, placebo-controlled, five-armed, multi-centre phase II/III study to evaluate the efficacy and safety of different concentrations of isotretinoin versus doxycycli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002410-35,0,0,0 2006-002411-27,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Universitair Psychiatrisch Centrum KU Leuven,Evaluation of the effect of escitalopram on cognitive and fine motor function in depressed elderly patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002411-27,0,0,0 2006-002412-10,1,2007-12-18,2007-12-18,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,AstraZeneca AB,"A randomized, double-blind, double-dummy, two-way cross-over study evaluating systemic bioavailability and airway clearance of Symbicort® Turbuhaler® 320/9μg/inhalation versus Seretide™ Diskus ™50/500...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002412-10,0,0,0 2006-002414-35,6,2007-02-21,2007-06-21,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Non-Malignant Pain.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002414-35,0,0,0 2006-002420-41,3,2010-05-21,2010-05-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Research, Division of Wyeth Pharmaceuticals, Inc.","A Randomized, Open-Label Study to Compare the Safety and Efficacy of Conversion From a Calcineurin Inhibitor to Sirolimus Versus Continued Use of a Calcineurin Inhibitor in Cardiac Transplant Recipien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002420-41,0,0,0 2006-002424-42,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE SACRO CUORE-DON CALABRIA,"Evaluation of Safety and Efficacy on Visual Acuity Outcome and Choroidal Neovascularization of Intravitreal Somministration of Bevacizumab Avastin, Roche, United Kingdom in patients with Subfoveal C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002424-42,0,0,0 2006-002434-38,1,,,0,0,0,0,1,3,4,0,0,0,0,0,0,0,0,Dr catenacci fabrice/ quartier operatoire,BLOC DU PLEXUS LOMBOSACRE PAR VOIE PARAVERTEBRALE : EVA-LUATION POUR LA PRATIQUE QUOTIDIENNNE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002434-38,0,0,0 2006-002447-81,5,2010-04-26,2010-04-26,5,0,0,1,0,0,1,0,0,1,0,0,0,0,1,"Talecris Biotherapeutics, Inc",A Sequential Phase I/II Dose Escalation and Dose Selection Safety Study of Regional Intra-thrombus Plasmin (Human) Infusion In Acute Lower Extremity Native Artery or Bypass Graft Occlusion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002447-81,0,0,0 2006-002449-36,1,,,0,1,0,0,1,0,4,0,0,1,0,0,0,1,1,Laboratorio de Aplicaciones Farmacodinámicas S.A.,"Ensayo clínico, multicéntrico, aleatorizado, simple ciego, paralelo, para evaluar la eficacia antipirética de lisinato de ibuprofeno versus ibuprofeno base en niños con procesos febriles. Multicenter,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002449-36,0,0,0 2006-002450-30,1,2010-02-17,2010-02-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hull and East Yorkshire Hospitals Trust,An Open label Study to Compare Systemic Side Effects of High Dose Fluticasone/Salmeterol with that of High Dose Ciclesonide /Salmeterol in Symptomatic Asthmatics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002450-30,0,0,0 2006-002455-33,2,2016-10-18,2016-10-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of AZD2171 45mg Versus Placebo following 12 Weeks of Treatment in Patients with Metastatic or Recurrent Renal Cell Car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002455-33,0,0,0 2006-002456-15,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,UZ Leuven,The influence of prophylactic ephedrine on arterial hypotension and fetal dysrhythmia after combined spinal-epidural anesthesia during labour,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002456-15,0,0,0 2006-002457-69,8,2009-04-14,2011-08-18,5,0,0,0,0,2,2,0,0,2,0,0,0,0,1,"MacroGenics, Inc.","A Phase 2/3, Randomized, Double-Blind, Multicenter, Multinational, 4-Arm, Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002457-69,1,0,0 2006-002460-26,1,2009-08-31,2009-08-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,UBHT,A trial of intranasal remifentanil for painful ophthalmic procedures.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002460-26,0,0,0 2006-002464-26,1,2009-07-07,2009-07-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Vejle Sygehus,EFFEKTEN AF VELCADE PÅ KNOGLEVÆVET VED MYELOMATOSE (KNOGLEMARVSKRÆFT).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002464-26,0,0,0 2006-002466-19,7,2008-05-20,2008-07-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd or Metformin 1500 mg daily in Elderly Drug Na ve Patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002466-19,0,0,0 2006-002466-19,7,2008-05-20,2008-07-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd or Metformin 1500 mg daily in Elderly Drug Na ve Patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002466-19,0,0,0 2006-002466-19,7,2008-05-20,2008-07-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd or Metformin 1500 mg daily in Elderly Drug Na ve Patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002466-19,0,0,0 2006-002468-24,13,2017-05-02,2017-05-02,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F.Hoffmann-La Roche Ltd.,"A double-blind, randomized, stratified, multi-center trial evaluating conventional and double dose oseltamivir in the treatment of immunocompromised patients with influenza",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002468-24,0,0,0 2006-002468-24,13,2017-05-02,2017-05-02,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ROCHE,"A double-blind, randomized, stratified, multi-center trial evaluating conventional and double dose oseltamivir in the treatment of immunocompromised patients with influenza",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002468-24,0,0,0 2006-002471-40,1,2007-03-22,2007-03-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Intendis GmbH,"A 6-week vehicle-controlled, randomized, double-blind, parallel-group multicenter pilot study of the efficacy and safety of Azelaic Acid (AzA) 15% gel in the topical treatment of mild to moderate peri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002471-40,0,0,0 2006-002472-17,8,2011-03-07,2011-04-07,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Genmab A/S,"An Open-labeled, Randomized, Parallel Group Trial of zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, versus Best Supportive Care, in Patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002472-17,0,0,0 2006-002473-47,11,2008-05-26,2008-06-03,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F.Hoffmann-La Roche Ltd.,"A double blind, randomized, placebo controlled, multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in immunocompromised patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002473-47,1,0,0 2006-002473-47,11,2008-05-26,2008-06-03,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ROCHE,"A double blind, randomized, placebo controlled, multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in immunocompromised patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002473-47,1,0,0 2006-002473-47,11,2008-05-26,2008-06-03,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,"A double blind, randomized, placebo controlled, multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in immunocompromised patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002473-47,1,0,0 2006-002477-45,2,2008-11-28,2008-11-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,ErgoNex Pharma GmbH,"A randomized, double-blind, placebo-controlled, multicenter evaluation of the efficacy and safety of terguride tablets, administered orally for 3 months, to patients with fibromyalgia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002477-45,0,0,0 2006-002478-23,7,2009-09-07,2009-09-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 52-Week, Multinational, Multi-Centre, Open-Labelled Extension Trial of Insulin Detemir in Children and Adolescents 3-17 years with Type 1 Diabetes on a Basal- Bolus Regimen with Insulin Aspart as Bo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002478-23,0,0,0 2006-002482-39,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,SANOFI-AVENTIS OTC,"Evaluation of the effects of Enterogermina, 2 billion Bacillus clausii spores, on the intestinal flora of children antibiotic treated for bacterial upper respiratory tract infections open, pilot stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002482-39,0,0,0 2006-002483-26,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA PISANA,Tailoring antiviral therapy of chronic hepatitis C to the single patient standard therapy versus treatment guided by a physic-mathematical model of the dynamics of Hepatitis C Virus infection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002483-26,0,0,0 2006-002484-99,1,2010-10-25,2010-10-25,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,South Devon Health Care NHS Foundation Trust,The Use of Nebulised Magnesium Sulphate in Exacerbations of Chronic Obstructive Pulmonary Disease (COPD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002484-99,0,0,0 2006-002485-19,4,2012-08-27,2012-08-27,3,1,0,0,0,0,2,0,0,1,1,0,1,0,0,EORTC-European Organisation for Research and Treatment of Cancer,Estudio de Fase II de sunitinib (SU011248) en pacientes con cáncer de pulmón de células pequeñas que nunca han recibido quimioterapia (enfermedad extensiva) o que presentan una recaída ?sensible?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002485-19,0,0,0 2006-002486-39,10,2010-09-01,2012-05-22,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND TOLERABILITY OF FLEXIBLY DOSED PREGABALIN IN THE TREATMENT OF CANCER-INDUCED BONE PAIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002486-39,0,0,0 2006-002486-39,10,2010-09-01,2012-05-22,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,PFIZER SLU,A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND TOLERABILITY OF FLEXIBLY DOSED PREGABALIN IN THE TREATMENT OF CANCER-INDUCED BONE PAIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002486-39,0,0,0 2006-002486-39,10,2010-09-01,2012-05-22,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Pfizer,A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND TOLERABILITY OF FLEXIBLY DOSED PREGABALIN IN THE TREATMENT OF CANCER-INDUCED BONE PAIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002486-39,0,0,0 2006-002486-39,10,2010-09-01,2012-05-22,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,PFIZER,A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND TOLERABILITY OF FLEXIBLY DOSED PREGABALIN IN THE TREATMENT OF CANCER-INDUCED BONE PAIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002486-39,0,0,0 2006-002486-39,10,2010-09-01,2012-05-22,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Pfizer Inc.,A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND TOLERABILITY OF FLEXIBLY DOSED PREGABALIN IN THE TREATMENT OF CANCER-INDUCED BONE PAIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002486-39,0,0,0 2006-002486-39,10,2010-09-01,2012-05-22,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Pfizer Ltd, Ramsgate Road Sandwich, UK",A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND TOLERABILITY OF FLEXIBLY DOSED PREGABALIN IN THE TREATMENT OF CANCER-INDUCED BONE PAIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002486-39,0,0,0 2006-002488-20,1,2008-05-27,2008-05-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,Studio Multicentrico randomizzato in doppio cieco per valutare la sicurezza e l'efficacia dell'aggiunta di sitagliptin MK 0431 in pazienti affetti da diabete mellito di tipo 2 in trattamento con metfo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002488-20,0,0,0 2006-002489-20,2,2008-08-07,2008-08-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A 48-WEEK, DOUBLE BLIND, DOUBLE DUMMY, RANDOMISED, MULTINATIONAL, MULTICENTRE, 3-ARM PARALLEL GROUP CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE ADMINISTE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002489-20,0,0,0 2006-002489-20,2,2008-08-07,2008-08-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CHIESI,"A 48-WEEK, DOUBLE BLIND, DOUBLE DUMMY, RANDOMISED, MULTINATIONAL, MULTICENTRE, 3-ARM PARALLEL GROUP CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE ADMINISTE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002489-20,0,0,0 2006-002494-48,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,University College London / University College London Hospitals NHS Foundation Trust,Sildenafil in Crohn’s disease: an open label pilot study of Sildenafil in 15 patients with active colonic Crohn’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002494-48,0,0,0 2006-002495-18,1,2009-05-14,2009-05-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Wrightington, Wigan and Leigh NHS Trust",The use of ketamine in combination with midazolam for the induction of conscious sedation during endoscopic retrograde cholangiopancreatography (ERCP).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002495-18,0,0,0 2006-002499-16,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Janssen R&D Ireland,Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002499-16,0,0,0 2006-002499-16,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,TIBOTEC PHARMACEUTICALS LTD.,Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002499-16,0,0,0 2006-002500-34,1,2007-12-17,2007-12-17,1,0,0,1,0,1,1,0,0,1,1,1,0,0,0,Ann Hellström,"A Phase I, Open-Label, Pharmacokinetic, Single-Center, Dose Evaluation Study to Determine the Dose of rhIGF-I/rhIGFBP-3 required to Increase Serum IGF-I levels to Physiological Levels in Premature Inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002500-34,0,0,0 2006-002506-58,5,2022-03-25,2022-03-25,5,1,0,0,0,0,4,0,0,1,0,0,0,0,1,Sandoz GmbH,Long-term phase IV multicentre study on the safety and efficacy of Omnitrope® (rhGH) in short children born Small for Gestational Age (SGA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002506-58,0,0,0 2006-002512-10,1,2012-12-31,2012-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,An-Institut für Qualitätssicherung in der operativen Medizin gGmbH,"Offene, unkontrollierte Phase II-Studie zur Überprüfung der Wirksamkeit und Verträglichkeit einer Kombination mit Cisplatin/Docetaxel und Cetuximab bei Patienten mit lokal fortgeschrittenem oder met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002512-10,0,0,0 2006-002513-12,5,2008-06-11,2008-06-11,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Sangart, Inc.","A multi-center, randomized, double-blind, controlled Phase III study of the efficacy and safety of an oxygen-carrying colloid and plasma expander, Hemospan, compared with colloid (Voluven) for prevent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002513-12,0,0,0 2006-002514-35,5,2008-04-27,2008-04-27,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Sangart, Inc.","A multi-center, randomized, double-blind, controlled Phase III study of the efficacy and safety of an oxygen-carrying colloid and plasma expander, Hemospan, compared with colloid (Voluven) for treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002514-35,0,0,0 2006-002515-27,9,2011-03-15,2011-03-15,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,EISAI LTD UK,"A double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in paediatric partial onset seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002515-27,0,0,0 2006-002515-27,9,2011-03-15,2011-03-15,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Eisai Ltd,"A double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in paediatric partial onset seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002515-27,0,0,0 2006-002516-10,6,2010-07-14,2010-11-23,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,EISAI LTD UK,"A randomised, double blind, placebo-controlled study to evaluate the safety and tolerability and to explore the efficacy of zonisamide as add-on therapy in elderly patients with refractory partial sei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002516-10,0,0,0 2006-002516-10,6,2010-07-14,2010-11-23,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Eisai Ltd,"A randomised, double blind, placebo-controlled study to evaluate the safety and tolerability and to explore the efficacy of zonisamide as add-on therapy in elderly patients with refractory partial sei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002516-10,0,0,0 2006-002517-12,4,2008-02-27,2009-11-13,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Celgene International Sarl,"A multicenter, single-arm, open-label expanded access study of lenalidomide plus dexamethasone in previously treated subjects with relapsed/refractory Multiple Myeloma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002517-12,0,0,0 2006-002517-12,4,2008-02-27,2009-11-13,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Celgene International Sàrl,"A multicenter, single-arm, open-label expanded access study of lenalidomide plus dexamethasone in previously treated subjects with relapsed/refractory Multiple Myeloma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002517-12,0,0,0 2006-002519-28,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Eli Lilly and Company Ltd.,Ensayo PRIME DT2: Regímenes prandiales-basales de Insulina para mejorar la glucemia post-pandrial en Diabetes Tipo 2.Comparación de dos enfoques con terapia basal y en bolo en pacientes con Diabetes t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002519-28,0,0,0 2006-002519-28,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Lilly S.A.,Ensayo PRIME DT2: Regímenes prandiales-basales de Insulina para mejorar la glucemia post-pandrial en Diabetes Tipo 2.Comparación de dos enfoques con terapia basal y en bolo en pacientes con Diabetes t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002519-28,0,0,0 2006-002520-41,1,2009-12-16,2009-12-16,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Kvinnokliniken,Generell anestesi versus Spinal-morfin anestesi vid hysterektomi En randomiserad prospektiv öppen studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002520-41,0,0,0 2006-002521-23,1,2015-08-07,2015-08-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI,Phase II study of VELCADE in combination with Rituximab in patients with relapsed or progressed Non Hodgkin's Follicular Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002521-23,0,0,0 2006-002523-16,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Synphora AB,None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002523-16,0,0,0 2006-002524-42,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI,"Use of mieloablative doses of zevalin in aggressive lymphomas of the elderly. Prospective randomized study Z-HDS1,2 vs R-CHOP",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002524-42,0,0,0 2006-002525-23,6,2010-05-24,2010-05-25,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A double-blind, placebo-controlled efficacy as assessed by post-bronchodilatator FEV1 and safety study of 5 mg RO3300074 once-daily for 2 years in subjects with smoking-related, moderate to severe C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002525-23,0,0,0 2006-002525-23,6,2010-05-24,2010-05-25,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"A double-blind, placebo-controlled efficacy as assessed by post-bronchodilatator FEV1 and safety study of 5 mg RO3300074 once-daily for 2 years in subjects with smoking-related, moderate to severe C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002525-23,0,0,0 2006-002527-17,1,2007-12-21,2007-12-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Prana Biotechnology,"A 12-Week randomised, double-blind, placebo-controlled, parallel three-group study to assess the safety, tolerability and efficacy of two dose levels of PBT2 to slow progression of disease in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002527-17,0,0,0 2006-002528-41,2,2009-08-13,2009-08-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Interdos Pharma bv,A comparison of the clinical efficacies of Fusidic acid hydrophilic cream 20 mg/g and Fucidin cream in the treatment of adult and paediatric patients with impetigo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002528-41,0,0,0 2006-002529-21,16,2010-06-30,2013-06-25,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"Estudio abierto de Bevacizumab (Avastin®) más Taxanos en monoterapia o en combinación, en primera linea de tratamiento de pacientes con cáncer de mama metastásico o locallmente recurrente(CMM o LR). ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002529-21,0,0,0 2006-002529-21,16,2010-06-30,2013-06-25,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche Ltd,"Estudio abierto de Bevacizumab (Avastin®) más Taxanos en monoterapia o en combinación, en primera linea de tratamiento de pacientes con cáncer de mama metastásico o locallmente recurrente(CMM o LR). ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002529-21,0,0,0 2006-002529-21,16,2010-06-30,2013-06-25,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"F.Hoffmann-La Roche Ltd Pharmaceutical Division, PDR","Estudio abierto de Bevacizumab (Avastin®) más Taxanos en monoterapia o en combinación, en primera linea de tratamiento de pacientes con cáncer de mama metastásico o locallmente recurrente(CMM o LR). ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002529-21,0,0,0 2006-002529-21,16,2010-06-30,2013-06-25,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"Estudio abierto de Bevacizumab (Avastin®) más Taxanos en monoterapia o en combinación, en primera linea de tratamiento de pacientes con cáncer de mama metastásico o locallmente recurrente(CMM o LR). ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002529-21,0,0,0 2006-002532-24,1,2013-08-15,2013-08-15,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,Pharmacogenetic study of FcγRIIIa and HER2 genes in relation to treatment of breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002532-24,0,0,0 2006-002543-92,6,2008-11-18,2008-11-18,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Schering-Plough Research Institute,A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002543-92,0,0,0 2006-002543-92,6,2008-11-18,2008-11-18,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SCHERING-PLOUGH,A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002543-92,0,0,0 2006-002544-28,3,2008-10-02,2008-11-13,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Phase IIb/III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0364 in Overweight and Obese Patients With Type 2 Diabetes Mellitus (T2DM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002544-28,0,0,0 2006-002544-28,3,2008-10-02,2008-11-13,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Merck & Co., Inc","A Phase IIb/III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0364 in Overweight and Obese Patients With Type 2 Diabetes Mellitus (T2DM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002544-28,0,0,0 2006-002544-28,3,2008-10-02,2008-11-13,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Merck & Co. Inc.,"A Phase IIb/III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0364 in Overweight and Obese Patients With Type 2 Diabetes Mellitus (T2DM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002544-28,0,0,0 2006-002546-11,1,2008-11-24,2008-11-24,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Medizinische Hochschule Hannover,Offene Phase IIIb Studie zur Elimination von CD4+CD25+ regulatorischen T-Zellen bei Patienten mit fortgeschrittenem HCC durch die Gabe von Cyclophosphamid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002546-11,0,0,0 2006-002547-83,1,2010-10-31,2010-10-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Dr. Peter Sydow,GnRH-Agonisten-Therapie bei Frauen mit Endometriose der Stadien III-IV nach rASRM-Kriterien vor reproduktionsmedizinischen Techniken (IVF / ICSI) (GARTE-Studie),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002547-83,0,0,0 2006-002550-30,2,2009-06-09,2009-06-09,1,1,0,0,2,0,2,0,0,1,0,0,1,0,1,CHIESI,A randomized controlled pilot study for the comparison of efficacy of bronchoalveolar lavage BAL with Curosurf in a dosage 50 mg/kg vs not treated control in adult patients affected by pulmonary con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002550-30,0,0,0 2006-002550-30,2,2009-06-09,2009-06-09,1,1,0,0,2,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S. p. A.,A randomized controlled pilot study for the comparison of efficacy of bronchoalveolar lavage BAL with Curosurf in a dosage 50 mg/kg vs not treated control in adult patients affected by pulmonary con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002550-30,0,0,0 2006-002553-80,1,2010-04-27,2010-04-27,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Karolinska Universitetssjukhuset,ADHD hos intagna inom Kriminalvården - förekomst/diagnos/behandling/uppföljning,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002553-80,0,0,0 2006-002554-29,1,2008-03-05,2008-03-05,1,0,0,0,0,0,4,0,1,1,1,1,1,0,0,Hammel neurocenter,Methylphenidat betydning for motorisk indlæring hos patienter med apopleksi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002554-29,0,0,0 2006-002555-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPICES CIVILS DE LYON,Comparaison de l'efficacité et de la tolérance de différentes doses de méthylprednisolone administrées par voie intraveineuse dans le traitement des formes actives et de sévérité moyenne d'orbitopathi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002555-33,0,0,0 2006-002557-68,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Hospital District of Southwest Finland,"A randomized, double-blind, placebo-controlled study to evaluate the efficacy of zoledronic acid in enhancement of early stability of cementless primary hip prosthesis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002557-68,0,0,0 2006-002562-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dipartimento di Neuroscienze Oftalmologia e Genetica DINOG - Universita di Genova,Immunoablation with Cyclophosphamide at high dosage and Rabbit antithymoglobulin followed by autologous hematopoietic stem cell transplantation in severe multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002562-19,0,0,0 2006-002564-25,1,2009-07-20,2009-07-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI,"A PHASE II MULTICENTER STUDY OF BORTEZOMIB, THALIDOMIDE, PEGHILATED LIPOSOMAL DOXORUBICIN, DEXAMETHASONE (ThaDD-V)IN PATIENTS AFFECTED BY RELAPSED-REFRACTORY MULTIPLE MYELOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002564-25,0,0,0 2006-002565-39,1,2009-06-25,2009-06-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,South Tees Acute Hospitals NHS Trust,Effects of the Modification of the Daily Flow Rate with a Constant Daily Dose on Patient's Reported Analgesia in Intathecal Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002565-39,0,0,0 2006-002567-62,5,2010-06-17,2010-06-17,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Cardiokine Biopharma, LLC",THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002567-62,1,0,0 2006-002567-62,5,2010-06-17,2010-06-17,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"CARDIOKINE BIOPHARMA, LLC",THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002567-62,1,0,0 2006-002571-40,1,2007-08-22,2007-08-22,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,NV Organon,"A randomized, double-blind, active and placebo controlled trial to compare the relative analgesic efficacy and safety of a single intravenous dose of Org 28611 3.0 µg/kg, morphine sulfate 0.12 mg/kg, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002571-40,0,0,0 2006-002572-17,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,LUSOFARMACO,"A double-blind, cross-over patient preference study of frovatriptan versus rizatriptan for the acute treatment of migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002572-17,0,0,0 2006-002576-18,3,2012-09-24,2012-09-24,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Pfizer Ltd.,"A PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN PATIENTS METASTATIC OR UNRESECTABLE LOCALLY-ADVANCED THYROID CANCER REFRACTORY TO, OR NOT SUITABLE CANDIDATES FOR 131I TREATMENT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002576-18,0,0,0 2006-002576-18,3,2012-09-24,2012-09-24,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,PFIZER,"A PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN PATIENTS METASTATIC OR UNRESECTABLE LOCALLY-ADVANCED THYROID CANCER REFRACTORY TO, OR NOT SUITABLE CANDIDATES FOR 131I TREATMENT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002576-18,0,0,0 2006-002576-18,3,2012-09-24,2012-09-24,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"PFIZER, S.A.","A PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN PATIENTS METASTATIC OR UNRESECTABLE LOCALLY-ADVANCED THYROID CANCER REFRACTORY TO, OR NOT SUITABLE CANDIDATES FOR 131I TREATMENT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002576-18,0,0,0 2006-002578-23,2,2008-07-11,2008-07-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UK- 432,097 DRY POWDER FOR INHALATION IN ADULTS WITH MODERATE TO SEVERE CHRONIC OB...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002578-23,0,0,0 2006-002578-23,2,2008-07-11,2008-07-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer bv,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UK- 432,097 DRY POWDER FOR INHALATION IN ADULTS WITH MODERATE TO SEVERE CHRONIC OB...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002578-23,0,0,0 2006-002578-23,2,2008-07-11,2008-07-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Ltd,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UK- 432,097 DRY POWDER FOR INHALATION IN ADULTS WITH MODERATE TO SEVERE CHRONIC OB...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002578-23,0,0,0 2006-002581-19,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,Nina Olofsson,A comparison of two methodes for pastoperative paintreatment after knee replacement. Pharmacokinetics and clinical effect of femoral block and local infiltration of the operation area of ropivacaine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002581-19,0,0,0 2006-002582-39,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,FONDAZIONE NADIR ONLUS,"A multicenter, randomized, prospective, controlled study to evaluate the efficacy and the tolerability of a switch to a two different-dosed, nevirapine-based HAARTs in HIV-1 infected patients with und...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002582-39,0,0,0 2006-002584-70,3,2008-10-15,2009-04-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Astellas Pharma US, Inc.","A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002584-70,0,0,0 2006-002585-19,1,2009-02-10,2009-02-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Free Hampstead NHS Trust,"A 24-week, randomised, open-label, 2-arm study to compare the tolerability and efficacy of saquinavir tablets with ritonavir versus lopinavir/ritonavir tablets in HIV 1 infected adults switching from ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002585-19,0,0,0 2006-002586-39,1,2010-10-08,2010-10-08,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Radiological dept. Aalborg Hospital,"Placebocontrolled trial, testing the efficacy of Polidocanol injections as a treatment of chronic achilles tendon tendinopatia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002586-39,0,0,0 2006-002588-22,1,2008-10-20,2008-10-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI,"A phase II, multicenter study of etoposide, aracytin, dexamethasone and bortezomib in patients affected by relapsed/refractory multiple myeloma previously treated with thalidomide",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002588-22,0,0,0 2006-002589-20,3,2009-03-25,2009-03-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Fresenius Medical Care Deutschland GmbH,Evaluación del acetato de calcio / carbonato de magnesio (OsvaRen®) en comparación con el sevelamer (Renagel®) en pacientes sometidos a hemodiálisis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002589-20,0,0,0 2006-002590-44,2,2007-11-19,2007-11-19,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development","A MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARISON OF 4 DOSE REGIMENS OF PLA-695, NAPROXEN, AND PLACEBO ADMINISTERED DAILY FOR 6 WEEKS IN SUBJECTS WITH ACTIVE OSTEOARTHRITIS OF THE KNEE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002590-44,0,0,0 2006-002591-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Timo Iirola,Pharmacokinetics of a single bolus of dexmedetomidine in ICU patients on continuous veno-venous haemodiafiltration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002591-18,0,0,0 2006-002595-17,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Recip AB,"A randomized, double-blind, parallel-group study evaluating efficacy and safety of MEGA tablets compared to Kalcipos® tablets in adult Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002595-17,0,0,0 2006-002596-40,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,World Health Organization,"Comparison of two doses and two routes of administration of misoprostol after pre-treatment with mifepristone for early pregnancy termination: a randomized, placebo-controlled, multicentre trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002596-40,0,0,0 2006-002600-33,3,2017-01-20,2017-01-20,3,0,0,0,0,0,3,0,0,1,0,0,1,0,0,IBCSG,"Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002600-33,0,0,0 2006-002600-33,3,2017-01-20,2017-01-20,3,0,0,0,0,0,3,0,0,1,0,0,1,0,0,International Breast Cancer Study Group (IBCSG),"Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002600-33,0,0,0 2006-002603-13,1,2019-10-19,2019-10-19,1,1,0,0,0,1,4,0,0,1,1,1,1,0,0,Leiden University Medical Center,Is treatment with octreotide effective in patients with head-and-neck paraganglioma?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002603-13,0,0,0 2006-002605-31,2,2012-05-22,2012-05-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Georg-August-Universität Göttingen,"ALDOSTERONE RECEPTOR BLOCKADE IN DIASTOLIC HEART FAILURE A double-blind, randomised, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002605-31,0,0,0 2006-002606-54,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASL SALERNO 1,Investigational use of 5-ALA for fluorescence-guided resection of malignant glioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002606-54,0,0,0 2006-002608-33,1,2007-12-31,2007-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Karolinska Institute, CLINTEC, div of orthopedics",En dubbelblind placebokontrollerad studie för utvärdering av postoperativa analgetikaeffekter via mikrodialys synovialt på patienter som genomgår artroskopi.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002608-33,0,0,0 2006-002614-36,2,2010-02-25,2010-02-25,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"IBSA, Institut Biochimique SA","Multicentre, controlled, randomised, open-label, cross-over clinical study of the efficacy and tolerability of L-thyroxine T4 soft capsules, in comparison to L-thyroxine tablets, in thyroidectomised...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002614-36,0,0,0 2006-002614-36,2,2010-02-25,2010-02-25,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,IBSA,"Multicentre, controlled, randomised, open-label, cross-over clinical study of the efficacy and tolerability of L-thyroxine T4 soft capsules, in comparison to L-thyroxine tablets, in thyroidectomised...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002614-36,0,0,0 2006-002616-96,3,2008-06-04,2008-06-04,2,1,1,0,0,2,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase IIIb, efficacy, and safety study of rosuvastatin in children and adolescents 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH): a 12-week, double-blind, randomized,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002616-96,1,1,0 2006-002618-37,1,2007-10-29,2007-10-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Cross-Over Study Comparing the Pharmacodynamic Response in Subjects with Acute Coronary Syndrome Receiving 14 Days 10-mg Maintenance Dose Prasugrel (LY640315) versus 14 Day...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002618-37,0,0,0 2006-002621-23,3,2008-01-09,2008-01-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services Ag,"A 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300mg/ valsartan 320 mg in patients with essential hypertension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002621-23,0,0,0 2006-002621-23,3,2008-01-09,2008-01-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmaceutica S.A.,"A 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300mg/ valsartan 320 mg in patients with essential hypertension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002621-23,0,0,0 2006-002621-23,3,2008-01-09,2008-01-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren 300mg/ valsartan 320 mg in patients with essential hypertension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002621-23,0,0,0 2006-002632-21,1,2007-02-22,2007-02-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,"A double-blind, randomised, placebo controlled, single dose, two-period crossover study to investigate the therapeutic potential of the TRPV1 antagonist SB-705498 in treatment of subjects with rectal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002632-21,0,0,0 2006-002633-20,9,2010-05-27,2010-05-27,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"Estudio aleatorizado, doble-ciego, controlado con placebo, de grupos paralelos, de definición de dosis, para investigar la eficacia mediante RM y la seguridad de la administración de firategrast (150 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002633-20,0,0,0 2006-002633-20,9,2010-05-27,2010-05-27,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline S.A,"Estudio aleatorizado, doble-ciego, controlado con placebo, de grupos paralelos, de definición de dosis, para investigar la eficacia mediante RM y la seguridad de la administración de firategrast (150 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002633-20,0,0,0 2006-002635-24,1,2018-12-14,2018-12-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Grifols Biological Inc,A STUDY OF IMMUNOLOGIC SAFETY FOR ALPHANATEŇ IN PREVIOUSLY TREATED PATIENTS DIAGNOSED WITH SEVERE HEMOPHILIA A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002635-24,0,0,0 2006-002638-39,1,,,0,0,0,0,1,0,2,0,0,3,0,0,0,0,0,University Hospitals of Birmingham NHS Foundation Trust,Mechanisms responsible for cardiac and skeletal muscle energetic impairment in type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002638-39,0,0,0 2006-002639-26,1,2010-03-01,2010-03-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Klinikum der Universität München, Kinderklinik und Poliklinik im Dr. von Haunersches Kinderspital","Treatment of Helicobacter pylori infection with high dose esomeprazole, amoxicillin and metronidazole in pediatric patients infected with double resistant Helicobacter pylori strains",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002639-26,0,0,0 2006-002645-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Kémia, Inc.",A Phase II randomized double-blind placebo-controlled Study of KC706 in patients with rheumatoid arthritis inadequately controlled with a stable dose of methotrexate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002645-37,0,0,0 2006-002647-86,1,2011-04-26,2011-04-26,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Heart of England NHS Foundation Trust,BALTI-2: Beta Agonists in Lung Injury Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002647-86,0,0,0 2006-002647-86,1,2011-04-26,2011-04-26,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Warwick Medical School,BALTI-2: Beta Agonists in Lung Injury Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002647-86,0,0,0 2006-002649-35,1,2006-11-22,2006-11-22,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase IV, Single-Centre, Observer-Blind, Controlled, Randomized Study to Compare the Safety and Immunogenicity of Fluvirin® to Influvac® Administered to Healthy Children 3 to 12 Years of Age.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002649-35,0,0,0 2006-002655-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Safety evaluation of the i.v. administration of Visipaque in patients with myeloma or monoclonal gammopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002655-33,0,0,0 2006-002657-71,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,"AtheroGenics, Inc.",FOCUS - Follow up Of Clinical Outcomes: The Long-term AGI-1067 Plus Usual Care Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002657-71,0,0,0 2006-002658-31,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"OPEN LABEL, PHASE II PILOT STUDY OF STI571 IN THE TREATMENT OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA PTCL REFRACTORY, RESISTANT OR NOT AMENABLE TO CONVENTIONAL THERAPY.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002658-31,0,0,0 2006-002660-26,7,2008-09-03,2009-01-22,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"ONO Pharmaceutical Co.,Ltd","A MULTI-CENTRE, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO, IN THE PRESENCE OF RILUZOLE, TO PATIENTS DIAGNO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002660-26,0,0,0 2006-002660-26,7,2008-09-03,2009-01-22,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,ONO PHARMA UK LTD,"A MULTI-CENTRE, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-2506PO COMPARED TO PLACEBO, IN THE PRESENCE OF RILUZOLE, TO PATIENTS DIAGNO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002660-26,0,0,0 2006-002662-19,5,2009-05-15,2009-05-15,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Amgen Inc.,A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis Studio randomizzato...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002662-19,0,0,0 2006-002662-19,5,2009-05-15,2009-05-15,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AMGEN S.P.A.,A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis Studio randomizzato...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002662-19,0,0,0 2006-002663-11,1,2008-03-11,2008-03-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Plethora Solutions Limited,"An open-label, escalating dose, proof of concept study to determine the effects of single oral doses of PSD506 on unstable urinary bladder contractions induced by volume provocation in subjects with d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002663-11,0,0,0 2006-002667-33,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,European Organisation for Research and Treatment of Cancer,"Phase I/II study on induction chemotherapy followed by chemoradiation with or without lapatinib, a dual EGFR/ErbB2 kinase inhibitor, in patients with locally advanced resectable larynx and hypopharynx...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002667-33,0,0,0 2006-002669-38,4,2007-11-21,2007-12-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women with Breast Cancer and Established Bone Metastases (MBD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002669-38,0,0,0 2006-002669-38,4,2007-11-21,2007-12-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MSD (Norge) AS,"A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women with Breast Cancer and Established Bone Metastases (MBD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002669-38,0,0,0 2006-002669-38,4,2007-11-21,2007-12-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck & Co Inc.,"A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women with Breast Cancer and Established Bone Metastases (MBD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002669-38,0,0,0 2006-002669-38,4,2007-11-21,2007-12-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women with Breast Cancer and Established Bone Metastases (MBD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002669-38,0,0,0 2006-002670-22,10,2009-10-15,2010-02-16,9,1,0,0,2,0,3,0,0,1,1,0,1,0,1,"Schering-Plough Research Institute, a division of Schering Corporation","Comparación de la eficacia y la seguridad del infliximab, en monoterapia o en combinación con azatioprina, y la azatioprina en monoterapia en la colitis ulcerosa activa de moderada a grave (1.ª parte)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002670-22,0,0,0 2006-002670-22,10,2009-10-15,2010-02-16,9,1,0,0,2,0,3,0,0,1,1,0,1,0,1,SCHERING-PLOUGH,"Comparación de la eficacia y la seguridad del infliximab, en monoterapia o en combinación con azatioprina, y la azatioprina en monoterapia en la colitis ulcerosa activa de moderada a grave (1.ª parte)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002670-22,0,0,0 2006-002673-52,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Universitetssjukhuset Örebro,"Postoperativ smärtlindring och mobilisering efter per- och postoperativ injektion av ropivakain, ketorolak och adrenalin givet i operationsområdet, infiltrativt och i knäleden, vid total knäplastikope...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002673-52,0,0,0 2006-002675-41,1,2010-07-01,2010-07-01,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,Universitaetsklinikum Schleswig-Holstein,"A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002675-41,0,0,0 2006-002676-18,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,WELEDA AG DEUTSCHLAND,"Randomized, open-label phase 2 study on post-relapse disease-free survival (PRDFS) with the Viscum-album Extract (VA-E) Iscador P or oral Etoposide in spindle-cell bone-sarcoma patients in complete re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002676-18,0,0,0 2006-002677-41,1,,,0,0,0,0,0,3,2,0,1,0,0,0,0,0,0,"Danishy Headache Center, KAS Glostrup, Dep. N01",Neuropeptides in the human intra - and extracerebral circulation - before and after affecting the trigeminovascular system with sumatriptan in healthy volunteers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002677-41,0,0,0 2006-002679-42,2,2010-02-19,2010-02-19,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Santhera Pharmaceuticals (Switzerland) Limited,"A double blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of idebenone in the treatment of patients with Leber's Hereditary Optic Neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002679-42,0,0,0 2006-002680-18,1,,,0,1,0,0,1,0,2,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase II, controlled, randomized, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine adjuvanted with AS03 compared to Fluarix™ (GlaxoSmith...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002680-18,0,0,0 2006-002682-40,1,2010-06-11,2010-06-11,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Aalborg Psychiatric Hospital, Research Unit",Augmenting clozapine with sertindole - A double-blinded randomized placebo study (SERCLOZ),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002682-40,0,0,0 2006-002686-39,1,2007-07-11,2007-07-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S),"LEO19123 Cream in the Treatment of Hand Eczema A Phase II, proof of concept study, testing once daily use of two dose-combinations of LEO19123 cream (calcipotriol and LEO80122) in the treatment of ha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002686-39,0,0,0 2006-002687-26,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Rigshospital, Finsencenter, Afsnit 3994",En fase I / II forsøg med intraperitoneal Paclitaxel og Carboplatin efter cytoreduktiv operation som behandling af Patienter med ovarie carcinoma med peritoneal carcinose eller primær peritoneal carci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002687-26,0,0,0 2006-002688-26,11,2011-06-13,2011-06-14,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Bayer Healthcare AG, D-51368 Leverkusen, Germany","A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002688-26,0,0,0 2006-002688-26,11,2011-06-13,2011-06-14,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer Schering Pharma AG,"A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002688-26,0,0,0 2006-002688-26,11,2011-06-13,2011-06-14,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BAYER,"A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002688-26,0,0,0 2006-002688-26,11,2011-06-13,2011-06-14,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer Healthcare AG,"A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002688-26,0,0,0 2006-002691-18,4,2007-03-29,2007-03-29,2,1,0,0,1,0,2,0,2,1,1,0,1,0,1,GlaxoSmithKline Research & Development,"A multi-centre, randomised, single-blind, placebo-controlled, parallel group study to investigate the efficacy of single pre-emptive doses of GW842166X, a non-cannabinoid CB2 receptor agonist, on pain...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002691-18,0,0,0 2006-002691-18,4,2007-03-29,2007-03-29,2,1,0,0,1,0,2,0,2,1,1,0,1,0,1,GLAXOSMITHKLINE,"A multi-centre, randomised, single-blind, placebo-controlled, parallel group study to investigate the efficacy of single pre-emptive doses of GW842166X, a non-cannabinoid CB2 receptor agonist, on pain...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002691-18,0,0,0 2006-002692-41,1,2008-03-15,2008-03-15,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Laboratoires Auris SAS,Safety of AM-101 in Patients with Acute Inner Ear Tinnitus from Noise Trauma: a Dose-Finding Phase I/II Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002692-41,0,0,0 2006-002694-52,3,2008-04-04,2008-04-04,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"A comparison of ipratropium bromide/salbutamol delivered by the Respimat inhaler to COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the Respimat in a 12-week, double-blind, safety an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002694-52,0,0,0 2006-002694-52,3,2008-04-04,2008-04-04,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A comparison of ipratropium bromide/salbutamol delivered by the Respimat inhaler to COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the Respimat in a 12-week, double-blind, safety an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002694-52,0,0,0 2006-002694-52,3,2008-04-04,2008-04-04,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A comparison of ipratropium bromide/salbutamol delivered by the Respimat inhaler to COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the Respimat in a 12-week, double-blind, safety an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002694-52,0,0,0 2006-002695-17,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,DEBIOPHARM S.A.,"A multi-centre, randomised, double-blind, placebo-controlled escalating dose ranging phase II study on the efficacy of DEBIO-025 to reduce HCV viral load in combination with PEGASYS 180 g/week in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002695-17,0,0,0 2006-002696-40,1,2007-02-08,2007-02-08,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Achillion Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Multiple Doses of ACH-0137171 in Subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002696-40,0,0,0 2006-002698-38,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AIR LIQUIDE Santé INTERNATIONAL,STUDY OF THE EFFICACY AND SAFETY OF KALINOX® 170 BAR FOR THE PERFORMANCE OF CARE PROCEDURES IN CHILDREN WITH BURNS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002698-38,0,0,0 2006-002698-38,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Air Liquide Sante International,STUDY OF THE EFFICACY AND SAFETY OF KALINOX® 170 BAR FOR THE PERFORMANCE OF CARE PROCEDURES IN CHILDREN WITH BURNS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002698-38,0,0,0 2006-002702-63,1,2006-11-20,2006-11-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,South Manchester University Hospital NHS Trust,Does oral Ranitidine improve magnetic resonance cholangio-pancreatogram images allowing clinically useful improvement?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002702-63,0,0,0 2006-002703-13,6,2008-02-13,2009-02-13,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Human Genome Sciences, Inc.","A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002703-13,0,0,0 2006-002704-34,6,2008-09-03,2008-10-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Human Genome Sciences, Inc.","A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002704-34,0,0,0 2006-002708-33,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,ISTITUTI FISIOTERAPICI OSPITALIERI,RANDOMIZED PHASE III TRIAL OF PREOPERATIVE VERSUS POSTOPERATIVE CHEMOTHERAPY WITH CISPLATIN AND GEMCITABINE IN STAGE IB-IIIA NON-SMALL CELL LUNG CANCER NSCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002708-33,0,0,0 2006-002716-94,1,2007-10-18,2007-10-18,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Mentis Cura ehf.,"AD/HD diagnosis through EEG, a pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002716-94,0,0,0 2006-002726-32,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,PROtection of coronary Microcirculation by Iloprost: Safety and Efficacy evaluation in PCI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002726-32,0,0,0 2006-002727-16,3,2013-04-26,2013-04-26,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Fresenius Biotech GmbH,"Multicenter, open-label phase II study to evaluate the safety and efficacy of the tri-functional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with gastric adenocarcinoma after n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002727-16,0,0,0 2006-002731-24,1,2008-07-01,2008-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Aberdeen,The use of morphine in addition to local anaesthetic for post operative analgesia in anterior cruciate reconstruction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002731-24,0,0,0 2006-002732-22,1,2009-02-26,2009-02-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of 2g per day of strontium ranelate versus alendronate 70mg per week in women with postme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002732-22,0,0,0 2006-002737-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE ONCOLOGICO DI BARI,A randomized phase II study in the advanced or metastatic transitional cell urotelium carcinoma between Gemcitabine + Cisplatin e Gemcitabine + Cisplatino + Taxolo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002737-21,0,0,0 2006-002738-39,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,"Astelleas Pharma US, Inc.",A Phase 1 Open-Label Study of the Pharmacokinetics of Tacrolimus Cream B 0.1% after Twice Daily Topical Administration in Adolescents (≥ 12 to ≤ 17 Years of Age ) with Psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002738-39,0,0,0 2006-002739-25,1,2007-11-21,2007-11-21,1,0,0,0,0,1,3,0,0,1,0,0,1,0,1,S.L.A. Pharma (UK) Ltd,"A double-blind, randomised, placebo-controlled study to evaluate topical 10%phenylephrine gel applied peri-anally in the management of ileal pouch anal anastomosis (IPAA)-related faecal incontinence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002739-25,0,0,0 2006-002742-11,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTI FISIOTERAPICI OSPITALIERI,"MULTICENTER PHASE II TRIAL OF TARCEVA COMBINED WITH FIXED DOSE-RATE GEMCITABINE INFUSION AS FIRST LINE TREATMENT OF ADVANCED, UNRESECTABLE PANCREATIC CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002742-11,0,0,0 2006-002743-89,1,,,0,1,0,0,0,1,3,0,0,1,1,1,0,1,0,Southwest Oncology Group (SWOG),A PHASE III STUDY OF THE ADDITION OF GEMTUZUMAB OZOGAMICIN (MYLOTARG®) DURING INDUCTION THERAPY VERSUS STANDARD INDUCTION WITH DAUNOMYCIN AND CYTOSINE ARABINOSIDE FOLLOWED BY CONSOLIDATION AND SUBSEQU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002743-89,0,0,0 2006-002744-28,1,2014-04-16,2014-04-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,iOMEDICO,Effektivitätsoptimierte und toxizitätsreduzierte Therapie des metastasierten Kolorektalkarzinoms in der First-line Therapie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002744-28,0,0,0 2006-002748-27,4,2009-05-15,2009-05-15,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals France,"A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients with Active, Severe and Advanced Axial Ankylosing Spondylitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002748-27,0,0,0 2006-002749-35,3,2008-07-21,2008-12-11,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals France,"A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients with Refractory Heel Enthesitis in Spondylarthropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002749-35,0,0,0 2006-002757-72,1,2007-10-25,2007-10-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Neosil Inc.,"A Phase 2 Multicenter, Randomized, Placebo- and Comparator Controlled, Double-Blind Parallel Group Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002757-72,0,0,0 2006-002758-31,2,2010-11-24,2010-11-24,1,0,0,0,0,0,2,0,0,1,1,0,1,0,1,EPOPLUS GmbH & Co.KG,"A randomized, double-blind, multi-centre, placebo-controlled, parallel-group study to examine the efficacy and safety of low dose Epoetin beta on wound healing in diabetes patients with foot ulcer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002758-31,0,0,0 2006-002766-20,3,2012-04-20,2012-04-20,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002766-20,0,0,0 2006-002767-41,1,2014-07-31,2014-07-31,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,Sonderforschungsbereich 656 (SFB 656),Kardiale Innervation bei genetischen Arrhythmiemodellen in Menschund Maus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002767-41,0,0,0 2006-002768-24,6,2012-01-23,2012-01-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Otsuka Pharmaceutical Development & Commercialization. Inc.,"A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Pol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002768-24,0,0,0 2006-002768-24,6,2012-01-23,2012-01-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Pol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002768-24,0,0,0 2006-002768-24,6,2012-01-23,2012-01-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALISATION INC,"A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Pol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002768-24,0,0,0 2006-002768-24,6,2012-01-23,2012-01-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Otsuka Maryland Research Institute, Inc.","A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Pol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002768-24,0,0,0 2006-002769-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOIM GRUPPO ONCOLOGICO MERIDIONALE,A MULTICENTER PHASE II STUDY TO EVALUATE ACTIVITY AND TOLERABILITY OF CISPLATIN (CDDP) AND FOTEMUSTINE (FTM) COMBINATION IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH BRAIN METASTASES.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002769-38,0,0,0 2006-002770-22,1,2011-11-21,2011-11-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,York Hospital NHS Trust,The effects of oral sodium bicarbonate on extracellular water in patients with chronic renal failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002770-22,0,0,0 2006-002771-40,1,2008-09-22,2008-09-22,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"S.G.O. Johansson, MD PhD Professor",Importance of IgE antibody fraction size on allergen sensitivity of basophils from cat allergic patients on Xolair. A pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002771-40,0,0,0 2006-002772-17,4,2014-01-05,2014-01-05,1,1,0,0,0,0,3,0,0,1,1,0,1,0,0,European Organisation for Research and Treatment of Cancer,Immediate or early salvage post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus immediate or early salvage postoperative external radiotherapy alone in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002772-17,0,0,0 2006-002777-42,1,2007-01-31,2007-01-31,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,ALTANA Pharma AG,Endoscopic healing and tolerability of Soraprazan 20 mg qd compared to Soraprazan 10 mg qd and to Esomeprazole 40 mg qd in patients suffering from GERD Grade A-D (LA classification),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002777-42,0,0,0 2006-002779-42,1,2007-01-31,2007-01-31,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,ALTANA Pharma AG,Symptom relief and tolerability of Soraprazan 20 mg qd and Soraprazan 10 mg qd compared to Esomeprazole 20 mg qd in patients with non-erosive gastroesophageal reflux disease (NERD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002779-42,0,0,0 2006-002780-14,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Hospital General Universitario Alicante, Dpto Farmacologia Clinica",Estudio comparativo de la eficacia de la bomba de jeringa Alaris® (Asena®) de uso polivalente en la administración de tres formulaciones de propofol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002780-14,0,0,0 2006-002781-20,8,2010-03-04,2010-08-18,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Multicenter, Randomized, Double-blind, Placebo controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Moderately to Severely A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002781-20,0,0,0 2006-002781-20,8,2010-03-04,2010-08-18,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH Co. KG,"A Multicenter, Randomized, Double-blind, Placebo controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Moderately to Severely A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002781-20,0,0,0 2006-002782-40,9,2010-03-02,2010-03-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Multicenter, Randomized, Double-blind, Placebo controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002782-40,0,0,0 2006-002786-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)","A PROSPECTIVE TRIAL , MONOCENTRIC, RANDOMIZED, TO EVALUATE THE RENAL'S FUNCTION IN SUBJECTS WITH CARDIAC TRANSPLANTED",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002786-39,0,0,0 2006-002787-26,6,2012-05-09,2014-08-31,6,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Department of Rheumatology, Medical University of Vienna","A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFα Chimeric Monoclonal Antibody (Infliximab, Remicade®) in Combination with Methotrexate in Patients with Very Early Inflam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002787-26,0,0,0 2006-002787-26,6,2012-05-09,2014-08-31,6,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Vienna Medical University,"A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFα Chimeric Monoclonal Antibody (Infliximab, Remicade®) in Combination with Methotrexate in Patients with Very Early Inflam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002787-26,0,0,0 2006-002789-20,1,2006-10-14,2006-10-14,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Omninvest Ltd.,FluvalAB Influenza Vaccine Serologic Clinical Trial for 2006-2007 Influenza Season,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002789-20,0,0,0 2006-002791-18,7,2009-08-12,2009-08-12,6,1,1,0,0,0,0,0,0,2,0,0,0,0,1,Laboratoires Merck Sharp & Dohme - Chibret,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Evaluating the Effects of 2 Different Regimens of Montelukast Daily Dosing and Intermittent, Episode-Driven Dosing Compare...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002791-18,1,1,0 2006-002791-18,7,2009-08-12,2009-08-12,6,1,1,0,0,0,0,0,0,2,0,0,0,0,1,MERCK SHARP DOHME,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Evaluating the Effects of 2 Different Regimens of Montelukast Daily Dosing and Intermittent, Episode-Driven Dosing Compare...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002791-18,1,1,0 2006-002791-18,7,2009-08-12,2009-08-12,6,1,1,0,0,0,0,0,0,2,0,0,0,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Evaluating the Effects of 2 Different Regimens of Montelukast Daily Dosing and Intermittent, Episode-Driven Dosing Compare...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002791-18,1,1,0 2006-002791-18,7,2009-08-12,2009-08-12,6,1,1,0,0,0,0,0,0,2,0,0,0,0,1,Suomen MSD Oy,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Evaluating the Effects of 2 Different Regimens of Montelukast Daily Dosing and Intermittent, Episode-Driven Dosing Compare...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002791-18,1,1,0 2006-002791-18,7,2009-08-12,2009-08-12,6,1,1,0,0,0,0,0,0,2,0,0,0,0,1,Merck & Co. Inc.,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Evaluating the Effects of 2 Different Regimens of Montelukast Daily Dosing and Intermittent, Episode-Driven Dosing Compare...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002791-18,1,1,0 2006-002792-41,5,2007-10-23,2009-06-30,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,FoldRx Pharmaceuticals Limited,"Safety and Efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): A Phase II/III, Randomised, Double-Blind, Placebo-Controlled Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002792-41,0,0,0 2006-002792-41,5,2007-10-23,2009-06-30,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"FoldRx Pharmaceuticals, Inc.","Safety and Efficacy of Orally Administered Fx-1006A in Patients with Familial Amyloid Polyneuropathy (FAP): A Phase II/III, Randomised, Double-Blind, Placebo-Controlled Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002792-41,0,0,0 2006-002793-21,1,2009-06-24,2009-06-24,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Lactest S.L.,"“ Ensayo Clinico para la evaluación no invasiva de la actividad lactasa intesttinal in vivo, mediante la administracción oral de 4-Galactosil-xilosa en sujetos con clinica sugerente de intolerancia a ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002793-21,0,0,0 2006-002794-51,5,2008-06-04,2008-06-06,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, active-controlled, multicenter study to compare the effect of 24 weeks treatment with a fixed combination therapy of vildagliptin and metformin to the individual monotherap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002794-51,0,0,0 2006-002794-51,5,2008-06-04,2008-06-06,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, active-controlled, multicenter study to compare the effect of 24 weeks treatment with a fixed combination therapy of vildagliptin and metformin to the individual monotherap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002794-51,0,0,0 2006-002798-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Koskela Heikki,Hyperglykemia äkillisissä keuhkosairauksissa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002798-38,0,0,0 2006-002801-30,6,2010-12-30,2010-12-31,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,MENARINI RICERCHE S.P.A.,"""Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo del tratamiento de mantenimiento con ABAGOVOMAB en pacientes con cáncer epitelial de ovario después de una respuesta completa ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002801-30,0,0,0 2006-002801-30,6,2010-12-30,2010-12-31,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,MENARINI RICERCHE S.p.A,"""Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo del tratamiento de mantenimiento con ABAGOVOMAB en pacientes con cáncer epitelial de ovario después de una respuesta completa ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002801-30,0,0,0 2006-002803-15,1,2007-02-01,2007-02-01,1,1,0,0,1,0,2,0,1,1,0,0,1,0,0,Aarhus Sygehus,"Bioavailability, Pharmacokinetics and Pharmacodynamics of Insulin Aspart administered in the Duodenum in healthy volunteers – an open single blinded and uncontrolled exploratory trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002803-15,0,0,0 2006-002805-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)","Strategic long term, immunologically driven treatment interruptions in previously naive patients starting HAART: a controlled, randomized, multicenter study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002805-30,0,0,0 2006-002808-34,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,,"A phase II study of isolated lung perfusion with melphalan followed by pulmonary metastasectomy in patients with resectable pulmonary metastases of colorectal carcinoma, soft tissue sarcoma and osteos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002808-34,0,0,0 2006-002808-34,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,St. Antonius Hospital,"A phase II study of isolated lung perfusion with melphalan followed by pulmonary metastasectomy in patients with resectable pulmonary metastases of colorectal carcinoma, soft tissue sarcoma and osteos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002808-34,0,0,0 2006-002809-31,14,2011-01-13,2011-07-25,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schering Plough Research Institute, a Division of Schering Corporation","""Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo, para evaluar la seguridad y eficacia de SCH 530348 añadido al tratamiento estándar, en sujetos con síndrome coronario agudo:...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002809-31,0,0,0 2006-002809-31,14,2011-01-13,2011-07-25,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Schering-Plough Research Institute,"""Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo, para evaluar la seguridad y eficacia de SCH 530348 añadido al tratamiento estándar, en sujetos con síndrome coronario agudo:...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002809-31,0,0,0 2006-002809-31,14,2011-01-13,2011-07-25,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Schering Plough Research Institute,"""Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo, para evaluar la seguridad y eficacia de SCH 530348 añadido al tratamiento estándar, en sujetos con síndrome coronario agudo:...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002809-31,0,0,0 2006-002809-31,14,2011-01-13,2011-07-25,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schering-Plough Research Institute, a division of Schering Corporation","""Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo, para evaluar la seguridad y eficacia de SCH 530348 añadido al tratamiento estándar, en sujetos con síndrome coronario agudo:...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002809-31,0,0,0 2006-002809-31,14,2011-01-13,2011-07-25,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation","""Estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo, para evaluar la seguridad y eficacia de SCH 530348 añadido al tratamiento estándar, en sujetos con síndrome coronario agudo:...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002809-31,0,0,0 2006-002811-29,3,2008-06-22,2010-04-21,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Allos Therapeutics, Inc.",A Multi-center Phase 2 Open-label Study of RS -10-Propargyl-10-Deazaaminopterin pralatrexate with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T ce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002811-29,0,0,0 2006-002811-29,3,2008-06-22,2010-04-21,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,ALLOS,A Multi-center Phase 2 Open-label Study of RS -10-Propargyl-10-Deazaaminopterin pralatrexate with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T ce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002811-29,0,0,0 2006-002813-11,5,2008-06-06,2008-06-06,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Xytis Pharmaceuticals Sàrl,"A phase II randomised, double blind, placebo-controlled, dose finding, safety and tolerability trial of XY2405 as a treatment for traumatic brain injury",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002813-11,1,0,0 2006-002814-37,1,2010-01-04,2010-01-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France S.A.S.,A phase II study of BIBW 2992 added to letrozole in patients with estrogen receptor positive hormone refractory metastatic breast cancer progressing on letrozole,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002814-37,0,0,0 2006-002815-28,1,2008-04-29,2008-04-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Affymax, Inc.","A Phase 2, Open-label, Multi-Center, Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of AF37702 Injection (HematideTM) for the Maintenance Treatment of Anemia in Hemodialysis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002815-28,0,0,0 2006-002818-35,1,2009-04-20,2009-04-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly Deutschland GmbH,A Randomized Phase 2 Study of Pemetrexed in Combination with Cisplatin or Carboplatin in the First Line Therapy of Advanced NSCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002818-35,0,0,0 2006-002828-42,1,2007-09-18,2007-09-18,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Medivir AB,"An open label, multi-centre, phase III, subject initiated safety study of ME-609 in treatment of recurrent herpes simplex labialis in adolescents.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002828-42,0,0,0 2006-002830-38,4,2009-01-05,2009-01-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Pemetrexed Versus Pemetrexed Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002830-38,0,0,0 2006-002832-10,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,Haukeland University Hospital,Liitännäishoitona annetun oksaliplatiinipohjaisen solusalpaajahoidon jälkeinen hedelmällisyys kolorektaalisyöpäpotilailla. Pohjoismainen prospektiivinen tutkimus. Fertility in colorectal cancer patien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002832-10,0,0,0 2006-002833-19,1,2006-11-03,2006-11-03,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Shire Pharmaceutical Development,"A randomised, multi-centre, open-label study to evaluate the efficacy of VANIQA with laser treatment versus laser treatment alone in female subjects with excessive facial hair (facial hirsutism)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002833-19,0,0,0 2006-002835-25,1,,,0,0,0,0,0,3,4,0,1,0,0,0,0,0,0,"HY, Kliinisen farmakologian yksikkö",Perinnöllisten tekijöiden vaikutus diabeteslääkkeisiin 3.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002835-25,0,0,0 2006-002836-18,1,2008-04-25,2008-04-25,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,S.L.A. Pharma (UK) Ltd,"A Two-Arm Chemoprevention Trial in Familial Adenomatous Polyposis Coli Patients Using the Purified Free Fatty Acid, Eicosapentaenoic Acid.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002836-18,0,0,0 2006-002837-19,1,2012-01-09,2012-01-09,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,DERBY HOSPITALS NHS FOUNDATION TRUST,A DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF TERLIPRESSIN IN THE MANAGEMENT OF SEVERE ALCOHOLIC HEPATITIS – A PRELIMINARY STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002837-19,0,0,0 2006-002838-38,2,2007-12-11,2007-12-11,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Abbott GmbH & Co. KG,A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT-751 in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002838-38,0,0,0 2006-002839-24,2,2007-06-07,2007-06-07,2,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A randomized, double-blind, placebo-controlled, multi-country and multi-center, phase IV study to demonstrate the efficacy of GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscularly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002839-24,0,0,0 2006-002841-34,1,2011-02-25,2011-02-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Dr. Gerhard Franz Kieselbach,Klinische Studie zum Vergleich des Einflusses der intravitrealen Injektion von Bevacizumab (Avastin®) und von Pegaptanib (Macugen®) auf den Visus bei neovaskulärer Alters-abhängiger Makula-Degeneratio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002841-34,0,0,0 2006-002845-36,1,2014-09-12,2014-09-12,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,Pharmacokinetics and pharmacogenetics of anticancer drugs in infants and young children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002845-36,0,0,0 2006-002847-96,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Sanofi aventis US Inc.,"A 13-week Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose-Response Trial Assessing the Safety, Tolerability and Efficacy of AVE0010 in Metformin-Treated Subjects with Type 2 Diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002847-96,0,0,0 2006-002848-28,1,2007-06-28,2007-06-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FOURNIER Laboratories Ireland Ltd,"An open label, multicenter trial assessing the acceptability of a new fixed dose combination of fenofibrate 80 mg bid and metformin 1000 mg bid in patients with type 2 diabetes (T2DM) and dyslipidemia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002848-28,0,0,0 2006-002850-31,1,2008-02-02,2008-02-02,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,TopoTarget A/S,APO866 for B-Cell Leukaemia. An open phase I/II clinical study assessing the safety and tolerability of APO866 in patients with refractory B-cell lymphocytic leukaemia not amenable to allogeneic hemop...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002850-31,0,0,0 2006-002851-33,1,2009-03-01,2009-03-01,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,Univ. Prof. Dr. Manuela Schmidinger,Sorafenib and Bevacizumab as first- line treatment in patients with advanced renal cell carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002851-33,0,0,0 2006-002852-13,1,2008-01-11,2008-01-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Bexel Pharmaceuticals Inc.,"Double blind, placebo-controlled dose escalating, multiple dose study with two groups of 30 volunteers with type II diabetes to assess efficacy on glucose-profile, triglycerides and blood pressure and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002852-13,0,0,0 2006-002856-14,1,2008-06-20,2008-06-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,medac Gesellschaft für klinische Spezialpräparate mbH,"Randomised, placebo-controlled, three-arm parallel-group, double-blind, multicentre, national clinical phase II study to evaluate the efficacy, safety, and tolerability of intravenous 3 and 6 g/m² tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002856-14,0,0,0 2006-002857-54,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Octapharma AG,International clinical study to investigate the efficacy and safety of Wiloctin in patients with inherited von willebrand disease (vWD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002857-54,0,0,0 2006-002858-29,1,2009-11-15,2009-11-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bracco Imaging Deutschland GmbH,A DOUBLE-BLIND INTER-INDIVIDUAL COMPARISON OF IOMEPROL 300 AND IOMEPROL 400 IN THE ASSESSMENT OF PERFUSION CT OF ADVANCED RENAL CARCINOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002858-29,0,0,0 2006-002860-25,6,2011-08-27,2011-08-27,2,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Roche Hungary Ltd.,A multicenter randomized phase II trial to compare trastuzumab (Herceptin®) continuation or discontinuation in combination with 2nd-line chemotherapies after progression on a 1st-line chemotherapy com...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002860-25,0,0,0 2006-002861-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Ziekenhuisapotheek Meppel-Hoogeveen,"Evaluation of the oral uracil loading test as a sensitive, simple and cheap method to detect DPD deficiency.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002861-37,0,0,0 2006-002862-20,1,2007-08-08,2007-08-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,NeuroSearch A/S,"Effect of tesofensine on weight reduction in patients with obesity. A randomised, double-blind, placebo-controlled, parallel-group, multi-centre study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002862-20,0,0,0 2006-002864-24,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,"Dept. of Clinical Pharmacy, Radboud UMC Nijmegen, The Netherlands",Drug interactions between ATOvaquone used in MAlaria prophylaxis and antiretroviral agents in HIV-1 infected patients (ATOMA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002864-24,0,0,0 2006-002867-19,1,2008-10-01,2008-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca S.A.S,"Evaluation de l’efficacité de 3 stratégies de prise en charge au long cours des symptômes de reflux gastro-oesophagien en médecine générale : étude multicentrique, randomisée, en ouvert, réalisée en g...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002867-19,0,0,0 2006-002873-35,6,2008-12-02,2009-03-18,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,LEO Pharma A/S,"Exploratory efficacy and safety, pharmacokinetics and dose-finding study of ATryn® (antithrombin alfa) in patients with disseminated intravascular coagulation associated with severe sepsis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002873-35,0,0,0 2006-002873-35,6,2008-12-02,2009-03-18,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,LEO Pharmaceutical Products Ltd A/S (LEO Pharma A/S),"Exploratory efficacy and safety, pharmacokinetics and dose-finding study of ATryn® (antithrombin alfa) in patients with disseminated intravascular coagulation associated with severe sepsis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002873-35,0,0,0 2006-002875-42,13,2010-06-10,2011-04-01,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,"A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capaci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002875-42,0,0,0 2006-002875-42,13,2010-06-10,2011-04-01,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capaci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002875-42,0,0,0 2006-002875-42,13,2010-06-10,2011-04-01,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV Ges mbH & Co KG,"A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capaci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002875-42,0,0,0 2006-002875-42,13,2010-06-10,2011-04-01,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capaci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002875-42,0,0,0 2006-002875-42,13,2010-06-10,2011-04-01,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capaci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002875-42,0,0,0 2006-002875-42,13,2010-06-10,2011-04-01,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capaci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002875-42,0,0,0 2006-002875-42,13,2010-06-10,2011-04-01,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capaci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002875-42,0,0,0 2006-002875-42,13,2010-06-10,2011-04-01,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capaci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002875-42,0,0,0 2006-002875-42,13,2010-06-10,2011-04-01,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France SAS,"A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capaci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002875-42,0,0,0 2006-002877-30,1,2007-02-09,2007-02-09,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,NOVARTIS FARMA,"An open label, multicenter, pilot phase II study of SOM230 s.c. in patients with duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonﾒs syndrome, non-functioning adeno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002877-30,0,0,0 2006-002880-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de psiquiatria. Hospital Universitario La Paz,Comparación de dos estrategias de intervención para el tratamiento de los trastornos depresivos en pacientes oncológicos,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002880-19,0,0,0 2006-002881-20,1,2009-10-31,2009-10-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Gasthuisberg,"HGG-2006: a phase I/II clinical trial for the treatment of newly diagnosed high grade glioma with tumor vaccination as ""add-on therapy"" to standard primary treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002881-20,0,0,0 2006-002883-24,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,3,,Deksametasonin annoksen vaikutus tähystyksen avulla tehtävän kohdunpoiston jälkeisen kivun hallinnassa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002883-24,0,0,0 2006-002886-38,1,2014-06-06,2014-06-06,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Faculty of Medicine, Technische Universitaet Muenchen",A Multicenter Study on Regenerative Effects of Erythropoitin (LDE) in Burn and Scaled Injuries,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002886-38,0,0,0 2006-002887-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOIM GRUPPO ONCOLOGICO MERIDIONALE,Bevacizumab+folfiri in untreated patients with advanced colorectal cancer. A phase II multicenter study of the Gruppo Oncologico dell'Italia Meridionale. (GOIM).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002887-25,0,0,0 2006-002890-31,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Dept. of Anaesthesia, Medical University of Vienna",Does Pregabalin reduce preoperative anxiety: a placebo controlled study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002890-31,0,0,0 2006-002891-17,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,Sanna Vilo,Parenteraalisen deksmedetomidiinin farmakikinetiikan tutkiminen 28 vrk - 11 v lapsilla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002891-17,0,0,0 2006-002893-23,2,2008-08-08,2008-08-08,1,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Lilly S.A.,An Open Label Single Arm Phase 1b/2 Study with Pharmacokinetic Sampling to Evaluate LY2181308 in Patients with Advanced Hepatocellular Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002893-23,1,0,0 2006-002893-23,2,2008-08-08,2008-08-08,1,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Eli Lilly and Company,An Open Label Single Arm Phase 1b/2 Study with Pharmacokinetic Sampling to Evaluate LY2181308 in Patients with Advanced Hepatocellular Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002893-23,1,0,0 2006-002897-23,1,2007-06-18,2007-06-18,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"An observational study to investigate the incidence of influenza and influenza-related complications, in adults between 50-64 years and elderly adults 65 years and over vaccinated with GSK Biologicals...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002897-23,0,0,0 2006-002898-47,2,2008-05-02,2008-05-02,1,1,0,0,0,0,3,0,1,2,0,0,0,0,1,GlaxoSmithKline Biologicals,A phase IIIb open study to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine when co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002898-47,1,0,0 2006-002898-47,2,2008-05-02,2008-05-02,1,1,0,0,0,0,3,0,1,2,0,0,0,0,1,GlaxoSmithKline S.A.,A phase IIIb open study to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine when co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002898-47,1,0,0 2006-002901-30,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,University Hospital Ghent,Tramadol iv. : influence of dose and dose intervals on therapeutic accuracy and side effects when used for postoperative pain relief in ambulatory surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002901-30,0,0,0 2006-002902-74,1,2007-03-23,2007-03-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Santé s.a.s.,"A double-blind, double-dummy, randomized, controlled, multi-centre study of the activity and safety of 2 daily doses of EMD 387008 versus placebo and metformin in parallel groups after 8 weeks of trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002902-74,0,0,0 2006-002907-15,8,2008-02-08,2008-05-06,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"Multicenter, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of tezosentan in patients with pre-operative pulmonary hypertension, due...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002907-15,0,0,0 2006-002907-15,8,2008-02-08,2008-05-06,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals LTD,"Multicenter, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of tezosentan in patients with pre-operative pulmonary hypertension, due...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002907-15,0,0,0 2006-002911-28,2,2006-06-15,2006-06-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D,"A multicentre, randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study to evaluate the efficacy, safety and tolerability of once daily oral dosing of GW501516 (2.5 mg, 5 mg an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002911-28,0,0,0 2006-002913-11,1,2009-02-07,2009-02-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,York Hospitals NHS Trust,"Randomised controlled, double blinded single centre trial to assess the effects of peri-operative dopexamine on morbidity after major abdominal surgery in patients with low anaerobic threshold.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002913-11,0,0,0 2006-002917-11,2,2008-07-15,2008-07-15,2,1,0,0,0,0,0,0,0,1,1,1,1,0,1,PFIZER,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY SYMPTOMS IN SUBJECTS WITH ADVANCED COLORECTAL CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002917-11,0,0,0 2006-002917-11,2,2008-07-15,2008-07-15,2,1,0,0,0,0,0,0,0,1,1,1,1,0,1,Pfizer Pharma GmbH,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY SYMPTOMS IN SUBJECTS WITH ADVANCED COLORECTAL CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002917-11,0,0,0 2006-002922-51,3,2008-01-03,2008-01-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly ICOS LLC,Tadalafil 5 mg Once a Day Compared to Placebo in Improving Erectile Dysfunction and Sexual Quality of Life,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002922-51,0,0,0 2006-002933-18,1,2011-06-28,2011-06-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,InfectoPharm Arzneimittel und Consilium GmbH,"Multizentrische, randomisierte, doppelblinde, placebokontrollierte Phase III-Studie zur (Langzeit-) Add On-Behandlung der COPD (Schweregrad III/IV) mit 2 x 80 mg inhalativem Tobramycin (Gernebcin)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002933-18,0,0,0 2006-002934-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOIM GRUPPO ONCOLOGICO MERIDIONALE,RANDOMIZED PHASE II TRIAL OF FIRST LINE CISPLATIN WITH DOCETAXEL OR VINORELBINE FOR 6 CYCLES IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002934-40,0,0,0 2006-002935-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOIM GRUPPO ONCOLOGICO MERIDIONALE,multicenter phase II study to evaluate palonosetron +desametasone in the prevention of nausea and vomiting in patientes resected for colon cancer and treated with moderate emetogenus chemotherapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002935-25,0,0,0 2006-002937-20,8,2008-04-10,2008-06-18,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,EISAI LTD UK,"A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002937-20,0,0,0 2006-002937-20,8,2008-04-10,2008-06-18,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eisai Limited,"A Multi-centre, Randomised, Double-blind, Placebo- and Entacapone-controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002937-20,0,0,0 2006-002938-38,1,2009-05-31,2009-05-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Hannover Medical School,EFFECT OF ERYTHROPOIETIN ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002938-38,0,0,0 2006-002940-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ICIN,"HEBE III: A prospective, randomised, double blind, placebo controlled clinical study to examine the effects of a single bolus erythropoietin on left ventricular function in patients with an acute myoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002940-28,0,0,0 2006-002940-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"UMCG, Van Buchem Stichting","HEBE III: A prospective, randomised, double blind, placebo controlled clinical study to examine the effects of a single bolus erythropoietin on left ventricular function in patients with an acute myoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002940-28,0,0,0 2006-002941-35,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,AZIENDA OSPEDALIERA S. LUIGI GONZAGA,EFFECTS OF PROSTAGLANDIN COMPOUNDS ON CONJUNTIVAL MELANOGENESIS: AN IMPRESSION CITOLOGY AND TYROSINASE MARKERS STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002941-35,0,0,0 2006-002942-12,15,2011-12-16,2011-12-23,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Schering-Plough Research Institute,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002942-12,0,0,0 2006-002942-12,15,2011-12-16,2011-12-23,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering Plough Research Institute, A Division of Schering Corporation","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002942-12,0,0,0 2006-002942-12,15,2011-12-16,2011-12-23,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, A Division of Schering Corporation","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002942-12,0,0,0 2006-002942-12,15,2011-12-16,2011-12-23,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHERING-PLOUGH,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002942-12,0,0,0 2006-002943-10,3,2007-07-06,2008-06-24,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"REPEAT. Repeated ExPosure To Eltrombopag in Adults with Idiopathic Thrombocytopenic Purpura. An Open-label repeat dosing study of eltrombopag olamine (SB-497115-GR) in adult subjects, with chronic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002943-10,0,0,0 2006-002943-10,3,2007-07-06,2008-06-24,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","REPEAT. Repeated ExPosure To Eltrombopag in Adults with Idiopathic Thrombocytopenic Purpura. An Open-label repeat dosing study of eltrombopag olamine (SB-497115-GR) in adult subjects, with chronic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002943-10,0,0,0 2006-002945-36,5,2013-03-07,2013-03-07,4,1,0,0,0,2,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,LENS – Long-term Eltrombopag ObservatioNal Study - A long term observational ocular safety study in adults who have received study medication (SB-497115-GR / eltrombopag olamine or placebo) in a phase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002945-36,0,0,0 2006-002945-36,5,2013-03-07,2013-03-07,4,1,0,0,0,2,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,LENS – Long-term Eltrombopag ObservatioNal Study - A long term observational ocular safety study in adults who have received study medication (SB-497115-GR / eltrombopag olamine or placebo) in a phase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002945-36,0,0,0 2006-002946-13,5,2014-02-03,2014-02-03,3,1,1,0,0,1,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A three part, staggered cohort, open-label and double blind, randomized, placebo controlled study to investigate the efficacy, safety, tolerability and pharmacokinetics of eltrombopag, a thrombopoieti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002946-13,1,1,0 2006-002946-13,5,2014-02-03,2014-02-03,3,1,1,0,0,1,2,0,0,2,0,0,0,0,1,GlaxoSmithKline S.A.,"A three part, staggered cohort, open-label and double blind, randomized, placebo controlled study to investigate the efficacy, safety, tolerability and pharmacokinetics of eltrombopag, a thrombopoieti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002946-13,1,1,0 2006-002947-94,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Minna Tallgren,"DEKSAMETASONIN VAIKUTUS RINTALEIKKAUKSEN JÄLKEISEN KIVUN HALLINTAAN - satunnaistettu, kakssoissokko, lumekontrolloitu tutkimus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002947-94,0,0,0 2006-002948-28,1,2008-02-29,2008-02-29,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,MAROS Arzneimittel GmbH,Prospective randomized monoinstitutional study of the treatment of therapy-associated diarrhea during percutaneous radiation therapy of the small pelvis. – Comparison of loperamide and tincture of opi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002948-28,0,0,0 2006-002950-32,1,2010-01-08,2010-01-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Gentofte University Hospital,Long term effects of DPP-IV inhibitor treatment on the secretion and action of the incretin hormones in patients with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002950-32,0,0,0 2006-002951-33,1,2009-01-29,2009-01-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"sanofi-aventis, S.A.","A 12-month multicentre, randomised, double-blind, placebo-controlled study with two parallel groups to assess the effects of rimonabant 20 mg in patients with abdominal obesity and microalbuminuria, w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002951-33,0,0,0 2006-002958-29,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO,STUDY OF CIRCULATING OSTEOBLAST-LINEAGE CELLS IN RELATION WITH TERIPARATIDE THERAPY.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002958-29,0,0,0 2006-002962-20,2,2015-02-08,2015-02-08,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,Hannover Medical School,Elimination of the preleukemic clone in children with Down syndrome and transient myeloproloferative disorder (TMD) to prevent AML - Model of leukemia prevention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002962-20,0,0,0 2006-002963-23,1,2007-04-27,2007-04-27,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Chr. Hansen A/S,The effect of probiotics on bloating in IBS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002963-23,0,0,0 2006-002965-38,1,2010-08-06,2010-08-06,1,0,0,0,1,0,3,0,0,1,0,0,1,0,0,Chirurgische Gemeinschaftspraxis Südstadt,"Comparison of sclerotherapy for first grade haemorrhoids using Aethoxylsklerol foam versus fluid: A randomised, controlled, multicentre, single blinded trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002965-38,0,0,0 2006-002971-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,Outpatients high-dose chemotherapy supported by autologus peripheral blood stem and single-dose pegfilgrastim in patients with lymphoproliferative malignances.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002971-42,0,0,0 2006-002977-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Eye Hospital,Safety and efficacy of intravitreal injections of ranibizumab/Lucentis in combination with verteporfin photodynamic therapy (PDT) in patients with choroidal neovascularisation (CNV) secondary to age r...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002977-33,0,0,0 2006-002978-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",SPERIMENTAL STUDY ON THE CLINICAL EFFECT OF POLI UNSATURATED FATTY ACIDS w-3 AND ON THEIR ANTIFLAMMATORY AND ANTI OXIDANT ACTION IN LUNG CANCER PATIENTS DURING CHEMIOTHERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002978-21,0,0,0 2006-002979-40,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,LUMC,Pharmacokinetic-pharmacodynamic modeling of S(+)-ketamine in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002979-40,0,0,0 2006-002980-17,6,2008-10-06,2008-10-30,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,OM PHARMA,"Double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® in children suffering from recurrent upper respiratory tract infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002980-17,0,0,0 2006-002982-38,14,2010-08-04,2011-09-16,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Serono S.A. - Geneva, an affiliate of Merck KGaA Darmstadt, Germany","A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation 44 mcg tiw and 44 mcg ow in subjects at high risk of converting to Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002982-38,0,0,0 2006-002982-38,14,2010-08-04,2011-09-16,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Serono International S.A.,"A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation 44 mcg tiw and 44 mcg ow in subjects at high risk of converting to Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002982-38,0,0,0 2006-002982-38,14,2010-08-04,2011-09-16,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Serono S.A.-Geneva, an affiliate of Merck KGaA Darmstadt, Germany","A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation 44 mcg tiw and 44 mcg ow in subjects at high risk of converting to Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002982-38,0,0,0 2006-002982-38,14,2010-08-04,2011-09-16,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Serono International SA,"A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation 44 mcg tiw and 44 mcg ow in subjects at high risk of converting to Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002982-38,0,0,0 2006-002982-38,14,2010-08-04,2011-09-16,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Serono International, a branch of Laboratoires Serono SA An affiliate of Merck KGaA","A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation 44 mcg tiw and 44 mcg ow in subjects at high risk of converting to Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002982-38,0,0,0 2006-002987-24,12,2010-03-22,2010-04-07,8,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Biogen Idec Ltd,"A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002987-24,0,0,0 2006-002987-24,12,2010-03-22,2010-04-07,8,1,0,0,0,2,2,0,0,1,1,0,1,0,1,BIOGEN IDEC LTD,"A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002987-24,0,0,0 2006-002992-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",A phase II study to evaluate the efficacy of bevacizumab in combination with capecitabine and concomitant radiotherapy in patients affected by non-resectable locally advanced pancreatic cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002992-42,0,0,0 2006-002999-17,3,2008-05-12,2008-05-14,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,"A Phase 3, Open-Label, Parallel-Group Study to Compare Two Dosing Algorithms for Preprandial Human Insulin Inhalation Powder (HIIP) in Insulin-Naïve Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002999-17,0,0,0 2006-002999-17,3,2008-05-12,2008-05-14,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly,"A Phase 3, Open-Label, Parallel-Group Study to Compare Two Dosing Algorithms for Preprandial Human Insulin Inhalation Powder (HIIP) in Insulin-Naïve Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002999-17,0,0,0 2006-003001-49,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,Anti-inflammatory effects of rosiglitazone in patients with stage 4 and 5 chronic kidney disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003001-49,0,0,0 2006-003002-26,1,,,0,0,0,0,0,1,2,1,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation du traitement par corticothérapie systémique ou par interféron alpha2a au cours de la Birdshot rétinochoroïdopathie compliquée d'oedeme maculaire,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003002-26,0,0,0 2006-003003-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Center,Methotrexate versus expectant management in women with ectopic pregnancy (METEX study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003003-39,0,0,0 2006-003004-19,1,2007-01-18,2007-01-18,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,FAES Farma S.A.,"A randomised, double-blind, four way cross-over, placebo controlled trial to evaluate the clinical efficacy, onset of action and drug activity at 22-26 hours following the drug intake of Bilastne 20 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003004-19,0,0,0 2006-003006-26,3,2007-09-04,2007-12-09,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Stallergenes S.A.,"A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT) administered as allergen-b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003006-26,1,0,0 2006-003007-39,2,2008-05-30,2008-05-30,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Eli Lilly and Company limited,"Phase I/II Study of Concurrent Cisplatin, Pemetrexed, and Radiotherapy for Limited Stage Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003007-39,0,0,0 2006-003011-46,1,2009-01-14,2009-01-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Dr. Olaf Stanger,Klinische Studie zur Überprüfung des Stellenwerts einer perioperativen Verabreichung der Vitamine E und C und/oder von Omega-3-Fettsäuren bei der Verminderung des Reperfusionsschadens nach Herzoperati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003011-46,0,0,0 2006-003012-21,1,2007-03-06,2007-03-06,1,0,0,0,0,0,3,0,1,1,0,0,1,0,1,"Acusphere, Inc.","A Phase 3, International, Exploratory, Open-Label, Multicenter, Dual-Injection, Echocardiographic Imaging Settings and Safety Study of AI-700 in Normal Volunteers and Stable Cardiac Patients (Acquirin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003012-21,0,0,0 2006-003013-41,1,2008-01-30,2008-01-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Children's Clinic Randers,Short-term and longterm growth in children with asthma treated with budesonide or montelukast,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003013-41,0,0,0 2006-003014-18,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Vicente Barrio Lucia,"Double blind randomized controlled clinical trial to evaluate the efficacy and safety of theophyline in the prevention of nephrotoxicity associated with cisplatin in oncology Estudio prospectivo, d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003014-18,0,0,0 2006-003023-37,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,GlaxoSmithKline UK,"A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase IV Study to Evaluate the Efficacy and Safety of Dutasteride 0.5mg Administered Orally Daily for 24 Weeks to Reduce the Risk of Acute U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003023-37,0,0,0 2006-003025-93,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude de la réduction des poussées de lupus érythémateux systémique par adaptation de la posologie de l'hydroxychloroquine à sa concentration sanguine. Etude randomisée multicentrique nationale.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003025-93,0,0,0 2006-003031-70,1,2007-12-12,2007-12-12,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,LABORATORIOS NORMON S.A.,"Evaluación de la profundidad anestésica de la lidocaína 1:100.000 frente a la articaína 1:100.000, en la cirugía del tercer molar inferior. Estudio comparativo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003031-70,0,0,0 2006-003034-15,1,2012-12-19,2012-12-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"Trattamento dell’epatocarcinoma (HCC) mediante chemioembolizzazione (TACE) selettiva tradizionale versus TACE selettiva con microsfere caricate con Doxorubicina: studio monocentrico, randomizzato, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003034-15,0,0,0 2006-003035-78,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,SICUREZZA ED EFFICACIA DI CICLOSPORINA A BASSE DOSI IN ASSOCIAZIONE AD EVEROLIMUS NEL PROTEGGERE LA FUNZIONE RENALE NEI PAZIENTI CON TRAPIANTO DI CUORE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003035-78,0,0,0 2006-003036-30,6,2008-05-08,2008-07-28,6,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"Ensaio clínico prospectivo, randomizado, de observador cego, com grupos paralelos e multicêntrico, para avaliar a eficácia e a segurança de duas diluições diferentes de NT 201 em pacientes com espasti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003036-30,0,0,0 2006-003036-30,6,2008-05-08,2008-07-28,6,1,0,0,2,0,3,0,0,1,0,0,1,0,1,MERZ PHARMACEUTICALS GMBH,"Ensaio clínico prospectivo, randomizado, de observador cego, com grupos paralelos e multicêntrico, para avaliar a eficácia e a segurança de duas diluições diferentes de NT 201 em pacientes com espasti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003036-30,0,0,0 2006-003037-32,5,2008-11-26,2009-02-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Serono International SA,"A TWO-ARM, RANDOMISED, DOUBLE-BLIND, CONTROL GROUP-COMPARED, MULTICENTRE, PHASE IIIB STUDY WITH MONTHLY MRI AND BIOMARKER ASSESSMENT TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF REBIF NEW FOR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003037-32,0,0,0 2006-003037-32,5,2008-11-26,2009-02-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SERONO INTERNATIONAL SA,"A TWO-ARM, RANDOMISED, DOUBLE-BLIND, CONTROL GROUP-COMPARED, MULTICENTRE, PHASE IIIB STUDY WITH MONTHLY MRI AND BIOMARKER ASSESSMENT TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF REBIF NEW FOR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003037-32,0,0,0 2006-003037-32,5,2008-11-26,2009-02-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Serono SA,"A TWO-ARM, RANDOMISED, DOUBLE-BLIND, CONTROL GROUP-COMPARED, MULTICENTRE, PHASE IIIB STUDY WITH MONTHLY MRI AND BIOMARKER ASSESSMENT TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF REBIF NEW FOR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003037-32,0,0,0 2006-003039-65,1,2009-04-15,2009-04-15,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Alfacell Corporation,A phase I / II trial of intravenous Onconase(R) in subjects with non-small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003039-65,0,0,0 2006-003047-24,6,2009-12-14,2009-12-31,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women with Early Stage Breast Cancer Revised Protocol 02...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003047-24,0,0,0 2006-003048-52,4,2009-02-12,2009-02-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A Phase IIb/III, multi-centre, double-blind, randomised, placebo-controlled, dose ranging study of Tamsulosin hydrochloride (low, medium and high dose) as treatment in children with neuropathic bladde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003048-52,0,0,0 2006-003048-52,4,2009-02-12,2009-02-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A Phase IIb/III, multi-centre, double-blind, randomised, placebo-controlled, dose ranging study of Tamsulosin hydrochloride (low, medium and high dose) as treatment in children with neuropathic bladde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003048-52,0,0,0 2006-003048-52,4,2009-02-12,2009-02-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A Phase IIb/III, multi-centre, double-blind, randomised, placebo-controlled, dose ranging study of Tamsulosin hydrochloride (low, medium and high dose) as treatment in children with neuropathic bladde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003048-52,0,0,0 2006-003048-52,4,2009-02-12,2009-02-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase IIb/III, multi-centre, double-blind, randomised, placebo-controlled, dose ranging study of Tamsulosin hydrochloride (low, medium and high dose) as treatment in children with neuropathic bladde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003048-52,0,0,0 2006-003049-17,1,2016-01-18,2016-01-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical Research Council,A two-arm randomised trial of intermittent chemotherapy plus continuous cetuximab and of intermittent chemotherapy plus intermittent cetuximab in first line treatment of metastatic colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003049-17,0,0,0 2006-003053-24,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Prophylaxis with fenoldopam in cardiac surgery patients at high risk of postoperative renal failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003053-24,0,0,0 2006-003054-26,3,2009-02-24,2009-02-24,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Takeda Global R&D (Europe) Ltd,"A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate the Safety and Efficacy of Oral TAK-783 in the Treatment of the Signs and Symptoms of in Subjects with Rheumatoid Arth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003054-26,0,0,0 2006-003055-20,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Metformin in pregnancy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003055-20,0,0,0 2006-003060-59,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,Novo Nordisk Limited,"A 32 week, national, single-centre, open-labelled, randomised, cross-over trial comparing energy expenditure with insulin detemir versus NPH insulin using a basal-bolus regimen with insulin aspart as ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003060-59,0,0,0 2006-003065-14,1,2009-09-24,2009-09-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LETI Pharma GmbH,Investigation of a preseasonal rush treatment scheme with Depigoid® Grass Mix as an add-on therapy in patients with allergic rhinitis and/or rhinoconjunctivitis sensitized to grass pollen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003065-14,0,0,0 2006-003066-34,1,2010-07-02,2010-07-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LETI Pharma GmbH,"A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® House dust mites (HDM) in patients suf-fering from moderate to severe atopic eczema.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003066-34,0,0,0 2006-003067-31,2,2008-08-05,2008-08-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LETI Pharma GmbH,"A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® tree pollen",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003067-31,0,0,0 2006-003073-27,3,2008-01-22,2008-01-22,2,1,0,0,1,0,3,0,0,1,0,0,1,0,1,GALDERMA R D SNC,"Subject preference comparison between Clobetasol propionate shampoo, 0.05 and three other topical corticosteroids in the treatment of moderate to severe scalp psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003073-27,0,0,0 2006-003073-27,3,2008-01-22,2008-01-22,2,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Galderma R&D,"Subject preference comparison between Clobetasol propionate shampoo, 0.05 and three other topical corticosteroids in the treatment of moderate to severe scalp psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003073-27,0,0,0 2006-003075-12,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,Department Of Paediatric Cardiology,Effect of carvedilol on left ventricular systolic and diastolic function and the neurohormonal axis in patients with Duchenne muscular dystrophy and left ventricular dysfunction.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003075-12,0,0,0 2006-003076-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Eli Lilly and Company Ltd.,Treatment Strategies in Patients with Type 2 Diabetes Mellitus Not Achieving Glycemic Control while on Therapy with Premixed Insulin Analogues and Metformin: A Comparison of Insulin Lispro MM Intensi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003076-35,0,0,0 2006-003080-31,4,2008-10-24,2008-10-24,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NV Organon,"A multi-center, double-blind, flexible-dose efficacy trial with Org 25935 versus placebo as add-on therapy in subjects with predominant, persistent negative symptoms of schizophrenia treated with a st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003080-31,0,0,0 2006-003085-34,1,2009-03-31,2009-03-31,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,sanofi-aventis recherche & developpement,"A Dose-escalating, Multicenter, Single arm, Open-label Study of XRP6258 in combination with capecitabine (Xeloda®), in patients with metastatic breast cancer with disease progressing after anthracycli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003085-34,0,0,0 2006-003086-14,8,2009-11-21,2009-12-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,2,sanofi-aventis recherche & developpement,"A Randomized, Open Label Multi-Center Study of Single Agent Larotaxel XRP9881 at 90 mg/m2 every 3 weeks Compared to Continuous Administration of 5-FU For The Treatment of Patients With Advanced Panc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003086-14,0,0,0 2006-003086-14,8,2009-11-21,2009-12-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,2,sanofi-aventis recherche developpement,"A Randomized, Open Label Multi-Center Study of Single Agent Larotaxel XRP9881 at 90 mg/m2 every 3 weeks Compared to Continuous Administration of 5-FU For The Treatment of Patients With Advanced Panc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003086-14,0,0,0 2006-003087-59,11,2009-09-25,2009-09-25,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi aventis recherche et developpement,"A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Ref...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003087-59,0,0,0 2006-003087-59,11,2009-09-25,2009-09-25,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et developpement,"A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Ref...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003087-59,0,0,0 2006-003096-12,1,2015-12-02,2015-12-02,1,0,0,0,1,1,2,0,0,1,0,0,1,0,0,FUNDACIÓN PARA LA FORMACIÓN E INVESTIGACIÓN SANITARIAS DE LA REGIÓN DE MURCIA,ENSAYO CLÍNICO EN FASE I/II DE UTILIZACIÓN DE LAS CÉLULAS MADRE DE MÉDULA ÓSEA AUTÓLOGAS EN PACIENTES CON ESCLEROSIS LATERAL AMIOTRÓFICA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003096-12,0,0,0 2006-003097-97,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HUS,Endoskooppinen kortisoni vaikean juveniilin parotiitin hoidossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003097-97,0,0,0 2006-003098-28,1,2008-11-19,2008-11-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"HUS, Korvaklinikka",Puudutteet tinnituksen hoidossa- ropivakaiinin ja lidokaiinin vertailu,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003098-28,0,0,0 2006-003101-53,3,2009-02-06,2009-02-26,3,0,0,0,0,0,0,0,0,1,0,0,1,0,0,Karolinska Institutet,"A randomised placebo controlled study of transdermal testosterone therapy (testosterone 1% hydroalcohol gel) to investigate the efficacy and safety in men with abdominal obesity, low testosterone leve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003101-53,0,0,0 2006-003103-39,1,2009-06-25,2009-06-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Glasgow & Greater Glasgow Health Board,Effect of statins on asthma control and airway inflammation in smokers with asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003103-39,0,0,0 2006-003107-39,4,2007-01-22,2010-08-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck & Co,"A Worldwide, Multicenter, Double-Blind, Randomized, Parallel Study to Evaluate the Efficacy of MK-0524 to Improve Tolerability of Extended Release Niacin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003107-39,0,0,0 2006-003107-39,4,2007-01-22,2010-08-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme GesmbH,"A Worldwide, Multicenter, Double-Blind, Randomized, Parallel Study to Evaluate the Efficacy of MK-0524 to Improve Tolerability of Extended Release Niacin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003107-39,0,0,0 2006-003107-39,4,2007-01-22,2010-08-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Worldwide, Multicenter, Double-Blind, Randomized, Parallel Study to Evaluate the Efficacy of MK-0524 to Improve Tolerability of Extended Release Niacin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003107-39,0,0,0 2006-003107-39,4,2007-01-22,2010-08-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Limited,"A Worldwide, Multicenter, Double-Blind, Randomized, Parallel Study to Evaluate the Efficacy of MK-0524 to Improve Tolerability of Extended Release Niacin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003107-39,0,0,0 2006-003108-20,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,URIACH J. URIACH Y COMPANIA S.A.,"A DOUBLE BLIND, RANDOMISED, PARALLEL, PLACEBO-CONTROLLED, PILOT STUDY TO EVALUATE THE ANTI-INFLAMMATORY EFFECTS AND THE EFFICACY OF RUPATADINE 10 MG ON THE SYMPTOMS OF PERSISTENT ALLERGIC RHINITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003108-20,0,0,0 2006-003109-23,4,2012-02-24,2012-02-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK- 0518 Versus Efavirenz in Treatment Na ve HIV-Infected Patients, Each in Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003109-23,0,0,0 2006-003109-23,4,2012-02-24,2012-02-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp and Dohme de España,"A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK- 0518 Versus Efavirenz in Treatment Na ve HIV-Infected Patients, Each in Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003109-23,0,0,0 2006-003109-23,4,2012-02-24,2012-02-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratoires Merck Sharp & Dohme-Chibret,"A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK- 0518 Versus Efavirenz in Treatment Na ve HIV-Infected Patients, Each in Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003109-23,0,0,0 2006-003109-23,4,2012-02-24,2012-02-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK- 0518 Versus Efavirenz in Treatment Na ve HIV-Infected Patients, Each in Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003109-23,0,0,0 2006-003113-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Department of Neurology UMCG,Dexamethason for the treatment of exacerbations in multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003113-40,0,0,0 2006-003114-17,2,2009-05-04,2012-08-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept-Based Corticosteroid-Free Regimens in Renal Transplant + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003114-17,0,0,0 2006-003114-17,2,2009-05-04,2012-08-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept-Based Corticosteroid-Free Regimens in Renal Transplant + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific, v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003114-17,0,0,0 2006-003115-49,1,2010-12-24,2010-12-24,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Technical University of Munich,Einsatz von Mycophenolsäure (Myfortic) bei antikörpervermittelten immunologischen Erkrankungen: Effekt auf Krankheitsverlauf und Organfunktionsparameter,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003115-49,0,0,0 2006-003116-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Prof. Sechtem, Department of Cardiology, Robert Bosch Hospital",Application of Sildenafil in patients with documented coronary vasospasm in order to explore the pathophysiology of coronary vasospasm and the therapeutic effects of Sildenafil in patients suffering f...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003116-22,0,0,0 2006-003119-35,1,2008-10-03,2008-10-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Medical University of Vienna, Department of Clinical Pharmacology",Effects of simvastatin in patients after cardioversion (SIPAC) of non valvular atrial fibrillation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003119-35,0,0,0 2006-003121-82,1,2018-05-22,2018-05-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Southampton NHS Foundation Trust,A prospective randomised open label trial of oxaliplatin / irinotecan plus fluorouracil versus oxaliplatin / irinotecan plus fluorouracil and cetuximab pre and post operatively in patients with resect...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003121-82,0,0,0 2006-003122-28,1,2012-03-31,2012-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Heinrich-Heine-Universität Düsseldorf,Argatroban versus Lepirudin in Critically Ill Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003122-28,0,0,0 2006-003123-37,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,University Hospital Sint Radboud,Treatment with high dose Methotrexate in patients with eosinophilic fasciitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003123-37,0,0,0 2006-003127-36,1,2010-01-04,2010-01-04,1,0,0,0,1,3,4,0,1,1,0,0,1,0,0,Matti Välimäki,Iäkkäään ihmisen D-vitamiinihoito: kaksi kertaa päivässä vai kolme kertaa vuodessa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003127-36,0,0,0 2006-003132-29,11,2008-01-14,2008-01-14,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Laboratorios Andrómaco, S.A.",Eficacia y Seguridad de un parche de lidocaína al 5% comparado con pregabalina en neuralgia post-herpética y dolor por polineuropatía diabética.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003132-29,0,0,0 2006-003132-29,11,2008-01-14,2008-01-14,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,Eficacia y Seguridad de un parche de lidocaína al 5% comparado con pregabalina en neuralgia post-herpética y dolor por polineuropatía diabética.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003132-29,0,0,0 2006-003132-29,11,2008-01-14,2008-01-14,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gruenenthal GmbH,Eficacia y Seguridad de un parche de lidocaína al 5% comparado con pregabalina en neuralgia post-herpética y dolor por polineuropatía diabética.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003132-29,0,0,0 2006-003133-33,1,2011-12-30,2011-12-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Hôpital Erasme,Etude des effets d’un antagoniste non spécifique de l’endothéline (le bosentan) sur l’activité orthosympathique et le chémoréflexe.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003133-33,0,0,0 2006-003134-14,3,2009-06-15,2010-04-07,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis U.S. Inc,"A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003134-14,0,0,0 2006-003134-14,3,2009-06-15,2010-04-07,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis U.S. Inc.,"A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003134-14,0,0,0 2006-003137-32,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY,"A randomized, open label, multicenter phase II study of first line therapy with Sorafenib in association with Interleukin 2 versus Sorafenib alone in patients with unresectable and/or metastatic renal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003137-32,0,0,0 2006-003138-13,2,2007-09-12,2007-09-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A randomized, double-blind, placebo-controlled, multinational study evaluating the safety and pharmacokinetics of 5 and 10 µg AVE0010 single doses and the efficacy, safety and pharmacokinetics of AVE0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003138-13,0,0,0 2006-003138-13,2,2007-09-12,2007-09-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi synthelabo recherche,"A randomized, double-blind, placebo-controlled, multinational study evaluating the safety and pharmacokinetics of 5 and 10 µg AVE0010 single doses and the efficacy, safety and pharmacokinetics of AVE0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003138-13,0,0,0 2006-003139-65,1,2007-06-01,2007-06-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Medway NHS Trust,The effect of clonidine on desflurane consumption using BIS monitoring.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003139-65,0,0,0 2006-003140-27,1,2007-12-05,2007-12-05,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Department of Clinical Pharmacology,Effects of non-specific Endothelin-A receptor blockade on ocular blood flow in patients with glaucoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003140-27,0,0,0 2006-003142-42,1,2007-10-08,2007-10-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,4SC AG,"A Randomized, Double Blind, Placebo-controlled, Proof of Concept Study to evaluate Efficacy, Safety and Pharmacokinetics of two Different Doses of SC12267 (20mg, 35 mg) in Patients with Rheumatoid Art...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003142-42,0,0,0 2006-003143-23,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,St Radboud UMC,To study the cardiovasculair effects of vasodilatation by nifedipine (Adalat gastrointestinal therapeutic system) with or without plasma volume expansion with Voluven (colloid) in women with preeclamp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003143-23,0,0,0 2006-003146-41,1,2011-04-28,2011-04-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité-Universitätsmedizin Berlin; Department of Rheumatology and Clinical Immunology,A CONTROLLED RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY COMPARING TWO THERAPY STRATEGIES IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS OVER 48 WEEKS: INDUCTION THERAPY WITH ADALIMUMAB AND METHOTRE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003146-41,0,0,0 2006-003147-23,2,2010-10-29,2010-10-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ImClone Systems Incorporated,"Estudio de Fase 2 abierto, multicentrico para evaluar la eficacia y tolerancia del IMC-11F8 en combinación con 5-FU/FA y Oxaliplatino (Folfox-6 modificado) en paciente con un cáncer colorectal no trat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003147-23,0,0,0 2006-003147-23,2,2010-10-29,2010-10-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ImClone LLC,"Estudio de Fase 2 abierto, multicentrico para evaluar la eficacia y tolerancia del IMC-11F8 en combinación con 5-FU/FA y Oxaliplatino (Folfox-6 modificado) en paciente con un cáncer colorectal no trat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003147-23,0,0,0 2006-003148-51,7,2010-04-06,2010-04-15,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Subjects with Congenital Factor XIII Def...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003148-51,0,0,0 2006-003148-51,7,2010-04-06,2010-04-15,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Subjects with Congenital Factor XIII Def...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003148-51,0,0,0 2006-003149-17,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,VU University Medical Center,"Phase I study of concurrent with involved-field thoracic radiotherapy for inoperable non-squamous cell lung cancer, followed by both concurrent and maintenance Bevacizumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003149-17,0,0,0 2006-003151-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Study to compare the tolerability of slow release oxycodone versus slow release morphine in the treatment of severe cancer pain. The study is geared towards a clinical practice improvement.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003151-21,0,0,0 2006-003156-37,3,2007-11-19,2007-11-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galderma Research and Development SNC,AN EXPLORATORY STUDY TO EVALUATE RELAPSES FOLLOWING AN INITIAL 12 WEEKS DOSE-RANGE STUDY WITH CD5024 CREAM VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM IN PAPULO-PUSTULAR ROSACEA – A 6 MONT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003156-37,0,0,0 2006-003158-12,8,2010-03-17,2010-03-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company limited,A Randomized Phase 3 Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003158-12,0,0,0 2006-003158-12,8,2010-03-17,2010-03-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,A Randomized Phase 3 Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003158-12,0,0,0 2006-003158-12,8,2010-03-17,2010-03-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Eli Lilly and Company Limited, Erl Wood Manor",A Randomized Phase 3 Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003158-12,0,0,0 2006-003163-31,1,2007-12-15,2007-12-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine with or without Tenofovir on the Pharmacokinetics of Atazanavir when given with Ritonavir in HIV-Infected Subjects....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003163-31,0,0,0 2006-003164-62,1,2010-04-30,2010-04-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Birmingham,Metabolic Support with Perhexilene to Protect Myocardium undergoing Coronary Artery Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003164-62,0,0,0 2006-003165-13,1,2009-09-01,2009-09-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Dep. Ophthalmology, Medical University of Vienna","A randomized, double-masked study with intraocular Bevacizumab (Avastin®) compared with non-treatment control in patients with persistent diabetic macular edema or persistent active neovascularisation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003165-13,0,0,0 2006-003169-15,8,2009-05-10,2009-06-11,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Schering Plough Research Institute, una División de Schering Corporation","""Estudio de fase 2 de temozolomida (SCH 52365) en sujetos con neoplasias avanzadas del tracto respiratorio y digestivo seleccionados por metilación del promotor de la O6-metil-guanina-ADN metiltransfe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003169-15,0,0,0 2006-003169-15,8,2009-05-10,2009-06-11,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Schering Plough Research Institute,"""Estudio de fase 2 de temozolomida (SCH 52365) en sujetos con neoplasias avanzadas del tracto respiratorio y digestivo seleccionados por metilación del promotor de la O6-metil-guanina-ADN metiltransfe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003169-15,0,0,0 2006-003169-15,8,2009-05-10,2009-06-11,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Schering-Plough Research Institute,"""Estudio de fase 2 de temozolomida (SCH 52365) en sujetos con neoplasias avanzadas del tracto respiratorio y digestivo seleccionados por metilación del promotor de la O6-metil-guanina-ADN metiltransfe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003169-15,0,0,0 2006-003169-15,8,2009-05-10,2009-06-11,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SCHERING-PLOUGH,"""Estudio de fase 2 de temozolomida (SCH 52365) en sujetos con neoplasias avanzadas del tracto respiratorio y digestivo seleccionados por metilación del promotor de la O6-metil-guanina-ADN metiltransfe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003169-15,0,0,0 2006-003170-99,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITA DEGLI STUDI DI UDINE,Evaluation of efficacy and safety of Intravitreal bevacizumab versus intravitreal bevacizumab combined with juxtascleral anecortave acetate for the treatment exudative age-related macular degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003170-99,0,0,0 2006-003173-27,18,2012-04-10,2012-04-10,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Ltd,"A Multi-Center, Single Arm Study Evaluating De Novo Once Monthly (QM) Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects with Chronic Kidney Disease (CKD) Not Receiving Dialysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003173-27,0,0,0 2006-003173-27,18,2012-04-10,2012-04-10,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Limited,"A Multi-Center, Single Arm Study Evaluating De Novo Once Monthly (QM) Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects with Chronic Kidney Disease (CKD) Not Receiving Dialysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003173-27,0,0,0 2006-003173-27,18,2012-04-10,2012-04-10,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AMGEN S.P.A.,"A Multi-Center, Single Arm Study Evaluating De Novo Once Monthly (QM) Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects with Chronic Kidney Disease (CKD) Not Receiving Dialysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003173-27,0,0,0 2006-003173-27,18,2012-04-10,2012-04-10,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Ltd.,"A Multi-Center, Single Arm Study Evaluating De Novo Once Monthly (QM) Darbepoetin Alfa Dosing for the Correction of Anemia in Subjects with Chronic Kidney Disease (CKD) Not Receiving Dialysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003173-27,0,0,0 2006-003180-31,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,medac GmbH,Comparative efficacy and safety of two asparaginase preparations in children with previously untreated acute lymphoblastic leukaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003180-31,0,0,0 2006-003181-34,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase II, Observer-Blind, Randomized, Parallel Groups, Single Center, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of FLUAD™ versus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003181-34,0,0,0 2006-003184-31,2,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Genmab A/S,"A double-blind, randomized, placebo-controlled, multi-center, Clinical Trial of ofatumumab, a fully human monoclonal anti-CD20 antibody in patients with moderate to severe stage Chronic Obstructive Pu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003184-31,0,0,0 2006-003189-33,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI,Phase II study with Palonosetron alone in preventing chemotherapy-induced nausea and vomiting in untreated patients with aggressive Non Hodgkin’s Lymphomas who underwent moderately emetogenic chemothe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003189-33,0,0,0 2006-003191-35,2,2007-04-20,2007-12-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Karo Bio AB,"A placebo controlled, double blind, randomised, 12-week, phase II study to assess the safety and efficacy of KB2115 in patients with primary hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003191-35,0,0,0 2006-003193-10,2,2012-08-31,2012-08-31,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Nerviano Medical Sciences S.r.l.,A phase I/II study of oral PHA-848125AC given daily for 14 consecutive days every 3 weeks in recurrent malignant glioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003193-10,0,0,0 2006-003194-27,1,2012-09-11,2012-09-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals KU Leuven,"mirtazapine versus placebo in functional dyspepsia: a randomized, double-blind, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003194-27,0,0,0 2006-003203-40,1,2015-05-13,2015-05-13,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,UCL University College London,"A RANDOMISED, CROSS-OVER, PHASE II STUDY, TO INVESTIGATE THE EFFICACY AND SAFETY OF GLUCARPIDASE FOR ROUTINE USE AFTER HIGH DOSE METHOTREXATE IN PATIENTS WITH BONE SARCOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003203-40,0,0,0 2006-003211-40,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,Laboratoires 3M Santé,A Randomized Double-blind Pilot Study Comparing Flecainide CR and Placebo in the Early Treatment of Patients with a Documented First Episode of Atrial Fibrillation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003211-40,0,0,0 2006-003215-52,2,2018-05-23,2018-05-23,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003215-52,0,0,0 2006-003216-22,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Effects of montelukast on airway inflammation in allergic children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003216-22,0,0,0 2006-003217-40,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Analgo-sedative therapy in neurosurgical pediatric patients Ketamine plus midazolam versus Remifentanyl plus Midazolam,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003217-40,0,0,0 2006-003225-87,1,2007-05-21,2007-05-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, multi-centre, double-blind, double dummy placebo controlled single-dose cross-over study to demonstrate that 12 and 24 µg of formoterol delivered by Concept1 has a bronchodilator efficac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003225-87,0,0,0 2006-003230-15,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,University Clinic Internal Medicine I,Phase I/II study investigating increasing doses of bevacizumab in patients with malignant effusion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003230-15,0,0,0 2006-003231-71,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dept of Anaesthesia, University College Hospital, Galway",Determination of the efficacy of the Transversus Abdominis Plane Block in the management of postoperative pain in children post open abdominal surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003231-71,0,0,0 2006-003233-32,1,2007-08-30,2007-08-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Mundipharma AB,"A randomized, open, controlled parallel group, multi-center study to evaluate the efficacy and safety of Norspan versus Tiparol Retard in subjects with chronic, moderate to severe osteoarthritis pain ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003233-32,0,0,0 2006-003236-30,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults previously vaccin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003236-30,0,0,0 2006-003237-32,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults previously vaccin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003237-32,0,0,0 2006-003238-14,3,2007-06-14,2007-06-14,3,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II/III, observer-blind, multicountry, multicentre, randomized study to demonstrate the superiority in terms of immunogenicity of AS25 adjuvanted influenza vaccine administered in adults aged 5...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003238-14,0,0,0 2006-003239-61,1,2007-08-24,2007-08-24,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, randomised study to evaluate the clinical consistency in terms of immunogenicity and reactogenicity of three production lots of the liquid formulation of GlaxoSmithKline (GSK) Biologicals...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003239-61,0,0,0 2006-003243-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",A Phase II Study of OXALIPLATIN and GEMCITABINE in Combination with IFOSFAMIDE plus RITUXIMAB (R-GIFOX) as 2nd-line Chemotherapy in Relapsed and Primary Refractory Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003243-23,0,0,0 2006-003250-18,1,2012-01-13,2012-01-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Poole Hospital NHS Trust,A two-centred randomised double blind controlled trial comparing intramuscular diamorphine and intramuscular pethidine for labour analgesia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003250-18,0,0,0 2006-003252-38,1,2008-01-31,2008-01-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Genmab A/S,An open label clinical pilot study with local injection of human antibody (HuMax-Inflam) for the treatment of inflammatory psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003252-38,0,0,0 2006-003255-20,1,2009-07-15,2009-07-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A single arm, multicenter phase II study of RAD001 in patients with metastatic colorectal adenocarcinoma whose cancer has progressed despite prior therapy with an anti-EGFR antibody (if appropriate), ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003255-20,0,0,0 2006-003258-98,7,2011-09-07,2011-09-07,6,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Stallergenes S.A.,"A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III study to assess the long term efficacy, carry-over effect and safety of two dosing regimens of 300 IR sublingual...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003258-98,1,0,0 2006-003258-98,7,2011-09-07,2011-09-07,6,0,0,0,0,0,3,0,0,2,0,0,0,0,1,STALLERGENES SA,"A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III study to assess the long term efficacy, carry-over effect and safety of two dosing regimens of 300 IR sublingual...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003258-98,1,0,0 2006-003260-53,2,2013-12-19,2013-12-19,2,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"The Faculty of Pharmaceutical Sciences, University of Copenhagen",Lokal administration af morfin: Evaluering af den smertestillende effekt på stomatitis hos børn.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003260-53,0,0,0 2006-003260-53,2,2013-12-19,2013-12-19,2,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Danmarks Farmaceutiske Universitet,Lokal administration af morfin: Evaluering af den smertestillende effekt på stomatitis hos børn.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003260-53,0,0,0 2006-003261-14,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Retinaklinikken Omnia,A randomized pilot study comparing the safety and efficacy of intravireal triamcinolone acetonide given 7 days prior to or after Photodynamic therapy with Visudyne in patients with subfoveal choroidal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003261-14,0,0,0 2006-003264-65,1,2009-08-31,2009-08-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,University of Dundee,A Proof-of-Concept Study to evaluate the benefit from add-on therapy with montelukast versus salmeterol in children with asthma carrying the Arg/Arg-16 beta2-receptor genotype,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003264-65,0,0,0 2006-003267-31,1,2007-07-24,2007-07-24,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Department of anesthesiology,En sammenlignende undersøgelse af iv. oxycodon og iv. fentanyl i behandlingen af postoperative smerter efter laparoskopisk cholecystektomi.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003267-31,0,0,0 2006-003269-15,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Karolinska University hospital,Impact of exercise training and insulin treatment in patients with type 2 diabetes treated with metformin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003269-15,0,0,0 2006-003270-95,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOIM GRUPPO ONCOLOGICO MERIDIONALE,Xelox-2 in untreated patients with advanced colorectal cancer.A Phase II multicenter study of the gruppo oncologico dell Italia meridionale GOIM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003270-95,0,0,0 2006-003275-12,3,2013-12-31,2013-12-31,1,0,0,0,0,1,4,0,0,2,0,0,0,0,0,Copenhagen CF-centre,Scandinavian Cystic Fibrosis Azithromycin Study Supplementary oral azithromycin in treatment of intermittent Pseudomonas aeruginosa colonization in CF-patients with inhaled colistin and oral ciproflox...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003275-12,1,0,0 2006-003278-93,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Johnson & Johnson Pharamceutical Research & Development, L.L.C.","Randomized, Double-Blind, Active-Control, Parallel Group, 90-Day Safety Study of CG5503 Immediate Release or Oxycodone Immediate Release in Subjects With Chronic Pain from Low Back Pain or Osteoarthri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003278-93,0,0,0 2006-003284-31,2,2007-05-23,2007-05-23,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F.Hoffmann-La Roche Ltd.,An open label multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003284-31,0,0,0 2006-003285-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,"Vergleich unterschiedlicher Strategien zur Analgosedierung in der interventionellen Radiologie bei der PTCD (perkutane transhepatische Cholangiodrainage): Eine kontrollierte, prospektive, randomisiert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003285-34,0,0,0 2006-003286-14,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,AstraZeneca UK Ltd,"A phase IV, 6-week, randomised, double-blind, multicentre, parallel group, comparative study to evaluate the efficacy of rosuvastatin 5 mg and atorvastatin 10 mg in UK Asian subjects with primary hype...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003286-14,0,0,0 2006-003288-29,6,2008-04-10,2008-04-10,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A multi-national, open-labelled, randomised, parallel group, 4 week run-in and 26 weeks treat-to-target comparison of biphasic insulin aspart 30 once daily versus insulin glargine once daily both in c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003288-29,0,0,0 2006-003291-35,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ROCHE,"Phase II, open label, neoadjuvant study of Bevacizumab in patients with inflammatory or locally advanced breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003291-35,0,0,0 2006-003293-10,9,2013-03-08,2013-03-08,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomised, open-label Phase III study to assess efficacy and safety of bevacizumab in combination with capecitabine as first line treatment for elderly patients with metastatic colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003293-10,0,0,0 2006-003293-10,9,2013-03-08,2013-03-08,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ROCHE,"A randomised, open-label Phase III study to assess efficacy and safety of bevacizumab in combination with capecitabine as first line treatment for elderly patients with metastatic colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003293-10,0,0,0 2006-003295-36,1,2009-08-06,2009-08-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"Randomised double-blind, placebo-controlled, cross-over study comparing the effects of single dose and repeated dosing treatment for 14 days of vestipitant / paroxetine combination in an enriched popu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003295-36,0,0,0 2006-003298-28,1,2010-12-29,2010-12-29,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,"Abbott Laboratories Limited (Queenborough, Kent, ME11 5EL, England)","A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Small Cell Lung Cancer (SCLC) or other non-hematological malignancies.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003298-28,0,0,0 2006-003302-25,1,2007-07-25,2007-07-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Barts and The London NHS Trust,"A prospective, randomised, double-blind, placebo-controlled trial to assess the respiratory effects of oxycodone versus morphine in anaesthetised patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003302-25,0,0,0 2006-003305-13,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,1,SIFI,Efficacy and safety of topical steroid/antibiotic association treatments following phacoemulsification cataract extraction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003305-13,0,0,0 2006-003318-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ERASME HOSPITAL,Prise en charge de l'hyperalgésie en salle de soins post-anesthésie: role de la ketamine et de la clonidine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003318-16,0,0,0 2006-003322-28,2,2009-06-10,2009-06-10,2,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Norpharma A/S,"A randomised, double-blind, multicentre equivalence study with active, parallel comparator group, to evaluate the efficacy and safety of Norspan® versus Tramadol in subjects with chronic, moderate to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003322-28,0,0,0 2006-003323-37,7,2009-11-06,2009-11-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma Corporation,"A Phase III, Randomised, Double-blind, Multi-centre, Withdrawal Study comparing MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (Incorporatin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003323-37,0,0,0 2006-003323-37,7,2009-11-06,2009-11-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mitsubishi Pharma Corporation,"A Phase III, Randomised, Double-blind, Multi-centre, Withdrawal Study comparing MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (Incorporatin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003323-37,0,0,0 2006-003323-37,7,2009-11-06,2009-11-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MITSUBISHI PHARMA CORPORATION,"A Phase III, Randomised, Double-blind, Multi-centre, Withdrawal Study comparing MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (Incorporatin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003323-37,0,0,0 2006-003324-11,7,2007-12-03,2010-01-07,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Mitsubishi Pharma Corporation,"A Phase III, Double-blind, Multi-centre, Randomised, Parallel Group Design, Placebo-controlled, Flexible Dose Study of MCI-196 in Combination with a Calcium-based Phosphate Binder in Chronic Kidney Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003324-11,0,0,0 2006-003324-11,7,2007-12-03,2010-01-07,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Mitsubishi Tanabe Pharma Corporation,"A Phase III, Double-blind, Multi-centre, Randomised, Parallel Group Design, Placebo-controlled, Flexible Dose Study of MCI-196 in Combination with a Calcium-based Phosphate Binder in Chronic Kidney Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003324-11,0,0,0 2006-003324-11,7,2007-12-03,2010-01-07,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MITSUBISHI PHARMA CORPORATION,"A Phase III, Double-blind, Multi-centre, Randomised, Parallel Group Design, Placebo-controlled, Flexible Dose Study of MCI-196 in Combination with a Calcium-based Phosphate Binder in Chronic Kidney Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003324-11,0,0,0 2006-003327-36,1,2011-01-13,2011-01-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's & St Thomas' NHS Foundation Trust,Evaluation of the efficacy of colchicine with and without betamethasone mouthwash in the management of recurrent aphthous stomatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003327-36,0,0,0 2006-003327-36,1,2011-01-13,2011-01-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,Evaluation of the efficacy of colchicine with and without betamethasone mouthwash in the management of recurrent aphthous stomatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003327-36,0,0,0 2006-003328-12,1,2010-01-31,2010-01-31,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Vifor Int.,"A multi-centre, randomized, controlled, single-blinded, phase II study to investigate the safety and efficacy of intravenous infusions of FERINJECT® versus placebo in patients with thrombocytosis seco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003328-12,0,0,0 2006-003330-15,8,2008-06-30,2010-08-06,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mitsubishi Pharma Corporation,"A Phase III, Multicentre, Open Label, Flexible dose, Long term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (incorporating a Comparison with S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003330-15,0,0,0 2006-003330-15,8,2008-06-30,2010-08-06,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma Corporation,"A Phase III, Multicentre, Open Label, Flexible dose, Long term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (incorporating a Comparison with S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003330-15,0,0,0 2006-003330-15,8,2008-06-30,2010-08-06,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MITSUBISHI PHARMA CORPORATION,"A Phase III, Multicentre, Open Label, Flexible dose, Long term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (incorporating a Comparison with S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003330-15,0,0,0 2006-003332-29,2,2009-06-26,2009-06-26,2,1,0,0,0,0,2,0,0,1,1,0,1,0,0,"ICORG, all-Ireland Cooperative Oncology Research Group","A Randomised Phase II trial of Epirubicin, Oxaliplatin and Capecitebine (EOX) versus Docetaxel and Oxaliplatin (EITax) in the treatment of Advanced Gastro-oesophageal cancer - The ELECT trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003332-29,0,0,0 2006-003333-33,1,2012-03-01,2012-03-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cardiff and Vale NHS Trust,"A randomised controlled, open label, phase II pilot study comparing the toxicity of rituximab plus CHOP chemotherapy with rituximab plus CHOP chemotherapy and bortezomib in adults with newly diagnosed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003333-33,0,0,0 2006-003336-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FNCLCC,Essai de phase II multicentrique étudiant l’impact de la séquence thérapeutique radiochimiothérapie pré opératoire (50 Gy + capecitabine + oxaliplatine + cetuximab) suivie d’une chirurgie TME puis d’u...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003336-30,0,0,0 2006-003337-32,1,2012-02-02,2012-02-02,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","?Estudio Fase II, multicéntrico, abierto y no comparativo para evaluar la eficacia y la seguridad de ICL670 administrado durante 1 año ajustando la dosis en función de los niveles de ferritina en suer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003337-32,0,0,0 2006-003340-33,1,2007-07-31,2007-07-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,BRACCO,"Preliminary evaluation of efficacy and tolerability of the association mesalazine 1g nifedipine 10mg in the treatment of tenesmus in patients suffering of distal ulcerative cholitis. Open study, pha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003340-33,0,0,0 2006-003346-42,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,University Hospital,Does substituting isoflurane with propofol during the last hour of intracranial surgery shorten recovery time and reduce PONV?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003346-42,0,0,0 2006-003349-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hvidovre Hospital,Applicability of TachoSil® in sealing rectal anastomoses. A feasibility trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003349-17,0,0,0 2006-003353-24,3,2009-11-16,2009-11-16,2,0,0,0,0,1,3,0,0,1,1,0,1,0,1,GENMAB,"Open-label, Dose escalation, followed by Double-blind, Randomized, Two-dose, Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Myco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003353-24,0,0,0 2006-003353-24,3,2009-11-16,2009-11-16,2,0,0,0,0,1,3,0,0,1,1,0,1,0,1,"TenX Biopharma, Inc.,","Open-label, Dose escalation, followed by Double-blind, Randomized, Two-dose, Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Myco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003353-24,0,0,0 2006-003353-24,3,2009-11-16,2009-11-16,2,0,0,0,0,1,3,0,0,1,1,0,1,0,1,Genmab A/S,"Open-label, Dose escalation, followed by Double-blind, Randomized, Two-dose, Parallel Group, Multi-center Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Myco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003353-24,0,0,0 2006-003356-38,6,2009-07-07,2009-09-07,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Alcon Research Limited,A Study of the Safety and Efficacy of Anecortave Acetate for Treatment of Steroid Induced IOP Elevation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003356-38,0,0,0 2006-003359-19,2,,,0,0,0,1,0,0,1,2,2,1,1,0,0,1,1,Janssen-Cilag International N.V.,"An open-label study of two single oral doses of galantamine, examining the pharmacokinetics, safety, and tolerability in children with Down syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003359-19,0,0,0 2006-003360-56,1,2014-10-08,2014-10-08,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,"Dept. of Pediatrics, The Childrens Hospital, Denver",Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003360-56,0,0,0 2006-003361-14,11,2015-12-23,2015-12-23,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"Long-term extension of the multinational, double-blind, placebo controlled study EFC6049 HMR1726D/3001 to document the safety of two doses of teriflunomide 7 and 14 mg in patients with multiple sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003361-14,0,0,0 2006-003361-14,11,2015-12-23,2015-12-23,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche de veloppement,"Long-term extension of the multinational, double-blind, placebo controlled study EFC6049 HMR1726D/3001 to document the safety of two doses of teriflunomide 7 and 14 mg in patients with multiple sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003361-14,0,0,0 2006-003364-64,9,2007-11-23,2008-07-30,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Shire Development Inc,"A Phase IV, Open-Label, Multi-Centre Trial Evaluating the Conversion from Standard Phosphate Binder Therapy to Fosrenol in Chronic Kidney Disease Stage 5 Patients on Haemodialysis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003364-64,0,0,0 2006-003364-64,9,2007-11-23,2008-07-30,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Shire Pharmaceutical Development Ltd,"A Phase IV, Open-Label, Multi-Centre Trial Evaluating the Conversion from Standard Phosphate Binder Therapy to Fosrenol in Chronic Kidney Disease Stage 5 Patients on Haemodialysis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003364-64,0,0,0 2006-003366-33,2,2012-03-29,2012-03-29,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Serono International, S.A.","A phase II, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability and efficacy study of add-on Cladribine tablet therapy with Rebif New Formulation in Multiple Scleroris Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003366-33,0,0,0 2006-003366-33,2,2012-03-29,2012-03-29,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,MERCK SERONO INTERNATIONAL SA,"A phase II, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability and efficacy study of add-on Cladribine tablet therapy with Rebif New Formulation in Multiple Scleroris Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003366-33,0,0,0 2006-003369-14,10,2007-07-25,2007-11-01,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pierre Fabre Medicament,"Efficacy and tolerance of the emollient cream V0034 CR in the symptomatic treatment of ichthyosis in children. International, multicentric, randomised, controlled, double blind study, in parallel grou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003369-14,0,0,0 2006-003369-14,10,2007-07-25,2007-11-01,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"Efficacy and tolerance of the emollient cream V0034 CR in the symptomatic treatment of ichthyosis in children. International, multicentric, randomised, controlled, double blind study, in parallel grou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003369-14,0,0,0 2006-003370-95,3,2009-09-04,2009-09-04,1,0,0,0,1,0,3,0,0,1,1,0,1,0,1,"CELLERIX, S.L.","""A Phase III multicenter, single blind, randomized, comparative, add?on clinical trial, in three parallel groups, to evaluate the efficacy and safety of a new therapy with adipose?derived autologous s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003370-95,0,0,0 2006-003371-13,10,2009-08-12,2009-08-12,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn’s Disease (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003371-13,0,0,0 2006-003374-10,2,2008-08-11,2008-09-26,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Sk...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003374-10,0,0,0 2006-003377-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fédération Nationale des Centres de Lutte Contre le Cancer,"Etude Intergroupe (SFCE/GSF/GETO) OS2006 Zolédronate-Ostéosarcome Protocole de traitement des ostéosarcomes de l’enfant, de l’adolescent et de l’adulte comportant : - un essai randomisé - et des étud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003377-27,0,0,0 2006-003378-90,1,2009-07-08,2009-07-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,TREAT STUDY : TREATMENT OF IRON DEFICIENCY ANAEMIA WITH TARDYFERON. Importance of prolonging iron supplementation in anemic women of childbearing age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003378-90,0,0,0 2006-003381-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institute of Oncology Ljubljana,Induction chemotherapy followed by chemoradiation with cetuximab and cisplatin for inoperable squamous cell carcinoma of the head and neck.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003381-33,0,0,0 2006-003384-30,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,The Immune Response Corporation,"A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003384-30,0,0,0 2006-003385-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,The effect of tiotropium-bromide on deep inspiration-induced bronchodilation and airway responsiveness in asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003385-34,0,0,0 2006-003387-55,2,2009-03-30,2009-03-30,2,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Laboratoire HRA Pharma,""" A Prospective, Randomized, Double Blind, Multicenter Study to Compare the Efficacy, Safety and Tolerability of CDB-2914 with Levonorgestrel as Emergency Contraception Within 120 Hours Unprotected In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003387-55,0,0,0 2006-003391-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Laboratoires THEA,Evaluation of the efficacy and safety of unpreserved dexamethasone phosphate 0.1% eye drops (T1910) versus placebo in patients with bilateral treated severe keratoconjunctivitis sicca due to Sjögrens'...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003391-35,0,0,0 2006-003395-35,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,ASAC PHARMACEUTICAL INTERNATIONAL A.I.E.,Clinical trial pilot noncontrolled of effectiveness of 600 mg/day of extract of curcuma standardized to 12% in curcumina in the treatment of patients with moderate-serious chronic psoriasis in plates....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003395-35,0,0,0 2006-003396-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Karolinska University Hospital, Huddinge",High-Dose Ribavirin in Combination With Standard Dose Peginterferon for Treatment of Chronic Hepatitis C Patients Who Are Nonresponders to Previous Standard Dosed Peginterferon/Ribavirin Combination T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003396-13,0,0,0 2006-003397-94,11,2009-01-30,2009-05-22,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Centocor BV,"A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects with Moderately ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003397-94,0,0,0 2006-003398-28,13,2010-08-25,2010-11-29,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Centocor BV,"A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003398-28,0,0,0 2006-003399-37,13,2012-10-15,2015-02-12,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen Biologics B.V.,"A Phase 3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003399-37,0,0,0 2006-003399-37,13,2012-10-15,2015-02-12,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen Biologics BV,"A Phase 3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003399-37,0,0,0 2006-003399-37,13,2012-10-15,2015-02-12,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Centocor BV,"A Phase 3 Multicenter, Randomized, Placebo-controlled, Double blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003399-37,0,0,0 2006-003403-39,1,2011-07-01,2011-07-01,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Novartis Pharma GmbH,Combination of antiangiogenic therapy using the mTOR-inhibitor RAD001 and low dose chemotherapy for locally advanced and/or metastatic pancreatic cancer – a dose finding study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003403-39,0,0,0 2006-003404-19,1,,,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,Nutrim,Ribavirin: its dosing regime.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003404-19,0,0,0 2006-003408-20,1,2007-11-29,2007-11-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios Leti, S.L.unipersonal",Extracto alergénico de Salsola oppositifolia Determinación de la potencia alergénica in vivo en unidades equivalentes de histamina (HEP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003408-20,0,0,0 2006-003409-18,3,2009-10-26,2013-09-06,3,0,0,0,0,0,3,0,0,1,0,0,1,0,0,HUS,"An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Chron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003409-18,0,0,0 2006-003409-18,3,2009-10-26,2013-09-06,3,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Relap-C study Steering Commitee,"An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Chron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003409-18,0,0,0 2006-003409-18,3,2009-10-26,2013-09-06,3,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Sahlgrenska University Hospital, Östra","An Open-label, Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 weeks pegylated interferon alfa-2a 40 kD (PEGASYS®) Combination Therapy with Ribavirin (Copegus®) in Patients with Chron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003409-18,0,0,0 2006-003410-18,1,2010-05-18,2010-05-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"Prospective, single-arm, multicenter trial to investigate the efficacy and safety of NT 201 (botulinum neurotoxin type A free of complexing proteins) and the duration of treatment effect after one inj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003410-18,0,0,0 2006-003415-46,1,2007-11-07,2007-11-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ALK-Abello, Group Clinical Development",A phase III trial investigating the efficacy and safety of Grazax in children aged 5-16 years with grass pollen induced rhinoconjunctivitis with or without asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003415-46,0,0,0 2006-003417-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical Centre Leeuwarden,The effect of nebulised MgSO4 on lung function in stable severe asthma patients with persistent airflow limitation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003417-41,0,0,0 2006-003418-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Center,The role of a hiatal hernia on the efficacy of anti-TLESR therapy in patients with gastroesophageal reflux disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003418-16,0,0,0 2006-003420-10,1,2010-08-18,2010-08-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Rigshospitalet,"Et fase II forsøg med Tarceva (erlotinib) og en undersøgelse af prædiktive markører ved første-line behandling af avanceret ikke-småcellet lungecancer hos patienter, der ikke er egnede til behandling ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003420-10,0,0,0 2006-003424-12,1,2013-10-31,2013-10-31,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,University Hospital Southampton NHS Foundation Trust,"A randomised phase II clinical trial using targeted radiotherapy delivered by an Yttrium-90 radiolabelled Anti-CD66 monoclonal antibody with high dose melphalan compared to melphalan alone, prior to a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003424-12,0,0,0 2006-003425-81,1,2011-10-20,2011-10-20,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Liverpool,Host genetic factors influencing drug disposition and response to HIV treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003425-81,0,0,0 2006-003426-28,1,2011-02-08,2011-02-08,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,University Hospitals Birmingham NHS Trust,Cortisol metabolism and impaired glucose tolerance,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003426-28,0,0,0 2006-003427-37,1,2009-07-24,2009-07-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,Sirolimus treatment in patients with autosomal dominant polycystic kidney disease renal efficacy and safety,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003427-37,0,0,0 2006-003429-95,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"SOGUG, Grupo español para el estudio del cancer genitourinario","A phase II, multicenter, non randomized, clinical study of Gemcitabine, ,Capecitabine and Sorafenib (BAY 43-9006) combination for the treatment of non resectable and/or metastatic patients with renal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003429-95,0,0,0 2006-003431-78,1,2009-12-15,2009-12-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Centocor BV,"A Multicenter, Observational Study of the Long-term Safety of Infliximab (REMICADE®) in Subjects with Moderate to Severe Chronic Obstructive Pulmonary disease (COPD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003431-78,0,0,0 2006-003432-30,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Interaction médicamenteuse entre la warfarine (Coumadine®) et l’association amoxicilline-acide clavulanique (Augmentin®),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003432-30,0,0,0 2006-003439-53,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Tibotec Pharmaceuticals Ltd,"A double blind, randomized, placebo-controlled study to evaluate the antiviral activity, safety and plasma pharmacokinetics of multiple intravenous doses of TMC353121 in hematopoietic stem cell transp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003439-53,0,0,0 2006-003441-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,N.V. Roche S.A.,OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS LOADING DOSE OF 3X 6MG IBANDRONIC ACID (BONDRONAT®) DURING 3 CONSECUTIVE DAYS IN PATIENTS WITH BREAST CANCER AND SKELETAL METASTASES...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003441-16,0,0,0 2006-003444-30,7,2009-01-15,2009-01-15,6,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Centocor B.V.,"A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003444-30,0,0,0 2006-003445-17,1,2014-03-31,2014-03-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Queen Mary, University of London","The probiotic Bifidobacterium breve strain BBG-01 admistered early to preterm infants to prevent infection, necrotising enterocolitis and death.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003445-17,0,0,0 2006-003451-20,1,2010-03-31,2010-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Technical University Dresden,Phase II study to evaluate the efficacy of a chemotherapy combination with Imatinib (Glivec®) and 5-FU/leucovorin in patients with advanced carcinoma of the gallbladder and bile duct,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003451-20,0,0,0 2006-003457-24,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Sevrage de la ventilation mécanique guidé par le peptide natriurétique de type B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003457-24,0,0,0 2006-003463-31,1,2010-09-03,2010-09-03,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Schering-Plough Research Institute,COVER- Registro de observación continua tras exposición Vicriviroc (VCV),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003463-31,0,0,0 2006-003466-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,NKI-AVL,Phase III randomised clinical trial for stage III ovarian carcinoma randomising between secondary debulking surgery with or without hyperthermic intraperitoneal chemotherapy (OVHIPEC-I),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003466-34,0,0,0 2006-003470-10,1,2013-06-06,2013-06-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Charité Universitätsmedizin Berlin, Campus Benjamin Franklin",Randomised Phase II study with non-pegylated liposomal Doxorubicin (Myocet) plus Ifosfamid versus Doxorubicin plus Ifosfamid in the first-line treatment of locally advanced or metastatic soft tissue c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003470-10,0,0,0 2006-003472-35,1,2016-03-23,2016-03-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche,"Essai randomisé de phase II évaluant l’efficacité et la tolérance de deux stratégies néoadjuvantes avec bevacizumab, visant à optimiser le traitement de patients atteints d’un cancer rectal localement...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003472-35,0,0,0 2006-003473-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,MedQuality Forschung GmbH,Wirkung von Telmisartan 80 mg im Vergleich zu Valsartan 160 mg auf die Insulinsensitivität (HOMA) - WITEVA -,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003473-27,0,0,0 2006-003475-13,2,2009-03-30,2009-03-31,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Hellas AE,"A SIXTEEN-WEEK, MULTI-CENTER, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF SWITCHING FROM QUETIAPINE TO ZIPRASIDONE IN SUBJECTS DIAGNOSED WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003475-13,0,0,0 2006-003475-13,2,2009-03-30,2009-03-31,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A SIXTEEN-WEEK, MULTI-CENTER, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF SWITCHING FROM QUETIAPINE TO ZIPRASIDONE IN SUBJECTS DIAGNOSED WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003475-13,0,0,0 2006-003476-35,1,2009-06-19,2009-06-19,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l,"A Phase II, Single Centre, Open-label, Randomized Study to Investigate Meningococcal Serogroup A, C, W-135 and Y Saccharide Specific B Cell Response to a Primary and a Booster Course of the Novartis M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003476-35,0,0,0 2006-003479-11,1,,,0,0,0,0,1,0,3,0,0,3,0,0,0,0,0,North Staffordshire Combined Healthcare Trust,The Stroke Oxygen Study. A randomised controlled study of the benefits and risks of routine oxygen treatment after acute stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003479-11,0,0,0 2006-003481-34,1,2008-09-24,2008-09-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Fertilitetsklinikken 4071, Rigshospitalet",Individuel versus standard rFSH dosis til kontrolleret ovariel stimulation og intrauterin insemination Et prospektivt randomiseret multicenter studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003481-34,0,0,0 2006-003482-14,11,2008-07-18,2018-07-28,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Johnson & Johnson Pharamceutical Resarch & Development, L.L.C","A One-Year, Randomized, Open-Label, Parallel-Arm, Phase III Long-Term Safety Trial, with Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR and Oxycodone CR in Subjects with Chronic Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003482-14,0,0,0 2006-003482-14,11,2008-07-18,2018-07-28,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C","A One-Year, Randomized, Open-Label, Parallel-Arm, Phase III Long-Term Safety Trial, with Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR and Oxycodone CR in Subjects with Chronic Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003482-14,0,0,0 2006-003482-14,11,2008-07-18,2018-07-28,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Laboratorios Andrómaco, S.A.","A One-Year, Randomized, Open-Label, Parallel-Arm, Phase III Long-Term Safety Trial, with Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR and Oxycodone CR in Subjects with Chronic Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003482-14,0,0,0 2006-003483-59,1,2009-11-03,2009-11-03,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,VU University Medical Centre,PRESERVE TRIAL: Pancreatic beta-cell dysfunction REStorEd by Rosiglitazone and Valsartan Effects; A 52-week randomized controlled factorial study in subjects with impaired fasting glucose and/or impai...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003483-59,0,0,0 2006-003484-31,3,2008-10-17,2008-10-17,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Ltd.,Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients with Chronic Low Back Pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003484-31,0,0,0 2006-003485-33,2,2008-05-04,2008-05-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,Duloxetine 60 to 120 mg versus Placebo in the Treatment of Patients with Osteoarthritis Knee Pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003485-33,0,0,0 2006-003490-27,1,2009-04-03,2009-04-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,BIOGEN IDEC LTD,"A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects with Moderate to Late Stage Parkinson’s Disease Who Are Als...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003490-27,0,0,0 2006-003491-35,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,PFIZER,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND-DOUBLE DUMMY STUDY, TO EVALUATE EFFICACY AND SAFETY OF TREATMENT WITH AZITHROMYCIN, MICROSPHERES, ORAL POWDER FOR SUSPENSION, 2 G, IN ONE ADMINISTRAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003491-35,0,0,0 2006-003493-97,7,2009-03-10,2009-03-10,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ARCHIMEDES,"A Multicentre, Double-Blind, Double-Dummy, Two-Phase Crossover Study of Nasalfent (Fentanyl Citrate Nasal Spray) Compared to Immediate Release Morphine Sulphate Tablets in the Treatment of Breakthroug...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003493-97,1,0,0 2006-003493-97,7,2009-03-10,2009-03-10,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Archimedes Development Ltd.,"A Multicentre, Double-Blind, Double-Dummy, Two-Phase Crossover Study of Nasalfent (Fentanyl Citrate Nasal Spray) Compared to Immediate Release Morphine Sulphate Tablets in the Treatment of Breakthroug...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003493-97,1,0,0 2006-003495-35,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO EUROPEO DI ONCOLOGIA,PHASE II TRIAL OF BORTEZOMIB (VELCADE) IN COMBINATION WITH CHLORAMBUCIL IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTROMﾑS MACROGLOBULINEMIA OR SMALL LYMPHOCYTIC LYMPHOMA. A MULTICENTER STUDY.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003495-35,0,0,0 2006-003500-19,4,2007-05-31,2007-05-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development,"A multi-centre, randomised, double-blind, double-dummy, placebo-controlled, 3-way crossover, incomplete block design study to investigate the efficacy, safety, tolerability, pharmacodynamics and pharm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003500-19,0,0,0 2006-003501-71,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,NOVARTIS FARMA,"Studio multicentrico controllato, randomizzato, per gruppi paralleli, per valutare l’efficacia e la tollerabilita' di Myfortic a dose piena, insieme a ciclosporina in microemulsione a dose ridotta, in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003501-71,0,0,0 2006-003502-26,1,2010-04-29,2010-04-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Barts and the London NHS Trust,A randomised control trial of the use of Epoetin Beta in the treatment of Post Transplant Anaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003502-26,0,0,0 2006-003503-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Jens Benn Sorensen, Dept. oncology, Finsen Centre/National University Hospital","Multicenter fase III undersøgelse af effekten af præoperativ (neoadjuverende) kemoterapi inden operation med efterfølgende adjuverende kemoterapi ved operabel NSCLC stadie IB, IIA; IIB, og IIIA/T3.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003503-39,0,0,0 2006-003506-25,1,2008-06-26,2008-06-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003506-25,0,0,0 2006-003508-21,2,2008-06-27,2008-06-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, vehicle-controlled, multicenter, parallel group study to assess the efficacy, safety, and tolerability of topical terbinafine hydrogen chloride (HCl) formulation for 24 or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003508-21,0,0,0 2006-003509-18,1,2015-01-09,2015-01-09,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Edinburgh,Mechanisms for the effect of acetylcysteine on renal function after exposure to radiographic contrast material,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003509-18,0,0,0 2006-003509-18,1,2015-01-09,2015-01-09,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,NHS Lothian Health Board,Mechanisms for the effect of acetylcysteine on renal function after exposure to radiographic contrast material,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003509-18,0,0,0 2006-003512-22,2,2008-11-19,2008-11-19,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003512-22,0,0,0 2006-003512-22,2,2008-11-19,2008-11-19,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratoires Merck Sharp & Dohme-Chibret,"A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003512-22,0,0,0 2006-003513-40,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Kalevi Pihlajamäki,Intrathecal bupivacaine and clonidine for ambulatory knee arthroscopy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003513-40,0,0,0 2006-003515-44,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FRANCISCO JAVIER BELDA,Cardioprotective effect of sevoflurane versus propofol used during anesthesia and the postoperative period in patients undergoing coronary bypass surgery. Impact on critical care unit stay. A double-b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003515-44,0,0,0 2006-003519-33,1,2007-09-19,2007-09-19,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,AstraZeneca UK Limited,"RAPID - An Open-Label, Randomised, Multicentre Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immedicate Release), over 14 days, in Acute Schizophrenia / Schizoaffective ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003519-33,0,0,0 2006-003520-10,1,2014-09-12,2014-09-12,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Bayer HealthCare AG,"A multicenter, non-randomized, non-blinded, non-controlled study to investigate the impact of multiple doses of BAY 63 2521 on safety, tolerability, pharmacokinetics, and pharmacodynamics in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003520-10,0,0,0 2006-003523-36,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Netherlands Heart Foundation,Magnesium in Aneurysmal Subarachnoid Haemorrhage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003523-36,0,0,0 2006-003524-11,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,University Hospital Gent,Clinical and biological effects of Anti-IgE (Omalizumab) in patients with bilateral nasal polyposis and asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003524-11,0,0,0 2006-003525-82,1,2008-12-23,2008-12-23,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Dirección General de Salud Pública; Conselleria de Sanidad de la Comunidad Valenciana,"“Estudio clínico multicéntrico, abierto, aleatorizado, fase IV, para evaluar la inmunogenicidad de las vacunas de polisacáridos de meningococo C conjugados con toxoide tetánico o con CRM197, administr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003525-82,0,0,0 2006-003532-30,3,2008-11-27,2008-11-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Berlin-Chemie AG (Menarini Group),Efficacy of two formulations of Sabal serrulata; a double-blind; randomized; placebo-controlled phase III study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003532-30,0,0,0 2006-003539-56,1,2010-10-01,2010-10-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medical University of Vienna, Department of Internal Medicine IV",Simvastatin in patients with septic shock,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003539-56,0,0,0 2006-003541-16,6,2007-06-01,2007-07-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomized, double-blind, placebo controlled, multi-centre, phase IIA study to assess the effect on GERD symptoms, pharmacokinetics, safety and tolerability of four weeks treatment with AZD3355 65 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003541-16,0,0,0 2006-003544-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Provident Clinical Research & Consulting, Inc.",An Evaluation of Simvastatin 20 mg Plus Omacor 4 g Compared to Simvastatin 20 mg Plus Placebo in Subjects with Mixed Dyslipidemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003544-27,0,0,0 2006-003547-23,7,2009-08-19,2009-08-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Group S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003547-23,0,0,0 2006-003548-42,7,2010-01-21,2010-03-19,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.","DORADO-AC-EX – A Double-Blind, Active-Controlled, Long-Term Safety Extension Study to the Phase 3 DORADO-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension A Double-Blind, Active-Con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003548-42,0,0,0 2006-003549-18,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Cliniques Universitaires SAINT-LUC,REDUCTION OF BONE MORBIDITY USING AN ORAL BISPHOSPHONATE IN FIBROUS DYSPLASIA OF BONE (PROFIDYS Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003549-18,0,0,0 2006-003549-18,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,ZonMw,REDUCTION OF BONE MORBIDITY USING AN ORAL BISPHOSPHONATE IN FIBROUS DYSPLASIA OF BONE (PROFIDYS Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003549-18,0,0,0 2006-003551-20,1,2008-01-14,2008-01-14,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,"Department of Oral Surgery Dental School Med. Univ. Graz, Austria",The Effect of adult MSC on Bone Regeneration and Osseointegration of Dental Implants following a Sinus Augmentation Procedure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003551-20,0,0,0 2006-003554-15,1,2009-02-28,2009-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,National Cancer Institute,The histone deacetylase inhibitor (HDAC) valproic acid as second line treatment for hormone refractory metastatic prostate cancer. A phase II. study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003554-15,0,0,0 2006-003560-62,9,2009-06-25,2009-07-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects with Schizop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003560-62,0,0,0 2006-003560-62,9,2009-06-25,2009-07-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen-Cilag International N.V., Turnhoutseweg 30, 2340 Beerse, Belgium","A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects with Schizop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003560-62,0,0,0 2006-003560-62,9,2009-06-25,2009-07-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects with Schizop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003560-62,0,0,0 2006-003561-13,1,2007-08-29,2007-08-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,imperial college,Reversal of steroid insensitivity in COPD by theophylline,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003561-13,0,0,0 2006-003563-31,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Red Europea de Mieloma (European Myeloma Network),"Estudio de fase II con Bortezomib, Dexametasona y Rituximab en combinación, en pacientes con Macroglobulinemia de Waldenström (MW) sin tratamiento previo (Phase II Study of Combination Bortezomib, Dex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003563-31,0,0,0 2006-003563-31,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,European Myeloma Network,"Estudio de fase II con Bortezomib, Dexametasona y Rituximab en combinación, en pacientes con Macroglobulinemia de Waldenström (MW) sin tratamiento previo (Phase II Study of Combination Bortezomib, Dex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003563-31,0,0,0 2006-003563-31,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Centre Hospitalier de Lens,"Estudio de fase II con Bortezomib, Dexametasona y Rituximab en combinación, en pacientes con Macroglobulinemia de Waldenström (MW) sin tratamiento previo (Phase II Study of Combination Bortezomib, Dex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003563-31,0,0,0 2006-003563-31,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,E.M.N. - EUROPEAN MYELOMA NETWORK,"Estudio de fase II con Bortezomib, Dexametasona y Rituximab en combinación, en pacientes con Macroglobulinemia de Waldenström (MW) sin tratamiento previo (Phase II Study of Combination Bortezomib, Dex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003563-31,0,0,0 2006-003564-57,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Kuopio University Hospital,"Adalimumab (anti TNF alfa) in the management of acute lumbar disc prolapses -a one year, randomized, placebo controlled, double blind, single center trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003564-57,0,0,0 2006-003567-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Med. Klinik II, Grosshadern, Klinikum der Universität München",Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003567-31,0,0,0 2006-003568-73,3,2008-10-15,2008-10-15,1,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Grupo Español de Cáncer de Pulmón,"Estudio fase III, multicéntrico, abierto, randomizado de tratamiento con erlotinib (Tarceva®) versus quimioterapia en pacientes con carcinoma no microcítico de pulmón avanzado que presentan mutaciones...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003568-73,1,0,0 2006-003568-73,3,2008-10-15,2008-10-15,1,0,0,0,0,0,3,0,0,2,1,0,0,0,0,SPANISH LUNG CANCER GROUP,"Estudio fase III, multicéntrico, abierto, randomizado de tratamiento con erlotinib (Tarceva®) versus quimioterapia en pacientes con carcinoma no microcítico de pulmón avanzado que presentan mutaciones...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003568-73,1,0,0 2006-003568-73,3,2008-10-15,2008-10-15,1,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Grupo Espagnol de Cancer de Pulmon,"Estudio fase III, multicéntrico, abierto, randomizado de tratamiento con erlotinib (Tarceva®) versus quimioterapia en pacientes con carcinoma no microcítico de pulmón avanzado que presentan mutaciones...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003568-73,1,0,0 2006-003570-10,6,2009-01-09,2009-06-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, open-label, active-controlled, multicenter, parallel group study to assess the efficacy, safety and tolerability of topical 10% terbinafine hydrogen chloride (HCl) formulation versus 5% ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003570-10,0,0,0 2006-003570-10,6,2009-01-09,2009-06-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica SA,"A randomized, open-label, active-controlled, multicenter, parallel group study to assess the efficacy, safety and tolerability of topical 10% terbinafine hydrogen chloride (HCl) formulation versus 5% ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003570-10,0,0,0 2006-003571-12,1,2008-05-02,2008-05-02,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Barts and the London NHS Trust,Breath Methionine and Other Indices of Oxidant Stress in the Critical Care Setting. The effect of two doses of Dipeptiven given independently of parenteral nutrition.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003571-12,0,0,0 2006-003577-27,3,2008-06-17,2008-07-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Ltd,"""ESTUDIO DE FASE IIA, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO, DE DOCE SEMANAS DE DURACIÓN PARA EVALUAR LA SEGURIDAD, FARMACOCINÉTICA Y EFICACIA DE PH-797804 ADMINISTRADO POR VIA ORAL UNA V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003577-27,0,0,0 2006-003577-27,3,2008-06-17,2008-07-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer S.A.,"""ESTUDIO DE FASE IIA, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO, DE DOCE SEMANAS DE DURACIÓN PARA EVALUAR LA SEGURIDAD, FARMACOCINÉTICA Y EFICACIA DE PH-797804 ADMINISTRADO POR VIA ORAL UNA V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003577-27,0,0,0 2006-003577-27,3,2008-06-17,2008-07-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Luxembourg SARL Branch Office Estonia,"""ESTUDIO DE FASE IIA, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO, DE DOCE SEMANAS DE DURACIÓN PARA EVALUAR LA SEGURIDAD, FARMACOCINÉTICA Y EFICACIA DE PH-797804 ADMINISTRADO POR VIA ORAL UNA V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003577-27,0,0,0 2006-003579-11,2,2007-11-28,2007-11-28,2,0,0,1,0,0,1,0,0,1,1,1,0,0,1,"TolerRx, Inc.",Tolerability and Safety of Multiple Dose Regimens of TRX4 Anti-CD3 Monoclonal Antibody in Type 1 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003579-11,0,0,0 2006-003580-31,2,2010-02-02,2010-02-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Morphotek,A Study of the Efficacy of MORAb-003 in Subjects with Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003580-31,0,0,0 2006-003581-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,DASATINIB compassionate use,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003581-34,0,0,0 2006-003584-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dept. Ob.Gyn, Univ Oulu","The effect of atorvastatin on insulin sensitivity, glucose metabolism and hormonal and inflammatory parameters in women with polycystic ovary syndrome (PCOS).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003584-31,0,0,0 2006-003585-34,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,3,,WEEKLY DOCETAXEL COMBINED WITH DAILY ORAL LOW DOSES OF PREDNISONE AND CYCLOPHOSPHAMIDE IN HORMONE-REFRACTORY PROSTATE CARCINOMA A PHASE I/II STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003585-34,0,0,0 2006-003590-27,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,"Technical University Dresden, Department of Dermatology","Untersuchungen zur antipsoriatischen Wirkung der UVB-induzierten Synthese von 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol) in Keratinozyten läsionaler psoriatischer Haut unter Verwen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003590-27,0,0,0 2006-003596-12,1,2011-08-31,2011-08-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Imperial College of Science Technology and Medicine,A neoadjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with primary breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003596-12,0,0,0 2006-003597-10,3,2007-08-30,2007-08-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,"Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003597-10,0,0,0 2006-003602-26,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,GlaxoSmithKline Research & Development Ltd,"A double-blind, two-period, placebo controlled cross-over study of the effects of the CB2 agonist GW842166 on pain and sensitisation in patients with osteoarthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003602-26,0,0,0 2006-003604-19,8,2009-08-19,2009-11-19,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Ulcerative Col...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003604-19,0,0,0 2006-003607-40,4,2014-10-17,2014-10-17,1,0,0,0,0,0,0,0,0,2,1,0,0,0,0,"GETAID, Jean Minjoz Hospital","A CONTROLLED, RANDOMISED, DOUBLE-BLIND, MULTICENTER STUDY, COMPARING METHOTREXATE VS PLACEBO IN CORTICOSTEROID-DEPENDENT ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003607-40,1,0,0 2006-003607-40,4,2014-10-17,2014-10-17,1,0,0,0,0,0,0,0,0,2,1,0,0,0,0,Besancon University Hospitaö,"A CONTROLLED, RANDOMISED, DOUBLE-BLIND, MULTICENTER STUDY, COMPARING METHOTREXATE VS PLACEBO IN CORTICOSTEROID-DEPENDENT ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003607-40,1,0,0 2006-003607-40,4,2014-10-17,2014-10-17,1,0,0,0,0,0,0,0,0,2,1,0,0,0,0,Besancon University Hospital,"A CONTROLLED, RANDOMISED, DOUBLE-BLIND, MULTICENTER STUDY, COMPARING METHOTREXATE VS PLACEBO IN CORTICOSTEROID-DEPENDENT ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003607-40,1,0,0 2006-003615-40,2,2007-08-07,2007-10-18,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Osteologix A/S,"A dose-response study with stronitum malonate in postmenopausal women. 12 week, multinational, double-blind, randomised, 5 arms, parallel group placebo controlled, open label active controlled, phase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003615-40,0,0,0 2006-003616-21,2,2008-12-03,2008-12-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"Prospective, single-arm, multi-center, open-label study to investigate the efficacy and tolerability of the once daily [OD] memantine treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003616-21,0,0,0 2006-003618-17,1,2009-06-30,2009-06-30,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,JDRF Danielle Alberti Memorial Centre For Diabetes Complications Baker Heart Research Institute,"A Randomozed, Placebo-Controlled Trial of Alagebrium in Patients with Insulin-Dependent Type 1 Diabetes and Microalbuminuria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003618-17,0,0,0 2006-003619-29,1,2013-05-27,2013-05-27,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Organisation name was not entered,"Vaccination med peptider deriveret fra anti-apoptotiske proteiner i Bcl-2 familien, administreret i kombination med adjuvant (Montanide ISA-51) i relation til proteasomhæmmerbehandling af patienter m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003619-29,0,0,0 2006-003620-11,1,2009-08-19,2009-08-19,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Biotec Pharmacon ASA,"A phase I/II study to assess the effect of soluble beta-1,3/1,6-glucan in combination with standard therapy in patients with breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003620-11,0,0,0 2006-003621-87,1,2008-03-17,2008-03-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Selbstmedikation GmbH,"Double-blind, placebo-controlled, randomised, parallel-groups, multi-centre clinical trial for the evaluation of efficacy and safety of an ointment of comfrey extract in comparison to placebo in the t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003621-87,0,0,0 2006-003622-29,5,2016-11-15,2017-11-15,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER,"Estudio ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events, aspirina para reducir el riesgo de accidentes vasculares iniciales) – Estudio aleatorizado, doble ciego, controlado con placebo, mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003622-29,0,0,0 2006-003622-29,5,2016-11-15,2017-11-15,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Consumer Care AG,"Estudio ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events, aspirina para reducir el riesgo de accidentes vasculares iniciales) – Estudio aleatorizado, doble ciego, controlado con placebo, mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003622-29,0,0,0 2006-003622-29,5,2016-11-15,2017-11-15,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealhCare AG,"Estudio ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events, aspirina para reducir el riesgo de accidentes vasculares iniciales) – Estudio aleatorizado, doble ciego, controlado con placebo, mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003622-29,0,0,0 2006-003622-29,5,2016-11-15,2017-11-15,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"Estudio ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events, aspirina para reducir el riesgo de accidentes vasculares iniciales) – Estudio aleatorizado, doble ciego, controlado con placebo, mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003622-29,0,0,0 2006-003627-37,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,ALCON ITALIA,"Hypotonic efficacy and tollerability of concomitant supply of Travoprost e Brinzolamide vs dorzolamide-timololo in fixed association in patient with glaucoma or ocular hypertension clinical study, mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003627-37,0,0,0 2006-003629-98,5,2008-03-08,2008-03-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 54-week, open label, multi-center study to assess the long-term safety and tolerability of the combination of aliskiren 300 mg/ amlodipine 10 mg in patients with essential hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003629-98,0,0,0 2006-003629-98,5,2008-03-08,2008-03-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 54-week, open label, multi-center study to assess the long-term safety and tolerability of the combination of aliskiren 300 mg/ amlodipine 10 mg in patients with essential hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003629-98,0,0,0 2006-003630-15,1,2011-11-08,2011-11-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Steno Diabetes Center,The effect of insulin analogues and human insulin on the incidence of severe hypoglycae-mia in hypoglycaemia prone type 1 diabetic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003630-15,0,0,0 2006-003633-32,4,2009-07-24,2009-07-30,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, multi-center, parallel-group, open-label study to evaluate the therapeutical benefit of an initially intensified dosing regimen of Myfortic vs. a standard dosing regimen of Myfortic in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003633-32,0,0,0 2006-003633-32,4,2009-07-24,2009-07-30,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, multi-center, parallel-group, open-label study to evaluate the therapeutical benefit of an initially intensified dosing regimen of Myfortic vs. a standard dosing regimen of Myfortic in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003633-32,0,0,0 2006-003634-15,3,2006-10-27,2006-10-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NovartisPharma Services AG,"An exploratory, double-blind comparison of inspiratory capacity (IC) and FEV1 in COPD patients following single dose administration of indacaterol and placebo and open-label b.i.d. administration of f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003634-15,0,0,0 2006-003636-30,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Karolinska University Hospital,"Effect of continuous versus cyclic dosing regimen of hormonal contraception on bleeding pattern, cardivascular risk marker, sexual function and satisfaction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003636-30,0,0,0 2006-003639-59,1,2008-05-08,2008-05-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Intercytex,A phase IIa open-label dose-escalation study using ICX-RHY to enhance the aesthetic appearance of nasolabial folds,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003639-59,0,0,0 2006-003643-23,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,1,Abiogen Pharma S.p.A.,Efficacy and tolerability study of a novel CNS drug ABIO 08/01 administered for 8 weeks to patients with generalised anxiety disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003643-23,0,0,0 2006-003644-31,3,2008-11-13,2008-11-13,2,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Genzyme Europe BV,An Open-Label Extension Study of Patients with Late-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU02704,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003644-31,0,0,0 2006-003644-31,3,2008-11-13,2008-11-13,2,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Genzyme Europe B.V.,An Open-Label Extension Study of Patients with Late-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU02704,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003644-31,0,0,0 2006-003648-46,1,2008-06-03,2008-06-03,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Merck & Co. Inc.,"A Study in Healthy Infants of the Safety, Tolerability, and Immunogenicity of Haemophilus influenzae, Type b/Hepatitis B Vaccine Manufactured With a Modified Process",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003648-46,0,0,0 2006-003649-18,3,2007-11-26,2008-02-19,3,1,0,0,0,0,3,0,1,1,0,0,1,0,2,Merck & Co. Inc.,"A Study in Healthy Adults of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003649-18,0,0,0 2006-003649-18,3,2007-11-26,2008-02-19,3,1,0,0,0,0,3,0,1,1,0,0,1,0,2,"Merck & Co Inc.,","A Study in Healthy Adults of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003649-18,0,0,0 2006-003650-20,3,2008-05-05,2008-05-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co Inc.,","A Study in Renal Predialysis and Dialysis Patients of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003650-20,0,0,0 2006-003650-20,3,2008-05-05,2008-05-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck and Co Inc.,"A Study in Renal Predialysis and Dialysis Patients of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003650-20,0,0,0 2006-003650-20,3,2008-05-05,2008-05-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme de España, S.A.","A Study in Renal Predialysis and Dialysis Patients of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003650-20,0,0,0 2006-003651-20,4,2010-08-20,2010-08-20,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Europe) Inc.,"A Phase III Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003651-20,0,0,0 2006-003651-20,4,2010-08-20,2010-08-20,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Laboratoires Merck Sharp & Dohme - Chibret,"A Phase III Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003651-20,0,0,0 2006-003651-20,4,2010-08-20,2010-08-20,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003651-20,0,0,0 2006-003651-20,4,2010-08-20,2010-08-20,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck & Co Inc.,","A Phase III Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003651-20,0,0,0 2006-003652-37,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,2,Laboratoires Merck Sharp & Dohme - Chibret,"A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZV) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003652-37,0,0,0 2006-003652-37,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,2,"Merck & Co., Inc.","A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212/Heat-Treated Varicella-Zoster Virus (VZV) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003652-37,0,0,0 2006-003655-20,1,2008-10-07,2008-10-07,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,GW Pharma Ltd,"A double blind, randomised, placebo controlled, parallel group study of Sativex® when added to the existing treatment regimen, in the relief of post-herpetic neuralgia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003655-20,0,0,0 2006-003656-38,1,2009-05-12,2009-05-12,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University of Surrey Clinical Research Centre,"A Double-blind, Randomised, Parallel Groups Investigation into the Effects of Pregabalin, Duloxetine and Amitriptyline on Aspects of Pain, Sleep, and Next Day Performance in Patients Suffering from Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003656-38,0,0,0 2006-003657-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,GIMURELL,"A PHASE II MULTICENTER NON-RANDOMIZED STUDY TO ASSESS SAFETY, TOXICITY AND CLINICAL ACTIVITY OF THE ASSOCIATION OF BORTEZOMID VELCADE WITH RITUXIMAB IN RELAPSED/REFRACTORY INDOLENT NON FOLLICULAR AN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003657-24,0,0,0 2006-003658-47,1,2018-04-15,2018-04-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pierre Fabre Médicament - IRPF,Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003658-47,0,0,0 2006-003659-19,1,2007-02-02,2007-02-02,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Double Blind, Placebo- and Active-Controlled, Randomized, Sequential Group, Multiple Dose Study to Examine the Effect of the CRF1-Receptor Antagonist R317573 on 7.5% CO2-Inhalation Induced Anxiety i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003659-19,0,0,0 2006-003667-31,2,2008-09-01,2008-09-01,2,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Medical Faculty, TU Dresden",Prednisolone vs. Ciclosporine in Severe Atopic Eczema. PROVE - Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003667-31,0,0,0 2006-003674-96,12,2011-05-18,2011-05-18,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"A Phase 3 Randomized, Double-blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Follo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003674-96,0,0,0 2006-003674-96,12,2011-05-18,2011-05-18,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb,"A Phase 3 Randomized, Double-blind, Parallel-group, Multi-center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Subjects During and Follo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003674-96,0,0,0 2006-003678-82,1,2008-12-15,2008-12-15,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Centre for Human Drug Research,Pharmacokinetics and effects of oral clonidine in children with suspected Growth Hormone deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003678-82,0,0,0 2006-003682-14,1,2014-01-25,2014-01-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GMIHO Gesellschaft für Medizinische Innovation/Hämatologie und Onkologie mbH,Randomised phase II study on the treatment with pegfilgrastim after autologous blood stem cell transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003682-14,0,0,0 2006-003683-54,1,2013-07-03,2013-07-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GMIHO Gesellschaft für medizinische Innovation/Hämatologie und Onkologie mbH,"Prospektive, offene, randomisierte, multizentrische Studie zur Effektivität von Palifermin in der Prophylaxe der Mukositis nach allogener Stammzelltransplantation mit myeloablativer Granzkörperbestrah...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003683-54,0,0,0 2006-003684-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,Integrilin plus stenting to avoid myocardial necrosis trial. Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003684-32,0,0,0 2006-003685-33,1,2009-04-27,2009-04-27,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA L. SACCO A.O. DI RILIEVO NAZIONALE,Study of viro-immunological dynamics and T-lymphocyte homeostasis in peripheral blood in the pathogenesisof HIV infection and in the response to antiretroviral therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003685-33,0,0,0 2006-003686-13,1,2010-08-30,2010-08-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Allergie-Centrum-Charite, Department of Dermatology, Charite - Universitätsmedizin Berlin","An exploratory phase III, randomised, double blind, therapeutic single dose-related effect, parallel group study to assess and compare the effects of 5mg vs. 20mg Desloratadine on skin lesions in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003686-13,0,0,0 2006-003688-30,6,2011-06-07,2011-06-07,5,0,0,0,0,0,2,0,0,1,0,0,1,0,2,KUROS BIOSURGERY AG,"A phase 2 randomized, controlled, open-label dose-blinded , multi-center, dose-finding study of the safety and efficacy of I-0401 in the treatment of patients with fractures of the tibial plateau req...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003688-30,0,0,0 2006-003688-30,6,2011-06-07,2011-06-07,5,0,0,0,0,0,2,0,0,1,0,0,1,0,2,Kuros Biosurgery AG,"A phase 2 randomized, controlled, open-label dose-blinded , multi-center, dose-finding study of the safety and efficacy of I-0401 in the treatment of patients with fractures of the tibial plateau req...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003688-30,0,0,0 2006-003689-32,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,UNIVERSITA CAMPUS BIOMEDICO,"Multicenter, randomised, double masked, controlled studies on the efficacy of Cyclosporine eye drop treatment in preventing Vernal Keratoconjunctivitis VKC relapses and in treating the acute phase.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003689-32,0,0,0 2006-003695-35,9,2009-10-16,2009-10-16,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 ZACTIMA in Combination with Pemetrexed Alimta versus Pemetrexed alone in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003695-35,1,0,0 2006-003695-35,9,2009-10-16,2009-10-16,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ASTRAZENECA,"A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 ZACTIMA in Combination with Pemetrexed Alimta versus Pemetrexed alone in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003695-35,1,0,0 2006-003696-12,11,2009-02-16,2011-02-17,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BIOGEN IDEC LTD,"A Randomized, Multicenter, Double-Blind, Place-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003696-12,0,0,0 2006-003696-12,11,2009-02-16,2011-02-17,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biogen Idec Ltd.,"A Randomized, Multicenter, Double-Blind, Place-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003696-12,0,0,0 2006-003696-12,11,2009-02-16,2011-02-17,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biogen Idec LtD.,"A Randomized, Multicenter, Double-Blind, Place-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003696-12,0,0,0 2006-003697-10,9,2011-08-24,2011-10-06,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biogen Idec Ltd.,"A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003697-10,0,0,0 2006-003698-29,13,2008-03-19,2008-06-11,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Amgen Inc.,A Long-term Assessment of Safety and Physical Function with AMG 108 Subcutaneous Monthly Treatment in Subjects with Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003698-29,0,0,0 2006-003698-29,13,2008-03-19,2008-06-11,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AMGEN S.P.A.,A Long-term Assessment of Safety and Physical Function with AMG 108 Subcutaneous Monthly Treatment in Subjects with Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003698-29,0,0,0 2006-003699-36,6,2008-12-02,2008-12-02,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AMGEN S.P.A.,"A Phase 2, Randomized, Double Blind, Placebo- Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Chemotherapy- Induced Thrombocytopenia in Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003699-36,0,0,0 2006-003699-36,6,2008-12-02,2008-12-02,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Amgen Inc.,"A Phase 2, Randomized, Double Blind, Placebo- Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Chemotherapy- Induced Thrombocytopenia in Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003699-36,0,0,0 2006-003700-18,9,2008-11-05,2009-11-05,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Amgen Inc.,"A Randomized, Controlled, Open- label Study Evaluating the Efficacy and Tolerability of AMG 531 versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects with Immune (Idiopath...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003700-18,0,0,0 2006-003702-26,6,2008-01-15,2008-01-15,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Limited,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients with Refractory Partial Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003702-26,0,0,0 2006-003707-40,2,2007-05-23,2007-05-23,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Galderma Research and Development SNC,"Activity of twice daily per os administration of CD06713 at 8mg versus its placebo during 4 weeks treatment, in patients with erythemato-telangiectatic rosacea.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003707-40,0,0,0 2006-003708-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZ-VUB,Concurrent helical tomotherapy with chemotherapy in unresectable stage III non-small cell lung cancer (NSCLC): a phase I/II trial of radiation dose escalation and fixed dose chemotherapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003708-21,0,0,0 2006-003709-15,12,2009-02-27,2011-11-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Swedish Orphan Biovitrum AB (publ),"A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin Pre- and Post Chemotherapy and Pre-Chemotherapy only for Reduction in Severity of Oral Mucositis in Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003709-15,0,0,0 2006-003709-15,12,2009-02-27,2011-11-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN S.P.A.,"A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin Pre- and Post Chemotherapy and Pre-Chemotherapy only for Reduction in Severity of Oral Mucositis in Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003709-15,0,0,0 2006-003709-15,12,2009-02-27,2011-11-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin Pre- and Post Chemotherapy and Pre-Chemotherapy only for Reduction in Severity of Oral Mucositis in Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003709-15,0,0,0 2006-003709-15,12,2009-02-27,2011-11-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biovitrum AB (publ),"A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin Pre- and Post Chemotherapy and Pre-Chemotherapy only for Reduction in Severity of Oral Mucositis in Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003709-15,0,0,0 2006-003711-51,1,2008-02-05,2008-02-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Otto M. Lesch,IBIS- International Baclofen Interventional Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003711-51,0,0,0 2006-003712-22,1,2009-11-25,2009-11-25,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Dr. Falk Pharma GmbH,Pharmacokinetics of UDCA in serum and bile in patients with early stage PBC (stage I-III) and in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003712-22,0,0,0 2006-003717-41,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,EVALUATE THE TOLERABILITY AND EFFICACY OF OMEGA 3 ON MOOD ANDMOTOR SYMPTOMS OF PATIENTS SUFFERING FROM PARKINSON DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003717-41,0,0,0 2006-003718-17,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,RANDOMIZED DOUBLE-BLIND STUDY TO EVALUATE THE ADJUVANT EFFECT OF POLYNSATURED FATTY ACIDS OMEGA 3 IN THERAPY WITH DISULFIRAM IN DETOXIFIED LCOHOL-DEPENDENT SUBJECTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003718-17,0,0,0 2006-003720-11,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,1,GE Healthcare Finland Oy,"Comparison of the quality of anesthesia and intraoperative stress responses to noxious stimulus with high opiate, low hypnotic versus low opiate high hypnotic drug administration during anesthesia usi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003720-11,0,0,0 2006-003727-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Haga Teaching Hospital,"A randomized, open label, multicentre trial to define the most effective haemoglobin concentration to start erythropoietin beta (neoRecormon) therapy in anaemic subjects with lymphoproliferative malig...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003727-37,0,0,0 2006-003730-15,7,2008-06-05,2008-06-05,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dainippon Sumitomo Pharma Europe Ltd.,"A 10-week randomised, double-blind, parallel-group, placebo-controlled phase 2 study to investigate the extent of symptom relief and the safety and tolerability of SMP-986 (20 mg, 40 mg, 80 mg and 120...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003730-15,0,0,0 2006-003732-30,3,2009-12-15,2009-12-15,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Axxonis Pharma AG,"Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003732-30,1,0,0 2006-003732-30,3,2009-12-15,2009-12-15,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NEUROBIOTEC GMBH,"Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003732-30,1,0,0 2006-003732-30,3,2009-12-15,2009-12-15,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NeuroBiotec Pharma AG,"Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003732-30,1,0,0 2006-003737-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Örebro University Hospital,"Continuous Intraperitoneal Infusion of Local Anesthetics vs. Patient Controlled Intraperitoneal injection for Postoperative Pain relief following Abdominal Hysterectomy. A randomized, double-blind stu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003737-33,0,0,0 2006-003739-57,2,2009-09-22,2009-11-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A double-blind, randomised, parallel-group, placebo-controlled study investigating the safety- and tolerability following fixed oral dose regimens (daily versus twice weekly administration) of Lu 31-1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003739-57,0,0,0 2006-003742-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO ONCOLOGICO ROMAGNOLO,"A dose finding phase II study of Alimta in i.v. continuous infusion in patients with malignant pleural mesothelioma, non small cell lung cancer, pancreatic cancer and breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003742-42,0,0,0 2006-003745-16,1,2011-08-31,2011-08-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Trust,Assessment of platelet-dependent thrombosis by an ex vivo arterial injury model: a placebo controlled trial of Clopidogrel as antiplatelet therapy in patients with type 2 diabetes mellitus and coronar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003745-16,0,0,0 2006-003746-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE ONCOLOGICO DI BARI,Immunotherapy vs immuno-chemotherapy in patients with metastatic kidney carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003746-42,0,0,0 2006-003748-43,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Ortopædkirurgisk Center, Aarhus Universitets Hospital",Kan topical bisfosfonat øge fiksation og overlevelse af ucementeret knæledsprotese? Et prospektivt randomiseret migrations- og knogledensitetsstudie på tibia-implantater af trabeculært metal.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003748-43,0,0,0 2006-003750-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación PETHEMA,Treatment With Dense Doses of Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immun...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003750-23,0,0,0 2006-003752-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE ONCOLOGICO DI BARI,A phase II study of Capecitabine in combination with oral vinorelbine in advanced Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003752-38,0,0,0 2006-003759-19,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"Department of Gynecological Oncology, University Hospital, Örebro",Cetuximab and cisplatin in addition to radiotherapy in the treatment of stage IIA-III carcinoma of the uterine cervix - a pilot phase II study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003759-19,0,0,0 2006-003762-33,3,2008-03-25,2008-03-31,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, double blind, randomised, placebo?controlled, multi?country, multicentre study to assess the safety, reactogenicity and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals? ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003762-33,0,0,0 2006-003762-33,3,2008-03-25,2008-03-31,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline,"A phase IIIb, double blind, randomised, placebo?controlled, multi?country, multicentre study to assess the safety, reactogenicity and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals? ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003762-33,0,0,0 2006-003765-14,1,2007-05-04,2007-05-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GE Healthcare Finland Oy,Stressi-indeksi (SSI) sevofluraani-alfentaniilianestesiassa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003765-14,0,0,0 2006-003768-67,7,2009-05-14,2010-05-25,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase III Multicenter, Randomized, Double-Blind, placebo-controlled Study to Assess short-term changes in synovitis and structural damage outcomes in subjects with active Rheumatoid Arthritis and in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003768-67,0,0,0 2006-003769-15,1,,,0,1,0,0,1,0,2,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase II, controlled, randomized, single centre, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine with various doses of AS03 adjuvant co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003769-15,0,0,0 2006-003771-12,6,2008-05-30,2008-08-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,NOVARTIS FARMA,"A multicenter, double-blind, randomized parallel-group study to demonstrate the effect of 24 weeks treatment with vildagliptin 100 mg qd as add-on to metformin 500 mg bid compared to metformin up t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003771-12,0,0,0 2006-003771-12,6,2008-05-30,2008-08-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Novartis Pharma Services AG,"A multicenter, double-blind, randomized parallel-group study to demonstrate the effect of 24 weeks treatment with vildagliptin 100 mg qd as add-on to metformin 500 mg bid compared to metformin up t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003771-12,0,0,0 2006-003772-35,6,2012-08-25,2012-08-25,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Nerviano Medical Sciences S.r.l.,"Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003772-35,0,0,0 2006-003772-35,6,2012-08-25,2012-08-25,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Nerviano Medical Sciences s.r.l,"Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003772-35,0,0,0 2006-003772-35,6,2012-08-25,2012-08-25,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NERVIANO MEDICAL SCIENCES,"Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003772-35,0,0,0 2006-003773-28,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,IBSA,"A multicentre, prospective, double-blind, in parallel groups randomised, versus placebo and versus reference product controlled, confirmatory clinical trial of the efficacy and tolerance of Flector Ti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003773-28,0,0,0 2006-003775-13,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE ONCOLOGICO DI BARI,A phase II study of Capecitabine in combination with Cisplatin in advanced head and neck Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003775-13,0,0,0 2006-003779-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oulun yliopisto,Treatment of phimosis with topical mometasonefuroate application,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003779-11,0,0,0 2006-003780-30,1,2007-08-13,2007-08-13,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Astion Danmark A/S,"Efficacy and safety of ASF-1096 cream 0.5 % in the treatment of patients with newly developed discoid lupus erythematosus (DLE) lesions. A multi-centre clinical phase 2, placebo controlled and double ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003780-30,0,0,0 2006-003784-32,12,2012-06-30,2012-12-14,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Phase 3, Multicenter, Randomized, Placebo Controlled, Double Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003784-32,0,0,0 2006-003784-32,12,2012-06-30,2012-12-14,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN S.P.A.,"A Phase 3, Multicenter, Randomized, Placebo Controlled, Double Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003784-32,0,0,0 2006-003785-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Amgen Inc,"A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003785-33,0,0,0 2006-003786-13,10,2012-03-12,2012-03-12,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003786-13,0,0,0 2006-003786-13,10,2012-03-12,2012-03-12,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN S.P.A.,A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003786-13,0,0,0 2006-003786-13,10,2012-03-12,2012-03-12,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003786-13,0,0,0 2006-003793-94,3,2008-02-12,2008-07-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"An Eight-Week, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Study, with Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003793-94,0,0,0 2006-003795-35,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen,Mannitol inhalations as a faster procedure for testing of airways hyperresponsiveness,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003795-35,0,0,0 2006-003796-12,1,,,0,1,0,1,0,0,1,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A Phase I-II partially-blinded, randomized, dose- ranging study (10-30-90 mcg) to compare the safety and immunogenicity of GSK Biologicals’ candidate HIV vaccine F4co (p24-RT-Nef-p17), adjuvanted or n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003796-12,0,0,0 2006-003799-36,1,2007-10-10,2007-10-10,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,"University of Iceland, Dept. Pharmacology",Effects of alcohol on brain function and autonomic nerves,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003799-36,0,0,0 2006-003801-21,1,2007-03-05,2007-03-05,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,Verus Pharmaceuticals Inc,"A Randomised, Open-Label, Active-Controlled, Two-Period Crossover Study to Evaluate Relative Efficacy and Safety of Investigational Captisol-Enabled® Budesonide Inhalation Solution (CBIS) Delivered vi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003801-21,0,0,0 2006-003805-19,4,2008-04-03,2008-04-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et développement,"An eight-week, multinational, multicenter, randomized, double-blind, placebo-controlled study, with escitalopram as an active control, to evaluate the efficacy, safety and tolerability of a saredutant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003805-19,0,0,0 2006-003805-19,4,2008-04-03,2008-04-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et de`veloppement,"An eight-week, multinational, multicenter, randomized, double-blind, placebo-controlled study, with escitalopram as an active control, to evaluate the efficacy, safety and tolerability of a saredutant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003805-19,0,0,0 2006-003807-38,3,2008-07-25,2008-07-25,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals? HPV-16/18 L1 AS04 vaccine co-administered with GlaxoSmithKline Biologicals? ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003807-38,0,0,0 2006-003807-38,3,2008-07-25,2008-07-25,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals? HPV-16/18 L1 AS04 vaccine co-administered with GlaxoSmithKline Biologicals? ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003807-38,0,0,0 2006-003811-36,5,2007-09-27,2007-09-27,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,"A phase III, randomized, double-blind, active-controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 µg Org 36286 (corifollitropin alfa) to induce m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003811-36,0,0,0 2006-003812-23,4,2008-06-15,2008-10-21,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,Pregnancy and neonatal follow-up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003812-23,0,0,0 2006-003813-42,4,2008-12-12,2008-12-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,Follow-up protocol to collect the outcome of frozen-thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003813-42,0,0,0 2006-003815-31,1,2007-02-05,2007-02-05,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIb, controlled, randomized, multicenter, observer blinded study to evaluate the immunogenicity, safety and reactogenicity of a second vaccination with the low dose influenza vaccine adjuvante...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003815-31,0,0,0 2006-003816-23,1,2009-12-15,2009-12-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Tübingen,Multicenter phase II study with pemetrexed in patients with pre-treated metastatic soft tissue sarcomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003816-23,0,0,0 2006-003817-42,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE,"A phase III trial in adult acute myelogenous leukemia AML comparing 1 standard-dose versus high-dose remission induction therapy and 2 , within a risk-oriented postremission strategy, an autologou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003817-42,0,0,0 2006-003819-45,1,2009-03-09,2009-03-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München","PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ERYTHROPOIETIN IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION. REVIVAL-3 (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003819-45,0,0,0 2006-003821-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"Roche Farma, S.A.","Estudio aleatorizado, abierto y cruzado para evaluar la tolerabilidad del dispositivo de inyección sin aguja B2000 para la administración de enfuvirtida.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003821-10,0,0,0 2006-003828-11,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,"Prim. Univ.Prof. Dr. Christian Pirich Department of Nuclear Medicine and Endocrinology, PMU Salzburg",Comparison of imaging pattern and diagnostic value of F-18 FLT and F-18 FDG PET in patients with rectal cancer before and after neoadjuvant radiochemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003828-11,0,0,0 2006-003833-33,1,2009-03-31,2009-03-31,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,"Imperial College, London",Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: A Phase I/II Clinical Trial Using AVI-4658,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003833-33,0,0,0 2006-003834-14,1,2010-04-01,2010-04-01,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Desitin Arzneimittel GmbH,"Safety and Efficacy of Novel Modified Release Formulation of Oxacarbazepine (OXC MR) vs an Immediate Release Oxacarbazepine (OXC IR) Product in Patients with Partial Epilepsy. Open-Labelled, Controlle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003834-14,0,0,0 2006-003836-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Gent,A protocol based treatment for early and severe systemic sclerosis with (anti-CD-20) rituximab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003836-31,0,0,0 2006-003838-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,CETUXIMAB IN COMBINATION WITH CISPLATIN PLUS DOCETAXEL TO EVALUATE THE ACTIVITY AND SAFETY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: PHASE I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003838-15,0,0,0 2006-003839-68,4,2010-04-30,2010-11-05,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RWJ-333369 as Adjunctive Therapy in Subjects with Partial Onset S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003839-68,0,0,0 2006-003841-17,1,2008-08-01,2008-08-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BioVex Inc,"A PHASE II STUDY OF THE EFFICACY, SAFETY AND IMMUNOGENICITY OF ONCOVEX GM CSF IN PATIENTS WITH STAGE IIIc AND STAGE IV MALIGNANT MELANOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003841-17,0,0,0 2006-003843-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,OSPEDALE POLICLINICO S. MATTEO,"prospeCtive study on intensive early rheumatoid arthritis treatment with adalimUmab: induction of REmission and maintenance - 'CURE' A Phase IV multicenter, randomized, double-blind study CURE-Pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003843-22,0,0,0 2006-003844-41,1,2010-06-15,2010-06-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Royal Marsden NHS Trust,Feasibility study of R-CHOP plus bevacizumab in patients with diffuse large B cell lymphoma (DLBCL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003844-41,0,0,0 2006-003846-41,2,2009-08-31,2009-09-02,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Affymax, Inc.","An Open-label, Multi-center, Extension Study to Evaluate the Safety and Tolerability of AF37702 Injection (Hematide™) for the Long-Term Maintenance Treatment of Anemia in Patients With Chronic Kidney ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003846-41,0,0,0 2006-003854-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"A multi-centre, randomised study of Zoledronic Acid versus Observation in Patients with Asymptomatic Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003854-33,0,0,0 2006-003868-59,8,2013-03-28,2013-03-28,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Astellas Global Pharma Development, Inc.","A Phase III,Double Blind, Randomized Study to evaluate safety and efficacy of BAL8557 versus Voriconazole for primary treatment of Invasive Fungal Disease Caused by Aspergillus species or other filame...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003868-59,0,0,0 2006-003868-59,8,2013-03-28,2013-03-28,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Basilea Pharmaceutica Ltd,"A Phase III,Double Blind, Randomized Study to evaluate safety and efficacy of BAL8557 versus Voriconazole for primary treatment of Invasive Fungal Disease Caused by Aspergillus species or other filame...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003868-59,0,0,0 2006-003868-59,8,2013-03-28,2013-03-28,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.","A Phase III,Double Blind, Randomized Study to evaluate safety and efficacy of BAL8557 versus Voriconazole for primary treatment of Invasive Fungal Disease Caused by Aspergillus species or other filame...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003868-59,0,0,0 2006-003868-59,8,2013-03-28,2013-03-28,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Astellas Pharma Global Development, Inc","A Phase III,Double Blind, Randomized Study to evaluate safety and efficacy of BAL8557 versus Voriconazole for primary treatment of Invasive Fungal Disease Caused by Aspergillus species or other filame...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003868-59,0,0,0 2006-003870-88,1,2009-07-09,2009-07-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"A Phase IIIb, multi-center, double-blind, placebo-controlled, randomized trial to examine the corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease (C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003870-88,0,0,0 2006-003871-11,1,2010-02-23,2010-02-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"An open-label, multi-center trial to examine the long term safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease who have failed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003871-11,0,0,0 2006-003876-37,4,2008-03-30,2008-03-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,DAIICHI SANKYO EUROPE GmbH,Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003876-37,0,0,0 2006-003877-28,4,2008-05-13,2008-10-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,DAIICHI SANKYO EUROPE GmbH,Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg versus 40/25 mg in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 4...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003877-28,0,0,0 2006-003879-12,7,2012-03-23,2012-03-23,1,1,0,0,0,1,3,0,0,1,1,0,1,0,2,,Compassionate Use of Vorinostat (MK-0683) for the Treatment of Patients with Advanced Cutaneous T-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003879-12,0,0,0 2006-003879-12,7,2012-03-23,2012-03-23,1,1,0,0,0,1,3,0,0,1,1,0,1,0,2,MERCK SHARP DOHME,Compassionate Use of Vorinostat (MK-0683) for the Treatment of Patients with Advanced Cutaneous T-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003879-12,0,0,0 2006-003879-12,7,2012-03-23,2012-03-23,1,1,0,0,0,1,3,0,0,1,1,0,1,0,2,"Merck & Co, Inc.",Compassionate Use of Vorinostat (MK-0683) for the Treatment of Patients with Advanced Cutaneous T-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003879-12,0,0,0 2006-003879-12,7,2012-03-23,2012-03-23,1,1,0,0,0,1,3,0,0,1,1,0,1,0,2,MSD Finland,Compassionate Use of Vorinostat (MK-0683) for the Treatment of Patients with Advanced Cutaneous T-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003879-12,0,0,0 2006-003879-12,7,2012-03-23,2012-03-23,1,1,0,0,0,1,3,0,0,1,1,0,1,0,2,"Merck & Co., Inc.",Compassionate Use of Vorinostat (MK-0683) for the Treatment of Patients with Advanced Cutaneous T-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003879-12,0,0,0 2006-003879-12,7,2012-03-23,2012-03-23,1,1,0,0,0,1,3,0,0,1,1,0,1,0,2,Merck Sharp & Dohme Ireland (Human Health) Limited,Compassionate Use of Vorinostat (MK-0683) for the Treatment of Patients with Advanced Cutaneous T-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003879-12,0,0,0 2006-003881-32,13,2010-07-14,2010-07-14,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck & Co, Inc",Early Access of MK-0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003881-32,0,0,0 2006-003881-32,13,2010-07-14,2010-07-14,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MERCK SHARP DOHME,Early Access of MK-0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003881-32,0,0,0 2006-003886-15,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,SANOFI-AVENTIS S.P.A,Steady state telithromycin pharmacokinetics and pharmacodynamic in adult patients with mild-moderate acute exacerbation of chronic obstructive pulmonary disease treated with a standard oral dose 8...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003886-15,0,0,0 2006-003887-76,1,2009-06-30,2009-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,ICT (Instituto Científico y Técnológico de Navarra),ENSAYO CLINICO PILOTO CON MEMANTINA EN EL DÉFICIT COGNITIVO DE LA ESCLEROSIS MÚLTIPLE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003887-76,0,0,0 2006-003896-11,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Helsinki University Central Hospital,Kolloidiliuosten vaikutus veren hyytymiseen ja hapentarjontaan sydänleikkauksen jälkeen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003896-11,0,0,0 2006-003897-87,2,2007-10-23,2007-10-23,1,1,0,0,0,0,2,0,0,1,1,0,1,0,2,"Wyeth Research Division of Wyeth Pharmaceutical Inc., Clinical Research and Development","A 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF PPM-204 IN SUBJECTS WITH TYPE 2 DIABETES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003897-87,0,0,0 2006-003897-87,2,2007-10-23,2007-10-23,1,1,0,0,0,0,2,0,0,1,1,0,1,0,2,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF PPM-204 IN SUBJECTS WITH TYPE 2 DIABETES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003897-87,0,0,0 2006-003900-20,1,2017-03-01,2017-03-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Institut Bergonié,Essai clinique de Phase II évaluant une chimitohérapie systémique associée au Cetuximab en traitement adjuvant chez des patients complètement résèques par chirurgie de leur carcinose péritonéale isolé...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003900-20,0,0,0 2006-003903-38,4,2007-06-01,2007-06-27,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"CoLucid Pharmaceuticals, Inc.",A Placebo-Controlled Group Sequential Adaptive Treatment Assignment Study of Intravenous COL-144 (LY573144) in the Acute Treatment of Migraine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003903-38,0,0,0 2006-003907-38,2,2008-07-24,2008-07-24,1,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Danube Pharmaceuticals Inc.,"A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo Controlled Phase II Study to Investigate the Safety, Efficacy, and Pharmacokinetic Profile of Twice-daily DNB-001 in Previously Untrea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003907-38,0,0,0 2006-003912-23,1,2007-12-03,2007-12-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Addex Pharmaceuticals SA,"A Phase IIa, double-blind, placebo-controlled, randomised, parallel-group study, to investigate the safety, tolerability and anxiolytic effect of the mGluR5 negative allosteric modulator ADX10059 in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003912-23,0,0,0 2006-003924-13,1,2007-11-16,2007-11-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Merck Sharp & Dohme Ltd,"A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Assess the Efficacy and Safety of MK-0952 in Patients With Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003924-13,0,0,0 2006-003929-83,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA,Phase II study of Bevacizumab in combination with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003929-83,0,0,0 2006-003931-63,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,S.L.A. Pharma (UK) Ltd,"A double-blind, placebo-controlled, randomised, multi-centre, dose-ranging study to determine the safety and efficacy of three concentrations of topical diltiazem cream in the treatment of chronic ana...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003931-63,0,0,0 2006-003932-32,1,2009-11-05,2009-11-05,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,The University of Leeds,Endocrine +/- Surgical Therapy for Elderly women with Mammary cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003932-32,0,0,0 2006-003932-32,1,2009-11-05,2009-11-05,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,The University of Sheffield,Endocrine +/- Surgical Therapy for Elderly women with Mammary cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003932-32,0,0,0 2006-003933-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Bundeswehr,Clinical value of Choline-Positron-Emission-Tomography combined with Magnetic Resonance Imaging by software fusion for pre-therapeutic staging of prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003933-33,0,0,0 2006-003934-14,1,2013-03-07,2013-03-07,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Universitätsmedizin Göttingen,"„Eine randomisierte, placebokontrollierte Doppelblindstudie zur Evaluation der Effektivität oral verabreichten Doxycyclins bei Patienten mit Creutzfeldt-Jakob-Krankheit“",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003934-14,0,0,0 2006-003935-56,7,2009-05-13,2010-12-12,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,THE MEDICINES COMPANY UK,"A clinical trial comparing treatment with cangrelor (in combination with usual care) to usual care, in subjects who require percutaneous coronary intervention",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003935-56,0,0,0 2006-003935-56,7,2009-05-13,2010-12-12,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,The Medicines Company,"A clinical trial comparing treatment with cangrelor (in combination with usual care) to usual care, in subjects who require percutaneous coronary intervention",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003935-56,0,0,0 2006-003940-50,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ANRS,ESSAI RANDOMISE MULTICENTRIQUE DE PHASE III COMPARANT L’IMMUNOGENICITE ET LA TOLERANCE DE TROIS SCHEMAS DE VACCINATION CONTRE LE VIRUS DE L’HEPATITE B CHEZ DES PATIENTS INFECTES PAR LE VIH AYANT DES L...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003940-50,0,0,0 2006-003941-17,2,2007-10-12,2007-10-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A randomized,double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety and tolerability of RWJ333369 as adjunctive therapy in subjects with partial onset se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003941-17,0,0,0 2006-003944-42,3,2008-05-06,2008-05-26,2,0,0,0,0,0,3,0,0,1,1,0,1,0,1,"REPLIDYNE, INC.","Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600 mg PO, BID for 5 Days Versus Placebo in the Treatment of Acute Exacerbation of Chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003944-42,0,0,0 2006-003944-42,3,2008-05-06,2008-05-26,2,0,0,0,0,0,3,0,0,1,1,0,1,0,1,"Replidyne, Inc.","Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600 mg PO, BID for 5 Days Versus Placebo in the Treatment of Acute Exacerbation of Chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003944-42,0,0,0 2006-003951-18,7,2015-03-03,2015-03-03,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Astellas Global Pharma Development, Inc.","A PHASE III, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BAL8557 VERSUS A CASPOFUNGIN FOLLOWED BY VORICONAZOLE REGIMEN IN THE TREATMENT OF CANDIDEMIA AND OTHER INVASIVE CANDI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003951-18,0,0,0 2006-003951-18,7,2015-03-03,2015-03-03,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.","A PHASE III, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BAL8557 VERSUS A CASPOFUNGIN FOLLOWED BY VORICONAZOLE REGIMEN IN THE TREATMENT OF CANDIDEMIA AND OTHER INVASIVE CANDI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003951-18,0,0,0 2006-003951-18,7,2015-03-03,2015-03-03,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Basilea Pharmaceutica Ltd.,"A PHASE III, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BAL8557 VERSUS A CASPOFUNGIN FOLLOWED BY VORICONAZOLE REGIMEN IN THE TREATMENT OF CANDIDEMIA AND OTHER INVASIVE CANDI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003951-18,0,0,0 2006-003957-25,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI,"Rare Diseases with microvascular involvement. High Dose Intravenous N-acetylcysteine versus Iloprost for early, rapidly progressive diffuse Systemic Sclerosis (Scleroderma)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003957-25,0,0,0 2006-003958-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,LUMC,"An open label, randomized phase III trial comparing 2.5 year duration of letrozole (Femara) treatment with 5 year duration in patients previously treated for endocrine sensitive early breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003958-16,0,0,0 2006-003959-21,3,2009-03-30,2009-03-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Basilea Pharmaceutica Ltd.,Open label treatment of patients with chronic hand dermatitis who have participated in a clincal trial involving oral alitretinoin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003959-21,0,0,0 2006-003963-30,7,2008-01-09,2008-02-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil 32 mg and Hydrochl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003963-30,0,0,0 2006-003970-89,1,2012-01-30,2012-01-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients three to six months after allogeneic hematopoietic cell transplantat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003970-89,0,0,0 2006-003971-11,1,2010-09-06,2010-09-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 in patients diagnosed with Low and INT-1 risk Myelodysplastic Syndrome (MDS) and transfusion-de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003971-11,0,0,0 2006-003976-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Professor Anita Leys - Dienst Oftalmologie UZ St. Rafaël,An academic monocenter study assessing the safety and efficacy of Lucentis (ranizumab 0.3 mg) administered in conjunction with photodynamic therapy with Visudyne in patients with occult or predominant...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003976-36,0,0,0 2006-003978-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SUPERIORE DI SANITA',Pilot Study with fixed dose of Cisplatinum in combination with esomeprazole (dose-ranging) as salvage treatment in patients with pre-treated advanced/methastatic melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003978-10,0,0,0 2006-003981-33,1,2013-01-07,2013-01-07,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,UMC ST Radboud,Application of fluorescence diagnosis (FDAP) and photodynamic therapy (PDT) in psoriasis and premalignancies of the skin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003981-33,0,0,0 2006-003983-73,2,2008-03-10,2008-03-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cliag International N.V.,"A Phase IIa Multicenter, Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study of RWJ-445380 Cathepsin-S Inhibitor in Patients with Active Rheumatoid Arthritis Despite Methotrexate Thera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003983-73,0,0,0 2006-003983-73,2,2008-03-10,2008-03-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase IIa Multicenter, Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study of RWJ-445380 Cathepsin-S Inhibitor in Patients with Active Rheumatoid Arthritis Despite Methotrexate Thera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003983-73,0,0,0 2006-003984-30,1,2007-01-18,2007-01-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, two-arm, vehicle-controlled, parallel-group, two stage study to evaluate and demonstrate the efficacy and to evaluate the safety of pimecrolimus 1% cream in th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003984-30,0,0,0 2006-003987-74,8,2009-01-08,2009-10-14,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biogen Idec Ltd.,"A Phase III, Open-Label, Multicenter, Single-Arm, Retreatment Study of Galiximab in Combination with Rituximab for Subjects with Relapsed, Follicular Non-Hodgkin’s Lymphoma who Previously Responded on...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003987-74,0,0,0 2006-003991-37,1,2013-02-13,2013-02-13,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,University Hospital Gent,Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003991-37,0,0,0 2006-003993-85,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",Phase II Study of neoadjuvant therapy with trastuzumab plus docetaxel followed by trastuzumab plus pegylated liposomal doxorubicin and cyclophosphamide in human ErbB-2-positive operable or locally adv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003993-85,0,0,0 2006-003994-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""","VINORELBINE, CARBOPLATIN AND TRASTUZUMAB IN ADVANCED HER-2 POSITIVE BREAST CANCER. A PHASE 2 STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003994-28,0,0,0 2006-003995-36,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",A MULTICENTER RANDOMIZED PHASE III STUDY COMPARING FIXED DOSES WITH TOXICITY-ADJUSTED DOSES OF STANDARD CHEMOTHERAPY WITH CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY ADVANCED SMALL CELL LUNG CANCE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003995-36,0,0,0 2006-003998-27,1,2010-06-09,2010-06-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Derby Hospitals NHS Foundation Trust,Cardiovascular and functional consquences of chronic kidney disease in older people,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003998-27,0,0,0 2006-003999-35,1,2009-12-31,2009-12-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Charité Campus Mitte, Klinik für Psychiatrie und Psychotherapie",Efficacy and safety of levetiracetam in prevention of alcohol relapse in recently detoxified alcohol dependent patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003999-35,0,0,0 2006-004001-26,1,2010-08-09,2010-08-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Nottingham University Hospitals NHS Trust,A Randomised Controlled Trial of Fascia Iliaca Compartment Block vs. Morphine For Pain in Fractured Neck of Femur in the Emergency Department: A Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004001-26,0,0,0 2006-004003-18,6,2008-02-02,2009-02-03,4,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, open-label, controlled, multi-center two-year study comparing efficacy and safety of telbivudine LDT600 600 mg PO in combination with peg alpha-2a sq 180 g with peg alpha-2a monothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004003-18,0,0,0 2006-004003-18,6,2008-02-02,2009-02-03,4,1,0,0,0,0,0,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A randomized, open-label, controlled, multi-center two-year study comparing efficacy and safety of telbivudine LDT600 600 mg PO in combination with peg alpha-2a sq 180 g with peg alpha-2a monothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004003-18,0,0,0 2006-004007-19,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Nycomed Austria GmbH,"A multi-centre, double-blind, placebo-controlled, randomised, parallel group clinical trial to evaluate efficacy and safety of Actovegin® in diabetic type 2 patients with symptomatic diabetic peripher...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004007-19,0,0,0 2006-004008-38,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,University Medical Center Utrecht,The Breast CARE Study: Capecitabine (Xeloda®) combined with RHenium-188-HEDP in breast cancer patients with bone metastses; a Re-188-HEDP phase I dose escalation study and phase II efficacy study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004008-38,0,0,0 2006-004009-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA,Randomized phase II study of pemetrexed versus pemetrexed and carboplatin as second line chemotherapy in advanced non-small-cell lung cancer (NSCLC).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004009-24,0,0,0 2006-004014-41,1,2011-05-30,2011-05-30,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,GlaxoSmithKline Research and Development,"A randomised, single-blind, placebo-controlled study to investigate the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous infusion of GSK933776A in patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004014-41,0,0,0 2006-004015-21,1,2007-03-15,2007-03-15,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,Johnson & Johnson Consumer and Personal Products Worldwide,Randomized Clinical Study Comparing Compeed Cold Sore Patch to Zovirax Cream 5% in the Treatment of Herpes Labialis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004015-21,0,0,0 2006-004016-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI,APPLICATION OF PHARMACOGENOMICS IN THE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED COLORECTAL CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004016-40,0,0,0 2006-004018-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II,"A phase III study comparing anastrozole, letrozole and exemestane, upfront (for 5 years) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004018-42,0,0,0 2006-004022-87,8,2009-03-10,2009-04-15,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc.,"A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004022-87,0,0,0 2006-004022-87,8,2009-03-10,2009-04-15,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004022-87,0,0,0 2006-004022-87,8,2009-03-10,2009-04-15,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer bv CR,"A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004022-87,0,0,0 2006-004022-87,8,2009-03-10,2009-04-15,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer bv RA,"A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004022-87,0,0,0 2006-004022-87,8,2009-03-10,2009-04-15,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer. S.A,"A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004022-87,0,0,0 2006-004024-37,13,2017-08-30,2017-09-07,12,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Pfizer Inc.,SUNITINIB COMO TRATAMIENTO ADYUVANTE DEL CÁNCER RENAL (S TRAC): ESTUDIO EN FASE 3 ALEATORIZADO Y DOBLE CIEGO DE SUNITINIB ADYUVANTE EN COMPARACIÓN CON PLACEBO EN PACIENTES CON CARCINOMA RENAL DE ALTO ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004024-37,0,0,0 2006-004024-37,13,2017-08-30,2017-09-07,12,1,0,0,0,2,3,0,0,1,0,0,1,0,1,PFIZER,SUNITINIB COMO TRATAMIENTO ADYUVANTE DEL CÁNCER RENAL (S TRAC): ESTUDIO EN FASE 3 ALEATORIZADO Y DOBLE CIEGO DE SUNITINIB ADYUVANTE EN COMPARACIÓN CON PLACEBO EN PACIENTES CON CARCINOMA RENAL DE ALTO ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004024-37,0,0,0 2006-004024-37,13,2017-08-30,2017-09-07,12,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, 10017",SUNITINIB COMO TRATAMIENTO ADYUVANTE DEL CÁNCER RENAL (S TRAC): ESTUDIO EN FASE 3 ALEATORIZADO Y DOBLE CIEGO DE SUNITINIB ADYUVANTE EN COMPARACIÓN CON PLACEBO EN PACIENTES CON CARCINOMA RENAL DE ALTO ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004024-37,0,0,0 2006-004024-37,13,2017-08-30,2017-09-07,12,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Pfizer Inc. - 235 East 42nd Street - New York - 10017,SUNITINIB COMO TRATAMIENTO ADYUVANTE DEL CÁNCER RENAL (S TRAC): ESTUDIO EN FASE 3 ALEATORIZADO Y DOBLE CIEGO DE SUNITINIB ADYUVANTE EN COMPARACIÓN CON PLACEBO EN PACIENTES CON CARCINOMA RENAL DE ALTO ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004024-37,0,0,0 2006-004024-37,13,2017-08-30,2017-09-07,12,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, 10017 US",SUNITINIB COMO TRATAMIENTO ADYUVANTE DEL CÁNCER RENAL (S TRAC): ESTUDIO EN FASE 3 ALEATORIZADO Y DOBLE CIEGO DE SUNITINIB ADYUVANTE EN COMPARACIÓN CON PLACEBO EN PACIENTES CON CARCINOMA RENAL DE ALTO ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004024-37,0,0,0 2006-004024-37,13,2017-08-30,2017-09-07,12,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Pfizer, S.A.",SUNITINIB COMO TRATAMIENTO ADYUVANTE DEL CÁNCER RENAL (S TRAC): ESTUDIO EN FASE 3 ALEATORIZADO Y DOBLE CIEGO DE SUNITINIB ADYUVANTE EN COMPARACIÓN CON PLACEBO EN PACIENTES CON CARCINOMA RENAL DE ALTO ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004024-37,0,0,0 2006-004025-28,1,2011-04-04,2011-04-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Liverpool Children’s NHS Trust,"MENDS: The use of MElatonin in children with Neuro-developmental Disorders and impaired Sleep; a randomised, double-blind, placebo-controlled, parallel study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004025-28,0,0,0 2006-004028-35,1,2008-05-21,2008-05-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Pharma GmbH,Effect of Pioglitazone compared to a combination therapy with Ramipril and to a Ramipril monotherapy on low grade inflammation and vascular function in patients with increased cardiovascular risk and ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004028-35,0,0,0 2006-004030-32,2,2017-11-21,2017-11-21,2,1,0,0,0,0,3,0,0,1,1,0,1,0,0,"Klinikum der Ludwig-Maximilians Universität München, Klinikum Großhadern",Randomised study for efficiency of FOLFIRI in combination with Cetuximab vs. Bevacizumab in first-line-therapy of metastatic colorectal cancer Randomisierte Studie zur Wirksamkeit von FOLFIRI in K...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004030-32,0,0,0 2006-004032-75,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Roche Pharma AG,"An open-label, multi-center study to demonstrate the efficacy and safety of C.E.R.A when administered intravenously with pre-filled syringes (PFS) for the treatment of anemia in patients with chronic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004032-75,0,0,0 2006-004033-15,1,2007-05-10,2007-05-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A multicentre, randomised, placebo-controlled, double-blind, 4-arm parallel-group, 2-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H (100 and 400mcg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004033-15,0,0,0 2006-004034-32,1,2013-09-10,2013-09-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Graz,Zur Frage des neuroleptikainduzierten metabolischen Syndroms. Studie 1: Fettverteilung und spezifische hormonelle Parameter. Eine prospektive Vergleichsstudie zwischen 5 atypischen Neuroleptika,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004034-32,0,0,0 2006-004035-30,1,2007-11-12,2007-11-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Verus Pharmaceuticals Inc,"A Randomised, Single Dose Exposure Study to Assess the Safety, Tolerability and Pharmacokinetics of Investigational Captisol-Enabled® Budesonide Inhalation Solution (CBIS) Delivered via eFlow® Nebulis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004035-30,0,0,0 2006-004036-71,1,2013-09-10,2013-09-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Graz,Zur Frage des neuroleptikainduzierten metabolischen Syndroms. Studie 2: Fettverteilung und spezifische hormonelle Parameter. Vergleich zwischen auf das metabolische Syndrom vulnerablen und nicht vulne...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004036-71,0,0,0 2006-004039-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ANRS,"Etude pilote de phase II évaluant l’intérêt d’un traitement séquentiel par de l’IL2 puis de l’IFN pegylé sur la réponse immunitaire cellulaire, l’efficacité et la tolérance clinique dans les vasculari...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004039-31,0,0,0 2006-004041-42,2,2008-03-05,2008-03-05,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, randomised, open study to evaluate the immunogenicity and safety of a single or double-dose of the pandemic influenza candidate vaccine split virus formulation adjuvanted with AS03 gi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004041-42,0,0,0 2006-004043-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Effects of Sulodexide on damaged endothelial Glycocalyx in pAtients with Diabetes Mellitus type II; Reversing damage.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004043-35,0,0,0 2006-004045-42,1,2007-02-22,2007-02-22,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,Verus Pharmaceuticals Inc,"Randomized, Open-Label, Active Controlled, Two-Period Crossover Study To Evaluate Relative Efficacy And Safety of Investigational Captisol-Enabled Budesonide Inhalation Solution (CBIS) Delivered via e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004045-42,0,0,0 2006-004048-21,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ZAMBON GROUP,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUPS STUDY ON EFFICACY AND SAFETY OF NAC 600 MG DAILY AND NAC 1200 MG DAILY AS MUCOLYTIC AGENT IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMON...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004048-21,0,0,0 2006-004049-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dept of Anaesthesia, University College Hospital, Galway",Determination of the efficacy of the Transversus Abdominis Plane (TAP) Block in the management of postoperative pain following Total Abdominal Hysterectomy (TAH).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004049-41,0,0,0 2006-004052-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Koningin Wilhelmina Fonds,Phase II study of definitive radiochemotherapy for locally advanced squamous cell cancer of the vulva: an efficacy study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004052-20,0,0,0 2006-004053-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dept of Anaesthesia, University College Hospital, Galway",Determination of the efficacy of the Transversus Abdominis Plane (TAP) Block in the management of postoperative pain following Caesarean Section.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004053-20,0,0,0 2006-004055-38,1,2008-05-12,2008-05-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Futura Medical Developments (FMD),A Phase II Clinical Study to Compare the Efficacy and Safety of Three Doses of Topical Glyceryl Trinitrate (GTN) to Placebo in Subjects with Mild and/or Moderate Erectile Dysfunction (ED),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004055-38,0,0,0 2006-004055-38,1,2008-05-12,2008-05-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,SSL International Plc,A Phase II Clinical Study to Compare the Efficacy and Safety of Three Doses of Topical Glyceryl Trinitrate (GTN) to Placebo in Subjects with Mild and/or Moderate Erectile Dysfunction (ED),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004055-38,0,0,0 2006-004062-13,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,A.U.S.L. RIMINI,"Randomised, open label, no profit, clinical, multicenter study of phase II and IIIB to assess efficacy and tolerability of oxycodone/paracetamol compared to anti-inflammatory non-steroidal drugs FANS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004062-13,0,0,0 2006-004063-66,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,CHIRON,"A Phase II, Randomized, Controlled, Observer-blind, Single-Center Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, and a Six Month Booster Dose of Two FLUAD-li...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004063-66,0,0,0 2006-004065-34,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,Technical University Dresden,"Open labeled, multicenter phase I / II study evaluating the dose escalation/ safety of Cetuximab and Oxaliplatin/ 5-FU/FA/ Irinotecan as first-line treatment of metastatic colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004065-34,0,0,0 2006-004066-14,1,,,0,1,0,0,1,0,4,0,1,0,0,0,0,0,0,Erasme hospital,Etude des effets de l'enoximone sur la sensibilité du chémorécepteur.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004066-14,0,0,0 2006-004067-53,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE POLICLINICO S. MATTEO,A multicenter randomized study on the use of rabbit anti-T-Lymphocite globulin ATG different doses to prevent GVHD in children receiving allogenic stem cell transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004067-53,0,0,0 2006-004069-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,NovartisPharma Services AG,"A randomized, double-blind, double-dummy, active (formoterol 12 µg b.i.d) and placebo controlled, multi-center, 5 period crossover, dose-ranging study to assess the bronchodilatory efficacy and safety...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004069-33,0,0,0 2006-004071-34,1,2013-01-17,2013-01-17,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,"Queen Mary, University of London (QMUL)","A single centre, parallel group, pilot study to investigate the effect of opioids on immunomarkers using gene expression profiling.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004071-34,0,0,0 2006-004072-12,2,2007-03-02,2007-03-02,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NV Organon,"A multi-center, randomized, parallel-group, safety assessor-blinded trial comparing efficacy and safety of 4.0 mg.kg-1 Org 25969, administered at T1 3-10% after continuous infusion of rocuronium, and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004072-12,0,0,0 2006-004073-10,1,2009-03-06,2009-03-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Giessen,Effect of Atomoxetine and a standardized behavior therapy on attention deficits in adult ADHD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004073-10,0,0,0 2006-004075-36,1,2008-03-20,2008-03-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Baxter R&D Europe S.C.R.L.,"A randomized, double blind, placebo-controlled, single-dose, parallel-group comparison of the analgesic efficacy, safety and local tolerability of intravenous Paracetamol 1% solution Bioren (test), Pe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004075-36,0,0,0 2006-004076-13,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Huvud- hals- lung- och hudcancer, Tema Cancer Karolinska Universitetssjukhuset",Secar I Part I: A study of MTD of Sodium selenite in patients with advanced carcinoma. A phase I study. Amendment 5: continuous treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004076-13,0,0,0 2006-004078-28,1,2007-03-05,2007-03-05,1,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Pharmaxis UK Limited,Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004078-28,0,0,0 2006-004080-55,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Erasmus MC,Stepwise Medical Treatment of Cushing’s Disease: a prospective open label multi-center trial with SOM230 mono- and combination therapy with dopamine agonists and ketoconazole,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004080-55,0,0,0 2006-004084-66,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE ONCOLOGICO DI BARI,A phase II study on the efficacy and safety of topotecan in the treatment of patients with brain metastases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004084-66,0,0,0 2006-004086-33,5,2009-01-29,2009-05-26,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BOEHRINGER ING.,Effect of inhalation of a free combination of tiotropium once daily 18 mcg and salmeterol twice daily 50 mcg versus a fixed combination of fluticasone and salmeterol twice daily (500/50 mcg) on stat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004086-33,0,0,0 2006-004086-33,5,2009-01-29,2009-05-26,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,Effect of inhalation of a free combination of tiotropium once daily 18 mcg and salmeterol twice daily 50 mcg versus a fixed combination of fluticasone and salmeterol twice daily (500/50 mcg) on stat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004086-33,0,0,0 2006-004086-33,5,2009-01-29,2009-05-26,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim,Effect of inhalation of a free combination of tiotropium once daily 18 mcg and salmeterol twice daily 50 mcg versus a fixed combination of fluticasone and salmeterol twice daily (500/50 mcg) on stat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004086-33,0,0,0 2006-004086-33,5,2009-01-29,2009-05-26,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Austria GmbH,Effect of inhalation of a free combination of tiotropium once daily 18 mcg and salmeterol twice daily 50 mcg versus a fixed combination of fluticasone and salmeterol twice daily (500/50 mcg) on stat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004086-33,0,0,0 2006-004086-33,5,2009-01-29,2009-05-26,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,Effect of inhalation of a free combination of tiotropium once daily 18 mcg and salmeterol twice daily 50 mcg versus a fixed combination of fluticasone and salmeterol twice daily (500/50 mcg) on stat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004086-33,0,0,0 2006-004087-31,4,2009-03-17,2009-12-25,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004087-31,0,0,0 2006-004087-31,4,2009-03-17,2009-12-25,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004087-31,0,0,0 2006-004088-77,2,2011-06-27,2011-06-27,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,BioAlliance Pharma,"Doxorubicin-Transdrug® in Advanced HepatoCellular Carcinoma A Randomized, Multicenter Phase 2-3 Study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004088-77,0,0,0 2006-004093-27,1,2011-05-25,2011-05-25,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Roche (Hungary) Ltd.,"A multicenter, phase II, open-label study evaluating the benefit of addition of MabThera (rituximab) to standard chemotherapies in patients with previously untreated mantle cell lymphoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004093-27,0,0,0 2006-004097-28,1,2019-11-06,2019-11-06,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University College Hospitals NHS Foundation Trust/ University College London,A Phase 1 Trial of Verteporfin Photodynamic Therapy in Unresectable Pancreatic Carcinoma (VERTPAC-01 study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004097-28,0,0,0 2006-004101-26,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,CHU Sart-Tilman,Mesenchymal stem cell infusion as prevention for graft rejection and graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004101-26,0,0,0 2006-004102-13,1,2009-09-25,2009-09-25,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Hull and east yorkshire Hospitals Trust,"An 8 week, non-selected, cohort, study to investigate whether the treatment of reflux induced cough alters associated bronchial hyperresponsiveness.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004102-13,0,0,0 2006-004105-25,4,2008-05-14,2008-06-09,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S p A,"AN INTERNATIONAL, OPEN, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE EFFICACY OF COMBINING PROPHYLACTIC CUROSURF WITH EARLY NASAL CPAP VERSUS EARLY NASAL CPAP ALONE IN VERY PRETERM INFANTS AT RISK OF ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004105-25,0,0,0 2006-004105-25,4,2008-05-14,2008-06-09,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,CHIESI,"AN INTERNATIONAL, OPEN, RANDOMIZED, CONTROLLED STUDY TO EVALUATE THE EFFICACY OF COMBINING PROPHYLACTIC CUROSURF WITH EARLY NASAL CPAP VERSUS EARLY NASAL CPAP ALONE IN VERY PRETERM INFANTS AT RISK OF ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004105-25,0,0,0 2006-004106-87,1,2014-11-06,2014-11-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Meical University, Dpt. Internal Medicine, Div. of General Internal Medicine",CLINICAL PHARMACOKINETICS OF CASPOFUNGIN IN CRITICALLY ILL PATIENTS DURING CONTINUOUS VENO-VENOUS HEMOFILTRATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004106-87,0,0,0 2006-004107-20,1,2008-12-01,2008-12-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical University, Dpt. Internal Medicine, Div. of General Internal Medicine",LUNG PENETRATION OF CASPOFUNGIN INTO EPITHELIAL LINING FLUID,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004107-20,0,0,0 2006-004110-40,1,2007-04-05,2007-04-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Single Centre, Single Arm, Exploratory, Open Label Study to Determine the Early Bone Formation and Bone Resorption Biomarker Response Profile of a Potent Bone Anabolic Treatment (PTH-1-34) with Dail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004110-40,0,0,0 2006-004111-22,11,2010-03-17,2014-05-21,10,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004111-22,0,0,0 2006-004111-22,11,2010-03-17,2014-05-21,10,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Novartis Farmaceútica S.A.,"A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004111-22,0,0,0 2006-004111-22,11,2010-03-17,2014-05-21,10,1,0,0,0,2,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004111-22,0,0,0 2006-004112-51,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,VERNALIS DEVELOPMENT LIMITED,"A randomised, double-blind, double-dummy, two-period, cross-over study to determine the pharmacokinetics, pharmacodynamics and safety of multiple doses of V1512 effervescent tablets in Parkinson s Dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004112-51,0,0,0 2006-004122-90,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,"Medizinische Fakultät der Technischen Universität München, Vertreten durch den Dekan","Levofloxacin vs Piperacillin/Sulbactam and Sultamicillin in patients with bacterial cholangitis. A double blind, randomiized study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004122-90,0,0,0 2006-004126-85,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dr. Lluis Arias,"Ensayo clínico de fase II, prospectivo, abierto, aleatorizado con grupos paralelos y multicéntrico para comparar la seguridad y la eficacia de ranibizumab intravítreo en monoterapia versus la combinac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004126-85,0,0,0 2006-004128-35,5,2008-05-20,2008-05-20,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus tacrolimus® in combination with myfortic®,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004128-35,0,0,0 2006-004128-35,5,2008-05-20,2008-05-20,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A,"A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus tacrolimus® in combination with myfortic®,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004128-35,0,0,0 2006-004129-27,2,2008-03-18,2008-03-27,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,CASA MADRE,"An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (Pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004129-27,0,0,0 2006-004129-27,2,2008-03-18,2008-03-27,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD,"An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (Pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004129-27,0,0,0 2006-004130-32,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,NKI/Antoni van Leeuwenhoek Ziekenhuis,A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer (CRITICS-study: ChemoRadioth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004130-32,0,0,0 2006-004130-32,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Department of Oncology Karolinska,A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer (CRITICS-study: ChemoRadioth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004130-32,0,0,0 2006-004131-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dr. Félix Armadá,"Ensayo clínico de fase II, piloto, prospectivo, controlado, abierto, aleatorizado con grupos paralelos y multicéntrico para comparar la seguridad y la eficacia del ranibizumab en monoterapia frente a ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004131-30,0,0,0 2006-004132-75,1,2010-06-10,2010-06-10,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Dr. Jordi Monés,"Ensayo clínico de fase II, prospectivo, controlado, abierto, aleatorizado con grupos paralelos para comparar la seguridad y la eficacia del ranibizumab en monoterapia frente a la combinación con tera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004132-75,0,0,0 2006-004136-73,1,2007-01-22,2007-01-22,1,0,0,0,1,0,3,0,0,1,0,0,1,0,1,Thornton & Ross Limited,"A randomised, controlled, assessor-blind, clinical trial to demonstrate superiority of Hedrin 4% dimeticone lotion compared with Derbac-M 0.5% malathion aqueous liquid in the treatment of head lice",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004136-73,0,0,0 2006-004139-31,13,2010-07-01,2010-09-03,10,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Abbott GmbH & Co. KG,"A Multicenter, Randomized, Double-Period, Double − Blind Study to Determine the Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab Combination Therapy in Patients with Early Rh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004139-31,0,0,0 2006-004140-23,13,2009-05-08,2009-09-29,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Serono Int, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt, Germany","A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004140-23,0,0,0 2006-004140-23,13,2009-05-08,2009-09-29,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Serono Int, a branch of Laboratoires Seron SA an affiliate of Merck KGaA, Darmstadt, Germany","A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004140-23,0,0,0 2006-004140-23,13,2009-05-08,2009-09-29,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SERONO INTERNATIONAL SA,"A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004140-23,0,0,0 2006-004140-23,13,2009-05-08,2009-09-29,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Serono International S.A.,"A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004140-23,0,0,0 2006-004140-23,13,2009-05-08,2009-09-29,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Serono International S.A.,"A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004140-23,0,0,0 2006-004140-23,13,2009-05-08,2009-09-29,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Serono Int, a branch of Laboratoires Serono SA, an affiliate of Merck KGaA, Darmstadt, Germany","A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004140-23,0,0,0 2006-004140-23,13,2009-05-08,2009-09-29,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Serono Int, a branch ofLaboratories Serono S.A. an affiliate of Merck KGaA, Darmstadt, Germany","A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004140-23,0,0,0 2006-004140-23,13,2009-05-08,2009-09-29,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Serono Int.a branch of Laboratoires Serono SA an affiliate of Merck KgaA, Darmstadt, Germany","A randomised, double-blind, placebo-controlled, multicentre, Phase II dose-finding study of atacicept given subcutaneously in subjects with rheumatoid arthritis and inadequate response to TNFa antagon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004140-23,0,0,0 2006-004144-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZ St Augustinus, Wilrijk",Clinical Trial Application for a Phase II study in patients with hormone receptor positive breast cancer with bortezomib (Velcade) in the reversal of endocrine resistance.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004144-23,0,0,0 2006-004146-16,5,2008-02-22,2008-02-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A multi-national, multi-center, double blind, placebo-controlled, parallel group, fixed dose efficacy and safety study of SR58611A 350 mg twice daily vs. placebo in adults with Major Depressive Disord...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004146-16,0,0,0 2006-004147-33,3,2007-08-29,2007-09-14,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,"An Eight-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Fixed Dose of SR58611A 350 mg Twice a Day in Elderly Patients with Generalized Anx...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004147-33,0,0,0 2006-004149-40,1,2007-10-04,2007-10-04,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cancer Research UK,"A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with letrozole versus letrozole alone in post-menopausal women with recurrent, oestrogen and/or progeste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004149-40,0,0,0 2006-004152-20,17,2009-05-30,2009-05-30,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,A 52-week open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-to-m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004152-20,0,0,0 2006-004152-20,17,2009-05-30,2009-05-30,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development,A 52-week open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) as adjunctive therapy to acetylcholinesterase inhibitors in subjects with mild-to-m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004152-20,0,0,0 2006-004153-22,4,2008-04-16,2008-06-04,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bayer Schering Pharma,"Open-label multi-center study of magnetic resonance imaging (MRI) with 0.1 mmol/kg BW Gadovist (1.0 M) to assess pharmacokinetics, safety and tolerability in children",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004153-22,0,0,0 2006-004153-22,4,2008-04-16,2008-06-04,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Bayer AB, Bayer Schering Pharma","Open-label multi-center study of magnetic resonance imaging (MRI) with 0.1 mmol/kg BW Gadovist (1.0 M) to assess pharmacokinetics, safety and tolerability in children",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004153-22,0,0,0 2006-004153-22,4,2008-04-16,2008-06-04,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Bayer AB, Bayer Health Care, Bayer Schering Pharma","Open-label multi-center study of magnetic resonance imaging (MRI) with 0.1 mmol/kg BW Gadovist (1.0 M) to assess pharmacokinetics, safety and tolerability in children",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004153-22,0,0,0 2006-004153-22,4,2008-04-16,2008-06-04,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bayer Schering Pharma AG,"Open-label multi-center study of magnetic resonance imaging (MRI) with 0.1 mmol/kg BW Gadovist (1.0 M) to assess pharmacokinetics, safety and tolerability in children",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004153-22,0,0,0 2006-004155-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hôpital Universitaire Des Enfants Reine Fabiola (H.U.D.E.R.F.),Biochemical effects of a long-term supplementation with omega-3 polyunsaturated fatty acids in cystic fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004155-38,0,0,0 2006-004159-39,5,2011-06-21,2011-06-21,4,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, double-dummy, randomised, place-controlled, mutli-centre phase III clinical study on the efficacy and tolerability on budesonide capsules vs. mesalazine granules vs. placebo for patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004159-39,0,0,0 2006-004160-32,1,2009-01-10,2009-01-10,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Queen Mary's University of London,Biological effects of Goal Directed Therapy in surgical patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004160-32,0,0,0 2006-004162-13,1,2008-08-31,2008-08-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Charité Universitätsmedizin, Campus Charité Mitte","Randomized, double-blind, placebo-controlled phase II pilot study of the impact of mesalazine enemas on the mucosal gut flora in patients with inflammatory bowel disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004162-13,0,0,0 2006-004164-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Laboratoires BIORGA,Evaluation de l'efficacité de l'isotrétinoïne versus placebo à travers le taux de patients répondeurs chez des patients présentant une rosacée papulo-pustuleuse résistant au traitement classique. Essa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004164-31,0,0,0 2006-004167-56,6,2010-11-12,2010-11-12,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ANGELINI,Prulifloxacin versus levofloxacin in the treatment of patients with Acute Exacerbations of Chronic Bronchitis AECB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004167-56,0,0,0 2006-004167-56,6,2010-11-12,2010-11-12,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,A.C.R.A.F. S.p.A.,Prulifloxacin versus levofloxacin in the treatment of patients with Acute Exacerbations of Chronic Bronchitis AECB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004167-56,0,0,0 2006-004169-33,8,2008-11-14,2008-11-14,6,1,0,0,1,0,3,0,0,1,1,0,1,0,1,"Schering-Plough Research Institute, a division of Schering Corporation",A 52-Week Efficacy and Safety Non-Inferiority Study of Fluticasone Propionate/Salmeterol 250/50 mcg BID Delivered by Dry Powder Inhaler (DISKUS®) Versus Mometasone Furoate/Formoterol Fumarate 200/10 m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004169-33,0,0,0 2006-004172-12,10,2009-06-26,2009-07-15,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 12-month randomized, double -masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin Visudyne photodynamic therapy administered in conjunction with Lucentis ve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004172-12,0,0,0 2006-004172-12,10,2009-06-26,2009-07-15,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 12-month randomized, double -masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin Visudyne photodynamic therapy administered in conjunction with Lucentis ve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004172-12,0,0,0 2006-004172-12,10,2009-06-26,2009-07-15,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A 12-month randomized, double -masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin Visudyne photodynamic therapy administered in conjunction with Lucentis ve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004172-12,0,0,0 2006-004172-12,10,2009-06-26,2009-07-15,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma,"A 12-month randomized, double -masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin Visudyne photodynamic therapy administered in conjunction with Lucentis ve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004172-12,0,0,0 2006-004176-13,1,2007-05-09,2007-05-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Speedel Pharma Ltd.,"A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Parallel-Design, Four-week Study to Investigate the Safety and Efficacy of Oral SPP635 450 mg Once Daily in Patients With Mild to Moderate Hy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004176-13,0,0,0 2006-004177-95,1,2006-11-29,2006-11-29,1,1,0,0,1,0,2,0,1,1,0,0,1,0,1,Novartis Pharma Services AG,"A single center, randomized, partially blind, placebo controlled, crossover, single oral dose study to assess the effect of concomitant antacid (calcium carbonate) on the pharmacokinetics and pharmaco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004177-95,0,0,0 2006-004187-32,1,2007-09-07,2007-09-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Avontec GmbH,"Efficacy and safety of AVT-01 5 mg once daily over 7 days in patients with moderate persistent atopic asthma – A double-blind, randomized, placebo-controlled clinical study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004187-32,0,0,0 2006-004189-14,5,2011-04-01,2011-04-01,4,1,0,0,0,0,2,0,0,1,0,0,1,0,0,EORTC,Randomized phase II feasibility study of Cetuximab combined with 4 cycles of TPF followed by platinum based chemo-radiation strategies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004189-14,0,0,0 2006-004189-14,5,2011-04-01,2011-04-01,4,1,0,0,0,0,2,0,0,1,0,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Randomized phase II feasibility study of Cetuximab combined with 4 cycles of TPF followed by platinum based chemo-radiation strategies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004189-14,0,0,0 2006-004190-94,1,2007-11-25,2007-11-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Avontec GmbH,"Efficacy and safety of AVT-01 10 mg once daily over 7 days in patients with moderate persistent atopic asthma – A double-blind, randomized, placebo-controlled clinical study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004190-94,0,0,0 2006-004191-13,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Avontec GmbH,"Efficacy and safety of AVT-01 10 mg single dose in patients with mild asthma challenged with inhaled tumor necrosis factor alpha – A double-blind, randomized, placebo-controlled clinical study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004191-13,0,0,0 2006-004193-27,1,2008-11-21,2008-11-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Neurim Pharmaceuticals (1991) Ltd,"A Double Blind, Parallel Group, Randomised, Placebo Controlled Study of Efficacy and Safety of CIRCADIN 2mg in the Treatment of Insomnia Patients with Low Endogenous Melatonin.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004193-27,0,0,0 2006-004194-10,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Institut de Recherches Internationales Servier,"Long-term effects of strontium ranelate on knee osteoarthritis symptoms. A 2-year prospective, randomised, placebo-controlled study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004194-10,0,0,0 2006-004199-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Center,"NOSTRADAMUS: Testing for thrombophilia in patients with a first episode of venous thromboembolism: a randomized controlled trial to assess effects on clinical outcomes, quality of life, and costs.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004199-11,0,0,0 2006-004201-26,1,2010-08-13,2010-08-13,1,0,0,0,0,0,4,0,0,1,1,1,1,0,1,Neuro-Consil GmbH,Efficacy and tolerability of flexible dose adjusted pregabalin as first-line add-on treatment of patients with focal seizures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004201-26,0,0,0 2006-004203-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,AIR LIQUIDE Santé INTERNATIONAL,Etude de l'efficacité du Kalinox 170 bar lors de la réalisation de biopsies de lésions focales hépatiques,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004203-19,0,0,0 2006-004204-39,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,GLAXO SMITHKLINE,"A randomized, open label, multicentre study to compare the pharmaco-economic implications of an analgesia based regimen with remifentanil and a conventional sedation based regimen using propofol in me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004204-39,0,0,0 2006-004205-26,1,2011-01-25,2011-01-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,OSPEDALE MAGGIORE DI MILANO IRCCS,A Randomised controlled tiral to evaluate the efficacy of low molecular-weight heparin on pregnancy outcome of women with previus pregnancy complication,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004205-26,0,0,0 2006-004212-48,1,2008-01-10,2008-01-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"Estudio doble ciego, aleatorizado, controlado con placebo y alprazolam, de diseño cruzado con tres periodos y bloques incompletos, para comparar mediante Resonancia Magnética Funcional, las posibles ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004212-48,0,0,0 2006-004214-41,6,2011-10-05,2011-10-05,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,LIGHT SCIENCES ONCOLOGY,A MULTICENTER MULTINATIONAL PHASE 3 RANDOMIZED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TREATING COLORECTAL CANCER PATIENTS WITH RECURRENT LIVER METASTASES USING THE LITX™ SYSTEM PLUS CHEMOTHER...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004214-41,0,0,0 2006-004214-41,6,2011-10-05,2011-10-05,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Light Science Oncology Inc.,A MULTICENTER MULTINATIONAL PHASE 3 RANDOMIZED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TREATING COLORECTAL CANCER PATIENTS WITH RECURRENT LIVER METASTASES USING THE LITX™ SYSTEM PLUS CHEMOTHER...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004214-41,0,0,0 2006-004214-41,6,2011-10-05,2011-10-05,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Light Sciences Oncology Inc.,A MULTICENTER MULTINATIONAL PHASE 3 RANDOMIZED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TREATING COLORECTAL CANCER PATIENTS WITH RECURRENT LIVER METASTASES USING THE LITX™ SYSTEM PLUS CHEMOTHER...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004214-41,0,0,0 2006-004215-21,2,2007-10-05,2007-10-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Galderma Research & Development Inc.,"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO DEMONSTRATE THE EFFICACY AND SAFETY OF ADAPALENE/BENZOYL PEROXIDE TOPICAL GEL COMPARED WITH ADAPALENE TOPICAL GEL, 0.1%; BENZOYL PEROX...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004215-21,0,0,0 2006-004217-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,The Impact of glutamine suppletion on outcome in patients undergoing high-risk cardiothoracic surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004217-18,0,0,0 2006-004218-42,1,2015-07-09,2015-07-09,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Essai thérapeutique de phase IIA évaluant l'efficacité du Bortezomib (velcade) chez les patients atteints de la maladie de Waldenstrom en phase avancée,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004218-42,0,0,0 2006-004222-93,1,2007-04-24,2007-04-24,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Curalogic A/S,"Assessment of the Maximal Tolerated Dose of a Microencapsulated Grass (Phleum pratense) Pollen Extract (MGPE) in Subjects with Grass Pollen Allergy in a Randomized, Double-Blind, Placebo-Controlled St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004222-93,0,0,0 2006-004224-37,1,2009-11-05,2009-11-05,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Universität Leipzig,Everolimus in der Therapie von Patienten mit pulmonaler Hypertonie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004224-37,0,0,0 2006-004226-82,1,2008-02-18,2008-02-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals of Leicester NHS Trust,PHARMACODYNAMIC STUDY OF ORAL MIRTOSELECT IN PATIENTS WITH SUSPECTED COLORECTAL DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004226-82,0,0,0 2006-004230-32,4,2008-12-02,2008-12-02,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,CHIESI Farmaceutici S.p.A.,"EFFICACY AND SAFETY OF BECLOMETHASONE DIPROPIONATE GASTRO-RESISTANT, PROLONGED RELEASE TABLETS (CHF 1514) COMPARED WITH ORAL PREDNISONE, IN A 8-WEEK TREATMENT PERIOD, IN PATIENTS WITH ACTIVE ULCERATIV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004230-32,0,0,0 2006-004230-32,4,2008-12-02,2008-12-02,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,CHIESI,"EFFICACY AND SAFETY OF BECLOMETHASONE DIPROPIONATE GASTRO-RESISTANT, PROLONGED RELEASE TABLETS (CHF 1514) COMPARED WITH ORAL PREDNISONE, IN A 8-WEEK TREATMENT PERIOD, IN PATIENTS WITH ACTIVE ULCERATIV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004230-32,0,0,0 2006-004230-32,4,2008-12-02,2008-12-02,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Chiesi Farmaceutici SpA,"EFFICACY AND SAFETY OF BECLOMETHASONE DIPROPIONATE GASTRO-RESISTANT, PROLONGED RELEASE TABLETS (CHF 1514) COMPARED WITH ORAL PREDNISONE, IN A 8-WEEK TREATMENT PERIOD, IN PATIENTS WITH ACTIVE ULCERATIV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004230-32,0,0,0 2006-004233-15,1,2009-05-19,2009-05-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,InfectoPharm Arzneimittel und Consilium GmbH,"Multicentric, randomized, double-blinded, vehicle-controlled, phase III-bilateral comparative study for treatment of staphylococcus superinfection in atopic dermatitis with hydrophobic Triclosan-cream...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004233-15,0,0,0 2006-004234-33,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Intensive chemo-immunotherapy as first-line treatment in adult patients with peripheral T-cell Lymphoma PTCL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004234-33,0,0,0 2006-004236-70,1,2007-12-03,2007-12-03,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIb, open, randomized, controlled primary vaccination study to evaluate the non-inferiority and the persistence of the immune response of GSK Biologicals’ meningococcal serogroup ACWY conjugat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004236-70,0,0,0 2006-004237-15,1,2008-09-01,2008-09-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galderma Research and Development,Comparison of Metvix® PDT with its vehicle in the treatment of photoaged skin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004237-15,0,0,0 2006-004245-42,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,University Hospitals of Leicester NHS Trust,PHARMACODYNAMIC STUDY OF ORAL MIRTOSELECT IN PATIENTS WITH SUSPECTED HEPATIC DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004245-42,0,0,0 2006-004247-29,1,2009-06-23,2009-06-23,1,1,0,0,1,1,2,0,0,1,0,0,1,0,1,Genzyme Europe BV,"A Multicenter, Randomized, Comparative, Patient-blinded Study to Evaluate the Safety and Efficacy of G-CSF Alone Versus AMD3100 (240 µg/kg) Added to a G-CSF Mobilization Regimen in Adult Patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004247-29,0,0,0 2006-004252-20,2,2014-10-31,2014-10-31,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Medizinische Universität Innsbruck - Univ.-Klinik f. Anästhesie u. Intensivmedizin,"A Multicenter, Randomized, Controlled Trial Assessing Arginine Vasopressin vs. Saline Placebo in Refractory Traumatic Hemorrhagic Shock Patients (VITRIS.at-Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004252-20,0,0,0 2006-004252-20,2,2014-10-31,2014-10-31,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Medizinische Universität Innsbruck - Univ.-Klinik für Anästhesie und Allgemeine Intensivmedizin,"A Multicenter, Randomized, Controlled Trial Assessing Arginine Vasopressin vs. Saline Placebo in Refractory Traumatic Hemorrhagic Shock Patients (VITRIS.at-Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004252-20,0,0,0 2006-004255-38,3,2010-03-24,2010-03-24,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bionorica research GmbH,"Multi-centre, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of the pain relieving effect of Dronabinol in patients with multiple sclerosis associated with c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004255-38,0,0,0 2006-004257-14,4,2007-10-02,2007-10-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo and Zolmitriptan for the Acute Treatment of Migraine Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004257-14,0,0,0 2006-004257-14,4,2007-10-02,2007-10-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (MSD),"A Multicenter, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo and Zolmitriptan for the Acute Treatment of Migraine Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004257-14,0,0,0 2006-004257-14,4,2007-10-02,2007-10-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Limited,"A Multicenter, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo and Zolmitriptan for the Acute Treatment of Migraine Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004257-14,0,0,0 2006-004257-14,4,2007-10-02,2007-10-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Multicenter, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo and Zolmitriptan for the Acute Treatment of Migraine Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004257-14,0,0,0 2006-004259-40,5,2009-01-22,2009-01-23,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine With or Without Aura",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004259-40,0,0,0 2006-004259-40,5,2009-01-22,2009-01-23,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratoires Merck Sharp & Dohme - Chibret,"A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine With or Without Aura",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004259-40,0,0,0 2006-004259-40,5,2009-01-22,2009-01-23,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine With or Without Aura",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004259-40,0,0,0 2006-004259-40,5,2009-01-22,2009-01-23,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme GmbH,"A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine With or Without Aura",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004259-40,0,0,0 2006-004259-40,5,2009-01-22,2009-01-23,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co Inc.,","A Multicenter, Double-Blind, Active-Controlled, Parallel Group Study to Examine the Safety, Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine With or Without Aura",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004259-40,0,0,0 2006-004260-31,1,2010-07-29,2010-07-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,UHL NHS Trust,An open label study of humira (adalimumab)in the treatment of patients with severe psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004260-31,0,0,0 2006-004264-31,2,2008-01-07,2008-01-14,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Ardana Bioscience Ltd,"A Phase II multi-centre, open-label study investigating the efficacy and safety of a new GnRH antagonist, Teverelix, long-acting formulation in patients with advanced prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004264-31,0,0,0 2006-004265-34,5,2020-03-04,2020-03-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004265-34,0,0,0 2006-004273-10,4,2007-11-20,2008-11-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Wyeth research Division of Wyeth Pharmaceuticals Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Intravenous (IV) Methylnaltrexone (MOA-728) for the Treatment of Post Operative Ileus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004273-10,0,0,0 2006-004273-10,4,2007-11-20,2008-11-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Intravenous (IV) Methylnaltrexone (MOA-728) for the Treatment of Post Operative Ileus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004273-10,0,0,0 2006-004275-35,2,2008-09-15,2008-10-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A randomized, double-blind, placebo-controlled, parallel group trial of HMR1766 assessing the efficacy and safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus placebo with cilostazol, 100 mg BID ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004275-35,0,0,0 2006-004278-28,4,2007-08-24,2007-10-16,3,1,0,0,1,0,3,0,0,1,0,0,1,0,1,GALDERMA R & D SNC,Efficacy and Safety of a Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Compared to Clindamycin 1% / Benzoyl Peroxide 5% Gel in the Treatment of Acne Vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004278-28,0,0,0 2006-004278-28,4,2007-08-24,2007-10-16,3,1,0,0,1,0,3,0,0,1,0,0,1,0,1,GALDERMA Research & Development,Efficacy and Safety of a Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Compared to Clindamycin 1% / Benzoyl Peroxide 5% Gel in the Treatment of Acne Vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004278-28,0,0,0 2006-004282-34,1,2010-09-01,2010-09-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Marsden NHS Foundation Trust,A phase II study of bethanechol chloride to treat pseudomembranous candidosis in cancer patients with salivary gland dysfunction.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004282-34,0,0,0 2006-004285-13,1,2008-05-08,2008-05-08,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Marinus Pharmaceuticals, Inc.","A double-blind, placebo-controlled, dose-ranging clinical study to evaluate the safety, tolerability, and antiepileptic activity of ganaxolone in treatment of patients with infantile spasms.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004285-13,0,0,0 2006-004286-33,2,2009-02-26,2009-02-26,1,1,0,0,0,1,2,0,0,2,0,0,0,0,1,"Marinus Pharmceuticals, Inc.",An open-label clinical study to evaluate the safety and antiepileptic activity of ganaxolaone in treatment of patients diagnosed with infantile spansms.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004286-33,1,0,0 2006-004290-97,1,2010-08-25,2010-08-25,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy","A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004290-97,0,0,0 2006-004291-12,7,2009-12-11,2009-12-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Optimer Pharmaceuticals, Inc.","'' A multi-national, multi-centre, double-blind,randomised, parallel group study to compare the safety and efficacy of 200mg PAR-101 taken q12h with 125mg Vancomycin taken q6h for ten days in subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004291-12,0,0,0 2006-004291-12,7,2009-12-11,2009-12-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Optimer Pharmaceuticals Inc.,"'' A multi-national, multi-centre, double-blind,randomised, parallel group study to compare the safety and efficacy of 200mg PAR-101 taken q12h with 125mg Vancomycin taken q6h for ten days in subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004291-12,0,0,0 2006-004291-12,7,2009-12-11,2009-12-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,OPTIMER PHARMACEUTICALS INC,"'' A multi-national, multi-centre, double-blind,randomised, parallel group study to compare the safety and efficacy of 200mg PAR-101 taken q12h with 125mg Vancomycin taken q6h for ten days in subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004291-12,0,0,0 2006-004291-12,7,2009-12-11,2009-12-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Par Pharmaceutical, Inc.","'' A multi-national, multi-centre, double-blind,randomised, parallel group study to compare the safety and efficacy of 200mg PAR-101 taken q12h with 125mg Vancomycin taken q6h for ten days in subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004291-12,0,0,0 2006-004292-35,1,2008-09-04,2008-09-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Kings College Hospital NHS Foundation Trust,A pillot study to examine the safety and efficacy of intravitreal ranubizimab/dexamethasone administration and oral minocycline in addition to Visudyne (verteporfin) photdynamic therapy for subfoveal ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004292-35,0,0,0 2006-004294-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IMAS,Efecto del ácido zoledrónico en la prevención de la pérdida ósea periprotésica precoz tras artroplastia total de cadera.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004294-10,0,0,0 2006-004296-35,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,"The Royal Group of Hospitals, Belfast Health and Social Care Trust","An investigation into the modulation of obesity associated monocyte/macrophage function, vascular inflammation and insulin resistance by PPAR agonist treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004296-35,0,0,0 2006-004296-35,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Queen's University Belfast,"An investigation into the modulation of obesity associated monocyte/macrophage function, vascular inflammation and insulin resistance by PPAR agonist treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004296-35,0,0,0 2006-004302-74,1,2009-12-17,2009-12-17,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Health Protection Agency,"A Phase IV, single group study to evaluate the immunogenicity and safety in UK laboratory workers of a licensed Hib and meningococcal C conjugate combined vaccine (Menitorix)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004302-74,0,0,0 2006-004303-19,4,2008-08-25,2008-08-25,3,0,0,0,0,0,2,0,0,1,1,0,1,0,1,"Cerimon Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004303-19,0,0,0 2006-004304-39,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Pfizer Pharma GmbH,"NEUROMUSCULAR CHANGES IN SMALL FOR GESTATIONAL AGE (SGA-) CHILDREN DURING SOMATROPIN THERAPY - A PROSPECTIVE, RANDOMIZED, CONTROLLED, OPEN-LABEL, MULTICENTER TRIAL (SGA-POWER STUDY)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004304-39,0,0,0 2006-004305-25,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Maastricht University,Residual effects of zopiclone 7.5 mg and temazepam 20 mg on cognition and actual driving performance in healthy elderly,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004305-25,0,0,0 2006-004306-50,12,2010-06-30,2010-06-30,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004306-50,0,0,0 2006-004306-50,12,2010-06-30,2010-06-30,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"PFIZER, S.A.","A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004306-50,0,0,0 2006-004306-50,12,2010-06-30,2010-06-30,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"A MULTI-CENTER, OPEN LABEL, EXPANDED ACCESS TRIAL OF MARAVIROC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004306-50,0,0,0 2006-004309-24,5,2009-11-23,2009-11-23,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Pfizer Inc. 232 East 42nd Street-New York-10017-USA,"A PHASE IIIB, RANDOMIZED, ACTIVE CONTROLLED OPEN-LABEL STUDY OF SUNITINIB (SUTENT) 37.5 MG DAILY VS IMATINIB MESYLATE 800 MG DAILY IN THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004309-24,0,0,0 2006-004309-24,5,2009-11-23,2009-11-23,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE IIIB, RANDOMIZED, ACTIVE CONTROLLED OPEN-LABEL STUDY OF SUNITINIB (SUTENT) 37.5 MG DAILY VS IMATINIB MESYLATE 800 MG DAILY IN THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004309-24,0,0,0 2006-004309-24,5,2009-11-23,2009-11-23,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A PHASE IIIB, RANDOMIZED, ACTIVE CONTROLLED OPEN-LABEL STUDY OF SUNITINIB (SUTENT) 37.5 MG DAILY VS IMATINIB MESYLATE 800 MG DAILY IN THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004309-24,0,0,0 2006-004309-24,5,2009-11-23,2009-11-23,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,PFIZER,"A PHASE IIIB, RANDOMIZED, ACTIVE CONTROLLED OPEN-LABEL STUDY OF SUNITINIB (SUTENT) 37.5 MG DAILY VS IMATINIB MESYLATE 800 MG DAILY IN THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004309-24,0,0,0 2006-004309-24,5,2009-11-23,2009-11-23,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Pfizer Inc., East 42nd Street, New York, NY 10017","A PHASE IIIB, RANDOMIZED, ACTIVE CONTROLLED OPEN-LABEL STUDY OF SUNITINIB (SUTENT) 37.5 MG DAILY VS IMATINIB MESYLATE 800 MG DAILY IN THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004309-24,0,0,0 2006-004317-18,1,,,0,1,0,0,1,0,4,0,0,1,1,1,0,1,0,"Dept of Anaesthesia, University College Hospital, Galway",Comparison of continuous Lumbar Epidural (LEP) and Transversus Abdominis Plane (TAP) Blockade in the management of postoperative pain post abdominal surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004317-18,0,0,0 2006-004318-42,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Department of Neurology UMCG,Influence on brain perfusion and metabolism through pharmacologic agents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004318-42,0,0,0 2006-004320-36,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA SENESE,Intravitreal Bevacizumab (Avastin) for neovascular age-related macular degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004320-36,0,0,0 2006-004323-10,1,2010-09-19,2010-09-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Technische Universität Dresden,"Effektivität und Verträglichkeit von Esomeprazol, Moxifloxacin und Amoxicillin in der Reservetherapie der Helicobacter pylori Infektion.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004323-10,0,0,0 2006-004327-11,1,2014-01-24,2014-01-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cardiff University,A randomised phase II multi-centre trial of topical treatment in women with vulval intraepithelial neoplasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004327-11,0,0,0 2006-004328-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ARCAGY,Etude de phase II de l'association CISPLATINE TOPOTECAN et CETUXIMAB chez les patientes atteintes d'un cancer épithelial du col de l'uterus avancé ou en rechute.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004328-35,0,0,0 2006-004332-79,1,2018-09-12,2018-09-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ARCAGY,"""Essai multicentrique de phase II randomisé évaluant la tolérance et l'efficacité du tamoxifène seul versus association Tamoxifène-RAD001 (Everolimus), chez les patientes atteintes de cancer du sein m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004332-79,0,0,0 2006-004335-29,1,2010-04-26,2010-04-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Newcastle Upon Tyne Hospitals NHS Foundation Trust,A randomised controlled factorial pilot study investigating Omacor and/or Fluvastatin in patients with chronic hepatitis C who have not responded to standard combination anti-viral therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004335-29,0,0,0 2006-004345-42,2,2012-10-29,2012-10-29,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,TopoTarget A/S,A Phase I/II Clinical Trial of PXD101 in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004345-42,0,0,0 2006-004345-42,2,2012-10-29,2012-10-29,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Topotarget A/S,A Phase I/II Clinical Trial of PXD101 in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004345-42,0,0,0 2006-004346-17,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Mediquest Therapeutics Inc,"Phase IIB Dose Response and Safety Study of Topical Formulations of Methotrexate (MQX-5902, MQX-5904 and MQX-5906) in the Treatment of Fingernail Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004346-17,0,0,0 2006-004349-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Universitätsklinikum Mannheim, Klinik für Anästhesiologie",Supportive Schmerztherapie-Studie - Einfluss von Physostigmin auf die patientenkontrollierte Analgesie (PCA) in der postoperativen Phase bei Intensivpatienten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004349-41,0,0,0 2006-004350-25,2,2010-05-20,2010-05-27,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Fresenius Kabi Deutschland GmbH,Crystalloids or colloids in patients with severe sepsis: effects on hemodynamics and tolerability of enteral nutrition,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004350-25,0,0,0 2006-004354-24,1,2006-12-08,2006-12-08,1,1,0,0,1,0,4,0,1,1,1,1,1,0,1,CSL Limited,"A Phase IV, Randomised, Observer-Blind,Comparator-Controlled, Single-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL Influenza Vaccine (Enzira) (2006/2007) in Healthy Older...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004354-24,0,0,0 2006-004355-38,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,ASSOCIAZIONE S.N.O.- SCIENZE NEUROLOGICHE OSPEDALIERE,"Multicenter, comparative, randomized, open trial to evaluate efficacy and safety of Levetiracetam versus Carbamazepine in post stroke late onset crisis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004355-38,0,0,0 2006-004366-14,2,2008-10-02,2008-10-02,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Merck & Co., Inc.",Full title of the trial A Study to Assess the Efficacy and Tolerability of MK-0364 in Maintaining Weight Loss Induced by Diet in Obese Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004366-14,0,0,0 2006-004366-14,2,2008-10-02,2008-10-02,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Merck Sharp & Dohme (Sweden) AB,Full title of the trial A Study to Assess the Efficacy and Tolerability of MK-0364 in Maintaining Weight Loss Induced by Diet in Obese Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004366-14,0,0,0 2006-004367-57,1,2013-09-10,2013-09-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Ophthalmology, Medical University of Graz",Treatment of retinal angiomatous proliferation lesions due to age-related macular degeneration with ranibizumab (Lucentis®) and photodynamic therapy with verteporfin (Visudyne®),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004367-57,0,0,0 2006-004373-10,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Top institute of Pharmaceutical Research,"The effect of short term Topiramate treatment on insulin secretion, glucose- and lipid metabolism in obese women",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004373-10,0,0,0 2006-004374-27,1,2010-02-17,2010-02-17,1,1,0,0,0,1,4,0,0,1,1,1,1,0,0,Philipps-University,"Prospective, randomized, doubleblind, placebo-controlled trial on changes in acetylcholine receptor antibody titres in autoimmune myasthenia gravis after influenza vaccination (ProPATIent)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004374-27,0,0,0 2006-004377-99,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,Medizinische Einrichtungen des Bezirks Oberpfalz GmbH,Phase I study of Somatostatin-Analogues as Second Line Treatment in Adult Patients with Recurrent Medulloblastoma (WHO IV),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004377-99,0,0,0 2006-004378-28,9,2008-04-16,2008-06-04,8,1,0,0,2,0,2,0,0,1,0,0,1,0,1,Pfizer Ltd,"A MULTI-CENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO CONTROLLED PROOF OF CONCEPT AND DOSE RANGING STUDY WITH AN ACTIVE CONTROL TO ASSESS THE EFFICACY AND SAFETY/TOLERABILITY OF UK-369,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004378-28,0,0,0 2006-004378-28,9,2008-04-16,2008-06-04,8,1,0,0,2,0,2,0,0,1,0,0,1,0,1,PFIZER,"A MULTI-CENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO CONTROLLED PROOF OF CONCEPT AND DOSE RANGING STUDY WITH AN ACTIVE CONTROL TO ASSESS THE EFFICACY AND SAFETY/TOLERABILITY OF UK-369,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004378-28,0,0,0 2006-004380-58,3,2008-06-13,2008-06-13,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent. UK. CT13 9NJ","A MULTI-CENTER, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, THIRD PARTY OPEN, PLACEBO CONTROLLED, PILOT STUDY TO ASSESS THE URODYNAMIC EFFECTS OF MODIFIED RELEASE UK-369,003 IN MEN WITH LOWER URINARY TRACT ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004380-58,0,0,0 2006-004380-58,3,2008-06-13,2008-06-13,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Limited,"A MULTI-CENTER, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, THIRD PARTY OPEN, PLACEBO CONTROLLED, PILOT STUDY TO ASSESS THE URODYNAMIC EFFECTS OF MODIFIED RELEASE UK-369,003 IN MEN WITH LOWER URINARY TRACT ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004380-58,0,0,0 2006-004389-15,1,2011-04-04,2011-04-04,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,"The use of Single dose intravenous paracetamol ""Perfalgan"" in Early extubation cardiac surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004389-15,0,0,0 2006-004396-35,1,2010-11-10,2010-11-10,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Belfast City Hospital Trust,Investigation of the anti-inflammatory effects of simvastatin in a model of acute lung injury after inhalation of lipopolysaccharide by healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004396-35,0,0,0 2006-004397-27,1,2009-04-22,2009-04-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer Schering Pharma AG,"Multi-center, double-blind, placebo-controlled study to investigate the efficacy and safety of daily oral 100 mg dehydroepiandrosterone (DHEA) over 6 treatment cycles as a concomitant therapy to oral ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004397-27,0,0,0 2006-004398-89,4,2008-08-25,2008-08-28,2,1,0,0,1,0,3,0,0,1,1,0,1,0,1,Medinova AG,Comparative Study of the Efficacy of 10 mg Dequalinium Chloride (Fluomizin®) in the Local Treatment of Bacterial Vaginosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004398-89,0,0,0 2006-004399-11,3,2009-05-13,2009-05-13,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Medinova AG,The Efficacy of 10 mg Dequalinium Chloride (Fluomizin®) in the Local Treatment of Aerobic Bacterial Vaginal Infections in Comparison to Placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004399-11,0,0,0 2006-004407-19,4,2007-09-04,2007-09-06,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A multi-center, double-blind, randomized, placebo controlled, dose-ranging phase 2 study to investigate pharmacodynamics, safety, tolerability and pharmacokinetics of RO5073031 in patients with type 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004407-19,0,0,0 2006-004411-21,1,2009-08-05,2009-08-05,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Organisation name was not entered,The effect of aldosterone inhibition on proteinuria in patients with progressive renal disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004411-21,0,0,0 2006-004415-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska University Hospital,Utvärdering av två oloika strategier att smärtbehandla patienter som genomgår ablationsbehandling mot hjärtrytmrubbningar i hjärtat,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004415-22,0,0,0 2006-004419-24,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Southampton University Hospitals Trust (R&D),The Use of Sulfasalazine as an Anti-fibrotic in Acute Alcoholic Hepatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004419-24,0,0,0 2006-004420-37,3,2009-05-27,2011-01-04,3,0,0,0,0,1,3,0,0,1,0,0,1,0,1,"Osiris Therapeutics, Inc.","A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004420-37,0,0,0 2006-004420-37,3,2009-05-27,2011-01-04,3,0,0,0,0,1,3,0,0,1,0,0,1,0,1,OSIRIS,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004420-37,0,0,0 2006-004421-28,6,2008-08-12,2008-08-29,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Inc,"A SIX MONTH, OPEN-LABEL OUTPATIENT, RANDOMIZED PARALLEL GROUP TRIAL ASSESSING THE IMPACT OF DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL COMPARED TO INSULIN GLARGINE (LANTUS®) IN PATIENTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004421-28,0,0,0 2006-004421-28,6,2008-08-12,2008-08-29,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Pharma GmbH,"A SIX MONTH, OPEN-LABEL OUTPATIENT, RANDOMIZED PARALLEL GROUP TRIAL ASSESSING THE IMPACT OF DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL COMPARED TO INSULIN GLARGINE (LANTUS®) IN PATIENTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004421-28,0,0,0 2006-004421-28,6,2008-08-12,2008-08-29,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Oy,"A SIX MONTH, OPEN-LABEL OUTPATIENT, RANDOMIZED PARALLEL GROUP TRIAL ASSESSING THE IMPACT OF DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL COMPARED TO INSULIN GLARGINE (LANTUS®) IN PATIENTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004421-28,0,0,0 2006-004421-28,6,2008-08-12,2008-08-29,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer N.V./S.A.,"A SIX MONTH, OPEN-LABEL OUTPATIENT, RANDOMIZED PARALLEL GROUP TRIAL ASSESSING THE IMPACT OF DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL COMPARED TO INSULIN GLARGINE (LANTUS®) IN PATIENTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004421-28,0,0,0 2006-004421-28,6,2008-08-12,2008-08-29,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,,"A SIX MONTH, OPEN-LABEL OUTPATIENT, RANDOMIZED PARALLEL GROUP TRIAL ASSESSING THE IMPACT OF DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL COMPARED TO INSULIN GLARGINE (LANTUS®) IN PATIENTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004421-28,0,0,0 2006-004423-11,4,2009-04-02,2009-06-12,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,BOEHRINGER ING.,"An uncontrolled, open-label, titration, long-term safety up to 12 months and efficacy study of tamsulosin hydrochloride in children with neuropathic bladder, with a randomized pharmacokinetic sub-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004423-11,0,0,0 2006-004423-11,4,2009-04-02,2009-06-12,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An uncontrolled, open-label, titration, long-term safety up to 12 months and efficacy study of tamsulosin hydrochloride in children with neuropathic bladder, with a randomized pharmacokinetic sub-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004423-11,0,0,0 2006-004423-11,4,2009-04-02,2009-06-12,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Boehringer Ingelheim España, S.A.","An uncontrolled, open-label, titration, long-term safety up to 12 months and efficacy study of tamsulosin hydrochloride in children with neuropathic bladder, with a randomized pharmacokinetic sub-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004423-11,0,0,0 2006-004423-11,4,2009-04-02,2009-06-12,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"An uncontrolled, open-label, titration, long-term safety up to 12 months and efficacy study of tamsulosin hydrochloride in children with neuropathic bladder, with a randomized pharmacokinetic sub-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004423-11,0,0,0 2006-004427-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Univ of Lund, Dept of Pediatrics",Effects of Omega-3-Fatty Acids on Arterial Endothelial Function and Intima Media Thickness in Children with Insulin-Dependent Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004427-11,0,0,0 2006-004429-27,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO CLINICO HUMANITAS,Phase II study of the combination of bevacizumab plus pemetrexed and carboplatin as first-line therapy in patients with malignant pleural mesothelioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004429-27,0,0,0 2006-004432-70,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,"A multicenter phase II study to evaluate the safety, tolerability and efficacy of caspofungin as prophylactic treatment of invasive fungal infections in patients with acute leukemia undergoing induct...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004432-70,0,0,0 2006-004434-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Technische Universität München, Fakultät für Medizin, Klinikum rechts der Isar",Prevention of postoperative delirium with donepezil,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004434-32,0,0,0 2006-004435-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE SANTA LUCIA,"Protocol of study for the evaluation of the efficacy of rivastigmine on cognitive and behavioural disorders, following traumatic brain injury TBI in chronic patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004435-30,0,0,0 2006-004437-15,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO CLINICO HUMANITAS,"FASE II PROSPECTIVE STUDY BAY-43-90006 IN ADVANCED, METASTATIC SOFT TISSUE SARCOMAS, AFTER ANTRACYCLINE-BASED THERAPY FASE II PROSPECTIVE STUDY BAY-43-90006 IN ADVANCED, METASTATIC SOFT TISSUE SARC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004437-15,0,0,0 2006-004441-42,1,2009-12-31,2009-12-31,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Southport and Ormskirk Hospital NHS Trust,A study to evaluate the role of tacrolimus ointment (Protopic®) 0.1% in the treatment of chronic otitis externa.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004441-42,0,0,0 2006-004442-16,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Imperial College London,Modulation of lung injury complicating lung resection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004442-16,0,0,0 2006-004445-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut for Pharmacology and Toxicology,Pharmacokinetics of Cetriaxon in bone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004445-42,0,0,0 2006-004447-35,1,2008-04-01,2008-04-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Hull and East Yorkshire Hospital Trust,"Biological Variation of Insulin Resistance, Testosterone and Cardiovascular Risk Factors In Women with Polycystic Ovarian Syndrome: modification with Rimonabant compared to Metformin.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004447-35,0,0,0 2006-004449-40,14,2008-09-19,2008-10-22,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with As...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004449-40,0,0,0 2006-004449-40,14,2008-09-19,2008-10-22,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BAYER,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with As...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004449-40,0,0,0 2006-004451-38,3,2009-02-10,2009-12-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc. - 235 East 42nd Street - New York - 10017,A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND BRAIN METASTASES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004451-38,0,0,0 2006-004451-38,3,2009-02-10,2009-12-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND BRAIN METASTASES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004451-38,0,0,0 2006-004451-38,3,2009-02-10,2009-12-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.L.U.",A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND BRAIN METASTASES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004451-38,0,0,0 2006-004452-20,1,2011-05-26,2011-05-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,King's College Hospital NHS Foundation Trust,"Pilot study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients with Poor Risk Myelodysplastic Syndrome and Acute Myeloid Leukaemia utilising conditioning with Fludarabine, Busul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004452-20,0,0,0 2006-004453-18,5,2009-08-03,2009-08-03,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals France, Wyeth Research Division","A Randomised, Open-Label Preliminary Study To Assess The Effects Of Etanercept 50 mg Once Weekly For 24 Weeks And Etanercept 50 mg Twice Weekly For 12 weeks Reducing To Etanercept 50 mg Once Weekly Fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004453-18,0,0,0 2006-004453-18,5,2009-08-03,2009-08-03,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Wyeth Pharmaceuticals France,"A Randomised, Open-Label Preliminary Study To Assess The Effects Of Etanercept 50 mg Once Weekly For 24 Weeks And Etanercept 50 mg Twice Weekly For 12 weeks Reducing To Etanercept 50 mg Once Weekly Fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004453-18,0,0,0 2006-004454-25,5,2009-11-06,2009-11-24,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals France,"'A multicenter double-blind, placebo-controlled randomized pilot study evaluating efficacy and safety of ETN in patients with moderate to severe plaque psoriasis after cessation of ciclosporin therapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004454-25,0,0,0 2006-004455-37,1,2009-05-13,2009-05-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Pharma GmbH,Effects of a Pioglitazone/ Metformin Fixed Combination in Comparison to Metformin in Combination with Glimepiride on Diabetic Dyslipidemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004455-37,0,0,0 2006-004457-20,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation de l'action neuroréparatrice fonctionnelle et morphologique du traitement antidepresseur au cours de la rémission clinique dans la dépression recurrente.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004457-20,0,0,0 2006-004458-26,7,2007-06-05,2007-06-15,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer Healthcare LLC,"Randomized, comparative, open label treatment with double-blind placebo-controlled periods within treatment study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004458-26,0,0,0 2006-004460-31,1,2015-05-11,2015-05-11,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Guy's & St Thomas' NHS Foundation Trust,A randomised controlled trial comparing the gonadotrophin releasing hormone (GnRH) agonist long regimen versus the GnRH agonist short regimen versus the GnRH antagonist regimen in poor responders unde...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004460-31,0,0,0 2006-004461-34,1,2013-09-17,2013-09-17,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Nottingham,Open label randomised trial of nicotine replacement therapy and oral smokeless tobacco (snus) in smoking cessation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004461-34,0,0,0 2006-004464-31,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,Eija Kalso,Ahdistuksen vaikutukset neuropaattisessa kivussa ja pregabaliinin ahdistusta moduloiva vaikutus funktionaalisella magneettikuvauksella (fMRI) tutkittuna,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004464-31,0,0,0 2006-004465-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Eero Kaasinen,"Oral Celecoxib combined with BCG instillation therapy in treatment of carcinoma in situ (CIS), TaG3 and T1 disease of urinary bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004465-33,0,0,0 2006-004467-65,1,2010-10-28,2010-10-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Technical University Dresden,Influence of pioglitazone for renal transplant function in diabetics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004467-65,0,0,0 2006-004469-32,4,2010-02-25,2010-02-25,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Celgene Corporation,"A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF TWO LENALIDOMIDE DOSE REGIMENS IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004469-32,0,0,0 2006-004469-32,4,2010-02-25,2010-02-25,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,CELGENE CORPORATION,"A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF TWO LENALIDOMIDE DOSE REGIMENS IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004469-32,0,0,0 2006-004470-26,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,The Institute of Cancer Research,"Triple Negative breast cancer Trial. A randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced ER-, PR- and HER2- breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004470-26,0,0,0 2006-004470-26,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Kings College London,"Triple Negative breast cancer Trial. A randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced ER-, PR- and HER2- breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004470-26,0,0,0 2006-004476-12,4,2011-12-11,2011-12-11,2,0,0,0,0,0,3,0,0,2,0,0,0,0,0,University of New South Wales,A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004476-12,1,0,0 2006-004478-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST,DOCETAXEL AND PREDNISON IN ASSOCIATION WITH METRONOMIC THERAPY WITH CICLOPHOSPHAMIDE AND CELECOXIN IN HORMONE-REFRACTORY PROSTATIC CANCER PATIENTS : PHASE II CLINICAL TRIAL WITH PHARMACODYNAMIC AND PH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004478-29,0,0,0 2006-004481-13,8,2009-04-30,2009-04-30,7,1,0,0,0,0,2,0,2,1,0,0,1,0,1,Novo Nordisk A/S,"Efecto de liraglutida sobre el peso corporal en sujetos obesos sin diabetes Ensayo de 20 semanas de duración, aleatorizado, doble ciego, controlado con placebo, en seis grupos paralelos, multicéntrico...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004481-13,0,0,0 2006-004482-33,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,University Medical Center Utrecht,Investigating the acute effects of THC on functional brain systems,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004482-33,0,0,0 2006-004484-54,2,2008-08-08,2008-08-08,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Fresenius Biotech GmbH,"Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004484-54,0,0,0 2006-004485-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Aarhus University Hospital, Skejby sygehus",Metabolic Modulation as treatment of acute heart failure in patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004485-14,0,0,0 2006-004486-34,1,2009-07-29,2009-07-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company limited,An Open-Label Study of Oral Enzastaurin HCI in Patients with Advanced or Metastatic Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004486-34,0,0,0 2006-004489-15,1,2009-01-31,2009-01-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,MannKind Corporation,"Comparison of Technosphere®/Insulin, Insulin Lispro and Exubera® Effect on Endogenous Glucose Production After a Meal Challenge and During a Euglycemic Glucose Clamp Procedure in Subjects with Type 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004489-15,0,0,0 2006-004490-10,1,2008-05-31,2008-05-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Laboratoires Menarini France,"Etude de phase IV, randomisée en double insu, double placebo sur deux groupes parallèles : KETUM® 2.5% gel versus diclofénac 50 mg per os dans l’arthrose symptomatique de la main.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004490-10,0,0,0 2006-004494-96,13,2009-08-31,2009-09-17,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary emboli...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004494-96,0,0,0 2006-004494-96,13,2009-08-31,2009-09-17,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER,Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary emboli...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004494-96,0,0,0 2006-004495-13,18,2011-10-11,2011-12-01,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Healthcare AG,Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004495-13,0,0,0 2006-004495-13,18,2011-10-11,2011-12-01,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER,Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004495-13,0,0,0 2006-004500-40,5,2011-04-27,2011-04-27,4,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Celgene Corporation,"A PHASE II, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE-AGENT LENALIDOMIDE (REVLIMID®) IN SUBJECTS WITH RELAPSED OR REFRACTORY AGGRESSIVE NON-HODGKIN’S LYMP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004500-40,0,0,0 2006-004500-40,5,2011-04-27,2011-04-27,4,1,0,0,0,2,2,0,0,1,1,0,1,0,1,CELGENE EUROPE LIMITED,"A PHASE II, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE-AGENT LENALIDOMIDE (REVLIMID®) IN SUBJECTS WITH RELAPSED OR REFRACTORY AGGRESSIVE NON-HODGKIN’S LYMP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004500-40,0,0,0 2006-004501-25,2,2008-02-01,2008-05-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A double-blind, placebo controlled, randomized, two centre phase IIa pharmacodynamic cross-over study to assess the effect of AZD3355, 65 mg bid, on transient lower esophageal sphincter relaxations (T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004501-25,0,0,0 2006-004504-39,1,2012-12-20,2012-12-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Martin-Luther-Universität Halle-Wittenberg, vertreten durch den Kanzler","Multizentrische Phase II-Studie mit Docetaxel, Oxaliplatin und Capecitabin (TEX) bei Patienten mit inoperablem oder metastasiertem Magenkarzinom",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004504-39,0,0,0 2006-004507-18,13,2013-06-13,2013-06-13,9,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR and RAD001 10 mg/d or Sandostatin LAR and placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004507-18,0,0,0 2006-004507-18,13,2013-06-13,2013-06-13,9,1,0,0,0,2,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR and RAD001 10 mg/d or Sandostatin LAR and placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004507-18,0,0,0 2006-004507-18,13,2013-06-13,2013-06-13,9,1,0,0,0,2,3,0,0,1,1,0,1,0,1,"Novartis Farmaceutica, S.A","A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR and RAD001 10 mg/d or Sandostatin LAR and placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004507-18,0,0,0 2006-004508-37,6,2008-01-31,2008-07-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALTANA Pharma AG,"Effect of roflumilast in COPD patients treated with tiotropium. A 24-week, double-blind study with 500 g roflumilast once daily versus placebo.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004508-37,0,0,0 2006-004508-37,6,2008-01-31,2008-07-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nycomed GmbH,"Effect of roflumilast in COPD patients treated with tiotropium. A 24-week, double-blind study with 500 g roflumilast once daily versus placebo.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004508-37,0,0,0 2006-004510-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GEICAM (GRUPO ESPAÑOL DE INVESTIGACION EN CANCER DE MAMA),"ESTUDIO MULTICÉNTRICO FASE II DE DISTRIBUCIÓN ALEATORIA, PARA EVALUAR LA EFICACIA DE TRATAMIENTO NEOADYUVANTE SELECTIVO SEGÚN SUBTIPO INMUNOHISTOQUÍMICO EN CÁNCER DE MAMA HER2 NEGATIVO",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004510-41,0,0,0 2006-004511-21,1,2012-04-27,2012-04-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Queen Mary University London,Upfront Sunitinib (SU011248)® therapy followed by surgery in patients with metastatic renal cancer: a pilot Phase II study [SuMR],https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004511-21,0,0,0 2006-004512-43,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Roche Farma, S.A.",Estudio Fase II abierto de Capecitabina (Xeloda®) como fluoropirimidina de elección en combinación con quimioterapia en pacientes con cáncer gástrico Avanzado y/o Metastático susceptibles de ser trata...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004512-43,0,0,0 2006-004513-18,10,2007-12-06,2007-12-22,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004513-18,0,0,0 2006-004514-40,1,2007-08-22,2007-08-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Johnson & Johnson Pharamceutical Research & Development, L.L.C.","A Randomized, Double-Blind, Active- And Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate The Efficacy And Safety of Multiple Doses of CG5503 Immediate Release Formulation In Subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004514-40,0,0,0 2006-004516-51,3,2008-12-01,2008-12-02,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Genmab A/S,"A multicentre open-label, dose-escalation, trial of zanolimumab in combination with CHOP chemotherapy in subjects with CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004516-51,0,0,0 2006-004516-51,3,2008-12-01,2008-12-02,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,SERONO INTERNATIONAL SA,"A multicentre open-label, dose-escalation, trial of zanolimumab in combination with CHOP chemotherapy in subjects with CD4 positive non-cutaneous peripheral T-Cell Lymphoma with nodal involvement",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004516-51,0,0,0 2006-004517-17,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Stragen France,A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Refractory or Relapsed Acute Myeloid Leukemia (AML),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004517-17,0,0,0 2006-004519-23,1,2011-12-31,2011-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik für Dermatologie",Comparison of fumaric acid ester-PUVA versus PUVA-etretinate in palmoplantar pustolosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004519-23,0,0,0 2006-004521-28,1,2012-07-02,2012-07-02,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Imperial College London,A multi-centre phase I/II safety and tolerability study following the infusion of expanded autologous progeny of an adult CD34 positive stem cell subset to patients with recent tibial fractures.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004521-28,0,0,0 2006-004522-85,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hyks,Paravertebraalipuudutuksen merkitys päiväkirurgisten potilaiden spinaalipuudutuksessa tehdyn nivustyräleikkauksen jälkeiseen kipuun,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004522-85,0,0,0 2006-004523-11,1,2007-09-04,2007-09-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,"Klinische Studie zur Untersuchung der Wirkung von Weißdorn-Extrakt WS® 1442 auf die Lebensqualität von Patienten mit Herzinsuffizienz NYHA II, die ein moderates Ausdauertraining absolvieren Eine monoz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004523-11,0,0,0 2006-004524-36,1,2006-12-18,2006-12-18,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Consumer Health SA,"A randomized, double-blind, vehicle controlled, single center, intra-individual comparative study of the efficacy and safety of diclofenac sodium 1 mg/g (0.1%) gel in subjects with painful UV-induced ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004524-36,0,0,0 2006-004526-90,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Klinik Löwenstein gGmbH,"TaxErb-Protokoll; Docetaxel-Carboplatin Chemotherapie in Kombination mit Cetuximab bei Patienten mit local fortgeschrittenem oder metastasiertem, nicht-kleinzelligem Bronchial-Karzinom (NSCLC)-ein nic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004526-90,0,0,0 2006-004528-35,3,2007-06-18,2007-06-18,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Boehringer Ingelheim España, S.A.","A multicenter, randomized, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2992...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004528-35,0,0,0 2006-004528-35,3,2007-06-18,2007-06-18,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim France SAS,"A multicenter, randomized, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2992...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004528-35,0,0,0 2006-004528-35,3,2007-06-18,2007-06-18,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A multicenter, randomized, open label phase II trial evaluating the efficacy and safety of mFOLFOX7 plus weekly alternating sequential oral administration of BIBF 1120 250 mg twice daily and BIBW 2992...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004528-35,0,0,0 2006-004529-27,5,2009-02-09,2009-02-09,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim bv,Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumours. A new drug screening program of the EORTC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004529-27,0,0,0 2006-004529-27,5,2009-02-09,2009-02-09,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim,Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumours. A new drug screening program of the EORTC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004529-27,0,0,0 2006-004529-27,5,2009-02-09,2009-02-09,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm.V,Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumours. A new drug screening program of the EORTC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004529-27,0,0,0 2006-004529-27,5,2009-02-09,2009-02-09,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim France SAS,Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumours. A new drug screening program of the EORTC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004529-27,0,0,0 2006-004529-27,5,2009-02-09,2009-02-09,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,Multicenter parallel phase II trial of BI 2536 administered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumours. A new drug screening program of the EORTC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004529-27,0,0,0 2006-004530-33,1,2016-08-23,2016-08-23,1,1,0,1,0,3,1,0,1,1,0,0,0,0,1,Oy Lundbeck,Rasagiliinin ja essitalopraamin yhteiskäytön turvallisuus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004530-33,0,0,0 2006-004532-73,1,2010-03-12,2010-03-12,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Celgene International Sàrl,"A MULTICENTER, SINGLE-ARM, OPEN-LABEL EXPANDED ACCESS PROGRAM FOR LENALIDOMIDE PLUS DEXAMETHASONE IN PREVIOUSLY TREATED SUBJECTS WITH MULTIPLE MYELOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004532-73,0,0,0 2006-004533-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Johannes Gutenberg-Universität Mainz, II. Med. Klinik (ausführende Stelle), Prof. Dr. T. Münzel","Effect of 8 weeks oral Pentaerithrityltetranitrate on endothelial dysfunction in patients with coronary artery disease: A prospective, randomized, double-blind, placebo-controlled, monocentric clin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004533-15,0,0,0 2006-004534-32,7,2008-10-02,2008-12-08,6,1,0,0,0,0,3,0,0,1,1,0,1,0,2,"Merck & Co., Inc.","A Phase III Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK-0364) in Obese Patients and in Overweight Patients with Obesity-related Co-morbidities, Fol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004534-32,0,0,0 2006-004534-32,7,2008-10-02,2008-12-08,6,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Merck & Co. Inc.,"A Phase III Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK-0364) in Obese Patients and in Overweight Patients with Obesity-related Co-morbidities, Fol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004534-32,0,0,0 2006-004534-32,7,2008-10-02,2008-12-08,6,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Merck Sharp & Dohme (Sweden) AB,"A Phase III Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK-0364) in Obese Patients and in Overweight Patients with Obesity-related Co-morbidities, Fol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004534-32,0,0,0 2006-004534-32,7,2008-10-02,2008-12-08,6,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Suomen MSD Oy,"A Phase III Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK-0364) in Obese Patients and in Overweight Patients with Obesity-related Co-morbidities, Fol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004534-32,0,0,0 2006-004534-32,7,2008-10-02,2008-12-08,6,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Laboratoires Merck Sharp & Dohme-Chibret,"A Phase III Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK-0364) in Obese Patients and in Overweight Patients with Obesity-related Co-morbidities, Fol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004534-32,0,0,0 2006-004534-32,7,2008-10-02,2008-12-08,6,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Merck Sharp & Dohme GesmbH,"A Phase III Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of Taranabant (MK-0364) in Obese Patients and in Overweight Patients with Obesity-related Co-morbidities, Fol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004534-32,0,0,0 2006-004535-30,10,2008-07-30,2009-06-01,7,1,0,0,0,2,2,0,0,1,1,0,1,0,2,Merck Sharp & Dohme Ltd,A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004535-30,0,0,0 2006-004535-30,10,2008-07-30,2009-06-01,7,1,0,0,0,2,2,0,0,1,1,0,1,0,2,"Merck & Co., Inc.",A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004535-30,0,0,0 2006-004535-30,10,2008-07-30,2009-06-01,7,1,0,0,0,2,2,0,0,1,1,0,1,0,2,Laboratoires Merck Sharp & Dohme - Chibret,A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004535-30,0,0,0 2006-004535-30,10,2008-07-30,2009-06-01,7,1,0,0,0,2,2,0,0,1,1,0,1,0,2,"Merck Sharp & Dohme de España, S.A.",A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004535-30,0,0,0 2006-004535-30,10,2008-07-30,2009-06-01,7,1,0,0,0,2,2,0,0,1,1,0,1,0,2,"Merck Sharp & Dohme, Lda.",A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004535-30,0,0,0 2006-004535-30,10,2008-07-30,2009-06-01,7,1,0,0,0,2,2,0,0,1,1,0,1,0,2,Merck Sharp & Dohme (Sweden) AB,A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004535-30,0,0,0 2006-004535-30,10,2008-07-30,2009-06-01,7,1,0,0,0,2,2,0,0,1,1,0,1,0,2,Merck Sharp & Dohme BV,A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004535-30,0,0,0 2006-004535-30,10,2008-07-30,2009-06-01,7,1,0,0,0,2,2,0,0,1,1,0,1,0,2,MERCK SHARP DOHME,A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004535-30,0,0,0 2006-004535-30,10,2008-07-30,2009-06-01,7,1,0,0,0,2,2,0,0,1,1,0,1,0,2,,A Phase II Study of MK-0457 in Patients With BCR-ABL T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004535-30,0,0,0 2006-004540-23,8,2011-04-20,2011-07-12,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus Neoral® in combination with Certican®, Sim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004540-23,0,0,0 2006-004540-23,8,2011-04-20,2011-07-12,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus Neoral® in combination with Certican®, Sim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004540-23,0,0,0 2006-004545-42,2,2008-08-12,2009-03-31,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,TROPHOS,"A double-blind, randomized, multi-center study with 500 mg QD of TRO19622 versus placebo in patients with painful peripheral diabetic neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004545-42,0,0,0 2006-004547-35,1,2008-07-25,2008-07-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Serono GmbH,Phase IV study to investigate neutrophil downregulation of Thy-1 by Raptiva® (Efalizumab) as a potential responder predictor in patients with moderate to severe plaque psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004547-35,0,0,0 2006-004552-21,8,2010-08-27,2010-09-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs darbepoetin alfa given according to local label in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004552-21,0,0,0 2006-004552-21,8,2010-08-27,2010-09-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"An open-label, randomized, multi-center, parallel group non-inferiority study of subcutaneous injections of RO0503821 given once monthly vs darbepoetin alfa given according to local label in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004552-21,0,0,0 2006-004553-17,5,2013-09-24,2013-09-24,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Celgene Corporation,"A PHASE 2, PROSPECTIVE, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, ACTIVE- CONTROL, PARALLEL-GROUP STUDY TO DETERMINE THE SAFETY OF AND TO SELECT A TREATMENT REGIMEN OF CC-4047 EITHER AS SINGLE-AGENT OR I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004553-17,0,0,0 2006-004561-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St. Olavs Hospital,Tranexamic acid to elderly patients undergoing combined AVR and CABG surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004561-34,0,0,0 2006-004564-32,1,2011-07-01,2011-07-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Medical center Utrecht,The Prostate CARE Study: Capecitabine (Xeloda®) combined with Rhenium-188-HEDP in hormone refractory prostate cancer patients with bone metastases; a Capecitabine phase I dose escalation study and ph...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004564-32,0,0,0 2006-004565-33,1,2007-12-07,2007-12-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chemische Fabrik Kreussler & Co.GmbH,Efficacy and safety of Aethoxysklerol compared to Sodium Tetradecyl Sulfate and Isotonic Saline (placebo) for the treatment of reticular veins and spider veins including subgroup to investigate the pl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004565-33,0,0,0 2006-004566-13,3,2010-01-15,2010-12-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"An open-label, randomised, phase II study in subjects with extensive disease, small cell lung cancer (ED-SCLC) after an initial response (complete response or partial response) to platinum-based thera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004566-13,0,0,0 2006-004566-13,3,2010-01-15,2010-12-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MERCK KGaA,"An open-label, randomised, phase II study in subjects with extensive disease, small cell lung cancer (ED-SCLC) after an initial response (complete response or partial response) to platinum-based thera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004566-13,0,0,0 2006-004571-36,1,2008-07-25,2008-07-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Cougar Biotechnology, Inc",A Phase II Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004571-36,0,0,0 2006-004572-13,2,2007-06-04,2007-07-09,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Ardana Bioscience Ltd,"A Phase II multi-centre, randomized, open-label study investigating the pharmacokinetics, pharmacodynamics, efficacy and safety of two loading dose regimens of a new GnRH antagonist, Teverelix, long-a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004572-13,0,0,0 2006-004573-95,1,,,0,1,0,0,0,1,2,0,0,0,0,0,0,0,0,Centre Oscar Lambret,Etude pharmacologique du Pemetrexed (Alimta) administré avec Cisplatine et supplémentation vitaminique chez des patients porteurs d'un mésothéliome pleural non résécable,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004573-95,0,0,0 2006-004578-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leids Universitair Medisch Centrum,"The efficacy of intravenous versus rectal paracetamol: A randomized, prospective, double-blind placebo-controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004578-29,0,0,0 2006-004582-33,1,2006-11-03,2006-11-03,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Vectura Group plc,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalating Study Investigating the Efficacy and Safety of VR040 in the Treatment of Unpredictable “Off” or End-of-Dose “Wearing Off...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004582-33,0,0,0 2006-004586-34,6,2007-10-31,2007-11-07,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004586-34,0,0,0 2006-004586-34,6,2007-10-31,2007-11-07,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004586-34,0,0,0 2006-004587-30,1,2008-04-28,2008-04-28,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVOSIS AG,"An open label, parallel group, Phase III clinical study in patients with advanced prostate cancer suitable for hormonal manipulation to demonstrate the non-inferiority of a new three-month Novosis Gos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004587-30,0,0,0 2006-004592-35,1,2015-04-30,2015-04-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Barts Health NHS Trust,A Randomised Stratified Multicentre Phase II Clinical Trial of Single-Agent ADI-PEG 20 (Pegylated Arginine Deiminase) in Patients with Malignant Pleural Mesothelioma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004592-35,0,0,0 2006-004595-13,16,2010-09-03,2010-10-08,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004595-13,0,0,0 2006-004595-13,16,2010-09-03,2010-10-08,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER,"A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004595-13,0,0,0 2006-004598-83,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,EBMT (European group for Blood and Marrow Transplantation),High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis ( ‘ASTIS’-TRIAL: Autologous Stem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004598-83,0,0,0 2006-004605-26,1,2010-06-12,2010-06-12,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Manchester Mental Health &Social Care Trust,Proposal to investigate the efficacy and tolerability of Aripiprazole as an add-on therapy in patients not responding to an adequate dose of an antidepressant therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004605-26,0,0,0 2006-004606-97,12,2009-03-30,2009-10-07,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Astellas Pharma Europe Ltd,"A MULTICENTER, SINGLE-ARM, OPEN, CONVERSION STUDY FROM A CYCLOSPORINE (CyA) BASED IMMUNOSUPPRESSIVE REGIMEN TO A TACROLIMUS MODFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004606-97,0,0,0 2006-004606-97,12,2009-03-30,2009-10-07,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ASTELLAS PHARMA,"A MULTICENTER, SINGLE-ARM, OPEN, CONVERSION STUDY FROM A CYCLOSPORINE (CyA) BASED IMMUNOSUPPRESSIVE REGIMEN TO A TACROLIMUS MODFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004606-97,0,0,0 2006-004606-97,12,2009-03-30,2009-10-07,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Astellas Pharma GmbH,"A MULTICENTER, SINGLE-ARM, OPEN, CONVERSION STUDY FROM A CYCLOSPORINE (CyA) BASED IMMUNOSUPPRESSIVE REGIMEN TO A TACROLIMUS MODFIED RELEASE, FK506E (MR4), BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004606-97,0,0,0 2006-004608-37,7,2009-06-17,2009-07-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Vifor (International) Inc,A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject) with placebo in patients with chronic heart failure and iron de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004608-37,0,0,0 2006-004608-37,7,2009-06-17,2009-07-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Vifor Pharma, Vifor (International) Ltd",A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject) with placebo in patients with chronic heart failure and iron de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004608-37,0,0,0 2006-004608-37,7,2009-06-17,2009-07-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Vifor Pharma, Vifor (International) Ltd.",A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject) with placebo in patients with chronic heart failure and iron de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004608-37,0,0,0 2006-004608-37,7,2009-06-17,2009-07-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,VIFOR (INTERNATIONAL) INC.,A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject) with placebo in patients with chronic heart failure and iron de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004608-37,0,0,0 2006-004610-41,5,2010-06-30,2010-06-30,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,BOEHRINGER ING.,"A randomised, double-blind, placebo-controlled two-year trial to examine the change in Exercise Endurance and COPD in Patients Treated with Tiotropium (Spiriva (R)) 18 µg once daily (EXACCT trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004610-41,0,0,0 2006-004610-41,5,2010-06-30,2010-06-30,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharmaceuticals Inc.,"A randomised, double-blind, placebo-controlled two-year trial to examine the change in Exercise Endurance and COPD in Patients Treated with Tiotropium (Spiriva (R)) 18 µg once daily (EXACCT trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004610-41,0,0,0 2006-004610-41,5,2010-06-30,2010-06-30,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Boehringer Ingelheim España, S. A.","A randomised, double-blind, placebo-controlled two-year trial to examine the change in Exercise Endurance and COPD in Patients Treated with Tiotropium (Spiriva (R)) 18 µg once daily (EXACCT trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004610-41,0,0,0 2006-004610-41,5,2010-06-30,2010-06-30,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Boehringer Ingelheim Austria GmbH,"A randomised, double-blind, placebo-controlled two-year trial to examine the change in Exercise Endurance and COPD in Patients Treated with Tiotropium (Spiriva (R)) 18 µg once daily (EXACCT trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004610-41,0,0,0 2006-004610-41,5,2010-06-30,2010-06-30,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Boehringer Ingelheim Pharmaceuticals, Inc","A randomised, double-blind, placebo-controlled two-year trial to examine the change in Exercise Endurance and COPD in Patients Treated with Tiotropium (Spiriva (R)) 18 µg once daily (EXACCT trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004610-41,0,0,0 2006-004611-21,1,2008-09-05,2008-09-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,"Does allopurinol (a xanthine oxidase inhibitor) have clinically useful anti-ischaemic effects in angina pectoris? - A randomised, double-blind, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004611-21,0,0,0 2006-004613-18,4,2009-11-10,2009-11-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bracco Imaging S.p.A.,"Phase III, Multicenter, Double-blind, Randomized, Crossover Study to Compare MultiHancE with MagnevisT in Contrast-Enhanced MagnetiC Resonance Imaging MRI of the BreasT. - DETECT -",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004613-18,0,0,0 2006-004613-18,4,2009-11-10,2009-11-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRACCO IMAGING,"Phase III, Multicenter, Double-blind, Randomized, Crossover Study to Compare MultiHancE with MagnevisT in Contrast-Enhanced MagnetiC Resonance Imaging MRI of the BreasT. - DETECT -",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004613-18,0,0,0 2006-004618-42,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PROVINCIALE DI LECCO,An evaluation of sodium removal with some peritoneal solutions a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004618-42,0,0,0 2006-004619-23,4,2009-03-26,2009-05-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Celgene Corporation,"A Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two dose regimens of CC-10004 in subjects with active psoriatic arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004619-23,0,0,0 2006-004622-81,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Novo Nordisk A/S,"Inhaled preprandial human insulin with the AERx® iDMS versus subcutaneous injected insulin aspart in subjects with diabetes and asthma: a 52-week, open-label, multinational, randomised, parallel trial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004622-81,0,0,0 2006-004623-12,4,2008-03-04,2008-03-04,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novo Nordisk A/S,"Inhaled human insulin with the AERx® iDMS as prandial monotherapy compared to combination therapy with metformin and glimepiride in type 2 diabetes: an eighteen-week, open-label, multicentre, randomis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004623-12,0,0,0 2006-004624-36,12,2011-04-26,2011-06-20,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc.,"A RANDOMIZED, PHASE 3 STUDY OF SUNITINIB IN COMBINATION WITH CAPECITABINE COMPARED WITH CAPECITABINE IN PATIENTS WITH PREVIOUSLY TREATED BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004624-36,0,0,0 2006-004624-36,12,2011-04-26,2011-06-20,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc - 235 East 42nd Street, New York, NY 10017","A RANDOMIZED, PHASE 3 STUDY OF SUNITINIB IN COMBINATION WITH CAPECITABINE COMPARED WITH CAPECITABINE IN PATIENTS WITH PREVIOUSLY TREATED BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004624-36,0,0,0 2006-004624-36,12,2011-04-26,2011-06-20,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc. 235 East 42nd street – New York – 10017 NY - USA,"A RANDOMIZED, PHASE 3 STUDY OF SUNITINIB IN COMBINATION WITH CAPECITABINE COMPARED WITH CAPECITABINE IN PATIENTS WITH PREVIOUSLY TREATED BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004624-36,0,0,0 2006-004624-36,12,2011-04-26,2011-06-20,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer, S.L.U.","A RANDOMIZED, PHASE 3 STUDY OF SUNITINIB IN COMBINATION WITH CAPECITABINE COMPARED WITH CAPECITABINE IN PATIENTS WITH PREVIOUSLY TREATED BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004624-36,0,0,0 2006-004624-36,12,2011-04-26,2011-06-20,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US","A RANDOMIZED, PHASE 3 STUDY OF SUNITINIB IN COMBINATION WITH CAPECITABINE COMPARED WITH CAPECITABINE IN PATIENTS WITH PREVIOUSLY TREATED BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004624-36,0,0,0 2006-004624-36,12,2011-04-26,2011-06-20,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc. - 235 East 42nd Street - New York - 10017,"A RANDOMIZED, PHASE 3 STUDY OF SUNITINIB IN COMBINATION WITH CAPECITABINE COMPARED WITH CAPECITABINE IN PATIENTS WITH PREVIOUSLY TREATED BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004624-36,0,0,0 2006-004624-36,12,2011-04-26,2011-06-20,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"A RANDOMIZED, PHASE 3 STUDY OF SUNITINIB IN COMBINATION WITH CAPECITABINE COMPARED WITH CAPECITABINE IN PATIENTS WITH PREVIOUSLY TREATED BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004624-36,0,0,0 2006-004626-93,6,2009-10-24,2010-05-17,5,1,0,0,0,2,2,0,0,1,0,0,1,0,1,THROMBOGENICS LTD.,"A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical PVD Induction for Treatment of Diabetic Macular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004626-93,0,0,0 2006-004626-93,6,2009-10-24,2010-05-17,5,1,0,0,0,2,2,0,0,1,0,0,1,0,1,ThromboGenics Ltd.,"A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical PVD Induction for Treatment of Diabetic Macular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004626-93,0,0,0 2006-004626-93,6,2009-10-24,2010-05-17,5,1,0,0,0,2,2,0,0,1,0,0,1,0,1,ThromboGenics N.V.,"A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical PVD Induction for Treatment of Diabetic Macular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004626-93,0,0,0 2006-004628-34,2,2015-06-30,2015-06-30,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,Topotecan plus Carboplatin im Vergleich zur Standardtherapie (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin oder pegyliertes liposomales Doxorubicin plus Carboplatin) in der Therapie vo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004628-34,0,0,0 2006-004629-28,1,,,0,1,0,0,0,0,4,0,0,0,0,0,0,0,0,UZ Leuven,Een gecombineerde spinale epidurale anesthesie (CSE) bij arbeid : nood aan een fluid load (colloïden) ?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004629-28,0,0,0 2006-004632-69,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Polymorphismes du gène codant pour le cytochrome 2C19 et réponse au clopidogrel chez le sujet sain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004632-69,0,0,0 2006-004633-15,1,2009-04-24,2009-04-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BAYER Vital GmbH,"A randomized, double-blind, parallel group prospective pilot study to assess the effect of vardenafil on clinical outcome and on procedure duration after green light laser-ablation of the prostate gla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004633-15,0,0,0 2006-004634-32,12,2013-05-31,2013-05-31,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"""Estudio de fase III randomizado, abierto del Intergroup: Efecto de la adición de bevacizumab a quimioterapia (QT) basada en fluoropirimidinas como tratamiento en segunda línea de pacientes con cáncer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004634-32,0,0,0 2006-004635-30,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CENTRE DU CANCER - CLINIQUES UNIVERSITAIRES SAINT-LUC,"A randomized multicentric phase II study of prolonged adjuvant Temozolomide or ""stop and go"" in glioblastoma patients : the PATSGO study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004635-30,0,0,0 2006-004638-33,1,2008-04-20,2008-04-20,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Department of Orthopedic Surgery, Aarhus University",Postoperative pain relief for primary total knee arthroplasty: A randomised clinical trial of local infiltration anaesthesia followed by intraaticulary infusion compared to epidural infusion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004638-33,0,0,0 2006-004639-31,1,2011-06-30,2011-06-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,TAKO,"Multicenter phase II study evaluating docetaxel, CDDP, and cetuximab as induction regimen prior to surgery in chemonaive patients with NSCLC stage IB, II, and IIIA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004639-31,0,0,0 2006-004641-42,1,2011-04-07,2011-04-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Gedeon Richter Plc,"Single center, exploratoric, open-label study to investigate the precise mechanism of action of Cavinton (vinpocetin)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004641-42,0,0,0 2006-004644-24,1,2008-06-16,2008-06-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Bonn,"Prospective, open label, multi center phase II clinical trial with neoadjuvant chemotherapy in addition with Sorafenib in patients with primarily advanced ovarian cancer (FIGO IIIC + IV) and ascites...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004644-24,0,0,0 2006-004647-37,1,2011-05-27,2011-05-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Bangor University,Folate Augmentation of Treatment – Evaluation of Depression: a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004647-37,0,0,0 2006-004650-24,1,2010-12-31,2010-12-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,IKP,Omeprazole and reflux disease - improvement of clinical outcome by genotype-adjusted dosing,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004650-24,0,0,0 2006-004661-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,HOSPICES CIVILS DE LYON,Evaluation d’un traitement par miglustat (Zavesca®) chez les patients atteints de mucopolysaccharidose de type III (maladie de Sanfilippo). Essai thérapeutique de phase IIb randomisé en aveugle contre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004661-34,0,0,0 2006-004662-14,1,2010-06-30,2010-06-30,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Swansea NHS Trust,"Randomized, controlled, parallel-group study to investigate the clinical effictiveness of early insulin treatment in patients with latent autoimmune diabetes in adults [LADA]",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004662-14,0,0,0 2006-004664-31,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,NOVARTIS FARMA,Not available,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004664-31,0,0,0 2006-004665-33,2,2009-04-17,2009-04-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Resp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004665-33,0,0,0 2006-004666-14,2,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,Novartis Pharma Services AG,"An exploratory, open label pharmacokinetic – pharmacodynamic study to compare subcutaneous versus intravenous administration of ACZ885 in adult patients with established rheumatoid arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004666-14,0,0,0 2006-004667-61,1,2009-07-24,2009-07-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Hamburg-Eppendorf,Prospective open-labeled non randomized Phase-II study of SU011248 (Sunitinib) in male patients with relapsed or cisplatin-refractory germ cell cancer - A CUOG/GTCSG cooperative phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004667-61,0,0,0 2006-004669-32,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Novartis Farmacéutica S.A,"Estudio multicéntrico, de fase II, aleatorizado, doble ciego, controlado con placebo, de 12 semanas de duración, para evaluar la respuesta al tratamiento (ACR20) y para determinar un perfil de biomarc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004669-32,0,0,0 2006-004673-98,1,2009-03-10,2009-03-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Roche (Hungary) Ltd.,Efficacy of Rituximab treatment in patients with rheumatoid arthritis having inadequate response to TNF blocker,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004673-98,0,0,0 2006-004674-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dutch Kidney Foundation,Effect of GM-CSF on development of antigen-specific T cell responses following hepatitis B vaccination,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004674-27,0,0,0 2006-004675-35,2,2009-05-14,2009-05-14,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Elan Regulatory Holdings Ltd,"A Phase II, Multicenter, Open-Label, Long-Term Treatment Study to Determine the Safety, Tolerability and Efficacy of AAB-001 (ELN115727) in Patients with Alzheimer's Disease who Participated in Study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004675-35,0,0,0 2006-004676-12,1,2009-06-15,2009-06-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, double-blind, multi-center comparison of the efficacy and safety of certoparin (3000 U anti-Xa o.d.) with unfractionated heparin (5000 IU t.i.d.) in the prophylaxis of thromboembolic eve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004676-12,0,0,0 2006-004679-36,4,2012-04-04,2012-04-04,2,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Laboratoire HRA Pharma,"Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing s syndrome caused by ectopic Adrenal Corticotrophin Hormone ACTH secretion",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004679-36,0,0,0 2006-004679-36,4,2012-04-04,2012-04-04,2,1,0,0,0,1,3,0,0,1,1,1,1,0,1,LABORATOIRE HRA PHARMA,"Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing s syndrome caused by ectopic Adrenal Corticotrophin Hormone ACTH secretion",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004679-36,0,0,0 2006-004684-58,3,2008-08-27,2008-08-27,3,1,0,0,1,0,2,0,1,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A randomised, assessor-blind, parallel groups, multi-centre, exploratory study assessing the impact of subcutaneous administration of degarelix 2.5 mg on synchronisation of follicle cohort compared to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004684-58,0,0,0 2006-004686-34,1,2010-11-30,2010-11-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Karolinska University Hospital,"Evaluation of Statin Therapy- Safety, Effect and Toxicity Mechanisms.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004686-34,0,0,0 2006-004693-27,15,2009-10-08,2011-07-15,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Limited.,"A RANDOMISED, PHASE 3 STUDY OF DOCETAXEL IN COMBINATION WITH SUNITINIB VERSUS DOCETAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004693-27,0,0,0 2006-004693-27,15,2009-10-08,2011-07-15,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc - 235 East 42nd Street, New York, NY 10017","A RANDOMISED, PHASE 3 STUDY OF DOCETAXEL IN COMBINATION WITH SUNITINIB VERSUS DOCETAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004693-27,0,0,0 2006-004693-27,15,2009-10-08,2011-07-15,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Ltd.,"A RANDOMISED, PHASE 3 STUDY OF DOCETAXEL IN COMBINATION WITH SUNITINIB VERSUS DOCETAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004693-27,0,0,0 2006-004693-27,15,2009-10-08,2011-07-15,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Pharma GmbH,"A RANDOMISED, PHASE 3 STUDY OF DOCETAXEL IN COMBINATION WITH SUNITINIB VERSUS DOCETAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004693-27,0,0,0 2006-004693-27,15,2009-10-08,2011-07-15,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Ltd,"A RANDOMISED, PHASE 3 STUDY OF DOCETAXEL IN COMBINATION WITH SUNITINIB VERSUS DOCETAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004693-27,0,0,0 2006-004693-27,15,2009-10-08,2011-07-15,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, UNITED KINGDOM","A RANDOMISED, PHASE 3 STUDY OF DOCETAXEL IN COMBINATION WITH SUNITINIB VERSUS DOCETAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004693-27,0,0,0 2006-004693-27,15,2009-10-08,2011-07-15,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer S.A.,"A RANDOMISED, PHASE 3 STUDY OF DOCETAXEL IN COMBINATION WITH SUNITINIB VERSUS DOCETAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004693-27,0,0,0 2006-004693-27,15,2009-10-08,2011-07-15,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"A RANDOMISED, PHASE 3 STUDY OF DOCETAXEL IN COMBINATION WITH SUNITINIB VERSUS DOCETAXEL IN THE FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004693-27,0,0,0 2006-004694-97,6,2008-02-05,2008-02-07,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,A Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment Naive Subjects.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004694-97,0,0,0 2006-004695-12,2,2006-11-23,2006-11-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,A Dose-Ranging Study of GSK189075 versus Placebo in the treatment of Type 2 Diabetes Mellitus in Subjects taking Metformin.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004695-12,0,0,0 2006-004696-35,1,2011-03-22,2011-03-22,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Greater Glasgow and Clyde Health Board,A pilot study into the effect of 5-Aminolevulinic Acid Photodynamic Therapy in the management of oral Lichen Planus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004696-35,0,0,0 2006-004698-86,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Schmerzambulanz Innenstadt der LMU,Untersuchung der analgetischen Wirkung der AKupunktur bei Patienten mit Herpes zoster im Vergleich mit einer medikamentösen Standardtherapie- Comparison of acupuncture treatment to medical standard th...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004698-86,0,0,0 2006-004702-56,9,2008-10-30,2009-12-19,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novo Nordisk A/S,"Outcome Trial Evaluating the Efficacy and Safety of Norditropin in Adult Patients on Chronic Haemodialysis A Randomised, Double-blind, Parallel group, Placebo controlled, Multi-centre trial Studio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004702-56,0,0,0 2006-004702-56,9,2008-10-30,2009-12-19,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVO NORDISK,"Outcome Trial Evaluating the Efficacy and Safety of Norditropin in Adult Patients on Chronic Haemodialysis A Randomised, Double-blind, Parallel group, Placebo controlled, Multi-centre trial Studio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004702-56,0,0,0 2006-004705-26,1,2009-02-27,2009-02-27,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Imperial College London,Safety and Tolerability of Sildenafil in Patients with Eisenmenger Physiology,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004705-26,0,0,0 2006-004708-38,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA,"Randomized evaluation of the effectiveness of clozapine and aripiprazole versus clozapine and haloperidol in the treatment of schizofrenia. An independent, pragmatic, multicentre, parallel-group, supe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004708-38,0,0,0 2006-004709-24,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,ErasmusMC,Mycophenolate sodium (Myfortic®) in the Treatment of Uveitis: a Pilot Study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004709-24,0,0,0 2006-004710-41,1,2015-10-25,2015-10-25,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,St. Anna Kinderkrebsforschung,Multizentrische Therapieoptimierungsstudie AML-BFM 2004 zur Behandlung der akuten myeloischen Leukämien bei Kindern und Jugendlichen Multicentric therapy optimizing study AML-BFM 2004 for the treatme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004710-41,0,0,0 2006-004713-18,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,European Lung Cancer Working Party,A phase II study assessing the curative effect of the combination of lobectomy followed by mediastinal concomitant radiochemotherapy in patients with locally advanced unresectable stage III non-small ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004713-18,0,0,0 2006-004714-40,3,2008-09-16,2012-08-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gilead Sciences Incorporated,"A Randomized, Double Blind Study Evaluating Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus the Combination of Emtricitabine and Tenofovir DF for the Treatment of Chronic Hepatitis B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004714-40,0,0,0 2006-004715-22,1,2007-07-16,2007-07-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, 12-Week, Randomized, Placebo-Controlled Study to Evaluate the Antiinflammatory Effects of VX-702 when Administered Concomitantly with Methotrexate",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004715-22,0,0,0 2006-004716-48,5,2008-10-16,2008-10-16,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,"Effects of agomelatine (25 to 50 mg/day) on sleep EEG parameters compared to escitalopram in patients with Major Depressive Disorder. A 6-week randomised, double-blind parallel groups study versus com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004716-48,0,0,0 2006-004716-48,5,2008-10-16,2008-10-16,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Servier Research and Development Limited,"Effects of agomelatine (25 to 50 mg/day) on sleep EEG parameters compared to escitalopram in patients with Major Depressive Disorder. A 6-week randomised, double-blind parallel groups study versus com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004716-48,0,0,0 2006-004717-17,4,2007-09-26,2007-09-26,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Institut de Recherches Internationales Servier,"The efficacy and safety of 2g strontium ranelate in the treatment of osteoporosis in men. A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004717-17,0,0,0 2006-004720-37,1,2009-04-03,2009-04-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"CUB Hôpital Erasme, Department of Anesthesiology",Effect of Voluven on postoperative morbidity after gynaecological surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004720-37,0,0,0 2006-004722-82,1,2007-04-04,2007-04-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,An exploratory study of the effects of Imatinib on allergic inflammation following out of allergy season repeated nasal allergen challenge in subjects with seasonal allergic rhinitis sensitive to Timo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004722-82,0,0,0 2006-004726-91,1,2015-12-31,2015-12-31,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,CHRU de Lille,A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004726-91,0,0,0 2006-004727-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Kuopion Yliopistollinen Sairaala,"Teofylliinin vaikutus sydämen oikean puolen toimintaan - randomisoitu, kaksoissokkoutettu, plasebokontrolloitu hemodynaaminen invasiivinen (PAC) ja echokardiografinen tutkimus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004727-10,0,0,0 2006-004729-27,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,Organisation name was not entered,Vähentääkö pintapuudutus karsastusleikkauksen aikaista nosiseptiivistä stressivastetta nukutetuilla lapsipotilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004729-27,0,0,0 2006-004731-29,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Novo Nordisk A/S,"Inhaled preprandial human insulin with the AERx® iDMS versus subcutaneous injected insulin aspart in subjects with diabetes and chronic obstructive pulmonary disease: A 52-week, open-label, multicentr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004731-29,0,0,0 2006-004733-15,1,2008-07-09,2008-07-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 12-months multi-national, multi-centre, double-blind, randomised, parallel safety and efficacy comparison of insulin detemir produced by the current process and insulin detemir produced by the NN729...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004733-15,0,0,0 2006-004735-30,1,2008-01-05,2008-01-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Ineos Healthcare Ltd,"An open label, dose-ranging study to establish the tolerability of Alpharen™ in haemodialysis subjects with hyperphosphataemia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004735-30,0,0,0 2006-004736-79,2,2008-04-09,2008-05-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Antisense Therapeutics Ltd.,"A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous injecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004736-79,0,0,0 2006-004738-33,1,2013-02-25,2013-02-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,"Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects. Subtitle: A 2-year randomised parallel group trial of alendronate, ibandronate and risedronate for postmenopau...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004738-33,0,0,0 2006-004740-22,1,,,0,1,0,0,1,0,3,0,0,1,0,0,0,1,1,Sanofi-Aventis,"A multicenter, multi-national, randomized, double-blind, placebo-controlled, study to assess the efficacy and safety of ciclesonide metered-dose inhaler at 80 μg BID or 40 μg BID for 12 weeks in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004740-22,0,0,0 2006-004746-16,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Atrium Medisch Centrum Parkstad,Darmvoorbereiding bij linkszijdige colonchirurgie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004746-16,0,0,0 2006-004748-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. LUIGI GONZAGA,phase II study of the combination of bevacizumab plus somatostatin analogue and metronomic capecitabine as first-line therapy in patients with advanced inoperable well-differentiated neuroendrocrine ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004748-22,0,0,0 2006-004749-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Pediatrics,Glucose metabolism in patients with neurological/neuromuscular diseases.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004749-40,0,0,0 2006-004751-38,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE ONCOLOGICO DI BARI,Vaccine with dendritic cells pulsed tumoral cell line or with autologue tumor in patients with kidney carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004751-38,0,0,0 2006-004752-21,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Karolinska Institute, Danderyds hospital",Pertubation with Lignocaine in Endometriosis Associated Symptoms Effect study (PLEASE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004752-21,0,0,0 2006-004756-20,13,2012-04-17,2012-04-17,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & de'veloppement,"A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004756-20,0,0,0 2006-004756-20,13,2012-04-17,2012-04-17,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004756-20,0,0,0 2006-004759-39,1,2010-03-03,2010-03-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dermapharm AG,"Doppelblinde, randomisierte klinische Studie zum Vergleich der Wirksamkeit und Verträglichkeit einer Nystatin (100 000 I.E./g)/Hydrocortisonacetat (5 mg/g) -haltigen Paste vs. einer Nystatin (100 000 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004759-39,0,0,0 2006-004760-31,1,2009-09-16,2009-09-16,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University of Dundee,Role and efficacy of topical 5-Aminolevulinic Acid (5-ALA) in Photodynamic detection (PDD) in determining malignant potential of oral lichen planus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004760-31,0,0,0 2006-004761-34,2,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Astellas US Pharma US Inc.(APUS),"A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacodynamics of YM150 in Subjects with Non-Valvular Atrial Fibrillation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004761-34,0,0,0 2006-004763-57,1,2013-09-01,2013-09-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Odense University Hospital,"Et ikke blindet randomiseret forsøg på effekten af metformin vs. metformin og p-piller vs. p-piller på glukosetolerance, insulinresistens, væksthormon og cortisol metabolisme ved polycystisk ovarie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004763-57,0,0,0 2006-004764-31,1,,,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,Max Planck Institute of Psychiatry,Effects of corticotropin-releasing hormone on sleep electroencephalogram and sleep associated hormone secretion in young healthy women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004764-31,0,0,0 2006-004768-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOELAMS,"Traitement de première ligne des lymphomes du manteau de patients agés de 65 à 80 ans. Evaluation de l'efficacité, de la toxicité et de facteurs pronostiques moléculaires de l'inhibiteur du protéasome...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004768-30,0,0,0 2006-004770-27,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,Fédération Francophone de Cancérologie Digestive - FFCD,"TRAITEMENT NEOADJUVANT DU CANCER DE L’ŒSOPHAGE OPERABLE A VISEE CURATIVE PAR 5-FLUOROURACILE, CISPLATINE ET CETUXIMAB + RADIOTHERAPIE CONCOMITANTE. ÉTUDE DE PHASE I-II",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004770-27,0,0,0 2006-004772-12,3,2022-07-13,2022-07-13,3,0,0,0,0,2,2,0,0,1,0,0,0,0,0,Nordic Lymphoma Group,"Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide and DepoCyte induction followed by ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004772-12,0,0,0 2006-004772-12,3,2022-07-13,2022-07-13,3,0,0,0,0,2,2,0,0,1,0,0,0,0,0,Nordic lymphoma group,"Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide and DepoCyte induction followed by ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004772-12,0,0,0 2006-004773-99,1,2010-06-28,2010-06-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Leicester,A RANDOMISED CONTROLLED TRIAL COMPARING THE USE OF SIROLIMUS BASED BIPHASIC IMMUNOSUPRESSION WITH MYFORTIC TO ALLOW EARLY CNI WITHDRAWAL IN RENAL TRNASPLANTATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004773-99,0,0,0 2006-004774-27,13,2009-07-31,2009-07-31,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Ltd,"An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5 mg subcutaneously) for the Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004774-27,0,0,0 2006-004774-27,13,2009-07-31,2009-07-31,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5 mg subcutaneously) for the Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004774-27,0,0,0 2006-004774-27,13,2009-07-31,2009-07-31,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd.,"An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5 mg subcutaneously) for the Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004774-27,0,0,0 2006-004774-27,13,2009-07-31,2009-07-31,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE R&D Ltd,"An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.5 mg subcutaneously) for the Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004774-27,0,0,0 2006-004775-35,1,2011-03-15,2011-03-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Barts and the London NHS Trust,The Effect of Treating Patients with Anaemia in Diabetic Nephropathy to different target haemoglobin levels with Epoetin Beta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004775-35,0,0,0 2006-004776-12,9,2010-02-13,2010-12-13,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,COSMO Technologies Ltd,"Efficacy and Safety of Oral Budesonide-MMX™ (CB 01 02) 6 mg and 9 mg Extended Release Tablets in Patients with Mild or Moderate Active Ulcerative Colitis. A Multicentre, Randomised, Double-Blind, Doub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004776-12,1,0,0 2006-004776-12,9,2010-02-13,2010-12-13,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,COSMO TECHNOLOGIES LTD,"Efficacy and Safety of Oral Budesonide-MMX™ (CB 01 02) 6 mg and 9 mg Extended Release Tablets in Patients with Mild or Moderate Active Ulcerative Colitis. A Multicentre, Randomised, Double-Blind, Doub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004776-12,1,0,0 2006-004777-10,5,2013-08-05,2013-08-08,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase I/II study to assess the safety and immunogenicity of recMAGE-A3+AS15 cancer immunotherapeutic given as adjuvant therapy, with or without adjuvant chemo(-radio)therapy, to patients with MAGE-A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004777-10,0,0,0 2006-004779-36,3,2010-09-02,2010-09-02,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,BioMimetic Therapeutic Inc,A Human Clinical Trial to Evaluate the Safety and Clinical Utility of GEM OS1 as a Bone Regeneration System in Foot and Ankle Arthrodesis Procedures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004779-36,0,0,0 2006-004779-36,3,2010-09-02,2010-09-02,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"BioMimetic Therapeutics, Inc",A Human Clinical Trial to Evaluate the Safety and Clinical Utility of GEM OS1 as a Bone Regeneration System in Foot and Ankle Arthrodesis Procedures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004779-36,0,0,0 2006-004783-31,2,2007-08-27,2007-08-27,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004783-31,0,0,0 2006-004784-58,4,2010-11-26,2010-11-26,4,1,0,0,0,0,4,0,0,1,1,0,1,0,0,University of Leuven Hospitals,"An Open Label, Prospective, Multi-Center Trial on the Effect of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) on Inflammatory and Fibrous Lesions in Patients with Intestinal Crohn's Die...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004784-58,0,0,0 2006-004784-58,4,2010-11-26,2010-11-26,4,1,0,0,0,0,4,0,0,1,1,0,1,0,0,CHRU de Lille,"An Open Label, Prospective, Multi-Center Trial on the Effect of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) on Inflammatory and Fibrous Lesions in Patients with Intestinal Crohn's Die...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004784-58,0,0,0 2006-004784-58,4,2010-11-26,2010-11-26,4,1,0,0,0,0,4,0,0,1,1,0,1,0,0,University of Leuven,"An Open Label, Prospective, Multi-Center Trial on the Effect of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) on Inflammatory and Fibrous Lesions in Patients with Intestinal Crohn's Die...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004784-58,0,0,0 2006-004785-14,2,2008-12-01,2009-01-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cabrellis Pharmaceuticals Corporation,A Phase II Trial of Single-Agent Amrubicin in Patients with Extensive Disease Small Cell Lung Cancer that is Refractory or Progressive within 90 Days of Completion of First-Line Platinum-based Chemoth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004785-14,0,0,0 2006-004785-14,2,2008-12-01,2009-01-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Celgene Corporation,A Phase II Trial of Single-Agent Amrubicin in Patients with Extensive Disease Small Cell Lung Cancer that is Refractory or Progressive within 90 Days of Completion of First-Line Platinum-based Chemoth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004785-14,0,0,0 2006-004790-10,1,2008-09-16,2008-09-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare,A Proof-of-Principle Analgesic Adjuvant Pilot Study in Post-Operative Dental Pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004790-10,0,0,0 2006-004791-12,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTI FISIOTERAPICI OSPITALIERI,VALUTATION OF AN ORAL HYPOSENSITIZATION TREATMENT IN PATIENTS WITH ALLERGIC CONTACT DERMATITIS TO NICKEL SULPHATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004791-12,0,0,0 2006-004794-10,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Pfizer Limited,A CLUSTER RANDOMIZED TRIAL ON CARDIOVASCULAR RISK FACTOR MANAGEMENT: CADUET® VERSUS USUAL CARE IN SUBJECTS WITH HYPERTENSION AND ADDITIONAL CARDIOVASCULAR RISK FACTORS IN CLINICAL PRACTICE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004794-10,0,0,0 2006-004796-35,1,2009-07-16,2009-07-16,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"R&D Department, Box 146, Addenbrooke's Hospital","A study of effect of epidural clonidine on postoperative pain relief, hyperalgesia and chronic pain in patients undergoing colorectal surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004796-35,0,0,0 2006-004799-11,1,2010-08-26,2010-08-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Coombe Women's Hospital,A randomised trial of oxytocin bolus versus oxytocin bolus and infusion for the control of blood loss at elective caesarean section.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004799-11,0,0,0 2006-004811-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medical Center Rotterdam,"A prospective, randomized, double-blind comparison of 5 % against 1 % povidone-iodine solution in preoperative antisepsis for strabismus surgery in young children.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004811-22,0,0,0 2006-004814-41,7,2010-07-29,2010-07-29,4,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Abbott GmbH & Co. KG,"A Multi-center, Double-blind Study to Evaluate the Safety, Efficacy and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Crohn's Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004814-41,1,1,0 2006-004815-24,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI,Bortezomib and dexamethasone treatment before donor lymphocyte infusions for myeloma patients progressing or relapsing after allogeneic transplantation of hematopoietic cells,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004815-24,0,0,0 2006-004816-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Essai randomisé contre placebo en double aveugle de l'efficacité d'un anti-TNF alpha chez des patients souffrant d'une arthrose digitale invalidante et réfractaire aux traitements usuels,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004816-37,0,0,0 2006-004817-16,6,2012-03-20,2013-03-20,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Genzyme Europe B.V.,"A Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study to Demonstrate the Superiority of Matrix-induced Autologous Chondrocyte Implantation (MACI® implant) versus Arthroscopic Micro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004817-16,0,0,0 2006-004817-16,6,2012-03-20,2013-03-20,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Genzyme Europe B.V, Netherlands","A Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study to Demonstrate the Superiority of Matrix-induced Autologous Chondrocyte Implantation (MACI® implant) versus Arthroscopic Micro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004817-16,0,0,0 2006-004820-35,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ALK-ABELLO,"Multicenter, randomized, parallel groups, semi-cross over, open Phase IIIB trial to evaluate treatment compliance for subglossal specific Immunotherapy oral lyophilisate tablets GrazaxR in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004820-35,0,0,0 2006-004822-97,1,2009-09-14,2009-09-14,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,The Royal Marsden NHSF Trust,A Phase I / II Trial to Evaluate the Combination of Infliximab and Sorafenib in the Treatment of Renal Cell Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004822-97,0,0,0 2006-004824-35,3,2007-02-28,2007-05-23,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Schering AG,"A double-blind, randomized phase II study of once daily versus twice daily PTK787/ZK 222584 treatment in patients with advanced, previously treated metastatic adenocarcinoma of the colon or rectum",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004824-35,0,0,0 2006-004826-10,1,2009-04-15,2009-04-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Moorfields Eye Hospital,An observational case series to assess the effects of intravitreal Bevacizumab on eyes with neovascular glaucoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004826-10,0,0,0 2006-004828-36,2,2008-01-14,2008-01-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (2 µg, 5 µg, 10 µg, 20 µg) Delivere...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004828-36,0,0,0 2006-004828-36,2,2008-01-14,2008-01-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (2 µg, 5 µg, 10 µg, 20 µg) Delivere...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004828-36,0,0,0 2006-004829-29,2,2008-10-03,2008-10-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"Randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy (bronchodilation) and safety of 4 weeks of once daily treatment of orally inhaled BI 1744 CL (2 µg, 5 µg, 10 µ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004829-29,0,0,0 2006-004829-29,2,2008-10-03,2008-10-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy (bronchodilation) and safety of 4 weeks of once daily treatment of orally inhaled BI 1744 CL (2 µg, 5 µg, 10 µ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004829-29,0,0,0 2006-004830-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITY HOSPITALS ST LUC,"TACROLIMUS AND PRETRANSPLANT HIGH-DOSE R-ATG INDUCTION VS TACROLIMUS MONOTHERAPY AS TOLEROGENIC IMMUNOSUPPRESSION IN ADULT LIVER TRANSPLANTATION.AN OPEN LABEL, RANDOMISED, PROSPECTIVE AND CONTROLLED T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004830-34,0,0,0 2006-004834-33,6,2009-08-06,2009-10-29,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,OxyPharma AB,"A Phase II, Randomised, Double-blind, International, Multicentre, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 when Added t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004834-33,0,0,0 2006-004836-61,1,2006-09-30,2006-09-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Royal Hospital for Sick Children, Glasgow",Dexmedetomidine as a sedative in paediatric intensive care.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004836-61,0,0,0 2006-004840-21,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,sanofi-aventis Netherlands B.V.,"Bone Histomorphometry, Microarchitecture and Matrix Structure and Properties in Patients Receiving Long-term Risedronate Treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004840-21,0,0,0 2006-004846-17,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Sheffield Teaching Hospitals NHS Foundation Trust,"A randomised, placebo controlled trial of the efficacy of the addition of spironolactone to modern antihypertensive treatment regimes in patients with resistant hypertension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004846-17,0,0,0 2006-004847-47,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jeroen Bosch - Groot Ziekengasthuis,A phase II study of docetaxel/carboplatin as secondline treatment in patients with refractory or relapsed SCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004847-47,0,0,0 2006-004848-23,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Sequential Oral Therapy (SOT trial) in elderly patients with metastatic breast cancer: a phase IV randomized trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004848-23,0,0,0 2006-004849-42,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Cetuximab + Irinotecano vs chemoterapia standard nel carcinoma colo-rettale avanzato pretrattato non resecabile esprimente EGFR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004849-42,0,0,0 2006-004850-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"A phase II, open-label, prospective, multicenter study to evaluate the efficacy and safety of subsequent treatment with the Zevalin (ibritumomab tiuxetan) study in patients with follicular grade I-I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004850-26,0,0,0 2006-004851-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"A PHASE II, OPEN-LABEL, PROSPECTIVE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBSEQUENT TREATMENT WITH THE ZEVALIN (IBRITUMOMAB TIUXETAN) IN ELDERLY ( 60 YEARS) PATIENTS WITH DIFFU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004851-39,0,0,0 2006-004852-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Nancy,Analyse en Morpho-TEP au FDG de l'évolutivité des anévrismes abdominaux aortiques non chirurgicaux,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004852-19,0,0,0 2006-004853-38,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Effects of Telmisartan on Early Markers of Atherosclerosis in Hypertension with and without Hyperlipidemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004853-38,0,0,0 2006-004854-26,2,2007-08-03,2007-08-03,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,elbion AG,"A multicenter, randomized, double-blind, parallel group, phase II, forced dose titration study to investigate the efficacy and safety of 400mg and 600mg flupirtine (ELB245) given once daily for 12 wee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004854-26,0,0,0 2006-004856-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,"PEGYLATED LIPOSOMAL DOXORUBICIN (CAELYX), CISPLATINUM AND FLUOROURACIL AS CONTINUOUS INFUSION (CCF) IN LOCALLY ADVANCED BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004856-19,0,0,0 2006-004857-86,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Caprion Pharmaceuticals Inc.,"A multi-centre, open-label, phase II study of the safety, efficacy and pharmacokinetic (PK) profile of CAP-232 administered through continuous intravenous infusion in patients with metastatic kidney c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004857-86,0,0,0 2006-004858-25,1,2007-11-29,2007-11-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Free Hampstead NHS Trust,Study to compare maternal cardiovascular stability with different phenylephrine dosing regimens used to maintain baseline systolic blood pressure following a spinal anaesthetic for elective caesarean ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004858-25,0,0,0 2006-004860-29,1,2010-01-31,2010-01-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité- Universitätsmedizin Berlin,D-Cycloserine supported exposure in panic disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004860-29,0,0,0 2006-004861-33,7,2010-08-05,2010-08-05,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A randomised, parallel-group, open-labelled, multinational trial comparing the efficacy and safety of insulin detemir (Levemir®) versus human insulin (NPH insulin), used in combination with insulin as...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004861-33,0,0,0 2006-004862-15,1,2019-02-15,2019-02-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre Oscar Lambret,Etude de Phase II de l'association Méta-lodobenzylguanidine I131 (MIBGI131) et Topotécan dans le traitement des neuroblastomes métastatiques réfractaires ou en rechute.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004862-15,0,0,0 2006-004863-69,4,2010-07-14,2014-07-14,3,1,0,0,1,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, single-blind, randomized, controlled, multicentre vaccination study to evaluate the safety and immune response of the GSK Biologicals Zoster vaccine, gE/AS01B, and to compare 3 doses of gE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004863-69,0,0,0 2006-004865-32,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Aktion Bronchialkarzinom e.V.,Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study with Bevacizumab plus Erlotinib Or Gemcitabin/Cisplatin plus Bevacizumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004865-32,0,0,0 2006-004866-14,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,TAYS,Aprotiinin keuhkojen toimintaa suojaava vaikutus sydänleikkauksissa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004866-14,0,0,0 2006-004870-28,1,2009-02-05,2009-02-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Prospective, randomized, national, multi-centre, open-label, blinded endpoint study to compare Aggrenox® b.i.d. (200 mg dipyridamole MR + 25 mg acetylsalicylic acid) when started within 24 hours of st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004870-28,0,0,0 2006-004872-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Role of testosterone and its metabolites on different physiological functions in subjects affected by gender identity disorde GID FtM transsexuals,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004872-11,0,0,0 2006-004874-29,1,2010-03-04,2010-03-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Almirall, SAS",EVAluation par une echelle visuelle analogique de la satisfaction de patients migraineux apres traitement de 3 crises consécutives par Almogran,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004874-29,0,0,0 2006-004876-10,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,Department of Ophthalmology at St. Franziskus Hospital,single center study on safety and efficacy of everolimus in patients with endogenous intermediate and posterior uveitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004876-10,0,0,0 2006-004878-28,1,2013-01-01,2013-01-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,UMCN farm-tox,Does caffeine reduce dipyridamole-induced protection against ischemia-reperfusion injury?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004878-28,0,0,0 2006-004879-35,5,2009-10-23,2010-06-18,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novo Nordisk A/S,"A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004879-35,0,0,0 2006-004879-35,5,2009-10-23,2010-06-18,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,NOVO NORDISK,"A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004879-35,0,0,0 2006-004881-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU DE POITIERS,"Efficiency and tolerance study of methylprednisolone on the fall of platelets complicating preeclampsia - Multicentric, prospective, controlled, randomised, double blind, versus placebo, with individu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004881-15,0,0,0 2006-004882-32,1,2009-03-13,2009-03-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ALTANA Pharma bv,Evaluation of clinical endpoints for treatment-induced changes in GERD-related symptoms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004882-32,0,0,0 2006-004886-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"University of Athens, Medical school",A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL OF THE SAFETY AND IMMUNOMODULATORY THERAPY FOR THE MANAGEMENT OF SEPSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004886-33,0,0,0 2006-004888-54,9,2009-03-27,2009-03-27,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Ltd,"Double-Blind, Parallel-Group Comparison of 23 mg Donepezil SR to 10 mg Donepezil IR in Patients with Moderate to Severe Alzheimer’s disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004888-54,0,0,0 2006-004888-54,9,2009-03-27,2009-03-27,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,EISAI LTD UK,"Double-Blind, Parallel-Group Comparison of 23 mg Donepezil SR to 10 mg Donepezil IR in Patients with Moderate to Severe Alzheimer’s disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004888-54,0,0,0 2006-004890-93,7,2010-04-01,2010-04-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Ltd,E2020-G000-328 Estudio de extensión abierto de donepezilo LP 23 mg en pacientes con enfermedad de Alzheimer moderada o grave. Open-Label Extension Study of 23 mg Donepezil SR in Patients with Mode...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004890-93,0,0,0 2006-004890-93,7,2010-04-01,2010-04-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Limited,E2020-G000-328 Estudio de extensión abierto de donepezilo LP 23 mg en pacientes con enfermedad de Alzheimer moderada o grave. Open-Label Extension Study of 23 mg Donepezil SR in Patients with Mode...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004890-93,0,0,0 2006-004891-10,1,2011-10-04,2011-10-04,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Charité - Universitätsmedizin Berlin,Future strategies for vocational rehabilitation schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004891-10,0,0,0 2006-004892-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Rheumatology,University hospital,Lund",An open randomized and comparative study on the efficacy and safety of additional treatment of subcutaneous immunoglobulin (Subcuvia) during cessation of Prednisolon in patients with active systemic l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004892-36,0,0,0 2006-004893-29,4,2009-07-07,2010-06-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis U.S. Inc.,"A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004893-29,0,0,0 2006-004899-13,2,2009-12-01,2009-12-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Schering Pharma AG,"A multi-center, open-label, randomized, controlled, parallel-group study to assess efficacy and safety of an extended flexible regimen of the combined oral contraceptive SH T00186D (0.02 mg ethinylest...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004899-13,0,0,0 2006-004902-16,1,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,Royal Bournemouth Hospital,A randomized phase II trial to determine whether the application of imiquimod cream to the vaccination site can improve the immune responsiveness to influenza vaccination in patients with untreated st...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004902-16,0,0,0 2006-004912-28,1,2014-07-24,2014-07-24,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,European Organisation for Research and Treatment on Cancer,Clofarabine in combination with a standard remission induction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004912-28,0,0,0 2006-004918-40,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,KYS,"Intravenöösi metoproli versus amiodaroni sydänleikkauksen jälkeisen eteisvärinän estossa: vertaileva tutkimus tehosta, sivuvaikutuksista ja kustannuksista",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004918-40,0,0,0 2006-004921-27,1,2009-03-25,2009-03-25,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Psykiatrisk Center Gentofte,Antabuse in severe alcoholism: an open controlled study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004921-27,0,0,0 2006-004927-12,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,St Helier Hospital NHS Trust,A double-blind randomised placebo controlled study of cotrimoxazole in the treatment of advanced pulmonary fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004927-12,0,0,0 2006-004929-28,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,GeneMedix plc,"Prospective, Multicentre, Randomised, Double-Blind, Parallel Group Study Comparing the Therapeutic Biosimilarity of Epostim (GMX) with Eprex (J&J) when given Intravenously to Patients undergoing Chron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004929-28,0,0,0 2006-004933-14,1,2007-02-22,2007-02-22,1,1,0,0,0,0,2,0,1,1,1,1,1,0,1,"Merck & Co., Inc.","A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus (HPV) L1 V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004933-14,0,0,0 2006-004937-13,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Universita di Firenze,multicentee randomized controlled study of azathioprine versus iterferon beta in relapsing remitting multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004937-13,0,0,0 2006-004942-18,8,2009-01-09,2009-03-11,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche et developpment,"Efficacy and safety of 2 mg/day of M100907 on Sleep Maintenance Insomnia with a sub-study of the effect of M100907 on stable Type II Diabetes Mellitus a One Year, multi-center, randomized, double-bli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004942-18,0,0,0 2006-004942-18,8,2009-01-09,2009-03-11,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche de veloppement,"Efficacy and safety of 2 mg/day of M100907 on Sleep Maintenance Insomnia with a sub-study of the effect of M100907 on stable Type II Diabetes Mellitus a One Year, multi-center, randomized, double-bli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004942-18,0,0,0 2006-004945-40,7,2008-10-01,2008-10-09,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Genmab A/S,"A Randomized, Open-label, Multi-center Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in Combination with Chemo-Radiation in Stage IIIA-IIIB Non Small Cell Lung Cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004945-40,0,0,0 2006-004946-17,9,2011-03-31,2011-04-08,5,1,0,0,2,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"ENABLE 1 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004946-17,0,0,0 2006-004946-17,9,2011-03-31,2011-04-08,5,1,0,0,2,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A. España,"ENABLE 1 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004946-17,0,0,0 2006-004949-41,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,RANDOMIZED DOUBLE-BLIND STUDY TO EVALUATE THE ADJUVANT EFFECT OF POLYNSATURED FATTY ACIDS OMEGA-3 IN THERAPY WITH S.S.R.I. PAROXETINE MESYLATE IN UNIPOLAR MOOD DEPRESSION AND RECURRENT DEPRESSION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004949-41,0,0,0 2006-004950-25,1,2018-04-17,2018-04-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cell Medica Ltd,WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004950-25,0,0,0 2006-004956-19,2,2013-01-18,2013-01-18,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Active Biotech Research AB,"A randomized, open-label, multi-center, phase II/III study on treatment with ABR-217620 combined with IFN-α vs. IFN-α alone in patients with advanced renal cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004956-19,0,0,0 2006-004956-19,2,2013-01-18,2013-01-18,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Active Biotech AB,"A randomized, open-label, multi-center, phase II/III study on treatment with ABR-217620 combined with IFN-α vs. IFN-α alone in patients with advanced renal cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004956-19,0,0,0 2006-004959-38,2,2008-07-03,2008-07-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shire Development Inc,"A prospective multicenter, open-label, randomised, cross-over study to compare the efficacy and safety of Fosrenol and Sevelemer Hydrochloride in patients receiving hemodialysis for end stage renal di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004959-38,0,0,0 2006-004963-68,1,2013-10-25,2013-10-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Prof Vassilis Georgoulias,"A Phase II, Open-Label Trial of Bortezomib (Velcade®) in Combination with Gemcitabine and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004963-68,0,0,0 2006-004968-32,1,2006-12-11,2006-12-11,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,Protocol for therapeutic use of Posaconazolo out of clinical trials in patients with invasive resistant micosis and/or in tolerant patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004968-32,0,0,0 2006-004971-37,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,King's College London,Adalimumab for psoriasis patients who are non-responders to etanercept: An open-label study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004971-37,0,0,0 2006-004971-37,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Guy's and St Thomas' NHS Foundation Trust,Adalimumab for psoriasis patients who are non-responders to etanercept: An open-label study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004971-37,0,0,0 2006-004972-11,4,2008-02-28,2008-03-24,3,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Solvay Pharmaceuticals Inc,"A multi-center, open-label, parallel-group, randomized, flexible dose study to evaluate the safety and tolerability of switching from existing atypical antipsychotics to bifeprunox in subjects with sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004972-11,0,0,0 2006-004973-83,4,2008-04-24,2008-04-24,4,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Solvay Pharmaceuticals. Inc.,"A Randomized, Multicenter, Double-blind, Parallel Group Study To Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004973-83,0,0,0 2006-004977-91,1,2008-03-01,2008-03-01,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,"Universitätsklinikum Mannheim, Klinik für Anästhesiologie","Inhalative Sedierung mit Sevofluran im Vergleich zu Propofol bei beatmeten, postoperativen Intensivpatienten – Einfluss auf Extubationszeiten und Aufwachverhalten, Nieren- und Leberfunktion, Hämodynam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004977-91,0,0,0 2006-004978-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Zentralklinikum St. Pölten,Initial Combination of Photodynamic Therapy with Verteporfin and Intravitreal Administration of Ranibizumab in Patients with Subfoveal Choroidal Neovascularisation due to Age-related Macular Degenerat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004978-27,0,0,0 2006-004979-35,1,2007-06-27,2007-06-27,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Andi - Ventis,"A RANDOMISED, FOUR WAY CROSS-OVER STUDY TO ASSESS BRONCHODILATION, SAFETY AND TOLERABILITY OF NEW GENERIC DRY POWDER FORMOTEROL FORMULATIONS GIVEN AS CUMULATIVE DOSES FROM A NOVEL DRY POWDER INHALER A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004979-35,0,0,0 2006-004980-79,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,0,Medical University of Vienna,Effect of the short –term thyrotropin increase after administration of Recombinant Human Thyrotropin on T lymphocyte cytokine production pattern and bone metabolism in healthy subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004980-79,0,0,0 2006-004981-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"National Institute of Oncology, Budapest, Hungary","Phase II., non randomized, open study: inoperable gall bladder or biliary tract EGFR expressing carcinoma treatment with Erbitux and 5-fluorouracil, epiadriamycin, mitomycin containing combination",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004981-14,0,0,0 2006-004982-32,1,2013-10-23,2013-10-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medical University of Vienna, Department of Pedatrics",Cerebrospinal fluid (CSF) and plasma pharmocokinetics of liposomal cytarabine (DepoCyte®) after intrathecal administration in children with malignant brain tumors and leptomeningeal dissemination,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004982-32,0,0,0 2006-004983-30,1,2011-11-30,2011-11-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ACO-ASSO,"Pre- and postoperative chemotherapy including Bevacizumab in potentially curable metastatic colorectal Cancer (mCRC). A multicenter, prospective Phase I/II academic trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004983-30,0,0,0 2006-004989-14,1,2010-11-01,2010-11-01,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Christie Hospital NHS Trust,The Effect of Raloxifene on Serum IGF-I in Patients with Acromegaly on long-term Octeotide Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004989-14,0,0,0 2006-004991-10,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"Universith Hospital of Heraklion, Department of Medical Oncology","A triplet combination with Irinotecan (CPT-11) plus Oxaliplatin (L-OHP), continuous infusion 5-fluorouracil (5-FU) and Leucovorin (LV) (FOLFOXIRI) plus Cetuximab (C-225) as first line treatment in met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004991-10,0,0,0 2006-004997-28,11,2012-06-04,2012-06-19,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Grünenthal GmbH,"A randomized withdrawal, active- and placebo-controlled, double-blind, multi-center Phase III trial assessing safety and efficacy of oral CG5503 PR in subjects with moderate to severe chronic malignan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004997-28,0,0,0 2006-004997-28,11,2012-06-04,2012-06-19,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Gruenenthal GmbH,"A randomized withdrawal, active- and placebo-controlled, double-blind, multi-center Phase III trial assessing safety and efficacy of oral CG5503 PR in subjects with moderate to severe chronic malignan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004997-28,0,0,0 2006-004997-28,11,2012-06-04,2012-06-19,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Laboratorios Andrómaco, S.A. (compañía perteneciente al Grupo Grünenthal España)","A randomized withdrawal, active- and placebo-controlled, double-blind, multi-center Phase III trial assessing safety and efficacy of oral CG5503 PR in subjects with moderate to severe chronic malignan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004997-28,0,0,0 2006-004998-95,4,2008-02-15,2008-02-16,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,"A randomized, double-blind, parallel-arm, placebo- and comparator-controlled trial of the efficacy and safety of multiple doses of immediate-release (IR) CG5503 for postoperative pain following abdomi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004998-95,0,0,0 2006-005000-13,8,2011-02-08,2011-02-08,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"Randomized Phase II trial with cetuximab and cisplatin in the treatment of ER negative, PgR negative, HER2 negative metastatic breast carcinoma (“basal-like”)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005000-13,0,0,0 2006-005003-33,6,2011-02-08,2016-05-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Basilea Pharmaceutica Ltd,"Estudio abierto de Isavuconazol en el tratamietno de pacientes con aspergilosis y deterioro de la función renal o de pacientes con enfermedad fúngica invasiva causada por mohos atípicos, levaduras u h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005003-33,0,0,0 2006-005003-33,6,2011-02-08,2016-05-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Astellas Global Pharma Development, Inc.","Estudio abierto de Isavuconazol en el tratamietno de pacientes con aspergilosis y deterioro de la función renal o de pacientes con enfermedad fúngica invasiva causada por mohos atípicos, levaduras u h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005003-33,0,0,0 2006-005003-33,6,2011-02-08,2016-05-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Astellas Global Pharma Development, Inc","Estudio abierto de Isavuconazol en el tratamietno de pacientes con aspergilosis y deterioro de la función renal o de pacientes con enfermedad fúngica invasiva causada por mohos atípicos, levaduras u h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005003-33,0,0,0 2006-005003-33,6,2011-02-08,2016-05-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Astellas Pharma Global Development, Inc.","Estudio abierto de Isavuconazol en el tratamietno de pacientes con aspergilosis y deterioro de la función renal o de pacientes con enfermedad fúngica invasiva causada por mohos atípicos, levaduras u h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005003-33,0,0,0 2006-005004-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,A phase II study about the use of intensified hybrid chemotherapy regimen ChLVVP/ABVVP in advanced Hodgkin lymphoma patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005004-14,0,0,0 2006-005006-31,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Merck Sante France,"A randomized, stratified on age, parallel group design study to investigate the safety, tolerability and pharmacokinetics after a 60 minutes application of 4% lidocaine cream compared to EMLA® cream f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005006-31,0,0,0 2006-005007-34,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,UMCU,Bortezomib re-induction therapy combined with donor lymphocyte infusion in patients with relapsed Multiple Myeloma following allogeneic stem cell transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005007-34,0,0,0 2006-005008-15,1,2009-12-09,2009-12-09,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Moorfields Eye Hospital NHS Foundation Trust,Exploratory study of intravitreal clindamycin and dexamethasone in the treatment of acute toxoplasma chorioretinitis associated vitritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005008-15,0,0,0 2006-005009-69,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,TRABECTEDIN (ET743) IN METASTATIC OR LOCALLY ADVANCED MYXOID/ROUND CELL LIPOSARCOMA PRETREATED WITH CHEMOTHERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005009-69,0,0,0 2006-005010-12,1,2008-11-17,2008-11-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, open-label, single-arm study to evaluate the single-dose pharmacokinetics, acceptability and safety of famciclovir oral pediatric formulation in infants 1 month to <1 year of age with h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005010-12,0,0,0 2006-005011-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITA DEGLI STUDI DI UDINE,LOW DOSE RITUXIMAB IN THE TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005011-10,0,0,0 2006-005014-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,The vasoconstrictor drugs in the treatment of the Hepatorenal syndrome. The randomized clinic end multicentric study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005014-13,0,0,0 2006-005017-36,5,2009-02-03,2009-02-03,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,FRESENIUS BIOTECH GMBH,Phase II Study for repeated dosing of the trifunctional bispecific anti-HER-2/neu x anti-CD3 antibody ertumaxomab in patients with HER-2/neu 1+ or 2+/FISH negative expressing advanced or metastatic br...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005017-36,1,0,0 2006-005017-36,5,2009-02-03,2009-02-03,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Fresenius Biotech GmbH,Phase II Study for repeated dosing of the trifunctional bispecific anti-HER-2/neu x anti-CD3 antibody ertumaxomab in patients with HER-2/neu 1+ or 2+/FISH negative expressing advanced or metastatic br...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005017-36,1,0,0 2006-005019-81,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,OPi,"A European Open-Label, Multicentre, Phase II Study of Inolimomab in the Treatment of Primary Steroid Resistant Acute Graft versus Host Disease (aGvHD) following allogeneic Stem Cell Transplantation fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005019-81,0,0,0 2006-005022-23,3,2016-11-11,2016-11-11,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AstraZeneca AB,"A Phase II, Double-Blind, Placebo Controlled, Randomised Study To Assess The Efficacy And Safety Of 2 Doses Of ZACTIMA (ZD6474) In Combination With FOLFOX vs FOLFOX Alone For The Treatment Of Colorect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005022-23,0,0,0 2006-005023-42,1,2008-04-21,2008-04-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A phase II, double-blind, placebo controlled, randomised study to assess the efficacy and safety of 2 doses of ZACTIMA (ZD6474) in combination with FOLFIRI vs. FOLFIRI alone for the treatment of color...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005023-42,0,0,0 2006-005025-31,1,2010-03-08,2010-03-08,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Universitätsmedizin der Johannes Gutenberg-Universität Mainz,Efficacy and Safety of St. John´s Wort/Valerian Extract (Sedariston Concentrate) versus Placebo in Children and Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005025-31,0,0,0 2006-005030-20,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO GIANNINA GASLINI,Secondary prophylaxis of invasive mycosis in immunocompromised patients by means of a weekly high dose of liposomal Amphotericin B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005030-20,0,0,0 2006-005031-21,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO GIANNINA GASLINI,Nebulized liposomial Amphotericin B as rescue treatment of pulmonary and or sinusal invasive fungal infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005031-21,0,0,0 2006-005032-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Vaxon Biotech,A multi-centre phase II controlled study of Vx-001 in Non Small Cell Lung Cancer (NSCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005032-25,0,0,0 2006-005034-20,1,2009-11-03,2009-11-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Klinik für Dermatologie und Venerologie, Universitätsklinikum Hamburg-Eppendorf","Doppelblinde, prospektiv-randomisierte, intraindividuell-halbseitenvergleichende Studie zur klinischen Wirksamkeit von Verrumal® Lsg. bei aktinischen Keratosen gegen Vehikel: Investigator-initiierte “...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005034-20,0,0,0 2006-005035-19,15,2016-11-30,2017-10-26,14,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A LONG TERM, OPEN LABEL FOLLOW UP STUDY OF CP 690,550, A MODERATELY SELECTIVE JANUS KINASE 3 INHIBITOR, FOR TREATMENT OF RHEUMATOID ARTHRITIS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005035-19,0,0,0 2006-005035-19,15,2016-11-30,2017-10-26,14,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,"A LONG TERM, OPEN LABEL FOLLOW UP STUDY OF CP 690,550, A MODERATELY SELECTIVE JANUS KINASE 3 INHIBITOR, FOR TREATMENT OF RHEUMATOID ARTHRITIS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005035-19,0,0,0 2006-005035-19,15,2016-11-30,2017-10-26,14,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A LONG TERM, OPEN LABEL FOLLOW UP STUDY OF CP 690,550, A MODERATELY SELECTIVE JANUS KINASE 3 INHIBITOR, FOR TREATMENT OF RHEUMATOID ARTHRITIS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005035-19,0,0,0 2006-005035-19,15,2016-11-30,2017-10-26,14,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY10017","A LONG TERM, OPEN LABEL FOLLOW UP STUDY OF CP 690,550, A MODERATELY SELECTIVE JANUS KINASE 3 INHIBITOR, FOR TREATMENT OF RHEUMATOID ARTHRITIS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005035-19,0,0,0 2006-005035-19,15,2016-11-30,2017-10-26,14,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer S.A.,"A LONG TERM, OPEN LABEL FOLLOW UP STUDY OF CP 690,550, A MODERATELY SELECTIVE JANUS KINASE 3 INHIBITOR, FOR TREATMENT OF RHEUMATOID ARTHRITIS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005035-19,0,0,0 2006-005036-24,5,2008-08-15,2008-08-15,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY10017","A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE TREA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005036-24,0,0,0 2006-005036-24,5,2008-08-15,2008-08-15,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Ltd - Ramsgate Road, Sandwich CT139NJ, UK.","A PHASE 2B, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE 6 DOSE REGIMENS OF CP 690,550 VS. PLACEBO, EACH COMBINED WITH METHOTREXATE, ADMINISTERED FOR 6 MONTHS IN THE TREA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005036-24,0,0,0 2006-005039-40,1,2010-02-18,2010-02-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Calcium and Bone Metabolic Unit Copenhange University Hospital Hvidovre,Vitamin D status hos patienter med HIV infektion - Intervention with vitamin D - a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005039-40,0,0,0 2006-005041-11,1,,,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),INSULINFARCT : Evaluation de l'insuline à la phase aigue de l'accident ischémique cérébral,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005041-11,0,0,0 2006-005044-86,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Roessingh Research and Development,Influence of long-term administration of fluoxetine on cerebral threshold and muscle activity patterns in chronic stroke patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005044-86,0,0,0 2006-005046-37,1,2013-11-28,2013-11-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust,COUGAR-02: A randomised phase III study of docetaxel vs active symptom control in patients with relapsed oesophago-gastric adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005046-37,0,0,0 2006-005047-28,7,2009-02-12,2009-02-12,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,DAIICHI SANKYO PHARMA DEVELOPMENT,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF RIVOGLITAZONE AS MONOTHERAPY TREATMENT OF TYPE 2 DIABETES MELLITUS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005047-28,0,0,0 2006-005048-97,5,2007-11-20,2007-11-20,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SCHWARZ BIOSCIENCES GmbH,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY AND SAFETY OF 400MG/DAY LACOSAMIDE IN SUBJECTS WITH OSTEOARTHRITIS OF THE KNEE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005048-97,0,0,0 2006-005049-12,3,2008-08-14,2008-08-14,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Renovo Ltd,"A Double Blind, Placebo Controlled Trial to Investigate the Efficacy of Zesteem in Accelerating the Healing of Split Thickness Skin Graft Donor Sites",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005049-12,0,0,0 2006-005051-15,10,2008-10-06,2008-10-13,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme BV,"A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients with Type 2 Diabetes Mellitus Who Have Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005051-15,0,0,0 2006-005051-15,10,2008-10-06,2008-10-13,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Suomen MSD Oy,"A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients with Type 2 Diabetes Mellitus Who Have Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005051-15,0,0,0 2006-005051-15,10,2008-10-06,2008-10-13,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Ireland (Human Health) Limited,"A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients with Type 2 Diabetes Mellitus Who Have Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005051-15,0,0,0 2006-005051-15,10,2008-10-06,2008-10-13,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck & Co. Inc.,"A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients with Type 2 Diabetes Mellitus Who Have Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005051-15,0,0,0 2006-005051-15,10,2008-10-06,2008-10-13,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MERCK SHARP DOHME,"A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients with Type 2 Diabetes Mellitus Who Have Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005051-15,0,0,0 2006-005051-15,10,2008-10-06,2008-10-13,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme GmbH,"A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients with Type 2 Diabetes Mellitus Who Have Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005051-15,0,0,0 2006-005051-15,10,2008-10-06,2008-10-13,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Laboratoires Merck Sharp & Dohme-Chibret,"A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients with Type 2 Diabetes Mellitus Who Have Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005051-15,0,0,0 2006-005051-15,10,2008-10-06,2008-10-13,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme, Lda.","A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients with Type 2 Diabetes Mellitus Who Have Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005051-15,0,0,0 2006-005051-15,10,2008-10-06,2008-10-13,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients with Type 2 Diabetes Mellitus Who Have Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005051-15,0,0,0 2006-005056-32,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Exploration clinique, biologique et pharmacologique d'un polymorphisme de NEDD 4-2, protéine régulatrice du canal sodium épithélial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005056-32,0,0,0 2006-005071-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Hormos Medical Ltd,"Preliminary efficacy of OphenaTM (ospemifene) in the treatment of vasomotor symptoms associated with the menopause: a 6-week, randomized, double-blind, placebo-controlled, parallel-group study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005071-17,0,0,0 2006-005072-40,13,2008-07-04,2008-07-04,12,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Cardiome Pharma Corp.,Vernakalant (oral) Prevention of Atrial Fbrillation Recurrence Post-Conversion Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005072-40,0,0,0 2006-005073-22,6,2008-09-18,2008-09-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomized, double-blind, parallel-group study to assess the effect of esomeprazole 20 and 40 mg od versus placebo on the occurrence of peptic ulcers during 26 weeks in patients on continous low-dos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005073-22,0,0,0 2006-005076-41,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Hvidovre Hospital,"Effect of nasal GLP-1 versus placebo on fasting state and postprandial hyperglycaemia in type 2 diabetes. A single centre, prospective, placebo controlled clinical trial evaluating efficacy and safet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005076-41,0,0,0 2006-005077-21,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Dutch Childhood Oncology Group (DCOG),A Phase II study of concurrent radiation and Temozolomide followed by Temozolomide and Lomustine (CCNU) in the treatment of Children with High Grade Glioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005077-21,0,0,0 2006-005078-28,7,2008-12-08,2009-02-12,6,1,0,0,0,0,3,0,0,1,1,1,1,0,1,GlaxoSmithKline Research & Development Ltd,A 52-week open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) in subjects with mild-to-moderate Alzheimer's disease (REFLECT-5).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005078-28,0,0,0 2006-005079-17,1,2007-08-06,2007-08-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Nektar Therapeutics,"An Open-Label, Multicenter, Multinational Study to Assess the Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-Ventilated Patients with Nosocomial Pneumo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005079-17,0,0,0 2006-005082-19,1,2009-12-02,2009-12-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Research Innovation Services, University of Nottingham","Effect of an angiotensin receptor antagonist on cerebral blood flow, cerebral perfusion pressure, and systemic and peripheral haemodynamics in patients with recent stroke.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005082-19,0,0,0 2006-005084-26,4,2008-11-03,2009-02-11,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc,"A 2-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OBESE SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005084-26,0,0,0 2006-005084-26,4,2008-11-03,2009-02-11,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc.,"A 2-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OBESE SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005084-26,0,0,0 2006-005087-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CHU Amiens,ETUDE DE PHASE II DU THALIDOMIDE DANS LES MASTOCYTOSES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005087-10,0,0,0 2006-005088-25,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Leiden University Medical Center,Phase I/II study of oxaliplatin combined with melphalan in isolated hepatic perfusion for the treatment of liver metastases.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005088-25,0,0,0 2006-005090-21,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO,Noradrenalin vs terlipressin in patients with hepatorenal syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005090-21,0,0,0 2006-005091-41,1,2008-03-28,2008-03-28,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,RIEMSER Arzneimittel AG,"A prospective, randomized, observer-blind, reference-controlled (Provicol ®) Phase III clinical study on the efficacy and safety of Ledermix® Zementpulver after the treatment (preparation) of teeth wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005091-41,0,0,0 2006-005092-18,1,2009-01-07,2009-01-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,KUROS BIOSURGERY AG,"A phase 2a, multi-centre, controlled study of the safety and efficacy of wound healing gel I-020502 in patients undergoing autologous meshed skin grafting.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005092-18,0,0,0 2006-005093-40,9,2011-05-19,2011-05-19,8,0,0,0,2,0,2,0,0,1,0,0,1,0,2,KUROS BIOSURGERY AG,"A phase II randomized, controlled, open-labeled (dose-blinded) dose finding study of the safety and efficacy of I-040202 in the treatment of patients with acute open tibial shaft fractures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005093-40,0,0,0 2006-005093-40,9,2011-05-19,2011-05-19,8,0,0,0,2,0,2,0,0,1,0,0,1,0,2,Kuros Biosurgery AG,"A phase II randomized, controlled, open-labeled (dose-blinded) dose finding study of the safety and efficacy of I-040202 in the treatment of patients with acute open tibial shaft fractures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005093-40,0,0,0 2006-005096-17,1,2009-03-30,2009-03-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck & Co., Inc","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House blinding Conditions of MK-0633 in Patients With COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005096-17,0,0,0 2006-005097-52,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Adelaide & Meath Hospital,"A Single-Centre, Randomised, double-blind, two month Interventional Parallel group Study Assessing the in vivo synergy of salmeterol xinafoate/fluticasone propionate (50/250 μg twice daily) via a sin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005097-52,0,0,0 2006-005097-52,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Adelaide & Meath Hospital, incorporating the National Children's hospital","A Single-Centre, Randomised, double-blind, two month Interventional Parallel group Study Assessing the in vivo synergy of salmeterol xinafoate/fluticasone propionate (50/250 μg twice daily) via a sin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005097-52,0,0,0 2006-005101-64,1,2008-04-28,2008-04-28,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,MERCK SHARP DOHME,"A Randomized, Placebo-Controlled Study to Evaluate the Safety, Efficacy and Mechanism of Action of MK-0431/Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005101-64,0,0,0 2006-005103-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Laboratoires WELEDA,"Study of sleep characteristics and parameters in patients suffering from minors sleep disorders treated by the homeopathic medicinal product Somnidoron®, oral drops, solution.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005103-33,0,0,0 2006-005104-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Universitätsklinikum Schleswig-Holstein,A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005104-14,0,0,0 2006-005107-34,1,2011-05-31,2011-05-31,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University of Nottingham,A double blind parallel group randomised placebo controlled trial of Propranolol and Pizotifen in preventing migraine in children.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005107-34,0,0,0 2006-005110-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Besançon,Evaluation de l'association Fofiri 3 et bévacizumab (Avastin) dans le traitement des cadénocarcinomes colorectaux métastasiques,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005110-12,0,0,0 2006-005113-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Limoges,Efficacité d'un ocytocique seul versus ocytocique/misoprostol sur la quantité des pertes sanguines liées à la délivrance,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005113-35,0,0,0 2006-005118-11,5,2010-07-27,2010-10-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,A Phase 2 Study of Pemetrexed versus Pemetrexed + Erlotinib in Second-Line Treatment in Patients with Nonsquamous NSCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005118-11,0,0,0 2006-005118-11,5,2010-07-27,2010-10-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli lilly and Company Limited,A Phase 2 Study of Pemetrexed versus Pemetrexed + Erlotinib in Second-Line Treatment in Patients with Nonsquamous NSCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005118-11,0,0,0 2006-005122-23,8,2008-10-14,2008-12-12,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MERCK SHARP DOHME,"A Phase II/III Randomized, Double-Blind Study of Paclitaxel plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with pleural effusion) or Stage IV Non-Sma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005122-23,0,0,0 2006-005122-23,8,2008-10-14,2008-12-12,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Limited,"A Phase II/III Randomized, Double-Blind Study of Paclitaxel plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with pleural effusion) or Stage IV Non-Sma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005122-23,0,0,0 2006-005122-23,8,2008-10-14,2008-12-12,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Phase II/III Randomized, Double-Blind Study of Paclitaxel plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with pleural effusion) or Stage IV Non-Sma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005122-23,0,0,0 2006-005122-23,8,2008-10-14,2008-12-12,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MSD Finland Oy,"A Phase II/III Randomized, Double-Blind Study of Paclitaxel plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with pleural effusion) or Stage IV Non-Sma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005122-23,0,0,0 2006-005122-23,8,2008-10-14,2008-12-12,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","A Phase II/III Randomized, Double-Blind Study of Paclitaxel plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with pleural effusion) or Stage IV Non-Sma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005122-23,0,0,0 2006-005123-42,5,2010-02-26,2010-02-26,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-1...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005123-42,0,0,0 2006-005127-42,1,2007-03-01,2007-03-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut für Klinische Forschung und Entwicklung (ikfe) GmbH,Effect of Prandial Treatment with Insulin Glulisine compared to Regular Human Insulin on Postprandial Endothelial Function and Microvascular Stress in Type 2 Diabetic Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005127-42,0,0,0 2006-005128-18,3,2012-02-16,2012-02-16,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Kuros Biosurgery AG,"A randomized, multi-center, controlled, parallel group, dose finding study of the efficacy and safety of topically applied I-020201 as an adjunct to good standard-of-care versus good standard-of-care ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005128-18,0,0,0 2006-005137-38,6,2009-04-28,2009-05-20,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals France,"A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study To Explore And Compare Perceptions And Satisfaction For Two Different Delivery Mechanisms For Etanercept (Etanercept Autoinjector A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005137-38,0,0,0 2006-005139-61,1,,,0,0,0,0,0,0,2,0,1,1,1,1,0,1,1,Emotional Brain,Neural correlates of sexual arousal during treatment of testosterone combined with sildenafil in healthy female subjects with FSD. Effects of differing levels of attentional engagement on neural corre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005139-61,0,0,0 2006-005140-89,1,2008-02-11,2008-02-11,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,TEVA Pharmaceuticals Industries Ltd,"A PHASE I, DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED (WITHIN EACH GROUP) STUDY TO EVALUATE THE INTERACTION BETWEEN ORALLY ADMINISTERED TYRAMINE HYDROCHLORIDE AND RASAGILINE MESILATE IN HEALTHY SUBJ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005140-89,0,0,0 2006-005143-28,1,2008-05-01,2008-05-01,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,Medicinsk Forskning,"Effects of HMG-CoA-reductase inhibition (atorvastatin) on renal sodium excretion, renal hemodynamics, tubular function and vasoactive hormones in healthy subjects under diet with normal and high sodiu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005143-28,0,0,0 2006-005144-84,1,2011-11-02,2011-11-02,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Roche SAS,"Essai de phase II évaluant l’efficacité et la tolérance de bevacizumab associé à une chimiothérapie dans le traitement de patients atteints de tumeurs endocrines digestives bien différenciées, progres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005144-84,0,0,0 2006-005145-11,8,2008-11-13,2008-11-13,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer Healthcare AG,"Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos con una dosis de 10 mg de vardenafilo dos veces al día para evaluar el efecto en la prueba urodinámica en pacientes con v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005145-11,0,0,0 2006-005147-28,7,2015-04-22,2016-04-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis continuing methotrex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005147-28,0,0,0 2006-005157-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHRU-TOURS,EFFET DU METHOTREXATE SUR LA RELATION DOSE - EFFET DE L'INFLIXIMAB DANS LA SPONDYLARTHRITE ANKYLOSANTE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005157-29,0,0,0 2006-005159-14,3,2014-01-13,2014-01-13,2,1,0,0,0,1,0,0,0,1,0,0,1,0,1,GamidaCell-Teva Joint Venture Ltd.,": A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx, Umbilical Cord Blood (UCB) Stem and Progenitor Cells Expanded Ex Vivo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005159-14,0,0,0 2006-005159-14,3,2014-01-13,2014-01-13,2,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Gamida Cell-Teva Joint Venture Ltd.,": A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx, Umbilical Cord Blood (UCB) Stem and Progenitor Cells Expanded Ex Vivo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005159-14,0,0,0 2006-005161-18,1,2009-04-15,2009-04-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Debiopharm,"A randomised, double-blind, double-dummy, oral donepezil controlled study on the safety and efficacy of repeated monthly subcutaneaous injections of a sustained-release implant of ZT-1 in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005161-18,0,0,0 2006-005163-26,1,2016-01-01,2016-01-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude de phase 3 comparant une chimiothérapie d'induction séquentielle systématique à une chimiothérapie d'induction séquentielle conditionnelle chez des patients atteints d'une Leucémie Aigüe Myéloïd...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005163-26,0,0,0 2006-005168-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Institut Sainte Catherine,Etude NESC : Etude multicentrique de phase II dans le traitement pré-opératoire des adénocarcinomes gastriques composé d'une chimiothérapie à base de docetaxel-cisplatine-5FU suivie d'une radiochimiot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005168-16,0,0,0 2006-005169-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"J. Uriach y Compañia, S. A.",Estudio piloto del uso del hierro endovenoso en el postoperatorio de cirugía mayor urológica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005169-21,0,0,0 2006-005174-42,3,2021-07-02,2022-06-03,3,0,0,0,0,0,3,0,0,1,0,0,0,0,0,HOVON Foundation,Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab maintenance in elderly patients (66-80 years) with d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005174-42,0,0,0 2006-005175-18,1,2008-09-30,2008-09-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Dpt. of Internal Medicine, Medical University of Innsbruck",Influence of insulin Levemir on endothelial function in type 2 diabetes mellitus. A prospective case-control study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005175-18,0,0,0 2006-005177-21,11,2009-11-04,2010-03-04,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Human Genome Sciences, Inc.","A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005177-21,0,0,0 2006-005177-21,11,2009-11-04,2010-03-04,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,HUMAN GENOME SCIENCES INC,"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 76 week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005177-21,0,0,0 2006-005179-17,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTI ORTOPEDICI RIZZOLI,Phase II clinical study on efficacy of proton pump inhibitors pre-treatment in osteosarcoma patients undergoing chemiotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005179-17,0,0,0 2006-005180-25,1,2008-04-23,2008-04-23,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Nordmark Arzneimittel GmbH,"A study investigating the safety, tolerability and pharmacodynamics of bacterial lipase in patients with cystic fibrosis and pancreatic insufficiency Randomized, double-blind, placebo-controlled, sing...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005180-25,0,0,0 2006-005182-20,2,2008-06-23,2008-06-23,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Solvay Pharmaceuticals,"A multicenter, randomized, double-blind, placebo-controlled, parallel group study of SLV308 as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005182-20,0,0,0 2006-005183-91,2,2009-07-07,2009-07-07,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Solvay Pharmaceuticals,An open label SLV308 safety extension to study S308.3.002 in patients with Parkinson’s disease experiencing motor fluctuations.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005183-91,0,0,0 2006-005186-18,8,2012-09-20,2012-09-20,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Abbott Healthcare Products B.V.,"Open-Label, 6-12 Months Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005186-18,0,0,0 2006-005186-18,8,2012-09-20,2012-09-20,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Solvay Pharmaceuticals B.V.,"Open-Label, 6-12 Months Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005186-18,0,0,0 2006-005186-18,8,2012-09-20,2012-09-20,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Solvay Pharmaceuticals BV.,"Open-Label, 6-12 Months Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005186-18,0,0,0 2006-005191-41,2,2007-09-25,2007-09-25,2,1,0,1,1,0,1,0,1,1,0,0,0,0,1,"Baxter Healthcare Corporation, Baxter BioScience","Single blind, randomized, active controlled Phase 1/2 study to compare the safety and immunogenicity of a Split Virus, Vero cell-derived, seasonal influenza vaccine (VCIV) with a licensed egg-derived,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005191-41,0,0,0 2006-005192-18,5,2008-11-03,2008-11-03,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc,"A 1-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OVERWEIGHT, ORAL AGENT-TREATED SUBJECTS WITH TYPE 2 DIABETES ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005192-18,0,0,0 2006-005192-18,5,2008-11-03,2008-11-03,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Ltd.,"A 1-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OVERWEIGHT, ORAL AGENT-TREATED SUBJECTS WITH TYPE 2 DIABETES ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005192-18,0,0,0 2006-005192-18,5,2008-11-03,2008-11-03,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc.,"A 1-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OVERWEIGHT, ORAL AGENT-TREATED SUBJECTS WITH TYPE 2 DIABETES ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005192-18,0,0,0 2006-005192-18,5,2008-11-03,2008-11-03,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A 1-YEAR, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CP-945,598 IN THE TREATMENT OF OVERWEIGHT, ORAL AGENT-TREATED SUBJECTS WITH TYPE 2 DIABETES ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005192-18,0,0,0 2006-005195-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leila Niemi-Murola,Comparsion between articaine and lignocaine regional anaesthesian in patients undergoing bone marrow biopsy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005195-40,0,0,0 2006-005196-17,1,2007-07-19,2007-07-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BioCryst Pharmaceuticals, Inc.","A phase II, Multicenter, Randomised, Double-Mask, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects with Uncomplicated Acute Influenza",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005196-17,0,0,0 2006-005197-51,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,The Netherlands Cancer Institute/ Antoni van Leeuwenhoek hospital,Accelerated growth of synchronous colorectal liver metastases: effects of neo-adjuvant therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005197-51,0,0,0 2006-005197-51,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud University Nijmegen Medical Center,Accelerated growth of synchronous colorectal liver metastases: effects of neo-adjuvant therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005197-51,0,0,0 2006-005200-13,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,Ipsen Pharma GmbH,"Phase II multi-centre, randomised, open, comparative study of the safety and efficacy of transdermal testosterone (Testim®) compared to intramuscular testosterone depot for the induction of puberty in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005200-13,0,0,0 2006-005201-60,1,2009-12-23,2009-12-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"LABORATORIOS FARMACÉUTICOS ROVI, S.A.","ENSAYO CLÍNICO, MULTICÉNTRICO, ALEATORIZADO, CONTROLADO Y DOBLE CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LA BEMIPARINA SÓDICA COMO TRATAMIENTO DE LAS ÚLCERAS DE PIE DIABÉTICO (ROV-BEM-2006-01)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005201-60,0,0,0 2006-005203-33,1,2008-01-19,2008-01-19,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics GmbH & Co. KG,"A Phase II, Multicenter, Exploratory Study to Evaluate Safety and Immunogenicity of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adults Unprimed and Primed with MF59-adjuvanted or Non-adjuvanted H5N3 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005203-33,0,0,0 2006-005206-31,1,2008-11-10,2008-11-10,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Örebro University Hospital,Perioperative Morbidity in Elderly patients undergoing Surgery for Fracture Neck of Femur. The Effect of Plasma or Ocplex® for reversal of Warfarin anticoagulation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005206-31,0,0,0 2006-005212-27,3,2008-07-03,2008-09-23,2,1,1,0,0,2,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Treatment-withdrawal Study to Evaluate the Efficacy and Safety of Esomeprazole for the Treatment of Gastroesopha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005212-27,1,1,0 2006-005215-98,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sanquin Plasma Products,"Treatment in patients with recurrent infections and IgG Subclass Deficiency, and/or Deficient Anti-Polysaccharide Antibody Response.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005215-98,0,0,0 2006-005216-27,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"HUS, Hospital for Children and Adolescents",Selkäytimeen annettu entsyymikorvaus mukopolysakkaridoosi I:n selkäytimen puristuman hoidossa. Kansainvälinen monikeskustutkimus. A study of intrathecal enzyme replacement therapy for spinal cord comp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005216-27,0,0,0 2006-005218-11,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ASSOCIAZIONE ITALIANA ENDOCRINOLOGIA-METABOLISMO-IPOFISI,EFFECTIVENESS AND TOLERABILITY OF TREATMENT WITH CABERGOLINE IN PATIENTS WITH CUSHING S SYNDROME,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005218-11,0,0,0 2006-005220-16,1,2010-11-08,2010-11-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Karolinska institutet,Cardiovascular fysiological effects of Exenatide on heart failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005220-16,0,0,0 2006-005221-37,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Astion Danmark A/S,"Efficacy and safety of ASF-1075 cream 2.5% and 5% on pruritus in patients with lichen simplex chronicus (neurodermatitis) of the anogenital region. A phase II, multi-centre, double-blind, vehicle-cont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005221-37,0,0,0 2006-005227-42,1,2008-04-23,2008-04-23,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A double-blind, placebo-controlled, parallel study to evaluate the effects of GW-856553 on endothelial function/ vascular compliance in subjects with dyslipidaemia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005227-42,0,0,0 2006-005228-18,1,2007-09-06,2007-09-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X 200mcg Twice Daily, GW685698X 200mcg and 400mcg Once Daily in the Mor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005228-18,0,0,0 2006-005230-20,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,OSPEDALE MAGGIORE DI MILANO (IRCCS),EX VIVO EFFECT OF AMINAFTONE (CAPILLAREMA) ON THE ENDOTELIAL FUNCTION IN SYSTEMIC SCLEROSIS. Effetto ex vivo dell’aminaftone (Capillarema) sulla funzione endoteliale nella Sclerosi Sistemica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005230-20,0,0,0 2006-005234-21,8,2009-05-28,2009-05-28,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Schering-Plough Research Institute,A RANDOMIZED ACCEPTABILITY AND SAFETY STUDY OF THE TRANSFER FROM SUBUTEX TO SUBOXONE IN OPIOID- DEPENDENT SUBJECTS- SWITCH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005234-21,0,0,0 2006-005234-21,8,2009-05-28,2009-05-28,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ESSEX ITALIA,A RANDOMIZED ACCEPTABILITY AND SAFETY STUDY OF THE TRANSFER FROM SUBUTEX TO SUBOXONE IN OPIOID- DEPENDENT SUBJECTS- SWITCH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005234-21,0,0,0 2006-005235-14,11,2009-12-10,2009-12-10,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Schering-Plough Research Institute - A division of Schering-Plough Corp.,"""Estudio aleatorizado de aceptabilidad y seguridad de la inducción con Suboxone en consumidores de heroína"" A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005235-14,0,0,0 2006-005235-14,11,2009-12-10,2009-12-10,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ESSEX ITALIA,"""Estudio aleatorizado de aceptabilidad y seguridad de la inducción con Suboxone en consumidores de heroína"" A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005235-14,0,0,0 2006-005235-14,11,2009-12-10,2009-12-10,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Integrated Therapeutics Group Inc,"""Estudio aleatorizado de aceptabilidad y seguridad de la inducción con Suboxone en consumidores de heroína"" A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005235-14,0,0,0 2006-005237-38,1,2008-12-17,2008-12-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Alcon Laboratories, Inc.",SAFETY AND EFFICACY OF SWITCHING TO THE TRAVOPROST/TIMOLOL MALEATE FIXED COMBINATION (DUOTRAV) FROM PRIOR MONO- OR TWO-DRUG THERAPY IN GERMANY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005237-38,0,0,0 2006-005238-19,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Instituto Cientifico y Tecnologico de Navarra,Estudio fase II con inmunoterapia mediante células dendríticas y linfocitos infiltrantes de tumor en tumores sólidos,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005238-19,0,0,0 2006-005239-32,1,,,0,0,0,0,1,1,4,0,0,0,0,0,0,0,0,"Medical Sciences, Akademiska sjukhuset",Fosfodiesterashämmares akuta hemodynamiska effekter vid pulmonell hypertension och utvärdering av kväveoxid mätningar som icke-invasiv diagnostisk metod,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005239-32,0,0,0 2006-005240-93,1,2010-05-17,2010-05-17,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Karolinska University Hospital,"The effect of localanastetic when the drainage is removed, including women operated for breast cancer. [Svensk titel: effekt av lokalbedövning vid dränage borttagning].",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005240-93,0,0,0 2006-005242-36,1,2007-06-11,2007-06-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Moberg Derma AB,"A multicenter, randomised, double-blind, placebo-controlled clinical study evaluating efficacy, safety and tolerability of topical K40 in 8 weeks treatment of adult patients with moderate to severe in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005242-36,0,0,0 2006-005249-13,1,2010-12-06,2010-12-06,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,"Department of Clinical Pharmacology, University of Greifswald",Influence of the OATP1B1 genotype on the hepatic uptake of Primovist® in healthy volunteers and in patients with liver disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005249-13,0,0,0 2006-005252-32,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,ANGELINI,A PILOT STUDY OF PRULIFLOXACIN VS. LEVOFLOXACIN IN PREVENTION OF POST-OPERATIVE URINARY BACTERIAL INFECTIONS IN PATIENTS UNDERGOING TURP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005252-32,0,0,0 2006-005254-68,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GEL/TAMO (Cooperative Spanish Group of Lymphoma/Autologous bone marrow transplant).,Treatment with R-MegaCHOP and early rescue with R-IFE and autologous stem cells transplant (ASCT) according response measured by positron emission tomography (PET) in patients with diffuse large B-cel...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005254-68,0,0,0 2006-005256-33,3,2008-05-16,2008-05-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A multicenter, randomized, open label, clinical trial to evaluate three doses of tipranavir boosted with ritonavir (500 mg/200 mg qd, 250 mg/100 mg bid and 500 mg/100 mg bid) by assessing the steady-s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005256-33,0,0,0 2006-005256-33,3,2008-05-16,2008-05-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A multicenter, randomized, open label, clinical trial to evaluate three doses of tipranavir boosted with ritonavir (500 mg/200 mg qd, 250 mg/100 mg bid and 500 mg/100 mg bid) by assessing the steady-s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005256-33,0,0,0 2006-005256-33,3,2008-05-16,2008-05-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A multicenter, randomized, open label, clinical trial to evaluate three doses of tipranavir boosted with ritonavir (500 mg/200 mg qd, 250 mg/100 mg bid and 500 mg/100 mg bid) by assessing the steady-s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005256-33,0,0,0 2006-005260-88,10,2009-02-17,2009-02-17,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, parallel-group, evaluation of 12 weeks of valsartan compared to enalapril on sitting systolic blood pressure in children 6 to 17 years of age with hypertensio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005260-88,0,0,0 2006-005260-88,10,2009-02-17,2009-02-17,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A multicenter, randomized, double-blind, parallel-group, evaluation of 12 weeks of valsartan compared to enalapril on sitting systolic blood pressure in children 6 to 17 years of age with hypertensio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005260-88,0,0,0 2006-005261-19,8,2009-01-21,2009-01-21,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, multicenter, double-blind, 6 week study to evaluate the dose response of valsartan on blood pressure reduction in children 1-5 years old with hypertension, followed by a 2 week placebo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005261-19,0,0,0 2006-005261-19,8,2009-01-21,2009-01-21,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A randomized, multicenter, double-blind, 6 week study to evaluate the dose response of valsartan on blood pressure reduction in children 1-5 years old with hypertension, followed by a 2 week placebo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005261-19,0,0,0 2006-005262-39,1,2012-11-26,2012-11-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité-Universitätsmedizin Berlin,Flupirtin as Oral Treatment in MS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005262-39,0,0,0 2006-005263-26,1,2007-08-31,2007-08-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ALK-Abelló, S.A.","A randomised, double-blind, placebo-controlled Phase IIIb Study investigating changes in immunological parameters and cutaneous reactivity induced by a short course immunotherapy with ALK grass tablet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005263-26,0,0,0 2006-005268-19,1,2010-10-31,2010-10-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck, S.L.",Lutropina alfa (Luveris®) en mitad de la fase folicular de la estimulación ovárica controlada (COS) en la edad reproductiva avanzada. Estudio clínico en fase II.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005268-19,0,0,0 2006-005269-20,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,LETI Pharma GmbH,"Randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy of Depigoid® Grass Mix as a rush immunotherapy in patients with allergic rhinitis using an environmental exp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005269-20,0,0,0 2006-005270-47,14,2008-03-14,2008-06-17,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Schering Pharma AG,"Estudio internacional, multicéntrico, de fase IIIb, sobre el tratamiento en días alternos de pacientes con Esclerosis Múltiple Recidivante con: (Fase A) Betaseron/Betaferon 250 µg ó 500 µg de forma do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005270-47,0,0,0 2006-005270-47,14,2008-03-14,2008-06-17,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Schering AG,"Estudio internacional, multicéntrico, de fase IIIb, sobre el tratamiento en días alternos de pacientes con Esclerosis Múltiple Recidivante con: (Fase A) Betaseron/Betaferon 250 µg ó 500 µg de forma do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005270-47,0,0,0 2006-005270-47,14,2008-03-14,2008-06-17,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Schering Pharma,"Estudio internacional, multicéntrico, de fase IIIb, sobre el tratamiento en días alternos de pacientes con Esclerosis Múltiple Recidivante con: (Fase A) Betaseron/Betaferon 250 µg ó 500 µg de forma do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005270-47,0,0,0 2006-005270-47,14,2008-03-14,2008-06-17,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHERING,"Estudio internacional, multicéntrico, de fase IIIb, sobre el tratamiento en días alternos de pacientes con Esclerosis Múltiple Recidivante con: (Fase A) Betaseron/Betaferon 250 µg ó 500 µg de forma do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005270-47,0,0,0 2006-005270-47,14,2008-03-14,2008-06-17,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Bayer AB, Bayer Health Care, Bayer Schering Pharma","Estudio internacional, multicéntrico, de fase IIIb, sobre el tratamiento en días alternos de pacientes con Esclerosis Múltiple Recidivante con: (Fase A) Betaseron/Betaferon 250 µg ó 500 µg de forma do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005270-47,0,0,0 2006-005275-18,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,3,Astellas,Therapy-optimizing pilot study to investigate the efficacy and safety of an induction therapy with Campath-1H in combination with Tacrolimus for prevention of acute and chronic rejection in patients a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005275-18,0,0,0 2006-005283-47,4,2007-12-19,2008-08-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cerexa, Inc.","A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin plus Aztreonam in Adult Subjects with Complicated Skin and Ski...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005283-47,0,0,0 2006-005287-94,1,2014-03-17,2014-03-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Wien,Impact of n-3 Polyunsaturated Fatty Acids on Adipose Tissue Inflammation in Morbidly Obese Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005287-94,0,0,0 2006-005289-37,1,,,0,0,0,0,1,0,3,0,1,0,0,0,0,0,0,University Witten/Herdecke,Anwendung von HELIOX an einem Modell der oberen Atemwegsobstruktion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005289-37,0,0,0 2006-005291-41,1,,,0,0,0,0,0,0,2,0,1,1,1,1,0,1,1,CYATHUS Exquirere PharmaforschungsGmbH,"A single center, open, pilot study to evaluate the pharmacokinetic profile of a new galenic formulation of an Ambroxol-Hydrochloride (Ambroxol-HCl) spray: Ambroxol “CYATHUS” 50 mg/mL Oral Spray, admin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005291-41,0,0,0 2006-005294-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Saint-Etienne,Performance de l’équation MDRD corrigée par la cimétidine chez le patient transplanté rénal,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005294-22,0,0,0 2006-005296-18,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Heinrich-Heine-Universität Duesseldorf,Einsatz von Haemateâ HS bei Patienten mit schweren Blutungskomplikationen bei Herzklappenersatz wegen Aortenstenose HAVAS-Studie (Haemate HS in patients with severe bleeding undergoing valve replace...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005296-18,0,0,0 2006-005297-48,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University of Copenhagen, Roskilde, Department of Dermatology","Adalimumab s.c. for the treatment of patients with hidradenitis suppurativa – clinical efficacy, safety and tolerability - SOPHISTICATE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005297-48,0,0,0 2006-005298-23,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,IPERBOREAL PHARMA,"Efficiency of L-Carnitine-containing Peritoneal Dialysis Solutions for diurnal exchanges in CAPD Patients with ESRD on Glucose and Lipid Metabolisms. Randomized, Parallel Study Compared versus a Stand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005298-23,0,0,0 2006-005299-42,4,2013-08-28,2013-08-28,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,GETAID,"A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005299-42,1,0,0 2006-005299-42,4,2013-08-28,2013-08-28,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives (G.E.T.A.I.D.),"A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005299-42,1,0,0 2006-005299-42,4,2013-08-28,2013-08-28,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,GETECCU (Grupo Español para el estudio de la enfermedad de Crohn y la colitis ulcerosa),"A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005299-42,1,0,0 2006-005300-13,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,IPERBOREAL PHARMA,"Efficiency of L-Carnitine-containing Peritoneal Dialysis Solutions for diurnal exchanges in diabetes type 2 CAPD patients with ESRD on glucose metabolism. Randomized, parallel study compared versus a ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005300-13,0,0,0 2006-005301-63,1,2008-12-31,2008-12-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Hospital Vienna,Phase II Trial of Docetaxel in Patients With Metastatic or Inoperable Medullary Thyroid Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005301-63,0,0,0 2006-005303-34,3,2008-01-16,2008-01-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"Efficacy and safety of 2 mg/day M100907 on Sleep Maintenance Insomnia: a 6-week, multicenter, randomized, double-blind, placebo-controlled Polysomnographic study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005303-34,0,0,0 2006-005304-14,1,2008-07-01,2008-07-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergopharma Joachim Ganzer KG,"Design of optimally-diagnostic skin test solutions for diagnosis of sensitisation to a 6-grass pollen mixture, house dust mite (Dermatophagoides pteronyssinus), birch pollen and mugwort pollen and alt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005304-14,0,0,0 2006-005305-58,5,2018-10-18,2018-10-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized, Double-Blind, Phase 2 Trial of Fulvestrant Plus Enzastaurin versus Fulvestrant Plus Placebo in Aromatase Inhibitor-Resistant Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005305-58,0,0,0 2006-005305-58,5,2018-10-18,2018-10-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company limited,"A Randomized, Double-Blind, Phase 2 Trial of Fulvestrant Plus Enzastaurin versus Fulvestrant Plus Placebo in Aromatase Inhibitor-Resistant Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005305-58,0,0,0 2006-005305-58,5,2018-10-18,2018-10-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ELI LILLY,"A Randomized, Double-Blind, Phase 2 Trial of Fulvestrant Plus Enzastaurin versus Fulvestrant Plus Placebo in Aromatase Inhibitor-Resistant Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005305-58,0,0,0 2006-005306-31,3,2008-08-25,2008-08-25,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ELI LILLY,"Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Gemcitabine and Cisplatin Plus Enzastaurin versus Gemcitabine and Cisplatin Plus Placebo, Followed by Maintenance Enzastaurin or Placebo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005306-31,0,0,0 2006-005306-31,3,2008-08-25,2008-08-25,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly and Company limited,"Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Gemcitabine and Cisplatin Plus Enzastaurin versus Gemcitabine and Cisplatin Plus Placebo, Followed by Maintenance Enzastaurin or Placebo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005306-31,0,0,0 2006-005308-15,1,2009-03-30,2009-03-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"University Heidelberg, Department of General Surgery",Pilot study of the safety and tolerance of preoperative melatonin application in patients undergoing major liver resection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005308-15,0,0,0 2006-005313-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GGZ Drenthe,"Clinical effects of low dose pipamperon (Dipiperon) versus placebo on cognitive functions of elderly patients suffering from cognitive dysfunction, admitted at a general hospital.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005313-35,0,0,0 2006-005314-12,4,2010-02-25,2010-02-25,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Wilex AG,"A randomised, open label, Phase II Proof of Concept study of WX-671 in combination with gemcitabine vs gemcitabine in patients with locally advanced, non-resectable pancreatic cancer in order to evalu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005314-12,1,0,0 2006-005314-12,4,2010-02-25,2010-02-25,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,WILEX AG,"A randomised, open label, Phase II Proof of Concept study of WX-671 in combination with gemcitabine vs gemcitabine in patients with locally advanced, non-resectable pancreatic cancer in order to evalu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005314-12,1,0,0 2006-005315-10,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE SACRO CUORE-DON CALABRIA,Evaluation of safety and efficacy on visual acuity outcome of intravitreal somministration of Bevacizumab in patients with diabetic retinopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005315-10,0,0,0 2006-005318-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU Toulouse,Effet de l'apomorphine sur la perception douloureuse chez le patient parkinsonien : étude clinique et en tomographie par émission de positons.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005318-11,0,0,0 2006-005320-16,1,2011-07-29,2011-07-29,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Genzyme Europe BV,"Long-term Observational Follow-up Study of a Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240 µg/kg) plus G-CSF (10 µg/kg) Versus G-CSF (10 µg/kg) plus Plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005320-16,0,0,0 2006-005321-40,6,2008-10-08,2009-11-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Clinuvel Pharmaceuticals Limited,"A Phase III, randomised, double blind, placebo controlled study to evaluate the safety and efficacy of subcutaneous implants of CUV1647 in patients suffering from polymorphic light eruption (PLE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005321-40,0,0,0 2006-005324-17,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Sint Maartenskliniek,"Influence of indometacin on reaction time, postural balance and obstacle avoidance in healthy subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005324-17,0,0,0 2006-005328-18,9,2013-10-03,2013-10-03,7,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Assistance Publique - Hôpitaux de Paris (AP-HP),"A prospective, randomized, double-blind, placebo-controlled, international, multicenter, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase as compare...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005328-18,0,0,0 2006-005328-18,9,2013-10-03,2013-10-03,7,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"A prospective, randomized, double-blind, placebo-controlled, international, multicenter, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase as compare...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005328-18,0,0,0 2006-005328-18,9,2013-10-03,2013-10-03,7,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS/ DE`LE`GATION A` LA RECHERCHE CLINIQUE ET AU DE`VELOPPEMENT,"A prospective, randomized, double-blind, placebo-controlled, international, multicenter, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase as compare...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005328-18,0,0,0 2006-005329-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Tratamiento de los Tumores de Cabeza y Cuello (TTCC),"Estudio fase II abierto y multicéntrico para evaluar la eficacia y seguridad de la combinación de Erbitux® con quimioterapia (combinación TPF: Taxotere®, cisplatino, fluorouracilo) administrada de for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005329-42,0,0,0 2006-005330-20,11,2013-05-17,2018-05-14,9,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005330-20,1,0,0 2006-005330-20,11,2013-05-17,2018-05-14,9,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ROCHE,"A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005330-20,1,0,0 2006-005331-25,1,2010-12-01,2010-12-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,3,Swansea NHS Trust,A study to examine the influence of repaglinide on the 'incretin effect' and oxidative damage associated with postprandial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005331-25,0,0,0 2006-005332-25,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Cerexa, Inc.","A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin plus Aztreonam in Adult Subjects with Complicated Skin and Ski...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005332-25,0,0,0 2006-005334-21,5,2008-03-06,2008-04-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche et developpement,"A randomized, double-blind, placebo-controlled, parallel group, fixed-dose, 8-week treatment, multi-center trial evaluating the dose effect relationship for efficacy and the safety of 3 oral doses of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005334-21,0,0,0 2006-005334-21,5,2008-03-06,2008-04-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche et développement,"A randomized, double-blind, placebo-controlled, parallel group, fixed-dose, 8-week treatment, multi-center trial evaluating the dose effect relationship for efficacy and the safety of 3 oral doses of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005334-21,0,0,0 2006-005335-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),OMEPRAZOLE 1 - Recherche de dose et Pharmacocinétique de population de l'Oméprazole chez le nouveau-né en traitement du reflux gastro-oesophagien.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005335-16,0,0,0 2006-005336-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Réduction de la prématurité spontanée : Impact d'un traitement antibiotique (JOSAMYCINE) en cas de PCR positive pour Ureaplasma spp. et/ou Mycoplasma hominis dans le liquide amniotique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005336-24,0,0,0 2006-005338-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,LABORATOIRES GRIMBERG,Evaluation versus placebo de l'intérêt d'un traitement d'un mois par le Carbosymag sur la prise en charge de patients atteints de dyspepsie fonctionnelle,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005338-19,0,0,0 2006-005341-11,1,2008-03-25,2008-03-25,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Shire Pharmaceuticals Ireland Limited,"A single center, open-label, non-randomized, uncontrolled, multiple-dose, dose escalation study of the safety, pharmacokinetics and efficacy of Metazym (recombinant human arylsulfatase A or rhASA) for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005341-11,0,0,0 2006-005342-36,1,2009-12-28,2009-12-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"A prospective, open-label, multicenter, repeat-dose trial to investigate the safety and efficacy of NT 201, free of complexing proteins, in the treatment of glabellar frown lines",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005342-36,0,0,0 2006-005344-83,1,2007-05-18,2007-05-18,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Probiodrug AG,"A Randomized, Double-blind, Placebo and Active Treatment-Controlled Study in Psoriatic Patients to Assess the Tolerability, Pharmacokinetics and Efficacy of a Cream Formulation Containing 3% of P32/98",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005344-83,0,0,0 2006-005345-11,1,2010-05-20,2010-05-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Nottingham,‘Stem cell Trial of recovery EnhanceMent after Stroke 2’ (STEMS2) pilot randomised placebo-controlled trial of granulocyte-colony stimulating factor in mobilising bone marrow stem cells in sub-acute s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005345-11,0,0,0 2006-005346-37,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,Eli Lilly and Company Limited,"A Randomized, Double-Blind, Placebo-Controlled Maintenance of Effect Study of Olanzapine in the Treatment of Disruptive Behavioral Symptoms in Children and Adolescents with Pervasive Developmental Dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005346-37,0,0,0 2006-005349-13,3,2009-01-24,2010-03-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici SpA,"ENSAYO CLÍNICO PROSPECTIVO, ALEATORIZADO, ABIERTO, MULTICÉNTRICO, CONTROLADO CON FÁRMACO ACTIVO, DE GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE DIPROPIONATO DE BECLOMETASONA 400 µG + F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005349-13,0,0,0 2006-005349-13,3,2009-01-24,2010-03-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CHIESI,"ENSAYO CLÍNICO PROSPECTIVO, ALEATORIZADO, ABIERTO, MULTICÉNTRICO, CONTROLADO CON FÁRMACO ACTIVO, DE GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE DIPROPIONATO DE BECLOMETASONA 400 µG + F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005349-13,0,0,0 2006-005349-13,3,2009-01-24,2010-03-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A,"ENSAYO CLÍNICO PROSPECTIVO, ALEATORIZADO, ABIERTO, MULTICÉNTRICO, CONTROLADO CON FÁRMACO ACTIVO, DE GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE DIPROPIONATO DE BECLOMETASONA 400 µG + F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005349-13,0,0,0 2006-005350-79,1,2008-06-25,2008-06-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A single arm, single-centre, open-label, exploratory trial of recombinant Interleukin-21 administered subcutaneously for 4 weeks as neo-adjuvant treatment prior to sentinel lymph node/complete lymph n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005350-79,0,0,0 2006-005351-14,8,2009-08-12,2009-09-05,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Hip Replacement Surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005351-14,0,0,0 2006-005352-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude randomisée, en double aveugle, évaluant l'efficacité et la tolérance de l'analgésie par mélange équimolaire protoxyde d'azote-oxygène contre oxygène chez des patients bénéficiant d'injection end...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005352-32,0,0,0 2006-005353-30,5,2013-08-29,2013-08-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab in combination with methotrexate (MTX) compared to MTX alone in methotrexate- naïve p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005353-30,0,0,0 2006-005353-30,5,2013-08-29,2013-08-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab in combination with methotrexate (MTX) compared to MTX alone in methotrexate- naïve p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005353-30,0,0,0 2006-005354-68,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,Confronto tra un regime terapeutico basato sui livelli sierici di procalcitonina rispetto ad un regime terapeutico standard in pazienti ospedalizzati per riacutizzazione di broncopneumopatia cronica o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005354-68,0,0,0 2006-005355-16,9,2008-05-09,2011-07-12,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005355-16,0,0,0 2006-005356-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),EVALUATION CLINIQUE DE LA 18 F-F DOPA EN TOMOGRAPHIE PAR EMISSION DE POSITONS DANS LES CANCERS MEDULLAIRES DE LA THYROÏDE.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005356-33,0,0,0 2006-005357-29,10,2010-10-06,2013-10-28,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Subjects With WHO or ISN Class III or IV Nephritis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005357-29,0,0,0 2006-005361-19,1,2007-04-30,2007-04-30,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,St Georges Hospital,Evaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005361-19,0,0,0 2006-005364-65,1,2011-11-03,2011-11-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,AUO,"Intermittent Treatment with Taxotere and Prednisone in patients with asymptomatic, hormone-refractory prostate cancer: A Multicenter Phase II Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005364-65,0,0,0 2006-005370-49,3,2010-05-10,2010-08-02,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Roche Latvia,Baltic Post-marketing Program of PEGASYS® (Peg interferon alpha-2a 40KD) in Patients with HBeAg-positive Chronic Hepatitis B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005370-49,0,0,0 2006-005370-49,3,2010-05-10,2010-08-02,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Roche Latvija SIA,Baltic Post-marketing Program of PEGASYS® (Peg interferon alpha-2a 40KD) in Patients with HBeAg-positive Chronic Hepatitis B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005370-49,0,0,0 2006-005373-22,1,2011-06-21,2011-06-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Central Manchester and Manchester Children's University Hospitals NHS Trust,Erythropoietin and Delayed Graft Function in Renal Allografts from Extended Criteria Donors.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005373-22,0,0,0 2006-005377-22,7,2008-06-12,2008-08-07,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, double-dummy, randomised, multi-centre, comparative phase III clinical study on the efficacy and tolerability of an 8 week oral treatment with 9 mg budesonide or 3 g mesalazine in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005377-22,0,0,0 2006-005380-25,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,Etude comparative de la lévobupivacaïne 0.568 mg/ml + sufentanyl 0.45 mcg/ml et de la lévobupivacaïne 1.136 mg/ml + sufentanyl 0.45 mcg/ml pour l'analgésie obstétricale par PCEA sur cathéter de péridu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005380-25,0,0,0 2006-005381-39,2,2008-10-03,2008-10-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Ltd, Ramsgate Road, Sandwich, Kent. UK","A PHASE 2a MULTI-CENTRE, DOUBLE BLIND, PLACEBO CONTROLLED CROSS-OVER TRIAL TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERATION OF CP-866,087 IN PRE-MENOPAUSAL WOMEN DIAGNOSED WITH FEMALE SEXUAL AROUSAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005381-39,0,0,0 2006-005382-19,1,2009-11-01,2009-11-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals of Leicester NHS Trust,"Helicobacter eradication therapy in Chronic Obstructive Pulmonary Disease: A pilot,randomised, double blinded, placebo controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005382-19,0,0,0 2006-005383-51,1,2008-05-29,2008-05-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Phase 3, Open-Label, Crossover Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared with Once-Daily Insulin Glargine in Insulin-Naïve Patients with Type 2 Dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005383-51,0,0,0 2006-005385-39,6,2009-03-04,2009-03-04,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,sanofi-aventis recherche et developpement,"A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess Glycemic Control with Rimonabant in Comparison with Glimepiride over 1 Year in Overweight/Obese Type 2 Diabetic P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005385-39,1,0,0 2006-005386-19,1,2008-12-24,2008-12-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cliniques Universitaires Saint-Luc,Cytokines and inflammatory proteins gene expression study in synovial biopsies from rheumatoid arthritis patients refractory to anti-TNF therapy treated with Rituximab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005386-19,0,0,0 2006-005391-40,1,,,0,0,0,0,1,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA SENESE,Study on the effect of intra-articular infiltrations of aulogous platelet gel as inhibitor of erosion in rheumatoid arthritis patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005391-40,0,0,0 2006-005394-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku university hospital,ESCITALOPRAM MONOTHERAPY COMPARED TO COMBINATION OF ESCITALOPRAM AND RISPERIDONE IN THE TREATMENT OF ACUTE PSYCHOTIC DEPRESSION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005394-22,0,0,0 2006-005395-40,1,2008-07-01,2008-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Barts and The London NHS Trust,"Is Buscopan, paracetamol or a combination of both the most effective analgesia for the treatment of non-specific abdominal pain?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005395-40,0,0,0 2006-005396-17,4,2008-05-12,2008-05-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"A prospective, randomized, double-blind, international multicenter trial to investigate the efficacy and safety of NT 201 in comparison to placebo and to compare two different application schemes of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005396-17,0,0,0 2006-005396-17,4,2008-05-12,2008-05-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERZ PHARMACEUTICALS GMBH,"A prospective, randomized, double-blind, international multicenter trial to investigate the efficacy and safety of NT 201 in comparison to placebo and to compare two different application schemes of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005396-17,0,0,0 2006-005399-42,1,2008-05-21,2008-05-21,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Guy's & St Thomas' NHS Foundation Trust,Improving symptoms of intermittent claudication in patients with erectile dysfunction and peripheral vascular disease: a pilot study assessing the benefit of daily dosing with tadalafil (Cialis) 10mg.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005399-42,0,0,0 2006-005400-14,1,2009-07-21,2009-07-21,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Moorfields Eye Hospital NHS Foundation Trust,PERIOPERATIVE INTRAVITREAL TRIAMCINOLONE IN PHAKOEMULSIFICATION FOR CONCURRENT CLINICALLY SIGNIFICANT DIABETIC MACULAR OEDEMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005400-14,0,0,0 2006-005403-34,7,2009-03-31,2011-11-22,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Archimedes Development Ltd,An Open-Label Study Investigating Long-Term Safety and Tolerability of Nasalfent (Fentanyl Citrate Nasal Spray) in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005403-34,1,0,0 2006-005403-34,7,2009-03-31,2011-11-22,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ARCHIMEDES,An Open-Label Study Investigating Long-Term Safety and Tolerability of Nasalfent (Fentanyl Citrate Nasal Spray) in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005403-34,1,0,0 2006-005404-13,1,2009-05-03,2009-05-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, 24-week, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of Omalizumab in adult patients with chronic urticaria who exhibit IgE agai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005404-13,0,0,0 2006-005405-67,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,LABCATAL,Etude de l'efficacité et de la tolérance du L35 versus placebo dans le traitement de l'hidradénite suppurée (Maladie de Verneuil),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005405-67,0,0,0 2006-005406-32,1,2009-12-01,2009-12-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Belfast City Hospital Trust,Doppler ultrasound investigation of microvasculature in health and disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005406-32,0,0,0 2006-005407-33,1,2006-12-20,2006-12-20,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,King's College London,The effect of long-term iron treatment on serum NTBI and plasma isoprostanes in anaemic women versus an anaemic control group,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005407-33,0,0,0 2006-005408-14,8,2009-06-09,2009-06-22,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 14 week extension to a randomized, double-blind, multicenter, parallel-group, active-controlled study to evaluate the long term safety, tolerability and efficacy of valsartan and enalapril combine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005408-14,0,0,0 2006-005408-14,8,2009-06-09,2009-06-22,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 14 week extension to a randomized, double-blind, multicenter, parallel-group, active-controlled study to evaluate the long term safety, tolerability and efficacy of valsartan and enalapril combine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005408-14,0,0,0 2006-005410-13,1,2010-04-28,2010-04-28,1,0,0,0,0,1,3,0,0,1,1,1,1,0,0,University Hospital of Ulm,"EFFICACY, SAFETY AND TOLERABILITY STUDY OF 45 mg PIOGLITAZONE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) RECEIVING STANDARD THERAPY (RILUZOLE).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005410-13,0,0,0 2006-005416-28,1,2007-04-01,2007-04-01,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Danish University of Pharmaceutical Sciences,Cytochrome P450 metabolism of lidokain in human skin (Cytochrom P450 metabolisme af lidokain i human hud),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005416-28,0,0,0 2006-005419-92,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HOSPICES CIVILS DE LYON,"ANALGESIE EPIDURALE CONTROLEE PAR LA PARTURIENTE (PCEA) PENDANT LE TRAVAIL OBSTETRICAL : ADJONCTION DE CLONIDINE AU MELANGE LEVOBUPIVACAÏNE BASE 0,0625 % + SUFENTANIL 0.25 MICROG.ML-1.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005419-92,0,0,0 2006-005420-17,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,LTB4 Sweden AB,"A double-blind, randomised, placebo-controlled, crossover, allergen challenge study, evaluating the safety, tolerability and effects of intranasal administration of recombinant human Clara Cell 10 kDa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005420-17,0,0,0 2006-005421-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,RER Saint Denis,Effets hémodynamiques de l’administration de vasopressine au décours de l’Arrêt Cardio-Respiratoire chez des patients en état de choc réfractaire Hemodynamic effects of vasopressin administration in p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005421-31,0,0,0 2006-005422-23,3,2008-10-06,2008-10-06,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et développement,"An open-label, multicenter study evaluating the long-term safety of satavaptan (SR121463B) and maintenance of normonatremia in patients with dilutional hyponatremia who have previously been treated in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005422-23,0,0,0 2006-005426-23,1,,,0,1,0,0,1,0,2,0,0,1,1,1,0,1,0,Pierre Schydlowsky,Evaluation of the efficacy and safety of adalimumab (Humira) s.c. injections eow. in patients with adhesive capsulitis (frozen shoulder).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005426-23,0,0,0 2006-005428-18,2,2007-10-03,2007-10-03,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics GmbH & Co. KG,"A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005428-18,0,0,0 2006-005432-24,1,2007-10-30,2007-10-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Hermal Kurt Herrmann GmbH & Co OHG,Clinical trial to investigate clinical efficacy and tolerability of Verrumal in actinic keratosis (PoC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005432-24,0,0,0 2006-005437-38,6,2008-06-30,2008-07-08,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, given as an Extended-release Formulation, in the Prevention of St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005437-38,0,0,0 2006-005438-19,1,2008-10-14,2008-10-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SCHWARZ PHARMA Deutschland GmbH,"An explorative, multicenter, open-label pilot trial with Neupro® (Rotigotine transdermal patch) once daily treatment administered perioperatively in Patients with idiopathic Parkinson´s disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005438-19,0,0,0 2006-005440-87,1,2017-10-31,2017-10-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre René Gauducheau,ETUDE MULTICENTRIQUE CLINIQUE ET RADIOBIOLOGIQUE DE PHASE II EVALUANT LA RADIOTHERAPIE STEREOTAXIQUE HYPOFRACTIONNEE AVEC IRINOTECAN (CAMPTOä) CONCOMITANT DANS LE TRAITEMENT DES METASTASES HEPATIQUES ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005440-87,0,0,0 2006-005442-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University Medical Center St Radboud, department of neurology","PITUITARY DAMAGE AFTER TRAUMATIC BRAIN INJURY; Occurrence of growth hormone deficiency at long term follow-up and the beneficial effects of growth hormone substitution on cardiovascular performance, q...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005442-37,0,0,0 2006-005444-88,5,2008-04-08,2008-04-15,2,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Theratechnologies Inc.,"A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005444-88,1,0,0 2006-005445-11,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Sanofi Pasteur MSD S.N.C.,"An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of the concomitant use of a live pentavalent rotavirus vaccine (RotaTeq®) and a meningococcal group C conjug...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005445-11,0,0,0 2006-005449-12,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Dipartimento di Pediatria,EVALUATION OF THE EFFICACY OF THE TREATMENT WITH ACE-INHIBITORS ON THE RENAL DAMAGE IN PATIENTS AFFECTED BY GLYCOGEN STORAGE DISEASE TYPE 1 AND OF THE VITAMINE E ON NEUTROPENIA OF PATIENTS WITH GSD1b,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005449-12,0,0,0 2006-005450-71,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Augenklinik der LMU München,INTRAVITREAL RANIBIZUMAB THERAPY FOR MACULA EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION (RAVO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005450-71,0,0,0 2006-005451-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MOLMED,"NGR006 A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by colorectal cancer CRC , previously treated with fluoropyrimidine, oxaliplatin and irinotecan ba...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005451-15,0,0,0 2006-005453-30,1,2010-06-23,2010-06-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Cubist Pharmaceuticals, Inc.","A Phase 2 Randomized Study Investigating the Safety, Efficacy and Pharmacokinetics of Daptomycin 6 mg/kg and 8 mg/kg Versus Comparator in the Treatment of Subjects Undergoing Surgical Standard of Car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005453-30,0,0,0 2006-005454-76,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IRCCS CASA SOLLIEVO DELLA SOFFERENZA,PPI as an adjunct to endoscopic hemostasis for bleeding peptic ulcer a randomized clinical trial of a high vs a standard regimen for the i.v. drug infusion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005454-76,0,0,0 2006-005455-15,5,2008-10-09,2008-10-29,3,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A three-part multicenter study, with a randomized, doubleblind, placebo controlled, withdrawal design in Part II to assess efficacy, safety, and tolerability of ACZ885 (antiinterleukin-1β monoclonal a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005455-15,1,1,0 2006-005455-15,5,2008-10-09,2008-10-29,3,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A.,"A three-part multicenter study, with a randomized, doubleblind, placebo controlled, withdrawal design in Part II to assess efficacy, safety, and tolerability of ACZ885 (antiinterleukin-1β monoclonal a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005455-15,1,1,0 2006-005456-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Chimiothérapie intra-arterielle lipiodolée (CIAL) versus chimiothérapie systémique par gemcitabine et oxaliplatine (GEMOX) versus surveillance simple après résection ou destruction des carcinomes hépa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005456-32,0,0,0 2006-005460-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALI CIVILI DI LIONE,POPART’MUS Prevention of Post Partum Relapses with Progestin and Estradiol in Multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005460-30,0,0,0 2006-005461-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Zentiva a.s.,"A Randomized, Double Blind, Placebo Controlled Multicenter Study to Assess the Tolerability and Safety of ANTIRIN® nasal spray and drops in two Age Groups of Children with Acute Rhinitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005461-19,0,0,0 2006-005462-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU Toulouse,Association du Velcade au Melphalan dans le conditionnement à l'autogreffe de celulles souches hématopoïétiques des patients de moins de 65 ans atteints de myélome. Etude pilote de l'Intergroupe Franc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005462-40,0,0,0 2006-005465-19,1,2008-08-12,2008-08-12,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,ITALFARMACO,"Open label, uncontrolled, pilot, phase II study of histone-deacetylase inhibitor ITF2357 administered orally to subjects with chronic lynphocytic leukemia (CLL) refractory/relapsed after conventional ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005465-19,0,0,0 2006-005466-39,2,2008-05-29,2008-10-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec Ltd,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BG9924 When Given in Combination W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005466-39,0,0,0 2006-005467-26,2,2008-10-09,2008-10-09,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Biogen Idec Ltd,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BG9924 When Given in Combination With Methotrexa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005467-26,0,0,0 2006-005468-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Retinaklinikken Aleris,A randomized study comparing the safety and efficacy of ranibizumab (Lucentis ®) to sham in patients with macular edema secondary to central retinal vein occlusion (CRVO).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005468-25,0,0,0 2006-005469-20,1,2007-10-26,2007-10-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A randomized, double-blind, parallel-group, placebo-controlled, ezetimibe-calibrated, multicenter study evaluating the safety and efficacy of four doses and two dose-regimens of AVE5530 over 4 weeks i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005469-20,0,0,0 2006-005470-41,1,2007-01-12,2007-01-12,1,1,0,0,1,0,4,0,1,1,0,0,1,0,1,Regent Medical,Hibiscrub EN12791 Testing using current application and 2 new application methods,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005470-41,0,0,0 2006-005471-18,1,2009-09-10,2009-09-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,"Topical Capsaicin 0.025% as a treatment for Achilles tendinopathy. A prospective, double blinded, randomised controlled trial with multiple outcome measures.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005471-18,0,0,0 2006-005473-21,7,2009-05-08,2009-05-25,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"An open label extension study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005473-21,0,0,0 2006-005473-21,7,2009-05-08,2009-05-25,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An open label extension study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005473-21,0,0,0 2006-005475-17,8,2009-05-06,2015-02-12,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier (I.R.I.S.),"Long-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at the therapeutic doses (2.5/5/7.5 mg b.i.d.) on top of anti-anginal background therapy, to pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005475-17,0,0,0 2006-005476-40,6,2011-12-15,2011-12-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Inc,"PHASE 2 SINGLE-ARM, OPEN LABEL STUDY OF IRINOTECAN IN COMBINATION WITH TEMOZOLOMIDE IN CHILDREN WITH RECURRENT OR REFRACTORY MEDULLOBLASTOMA AND IN CHILDREN WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005476-40,0,0,0 2006-005476-40,6,2011-12-15,2011-12-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,PFIZER,"PHASE 2 SINGLE-ARM, OPEN LABEL STUDY OF IRINOTECAN IN COMBINATION WITH TEMOZOLOMIDE IN CHILDREN WITH RECURRENT OR REFRACTORY MEDULLOBLASTOMA AND IN CHILDREN WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005476-40,0,0,0 2006-005476-40,6,2011-12-15,2011-12-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer S.A.,"PHASE 2 SINGLE-ARM, OPEN LABEL STUDY OF IRINOTECAN IN COMBINATION WITH TEMOZOLOMIDE IN CHILDREN WITH RECURRENT OR REFRACTORY MEDULLOBLASTOMA AND IN CHILDREN WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005476-40,0,0,0 2006-005477-22,1,2008-10-20,2008-10-20,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, open, randomized study in adults aged between 18 and 60 years designed to evaluate the reactogenicity and immunogenicity of a 1- and 2-dose prime-boost concept of pandemic monovalent (H5N1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005477-22,0,0,0 2006-005485-40,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Regulon Α.Ε.,"Multicenter Phase II/III Clinical Study of Lipoplatin plus Gemcitabine as First-Line Treatment in Inoperable, Locally Advanced or Metastatic Pancreatic Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005485-40,0,0,0 2006-005491-40,1,2007-12-26,2007-12-26,1,0,0,0,1,0,2,0,0,1,1,1,1,0,1,"ImaRx Therapeutics, Inc","A Phase 1-2, Randomized, Placebo-Controlled, Single-Blind, Dose Escalation Study to Evaluate the Safety, Tolerability, and Activity of Ascending Single Doses of MRX-801 with Continuous Ultrasound Admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005491-40,0,0,0 2006-005492-17,6,2008-02-13,2008-02-13,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Takeda Global Research & Development Centre (Europe) Ltd.,","A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 plus Pioglitazone HCl (Actos), SYR-322 Alone or Pioglitazone HCl Alone in Subjects with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005492-17,0,0,0 2006-005493-52,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Division K Kärnsjukhuset,A pilot phase II study of digitoxin for Androgen-Independent Prostate Cancer (AIPC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005493-52,0,0,0 2006-005494-21,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,HYKS Marian sairaala,Hyperbaarisen artikaiini-glukoosiliuoksen ja pelkän artikaiinin vertailu spinaalipuudutuksessa nivustyräpotilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005494-21,0,0,0 2006-005499-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ACROSS (Associació Catalana de Recerca Oncològica i les seves implicacions Sanitàries i Socials),Tratamiento de inducción con XELOX-Bevacizumab en el adenocarcinoma localmente avanzado de recto: Estudio fase II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005499-42,0,0,0 2006-005500-14,1,2011-02-23,2011-02-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsmedizin der Johannes-Gutenberg Universität Mainz,"A Randomized, Open-label, Multicenter, Efficacy and Safety Study Examining the Effects on Viral Kinetics of All-trans Retinoic Acid (Tretinoin) (VESANOID®)in Combination with PEG-IFN alfa 2a (PEGASYS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005500-14,0,0,0 2006-005504-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOSPICES CIVILS DE LYON,ETUDE MULTICENTRIQUE FAG-3 : TRAITEMENT PAR CARBOPLATINE DES PATIENTES DE PLUS DE 70 ANS ATTEINTES DE CANCER AVANCE DE L’OVAIRE : PREDICTION DE LA VULNERABILITE INDIVIDUELLE PAR UNE EVALUATION PSYCHO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005504-13,0,0,0 2006-005505-64,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,"Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital","A Randomised Trial Evaluating the VEGF Inhibitor, Bevacizumab (Avastin), as Adjuvant Therapy following Resection of AJCC Stage IIB (T3bN0M0 & T4aN0M0), IIC (T4bN0M0) and III (TxN1-3M0) Cutaneous Mel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005505-64,0,0,0 2006-005506-32,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Danish Pain Research Center,"Pain, anxiety and depression in neuropathic and non-neuropathic pain: Effect of monoamine modulation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005506-32,0,0,0 2006-005508-14,1,2007-04-23,2007-04-23,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Bayer Consumer Care AG,"A randomized, , double-blind, single centre, intra-individual comparison study with repeated application to assess the wound-healing efficacy of a 5 % Dexpanthenol ointment compared with placebo in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005508-14,0,0,0 2006-005509-79,1,2007-08-29,2007-08-29,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Vectura Group plc,"A Clinic-Based, Phase IIa, Randomised, Double-Blind, Placebo-Controlled, Ascending-Dose, Multicentre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040 in Patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005509-79,0,0,0 2006-005512-27,8,2009-07-03,2009-10-07,4,1,0,0,0,0,0,0,0,2,0,0,0,0,1,Lilly S.A.,"A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005512-27,1,0,0 2006-005512-27,8,2009-07-03,2009-10-07,4,1,0,0,0,0,0,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005512-27,1,0,0 2006-005512-27,8,2009-07-03,2009-10-07,4,1,0,0,0,0,0,0,0,2,0,0,0,0,1,Eli Lilly and Company Limited,"A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005512-27,1,0,0 2006-005512-27,8,2009-07-03,2009-10-07,4,1,0,0,0,0,0,0,0,2,0,0,0,0,1,Eli Lilly & Co.,"A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005512-27,1,0,0 2006-005513-35,10,2008-03-07,2008-03-30,10,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Merck & Co. Inc,"A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005513-35,0,0,0 2006-005513-35,10,2008-03-07,2008-03-30,10,1,0,0,0,0,4,0,0,1,0,0,1,0,2,"Merck & Co., Inc","A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005513-35,0,0,0 2006-005513-35,10,2008-03-07,2008-03-30,10,1,0,0,0,0,4,0,0,1,0,0,1,0,2,"Merck Sharp & Dohme, Lda.","A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005513-35,0,0,0 2006-005513-35,10,2008-03-07,2008-03-30,10,1,0,0,0,0,4,0,0,1,0,0,1,0,2,"Merck&co., Inc.","A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005513-35,0,0,0 2006-005513-35,10,2008-03-07,2008-03-30,10,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Merck Sharp & Dohme BV,"A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005513-35,0,0,0 2006-005513-35,10,2008-03-07,2008-03-30,10,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Laboratoires Merck Sharp & Dohme - Chibret,"A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005513-35,0,0,0 2006-005513-35,10,2008-03-07,2008-03-30,10,1,0,0,0,0,4,0,0,1,0,0,1,0,2,,"A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005513-35,0,0,0 2006-005513-35,10,2008-03-07,2008-03-30,10,1,0,0,0,0,4,0,0,1,0,0,1,0,2,MERCK SHARP DOHME,"A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005513-35,0,0,0 2006-005513-35,10,2008-03-07,2008-03-30,10,1,0,0,0,0,4,0,0,1,0,0,1,0,2,"Merck & Co., Inc.","A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005513-35,0,0,0 2006-005513-35,10,2008-03-07,2008-03-30,10,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Merck Sharp & Dohme oü,"A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combination tablet Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005513-35,0,0,0 2006-005514-12,2,2008-04-24,2008-04-24,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,INNOVIVE Pharmaceuticals,"A Phase II, Open-label Study of INNO-206 in Patients with Recurrent Extensive Small Cell Lung Cancer after First-line Platinum-based Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005514-12,0,0,0 2006-005515-10,7,2014-01-20,2014-02-10,6,1,1,0,0,0,1,0,0,2,1,0,0,0,2,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","""Estudio multicéntrico, abierto, de 5 partes para evaluar la farmacocinética, seguridad y tolerabilidad del aprepitant y de la dimeglumina de fosaprepitant en pacientes pediátricos que reciben quimiot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005515-10,1,1,0 2006-005515-10,7,2014-01-20,2014-02-10,6,1,1,0,0,0,1,0,0,2,1,0,0,0,2,Laboratoires Merck Sharp & Dhome-Chibret,"""Estudio multicéntrico, abierto, de 5 partes para evaluar la farmacocinética, seguridad y tolerabilidad del aprepitant y de la dimeglumina de fosaprepitant en pacientes pediátricos que reciben quimiot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005515-10,1,1,0 2006-005515-10,7,2014-01-20,2014-02-10,6,1,1,0,0,0,1,0,0,2,1,0,0,0,2,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA","""Estudio multicéntrico, abierto, de 5 partes para evaluar la farmacocinética, seguridad y tolerabilidad del aprepitant y de la dimeglumina de fosaprepitant en pacientes pediátricos que reciben quimiot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005515-10,1,1,0 2006-005515-10,7,2014-01-20,2014-02-10,6,1,1,0,0,0,1,0,0,2,1,0,0,0,2,Merck Sharp & Dohme Corp,"""Estudio multicéntrico, abierto, de 5 partes para evaluar la farmacocinética, seguridad y tolerabilidad del aprepitant y de la dimeglumina de fosaprepitant en pacientes pediátricos que reciben quimiot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005515-10,1,1,0 2006-005515-10,7,2014-01-20,2014-02-10,6,1,1,0,0,0,1,0,0,2,1,0,0,0,2,"Merck & Co., Inc","""Estudio multicéntrico, abierto, de 5 partes para evaluar la farmacocinética, seguridad y tolerabilidad del aprepitant y de la dimeglumina de fosaprepitant en pacientes pediátricos que reciben quimiot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005515-10,1,1,0 2006-005518-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Örebro University Hospital,"Epidural analgesia or opatient controlled regional analgesia for radical Retropubic Prostatectomy. A randomized, double-blind study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005518-11,0,0,0 2006-005520-16,14,2011-11-30,2012-05-08,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A multi-center, randomized, double-blind, placebo-controlled phase III trial comparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005520-16,0,0,0 2006-005520-16,14,2011-11-30,2012-05-08,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A multi-center, randomized, double-blind, placebo-controlled phase III trial comparing the efficacy of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus rituximab and CHOP (R-CHOP) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005520-16,0,0,0 2006-005523-42,9,2011-01-28,2011-04-12,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg once daily) against Placebo and Oxybutynin Hydrochloride (5 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005523-42,0,0,0 2006-005525-33,1,2008-01-09,2008-01-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Heidelberg Pharma GmbH,A Multi-Centre Double-Blind Randomised Placebo-Controlled Phase II Study of HDP 99.0006 in Patients with Actinic Keratosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005525-33,0,0,0 2006-005526-23,1,2011-11-18,2011-11-18,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Provexis Plc,Randomised controlled trial of soluble plantain fibre for maintenance of health during periods of remission in Crohn's disease v2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005526-23,0,0,0 2006-005530-21,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,University Hospital Gent,"Comparison of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with gadofosveset trisodium (Vasovist, Schering, Berlin, Germany) to gadopentetate dimeglumine (GD-DTPA, Magnevist, Scherin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005530-21,0,0,0 2006-005531-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Klinik für Anästhesiologie Universitätsklinikum Aachen,Xenon als Antidepressivum,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005531-17,0,0,0 2006-005533-38,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,3,there is no sponsor.,'Studies in patients with chronic cough; montelukast and amitriptyline studies’.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005533-38,0,0,0 2006-005534-20,1,2012-04-30,2012-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London,Effect of Erdosteine on inflammatory and oxidative biomarkers in sputum and exhaled breath in patients with COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005534-20,0,0,0 2006-005537-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Nîmes,"Etude de prédiction de la réponse à une chimiothérapie d’induction de 3 cures de Docetaxel, Cisplatine et 5-Fluorouracile, des carcinomes épidermoïdes des voies aéro-digestives supérieures de stades T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005537-38,0,0,0 2006-005545-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hôpitaux Universitaires de Strasbourg,Efficacité et sécurité du traitement de l'hypertension artérielle au cours de la pré-éclampsie sévère. Etude préliminaire d'équivalence entre l'Urapidil(Eupressyl*) et la nicardipine(Loxen*),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005545-11,0,0,0 2006-005546-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Effet d'une héparine de bas poids moléculaire sur la mortalité du cancer bronchique non à petites cellules de stade I, II ou IIIa. Un essai multicentrique, randomisé, ouvert.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005546-36,0,0,0 2006-005549-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Chimiothérapie par Témozolomide dans le traitement des glioblastomes supratentoriels des sujets de 70 ans et plus présentant un état fonctionnel altéré (IK<70).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005549-12,0,0,0 2006-005550-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Essai de phase II évaluant l'association de FOLFOX et CETUXIMAB avec radiothérapie concomitante en traitement des cancers de l'oesophage de stade III,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005550-72,0,0,0 2006-005552-33,3,2010-05-05,2010-05-31,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GENENTECH , INC","A PHASE Ib/II, OPEN LABEL, MULTICENTER STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF Apo2L/TRAIL ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB TO SUBJECTS WITH FOLLICULAR AND OTHER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005552-33,0,0,0 2006-005552-33,3,2010-05-05,2010-05-31,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Genentech Inc.,"A PHASE Ib/II, OPEN LABEL, MULTICENTER STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF Apo2L/TRAIL ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB TO SUBJECTS WITH FOLLICULAR AND OTHER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005552-33,0,0,0 2006-005554-74,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació de LLuita contra la Sida,Estudio piloto para evaluar la eficacia y seguridad en las 12 primeras semanas de altas dosis de Ribavirina (1600 mg/día) con apoyo de Epoetina β (450 UI/kg/semana) en la terapia de inducción en pacie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005554-74,0,0,0 2006-005555-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Univ.-Prof. Dr. Doris Balogh,increased efficacy of lidocaine when amitriptyline is added for local anaesthesia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005555-15,0,0,0 2006-005556-32,4,2008-05-28,2008-08-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MENARINI RICERCHE S.P.A.,Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy versus Olmesartan Medoxomil 40 mg Monotherapy in Patients with Essential H...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005556-32,0,0,0 2006-005556-32,4,2008-05-28,2008-08-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Menarini Ricerche S.p.A.,Phase III Study Evaluating the Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide 40/12.5 mg Combination Therapy versus Olmesartan Medoxomil 40 mg Monotherapy in Patients with Essential H...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005556-32,0,0,0 2006-005557-30,1,2007-05-04,2007-05-04,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Chiesi Farmaceutici S.p.A.,"In-vivo deposition measurement of formoterol and beclomethasone after inhalation of a single dose of the combination Formoterol plus BDP HFA pMDI (Foster®, Chiesi) in healthy volunteers, asthmatic an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005557-30,0,0,0 2006-005558-63,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Novartis Vaccines and Diagnostics S.r.l.,"A phase III, randomized, controlled, observer-blind, single-center study to compare immunogenicity and safety of an MF59-adjuvanted inactivated subunit influenza vaccine (FLUAD™) to those of a nonadju...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005558-63,0,0,0 2006-005562-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),ALFA 0703 : A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination with Chemotherapy or azacitidine as salvage therapy and Azacitidine as Mainte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005562-39,0,0,0 2006-005564-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Laboratoire IASON,Imagerie fonctionnelle de l'hypoxie du cancer du col utérin par 18F-FETNIM TEP/TDM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005564-12,0,0,0 2006-005565-18,1,2008-08-04,2008-08-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Research and Development Department, University Hospital of South Manchester NHS Foundation Trust",Efficacy and tolerability of Ezetimibe in cardiac transplant recipients taking Cyclosporin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005565-18,0,0,0 2006-005566-39,1,2010-10-21,2010-10-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Christie Hospital NHS Foundation Trust,Concurrent chemoradiotherapy for stage III non small cell lung cancer followed by consolidation pemetrexed: a phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005566-39,0,0,0 2006-005567-26,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,University of Aachen,Effects of deep brain stimulation of the nucleus accumbens on the dopaminergic activity in patients with Gilles-de-la-Tourette-syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005567-26,0,0,0 2006-005568-24,1,2007-09-17,2007-09-17,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,Dermatologikum Hamburg,Prüfung der Wirksamkeit und der Verträglichkeit von Botulinum-Toxin (Xeomin®) in verschiedenen Verdünnungen Evaluation of the Efficacy and Safety of Botulinumtoxin (Xeomin®) in different dilutions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005568-24,0,0,0 2006-005570-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,NYCOMED PHARMA S.A.,"""Ensayo clínico multicéntrico, longitudinal, prospectivo, fase IV que compara dos técnicas de imagen (ImaTx y DXA) para evaluar el efecto anabólico de la PTH (1-84) en mujeres postmenopáusicas con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005570-42,0,0,0 2006-005573-21,5,2013-12-03,2014-06-10,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Pfizer Inc,","A TWO-ARM RANDOMIZED OPEN LABEL PHASE 2 STUDY OF CP-751,871 IN COMBINATION WITH EXEMESTANE VERSUS EXEMESTANE ALONE AS FIRST LINE TREATMENT FOR POSTMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR POSITIVE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005573-21,1,0,0 2006-005573-21,5,2013-12-03,2014-06-10,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A TWO-ARM RANDOMIZED OPEN LABEL PHASE 2 STUDY OF CP-751,871 IN COMBINATION WITH EXEMESTANE VERSUS EXEMESTANE ALONE AS FIRST LINE TREATMENT FOR POSTMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR POSITIVE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005573-21,1,0,0 2006-005575-17,4,2018-04-18,2018-04-18,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"An Open-Label Study to Evaluate Prophylaxis Treatment, and to Characterize the , Efficacy, Safety and Pharmacokinetics of B Domain Deleted Recombinant Factor VIII Albumin Free (ReFacto AF) in Children...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005575-17,0,0,0 2006-005575-17,4,2018-04-18,2018-04-18,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc. acting through its division Wyeth Research, a Pfizer Company","An Open-Label Study to Evaluate Prophylaxis Treatment, and to Characterize the , Efficacy, Safety and Pharmacokinetics of B Domain Deleted Recombinant Factor VIII Albumin Free (ReFacto AF) in Children...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005575-17,0,0,0 2006-005576-40,1,2013-10-31,2013-10-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU-Hôpitaux de ROUEN,Etude de faisabilité de 2 phases II parallèles pré et post-gastrectomie : étude de faisabilité d'un traitement de chimiothérapie et radiothérapie pré-opératoire de l'adénocarcinome gastrique (LV5FU2s ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005576-40,0,0,0 2006-005578-39,1,2008-06-30,2008-06-30,1,1,0,0,0,0,2,0,1,1,1,1,1,0,1,GlaxoSmithKline,"A randomised, double-blind, placebo-controlled study to explore the antidepressant properties of the P38a kinase inhibitor GW856553X 15mg compared to placebo in subjects with Major Depressive Disorder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005578-39,0,0,0 2006-005579-16,6,2008-07-18,2008-08-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research Development,"Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005579-16,0,0,0 2006-005579-16,6,2008-07-18,2008-08-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005579-16,0,0,0 2006-005579-16,6,2008-07-18,2008-08-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A. España,"Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir, Administered with Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005579-16,0,0,0 2006-005581-39,9,2010-02-11,2010-02-11,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,"A double blind, multicenter, international randomised study to assess the effects of 6 months or 12 months administration of 2 g per day of strontium ranelate versus alendronate 70 mg per week on bone...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005581-39,0,0,0 2006-005581-39,9,2010-02-11,2010-02-11,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Servier Research and Development Ltd,"A double blind, multicenter, international randomised study to assess the effects of 6 months or 12 months administration of 2 g per day of strontium ranelate versus alendronate 70 mg per week on bone...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005581-39,0,0,0 2006-005581-39,9,2010-02-11,2010-02-11,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Institut de Recherches Internatinales Servier,"A double blind, multicenter, international randomised study to assess the effects of 6 months or 12 months administration of 2 g per day of strontium ranelate versus alendronate 70 mg per week on bone...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005581-39,0,0,0 2006-005581-39,9,2010-02-11,2010-02-11,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"A double blind, multicenter, international randomised study to assess the effects of 6 months or 12 months administration of 2 g per day of strontium ranelate versus alendronate 70 mg per week on bone...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005581-39,0,0,0 2006-005585-40,1,2008-12-20,2008-12-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,"A randomized, parallel group, multiple dose, 6 week study to evaluate safety, tolerability, and pharmacokinetics of asenapine in elderly subjects with psychosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005585-40,0,0,0 2006-005588-24,1,2008-08-07,2008-08-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"Multi-center, open-label, multiple dose study in mild to moderate asthmatics (with IgE/body weight combinations above that in the SmPC dosing table) to determine safety, tolerability, pharmacokinetics...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005588-24,0,0,0 2006-005589-38,1,2008-06-05,2008-06-05,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 2, Single Blind, Single Center, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, when Administered to Healthy Infants 6-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005589-38,0,0,0 2006-005592-17,1,2009-10-16,2009-10-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Schering-Plough AB Sweden,Caelyx® in Breast Cancer in the Elderly Pegylated Liposomal Doxorubicin (Caelyx®) as monotherapy in elderly patients with locally advanced and/or metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005592-17,0,0,0 2006-005594-21,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire,Intérêt de l'association d'un bloc périphérique (pudendal et paracervical) dans l'analgésie post-opératoire d'une chirurgie pelvienne par voie vaginale,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005594-21,0,0,0 2006-005597-43,1,2013-07-03,2013-07-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Birmingham,Topical Retinoids and Diabetic Neuropathic Ulceration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005597-43,0,0,0 2006-005597-43,1,2013-07-03,2013-07-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Birmingham Heartlands Hospital,Topical Retinoids and Diabetic Neuropathic Ulceration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005597-43,0,0,0 2006-005602-31,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Academic Medical Center,Excimer laser versus clobetason propionaat in prurigo form of atopic dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005602-31,0,0,0 2006-005604-14,1,2017-11-29,2017-11-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"A randomized, prospective, multicenter trial to compare the effect on chronic allograft nephropathy prevention of mycophenolate mofetil versus azathioprine as the sole immunosuppressive therapy for k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005604-14,0,0,0 2006-005607-33,1,2009-05-07,2009-05-07,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"KOMINOX USA, Inc.",A Clinical Phase II Study in Patients with Prostate Cancer and Bone Metastases with KML001 (KOMINOX®),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005607-33,0,0,0 2006-005608-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Institut für Atemwegsforschung GmbH,Efficacy of Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005608-15,0,0,0 2006-005609-76,1,2007-03-02,2007-03-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,St Stephens Aids Trust,EFFECT OF DIFFERENT MEALS ON THE PHARMACOKINETIC PROFILE OF SAQUINAVIR AT STEADY STATE IN HIV-INFECTED PATIENTS TREATED WITH SAQUINAVIR/RITONAVIR 1000/100 mg BID.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005609-76,0,0,0 2006-005614-12,1,2007-12-21,2007-12-21,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Medical University Vienna,CSE at Vaginal Delivery - MLAD of Ropivacain and the Effect of Sufentanil,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005614-12,0,0,0 2006-005619-88,1,2011-07-18,2011-07-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farma, S.A.","Estudio Fase II de bevacizumab en combinación con docetaxel y cisplatino, como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico metastásico o localmente avanzado",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005619-88,0,0,0 2006-005621-28,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Roche (Hungary) Ltd,"A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin levels in dialysis patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005621-28,0,0,0 2006-005626-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,PHASE II STUDY ON PEMETREXED IN ADVANCED AND/OR RECURRENT CERVICAL CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005626-24,0,0,0 2006-005628-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPO DE TERAPIA CELULAR Y CARDIOVASCULAR DEL HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS,Estudio abierto con evaluador ciego de la eficacia de las células mononucleares autólogas de médula ósea en la regeneración muscular y vascular en pacientes con disfunción ventricular izquierda tras i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005628-17,0,0,0 2006-005630-21,1,2014-05-19,2014-05-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Birmingham,The effect of Pregabalin on Pain progressing in Painful Diabetic Neuropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005630-21,0,0,0 2006-005630-21,1,2014-05-19,2014-05-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Birmingham Heartlands Hospital,The effect of Pregabalin on Pain progressing in Painful Diabetic Neuropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005630-21,0,0,0 2006-005635-25,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Postoperative pain after cesarean section :efficacy of S-ketamine at antihyperalgesic doses.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005635-25,0,0,0 2006-005637-37,1,2007-05-24,2007-05-24,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Astion Danmark A/S,"Comparative, placebo controlled, double-blind efficacy and safety study in patients with seborrhoeic dermatitis comparing a topical cream containing 2% Nicotinamide combined with either 0%, 0.5% or 1....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005637-37,0,0,0 2006-005640-81,1,2010-04-09,2010-04-09,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University of Leeds,A PLACEBO CONTROLLED STUDY OF THE EFFECT OF EXTENDED TREATMENT WITH RITUXIMAB ON RESISTANT RHEUMATOID ARTHRITIS:,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005640-81,0,0,0 2006-005642-37,1,2011-03-10,2011-03-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"University of Leuven, Division of Gastroenterology",Sandostatin® in the treatment of diarrhea in patients with ileal pouch anal anastomosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005642-37,0,0,0 2006-005644-92,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Antonio Cubillo Gracián (Servicio de Oncología Médica - Hospital MD Anderson),"ENSAYO CLÍNICO ABIERTO, NO ALEATORIZADO, PILOTO, EN FASE II, DE LA COMBINACIÓN DE IFOSFAMIDA Y DOXORRUBICINA LIPOSÓMICA SEGUIDO DE RADIOTERAPIA COMO TRATAMIENTO ANTINEOPLÁSICO NEOADYUVANTE EN PACIENTE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005644-92,0,0,0 2006-005649-12,1,,,0,0,0,0,0,0,4,0,1,3,0,0,0,0,1,Regent Medical,A 96 hour (4-application) patch test and TEWL assessment in healthy volunteers to investigate the comparative skin irritation potential of six antiseptics and two controls following cutaneous patch ap...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005649-12,0,0,0 2006-005654-77,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Labetalol versus MgSO4 for the Prevention of Eclampsia Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005654-77,0,0,0 2006-005657-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Assistance Publique Hopitaux de marseille,"Etude pharmacocinétique, prospective, ouverte, de la diffusion de l’Ertapénème dans le muscle par microdialyse chez des patients de réanimation sous ventilation mécanique, recevant ou non des vasopres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005657-30,0,0,0 2006-005658-66,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation de l'efficacité des corticoïdes dans la prévention de la paralysie faciale après chirurgie d'exérése d'une tumeur du méat auditif interne et /ou de l'angle ponto-cérébelleux,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005658-66,0,0,0 2006-005667-26,1,2008-05-15,2008-05-15,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Ninewells Hospital,"A randomised, placebo controlled trial of levobupivacaine or the combination of levobupivacaine and clonidine when administered as a sciatic perineural infusion for the prevention of phantom limb pain...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005667-26,0,0,0 2006-005668-21,1,2008-05-27,2008-05-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare International Limited,"A randomised, double-blind, parallel group, multiple-dose 3 month study of ibuprofen 400mg alone, paracetamol (acetaminophen) 1000mg alone, ibuprofen 200mg plus paracetamol 500mg and ibuprofen 400mg p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005668-21,0,0,0 2006-005670-45,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St. Antonius hospital Nieuwegein,Population pharmacokinetics/pharmacodynamics of Propofol in morbidly obese patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005670-45,0,0,0 2006-005672-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Pierre Fabre Médicament,Etude de l’efficacite de la dihydroergotamine par voie orale dans l’hypotension orthostatique de patients dysautonomiques,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005672-41,0,0,0 2006-005673-21,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,0,A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA,PROTOCOL OF DIAGNOSIS AND THERAPY FOR RETINOBLASTOMA - AIEOP RB 05,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005673-21,0,0,0 2006-005674-47,5,2009-09-14,2009-09-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Long-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an ope...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005674-47,0,0,0 2006-005677-22,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,AstraZeneca AB,A follow-up programme for patients using Symbicort® Turbuhaler® maintenance and reliever therapy in normal clinical practice,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005677-22,0,0,0 2006-005678-36,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,CHU de Nice,Oral alendronate for osteoporosis treatment in non-walking children with cerebral palsy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005678-36,0,0,0 2006-005681-39,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,FARMIGEA,"A RANDOMIZED, DOUBLE-BLIND, MULTICENTER PARALLEL GROUP STUDY ON EFFICACY AND SAFETY OF KETOTIFEN FUMARATE 0.05 OPHTHALMIC SOLUTION VERSUS KETOTIFEN FUMARATE 0.025",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005681-39,0,0,0 2006-005684-26,1,2013-04-30,2013-04-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Universitätsklinik für Augenheilkunde und Optometrie, AKH Wien",Identification and Quantification of Cytokines in Anti-VEGF Therapy and Genetic Risk Factors in Exsudative Age-related Macular Degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005684-26,0,0,0 2006-005687-44,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Wyeth Research,"A Randomized, Open-Label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005687-44,0,1,1 2006-005689-38,3,2007-07-18,2007-10-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,EVALUATION OF THE EFFECT OF 4 WEEKS TREATMENT WITH CHF 4226 pMDI 2µg DOSE GIVEN ONCE DAILY IN THE EVENING ON 24-HOUR TROUGH FEV1 IN ADULT AND ADOLESCENT PATIENTS AGED 15 YEARS OR OVER WITH MODERATE OR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005689-38,0,0,0 2006-005691-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AIR LIQUIDE SANTE INTERNATIONAL,Faisabilité de la sédation par inhalation de Kalinox® 170 bar au cours des actes thérapeutiques en odontologie de ville,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005691-40,0,0,0 2006-005692-18,7,2008-06-03,2009-05-23,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,VIROPHARMA INCORPORATED,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECIPIENTS OF ALLOGENEIC STEM C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005692-18,0,0,0 2006-005692-18,7,2008-06-03,2009-05-23,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ViroPharma Incorporated,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECIPIENTS OF ALLOGENEIC STEM C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005692-18,0,0,0 2006-005694-21,4,2015-06-30,2016-07-01,2,0,0,0,0,2,2,0,0,2,0,0,0,0,0,HOPITAL MIGNOT,AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH DASATINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHILADE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005694-21,1,0,0 2006-005694-21,4,2015-06-30,2016-07-01,2,0,0,0,0,2,2,0,0,2,0,0,0,0,0,CH Versailles,AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH DASATINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHILADE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005694-21,1,0,0 2006-005694-21,4,2015-06-30,2016-07-01,2,0,0,0,0,2,2,0,0,2,0,0,0,0,0,CH-Versailles,AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH DASATINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHILADE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005694-21,1,0,0 2006-005696-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MOLMED,NGR008 A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by advanced or metastatic hepatocellular carcinoma HCC previously treated with no more than one s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005696-18,0,0,0 2006-005697-46,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,SOFAR SPA,"Prevention of actinic proctitis by beclomethasone dipropionate. A prospectic,randomised, double blind placebo controlled pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005697-46,0,0,0 2006-005700-14,1,2015-12-03,2015-12-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MOLMED,NGR007 A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by advanced or metastatic small cell lung carcinoma SCLC previously treated with no more than one...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005700-14,0,0,0 2006-005703-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Ageo,Essai de phase II : Folfiri.3 (CPT-11/acide folinique/5-FU) / gemzar en traitement sequentiel des cancers du pancréas métastatiques non pré-traités,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005703-34,0,0,0 2006-005704-13,1,2010-09-01,2010-09-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Queen Mary, University of London",A Phase II Study of Intravenous CNTO328 in Patients with Recurrent Epithelial Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005704-13,0,0,0 2006-005710-12,1,2010-02-28,2010-02-28,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Charité Universitätsmedizin Berlin,Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005710-12,0,0,0 2006-005711-10,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Orexo AB,"A double-blind, randomised, two-period crossover study to evaluate the hypnotic effects and safety of sublingual zolpidem for the treatment of insomnia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005711-10,0,0,0 2006-005712-27,12,2015-12-22,2015-12-22,11,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philadelphia Chromoso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005712-27,0,0,0 2006-005712-27,12,2015-12-22,2015-12-22,11,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL®) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philadelphia Chromoso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005712-27,0,0,0 2006-005713-35,2,2007-11-19,2007-11-19,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Curalogic A/S,"A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSEST THE EFFICACY AND SAFETY OF ORAL MICROENCAPSULED RAGWEED POLLEN EXTRACT ADMINISTERED PRIOR TO AND DURING THE RAGWEED POLLE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005713-35,0,0,0 2006-005713-35,2,2007-11-19,2007-11-19,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,CURALOGIC,"A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSEST THE EFFICACY AND SAFETY OF ORAL MICROENCAPSULED RAGWEED POLLEN EXTRACT ADMINISTERED PRIOR TO AND DURING THE RAGWEED POLLE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005713-35,0,0,0 2006-005715-10,1,2011-09-30,2011-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Brompton & Harefield NHS Trust,The Control of Hyperglycaemia In Paediatric intensive care (The CHIP Trial).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005715-10,0,0,0 2006-005719-89,1,2009-12-01,2009-12-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Meander Medical Center,Double blind placebo controlled study on the efficacy of melatonin on sleep parameters and quality of life in hemodialysis patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005719-89,0,0,0 2006-005721-28,1,2008-04-08,2008-04-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Servier s.r.o.,"EDET study - Efficacy of Detralex® in Edema Treatment. An open, 6-month, multicentre study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005721-28,0,0,0 2006-005722-23,3,2010-02-02,2010-02-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"Open-label, single-arm, multi-center, pharmacokinetic, safety and tolerability study of levetiracetam intravenous infusion in children (4 - 16 years old) with epilepsy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005722-23,0,0,0 2006-005727-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Laboratorios LETI S.L.,"Ensayo clínico, multicéntrico, aleatorizado, doble ciego controlado con placebo, de inmunoterapia subcutánea con extracto despigmentado y polimerizado de polen de Olea europaea en pacientes con hipers...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005727-41,0,0,0 2006-005728-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO,Hormone-refractory Prostate cancer first Line Intermittent Taxotere and Estramustine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005728-17,0,0,0 2006-005731-16,1,2008-09-12,2008-09-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ThromboGenics Ltd.,An Open Label Clinical Trial of Microplasmin Administered via the Trellis-8 Infusion System for the Treatment of Acute Iliofemoral Deep Vein Thrombosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005731-16,0,0,0 2006-005733-38,3,2008-06-14,2008-06-14,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, open, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine or Prevenar when given as a b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005733-38,0,0,0 2006-005733-38,3,2008-06-14,2008-06-14,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A phase III, open, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine or Prevenar when given as a b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005733-38,0,0,0 2006-005734-20,1,2008-06-27,2008-06-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen L.P.,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Flexible Dose Paliperidone ER in the Treatment of Subjects with Schizoaffective Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005734-20,0,0,0 2006-005740-83,1,2012-03-12,2012-03-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Southampton,"A Pragmatic Randomised Trial of Ibuprofen, Paracetamol, Steam and Delayed Prescribing for Patients with Respiratory Tract Infections in Primary Care",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005740-83,0,0,0 2006-005742-37,1,2010-05-31,2010-05-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,NHS Glasgow and Clyde / University of Glasgow,Randomised clinical trial of the effects of total intravenous anaesthesia (TIVA: propofol) versus volatile anaesthesia (sevoflurane-N20 induction and isoflurane-N20 maintenance) on children’s post-op...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005742-37,0,0,0 2006-005744-92,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU - Hôpitaux de Rouen,Evaluation de l'efficacité et de la tolérance d'un anticorps monoclonal anti-CD20 : Rituximab (Mabthera(R)) dans le traitement des rechutes de pemphigoïde bulleuse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005744-92,0,0,0 2006-005745-11,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Efficacité du minoxidil chez les enfants atteints du syndrome de Williams et Beuren : un essai clinique randomisé,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005745-11,0,0,0 2006-005746-36,1,2008-04-30,2008-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs. capecitabine (Xeloda) in Patients with Advanced or Metastatic Pancreatic Cancer, who have Failed First Line gemcitab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005746-36,0,0,0 2006-005747-29,2,2008-10-10,2008-10-10,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005747-29,0,0,0 2006-005747-29,2,2008-10-10,2008-10-10,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,F. HOFFMANN-LA ROCHE LTD,Evaluation of the relationship between HDL quantity and HDL functionality in patients treated with HDL-C raising drugs,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005747-29,0,0,0 2006-005748-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU - Hôpitaux de Rouen,Traitement des syndromes d'hypersensibilité médicamenteuse par Immunoglobuline polyvalente IV (Tégéline ),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005748-10,0,0,0 2006-005750-68,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,ADENOBIO N.V.,"Etude clinique de phase II, monocentrique, en simple aveugle comparant l'efficacité et la tolérance de l'administration intraveineuse de dipyridamole et d'adénosine donnés séquentiellement ou de façon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005750-68,0,0,0 2006-005751-16,3,2008-06-30,2008-06-30,2,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Novo Nordisk A/S,"An open label, dose escalation safety and tolerability trial of the combination of s.c. recombinant human IL-21 (rIL-21) and sunitinib (phase 1) followed by an open label stratified randomized 2-arm t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005751-16,0,0,0 2006-005753-29,6,2008-12-03,2008-12-12,5,1,0,0,1,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche et développement,"A single-blind, placebo-controlled, multicentre study evaluating continued long-term treatment with satavaptan (SR121463B) in patients with ascites due to liver cirrhosis who have previously been trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005753-29,0,0,0 2006-005753-29,6,2008-12-03,2008-12-12,5,1,0,0,1,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche et de'veloppement,"A single-blind, placebo-controlled, multicentre study evaluating continued long-term treatment with satavaptan (SR121463B) in patients with ascites due to liver cirrhosis who have previously been trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005753-29,0,0,0 2006-005754-80,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Karolinska University Hospital,"Standard treatment compared to intensified treatment with pegfilgrastim support in patients with small-cell lung cancer, limited disease. A phase III study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005754-80,0,0,0 2006-005754-80,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Swedish Lung Cancer Group,"Standard treatment compared to intensified treatment with pegfilgrastim support in patients with small-cell lung cancer, limited disease. A phase III study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005754-80,0,0,0 2006-005756-32,1,2008-04-20,2008-04-20,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Fredericia Hospital,Pharmacological modulation of the intrarenal pressure during endourological procedures in the upper urinary tract,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005756-32,0,0,0 2006-005757-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI,MIRACL IN CABG - Statins in cardiac surgery. Effect of doses on inflammatory response and early results,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005757-30,0,0,0 2006-005758-64,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHRU TOURS,Evaluation médico-économique de l'échographie de contraste pour l'appréciation précoce de l'effet du bevacizumab sur les métastases hépatiques de cancer colorectal,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005758-64,0,0,0 2006-005759-13,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,"MADAUS, S.A.","Ensayo clínico multicéntrico, aleatorizado, con grupos paralelos, controlado con placebo y doble ciego, para valorar la eficacia del tratamiento con 320 mg al día de Acetato de Megestrol durante 24 se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005759-13,0,0,0 2006-005761-19,1,,,0,0,0,0,1,0,4,1,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Ketamine versus etomidate au cours de l'intubation en séquence rapide : conséquences sur la morbidité hospitalière,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005761-19,0,0,0 2006-005764-81,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,LUSOFARMACO,FROVATRIPTAN VERSUS ZOLMITRIPTAN IN THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA A PATIENT PREFERENCE STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005764-81,0,0,0 2006-005766-39,5,2009-03-05,2010-02-02,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Centocor B.V.,"A Randomized, Double-blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human aV Integrins (CNTO 95) in Combination With Docetaxel and Prednisone for the First-Line Treatment of Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005766-39,0,0,0 2006-005767-26,1,2011-09-23,2011-09-23,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,The Department of Calcium- and Bone-metabolic Diseases,The effect of calcium and vitamin D on the heartmusclef unction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005767-26,0,0,0 2006-005770-44,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Clermont-Ferrand,MESURE ET COMPARAISON DES CONCENTRATIONS PLASMATIQUES ARTERIELLES ET VEINEUSES DE PROPOFOL CHEZ DES PATIENTS DE REANIMATION SOUS SEDATION PAR LE SYSTEME AIVOC.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005770-44,0,0,0 2006-005772-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"investigator-driven research: Erasmus MC, Neurovascular Section","LIMIT: Lowering the Incidence of vascular complications with Metformin in patients with Impaired glucose tolerance and a recent TIA or minor ischemic stroke: a phase 2, randomized, controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005772-41,0,0,0 2006-005774-50,1,2011-03-11,2011-03-11,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Central Manchester & Manchester Children's University Hospitals NHS Trust,Protocol for taking pharmacogenetic testing of tacrolimus into the clinical arena: patient tailored anti-rejection therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005774-50,0,0,0 2006-005777-22,1,2011-09-29,2011-09-29,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Dermal Laboratories,Control of MRSA skin and wound colonisation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005777-22,0,0,0 2006-005778-34,3,2013-09-10,2015-06-30,2,0,0,0,0,0,2,0,0,2,0,0,0,0,0,"Charité-Universitätsmedizin Berlin, Germany",Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma (and selected patients with extended stage II) followed by consolidatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005778-34,1,0,0 2006-005778-34,3,2013-09-10,2015-06-30,2,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Charite-Universitätsmedizin Berlin Germany,Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma (and selected patients with extended stage II) followed by consolidatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005778-34,1,0,0 2006-005780-26,6,2010-08-20,2010-08-20,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Integrated Therapeutics Group Inc.,"Ensayo en fase II, multinacional, aleatorizado para evaluar la seguridad de dos pautas de quimioterapia más trastuzumab como terapia adyuvante en pacientes con cáncer de mama HER2-positivo: Caelyx + c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005780-26,0,0,0 2006-005780-26,6,2010-08-20,2010-08-20,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Schering Plough Research Institute, a Division of Schering Corporation","Ensayo en fase II, multinacional, aleatorizado para evaluar la seguridad de dos pautas de quimioterapia más trastuzumab como terapia adyuvante en pacientes con cáncer de mama HER2-positivo: Caelyx + c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005780-26,0,0,0 2006-005780-26,6,2010-08-20,2010-08-20,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SCHERING-PLOUGH,"Ensayo en fase II, multinacional, aleatorizado para evaluar la seguridad de dos pautas de quimioterapia más trastuzumab como terapia adyuvante en pacientes con cáncer de mama HER2-positivo: Caelyx + c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005780-26,0,0,0 2006-005780-26,6,2010-08-20,2010-08-20,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Schering-Plough Research Institute, a Divison of Schering Corporation","Ensayo en fase II, multinacional, aleatorizado para evaluar la seguridad de dos pautas de quimioterapia más trastuzumab como terapia adyuvante en pacientes con cáncer de mama HER2-positivo: Caelyx + c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005780-26,0,0,0 2006-005780-26,6,2010-08-20,2010-08-20,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Integrated Therapeutics Group, Inc - A Subsidiary of Schering-Plough","Ensayo en fase II, multinacional, aleatorizado para evaluar la seguridad de dos pautas de quimioterapia más trastuzumab como terapia adyuvante en pacientes con cáncer de mama HER2-positivo: Caelyx + c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005780-26,0,0,0 2006-005780-26,6,2010-08-20,2010-08-20,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Schering Plough,"Ensayo en fase II, multinacional, aleatorizado para evaluar la seguridad de dos pautas de quimioterapia más trastuzumab como terapia adyuvante en pacientes con cáncer de mama HER2-positivo: Caelyx + c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005780-26,0,0,0 2006-005783-67,10,2008-07-18,2008-07-18,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,"A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial with Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Prolonged-Release (PR) in Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005783-67,0,0,0 2006-005783-67,10,2008-07-18,2008-07-18,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gruenenthal GmbH,"A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial with Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Prolonged-Release (PR) in Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005783-67,0,0,0 2006-005783-67,10,2008-07-18,2008-07-18,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Laboratorios Andrómaco, S.A (compañía perteneciente al Grupo Grünenthal España)","A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial with Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Prolonged-Release (PR) in Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005783-67,0,0,0 2006-005788-24,4,2009-04-17,2009-09-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bioalliance Pharma,"A Randomised, Double-Blind, Single dose, One-Day Early Administration, Multicentre Study comparing the Efficacy and Safety of Acyclovir Lauriad 50 mg muco-adhesive buccal tablet to matching Placebo, i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005788-24,0,0,0 2006-005789-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hôpital Universitaire Des Enfants Reine Fabiola (H.U.D.E.R.F.),Dexaméthasone et Amygdalectomie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005789-38,0,0,0 2006-005794-22,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,IELSG (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP),A CLINICO-PATHOLOGIC STUDY OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005794-22,0,0,0 2006-005795-41,1,2012-08-02,2012-08-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG),A CLINICO-PATHOLOGICAL PHASE II STUDY WITH TRANSLATIONAL ELEMENTS TO INVESTIGATE THE POSSIBLE INFECTIVE CAUSES OF NON-HODGKIN LYMPHOMA OF THE OCULAR ADNEXAE WITH PARTICULAR REFERENCE TO CHLAMYDIA SPE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005795-41,0,0,0 2006-005796-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,WKZ / UMC Utrecht,Does antenatal allopurinol during asphyxia reduce post-hypoxic-ischemic reperfusion damage in the newborn?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005796-18,0,0,0 2006-005797-44,4,2008-12-30,2008-12-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Efficacy and safety of the fixed oral low-dose perindopril arginine 3.5 mg/amlodipine 2.5 mg combination compared with each component (perindopril arginine 3.5 mg and amlodipine 2.5 mg) and with perin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005797-44,0,0,0 2006-005799-42,3,2009-08-13,2009-08-13,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Perindopril Amlodipine Regimen versus AT1-Receptor Blocker/thiazide: a comparison of Blood pressure Lowering: Efficacy and Safety. A randomised, double blind, 9 month study of the efficacy and safety ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005799-42,0,0,0 2006-005799-42,3,2009-08-13,2009-08-13,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Servier Research and Development Ltd. (S.R.D.L) (for UK only),"Perindopril Amlodipine Regimen versus AT1-Receptor Blocker/thiazide: a comparison of Blood pressure Lowering: Efficacy and Safety. A randomised, double blind, 9 month study of the efficacy and safety ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005799-42,0,0,0 2006-005800-15,1,2015-09-30,2015-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,2,University of Edinburgh,Randomised controlled trial of 6-Mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005800-15,0,0,0 2006-005800-15,1,2015-09-30,2015-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,2,NHS Lothian,Randomised controlled trial of 6-Mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005800-15,0,0,0 2006-005800-15,1,2015-09-30,2015-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,2,,Randomised controlled trial of 6-Mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005800-15,0,0,0 2006-005802-29,1,2010-08-31,2010-08-31,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Gwent Healthcare NHS Trust,Postoperative analgesia for Total knee replacement: A comparision between intrathecal morphine and peripheral nerve block.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005802-29,0,0,0 2006-005803-33,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,THERABEL LUCIEN PHARMA,"ÉTUDE PILOTE OBSERVATIONNELLE CHEZ DES PATIENTES SOUFFRANT D’UN CANCER DU SEIN ET RECEVANT UNE CHIMIOTHÉRAPIE ÉMÉTISANTE TRAITÉES PAR UNE DOSE UNIQUE DE ALOXI® (PALONOSÉTRON) 0,25 MG ASSOCIÉE À UNE CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005803-33,0,0,0 2006-005804-15,10,2008-10-03,2008-10-03,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,Randomized double blind trial to evaluate the efficacy and safety of dronedarone (400 mg BID) versus amiodarone (600 mg daily for 28 days then 200 mg daily thereafter) for at least 6 months for the ma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005804-15,0,0,0 2006-005804-15,10,2008-10-03,2008-10-03,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & de'veloppement,Randomized double blind trial to evaluate the efficacy and safety of dronedarone (400 mg BID) versus amiodarone (600 mg daily for 28 days then 200 mg daily thereafter) for at least 6 months for the ma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005804-15,0,0,0 2006-005807-32,5,2008-11-17,2011-06-16,4,1,0,0,0,0,2,0,2,1,1,0,1,0,1,GlaxoSmithKline Research and Development,"A randomized, double-blind, placebo-controlled, dose ranging study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK221149A administered intravenously and the pharm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005807-32,0,0,0 2006-005807-32,5,2008-11-17,2011-06-16,4,1,0,0,0,0,2,0,2,1,1,0,1,0,1,GlaxoSmithKline S.A.,"A randomized, double-blind, placebo-controlled, dose ranging study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK221149A administered intravenously and the pharm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005807-32,0,0,0 2006-005809-65,1,2007-03-16,2007-03-16,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,"Department of pharmacy, Uppsala University","An open, fixed order, single center pharmacokinetic study of the influence of St John's wort on the pharmacokinetics and metabolism of fiansteride in healthy male subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005809-65,0,0,0 2006-005816-29,1,2011-02-15,2011-02-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Royal Wolverhampton Hospitals Trust,"A Pilot Study of Taxotere (Docetaxel), Cisplatin and 5FU (TPF) in the Palliative Treatment of Squamous Cell Carcinoma of the Head and Neck",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005816-29,0,0,0 2006-005817-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr Manuel Pérez Maraver.Servicio de Endocrinologia. Hospital de Bellvitge,Ensayo Clínico en fase IV para la comparación entre dos pautas de tratamiento (insulina humana vs análogos de insulina) respecto al riesgo de hipoglicemia y la variabilidad del control glicémico en pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005817-36,0,0,0 2006-005819-10,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Philipps-University Marburg,Influence of tiotropium bromide (Spiriva ®) plus salbutamol versus salbutamol on the mucin secretion and sputum properties in subjects with a COPD exacerbation -TIBROMUC-,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005819-10,0,0,0 2006-005831-44,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,A new induction therapy (ThalDoDex) for multiple myeloma. A phase II study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005831-44,0,0,0 2006-005834-19,1,2015-10-15,2015-10-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GBG Forschungs GmbH,"A phase III trials program exploring the integration of Bevacizumab, Everolimus (RAD001), and Lapatinib into current neoadjuvant chemotherapy regimes for primary breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005834-19,0,0,0 2006-005839-20,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Dilafor AB,"A randomised, double-blind, placebo-controlled, multicentre trial to access the safety and efficacy of pre-treatment with DF01 during late pregnancy in reducing prolonged labour.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005839-20,0,0,0 2006-005841-13,1,2009-12-30,2009-12-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Gedeon Richter Plc,"Multicenter, open-label study to investigate the efficacy and safety of Cavinton Forte (vinpocetine) tablet in patients with mild cognitive impairment (MCI).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005841-13,0,0,0 2006-005842-35,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Dipartimento di Pediatria Universita` di Napoli Federico II,Efficacy and safety of treatment with N-butyl-deoxynojirimycin (NB-DNJ-miglustat) in patients with Niemann-Pick disease type C.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005842-35,0,0,0 2006-005845-12,1,2008-09-08,2008-09-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"UZ leuven, Marc Van de Velde",Combined spinal-epidural anaesthesia during labour : has the epidural administration of clonidine and neostigmine a positive influence on the quality of analgesia ?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005845-12,0,0,0 2006-005846-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Centre Hospitalier Universitaire de Montpellier Direction Recherche, Qu",COMPARISON OF TWO KINETICS OF ADMINISTRATION OF BOLUS BY INSULIN PORTABLE PUMP ON THE GLUCOSE BLOOD STABILITY FOR INSULIN-DEPENDENT PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005846-35,0,0,0 2006-005848-87,1,2008-02-04,2008-02-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"CombinatoRx, Inc.","A single-center, randomized, double-blind, vehicle-controlled study to assess the activity of CRx-191 in reducing the psoriatic infiltrate band thickness in plaque psoriasis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005848-87,0,0,0 2006-005851-14,4,2008-08-26,2008-08-26,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FOURNIER LABORATORIES IRELAND Ltd,"A multicenter, double-blind, randomized study to compare the efficacy and safety of the combination of 145 mg fenofibrate and 40 mg simvastatin with 40 mg simvastatin monotherapy in patients with mixe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005851-14,0,0,0 2006-005854-61,1,2011-12-31,2011-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Muenster,Adjunctive antimicrobial therapy of periodontitis: Long-term effects on disease progression and oral microbiological colonization,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005854-61,0,0,0 2006-005855-14,2,2008-02-27,2008-02-27,2,0,0,0,0,1,3,0,0,1,0,0,1,0,1,Ambrilia Biopharma Inc.,"OPEN LABEL, RANDOMIZED STUDY COMPARING THE BIOLOGICAL EFFICACY AND SAFETY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, 30 MG ADMINISTERED INTRA MUSCULARLY EVERY 42 DAYS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005855-14,0,0,0 2006-005856-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"The Department of Molecular Medicin and Surgery, P9:03, Karolinska Institutet","Local Glucocorticoid Injektion in the Treatment of Benign Oesophageal Strictures, a Randomized Clinical Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005856-33,0,0,0 2006-005860-14,1,2008-10-30,2008-10-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NEWRON PHARMACEUTICALS,"A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in patients with idiopathic p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005860-14,0,0,0 2006-005861-21,1,2010-04-29,2010-04-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NEWRON PHARMACEUTICALS,"A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-MONTH EXTENSION STUDY TO INVESTIGATE THE LONG-TERM EFFICACY AND SAFETY OF A LOW (50 MG/DAY) AND HIGH (100 MG/DAY) DOSE OF SAFINAMIDE, AS ADD-ON THERA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005861-21,0,0,0 2006-005862-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UCL Mont Godinne,"Prevention of Postmenopausal Bone Loss in Osteopenic Women with Alendronate given on a 70 mg Once-every two week Regimen : a 2-year, Double-blind, Placebo-controlled Clinical Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005862-38,0,0,0 2006-005868-10,2,2013-01-28,2013-01-28,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratorios LETI S.L.,"Ensayo clínico, multicéntrico, aleatorizado, doble ciego controlado con placebo, de inmunoterapia subcutánea con extracto despigmentado y polimerizado de polen de Phleum pratense en pacientes con hipe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005868-10,0,0,0 2006-005871-17,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Laboratorios LETI S.L.,"Ensayo clínico, multicéntrico, aleatorizado, doble ciego controlado con placebo, de inmunoterapia subcutánea con extracto despigmentado y polimerizado de polen de Parietaria judaica en pacientes con h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005871-17,0,0,0 2006-005872-42,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,1,Pharmion GmbH,A Phase II study of MGCD0103 (MG-0103) in patients with acute myelogenous leukemia/high risk MDS who are elderly and have previously untreated disease or who are adult and have relapsed/refractory dis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005872-42,0,0,0 2006-005883-25,1,2008-08-26,2008-08-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Scil Technology GmbH,Pilot Study on Safety and Explorative Efficacy of MD05 in Comparison with Open Flap Debridement in Patients Undergoing Periodontal Surgery to Treat Deep Intrabony Defects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005883-25,0,0,0 2006-005886-21,1,2009-05-07,2009-05-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Evaluation des effets de l’ivabradine 5 mg et 7.5 mg en 2 prises par jour par voie orale chez des patients insuffisants cardiaques avec une hypertension artérielle insuffisamment équilibrée par Perind...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005886-21,0,0,0 2006-005889-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Centre,N-Acetylcysteine for Treatment of Sickle Cell Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005889-40,0,0,0 2006-005890-24,1,2016-11-16,2016-11-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Leeds Teaching Hospitals NHS Trust,Myeloma X Relapse (Intensive) - A randomised controlled trial to determine the role of a second autologous stem cell transplant as consolidation therapy in patients with relapsed multiple myeloma foll...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005890-24,0,0,0 2006-005891-41,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, observer-blind, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine or Prevenar when g...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005891-41,0,0,0 2006-005893-37,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,NOVARTIS FARMA,"A one year multicenter, randomized, double-blind, placebocontrolled, parallel group study to evaluate the efficacy and safety of a single intravenous 5 mg dose zoledronic acid for the treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005893-37,0,0,0 2006-005894-22,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Evaluation de l'efficacité des traitements substitutifs nicotiniques (dispositifs transdermiques délivrant la nicotine pendant 16h/24h) chez 400 femmes enceintes fumeuses. Essai multicentrique, nation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005894-22,0,0,0 2006-005895-42,1,2009-10-15,2009-10-15,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,TLT Medical Ltd.,A study to determine the safety and efficacy of a terbinafine topical formulation system in subjects with onychomycosis in laser treated toenails versus ciclopirox lacquer in intact toenails,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005895-42,0,0,0 2006-005897-28,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Utilisation du rituximab dans le purpura thrombotique thrombocytopénique autoimmun en association aux échanges plasmatiques,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005897-28,0,0,0 2006-005900-15,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),FORCE : rituximab (anticorps monoclonal anti-CD20 dépléteur des lymphocytes B) pour le traitement des myopathies inflammatoires réfractaires avec auto-anticorps spécifiques et des myasthénies générali...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005900-15,0,0,0 2006-005905-79,1,2010-03-08,2010-03-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"OSI Pharmaceuticals, Inc.",A Phase 2 Randomized Study of Tarceva® (erlotinib) as a Single Agent or Intercalated with Combination Chemotherapy in Patients with Newly Diagnosed Advanced Non-Small Cell Lung Cancer who have Tumors ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005905-79,0,0,0 2006-005906-30,1,2010-05-19,2010-05-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Universitätsklinikum Freiburg, Abteilung klinische Chemie","The effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg plus 10 mg Ezetimibe on LDL-Subfractions in patients with Type 2 Diabetes (Die Wirkung einer Monotherapie mit ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005906-30,0,0,0 2006-005910-11,5,2008-09-19,2009-01-30,5,1,0,0,2,0,3,0,0,1,0,0,1,0,1,GW PHARMA LTD,"A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005910-11,0,0,0 2006-005910-11,5,2008-09-19,2009-01-30,5,1,0,0,2,0,3,0,0,1,0,0,1,0,1,GW Pharma Ltd.,"A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005910-11,0,0,0 2006-005910-11,5,2008-09-19,2009-01-30,5,1,0,0,2,0,3,0,0,1,0,0,1,0,1,GW Pharma Ltd,"A two-phase Phase 3 study of the safety and efficacy of Sativex®, in the symptomatic relief of spasticity in subjects with spasticity due to multiple sclerosis: Phase A – single blind response assessm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005910-11,0,0,0 2006-005911-82,2,2015-08-17,2015-08-17,2,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Allergopharma GmbH & Co. KG,"A multicenter, placebo-controlled, double-blind study to evaluate efficacy and safety of a perennial sublingual specific immunotherapy with a solution of grass pollen allergen extract in children with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005911-82,0,0,0 2006-005911-82,2,2015-08-17,2015-08-17,2,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Allergopharma Joachim Ganzer KG,"A multicenter, placebo-controlled, double-blind study to evaluate efficacy and safety of a perennial sublingual specific immunotherapy with a solution of grass pollen allergen extract in children with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005911-82,0,0,0 2006-005912-28,9,2010-03-17,2010-03-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd.,A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005912-28,0,0,0 2006-005912-28,9,2010-03-17,2010-03-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithkline Research & Development Ltd.,A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005912-28,0,0,0 2006-005912-28,9,2010-03-17,2010-03-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005912-28,0,0,0 2006-005913-37,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,UMC Utrecht,Intratympanic gentamicin therapy for M Meniere: a comparison of two regimes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005913-37,0,0,0 2006-005914-10,4,2007-08-14,2007-08-14,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A,"A Multicentre, Randomised, Double-blind, Placebo and Naproxen (500mg) BID controlled, Phase II Proof of Concept, Parallel Group Study to Assess the Efficacy and Safety of Oral GW842166 at Two Dose Lev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005914-10,0,0,0 2006-005914-10,4,2007-08-14,2007-08-14,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Multicentre, Randomised, Double-blind, Placebo and Naproxen (500mg) BID controlled, Phase II Proof of Concept, Parallel Group Study to Assess the Efficacy and Safety of Oral GW842166 at Two Dose Lev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005914-10,0,0,0 2006-005916-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Westpfalz-Klinikum GmbH,IFEROS – Influence of intravenous iron therapeutics on oxidative stress in hemodialysis patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005916-29,0,0,0 2006-005917-36,2,2008-09-22,2008-09-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open label, single arm study to assess the safety and immunogenicity of omalizumab liquid administered subcutaneously in a pre-filled safety syringe (75 mg or 150 mg) over a period of 6 months to m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005917-36,0,0,0 2006-005917-36,2,2008-09-22,2008-09-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","An open label, single arm study to assess the safety and immunogenicity of omalizumab liquid administered subcutaneously in a pre-filled safety syringe (75 mg or 150 mg) over a period of 6 months to m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005917-36,0,0,0 2006-005920-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Bordeaux,"""Etude d'évaluation du profil d'efficacité/tolérance de 2 doses de dropéridol intraveineux dans la prévention des nausées et des vomissements post-opératoires (NVPO) liés à la chirurgie de la thyroïde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005920-18,0,0,0 2006-005926-22,3,2008-03-13,2008-03-13,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research Ltd.,"An open, randomised, parallel group, multicentre study to compare the efficacy and safety of FlutiForm pMDI vs Seretide pMDI in adult subjects with mild to moderate-severe persistent, reversible asthm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005926-22,0,0,0 2006-005928-16,4,2008-05-20,2008-06-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research Ltd.,"An open, randomised, parallel group, multicentre study to compare the efficacy and safety of FlutiForm pMDI vs Seretide pMDI in paediatric subjects with mild to moderate persistent, reversible asthma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005928-16,0,0,0 2006-005931-56,2,2009-01-23,2009-01-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Initial Therapy With Coadministration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005931-56,0,0,0 2006-005940-99,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,vicente soriano,"Open, multicentral and randomized study of phase IV to evaluate efficacy and safety to extent of treatment with Peginterferon alpha-2a (40 KD) combined with high doses of Ribavirin with support of Ep...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005940-99,0,0,0 2006-005942-35,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Simvastatin therapy in IBM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005942-35,0,0,0 2006-005943-27,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Evaluation of the retinal electrofisiological response in patients with compensated GLAUCOMA POAG in treatment with epigallocatechin-gallate Epinerve .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005943-27,0,0,0 2006-005946-35,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,sanofi-aventis recherche & développement,"Efficacy and safety of 3 intra-articular injections of 500 µg icatibant in a randomized, double-blind, parallel-group, placebo-controlled 13-week multi-centre study in patients with symptomatic knee o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005946-35,0,0,0 2006-005948-90,1,2010-07-31,2010-07-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Serono España, S.A.","Tratamiento con hormona de crecimiento del síndrome de fibromialgia grave asociado a fallo funcional del eje somatotropo. Estudio multicéntrico, aleatorizado, doble ciego y controlado frente a placebo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005948-90,0,0,0 2006-005950-57,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,French Society of Cardiology,Assessment of Endothelial VAsomotricity after treatment by Nicotinic Acid in Patients presenting a recent Acute Coronary Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005950-57,0,0,0 2006-005951-14,2,2016-01-19,2016-04-01,2,1,0,0,0,0,0,0,0,1,0,0,1,0,0,Italian Drug Agency,"A prospective, randomised, open-label blinded end point (PROBE) trial to evaluate, whether, at comparable blood pressure control, combined therapy with the ACE inhibitor benazepril and the angiotensin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005951-14,0,0,0 2006-005951-14,2,2016-01-19,2016-04-01,2,1,0,0,0,0,0,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"A prospective, randomised, open-label blinded end point (PROBE) trial to evaluate, whether, at comparable blood pressure control, combined therapy with the ACE inhibitor benazepril and the angiotensin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005951-14,0,0,0 2006-005953-31,1,2007-08-24,2007-08-24,1,1,0,0,1,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare GmbH & Co. KG,"Inhibition of Dental Plaque Regrowth by an Ethanol-Free 0,2% Chlorhexidine Mouth Rinsing Solution",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005953-31,0,0,0 2006-005954-62,1,2018-06-28,2018-06-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"A prospective, randomized, open label blinded end point probe trial to evaluate whether, at comparable blood pressure control, combined therapy with the ACE inhibitor Benazepril and the angiotensin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005954-62,0,0,0 2006-005956-34,1,2007-04-23,2007-04-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Ltd,"A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0822 in Patients with Osteoarthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005956-34,0,0,0 2006-005962-38,1,2011-02-07,2011-02-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Agence nationale de recherches sur le sida et les hépatites virales ANRS,"Essai randomisé de non-infériorité comparant la capacité à maintenir le succès virologique d’une stratégie de traitement simplifié par une monothérapie d’inhibiteur de protéase boosté, le darunavir/r ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005962-38,0,0,0 2006-005964-24,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,Italfarmaco S.p.A.,"Pharmacokinetics, pharmacodynamics and safety of a new Leuprolide acetate 22.5 mg depot formulation, when given as palliative treatment to prostate cancer patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005964-24,0,0,0 2006-005965-20,1,2007-04-19,2007-04-19,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Roche AB,EFFECTS OF THREE TREATMENT STRATEGIES ON ANEMIA AND QUALITY OF LIFE IN PATIENTS WITH SOLID TUMORS OR LYMPHOPROLIFERATIVE MALIGNANCIES: A RANDOMIZED 3-ARM STUDY ON ACTIVE (A) OR CONVENTIONAL (C) TRANSF...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005965-20,0,0,0 2006-005967-25,3,2007-12-27,2007-12-27,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Biovitrum AB,"A double-blind, placebo-controlled, randomized, parallel-group study evaluating the efficacy and tolerability of oral BVT.115959, a novel A2A agonist, versus placebo in the treatment of diabetic neuro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005967-25,0,0,0 2006-005968-13,3,2007-11-20,2008-11-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ACHILLION PHARMACEUTICALS, INC.","A 14-DAY, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE VIRAL KINETIC STUDY OF ELVUCITABINE VERSUS LAMIVUDINE ADMINISTERED ONCE DAILY TO HIV-1 INFECTED SUBJECTS WITH A DOCUMENTED M184V VARIANT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005968-13,0,0,0 2006-005968-13,3,2007-11-20,2008-11-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Achillion Pharmaceuticals, Inc","A 14-DAY, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE VIRAL KINETIC STUDY OF ELVUCITABINE VERSUS LAMIVUDINE ADMINISTERED ONCE DAILY TO HIV-1 INFECTED SUBJECTS WITH A DOCUMENTED M184V VARIANT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005968-13,0,0,0 2006-005969-18,2,2008-01-28,2008-01-28,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Demonstrate the Effect of 12 Weeks Treatment with Initial Combination of Vildagliptin 100 mg qd plus Metformin 1000 mg bid as compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005969-18,0,0,0 2006-005969-18,2,2008-01-28,2008-01-28,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Demonstrate the Effect of 12 Weeks Treatment with Initial Combination of Vildagliptin 100 mg qd plus Metformin 1000 mg bid as compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005969-18,0,0,0 2006-005970-26,1,2010-01-21,2010-01-21,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,Universitätsklinikum Münster,"A Randomized (Phase II), Double-blind, Multicenter Phase I/II trial of Pemetrexed, Carboplatin plus or minus Sorafenib in the First-line Treatment of Patients with Stage IIIb or IV Non-Small Cell Lung...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005970-26,0,0,0 2006-005971-17,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ELI LILLY,A Phase 2 Study of LY573636 as Treatment for Patients with Platinum-Resistant Ovarian Cancer Protocol H8K-MC-JZAG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005971-17,0,0,0 2006-005972-42,2,2008-05-23,2008-05-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Serono International SA,"A randomized, multicenter, two-arm, open-label, phase IIIb study to evaluate the satisfaction in relapsing Multiple Sclerosis subjects transitioning to Rebif® New Formulation (RNF) from Rebif® (Interf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005972-42,0,0,0 2006-005978-51,1,2009-12-21,2009-12-21,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,sanofi-aventis recherche & développement,"Uncontrolled, multicenter, dose finding, safety and pharmacokinetic study of AVE1642, an anti-Insulin-like Growth Factor-1 Receptor (IGF-1R/ CD221) monoclonal antibody, administered as single agent an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005978-51,0,0,0 2006-005981-37,1,2010-10-28,2010-10-28,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Roskilde Amts Sygehus,Behandling af sekundær hyperparathyreoidisme hos uræmiske patienter. En sammenlignenede undersøgelse mellem virkningen af alfacalcidol og paricalcitol.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005981-37,0,0,0 2006-005991-41,1,2007-09-13,2007-09-13,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,OptiNose UK Ltd.,"A multicentre, double-blind, placebo-controlled evaluation of intranasal sumatriptan delivered with the OptiNose powder device in the treatment of acute migraine.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005991-41,0,0,0 2006-005993-39,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,MOLMED,NGR010: A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by advanced or metastatic malignant pleural mesothelioma previously treated with no more than one s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005993-39,0,0,0 2006-005996-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,"A pilot, open label, multicenter, randomized clinical trial on Lopinavir/ritonavir-monotherapy vs Lopinavir/ritonavir plus selected Nucs, in HIV/HCV ARV-naive coinfected patients with chronic hepatiti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005996-17,0,0,0 2006-005998-21,1,2007-03-21,2007-03-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Laboratoire GlaxoSmithKline,"A multicentre randomised, double-blind, parallel-group study to compare the salmeterol xinafoate/fluticasone propionate combination (Seretide® Diskus® 50/100) 50/100 micrograms one inhalation twice da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005998-21,0,0,0 2006-005999-41,2,2008-04-08,2008-04-28,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, randomized, open, controlled, multicenter primary vaccination study to demonstrate the non inferiority of the immunogenicity of GSK Biologicals’ meningococcal serogroup ACWY conjugate vac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005999-41,0,0,0 2006-006000-11,1,2008-02-04,2008-02-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"An 8 day, randomised, double blinded, placebo-controlled 2-way crossover trial of repeat doses of intranasal GSK256066 and placebo in the Vienna Challenge Chamber in subjects with seasonal allergic rh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006000-11,0,0,0 2006-006004-11,1,2018-07-31,2018-07-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Martin-Luther-Universität Halle-Wittenberg, vertreten durch den Kanzler","Phase II – Studie P-ICE Hochdosischemotherapie mit Paclitaxel, Ifosfamid,Carboplatin und Etoposid mit autologem Stammzellsupport bei männlichen Patienten mit refraktären oder rezidivierten Keimzelltum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006004-11,0,0,0 2006-006010-15,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO EUROPEO DI ONCOLOGIA,"PEGYLATED LIPOSOMAL DOXORUBICIN (CAELYX), CISPLATINUM AND FLUOROURACIL AS CONTINUOUS INFUSION (CCF) PLUS TRASTUZUMAB (HERCEPTIN) IN THE PREOPERATIVE TREATMENT OF LOCALLY ADVANCED BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006010-15,0,0,0 2006-006011-74,1,2011-06-27,2011-06-27,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Rigshospitalet,A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006011-74,0,0,0 2006-006015-72,4,2008-12-18,2008-12-26,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithkline S.A.,Estudio CR9108963: Estudio de búsqueda de dosis optima de SB-751689 en mujeres posmenopáusicas con osteoporosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006015-72,0,0,0 2006-006015-72,4,2008-12-18,2008-12-26,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Ltd.,Estudio CR9108963: Estudio de búsqueda de dosis optima de SB-751689 en mujeres posmenopáusicas con osteoporosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006015-72,0,0,0 2006-006015-72,4,2008-12-18,2008-12-26,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithkline Research and Development Ltd,Estudio CR9108963: Estudio de búsqueda de dosis optima de SB-751689 en mujeres posmenopáusicas con osteoporosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006015-72,0,0,0 2006-006023-39,1,2008-05-15,2008-05-15,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,CSL Behring GmbH,Pharmacokinetics of Haemocomplettan P in subjects with congenital fibrinogen deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006023-39,0,0,0 2006-006025-73,11,2009-06-05,2009-06-05,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Takeda Global Research & Development Centre (Europe) Limited,","A Multicenter, Randomized, Double-Blind Study to Determine the Efficacy and Safety of the Addition of SYR-322 25 mg versus Dose Titration from 30 mg to 45 mg of ACTOS Pioglitazone HCl in Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006025-73,0,0,0 2006-006025-73,11,2009-06-05,2009-06-05,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Global Research & Development Center Inc.,"A Multicenter, Randomized, Double-Blind Study to Determine the Efficacy and Safety of the Addition of SYR-322 25 mg versus Dose Titration from 30 mg to 45 mg of ACTOS Pioglitazone HCl in Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006025-73,0,0,0 2006-006026-25,1,2007-11-26,2007-11-26,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,"Coloplast A/S, Consumer Products",Psoriasis Investigation of 4 different treatment regimes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006026-25,0,0,0 2006-006030-17,5,2010-03-03,2010-03-03,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Orion Corporation Orion Pharma,"A PROSPECTIVE, MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND COMPARISON OF INTRAVENOUS DEXMEDETOMIDINE WITH PROPOFOL FOR CONTINUOUS SEDATION OF VENTILATED PATIENTS IN INTENSIVE CARE UNIT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006030-17,0,0,0 2006-006031-50,7,2009-10-07,2009-10-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Orion Corporation Orion Pharma,"A PROSPECTIVE, MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND COMPARISON OF INTRAVENOUS DEXMEDETOMIDINE WITH MIDAZOLAM FOR CONTINUOUS SEDATION OF VENTILATED PATIENTS IN INTENSIVE CARE UNIT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006031-50,0,0,0 2006-006032-22,1,2013-01-31,2013-01-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Manchester,TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006032-22,0,0,0 2006-006032-22,1,2013-01-31,2013-01-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Dudley Group of Hospitals NHS Trust,TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006032-22,0,0,0 2006-006034-18,1,2008-03-05,2008-03-05,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Medicure International Inc.,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE CARDIOPROTECTIVE EFFECTS OF MC-1 IN PATIENTS UNDERGOING HIGH-RISK CORONARY ARTERY BYPASS GRAFT (CABG) SURGERY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006034-18,0,0,0 2006-006037-41,1,,,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,Klaus Olkkola,Interaction of cisatracurium with nitrous oxide as quantified by closed-loop feedback control / Typpioksiduulin vaikutus sisatrakuurin annostarpeeseen käytettäessä sisatrakuurin tietokoneohjattua anno...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006037-41,0,0,0 2006-006041-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Ramón y Cajal,“ESTUDIO EN FASE IV de la Pauta de Rescate a través de OptimizacióN y simplificacióN de las dosis de Ritonavir en un régimen que contiene Tipranavir como parte del tratamiento”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006041-13,0,0,0 2006-006042-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,"A pilot, open label, multicenter, randomized clinical trial on Lopinavir/Ritonavir-monotherapy vs Lopinavir/Ritonavir plus selected Nucs, in HIV/HCV coinfected patients with chronic hepatitis C or co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006042-33,0,0,0 2006-006043-32,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,ELI LILLY,An open label pilot study on the tolerability of duloxetine in the treatment of depressed patients with Parkinson s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006043-32,0,0,0 2006-006047-30,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,"First line treatment in HIV-related diffuse large cell non Hodgkin Lymphoma at ''high risk'', including early consolidation with high dose chemotherapy and autologous peripheral blood stem cell transp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006047-30,0,0,0 2006-006050-10,6,2013-09-23,2013-10-16,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL NV,"A Phase 2, Randomized Study of VELCADE (bortezomib), Dexamethasone and Thalidomide versus VELCADE (bortezomib), Dexamethasone, Thalidomide and Cyclophosphamide in Subjects with Previously Untreated Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006050-10,0,0,0 2006-006050-10,6,2013-09-23,2013-10-16,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A Phase 2, Randomized Study of VELCADE (bortezomib), Dexamethasone and Thalidomide versus VELCADE (bortezomib), Dexamethasone, Thalidomide and Cyclophosphamide in Subjects with Previously Untreated Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006050-10,0,0,0 2006-006050-10,6,2013-09-23,2013-10-16,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Janssen-Cilag International, N.V.Turnhoutseweg 30, 2340 Beerse, Belgium","A Phase 2, Randomized Study of VELCADE (bortezomib), Dexamethasone and Thalidomide versus VELCADE (bortezomib), Dexamethasone, Thalidomide and Cyclophosphamide in Subjects with Previously Untreated Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006050-10,0,0,0 2006-006050-10,6,2013-09-23,2013-10-16,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Janssen-Cilag International, N.V.","A Phase 2, Randomized Study of VELCADE (bortezomib), Dexamethasone and Thalidomide versus VELCADE (bortezomib), Dexamethasone, Thalidomide and Cyclophosphamide in Subjects with Previously Untreated Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006050-10,0,0,0 2006-006051-12,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ICORG,PHASE II TRIAL OF THE MULTI-DRUG RESISTANCE PROTEIN MODULATING AGENT SULINDAC IN COMBINATION WITH EPIRUBICIN IN PATIENTS WITH ADVANCED MELANOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006051-12,0,0,0 2006-006052-35,1,2008-08-14,2008-08-14,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,S.L.A. PHARMA (UK) LTD,"An open label study to determine the safety and tolerability of two dose escalation treatment regimens with an oral, delayed release preparation of nicotine in patients with stable ulcerative colitis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006052-35,0,0,0 2006-006058-83,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU Medisch Centrum,"Phase II randomized trial of combination therapy of paclitaxel and bevacizumab versus paclitaxel, capecitabine and bevacizumab as first-line treatment for locally recurrent or metastatic breast cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006058-83,0,0,0 2006-006064-32,8,2009-09-11,2010-05-06,6,0,0,0,0,0,4,0,0,1,1,0,1,0,1,Nycomed Danmark Aps,"A 24-week, international, multi centre, randomised, double-blind, double-dummy, parallel group, phase IV clinical trial investigating changes in back pain in postmenopausal women with an osteoporosis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006064-32,0,0,0 2006-006064-32,8,2009-09-11,2010-05-06,6,0,0,0,0,0,4,0,0,1,1,0,1,0,1,NYCOMED (HEADQUARTER),"A 24-week, international, multi centre, randomised, double-blind, double-dummy, parallel group, phase IV clinical trial investigating changes in back pain in postmenopausal women with an osteoporosis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006064-32,0,0,0 2006-006065-16,2,2009-01-26,2009-01-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Nycomed Danmark ApS,"A 24-week, international, multi centre, randomised, open label, parallel group, phase IV clinical trial investigating changes in bone formation markers in postmenopausal women with primary osteoporosi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006065-16,0,0,0 2006-006066-42,6,2009-05-28,2009-05-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, eight-week double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / amlodipine (300/5 mg and 300/10 mg) in comparison with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006066-42,0,0,0 2006-006066-42,6,2009-05-28,2009-05-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmaceutica S.A.,"A randomized, eight-week double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / amlodipine (300/5 mg and 300/10 mg) in comparison with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006066-42,0,0,0 2006-006066-42,6,2009-05-28,2009-05-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, eight-week double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / amlodipine (300/5 mg and 300/10 mg) in comparison with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006066-42,0,0,0 2006-006068-44,3,2009-06-05,2009-06-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, eight week double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / amlodipine (150/10 mg and 300/10 mg) in comparison with a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006068-44,0,0,0 2006-006070-22,4,2007-10-11,2007-10-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A 12-WEEK, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTS OF FESOTERODINE ON TREATMENT SATISFACTION AND SYMPTOM RELIEF IN OVERACTIVE BLADDER PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006070-22,0,0,0 2006-006070-22,4,2007-10-11,2007-10-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc,"A 12-WEEK, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTS OF FESOTERODINE ON TREATMENT SATISFACTION AND SYMPTOM RELIEF IN OVERACTIVE BLADDER PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006070-22,0,0,0 2006-006072-38,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,the Dutch Colorectal Cancer Group,A Randomised Two Arm Phase III Study in Patients Post Radical Resection of Liver Metastasis of Colorectal Cancer to Investigate Bevacizumab (q3w) in Combination With Capecitabine Plus Elaoxantin (XELO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006072-38,0,0,0 2006-006073-24,1,2011-04-11,2011-04-11,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Royal Marsden Hospital,CINATRA: Chromosomal Instability and Anti-Tubulin Response Assessment: A Phase II Study of Epothilone B in Metastatic Colon Carcinoma in patients with Microsatellite Instability or Chromosomal Instabi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006073-24,0,0,0 2006-006075-20,7,2009-04-13,2009-09-08,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"JAZZ PHARMACEUTICALS, INC.","A Randomized, Double Blind, Placebo Controlled, Safety and Efficacy Study of Xyrem (sodium oxybate) in Subjects with Fibromyalgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006075-20,1,0,0 2006-006075-20,7,2009-04-13,2009-09-08,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Jazz Pharmaceuticals, Inc.","A Randomized, Double Blind, Placebo Controlled, Safety and Efficacy Study of Xyrem (sodium oxybate) in Subjects with Fibromyalgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006075-20,1,0,0 2006-006076-38,1,2015-12-30,2015-12-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Liverpool,The Liverpool HIV TDM Registry: Studying influences upon plasma HIV drug exposure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006076-38,0,0,0 2006-006076-38,1,2015-12-30,2015-12-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Liverpool & Broadgreen University Hospitals Trust,The Liverpool HIV TDM Registry: Studying influences upon plasma HIV drug exposure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006076-38,0,0,0 2006-006079-19,5,2020-03-10,2020-10-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University College London,A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006079-19,0,0,0 2006-006079-19,5,2020-03-10,2020-10-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Medical Research Council Clinical Trial Unit,A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006079-19,0,0,0 2006-006079-19,5,2020-03-10,2020-10-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Medical Research Council,A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006079-19,0,0,0 2006-006080-23,1,,,0,0,0,0,1,0,4,0,0,3,0,0,0,0,0,Institute of Obstetrics and Gynaecology Trust,Vitamin D status in pregnancy and the effects of vitamin D supplementation in ethnic minority groups,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006080-23,0,0,0 2006-006083-33,1,2007-10-11,2007-10-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice-daily inhaled doses o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006083-33,0,0,0 2006-006084-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude multicentrique, randomisée , de phase II évaluant l'association méthotrexate et témozolomide (MT) à l'association méthotrexate, procarbazine, vincristine et cytarabine (MPV-A) dans le traitement...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006084-23,0,0,0 2006-006085-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ThromboGenics Ltd.,"A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding, Multicenter Trial of Microplasmin Intravitreal Injection for Non-Surgical PVD Induction for Treatment of Vit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006085-42,0,0,0 2006-006086-16,11,2011-02-25,2011-03-04,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Servier Research and Development Ltd,"The efficacy and safety of 2g strontium ranelate in the treatment of male osteoporosis. A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006086-16,0,0,0 2006-006086-16,11,2011-02-25,2011-03-04,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"The efficacy and safety of 2g strontium ranelate in the treatment of male osteoporosis. A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006086-16,0,0,0 2006-006086-16,11,2011-02-25,2011-03-04,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"The efficacy and safety of 2g strontium ranelate in the treatment of male osteoporosis. A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006086-16,0,0,0 2006-006086-16,11,2011-02-25,2011-03-04,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratorios Servier S.L.,"The efficacy and safety of 2g strontium ranelate in the treatment of male osteoporosis. A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006086-16,0,0,0 2006-006088-22,1,2021-06-09,2021-06-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Klinik für Chirurgie, Charité Campus Virchow-Klinikum",Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) after preoperative chemotherapy in patients with peritoneal carcinom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006088-22,0,0,0 2006-006089-40,1,2011-12-12,2011-12-12,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospitals Bristol NHS Foundation Trust,High dose corticosteroid pulses in treatment-resistant depression : a randomized double-blind placebo-controlled pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006089-40,0,0,0 2006-006090-24,1,2014-08-11,2014-08-11,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Plymouth Hospitals NHS Trust,A Parallel Randomised Phase II Trial of CHOP Chemotherapy With or Without Bortezomib in Relapsed Mantle Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006090-24,0,0,0 2006-006091-38,2,2015-08-25,2015-08-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Universität Leipzig, HNO","Randomisierte Phase II Screeningstudie zum Einsatz einer TP/TPF-Chemotherapie (Kurzinduktion) vor TP/TPF-Induktion, Radiotherapie mit und ohne Cetuximab in der Primärtherapie des nur durch Laryngektom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006091-38,0,0,0 2006-006091-38,2,2015-08-25,2015-08-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Universität Leipzig,"Randomisierte Phase II Screeningstudie zum Einsatz einer TP/TPF-Chemotherapie (Kurzinduktion) vor TP/TPF-Induktion, Radiotherapie mit und ohne Cetuximab in der Primärtherapie des nur durch Laryngektom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006091-38,0,0,0 2006-006092-21,10,2009-04-09,2009-04-14,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk a/s,"Efecto y acción de liraglutida en diabetes (LEAD-6): efecto sobre el control glucémico de liraglutida o exenatida en combinación con metformina, sulfonilurea o ambas en sujetos con diabetes tipo 2. En...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006092-21,0,0,0 2006-006092-21,10,2009-04-09,2009-04-14,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Efecto y acción de liraglutida en diabetes (LEAD-6): efecto sobre el control glucémico de liraglutida o exenatida en combinación con metformina, sulfonilurea o ambas en sujetos con diabetes tipo 2. En...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006092-21,0,0,0 2006-006099-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Department of Endocrinology University of Debrecen Medical and Health Science Center,"Anti-CD20 antitest alkalmazása súlyos, hagyományos kezelésekre nem reagáló endokrin orbitopátiában",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006099-39,0,0,0 2006-006100-11,2,2008-02-06,2009-10-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergan Ltd,"A multicenter, multiple dose, double-blind, randomized, placebo-controlled, parallel group study of the safety and efficacy of AGN 203818 in female patients with fibromyalgia syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006100-11,0,0,0 2006-006104-11,2,2009-08-31,2009-08-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,CHX Technologies Inc.,Phase IV Open-label Pharmaco-economic and Practice Management Study of a New Preventive Treatment for Adult Caries in the U.K. and Germany,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006104-11,0,0,0 2006-006104-11,2,2009-08-31,2009-08-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,CHX Technologies Europe Ltd.,Phase IV Open-label Pharmaco-economic and Practice Management Study of a New Preventive Treatment for Adult Caries in the U.K. and Germany,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006104-11,0,0,0 2006-006105-86,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,LUMC,The effect of pre-operative Ramipril treatment on vascular inflammation in the abdominal aneurysm,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006105-86,0,0,0 2006-006109-97,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Sinikka Oksa,THE EFFECT OF TOREMIFENE TO THE FINDINGS OF MAGNETIC RESONANCE IMAGING IN WOMEN WITH PREMENSTRUAL MASTALGIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006109-97,0,0,0 2006-006111-77,1,2008-09-30,2008-09-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche s.r.o.,Otevřená studie fáze II hodnotící bezpečnost a účinnost indukční analgetické léčby kyselinou ibandronovou (Bondronat) podávanou intravenózně po dobu 15 minut v dávce 6 mg 3 po sobě následující dny pac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006111-77,0,0,0 2006-006112-30,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude multicentrique, randomisée, en double aveugle, évaluant l'efficacité du losartan versus placebo sur la dilatation de l'aorte chez des patients présentant un syndrome de Marfan",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006112-30,0,0,0 2006-006117-32,1,2009-12-21,2009-12-21,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,Tipranavir/ritonavir 500/100 mg bid as a simplification strategy in HIV-1 infected subjects with an ongoing Tipranavir 500mg/Ritonavir 200mg bid regimen and undetectable viral load.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006117-32,0,0,0 2006-006126-25,1,,,0,0,0,0,1,1,3,0,1,1,0,0,0,1,0,CNRS: VAN DER REST Michel,Emotional and Social deficits in Asperger syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006126-25,0,0,0 2006-006127-40,1,2009-03-31,2009-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Newcastle-upon-Tyne Hospitals NHS Foundation Trust,Cerebral Blood Flow following TNF-alpha Antagonism in Rheumatoid Arthritis - a Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006127-40,0,0,0 2006-006130-17,10,2016-12-31,2016-12-31,5,0,0,0,0,2,3,0,0,2,0,0,0,0,0,Aarhus University Hospital,ACT-1 (younger patients) A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006130-17,1,0,0 2006-006130-17,10,2016-12-31,2016-12-31,5,0,0,0,0,2,3,0,0,2,0,0,0,0,0,Nordic Lymphoma Group,ACT-1 (younger patients) A randomized phase III study to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006130-17,1,0,0 2006-006131-53,1,2011-07-20,2011-07-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Society (institute) for clinical research,Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006131-53,0,0,0 2006-006136-21,3,2011-03-23,2011-03-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Nerviano Medical Sciences S.r.l.,A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006136-21,0,0,0 2006-006136-21,3,2011-03-23,2011-03-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NERVIANO MEDICAL SCIENCES,A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006136-21,0,0,0 2006-006137-41,1,2009-09-22,2009-09-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Fakultät der Technischen Universität München, vertreten durch den Dekan","Prospective, randomized, open, 2-arm national multi-center study to evaluate the value of Rituximab in humoral chronic rejection after renal transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006137-41,0,0,0 2006-006143-31,4,2008-12-19,2008-12-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Auxilium UK Limited,"A Phase 3, Open Label Study of Safety and Efficacy of AA4500 in the Treatment of Subjects With Dupuytren's Contracture",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006143-31,0,0,0 2006-006144-55,1,2008-07-18,2008-07-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A multicenter, open-label, single-arm, two-stage study of the efficacy and safety of AVE0005 (VEGF Trap) administered intravenously every 2 weeks in patients with platinum- and erlotinib-resistant, lo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006144-55,0,0,0 2006-006146-34,1,,,0,0,0,1,0,1,1,0,0,1,0,0,0,1,1,Stage Pharmaceuticals GmbH,Adoptive Immunotherapy of chemotherapy refractory CMV infections using Streptamer-isolated T cells after allogeneic bone marrow or peripheral blood stem cell transplantation: a phase I/II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006146-34,0,0,0 2006-006147-31,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,"An open multicenter clinical trial to evaluate the safety, tolerability and efficacy of Deferasirox (ICL670) in patients affected by Myelodysplastic syndrome and transfusional chronic hemosiderosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006147-31,0,0,0 2006-006148-69,1,2009-05-15,2009-05-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AiCuris GmbH & Co. KG,"Phase 2a Randomized, Controlled, Multi-center, Open-label Dose Ranging Proof of Concept Study to Evaluate the Safety, Tolerability and Antiviral Activity of AIC-001 Over 14 Days of Dosing in Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006148-69,0,0,0 2006-006149-15,2,2008-04-29,2008-04-29,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Eli lilly and Company,An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients with Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006149-15,0,0,0 2006-006149-15,2,2008-04-29,2008-04-29,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Eli Lilly and Company,An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients with Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006149-15,0,0,0 2006-006152-34,6,2011-12-06,2012-01-16,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & de'veloppement,"A Multicenter, Open-Label, Single Arm Study of Weekly Alvocidib in Patients with Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising from CLL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006152-34,0,0,0 2006-006152-34,6,2011-12-06,2012-01-16,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A Multicenter, Open-Label, Single Arm Study of Weekly Alvocidib in Patients with Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising from CLL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006152-34,0,0,0 2006-006152-34,6,2011-12-06,2012-01-16,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & développement,"A Multicenter, Open-Label, Single Arm Study of Weekly Alvocidib in Patients with Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising from CLL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006152-34,0,0,0 2006-006154-97,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"HEMOS ALL 0105 Intensification therapy of mature B-ALL, Burkitt and Burkitt like and other HIgh Grade Non-Hodgkinﾒs Lymphoma in Adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006154-97,0,0,0 2006-006156-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Hospital Clinic, Barcelona",Papel de los niveles plasmáticos de fitosterol en la predicción del efecto hipolipemiante de la ezetimiba en sujetos infectados por VIH que reciben inhibidores de la proteasa. ROLE OF PHYTOSTEROL PLA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006156-36,0,0,0 2006-006157-27,1,2011-11-07,2011-11-07,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Bama-Geve S.L.,"Estudio abierto, aleatorizado, de grupos paralelos y un año de seguimiento para evaluar la eficacia y tolerabilidad de rifaximina en la prevención de recaídas de diverticulitis y en la mejoría de los ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006157-27,0,0,0 2006-006165-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,PIERRE FABRE MEDICAMENT,"EFFICACY OF AN EARLY ADMINISTRATION OF L0013CP 10 MG/DAY VERSUS PLACEBO DURING 4 WEEKS IN THE TREATMENT OF INFECTIOUS DISEASES INDUCED ARTHRITIS PAINFUL SYMPTOMS. A MULTICENTER, RANDOMISED, DOUBLE BLI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006165-17,0,0,0 2006-006166-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Tuebingen,"Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese - offene, prospektive Phase II-Studie -",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006166-42,0,0,0 2006-006168-46,1,2007-04-24,2007-04-24,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Schering-Plough Research Institute,Thorough QT/QTc study for Garenoxacin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006168-46,0,0,0 2006-006171-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Angers,Evaluation de l'efficacité de la thérapie photodynamique par Photofrin sur les cholangiocarcinomes non résécables de type III ou IV,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006171-20,0,0,0 2006-006174-19,1,2008-04-02,2008-04-02,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,St Stephens AIDS Trust,"A randomised, open label, phase IV comparative study to determine the effects on renal function of continuing treatment with tenofovir versus replacement with abacavir in HIV positive persons",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006174-19,0,0,0 2006-006175-20,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNICANCER,Essai de phase III évaluant la place de la ChimioHyperthermie IntraPéritonéale per opératoire (CHIP) après résection maximale d'une carcinose péritonéale d'origine colorectale associée à une chimioth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006175-20,0,0,0 2006-006175-20,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FNCLCC,Essai de phase III évaluant la place de la ChimioHyperthermie IntraPéritonéale per opératoire (CHIP) après résection maximale d'une carcinose péritonéale d'origine colorectale associée à une chimioth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006175-20,0,0,0 2006-006179-19,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CENTRE ANTOINE LACASSAGNE,ESTUDIO INTERNACIONAL DE FASE II PARA EVALUAR UNA ASOCIACIÓN CHOP-RITUXIMAB CON CONSOLIDACIÓN PRECOZ CON IBRITUMOMAB-TIUXETAN-Y90 EN PACIENTES DE EDADES ENTRE 65 Y 80 AÑOS AFECTADOS DE UN LINFOMA MALI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006179-19,0,0,0 2006-006180-23,1,2008-06-30,2008-06-30,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Johann Wolfgang Goethe Universität,"Einfluss einer Vitamin D-Substitution auf die Insulinresistenz, die Stoffwechseleinstellung und die Lymphozytenfunktion bei Patienten mit Typ 2 Diabetes mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006180-23,0,0,0 2006-006181-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMC St Radboud,The use of USPIO enhanced MRI in the assessment of axillary lymph node status in patients with invasive breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006181-42,0,0,0 2006-006182-16,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"NOVARTIS FARMACÉUTICA, S.A","Estudio multicéntrico, aleatorizado, abierto, para evaluar la conveniencia, en base a la seguridad, del cambio en la vía de administración de Rivastigmina (paso de la administración en forma de cápsul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006182-16,0,0,0 2006-006184-23,1,2010-04-18,2010-04-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"A randomised, double-blind, placebo- and olanzapine- controlled, parallel-group study to evaluate the efficacy and safety of 3 fixed doses of S 33138 in treatment of patients with an acute episode of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006184-23,0,0,0 2006-006186-16,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Leiden University Medical Center, department of rheumatology",IMPROVED: Induction therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic Disease A randomized clinical trial in patients with recent-onset arthritis to compare the efficacy ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006186-16,0,0,0 2006-006187-35,3,2008-01-11,2008-01-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme GmbH,"A phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK-0974 in the Acute Treatment of Migraine with or Without Aura.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006187-35,0,0,0 2006-006187-35,3,2008-01-11,2008-01-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratoires Merck Sharp & Dohme - Chibret,"A phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK-0974 in the Acute Treatment of Migraine with or Without Aura.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006187-35,0,0,0 2006-006187-35,3,2008-01-11,2008-01-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK-0974 in the Acute Treatment of Migraine with or Without Aura.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006187-35,0,0,0 2006-006188-22,3,2018-11-01,2018-11-01,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,"A randomised phase III study to compare arsenic trioxide (ATO) combined to ATRA versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for newly diagnosed, non high-risk acute promye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006188-22,0,0,0 2006-006189-40,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL ADULTO,PHASE II MULTICENTER STUDY OF P210-B3A2 DERIVED PEPTIDE VACCINE IN CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITH PERSISTENT MOLECULAR RESIDUAL DISEASE DURING IMATINIB TREATME...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006189-40,0,0,0 2006-006191-38,2,2008-12-02,2008-12-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ANGELINI,The effects of the association bindarit irbesartan versus irbesartan alone on albuminuria of patients with Diabetic Nephropathy. Placebo-controlled study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006191-38,0,0,0 2006-006191-38,2,2008-12-02,2008-12-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Angelini Farmaceutici, ACRAF S.p.A.",The effects of the association bindarit irbesartan versus irbesartan alone on albuminuria of patients with Diabetic Nephropathy. Placebo-controlled study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006191-38,0,0,0 2006-006194-25,2,2008-10-23,2008-11-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Achillion Pharmaceuticals, Inc","An open-label, 48-week extension study of elvucitabine administered in combination with background antiretroviral agents in subjects who have completed 14 days of treatment in Protocol ACH443-014A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006194-25,0,0,0 2006-006198-26,1,2011-01-11,2011-01-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Nottingham,Mechanistic randomised contorlled trial of Mesalazine in symptomatic diverticular disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006198-26,0,0,0 2006-006199-39,3,2009-07-22,2009-08-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Bayer AB, Bayer Schering Pharma","A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17β-estradiol [E2] / 0.25 mg drospire...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006199-39,0,0,0 2006-006199-39,3,2009-07-22,2009-08-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Schering Pharma AG,"A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17β-estradiol [E2] / 0.25 mg drospire...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006199-39,0,0,0 2006-006199-39,3,2009-07-22,2009-08-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHERING,"A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17β-estradiol [E2] / 0.25 mg drospire...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006199-39,0,0,0 2006-006200-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Agence nationale de recherches sur le sida et les hépatites virales. ANRS,Prévention de la transmission du VIH-1 de la mère à l’enfant sans utilisation d’analogue nucléosidique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006200-11,0,0,0 2006-006203-36,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,Academic Medical Centre (AMC),Dopaminergic neurotransmission and cognitive decline in velocardiofacial syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006203-36,0,0,0 2006-006204-11,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Manufacturing Scale 13-valent Pneumococcal Conjugate Vaccine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006204-11,0,0,0 2006-006209-94,1,2007-08-29,2007-08-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"An open label, repeat dose, dose escalation study conducted in Parkinson’s Disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR) 12mg tablets...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006209-94,0,0,0 2006-006210-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITA' DEGLI STUDI DI PERUGIA,"PIPERACILLIN/TAZOBACTAM PLUS TIGECYCLINE VS. PIPERACILLIN/TAZOBACTAM ALONE AS EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC CANCER PATIENTS : A PROSPECTIVE, RANDOMISED, MULTI-CENTRE, STUDY.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006210-14,0,0,0 2006-006212-30,1,2011-10-03,2011-10-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London,"A Randomised, Open labelled, Phase II, Immunogenicity, and Exploratory Efficacy Evaluation of Therapeutic Immunisations +/- IL-2, GM-CSF and Growth Hormone in HIV-1 Infected Subjects Receiving Highly ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006212-30,0,0,0 2006-006214-16,1,2014-05-16,2014-05-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College,A randomised placebo controlled trial of rosuvastatin in systemic lupus erythematosus.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006214-16,0,0,0 2006-006215-68,5,2010-05-24,2010-05-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A,"A MULTICENTRE,MULTINATIONAL, OPEN-LABEL, RANDOMISED, PARALLEL GROUP CLINICAL TRIAL OF TOBRINEB®/ACTITOB®/ BRAMITOB® (TOBRAMYCIN SOLUTION FOR NEBULISATION, 300 MG TWICE DAILY IN 4 ML UNIT DOSE VIALS) C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006215-68,0,0,0 2006-006219-56,1,2008-05-31,2008-05-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Merck & Co Inc.,","A multicentre, double-blind, randomised, parallel-group study to evaluate the efficacy, safety and tolerability of ezetimibe/simvastatin 10/40mg, atorvastatin 40mg, and rosuvastatin 10mg to achieve an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006219-56,0,0,0 2006-006220-19,2,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,1,PLIVA Hrvatska d.o.o.,"Safety and Efficacy of Sumamed® Therapy in the Treatment of Respiratory Tract Infections in Adults and Children: International, Multicenter, Non-Comparative Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006220-19,0,0,0 2006-006221-77,1,2012-07-01,2012-07-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Clinical Research office, Faculty of Medicine, Imperial College London",Warfarin Anticoagualtion for liver fibrosis in patients transplanted for hepatitis C virus infection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006221-77,0,0,0 2006-006228-21,7,2009-11-29,2018-05-17,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Gloucester Pharmaceuticals Inc.,"A PHASE II, MULTICENTER, OPEN-LABEL TRIAL EVALUATING THE ACTIVITY AND TOLERABILITY OF ROMIDEPSIN (DEPSIPEPTIDE, FK228) IN PROGRESSIVE OR RELAPSED PERIPHERAL T-CELL LYMPHOMA FOLLOWING PRIOR SYSTEMI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006228-21,0,0,0 2006-006228-21,7,2009-11-29,2018-05-17,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GLOUCESTER PHARMACEUTICALS INC.,"A PHASE II, MULTICENTER, OPEN-LABEL TRIAL EVALUATING THE ACTIVITY AND TOLERABILITY OF ROMIDEPSIN (DEPSIPEPTIDE, FK228) IN PROGRESSIVE OR RELAPSED PERIPHERAL T-CELL LYMPHOMA FOLLOWING PRIOR SYSTEMI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006228-21,0,0,0 2006-006231-49,1,2010-04-01,2010-04-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Department of Ophthalmology, Bonn University","Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006231-49,0,0,0 2006-006233-40,1,2009-07-10,2009-07-10,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Department of Ophthalmology, Bonn University","Ranibizumab in idiopathic macular telangiectasia, type2 A prospective interventional non-randomized study comparing the efficacy and safety of intravitreal ranibizumab (dosing regimen 0.5mg every mon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006233-40,0,0,0 2006-006234-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Medisch Centrum Leeuwarden,Treatment of intertrigo: zinc oxide in ketoconazolecream with or without substitution of hydrocortisone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006234-18,0,0,0 2006-006236-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA O.I.R.M. - S. ANNA,Use of Metformin to reduce serum level of Testosterone and improve the metabolic picture in women treated for breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006236-22,0,0,0 2006-006240-63,1,2008-05-23,2008-05-23,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,GlaxoSmithKline Research and Development,"A study to assess the pharmacokinetics of single escalating doses of inhaled GSK961081 DPI (a dual pharmacophore) in healthy subjects (Part 1) and a randomised, double-blind, double dummy, crossover (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006240-63,0,0,0 2006-006242-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU DIJON,"Evaluation comparée du bloc paravertébral thoracique continu, de l’infiltration cicatricielle continue et de l’analgésie systémique pour la prise en charge de la douleur postopératoire après thoracot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006242-34,0,0,0 2006-006243-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset,Antioxidanter vid Stapedotomi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006243-31,0,0,0 2006-006244-58,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"LKH-Universitätsklinikum Graz,Universitäre Palliativmedizinische Einrichtung",Verabreichung von Ketamin als Koanalgetikum tumorbedingter Schmerzen - Phase II-Studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006244-58,0,0,0 2006-006245-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier de Tourcoing,Comparaison de deux durées (6 versus 12 semaines) de traitement antibiotique des ostéites du pied neuropathique chez le patient diabétique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006245-14,0,0,0 2006-006246-34,7,2012-09-04,2012-09-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo on top of a background therapy with a calcium antagonist (amlodipine or nifedipine) in patie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006246-34,0,0,0 2006-006247-31,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO A.O. DI RILIEVO NAZIONALE,TIPRANAVIR MONOTHERAPY IN EXPERIENCED PATIENTS WITH MULTIPLE REVERSE TRANSCRIPTASE MUTATIONS A PROOF-OF-CONCEPT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006247-31,0,0,0 2006-006251-12,1,2007-03-23,2007-03-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Diabetology Ltd,"A Phase Ib, Single Centre, Open Label, Parallel-Group, Controlled Study of Effects on Metabolic Control of an Oral Insulin Formulation in a Type 2 Diabetic Population.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006251-12,0,0,0 2006-006263-23,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,ROCHE,Efficacy of Oseltamivir treatment in laboratory- confirmed influenza: evaluation of effect on viral shedding and on serum and cytoplasmatic inflammatory cytokine concentration. Efficacia del tratta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006263-23,0,0,0 2006-006264-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Medeca Pharma AB,Smärtskattning av adrenalinpenna,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006264-27,0,0,0 2006-006268-42,1,2012-05-22,2012-05-22,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Hospital Clinic, Barcelon","Tratamiento antirretroviral una vez al día en pacientes con infección por el VIH-1 no tratados previamente y con cifras de linfocitos CD4+ inferiores a 100 céls/mm3. Estudio prospectivo aleatorizado, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006268-42,0,0,0 2006-006273-25,2,2007-10-17,2007-10-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A multi-center, double-blind, randomized, placebo-controlled, titration study to investigate the safety, the tolerability and the pharmacodynamic profiles of different doses of RO5073031 in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006273-25,0,0,0 2006-006275-21,1,2011-07-05,2011-07-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Birmingham NHS Foundation Trust,"A Randomised, Pragmatic, Open-label study of Adalimumab versus Etanercept for Rheumatoid Arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006275-21,0,0,0 2006-006276-38,7,2009-04-15,2010-07-02,4,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Boehringer-Ingelheim,"A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18 MCG of Tiotropium inhalation capsules administered by Handihaler® once-daily plus P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006276-38,0,0,0 2006-006276-38,7,2009-04-15,2010-07-02,4,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18 MCG of Tiotropium inhalation capsules administered by Handihaler® once-daily plus P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006276-38,0,0,0 2006-006276-38,7,2009-04-15,2010-07-02,4,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Boehringer Ingelheim Hellas AE,"A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18 MCG of Tiotropium inhalation capsules administered by Handihaler® once-daily plus P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006276-38,0,0,0 2006-006276-38,7,2009-04-15,2010-07-02,4,1,0,0,0,0,4,0,0,1,0,0,1,0,2,SCS Boehringer Ingelheim Comm.V,"A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18 MCG of Tiotropium inhalation capsules administered by Handihaler® once-daily plus P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006276-38,0,0,0 2006-006276-38,7,2009-04-15,2010-07-02,4,1,0,0,0,0,4,0,0,1,0,0,1,0,2,"Boehring Ingelheim Pharma Ges mbH, Regional Division Medicine, Regional Centre Vienna","A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18 MCG of Tiotropium inhalation capsules administered by Handihaler® once-daily plus P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006276-38,0,0,0 2006-006276-38,7,2009-04-15,2010-07-02,4,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Boehringer Ingelheim Limited,"A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18 MCG of Tiotropium inhalation capsules administered by Handihaler® once-daily plus P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006276-38,0,0,0 2006-006277-24,15,2012-08-08,2012-08-08,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et développement,A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 4 ADMINISTRATIONS OF XRP0038/NV1FGF 4mg AT 2–WEEK INTERVALS ON AMPUTATION OR ANY DEATH IN CRITICAL LIMB ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006277-24,0,0,0 2006-006277-24,15,2012-08-08,2012-08-08,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et de'veloppement,A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF 4 ADMINISTRATIONS OF XRP0038/NV1FGF 4mg AT 2–WEEK INTERVALS ON AMPUTATION OR ANY DEATH IN CRITICAL LIMB ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006277-24,0,0,0 2006-006291-38,6,2010-01-22,2010-01-22,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"JAZZ PHARMACEUTICALS, INC.","A Long-Term, Open-Label Safety and Efficacy Study of Xyrem (sodium oxybate) in Subjects with Fibromyalgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006291-38,1,0,0 2006-006291-38,6,2010-01-22,2010-01-22,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Jazz Pharmaceuticals, Inc.","A Long-Term, Open-Label Safety and Efficacy Study of Xyrem (sodium oxybate) in Subjects with Fibromyalgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006291-38,1,0,0 2006-006295-37,2,2018-09-19,2018-09-19,1,0,0,0,1,0,4,0,0,2,0,0,0,0,0,UMC Utrecht,A multi-site RCT comparing regional and general anaesthesia for effects on neurodevelopmental outcome and apnoea in infants.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006295-37,1,0,0 2006-006295-37,2,2018-09-19,2018-09-19,1,0,0,0,1,0,4,0,0,2,0,0,0,0,0,NHS Greater Glasgow & Clyde,A multi-site RCT comparing regional and general anaesthesia for effects on neurodevelopmental outcome and apnoea in infants.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006295-37,1,0,0 2006-006297-23,1,2009-09-01,2009-09-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Guy's & St Thomas' NHS Foundation Trust,A study of the pharmacokinetics of new formulation lopinavir/ritonavir in the genital tract and plasma of HIV infected women in pregnancy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006297-23,0,0,0 2006-006298-26,3,2009-05-11,2009-05-11,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,IDEA AG,"Multicenter, randomized, double-blind, placebo- and active-controlled study of safety and efficacy of two dosages of epicutaneously applied Diractin® (ketoprofen in Transfersome® gel) for the treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006298-26,0,0,0 2006-006299-39,2,2012-12-05,2012-12-05,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Allergan,"A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respirator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006299-39,0,0,0 2006-006302-29,1,2019-01-28,2019-01-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Hannu Kokki,NUROFEN MELTLETS TABLETTIEN FARMAKOKINETIIKKA SELKÄLEIKATTAVILLA POTILAILLA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006302-29,0,0,0 2006-006304-11,4,2008-06-26,2009-08-27,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Shire Human Genetic Therapies Inc,A Multicenter Open-Label Study of Gene-Activated Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease Previously Treated with Imiglucerase,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006304-11,0,0,0 2006-006304-11,4,2008-06-26,2009-08-27,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"SHIRE HUMAN GENETIC THERAPIES, INC.",A Multicenter Open-Label Study of Gene-Activated Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease Previously Treated with Imiglucerase,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006304-11,0,0,0 2006-006307-37,2,2009-10-28,2009-10-28,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Baxter Innovations GmbH,AN OPEN LABEL PHASE III STUDY OF A VERO CELL-DERIVED WHOLE VIRUS H5N1 INFLUENZA VACCINE TO ASSESS THE IMMUNOGENICITY AND SAFETY AND TO INVESTIGATE THE NEED FOR AND TIMING OF A BOOSTER VACCINATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006307-37,0,0,0 2006-006309-96,9,2009-04-22,2009-04-22,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals France,"A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Autoinjector a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006309-96,0,0,0 2006-006312-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dept. of Ophthalmol, Semmelweis University","A phase IV non-randomized, uncontrolled, open-label, single-center trial to evaluate the safety and efficacy of Macugen (pegaptanib sodium) given by intravitreal injections every 6 weeks in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006312-30,0,0,0 2006-006315-68,4,2010-10-06,2010-10-06,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Volumetric Bone Mineral Density in Glucocorticoid-Induced Osteoporosis in Men,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006315-68,0,0,0 2006-006315-68,4,2010-10-06,2010-10-06,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Volumetric Bone Mineral Density in Glucocorticoid-Induced Osteoporosis in Men,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006315-68,0,0,0 2006-006315-68,4,2010-10-06,2010-10-06,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Volumetric Bone Mineral Density in Glucocorticoid-Induced Osteoporosis in Men,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006315-68,0,0,0 2006-006318-14,1,,,0,0,0,0,1,0,3,0,0,1,1,1,0,1,1,"Pharmazam, S.A.","Evaluación de una nueva pauta terapéutica con Fosfomicina trometamol en el tratamiento de las ITUs bajas de la mujer postmenopáusica. Estudio multicéntrico, aleatorizado, prospectivo y controlado, com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006318-14,0,0,0 2006-006319-54,4,2008-09-29,2008-10-30,2,0,0,0,0,0,2,0,0,1,1,0,1,0,1,"Cerimon Pharmaceuticals, Inc.",An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006319-54,0,0,0 2006-006322-26,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"MESALAZINE AND/OR LACTOBACILLUS CASEI IN MAINTAINING REMISSION OF SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE OF THE COLON: A PROSPECTIVE, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED STUDY Me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006322-26,0,0,0 2006-006323-39,1,2012-11-06,2012-11-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Charité-Universitätsmedizin Berlin,Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006323-39,0,0,0 2006-006328-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,HELP Pharmaceuticals S.A.,"A multicentre, randomised, double-blind, controlled with placebo clinical trial with parallel groups, for the evaluation of the efficacy and safety of combined treatment with L-carnitine and simvastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006328-20,0,0,0 2006-006334-18,1,2012-09-24,2012-09-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Gent,Farmacokinetische evaluatie van de overschakeling van intraveneuze naar enterale toediening van moxifloxacine bij Intensieve Zorgen patiënten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006334-18,0,0,0 2006-006338-17,1,2009-03-03,2009-03-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"CPDS BERMUDA, LTD.",OPEN-LABEL STUDY OF EFFICACY AND SAFETY OF 067 (TERBINAFINE IN TRANSFERSOME®) FOR THE TREATMENT OF ONYCHOMYCOSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006338-17,0,0,0 2006-006339-31,4,2008-01-31,2008-01-31,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United states","AN 8 WEEK, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 3 TRIAL OF PREGABALIN (150 600 MG/DAY) IN THE ADJUNCTIVE TREATMENT OF PATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD) WHO HAVE NOT OPTIMALLY RESPOND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006339-31,0,0,0 2006-006339-31,4,2008-01-31,2008-01-31,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Oy,"AN 8 WEEK, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 3 TRIAL OF PREGABALIN (150 600 MG/DAY) IN THE ADJUNCTIVE TREATMENT OF PATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD) WHO HAVE NOT OPTIMALLY RESPOND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006339-31,0,0,0 2006-006340-60,1,2009-09-09,2009-09-09,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,OptiNose UK Ltd,"A Double Blind, Randomised, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy and Tolerability of Intranasal Fluticasone Propionate Delivered by the Optinose Device in Adult Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006340-60,0,0,0 2006-006344-59,9,2009-02-09,2009-02-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (>= 16 to 70 years old) with Partial Onset Seizure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006344-59,0,0,0 2006-006344-59,9,2009-02-09,2009-02-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma,"A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (>= 16 to 70 years old) with Partial Onset Seizure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006344-59,0,0,0 2006-006345-14,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,"UCB, Inc.","An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006345-14,0,1,1 2006-006346-34,6,2008-10-15,2008-11-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma,"An international, randomized, double-blind, parallel-group, placebo-controlled, flexible dose study: evaluation of the safety and efficacy of brivaracetam in subjects (>= 16 to 70 years old) sufferi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006346-34,0,0,0 2006-006346-34,6,2008-10-15,2008-11-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"An international, randomized, double-blind, parallel-group, placebo-controlled, flexible dose study: evaluation of the safety and efficacy of brivaracetam in subjects (>= 16 to 70 years old) sufferi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006346-34,0,0,0 2006-006346-34,6,2008-10-15,2008-11-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Casa Madre,"An international, randomized, double-blind, parallel-group, placebo-controlled, flexible dose study: evaluation of the safety and efficacy of brivaracetam in subjects (>= 16 to 70 years old) sufferi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006346-34,0,0,0 2006-006347-31,1,2012-11-14,2012-11-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London,A Phase II randomised placebo controlled clinical trial of Simvastatin in patients with secondary progressive multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006347-31,0,0,0 2006-006349-15,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Roche (HELLAS) SA,"A single arm, open label study to assess the efficacy, safety and tolerability of once- monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin levels in dyalysis patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006349-15,0,0,0 2006-006350-10,1,2009-02-28,2009-02-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici,"DOUBLE BLIND, RANDOMISED, PARALLEL GROUP, MULTICENTRE STUDY TO EVALUATE THE EFFECTS OF MANIDIPINE 20 MG VS AMLODIPINE 10 MG AND THE COMBINATION OF MANIDIPINE 10 MG PLUS DELAPRIL 30 MG VS AMLODIPINE 5 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006350-10,0,0,0 2006-006353-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Rennes,"Etude prospective, randomisée, en double aveugle, comparant l'effet d'une décontamination oro-pharyngée par la povidone-iodée à un placebo sur la réduction des pneumopathies acquises sous ventilation ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006353-27,0,0,0 2006-006354-98,1,2008-05-15,2008-05-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"“Transdermal testosterone supplementation in elderly hypogonadal men with sarcopenia: effects on muscle function, physical performance, body composition and quality of life.” A randomized, double-blin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006354-98,0,0,0 2006-006358-86,1,2009-06-02,2009-06-02,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"CoMentis, Inc., USA","A PHASE II RANDOMIZED, DOUBLE-MASKED, STUDY COMPARING THE SAFETY AND EFFICACY OF ATG003 (MECAMYLAMINE HCL) 1.0% and 0.3% OPHTHALMIC SOLUTIONS TO PLACEBO IN PATIENTS WITH NEOVASCULAR (""WET"") AGE-RELATE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006358-86,0,0,0 2006-006359-11,8,2009-01-07,2011-05-12,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche,A Phase II study of Tarceva in Combination with Avastin versus chemotherapy plus Avastin in 1st line advanced NSCLC patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006359-11,0,0,0 2006-006359-11,8,2009-01-07,2011-05-12,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ROCHE,A Phase II study of Tarceva in Combination with Avastin versus chemotherapy plus Avastin in 1st line advanced NSCLC patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006359-11,0,0,0 2006-006362-41,1,2010-04-15,2010-04-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Leeds Teaching Hospital NHS Trust,An open study on the pharmacokinetics and safety of oral voriconazole in adult patients with cystic fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006362-41,0,0,0 2006-006363-24,1,2010-03-30,2010-03-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),An Phase 2 Clinical Trial of Panitumumab in Conbination vith Irinotecan chemotherapy as 2nd line Therapy in subjects with Metastatic Colorectal Cancer. Ensayo Clínico fase II de Panitumumab combinado...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006363-24,0,0,0 2006-006370-25,7,2009-02-02,2009-08-24,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,immatics biotechnologies GmbH,"Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006370-25,0,0,0 2006-006371-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,LUMC,"Misoprostol in the management of retained placenta, a safe alternative for manual removal? A randomised controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006371-20,0,0,0 2006-006373-25,10,2010-02-27,2012-03-27,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY10017","A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP-690,550",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006373-25,0,0,0 2006-006373-25,10,2010-02-27,2012-03-27,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY10017","A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP-690,550",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006373-25,0,0,0 2006-006373-25,10,2010-02-27,2012-03-27,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Ltd, Ramsgate Road, Sandwich CT139NJ, UK","A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP-690,550",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006373-25,0,0,0 2006-006373-25,10,2010-02-27,2012-03-27,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP-690,550",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006373-25,0,0,0 2006-006374-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Intérêt du dosage sérique de la procalcitonine pour réduire la consommation d'antibiotiques en réanimation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006374-13,0,0,0 2006-006375-21,2,2008-08-18,2008-08-19,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company Ltd.,The COMPLETE T1D Trial: COMParison of Insulin Lispro Protamine Suspension and DETEmir in Type 1 Diabetes Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Insulin Detemi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006375-21,0,0,0 2006-006377-24,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude bicentrique randomisée en double aveugle comparant l'effet de l'oxyde nitrique inhalé à fortes doses à un placebo au cours du syndrome thoracique aigu des patients drépanocytaires adultes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006377-24,0,0,0 2006-006378-32,2,2009-08-18,2009-08-18,1,0,0,0,0,0,2,0,0,1,1,0,1,0,1,"ParinGenix, Inc","An Open-Label Phase Followed by a Randomized, Double-Blind, Placebo-Controlled Phase in a Study Designed to Evaluate Intravenous 2-O, 3-O Desulfated Heparin (ODSH) in Hospitalized Subjects with Exacer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006378-32,0,0,0 2006-006379-19,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,ISTITUTO GIANNINA GASLINI,Evaluation of a treatment with levocetirizine in children allergic to mites suffering for recurrent respiratory infections with or without concomitant asthma symptoms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006379-19,0,0,0 2006-006380-22,1,2007-12-03,2007-12-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,CIS bio international,Biological dosimetry in radiation synovectomy of small finger joints with Erbium [169Er] citrate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006380-22,0,0,0 2006-006383-29,2,2008-02-06,2008-02-06,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Progenics Pharmaceuticals, Inc.","A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the treatment of Post-Operative Ileus (POI)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006383-29,0,0,0 2006-006384-24,1,2008-06-30,2008-06-30,1,1,0,0,0,0,3,0,1,1,1,1,1,0,0,"Johan Wolfgang Goethe Universität - Department of Internal medicine I, Division Endocrinology",Bestimmung der stimulierten ß-Zell-Kapazität im oralen Nateglinide 50 g Glukose-Toleranz-Test - „Nateglinide-Test“,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006384-24,0,0,0 2006-006386-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),La reviviscence dans l'état de stress post-traumatique : une pathologie du rappel émotionnel ? Application thérapeutique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006386-16,0,0,0 2006-006390-24,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,WALA Heilmittel GmbH,"Prospektive, randomized, controlled, multicentre, partly double blind study to compare Disci/Rhus toxicodendron comp., placebo and waiting list in patients with chronic low back pain.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006390-24,0,0,0 2006-006392-21,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude des effets des immunoglobulines intraveineuses sur l'excitabilité nerveuse dans les neuropathies démyélinisantes dysimmunes chroniques,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006392-21,0,0,0 2006-006393-14,4,2012-10-01,2012-10-31,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, Multi-Centre Phase II Clinical Study on the Efficacy and Safety of Different Doses of Udenafil in Cirrhotic Patients with Portal Hypertens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006393-14,0,0,0 2006-006395-37,1,2009-08-21,2009-08-21,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Joint UCLH and UCL Biomedical Research Unit,"A randomised, multi-centre feasibility trial in AL Amyloidosis, comparing CTD with SCT in patients with low risk of Treatment Related Mortality and CTD with Mel-Dex in patients in whom SCT would not b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006395-37,0,0,0 2006-006398-26,1,2008-03-31,2008-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Georg-August-Universität Göttingen, Universitätsmedizin",Antibiotika versus Ibuprofen zur Therapie unkomplizierter Harnwegsinfekte: Eine Therapie-Pilotstudie in hausärztlichen Praxen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006398-26,0,0,0 2006-006404-11,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,Miltenyi Biotec GmbH,"INTRAMYOCARDIAL TRANSPLANTATION OF BONE MARROW STEM CELLS FOR IMPROVEMENT OF POST-INFARCT MYOCARDIAL REGENERATION IN ADDITION TO CABG SURGERY: a controlled prospective, randomized, double blinded mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006404-11,0,0,0 2006-006409-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fédération Nationale des Centres de Lutte Contre le Cancer,"Étude multicentrique de phase II randomisée, évaluant l’efficacité de l’anastrozole et du fulvestrant dans le traitement néo-adjuvant du cancer du sein opérable chez les femmes ménopausées et ayant po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006409-10,0,0,0 2006-006410-15,1,2008-11-03,2008-11-03,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blinded, placebo-controlled, multiple dose study to assess the efficacy of intravenously administered RSV604 in immunocompromised adults with evidence of RSV infecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006410-15,0,0,0 2006-006412-29,1,2018-02-07,2018-02-07,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,A Phase 1 / 2 Study of HKI-272 in combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006412-29,0,0,0 2006-006413-33,1,2008-03-27,2008-03-27,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc,A Phase 1/2 Dose Escalation Study of TRU-015 in Subjects with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006413-33,0,0,0 2006-006415-74,7,2011-03-31,2011-03-31,6,1,1,0,0,0,0,0,0,2,0,0,0,0,1,"Merck & Co, Inc.","A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006415-74,1,1,0 2006-006415-74,7,2011-03-31,2011-03-31,6,1,1,0,0,0,0,0,0,2,0,0,0,0,1,Merck Sharp & Dohme Corp.,"A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006415-74,1,1,0 2006-006415-74,7,2011-03-31,2011-03-31,6,1,1,0,0,0,0,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme de España, S.A.","A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006415-74,1,1,0 2006-006415-74,7,2011-03-31,2011-03-31,6,1,1,0,0,0,0,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006415-74,1,1,0 2006-006415-74,7,2011-03-31,2011-03-31,6,1,1,0,0,0,0,0,0,2,0,0,0,0,1,"Merck & Co., Inc.","A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006415-74,1,1,0 2006-006415-74,7,2011-03-31,2011-03-31,6,1,1,0,0,0,0,0,0,2,0,0,0,0,1,"Merck & Co., Inc","A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006415-74,1,1,0 2006-006415-74,7,2011-03-31,2011-03-31,6,1,1,0,0,0,0,0,0,2,0,0,0,0,1,MSD (Norge) AS,"A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006415-74,1,1,0 2006-006416-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Unité de Recherches Thérapeutiques,Effect of two distinct dosing regimen of acetaminophen on the anticoagulant effect of warfarin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006416-30,0,0,0 2006-006417-32,6,2009-08-19,2010-10-26,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Schering Plough Research Institute,Vicriviroc en combinación con un régimen TAR optimizado en sujetos infectados por el VIH tratados previamente (VICTOR-E4),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006417-32,0,0,0 2006-006417-32,6,2009-08-19,2010-10-26,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Schering-Plough Research Institute,Vicriviroc en combinación con un régimen TAR optimizado en sujetos infectados por el VIH tratados previamente (VICTOR-E4),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006417-32,0,0,0 2006-006424-18,1,,,0,1,0,0,0,0,4,0,1,1,1,1,0,1,0,University of Surrey,"THE EFFECT OF RIMONABANT ON ENERGY EXPENDITURE, FATTY ACID METABOLISM, TRIACYLGLYCEROL METABOLISM AND BODY FAT DISTRIBUTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006424-18,0,0,0 2006-006426-26,1,2008-04-23,2008-04-23,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,AstraZeneca AB,"FAST – A randomised, open-label, parallel, multicentre Phase IIIb Study to evaluate the Efficacy and Safety of Quetiapine IR titrared over 4 Days in Patients with Acute Psychosis (Rapid versus Convent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006426-26,0,0,0 2006-006427-39,1,2008-10-29,2008-10-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca GmbH,The Effect of the Atypical Antipsychotic Quetiapine in the Treatment of Postpartum Depressive Disorders with or without Psychotic Symptoms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006427-39,0,0,0 2006-006429-24,1,2008-04-01,2008-04-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,"Ensayo Fase II de Pemetrexed más Cisplatino como tratamiento de pacientes con cáncer microcítico de pulmón, enfermedad extendida",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006429-24,0,0,0 2006-006431-42,9,2008-07-03,2008-08-28,6,1,0,0,0,0,4,0,0,1,1,0,1,0,2,"Boehringer Ingelheim España, S.A.","A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/day per os to investigate the long-term efficacy, safety and tolerabi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006431-42,0,0,0 2006-006431-42,9,2008-07-03,2008-08-28,6,1,0,0,0,0,4,0,0,1,1,0,1,0,2,Boehringer Ingelheim,"A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/day per os to investigate the long-term efficacy, safety and tolerabi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006431-42,0,0,0 2006-006431-42,9,2008-07-03,2008-08-28,6,1,0,0,0,0,4,0,0,1,1,0,1,0,2,Boehringer Ingelheim Limited,"A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/day per os to investigate the long-term efficacy, safety and tolerabi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006431-42,0,0,0 2006-006431-42,9,2008-07-03,2008-08-28,6,1,0,0,0,0,4,0,0,1,1,0,1,0,2,Boehringer Ingelheim Austria GmbH,"A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/day per os to investigate the long-term efficacy, safety and tolerabi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006431-42,0,0,0 2006-006431-42,9,2008-07-03,2008-08-28,6,1,0,0,0,0,4,0,0,1,1,0,1,0,2,SCS Boehringer Ingelheim Comm.V,"A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/day per os to investigate the long-term efficacy, safety and tolerabi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006431-42,0,0,0 2006-006431-42,9,2008-07-03,2008-08-28,6,1,0,0,0,0,4,0,0,1,1,0,1,0,2,Boehringer Ingelheim Finland Ky,"A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/day per os to investigate the long-term efficacy, safety and tolerabi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006431-42,0,0,0 2006-006431-42,9,2008-07-03,2008-08-28,6,1,0,0,0,0,4,0,0,1,1,0,1,0,2,Boehringer Ingelheim Pharma Ges mbH,"A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/day per os to investigate the long-term efficacy, safety and tolerabi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006431-42,0,0,0 2006-006431-42,9,2008-07-03,2008-08-28,6,1,0,0,0,0,4,0,0,1,1,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase IV randomised, double-blind, placebo-controlled, dose titration trial with pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/day per os to investigate the long-term efficacy, safety and tolerabi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006431-42,0,0,0 2006-006434-17,1,2008-03-24,2008-03-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmita...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006434-17,0,0,0 2006-006436-22,2,2009-11-06,2009-11-06,2,1,0,0,0,0,4,0,0,1,0,0,1,0,2,BAYER,A multicenter Study Evaluating the Efficacy of Nifedipine GITS ﾖ Telmisartan Combination in Blood Pressure Control and Beyond: comparison of two strategies.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006436-22,0,0,0 2006-006436-22,2,2009-11-06,2009-11-06,2,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Bayer SpA,A multicenter Study Evaluating the Efficacy of Nifedipine GITS ﾖ Telmisartan Combination in Blood Pressure Control and Beyond: comparison of two strategies.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006436-22,0,0,0 2006-006437-40,9,2011-01-13,2011-01-13,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006437-40,0,0,0 2006-006437-40,9,2011-01-13,2011-01-13,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"A randomised, controlled, opel-label trial to compare the efficacy, safety and tolerability of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple combination the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006437-40,0,0,0 2006-006439-39,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Lund University Hospital,"Bisfosfonatbehandling av bentransplantat vid höftrevisionhöftplastikrevision utvärderat med radiostereofotogrametri. En randomiserad, dubbel-blind studie hos patienter opererade för osteolys och asept...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006439-39,0,0,0 2006-006440-55,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Childrin's Hospital,Effect on metabolic acidosis due to hyperammonemia of high versus low intake of amino acid in VLBW infants.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006440-55,0,0,0 2006-006441-14,1,2007-12-18,2007-12-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, rater-blinded cross-over multicenter study comparing the clinical efficacy of Ritalin® LA (methylphenidate) treatment (20 or 40 mg orally o.d.) in children with ADHD under different brea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006441-14,0,0,0 2006-006443-30,1,2008-05-23,2008-05-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Intercytex,A phase IIa open-label study using ICX-RHY to enhance the aesthetic appearance of facial skin imperfections.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006443-30,0,0,0 2006-006444-63,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VO Anesthesia/ICU Lunds University Hospital,The addition of clonidine to bupivacaine/adrenaline intercostal nerve blockades in patients undergoing open cholecystectomies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006444-63,0,0,0 2006-006445-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre hospitalier Régional et Universitaire,Programme de réhabilitation précoce dans les Néphrectomie totales pour cancer du rein,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006445-13,0,0,0 2006-006446-33,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ITALIAN SARCOMA GROUP,Open-label trial of Imatinib in patients with Desmoid Tumor and Chondrosarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006446-33,0,0,0 2006-006449-14,2,2009-09-23,2009-09-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ALLERGAN,A study to compare the efficacy and safety of two different types of Botulinum Toxin Type A (BOTOX or Dysport) in the Treatment of Moderate to Severe Cervical Dystonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006449-14,0,0,0 2006-006449-14,2,2009-09-23,2009-09-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Allergan Inc.,A study to compare the efficacy and safety of two different types of Botulinum Toxin Type A (BOTOX or Dysport) in the Treatment of Moderate to Severe Cervical Dystonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006449-14,0,0,0 2006-006452-35,2,2010-06-14,2010-06-14,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,PharmaEngine Inc.,"A Randomised Phase II Study of PEP02, Irinotecan or Docetaxel as a Second Line Therapy in Patients with Locally Advanced or Metastatic Gastric of Gastroesophageal Junction Adenocarcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006452-35,1,0,0 2006-006453-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Zdravstveni dom dr. Adolfa Drolca Maribor,The use of epoetin beta in cardiac arrest victims: the impact on survival and neurological outcome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006453-27,0,0,0 2006-006457-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,"Essai clinique de phase II, comparatif, randomisé, en double insu, de l’imatinib mésylate STI571 (Glivec®) versus placebo chez des malades atteints de sclérodermie cutanée grave et de sclérodermie sys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006457-27,0,0,0 2006-006458-91,4,2009-02-01,2009-02-01,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,KuDOS Pharmaceuticals Ltd. (a member of the AstraZeneca group of companies),"A phase II, open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU 0059436 given orally twice daily in patients with advanced BRCA1- or BRCA2-associated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006458-91,1,0,0 2006-006459-10,4,2017-07-20,2017-07-20,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,KuDOS Pharmaceuticals Ltd. (a member of the AstraZeneca group of companies),"A phase II, open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU 0059436 given orally twice daily in patients with advanced BRCA1- or BRCA2-associated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006459-10,0,0,0 2006-006460-32,1,2010-05-18,2010-05-18,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IV, open, multicenter, multicountry study to assess the long-term antibody persistence of a booster dose of GlaxoSmithKline (GSK) Biologicals’ Haemophilus influenzae type b – meningococcal ser...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006460-32,0,0,0 2006-006462-42,1,2008-09-16,2008-09-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V,"A PHASE IV, OPEN LABEL, PILOT STUDY OF THE TREATMENT OF CHILDREN WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) USING LOCOBASE REPAIR® AS AN ADJUNCTIVE TO STANDARD TREATMENT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006462-42,0,0,0 2006-006465-16,1,2016-03-15,2016-03-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Leipzig,Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006465-16,0,0,0 2006-006469-17,1,,,0,0,0,0,1,0,4,0,0,4,0,0,0,0,0,"St Olavs Hospital, University Hospital of Trondheim",A multicenter study to investigate the Sensitivity and Specificity of Aridol (Mannitol)Challenge as compared with Methacholine Challenge to predict a diagnosis of Asthma by a Specialist Pulmonologist ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006469-17,0,0,0 2006-006469-17,1,,,0,0,0,0,1,0,4,0,0,4,0,0,0,0,0,Haukeland University Hospital,A multicenter study to investigate the Sensitivity and Specificity of Aridol (Mannitol)Challenge as compared with Methacholine Challenge to predict a diagnosis of Asthma by a Specialist Pulmonologist ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006469-17,0,0,0 2006-006473-24,4,2009-07-03,2010-03-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & developpement,"A randomized, open-label, multi-center study of larotaxel at 90mg/m² or docetaxel every 3 weeks, alone or in combination with trastuzumab according to Her2neu status, administered after a combination ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006473-24,0,0,0 2006-006474-21,1,2009-03-16,2009-03-16,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,sanofi-aventis recherche et développement,"A dose-escalating, multicenter, single arm, open-label study of XRP9881 in combination with capecitabine (Xeloda®), in metastatic breast cancer patients with disease progressing after anthracycline an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006474-21,0,0,0 2006-006478-79,1,2011-06-30,2011-06-30,1,0,0,0,1,0,4,0,0,1,0,0,1,0,1,SIRTEX Medical Europe,"Study of Radioembolization (RE) with SIR-Spheres® versus Transarterial Chemoembolisation (TACE) in patients with unresectable primary Hepatocellular Carcinoma. A comparative, prospective, randomised, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006478-79,0,0,0 2006-006480-23,1,2008-09-30,2008-09-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospitals of Leicester,Autologous Bone Marrow-Derived Cells for Cardioprotection During Heart Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006480-23,0,0,0 2006-006481-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Orbus International BV,"HEALING IIB - Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth A Clinical, Multi-center, Prospective, non-Randomized Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006481-42,0,0,0 2006-006482-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FISM ONLUS,COMPARISON BETWEEN EPOYETIN ALONE ET EPOYETIN ASSOCIATED TO DIFFERENTIATING TERAPY WITH ACID 13-CIS-RETINOICO AND VITAMIN D3 DIIDROXILATED IN MYELODISPLASTIC SYNDROMES WITHOUT BLASTS EXCESS. CONF...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006482-16,0,0,0 2006-006485-42,2,2008-11-12,2008-11-12,2,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Q-Med AB,"Double-Blind, Randomized, Parallel Group, Multicenter Study of Durolane Compared to Methylprednisolone in Subjects with Osteoarthritis of the Knee",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006485-42,0,0,0 2006-006487-32,1,2007-05-14,2007-05-14,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GALDERMA R&D SNC,"CLINICAL EFFICACY EVALUATION OF A FIXED COMBINATION OF CALCITRIOL 3 µg/g WITH THREE CONCENTRATIONS (100, 250, 500µg/g) OF CLOBETASOL PROPIONATE AS SPRAY FORMULATION USING THE MODIFIED DUMAS-SCHOLTZ PS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006487-32,0,0,0 2006-006488-22,4,2008-07-11,2008-07-11,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Limited,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Trial to Evaluate the Efficacy and Safety of E2007 in Patients with Painful Diabetic Neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006488-22,0,0,0 2006-006490-24,4,2007-11-08,2007-11-08,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Neurochem Inc,An Open-Label Extension of the Phase III Study CL-758010 with Alzhemed™ in Patients with Alzheimer’s Disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006490-24,1,0,0 2006-006491-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,Sunitinib prior to nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006491-38,0,0,0 2006-006494-24,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Fédérationa Nationale des Centres de Lutte Contre le Cancer,"Randomized, open label, multicentric phase III trial evaluating the benefit of a sequential regimen associating FEC100 and Ixabepilone in adjuvant treatment of non metastatic, poor prognosis breast c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006494-24,0,0,0 2006-006494-24,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Fédération Nationale des Centres de Lutte Contre le Cancer,"Randomized, open label, multicentric phase III trial evaluating the benefit of a sequential regimen associating FEC100 and Ixabepilone in adjuvant treatment of non metastatic, poor prognosis breast c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006494-24,0,0,0 2006-006497-17,5,2008-07-16,2008-07-16,5,1,0,0,0,0,0,0,0,1,0,0,1,0,2,"MSP Singapore Co., LLC c/o Merck & Co., Inc.","""A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients with Metabolic Syndrome and Hyperchole...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006497-17,0,0,0 2006-006497-17,5,2008-07-16,2008-07-16,5,1,0,0,0,0,0,0,0,1,0,0,1,0,2,,"""A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients with Metabolic Syndrome and Hyperchole...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006497-17,0,0,0 2006-006497-17,5,2008-07-16,2008-07-16,5,1,0,0,0,0,0,0,0,1,0,0,1,0,2,MERCK SHARP DOHME,"""A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients with Metabolic Syndrome and Hyperchole...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006497-17,0,0,0 2006-006497-17,5,2008-07-16,2008-07-16,5,1,0,0,0,0,0,0,0,1,0,0,1,0,2,"Merck & Co., Inc.","""A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients with Metabolic Syndrome and Hyperchole...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006497-17,0,0,0 2006-006497-17,5,2008-07-16,2008-07-16,5,1,0,0,0,0,0,0,0,1,0,0,1,0,2,Merck & Co. Inc,"""A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients with Metabolic Syndrome and Hyperchole...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006497-17,0,0,0 2006-006507-36,6,2012-02-06,2012-03-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genentech Inc.,"A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY REGIMENS IN SUBJECTS WITH PREVIOUSLY TREATED METASTATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006507-36,0,0,0 2006-006507-36,6,2012-02-06,2012-03-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GENENTECH , INC","A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY REGIMENS IN SUBJECTS WITH PREVIOUSLY TREATED METASTATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006507-36,0,0,0 2006-006512-30,13,2008-03-31,2009-01-16,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006512-30,0,0,0 2006-006512-30,13,2008-03-31,2009-01-16,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/4.5...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006512-30,0,0,0 2006-006513-33,1,2009-02-26,2009-02-26,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Janssen Pharmaceutica NV,"A double-blind, randomized, parallel group comparison of Nizoral® cream (F012), ketoconazole 2% cream (F126) and placebo (F000) in the treatment of interdigital Tinea Pedis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006513-33,0,0,0 2006-006514-15,1,2014-06-30,2014-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The University of Nottingham,Double blind crossover randomised controlled trial comparing letrozole versus clomifene citrate for ovulation induction in women with polycystic ovarian syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006514-15,0,0,0 2006-006514-15,1,2014-06-30,2014-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Derby Hospitals NHS Foundation Trust,Double blind crossover randomised controlled trial comparing letrozole versus clomifene citrate for ovulation induction in women with polycystic ovarian syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006514-15,0,0,0 2006-006515-76,1,2009-12-16,2009-12-16,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Oncolytics Biotech Inc,"A Dose Targeted Phase I/II Study To Evaluate The Feasibility, Safety, And Biological Effects Of Intravenous Administration of A Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Carbop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006515-76,0,0,0 2006-006516-30,1,2012-01-02,2012-01-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité-Universitätsmedizin Berlin,Combined systemic an intrathecal chemotherapy with succeeding high dosis chemotherapy and autologous stem cell transplantation of patients with CNS relapses of agressive lymphomas.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006516-30,0,0,0 2006-006518-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire Rennes,"Etude prospective, randomisée, en double aveugle, comparant l’efficacité du lévétiracétam à un placebo sur la prévention des crises d’épilepsie précoces et tardives chez les patients présentant un tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006518-13,0,0,0 2006-006519-60,1,2008-08-22,2008-08-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca AB,"A multi-centre, randomised, double-blind, cross-over design study to evaluate efficacy on exercise tolerance of budesonide/formoterol (Symbicort®Turbuhaler®) 320/9 μg one inhalation twice daily compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006519-60,0,0,0 2006-006520-19,1,2014-11-26,2014-11-26,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Amgen Research (Munich) GmbH,"An open-label, multicenter phase II study to investigate the efficacy, safety, and tolerability of the bi-specific T-cell engager (BITE) MT103 in patients with minimal residual disease (MRD) of positi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006520-19,0,0,0 2006-006521-30,12,2008-11-10,2009-01-10,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,Long term safety and tolerability of satavaptan in patients with cirrhosis of the liver that have been previously randomized and completed treatment in any of the phase III studies: EFC4492; EFC4493 o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006521-30,0,0,0 2006-006521-30,12,2008-11-10,2009-01-10,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & de'veloppement,Long term safety and tolerability of satavaptan in patients with cirrhosis of the liver that have been previously randomized and completed treatment in any of the phase III studies: EFC4492; EFC4493 o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006521-30,0,0,0 2006-006522-25,6,2007-09-10,2008-10-31,5,1,0,0,0,0,0,0,0,1,1,0,1,0,1,CSL Behring AG,A Multicenter study on the efficacy and safety of Vivaglobin in Previously Untreated Patients (PUPs) with Primary Immunodeficiency (PID),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006522-25,0,0,0 2006-006523-40,1,2009-06-16,2009-06-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche AB,"A single arm open label study to assess the efficacy, safety and tolerability and of once-monthly administration of subcutaneous C.E.R.A. for the maintenance of haemoglobin levels in pre-dialysis pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006523-40,0,0,0 2006-006526-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,Confirmation clinique d'une interaction pharmacodynamique entre tropisétron et paracétamol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006526-26,0,0,0 2006-006529-25,6,2014-09-30,2014-10-13,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 CLinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006529-25,0,0,0 2006-006529-25,6,2014-09-30,2014-10-13,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Schering-Plough Research Institute,"Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 CLinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006529-25,0,0,0 2006-006529-25,6,2014-09-30,2014-10-13,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,SCHERING-PLOUGH,"Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 CLinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006529-25,0,0,0 2006-006532-21,4,2011-07-28,2015-12-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,EORTC,Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006532-21,0,0,0 2006-006532-21,4,2011-07-28,2015-12-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,European Organization for Research and Treatment of Cancer,Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006532-21,0,0,0 2006-006534-17,1,2007-11-23,2007-11-23,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Egalet a/s,"A Phase II, Multi-center, Multiple-dose, Double-blind, Randomized, Crossover Study Comparing the Pharmacodynamic Effects of a Once-daily Controlled-Release Carvedilol (CRC; Egalet® Formulation) and a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006534-17,0,0,0 2006-006535-53,2,2009-11-12,2009-11-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MITSUBISHI PHARMA CORPORATION,"A Phase III, Multi-centre, Double-blind, Randomised, Placebo-controlled, Multiple Fixed-dose Study of MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphatae...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006535-53,0,0,0 2006-006535-53,2,2009-11-12,2009-11-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma Corporation,"A Phase III, Multi-centre, Double-blind, Randomised, Placebo-controlled, Multiple Fixed-dose Study of MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphatae...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006535-53,0,0,0 2006-006536-22,5,2013-03-13,2013-03-13,4,1,1,0,0,0,2,0,0,2,0,0,0,0,1,UCB Pharma SA,"ESTUDIO MULTICÉNTRICO, ABIERTO, DE UN SOLO BRAZO DE TRATAMIENTO, PARA EVALUAR LA FARMACOCINÉTICA, SEGURIDAD Y EFICACIA DE LA ADMINISTRACIÓN DE BRIVARACETAM COMO TRATAMIENTO ADYUVANTE EN PACIENTES DE 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006536-22,1,1,0 2006-006537-40,8,2011-12-20,2011-12-20,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline S.A.,"A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006537-40,0,0,0 2006-006537-40,8,2011-12-20,2011-12-20,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithkline Research & Development Limited,"A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006537-40,0,0,0 2006-006537-40,8,2011-12-20,2011-12-20,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithkline Research & Development Ltd,"A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006537-40,0,0,0 2006-006538-16,8,2014-08-12,2014-08-12,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNITIN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006538-16,0,0,0 2006-006538-16,8,2014-08-12,2014-08-12,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer,AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNITIN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006538-16,0,0,0 2006-006538-16,8,2014-08-12,2014-08-12,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer, S.A.",AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNITIN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006538-16,0,0,0 2006-006538-16,8,2014-08-12,2014-08-12,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER Inc,AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNITIN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006538-16,0,0,0 2006-006538-16,8,2014-08-12,2014-08-12,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, US",AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNITIN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006538-16,0,0,0 2006-006539-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,hospices civils de Lyon,Anti-GPIIbIIIa et Infarctus aigu du myocarde dans les réseaux RESCUe-RESURCOR AGIR2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006539-37,0,0,0 2006-006540-54,2,2008-09-06,2008-09-06,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder. A randomised, double-blind, flexible-dose international multicentr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006540-54,0,0,0 2006-006540-54,2,2008-09-06,2008-09-06,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Servier Research and Development Limited,"Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder. A randomised, double-blind, flexible-dose international multicentr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006540-54,0,0,0 2006-006541-14,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,A phase II pilot trial to evaluate the efficacy of treatment with Pegilate G-CSF in a group of elderly patients AML without chemotherapy indications,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006541-14,0,0,0 2006-006542-34,1,2009-02-03,2009-02-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pantarhei Bioscience B.V.,"Preoperative hormone therapy for pre- and postmenopausal women with ER positive breast cancer: A double blind randomized parallel group phase II trial, comparing the effect of 2 weeks of preoperative ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006542-34,0,0,0 2006-006543-31,4,2009-05-12,2009-05-13,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Lux Biosciences GmbH,"A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006543-31,0,0,0 2006-006544-66,4,2009-05-12,2009-05-18,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Lux Biosciences GmbH,"A Double-Masked, Placebo-Controlled, Multi-Centre, Parallel Group, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Clinically Quiescent Sight Threatening, Non...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006544-66,0,0,0 2006-006545-13,4,2009-05-12,2009-05-12,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Lux Biosciences GmbH,"A Double-Masked, Placebo-Controlled, Multi-Centre, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Uveitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006545-13,0,0,0 2006-006550-96,5,2017-06-30,2017-11-01,4,1,0,0,0,0,3,0,1,1,0,0,1,0,0,NIDDK TYPE 1 DIABETES TRIALNET,ORAL INSULIN FOR PREVENTION OF DIABETES IN RELATIVES AT RISK FOR TYPE 1 DIABETES MELLITUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006550-96,0,0,0 2006-006550-96,5,2017-06-30,2017-11-01,4,1,0,0,0,0,3,0,1,1,0,0,1,0,0,TrialNet Study Group,ORAL INSULIN FOR PREVENTION OF DIABETES IN RELATIVES AT RISK FOR TYPE 1 DIABETES MELLITUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006550-96,0,0,0 2006-006550-96,5,2017-06-30,2017-11-01,4,1,0,0,0,0,3,0,1,1,0,0,1,0,0,TrialNet Coordinating Center,ORAL INSULIN FOR PREVENTION OF DIABETES IN RELATIVES AT RISK FOR TYPE 1 DIABETES MELLITUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006550-96,0,0,0 2006-006552-36,1,2007-08-08,2007-08-08,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline,A phase IIIb open study to assess the long-term efficacy and safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine approximately three years after vaccination...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006552-36,0,0,0 2006-006553-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hôpital Universitaire Des Enfants Reine Fabiola (H.U.D.E.R.F.),"Détermination de la MLAC (Minimum Local Analgesic Concentration) pour le Ropivacaine, la Levobupivacaine et la Bupivacaine dans l'analgésie caudale chez l'enfant.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006553-26,0,0,0 2006-006555-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU Angers,"Étude de phase II, multicentrique, en ouvert, évaluant le dasatinib chez les patients atteints de leucémie aiguë myéloblastique (LAM) à core binding factors (CBF) résistants à la chimiothérapie conven...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006555-12,0,0,0 2006-006557-28,3,2008-10-15,2008-12-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratoires SMB S.A.,"A phase III, four-armed, randomised, double blind, parallel study to compare the efficacy and safety in type 2 diabetic patients with combined hyperlipidemia of a 12-week administration of Fenofibrate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006557-28,0,0,0 2006-006562-42,1,2011-08-01,2011-08-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Derby Hospitals NHS Foundation Trust,An Observational and Exploratory Study to determine the effect of anti TNF Biologic Treatment in Rheumatoid Cachexia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006562-42,0,0,0 2006-006563-23,1,2007-08-06,2007-08-06,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,Health Protection Agency,"A Phase IV, single group study to evaluate the immune response to licensed seasonal influenza vaccine and relationship of this to cytomegalovirus-associated immunosenescence in UK older adults aged 50...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006563-23,0,0,0 2006-006564-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,C.H.U de Clermont Ferrand,EFFET DU PARACETAMOL SUR LE STATUT EN GLUTATHION DE LA PERSONNE AGEE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006564-36,0,0,0 2006-006566-42,1,2008-07-15,2008-07-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Universität Mainz, III. Medizinische Klinik",Sorafenib in Resected NSCLC (SIRN) - A Phase II Study to Investigate the Efficacy and Safety of Sorafenib as Adjuvant Treatment following Resection of Non-small Cell Lung Carcinoma (NSCLC) in Patients...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006566-42,0,0,0 2006-006569-18,1,2007-11-12,2007-11-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE DERMATOLOGIE represented by INSTITUT DE RECHERCHE PIERRE FABRE,EFFICACY AND SAFETY OF 8% CLOBETASOL NAIL LACQUER FORMULATION VERSUS VEHICLE IN NAIL PSORIASIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006569-18,0,0,0 2006-006573-24,1,2009-06-17,2009-06-17,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital of Heidelberg,"Prospective influence of bedtime insulin glargine on mobilization and function of endothelial progenitor cells in patients with type 2 diabetes: a partially double-blind, randomized, three-arm unicent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006573-24,0,0,0 2006-006574-21,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,GUIDOTTI,A PATIENT PREFERENCE STUDY OF FROVATRIPTAN VERSUS ZOLMITRIPTAN FOR THE ACUTE TREATMENT OF MIGRAINE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006574-21,0,0,0 2006-006576-38,1,2008-10-02,2008-10-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Siegfried KASPER, O.Univ.Prof.Dr.Dr.h.c., Medizinische Universität Wien",Longitudinal imaging of serotonin transporter occupancy using PET and [11C]DASB in patients with major depression treated with escitalopram or citalopram,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006576-38,0,0,0 2006-006577-25,2,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,0,Karolinska Institutet,"A prospective randomized study comparing rapamune and tacrolimus vs. cyclosporine and methotrexate as immune prophylaxis in allogeneic hematopoietic stem cell transplantation, using HLA-A, -B, -DRB1 i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006577-25,0,0,0 2006-006577-25,2,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,0,Nordic Bone Marrow Transplant Group (NBMT),"A prospective randomized study comparing rapamune and tacrolimus vs. cyclosporine and methotrexate as immune prophylaxis in allogeneic hematopoietic stem cell transplantation, using HLA-A, -B, -DRB1 i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006577-25,0,0,0 2006-006579-19,1,2008-07-03,2008-07-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Egalet a/s,"A double-blind, randomized, 2-way cross-over, phase II, efficacy trial in cancer patients to assess the overall efficacy, patient preference, morphine related side effect profile and safety of the Ega...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006579-19,0,0,0 2006-006580-23,1,2008-03-26,2008-03-26,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,Immunogenicity & safety study of GSK Biologicals’ meningococcal vaccine GSK134612 when co-administered with GSK Biologicals’ MMRV vaccine (Priorix-Tetra™) in healthy 12 to 23-month-old children.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006580-23,0,0,0 2006-006583-35,1,2007-12-18,2007-12-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Shrewsbury & Telford Hospital NHS Trust,A comparison of two diluents commonly used in epidural steroid injection for the treatment of low back pain and sciatica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006583-35,0,0,0 2006-006588-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),Fluvastatin as adjuvant therapy to alfa-interferon and ribavirin in the treatment of chronic hepatitis C in patients with HIV-1 coinfection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006588-21,0,0,0 2006-006589-41,2,2008-12-29,2008-12-29,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Novo Nordisk Pharmaceutique S.A.S,Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning ve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006589-41,0,0,0 2006-006589-41,2,2008-12-29,2008-12-29,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Novo Nordisk Ltd,Levemir® in ageing patients with type 2 diabetes A seven-month open-labelled randomised multi-centre two-group parallel trial comparing administration of insulin detemir once daily in the morning ve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006589-41,0,0,0 2006-006591-37,3,2009-04-13,2009-04-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals France,"A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Auto-Injector ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006591-37,0,0,0 2006-006595-38,1,2010-12-15,2010-12-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospitals Bristol NHS Foundation Trust,"A Phase II, Open-Label, Single-Arm Study to Assess the Efficacy and Safety of Decapeptyl® SR (3 mg and 11.25 mg formulations) when administered by subcutaneous injection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006595-38,0,0,0 2006-006599-39,1,2008-07-14,2008-07-14,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,BIODEL Inc.,"An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAJECT™ and Regular Human Insulin in Patients with Type 1 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006599-39,0,0,0 2006-006600-11,1,2008-07-07,2008-07-07,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,BIODEL Inc.,"An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAJECT™ and Regular Human Insulin in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006600-11,0,0,0 2006-006601-83,1,2007-10-31,2007-10-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a division of Schering Corp.",A Study to Assess the Clinical Effects of SCH 527123 in Psoriasis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006601-83,0,0,0 2006-006604-11,5,2009-07-21,2009-08-05,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) When Given in Combination with Pegasys a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006604-11,0,0,0 2006-006604-11,5,2009-07-21,2009-08-05,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) When Given in Combination with Pegasys a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006604-11,0,0,0 2006-006611-68,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,academic hospital Maastricht,Valsartan on top of standard therapy as a novel therapeutic strategy to treat cardiac dysfunction in patients with infammatory cardiomyopathies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006611-68,0,0,0 2006-006615-80,1,2011-08-11,2011-08-11,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Royal Marsden Nhs Foundation Trust,A Pilot Study in Metastatic Advanced Thyroid Cancer Evaluating the Safety and Efficacy of Sorafenib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006615-80,0,0,0 2006-006616-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Haukeland University Hospital,Behandling med hyperton-kolloidal infusjon ved hjertekirurgi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006616-30,0,0,0 2006-006617-32,1,2008-10-25,2008-10-25,1,1,0,0,0,0,0,0,0,1,1,1,1,0,0,Kings College Hospital Trust R&D,A prospective randomised double blind parallel trial comparing Articaine versus Lignocaine for mandibular dentistry,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006617-32,0,0,0 2006-006619-64,1,2010-01-12,2010-01-12,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Hospital of South Manchester NHS Foundation Trust,Randomised Controlled Trial of Lapatinib (A Her1/2 Tyrosine Kinase Inhibitor) on Epithelial Proliferation and Apoptosis in Ductal Cancer in Situ.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006619-64,0,0,0 2006-006619-64,1,2010-01-12,2010-01-12,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Manchester,Randomised Controlled Trial of Lapatinib (A Her1/2 Tyrosine Kinase Inhibitor) on Epithelial Proliferation and Apoptosis in Ductal Cancer in Situ.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006619-64,0,0,0 2006-006624-19,5,2009-06-19,2014-11-24,3,1,0,0,0,0,3,0,0,1,1,0,1,0,2,"Genentech, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IIIb TRIAL COMPARING BEVACIZUMAB THERAPY WITH OR WITHOUT ERLOTINIB AFTER COMPLETION OF CHEMOTHERAPY WITH BEVACIZUMAB FOR THE FIRST-LINE TREATMENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006624-19,0,0,0 2006-006624-19,5,2009-06-19,2014-11-24,3,1,0,0,0,0,3,0,0,1,1,0,1,0,2,"GENENTECH , INC","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IIIb TRIAL COMPARING BEVACIZUMAB THERAPY WITH OR WITHOUT ERLOTINIB AFTER COMPLETION OF CHEMOTHERAPY WITH BEVACIZUMAB FOR THE FIRST-LINE TREATMENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006624-19,0,0,0 2006-006626-26,5,2019-12-23,2019-12-23,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Genentech, Inc.","A Phase III, Multicenter, Placbo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva (erlotinib) Compared With Tarceva Alone For Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006626-26,0,0,0 2006-006626-26,5,2019-12-23,2019-12-23,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"GENENTECH , INC","A Phase III, Multicenter, Placbo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva (erlotinib) Compared With Tarceva Alone For Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006626-26,0,0,0 2006-006632-22,1,2010-05-15,2010-05-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"University of Leuven, Division of Gastroenterology",Change from infliximab to adalimumab in patients with Crohn’s disease in remission on infliximab: a randomized comparative case control study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006632-22,0,0,0 2006-006633-41,1,2008-06-03,2008-06-03,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Bayer Schering Pharma AG,"Monocenter, open-label, randomized study to determine the ovulation inhibitory effect of the combined oral contraceptives SH T04769G (0.015 mg Ethinylestradiol and 1.5 mg Dienogest in a modified relea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006633-41,0,0,0 2006-006636-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Jesper Ekelund,Histamiini H2 salpaus liitännäishoitona puutteellisen hoitovasteen skitsofreniassa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006636-22,0,0,0 2006-006638-16,1,2013-10-07,2013-10-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 and IV bortezomib in adult patients with multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006638-16,0,0,0 2006-006642-34,4,2009-05-12,2009-05-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen-Cilag International NV, Turnhoutsweg 30, 2340 BEERSE, Belgium","Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER acutely exacerbated subjects with schizofrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006642-34,0,0,0 2006-006642-34,4,2009-05-12,2009-05-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER acutely exacerbated subjects with schizofrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006642-34,0,0,0 2006-006642-34,4,2009-05-12,2009-05-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER acutely exacerbated subjects with schizofrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006642-34,0,0,0 2006-006646-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasme Hospital - Department of Gastroenterology,OXALIPLATIN PLUS 5-FLUOROURACIL BASED-CHEMOTHERAPY INDUCTION FOLLOWED BY PREOPERATIVE CHEMORADIATION VERSUS PREOPERATIVE CHEMORADIATON ALONE IN ADVANCED RECTAL ADENOCARCINOMA: RANDOMIZED CONTROLLED PH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006646-34,0,0,0 2006-006647-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,The Austrian Society of Surgical Oncology (ACO-ASSO),"p53-Adjusted Neoadjuvant Chemotherapy for potentially resectable Oesophageal Cancer ""pANCHO"".",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006647-31,0,0,0 2006-006652-35,1,2012-01-08,2012-01-08,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Queen Mary University of London,"A pilot study to evaluate of the impact on bone density during treatment with mycophenolate mofetil, daclizumab in combination with ciclosporin converted to sirolimus with steroid as mainstay immunosu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006652-35,0,0,0 2006-006653-27,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Biofrontera Bioscience GmbH,"Phase IIa, single-center, randomized, double-blind, vehicle-controlled study to determine the efficacy and safety/tolerability of a topical riluzole formulation in patients with atopic eczema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006653-27,0,0,0 2006-006656-35,9,2008-05-15,2008-06-20,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,"""A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Estimation Study to Assess the Efficacy and Safety of Modified Release UK-369,003 in the Treatment of Men with Storage Low...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006656-35,0,0,0 2006-006656-35,9,2008-05-15,2008-06-20,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Ltd, Ramsgate Road, Sandwich, Kent. UK","""A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Estimation Study to Assess the Efficacy and Safety of Modified Release UK-369,003 in the Treatment of Men with Storage Low...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006656-35,0,0,0 2006-006656-35,9,2008-05-15,2008-06-20,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Ltd,"""A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Estimation Study to Assess the Efficacy and Safety of Modified Release UK-369,003 in the Treatment of Men with Storage Low...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006656-35,0,0,0 2006-006657-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dutch Colorectal Cancer Group,"Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with capecitabine, oxaliplatin, and bevacizumab as first-line treatment in patients with advanced c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006657-27,0,0,0 2006-006658-89,6,2011-03-23,2011-03-23,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Amgen Inc,A Phase 1b/2 study of AMG 655 Combination with Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006658-89,0,0,0 2006-006669-17,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO,PILOT STUDY OF OXCARBAZEPINE TOLEP ACTIVITY IN ANTICANCER DRUGS NEUROPHATIES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006669-17,0,0,0 2006-006673-24,1,2009-09-24,2009-09-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BAYER SANTE,"Etude pilote multicentrique de phase IV, en ouvert, randomisée, en groupe parallèles destinée à évaluer l'éfficacité d'un protocole de rééducation fonctionnelle des patients atteints d'une forme récur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006673-24,0,0,0 2006-006677-25,6,2008-10-30,2008-10-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & de'veloppement,"Efficacy and safety of 2mg/day of M100907 on Sleep Maintenance Insomnia with a sub-study of the effect of M100907 on stable Type II Diabetes Mellitus: a 12-week, multi-center, randomized, double-blind...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006677-25,0,0,0 2006-006677-25,6,2008-10-30,2008-10-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"Efficacy and safety of 2mg/day of M100907 on Sleep Maintenance Insomnia with a sub-study of the effect of M100907 on stable Type II Diabetes Mellitus: a 12-week, multi-center, randomized, double-blind...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006677-25,0,0,0 2006-006678-12,3,,,0,0,0,0,0,0,3,0,0,1,1,0,0,1,1,Haupt Pharma Wolfratshausen GmbH,"Nasal Transmucosal Fentanyl Citrate (NTFC) versus Oral Morphine Sulphate (OMS): A double-blind, double dummy, randomised, multi-centre, comparative cross-over study for the treatment of breakthrough p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006678-12,0,0,0 2006-006679-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University of Oslo, institute for basic medical sciences, department of nutrition.",Prostate Phytochemical & PUFA Intervention (PFPI) Norwegian title: Prostata Fytokjemikalie & PUFA Intervensjon (PFPI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006679-18,0,0,0 2006-006680-23,3,2008-10-27,2008-10-27,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, open, randomized, controlled study to demonstrate the immunogenicity, reactogenicity and safety of GSK Biologicals meningococcal serogroup ACWY conjugate vaccine (GSK134612, MenACWY-TT) c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006680-23,0,0,0 2006-006684-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Toulouse,Evaluation des effets à long terme de l’amantadine chez le parkinsonien souffrant de dyskinésies induites par la lévodopa : Etude randomisée en double-insu versus placebo de l’arrêt d’une prescriptio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006684-22,0,0,0 2006-006686-17,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Schering-Plough,"Evaluation of preference for a buprenorphine-based maintenance therapy, after a switch from buprenorphine alone (Subutex®) to the buprenorphine/naloxone combination (Suboxone®), in opioid-dependent pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006686-17,0,0,0 2006-006690-25,1,2007-04-30,2007-04-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Consumer Health SA,"A Double-Blind, Randomized, Parallel Group, Placebo Controlled Study, Evaluating the Decongestant Effect, Time to Onset, Duration of Effect and Impact on Sleep and General Well-being of Otrivin F2 in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006690-25,0,0,0 2006-006692-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"St. Vincent Hospital, Medical Department II","The TOMIBA study Treatment of Osteoporotic Men With Intravenous Ibandronate An open-label, single-center, prospective Phase III study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006692-20,0,0,0 2006-006693-24,9,2009-07-15,2009-07-15,8,1,0,0,0,1,2,0,0,2,0,0,0,0,1,AOP ORPHAN PHARMACEUTICALS,"A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006693-24,1,0,0 2006-006693-24,9,2009-07-15,2009-07-15,8,1,0,0,0,1,2,0,0,2,0,0,0,0,1,AOP Orphan Pharmaceuticals AG,"A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006693-24,1,0,0 2006-006694-24,1,2009-02-03,2009-02-03,1,0,0,1,0,1,1,0,0,1,1,1,0,0,1,Fresenius Biotech GmbH,Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in relapsed or refractory chronic lymphocytic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006694-24,0,0,0 2006-006695-38,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,CHU Toulouse,Evaluation pharmacologique des antagonistes du récepteur P2Y12 à l'ADP chez le volontaire sain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006695-38,0,0,0 2006-006697-15,1,2008-10-01,2008-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca SAS,Evaluation de l'efficacité et de la tolérance de rosuvastatine 5 mg versus pravastatine 40 mg et atorvastatine 10 mg chez des patients hypercholestérolémiques de type IIa et IIb,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006697-15,0,0,0 2006-006698-25,4,2008-08-01,2008-10-01,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly and Company limited,A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl versus Placebo Concurrently with Pemetrexed (Alimta) as Second-Line Therapy in Patients with Advanced or Metastatic Non-Small Cell L...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006698-25,0,0,0 2006-006698-25,4,2008-08-01,2008-10-01,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly and Company Limited,A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl versus Placebo Concurrently with Pemetrexed (Alimta) as Second-Line Therapy in Patients with Advanced or Metastatic Non-Small Cell L...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006698-25,0,0,0 2006-006698-25,4,2008-08-01,2008-10-01,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ELI LILLY,A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl versus Placebo Concurrently with Pemetrexed (Alimta) as Second-Line Therapy in Patients with Advanced or Metastatic Non-Small Cell L...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006698-25,0,0,0 2006-006699-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Clínic,Estudio aleatorizado y doble ciego para establecer el momento más apropiado de la administración de la profilaxis antibiótica en la artroplastia total de rodilla cuando se realiza bajo isquemia Random...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006699-40,0,0,0 2006-006704-10,1,2007-07-20,2007-07-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,JADO Technologies GmbH,Efficacy and Safety of Miltefosine in Cutaneous Mastocytosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006704-10,0,0,0 2006-006706-29,1,2013-01-01,2013-01-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,UMCN department Pharm-Tox,Does atorvastatin reduce ischemia-reperfusion injury in humans in-vivo?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006706-29,0,0,0 2006-006707-36,3,2010-05-05,2010-05-05,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"F. Hoffman-La Roche Ltd., Roche Oy","A single arm, open label study to assess the efficacy, safety, and tolerability of monthly administration of RO0503821 for the treatment of chronic renal anaemia in patients not on dialysis and not cu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006707-36,0,0,0 2006-006707-36,3,2010-05-05,2010-05-05,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Roche Oy,"A single arm, open label study to assess the efficacy, safety, and tolerability of monthly administration of RO0503821 for the treatment of chronic renal anaemia in patients not on dialysis and not cu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006707-36,0,0,0 2006-006710-15,1,2007-05-16,2007-05-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A randomised, single blind, placebo-controlled 5-way crossover trial of single doses of intranasal GSK256066 in subjects with seasonal allergic rhinitis (SAR)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006710-15,0,0,0 2006-006714-14,1,2012-07-01,2012-07-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Kvinnokliniken i Östergötland,Tranexamsyra (Cyklokapron®) vid kirurgi för avancerad ovarialcancer - en prospektiv randomiserad dubbelblind studie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006714-14,0,0,0 2006-006715-77,1,2009-03-13,2009-03-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novo Nordisk Pharmaceutique S.A.S.,"A randomised, multicentric, open labelled, parallel group trial with insulin aspart and insulin detemir, investigating the glycaemic effect and profile in children with Type 1 diabetes, of two separ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006715-77,0,0,0 2006-006716-30,1,2010-08-30,2010-08-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"Randomized, controlled, multicentric trial to evaluate efficacy and safety of the switch from a LPV/r based therapy to an ATV/r or a NVP based treatment in association with ABC/3TC, in HIV patient wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006716-30,0,0,0 2006-006717-32,1,2008-06-03,2008-06-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Stefan Lundeberg,Pharmacokinetic study of the opioid ketobemidone in children and adolescens after intravenous administration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006717-32,0,0,0 2006-006718-13,1,2009-08-18,2009-08-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Hull and East Yorkshire NHS Trust,Opioids in the management of breathlessness in chronic heart failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006718-13,0,0,0 2006-006719-66,1,2008-08-15,2008-08-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma S.A.S.,"Efficacité d’un traitement par l’association amlodipine et valsartan en monoprise vespérale ou matinale, chez des Patients présentant une HTA Essentielle moyenne à modérée, non contRôlée par amlodipin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006719-66,0,0,0 2006-006726-26,1,2007-11-27,2007-11-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Orexo AB,An open-label randomised observer-blind study to evaluate 24-hour intragastric pH profile at day 1 and day 14 during treatment with a fixed combination of a histamine type 2 receptor antagonist and a ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006726-26,0,0,0 2006-006727-39,1,,,0,1,0,0,1,0,4,0,0,1,0,0,0,1,0,University Hospital Ghent,A prospective randomised controlled trial on the use of BMP-7 (Bone Morphogenetic Protein-7) (OP-1®) and demineralised bone matrix (DBM) in tibial non-union.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006727-39,0,0,0 2006-006728-20,1,2009-09-16,2009-09-16,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Moorfields Eye Hospital,The use of intraocular methotrexate to treat uveitis: a safety and efficacy study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006728-20,0,0,0 2006-006730-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),AMBIZYGO. Etude de phase II de l'efficacité d'une posologie initiale élevée d'amphotéricine B liposomale (AmBisome) (10mg/kg/j) dans le traitement des zygomycoses,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006730-18,0,0,0 2006-006731-45,1,2008-06-10,2008-06-10,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Køge Sygehus,PPI-Rebound-Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006731-45,0,0,0 2006-006733-41,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Novartis Pharma S.A.S.,Effet de l’association fixe amlodipine/valsartan sur la Pression artérielle centrale chez des hypertendus essentiels non contrôlés par amlodipine 5mg,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006733-41,0,0,0 2006-006736-22,1,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Netherlands Asthma Foundation (NAF),"An early diagnosis of asthma in young children by using non-invasive biomarkers of oxidative stress/airway inflammation, and early lung function measurements",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006736-22,0,0,0 2006-006736-22,1,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Stichting astma bestrijding,"An early diagnosis of asthma in young children by using non-invasive biomarkers of oxidative stress/airway inflammation, and early lung function measurements",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006736-22,0,0,0 2006-006739-36,5,2012-06-12,2012-08-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,A Single Arm Multicentre Phase II Study of Panitumumab in Combination with Irinotecan/5-Fluorouracil/Leucovorin in Patients with Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006739-36,0,0,0 2006-006742-34,1,2013-03-08,2013-03-08,1,1,0,0,0,1,4,0,0,1,1,1,1,0,0,Barts and The London NHS Trust,The effect of Ezetimibe or pyridoxine in Patients with Primary Biliary Cirrhosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006742-34,0,0,0 2006-006743-31,1,2008-07-11,2008-07-11,1,1,0,0,1,0,3,0,1,1,0,0,1,0,1,Dynavax Technologies Corporation,A Phase III Safety and Efficacy Study to Compare Immune Responses following Injection with Either Two Doses of HEPLISAV™ or Three Doses of Engerix-B®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006743-31,0,0,0 2006-006745-13,7,2009-01-22,2009-08-31,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CSL Behring,"A Multicenter Study of the Efficacy, Tolerability, Safety and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects with Primary Immunodeficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006745-13,0,0,0 2006-006745-13,7,2009-01-22,2009-08-31,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CSL Behring AG,"A Multicenter Study of the Efficacy, Tolerability, Safety and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects with Primary Immunodeficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006745-13,0,0,0 2006-006745-13,7,2009-01-22,2009-08-31,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CSL Behring AG (casa madre),"A Multicenter Study of the Efficacy, Tolerability, Safety and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects with Primary Immunodeficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006745-13,0,0,0 2006-006746-33,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Roche Pharma AG,Re-Treatment with Rituximab in patients with rheumatoid arthritis who have had an inadequate response to not more than one aTNF (extension study to ML19070),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006746-33,0,0,0 2006-006748-76,8,2010-03-23,2010-03-23,5,1,0,0,0,1,4,0,0,1,1,0,1,0,1,"Pfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK","A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006748-76,0,0,0 2006-006748-76,8,2010-03-23,2010-03-23,5,1,0,0,0,1,4,0,0,1,1,0,1,0,1,PFIZER,"A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006748-76,0,0,0 2006-006748-76,8,2010-03-23,2010-03-23,5,1,0,0,0,1,4,0,0,1,1,0,1,0,1,"Pfizer Ltd. Ramsgate Road, Sandwich, Kent, UK","A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006748-76,0,0,0 2006-006748-76,8,2010-03-23,2010-03-23,5,1,0,0,0,1,4,0,0,1,1,0,1,0,1,"Pfizer Ltd, Ramsgate Road, Sandwich, Kent UK","A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006748-76,0,0,0 2006-006749-15,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Institut de Recerca Hospital de Sant Pau,NEUROIMAGEN MOLECULAR EN EL TEMBLOR ESENCIAL: ESTUDIO PET MULTITRAZADOR.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006749-15,0,0,0 2006-006752-35,7,2008-12-19,2009-03-09,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schwarz Biosciences GmbH, UCB Group","PHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006752-35,0,0,0 2006-006752-35,7,2008-12-19,2009-03-09,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SCHWARZ PHARMA,"PHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006752-35,0,0,0 2006-006752-35,7,2008-12-19,2009-03-09,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Schwarz Biosciences GmbH,"PHASE 3B, MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM TRIAL TO EVALUATE THE EFFECT OF THE 24-HOUR TRANSDERMAL DELIVERY OF ROTIGOTINE ON THE CONTROL OF EARLY MORNING MOTOR FUNCT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006752-35,0,0,0 2006-006753-27,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Effects of oral CYTIDIN-5 -DIPHOSFOCHOLINE on vision function in the amblyopia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006753-27,0,0,0 2006-006754-10,1,2008-05-13,2008-05-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Efficacy and safety of gliclazide MR (30 to 120 mg per day) associated or not to metformine or to an α-glucosidase inhibitor during the fast of the Ramadan in type 2 diabetic patients. A 5 to 8 months...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006754-10,0,0,0 2006-006755-12,1,2012-09-04,2012-09-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Janssen Oncology, Inc.",An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006755-12,0,0,0 2006-006760-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Ludwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie,Comparision of Ranibizumab (Lucentis) Monotherapy versus Combination of Ranibizumab (Lucentis) with Photodynamic Therapy (Verteporfin) in Patients with Subfoveal Choroidal Neovascularisation due to Ag...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006760-28,0,0,0 2006-006766-41,1,2008-09-01,2008-09-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Clavis Pharma ASA,A phase II Clinical Study of CP-4055 as second line therapy in patients with advanced colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006766-41,0,0,0 2006-006768-53,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Pfizer Global Research & Development,"A DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF PF-00915275 AFTER ORAL ADMINISTRATION TO SUBJECTS WITH TYPE 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006768-53,0,0,0 2006-006769-17,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Reckitt Benckiser Healthcare International Ltd,"A randomised, controlled, open-label, single-centre, parallel group, pilot study to investigate the onset of action of a lozenge compared with a caplet in patients with sore throat.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006769-17,0,0,0 2006-006772-38,7,2008-06-26,2008-06-30,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose Ranging Study to Investigate the Safety and Efficacy of JNJ-16269110 in Overweight and Obese Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006772-38,0,0,0 2006-006776-37,1,,,0,0,0,0,0,1,2,0,1,0,0,0,0,0,0,Radboud University Nijmegen Medical Center,Towards the assessment of metabolic biomarkers and creatine uptake and turnover in skeletal muscles of patients with Facioscapulohumeral muscular dystrophy using MR spectroscopy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006776-37,0,0,0 2006-006778-11,1,2012-08-31,2012-08-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medical University of Vienna, Department of Internal Medicine II",ENDOTHELIN RECEPTOR BLOCKADE IN ACUTE ST-ELEVATION MYOCARDIAL INFARCTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006778-11,0,0,0 2006-006779-19,1,2008-03-31,2008-03-31,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc,"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Older Infants and Children Who Are Naive to Previous Vaccination Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006779-19,0,0,0 2006-006793-26,1,2008-07-03,2008-07-03,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,mibe GmbH Arzneimittel,"Randomised, double-blind, double-dummy, cross-over trial comparing salmeterol 50 µg b.i.d. via a novel DPI versus salmeterol 50 µg b.i.d. via Diskus in adult patients with persistent asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006793-26,0,0,0 2006-006796-21,6,2008-06-16,2008-07-15,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 12-week, double-blind, randomised, parallel group, multi-centre, study to evaluate efficacy and safety of budesonide/formoterol (Symbicort® Turbuhaler®) 320/9 µg one inhalation twice daily on top of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006796-21,0,0,0 2006-006803-35,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,NOVARTIS FARMA,"An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon alfa-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006803-35,0,0,0 2006-006804-12,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,ErasmusMedical Center-Sophia,Levetiracetam (Keppra®) in neonates,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006804-12,0,0,0 2006-006808-11,1,2016-07-03,2016-07-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA,Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with untreated follicular non-Hodgkin's lymphoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006808-11,0,0,0 2006-006812-31,1,2013-06-13,2013-06-13,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,university medical centre utrecht,Multicenter randomized clinical trial in Patients with Juvenile Idiopathic Arthritis and Methotrexate related side effects: Psychological Behavioural therapy versus switch to MTX parenteral versus sta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006812-31,0,0,0 2006-006815-62,1,2009-09-08,2009-09-08,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospitals of South Manchester NHS Foundation Trust,Does N-Acetylcysteine (Parvolex) prophylaxis reduce the incidence of renal impairment after on pump Coronary artery bypass surgery? A prospective randomised controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006815-62,0,0,0 2006-006816-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Effet du mazindol sur le Trouble Déficit de l'Attention/Hyperactivité chez l'enfant : étude prospective pilote (phase II) d'efficacité, de tolérance et de pharmacocinétique",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006816-31,0,0,0 2006-006819-75,10,2014-03-05,2014-03-05,7,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006819-75,0,0,0 2006-006819-75,10,2014-03-05,2014-03-05,7,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A:",A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006819-75,0,0,0 2006-006819-75,10,2014-03-05,2014-03-05,7,1,0,0,0,2,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,A randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006819-75,0,0,0 2006-006820-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Réduction de la douleur lors des prélèvements veineux chez le nouveau-né prématuré : apport de la crème Emla et du saccharose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006820-21,0,0,0 2006-006821-15,1,2008-09-15,2008-09-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A RANDOMISED, DOUBLE-BLIND (SPONSOR-OPEN), PLACEBO-CONTROLLED, MULTICENTRE STUDY IN ASYMPTOMATIC HIV-INFECTED PATIENTS TO INVESTIGATE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERATION OF ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006821-15,0,0,0 2006-006823-38,1,2012-05-31,2012-05-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Rheinische Friedrichs-Wilhelms-Universität Bonn,D-Dimer guided oral anticoagulation therapy for secondary prevention after venous thrombosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006823-38,0,0,0 2006-006824-20,1,2009-10-01,2009-10-01,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Universitätsklinikum Essen - Zentrum für Innere Medizin - Klinik für Endokrinologie,"Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Pheochromocytoma – proof of concept study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006824-20,0,0,0 2006-006829-13,1,,,0,0,0,0,1,0,3,0,0,1,1,1,0,1,0,Netherlands Heart Foundation,Antiplatelet therapy in combination with Recombinant t-PA Thrombolysis in Ischemic Stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006829-13,0,0,0 2006-006832-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Limoges,"PIGREC Pharmacocinétique des Immunosuppresseurs chez les patients GREffés Cardiaques Étude multicentrique, ouverte, de mise au point de modèles pharmacocinétiques de population et d’estimateurs Bayés...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006832-23,0,0,0 2006-006838-17,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,NOVARTIS FARMA,Phase I study to examine the effect of deferasirox on renal hemodynamics in β-thalassemia patients with transfusional iron overload,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006838-17,0,0,0 2006-006839-51,1,2010-01-28,2010-01-28,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Dr. Franz Köhler Chemie GmbH,Physostigmine induced reduction of analgetic treatment (PIRAT trial): Randomisiert kontrollierte Doppelblind-Studie zur analgetischen Wirkung einer postoperativen systemischen Applikation von Physosti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006839-51,0,0,0 2006-006842-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para Investigación y Desarrollo en el Área Cardiovascular del Hospital Clínico San Carlos,"Estudio Piloto Comparativo de Eficacia, Tolerancia y Seguridad de Moxifloxacino VO frente a Levofloxacino en Terapia Secuencial en Adultos Inmunocompetentes con Neumonía Adquirida en la Comunidad.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006842-33,0,0,0 2006-006843-29,7,2009-01-12,2009-01-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,NovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc),"A multicentre, randomized, double-blind, placebo controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms, diuresis, renal function, and clinical outcomes in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006843-29,0,0,0 2006-006843-29,7,2009-01-12,2009-01-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,NovaCardia Inc,"A multicentre, randomized, double-blind, placebo controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms, diuresis, renal function, and clinical outcomes in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006843-29,0,0,0 2006-006843-29,7,2009-01-12,2009-01-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,NovaCardia Inc.,"A multicentre, randomized, double-blind, placebo controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms, diuresis, renal function, and clinical outcomes in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006843-29,0,0,0 2006-006845-14,1,2008-11-06,2008-11-06,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,TROPHOS,"Open-label Phase 1b, Dose-ranged, Single and Multiple Dose Study to assess Safety and Pharmacokinetics of TRO19622 in 6-25 year old Spinal Muscular Atrophy (SMA) patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006845-14,0,0,0 2006-006851-11,1,2008-01-22,2008-01-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,UTILITY IN RM OF GD-BOBPTA VERSUS GD-DTPA IN THE DEFINITION OF THE RESIDUAL OF THE ADENOMA OF THE HYPOPHYSIS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006851-11,0,0,0 2006-006852-37,11,2010-12-16,2022-03-26,9,0,0,0,0,1,3,0,0,2,0,0,0,0,1,NOVARTIS FARMA,"A phase III randomized, double-blind study of induction (daunorubicin/cytarabine) and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients < ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006852-37,1,0,0 2006-006852-37,11,2010-12-16,2022-03-26,9,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A phase III randomized, double-blind study of induction (daunorubicin/cytarabine) and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients < ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006852-37,1,0,0 2006-006852-37,11,2010-12-16,2022-03-26,9,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A.,"A phase III randomized, double-blind study of induction (daunorubicin/cytarabine) and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients < ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006852-37,1,0,0 2006-006855-10,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Buckinghamshire Hospitals NHS Trust,A randomised trial of rectal stimulants for neurogenic bowel management after spinal cord injury,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006855-10,0,0,0 2006-006861-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Department of Cardiology,Comparison between beta-adrenergic blockers and angiotensin II receptor antagonists for the treatment of late hypertension in patients with repaired aortic coarctation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006861-18,0,0,0 2006-006862-41,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,1,MOLMED,TK008: Randomized phase III trial of haploidentical HCT followed by add back of HSV-Tk donor lymphocytes versus haploidentical HCT followed by any T cell repletion strategy in patients with high risk ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006862-41,0,0,0 2006-006863-22,1,2009-09-14,2009-09-14,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital of South Manchester NHS Foundation Trust,Role of Poly Unsaturated Fatty Acids (PUFAs) in the management of Paroxysmal Atrial Fibrillation (PAF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006863-22,0,0,0 2006-006865-17,1,2009-06-30,2009-06-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farma, S.A.","Estudio multicéntrico, no aleatorizado, abierto, para valorar la eficacia y la seguridad de la combinación de micofenolato mofetilo (MMF), prednisona y eritropoyetina beta en pacientes con síndromes m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006865-17,0,0,0 2006-006867-22,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,University Hospital Motol,Treatment of proteinuria with angiotensin-converting enzyme inhibitor in children after renal transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006867-22,0,0,0 2006-006871-19,1,2010-02-03,2010-02-03,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Universitätsklinik für Augenheilkunde und Optometrie, MUW",None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006871-19,0,0,0 2006-006872-39,1,2012-01-27,2012-01-27,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Daval International Limited,"A randomised, double-blind, placebo controlled study of AIMSPRO in Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006872-39,0,0,0 2006-006873-25,1,2007-12-28,2007-12-28,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,Norgine Pharma,"A randomised, multicentre, single-blind, phase IV study, of the efficacy, safety and acceptability of MoviPrep® versus Colopeg® in colonoscopy preparation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006873-25,0,0,0 2006-006878-22,2,2009-04-20,2009-04-20,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Orfagen,Efficacy and tolerance of Tazarotene cream in lamellar ichthyosis (LI): a dose-finding study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006878-22,0,0,0 2006-006881-40,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,NERVIANO MEDICAL SCIENCES,A pilot Phase II study of PHA-739358 in patients with Chronic Myeloid Leukemia relapsing on Gleevec or c-ABL therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006881-40,0,0,0 2006-006886-18,2,2011-01-04,2011-01-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Alkermes Inc,Efficacy and Safety of Vivitrol® in Adults Completing Inpatient Treatment for Alcohol Dependence,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006886-18,0,0,0 2006-006887-44,1,2013-09-21,2013-09-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Group Hospitals Trust,Non-invasive bed-side measurement of systemic endothelial function in patients undergoing abdominal aortic aneurysm repair; modulation by ascorbic acid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006887-44,0,0,0 2006-006889-42,1,2011-01-28,2011-01-28,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Faculdade de Ciências Médicas – Universidade Nova de Lisboa,"Exploratory, double blind placebo controlled, randomized, single cross-over study to evaluate the potential anti-oxidant action of Niaspan",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006889-42,0,0,0 2006-006891-39,2,2010-01-27,2010-01-27,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,Innate Pharma,A phase I/II open label study of IPH1101 (with low dose of interleukin-2 [IL-2]) in combination with rituximab re-treatment in patients with Follicular Lymphoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006891-39,0,0,0 2006-006891-39,2,2010-01-27,2010-01-27,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,Innate Pharma S.A.,A phase I/II open label study of IPH1101 (with low dose of interleukin-2 [IL-2]) in combination with rituximab re-treatment in patients with Follicular Lymphoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006891-39,0,0,0 2006-006896-19,12,2008-12-30,2009-01-30,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Bristol Myers Squibb International Corporation,"A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total K...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006896-19,0,0,0 2006-006896-19,12,2008-12-30,2009-01-30,11,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total K...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006896-19,0,0,0 2006-006897-60,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Leids Universitair Medisch Centrum,"Does Misoprostol facilitate the insertion of an Intra Uterine device (IUD), both copper-containing as well as levonorgestrel-releasing, with nulli- and multipara?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006897-60,0,0,0 2006-006898-24,1,,,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,HOSPICES CIVILS DE LYON,Etude TETRAM 2 : Traitement par l’Epo des TRAumatisés Médullaires : recherche de la dose maximum tolérée,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006898-24,0,0,0 2006-006902-27,1,2007-12-12,2007-12-12,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Alnylam Pharmaceuticals, Inc.","A randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety and efficacy of intranasal ALN-RSV01 administered to adult volunteers experimentally inoculated with Resp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006902-27,0,0,0 2006-006907-35,7,2009-04-24,2009-05-05,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Schwarz Biosciences GmbH,"A multicenter, multinational, phase 3b, open label extension trial, to evaluate the long term effect of the 24 hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006907-35,0,0,0 2006-006907-35,7,2009-04-24,2009-05-05,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SCHWARZ PHARMA,"A multicenter, multinational, phase 3b, open label extension trial, to evaluate the long term effect of the 24 hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006907-35,0,0,0 2006-006907-35,7,2009-04-24,2009-05-05,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schwarz Biosciences GmbH, UCB Group","A multicenter, multinational, phase 3b, open label extension trial, to evaluate the long term effect of the 24 hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006907-35,0,0,0 2006-006911-60,3,2008-04-16,2008-11-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"Randomised, double-blind, placebo-controlled, parallel-group trial to investigate the analgesic effect of OROS hydromorphone hydrochloride in comparison with placebo in subjects with moderate to sever...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006911-60,0,0,0 2006-006912-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitätsklinikum Schleswig-Holstein,Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006912-31,0,0,0 2006-006913-34,5,2011-10-20,2011-10-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006913-34,0,0,0 2006-006915-61,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI,Prospective Randomized Trial of Immediate Treatment with Campath versus Deferred Therapy in Patients with Previously Untreated Binet Stage A B-Cell Chronic Lymphocytic Leukemia at High Risk for Di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006915-61,0,0,0 2006-006925-26,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Rijnstate hospital,Optimalising the Androgen-Oestrogen Balance in Testosterone Substituted Hypogonadal Men by Aromatase Inhibition.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006925-26,0,0,0 2006-006928-18,1,2011-05-12,2011-05-12,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Barts and The London NHS Trust,Randomised trial of Prontosan wound gel for prevention of exit site infection in peritoneal dialysis patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006928-18,0,0,0 2006-006930-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL GENERAL DE VIC,ANESTESIA SUBARACNOIDEA SELECTIVA. COMPARACIÓN DE BUPIVACAINA HIPERBÁRICA CON PRILOCAINA HIPERBÁRICA PARA ARTROSCOPIA DE RODILLA O HERNIOPLASTIA INGUINAL EN CIRUGIA MAYOR AMBULATORIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006930-17,0,0,0 2006-006935-38,9,2008-07-17,2008-07-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. NYO-685-21-14,685 3rd Avenue, NEW YORK, NY 10017. US","12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENTS W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006935-38,0,0,0 2006-006935-38,9,2008-07-17,2008-07-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer, S.A.","12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENTS W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006935-38,0,0,0 2006-006935-38,9,2008-07-17,2008-07-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER,"12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENTS W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006935-38,0,0,0 2006-006935-38,9,2008-07-17,2008-07-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US","12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENTS W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006935-38,0,0,0 2006-006936-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Krankenhaus Nordwest GmbH,"A multicenter, randomised phase II trial on the therapy of advanced gastric cancer or adenocarcinoma of the esophagogastric junction in patients older than 65 years with special regard on quality of l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006936-24,0,0,0 2006-006940-69,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Lund University Hospital,Add-on treatment of mental illness with anti-viral medicine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006940-69,0,0,0 2006-006941-15,7,2013-10-21,2013-10-21,6,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CECOG (Central European Cooperative Oncology Group),"A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX4 + weekly Cetuximab versus FOLFOX4 + bi-weekly Cetuximab as first-line therapy in patients with K-ras wild type met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006941-15,0,0,0 2006-006942-33,1,2007-12-04,2007-12-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Zentiva a.s.,"Randomised, Double Dummy, Placebo Controlled, Multicentre, Parallel-Group, Single Dose Study to Compare the Analgesic Efficacy and Safety of IBALGIN Extra Fast /ibuprofen lysin/ to conventional Ibupro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006942-33,0,0,0 2006-006943-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,"ESSAI RANDOMISE, EN DOUBLE AVEUGLE CONTRE PLACEBO EVALUANT L’EFFICACITE DU RISEDRONATE ORAL 35 MG PAR SEMAINE DANS LA PREVENTION DE LA PERTE OSSEUSE CHEZ LA FEMME ATTEINTE D’UN CANCER DU SEIN TRAITE P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006943-29,0,0,0 2006-006944-78,2,2011-01-11,2011-01-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Centre Hospitalier Régional et Universitaire de Lille,Evaluation du bénéfice de survie lors de l'adjonction de pentoxifylline à la corticothérapie dans l'hépatite alcoolique sévère,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006944-78,0,0,0 2006-006944-78,2,2011-01-11,2011-01-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Hôpital ERASME,Evaluation du bénéfice de survie lors de l'adjonction de pentoxifylline à la corticothérapie dans l'hépatite alcoolique sévère,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006944-78,0,0,0 2006-006946-32,1,2009-03-25,2009-03-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"AstraZeneca AB, European Regulatory Affairs","A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of the Antiplatelet Effects of AZD6140 Compared with Clopidogrel and Placebo With Aspirin as Backgrou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006946-32,0,0,0 2006-006947-30,4,2007-07-25,2007-07-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"EFFICACY STUDY OF THE ANTIHISTAMINE V0114 CP 2.5MG TABLET IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006947-30,0,0,0 2006-006948-65,1,2009-07-04,2009-07-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals of Leicester NHS Trust,The effect of acidosis correction and exercise on tissue wasting and immune function in renal patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006948-65,0,0,0 2006-006949-13,1,2010-09-30,2010-09-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University College London,A multi-centre exploratory study to evaluate the efficacy of the dopamine receptor agonist rotigotine in the treatment of hemispatial neglect and motor deficits following stroke.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006949-13,0,0,0 2006-006950-81,4,2013-05-07,2013-05-07,3,0,0,0,0,0,3,0,0,1,1,1,1,0,1,"BioNumerik Pharmaceuticals, Inc.",A PHASE 3 STUDY OF SAFETY AND EFFICACY OF KARENITECIN VERSUS TOPOTECAN ADMINISTERED FOR 5 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006950-81,0,0,0 2006-006955-10,2,2010-01-07,2010-01-07,1,0,0,0,0,0,2,0,1,1,1,1,1,0,0,Univ.-Prof. Dr. Helmut Mittermayer,Klinická studie k ověření imunogenity různých variant rychlé imunizace FSME s inaktivovanou vakcínou proti letní meningoencefalitidě,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006955-10,0,0,0 2006-006956-36,1,2012-03-05,2012-03-05,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department og Gynaecology and Obstetric, Randers Hospital",Hvor længe skal oxytocin anvendes ved stimulation af fødsler,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006956-36,0,0,0 2006-006957-29,1,2009-09-03,2009-09-03,1,0,0,0,0,0,3,0,1,1,0,0,1,0,0,"Department of Psychiatry and Psychotherapy, Friedrich-Schiller-University Jena",Influence of Duloxetin on C-fiber function and perception of deep somatic pain in major depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006957-29,0,0,0 2006-006958-10,1,2011-09-28,2011-09-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pharmanord, UK, LTD","Anticipate Trial - Randomized, Double blind, placebo-controlled, multicentre Trial of Anti-oxidant therapy in painful chronic pancreatitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006958-10,0,0,0 2006-006962-41,1,2020-04-30,2020-04-30,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,Charité Universitätsmedizin Berlin,Dendritic cells as autologous vaccine in patients with chronic myeloid leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006962-41,0,0,0 2006-006964-48,1,2010-11-16,2010-11-16,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Amgen Inc,"An Open-Label, Multi-Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects with Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006964-48,0,0,0 2006-006965-18,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,0,University Hospital Ghent,Acute hemodynamische impact van een intraveneuze glucose injectie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006965-18,0,0,0 2006-006967-22,10,2009-04-06,2009-04-07,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium",A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006967-22,0,0,0 2006-006967-22,10,2009-04-06,2009-04-07,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Janssen-Cilag International NV,Turnhoutseweg 30, 2340 Beerse, Belgium",A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006967-22,0,0,0 2006-006967-22,10,2009-04-06,2009-04-07,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006967-22,0,0,0 2006-006970-45,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,EVALUATION DE L’ASSOCIATION RADIOTHERAPIE DE CONFORMATION ET CHEMOEMBOLISATION INTRA-ARTERIELLE HEPATIQUE EN NEOADJUVANT DE LA RESECTION CHIRURGICALE DES CARCINOMES HEPATOCELLULAIRES DE GRANDE TAILLE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006970-45,0,0,0 2006-006971-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aker universitetssykehus,"Effect of Aggrenox® / Asasantin® Retard compared with Clopidogrel on Endothelial function as measured by Microalbuminuria, Inflammatory markers CRP, MCP-1, and MMP-9 in Patients with Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006971-19,0,0,0 2006-006978-20,2,2010-09-30,2010-09-30,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Hana Biosciences, Inc.",A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo® (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Le...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006978-20,0,0,0 2006-006978-20,2,2010-09-30,2010-09-30,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Talon Therapeutics , Inc.",A Phase 2 Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo® (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Le...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006978-20,0,0,0 2006-006980-22,4,2010-11-02,2010-11-02,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Transave, Inc.",MULTIDOSE SAFETY AND TOLERABILITY STUDY OF DOSE ESCALATION OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006980-22,0,0,0 2006-006981-40,2,2010-05-26,2010-05-26,2,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust jointly with University of Cambridge,Does the underlying haemodynamic abnormality determine response to antihypertensive therapy in patients with hypertension?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006981-40,0,0,0 2006-006982-17,1,2009-01-13,2009-01-13,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Division of Special and Environmental Dermatology,UVA 1 therapy versus 5-MOP UVA photochemotherapy for patients with severe generalized atopic dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006982-17,0,0,0 2006-006984-21,1,2011-11-30,2011-11-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Friedrich-Schiller-University of Jena,"prospective, randomized, open, multicentre trial to assess the influence of empiric antibiotic monotherapy with meropenem (Meronem) versus combination with moxifloxacin (Avalox) on the organ function ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006984-21,0,0,0 2006-006985-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,JOAQUIN PORTILLA,"Estudio piloto en fase III, mutlicéntrico, aleatorizado, controlado y abierto, sobre la eficacia de Interferón Pegilado alfa-2a a dosis de 90 mcg semanal en retrasar la aparición del primer evento de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006985-41,0,0,0 2006-006999-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND RITUXIMAB (R-HDS) SUPPORTED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH SYSTEMIC B-CELL LYMPHOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-006999-38,0,0,0 2006-007011-24,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Assessment of endothelial function in patients with psoriasis before and after Etanercept treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007011-24,0,0,0 2006-007013-20,1,2012-11-19,2012-11-19,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Onkologisk afdeling R and the Unit for Experimental Chemotherapy,"A Phase I/II non-comparative Study of Paclitaxel plus Carboplatin in combination with Vorinostat in patients with advanced, recurrent epithelial ovarian cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007013-20,0,0,0 2006-007018-39,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Cambridge Hospitals NHS Foundation Trust and Cambridge University,Persephone : Duration of Trastuzumab with Chemotherapy in patients with early breast cancer : Six months versus twelve,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007018-39,0,0,0 2006-007019-25,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Barts and the London NHS Trust,Pilot open trial of efficacy of Risperidone in Delusional Parasitosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007019-25,0,0,0 2006-007021-32,1,2015-06-04,2015-06-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"Multi-center, open-label, prospective, randomized, parallel group, long-term study investigating a standard regimen in de novo kidney transplant patients versus a CNI-free regimen and a CNI-low dose r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007021-32,0,0,0 2006-007022-64,2,2010-10-01,2010-10-01,1,0,0,0,0,2,2,0,0,2,0,0,0,0,0,Rigshospitalet,Phase II study of bortezomib-dexametason and high-dose melphalan in patients relapsing after high-dose melphalan with autologous stem cell support,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007022-64,1,0,0 2006-007024-34,1,2010-12-31,2010-12-31,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,General Teaching Hospital,Treatment of alveolar osteitis using ozonated water,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007024-34,0,0,0 2006-007027-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,INSERM,Influence du traitement par Pioglitazone sur l'Ostéoprotégérine dans le diabète de tye II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007027-14,0,0,0 2006-007029-29,6,2007-05-13,2008-05-13,6,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Pierre Fabre Dermatologie represented by Institut de Recherche Pierre Fabre,NON-INFERIORITY STUDY OF A METRONIDAZOLE 0.75% CREAM VERSUS REFERENCE THERAPY IN THE LOCAL TREATMENT OF PAPULOPUSTULAR ROSACEA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007029-29,0,0,0 2006-007030-35,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,NOVARTIS FARMA,"A phase Ib, multi-center, open-label, dose-escalation study of oral LBH589 when administered in combination with oral lenalidomide & dexamethasone in adult patients with multiple myeloma Studio ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007030-35,0,0,0 2006-007031-27,1,2011-07-09,2011-07-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Karolinska Institute,Effects of insulin treatment on postprandial platelet activation in patients with NIDDM: a placebo-controlled dose-response study with insulin aspart (Novorapid®),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007031-27,0,0,0 2006-007034-36,1,2007-10-26,2007-10-26,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY10017","A 16 WEEK OPEN-LABEL OUTPATIENT, RANDOMIZED, PARALLEL STUDY ASSESSING THE IMPACT OF TWO DIFFERENT INITIAL DOSE PRESCRIPTIONS FOR DRY POWDER INHALED INSULIN (EXUBERA®) ON GLYCEMIC CONTROL IN PATIENTS W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007034-36,0,0,0 2006-007035-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude du rapport urinaire des isomères I et III de la coproporphyrine : Relation avec les retards d'élimination du méthotrexate administré à haute dose chez des patients atteints d'une hémopathie lymp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007035-27,0,0,0 2006-007036-95,1,2009-12-17,2009-12-17,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Universitätsklinikum Essen - Zentrum für Innere Medizin - Klinik für Endokrinologie,"Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007036-95,0,0,0 2006-007041-39,1,2010-05-15,2010-05-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRACCO IMAGING,A Phase II Multicenter Randomized Double-Blind Dose-Finding Study of Iopamidol Injection 370 in Multidetector Computed Tomographic Angiography (MDCTA) in Patients with Suspected Coronary Artery Stenos...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007041-39,0,0,0 2006-007042-18,1,2009-07-04,2009-07-04,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Kings College London,Improved Diagnosis of Congenital Heart Disease by MRI using Vasovist - CHD Vasovist,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007042-18,0,0,0 2006-007042-18,1,2009-07-04,2009-07-04,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Guy's & St Thomas'NHS Foundation Trust,Improved Diagnosis of Congenital Heart Disease by MRI using Vasovist - CHD Vasovist,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007042-18,0,0,0 2006-007053-51,1,2014-11-17,2014-11-17,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Gloucestershire Hospitals NHS Foundation Trust,Diamorphine or alfentanil for subcutaneous use in hospice in-patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007053-51,0,0,0 2006-007055-41,1,2007-06-08,2007-06-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Beaufour Ipsen Pharma - 24, rue Erlanger 75016 Paris FRANCE","A phase II, open-label, multicentre study to evaluate the pharmacodynamic profile, the efficacy and the safety of a 6-month sustained-release formulation of triptorelin in patients with prostate cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007055-41,0,0,0 2006-007056-18,1,2010-05-17,2010-05-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Newcastle upon tyne Hospitals NHS Trust,The Discoid Lupus Research Project,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007056-18,0,0,0 2006-007057-42,4,2010-02-12,2010-02-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007057-42,0,0,0 2006-007060-28,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Cruz Bartolome Moreno,"""Influencia de la fase del ciclo hormonal en la efectividad de nicotina y bupropion para ayudar a dejar de fumar"" ""Influence of the fase of the hormone´s cicle in the efectivity of nicotine and Buprop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007060-28,0,0,0 2006-007062-11,1,2008-08-21,2008-08-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,3,Grupo de Tratamiento de los Tumores Digestivos (TTD),"ESTUDIO FASE II, MULTICÉNTRICO, ABIERTO, NO RANDOMIZADO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE CETUXIMAB (ERBITUX®) EN COMBINACIÓN CON OXALIPLATINO Y CAPECITABINA (XELOX) DURANTE 12 SEMANAS SEGUIDO D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007062-11,0,0,0 2006-007066-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GELA,"A phase II study evaluating the efficacy and safety of the farnesyltransferase inhibitor ZARNESTRA® (R115777, tipifarnib) in patients with relapsed , refractory or progressive mantle cell lymphoma not...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007066-11,0,0,0 2006-007067-85,1,2010-10-08,2010-10-08,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,CHU de Brest,Impact d'une campagne de vaccination des nourissons sur les hospitalisations pour le GEA à rotavirus : Etude prospective sur la communauté urbaine de Brest- protocole IVANHOE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007067-85,0,0,0 2006-007068-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU Toulouse,Réduction de la reconsolidation du souvenir traumatique par le propranolol : un essai pilote.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007068-27,0,0,0 2006-007069-35,1,2013-01-07,2013-01-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"University Medical Centre St Radboud, Department of Dermatology",Evaluation of Neodymium YAG laser-treatment compared to topical treatment with betamethasondipropionaat/calcipotriol ointment (Dovobet) for patients with chronic plaque type psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007069-35,0,0,0 2006-007070-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Stockholms Läns Landsting,Farmakokinetik och effekt av glipizid på insulin och glukos hos patienter med nyupptäckt typ 2-diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007070-30,0,0,0 2006-007073-75,1,2009-01-23,2009-01-23,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,mibe GmbH Arzneimittel,"Randomised, double-blind, double-dummy, parallel trial comparing a novel DPI with 250 µg fluticasone versus Flutide® 250 Diskus® in patients with persistent asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007073-75,0,0,0 2006-007074-29,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Vanda Pharmaceuticals Inc.,"A randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of three oral doses of VSF-173 (50 mg , 100 mg, and 200 mg total daily dose; given twice, 4 hours ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007074-29,0,0,0 2006-007076-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Dana Farber Cancer Institute,A Randomized Phase III Trial Comparing Sequential Therapy With TPF/Chemoradiation (ST) To Cisplatin-Based Chemoradiotherapy with Accelerated Concomitant Boost Radiotherapy (CRT) For Locally Advanced S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007076-15,0,0,0 2006-007082-36,1,2011-11-30,2011-11-30,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Hellenic Oncology Cooperative Group,A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethasone in patients with primary (AL) systemic amyloidosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007082-36,0,0,0 2006-007083-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON foundation,Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007083-28,0,0,0 2006-007084-89,1,2009-01-28,2009-01-28,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,DuoCort Pharma AB,"A randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modified-release hydrocorti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007084-89,0,0,0 2006-007087-28,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,"A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF LENALIDOMIDE, MELPHALAN, PREDNISONE AND THALIDOMIDE R-MPT IN ADVANCED, RELAPSED, REFRACTORY MULTIPLE MYELOMA PATIENTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007087-28,0,0,0 2006-007089-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOIM GRUPPO ONCOLOGICO MERIDIONALE,Liposomial pegylate doxorubicine and trasuzumab in the first line treatment of the metastatised Her2 positive breast cancer for senior women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007089-12,0,0,0 2006-007090-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Central Institute of Mental Health,The role of the glutamatergic system in the extinction of conditioned reinforcement processes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007090-72,0,0,0 2006-007091-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ErasmusMC,"Glivec (imatinib mesylate) in systemic sclerosis, a pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007091-15,0,0,0 2006-007096-32,1,2012-08-01,2012-08-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ. Kinderklinik",Prevention od new sensitization by sublingual immunotherapy in children 2-4 years of age with allergic mono-sensitization,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007096-32,0,0,0 2006-007100-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Turku University Hospital,Viral Inception of Asthma: Prospective study from infancy to early school-age.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-007100-42,0,0,0 2007-000004-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,MOLMED,NGR012: A phase II study of NGR-hTNF administered in combination with doxorubicin every 3 weeks in patients affected by advanced or metastatic ovarian cancer NGR012: studio di fase II relativo alla...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000004-33,0,0,0 2007-000006-67,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,LALLEMAND PHARMA INTERNATIONAL,Sub-lingual administration of a Polyvalent Mechanical Bacterial Lysate (PMBL) in patients with Moderate or Severe and very Severe Chronic Obstructive Pulmonary Disease (COPD) according to GOLD classif...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000006-67,0,0,0 2007-000008-34,1,2009-03-21,2009-03-21,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,North West London Hospitals NHS Trust,Bacteria and host immune response as factors modulating visceral afferent processing in Irritable Bowel Syndrome: manipulation of visceral hypersensitivity with probiotic bacteria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000008-34,0,0,0 2007-000010-36,2,2008-03-13,2008-03-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios Almirall, S.A.","A multiple dose, double-blind, double-dummy, 3 period cross-over, placebo controlled clinical trial to assess the efficacy and safety of once daily inhaled aclidinium bromide 200 µg given either in th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000010-36,0,0,0 2007-000012-90,3,2015-08-28,2015-08-28,2,1,0,0,2,2,4,0,0,1,1,0,1,0,0,University of Dundee,The Standard care versus Celecoxib Outcome Trial (SCOT): A Large Streamlined Safety Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000012-90,0,0,0 2007-000013-10,1,2009-06-16,2009-06-16,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Pantarhei Bioscience B.V.,"A double-blind, placebo controlled, randomised, comparative 2-way crossover study to determine the effect of concomitant treatment with dehydroepiandrosterone (50 mg) on sexual arousability and the va...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000013-10,0,0,0 2007-000017-11,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Oxagen Ltd.,"A study of the effects of OC000459 on responses to allergen challenge in the Vienna Chamber in subjects known to suffer from grass pollen induced allergic rhinitis: A randomised, double blind placebo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000017-11,0,0,0 2007-000019-27,12,2008-07-25,2008-08-15,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck & Co. Inc.,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000019-27,0,0,0 2007-000019-27,12,2008-07-25,2008-08-15,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"MERCK&Co,Inc","A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000019-27,0,0,0 2007-000019-27,12,2008-07-25,2008-08-15,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme GmbH,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000019-27,0,0,0 2007-000019-27,12,2008-07-25,2008-08-15,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co Inc.,","A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000019-27,0,0,0 2007-000019-27,12,2008-07-25,2008-08-15,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme de España, S.A.","A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000019-27,0,0,0 2007-000019-27,12,2008-07-25,2008-08-15,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck & co. Inc.,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000019-27,0,0,0 2007-000019-27,12,2008-07-25,2008-08-15,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000019-27,0,0,0 2007-000019-27,12,2008-07-25,2008-08-15,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MSD Finland Oy,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000019-27,0,0,0 2007-000019-27,12,2008-07-25,2008-08-15,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Ireland (Human Health) Limited,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000019-27,0,0,0 2007-000019-27,12,2008-07-25,2008-08-15,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc","A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000019-27,0,0,0 2007-000026-44,1,2008-04-20,2008-04-20,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Aarhus Universityhospital,Hydroxyethylstarch induced coagulopathy and haemostatic potential of fibrinogen - in vivo placebo controlled clinical trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000026-44,0,0,0 2007-000029-23,6,2009-09-08,2010-08-10,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVAGALI PHARMA S.A.,"A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000029-23,0,0,0 2007-000029-23,6,2009-09-08,2010-08-10,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novagali Pharma S.A.,"A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000029-23,0,0,0 2007-000030-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Ministery of Defense, Military Mental Health - Research Centre","Prazosin as add-on therapy in the pharmacological treatment of sleep disturbances in post traumatic stress disorder, a placebo-controlled study using polysomnography",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000030-39,0,0,0 2007-000031-26,6,2008-09-02,2008-09-12,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor JNJ-16269110",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000031-26,0,0,0 2007-000031-26,6,2008-09-02,2008-09-12,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study in Type 2 Diabetes Mellitus Subjects to Evaluate the Efficacy, Safety and Tolerability of MTP Inhibitor JNJ-16269110",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000031-26,0,0,0 2007-000032-68,12,2009-03-16,2009-03-20,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in premenopausal European Women With Hypoactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000032-68,0,0,0 2007-000032-68,12,2009-03-16,2009-03-20,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in premenopausal European Women With Hypoactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000032-68,0,0,0 2007-000032-68,12,2009-03-16,2009-03-20,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in premenopausal European Women With Hypoactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000032-68,0,0,0 2007-000032-68,12,2009-03-16,2009-03-20,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in premenopausal European Women With Hypoactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000032-68,0,0,0 2007-000032-68,12,2009-03-16,2009-03-20,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in premenopausal European Women With Hypoactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000032-68,0,0,0 2007-000032-68,12,2009-03-16,2009-03-20,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in premenopausal European Women With Hypoactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000032-68,0,0,0 2007-000032-68,12,2009-03-16,2009-03-20,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Austria GesmbH,"A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in premenopausal European Women With Hypoactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000032-68,0,0,0 2007-000032-68,12,2009-03-16,2009-03-20,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in premenopausal European Women With Hypoactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000032-68,0,0,0 2007-000032-68,12,2009-03-16,2009-03-20,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH,"A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in premenopausal European Women With Hypoactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000032-68,0,0,0 2007-000032-68,12,2009-03-16,2009-03-20,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in premenopausal European Women With Hypoactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000032-68,0,0,0 2007-000032-68,12,2009-03-16,2009-03-20,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.v,"A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in premenopausal European Women With Hypoactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000032-68,0,0,0 2007-000033-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMC Utrecht,An open study to investigate the effect of 4 instead of 2 daily dosing mycophenolate mofetil (MMF) in renal transplant patients on diarrhea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000033-19,0,0,0 2007-000035-25,3,2010-01-13,2010-01-13,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,PHARMA MAR,A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (YONDELIS®) in Patients with Localized Myxoid / Round Cell Liposarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000035-25,0,0,0 2007-000035-25,3,2010-01-13,2010-01-13,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Pharma Mar, S.A.",A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (YONDELIS®) in Patients with Localized Myxoid / Round Cell Liposarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000035-25,0,0,0 2007-000037-19,5,2010-06-08,2010-08-06,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co Inc.,","A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK-0524B (dosed as coadministered MK-0524A and Simvastatin Tablets) Versus Atorvastatin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000037-19,0,0,0 2007-000037-19,5,2010-06-08,2010-08-06,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK-0524B (dosed as coadministered MK-0524A and Simvastatin Tablets) Versus Atorvastatin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000037-19,0,0,0 2007-000037-19,5,2010-06-08,2010-08-06,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MSD Finland Oy,"A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK-0524B (dosed as coadministered MK-0524A and Simvastatin Tablets) Versus Atorvastatin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000037-19,0,0,0 2007-000037-19,5,2010-06-08,2010-08-06,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme de España S.A,"A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK-0524B (dosed as coadministered MK-0524A and Simvastatin Tablets) Versus Atorvastatin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000037-19,0,0,0 2007-000037-19,5,2010-06-08,2010-08-06,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK-0524B (dosed as coadministered MK-0524A and Simvastatin Tablets) Versus Atorvastatin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000037-19,0,0,0 2007-000042-12,3,2007-11-09,2007-11-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Ltd. Ramsgate Road, Sandwich, Kent, UK","A PHASE IIA RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED 5-WAY CROSS-OVER TRIAL TO EXAMINE THE BRONCHODILATOR EFFECTS OF PF-610,355 AND TO TEST FOR SUPERIORITY VERSUS PLACEBO ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000042-12,0,0,0 2007-000043-10,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Fakultní nemocnice Královské Vinohrady,"Combination of alpha2-adrenoreceptor agonists, opioids and ketamine for improving of perioperative course",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000043-10,0,0,0 2007-000047-99,1,2013-08-28,2013-08-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Tari Haahtela,Montelukast as a controller of atopic syndrome - MONTAS-study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000047-99,0,0,0 2007-000048-28,1,2009-04-30,2009-04-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospitals Bristol NHS Foundation Trust,"An open lable, randomised, controlled two centre study to evaluate the mucosal immune response to a quadrivalent meningococcal conjugate vaccine in healthy adults.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000048-28,0,0,0 2007-000049-36,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,ITALFARMACO,Phase II study of the histone-deacetylase inhibitor ITF2357 in very high-risk relapsed/refractory Hodgkin's lymphoma patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000049-36,0,0,0 2007-000051-34,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,ITALFARMACO,"Randomized, open-label, controlled and multicenter trial on a new pattern of Paroxetine up-titration for Panic Disorder. Comparison between two different dose regimens.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000051-34,0,0,0 2007-000053-62,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Ashford & St. Peter's Hospitals NHS Trust,The effects of helium-oxygen gas mixture (Heliox) on airway pressures in mechanically ventilated adult patients with acute lung injury,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000053-62,0,0,0 2007-000054-31,9,2008-07-30,2008-10-30,6,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Shire,"An Open-Label, Phase IV, Multi-Centre Study to Investigate the Long-Term Safety and Efficacy of Subcutaneous Dynepo in Adult Patients with Anaemia Associated with Chronic Kidney Disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000054-31,0,0,0 2007-000054-31,9,2008-07-30,2008-10-30,6,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Shire Pharmaceutical Contracts Ltd,"An Open-Label, Phase IV, Multi-Centre Study to Investigate the Long-Term Safety and Efficacy of Subcutaneous Dynepo in Adult Patients with Anaemia Associated with Chronic Kidney Disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000054-31,0,0,0 2007-000056-14,1,2013-01-31,2013-01-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Cardiff University,Determination of method-specific normal cortisol and adrenal hormone responses to the short Synacthen test,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000056-14,0,0,0 2007-000059-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dra. Carmen Ispa Callén,"""Eficacia y seguridad en el tratamiento de conjuntivitis por adenovirus tratados con olopatadina (Opatanol®) y lágrimas artificiales (Acuolens®)) vs pranoprofeno (Oftalar®) y lágrimas artificiales (Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000059-33,0,0,0 2007-000060-25,1,2008-07-17,2008-07-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Laboratoires Mayoly Spindler SA,"Efficacy and Safety of Meteospasmyl in Irritable Bowel Syndrome. a 4-week, multicentre, double-blind, randomised, placebo-controlled phase IV trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000060-25,0,0,0 2007-000062-20,11,2013-01-04,2013-07-01,10,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000062-20,0,0,0 2007-000062-20,11,2013-01-04,2013-07-01,10,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Global Medical Affairs,A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000062-20,0,0,0 2007-000062-20,11,2013-01-04,2013-07-01,10,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. (A Pfizer Company),A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000062-20,0,0,0 2007-000062-20,11,2013-01-04,2013-07-01,10,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc Global Medical Affairs,A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000062-20,0,0,0 2007-000065-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA USL 6 LIVORNO ZONA LIVORNESE,"METRONOMIC CHEMOTHERAPY WITH URACIL/TEGAFUR (UFT), CYCLOPHOSPHAMIDE (CTX) AND CELECOXIB IN PRETREATED PATIENTS WITH ADVANCED GASTROINTESTINAL MALIGNANCIES: A PILOT CLINICAL STUDY WITH PHARMACOKINETIC ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000065-38,0,0,0 2007-000067-15,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Grupo Español de Cáncer de Pulmón,Estudio aleatorizado de quimioterapia adyuvante individualizada según los niveles de ARNm de BRCA1 en pacientes con cáncer de pulmón no microcítico (estadios II-IIIA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000067-15,0,0,0 2007-000072-16,13,2012-06-26,2012-07-27,12,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"Ensayo clínico, multinacional, multicéntrico, aleatorizado ,doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de BAY 63-2521 (1 mg, 1.5 mg, 2mg, o 2.5 mg,tid), administrado ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000072-16,0,0,0 2007-000072-16,13,2012-06-26,2012-07-27,12,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Bayer HealthCare AG, D-51368 Leverkusen","Ensayo clínico, multinacional, multicéntrico, aleatorizado ,doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de BAY 63-2521 (1 mg, 1.5 mg, 2mg, o 2.5 mg,tid), administrado ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000072-16,0,0,0 2007-000073-39,6,2008-11-25,2008-11-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000073-39,0,0,0 2007-000073-39,6,2008-11-25,2008-11-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,"A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000073-39,0,0,0 2007-000073-39,6,2008-11-25,2008-11-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000073-39,0,0,0 2007-000073-39,6,2008-11-25,2008-11-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000073-39,0,0,0 2007-000074-23,8,2008-11-17,2008-12-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,"A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000074-23,0,0,0 2007-000074-23,8,2008-11-17,2008-12-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000074-23,0,0,0 2007-000074-23,8,2008-11-17,2008-12-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000074-23,0,0,0 2007-000074-23,8,2008-11-17,2008-12-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000074-23,0,0,0 2007-000074-23,8,2008-11-17,2008-12-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000074-23,0,0,0 2007-000074-23,8,2008-11-17,2008-12-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000074-23,0,0,0 2007-000074-23,8,2008-11-17,2008-12-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A double-blind, double-dummy, placebo-controlled, randomized, three parallel groups study comparing the Efficacy, Safety and Tolerability of Pramipexole ER versus placebo and versus Pramipexole IR adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000074-23,0,0,0 2007-000078-21,6,2008-09-01,2008-12-18,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,NicOx S.A,"A 13-Week, Phase 3, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo bid and Naproxen 500 mg bid, Controlled Study on the Efficacy on Signs and Symptoms, and Safety of Naproxcinod (HCT 3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000078-21,0,0,0 2007-000078-21,6,2008-09-01,2008-12-18,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,NICOX S.A.,"A 13-Week, Phase 3, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo bid and Naproxen 500 mg bid, Controlled Study on the Efficacy on Signs and Symptoms, and Safety of Naproxcinod (HCT 3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000078-21,0,0,0 2007-000082-38,1,2011-12-30,2011-12-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Aarhus University Hospital, Denmark",The OPERA Study. Optimized treatment algorithm in early rheumatoid arthritis: Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid ar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000082-38,0,0,0 2007-000083-24,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Regen Therapeutics PLC,A survey of efficacy of zolpidem in patients with brain injury including SPECT brain scans in selected patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000083-24,0,0,0 2007-000084-24,4,2010-10-05,2012-05-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer S.A,"A MULTIPLE DOSE, RANDOMIZED, DOUBLE-BLIND MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN COMPARED TO PLACEBO IN THE TREATMENT OF PATIENTS WITH POST-SURGICAL PAIN FROM HYSTERECTOMY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000084-24,0,0,0 2007-000084-24,4,2010-10-05,2012-05-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, United States","A MULTIPLE DOSE, RANDOMIZED, DOUBLE-BLIND MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN COMPARED TO PLACEBO IN THE TREATMENT OF PATIENTS WITH POST-SURGICAL PAIN FROM HYSTERECTOMY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000084-24,0,0,0 2007-000084-24,4,2010-10-05,2012-05-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A MULTIPLE DOSE, RANDOMIZED, DOUBLE-BLIND MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN COMPARED TO PLACEBO IN THE TREATMENT OF PATIENTS WITH POST-SURGICAL PAIN FROM HYSTERECTOMY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000084-24,0,0,0 2007-000087-25,1,2010-10-29,2010-10-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust,An open label pilot study of Zoledronate (Aclasta 5mg iv) in the treatment of Ankylosing Spondylitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000087-25,0,0,0 2007-000088-12,1,2012-12-31,2012-12-31,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,"Department of Psychiatry, LMU Munich","A prospective, single-blinded (rater-blinded), randomized, parallel group study of the efficacy of Quetiapine XR in the treatment of patients with Acute Stress Disorder (DSM-VI 308.3)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000088-12,0,0,0 2007-000093-23,1,2008-12-02,2008-12-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,Clinical trial to investigate clinical efficacy and tolerability of Tretinoin in actinic keratosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000093-23,0,0,0 2007-000097-23,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,GlaxoSmithKline,Rationale for therapy with low dose steroids combined with long-acting beta2-agonists in patients with allergic asthma: redirecting innate immune responses by long-term treatment with high doses of in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000097-23,0,0,0 2007-000099-17,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,University Hospital Gent,Farmacokinetische evaluatie van enteraal toegediende omeprazole-suspensie bij patiënten met cerebral palsy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000099-17,0,0,0 2007-000115-28,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase II, open, non-randomized study designed to evaluate the reactogenicity and immunogenicity of one or two booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in adul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000115-28,0,0,0 2007-000116-81,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Hospital Clinic Barcelona,"Estudio de los efectos agudos de la administración de una dosis única de sildenafilo de 20 o 40 mg sobre el intercambio de gases y la hemodinámica pulmonar, en reposo y durante el esfuerzo, en pacient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000116-81,0,0,0 2007-000120-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Hospitalier Régional et Universitaire,"Etude contrôlée comparative en double aveugle de l'effet d'un traitement par le fénofibrate sur l'expression des génes de l'homéostasie du cholestérol, de l'inflammation et de la prolifération cellula...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000120-40,0,0,0 2007-000123-18,7,2009-03-16,2009-05-06,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A randomised, controlled, parallel, open-labelled, multinational, trial comparing the efficacy and safety of step-wise addition of insulin aspart (NovoRapid®) according to the largest meals (Basic Bas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000123-18,0,0,0 2007-000124-41,1,2012-01-02,2012-01-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GBG Forschungs GmbH,"Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) + sorafenib followed by paclitaxel (P) + sorafenib in women with previously untreated primary breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000124-41,0,0,0 2007-000126-46,1,2010-06-11,2010-06-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche Pharma AG,"Einarmige, offene Studie zur Untersuchung der Wirksamkeit, Sicherheit und Verträglichkeit von monatlich subkutan verabreichtem C.E.R.A. an Patienten mit renaler Anämie, die noch nicht dialysepflichtig...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000126-46,0,0,0 2007-000128-42,2,2019-06-30,2019-06-30,2,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Martin-Luther-University Halle-Wittenberg,"International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children ≥ 3 years and adolesce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000128-42,0,0,0 2007-000130-39,1,2007-06-19,2007-06-19,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Neolab Ltd,"A PHASE III, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED CROSSOVER STUDY TO COMPARE THE SYSTEMIC EFFECTS OF INHALED FLUTICASONE PROPIONATE HFA MDI 200g PER DAY VERSUS THE REFERENCE FLU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000130-39,0,0,0 2007-000134-39,3,2008-01-03,2008-01-08,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Hexal AG,"Double-blind, double-dummy, multi-center, randomized parallel group trial to demonstrate therapeutic equivalence of Salmeterol/Fluticasone MDI HEXAL (25 µg/125 µg per actuation) versus SeretideTM 125 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000134-39,1,0,0 2007-000135-26,1,2008-06-05,2008-06-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Hexal AG,"Double-blind, double-dummy, multi-center, randomized parallel group trial to demonstrate therapeutic equivalence of Salmeterol/Fluticasone MDI HEXAL (25 µg/50 µg per actuation) versus SeretideTM 50 (2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000135-26,0,0,0 2007-000137-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,Metyrapone as additive treatment in patients with major depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000137-19,0,0,0 2007-000145-35,7,2009-10-27,2009-10-27,7,1,0,0,2,0,3,0,0,1,0,0,1,0,1,"Merck & Co Inc.,","A Phase III, Multicenter, Double-Blind, Randmoized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000145-35,0,0,0 2007-000145-35,7,2009-10-27,2009-10-27,7,1,0,0,2,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme de España, S.A.","A Phase III, Multicenter, Double-Blind, Randmoized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000145-35,0,0,0 2007-000145-35,7,2009-10-27,2009-10-27,7,1,0,0,2,0,3,0,0,1,0,0,1,0,1,MERCK SHARP DOHME ITALIA S.P.A.,"A Phase III, Multicenter, Double-Blind, Randmoized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000145-35,0,0,0 2007-000145-35,7,2009-10-27,2009-10-27,7,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme GmbH,"A Phase III, Multicenter, Double-Blind, Randmoized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000145-35,0,0,0 2007-000145-35,7,2009-10-27,2009-10-27,7,1,0,0,2,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Phase III, Multicenter, Double-Blind, Randmoized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000145-35,0,0,0 2007-000145-35,7,2009-10-27,2009-10-27,7,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Laboratoires Merck Sharp & Dhome-Chibret,"A Phase III, Multicenter, Double-Blind, Randmoized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000145-35,0,0,0 2007-000146-13,1,2008-10-23,2008-10-23,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Kythera Biopharmaceuticals, Inc.","Phase 1-2, Multi-Centre, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) for the Reduction of Subcutaneous Fat in the Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000146-13,0,0,0 2007-000147-98,3,2014-06-10,2014-06-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG 386 or Placebo in Subjects with Metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000147-98,0,0,0 2007-000148-28,1,2011-02-15,2011-02-15,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,"Department of Neurology, Medical University of Vienna",Amyloid Imaging in Alzheimer´s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000148-28,0,0,0 2007-000150-31,1,,,0,1,0,0,0,0,4,0,0,0,0,0,0,0,0,Medizinische Universität Wien,"PHARMACOKINETICS OFDANAPAROID SODIUM (ORGARAN®), FONDAPARINUX SODIUM(ARIXTRA®) AND NADROPARIN CALCIUM (FRAXIPARIN®) IN PATIENTS AFTER CPB: A PILOT STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000150-31,0,0,0 2007-000151-33,1,2013-01-01,2013-01-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,UMCN,Does caffeine reduce rosuvastatin-induced protection against ischemia-reperfusion injury?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000151-33,0,0,0 2007-000152-14,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,CHRU-TOURS,Efficacité de la rapamycine topique dans le traitement des lichens érosifs chroniques de la muqueuse buccale:Etude en double aveugle randomisée rapamycine vs corticoïdes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000152-14,0,0,0 2007-000155-34,10,2012-02-13,2012-02-13,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Ipsen Pharma SAS,"PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000155-34,0,0,0 2007-000155-34,10,2012-02-13,2012-02-13,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Beaufour Ipsen Pharma,"PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000155-34,0,0,0 2007-000155-34,10,2012-02-13,2012-02-13,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,BEAUFOUR IPSEN PHARMA,"PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000155-34,0,0,0 2007-000160-25,1,2010-09-28,2010-09-28,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,University of Kuopio,Tramadolin plasmapitoisuus lääkettä säännöllisesti käyttävillä potilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000160-25,0,0,0 2007-000162-20,1,2008-09-05,2008-09-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Agence nationale de recherches sur le sida et les hépatites virales. ANRS,Essai randomisé de non-infériorité comparant une stratégie de maintien du traitement antirétroviral en cours à une stratégie de substitution de l’enfuvirtide par un inhibiteur de l’intégrase (MK 0518)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000162-20,0,0,0 2007-000163-26,1,2007-11-04,2007-11-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Camurus AB,"A randomised, two-period cross-over, multicentre, double-blind, single-dose, placebo-controlled study to assess the local analgesic effect of CAM2028 in head-and-neck cancer patients suffering from ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000163-26,0,0,0 2007-000164-24,1,,,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase I/II, partially-blind, randomized multicentre study to assess the safety and immunogenicity of an HPV-16/18/33/58 L1 VLP vaccine formulated with different adjuvant systems when administered in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000164-24,0,0,0 2007-000165-38,1,,,0,1,0,0,0,1,2,0,1,1,0,0,0,1,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of FLUAD-H5N1 (Surface Antigen Adjuvanted with MF59C.1) Influenza Vaccine in Non-elderly Adult and E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000165-38,0,0,0 2007-000166-21,1,,,0,1,0,0,1,0,4,0,0,1,1,1,0,1,0,Whipps Cross University Hospital,A comparison of the efficacy of 10% lidocaine solution and EMLA cream as local anaesthetic for the insertion of tympanic membrane ventilation tubes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000166-21,0,0,0 2007-000169-40,1,2011-08-11,2011-08-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Catholic University Leuven,Impact of early parenteral nutrition completing enteral nutrition in adult critically ill patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000169-40,0,0,0 2007-000171-41,3,2008-06-12,2008-06-12,2,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Altus Pharmaceuticals Inc,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insuffici...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000171-41,1,0,0 2007-000171-41,3,2008-06-12,2008-06-12,2,0,0,0,0,1,3,0,0,2,0,0,0,0,1,ALTUS PHARMACEUTICALS INC,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insuffici...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000171-41,1,0,0 2007-000172-16,1,2012-04-12,2012-04-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Limited,An open-label study to characterize the safety and response rate of MabThera (Rituximab) plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000172-16,0,0,0 2007-000175-42,5,2009-11-30,2013-11-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A double-blind, randomised, multicenter, phase III study of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000175-42,0,0,0 2007-000175-42,5,2009-11-30,2013-11-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A double-blind, randomised, multicenter, phase III study of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000175-42,0,0,0 2007-000176-17,1,2009-04-20,2009-04-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Effects of terutroban versus aspirin on composition of atherosclerotic plaque in patients undergoing a carotid endarterectomy.A multicentre, randomised, double blind, two parallel group study comparin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000176-17,0,0,0 2007-000178-21,3,2009-04-30,2009-04-30,2,0,0,0,0,1,3,0,0,1,0,0,1,0,1,ALTUS PHARMACEUTICALS INC,An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000178-21,0,0,0 2007-000178-21,3,2009-04-30,2009-04-30,2,0,0,0,0,1,3,0,0,1,0,0,1,0,1,Altus Pharmaceuticals Inc.,An Open-Label Clinical Study Evaluating the Long-Term Safety of ALTU-135 for the Treatment of Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000178-21,0,0,0 2007-000179-41,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Mundipharma Research Ltd,Intrathecal chemotherapy with liposomal ara-C (Depocyte) in leptomeningeal metastases of solid tumors: a phase III study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000179-41,0,0,0 2007-000180-13,6,2015-12-10,2015-12-10,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A Randomized, Open-label, 104-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Conce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000180-13,0,0,0 2007-000180-13,6,2015-12-10,2015-12-10,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Randomized, Open-label, 104-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Conce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000180-13,0,0,0 2007-000180-13,6,2015-12-10,2015-12-10,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A Randomized, Open-label, 104-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Conce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000180-13,0,0,0 2007-000182-38,2,2008-08-01,2008-08-01,2,0,0,0,1,0,3,0,0,1,1,1,1,0,1,Mipharm SpA,"EFFICACY AND SAFETY OF A NEW TOPICAL FORMULATION OF ACYCLOVIR GEL (LP) IN THE TREATMENT OF HERPES SIMPLEX LABIALIS A RANDOMIZED, Single-BLIND, MULTICENTER, CONTROLLED CLINICAL TRIAL versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000182-38,0,0,0 2007-000182-38,2,2008-08-01,2008-08-01,2,0,0,0,1,0,3,0,0,1,1,1,1,0,1,MIPHARM,"EFFICACY AND SAFETY OF A NEW TOPICAL FORMULATION OF ACYCLOVIR GEL (LP) IN THE TREATMENT OF HERPES SIMPLEX LABIALIS A RANDOMIZED, Single-BLIND, MULTICENTER, CONTROLLED CLINICAL TRIAL versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000182-38,0,0,0 2007-000183-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CONSORZIO MARIO NEGRI SUD,A randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000183-24,0,0,0 2007-000187-25,1,2007-10-15,2007-10-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000187-25,0,0,0 2007-000189-19,3,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,ITALFARMACO,"Multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000189-19,0,0,0 2007-000189-19,3,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,Italfarmaco S.p.A.,"Multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000189-19,0,0,0 2007-000190-28,1,2007-05-08,2007-05-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Institute of Medicinal Molecular Design Inc,"A Single Centre, Double-blind, Randomised Study To Investigate a Single Oral Dose of IMD-1041 in A Nasal Allergen Challenge (NAC) Model",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000190-28,0,0,0 2007-000192-42,7,2010-04-08,2010-04-15,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALLERGAN,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment with Two Dose Levels of BOTOX (Botulinum Toxin Type A) Purified Neuro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000192-42,0,0,0 2007-000192-42,7,2010-04-08,2010-04-15,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment with Two Dose Levels of BOTOX (Botulinum Toxin Type A) Purified Neuro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000192-42,0,0,0 2007-000193-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio Anestesia Hopsital del Mar,"Efectividad y seguridad del ácido tranexámico para reducir los requerimientos sanguíneos en artroplastia de cadera y rodilla. Evaluación de factores humorales, de hemostasia y complicaciones trombótic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000193-22,0,0,0 2007-000197-24,1,2010-02-28,2010-02-28,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"MUW, Univ.Klinik f. Innere Medizin II, Abteilung f. Angiologie",EFFECTS OF NICOTINIC ACID PLUS SIMVASTATIN VS. SIMVASTATIN ALONE ON CAROTID AND FEMORAL INTIMA-MEDIA THICKNESS IN PATIENTS WITH PERIPHERAL ARTERY DISEASE (NASCIT) – A RANDOMIZED CONTROLLED TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000197-24,0,0,0 2007-000198-53,9,2012-03-08,2012-03-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Ltd,"An open-label extension study following a double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in paediatric partial onset seizur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000198-53,0,0,0 2007-000198-53,9,2012-03-08,2012-03-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,EISAI LTD UK,"An open-label extension study following a double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in paediatric partial onset seizur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000198-53,0,0,0 2007-000200-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,KANEKA coorporation,First in Man Feasibility Study with the MAHOROBA Stent,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000200-32,0,0,0 2007-000202-75,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Leids Universitair Medisch Centrum,"A comparison of the efficacy of levobupivacaine 0,125%, ropivacaine 0,125% and ropivacaine 0,2%, all combined with sufentanil 0.5 micrograms/mL, in patient-controlled epidural analgesia after hysterec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000202-75,0,0,0 2007-000204-33,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE DI CIRCOLO A.O. DI RILIEVO REGIONALE,REPEATED I.V. BOLUSES FLECAINIDE FOR ACUTE ATRIAL FIBRILLATION TERMINATION A SINGLE BLIND RANDOMIZED REGIMEN CONTROLLED TRIAL.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000204-33,0,0,0 2007-000207-15,2,2009-06-30,2009-06-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A randomised, open-label, 4-way crossover study to characterize the pharmacokinetics, safety and efficacy of tiotropium and salmeterol after inhalation of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhalati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000207-15,0,0,0 2007-000207-15,2,2009-06-30,2009-06-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A randomised, open-label, 4-way crossover study to characterize the pharmacokinetics, safety and efficacy of tiotropium and salmeterol after inhalation of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhalati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000207-15,0,0,0 2007-000208-34,15,2019-08-21,2019-08-21,13,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A phase III multi-center, open label, randomised study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000208-34,0,0,0 2007-000208-34,15,2019-08-21,2019-08-21,13,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma Services,"A phase III multi-center, open label, randomised study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000208-34,0,0,0 2007-000208-34,15,2019-08-21,2019-08-21,13,1,0,0,0,1,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A phase III multi-center, open label, randomised study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000208-34,0,0,0 2007-000208-34,15,2019-08-21,2019-08-21,13,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A phase III multi-center, open label, randomised study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000208-34,0,0,0 2007-000209-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITA CAMPUS BIOMEDICO,Efficacy of Lactobacillus Rhamnosus GG on preventing acute phases in patients affected by allergic conjunctivitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000209-31,0,0,0 2007-000210-36,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,UMC St Radboud University Hospital Center,"A prospective, randomized, open, multicenter study to evaluate the efficacy and tolerability of induction therapy with a single high-dose anti-T-lymphocyte globulin (ATG-Fresenius) in renal transplant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000210-36,0,0,0 2007-000212-89,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Instituto Universitario IVI Valencia,Uso de antagonistas de la GnRH en la preparación endometrial de las receptoras de ovocitos.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000212-89,0,0,0 2007-000213-11,4,2011-05-04,2011-05-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon 10 and 15 cm2 Patch in Patients with Alzheimer’s Disease S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000213-11,0,0,0 2007-000213-11,4,2011-05-04,2011-05-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica,"A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon 10 and 15 cm2 Patch in Patients with Alzheimer’s Disease S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000213-11,0,0,0 2007-000213-11,4,2011-05-04,2011-05-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon 10 and 15 cm2 Patch in Patients with Alzheimer’s Disease S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000213-11,0,0,0 2007-000214-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UMC St Radboud,Biological and biochemical markers of aneurysm wall degradation; towards non-invasive wall strength analysis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000214-37,0,0,0 2007-000219-27,8,2009-01-16,2011-07-04,5,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc,"An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000219-27,0,0,0 2007-000219-27,8,2009-01-16,2011-07-04,5,1,0,0,0,2,3,0,0,1,1,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., a Pfizer Company","An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000219-27,0,0,0 2007-000219-27,8,2009-01-16,2011-07-04,5,1,0,0,0,2,3,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals Inc. acting through its division Wyeth Research, a Pfizer Company","An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000219-27,0,0,0 2007-000221-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,John Pernow,Effect of bosentan on macro- and microvascular function in patients with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000221-22,0,0,0 2007-000222-51,1,2015-01-06,2015-01-06,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Southampton University Hospitals NHS Trust,Short CHemo RadioImmunotherapy in Follicular Trial of 90Y Ibritumomab tiuxetan (ZevalinTM) as therapy for first and second relapse in Follicular Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000222-51,0,0,0 2007-000223-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,M.S. Arbous,PRACDICAL Study Prevention and Risk factors of Arterial Complications in DIabetics after non-CArdiac surgicaL interventions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000223-17,0,0,0 2007-000224-41,2,2010-09-15,2010-09-15,2,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University of Cologne,"A double-blind, multicentre, parallel group, randomised, controlled trial to evaluate the possible benefit of isoniazid dose adjustment according to the genotype for NAT2 (arylamine N-acetyltransferas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000224-41,0,0,0 2007-000226-43,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ROCHE,"BONDIR : Bonviva IV dans le traitement des Douleurs liées aux fractures vertébrales ostéoporotiques Récentes. Etude multicentrique, randomisée, comparative en double aveugle contrôlée versus placebo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000226-43,0,0,0 2007-000229-23,4,2011-05-09,2011-05-09,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GUERBET,EVALUACIÓN DE LA SEGURIDAD RENAL TRAS ARM POTENCIADA CON DOTAREM EN COMPARACIÓN CON LA RM SIN CONTRASTE ENTRE PACIENTES CON ALTO RIESGO DE PADECER NEFROPATIA PROVOCADA POR EL MEDIO DE CONTRASTE RENA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000229-23,0,0,0 2007-000230-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Endocrine Society of Czech Republic,Protective effect of gonadoliberin analogues on endocrine and reproduction ovarian function during antitumour treatment in young girls and women in fertile period: Project of pharmacological gonadal p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000230-39,0,0,0 2007-000232-12,1,2007-07-02,2007-07-02,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,Syntopix Group plc,"Novel topical therapies for acne vulgaris: a randomised, controlled, double blind comparison of the antibacterial efficacy of 1% w/v formulations of tert-butylhydroquinone, zinc pyrithione and benzoyl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000232-12,0,0,0 2007-000233-18,1,2012-06-19,2012-06-19,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Universität zu Köln,Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Bevacizumab und Imatinib in der Erstlinientherapie von Patienten mit fortgeschrittenem kolorektalem Karzinom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000233-18,0,0,0 2007-000236-16,2,2008-05-06,2008-05-06,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"IMPAX Laboratories, Inc.","A Double-Blind, Randomized, Placebo- and Active Comparator- Controlled, Parallel Group, Multinational Study to Evaluate the Pharmacokinetics and Pharmacodynamics of IPX056 in Subjects with Established...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000236-16,0,0,0 2007-000240-27,5,2008-03-13,2008-03-13,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Weekly Treatment with SYR-472 in Subjects with Type 2 Diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000240-27,0,0,0 2007-000241-35,3,2009-05-26,2009-11-27,3,1,0,1,0,1,1,0,0,1,0,0,0,0,1,TopoTarget A/S,A Phase I/II Clinical Trial of PXD101 in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000241-35,0,0,0 2007-000242-12,1,2009-09-08,2009-09-08,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Hannover Clinical Trial Center GmbH,"Monozentrische, prospektiv durchgeführte Studie zur Untersuchung der Pharmakokinetik von Voriconazol nach einmaliger und wiederholter Gabe von 2x4mg/kg pro Tag bei niereninsuffizienten Patienten mit G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000242-12,0,0,0 2007-000243-10,4,2013-05-21,2013-05-21,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Glaxo SmithKline Research and Development Limited,"An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with fludarabine and cyclophosphamide, in patients with previous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000243-10,0,0,0 2007-000243-10,4,2013-05-21,2013-05-21,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with fludarabine and cyclophosphamide, in patients with previous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000243-10,0,0,0 2007-000244-27,4,2014-01-07,2014-03-07,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with CHOP, in patients with previously untreated Follicular Lymp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000244-27,0,0,0 2007-000246-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Groupe Français des myélodysplasies,A phase II study of the efficacity and the safety of lenalidomide in subjects with intermediate or the high risk myelodysplastic syndromes (MSD) associated with a deletion (Del) 5q[31],https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000246-13,0,0,0 2007-000255-34,1,2008-06-10,2008-06-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Asklepios-Klinik Sankt Augustin,"a multicentre, open, uncontrolled phase IIIb study to evaluate the efficacy and safety of Etanercept 0,8 mg/kg body weight (bw) given once weekly to patients with polyarticular-course juvenile idiopa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000255-34,0,0,0 2007-000257-56,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Emotional Brain BV,Neural correlates of sexual arousal during treatment of testosterone combined with sildenafil in healthy female subjects with FSD. Effects of differing levels of attentional engagement on neural corre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000257-56,0,0,0 2007-000259-33,1,2014-03-17,2014-03-17,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,"Department of Anesthesiology and Intensive Care, University Hospital Münster",Perioperative protective effects of lidocaine - clinical study on the route and timing of administration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000259-33,0,0,0 2007-000260-24,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,ZAMBON ITALIA,"EVALUATION OF THE CLINICAL AND MICROBIOLOGICAL EFFICACY OF N-ACETILCISTEINA 600 MG, IN COMBINATION TO CEFPODOXIMA PROXETILE, IN THE THERAPY OF THE INFECTIONS OF THE HIGH RESPIRATORY WAYS IN ADULT PATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000260-24,0,0,0 2007-000261-38,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase IV, open, multicentric study to evaluate the immune response to a hepatitis B challenge dose in healthy subjects, 72 to 78 months after they received a primary vaccination course of GSK Biolog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000261-38,0,0,0 2007-000262-20,1,2007-11-30,2007-11-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Stanmore Clinical Research Facility Ltd,"A phase III, 7 days randomised, double-blind, placebo-controlled, parallel group study to assess efficacy of DPZ for reducing the symptoms of post-operative delirium after an elective hip or knee repl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000262-20,0,0,0 2007-000266-21,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Medical University, Dpt. Internal Medicine, Div. of General Internal Medicine",PHARMAKOKINETIK VON KOLLOIDALEM AMPHOTERICIN B BEI KRITISCH KRANKEN MIT EINGESCHRÄNKTER LEBERFUNKTION (Pharmacokinetics of colloidal Amphotericin B in critically ill Patients with hepatic impairment),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000266-21,0,0,0 2007-000267-17,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Verus Pharmaceuticals Inc,"A SINGLE CENTRE, GAMMA SCINTIGRAPHY STUDY IN ASTHMATIC PATIENTS TO COMPARE PULMONARY DEPOSITION AND PHARMACOKINETICS OF ALBUTEROL INHALATION SOLUTION (AIS) DELIVERED VIA eFLOW NEBULISER AND SALBUTAMOL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000267-17,0,0,0 2007-000270-23,1,2014-01-29,2014-01-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GELA,TARGETED INTENSIFICATION BY A PREPARATIVE REGIMEN FOR PATIENTS WITH HIGH-GRADE B-CELL LYMPHOMA UTILIZING STANDARD-DOSE YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN) RADIOIMMUNOTHERAPY (RIT) COMBINED WITH ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000270-23,0,0,0 2007-000271-42,1,2013-09-02,2013-09-02,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,Matti Eskelinen,OKSIKODONIN ANALGEETTINEN PITOISUUS PLASMASSA YHDESSÄ PARASETAMOLIN 1g TAI 2g IV KANSSA ANNETTUNA MAHAKIRURGISILLA POTILAILLA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000271-42,0,0,0 2007-000272-16,1,2008-06-19,2008-06-19,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,CSL Limited,"A Phase II, Double Blind, Randomised, Controlled, Multi-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of Three Formulations of CSL412 in Adults (≥ 18 to ≤ 45 years) and Older Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000272-16,0,0,0 2007-000273-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"A Phase II, Open-Label, Multi-centre, 2-part study to assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Newly Diagnosed Acute Myeloid Leukemia AML unf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000273-35,0,0,0 2007-000275-42,1,2013-11-22,2013-11-22,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,IIL INTERGRUPPO ITALIANO LINFOMI ONLUS,"A phase III, multicentric randomized study for the treatment of young patients with unfavorable prognosis Diffuse Large Cell B Lymphoma IPI 2-3 . Dose-dense chemotherapy Rituximab +/- intensive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000275-42,0,0,0 2007-000278-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"GiSAS trial aripiprazole, olanzapine and haloperidol in the long term treatment of schizophrenia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000278-22,0,0,0 2007-000279-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,A.S.L. 2,"Randomised phase 3B study on comparison of 2 treatment schedules with peginterferon alpha 2b and ribavirin short term versus standard term schedules in patients with chronic hepatitis C, genotype 2 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000279-40,0,0,0 2007-000280-17,2,2008-08-28,2008-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"An Open Label Single and Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-17299425 in Patients with Traumatic Brain Injury.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000280-17,0,0,0 2007-000280-17,2,2008-08-28,2008-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V,"An Open Label Single and Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-17299425 in Patients with Traumatic Brain Injury.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000280-17,0,0,0 2007-000281-21,1,2016-03-24,2016-03-24,1,1,0,0,0,3,2,0,0,1,0,0,1,0,3,Eli Lilly and Company,"Enzastaurin (LY317615) Before and Concomitant with Radiation Therapy, Followed by Enzastaurin Maintenance Therapy in Patients with Newly Diagnosed Glioblastoma without Methylation of the Promoter Gene...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000281-21,0,0,0 2007-000284-21,1,2014-03-30,2014-03-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,York Hospitals NHS Foundation Trust,"A multicentre, multinational randomised control trial of prophylactic low molecular weight heparin(LMWH) in high risk pregnant thrombophilic women",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000284-21,0,0,0 2007-000284-21,1,2014-03-30,2014-03-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of York,"A multicentre, multinational randomised control trial of prophylactic low molecular weight heparin(LMWH) in high risk pregnant thrombophilic women",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000284-21,0,0,0 2007-000290-32,2,2009-03-27,2010-11-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,SOLTI,"A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Capecitabine in Patients with Locally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000290-32,0,0,0 2007-000292-42,9,2011-08-11,2011-08-23,8,1,0,0,2,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000292-42,0,0,0 2007-000292-42,9,2011-08-11,2011-08-23,8,1,0,0,2,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline S.A. España,"ENABLE 2 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE) Randomised, placebo-controlled, multi-centre study to assess t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000292-42,0,0,0 2007-000293-23,1,2009-01-30,2009-01-30,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,"Karolinska Universitetssjukhuset i Solna, Thoraxanestesi & intensivvård",Narkosgas jämfört med konventionell intravenös sedering vid respiratorvård efter kranskärlskirurgi.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000293-23,0,0,0 2007-000294-33,1,2009-12-30,2009-12-30,1,0,0,0,1,1,2,0,0,1,0,0,1,0,1,"Lux Biosciences, Inc.","A MULTI-CENTER, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL-GROUP, DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF LX201 IMPLANTATION FOR THE PREVENTION OF CORNEAL ALLOGRAFT REJECTION EPISODES OR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000294-33,0,0,0 2007-000295-16,1,2009-10-22,2009-10-22,1,0,0,0,1,1,2,0,0,1,0,0,1,0,1,"Lux Biosciences, Inc.","A MULTI-CENTER, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL-GROUP DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF LX201 FOR PREVENTION OF CORNEAL ALLOGRAFT REJECTION EPISODES AND GRAFT FAILURE FO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000295-16,0,0,0 2007-000298-49,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,CHU - Hôpitaux de Rouen,"EVALUATION DE LA REPONSE IMMUNITAIRE CONTRE LA SOUCHE DE NEISSERIA MENINGITIDIS B:14,P1.7,16 CHEZ LES SUJETS VACCINES PAR MenBVac",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000298-49,0,0,0 2007-000304-32,1,2009-03-23,2009-03-23,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc,"Estudio fase 3, randomizado, controlado, doble ciego para evaluar la seguridad, tolerabilidad e inmunogenicidad de la Vacuna Neumocócica Conjugada 13-valente en niños sanos administrada con la vacuna...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000304-32,0,0,0 2007-000306-70,1,2009-08-06,2009-08-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,The effect of metformin on biomarker activity in primary breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000306-70,0,0,0 2007-000307-15,1,2008-09-30,2008-09-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,OVATION PHARMACEUTICALS INC,Safety and Efficacy of Melperone in the Treatment of Patients with Psychosis Associated with Parkinson's Disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000307-15,0,0,0 2007-000310-36,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Radboud University Medical Center Njmegen,Does statin therapy reduce sympathoexcitation in hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000310-36,0,0,0 2007-000319-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Alteon, Inc.","A Double-blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients with Chronic Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000319-27,0,0,0 2007-000320-40,1,2008-01-09,2008-01-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Surface Logix, Inc.","A pilot Phase IIa randomised, double blind, placebo-controlled, crossover study to examine the safety, tolerability and pharmacodynamic effects on blood pressure of repeat oral doses of SLx-2101 5, 10...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000320-40,0,0,0 2007-000323-17,6,2012-09-05,2012-10-05,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis US,"A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation with Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following De...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000323-17,0,0,0 2007-000325-21,12,2010-03-09,2010-03-09,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc. - 235 East 42nd Street - New York - 10017,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) AS FIRST LINE TREATMENT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000325-21,0,0,0 2007-000325-21,12,2010-03-09,2010-03-09,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer. S.A,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) AS FIRST LINE TREATMENT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000325-21,0,0,0 2007-000326-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation de l'apport du MEOPA en termes de gain d'amplitude articulaire à court terme lors des séances de kinésithérapie après chirurgie multisites des membres inférieurs chez des enfants présentant...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000326-40,0,0,0 2007-000327-18,2,2013-01-07,2013-01-07,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,GOELAMS,"Phase III, multicenter, European, randomized trial comparing the combination Fludarabine-Cyclophosphamide-Rituximab (FCR) with the combination Fludarabine-Cyclophosphamide-Campath (FCCam) in previousl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000327-18,1,0,0 2007-000328-42,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Arrow Therapeutics Ltd,"A clinical pharmacology study to determine the pharmacokinetic , safety and tolerability profile and antiviral activity of multiple oral doses of A-831 in otherwise healthy male Hepatitis C carriers ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000328-42,0,0,0 2007-000329-22,1,2008-07-02,2008-07-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare (UK) Limited,"A randomised, double blind, crossover pilot study of intravenous buprenorphine versus intravenous buprenorphine/ naloxone in patients with chronic pain.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000329-22,0,0,0 2007-000335-25,1,2010-01-31,2010-01-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Riika Merivirta,"Treatment of postoperative pain after arthroscopic shoulder surgery, a comparison between a fentanyl patch and local anaesthetic",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000335-25,0,0,0 2007-000336-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Assistance Publique Hopitaux de marseille,Kétamine IV et analgésie péridurale thoracique: effet sur la douleur et l afonction respiratoire postopératoires après thoracotomie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000336-20,0,0,0 2007-000338-38,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Oncoscience AG,"A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREAMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000338-38,0,0,0 2007-000339-24,2,2012-04-19,2012-04-19,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,"Cytori Therapeutics, Inc",A randomized clinical trial of AdiPOse-derived stem ceLLs in the treatment of patients with ST elevation myOcardial infarction – The APOLLO Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000339-24,0,0,0 2007-000342-12,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,Axcan Pharma Inc.,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE SAFETY AND EFFICACY OF VIOKASE® 16 FOR THE CORRECTION OF STEATORRHEA IN PATIENTS WITH EXOCRINE PANC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000342-12,0,0,0 2007-000343-10,3,2009-01-15,2009-02-24,3,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Merck & Co. Inc.,A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥60 Years of Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000343-10,0,0,0 2007-000343-10,3,2009-01-15,2009-02-24,3,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Merck and Co. Inc.,A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥60 Years of Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000343-10,0,0,0 2007-000343-10,3,2009-01-15,2009-02-24,3,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"Merck & Co., Inc.",A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥60 Years of Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000343-10,0,0,0 2007-000344-26,4,2008-02-11,2008-05-12,4,1,0,0,0,0,3,0,2,1,0,0,1,0,1,MERCK SHARP DOHME,"A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000344-26,0,0,0 2007-000344-26,4,2008-02-11,2008-05-12,4,1,0,0,0,0,3,0,2,1,0,0,1,0,1,"Merck Sharp & Dohme de España, S.A.","A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000344-26,0,0,0 2007-000344-26,4,2008-02-11,2008-05-12,4,1,0,0,0,0,3,0,2,1,0,0,1,0,1,Merck Sharp & Dohme Limited,"A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000344-26,0,0,0 2007-000344-26,4,2008-02-11,2008-05-12,4,1,0,0,0,0,3,0,2,1,0,0,1,0,1,"Merck & Co., Inc.","A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000344-26,0,0,0 2007-000348-28,3,2015-02-11,2015-02-11,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,F. Hoffman-La Roche Ltd,"A single arm, multi-centre, international, continuation trial of recombinant humanized antibody Herceptin® (trastuzumab) in patients with HER2 overexpressing tumors.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000348-28,0,0,0 2007-000348-28,3,2015-02-11,2015-02-11,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A single arm, multi-centre, international, continuation trial of recombinant humanized antibody Herceptin® (trastuzumab) in patients with HER2 overexpressing tumors.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000348-28,0,0,0 2007-000350-31,3,2010-11-02,2010-11-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000350-31,0,0,0 2007-000350-31,3,2010-11-02,2010-11-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000350-31,0,0,0 2007-000350-31,3,2010-11-02,2010-11-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 76-week prospective, open-label, multicenter study to evaluate the long-term effect of Exelon capsule and transdermal patch on worsening of the underlying motor symptoms of PD in patients with mil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000350-31,0,0,0 2007-000351-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset Solna,Will paracetamol reduce the opioid requirements and the (opioid)related postoperative nausea?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000351-33,0,0,0 2007-000353-65,2,2012-10-18,2012-10-18,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital Tübingen,"Weight gain, eating patterns and development of body composition during initiation of basal insulin therapy: a comparison of insulin determir and insulin glargine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000353-65,0,0,0 2007-000354-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,GISCAD,A randomized trial investigating the role of FOLFOX-4 regimen duration (3 versus 6 months) and bevacizumab as adjuvant therapy for patients with stage II/III colon cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000354-31,0,0,0 2007-000357-54,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UniversityHospitalGrenoble,"Chemotherapy of first line ""reinforced"" for cancers of the colonist and the rectum with hepatic and/or pulmonary metastases potentially résécables: Strong association FOLFIRI and ERBITUX",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000357-54,0,0,0 2007-000359-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU Toulouse,PENOMBRE HYPOXIQUE ET ISCHEMIE SEMI-TARDIVE ETUDIEE EN TEP AU 18F-FLUOROMISONIDAZOLE : IMPACT SUR LA RECUPERATION FONCTIONNELLE DANS LES SUITES D’UN AVC ISCHEMIQUE AVEC DEFICIT MOTEUR. Etude de fai...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000359-33,0,0,0 2007-000363-20,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Ritva Nissi,Kalsineuriini-inhibiittori pimekrolimuusin aikaansaamat histologiset muutokset valkojäkälän paranemisvaiheessa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000363-20,0,0,0 2007-000367-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Meerkanten GGz,"The effect of the addition of D-cycloserine to exposure sessions in the treatment of patients with obsessive-compulsive disorder. A randomized, placebo-controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000367-18,0,0,0 2007-000371-42,3,2012-01-04,2012-01-04,3,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Wyeth Research Division of Wyeth Pharmaeuticals Inc.,A Phase I/II Safety and Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed/Refractory Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000371-42,0,0,0 2007-000371-42,3,2012-01-04,2012-01-04,3,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Wyeth Research Division of Wyeth Pharmaeuticals Inc. (A Pfizer Company),A Phase I/II Safety and Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed/Refractory Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000371-42,0,0,0 2007-000371-42,3,2012-01-04,2012-01-04,3,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,A Phase I/II Safety and Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed/Refractory Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000371-42,0,0,0 2007-000375-42,5,2009-03-05,2009-03-05,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Solvay Pharmaceuticals GmbH,"A multi-center, double-blind, parallel-design, randomized, placebo-controlled, dose-ranging study to assess the efficacy and safety of oral recombinant microbial lipase (SLV339) in subjects with pancr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000375-42,0,0,0 2007-000379-41,1,2010-11-19,2010-11-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Royal Liverpool & Broadgreen University hospital,Liverpool Avastin Dose Response and Retreatment Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000379-41,0,0,0 2007-000381-20,16,2009-04-20,2012-02-16,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Serono S.A. - Geneva,"A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000381-20,0,0,0 2007-000381-20,16,2009-04-20,2012-02-16,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Serono International S.A.,"A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000381-20,0,0,0 2007-000381-20,16,2009-04-20,2012-02-16,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SERONO SA,"A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000381-20,0,0,0 2007-000383-24,7,2016-09-26,2016-09-26,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000383-24,0,0,0 2007-000383-24,7,2016-09-26,2016-09-26,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000383-24,0,0,0 2007-000386-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",PRIMARY CHEMOTHERAPY WITH AN EXTENDED SCHEDULE OF TEMOZOLOMIDE (1 WWEK ON / 1 WEEK OFF) FOR LOW GRADE OLIGODENDROGLIAL TUMORS AT RELAPSE OR PROGRESSION AFTER SURGERY: PHASE II TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000386-38,0,0,0 2007-000390-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitätsklinikum Erlangen,"Application of hypertonic hyperoncotic solutions for improvement of cardiac output after open heart surgery in children - monocentric, randomised, placebo controlled, double-blind clinical trial (phas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000390-31,0,0,0 2007-000392-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Anaesthesia, Rotunda Hospital",Transversus Abdominis Plane (TAP) Block with or without intrathecal morphine for analgesia following lower segment Caesarean Section,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000392-42,0,0,0 2007-000394-36,8,2008-09-30,2008-09-30,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Hospira UK Ltd,"A PHASE III RANDOMISED, MULTICENTRE, DOUBLE-BLIND, THERAPEUTIC EQUIVALENCE STUDY OF BIOSIMILAR G-CSF (PLIVA/MAYNE FILGRASTIM) VERSUS NEUPOGEN (FILGRASTIM – AMGEN) IN SUBJECTS RECEIVING DOXORUBICIN AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000394-36,0,0,0 2007-000394-36,8,2008-09-30,2008-09-30,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mayne Pharma Plc,"A PHASE III RANDOMISED, MULTICENTRE, DOUBLE-BLIND, THERAPEUTIC EQUIVALENCE STUDY OF BIOSIMILAR G-CSF (PLIVA/MAYNE FILGRASTIM) VERSUS NEUPOGEN (FILGRASTIM – AMGEN) IN SUBJECTS RECEIVING DOXORUBICIN AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000394-36,0,0,0 2007-000394-36,8,2008-09-30,2008-09-30,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Hospira UK limited,"A PHASE III RANDOMISED, MULTICENTRE, DOUBLE-BLIND, THERAPEUTIC EQUIVALENCE STUDY OF BIOSIMILAR G-CSF (PLIVA/MAYNE FILGRASTIM) VERSUS NEUPOGEN (FILGRASTIM – AMGEN) IN SUBJECTS RECEIVING DOXORUBICIN AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000394-36,0,0,0 2007-000397-23,1,2008-10-02,2008-10-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Surface Logix, Inc.","A randomised, double blind, placebo-controlled, cross-over pilot study to examine the safety, tolerability and pharmacodynamic profile of repeat oral doses of SLx-2101 once daily for up to 14 days in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000397-23,0,0,0 2007-000402-67,1,2008-04-01,2008-04-01,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,ALK-Abelló S.A,"Estudio multicéntrico, randomizado, doble ciego-placebo en Fase I para evaluar la seguridad en niños del liofilizado oral ALK de ácaros",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000402-67,0,0,0 2007-000403-15,5,2008-03-28,2008-03-28,5,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Randomized, Double-Blind, Placebo-Controlled, Polysomnography plus Outpatient Study to Determine the Safety and Efficacy of 4 mg Ramelteon in Adults with Chronic Insomnia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000403-15,0,0,0 2007-000406-79,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Caen,"Evolution clinique de la nucléolyse à l’éthanol sur la douleur, l’incapacité fonctionnelle et la qualité de vie de patients souffrant de sciatique ou de cruralgie par hernie discale.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000406-79,0,0,0 2007-000410-37,1,2009-07-16,2009-07-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Of Tuebingen,Determination of glomerular filtration rate (GFR) using MR nephrography in patients with chronic kidney disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000410-37,0,0,0 2007-000412-82,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,NKI-AVL,PHARMACOGENOMIC AND PHARMACOKINETIC SAFETY AND COST-SAVING ANALYSIS IN PATIENTS TREATED WITH FLUOROPYRIMIDINES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000412-82,0,0,0 2007-000414-36,1,2011-03-07,2011-03-07,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,"Instituto Grifols, S.A.","ESTUDIO FASE II PARA VALORAR LA EFICACIA Y SEGURIDAD DEL RECAMBIO PLASMÁTICO CON ALBÚMINA 5% EN EL ACLARAMIENTO DEL PÉPTIDO BETA-AMILOIDE EN LÍQUIDO CEFALORRAQUÍDEO, Y SUS EFECTOS EN PACIENTES CON ENF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000414-36,0,0,0 2007-000416-91,1,2008-12-30,2008-12-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase I/II, Ascending, Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137 Monoclonal Antibody, Administered Every Three Weeks to Patients with Metastatic or Locally Advanced Solid Malignancies....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000416-91,0,0,0 2007-000418-35,2,2008-08-22,2008-08-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TopoTarget A/S,"A double-blind, randomised, parallel group, placebo-controlled dose finding Phase II study to compare the efficacy and safety of topically applied Avugane™ of different concentrations in subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000418-35,0,0,0 2007-000420-40,5,2013-06-03,2013-06-03,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Bayer Schering Pharma Oy,"Multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses (in vitro 12 µg/24 h and 16 µg/24 h) of the ultra low dose levonorgestrel contraceptive intraute...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000420-40,0,0,0 2007-000420-40,5,2013-06-03,2013-06-03,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Bayer Oy,"Multi-center, open-label, randomized study to assess the safety and contraceptive efficacy of two doses (in vitro 12 µg/24 h and 16 µg/24 h) of the ultra low dose levonorgestrel contraceptive intraute...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000420-40,0,0,0 2007-000421-21,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,OSPEDALE S. RAFFAELE,"PROSPECTIVE, RANDOMIZED, DUOBLE BLIND COMPARISON BETWEEN SUBARACNOID ANAESTHESIA AND SUBARACNOID ANAESTHESIA WITH BLOCK OF FEMORAL NERVE IN PATIENTS UNDERGOING SURGERY FOR ANTERIOR LIGAMENT REPAIR.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000421-21,0,0,0 2007-000425-22,2,2008-03-20,2008-03-20,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Bayer Healthcare AG,Phase IIa Efficacy and Safety Trial of capadenoson in Patients with Chronic Stable Angina,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000425-22,0,0,0 2007-000427-17,1,2011-12-31,2011-12-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,CYTAVIS BioPharma GmbH,A phase II multicenter study to test progression- free and overall survival of CY-503 in the treatment of patients with unresectable stage IV metastatic melanoma after antineoplastic treatment failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000427-17,0,0,0 2007-000436-74,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Poissy Hospital,Impact of two glucose control regimens by insulin on hospital mortality in intensive care unit patients (INSUREA Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000436-74,0,0,0 2007-000438-38,1,2010-07-28,2010-07-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London,Efficacy of Lopinavir in Pregnancy: Pharmacokinetic and Virological Studies with Kaletra melt extruded tablet formulation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000438-38,0,0,0 2007-000439-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,"NORA TRIAL (oral Navelbine in adjuvabt):multicenter,prospective,phase II, randomized clinical trial concerning about adjuvant chemioterapy with cisplatino and vinorelbine according to an advanced sche...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000439-24,0,0,0 2007-000440-27,1,2010-07-17,2010-07-17,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Baxter AG,OPEN-LABEL PHASE IV STUDY TO INVESTIGATE THE SEROPERSISTENCE OF TICK-BORNE ENCEPHALITIS (TBE) VIRUS ANTIBODIES AFTER THE FIRST BOOSTER AND THE RESPONSE TO A SECOND BOOSTER VACCINATION WITH FSME-IMMUN ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000440-27,0,0,0 2007-000442-12,3,2010-03-31,2010-03-31,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Kenta Biotech Ltd,A non-comparative open pilot trial to assess the safety and pharmacokinetics of up to three single doses of AERUMAB 11 in patients with hospital acquired pneumonia caused by serotype O11 P. aeruginosa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000442-12,0,0,0 2007-000442-12,3,2010-03-31,2010-03-31,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Kenta Biotech,A non-comparative open pilot trial to assess the safety and pharmacokinetics of up to three single doses of AERUMAB 11 in patients with hospital acquired pneumonia caused by serotype O11 P. aeruginosa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000442-12,0,0,0 2007-000443-99,1,2008-10-31,2008-10-31,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Universitätsklinikum Ulm,"Comparison of the sequential maintenance therapy with Mycophenolat and Prednisolon to standard therapy after completed induction therapy – a multicenter, randomised, phase III intervention study for p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000443-99,0,0,0 2007-000444-27,1,2010-01-21,2010-01-21,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Bionorica research GmbH,Treatment of Patients Suffering from Nausea/Vomiting with Dronabinol (tetrahydrocannabinol) Comparsion of three dosages versus standard therapy in a cross-over design,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000444-27,0,0,0 2007-000446-12,1,2009-07-08,2009-07-08,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Imperial College London,Treatment of Pulmonary Hypertension and Sickle Cell Disease with Sildenafil Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000446-12,0,0,0 2007-000450-31,2,2010-01-01,2010-04-12,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,The Nordic MDS group,A multicentre phase II study of the efficacy and safety of lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) or monosomy 5.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000450-31,0,0,0 2007-000451-34,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI,Therapy of hyperhomocysteinemia in hemodialysis patients:effects of acetylcysteine and folates.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000451-34,0,0,0 2007-000452-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CONSORZIO MARIO NEGRI SUD,Long term impact of renin angiotensin system RAS inhibition on cardiorenal outcomes. A randomized controlled trial of cardio-renal effects of RAS inhibition in patients with cardio-renal risk. A co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000452-14,0,0,0 2007-000454-31,11,2009-11-26,2009-11-26,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithkline Research & Development Limited,"Study of Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine, Administered with Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000454-31,0,0,0 2007-000454-31,11,2009-11-26,2009-11-26,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"Study of Once-Daily Abacavir/Lamivudine versus Tenofovir/Emtricitabine, Administered with Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000454-31,0,0,0 2007-000456-13,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Institut Català d'Oncologia (ICO),Estudio fase II de Bevacizumab en combinación con Capecitabina y radioterapia como tratamiento preoperatorio en pacinetes con cáncer rectal localmente avanzado resecable.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000456-13,0,0,0 2007-000460-24,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,University of Duisburg-Essen,Bi-weekly Cetuximab combined with FOLFOX-6 as first-line treatment in metastatic colorectal cancer patients with wild-type k-ras status,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000460-24,0,0,0 2007-000462-21,1,2008-06-06,2008-06-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Avontec GmbH,"A multicenter, randomized, double-blind, placebo-controlled, intraindividual-comparison phase IIa trial to evaluate the efficacy and safety of 2% AVT-02 UE ointment in the treatment of mild to moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000462-21,0,0,0 2007-000467-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Maternal and fetal haemodynamic response to Nifedipine tocolysis in normotensive pregnant women.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000467-23,0,0,0 2007-000468-26,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,A phase I/II multicentre study to evaluate the safety and efficacy of rituximab (monoclonal antibody anti-CD20) for prevention and/or therapy of EBV-disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000468-26,0,0,0 2007-000469-39,1,2007-09-21,2007-09-21,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Oy Eli Lilly Finland Ab,"An Open Label Follow-up Study of Patients Who Participated in Clinical Study B9R-HL-GDDV. A Phase IV, one-arm follow-up study to assess final adult results of GH treatment in patients with the Prader...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000469-39,0,0,0 2007-000479-40,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Department of Psychiatry, RWTH Aachen",Effects of quetiapine on ultrastructural hippocampal and neurochemical changes in patients with bipolar disorder: searching for the antidepressant and mood stabilising neurophysiology,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000479-40,0,0,0 2007-000483-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,OSPEDALE ISRAELITICO DI ROMA,"Buprenorfina TDS in old patients with chronic pain not give moderated cancer of intensita serious. Study in open, of Phase IV, not controlled, multicentric, spontaneous",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000483-25,0,0,0 2007-000486-38,2,2009-12-17,2009-12-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Takeda Global Research & Development Centre (Europe) Ltd.,","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 with Pioglitazone versus Placebo on Postprandial Lipids in Subjects w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000486-38,0,0,0 2007-000488-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Center,Bevacizumab in combination with metronomic dose temozolomide in patients with relapsed high grade gliomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000488-38,0,0,0 2007-000490-40,4,2008-03-31,2008-03-31,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Solvay Pharmaceuticals GmbH,"Randomised, Double-Blind, Placebo-Controlled, Multi-Center, Sequential Cohort Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects with Cong...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000490-40,1,0,0 2007-000491-16,4,2009-10-19,2009-10-19,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 76-week open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1β monoclonal antibody) in patients with active rheumatoid arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000491-16,0,0,0 2007-000491-16,4,2009-10-19,2009-10-19,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A 76-week open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1β monoclonal antibody) in patients with active rheumatoid arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000491-16,0,0,0 2007-000493-23,1,2007-11-30,2007-11-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare,A Comparison of Two Analgesic Products for the Treatment of Headache,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000493-23,0,0,0 2007-000497-23,1,2013-02-22,2013-02-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,Do sulphponylureas preserve cortical function during hypoglycaemia in patients with type 1 diabetes and hypoglycaemia unawareness?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000497-23,0,0,0 2007-000497-23,1,2013-02-22,2013-02-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,Do sulphponylureas preserve cortical function during hypoglycaemia in patients with type 1 diabetes and hypoglycaemia unawareness?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000497-23,0,0,0 2007-000498-42,4,2009-09-10,2009-09-10,2,1,1,0,0,2,3,0,0,2,0,0,0,0,2,PROTALIX BIOTHERAPEUTICS,"A Phase III Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000498-42,1,1,0 2007-000498-42,4,2009-09-10,2009-09-10,2,1,1,0,0,2,3,0,0,2,0,0,0,0,2,Protalix Biotherapeutics,"A Phase III Multicenter, Randomized, Double-Blind Trial to Assess the Safety and Efficacy of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000498-42,1,1,0 2007-000501-29,1,2013-01-26,2013-01-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital of Erlangen,Low grade albuminuria: reaching a new target for irbesartan,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000501-29,0,0,0 2007-000502-70,1,2012-06-29,2012-06-29,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Technical University of Munich,An open-label phase I/II (proof of concept) trial of an combination of Nilotinib (AMN 107) and RAD001 in patients with acute myeloid leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000502-70,0,0,0 2007-000503-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZ. OSPEDALIERA GARIBALDI, S.LUIGI CURRO , ASCOLI TOMASELLI","Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of memant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000503-15,0,0,0 2007-000504-32,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,1,Pierre Fabre Médicament,"Analyse du profil sensoriel du sirop antihistaminique Primalan®, versus un sirop antihistaminique de reference : Aerius®",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000504-32,0,0,0 2007-000506-78,1,2008-07-22,2008-07-22,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Hannover Clinical Trial Center GmbH,"Monozentrische, prospektive, offene Studie zur Untersuchung der „steady state“-Pharmakokinetik von Tigecyclin im Plasma, im ELF und in Alveolarmakrophagen bei Intensivpatienten mit tiefer Atemwegsinfe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000506-78,0,0,0 2007-000509-31,4,2009-10-20,2009-10-23,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Biogen Idec Ltd,"A Phase 1/2, Open-Label, Adaptive, Randomized Study of Liposomal Doxorubicin With or Without M200 (Volociximab) for the Treatment of Subjects With Advanced Epithelial Ovarian Cancer or Primary Periton...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000509-31,0,0,0 2007-000509-31,4,2009-10-20,2009-10-23,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,BIOGEN IDEC LTD,"A Phase 1/2, Open-Label, Adaptive, Randomized Study of Liposomal Doxorubicin With or Without M200 (Volociximab) for the Treatment of Subjects With Advanced Epithelial Ovarian Cancer or Primary Periton...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000509-31,0,0,0 2007-000510-37,1,2009-06-09,2009-06-09,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Nottingham Univeristy Hospitals NHS Trust,The effect of transdermal GTN on arterial size and procedure outcomes in transradial coronary angiography - pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000510-37,0,0,0 2007-000511-28,1,2008-02-08,2008-02-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Neosil Inc.,"A Phase 2 Multicenter, Randomized, Placebo-Controlled, Double-Blind Parallel Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Topical NEOSH101 in the Treatment of Androgenetic Alopecia ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000511-28,0,0,0 2007-000512-82,1,2008-03-28,2008-03-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Charité Universitätsmedizin Berlin,"Optimal Duration of Olazapine Add-on therapy in Major Depression: A double-blind, placebo-controlled, randomized, Phase III, Pilot Study in parallel group Design",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000512-82,0,0,0 2007-000513-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Úrazová nemocnice brno,Terlipressin in the treatment of catecholamine-resistant septic shock,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000513-12,0,0,0 2007-000515-29,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Alcon Laboratories Inc.,Adherencia de los pacientes en el uso de Travalert® para la instilación de una combinación fija de travoprost 0.004% / timolol 0.5% comparado con un régimen concomitante de travoprost 0.004% y timolol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000515-29,0,0,0 2007-000516-93,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CESAR MARGARIT FERRI,“Eficacia analgésica del escitalopram vs. amitriptilina en la neuropatía periférica dolorosa asociada a la infección por el VIH”.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000516-93,0,0,0 2007-000517-10,1,2008-07-22,2008-07-22,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Hannover Clinical Trial Center GmbH,"Monozentrische, prospektiv durchgeführte Studie zur Untersuchung der „steady state“ - Pharmakokinetik von Caspofungin im Plasma, im ELF und in Alveolarmakrophagen bei beatmeten Intensivpatienten mit n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000517-10,0,0,0 2007-000518-34,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Rikshospitalet,Effect of beta blockade on left ventricular remodeling and function in aortic regurgitation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000518-34,0,0,0 2007-000522-46,4,2008-05-31,2008-05-31,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Chiesi Farmaceutici S.p.A,"A 12-WEEK, MULTICENTER, MULTINATIONAL, RANDOMISED, DOUBLE BLIND, DOUBLE-DUMMY (OPEN LABEL FOR THE SPACER GROUP), 3-ARM PARALLEL GROUP STUDY COMPARING THE EFFICACY AND THE SAFETY OF CHF 1535 HFA pMDI (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000522-46,1,0,0 2007-000526-48,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,"Randomized, monocentric trial on sintoms, adherence,toxicity of alternate antiretrovirale regimen",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000526-48,0,0,0 2007-000527-18,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Institut Gustave Roussy,"Monocentric, open label, uncontrolled phase I-II study to evaluate the safety and the maximum tolerated dose of sorafenib given daily in combination with temozolomide (extended schedule) in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000527-18,0,0,0 2007-000528-42,3,2010-03-31,2010-03-31,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Poniard Pharmaceuticals, Inc.","A Randomized, Controlled Phase III Trial of Picoplatin and Best Supportive Care (BSC) versus BSC Alone in Patients with Small Cell Lung Cancer (SCLC), Refractory or Progressive within Six Months of Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000528-42,0,0,0 2007-000532-47,1,2012-10-01,2012-10-01,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,"ICHTHYOL-GESELLSCHAFT Cordes, Hermanni & Co. (GmbH & Co.) KG","Singleblind, randomized, verum-controlled, multicentric study to confirm the non-inferiority of Leukichtan Gel versus Betaisodona Salbe in the treatment of cuts, abrasions and burns",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000532-47,0,0,0 2007-000534-39,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,acep,etude comparative randomisee intra-individuelle de l'efficacite du traitement d'hidradenite suppuree ou maladie de verneuil par injections sous cutanee de toxine botulinique versus placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000534-39,0,0,0 2007-000535-26,2,2010-10-22,2010-10-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SCHERING-PLOUGH,"SwiTching from etAnercept to iNfliximab in the treatment of moderate to severe psoriasis; a multi-center, open label trial evaluating the efficacy, tOlerance and safety (TANGO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000535-26,0,0,0 2007-000535-26,2,2010-10-22,2010-10-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Schering Plough S.p.A.,"SwiTching from etAnercept to iNfliximab in the treatment of moderate to severe psoriasis; a multi-center, open label trial evaluating the efficacy, tOlerance and safety (TANGO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000535-26,0,0,0 2007-000536-95,1,2008-02-12,2008-02-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Surface Logix,"A randomised, double-blind, placebo controlled study to evaluate the pharmacodynamics, safety, tolerability and pharmacokinetics profile of SLx-4090 over 14 days dosing in subjects with high triglycer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000536-95,0,0,0 2007-000538-37,1,2008-07-07,2008-07-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A multicenter, randomized, double-blind, parallel-group study to investigate the glucose lowering effect, safety and tolerability of a 24 week treatment with Vildagliptin 100 mg o.a.d. versus placebo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000538-37,0,0,0 2007-000541-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Montpellier,Etude pilote de comparaison de la méthode EMIT et de la chromotographie liquide couplée à la spectométrie de masse pour l'étude de la pharmacocinétique du mycophénolate mofétil chez des patients trans...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000541-35,0,0,0 2007-000543-98,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,A. N. M. C. O. - FONDAZIONE ITALIANA LOTTA MALATTIE CARDIOVASCOLARI,SWEET-ACS INTENSIFIED MULTIFACTORIAL INTERVENTION ON HYPERGLYCEMIC PATIENTS WITH ACUTE CORONARY SYNDROMES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000543-98,0,0,0 2007-000545-35,1,2011-07-31,2011-07-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical Institutions of the District Oberpfalz/Bayern (MedBO GmbH),Quetiapine induced neuroplasticity in schizophrenic patients: A combined TMS and VBM study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000545-35,0,0,0 2007-000548-29,3,2007-05-21,2007-10-31,2,1,0,0,0,0,4,0,0,2,1,0,0,0,1,GlaxoSmithKline R&D,"A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg OD versus Montelu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000548-29,1,0,0 2007-000550-31,1,2010-06-11,2010-06-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"IFS gGmbH, Universitätsmedizin Göttingen",Quetiapine vs. Placebo in alcohol relapse prevention- a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000550-31,0,0,0 2007-000557-61,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,PROSPECTIVE RANDOMIZED STUDY ON NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY VS. SURGERY ALONE IN PATIENTS WITH RESECTABLE PANCREATIC ADENOCARCINOMA' 'STUDIO PROSPETTICO RANDOMIZZATO SULLA CHEMIORAD...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000557-61,0,0,0 2007-000558-30,4,2008-05-15,2008-05-15,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Sosei R&D Ltd,"A Multicentre, Randomised, Double-Blind, Double-Dummy, Crossover Study to Evaluate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) in Comparison to Morphine Sulphate Immediate Release (MSIR) f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000558-30,1,0,0 2007-000559-32,6,2008-05-15,2008-05-15,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Sosei R&D Ltd,"A Multicentre, Open-Label, Extension Study to Investigate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) for the Treatment of Breakthrough Cancer Pain in Subjects with Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000559-32,1,0,0 2007-000562-21,1,2008-10-07,2008-10-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT - IDPF,Effects of TANGANIL (three 500 mg tablets twice daily) on postural disturbances in the elderly.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000562-21,0,0,0 2007-000564-25,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,OSPEDALE POLICLINICO S. MATTEO,"Fondaparinux vs Lepirudin in the treatment of heparin-induced thrombocytopenia, with or without thrombosis. A multicenter, randomized, parallel group study of treatment with fondaparinux (7.5 mg s.c....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000564-25,0,0,0 2007-000565-37,1,2011-12-31,2011-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Nottingham,A Prospective Study to Determine the Adverse Drug Reactions Profile of Anticonvulsants in Children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000565-37,0,0,0 2007-000567-26,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,ISTITUTO SUPERIORE DI SANITA`,Phase II Trial for the Treatment of Advanced Classical Kaposi’s Sarcoma with the HIV Protease Inhibitor Indinavir in Combination with Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000567-26,0,0,0 2007-000570-22,2,2008-01-10,2008-01-10,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Amgen Inc,"A Randomized, Double-Blind, Trial of AMG 745 or Placebo for the Treatment of Cachexia in Subjects with Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000570-22,0,0,0 2007-000573-29,6,2013-04-16,2013-06-17,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroidism",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000573-29,0,0,0 2007-000576-16,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizophren...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000576-16,0,1,1 2007-000577-38,6,2012-07-16,2013-07-16,3,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A 2 Year, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5-12 mg/day) in the Treatment of Adolescents (12 to 17 Years of Age) with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000577-38,1,1,0 2007-000577-38,6,2012-07-16,2013-07-16,3,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A 2 Year, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5-12 mg/day) in the Treatment of Adolescents (12 to 17 Years of Age) with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000577-38,1,1,0 2007-000579-40,1,2012-12-31,2012-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Charité Universitätsmedizin Berlin,"Effects of atypical versus typical neuroleptics on motivation, hedonia, and social cognition in patients with schizophrenia – an fMRI study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000579-40,0,0,0 2007-000582-37,4,2008-12-09,2009-10-22,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Genzyme Europe BV,"A Phase 4 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study of Colesevelam as Add-on Therapy in Patients with Familial Hypercholesterolaemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000582-37,0,0,0 2007-000583-25,13,2011-08-11,2011-08-11,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER,"A randomized, double masked, active controlled, phase 3 study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap-Eye in subjects with neovascular age-related macular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000583-25,0,0,0 2007-000583-25,13,2011-08-11,2011-08-11,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Schering Pharma AG,"A randomized, double masked, active controlled, phase 3 study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap-Eye in subjects with neovascular age-related macular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000583-25,0,0,0 2007-000584-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,OSPEDALE MAGGIORE DI MILANO (IRCCS),Normothermia in patients with acute cerebral damage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000584-13,0,0,0 2007-000585-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Royal Victoria Eye and Ear hospital,Randomised controlled trial of intravitreal Bevacizumab vs. conventional treatment for rubeotic glaucoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000585-21,0,0,0 2007-000586-38,1,2013-07-08,2013-07-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,HIGH-DOSE IMMUNOSUPPRESSION WITH THIOTEPA AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000586-38,0,0,0 2007-000590-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Rennes,"Etude randomisée, en double aveugle, comparant l’efficacité et la tolérance de la méthylprednisolone administrée à forte dose par voie orale ou par voie intraveineuse dans le traitement des poussées d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000590-37,0,0,0 2007-000593-24,2,2009-07-10,2009-07-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,F.Hoffmann-La Roche Ltd,"An Open-Label, Observational Study of the Effects of Anti-TNF Therapy on Peripheral Blood and Synovial Biomarkers in Patients with Active Rheumatoid Arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000593-24,0,0,0 2007-000593-24,2,2009-07-10,2009-07-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,F. Hoffmann-La Roche Ltd,"An Open-Label, Observational Study of the Effects of Anti-TNF Therapy on Peripheral Blood and Synovial Biomarkers in Patients with Active Rheumatoid Arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000593-24,0,0,0 2007-000594-29,1,2009-10-01,2009-10-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,NHS Tayside,The use of glycaemic response to sulphonylureas as a tool to investigate Type 2 diabetes pathophysiology,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000594-29,0,0,0 2007-000596-42,2,2009-03-23,2009-03-30,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline SA,"A phase III open study to assess the safety, reactogenicity and immunogenicity following booster administration of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine, co-admin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000596-42,0,0,0 2007-000596-42,2,2009-03-23,2009-03-30,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III open study to assess the safety, reactogenicity and immunogenicity following booster administration of GlaxoSmithKline (GSK) Biologicals´ 10-valent pneumococcal conjugate vaccine, co-admin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000596-42,0,0,0 2007-000597-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,"The protein tyrosine kinase inhibitor nilotinib as first-line treatment of Ph+ chronic myeloid leucemia (CML) in early chronic phase: a Phase II exploratory, multicenter study The protein tyrosine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000597-22,0,0,0 2007-000598-41,8,2008-08-27,2009-04-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cerexa, Inc.","""A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline versus Ceftriaxone, with Adjunctive Clarithromycin, in the Treatment of Adult Su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000598-41,0,0,0 2007-000599-18,5,2008-08-27,2009-04-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cerexa, Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline versus Ceftriaxone in the Treatment of Adult Subjects with Community-Acquired Pne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000599-18,0,0,0 2007-000602-73,1,2011-04-16,2011-04-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,OCTAPHARMA AG,"Efficacy and Safety of two doses regimens of Octaplex in patients with cerebral haemorrhage related to oral anticoagulant therapy: A phase IV, prospective, randomised, open-label study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000602-73,0,0,0 2007-000604-32,1,2010-02-16,2010-02-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Tartu University Hospital,EFFECT OF SERTINDOLE TREATMENT ON THE COGNITIVE FUNCTION IN PATIENTS WITH CHRONIC SCHIZOPHRENIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000604-32,0,0,0 2007-000606-75,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,IPERBOREAL PHARMA,Assessment of dialytic efficacy and tolerability of a peritoneal dialysis solution for notturnal exchange containing L-Carnitine in End Stage Renal Disease Patients (ESRD) in Automatised Peritoneal D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000606-75,0,0,0 2007-000607-15,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GILEAD SCIENCES S.R.L.,Phase II pilot multicenter study on efficacy and safety of liposomal amphotericin B (AmBisome) at 2 mg/kg/day in the treatment of candidemia and invasive candidiasis in nonneutropenic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000607-15,0,0,0 2007-000618-35,3,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,NATIONAL CANCER INSTITUTE,"PHASE II TRIAL OF PACLITAXEL, GEMCITABINE AND CISPLATIN IN PATIENTS WITH RELAPSING GERM CELL CANCER AFTER FIRST LINE CHEMOTHERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000618-35,0,0,0 2007-000618-35,3,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,Rigshospitalet,"PHASE II TRIAL OF PACLITAXEL, GEMCITABINE AND CISPLATIN IN PATIENTS WITH RELAPSING GERM CELL CANCER AFTER FIRST LINE CHEMOTHERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000618-35,0,0,0 2007-000619-27,1,2014-10-08,2014-10-08,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospitals of Leicester NHS Trust,"Prospective, double-blind, randomised trial to assess the efficacy of continuous sciatic/posterior tibial nerve blockade via a neural sheath catheter in lower limb amputees",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000619-27,0,0,0 2007-000623-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Dept of Anaesthesia, University College Hospital, Galway",A comparison between the use of opioid based patient controlled analgesia and ultrasound guided continuous Transversus Abdominis Plane Block in the management of postoperative pain following unilatera...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000623-18,0,0,0 2007-000624-40,1,2015-09-30,2015-09-30,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Heidelberg,PHASE II STUDY TO EVALUATE GLIVEC (IMATINIB MESYLATE) TO INDUCE PROGRESSION ARREST IN AGGRESSIVE FIBROMATOSIS / DESMOID TUMORS NOT AMENABLE TO SURGICAL RESECTION WITH R0 INTENT OR ACCOMPANIED BY UNACC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000624-40,0,0,0 2007-000627-17,1,2012-09-09,2012-09-09,1,0,0,0,0,0,4,0,1,1,1,1,1,0,0,University of Iceland,Serum profiles of paracetamol and glutathione after high doses of paracetamol for 6 days,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000627-17,0,0,0 2007-000628-41,4,2009-11-12,2009-11-12,2,1,1,0,0,0,1,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase I, Randomized, Open-Label, Multi-National Study to Evaluate the Pharmacokinetics of Repeated Once-Daily Intravenous Doses of Esomeprazole in Paediatric Patients 0 to 17 Years Old, Inclusive",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000628-41,1,1,0 2007-000631-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,KAROLINSKA INSTITUTET,THE ANTITTHROMBOTIC EFFECTS OF DOXAZOSIN AND RAMIPRIL IN ESSENTIAL HYPERTENSION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000631-25,0,0,0 2007-000634-39,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Forschergruppe Diabetes e. V. am Helmholtz Zentrum München,Postpartum Intervention in Women with Gestational Diabetes using Insulin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000634-39,0,0,0 2007-000636-13,6,2009-12-09,2009-12-09,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Clinuvel Pharmaceuticals Limited,"A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable CUV1647 Implants in Patients with Erythropoietic Protoporphyria (EPP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000636-13,0,0,0 2007-000636-13,6,2009-12-09,2009-12-09,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,CLINUVEL PHARMACUETICALS LTD,"A Phase III, Multicentre, Randomised, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable CUV1647 Implants in Patients with Erythropoietic Protoporphyria (EPP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000636-13,0,0,0 2007-000638-37,9,2011-01-05,2011-01-05,4,1,0,0,0,1,0,0,0,1,1,0,1,0,1,Amgen Inc.,An Open Label Study of AMG 531 in Severely Refractory Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000638-37,0,0,0 2007-000638-37,9,2011-01-05,2011-01-05,4,1,0,0,0,1,0,0,0,1,1,0,1,0,1,AMGEN S.P.A.,An Open Label Study of AMG 531 in Severely Refractory Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000638-37,0,0,0 2007-000642-13,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, 4 period incomplete block cross-over, multi-center, multiple dose (7 days) dose-ranging study to assess the efficacy and safety of 4 doses of NVA237 in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000642-13,0,0,0 2007-000643-95,3,2008-01-11,2008-01-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A randomized, double-blind, placebo controlled, parallel group, multi-center study, to assess the safety and tolerability of 28 days treatment with NVA237 (100 or 200µg once a day) in patients with mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000643-95,0,0,0 2007-000643-95,3,2008-01-11,2008-01-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled, parallel group, multi-center study, to assess the safety and tolerability of 28 days treatment with NVA237 (100 or 200µg once a day) in patients with mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000643-95,0,0,0 2007-000649-36,2,2018-09-04,2018-09-04,1,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Fundación PETHEMA,"A phase III multicentre, randomized open-label study of Revlimid (lenalidomide) plus dexamethasone (ReDex) versus observation in patients with smoldering multiple myeloma (MM) at high risk of progress...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000649-36,1,0,0 2007-000652-14,1,2007-12-13,2007-12-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,Etude en double aveugle versus placebo de l’efficacité et de la tolérance de Cirkan® sur la symptomatologie fonctionnelle veineuse éprouvée (C0s à C3s) par les patientes obèses,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000652-14,0,0,0 2007-000658-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Royal Victoria Eye and Ear hospital,Randomised controlled trial of Intravitreal Bevacizumab vs. conventional treatment for proliferative diabetic retinopathy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000658-30,0,0,0 2007-000663-18,1,2009-09-07,2009-09-07,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Rigshospitalet, Onkologisk Klinik","Randomized fase II trial: comparing Cisplatin, Paclitaxel and Gemcitabine vs. Cisplatin, Paclitaxel, Gemcitabine and Avastin in patients with unknown primary tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000663-18,0,0,0 2007-000666-20,1,2009-05-22,2009-05-22,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Royal Bournemouth Hospital,Influence of insulin therapy in non-diabetic patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease (COPD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000666-20,0,0,0 2007-000670-23,1,2009-09-16,2009-09-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Agence nationale de recherches sur le sida et les hépatites virales. ANRS,"Essai pilote évaluant un traitement antirétroviral associant le MK-0518, le darunavir/ritonavir (TMC114/r) et l’etravirine (TMC125) chez les patients infectés par le VIH-1, en échec virologique et por...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000670-23,0,0,0 2007-000680-22,10,2011-11-15,2011-11-15,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomized, placebo-controlled, parallel group, multi-centre phase III clinical study on the efficacy and tolerability of mesalazine granules vs. placebo for the prevention of recurrence...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000680-22,0,0,0 2007-000683-24,2,2008-04-29,2008-04-29,2,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"Phase II, double blind, randomized, comparative study of the immunogenicity and safety of GlaxoSmithKline Biologicals’ modified formulation varicella vaccine and Varilrix™ given as a 2 dose course in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000683-24,0,0,0 2007-000684-16,1,2018-12-18,2018-12-18,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,Great Ormond Street Hospital NHS Trust / University College London - Institute of Child Health,Gene therapy for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000684-16,0,0,0 2007-000687-24,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,FNCLCC,Prévention du cancer du sein par le létrozole chez la femme ménopausée porteuse d'une mutation brca 1/2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000687-24,0,0,0 2007-000690-34,6,2007-10-05,2007-10-22,6,1,0,0,2,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme OÜ,"A Randomized, Double-Blind, Active Comparator Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan/HCTZ Combination as Compared to Losartan Monotherapy in Pediatric Patients With Ess...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000690-34,0,0,0 2007-000690-34,6,2007-10-05,2007-10-22,6,1,0,0,2,0,3,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","A Randomized, Double-Blind, Active Comparator Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan/HCTZ Combination as Compared to Losartan Monotherapy in Pediatric Patients With Ess...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000690-34,0,0,0 2007-000690-34,6,2007-10-05,2007-10-22,6,1,0,0,2,0,3,0,0,1,1,0,1,0,1,"Merck & Co., Inc","A Randomized, Double-Blind, Active Comparator Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan/HCTZ Combination as Compared to Losartan Monotherapy in Pediatric Patients With Ess...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000690-34,0,0,0 2007-000690-34,6,2007-10-05,2007-10-22,6,1,0,0,2,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Ltd,"A Randomized, Double-Blind, Active Comparator Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan/HCTZ Combination as Compared to Losartan Monotherapy in Pediatric Patients With Ess...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000690-34,0,0,0 2007-000690-34,6,2007-10-05,2007-10-22,6,1,0,0,2,0,3,0,0,1,1,0,1,0,1,MSD Finland Oy,"A Randomized, Double-Blind, Active Comparator Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan/HCTZ Combination as Compared to Losartan Monotherapy in Pediatric Patients With Ess...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000690-34,0,0,0 2007-000697-23,1,2008-02-28,2008-02-28,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Merz Pharmaceuticals GmbH,"Prospective, single-arm, single-center, open-label trial to investigate the tolerability of NT 201 and quality of life of patients in the treatment of blepharospasm with shortened injection intervals",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000697-23,0,0,0 2007-000699-18,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Groupe d'Etude des Lymphomes de l'Adulte(GELA),"Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000699-18,0,0,0 2007-000699-18,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Hospices Civils de Lyon,"Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000699-18,0,0,0 2007-000700-32,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,University hospitals Leuven,"A randomised, double-blind, prospective study to compare the analgesic efficacy of 10 ml epidural loading dose levobupivacaine 0.5% versus levobupivacaine 0.25% in patients after major abdominal or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000700-32,0,0,0 2007-000702-71,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Alysis Zorggroep,The effect of intravenous fluid preload on diuresis during spinal anesthesia-induced detrusor blockade,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000702-71,0,0,0 2007-000703-15,2,2008-11-03,2008-11-03,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, United States","A 14 MONTH, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED PHASE 3 STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF CP 945,598 IN PREVENTION OF WEIGHT REGAIN IN OBESE SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000703-15,0,0,0 2007-000704-32,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,CONSORCI SANITARI TERRASSA,Ensayo clínico fase IV de comparación de la efectividad de dos pautas de administración de dinoprostona intravaginal en la inducción del parto en gestantes a término.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000704-32,0,0,0 2007-000705-30,1,2010-06-28,2010-06-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Moorfields Eye Hospital Foundation Trust,efficacy of pegaptanib sodium (macugen) on uveitic cystoid macular oedema: an exploratory study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000705-30,0,0,0 2007-000710-37,3,2009-01-05,2009-01-05,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,CSL Behring AG,A multicentre study of subcutaneous immunoglobulin in patients with Multifocal Motor Neuropathy (MMN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000710-37,0,0,0 2007-000713-11,4,2008-06-30,2008-06-30,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"An Exploratory, Multi-center, Open-Label, Single-Arm study to evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent (DECADES) on Inflammatory and Platelet Activation Markers in S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000713-11,0,0,0 2007-000715-29,1,2008-06-03,2008-06-03,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospitals of Leicester - Research & Development,Serum and urinary strontium levels and possible interference with measurement of other minerals in subjects taking Strontium ranelate (Protelos) for osteoporosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000715-29,0,0,0 2007-000718-35,1,2017-08-31,2017-08-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,"CONKO-006 Additive Therapie beim R1-resezierten Pankreaskarzinom mit Gemcitabin plus Sorafenib versus Gemcitabin plus Placebo über 12 Monate - eine doppelblinde, placebokontrollierte Phase IIb Studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000718-35,0,0,0 2007-000721-21,4,2011-11-28,2011-11-30,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,Randomized Phase II study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects with Her2+ Locally Advanced and/or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000721-21,0,0,0 2007-000724-40,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,"PTC Therapeutics, Inc.",A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000724-40,0,0,0 2007-000725-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ACROSS (Associació catalana per la recerca oncològica i les seves implicacions sanitàries i socials),"“Estudio abierto, para evaluar el tratamiento con taxotere, cisplatino y capecitabina (TCX) en pacientes con Cáncer Gástrico Avanzado”",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000725-22,0,0,0 2007-000727-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,"Maternal, uteroplacental and fetal haemodynamic effect of Nicardipine in severe pre-eclampsia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000727-17,0,0,0 2007-000728-41,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,Maastro clinic,"A phase I/II trial testing nelfinavir, an inhibitor of Akt signaling, in combination with preoperative chemoradiotherapy in patients with locally advanced rectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000728-41,0,0,0 2007-000729-24,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,University Hospital Linköping,Coagulation effect of four common plasma volume expanders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000729-24,0,0,0 2007-000730-40,1,2010-09-15,2010-09-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Heinrich-Heine-Universität Düsseldorf,Phase II study evaluating transarterial chemoembolization (TACE) in combination with sorafenib for the treatment of advanced hepatocellular carcinoma (HCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000730-40,0,0,0 2007-000733-19,2,2008-10-09,2008-10-09,1,1,0,0,1,0,2,0,0,1,1,1,1,0,1,Biogen Idec Ltd,"A Phase 2B, Blinded Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects with Rheumatoid Arthritis Who Previously Participated in Study...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000733-19,0,0,0 2007-000734-38,2,2008-10-09,2008-10-09,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Biogen Idec Ltd,An Open-Label Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects with Rheumatoid Arthritis Who Previously Participated in Study 104RA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000734-38,0,0,0 2007-000735-26,3,2010-07-26,2010-07-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd.,"A Multicentre, Double-Blind, Prospective, Randomised, European and Canadian Study to Evaluate Patient Outcomes and Costs of Managing Adults with Spasticity and Associated Focal Spasticity.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000735-26,0,0,0 2007-000736-10,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,3,,A comparison of pethidine/meperidine intramusculary and remifentanil patient-controlled analgesia during labor in Westfriesgasthuis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000736-10,0,0,0 2007-000739-25,9,2012-04-19,2012-04-19,5,1,0,0,2,2,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000739-25,0,0,0 2007-000739-25,9,2012-04-19,2012-04-19,5,1,0,0,2,2,3,0,0,1,1,0,1,0,1,"Novartis Farmaceutica, S.A","A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000739-25,0,0,0 2007-000739-25,9,2012-04-19,2012-04-19,5,1,0,0,2,2,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000739-25,0,0,0 2007-000741-36,1,2015-05-29,2015-05-29,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Christie Hospital NHS Trust,Study of radiotherapy dose escalation with Intensity Modulated Radiation Therapy (IMRT) and synchronous Cetuximab for intermediate stage head and neck cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000741-36,0,0,0 2007-000743-95,7,2010-01-05,2010-01-28,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-rel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000743-95,0,0,0 2007-000743-95,7,2010-01-05,2010-01-28,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-rel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000743-95,0,0,0 2007-000743-95,7,2010-01-05,2010-01-28,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma,"A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-rel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000743-95,0,0,0 2007-000744-28,5,2009-09-15,2009-09-15,5,1,0,0,0,0,3,0,2,1,0,0,1,0,1,Sanofi Pasteur MSD S.N.C.,"An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 1-dose regimen and different 2-dose regimens of a Zoster vaccine (Live), ZOSTAVAX , in subjects equal o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000744-28,0,0,0 2007-000747-10,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PISANA,PHASE II STUDY OF BAY 43-9006 AND INFUSIONAL 5-FLUOROURACIL IN ADVANCED HEPATOCELLULAR CARCINOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000747-10,0,0,0 2007-000750-31,1,2009-05-18,2009-05-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals of Leciester NHS trust,"The effect of long term low dose erythromycin on cough frequency in chronic unexplained cough: a randomised, double blind, placebo conrolled, parallel group trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000750-31,0,0,0 2007-000752-14,1,2007-07-03,2007-07-03,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000752-14,0,0,0 2007-000755-33,1,2009-11-19,2009-11-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratoires Merck Sharp & Dohme - Chibret,"Multicenter, open, pragmatic, randomized trial comparing the efficacy of 3 different lifestyle interventions after addition of sitagliptin to patients with type 2 diabetes mellitus who have inadequate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000755-33,0,0,0 2007-000758-30,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO CLINICO HUMANITAS,"Randomized continuation, dose escalation trial of Sorafenib in pts with advanced HCC with radiological progression on prior sorafenib treatment (Phase II study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000758-30,0,0,0 2007-000759-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SOFAR SPA,"Evaluation of the efficacy of green tea catechins (Categ Plus) in the chemoprevention of prostatic carcinoma in patients with high grade PIN. A randomised multicentric, double blind clinical study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000759-32,0,0,0 2007-000760-24,2,2008-06-06,2011-11-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"Activity and safety of oral administration of SSR150106XB for the reduction of inflammation in patients with active rheumatoid arthritis (RA): A 4-week, multi-center, randomized, double-blind, placebo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000760-24,0,0,0 2007-000762-20,1,2008-06-30,2008-06-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Theracos, Inc.","A Phase II Randomized, Double-Blind, Double-Dummy, Parallel Group, Placebo Controlled Study of Galantamine + Sertraline, Galantamine or Sertraline in Obese Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000762-20,0,0,0 2007-000763-18,1,2009-05-14,2009-05-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,"ACUTE CHANGES OF ENERGETIC SUBSTRATES ON MIOCARDIAL FUNCTION AND METABOLISM, IN PATIENTS WITH CRONIC HEART FAILURE ACITRIM",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000763-18,0,0,0 2007-000764-25,2,2008-08-26,2008-08-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharmacosmos A/S,A non-comparative open-label study of Iron Oligosaccharide in CHF patients with iron deficiency (either absolute or functional) anaemia and a need for parenteral iron.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000764-25,0,0,0 2007-000765-37,3,2008-08-26,2008-08-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharmacosmos A/S,A non-comparative open-label study of Iron Oligosaccharide in Chronic Kidney Disease patients with a need for parenteral iron,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000765-37,0,0,0 2007-000766-20,2,2013-03-05,2013-03-05,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000766-20,0,0,0 2007-000766-20,2,2013-03-05,2013-03-05,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000766-20,0,0,0 2007-000767-20,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Koagulationscentrum UMAS,Daglig profylax vid svår hemofili,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000767-20,0,0,0 2007-000771-42,2,2013-05-07,2013-05-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services,A controlled randomized open-label multicentre study evaluatiing if early conversion to everolimus (Certican) from cyclosporine (Neoral) in de novo renal transplant receipients can improve long-term r...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000771-42,0,0,0 2007-000774-23,1,2007-07-25,2007-07-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A,"EVALUATION OF CARDIAC SAFETY, TOLERABILITY AND EFFICACY OF CUMULATIVE DOSES OF CHF5188 pMDI (FIXED COMBINATION BUDESONIDE/CARMOTEROL 200/1 µg) COMPARED TO SAME CUMULATIVE DOSES OF CARMOTEROL pMDI AND ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000774-23,0,0,0 2007-000775-42,1,2008-12-15,2008-12-15,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital Tübingen,"Effects of Rimonabant on Liver Fat, Visceral Adipose Tissue Mass and early Markers of CardioDiabetes in obese Subjects with the Metabolic Syndrome – a randomized, double-blind clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000775-42,0,0,0 2007-000776-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Masaryk University,Development of Tumor Infiltrating Lymphocytes in Patients with Metastatic melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000776-16,0,0,0 2007-000779-40,1,2008-09-29,2008-09-29,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline Research & Development Limited,"A Phase II Trial of Pazopanib, a Pan Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitor, in Relapsed or Refractory Small Cell Lung Cancer (SCLC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000779-40,0,0,0 2007-000780-21,1,2008-08-22,2008-08-22,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Moorfields Eye Hospital,"A randomised, single-masked, Phase IV pilot study of the efficacy and safety of adjunctive intravitreal Avastin® (bevacizumab) in the prevention of early postoperative vitreous haemorrhage following d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000780-21,0,0,0 2007-000783-25,6,2008-12-19,2009-04-21,6,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Merck Sharp & Dohme Limited,"A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected Patients Switched from a Stable KALETRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000783-25,0,0,0 2007-000783-25,6,2008-12-19,2009-04-21,6,1,0,0,0,0,3,0,0,1,1,1,1,0,1,MERCK SHARP DOHME,"A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected Patients Switched from a Stable KALETRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000783-25,0,0,0 2007-000783-25,6,2008-12-19,2009-04-21,6,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Merck & Co., Inc.","A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected Patients Switched from a Stable KALETRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000783-25,0,0,0 2007-000783-25,6,2008-12-19,2009-04-21,6,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme de España, S.A.","A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected Patients Switched from a Stable KALETRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000783-25,0,0,0 2007-000783-25,6,2008-12-19,2009-04-21,6,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme, Lda.","A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected Patients Switched from a Stable KALETRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000783-25,0,0,0 2007-000789-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"CHU de Liège, Domaine Universitaire du Sart Tilman",Withdrawal of Calcineurin Inhibitors (CNIs) during administration of Mycophenolate Mofetil (MMF) in liver transplant patients suffering adverse effects from CNIs: Study of the reduction in rejection r...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000789-19,0,0,0 2007-000790-36,1,2008-12-15,2008-12-15,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Pfizer Pharma GmbH,"Prospective, randomized, double blind placebo-controlled trial on the efficacy of growth hormone replacement therapy in adult patients with isolated growth hormone deficiency (PRO ISO-GHD Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000790-36,0,0,0 2007-000794-31,3,2011-08-11,2011-08-11,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,PHARMA MAR,"Phase II, multicenter, open-label, clinical trial of Trabectedin (Yondelis) in Metastatic Breast Cancer Patients with triple negative profile (ER-, PR-, HER2-),HER2 overexpressing tumors and BRCA1 or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000794-31,0,0,0 2007-000794-31,3,2011-08-11,2011-08-11,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pharma Mar, S.A.","Phase II, multicenter, open-label, clinical trial of Trabectedin (Yondelis) in Metastatic Breast Cancer Patients with triple negative profile (ER-, PR-, HER2-),HER2 overexpressing tumors and BRCA1 or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000794-31,0,0,0 2007-000796-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Assistance Publique Hopitaux de marseille,CARACTERISTIQUES PHARMACOCINETIQUES DE LA LEVOBUPIVACAINE APRES BLOC SCIATIQUE CHEZ L’ENFANT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000796-42,0,0,0 2007-000800-34,3,2008-10-06,2008-10-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company Ltd.,"A Multi-center, Inpatient, Phase 2, Double-blind, Placebo-controlled Dose Ranging Study of LY2140023 in Patients with DSM-IV Schizophrenia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000800-34,0,0,0 2007-000801-30,9,2008-04-10,2008-06-27,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,EISAI LTD UK,"A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Flu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000801-30,0,0,0 2007-000801-30,9,2008-04-10,2008-06-27,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eisai Limited,"A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor Flu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000801-30,0,0,0 2007-000805-32,1,2010-09-16,2010-09-16,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,The Royal Marsden NHS Foundation Trust,AN INVESTIGATION INTO THE ROLE OF PARACETAMOL (ACETAMINOPHEN) AT STEP 3 OF THE WHO ANALGESIC LADDER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000805-32,0,0,0 2007-000806-64,1,2014-11-11,2014-11-11,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Barts Health NHS Trust,"A Phase II Trial of Sequential treatment with Cytoreductive therapy and Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Relapsed/ Refractory Acute Myeloid Leukemia, High Risk M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000806-64,0,0,0 2007-000808-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Leiden University Medical Center,A comparison of remifentanil patient-controlled analgesia with epidural analgesia during labor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000808-32,0,0,0 2007-000810-35,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,BIOVOMED,Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25 ml JUNIOR in Healthy Children aged 3 - 15 Years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000810-35,0,0,0 2007-000811-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Ophthalmology, SEmmelweis University","Evaluation of additional intraocular pressure reduction with once daily, evening administration of travoprost 0.004%, once daily, evening administration of travoprost 0.004%/timolol 0.5% fixed combina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000811-27,0,0,0 2007-000814-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Luis Fernando López Cortés,Eficacia de dosis bajas de interferón pegilado alfa-2a junto con ribavirina en el tratamiento de la hepatopatía crónica por virus C (genotipos 2 o 3) en pacientes coinfectados por el VIH (Efficacy of ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000814-35,0,0,0 2007-000818-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CENTRE ANTOINE LACASSAGNE,Etude de phase III randomisée comparant deux modes d’administration des facteurs de croissance (G-CSF) non pégylés dans la prévention secondaire des neutropénies sévères,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000818-36,0,0,0 2007-000819-29,14,2011-10-04,2011-10-13,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,"A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated with Second-Line Docetaxel after Failure of One Platinum Based Therapy for Locally Advanced or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000819-29,0,0,0 2007-000819-29,14,2011-10-04,2011-10-13,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & de'veloppement,"A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated with Second-Line Docetaxel after Failure of One Platinum Based Therapy for Locally Advanced or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000819-29,0,0,0 2007-000820-42,13,2012-06-27,2012-06-29,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & de'veloppement,"A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients with Metastatic Colorectal Cancer (MCRC) Treated with Irinotecan /...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000820-42,0,0,0 2007-000820-42,13,2012-06-27,2012-06-29,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients with Metastatic Colorectal Cancer (MCRC) Treated with Irinotecan /...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000820-42,0,0,0 2007-000821-23,7,2016-03-31,2016-03-31,6,1,0,0,0,2,3,0,0,1,0,0,1,0,0,"Faculty of Medicine at Georg August University,Goettingen, Germany","A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000821-23,0,0,0 2007-000821-23,7,2016-03-31,2016-03-31,6,1,0,0,0,2,3,0,0,1,0,0,1,0,0,University Medicine Goettingen,"A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000821-23,0,0,0 2007-000821-23,7,2016-03-31,2016-03-31,6,1,0,0,0,2,3,0,0,1,0,0,1,0,0,"Faculty of Medicine at the Georg-August University, Göttingen","A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000821-23,0,0,0 2007-000823-16,2,2011-10-20,2011-10-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALLERGOPHARMA JOACHIM GANZER KG,"A multicenter, multinational, placebo-controlled, double-blind, randomized study to evaluate efficacy and safety of a perennial, sublingual specific immunotherapy in patielnts with rhinoconjunctivitis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000823-16,0,0,0 2007-000823-16,2,2011-10-20,2011-10-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergopharma Joachim Ganzer KG,"A multicenter, multinational, placebo-controlled, double-blind, randomized study to evaluate efficacy and safety of a perennial, sublingual specific immunotherapy in patielnts with rhinoconjunctivitis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000823-16,0,0,0 2007-000828-40,5,2010-12-10,2010-12-10,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFα Fab′ fragment, certolizumab pegol, a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000828-40,0,0,0 2007-000828-40,5,2010-12-10,2010-12-10,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB S.A. (Casa Madre),"A Phase IIIB, multi-centre, double-blind randomized, placebo-controlled, parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti-TNFα Fab′ fragment, certolizumab pegol, a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000828-40,0,0,0 2007-000830-38,5,2012-12-14,2012-12-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"A Phase IIIB, multi-centre open label, follow-up study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with DMARDs in subjects with active rheumatoid arthritis w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000830-38,0,0,0 2007-000830-38,5,2012-12-14,2012-12-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB S.A. (Casa Madre),"A Phase IIIB, multi-centre open label, follow-up study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with DMARDs in subjects with active rheumatoid arthritis w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000830-38,0,0,0 2007-000832-16,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Department of Anaesthesia, University College Hospital Galway",Determination of dermatomal distribution and duration of action for a catheter delivery system in the Transversus Abdominis Plane (TAP) block in continous infusion versus bolus local anaesthetic agent...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000832-16,0,0,0 2007-000835-24,7,2008-08-01,2008-08-27,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multi-centre, Double-blind, Double-Dummy, Placebo-controlled, Parallel Group, Randomised, Phase IIb Proof of Concept Study with 3 oral dose groups of AZD3480 or donepezil during 12 weeks treatment i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000835-24,0,0,0 2007-000838-39,8,,,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000838-39,0,0,0 2007-000838-39,8,,,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,"GlaxoSmithKline, S.A.",A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000838-39,0,0,0 2007-000838-39,8,,,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,GlaxoSmithKline Resaearch and Development Ltd,A Compassionate Use Open-Label Study of Anti IL-5 (Mepolizumab) Treatment in Subjects with Hypereosinophilic Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000838-39,0,0,0 2007-000841-36,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Rottapharm Madaus, Madaus GmbH","Multicenter, randomized, double-blind, placebo-controlled parallel group study to demonstrate the efficacy (quality of life) and safety of the standardized mistletoe extract PS76A2 during chemotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000841-36,0,0,0 2007-000842-11,1,2010-09-01,2010-09-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical University of Graz,99Tc labled Inliximab for evaluation of inflammatory activity in patients with inflammtory bowel disease (IBD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000842-11,0,0,0 2007-000847-89,1,2010-07-26,2010-07-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Moorfields Eye Hospital NHS Foundation Trust,Full Title of Study: Diabetic macular oedema: a prospective randomised trial of management with intravitreal bevacizumab (Avastin) versus conventional laser therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000847-89,0,0,0 2007-000851-33,1,2011-01-31,2011-01-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Medizinische Unversität Wien, Abteilung für Kinder- und Jugendheilkunde",Impact of oral application of Gastrografin on the meconium evacuation in very low birth weight infants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000851-33,0,0,0 2007-000854-30,10,2010-12-02,2012-07-27,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Salix Pharmaceuticals Inc,"A Randomized, Double-Blind, Placebo-Controlled Study of a Fixed Dose of Subcutaneous Methylnaltrexone in Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Additional ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000854-30,0,0,0 2007-000854-30,10,2010-12-02,2012-07-27,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Salix Pharmaceuticals Inc.,"A Randomized, Double-Blind, Placebo-Controlled Study of a Fixed Dose of Subcutaneous Methylnaltrexone in Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Additional ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000854-30,0,0,0 2007-000854-30,10,2010-12-02,2012-07-27,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Global Medical Affairs","A Randomized, Double-Blind, Placebo-Controlled Study of a Fixed Dose of Subcutaneous Methylnaltrexone in Adults With Advanced Illness and Opioid-Induced Constipation: Efficacy, Safety, and Additional ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000854-30,0,0,0 2007-000860-25,17,2011-12-20,2013-02-06,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, parallel-group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, aliskiren, on top of conve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000860-25,0,0,0 2007-000860-25,17,2011-12-20,2013-02-06,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled, parallel-group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, aliskiren, on top of conve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000860-25,0,0,0 2007-000860-25,17,2011-12-20,2013-02-06,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, SA","A randomized, double-blind, placebo-controlled, parallel-group study to determine whether, in patients with type 2 diabetes at high risk for cardiovascular and renal events, aliskiren, on top of conve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000860-25,0,0,0 2007-000863-73,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Philips,Protocol Placebo gecontroleerde dubbelblinde studie naar de behandeling van acne vulgaris van het gelaat met blauw licht en benzoylperoxide 5%.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000863-73,0,0,0 2007-000870-21,1,2010-12-29,2010-12-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,EVER Neuro Pharma GmbH,"Cerebrolysin and Recovery after Stroke (CARS) - A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase II Clinical Study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000870-21,0,0,0 2007-000871-41,1,2015-02-28,2015-02-28,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,RWTH Aachen,Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000871-41,0,0,0 2007-000872-18,12,2014-08-05,2014-08-05,8,1,1,0,0,1,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,"A 12- week randomized, double blind, placebo - controlled, parallel group, 2- arm study to evaluate the efficacy and safety of tocilizumab in patients with active systemic juvenile idiopathic arthriti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000872-18,1,0,0 2007-000872-18,12,2014-08-05,2014-08-05,8,1,1,0,0,1,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Limited,"A 12- week randomized, double blind, placebo - controlled, parallel group, 2- arm study to evaluate the efficacy and safety of tocilizumab in patients with active systemic juvenile idiopathic arthriti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000872-18,1,0,0 2007-000872-18,12,2014-08-05,2014-08-05,8,1,1,0,0,1,3,0,0,2,0,0,0,0,1,ROCHE,"A 12- week randomized, double blind, placebo - controlled, parallel group, 2- arm study to evaluate the efficacy and safety of tocilizumab in patients with active systemic juvenile idiopathic arthriti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000872-18,1,0,0 2007-000875-40,2,2007-07-07,2007-08-08,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Solvay Pharmaceuticals B.V.,"Immunogenicity and reactogenicity of the trivalent influenza subunit vaccine Influvac® for the season 2007/2008. An open, baseline-controlled multi-centre study in two groups of healthy subjects: Adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000875-40,0,0,0 2007-000885-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,academic hospital Maastricht,Open label study to establish the efficacy of intravenous loading doses of Ibandronate 6 mg in patients with lung cancer and skeletal metastased experiencing moderate to severe bone pain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000885-20,0,0,0 2007-000886-40,3,2009-10-16,2009-10-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Groupe,Assessment of the early efficacy response rate of leflunomide according to the initial dosing regimen in the treatment of naive - DMARD early RA-patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000886-40,0,0,0 2007-000886-40,3,2009-10-16,2009-10-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis groupe,Assessment of the early efficacy response rate of leflunomide according to the initial dosing regimen in the treatment of naive - DMARD early RA-patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000886-40,0,0,0 2007-000888-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Neurología,"ENSAYO CLÍNICO, MULTICÉNTRICO, CON ASIGNACIÓN ALEATORIA Y DOBLE CIEGO, PARA COMPARAR LA EFICACIA CLÍNICA Y RADIOLÓGICA DE DOSIS EQUIVALENTES DE METILPREDNISOLONA ADMINISTRADAS POR VÍA ORAL O VÍA INTRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000888-15,0,0,0 2007-000890-51,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Biosensors in the exhaled breath analysis: comparison between healthy and asthmatic adults and effect of montelukast and fluticasone on frequency pattern detected by biosensors in adults with asthma ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000890-51,0,0,0 2007-000891-17,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Biosensors in the exhaled breath analysis comparison between healthy and asthmatic children and effect of montelukast and fluticasone on frequency pattern detected by biosensors in children with ast...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000891-17,0,0,0 2007-000896-41,11,2011-03-30,2011-05-30,10,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals France, Wyeth Research Division","A RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE SAFETY AND EFFICACY OF ONCE-WEEKLY ADMINISTRATION OF ETANERCEPT 50 MG, ETANERCEPT 25 MG, AND PLACEBO IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000896-41,0,0,0 2007-000896-41,11,2011-03-30,2011-05-30,10,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA","A RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE SAFETY AND EFFICACY OF ONCE-WEEKLY ADMINISTRATION OF ETANERCEPT 50 MG, ETANERCEPT 25 MG, AND PLACEBO IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000896-41,0,0,0 2007-000896-41,11,2011-03-30,2011-05-30,10,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA","A RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE SAFETY AND EFFICACY OF ONCE-WEEKLY ADMINISTRATION OF ETANERCEPT 50 MG, ETANERCEPT 25 MG, AND PLACEBO IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000896-41,0,0,0 2007-000896-41,11,2011-03-30,2011-05-30,10,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals France,"A RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE SAFETY AND EFFICACY OF ONCE-WEEKLY ADMINISTRATION OF ETANERCEPT 50 MG, ETANERCEPT 25 MG, AND PLACEBO IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000896-41,0,0,0 2007-000896-41,11,2011-03-30,2011-05-30,10,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmceuticals Inc. A Pfizer Company, Philadelphia, PA-19101, USA","A RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE SAFETY AND EFFICACY OF ONCE-WEEKLY ADMINISTRATION OF ETANERCEPT 50 MG, ETANERCEPT 25 MG, AND PLACEBO IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000896-41,0,0,0 2007-000897-21,1,2009-09-14,2009-09-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"UCB, Inc.","A multi-center, double-blind, historical control, randomized conversion to monotherapy study with Keppra XR for treatment of partial onset seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000897-21,0,0,0 2007-000899-17,1,2010-03-31,2010-03-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"UCB, Inc.","An open-label, long-term follow-up study with Keppra XR for treatment of partial-onset seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000899-17,0,0,0 2007-000900-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Val d'Aurelle - Paul Lamarque,"Essai randomisé, en double aveugle, chez les femmes ménopausées ayant un cancer du sein RE+ comparant deux traitements néo-adjuvants : un anti-aromatase (Letrozole) VS un SERM (Tamoxifène). Effet sur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000900-34,0,0,0 2007-000901-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitair Ziekenhuis Antwerpen,A DOUBLE-BLIND? PLACEBO-CONTROLLED PARALLEL ARM TRIAL TO STUDY THE EFFICACY OF A SINGLE ORAL DOSE OF THE NUCLEOSIDE TRANSPORT INHIBITOR DIPYRIDAMOLE FOR PAIN RELIEF IN PATIENTS AFTER THIRD MOLAR SURGE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000901-31,0,0,0 2007-000902-55,3,2012-10-27,2012-10-27,3,0,0,0,0,1,2,0,0,1,0,0,1,0,0,EBMT (European Group for Blood and Marrow Transplantation),"Prospective Phase II Pilot study of Rabbit Antithymocyte globulin (ATG, Thymoglobuline®, Genzyme) with Ciclosporin for Patients with Acquired Aplastic Anaemia and comparison with matched historical pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000902-55,0,0,0 2007-000902-55,3,2012-10-27,2012-10-27,3,0,0,0,0,1,2,0,0,1,0,0,1,0,0,EBMT (European group for Blood and Marrow Transplantation),"Prospective Phase II Pilot study of Rabbit Antithymocyte globulin (ATG, Thymoglobuline®, Genzyme) with Ciclosporin for Patients with Acquired Aplastic Anaemia and comparison with matched historical pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000902-55,0,0,0 2007-000903-14,1,2010-06-15,2010-06-15,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"Imperial College, London",Randomized Phase III Trial to evaluate the effect of statins on tumour biology in non-small cell lung cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000903-14,0,0,0 2007-000904-33,1,2010-05-11,2010-05-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"LABORATORIOS LETI, S.L.U",Extracto alergénico de Glycyphagus domesticus. Determinación de la potencia alergénica in vivo en unidades equivalentes de histamina (HEP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000904-33,0,0,0 2007-000905-31,5,2008-08-19,2008-10-07,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A long term open label, flexiable dose, extension study evaluationg the safety and tolerability of Lu AA21004 in patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000905-31,0,0,0 2007-000907-13,1,2010-03-16,2010-03-16,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,"MUW, Innere Med III, Abt.für Endokrinologie & Stoffwechsel",The impact of Rimonabant in overweight women with prior gestational diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000907-13,0,0,0 2007-000911-27,1,2008-04-22,2008-04-22,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ORFAGEN,"Evaluation of the protection activity of microfine Ti02, pigmentary Ti02 and bisoctrizole and their combinations in voluntary patients with idiopathic solar urticaria (SU): phase II photoprovocation t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000911-27,0,0,0 2007-000912-97,5,2010-06-30,2010-07-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000912-97,0,0,0 2007-000912-97,5,2010-06-30,2010-07-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ELI LILLY,Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000912-97,0,0,0 2007-000912-97,5,2010-06-30,2010-07-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000912-97,0,0,0 2007-000913-13,3,2008-10-18,2008-12-20,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Lilly S.A.,"Phase 2 Study of Concurrent Carboplatin, Pemetrexed, and Radiotherapy for Limited Stage Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000913-13,0,0,0 2007-000913-13,3,2008-10-18,2008-12-20,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,ELI LILLY,"Phase 2 Study of Concurrent Carboplatin, Pemetrexed, and Radiotherapy for Limited Stage Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000913-13,0,0,0 2007-000913-13,3,2008-10-18,2008-12-20,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Eli Lilly and Company Limited,"Phase 2 Study of Concurrent Carboplatin, Pemetrexed, and Radiotherapy for Limited Stage Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000913-13,0,0,0 2007-000915-28,1,2008-08-25,2008-08-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Clavis Pharma ASA,"A multicentre, dose finding, phase II Study of CP-4055 in combination with Sorafenib in patients with metastatic malignant melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000915-28,0,0,0 2007-000919-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTI ORTOPEDICI RIZZOLI,Study on reversible effect on muscle of the botulinica toxin on the prevention of the post-traumatic rigidity of elbow,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000919-29,0,0,0 2007-000921-23,1,2008-10-31,2008-10-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-SCHERAX Arzneimittel GmbH,"A randomised, parallel-group, double-blind, placebo-controlled, multicentre Phase III trial assessing the pharmacodynamic efficacy and safety of an intraseasonal short-time updosing schedule for Aluta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000921-23,0,0,0 2007-000924-42,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,Sana Klinikum Lichtenberg,"Phase I/II-Studie zur neoadjuvanten Chemotherapie mit nicht-pegyliertem liposomalem Doxorubicin, Paclitaxel und Lapatinib bei Patientinnen mit HER2-überexprimierenden, primärem Mammakarzinomen",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000924-42,0,0,0 2007-000929-22,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,GlaxoSmithKline R & D Limited,"A double-blind, randomised, placebo controlled, three-period crossover study to investigate the pharmacodynamic effect of two CRF-1 antagonists GSK561679 and GW876008 on meal induced cortisol response...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000929-22,0,0,0 2007-000932-19,1,2008-11-10,2008-11-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,St Stephen's AIDS Trust,A phase IV study to assess the feasibility of substituting double ritonavir-boosted protease inhibitors (PI) with ritonavir-boosted darunavir (DRV/r) in HIV-infected individuals with viral suppression...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000932-19,0,0,0 2007-000934-38,1,2018-04-26,2018-04-26,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,Generex Biotechnology Corporation,"Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/neu Peptide GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2+ OR the Modified HER2/neu Peptide AE37 + GM-CSF Vaccine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000934-38,0,0,0 2007-000935-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ErasmusMC - Sophia Children's Hospital,‘Peripheral targeting of inhaled rhDNase in stable CF patients.’,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000935-25,0,0,0 2007-000936-21,1,2015-04-20,2015-04-20,1,1,0,0,1,0,3,0,0,1,1,1,1,0,0,Royal Brompton,"THE EFFECT ON ALVEOLAR NITRIC OXIDE OF SALMETEROL, FLUTICASONE, AND IN COMBINATION, IN STABLE BRONCHIECTASIS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000936-21,0,0,0 2007-000940-28,1,2009-02-10,2009-02-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospitals of Leicester NHS Trust,The Rimonabant in treatment of Prediabetes Study: a randomised clinical trial of Rimonabant in the treatment of patients with Prediabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000940-28,0,0,0 2007-000942-11,1,2011-12-31,2011-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Wien/ Universitätsklinik für Innere Medizin II/ Angiologie und Kardiologie,Vienna-Resistance to Antithrombotic Therapy (REACT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000942-11,0,0,0 2007-000945-36,6,2009-08-03,2009-11-27,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis groupe,"""A multicenter, randomized, double blind, placebo controlled Phase III study to assess the efficacy of xaliproden in patients with oxaliplatin-induced peripheral sensory neuropathy (PSN) following adj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000945-36,0,0,0 2007-000947-88,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,ISTITUTO AUXOLOGICO ITALIANO,Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects with Metabolic Syndrome and High-Normal Blood Pressure.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000947-88,0,0,0 2007-000950-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"H-PHAR,sa","Estudio piloto, doble ciego, aleatorizado, controlado con placebo, de dosis repetida, para la evaluación de la seguridad y la eficacia antiviral de HPH116 en pacientes infectados por VIH-1 que no haya...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000950-30,0,0,0 2007-000959-33,1,2007-12-18,2007-12-18,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,PARI GmbH,"Randomized, open labelled, cross over deposition study of Tobramycin 100 PARI nebulized with eFlow® versus TOBI® nebulized with PARI LC PLUS® in subjects with CF",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000959-33,0,0,0 2007-000960-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital de Cruces,Influencia del tratamiento con vitamina E sobre la composición ácido-graso de la membrana de espermatozoides de pacientes en programas de fertilización in vitro.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000960-25,0,0,0 2007-000963-28,2,2007-07-17,2007-07-17,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2007-2008, when Administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000963-28,0,0,0 2007-000963-28,2,2007-07-17,2007-07-17,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2007-2008, when Administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000963-28,0,0,0 2007-000964-26,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase II, Open Label, Uncontrolled, Multi-Center Study to support annual strain update and to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, (Adjuvanted with MF59C.1) Infl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000964-26,0,0,0 2007-000966-19,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, (Adjuvanted with MF59C.1) Influenza Vaccine, Formulation 2007-2008...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000966-19,0,0,0 2007-000968-25,2,2008-11-19,2009-03-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sintetica SA,"Prospective, blind observer, randomised clinical study to investigate and compare the efficacy of intrathecal plain solutions containing Chloroprocaine 1% (50 mg) versus Bupivacaine 0.5% (10 mg)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000968-25,0,0,0 2007-000968-25,2,2008-11-19,2009-03-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SINTETICA ITALIA S.R.L.,"Prospective, blind observer, randomised clinical study to investigate and compare the efficacy of intrathecal plain solutions containing Chloroprocaine 1% (50 mg) versus Bupivacaine 0.5% (10 mg)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000968-25,0,0,0 2007-000969-37,2,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Anthera Pharmaceuticals Incorporated,IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk Pat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000969-37,0,0,0 2007-000971-41,1,2011-03-02,2011-03-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo Gallego de Cáncer de Pulmón,"Estudio fase II de bevacizumab en combinación con vinorelbina y cisplatino, como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico,no epidermoide, estadio IIIB con derrame ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000971-41,0,0,0 2007-000972-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Pethema,"Estudio multicéntrico, no aleatorizado, abierto, para valorar la eficacia y la seguridad de la combinación de azacitidina y eritropoyetina beta en pacientes con síndromes mielodisplásicos (SMDs) depen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000972-18,0,0,0 2007-000973-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Karolinska University Hospital, Huddinge",Efficacy of cetuximab for preventing progression of CRC liver metastases after selective portal embolisation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000973-41,0,0,0 2007-000974-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Inserm,"Essai thérapeutique de phase II séquentiel non randomisé non contrôlé, multicentrique de traitement par everolimus de la maladie de Kaposi classique ou endémique.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000974-22,0,0,0 2007-000982-38,1,2011-07-20,2011-07-20,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Greenpark Health Care Trust,Pain and mobility outcomes following patient controlled lumbar plexus block for primary joint arthroplasty,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000982-38,0,0,0 2007-000983-26,5,2009-10-09,2009-10-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et développement,"12-week, multicenter, open-label, non-comparative study to investigate pharmacodynamic and safety of alfuzosin 0.2 mg/kg/day in the treatment of children and adolescents 2 - 16 years of age with hydro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000983-26,0,0,0 2007-000985-19,1,2014-06-01,2014-06-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Leuven,the effect of simvastatin (Zocor) on enhancement of ocular blood flow in glaucoma patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000985-19,0,0,0 2007-000986-40,1,2007-12-18,2007-12-18,1,1,0,0,0,3,2,0,1,1,0,0,1,0,1,Evotec NeurosciencesGmbH,"A double blind, placebo controlled study to investigate the role of NMDA receptor NR2B subunit selective antagonism on cognitive functions and neurophysiology in healthy subjects as measured with MRI",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000986-40,0,0,0 2007-000993-22,1,2007-10-30,2007-10-30,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,7TM Pharma A/S,"A multi-centre, randomized, double-blind, placebo-controlled, parallel-group study in obese subjects investigating weight loss after repeated, subcutaneous doses of TM30338",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000993-22,0,0,0 2007-000994-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Hospital General ""Gregorio Marañón""","ESTUDIO MULTICENTRICO PROSPECTIVO, DOBLE CIEGO, CONTROLADO CON PLACEBO, ALEATORIZADO, DE TRES GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO CON ERITROPOYETINA RECOMBINANTE HUMA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000994-40,0,0,0 2007-000995-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,EFFICACY AND TOLERABILITY OF TWO REPLACEMENT THERAPIES FOR AMENORRHEA IN CHILDREN TREATED FOR CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000995-18,0,0,0 2007-000998-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,Intra-erythrocytes dexamethasone in children with cortico-dependent nephrotic syndrome a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-000998-30,0,0,0 2007-001005-16,7,2008-08-20,2008-08-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A 26 week treatment, multi center, randomized, double-blind, double dummy, parallel group study with to assess the safety of indacaterol (300 and 600 ug o.d.) in patients with persistent asthma, using...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001005-16,0,0,0 2007-001005-16,7,2008-08-20,2008-08-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 26 week treatment, multi center, randomized, double-blind, double dummy, parallel group study with to assess the safety of indacaterol (300 and 600 ug o.d.) in patients with persistent asthma, using...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001005-16,0,0,0 2007-001005-16,7,2008-08-20,2008-08-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 26 week treatment, multi center, randomized, double-blind, double dummy, parallel group study with to assess the safety of indacaterol (300 and 600 ug o.d.) in patients with persistent asthma, using...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001005-16,0,0,0 2007-001006-24,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,CHU Gabriel Montpied,Effet du tramadol sur la sensibilisation centrale à la douleur chez le sujet volontaire sain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001006-24,0,0,0 2007-001007-38,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ORPHAN,STUDY OF THE LONG TERM BIOLOGICAL EFFICACY AND TOLERABILITY OF VEDROP (VITAMIN E-TPGS FORMULATION) AFTER DAILY ORAL ADMINISTRATION IN 30 PAEDIATRIC PATIENTS WITH CYSTIC FIBROSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001007-38,0,0,0 2007-001012-23,1,2007-06-07,2007-06-07,1,1,0,0,0,0,2,1,0,1,0,0,1,0,1,Auxilium UK Limited,"A Randomized, Double-Blind, Two-Way Crossover Study to Determine the Bioequivalence of a Single Dose of Testim® 1% With Pentadecalactone 1% Relative to a Single Dose of Testim® 1% With Pentadecalacton...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001012-23,0,0,0 2007-001013-41,2,2009-01-09,2009-01-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,NovartisPharma Services AG,"A randomized, double-blind, placebo-controlled study to demonstrate the efficacy of Xolair in an allergen bronchoprovocation study in two asthmatic populations defined by serum IgE concentrations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001013-41,0,0,0 2007-001013-41,2,2009-01-09,2009-01-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled study to demonstrate the efficacy of Xolair in an allergen bronchoprovocation study in two asthmatic populations defined by serum IgE concentrations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001013-41,0,0,0 2007-001014-17,4,2009-09-10,2009-09-23,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Alfa Wassermann S.p.A.,"A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Cr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001014-17,0,0,0 2007-001014-17,4,2009-09-10,2009-09-23,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALFA WASSERMANN,"A Phase II, multicentre, double-blind, randomized, dose range finding placebo controlled study of Rifaximin- EIR tablet: clinical effectiveness and tolerability in the treatment of moderate, active Cr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001014-17,0,0,0 2007-001015-28,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CHU TOURS,"Single-agent rituximab as maintenance treatment versus observation after combined induction immunochemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) in patients older than 65 years wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001015-28,0,0,0 2007-001028-11,2,2009-01-15,2009-01-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Moberg Derma AB,"A double-blind, placebo-controlled study of efficacy, safety and tolerability of topical Kaprolac® K70 in six months treatment of distal subungual onychomycosis (DSO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001028-11,0,0,0 2007-001029-84,3,2011-05-31,2011-05-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergopharma Joachim Ganzer KG,"A multicentre randomised, placebo-controlled, double-blind pivotal clinical trial for the evaluation of safety and efficacy of specific of immunotherapy with an aluminium hydroxide-adsorbed hypoallerg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001029-84,0,0,0 2007-001030-13,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,IMAS,PREVENCIÓN DE LA PÉRDIDA DE MASA ÓSEA EN MUJERES POSTMENOPÁUSICAS CON OSTEOPENIA EN COLUMNA LUMBAR (PREPEMO) PREVENTION OF BONE DENSITY LOSS IN LUMBAR SPINE IN OSTEOPENIC POSTMENOPAUSAL WOMEN (PREPEM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001030-13,0,0,0 2007-001031-63,2,2008-10-21,2008-10-21,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Avigen Inc,"AV650-018: A two-part (double-blind followed by open-label), placebo-controlled, randomized trial to assess the safety, tolerability, and preliminary efficacy of AV650 (tolperisone HCl) in subjects wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001031-63,0,0,0 2007-001034-14,1,2009-09-30,2009-09-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,2,St George's Healthcare NHS Trust,The effect of omega-3 fatty acids on Barrett's oesophagus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001034-14,0,0,0 2007-001034-14,1,2009-09-30,2009-09-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,2,SLA Pharma,The effect of omega-3 fatty acids on Barrett's oesophagus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001034-14,0,0,0 2007-001035-58,3,2008-10-02,2008-10-07,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE SAFETY AND EFFICACY OF MARAVIROC (UK-427,857) IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN SUBJECTS RECEI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001035-58,0,0,0 2007-001035-58,3,2008-10-02,2008-10-07,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S. A.","A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE SAFETY AND EFFICACY OF MARAVIROC (UK-427,857) IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN SUBJECTS RECEI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001035-58,0,0,0 2007-001035-58,3,2008-10-02,2008-10-07,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street,New York, NY 10017","A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE SAFETY AND EFFICACY OF MARAVIROC (UK-427,857) IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN SUBJECTS RECEI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001035-58,0,0,0 2007-001036-31,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent. UK. CT13 9NJ","A 2-COHORT, MULTI-CENTRE, RANDOMIZED, DOUBLE BLIND (3RD PARTY OPEN), PLACEBO CONTROLLED 4-WAY CROSSOVER STUDY TO ASSESS THE EFFICACY OF SINGLE ORAL DOSES OF PF-00446687 ON ERECTILE FUNCTION IN MEN SUF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001036-31,0,0,0 2007-001037-34,2,2008-02-25,2008-02-25,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent. UK. CT13 9NJ","PHASE 2A MULTI-CENTRE, DOUBLE BLIND (3RD PARTY OPEN), PLACEBO CONTROLLED 3-WAY CROSS-OVER STUDY TO INVESTIGATE THE EFFECT OF SINGLE DOSES OF PF-00446687 ON SEXUAL AROUSAL AND SEXUAL DESIRE IN WOMEN SU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001037-34,0,0,0 2007-001039-72,1,2016-11-28,2016-11-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Cambridge University Hospitals NHS Foundation Trust, jointly with University of Cambridge",Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001039-72,0,0,0 2007-001041-17,19,2015-06-19,2015-07-29,18,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,"An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001041-17,0,0,0 2007-001041-17,19,2015-06-19,2015-07-29,18,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN S.P.A.,"An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001041-17,0,0,0 2007-001043-22,2,2007-12-17,2013-07-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme Europe BV,"A Multicenter, Open-Label Study of Hectorol (doxercalciferol capsules) for the Treatment of Secondary Hyperparathyroidism in Stage 3 or Stage 4 Chronic Kidney Disease (CKD) Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001043-22,0,0,0 2007-001044-44,6,2009-09-14,2009-09-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec BVBA,"A Phase IIa randomized, open-label study of telaprevir (VX-950) administered every 12 or every 8 hours in combination with either Peg-IFN alfa2a (Pegasys) and ribavirin (Copegus) or Peg-IFN alfa2b (P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001044-44,0,0,0 2007-001044-44,6,2009-09-14,2009-09-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TIBOTEC BVBA,"A Phase IIa randomized, open-label study of telaprevir (VX-950) administered every 12 or every 8 hours in combination with either Peg-IFN alfa2a (Pegasys) and ribavirin (Copegus) or Peg-IFN alfa2b (P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001044-44,0,0,0 2007-001046-41,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Nottingham University Hospital NHS Trust (Research & Development),Effectiveness of GANfort® in reducing intraocular pressure in patients presenting with significantly elevated intraocular pressure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001046-41,0,0,0 2007-001048-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU SAINT-ETIENNE,"Prospective, multicentre, open-label study evaluating Fondaparinux (1,5 mg/day) in venous thromboembolic events prevention in patients with renal impairment defined by a creatinin clearance between 20...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001048-32,0,0,0 2007-001049-16,1,2008-08-27,2008-08-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"A multi-centre, randomised, double blind, parallel group study to investigate the efficacy and tolerability of treatment (24 weeks double blind phase followed by open-label extension) with either v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001049-16,0,0,0 2007-001051-19,3,2008-06-16,2008-06-16,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A double-blind, randomized, cross-over, placebo-controlled, 2-part study to compare the effect of exercise and high-dose salbutamol on maximal heart-rate in patients with COPD following therapeutic do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001051-19,0,0,0 2007-001051-19,3,2008-06-16,2008-06-16,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A double-blind, randomized, cross-over, placebo-controlled, 2-part study to compare the effect of exercise and high-dose salbutamol on maximal heart-rate in patients with COPD following therapeutic do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001051-19,0,0,0 2007-001052-39,1,2014-08-08,2014-08-08,1,1,0,0,0,1,3,0,0,1,1,1,1,0,0,University Medicine Goettingen,Auto-versus Allotransplantation in T-NHL - Autologous or allogeneic transplantation following conventional chemotherapy in younger patients (18-60 yrs.) with mature (peripheral) T-cell lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001052-39,0,0,0 2007-001058-16,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,PIERRE FABRE MEDICAMENT,A PHASE II DOUBLE-BLIND VEHICLE-CONTROLLED CROSSOVER SINGLE DOSE (400 µG) V0147 GEL EFFECT AND TOLERANCE STUDY IN SPINAL CORD INJURED PATIENTS WITH ERECTILE DYSFUNCTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001058-16,0,0,0 2007-001060-80,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ABIOGEN PHARMA,"A multicenter, parallel-group, double-blind, randomized, placebo-controlled, increasing-dose study, to evaluate preliminarily the clinical effects, the safety and tolerability of ABIO 08/01, in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001060-80,0,0,0 2007-001061-14,4,2009-06-09,2009-11-13,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pharmasset, Inc.","A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001061-14,0,0,0 2007-001063-30,4,2009-05-31,2009-11-13,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pharmasset, Inc.","A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001063-30,0,0,0 2007-001068-55,1,2009-03-27,2009-03-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Clinuvel Pharmaceuticals Limited,"A Phase II, Open Label Pilot Study to Evaluate the Safety and Efficacy of A Bioresorbable Subcutaneous Implant of CUV1647 in Patients with Solar Urticaria (SU)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001068-55,0,0,0 2007-001069-14,1,2008-10-27,2008-10-27,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Aktion Bronchialkarzinom e.V.,"A phase II open-label, multi-centre, randomised, prospective, parallel-group study comparing Topotecan/Carboplatin administered 5 days versus 3 days versus Topotecan monotherapy daily x 5 as second li...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001069-14,0,0,0 2007-001071-11,8,2007-12-26,2009-03-13,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,H. Lundbeck a/s,"Randomised, double-blind, parallel-group, placebo-controlled, duloxetine referenced, dose-finding study of Lu AA24530 in Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001071-11,0,0,0 2007-001071-11,8,2007-12-26,2009-03-13,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Randomised, double-blind, parallel-group, placebo-controlled, duloxetine referenced, dose-finding study of Lu AA24530 in Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001071-11,0,0,0 2007-001073-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fernando Lago Deibe,"Ensayo clínico prospectivo, en fase IV, controlado, aleatorizado, doble ciego y en grupos paralelos para evaluar la efectividad y seguridad de la vacunación antitetánica en pacientes en tratamiento co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001073-29,0,0,0 2007-001078-94,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Radboud University medical centre,Treatment of dumping syndrome with Lanreotide Autogel,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001078-94,0,0,0 2007-001080-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Toulouse,Etude de pharmacocinétique de population du linézolide chez des patients de réanimation présentant une infection sévère à Staphylocoque doré méticillino-résistant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001080-29,0,0,0 2007-001082-15,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Institut Paoli Calmette,Etude de Phase I-II multicentrique de l'association Cloretazine-Daunorubicine-Aracytine dans le traitement des leucémies aigües myéloïdes du groupe cytogénétique défavorable.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001082-15,0,0,0 2007-001088-32,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""","A PHASE II RANDOMIZED, DOUBLE-BLIND STUDY VS. PLACEBO FOR THE EVALUATION OF EFFICACY AND TOLERABILITY OF SALBUTAMOL ADMINISTERED BY ORAL ROUTE IN PATIENTS AFFECTED BY SPINAL MUSCULAR ATHROPHY.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001088-32,0,0,0 2007-001089-33,1,2013-01-01,2013-01-01,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,"University Medical Center Groningen, dept. of Cardiology",Infusion of a single dose of erythropoietin to Prevent Injury in an Ischemia Reperfusion forearm model - A randomised cross-over study to evaluate if infusion of a single dose of EPO protects against ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001089-33,0,0,0 2007-001089-33,1,2013-01-01,2013-01-01,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,"University Medical Center Nijmegen, dept. of Pharmacology-Toxicology",Infusion of a single dose of erythropoietin to Prevent Injury in an Ischemia Reperfusion forearm model - A randomised cross-over study to evaluate if infusion of a single dose of EPO protects against ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001089-33,0,0,0 2007-001094-29,1,2015-03-15,2015-03-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Klinikum der LMU,"Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Biological Targeted Treatment SUCCESS B-Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001094-29,0,0,0 2007-001095-36,2,2008-04-24,2008-04-24,1,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Solvay Pharmaceuticals,"The Van Gogh Study: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 as Adjunct Therapy to L-dopa in Patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001095-36,0,0,0 2007-001096-10,2,2008-04-24,2008-04-24,1,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Solvay Pharmaceuticals,An Extension of the Van Gogh Study: An Open Label SLV308 Safety Extension to Study S308.3.004 in Patients with Parkinson’s Disease Experiencing Motor Fluctuations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001096-10,0,0,0 2007-001097-90,2,2009-06-19,2009-06-19,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,H. Lundbeck A/S,"A one-year multinational, multi-centre, randomised, double-blind, parallel-group, fixed-dose, bifeprunox study combining a 12 week placebo-controlled, quetiapine-referenced phase with a 12-month queti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001097-90,0,0,0 2007-001103-37,1,2012-07-03,2012-07-03,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"An open-label, multicentre, non-randomised, dose-escalating phase I/II study, with a randomized phase II part, to investigate the safety and tolerability of RO5072759 given as monotherapy in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001103-37,0,0,0 2007-001104-21,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"VU Cancer Centre, Afdeling Geneeskundige Oncologie",A PHASE I/II TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS (DELTA-24-RGD) ADMINISTERED BY CONVECTION ENHANCED DELIVERY IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001104-21,0,0,0 2007-001105-13,6,2014-09-22,2014-12-19,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomised, multicenter, multinational Phase II study on trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab in patients with locally adv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001105-13,0,0,0 2007-001105-13,6,2014-09-22,2014-12-19,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"F. Hoffmann-La Roche Ltd, Pharmaceuticals Division, PDR","A randomised, multicenter, multinational Phase II study on trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab in patients with locally adv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001105-13,0,0,0 2007-001105-13,6,2014-09-22,2014-12-19,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Hoffman - La Roche,"A randomised, multicenter, multinational Phase II study on trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab in patients with locally adv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001105-13,0,0,0 2007-001107-38,1,2012-04-18,2012-04-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cefak KG,"Dose finding study to investigate efficacy and tolerability of a 6 month oral treatment with selenium in patients with autoimmune thyroiditis: prospective, controlled parallel group study with Cefasel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001107-38,0,0,0 2007-001108-19,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SAKK - GRUPPO SVIZZERO DI RICERCA CLINICA SUL CANCRO,Master protocol for mantle cell lymphoma A multicenter stratified phase II trial testing Everolimus (RAD001) for the treatment of patients with newly diagnosed and relapsed or therapy resistant mant...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001108-19,0,0,0 2007-001108-19,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SAKK,Master protocol for mantle cell lymphoma A multicenter stratified phase II trial testing Everolimus (RAD001) for the treatment of patients with newly diagnosed and relapsed or therapy resistant mant...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001108-19,0,0,0 2007-001109-26,1,2012-07-19,2012-07-19,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Oxford BioMedica (UK) Ltd,"A phase I/II study of the safety, efficacy and dose evaluation of ProSavin®, administered using stereotactic injection to the striatum of patients with bilateral, idiopathic Parkinson’s disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001109-26,0,0,0 2007-001114-17,1,2011-01-26,2011-01-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Limited,"A Mechanism of Action study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) on lipids, arterial stiffness, and markers of atherogenic risk in patients with moderate to severe ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001114-17,0,0,0 2007-001116-22,12,2010-11-15,2012-03-07,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck & Co., Inc.",A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001116-22,0,0,0 2007-001116-22,12,2010-11-15,2012-03-07,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MSD ITALIA S.R.L.,A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001116-22,0,0,0 2007-001116-22,12,2010-11-15,2012-03-07,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme,A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001116-22,0,0,0 2007-001116-22,12,2010-11-15,2012-03-07,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Europe) Inc.,A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001116-22,0,0,0 2007-001116-22,12,2010-11-15,2012-03-07,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Laboratoires Merck Sharp & Dohme - Chibret,A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001116-22,0,0,0 2007-001116-22,12,2010-11-15,2012-03-07,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MSD Finland Oy,A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001116-22,0,0,0 2007-001116-22,12,2010-11-15,2012-03-07,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Corp.,A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001116-22,0,0,0 2007-001116-22,12,2010-11-15,2012-03-07,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme de España, S.A.",A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001116-22,0,0,0 2007-001116-22,12,2010-11-15,2012-03-07,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001116-22,0,0,0 2007-001116-22,12,2010-11-15,2012-03-07,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck & Co., Inc",A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001116-22,0,0,0 2007-001116-22,12,2010-11-15,2012-03-07,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,A Phase II/II Study of MK-0646 Treatment in Combination with Cetuximab and Irinotecan for Patients with Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001116-22,0,0,0 2007-001117-42,2,2008-11-05,2008-11-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen Cilag International NV,"A Randomized, Open-Label, Multicenter Study to Assess the Safety and Tolerability of Doripenem Compared With Imipenem in the Treatment of Subjects With Complicated Intra-Abdominal Infections or Ventil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001117-42,0,0,0 2007-001121-10,1,2008-09-23,2008-09-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,NeuroSearch A/S,Evaluation of long term safety of tesofensine in patients with obesety.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001121-10,0,0,0 2007-001122-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Västra Götalandsregionen,Tailored treatment of hepatitis C genotype 1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001122-27,0,0,0 2007-001123-35,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO DERMOPATICO IMMACOLATA,PHASE II STUDY OF DOCETAXEL AND OXALIPLATIN ASSOCIATION AS I LINE THERAPY IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS: SCHEDULE-DEPENDENT ACTIVITY AND MOLECULAR TARGETS EVALUATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001123-35,0,0,0 2007-001125-97,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,alberto forteza,Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001125-97,0,0,0 2007-001128-11,14,2012-02-29,2014-09-30,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001128-11,0,0,0 2007-001128-11,14,2012-02-29,2014-09-30,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001128-11,0,0,0 2007-001128-11,14,2012-02-29,2014-09-30,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"F. Hoffmann-La Roche Ltd, Pharmaceuticals Divison, PDR",An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001128-11,0,0,0 2007-001130-13,1,2013-10-07,2013-10-07,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Malmö University Hospital,"Hepatitis C in a cohort of patients with maintenance therapy for opiate dependence - prevalence, severity and outcome of antiviral therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001130-13,0,0,0 2007-001131-61,1,2013-11-19,2013-11-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Belgian Group of Digestive Oncology,A national randomised multi-centre trial to assess the effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001131-61,0,0,0 2007-001139-71,3,2008-10-07,2008-11-03,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects with Diabetic Neuropathic Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001139-71,0,0,0 2007-001140-47,6,2008-12-02,2008-12-23,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-894 versus Placebo in Subjects with Diabetic Neuropathic Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001140-47,0,0,0 2007-001150-87,11,2010-09-30,2010-10-04,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Astellas Pharma Europe B.V.,"A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study to Investigate the Safety and Tolerability of YM150 in Subjects with Non-Valvular Atrial Fibrillation and to Compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001150-87,0,0,0 2007-001151-19,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Sint Maartenskliniek,Placebo controlled trial to evaluate the effect on pain and function of six months treatment doxycycline in established knee osteoarthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001151-19,0,0,0 2007-001152-39,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Scandinavian Sarcoma Group,A Scandinavian Sarcoma Group treatment protocol for adult patients with non-metastatic high-risk soft tissue sarcoma of the extremities and trunk wall,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001152-39,0,0,0 2007-001159-20,1,2016-05-09,2016-05-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,"A Prospective, Multi-centre, Single-Arm, Open Label Study of the Long term Use of a LHRH Agonist (Decapeptyl® SR, 11.25 mg) in Combination with Livial® Add-back Therapy in the Management of Chronic Cy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001159-20,0,0,0 2007-001161-14,6,2011-04-27,2011-05-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme Corporation,"A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Relapsi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001161-14,0,0,0 2007-001162-32,12,2011-09-15,2011-09-15,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme Corporation,"A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001162-32,0,0,0 2007-001163-30,1,,,0,1,0,0,0,1,2,0,0,4,0,0,0,0,1,"Genzyme, a Sanofi Company",A trial of antigen-specific immune tolerance induction in mucopolysaccharidosis I (MPS I) patients initiating enzyme replacement therapy with Aldurazyme® (laronidase),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001163-30,0,1,1 2007-001165-15,1,2012-02-10,2012-02-10,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Hospital of Wuerzburg,Sunitinib in Refractory Adrenocortical-Carcinoma patients progressing after cytotoxic chemotherapy (SIRAC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001165-15,0,0,0 2007-001166-33,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Universitaetsklinikum Erlangen-Nuernberg,"A prospective, randomised, multicenter clinical trial investigating the reduction of Calcineurin inhibitor toxicity by means of steroid free long-term immune suppression with Ciclosporin A and Mycophe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001166-33,0,0,0 2007-001167-29,1,2008-12-30,2008-12-30,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A phase IIIb multi-centre, open, controlled study to assess the immunogenicity, reactogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Haemophilus influenzae type b – meningococcal serogroup ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001167-29,0,0,0 2007-001168-55,1,2008-04-12,2008-04-12,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Teikoku Pharma USA, Inc.","A Multi Center Randomized, Double-Blind, Placebo-Controlled Trial of Flurbiprofen Patch for Treatment of Chronic Low Back Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001168-55,0,0,0 2007-001170-92,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Dexamethasone for postoperative pain relief following tonsillectomy in children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001170-92,0,0,0 2007-001172-36,1,2011-03-07,2011-03-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,Donepezil and Memantine in moderate to severe Alzheimer's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001172-36,0,0,0 2007-001174-81,3,2014-01-31,2014-01-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,GOF pancreatic cancer collaborative group,RANDOMIZED MULTICENTER PHASE III STUDY IN PATIENTS WITH LOCALLY ADVANCED ADENOCARCINOMA OF THE PANCREAS: GEMCITABINE WITH OR WITHOUT CHEMORADIOTHERAPY AND WITH OR WITHOUT ERLOTINIB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001174-81,0,0,0 2007-001174-81,3,2014-01-31,2014-01-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,ULB Erasme Hospital,RANDOMIZED MULTICENTER PHASE III STUDY IN PATIENTS WITH LOCALLY ADVANCED ADENOCARCINOMA OF THE PANCREAS: GEMCITABINE WITH OR WITHOUT CHEMORADIOTHERAPY AND WITH OR WITHOUT ERLOTINIB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001174-81,0,0,0 2007-001174-81,3,2014-01-31,2014-01-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,GERCOR,RANDOMIZED MULTICENTER PHASE III STUDY IN PATIENTS WITH LOCALLY ADVANCED ADENOCARCINOMA OF THE PANCREAS: GEMCITABINE WITH OR WITHOUT CHEMORADIOTHERAPY AND WITH OR WITHOUT ERLOTINIB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001174-81,0,0,0 2007-001176-37,1,2011-03-03,2011-03-03,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,NHS Tayside,"A randomised, controlled trial to determine the median effective concentration of bupivacaine, levobupivacaine and ropivacaine after intrathecal and extradural injection for pain relief in the first s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001176-37,0,0,0 2007-001179-13,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Dutch Cancer Society,Neo-adjuvant Simvastatin therapy in colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001179-13,0,0,0 2007-001185-32,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Protocol for the experimental study about Peritonectomy (CCR) associated with Chemo-Hyperthermic intra-peritonel (CHIP) treatment for primary or secondary peritoneal neoplastic desease (Peritoneal Car...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001185-32,0,0,0 2007-001187-78,1,2012-07-25,2012-07-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,The 3Mg Trial: A randomised controlled trial of intravenous or nebulised magnesium sulphate versus standard therapy for acute severe asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001187-78,0,0,0 2007-001190-28,1,2011-12-14,2011-12-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001190-28,0,0,0 2007-001193-81,1,2008-09-26,2008-09-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,EGIS Gyógyszergyár Nyrt.,"KETILEPT® hatékonyságának és biztonságosságának ellenőrzése szkizofrénia és szkizoaffektiv betegség akut epizódjának kezelésében, multicentrikus, nyílt, megfigyeléses vizsgálatban (Controll of ef...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001193-81,0,0,0 2007-001194-29,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Universität Leipzig,"An open-label, multi-center Phase I/II trial evaluating the safety and efficacy of azacitidine (Vidaza®) in patients with acute myeloid leukaemia not eligible for or resistant to chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001194-29,0,0,0 2007-001195-36,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,All Ireland Cooperative Oncology Research Group (ICORG),"A Randomised Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001195-36,0,0,0 2007-001196-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Laboratoire BOIRON,Etude d’évaluation de l’effet de Cuprum Metallicum 15 CH sur les crampes musculaires survenant en cours de dialyse chez des patients hémodialysés chroniques. Effect of Cuprum Metallicum 15 CH on musc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001196-10,0,0,0 2007-001197-93,2,2008-09-04,2008-09-04,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"CrystalGenomics, Inc.","Double-blind, placebo controlled Phase II repeat dose study of the safety and efficacy of three parallel loading and maintenance dose regimens of CG100649 versus placebo for the treatment of primary o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001197-93,0,0,0 2007-001200-20,2,2010-07-27,2010-07-27,1,0,0,0,0,1,2,0,0,2,0,0,0,0,0,Medizinische Hochschule Hannover,"A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine – Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001200-20,1,0,0 2007-001200-20,2,2010-07-27,2010-07-27,1,0,0,0,0,1,2,0,0,2,0,0,0,0,0,Institut Gustave Roussy,"A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine – Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001200-20,1,0,0 2007-001205-17,1,,,0,0,0,0,0,0,4,0,1,1,1,1,0,1,0,Medizinische Universität Graz_Universitätsklinik für Innere Medizin_Diabetes und Stoffwechsel,"An open, mono-centre study to investigate the effect of the local application of an anti-inflammatory agent on the concentration of different cytokines in interstitial fluid af subcutaneous adipose ti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001205-17,0,0,0 2007-001206-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UMCG,Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001206-24,0,0,0 2007-001209-64,1,2016-09-26,2016-09-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Centre Hospitalier Universitaire de Nantes,Etude multicentrique de phase III randomisée ouverte testant l’efficacité du gemtuzumab ozogamycin (MYLOTARG®) en association avec la chimiothérapie intensive chez les patients de 18 à 60 ans atteints...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001209-64,0,0,0 2007-001211-33,6,2012-02-23,2012-04-24,4,1,1,0,0,2,2,0,0,2,1,0,0,0,1,sanofi-aventis recherche & de'veloppement,International randomized study to evaluate the addition of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF) in the induction treatment of nasopharyngeal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001211-33,1,1,0 2007-001211-33,6,2012-02-23,2012-04-24,4,1,1,0,0,2,2,0,0,2,1,0,0,0,1,sanofi-aventis recherche & développement,International randomized study to evaluate the addition of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF) in the induction treatment of nasopharyngeal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001211-33,1,1,0 2007-001214-16,6,2009-02-12,2009-04-30,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,BioXell SpA,"A randomized, double blind, placebo controlled, parallel-group, multi-centre, Phase IIb, study to determine the effect of BXL628 in women with detrusor overactivity",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001214-16,0,0,0 2007-001214-16,6,2009-02-12,2009-04-30,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,BIOXELL SPA,"A randomized, double blind, placebo controlled, parallel-group, multi-centre, Phase IIb, study to determine the effect of BXL628 in women with detrusor overactivity",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001214-16,0,0,0 2007-001216-23,1,2007-12-31,2007-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Phoenux AG,Phase I Studie bei substituirten chronischen Opiatgebrauchern zur Aufhebung zusätzlicher Opioidwirkungen einer weiteren Opiatgebrauchern zur Aufhebung zusätlicher Opioidwirkungen einer weiteren Opiatd...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001216-23,0,0,0 2007-001217-42,10,2009-01-23,2019-03-17,7,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Bristol Myers Squibb International Corporation,"A 16-Week, Multicenter, Randomized, Open-label Study to Assess the Effects of Aripiprazole versus other Atypical Antipsychotics in the Treatment of Schizophrenic Patients with Metabolic Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001217-42,0,0,0 2007-001219-44,8,2012-08-29,2012-09-07,7,1,0,0,0,0,0,0,0,1,0,0,1,0,2,,Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-2...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001219-44,0,0,0 2007-001219-44,8,2012-08-29,2012-09-07,7,1,0,0,0,0,0,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-2...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001219-44,0,0,0 2007-001219-44,8,2012-08-29,2012-09-07,7,1,0,0,0,0,0,0,0,1,0,0,1,0,2,BOEHRINGER ING.,Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-2...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001219-44,0,0,0 2007-001219-44,8,2012-08-29,2012-09-07,7,1,0,0,0,0,0,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A.",Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-2...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001219-44,0,0,0 2007-001219-44,8,2012-08-29,2012-09-07,7,1,0,0,0,0,0,0,0,1,0,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co KG,Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-2...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001219-44,0,0,0 2007-001219-44,8,2012-08-29,2012-09-07,7,1,0,0,0,0,0,0,0,1,0,0,1,0,2,Boehringer Ingelheim France,Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-2...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001219-44,0,0,0 2007-001219-44,8,2012-08-29,2012-09-07,7,1,0,0,0,0,0,0,0,1,0,0,1,0,2,Boehringer Ingelheim Ltd,Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-2...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001219-44,0,0,0 2007-001219-44,8,2012-08-29,2012-09-07,7,1,0,0,0,0,0,0,0,1,0,0,1,0,2,SCS Boehringer Ingelheim Comm.V,Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with tenecteplase and additional antiplatelet and antithrombin therapy followed by catheterisation within 6-2...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001219-44,0,0,0 2007-001221-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Rigshospitalet, University of Copenhagen",Postconditioning used for the limitation of infarct size in patients with ST-elevation myocardial infarction (POSTCON).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001221-10,0,0,0 2007-001222-27,1,2010-04-01,2010-04-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London,The effect of Pioglitazone on vascular and ventricular function in people with type 2 diabetes PICCOLA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001222-27,0,0,0 2007-001256-39,3,2010-07-16,2013-07-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Bristol-Myers Squibb International Corporation,"A Randomized, Double-Blind, Parallel, Three Arm, Multicenter, Phase II Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Taxol/Paraplatin (Paclitaxel/Carboplatin)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001256-39,0,0,0 2007-001257-25,2,2008-04-28,2008-04-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"Ensayo clínico en fase 2 de búsqueda de dosis, multicéntrico, doble- ciego, aleatorizado y controlado con placebo para investigar la eficacia, seguridad, tolerancia y farmacocinética del inhibidor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001257-25,0,0,0 2007-001262-32,1,2012-10-12,2012-10-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH,"Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001262-32,0,0,0 2007-001264-72,1,2010-10-13,2010-10-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Oxford Radcliffe Hospitals NHS Trust,A Phase II Trial of Erlotinib as first line therapy in Non- Small Cell Lung Cancer over-expressing EGFR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001264-72,0,0,0 2007-001268-57,4,2008-08-18,2008-08-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Astellas Pharma US, Inc.","A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate with 0.4 mg Tamsulosin Hydrochlorid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001268-57,0,0,0 2007-001269-14,3,2009-02-03,2009-02-03,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BRISTOL-M.SQUIBB,A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovir versus Adefovir Added to Continuing Lamivudine in Adults with Lamivudine Resistant Chronic Hepatitis B Virus Infect...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001269-14,0,0,0 2007-001269-14,3,2009-02-03,2009-02-03,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovir versus Adefovir Added to Continuing Lamivudine in Adults with Lamivudine Resistant Chronic Hepatitis B Virus Infect...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001269-14,0,0,0 2007-001271-11,5,2007-12-12,2008-08-19,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Daiichi Sankyo Pharma Development,"A PHASE 2, RANDOMIZED, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR THE EVALUATION OF SAFETY OF FOUR FIXED DOSE REGIMENS OF DU-176b IN SUBJECTS WITH NON-VALVULAR ATRIAL FIBRILLATION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001271-11,0,0,0 2007-001280-30,1,2013-11-08,2013-11-08,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,LFB SA,INTERNATIONAL NON -CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF FIBRINOGENE T-I IN ADOLESCENTS AND ADULTS WITH AFIBRINOGENAEMIA OR SEVERE HYPOFIBRINOGENAEMIA UNDERGOING SURGERY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001280-30,0,0,0 2007-001281-33,1,2013-12-31,2013-12-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Belfast Health and Social Care Trust,A randomised control trial of alternative treatments to Inhibit VEGf in Age-related choroidal Neovascularisation(IVAN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001281-33,0,0,0 2007-001281-33,1,2013-12-31,2013-12-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Queen's University Belfast, Research and Regional Services",A randomised control trial of alternative treatments to Inhibit VEGf in Age-related choroidal Neovascularisation(IVAN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001281-33,0,0,0 2007-001283-73,17,2014-04-01,2014-09-23,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Biologicals,"A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001283-73,0,0,0 2007-001283-73,17,2014-04-01,2014-09-23,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.","A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001283-73,0,0,0 2007-001286-15,5,2011-03-07,2013-06-27,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Stragen France,A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) who have failed or are intolerant to tyro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001286-15,0,0,0 2007-001286-15,5,2011-03-07,2013-06-27,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,STRAGEN FRANCE SAS,A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) who have failed or are intolerant to tyro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001286-15,0,0,0 2007-001287-75,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CENTRE PAUL PAPIN - IRCAM,Proteomic and genetic analysis of neurotoxicity predicting markers in oxaliplatine treated patients with colorectal carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001287-75,0,0,0 2007-001292-11,2,2010-09-30,2010-12-31,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Nordic Myeloma Study Group,Talidomid vs Velcade vid melfalanrefraktärt myelom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001292-11,0,0,0 2007-001295-36,5,2008-07-23,2008-07-30,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A parallel-group, double-blind, randomized, placebo-controlled, active comparator, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of two doses of GSK232802 adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001295-36,0,0,0 2007-001295-36,5,2008-07-23,2008-07-30,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A parallel-group, double-blind, randomized, placebo-controlled, active comparator, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of two doses of GSK232802 adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001295-36,0,0,0 2007-001295-36,5,2008-07-23,2008-07-30,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A parallel-group, double-blind, randomized, placebo-controlled, active comparator, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of two doses of GSK232802 adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001295-36,0,0,0 2007-001298-27,5,2008-12-02,2008-12-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of Intravenous Methylnaltrexone (MOA 728) for the Treatment of Postoperative Ileus After Ventral Hernia Repair",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001298-27,0,0,0 2007-001302-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Lab for pharmaceutical biology,Evaluation of the benefits and effects of hypericin Photodynamic therapy (PDT) in the clinical treatment of superficial bladder carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001302-25,0,0,0 2007-001302-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Department of Urology,Evaluation of the benefits and effects of hypericin Photodynamic therapy (PDT) in the clinical treatment of superficial bladder carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001302-25,0,0,0 2007-001313-42,6,2009-12-17,2010-08-17,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"A randomised, double-blind, active-controlled, double-dummy, parallel group study to determine the safety and efficacy of oxycodone / naloxone prolonged release tablets in subjects with moderate to se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001313-42,0,0,0 2007-001314-17,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,ERASME HOSPITAL,EVALUATION OF A PROTOCOLE FOR ADENOTONSILLECTOMY IN CHILDREN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001314-17,0,0,0 2007-001315-31,6,2013-03-12,2013-03-12,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study on the efficacy and tolerability of budesonide capsules versus placebo for maintenance of remission in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001315-31,0,0,0 2007-001317-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Prof. Dr. Istvan Racz,"Open label, uncontrolled pilot study on the effect of mucosal healing with 3 g mesalazine granules in NSAID induced small bowel enteropathy, evaluated by video capsule endoscopy after 4 weeks of treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001317-42,0,0,0 2007-001318-18,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA PISANA,"PHASE II STUDY OF BAY 43-9006, DOCETAXEL AND PREDNISONE IN METASTATIC PROSTATE CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001318-18,0,0,0 2007-001320-12,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,BAYER,"A national, prospective, randomized, open label study to asses the efficacy and safety of IV/PO moxifloxacin vs IV ceftriaxone + IV azithromicin followed by PO amoxicilline/clavulanate and PO claritr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001320-12,0,0,0 2007-001324-13,1,2008-12-31,2008-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Research and Innovation Services, University of Dundee",Does Vitamin D improve markers of vascular health in stroke patients?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001324-13,0,0,0 2007-001325-96,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Pilar Samper Ots,Estudio de dos pautas de hierro intravenoso para la optimización del tratamiento con epoetina recombinante humana en pacientes con anemia inducida por la radio quimioterapia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001325-96,0,0,0 2007-001326-26,3,2007-12-21,2008-09-30,3,0,0,1,1,0,1,0,0,1,1,0,0,0,1,Omrix Biopharmaceuticals Ltd.,"A Prospective, Controlled, Randomized, Multi-Center, Phase I/II Study Evaluating the Safety and Efficacy of Adhexil™",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001326-26,0,0,0 2007-001335-54,3,2010-02-16,2010-02-16,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Affectis Pharmaceuticals AG,"SAFETY AND EFFICACY OF CIMICOXIB, A SELECTIVE COX-2 INHIBITOR, IN COMBINATION WITH SERTRALINE COMPARED TO SERTRALINE COMBINED WITH PLACEBO IN TREATMENT OF MAJOR DEPRESSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001335-54,0,0,0 2007-001337-34,4,2008-08-06,2008-11-12,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca AB,"A double-blind, randomised, cross-over, multi-centre study, to evaluate onset of effect in the morning in patients with severe Chronic Obstructive Pulmonary Disease (COPD) treated with budesonide/form...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001337-34,0,0,0 2007-001339-69,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,THE TECHNICAL UNIVERSITY OF DRESDEN,"Protocol for standardized diagnostic procedures, registration, and treatment recommendations in children and adolescents with Philadelphia chromosome-positive chronic myeloid leukemia (CML). A multice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001339-69,0,0,0 2007-001345-18,1,2008-07-23,2008-07-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A 19-week, randomized, double-blind, placebo-controlled, three-period, cross-over pilot study comparing the effect of salmeterol/fluticasone propionate 50/100mcg BID, fluticasone propionate 100mcg BID...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001345-18,0,0,0 2007-001346-41,2,2018-10-01,2019-08-30,2,1,0,0,0,0,3,0,0,1,1,0,1,0,0,Medical Research Council,"A double-blind, placebo-controlled, three arm randomised multi-centre Gynaecologic Cancer InterGroup trial of AZD2171, in combination with platinum-based chemotherapy and as a single agent maintenance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001346-41,0,0,0 2007-001346-41,2,2018-10-01,2019-08-30,2,1,0,0,0,0,3,0,0,1,1,0,1,0,0,Grupo Español de Investigación en Cáncer de Ovario (GEICO),"A double-blind, placebo-controlled, three arm randomised multi-centre Gynaecologic Cancer InterGroup trial of AZD2171, in combination with platinum-based chemotherapy and as a single agent maintenance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001346-41,0,0,0 2007-001347-21,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,"A randomised clinical trial on heparin versus saline solution (NaCl 0,9%) in the maintenance of peripherical venous catheters",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001347-21,0,0,0 2007-001349-17,1,2010-10-05,2010-10-05,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Oxford,"A single centre, open-label, randomised clinical trial to investigate Meningococcal serogroup A, C, W-135 and Y saccharide specific B cell response to a primary and a booster dose of the Meningococcal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001349-17,0,0,0 2007-001360-76,12,2008-07-07,2008-07-23,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose range study to evaluate the efficacy and safety of LCZ696 comparatively to valsartan, and to evaluate AHU3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001360-76,0,0,0 2007-001360-76,12,2008-07-07,2008-07-23,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS PHARMA SERVICES AG,"A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose range study to evaluate the efficacy and safety of LCZ696 comparatively to valsartan, and to evaluate AHU3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001360-76,0,0,0 2007-001360-76,12,2008-07-07,2008-07-23,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS PHARMA Services AG,"A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose range study to evaluate the efficacy and safety of LCZ696 comparatively to valsartan, and to evaluate AHU3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001360-76,0,0,0 2007-001360-76,12,2008-07-07,2008-07-23,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMACEUTICA S.A.,"A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose range study to evaluate the efficacy and safety of LCZ696 comparatively to valsartan, and to evaluate AHU3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001360-76,0,0,0 2007-001360-76,12,2008-07-07,2008-07-23,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose range study to evaluate the efficacy and safety of LCZ696 comparatively to valsartan, and to evaluate AHU3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001360-76,0,0,0 2007-001361-15,2,2008-02-17,2008-02-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An open-label, two-period, multi-center, single dose study to assess the pharmacokinetics of AEB071 in de novo liver transplant patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001361-15,0,0,0 2007-001361-15,2,2008-02-17,2008-02-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label, two-period, multi-center, single dose study to assess the pharmacokinetics of AEB071 in de novo liver transplant patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001361-15,0,0,0 2007-001362-32,1,2011-07-01,2011-07-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Hospitals Of Leicester NHS Trust,The use of non-ionic contrast media to clear corneal scars,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001362-32,0,0,0 2007-001364-72,4,2018-07-19,2018-07-19,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Sandoz GmbH,Long-term safety follow-up after growth hormone treatment (rhGH) of short children born Small for Gestational Age (SGA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001364-72,0,0,0 2007-001370-88,12,2018-12-31,2019-05-15,12,1,0,0,0,0,3,0,0,1,0,0,1,0,0,International Breast Cancer Study Group (IBCSG),A PHASE III TRIAL EVALUATING THE ROLE OF CONTINOUS LETROZOLE VERSUS INTERMITTENT LETROZOLE FOLLOWING 4 TO 6 YEARS OF PRIOR ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH HORMONE-RECEPTOR POS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001370-88,0,0,0 2007-001370-88,12,2018-12-31,2019-05-15,12,1,0,0,0,0,3,0,0,1,0,0,1,0,0,IBCSG,A PHASE III TRIAL EVALUATING THE ROLE OF CONTINOUS LETROZOLE VERSUS INTERMITTENT LETROZOLE FOLLOWING 4 TO 6 YEARS OF PRIOR ADJUVANT ENDOCRINE THERAPY FOR POSTMENOPAUSAL WOMEN WITH HORMONE-RECEPTOR POS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001370-88,0,0,0 2007-001374-87,1,2007-12-19,2007-12-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001374-87,0,0,0 2007-001375-11,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,3,,Effects and health economic aspects of enzyme therapy in children and adults with Pompe disease Long-term follow-up of patients receiving commercially available Myozyme,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001375-11,0,0,0 2007-001377-28,5,2009-07-31,2009-07-31,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Merck Serono International S.A.,"Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001377-28,0,0,0 2007-001378-97,2,2008-12-22,2008-12-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Baxter SAS,Safety during use of paediatric triple chamber bag formulas administered IV at a weight dependant dose during 5 consecutive days in paediatric patients up to 18 years requiring parenteral nutrition. A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001378-97,0,0,0 2007-001382-15,1,2008-12-16,2008-12-16,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,ARYx Therapeutics,"A Randomized, Double-Blind, Placebo-Controlled Study of ATI-2042 in Patients with Paroxysmal Atrial Fibrillation and Pacemakers with Atrial Fibrillation Data Logging Capabilities",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001382-15,0,0,0 2007-001383-70,1,2008-10-24,2008-10-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 24 week, multicenter, open evaluation of the clinical effectiveness of the once-daily 10 cm2 Exelon® patch formulation in patients with probable Alzheimer’s disease (MMSE10-26)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001383-70,0,0,0 2007-001389-34,1,2008-07-07,2008-07-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Plethora Solutions Limited,"A multi-centre, double-blind, placebo-controlled, multiple-dose crossover proof of concept study to compare the efficacy of mefenamic acid administered vaginally and orally in healthy menstruating wom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001389-34,0,0,0 2007-001391-37,1,2007-11-09,2007-11-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A randomised, single-dose, dose ascending, double-blind, placebo controlled, four-way, incomplete block crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001391-37,0,0,0 2007-001394-29,6,2011-07-30,2011-07-30,2,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Baxter Healthcare Corporation,"Estudio IMPENDIA: estudio multicéntrico, prospectivo y aleatorizado para demostrar un mejor control metabólico de la prescripción de (Physioneal-Physioneal-Extraneal-Nutrineal) (PPEN) frente a Dianeal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001394-29,0,0,0 2007-001394-29,6,2011-07-30,2011-07-30,2,1,0,0,0,0,4,0,0,1,1,0,1,0,1,BAXTER HEALTHCARE CORPORATION,"Estudio IMPENDIA: estudio multicéntrico, prospectivo y aleatorizado para demostrar un mejor control metabólico de la prescripción de (Physioneal-Physioneal-Extraneal-Nutrineal) (PPEN) frente a Dianeal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001394-29,0,0,0 2007-001396-11,2,2009-07-16,2009-07-16,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,TopoTarget A/S,A Phase II Clinical Trial of PXD101 in Patients with Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001396-11,0,0,0 2007-001396-11,2,2009-07-16,2009-07-16,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,CuraGen Corporation,A Phase II Clinical Trial of PXD101 in Patients with Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001396-11,0,0,0 2007-001401-15,1,2014-10-01,2014-10-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,Treatment of patients with cystic fibrosis with N-acetylcysteine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001401-15,0,0,0 2007-001402-24,1,2010-02-10,2010-02-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,Estudio fase II de LY573636 sódico administrado como tratamiento de segunda o tercera línea en pacientes con sarcoma de tejido blando irresecable o metastásico A Phase 2 Study of LY573636-sodium Admi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001402-24,0,0,0 2007-001403-38,1,2007-07-10,2007-07-10,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics GmbH & Co. KG,"A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of Begrivac®, preservative free, inactivated split influenza vaccine, using the strain composition 2007/2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001403-38,0,0,0 2007-001404-20,1,2007-08-01,2007-08-01,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics GmbH & Co. KG,"A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of a single intramuscular dose of a trivalent subunit influenza vaccine produced in mammalian cell cultur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001404-20,0,0,0 2007-001407-37,7,2009-07-25,2009-07-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,NovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc),"A multicenter,randomized,doubleblind, placebo-controlled study of the effects of KW-3902 injectable emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001407-37,0,0,0 2007-001407-37,7,2009-07-25,2009-07-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,NovaCardia Inc.,"A multicenter,randomized,doubleblind, placebo-controlled study of the effects of KW-3902 injectable emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001407-37,0,0,0 2007-001407-37,7,2009-07-25,2009-07-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,NovaCardia Inc,"A multicenter,randomized,doubleblind, placebo-controlled study of the effects of KW-3902 injectable emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001407-37,0,0,0 2007-001410-17,1,2011-01-28,2011-01-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LFB SA,"LONG-TERM SAFETY AND EFFICACY STUDY OF IGNG, A NEW LIQUID PREPARATION OF HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE, ADMINISTERED IN CURRENT PRACTICE TO PRIMARY IMMUNODEFICIENT PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001410-17,0,0,0 2007-001412-23,3,2010-03-26,2010-03-26,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Pharmaxis Pharmaceuticals Limited,Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis – A Safety and Efficacy Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001412-23,0,0,0 2007-001413-42,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)",Study of Fludarabine based conditioning for Allogeneic Stem cell Transplantation for Myelofibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001413-42,0,0,0 2007-001416-23,2,2013-01-16,2013-01-16,1,0,0,0,0,0,2,0,0,1,1,0,1,0,0,FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI,"A Multinational Double-Blind, Randomized Phase IIb Cooperative Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001416-23,0,0,0 2007-001416-23,2,2013-01-16,2013-01-16,1,0,0,0,0,0,2,0,0,1,1,0,1,0,0,FONDAZIONE MICHELANGELO,"A Multinational Double-Blind, Randomized Phase IIb Cooperative Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001416-23,0,0,0 2007-001417-41,1,2008-05-01,2008-05-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Stockholm Spine Center,"Postoperative epidural analgesia with Breivik's mixture (bupivacain, fentanyl, epinephrine) compared to Narop (rupivacain) combined with oral oxycodon after posterior lumbar fusion.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001417-41,0,0,0 2007-001418-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,"efficacy of treatment with bevacizumab,in the macular degeneration.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001418-17,0,0,0 2007-001420-12,6,2009-04-08,2009-05-14,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Randomised, Double-Blind (with Open Comparator Etanercept Limb), Placebo-Controlled, Phase IIb, Multicentre Study to Evaluate the Efficacy of 4 Doses of AZD9056 Administered for 6 Months on the Sign...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001420-12,0,0,0 2007-001421-10,7,2009-02-26,2009-02-26,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Synta Pharmaceuticals Corp.,"A Randomized, Double-Blind, Phase III Trial of STA-4783 in Combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects with Stage IV Metastatic Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001421-10,1,0,0 2007-001421-10,7,2009-02-26,2009-02-26,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,SYNTA PHARMACEUTICALS,"A Randomized, Double-Blind, Phase III Trial of STA-4783 in Combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects with Stage IV Metastatic Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001421-10,1,0,0 2007-001424-12,5,2017-09-25,2017-09-25,5,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Intercept Pharmaceuticals,A Study of INT-747 (6-ECDCA) Monotherapy in Patients with Primary Biliary Cirrhosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001424-12,0,0,0 2007-001425-10,6,2009-08-26,2011-01-19,5,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Intercept Pharmaceuticals,"A Study of INT-747 (6-ECDCA) in Combination with Ursodeoxycholic Acid (URSO®, UDCA) in Patients with Primary Biliary Cirrhosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001425-10,0,0,0 2007-001428-11,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,SOLTI,"Ensayo clínico multicéntrico, abierto, de Fase II con doxorubicina liposomal pegilada (Caelyx®) como tratamiento Primario en pacientes con cáncer de mama y antecedentes de Cardiopatía o con Edad supe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001428-11,0,0,0 2007-001430-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,Peg-filgrastim Vs filgrastrim in pediatric patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001430-14,0,0,0 2007-001431-58,2,2008-02-22,2008-02-22,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"ROXRO PHARMA, Inc.","A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of the Safety, Tolerability, and Analgesic Efficacy of Ketorolac Tromethamine Administered Intranasally for the Acute Treatment of Migrai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001431-58,0,0,0 2007-001432-31,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,1,Bristol-Myers Squibb International Corporation,"A Phase 1/2a, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects with Advanced Cancer. Revised Protocol 02, incorporating Protocol Amendmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001432-31,0,0,0 2007-001433-34,1,2009-12-10,2009-12-10,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects with Advanced Cancer. Revised Protocol 04, incorporating Protocol Amendment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001433-34,0,0,0 2007-001435-63,1,,,0,1,0,0,1,0,3,0,0,1,0,0,0,1,1,ZAMBON ITALIA,"AEROSOLIC TREATMENT OF ACUTE AND RECURRENT RHINOSINUSITIS DURING INTERCRITICAL STAGES : SINGLE BLIND CLINICAL STUDY, N-ACETYLCISTEIN VS AMBROXOL, ASSOCIATED WITH CORTISONE THERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001435-63,0,0,0 2007-001438-15,4,2011-12-16,2011-12-16,4,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Amgen Inc.,"A Phase 2 Randomized Trial of Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001438-15,0,0,0 2007-001439-74,6,2008-07-15,2011-04-26,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Amgen Inc,"A Phase 2, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001439-74,0,0,0 2007-001439-74,6,2008-07-15,2011-04-26,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AMGEN S.P.A.,"A Phase 2, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001439-74,0,0,0 2007-001442-41,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,Identification of facial mimicking in patients with disorder bipolar treated with quetiapine and healthy subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001442-41,0,0,0 2007-001443-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,Effects of the administrartion of two different dosages of eparin on activation of coagulation pathway and of fibrinolisis and on platenet function in patients with myocardial revascolarization open h...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001443-22,0,0,0 2007-001448-33,2,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,0,Cardiovascular Centre Aalst,"A multi-centre, double-blind, randomised, placebo-controlled trial using CD133 enriched bone marrow cells following primary angioplasty for acute myocardial infarction with central core laboratory ana...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001448-33,0,0,0 2007-001448-33,2,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,0,King’s College London,"A multi-centre, double-blind, randomised, placebo-controlled trial using CD133 enriched bone marrow cells following primary angioplasty for acute myocardial infarction with central core laboratory ana...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001448-33,0,0,0 2007-001448-33,2,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,0,Catharina Hospital Eindhoven,"A multi-centre, double-blind, randomised, placebo-controlled trial using CD133 enriched bone marrow cells following primary angioplasty for acute myocardial infarction with central core laboratory ana...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001448-33,0,0,0 2007-001449-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Andrés Ignacio Bodegas Cañas,EFICACIA DEL IRBESARTAN EN LA FIBRILACION AURICULAR PERSISTENTE SOMETIDA A ABLACION CON RADIOFRECUENCIA POR EL SISTEMA CARTO-MERGE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001449-16,0,0,0 2007-001450-66,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Karolinska Institutet,Improved management of depression in primary health care – a randomized study of two structured programs with reference to the role of genetic predisposition,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001450-66,0,0,0 2007-001451-19,21,2008-06-12,2009-03-24,20,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Sy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001451-19,0,0,0 2007-001452-39,20,2009-03-18,2010-05-06,18,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001452-39,0,0,0 2007-001452-39,20,2009-03-18,2010-05-06,18,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma B.V.,"A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001452-39,0,0,0 2007-001453-26,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,3,,"Natural course, effects of enzyme therapy and health economic aspects in patients with mucopolysaccharidosis type I, II and VI. Long-term folloe-up of untreated patients and patients receiving commer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001453-26,0,0,0 2007-001454-77,6,2010-02-03,2010-02-03,6,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Stallergenes S.A,"A randomised, double-blind, placebo-controlled, multi-national Phase II/III study of the safety and efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets once...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001454-77,0,0,0 2007-001457-26,7,2011-11-09,2011-11-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, RADIOGRAPHIC STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ORALLY ADMINISTERED SD-6010 IN SUBJECTS WITH SYMPTOMATIC OSTEOAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001457-26,0,0,0 2007-001457-26,7,2011-11-09,2011-11-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, RADIOGRAPHIC STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ORALLY ADMINISTERED SD-6010 IN SUBJECTS WITH SYMPTOMATIC OSTEOAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001457-26,0,0,0 2007-001457-26,7,2011-11-09,2011-11-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA","A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, RADIOGRAPHIC STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ORALLY ADMINISTERED SD-6010 IN SUBJECTS WITH SYMPTOMATIC OSTEOAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001457-26,0,0,0 2007-001457-26,7,2011-11-09,2011-11-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,"A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, RADIOGRAPHIC STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ORALLY ADMINISTERED SD-6010 IN SUBJECTS WITH SYMPTOMATIC OSTEOAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001457-26,0,0,0 2007-001458-22,10,2012-05-22,2012-05-25,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc,East 42nd street,New york, NY10017, USA","""ESTUDIO ALEATORIZADO, DOBLE CIEGO, DE GRUPOS PARALELOS, MULTICÉNTRICO, CON DOSIS FLEXIBLES, COMPARATIVO DE PREGABALINA Y LEVETIRACETAM COMO TRATAMIENTO ADYUVANTE PARA REDUCIR LA FRECUENCIA DE LAS CRI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001458-22,0,0,0 2007-001458-22,10,2012-05-22,2012-05-25,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"""ESTUDIO ALEATORIZADO, DOBLE CIEGO, DE GRUPOS PARALELOS, MULTICÉNTRICO, CON DOSIS FLEXIBLES, COMPARATIVO DE PREGABALINA Y LEVETIRACETAM COMO TRATAMIENTO ADYUVANTE PARA REDUCIR LA FRECUENCIA DE LAS CRI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001458-22,0,0,0 2007-001458-22,10,2012-05-22,2012-05-25,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc., East 42nd street, New York, NY10017, USA","""ESTUDIO ALEATORIZADO, DOBLE CIEGO, DE GRUPOS PARALELOS, MULTICÉNTRICO, CON DOSIS FLEXIBLES, COMPARATIVO DE PREGABALINA Y LEVETIRACETAM COMO TRATAMIENTO ADYUVANTE PARA REDUCIR LA FRECUENCIA DE LAS CRI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001458-22,0,0,0 2007-001458-22,10,2012-05-22,2012-05-25,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, East 42nd street, New York, NY10017, USA","""ESTUDIO ALEATORIZADO, DOBLE CIEGO, DE GRUPOS PARALELOS, MULTICÉNTRICO, CON DOSIS FLEXIBLES, COMPARATIVO DE PREGABALINA Y LEVETIRACETAM COMO TRATAMIENTO ADYUVANTE PARA REDUCIR LA FRECUENCIA DE LAS CRI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001458-22,0,0,0 2007-001462-33,7,2011-08-02,2011-08-02,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of VELCADE® in combination with Dexamethasone or VELCADE® in combination with Dexamethasone and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001462-33,0,0,0 2007-001463-29,6,2008-06-05,2008-06-05,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline R&D Ltd,A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001463-29,0,0,0 2007-001465-14,1,2007-06-22,2007-06-22,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,CSL Limited,"A Single Centre, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira Vaccine in Healthy Adults aged ≥ 18 to < 60 years and in Healthy Older Adults aged ≥ 60 years for the 2007/2008 No...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001465-14,0,0,0 2007-001471-11,1,2007-11-16,2007-11-16,1,1,0,0,1,0,4,0,0,1,1,1,1,0,1,Chemische Fabrik Kreussler & Co. GmbH,Efficacy and safety of Aethoxysklerol 4% compared to 5% phenol in oil for the treatment of the first and second degree hemorrhoids - a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001471-11,0,0,0 2007-001473-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Asociación Terapéutica en Hematología y Oncología Médicas del Hospital Arnau de Vilanova de Valencia,Ensayo clínico fase II de Gemcitabina y Docetaxel quincenal como tratamiento de 1ª línea para la enfermedad avanzada en pacientes con carcinoma no microcítico de pulmón y estado funcional ECOG 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001473-28,0,0,0 2007-001474-91,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Asociación Terapéutica en Hematología y Oncología Médicas del Hospital Arnau de Vilanova de Valencia,Ensayo clínico fase II de Gemcitabina y Docetaxel quincenal como tratamiento de 1ª línea para la enfermedad avanzada en pacientes ancianos con carcinoma no microcítico de pulmón.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001474-91,0,0,0 2007-001475-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Assistance Publique Hopitaux de marseille,Influence de la vitesse de perfusion du sérum salé hypertonique/hydroxyethylamidon sur l’hémodynamique systémique au cours du choc septique et hémorragique.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001475-11,0,0,0 2007-001477-29,5,2008-11-20,2008-11-20,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline S.A.,A proof-of-concept study of SB-751689 in male and female subjects with a fractured distal radius.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001477-29,0,0,0 2007-001477-29,5,2008-11-20,2008-11-20,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline R & D Limited,A proof-of-concept study of SB-751689 in male and female subjects with a fractured distal radius.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001477-29,0,0,0 2007-001478-10,4,2022-06-30,2022-06-30,2,0,0,0,0,1,3,0,0,2,0,0,0,0,0,Universitätsklinikum Tübingen,"CWS-2007-HR: A randomised phase-III trial of the Cooperative Weichteilsarkom Studiengruppe for localised high-risk Rhabdomyosarcoma and localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in children,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001478-10,1,0,0 2007-001481-32,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,Evaluation of the anti-inflammatory effect of continous insulin infusion in non-diabetic patients undergoing cardia surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001481-32,0,0,0 2007-001486-15,2,2009-12-21,2010-06-14,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"TEDEC-MEIJI FARMA, S.A.","Multicentre, prospective, comparative, randomized, double-blind, double-dummy study to assess the efficacy and safety of cefditoren pivoxil versus ciprofloxacin in acute uncomplicated cystitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001486-15,0,0,0 2007-001487-67,5,2008-10-05,2008-11-25,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, CT13 9NJ Kent, UK","A PARALLEL-GROUP, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER DOSE RESPONSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF- 00885706, A 5-HT4 RECEPTOR PARTIAL AGONIST, AS ADD-ON THERAPY TO ESOMEPRAZOLE FO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001487-67,0,0,0 2007-001487-67,5,2008-10-05,2008-11-25,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer, S.A.","A PARALLEL-GROUP, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER DOSE RESPONSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF- 00885706, A 5-HT4 RECEPTOR PARTIAL AGONIST, AS ADD-ON THERAPY TO ESOMEPRAZOLE FO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001487-67,0,0,0 2007-001487-67,5,2008-10-05,2008-11-25,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent, UK","A PARALLEL-GROUP, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER DOSE RESPONSE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF- 00885706, A 5-HT4 RECEPTOR PARTIAL AGONIST, AS ADD-ON THERAPY TO ESOMEPRAZOLE FO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001487-67,0,0,0 2007-001489-34,7,2008-03-28,2008-05-07,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd,"A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 50 mg versus Placebo in Subjects with Hypercholesterolemia, With an Optional Open-Label Extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001489-34,0,0,0 2007-001491-36,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,BAYER,"''A prospective, randomized, open label, active comparator, multicenter, national trial to compare the efficacy and safety of sequential IV/PO moxifloxacin 400 mg once daily versus IV amoxicillin/clav...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001491-36,0,0,0 2007-001493-91,4,2014-03-21,2015-12-15,2,0,0,0,0,0,0,0,1,2,0,0,0,0,0,"Population Health Research Institute, McMaster University/Hamilton Health Sciences","A LARGE SIMPLE RANDOMIZED TRIAL OF COMBINED CHOLESTEROL MODIFICATION, BLOOD PRESSURING LOWERING IN MIDDLE AGED PEOPLE AT INTERMEDIATE (MODERATE) RISK.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001493-91,1,0,0 2007-001493-91,4,2014-03-21,2015-12-15,2,0,0,0,0,0,0,0,1,2,0,0,0,0,0,"Population Health Research Institute, Hamilton Health Sciences Corporation","A LARGE SIMPLE RANDOMIZED TRIAL OF COMBINED CHOLESTEROL MODIFICATION, BLOOD PRESSURING LOWERING IN MIDDLE AGED PEOPLE AT INTERMEDIATE (MODERATE) RISK.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001493-91,1,0,0 2007-001493-91,4,2014-03-21,2015-12-15,2,0,0,0,0,0,0,0,1,2,0,0,0,0,0,"Population Health Research Institute (PHRI), McMaster University/Hamilton Health Sciences","A LARGE SIMPLE RANDOMIZED TRIAL OF COMBINED CHOLESTEROL MODIFICATION, BLOOD PRESSURING LOWERING IN MIDDLE AGED PEOPLE AT INTERMEDIATE (MODERATE) RISK.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001493-91,1,0,0 2007-001496-11,1,2012-12-18,2012-12-18,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Nottingham,The Effects of Tetanus Vaccination on Mediators of Autoimmunity in Patients with Multiple Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001496-11,0,0,0 2007-001501-13,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,ROTTAPHARM / ROTTA RESEARCH LABORATORIUM,"An open, randomized study to investigate the plasma and synovial fluid concentrations of glucosamine before and after repeated doses of crystalline glucosamine sulfate administered as oral soluble pow...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001501-13,0,0,0 2007-001503-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA PROVINCIALE DI LECCO,effect of everolimus on adult polycystic nephropaty; a study pilot,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001503-38,0,0,0 2007-001506-25,2,2008-09-25,2009-01-07,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novo Nordisk A/S,"An open–label Phase 2 Trial of Pegylated Liposomal Doxorubicin and rIL-21 in Ovarian Cancer Patients with Persistent or Progressive Disease after, or Relapse within One Year of, Completion of Standard...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001506-25,0,0,0 2007-001508-19,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA S. CARLO,TRATTAMENTO CON IMATINIB MESILATO DELLA GVH CRONICA SEVERA SCLERODERMA-LIKE REFRATTARIA ALLA TERAPIA IMMUNOSOPRESSIVA CONVENZIONALE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001508-19,0,0,0 2007-001509-11,4,2011-04-07,2011-04-07,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of 2 g per day of strontium ranelate versus alendronate 70 mg per week in women with post...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001509-11,0,0,0 2007-001509-11,4,2011-04-07,2011-04-07,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of 2 g per day of strontium ranelate versus alendronate 70 mg per week in women with post...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001509-11,0,0,0 2007-001516-24,13,2011-02-23,2012-06-12,11,1,0,0,0,2,0,0,0,2,0,0,0,0,1,Amgen Inc,An Open Label Extension Study Evaluating the Safety of Long Term Dosing of AMG 531 in Thrombocytopenic Subjects with Myelodysplastic Syndromes (MDS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001516-24,1,0,0 2007-001517-41,4,2009-09-11,2009-09-11,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Vifor (International) Inc.,Comparative study of the efficacy and tolerability of iron polymaltose complex film-coated tablets with folic acid (Maltofer® Fol film-coated tablets) compared to a generic iron sulphate product in pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001517-41,0,0,0 2007-001519-52,1,2012-04-06,2012-04-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Groupe d'Etudes des Lymphomes de l'Adult,Randomized study of intensified CHOP plus Rituximab (R-CHOP given every 14 days: R-CHOP 14) versus CHOP plus Rituximab given every 21 days (R-CHOP 21) and randomized study of frontline-prophylatic Dar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001519-52,0,0,0 2007-001520-12,1,2008-12-02,2008-12-02,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Unidade de Investigação em Saúde Mental e Psiquiatria do Centro Hospitalar Conde de Ferreira,"Efficacy and distinctive effects of atypical antipsychotics on cognitive symptoms in dual diagnosis – A phase IIIb, randomized, open-labelled study to evaluate the cognitive effects of quetiapine XR a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001520-12,0,0,0 2007-001521-98,5,2010-04-28,2010-04-28,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Procter & Gamble Pharmaceuticals,"A Non-inferiority Comparison of 35mg Delayed-release Risedronate, Administered Once-weekly Either Before or After Breakfast, and 5mg Immediate-release Risedronate, Administered Once-daily Before Break...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001521-98,0,0,0 2007-001526-27,1,2010-01-05,2010-01-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,ANZAC: A Randomised Phase II Feasibility Study Investigating The Biological Effects of the Addition of Zoledronic Acid To Neoadjuvant Comnination Chemotherapy On Invasive Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001526-27,0,0,0 2007-001530-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,GORTEC,"Essai de Phase III, Multicentrique, Randomisé, comparant la Chimiothérapie d’induction par Docétaxel, Cisplatine et 5-Fluorouracile (TPF) suivie d’une chimio-radiothérapie concomitante versus une chim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001530-14,0,0,0 2007-001533-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,A Phase II Study of Panitumumab 5-Fluorouracil and Oxaliplatin in combination with pelvic radiotherapy as treatment of resectable and locally advanced rectal cancer (StarPan Study ﾖ STAR 02),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001533-34,0,0,0 2007-001534-13,4,2008-06-30,2008-07-24,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Combined Phase II/III, Observer-Blind, Randomized, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001534-13,0,0,0 2007-001534-13,4,2008-06-30,2008-07-24,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Combined Phase II/III, Observer-Blind, Randomized, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001534-13,0,0,0 2007-001538-15,1,,,0,0,0,0,1,0,2,0,0,1,1,1,0,1,1,Sangart Inc,"A randomized, single-blind, controlled Phase II pilot study of Hemospan® compared with colloid (Voluven®) to evaluate vascular resistance and blood flow in the forearm, and to assess local skin blood ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001538-15,0,0,0 2007-001540-45,1,2012-10-08,2012-10-08,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Institute of Psychophysiology and Rehabilitation (IRP) of the Kaunas University of Medicine,Triiodothyronine as an adjunct to accelerate the antidepressant effects of the selective serotonin reuptake inhibitor (SSRI) escitalopram,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001540-45,0,0,0 2007-001541-18,1,2012-10-08,2012-10-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Institute of Psychophysiology and Rehabilitation (IRP) of the Kaunas University of Medicine,Triiodothyronine as an adjunct in treatment of acute schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001541-18,0,0,0 2007-001545-17,5,2009-09-09,2009-09-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,An Open-Label Extension Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects Ages 1 to <11 Years: A Long Term Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001545-17,0,0,0 2007-001545-17,5,2009-09-09,2009-09-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,An Open-Label Extension Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects Ages 1 to <11 Years: A Long Term Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001545-17,0,0,0 2007-001548-36,1,2009-02-12,2009-02-12,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,University of Jena,"Nasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und chronischer Rhinosinusitis mit dem Pari Sinus-Vernebler. - bizentrische, randomisierte, doppel-blinde, placebo-kontrollierte, prosp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001548-36,0,0,0 2007-001553-26,1,2014-07-29,2014-07-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Vienna Medical University, Dept. of Ophthalmology","A randomized, double-masked study with intraocular bevacizumab (Avastin®) compared with intraocular triamcinolone (Volon A®) in patients with clinical significant diabetic macular edema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001553-26,0,0,0 2007-001555-19,1,2010-05-31,2010-05-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Hellenic Cooperative Oncology Group,DOCETAXEL COMBINED WITH PULSATILE ERLOTINIB (TARCEVA) IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER (NSCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001555-19,0,0,0 2007-001557-26,13,2017-04-13,2018-05-25,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,Apixaban Versus Acetylsalicyclic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double Blind Trial +...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001557-26,0,0,0 2007-001558-21,1,2012-11-20,2012-11-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Schleswig-Holstein,Phase II Studie: Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001558-21,0,0,0 2007-001559-20,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Cliniques Universitaires Saint-Luc,Steady-state pharmacokinetics of high dose acetaminophen inpost-op children. Rational use of N-acetyl cysteine for prevention of liver toxicity related to cumulative doses.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001559-20,0,0,0 2007-001563-29,2,2009-11-09,2009-11-09,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001563-29,0,0,0 2007-001563-29,2,2009-11-09,2009-11-09,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 2, Multi-Center, Open-label Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2, 6-Month Schedule and of a Single d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001563-29,0,0,0 2007-001565-15,1,2009-12-31,2009-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Universityhospital Ulm,Konzentrationen von Ertapenem in kolorektalem Gewebe.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001565-15,0,0,0 2007-001568-66,12,2010-11-11,2011-01-12,6,1,0,0,0,2,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017 USA","A RANDOMIZED, DOUBLE BLIND PHASE 3 STUDY OF GEMCITABINE PLUS AG 013736 VERSUS GEMCITABINE PLUS PLACEBO FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC PANCRE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001568-66,0,0,0 2007-001568-66,12,2010-11-11,2011-01-12,6,1,0,0,0,2,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA","A RANDOMIZED, DOUBLE BLIND PHASE 3 STUDY OF GEMCITABINE PLUS AG 013736 VERSUS GEMCITABINE PLUS PLACEBO FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC PANCRE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001568-66,0,0,0 2007-001568-66,12,2010-11-11,2011-01-12,6,1,0,0,0,2,3,0,0,1,1,0,1,0,1,"Pfizer, S.A.","A RANDOMIZED, DOUBLE BLIND PHASE 3 STUDY OF GEMCITABINE PLUS AG 013736 VERSUS GEMCITABINE PLUS PLACEBO FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC PANCRE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001568-66,0,0,0 2007-001573-28,1,2014-10-28,2014-10-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Universität zu Köln,Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001573-28,0,0,0 2007-001581-32,1,2010-08-03,2010-08-03,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,Joint UCLH & UCL Biomedical Research Unit,Phase I trial of photodynamic therapy using systemic 5-aminolaevulinic acid for the treatment of grade 3 anal intraepithelial neoplasia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001581-32,0,0,0 2007-001585-33,10,2013-05-28,2014-05-29,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomized, placebo controlled, multicenter clinical study investigating efficacy of rituximab (MabThera/Rituxan) in the inhibition of joint structural damage assessed by magnetic resonance imaging ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001585-33,0,0,0 2007-001585-33,10,2013-05-28,2014-05-29,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffman-La Roche Ltd.,"A randomized, placebo controlled, multicenter clinical study investigating efficacy of rituximab (MabThera/Rituxan) in the inhibition of joint structural damage assessed by magnetic resonance imaging ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001585-33,0,0,0 2007-001585-33,10,2013-05-28,2014-05-29,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffman- La Roche Ltd.,"A randomized, placebo controlled, multicenter clinical study investigating efficacy of rituximab (MabThera/Rituxan) in the inhibition of joint structural damage assessed by magnetic resonance imaging ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001585-33,0,0,0 2007-001586-15,9,2010-04-01,2011-04-05,9,1,0,0,0,0,0,0,0,1,0,0,1,0,0,University of Southampton,(GRACE Antibiotic Trial One – GRACE AT ONE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001586-15,0,0,0 2007-001586-15,9,2010-04-01,2011-04-05,9,1,0,0,0,0,0,0,0,1,0,0,1,0,0,OSPEDALE MAGGIORE DI MILANO (IRCCS),(GRACE Antibiotic Trial One – GRACE AT ONE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001586-15,0,0,0 2007-001587-70,1,2008-01-09,2008-01-09,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Fraunhofer Gesellschaft,"A randomized, double-blind, placebo-controlled crossover study to assess the efficacy's reproducibility of a combination of Pseudoephedrine and Cetirizine on symptom scores and rhinomanometry in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001587-70,0,0,0 2007-001589-34,1,2010-06-25,2010-06-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GELA Group,Phase II study of mini CHOP plus Rituximab in non previously treated patient aged over 80 years with CD20+ Diffuse Large B-cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001589-34,0,0,0 2007-001590-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Herz-, Thorax- und Gefäßchirurgische Anästhesie und Intensivmedizin","Insulin aspart (NovoRapid®, Novo Nordisk) vs. human insulin (Actrapid®, Novo Nordisk) in intravenous treatment of high blood glucose concentrations in the ICU",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001590-29,0,0,0 2007-001592-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""","A randomized, double-blind pilot study vs. placebo for the evaluation of efficacy and tolerability of tauroursodeoxycholic acid administered by oral route as add on treatment in patients affected by a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001592-10,0,0,0 2007-001600-20,1,2011-06-30,2011-06-30,1,0,0,0,1,0,2,0,0,1,1,1,1,0,0,Dr. Martin Pinsger & Univ.-Prof. Dr. Rupert Prokesch,Klinische Studie zur Überprüfung des Einflusses einer Add-On-Verabreichung von Piritramid auf die mittelfristige Schmerzsymptomatik bei der Behandlung des chronischen Lendenwirbelsäulen-Schmerzsyndrom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001600-20,0,0,0 2007-001601-16,3,2009-03-18,2009-03-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gilead Sciences Incorporated,"A Phase IIa, Double-blind, Randomised, Placebo-Controlled Dose Escalation Study to Evalulate the Safety, Tolerability, Pharmacokinetics and Activity of GS-9450, a Caspase Inhibitor, in Subjects with C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001601-16,0,0,0 2007-001602-24,1,2012-07-29,2012-07-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Department of Urology and Pediatric Urology - Justus-Liebig-University Giessen,Intraprostatic injection of Botulinumtoxin type A in patients with chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001602-24,0,0,0 2007-001604-20,1,2014-06-12,2014-06-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Radboud University Nijmegen Medical Center,"A PROSPECTIVE RANDOMIZED STUDY ON THE EFFICACY AND SAFETY OF THE PROPHYLACTIC USE OF RITUXIMAB, ADDED TO STANDARD IMMUNOSUPPRESSIVE TREATMENT IN COMPARISON WITH STANDARD IMMUNOSUPPRESSIVE TREATMENT AL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001604-20,0,0,0 2007-001609-81,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,1,Philogen S.pA.,Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine in patients with advanced pancreatic cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001609-81,0,0,0 2007-001610-16,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,"A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001610-16,0,0,0 2007-001611-32,1,2009-01-01,2009-01-01,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,NV Organon,A multi-center cardiac safety study of subjects who participated in Organon sponsored Phase 1 and Phase 2 completed and discontinued trials with Org 24448 (Protocols: 22601;22602;22603; 153001;153002;...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001611-32,0,0,0 2007-001621-94,1,2012-04-30,2012-04-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Lothian Health Board,Pregabalin Bone Trial. A double-blind randomised controlled trial of pregabalin versus placebo in conjunction with palliative radiotherapy for malignant bone pain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001621-94,0,0,0 2007-001621-94,1,2012-04-30,2012-04-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Edinburgh,Pregabalin Bone Trial. A double-blind randomised controlled trial of pregabalin versus placebo in conjunction with palliative radiotherapy for malignant bone pain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001621-94,0,0,0 2007-001625-10,12,2009-09-03,2010-01-27,11,1,0,0,0,0,4,0,0,1,1,0,1,0,2,Wyeth Pharmaceuticals France,"AN OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE RADIOGRAPHIC EFFICACY AND SAFETY OF ENBREL™ (ETANERCEPT) ADDED TO METHOTREXATE IN COMPARISON WITH USUAL TREATMENT IN SUBJECTS WITH MODERATE RHEUMATOID A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001625-10,0,0,0 2007-001625-10,12,2009-09-03,2010-01-27,11,1,0,0,0,0,4,0,0,1,1,0,1,0,2,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"AN OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE RADIOGRAPHIC EFFICACY AND SAFETY OF ENBREL™ (ETANERCEPT) ADDED TO METHOTREXATE IN COMPARISON WITH USUAL TREATMENT IN SUBJECTS WITH MODERATE RHEUMATOID A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001625-10,0,0,0 2007-001626-27,15,2017-09-05,2020-11-09,12,1,0,0,0,2,3,0,0,2,1,0,0,0,1,Celgene Corporation,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) AS MAINTENANCE THERAPY FOR PATIENTS WITH B-CELL CHRONIC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001626-27,1,0,0 2007-001630-14,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,"University Medical Centre St. Radboud, Department of Dermatology",Safety and efficacy of efalizumab in combination with methotrexate in patients with severe psoriasis: a comparative study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001630-14,0,0,0 2007-001631-55,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Caen,Evaluation des performances de l’échographie avec injection de produit de contraste (Sonovue®) dans la détection des métastases hépatiques synchrones ou métachrones d’un cancer colo-rectal.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001631-55,0,0,0 2007-001633-34,4,2009-08-27,2009-08-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research Ltd,"A double blind, double dummy, randomised, multicentre, four arm parallel group study to assess the efficacy and safety of FlutiForm™ pMDI 250/10 µg (2 puffs bid) vs Fluticasone pMDI 250 µg (2 puffs bi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001633-34,0,0,0 2007-001634-13,5,2008-04-01,2008-04-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research Limited,"An open, randomised, parallel group, multicentre study to compare the efficacy and safety of FlutiFormTM pMDI compared with Fluticasone pMDI plus Formoterol DPI in adolescent and adult subjects with m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001634-13,0,0,0 2007-001634-13,5,2008-04-01,2008-04-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research Ltd.,"An open, randomised, parallel group, multicentre study to compare the efficacy and safety of FlutiFormTM pMDI compared with Fluticasone pMDI plus Formoterol DPI in adolescent and adult subjects with m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001634-13,0,0,0 2007-001639-80,4,2008-07-10,2008-07-24,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,sanofi-aventis recherche & de'veloppement,"A multicenter, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance and safety/tolerability of SSR180711C, at the doses of 2, 8 and 20 mg/d for 4 weeks, using ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001639-80,0,0,0 2007-001639-80,4,2008-07-10,2008-07-24,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,"A multicenter, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance and safety/tolerability of SSR180711C, at the doses of 2, 8 and 20 mg/d for 4 weeks, using ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001639-80,0,0,0 2007-001643-21,1,2012-07-01,2012-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Brompton and Harefield NHS Trust,"Use of endothelin-1 antagonists in patients with Established Pulmonary Hypertension and Fibrotic Lung Disease. – A randomised, placebo-controlled, double-blinded study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001643-21,0,0,0 2007-001645-17,1,2007-11-28,2007-11-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Brompton and Harefield NHS Trust,"Prevention of Established Pulmonary Hypertension in High Risk patients with Fibrotic Lung Disease – a double-blinded, randomised, placebo controlled trial with endothelin-1 receptor antagonist therap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001645-17,0,0,0 2007-001646-40,6,2012-06-07,2012-07-16,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Santhera Pharmaceuticals (Switzerland) Ltd,"A Phase III Open-Label, Single-Group Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001646-40,0,0,0 2007-001646-40,6,2012-06-07,2012-07-16,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Santhera Pharmaceuticals (Switzerland) Limited,"A Phase III Open-Label, Single-Group Extension Study to Obtain Long-Term Safety and Tolerability Data of Idebenone in the Treatment of Friedreich's Ataxia Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001646-40,0,0,0 2007-001650-77,2,2008-08-18,2008-08-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"An Open-Label, Multi-Centre, Randomised Parallel-Group Dose-Finding Study, Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring And...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001650-77,0,0,0 2007-001657-26,1,2011-12-19,2011-12-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,Single Centre Phase II Pilot study of Unrelated Cord Blood Transplantation in Patients with Poor Risk Haematological Malignancies.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001657-26,0,0,0 2007-001661-15,1,2008-11-06,2008-11-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Astellas Pharma US, Inc","A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Assess the Safety and Effects of Intravenous Conivaptan on the Hepatic Hemodynamic Response in Stable Euvolemic or Hyp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001661-15,0,0,0 2007-001665-15,5,2009-06-10,2009-08-13,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1 monoclonal antibody) in patients with rheumatoid a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001665-15,0,0,0 2007-001665-15,5,2009-06-10,2009-08-13,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1 monoclonal antibody) in patients with rheumatoid a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001665-15,0,0,0 2007-001665-15,5,2009-06-10,2009-08-13,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmaceutica S.A.,"A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1 monoclonal antibody) in patients with rheumatoid a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001665-15,0,0,0 2007-001666-32,4,2009-12-31,2009-12-31,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Genentech Inc,"A PHASE II, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF THE SAFETY,PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF APOMAB ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB IN PATIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001666-32,0,0,0 2007-001668-62,1,2007-12-07,2007-12-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Surface Logix, Inc.","A pilot Phase IIa, randomised, double blind, placebocontrolled, crossover study to examine the safety, tolerability and pharmacodynamic effects on blood pressure of repeat oral doses of SLx-2101 5 mg ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001668-62,0,0,0 2007-001670-84,10,2011-03-15,2011-03-15,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Jassen-Cilag International NV,Turnhoutseweg 30, 2340 Beerse, Belgium","Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001670-84,0,0,0 2007-001670-84,10,2011-03-15,2011-03-15,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001670-84,0,0,0 2007-001670-84,10,2011-03-15,2011-03-15,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Jassen-Cilag International NV,"Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001670-84,0,0,0 2007-001670-84,10,2011-03-15,2011-03-15,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen-Cilag International NV,Turnhoutseweg 30, 2340 Beerse, Belgium","Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001670-84,0,0,0 2007-001670-84,10,2011-03-15,2011-03-15,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL NV,"Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001670-84,0,0,0 2007-001671-11,1,2007-11-01,2007-11-01,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,Medizinische Universität Graz,Influence of urinary acidification by l-Methionine on bone metabolism and acid base status,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001671-11,0,0,0 2007-001675-11,8,2013-09-09,2013-09-09,7,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Wyeth Parmaceuticals Inc.,"A Randomised, Placebo Controlled, Double-Blinded Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Translplant Patients Converted to Sirolimus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001675-11,0,0,0 2007-001675-11,8,2013-09-09,2013-09-09,7,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals, a Pfizer Company","A Randomised, Placebo Controlled, Double-Blinded Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Translplant Patients Converted to Sirolimus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001675-11,0,0,0 2007-001675-11,8,2013-09-09,2013-09-09,7,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals, a Pfizer company","A Randomised, Placebo Controlled, Double-Blinded Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Translplant Patients Converted to Sirolimus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001675-11,0,0,0 2007-001675-11,8,2013-09-09,2013-09-09,7,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals Inc acting through its division Wyeth Research , a Pfizer company","A Randomised, Placebo Controlled, Double-Blinded Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Translplant Patients Converted to Sirolimus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001675-11,0,0,0 2007-001675-11,8,2013-09-09,2013-09-09,7,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Wyeth Pharmaceuticals,"A Randomised, Placebo Controlled, Double-Blinded Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Translplant Patients Converted to Sirolimus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001675-11,0,0,0 2007-001676-36,1,2007-07-01,2007-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ORION PHARMA,"Non-inferiority study; Comparison of polyethylene glycol solution with and without electrolytes for treatment of chronic constipation in elderly institutionalised patients: a double-blind, randomised,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001676-36,0,0,0 2007-001677-28,3,2009-01-30,2009-01-30,3,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,Evaluation de l’effet anesthésique du protoxyde d’azote dans une population d’opérés recevant une anesthésie totale intraveineuse en « boucle » guidée par l’index bispectral (Effect of nitrous oxide o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001677-28,0,0,0 2007-001677-28,3,2009-01-30,2009-01-30,3,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Hopital Foch,Evaluation de l’effet anesthésique du protoxyde d’azote dans une population d’opérés recevant une anesthésie totale intraveineuse en « boucle » guidée par l’index bispectral (Effect of nitrous oxide o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001677-28,0,0,0 2007-001678-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON,Suplementación con LH recombinante de la fase lútea previa a la estimulación ovárica con FSH recombinante para Fecundación ‘In Vitro’ en mujeres con edad avanzada. Estudio exploratorio para prueba de ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001678-10,0,0,0 2007-001680-30,4,2009-05-05,2009-11-17,2,1,0,0,1,0,4,0,0,1,0,0,1,0,1,Bausch&Lomb Dr Gerhard Mann chem.-Fabrik GmbH,"Randomized parallel-group, multicentre study to evaluate the after-use sensation and safety of carteolol LA 2% versus timolol LA 0.5% in simple intra-ocular hypertension and glaucoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001680-30,0,0,0 2007-001685-33,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,RWTH Aachen University,Prospective Comparison of Phenpocoumon (Marcumar) and Acetylsalicylic Acid (ASS) as to Progression of the Valvular and Coronary Calcification. Prospektiver Vergleich von Phenprocoumon (Marcumar) un...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001685-33,0,0,0 2007-001688-31,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Larime company of the Mediscis group,"Monitoring des états cognitifs chez des sujets volontaires sains, sur 2 périodes, l'une avant et après administration d'une dose unique de Zolpidem, l'autre sans administration de traitement",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001688-31,0,0,0 2007-001689-34,6,2011-03-08,2012-09-14,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Abbott GmbH & Co. KG,Paricalcitol capsules benefits in Renal failure Induced cardiac MOrbidity in subjects with Chronic Kidney Disease Stage 3B/4.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001689-34,0,0,0 2007-001690-28,1,2009-09-20,2009-09-20,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Dept of Endocrinology, Odense University Hospital","Odense Androgen Study - The effect of Testim vs strength training i a populationbased, randomised, placebocontrolled, doubleblinded study in hypogonadal men",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001690-28,0,0,0 2007-001691-36,3,2008-05-28,2009-03-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme GmbH,"A Multicenter, Double-Blind, Randomized, Placebo and Active Comparator Controlled Dose Range Finding Study in MK-0893 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001691-36,0,0,0 2007-001691-36,3,2008-05-28,2009-03-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Double-Blind, Randomized, Placebo and Active Comparator Controlled Dose Range Finding Study in MK-0893 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001691-36,0,0,0 2007-001694-28,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,"Department of Rheumatology, Hvidovre Hospital",SPARTA – spondyloarthritis remission trial after adalimumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001694-28,0,0,0 2007-001697-84,1,2010-12-07,2010-12-07,1,0,0,0,1,0,2,0,1,1,0,0,1,0,0,"Department of Ophthalmology, Aarhus University Hospital",Pharmacological intervention of blood flow disturbances in diabetic retinal disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001697-84,0,0,0 2007-001701-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU DE POITIERS,pharmacokinetic study by microdialysis of the distribution of ertapeneme and levofloxacine in infected foot ulcers of diabetics patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001701-19,0,0,0 2007-001702-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,LABORATOIRE TOP PHARM,Traitement des rhinopharyngites et des bronchites aigues de l'adulte par une association de chlorydrate d'ambroxol et d'alfa-amylase,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001702-24,0,0,0 2007-001703-38,10,2011-03-15,2011-03-15,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride (AVODART™) 0.5 mg in Extending the Time to PSA Doubling in Men with Prostate Cancer and Biochemica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001703-38,0,0,0 2007-001703-38,10,2011-03-15,2011-03-15,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithkline S.A.,"A Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride (AVODART™) 0.5 mg in Extending the Time to PSA Doubling in Men with Prostate Cancer and Biochemica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001703-38,0,0,0 2007-001705-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO,Phase II study to evaluate hepatic function and clinical aspects in patients with severe hepatic cirrhosis treated with multiple cycle of stem cells mobilisation by G-CSF administration.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001705-21,0,0,0 2007-001707-38,1,2009-07-14,2009-07-14,1,0,0,0,0,0,3,0,1,1,0,0,1,0,0,University Hospital,"A phase IIIb, open, controlled study to evaluate the immunogenicity, and safety of 7PCV Prevenar vaccine in pre-term infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001707-38,0,0,0 2007-001708-19,2,2010-03-02,2010-03-02,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,TRB CHEMEDICA INTERNATIONAL SA,"A 3-month study of the efficacy and safety of SVS20 in patients with bilateral moderate dry eye syndrome : A prospective, double-masked, randomised, controlled, parallel-group, 3-arm, multicentre, pha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001708-19,0,0,0 2007-001709-85,1,2010-06-29,2010-06-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,South Eastern Health and Social Care Trust,Treatment of Shoulder Capsulitis by single or Multiple Corticosteroid Injections,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001709-85,0,0,0 2007-001711-31,2,2007-12-21,2007-12-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Movetis NV,"A randomized, double blind, placebo controlled, phase II, dose-titration trial to explore the safety, tolerability, pharmacokinetic profile and efficacy of M0002 in cirrhotic subjects with ascites and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001711-31,0,0,0 2007-001713-42,6,2008-08-10,2008-09-10,4,1,0,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development,"A randomised, double-blind, placebo-controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily compared with placebo for 28 days in adolesce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001713-42,1,0,0 2007-001714-16,1,2009-02-25,2009-02-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A double-blind, randomized, placebo-controlled, parallel, time-lagged, ascending, multi-centre, multiple-dose study to measure the magnitude and time course of the effect of FTY720 on FEV1 and other p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001714-16,0,0,0 2007-001715-36,1,2008-07-13,2008-07-13,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Tranzyme, Inc","A Multicenter, Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of TZP-101 when Administered as a 30 Minute IV Infusion for Postoperative Ileus to Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001715-36,0,0,0 2007-001716-23,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,0,Southampton University Hospitals NHS Trust,A Double-Blind Randomised Placebo-Controlled Trial of Vitamin D Supplements for Pregnant Women with Low Levels of Vitamin D in Early Pregnancy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001716-23,0,0,0 2007-001717-42,2,2009-11-19,2009-11-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Schering Plough Research Institute,"A Phase 2, 36 Week, Open-Label, Uncontrolled Safety Follow-Up Study Assessing SCH 420814 5 mg BID",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001717-42,0,0,0 2007-001720-13,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Roche Nederland B.V.,"A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of subcutaneous RO0503821 for the maintenance of haemoglobine levels in patients with chro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001720-13,0,0,0 2007-001721-97,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Roche Pharma (Schweiz) AG,"An single arm, open label, interventional multicenter study to assess the efficacy, safety and tolerability of once-monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001721-97,0,0,0 2007-001722-27,4,,,0,1,0,0,0,0,2,0,0,2,1,0,0,0,1,AstraZeneca AB,"Long-term treatment with the oral direct thrombin inhibitor AZD0837, compared to Vitamin-K antagonists, as stroke prevention in patients with non-valvular atrial fibrillation and one or more risk fact...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001722-27,0,0,0 2007-001723-36,3,2008-11-27,2008-11-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A controlled, randomized, parallel, multi-centre, feasibility study of the oral direct thrombin inhibitor AZD0837, given as extended-release formulation, in the prevention of stroke and systemic embol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001723-36,0,0,0 2007-001724-12,7,2009-12-20,2010-01-18,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals France,"A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001724-12,0,0,0 2007-001724-12,7,2009-12-20,2010-01-18,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Pharmaceutricals France Wyeth Research Division,"A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001724-12,0,0,0 2007-001724-12,7,2009-12-20,2010-01-18,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001724-12,0,0,0 2007-001728-10,1,2011-01-23,2011-01-23,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Sussex NHS Research Consortium,Post-operative analgesia for day-case ankle arthroscopy: Comparison of intra-articular racemic (RS)-bupivicaine with S(-)-bupivicaine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001728-10,0,0,0 2007-001731-55,1,2014-12-17,2014-12-17,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III/IV, community-randomized, controlled study to evaluate the effectiveness of two vaccination strategies using GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in reducing the prev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001731-55,0,0,0 2007-001733-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO,Albumin 4 gr/L vs 8 gr/L in the Prevention of Post-Paracentesis Circulatory Dysfunction in Cirrhotic Patients With Ascites,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001733-34,0,0,0 2007-001735-66,2,2008-07-03,2008-07-03,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Novexel S. A.,"A double blind, multicentre, multinational, randomized, double dummy, three-arm parallel-group comparative study of the efficacy, safety and tolerance of oral NXL103 (500 mg twice daily) versus NXL103...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001735-66,0,0,0 2007-001741-18,10,2009-10-16,2010-04-16,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,Estudio de extensión abierta en pacientes con Fibrosis Pulmonar Idiopática que hayan completado el protocolo AC-052-321 / BUILD 3,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001741-18,0,0,0 2007-001741-18,10,2009-10-16,2010-04-16,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Registration Ltd,Estudio de extensión abierta en pacientes con Fibrosis Pulmonar Idiopática que hayan completado el protocolo AC-052-321 / BUILD 3,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001741-18,0,0,0 2007-001742-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Daniel López Aguado. Servicio de Otorrinolaringología. Hospital Universitario de Canarias,"ENSAYO CLÍNICO ALEATORIZADO FASE IV PARA EVALUAR LA EFICACIA COMPARATIVA DEL TRATAMIENTO CON VASODILATADORES, GLUCOCORTICOIDES Y MINERALOCORTICOIDES EN PACIENTES CON HIPOACUSIA NEUROSENSORIAL IDIOPÁT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001742-41,0,0,0 2007-001743-21,1,2007-11-02,2007-11-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Generics (UK) Ltd.,A PHASE II DOUBLE BLIND MODIFIED CROSS OVER DESIGN STUDY EVALUATING THE EFFICACY AND SAFETY OF TRIMETAZIDINE (GENERICS UK LIMITED) AND PLACEBO IN THE TREATMENT OF FIBROMYALGIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001743-21,0,0,0 2007-001744-53,1,2010-03-09,2010-03-09,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,University of Leipzig,"Open, randomized study for evaluation of an active Hepatitis B vaccination(HBVAXPRO) in combination with a passive immunisation with Hepatitis B immunoglobulins (Hepatect) for subjects, who did not sh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001744-53,0,0,0 2007-001746-40,1,2010-03-30,2010-03-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Ambrx, Inc., USA","A Phase IIb study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of ARX201 Following Repeated Dosing to Young Adult Patients with Childhood Onset Growth Hormone Defi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001746-40,0,0,0 2007-001751-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Miquel Gómez. Servicio de Cardiología. Hospital del Mar,"Estudio aleatorizado, unicéntrico, fase IV, para evaluar la corrección de la anemia asociada a la estenosis aórtica severa.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001751-19,0,0,0 2007-001754-11,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,ROCHE,"Pilot study to evaluate the effect of Rituximab in combination with MTX in the inhibition of progression of synovitis, bone marrow edema, and erosions evaluated by magnetic resonance imaging (MRI) in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001754-11,0,0,0 2007-001755-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMCG,A double-blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001755-19,0,0,0 2007-001767-30,2,2007-12-01,2007-12-01,1,1,0,1,0,0,1,0,0,2,0,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, United States","PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE MULTIPLE-DOSE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF VARENICLINE IN HEALTHY ADOLESCENT SMOKERS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001767-30,1,0,0 2007-001767-30,2,2007-12-01,2007-12-01,1,1,0,1,0,0,1,0,0,2,0,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE MULTIPLE-DOSE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF VARENICLINE IN HEALTHY ADOLESCENT SMOKERS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001767-30,1,0,0 2007-001768-60,1,2011-05-06,2011-05-06,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Birmingham,A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide with Radiotherapy in Diffuse Pontine Gliomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001768-60,0,0,0 2007-001771-11,1,2009-02-24,2009-02-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Phase I Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Study the Safety, Efficacy, and Mechanism of Action of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001771-11,0,0,0 2007-001772-37,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fédération Francophone de Cancérologie Digestive - FFCD,"Essai de phase II, multicentrique, évaluant le G-CSF en prophylaxie primaire associé au schéma de chimiothérapie FOLFIRI + bévacizumab en 1ère ligne dans le cancer colorectal métastatique chez des pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001772-37,0,0,0 2007-001774-88,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Targanta Therapeutics Corporation,Nuvocid™ (oritavancin) at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (SIMPLIFI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001774-88,0,0,0 2007-001776-36,9,2012-07-20,2012-07-26,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 24-month randomized, multicenter study, evaluating efficacy, safety, tolerability and pharmacokinetics of sotrastaurin (STN) combined with tacrolimus (TAC) vs a tacrolimus / mycophenolate mofetil (M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001776-36,0,0,0 2007-001776-36,9,2012-07-20,2012-07-26,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 24-month randomized, multicenter study, evaluating efficacy, safety, tolerability and pharmacokinetics of sotrastaurin (STN) combined with tacrolimus (TAC) vs a tacrolimus / mycophenolate mofetil (M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001776-36,0,0,0 2007-001776-36,9,2012-07-20,2012-07-26,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A,"A 24-month randomized, multicenter study, evaluating efficacy, safety, tolerability and pharmacokinetics of sotrastaurin (STN) combined with tacrolimus (TAC) vs a tacrolimus / mycophenolate mofetil (M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001776-36,0,0,0 2007-001781-32,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,GISCAD,A randomized phase II study of gemcitabine/cisplatin with or without sorafenib to evaluate the efficacy and safety in patients with locally advanced or metastatic pancreatic cancer. MAPS trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001781-32,0,0,0 2007-001782-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,Efficacy and safety of Intra-erythrocytes dexamethasone in cystic fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001782-15,0,0,0 2007-001783-75,1,2015-02-12,2015-02-12,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,"Department of Oncology, Lund University Hospital",Phase 2 trial with Avastin and Doxorubicin postoperatively for patients with anaplastic thyroid carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001783-75,0,0,0 2007-001784-30,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,BIOCODEX,"Population pharmacokinetic study in Dravet's syndrome patients treated with stiripentol, valproate and clobazam. Open pharmacokinetic multicenter study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001784-30,0,0,0 2007-001787-71,1,2008-12-12,2008-12-12,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Charité - Universitätsmedizin Berlin,The influence of Rimonabant induced cannabinoid receptor blocking on the mass and function of the left ventricle in patients with abdominal adiposity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001787-71,0,0,0 2007-001789-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,"A multicenter open label study to explore the efficacy and tolerability of Tenofovir DF (TDF) (300 mg) in chronic hepatitis B, HBeAg positive or negative, patients with suboptimal response to adefovir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001789-34,0,0,0 2007-001791-36,3,2008-12-22,2009-02-11,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer Schering Pharma AG,"A double-blind, randomized, placebo and active controlled, multicenter study to investigate efficacy and safety after oral administration of 2 and 3 mg ZK 283197, 1 mg 17ß-estradiol and placebo once d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001791-36,0,0,0 2007-001793-87,1,2008-01-21,2008-01-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios Almirall, S.A.","A Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle and Active Controlled Trial, to Assess the Efficacy and Safety of LAS37779 Cream for the Treatment of Chronic Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001793-87,0,0,0 2007-001794-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,OrbusNeich Medical BV,Endothelial Function following stenting with Genous vs Drug-Eluting Stents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001794-28,0,0,0 2007-001795-37,1,2016-03-01,2016-03-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical University Innsbruck, Dpt. Internal Medicine, Div. Internal Medicine","WIRKORTKONZENTRATIONEN VON AMPHOTERICIN B FORMULIERUNGEN IN ASZITES, LIQUOR, PLEURAERGUSS, GALLE UND LIQUOR BEI KRITISCH KRANKEN (Target-site concentrations of Amphotericin B preparations in ascites,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001795-37,0,0,0 2007-001796-11,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,"Institute for Diagnostic Radiology and Neuroradiology, Ernst-Moritz-Arndt University Greifswald",None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001796-11,0,0,0 2007-001800-20,1,2008-12-19,2008-12-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,"A randomised, placebo-controlled trial of the effect of pioglitazone on vascular endothelial function and novel biomarkers for macrovascular events in diabetics with established peripheral arterial di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001800-20,0,0,0 2007-001801-99,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Janssen-Cilag International N.V.,"An open label study to evaluate the efficacy, safety and tolerability of RWJ333369 as adjunctive therapy in subjects with partial onset seizure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001801-99,0,0,0 2007-001802-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Johann-Wolfgang Goethe-Universität,"An exploratory, open label phase II study to evaluate the feasibility of contrast-enhanced MRI for measurement of perfusion in squamous cell cancer of the head & neck: comparison of the intravascular ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001802-25,0,0,0 2007-001810-18,1,2013-01-25,2013-01-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Of North Staffordshire,Treatment of gastrostomy related granuloma using hydrocortisone or tea tree oil: A randomized controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001810-18,0,0,0 2007-001815-51,1,2013-08-31,2013-08-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"General Hospital Vienna, Dept Cardio-thoracic surgeray","AN OPEN-LABEL, RANDOMIZED PROSPECTIVE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CAMPATH-1H AS AN INDUCTION AGENT IN COMBINATION WITH LOW DOSE-TACROLIMUS, LOW DOSE –MMF AND REDUCED STEROID THERAP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001815-51,0,0,0 2007-001816-22,1,2011-05-13,2011-05-13,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Anne Ristikankare,Vasopressiinin vaikutus munuaisten toimintaan sydänleikkauksen jälkeisessä vasodilatoivassa shokissa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001816-22,0,0,0 2007-001817-40,1,,,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,Netherlands Asthma Foundation (NAF),An early diagnosis of asthma in young children by using non-invasive biomarkers of oxidative stress/airway inflammation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001817-40,0,0,0 2007-001817-40,1,,,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,Stichting astma bestrijding,An early diagnosis of asthma in young children by using non-invasive biomarkers of oxidative stress/airway inflammation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001817-40,0,0,0 2007-001818-16,1,2011-12-16,2011-12-16,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Vilnius University Hospital Santariskiu Clinics,Phase II Study of High-dose Methylprednisolone and Rituximab in Previously Treated Patients with High Risk Chronic B Lymphocytic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001818-16,0,0,0 2007-001821-85,11,2012-04-12,2012-04-12,7,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A,"A 24 month, multi-center, open-label, randomized, controlled study to evaluate the efficacy and safety of concentration-controlled everolimus to eliminate or to reduce tacrolimus compared to tacrol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001821-85,0,0,0 2007-001821-85,11,2012-04-12,2012-04-12,7,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 24 month, multi-center, open-label, randomized, controlled study to evaluate the efficacy and safety of concentration-controlled everolimus to eliminate or to reduce tacrolimus compared to tacrol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001821-85,0,0,0 2007-001821-85,11,2012-04-12,2012-04-12,7,1,0,0,0,2,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 24 month, multi-center, open-label, randomized, controlled study to evaluate the efficacy and safety of concentration-controlled everolimus to eliminate or to reduce tacrolimus compared to tacrol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001821-85,0,0,0 2007-001826-28,1,2015-06-09,2015-06-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Queen Mary University London,"A phase II/III, randomised, two-arm comparison of maintenance lapatinib versus placebo after firrst-line chemotherapy in patients with HER1 and/or HER2 over expressing locally advanced or metastatic b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001826-28,0,0,0 2007-001828-12,1,2007-07-11,2007-07-11,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase III, open, non-randomized, multi-centric, single dose study to assess immunogenicity and safety of Fluarix™ (Influsplit SSW®) 2007/2008 injected intramuscularly in young adults (18 to 60 years...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001828-12,0,0,0 2007-001831-73,1,2012-06-23,2012-06-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Kingston General Hospital, Queen's University of Kingston",REducing Deaths due to OXidative Stress The REDOXS© Study A 2×2 factorial randomized trial of glutamine and antioxidant supplementation in critically ill patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001831-73,0,0,0 2007-001834-15,1,2010-06-25,2010-06-25,1,0,0,0,1,0,3,0,0,1,0,0,1,0,1,"Casen Fleet, S.L.U","“ESTUDIO EN FASE III, CIEGO, ALEATORIZADO, MULTICÉNTRICO, PARA LA EVALUACIÓN DE SEGURIDAD Y EFICACIA DEL CITRAFLEET® (PICOSULFATO SÓDICO) COMO TRATAMIENTO EVACUANTE PREVIO A EXPLORACIÓN ENDOSCÓPICA CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001834-15,0,0,0 2007-001838-13,1,2012-10-04,2012-10-04,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Amicus Therapeutics, Inc.",Open Label Extension Study to Evaluate the Long-term Safety Tolerability and Pharmacodynamics of AT1001 in Patients with Fabry Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001838-13,0,0,0 2007-001840-33,18,2010-04-01,2010-04-01,16,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"Effect of inhalation of tiotropium once daily 18 mcg versus salmeterol twice daily 50 mcg on time to first exacerbation in COPD patients (a randomised, double-blind, double-dummy, parallel group, on...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001840-33,0,0,0 2007-001840-33,18,2010-04-01,2010-04-01,16,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Effect of inhalation of tiotropium once daily 18 mcg versus salmeterol twice daily 50 mcg on time to first exacerbation in COPD patients (a randomised, double-blind, double-dummy, parallel group, on...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001840-33,0,0,0 2007-001840-33,18,2010-04-01,2010-04-01,16,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co. KG,"Effect of inhalation of tiotropium once daily 18 mcg versus salmeterol twice daily 50 mcg on time to first exacerbation in COPD patients (a randomised, double-blind, double-dummy, parallel group, on...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001840-33,0,0,0 2007-001841-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Melchor Riera Jaume,ENSAYO CLÍNICO ALEATORIZADO Y CONTROLADO DE VORICONAZOL FRENTE A PLACEBO EN LA PROFILAXIS DE ASPERGILOSIS PULMONAR EN PACIENTES COLONIZADOS CON PATOLOGÍA RESPIRATORIA CRÓNICA (ESTUDIO VOCARE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001841-16,0,0,0 2007-001842-42,1,2011-03-03,2011-03-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Caen,Fixation de prothèses par Tissucol dans la cure de prolapsus par voie vaginale,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001842-42,0,0,0 2007-001844-34,4,2009-01-21,2009-11-02,3,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Pierre Fabre Dermo-Cosmétique,"NON INFERIORITY STUDY OF A MALATHION 0.5% LOTION VERSUS REFERENCE THERAPY IN THE TREATMENT OF HEAD LICE: MULTICENTRE, RANDOMISED, INVESTIGATOR MASKED, PARALLEL GROUP.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001844-34,0,0,0 2007-001844-34,4,2009-01-21,2009-11-02,3,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Pierre Fabre Dermocosmetique,"NON INFERIORITY STUDY OF A MALATHION 0.5% LOTION VERSUS REFERENCE THERAPY IN THE TREATMENT OF HEAD LICE: MULTICENTRE, RANDOMISED, INVESTIGATOR MASKED, PARALLEL GROUP.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001844-34,0,0,0 2007-001846-42,1,2009-05-18,2009-05-18,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma AG,"A 4-week, parallel-group, randomized, double-blind, placebo-controlled, adaptive proof of concept study of AQW051 at up to three dose levels for the treatment of patients with findings consistent with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001846-42,0,0,0 2007-001850-18,1,2010-09-03,2010-09-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Tayside,A randomised controlled study on the effects of Mitomycin C versus placebo in adult endoscopic dacrocystorhinostomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001850-18,0,0,0 2007-001852-38,6,2010-03-22,2010-06-08,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & developpement,"A Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of S-1 as a Single Agent at 30 mg/m2 BID versus 5-FU Bolus Infusion for the Treatment of Patients with Metastatic Pancrea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001852-38,0,0,0 2007-001855-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Faculty of Social Sciences, Utrecht University",A double blind placebo controlled crossover study to determine the effects of atomoxetine on event-related potentials in response to auditory oddball stimuli during an on-the-road driving test in adul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001855-20,0,0,0 2007-001857-24,3,2008-12-03,2008-12-03,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,NovImmune S.A.,"A Phase IIa, open-label, dose-titration, multicenter study to assess the safety and preliminary efficacy of NI-0401 in patients with acute cellular renal allograftt rejection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001857-24,0,0,0 2007-001858-70,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,University Hospital Ghent,Effect of inhaled tiotropium bromide on neurokinin-A induced bronchoconstriction in asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001858-70,0,0,0 2007-001861-14,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,University Medical Center Utrecht,"Multicenter randomized clinical trial in Patients with Juvenile Idiopathic Athritis: Safety and efficacy of vaccination with live attenuated Measles, Mumps, Rubella vaccine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001861-14,0,0,0 2007-001863-31,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Hospital Universitario de Bellvitge,Estudio Comparativo de la Eficacia de Pautas “Cortas” y “Largas” de la Combinación Rifampicina-Levofloxacino en la Infección Estafilocócica Postquirúrgica Precoz y Hematógena de Prótesis Articular o ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001863-31,0,0,0 2007-001870-95,9,2008-06-17,2009-04-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of three dosages of Lu AA21004, in acute treatment of Major D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001870-95,0,0,0 2007-001871-13,7,2008-05-09,2009-09-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with two doses of Lu AA21004 in patients with Major Depressive Disorder.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001871-13,0,0,0 2007-001872-36,1,2008-05-30,2008-05-30,1,0,0,0,1,0,3,0,0,1,0,0,1,0,1,EctoPharma Limited,"A Multicentre Phase III trial of 1,2-octanediol at 5%(w/v (KindaPed™) compared with Malathion 0.5% (w/v) (Derbac-M Liquid) in the treatment of head lice",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001872-36,0,0,0 2007-001881-33,1,2008-05-08,2008-05-08,1,0,0,0,0,3,2,0,1,1,0,0,1,0,0,"Medicinsk gastroenterologisk afdeling, Aalborg sygehus S.","Undersøgelse af opioiders effekt på eksperimentel hyperalgesi i spiserør og hud samt på en iskæmisk muskelmodel, inklusiv et eksplorativt studie af morfins ændringer i hjernens smerte processering.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001881-33,0,0,0 2007-001887-55,10,2017-08-24,2017-08-24,8,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"BIAL - Portela & Ca, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2 093) AS ADJUNCTIVE THERAPY FOR REFRACTORY PARTIAL SEIZURES IN CHILDREN: A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001887-55,0,0,0 2007-001887-55,10,2017-08-24,2017-08-24,8,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"BIAL - PORTELA & C, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2 093) AS ADJUNCTIVE THERAPY FOR REFRACTORY PARTIAL SEIZURES IN CHILDREN: A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001887-55,0,0,0 2007-001888-29,1,2012-07-27,2012-07-27,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Leipzig,Chronic inflammatory activation in fat tissue: an atherogenic factor in severe coronary artery disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001888-29,0,0,0 2007-001889-33,1,2008-06-01,2008-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,North Bristol NHS Trust,Does an 8 week course of Ambulatory Oxygen Increase Diffuse Parenchymal Lung Diseases Patients Ability to Perform a 6 Minute Walk Test and/or Improve Patients Perception of Quality of Life as measured...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001889-33,0,0,0 2007-001890-27,6,2008-09-22,2008-09-22,1,0,0,0,0,2,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Randomised, double blind, placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Zactima™ in Patients with locally advanced or metastatic papillary or follicular Thyroi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001890-27,1,0,0 2007-001890-27,6,2008-09-22,2008-09-22,1,0,0,0,0,2,2,0,0,2,0,0,0,0,1,AstraZeneca SAS,"A Randomised, double blind, placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Zactima™ in Patients with locally advanced or metastatic papillary or follicular Thyroi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001890-27,1,0,0 2007-001891-35,1,2011-07-07,2011-07-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca SAS,"A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001891-35,0,0,0 2007-001892-12,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University Medical Centre Freiburg,Everolimus and mycophenolate as GvHD-prophylaxis in the allogenous blood stem cell transplantation (Everolimus und Mycophenolsäure als GvHD-Prophylaxe in der allogenen Blutstammzelltransplantation),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001892-12,0,0,0 2007-001904-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ROCHE FARMA S.A.,"An open label randomised controlled study to compare the efficacy, safety and tolerability of once every four weeks administration of subcutaneous C.E.R.A. versus darboepoetin alfa for the maintenance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001904-18,0,0,0 2007-001905-10,1,2009-07-31,2009-07-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche Farma S.A,"""Estudio abierto, randomizado, controlado para comparar la eficacia, seguridad y tolerancia de la administración una vez cada cuatro semanas de C.E.R.A por vía subcutánea frente a darbepoetina alfa pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001905-10,0,0,0 2007-001906-26,5,2009-01-11,2010-02-19,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,HEXAL Biotech ForschungsGmbH,"Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001906-26,0,0,0 2007-001906-26,5,2009-01-11,2010-02-19,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,HEXAL AG,"Randomized, controlled, double-blind multicenter safety study to evaluate the safety and immunogenicity of subcutaneous EPO HEXAL vs. ERYPO® in the treatment of anemia associated with chronic renal in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001906-26,0,0,0 2007-001912-21,1,2008-07-08,2008-07-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Aarhus Sygehus, Universityhospital of Aarhus","Bioavailability, Pharmacokinetics and Pharmacodynamics of Insulin Aspart following Subcutaneous Insulin Infusion (CSII) - Basal Rate Resolution.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001912-21,0,0,0 2007-001913-41,9,2009-11-25,2009-11-25,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,UCB Celltech,"A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001913-41,0,0,0 2007-001913-41,9,2009-11-25,2009-11-25,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,UCB Celletech,"A phase IIIb, multinational, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti-TNF-alpha monoclo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001913-41,0,0,0 2007-001915-52,12,2012-04-10,2012-12-20,7,1,0,0,0,0,3,0,2,1,1,0,1,0,1,Pfizer Inc. - 235 East 42nd Street - New York - 10017,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIB",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001915-52,0,0,0 2007-001915-52,12,2012-04-10,2012-12-20,7,1,0,0,0,0,3,0,2,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, 10017","A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIB",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001915-52,0,0,0 2007-001915-52,12,2012-04-10,2012-12-20,7,1,0,0,0,0,3,0,2,1,1,0,1,0,1,Pfizer Inc. - 235 East 42nd Street - New York - 10017 - USA,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIB",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001915-52,0,0,0 2007-001915-52,12,2012-04-10,2012-12-20,7,1,0,0,0,0,3,0,2,1,1,0,1,0,1,PFIZER,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIB",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001915-52,0,0,0 2007-001915-52,12,2012-04-10,2012-12-20,7,1,0,0,0,0,3,0,2,1,1,0,1,0,1,"Pfizer, S.A.","A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED PHASE 3, EFFICACY AND SAFETY STUDY OF SUNITINIB (SU011248) IN PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER TREATED WITH ERLOTINIB",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001915-52,0,0,0 2007-001916-22,1,2010-08-23,2010-08-23,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Central Manchester and Manchester Children's Hospital University NHS Trust,Study to assess the optimum dose of intravenous adenosine in the assessment of fractional flow reserve,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001916-22,0,0,0 2007-001918-16,1,2009-11-04,2009-11-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Universitätsklinikum Schleswig-Holstein, Campus Kiel","Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study SoraPeg Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001918-16,0,0,0 2007-001921-86,2,2008-12-18,2008-12-18,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Solvay Pharmaceuticals GmbH,"A double-blind, placebo-controlled, parallel-group, multi-center study to investigate the effect of Omacor (n-3 PUFA) on lipid parameters in HIV infected patients treated with HAART",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001921-86,0,0,0 2007-001922-28,4,2008-06-26,2008-06-26,4,1,0,0,2,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","""Estudio en fase 2a, aleatorizado, controlado con placebo, en grupos paralelos, de dosis múltiples para evaluar la eficacia, la seguridad y la tolerabilidad de la administración oral durante 12 semana...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001922-28,0,0,0 2007-001922-28,4,2008-06-26,2008-06-26,4,1,0,0,2,0,2,0,0,1,0,0,1,0,1,PFIZER,"""Estudio en fase 2a, aleatorizado, controlado con placebo, en grupos paralelos, de dosis múltiples para evaluar la eficacia, la seguridad y la tolerabilidad de la administración oral durante 12 semana...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001922-28,0,0,0 2007-001924-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Primary fungal profilaxis with Liposomal Amphotericin B at the dose of 10 mg/kg a week in adult patient undergoing orthotopic liver transplantation and high risk for postoperative fungal infection: a ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001924-11,0,0,0 2007-001927-36,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Early ultrasonography role by Contrast enhanced ultrasonography ( CEUS) evaluating therapy effectiveness in patients with hepatic metastasis of colorectal cancer treated with antiangiogenetic drug.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001927-36,0,0,0 2007-001928-12,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Contrast enhanced ultrasonography effectiveness in early evaluating of the response to the Sunitinib in the patients with advanced GIST. A pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001928-12,0,0,0 2007-001938-14,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AVAPO RICERCHE - VENEZIA,"Neoadjuvant docetaxel, cisplatin and 5-fluororacil (TPF) followed by radiotherapy plus concomitant chemotherapy or cetuximab versus radiotherapy plus concomitant chemotherapy or cetuximab in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001938-14,0,0,0 2007-001939-61,8,2009-07-30,2011-10-05,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Ltd.,"A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early treatment-experienced HIV-1 infected subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001939-61,0,0,0 2007-001939-61,8,2009-07-30,2011-10-05,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,"A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) b.i.d. in early treatment-experienced HIV-1 infected subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001939-61,0,0,0 2007-001942-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",Pharmacokinetical-clinical study of intravescical gemcitabine in patients with marker lesion of superficial transitional cell carcinoma of the bladder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001942-42,0,0,0 2007-001943-23,8,2010-02-11,2011-02-16,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-Aventis Recherche et De'veloppement,Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced /Metastatic Urothelial Tract or Bladder Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001943-23,0,0,0 2007-001943-23,8,2010-02-11,2011-02-16,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced /Metastatic Urothelial Tract or Bladder Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001943-23,0,0,0 2007-001943-23,8,2010-02-11,2011-02-16,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-Aventis Recherche et Développement,Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced /Metastatic Urothelial Tract or Bladder Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001943-23,0,0,0 2007-001946-42,4,2009-05-04,2009-05-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A multinational, randomised, double-blind, placebo. and active-controlled, parallel group efficacy and safety comparison over 24 weeks of three doses (50µg, 100µg, 200µg) of BEA 2180 to tiotropium 5 µ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001946-42,0,0,0 2007-001946-42,4,2009-05-04,2009-05-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim Pharma, GesmbH","A multinational, randomised, double-blind, placebo. and active-controlled, parallel group efficacy and safety comparison over 24 weeks of three doses (50µg, 100µg, 200µg) of BEA 2180 to tiotropium 5 µ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001946-42,0,0,0 2007-001946-42,4,2009-05-04,2009-05-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A multinational, randomised, double-blind, placebo. and active-controlled, parallel group efficacy and safety comparison over 24 weeks of three doses (50µg, 100µg, 200µg) of BEA 2180 to tiotropium 5 µ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001946-42,0,0,0 2007-001947-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,HELP Pharmaceuticals S.A.,"A multicenter, randomized, parallel patients’ group, comparative clinical trial for the assessement of efficacy and safety of Pelethrocin®/HELP 500 mg (generic diosmin & hesperidin MPFF) versus Daflon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001947-23,0,0,0 2007-001949-18,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Valeur prédictive du statut mutationnel de l'oncogène KRAS sur la réponse aux anticorps monoclonaux recombinants anti-EGFR chez les malades atteints d'un cancer colorectal métastatique. Etude prospect...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001949-18,0,0,0 2007-001950-18,1,,,0,0,0,0,1,0,2,0,0,1,0,0,0,1,1,"Ocera Therapeutics, Inc.","A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF AST-120 IN PATIENTS WITH NON-CONSTIPATING IRRITABLE BOWEL SYNDROME",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001950-18,0,0,0 2007-001951-20,1,2011-04-07,2011-04-07,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,University College London,A phase I and randomised phase II study of Docetaxel and RAD001 (Everolimus) in advanced/recurrent or metastatic squamous cell carcinoma of the head and neck,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001951-20,0,0,0 2007-001953-24,1,2010-03-09,2010-03-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,"''Metformin in Insulin Resistant LV Dysfunction, a double-blind, placebo-controlled trial''",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001953-24,0,0,0 2007-001955-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Genetic Immunity Kft.,"A PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND ANTIRETROVIRAL ACTIVITY OF DERMAVIR (LC002) PATCH IN TREATMENT-NAÏVE HIV-1-INFE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001955-20,0,0,0 2007-001958-99,1,2011-05-30,2011-05-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Merja Soilu Häninen,Collecalciferol as an Add-on Treatment to Subcutaneously-Administred Interferon-beta-1b for Treatment MS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001958-99,0,0,0 2007-001959-19,3,2009-06-05,2009-06-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation","A 2-Week Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Anti- Inflammatory Effects of Low, Medium, and High Dose Mometasone Furoate/Formoterol Fumarate MDI Formulation and Medium...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001959-19,0,0,0 2007-001961-14,1,2008-05-26,2008-05-26,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Greater Glasgow and Clyde,A pilot study of the treatment of facial nodular and nodulocystic basal cell carcinoma with double curettage and cautery followed by application of imiquimod to the base.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001961-14,0,0,0 2007-001961-14,1,2008-05-26,2008-05-26,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Glasgow,A pilot study of the treatment of facial nodular and nodulocystic basal cell carcinoma with double curettage and cautery followed by application of imiquimod to the base.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001961-14,0,0,0 2007-001962-34,1,2008-12-31,2008-12-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,University Medical Center Hamburg Eppendorf,Klassische Konditionierung immunologischer Reaktionen bei Patienten mit Multipler Sklerose während Mitoxantrontherapie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001962-34,0,0,0 2007-001968-78,1,2009-01-06,2009-01-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Argenta Discovery Ltd.,"A Phase II, Randomised, Double-Blind, Placebo-Controlled Pilot Efficacy Study of ADC4022 (Theophylline Solution for Inhalation) on Markers of Pulmonary Inflammation in Subjects with Moderate to Severe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001968-78,0,0,0 2007-001969-15,1,2009-04-27,2009-04-27,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Avontec GmbH,"A multicenter, randomized, double-blind, placebo-controlled, intraindividual-comparison phase IIa trial to evaluate the efficacy and safety of 2% AVT-02 UE ointment in the topical treatment of mild to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001969-15,0,0,0 2007-001972-36,14,2016-03-11,2016-03-11,13,1,0,0,2,1,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, blinded study to assess safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001972-36,0,0,0 2007-001972-36,14,2016-03-11,2016-03-11,13,1,0,0,2,1,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S. A","A multicenter, randomized, blinded study to assess safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001972-36,0,0,0 2007-001972-36,14,2016-03-11,2016-03-11,13,1,0,0,2,1,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A multicenter, randomized, blinded study to assess safety and efficacy of pasireotide LAR vs. octreotide LAR in patients with active acromegaly",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001972-36,0,0,0 2007-001974-10,12,2018-11-26,2018-11-26,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, doubleblind Phase 3 trial of the EORTC M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001974-10,0,0,0 2007-001974-10,12,2018-11-26,2018-11-26,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International,"Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, doubleblind Phase 3 trial of the EORTC M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001974-10,0,0,0 2007-001975-12,5,2009-12-04,2010-01-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT - IDPF,"Evaluación del efecto de 6 meses de tratamiento con V0191 sobre la evolución de los síntomas en pacientes con un déficit cognitivo leve. Estudio multicéntrico, de asignación aleatoria, doble ciego, en...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001975-12,0,0,0 2007-001979-10,3,2012-01-31,2012-01-31,3,0,0,0,1,0,3,0,0,1,1,0,1,0,1,AIR LIQUIDE,AN INTERNATIONAL PHASE III RANDOMISED TRIAL COMPARING THE PROPOFOL CONSUMPTION DURING GENERAL ANAESTHESIA WITH XENON IN INSPIRATORY CONCENTRATIONS OF 50 % AND 70% AND TOTAL IV ANAESTHESIA ALONE IN A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001979-10,0,0,0 2007-001984-31,8,2010-04-15,2010-04-16,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A","A PHASE 2 RANDOMIZED, MULTICENTER, ACTIVE COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF COADMINISTRATION OF CP-690,550 AND MYCOPHENOLATE MOFETIL / MYCOPHENOLATE SODIUM IN DE NO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001984-31,0,0,0 2007-001984-31,8,2010-04-15,2010-04-16,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY10017","A PHASE 2 RANDOMIZED, MULTICENTER, ACTIVE COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF COADMINISTRATION OF CP-690,550 AND MYCOPHENOLATE MOFETIL / MYCOPHENOLATE SODIUM IN DE NO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001984-31,0,0,0 2007-001984-31,8,2010-04-15,2010-04-16,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,"A PHASE 2 RANDOMIZED, MULTICENTER, ACTIVE COMPARATOR-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF COADMINISTRATION OF CP-690,550 AND MYCOPHENOLATE MOFETIL / MYCOPHENOLATE SODIUM IN DE NO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001984-31,0,0,0 2007-001985-34,2,2009-02-02,2009-05-05,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"& Johnson Pharmaceutical Research & Development, L.L.C.","A randomized withdrawal, active- and placebo-controlled, double-blind, multi-center Phase III trial assessing safety and efficacy of oral CG5503 PR* in subjects with moderate to severe chronic maligna...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001985-34,0,0,0 2007-001985-34,2,2009-02-02,2009-05-05,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","A randomized withdrawal, active- and placebo-controlled, double-blind, multi-center Phase III trial assessing safety and efficacy of oral CG5503 PR* in subjects with moderate to severe chronic maligna...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001985-34,0,0,0 2007-001987-55,4,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,University Of Birmingham,A randomised trial assessing whether preoperative chemotherapy improves outcome in high-risk operable colon cancer Ensayo clínico aleatorizado para evaluar si la quimioterapia preoperatoria mejora ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001987-55,0,0,0 2007-001991-34,1,2009-06-02,2009-06-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,3,Boehringer Ingelheim Limited,"A randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of 4 weeks treatment with bisacodyl (Dulcolax®) tablets 10 mg administered orally, once daily, in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001991-34,0,0,0 2007-001994-27,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Netherlands Heart Foundation,The effect of beta-adrenergic receptor blockade on sympathetic activity and coagulation in patients with heart failure (BACH-F study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001994-27,0,0,0 2007-001996-13,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SENESE,Intravenous glycoprotein IIbIIIa inhibitor (Tirofiban) combined with low dose of intra-arterial Urokinase for the endovascolar treatment of patients with acute major ischemic stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001996-13,0,0,0 2007-001997-97,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,IFCT,COMPARISON OF 2 CHEMOTHERAPY REGIMENS IN NON SMALL CELL LUNG CANCER PATIENTS RELAPSING AFTER SURGERY AND PERI OPERATIVE CHEMOTHERAPY A RANDOMIZED PHASE III STUDY.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001997-97,0,0,0 2007-002004-18,1,2019-03-26,2019-03-26,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,GORTEC,"Essai randomisé multicentrique de phase III, évaluant l’apport d’une chimiothérapie concomitante chez les patients traités par Radiothérapie–Erbitux pour un carcinome localement évolué des VADS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002004-18,0,0,0 2007-002005-45,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,A.O. San Gerardo di Monza,Comparative trial between HyperHAES (7.2% sodio cloruro / 6% hydrxyethyl starch) and 20% mannitol for treatmenti intracranial hypertension in traumatic brain injury,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002005-45,0,0,0 2007-002007-41,1,2014-07-11,2014-07-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA ORDINE MAURIZIANO,A Phase II Clinical Trial of Panitumumab in Combination with Infusional Oxaliplatin and Oral Capecitabine (XELOX) Chemotherapy as 1st line Therapy in Patients with Colorectal Cancer and Advanced Liver...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002007-41,0,0,0 2007-002009-31,1,,,0,0,0,0,0,0,2,0,1,1,1,1,0,1,1,Emotional Brain BV,"A double blind randomized placebo controlled cross-over study to validate the distinction between women with different levels of attention and valence direction for erotic stimuli, in relation with ge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002009-31,0,0,0 2007-002010-19,1,2009-04-09,2009-04-09,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,University of Dundee,The TASCFORCE Project: Tayside Screening For risk of Cardiac Events and the effect of statin on risk reduction (as evidenced by change in LV mass),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002010-19,0,0,0 2007-002015-38,5,2009-10-27,2010-01-07,2,0,0,0,0,1,2,0,0,2,0,0,0,0,1,ISDIN S.A.,"""ENSAYO CLÍNICO MULTICÉNTRICO, FASE II, ALEATORIZADO, DOBLE CIEGO, CONTROLADO INTRAINDIVIDUALMENTE CON PLACEBO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE P144 EN EL TRATAMIENTO TÓPICO DE LA FIBROSIS CUT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002015-38,1,0,0 2007-002015-38,5,2009-10-27,2010-01-07,2,0,0,0,0,1,2,0,0,2,0,0,0,0,1,ISDIN,"""ENSAYO CLÍNICO MULTICÉNTRICO, FASE II, ALEATORIZADO, DOBLE CIEGO, CONTROLADO INTRAINDIVIDUALMENTE CON PLACEBO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE P144 EN EL TRATAMIENTO TÓPICO DE LA FIBROSIS CUT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002015-38,1,0,0 2007-002016-26,4,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Finnish Braest Cancer Group,"A randomised Phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002016-26,0,0,0 2007-002016-26,4,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Finnish Breast Cancer Group,"A randomised Phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002016-26,0,0,0 2007-002016-26,4,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,FBCSG (Finish Breast Cancer Study Group),"A randomised Phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002016-26,0,0,0 2007-002016-26,4,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,The Finnish Breast Cancer Group,"A randomised Phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002016-26,0,0,0 2007-002017-39,10,2008-07-10,2008-10-10,10,1,0,0,0,0,0,0,0,1,0,0,1,0,2,MERCK SHARP DOHME,"A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002017-39,0,0,0 2007-002017-39,10,2008-07-10,2008-10-10,10,1,0,0,0,0,0,0,0,1,0,0,1,0,2,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002017-39,0,0,0 2007-002017-39,10,2008-07-10,2008-10-10,10,1,0,0,0,0,0,0,0,1,0,0,1,0,2,Laboratoires Merck Sharp & Dohme - Chibret,"A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002017-39,0,0,0 2007-002017-39,10,2008-07-10,2008-10-10,10,1,0,0,0,0,0,0,0,1,0,0,1,0,2,"Merck Sharp & Dohme de España, S.A.","A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002017-39,0,0,0 2007-002017-39,10,2008-07-10,2008-10-10,10,1,0,0,0,0,0,0,0,1,0,0,1,0,2,Merck Sharp & Dohme BV,"A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002017-39,0,0,0 2007-002017-39,10,2008-07-10,2008-10-10,10,1,0,0,0,0,0,0,0,1,0,0,1,0,2,Merck Sharp & Dohme GmbH,"A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002017-39,0,0,0 2007-002017-39,10,2008-07-10,2008-10-10,10,1,0,0,0,0,0,0,0,1,0,0,1,0,2,Merck Sharp & Dohme (Sweden) AB,"A Multicenter, Randomized, Double-Blind, Parallel Group, 12-Week Study to Evaluate the Efficacy and Safety of Extended-Release (ER) Niacin/Laropiprant Added to Statin Versus Doubling the Dose of Sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002017-39,0,0,0 2007-002023-32,1,2013-02-18,2013-02-18,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Charité - Universitätsmedizin Berlin,Niaspan for the treatment of endothelial dysfunction in patients without hyperlipoproteinemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002023-32,0,0,0 2007-002031-92,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Otto-von-Guericke University,"Proliferation and differentiation markers, involved in erosive and non-erosive reflux esophagitis, Barrett´s esophagus and esophageal adenocarcinoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002031-92,0,0,0 2007-002035-81,5,2010-05-22,2010-05-22,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Artisan Pharma, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated Intravascular Coagulation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002035-81,0,0,0 2007-002036-28,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Universitätsklinikum Essen,"Prospektive, randomisierte, kontrollierte, unizentrische, offene, Studie zur Thromboembolieprophylaxe mit Enoxaparin bei nicht-chirurgischen onkologischen Patienten unter systemischer antineoplasti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002036-28,0,0,0 2007-002041-20,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Essai de prévention de la dysplasie broncho-pulmonaire par l'hydrocortisone postnatale précoce chez le très grand prématuré,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002041-20,0,0,0 2007-002047-24,2,2018-05-16,2018-05-16,1,1,0,0,0,1,2,0,0,2,0,0,0,0,0,Swiss Group for Clinical Cancer Reaserch (SAKK),Trial SAKK 56/07 Dasatinib first-line treatment in gastrointestinal stromal tumors. A multicenter phase II trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002047-24,1,0,0 2007-002053-24,1,2013-05-15,2013-05-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,The Christie NHS Foundation Trust,"A phase II study evaluating the use of concurrent cetuximab, irinotecan, oxaliplatin and UFT in the first line treatment of patients with metastatic colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002053-24,0,0,0 2007-002058-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",EFFICACY EVALUATION OF TADALAFIL 20 MG ON DEMAND VS TADALAFIL 5 MG DAILY AS TREATMENT MODALITY FOR ERECTILE DYSFUNCTION FOLLOWING RADICAL RADIOTHERAPY IN PROSTATIC CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002058-41,0,0,0 2007-002059-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,"A Phase II study evaluating intermittent letrozole as adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, early stage breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002059-18,0,0,0 2007-002060-10,1,2007-11-01,2007-11-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ikfe GmbH,Pharmacokinetics and Pharmacodynamics of subcutaneous applied insulin aspart administered with the FlexPen® insulin pen compared to inhaled insulin administered with the Exubera® device,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002060-10,0,0,0 2007-002061-12,3,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,SBG,A randomized phase III study Comparing biweekly and tailored epirubicin + cyclophosphamide followed by biweekly tailored docetaxel (dtEC -- dtT)(A-arm) versus three weekly epirubicin + cyclophosphamid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002061-12,0,0,0 2007-002061-12,3,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,ABCSG (Austrian Breast & Colorectal Cancer Study Group),A randomized phase III study Comparing biweekly and tailored epirubicin + cyclophosphamide followed by biweekly tailored docetaxel (dtEC -- dtT)(A-arm) versus three weekly epirubicin + cyclophosphamid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002061-12,0,0,0 2007-002061-12,3,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,SBG (Scandinivian Breast Cancer Group),A randomized phase III study Comparing biweekly and tailored epirubicin + cyclophosphamide followed by biweekly tailored docetaxel (dtEC -- dtT)(A-arm) versus three weekly epirubicin + cyclophosphamid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002061-12,0,0,0 2007-002063-27,1,2007-08-16,2007-08-16,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics Limited,"A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of FLUVIRIN® Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2007-2008, when Admini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002063-27,0,0,0 2007-002065-12,1,2010-01-20,2010-01-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche Farma. S.A,"""Estudio abierto, randomizado, controlado para comparar la eficacia, seguridad y tolerancia de la administración una vez al mes de C.E.R.A por vía intravenosa frente a epoetina alfa para el mantenimie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002065-12,0,0,0 2007-002066-35,7,2009-01-13,2009-01-14,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED ACTIVE COMPARATOR, MULTICENTER STUDY TO COMPARE 5 DOSE REGIMENS OF CP-690,550 AND ADALIMUMAB VERSUS PLACEBO, ADMINISTERED FOR 6 MONTHS IN THE T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002066-35,0,0,0 2007-002066-35,7,2009-01-13,2009-01-14,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,"A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED ACTIVE COMPARATOR, MULTICENTER STUDY TO COMPARE 5 DOSE REGIMENS OF CP-690,550 AND ADALIMUMAB VERSUS PLACEBO, ADMINISTERED FOR 6 MONTHS IN THE T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002066-35,0,0,0 2007-002069-11,1,2009-08-01,2009-08-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ. Klinik für Innere Medizin III, Abteilung für Gastroenterologie",PHARMACOKINETICS OF GANCICLOVIR DURING CONTINUOUS RENAL REPLACEMENT THERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002069-11,0,0,0 2007-002070-61,10,2008-06-26,2008-06-26,7,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"MedImmune, LLC","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002070-61,1,1,0 2007-002070-61,10,2008-06-26,2008-06-26,7,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"MedImmune, Inc.","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002070-61,1,1,0 2007-002070-61,10,2008-06-26,2008-06-26,7,1,1,0,0,0,2,0,0,2,0,0,0,0,1,MedImmune LLC,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002070-61,1,1,0 2007-002074-58,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Instituto de Investigaciones del Sueño,"Estudio unicéntrico, aleatorizado, doble ciego, de diseño cruzado, controlado con placebo, de nueve semanas de duracion para evaluar la eficacia de oxibato sodico en pacientes con el síndrome de las p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002074-58,0,0,0 2007-002077-31,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,SANOFI-AVENTIS S.P.A,Effects of Rimonabant on urinary albumin excretion rate on the components of the metabolic syndrome in patients with type 2 diabetes mellitus and microalbuminuria on background ramipril treatment. A p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002077-31,0,0,0 2007-002078-71,1,,,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,Wilhelmina Children's Hospital/UMC Utrecht,Reductie van Hersenschade na “Perinatal Arterial Stroke”of PAS met recombinant humaan Erythropoietine (rhEPO): Een “Proof of Concept” en “Safety” studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002078-71,0,0,0 2007-002080-27,1,2015-07-05,2015-07-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Greater Glasgow Health Board/University of Glasgow,"A randomised, double-blind controlled trial of ketamine versus placebo in conjunction with best pain management in neuropathic pain in cancer patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002080-27,0,0,0 2007-002082-13,1,2011-08-22,2011-08-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Randomised, double-blind, placebo-controlled, multicentre, comparative phase II pilot study on the efficacy and tolerability of an 8-week rectal treatment with 2 mg budesonide or placebo for the preve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002082-13,0,0,0 2007-002083-98,1,2008-12-15,2008-12-15,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Taxolog, Inc.",A Phase II Study of Milataxel (TL139) Administered Orally or Intravenously in Taxane Naïve Patients with Metastatic Breast Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002083-98,0,0,0 2007-002084-27,1,2013-11-12,2013-11-12,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Imperial College,The pharmacokinetics and anti-inflammatory effects of prednisolone in severe asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002084-27,0,0,0 2007-002087-10,1,2009-01-07,2009-01-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double -blind, placebo-controlled, parallel group study to assess the efficacy and safety of 4 weeks treatment with sodium picosulphate [Dulcolax®, Laxoberal®] drops 10 mg administered o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002087-10,0,0,0 2007-002088-29,3,2009-07-06,2009-07-06,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Rheoscience A/S,Efficacy and Safety of Treatment with Balaglitazone in Type 2 Diabetes Patients on Stable Insulin Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002088-29,0,0,0 2007-002090-31,3,2008-10-10,2008-10-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,MedImmune Limited,"A double-blind, placebo-controlled parallel-group study to assess the efficacy, safety, and tolerability of CAT-354",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002090-31,0,0,0 2007-002092-14,11,2009-05-30,2009-09-18,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"Efficacy and safety of Alefacept in combination with Tacrolimus, Mycophenolate Mofetil and Steroids in de-novo kidney transplantation - a multicenter, randomized, double-blind, placebo controlled, par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002092-14,0,0,0 2007-002093-60,8,2011-12-07,2011-12-07,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"BioCryst Pharmaceuticals, Inc.",Ensayo de agente único en fase II sobre la forodesina (BCX1777) en el tratamiento del linfoma cutáneo de células T,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002093-60,0,0,0 2007-002093-60,8,2011-12-07,2011-12-07,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,BIOCRYST PHARMACEUTICALS INC.,Ensayo de agente único en fase II sobre la forodesina (BCX1777) en el tratamiento del linfoma cutáneo de células T,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002093-60,0,0,0 2007-002097-61,1,2012-10-31,2012-10-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Danish Head and Neck Cancer Group,Undersøgelse af betydningen af EGFr antistoffet Zalutumumab for effekten af strålebehandling til patienter med primært planocellulært hoved-hals karcinom.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002097-61,0,0,0 2007-002098-30,1,2008-07-08,2008-07-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,MannKind Corporation,Evaluation of the Effect of Symptomatic Upper Respiratory Infections on Pharmacological Characteristics of Technosphere®/Insulin in Subjects with Diabetes Mellitus after a Meal Challenge,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002098-30,0,0,0 2007-002101-50,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Acuity Pharmaceuticals, LLC","A Phase 2, randomized, double-masked, placebo-controlled, parallel-assignment study of topical N-Chlorotaurine (NCT) formulated with ammonium chloride administered for 10 days in patients with epidemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002101-50,0,0,0 2007-002102-22,1,2013-11-04,2013-11-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Gasthuisberg Leuven,"Multicenter, prospective, randomized, open-label study of the safety and efficacy of a Certican® -based regimen versus a calcineurin inhibitor (CNI)-based regimen in maintenance heart transplant recip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002102-22,0,0,0 2007-002104-18,1,2008-05-05,2008-05-05,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated either with an Inactivated Influenza Vaccine Administered via the Intradermal Route or an Inac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002104-18,0,0,0 2007-002105-44,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,"Military Medical Academy Hospital for Active Treatment, Sofia","Open – label, non randomized clinical study of Neoadjuvant chemotherapy with FOLFIRI and Avastin in patients with non-resectable liver metastases of colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002105-44,0,0,0 2007-002109-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO,USE OF FENOLDOPAM TO IMPROVE GLOMERULAR FILTRATION RATE IN EARLY RENAL DYSFUNCTION AFTER LIVER TRANSPLANTATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002109-32,0,0,0 2007-002111-82,9,2009-04-02,2009-04-02,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen-Cilag International N.V., Turnhoutseweg 30, 2340 Beerse, Belgium","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) in A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002111-82,0,0,0 2007-002111-82,9,2009-04-02,2009-04-02,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) in A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002111-82,0,0,0 2007-002111-82,9,2009-04-02,2009-04-02,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen-Cilag International N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) in A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002111-82,0,0,0 2007-002112-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,YORK Pharma GmbH,"Open, single-arm phase-III study to investigate the percutaneous absorption of abafungin after topical dermal application of Abafungin cream 1.0 % (YORK Pharma GmbH) in 20 patients with tinea pedis in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002112-26,0,0,0 2007-002114-19,5,2010-10-08,2010-10-08,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A phase II, randomized, double-blind, parallel-group, placebo-controlled, 12-week treatment, adaptive proof-of-principle study of twice daily oral dosing of a novel PDE4 inhibitor (ASP9831) in subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002114-19,0,0,0 2007-002115-59,1,2012-11-06,2012-11-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,GERCOR,CHIMIOTHERAPIE AVEC OU SANS ANTICOAGULATION PREVENTIVE DANS LES CANCERS DU PANCREAS METASTATIQUES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002115-59,0,0,0 2007-002116-25,1,2013-10-30,2013-10-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GERCOR,chimiothérapie d'induction par Erbitux-Taxotère-Cisplatine-5FU (ETPF) dans les carcinomes épidermoides de l'oropharynx de stade III-IV opérables,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002116-25,0,0,0 2007-002117-39,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Jorge Matias-Guiu Guia,MEMANTINA (Ebixa X) PARA LA DISCAPACIDAD FUNCIONAL EN LA ESCLEROSIS LATERAL AMIOTRÓFICA MEMANTINE (Ebixa R) FOR FUNCTIONAL DISABILITY IN AMYOTROPHIC LATERAL SCLEROSIS .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002117-39,0,0,0 2007-002119-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universität des Saarlandes,EPLERAF-Studie: Eplerenon in der Prävention von Vorhofflimmer-Rezidiven nach Kardioversion / [EPLERAF-Study: Eplerenone in the prevention of atrial fibrillation recurrences after cardioversion],https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002119-17,0,0,0 2007-002120-14,3,2009-09-25,2009-09-25,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,Wyeth Research Division of Wyeth Pharmaceutical Inc.,"A Multicenter, Open-Label, Ascending Multiple-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002120-14,1,1,0 2007-002120-14,3,2009-09-25,2009-09-25,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"Wyeth Parmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA","A Multicenter, Open-Label, Ascending Multiple-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002120-14,1,1,0 2007-002121-80,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"A prospective, double-blind, multi center, randomized clinical study to compare the efficacy and safety of Ertapenem 3 days versus Ampicillin- Sulbactam 3 days in the treatment of localized community ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002121-80,0,0,0 2007-002122-30,1,2008-12-31,2008-12-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Medical University Vienna Division of Anesthesie and Pain Management,The effect of different solvents of HES preparations on coagulation and platelet function (Effekt der Trägerlösung von HES Präparaten auf Blutgerinnung und Thrombozytenfunktion),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002122-30,0,0,0 2007-002123-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Use of Bone Morphogenic Protein 7 in the atrophic maxilla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002123-32,0,0,0 2007-002125-68,5,2011-01-21,2011-05-02,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,Evaluation of Belatacept as First-line Immunosuppression in De Novo Liver Transplant Recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002125-68,0,0,0 2007-002128-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Nîmes,Anesthésie topique versus anesthésie épisclérale pour chirurgie de la cataracte,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002128-14,0,0,0 2007-002130-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació de l'Institut de Recerca HSCSP,"Estrategias terapéuticas en Trastorno Depresivo Mayor resistente a tratamiento con Inhibidores Selectivos de la Recaptación de la Serotonina. Ensayo clínico pragmático, paralelo, aleatorizado con eval...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002130-11,0,0,0 2007-002132-29,1,2011-02-15,2011-02-15,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Oxford Radcliffe Hospitals NHS Trust,A Phase II Trial of Sorafenib (a tyrosine kinase inhibitor) given orally twice daily in renal cancer patients with vHL syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002132-29,0,0,0 2007-002133-36,3,2008-07-01,2008-08-04,3,0,0,0,0,0,4,0,0,1,0,0,1,0,1,INTENDIS GmbH,"A multicenter, randomised, double-blind clinical study to examine the efficacy and safety of ZARZENDA in comparison to Elidel in the management of mild to moderate Atopic Dermatitis in children and ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002133-36,0,0,0 2007-002133-36,3,2008-07-01,2008-08-04,3,0,0,0,0,0,4,0,0,1,0,0,1,0,1,INTENDIS GMBH,"A multicenter, randomised, double-blind clinical study to examine the efficacy and safety of ZARZENDA in comparison to Elidel in the management of mild to moderate Atopic Dermatitis in children and ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002133-36,0,0,0 2007-002135-83,1,2011-08-12,2011-08-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche Romania SRL,An open label study to evaluate the effect of first line treatment with Tarceva in combination with Gemcitabine on disease progression in patients with unresectable advanced and/or metastatic non-smal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002135-83,0,0,0 2007-002137-37,1,2012-07-18,2012-07-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TRIO Medicines Ltd,Does adding YF476 to amoxicillin and clarithromycin aid eradication of H. pylori from healthy carriers?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002137-37,0,0,0 2007-002138-13,1,2009-01-16,2009-01-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GW Pharma Ltd.,"A placebo controlled, parallel group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term GW-1000-02 (Sativex®).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002138-13,0,0,0 2007-002139-94,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Innate Pharma,Multiple dose Phase II study of IPH1101 in monotherapy or associated with a low dose of IL2 (2MIU) in non previously treated hepatitis C patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002139-94,0,0,0 2007-002140-24,1,2009-02-28,2009-02-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,CSC Pharmaceuticals Handels GmbH.,"Open-label, Multicenter Clinical Study of Dose-dependent Efficacy and Safety of Trazodone Hydrochloride in Patients wirh Major Depressive Disorder ans Pain (TIPAD Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002140-24,0,0,0 2007-002142-37,2,2012-11-01,2012-11-01,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Innsbruck,"SUNITINIB (SUTENT, SU11248) in Patients with Recurrent or Progressive Glioblastoma multiforme An Academic Prospective Single-arm Phase II Clinical Trial including Translational Research Studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002142-37,0,0,0 2007-002143-25,2,2012-11-23,2012-11-23,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,Abbott GmbH & Co. KG,"A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002143-25,0,0,0 2007-002143-25,2,2012-11-23,2012-11-23,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002143-25,0,0,0 2007-002145-21,3,2007-07-03,2008-07-03,2,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Procter & Gamble Pharmaceuticals,"A Phase II, Randomized, Placebo-controlled Study of ATI-7505 in Patients with Chronic Idiopathic Constipation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002145-21,0,0,0 2007-002149-20,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA,Contrast indiced nephropaty (CIN) in patients undergoing primary angioplasty for acute myocardial infarction. Randomized trial on the effects of hydration with saline or sodium bicarbonate.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002149-20,0,0,0 2007-002150-39,2,2008-09-26,2008-09-26,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company Ltd.,Estudio COMPLETE DT2: COMParación de una suspensión de insulina Lispro protamina y DETEmir en Diabetes mellitus Tipo 2 Comparación de dos análogos de insulina basal (suspensión de insulina Lispro pro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002150-39,0,0,0 2007-002150-39,2,2008-09-26,2008-09-26,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Lilly S.A.,Estudio COMPLETE DT2: COMParación de una suspensión de insulina Lispro protamina y DETEmir en Diabetes mellitus Tipo 2 Comparación de dos análogos de insulina basal (suspensión de insulina Lispro pro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002150-39,0,0,0 2007-002154-28,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Maastricht University,Effects of insomnia and chronic use of hypnotics on driving performance,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002154-28,0,0,0 2007-002155-17,2,2011-12-20,2011-12-20,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002155-17,0,0,0 2007-002155-17,2,2011-12-20,2011-12-20,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002155-17,0,0,0 2007-002156-42,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,VALEAS,Effects of Treatment with Cefaclor in acute pharyngotonsillitis and activity on the immune system,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002156-42,0,0,0 2007-002157-23,1,2010-01-15,2010-01-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Elpen Pharmaceutical Co. Inc.,"A 8-week, multicentre, randomized, double-blind, double-dummy, parallel group, non-inferiority study, comparing Formoterol (Formopen®) administered via Elpenhaler® Dry Powder Inhaler versus the innova...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002157-23,0,0,0 2007-002160-10,1,2007-07-26,2007-07-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A prospective, open-label, single arm, multinational, multi-centre, flexible dose, extension study of the SCoP 99824 with sertindole for patients suffering from schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002160-10,0,0,0 2007-002168-84,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Kneipp-Werke,Wirksamkeit und Verträglichkeit von Kneipp Arnika Salbe S bei stumpfen Sportverletzungen im Vergleich zu Ibutop Creme (Efficacy and Safety of Kneipp Arnika Salbe S for blunt impact sport injuries comp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002168-84,0,0,0 2007-002169-11,1,2011-09-23,2011-09-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Wolverhampton Hospitals Trust,Cost Analysis Of Cetuximab (Erbitux) Plus Radiotherapy (ERT) Versus Concomitant Cisplatin Plus Radiotherapy (CRT) Within An NHS Oncology Unit (New Cross Hospital Wolverhampton): A Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002169-11,0,0,0 2007-002171-13,2,2010-04-06,2010-04-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Celgene International Sàrl,"A PHASE II, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE-AGENT LENALIDOMIDE (REVLIMID®) IN SUBJECTS WITH RELAPSED OR REFRACTORY T-CELL NON-HODGKIN’S LYMPHOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002171-13,0,0,0 2007-002172-34,3,2009-03-30,2009-03-30,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,"A double-blind, randomized, placebo-controlled, study evaluating the safety and activity of four escalating single doses of AVE0657 in congestive heart failure patients presenting as Cheyne-Stokes Bre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002172-34,0,0,0 2007-002174-58,3,2009-01-19,2009-01-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A double-blind, randomized, placebo-controlled, study of the safety and activity of four escalating single doses of AVE0657 in patients suffering from Obstructive Sleep Apnea Hypopnea Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002174-58,0,0,0 2007-002176-34,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,GEIS,"Ensayo clínico de fase I-II, no aleatorizado, multicentrico para evaluar la seguridad y la eficacia de la combinación de sorafenib (BAY 43-9006) e ifosfamida en el tratamiento de pacientes con sarcoma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002176-34,0,0,0 2007-002179-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude des effets de la méthylprednisolone à fortes doses sur les caractéritiques électrophysiologiques de la fatigabilité à l'effort au cours des poussées de sclérose en plaques,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002179-15,0,0,0 2007-002182-12,1,,,0,0,0,0,1,0,3,0,0,4,0,0,0,0,1,Stiefel Laboratories,"A SINGLE CENTER, SINGLE-BLIND, PARALLEL GROUP CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF W0153 VS. STANDARD MOISTURIZER IN THE MAINTENANCE OF PATIENTS WITH ATOPIC DERMATITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002182-12,0,0,0 2007-002183-99,3,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,INNOVIVE PHARMACEUTICALS,A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy with ATRA and Arsenic Trioxide (STAR-1),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002183-99,0,0,0 2007-002183-99,3,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,INNOVIVE Pharmaceuticals,A Phase II Study of Oral Tamibarotene in Acute Promyelocytic Leukemia Patients Who Have Received Prior Therapy with ATRA and Arsenic Trioxide (STAR-1),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002183-99,0,0,0 2007-002195-34,1,2010-07-02,2010-07-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"Evaluation of the effect of 6 months treatment with DC158AM on fatigue in patients with Parkinson’s disease. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002195-34,0,0,0 2007-002198-30,1,2011-06-30,2011-06-30,1,0,0,0,0,1,3,0,0,1,1,1,1,0,0,Inserm-ISP Pole Recherches cliniques et thérapeutiques,"A MULTICENTRE RANDOMIZED CONTROLLED TRIAL COMPARING TOPIRAMATE, STIRIPENTOL AND CLOBAZAM AT THE MAXIMAL TOLERATED DOSAGE, AS ADJUNCTIVE THERAPY TO VALPROATE AND CLOBAZAM IN PAEDIATRIC PATIENTS WITH DR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002198-30,0,0,0 2007-002201-53,1,2010-07-19,2010-07-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital of South Manchester Nhs Foundation Trust,An observational study of i)mini-area-under-the-curve (mini-AUC) estimation of exposure to mycophenolic acid (MPA) in heart transplant and lung transplant recipients on mycophenolate mofetil (MMF)or M...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002201-53,0,0,0 2007-002203-40,1,2008-12-15,2008-12-15,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"St. George's, University of London",Effect of hydrocortisone on desire to smoke and tobacco withdrawal symptoms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002203-40,0,0,0 2007-002205-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dra. Irene Halperin Rabinovich. Servicio de Endocrinología. Hospital Clínic de Barcelona,UTILIDAD DE LA GAMMAGRAFÍA CON 99mTc-DEPREOTIDE EN PACIENTES CON NEOPLASIA DIFERENCIADA DE TIROIDES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002205-41,0,0,0 2007-002208-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Danube Pharmaceuticals,"A Phase IIa, Multi-Center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DNB-001 in Patients with Angina Pectoris and Moderate Chronic Kid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002208-17,0,0,0 2007-002211-11,1,2008-02-07,2008-02-07,1,0,0,1,0,1,1,0,0,1,1,1,0,0,1,"Molecular Insight Pharmaceuticals, Inc","A PHASE I-II STUDY EVALUATING THE MAXIMUM TOLERATED DOSE, DOSIMETRY, SAFETY, AND EFFICACY OF ULTRATRACE™ IOBENGUANE I 131 IN PATIENTS WITH MALIGNANT PHEOCHROMOCYTOMA/PARAGANGLIOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002211-11,0,0,0 2007-002212-26,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Groupe Francophone des Myélodysplasies,A Phase I/II Study of Vorinostat in Combination with Low Dose Ara-C for Patients with Intermediate-2 or High Risk Myelodysplastic Syndromes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002212-26,0,0,0 2007-002218-21,5,2010-01-16,2010-01-27,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of Sitagliptin and MK-0431A (A Fixed-DOse Combination Tablet of Sitagliptin and Metf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002218-21,0,0,0 2007-002218-21,5,2010-01-16,2010-01-27,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co, Inc.","A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of Sitagliptin and MK-0431A (A Fixed-DOse Combination Tablet of Sitagliptin and Metf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002218-21,0,0,0 2007-002218-21,5,2010-01-16,2010-01-27,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck & Co inc,"A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of Sitagliptin and MK-0431A (A Fixed-DOse Combination Tablet of Sitagliptin and Metf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002218-21,0,0,0 2007-002218-21,5,2010-01-16,2010-01-27,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of Sitagliptin and MK-0431A (A Fixed-DOse Combination Tablet of Sitagliptin and Metf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002218-21,0,0,0 2007-002221-76,1,2007-12-31,2007-12-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GSK Biologicals,"An open, phase IV, single-group, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B (HBV) vaccine challenge in children ag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002221-76,0,0,0 2007-002222-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Jazz Pharmaceuticals Inc.,"Single- and Multiple-Dose Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Sodium Oxybate (Xyrem®) in Subjects with Moderate to Severe Essential Tremor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002222-30,0,0,0 2007-002223-32,2,2010-09-01,2011-11-26,2,1,0,0,0,0,3,0,0,1,1,0,1,0,0,Charité Universitaetsmedizin,"A multicentre, double-blind, randomised controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002223-32,0,0,0 2007-002224-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Göteborgs Universitet,Individual GH dosing using 1st year GH responsiveness for prepubertal growth response in short GHD/ISS children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002224-15,0,0,0 2007-002237-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut de Recerca del Hopsital de la Santa Creu i Sant Pau,"TRATAMIENTO GUIADO SEGÚN RESPUESTA HEMODINÁMICA, PARA LA PREVENCIÓN DE RECIDIVA HEMORRÁGICA POR VARICES ESOFÁGICAS. ESTUDIO CONTROLADO Y ALEATORIZADO, FASE IV.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002237-37,0,0,0 2007-002239-97,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Ketamine en association avec une PCA morphine dans le traitement analgésique postopératoire de patients opérés de prothèse totale de hanche (PTH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002239-97,0,0,0 2007-002243-25,6,2008-09-25,2008-10-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002243-25,0,0,0 2007-002243-25,6,2008-09-25,2008-10-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002243-25,0,0,0 2007-002245-20,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,Zentralinstitut für Seelische Gesundheit Mannheim,Evaluation of potential central glucoregulatory compounds to treat/ameliorate the symptoms of schizophrenia: a proof-of-concept study in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002245-20,0,0,0 2007-002254-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU d'Amiens,"omparaison randomisée en double aveugle du délai d’action de la Ropivacaïne 0,75% contre un mélange [Ropivacaïne 0,75% + Mépivacaïne 1,5%] pour le bloc du nerf sciatique par voie subglutéale",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002254-31,0,0,0 2007-002256-42,1,2010-11-30,2010-11-30,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Bayer Schering Pharma AG,"An open-label, non-randomized, multi-center study to optimize image assessment and evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) for detection/exclusi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002256-42,0,0,0 2007-002257-23,4,2011-03-11,2011-03-11,3,1,0,0,0,1,3,0,0,1,1,1,1,0,0,European Organization for Research and Treatment of Cancer,A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002257-23,0,0,0 2007-002257-23,4,2011-03-11,2011-03-11,3,1,0,0,0,1,3,0,0,1,1,1,1,0,0,ITALIAN SARCOMA GROUP,A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002257-23,0,0,0 2007-002293-54,1,2010-04-02,2010-04-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,The APEX Trial: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients with Cardiac Syndrome X,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002293-54,0,0,0 2007-002314-19,1,2009-02-04,2009-02-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical University of Vienna, Department of Anesthesiology",Larynxmaske bei Kindern nach Atemwegsinfekt: Der Effekt topischer Anästhesie mit Lidocain Effect of Lidocain-gel for laryngeal mask lubrification in pediatric patients after acute respiratory disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002314-19,0,0,0 2007-002315-92,7,2010-11-03,2010-11-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A 52-week, randomised, double-blind, placebo-controlled, parallel-group, safety and tolerability study of nalmefene, as needed use, in patients with alcohol dependence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002315-92,0,0,0 2007-002319-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Nancy,Modulation de la vasoréactivité dans le choc septique : impact de la protéine C recombinante,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002319-16,0,0,0 2007-002321-74,1,2009-04-30,2009-04-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Aarhus University Hospital, Skejby sygehus","Effect of 4 weeks treatment with Acipimox on left ventricular function, work capacity, insulin sensitivity and substrate metabolism in patients with chronic heart failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002321-74,0,0,0 2007-002324-15,1,2010-12-13,2010-12-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of East Anglia,The efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial pneumonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002324-15,0,0,0 2007-002326-29,4,2008-02-13,2008-02-13,4,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Phase 3, Randomized, Double-blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Trivalent Inactiva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002326-29,0,0,0 2007-002328-14,4,2008-09-12,2008-09-12,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,OxThera Inc.,"A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, International Study to Evaluate the Efficacy and Safety of Oxabact(TM) to Reduce Urinary Oxalate in Subjects with Primary Hype...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002328-14,0,0,0 2007-002331-89,1,2011-11-24,2011-11-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Universität Magdeburg, Medizinische Fakultät",Randomisierte Phase II Studie zur Therapieoptimierung der Behandlung des hormonrefraktären Prostatakarzinoms mit Docetaxel + Prednison versus Docetaxel + Prednison + low dose Cyclophosphamid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002331-89,0,0,0 2007-002334-11,4,2010-10-14,2010-10-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Nalmefene Efficacy Study I: Randomised, double-blind, placebo-controlled, parallel-group, efficacy study of 20 mg nalmefene, as needed use, in patients with alcohol dependence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002334-11,0,0,0 2007-002337-36,1,2009-01-13,2009-01-13,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Salford Royal NHS Foundation Trust,An open-labelled study of the cerebrospinal fluid pharmacokinetics of intravenous Kineret® in patients with subarachnoid haemorrhage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002337-36,0,0,0 2007-002341-20,1,2008-12-30,2008-12-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Queen Charlotte's and Chelsea Hospital,Randomized controlled trial comparing the effect of carbetocin vs syntocinon and ergometrine on postpartum haemorrhage in patients undergoing elective caesarean section,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002341-20,0,0,0 2007-002352-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsingin Diakonissalaitos,Lyhyt ja pitkä buprenorfiini-naloksoni -hoito suonensisäisen buprenorfiiniriippuvuuden vieroitushoidossa. Satunnaistettu kontrolloitu tutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002352-41,0,0,0 2007-002357-23,1,2009-12-29,2009-12-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Newcastle Upon Tyne NHS Foundation Trust,"An open label, randomized 2 part crossover study to investigate the effect of buprenorphine transdermal delivery system (BTDS) compared with co-codamol on physical activity in subjects aged 60 years o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002357-23,0,0,0 2007-002359-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Swedish Institute for Infectious Disease Control,DNA vaccination in HIV-vertically infected children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002359-18,0,0,0 2007-002360-10,2,2008-04-10,2008-04-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An exploratory, multi-centre, double-blind, placebo-controlled crossover study, to investigate the bronchodilatory efficacy of a single dose of indacaterol in fixed combination with mometasone furoate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002360-10,0,0,0 2007-002365-13,1,2008-12-10,2008-12-10,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Bayer B.V.,Sorafenib as adjuvant to radioiodine therapy in non-medullary thyroid carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002365-13,0,0,0 2007-002368-83,2,2008-04-06,2008-04-06,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, observer-blind, multicountry, multicenter, study to evaluate the safety, reactogenicity and immunogenicity, of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine administered i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002368-83,0,0,0 2007-002370-64,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Austrian Prostate Study Group (AUPSG),"Multi-center, randomized, double-blind phase II study of sorafenib or placebo with best supportive care after failure of deocetaxol in metastatic hormone-refractory prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002370-64,0,0,0 2007-002371-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Jean Perrin,A Pilot Phase II combination study of Taxotere (Docetaxel) and Erbitux (Cetuximab) as a NEOadjuvant therapy in patients with “triple-negative” (HR and Her2 negative) operable breast cancer. TENEO Stud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002371-13,0,0,0 2007-002372-33,1,2008-01-11,2008-01-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Hormos Medical Ltd,"Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A Phase II dose ranging, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002372-33,0,0,0 2007-002374-55,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,GlaxoSmithKline Consumer Healthcare,Simultaneous fMRI/EEG of the 4 mg nicotine lozenge in relief of cognitive impairment associated with nicotine withdrawal,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002374-55,0,0,0 2007-002376-34,9,2009-01-28,2009-01-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 26-week treatment, multi center, randomized, double blind, double dummy, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 μg o.d.) in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002376-34,0,0,0 2007-002376-34,9,2009-01-28,2009-01-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 26-week treatment, multi center, randomized, double blind, double dummy, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 μg o.d.) in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002376-34,0,0,0 2007-002378-68,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SERVICIO NEFROLOGIA HOSPITAL BELLVITGE,Estudio piloto de Selección de la Inmunosupresión basado en un régimen basado en inhibidores de CNI o libre de CNI dependiendo de la aloreactividad donante-especifica mediante el ensayo ELISPOT en rec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002378-68,0,0,0 2007-002379-16,1,,,0,0,0,0,1,0,4,0,0,1,1,1,0,1,0,I.N.M. NEUROMED (I.R.C.C.S.) S.R.L. GIA' SANATRIX,MULTICENTER TRIAL (SINGLE BLIND)VS ON THE EFFICACY OF LITHIUM SALTS +RILUZOLE VS PLACEBO+RILUZOLE IN PATIENTS AFFECTED BY AMYOTROPHIC LATERAL SCLEROSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002379-16,0,0,0 2007-002380-27,1,2009-07-29,2009-07-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche s.r.o.,"A single arm open label study to assess the efficacy, safety and tolerability and of once-monthly administration of intravenous C.E.R.A. for the maintanance of haemoglobin levels in dialysis patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002380-27,0,0,0 2007-002381-36,7,2009-02-17,2009-06-30,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc.,","A MULTI-CENTER, LONG TERM, OPEN-LABEL STUDY OF [S,S]-REBOXETINE (PNU-165442G) ADMINISTERED ONCE DAILY IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002381-36,0,0,0 2007-002381-36,7,2009-02-17,2009-06-30,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Ltd, Ramsgate Road, Sandwich, Kent UK","A MULTI-CENTER, LONG TERM, OPEN-LABEL STUDY OF [S,S]-REBOXETINE (PNU-165442G) ADMINISTERED ONCE DAILY IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002381-36,0,0,0 2007-002381-36,7,2009-02-17,2009-06-30,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Inc.,"A MULTI-CENTER, LONG TERM, OPEN-LABEL STUDY OF [S,S]-REBOXETINE (PNU-165442G) ADMINISTERED ONCE DAILY IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002381-36,0,0,0 2007-002383-95,7,2009-02-09,2009-10-01,7,1,0,0,0,0,2,0,2,1,0,0,1,0,1,"Merck & Co., Inc.","A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients with Sarcopenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002383-95,0,0,0 2007-002383-95,7,2009-02-09,2009-10-01,7,1,0,0,0,0,2,0,2,1,0,0,1,0,1,"Merck Sharp & Dohme de España, S.A.","A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients with Sarcopenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002383-95,0,0,0 2007-002383-95,7,2009-02-09,2009-10-01,7,1,0,0,0,0,2,0,2,1,0,0,1,0,1,"Merck & Co Inc.,","A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients with Sarcopenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002383-95,0,0,0 2007-002383-95,7,2009-02-09,2009-10-01,7,1,0,0,0,0,2,0,2,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients with Sarcopenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002383-95,0,0,0 2007-002383-95,7,2009-02-09,2009-10-01,7,1,0,0,0,0,2,0,2,1,0,0,1,0,1,MSD Finland Oy,"A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients with Sarcopenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002383-95,0,0,0 2007-002383-95,7,2009-02-09,2009-10-01,7,1,0,0,0,0,2,0,2,1,0,0,1,0,1,Laboratoires Merck Sharp & Dohme- Chibret,"A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0773 in Patients with Sarcopenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002383-95,0,0,0 2007-002384-27,1,2011-03-24,2011-03-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Martin-Luther-Universität Halle Wittenberg,"Hyperbarer Sauerstoff (HBO) in der Behandlung der radiogenen Xerostomie - Eine randomisierte, prospektive Multizenter-Studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002384-27,0,0,0 2007-002402-21,6,2018-05-08,2018-10-31,4,1,0,0,0,2,3,0,0,2,0,0,0,0,2,University of Birmingham,A multi-centre open label randomised phase III trial of the efficacy of Sodium Thiosulphate in reducing ototoxicity in patients receiving Cisplatin chemotherapy for standard risk hepatoblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002402-21,1,0,0 2007-002402-21,6,2018-05-08,2018-10-31,4,1,0,0,0,2,3,0,0,2,0,0,0,0,2,University Hospitals of Leicester NHS Trust,A multi-centre open label randomised phase III trial of the efficacy of Sodium Thiosulphate in reducing ototoxicity in patients receiving Cisplatin chemotherapy for standard risk hepatoblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002402-21,1,0,0 2007-002402-21,6,2018-05-08,2018-10-31,4,1,0,0,0,2,3,0,0,2,0,0,0,0,2,,A multi-centre open label randomised phase III trial of the efficacy of Sodium Thiosulphate in reducing ototoxicity in patients receiving Cisplatin chemotherapy for standard risk hepatoblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002402-21,1,0,0 2007-002402-21,6,2018-05-08,2018-10-31,4,1,0,0,0,2,3,0,0,2,0,0,0,0,2,Sociedad Española de Hematología-Oncología Pediátrica,A multi-centre open label randomised phase III trial of the efficacy of Sodium Thiosulphate in reducing ototoxicity in patients receiving Cisplatin chemotherapy for standard risk hepatoblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002402-21,1,0,0 2007-002402-21,6,2018-05-08,2018-10-31,4,1,0,0,0,2,3,0,0,2,0,0,0,0,2,Our lady's Children's Hospital,A multi-centre open label randomised phase III trial of the efficacy of Sodium Thiosulphate in reducing ototoxicity in patients receiving Cisplatin chemotherapy for standard risk hepatoblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002402-21,1,0,0 2007-002402-21,6,2018-05-08,2018-10-31,4,1,0,0,0,2,3,0,0,2,0,0,0,0,2,Children's Cancer and Leukaemia Group,A multi-centre open label randomised phase III trial of the efficacy of Sodium Thiosulphate in reducing ototoxicity in patients receiving Cisplatin chemotherapy for standard risk hepatoblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002402-21,1,0,0 2007-002402-21,6,2018-05-08,2018-10-31,4,1,0,0,0,2,3,0,0,2,0,0,0,0,2,Centre Hospitalier Universitaire de Besançon,A multi-centre open label randomised phase III trial of the efficacy of Sodium Thiosulphate in reducing ototoxicity in patients receiving Cisplatin chemotherapy for standard risk hepatoblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002402-21,1,0,0 2007-002403-41,1,2010-02-23,2010-02-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE SAS,Etude clinique ouverte randomisée évaluant le traitement préventif par doxycycline sur la survenue d’éruption type folliculite lors du traitement par erlotinib chez les patients atteints d’un cancer b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002403-41,0,0,0 2007-002404-18,6,2009-06-30,2009-06-30,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Norgine Limited,"A multi-centre, multi-national open study in patients with hepatic cirrhosis to characterise the association between the pharmacokinetics of NRL972 and disease severity",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002404-18,0,0,0 2007-002404-18,6,2009-06-30,2009-06-30,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NORGINE LIMITED,"A multi-centre, multi-national open study in patients with hepatic cirrhosis to characterise the association between the pharmacokinetics of NRL972 and disease severity",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002404-18,0,0,0 2007-002405-47,1,2014-10-01,2014-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College,"A randomised prospective study assessing changes in neuro-cognitive function, using a computerised test battery, in treatment naïve HIV-1 positive subjects commencing two different antiretroviral regi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002405-47,0,0,0 2007-002409-36,5,2008-08-18,2008-10-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"An eight-week randomised, 4-arm, double-blind study to compare the efficacy and safety of combinations of telmisartan 40mg + amlodipine 5mg versus telmisartan 80mg + amlodipine 5mg versus amlodipine 5...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002409-36,0,0,0 2007-002409-36,5,2008-08-18,2008-10-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"An eight-week randomised, 4-arm, double-blind study to compare the efficacy and safety of combinations of telmisartan 40mg + amlodipine 5mg versus telmisartan 80mg + amlodipine 5mg versus amlodipine 5...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002409-36,0,0,0 2007-002409-36,5,2008-08-18,2008-10-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"An eight-week randomised, 4-arm, double-blind study to compare the efficacy and safety of combinations of telmisartan 40mg + amlodipine 5mg versus telmisartan 80mg + amlodipine 5mg versus amlodipine 5...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002409-36,0,0,0 2007-002409-36,5,2008-08-18,2008-10-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"An eight-week randomised, 4-arm, double-blind study to compare the efficacy and safety of combinations of telmisartan 40mg + amlodipine 5mg versus telmisartan 80mg + amlodipine 5mg versus amlodipine 5...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002409-36,0,0,0 2007-002410-19,6,2009-03-20,2009-04-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim bv,An open label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 5mg or the combination of telmisartan 80mg + amlodipine 5mg table...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002410-19,0,0,0 2007-002410-19,6,2009-03-20,2009-04-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Finland Ky,An open label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 5mg or the combination of telmisartan 80mg + amlodipine 5mg table...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002410-19,0,0,0 2007-002410-19,6,2009-03-20,2009-04-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,,An open label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 5mg or the combination of telmisartan 80mg + amlodipine 5mg table...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002410-19,0,0,0 2007-002410-19,6,2009-03-20,2009-04-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim AB,An open label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 5mg or the combination of telmisartan 80mg + amlodipine 5mg table...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002410-19,0,0,0 2007-002410-19,6,2009-03-20,2009-04-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,SCS Boehringer Ingelheim Comm.V,An open label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 5mg or the combination of telmisartan 80mg + amlodipine 5mg table...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002410-19,0,0,0 2007-002411-36,1,2010-08-31,2010-08-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Imperial College, London",LungstarPK: Multi centre Phase II Trial of Pravastatin added to chemotherapy with Cisplatin and Docetaxel in patients with non-small cell lung cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002411-36,0,0,0 2007-002414-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOELAMS,Etude prospective multicentrique de phase II évaluant la radioimmunothérapie fractionnée avec un anticorps humanisé anti-CD22 marqué à l'yttrium 90 (90Y-DOTA-hLL2) en consolidation après immuno-chimio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002414-19,0,0,0 2007-002417-39,6,2010-08-26,2010-08-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Ono Pharmaceutical Co., Ltd.","A MULTI-CENTRE RANDOMISED DOUBLE BLIND, PLACEBO AND ACTIVE CONTROLLED PARALLEL GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ONO-5334 IN POST MENOPAUSAL WOMEN WITH OSTEOPENIA OR OSTEOPOROSIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002417-39,0,0,0 2007-002418-20,2,2008-10-02,2008-10-03,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Lilly S.A.,Estudio PERSISTENT: Estudio prospectivo y aleatorizado en el que se compara la suspensión de insulina lispro con protamina con la insulina glargina en pacientes con diabetes tipo 2 que reciben medicac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002418-20,0,0,0 2007-002418-20,2,2008-10-02,2008-10-03,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company Ltd.,Estudio PERSISTENT: Estudio prospectivo y aleatorizado en el que se compara la suspensión de insulina lispro con protamina con la insulina glargina en pacientes con diabetes tipo 2 que reciben medicac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002418-20,0,0,0 2007-002420-15,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Universität Leipzig,Phase II-Studie zur Effizienz der vorzeitigen Reduktion von CSA/MMF bei fallendem linienspezifischen Chimärismus nach allogener Stammzelltransplantation nach Konditionierung mit low-dose TBI/Fludara...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002420-15,0,0,0 2007-002421-68,8,2008-10-17,2009-02-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,"An eight-week randomised, 3-arm, double blind study to compare the safety and efficacy of the combination of telmisartan 40mg + amlodipine 10mg versus telmisartan 80mg + amlodipine 10 mg versus amlodi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002421-68,0,0,0 2007-002421-68,8,2008-10-17,2009-02-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"An eight-week randomised, 3-arm, double blind study to compare the safety and efficacy of the combination of telmisartan 40mg + amlodipine 10mg versus telmisartan 80mg + amlodipine 10 mg versus amlodi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002421-68,0,0,0 2007-002421-68,8,2008-10-17,2009-02-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GesmbH,"An eight-week randomised, 3-arm, double blind study to compare the safety and efficacy of the combination of telmisartan 40mg + amlodipine 10mg versus telmisartan 80mg + amlodipine 10 mg versus amlodi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002421-68,0,0,0 2007-002421-68,8,2008-10-17,2009-02-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"An eight-week randomised, 3-arm, double blind study to compare the safety and efficacy of the combination of telmisartan 40mg + amlodipine 10mg versus telmisartan 80mg + amlodipine 10 mg versus amlodi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002421-68,0,0,0 2007-002421-68,8,2008-10-17,2009-02-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","An eight-week randomised, 3-arm, double blind study to compare the safety and efficacy of the combination of telmisartan 40mg + amlodipine 10mg versus telmisartan 80mg + amlodipine 10 mg versus amlodi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002421-68,0,0,0 2007-002421-68,8,2008-10-17,2009-02-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Austria GmbH,"An eight-week randomised, 3-arm, double blind study to compare the safety and efficacy of the combination of telmisartan 40mg + amlodipine 10mg versus telmisartan 80mg + amlodipine 10 mg versus amlodi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002421-68,0,0,0 2007-002421-68,8,2008-10-17,2009-02-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd,"An eight-week randomised, 3-arm, double blind study to compare the safety and efficacy of the combination of telmisartan 40mg + amlodipine 10mg versus telmisartan 80mg + amlodipine 10 mg versus amlodi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002421-68,0,0,0 2007-002421-68,8,2008-10-17,2009-02-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd,"An eight-week randomised, 3-arm, double blind study to compare the safety and efficacy of the combination of telmisartan 40mg + amlodipine 10mg versus telmisartan 80mg + amlodipine 10 mg versus amlodi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002421-68,0,0,0 2007-002422-29,8,2009-06-15,2009-09-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GesmbH,An open-label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 10mg or the combination of telmisartan 80mg + amlodipine 10mg ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002422-29,0,0,0 2007-002422-29,8,2009-06-15,2009-09-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,An open-label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 10mg or the combination of telmisartan 80mg + amlodipine 10mg ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002422-29,0,0,0 2007-002422-29,8,2009-06-15,2009-09-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.",An open-label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 10mg or the combination of telmisartan 80mg + amlodipine 10mg ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002422-29,0,0,0 2007-002422-29,8,2009-06-15,2009-09-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd,An open-label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 10mg or the combination of telmisartan 80mg + amlodipine 10mg ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002422-29,0,0,0 2007-002422-29,8,2009-06-15,2009-09-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,An open-label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 10mg or the combination of telmisartan 80mg + amlodipine 10mg ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002422-29,0,0,0 2007-002422-29,8,2009-06-15,2009-09-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd.,An open-label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 10mg or the combination of telmisartan 80mg + amlodipine 10mg ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002422-29,0,0,0 2007-002422-29,8,2009-06-15,2009-09-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,An open-label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 10mg or the combination of telmisartan 80mg + amlodipine 10mg ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002422-29,0,0,0 2007-002422-29,8,2009-06-15,2009-09-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Austria GmbH,An open-label follow-up trial of the efficacy and safety of chronic administration of the combination of telmisartan 40mg + amlodipine 10mg or the combination of telmisartan 80mg + amlodipine 10mg ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002422-29,0,0,0 2007-002423-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,BIOVITRUM AB,"A prospective, randomised, double-blind crossover study comparing 0.15 g/L rhBSSL added to infant formula versus placebo during one week of treatment in preterm infants born before week 32 of gestatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002423-33,0,0,0 2007-002427-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITA' DEGLI STUDI DI FERRARA,Ajuste del tratamiento con tirofibán en pacientes que presentan resistencia a la aspirina o al clopidogrel: 3T/2R Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/or R...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002427-32,0,0,0 2007-002431-80,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,Renal Effects of Levosimendan in Patients Admitted with Acute Decompensated Heart Failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002431-80,0,0,0 2007-002433-37,1,2011-01-07,2011-01-07,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Technische Universität Dresden,Lenalidomide maintenance therapy in patients with MDS or AML with cytogenetic abnormalities involving monosomy 5 or del5q after allogeneic hematopoietic stem cell transplantation (HSCT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002433-37,0,0,0 2007-002434-10,2,2010-02-16,2010-02-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BIOVITRUM AB,"A prospective, randomised, double-blind crossover study comparing 0.15 g/L rhBSSL added to pasteurized breast milk versus placebo during one week of treatment in preterm infants born before week 32 of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002434-10,0,0,0 2007-002434-10,2,2010-02-16,2010-02-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biovitrum AB (publ.),"A prospective, randomised, double-blind crossover study comparing 0.15 g/L rhBSSL added to pasteurized breast milk versus placebo during one week of treatment in preterm infants born before week 32 of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002434-10,0,0,0 2007-002435-93,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,UNITHER PHARMACEUTICALS,"Evaluation d'une solution hydro-alcoolique de sumatriptan administrée par voie sublinguale dans le traitement d'une crise d'algie vasculaire de la face, à la dose de 2mg, 4mg ou 6mg déterminée par une...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002435-93,0,0,0 2007-002438-12,7,2008-11-24,2008-11-24,6,1,0,0,0,0,3,0,1,2,0,0,0,0,1,CASA MADRE,"An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad) Manufactured with Recombinant Human Albumin (rHA) when ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002438-12,1,0,0 2007-002438-12,7,2008-11-24,2008-11-24,6,1,0,0,0,0,3,0,1,2,0,0,0,0,1,Sanofi Pasteur MSD S.N.C.,"An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad) Manufactured with Recombinant Human Albumin (rHA) when ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002438-12,1,0,0 2007-002440-14,13,2012-03-15,2012-03-15,12,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Actelion Pharmaceuticals Ltd.,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel group, Event driven, Phase III study to assess the effects of ACT-064992 on Morbidity and Mortality in patients with Symptomatic P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002440-14,0,0,0 2007-002445-20,12,2011-05-12,2011-05-12,8,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE EFFICACY OF ANIDULAFUNGIN AND VORICONAZOLE IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF PROVEN OR PROBABLE INVASIVE AS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002445-20,1,0,0 2007-002445-20,12,2011-05-12,2011-05-12,8,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Pfizer Inc.,"A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE EFFICACY OF ANIDULAFUNGIN AND VORICONAZOLE IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF PROVEN OR PROBABLE INVASIVE AS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002445-20,1,0,0 2007-002445-20,12,2011-05-12,2011-05-12,8,1,0,0,0,0,3,0,0,2,1,0,0,0,1,PFIZER,"A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE EFFICACY OF ANIDULAFUNGIN AND VORICONAZOLE IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF PROVEN OR PROBABLE INVASIVE AS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002445-20,1,0,0 2007-002445-20,12,2011-05-12,2011-05-12,8,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer, S.A.","A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE EFFICACY OF ANIDULAFUNGIN AND VORICONAZOLE IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF PROVEN OR PROBABLE INVASIVE AS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002445-20,1,0,0 2007-002446-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU de Tours,Effets de la supplémentation parentérale en carnitine chez le nouveau-né prématuré,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002446-37,0,0,0 2007-002447-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE,"Ensayo clínico en fase IV, aleatorizado, enmascarado para el evaluador, de la eficacia de la introducción precoz de levosimendan en pacientes con descompensación aguda de insuficiencia cardiaca cróni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002447-25,0,0,0 2007-002448-10,3,2009-05-06,2009-06-17,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,,"A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks, in drug naive or previously treated (6 weeks w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002448-10,0,0,0 2007-002448-10,3,2009-05-06,2009-06-17,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks, in drug naive or previously treated (6 weeks w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002448-10,0,0,0 2007-002448-10,3,2009-05-06,2009-06-17,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer ingelheim BV,"A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks, in drug naive or previously treated (6 weeks w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002448-10,0,0,0 2007-002449-19,4,2011-05-02,2011-05-02,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A phase Ib/IIa, trial of LBH589 in combination with trastuzumab in adult female patients with HER2 positive metastatic breast cancer whose disease has progressed during or following therapy with tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002449-19,0,0,0 2007-002449-19,4,2011-05-02,2011-05-02,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase Ib/IIa, trial of LBH589 in combination with trastuzumab in adult female patients with HER2 positive metastatic breast cancer whose disease has progressed during or following therapy with tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002449-19,0,0,0 2007-002450-28,3,2009-05-21,2009-05-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg) administered orally once daily over 24 weeks in type 2 diabetic patients with insufficient gly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002450-28,0,0,0 2007-002450-28,3,2009-05-21,2009-05-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg) administered orally once daily over 24 weeks in type 2 diabetic patients with insufficient gly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002450-28,0,0,0 2007-002450-28,3,2009-05-21,2009-05-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg) administered orally once daily over 24 weeks in type 2 diabetic patients with insufficient gly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002450-28,0,0,0 2007-002454-37,1,2013-11-10,2013-11-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The Royal Group Hospitals Trust,Prevention by HMGCoA reductase inhibition of ALI associated with one lung ventilation following oesophagectomy by a Reduction of Pulmonary vascular dysfunction and inflammation (Prevention-HARP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002454-37,0,0,0 2007-002455-16,1,2011-02-18,2011-02-18,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratoires Théa,Efficacy and safety of GV 550 in acute adenoviral keratoconjunctivitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002455-16,0,0,0 2007-002456-41,5,2009-06-19,2010-01-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Boehringer Ingleheim España, S.A.","A randomised, double-blind, placebo controlled, parallel group 24 week study to assess the efficacy and safety of BI 1356 (5 mg) in combination with 30 mg pioglitazone (both administered orally once d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002456-41,0,0,0 2007-002456-41,5,2009-06-19,2010-01-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Austria GesmbH,"A randomised, double-blind, placebo controlled, parallel group 24 week study to assess the efficacy and safety of BI 1356 (5 mg) in combination with 30 mg pioglitazone (both administered orally once d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002456-41,0,0,0 2007-002456-41,5,2009-06-19,2010-01-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A.","A randomised, double-blind, placebo controlled, parallel group 24 week study to assess the efficacy and safety of BI 1356 (5 mg) in combination with 30 mg pioglitazone (both administered orally once d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002456-41,0,0,0 2007-002456-41,5,2009-06-19,2010-01-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim,"A randomised, double-blind, placebo controlled, parallel group 24 week study to assess the efficacy and safety of BI 1356 (5 mg) in combination with 30 mg pioglitazone (both administered orally once d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002456-41,0,0,0 2007-002456-41,5,2009-06-19,2010-01-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer-Ingelheim Ellas AE,"A randomised, double-blind, placebo controlled, parallel group 24 week study to assess the efficacy and safety of BI 1356 (5 mg) in combination with 30 mg pioglitazone (both administered orally once d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002456-41,0,0,0 2007-002457-24,4,2009-05-18,2009-07-16,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges.m.b.H.,"A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient gly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002457-24,0,0,0 2007-002457-24,4,2009-05-18,2009-07-16,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient gly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002457-24,0,0,0 2007-002457-24,4,2009-05-18,2009-07-16,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas A.E,"A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient gly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002457-24,0,0,0 2007-002457-24,4,2009-05-18,2009-07-16,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient gly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002457-24,0,0,0 2007-002460-98,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"VIROSTATICS, SRL",A randomized double-blind dose-finding multi-centre phase IIa study with VS411 for HIV-1 infection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002460-98,0,0,0 2007-002461-12,6,2009-03-25,2010-03-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BIAL - Portela & Ca, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS THERAPY FOR PATIENTS WITH PAINFUL DIABETIC NEUROPATHY: A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002461-12,0,0,0 2007-002462-35,4,2008-08-27,2008-08-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 16 week randomised, open labelled, 3-armed, parallel group, treat-to-target trial comparing twice daily (BID) injections of SIAC 30 (B), SIAC 45 (B) and NovoMix® 30, all in combination with metform...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002462-35,0,0,0 2007-002463-27,1,2008-04-23,2008-04-23,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Lybar a.s.,Clinical study phase III evaluating the safety of Diffusil H Forte spray.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002463-27,0,0,0 2007-002466-35,2,2009-12-22,2010-04-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Imperial Ciollege,A randomised placebo-controlled trial of fixed-dose combination medication in those at raised risk of cardiovascular disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002466-35,0,0,0 2007-002466-35,2,2009-12-22,2010-04-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,St Mary's NHS Trust,A randomised placebo-controlled trial of fixed-dose combination medication in those at raised risk of cardiovascular disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002466-35,0,0,0 2007-002466-35,2,2009-12-22,2010-04-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Medical Center Utrecht,A randomised placebo-controlled trial of fixed-dose combination medication in those at raised risk of cardiovascular disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002466-35,0,0,0 2007-002467-27,1,2011-05-31,2011-05-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Salford Royal NHS Foundation Trust,"Antidyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients with Parkinson's Disease and Levodopa-Induced Dyskinesias",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002467-27,0,0,0 2007-002468-88,3,2008-12-29,2008-12-29,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD SNC,"An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of a 2-dose regimen of ProQuad® manufactured with rHA administered to healthy children from 9 months of age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002468-88,0,0,0 2007-002469-11,2,2008-11-21,2008-11-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Farmaceutica S.A.,"A 10 week, randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of once daily dosing of aliskiren (300 mg qd) to twice daily dosing of aliskiren (150 mg bid)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002469-11,0,0,0 2007-002469-11,2,2008-11-21,2008-11-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 10 week, randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of once daily dosing of aliskiren (300 mg qd) to twice daily dosing of aliskiren (150 mg bid)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002469-11,0,0,0 2007-002470-59,1,2010-12-02,2010-12-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TauRx Therapeutics Ltd,AN OPEN LABEL CONTINUATION STUDY OF THE EFFECTS OF MTC 30 MG TID AND 60 MG TID IN PATIENTS WITH ALZHEIMER’S DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002470-59,0,0,0 2007-002472-34,3,2009-06-30,2009-06-30,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithkine Research and Development Ltd,"A single-arm, two-stage Phase II study of Lapatinib and Pemetrexed in the second line treatment of advanced or metastatic Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002472-34,0,0,0 2007-002472-34,3,2009-06-30,2009-06-30,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline Research and Development Limited,"A single-arm, two-stage Phase II study of Lapatinib and Pemetrexed in the second line treatment of advanced or metastatic Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002472-34,0,0,0 2007-002473-31,9,2010-05-19,2010-05-19,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BIAL - Portela & Ca, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2 093) AS THERAPY FOR PATIENTS WITH POST-HERPETIC NEURALGIA: A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002473-31,0,0,0 2007-002474-60,2,2008-06-20,2008-06-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 16 week randomised, open labelled, 3-armed, treat-to-target, parallel group trial comparing SIBA (D) once daily + NovoRapid®, SIBA (E) once daily + NovoRapid® and insulin glargine once daily + NovoR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002474-60,0,0,0 2007-002476-33,3,2008-07-23,2008-08-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 16 week randomised, open labelled, 3 armed, parallel group, treat-to-target trial comparing once daily injection of SIAC 30 (B), SIAC 45 (B) and insulin glargine, all in combination with metformin i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002476-33,0,0,0 2007-002477-31,6,2008-09-23,2009-02-12,6,0,0,0,0,2,2,0,0,1,0,0,1,0,1,Artu Biologicals Europe B.V.,"A randomised, double-blind, placebo-controlled, multi-centre, multi-national Phase II / III follow-up study to assess long-term efficacy and safety of three different dose regimens of Oralgen® Grass P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002477-31,0,0,0 2007-002477-31,6,2008-09-23,2009-02-12,6,0,0,0,0,2,2,0,0,1,0,0,1,0,1,Artu Biologicaks Europe B.V.,"A randomised, double-blind, placebo-controlled, multi-centre, multi-national Phase II / III follow-up study to assess long-term efficacy and safety of three different dose regimens of Oralgen® Grass P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002477-31,0,0,0 2007-002478-76,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Lybar a.s.,Clinical study phase III evaluating the efficacy of Diffusil H Forte spray,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002478-76,0,0,0 2007-002480-27,1,2009-05-18,2009-05-18,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics GmbH & Co. KG,"A Phase II, Randomized, Controlled, Observer-blind, Single-center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Subjects aged 6 months t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002480-27,0,0,0 2007-002481-35,1,2009-10-01,2009-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital of South Manchester NHS Foundation Trust,COMPARISON OF HIGH FLOW VERSUS TITRATED OXYGEN THERAPY IN THE ACUTE MANAGEMENT OF ST ELEVATION MYOCARDIAL INFARCTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002481-35,0,0,0 2007-002492-14,3,2009-02-26,2009-02-27,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & developpement,"A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant 20 mg after an initial treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002492-14,0,0,0 2007-002495-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FNCLCC,Etude randomisée multicentrique comparant une radiothérapie adjuvante immédidate associée à une hormonothérapie courte par analogue LH-RH (Décapeptyl LP®) vs une radiothérapie différée à la rechute b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002495-34,0,0,0 2007-002496-14,1,2008-03-27,2008-03-27,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Orion Corporation Orion Pharma,"Effects of single doses of Stalevo 200 and levodopa/carbidopa 200/50 mg on striatal 11C-raclopride binding potential in Parkinson’s disease patients with wearing-off symptoms. An open, randomised, act...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002496-14,0,0,0 2007-002501-45,1,2010-10-01,2010-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Alcon Laboratories Inc.,Phase IV randomised double masked clinical trial: Assessing morning versus evening dosing of a fixed dose combination of Travoprost 0.004% / Timolol Maleate 0.5% in patients with primary open angle gl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002501-45,0,0,0 2007-002515-75,6,2008-08-05,2008-08-05,6,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Merck Sharp & Dohme BV,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 36-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002515-75,0,0,0 2007-002515-75,6,2008-08-05,2008-08-05,6,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 36-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002515-75,0,0,0 2007-002515-75,6,2008-08-05,2008-08-05,6,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 36-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002515-75,0,0,0 2007-002515-75,6,2008-08-05,2008-08-05,6,1,0,0,0,0,0,0,0,1,0,0,1,0,1,MSD Finland Oy,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 36-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002515-75,0,0,0 2007-002515-75,6,2008-08-05,2008-08-05,6,1,0,0,0,0,0,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 36-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002515-75,0,0,0 2007-002516-26,7,2008-06-13,2008-06-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme GesmbH,"A Multicenter, Randomized, Double-Blind, “Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministration ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002516-26,0,0,0 2007-002516-26,7,2008-06-13,2008-06-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind, “Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministration ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002516-26,0,0,0 2007-002516-26,7,2008-06-13,2008-06-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck & Co.,"A Multicenter, Randomized, Double-Blind, “Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministration ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002516-26,0,0,0 2007-002516-26,7,2008-06-13,2008-06-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratoires Merck Sharp & Dohme-Chibret,"A Multicenter, Randomized, Double-Blind, “Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministration ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002516-26,0,0,0 2007-002516-26,7,2008-06-13,2008-06-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Multicenter, Randomized, Double-Blind, “Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministration ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002516-26,0,0,0 2007-002516-26,7,2008-06-13,2008-06-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck, Sharp & Dohme Ireland (Human Health) Limited","A Multicenter, Randomized, Double-Blind, “Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministration ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002516-26,0,0,0 2007-002519-22,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,Endothelial progenitor cells mobilization induced by atorvastatin in patients with chronic coronaric disease (stable angina) treated with revascularization with antibody antiCD34 covered stent,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002519-22,0,0,0 2007-002520-16,1,2011-03-16,2011-03-16,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Universitätsklinik für klinische Pharmakologie, Medizinische Universität Wien",The effects of post-conditioning and administration of Vitamin C on intramuscular high energy phosphate levels,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002520-16,0,0,0 2007-002522-29,11,2013-07-01,2013-07-03,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas A.E.,"A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulmona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002522-29,0,0,0 2007-002522-29,11,2013-07-01,2013-07-03,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulmona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002522-29,0,0,0 2007-002522-29,11,2013-07-01,2013-07-03,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim UK Ltd,"A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulmona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002522-29,0,0,0 2007-002522-29,11,2013-07-01,2013-07-03,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulmona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002522-29,0,0,0 2007-002522-29,11,2013-07-01,2013-07-03,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co.KG,"A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulmona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002522-29,0,0,0 2007-002522-29,11,2013-07-01,2013-07-03,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulmona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002522-29,0,0,0 2007-002522-29,11,2013-07-01,2013-07-03,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulmona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002522-29,0,0,0 2007-002522-29,11,2013-07-01,2013-07-03,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulmona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002522-29,0,0,0 2007-002522-29,11,2013-07-01,2013-07-03,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulmona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002522-29,0,0,0 2007-002522-29,11,2013-07-01,2013-07-03,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulmona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002522-29,0,0,0 2007-002523-33,8,2009-12-21,2009-12-21,6,1,0,0,2,0,3,0,0,1,0,0,1,0,1,NV Organon,"A double-blind, randomized, parallel group, placebo-controlled sleep laboratory efficacy and safety study with Org 50081 in elderly subjects with chronic primary insomnia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002523-33,0,0,0 2007-002523-33,8,2009-12-21,2009-12-21,6,1,0,0,2,0,3,0,0,1,0,0,1,0,1,ORGANON ITALIA,"A double-blind, randomized, parallel group, placebo-controlled sleep laboratory efficacy and safety study with Org 50081 in elderly subjects with chronic primary insomnia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002523-33,0,0,0 2007-002527-32,8,2008-01-23,2008-01-23,5,0,0,0,0,0,3,0,0,1,1,0,1,0,1,BioCryst Pharmaceuticals,"A Phase II/III, Multicenter, Ramdomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects with Uncomplicated Acute Influenza",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002527-32,0,0,0 2007-002530-11,1,2007-12-03,2007-12-03,1,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Affibody AB,An exploratory study to assess the distribution of 111In-ABY-002 tracer uptake for SPECT imaging in subjects with metastatic HER2-positive breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002530-11,0,0,0 2007-002531-83,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Curie,Etude de phase 2 randomisée comparant une irradiation encéphalique associée au témozolomide à une irradiation seule chez des patientes présentant des métastases cérébrales d'un cancer du sein.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002531-83,0,0,0 2007-002532-28,4,2009-05-06,2009-07-03,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Genzyme Europe BV,A Phase II Study of Efficacy of Rabbit Anti-thymocyte Globulin (rATG) in patients with Low and Itermediate-1 Risk Mylodysplastic Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002532-28,0,0,0 2007-002533-37,2,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,0,HOVON Foundation,Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in elderly patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002533-37,0,0,0 2007-002534-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Caen,EFFICACITE D’UN TRAITEMENT PAR CINACALCET SUR LE METABOLISME OSSEUX CHEZ LES TRANSPLANTES RENAUX AVEC HYPERPARATHYROIDIE PERSISTANTE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002534-11,0,0,0 2007-002536-29,13,2009-10-30,2009-10-30,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Serono International,A RANDOMISED DOUBLE-BLIND PLACEBO CONTROLLED MULTICENTRE PHASE II STUDY OF ATACICEPT IN ANTI-TNFA NAIVE PATIENTS WITH MODERATE TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO MET...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002536-29,0,0,0 2007-002536-29,13,2009-10-30,2009-10-30,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MERCK SERONO INTERNATIONAL SA,A RANDOMISED DOUBLE-BLIND PLACEBO CONTROLLED MULTICENTRE PHASE II STUDY OF ATACICEPT IN ANTI-TNFA NAIVE PATIENTS WITH MODERATE TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO MET...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002536-29,0,0,0 2007-002541-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,NUTRIALYS,Etude de tolérance d'une association d'un aliment diététique destiné à une fin médicale spéciale caractérisé par une faible teneur en polyamines et une chimiothérapie par docetaxel chez des patients a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002541-21,0,0,0 2007-002542-38,2,2012-01-02,2012-04-03,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double blind, placebo controlled, parallel group design study to explore the efficacy, safety and tolerability of AEB071 in patients with active, moderate to severe ulcerative colitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002542-38,0,0,0 2007-002544-25,3,2009-09-14,2009-09-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb Company,"A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (anti-CXCL10 Human Monoclonal Antibody) in Subjects with Active Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002544-25,0,0,0 2007-002544-25,3,2009-09-14,2009-09-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (anti-CXCL10 Human Monoclonal Antibody) in Subjects with Active Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002544-25,0,0,0 2007-002547-25,2,2008-03-18,2008-03-18,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Archemix Corp.,"A Phase 2 Study of an Aptameric von Willebrand Factor Antagonist, ARC1779, in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002547-25,0,0,0 2007-002548-12,2,2016-07-08,2016-07-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU-ULG,Allogeneic hematopoietic cell transplantation with HLA-matched donors : a phase II randomized study comparing 2 nonmyeloablative conditionings,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002548-12,0,0,0 2007-002550-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Palau Pharma SA,"DOUBLE-BLIND, RANDOMISED, ACTIVE AND PLACEBO CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY, SKIN TOLERABILITY AND PHARMACOLOGICAL ACTIVITY OF A NEW TOPICAL COMPOUND (UR-1505 0.5%, 1% AND 2%) IN PAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002550-27,0,0,0 2007-002551-17,8,2008-06-19,2009-10-30,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,H. Lundbeck a/s,"Randomised, double-blind, parallel-group, placebo-controlled, and active referenced study of Lu AA34893 to evaluate the efficacy and safety of three doses Lu AA34893 and quetiapine versus placebo in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002551-17,0,0,0 2007-002551-17,8,2008-06-19,2009-10-30,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,H. Lundbeck A/S,"Randomised, double-blind, parallel-group, placebo-controlled, and active referenced study of Lu AA34893 to evaluate the efficacy and safety of three doses Lu AA34893 and quetiapine versus placebo in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002551-17,0,0,0 2007-002552-42,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,"Novartis Farmacéutica, S.A","Estudio de fase I/II, multicéntrico, abierto de BGT226, administrado por vía oral a pacientes adultos con tumores sólidos avanzados, incluyendo pacientes con cáncer de mama avanzado",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002552-42,0,0,0 2007-002553-23,1,2008-10-30,2008-10-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MEDA Pharma GmbH & Co. KG,Clinical trial to assess the protective effect of the fixed drug combination of disodium cromoglycate plus reproterol in comparison to the single components and placebo in adults with exercise induced...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002553-23,0,0,0 2007-002556-41,2,2011-03-28,2011-03-28,1,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Trimed Biotech GmbH,"A randomized, open-label, 2-arm, multicentre, Phase II study to evaluate the safety and efficacy of Trivax, a dendritic cell-based interleukin-12 secreting autologous cancer vaccine, in combination wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002556-41,0,0,0 2007-002557-23,3,,,0,0,0,1,0,1,1,0,0,2,0,0,0,0,1,Protherics Medicines Development Ltd,A Phase I/II Open-Label Dose Escalation Study to Investigate the Safety and Tolerability of Acadesine in Patients with B-Cell Chronic Lymphocytic Leukaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002557-23,0,0,0 2007-002557-23,3,,,0,0,0,1,0,1,1,0,0,2,0,0,0,0,1,"Advancell Advanced In Vitro Cell Technologies, S.A",A Phase I/II Open-Label Dose Escalation Study to Investigate the Safety and Tolerability of Acadesine in Patients with B-Cell Chronic Lymphocytic Leukaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002557-23,0,0,0 2007-002560-10,1,2018-10-12,2018-10-12,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,"Freistaat Bayern, represented by the University of Regensburg",Multicentre pilot-study for the therapy of medulloblastoma of adults (NOA-07),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002560-10,0,0,0 2007-002562-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU AMIENS,ffet de l’Epoetin Beta sur la fonction rénale et l’anémie dans les trente jours suivant une transplantation rénale,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002562-35,0,0,0 2007-002563-27,7,2009-11-17,2011-03-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Estudio II de eficacia de Nalmefene: Estudio de eficacia aleatorizado, doble ciego, controlado por placebo, de grupo paralelo, con 20 mg de nalmefene, según se necesite, en pacientes con dependencia d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002563-27,0,0,0 2007-002566-35,5,2009-08-17,2009-08-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Inc,"A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002566-35,0,0,0 2007-002567-27,1,2009-09-08,2009-09-08,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,RIEMSER Arzneimittel AG,"CLINICAL PHASE III MULTI-CENTRIC, DOUBLE-BLIND, DOUBLE DUMMY, RANDOMISED STUDY TO COMPARE SAFETY AND EFFICACY OF DOPRAM® (DOXAPRAM HYDROCHLORIDE) TO CAFEINE COOPER (CAFFEINE CITRATE) IN THE TREATMENT ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002567-27,0,0,0 2007-002568-89,1,2013-01-07,2013-01-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Tecnimede - Sociedade Técnico-Medicinal, S.A.",Estudo clínico exploratório para avaliar a eficácia e a segurança do pangamato de cálcio em doentes com diabetes mellitus de tipo 2 e dislipidemia tratados com estatinas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002568-89,0,0,0 2007-002571-14,1,2009-03-31,2009-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The University of Manchester,The Potential use of Larval Therapy/Biogun and Silver to Reduce Colonisation of MRSA in Diabetic Foot Ulcers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002571-14,0,0,0 2007-002571-14,1,2009-03-31,2009-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Central Manchester and Manchester Children's University Hospital NHS Trust,The Potential use of Larval Therapy/Biogun and Silver to Reduce Colonisation of MRSA in Diabetic Foot Ulcers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002571-14,0,0,0 2007-002574-63,1,2016-07-31,2016-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU de Caen,"Essai randomisé de phase 2-3 testant l’association Pemetrexed-Cisplatine avec ou sans bevacizumab à 15 mg/kg, dans le mésothéliome malin de la plèvre (MPM).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002574-63,0,0,0 2007-002581-35,1,2008-03-25,2008-03-25,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,IDEA AG,"Multiple dose, double-blind, double-dummy, placebo and active controlled study of pharmacokinetics of Diractin® as well as safety and efficacy for the treatment of muscle soreness from exercise",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002581-35,0,0,0 2007-002583-10,7,2009-04-21,2009-04-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Ramipril in Subjects With Essential Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002583-10,0,0,0 2007-002584-27,12,2010-07-13,2010-08-02,10,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002584-27,0,0,0 2007-002584-27,12,2010-07-13,2010-08-02,10,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals LTD,"A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002584-27,0,0,0 2007-002586-12,11,2011-12-28,2011-12-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,Twice-daily oral direct thrombin inhibitor dabigatran etexilate in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002586-12,0,0,0 2007-002586-12,11,2011-12-28,2011-12-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,Twice-daily oral direct thrombin inhibitor dabigatran etexilate in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002586-12,0,0,0 2007-002586-12,11,2011-12-28,2011-12-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GesmbH,Twice-daily oral direct thrombin inhibitor dabigatran etexilate in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002586-12,0,0,0 2007-002586-12,11,2011-12-28,2011-12-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,Twice-daily oral direct thrombin inhibitor dabigatran etexilate in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002586-12,0,0,0 2007-002586-12,11,2011-12-28,2011-12-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,Twice-daily oral direct thrombin inhibitor dabigatran etexilate in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002586-12,0,0,0 2007-002586-12,11,2011-12-28,2011-12-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,Twice-daily oral direct thrombin inhibitor dabigatran etexilate in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002586-12,0,0,0 2007-002586-12,11,2011-12-28,2011-12-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,Twice-daily oral direct thrombin inhibitor dabigatran etexilate in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002586-12,0,0,0 2007-002587-99,10,2009-04-13,2009-09-10,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CHIESI FARMACEUTICI S.p.A.,"A 24-week, multicenter, multinational, randomized, double-blind, triple-dummy, 3-arm parallel group study comparing the efficacy and safety of CHF 1535 200/6 (beclomethasone dipropionate 200 g...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002587-99,0,0,0 2007-002587-99,10,2009-04-13,2009-09-10,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CHIESI,"A 24-week, multicenter, multinational, randomized, double-blind, triple-dummy, 3-arm parallel group study comparing the efficacy and safety of CHF 1535 200/6 (beclomethasone dipropionate 200 g...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002587-99,0,0,0 2007-002588-28,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO EUROPEO DI ONCOLOGIA,PHASE II STUDY OF METRONOMIC ORAL VINORELBINE IN ADVANCED BREAST CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002588-28,0,0,0 2007-002589-37,5,2011-12-28,2011-12-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Inc,"A Phase IIb, Multi-center, Open-label, Follow-up Study to Assess the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease Who Particip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002589-37,0,0,0 2007-002595-34,1,2009-11-06,2009-11-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"Efficacy and safety of neramexane mesylate in congenital idiopathic nystagmus and acquired nystagmus: a randomized, double-blind, placebo-controlled, single center, proof of concept study using a two-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002595-34,0,0,0 2007-002598-30,7,2009-12-16,2009-12-16,6,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Aeterna Zentaris GmbH,Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: a double-blind placebo-controlled efficacy study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002598-30,0,0,0 2007-002598-30,7,2009-12-16,2009-12-16,6,0,0,0,0,0,3,0,0,1,1,0,1,0,1,AETERNA ZENTARIS GMBH,Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: a double-blind placebo-controlled efficacy study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002598-30,0,0,0 2007-002600-18,1,,,0,1,0,0,0,0,4,0,1,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,EVALUATION OF THE RELATIONSHIP BETWEEN INFLAMMATION-PHYSICAL ACTIVITY AND THE ACTIVITY OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002600-18,0,0,0 2007-002604-17,8,2016-05-27,2021-09-24,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Bayer AG,Programa de extensión a largo plazo con sorafenib Sorafenib Long Term Extension Program (STEP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002604-17,0,0,0 2007-002604-17,8,2016-05-27,2021-09-24,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,Programa de extensión a largo plazo con sorafenib Sorafenib Long Term Extension Program (STEP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002604-17,0,0,0 2007-002604-17,8,2016-05-27,2021-09-24,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Bayer HealthCare AG, D-51368 Leverkusen, Germany",Programa de extensión a largo plazo con sorafenib Sorafenib Long Term Extension Program (STEP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002604-17,0,0,0 2007-002604-17,8,2016-05-27,2021-09-24,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Bayer AG, D-51368 Leverkusen, Germany",Programa de extensión a largo plazo con sorafenib Sorafenib Long Term Extension Program (STEP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002604-17,0,0,0 2007-002604-17,8,2016-05-27,2021-09-24,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,BAYER,Programa de extensión a largo plazo con sorafenib Sorafenib Long Term Extension Program (STEP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002604-17,0,0,0 2007-002605-53,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Institut de Recerca de l'Hospital de la Santa Creu i de Sant Pau,Antagonistas aldosterónicos en el tratamiento de pacientes con ventrículo derecho sistémico: ensayo clínico aleatorizado.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002605-53,0,0,0 2007-002608-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UMCG,A randomized phase III study of adjuvant chemotherapy with or without low-molecular weight heparin in patients with high risk for recurrence and completely resected non-small-cell lung cancer: NVALT-8...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002608-16,0,0,0 2007-002610-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Dota-Toc-(68Ga) dans les tumeurs endocrines digestives. Intérêt de l'imagerie TEP-TDM.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002610-19,0,0,0 2007-002611-27,3,2010-09-30,2010-09-30,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Octapharma AG,"Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002611-27,0,0,0 2007-002612-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St. Antonius Hospital,Dexamethasone infusion in community-acquired pneumonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002612-25,0,0,0 2007-002614-19,1,2007-10-06,2007-10-06,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Omninvest Ltd.,FluvalAB Seasonal Influenza Vaccine Serologic Clinical Trial for 2007-2008 Influenza Season,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002614-19,0,0,0 2007-002617-39,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,Fondazione Mediolanum Onlus,INtegrilin plus STenting to Avoid Myocardial Necrosis Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002617-39,0,0,0 2007-002619-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"""Physiopathologie de la rétention rénale de sodium dans l'acromégalie"" -Etude ACROMENAC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002619-25,0,0,0 2007-002624-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",Fertomcidina ﾓUﾔ vs chlorhexidine 0.2% in recurrent aphthous stomatitis: randomized comparative double-blind study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002624-15,0,0,0 2007-002625-77,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,FONDAZIONE ISTITUTO SAN RAFFAELE-G.GIGLIO,Randomized phase II trial of first line chemoterapy Docetaxel given in combination with Cisplatin for 6 cycles or Docetaxel given in combination with Cisplatin for 3 cycles followed by Docetaxel alone...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002625-77,0,0,0 2007-002627-32,12,2014-09-02,2014-12-18,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002627-32,0,0,0 2007-002627-32,12,2014-09-02,2014-12-18,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002627-32,0,0,0 2007-002627-32,12,2014-09-02,2014-12-18,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002627-32,0,0,0 2007-002627-32,12,2014-09-02,2014-12-18,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002627-32,0,0,0 2007-002627-32,12,2014-09-02,2014-12-18,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Services Pharma AG,"A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002627-32,0,0,0 2007-002630-11,11,2009-08-18,2009-11-16,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A Phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of oral 220 mg dabigatran etexilate (110 mg on the day of surgery followed by 220...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002630-11,0,0,0 2007-002630-11,11,2009-08-18,2009-11-16,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GesmbH,"A Phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of oral 220 mg dabigatran etexilate (110 mg on the day of surgery followed by 220...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002630-11,0,0,0 2007-002630-11,11,2009-08-18,2009-11-16,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of oral 220 mg dabigatran etexilate (110 mg on the day of surgery followed by 220...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002630-11,0,0,0 2007-002630-11,11,2009-08-18,2009-11-16,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A Phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of oral 220 mg dabigatran etexilate (110 mg on the day of surgery followed by 220...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002630-11,0,0,0 2007-002630-11,11,2009-08-18,2009-11-16,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & CoKG,"A Phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of oral 220 mg dabigatran etexilate (110 mg on the day of surgery followed by 220...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002630-11,0,0,0 2007-002630-11,11,2009-08-18,2009-11-16,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH and Co KG,"A Phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of oral 220 mg dabigatran etexilate (110 mg on the day of surgery followed by 220...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002630-11,0,0,0 2007-002630-11,11,2009-08-18,2009-11-16,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A Phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of oral 220 mg dabigatran etexilate (110 mg on the day of surgery followed by 220...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002630-11,0,0,0 2007-002630-11,11,2009-08-18,2009-11-16,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A Phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of oral 220 mg dabigatran etexilate (110 mg on the day of surgery followed by 220...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002630-11,0,0,0 2007-002630-11,11,2009-08-18,2009-11-16,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase III randomised, parallel group, double-blind, active controlled study to investigate the efficacy and safety of oral 220 mg dabigatran etexilate (110 mg on the day of surgery followed by 220...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002630-11,0,0,0 2007-002631-86,11,2011-05-05,2011-05-05,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A phase III randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sympto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002631-86,0,0,0 2007-002631-86,11,2011-05-05,2011-05-05,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co KG,"A phase III randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sympto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002631-86,0,0,0 2007-002631-86,11,2011-05-05,2011-05-05,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,"A phase III randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sympto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002631-86,0,0,0 2007-002631-86,11,2011-05-05,2011-05-05,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A phase III randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sympto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002631-86,0,0,0 2007-002631-86,11,2011-05-05,2011-05-05,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A phase III randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sympto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002631-86,0,0,0 2007-002631-86,11,2011-05-05,2011-05-05,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A phase III randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sympto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002631-86,0,0,0 2007-002631-86,11,2011-05-05,2011-05-05,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Danmark A/S,"A phase III randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sympto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002631-86,0,0,0 2007-002631-86,11,2011-05-05,2011-05-05,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A phase III randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sympto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002631-86,0,0,0 2007-002631-86,11,2011-05-05,2011-05-05,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A phase III randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sympto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002631-86,0,0,0 2007-002631-86,11,2011-05-05,2011-05-05,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Austia Gm.b.H,"A phase III randomised, double blind, parallel-group study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute sympto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002631-86,0,0,0 2007-002640-19,1,2012-03-15,2012-03-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Gent,Effect of strategy for blood pressure control on cerebral oxygen balance during aortic coarctation repair: a randomized study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002640-19,0,0,0 2007-002644-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UMCG,A randomized phase III study of adjuvant chemotherapy in patients with completely resected Non-Small-Cell Lung Cancer and low-risk for recurrence: NVALT-8A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002644-21,0,0,0 2007-002646-38,9,2011-12-15,2011-12-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,"A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricita...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002646-38,0,0,0 2007-002646-38,9,2011-12-15,2011-12-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricita...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002646-38,0,0,0 2007-002646-38,9,2011-12-15,2011-12-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Limited,"A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a fixed background regimen consisting of tenofovir disoproxil fumarate and emtricita...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002646-38,0,0,0 2007-002647-25,6,2012-02-08,2012-02-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,"A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibito...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002647-25,0,0,0 2007-002647-25,6,2012-02-08,2012-02-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibito...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002647-25,0,0,0 2007-002647-25,6,2012-02-08,2012-02-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Limited,"A Phase III, randomized, double-blind trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibito...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002647-25,0,0,0 2007-002649-19,1,2015-08-01,2015-08-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Tartu University Hospital Psychiatry Clinic,Investigation of genetic predictors of the response to SSRI treatment in patients with panic disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002649-19,0,0,0 2007-002652-42,1,2007-11-15,2007-11-15,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Royal Brompton and Harefield NHS Trsut,The use of clopidogrel and aprotonin in off pump coronary artery bypass grafting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002652-42,0,0,0 2007-002653-23,1,2009-02-06,2009-02-06,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,"The Police Rehabilitation Centre, Flint House",A pilot for a case control study to evaluate the effects of High Dosage Oxygen Therapy as an adjunct to an established program of physiotherapy and rehabilitation for sub acute soft tissue knee condit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002653-23,0,0,0 2007-002654-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Carl Dahlöf,A randomised prospective open multi-attack study of patient preference and efficacy between zolmitriptan nasal spray 5 mg and sumatriptan RDT 100 mg in the acute treatment of migraine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002654-36,0,0,0 2007-002655-16,1,2021-04-01,2021-04-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Karolinska Institutet,Androgen metabolism and doping tests,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002655-16,0,0,0 2007-002656-42,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,SOFAR SPA,"Efficacy and tolerability of a 0.25%glyceryl trinitrate ointment in the treatment of chronic rectal fissures.A multicentric, randomised, open study,controlled vs. Antrolin cream.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002656-42,0,0,0 2007-002657-23,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Vertex Pharmaceuticals Incorporated,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis (CF) Subjects with Genotype G551D",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002657-23,0,0,0 2007-002659-17,1,2013-07-09,2013-07-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Heinrich-Heine-Universität Düsseldorf,"Multicenter, open-label phase II trial on post-surgery chemoradiation in combination with cetuximab in squamous cell carcinoma of the head and neck with high risk of locoregional recurrence.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002659-17,0,0,0 2007-002663-26,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,AEterna Zentaris GmbH,"Antitumoral activity and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin, in women with LHRH receptor positive gynecological tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002663-26,0,0,0 2007-002664-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,A Randomised Comparison Between 150 mg/die Clopidogrel Maintenance Dose Versus 75 mg/die in Patients with ST Segment Elevation Acute Myocardial Infarction: Effects on Platelet Aggregation and Inflamma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002664-10,0,0,0 2007-002667-28,10,2009-03-27,2009-03-27,10,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Merck & Co., Inc.","A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Witho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002667-28,0,0,0 2007-002667-28,10,2009-03-27,2009-03-27,10,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"MERCK & CO., INC.","A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Witho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002667-28,0,0,0 2007-002667-28,10,2009-03-27,2009-03-27,10,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Merck Sharpe & Dohme BV,"A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Witho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002667-28,0,0,0 2007-002667-28,10,2009-03-27,2009-03-27,10,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Laboratoires Merck Sharp & Dohme - Chibret,"A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Witho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002667-28,0,0,0 2007-002667-28,10,2009-03-27,2009-03-27,10,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Merck & Co. Inc.,"A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Witho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002667-28,0,0,0 2007-002667-28,10,2009-03-27,2009-03-27,10,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Merck Sharp & Dohme de España, S.A.","A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Witho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002667-28,0,0,0 2007-002667-28,10,2009-03-27,2009-03-27,10,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Merck & Co, Inc.","A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Witho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002667-28,0,0,0 2007-002667-28,10,2009-03-27,2009-03-27,10,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Merck Sharp & Dohme (Sweden) AB,"A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Witho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002667-28,0,0,0 2007-002667-28,10,2009-03-27,2009-03-27,10,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Merck Sharp & Dohme GmbH,"A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Witho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002667-28,0,0,0 2007-002671-14,1,2017-03-06,2017-03-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 15-month, multi-center, randomized, open-label, parallel group study investigating the renal tolerability, efficacy and safety of a CNI-free regimen (Certican® and MPA) versus a low-dose CNI- regime...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002671-14,0,0,0 2007-002678-77,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Caen,"Analgésie Postopératoire des Appendicectomies en urgence : Effets de l'Instillation Intrapéritonéale et de l’Infiltration Pariétale Locale de Ropivacaine. Etude monocentrique, randomisée en double ave...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002678-77,0,0,0 2007-002681-34,1,2008-07-03,2008-07-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,St Georges Healthcare NHS Trust,Dual antiplatelet therapy in the acute phase following stroke and TIA; which is the best regimen?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002681-34,0,0,0 2007-002682-12,1,2017-01-16,2017-01-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ICORG,Protocol GI-04 A PHASE II TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (XELODA) IN FRAIL PATIENTS WITH UNTREATED METASTATIC COLORECTAL CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002682-12,0,0,0 2007-002683-10,2,2009-04-16,2009-04-16,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Reactogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Ambulatory Elderly Adults Aged 68 Years and Older Who R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002683-10,0,0,0 2007-002687-95,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Hospital Clínico de Barcelona,"Estudio doble ciego, aleatorizado frente a vehículo de la eficacia clínica del tratamiento combinado con ácido úrico y rtPA administrados por vía intravenosa en pacientes con ictus isquémico de menos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002687-95,0,0,0 2007-002688-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Pilot study on the short-term effects of Sildenafil on hemodynamic response to exercise and exercise capacity in Fontan patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002688-28,0,0,0 2007-002691-33,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Eli Lilly and Company Ltd,A Study to Assess the Effect of Exenatide Treatment on Mean 24-hour Heart Rate in Patients with Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002691-33,0,0,0 2007-002693-66,13,2012-11-14,2017-02-01,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MERCK SHARP DOHME ITALIA S.P.A.,"1st extension (MK-0822-018-06, issue date 19-Jun-2013) A Blinded Extension to 5 Years of a Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002693-66,0,0,0 2007-002693-66,13,2012-11-14,2017-02-01,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","1st extension (MK-0822-018-06, issue date 19-Jun-2013) A Blinded Extension to 5 Years of a Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002693-66,0,0,0 2007-002693-66,13,2012-11-14,2017-02-01,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck & Co., Inc","1st extension (MK-0822-018-06, issue date 19-Jun-2013) A Blinded Extension to 5 Years of a Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002693-66,0,0,0 2007-002693-66,13,2012-11-14,2017-02-01,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","1st extension (MK-0822-018-06, issue date 19-Jun-2013) A Blinded Extension to 5 Years of a Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002693-66,0,0,0 2007-002693-66,13,2012-11-14,2017-02-01,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Laboratoires Merck Sharp & Dohme - Chibret,"1st extension (MK-0822-018-06, issue date 19-Jun-2013) A Blinded Extension to 5 Years of a Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002693-66,0,0,0 2007-002693-66,13,2012-11-14,2017-02-01,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co.","1st extension (MK-0822-018-06, issue date 19-Jun-2013) A Blinded Extension to 5 Years of a Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002693-66,0,0,0 2007-002693-66,13,2012-11-14,2017-02-01,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.","1st extension (MK-0822-018-06, issue date 19-Jun-2013) A Blinded Extension to 5 Years of a Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002693-66,0,0,0 2007-002693-66,13,2012-11-14,2017-02-01,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc.","1st extension (MK-0822-018-06, issue date 19-Jun-2013) A Blinded Extension to 5 Years of a Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002693-66,0,0,0 2007-002693-66,13,2012-11-14,2017-02-01,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","1st extension (MK-0822-018-06, issue date 19-Jun-2013) A Blinded Extension to 5 Years of a Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002693-66,0,0,0 2007-002693-66,13,2012-11-14,2017-02-01,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., U.S.A.","1st extension (MK-0822-018-06, issue date 19-Jun-2013) A Blinded Extension to 5 Years of a Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002693-66,0,0,0 2007-002693-66,13,2012-11-14,2017-02-01,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MERCK SHARP & DOHME CORP.,"1st extension (MK-0822-018-06, issue date 19-Jun-2013) A Blinded Extension to 5 Years of a Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002693-66,0,0,0 2007-002695-34,1,2010-03-01,2010-03-01,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,Kringle Pharma Europe AB,"A Phase I/II Double-Blind, Dose Ranging, Vehicle Controlled, Randomized, Parallel Groups, Safety, Tolerability and Efficacy Study of ChronSeal® (5-amino-acid deleted recombinant human Hepatocyte Growt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002695-34,0,0,0 2007-002698-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Clinic Barcelona,Efectos del tratamiento inicial con 2 pautas antirretrovirales estándares actuales sobre el metabolismo lipídico,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002698-29,0,0,0 2007-002700-18,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Neose Technologies, Inc.","An Open-Label, Sequential, Ascending dose study, to Evaluate the safety, Pharmacokinetics, and Dose Response, of fixed, Repeated Doses of NE-180 (GlycoPEGylated™rHuEPO) in Anemic Cancer Patients Recei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002700-18,0,0,0 2007-002702-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Hybrigenics SA,Dose finding Phase 2a Study of Inecalcitol in Combination with Standard Docetaxel Prednisone Regimen in Hormone-Refractory Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002702-21,0,0,0 2007-002707-40,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,University Hospital Ghent,The effect of inhalation with hypertonic saline (7%) on lung function and sputum rheology in Cystic Fibrosis patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002707-40,0,0,0 2007-002712-25,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Novartis Vaccines and Diagnostics GmbH & Co. KG,"A Phase II, Randomized, Placebo-controlled, Observer-blind, Multi Center Study on the Safety and Immunogenicity of Novartis Tetravalent Influenza Vaccine (containing both interpandemic strains and H5N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002712-25,0,0,0 2007-002713-39,1,2012-01-01,2012-01-01,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"dept of endocrinology J 106, herlev Hosptial","Quality of life related to recombinant TSH treatment compared to no treatment related to iodine uptake, in patient with thyroid cancer. A double blinded, randomized crossover study. Dathyrca I",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002713-39,0,0,0 2007-002715-11,1,2008-10-23,2008-10-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Circassia Ltd,An Escalating Single Intradermal or Subcutaneous Dose Study in Cat Allergic Subjects to Assess the Safety of Cat-PAD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002715-11,0,0,0 2007-002716-26,8,2014-12-22,2014-12-22,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,UCB Celltech,"A phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti TNF alpha monoclonal ant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002716-26,0,0,0 2007-002717-39,1,2011-01-17,2011-01-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Nottingham,Pilot study for a trial of ursodeoxycholic acid (UDCA) and/or early delivery for obstetric cholestasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002717-39,0,0,0 2007-002722-29,1,2008-03-12,2008-03-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 4-week, open-label, randomized, multi-centre, parallel-group study evaluating the safety and efficacy of 4 actuations Symbicort (budesonide/formoterol) HFA pMDI 40/2.25ug twice daily, with and witho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002722-29,0,0,0 2007-002725-74,1,2009-09-17,2009-09-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Cougar Biotechnology, Inc",A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002725-74,0,0,0 2007-002727-32,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,ArQule Inc.,A Randomized Phase 2 Study of ARQ 197 versus Gemcitabine in Treatment-naïve Patients with Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002727-32,0,0,0 2007-002728-13,9,2011-06-01,2011-06-01,7,0,0,0,0,0,3,0,0,2,1,0,0,0,1,DIAMYD THERAPEUTICS AB,A Phase III 3-Arm Randomized Double-Blind Placebo-Controlled Multicenter Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed with Type 1 Diabetes Melli...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002728-13,1,0,0 2007-002728-13,9,2011-06-01,2011-06-01,7,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Diamyd Therapeutics AB,A Phase III 3-Arm Randomized Double-Blind Placebo-Controlled Multicenter Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed with Type 1 Diabetes Melli...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002728-13,1,0,0 2007-002730-11,1,2010-11-30,2010-11-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust,Magnetic resonance (MR) angiography with a blood pool contrast medium.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002730-11,0,0,0 2007-002733-36,1,2016-05-20,2016-05-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE FARMA S.A.,"“Estudio multicéntrico, no aleatorizado, abierto, en Fase II, para valorar la eficacia y seguridad de la inducción con Rituximab, Fludarabina, Ciclofosfamida seguido de Rituximab como mantenimiento (R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002733-36,0,0,0 2007-002734-11,3,2008-04-17,2008-04-17,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A 6-week, phase III, double-blind, randomized, multi-centre, parallel-group study evaluating the efficacy and safety of 2 actuations Symbicort® (budesonide/formoterol) pMDI 40/2.25 μg twice daily comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002734-11,1,0,0 2007-002736-28,1,2012-01-13,2012-01-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ARCAGY-GINECO,A multicentre study DOGMES: Liposomal doxorubicin in geriatric oncology - Metastatic breast cancer - first line treatment by pegylated liposomal doxorubicin in patients of more than 70 years old with ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002736-28,0,0,0 2007-002740-16,4,2008-09-29,2008-09-29,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,M's Science Corporation,"A Phase II, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Safety and Efficacy of Treatment with SA4503, 1 mg or 3 mg Once Daily for 8 Weeks, in Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002740-16,0,0,0 2007-002742-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre François Baclesse,Neutropénie modérée persistante : intérêt d'une administration du G-CSF (granocytes colony stimulating factor) 1 jour sur 2 pour maintenir la dose intensité. Essai de phase III multicentrique chez des...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002742-38,0,0,0 2007-002743-24,1,2012-08-17,2012-08-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Queen Mary University of London,Study to evaluate different duration of treatment regimes of 40kD pegylated interferon alfa 2a (Pegasys) plus ribavirin on sustained virological responses (SVR) in Genotype 3 HCV infected cirrhotic pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002743-24,0,0,0 2007-002744-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Hospital of Montpellier,Effet d'un traitement anti-résorptif sur la perte osseuse chez le patient blessé médullaire,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002744-22,0,0,0 2007-002750-31,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,CONSORCI SANITARI TERRASSA,Evaluación de la efectividad analgésica del EMLA (euthetic mixture of local anesthetic) en la práctica de la histeroscopia diagnóstica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002750-31,0,0,0 2007-002752-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHRU de Tours,FAKIR : Variabilité pharmacocinétique et de la relation pharmacocinétique-phamacodynamique de l'infliximab (Remicade®) dans la polyarthrite rhumatoide,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002752-42,0,0,0 2007-002755-16,1,2009-08-07,2009-08-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Heidelberg,Pharmakokinetik von Posaconazol verabreicht über Magensonde - POLICE-Studie (POsaconazoLe via gastrIC tubE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002755-16,0,0,0 2007-002763-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,"A multi-center, randomized, controlled trial with programmed introduction of Sirolimus-based, Calcineurin inhibitor free immunosuppression in recipients of non-heart-beating donor kidney grafts.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002763-27,0,0,0 2007-002765-12,1,2009-01-13,2009-01-13,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,RWTH Aachen University,Influence of the angiotensin receptor blocker Telmisartan on the red blood cell function and the microcirculatory perfusion (ITEM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002765-12,0,0,0 2007-002769-11,1,2014-05-06,2014-05-06,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Department of Cardiothoracic and Vascular Surgery,"THE EFFECT OF GABAPENTIN ON THORACIC EPIDURAL ANALGESIA FOLLOWING THORACOTOMY – A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002769-11,0,0,0 2007-002771-14,2,2008-02-25,2008-02-25,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Intercell AG,"COMPARISON OF THREE COMMERCIAL BATCHES OF THE JAPANESE ENCEPHALITIS VACCINE IC51. DOUBLE BLIND, RANDOMIZED, CONTROLLED PHASE 3 STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002771-14,0,0,0 2007-002773-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Herz-, Thorax- und Gefäßchirurgische Anästhesie und Intensivmedizin",Subcutaneous insulin therapy of hyperglycemia after initiation of oral intake in the ICU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002773-30,0,0,0 2007-002774-64,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,0,"Deutsches Herzzentrum Berlin, Kompetenznetz Angeborene Herzfehler",Therapy of PAH – Treatment with Sildenafil in Eisenmenger Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002774-64,0,0,0 2007-002776-33,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Academic hospital Maastricht,Treatment of superficial basal cell carcinoma by three non-invasive modalities: PDT vs. imiquimod vs. 5-fluorouracil,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002776-33,0,0,0 2007-002777-32,1,2013-03-18,2013-03-18,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase I/II, partially blind, randomized, multicentre, age-stratified, dose-range study in healthy females aged 9 - 25 years to assess the safety and immunogenicity of GlaxoSmithKline Biologicals’ HP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002777-32,0,0,0 2007-002780-27,11,2012-03-20,2012-05-20,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen Cilag International NV,"A Randomized, Double-blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-severe Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002780-27,0,0,0 2007-002780-27,11,2012-03-20,2012-05-20,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International,"A Randomized, Double-blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-severe Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002780-27,0,0,0 2007-002782-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,National Institute of Oncology,"Open, uncontrolled, non-commercial Clinical Trial of induction chemotherapy with Cetuximab, Docetaxel, Cisplatin, 5FU followed by Cetuximab + radiotherapy in the responders in locally advanced ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002782-12,0,0,0 2007-002783-10,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase II, controlled, single centre, open study to evaluate the safety, reactogenicity and immunogenicity of a second vaccination with the low dose influenza vaccine adjuvanted with a reduced dose o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002783-10,0,0,0 2007-002784-27,1,2010-12-01,2010-12-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Steiner & Co. Deutsche Arzneimittelgesellschaft mbH & Co. KG,"Randomised, double-blind, prospective multi-centre study to compare the analgesic efficacy and safety of a paracetamol/codeine/caffeine fixed-dose combination (Azur® compositum) with paracetamol/codei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002784-27,0,0,0 2007-002787-95,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"Department of Pulmonology, Rijnstate Hospital",A randomized double-blind study of N-Acetylcysteine vs. placebo to Prevent Neurotoxicity induced by Platinum containing chemotherapy in patients treated for (Non)Small Cell Lung Cancer and Malignant M...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002787-95,0,0,0 2007-002788-28,1,2012-06-30,2012-06-30,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Southampton University Hospital NHS Trust,"Evaluation of Corticosteroid therapy in Childhood Severe Sepsis (Steroids in Paediatric Sepsis, StePS) - a randomised pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002788-28,0,0,0 2007-002791-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Assistance Publique Hopitaux de marseille,Effet aigu d’une insulinothérapie intensive sur le métabolisme des lipoparticules riches en triglycérides (LRT) intestinales chez le patient diabétique de type 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002791-33,0,0,0 2007-002793-64,2,2009-02-16,2009-02-16,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Intercell AG,"EFFECT OF A BOOSTER DOSE OF THE JAPANESE ENCEPHALITIS VACCINE IC51 ON LONG TERM IMMUNOGENICITY. AN UNCONTROLLED, OPEN-LABEL PHASE 3 STUDY.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002793-64,0,0,0 2007-002797-56,1,2014-12-10,2014-12-10,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Gercor,Phase III study of an optimized chemotherapy + Avastin strategy +/- Tarceva in metastatic colorectal cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002797-56,0,0,0 2007-002800-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Clermont-Ferrand,Reconnaissance des expressions émotionnelles du visage et classification émotionnelle de mots dans la maladie de Parkinson : Influence de la stimulation cérébrale profonde du noyau sous thalamique et ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002800-16,0,0,0 2007-002803-42,1,2008-12-06,2008-12-06,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,"Univ.Clinic of Internal Medicine II, Department of Cardiology, Medical University of Vienna, Austria",Inhaled Iloprost for patients with pulmonary arterial hypertension and right heart failure:a pilot feasibility trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002803-42,0,0,0 2007-002808-18,1,2010-01-26,2010-01-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALLERGOPHARMA JOACHIM GANZER KG,A double-blind placebo controlled dose-response study for evaluation of safety and efficacy of immunotherapy with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense) ad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002808-18,0,0,0 2007-002809-48,1,2015-09-19,2015-09-19,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Imperial College London and Imperial College Healthcare NHS Trust,Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure and a left ventricular assist device,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002809-48,0,0,0 2007-002810-20,2,2008-08-29,2008-12-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 12-week Open-Label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to compare the Efficacy and Safety of rosuvastatin (CRESTOR) 10 mg and 20 mg in Combination with Ezetimibe 10 mg and Siv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002810-20,0,0,0 2007-002812-24,1,,,0,1,0,0,1,1,4,0,0,1,1,1,0,1,0,"AKH Wien, Universitätsklinik für Physikalische Medizin und Rehabilitation",Behandlung mit Botulinum Toxin A bei Kindern mit Morbus Perthes (Treatment with Botulinum Toxin A in Infants with Perthes Disease),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002812-24,0,0,0 2007-002815-20,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Royal Surrey County Hospital,A Prospective Randomised Pilot Study of Metformin and Lifestyle Intervention in the Prevention of Metabolic Syndrome due to Androgen Deprivation Therapy in Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002815-20,0,0,0 2007-002816-25,2,2009-01-24,2009-01-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici SpA,"Multicentre, multinational, randomised, double blind, double dummy, active drug controlled, parallel group study design clinical trial of the efficacy and tolerability of beclomethasone dipropionate 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002816-25,0,0,0 2007-002816-25,2,2009-01-24,2009-01-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CHIESI,"Multicentre, multinational, randomised, double blind, double dummy, active drug controlled, parallel group study design clinical trial of the efficacy and tolerability of beclomethasone dipropionate 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002816-25,0,0,0 2007-002817-37,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""","A PHASE II, PLACEBO CONTROLLED, DOSE FINDING PILOT STUDY OF PIXANTRONE EFFICACY ADMINISTERED INTRAVENOUSLY IN PATIENTS AFFECTED WITH MYASTHENIA GRAVIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002817-37,0,0,0 2007-002819-99,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Nancy,L’administration d’ondansetron dans le cadre d’une prophylaxie des nausées et vomissements postopératoires réduirait-il l’effet analgésique du paracétamol ?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002819-99,0,0,0 2007-002822-31,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Centre Hospitalier Universitaire de Nancy,Mesure de l’admittance respiratoire pour le diagnostic de l’asthme infantile,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002822-31,0,0,0 2007-002823-34,9,2009-03-11,2009-05-19,7,1,0,0,1,0,2,0,0,1,1,0,1,0,1,Merck Serono International S.A,"A phase II, multicentre, randomised, assessor-blinded, active-comparator, parallel-group dose finding trial to evaluate AS900672-Enriched versus follitropin alfa (GONAL-f)in oligo-anovulatory infertil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002823-34,0,0,0 2007-002823-34,9,2009-03-11,2009-05-19,7,1,0,0,1,0,2,0,0,1,1,0,1,0,1,Merck Serono International SA,"A phase II, multicentre, randomised, assessor-blinded, active-comparator, parallel-group dose finding trial to evaluate AS900672-Enriched versus follitropin alfa (GONAL-f)in oligo-anovulatory infertil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002823-34,0,0,0 2007-002823-34,9,2009-03-11,2009-05-19,7,1,0,0,1,0,2,0,0,1,1,0,1,0,1,MERCK SERONO INTERNATIONAL SA,"A phase II, multicentre, randomised, assessor-blinded, active-comparator, parallel-group dose finding trial to evaluate AS900672-Enriched versus follitropin alfa (GONAL-f)in oligo-anovulatory infertil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002823-34,0,0,0 2007-002823-34,9,2009-03-11,2009-05-19,7,1,0,0,1,0,2,0,0,1,1,0,1,0,1,Merck Serono SA International,"A phase II, multicentre, randomised, assessor-blinded, active-comparator, parallel-group dose finding trial to evaluate AS900672-Enriched versus follitropin alfa (GONAL-f)in oligo-anovulatory infertil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002823-34,0,0,0 2007-002823-34,9,2009-03-11,2009-05-19,7,1,0,0,1,0,2,0,0,1,1,0,1,0,1,Merck Serono International S.A.,"A phase II, multicentre, randomised, assessor-blinded, active-comparator, parallel-group dose finding trial to evaluate AS900672-Enriched versus follitropin alfa (GONAL-f)in oligo-anovulatory infertil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002823-34,0,0,0 2007-002824-13,1,2010-07-17,2010-07-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Cologne,"Prospective, placebo-controlled blinded clinical trial to study the efficacy of orally administered Glucose 20% for relieving pain during nasopharyngeal suctioning in preterm infants > 1500g under CP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002824-13,0,0,0 2007-002826-31,1,2010-02-10,2010-02-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical University of Vienna,Response of retinal vessels to anti vascular endothelial growth factor (VEGF) treatment in patients with branch retinal vein occlusion (BRVO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002826-31,0,0,0 2007-002828-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Krankenhaus Nordwest GmbH,"An open-label, uncontrolled phase II trial of single agent sunitinib (SU 11248) for patients with chemo-refractory metastatic melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002828-15,0,0,0 2007-002838-10,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,SANT JOAN DE DEU - SSM,Ensayo doble ciego controlado con placebo de la eficacia de reboxetina y citalopram como tratamiento coadyuvante de los antipsicóticos de segunda generación en el tratamiento de los síntomas negativos...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002838-10,0,0,0 2007-002840-21,3,2009-05-05,2009-07-28,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Shire Human Genetic Therapies, Inc.","A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared with Imiglucerase in Patients with Type I Gaucher ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002840-21,0,0,0 2007-002840-21,3,2009-05-05,2009-07-28,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Shire Human Genetic Therapies Inc,"A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared with Imiglucerase in Patients with Type I Gaucher ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002840-21,0,0,0 2007-002840-21,3,2009-05-05,2009-07-28,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"SHIRE HUMAN GENETIC THERAPIES, INC.","A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared with Imiglucerase in Patients with Type I Gaucher ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002840-21,0,0,0 2007-002841-19,2,2013-08-26,2013-08-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Grupo Español de Investigación en Cáncer de Mama (GEICAM),"""Estudio aleatorizado, multicéntrico para evaluar la eficacia y seguridad de bevacizumab en combinación con letrozol comparado con letrozol solo, en mujeres postmenopáusicas con cáncer de mama localme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002841-19,0,0,0 2007-002846-38,3,2010-02-11,2010-02-11,1,0,0,0,0,1,2,0,0,1,1,0,1,0,1,"OXiGENE, Inc.","A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE II/III STUDY TO EVALUATE THE SAFETY AND EFFICACY OF COMBRETASTATIN A-4 PHOSPHATE IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN COMPARISON WITH PACLITAX...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002846-38,0,0,0 2007-002846-38,3,2010-02-11,2010-02-11,1,0,0,0,0,1,2,0,0,1,1,0,1,0,1,"OXIGENE, INC.","A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE II/III STUDY TO EVALUATE THE SAFETY AND EFFICACY OF COMBRETASTATIN A-4 PHOSPHATE IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN IN COMPARISON WITH PACLITAX...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002846-38,0,0,0 2007-002853-21,1,2009-07-07,2009-07-07,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Belfast Health & Social Care Trust,A randomized controlled trial of tea tree oil (5%) body wash versus standard body wash to prevent colonization with methicillin-resistant Staphylococcus aureus (MRSA) in critically ill adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002853-21,0,0,0 2007-002853-21,1,2009-07-07,2009-07-07,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,South Eastern Health & Social Care Trust,A randomized controlled trial of tea tree oil (5%) body wash versus standard body wash to prevent colonization with methicillin-resistant Staphylococcus aureus (MRSA) in critically ill adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002853-21,0,0,0 2007-002854-52,1,2009-10-08,2009-10-08,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,"Folktandvården, Landstinget Dalarna",Postoperativ smärta och analgetika konsumtion efter visdomstandskirurgi – en kontrollerad randomiserad enkelblind jämförelse med och utan tramadol vid intravenös midazolamsedering.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002854-52,0,0,0 2007-002858-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FUNDACIÓN IBEROAMERICANA ITACA,"ENSAYO CLÍNICO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, PARALELO, COMPARADO CON PLACEBO PARA VALORAR LA EFICACIA DEL DOBESILATO CÁLCICO EN EL TRATAMIENTO DE LAS ÚLCERAS SECUNDARIAS A INSUFICIENCIA VE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002858-37,0,0,0 2007-002859-16,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,BIOXELL SPA,"A randomized, double blind, placebo controlled, parallel group study to determine the effect of Elocalcitol on sperm parameters in infertile male patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002859-16,0,0,0 2007-002860-86,1,2008-04-08,2008-04-08,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,Radboud University Nijmegen Medical Centre,The adenosine receptor; a new pharmacological tool in the treatment of sepsis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002860-86,0,0,0 2007-002861-11,2,2007-12-13,2007-12-13,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD,"An Open-label, Multi-centre, Randomised, Comparative Study of the Immunogenicity and Safety of an Inactivated Split-Virion Influenza Vaccine administered by Intradermal Route (Flu-ID 15μg) versus an I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002861-11,0,0,0 2007-002863-28,1,2009-11-03,2009-11-03,1,1,0,0,0,1,4,0,0,1,1,1,1,0,0,Guy's & St Thomas' NHS Foundation Trust,Investigation into the use of colestyramine as a therapy for patients with erythropoietic protoporphyria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002863-28,0,0,0 2007-002871-15,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002871-15,0,0,0 2007-002872-32,1,2008-07-03,2008-07-03,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase IV, Multi-Center, Active-Controlled, Observer-Blind Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture (Optaflu®) or in Embryonated...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002872-32,0,0,0 2007-002874-75,1,2008-10-15,2008-10-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,OVATION PHARMACEUTICALS INC,Safety and effectivness of Open- Label Melperone in the treatment of Patients with Psycosis Associated with Parkinson's Disease'',https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002874-75,0,0,0 2007-002875-15,1,2008-05-05,2008-05-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Takeda,"A Single-Center, Randomized, Double-Blind, Double-Dummy Placebo Controlled, Cross-Over Study to Investigate the Next Morning Effects of Ramelteon (8mg), Zopiclone (7.5mg) and Placebo on Actual Driving...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002875-15,0,0,0 2007-002876-32,1,2012-04-30,2012-04-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Wales Swansea,"A multicentre, randomised, placebo controlled trial of lactic acid bacteria in the prevention of antibiotic-associated diarrhoea (AAD) and Clostridium difficile diarrhoea (CDD) in patients aged 65 yea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002876-32,0,0,0 2007-002880-29,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults (≥66 years) previo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002880-29,0,0,0 2007-002881-36,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase II, open, controlled study to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals AS25 adjuvanted influenza vaccine (FluAS25) in elderly adults (≥67 years) previo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002881-36,0,0,0 2007-002886-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST,"AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLUS B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002886-11,0,0,0 2007-002888-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Knappschaftskrankenhaus Bochum,"Intra-individual, randomized comparison of the MRI contrast agents Gadovist® 1.0 versus Prohance® in patients with primary and secondary brain tumors, evaluated in a blinded read",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002888-27,0,0,0 2007-002893-76,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Charles University in Prague, Third Faculty of Medicine",MEtabolic Therapy with Trimetazidine in Acute heart failure: an open pilot randomized trial (The METTA – PRAGUE 10 Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002893-76,0,0,0 2007-002894-30,1,2008-04-30,2008-04-30,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Baxter AG,AN OPEN-LABEL PHASE II STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF A BOOSTER VACCINATION WITH A HETEROLOGOUS VERO CELL-DERIVED WHOLE VIRUS H5N1 INFLUENZA VACCINE IN A HEALTHY YOUNG ADULT POPULATI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002894-30,0,0,0 2007-002895-32,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Roche AB,A phase II trial assessing Metronidazol Actavis 1% topical cream in the prevention and treatment of Erlotinib associated rash,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002895-32,0,0,0 2007-002899-34,1,2008-08-31,2008-08-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Newcastle Upon tyne Hospitals NHS Foundation Trust,Pilot Controlled Clinical Trial of Salvia Officinalis (Sage) for cognitive impairments in Parkinson's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002899-34,0,0,0 2007-002900-16,1,2008-05-14,2008-05-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration study in patients with Parkinson’s disease to assess the efficacy of AFQ056 in reducing L-dop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002900-16,0,0,0 2007-002901-33,1,2010-03-08,2010-03-08,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Tripep AB,"A Phase I/IIa Open-Label, Dose Ranging, Parallel, Safety, Tolerability and Efficacy Study of i.m. Administered ChronVac-C® in Combination with Electroporation in Chronic Hepatitis C Virus Genotype 1 I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002901-33,0,0,0 2007-002902-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"CHU Angers, directeur général, Yvonnick Morice",EPOMI (ERYTHROPOIETIN IN MYOCARDIAL INFARCTION) : ESSAI RANDOMISE MULTICENTRIQUE EVALUANT L’EFFET D’UNE INJECTION D’ERYTHROPOÏETINE A LA PHASE AIGUË DE L’INFARCTUS DU MYOCARDE SUR LA TAILLE DE LA CICA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002902-23,0,0,0 2007-002905-34,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,1,PledPharma AB,A LOCAL FEASIBILITY STUDY ON MANGAFODIPIR AS AN ADJUNCT TO FOLFOX6 CHEMOTHERAPY IN PATIENTS OPERATED FOR COLORECTAL CANCER STAGE DUKE C (MANFOL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002905-34,0,0,0 2007-002906-23,3,2009-06-27,2009-07-02,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Acadia Pharmaceuticals Inc,"A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002906-23,0,0,0 2007-002909-49,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST,Neoadjuvant chemotherapy in patients affected by prostatic cancer locally advanced (non metastatic. Phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002909-49,0,0,0 2007-002911-18,2,2008-02-07,2008-02-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,Comparison of the T4/T1 ratio measured by means of the TOF-Watch® SX with the reappearance of T4 measured by means of a peripheral nerve stimulator in adult subjects receiving 4.0 mg.kg-1 sugammadex a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002911-18,0,0,0 2007-002912-24,1,2008-07-07,2008-07-07,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Bayer HealthCare AG,Study to evaluate the safety and pharmacokinetics of ciprofloxacin following inhalation of ciprofloxacin dry powder for inhalation administered to pediatric patients with cystic fibrosis aged 12-17 ye...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002912-24,0,0,0 2007-002913-38,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Oscar Lambret,Essai de phase II multicentrique sur le traitement préventif de la folliculite induite par les anti-EGFR chez des patients atteints de cancer colorectal métastatique sous Cetuximab ou atteints de canc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002913-38,0,0,0 2007-002914-20,1,2009-05-29,2009-05-29,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital Birmingham NHS Foundation Trust,Calcineurin Inhibitor Minimisation in Renal Transplant Recipients with Stable Allograft Function: A Prospective Randomised Controlled Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002914-20,0,0,0 2007-002916-24,1,2020-01-27,2020-01-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Trio Medicines Ltd,"A single centre, pilot trial of YF476 in patients with chronic atrophic gastritis, hypergastrinaemia and type I gastric carcinoids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002916-24,0,0,0 2007-002917-38,7,2011-04-29,2011-05-05,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Seattle Genetics, Inc.","A Randomised, Phase IIb Placebo-controlled Study of R-ICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for Second-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002917-38,0,0,0 2007-002917-38,7,2011-04-29,2011-05-05,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SEATTLE GENETICS INC.,"A Randomised, Phase IIb Placebo-controlled Study of R-ICE Chemotherapy (Rituximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for Second-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002917-38,0,0,0 2007-002918-19,3,2008-04-15,2008-04-15,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,GlaxoSmithkline Research & Development Limited,"A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women with Newly Diagnosed, Previously Untreated, Gynaecological Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002918-19,0,0,0 2007-002920-14,4,2009-05-28,2009-05-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TIBOTEC BVBA,"A Phase IIa randomized, partially blinded trial of telaprevir (VX-950) in treatment-naïve subjects with chronic genotype 2 or 3 hepatitis C infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002920-14,0,0,0 2007-002920-14,4,2009-05-28,2009-05-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec BVBA,"A Phase IIa randomized, partially blinded trial of telaprevir (VX-950) in treatment-naïve subjects with chronic genotype 2 or 3 hepatitis C infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002920-14,0,0,0 2007-002925-64,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Clermont-Ferrand,Pharmacocinétique du sévoflurane lors d’une sédation sur 48h en Réanimation avec le système AnaConDa : étude pilote.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002925-64,0,0,0 2007-002929-78,8,2010-01-20,2010-05-09,7,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Ortho-McNeil Janssen Scientific Affairs, LLC","A Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002929-78,1,0,0 2007-002929-78,8,2010-01-20,2010-05-09,7,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"ORTHO-MCNEIL JANSSEN SCIENTIFIC AFFAIRS, LLC","A Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of Carisbamate, Topiramate and Levetiracetam as Adjunctive Therapy in S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002929-78,1,0,0 2007-002931-95,3,2008-06-20,2008-06-20,2,0,0,0,0,0,2,0,0,2,1,0,0,0,2,UZ Leuven,The Effects of Nitric Oxide for Inhalation on Myocardial Infarction Size.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002931-95,1,0,0 2007-002931-95,3,2008-06-20,2008-06-20,2,0,0,0,0,0,2,0,0,2,1,0,0,0,2,INO Therapeutics,The Effects of Nitric Oxide for Inhalation on Myocardial Infarction Size.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002931-95,1,0,0 2007-002932-27,1,2012-01-26,2012-01-26,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Turun yliopistollinen keskussairaala,Population pharmacokinetics of dexmedetomidine in ICU patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002932-27,0,0,0 2007-002933-36,1,2016-06-28,2016-06-28,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,CH-Versailles,Etude de phase 3 randomisée multicentrique étudiant l’effet de l’addition de l’anticorps monoclonal Gemtuzumab Ozogamicin (Mylotarg) utilisé en doses fractionnées au traitement d’induction et de conso...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002933-36,0,0,0 2007-002934-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,MANTEINANCE TREATMENT IN NERD PATIENT. A COMPARATIVE RANDOMIZED OPEN STUDY BETWEEN ALGINATE AND MAGALDRATE.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002934-12,0,0,0 2007-002936-27,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO ONCOLOGICO ROMAGNOLO,A Phase II Dose-Finding Study of weekly pemetrexed in combination with Radiotherapy in locally advanced pancreatic adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002936-27,0,0,0 2007-002939-90,4,2009-06-26,2009-06-26,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Hormos Medical Ltd,"Efficacy and Long-Term Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002939-90,0,0,0 2007-002940-86,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Cliniques Universitaires Saint-Luc – Université catholique de Louvain,"Sepsis, Endothelial function, and Lipids in critically ill patients with Liver Failure (SELLIFA). Nutritional sub-study : Randomized controlled trial comparing the tolerance on lipid metabolism and sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002940-86,0,0,0 2007-002941-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SECONDA UNIVERSITA' DEGLI STUDI DI NAPOLI,RANDOMIZED PHASE II STUDY OF SORAFENIB PLUS GEMCITABINE OR SORAFENIB PLUS ERLOTINIB IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) ELDERLY OR PS 2 PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002941-20,0,0,0 2007-002942-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación de la Comunidad Valenciana Hospital Provincial de Castellón,"EXPLORATORY STUDY OF THE EFFECT OF THREE DIFFERENT LEVELS OF DOSES OF TAMOXIFEN (20, 40 Y 60 MG/DAY) OVER THE PLASMATIC CONCENTRATION OF THE MAIN ACTIVE TAMOXIFEN METABOLITE (ENDOXIFEN) IN PATIENTS WI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002942-40,0,0,0 2007-002945-18,2,2007-11-16,2007-12-17,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,GENMAB A/S,"A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy and safety in adult patients with active rheumatoid arthriti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002945-18,0,0,0 2007-002945-18,2,2007-11-16,2007-12-17,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Genmab A/S,"A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy and safety in adult patients with active rheumatoid arthriti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002945-18,0,0,0 2007-002949-20,1,2009-01-10,2009-01-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Liverpool Women's NHS Foundation Trust,Randomised controlled trial comparing the effects of oxytocin 5 units IV bolus vs oxytocin 5 units IV infusion on cardiac output during caesarean section,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002949-20,0,0,0 2007-002950-42,7,2013-07-15,2015-07-15,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Genmab A/S,"A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002950-42,0,0,0 2007-002950-42,7,2013-07-15,2015-07-15,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development,"A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002950-42,0,0,0 2007-002950-42,7,2013-07-15,2015-07-15,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development,"A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002950-42,0,0,0 2007-002951-18,8,2013-07-15,2013-07-15,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Genmab A/S,"A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002951-18,0,0,0 2007-002951-18,8,2013-07-15,2013-07-15,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development,"A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002951-18,0,0,0 2007-002957-22,9,2012-01-30,2012-01-30,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,Efficacy of once weekly exenatide long acting release and once daily insulin glargine in patients with Type 2 diabetes treated with metformin alone or in combination with sulphonylurea.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002957-22,0,0,0 2007-002957-22,9,2012-01-30,2012-01-30,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,Efficacy of once weekly exenatide long acting release and once daily insulin glargine in patients with Type 2 diabetes treated with metformin alone or in combination with sulphonylurea.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002957-22,0,0,0 2007-002960-85,4,2009-09-28,2010-01-27,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche Ltd,"Randomized, double-blind, placebo-controlled add-on trial of the safety and efficacy of RO4917838 in outpatients on olanzapine, quetiapine, risperidone or paliperidone with prominent negative or disor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002960-85,0,0,0 2007-002962-37,1,2015-10-14,2015-10-14,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,VU Medical Center Amsterdam,"Phase I/II study of dalteparin, a low molecular weight heparin (LMWH), in combination with Sunitinib (SU11248), an oral, selective multitargeted tyrosine kinase inhibitor, as first line treatment, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002962-37,0,0,0 2007-002963-28,9,2012-03-06,2012-03-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Newron Pharmaceuticals SpA,"A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002963-28,0,0,0 2007-002963-28,9,2012-03-06,2012-03-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Serono S.A-Geneva,"A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002963-28,0,0,0 2007-002963-28,9,2012-03-06,2012-03-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Serono S.A. - Geneva,"A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002963-28,0,0,0 2007-002963-28,9,2012-03-06,2012-03-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SERONO INTERNATIONAL SA,"A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002963-28,0,0,0 2007-002963-28,9,2012-03-06,2012-03-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Serono International S.A.,"A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002963-28,0,0,0 2007-002964-90,12,2012-03-29,2012-03-29,10,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Serono S.A - Geneva,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002964-90,0,0,0 2007-002964-90,12,2012-03-29,2012-03-29,10,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Newron Pharmaceuticals SpA,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002964-90,0,0,0 2007-002964-90,12,2012-03-29,2012-03-29,10,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Serono International S.A.,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002964-90,0,0,0 2007-002964-90,12,2012-03-29,2012-03-29,10,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Serono S.A. - Geneva,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002964-90,0,0,0 2007-002964-90,12,2012-03-29,2012-03-29,10,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Serono S.A.-Geneva,"A phase III, double-blind, placebo-controlled, randomised trial to determine the efficacy and safety of a dose range of 50 to 100 mg/day of safinamide, as add-on therapy, in subjects with idiopathic P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002964-90,0,0,0 2007-002967-28,1,2011-05-01,2011-05-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité University Medicine,Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002967-28,0,0,0 2007-002968-10,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"Department of Medicine I, Clinical Dep. f. Oncology, University Hospital,","Treatment of Patients Suffering from Tumour Cachexia with Dronabinol (tetrahydrocannabinol) or Placebo Comparison of individually optimised dosages in a double blind, randomised parallel design",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002968-10,0,0,0 2007-002969-12,3,2010-08-15,2010-08-15,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,A PHASE 3 STUDY OF SU011248 IN COMBINATION WITH PACLITAXEL VERSUS BEVACIZUMAB WITH PACLITAXEL IN THE FIRST-LINE ADVANCED DISEASE SETTING IN PATIENTS HAVING BREAST CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002969-12,0,0,0 2007-002969-12,3,2010-08-15,2010-08-15,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer, S.A.",A PHASE 3 STUDY OF SU011248 IN COMBINATION WITH PACLITAXEL VERSUS BEVACIZUMAB WITH PACLITAXEL IN THE FIRST-LINE ADVANCED DISEASE SETTING IN PATIENTS HAVING BREAST CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002969-12,0,0,0 2007-002969-12,3,2010-08-15,2010-08-15,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc. - 235 East 42nd Street - New York - 10017,A PHASE 3 STUDY OF SU011248 IN COMBINATION WITH PACLITAXEL VERSUS BEVACIZUMAB WITH PACLITAXEL IN THE FIRST-LINE ADVANCED DISEASE SETTING IN PATIENTS HAVING BREAST CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002969-12,0,0,0 2007-002976-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,TIPharma,"COBRA-light study, an open randomised trial comparing a modified COBRA therapy with the COBRA therapy according to BeSt in early rheumatoid arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002976-32,0,0,0 2007-002977-30,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire d'Angers,Essai multicentrique évaluant l'effet de la cystéamine sur le BDNF sérique dans la maladie de Huntington.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002977-30,0,0,0 2007-002978-62,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hopital Foch,Influence de l’analgésie peropératoire (sufentanil administré selon les critères usuels ou rémifentanil administré par un système automatisé à partir de l’Index Bispectral) sur la consommation de morp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002978-62,0,0,0 2007-002983-89,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Nantes,Intérêt de l’administration continue de ropivacaïne à l’aide du Pain – Buster™ dans la chirurgie des lambeaux microanastomosés de latissimus dorsi et de serratus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002983-89,0,0,0 2007-002984-28,2,2010-04-19,2010-04-19,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,STADA R&D GmbH,Evaluation of the Therapeutic Equivalence of Two Different Formulations Containing Epoetin (Epoetin STADA vs. Erypo®) Administered Subcutaneously for the Maintenance Treatment of Renal Anaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002984-28,0,0,0 2007-002986-11,5,2008-03-17,2008-05-30,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 24 month extension to a 12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic after 3 months), vs. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002986-11,0,0,0 2007-002986-11,5,2008-03-17,2008-05-30,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 24 month extension to a 12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic after 3 months), vs. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002986-11,0,0,0 2007-002986-11,5,2008-03-17,2008-05-30,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A,"A 24 month extension to a 12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic after 3 months), vs. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002986-11,0,0,0 2007-002987-84,2,2010-05-09,2011-07-06,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US","A RANDOMIZED, PHASE 2B STUDY OF SUNITINIB PLUS OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFOX) VERSUS BEVACIZUMAB PLUS FOLFOX AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002987-84,0,0,0 2007-002995-33,1,2007-11-16,2007-11-16,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,MUCOS Pharma GmbH Co. KG,"Efficacy and safety of three dosages of Wobenzym mono in patients with acute rhinosinusitis Randomised, comparative, parallell group, placebo controlled, double-blind, multicentre, two phase adaptive ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002995-33,0,0,0 2007-002997-72,7,2018-01-29,2018-11-23,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PERTUZUMAB + TRASTUZUMAB + DOCETAXEL vs. PLACEBO + TRASTUZUMAB + DOCETAXEL IN PREVIOUSLY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002997-72,0,0,0 2007-002997-72,7,2018-01-29,2018-11-23,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"F. Hoffmann - La Roche Ltd. - Pharmaceuticals Division, PDR","A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PERTUZUMAB + TRASTUZUMAB + DOCETAXEL vs. PLACEBO + TRASTUZUMAB + DOCETAXEL IN PREVIOUSLY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002997-72,0,0,0 2007-002999-34,8,2009-12-15,2009-12-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Ipsen Limited,"A PHASE II, INTERNATIONAL, MULTI-CENTRE, PROSPECTIVE, RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, DOSE-RANGING, PLACEBO-CONTROLLED, 12-WEEK, PRINCEPS STUDY TO ASSESS THE EFFICACY AND SAFETY OF A ONE INJ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002999-34,0,0,0 2007-002999-34,8,2009-12-15,2009-12-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,IPSEN LIMITED,"A PHASE II, INTERNATIONAL, MULTI-CENTRE, PROSPECTIVE, RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, DOSE-RANGING, PLACEBO-CONTROLLED, 12-WEEK, PRINCEPS STUDY TO ASSESS THE EFFICACY AND SAFETY OF A ONE INJ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-002999-34,0,0,0 2007-003000-35,1,,,0,0,0,0,1,1,4,0,0,0,0,0,0,0,0,"Department of Occupational and Environmental Dermatology, Malmö University Hospital",A randomized controlled single blind multicenter study to investigate the induction of aluminium contact allergy in children/adults receiving hyposensitisation therapy due to allergic disease. Childr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003000-35,0,0,0 2007-003002-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ARCAGY-GINECO,"A multicentre phase II study, estimating the efficiency and the tolerance of RAD001 (Everolimus) , in patients with endometrial metastatic cancer resistant to a first line of chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003002-10,0,0,0 2007-003003-12,1,2014-07-21,2014-07-21,1,0,0,0,0,0,2,0,1,1,1,1,1,0,0,Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg,Die Bedeutung der Inflammationslast („inflammatory/pathogen burden“) für das kardiale Altern,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003003-12,0,0,0 2007-003005-27,1,2008-02-07,2008-02-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Dept. of Anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital Rigshospitalet",Pharmacodynamic trial on rocuronium in obese patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003005-27,0,0,0 2007-003006-98,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Cirugía General II. Hospital General Universitario “Gregorio Marañón”,"ESTUDIO FASE IV, UNICENTRICO, ALEATORIZADO, SIMPLE CIEGO, CONTROLADO, COMPARATIVO DE DOS GRUPOS PARALELOS PARA EVALUAR LA EFICACIA DE TISSUCOL DUO (ADHESIVO BIOLOGICO A BASE DE FIBRINA) EN LA PREVENCI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003006-98,0,0,0 2007-003009-28,1,2009-07-03,2009-07-03,1,0,0,0,0,0,3,0,1,1,0,0,1,0,0,Department of Rheumatology,The effect of TNF alpha inhibition on the early clinical course of Polymyalgia Rheumatica (pilot study).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003009-28,0,0,0 2007-003012-61,8,2008-11-05,2009-02-27,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,sanofi-aventis Recherche & D2veloppement,"A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003012-61,1,0,0 2007-003012-61,8,2008-11-05,2009-02-27,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,sanofi recherche & developpement,"A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003012-61,1,0,0 2007-003012-61,8,2008-11-05,2009-02-27,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,sanofi-aventis recherche & developpement,"A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003012-61,1,0,0 2007-003012-61,8,2008-11-05,2009-02-27,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,sanofi-aventis recherche & development,"A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003012-61,1,0,0 2007-003013-14,8,2008-11-05,2009-02-23,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,sanofi-aventis recherche & development,"A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of Type 2 diabetic patients with nonalcoholic steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003013-14,1,0,0 2007-003013-14,8,2008-11-05,2009-02-23,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,sanofi-aventis Recherche & Dévelopment,"A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of Type 2 diabetic patients with nonalcoholic steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003013-14,1,0,0 2007-003016-60,6,2011-04-06,2011-04-30,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Nordic Bioscience A/S,"A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects with Knee Osteoarthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003016-60,0,0,0 2007-003017-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Käkkliniken, Universitetssjukhuset i Linköping",A comparison of the effect of Atropine and Botulinum-toxin in patients with severe drooling,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003017-14,0,0,0 2007-003023-20,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Cliniques universitaires Saint-Luc,"TACROLIMUS – DACLIZUMAB - MYCOPHENOLATE MOFETIL IMMUNE PROPHYLAXIS IN PEDIATRIC LIVER TRANSPLANTATION. An open, pilot, investigator-driven study in 20 recipients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003023-20,0,0,0 2007-003026-14,1,2011-07-01,2011-07-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,KA Rudolfstiftung - 2. Medizinische Abteilung,None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003026-14,0,0,0 2007-003032-37,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,Comparative study on triamcinolone and bevacizumab efficacy in macular edema treatment and in retinic or chorioretinic neovessels treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003032-37,0,0,0 2007-003035-22,7,2018-05-30,2018-05-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ACADIA PHARMACEUTICALS INC.,"A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003035-22,0,0,0 2007-003035-22,7,2018-05-30,2018-05-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Acadia Pharmaceuticals Inc,"A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003035-22,0,0,0 2007-003035-22,7,2018-05-30,2018-05-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ACADIA Pharmaceuticals Inc.,"A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003035-22,0,0,0 2007-003035-22,7,2018-05-30,2018-05-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ACADIA Pharmaceuticals Inc,"A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003035-22,0,0,0 2007-003037-17,1,2009-10-23,2009-10-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services,"A randomized, double-blind, double-dummy, active-controlled, parallel group study of single doses of ACZ885 in hospitalized patients with acute gout",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003037-17,0,0,0 2007-003042-15,4,2009-05-04,2009-05-04,2,0,0,0,0,0,3,0,0,1,1,0,1,0,1,"Opko Health, Incorporated","A Phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003042-15,0,0,0 2007-003042-15,4,2009-05-04,2009-05-04,2,0,0,0,0,0,3,0,0,1,1,0,1,0,1,OPKO HEALTH INC,"A Phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003042-15,0,0,0 2007-003045-33,1,2013-06-28,2013-06-28,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,Fenoldopam and renal insufficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003045-33,0,0,0 2007-003048-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude de phase II du sunitinib ( SUTENT®) pour le traitement de patients atteints de cancer de la prostate hormono-résistant après progression sous docétaxel.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003048-31,0,0,0 2007-003051-36,5,2009-12-22,2009-12-22,4,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Acadia Pharmaceuticals Inc,"A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003051-36,0,0,0 2007-003054-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude des marqueurs biologiques, histologiques et d’imagerie dans le traitement de 1ère ligne du carcinome à cellules claires du rein en situation métastatique par Sunitinib avant et après néphrectomi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003054-28,0,0,0 2007-003056-12,1,2012-09-30,2012-09-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ASTRAZENECA,"A RANDOMISED, MULTICENTRE, PHASE II, PARALLEL-GROUP TRIAL OF VANDETANIB MONOTHERAPY OR VANDETANIB IN COMBINATION WITH GEMCITABINE VERSUS GEMCITABINE PLUS VANDETANIB MATCHING PLACEBO IN SUBJECTS WITH A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003056-12,0,0,0 2007-003058-26,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,LOFARMA,Pilot study on tolerability of specific immunotherapywith injective allergoid adsorbed on calcium phosphate in patients with respiratory allergy to house dust mite.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003058-26,0,0,0 2007-003059-36,11,2009-03-06,2009-03-26,7,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Bayer Healthcare AG,"Estudio aleatorizado, doble ciego, controlado con placebo, multicéntrico y multinacional de fase IIb para evaluar la eficacia y la tolerabilidad de BAY 58 2667 administrado por vía intravenosa en paci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003059-36,0,0,0 2007-003059-36,11,2009-03-06,2009-03-26,7,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Bayer HealthCare AG,"Estudio aleatorizado, doble ciego, controlado con placebo, multicéntrico y multinacional de fase IIb para evaluar la eficacia y la tolerabilidad de BAY 58 2667 administrado por vía intravenosa en paci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003059-36,0,0,0 2007-003059-36,11,2009-03-06,2009-03-26,7,1,0,0,0,0,2,0,0,1,1,1,1,0,1,BAYER,"Estudio aleatorizado, doble ciego, controlado con placebo, multicéntrico y multinacional de fase IIb para evaluar la eficacia y la tolerabilidad de BAY 58 2667 administrado por vía intravenosa en paci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003059-36,0,0,0 2007-003060-22,4,2008-11-12,2009-08-12,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,DAIICHI SANKYO EUROPE GmbH,"A 24-WEEK MULTICENTRE, RANDOMISED, DOUBLE BLIND, CONTROLLED, PARALLEL GROUP NON-INFERIORITY STUDY TO ASSESS THE EFFICACY AND SAFETY OF OLMESARTAN MEDOXOMIL VERSUS CANDESARTAN CILEXETIL IN PATIENTS WIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003060-22,0,0,0 2007-003061-40,1,2011-04-15,2011-04-15,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Næstved Sygehus,JERNPROFYLAKSE TIL GRAVIDE – ER FERROAMINOCHELAT MERE EFFEKTIVT END FERROSULFAT? EN SAMMENLIGNING MELLEM 25 MG FERROCHEL® OG 50 MG FERROSULFAT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003061-40,0,0,0 2007-003062-18,1,2011-05-05,2011-05-05,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Trust,Immunotherapeutic Rescue of steroidogenic function in autoimmune Addison’s Disease (RAD): Pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003062-18,0,0,0 2007-003066-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Miguel Cervero,"Estudio piloto, aleatorizado, nacional, multicéntrico, de eficacia inmunológica, comparando un régimen TARGA de tres fármacos (Tenofovir + Emtricitabina + Lopinavir/r) y cuatro fármacos (Tenofovir + E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003066-18,0,0,0 2007-003067-46,1,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Flevoziekenhuis,Effect of domperidone and omeprazole in gastro-oesophageal reflux disease in infants between 0 and 2 years.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003067-46,0,0,0 2007-003069-42,4,2008-07-23,2008-11-10,4,0,0,0,0,0,2,0,0,1,1,0,1,0,1,"CombinatoRx, Incorporated","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SUPERIORITY OF CRX-102 OVER EACH OF ITS COMPONENTS WHEN GIVEN TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003069-42,0,0,0 2007-003070-26,1,2008-10-31,2008-10-31,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Takeda Pharma GmbH,"Candesartan “added” therapy for treatment optimization of symptomatic heart failure with diastolic dysfunction in diabetic and hypertensive patients. A randomized, placebo-controlled, double-blind, pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003070-26,0,0,0 2007-003072-19,1,2008-04-30,2008-04-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,Remifentanil administered by controlled tecnique PCSA by patients versus Meperidina administered by physician for diagnostic and operative endoscopic procedures.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003072-19,0,0,0 2007-003073-97,13,2008-10-28,2008-12-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH &Co. KG,"A Multi-center, Randomized, Vehicle-Controlled Study to Assess the Efficacy and Safety of Adalimumab in Combination with Topical Treatment (Calcipotriol/Betamethasone) in Subjects with Moderate to Sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003073-97,0,0,0 2007-003073-97,13,2008-10-28,2008-12-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Multi-center, Randomized, Vehicle-Controlled Study to Assess the Efficacy and Safety of Adalimumab in Combination with Topical Treatment (Calcipotriol/Betamethasone) in Subjects with Moderate to Sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003073-97,0,0,0 2007-003074-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,"Oral iron challange on urinary excretion of hepcidin, the key iron regulatory hormone in hemochromatosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003074-26,0,0,0 2007-003075-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""","PROTOCOL OF TREATMENT WITH DOCETAXEL-GEMCITABINE IN OLD OR UNFIT PATIENTS WITH NSCLC STAGE IIIA, IIIB E IV. PHASE II TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003075-39,0,0,0 2007-003077-44,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,TAKEDA,EffectS of PiogLitazone on ENDOthelial progenitoR cells in type 2 diabetic patients with vascular complications - The SPLENDOR Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003077-44,0,0,0 2007-003080-45,1,2012-09-19,2012-09-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,Phase ll study evaluating the toxicity and efficacy of a modified German Paediatric Hodgkin's Lymphoma protocol (HD95) in young adults (aged 18-30 years) with Hodgkin's Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003080-45,0,0,0 2007-003081-18,1,2012-11-08,2012-11-08,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University College Hospital,Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003081-18,0,0,0 2007-003085-17,1,2012-08-08,2012-08-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Surrey,"The effect of insulin detemir on energy balance, postprandial nutrient handling, body fat distribution,and adipose tissue metabolism and gene expression in patients with type 2 diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003085-17,0,0,0 2007-003086-40,2,2012-05-07,2012-05-07,1,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Fondation Charcot Stichting,A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003086-40,1,0,0 2007-003088-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AININCAR,Efecto de la Infusión Intracoronaria de Células Progenitoras de Médula Ósea sobre la Regeneración Miocárdica en Pacientes con Miocardiopatía Dilatada. Estudio Cínico-Biológico. Effects of intracoronar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003088-36,0,0,0 2007-003089-16,1,2012-06-05,2012-06-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AGO Research GmbH,"Phase II trial in platinum-refractory ovarian cancer: a randomized multicenter trial with SU11248 to evaluate dosage, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003089-16,0,0,0 2007-003091-19,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,GOTEL (Grupo Oncológico para el Tratamiento y Estudio de Los linfomas),"""Tratamiento de consolidación con Y90-Ibritumomab Tiuxetan en Pacientes con Linfoma Folicular de Alto Riesgo, en respuesta parcial o completa a Quimioterapia de Inducción con R-CHOP""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003091-19,0,0,0 2007-003092-39,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,CHU DE POITIERS,Pharmacokinetics of colistimethate and colistine after a 60 minutes intravenous infusion of colistimethate 1 million UI (80 mg) in 12 healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003092-39,0,0,0 2007-003096-39,1,2011-10-25,2011-10-25,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,WYETH LEDERLE,"Effects of Etanercept on Endothelial Function and Carotid Intima-Media Thickness In Patients With Active Ankylosing Spondylitis: a 52-Weeks, Randomized, Double Blind, Placebo-Controlled Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003096-39,0,0,0 2007-003097-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Francesc Bosch Albareda,Tratamiento de rescate con Rituximab-CHOP seguido de Alemtuzumab (R-CHOP-A) en pacientes con leucemia linfática crónica refractarios o racaidos tras tratamiento con análogos de las purinas.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003097-26,0,0,0 2007-003098-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",INTEGRATED PROTOCOL OF CHEMO-RADIOTHERAPY IN THE TREATMENT OF THE OLD PATIENTS WITH NSCLC STAGE III. PHASE II TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003098-21,0,0,0 2007-003099-20,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitätsklinikum Ulm,"A prospective, multi-center phase II study of subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allogeneic stem-cell transplantation, in chronic lymphoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003099-20,0,0,0 2007-003102-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,fonds NutsOhra,"The effect of modafinil on fatigue, cognition and functional connectivity in low-grade glioma patients: a double-blind randomized trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003102-10,0,0,0 2007-003103-12,1,2017-07-05,2017-07-05,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,Hospital of the University of Munich,"A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus Standard Double Induction for Initial Chemotherapy of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003103-12,0,0,0 2007-003106-99,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University of Kiel, Department of Dermatology","Pimecrolimus and Epidermal Barrier Function: Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, int...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003106-99,0,0,0 2007-003109-28,3,2009-01-14,2009-01-14,2,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Arpida AG,"Randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin in the treatment of hospital-acquired, ventilator-associated, or health-care-assoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003109-28,0,0,0 2007-003111-31,1,2011-09-30,2011-09-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Charité - Universitaetsmedizin Berlin,Influence of postoperative influenza vaccination versus GM-CSF in immune-compromised patients undergoing pancreatic or esophageal resection on the course of immunosuppression and the postoperative inf...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003111-31,0,0,0 2007-003114-34,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Department of Nephrology and Renal Transplantation, University Hospitals Leuven",The impact of oral curcumin (Curcuma longa) on mycophenolic acid and metabolite pharmacokinetics in stable renal allograft recipients: exploratory investigation of the role of intestinal uridine-dipho...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003114-34,0,0,0 2007-003122-24,1,2011-09-02,2011-09-02,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Daval International Limited,A Double-Blind Placebo-Controlled Pilot Study of the Safety and Tolerability of AIMSPRO in established Diffuse Cutaneous Systemic Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003122-24,0,0,0 2007-003126-15,1,2012-12-14,2012-12-14,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,DBCG,Randomized trial of sequential epirubicin and docetaxel against docetaxel in patients with early operable breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003126-15,0,0,0 2007-003130-41,1,2010-12-02,2010-12-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,DAIICHI-SANKYO EUROPE GmbH,Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients with Metabolic Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003130-41,0,0,0 2007-003131-23,6,2010-04-13,2011-08-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANKYO EUROPE,Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects with Metabolic Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003131-23,0,0,0 2007-003131-23,6,2010-04-13,2011-08-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,DAIICHI SANKYO EUROPE GmbH,Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects with Metabolic Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003131-23,0,0,0 2007-003133-16,4,2010-07-09,2010-07-09,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Schering-Plough Research Institute,Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003133-16,0,0,0 2007-003133-16,4,2010-07-09,2010-07-09,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,SCHERING-PLOUGH,Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003133-16,0,0,0 2007-003134-42,1,2008-08-27,2008-08-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-Week, Multi-center, Randomized, Prospective, Open-Label, Blinded Rater, Crossover Study of the Effects of Immediate-Release Carbidopa/Levodopa Versus Stalevo® on Markers of Event-Related Potentia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003134-42,0,0,0 2007-003137-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Grupo de Investigación en Oncología Médica del Hospital de Navarra,Tratamiento neoadyuvante con quimioterapia (Taxotere) y hormonoterapia en cáncer de próstata localizado de alto riesgo.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003137-17,0,0,0 2007-003138-41,1,2010-12-31,2010-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hospital Universitario Vall d’Hebron. Barcelona. Spain,Ensayo clínico para evaluar la seguridad de la toxina botulínica inyectada en esfínter uretral externo vía transperineal (esfinterotomía química) en la retención urinaria crónica secundaria a una les...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003138-41,0,0,0 2007-003148-31,2,2009-04-24,2009-04-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, A Division of Schering Corporation",A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole Among Patients with Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003148-31,0,0,0 2007-003151-36,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,University Hospital Ghent,"Sevoflurane-Remifentanil interaction: Multiple response surfaces, validation of calibration stimuli, validation of the intraoperative isobole concept and investigating remifentanil induced opioid tole...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003151-36,0,0,0 2007-003152-10,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,CHU DIJON,"Influence du traitement par glitazones sur les Phospholipases A2 et sur l'effet des Lipoprotéines de haute densité (HDL) sur la réactivité artérielle, au cours du diabète de type 2",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003152-10,0,0,0 2007-003153-90,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Traitement par érythropoïétine de l'anémie associée à la bronchopneumopathie chronique obstructive : conséquences fonctionnelles à l'effort,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003153-90,0,0,0 2007-003156-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOIM GRUPPO ONCOLOGICO MERIDIONALE,"Trastuzumab, docetaxel and gemcitabine as first line treatment for HER-2 positive advanced breast cancer: a phase II of G.O.I.M.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003156-11,0,0,0 2007-003158-27,3,2008-09-11,2008-09-11,2,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A randomised, double-blind, parallel groups, placebo-controlled, multi-centre study assessing the effects of a selective oxytocin antagonist (barusiban) and a mixed oxytocin antagonist – vasopressin V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003158-27,0,0,0 2007-003159-36,3,2009-01-10,2009-01-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003159-36,0,0,0 2007-003161-40,4,2013-07-24,2013-07-24,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc,East 42nd street,New york, NY10017, USA","A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTI-CENTER, COMPARATIVE, FLEXIBLE DOSE TRIAL OF PREGABALIN VERSUS GABAPENTIN AS ADJUNCTIVE THERAPY IN SUBJECTS WITH PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003161-40,0,0,0 2007-003161-40,4,2013-07-24,2013-07-24,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTI-CENTER, COMPARATIVE, FLEXIBLE DOSE TRIAL OF PREGABALIN VERSUS GABAPENTIN AS ADJUNCTIVE THERAPY IN SUBJECTS WITH PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003161-40,0,0,0 2007-003162-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Markku Kupari,"Lääkehoito aorttaläpän stenoosin ehkäisyssä Angiotensiinireseptorin salpaajan vaikutukset stenoottisen aorttaläpän tulehdukseen, fibroosiin ja kalkkiutumiseen",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003162-17,0,0,0 2007-003165-41,1,2011-07-31,2011-07-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"Étude prospective, multicentrique, ouverte et randomisée évaluant l’efficacité et la tolérance de Cellcept® (MMF) avec suivi thérapeutique pharmacologique, tacrolimus et épargne en corticoïdes versus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003165-41,0,0,0 2007-003166-18,1,2012-01-02,2012-01-02,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,CHU de Brest,Tolérance et efficacité du Rituximab dans le syndrome du Sjögren,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003166-18,0,0,0 2007-003169-42,4,2008-09-30,2008-09-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A Randomised, Phase II, Double-Blind, Double-Dummy, four-period Crossover Efficacy and Safety Comparison of 4-Week Treatment Periods of Blinded Fluticasone (500 μg bid, MDI), Ciclesonide (400 μg qd, M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003169-42,0,0,0 2007-003169-42,4,2008-09-30,2008-09-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Denmark,"A Randomised, Phase II, Double-Blind, Double-Dummy, four-period Crossover Efficacy and Safety Comparison of 4-Week Treatment Periods of Blinded Fluticasone (500 μg bid, MDI), Ciclesonide (400 μg qd, M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003169-42,0,0,0 2007-003169-42,4,2008-09-30,2008-09-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Randomised, Phase II, Double-Blind, Double-Dummy, four-period Crossover Efficacy and Safety Comparison of 4-Week Treatment Periods of Blinded Fluticasone (500 μg bid, MDI), Ciclesonide (400 μg qd, M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003169-42,0,0,0 2007-003169-42,4,2008-09-30,2008-09-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A Randomised, Phase II, Double-Blind, Double-Dummy, four-period Crossover Efficacy and Safety Comparison of 4-Week Treatment Periods of Blinded Fluticasone (500 μg bid, MDI), Ciclesonide (400 μg qd, M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003169-42,0,0,0 2007-003171-39,3,2009-07-16,2009-07-16,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Plethora Solutions Ltd,"A phase III, multi-centre, randomized, double-blind, placebo-controlled study, with open-label follow on, to evaluate the efficacy, safety and tolerability of PDS502 in subjects with Premature Ejacula...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003171-39,0,0,0 2007-003186-40,1,2010-10-06,2010-10-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Karolinska Institute,Evaluation of antiplatelet effects of different dosages of aspirin in type 2 diabetic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003186-40,0,0,0 2007-003187-22,4,2019-07-18,2019-07-18,4,1,0,0,0,0,3,0,0,1,0,0,1,0,0,VU University Medical Center,Clinical trials for adults HD18 for advanced stages Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; treatment stratification by means of FDG-PET Therapi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003187-22,0,0,0 2007-003187-22,4,2019-07-18,2019-07-18,4,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Cologne,Clinical trials for adults HD18 for advanced stages Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; treatment stratification by means of FDG-PET Therapi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003187-22,0,0,0 2007-003189-16,9,2008-05-08,2008-05-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, multi center, parallel group, double-blind, placebo and formoterol controlled 14 day dose ranging trial 4 doses of indacaterol delivered via Twisthaler®, in patients with COPD.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003189-16,0,0,0 2007-003189-16,9,2008-05-08,2008-05-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, multi center, parallel group, double-blind, placebo and formoterol controlled 14 day dose ranging trial 4 doses of indacaterol delivered via Twisthaler®, in patients with COPD.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003189-16,0,0,0 2007-003191-19,8,2007-04-18,2008-04-18,6,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A randomized, multi-center, parallel group, double-blind, placebo and formetrol controlled 14 day dose ranging trial of 4 doses of indacaterol delivered via Twisthaler®, in adult and adolescent patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003191-19,1,0,0 2007-003191-19,8,2007-04-18,2008-04-18,6,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A.,"A randomized, multi-center, parallel group, double-blind, placebo and formetrol controlled 14 day dose ranging trial of 4 doses of indacaterol delivered via Twisthaler®, in adult and adolescent patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003191-19,1,0,0 2007-003192-39,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, double dummy, placebo controlled crossover study, to investigate the 24 hour FEV1 profile of a single dose of QMF Twisthaler® (500/400 μg o.d.) delivered in th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003192-39,0,0,0 2007-003194-82,1,2009-05-04,2009-05-04,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Dundee,A proof of concept study to evaluate differential tachyphylaxis of α1 and α2 adrenoreceptor mediated decongestant response to oxymetazoline and its acute reversal by corticosteroid in healthy voluntee...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003194-82,0,0,0 2007-003195-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ICORG,A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) - IIIA Non- Small Cell Lung Cancer (NSCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003195-19,0,0,0 2007-003197-26,2,2009-04-19,2009-04-19,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bracco Imaging S.p.A.,"A PHASE IV RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY FOR THE COMPARISON OF IOMERON®-400 VS VISIPAQUE™ 320 IN CORONARY DUAL-SOURCE COMPUTED TOMOGRAPHIC ANGIOGRAPHY (DS-CTA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003197-26,0,0,0 2007-003197-26,2,2009-04-19,2009-04-19,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BRACCO IMAGING,"A PHASE IV RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY FOR THE COMPARISON OF IOMERON®-400 VS VISIPAQUE™ 320 IN CORONARY DUAL-SOURCE COMPUTED TOMOGRAPHIC ANGIOGRAPHY (DS-CTA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003197-26,0,0,0 2007-003198-22,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,GELTAMO (Grupo Español de Linfomas y Trasplante autólogo de Médula Ósea),Trasplante autologo de progenitores hemopoyéticos con acondicionamiento que incluye Zevalin + BEAM en pacientes con linfoma difuso de célula grande B refractario,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003198-22,0,0,0 2007-003203-12,1,2008-11-19,2008-11-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Agence nationale de recherches sur le sida et les hépatites virales. ANRS,"Pharmacocinétique de l’atazanavir chez des patients infectés par le VIH, traités en première ligne par l’association atazanavir+ritonavir et emtricitabine+ténofovir en prise unique.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003203-12,0,0,0 2007-003206-96,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Gallego de Investigaciones Oncológicas (GGIO),“Estudio Fase II de Capecitabina y Erlotinib como tratamiento de primera línea en pacientes con cáncer de páncreas metastático (estadio IV)”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003206-96,0,0,0 2007-003208-37,2,2012-03-29,2012-03-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALLERGOPHARMA JOACHIM GANZER KG,"A multicentre multinational randomised, placebo-controlled, double-blind pivotal trial for the evaluation of safety and efficacy of specific immunotherapy with a cocktail of recombinant major allergen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003208-37,0,0,0 2007-003208-37,2,2012-03-29,2012-03-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergopharma Joachim Ganzer KG,"A multicentre multinational randomised, placebo-controlled, double-blind pivotal trial for the evaluation of safety and efficacy of specific immunotherapy with a cocktail of recombinant major allergen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003208-37,0,0,0 2007-003210-33,1,2013-10-21,2013-10-21,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,"Department of Neurology, Turku University Hospital",Effect of ropinirole hydrochloride in progressive myoclonic epilepsy of Unverricht–Lundborg type,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003210-33,0,0,0 2007-003211-31,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,GRUPO ESPAÑOL MULTIDISCIPLINARIO DEL CANCER DIGESTIVO(GEMCAD),"ENSAYO CLÍNICO DE FASE I-II, NO ALEATORIZADO, MULTICENTRICO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE LA COMBINACIÓN DE SORAFENIB (BAY 43-9006), GEMCITABINA Y RADIOTERAPIA CONCURRENTE EN EL TRATAMIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003211-31,0,0,0 2007-003212-65,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Astion Pharma A/S,"Efficacy and safety of ASF-1075 cream 5% on pruritus in adult patients with atopic dermatitis. A multi-centre, randomised, double-blind, vehicle-controlled, parallel groups, proof of concept study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003212-65,0,0,0 2007-003213-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU-Tours,Impact d'un traitement par le rituximab sur l'évolution des rejets aigus humoraux après transplantation rénale,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003213-13,0,0,0 2007-003218-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Blood bank, Rigshospitalet, University Hospital of Copenhagen",Antitrombotisk effekt af ADP receptor inhibitor i tillæg til Aspirin til hyperkoagulable patienter der gennemgår CABG kirurgi.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003218-33,0,0,0 2007-003221-25,1,2016-12-31,2016-12-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,United Lincolnshire Hospitals NHS Trust,"Phase II study of the effectiveness of the addition of Capecitabine to a standard regimen containing Adriamycin, Cyclophosphamide and Docetaxel as neoadjuvant treatment in large or locally advanced br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003221-25,0,0,0 2007-003223-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Cliniques Universitaires St Luc - UCL,Temocillin use in intensive care units: A Pharmacokinetic study of 6g per day in conventional administration vs. continuous infusion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003223-20,0,0,0 2007-003224-38,16,2011-02-07,2011-05-01,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003224-38,0,0,0 2007-003224-38,16,2011-02-07,2011-05-01,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ASTRAZENECA,"A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-metastatic Hormone-resistant Prostate Cancer P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003224-38,0,0,0 2007-003226-19,15,2010-08-11,2010-11-08,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Teva Pharmaceutical Industries Ltd,"A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003226-19,0,0,0 2007-003226-19,15,2010-08-11,2010-11-08,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,TEVA ITALIA srl,"A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003226-19,0,0,0 2007-003227-20,13,2011-06-30,2011-08-01,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003227-20,0,0,0 2007-003227-20,13,2011-06-30,2011-08-01,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ASTRAZENECA,"A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003227-20,0,0,0 2007-003228-39,11,2011-06-30,2011-07-01,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ASTRAZENECA,"A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003228-39,0,0,0 2007-003228-39,11,2011-06-30,2011-07-01,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003228-39,0,0,0 2007-003228-39,11,2011-06-30,2011-07-01,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca BV,"A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003228-39,0,0,0 2007-003230-42,7,2008-12-03,2009-05-18,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,PIERRE FABRE MEDICAMENT,"STUDY OF THE ANALGESIC EFFECTS OF REPEATED DOSES OF F13640 IN SPINAL CORD INJURY PATIENTS WITH MODERATE TO SEVERE CENTRAL NEUROPATHIC PAIN A multinational, multicenter, randomized, double blind, para...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003230-42,0,0,0 2007-003230-42,7,2008-12-03,2009-05-18,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pierre Fabre Me'dicament,"STUDY OF THE ANALGESIC EFFECTS OF REPEATED DOSES OF F13640 IN SPINAL CORD INJURY PATIENTS WITH MODERATE TO SEVERE CENTRAL NEUROPATHIC PAIN A multinational, multicenter, randomized, double blind, para...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003230-42,0,0,0 2007-003232-35,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Medizin Universität Wien,Dantrolen as treatment for hyperthermia in patients with subarachnoidal hemorrhage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003232-35,0,0,0 2007-003233-16,4,2010-05-21,2010-05-21,2,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Theratechnologies Inc.,"A Multicenter, Double-blind, Randomized, Placebo-Controlled Extension Study Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003233-16,1,0,0 2007-003235-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Inserm,"Essai randomisé multicentrique de phase II d'évaluation immunologique d'une stratégie vaccinale de type ""prime boost"" associant une administration du vaccin conjugué anti-pneumococcique à S0 suivie de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003235-23,0,0,0 2007-003237-16,1,2008-01-15,2008-01-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GENFIT,"A Pilot study to evaluate the Efficacy and Safety of GFT505 (30 mg) orally administered for 28 days in patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia). A double blind, placebo-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003237-16,0,0,0 2007-003239-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,UCB PHARMA S.A.,"A phase IIIb, open label, randomized, exploratory clinical study exploring efficacy, safety and patients’ satisfaction with Certolizumab pegol treatment in moderate to severe Crohn’s disease when trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003239-21,0,0,0 2007-003240-30,1,2016-06-04,2016-06-04,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Cancer Research UK,"A Cancer Research UK Phase I/II Open Label Study to Evaluate the Safety, Endocrine Effects, and Anti-tumour Activity of Abiraterone Acetate (CB7630) in Patients with Oestrogen (ER) or Androgen Recepto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003240-30,0,0,0 2007-003244-30,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Rijnstate Hospital,"Diazoxide-Mediated Insulin Suppression in Hyperinsulinemic Obese Men, part III.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003244-30,0,0,0 2007-003247-70,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Belgian Study Group for Pediatric Endocrinology,Efficacy and safety of a 4 year combination therapy of growth hormone and gonadotropin- releasing hormone agonist in children with a short predicted height.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003247-70,0,0,0 2007-003248-31,1,2008-04-30,2008-04-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GSK Biologicals,"An open, phase IV, non-randomised, single-centre study with two study groups to assess the immunogenicity and reactogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals' combined reduced an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003248-31,0,0,0 2007-003249-34,5,2009-05-18,2009-05-18,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pierre Fabre Medicament,"Proof of Concept study of the efficacy and tolerability of a 4-week treatment with F13640 in patients in whom the adaptation of opioid therapy of cancer pain has failed. A prospective, multinational, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003249-34,0,0,0 2007-003249-34,5,2009-05-18,2009-05-18,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,PIERRE FABRE MEDICAMENT,"Proof of Concept study of the efficacy and tolerability of a 4-week treatment with F13640 in patients in whom the adaptation of opioid therapy of cancer pain has failed. A prospective, multinational, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003249-34,0,0,0 2007-003250-29,2,2009-09-11,2009-09-11,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Independent Pharmaceutica AB,"A randomised, placebo-controlled, multi-centre study on the efficacy of Niccine, a vaccine for nicotine, in smoking relapse prevention, assessed in abstinent, adult smokers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003250-29,0,0,0 2007-003253-88,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,morpho-functional evaluation of eye disease with corneal neovascularitation after subconjuctival injection of bevacizumab. Interventional pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003253-88,0,0,0 2007-003254-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,RADIOCHEMIOTERAPIA CON TEMOZOLOMIDE CONCOMITANTE E ADIUVANTE NEL TRATTAMENTO DEI LINFOMI CEREBRALI PRIMITIVI DOPO METOTREXATE AD ALTE DOSI: STUDIO DI DOSE ESCALATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003254-28,0,0,0 2007-003256-11,2,2009-07-27,2009-07-27,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GLAXO SMITHKLINE,"A phase IIIb open, randomized multi-center study to evaluate the immunogenicity and safety of GSK Biologicals HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to an alternativ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003256-11,0,0,0 2007-003256-11,2,2009-07-27,2009-07-27,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIb open, randomized multi-center study to evaluate the immunogenicity and safety of GSK Biologicals HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to an alternativ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003256-11,0,0,0 2007-003262-17,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,University Hospital Magdeburg,Impact of irbesartan on oxidative stress and C-reactive protein levels in patients with persistent atrial fibrillation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003262-17,0,0,0 2007-003263-52,1,2010-04-15,2010-04-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Bonn,Gadofosveset Trisodium (Vasovist®) zur kontrastverstärkten MR-Angiographie der supraaortalen Arterien und zur Darstellung der Gefäßwand in der primären Kontrastmittelpassage („first pass“) und in der ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003263-52,0,0,0 2007-003272-19,1,2009-04-03,2009-04-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Krewel Meuselbach GmbH,"Acute bronchitis therapy with ivy leaves extracts in a two-arm study: a double-blind, ransomised study vs. comparator",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003272-19,0,0,0 2007-003275-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,New immunosuppressive treatments to reduce the rate of recurrence of hepatocellular carcinoma after liver transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003275-40,0,0,0 2007-003276-19,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Efficacy and safety of s- Ketamine and Remifentanil for endovenous analgesy in labour pains,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003276-19,0,0,0 2007-003277-19,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,modifications on the pain-threshold in labour and the effects of the epidural analgesia and S-Ketamina on the pai-threshold,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003277-19,0,0,0 2007-003278-24,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA SENESE,A PHASE II STUDY OF THE EFFECTIVENESS AND TOLERABILITY OF PEGYLATED LIPOSOMAL DOXORUBICIN IN ASSOCIATION WITH DAILY ORAL CYCLOPHOSPHAMIDE IN METASTATIC BREAST CANCER PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003278-24,0,0,0 2007-003279-38,3,2009-01-20,2009-01-20,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Tranzyme Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Efficacy and Safety of TZP-101 when Administered as a 30 Minute I.V. Infusion to Subjects with Severe Gast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003279-38,0,0,0 2007-003280-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SOFAR SPA,A randomised controlled multicenter trial assessing the efficacy and safety of mesalazine therapy in patients with irritable bowel syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003280-41,0,0,0 2007-003281-18,6,2009-08-20,2010-01-13,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Avexa Limited,"A phase 2b/3, randomized, double blind, dose confirming study of the safety, efficacy and tolerability of apricitabine versus lamivudine in treatment-experienced HIV-1 infected patients with the M184V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003281-18,1,0,0 2007-003288-36,7,2010-06-06,2010-06-07,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Centocor BV,"A Phase 4, Multicenter, Open-Label, Assessor-blinded, Switch Study o fthe Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003288-36,0,0,0 2007-003289-16,5,2010-04-26,2010-05-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"A blinded, randomized, placebo-controlled trial in genotype 1 hepatitis C-infected subjects to evaluate the efficacy, safety, tolerability and pharmacokinetics of repeated doses of TMC435350, with or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003289-16,0,0,0 2007-003289-16,5,2010-04-26,2010-05-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Ltd,"A blinded, randomized, placebo-controlled trial in genotype 1 hepatitis C-infected subjects to evaluate the efficacy, safety, tolerability and pharmacokinetics of repeated doses of TMC435350, with or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003289-16,0,0,0 2007-003290-29,2,2007-11-02,2007-11-02,2,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, observer-blind, multicountry, multicentre, randomized study to demonstrate the non-Inferiority of GlaxoSmithKline Biologicals’ one-container AS25 adjuvanted influenza vaccine compared to G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003290-29,0,0,0 2007-003291-19,1,2011-01-19,2011-01-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Dundee,A proof of concept study to evaluate if concomitant topical intranasal steroid prevents tolerance and rebound congestion due to regular oxymetazoline in persistent allergic rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003291-19,0,0,0 2007-003293-25,1,2008-06-30,2008-06-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Medivation, Inc.","A MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003293-25,0,0,0 2007-003302-10,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,GELTAMO (Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea),"Trasplante alogénico de progenitores hematopoyéticos tras acondicionamiento no mieloablativo con melfalan ,fludarabina y zevalin en pacientes con linfoma No Hodgkin B agresivo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003302-10,0,0,0 2007-003307-13,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,1,"Jazz Pharmaceuticals, Inc.","A Phase 2a, Open-label, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intranasal Clonazepam in Adult Subjects with Epileptic Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003307-13,0,0,0 2007-003309-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,EFFECT OF MECHANICAL BOWEL PREPARATION WITH POLYETHYLENE GLYCOL PLUS BOWEL ENEMA (GLYCERIN 5%) VS BOWEL ENEMA ALONE IN PATIENTS CANDIDATES TO COLORECTAL RESECTION FOR MALIGNANCY. PROSPECTIVE RANDOMIZE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003309-28,0,0,0 2007-003311-32,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,FORIM GmbH,Comparative surveillance study to assess the effect of lipid based nutrition vs. standard regimen on clinical outcome in ventilated patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003311-32,0,0,0 2007-003312-65,5,2009-04-24,2009-04-24,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Efficacy and safety of 2 doses of S 90098 (1 and 2mg/day), sublingual formulation for 8 weeks in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, internatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003312-65,0,0,0 2007-003323-20,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Clavis Pharma ASA,A Phase I/II Study of CP-4055 in Patients with Platinum Resistant Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003323-20,0,0,0 2007-003327-21,1,2010-12-03,2010-12-03,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Heart of England NHS Foundation Trust Radiology Department,Oral Contrast Agent for Elective Abdominopelvic CT: Water versus Dilute Gastrografin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003327-21,0,0,0 2007-003328-39,7,2009-06-09,2009-06-23,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"NIPPON SHINYAKU CO., LTD.","A multi-centre, multinational, open-label single-dose acute hemodynamic study followed by a multi-centre, multinational, randomized, double-blind, parallel-group, placebo controlled study to assess ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003328-39,0,0,0 2007-003328-39,7,2009-06-09,2009-06-23,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Nippon Shinyaku Co., LTD","A multi-centre, multinational, open-label single-dose acute hemodynamic study followed by a multi-centre, multinational, randomized, double-blind, parallel-group, placebo controlled study to assess ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003328-39,0,0,0 2007-003328-39,7,2009-06-09,2009-06-23,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"A multi-centre, multinational, open-label single-dose acute hemodynamic study followed by a multi-centre, multinational, randomized, double-blind, parallel-group, placebo controlled study to assess ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003328-39,0,0,0 2007-003331-23,5,2009-02-03,2009-07-09,3,0,0,0,0,1,0,0,0,1,0,0,1,0,1,"APOPHARMA INC., TORONTO, ONTARIO","A six-month double-blind, randomized, placebo-controlled study investigating the safety and tolerability of deferiprone in participants with Friedreich's ataxia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003331-23,0,0,0 2007-003331-23,5,2009-02-03,2009-07-09,3,0,0,0,0,1,0,0,0,1,0,0,1,0,1,ApoPharma Inc.,"A six-month double-blind, randomized, placebo-controlled study investigating the safety and tolerability of deferiprone in participants with Friedreich's ataxia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003331-23,0,0,0 2007-003339-22,1,2008-06-11,2008-06-11,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase II, Observer-Blind, Parallel Groups, Single-Center, Extension Study to Evaluate the Immunogenicity and Safety Following a Single Intramuscular Dose of FLUAD or Vaxigrip Influenza Vaccines in H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003339-22,0,0,0 2007-003340-30,8,2011-04-28,2011-04-28,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Genta Incorporated,"A multicenter, randomized, double-blind study of dacarbazine with or without Genasense in chemotherapy naïve subjects with advanced melanoma and low LDH (The AGENDA Trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003340-30,1,0,0 2007-003341-32,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,University medical Center Utrecht,Treatment of steroid resistant grade II to IV acute GVHD by infusion of mesenchymal stem cells expanded with human plasma and platelet lysate ; a phase I/II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003341-32,0,0,0 2007-003342-15,3,2008-06-13,2008-06-13,3,0,0,0,0,0,4,0,0,1,1,0,1,0,1,Eli Lilly and Company Limited,"A Randomized, Open-Label Study Comparing the Effectiveness of Olanzapine Pamoate Depot with Haloperidol Decanoate in the Treatment of Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003342-15,0,0,0 2007-003343-74,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Academic Medical Center,A methodological investigation to test acute changes in female sexual desire in healthy volunteersand pre- and postmenopausal women diagnosed with hypoactive sexual desiredisordersusing explicit measu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003343-74,0,0,0 2007-003345-33,5,2008-01-21,2008-01-21,5,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Curalogic A/S,"A randomized, double-blind, parallel group, placebo-controlled study to assess the efficacy and safety of two doses of oral microencapsulated grass pollen extract administered prior to and during the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003345-33,0,0,0 2007-003347-73,1,2009-04-29,2009-04-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,A pharmacokinetic evaluation of the addition of Aprepitant to the Cisplatin - Etoposide (CE) treatment of patients with metastatic lung carcinoma (ACE).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003347-73,0,0,0 2007-003348-31,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,"Department of Woman and Child health, Karolinska University Hospital",Progesterone at imminent premature birth Progesteron vid hotande förtidsbörd,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003348-31,0,0,0 2007-003353-90,3,2008-05-22,2008-05-22,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A double-blind, double-dummy, randomized, parallel groups study to assess the Efficacy, Safety and Tolerability of switching patients with early Parkinson’s disease (PD) from Pramipexole IR to Pramipe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003353-90,0,0,0 2007-003353-90,3,2008-05-22,2008-05-22,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"A double-blind, double-dummy, randomized, parallel groups study to assess the Efficacy, Safety and Tolerability of switching patients with early Parkinson’s disease (PD) from Pramipexole IR to Pramipe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003353-90,0,0,0 2007-003353-90,3,2008-05-22,2008-05-22,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER INGELHEIM,"A double-blind, double-dummy, randomized, parallel groups study to assess the Efficacy, Safety and Tolerability of switching patients with early Parkinson’s disease (PD) from Pramipexole IR to Pramipe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003353-90,0,0,0 2007-003354-28,1,2010-01-12,2010-01-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Gilead Sciences Limited,"A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching from a Stable HAART Regimen of fixed dose Abacavir/Lamivuidine (Kivexa) Plus Efavirenz, to Once D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003354-28,0,0,0 2007-003357-85,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""",Randomized placebo-controlled double-blind trial to assess safety and efficacy of erythropoietin in adult patients with Friedreich's ataxia (a pilot study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003357-85,0,0,0 2007-003358-27,1,2011-03-24,2011-03-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin","Phase III, multi-center, randomized, double blind, placebo-controlled study for treatment of juvenile ankylosing spondylitis with Adalimumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003358-27,0,0,0 2007-003359-35,2,2009-01-30,2009-11-16,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Amicus Therapeutics, Inc.","A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF AT2101 IN TREATMENT-NAIVE ADULT PATIENTS WITH TYPE 1 GAUCHER DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003359-35,0,0,0 2007-003360-22,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,"Novartis Farmacéutica, S.A.",Estudio prospectivo exploratorio para describir en pacientes naïve y no naïve la cinética del virus de la hepatitis B durante las primeras 24 semanas en tratamiento con telbivudina.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003360-22,0,0,0 2007-003361-40,1,2008-04-08,2008-04-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Design Clinical Trial to Study the Efficacy and Safety of MK-0462 / Rizatriptan 10 mg for the Early Treatment of Acute Migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003361-40,0,0,0 2007-003362-17,6,2008-06-30,2008-06-30,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Myriad Pharmaceuticals, Inc",Open Label Study of the Effect of Daily Treatment with MPC-7869 in Subjects with Dementia of the Alzheimer’s Type,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003362-17,1,0,0 2007-003364-21,5,2010-03-20,2010-03-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma Corporation,"A Phase III, Multicentre, Double-blind, Double-Dummy, Randomised, Flexible-dose, Comparative Study of MCI-196 versus Simvastatin for the Treatment of Dyslipidaemia in Subjects with Chronic Kidney Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003364-21,0,0,0 2007-003364-21,5,2010-03-20,2010-03-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MITSUBISHI PHARMA CORPORATION,"A Phase III, Multicentre, Double-blind, Double-Dummy, Randomised, Flexible-dose, Comparative Study of MCI-196 versus Simvastatin for the Treatment of Dyslipidaemia in Subjects with Chronic Kidney Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003364-21,0,0,0 2007-003365-41,2,2009-04-14,2009-06-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S),Calcipotriol Plus Hydrocortisone Ointment Compared with Tacalcitol Ointment in Patients with Psoriasis Vulgaris on the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment conta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003365-41,0,0,0 2007-003365-41,2,2009-04-14,2009-06-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharma A/S,Calcipotriol Plus Hydrocortisone Ointment Compared with Tacalcitol Ointment in Patients with Psoriasis Vulgaris on the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment conta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003365-41,0,0,0 2007-003369-42,1,2012-01-13,2012-01-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,CENTRE LEON BERARD,"Etude de phase II randomisée, multicentrique, en ouvert, évaluant l'efficacité de l’association Avastin (bevacizumab) + Torisel (temsirolimus) versus Sutent (sunitinib) versus Avastin+ Roféron(interfé...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003369-42,0,0,0 2007-003370-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Charite Universitätsmedizin Berlin,"A prospective, single center, double blind, placebo controlled study of adipocytokines, adipose tissue gene expression and hepatic insulin clearance in the therapeutic response to vildagliptin in man",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003370-26,0,0,0 2007-003371-39,1,2008-12-09,2008-12-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biofrontera Bioscience GmbH,"A randomized, double-blind, phase III multicenter study evaluating the safety and efficacy of BF-200 ALA versus placebo in the treatment of actinic keratosis when using PDT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003371-39,0,0,0 2007-003372-18,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ABIOGEN PHARMA,"A randomised, double-blind, placebo controlled study to assess the safety and the efficacy of neridronate 100 mg - 4 i.v. infusions in a course of 10 days treatment - in patients with algodystrophic s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003372-18,0,0,0 2007-003376-20,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,ANTITHROMBOTIC THERAPY IN THE DIABETIC PATIENT: STUDY ON THE EFFECT ON PLATELET FUNCTIONALITY OF A GREATER DOSAGE OF ASPIRIN OR THE ASSOCIATION OF LOW DOSES OF ASPIRIN PLUS SELECTIVE INHIBITOR OF THE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003376-20,0,0,0 2007-003377-15,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Erasmus Hospital,"Chemoreflex sensitivity, exercise and beta agonists",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003377-15,0,0,0 2007-003381-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,ROCHE,"Etude multicentrique française, ouverte, non-comparative, évaluant la tolérance clinique et biologique de l’utilisation de l'epoetin beta (NeoRecormon®) chez des patients présentant une anémie au cour...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003381-18,0,0,0 2007-003384-51,9,2014-05-19,2014-05-19,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination with Bevacizumab and Paclitaxel or AMG386 plus Paclitaxel as First-Line Therapy in Subjects with Her2-Negative, Metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003384-51,0,0,0 2007-003387-22,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Pharma 2100 ApS,Et velkendt lægemiddels helende effekt på iskæmiske sår: et randomiseret dobbelt-blindt placebokontrolleret pilotforsøg,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003387-22,0,0,0 2007-003392-39,2,2009-03-23,2009-03-23,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Laboratorios Almirall S.A.,"Standardized sTudy with Almotriptan in eaRly Treatment of migraine, START. An international, open label, single arm, effectiveness and safety study of Almotriptan in primary care",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003392-39,0,0,0 2007-003392-39,2,2009-03-23,2009-03-23,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Laboratorios Almirall SA,"Standardized sTudy with Almotriptan in eaRly Treatment of migraine, START. An international, open label, single arm, effectiveness and safety study of Almotriptan in primary care",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003392-39,0,0,0 2007-003393-25,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,"sanofi-aventis, s.r.o.",None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003393-25,0,0,0 2007-003398-24,1,2008-02-01,2008-02-01,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,The Whittington Hospital NHS Trust,"A randomised, double blind validation of the significance of occult pyuria for the symptoms of the overactive bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003398-24,0,0,0 2007-003399-20,1,2009-02-23,2009-02-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ITALFARMACO S.A,"Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, para determinar la eficacia y seguridad de una nueva formulación de estriol en baja concentración (ITFE-2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003399-20,0,0,0 2007-003401-27,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Servicio de Infecciones. Hospital Clinic de Barcelona,"Ensayo clínico controlado, aleatorizado, abierto, de 48 semanas de duración, para evaluar la seguridad, tolerabilidad y actividad de raltegravir en sustitución de los inhibidores de la proteasa (IP) p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003401-27,0,0,0 2007-003403-13,2,2008-08-07,2008-08-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A proof of concept study of the effects of QAX576 (an interleukin-13 monoclonal antibody) on allergic inflammation following out of allergy season repeated nasal allergen challenge in subjects with se...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003403-13,0,0,0 2007-003405-27,1,2009-09-19,2009-09-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS PHARMA SAS,"Etude ouverte, multicentrique, de 24 semaines, évaluant l'efficience clinique de la forme Exelon patch 10 cm2 chez des patients avec une maladie d'Alzheimer (MMSE 10-26)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003405-27,0,0,0 2007-003406-10,5,2010-05-06,2010-05-06,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A Phase IIB, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Arte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003406-10,0,0,0 2007-003406-10,5,2010-05-06,2010-05-06,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"A Phase IIB, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Arte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003406-10,0,0,0 2007-003406-10,5,2010-05-06,2010-05-06,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche Ltd.,"A Phase IIB, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study, Evaluating the Safety, Tolerability and Efficacy of RO4607381 by Measuring Flow Mediated Dilatation in the Brachial Arte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003406-10,0,0,0 2007-003407-12,2,2010-07-15,2010-07-16,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Allergan Limited,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Explore the Dose Dependent Response to Three Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003407-12,0,0,0 2007-003412-59,1,2007-12-27,2007-12-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A,"A SINGLE CENTRE DOUBLE-BLIND, RANDOMISED 3 PERIOD CROSS OVER STUDY TO COMPARE SAFETY ASSESSED BY KNEMOMETRY AND URINARY CORTISOL MEASUREMENTS OF BECLOMETHASONE DIPROPIONATE HFA pMDI 100 AND 200 µg B.I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003412-59,0,0,0 2007-003414-34,2,2009-12-16,2009-12-16,2,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Aeterna Zentaris GmbH,Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1year placebo-controlled efficacy study and long-term safety assessment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003414-34,0,0,0 2007-003415-31,1,2008-02-19,2008-02-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios Almirall, S.A.","A PHASE IIa, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE COMPARATOR CONTROLLED, 5-WAY CROSSOVER CLINICAL TRIAL TO ASSESS THE ACTIVITY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SING...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003415-31,0,0,0 2007-003416-61,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Sociedad Española de Cirugía Pediátrica,Estudio exploratorio multicéntrico para la comparación de la eficacia de la uroquinasa y la videotoracoscopia en el tratamiento del empiema paraneumónico complicado en la infancia Exploratory multice...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003416-61,0,0,0 2007-003417-14,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Grupo Español de Investigación en Cáncer de Mama (GEICAM),"Ensayo fase III aleatorizado, multicéntrico, abierto, de grupos paralelos para comparar la eficacia y tolerabilidad de Fulvestrant (Faslodex®) durante tres años en combinación con Anastrozol (Arimidex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003417-14,0,0,0 2007-003418-32,2,2009-03-06,2009-03-06,1,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Gilead Sciences Incorporated,"A Phase III, Randomised, Open- Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate versus Continuing Stavudine or Zidovudine in Virologi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003418-32,1,1,0 2007-003418-32,2,2009-03-06,2009-03-06,1,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Gilead Sciences,Inc.","A Phase III, Randomised, Open- Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate versus Continuing Stavudine or Zidovudine in Virologi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003418-32,1,1,0 2007-003420-38,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Umeå University,The effect of Rapydan lidocain/tetracain patch on pain-response and reproducibilty in Tuberculin test,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003420-38,0,0,0 2007-003428-38,2,2008-01-31,2008-02-01,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","A Phase III Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Prospectively Evaluate Efficacy of Montelukast in Patients Aged 6 Months to 5 Years With Chronic Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003428-38,0,0,0 2007-003430-42,1,2008-06-10,2008-06-10,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,MannKind Corporation,"A Phase 1, Repeated Single-Dose, Double Blind, Randomized Five Treatment Controlled Safety and Pharmacological Response Evaluation Trial of MKC253 Inhalation Powder in Adult Male and Postmenopausal Fe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003430-42,0,0,0 2007-003450-28,1,2006-06-10,2006-06-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ChemoCentryx, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003450-28,0,0,0 2007-003454-29,1,2009-03-27,2009-03-27,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Cytos Biotechnology AG,"Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, Immunogenicity and Clinical Efficacy of a Specific Immuotherapy Combining Allergen with CYT003-QbG10 (CYT005-AllQbG10) in Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003454-29,0,0,0 2007-003455-36,3,2008-06-29,2008-07-09,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AstraZeneca AB,"A Multi-centre, Double-blind, Randomised, Placebo-controlled, Single-dose, Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness and Haemodynamics of an Intravenous Infusion of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003455-36,0,0,0 2007-003458-28,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"UCB, Inc.","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months With Sy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003458-28,0,1,1 2007-003461-41,1,2012-07-05,2012-07-05,1,0,0,0,0,0,3,0,0,1,1,1,1,0,3,"Deutsche Herzzentrum Berlin, Kompetenznetz Angeborene Herzfehler",Cardiac imaging under dobutamine stress for early assessment of right ventricular function in patients with tetralogy of Fallot and pulmonary regurgitation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003461-41,0,0,0 2007-003462-18,11,2010-11-11,2014-09-18,10,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"ARIAD PHARMACEUTICALS,INC.",A Pivotal Trial to Determine the Efficacy and Safety of AP23573 (Ridaforolimus) when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003462-18,0,0,0 2007-003462-18,11,2010-11-11,2014-09-18,10,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"ARIAD Pharmaceuticals, Inc.",A Pivotal Trial to Determine the Efficacy and Safety of AP23573 (Ridaforolimus) when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003462-18,0,0,0 2007-003462-18,11,2010-11-11,2014-09-18,10,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc",A Pivotal Trial to Determine the Efficacy and Safety of AP23573 (Ridaforolimus) when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003462-18,0,0,0 2007-003462-18,11,2010-11-11,2014-09-18,10,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corporation, a subsidiary of Merck & Co, Inc.",A Pivotal Trial to Determine the Efficacy and Safety of AP23573 (Ridaforolimus) when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003462-18,0,0,0 2007-003464-22,3,,,0,1,0,0,0,0,3,0,0,1,1,0,0,1,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Noninferiority, Multicenter Study of Ceftobiprole Medocaril Versus Cefepime With or Without Vancomycin in the Treatment of Subjects With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003464-22,0,0,0 2007-003464-22,3,,,0,1,0,0,0,0,3,0,0,1,1,0,0,1,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Noninferiority, Multicenter Study of Ceftobiprole Medocaril Versus Cefepime With or Without Vancomycin in the Treatment of Subjects With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003464-22,0,0,0 2007-003466-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTI FISIOTERAPICI OSPITALIERI,PHASE II TRIAL OF PRIMARY CHEMOTHERAPY WITH TRASTUZUMAB IN COMBINATION WITH DOCETAXEL FOLLOWED BY EPIRUBICIN-CYCLOPHOSPHAMIDE IN PATIENTS WITH HER2-OVEREXPRESSING OPERABLE BREAST CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003466-18,0,0,0 2007-003467-48,1,2013-11-17,2013-11-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universität zu Köln,"A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003467-48,0,0,0 2007-003470-26,1,2015-08-18,2015-08-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Active Biotech Research AB,Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer. Final Protocol dated 2007...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003470-26,0,0,0 2007-003471-39,1,2008-01-31,2008-01-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Prof. Dr. med. Margitta Worm,Explorative analysis of topical miltefosine application in adult patients with atopic dermatitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003471-39,0,0,0 2007-003472-19,1,2012-03-01,2012-03-01,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Royal Free Hampstead NHS Trust,Determining a viral load threshold for pre-emptive therapy for cytomegalovirus infection in transplant patients using real time PCR monitoring.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003472-19,0,0,0 2007-003476-19,11,2009-10-28,2010-11-26,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,"A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003476-19,0,0,0 2007-003476-19,11,2009-10-28,2010-11-26,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & de'veloppement,"A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003476-19,0,0,0 2007-003477-94,1,2008-07-08,2008-07-08,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IV, open, non-randomised, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria-tetanus, acellular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003477-94,0,0,0 2007-003478-25,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,ROTTAPHARM / ROTTA RESEARCH LABORATORIUM,"“The effect of acute and chronic administration of the CCK1 receptor antagonist Dexloxiglumide (CR2017) on 24-h pH metry, LES motor and symptoms’ pattern, in patients with gastroesophageal reflux dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003478-25,0,0,0 2007-003479-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital of Geneva,Efficacy of Methotrexate on Chronic Chondrocalcinosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003479-37,0,0,0 2007-003479-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University Hospital Geneva, Switzerland",Efficacy of Methotrexate on Chronic Chondrocalcinosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003479-37,0,0,0 2007-003481-18,1,2013-07-31,2013-07-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TBF,PHASE III PROTOCOL COMPARING A MICROFRACTURE TREATMENT TO A CARTIPATCH® CHONDROCYTE GRAFT TREATMENT IN FEMORAL CONDYLE LESIONS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003481-18,0,0,0 2007-003483-22,1,,,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,Medisch Centrum Haaglanden,a double blind randomized study on the effectiveness of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in dark irided hypermetropic children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003483-22,0,0,0 2007-003484-45,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO ONCOLOGICO VENETO,PHASE II TRIAL OF FOLFIRI REGIMEN PLUS BEVACIZUMAB ALTERNATED WITH OXALIPLATIN-BASED HEPATIC ARTERIAL INFUSION PLUS DE GRAMONT REGIMEN AND BEVACIZUMAB IN THE TREATMENT OF UNRESECTABLE LIVER METASTASES...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003484-45,0,0,0 2007-003492-39,8,2010-01-21,2011-06-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bracco Imaging S.p.A.,"A phase III study to compare SonoVue enhanced myocardial echocardiography (MCE) to single photon emission computerized tomography (ECG-GATED SPECT), at rest and at peak of low-dose Dipyridamole stres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003492-39,0,0,0 2007-003492-39,8,2010-01-21,2011-06-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRACCO IMAGING,"A phase III study to compare SonoVue enhanced myocardial echocardiography (MCE) to single photon emission computerized tomography (ECG-GATED SPECT), at rest and at peak of low-dose Dipyridamole stres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003492-39,0,0,0 2007-003492-39,8,2010-01-21,2011-06-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bracco Research S.P.A,"A phase III study to compare SonoVue enhanced myocardial echocardiography (MCE) to single photon emission computerized tomography (ECG-GATED SPECT), at rest and at peak of low-dose Dipyridamole stres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003492-39,0,0,0 2007-003508-36,3,2009-05-13,2009-05-13,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nitec Pharma AG,"A randomised multi-centre, double-blind, placebo-controlled study of a new modified-release tablet formulation of prednisolone (Lodotra®) in patients with rheumatoid arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003508-36,0,0,0 2007-003509-28,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,"CHRU Montpellier - Direction de la Recherche, Partenariats et Réseaux, Relations avec l'Université",Intérêt de l’administration intra-coronaire d’une dose unique d’EPO lors de la reperfusion chez des patients hospitalisés pour un primo infarctus avec sus-décalage persistant du segment ST,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003509-28,0,0,0 2007-003511-31,1,2010-03-08,2010-03-08,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Novartis Vaccines and Diagnostics GmbH & Co. KG,"Phase I/II, Randomized, Observer-blind, Placebo-controlled, Single-Center Study of the Tolerability, Immunogenicity and Efficacy (following Helicobacter pylori infectious challenge) of Novartis’ Inves...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003511-31,0,0,0 2007-003512-57,1,2009-01-09,2009-01-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bioprojet,"Randomized, dose-finding study of BF 2.649 5, 10, 20 and 40 mg/d in comparison to placebo in Excessive Daytime Sleepiness in Parkinson’s Disease patients (PD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003512-57,0,0,0 2007-003513-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Department of Neurology, Karolinska University Hospital",Imune therapy of High Grade Glioma with dendritic cell vaccination. A phase II study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003513-14,0,0,0 2007-003513-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Dept. of Pediatric hematology and oncology, Astrid Lindgren Children´s Hosp,Karolinska Univ Hospital",Imune therapy of High Grade Glioma with dendritic cell vaccination. A phase II study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003513-14,0,0,0 2007-003514-34,4,2016-11-23,2020-08-31,3,1,0,0,0,2,3,0,0,1,1,0,1,0,0,EBMT,A Randomized Phase III study comparing conventional chemotherapy to low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors as conso...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003514-34,0,0,0 2007-003514-34,4,2016-11-23,2020-08-31,3,1,0,0,0,2,3,0,0,1,1,0,1,0,0,European Group for Blood and Marrow trasnplantation,A Randomized Phase III study comparing conventional chemotherapy to low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors as conso...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003514-34,0,0,0 2007-003514-34,4,2016-11-23,2020-08-31,3,1,0,0,0,2,3,0,0,1,1,0,1,0,0,European Society for Blood and Marrow Transplantation EBMT,A Randomized Phase III study comparing conventional chemotherapy to low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors as conso...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003514-34,0,0,0 2007-003514-34,4,2016-11-23,2020-08-31,3,1,0,0,0,2,3,0,0,1,1,0,1,0,0,European Group for Blood and Marrow Transplantation,A Randomized Phase III study comparing conventional chemotherapy to low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors as conso...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003514-34,0,0,0 2007-003516-62,3,2009-01-28,2009-01-28,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Cytos Biotechnology AG,"Double-blind, Placebo-controlled Study to Investigate an Immunomodulatory Therapy (CYT003-QbG10) in Adult Patients with Perennial Allergic Rhinoconjunctivitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003516-62,0,0,0 2007-003517-13,3,2010-03-11,2010-03-11,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"Open-label, single-arm, multi-center, pharmacokinetic, safety and tolerability study of levetiracetam intravenous infusion in children (1 month to 4 years old) with epilepsy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003517-13,0,0,0 2007-003528-39,5,2016-07-08,2016-07-08,4,1,1,0,0,0,0,0,1,2,0,0,0,0,1,Merck & Co. Inc.,"""A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003528-39,1,1,0 2007-003528-39,5,2016-07-08,2016-07-08,4,1,1,0,0,0,0,0,1,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA","""A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003528-39,1,1,0 2007-003528-39,5,2016-07-08,2016-07-08,4,1,1,0,0,0,0,0,1,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","""A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003528-39,1,1,0 2007-003529-26,1,2011-03-14,2011-03-14,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and End-Stage Renal Disease Who Are on Dialy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003529-26,0,0,0 2007-003537-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC,Estetrol Therapy in Sjogren's Syndrome: An Open Proof of Concept Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003537-16,0,0,0 2007-003539-22,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,GIMURELL,Two repeated doses of Yttrium-90 labeled Ibritumomab-Tiuxetan (Zevalin) as salvage treatment for patients with relapsed or refractory aggressive B-cell lymphoma: a phase II study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003539-22,0,0,0 2007-003543-67,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset,Assessment of bronchial hyperresponsiveness in children - inhalation of Mannitol compared to eucapnic voluntary hyperventilation and methacholine provocation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003543-67,0,0,0 2007-003544-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Ortega: Hospital General de Valencia,"Estudio piloto, multicéntrico, aleatorizado y abierto, para evaluar el tratamiento concomitante de la co-infección por el VHC/VIH con peg-interferón + ribavirina, y lopinavir/r como único agente antir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003544-30,0,0,0 2007-003545-32,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CHU de Limoges,Etude prospective ouverte de l'efficacité du leflunomide dans le traitement de la pemphigoïde bulleuse en association aux dermocorticoïdes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003545-32,0,0,0 2007-003548-32,6,2011-03-16,2011-03-16,6,1,0,0,2,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Ina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003548-32,0,0,0 2007-003548-32,6,2011-03-16,2011-03-16,6,1,0,0,2,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Ina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003548-32,0,0,0 2007-003548-32,6,2011-03-16,2011-03-16,6,1,0,0,2,0,3,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Ina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003548-32,0,0,0 2007-003548-32,6,2011-03-16,2011-03-16,6,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Laboratoires Merck Sharp & Dohme-Chibret,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Ina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003548-32,0,0,0 2007-003548-32,6,2011-03-16,2011-03-16,6,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Ina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003548-32,0,0,0 2007-003549-33,1,2009-06-03,2009-06-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Laboratorios MENARINI, S. A.",Efectos de Nebivolol y Atenolol sobre la Presión Central Aórtica en Pacientes Hipertensos,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003549-33,0,0,0 2007-003553-82,3,2009-04-06,2009-04-06,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,AGI Therapeutics Research Ltd,"A Randomized, Double-blind, Placebo-controlled Study of AGI-003 (Arverapamil) in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003553-82,0,0,0 2007-003556-10,8,2008-12-11,2009-01-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eisai Limited,"A double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in myoclonic seizures associated with idiopathic generalised epilepsy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003556-10,0,0,0 2007-003557-91,6,2009-01-05,2009-01-28,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eisai Limited,"A double-blind, randomised, placebo-controlled, multicentre study to assess the efficacy and safety of adjunctive zonisamide in primary generalised tonic clonic seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003557-91,0,0,0 2007-003558-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Olomouc University Hospital and Palacký University School of Medicine, Internal Medicine Dept. I",Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003558-27,0,0,0 2007-003560-21,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,GIMURELL,Prospective multicenter dose finding phase II pilot trial to evaluate efficacy and safety of treatment with Lenalidomide puls R-CHOP21 (LR-CHOP21) for elderly patients with untreated Diffuse Large B-C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003560-21,0,0,0 2007-003560-21,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie Onlus (GIMURELL),Prospective multicenter dose finding phase II pilot trial to evaluate efficacy and safety of treatment with Lenalidomide puls R-CHOP21 (LR-CHOP21) for elderly patients with untreated Diffuse Large B-C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003560-21,0,0,0 2007-003561-40,1,2012-06-02,2012-06-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Regensburg University Medical Center, Department of Surgery","A Pilot Study to Determine the Safety and Efficacy of Induction-Therapy, De Novo MPA and Delayed mTOR-Inhibition in Liver Transplant Recipients with Impaired Renal Function - PATRON-Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003561-40,0,0,0 2007-003565-40,3,2007-12-13,2007-12-13,3,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Vifor (International) Inc.,An open-label randomized Phase II study of PA21 compared to sevelamer to evaluate the ability of PA21 to control serum phosphate levels and the tolerability in patients with chronic kidney disease und...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003565-40,0,0,0 2007-003569-42,1,2009-03-03,2009-03-03,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Amgen Inc.,"Estudio Aleatorizado, Doble Ciego, Controlado con Placebo, de Fase 1/2 para Determinar la Seguridad y la Eficacia de AMG 531 en Sujetos Pediátricos Trombocitopénicos con Púrpura Trombocitopénica Inmu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003569-42,0,0,0 2007-003571-39,1,2008-09-24,2008-09-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,B. Braun Melsungen AG,"Prospective, monocentric, controlled, randomized, double-blind study to compare two different propofol emulsions regarding tolerability and injection pain during the induction of anesthesia in adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003571-39,0,0,0 2007-003572-19,8,2009-05-19,2009-08-27,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pierre Fabre Médicament,"EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF PERENNIAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003572-19,0,0,0 2007-003573-50,7,2012-05-25,2012-06-06,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination with AMG 386 or Placebo in Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003573-50,0,0,0 2007-003574-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Sant Joan de Deu,MODULACIÓN DE LA RESPUESTA INFLAMATORIA SISTÉMICA EN NIÑOS CRÍTICAMENTE ENFERMOS TRAS LA SUPLEMENTACIÓN CON GLUTAMINA MODULATION OF THE SYSTEMIC INFLAMMATORY RESPONSE IN CRITICAL ILL CHILDREN AFTER G...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003574-26,0,0,0 2007-003576-19,1,2011-06-23,2011-06-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de LIMOGES,Evaluation de l'efficacité et de la tolérance du Lanreotide LP 90 mg versus placebo dans la diminution de la lyphorrhée post curage axillaire dans les cancers du sein.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003576-19,0,0,0 2007-003577-74,1,2009-05-01,2009-05-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Nottingham,Helicobacter pylori Eradication vs Aspirin Toxicity Trial Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003577-74,0,0,0 2007-003578-24,1,2009-03-23,2009-03-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A single-centre, open-label, randomised explorative pharmacokinetic/pharmacodynamic study of the gonadotropin-releasing hormone receptor antagonist degarelix (FE 200486) in patients with benign prosta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003578-24,0,0,0 2007-003579-38,8,2009-06-15,2009-06-15,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,sanofi-aventis groupe,Efecto de la insulina glulisina en comparación con la insulina aspart y la insulina lispro cuando se administran mediante Infusión Subcutánea Continua de Insulina (ISCI) sobre parámetros específicos d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003579-38,0,0,0 2007-003579-38,8,2009-06-15,2009-06-15,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SANOFI AVENTIS GROUPE,Efecto de la insulina glulisina en comparación con la insulina aspart y la insulina lispro cuando se administran mediante Infusión Subcutánea Continua de Insulina (ISCI) sobre parámetros específicos d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003579-38,0,0,0 2007-003584-45,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Daniel Podzamczer Palter,Estudio piloto de simplificación a Fosamprenavir/ritonavir (FPV/r) en monoterapia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003584-45,0,0,0 2007-003586-41,6,2008-12-15,2009-01-20,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,PFIZER,PLACEBO-CONTROLLED TRIAL ON THE EFFICACY OF GROWTH HORMONE REPLACEMENT THERAPY IN PATIENTS WITH GROWTH HORMONE DEFICIENCY AFTER TRAUMATIC BRAIN INJURY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003586-41,0,0,0 2007-003586-41,6,2008-12-15,2009-01-20,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK",PLACEBO-CONTROLLED TRIAL ON THE EFFICACY OF GROWTH HORMONE REPLACEMENT THERAPY IN PATIENTS WITH GROWTH HORMONE DEFICIENCY AFTER TRAUMATIC BRAIN INJURY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003586-41,0,0,0 2007-003586-41,6,2008-12-15,2009-01-20,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Pfizer, S.A",PLACEBO-CONTROLLED TRIAL ON THE EFFICACY OF GROWTH HORMONE REPLACEMENT THERAPY IN PATIENTS WITH GROWTH HORMONE DEFICIENCY AFTER TRAUMATIC BRAIN INJURY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003586-41,0,0,0 2007-003589-16,2,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,1,Bracco Imaging S.p.A.,A PROSPECTIVE COHORT STUDY EVALUATING THE INCIDENCE OF NEPHROGENIC SYSTEMIC FIBROSIS IN PATIENTS WITH STAGES 3 TO 5 CHRONIC KIDNEY DISEASE UNDERGOING MRI WITH THE INJECTION OF PROHANCE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003589-16,0,0,0 2007-003589-16,2,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,1,BRACCO IMAGING,A PROSPECTIVE COHORT STUDY EVALUATING THE INCIDENCE OF NEPHROGENIC SYSTEMIC FIBROSIS IN PATIENTS WITH STAGES 3 TO 5 CHRONIC KIDNEY DISEASE UNDERGOING MRI WITH THE INJECTION OF PROHANCE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003589-16,0,0,0 2007-003591-19,1,2009-02-16,2009-02-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,medac Gesellschaft für klinische Spezialpräparate mbH,"AN OPEN, COMPARATIVE, WITHIN PATIENT CONTROLLED MULTICENTRE STUDY OF REPEATED SUBCUTANEOUS INJECTIONS OF METHOTREXATE 50MG/ML AND 10MG/ML TO COMPARE PATIENT SATISFACTION AND LOCAL TOLERABILITY IN PATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003591-19,0,0,0 2007-003592-39,6,2012-11-30,2013-04-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et développement,"A multinational, randomized, double-blind placebo controlled study of AVE8062 (25 mg/m²) administered every 3 weeks in patients with advanced-stage soft tissue sarcoma, treated with cisplatin (75 mg/m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003592-39,0,0,0 2007-003592-39,6,2012-11-30,2013-04-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et de'veloppement,"A multinational, randomized, double-blind placebo controlled study of AVE8062 (25 mg/m²) administered every 3 weeks in patients with advanced-stage soft tissue sarcoma, treated with cisplatin (75 mg/m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003592-39,0,0,0 2007-003597-25,1,2009-06-25,2009-06-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline GmbH & Co. KG,"A 12-month open-label, randomized parallel-group study to investigate the influence of salmeterol/fluticasone either in fixed combination (SFC500/50 µg bid) or seperately (SAL 50 µg and FP 500 µg bid)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003597-25,0,0,0 2007-003612-53,1,2012-10-01,2012-10-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"National Institutes of Health, National Eye Institute",Multicenter Uveitis Steroid Treatment Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003612-53,0,0,0 2007-003619-30,1,2009-03-05,2009-03-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,Study to investigate the effect of the A1 agonist capadenoson on ventricular HR in patients with persistent or permanent atrial fibrillation by administration of capadenoson in a dose of 4 mg once dai...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003619-30,0,0,0 2007-003621-24,8,2010-02-19,2010-08-04,5,0,0,0,0,1,2,0,0,1,1,0,1,0,1,MondoGEN AG,"Double-blind, randomized, placebo-controlled, dose-finding, parallel-group study to assess the hemodynamic effects, clinical efficacy, tolerability and safety of Aviptadil (Vasoactive Intestinal Pepti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003621-24,0,0,0 2007-003621-24,8,2010-02-19,2010-08-04,5,0,0,0,0,1,2,0,0,1,1,0,1,0,1,MONDOGEN AG,"Double-blind, randomized, placebo-controlled, dose-finding, parallel-group study to assess the hemodynamic effects, clinical efficacy, tolerability and safety of Aviptadil (Vasoactive Intestinal Pepti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003621-24,0,0,0 2007-003622-18,1,2009-12-31,2009-12-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,State University Hospital,Efficacy and safety of TachoSil in patients undergoing cystectomy. A pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003622-18,0,0,0 2007-003623-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dr. Juan D. Cañete Crespillo, Hospital Clínic de Barcelona",Estudio de los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide (Estudio TESICE-AR). Study of t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003623-20,0,0,0 2007-003624-37,8,2014-12-12,2014-12-12,7,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit on Current START or CA180039 Protocols: Long T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003624-37,0,0,0 2007-003624-37,8,2014-12-12,2014-12-12,7,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit on Current START or CA180039 Protocols: Long T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003624-37,0,0,0 2007-003627-20,1,2009-12-30,2009-12-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"University of Dundee, Research & Innovation Services",Comparative Relative Lung Bioavailability of HFA-Seretide via spacer devices in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003627-20,0,0,0 2007-003628-39,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,1,ECUPHARMA S.R.L.,"Pilot study to evaluate the local tollerability and efficacy of a new tobramycin 3% nasal spray formulation to reduce the bacterial density of Pseudomonas aeruginosa and/or Staphylococcus aureus, in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003628-39,0,0,0 2007-003633-16,1,2009-08-26,2009-08-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A RANDOMIZED PHASE II TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF VANDETANIB (ZD6474, ZACTIMATM) VERSUS VINORELBINE IN PATIENTS WITH INOPERABLE OR RELAPSED MALIGNANT MESOTHELIOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003633-16,0,0,0 2007-003634-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Klinikum der Universität München, Standort Großhadern","Prospective phase II trial using Capecitabine and Trastuzumab for therapy of female patients with cerebral metastasizing, HER2-overexpressing breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003634-42,0,0,0 2007-003635-23,1,2011-10-19,2011-10-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Central Manchester and Manchester Children's Hospitals NHS Trust,A PRELIMINARY EVALUATION OF THE SAFETY PROFILE OF TWENTY-FOUR HOUR INFUSION OF HUMAN RECOMBINANT ACTIVATED PROTEIN C (XIGRIS) EARLY IN SEVERE ACUTE PANCREATITIS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003635-23,0,0,0 2007-003636-35,5,2010-02-19,2010-02-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,A randomized long-term safety study of Org 50081 in elderly outpatients with chronic primary insomnia examining the effects of 1.5 mg or 3.0 mg of Org 50081,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003636-35,0,0,0 2007-003638-40,1,2008-12-18,2008-12-18,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,XTL Development Inc.,"A Double-blind, Randomized, Placebo-controlled, Parallel, Multicenter Study of the Safety and Efficacy of Two Dosages of Bicifadine SR in Adult Outpatients with Chronic Neuropathic Pain Associated wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003638-40,0,0,0 2007-003642-15,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,Charité Universitätsmedizin Berlin,"A Randomized, Double-blind Superiority Trial to Evaluate the Safety, Tolerability, and Efficacy of Belimumab in Refractory ITP Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003642-15,0,0,0 2007-003643-71,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Direction Centrale du Service de Santé des Armées (DCSSA),Evaluation chez l'homme de l'effet otoprotecteur de la N-Acetyl-Cysteine par voie orale en prévention des effets délétères de l'exposition au bruit impulsionnel,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003643-71,0,0,0 2007-003647-75,5,2011-01-31,2011-05-19,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Serono International,"A randomised, double-blind, placebo controlled, multi-centre, exploratory, pilot, phase II trial of 150 mg atacicept given subcutaneously in combination with rituximab in subjects with rheumatoid arth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003647-75,0,0,0 2007-003647-75,5,2011-01-31,2011-05-19,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Serono SA - Geneva,"A randomised, double-blind, placebo controlled, multi-centre, exploratory, pilot, phase II trial of 150 mg atacicept given subcutaneously in combination with rituximab in subjects with rheumatoid arth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003647-75,0,0,0 2007-003648-31,1,2007-12-12,2007-12-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios Almirall, S.A.","A phase IIa, randomised, multicentre, evaluator-blinded, 4-way crossover clinical trial to study the pharmacokinetics, safety, tolerability and effects on lung function of one day treatment of formote...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003648-31,0,0,0 2007-003649-34,1,2012-01-31,2012-01-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital of South Manchester NHS Foundation Trust,RENAL RESCUE IMMUNOSUPPRESSION FOLLOWING HEART TRANSPLANTATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003649-34,0,0,0 2007-003652-11,1,2010-03-11,2010-03-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,A proof of concept study to evaluate the peak bronchoprotection conferred by single and chronic dosing with levosalbutamol and racemic salbutamol in persistent asthmatics.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003652-11,0,0,0 2007-003654-29,10,2011-11-13,2011-11-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim bv,"A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD nevirapine extended release formulation in comparison to 200 mg BID ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003654-29,0,0,0 2007-003654-29,10,2011-11-13,2011-11-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,2,,"A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD nevirapine extended release formulation in comparison to 200 mg BID ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003654-29,0,0,0 2007-003654-29,10,2011-11-13,2011-11-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A.","A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD nevirapine extended release formulation in comparison to 200 mg BID ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003654-29,0,0,0 2007-003654-29,10,2011-11-13,2011-11-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,2,BOEHRINGER ING.,"A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD nevirapine extended release formulation in comparison to 200 mg BID ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003654-29,0,0,0 2007-003654-29,10,2011-11-13,2011-11-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,2,SCS Boehringer Ingelheim Comm.V,"A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD nevirapine extended release formulation in comparison to 200 mg BID ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003654-29,0,0,0 2007-003654-29,10,2011-11-13,2011-11-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD nevirapine extended release formulation in comparison to 200 mg BID ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003654-29,0,0,0 2007-003654-29,10,2011-11-13,2011-11-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Boehringer Ingelheim Pharmaceuticals, Inc.","A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD nevirapine extended release formulation in comparison to 200 mg BID ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003654-29,0,0,0 2007-003654-29,10,2011-11-13,2011-11-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Limited,"A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD nevirapine extended release formulation in comparison to 200 mg BID ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003654-29,0,0,0 2007-003654-29,10,2011-11-13,2011-11-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim France,"A randomised, double blind, double dummy, parallel group, active controlled trial to evaluate the antiviral efficacy of 400 mg QD nevirapine extended release formulation in comparison to 200 mg BID ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003654-29,0,0,0 2007-003655-36,3,2008-09-03,2008-09-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled, multicentre study to determine the effect of QVA149 on lung function in patients with Chronic Obstructive Pulmonary Disease (COPD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003655-36,0,0,0 2007-003655-36,3,2008-09-03,2008-09-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma,"A randomized, double-blind, placebo controlled, multicentre study to determine the effect of QVA149 on lung function in patients with Chronic Obstructive Pulmonary Disease (COPD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003655-36,0,0,0 2007-003656-11,2,2009-09-14,2009-09-18,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY10017","A RANDOMIZED, DOUBLE BLIND MULTI CENTER DOSE RANGING STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN COMPARED TO PLACEBO IN THE ADJUNCTIVE TREATMENT OF POST SURGICAL PAIN AFTER PRIMARY INGUINAL HERNIA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003656-11,0,0,0 2007-003656-11,2,2009-09-14,2009-09-18,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer, S.A","A RANDOMIZED, DOUBLE BLIND MULTI CENTER DOSE RANGING STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN COMPARED TO PLACEBO IN THE ADJUNCTIVE TREATMENT OF POST SURGICAL PAIN AFTER PRIMARY INGUINAL HERNIA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003656-11,0,0,0 2007-003657-87,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Reduced intensity conditioning with high-dose rituximab followed by allogeneic transplantation of hematopoietic cells for the treatment of relapsed/refractory B-cell non Hodgkin’s lymphomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003657-87,0,0,0 2007-003658-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,TECHNI-PHARMA,"Étude comparative, randomisée, double-insu, en groupes parallèles évaluant l’efficacité de l’Eductyl® versus placebo chez des patients présentant des dyschésies traitées par rééducation colo-proctolog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003658-27,0,0,0 2007-003664-22,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO ONCOLOGICO VENETO,INTRAPLEURAL PACLITAXEL IN PATIENTS WITH MALIGNANT PLEURAL EFFUSIONS SECONDARY TO OVARIAN CANCER AND OTHER NEOPLASMS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003664-22,0,0,0 2007-003666-17,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,University Hospitals Bristol NHS Foundation Trust,The ATACAS Trial: Aspirin and Tranexamic Acid for Coronary Artery Surgery Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003666-17,0,0,0 2007-003668-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MOLMED,“NGR005: Pilot study of NGR-hTNF administered at low and high doses in combination with a standard oxaliplatin-based regimen in patients wit metastatic colorectal cancer”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003668-24,0,0,0 2007-003670-25,5,2008-07-02,2008-07-15,3,1,0,0,0,0,2,0,2,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double blind, placebo controlled, multicenter study to determine the effect of QVA149 on mean 24-hours heart rate in patients with Chronic Obstructive Pulmonary Disease (COPD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003670-25,0,0,0 2007-003670-25,5,2008-07-02,2008-07-15,3,1,0,0,0,0,2,0,2,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double blind, placebo controlled, multicenter study to determine the effect of QVA149 on mean 24-hours heart rate in patients with Chronic Obstructive Pulmonary Disease (COPD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003670-25,0,0,0 2007-003670-25,5,2008-07-02,2008-07-15,3,1,0,0,0,0,2,0,2,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double blind, placebo controlled, multicenter study to determine the effect of QVA149 on mean 24-hours heart rate in patients with Chronic Obstructive Pulmonary Disease (COPD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003670-25,0,0,0 2007-003670-25,5,2008-07-02,2008-07-15,3,1,0,0,0,0,2,0,2,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double blind, placebo controlled, multicenter study to determine the effect of QVA149 on mean 24-hours heart rate in patients with Chronic Obstructive Pulmonary Disease (COPD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003670-25,0,0,0 2007-003672-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,NON APPLICABILE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003672-19,0,0,0 2007-003673-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ramón Tormo Carnicé,"ENSAYO CLÍNICO DOBLE CIEGO, CONTROLADO, ALEATORIZADO, EN FASE IV, COMPARATIVO DEL EFECTO DE LA COMBINACIÓN DE SRO Y RACECADOTRILO VERSUS SRO Y PLACEBO EN NIÑOS CON DIARREA AGUDA Double blind clinical...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003673-21,0,0,0 2007-003674-26,1,2008-07-30,2008-07-30,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,MERCK SHARP DOHME,A Phase I Dose Escalation of MK-0457 in Combination With Dasatinib in Patients With Refractory Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003674-26,0,0,0 2007-003677-10,1,2009-07-14,2009-07-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"A twelve week, randomized, double-blind, parallel-group multicentre study to evaluate the efficacy and safety of the combination of aliskiren/ramipril/amlodipine (300/10/10mg), compared to the combin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003677-10,0,0,0 2007-003679-37,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,Roche a/s,"A single arm, open label study to assess the efficacy, safety, and tolerability of once-monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin levels in haemodialysis pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003679-37,0,0,0 2007-003684-41,4,2009-01-08,2009-01-08,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled Dose-Ranging Study with Active-Controlled Long- Term Safety Phase to Assess the Efficacy, Safety and Tolerability of MK-6213 in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003684-41,0,0,0 2007-003684-41,4,2009-01-08,2009-01-08,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MSD Finland Oy,"A Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled Dose-Ranging Study with Active-Controlled Long- Term Safety Phase to Assess the Efficacy, Safety and Tolerability of MK-6213 in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003684-41,0,0,0 2007-003684-41,4,2009-01-08,2009-01-08,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme BV,"A Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled Dose-Ranging Study with Active-Controlled Long- Term Safety Phase to Assess the Efficacy, Safety and Tolerability of MK-6213 in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003684-41,0,0,0 2007-003684-41,4,2009-01-08,2009-01-08,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled Dose-Ranging Study with Active-Controlled Long- Term Safety Phase to Assess the Efficacy, Safety and Tolerability of MK-6213 in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003684-41,0,0,0 2007-003690-11,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Nouvelle stratégie de traitement de la polyangeite microscopique, de la periartérite noueuse et du syndrome de la churg-strauss sans facteur de mauvais pronostic : Etude prospective multicentrique ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003690-11,0,0,0 2007-003691-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dept of Molecular Medicin and Surgery,Tillskott av vitamin D efter framgångsrik operation för primär hyperparatyreoidism (pHPT) - prospektiv randomiserad dubbelblind studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003691-19,0,0,0 2007-003692-39,1,2008-05-30,2008-05-30,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA,"Evaluation of immunogenicity of 7-valent Pneumococcal Conjugate Vaccine (Prevenar) and Hexavalent DtPa-HBV-IPV-Hib (InfaNrix Hexa), co-administered at the same time, versus Hexavalent vaccine, used i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003692-39,0,0,0 2007-003694-27,14,2020-12-07,2020-12-07,13,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Actelion Pharmaceuticals Ltd,"Long-term, single-arm, open label extension study of the SERAPHIN study to assess the safety and tolerability of ACT 064992 in patients with symptomatic pulmonary arterial hypertension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003694-27,1,0,0 2007-003694-27,14,2020-12-07,2020-12-07,13,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Actelion Pharmaceuticals Ltd.,"Long-term, single-arm, open label extension study of the SERAPHIN study to assess the safety and tolerability of ACT 064992 in patients with symptomatic pulmonary arterial hypertension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003694-27,1,0,0 2007-003698-13,11,2010-10-29,2012-10-31,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Serono S.A. Geneva. An affiliate of Merck KGaA, Darmstadt, Germany","A randomised, double-blind, placebo-controlled, multicentre prospective dose-finding Phase II/III study with atacicept given subcutaneously to subjects having recently experienced a flare of systemic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003698-13,0,0,0 2007-003698-13,11,2010-10-29,2012-10-31,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Serono International,"A randomised, double-blind, placebo-controlled, multicentre prospective dose-finding Phase II/III study with atacicept given subcutaneously to subjects having recently experienced a flare of systemic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003698-13,0,0,0 2007-003698-13,11,2010-10-29,2012-10-31,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Serono SA - Geneva,"A randomised, double-blind, placebo-controlled, multicentre prospective dose-finding Phase II/III study with atacicept given subcutaneously to subjects having recently experienced a flare of systemic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003698-13,0,0,0 2007-003698-13,11,2010-10-29,2012-10-31,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Serono International SA, An affiliate of Merck KGaA, Darmstadt, Germany","A randomised, double-blind, placebo-controlled, multicentre prospective dose-finding Phase II/III study with atacicept given subcutaneously to subjects having recently experienced a flare of systemic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003698-13,0,0,0 2007-003700-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Unidad de Trasplantes y Terapia Celular del Hospital General Universitario Central de Asturias,Estudio abierto con evaluador ciego de la eficacia de las células mononucleares autólogas de médula ósea en la regeneración celular de un paciente con ictus isquémico agudo de la ACM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003700-36,0,0,0 2007-003701-27,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Portola Pharmaceuticals, Inc.","A Randomized Trial to Evaluate the Effect of Adjunctive Antiplatelet Therapy with Intravenous PRT060128, a Selective P2Y12-Receptor Inhibitor, Before Primary Percutaneous Intervention in Patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003701-27,0,0,0 2007-003702-95,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ISTITUTO C. MONDINO,"A MULTICENTRE RANDOMIZED CONTROLLED TRIAL COMPARING TOPIRAMATE, STIRIPENTOL AND CLOBAZAM AS ADJUNCTIVE THERAPY TO VALPROATE AND CLOBAZAM IN PAEDIATRIC PATIENTS WITH DRAVET'S SYNDROME (SMEI) NOT ADEQUA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003702-95,0,0,0 2007-003703-13,3,2008-07-29,2008-07-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase III randomized, double-blind, double dummy, placebo controlled, multicenter, 4 treatments, 3 period incomplete block crossover study to assess the effect on FEV1 of indacaterol 300 µg o.d. dos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003703-13,0,0,0 2007-003703-13,3,2008-07-29,2008-07-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A phase III randomized, double-blind, double dummy, placebo controlled, multicenter, 4 treatments, 3 period incomplete block crossover study to assess the effect on FEV1 of indacaterol 300 µg o.d. dos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003703-13,0,0,0 2007-003704-35,8,2008-12-23,2015-12-02,5,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Gilead Science Incorporated,"A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Adolescents with Chronic Hepatitis B Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003704-35,1,1,0 2007-003705-27,1,2013-10-23,2013-10-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AKH Vienna,"RANDOMIZED, CONTROLLED BIOMARKER STUDY EVALUATING THE ANTI-ANGIOGENIC ACTIVITY OF SUNITINIB IN HORMONE REFRACTORY PROSTATE CANCER PATIENTS TREATED BY DOCETAXEL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003705-27,0,0,0 2007-003706-10,1,2013-09-13,2013-09-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Maarit Mentula,"Satunnaistettu, etenevä tutkimus keskeytyslääkkeiden annostelusta toisen raskauskolmanneksen aikaisissa keskeytyksissä",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003706-10,0,0,0 2007-003707-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,Tandem Autografting-Allografting after Induction Chemotherapy with “New Drugs” For Newly Diagnosed Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003707-12,0,0,0 2007-003709-29,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO CLINICO HUMANITAS,"Prospective phase II trial evaluating efficacy of Trastuzumab therapy in HER2 FISH positive and/or HER2 mutation positive, pretreated, Non-Small Cell Lung Cancer patients (MO20509)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003709-29,0,0,0 2007-003710-34,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,Medizinische Hochschule Hannover,EFFECT OF BROMOCRIPTINE ON LEFT VENTRICULAR FUNCTION IN WOMEN WITH PERIPARTUM CARDIOMYOPATHY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003710-34,0,0,0 2007-003718-32,10,2010-10-05,2010-10-05,7,1,0,0,0,2,2,0,0,1,1,0,1,0,1,BAYER,"Ensayo clínico, controlado , doble ciego, paralelo, para evaluar la eficacia y seguridad del tratamiento profiláctico con BAY 79-4980 administrado una vez por semana, comparado con el tratamiento con ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003718-32,0,0,0 2007-003718-32,10,2010-10-05,2010-10-05,7,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"Ensayo clínico, controlado , doble ciego, paralelo, para evaluar la eficacia y seguridad del tratamiento profiláctico con BAY 79-4980 administrado una vez por semana, comparado con el tratamiento con ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003718-32,0,0,0 2007-003722-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St. Antonius Ziekenhuis,Randomized clinical trial of the optimization of procedural pain control in Intensive Care patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003722-18,0,0,0 2007-003723-21,5,2010-09-29,2010-10-13,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003723-21,0,0,0 2007-003723-21,5,2010-09-29,2010-10-13,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmaceutica S.A.,"A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd or 100 mg qd) versus placebo in patients with type 2 d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003723-21,0,0,0 2007-003728-39,1,2011-09-26,2011-09-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Centre Hospitalier Universitaire de Liège,A EUROPEAN MULTICENTER OPEN-LABEL RANDOMIZED TRIAL TO EVALUATE THE REDUCTION OF ISCHEMIA / REPERFUSION INJURY AFTER DE NOVO SIMULTANEOUS PANCREAS/KIDNEY TRANSPLANTATION IN TYPE 1-DIABETIC PATIENTS CO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003728-39,0,0,0 2007-003730-42,1,2014-10-10,2014-10-10,1,0,0,0,1,0,3,0,0,1,0,0,1,0,0,CHU DIJON,"INTERET DE LA CORTICOTHERAPIE EN PREMIERE INTENTION, EN INJECTIONS INTRAVITREENES LORS DES ENDOPHTALMIES POST-OPERATOIRES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003730-42,0,0,0 2007-003731-23,1,2009-06-30,2009-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Österreichische Gesellschaft zur Erforschung komplementär – alternativer Therapien in der Onkologie,Effects of pomegrante seed oil on menopausal symptoms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003731-23,0,0,0 2007-003735-23,1,2010-12-23,2010-12-23,1,1,0,0,1,0,3,0,0,1,1,1,1,0,1,Ferring Pharmaceuticals Ltd.,"A prospective, randomised study comparing a 3-sachet Picolax® treatment with the standard 2-sachet Picolax® for bowel cleansing prior to colonoscopy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003735-23,0,0,0 2007-003736-34,1,2009-06-25,2009-06-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nycomed Canada Inc.,Effect of low dose continuous treatment with Ciclesonide over one year on the time to first exacerbation in children with mild asthma versus intermittent treatment for exacerbations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003736-34,0,0,0 2007-003738-40,7,2011-09-02,2015-03-04,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche,A phase II Biomarker Identification Trial for Erlotinib (Tarceva) in Patients with Advanced Pancreatic Carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003738-40,0,0,0 2007-003738-40,7,2011-09-02,2015-03-04,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,A phase II Biomarker Identification Trial for Erlotinib (Tarceva) in Patients with Advanced Pancreatic Carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003738-40,0,0,0 2007-003739-22,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,GALSOR S.R.L.,"Safety and efficacy (for the symptom remission) of the treatment adjuvant of the antibiotic therapy of the acute episode of sinusitis (acute, subacute, chronic)with Ecballium Elaterium (SINUclean DM):...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003739-22,0,0,0 2007-003741-33,1,2010-01-01,2010-01-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Barts and the London NHS Trust,A Study To Determine The Optimum Serum IGF-I Range In Patients With Acromegaly Treated With Pegvisomant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003741-33,0,0,0 2007-003742-15,1,2008-09-16,2008-09-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of four weeks treatment of 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS (inhalation po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003742-15,0,0,0 2007-003745-32,1,2014-05-01,2014-05-01,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,University of Nottingham,"A randomised, double blind, placebo controlled trial of doxycycline in lymphangioleiomyomatosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003745-32,0,0,0 2007-003746-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ammerland-Klinik Westerstede,prospective randomized open study on the comparison of fondaparinux with the low-molecular-weight heparin enoxaparin in patients undergoing femoro-distal venous bypass operation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003746-15,0,0,0 2007-003747-75,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Servei Pneumologia. Hospital Universitari Son Dureta,EFECTOS ANTIINFLAMATORIOS DE LA OXIGENOTERAPIA DOMICILIARIA EN PACIENTES CON ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA ANTIINFLAMMATORY EFFECTS OF DOMICILIARY OXYGENTHERAPY IN PATIENTS WITH CHRONIC OBST...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003747-75,0,0,0 2007-003751-37,9,2012-02-20,2012-02-20,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche,"A Phase II, Dose-Escalation to Rash Trial of Erlotinib (Tarceva®) plus Gemcitabine in Patients With Metastatic Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003751-37,0,0,0 2007-003751-37,9,2012-02-20,2012-02-20,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Phase II, Dose-Escalation to Rash Trial of Erlotinib (Tarceva®) plus Gemcitabine in Patients With Metastatic Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003751-37,0,0,0 2007-003751-37,9,2012-02-20,2012-02-20,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A Phase II, Dose-Escalation to Rash Trial of Erlotinib (Tarceva®) plus Gemcitabine in Patients With Metastatic Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003751-37,0,0,0 2007-003751-37,9,2012-02-20,2012-02-20,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann- La Roche Ltd,"A Phase II, Dose-Escalation to Rash Trial of Erlotinib (Tarceva®) plus Gemcitabine in Patients With Metastatic Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003751-37,0,0,0 2007-003751-37,9,2012-02-20,2012-02-20,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche Ltd,"A Phase II, Dose-Escalation to Rash Trial of Erlotinib (Tarceva®) plus Gemcitabine in Patients With Metastatic Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003751-37,0,0,0 2007-003756-11,1,2009-07-14,2009-07-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ardeypharm GmbH,Behandlung der Darm-assoziierten Halitosis mit E. coli Stamm Nissle 1917 Treatment for GUT-Caused Halitosis With with E. coli strain Nissle 1917,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003756-11,0,0,0 2007-003762-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Prospective monocenter accuracy study of Vasovist contrast enhanced magnetic resonance venography (CE-MRV) to detect venous thrombi in patients with Ultrasonography detected peripheral acute deep ven...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003762-18,0,0,0 2007-003765-40,1,2008-07-01,2008-07-01,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,Organisation name was not entered,Bronkial respons på inhaleret Mannitol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003765-40,0,0,0 2007-003765-40,1,2008-07-01,2008-07-01,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,Respiratory research UNit,Bronkial respons på inhaleret Mannitol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003765-40,0,0,0 2007-003766-17,1,2013-05-27,2013-05-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The Eye Hospital Rotterdam,Avastin-Injections in Age Related Macular Degeneration: Prospective Study for Optimal Frequency and Follow-up Determination,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003766-17,0,0,0 2007-003767-51,1,2009-10-23,2009-10-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Research and Innovation Services, University of Dundee",Vitamin D therapy to reduce cardiovascular risk in Type 2 diabetes – the next steps,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003767-51,0,0,0 2007-003769-41,1,2011-11-08,2011-11-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical University Graz,"Albumin in acute-on-chronic liver failure: More than just volume? A randomized, controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003769-41,0,0,0 2007-003770-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hôpitaux Universitaires de Strasbourg,ACIDE TRANEXAMIQUE VERSUS PLACEBO DANS LA REDUCTION DES SAIGNEMENTS PERIOPERATOIRES APRES HEPATECTOMIES MAJEURES : ETUDE PROSPECTIVE RANDOMISEE EN DOUBLE AVEUGLE.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003770-25,0,0,0 2007-003772-20,1,2010-10-11,2010-10-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,LABORATOIRE ALLERBIO,Etude clinique nationale observationnelle de tolérance chez des patients souffrant d'une rhinite allergique aux pollens de graminées et traités par GRAZAX en pratique courante.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003772-20,0,0,0 2007-003775-39,1,2012-07-10,2012-07-10,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Charité – Universitätsmedizin Berlin,"Randomised, placebo-controlled parallel-group trial to evaluate an oral dose of 10 mg Olanzapin combined with Riluzol for the treatment of appetite loss on patients with amyotrophic lateral sklerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003775-39,0,0,0 2007-003776-18,3,2008-05-08,2008-05-08,3,1,0,0,1,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, controlled, randomized, multicentre, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine with various doses of the AS03 adjuvant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003776-18,0,0,0 2007-003776-18,3,2008-05-08,2008-05-08,3,1,0,0,1,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A phase II, controlled, randomized, multicentre, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine with various doses of the AS03 adjuvant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003776-18,0,0,0 2007-003777-13,1,2012-01-04,2012-01-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Hæmatologisk Afsnit, Vejle Sygehus",Knoglebinding af bisfosfonat (Zometa) hos patienter med myelomatose eller brystkræft med knoglemetastaser,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003777-13,0,0,0 2007-003780-50,10,2015-05-25,2015-06-27,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003780-50,0,0,0 2007-003780-50,10,2015-05-25,2015-06-27,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA","A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003780-50,0,0,0 2007-003780-50,10,2015-05-25,2015-06-27,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc.,","A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003780-50,0,0,0 2007-003780-50,10,2015-05-25,2015-06-27,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. (A Pfizer Company),"A Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003780-50,0,0,0 2007-003781-17,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,FONDAZIONE MONZINO CENTRO CARDIOLOGICO,"COMPARED EFFECTS OF THREE DIFFERENT BETA BLOCKERS (CARVEDILOL, BISOPROLOL AND NEBIVOLOL) ON EXERCISE CAPACITY, PULMONARY FUNCTION AND RESPONSE TO HYPOXIA IN CHRONIC HEART FAILURE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003781-17,0,0,0 2007-003783-22,3,2017-04-03,2017-04-03,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Janssen-Cilag International N.V.,"Daratumumab (HuMax-CD38) safety study in multiple myeloma – Open label, dose-escalation followed by open label, single-arm study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003783-22,0,0,0 2007-003784-42,1,2013-04-30,2013-04-30,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,University Medical Center Hamburg-Eppendorf,Dose-finding study of lenalidomide as maintenance therapy in multiple myeloma after allogeneic stem cell transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003784-42,0,0,0 2007-003786-41,5,2010-08-05,2010-08-05,3,1,0,0,0,0,3,0,1,1,1,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase III, randomized, observer-blind, controlled, multi-center clinical study to evaluate the efficacy, safety and immunogenicity of one and two intramuscular doses of FLUAD versus control vaccines...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003786-41,0,0,0 2007-003786-41,5,2010-08-05,2010-08-05,3,1,0,0,0,0,3,0,1,1,1,0,1,0,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase III, randomized, observer-blind, controlled, multi-center clinical study to evaluate the efficacy, safety and immunogenicity of one and two intramuscular doses of FLUAD versus control vaccines...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003786-41,0,0,0 2007-003787-21,1,2008-06-20,2008-06-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Allergan Ltd,"A Pilot, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with a 4-Week Treatment Period Followed by a 4-week Observation Period and an Optional 4 Month Observation Period of the Safet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003787-21,0,0,0 2007-003788-28,1,2010-05-04,2010-05-04,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Pantarhei Bioscience B.V.,"A double-blind, placebo controlled, randomized, comparative, mono-centre trial to assess the effects on the androgen metabolism and its effects on biochemical parameters, mood, fat, muscle and bone of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003788-28,0,0,0 2007-003793-26,11,2015-04-27,2015-04-27,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA","Estudio de fase 3b, aleatorizado y abierto de bevacizumab (Avastin®) + temsirolimus (Torisel®) frente a bevacizumab (Avastin®) + interferón alfa (Roferon®) como tratamiento de primera línea en pacient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003793-26,0,0,0 2007-003793-26,11,2015-04-27,2015-04-27,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"Estudio de fase 3b, aleatorizado y abierto de bevacizumab (Avastin®) + temsirolimus (Torisel®) frente a bevacizumab (Avastin®) + interferón alfa (Roferon®) como tratamiento de primera línea en pacient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003793-26,0,0,0 2007-003797-25,1,2008-06-26,2008-06-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Consumer Health SA,"A randomized, double-blind, multi-center, vehicle-controlled, parallel group study to evaluate the efficacy and safety of diclofenac diethylamine 2.32% gel applied once or twice daily in subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003797-25,0,0,0 2007-003798-16,3,2022-06-14,2022-06-14,1,0,0,0,2,0,2,0,0,2,0,0,0,0,0,Cardiff University,AML 17: A Programme of Treatment Development in Younger Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003798-16,1,0,0 2007-003801-28,1,2009-09-30,2009-09-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Fundació de Lluita contra la SIDA,IMPACTO DE LA INTENSIFICACIÓN CON RALTEGRAVIR EN LA LATENCIA VIRAL DE VIH-1 EN PACIENTES CON SUPRESIÓN VIRAL COMPLETA (IMPACT OF RALTEGRAVIR INTENSIFICATION ON HIV-1 VIRAL LATENCY IN PATIENTS WITH PRE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003801-28,0,0,0 2007-003802-86,4,2008-06-10,2008-06-10,4,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, observer-blind, multicountry, multicentre, randomized study to evaluate the immunogenicity, safety and reactogenicity of the GlaxoSmithKline Biologicals’ influenza vaccine adjuvanted with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003802-86,0,0,0 2007-003803-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Bordeaux,Essai multicentrique randomisé ouvert évaluant l'apport du CCNU dans le traitement des leucémies aigues myéloïdes (LAM) des sujets de plus de 60 ans à cytogénétique non défavorable et la faisabilité d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003803-11,0,0,0 2007-003808-35,3,2009-04-03,2009-04-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Laboratorios Servier S.L.,"Dose ranging study of S 44497 administered orally once daily for four weeks in type 2 diabetic patients. A multicentre, randomised, double-blind, double-dummy, phase II study versus placebo and glimep...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003808-35,0,0,0 2007-003808-35,3,2009-04-03,2009-04-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Servier Research and Development Ltd.,"Dose ranging study of S 44497 administered orally once daily for four weeks in type 2 diabetic patients. A multicentre, randomised, double-blind, double-dummy, phase II study versus placebo and glimep...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003808-35,0,0,0 2007-003808-35,3,2009-04-03,2009-04-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Institut de Recherches Internationales,"Dose ranging study of S 44497 administered orally once daily for four weeks in type 2 diabetic patients. A multicentre, randomised, double-blind, double-dummy, phase II study versus placebo and glimep...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003808-35,0,0,0 2007-003810-32,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,the All-Ireland cooperative oncology research group (ICORG),Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003810-32,0,0,0 2007-003813-15,1,2016-10-31,2016-10-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,"CONKO-005: Adjuvante Therapie des R0-resezierten Pankreaskarzinoms mit Gemcitabin plus Erlotinib versus Gemcitabin über 24 Wochen – eine prospektive, randomisierte, Phase III Studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003813-15,0,0,0 2007-003815-30,2,2013-07-12,2013-07-12,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa),An Open Randomized Multicenter Clinical Investigation to Compare the Efficacy and Safety of Prednisone plus Adacolumn® GMA Apheresis versus Prednisone Alone in the Treatment of Patients with Mild or M...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003815-30,0,0,0 2007-003816-77,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Rigshospitalet,"Effekten af Flolan® på hæmning af trombocytternes ADP receptor hos raske frivillige forsøgspersoner, evalueret med TEG Platelet Mapping™ Assay",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003816-77,0,0,0 2007-003817-15,1,2010-09-21,2010-09-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA SANITARIA LOCALE N 15 DI CUNEO,"Prospective, open-label, multi-center trial to investigate efficacy and safety of Xeomin in the treatment of post-stroke spasticity in the lower limb",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003817-15,0,0,0 2007-003819-31,1,2010-10-31,2010-10-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Dainippon Sumitomo Pharma America, Inc","A Phase 3 Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of Three Doses of Lurasidone HCl in Acutely Psychotic Patients with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003819-31,0,0,0 2007-003820-40,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Dainippon Sumitomo Pharma America, Inc.","A Phase 3 Randomized, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003820-40,0,0,0 2007-003821-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,"Etude de la tolérance et de l'efficacité du Zevalin dans un conditionnement à intensité réduite avant allogreffe de cellules souches hématopoïétiques dans les lymphomes B CD20+ agressifs de l'adulte, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003821-25,0,0,0 2007-003822-28,6,2009-03-06,2009-03-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et développement,"Comparison of the safety and efficacy of eplivanserin and lormetazepam in the treatment of insomnia characterized by sleep maintenance difficulties. A 4 week, randomized, double-blind, comparative, pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003822-28,0,0,0 2007-003827-19,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Efficacité comparative de l'éradication de H.pylori et d'un inhibiteur de pompe à proton vs. l'abstention thérapeutique sur lésions gastriques induite par l'aspirine à faible dose chez les malades tra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003827-19,0,0,0 2007-003831-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA PISANA,PHARMACOKINETIC PERSPECTIVE STUDY IN COLORECTAL CANCER PATIENTS AND CANDIDATE FOR FLUOROPYRIMIDINE THERAPY: 5-FLUORO TEST,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003831-21,0,0,0 2007-003834-40,1,2013-05-20,2013-05-20,1,1,0,0,0,0,0,0,0,1,1,1,1,0,0,UCL-INSTITUTE OF CHILD HEALTH,THE IMPACT OF REDUCING OVERTREATMENT ON QUALITY OF LIFE IN CHILDREN WITH REFRACTORY EPILEPSY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003834-40,0,0,0 2007-003835-22,1,,,0,0,0,0,1,1,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Evaluation d’une protéine ostéo-inductrice (rhBMP-2) dans le traitement de la pseudarthrose congénitale du tibia de l’enfant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003835-22,0,0,0 2007-003836-53,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,FONDAZIONE MONZINO CENTRO CARDIOLOGICO,INFLUENCE OF ACETAZOLAMIDE AND CO2 INHALATION ON PERIODIC BREATHING DURING EXERCISE IN CHRONIC HEART FAILURE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003836-53,0,0,0 2007-003844-31,4,2010-05-18,2011-11-28,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly and Company limited,"A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin with 5 FU/LV plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003844-31,0,0,0 2007-003844-31,4,2010-05-18,2011-11-28,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin with 5 FU/LV plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003844-31,0,0,0 2007-003847-66,5,2018-09-05,2018-09-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,"Dose Finding and Randomized, Multicenter, Placebo- Controlled, Phase 2 Study of Enzastaurin and Sunitinib versus Placebo and Sunitinib in Patients with Metastatic Renal Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003847-66,0,0,0 2007-003847-66,5,2018-09-05,2018-09-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ELI LILLY,"Dose Finding and Randomized, Multicenter, Placebo- Controlled, Phase 2 Study of Enzastaurin and Sunitinib versus Placebo and Sunitinib in Patients with Metastatic Renal Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003847-66,0,0,0 2007-003847-66,5,2018-09-05,2018-09-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,"Dose Finding and Randomized, Multicenter, Placebo- Controlled, Phase 2 Study of Enzastaurin and Sunitinib versus Placebo and Sunitinib in Patients with Metastatic Renal Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003847-66,0,0,0 2007-003847-66,5,2018-09-05,2018-09-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and company,"Dose Finding and Randomized, Multicenter, Placebo- Controlled, Phase 2 Study of Enzastaurin and Sunitinib versus Placebo and Sunitinib in Patients with Metastatic Renal Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003847-66,0,0,0 2007-003848-30,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,IBSA,Effects of a plaster containing diclofenac epolamine (DHEP) and heparin on the pain threshold in asymptomatic subjects (no spon-taneous pain) with a latent algogenic condition (subcutaneous and/or mus...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003848-30,0,0,0 2007-003849-32,4,2009-05-29,2009-05-29,2,0,0,0,0,0,3,0,0,1,1,0,1,0,1,AGI Therapeutics Research Ltd,"An Open-label, Roll-over Safety Study of AGI-003 (Arverapamil) in the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003849-32,0,0,0 2007-003850-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude des effets métaboliques et staturaux de deux modes de traitement par hormone de croissance recombinante des enfants nés petits pour l'âge gestationnel avec déficit statural persistant. Pharmacog...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003850-26,0,0,0 2007-003852-13,3,2008-12-01,2009-05-20,3,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Merck and Co., Inc.","A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus- Like Particle (VLP) Vaccine (V504) Administered Concomitantly with GARDASIL™ t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003852-13,0,0,0 2007-003852-13,3,2008-12-01,2009-05-20,3,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus- Like Particle (VLP) Vaccine (V504) Administered Concomitantly with GARDASIL™ t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003852-13,0,0,0 2007-003853-97,1,2013-05-31,2013-05-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Central Manchester University Hospitals NHS Foundation Trust,"A 23-month randomised, masked, prospective phase IV study assessing the safety and efficacy of two alternative treatment regimes using Bevacizumab (AvastinTM) to treat patients with subfoveal and juxt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003853-97,0,0,0 2007-003854-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Replidyne, Inc.","Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600 mg PO, BID for 10 Days Versus Clarithromycin in the Treatment of Community-Acquired Pneu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003854-28,0,0,0 2007-003856-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,PREvention of atrial fibrillation in patientS undergoing thorAcic surGEry for lung cance,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003856-12,0,0,0 2007-003858-29,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Universitätsklinikum Tübingen, Medizinische Klinik I",Prospektive multizentrische Phase-III-Studie zur ambulanten Therapie mit Capecitabin versus Cisplatin plus Capecitabin beim fortgeschrittenen Adenokarzinom der Gallenblase und Gallenwege („CISCA-Studi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003858-29,0,0,0 2007-003863-31,2,2009-02-27,2009-02-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis recherche & développement,"An eight-week, double-blind study to evaluate the efficacy, safety, and tolerability of two fixed doses of saredutant (100 mg and 30 mg) once daily in combination with paroxetine 20 mg once daily comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003863-31,0,0,0 2007-003866-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,AM-Pharma B.V.,"A Phase-II, double-blind, randomized, placebo-controlled proof of concept study on the safety and early efficacy of Alkaline Phosphatase in sepsis patients with Renal Failure.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003866-16,0,0,0 2007-003867-36,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PISANA,"PILOT STUDY OF PHARMACOGENETICS, CLINICAL EFFICACY AND TOLERABILITY OF CLOZAPINE IN PATIENTS AFFECTED BY SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDERS AND BIPOLAR DISORDERS WITH PSYCHOTIC FEATURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003867-36,0,0,0 2007-003868-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Laboratoire Erempharma,ASSESMENT OG EFFICACY AND TOLERABILITY OF INHABLED TOBRAMYCIN VS PLACEBO IN CYSTIC FIBROSIS PATIENTS REVEIVING ANTIBIOTHERAPY FOR 28 DAYS FOR PSEUDOMONAS AERUGINOSA PRIMO COLONISATION.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003868-22,0,0,0 2007-003872-20,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,Laboratorios Liconsa S.A.,"A RANDOMISED, DOUBLE-BLIND, SINGLE-DOSE, TWO-WAY CROSSOVER STUDY TO ASSESS THE BRONCHODILATING PROPERTIES OF A NEW GENERIC DRY POWDER FORMOTEROL FORMULATION GIVEN FROM A NOVEL DRY POWDER INHALER COMPA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003872-20,0,0,0 2007-003877-21,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Institute of Cancer Research,Trial of Perioperative Endocrine Therapy - Individualising Care (POETIC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003877-21,0,0,0 2007-003877-21,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,Trial of Perioperative Endocrine Therapy - Individualising Care (POETIC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003877-21,0,0,0 2007-003884-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"Open label, non-randomized, phase II study on fractioned cyclophosphamide, vincristine, liposomal doxorubicin or doxorubicin, and dexamethasone (MY HYPER-CVAD) in the treatment of relapsed refractory ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003884-30,0,0,0 2007-003885-16,9,2009-08-20,2009-09-08,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Genzyme Europe BV,"A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003885-16,0,0,0 2007-003889-18,1,2009-10-07,2009-10-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,Study on the efficacy of Verrumal(R) compared to placebo and Solaraze(R) in the treatment of actinic keratosis grade I to II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003889-18,0,0,0 2007-003890-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Vejle Hospital,"Postoperativ smertebehandling efter total hoftealloplastik Et randomiseret, dobbeltblindet og placebo-kontrolleret studie til vurdering af effekten af lokalanalgesi",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003890-20,0,0,0 2007-003891-20,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,GGZ Nijmegen,Een gerandomiseerde placebo gecontroleerde studie naar de toegevoegde waarde van D-cycloserine aan exposure therapie bij patiënten met een poststraumatische stress stoornis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003891-20,0,0,0 2007-003894-18,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,NKI-AVL,"Open-label, randomised, multi-center study investigating Cetuximab, in combination with concurrent chemo- / radiotherapy in locally advanced non-small cell lung carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003894-18,0,0,0 2007-003896-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA,PHARMACOKINETICS AND PHARMACODYNAMICS IN THE OPTIMIZATION OF ANTIRETROVIRAL TREATMENT.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003896-38,0,0,0 2007-003898-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut for Pharmacology and Toxicology,Pharmacokinetica of levofloxacine in bone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003898-42,0,0,0 2007-003905-28,1,2009-02-24,2009-02-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pierre Fabre Médicament,"Etude randomisée, en groupes parallèles, en double insu, de l’efficacité de la méquitazine sur la symptomatologie et l’obstruction nasale chez des patients présentant une rhinite allergique perannuell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003905-28,0,0,0 2007-003906-89,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"Istituto Fisiologia Clinica, CNR","Insulin Therapy in non-diabetic patients with Acute Coronary Syndromes: Effect of strict glycemic control on systemic endothelial function, coronary flow reserve, and left ventricular contractility",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003906-89,0,0,0 2007-003907-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Grupo de Investigación ICP,"Estudio aleatorizado, unicéntrico, que compara un régimen de dosis elevada de clopidogrel frente a la dosis estándar en pacientes diabéticos tipo 2 revascularizados mediante una estrategia invasiva p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003907-11,0,0,0 2007-003910-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE MAGGIORE DI MILANO (IRCCS),Randomized controlled study of rituximab and steroid treatment in thyroid-associeted ophthalmopathy (TAO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003910-33,0,0,0 2007-003912-72,1,2012-01-05,2012-01-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,"A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed alone, and Erlotinib alone, as Second-Line Treatment for Non-Smoker Patients with Locally Advanced or Metastatic Non-Small Cell Lu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003912-72,0,0,0 2007-003913-15,1,2009-12-31,2009-12-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Medical University Innsbruck,Wirkung von Oxcarbazepin (Trileptal) auf den Kortikosteroid-Metabolismus - Pilotstudie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003913-15,0,0,0 2007-003915-30,1,2012-10-19,2012-10-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Gloucestershire Hospitals NHS Foundation Trust,The efficacy of maggots as a debridement agent for venous leg ulcers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003915-30,0,0,0 2007-003916-74,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospital Son Dureta,Estudio piloto de la eficacia de las estatinas en el tratamiento de la enfermedad pulmonar obstructiva crónica. (Pilot study on the efficacy of statins for the treatment of Chronic Obstructive Pulmon...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003916-74,0,0,0 2007-003921-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Västra Götalandsregionen,"The effect of selective PDE-5 inhibition on capillary recruitment, glucose uptake and endothelial function following a mixed meal in patients with type 2 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003921-25,0,0,0 2007-003922-70,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Technische Universität Dresden,"Uncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003922-70,0,0,0 2007-003924-39,1,2008-01-21,2008-01-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Becton, Dickinson and Company","A mono center, open-label, randomized study examining the effects of intra-dermal vs. subcutaneous application of regular human insulin or rapid-acting insulin analogue on postprandial glycemic excurs...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003924-39,0,0,0 2007-003925-26,6,2010-08-30,2011-06-24,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Serono S.A. - Geneva,"A two-arm, randomised, double-blind, placebo-controlled, multicenter phase II study to evaluate safety and tolerability and to explore the neuroprotective effect of atacicept as assessed by Optical Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003925-26,0,0,0 2007-003925-26,6,2010-08-30,2011-06-24,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Serono International S.A.,"A two-arm, randomised, double-blind, placebo-controlled, multicenter phase II study to evaluate safety and tolerability and to explore the neuroprotective effect of atacicept as assessed by Optical Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003925-26,0,0,0 2007-003926-11,1,2008-05-06,2008-05-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Leuven,Low dose of ephedrine versus phenylephrine in the prevention of arterial hypotension after low dosed CSE for elective C-section : is there a difference in umbilical blood gas values ?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003926-11,0,0,0 2007-003928-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bayer AG,"A multicenter, non-randomized, non-blinded, non-controlled study to investigate the impact of multiple doses of BAY 63-2521 on safety, tolerability, pharmacokinetics and pharmacodynamics in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003928-37,0,0,0 2007-003930-41,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,Curalogic A/S,Assessment of the Maximal Tolerated Dose of a Microencapsulated House Dust Mite (Dermatophagoides pteronyssinus and Dermatophagoides farinae) Extract (MHDME) in Subjects with House Dust Mite Allergy i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003930-41,0,0,0 2007-003934-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,HELP Pharmaceuticals SA,"A multicenter, randomised, double-blind, placebo-controlled, parallel groups clinical trial for the evaluation of efficacy and safety of diclofenac sodium 3% administered topically in patients with ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003934-40,0,0,0 2007-003936-50,9,2009-09-09,2011-05-30,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Merck Serono S.A. - Geneva,"A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003936-50,1,0,0 2007-003936-50,9,2009-09-09,2011-05-30,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Merck Serono SA - Geneva, an affiliate of Merck KGaA, Darmstadt, Germany","A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003936-50,1,0,0 2007-003936-50,9,2009-09-09,2011-05-30,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Merck Serono International S.A.,"A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003936-50,1,0,0 2007-003936-50,9,2009-09-09,2011-05-30,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Merck Serono Geneva- an affiliate of Merck KGaA, Darmstadt Germany","A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003936-50,1,0,0 2007-003936-50,9,2009-09-09,2011-05-30,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Merck Serono SA-Geneva,"A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003936-50,1,0,0 2007-003937-17,9,2010-06-03,2010-06-03,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Efecto de liraglutida en comparación con sitagliptina, ambas en combinación con metformina en sujetos con diabetes tipo 2. Ensayo de 26 semanas, aleatorizado, abierto, con comparador activo, de tres g...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003937-17,0,0,0 2007-003937-17,9,2010-06-03,2010-06-03,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"Efecto de liraglutida en comparación con sitagliptina, ambas en combinación con metformina en sujetos con diabetes tipo 2. Ensayo de 26 semanas, aleatorizado, abierto, con comparador activo, de tres g...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003937-17,0,0,0 2007-003938-41,1,2010-08-30,2010-08-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Merck Lipha Santé SAS,Open label pilot study on gene expression profiling of the endometrial tissue in patients undergoing Assisted Reproductive Technology (ART: only IVF) with GONAL-f.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003938-41,0,0,0 2007-003940-30,7,2014-02-19,2014-02-19,5,1,0,0,0,2,2,0,0,1,0,0,1,0,1,ROCHE,"A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the treatment of patients with recurrent or refractory Ewing’s sarcoma, osteosarcoma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003940-30,0,0,0 2007-003940-30,7,2014-02-19,2014-02-19,5,1,0,0,0,2,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the treatment of patients with recurrent or refractory Ewing’s sarcoma, osteosarcoma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003940-30,0,0,0 2007-003941-34,1,2013-06-25,2013-06-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Vorstand des Klinikums der Universität München - Grosshadern,SAFETY AND EFFICACY OF SITAGLIPTIN PLUS GRANULOCYTE-COLONY STIMULATING FACTOR IN PATIENTS SUFFERING FROM ACUTE MYOCARDIAL INFARCTION - SITAGRAMI-Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003941-34,0,0,0 2007-003943-55,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,“Clinical and biological effects of 5-Azacitidine five days/monthly schedule in symptomatic low-risk myelodysplastic syndromes (MDSs)”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003943-55,0,0,0 2007-003945-33,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,0,Gesellschaft für Medizinische Innovation –Hämatologie und Onkologie mbH (GMIHO),A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma. Randomis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003945-33,0,0,0 2007-003946-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Antwerp; Department Respiratory Medicine,"Double blind, randomized, placebo-controlled, two-way crossover, pilot study to assess the effect of high dose N acetylcysteine on small airways and on inflammation and oxidative stress in COPD patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003946-13,0,0,0 2007-003949-32,10,2010-02-08,2013-12-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK","A TWO-YEAR MULTI-CENTRE, RANDOMIZED TWO ARM STUDY OF GENOTROPIN TREATMENT IN VERY YOUNG CHILDREN BORN SMALL FOR GESTATIONAL AGE: EARLY GROWTH AND NEURODEVELOPMENT (EGN)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003949-32,0,0,0 2007-003949-32,10,2010-02-08,2013-12-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER,"A TWO-YEAR MULTI-CENTRE, RANDOMIZED TWO ARM STUDY OF GENOTROPIN TREATMENT IN VERY YOUNG CHILDREN BORN SMALL FOR GESTATIONAL AGE: EARLY GROWTH AND NEURODEVELOPMENT (EGN)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003949-32,0,0,0 2007-003949-32,10,2010-02-08,2013-12-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK","A TWO-YEAR MULTI-CENTRE, RANDOMIZED TWO ARM STUDY OF GENOTROPIN TREATMENT IN VERY YOUNG CHILDREN BORN SMALL FOR GESTATIONAL AGE: EARLY GROWTH AND NEURODEVELOPMENT (EGN)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003949-32,0,0,0 2007-003949-32,10,2010-02-08,2013-12-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Ltd. Ramsgate Road, Sandwich, Kent CT13 9NJ, UK","A TWO-YEAR MULTI-CENTRE, RANDOMIZED TWO ARM STUDY OF GENOTROPIN TREATMENT IN VERY YOUNG CHILDREN BORN SMALL FOR GESTATIONAL AGE: EARLY GROWTH AND NEURODEVELOPMENT (EGN)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003949-32,0,0,0 2007-003949-32,10,2010-02-08,2013-12-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A TWO-YEAR MULTI-CENTRE, RANDOMIZED TWO ARM STUDY OF GENOTROPIN TREATMENT IN VERY YOUNG CHILDREN BORN SMALL FOR GESTATIONAL AGE: EARLY GROWTH AND NEURODEVELOPMENT (EGN)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003949-32,0,0,0 2007-003951-35,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Alimentary Health Ltd,None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003951-35,0,0,0 2007-003955-35,6,2008-05-28,2008-05-28,6,0,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A controlled open label randomised parallel group study to evaluate the efficacy, safety, and tolerability of subcutaneous MIRCERA, versus no ESA therapy, in the treatment of anaemia in CKD patients a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003955-35,0,0,0 2007-003955-35,6,2008-05-28,2008-05-28,6,0,0,0,0,0,3,0,0,1,1,0,1,0,1,ROCHE,"A controlled open label randomised parallel group study to evaluate the efficacy, safety, and tolerability of subcutaneous MIRCERA, versus no ESA therapy, in the treatment of anaemia in CKD patients a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003955-35,0,0,0 2007-003956-12,8,2009-02-05,2009-02-05,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVO NORDISK,"Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003956-12,0,0,0 2007-003956-12,8,2009-02-05,2009-02-05,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Investigation of safety and efficacy of five doses of NNC 0113-0217 versus placebo and open-label liraglutide, as add on therapy, in subjects diagnosed with type 2 diabetes currently treated with metf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003956-12,0,0,0 2007-003957-10,5,2013-11-30,2019-05-30,5,1,0,0,0,0,0,0,0,1,0,0,1,0,0,Gastrointestinal Onkologisk Förening,SCOT - Short Course Oncology Therapy - A Study of Adjuvant Chemotherapy in Colorectal Cancer SCOT - Et forsøg med adjuverende kemoterapi af kolorektal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003957-10,0,0,0 2007-003957-10,5,2013-11-30,2019-05-30,5,1,0,0,0,0,0,0,0,1,0,0,1,0,0,Greater Glasgow Health Board/University of Glasgow (GU),SCOT - Short Course Oncology Therapy - A Study of Adjuvant Chemotherapy in Colorectal Cancer SCOT - Et forsøg med adjuverende kemoterapi af kolorektal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003957-10,0,0,0 2007-003957-10,5,2013-11-30,2019-05-30,5,1,0,0,0,0,0,0,0,1,0,0,1,0,0,NHS Greater Glasgow and Clyde (NHSGG&C)/University of Glasgow (GU),SCOT - Short Course Oncology Therapy - A Study of Adjuvant Chemotherapy in Colorectal Cancer SCOT - Et forsøg med adjuverende kemoterapi af kolorektal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003957-10,0,0,0 2007-003957-10,5,2013-11-30,2019-05-30,5,1,0,0,0,0,0,0,0,1,0,0,1,0,0,Greater Glasgow Health Board (GGHB)/ University of Glasgow,SCOT - Short Course Oncology Therapy - A Study of Adjuvant Chemotherapy in Colorectal Cancer SCOT - Et forsøg med adjuverende kemoterapi af kolorektal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003957-10,0,0,0 2007-003957-10,5,2013-11-30,2019-05-30,5,1,0,0,0,0,0,0,0,1,0,0,1,0,0,CAIBER,SCOT - Short Course Oncology Therapy - A Study of Adjuvant Chemotherapy in Colorectal Cancer SCOT - Et forsøg med adjuverende kemoterapi af kolorektal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003957-10,0,0,0 2007-003962-16,4,2008-08-06,2008-08-06,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 4-week double-blind, placebo-controlled, randomised, parallel group phase IIa study to assess the tolerability/safety and efficacy of inhaled AZD4818 in patients with moderate to severe Chronic Obst...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003962-16,0,0,0 2007-003963-31,1,2010-11-30,2010-11-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Karolinska Institutet,"A three months, double-blind, randomized, parallell-group study evaluating the efficacy of sitagliptin (Januvia®) versus placebo on beta-cell function in patients with newly detected glucose abnormali...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003963-31,0,0,0 2007-003965-42,1,,,0,0,0,0,1,0,4,0,0,1,1,1,0,1,0,University Medical Centre Utrecht,"Methylphenidate, rivastigmine or haloperidol in hypoactive delirious intensive care patients: a single centre, randomized, mono-blind pilot trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003965-42,0,0,0 2007-003968-22,2,2015-09-30,2015-09-30,2,0,0,0,0,0,0,0,0,1,0,0,1,0,0,University Hospital Birmingham,European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003968-22,0,0,0 2007-003971-38,3,2008-01-07,2011-10-28,3,1,0,0,0,0,0,0,2,1,0,0,1,0,1,"Merck & Co., Inc.",An Observational Follow-Up Study of Pediatric Patients Who Participated in a Previous Respiratory Syncytial Virus (RSV)-Induced Bronchiolitis Study of Montelukast,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003971-38,0,0,0 2007-003971-38,3,2008-01-07,2011-10-28,3,1,0,0,0,0,0,0,2,1,0,0,1,0,1,"Merck Sharp & Dohme de España, S.A.",An Observational Follow-Up Study of Pediatric Patients Who Participated in a Previous Respiratory Syncytial Virus (RSV)-Induced Bronchiolitis Study of Montelukast,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003971-38,0,0,0 2007-003971-38,3,2008-01-07,2011-10-28,3,1,0,0,0,0,0,0,2,1,0,0,1,0,1,Laboratoires Merck Sharp & Dohme - Chibret,An Observational Follow-Up Study of Pediatric Patients Who Participated in a Previous Respiratory Syncytial Virus (RSV)-Induced Bronchiolitis Study of Montelukast,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003971-38,0,0,0 2007-003973-16,5,2010-01-05,2010-02-18,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS PHARMA SERVICES AG,"A 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tolerability of repeated subcut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003973-16,0,0,0 2007-003973-16,5,2010-01-05,2010-02-18,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tolerability of repeated subcut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003973-16,0,0,0 2007-003975-38,4,2011-09-20,2011-09-20,3,0,0,0,0,2,2,0,0,1,0,0,1,0,1,Ergonex Pharma GmbH,"Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003975-38,0,0,0 2007-003976-20,1,2008-02-25,2008-02-25,1,0,0,0,0,0,2,0,1,1,1,1,1,0,1,GLENMARK PHARMACEUTICALS SA,"A randomised, double blind, placebo and active controlled, parallel group study to evaluate the analgesic effect of a single dose of GRC 6211, a TRPV1 receptor antagonist on pain following third mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003976-20,0,0,0 2007-003977-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Swiss Group for Clinical Cancer Research (SAKK),Protocol SAKK 77/06 and SASL 23 Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma A multicenter phase II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003977-22,0,0,0 2007-003984-33,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Biogen Idec Limited,"A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003984-33,0,0,0 2007-003986-42,1,2012-09-21,2012-09-21,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,University Hospital of Tübingen,"Prospective, randomised, placebo controlled, double blind monocenter trial for the prophylactic treatment of diarrhoea with rifaximin for travellers to South- and Southeast-Asia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003986-42,0,0,0 2007-003987-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Pierre Fabre Ibérica, S.A.",Estudio en fase II de vinorelbina oral como tratamiento neoadyuvante en pacientes de más de 60 años con cáncer de mama localmente avanzado,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003987-23,0,0,0 2007-003989-18,12,2011-05-23,2011-05-23,10,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003989-18,0,0,0 2007-003989-18,12,2011-05-23,2011-05-23,10,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Pharmion Corporation,"A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003989-18,0,0,0 2007-003989-18,12,2011-05-23,2011-05-23,10,1,0,0,0,2,3,0,0,1,0,0,1,0,1,PHARMION CORPORATION,"A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003989-18,0,0,0 2007-003993-24,4,2009-10-12,2009-10-12,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or Stage IV Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003993-24,0,0,0 2007-003994-18,3,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,0,"Medizinische Universität Wien, Universitätsklinik für Innere Medizin III/Rheumatologie","EHOA: Etanercept as treatment for Hand OsteoArthritis A randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy and the structure modifying properties of etanercept 50/25...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003994-18,0,0,0 2007-003994-18,3,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,0,Leiden University Medical Center,"EHOA: Etanercept as treatment for Hand OsteoArthritis A randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy and the structure modifying properties of etanercept 50/25...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003994-18,0,0,0 2007-003994-18,3,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,0,University Hospital Ghent,"EHOA: Etanercept as treatment for Hand OsteoArthritis A randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy and the structure modifying properties of etanercept 50/25...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003994-18,0,0,0 2007-003995-21,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal,Estudio piloto del efecto de un antagonista de co-receptores CCR5 sobre la latencia y el reservorio del VIH-1 en pacientes que reciben tratamiento antirretroviral de gran actividad,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003995-21,0,0,0 2007-003997-24,4,2010-04-07,2010-04-30,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Sanofi-Aventis recherche & de'veloppement,"Long-term extension of the multinational, double-blind, placebo controlled study PDY6045 and PDY6046 to document the safety of teriflunomide when added to treatment with interferon-beta or glatiramer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003997-24,0,0,0 2007-003997-24,4,2010-04-07,2010-04-30,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Sanofi-Aventis recherche & développement,"Long-term extension of the multinational, double-blind, placebo controlled study PDY6045 and PDY6046 to document the safety of teriflunomide when added to treatment with interferon-beta or glatiramer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003997-24,0,0,0 2007-003998-55,6,2010-08-01,2010-09-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-003998-55,0,0,0 2007-004000-13,6,2011-06-01,2011-08-10,5,1,0,0,0,0,3,0,2,1,0,0,1,0,1,AstraZeneca AB,"A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effect of treatment with rosuvastatin 40mg or atorvastatin 80mg on atherosclerotic disease burden as m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004000-13,0,0,0 2007-004000-13,6,2011-06-01,2011-08-10,5,1,0,0,0,0,3,0,2,1,0,0,1,0,1,ASTRAZENECA,"A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing the effect of treatment with rosuvastatin 40mg or atorvastatin 80mg on atherosclerotic disease burden as m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004000-13,0,0,0 2007-004001-96,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Hospital Sant Joan de Déu,Efectos del tratamiento con deferiprone sobre la hipertrofia miocárdica y los parámetros de función cardiaca en pacientes afectos de Ataxia de Friedreich,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004001-96,0,0,0 2007-004002-26,1,2010-12-01,2010-12-01,1,1,0,0,1,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III randomized, single-blind, controlled study to demonstrate the non-inferiority of co-administration of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine with Pediacel™ versus co-ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004002-26,0,0,0 2007-004004-12,1,2009-02-11,2009-02-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Solvay Pharmaceuticals GmbH,A STUDY TO INVESTIGATE THE EFFECT OF PANCRELIPASE DELAYED RELEASE CAPSULES ON MALDIGESTION IN PATIENTS WITH EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004004-12,0,0,0 2007-004007-34,4,2020-05-11,2020-06-15,2,0,0,0,0,0,3,0,0,2,0,0,0,0,0,HOVON Foundation,Randomized phase III trial in elderly patients with previously untreated symptomatic Multiple Myeloma comparing MP-Thalidomide (MP-Thal) followed by Thalidomide maintenance versus MP-Lenalidomide (MP-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004007-34,1,0,0 2007-004008-10,1,,,0,1,0,0,0,1,4,0,0,1,0,0,0,1,1,Novartis Hungária Kft.,"Evaluating the efficacy of Exjade® (deferasirox) in transfusion dependent chronic anaemias ( Myelodysplasia Syndrome, Beta-thalassaemia major patients) with chronic iron overload",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004008-10,0,0,0 2007-004009-93,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,LUNDBECK ITALIA,"Prevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopram Prevalenza di depressione, disturbi d'ansia e di controllo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004009-93,0,0,0 2007-004010-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO,PILOT STUDY ON THE ACTIVITY OF TROPISETRON IN myofascial and neuropathic pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004010-14,0,0,0 2007-004011-54,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Valletta Health BV,"Ensayo en fase IIa, aleatorizado, doble ciego, controlado con placebo y de comparación intra-individual entre los miembros izquierdo-derecho en 25 pacientes con dermatitis atópica moderada, para inves...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004011-54,0,0,0 2007-004012-31,1,2012-08-15,2012-08-15,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Derby Hospitals NHS Foundation Trust,The effects of improving oxygen concentration in the reduction of dialysis induced myocardial stunning – A pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004012-31,0,0,0 2007-004012-31,1,2012-08-15,2012-08-15,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,The University of Nottingham-Research innovation services,The effects of improving oxygen concentration in the reduction of dialysis induced myocardial stunning – A pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004012-31,0,0,0 2007-004014-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ROCHE,"Etude française, randomisée, controlée, parallèle, en ouvert, multicentrique, comparant le maintien du taux d’hémoglobine avec une administration mensuelle de C.E.R.A. (activateur continu du récepteur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004014-13,0,0,0 2007-004017-33,1,2009-01-20,2009-01-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals France,Reformulated BeneFIX efficacy and safety after conversion from a pdFIX.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004017-33,0,0,0 2007-004018-15,12,2011-06-06,2011-08-18,10,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Laboratoires Merck Sharp and Dohme-Chibret,"A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004018-15,0,0,0 2007-004018-15,12,2011-06-06,2011-08-18,10,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Merck Sharp & Dohme GmbH,"A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004018-15,0,0,0 2007-004018-15,12,2011-06-06,2011-08-18,10,1,0,0,0,0,0,0,0,1,1,0,1,0,1,MERCK SHARP DOHME,"A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004018-15,0,0,0 2007-004018-15,12,2011-06-06,2011-08-18,10,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Corp.,"A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004018-15,0,0,0 2007-004018-15,12,2011-06-06,2011-08-18,10,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Merck Sharp & Dohme BV,"A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004018-15,0,0,0 2007-004018-15,12,2011-06-06,2011-08-18,10,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004018-15,0,0,0 2007-004018-15,12,2011-06-06,2011-08-18,10,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme de España, S.A.","A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004018-15,0,0,0 2007-004018-15,12,2011-06-06,2011-08-18,10,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004018-15,0,0,0 2007-004018-15,12,2011-06-06,2011-08-18,10,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Merck & Co.,"A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004018-15,0,0,0 2007-004018-15,12,2011-06-06,2011-08-18,10,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Ireland (Human Health) Limited,"A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004018-15,0,0,0 2007-004018-15,12,2011-06-06,2011-08-18,10,1,0,0,0,0,0,0,0,1,1,0,1,0,1,MSD Finland Oy,"A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004018-15,0,0,0 2007-004020-20,3,2010-01-05,2010-01-05,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,MSD Finland,"A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004020-20,0,0,0 2007-004020-20,3,2010-01-05,2010-01-05,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Merck Sharp & Dohme BV,"A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004020-20,0,0,0 2007-004020-20,3,2010-01-05,2010-01-05,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Merck & Co., Inc.","A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004020-20,0,0,0 2007-004021-19,3,2009-07-01,2009-07-01,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Rigshospitalet,NOPHO ALL-2008 PILOT STUDY ON CONSOLIDATION THERAPY FOR CHILDREN AND YOUNG ADULTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004021-19,0,0,0 2007-004023-38,3,2009-02-02,2009-04-16,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,GB Bietti Eye Foundation - IRCCS,"Prospective, multicentric, double-masked clinical study to compare the efficacy and safety of Ganfort and Duotrav in primary open angle and pseudoexfoliative glaucoma patients previously treated with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004023-38,0,0,0 2007-004023-38,3,2009-02-02,2009-04-16,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS,"Prospective, multicentric, double-masked clinical study to compare the efficacy and safety of Ganfort and Duotrav in primary open angle and pseudoexfoliative glaucoma patients previously treated with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004023-38,0,0,0 2007-004025-20,1,2007-11-29,2007-11-29,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,GlaxoSmithKline,"A randomised, double-blind, parallel-group, fixed-dose, placebo-controlled study comparing correlates of brain functional activation before and after treatment with placebo and Paroxetine in participa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004025-20,0,0,0 2007-004033-42,8,2009-07-27,2009-10-02,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004033-42,0,0,0 2007-004035-35,1,2008-05-07,2008-05-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Devleopment Ltd,"A multi-centre, randomized, double-blind, placebo-controlled, cross-over study to evaluate the effects of GW597599 and GR205171 on sleep continuity, PSG sleep recordings, subjective sleep assessment a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004035-35,0,0,0 2007-004036-23,1,,,0,0,0,0,0,1,4,0,0,1,0,0,0,1,0,FONDAZIONE MALATTIE RARE MAURO BASCHIROTTO B.I.R.D. ONLUS,Efficacy and safety of S-adenosil-methionine on depression of patients with Lesch - Nyhan Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004036-23,0,0,0 2007-004038-18,1,2009-08-14,2009-08-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,MediGene AG,"An open-label, uncontrolled, Phase II trial evaluating the single-dose and steady-state pharmacokinetics of EndoTAG®-1 and its effect on the blood supply and the angiogenesis of hepatic metastases in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004038-18,0,0,0 2007-004040-70,13,2015-10-19,2015-10-19,12,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study comparing the combination of ursodeoxycholic acid capsules plus budesonide capsules to ursodeoxycholic acid capsules...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004040-70,0,0,0 2007-004040-70,13,2015-10-19,2015-10-19,12,1,0,0,0,2,3,0,0,1,0,0,1,0,1,DR. FALK PHARMA GMBH,"Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study comparing the combination of ursodeoxycholic acid capsules plus budesonide capsules to ursodeoxycholic acid capsules...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004040-70,0,0,0 2007-004043-30,10,2008-12-19,2009-06-29,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004043-30,0,0,0 2007-004043-30,10,2008-12-19,2009-06-29,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp and Dohme de España, S.A.","A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004043-30,0,0,0 2007-004043-30,10,2008-12-19,2009-06-29,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004043-30,0,0,0 2007-004043-30,10,2008-12-19,2009-06-29,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme de España, S.A.","A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004043-30,0,0,0 2007-004043-30,10,2008-12-19,2009-06-29,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004043-30,0,0,0 2007-004043-30,10,2008-12-19,2009-06-29,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme BV,"A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of a Single Dose of Intr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004043-30,0,0,0 2007-004049-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU TOULOUSE,Douleur aiguë sévère traumatique en pré-hospitalier : Etude prospective randomisée en double aveugle comparant morphine et sufentanil,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004049-14,0,0,0 2007-004050-85,1,2011-06-08,2011-06-08,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,Imperial College,Evaluation of safety and gene expression with a single dose of pGM169/GL67A administered to the nose and lung of individuals with cystic fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004050-85,0,0,0 2007-004051-11,1,2010-12-01,2010-12-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Oxford Racliffe NHS Trust,Amiloride Treatment in Multiple Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004051-11,0,0,0 2007-004052-37,1,2009-06-29,2009-06-29,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Steno Diabetes Center,"Effekten af Nexium og Cardi 04- Yoghurt på insulin sekretion og - virkning samt CVD risikofatorer associeret med insulinresistens syndromet for patienter med type 2 diabetes - Et randomiseret, dobbelt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004052-37,0,0,0 2007-004053-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO ONCOLOGICO VENETO,Combined chemio-radioterapy regimen of 5-FU plus irinotecan followed by chemotherapy for the treatment of colorectal cancer with resectable metastases at diagnosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004053-28,0,0,0 2007-004056-36,1,2010-03-04,2010-03-04,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Health Protection Agency,"A Phase IV, randomised study to evaluate the immune response of UK infants receiving DTaP/Hib/IPV, meningococcal C conjugate and pneumococcal conjugate vaccines, antibody persistence and responses to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004056-36,0,0,0 2007-004060-40,1,2012-09-27,2012-09-27,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Studienzentrale AGO Austria,Phase II multicenter trial of the Austrian AGO of the combination of liposomal Doxorubicin (Myocet®) and Carboplatin in primary advanced or metastatic and recurrent endometrial cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004060-40,0,0,0 2007-004062-41,1,,,0,0,0,0,0,3,4,0,1,1,0,0,0,1,0,Jarmo Hietala,Effect differences of conventional and newer atypical antipsychotics – Perphenazine and brain dopamine D2 receptor blockade,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004062-41,0,0,0 2007-004063-21,1,2009-06-26,2009-06-26,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Biovitrum AB,"An open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004063-21,0,0,0 2007-004069-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Nephrology and Renal Transplantation, KU Leuven",Hepatic and intestinal CYP3A4/5 activity in renal transplantation. A study assessing in vivo hepatic and intestinal CYP3A4/5 activity at different time-points and in different clinical settings after...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004069-16,0,0,0 2007-004071-19,3,2008-12-30,2008-12-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase III, randomized, double-blind, double-dummy, placebo-controlled, multicenter, 3-period incomplete block, multidose crossover study to determine the effect on lung function of indacaterol (150 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004071-19,0,0,0 2007-004071-19,3,2008-12-30,2008-12-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica,"A phase III, randomized, double-blind, double-dummy, placebo-controlled, multicenter, 3-period incomplete block, multidose crossover study to determine the effect on lung function of indacaterol (150 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004071-19,0,0,0 2007-004074-10,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,“Idiopathic sudden sensorineural hearing loss treatment by Infliximab injection (TNF-alfa blocker)”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004074-10,0,0,0 2007-004076-38,12,2009-10-23,2009-11-06,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Austria GesmbH,"A Twenty Eight –Week, Open-Label, Safety Study of Flibanserin 50 milligrams to 100 milligrams daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004076-38,0,0,0 2007-004076-38,12,2009-10-23,2009-11-06,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim AB,"A Twenty Eight –Week, Open-Label, Safety Study of Flibanserin 50 milligrams to 100 milligrams daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004076-38,0,0,0 2007-004076-38,12,2009-10-23,2009-11-06,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim España S.A.,"A Twenty Eight –Week, Open-Label, Safety Study of Flibanserin 50 milligrams to 100 milligrams daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004076-38,0,0,0 2007-004076-38,12,2009-10-23,2009-11-06,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim bv,"A Twenty Eight –Week, Open-Label, Safety Study of Flibanserin 50 milligrams to 100 milligrams daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004076-38,0,0,0 2007-004076-38,12,2009-10-23,2009-11-06,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim France,"A Twenty Eight –Week, Open-Label, Safety Study of Flibanserin 50 milligrams to 100 milligrams daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004076-38,0,0,0 2007-004076-38,12,2009-10-23,2009-11-06,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Limited,"A Twenty Eight –Week, Open-Label, Safety Study of Flibanserin 50 milligrams to 100 milligrams daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004076-38,0,0,0 2007-004076-38,12,2009-10-23,2009-11-06,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A Twenty Eight –Week, Open-Label, Safety Study of Flibanserin 50 milligrams to 100 milligrams daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004076-38,0,0,0 2007-004076-38,12,2009-10-23,2009-11-06,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BOEHRINGER ING.,"A Twenty Eight –Week, Open-Label, Safety Study of Flibanserin 50 milligrams to 100 milligrams daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004076-38,0,0,0 2007-004076-38,12,2009-10-23,2009-11-06,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Twenty Eight –Week, Open-Label, Safety Study of Flibanserin 50 milligrams to 100 milligrams daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004076-38,0,0,0 2007-004076-38,12,2009-10-23,2009-11-06,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,"A Twenty Eight –Week, Open-Label, Safety Study of Flibanserin 50 milligrams to 100 milligrams daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004076-38,0,0,0 2007-004076-38,12,2009-10-23,2009-11-06,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Finland Ky,"A Twenty Eight –Week, Open-Label, Safety Study of Flibanserin 50 milligrams to 100 milligrams daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004076-38,0,0,0 2007-004085-41,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Royal Wolverhampton Hospitals NHS Trust,Photodynamic Therapy for Basal Cell Carcinoma of the Eyelid and Periocular Skin with methyl aminolevulinate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004085-41,0,0,0 2007-004088-22,2,2014-02-28,2014-02-28,1,1,0,0,0,1,3,0,0,1,1,1,1,0,1,CSL Behring GmbH,Efficacy and safety of Fibrinogen Concentrate (Human) for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004088-22,0,0,0 2007-004088-22,2,2014-02-28,2014-02-28,1,1,0,0,0,1,3,0,0,1,1,1,1,0,1,CSL BEHRING GmbH,Efficacy and safety of Fibrinogen Concentrate (Human) for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004088-22,0,0,0 2007-004090-26,1,2012-08-15,2012-08-15,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,Rigshospitalet,IMPROVING THIOPURINE/METHOTREXATE MAINTENANCE THERAPY OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004090-26,0,0,0 2007-004092-19,6,,,0,0,0,0,0,2,0,0,0,3,0,0,0,0,0,Martin Luther University of Halle/Wittenberg,EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Study for nodular lymphocyte-predominant Hodgkin’s Lymphoma in Children and Adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004092-19,0,0,0 2007-004096-19,1,2011-12-01,2011-12-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Birmingham Heartlands Hospital,Beta Agonist Lung injury Trial - Prevention Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004096-19,0,0,0 2007-004097-32,6,2014-01-31,2014-01-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Abraxis BioScience, LLC","An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004097-32,0,0,0 2007-004097-32,6,2014-01-31,2014-01-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ABRAXIS BIOSCIENCE, LLC","An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004097-32,0,0,0 2007-004097-32,6,2014-01-31,2014-01-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Abraxis BioScience, LLC, a wholly owned subsidiary of Celgene Corporation","An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004097-32,0,0,0 2007-004098-24,1,2015-03-31,2015-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,FNCLCC,"A phase II, randomized, multi-center study, assessing value of adding RAD 001 to Trastuzumab as preoperative therapy of HER-2 positive primary breast cancer amenable to surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004098-24,0,0,0 2007-004099-38,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",INDUCTION CHEMOTHERAPY FOLLOWED BY RADIOTHERAPY CONCOMITANT TO CETUXIMAB IN HEAD AND NECK SQUAMOUS CELL CARCINOMA: PHASE II STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004099-38,0,0,0 2007-004102-27,5,2009-10-02,2009-10-02,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"SciClone Pharmaceuticals, Inc.","A Randomized, Double Blind, Placebo Controlled, Phase II Study Evaluating the Efficacy and Safety of RP101 in Combination with Gemcitabine Administered as First-Line Treatment to Subjects with Unresec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004102-27,1,0,0 2007-004105-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Wilhelmina Children's Hospital,Effect of palivizumab on respiratory syncytial virus-associated burden of disease – a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004105-10,0,0,0 2007-004114-13,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,TOPIC LEVETIRACETAM IN ANAL FISSURE. A PILOT STUDY ABOUT EFFECTIVENESS AND TOLERABLENESS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004114-13,0,0,0 2007-004116-32,2,2013-03-07,2013-03-07,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,LFB BIOTECHNOLOGIES,EFFICACY AND SAFETY STUDY OF WILFACTIN ADMINISTERED BY CONTINUOUS INFUSION IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING MAJOR SURGICAL PROCEDURES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004116-32,0,0,0 2007-004117-33,2,2009-06-16,2009-06-16,2,1,0,0,1,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline R&D Ltd,"A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer's disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selectiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004117-33,0,0,0 2007-004120-21,6,2013-08-12,2013-08-12,5,0,0,0,0,0,3,0,0,2,1,0,0,0,1,VICAL INCORPORATED,A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004120-21,1,0,0 2007-004120-21,6,2013-08-12,2013-08-12,5,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Vical Incorporated,A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004120-21,1,0,0 2007-004122-24,13,2011-06-14,2011-06-22,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"An extension of the 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 0,5 mg and 0.5 mg administered orally once daily v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004122-24,0,0,0 2007-004122-24,13,2011-06-14,2011-06-22,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An extension of the 24-month, double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing efficacy and safety of FTY720 0,5 mg and 0.5 mg administered orally once daily v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004122-24,0,0,0 2007-004124-20,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,LUMC,Doxycycline for Stabilization of Abdominal Aortic Aneurysms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004124-20,0,0,0 2007-004126-24,5,2009-02-07,2009-02-07,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,"A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004126-24,0,0,0 2007-004127-38,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,USE OF ORAL TILACTASE ENZYMES IN SUBJECTS WITH LACTOSE MALABSORPTION AND INTOLERANCE. CLINICAL RELEVANCE IN A POPULATION WITH HIGH PREVALENCE OF LACTASE DEFICIENCY IN SOUTHERN ITALY. Impiego delle ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004127-38,0,0,0 2007-004134-16,1,2011-06-17,2011-06-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Charité Universitätsmedizin Berlin,Effectiveness and Safety of Pregabalin (Lyrica) in treatment of in-patients with ethanol withdrawal syndrom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004134-16,0,0,0 2007-004137-42,6,2009-10-15,2009-10-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Merck & Co Inc.,","A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004137-42,0,0,0 2007-004137-42,6,2009-10-15,2009-10-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Merck Sharp & Dohme (Sweden) AB,"A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004137-42,0,0,0 2007-004137-42,6,2009-10-15,2009-10-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Merck & Co., Inc.","A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004137-42,0,0,0 2007-004137-42,6,2009-10-15,2009-10-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Merck Sharp & Dohme GmbH,"A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004137-42,0,0,0 2007-004137-42,6,2009-10-15,2009-10-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Merck & Co, Inc.","A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004137-42,0,0,0 2007-004137-42,6,2009-10-15,2009-10-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Merck Sharp & Dohme Ireland (Human Healthcare) Ltd,"A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial to Study the Efficacy and Safety of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004137-42,0,0,0 2007-004138-17,5,2009-12-14,2010-03-15,3,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"KOSAN BIOSCIENCES, INC.","Ensayo Clínico fase 3, aleatorizado, en régimen abierto de Tanespimicina (KOS-953) más Bortezomib en comparación con Bortezomib solo, en pacientes con Mieloma Múltiple en primera recaída. Phase 3 Ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004138-17,0,0,0 2007-004138-17,5,2009-12-14,2010-03-15,3,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Bristol Myers Squibb International Corporation,"Ensayo Clínico fase 3, aleatorizado, en régimen abierto de Tanespimicina (KOS-953) más Bortezomib en comparación con Bortezomib solo, en pacientes con Mieloma Múltiple en primera recaída. Phase 3 Ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004138-17,0,0,0 2007-004139-49,1,2009-03-31,2009-03-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"Efficacy and tolerability of 12-weeks oral treatment with V0355CP3A versus Ferrograd, in iron deficiency anaemia. Multicenter, randomised, open-label trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004139-49,0,0,0 2007-004143-30,4,2009-01-13,2009-01-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase III randomized, double-blind, placebo controlled, 2 period crossover, multicenter study to assess the effect of indacaterol (300 µg o.d.) on exercise endurance in patients with moderate to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004143-30,0,0,0 2007-004143-30,4,2009-01-13,2009-01-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A phase III randomized, double-blind, placebo controlled, 2 period crossover, multicenter study to assess the effect of indacaterol (300 µg o.d.) on exercise endurance in patients with moderate to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004143-30,0,0,0 2007-004143-30,4,2009-01-13,2009-01-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmaceutica S.A.,"A phase III randomized, double-blind, placebo controlled, 2 period crossover, multicenter study to assess the effect of indacaterol (300 µg o.d.) on exercise endurance in patients with moderate to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004143-30,0,0,0 2007-004144-74,1,2016-12-23,2016-12-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust,A comparison of the effects of insulin Detemir with insulin Glargine on weight gain in female adolescents and young adults with Type 1 Diabetes (T1D) on a basal bolus regime,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004144-74,0,0,0 2007-004146-32,8,2009-12-21,2009-12-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Affymax Inc.,"AFX01-13: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of AF37702 Injection for the Correction of Anemia in Patients with Chronic Renal Failure (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004146-32,0,0,0 2007-004146-32,8,2009-12-21,2009-12-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AFFYMAX INC.,"AFX01-13: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of AF37702 Injection for the Correction of Anemia in Patients with Chronic Renal Failure (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004146-32,0,0,0 2007-004150-85,1,2010-02-23,2010-02-23,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Charité Universitaetsmedizin Berlin,Cardiac failure with normal ejection fraction: possible role of phosphodiesterase type 5 inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004150-85,0,0,0 2007-004151-11,5,2011-09-13,2011-09-13,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Open-Label, Multicenter Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Subjects Previously Treated With Rituximab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004151-11,0,0,0 2007-004151-11,5,2011-09-13,2011-09-13,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Randomized, Open-Label, Multicenter Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Subjects Previously Treated With Rituximab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004151-11,0,0,0 2007-004153-28,7,2010-01-12,2010-01-22,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Affymax Inc.,"A Phase 3, Randomized, Active-controlled, Open-label, Multi-Center Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004153-28,0,0,0 2007-004153-28,7,2010-01-12,2010-01-22,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AFFYMAX INC.,"A Phase 3, Randomized, Active-controlled, Open-label, Multi-Center Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004153-28,0,0,0 2007-004155-11,1,2009-01-28,2009-01-28,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Renovo Ltd,"A double blind, placebo controlled trial to investigate the efficacy and safety of two concentrations of Juvidex in accelerating the healing of split thickness skin graft donor sites using different d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004155-11,0,0,0 2007-004157-28,12,2010-01-22,2016-12-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Ulcera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004157-28,0,0,0 2007-004157-28,12,2010-01-22,2016-12-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate the Long Term Safety and Tolerability of Repeated Administration of Adalimumab in Subjects with Ulcera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004157-28,0,0,0 2007-004158-10,1,2009-02-19,2009-02-19,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,AIR LIQUIDE,"A single site, exploratory, phase I / II, randomised trial comparing the effect of Helium/Oxygen mixtures (He/O2 78:22 and He/O2 65:35) to medical air on pulmonary function in moderate / severe asthma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004158-10,0,0,0 2007-004162-41,1,2009-07-24,2009-07-24,1,0,0,0,0,1,3,0,0,1,1,1,1,0,1,Mallinckrodt Inc.,"SAFETY AND BIOLOGICAL ACTIVITY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, ADMINISTERED INTRA MUSCULARLY EVERY 6 WEEKS IN ACROMEGALIC PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004162-41,0,0,0 2007-004164-51,1,,,0,0,0,0,0,1,4,0,0,1,0,0,0,1,0,"FONDAZIONE ITALIANA ""LEONARDO GIAMBRONE""PER LA GUARIGIONE DALLA TALASSEMIA - ONLUS",LPI-Labile Plasma Iron in Deferasirox-Treated Thalassemic Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004164-51,0,0,0 2007-004165-17,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PISANA,Efficacy assessment of ceftriaxone therapy in patients with amyotrophic lateral sclerosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004165-17,0,0,0 2007-004167-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Cell Therapeutics, Inc.",Paclitaxel poliglumex (CT-2103)/Carboplatin vs Paclitaxel/Carboplatin for the Treatment of Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer (NSCLC) in Women with Estradiol > 30 pg/ml,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004167-22,0,0,0 2007-004169-16,1,2011-03-07,2011-03-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farma, S.A.","Estudio fase II multicéntrico, abierto, no aleatorizado para evaluar la eficacia de una combinación con bevacizumab y quimioterapia secuencial, como tratamiento de pacientes con cáncer de mama operabl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004169-16,0,0,0 2007-004190-26,6,2014-08-19,2014-08-19,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,GENMAB,"An open-label, single-arm, multi-center phase 2 trial with ofatumumab in patients with relapsed Diffuse Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004190-26,0,0,0 2007-004190-26,6,2014-08-19,2014-08-19,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Genmab A/S,"An open-label, single-arm, multi-center phase 2 trial with ofatumumab in patients with relapsed Diffuse Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004190-26,0,0,0 2007-004190-26,6,2014-08-19,2014-08-19,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"An open-label, single-arm, multi-center phase 2 trial with ofatumumab in patients with relapsed Diffuse Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004190-26,0,0,0 2007-004208-11,1,2008-06-01,2008-06-01,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.-Klinik für Spezielle Anästhesie und Schmerztherapie",Effect of chronic garlic intake on platelet function,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004208-11,0,0,0 2007-004212-31,2,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,"Alcon Laboratories, Inc.","A Double-Masked, Multiple-Dose, Study of the IOP-Lowering Efficacy of Brinzolamide 1.0% Compared to Placebo When Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy in Prim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004212-31,0,0,0 2007-004216-31,1,2017-03-28,2017-03-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Institut Bergonié,Réponse au traitement néoadjuvant par l'anti-aromatase anastrozole et l'anti-oestrogène pur fulvestrant : étude de phase II randomisée chez des patientes ménopausées atteintes d'un cancer du sein non ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004216-31,0,0,0 2007-004219-75,13,2012-09-28,2013-02-17,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck KGaA,"Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004219-75,0,0,0 2007-004222-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dekan des FB Medizin der Johann-Wolfgang Goethe-Universität,"Intra-individual, randomized comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem when imaging the pelvis in patients with spondylarthritides, evaluated in a blinded read",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004222-24,0,0,0 2007-004223-38,6,2011-10-26,2011-10-26,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline AB,"A double-blind, randomized, placebo-controlled, multicenter, dose-finding trial of ofatumumab in RRMS patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004223-38,0,0,0 2007-004223-38,6,2011-10-26,2011-10-26,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline UK,"A double-blind, randomized, placebo-controlled, multicenter, dose-finding trial of ofatumumab in RRMS patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004223-38,0,0,0 2007-004223-38,6,2011-10-26,2011-10-26,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline s.r.o.,"A double-blind, randomized, placebo-controlled, multicenter, dose-finding trial of ofatumumab in RRMS patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004223-38,0,0,0 2007-004223-38,6,2011-10-26,2011-10-26,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Genmab A/S,"A double-blind, randomized, placebo-controlled, multicenter, dose-finding trial of ofatumumab in RRMS patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004223-38,0,0,0 2007-004223-38,6,2011-10-26,2011-10-26,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A double-blind, randomized, placebo-controlled, multicenter, dose-finding trial of ofatumumab in RRMS patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004223-38,0,0,0 2007-004225-26,8,2015-04-22,2015-04-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Incorporated,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004225-26,0,0,0 2007-004226-25,1,2010-06-17,2010-06-17,1,1,0,0,0,1,4,0,0,1,1,1,1,0,0,UCL,Low-dose intravenous immunoglobulin or 0.9% saline in the treatment of trigeminal neuralgia refractory to carbamazepine – a randomized double blind parallel placebo-controlled multicentre trial in an ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004226-25,0,0,0 2007-004226-25,1,2010-06-17,2010-06-17,1,1,0,0,0,1,4,0,0,1,1,1,1,0,0,,Low-dose intravenous immunoglobulin or 0.9% saline in the treatment of trigeminal neuralgia refractory to carbamazepine – a randomized double blind parallel placebo-controlled multicentre trial in an ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004226-25,0,0,0 2007-004227-37,8,2009-03-03,2009-03-03,6,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Merck Serono International SA,"""Ensayo clínico en fase IV, multicéntrico, aleatorizado, doble ciego y controlado frente a placebo, para evaluar la seguridad y la eficacia de Raptiva® en el tratamiento de pacientes con psoriasis en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004227-37,0,0,0 2007-004227-37,8,2009-03-03,2009-03-03,6,1,0,0,0,0,4,0,0,1,1,0,1,0,1,MERCK SERONO INTERNATIONAL SA,"""Ensayo clínico en fase IV, multicéntrico, aleatorizado, doble ciego y controlado frente a placebo, para evaluar la seguridad y la eficacia de Raptiva® en el tratamiento de pacientes con psoriasis en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004227-37,0,0,0 2007-004227-37,8,2009-03-03,2009-03-03,6,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Merck Serono International, 9 Chemin des Mines, 1202 Geneva, Switzerland","""Ensayo clínico en fase IV, multicéntrico, aleatorizado, doble ciego y controlado frente a placebo, para evaluar la seguridad y la eficacia de Raptiva® en el tratamiento de pacientes con psoriasis en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004227-37,0,0,0 2007-004227-37,8,2009-03-03,2009-03-03,6,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Merck Serono S.A. - Geneva,"""Ensayo clínico en fase IV, multicéntrico, aleatorizado, doble ciego y controlado frente a placebo, para evaluar la seguridad y la eficacia de Raptiva® en el tratamiento de pacientes con psoriasis en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004227-37,0,0,0 2007-004232-22,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Odense University Hospital,"Phase II study with cetuximab, irinotecan and sunitinib (CIS) for patients with treatment resistant colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004232-22,0,0,0 2007-004234-16,7,2010-06-09,2010-07-23,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER INGELHEIM,Long-term safety study of open-label pramipexole extended release (ER) in patients with early Parkinson’s disease (PD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004234-16,0,0,0 2007-004234-16,7,2010-06-09,2010-07-23,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,Long-term safety study of open-label pramipexole extended release (ER) in patients with early Parkinson’s disease (PD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004234-16,0,0,0 2007-004234-16,7,2010-06-09,2010-07-23,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,Long-term safety study of open-label pramipexole extended release (ER) in patients with early Parkinson’s disease (PD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004234-16,0,0,0 2007-004234-16,7,2010-06-09,2010-07-23,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,Long-term safety study of open-label pramipexole extended release (ER) in patients with early Parkinson’s disease (PD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004234-16,0,0,0 2007-004234-16,7,2010-06-09,2010-07-23,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,Long-term safety study of open-label pramipexole extended release (ER) in patients with early Parkinson’s disease (PD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004234-16,0,0,0 2007-004235-37,9,2010-06-14,2010-08-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.",Long-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinson’s disease (PD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004235-37,0,0,0 2007-004235-37,9,2010-06-14,2010-08-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,Long-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinson’s disease (PD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004235-37,0,0,0 2007-004235-37,9,2010-06-14,2010-08-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,Long-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinson’s disease (PD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004235-37,0,0,0 2007-004235-37,9,2010-06-14,2010-08-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,Long-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinson’s disease (PD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004235-37,0,0,0 2007-004235-37,9,2010-06-14,2010-08-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,Long-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinson’s disease (PD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004235-37,0,0,0 2007-004235-37,9,2010-06-14,2010-08-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,Long-term safety study of open-label pramipexole extended release (ER) in patients with advanced Parkinson’s disease (PD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004235-37,0,0,0 2007-004241-15,7,2011-01-18,2011-01-19,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol Myers Squibb International Corporation,"A Phase IIB, Multi-Dose, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004241-15,0,0,0 2007-004241-15,7,2011-01-18,2011-01-19,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase IIB, Multi-Dose, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004241-15,0,0,0 2007-004243-29,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,"Merck Serono International SA. An Affiliate of Merck KGaA, Darmstadt, Germany","A Phase IV open label study in moderate to severe chronic plaque psoriasis subjects transitioning from previous systemic antipsoriasis therapies (methotrexate, cyclosporine, retinoids or PUVA, NBUVB) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004243-29,0,0,0 2007-004246-32,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ASTRAZENECA,"Comparison of Quetiapine Extended-Release (Seroquel XR™ ) and Risperidone in the treatment of depressive symptoms, in schizophrenic or schizoaffective patients: A randomized, open label, flexible-dose...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004246-32,0,0,0 2007-004247-30,1,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,University Medical Center Utrecht,The Role of the Endocannabinoid System in Psychiatric Disorders and Symptoms: a Pharmacological fMRI study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004247-30,0,0,0 2007-004250-81,1,2013-09-04,2013-09-04,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Helsinki University Central Hospital, Pain Clinic",Acute opioid tolerance as revealed by functional magnetic resonance imaging.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004250-81,0,0,0 2007-004251-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut Claudius Regaud,EVALUATION BIOLOGIQUE DE LA TOXICITE RENALE DU CISPLATINE ET DE L’IFOSFAMIDE (TOXIPLAT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004251-12,0,0,0 2007-004252-37,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Innate Pharma,"A Phase I/II open label study to assess efficacy and safety of IPH1101 associated with low dose of interleukin 2, as add-on therapy to imatinib in CML patients with residual molecular disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004252-37,0,0,0 2007-004254-93,1,2008-07-21,2008-07-21,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V,"A Non-Randomized, Within Subject Placebo-Controlled Exploratory Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal EEG Response in Subjects with Photosensitive Epilepsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004254-93,0,0,0 2007-004255-10,1,2008-09-22,2008-09-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LETI Pharma GmbH,"Randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Depigoid® Grass Mix in patients with al-lergic rhinitis and/or rhinoconjunctivitis with or wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004255-10,0,0,0 2007-004266-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ICORG,A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen F...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004266-40,0,0,0 2007-004267-22,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PISANA,Pharmacogenetic evaluation of oxicodone in patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004267-22,0,0,0 2007-004269-16,1,2010-09-27,2010-09-27,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,"Queen Mary, University of London",Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I) in children with Crohn’s disease-induced growth retardation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004269-16,0,0,0 2007-004270-43,4,2021-12-31,2021-12-31,2,0,1,0,0,1,3,0,0,2,0,0,0,0,0,"Universitätsklinikum Schleswig-Holstein, Campus Kiel",INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR CHILDREN AND ADOLESCENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004270-43,1,0,0 2007-004270-43,4,2021-12-31,2021-12-31,2,0,1,0,0,1,3,0,0,2,0,0,0,0,0,UNIVERSITY HOSPITAL SCHLESWIG-HOLSTEIN CAMPUS KIEL,INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR CHILDREN AND ADOLESCENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004270-43,1,0,0 2007-004271-19,7,2012-08-08,2012-08-14,7,1,0,0,0,0,0,0,0,1,0,0,1,0,2,"Corthera, Inc.","A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004271-19,0,0,0 2007-004271-19,7,2012-08-08,2012-08-14,7,1,0,0,0,0,0,0,0,1,0,0,1,0,2,BAS Medical Inc.,"A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004271-19,0,0,0 2007-004274-10,1,2010-01-22,2010-01-22,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Freistaat Bayern,Analgesic efficacy and safety of etoricoxib in ear nose throat surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004274-10,0,0,0 2007-004276-39,1,2009-07-30,2009-07-30,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Baxter Innovations GmbH,"OPEN-LABEL, RANDOMIZED, THREE-ARM, PHASE IIIB CLINICAL STUDY TO INVESTIGATE THE SAFETY AND IMMUNOGENICITY OF A CONCOMITANT ADMINISTRATION OF GROUP C MENINGOCOCCAL POLYSACCHARIDE-TETANUS TOXOID CONJUGA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004276-39,0,0,0 2007-004277-26,12,2010-11-22,2010-11-22,10,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Gilead Sciences Inc,"An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam 75 mg Powder and Diluent for Nebuliser Solution (AZLI) versus Tobramycin Nebuliser Solution (TNS) in an Interm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004277-26,1,1,0 2007-004278-20,2,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,GECP(Grupo Español de cancer de Pulmón),"""MULTINATIONAL, PHASE III, RANDOMIZED STUDY TO EVALUATE TREATMENT CUSTOMIZED ACCORDING TO RAP 80 AND BRCA1 mRNA ASSESSMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (modification of the BRE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004278-20,0,0,0 2007-004278-20,2,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,ADDS (Advanced Drug Development Services),"""MULTINATIONAL, PHASE III, RANDOMIZED STUDY TO EVALUATE TREATMENT CUSTOMIZED ACCORDING TO RAP 80 AND BRCA1 mRNA ASSESSMENT IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (modification of the BRE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004278-20,0,0,0 2007-004279-20,1,2008-07-15,2008-07-15,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Technical University Dresden,Comparison of the atrophogenic effect of hydrocortisone 1% cream and Elidel (Pimecrolimus 1% cream) assessed by Optical Coherence Tomography (OCT) and 20-MHZ ultrasound of uninvolved skin in patients ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004279-20,0,0,0 2007-004280-22,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"Universitätsklinikum Schleswig-Holstein, Campus Lübeck: Klinik für Strahlentherapie",Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004280-22,0,0,0 2007-004284-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,A prospective randomized study of antibiotic prophylaxis for renal transplantation: short term vs standard treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004284-21,0,0,0 2007-004286-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Central Institute of Mental Health,"Monocentric, Double-blind Placebo-Controlled, Randomized Cross-Sectional Clinical Trial of Hydrocortisone (10 and 30mg/d) in Outpatients with Posttraumatic-Stress- Disorder (PTSD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004286-18,0,0,0 2007-004288-23,1,2009-08-27,2009-08-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Medizinische Universität Graz,Frühtherapie der pulmonal arteriellen Hypertonie (PAH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004288-23,0,0,0 2007-004289-42,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,National and Kapodistrian University of Athens,90Y ibritumomab tiuxetan (Zevalin®) in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004289-42,0,0,0 2007-004290-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"J. Uriach y Compañía, S.A",Evaluación del tratamiento con triflusal en pacientes con cardiopatía isquémica estable con no respuesta a AAS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004290-26,0,0,0 2007-004291-39,1,2008-11-04,2008-11-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,AGI Therapeutics Research Ltd,"A randomised, multi-centre, double-blind, balanced, parallel group placebo-controlled study of AGI004 for the control of chemotherapy-induced diarrhoea.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004291-39,0,0,0 2007-004296-19,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,Association of Dutch Burn Centres,Application of cultured autologous keratinocytes in combination with a meshed split skin autograft for burn wound healing,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004296-19,0,0,0 2007-004297-40,1,2014-12-08,2014-12-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospitals of Leicester NHS Trust,Pharmacological treatment of nystagmus: A randomised double masked placebo controlled crossover study using gabapentin and memantine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004297-40,0,0,0 2007-004298-24,1,2014-09-18,2014-09-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,A cluster randomised trial of different strategies of antibiotic use to reduce the incidence and consequences of chest infection in acute stroke patients with swallowing problems.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004298-24,0,0,0 2007-004298-24,1,2014-09-18,2014-09-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,A cluster randomised trial of different strategies of antibiotic use to reduce the incidence and consequences of chest infection in acute stroke patients with swallowing problems.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004298-24,0,0,0 2007-004299-38,4,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,The University of Liverpool,European Study Group for Pancreatic Cancer - Trial 4. Combination versus single agent adjuvant chemotherapy in resectable pancreatic cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004299-38,0,0,0 2007-004299-38,4,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,The Royal Liverpool and Broadgreen University Hospital NHS Trust,European Study Group for Pancreatic Cancer - Trial 4. Combination versus single agent adjuvant chemotherapy in resectable pancreatic cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004299-38,0,0,0 2007-004299-38,4,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Pirkanmaan sairaanhoitopiiri,European Study Group for Pancreatic Cancer - Trial 4. Combination versus single agent adjuvant chemotherapy in resectable pancreatic cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004299-38,0,0,0 2007-004301-99,14,2009-09-30,2009-10-28,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"Estudio aleatorizado de búsqueda de dosis de dabigatran etexilato en pacientes con síndrome coronario agudo, tras un evento determinado, con factores de riesgo adicionales de complicaciones cardiovasc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004301-99,0,0,0 2007-004301-99,14,2009-09-30,2009-10-28,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GesmbH,"Estudio aleatorizado de búsqueda de dosis de dabigatran etexilato en pacientes con síndrome coronario agudo, tras un evento determinado, con factores de riesgo adicionales de complicaciones cardiovasc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004301-99,0,0,0 2007-004301-99,14,2009-09-30,2009-10-28,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"Estudio aleatorizado de búsqueda de dosis de dabigatran etexilato en pacientes con síndrome coronario agudo, tras un evento determinado, con factores de riesgo adicionales de complicaciones cardiovasc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004301-99,0,0,0 2007-004301-99,14,2009-09-30,2009-10-28,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd,"Estudio aleatorizado de búsqueda de dosis de dabigatran etexilato en pacientes con síndrome coronario agudo, tras un evento determinado, con factores de riesgo adicionales de complicaciones cardiovasc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004301-99,0,0,0 2007-004301-99,14,2009-09-30,2009-10-28,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd.,"Estudio aleatorizado de búsqueda de dosis de dabigatran etexilato en pacientes con síndrome coronario agudo, tras un evento determinado, con factores de riesgo adicionales de complicaciones cardiovasc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004301-99,0,0,0 2007-004301-99,14,2009-09-30,2009-10-28,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"Estudio aleatorizado de búsqueda de dosis de dabigatran etexilato en pacientes con síndrome coronario agudo, tras un evento determinado, con factores de riesgo adicionales de complicaciones cardiovasc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004301-99,0,0,0 2007-004301-99,14,2009-09-30,2009-10-28,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","Estudio aleatorizado de búsqueda de dosis de dabigatran etexilato en pacientes con síndrome coronario agudo, tras un evento determinado, con factores de riesgo adicionales de complicaciones cardiovasc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004301-99,0,0,0 2007-004301-99,14,2009-09-30,2009-10-28,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"Estudio aleatorizado de búsqueda de dosis de dabigatran etexilato en pacientes con síndrome coronario agudo, tras un evento determinado, con factores de riesgo adicionales de complicaciones cardiovasc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004301-99,0,0,0 2007-004301-99,14,2009-09-30,2009-10-28,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"Estudio aleatorizado de búsqueda de dosis de dabigatran etexilato en pacientes con síndrome coronario agudo, tras un evento determinado, con factores de riesgo adicionales de complicaciones cardiovasc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004301-99,0,0,0 2007-004301-99,14,2009-09-30,2009-10-28,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"Estudio aleatorizado de búsqueda de dosis de dabigatran etexilato en pacientes con síndrome coronario agudo, tras un evento determinado, con factores de riesgo adicionales de complicaciones cardiovasc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004301-99,0,0,0 2007-004301-99,14,2009-09-30,2009-10-28,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Estudio aleatorizado de búsqueda de dosis de dabigatran etexilato en pacientes con síndrome coronario agudo, tras un evento determinado, con factores de riesgo adicionales de complicaciones cardiovasc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004301-99,0,0,0 2007-004304-12,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PISANA,"Pilot study, randomised, open-label, monocentre, case vs control study to assess the effect of topically and parenterally Heparin administration treatment in superficial and deep second grade burns...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004304-12,0,0,0 2007-004308-11,1,2019-11-13,2019-11-13,1,1,1,0,0,1,1,0,0,1,0,0,1,0,0,Genethon,PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004308-11,0,0,0 2007-004309-90,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Zentralinstitut für Seelische Gesundheit Mannheim,Fahrtüchtigkeit bei Erwachsenen mit Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung (ADHS) vor und nach 10wöchiger Behandlung mit 40-80 mg Atomoxetin im Vgl. zu unbehandelten Erwachsenen mit ADHS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004309-90,0,0,0 2007-004310-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU-ULG,Infusion of mesenchymal stem cells as treatment for steroid resistant grade II to IV acute GVHD or poor graft function: a multicenter phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004310-14,0,0,0 2007-004316-31,1,2009-11-16,2009-11-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Consumer Health S.A.,"A randomised, double-blind, vehicle controlled, single centre, parallel group, comparative study of the efficacy of penciclovir 10 mg/g (1%) cream in preventing the appearance of classical lesions in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004316-31,0,0,0 2007-004320-21,2,2009-05-13,2009-05-13,1,0,0,0,0,1,3,0,0,1,1,0,1,0,1,Ambrilia Biopharma Inc.,"OPEN LABEL EXTENSION STUDY EVALUATING THE SAFETY AND BIOLOGICAL ACTIVITY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, ADMINISTERED INTRA MUSCULARLY EVERY 6 WEEKS IN ACR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004320-21,0,0,0 2007-004321-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Eli Lilly and Company Limited,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Pros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004321-15,0,0,0 2007-004322-24,2,2010-04-23,2010-04-23,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Ovation Pharmaceuticals Inc.,"Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004322-24,0,0,0 2007-004322-24,2,2010-04-23,2010-04-23,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Lundbeck Inc,"Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004322-24,0,0,0 2007-004326-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,SHORT-HER: MULTICENTRIC RANDOMISED PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY PLUS 3 VS 12 MONTHS OF TRASTUZUMAB IN BREAST CANCER PATIENTS WITH HER2 POSITIVE DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004326-25,0,0,0 2007-004328-18,2,2008-06-09,2008-06-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A 12 week double-blind, randomised, placebo-controlled, modified dose-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584XX tablets at doses of 100, 300 and 500 mg admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004328-18,0,0,0 2007-004328-18,2,2008-06-09,2008-06-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A 12 week double-blind, randomised, placebo-controlled, modified dose-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584XX tablets at doses of 100, 300 and 500 mg admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004328-18,0,0,0 2007-004331-27,7,2010-02-10,2010-02-12,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation","A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of SCH 900340 5% Solution Compared with Vehicle Administered Topically in the Treatment of Distal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004331-27,0,0,0 2007-004333-42,1,2014-11-30,2014-11-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Friedrich-Schiller-University of Jena,"Prospective randomized clinical multicenter trial about the effect of an adjunctive intravenous treatment with sodium selenite (selenase®T, double-blind) and a procalcitonin guided causal therapy (ope...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004333-42,0,0,0 2007-004335-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU Medical Center,A randomized phase II trial of docetaxel plus carboplatin versus docetaxel in hormone refractory prostate cancer patients who have progressed after response to prior docetaxel chemotherapy: RECARDO ST...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004335-39,0,0,0 2007-004337-41,1,2008-03-07,2008-03-07,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GENFIT,"A Pilot study to evaluate the Efficacy and Safety of GFT505 orally administered once daily (30 mg) for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004337-41,0,0,0 2007-004340-67,4,2009-09-11,2010-01-11,3,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Ark Therapeutics Limited,"A multi-centre, double-blind, randomised, placebo-controlled, phase IIa exploratory study of the effects of Imidapril on body weight and body composition in Non-Small Cell Lung Cancer patients with ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004340-67,0,0,0 2007-004344-78,11,2012-11-19,2013-07-30,10,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Merck KGaA,"Cilengitida en pacientes con gioblastoma multiforme recién diagnosticado y con promotor metilado del gen MGMT-estudio multicéntrico, abierto y controlado en fase III para evaluar cilengitida en combin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004344-78,0,0,0 2007-004344-78,11,2012-11-19,2013-07-30,10,1,0,0,0,1,3,0,0,1,1,0,1,0,1,MERCK KGAA,"Cilengitida en pacientes con gioblastoma multiforme recién diagnosticado y con promotor metilado del gen MGMT-estudio multicéntrico, abierto y controlado en fase III para evaluar cilengitida en combin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004344-78,0,0,0 2007-004345-14,1,2008-08-28,2008-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici SpA,"Dose response evaluation of CHF 1535 HFA pMDI in asthmatic patients using lung function, adenosine monophosphate bronchial challenge and fractional exhaled nitric oxide (FENO). Randomized, double-bl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004345-14,0,0,0 2007-004347-30,3,2009-04-28,2009-04-28,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine co-administered with GlaxoSmithKline Biologica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004347-30,0,0,0 2007-004349-13,2,2008-06-30,2008-08-18,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Ardana Bioscience Ltd,"A Phase II multi-centre, open-label study investigating the long-term safety and efficacy of Teverelix, long-acting formulation in patients with advanced prostate cancer – follow on study to Study N°....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004349-13,0,0,0 2007-004350-82,2,2012-09-18,2012-09-18,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Ovation Pharmaceuticals,Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox Gastaut Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004350-82,0,0,0 2007-004350-82,2,2012-09-18,2012-09-18,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Lundbeck Inc,Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox Gastaut Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004350-82,0,0,0 2007-004353-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitario La Paz,UTILIDAD DE LA SUPLEMENTACIÓN CON ÁCIDO FÓLICO SOBRE MARCADORES CLÍNICOS Y BIOQUÍMICOS EN PACIENTES CON TCA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004353-28,0,0,0 2007-004354-90,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,academisch ziekenhuis Maastricht,Effecten van aspirine op de plaatjesfunctie bij gezonde vrijwillige proefpersonen.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004354-90,0,0,0 2007-004358-10,1,,,0,0,0,0,0,1,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE),EVALUATION OF THE TOLERABILITY AND EFFICACY OF ERYTHROPOIETIN (EPO) TREATMENT IN SPINAL SHOCK: COMPARATIVE STUDY VS METHYLPREDNISOLONE (MP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004358-10,0,0,0 2007-004359-12,1,,,0,0,0,0,0,1,3,0,0,1,0,0,0,1,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""",Simvastatin treatment in inclusion body myositis (IBM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004359-12,0,0,0 2007-004360-44,1,2008-11-26,2008-11-26,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,University of Oxford,Assessment of protection against malaria by sporozoite challenge of healthy adults vaccinated with AdCh63 ME-TRAP and MVA ME-TRAP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004360-44,0,0,0 2007-004367-22,7,2010-04-29,2010-04-30,3,1,1,0,0,1,3,0,0,2,1,0,0,0,1,NOVARTIS FARMA,"An open-label, long-term safety and efficacy study of ACZ885 (anti-interleukin-1β monoclonal antibody) administered for at least 6 months in patients with the following cryopyrin-associated peri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004367-22,1,1,0 2007-004367-22,7,2010-04-29,2010-04-30,3,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,"An open-label, long-term safety and efficacy study of ACZ885 (anti-interleukin-1β monoclonal antibody) administered for at least 6 months in patients with the following cryopyrin-associated peri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004367-22,1,1,0 2007-004367-22,7,2010-04-29,2010-04-30,3,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Novartis Farmacéutica S.A.,"An open-label, long-term safety and efficacy study of ACZ885 (anti-interleukin-1β monoclonal antibody) administered for at least 6 months in patients with the following cryopyrin-associated peri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004367-22,1,1,0 2007-004368-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Academic Endocrinology, Beaumont Hospital","The effects of statin therapy on the osteoprotegerin-RANKL system, correlation with vascular disease and bone metabolism in patients with Type 2 diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004368-34,0,0,0 2007-004369-16,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,"St Raphael's Hospice, Surrey",''Evaluation of the efficacy of 'TRANS-DERMAL NITRATE' in reducing the severity of 'death-rattle' (i.e 'terminal lung secretions' ) in patients dying from end stage malignancy'',https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004369-16,0,0,0 2007-004370-55,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE),Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004370-55,0,0,0 2007-004371-19,1,2008-12-09,2008-12-09,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Archemix Corp.,"A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients with von Willebrand Factor-Related Platelet Function Disorders",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004371-19,0,0,0 2007-004372-39,1,2009-11-01,2009-11-01,1,0,0,0,0,0,4,0,1,1,1,1,1,0,0,"Department of Infectious Diseases, Aarhus University Hospital, Skejby",Effect and safety of switching from zidovudin to either tenofovir or abacavir in patients suffering from HIV. An open label study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004372-39,0,0,0 2007-004375-19,1,2008-02-19,2008-02-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare,"A multi-centre, randomised, double-blind, parallel-group, placebo-controlled, multiple dose study of the efficacy of Strepsils original throat lozenges in the relief of sore throat due to upper respir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004375-19,0,0,0 2007-004377-26,1,2009-10-01,2009-10-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Chiesi Farmaceutici S.p.A.,"Effect of fixed combination of beclomethasone dipropionate/formoterol fumarate (BDP/FF), as reliever, upon exhaled nitric oxide in asthma. FENOMENO study (Fractional Exhaled Nitric Oxide-Multiple Expi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004377-26,0,0,0 2007-004379-20,3,2011-09-30,2011-10-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,"A PHASE 2B MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE TRIAL OF UK-453,061, IN COMBINATION WITH TENOFOVIR AND EMTRICITABINE VERSUS EFAVIRENZ IN COMBINATION WITH TENOFOVIR DF AND EMTRICITABINE F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004379-20,0,0,0 2007-004379-20,3,2011-09-30,2011-10-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2B MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE TRIAL OF UK-453,061, IN COMBINATION WITH TENOFOVIR AND EMTRICITABINE VERSUS EFAVIRENZ IN COMBINATION WITH TENOFOVIR DF AND EMTRICITABINE F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004379-20,0,0,0 2007-004384-22,1,2014-06-16,2014-06-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,CENTRE ANTOINE LACASSAGNE,"ETUDE DE PHASE II EVALUANT UNE RADIOTHERAPIE - CHIMIOTHERAPIE + CETUXIMAB CHEZ DES PATIENTS PORTEURS D’UN CARCINOME EPIDERMOÏDE DE LA CAVITE BUCCALE, DE L’OROPHARYNX, DE L’HYPOPHARYNX OU DU LARYNX HIS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004384-22,0,0,0 2007-004391-39,3,2012-08-18,2012-08-18,1,1,0,1,0,2,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A Phase I/II multi-center, open label study of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004391-39,0,0,0 2007-004391-39,3,2012-08-18,2012-08-18,1,1,0,1,0,2,1,0,0,1,0,0,0,0,1,Novartis Pharma Services,"A Phase I/II multi-center, open label study of TKI258 administered orally on an intermittent schedule in adult patients with advanced or metastatic Renal Cell Cancer (RCC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004391-39,0,0,0 2007-004392-19,6,2011-10-14,2012-10-18,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Inc,"""Ensayo en fase 2b multicéntrico, aleatorizado, comparativo de UK 453,061 frente a etravirina en combinación con darunavir/ritonavir y un inhibidor de la transcriptasa inversa análogos de los nucleósi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004392-19,0,0,0 2007-004392-19,6,2011-10-14,2012-10-18,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer,"""Ensayo en fase 2b multicéntrico, aleatorizado, comparativo de UK 453,061 frente a etravirina en combinación con darunavir/ritonavir y un inhibidor de la transcriptasa inversa análogos de los nucleósi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004392-19,0,0,0 2007-004392-19,6,2011-10-14,2012-10-18,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","""Ensayo en fase 2b multicéntrico, aleatorizado, comparativo de UK 453,061 frente a etravirina en combinación con darunavir/ritonavir y un inhibidor de la transcriptasa inversa análogos de los nucleósi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004392-19,0,0,0 2007-004393-81,1,2009-04-28,2009-04-28,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Medizinische Universität Innsbruck - Universitätsklinik für Radiodiagnostik (Radiologie I),Prospektive Evaluation von Multimodality Imaging Verfahren (PET - CT - MRT - US - Bildfusion) bei malignen Tumoren der Kopf-Hals-Region,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004393-81,0,0,0 2007-004396-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ITALIAN SARCOMA GROUP,"Phase II, open label, non-randomized study of second or third line treatment with sorafenib (BAY 43-9006) in patients affected by relapsed high-grade osteosarcoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004396-19,0,0,0 2007-004397-62,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Servicio Andaluz de Salud,Análisis aleatorizado y doble ciego sobre la utilidad del extracto de arándano rojo vs profilaxis antibiótica con Trimetoprima en la infección urinaria recurrente infantil,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004397-62,0,0,0 2007-004399-38,3,2008-07-23,2008-07-23,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"CombinatoRx, Incorporated","A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, 1-YEAR EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFECTIVENESS OF CRx-102 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004399-38,0,0,0 2007-004400-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut de Recerca de l'Hospital de la santa Creu i Sant Pau,ENSAYO RANDOMIZADO A DOBLE CIEGO Y CONTROLADO CON PLACEBO DE RASAGILINA EN PACIENTES CON ENFERMEDAD DE PARKINSON Y SINTOMAS DE APATIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004400-12,0,0,0 2007-004401-10,1,2015-01-29,2015-01-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Charité Universitätsmedizin Berlin,"Hydrocortisone for Prevention of Septic Shock Placebo-controlled, randomised, double-blind study to investigate the efficacy and safety of low dose hydrocortisone to prevent the development of septic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004401-10,0,0,0 2007-004403-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Puigvert,Eficacia y seguridad del telmisartan en pacientes hipertensos con insuficiencia renal crónica en hemodiálisis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004403-34,0,0,0 2007-004406-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AVAX Technologies Inc.,Comparison of M-Vax plus Low Dose Interleukin-2 versus Placebo Vaccine plus Low Dose Interleukin-2 in patients with Stage IV Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004406-26,0,0,0 2007-004410-13,2,,,0,0,0,0,1,1,3,0,0,0,0,0,0,0,0,Institute od Rheumatology Prague,"A PROSPECTIVE, RANDOMISED, ASSESSOR-BLIND, MULTICENTER STUDY OF EFFICACY AND SAFETY OF COMBINED TREATMENT OF METHOTREXATE + GLUCOCORTICOIDS VERSUS GLUCOCORTICOIDS ALONE IN PATIENTS WITH POLYMYOSITIS A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004410-13,0,0,0 2007-004413-33,2,2009-05-26,2009-05-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Karo Bio AB,"A Phase II, Placebo-Controlled, Double-Blind, Randomised, 12-Week, Parallel-group Study to Assess the Efficacy of Different Doses of KB 2115 as add on to Statin Treatment in Patients With Dyslipidemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004413-33,0,0,0 2007-004416-31,4,2009-03-08,2009-03-08,4,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Allergan Limited,"A 6 MONTH, SINGLE-MASKED, MULTICENTER, RANDOMIZED, CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF 700 µg DEXAMETHASONE POSTERIOR SEGMENT DRUG DELIVERY SYSTEM APPLICATOR SYSTEM AS ADJUNTIVE THER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004416-31,0,0,0 2007-004416-31,4,2009-03-08,2009-03-08,4,1,0,0,1,0,2,0,0,1,0,0,1,0,1,ALLERGAN UK Limited,"A 6 MONTH, SINGLE-MASKED, MULTICENTER, RANDOMIZED, CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF 700 µg DEXAMETHASONE POSTERIOR SEGMENT DRUG DELIVERY SYSTEM APPLICATOR SYSTEM AS ADJUNTIVE THER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004416-31,0,0,0 2007-004419-69,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Impact de la TEP-TDM à la Fluorométhylcholine-(18F) sur la prise en charge de la récidive biologique occulte du cancer de la prostate. Etude multicentrique nationale de phase III. (ICHOROPRO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004419-69,0,0,0 2007-004424-20,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Helsinki Uniersity Central Hospital,HES 130/0.4 vaikutus hyytymisjärjestelmään off-pump-sepelvaltimokirurgian jälkeen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004424-20,0,0,0 2007-004426-24,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,PROSTACYCLIJN VERSUS HEPARIN AS ANTICOAGULANT IN CONTINUOUS VENO-VENOUS HEMODIAFILTRATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004426-24,0,0,0 2007-004427-38,11,2011-01-31,2011-01-31,7,0,0,0,0,2,3,0,0,2,1,0,0,0,1,ANTISOMA,Estudio abierto y aleatorizado en fase 3 de L-malato de amonafida en combinación con citarabina comparado con daunorrubicina en combinación con citarabina en pacientes con leucemia mieloide aguda (LMA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004427-38,1,0,0 2007-004427-38,11,2011-01-31,2011-01-31,7,0,0,0,0,2,3,0,0,2,1,0,0,0,1,Antisoma Research Ltd.,Estudio abierto y aleatorizado en fase 3 de L-malato de amonafida en combinación con citarabina comparado con daunorrubicina en combinación con citarabina en pacientes con leucemia mieloide aguda (LMA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004427-38,1,0,0 2007-004429-45,1,2014-10-16,2014-10-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Medical Research Council,"A randomised trial to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004429-45,0,0,0 2007-004435-30,3,2008-11-10,2008-11-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios Almirall, S.A","A RANDOMISED, 4-WEEK, PLACEBO-CONTROLLED, DOUBLE-BLIND, 6 ARM PARALLEL GROUP, DOSE-FINDING CLINICAL TRIAL, TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF THREE DIFFERENT DOSES OF FORMOTEROL (6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004435-30,0,0,0 2007-004438-18,4,2008-05-07,2008-05-07,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,A. Menarini Farmaceutica Internazionale s.r.l.,Comparative effects of Nebivolol and Carvedilol on orthostatic hypotension in hypertensive patients with type 2 diabetes mellitus (DIANECA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004438-18,0,0,0 2007-004438-18,4,2008-05-07,2008-05-07,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Menarini International Operation Luxembourg S.A.,Comparative effects of Nebivolol and Carvedilol on orthostatic hypotension in hypertensive patients with type 2 diabetes mellitus (DIANECA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004438-18,0,0,0 2007-004438-18,4,2008-05-07,2008-05-07,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Menarini International Operations, Luxembourg S.A",Comparative effects of Nebivolol and Carvedilol on orthostatic hypotension in hypertensive patients with type 2 diabetes mellitus (DIANECA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004438-18,0,0,0 2007-004442-32,7,2008-10-02,2008-10-02,6,1,0,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research and Development Ltd,"A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticaso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004442-32,1,0,0 2007-004444-71,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,FOVEA,Traitement préemptif des colonisations multiples à candida chez des patients de réanimation présentant un sepsis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004444-71,0,0,0 2007-004448-60,9,2009-03-19,2009-03-29,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Merck & Co. Inc.,"A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hyperc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004448-60,0,0,0 2007-004448-60,9,2009-03-19,2009-03-29,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Merck Sharp & Dohme GmbH,"A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hyperc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004448-60,0,0,0 2007-004448-60,9,2009-03-19,2009-03-29,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,MERCK SHARP DOHME,"A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hyperc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004448-60,0,0,0 2007-004448-60,9,2009-03-19,2009-03-29,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck and Co., Inc.","A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hyperc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004448-60,0,0,0 2007-004448-60,9,2009-03-19,2009-03-29,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Merck Sharp & Dohme BV,"A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hyperc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004448-60,0,0,0 2007-004448-60,9,2009-03-19,2009-03-29,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,MSD Finland Oy,"A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hyperc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004448-60,0,0,0 2007-004448-60,9,2009-03-19,2009-03-29,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hyperc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004448-60,0,0,0 2007-004448-60,9,2009-03-19,2009-03-29,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck, Sharp & Dohme Ireland (Human Health) Limited","A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hyperc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004448-60,0,0,0 2007-004452-36,12,2015-06-18,2015-06-18,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & développement,A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004452-36,0,0,0 2007-004452-36,12,2015-06-18,2015-06-18,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004452-36,0,0,0 2007-004458-98,7,2008-09-20,2008-09-20,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticason...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004458-98,0,0,0 2007-004459-13,5,2008-11-24,2008-11-24,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Randomized Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticaso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004459-13,0,0,0 2007-004462-40,1,2012-10-09,2012-10-09,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Tibotec BVBA,"A Phase II, placebo-controlled, double-blind, randomized trial to evaluate the anti-bacterial activity, safety, and tolerability of TMC207 in subjects with sputum smear-positive pulmonary infection wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004462-40,0,0,0 2007-004465-18,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared With a 23-Valent P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004465-18,0,0,0 2007-004466-41,6,2009-12-14,2010-12-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Ltd, Ramsgate Road, Sandwich, Kent","A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED PH-797804 (0.5, 3, 6 AND 10 MG) IN ADULTS WITH MODE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004466-41,0,0,0 2007-004470-10,1,2008-08-21,2008-08-21,1,1,0,0,0,3,4,0,1,1,0,0,1,0,0,"Institut for Sundhedstjenesteforskning, Klinisk Farmakologi, Syddansk Universitet","""Effekten af escitalopram på tramdadols farmakokinetik og farmakodynamik""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004470-10,0,0,0 2007-004473-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Laboratoires Théa,Efficacy and safety of sodium cromolyn eye drops compared with placebo eye drops in patients with a history of allergic conjunctivitis using the Conjunctival Allergen Challenge model.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004473-26,0,0,0 2007-004474-24,3,2020-12-29,2020-12-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Cologne,HD 16 for early stages: treatment optimization trial in the first-line treatment of early stage Hodgkin lymphoma; treatment stratification by means of FDG-PET.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004474-24,0,0,0 2007-004474-24,3,2020-12-29,2020-12-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,VU University Medical Center,HD 16 for early stages: treatment optimization trial in the first-line treatment of early stage Hodgkin lymphoma; treatment stratification by means of FDG-PET.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004474-24,0,0,0 2007-004480-21,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ITALFARMACO,A phase IIA study of the histone-deacetylase inhibitor ITF2357 in patients with JAK-2 V617F positive chronic myeloproliferative diseases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004480-21,0,0,0 2007-004482-18,2,2008-06-18,2008-07-18,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Ortho-McNeil Janssen Scientific Affairs, LLC",A blinded-initiation study of medication satisfaction in subjects with schizophrenia treated with paliperidone ER after suboptimal response to oral risperidone.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004482-18,0,0,0 2007-004483-41,1,,,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Effet de l’espacement des doses d’anti-TNF sur l’activité inflammatoire chez des polyarthrites rhumatoïdes en rémission ou en faible activité inflammatoire : essai randomisé contrôlé.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004483-41,0,0,0 2007-004484-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation prospective de l’efficacité du Budesonide/Formotérol chez les patients ayant développé un syndrome obstructif bronchique fixé au décours d’une allogreffe de cellules souches hématopoïétique...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004484-22,0,0,0 2007-004485-40,1,2016-02-09,2016-02-09,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude prospective, multicentrique contrôlée vs placebo, randomisée, en double insu comparant la protéine C activée, les faibles doses de corticoïdes et leur association dans le traitement du choc sept...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004485-40,0,0,0 2007-004486-17,6,2012-10-24,2012-10-24,2,1,0,1,0,2,1,0,0,2,0,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 1/PHASE 2 STUDY OF CP-751,871 IN PATIENTS WITH RELAPSED AND/OR REFRACTORY EWING S SARCOMA FAMILY OF TUMORS STUDIO DI FASE 1/FASE 2 SUL CP-751,871 IN PAZIENTI CON TUMORI DELLA FAMIGLIA DEL ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004486-17,1,0,0 2007-004486-17,6,2012-10-24,2012-10-24,2,1,0,1,0,2,1,0,0,2,0,0,0,0,1,PFIZER,"A PHASE 1/PHASE 2 STUDY OF CP-751,871 IN PATIENTS WITH RELAPSED AND/OR REFRACTORY EWING S SARCOMA FAMILY OF TUMORS STUDIO DI FASE 1/FASE 2 SUL CP-751,871 IN PAZIENTI CON TUMORI DELLA FAMIGLIA DEL ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004486-17,1,0,0 2007-004486-17,6,2012-10-24,2012-10-24,2,1,0,1,0,2,1,0,0,2,0,0,0,0,1,"Pfizer, S.A","A PHASE 1/PHASE 2 STUDY OF CP-751,871 IN PATIENTS WITH RELAPSED AND/OR REFRACTORY EWING S SARCOMA FAMILY OF TUMORS STUDIO DI FASE 1/FASE 2 SUL CP-751,871 IN PAZIENTI CON TUMORI DELLA FAMIGLIA DEL ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004486-17,1,0,0 2007-004487-53,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA PISANA,Pilot study of association of VEGF polymorphisms with clinical efficacy and tolerability of therapy in patients affected by exudative (neovascular) age-related macular degeneration.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004487-53,0,0,0 2007-004489-41,1,2009-06-23,2009-06-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"Prospective, single-arm, multi-center, open-label study to investigate the potential to reduce concomitant antipsychotics use in subjects with moderate dementia of Alzheimer’s type [DAT] treated with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004489-41,0,0,0 2007-004497-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Impact des Inhibiteurs de Tyrosine Kinase sur la fertilité masculine. GLIFERTI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004497-11,0,0,0 2007-004506-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de CAEN,Intérêt de la tocolyse dans la prise en charge des ruptures prématurées des membranes entre 24 et 34 semaines d’aménorrhée.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004506-27,0,0,0 2007-004507-36,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma GmbH,"A multicenter, open label, 2 period cross-over study to evaluate the Pharmacokinetics of an 8 week continuous treatment with 1x300mg/d and 2x300mg/d TOBI® inhaled with the PARI eFlow® rapid in Cystic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004507-36,0,0,0 2007-004512-32,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE),SYNTHESIS: A RANDOMIZED CONTROLLED TRIAL ON INTRA-ARTERIAL VERSUS INTRAVENOUS THROMBOLYSIS IN ACUTE ISCHEMIC STROKE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004512-32,0,0,0 2007-004513-33,1,2013-04-27,2013-04-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford,Comparative Evaluation of QUEtiapine-Lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in patients with bipolar depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004513-33,0,0,0 2007-004515-56,1,2013-12-31,2013-12-31,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universitätsklinik, MUG",Efficacy of ursodeoxycholic acid in the treatment of insulin resistance and vascular dysfunction in non-alcoholic fatty liver disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004515-56,0,0,0 2007-004517-34,3,2021-02-24,2021-02-24,2,0,0,0,0,2,3,0,0,2,0,0,0,0,0,Hannover Clinical Trial Center GmbH,"Allogeneic stem cell transplantation for children, adolescents and young adults with relapsed or refractory AML",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004517-34,1,0,0 2007-004517-34,3,2021-02-24,2021-02-24,2,0,0,0,0,2,3,0,0,2,0,0,0,0,0,Hannover Medical School,"Allogeneic stem cell transplantation for children, adolescents and young adults with relapsed or refractory AML",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004517-34,1,0,0 2007-004518-15,2,2008-10-06,2008-10-06,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Merck Serono International,"A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects with Lupus Nephritis in Combination with Mycophenolate Mofetil Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004518-15,0,0,0 2007-004519-67,1,2008-12-01,2008-12-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Fundació de Lluita Contra la Sida,"ENSAYO CLÍNICO PROSPECTIVO, ABIERTO Y ALEATORIZADO, SOBRE LA SEGURIDAD HEPÁTICA DEL TRATAMIENTO ANTIRRETROVIRAL QUE INCLUYE KALETRA VS NEVIRAPINA EN PACIENTES COINFECTADOS VIH/VHC. ESTUDIO KANELA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004519-67,0,0,0 2007-004521-22,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ASTRAZENECA,"Phase II, Randomised, double-blind, two-arm, parallel study of Vandetanib (ZACTIMA , ZD6474) plus Gemcitabine (Gemzar ) or Gemcitabine plus Placebo as first line treatment of advanced (stage IIIB or I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004521-22,0,0,0 2007-004524-21,1,2009-08-25,2009-08-25,1,0,0,0,0,3,2,0,1,1,0,0,1,0,0,"Medicinsk gastroenterologisk afdeling, Aalborg Sygehus S","Undersøgelse af opioiders analgetiske og anti-hyperalgesiske effekt på eksperimentelle smertemodeller i huden, musklerne og knoglerne",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004524-21,0,0,0 2007-004526-24,1,2010-03-15,2010-03-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Panacea Biotec Ltd,"A double-blind, randomized, placebo-controlled, multicentre study to assess the efficacy and safety of Euphorbia Prostrata Dry Extract Tablets in patients of 1° and 2° internal haemorrhoids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004526-24,0,0,0 2007-004528-19,1,,,0,1,0,0,1,0,4,0,0,0,0,0,0,0,0,University of Wuerzburg,Electrophysiological measurement of anterior cingulate cortex (ACC) function in schizophrenic patients treated with Seroquel® or Fluanxol®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004528-19,0,0,0 2007-004529-57,1,2011-02-24,2011-02-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Greenpark Healthcare Trust,Vascular Pleiotrophic Effects of Bisphosphonates in Post Menopausal Women with Osteoporosis: Cellular Mechanisms and Functional Consequences,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004529-57,0,0,0 2007-004530-16,5,2009-12-28,2009-12-28,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Allergan, Ltd.","A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Single Treatment Cycle, Parallel Evaluation of the Safety, Efficacy and Immunogenicity of Two Formulations of BOTOX® (Botulinum Toxin Type ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004530-16,0,0,0 2007-004535-33,1,2011-03-16,2011-03-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Universitätsklinikum Heidelberg,Phase II study on curative resectability of not optimally resectable liver and/or lung metastases from colorectal carcinoma (CRC) under intensified chemotherapy (FLOFOXIRI/Bevacizumab).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004535-33,0,0,0 2007-004538-18,1,2008-01-31,2008-01-31,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Curalogic A/S,A randomized doble-blind placebo-controlled study to assess the safety in a one-year of orally administered microencapsulated ragweed pollen extract,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004538-18,0,0,0 2007-004539-44,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,SEQUENTIAL TREATMENT STRATEGY FOR METASTATIC COLORECTAL CANCER: A PHASE III PROSPECTIVE RANDOMIZED MULTICENTER STUDY OF CHEMOTHERAPY (CT) WITH OR WITHOUT BEVACIZUMAB AS FIRST-LINE THERAPY FOLLOWED BY ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004539-44,0,0,0 2007-004541-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Johann Wolfgang Goethe-Universität Frankfurt am Main,A Randomized Controlled Open-Label Phase IV Mono Center Study to Compare the Reponse Profiles of Montelukast versus Fluticason in Children with Preschool Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004541-15,0,0,0 2007-004543-30,13,2009-11-11,2009-11-11,10,1,1,0,0,0,3,0,0,2,1,0,0,0,1,PFIZER,"A PHASE 3 PROSPECTIVE, RANDOMIZED, DOUBLE MASKED, 12 WEEK, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF LATANOPROST AND TIMOLOL IN PAEDIATRIC SUBJECTS WITH GLAUCOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004543-30,1,1,0 2007-004543-30,13,2009-11-11,2009-11-11,10,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US","A PHASE 3 PROSPECTIVE, RANDOMIZED, DOUBLE MASKED, 12 WEEK, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF LATANOPROST AND TIMOLOL IN PAEDIATRIC SUBJECTS WITH GLAUCOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004543-30,1,1,0 2007-004543-30,13,2009-11-11,2009-11-11,10,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Pfizer Inc.,"A PHASE 3 PROSPECTIVE, RANDOMIZED, DOUBLE MASKED, 12 WEEK, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF LATANOPROST AND TIMOLOL IN PAEDIATRIC SUBJECTS WITH GLAUCOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004543-30,1,1,0 2007-004543-30,13,2009-11-11,2009-11-11,10,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Pfizer S.A.,"A PHASE 3 PROSPECTIVE, RANDOMIZED, DOUBLE MASKED, 12 WEEK, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF LATANOPROST AND TIMOLOL IN PAEDIATRIC SUBJECTS WITH GLAUCOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004543-30,1,1,0 2007-004544-73,1,2009-01-26,2009-01-26,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Bayer Schering Pharma AG,"A double-blind, randomized, uncontrolled study to evaluate inhibition of ovulation of two oral estradiol / drospirenone regimens in healthy young female volunteers over a period of 3 treatment cycles",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004544-73,0,0,0 2007-004545-15,1,2011-05-03,2011-05-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Medical Center Utrecht,The Split Dose Study: Split dose Rhenium-188-HEDP regimen in hormone refractory prostate cancer patients with bone metastases; a phase I toxicity study and phase II efficacy study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004545-15,0,0,0 2007-004546-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hôpitaux Universitaires de strasbourg,ANALGESIE POSTOPERATOIRE APRES THORACOTOMIE SANS PERIDURALE THORACIQUE : INTERET DU CATHETER PARAVERTEBRAL ASSOCIE A UNE ANALGESIE MORPHINIQUE AUTOCONTROLEE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004546-33,0,0,0 2007-004549-14,1,2007-10-31,2007-10-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Department of Anaesthesie, General Intensive Care and Pain Therapy, Medical University of Vienna",A novel role for remifentanil: the reversal of established capsaicin-induced hyperalgesia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004549-14,0,0,0 2007-004553-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Roche,"Essai en ouvert, randomisé et multicentrique évaluant l’efficacité et la tolérance de l’association de l’Enfuvirtide en cure d’induction de 3 mois à un traitement optimisé (TO) comprenant au moins 2 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004553-29,0,0,0 2007-004555-11,7,2009-02-03,2009-02-03,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE AS AN ""ADD-ON"" THERAPY IN MEN WITH PERSISTENT OVERACTIVE BLADDER SYMPTOMS UNDER MONOTHERAPY OF ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004555-11,0,0,0 2007-004555-11,7,2009-02-03,2009-02-03,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE AS AN ""ADD-ON"" THERAPY IN MEN WITH PERSISTENT OVERACTIVE BLADDER SYMPTOMS UNDER MONOTHERAPY OF ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004555-11,0,0,0 2007-004559-12,2,2008-09-29,2008-09-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Speedel Pharma Ltd.,"A Phase II a, Double-Blind, Randomized, Parallel-Design, Four-week Study to Investigate the Efficacy and Safety of Two Different Doses of the Renin-inhibitor SPP635 Once Daily in Type II Diabetic Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004559-12,0,0,0 2007-004562-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Gynecologic Oncology Group,"A PHASE II EVALUATION OF TOPOTECAN ADMINISTERED WEEKLY IN THE TREATMENT OF RECURRENT PLATINUM-SENSITIVE OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004562-40,0,0,0 2007-004568-27,7,2012-05-07,2022-07-27,5,0,0,0,0,0,3,0,0,2,1,0,0,0,1,GlaxoSmithKline Research and Development Ltd,"A Randomised, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/neu Positive Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004568-27,1,0,0 2007-004568-27,7,2012-05-07,2022-07-27,5,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,"A Randomised, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/neu Positive Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004568-27,1,0,0 2007-004568-27,7,2012-05-07,2022-07-27,5,0,0,0,0,0,3,0,0,2,1,0,0,0,1,GlaxoSmithKline S. A.,"A Randomised, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women With HER2/neu Positive Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004568-27,1,0,0 2007-004574-11,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Daiichi Sankyo Development Limited,"RANDOMISED, DOUBLE-BLINDED, PLACEBO- CONTROLLED PHASE 2 STUDY OF CS-1008 IN COMBINATION WITH CARBOPLATIN/PACLITAXEL IN CHEMOTHERAPY NAÏVE SUBJECTS WITH METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004574-11,0,0,0 2007-004578-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dutch Heart Foundation,"A randomised, double blind placebo controlled trial to (A) assess the optimal vitamin K dosage for supplementation, and (B) to access whether complications of anticoagulation treatment will diminish b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004578-15,0,0,0 2007-004579-21,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University Medical Center Groningen,Does booster influenza vaccination improve vaccination efficacy in patients with quiescent systemic lupus erythematosus?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004579-21,0,0,0 2007-004580-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasme Hostpital - ULB,3T versus 1.5 T MR cholangiography using Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic acid (Primovist),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004580-21,0,0,0 2007-004584-22,1,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,1,AstraZeneca AB,"A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD9668 on Airway Inflammation as Assessed in Induced Sputum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004584-22,0,0,0 2007-004585-40,10,2010-11-30,2010-12-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 1356 (5.0 mg, administered orally once daily) compared to glimepiride (1 to 4 mg once daily) over two yea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004585-40,0,0,0 2007-004585-40,10,2010-11-30,2010-12-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,"A randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 1356 (5.0 mg, administered orally once daily) compared to glimepiride (1 to 4 mg once daily) over two yea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004585-40,0,0,0 2007-004585-40,10,2010-11-30,2010-12-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 1356 (5.0 mg, administered orally once daily) compared to glimepiride (1 to 4 mg once daily) over two yea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004585-40,0,0,0 2007-004585-40,10,2010-11-30,2010-12-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd,"A randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 1356 (5.0 mg, administered orally once daily) compared to glimepiride (1 to 4 mg once daily) over two yea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004585-40,0,0,0 2007-004585-40,10,2010-11-30,2010-12-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 1356 (5.0 mg, administered orally once daily) compared to glimepiride (1 to 4 mg once daily) over two yea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004585-40,0,0,0 2007-004585-40,10,2010-11-30,2010-12-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 1356 (5.0 mg, administered orally once daily) compared to glimepiride (1 to 4 mg once daily) over two yea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004585-40,0,0,0 2007-004585-40,10,2010-11-30,2010-12-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim UK Ltd.,"A randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 1356 (5.0 mg, administered orally once daily) compared to glimepiride (1 to 4 mg once daily) over two yea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004585-40,0,0,0 2007-004585-40,10,2010-11-30,2010-12-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 1356 (5.0 mg, administered orally once daily) compared to glimepiride (1 to 4 mg once daily) over two yea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004585-40,0,0,0 2007-004586-17,3,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,OM PHARMA,"Multicentre, double-blind, placebo controlled randomised clinical study of URO-VAXOM® in female patients suffering from uncomplicated recurrent urinary tract infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004586-17,0,0,0 2007-004590-25,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Medical University of Vienna,Determination of immune response after sequential pneumococcal vaccination using the 7-valent conjugate pneumococcal and the 23-valent pneumococcal polysaccharide vaccine in renal transplant recipient...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004590-25,0,0,0 2007-004603-35,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,University of Heidelberg,"Radiotherapy (IMRT), Erbitux And Chemotherapy For Unresectable Carcinomas Of Head and Neck. REACH-Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004603-35,0,0,0 2007-004608-11,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, parallel group study to investigate the safety and tolerability of 14-days treatment with an inhaled dose of QMF149 (500/800) in mild to moderate asthma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004608-11,0,0,0 2007-004609-85,3,2011-12-22,2011-12-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,OM PHARMA,"Multicentre, randomised, double-blind, placebo-controlled clinical study to assess the efficacy and safety of UroVaxom in chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004609-85,0,0,0 2007-004609-85,3,2011-12-22,2011-12-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,OM Pharma SA,"Multicentre, randomised, double-blind, placebo-controlled clinical study to assess the efficacy and safety of UroVaxom in chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004609-85,0,0,0 2007-004611-61,1,2012-03-12,2012-03-12,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Hochschule Hannover (MHH),"Prospektive, randomisierte, monozentrische 2-armige Studie zum Einsatz von Daptomycin in der antibiotischen Prophylaxe von sternalen Wundinfektionen nach medianer Sternotomie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004611-61,0,0,0 2007-004612-31,1,2010-04-21,2010-04-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CSL Behring GmbH,Efficacy and safety of Haemocomplettan® P in patients experiencing acute bleeding while undergoing aortic replacement surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004612-31,0,0,0 2007-004613-34,2,2015-12-31,2015-12-31,1,0,0,1,0,0,1,0,0,2,0,0,0,0,0,"The Centre for Child and Adolescent Mental Health, Eastern and Southern Norway (R-BUP)","Nordic Longterm OCD treatment Study: A Nordic Multicenter treatment study evaluating a stepped care model based on the ""Expert Clinical Guidelines"". The study is performed with no sponsor from pharmac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004613-34,1,0,0 2007-004613-34,2,2015-12-31,2015-12-31,1,0,0,1,0,0,1,0,0,2,0,0,0,0,0,"The Centre for Child and Adolescent Mental Health, Eastern and Southern Norway (R.BUP)","Nordic Longterm OCD treatment Study: A Nordic Multicenter treatment study evaluating a stepped care model based on the ""Expert Clinical Guidelines"". The study is performed with no sponsor from pharmac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004613-34,1,0,0 2007-004614-14,22,2010-09-30,2010-11-24,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"MAGELLAN - Estudio Multicéntrico, Aleatorizado, de Grupos paralelos, para evaluar la superioridad de la Eficacia de rivaroxabAN frente enoxaparina en la profilaxis de sujetos médicos hospitalizados.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004614-14,0,0,0 2007-004614-14,22,2010-09-30,2010-11-24,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER,"MAGELLAN - Estudio Multicéntrico, Aleatorizado, de Grupos paralelos, para evaluar la superioridad de la Eficacia de rivaroxabAN frente enoxaparina en la profilaxis de sujetos médicos hospitalizados.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004614-14,0,0,0 2007-004616-31,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,0,Universitair Medisch Cemtrum Utrecht,Prevention of neutrophil induced extracellular matrix damage following skin exposure to solar simulating radiation (SSR),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004616-31,0,0,0 2007-004617-34,1,2010-03-11,2010-03-11,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,F. Hoffmann-La Roche Ltd,A phase I/II study of Invirase® boosted with Ritonavir in HIV infected infants and children 4 months to less than 6 years old,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004617-34,0,0,0 2007-004620-20,1,2013-01-01,2013-01-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,department of Pharmacology-Toxicology RUNMC,Persantin Preceding PCI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004620-20,0,0,0 2007-004622-25,1,2008-11-07,2008-11-07,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,ArQule Inc.,A Randomized Phase 2 Study of ARQ 197 versus Investigator’s Choice of Second-Line Chemotherapy in Patients with Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Fo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004622-25,0,0,0 2007-004625-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU University Medical Centre,A phase II study of erlotinib and sorafenib in patients with locally advanced and/or metastatic (stage IIIB or IV) Non-Small cell lung cancer (NSCLC) who have not received prior chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004625-14,0,0,0 2007-004627-38,6,2008-05-15,2008-05-15,6,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Astion Pharma A/S,"Efficacy and safety of ASF 1057 cream 0.5% in the treatment of seborrhoeic dermatitis: A phase III randomised, double-blind, vehicle- and placebo controlled, parallel groups, multi-centre trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004627-38,0,0,0 2007-004632-24,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ARTBC,OPTIMAL CONTROL OF LIVER METASTASES WITH INTRAVENOUS CETUXIMAB AND HEPATIC ARTERY INFUSION OF THREE-DRUG CHEMOTHERAPY IN PATIENT WITH LIVER-ONLY METASTASES FROM COLORECTAL CANCER. A PHASE II TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004632-24,0,0,0 2007-004633-41,2,2009-03-09,2009-03-09,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,TransPharma Medical,"A Multicenter, Randomized, Parallel Study to Assess the Clinical Efficacy, Safety, and Tolerability of ViaDerm-hPTH (1-34) (Double-Blinded for 2 Different Dosages) in Comparison to Subcutaneous Inject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004633-41,0,0,0 2007-004634-17,2,2011-05-19,2011-05-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ArQule Inc.,A Randomized Phase 2 Study of Erlotinib plus ARQ 197 versus Erlotinib plus Placebo in Previously Treated Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004634-17,0,0,0 2007-004635-29,3,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Astion Pharma A/S,"Estudio aleatorizado, controlado con placebo, internacional, multicéntrico, doble ciego, de confirmación de dosis, para evaluar la seguridad y la eficacia de la crema ASF-1096 0,25%, 0,5% y 1% y place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004635-29,0,0,0 2007-004640-78,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Intra-Cellular Therapies, Inc","A randomized, double-blind, placebo-controlled, 4-way crossover study of ITI-007 in subjects with sleep maintenance insomnia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004640-78,0,0,0 2007-004642-32,1,2012-06-17,2012-06-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of East Anglia,THE EFFECT OF THEOPHYLLINE IN PATIENTS WITH RHINITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004642-32,0,0,0 2007-004644-70,2,2019-04-15,2019-04-15,1,0,0,0,0,0,3,0,0,1,1,0,1,0,0,GOELAMS,"Etude de phase III ouverte, randomisée portant sur l’intérêt d’un traitement d’entretien par rituximab en post-autogreffe dans le traitement des lymphomes à cellules du manteau chez des patients âgés ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004644-70,0,0,0 2007-004645-15,5,2015-07-10,2015-07-10,3,1,1,0,0,0,1,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.","Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004645-15,1,1,0 2007-004645-15,5,2015-07-10,2015-07-10,3,1,1,0,0,0,1,0,0,2,1,0,0,0,1,"Schering Plough Research Institute, A Division of Schering Corporation","Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004645-15,1,1,0 2007-004645-15,5,2015-07-10,2015-07-10,3,1,1,0,0,0,1,0,0,2,1,0,0,0,1,Schering Plough Research Institute,"Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004645-15,1,1,0 2007-004645-15,5,2015-07-10,2015-07-10,3,1,1,0,0,0,1,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004645-15,1,1,0 2007-004646-33,6,2011-05-25,2011-06-15,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"A Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Study to Assess the Safety and Efficacy of Doripenem Compared With Imipenem in the Treatment of Subjects with Ventilator-Associated P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004646-33,0,0,0 2007-004648-54,2,2008-05-15,2008-05-15,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Astion Pharma A/S,"Efficacy and safety of ASF-1057 cream 0.5% in the treatment of seborrhoeic dermatitis: A phase III randomised, multi-centre, double-blind, active comparator (ketoconazole cream 2%) and placebo control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004648-54,0,0,0 2007-004649-14,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Astion Pharma A/S,Safety of ASF 1057 cream 0.5% under long term use in the treatment of seborrhoeic dermatitis: A 12 month open label extension multi-centre phase III trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004649-14,0,0,0 2007-004650-93,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,The effect of Botulinum toxin A injections for overactive bladder on detrusor contractility,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004650-93,0,0,0 2007-004651-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Oscar Lambret,Etude de phase II multicentrique stratifiée évaluant l’efficacité et la toxicité du Sorafenib dans le traitement des angiosarcomes localement avancés ou métastatiques non accessibles à une chirurgie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004651-10,0,0,0 2007-004652-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HOSPICES CIVILS DE LYON,Étude randomisée multicentrique de l’efficacité du méthotrexate (MTX) comprimés versus ciclosporine (Cy) capsules dans la dermatite atopique (DA) de forme modérée à sévère de l’adulte,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004652-36,0,0,0 2007-004653-29,5,2011-11-21,2011-11-21,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, multi-center, double-blind, placebo-controlled, parallel-group trial to explore the effects of 78 weeks omalizumab treatment as add on therapy on airway inflammation and remodeling in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004653-29,0,0,0 2007-004653-29,5,2011-11-21,2011-11-21,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,NovartisPharma Services AG,"A randomized, multi-center, double-blind, placebo-controlled, parallel-group trial to explore the effects of 78 weeks omalizumab treatment as add on therapy on airway inflammation and remodeling in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004653-29,0,0,0 2007-004654-81,1,2008-06-10,2008-06-10,1,0,0,0,1,0,2,0,0,1,1,1,1,0,1,Summit (Cambridge) Ltd.,A phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a combination treatment for reducing saliva secretion in Parkinson’s disease patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004654-81,0,0,0 2007-004660-47,1,2008-08-28,2008-08-28,1,0,0,0,0,0,2,0,1,1,1,1,1,0,1,BioCryst Pharmaceuticals Inc,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Virologic Activity, Safety, and Pharmacodynamics of Intravenous Peramivir for the Treatment of Experimental Influenza",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004660-47,0,0,0 2007-004663-22,2,2011-01-21,2011-01-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Norgine Limited,"A multi-centre, open short term follow-up Phase II study to evaluate the clearance of NRL972 in patients undergoing alcohol withdrawal commencing in a controlled clinical setting.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004663-22,0,0,0 2007-004664-46,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,No Sponsor,Influence of methylphenidate on sleep and circadian rhythm in children with Attention-Deficit/Hyperactivity Disorder (ADHD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004664-46,0,0,0 2007-004669-17,3,2010-01-13,2010-01-13,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multi-center, open-label, Proof of Concept (PoC) study to evaluate the efficacy and tolerability of STI571 for the treatment of fibrosis in patients with systemic sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004669-17,0,0,0 2007-004669-17,3,2010-01-13,2010-01-13,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, open-label, Proof of Concept (PoC) study to evaluate the efficacy and tolerability of STI571 for the treatment of fibrosis in patients with systemic sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004669-17,0,0,0 2007-004671-19,3,2011-09-22,2011-09-22,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Allos Therapeutics, Inc.","A Phase 2, Single-Arm Study of Pralatrexate in Patients with Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004671-19,1,0,0 2007-004673-26,1,2011-05-25,2011-05-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Allos Therapeutics Inc.,","Protocol PDX-012: A Randomized, Phase 2b, Multi-center Study of Pralatrexate Versus Erlotinib in Patients with Stage IIIB/IV Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004673-26,0,0,0 2007-004674-49,1,2010-08-18,2010-08-18,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Charité - Universitätsmedizin Berlin,Levosimendan vor Herz-Lungen-Maschine bei Coronary artery bypass graft-Operationen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004674-49,0,0,0 2007-004675-19,1,2011-02-18,2011-02-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of East Anglia,THE EFFECTS OF SIMVASTATIN IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004675-19,0,0,0 2007-004683-45,1,2009-05-11,2009-05-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCHERING-PLOUGH,An exploratory study of mometasone furoate nasal spray in patients with moderate-severe persistent allergic rhinitis and intermittent asthma: effects on the quality of life evaluated with the Rhinasth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004683-45,0,0,0 2007-004684-22,1,2008-08-05,2008-08-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An exploratory, double-blind, randomized, placebocontrolled, 2-way cross-over study to assess the effect of repeat-dose inhaled indacaterol maleate (300 mcg) on dynamic and static lung hyperinflation,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004684-22,0,0,0 2007-004686-18,3,2009-07-27,2009-07-27,3,1,0,0,1,0,0,0,0,1,0,0,1,0,1,Bausch&Lomb Dr Gerhard Mann chem.-Fabrik GmbH,"A multicenter, Investigator-Masked, Parallel Group, Randomized, Study of the Efficacy and Safety of Indomethacin 0.1 % Eyedrops Compared with Ketorolac 0.5% Eyedrops in the Ocular Inflammation After C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004686-18,0,0,0 2007-004686-18,3,2009-07-27,2009-07-27,3,1,0,0,1,0,0,0,0,1,0,0,1,0,1,Dr. Gerhard Mann chem.-pharm. Fabrik GmbH,"A multicenter, Investigator-Masked, Parallel Group, Randomized, Study of the Efficacy and Safety of Indomethacin 0.1 % Eyedrops Compared with Ketorolac 0.5% Eyedrops in the Ocular Inflammation After C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004686-18,0,0,0 2007-004687-47,11,2009-11-23,2009-12-28,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. K.G.,"A Phase 3, Multicenter, Randomized, Double-Blind Study Comparing the Safety and Efficacy of ABT-874 to Methotrexate in Subjects with Moderate to Severe Chronic Plaque Psoriasis, Incorporating Amendmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004687-47,0,0,0 2007-004689-42,1,2010-09-15,2010-09-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Belfast Health and Social Care Trust,Insulin action and hypertension: effects of hyperaldosteronism and its treatment.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004689-42,0,0,0 2007-004692-19,5,2016-12-22,2016-12-22,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,BIOTEST AG,"Prevention of congenital cytomegalovirus infection in infants of mothers with primary cytomegalovirus during pregnancy. A randomised, open, controlled, prospective, multicentre and multinational stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004692-19,0,0,0 2007-004692-19,5,2016-12-22,2016-12-22,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Biotest AG,"Prevention of congenital cytomegalovirus infection in infants of mothers with primary cytomegalovirus during pregnancy. A randomised, open, controlled, prospective, multicentre and multinational stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004692-19,0,0,0 2007-004693-34,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA,"Multicenter, phase II study of chemotherapy with dose-dense modified TCF in locally advanced or metastatic gastric cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004693-34,0,0,0 2007-004694-26,1,2012-09-04,2012-09-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Saint-Luc Universitary Hospital,"A Comparative Study Of A 6-Month Infliximab (Remicade) Or Placebo Regimen In Undifferentiated Arthritis At High Risk For The Development Of Rheumatoid Arthritis : Clinical, Radiological (MRI) And Syno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004694-26,0,0,0 2007-004695-39,1,2011-06-08,2011-06-08,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"AVI BioPharma, Inc.",Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004695-39,0,0,0 2007-004699-38,1,2009-11-24,2009-11-24,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Klinikum der Universität Regensburg,"A prospective phase I/II, one-arm, multi-center, open label study of pioglitazone in combination with sorafenib and low dose IFN alpha in metastatic, non-resectable renal clear cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004699-38,0,0,0 2007-004702-27,4,2010-04-21,2010-06-22,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,OM PHARMA,"Multicentre, double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom (Broncho-Munal) for the protection from acute exacerbations of COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004702-27,0,0,0 2007-004714-14,1,2009-11-10,2009-11-10,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,"Aarhus University Hospital, Aarhus Sygehus",The effect of glitazone-treatment on bone turn-over and bone marrow cells,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004714-14,0,0,0 2007-004716-31,1,,,0,0,0,0,0,1,4,0,0,1,0,0,0,1,0,Dutch Growth Foundation,"Effects of growth hormone treatment after final height in Prader-Willi Syndrome: A double-blind multicenter, cross-over study on the effects of growth hormone versus placebo on body composition and ps...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004716-31,0,0,0 2007-004720-20,6,2010-03-16,2010-10-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004720-20,0,0,0 2007-004720-20,6,2010-03-16,2010-10-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,VERTEX PHARMACEUTICALS INCOPORATED,A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004720-20,0,0,0 2007-004721-23,1,2015-06-30,2015-06-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Klinikum Bremen-Mitte gGmbH,Prevention of vision loss in patients with age-related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004721-23,0,0,0 2007-004722-25,2,2010-11-04,2010-11-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,A Phase 1b/2 Trial of AMG 655 in Combination with Panitumumab in Subjects with Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004722-25,0,0,0 2007-004723-37,4,2008-09-03,2008-10-24,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"ONO Pharmaceutical Co., Ltd.","A Phase II multi-centre, extension study to investigate the long term safety of ONO-2506PO in patients diagnosed with Amyotrophic Lateral Sclerosis (ALS).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004723-37,0,0,0 2007-004724-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hôpitaux Universitaires de Strasbourg,INTERET DES STATINES DANS LE RETRECISSEMENT AORTIQUE CHIRURGICAL : DU PRECONDITIONNEMENT MYOCARDIAQUE A L’INVERSION DU REMODELAGE VENTRICULAIRE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004724-21,0,0,0 2007-004726-24,9,2009-05-21,2009-12-10,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, double-blind, randomized, parallel-group study to evaluate the safety, tolerability, and efficacy of once daily amlodipine/valsartan 5/80 mg as compared to amlodipine/valsartan 5/40 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004726-24,0,0,0 2007-004726-24,9,2009-05-21,2009-12-10,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A multicenter, double-blind, randomized, parallel-group study to evaluate the safety, tolerability, and efficacy of once daily amlodipine/valsartan 5/80 mg as compared to amlodipine/valsartan 5/40 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004726-24,0,0,0 2007-004726-24,9,2009-05-21,2009-12-10,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multicenter, double-blind, randomized, parallel-group study to evaluate the safety, tolerability, and efficacy of once daily amlodipine/valsartan 5/80 mg as compared to amlodipine/valsartan 5/40 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004726-24,0,0,0 2007-004729-16,8,2009-09-14,2009-09-14,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ViroPharma Incorporated,"A RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR VERSUS ORAL GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECIPIENTS OF ORTHOTOPIC LI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004729-16,0,0,0 2007-004729-16,8,2009-09-14,2009-09-14,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,VIROPHARMA INCORPORATED,"A RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR VERSUS ORAL GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECIPIENTS OF ORTHOTOPIC LI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004729-16,0,0,0 2007-004732-23,3,2009-09-17,2009-12-22,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,EMET Pharmaceuticals LLC,"A MULTICENTER, RANDOMIZED, BLINDED, PLACEBO CONTROLLED, PARALLEL DESIGN, THREE-ARM, BIOEQUIVALENCE STUDY WITH CLINICAL ENDPOINTS COMPARING MESALAMINE DELAYED RELEASE TABLETS 400mg TO THE REFERENCE LIS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004732-23,0,0,0 2007-004732-23,3,2009-09-17,2009-12-22,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"EMET Pharmaceuticals, LLC","A MULTICENTER, RANDOMIZED, BLINDED, PLACEBO CONTROLLED, PARALLEL DESIGN, THREE-ARM, BIOEQUIVALENCE STUDY WITH CLINICAL ENDPOINTS COMPARING MESALAMINE DELAYED RELEASE TABLETS 400mg TO THE REFERENCE LIS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004732-23,0,0,0 2007-004733-41,3,2008-08-04,2008-11-06,2,1,0,0,2,0,2,0,0,1,1,0,1,0,1,Pfizer. S.A,"A RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF [S,S]-REBOXETINE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATHY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004733-41,0,0,0 2007-004733-41,3,2008-08-04,2008-11-06,2,1,0,0,2,0,2,0,0,1,1,0,1,0,1,Pfizer Ltd,"A RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF [S,S]-REBOXETINE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATHY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004733-41,0,0,0 2007-004734-17,1,2010-01-21,2010-01-21,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,Terho Heikkinen,"A double-blind, randomized, placebo-controlled study of early oseltamivir treatment of influenza in children 1-3 years of age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004734-17,0,0,0 2007-004736-23,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Gilead Sciences Inc.,"A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination with Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004736-23,0,1,1 2007-004737-42,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,0,University Hospital Ghent,Moviprep versus fleet phospho-soda (golden standard): een vergelijkende studie van laxativa als voorbereiding van de darm op een chirurgische ingreep,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004737-42,0,0,0 2007-004740-79,6,2009-10-01,2010-02-09,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,AstraZeneca GmbH,"A One-Year Randomized, Prospective, Parallel, Open Comparison of Subjective Well-being in Schizophrenic Out-patients Treated with Quetiapine XR (SEROQUEL XR™) or Oral Risperidone at Flexible Dose in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004740-79,0,0,0 2007-004740-79,6,2009-10-01,2010-02-09,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,ASTRAZENECA,"A One-Year Randomized, Prospective, Parallel, Open Comparison of Subjective Well-being in Schizophrenic Out-patients Treated with Quetiapine XR (SEROQUEL XR™) or Oral Risperidone at Flexible Dose in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004740-79,0,0,0 2007-004746-33,2,2009-04-05,2009-04-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare Pharmaceuticals INC,"A multicenter, randomized, double-blind, crossover, phase 3 study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist®) in patients referred for contrast-enhanced MRI of the central...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004746-33,0,0,0 2007-004749-14,1,2009-06-30,2009-06-30,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Christie Hospital NHS Foundation Trust,Assessing the Feasibility of a Single Blind Randomised Controlled Trial to Measure the Effectiveness of D-Alpha-Tocopherol in the Management of Oral Mucositis in Patients Undergoing Conditioning for B...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004749-14,0,0,0 2007-004754-82,1,2010-10-22,2010-10-22,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity after One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004754-82,0,0,0 2007-004755-11,1,2021-07-01,2021-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"University Hospital, Catholic University of Leuven",Vitamin D as treatment for COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004755-11,0,0,0 2007-004757-28,1,2013-05-10,2013-05-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leeds,A randomised controlled single-blind trial to compare intensive management vs standard care in early psoriatic arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004757-28,0,0,0 2007-004760-49,1,2009-08-28,2009-08-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,Do Xanthine Oxidase Inhibitors reduce both Left Ventricular Hypertrophy and Vascular Dysfunction in Cardiovascular patients with Renal Dysfunction?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004760-49,0,0,0 2007-004761-17,6,2010-09-14,2010-09-14,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Seattle Genetics, Inc.","A Phase IIB, Randomized, Double-Blinded, Placebo-Controlled Study of Low Dose Cytarabine and Lintuzumab Compared to Low Dose Cytarabine and Placebo in Patients 60 Years of Age and Older with Previousl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004761-17,0,0,0 2007-004762-40,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Dept. Pharmacology and Toxicology,Rosuvastatin augments dipyridamole induced vasodilation by increased adenosine receptor stimulation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004762-40,0,0,0 2007-004766-40,1,2012-03-15,2012-03-15,1,1,0,0,1,0,2,0,0,1,1,1,1,0,0,University of Nottingham,Rapid Intervention with GTN in Hypertensive stroke Trial (RIGHT). Determining the potential of ambulance-based randomised controlled trials in patients with hyperacute stroke; assessment of glyceryl t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004766-40,0,0,0 2007-004768-32,7,2012-04-02,2012-04-02,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",LONG TERM SAFETY AND EFFICACY STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004768-32,0,0,0 2007-004768-32,7,2012-04-02,2012-04-02,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer S.A.,LONG TERM SAFETY AND EFFICACY STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004768-32,0,0,0 2007-004768-32,7,2012-04-02,2012-04-02,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Inc.,LONG TERM SAFETY AND EFFICACY STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004768-32,0,0,0 2007-004772-39,1,2009-03-20,2009-03-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Sahlgrenska Acadademy, GU",AN EXPLORATORY OPEN LABEL STUDY OF ADJUNCTIVE L-LYSINE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004772-39,0,0,0 2007-004779-21,1,2008-11-20,2008-11-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Radius Health, Inc","A Randomized, Parallel-Group, Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women with Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004779-21,0,0,0 2007-004782-18,9,2009-02-27,2010-11-11,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,LEO Pharmaceuticals Products Ltd. A/S (LEO Pharma A/S),Calcipotriol Plus Hydrocortisone in Psoriasis Vulgaris on the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004782-18,0,0,0 2007-004782-18,9,2009-02-27,2010-11-11,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,LEO Pharma A/S,Calcipotriol Plus Hydrocortisone in Psoriasis Vulgaris on the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004782-18,0,0,0 2007-004782-18,9,2009-02-27,2010-11-11,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S),Calcipotriol Plus Hydrocortisone in Psoriasis Vulgaris on the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004782-18,0,0,0 2007-004786-17,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,OSPEDALE FATEBENEFRATELLI E OFTALMICO DI MILANO,Tailor (Tarceva Italian Lung Optimization tRial) Optimization of erlotinib for the treatment of patients with advanced non small cell lung cancer: an Italian randomised trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004786-17,0,0,0 2007-004787-49,2,2009-03-26,2010-09-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc - 235 East 42nd Street, New York, NY 10017","A PHASE II, SINGLE ARM STUDY OF CP-751,871 IN PATIENTS WITH REFRACTORY METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004787-49,0,0,0 2007-004787-49,2,2009-03-26,2010-09-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A PHASE II, SINGLE ARM STUDY OF CP-751,871 IN PATIENTS WITH REFRACTORY METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004787-49,0,0,0 2007-004790-25,1,2008-11-03,2008-11-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Leipzig,Evaluation of the benefit of fluorescence diagnostics using Metvix® and the Dyaderm system for the preoperational estimation of the lateral tumour spread in basal cell carcinomas.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004790-25,0,0,0 2007-004791-39,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Vejle Hospital,Et prospektivt randomiseret fase II studie til evaluering af Gabapentin og Venlafaxin´s virkning mod hedestigninger hos kvinder opereret for brystkræft og i antihormonbehandling i form af aromata...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004791-39,0,0,0 2007-004795-39,3,2008-11-25,2012-09-17,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,LIGHT SCIENCES ONCOLOGY,A PHASE 3 RANDOMIZED STUDY TO EVALUATE SURVIVAL OF PATIENTS TREATED WITH TALAPORFIN SODIUM (LS11) AND INTERSTITIAL LIGHT EMITTING DIODES (LED) AS COMPARED TO THE STANDARD OF CARE THERAPIES IN THE TR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004795-39,0,0,0 2007-004795-39,3,2008-11-25,2012-09-17,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Light Sciences Oncology Inc.,A PHASE 3 RANDOMIZED STUDY TO EVALUATE SURVIVAL OF PATIENTS TREATED WITH TALAPORFIN SODIUM (LS11) AND INTERSTITIAL LIGHT EMITTING DIODES (LED) AS COMPARED TO THE STANDARD OF CARE THERAPIES IN THE TR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004795-39,0,0,0 2007-004797-79,1,2007-11-24,2007-11-24,1,1,0,0,0,0,3,1,1,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare,A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004797-79,0,0,0 2007-004803-36,14,2017-11-13,2017-11-13,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim International GmbH,"Multicentre, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004803-36,0,0,0 2007-004803-36,14,2017-11-13,2017-11-13,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"Multicentre, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004803-36,0,0,0 2007-004805-80,1,2009-08-28,2009-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast cancer after failure of trastuzumab therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004805-80,0,0,0 2007-004806-28,1,2012-06-30,2012-06-30,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,GERCOR,An Open-label Phase II Clinical trial of Panitumumab in Combination with Irinotecan for Patients with Advanced Metastatic Colorectal Cancer without KRAS mutation (Wild type) in third line chemotherapy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004806-28,0,0,0 2007-004807-37,4,2008-10-21,2008-10-24,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"Study B2C111045, A Dose-Finding Study of GW642444 versus Placebo in Patients with COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004807-37,0,0,0 2007-004814-15,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"Radiochemotherapy in association with capecitabine and oxaliplatin in the treatment of pancreatic and biliary tract, unresectable cancer: a dose escalation study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004814-15,0,0,0 2007-004817-33,15,2010-10-01,2010-11-01,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche&développement,"A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjusted-d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004817-33,0,0,0 2007-004817-33,15,2010-10-01,2010-11-01,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche&de'veloppement,"A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjusted-d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004817-33,0,0,0 2007-004819-54,3,2016-09-09,2016-09-09,1,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Prosensa Holding B.V.,"A phase I/II, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO051 in patients with Duchenne muscular dystr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004819-54,0,0,0 2007-004819-54,3,2016-09-09,2016-09-09,1,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Prosensa Therapeutics BV,"A phase I/II, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO051 in patients with Duchenne muscular dystr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004819-54,0,0,0 2007-004822-26,1,2011-08-31,2011-08-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Birmingham Children's Hospital,A randomised pilot trial of a steroid-free immunosuppressant regimen in paediatric liver transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004822-26,0,0,0 2007-004823-39,11,2016-04-11,2016-07-14,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Celgene Corporation,"A PHASE III, RANDOMIZED, OPEN-LABEL, 3-ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) PLUS LOW-DOSE DEXAMETHASONE WHEN GIVEN UNTIL PROGRESSIVE DISEASE OR FOR 18 FOUR-WEEK CY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004823-39,0,0,0 2007-004824-19,1,2010-06-24,2010-06-24,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Roche Austria GmbH,Bevacizumab in Chronic Lymphocytic Leukemia: a proof of concept study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004824-19,0,0,0 2007-004825-35,1,2009-05-20,2009-05-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Lluita contra la SIDA,ENSAYO CLÍNICO PILOTO PARA EVALUAR LA SEGURIDAD DE LA REDUCCION DE DOSIS DE RITONAVIR EN PACIENTES INFECTADOS POR EL VIH EN TRATAMIENTO CON TIPRANAVIR/RITONAVIR 500/200 MG CADA 12 HORAS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004825-35,0,0,0 2007-004831-47,1,2007-12-13,2007-12-13,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Linde Gas Therapeutics,"Topical Wound Oxygen vs. Compression Therapy in the Management of Refractory, Non-Healing Venous Leg Ulcers; A prospective Randomised Controlled Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004831-47,0,0,0 2007-004833-40,2,2009-02-17,2009-02-18,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & developpement,"A randomized, double blind, placebo controlled study evaluating the glycemic effect of rimonabant added to metformin in patients with type 2 diabetes insufficiently controlled with metformin monothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004833-40,0,0,0 2007-004834-18,1,2009-02-18,2009-02-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,"PHARMACOKINETIC COMPARISON OF ADVATE rAHF-PFM WITH RECOMBINATE rAHF IN PATIENTS WITH SEVERE HEMOPHILIA A: A PHASE IV, PROSPECTIVE, RANDOMIZED, CONTROLLED, CROSS-OVER, SINGLE CENTER STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004834-18,0,0,0 2007-004837-41,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,DiaMedica Inc.,"A phase IIa, placebo controlled, randomized, cross-over study to evaluate the effects of DM-83 on a meal tolerance test in subjects with type 2 diabetes mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004837-41,0,0,0 2007-004840-60,2,2009-06-24,2009-06-24,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,M's Science Corporation,"A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Phase IIa Study of Safety and Motor Function Restoration in Subjects Treated with SA4503 following Acute Ischemic Stroke",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004840-60,0,0,0 2007-004844-59,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Novartis Pharma Services AG,"A two part, randomized, placebo controlled study to evaluate the pharmacokinetics and cardiovascular pharmacodynamics of AEB071 in combination with ritonavir in healthy volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004844-59,0,0,0 2007-004845-14,1,2011-12-28,2011-12-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A single-arm, multinational, two year study evaluating the efficacy and safety of lead-in telbivudine for 24 weeks with or without tenofovir treatment intensification in adult patients with HBeAg-posi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004845-14,0,0,0 2007-004851-12,1,,,0,0,0,0,1,0,4,0,0,3,0,0,0,0,0,Whittington Hospital NHS Trust,Prospective randomised cross over comparison on the physiological response to non-invasive ventilation using either Air O2 or Heliox21,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004851-12,0,0,0 2007-004853-27,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,"A phase IV monocentre study to evaluate palonosetron in nausea/vomiting prevention in patients with breast or colon cancer, treated with moderately aemotogenic chemotherapic agents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004853-27,0,0,0 2007-004854-97,13,2009-05-27,2010-05-27,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Ltd,"OPEN-LABEL, NON-COMPARATIVE, STUDY OF INTRAVENOUS ANIDULAFUNGIN, FOLLOWED OPTIONALLY BY ORAL VORICONAZOLE OR FLUCONAZOLE THERAPY, FOR TREATMENT OF DOCUMENTED CANDIDEMIA/INVASIVE CANDIDIASIS IN INTE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004854-97,0,0,0 2007-004854-97,13,2009-05-27,2010-05-27,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER,"OPEN-LABEL, NON-COMPARATIVE, STUDY OF INTRAVENOUS ANIDULAFUNGIN, FOLLOWED OPTIONALLY BY ORAL VORICONAZOLE OR FLUCONAZOLE THERAPY, FOR TREATMENT OF DOCUMENTED CANDIDEMIA/INVASIVE CANDIDIASIS IN INTE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004854-97,0,0,0 2007-004856-35,1,2011-05-02,2011-05-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London,Scavenging free haemoglobin atenuates the systemic inflmmatory response following surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004856-35,0,0,0 2007-004857-27,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich",Ventral striatal function in patients with schizophrenia before and under medication with atypical antipsychotics: a comparison of sertindole and risperidone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004857-27,0,0,0 2007-004864-29,7,2010-02-25,2010-02-25,6,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004864-29,0,0,0 2007-004864-29,7,2010-02-25,2010-02-25,6,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004864-29,0,0,0 2007-004864-29,7,2010-02-25,2010-02-25,6,1,0,0,0,0,0,0,0,1,0,0,1,0,1,ELI LILLY,A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004864-29,0,0,0 2007-004865-17,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,Aeterna Zentaris GmbH,Cetrorelix pamoate (AEZS-102) in patients with symptomatic BPH: an open-labeled safety and efficacy assessment study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004865-17,0,0,0 2007-004866-42,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,AIO-Studien-gGmbH,An Open-label Randomized Phase II Study of Panitumumab Plus Oral Capecitabine and Infusional Oxaliplatin (XELOX) or XELOX alone for Second-line Treatment of Patients with Metastatic Clororectal Cancer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004866-42,0,0,0 2007-004867-22,3,2010-03-08,2010-03-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec Ltd,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AVONEX® in Subjects with Moderate to Severe Ulcerative Colitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004867-22,0,0,0 2007-004869-18,1,2010-09-30,2010-09-30,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,UHB NHS Foundation Trust,Evaluation of the relative severity of pulmonary neutrophilic inflammation and therapeutic modification with IV Prolastin by means of 18 FDG PET/CT scanning in subjects with alpha1-antitrypsin deficie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004869-18,0,0,0 2007-004872-37,3,2008-07-11,2008-07-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Santen Oy,"A phase IIIb study on the changes in ocular signs, symptoms and conjunctival inflammatory markers in patients with ocular hypertension or open-angle glaucoma switched from preserved latanoprost 0.005%...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004872-37,0,0,0 2007-004874-14,1,2017-06-30,2017-06-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Cardiology, J. W. Goethe University Frankfurt","Doppel-blinde, randomisierte, kontrollierte Studie zur Erfassung des Effektes einer intrakoronaren Applikation von Knochenmark-Progenitorzellen auf die koronare Flußreserve bei Patienten mit akutem Ko...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004874-14,0,0,0 2007-004875-21,4,2011-01-13,2011-01-13,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,"Bayer Healthcare AG, D-51368 Leverkusen, Germany","A Phase II, Multi-centre, Open-label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004875-21,0,0,0 2007-004875-21,4,2011-01-13,2011-01-13,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,BAYER,"A Phase II, Multi-centre, Open-label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004875-21,0,0,0 2007-004876-38,1,2009-01-06,2009-01-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LETI Pharma GmbH,An open label multicenter phase 2 study for the initial evaluation of the tolerability of Birch pollen extract in patients suffering from atopic eczema and clinical relevant IgE-mediated sensitization...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004876-38,0,0,0 2007-004877-24,9,2009-01-27,2010-01-27,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-masked, multicenter, laser-controlled Phase III study assessing the efficacy and safety of ranibizumab (intravitreal injections) as adjunctive and mono-therapy in patients with vi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004877-24,0,0,0 2007-004877-24,9,2009-01-27,2010-01-27,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-masked, multicenter, laser-controlled Phase III study assessing the efficacy and safety of ranibizumab (intravitreal injections) as adjunctive and mono-therapy in patients with vi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004877-24,0,0,0 2007-004877-24,9,2009-01-27,2010-01-27,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-masked, multicenter, laser-controlled Phase III study assessing the efficacy and safety of ranibizumab (intravitreal injections) as adjunctive and mono-therapy in patients with vi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004877-24,0,0,0 2007-004878-31,3,2013-03-19,2013-03-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd.,"An open-label, international, multi-center, phase II, extension trial investigating long-term efficacy and safety of repeated treatment courses of ofatumumab, a fully human monoclonal anti-CD20 antibo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004878-31,0,0,0 2007-004878-31,3,2013-03-19,2013-03-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"An open-label, international, multi-center, phase II, extension trial investigating long-term efficacy and safety of repeated treatment courses of ofatumumab, a fully human monoclonal anti-CD20 antibo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004878-31,0,0,0 2007-004879-19,1,2010-03-26,2010-03-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Double-Blind, Placebo-Controlled, Multicenter, Crossover Study to Evaluate the Effects of a Single Oral Dose of Montelukast, Compared With Placebo, on Exercise-Induced Bronchoconstriction (EIB) in P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004879-19,0,0,0 2007-004883-29,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO CLINICO HUMANITAS,IGEV +/- Bortezomib (VelcadeTM) as induction before high dose consolidation in relapsed/ refractory Hodgkin’s lymphoma after first line treatment : a randomized phase II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004883-29,0,0,0 2007-004884-24,3,2012-11-20,2012-11-20,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MEDA Pharma GmbH & Co. KG,Long-term effects of Aldara® 5% cream and Solaraze® 3% gel in the treatment of actinic keratoses on the face or scalp (LEIDA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004884-24,0,0,0 2007-004886-16,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Teikoku Pharma USA, Inc.","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled 12-week Pilot Exploratory Study to Evaluate the Efficacy and Safety of Teikoku Tulobuterol Tape (6 mg) in Adults with Bronchial Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004886-16,0,0,0 2007-004888-22,4,2013-02-06,2013-02-06,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Novartis Pharma AG,"A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed af...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004888-22,0,0,0 2007-004888-22,4,2013-02-06,2013-02-06,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed af...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004888-22,0,0,0 2007-004890-24,2,2009-02-02,2009-02-02,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Juvantia Pharma Ltd,"A Phase II, Randomised, Placebo-Controlled, Double-Blind, Replicated Crossover, Pilot Study on the Effect of Fipamezole on Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004890-24,1,0,0 2007-004891-38,2,2008-09-25,2008-11-25,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer S.A,"A 12-week, phase 2A, radomized, subject and investigator blinded, placebo-controlled trial to evaluate the safety, tolerability and efficacy of CE-326,597 on glucose control and body weight in overwei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004891-38,0,0,0 2007-004891-38,2,2008-09-25,2008-11-25,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A 12-week, phase 2A, radomized, subject and investigator blinded, placebo-controlled trial to evaluate the safety, tolerability and efficacy of CE-326,597 on glucose control and body weight in overwei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004891-38,0,0,0 2007-004892-21,2,2009-07-21,2009-07-21,2,0,0,0,0,0,2,0,0,1,0,0,1,0,2,IMMUPHARMA SA,"A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Two Doses of Subcutaneous IPP-201101 Plus Standard of Car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004892-21,0,0,0 2007-004894-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska University Hospital Huddinge,Effect of rosuvastatin on cardiovascular events and mortality after pneumonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004894-25,0,0,0 2007-004895-37,4,2012-02-27,2012-03-05,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shire Pharmaceutical Development Limited,"A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004895-37,0,0,0 2007-004895-37,4,2012-02-27,2012-03-05,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shire Pharmaceutical Development Ltd,"A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004895-37,0,0,0 2007-004896-20,5,2011-11-28,2011-11-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shire Pharmaceuticals Development Ltd,"A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004896-20,0,0,0 2007-004896-20,5,2011-11-28,2011-11-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shire Pharmaceutical Development Ltd,"A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004896-20,0,0,0 2007-004896-20,5,2011-11-28,2011-11-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shire Pharmaceutical Development Limited,"A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004896-20,0,0,0 2007-004897-26,1,2012-03-31,2012-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,Memantine for the Long Term Management of Neuropsychiatric Symptoms in Alzheimer's disease - MAIN-AD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004897-26,0,0,0 2007-004897-26,1,2012-03-31,2012-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,North Essex Partnership NHS Foundation Trust,Memantine for the Long Term Management of Neuropsychiatric Symptoms in Alzheimer's disease - MAIN-AD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004897-26,0,0,0 2007-004901-91,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Exploration de l'influence du polymorphisme *2 du gène codant pour le cytochrome 2C19 sur la réponse au clopidogrel chez le jeune coronarien,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004901-91,0,0,0 2007-004906-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación General de la Universidad de Valladolid,Estudio aleatorizado del efecto del trasplante de células madre mononucleadas autólogas derivadas de la médula ósea mediante inyección directa intramiocárdica en asociación con revascularización quirú...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004906-28,0,0,0 2007-004907-37,2,2012-04-02,2012-04-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,A randomized phase 2 study of LY2181308 in combination with docetaxel versus docetaxel in hormone refractory prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004907-37,0,0,0 2007-004907-37,2,2012-04-02,2012-04-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company limited,A randomized phase 2 study of LY2181308 in combination with docetaxel versus docetaxel in hormone refractory prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004907-37,0,0,0 2007-004911-79,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,cliniques Universitaires st luc-ucl,Pharmacodynamics of Fondaparinux subcutaneous versus continuous intravenous infusion in critically ill patients with or without vasopressors.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004911-79,0,0,0 2007-004912-30,1,2008-10-12,2008-10-12,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Karolinska Institutet,Modulation of opiate reward by NK1 antagonism: A laboratory based proof of concept study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004912-30,0,0,0 2007-004913-32,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,deCODE genetics ehf.,"A randomized, double-blind, placebo-controlled evaluation of the pharmacodynamics, pharmacokinetics, and safety of DG-051 in patients with a history of MI",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004913-32,0,0,0 2007-004917-33,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Leiden University Medical Centre,A Randomised Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004917-33,0,0,0 2007-004917-33,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,A Randomised Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004917-33,0,0,0 2007-004918-14,1,2008-05-09,2008-05-09,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York,NY 10017","A 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE IMPACT OF DONEPEZIL HYDROCHLORIDE (ARICEPT®) ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN PATIENTS WITH SEVERE ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004918-14,0,0,0 2007-004919-55,1,2011-12-01,2011-12-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Medizinische Universität Innsbruck, Universitätsklinik für Neurologie",Untersuchung der Dosis-Wirk-Beziehung unterschiedlicher Erythropoetin-Dosen auf Frataxin bei Friedreich Ataxie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004919-55,0,0,0 2007-004922-26,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CHU Toulouse,Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004922-26,0,0,0 2007-004923-39,1,2010-07-13,2010-07-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,Efficacy and tolerability of EPs 7630 solution in patients (> = 18 years old) with Acute Rhinopharyngitis (ARP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004923-39,0,0,0 2007-004925-64,1,2009-03-03,2009-03-03,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,HSK Research GmbH,"A Phase II Controlled Study of pegylated liposomal Doxorubicin (PLD, CAELYX) and Carboplatin for the Preoperative Treatment of Advanced Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004925-64,0,0,0 2007-004928-21,1,2018-04-17,2018-04-17,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Medical Center Hamburg-Eppendorf,Autologous-Allogeneic Tandem Stem Cell Transplantation and Maintenance Therapy with Thalidomide / DLI for patients with Multiple Myeloma (MM) and age <= 60 years: A phase II-study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004928-21,0,0,0 2007-004936-22,1,2009-12-31,2009-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Leuven,"A comparative, double blind trial between'older' and 'newer' local anesthetics in forefoot surgery under echographic popliteal block.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004936-22,0,0,0 2007-004937-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier de Nancy,"Etude du lien entre les marqueurs biologiques, la fatigue et les troubles cognitifs au cours de la sclérose en plaques de diagnostic récent et traitée par Interféron Bêta 1a SC (Rebif 44)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004937-41,0,0,0 2007-004938-16,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,Astellas Pharma Europe B.V.,"A RANDOMISED, DOUBLE-BLIND STUDY TO COMPARE THE EFFECT ON SYMPATHETIC ACTIVITY AND HEMODYNAMIC PROFILE OF BARNIDIPINE AND AMLODIPINE IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004938-16,0,0,0 2007-004941-13,1,2012-12-31,2012-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"University Hospital Tubeingen, Department for Anaesthesiology and Intensive Care Medicine",Serumspiegel von intravenös und enteral appliziertem Moxifloxacin bei kritisch kranken Intensivpatienten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004941-13,0,0,0 2007-004943-31,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Centre of Thrombosis and Haemostasis,The VWD International Prophylaxis (VIP) Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004943-31,0,0,0 2007-004947-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Biomet Nederland BV,Injectie van autologe bloedplaatjes bij epicondylitis lateralis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004947-31,0,0,0 2007-004950-10,2,2010-06-09,2010-06-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,Pemetrexed con suplemento simplificado de folato y dexametasona frente a pemetrexed con suplemento estándar como segunda línea de quimioterapia en pacientes con cáncer de pulmón no microcítico Pemet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004950-10,0,0,0 2007-004950-10,2,2010-06-09,2010-06-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ELI LILLY,Pemetrexed con suplemento simplificado de folato y dexametasona frente a pemetrexed con suplemento estándar como segunda línea de quimioterapia en pacientes con cáncer de pulmón no microcítico Pemet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004950-10,0,0,0 2007-004951-12,6,2010-03-09,2010-04-09,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Short-term 12-Week, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study to Evaluate the Treatment Effect of Saxagliptin compared with Placebo in Adult Patients with Type...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004951-12,0,0,0 2007-004953-27,9,2012-08-24,2012-08-24,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM (Apixaban after the initial Management of PuLmonary embolIsm and de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004953-27,0,0,0 2007-004953-27,9,2012-08-24,2012-08-24,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM (Apixaban after the initial Management of PuLmonary embolIsm and de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004953-27,0,0,0 2007-004954-99,1,2011-01-21,2011-01-21,1,0,0,0,1,0,2,0,1,1,0,0,1,0,0,"Göteborg University, Sect. Psyhiatry and Neurochemistry",Does varenicline influence alcohol consumption in alcohol dependent individuals?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004954-99,0,0,0 2007-004954-99,1,2011-01-21,2011-01-21,1,0,0,0,1,0,2,0,1,1,0,0,1,0,0,"Göteborg University, Sect. Psychiatry and Neurochemistry",Does varenicline influence alcohol consumption in alcohol dependent individuals?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004954-99,0,0,0 2007-004956-35,1,2010-02-01,2010-02-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"St George's, University of London",The effect of intensive blood glucose control with insulin on markers of short and medium term outcomes in patients hospitalised with acute exacerbations of chronic lung disease. Pilot Study to test ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004956-35,0,0,0 2007-004968-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU DE NANCY - DIRECTION DE LA RECHERCHE CLINIQUE ET DE L'INNOVATION,Essai de phase II testant une association concomitante irradiation cérébrale ultra-fractionnée – témozolomide pour des glioblastomes multiformes inopérables de novo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004968-41,0,0,0 2007-004969-18,1,2011-08-25,2011-08-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"Open-label, efficacy and safety study of bevacizumab (Avastin) in combination with XELOX (Oxaliplatin plus Xeloda) for the first-line treatment of patients with locally advanced or metastatic cancer o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004969-18,0,0,0 2007-004970-24,1,2012-01-13,2012-01-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AGMT - Arbeitsgemeinschaft Medikamentöse Tumortherapie Gemeinnützige GmbH,"Multizentrische Studie über die Cardiotoxizität von R-CHOP (Rituximab, Cyclophosphamid, Doxorubicin, Vincristin und Prednisolon) v. R-COMP (Rituximab, Cyclophosphamid, liposomalem Doxorubicin, Vincris...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004970-24,0,0,0 2007-004973-25,1,2009-11-02,2009-11-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Laboratoire Expanscience,Prospective multicentric open clinical study comparing the efficacy and safety of piascledine 300 plus standard treatment versus standard treatment only in patients with osteoarthritis of the knee,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004973-25,0,0,0 2007-004978-16,1,2010-09-20,2010-09-20,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 2, Open-label, Controlled, Multi-center Study to Evaluate Meningococcal ACWY Antibody Response in Children Aged 40 and 60 Months who Have Previously Received Novartis MenACWY Conjugate Vaccine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004978-16,0,0,0 2007-004979-19,1,2016-11-01,2016-11-01,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Leipzig,In-vivo assessment of nicotinic acetylcholine receptor binding in neurodegenerative diseases using the radioligand 2-[18F]FA-85380 and positron emission tomography (PET),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004979-19,0,0,0 2007-004980-23,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,"Schering-Plough Farma, Lda.","Double-Blind evaluation of the safety and efficacy of Quadriderme cream (betamethasone dipropionate, clotrimazole and gentamicin sulphate ) compare with betamethasone dipropionate combined with gentam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004980-23,0,0,0 2007-004981-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Narodny onkologicky ustav,Phase II study of sunitinib malate (SUTENT®) in relapsed germ cell tumors in males.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004981-42,0,0,0 2007-004984-23,1,2013-08-26,2013-08-26,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Department of Obstetrics and Gynecology, Oulu University Hospital","Ehkäisylaastarin, ehkäisytabletin ja ehkäisyrenkaan vaikutukset hormonaalisiin, tulehduksellisiin ja aineenvaihdunnallisiin parametreihin hedelmällisessä iässä olevilla terveillä naisilla.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004984-23,0,0,0 2007-004985-41,1,2008-05-22,2008-05-22,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Neuroscience, neurology",Different dyskinesias in Parkinson's disease and their relation to levodopa pharmacokinetics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004985-41,0,0,0 2007-004988-22,8,2010-10-07,2010-10-07,4,0,0,0,0,1,3,0,0,2,0,0,0,0,1,NEUROSEARCH SWEDEN AB,"A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004988-22,1,0,0 2007-004988-22,8,2010-10-07,2010-10-07,4,0,0,0,0,1,3,0,0,2,0,0,0,0,1,NeuroSearch Sweden AB,"A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004988-22,1,0,0 2007-004990-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Freiburg,"Comparison of the concentrations of the antibiotic compound Daptomycin in serum, cartilage-, muscle and subcutaneous tissue after a preoperative intravenous administration (Klinische Studie zum Ver...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004990-24,0,0,0 2007-004992-21,9,2009-06-29,2010-03-23,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 in patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004992-21,0,0,0 2007-004993-15,3,2012-05-02,2012-05-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Randomized, Open-Label, Multicenter Study Examining the Effects of 24 Versus 48 Weeks of Combination Therapy with PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained Virol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004993-15,0,0,0 2007-004994-25,2,2009-03-23,2009-04-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind, placebo-controlled, crossover study in women with irritable bowel syndrome to evaluate feasibility and reproducibility of barostat assessments of colorectal s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004994-25,0,0,0 2007-004997-23,4,2008-08-18,2008-08-28,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Movetis NV,"An exploratory, double-blind, randomized, stratified, placebo-controlled, repeated dose trial to investigate the efficacy of M0003 on symptoms suggestive for gastroparesis, to assess the pharmacodynam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-004997-23,0,0,0 2007-005004-40,1,2011-12-16,2011-12-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Cassella-med,"Multizentrischer, randomisierter, doppelblinder, Placebo-kontrollierter Parallelgruppenvergleich zum Nachweis der Wirksamkeit und Unbedenklichkeit von Chinin bei Patienten mit Fibromyalgie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005004-40,0,0,0 2007-005008-41,3,2008-07-03,2008-07-03,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Procter & Gamble Pharmaceuticals,"A Phase II, Randomized, Adaptive Design, Multicenter, Parallel Group, Placebo-controlled, 58-day, Dose-ranging Study of ATI-7505 in Patients with Postprandial Distress Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005008-41,0,0,0 2007-005009-24,2,2015-02-16,2015-02-16,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,EUSA pharma SAS,"An international randomised, multicentre, parallel-group, Phase III comparative study of inolimomab against usual care in the Treatment of Primary Steroid Refractory Acute Graft versus Host Disease (a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005009-24,0,0,0 2007-005009-24,2,2015-02-16,2015-02-16,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,EUSA Pharma,"An international randomised, multicentre, parallel-group, Phase III comparative study of inolimomab against usual care in the Treatment of Primary Steroid Refractory Acute Graft versus Host Disease (a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005009-24,0,0,0 2007-005010-40,1,2008-12-31,2008-12-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Univ.-Prof. Dr. Volker Wenzel,Arginin Vasopressin im fortgeschrittenen vasodilatorischen Schock: Ein Dosisvergleich 2 vs. 4 IU/h,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005010-40,0,0,0 2007-005011-25,2,2008-08-22,2008-08-22,1,0,0,0,0,2,3,0,0,2,1,0,0,0,1,PROGEN PHARMACEUTICALS LIMITED,"A Prospective, Randomised, Double-blind, Placebo-controlled, Parallel-group, International Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma (PA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005011-25,1,0,0 2007-005011-25,2,2008-08-22,2008-08-22,1,0,0,0,0,2,3,0,0,2,1,0,0,0,1,Progen Pharmaceuticals Limited,"A Prospective, Randomised, Double-blind, Placebo-controlled, Parallel-group, International Multicentre Phase III Trial of PI-88 in the Adjuvant Treatment of Post-resection Hepatocellular Carcinoma (PA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005011-25,1,0,0 2007-005017-19,10,2019-04-25,2019-04-30,9,1,1,0,0,1,2,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"Estudio abierto, multicéntrico y aleatorizado en fase II para evaluar la adición de bevacizumab a la quimioterapia en niños y adolescentes con diganóstico inicial de sarcoma metastásico de tejidos bla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005017-19,1,1,0 2007-005017-19,10,2019-04-25,2019-04-30,9,1,1,0,0,1,2,0,0,2,0,0,0,0,1,ROCHE,"Estudio abierto, multicéntrico y aleatorizado en fase II para evaluar la adición de bevacizumab a la quimioterapia en niños y adolescentes con diganóstico inicial de sarcoma metastásico de tejidos bla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005017-19,1,1,0 2007-005018-37,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Amar Agha,Optimal glucocorticoid replacement therapy in adrenocorticotropin (ACTH) deficient hypopituitary patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005018-37,0,0,0 2007-005019-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"MADAUS, S.A.","Ensayo clínico, multicéntrico, aleatorizado, con grupos paralelos, controlado con placebo y doble ciego, para analizar el efecto del tratamiento con cutículas de semillas de Plantago Ovata sobre la in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005019-25,0,0,0 2007-005021-30,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,REGIONE LOMBARDIA - DIREZIONE GENERALE SANITA',TOP TRIAL. A RANDOMISED PHASE III CLINICAL TRIAL OF TRASTUZUMAB (HERCEPTIN) OPTIMIZATION IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER OVEREXPRESSING HER2 AFTER A FIRST LINE CHEMOT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005021-30,0,0,0 2007-005022-71,1,2011-11-08,2011-11-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,CESAR Central European Society for Anticancer Drug Research – EWIV,Prospective randomized Phase II trial with gemcitabine plus sunitinib versus gemcitabine alone in first-line therapy of metastatic or locally advanced pancreatic cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005022-71,0,0,0 2007-005023-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ANRS,"ETUDE MULTICENTRIQUE RANDOMISEE, DE PHASE III, COMPARANT L’IMMUNOGENICITE D’UN SCHEMA VACCINAL RENFORCE CONTRE LE VHB (40 µg à S0, S4, et S24), A UN SCHEMA CLASSIQUE (20 µg à S0, S4, et S24), CHEZ DES...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005023-15,0,0,0 2007-005026-76,1,2013-08-27,2013-08-27,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,Anne Pesonen,"Vähentääkö pregabaliini opioidikipulääkityksen tarvetta, postoperatiivista sekavuutta ja kroonisen kivun esiintyvyyttä sydänleikkauksen jälkeen iäkkäillä potilailla?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005026-76,0,0,0 2007-005033-11,1,2010-05-07,2010-05-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"CombinatoRx, Inc",A Comparison Of The Safety And Bioavailability Of Modified-Release Formulations Of Levodopa-Carbidopa In Subjects With Parkinson’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005033-11,0,0,0 2007-005034-36,5,2010-05-12,2010-05-12,3,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Kwizda Pharma GmbH,"A non comparative, multicentre, repeat dose safety in use study of Neukine® (Filgrastim) in patients receiving chemotherapy known to induce neutropenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005034-36,0,0,0 2007-005034-36,5,2010-05-12,2010-05-12,3,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Apotex Inc.,"A non comparative, multicentre, repeat dose safety in use study of Neukine® (Filgrastim) in patients receiving chemotherapy known to induce neutropenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005034-36,0,0,0 2007-005035-29,1,2008-02-12,2008-02-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Valderm ApS,"A 13 day placebo- and reference-controlled, double-blind, monocentric, randomized, intraindividual comparative clinical phase IIa study, investigating the efficacy and tolerability of valrubicin cream...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005035-29,0,0,0 2007-005037-11,1,2008-07-10,2008-07-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche Ltd,"An open-label, randomized 2-period crossover study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability of warfarin in combination with oseltamivir in volunteers stabilized o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005037-11,0,0,0 2007-005045-38,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,Pharmacokinetic and colimicine (ColistinaR) concentrations in broncho alveolar lavage in patients affected by pulmonary infections caused by Gram - bacteria.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005045-38,0,0,0 2007-005047-21,1,2012-07-16,2012-07-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,Effects of Sirolimus on disease progression in patients with Autosomal Dominant Polycystic Kidney Disease and severe renal insufficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005047-21,0,0,0 2007-005051-42,2,2011-04-05,2011-04-05,1,0,0,0,0,1,2,0,0,1,1,0,1,0,1,"Protherics Salt Lake City, Inc",A randomized study of the efficacy and safety of OncoGel™ treatment as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation prior to surgery in subjects with localized...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005051-42,0,0,0 2007-005054-23,6,2010-04-19,2010-04-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT - IRPF,"A DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF 1g, 2g, AND 4 g V0251 EFFICACY AND TOLERANCE IN VESTIBULAR NEURITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005054-23,0,0,0 2007-005054-23,6,2010-04-19,2010-04-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"A DOUBLE-BLIND PLACEBO CONTROLLED STUDY OF 1g, 2g, AND 4 g V0251 EFFICACY AND TOLERANCE IN VESTIBULAR NEURITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005054-23,0,0,0 2007-005056-16,1,2009-02-13,2009-02-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,Atorvastatin at high dosage before coronary stent surgery: effect on peri-procedure miocardic stroke .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005056-16,0,0,0 2007-005057-36,1,2011-02-28,2011-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical Research Council,Evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic HIV-infected patients (HCQ-01),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005057-36,0,0,0 2007-005061-36,2,2010-11-10,2010-11-10,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Lilly S.A.,"Comparación de un régimen de insulina lispro premezclada (proporción baja, 25/75; y proporción media, 50/50) con un régimen de inyecciones separadas de insulina basal y en bolos, en pacientes con diab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005061-36,0,0,0 2007-005061-36,2,2010-11-10,2010-11-10,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company Ltd.,"Comparación de un régimen de insulina lispro premezclada (proporción baja, 25/75; y proporción media, 50/50) con un régimen de inyecciones separadas de insulina basal y en bolos, en pacientes con diab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005061-36,0,0,0 2007-005063-96,1,2009-08-19,2009-08-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Tübingen,Prospective trial of intravenous levetiracetam in patients with primary brain tumors and at least one symptomatic seizure who undergo biopsy or cytoreductive surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005063-96,0,0,0 2007-005068-29,1,2008-11-19,2008-11-19,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"A.P. Pharma, Inc.","A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi® for the Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005068-29,0,0,0 2007-005070-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Bordeaux,Analyse prospective des pontages et valves aortiques sous anticoagulation conventionnelle versus hemi-dose en système clos et coa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005070-31,0,0,0 2007-005079-32,1,2015-12-31,2015-12-31,1,1,0,0,0,1,4,0,0,1,1,1,1,0,0,Medical University of Vienna,Treatment of secondary renal amyloidosis A with the Intereleukin – 1 antagonist anakinra,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005079-32,0,0,0 2007-005080-10,1,2013-12-31,2013-12-31,1,1,0,0,1,0,4,0,1,1,1,1,1,0,0,University Hospitals of Leicester NHS Trust,Irregular vaginal bleeding with etonorgestrel contraceptive implant - A pilot randomised controlled trial of prophylactic down regulation with a Gonadotrophin releasing hormone analogue prior to impla...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005080-10,0,0,0 2007-005082-34,1,2008-06-12,2008-06-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare,A Proof of Principle Study to Investigate the Efficacy of a Medical Device and Topical Analgesic Combination for the Treatment of Pain and Performance Related Function in Osteoarthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005082-34,0,0,0 2007-005083-28,7,2008-12-18,2009-06-26,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,BAYER,"A Phase II, Randomized, Open-label, MultiCenter, Study Evaluating the Efficacy of SOrafenib AloNe and Sorafenib in Combination with Low DosE InterfeRon Alpha-2a as Second-line Treatment of Sunitinib F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005083-28,0,0,0 2007-005083-28,7,2008-12-18,2009-06-26,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Bayer Healthcare AG, D-51368, Leverkusen, Germany","A Phase II, Randomized, Open-label, MultiCenter, Study Evaluating the Efficacy of SOrafenib AloNe and Sorafenib in Combination with Low DosE InterfeRon Alpha-2a as Second-line Treatment of Sunitinib F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005083-28,0,0,0 2007-005083-28,7,2008-12-18,2009-06-26,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Bayer Healthcare AG, Leverkusen","A Phase II, Randomized, Open-label, MultiCenter, Study Evaluating the Efficacy of SOrafenib AloNe and Sorafenib in Combination with Low DosE InterfeRon Alpha-2a as Second-line Treatment of Sunitinib F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005083-28,0,0,0 2007-005087-26,1,2009-02-10,2009-02-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim GmbH & Co. KG,"Randomised, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 3 Doses of Orally Inhaled BI 1744 CL, each in fixed dose combination with 5µg Tio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005087-26,0,0,0 2007-005088-82,2,2009-02-19,2009-02-19,2,1,0,0,0,1,2,0,2,1,0,0,1,0,1,NOVARTIS FARMA,"A multi-centre, randomized, double-blind, placebo-controlled, two-period, crossover proof-of-concept study in male patients with Fragile X Syndrome to assess the efficacy, safety and tolerability of m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005088-82,0,0,0 2007-005088-82,2,2009-02-19,2009-02-19,2,1,0,0,0,1,2,0,2,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-centre, randomized, double-blind, placebo-controlled, two-period, crossover proof-of-concept study in male patients with Fragile X Syndrome to assess the efficacy, safety and tolerability of m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005088-82,0,0,0 2007-005089-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,TROPHOS,"Study title: Double-blind vs Placebo, Randomized, Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 500 mg QD for One Month in Patients with Non-Alcoholic S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005089-12,0,0,0 2007-005090-65,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",New therapeutic approaches in the treatment of anaplastic thyroid cancer: a phase II trial of valproic acid and paclitaxel in solid tumours,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005090-65,0,0,0 2007-005091-13,1,2012-10-12,2012-10-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's & St Thomas' NHS Foundation Trust,Phase II study of sorafenib in malignant mesothelioma previously treated with platinum-based chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005091-13,0,0,0 2007-005091-13,1,2012-10-12,2012-10-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Kings College London (University),Phase II study of sorafenib in malignant mesothelioma previously treated with platinum-based chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005091-13,0,0,0 2007-005092-33,6,2009-05-04,2009-05-22,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Abbott GmbH & Co. KG,Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5. Benefici del paracalcitolo iniettabile sulla morbilita` cardiaca indotta ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005092-33,0,0,0 2007-005094-54,2,2008-09-08,2008-09-08,2,0,0,0,0,0,2,0,0,1,0,0,1,0,2,TOPIGEN PHARMACEUTICALS INC.,"A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 14-DAY INHALED TPI ASM8 IN SUBJECTS WITH ASTHMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005094-54,0,0,0 2007-005094-54,2,2008-09-08,2008-09-08,2,0,0,0,0,0,2,0,0,1,0,0,1,0,2,Topigen Pharmaceuticals Inc.,"A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 14-DAY INHALED TPI ASM8 IN SUBJECTS WITH ASTHMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005094-54,0,0,0 2007-005095-14,1,2012-03-20,2012-03-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Max Zeller Söhne AG,"Randomisierte, placebo-kontrollierte prospektive, klinische Studie der Wirksamkeit von Schlaf-Filmtabletten Ze 91019 (ALLUNA Nacht zum Einschlafen®, Baldrian/Hopfen) bei Patienten/innen mit Schlafstör...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005095-14,0,0,0 2007-005097-31,3,2012-12-21,2012-12-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"A Blinded, Randomized, Phase 1/2 Study of Brivanib Alaninate vs. Placebo in Combination with Erbitux and Irinotecan in K-Ras wild type Subjects with Metastatic Colorectal Cancer. Revised Protocol 03...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005097-31,0,0,0 2007-005100-41,4,2016-12-31,2016-12-31,1,0,1,0,0,1,1,0,0,2,0,0,0,0,1,Inspiration Biopharmaceuticals,"Phase I/II/III Pharmacokinetic and Outcome Study of Inspiration's Recombinant Factor IX Product, IB1001, in Subjects with Hemophilia B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005100-41,1,0,0 2007-005100-41,4,2016-12-31,2016-12-31,1,0,1,0,0,1,1,0,0,2,0,0,0,0,1,INSPIRATION BIOPHARMACEUTICALS,"Phase I/II/III Pharmacokinetic and Outcome Study of Inspiration's Recombinant Factor IX Product, IB1001, in Subjects with Hemophilia B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005100-41,1,0,0 2007-005100-41,4,2016-12-31,2016-12-31,1,0,1,0,0,1,1,0,0,2,0,0,0,0,1,Aptevo Europe Limited,"Phase I/II/III Pharmacokinetic and Outcome Study of Inspiration's Recombinant Factor IX Product, IB1001, in Subjects with Hemophilia B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005100-41,1,0,0 2007-005101-21,1,2009-05-29,2009-05-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research Limited,"An open, multi-centre, non-comparative observational study to assess the safety and tolerability of Oxycodone hydrochloride injection 50 mg/mL as a subcutaneous infusion in subjects with severe cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005101-21,0,0,0 2007-005102-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,Phase II explorative study of intermittent Imatinib (IM) treatment (INTERIM) in elderly patients with Ph+ chronic myeloid leukemia (CML) who achieved a stable complete cytogenetic response (CCgR) with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005102-42,0,0,0 2007-005103-18,15,2012-05-06,2012-09-01,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ROCHE,"A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005103-18,0,0,0 2007-005103-18,15,2012-05-06,2012-09-01,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F.Hoffmann-La Roche Ltd.,"A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005103-18,0,0,0 2007-005103-18,15,2012-05-06,2012-09-01,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"F.Hoffmann-La Roche Ltd., Pharmaceuticals Division, PDR","A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005103-18,0,0,0 2007-005103-18,15,2012-05-06,2012-09-01,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005103-18,0,0,0 2007-005107-17,17,2008-10-31,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BOEHRINGER ING.,"A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double–blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005107-17,0,0,0 2007-005107-17,17,2008-10-31,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer-Ingelheim Pharma GesmbH,"A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double–blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005107-17,0,0,0 2007-005107-17,17,2008-10-31,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Austria GmbH,"A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double–blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005107-17,0,0,0 2007-005107-17,17,2008-10-31,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Ellas A.E.,"A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double–blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005107-17,0,0,0 2007-005107-17,17,2008-10-31,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,"A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double–blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005107-17,0,0,0 2007-005107-17,17,2008-10-31,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Boehringer Ingelheim bv, Medical department","A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double–blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005107-17,0,0,0 2007-005107-17,17,2008-10-31,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim AB,"A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double–blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005107-17,0,0,0 2007-005107-17,17,2008-10-31,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim,"A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double–blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005107-17,0,0,0 2007-005107-17,17,2008-10-31,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double–blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005107-17,0,0,0 2007-005107-17,17,2008-10-31,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Finland Ky,"A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double–blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005107-17,0,0,0 2007-005107-17,17,2008-10-31,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim España S.A.,"A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double–blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005107-17,0,0,0 2007-005107-17,17,2008-10-31,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim bv,"A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double–blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005107-17,0,0,0 2007-005107-17,17,2008-10-31,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GesmbH,"A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double–blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005107-17,0,0,0 2007-005107-17,17,2008-10-31,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A 24−week (+ 24 week extension), randomised, placebo−controlled (only 1st 12−week period), double–blind, parallel−group, efficacy and safety comparison of Tiotropium/Salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005107-17,0,0,0 2007-005109-23,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Uppsala University Hospital,"Low-Dose Hormone Therapy Initiated early after Menopause and Changes in Artery Wall Composition (AWC), as Assesssed by High-Frequency Ultrasound.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005109-23,0,0,0 2007-005112-37,1,,,0,1,0,0,1,0,4,0,0,1,1,1,0,1,0,"Medizinische Universität Wien, Abteilung für Interne Medizin I","An randomized, controlled, investigator-blinded, prospective, mono-centre study to evaluate the efficacy of fosfomycin versus meropenem in patients with complicated urinary tract infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005112-37,0,0,0 2007-005115-26,4,2008-07-03,2008-07-03,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pacira Pharmaceuticals, Inc.","A Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control, Dose-Ranging Study to Evaluate the Safety, Efficacy and Comparative Systemic Bioavailability of a Single Administration of SKY0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005115-26,0,0,0 2007-005115-26,4,2008-07-03,2008-07-03,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pacira Pharmaceuticals Inc.,"A Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control, Dose-Ranging Study to Evaluate the Safety, Efficacy and Comparative Systemic Bioavailability of a Single Administration of SKY0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005115-26,0,0,0 2007-005116-12,1,2012-10-08,2012-10-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Technical University of Munich,"Phase II study of the mTOR-Inhibitor EVEROLIMUS as maintenance therapy in patients aged over 60 years with Mantle Cell Lymphoma (MCL) after first, second, third or fourth line chemotherapy New title s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005116-12,0,0,0 2007-005117-18,1,2010-03-08,2010-03-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Medical University of Vienna, Department of Clinical Pharmacology",Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005117-18,0,0,0 2007-005118-37,10,2011-04-08,2011-04-12,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ELI LILLY,Efecto de la inhibición de la γ-Secretasa sobre la progresión de la enfermedad de Alzheimer: LY450139 frente a placebo / Effect of γ-Secretase Inhibition on the Progression of Alzheimer’s Disease:...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005118-37,0,0,0 2007-005118-37,10,2011-04-08,2011-04-12,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,Efecto de la inhibición de la γ-Secretasa sobre la progresión de la enfermedad de Alzheimer: LY450139 frente a placebo / Effect of γ-Secretase Inhibition on the Progression of Alzheimer’s Disease:...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005118-37,0,0,0 2007-005125-30,1,2012-08-30,2012-08-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Medizinische Universität Wien, Univ.Klinik für Dermatologie, Abteilung für Immundermatologie",Rituximab (Mabthera) in metastatic melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005125-30,0,0,0 2007-005129-31,9,2017-07-27,2017-07-27,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche Ltd,"A randomized, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005129-31,0,0,0 2007-005129-31,9,2017-07-27,2017-07-27,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ROCHE,"A randomized, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005129-31,0,0,0 2007-005129-31,9,2017-07-27,2017-07-27,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, controlled, open-label, multi-centre, parallel-group study to assess all-cause mortality and cardiovascular morbidity in patients with chronic kidney disease on dialysis and those not on...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005129-31,0,0,0 2007-005134-36,16,2008-10-30,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GesmbH,"A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005134-36,0,0,0 2007-005134-36,16,2008-10-30,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Ellas A.E.,"A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005134-36,0,0,0 2007-005134-36,16,2008-10-30,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim AB,"A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005134-36,0,0,0 2007-005134-36,16,2008-10-30,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim,"A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005134-36,0,0,0 2007-005134-36,16,2008-10-30,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005134-36,0,0,0 2007-005134-36,16,2008-10-30,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma Ges mbH,"A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005134-36,0,0,0 2007-005134-36,16,2008-10-30,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim bv,"A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005134-36,0,0,0 2007-005134-36,16,2008-10-30,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Austria GmbH,"A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005134-36,0,0,0 2007-005134-36,16,2008-10-30,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer-Ingelheim Pharma GesmbH,"A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005134-36,0,0,0 2007-005134-36,16,2008-10-30,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BOEHRINGER ING.,"A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005134-36,0,0,0 2007-005134-36,16,2008-10-30,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Boehringer Ingelheim bv, Medical department","A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005134-36,0,0,0 2007-005134-36,16,2008-10-30,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005134-36,0,0,0 2007-005134-36,16,2008-10-30,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Finland Ky,"A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005134-36,0,0,0 2007-005134-36,16,2008-10-30,2008-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim España S.A.,"A 24-week (+ 24 week extension), randomised, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhala...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005134-36,0,0,0 2007-005135-28,1,2009-08-26,2009-08-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co.KG,"A randomised, double–blind, crossover efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/ 25 µg) Inhalation Powder in the morning (PE Capsule via tiotropium/salmeterol HandiHaler®), Tiotr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005135-28,0,0,0 2007-005138-35,1,2013-12-02,2013-12-02,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Moorfields Eye Hospital,Triamcinolone acetonide to prevent PVR in eyes undergoing vitreoretinal surgery for open globe trauma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005138-35,0,0,0 2007-005140-24,1,2011-01-07,2011-01-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Isis Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled STudy to Assess Safety and Efficacy of ISIS 301012 Administration in Statin Intolerant Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005140-24,0,0,0 2007-005148-26,2,2011-03-17,2011-03-17,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Effects of a One-Year Course of Fluticasone Furoate Nasal Spray 110mcg QD on Growth in Pre-Pubescent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005148-26,0,0,0 2007-005151-42,7,2008-10-29,2010-04-15,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schering Plough Research Institute, A Division of Schering Corporation","""Estudio fase 3 de Seguridad y Eficacia de Boceprevir en pacientes con Hepatitis C Crónica genotipo 1 que recayeron tras el tratamiento previo con Peginterferón/Ribavirina"". ""A Phase 3 Safety and Eff...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005151-42,0,0,0 2007-005151-42,7,2008-10-29,2010-04-15,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SCHERING PLOUGH RESEARCH INSTITUTE,"""Estudio fase 3 de Seguridad y Eficacia de Boceprevir en pacientes con Hepatitis C Crónica genotipo 1 que recayeron tras el tratamiento previo con Peginterferón/Ribavirina"". ""A Phase 3 Safety and Eff...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005151-42,0,0,0 2007-005151-42,7,2008-10-29,2010-04-15,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schering Plough Research Institute, una División de Schering Corporation","""Estudio fase 3 de Seguridad y Eficacia de Boceprevir en pacientes con Hepatitis C Crónica genotipo 1 que recayeron tras el tratamiento previo con Peginterferón/Ribavirina"". ""A Phase 3 Safety and Eff...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005151-42,0,0,0 2007-005152-16,2,2010-05-28,2010-05-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,OM PHARMA,"Multicentre, randomised, double-blind, placebo-controlled study of the efficacy and safety of Broncho-Vaxom in adults suffering from chronic rhinosinusitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005152-16,0,0,0 2007-005152-16,2,2010-05-28,2010-05-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,OM Pharma SA,"Multicentre, randomised, double-blind, placebo-controlled study of the efficacy and safety of Broncho-Vaxom in adults suffering from chronic rhinosinusitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005152-16,0,0,0 2007-005153-32,2,2012-03-29,2012-03-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Human Genome Sciences Inc.,"A PHASE 2, RANDOMIZED, MULTI-CENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAPATUMUMAB ( [HGS1012], A FULLY HUMAN MONOCLONAL ANTIBODY TO TRAIL-R1) IN COMBINATION WITH CARBOPLATIN AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005153-32,0,0,0 2007-005157-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ludwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie,A randomized observer and subject masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration Multicenter An...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005157-33,0,0,0 2007-005160-27,1,2012-04-24,2012-04-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The University of Dundee,A proof of concept study to evaluate rebound trough airway hyper-responsiveness after single and chronic dosing with levosalbutamol and racemic salbutamol in persistent asthmatics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005160-27,0,0,0 2007-005163-94,1,2014-06-03,2014-06-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A prospective, randomized, verum controlled, open label, parallel group multi-center phase III clinical trial to demonstrate the superiority of 500 or 250 mg Aspirin® i.v. (BAY 81-8781) treatment vers...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005163-94,0,0,0 2007-005164-27,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,research office urology VUmc,Botulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/ Interstitial Cystitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005164-27,0,0,0 2007-005166-12,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Hutchison MediPharma Enterprises Limited,"A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis with or without Mesalamine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005166-12,0,0,0 2007-005168-29,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,SANOFI PASTEUR MSD S.N.C,"An Open-label, randomised, controlled, multi-centre study of the immunogenicity and safety of a booster dose of two different Hepatitis B vaccines to explore the anamnestic immune response in healthy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005168-29,0,0,0 2007-005169-36,7,2009-04-07,2009-04-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,A Study of Single Dose Intravenous Casopitant in Combination with Ondansetron and Dexamethasone for the Prevention of Oxaliplatin-Induced Nausea and Vomiting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005169-36,0,0,0 2007-005170-30,1,2010-12-16,2010-12-16,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,CHU CAEN,Pharmacocinétique de l’Hydrocortisone chez le patient ADdisonien : évaluation de la valeur prédictive de l’ACTH plasmatique pour la titration du traitement substitutif,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005170-30,0,0,0 2007-005173-56,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo Oncológico Gallego (GOG),"ENSAYO CLÍNICO ABIERTO, NO ALEATORIZADO, EN FASE II, DE TRATAMIENTO SECUENCIAL CON TAXOTERE® (T) SEGUIDO DE MYOCET® Y CICLOFOSFAMIDA (MC), COMO TRATAMIENTO ANTINEOPLASICO PRIMARIO EN PACIENTES CON CAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005173-56,0,0,0 2007-005178-30,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Life Recovery Systems,Clinical Study of the LRS ThermoSuit™ System in Post Arrest Patients with Intravenous Infusion of Magnesium Sulfate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005178-30,0,0,0 2007-005179-32,1,2009-09-17,2009-09-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Joint Stock Company ""Grindeks""",Mildronate - Efficacy And Safety Of Treatment For Chronic Coronary Heart Disease (Stable Angina) I,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005179-32,0,0,0 2007-005180-10,1,2010-01-11,2010-01-11,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Frederiksberg Hospital,Hvilken infusionshastighed for smertepumpen giver bedst smertelindring efter fodoperation?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005180-10,0,0,0 2007-005181-12,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Analgésie inhalatoire par protoxyde d'azote vs anesthésie locale, pour le recueil ovocytaire en Assistance Médicale à la Procréation. Etude contrôlée, randomisée et prospective",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005181-12,0,0,0 2007-005182-35,18,2014-04-17,2014-04-17,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann- La Roche Ltd.,A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemoth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005182-35,0,0,0 2007-005182-35,18,2014-04-17,2014-04-17,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemoth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005182-35,0,0,0 2007-005182-35,18,2014-04-17,2014-04-17,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ROCHE,A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemoth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005182-35,0,0,0 2007-005194-56,14,2009-09-24,2009-10-16,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"Estudio multicéntrico de polisomnografía, aleatorizado, a doble ciego y controlado con placebo, de grupos paralelos, con grupo de referencia con tratamiento activo, para evaluar la eficacia y la segu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005194-56,0,0,0 2007-005194-56,14,2009-09-24,2009-10-16,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"Estudio multicéntrico de polisomnografía, aleatorizado, a doble ciego y controlado con placebo, de grupos paralelos, con grupo de referencia con tratamiento activo, para evaluar la eficacia y la segu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005194-56,0,0,0 2007-005195-14,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,ABIOGEN PHARMA,"A monocentre, randomised, double-blind, between-patient study to compare the effect of Vitamin D 300.000 IU orally vs placebo on bone metabolism, muscolar function, vascular system and infection in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005195-14,0,0,0 2007-005198-67,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Sécurité et tolérance des beta-bloquants cardiosélectifs au cours de la Broncho-Pneumopathie Chronique Obstructive (Reactive Airway Diseases And beta-Blockers : RADAB),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005198-67,0,0,0 2007-005199-15,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,HOSPITAL SANT JOAN DE DÉU,TRATAMIENTO DE LOS TUMORES VASCULARES DEL DESARROLLO CON BEVACIZUMAB A PHASE II STUDY OF BEVACIZUMAB FOR VASCULAR TUMORS OF CHILDHOOD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005199-15,0,0,0 2007-005201-21,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Karolinska University Hospital Huddinge, Department of Anaesthesiology and Intensive Care",Effects of the combination ketamine-dexmedetomidine in experimental pain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005201-21,0,0,0 2007-005203-18,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,GlaxoSmithKline Biologicals,An open Phase II study of immunization with the recMAGE-A3 + AS01B Antigen-Specific Cancer Immunotherapeutic in patients with MAGE-A3-positive unresectable and progressive metastatic cutaneous melanom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005203-18,0,0,0 2007-005204-40,2,2009-07-02,2009-07-02,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Intergroupe Francophone du Myélome,A PHASE III STUDY OF VELCADE (BORTEZOMIB) DEXAMETHASONE (VD) VERSUS VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005204-40,1,0,0 2007-005209-23,6,2011-03-30,2011-05-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Randomized Phase II of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects with Triple Negative (ER, PR, Her2 negative) Locally Advanced non-resectable and/or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005209-23,0,0,0 2007-005210-39,20,2012-03-30,2012-03-30,18,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Who are Medically Managed - The TRILOGY ACS ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005210-39,0,0,0 2007-005210-39,20,2012-03-30,2012-03-30,18,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Who are Medically Managed - The TRILOGY ACS ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005210-39,0,0,0 2007-005212-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL SANT JOAN DE DÉU,"ESTUDIO COMPARATIVO DEL TRATAMIENTO CON BOMBA DE INSULINA SUBCUTANEA, INSULINA GLARGINA E INSULINA NPH EN NIÑOS DIABÉTICOS DE 0 A 6 AÑOS DE EDAD Comparative study between treatment with insulin pump, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005212-41,0,0,0 2007-005218-38,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Essai prospectif Randomisé contre placebo en double aveugle de l’hydroxychloroQUine dans le traitement du syndrome de sJOgren primitif (JOQUER),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005218-38,0,0,0 2007-005219-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU - Hôpitaux de Rouen,Effets de l’administration orale d'arginine sur le métabolisme protéique intestinal chez des patients porteurs d’une iléo-jéjunostomie après résection intestinale étendue.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005219-25,0,0,0 2007-005220-33,7,2013-01-13,2013-02-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005220-33,0,0,0 2007-005220-33,7,2013-01-13,2013-02-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005220-33,0,0,0 2007-005221-29,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,Curve di Wash-in/wash-out e tempi di recupero dopo anestesia con Sevoflurane vs. Desflurane in pazienti affetti da obesita' patologica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005221-29,0,0,0 2007-005222-69,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Associazione Progetto Oncologia UMAN.A,Randomized phase II trial evaluating the activity and the tolerability of fixed dose of oxycodone and increasing dose of pregabalin versus increasing dose of oxycodone and fixed dose of pregabalin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005222-69,0,0,0 2007-005224-32,1,2012-06-01,2012-06-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Oxford,A randomised controlled trial of the angiotensin converting enzyme inhibitor ramipril in asymptomatic aortic stenosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005224-32,0,0,0 2007-005225-30,8,2010-01-04,2041-01-04,7,1,0,0,0,0,2,0,0,1,0,0,0,0,1,GW Pharma Ltd.,"A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP DOSE-RANGE EXPLORATION STUDY OF SATIVEX IN RELIEVING PAIN IN PATIENTS WITH ADVANCED CANCER, WHO EXPERIENCE INADEQUATE ANALGESIA DURING OP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005225-30,0,0,0 2007-005225-30,8,2010-01-04,2041-01-04,7,1,0,0,0,0,2,0,0,1,0,0,0,0,1,GW PHARMA LTD,"A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP DOSE-RANGE EXPLORATION STUDY OF SATIVEX IN RELIEVING PAIN IN PATIENTS WITH ADVANCED CANCER, WHO EXPERIENCE INADEQUATE ANALGESIA DURING OP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005225-30,0,0,0 2007-005229-31,2,2010-06-22,2010-06-22,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development and Commercialization, Inc.","A Multi center, Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of OPC-67683 in Patients with Pulmonary Sputum Cultu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005229-31,0,0,0 2007-005230-37,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Leiden University Medical Center,"Randomised Controlled Study on the Effects of Imiquimod, a TLR 7 Activating Agent, on the HPV16-Specific Immune Response Following HPV16 E6/E7 Synthetic Long Peptides Vaccination in Women with HPV16 P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005230-37,0,0,0 2007-005231-28,1,2009-04-15,2009-04-15,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,"Med. Univ. Wien, Universitätsklinik für Anästhesie, allgemeine Intensivmedizin und Schmerzmedizin",Postoperative Analgesie and Antihyperalgesia of Tramadol and Acetaminophen peroral after Caesarean Section,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005231-28,0,0,0 2007-005232-81,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Havenziekenhuis/ErasmusMC,Wet-wrap treatment in children with atopic eczema using the wet-wrap method with diluted corticosteroids versus emollients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005232-81,0,0,0 2007-005233-11,1,2013-09-17,2013-09-17,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"University Hospitals Of Leicester NHS Trust, Gwendolen Road","A Phase II, Randomized, Partially observer-blind, Single-centre study to Evaluate Safety and Immunogenicity of MF59-adjuvanted or Non-adjuvanted H5N1 Booster Influenza Vaccines in Adults Primed with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005233-11,0,0,0 2007-005234-36,4,2013-01-24,2013-01-24,2,0,0,0,0,0,3,0,0,1,1,0,1,0,1,NovaRx Corporation,"Registration Phase III Study of Lucanix™ (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer: An International Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Lucanix™ Ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005234-36,0,0,0 2007-005235-29,3,2009-04-27,2009-04-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,HEXAL AG,"Efficacy and safety of Salmeterol/Fluticasone MDI HEXAL versus SeretideTM EvohalerTM in adolescent and adult patients with moderate-to-severe persistent asthma: A 12-week, multicenter, randomized, dou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005235-29,0,0,0 2007-005236-92,8,2009-11-19,2009-11-19,7,1,0,0,2,0,3,0,0,1,1,0,1,0,1,ORGANON ITALIA,"A 6-month, double-blind, randomized, placebo-controlled, parallel group outpatient trial, investigating the efficacy and safety of Org 50081 in adult patients with chronic primary insomnia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005236-92,0,0,0 2007-005236-92,8,2009-11-19,2009-11-19,7,1,0,0,2,0,3,0,0,1,1,0,1,0,1,NV Organon,"A 6-month, double-blind, randomized, placebo-controlled, parallel group outpatient trial, investigating the efficacy and safety of Org 50081 in adult patients with chronic primary insomnia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005236-92,0,0,0 2007-005237-10,6,2009-11-05,2010-04-13,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NV Organon,"A twenty-six weeks, open-label extension trial to evaluate safety and efficacy of Org 50081 in outpatients with chronic primary insomnia who completed clinical trial protocol 21106.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005237-10,0,0,0 2007-005241-38,1,2008-09-24,2008-09-24,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Lexicon Pharmaceuticals Incorporated,"A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI) wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005241-38,0,0,0 2007-005242-21,1,2011-04-08,2011-04-08,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,THE CHRISTIE NHS FOUNDATION TRUST,A pilot study of replacement therapy with recombinant TSH in central hypothyroidism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005242-21,0,0,0 2007-005244-25,1,2009-12-04,2009-12-04,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,"Aarhus University Hospital, Department M","Co-treatment with pegvisomant and a somatostatin analogue (SA) in SA-responsive acromegalic patients: impact on insulin sensitivity, glucose tolerance, and pharmacoeconomics",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005244-25,0,0,0 2007-005245-37,3,2012-06-14,2012-06-14,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Abbott GmbH & Co. KG,"An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005245-37,0,0,0 2007-005246-20,1,2011-12-31,2011-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Aarhus University Hospital, Skejby","Amiodarone prophylaxis for atrial fibrillation in patients undergoing surgery for lung cancer: A controlled, randomized, double blinded trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005246-20,0,0,0 2007-005248-26,1,2016-03-31,2016-03-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA S. MARIA DELLA MISERICORDIA,"INDUCTION, CONSOLIDATION AND INTENSIFICATION PROTOCOL FOR PATIENTS YOUNGER THAN 66 YEARS WITH PREVIOUSLY UNTREATED CD33 POSITIVE ACUTE MYELOID LEUKEMIA (AML)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005248-26,0,0,0 2007-005254-24,1,2008-03-17,2008-03-17,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Nuvelo, Inc","PHASE 2, MULTICENTER, OPEN-LABEL, TWO-STAGE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRA-ARTERIAL CATHETER-DIRECTED ALFIMEPRASE FOR RESTORATION OF NEUROLOGIC FUNCTION AND RAPID OPENING OF ARTERI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005254-24,0,0,0 2007-005256-16,3,2009-09-01,2009-09-01,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A 54 week, randomized, double-blind, parallel-group, multicenter study evaluating the long-term gastrointestinal (GI) safety and tolerability of aliskiren (300 mg) compared to ramipril (10 mg) in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005256-16,0,0,0 2007-005256-16,3,2009-09-01,2009-09-01,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 54 week, randomized, double-blind, parallel-group, multicenter study evaluating the long-term gastrointestinal (GI) safety and tolerability of aliskiren (300 mg) compared to ramipril (10 mg) in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005256-16,0,0,0 2007-005258-22,1,2009-07-23,2009-07-23,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Bayer Schering Pharma AG,"A multi-center, double-blind, randomized, parallel-group study to evaluate cycle control and safety of 6 different regimens of an oral contraceptive containing estradiol and drospirenone in healthy fe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005258-22,0,0,0 2007-005261-35,1,,,0,0,0,0,0,3,2,0,0,1,1,1,0,1,1,Fresenius Biotech GmbH,"Treatment of Graves’ Orbitopathy (GO) with ATG-Fresenius: A prospective, randomized, open, controlled phase II study to assess the efficacy and safety of an add-on ATG-Fresenius treatment versus a sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005261-35,0,0,0 2007-005263-97,3,2008-04-23,2008-04-23,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,DAIICHI SANKYO PHARMA DEVELOPMENT,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE COMPARATOR-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF RIVOGLITAZONE AS MONOTHERAPY TREATMENT OF TYPE 2 DIABETES MELLITUS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005263-97,0,0,0 2007-005268-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University Hospital Virgen del Rocío, Andalousian Health Service",Eficacia y seguridad del tratamiento de infecciones nosocomiales graves causadas por Acinetobacter baumannii multirresistente con rifampicina más imipenem. Efficacy and safety to the treatment of seve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005268-29,0,0,0 2007-005269-36,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,INTRATHECAL ROPIVACAINE USE IN CESAREAN SECTION : DETERMINATION OF “MINIMUM LOCAL ANESTHETIC DOSE (MLAD)”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005269-36,0,0,0 2007-005274-31,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PISANA,Efficacy assessment of tetracycline in patients with progressive external ophthalmoplegia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005274-31,0,0,0 2007-005275-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,,Postoperative analgesia with continuous epidural bupivacaine/sufentanil versus bupivacaine/morphine in patients scheduled for major surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005275-33,0,0,0 2007-005279-32,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,A.O. San Gerardo di Monza,"ANESTHESIOLOGICAL STRATEGIES IN ELECTIVE CRANIOTOMY: RANDOMIZED, EQUIVALENCE, OPEN TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005279-32,0,0,0 2007-005281-12,1,2010-01-11,2010-01-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec BVBA,"A Phase IIa randomized, partially blinded trial of telaprevir (VX-950) in treatment-naïve subjects with chronic genotype 4 hepatitis C infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005281-12,0,0,0 2007-005284-98,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Servicio de Anestesiología y Reanimación,Ensayo Clínico aleatorio y a doble cieo de eficacia analgésica postoperatoria en cirugía colo-rectal y cirugía hepática con infusión contínua de anestesico local verus suero salino en la incisión quir...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005284-98,0,0,0 2007-005287-27,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,OSPEDALE POLICLINICO S. MATTEO,A Phase II Multicenter Pilot Study of the Safety and Efficacy of Doxycycline on disease progression in early to moderate ATTR amyloidosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005287-27,0,0,0 2007-005288-86,1,2011-03-01,2011-03-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"A Phase IIIb, open-label, run-in and double-blind, placebo-controlled, randomized study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with stable-dose methotrexa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005288-86,0,0,0 2007-005289-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Jules Bordet,"A non randomized , stratified phase II trial evaluating efficacy and safety of oxaliplatin in combination with 5-Fluorouracil in patients with platinum-sensitive and platinum-resistant recurrent ovari...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005289-11,0,0,0 2007-005291-14,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,CHU Clermont-Ferrand,Evaluation des seuils nociceptifs chez les patients dépendants aux opiacés sous traitement de substitution par méthadone ou buprénorphine haute dose.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005291-14,0,0,0 2007-005294-60,2,2017-05-17,2017-05-17,1,1,0,0,0,2,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"Multicenter, single-arm, single-stage, phase II trial to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005294-60,0,0,0 2007-005294-60,2,2017-05-17,2017-05-17,1,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"Multicenter, single-arm, single-stage, phase II trial to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or soft tis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005294-60,0,0,0 2007-005299-15,1,2008-04-15,2008-04-15,1,0,0,1,0,1,1,0,0,1,1,1,0,0,1,Astex Therapeutics Ltd,"A Phase I/IIa Open-label Dose Escalation Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283 in Patients with Intermediate or High-Risk Myelofibrosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005299-15,0,0,0 2007-005300-41,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,University Medical Center Utrecht,"Rivastigmine for delirium in Intensive Care patients, a double-blind, randomised, placebo-controlled, multi-center add-on trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005300-41,0,0,0 2007-005301-22,1,2008-05-26,2008-05-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"An 8 day, randomised, double blind, 3-way crossover trial of repeat doses of intranasal GSK256066 and fluticasone propionate in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005301-22,0,0,0 2007-005302-44,1,2008-05-21,2008-05-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A randomised, double blind, 2-way crossover trial of 8 days repeat dosing with intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects with seasonal allergic rhin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005302-44,0,0,0 2007-005306-49,4,2011-11-14,2012-08-15,4,0,0,0,0,2,2,0,0,1,0,0,1,0,0,"Department of Haematology, Herlev Hospital, University of Copenhagen",A Phase II Study Of Vorinostat (MK-0683) In Patients With Polycythaemia Vera And Essential Thrombocythaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005306-49,0,0,0 2007-005306-49,4,2011-11-14,2012-08-15,4,0,0,0,0,2,2,0,0,1,0,0,1,0,0,VUmc,A Phase II Study Of Vorinostat (MK-0683) In Patients With Polycythaemia Vera And Essential Thrombocythaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005306-49,0,0,0 2007-005306-49,4,2011-11-14,2012-08-15,4,0,0,0,0,2,2,0,0,1,0,0,1,0,0,Herlev Hospital,A Phase II Study Of Vorinostat (MK-0683) In Patients With Polycythaemia Vera And Essential Thrombocythaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005306-49,0,0,0 2007-005311-25,1,2013-08-30,2013-08-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Ritva Jokela,Ondansetronin vaikutus parasetamolin kipulääkevasteeseen tähystyksen kautta tehtävän kohdunpoiston yhteydessä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005311-25,0,0,0 2007-005312-62,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Pierre Fabre Médicament,Etude chez le sujet volontaire sain de l’effet de carbolevure versus placebo sur la fermentation intestinale induite par l’ingestion de lactulose.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005312-62,0,0,0 2007-005313-19,8,2008-12-08,2008-12-08,3,1,0,0,2,0,4,0,0,1,1,0,1,0,1,Eisai Ltd,"A multicentre, randomised, active comparator, parallel group study to compare the effect on cognition of adjunctive therapy with zonisamide versus sodium valproate.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005313-19,0,0,0 2007-005315-26,3,2011-04-07,2011-04-07,1,0,0,0,0,0,2,0,1,2,1,0,0,0,0,"CONRAD, Eastern Virgina Medical School",SPERM SUPPRESSION AND CONTRACEPTIVE PROTECTION PROVIDED BY NORETHISTERONE ENANTATE (NET-EN) COMBINED WITH TESTOSTERONE UNDECANOATE (TU) IN HEALTHY MEN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005315-26,1,0,0 2007-005315-26,3,2011-04-07,2011-04-07,1,0,0,0,0,0,2,0,1,2,1,0,0,0,0,CONRAD EASTERN VIRGINIA MEDICAL SCHOOL,SPERM SUPPRESSION AND CONTRACEPTIVE PROTECTION PROVIDED BY NORETHISTERONE ENANTATE (NET-EN) COMBINED WITH TESTOSTERONE UNDECANOATE (TU) IN HEALTHY MEN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005315-26,1,0,0 2007-005317-19,7,2010-11-01,2010-11-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Efecto de insulina detemir en combinación con liraglutida y metformina en comparación con liraglutida y metformina en sujetos con diabetes tipo 2. Ensayo de 26 semanas, aleatorizado, abierto, de grupo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005317-19,0,0,0 2007-005317-19,7,2010-11-01,2010-11-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"Efecto de insulina detemir en combinación con liraglutida y metformina en comparación con liraglutida y metformina en sujetos con diabetes tipo 2. Ensayo de 26 semanas, aleatorizado, abierto, de grupo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005317-19,0,0,0 2007-005322-68,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI,Low-dose oral imatinib in the treatment of scleroderma pulmonary involvement: a phase II pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005322-68,0,0,0 2007-005325-30,7,2012-01-01,2012-02-21,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Double-Blind, Placebo Controlled, Multi-Centre, Randomised Study of AZD0530 in Patients with Advanced Ovarian Cancer Sensitive to Platinum-Based Chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005325-30,0,0,0 2007-005330-37,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),"Pharmacokinetics of atazanavir at the dose of 300mg or 400mg in subjects with HIV-1 infection and non-decompensated hepatic cirrhosis (Child-Pugh A o B, Metavir F4), crossover study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005330-37,0,0,0 2007-005332-83,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA DI CASERTA,"Combined therapy with Adefovir and Interferon-Pegylated alfa 2a vs Adefovir alone, in patients affected by chronic hepatitis B, HbeAg negative (The PAC (Peg Adefovir Combination) Study).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005332-83,0,0,0 2007-005333-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital of Grenoble,Comparaison des effets du bosentan et de la pression positive continue sur les complications cardiovasculaires du syndrome d’apnées du sommeil,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005333-11,0,0,0 2007-005338-35,1,2009-12-03,2009-12-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A double-blind, placebo-controlled, parallel group study to evaluate the effects of two regimens of GW856553, over a period of 3 months, on in-vivo macrophage activity, as assessed by FDG-PET/CT imagi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005338-35,0,0,0 2007-005341-38,11,2011-08-31,2013-08-31,8,1,0,0,2,0,2,0,0,1,1,0,1,0,1,Schering Plough Research Institute,"""Estudio para determinar la actividad de SCH 717454 en sujetos con Osteosarcoma o Sarcoma de Ewing que hayan recaído después de terapia sistémica estándar."" ""A Study to Determine the Activity of SCH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005341-38,0,0,0 2007-005341-38,11,2011-08-31,2013-08-31,8,1,0,0,2,0,2,0,0,1,1,0,1,0,1,SCHERING PLOUGH RESEARCH INSTITUTE,"""Estudio para determinar la actividad de SCH 717454 en sujetos con Osteosarcoma o Sarcoma de Ewing que hayan recaído después de terapia sistémica estándar."" ""A Study to Determine the Activity of SCH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005341-38,0,0,0 2007-005343-16,1,2008-08-18,2008-08-18,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, open, study to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine when administered as a booster dose to children aged 16-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005343-16,0,0,0 2007-005344-25,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Foundation for Liver Research,High-dose versus standard-dose weight-based ribavirin in combination with peginterferon alfa-2a for patients infected with hepatitis C virus genotype 1 or 4,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005344-25,0,0,0 2007-005346-20,1,2009-06-26,2009-06-26,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Leeds Teaching Hospitals NHS Trust,Does nebulised tobramycin (TOBI) via e-flow delivery systems cause a raised peak serum tobramycin level in children with Cystic Fibrosis?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005346-20,0,0,0 2007-005349-39,3,2009-10-12,2009-12-10,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,BioGeneriX AG,Dose-finding of a fixed dose XM22 in patients with breast cancer receiving 4 cycles of chemotherapy versus 6 mg Neulasta®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005349-39,0,0,0 2007-005352-17,1,2014-07-22,2014-07-22,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,University Bonn,"A twelve-week, multicenter, randomized, double-blind, placebo-controlled trail of Bupropion for the treatment of apathy in Alzheimer’s Dementia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005352-17,0,0,0 2007-005353-28,1,2011-08-17,2011-08-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A randomised, double-blind, evaluation of the effects of paracetamol on the BOLD fMRI response to painful stimuli in subjects with osteoarthritis. Estudio doble-ciego, aleatorizado para evaluar los e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005353-28,0,0,0 2007-005362-12,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,C.H.U. de RENNES,Etude comparative de l'imagerie cellulaire et inflammatoire (USPIO (SH U 555 C)) et de l'IRM multimodale 3 tesla dans l'analyse des lésions de la SEP et leur progression. Etude longitudinale sur 3 ans...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005362-12,0,0,0 2007-005363-10,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,C.H.U. de RENNES,Etude comparative de l'imagerie cellulaire et inflammatoire (USPIO (SH U 555 C)) et de la RMN multimodale dans l'analyse des lésions de sclérose en plaques : étude longitudinale sur 3 ans d'une cohort...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005363-10,0,0,0 2007-005364-27,1,2022-07-15,2022-07-15,1,1,0,0,0,0,4,0,0,1,1,1,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Ultrasonographic characterization of small nodules in cirrhotic patients using contrast media through splancnic infusion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005364-27,0,0,0 2007-005365-35,5,2014-10-14,2014-10-28,5,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Fresenius Medical Care Deutschland GmbH,"Multicenter, parallel, controlled, randimized, single-blind clinical evaluation of new low sodium peritoneal dialysis solution on patients with hypertension treated with continuous ambulatory or autom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005365-35,0,0,0 2007-005365-35,5,2014-10-14,2014-10-28,5,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Gambro Lundia AB,"Multicenter, parallel, controlled, randimized, single-blind clinical evaluation of new low sodium peritoneal dialysis solution on patients with hypertension treated with continuous ambulatory or autom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005365-35,0,0,0 2007-005365-35,5,2014-10-14,2014-10-28,5,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Fresenius Medcial Care Deutschland GmbH,"Multicenter, parallel, controlled, randimized, single-blind clinical evaluation of new low sodium peritoneal dialysis solution on patients with hypertension treated with continuous ambulatory or autom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005365-35,0,0,0 2007-005367-10,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"A Phase I/II, open-label, dose escalation trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of RAF265 (CHIR-265) administered orally to patients with locally advanced or metastatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005367-10,0,0,0 2007-005371-34,1,2011-10-20,2011-10-20,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,BEAUFOUR IPSEN PHARMA,"EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIA A 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005371-34,0,0,0 2007-005373-58,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,EVALUATION OF DIAGNOSTIC ACCURACY OF 68GA-CITRATE PET/CT IN PATIENTS WITH INFLAMMATORY-INFECTIOUS DISEASES.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005373-58,0,0,0 2007-005374-31,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL`ADULTO,An open label phase II trial of Clofarabine and Temsirolimus in older patients with relapsed or refractory Acute Myeloid Leukemia (AML),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005374-31,0,0,0 2007-005376-13,15,2010-03-02,2010-03-02,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd.,"A MULTICENTER, FOUR ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING OPTIMIZED DOSING IN A PROGRAF-/ ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT SUBJECTS. Protocol for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005376-13,0,0,0 2007-005377-63,1,2012-07-17,2012-07-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Beaufour Ipsen pharma,"Effect of oral EGb 761® on Brain Glucose Metabolism in Three Groups of Elderly with Memory Complaint, mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, randomised, double-blind, par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005377-63,0,0,0 2007-005382-35,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Akela Pharma Inc,"A Multicenter, Multinational, Randomized, Open-Label, Parallel-Group Trial to Evaluate the Safety of Fentanyl TAIFUN® Treatment after Titrated Dose Administration and the Current Breakthrough Pain Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005382-35,0,0,0 2007-005383-27,8,2013-04-01,2013-04-11,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 3-year, multicenter, double-blind, randomized, placebo-controlled extension to CZOL446H2301E1 to evaluate the efficacy and long term safety of 6 and 9 years zoledronic acid treatment of postmenopaus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005383-27,0,0,0 2007-005383-27,8,2013-04-01,2013-04-11,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 3-year, multicenter, double-blind, randomized, placebo-controlled extension to CZOL446H2301E1 to evaluate the efficacy and long term safety of 6 and 9 years zoledronic acid treatment of postmenopaus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005383-27,0,0,0 2007-005385-12,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"GlobeImmune, Inc.","A Phase 2 Randomized, Open Label, Multi-center, Therapeutic Trial of the Efficacy, Immunogenicity, and Safety of GI-5005; an Inactivated Recombinant Saccharomyces cerevisiae Expressing a Hepatitis C V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005385-12,0,0,0 2007-005386-35,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"GlobeImmune, Inc.","A Phase 2 Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces cerevisiae Expressing Mutant Ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005386-35,0,0,0 2007-005388-85,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Nancy,’addition de kétoprofène à la lidocaïne en anesthésie locorégionale intraveineuse améliore-t-elle la tolérance du garrot pneumatique et l’analgésie postopératoire lors d’une chirurgie du canal carpien,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005388-85,0,0,0 2007-005389-11,1,2010-09-28,2010-09-28,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Oxford,"A Phase I/IIa Study of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium falciparum Malaria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005389-11,0,0,0 2007-005391-13,1,2012-05-18,2012-05-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Oxford,"Cancer Oesophagus Gefitinib(COG) - Phase III randomised, double-blind, placebo-controlled trial of gefitinib (Iressa®) versus placebo in oesophageal cancer progressing after chemotherapy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005391-13,0,0,0 2007-005391-13,1,2012-05-18,2012-05-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Royal Wolverhampton Hospitals NHS Trust,"Cancer Oesophagus Gefitinib(COG) - Phase III randomised, double-blind, placebo-controlled trial of gefitinib (Iressa®) versus placebo in oesophageal cancer progressing after chemotherapy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005391-13,0,0,0 2007-005392-34,1,2011-11-21,2011-11-21,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,A phase III long-term follow-up study to assess antibody persistence and immunological memory in children previously vaccinated with four doses of pneumococcal conjugate vaccine in primary vaccination...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005392-34,0,0,0 2007-005393-31,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Akela Pharma Inc,"A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial to Evaluate Efficacy and Safety of Fentanyl TAIFUN® Treatment after Titrated Dose Administration for Breakt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005393-31,0,0,0 2007-005395-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,RICARDO MORENO OTERO/MARIA CHAPARRO SANCHEZ,EFECTO DE SORAFENIB SOBRE LA MODULACION DE LOS FACTORES SOLUBLES ANGIOGIOGÉNICOS EN PACIENTES CON CARCINOMA HEPATOCELULAR IRRESECABLE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005395-14,0,0,0 2007-005396-34,1,2008-12-19,2008-12-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Birmingham,Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005396-34,0,0,0 2007-005397-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI,EFFECT OF FSH TREATMENT ON ANEUPLOIDIC RATE IN OLIGOASTENOZOOSPERMIC PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005397-31,0,0,0 2007-005398-73,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Karolinska University Hospital,Treatment of malignant mesothelioma with pemetrexed (Alimta) + platinum (4 courses) or pemetrexed (Alimta) + platinum (4 courses) followed by Caelyx single drug (4 courses).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005398-73,0,0,0 2007-005399-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medizinische Universität Graz - Abteilung für Thorax- und Hyperbare Chirurgie,"Penetration of Cubicin® and Fosfomycin® into skeletal muscle and subcutaneous adipose tissue of necrotizing soft tissue infections, measured by in-vivo microdialysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005399-15,0,0,0 2007-005400-40,1,2014-04-07,2014-04-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Vassilis Georgoulias, Prof. of Internal Medicine-Oncology of Medical Dpt University of Crete",A pilot feasibility study to evaluate the efficacy of lapatinib in eliminating cytokeratin-positive tumor cells circulating in the blood of women with brest cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005400-40,0,0,0 2007-005401-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Effect of Aliskiren on Muscle Sympathetic Nerve Activity in hypertensive patients with chronic kidney disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005401-22,0,0,0 2007-005402-53,1,2009-12-15,2009-12-15,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Academisch Ziekenhuis Maastricht,Primary G-CSF prophylaxis during the first two cycles only or throughout all chemotherapy cycles in breast cancer patients at risk of febrile neutropenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005402-53,0,0,0 2007-005403-17,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,GE Healthcare,"A prospective, comparative single center study of Hexvix® fluorescence uretero-renoscopy and white light uretero-renoscopy in the detection of upper urinary tract urothelial cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005403-17,0,0,0 2007-005405-21,1,2008-05-10,2008-05-10,1,1,0,1,0,0,1,0,1,1,0,0,0,0,3,Radboud University Nijmegen Medical Centre,The influence of Raltegravir (MK_0518) on the pharmacokinetics of single-dose Lamotrigine in healthy male subjects (GRANOLA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005405-21,0,0,0 2007-005409-22,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI,RANDOMIZED MULTICENTER STUDY ON DALTEPARIN TREATMENT IN IVF PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005409-22,0,0,0 2007-005410-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.,“Estudio piloto aleatorizado comparativo de tacrolimus vs ciclofosfamida-prednisona en la nefropatía membranosa idiopática”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005410-39,0,0,0 2007-005414-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA SANITARIA N. 3 GENOVESE,"Efficacy and activity of levetiracetam on Multiple Sclerosis cerebellar symptoms: a multicenters double blind, randomized, placebo-controlled, cross over study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005414-40,0,0,0 2007-005421-30,1,2009-03-01,2009-03-01,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Nektar Therapeutics,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Dose Escalation Study to Evaluate the Efficacy, Safety and Tolerability of NKTR-118 in Patients with Opioid-Induced Constipation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005421-30,0,0,0 2007-005422-76,1,2011-05-01,2011-05-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,PD Dr. Gerhard Treiber,"Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An open label, stratified, single-arm phase II study of Bevacizumab and RAD001",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005422-76,0,0,0 2007-005424-33,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Sint Lucas Andreas,Epidural analgesia versus Remifentanil PCA during labour,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005424-33,0,0,0 2007-005425-30,1,2009-09-21,2009-09-21,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Nerviano Medical Sciences S.r.l.,An Exploratory Phase II Study of PHA-739358 in Patients with Multiple Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005425-30,0,0,0 2007-005429-31,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Comparison of desflurane versus sevoflurane during anaesthesia with low dosage of remifentanil in ginecological laparoscopic interventions: neuroendocrine and cellular response.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005429-31,0,0,0 2007-005434-37,10,2014-09-12,2014-09-12,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bristol Myers Squibb International Corporation,"A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects with Rheumatoid Arthrit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005434-37,0,0,0 2007-005434-37,10,2014-09-12,2014-09-12,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects with Rheumatoid Arthrit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005434-37,0,0,0 2007-005435-28,5,2009-06-18,2009-09-18,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Limited,"Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005435-28,0,0,0 2007-005437-11,1,,,0,1,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de NICE,Arthrose érosive des doigts : traitement par méthotrexate versus placebo- évaluation de l’action clinique et structurale (IRM dédiée)- Etude ADEM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005437-11,0,0,0 2007-005439-27,9,2012-12-06,2012-12-06,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"UCB BIOSCIENCES, Inc.","A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/day Monotherapy in Subjects with Partial-onset Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005439-27,1,0,0 2007-005439-27,9,2012-12-06,2012-12-06,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"SCHWARZ BIOSCIENCES, Inc.","A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/day Monotherapy in Subjects with Partial-onset Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005439-27,1,0,0 2007-005440-25,10,2014-12-10,2015-02-04,7,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"SCHWARZ BIOSCIENCES, Inc.","A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005440-25,1,1,0 2007-005440-25,10,2014-12-10,2015-02-04,7,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"UCB BIOSCIENCES, Inc.","A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005440-25,1,1,0 2007-005440-25,10,2014-12-10,2015-02-04,7,1,1,0,0,0,3,0,0,2,0,0,0,0,1,UCB BIOSCIENCES INC.,"A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005440-25,1,1,0 2007-005441-38,10,2012-02-26,2012-02-29,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005441-38,0,0,0 2007-005441-38,10,2012-02-26,2012-02-29,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005441-38,0,0,0 2007-005442-20,5,2009-05-12,2009-05-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Limited,"Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children with Attention Impairment Following Cancer Treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005442-20,0,0,0 2007-005446-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Impact de la variabilité des paramètres pharmacocinétiques et pharmacodynamiques de l'imipénème en association avec l'amikacine sur l'évolution des pneumonies acquises sous ventilation mécanique à bac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005446-20,0,0,0 2007-005450-23,8,2011-06-29,2011-06-29,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Teva Pharmaceutical Industries Ltd,"A Multinational, Multicenter, Randomized, Parallel-Group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod ov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005450-23,0,0,0 2007-005450-23,8,2011-06-29,2011-06-29,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TEVA ITALIA srl,"A Multinational, Multicenter, Randomized, Parallel-Group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of laquinimod ov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005450-23,0,0,0 2007-005451-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Long-term use of antipsychotics for behavioral symptoms in patients with mental retardation; a controlled discontinuation study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005451-42,0,0,0 2007-005452-16,1,2009-11-23,2009-11-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,"Allergopharma Joachim Ganzer KG an afilliate of Merck KGaA, Darmstadt","A multicentre randomised placebo-controlled, double-blind clinical trial for eval¬ua¬tion of safety and efficacy of pre-seasonal specific immunotherapy with a hypoallergenic extract of a 6 grass and r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005452-16,0,0,0 2007-005453-36,1,2012-01-14,2012-01-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Central and North West London NHS Foundation Trust (Camden Provider Services),The Effects of Standard vs. Tailored use of the Combined Oral Contraceptive on Continuation Rates at one year.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005453-36,0,0,0 2007-005455-42,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,University Medical Center Utrecht,ENDO ACE TRIAL Endoscopic Balloon Dilatation of stenotic ileocecal anastomosis in Crohn´s disease with or without additive local steroid injection and oral Budenofalk; a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005455-42,0,0,0 2007-005459-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,Study of superficial lynmph nodes whit superparamagnetic contrast and RMN in patient affected by melanoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005459-41,0,0,0 2007-005460-28,13,2010-07-13,2014-03-11,8,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label, multi-center, expanded access study of RAD001 in patients with metastatic carcinoma of the kidney who are intolerant of or have progressed despite any available vascular endothelial gro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005460-28,0,0,0 2007-005460-28,13,2010-07-13,2014-03-11,8,1,0,0,0,1,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An open-label, multi-center, expanded access study of RAD001 in patients with metastatic carcinoma of the kidney who are intolerant of or have progressed despite any available vascular endothelial gro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005460-28,0,0,0 2007-005460-28,13,2010-07-13,2014-03-11,8,1,0,0,0,1,0,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A","An open-label, multi-center, expanded access study of RAD001 in patients with metastatic carcinoma of the kidney who are intolerant of or have progressed despite any available vascular endothelial gro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005460-28,0,0,0 2007-005461-35,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Servicio de Oncología. Hospital Vall d'Hebron,"Individualización de la dosis de docetaxel en el tratamiento de pacientes oncológicos mediante monitorización terapéutica de los niveles plasmáticos de docetaxel libre, tras test de minidosis y ajuste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005461-35,0,0,0 2007-005462-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,St. Eriks Eye Hospital,"A prospective, randomized, masked and controlled trial of intravitreal ranibizumab (Lucentis®) combined with transpupillary thermotherapy (TTT) in patients with neovascular age-related macular degener...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005462-12,0,0,0 2007-005463-10,1,2008-03-31,2008-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharma A/S,A plaque test comparing three marketed products and two products in development and a vehicle control for the treatment of psoriasis vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005463-10,0,0,0 2007-005464-26,1,2012-03-12,2012-03-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Kings College London,The role of inflammatory biomarkers in pathophysiology of cardiovascular dysfunction in systemic inflammatory conditions- Part II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005464-26,0,0,0 2007-005464-26,1,2012-03-12,2012-03-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guys and St Thomas'NHS Foundation Trust,The role of inflammatory biomarkers in pathophysiology of cardiovascular dysfunction in systemic inflammatory conditions- Part II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005464-26,0,0,0 2007-005465-36,1,2011-03-31,2011-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Meletios Athanasios Dimopoulos,"Pilot study of the significance of PTEN expression in patients with hormone refractory prostate cancer (HRPC) treated with Cetuximab as monotherapy for 8 weeks, followed by Docetaxel plus Cetuximab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005465-36,0,0,0 2007-005468-28,2,2008-07-31,2008-07-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica,"A Phase III, randomized, double-blind, placebo controlled, multicenter, 3-period, 14 day crossover study to determine the 24-h lung function profile of indacaterol (300 μg o.d.) in patients with moder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005468-28,0,0,0 2007-005468-28,2,2008-07-31,2008-07-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Phase III, randomized, double-blind, placebo controlled, multicenter, 3-period, 14 day crossover study to determine the 24-h lung function profile of indacaterol (300 μg o.d.) in patients with moder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005468-28,0,0,0 2007-005472-13,1,2016-12-16,2016-12-16,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Plymouth Hospitals NHS Trust,Phase II Single Agent Lenalidomide (Revlimid) in Relapsed / Refratory Mantle Cell Lymphoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005472-13,0,0,0 2007-005474-31,1,2008-09-26,2008-09-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Akros Pharma Inc.,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-305 Administered for Six Months in Postmenopausal Women with Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005474-31,0,0,0 2007-005475-34,1,2013-03-18,2013-03-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,Prospektive Studie zur potentiellen Protektion der Ovarfunktion von Frauen mit gynäkologischen Malignomen unter Chemotherapie mittels GnRH-Analoga-Applikation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005475-34,0,0,0 2007-005476-14,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Pantarhei Bioscience BV,A feasibility study into the contraceptive effect of estetrol alone or combined with either progesterone or desogestel by daily oral administration to healthy female volunteers for 28 days,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005476-14,0,0,0 2007-005477-54,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE DI MILANO,Treosulfan-based conditioning and Rapamycin-base GvHD prophylaxis prior to un-manipulated allogeneic haematopoietic stem cell transplantation from a mismatched donor in patients with high risk haemato...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005477-54,0,0,0 2007-005478-29,7,2009-12-17,2009-12-31,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"PTC Therapeutics, Inc.",A Phase 2b Efficacy and Safety Study of PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005478-29,0,0,0 2007-005478-29,7,2009-12-17,2009-12-31,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"PTC THERAPEUTICS, INC.",A Phase 2b Efficacy and Safety Study of PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne and Becker Muscular Dystrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005478-29,0,0,0 2007-005486-34,1,2008-07-21,2008-07-21,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare,A Pilot Study to Evaluate the Relative Bioavailability of Diclofenac as Measured by Microdialysis After Repeated Doses of Two Topical Diclofenac Formulations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005486-34,0,0,0 2007-005487-28,2,2016-11-18,2016-11-18,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,HOVON Foundation,Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-risk Relapsed or Refractory CLL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005487-28,0,0,0 2007-005491-14,1,2010-06-30,2010-06-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,SCHERING-PLOUGH,TEMOZOLOMIDE IN METASTATIC BREAST CANCER PATIENTS AT HIGH RISK OF BRAIN RECURRENCE: IMPACT ON THE INCIDENCE OF BRAIN METASTASES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005491-14,0,0,0 2007-005495-13,4,2009-07-29,2009-11-12,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Limited,"A Multi-Center, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 (Perampanel) in Patients with Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neural...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005495-13,0,0,0 2007-005501-22,2,2009-11-10,2009-12-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharmaceuticals Products Ltd. A/S (LEO Pharma A/S),Effect of Calcipotriol Plus Hydrocortisone Ointment on the HPA Axis and Calcium Metabolism in Patients with Psoriasis Vulgaris on the Face and on the Intertriginous Areas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005501-22,0,0,0 2007-005501-22,2,2009-11-10,2009-12-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharma A/S,Effect of Calcipotriol Plus Hydrocortisone Ointment on the HPA Axis and Calcium Metabolism in Patients with Psoriasis Vulgaris on the Face and on the Intertriginous Areas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005501-22,0,0,0 2007-005503-17,1,2016-05-02,2016-05-02,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Medizinische Hochschule Hannover,Randomized multicenter double-blind study of phase III in patients after kidney transplantation with an acute cellular rejection with a tubulointerstinal component in kidney transplant with histologic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005503-17,0,0,0 2007-005506-42,1,2013-11-07,2013-11-07,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND RITUXIMAB (R-HDS) IN HIV+ PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL) REFRACTORY OR RELAPSED AFTER 1st LINE TREATMENT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005506-42,0,0,0 2007-005508-42,8,2008-10-29,2010-05-19,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation","""Estudio Fase 3 de Seguridad y Eficacia de Boceprevir en Pacientes con Hepatitis C Crónica Genotipo 1 No Tratados Previamente."" ""A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005508-42,0,0,0 2007-005508-42,8,2008-10-29,2010-05-19,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Schering Plough Research Institute,"""Estudio Fase 3 de Seguridad y Eficacia de Boceprevir en Pacientes con Hepatitis C Crónica Genotipo 1 No Tratados Previamente."" ""A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005508-42,0,0,0 2007-005512-12,1,2008-12-31,2008-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Leuven,Een verbetering van de analgesie na episiotomie door epidurale toediening van neostigmine en clonidine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005512-12,0,0,0 2007-005513-18,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA,Double blind randomized controlled study on the benefit-risk profile of in the treatment of at term or late preterm newborn infants with severe respiratory disorders and pulmonary hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005513-18,0,0,0 2007-005516-61,1,,,0,0,0,0,0,1,4,0,0,1,0,0,0,1,0,ISTITUTO GIANNINA GASLINI,Multicenter randomized study to assess the efficacy and the safety of two therapeutic regimens(high dose of imiglucerase versus co-administration of imiglucerase and miglustat) in type I Gaucher disea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005516-61,0,0,0 2007-005517-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,"Receptor radionuclide therapy with [177Lu- DOTA]0,Tyr3-octreotate (177Lu-DOTATATE): a phase II trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005517-20,0,0,0 2007-005520-32,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,GlaxoSmithKline R&D Ltd,"An open label, 7-day repeat dose study to evaluate the pharmacodynamics of SB-656933-AAA in patients with Ulcerative Colitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005520-32,0,0,0 2007-005523-15,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Radboud University Medical Centre,A phase II study of carboplatin –paclitaxel with bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small cell ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005523-15,0,0,0 2007-005525-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Traitement in utero de l’infection congénitale à cytomegalovirus (CMV) par valaciclovir : essai prospectif randomisé contre placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005525-29,0,0,0 2007-005528-34,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,N.V. Roche S.A.,Subcutaneous Treatment of Anemia in patients with a GFR Below 45 ml/min/1.73m2 through Injections with Mircera as low frequent as Once monthly,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005528-34,0,0,0 2007-005531-28,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Hanns-Ulrich Marschall,Ursodeoxycholic Acid in Morbidly Obese Patients Before Bariatric Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005531-28,0,0,0 2007-005534-36,1,2011-01-05,2011-01-05,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,King's College Hospital,"The effect of Exenatide on satiety, metabolic parameters and regional brain activation in response to nutrient ingestion in Type 2 diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005534-36,0,0,0 2007-005534-36,1,2011-01-05,2011-01-05,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,King's College London,"The effect of Exenatide on satiety, metabolic parameters and regional brain activation in response to nutrient ingestion in Type 2 diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005534-36,0,0,0 2007-005537-11,1,2017-03-24,2017-03-24,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,University Hospital Heidelberg,"Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005537-11,0,0,0 2007-005540-24,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Grupo Español de Tratamiento de los Tumores de Cabeza y Cuello (TTCC),"Ensayo clínico fase III aleatorizado, multicéntrico, de quimioterapia de inducción con la combinación docetaxel, cisplatino y 5-fluorouracilo (TPF) seguido de tratamiento concomitante con Cisplatino y...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005540-24,0,0,0 2007-005543-22,4,2012-07-05,2012-07-05,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Shire Human Genetic Therapies, Inc. (Shire HGT)","A Multi-center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients with Fabry Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005543-22,0,0,0 2007-005544-24,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI PADOVA,"Sperimental, controlled, randomized single blind study. Sufentanil vs fentanyl in patientes with thoracotomy for pulmonary resection and videolaparoscopic surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005544-24,0,0,0 2007-005546-20,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,academisch ziekenhuis Maastricht,Systemic effects of mild renal insufficiency: the relation between forearm blood flow and ADMA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005546-20,0,0,0 2007-005547-17,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Southampton University Hospital NHS Trust,Refeeding risks in patients requiring nutrition support. A twin centre double-blind randomised controlled trial of parenteral nutrition support.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005547-17,0,0,0 2007-005548-25,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,"Freistaat Bayern, vertreten durch Klinikum der Universität Regensburg","Prospective, randomised (using minimisation), double-blind, placebo controlled study to evaluate the safety and efficacy of human normal immunoglobulin as a prophylactic agent against infections in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005548-25,0,0,0 2007-005549-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,EXONHIT,"A pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, phase IIa study to determine the clinical safety/tolerability and exploratory efficacy of EHT 0202 (40 and 80 mg bid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005549-39,0,0,0 2007-005550-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,Ipratropio bromuro-albuterol association vs salbutamolo in asthma and gastroesophageal reflux,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005550-23,0,0,0 2007-005553-34,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Efficacité et tolérance de la doxycycline dans le traitement des maladies humaines à prions : un essai randomisé en double aveugle versus placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005553-34,0,0,0 2007-005554-23,1,2010-12-21,2010-12-21,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Imperial College London,"AN OPEN, NON-RANDOMISED PILOT STUDY OF ANTI-TNF-ALPHA THERAPY IN EARLY OR PROGRESSING HAM/TSP",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005554-23,0,0,0 2007-005563-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005563-10,0,0,0 2007-005564-27,1,2011-10-19,2011-10-19,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Effect of agomelatine (25 mg) given orally once a day for 7 days on cerebral activity measured by functional MRI during processing of emotional stimuli in patients with Major Depressive Disorder. A ra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005564-27,0,0,0 2007-005568-28,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PISANA,Safety study of rosiglitazone in patients with acromegaly and assessment of biochemical parameters of disease's activity.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005568-28,0,0,0 2007-005570-32,8,2009-09-10,2009-09-14,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Limited,A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Diseas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005570-32,0,0,0 2007-005570-32,8,2009-09-10,2009-09-14,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Medical Research Inc,A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Diseas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005570-32,0,0,0 2007-005570-32,8,2009-09-10,2009-09-14,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Manufacturing Limited,A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Diseas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005570-32,0,0,0 2007-005575-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Comparaison de la tolérance et de l'acceptabilité de la coloscopie sous sédation par mélange équimolaire d'oxygène et de protoxyde d'azote par rapport à l'anesthésie générale : Etude randomisée multic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005575-34,0,0,0 2007-005578-29,1,2012-08-31,2012-08-31,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,Mª Luz Couce,ESTUDIO PARA EVALUAR LA EFECTIVIDAD DEL TRATAMIENTO DIETÉTICO CON TRIHEPTANOINA EN PACIENTES CON DEFECTOS DE LA BETA OXIDACIÓN DE LOS ÁCIDOS GRASOS DE CADENA LARGA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005578-29,0,0,0 2007-005579-33,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Dr. Willmar Schwabe GmbH &Co. KG,Efficacy and tolerability of EPs® 7630 solution in patients (>=18 years old) with Acute Rhinopharyngitis (ARP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005579-33,0,0,0 2007-005580-95,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Goelams,"An open label, multicenter, non randomized phase II study to evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with Rituximab (MabThera®) in patients with follicula...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005580-95,0,0,0 2007-005582-36,1,2009-12-02,2009-12-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"DEFIANTE FARMACEUTICA,LDA","A RANDOMIZED MULTICENTRE PHASE II STUDY TESTING TOLERABILITY AND EFFICACY ON SURROGATE ENDPOINTS (LIPID PROFILE, VASCULAR INFLAMMATORY MARKERS AND THROMBOGENESIS) OF SIMVAPUFA FORMULATION (ASSOCIATION...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005582-36,0,0,0 2007-005583-27,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,KEDRION,"A multi-center, randomized, prospective, controlled open-label Phase II/III study to assess the safety and sealing efficacy of Kedrion Fibrin Sealant in patients eligible for anatomical pulmonary rese...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005583-27,0,0,0 2007-005584-10,3,2008-11-01,2008-11-01,2,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Pharmion Corporation,"A Phase 2, Randomized, Open-Label Study of Single Agent Azacitidine (Vidaza®) vs. Single Agent MGCD0103 vs. Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005584-10,1,0,0 2007-005584-10,3,2008-11-01,2008-11-01,2,0,0,0,0,1,2,0,0,2,1,0,0,0,1,MethylGene Inc,"A Phase 2, Randomized, Open-Label Study of Single Agent Azacitidine (Vidaza®) vs. Single Agent MGCD0103 vs. Azacitidine in Combination With MGCD0103 for the Treatment of Elderly Subjects With Newly Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005584-10,1,0,0 2007-005585-12,1,2008-03-28,2008-03-28,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Department of Internal Medicine of the University of Munich,"Prospektive, offene Studie zur Prüfung der Wirksamkeit der zusätzlichen Gabe des Somatostatinanalogon Octreotid (Sandostatin) bzw. des Dopaminagonisten Cabergolin (Dostinex) bei Patientin mit Akromega...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005585-12,0,0,0 2007-005601-22,1,2012-06-01,2012-06-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,,Proof–of–concept study 1 (POC1): Evaluation of effect of doxycycline versus placebo on retinal function and posterior segment neovascularization in patients with severe non-proliferative or early (no...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005601-22,0,0,0 2007-005607-18,1,2007-03-11,2007-03-11,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Ursapharm Arzneimittel GmbH & Co KG,"An open study comparing the effects of moxaverine on ocular blood flow in patients with age- related macular degeneration, primary open angle glaucoma and healthy control subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005607-18,0,0,0 2007-005611-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Fundació Institut de Recerca, Hospital Santa Creu i Sant Pau","Estudio comparativo del impacto de dos emulsiones lipídicas, una formulada con MCT, LCT, aceite de oliva y ácidos grasos omega 3 versus otra emulsión lipídica formulada con MCT y LCT, administradas po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005611-26,0,0,0 2007-005612-91,1,2013-09-10,2013-09-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Sektion Chirurgische Forschung, Univ.Klinik f.Chirurgie",Improving wound healing in chronic ulcus cruris venosum with native fibrin enriched with endogenous thrombocytes (controlled prospective randomized study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005612-91,0,0,0 2007-005613-19,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE,R-COMP 14 in elderly patients with high grade non-Hodgkin lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005613-19,0,0,0 2007-005615-26,5,2009-02-20,2009-02-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation",Safety of SCH 527123 in Subjects With Neutrophilic Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005615-26,0,0,0 2007-005615-26,5,2009-02-20,2009-02-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Schering Plough Research Institute, a division of Schering Corporation",Safety of SCH 527123 in Subjects With Neutrophilic Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005615-26,0,0,0 2007-005618-38,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,U.L.S.S. 9 DI TREVISO,The OPG/RANKL/RANK system: implication for osteoporosis and atherosclerosis development. Potential role of the treatment with Atorvastatin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005618-38,0,0,0 2007-005619-24,1,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,ErasmusmMC/ Sophia Children Hospital,Morphine intravenous vs. Acetaminophen intravenous in neonates and young infants undergoing major non-cardiac surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005619-24,0,0,0 2007-005620-32,3,2010-02-22,2010-04-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,HEXAL AG,"Efficacy and safety of Salmeterol/Fluticasone DPI HEXAL versus Seretide™ Accuhaler™ in adolescent and adult patients with moderate-to-severe persistent asthma: A 12-week, multicenter, randomized, doub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005620-32,0,0,0 2007-005621-30,1,2009-04-08,2009-04-08,1,0,0,0,1,0,4,0,0,1,1,1,1,0,1,BAUSCH&LOMB,"A multicenter, Investigator - masked, parallel-group, randomized study of the efficacy and safety of loteprednol etabonate 0.5% eyedrops versus dexamethasone 0.1% eyedrops in the treatment of ocular i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005621-30,0,0,0 2007-005625-29,11,2009-11-20,2009-11-23,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Cardiome Pharma Corp.,"A Phase III Prospective, Randomized, Double-Blind, Active-Controlled, Multi-Center, Superiority Study of Vernakalant Injection versus Amiodarone in Subjects with Recent Onset Atrial Fibrillation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005625-29,0,0,0 2007-005627-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHRU de TOURS,Evaluation de l'échographie de contraste pour l'appréciation précoce de l'effet d'un traitement anti-angiogénique sur le carcinome rénal avancé,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005627-15,0,0,0 2007-005628-34,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude de phase II d’identification de biomarqueurs de réponse au sunitinib chez des patients atteints d’une tumeur neuroendocrine peu différenciée avancée inopérable.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005628-34,0,0,0 2007-005630-36,2,2010-02-22,2010-02-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,HEXAL AG,"Double-blind, double-dummy, multi-center, randomized parallel group study to demonstrate therapeutic equivalence of Salmeterol/Fluticasone DPI HEXAL versus Seretide™ 100 Accuhaler™ over a period of 12...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005630-36,0,0,0 2007-005631-29,1,2011-12-12,2011-12-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Center for Spiseforstyrrelse, Endokrinologisk Afdeling M, Odense Universitetshospital",Cannabinoid CB1 receptor agonist treatment in severe chronic anorexia nervosa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005631-29,0,0,0 2007-005633-10,1,2008-11-25,2008-11-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ORTHO MCNEIL JANSSEN SCIENTIFIC AFFAIRS, LLC","A Phase 2, Open-Label, Non-Comparative Study of Doripenem in the Treatment of Nosocomial and Ventilator-Associated Pneumonia in Hospitals where Pseudomonas aeruginosa may be a Prevalent Pathogen.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005633-10,0,0,0 2007-005637-11,1,2010-12-08,2010-12-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,OM Pharma SA,"Efficacy of Broncho-Vaxom in elderly patients with chronic bronchitis; a double-blind, randomised, placebo-controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005637-11,0,0,0 2007-005639-26,3,2009-10-31,2009-10-31,3,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Oxford BioMedica,"A Multicenter, Double Blind, Placebo controlled, Randomized study of TroVax vs Placebo in the First Line treatment of Patients with Metastatic Colorectal Cancer receiving Chemo-based Therapy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005639-26,0,0,0 2007-005639-26,3,2009-10-31,2009-10-31,3,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Oxford BioMedica (UK) Limited,"A Multicenter, Double Blind, Placebo controlled, Randomized study of TroVax vs Placebo in the First Line treatment of Patients with Metastatic Colorectal Cancer receiving Chemo-based Therapy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005639-26,0,0,0 2007-005640-25,1,2010-09-21,2010-09-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Greater Glasgow & Clyde Health Board,"Effect of Tostran 2% Gel on Growth, Development & Bone Turnover in Hypogonadal Adolescent Boys",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005640-25,0,0,0 2007-005644-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AMC-UvA,"Bevacizumab, Radiotherapy and Temozolomide Safety study in resected and irresectable primary GBM patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005644-24,0,0,0 2007-005645-38,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,"Clinical Institute of Virology, Medical University of Vienna",B-cell memory and humoral immune response after primary immunization against tick borne encephalitis (TBE) in the elderly,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005645-38,0,0,0 2007-005647-14,1,2010-10-05,2010-10-05,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Cardiff University,Gamma Delta T Cells and their role in the acute phase reaction to intravenous bisphosphonates,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005647-14,0,0,0 2007-005648-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,C.H.U. de RENNES,Carcinome rénal à cellules claires (CRCC) traité par molécules antiangiogéniques en situation adjuvante: valeur pronostique et thérapeutique des altérations du gène VHL et de l’expression plasmatique ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005648-25,0,0,0 2007-005651-41,1,2010-02-02,2010-02-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Peter Lommer Kristensen,Erythropoietins betydning for den kognitive funktion hos diabetikere under eksperimentel hypoglykæmi.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005651-41,0,0,0 2007-005653-37,3,,,0,1,0,0,0,0,3,0,0,2,1,0,0,0,1,SkyePharma AG,"A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 250/10mcg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005653-37,0,0,0 2007-005654-22,1,2013-06-20,2013-06-20,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Transit-times of ultrasound contrast agent and flow pattern in sovrahepatic vein: effects of therapy with non selective beta blocker,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005654-22,0,0,0 2007-005655-42,1,2010-02-08,2010-02-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital",STUDY TITLE: - Early Metabolic Changes with Thiazide or Beta blocker Therapy for Essential Hypertension – open label extension phase with the potassium sparing diuretic- Amiloride.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005655-42,0,0,0 2007-005660-27,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,OraPharma Inc.,Multi-Center Phase 3 Trial of Minocycline HCl 1mg Microspheres for the Use in Subjects with Peri-Implantitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005660-27,0,0,0 2007-005665-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Montse Palacio Riera - Hospital Clínic de Barcelona - Maternitat,"Progesterona vaginal como tratamiento de mantenimiento en gestantes con amenaza de parto pretérmino. Ensayo clínico aleatorizado, enmascarado a doble ciego y controlado con placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005665-35,0,0,0 2007-005666-12,6,2011-01-11,2011-01-11,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,immatics biotechnologies GmbH,"An open label, multicenter Phase 1-2 study to investigate the effectiveness, safety and immunogenicity of a monotherapy with intradermal IMA910 plus GM-CSF following pre-treatment with low-dose cyclop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005666-12,0,0,0 2007-005668-28,6,2015-06-22,2015-06-22,3,1,0,0,0,1,0,0,0,1,1,0,1,0,1,Genzyme Europe BV,"A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (agalsidase beta) in Treatment-Naive Male Pediatric Patients with Fabry Disease Without Severe Symptom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005668-28,0,0,0 2007-005669-37,9,2017-06-23,2017-06-30,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Randomised Open Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincris...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005669-37,0,0,0 2007-005669-37,9,2017-06-23,2017-06-30,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL BV,"A Randomised Open Label, Multicentre Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincris...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005669-37,0,0,0 2007-005670-31,1,2008-09-17,2008-09-17,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Celgene Corporation,"A phase 2, multicenter, open-label, single arm, two-stage study to evaluate the efficacy and safety of CC-4047 (Pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005670-31,0,0,0 2007-005672-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,PALAU PHARMA SA,"DOUBLE-BLIND STUDY, RANDOMISED, ACTIVE AND PLACEBO CONTROLLED TO ASSESS THE CLINICAL EFFICACY, SKIN TOLERABILITY AND PHARMACOLOGICAL ACTIVITY OF UR-1505 OINTMENT AT THREE DIFFERENT STRENGHTS IN PATIEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005672-13,0,0,0 2007-005673-60,1,2009-08-10,2009-08-10,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Chelsea Therapeutics Inc,"A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP WITHDRAWAL-DESIGN STUDY TO ASSESS THE CLINICAL EFFECT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE BET...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005673-60,0,0,0 2007-005674-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SENESE,NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGICAL DEBULKING AND INTRAPERITONEAL CHEMOHYPERTHERMIA FOR STAGE III OVARIAN CANCER. A PROSPECTIVE PHASE II STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005674-31,0,0,0 2007-005675-34,1,2011-05-30,2011-05-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Daiichi Sankyo Development Ltd,"A PHASE 2 OPEN-LABEL RANDOMISED, TRIAL OF CS-1008 IN COMBINATION WITH IRINOTECAN VS IRINOTECAN ALONE IN SUBJECTS WITH METASTATIC COLORECTAL CARCINOMA WHO FAILED FIRST LINE OXALIPLATIN BASED CHEMOTHERA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005675-34,0,0,0 2007-005677-59,1,2009-03-10,2009-03-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Steno Diabetes Center,"Dobbeltblindet, randomiseret, enkeltcenter, investigator-sponsoreret studie af reaktioner ved applikationssted efter dyb samt superficiel subkutan og intradermal injektion af insulin detemir og saltva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005677-59,0,0,0 2007-005679-33,1,2016-12-12,2016-12-12,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg,Influence of the selective endothelin receptor-blocker Ambrisetan on the portal pressure in patients with cirrhosis Einfluss des selektiven Endothelin-Rezeptorblockers Ambrisentan auf den portalen ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005679-33,0,0,0 2007-005681-13,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"A pilot, single-blind, forced-titration study to assess the hemodynamic and hormonal effects, safety and tolerability of the aldosterone synthase inhibitor LCI699 in patients with primary hyperaldoste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005681-13,0,0,0 2007-005684-10,2,2010-03-30,2010-03-30,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"An open Phase I/IIa trial to investigate the maximum tolerated dose, safety, efficacy and pharmacokinetics of BI 811283 in combination with cytarabine in patients with previously untreated acute myelo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005684-10,0,0,0 2007-005684-10,2,2010-03-30,2010-03-30,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Boehringer Ingelheim España S.A.,"An open Phase I/IIa trial to investigate the maximum tolerated dose, safety, efficacy and pharmacokinetics of BI 811283 in combination with cytarabine in patients with previously untreated acute myelo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005684-10,0,0,0 2007-005685-12,1,2011-05-27,2011-05-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Universitätsklinik für Psychiatrie und Psychotherapie, Klin. Abteilung f. Biologische Psychiatrie",The influence of hormone replacement therapy on the cerebral serotonin-1A receptor distribution and mood in postmenopausal women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005685-12,0,0,0 2007-005687-27,11,2009-02-02,2009-02-28,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Takeda Global Research & Development Centre (Europe), Ltd.","A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of TAK-242 Versus Placebo in Subjects With Sepsis Induced Cardiovascular and Respiratory Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005687-27,0,0,0 2007-005690-59,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Genmab A/S,"A Dose-Escalation, Randomized Phase I/II trial of Zalutumumab - a Human Monoclonal Anti-EGF receptor Antibody - With or Without Irinotecan chemotherapy in Cetuximab refractory Colorectal Cancer patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005690-59,0,0,0 2007-005693-31,1,2009-05-05,2009-05-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BAYER,Contrast-enhanced MRI examination of cerebral neoplastic enhancing lesions: comparison of diagnostic efficacy of Gd-DOTA 0.5 M and gadobutrol 1.0 M at 0.1 mmol Gd/kg body weight: Intra-individual com...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005693-31,0,0,0 2007-005695-14,1,2008-08-07,2008-08-07,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A Double-Blind, Placebo-Controlled, Randomized, Single-Dose, 2-Period Crossover Study of the Pharmacodynamics of Orally Administered PSI-697 in Healthy Subjects Who Smoke",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005695-14,0,0,0 2007-005698-76,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),Evaluation of chronic hepatitis C treatment with PEG-IFN ALFA-2a and ribavirin in HIV-positive subjects with persistently normal transaminase levels.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005698-76,0,0,0 2007-005701-22,2,2010-08-05,2010-08-05,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Chelsea Therapeutics Inc,"A MULTI-CENTER, OPEN-LABEL STUDY, WITH A TWO WEEK RANDOMIZED, PLACEBO-CONTROLLED, WITHDRAWAL PERIOD, TO ASSESS THE LONG-TERM SAFETY AND CLINICAL BENEFIT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONOMIC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005701-22,0,0,0 2007-005702-49,1,2011-03-08,2011-03-08,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Procter & Gamble Pharmaceuticals,"A Randomized, Double-blind, Parallel-group Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8 g/day) Administered as 400 mg Delayed-release Tablets Given Every 12 Hours for 6 Weeks to Chil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005702-49,0,0,0 2007-005706-44,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre François Baclesse,"Etude de phase II évaluant l'association topotécan-lapatinib chez des patientes en rechute moins de 12 mois après une première ligne de chimiothérapie à base de platine pour un cancer de l'ovaire, de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005706-44,0,0,0 2007-005707-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Infectious Diseases, Aarhus university Hospital, Skejby",Clinical study of cerebral function in chronic hepatitis C virus patients treated with pegylated interferon alpha-2a and ribivirin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005707-18,0,0,0 2007-005711-26,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO DERMOPATICO IMMACOLATA,"An open prospective, monocenter, consecutive non randomized clinical trial on therapy with monoclonal antibodies anti-CD20 in the treatment of pemphigus vulgare or foliaceus, serious and resistant to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005711-26,0,0,0 2007-005716-64,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Universitätsklinik für Psychiatrie des Kindes- und Jugendalters, AKH Wien, Medizinische Universität","Elevated elimination rates of quetiapine in adolescent patients with schizophrenia (ICD 10: F 20.-), bipolar affective disorder (ICD 10: F 31.-), disorders in impulse control with current PTSD (ICD 10...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005716-64,0,0,0 2007-005717-19,1,,,0,0,0,0,0,0,4,0,1,1,1,1,0,1,0,Oulu University Hospital Department of Internal Medicine,Lakritsin ja tiatsididiureetin yhteiskäytön vaikutus kaliumpitoisuuteen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005717-19,0,0,0 2007-005721-30,2,2009-12-14,2009-12-14,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Biogen Idec Limited,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients with Heart Failure and Renal Insufficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005721-30,0,0,0 2007-005721-30,2,2009-12-14,2009-12-14,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Biogen Idec,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral Tonapofylline in Patients with Heart Failure and Renal Insufficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005721-30,0,0,0 2007-005722-79,7,2014-03-06,2014-03-06,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First-line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer, and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005722-79,0,0,0 2007-005723-14,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Clinic per a la recerca biomèdica,EFECTO DE LA ADMINISTRACIÓN PROLONGADA DE ALBÚMINA Y MIDODRINA EN LA PREVENCIÓN DE COMPLICACIONES EN PACIENTES EN LISTA DE ESPERA DE TRASPLANTE HEPÁTICO Midodrine and Albumin for CirrHotic patients in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005723-14,0,0,0 2007-005725-29,4,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research and Development,A PHASE III STUDY OF ERBB2 POSITIVE ADVANCED OR METASTATIC GASTRIC OR ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA TREATED WITH CAPECITABINE PLUS OXALIPLATIN WITH OR WITHOUT LAPATINIB A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005725-29,0,0,0 2007-005728-34,6,2009-07-30,2010-02-10,6,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Hexal AG,Post authorisation safety study to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among CKD subjects receiving HX575 recombinant human ery...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005728-34,0,0,0 2007-005728-34,6,2009-07-30,2010-02-10,6,1,0,0,0,0,4,0,0,1,1,0,1,0,1,HEXAL AG,Post authorisation safety study to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among CKD subjects receiving HX575 recombinant human ery...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005728-34,0,0,0 2007-005728-34,6,2009-07-30,2010-02-10,6,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Hexal Biotech ForschungsGmbH,Post authorisation safety study to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among CKD subjects receiving HX575 recombinant human ery...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005728-34,0,0,0 2007-005728-34,6,2009-07-30,2010-02-10,6,1,0,0,0,0,4,0,0,1,1,0,1,0,1,HEXAL BIOTECH,Post authorisation safety study to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among CKD subjects receiving HX575 recombinant human ery...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005728-34,0,0,0 2007-005729-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitetssjukhuset Örebro,"Påverkas postoperativ minnesfunktion och tillfällig postoperativ förvirring av valet av lugnande medel, propofol eller midazolam, vid höftfrakturoperation under ryggbedövning?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005729-30,0,0,0 2007-005737-11,3,2012-08-22,2012-08-22,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,PHILOGEN S.P.A.,Dose definition and activity evaluation study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine in patients with metastatic melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005737-11,0,0,0 2007-005737-11,3,2012-08-22,2012-08-22,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Philogen S.p.A.,Dose definition and activity evaluation study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine in patients with metastatic melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005737-11,0,0,0 2007-005744-24,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,DiaMedica Inc.,"A phase IIa, placebo controlled, randomized, cross-over study to evaluate the effects of DM-99 on a meal tolerance test in subjects with type 2 diabetes mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005744-24,0,0,0 2007-005752-16,1,2008-10-28,2008-10-28,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cancer Research UK,"A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with exemestane versus exemestane alone in post-menopausal women with recurrent or advanced, oestrogen a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005752-16,0,0,0 2007-005755-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Sarcomas,ENSAYO CLÍNICO FASE II DE TRATAMIENTO NEOADYUVANTE CON IFOSFAMIDA A DOSIS ALTAS Y RADIOTERAPIA CONCOMITANTE EN SARCOMAS DE PARTES BLANDAS E IDENTIFICACION DE MARCADORES PREDICTORES DE RESPUESTA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005755-42,0,0,0 2007-005757-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Roche,Etude française multi-centrique évaluant le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) chez des pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005757-28,0,0,0 2007-005759-41,5,2010-05-19,2013-08-05,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given as a Single Infusion or Dual Infusion Compared with Placebo in Patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005759-41,0,0,0 2007-005759-41,5,2010-05-19,2013-08-05,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ROCHE,"A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given as a Single Infusion or Dual Infusion Compared with Placebo in Patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005759-41,0,0,0 2007-005769-36,1,2010-12-20,2010-12-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Gilead Sciences Limited,"A Phase IV, Open-label, Prospective Observational Study to Evaluate Virological Response in Antiretroviral-Experienced HIV-1 infected Subjects Switching to Atripla (efavirenz/emtricitabine/tenofovir D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005769-36,0,0,0 2007-005772-13,1,2010-01-15,2010-01-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,sanofi-aventis Zrt.,Comparative efficacy of amisulpride vs. risperidone on cognitive functions in patients with chronic schizophrenia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005772-13,0,0,0 2007-005773-63,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,AstraZeneca Oy,"A Pilot Study of Three-Weeks, Randomized, Prospective, Open Comparison in Schizophrenic In-patients Treated with Quetiapine Prolong or Oral Risperidone at Flexible Dose",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005773-63,0,0,0 2007-005775-34,1,2012-04-13,2012-04-13,1,0,0,0,1,0,3,0,0,1,1,1,1,0,1,ZooBiotic Limited,A Randomised Controlled Trial of Larval Therapy in the Debridement of Leg Ulcers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005775-34,0,0,0 2007-005777-57,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Hospital Errikos Dunant- Department of Hematology,A comparative study of low molecular weight IV iron dextran (CosmoFer®) versus per os iron for the treatment of anaemia in patients with haematological malignancies receiving epoietin treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005777-57,0,0,0 2007-005780-99,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Identification des sources génétiques de variabilité de l'adaptation de la repolarisation ventriculaire à un stimulus pharmacologique et physiologique dans une population apparemment normale,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005780-99,0,0,0 2007-005781-12,3,2008-12-05,2008-12-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent UK","A FOUR WEEK, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2A STUDY OF PH-797804 IN THE TREATMENT OF POST-HERPETIC NEURALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005781-12,0,0,0 2007-005781-12,3,2008-12-05,2008-12-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,"A FOUR WEEK, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2A STUDY OF PH-797804 IN THE TREATMENT OF POST-HERPETIC NEURALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005781-12,0,0,0 2007-005782-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Efficacité du levetiracetam intra-veineux en association avec le clonazepam versus clonazepam seul dans la prise en charge pré-hospitalière de l'état de mal épileptique généralisé tonico-clonique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005782-35,0,0,0 2007-005783-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Tapestry Pharmaceuticals Ltd,"Ensayo de fase 2, en abierto, con un solo grupo de ensayo de TPI 287 en pacientes con cáncer de páncreas avanzado, no resecable, tras tratamiento anterior con una terapia de gemcitabina",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005783-27,0,0,0 2007-005784-10,14,2010-05-13,2010-10-05,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Ltd., Ramsgate Rd., Sandwich, Kent","A 6 MONTH, PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FRAGMIN IN THE TREATMENT OF CHRONIC NEUROISCHAEMIC FO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005784-10,0,0,0 2007-005784-10,14,2010-05-13,2010-10-05,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"A 6 MONTH, PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FRAGMIN IN THE TREATMENT OF CHRONIC NEUROISCHAEMIC FO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005784-10,0,0,0 2007-005784-10,14,2010-05-13,2010-10-05,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent,CT13 9NJ,UK","A 6 MONTH, PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FRAGMIN IN THE TREATMENT OF CHRONIC NEUROISCHAEMIC FO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005784-10,0,0,0 2007-005784-10,14,2010-05-13,2010-10-05,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A 6 MONTH, PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FRAGMIN IN THE TREATMENT OF CHRONIC NEUROISCHAEMIC FO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005784-10,0,0,0 2007-005784-10,14,2010-05-13,2010-10-05,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent,CT13,UK","A 6 MONTH, PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FRAGMIN IN THE TREATMENT OF CHRONIC NEUROISCHAEMIC FO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005784-10,0,0,0 2007-005784-10,14,2010-05-13,2010-10-05,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc - 235 East 42nd Street - New York - 10017,"A 6 MONTH, PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FRAGMIN IN THE TREATMENT OF CHRONIC NEUROISCHAEMIC FO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005784-10,0,0,0 2007-005784-10,14,2010-05-13,2010-10-05,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer, S.A.","A 6 MONTH, PROSPECTIVE, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTIPLE CENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FRAGMIN IN THE TREATMENT OF CHRONIC NEUROISCHAEMIC FO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005784-10,0,0,0 2007-005786-35,2,2008-08-23,2008-08-23,2,0,0,0,0,0,0,0,0,1,0,0,1,0,1,Uriach Pharma,"Estudio de prueba de concepto, cruzado, doble ciego, controlado con placebo para valorar si la Rupatadina 20 mg puede mejorar el umbral del tiempo critico de estimulación en pacientes con urticaria a ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005786-35,0,0,0 2007-005789-11,1,2013-01-01,2013-01-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,RUNMC,Does atorvastatin have an acute and prolonged inhibitory effect on ischemia-reperfusion injury in humans in-vivo?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005789-11,0,0,0 2007-005791-14,1,2009-11-03,2009-11-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A randomised, placebo-controlled, incomplete block, three-way cross-over study to evaluate the effect of treatment with repeat inhaled doses of GW870086X on the allergen-induced early and late asthmat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005791-14,0,0,0 2007-005792-34,12,2015-06-05,2018-06-05,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 μg Once-Every-3-Weeks (Q3W) in Anemic Subjects With Advanced ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005792-34,0,0,0 2007-005793-31,3,2008-08-18,2008-08-18,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NV Organon,"A phase II, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Org 3236 tablets in men with Lower Urinary Tract Symptoms (LUTS) suggestive of Benign Prostatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005793-31,0,0,0 2007-005795-13,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,MIPHARM,"EFFICACY AND SAFETY ASSESSMENT OF KETOIL, SHAMPOO CONTAINING KETOCONAZOLE 0.5% SERENOA REPENS (SAW PALM) AND TAURINE, IN THE TREATMENT OF PATIENTS AFFECTED BY DANDRUFF AND SEBORRHEIC DERMATITIS COMPAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005795-13,0,0,0 2007-005796-34,1,2011-07-20,2011-07-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Universität Mainz, I. Medizinische Klinik und Poliklinik","A randomized, double-blind, multicenter phase II trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemo-naive advanced or metastatic adenocarcinoma of the biliary...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005796-34,0,0,0 2007-005797-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Dr. Willmar Schwabe GmbH & Co. KG,Efficacy and tolerability of EPs® 7630 film-coated tablets in patients (>=18 years old) with Acute Rhinopharyngitis (ARP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005797-31,0,0,0 2007-005798-75,2,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Neo Vista Inc.,"A Randomized, Prospective, Active Controlled, Study of the Epi-Rad90™ Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age-Related Macular Degeneratio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005798-75,0,0,0 2007-005799-15,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ROCHE,"A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of intravenous C.E.R.A. for the maintenance of haemoglobin levels in haemodialysis patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005799-15,0,0,0 2007-005802-38,6,2012-01-10,2012-01-10,5,0,0,0,0,1,3,0,0,1,1,0,1,0,1,Antisense Pharma GmbH,"Efficacy and Safety of AP 12009 in Adult Patients with Recurrent or Refractory Anaplastic Astrocytoma (WHO grade III) as Compared to Standard Treatment with Temozolomide or BCNU: A Randomized, Active...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005802-38,0,0,0 2007-005803-16,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,GITMO (GRUPPO ITALIANO DI MIDOLLLO OSSEO),RANDOMIZED STUDY COMPARING INTRAVENOUS BUSULFAN (I.V. BU; BUSILVEX) PLUS FLUDARABINE (BUFLU) VERSUS INTRAVENOUS BUSULFAN PLUS CYCLOPHOSPHAMIDE (BUCY2) AS CONDITIONING REGIMENS PRIOR TO ALLOGENEIC HEMA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005803-16,0,0,0 2007-005806-29,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,"Medical University of Vienna, Dep. of Internal Medicine I, division of Hematology & Hemostaseology",Evaluation of Efficacy and Toxicity of Intensified Consolidation Therapy in AML Patients ≥60 Years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005806-29,0,0,0 2007-005808-41,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Estudio multicéntrico para comprobar la respuesta clínico-analítica de pacientes portadores sintomáticos de Disferlinopatía al tratamiento con Calcifediol Multicentric study to assess the clinical a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005808-41,0,0,0 2007-005809-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE RICERCA TRAPIANTO DI MIDOLLO OSSEO,Treatment of Steroid refractory Graft versus Host Disease with monoclonal antibody B T 5/9 (anti-CD26),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005809-21,0,0,0 2007-005819-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Laboratoire BAILLY-CREAT,None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005819-25,0,0,0 2007-005821-31,1,2008-02-21,2008-02-21,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Reckitt Benckiser Healthcare UK) Limited,"A single-centre randomised, partially blind, single dose, crossover pilot study investigating the use of stopwatches to assess the onset of action of soothing and cooling of Gaviscon Peppermint Liquid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005821-31,0,0,0 2007-005821-31,1,2008-02-21,2008-02-21,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Reckitt Benckiser Healthcare (UK) Limited,"A single-centre randomised, partially blind, single dose, crossover pilot study investigating the use of stopwatches to assess the onset of action of soothing and cooling of Gaviscon Peppermint Liquid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005821-31,0,0,0 2007-005823-14,1,2013-05-01,2013-05-01,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,CHU de LIMOGES,Impact de la TEP dans la stratégie diagnostique des fièvres d'origine indéterminée ou des syndromes inflammatoires nus chez l'adulte immunocompétent.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005823-14,0,0,0 2007-005828-32,6,2014-12-15,2014-12-15,6,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CECOG,A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005828-32,0,0,0 2007-005831-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE),"Use of rHuEpo before autologous hematopoietic stem cell transplantation in patients affected by multiple myeloma, non Hodgkin disease and breast cancer to reduce transfusional requirement after myeloa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005831-27,0,0,0 2007-005835-27,1,2011-05-01,2011-05-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Odense University Hospital,Local Infiltration with Ropivacaine for Postoperative Analgesia after Hip Fracture,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005835-27,0,0,0 2007-005836-98,1,2010-07-01,2010-07-01,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Salford Royal Foundation Trust,The effect of Kineret® on brain biomarkers in patients with subarachnoid haemorrhage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005836-98,0,0,0 2007-005837-13,10,2012-10-01,2012-10-11,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,COUGAR BIOTECHNOLOGY,"A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetax...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005837-13,0,0,0 2007-005837-13,10,2012-10-01,2012-10-11,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cougar Biotechnology, Inc","A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetax...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005837-13,0,0,0 2007-005837-13,10,2012-10-01,2012-10-11,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen Oncology, Inc.","A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetax...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005837-13,0,0,0 2007-005838-37,7,2012-05-20,2013-05-20,5,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Beaufour Ipsen Pharma,"A PROSPECTIVE, INTERNATIONAL, MULTI-CENTRIC, OPEN-LABEL STUDY TO ASSESS THE EFFICACY OF AN EXTENDED INJECTION INTERVAL SCHEDULE OF LANREOTIDE AUTOGEL 120 MG IN ACROMEGALIC SUBJECTS WHO ARE BIOCHEMICAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005838-37,0,0,0 2007-005838-37,7,2012-05-20,2013-05-20,5,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Ipsen Pharma,"A PROSPECTIVE, INTERNATIONAL, MULTI-CENTRIC, OPEN-LABEL STUDY TO ASSESS THE EFFICACY OF AN EXTENDED INJECTION INTERVAL SCHEDULE OF LANREOTIDE AUTOGEL 120 MG IN ACROMEGALIC SUBJECTS WHO ARE BIOCHEMICAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005838-37,0,0,0 2007-005839-28,8,2016-03-31,2017-11-23,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A 2-year Extension to: A 76-week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005839-28,0,0,0 2007-005839-28,8,2016-03-31,2017-11-23,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,MSD Finland Oy,"A 2-year Extension to: A 76-week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005839-28,0,0,0 2007-005839-28,8,2016-03-31,2017-11-23,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Merck, Sharp & Dohme b.v.","A 2-year Extension to: A 76-week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005839-28,0,0,0 2007-005839-28,8,2016-03-31,2017-11-23,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","A 2-year Extension to: A 76-week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005839-28,0,0,0 2007-005839-28,8,2016-03-31,2017-11-23,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Laboratoires Merck Sharp & Dhome-Chibret,"A 2-year Extension to: A 76-week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005839-28,0,0,0 2007-005839-28,8,2016-03-31,2017-11-23,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme de España, S.A.","A 2-year Extension to: A 76-week, Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Tolerability and Efficacy of Anacetrapib When Added to Ongoing Therapy With a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005839-28,0,0,0 2007-005843-93,1,2009-09-23,2009-09-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Cytos Biotechnology AG,"A Double Blind, Randomized, Placebo Controlled, Parallel Group Phase IIa Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of an Anti-Angiotensin II Vaccine (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005843-93,0,0,0 2007-005844-26,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Antwerp University Hospital,"Multicentre, prospective, randomized, open-label, controlled study in de novo kidney transplant recipients to evaluate the impact of cyclosporine or steroid withdrawal at 3 months on graft function, p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005844-26,0,0,0 2007-005850-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,BGDO,GEMCITABINE AND CETUXIMAB IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER: A BGDO MULTICENTER PHASE II STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005850-22,0,0,0 2007-005851-40,5,2009-10-15,2009-11-03,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005851-40,0,0,0 2007-005851-40,5,2009-10-15,2009-11-03,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline S.A. España,"A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005851-40,0,0,0 2007-005853-47,1,2009-11-09,2009-11-09,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Medicinsk afdeling,Evaluering af røde morfindråber til behandling af dyspnø hos lungecancerpatienter,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005853-47,0,0,0 2007-005854-21,3,2008-06-02,2008-06-23,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Ardea Biosciences Inc.,"A multicenter Phase 2a, randomized, double-blind, placebo-controlled, proof-of-concenpt trial to determine the antiviral activity, pharmacokinetics, tolerability and safety of RDEA806 in HIV-1 positiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005854-21,0,0,0 2007-005858-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,PROMIX Trial Group,"Preoperative treatment of breast cancer with a combination of epirubicin, docetaxel and bevacizumab. A translational trial on molecular markers and functional imaging to predict response early",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005858-23,0,0,0 2007-005862-10,1,,,0,0,0,0,0,1,3,0,0,1,0,0,0,1,0,University Hospital Ghent,"Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005862-10,0,0,0 2007-005864-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE RICERCA TRAPIANTO DI MIDOLLO OSSEO,TREATMENT OF MINIMAL RESIDUAL DISEASE (MRD) IN ACUTE LEUKEMIA AFTER AN ALLOGENEIC STEM CELL TRANSPLANT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005864-28,0,0,0 2007-005865-37,1,2012-05-16,2012-05-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Medizinische Fakultät der Technischen Universität München, Vertreten durch den Dekan","Levofloxacin vs Piperacillin/Sulbactam and Sultamicillin in patients with acute cholecystitis. A double blind, randomized study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005865-37,0,0,0 2007-005868-26,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Neurovascular Research Group-IRVH,Estrategias para mejorar la eficacia y seguridad del tratamiento con Simvastatina en la Fase Aguda del Ictus Isquémico: STARS trial. Improving Safety and Efficacy of Simvastatin Treatment for the Ac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005868-26,0,0,0 2007-005880-80,3,2011-03-09,2011-03-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin in patients with typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005880-80,0,0,0 2007-005881-11,4,2011-01-14,2011-01-14,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche&Développement,"A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of a sulfonylurea in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005881-11,0,0,0 2007-005882-37,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,BAUSCH&LOMB,RANDOMIZED CONTROLLED CLINICAL STUDY ON THE EFFICACY AND TOLERABILITY OF 0.4% HYALURONIC ACID HYPOTONIC EYE DROPS (IALUREX) VS. HYDROXYPROPYL-GUAR EYE DROPS (SYSTANE) IN THE TREATMENT OF DRY EYE SYNDR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005882-37,0,0,0 2007-005883-28,10,2010-11-18,2010-11-18,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & De'veloppement,"A randomized, open-label, active-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 versus exenatide on top of metformin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005883-28,0,0,0 2007-005883-28,10,2010-11-18,2010-11-18,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, open-label, active-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 versus exenatide on top of metformin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005883-28,0,0,0 2007-005884-92,4,2011-06-29,2011-06-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 on top of pio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005884-92,0,0,0 2007-005886-36,4,2011-02-08,2011-02-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi -Aventis Recherche & Développement,"A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005886-36,0,0,0 2007-005886-36,4,2011-02-08,2011-02-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi -Aventis Recherche & De'veloppement,"A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005886-36,0,0,0 2007-005887-29,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Sanofi-Aventis Recherche & Développement,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter 12-week study assessing the efficacy and safety of AVE0010 in patients with type 2 diabetes not treated with antidiabetic ag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005887-29,0,0,0 2007-005891-15,6,2009-01-14,2009-01-14,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Cogentus Pharmaceuticals, Inc.","A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events including Bleeding and Symptom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005891-15,1,0,0 2007-005891-15,6,2009-01-14,2009-01-14,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,COGENTUS PHARMACEUTICALS INTERNATIONAL LIMITED,"A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events including Bleeding and Symptom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005891-15,1,0,0 2007-005893-29,1,2013-01-01,2013-01-01,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,RUNMC,Does ATP cause Annexin A5 targeting in the human forearm?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005893-29,0,0,0 2007-005894-77,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Phase I/II study with cisplatin and pemetrexed +/- sorafenib in malignant pleural mesothelioma (SoMe study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005894-77,0,0,0 2007-005899-13,1,2011-06-29,2011-06-29,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Generex Biotechnology Corp.,"A 26-Week, Open-Label, Randomized, Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin In Subjects With Type-1 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005899-13,0,0,0 2007-005901-23,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"Prospective,Double-Blind Randomized Clinical Trial on the Effects of Early Administration of Prolonged Methylprednisolone Therapy in early Acute Lung Injury (ALI) and Acute Respiratory Distress Syndro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005901-23,0,0,0 2007-005905-23,2,2009-06-15,2009-06-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Multi-center, Randomized, Double-blind, Placebo − controlled Study Comparing 80 mg of Adalimumab with Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005905-23,0,0,0 2007-005911-25,1,,,0,0,0,0,0,0,4,0,1,3,0,0,0,0,0,Imperial College Healthcare NHS Trust,"A randomised, placebo controlled, double blind study to evaluate the effect of 300mcg testosterone patches in addition to HRT on arterial compliance, insulin resistance and sexual desire.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005911-25,0,0,0 2007-005912-23,3,2009-12-18,2009-12-18,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer España,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, ACTIVE-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CELECOXIB (CELEBREX) AND INDOMETHACIN IN THE TREATMENT OF MODERATE TO SEVERE ACUTE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005912-23,0,0,0 2007-005912-23,3,2009-12-18,2009-12-18,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, ACTIVE-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CELECOXIB (CELEBREX) AND INDOMETHACIN IN THE TREATMENT OF MODERATE TO SEVERE ACUTE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005912-23,0,0,0 2007-005912-23,3,2009-12-18,2009-12-18,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc.,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, ACTIVE-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CELECOXIB (CELEBREX) AND INDOMETHACIN IN THE TREATMENT OF MODERATE TO SEVERE ACUTE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005912-23,0,0,0 2007-005914-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Digetivo del Hospital Valle Hebrón del Instituto Catalán de Salud. NIF Q5855029D,Efecto de la estabilización prolongada del mastocito intestinal con cromoglicato disódico en la evolución clínica y la microinflamación de la mucosa intestinal en los pacientes con síndrome de intesti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005914-38,0,0,0 2007-005916-15,1,2009-05-13,2009-05-13,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,medac Gesellschaft für klinische Spezialpräparate mbH,"Low dose Urokinase therapy by patients with diabetic foot syndrom and critical limb ischemia versus conventionel standard therapy. A randomised, open, controlled Phase III-study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005916-15,0,0,0 2007-005920-34,3,2020-03-21,2020-03-21,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,VU University Medical Center,HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005920-34,0,0,0 2007-005920-34,3,2020-03-21,2020-03-21,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Cologne,HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005920-34,0,0,0 2007-005921-31,1,2008-10-06,2008-10-06,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Pierre Fabre Médicament,Evaluation du pouvoir bactériostatique de la préparation V0079CR CETAVLON sur la flore cutanée au niveau des mains. Etude preuve de concept.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005921-31,0,0,0 2007-005922-62,4,2008-12-26,2008-12-26,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"An exploratory, randomised, active-controlled, double-blind, double-dummy, parallel group pilot study to determine the ability of oxycodone/naloxone prolonged release tablets (OXN) to reduce the numbe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005922-62,0,0,0 2007-005925-31,1,2012-03-26,2012-03-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFECT OF 6-MONTH ACETYLCARNITINE THERAPY ON ARTERIAL BLOOD PRESSURE, LIPID AND METABOLIC PROFILE, AND KIDNEY FUNCTION...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005925-31,0,0,0 2007-005929-30,1,,,0,0,0,0,0,0,4,0,1,1,1,1,0,1,0,Maastricht University,Disruption of memory reconsolidation of alcohol-related memory associations by propanolol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005929-30,0,0,0 2007-005931-27,3,2010-06-28,2010-06-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 24-Week Randomised, Double-blind, Parallel-group, Multi-centre, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Glimepiride (a Sulphonylur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005931-27,0,0,0 2007-005932-10,1,2018-03-23,2018-03-23,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,"A double-blind randomised multi-centre, placebo-controlled trial of combined ACE-inhibitor and beta-blocker therapy in preventing the development of cardiomyopathy in genetically characterised males w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005932-10,0,0,0 2007-005933-12,4,2019-02-18,2019-02-18,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Eisai Limited,"Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005933-12,0,0,0 2007-005933-12,4,2019-02-18,2019-02-18,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,EISAI LIMITED,"Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005933-12,0,0,0 2007-005936-99,1,2012-01-31,2012-01-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.",Effects of Topical Hypotensive Drugs on Circadian Ocular Perfusion Pressure and Ocular Blood Flow in Patients with Open-Angle Glaucoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005936-99,0,0,0 2007-005939-28,2,2011-06-21,2011-06-21,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"Estudio de fase I/II multicéntrico, abierto, de escalada de dosis, para evaluar la seguridad, farmacocinética y actividad de RO5083945, un anticuerpo glico-modificado anti-EGFR, en pacientes con tumor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005939-28,0,0,0 2007-005941-39,8,2012-02-13,2012-02-13,7,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Laboratoires Merck Sharp & Dohme - Chibret,"An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005941-39,0,0,0 2007-005941-39,8,2012-02-13,2012-02-13,7,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Merck & Co. Inc.,"An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005941-39,0,0,0 2007-005941-39,8,2012-02-13,2012-02-13,7,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Merck & Co., Inc.","An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005941-39,0,0,0 2007-005941-39,8,2012-02-13,2012-02-13,7,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Merck Sharp & Dohme (Sweden) AB,"An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005941-39,0,0,0 2007-005941-39,8,2012-02-13,2012-02-13,7,1,0,0,0,0,2,0,0,1,0,0,1,0,2,MERCK SHARP DOHME ITALIA S.P.A.,"An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005941-39,0,0,0 2007-005941-39,8,2012-02-13,2012-02-13,7,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Merck, Sharp & Dohme b.v.","An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005941-39,0,0,0 2007-005941-39,8,2012-02-13,2012-02-13,7,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Merck & Co Inc,"An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005941-39,0,0,0 2007-005941-39,8,2012-02-13,2012-02-13,7,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Merck Sharp & Dohme GmbH,"An Open Label, Randomized Phase I/IIa Trial Evaluating MK-0646 in Combination With Erlotinib (TARCEVA™) for Patients With Recurrent Non-Small Cell Lung Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005941-39,0,0,0 2007-005945-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),Phase II open label study of Pegaptanib sodium on patients with subfoveal choroidal neovascularization caused by pathologic myopia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005945-39,0,0,0 2007-005948-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Miguel Ferrer. Servicio de Neumología. Hospital Clínic de Barcelona,"Eficacia de los glucocorticoides en la neumonía asociada a la ventilación mecánica. Ensayo clínico aleatorizado, enmascarado a doble ciego y controlado con placebo.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005948-24,0,0,0 2007-005949-38,4,2009-12-14,2009-12-14,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Abbott GmbH & Co. KG,"A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone as First-line Treatment in Subjects With Locally Recurrent or Metastatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005949-38,0,0,0 2007-005951-40,1,2009-10-05,2009-10-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Fundació Lluita contra la Sida,DINAMICA VIRAL DEL VIH-1 EN SUJETOS QUE INICIAN TERAPIA CON RALTEGRAVIR (HIV-1 VIRAL DYNAMICS IN SUBJECTS INITIATING RALTEGRAVIR THERAPY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005951-40,0,0,0 2007-005953-49,1,2013-05-15,2013-05-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Prof. M.A. Dimopoulos,"A Prospective, Multicenter, Non-comparative, Open-label, Phase II Study to Evaluate the Effects of the Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Mineral Density, Bone Metabolism,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005953-49,0,0,0 2007-005954-22,1,2008-07-10,2008-07-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A randomized, double-blind, placebo-controlled, multicenter Phase II study to compare the efficacy and tolerability of pazopanib administered in combination with exemestane versus exemestane plus plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005954-22,0,0,0 2007-005955-40,11,2011-06-10,2011-11-14,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Abbott GmbH & Co. K.G.,"A Phase 3, Multi-center, Open-label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study With ABT-874",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005955-40,0,0,0 2007-005955-40,11,2011-06-10,2011-11-14,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Abbott GmbH & Co. K. G.,"A Phase 3, Multi-center, Open-label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study With ABT-874",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005955-40,0,0,0 2007-005956-18,1,2013-10-30,2013-10-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Timo Jahnukainen,Tubulointerstitiaalinefriitti - Riskitekijöiden kartoitus ja lääkehoidon vaikutus sairauden kulkuun.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005956-18,0,0,0 2007-005958-23,1,2008-08-14,2008-08-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Ipsen Group, SCRAS Institut Henri Beaufour","A Phase II, Randomised, Double-Blind Study to Compare the Safety and Efficacy of One Treatment Cycle of Clostridium Botulinum Type A Toxin (50 Units) When Reconstituted from Either a 125 Unit or a 500...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005958-23,0,0,0 2007-005959-42,9,2011-10-05,2012-10-05,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolar I Disorder Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005959-42,0,0,0 2007-005961-36,1,2008-08-22,2008-08-22,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,Aegera Therapeutics Inc.,"A Phase 1-2, Multicenter, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005961-36,0,0,0 2007-005976-15,1,2014-02-28,2014-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Marsden Hospital NHS Trust,"A randomised open-labelled multicentre trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophago-gastric cancer (RE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005976-15,0,0,0 2007-005977-67,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,CONSORZIO ONCOTECH,SUNITINIB EITHER BEFORE OR AFTER CYTOREDUCTIVE NEPHRECTOMY A PHASE II TRIAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005977-67,0,0,0 2007-005978-30,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,FUNDACIÓ PUIGVERT,Ensayo clínico para evaluar la eficacia y seguridad de la rapamicina en los angiomiolipomas en pacientes con esclerosis tuberosa Clinical Trial to Determine the Efficacy and Safety of Rapamycin in Ang...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005978-30,0,0,0 2007-005979-34,1,2009-07-31,2009-07-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Lluita contra la SIDA,"ESTUDIO PILOTO, ABIERTO, COMPARATIVO Y ALEATORIZADO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE DARUNAVIR/RITONAVIR 900/100 MG UNA VEZ AL DIA COMO ESTRATEGIA DE SIMPLIFICACION DEL TRATAMIENTO ANTIRRETROVI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005979-34,0,0,0 2007-005980-83,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO,"MULTICENTRIC, PERSPECTIVE, RANDOMIZED TRIAL TO ASSESS THE INTRAOPERATIVE USE OF HYPERTHERMIC CHEMOTHERAPY IN LOCALLY ADVANCED NON SMALL CELL LUNG CANCER. COMPARISON BETWEEN LOCO-REGIONAL + SYSTEMIC CH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005980-83,0,0,0 2007-005983-28,7,2010-07-02,2013-10-05,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"Ensayo clínico de fase IIb/III, aleatorizado, doble ciego con BIBW 2992 frente a placebo, ambos asociados a tratamiento de soporte, en pacientes con carcinoma no microcítico de pulmón que fracasan al ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005983-28,0,0,0 2007-005983-28,7,2010-07-02,2013-10-05,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"Ensayo clínico de fase IIb/III, aleatorizado, doble ciego con BIBW 2992 frente a placebo, ambos asociados a tratamiento de soporte, en pacientes con carcinoma no microcítico de pulmón que fracasan al ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005983-28,0,0,0 2007-005983-28,7,2010-07-02,2013-10-05,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"Ensayo clínico de fase IIb/III, aleatorizado, doble ciego con BIBW 2992 frente a placebo, ambos asociados a tratamiento de soporte, en pacientes con carcinoma no microcítico de pulmón que fracasan al ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005983-28,0,0,0 2007-005983-28,7,2010-07-02,2013-10-05,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"Ensayo clínico de fase IIb/III, aleatorizado, doble ciego con BIBW 2992 frente a placebo, ambos asociados a tratamiento de soporte, en pacientes con carcinoma no microcítico de pulmón que fracasan al ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005983-28,0,0,0 2007-005983-28,7,2010-07-02,2013-10-05,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co.KG,"Ensayo clínico de fase IIb/III, aleatorizado, doble ciego con BIBW 2992 frente a placebo, ambos asociados a tratamiento de soporte, en pacientes con carcinoma no microcítico de pulmón que fracasan al ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005983-28,0,0,0 2007-005983-28,7,2010-07-02,2013-10-05,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","Ensayo clínico de fase IIb/III, aleatorizado, doble ciego con BIBW 2992 frente a placebo, ambos asociados a tratamiento de soporte, en pacientes con carcinoma no microcítico de pulmón que fracasan al ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005983-28,0,0,0 2007-005983-28,7,2010-07-02,2013-10-05,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"Ensayo clínico de fase IIb/III, aleatorizado, doble ciego con BIBW 2992 frente a placebo, ambos asociados a tratamiento de soporte, en pacientes con carcinoma no microcítico de pulmón que fracasan al ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005983-28,0,0,0 2007-005985-10,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Juan Francisco Navarro González,Análisis del Efecto Renoprotector de la Pentoxifilina en Pacientes con Enfermedad Renal Crónica Secundaria a Nefropatía Diabética,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005985-10,0,0,0 2007-005986-36,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,University of Bergen,"DELAYED SLEEP PHASE SYNDROME. SLEEP, PERSONALITY, DEVELOPMENTAL HISTORY, CIRCADIAN RHYTHM AND TREATMENT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005986-36,0,0,0 2007-005994-79,14,2012-08-06,2012-11-27,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005994-79,0,0,0 2007-005994-79,14,2012-08-06,2012-11-27,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005994-79,0,0,0 2007-005994-79,14,2012-08-06,2012-11-27,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Wyeth, a Pfizer company","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005994-79,0,0,0 2007-005994-79,14,2012-08-06,2012-11-27,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005994-79,0,0,0 2007-005995-14,14,2012-08-06,2012-12-03,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005995-14,0,0,0 2007-005995-14,14,2012-08-06,2012-12-03,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005995-14,0,0,0 2007-005995-14,14,2012-08-06,2012-12-03,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Wyeth Research Division, Wyeth Pharmeceuticals Inc.","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005995-14,0,0,0 2007-005996-32,1,2010-01-13,2010-01-13,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Luton & Dunstable Hospital NHS Foundation Trust,To determine the pre-emptive effect of Gabapentin on acute and chronic post-operative pain after spinal surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005996-32,0,0,0 2007-005999-13,5,2010-01-20,2012-08-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Randomised, Open-label, Pilot Study to Evaluate the Safety and the Effects on Bone Resorption of AZD0530 in Patients with Prostate Cancer or Breast Cancer with Metastatic Bone Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005999-13,0,0,0 2007-006003-21,1,2010-11-23,2010-11-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Nuvo Research GmbH,"A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY OF THE EFFICACY AND SAFETY OF WF10 IN SUBJECTS SUFFERING FROM PERSISTENT ALLERGIC RHINITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006003-21,0,0,0 2007-006006-22,2,2013-04-08,2014-09-02,2,1,0,0,2,0,2,0,0,1,0,0,1,0,0,"Johns Hopkins University, Department of Neurology",Minimally Invasive Surgery plus rt-PA for ICH Evacuation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006006-22,0,0,0 2007-006006-22,2,2013-04-08,2014-09-02,2,1,0,0,2,0,2,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Trust,Minimally Invasive Surgery plus rt-PA for ICH Evacuation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006006-22,0,0,0 2007-006006-22,2,2013-04-08,2014-09-02,2,1,0,0,2,0,2,0,0,1,0,0,1,0,0,Johns Hopkins University,Minimally Invasive Surgery plus rt-PA for ICH Evacuation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006006-22,0,0,0 2007-006009-26,2,2008-02-03,2009-02-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-Abelló A/S,A Phase III trial assessing the pharmacodynamic efficacy and the tolerability of Grazax® treatment initiated in the grass pollen season in subjects with seasonal grass pollen induced rhinoconjunctivit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006009-26,0,0,0 2007-006014-41,2,2010-11-17,2010-11-17,1,1,0,0,0,0,4,0,0,1,1,0,1,0,0,"University Heidelberg, University Hospital Mannheim",Determination of Diagnostic Accuracy and Added Value of Vasovist®-Enhanced Peripheral MRA in Comparison to Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients with Peripheral Artery ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006014-41,0,0,0 2007-006016-33,1,2015-12-30,2015-12-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Uniklinikum Tuebingen,Multicenter Phase II study of haploidentical hematopoietic cell transplantation with CD3/CD19 depleted grafts after a reduced intensity conditioning regimen for adult patients with acute leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006016-33,0,0,0 2007-006024-35,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Orphan Europe SARL,"Adaptive dose regimen of Cystadrops for cOrneal Crystal deposiTs and ocular manifestations in nephropathic cystinosis : an open label, dose-response pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006024-35,0,0,0 2007-006025-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,"A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006025-27,0,0,0 2007-006026-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,PREOPERATIVE ENDOCRINE TREATMENT WITH LETROZOLE ± TRIPTORELIN IN PATIENTS WITH ER AND PgR POSITIVE LOCALLY ADVANCED BREAST CANCER Trattamento preoperatorio con letrozolo ± Triptorelin nel carcino...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006026-10,0,0,0 2007-006029-29,1,2009-12-10,2009-12-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,Etude de l'efficacité de CIRKALM crème versus placebo dans le traitement des douleurs anales,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006029-29,0,0,0 2007-006031-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CONSORZIO ONCOTECH,A Randomized Trial with factorial Design comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in metastatic breast cancer progressing after Aromatase Inhibitor therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006031-30,0,0,0 2007-006033-14,2,2017-05-05,2017-05-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"University Hospital Lund, Thoracic Oncology Unit, Dept of Respiratory Medicine",A randomized phase III study of standard treatment +/- enoxaparin in small cell lung cancer. Randomiserad fas III studie av standard behandling +/- enoxaparin vid småcellig lungcancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006033-14,0,0,0 2007-006035-32,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PISANA,"Assessment of endothelial function and vasal response in patients with Systemic Sclerosis and Hypercholesterolemia, before and after simvastatin treatment.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006035-32,0,0,0 2007-006037-13,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,OSPEDALE POLICLINICO S. MATTEO,"An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006037-13,0,0,0 2007-006040-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. J.A. Barberà. Servicio de Neumología. Hospital Clínic de Barcelona,Estudio de los efectos de sildenafilo en combinación con rehabilitación pulmonar sobre la tolerancia al esfuerzo en pacientes con enfermedad pulmonar obstructiva crónica e hipertensión pulmonar,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006040-21,0,0,0 2007-006044-22,1,2011-07-08,2011-07-08,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,"Shire Human Genetic Therapies, Inc. (Shire HGT)","A Multi-Center, Open-Label Study Evaluating Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Enzyme Replacement Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006044-22,0,0,0 2007-006046-17,8,2009-09-02,2009-09-10,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Limited,A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Diseas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006046-17,0,0,0 2007-006046-17,8,2009-09-02,2009-09-10,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Medical Research Inc,A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Diseas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006046-17,0,0,0 2007-006046-17,8,2009-09-02,2009-09-10,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Manufacturing Limited,A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive gastroesophageal Reflux Diseas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006046-17,0,0,0 2007-006049-41,1,2012-12-01,2012-12-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Wien; Univ.Klin.f. Chirurgie; Klin. Abtlg. f. Transplantation,Evaluation of Tacrolimus (Prograf®) intraportal infusion during the implantation and the protective effect on ischemia-reperfusion injury in orthotopic liver transplant recipients - single center stud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006049-41,0,0,0 2007-006050-25,5,2011-08-08,2011-09-23,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Amgen Inc.,"An International, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of AMG 479 with Exemestane or Fulvestrant in Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006050-25,0,0,0 2007-006051-39,1,2012-03-28,2012-03-28,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Philipps Universität Marburg,Pharmakokinetic investigation on the tissue penetration of moxifloxacin within the pericardial space,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006051-39,0,0,0 2007-006055-39,5,2008-05-15,2008-05-15,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Ferring Pharmaceuticals A/S,"An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006055-39,0,0,0 2007-006059-37,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"Programa de Medicina Molecular y Genética, Hospital Vall d´Hebron","ENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006059-37,0,0,0 2007-006060-29,1,2011-12-21,2011-12-21,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO,Efficacy and toxicity of Trastuzumab at the maintaining dose of 1 mg/kg/week versus the standard dose of 2 mg/kg/week in combination with chemotherapy in metastatic breast cancer patients. A phase III...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006060-29,0,0,0 2007-006064-30,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,University College London,"A RANDOMISED PHASE III TRIAL TO ASSESS RESPONSE ADAPTED THERAPY USING FDG-PET IMAGING IN PATIENTS WITH NEWLY DIAGNOSED, ADVANCED HODGKIN LYMPHOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006064-30,0,0,0 2007-006064-30,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI,"A RANDOMISED PHASE III TRIAL TO ASSESS RESPONSE ADAPTED THERAPY USING FDG-PET IMAGING IN PATIENTS WITH NEWLY DIAGNOSED, ADVANCED HODGKIN LYMPHOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006064-30,0,0,0 2007-006065-32,1,2009-12-17,2009-12-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Fresenius Kabi Deutschland GmbH,"Evaluation of the efficacy of 6% hydroxyethyl starch (HES, 130/0.4) in normal saline compared to Ringer’s lactate solution for the prevention of hypotension during spinal anaesthesia for caesarean sec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006065-32,0,0,0 2007-006069-34,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Clinical efficacy and cell mobilization activity of pegfilgrastim in patients with gynaecological malignancies in therapy with topotecan.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006069-34,0,0,0 2007-006072-11,12,2010-03-28,2010-05-20,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi- Center Study of ASA404 in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006072-11,0,0,0 2007-006072-11,12,2010-03-28,2010-05-20,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S. A","A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi- Center Study of ASA404 in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006072-11,0,0,0 2007-006072-11,12,2010-03-28,2010-05-20,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi- Center Study of ASA404 in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006072-11,0,0,0 2007-006073-84,2,2009-01-27,2009-01-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKiline Research and Development,"A double-masked, randomized, parallel-group study to investigate the pharmacodynamics, safety, and systemic pharmacokinetics of pazopanib eye drops, administered for 28 days to adult subjects with cho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006073-84,0,0,0 2007-006073-84,2,2009-01-27,2009-01-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development,"A double-masked, randomized, parallel-group study to investigate the pharmacodynamics, safety, and systemic pharmacokinetics of pazopanib eye drops, administered for 28 days to adult subjects with cho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006073-84,0,0,0 2007-006074-28,5,2009-01-16,2009-02-04,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme de España, S.A.","A Phase IIa, Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0893 in Combination With Sitagliptin or in Combination With Metfo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006074-28,0,0,0 2007-006074-28,5,2009-01-16,2009-02-04,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratoires Merck Sharp & Dohme - Chibret,"A Phase IIa, Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0893 in Combination With Sitagliptin or in Combination With Metfo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006074-28,0,0,0 2007-006074-28,5,2009-01-16,2009-02-04,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Phase IIa, Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0893 in Combination With Sitagliptin or in Combination With Metfo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006074-28,0,0,0 2007-006074-28,5,2009-01-16,2009-02-04,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Phase IIa, Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0893 in Combination With Sitagliptin or in Combination With Metfo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006074-28,0,0,0 2007-006078-27,2,2012-06-15,2013-06-15,2,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Wilex AG,"A PHASE 2, TWO-ARM, DOUBLE-BLIND, MULTICENTER, RANDOMIZED STUDY OF THE COMBINATION OF ORAL WX-671 PLUS CAPECITABINE VS. CAPECITABINE MONOTHERAPY IN FIRST-LINE HER2-NEGATIVE METASTATIC BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006078-27,0,0,0 2007-006081-15,4,2011-08-08,2011-08-08,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Symphogen A/S,"A multi-centre, single intravenous dose, exploratory dose-finding, open label trial on the safety and efficacy of Sym001 in the treatment of Immune Thrombocytopenic Purpura (ITP) in RhD positive, non-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006081-15,1,0,0 2007-006082-32,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PISANA,Female steroid hormones and protection from cardiovascular risk: staminal endothelial progenitor cells and menopause.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006082-32,0,0,0 2007-006084-73,1,2010-01-19,2010-01-19,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,BIODEL Inc,"An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAjectTM in Subjects with Type 1 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006084-73,0,0,0 2007-006085-15,1,2010-01-13,2010-01-13,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Biodel Inc.,"An Open Label, Multi-Center, Follow-on Study Examining the Long- Term Safety and Efficacy of Insulin VIAject™ in Subjects with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006085-15,0,0,0 2007-006087-30,1,2012-10-04,2012-10-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Martin-Luther-Universität Halle-Wittenberg, vertreten durch den Kanzler",Prospektive randomisierte klinische Studie zur Beurteilung der Effizienz und Sicherheit einer inhalativen Sedierung mit Sevofluran im Vergleich zu einem intravenösen Sedierungskonzept mit Propofol bei...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006087-30,0,0,0 2007-006089-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Neus Fabregas Julia - Hospital Clinic de Barcelona,Farmacocinética y farmacodinámica del mivacurio en los pacientes tratados de forma crónica con anticomiciales,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006089-14,0,0,0 2007-006093-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación de Investigación Biomédica Hospital de Getafe,"ENSAYO CLÍNICO, ALEATORIZADO, CONTROLADO DOBLE CIEGO, MULTICÉNTRICO PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL BEVACIZUMAB (AVASTIN, Genentech, Inc.) VS RANIBIZUMAB (LUCENTIS, Genentech, Inc.) INTRAVÍT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006093-28,0,0,0 2007-006095-11,5,2009-03-01,2009-04-07,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"An 18-week, International, Multi-centre, Randomized, Parallel-group, Double-Blind, Active-Controlled Phase IIIb Study to Evaluate the Efficacy and Safety of Saxagliptin in combination with Metformin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006095-11,0,0,0 2007-006095-11,5,2009-03-01,2009-04-07,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"An 18-week, International, Multi-centre, Randomized, Parallel-group, Double-Blind, Active-Controlled Phase IIIb Study to Evaluate the Efficacy and Safety of Saxagliptin in combination with Metformin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006095-11,0,0,0 2007-006096-37,12,2010-12-15,2011-03-04,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BAYER,"A prospective, multinational, multicenter, randomized, double blind, double dummy, controlled study comparing the efficacy and safety of moxifloxacin to that of amoxicillin clavulanic acid for the tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006096-37,0,0,0 2007-006096-37,12,2010-12-15,2011-03-04,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Bayer HealthCare AG, Leverkusen, Germany","A prospective, multinational, multicenter, randomized, double blind, double dummy, controlled study comparing the efficacy and safety of moxifloxacin to that of amoxicillin clavulanic acid for the tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006096-37,0,0,0 2007-006096-37,12,2010-12-15,2011-03-04,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Bayer HealthCare AG, D-51368 Leverkusen, Germany","A prospective, multinational, multicenter, randomized, double blind, double dummy, controlled study comparing the efficacy and safety of moxifloxacin to that of amoxicillin clavulanic acid for the tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006096-37,0,0,0 2007-006096-37,12,2010-12-15,2011-03-04,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A prospective, multinational, multicenter, randomized, double blind, double dummy, controlled study comparing the efficacy and safety of moxifloxacin to that of amoxicillin clavulanic acid for the tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006096-37,0,0,0 2007-006097-28,1,2008-12-22,2008-12-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck & Co Inc.,","Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of Inhaled Corticosteroid Plus Montelukast Compared with Inhaled Corticosteroid Therapy Alone in Patients with Chronic As...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006097-28,0,0,0 2007-006099-12,1,2008-10-30,2008-10-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Statens Serum Institut,Oral treatment of allergy with a non-pathogenic microorganism: A randomised clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006099-12,0,0,0 2007-006102-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital General Universitario Gregorio Marañón de Madrid,Tratamiento con omeprazol para la profilaxis de la hemorragia digestiva y el reflujo gastroesofágico en niños críticos Omeprazol treatment for prophylaxis of gastrointestinal bleeding and gastroesoph...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006102-19,0,0,0 2007-006107-20,10,2010-11-15,2012-09-27,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Global Medical Affairs",Estudio de extensión abierto para evaluar la seguridad de una dosis fija de metilnaltrexona subcutánea en sujetos con enfermedad avanzada y estreñimiento inducido por opiáceos Open-Label Extension St...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006107-20,0,0,0 2007-006107-20,10,2010-11-15,2012-09-27,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Salix Pharmaceuticals Inc,Estudio de extensión abierto para evaluar la seguridad de una dosis fija de metilnaltrexona subcutánea en sujetos con enfermedad avanzada y estreñimiento inducido por opiáceos Open-Label Extension St...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006107-20,0,0,0 2007-006107-20,10,2010-11-15,2012-09-27,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Salix Pharmaceuticals Inc.,Estudio de extensión abierto para evaluar la seguridad de una dosis fija de metilnaltrexona subcutánea en sujetos con enfermedad avanzada y estreñimiento inducido por opiáceos Open-Label Extension St...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006107-20,0,0,0 2007-006109-26,1,2009-03-17,2009-03-17,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Institut für Klinische Forschung und Entwicklung (ikfe) GmbH,Impact of Insulin Glargine compared to Insulin Detemir in combination with Metformin (BOT) on prandial beta cell function and overall metabolic control in type 2 diabetic patients with insufficient me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006109-26,0,0,0 2007-006115-23,1,2010-01-18,2010-01-18,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Berlin-Chemie AG,"Effects of nebivolol on the cardiovascular functions, thermoregulation and blood flow during real and simulated conditions of microgravity",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006115-23,0,0,0 2007-006117-16,1,2012-02-15,2012-02-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Betsi Cadwaladr University Health Board,"A prospective, randomised, phase IV, open label clinical trial to study the therapeutic use of buprenorphine 20 mg (BuTrans 20µg/h) matrix transdermal patch in the management of post tonsillectomy pai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006117-16,0,0,0 2007-006119-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II,Phase II monitored clinical trial for evaluation of treatment of patients with Thymic Epithelial Tumours (TET) or Histiocitosi X (LCH) with Imatinib Mesylate.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006119-22,0,0,0 2007-006120-36,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,3,,"Phase I/II Study of Combined Treatment with AT-101, Cisplatin and Radiotherapy in Patients with Locally Advanced Head and Neck Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006120-36,0,0,0 2007-006121-26,6,2010-02-05,2010-06-01,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Nycomed Danmark ApS,"An international, randomised, double blinded, multi-centre, active- and placebo-controlled dose response trial to evaluate the efficacy and safety of SABER-Bupivacaine for postoperative pain control i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006121-26,0,0,0 2007-006122-96,6,2011-02-04,2011-02-04,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Nycomed Danmark ApS,"An international, randomised, double blinded, multi-centre, active- and placebo-controlled dose response trial to evaluate the efficacy and safety of SABER-Bupivacaine for postoperative pain control i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006122-96,0,0,0 2007-006123-13,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,"A MULTICENTER, OPEN LABEL STUDY OF VELCADE, MELPHALAN AND PREDNISONE (VMP) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006123-13,0,0,0 2007-006125-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospitals Leuven,"Comparison of intrathecal low-dose ropivacaine, bupivacaine and lidocaine for knee arthroscopy in ambulatory setting. a randomised, double-blind trial;",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006125-28,0,0,0 2007-006126-10,1,2011-03-11,2011-03-11,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Charité - University Hospital Berlin,pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006126-10,0,0,0 2007-006127-12,1,2009-02-06,2009-02-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,PharmaNeuroBoost N.V. (PNB),Pipamperone/Citalopram (PipCit) versus Citalopram in the Treatment of Major Depressive disorder (MDD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006127-12,0,0,0 2007-006129-29,4,2012-06-14,2012-06-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MorphoSys AG,"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, preliminary clinical activity and immunogenicity of multiple doses of MOR103 administered intravenously to pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006129-29,0,0,0 2007-006135-32,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,Klaus Tapio Olkkola,Effect of St. John`s wort on the pharmacokinetics and pharmacodynamics of oral oxycodone: A two-phase double-blind cross-over study in healthy volunteers /Mäkikuisman vaikutus suun kautta annetun oksi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006135-32,0,0,0 2007-006137-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Hospitales Universitarios Virgen del Rocío, Servicio Andaluz de Salud.","Estudio aleatorizado, doble ciego, comparando colistina intravenosa con colistina intravenosa más colistina intravenosa más colistina nebulizada en pacientes con neumonía asociada a ventilación mecáni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006137-13,0,0,0 2007-006150-25,6,2010-06-28,2012-10-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006150-25,0,0,0 2007-006150-25,6,2010-06-28,2012-10-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc.","A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006150-25,0,0,0 2007-006151-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. LUIGI GONZAGA,UFT/LEUCOVORIN AND MITOMYCIN C IN THE TREATMENT OF METASTATIC COLORECTAL CANCER OXALIPLATIN AND IRINOTECAN RESISTANT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006151-40,0,0,0 2007-006153-31,1,2010-04-09,2010-04-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Baxter R and D Europe SCRL,"Safety and efficacy of subcutaneous (SC) administration of Clinimix N9G15E in elderly patients at risk for malnutrition, at a dose of 1 liter infused over 12 hours for 7 to 10 consecutive days. A pros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006153-31,0,0,0 2007-006165-32,1,2008-11-28,2008-11-28,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Dr. Kade Pharmazeutische Fabrik GmbH,Studie zur Verträglichkeit von Posterisan corte Placebozäpfchen an gesunden Probanden,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006165-32,0,0,0 2007-006168-31,11,2010-12-01,2011-02-12,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Ltd,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel- Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006168-31,0,0,0 2007-006168-31,11,2010-12-01,2011-02-12,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,EISAI Ltd,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel- Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006168-31,0,0,0 2007-006169-33,11,2010-06-09,2010-06-09,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Ltd,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel- Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Sei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006169-33,0,0,0 2007-006169-33,11,2010-06-09,2010-06-09,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,EISAI Ltd,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel- Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Sei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006169-33,0,0,0 2007-006170-28,19,2014-09-18,2014-09-18,14,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Eisai Ltd,"A 14-Month Open-Label Extension Phase of the Double-Blind, Placebo- Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006170-28,0,0,0 2007-006175-36,3,2008-10-06,2008-10-08,3,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of JNJ-16269110 on Hepatic Triglyceride Content in Obese Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006175-36,0,0,0 2007-006177-88,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,A randomized controlled trial of alteplase (rt-PA) vs standard treatment in acute ischemic hemispheric stroke in patients aged more than 80 years where thrombolysis is initiated within 3 hours after s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006177-88,0,0,0 2007-006182-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Anaesthesiology Department. Universitary Hospital Vall d'Hebron, Barcelona.",Ensayo clínico controlado y aleatorizado para evaluar el efecto de los gabapentinoides sobre el dolor agudo postoperatorio en pacientes quemados,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006182-32,0,0,0 2007-006184-70,1,2014-10-01,2014-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Leeds Teaching Hospitals NHS Trust,"A POPULATION STUDY INTO THE PREVALENCE AND GENETIC PROFILE OF PATIENTS WITH CHRONIC PAIN WHO DO NOT RESPOND TO ORAL CODEINE A single site, pilot population study into the prevalence and genetic profi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006184-70,0,0,0 2007-006185-15,1,2018-03-07,2018-03-07,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Newcastle-upon-Tyne Hospitals NHS Trust,"STI571 Prospective International RandomIsed Trial 2 - A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006185-15,0,0,0 2007-006187-30,4,2009-03-02,2009-03-27,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"OxThera, Inc.",An Open-label (OL) Extension Study evaluating the Long-Term Safety of OxabactTM in Subjects with Primary Hyperoxaluria (PH) who participated in the Double-Blind (DB) Efficacy Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006187-30,0,0,0 2007-006188-59,1,2008-05-30,2008-05-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Moberg Derma AB,"A multicenter, randomised double blind, placebo-controlled study of efficacy, safety and tolerability of Kaprolac® K301 for the treatment of seborrhoeic eczema (SE) of the scalp.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006188-59,0,0,0 2007-006189-14,3,2008-08-29,2008-09-06,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase III, randomized, double-blind, triple-dummy, placebo controlled, multicenter, 5- period, single-dose complete block crossover study to determine the onset of action of indacaterol (150 and 300...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006189-14,0,0,0 2007-006190-87,1,2008-10-19,2008-10-19,1,0,0,0,1,0,4,0,0,1,0,0,1,0,1,Omega Pharma N.V.,"A randomised, controlled, assessor-blind, clinical trial to investigate superiority of Lyclear spray away (ParaNix spray) compared with Infectopedicul permethrin 0.5% lotion in the treatment of head l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006190-87,0,0,0 2007-006191-11,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Eisai Inc.,"A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006191-11,0,1,1 2007-006193-29,1,2008-08-07,2008-08-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"KOSAN BIOSCIENCES, INC","OPEN LABEL, MULTI-CENTER, PHASE 2 STUDY OF KOS-1584 IN PATIENTS WITH ADVANCED OR METASTATIC STAGE IIIB/IV NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH FIRST-LINE CHEMOTHERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006193-29,0,0,0 2007-006195-11,10,2014-02-13,2014-02-13,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Algeta ASA,"A double blind, randomised, multiple dose, phase III, multicentre study of AlpharadinTM in the treatment of patients with hormone-refractory prostate cancer with skeletal metastases",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006195-11,0,0,0 2007-006195-11,10,2014-02-13,2014-02-13,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALGETA ASA,"A double blind, randomised, multiple dose, phase III, multicentre study of AlpharadinTM in the treatment of patients with hormone-refractory prostate cancer with skeletal metastases",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006195-11,0,0,0 2007-006198-98,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Isala klinieken Zwolle,"Pain management in renal colic; The efficacy of continuous intravenous administration of tramadol versus butylscopolamine. A double blinded, randomized placebo controlled, prospective multicenter tria...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006198-98,0,0,0 2007-006204-37,1,2011-03-17,2011-03-17,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,University of Nottingham,Glutamine supplementation for cystic fibrosis: a parallel group randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006204-37,0,0,0 2007-006205-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hôpitaux Universitaires de Strasbourg,Suivi IRM de l’infiltration macrophagique chez des patients présentant une SEP traitée par Tysabri,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006205-25,0,0,0 2007-006206-24,1,2016-06-30,2016-06-30,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,Hillbom Matti OYS/neurologian klinikka,A blind randomized trial to compare the efficacy of intermittent pneumatic compression (IPC) with and without early anticoagulant treatment for prevention of venous thromboembolism (VTE) in patients w...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006206-24,0,0,0 2007-006217-16,1,2009-09-08,2009-09-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Ghent,"Evaluation of the accuracy, safety and robustness of a single-input-single output (SISO) model-based predictive closed-loop system to guide patient-individualized ICU sedation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006217-16,0,0,0 2007-006218-40,5,2012-03-08,2012-03-08,2,1,1,0,0,0,1,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,"A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Telbivudine (LdT) in Children and Adolescents with Chronic Hepatitis B Virus Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006218-40,1,1,0 2007-006220-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Efficacy of Oral Leukotriene in long term therapy of mild and moderate obstructive sleep apnea syndrome (OSAS) in children.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006220-35,0,0,0 2007-006221-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Immunosuppression without calcineurin inhibitors and with the use of everolimus (Certican) in HCV-infected liver transplant patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006221-27,0,0,0 2007-006224-35,1,2008-04-15,2008-04-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Leuven,"The use of IV Tramadol (Contramal) versus immediate release Tramadol (Tradonal odis) in the postoperative period after knee surgery in a day surgery setting. A raondomised , open label",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006224-35,0,0,0 2007-006225-27,1,2018-05-15,2018-05-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,The University of Liverpool,Hyperbaric Oxygen to Prevent Osteoradionecrosis of the Irradiated Mandible (HOPON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006225-27,0,0,0 2007-006225-27,1,2018-05-15,2018-05-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Aintree University Hospital NHS Trust,Hyperbaric Oxygen to Prevent Osteoradionecrosis of the Irradiated Mandible (HOPON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006225-27,0,0,0 2007-006227-12,1,2011-10-25,2011-10-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Cardiff University,"A randomised, placebo controlled study of nebulised magnesium in acute severe asthma in children",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006227-12,0,0,0 2007-006228-36,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Laboratoires Théa,Efficacy and Safety Assessment of Azyter® (T1225) in Peri-Operative Antibio-Prophylaxis (ocular surface decontamination) for Cataract Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006228-36,0,0,0 2007-006231-31,1,2008-03-05,2008-03-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Roche Diagnostics GmbH,"A mono center, open-label glucose clamp study examining the metabolic effect of the frequency of insulin infusion intervals for basal insulin infusion in patients with type 1 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006231-31,0,0,0 2007-006232-58,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Hospital general Universitario de Alicante,Ensayo clínico aleatorizado y controlado con paracetamol de la seguridad renal de metamizol en el tratamiento de pacientes cirróticos con y sin ascitis (Randomized Controlled Clinical Trial to study ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006232-58,0,0,0 2007-006233-14,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Academic Medical Center,Organ protection by noble gases – Helium induced Early and Late Preconditioning (HELP) in human endothelium,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006233-14,0,0,0 2007-006234-34,1,2011-07-19,2011-07-19,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,University of Leeds,3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: endothelial and endothelial progenitor cell function in men,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006234-34,0,0,0 2007-006235-31,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS,12 MONTHS CASE SERIES OPEN STUDY TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL INJECTION OF LUCENTIS (RANIBIZUMAB 0.5 MG) USED IN COMBINATION WITH VISUDYNE (VERTEPORFIN PDT) IN NAIVE SIBJECTS WITH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006235-31,0,0,0 2007-006236-63,1,2008-11-28,2008-11-28,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Evotec Neurosciences GmbH,"A double-blind, randomized, placebo- and NRT-controlled Phase II study to assess the effects of EVT 302 alone and in combination with NRT on craving and withdrawal in healthy male smokers deprived of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006236-63,0,0,0 2007-006246-17,1,2014-12-17,2014-12-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Phase 2 Study of Enzastaurin in Patients with Follicular Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006246-17,0,0,0 2007-006249-42,1,2009-05-19,2009-05-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase 3, randomised, open-label, cross-over study to compare HFA vs CFC pMDI formulations of budesonide on methacholine hyper-reactivity in patients with stable, persistent, mild to moderate asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006249-42,0,0,0 2007-006250-25,2,2008-09-18,2008-09-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Phase III, Randomised, Double-blind, Multi-centre, Parallel Group Study to Compare the Efficacy of Cediranib (AZD2171, RECENTIN™) (30 mg) When Added to Gemcitabine and Cisplatin versus the Efficacy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006250-25,0,0,0 2007-006252-19,1,2013-09-10,2013-09-10,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Univ.-Prof. DDr. Norbert Jakse, Universitätszahnklinik Graz, Dep. f. Orale Chirurgie u. Röntgenologi",Einfluss von peroraler Methylprednisolon-Gabe auf die postoperative Morbidität nach operativer Weisheitszahnenfernung im Unterkiefer. (Influence of peroral Methylprednisolone administration on the po...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006252-19,0,0,0 2007-006253-60,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,MAR ESPINO HERNANDEZ,Eficacia de la profilaxis antibiótica en dosis única nocturna frente al control clínico y tratamiento precoz de las infecciones urinarias para prevenir secuelas parenquimatosas y pielonefritis de repe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006253-60,0,0,0 2007-006254-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,GISCAD,"Open-label randomized, parallel group, phase III, multicenter trial comparing two different sequences of therapy (irinotecan/cetuximab followed by fluorouracil/leucovorin with oxaliplatin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006254-26,0,0,0 2007-006260-29,1,2011-02-10,2011-02-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundación Hospital de Madrid,"""Estudio farmacodinámico Fase ""0"" de Micofenolato Mofetil (MMF, CellCept) en pacientes con cáncer de pancreas""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006260-29,0,0,0 2007-006262-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Transporteur de la Dopamine (DAT) dans les traitements pharmacologiques de la dépendance à la cocaïne,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006262-16,0,0,0 2007-006263-68,3,2016-06-14,2016-06-14,3,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Deutsches Herzzentrum Muenchen,"RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF 6 MONTHS VERSUS 12 MONTHS CLOPIDOGREL THERAPY AFTER IMPLANTATION OF A DRUG-ELUTING STENT SAFETY AND EFFICACY OF SIX MONTHS DUAL ANTIPLATELET THER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006263-68,0,0,0 2007-006263-68,3,2016-06-14,2016-06-14,3,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen","RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF 6 MONTHS VERSUS 12 MONTHS CLOPIDOGREL THERAPY AFTER IMPLANTATION OF A DRUG-ELUTING STENT SAFETY AND EFFICACY OF SIX MONTHS DUAL ANTIPLATELET THER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006263-68,0,0,0 2007-006268-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,EFFICACY AND SAFETYOF BOTULINUM TOXIN THERAPY ON UPPER LIMB SPASTICITY IN INFLAMMATORY AND DEMIELINIZZATING DISEASE OF CENTRAL NERVOUS SYSTEM.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006268-32,0,0,0 2007-006271-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Medical and Health Science Center, University of Debrecen Dept. of Otolaryngology",Dopamin agonista pramipexol hatása tinnitusra presbyacusisban,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006271-37,0,0,0 2007-006272-11,1,2011-11-30,2011-11-30,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,J.W. Goethe University Hospital,Validation of Dermatophot for the assessment of steroid induced skin atrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006272-11,0,0,0 2007-006274-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska Institutet at Danderyd University Hospital,"Sympathetic activation, microcirculation, haemostasis and inflammation in diabetic and non-diabetic kidney disease: disease modification by vitamin D receptor activation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006274-29,0,0,0 2007-006275-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Saint-Etienne,Levobupivacaine into post-caesarian analgesia: randomized monocentric study against placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006275-36,0,0,0 2007-006276-11,4,2010-10-25,2010-10-25,4,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Vectura Limited,"A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cyst...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006276-11,0,0,0 2007-006276-11,4,2010-10-25,2010-10-25,4,1,0,0,0,1,0,0,0,1,0,0,1,0,1,VECTURA LIMITED,"A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cyst...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006276-11,0,0,0 2007-006277-92,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Academic Medical Center, department of infectious diseases","Treatment of anal intraepithelial neoplasia in HIV-positive patients, a triple-arm randomized clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006277-92,0,0,0 2007-006279-35,1,2011-02-18,2011-02-18,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Novartis Pharma Services AG,"An open-label, multi-center, Phase I-Ib/II study of AUY922 administered as single agent and in combination with bortezomib with or without dexamethasone in adult patients with relapsed or refractory m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006279-35,0,0,0 2007-006280-78,8,2009-03-11,2009-10-30,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Axcan Pharma Inc.,"Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given x 10 days With Omeprazole in Eradication of Helicobacter pylori: A Comparison to Omepraz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006280-78,0,0,0 2007-006280-78,8,2009-03-11,2009-10-30,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,APTALIS PHARMA CANADA INC.,"Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given x 10 days With Omeprazole in Eradication of Helicobacter pylori: A Comparison to Omepraz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006280-78,0,0,0 2007-006283-30,5,2012-04-12,2012-04-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA","A RANDOMIZED, PHASE 2 STUDY OF FOLFOX OR FOLFIRI WITH AG-013736 OR BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER AFTER FAILURE OF AN IRINOTECAN OR OXALIPLATINCONTAINING FIRST-LINE REGIMEN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006283-30,0,0,0 2007-006283-30,5,2012-04-12,2012-04-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,"A RANDOMIZED, PHASE 2 STUDY OF FOLFOX OR FOLFIRI WITH AG-013736 OR BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER AFTER FAILURE OF AN IRINOTECAN OR OXALIPLATINCONTAINING FIRST-LINE REGIMEN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006283-30,0,0,0 2007-006283-30,5,2012-04-12,2012-04-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A RANDOMIZED, PHASE 2 STUDY OF FOLFOX OR FOLFIRI WITH AG-013736 OR BEVACIZUMAB IN PATIENTS WITH METASTATIC COLORECTAL CANCER AFTER FAILURE OF AN IRINOTECAN OR OXALIPLATINCONTAINING FIRST-LINE REGIMEN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006283-30,0,0,0 2007-006287-29,5,2008-11-30,2009-02-06,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,Dose ranging study for GSK233705B delivered once daily in subjects with COPD.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006287-29,0,0,0 2007-006288-56,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,"Ludwig Boltzmann Cluster für Rheumatologie, Balneologie und Rehabilitation",Methotrexat-Polyglutamate als Marker fuer das klinische Outcome in der Therapie der rheumatoiden Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006288-56,0,0,0 2007-006290-90,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Society (Institute) for clinical research,Subretinal Macugen for neovascular age-related macular degeneration (SUMANA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006290-90,0,0,0 2007-006295-11,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Instituto de Investigación del Hospital de la Santa Creu i Sant Pau,"TREATMENT OF PRIMARY ACUTE MYELOID LEUKEMIA WITH THE COMBINATION OF IDARUBICIN, CYTARABINE AND GEMTUZUMAB OZOGAMYCIN (MYLOTARG) ASSOCIATED OR NOT TO G-CSF PRIMING: PROSPECTIVE STUDY OF EFFICACY AND TO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006295-11,0,0,0 2007-006297-28,1,2009-07-09,2009-07-09,1,1,0,0,0,1,2,0,1,1,0,0,1,0,1,Bavarian Nordic A/S,An open-label Phase II study to evaluate immunogenicity and safety of a single IMVAMUNE® booster vaccination two years after the last IMVAMUNE® vaccination in former POX-MVA-005 vaccinees,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006297-28,0,0,0 2007-006299-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,Randomised proteomic based phase II study of second-line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006299-13,0,0,0 2007-006301-24,1,2013-05-20,2013-05-20,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"University College London, Joint Research Office",MULTI CENTRE CONTROLLED STUDY ON THE IMPACT OF STEM CELL DONATION EITHER AFTER MOBILISATION WITH GRANULOCYTE COLONY STIMULATING FACTOR OR BONE MARROW HARVEST ON UNRELATED BONE MARROW DONORS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006301-24,0,0,0 2007-006302-13,4,2011-06-07,2011-12-31,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Bionor Immuno AS,"A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006302-13,0,0,0 2007-006302-13,4,2011-06-07,2011-12-31,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,BIONOR IMMUNO AS,"A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006302-13,0,0,0 2007-006303-21,1,2008-12-17,2008-12-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Kythera Biopharmaceuticals, Inc.","Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of ATX-101 (Sodium Deoxycholate for Injection) Given by Three Dosing Paradigms for t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006303-21,0,0,0 2007-006304-37,2,2010-09-01,2010-09-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,"A multi-center, randomized, parallel-group, active-controlled, safety-assessor blinded trial, comparing the efficacy and safety of 2.0 mg.kg-1 sugammadex with 50 μg.kg-1 neostigmine administered at re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006304-37,0,0,0 2007-006305-25,1,2008-11-25,2008-11-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Karolinska University Hospital,Effects of rimonabant (Acomplia) on obesity in adults with Prader-Willi Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006305-25,0,0,0 2007-006306-25,1,2009-05-04,2009-05-04,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,"A phase II study of primary chemotherapy with pegylated liposomal doxorubicin (Caelyx), Cisplatin, and Fluorouracil (CCF) followed by metronomic Capecitabine, Cyclophosphamide and Sorafenib (CCS) in e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006306-25,0,0,0 2007-006334-33,1,2010-06-30,2010-06-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Dr. Josep Brugada Terradellas- Hospital Clínic,Utilidad de la ajmalina intravenosa en el diagnóstico y tratamiento de las arritmias cardíacas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006334-33,0,0,0 2007-006338-32,12,2011-02-16,2012-03-09,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche Ltd.,"Estudio en fase II de búsqueda de dosis, multicéntrico, aleatorio, de grupos paralelos, parcialmente enmascarado, con placebo y Avonex® como fármacos control, para evaluar la eficacia, determinada por...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006338-32,0,0,0 2007-006338-32,12,2011-02-16,2012-03-09,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Hoffman La Roche Ltd,"Estudio en fase II de búsqueda de dosis, multicéntrico, aleatorio, de grupos paralelos, parcialmente enmascarado, con placebo y Avonex® como fármacos control, para evaluar la eficacia, determinada por...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006338-32,0,0,0 2007-006338-32,12,2011-02-16,2012-03-09,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffman-La Roche Ltd,"Estudio en fase II de búsqueda de dosis, multicéntrico, aleatorio, de grupos paralelos, parcialmente enmascarado, con placebo y Avonex® como fármacos control, para evaluar la eficacia, determinada por...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006338-32,0,0,0 2007-006345-40,1,2008-09-23,2008-09-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Shire Pharmaceutical Ireland Limited,"A single center, open-label, non-randomized, uncontrolled, multiple-dose study of the efficacy and long-term safety of Metazym (recombinant human arylsulfatase A or rhASA) for the treatment of patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006345-40,0,0,0 2007-006346-17,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Gruppo Italiano Mesotelioma (G.I.Me.),"A phase II study of the association of Glivec (imatinib mesylate, formerly known as STI 571) plus Gemzar (gemcitabine) in patients with unresectable, refractory, malignant mesothelioma expressing eith...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006346-17,0,0,0 2007-006393-29,1,2008-09-02,2008-09-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT represented by Institut de Recherche Pierre Fabre,"A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006393-29,0,0,0 2007-006415-23,2,2009-11-24,2009-11-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Syndax Pharmaceuticals,"A Phase 2, Multicenter, Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women with ER+ Breast Cancer Whose Disease is Progressing",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006415-23,0,0,0 2007-006416-32,1,2011-01-11,2011-01-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Fundación GEL-TAMO,Trasplante alogénico de progenitores hematopoyéticos de donante no emparentado tras acondicionamiento no mieloablativo e inmunosupresión postrasplante con Rapamicina Alogenic transplantation of unre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006416-32,0,0,0 2007-006433-13,1,2009-02-26,2009-02-26,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,Tengion Inc.,"An open-label, multicentre study of augmentation cystoplasty using an autologous Neo-Bladder construct in subjects with spina bifida.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006433-13,0,0,0 2007-006438-33,1,2011-08-23,2011-08-23,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,Influence of I(f) blockade on orthostatic tolerance and sympathic activity in healthy subjects.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006438-33,0,0,0 2007-006440-22,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo Español de Linfomas y transplantes Autólogos de Médula Osea (GELTAMO),"Ensayo intergrupos (GELTAMO/GETH) Fase II, Abierto, Multicéntrico, de uso de Alemtuzumab (MabCampath®) en Trasplante Alogénico de Donante no Emparentado con Acondicionamiento de Intensidad Reducida en...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006440-22,0,0,0 2007-006443-50,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,University Hospital Ghent,"Prospective, randomized trial to evaluate the administration of 2 different doses of recombinant FSH to patients with age depended insufficient ovarian response during IVF/ICSI",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006443-50,0,0,0 2007-006444-21,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Fundación para la Investigación Biomédica Hospital Gregorio Marañón,EFFECT OF 8-WEEK FATTY ACIDS OMEGA-3 TREATMENT ON OXIDATIVE METABOLISM IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMISED DOUBLE-BLIND CROSSOVER PLACEBO-CONTROLLED TRIAL.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006444-21,0,0,0 2007-006445-41,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,HEALTH RICERCAE SVILUPPO SRL,The irreversibility of hemorrhagic shock treatment with anti-opiod neuropeptide TRATTAMENTO DELLA IRREVERSIBILITA' DELLO SHOCK EMORRAGICO CON NEUROPETIDI ANTI OPPIOIDI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006445-41,0,0,0 2007-006448-23,1,2018-12-31,2018-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical Research Council,A randomised controlled trial of a strategy of switching to boosted protease inhibitor monotherapy versus continuing combination antiretroviral therapy for the long-term management of HIV-1 infected p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006448-23,0,0,0 2007-006451-39,11,2009-10-20,2009-10-20,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENTS W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006451-39,0,0,0 2007-006451-39,11,2009-10-20,2009-10-20,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer S.A.,"12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENTS W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006451-39,0,0,0 2007-006453-12,7,2017-12-19,2017-12-19,7,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"A multi-centre, multinational, open- label study to evaluate the long-term safety, tolerability and efficacy of ACT-293987 (NS-304) in the treatment of pulmonary arterial hypertension in subjects aged...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006453-12,0,0,0 2007-006453-12,7,2017-12-19,2017-12-19,7,1,0,0,0,2,2,0,0,1,0,0,1,0,1,"NIPPON SHINYAKU CO., LTD.","A multi-centre, multinational, open- label study to evaluate the long-term safety, tolerability and efficacy of ACT-293987 (NS-304) in the treatment of pulmonary arterial hypertension in subjects aged...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006453-12,0,0,0 2007-006453-12,7,2017-12-19,2017-12-19,7,1,0,0,0,2,2,0,0,1,0,0,1,0,1,"Nippon Shinyaku Co., Ltd.","A multi-centre, multinational, open- label study to evaluate the long-term safety, tolerability and efficacy of ACT-293987 (NS-304) in the treatment of pulmonary arterial hypertension in subjects aged...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006453-12,0,0,0 2007-006453-12,7,2017-12-19,2017-12-19,7,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"A multi-centre, multinational, open- label study to evaluate the long-term safety, tolerability and efficacy of ACT-293987 (NS-304) in the treatment of pulmonary arterial hypertension in subjects aged...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006453-12,0,0,0 2007-006458-24,1,2008-02-07,2008-02-07,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,Analysis of the sensory profile of two new transdermal patches (V0116TD07AF019 and V0116TD07AF020) 21 mg/24h versus a reference transdermal patch (NICOTINELL TTS) 21 mg/24h.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006458-24,0,0,0 2007-006459-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,St Augustinus,CONTINUOUS TREATMENT WITH SUNITINIB IN PATIENTS WITH SYMPTOMATIC PLEURAL AND/OR PERITONEAL MALIGNANT EFFUSIONS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006459-38,0,0,0 2007-006474-28,3,2010-05-24,2010-05-24,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Neurocrine Biosciences, INC","A Phase II, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects with Endometriosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006474-28,0,0,0 2007-006475-36,1,2014-01-31,2014-01-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Birmingham,Phase ll Study of the Adjunctive Use of Azacitidine in Patients Undergoing Reduced Intensity Allogeneic Transplantation for Acute Myeloid Leukaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006475-36,0,0,0 2007-006487-30,1,,,0,0,0,0,0,0,2,0,1,1,1,1,0,1,0,St. James's Hospital,Differential Effects of donepezil and placebo in mild cognitive impairment and elderly controls.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006487-30,0,0,0 2007-006494-90,4,2012-05-11,2017-04-04,3,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Abbott GmbH & Co. K.G.,"A Multi-center, Open-label Study of the Human Anti−TNF Monoclonal Antibody Adalimumab to Evaluate the Efficacy and the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Ped...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006494-90,1,1,0 2007-006494-90,4,2012-05-11,2017-04-04,3,1,1,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multi-center, Open-label Study of the Human Anti−TNF Monoclonal Antibody Adalimumab to Evaluate the Efficacy and the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Ped...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006494-90,1,1,0 2007-006494-90,4,2012-05-11,2017-04-04,3,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Abbvie Deutschland GmbH & Co. K.G.,"A Multi-center, Open-label Study of the Human Anti−TNF Monoclonal Antibody Adalimumab to Evaluate the Efficacy and the Long-term Safety and Tolerability of Repeated Administration of Adalimumab in Ped...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006494-90,1,1,0 2007-006514-42,2,2010-10-20,2010-10-20,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Institut Produits Synthèse (IPSEN) AB,"A PHASE IV, OPEN-LABEL, RANDOMISED, CROSS-OVER STUDY TO ASSESS PATIENT PREFERENCE AND HEALTH ECONOMY IN PATIENTS WITH NEUROENDOCRINE TUMOURS, TREATED WITH LANREOTIDE AUTOGEL GIVEN AS SELF ADMINISTRATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006514-42,0,0,0 2007-006515-23,1,,,0,0,0,0,1,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SENESE,Randomized clinical trial for the local therapy of carpal tunnel syndrome: cortisone vs progesterone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006515-23,0,0,0 2007-006516-31,1,2014-07-31,2014-07-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"University Hospital Freiburg, represented by the Executive Medical Director (LÄD)","Triple arm, prospective-randomised multi centre study phase IV to evaluate calcineurin inhibitor reduced, steroid free immunosuppression after renal transplantation in low-risk patients (HARMONY-Study...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006516-31,0,0,0 2007-006523-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Julio Bobes,Mejora de la efectividad de los tratamientos de mantenimiento con naltrexona en adictos a opiáceos con la adicción de buprenorfina sublingual. Improvement of naltrexone maintenance treatment effectiv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006523-12,0,0,0 2007-006525-26,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SENESE,efficacy of TachoSil on air leakage in chest surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006525-26,0,0,0 2007-006527-13,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,Can-Fite BioPharma Ltd.,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006527-13,0,0,0 2007-006532-66,1,2008-06-25,2008-06-25,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD SNC,"An open-label, single-arm, phase IV study assessing the immunogenicity and safety of ZOSTAVAX at minimum release specification approaching expiry potency in subjects ≥50 years old",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006532-66,0,0,0 2007-006537-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sven-Åke Lundin,"2-geltest: Comparison of plaque-inhibiting efect of toothbrushing with Sodium Fluoride el 0,2 % and Sodium Fluoride.Chlorhexidine Gel 0,2 % + 0,2 % respectively, in treatment of initial and manifest d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006537-14,0,0,0 2007-006538-33,4,2010-05-25,2010-05-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ono Pharmaceutical Co. Ltd.,"A RANDOMISED, MULTI-CENTRE, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED, 5-WAY, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF ONO-8539 IN PATIENTS WITH OVERACTIVE BLADD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006538-33,0,0,0 2007-006539-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dept of Rheumatology, Lund University Hospital, Lund, Sweden",Effects of different anti-rheumatic treatments of arthritis on antibody response following pneumococcal vaccination using Prevenar,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006539-29,0,0,0 2007-006545-41,3,2010-03-01,2010-03-01,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Aerovance, inc",A PHASE IIB STUDY TO INVESTIGATE THE TREATMENT-SPARING EFFECTS OF AEROVANT™ (AER 001 INHALATION POWDER) IN ASTHMA PATIENTS NOT FULLY CONTROLLED ON CURRENT THERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006545-41,0,0,0 2007-006545-41,3,2010-03-01,2010-03-01,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Aerovance, Inc",A PHASE IIB STUDY TO INVESTIGATE THE TREATMENT-SPARING EFFECTS OF AEROVANT™ (AER 001 INHALATION POWDER) IN ASTHMA PATIENTS NOT FULLY CONTROLLED ON CURRENT THERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006545-41,0,0,0 2007-006549-42,1,2008-07-08,2008-07-08,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Endo Pharmaceuticals Inc.,"A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of EN3285 for the Prevention or Delay to Onset of Severe Oral Mucositis in Subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006549-42,0,0,0 2007-006551-39,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Resistentia Pharmaceuticals AB,"A randomized, double-blind, placebo-controlled dose selection study with two RP 01 formulations evaluating anti-IgE immunotherapy in allergic patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006551-39,0,0,0 2007-006557-25,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,RAPAMYCIN FOR TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006557-25,0,0,0 2007-006558-24,2,2008-03-31,2008-03-31,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Schwarz Biosciences GmbH,"PHASE 3B, OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE PRACTICABILITY AND TOLERABILITY OF SWITCHING SUBJECTS OVERNIGHT FROM PRAMIPEXOLE OR ROPINIROLE TO ROTIGOTINE TRANSDERMAL PATCH AND ITS EFFECT ON S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006558-24,0,0,0 2007-006561-32,1,2014-03-31,2014-03-31,1,1,0,0,1,0,2,0,1,1,0,0,1,0,0,LWL University Hospital Bochum,Effects of intranasal application of oxytocin on empathy and mentalising in patients with psychotic disorders and severe personality disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006561-32,0,0,0 2007-006562-15,4,2008-06-26,2008-06-30,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006562-15,0,0,0 2007-006576-11,1,2013-01-23,2013-01-23,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Nottingham University,Macrolides in Refractory Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006576-11,0,0,0 2007-006595-11,4,2012-01-31,2012-01-31,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,IBSA Institute Biochimique SA,Efficacy and Tolerability of Subcutaneous Progesterone (IBSA) versus Vaginal Progesterone Gel (Crinone) for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF). Efficacia e to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006595-11,0,0,0 2007-006595-11,4,2012-01-31,2012-01-31,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,IBSA Institut Biochimique SA,Efficacy and Tolerability of Subcutaneous Progesterone (IBSA) versus Vaginal Progesterone Gel (Crinone) for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF). Efficacia e to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006595-11,0,0,0 2007-006595-11,4,2012-01-31,2012-01-31,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,IBSA,Efficacy and Tolerability of Subcutaneous Progesterone (IBSA) versus Vaginal Progesterone Gel (Crinone) for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF). Efficacia e to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006595-11,0,0,0 2007-006601-25,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,FUNDACION PETHEMA,"Estudio abierto, multicéntrico, aleatorizado en fase II, para evaluar la eficacia de tratamiento tras la respuesta terapéutica inicial al régimen R-CHOP en pacientes con linfoma folicular no tratados ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006601-25,0,0,0 2007-006602-24,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Department of Pediatrics, Medical and Health Science Center, University of Debrecen","Relative adrenal insufficiency in children with pneumonia and sepsis. Efficacy of i.v. prednisolon for prevention of complication of pneumonia. A prospective, parallel-group, randomised trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006602-24,0,0,0 2007-006603-20,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Centocor B.V.,"A Phase 2, 2-Part, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept, dose-finding Study Evaluating the Efficacy and Safety of CNTO 136 Administered Subcutane...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006603-20,0,0,0 2007-006604-38,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,HOSPITAL CLINIC,Prevención de la disfunción ventricular con enalapril y carvedilol en pacientes sometidos a quimioterapia intensiva para el tratamiento de hemopatías malignas. Prevention of ventricular dysfunction w...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006604-38,0,0,0 2007-006606-16,1,2011-03-28,2011-03-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Wuerzburg,The Effects of Paricalcitol capsules on Inflammation (CRP levels) and Calcification regulation (fetuin-A levels) in CKD stage 5D patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006606-16,0,0,0 2007-006609-25,1,2014-09-02,2014-09-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Julius Maximilians Universität Würzburg,"Effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in Depressed Heart Failure patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006609-25,0,0,0 2007-006611-23,11,2012-02-03,2012-12-03,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"Open-label, single-arm, phase II study of bevacizumab (AVASTIN) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell carcin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006611-23,0,0,0 2007-006611-23,11,2012-02-03,2012-12-03,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"Open-label, single-arm, phase II study of bevacizumab (AVASTIN) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell carcin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006611-23,0,0,0 2007-006637-14,10,2011-05-09,2011-12-08,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc. - 235 East 42nd Street - New York - 10017,"""Estudio en fase 3, abierto, aleatorizado, multinacional de malato de sunitinib frente a sorafenib en pacientes con carcinoma hepatocelular avanzado"" A MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006637-14,0,0,0 2007-006637-14,10,2011-05-09,2011-12-08,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA","""Estudio en fase 3, abierto, aleatorizado, multinacional de malato de sunitinib frente a sorafenib en pacientes con carcinoma hepatocelular avanzado"" A MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006637-14,0,0,0 2007-006637-14,10,2011-05-09,2011-12-08,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, 10017","""Estudio en fase 3, abierto, aleatorizado, multinacional de malato de sunitinib frente a sorafenib en pacientes con carcinoma hepatocelular avanzado"" A MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006637-14,0,0,0 2007-006637-14,10,2011-05-09,2011-12-08,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"""Estudio en fase 3, abierto, aleatorizado, multinacional de malato de sunitinib frente a sorafenib en pacientes con carcinoma hepatocelular avanzado"" A MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PHASE 3 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006637-14,0,0,0 2007-006640-22,8,2012-07-17,2012-07-17,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SANOFI-AVENTIS GROUPE,Superioridad de insulina glargina Lantus frente a NPH: “Tratar hasta alcanzar la Normoglucemia”. Comparación del efecto de insulina glargina vs insulina NPH en pacientes con diabetes mellitus de tipo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006640-22,0,0,0 2007-006640-22,8,2012-07-17,2012-07-17,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SANOFI AVENTIS GROUPE,Superioridad de insulina glargina Lantus frente a NPH: “Tratar hasta alcanzar la Normoglucemia”. Comparación del efecto de insulina glargina vs insulina NPH en pacientes con diabetes mellitus de tipo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006640-22,0,0,0 2007-006645-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sint Lucas Andreas Hospital,The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006645-41,0,0,0 2007-006647-45,1,2014-08-25,2014-08-25,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,AstraZeneca AB,"A Phase I/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 inhibitor AZD1480 Administered Orally to Patients with Primary Mye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006647-45,0,0,0 2007-006648-23,6,2010-06-04,2010-06-04,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab (Xolair) in cystic fibrosis complicated by allergic bronchopulmonary aspergill...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006648-23,0,0,0 2007-006648-23,6,2010-06-04,2010-06-04,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab (Xolair) in cystic fibrosis complicated by allergic bronchopulmonary aspergill...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006648-23,0,0,0 2007-006651-39,1,2009-05-05,2009-05-05,1,1,0,0,0,0,4,0,1,1,1,1,1,0,1,GlaxoSmithKline Biologicals,"A phase IV, randomized, open-label, controlled, post-licensure study to evaluate the safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix®) when administered intramuscularly ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006651-39,0,0,0 2007-006652-19,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,NILG,A Randomized Pilot Study on Central Nervous System (CNS) Prophylaxis with Liposome-Encapsulated Cytarabine (DepoCyte) in a Population of Adult Patients with Acute Lymphoblastic Leukemia (ALL) Treated ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006652-19,0,0,0 2007-006656-19,1,2014-10-02,2014-10-02,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Hellenic Cooperative Oncology Group,"INVESTIGATION OF THE EFFICACY OF LAPATINIB MONOTHERAPY AND TEMOZOLOMIDE PLUS LAPATINIB COMBINATION, IN RECURRENT HIGH GRADE GLIOMAS. A PHASE I/II STUDY.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006656-19,0,0,0 2007-006657-63,5,2012-06-20,2012-06-20,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom",Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006657-63,0,0,0 2007-006657-63,5,2012-06-20,2012-06-20,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals France,Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006657-63,0,0,0 2007-006658-24,2,2014-10-10,2014-10-31,2,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Universitätsklinikum Schleswig-Holstein,A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006658-24,0,0,0 2007-006658-24,2,2014-10-10,2014-10-31,2,1,0,0,0,1,4,0,0,1,0,0,1,0,0,University of Nottingham,A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006658-24,0,0,0 2007-006660-30,1,2012-10-24,2012-10-24,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Hull and East Yorkshire Hospitals NHS Trust,"Contemporary Heart Failure Management : A Randomised, Placebo-Controlled Trial to Measure the Effects of Low Dose Digoxin on Haemodynamics and Symptoms in Patients with Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006660-30,0,0,0 2007-006664-29,1,2010-07-31,2010-07-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Imperial College,The effect of inhaled corticosteroids (ICS) on airway smooth muscle in asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006664-29,0,0,0 2007-006665-33,1,2012-12-10,2012-12-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CIMT group,Effekten af metformin versus placebo samt tre insulinanalog regimer med variende postprandial glukose regulation på carotis intima media tykkelse hos patienter med type 2 diabetes – et randomiseret mu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006665-33,0,0,0 2007-006670-29,1,2008-06-23,2008-06-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Elpen Pharmaceutical Co. Inc.,"A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006670-29,0,0,0 2007-006671-36,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,VALLE HEBRON HOSPITAL,Protección miocárdica durante la reperfusión en pacientes con síndrome coronario agudo con elevación del segmento ST sometidos a angioplastia primaria: efecto de la adenosina intracoronaria sobre el t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006671-36,0,0,0 2007-006673-91,6,2009-02-17,2009-04-17,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GALDERMA R&D SNC,"A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CD5024 1% CREAM TREATMENT FOR UP TO 52 WEEKS IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006673-91,0,0,0 2007-006674-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,UNIMED PHARMA spol. s r. o.,Klinické skúšanie účinnosti a bezpečnosti generického produktu UNILAT v terapii glaukómu a vnútroočnej hypertenzie – non-inferiority štúdia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006674-28,0,0,0 2007-006677-83,2,2016-10-05,2016-10-05,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Facet Biotech Corporation,"A Phase 1b/II, Multicenter, Open-Label, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006677-83,0,0,0 2007-006677-83,2,2016-10-05,2016-10-05,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,AbbVie Biotherapeutics Inc. (AbbVie),"A Phase 1b/II, Multicenter, Open-Label, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006677-83,0,0,0 2007-006681-15,1,2010-10-01,2010-10-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pharma Mar, S.A.","Ensayo Clínico de Fase II de Trabectedina tras Progresión a Terapia Antitumoral basada en Platino en Pacientes con Cáncer No Microcítico de Pulmón (CNMP) Avanzado con Sobreexpresión de XPG y/o ERCC1, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006681-15,0,0,0 2007-006682-33,4,2011-04-20,2012-10-16,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA",Randomzied Phase 2 Trial of AG-013736 or Bevacizumab in Combination with Paclitaxel and Carboplatin as First Line Treatment For Patients with Advanced Non-small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006682-33,0,0,0 2007-006682-33,4,2011-04-20,2012-10-16,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.",Randomzied Phase 2 Trial of AG-013736 or Bevacizumab in Combination with Paclitaxel and Carboplatin as First Line Treatment For Patients with Advanced Non-small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006682-33,0,0,0 2007-006686-32,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,FUNDACIÓN INVESTIGACIÓN BIOMEDICA DEL HOSPITAL CLINICO SAN CARLOS,Identificación de biomarcadores proteicos asociados a resistencia a la aspirina y a tienopiridinas en pacientes con cardiopatía isquémica establecida. (ESTUDIO BIRAT). Identification of new protein b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006686-32,0,0,0 2007-006692-37,1,2010-05-01,2010-05-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Imperial College London,The Immunomodulatory Role of Vitamin D in Inflammatory Bowel Disease (IBDVit): IBDVit1 - Trial of Adjuvant Vitamin D with Corticosteroids in Active Crohn’s Disease; IBDVit2 - Trial of Adjuvant Vitamin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006692-37,0,0,0 2007-006693-28,3,2009-01-22,2009-01-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A Randomised, double blind, Placebo controlled, double dummy, parallel group, multicentre, dose ranging study in subjects with T2DM to evaluate the efficacy, safety, and tolerability of orally adminis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006693-28,0,0,0 2007-006694-91,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,0,G.I.M.E.M.A.,A large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events In patients with Polycythemia Vera (PV) – CYTO-PV.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006694-91,0,0,0 2007-006695-10,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,Eisai Limited,"Open Label Extension Study Following Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess Efficacy and Safety of Adjunctive Zonisamide in Primary Generalized Tonic-Clonic Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006695-10,0,0,0 2007-006696-36,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,Eisai Limited,"Open label Extension Study Following Double-blind, Randomized, Placebo-controlled, Multicentre Study to Assess Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures associated with Idiopa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006696-36,0,0,0 2007-006700-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Instituto Andaluz de Sexología,Cambios en la calidad de vida sexual en pacientes con disfunción eréctil tratados con vardenafilo tras una respuesta parcial a sildenafilo o tadalafilo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006700-37,0,0,0 2007-006701-25,1,2016-12-31,2016-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,"EXCITE: Erbitux, Xeloda, Campto, Irradiation Then Excision for locally advanced rectal cancer. (North West Clinical Oncology Group-04 on behalf of the NCRI rectal cancer subgroup)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006701-25,0,0,0 2007-006706-14,2,2010-07-28,2010-07-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Pharma GmbH,"Impact of Pioglitazone, Metformin and the combination of both on cardiovascular risk in insulin-treated patients with Type 2 diabetes – The PIOcomb Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006706-14,0,0,0 2007-006707-21,1,2014-03-12,2014-03-12,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Martina Bachmann,Päiväkirurginen spinaalipuudutus artikaiinilla verrattuna bupivakaiini-fentanyyliin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006707-21,0,0,0 2007-006713-16,1,2008-10-27,2008-10-27,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,ImClone Systems Incorporated,"Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients with Metastatic Malignant Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006713-16,0,0,0 2007-006715-22,1,2011-10-04,2011-10-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ImClone LLC,"A Phase 2, Open-label Study of IMC-1121B in Combination with Paclitaxel and Carboplatin as First-line Therapy in Patients with Stage IIIB/IV Non-small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006715-22,0,0,0 2007-006717-17,1,2012-04-25,2012-04-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ImClone LLC,"A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006717-17,0,0,0 2007-006719-21,5,2010-05-11,2012-06-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ImClone Systems Incorporated,"A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously- Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006719-21,0,0,0 2007-006719-21,5,2010-05-11,2012-06-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ImClone LLC,"A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously- Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006719-21,0,0,0 2007-006719-21,5,2010-05-11,2012-06-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ImClone Systems Corporation,"A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously- Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006719-21,0,0,0 2007-006721-27,2,2008-12-03,2008-12-03,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Ceregene Inc.,"A Phase II, Multicenter, Randomized and Controlled Open-Label Trial Comparing the Safety and Efficacy of Bilateral Intraputaminal (IPu) Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006721-27,0,0,0 2007-006724-35,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,CMIV,Functional MRI after administration of Gd-based blood pool contrast agents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006724-35,0,0,0 2007-006727-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut Català de la Salut,Efectividad del tratamiento antiinflamatorio versus antibiótico y placebo en pacientes con bronquits aguda no complicada con esputo purulento,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006727-12,0,0,0 2007-006729-28,1,2009-06-30,2009-06-30,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Trafford NHS Trust,Is a single dose intramuscular (IM) triamcinolone acetonide injection more effective in treating symptomatic flare in established rheumatoid arthritis than equivalent dose of oral prednisolone?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006729-28,0,0,0 2007-006730-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitario Virgen del Rocío,"Estudio de los mecanismos implicados en la recuperación de linfocitos CD4+ propiciada por el tratamiento con Interleuquina 2 en pacientes bajo TARGA efectivo, pero con escasa ganancia de linfocitos CD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006730-33,0,0,0 2007-006731-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol,"Estudio doble ciego, aleatorizado, controlado con placebo de dosis escaladas de deferoxamina intravenosa en pacientes con ictus isquémico agudo tratado con activador tisular del plasminógeno. Double-b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006731-31,0,0,0 2007-006738-33,2,2010-04-01,2010-04-01,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,NatImmune A/S,"bLAC - A phase II double-blind, placebo controlled, clinical proof of concept trial of the efficacy of 8 weeks treatment of cutaneous warts with bLAC in immune suppressed, kidney transplanted patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006738-33,0,0,0 2007-006739-30,1,2014-08-11,2014-08-11,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Assistance Publique Hopitaux de marseille,etude pilote des effets de la désipramine sur les parametres neurovégétatifs de l'enfant porteur de syndrome de rett,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006739-30,0,0,0 2007-006741-40,1,2009-10-29,2009-10-29,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Pharma Services AG,"A double blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, tolerability and immunogenicity of repeated s.c administrations of 100µg NIC002 vaccine in cigarette smokers wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006741-40,0,0,0 2007-006742-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Evaluation de l'intérêt de la loxapine dans le contrôle de l'agitation au cours du sevrage de la ventilation mécanique. Etude randomisée, contrôlée.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006742-18,0,0,0 2007-006744-21,1,2010-06-29,2010-06-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Pharma GmbH,Comparison of the Effects of Pioglitazone vs. Placebo when given in addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus and Renal Failure – The PIOren Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006744-21,0,0,0 2007-006748-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,HOSPITAL SANT JOAN DE DÉU,Tratamiento con ácido fólico en pacientes con defectos de la fosforilización oxidativa mitocondrial. TREATMENT WITH FOLINIC ACID IN PATIENTS WITH TROUBLES OF MITOCHONDRIAL OXIDATIVE FOSFORILATION.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006748-23,0,0,0 2007-006749-42,2,2016-04-12,2016-04-12,2,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University of Nottingham,Safety and efficacy of clopidogrel when added to aspirin and dipyridamole in high risk patients with recent ischaemic stroke or TIA: a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006749-42,0,0,0 2007-006750-26,1,2009-02-27,2009-02-27,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Austrian Breast & Colorectal Cancer Study Group (ABCSG),"Preoperative combined RadioChemo-MolecularTargetedTherapie (RC-MTTx) of the locally advanced rectal carcinoma (cT3NxM0) – a phase II pilot study with preoperative application of capecitabine (Xeloda),...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006750-26,0,0,0 2007-006754-26,2,2011-12-19,2011-12-19,2,0,0,0,0,0,4,0,0,1,0,0,1,0,1,MASTELLI SRL,DIABETIC FOOT ULCERS AND POLYDEOXYRIBONUCLEOTIDE (PLACENTEX INTEGRO MASTELLI) AS A TREATMENT FOR WOUND HEALING,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006754-26,0,0,0 2007-006755-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Clermont-Ferrand,Intérêt du Néfopam dans le traitement de la douleur au cours des coliques néphrétiques intenses non compliquées de l'adulte aux urgences.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006755-39,0,0,0 2007-006761-32,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge,Vulval intraepithelial neoplasia: immune responses to human papillpmavirus.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006761-32,0,0,0 2007-006763-77,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU-Hôpitaux de Rouen,"Etude prospective, ouverte randomisée, comparant l'efficacité et la tolérance du Sirolimus (Rapamune R) au Tacrolimus (Prograf R) associé à un traitement de fond par Mycophénolate mofétil (Cellcept R)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006763-77,0,0,0 2007-006764-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"KaloBios Pharmaceuticals, Inc.","A Randomized, double-blind, placebo-controlled pilot study of KB001 in mechanically-ventilated patients colonized with pseudomonas aeruginosa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006764-29,0,0,0 2007-006767-69,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Pharmacocinétique de la caspofungine chez le patient brûlé,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006767-69,0,0,0 2007-006773-92,1,,,0,0,0,0,0,0,3,0,1,1,0,0,0,1,0,UNIVERSITA' DEGLI STUDI DI PERUGIA,Sodium Valproate in the treatment of medication overuse headache: a controlled randomized clinical trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006773-92,0,0,0 2007-006776-11,1,2008-11-14,2008-11-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,gepepharm GmbH,Investigation of the local tolerability of pedimitex Lösung 0.5% - a permethrin containing solution - in 100 patients with head lice infection of both gender,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006776-11,0,0,0 2007-006778-26,1,2009-07-15,2009-07-15,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,gepepharm GmbH,Investigation of the local tolerability of pedimitex creme 5% - a permethrine containing creme - in 100 patients with scabies infection of both gender,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006778-26,0,0,0 2007-006780-70,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Tampereen yliopistollinen sairaala,METYYLIPREDNISOLONIN IMEYTYMINEN VAIKEAA KOLIITTIA SAIRASTAVILLA Suonensisäistä ja suun kautta tapahtuvaa annostelua vertaileva lääkeainepitoisuusmäärityksiin perustuva tutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006780-70,0,0,0 2007-006785-15,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,IOBA - Instituto Universitario de Oftalmobiología Aplicada,EFFICACY AND SECURITY OF INTRAVITREAL BEVACIZUMAB IN THE TREATMENT OF CHOROIDAL NEOVASCULAR MEMBRANES ASSOCIATED TO HIGH MYOPIA EVALUACIÓN DE LA EFICACIA Y SEGURIDAD DE LA INYECCIÓN INTRAVÍTREA DE B...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006785-15,0,0,0 2007-006790-81,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,APREC,Phase II study of pegylated liposomal doxorubicin (Caelyxâ) in breast cancer patients with brain metastases and not candidate for an antiHER2 therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006790-81,0,0,0 2007-006791-12,3,2010-01-26,2010-02-18,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,FoldRx Pharmaceuticals Limited,The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with Non-V30M Transthyretin Amyloidosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006791-12,0,0,0 2007-006791-12,3,2010-01-26,2010-02-18,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"FOLDRX PHARMACEUTICALS, INC.",The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with Non-V30M Transthyretin Amyloidosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006791-12,0,0,0 2007-006791-12,3,2010-01-26,2010-02-18,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"FoldRx Pharmaceuticals, Inc.",The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with Non-V30M Transthyretin Amyloidosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006791-12,0,0,0 2007-006793-28,12,2009-06-08,2009-09-25,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier (I.R.I.S),Effects of a 10 or 15 mg single intravenous bolus of ivabradine versus placebo on heart rate control during a multislice computed tomography coronary angiography for the evaluation of coronary artery ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006793-28,0,0,0 2007-006793-28,12,2009-06-08,2009-09-25,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Effects of a 10 or 15 mg single intravenous bolus of ivabradine versus placebo on heart rate control during a multislice computed tomography coronary angiography for the evaluation of coronary artery ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006793-28,0,0,0 2007-006793-28,12,2009-06-08,2009-09-25,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratorios Servier S.L,Effects of a 10 or 15 mg single intravenous bolus of ivabradine versus placebo on heart rate control during a multislice computed tomography coronary angiography for the evaluation of coronary artery ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006793-28,0,0,0 2007-006794-93,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Randomized Evaluation of Intracoronary nitroprusside vs adenosine after thrombus aspiration during primary PErcutaneous coronary intervention for the prevention of No reflow in Acute Myocardial Infar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006794-93,0,0,0 2007-006795-10,1,2011-06-07,2011-06-07,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Frimley Park Hospital NHS Foundation Trust,A randomised controlled trial of efficacy of Pegaptanib sodium in the prevention of proliferative diabetic retinopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006795-10,0,0,0 2007-006854-24,3,2009-08-21,2010-05-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biofrontera Bioscience GmbH,"A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of a nanoemulsion gel formulation BF-200 ALA, in comparison with Metvix® and placebo, for the treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006854-24,0,0,0 2007-006875-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IMAS,"Administración perioperatoria de aspirina a baja dosis como prevención secundaria de muerte súbita, apoplejía, infarto de miocardio y otros accidentes isquémicos postoperatorios. Ensayo clínico multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006875-35,0,0,0 2007-006914-41,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Dept. of Psychiaty, University of Freiburg",Differential responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP) versus escitalopram in chronic major depression with and without early trauma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006914-41,0,0,0 2007-006934-33,1,2009-07-08,2009-07-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,"A single center, open-label trial in subjects with severe renal impairment evaluating the dialysability of the sugammadex-rocuronium complex",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006934-33,0,0,0 2007-006935-29,4,2010-03-15,2010-03-15,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,"A multi-center, parallel-group, comparative trial evaluating the efficacy, pharmacokinetics and safety of 4.0 mg.kg-1 sugammadex administered at 1-2 PTC in subjects with normal or severely impaired re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006935-29,0,0,0 2007-006935-29,4,2010-03-15,2010-03-15,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Organon Nederland BV,"A multi-center, parallel-group, comparative trial evaluating the efficacy, pharmacokinetics and safety of 4.0 mg.kg-1 sugammadex administered at 1-2 PTC in subjects with normal or severely impaired re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006935-29,0,0,0 2007-006994-10,1,,,0,0,0,0,1,0,4,0,0,1,1,1,0,1,0,Fundación Investigación Biomédica Hospital Príncipe de Asturias,Evaluación de la utilidad del alopurinol en la prevención de la morbimortalidad cardiovascular de los pacientes con enfermedad renal crónica (ERC) e hiperuricemia EVALUATION OF THE USE OF ALLOPURINOL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006994-10,0,0,0 2007-006997-27,5,2014-10-02,2014-10-14,3,1,1,0,0,2,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006997-27,0,0,0 2007-006997-27,5,2014-10-02,2014-10-14,3,1,1,0,0,2,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-006997-27,0,0,0 2007-007000-15,3,2012-06-13,2012-06-13,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, phase II study to evaluate efficacy and safety of deferasirox in non-transfusion-dependent thalassemia patients with iron overload",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007000-15,0,0,0 2007-007000-15,3,2012-06-13,2012-06-13,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled, phase II study to evaluate efficacy and safety of deferasirox in non-transfusion-dependent thalassemia patients with iron overload",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007000-15,0,0,0 2007-007003-33,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,1,Genzyme Europe BV,"A Multicenter, Multinational, Open-Label Study of the Effects of Aldurazyme(laronidase) Treatment on Lactation in Women with Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007003-33,0,0,0 2007-007007-32,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE),Efficacy of IVIG in the treatment of treatment-resistent painful neuropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007007-32,0,0,0 2007-007011-85,1,2012-12-31,2012-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charite Universitätsmedizin Berlin,Topical application of morphine for wound healing and analgesia in patients with painful oral lesions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007011-85,0,0,0 2007-007013-37,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Bernardino Clavo - Hospital Dr. Negrin,Ensayo Clínico aleatorizado del efecto de la Ozonoterapia en el tratamiento de la hernia de disco candidata a cirugía.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007013-37,0,0,0 2007-007015-89,5,2012-07-26,2012-08-26,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,CLINUVEL PHARMACUETICALS LTD,"A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of CUV1647 for the Prophylactic Treatment of Pre-C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007015-89,1,0,0 2007-007015-89,5,2012-07-26,2012-08-26,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Clinuvel Pharmaceuticals Limited,"A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of CUV1647 for the Prophylactic Treatment of Pre-C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007015-89,1,0,0 2007-007018-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Carlos Alonso-Villaverde Lozano, Hospital Universitari Sant Joan de Reus","“Estudio prospectivo, abierto, aleatorizado y cruzado sobre el efecto de la Hidroxicloroquina, 200mg al día, en factores inflamatorios y metabólicos relacionados con la enfermedad cardiovascular en pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007018-12,0,0,0 2007-007019-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Ghent,Comparison of the therapeutic efficacy and side effects of tramadol per os (Tradonal Odis® orodispersible tablets) versus an optimised dosis of travenous tramadol for postoperative pain relief in ambu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007019-10,0,0,0 2007-007020-18,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"Efficacy of baclofen in the treatment of nicotine addicted patients:randomized, double blind study of Baclofen versus placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007020-18,0,0,0 2007-007025-51,6,2008-12-29,2009-04-14,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,H. Lundbeck A/S,"A randomised, double-blind, parallel-group, placebo-controlled and active-referenced study evaluating the efficacy and safety of three fixed dose regimens of Lu AA34893 in the treatment of Major Depre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007025-51,0,0,0 2007-007026-22,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Institut de Recherches Internationales Servier,Assessment of the effects on 24-hour ambulatory blood pressure and the safety of a once-a-day oral 8 mg perindopril morning administration versus evening administration in hypertensive patients. An 8-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007026-22,0,0,0 2007-007027-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Georges-François Leclerc,"A Multicenter open-label, phase I/II dose escalation study of oral lapatinib in combination with docetaxel in patients with HER2 positive advanced or metastatic breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007027-40,0,0,0 2007-007029-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FNCLCC,Essai de phase II multicentrique non randomisée étudiant l’impact de l’association radiochimiothérapie (65 Gy + cisplatine + 5FU) au cetuximab chez les patients présentant un cancer anal localement av...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007029-38,0,0,0 2007-007030-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,RANDOMIZED PHASE II/III STUDY OF SECOND-LINE ENDOCRINE TREATMENT FOLLOWED BY CAPECITABINE VERSUS CAPECITABINE FOLLOWED BY ENDOCRINE TREATMENT IN PATIENTS WITH METASTATIC ER POSITIVE BREAST CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007030-20,0,0,0 2007-007031-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPO ESPAÑOL DE INVESTIGACIÓN EN CÁNCER DE MAMA (GEICAM),"ESTUDIO MULTICÉNTRICO FASE II DE DISTRIBUCIÓN ALEATORIA, PARA COMPARAR EL TRATAMIENTO DE EPIRUBICINA Y CICLOFOSFAMIDA SEGUIDO DE DOCETAXEL Y TRASTUZUMAB VERSUS EPIRUBICINA Y CICLOFOSFAMIDA SEGUIDO DE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007031-13,0,0,0 2007-007033-40,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,1,Fundación para La Investigación Biomedica del Hospital Gregorio Marañón,Estudio SIOVAC (Sildenafilo en Pacientes con Hipertensión Pulmonar tras Corrección de la Enfermedad Valvular),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007033-40,0,0,0 2007-007034-18,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Charité Universitätsmedizin Berlin - CVK,Phase II-Studie zur Erfassung der Effektivität einer wöchentlich verabreichten Docetaxel-Carboplatin/Cisplatin-Cetuximab-Kombination (DCC) bei fortgeschrittenen Plattenepithelkarzinomen des Oropharynx...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007034-18,0,0,0 2007-007037-39,1,2009-01-23,2009-01-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biofrontera Bioscience GmbH,"A Phase II Proof-of-Concept, Randomized, Double-blind, Vehicle-controlled Study, Including an Open-label Comparison to an Active Control, To Assess the Efficacy and Safety/Tolerability of Topical Rilu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007037-39,0,0,0 2007-007042-35,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Phase II trial of transdermic buprenorfine in children with pain cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007042-35,0,0,0 2007-007043-27,1,2008-04-11,2008-04-11,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, double-blind, multicentre, randomized study to demonstrate the non-inferiority of GlaxoSmithKline Biologicals’ thiomersal-free adjuvanted influenza vaccine compared to GlaxoSmithKline Biol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007043-27,0,0,0 2007-007044-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,JOSÉ ANTONIO SERRANO TRENAS,UTILIDAD DEL HIERO INTRAVENOSO EN EL PACIENTE ANCIANO CON FRACTURA DE CADERA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007044-10,0,0,0 2007-007045-12,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,OSPEDALE POLICLINICO S. MATTEO,"An open label, single institution, phase II study of the mTOR inhibitor temsirolimus in unresectable and/or metastatic renal cell carcinoma (RCC) in patients previously treated with both cytokines and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007045-12,0,0,0 2007-007055-13,1,2011-04-16,2011-04-16,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,RIEMSER Arzneimittel AG,"DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED PROSPECTIVE MULTI-CENTRE PHASE III TRIAL TO ASSESS THE EFFICACY AND SAFETY OF METHANTHELINIUM BROMIDE (VAGANTIN®) IN THE TREATMENT OF FOCAL PALMAR-AXILLARY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007055-13,0,0,0 2007-007056-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Goelams,"An open label, multicenter, non randomized phase II study to evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with RCHOP chemotherapy and Rituximab (MabThera®) mai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007056-33,0,0,0 2007-007058-79,3,2008-09-30,2008-09-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Placebo-controlled, Double-blind, Parallel-group, Multicentre, Phase IIa Study to Explore the Relationship between QTcF Interval at First Dose (Loading Dose) and at Steady State after Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007058-79,0,0,0 2007-007059-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AZIENDA DI RILIEVO NAZIONALE E DI ALTA SPECIALIZZAZIONE OSPEDALE CIVICO E BENFRATELLI, G.DI CRISTINA E M.ASCOLI",Role of the Glutatione reduced in the prevention of neuro-toxicity from Oxaliplatino. Ruolo del Glutatione ridotto nella prevenzione della neurotossicita' da Oxaliplatino.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007059-14,0,0,0 2007-007062-38,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón (FIBHGUGM),“Necesidad de tratamiento antibiótico de la bacteriemia relacionada con catéteres venosos centrales producida por Staphylococcus coagulasa-negativa tras la retirada del catéter en pacientes de bajo ri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007062-38,0,0,0 2007-007063-24,1,2012-06-25,2012-06-25,1,0,0,0,1,0,3,0,0,1,1,1,1,0,0,Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón (FIBHGUGM),“Estudio de la terapia de cierre con etanol en la prevención de la infección relacionada con catéteres venosos centrales no tunelizados de corta duración” “Clinical study of ethanol lock-therapy in t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007063-24,0,0,0 2007-007072-42,1,2010-05-29,2010-05-29,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,University Medical Center Utrecht,Double-blind placebo-controlled randomized study to determine the effectiveness of magnesium oxide to reduce the prostate motion.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007072-42,0,0,0 2007-007075-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VU university medical center,"The effect of peroxisome proliferator activator receptor γ agonist pre-treatment on pegylated interferon-α2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007075-16,0,0,0 2007-007081-38,5,2012-05-07,2012-05-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co KG,"An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination With mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination With mFOLFOX6 as Second-line Treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007081-38,0,0,0 2007-007083-22,3,2010-02-01,2010-02-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of JNJ-37822681 Administered Twice Daily in Subjects With Schizoph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007083-22,0,0,0 2007-007085-38,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,Kuopio University Hospital,Estääkö postoperatiivisesti annettu kortikosteroidi hiippaläppäleikkauksen jälkeisen eteisvärinän ilmaantumista?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007085-38,0,0,0 2007-007086-21,8,2010-12-03,2011-08-30,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,"A Phase II, open-label trial to evaluate the safety, tolerability and antiviral activity of TMC125 in antiretroviral experienced HIV-1 infected children and adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007086-21,0,0,0 2007-007086-21,8,2010-12-03,2011-08-30,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"A Phase II, open-label trial to evaluate the safety, tolerability and antiviral activity of TMC125 in antiretroviral experienced HIV-1 infected children and adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007086-21,0,0,0 2007-007086-21,8,2010-12-03,2011-08-30,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals Limited,"A Phase II, open-label trial to evaluate the safety, tolerability and antiviral activity of TMC125 in antiretroviral experienced HIV-1 infected children and adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007086-21,0,0,0 2007-007087-17,11,2009-01-02,2010-09-08,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"PFIZER, S.A.","A 24-WEEK, MULTICENTRE TRIAL, COMPRISING A 12-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE FOLLOWED BY A 12-WEEK OPEN-LABEL PHASE, TO EVALUATE THE EFFICACY AND SAFETY OF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007087-17,0,0,0 2007-007087-17,11,2009-01-02,2010-09-08,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,PFIZER,"A 24-WEEK, MULTICENTRE TRIAL, COMPRISING A 12-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE FOLLOWED BY A 12-WEEK OPEN-LABEL PHASE, TO EVALUATE THE EFFICACY AND SAFETY OF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007087-17,0,0,0 2007-007087-17,11,2009-01-02,2010-09-08,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent, UK","A 24-WEEK, MULTICENTRE TRIAL, COMPRISING A 12-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE FOLLOWED BY A 12-WEEK OPEN-LABEL PHASE, TO EVALUATE THE EFFICACY AND SAFETY OF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007087-17,0,0,0 2007-007087-17,11,2009-01-02,2010-09-08,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A 24-WEEK, MULTICENTRE TRIAL, COMPRISING A 12-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP PHASE FOLLOWED BY A 12-WEEK OPEN-LABEL PHASE, TO EVALUATE THE EFFICACY AND SAFETY OF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007087-17,0,0,0 2007-007088-25,1,2009-01-23,2009-01-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Dermatologie,Efficacy and tolerance of V0071 GM 01A in inflammatory seborrhoeic dermatitis of the scalp.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007088-25,0,0,0 2007-007091-41,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ITALFARMACO,Phase II Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin’s Lymphoma Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007091-41,0,0,0 2007-007094-23,1,2009-06-30,2009-06-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Nottingham,Nitrous oxide and cerebral vasodilatation: a dose-response study in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007094-23,0,0,0 2007-007096-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Agustín Albillos Martinez,"Estudio en fase II aleatorizado, controlado. Multicéntrico para evaluar la eficacia y la seguridad de la monoterapia prolongada con ribavirina frente a colchicina sobre la progresión de la hepatitis c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007096-16,0,0,0 2007-007103-32,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,DermaGen AB,"A randomized, double blinded placebo controlled study to investigate antimicrobial efficacy and safety following topical application of DPK-060. Final protocol dated 2007-12-19. CRO protocol no. Q-273...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007103-32,0,0,0 2007-007106-30,1,2013-09-23,2013-09-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"HUS, ATEK, Töölön sairaala, Neurokirurgian klinikka",Tavoite-ohjattu nestehoito istuvan neurokirurgisen potilaan anestesiassa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007106-30,0,0,0 2007-007107-32,1,2012-04-04,2012-04-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin /Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-Smal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007107-32,0,0,0 2007-007115-87,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,FUNDACION CV INVESTIGACION HOSPITAL DR PESET,ENSAYO CLÍNICO UNICÉNTRICO PARA VALORAR LA EFICACIA DE LA ADMINISTRACIÓN EXÓGENA DE LH EN FORMA DE HCG EN EL TRATAMIENTO DE LA DISFUNCIÓN SEXUAL FEMENINA POR DISMINUCIÓN DEL DESEO SEXUAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007115-87,0,0,0 2007-007117-36,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Lourdes Grande Santamaria,UTILIDAD DE LA RIFAXIMINA EN EL TRATAMIETNO DE LA ENCEFALOPATÍA HEPÁTICA MÍNIMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007117-36,0,0,0 2007-007118-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Emilio Garcia Garcia,TRATAMIENTO CON METFORMINA EN NIÑOS OBESOS NO DIABÉTICOS CON HIPERINSULINEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007118-12,0,0,0 2007-007127-40,1,2008-09-30,2008-09-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Astra ZenecaGmbH,"CARE II - Evaluation of treatment outcomes in schizophrenic patients taking part in the integrated care program - a single-country, multi-centre phase IV study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007127-40,0,0,0 2007-007129-38,7,2014-09-09,2015-09-18,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,CSL Behring GmbH,"An open, non-controlled, multicenter, multinational Study to evaluate the Efficacy and Safety of Zemaira® administration in Chronic Augmentation and Maintenance Therapy in Subjects with Emphysema due ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007129-38,0,0,0 2007-007130-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Allerderm,Clinical Evaluation of TRUE TEST® Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007130-19,0,0,0 2007-007132-25,1,2009-07-30,2009-07-30,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,EBI Anti Sepsis B.V.,"A randomized, double blind, parallel, placebo controlled, exploratory study to assess the effect of EA-230 on renal function and on safety and tolerability in patients at increased risk of developing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007132-25,0,0,0 2007-007134-19,1,2010-09-21,2010-09-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Octapharma AG,"Prospective 24-week, double-blind, randomized, placebo-controlled, multicenter study evaluating safety and change in efficacy-related surrogate parameters in patients with dementia of the Alzheimer’s ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007134-19,0,0,0 2007-007137-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Vejle Hospital,"En åbent randomiseret fase II undersøgelse af effekten af darbepoietin alfa (Aranesp®) til behandling af anæmi hos patienter med hormonrefraktær prostatacancer, der behandles med Taxotere",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007137-38,0,0,0 2007-007139-26,3,2009-05-27,2009-07-01,2,0,0,0,0,0,2,0,0,1,1,0,1,0,2,SENDO TECH,A phase II study of the histone deacetylase inhibitor Panobinostat (LBH589) in patients with advanced Small Cell Lung Cancer (SCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007139-26,0,0,0 2007-007139-26,3,2009-05-27,2009-07-01,2,0,0,0,0,0,2,0,0,1,1,0,1,0,2,Southern Europe New Drug Organization (SENDO),A phase II study of the histone deacetylase inhibitor Panobinostat (LBH589) in patients with advanced Small Cell Lung Cancer (SCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007139-26,0,0,0 2007-007142-36,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,CH Pau,Evaluation des traitements anticoagulants lors d'angioplasties coronaires transcutanées non urgentes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007142-36,0,0,0 2007-007146-34,3,2012-01-18,2012-04-30,3,0,0,0,0,0,2,0,0,1,1,0,1,0,0,Steno Diabetes Center,"Estudio aleatorizado del efecto del antagonista del receptor de interleucina 1 (anakinra, Kineret®) sobre la producción de insulina en pacientes con diabetes tipo 1 - The Anti-Interleukin-1 in Diabete...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007146-34,0,0,0 2007-007147-28,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,CYTHERIS,A PHASE I/IIa DOSE ESCALATION STUDY OF REPEATED ADMINISTRATION OF “CYT107” (glyco-r-hIL-7) ADD ON TREATMENT IN GENOTYPE 1 or 4 HCV INFECTED PATIENTS RESISTANT TO PEGYLATED INTERFERON-ALPHA AND RIBAVIR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007147-28,0,0,0 2007-007156-33,1,2011-02-22,2011-02-22,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Imperial College,Melatonin As A Novel Neuroprotectant in Preterm Infants- Dosage study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007156-33,0,0,0 2007-007157-31,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Sahlgrenska Universitetssjukhuset,FIBRINOGEN AND BLEEDING AFTER CARDIAC SURGERY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007157-31,0,0,0 2007-007160-19,5,2011-08-29,2011-08-29,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A double blind, randomized, placebo controlled, multicenter, dose finding study of oral AEB071 assessing Psoriasis Area and Severity Index (PASI) response as a function of dose and treatment duration...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007160-19,0,0,0 2007-007160-19,5,2011-08-29,2011-08-29,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A double blind, randomized, placebo controlled, multicenter, dose finding study of oral AEB071 assessing Psoriasis Area and Severity Index (PASI) response as a function of dose and treatment duration...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007160-19,0,0,0 2007-007161-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,BIO-KER S.R.L,"Comparable efficacy and safety profiles of daily injection of BK0023 and filgrastim (Neupogen®) in chemotherapy-induced neutropenia: a multinational, multicenter, investigator blind, randomised, paral...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007161-20,0,0,0 2007-007162-38,2,2010-08-25,2010-08-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,"A multi-center, open label trial, to show efficacy and safety of 4.0 mg.kg-1 sugammadex administered at a depth of neuromuscular blockade of 1-2 PTC induced by rocuronium in Chinese and European ASA I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007162-38,0,0,0 2007-007164-20,1,2010-12-27,2010-12-27,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD,Uso racional de los tratamientos por inhibición de sustrato y enzimático sustitutivo en pacientes con Enfermedad de Gaucher tipo 1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007164-20,0,0,0 2007-007165-20,1,2008-12-04,2008-12-04,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Shire Pharmaceuticals Ireland Limited,"A single center, open-label, non-randomized, uncontrolled, multiple-dose study of the efficacy and safety of Metazym (recombinant human arylsulfatase A or rhASA) for the treatment of MLD patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007165-20,0,0,0 2007-007166-37,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,MIKEL URRETAVIZCAYA SARACHAGA,"“TERAPIA ELECTROCONVULSIVA DE CONSOLIDACIÓN ASOCIADA A PSICOFÁRMACOS VERSUS FARMACOTERAPIA EN LA PREVENCIÓN DE RECIDIVAS EN EL TRASTORNO DEPRESIVO MAYOR. UN ENSAYO CLÍNICO, PRAGMÁTICO, PROSPECTIVO ALE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007166-37,0,0,0 2007-007168-94,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA ""S. CROCE E CARLE""","PHASE II MULTICENTRE CLINICAL STUDY WITH EARLY TREATMENT INTENSIFICATION IN PTS WITH HIGH-RISK HODGKIN LYMPHOMA, IDENTIFIED AS FDG-PET SCAN POSITIVE AFTER TWO CONVENTIONAL ABVD COURSES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007168-94,0,0,0 2007-007170-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Technical University of Dresden, faculty of medicine",Untersuchung des Phänotyps und der Funktion proinflammatorischer dendritischer Zellen während einer Therapie der Psoriasis vulgaris mit einem TNFalpha Antagonisten Investigation of phenotype and func...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007170-30,0,0,0 2007-007174-35,1,2010-03-12,2010-03-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Dr. Franz Köhler Chemie GmbH,"Randomized, placebo-controlled phase-IV clinical trial for the application of physostigmine salicylate for an early post-operative restoration of vigilance and cognition after cardiopulmonary bypass s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007174-35,0,0,0 2007-007177-23,1,2016-04-21,2016-04-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,U.Z. Gasthuisberg,"A randomized phase II of bevacizumab, capecitabine and radiation therapy with or without oxaliplatin in the preoperative treatment of locally advanced rectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007177-23,0,0,0 2007-007179-18,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,SOFAR SPA,Evaluation of the ability of the probiotic Lactobacillus casei DG (Enterolactis) to remain into the bladder of patients with spinal cord injury and subject to intermitted catheterization. An open-labe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007179-18,0,0,0 2007-007197-31,4,2009-09-18,2009-09-18,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Orion Corporation Orion Pharma,"EFFECTS OF ORAL LEVOSIMENDAN ON AMBULATORY ELECTROCARDIOGRAPHIC VARIABLES AND CEREBROVASCULAR REACTIVITY IN PATIENTS WITH RECENT STROKE OR TIA. A RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED, DOSE FIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007197-31,0,0,0 2007-007198-21,3,2012-07-06,2012-07-13,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients with Type 2 Diabetes Mellitus on Metformin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007198-21,0,0,0 2007-007198-21,3,2012-07-06,2012-07-13,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company - Indianapolis,"A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients with Type 2 Diabetes Mellitus on Metformin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007198-21,0,0,0 2007-007200-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO SUPERIORE DI SANITA',"A Phase II randomized, open label, immunogenicity and safety trial of the vaccine based on the recombinant biologically active HIV-1 Tat protein in anti-Tat negative HIV-1 infected HAART-treated adult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007200-16,0,0,0 2007-007241-12,1,2011-02-26,2011-02-26,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,Philogen S.p.A.,A PHASE I/II DOSE FINDING AND EFFICACY STUDY OF THE TUMOUR TARGETING HUMAN 131I-L19SIP MONOCLONAL ANTIBODY IN PATIENTS WITH CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007241-12,0,0,0 2007-007254-62,3,2009-06-29,2009-07-16,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Nycomed Danmark ApS,"Non-randomised, open, multi-center trial evaluating feasibility and safety of TachoSil application on a colorectal anastomosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007254-62,0,0,0 2007-007257-31,1,2010-08-16,2010-08-16,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,IPOLFG,"Open-label, single arm, phase II study for evaluation of complete response rate at surgery after NEOadjuvant treatment with SUnitinib and docetaxel in patients with newly diagnosed large operable or l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007257-31,0,0,0 2007-007258-75,14,2011-03-31,2015-12-10,12,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Amgen Inc,"A Randomized Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007258-75,0,0,0 2007-007258-75,14,2011-03-31,2015-12-10,12,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Amgen Inc.,"A Randomized Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007258-75,0,0,0 2007-007262-38,3,2020-12-30,2020-12-30,1,0,0,0,0,1,3,0,0,2,0,0,0,0,0,University Hospital Azienda Ospedaliero S.Luigi Gonzaga Orbassano,Efficacy of adjuvant mitotane in prolonging recurrence-free survival in patients with adrenocortical carcinoma at low-intermediate risk of recurrence,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007262-38,1,0,0 2007-007262-38,3,2020-12-30,2020-12-30,1,0,0,0,0,1,3,0,0,2,0,0,0,0,0,University of Birmingham,Efficacy of adjuvant mitotane in prolonging recurrence-free survival in patients with adrenocortical carcinoma at low-intermediate risk of recurrence,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007262-38,1,0,0 2007-007262-38,3,2020-12-30,2020-12-30,1,0,0,0,0,1,3,0,0,2,0,0,0,0,0,AZIENDA OSPEDALIERA S. LUIGI GONZAGA,Efficacy of adjuvant mitotane in prolonging recurrence-free survival in patients with adrenocortical carcinoma at low-intermediate risk of recurrence,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007262-38,1,0,0 2007-007265-20,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Innate Pharma,"A Phase II open label randomized parallel group non comparative trial to assess efficacy and safety of the association of IPH1101 and IL-2 alone and in combination with dacarbazine, in patients with m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007265-20,0,0,0 2007-007267-25,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,INSERM,Immunothérapie par vaccination anti-rougeoleuse chez l'adulte atteint de dermatite atopique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007267-25,0,0,0 2007-007273-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jeroen Bosch Hospital,"A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine combined with Protocolized Surgery in Resectable Gastric Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007273-23,0,0,0 2007-007275-16,1,2010-06-10,2010-06-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Department of Infetious Diseases, Odense University Hospital",Antibiotic treatment in patients hospitalized with an acute exacerbation in chronic obstructive pulmonary disease. Effect of one day of antibiotic treatment compared t0 6 days of antibiotic treatment ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007275-16,0,0,0 2007-007276-41,1,2010-04-23,2010-04-23,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie",Gene expression profiling in skeletal muscle of healthy subjects treated with ramipril,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007276-41,0,0,0 2007-007315-93,1,2008-07-11,2008-07-11,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Pierre Fabre dermatologie,Human skin blanching essay comparing a new shampoo containing betamethasone dipropionate at 0.025% and 0.050% to three reference marketed formulations in healthy subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007315-93,0,0,0 2007-007316-29,1,2010-05-03,2010-05-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Nitec Pharma AG,A New Modified-Release Tablet Formulation of Prednisone (Lodotra) in Patients with Nocturnal Asthma An open-label explorative study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007316-29,0,0,0 2007-007335-99,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Herlev Hospital, Dept. of Haematology (L121)",A Phase II Study of Erlotinib in Patients with Polycythaemia Vera and Essential Thrombocythemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007335-99,0,0,0 2007-007394-22,1,2013-10-03,2013-10-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London,The role of white and grey matter and meningeal inflammation in multiple sclerosis (MS) and clinically isolated syndromes (CIS) as quantified using [(11)C](R)-PK11195 positron emission tomography (PET...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007394-22,0,0,0 2007-007395-42,7,2009-08-17,2009-11-10,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biogen Idec Ltd,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess The Effects of Intravenous BG9928 on Body Weight in Subjects with Acute Decompensated Heart Failure and Renal Insufficien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007395-42,0,0,0 2007-007395-42,7,2009-08-17,2009-11-10,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BIOGEN IDEC LTD,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess The Effects of Intravenous BG9928 on Body Weight in Subjects with Acute Decompensated Heart Failure and Renal Insufficien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007395-42,0,0,0 2007-007397-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Qualissima,Evaluation de la tolérance et de l’acceptabilité de la Rasagiline dans le traitement de la maladie de Parkinson au stade précoce,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007397-28,0,0,0 2007-007434-20,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,"Deptartment of Hematology, Karolinska University Hospital",Phase I (II) study of the combination of lenalidomide and alemtuzumab in patients with chemotherapy refractory chronic lymphocytic leukemia (CLL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007434-20,0,0,0 2007-007455-14,1,2008-12-18,2008-12-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TEVA UK Ltd,"A single-centre, open-label, randomised, 2-way cross-over study to determine the effects on the short-term lower leg growth rate between Qvar® 100 μg bd delivered via a metered dose inhaler (MDI) (TEV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007455-14,0,0,0 2007-007456-34,5,2015-04-24,2015-04-24,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc,"A Phase 2, Multicenter, Randomized, Active-Controlled, Parallel-Group, Dose-Finding and Safety Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) in Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007456-34,0,0,0 2007-007456-34,5,2015-04-24,2015-04-24,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc (a Pfizer Company),"A Phase 2, Multicenter, Randomized, Active-Controlled, Parallel-Group, Dose-Finding and Safety Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) in Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007456-34,0,0,0 2007-007460-22,4,2010-03-31,2010-03-31,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Antigenics Inc.,International Survival Follow-up of Patients Enrolled In the Renal Cell Carcinoma Evaluation of Adjuvant Oncophage® Treatment in the Antigenics C-100-12 (Part I) Protocol (INSPIRE).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007460-22,1,0,0 2007-007474-33,1,2011-10-15,2011-10-15,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,"Dr. Harald Dobnig, Medizinische Univ. Klinik Graz, Abteilung für Endokrinologie und Nuklearmedizin","Prospective, placebo-controlled trial of vitamin D supplementation in patients with low-levels of 25-OH vitamin D to evaluate changes in markers of cardiovascular risk",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007474-33,0,0,0 2007-007476-42,3,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Clavis Pharma ASA,A phase II study of CP-4126 in patients with advanced pancreatic cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007476-42,0,0,0 2007-007479-18,1,2009-04-30,2009-04-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,Postoperative analgesia in major ortopedic surgery: continuos epidural perfusion with laevobupivacaine 0.125% vs continuos epidural perfusion with laevobupivacaine 0.125% + sufentanil 0.5 gamma/ml.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007479-18,0,0,0 2007-007481-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,INSERM,"Effet d'un antagoniste du récepteur de l'endothéline 1 (Sitaxentan, Thelin) sur le remodelage bronchique au cours de l'asthme sévère avec obstruction bronchique persistante.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007481-38,0,0,0 2007-007482-21,1,2010-01-31,2010-01-31,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Salford Royal NHS Foundation Trust,"Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007482-21,0,0,0 2007-007489-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University of Hamburg, MIN-Faculty, Department of Chemistry, Division of Cosmetetic Science","Effects of the oral monophasic contraceptive pill CG 5025 (Belara/0,03 mg etinyl estradiol and 2 mg chlormadinonacetate) on the cosmetic hairquality in women wishing to use hormonal contraception",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007489-39,0,0,0 2007-007491-42,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,"Istituto Fisiologia Clinica, CNR",GAMMAGLUTAMYLTRANSFERASE: CHARACTERIZATION OF ITS ISOFORMS IN DYSLIPIDEMICS UNDERGOING LIPID-LOWERING TREATMENT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007491-42,0,0,0 2007-007516-28,1,2010-03-19,2010-03-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Cytos Biotechnology AG,"A Double Blind, Randomized, Placebo Controlled, Parallel Group, Dose-Titration Phase II Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Efficacy of an Anti-Angiotensin II Vaccin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007516-28,0,0,0 2007-007518-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Centre Ljubljana,THE EFFECTS OF LEVOSIMENDAN ON ARTERIALL STIFFNESS IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007518-13,0,0,0 2007-007520-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Janssen-Cilag International N.V, Turnhoutseweg 30, 2340 Beerse, Belgium","A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Effect of RWJ-800088 on The Prevention of Chemotherapy-Induced Anemia and The Prevention of Chemotherapy-Induced Thrombocy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007520-17,0,0,0 2007-007535-23,1,2014-04-22,2014-04-22,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,St George's University of London,A phase IV study to evaluate the primary and booster immune responses of UK preterm infants receiving licensed DTaP/Hib/IPV and meningococcal C conjugate vaccine and incorporating a randomisation stud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007535-23,0,0,0 2007-007536-25,1,2010-08-07,2010-08-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim b.v.,"Randomized, Open-label study of Dabigatran Etexilate, a Novel, oral, Direct Thrombin-inhibitor in clinical development, in Elective Percutaneous Coronary Intervention. (D-Fine)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007536-25,0,0,0 2007-007538-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,CYRENAIC,"A Multi-center, Inpatient and ambulatory, Phase 2, Double-blind, Randomised, Placebo-controlled Proof of Concept Study of CYR-101 in Patients with DSM-IV Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007538-21,0,0,0 2007-007539-14,8,2009-05-19,2009-05-19,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Double-Blind, Placebo-Controlled, Phase IIb Dose-Ranging Study (with Open-label Etanercept Treatment Group) to Investigate Efficacy, Safety and Pharmacokinetics of AZD5672 Administered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007539-14,0,0,0 2007-007539-14,8,2009-05-19,2009-05-19,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Randomised, Double-Blind, Placebo-Controlled, Phase IIb Dose-Ranging Study (with Open-label Etanercept Treatment Group) to Investigate Efficacy, Safety and Pharmacokinetics of AZD5672 Administered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007539-14,0,0,0 2007-007540-10,9,2009-11-18,2011-03-14,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 24-week international, randomized, parallel-group, double-blind, placebo-controlled Phase III study with a 24-week extension period to evaluate the efficacy and safety of dapagliflozin therapy when ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007540-10,0,0,0 2007-007545-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Sahlgrenska Universitetssjukhuset,Nytt protokoll för ABO-inkompatibel levertransplantation med Mabthera® och immunadsorption: en pilotstudie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007545-13,0,0,0 2007-007546-36,1,2013-11-18,2013-11-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Institute for Clinical and Experimental Medicine,Sodium Bicarbonate for Prevention of Contrast-Induced Nephropathy in Diabetic Patients with Renal Insufficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007546-36,0,0,0 2007-007550-66,1,2014-03-12,2014-03-12,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,OSPEDALE POLICLINICO S. MATTEO,Lipidic emulsions influence on immune response of pre-term VLBW newborns treated with total parenteral nutrition,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007550-66,0,0,0 2007-007552-33,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,CHU d'Amiens,Effets du méthylphénidate dans le Trouble Déficitaire d’Attention avec Hyperactivité : Etude longitudinale en imagerie par résonance magnétique chez l’enfant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007552-33,0,0,0 2007-007553-31,1,2013-07-30,2013-07-30,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,University Medical Center Hamburg-Eppendorf,Phase I/II Clinical Study of SU11248 (Sutent) combined with Standard Chemotherapy with Cytosine Arabinoside and Daunorubicin in Patients with FLT3 mutated AML over 60 years of age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007553-31,0,0,0 2007-007555-14,2,2008-12-31,2009-03-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Cephalon, Inc.","An 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Dep...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007555-14,0,0,0 2007-007580-24,1,2009-10-15,2009-10-15,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Emotional Brain,"A double blind, randomized, 3-arm placebo controlled study to investigate the subjective and physiological efficacy and safety of Lybrido and Lybridos in the domestic setting in healthy female subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007580-24,0,0,0 2007-007583-20,1,,,0,0,0,0,1,3,4,0,0,0,0,0,0,0,0,Marja-Liisa Korhonen,Yleisanestesian-sevofluraani-induktion aiheuttamat EEG-muutokset alle 2-vuotiailla lapsilla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007583-20,0,0,0 2007-007587-21,4,2018-01-01,2018-01-01,4,1,0,0,0,0,3,2,0,1,0,0,1,0,0,"GCLLSG - Dept. of Internal Medicine I, University Hospital Cologne","Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007587-21,0,0,0 2007-007587-21,4,2018-01-01,2018-01-01,4,1,0,0,0,0,3,2,0,1,0,0,1,0,0,"University of Cologne, Sponsor-Quality Management","Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007587-21,0,0,0 2007-007587-21,4,2018-01-01,2018-01-01,4,1,0,0,0,0,3,2,0,1,0,0,1,0,0,University of Cologne,"Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007587-21,0,0,0 2007-007588-26,1,2008-08-26,2008-08-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 12-WEEK ADMINISTRATION OF PF-00734200 TO SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007588-26,0,0,0 2007-007591-42,1,2013-07-18,2013-07-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cardiff University,A Phase II single-arm trial to evaluate cisplatin and gemcitabine chemotherapy in combination with sunitinib for first-line treatment of patients with advancd transitional carcinoma of the urothelium.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007591-42,0,0,0 2007-007593-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE RICERCA TRAPIANTO DI MIDOLLO OSSEO,Thiotepa dose finding study for allogeneic SCT in adult patients with high risk haematological malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007593-31,0,0,0 2007-007595-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Cardiac Reserch Unit,Chest pain or other pain raising suspicion of an acute coronary syndrome. An evaluation of benzodiazipines and prehospital care.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007595-42,0,0,0 2007-007596-16,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"CCIT Center for Cancer ImmunTerapi, Herlev Hospital, Hæmatologisk afd 54P4",Evaluering af p53-pulset dendritiske celler i kombination med aromatase inhibitor som behandling til brystkræft-patienter med recidiv / progression efter adjuverende eller 1. linje endokrin behandling...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007596-16,0,0,0 2007-007603-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Grenoble,Opothérapie par hydrocortisone après injection unique d'etomidate chez le patient de réanimation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007603-32,0,0,0 2007-007604-15,1,2010-05-04,2010-05-04,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,A Pilot Study of the Effect of Glucocorticoid Receptor Antagonism in Patients with Sub-Clinical Cushing's Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007604-15,0,0,0 2007-007610-10,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,UMC Utrecht,Prevention of constipation during treatment with opioids: magnesiumoxide versus macrogol/elektrolytes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007610-10,0,0,0 2007-007612-29,2,2019-03-18,2019-03-18,1,1,0,1,0,0,1,0,0,2,0,0,0,0,0,University College London,Immunotherapy with CD19ζ chimeric antigen receptor gene-modified EBV-specific CTLs after stem cell transplant in children with high-risk acute lymphoblastic leukaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007612-29,1,0,0 2007-007615-82,1,2016-03-15,2016-03-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cardiff University,"A Phase I/II single-arm trial to evaluate the combination of cisplatin and gemcitabine with the mTOR inhibitor temsirolimus for treatment of advanced cancers, including first-line treatment of patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007615-82,0,0,0 2007-007616-28,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,"A MULTICENTER, OPEN LABEL STUDY OF ORAL REVLIMID AND PREDNISONE (RP) FOLLOWED BY ORAL REVLIMID MELPHALAN AND PREDNISONE (MPR) IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007616-28,0,0,0 2007-007620-17,1,2009-02-19,2009-02-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pantarhei Bioscience BV,"A double-blind, placebo-controlled, randomized, N=1 study to determine the effect of concomitant treatment with dehydroepiandrosterone (50 mg) on sexual functioning in 6 women who experience a decreas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007620-17,0,0,0 2007-007622-22,5,2018-09-19,2018-09-19,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II Open-Label, Randomised, Comparative, International Multicentre Study to Compare the Safety and Efficacy of Two Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007622-22,0,0,0 2007-007623-40,3,2010-09-24,2010-09-24,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase II, Double-blind, Placebo-Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 in Combination with Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients with Non-small Cell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007623-40,1,0,0 2007-007625-43,1,,,0,0,0,0,1,0,4,0,0,3,0,0,0,0,0,Birmingham Children’s Hospital NHS Foundation Trust,A randomised controlled trial of two analgesic techniques for the control of pain and post-operative nausea and vomiting in paediatric day-case tonsillectomy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007625-43,0,0,0 2007-007629-32,6,2010-05-07,2010-05-10,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,"Taiho Pharma USA, Inc.","A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, INTERNATIONAL, MULTICENTER STUDY OF ORAL TAC 101 AS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA WHO RECEIVED SORAF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007629-32,0,0,0 2007-007629-32,6,2010-05-07,2010-05-10,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,"TAIHO PHARMA USA, INC","A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, INTERNATIONAL, MULTICENTER STUDY OF ORAL TAC 101 AS SECOND LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA WHO RECEIVED SORAF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007629-32,0,0,0 2007-007630-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospital Clinico San Carlos,TRATAMIENTO DE LAS LESIONES DEL MANGUITO ROTADOR MEDIANTE EL TRASPLANTE AUTÓLOGO DE CÉLULAS MADRE MESENQUIMALES DE ASPIRADOS DE MÉDULA ÓSEA. TREATMENT OF ROTATOR CUFF TEARS USING AUTOLOGOUS BONE MARR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007630-19,0,0,0 2007-007633-39,3,2009-12-16,2009-12-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Morphotek, Inc.","A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study Of The Efficacy Of MORAb-009 In Combination With Gemcitabine In Patients With Advanced Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007633-39,0,0,0 2007-007637-39,1,2014-01-09,2014-01-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Charité - Campus Mitte,Effects of NSAIDs on RAdiographic Damage in AS (ENRADAS) – a prospective randomised controlled trial - Amendment 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007637-39,0,0,0 2007-007638-21,1,2012-07-24,2012-07-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Aberdeen,Is cessation of clopidogrel therapy associated with rebound of platelet activity in stable vascular disease patients?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007638-21,0,0,0 2007-007638-21,1,2012-07-24,2012-07-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Grampian Health Board,Is cessation of clopidogrel therapy associated with rebound of platelet activity in stable vascular disease patients?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007638-21,0,0,0 2007-007639-17,1,2014-11-04,2014-11-04,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University College London,"A multicentre, randomised, phase III trial of platinum-based chemotherapy versus non-platinum chemotherapy, after ERCC1 stratification, in patients with advanced/metastatic non-small cell lung cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007639-17,0,0,0 2007-007640-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,PD Dr. med. K-H. Konz,Tissue pharmacokinetics of daptomycin measured by in vivo microdialysis in patients with diabetic foot infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007640-10,0,0,0 2007-007643-27,3,2008-08-28,2008-08-28,3,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Vernalis (R & D) Limited,"A Phase IIa, Multi-Centre Study to Evaluate the Safety and Efficacy of V10153 in Acute Ischaemic Stroke",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007643-27,0,0,0 2007-007645-12,1,2008-10-15,2008-10-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of York,The Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007645-12,0,0,0 2007-007648-85,11,2012-10-15,2016-12-09,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Human Genome Sciences, Inc.","A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007648-85,0,0,0 2007-007648-85,11,2012-10-15,2016-12-09,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,HUMAN GENOME SCIENCES INC,"A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007648-85,0,0,0 2007-007648-85,11,2012-10-15,2016-12-09,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)","A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007648-85,0,0,0 2007-007648-85,11,2012-10-15,2016-12-09,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Human Genome Sciences, Inc","A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) who Completed the Phase 3 Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007648-85,0,0,0 2007-007652-34,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"Herlev Hospital, Dept. of haematology (L121)","Kan mineraltilskud med bismuth mindske toksiciteten af kemoterapi og strålebehandling? En klinisk prospektiv, dobbeltblind randomiseret undersøgelse af patienter med hæmatologiske sygdomme som modtage...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007652-34,0,0,0 2007-007653-31,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Fundación Investigación Biomédica Hospital La Paz,"Estudio aleatorizado, doble ciego, controlado con placebo, de 6 meses de duración para evaluar la eficacia de eritropoyetina recombinante humana en pacientes con ataxia de Friedreich. Randomized, doub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007653-31,0,0,0 2007-007657-31,1,2010-04-30,2010-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité-University Berlin,Efficacy and safety of Miltefosine in antihistamine resistant chronic urticaria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007657-31,0,0,0 2007-007659-15,3,2010-03-03,2010-03-03,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Lumavita AG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Investigate the Efficacy, Safety, and Tolerability of 3 doses of SPK 0602 (pentamycin) Vaginal Tablets vs Placebo (vehicl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007659-15,0,0,0 2007-007661-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Lil Valentin, Region Skåne, Malmö University Hospital, Dpt Obstetrics and Gynecology",Which is the optimal treatment for miscarriage with a gestational sac in the uterus and which factors can predict if the treatment will be successful?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007661-20,0,0,0 2007-007662-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Facteurs de variabilité des doses de méthadone nécessaires pour atteindre l'équilibre du traitement de substitution de la dépendance aux opiacés : Approches phénotypique et génotypique des biomarqueur...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007662-37,0,0,0 2007-007663-25,1,2010-06-10,2010-06-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Merz Pharmaceuticals GmbH,"A Long-Term Open Label Extension Study to assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007663-25,0,0,0 2007-007666-38,7,2011-03-15,2011-03-15,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BRACCO IMAGING,A phase III study to compare SonoVue guided prostate biopsy with systematic biopsy in the detection of prostate malignant lesions in patients with suspected prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007666-38,0,0,0 2007-007666-38,7,2011-03-15,2011-03-15,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bracco Imaging SPA,A phase III study to compare SonoVue guided prostate biopsy with systematic biopsy in the detection of prostate malignant lesions in patients with suspected prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007666-38,0,0,0 2007-007668-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Ghent,Evaluatie van Arthroscopisch Voorste Kruisband Herstel via Ziekenhuisopname of via Dagopname: een Gerandomiseerde Prospectieve Klinische Studie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007668-15,0,0,0 2007-007669-20,4,2008-12-18,2009-01-12,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stable S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007669-20,0,0,0 2007-007670-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Pierre Fabre Médicament,"""Evaluation of erectyle disfonction in patients suffering from testosterone deficiency, before and after tretament by Testopatch""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007670-38,0,0,0 2007-007672-41,12,2013-10-02,2013-10-02,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Maintenance of Response After Open-Label Treatment with Atomoxetine Hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007672-41,0,0,0 2007-007672-41,12,2013-10-02,2013-10-02,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limitated,"Maintenance of Response After Open-Label Treatment with Atomoxetine Hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007672-41,0,0,0 2007-007672-41,12,2013-10-02,2013-10-02,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"Maintenance of Response After Open-Label Treatment with Atomoxetine Hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007672-41,0,0,0 2007-007673-23,1,2012-03-31,2012-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cambridge University Hospitals Foundation Trust,Evaluation of carotid atheroma with contrast enhanced magnetic resonance imaging,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007673-23,0,0,0 2007-007676-42,3,2010-09-15,2010-09-15,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Acute STEMI treated with primary angioplasty and intravenous enoxaparin or UFH to lower ischemic and bleeding events at short- and long-term follow-up.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007676-42,0,0,0 2007-007678-43,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation de l'efficacité et de la tolérance de deux stratégies de prescription du Méthotrexate dans le traitement du psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007678-43,0,0,0 2007-007694-23,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Forschergruppe Diabetes e. V.,Transfusion of Autologous Umbilical Cord Blood to Reverse Hyperglycemia in Children with Type 1 Diabetes - A Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007694-23,0,0,0 2007-007696-16,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,TOGA Thoracic Oncology Group Antwerp,Low molecular weight heparin in advanced non small cell lung cancer (NSCLC): a randomized open label phase III study evaluating the effect of enoxaparin (Clexane) on survival and symptom control in pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007696-16,0,0,0 2007-007697-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Instituto de Investigación del Hospital de la Santa Creu i Sant Pau,"EVALUACION DE LOS EFECTOS DE LA PREGABALINA EN EL TEMBLOR ESENCIAL: ENSAYO CLÍNICO CRUZADO, RANDOMIZADO A DOBLE CIEGO Y CONTROLADO CON PLACEBO",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007697-39,0,0,0 2007-007698-22,1,2015-11-23,2015-11-23,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,GELARC,A PHASE IB/II STUDY OF ESCALATING DOSES OF REVLIMID IN ASSOCIATION WITH R-CHOP (R2-CHOP) IN THE TREATMENT OF B-CELL LYMPHOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007698-22,0,0,0 2007-007699-40,1,2012-01-12,2012-01-12,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Cardio3 BioSciences,"C-Cure - Safety, feasibility and efficacy of guided bone marrow-derived cardiopoietic mesenchymal stem cells for the treatment of heart failure secondary to ischemic cardiomyopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007699-40,0,0,0 2007-007702-30,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,COSMO TECHNOLOGIES LTD,"Feasibility and safety of Infliximab enema treatment in patients with active left-sided ulcerative colitis. An open-label, non comparative, pilot study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007702-30,0,0,0 2007-007723-40,3,2009-09-02,2009-09-02,2,1,0,0,0,0,3,0,2,1,0,0,1,0,1,MERCK SHARP DOHME ITALIA S.P.A.,"A Multicenter, Randomized, Double-Blind, Active- and Placebo-Controlled, Period Crossover Study to Evaluate the Safety and Efficacy of MK-0974 in the Treatment of Acute Migraine in Patients With Stabl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007723-40,0,0,0 2007-007723-40,3,2009-09-02,2009-09-02,2,1,0,0,0,0,3,0,2,1,0,0,1,0,1,Merck Sharp & Dohme GmbH,"A Multicenter, Randomized, Double-Blind, Active- and Placebo-Controlled, Period Crossover Study to Evaluate the Safety and Efficacy of MK-0974 in the Treatment of Acute Migraine in Patients With Stabl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007723-40,0,0,0 2007-007723-40,3,2009-09-02,2009-09-02,2,1,0,0,0,0,3,0,2,1,0,0,1,0,1,Merck Sharp & Dohme (Europe) Inc.,"A Multicenter, Randomized, Double-Blind, Active- and Placebo-Controlled, Period Crossover Study to Evaluate the Safety and Efficacy of MK-0974 in the Treatment of Acute Migraine in Patients With Stabl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007723-40,0,0,0 2007-007725-46,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Asubio Pharmaceuticals, Inc.","A Phase 2b, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007725-46,0,0,0 2007-007727-41,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Diatos S.A.,"An open-label, one arm, multi-centre Phase II trial evaluating the efficacy and safety of DTS-201 as a second-line chemotherapy in patients with hormone refractory prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007727-41,0,0,0 2007-007727-41,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,DIATOS.SA.,"An open-label, one arm, multi-centre Phase II trial evaluating the efficacy and safety of DTS-201 as a second-line chemotherapy in patients with hormone refractory prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007727-41,0,0,0 2007-007728-16,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Comparaison de deux stratégies de sevrage de la corticothérapie chez les myasthéniques traités par Prednisone-Azathioprine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007728-16,0,0,0 2007-007734-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University Medical Center Groningen, UMCG-Department of Gynaecologic Oncology","p53 synthetic long peptides vaccine with cyclophosphamide for ovarian cancer, a phase II trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007734-19,0,0,0 2007-007740-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALI GALLIERA,Randomized placebo-controlled phase III trial of low-dose tamoxifen women whit IntraEphitelial Neoplasia(IEN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007740-10,0,0,0 2007-007742-35,1,2009-05-14,2009-05-14,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,MerLion Pharmaceuticals GmbH,"A double-blind, double-dummy, prospective, randomized multiple-site study of oral Finafloxacin 300 mg b.i.d. versus oral Ciprofloxacin 250 mg b.i.d. in patients with lower uncomplicated UTI (uUTI) wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007742-35,0,0,0 2007-007744-98,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,INTERFERON alpha2 (IFN alpha2) as anti-angiogenic agent for the treatment of neovascular age-related macular degeneration: a pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007744-98,0,0,0 2007-007748-85,1,2010-10-01,2010-10-01,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,DermaTools Biotech GmbH,"A Prospective, Randomized, Open Label, Add-On, Parallel Arm, In-Patient Comparison Phase II Study to Evaluate the Safety and Efficacy of Diperoxochloric Acid (DermaPro®) in Wounds with Impaired Healin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007748-85,0,0,0 2007-007749-11,1,2008-12-19,2008-12-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MerLion Pharmaceuticals GmbH,"An open-label, randomized, multicenter, two-arm efficacy and safety study of 14 days treatment with Finafloxacin 400 mg b.i.d. plus Amoxicillin 1000 mg b.i.d. versus Finafloxacin 400 mg b.i.d. plus Es...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007749-11,0,0,0 2007-007752-34,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Santhera Pharmaceuticals (Switzerland) Ltd,"A Phase II open-label extension study to obtain long-term safety, tolerability and efficacy data of Idebenone in the treatment of Duchenne Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007752-34,0,0,0 2007-007756-34,8,2017-11-08,2018-01-08,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Celgene Corporation,"A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF SINGLE-AGENT LENALIDOMIDE (REVLIMID) IN PATIENTS WITH MANTLE CELL NHL WHO HAVE RELAPSED OR PROGRESSED AFTER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007756-34,0,0,0 2007-007758-70,6,2016-03-29,2016-03-29,6,1,1,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"An open-label multi-center, multiple dose study to determine the optimum starting dose of intravenous MIRCERA for maintenance treatment of anemia in pediatric patients with chronic kidney disease on h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007758-70,0,0,0 2007-007758-70,6,2016-03-29,2016-03-29,6,1,1,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"An open-label multi-center, multiple dose study to determine the optimum starting dose of intravenous MIRCERA for maintenance treatment of anemia in pediatric patients with chronic kidney disease on h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007758-70,0,0,0 2007-007759-15,1,2009-06-05,2009-06-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,PEPTIMMUNE Inc,"The Effect of the Dose of PI-2301 on Safety, Tolerability, and Pharmacokinetics in Subjects with the Secondary Progressive Form of Multiple Sclerosis A double-blind, placebo-controlled, randomized, mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007759-15,0,0,0 2007-007764-14,1,2008-12-10,2008-12-10,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,XTL Development Inc.,An Open-label 52-Week Safety Study of Bicifadine SR in Adult Outpatients with Chronic Neuropathic Pain Associated with Diabetic Peripheral Neuropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007764-14,0,0,0 2007-007775-17,1,2011-08-21,2011-08-21,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Air Liquide,"A single centre, exploratory, phase II, cross-over, randomised trial, evaluating the effect of spontaneously breathing Helium/Oxygen (65%/35%), to either spontaneously breating Nitrogen/Oxygen (65%/35...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007775-17,0,0,0 2007-007781-38,5,2010-01-22,2010-01-22,2,1,0,0,0,2,3,0,1,1,0,0,1,0,2,Novartis Vaccines and Diagnostics GmbH & Co KG,"A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007781-38,0,0,0 2007-007781-38,5,2010-01-22,2010-01-22,2,1,0,0,0,2,3,0,1,1,0,0,1,0,2,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007781-38,0,0,0 2007-007781-38,5,2010-01-22,2010-01-22,2,1,0,0,0,2,3,0,1,1,0,0,1,0,2,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007781-38,0,0,0 2007-007781-38,5,2010-01-22,2010-01-22,2,1,0,0,0,2,3,0,1,1,0,0,1,0,2,Novartis Vaccines and Diagnostics S.r.l,"A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007781-38,0,0,0 2007-007782-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Mª ANGELES CALDERON,Estimulación ovárica para ciclos de fecundación in Vitro con dosis mínimas de gonadotropinas y antagonistas de la GnRH frente a tratamiento habitual con altas dosis de gonadotropinas y agonistas de la...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007782-21,0,0,0 2007-007783-14,2,2010-01-08,2010-01-08,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, randomized, open, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix™) co-administrated with GlaxoSmithKl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007783-14,0,0,0 2007-007787-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA,Use of subconjunctival Bevacizumab (Avastin) in treatment of corneal neovascularization non curable with standard protocols (topical and sistemic steroids).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007787-25,0,0,0 2007-007789-39,1,2009-12-03,2009-12-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GALDERMA R&D SNC,Efficacy and safety comparison of CD4802 0.1% ointment versus vehicle in the treatment of target lesions in adults with atopic dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007789-39,0,0,0 2007-007792-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Universität Heidelberg, Medizinische Fakultät Mannheim",Vasovist®-enhanced MRI in Preoperative Lymph Node Staging of Lung Cancer: Comparison with 18F FDG PET/CT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007792-17,0,0,0 2007-007793-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,Efficacy of long acting steroids intramuscular therapy in nephrotic syndrome: pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007793-29,0,0,0 2007-007794-23,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,0,Justus-Liebig-University,"Prospektive, doppelblinde, randomisierte, Plazebo-kontrollierte Cross-over Studie zur Wirkung von intravenösen Immunglobulinen bei komplex-regionalem Schmerzsyndrom Typ I (M. Sudeck)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007794-23,0,0,0 2007-007799-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Evaluation of intralesional administration of rituximab for treatment of orbital lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007799-40,0,0,0 2007-007800-13,7,2016-02-11,2016-02-11,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"InterMune, Inc.",An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007800-13,0,0,0 2007-007800-13,7,2016-02-11,2016-02-11,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,INTERMUNE,An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007800-13,0,0,0 2007-007801-63,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,International Study using Clopidogrel and Aspirin for the treatment of Polycythemia Vera.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007801-63,0,0,0 2007-007804-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Coombe Women's Hospital,A comparison of intravenous oxycodone with morphine in day-case laparoscopic gynaecological surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007804-14,0,0,0 2007-007805-58,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Med. Klinik II, Grosshadern, Klinikum der Universität München",The effect of sitagliptin on postprandial lipoprotein metabolism in patients with diabetes mellitus type 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007805-58,0,0,0 2007-007813-35,1,2010-12-30,2010-12-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital of North Tees and Hartlepool,Randomised Controlled Trial of the Use of Topical Application of Tranexamic Acid in Primary Cemented Total Knee Replacement (TRANX-K).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007813-35,0,0,0 2007-007815-99,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Leeds Teaching Hospitals NHS Trust,The optimal dose of subcutaneous naloxone for the treatment of intrathecal opioid- induced pruritus following elective caesarean section delivery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007815-99,0,0,0 2007-007831-24,1,2009-08-28,2009-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Karo Bio AB,"A Phase II, Placebo-Controlled, Double-Blind, Randomised, 10-Week, Parallel-group Study to Assess the Efficacy of Different Doses of KB2115 as add on to Ezetimibe treatment in Patients with Primary Hy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007831-24,0,0,0 2007-007834-21,2,2011-05-01,2011-05-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Odense University Hospital,"FLOX + Erbitux, 1a linjens-behandling till patienter med metastaserende kolorektalcancer och wild type K-RAS tumor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007834-21,0,0,0 2007-007835-16,5,2010-02-24,2010-02-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients with Subjective Tinnitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007835-16,0,0,0 2007-007837-38,2,2009-01-08,2009-01-08,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, open, randomized, controlled, primary vaccination study to demonstrate non-inferiority of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroup ACWY conjugate vaccine compared to lic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007837-38,0,0,0 2007-007839-33,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)","Adherence to a one pill, once-a-day antiretroviral regimen",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007839-33,0,0,0 2007-007842-36,3,2018-10-16,2018-12-31,3,1,0,0,0,0,0,0,0,1,0,0,1,0,0,"Copenhagen University Hospital, Rigshospitalet",Hyperbaric oxygen treatment of mandibular osteoradionecrosis. A randomized clinical study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007842-36,0,0,0 2007-007842-36,3,2018-10-16,2018-12-31,3,1,0,0,0,0,0,0,0,1,0,0,1,0,0,Lone Elisabeth Forner,Hyperbaric oxygen treatment of mandibular osteoradionecrosis. A randomized clinical study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007842-36,0,0,0 2007-007847-28,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,0,Universitätsklinikum Erlangen,"A multicenter, randomized, two-armed, open-label Phase III study to evaluate the adjuvant vaccination with tumor RNA-loaded autologous Dendritic Cells versus observation of patients with resected mono...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007847-28,0,0,0 2007-007849-13,3,2011-03-24,2013-10-23,2,0,0,0,0,1,3,0,0,2,0,0,0,0,0,Japanese Gynecologic Oncology Group (JGOG),Randomised Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007849-13,1,0,0 2007-007849-13,3,2011-03-24,2013-10-23,2,0,0,0,0,1,3,0,0,2,0,0,0,0,0,Greater Glasgow Health Board(GGHB)/ University of Glasgow,Randomised Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007849-13,1,0,0 2007-007849-13,3,2011-03-24,2013-10-23,2,0,0,0,0,1,3,0,0,2,0,0,0,0,0,Kitasato institute clinical trial coordinating center,Randomised Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007849-13,1,0,0 2007-007853-30,1,2011-03-22,2011-03-22,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,NeuroNova AB,"A randomized, double-blind, placebo controlled, safety and tolerability study of intracerebroventricular administration of sNN0031 to patients with idiopathic Parkinson's disease (PD) of moderate seve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007853-30,0,0,0 2007-007859-14,2,2009-07-07,2009-07-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Array BioPharma Inc.,"A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF ARRY-438162, ADMINISTERED ORALLY DAILY IN PATIENTS WITH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007859-14,0,0,0 2007-007861-19,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,CSL Behring GmbH,"An open-label, randomized, multicenter Phase IIIb study to assess the efficacy, safety and tolerance of BERIPLEX® P/N compared with plasma for rapid reversal of coagulopathy induced by coumarin deriva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007861-19,0,0,0 2007-007862-39,3,2013-02-22,2013-02-22,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,CSL BEHRING GmbH,"A open-label, randomized, multicenter Phase IIIb study to assess the efficacy, safety and tolerance of BERIPLEX® P/N compared with plasma for rapid reversal of coagulopathy induced by coumarin derivat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007862-39,0,0,0 2007-007862-39,3,2013-02-22,2013-02-22,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,CSL Behring GmbH,"A open-label, randomized, multicenter Phase IIIb study to assess the efficacy, safety and tolerance of BERIPLEX® P/N compared with plasma for rapid reversal of coagulopathy induced by coumarin derivat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007862-39,0,0,0 2007-007863-26,4,2013-10-21,2013-10-21,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,A multicentre randomized phase II study to assess the safety and resectability in patients with primarily unresectable liver metastases secondary to colorectal cancer receiving 1st line treatment eith...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007863-26,0,0,0 2007-007864-63,1,2012-06-11,2012-06-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Leipzig,"Prospective, randomized and controlled clinical trial comparing i.v. bolus application of Abciximab to i.c.application of Abciximab during primary PCU in patients with acute ST-elevation myocardial in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007864-63,0,0,0 2007-007865-19,1,2008-11-19,2008-11-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A 4-week, randomized, double blind, double dummy, placebo controlled, parallel group study comparing the influence of BI 1356 (5 mg) and sitagliptin (100 mg) administered orally once daily on various ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007865-19,0,0,0 2007-007867-25,9,2013-02-12,2013-03-12,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Meyers Squibb International Corporation,A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism. Revised Protocol Number 02 incorporating Amendment(s) 04 and Ad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007867-25,0,0,0 2007-007867-25,9,2013-02-12,2013-03-12,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism. Revised Protocol Number 02 incorporating Amendment(s) 04 and Ad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007867-25,0,0,0 2007-007867-25,9,2013-02-12,2013-03-12,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism. Revised Protocol Number 02 incorporating Amendment(s) 04 and Ad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007867-25,0,0,0 2007-007869-21,6,2009-06-25,2009-06-25,6,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Stallergenes S.A.,"A multi-national, randomised, double-blind, placebo-controlled, Phase II study to assess the efficacy and safety of three doses of sublingual immunotherapy administered as recombinant Bet v 1 tablets ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007869-21,0,0,0 2007-007872-40,5,2016-03-30,2016-03-30,3,1,0,0,0,1,2,0,0,2,1,0,0,0,1,"Premacure AB, A member of the Shire Group of Companies","Determination of the rhIGF-I/rhIGFBP-3 Dose; Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal SErum IGF-I Levels within Physiological Levels in Premature Infants,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007872-40,1,0,0 2007-007873-22,1,2011-03-01,2011-03-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,Uso del Nabilone nel trattamento del dolore cronico in pazienti con MOH non rispondenti ad altri trattamenti,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007873-22,0,0,0 2007-007876-41,1,2009-06-18,2009-06-18,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, randomized, open study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ Hepatitis B vaccine (Engerix-B™) when co-administered with GlaxoSmithKline Biologicals’ H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007876-41,0,0,0 2007-007877-22,1,2011-12-13,2011-12-13,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Royal Brompton & Harefield NHS Trust,A prospective blinded randomised placebo controlled trial investigating whether oxycodone modified release reduces parenteral opioid use following intermediate thoracic surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007877-22,0,0,0 2007-007882-19,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,"A pilot, randomized trial to evaluate the lipid profile after antiretroviral regimens including nevirapine or atazanavir boosted with ritonavir in HIV-positive patients naive for antiretrovirals",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007882-19,0,0,0 2007-007884-26,1,2013-08-20,2013-08-20,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"HUS, HYKS, Diabetesklinikka","Pioglitatsonin käyttö potilailla, joilla krooninen rasvamaksasairaus ja tuore tyypin 2 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007884-26,0,0,0 2007-007885-39,6,2018-06-07,2018-06-07,5,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Puma Biotechnology, Inc",A Phase 1/2 Study of HKI-272 in Combination with Vinorelbine in Subjects with Solid Tumors and Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007885-39,0,0,0 2007-007885-39,6,2018-06-07,2018-06-07,5,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,A Phase 1/2 Study of HKI-272 in Combination with Vinorelbine in Subjects with Solid Tumors and Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007885-39,0,0,0 2007-007888-24,1,2010-04-09,2010-04-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals France,"Open-label Study to Evaluate the EULAR-RAID Score, Rheumatoid Arthritis Impact of Disease Score, in Rheumatoid Arthritis Patients Eligible to Etanercept and Who Will Receive Etanercept.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007888-24,0,0,0 2007-007890-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,Prevention of portal vein Thrombosis with anticoagulant therapy in patients with hepatic cirrhosis (Child B and C),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007890-22,0,0,0 2007-007907-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,"Conversione della terapia immunosoppressiva a Sirolimus (Rapamune) monoterapia per complicanze da inibitori della calcineurina, in pazienti sottoposti a trapianto ortotopico di fegato.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007907-34,0,0,0 2007-007927-42,1,2008-12-31,2008-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,Nessuna correzione vs nuova formula per l’impostazione delle caratteristiche antropometriche per Target Controlled Infusion (TCI) di remifentanil in pazienti obesi.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007927-42,0,0,0 2007-007928-18,1,2010-08-31,2010-08-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,REPHA GmbH,"Evaluation of efficacy and safety of the herbal drug Myrrhinil-Intest vs. mesalazine in maintaining clinical remission of ulcerative colitis - a 12-month, multicenter, randomized, prospective, double-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007928-18,0,0,0 2007-007931-25,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,"Prospective evaluation on the role exerted by the association of ethinylestradiol (0,03 mg) plus clormadinone acetate (2 mg) or ethinylestradiol (0,02 mg) plus desogestrel (0,15 mg) on insulin sensiti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007931-25,0,0,0 2007-007932-25,1,2012-02-28,2012-02-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Lipha Santé,A phase IIIb randomized open-label study to compare between IVF/ICSI outcomes two regimen of Cetrotide 0.25 mg used from Day 1 or from Day 7 of the menstrual cycle (Day 0 or Day 6 of stimulation) in ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007932-25,0,0,0 2007-007934-21,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,Intracellular concentration of Antiretrovirals)INCA STADY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007934-21,0,0,0 2007-007935-14,1,2011-04-19,2011-04-19,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,RIFART,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007935-14,0,0,0 2007-007939-29,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,"A PHASE II,MULTI-CENTER, OPEN LABEL STUDY OF ORAL LBH589 PLUS MELPHALAN, PREDNISONE AND THALIDOMIDE (LB-MPT)IN ADVANCED, REFRACTORY MULTIPLE MYELOMA PATIENTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007939-29,0,0,0 2007-007940-92,5,2009-10-14,2009-10-14,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Transave, Inc.","A PLACEBO CONTROLLED, RANDOMIZED, PARALLEL COHORT, SAFETY AND TOLERABILITY STUDY OF TWO DOSE LEVELS OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN PATIENTS WITH BRONCHIECTASIS COMPLICATED BY CHRON...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007940-92,0,0,0 2007-007941-10,4,2008-11-10,2008-12-10,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche et développement,"A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of two doses of Satavaptan (SR121463B) Versus Placebo in Patients with Dilutional Hyponatremia due t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007941-10,0,0,0 2007-007942-36,16,2010-08-12,2010-08-12,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A Multinational, Multicenter, Randomized, Double Blind Study comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007942-36,0,0,0 2007-007942-36,16,2010-08-12,2010-08-12,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & developpement,"A Multinational, Multicenter, Randomized, Double Blind Study comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007942-36,0,0,0 2007-007943-29,20,2010-11-16,2010-11-18,15,1,0,0,0,0,3,0,2,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007943-29,0,0,0 2007-007943-29,20,2010-11-16,2010-11-18,15,1,0,0,0,0,3,0,2,1,0,0,1,0,1,sanofi-aventis recherche & de'veloppement,"A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007943-29,0,0,0 2007-007944-80,10,2009-06-30,2009-06-30,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A Multinational, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007944-80,0,0,0 2007-007944-80,10,2009-06-30,2009-06-30,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & de'veloppement,"A Multinational, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Elective T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007944-80,0,0,0 2007-007945-11,9,2009-10-28,2009-10-28,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A Multinational, Multicenter, Randomized, Double-Blind study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fractu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007945-11,0,0,0 2007-007945-11,9,2009-10-28,2009-10-28,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & de'veloppement,"A Multinational, Multicenter, Randomized, Double-Blind study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Hip Fractu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007945-11,0,0,0 2007-007946-37,5,2009-05-04,2009-05-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A Multinational, Multicenter, Randomized, Double-blind Study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the prevention of Venous Thromboembolism in Patients Undergoing Elective K...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007946-37,0,0,0 2007-007947-28,1,2010-01-22,2010-01-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A Multinational, Multicenter, Randomized, Double-Blind study Comparing the Efficacy and Safety of AVE5026 with placebo for the Extended Prevention of Venous Thromboembolism in Patients Having Undergon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007947-28,0,0,0 2007-007949-13,1,2016-05-31,2016-05-31,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA,Multicenter phase III randomized study of cisplatin and etoposide with or without bevacizumab as first-line treatment in extensive stage (ED) small cell lung cancer (SCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007949-13,0,0,0 2007-007950-77,2,2015-08-15,2015-12-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Edinburgh and NHS Lothian Health Board,Does progesterone prophylaxis to prevent preterm labour improve outcome? - a randomised double blind placebo controlled trial (OPPTIMUM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007950-77,0,0,0 2007-007951-14,3,2009-05-04,2009-05-04,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV Organon,"A multi-center, randomized, parallel-group, comparative, active-controlled, safety-assessor blinded trial in adult subjects comparing the efficacy and safety of sugammadex administered at 1-2 PTC with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007951-14,0,0,0 2007-007953-30,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Fundación Investigación y Desarrollo en el Área Cardiovascular,Levosimendan como agente inmunomodulador en la insuficiencia cardiaca aguda. Estudio Piloto Levosimendan as an immunomodulatory agent in acute heart failure. Pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007953-30,0,0,0 2007-007956-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Cytori Therapeutics Inc,A clinical evaluation of adipose derived Regenerative cells in the treatment of patients with brEast deformities post Segmental breast resection (lumpectomy) with Or without Radiation therapy. A phase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007956-33,0,0,0 2007-007958-54,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Department of Clinical Pharmacology, Medical University of Vienna",Target site pharmacokinetics of linezolid after single and multiple doses in diabetes patients with soft tissue infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007958-54,0,0,0 2007-007968-19,1,2014-02-17,2014-02-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CENTRE LEON BERARD,"Evaluation comparative, en double aveugle, de l'efficacité d'infiltrations locales per et post opératoires de ropivacaïne dans la prise en charge de la douleur après chirurgie hépatique chez l'adulte",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007968-19,0,0,0 2007-007970-47,1,2012-07-01,2012-07-01,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Leipzig,Central nervous effects of exendin-4 on hunger and satiety in obesity and diabetes mellitus type 2: an fMRI study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007970-47,0,0,0 2007-007971-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,C.H.U. de RENNES,"Evaluation des effets de la 9 alpha fluorohydrocortisone sur la réponse pressive à la noradrénaline, la perfusion gastrique, le débit huméral et la rigidité artérielle dans le choc septique.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007971-18,0,0,0 2007-007974-45,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AMC,Phase II trial of the addition of gemcitabine to 131I-MIBG therapy in paediatric patients with relapsed or progressive neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007974-45,0,0,0 2007-007977-21,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Leeds Teaching Hospitals Trust,ASSESSMENT OF THE ROLE OF THE PROBIOTIC VSL3® IN THE TREATMENT OF POUCHITIS AFTER ILEAL POUCH-ANAL ANASTOMOSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-007977-21,0,0,0 2008-000007-28,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,0,Universitaetsklinikum Wuerzburg,"Lenalidomide (Revlimid®), Adriamycin and Dexamethasone (RAD) as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance – A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000007-28,0,0,0 2008-000023-26,1,2013-10-01,2013-10-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community Acquired Pneumonia and Invasive P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000023-26,0,0,0 2008-000025-19,3,2009-01-02,2009-01-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","""ESTUDIO DE PREGABALINA, ALEATORIZADO, DOBLE CIEGO, DE 6 SEMANAS DE DURACIÓN EN SUJETOS CON SÍNDROME DE PIERNAS INQUIETAS"" RANDOMIZED, DOUBLE-BLIND, 6-WEEK STUDY OF PREGABALIN IN SUBJECTS WITH RESTLE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000025-19,0,0,0 2008-000025-19,3,2009-01-02,2009-01-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.","""ESTUDIO DE PREGABALINA, ALEATORIZADO, DOBLE CIEGO, DE 6 SEMANAS DE DURACIÓN EN SUJETOS CON SÍNDROME DE PIERNAS INQUIETAS"" RANDOMIZED, DOUBLE-BLIND, 6-WEEK STUDY OF PREGABALIN IN SUBJECTS WITH RESTLE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000025-19,0,0,0 2008-000036-41,1,2019-02-27,2019-02-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dermal Laboratories Ltd,An antimicrobial cream for the treatment of impetigo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000036-41,0,0,0 2008-000040-13,1,2012-08-01,2012-08-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Medizinische Universität Innsbruck, Univ.-Klinik für Neurologie","Effects of recombinant human Erythropoietin on circulating and intramuscular endothelial progenitor cells, neovascularisation and oxidative metabolism of skeletal muscle in Friedreich’s Ataxia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000040-13,0,0,0 2008-000041-60,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,LWL Universitätsklinik für Psychiatrie Bochum,Quetiapine in the treatment of psychotic depression. A pilot study (QTP-Dep-Bo),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000041-60,0,0,0 2008-000042-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Univ. Klinik f. Anästhesie, Intensivmedizin und Schmerztherapie",Anticoagulation with argatroban and prostacyclin compared to unfractionated heparin and prostacyclin during continous venovenous haemodialfiltation: a crossover trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000042-31,0,0,0 2008-000044-14,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,IIL INTERGRUPPO ITALIANO LINFOMI ONLUS,SALVAGE TREATMENT WITH LENALIDOMIDE AND DEXAMETHASONE (LEN-DEX) IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000044-14,0,0,0 2008-000045-59,4,2010-06-16,2010-06-16,4,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Ferring SAS,"Multicentre, controlled, randomized, investigator-blinded, comparative study of oral Mesalazine 4g per day Once daily versus 4g per day in Two divided doses in patients with active Ulcerative coliti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000045-59,0,0,0 2008-000045-59,4,2010-06-16,2010-06-16,4,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals Ltd.,"Multicentre, controlled, randomized, investigator-blinded, comparative study of oral Mesalazine 4g per day Once daily versus 4g per day in Two divided doses in patients with active Ulcerative coliti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000045-59,0,0,0 2008-000046-31,1,,,0,0,0,0,1,1,4,0,0,0,0,0,0,0,0,The Sahlgrenska Center for Pediatric Ophtalmology Research,"A randomised Intervention, Single-Center Study to Determine the Role of Fatty Acids in Serum in preventing Retinopathy of Prematurity",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000046-31,0,0,0 2008-000051-10,1,2011-05-23,2011-05-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,11C metomidate PET scanning for Conn's syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000051-10,0,0,0 2008-000053-35,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Erasmus MC,A phase II study to assess engraftment and engraftment kinetics after double cord blood transplantation with a reduced-intensity conditioning regimen in patients eligible for allogeneic stem cell tran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000053-35,0,0,0 2008-000061-37,1,2009-02-25,2009-02-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,EURAND SPA,"A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of two doses of Zentase™ (EUR-1008) in Chronic Pancreatitis (CP) patients with Exocrine Pancreatic I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000061-37,0,0,0 2008-000062-24,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,AstraZeneca AB,"Ensayo fase I/II, abierto, multicéntrico, de AZD2281 oral en combinación con Cisplatino, para valorar la seguridad y tolerabilidad en pacientes con tumores sólidos avanzados, y para valorar la eficaci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000062-24,0,0,0 2008-000066-22,1,2013-06-12,2013-06-12,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Christie Hospital NHS Foundation Trust,A Phase 2 study of Sorafenib (BAY 43-9006) in patients with advanced salivary Adenoid Cystic Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000066-22,0,0,0 2008-000069-41,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Regulation of colloid osmotic pressure during cardiopulmonary bypass in infants: prospective randomised trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000069-41,0,0,0 2008-000071-25,7,2011-06-22,2011-10-20,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,JERINI AG,"""Estudio multicéntrico en abierto para evaluar la seguridad, la tolerabilidad local, la comodidad posológica y la eficacia de una formulación autoadministrada por vía subcutánea de icatibant en el tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000071-25,0,0,0 2008-000071-25,7,2011-06-22,2011-10-20,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Jerini AG,"""Estudio multicéntrico en abierto para evaluar la seguridad, la tolerabilidad local, la comodidad posológica y la eficacia de una formulación autoadministrada por vía subcutánea de icatibant en el tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000071-25,0,0,0 2008-000072-25,2,2014-05-05,2014-05-05,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Instituto Grifols S.A.,"A Prospective, Single-blind, Randomized, Phase II/III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis during Peripheral Vascular Surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000072-25,0,0,0 2008-000073-37,1,2010-02-17,2010-02-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Oxford Radcliffe Hospitals NHS Trust,Assessment of the effects of pressors on graft blood flow after free tissue transfer surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000073-37,0,0,0 2008-000077-38,10,2013-04-15,2013-04-15,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa- 2a plus bevacizumab for the first-line treatment of patients with metastatic clear cel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000077-38,0,0,0 2008-000077-38,10,2013-04-15,2013-04-15,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A,"A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa- 2a plus bevacizumab for the first-line treatment of patients with metastatic clear cel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000077-38,0,0,0 2008-000077-38,10,2013-04-15,2013-04-15,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa- 2a plus bevacizumab for the first-line treatment of patients with metastatic clear cel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000077-38,0,0,0 2008-000078-19,1,2013-04-18,2013-04-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospitals Bristol NHS Foundation Trust,"Safety profiLe, Efficacy and Equivalence in Paediatric intensive care Sedation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000078-19,0,0,0 2008-000079-31,8,2009-05-25,2009-07-06,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A randomised, double-blind, placebo- and active comparator-controlled, five parallel groups study to investigate the efficacy and safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) administered orally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000079-31,0,0,0 2008-000079-31,8,2009-05-25,2009-07-06,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A randomised, double-blind, placebo- and active comparator-controlled, five parallel groups study to investigate the efficacy and safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) administered orally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000079-31,0,0,0 2008-000079-31,8,2009-05-25,2009-07-06,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, placebo- and active comparator-controlled, five parallel groups study to investigate the efficacy and safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) administered orally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000079-31,0,0,0 2008-000079-31,8,2009-05-25,2009-07-06,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A randomised, double-blind, placebo- and active comparator-controlled, five parallel groups study to investigate the efficacy and safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) administered orally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000079-31,0,0,0 2008-000079-31,8,2009-05-25,2009-07-06,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A randomised, double-blind, placebo- and active comparator-controlled, five parallel groups study to investigate the efficacy and safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) administered orally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000079-31,0,0,0 2008-000079-31,8,2009-05-25,2009-07-06,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A randomised, double-blind, placebo- and active comparator-controlled, five parallel groups study to investigate the efficacy and safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) administered orally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000079-31,0,0,0 2008-000079-31,8,2009-05-25,2009-07-06,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A randomised, double-blind, placebo- and active comparator-controlled, five parallel groups study to investigate the efficacy and safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) administered orally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000079-31,0,0,0 2008-000080-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,A Phase II study of Chetoconazolo in patients with Metastatic Hormone-Refractory Prostate Cancer. Pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000080-42,0,0,0 2008-000083-17,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,0,Nederlands Vaccin Instituut,"Nasopharyngeal pneumococcal colonization data in infants at the age of 12, 18 and 24 months",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000083-17,0,0,0 2008-000084-41,4,2010-10-22,2010-10-22,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Shire Human Genetic Therapies Inc,"A Multi-center, Open-Label Extension Study of HGT-1111 (Recombinant Human Arylsulfatase A or rhASA) Treatment in Patients with Late Infantile Metachromatic Leukodystrophy (MLD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000084-41,0,0,0 2008-000086-38,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,"A PHASE 2, SINGLE ARM, MULTI-CENTER STUDY ON THE BENEFIT/COST/SAFETY PROFILE OF LOW-DOSE RITUXIMAB FOR REFRACTORY MIXED CRYOGLOBULINEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000086-38,0,0,0 2008-000087-16,5,2012-03-26,2013-12-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A randomized Discontinuation Study of Brivanib alaninate (BMS-582664) versus Placebo in Subjects with Advanced Tumors. Revised protocol 02 incorporating Amendment 02 & 03 & Administrative Letter 01 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000087-16,0,0,0 2008-000087-16,5,2012-03-26,2013-12-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,A randomized Discontinuation Study of Brivanib alaninate (BMS-582664) versus Placebo in Subjects with Advanced Tumors. Revised protocol 02 incorporating Amendment 02 & 03 & Administrative Letter 01 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000087-16,0,0,0 2008-000088-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de TOULOUSE,"Pharmacocinétique de l’association pipéracilline-tazobactam chez les patients septiques, en insuffisance rénale oligo-anurique, traités par hémodiafiltration veino-veineuse continue",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000088-40,0,0,0 2008-000091-24,6,2009-06-26,2010-06-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Phase 2, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000091-24,0,0,0 2008-000094-37,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Glostrup University Hospital,Effect of PTH(1-34)-treatment on fracture healing in vivo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000094-37,0,0,0 2008-000095-25,5,2009-12-10,2009-12-10,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Medivation, Inc.","CONNECTION: A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients with Mild-to-Moderate Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000095-25,0,0,0 2008-000101-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE POLICLINICO S. MATTEO,"Multicenter, prospective, randomized clinical trial to assess two different doses of anti-human-T-lymphocyte immune serum preparation derived from rabbit in GVHD profilaxis in pediatric population wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000101-11,0,0,0 2008-000102-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE POLICLINICO S. MATTEO,Immunosoppressive protocol based on everolimus and calcineurin inhibitor low doses in lung transplant recipients with moderate-severe kidney disease after standard immnuotherapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000102-36,0,0,0 2008-000103-29,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,A single arm phase 2 study on the efficacy of Pegfilgrastim (Neulasta) after DCEP chemotherapy: a feasibility study in multiple myeloma patients eligible for autologous transplant.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000103-29,0,0,0 2008-000105-11,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Roche Pharma AG,Effectiveness after 4 and 24 weeks and safety of tocilizumab in patients with active RA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000105-11,0,0,0 2008-000106-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Klinik für Dermatologie und Allergologie der RUB, St. Josef Hospital",Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000106-37,0,0,0 2008-000107-28,4,2018-06-12,2019-04-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare Pharmaceuticals Inc,A Phase II uncontrolled study of BAY 73-4506 (DAST) in previously untreated patients with metastatic or unresectable renal cell cancer (RCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000107-28,0,0,0 2008-000107-28,4,2018-06-12,2019-04-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,A Phase II uncontrolled study of BAY 73-4506 (DAST) in previously untreated patients with metastatic or unresectable renal cell cancer (RCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000107-28,0,0,0 2008-000107-28,4,2018-06-12,2019-04-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,A Phase II uncontrolled study of BAY 73-4506 (DAST) in previously untreated patients with metastatic or unresectable renal cell cancer (RCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000107-28,0,0,0 2008-000107-28,4,2018-06-12,2019-04-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare Pharmaceutical Inc,A Phase II uncontrolled study of BAY 73-4506 (DAST) in previously untreated patients with metastatic or unresectable renal cell cancer (RCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000107-28,0,0,0 2008-000121-19,1,2010-05-14,2010-05-14,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Heidelberg,A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Resected Pancreatic Adenocarcinoma Treated with Interferon Alpha-2b and 5-FU Alone or in Combination with Either Ext...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000121-19,0,0,0 2008-000123-26,1,2015-08-10,2015-08-10,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre Val d'Aurelle Paul Lamarque,"Etude de phase II, randomisée, testant l'association Nexavar (sorafenib) gemcitabine et oxaliplatine (GEMOX) dans le traitement des carcinomes hépatocellulaires non accessibles à un traitement chirurg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000123-26,0,0,0 2008-000126-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Caen,"Analgésie post-opératoire pour prothèse totale de genou par cathéter péri-nerveux fémoral: Etude comparative de la levobupivacaine 0,125% versus ropivacaine 0, 2%. Protocole LPTG",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000126-39,0,0,0 2008-000132-40,2,2012-07-17,2015-03-17,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Auris Medical AG,"Efficacy of AM 111 in Patients with Acute Sensorineural Hearing Loss: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalation Phase II Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000132-40,0,0,0 2008-000133-22,11,2008-08-27,2008-08-30,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pierre Fabre Médicament,"EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000133-22,0,0,0 2008-000133-22,11,2008-08-27,2008-08-30,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000133-22,0,0,0 2008-000140-13,1,2011-09-22,2011-09-22,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,Faron Pharmaceuticals Limited,"A Phase I/II Open–Label study to Assess the Safety, Tolerability and Preliminary Efficacy of FP-1201 (Recombinant Human Interferon Beta) in the treatment of patients with Acute Lung Injury and Acute R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000140-13,0,0,0 2008-000144-14,4,2010-05-17,2010-05-17,3,1,0,0,0,0,3,0,0,1,1,0,1,0,2,UCB Inc,"An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (≥ 16 to 75...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000144-14,0,0,0 2008-000145-58,6,2010-03-09,2010-05-17,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,UCB Pharma S.A.,"An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (#8805; 16 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000145-58,0,0,0 2008-000149-72,6,2010-04-14,2010-04-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Merck & Co.,"A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000149-72,0,0,0 2008-000149-72,6,2010-04-14,2010-04-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Merck Sharp & Dohme GmbH,"A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000149-72,0,0,0 2008-000149-72,6,2010-04-14,2010-04-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Merck & Co., Inc.","A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000149-72,0,0,0 2008-000149-72,6,2010-04-14,2010-04-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Laboratoires Merck Sharp & Dohme - Chibret,"A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000149-72,0,0,0 2008-000149-72,6,2010-04-14,2010-04-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Merck & Co, Inc.","A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000149-72,0,0,0 2008-000149-72,6,2010-04-14,2010-04-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Merck Sharp & Dohme de España, S.A.","A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naïve Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000149-72,0,0,0 2008-000150-12,8,2008-07-21,2012-09-10,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Tolerability of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Patients With Chronic Hepa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000150-12,0,0,0 2008-000150-12,8,2008-07-21,2012-09-10,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Tolerability of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Patients With Chronic Hepa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000150-12,0,0,0 2008-000150-12,8,2008-07-21,2012-09-10,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Tolerability of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Patients With Chronic Hepa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000150-12,0,0,0 2008-000150-12,8,2008-07-21,2012-09-10,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Europe) Inc.,"A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Tolerability of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Patients With Chronic Hepa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000150-12,0,0,0 2008-000150-12,8,2008-07-21,2012-09-10,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Tolerability of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Patients With Chronic Hepa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000150-12,0,0,0 2008-000150-12,8,2008-07-21,2012-09-10,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.","A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety and Tolerability of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Patients With Chronic Hepa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000150-12,0,0,0 2008-000164-17,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,0,University of Jena,Nasale Inhalation von Tobramycin mit dem Pari Sinus-Vernebler bei Patienten mit Mukoviszidose und Pseudomonasnachweis im Nasen-Nasennebenhöhlenbereich. Nasal inhalation of tobramycin by the Pari Sin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000164-17,0,0,0 2008-000168-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Allerderm,"Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Gold Sodium Thiosulfate, Hydrocortisone-17-butyrate, Methyldibromoglutaronitrile, Bacitracin, Parthenolide, Disperse Blue 106, and Bronopol",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000168-18,0,0,0 2008-000170-20,3,2009-09-30,2009-09-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"A Randomized, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Clinical Efficacy and Safety of BMS-582949 Given Orally to Subjects with Rheumatoid Arthritis Having an Inadequate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000170-20,0,0,0 2008-000191-24,1,,,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,Eli Lilly Nederland,An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents with Attentioin-Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000191-24,0,0,0 2008-000193-21,2,2009-02-02,2009-02-02,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Elpen Pharmaceutical Co. Inc.,"A multicenter, randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000193-21,0,0,0 2008-000196-23,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ALK-ABELLO',Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild-to-moderate atopic eczema (AE) and sensitization to HDM (SPT positive).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000196-23,0,0,0 2008-000197-20,1,2009-08-20,2009-08-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Revotar Biopharmaceuticals AG,"Multi-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate the safety and efficacy of Bimosiamose 5% Cream for the treatment of patients with chronic plaque type psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000197-20,0,0,0 2008-000198-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation de l'activité protectrice du mangafodipir contre la neuropathie induite par l'oxaliplatine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000198-39,0,0,0 2008-000201-11,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Instituto Valenciano de Infertilidad,"Ensayo piloto randomizado, doble-ciego, en grupos paralelos, placebo-controlado, monocéntrico evaluando la tolerabilidad de la quinagolida 200mcg/día en un régimen de aumento de dosis en donantes de o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000201-11,0,0,0 2008-000202-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Bordeaux,Etude clinique randomisée du propranolol versus placebo dans le traitement des hémangiomes capillaires infantiles.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000202-36,0,0,0 2008-000207-28,1,2009-05-12,2009-05-12,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Innocoll Technologies,"A Randomized, Controlled, Open-Label Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge (Collatamp® G) Compared to Levofloxacin in Diabetic Patients with a Mild Infec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000207-28,0,0,0 2008-000209-12,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,CHU de Bordeaux,Effet comparé sur le débit sanguin et le métabolisme cérébral de deux types de prise en charge des accès d'hypertension intracrânienne après traumatisme crânien sévère : mannitol vs sérum salé hyperto...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000209-12,0,0,0 2008-000213-30,1,2009-06-02,2009-06-02,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,immatics biotechnologies GmbH,Extension study to evaluate long-term-safety of IMA901 plus GM-CSF in advanced renal cell carcinoma patients who achieved a decrease in tumor load or stabilization of their disease after participation...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000213-30,0,0,0 2008-000214-71,7,2008-02-18,2009-02-18,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratorios Menarini S.A. (Menarini Group),"DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFECT OF A 4-WEEK TREATMENT WITH ORAL DOSES OF MEN15596 IN IRRITABLE BOWEL SYNDROME",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000214-71,0,0,0 2008-000214-71,7,2008-02-18,2009-02-18,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratorios Menarini S.A. - Menarini Group,"DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFECT OF A 4-WEEK TREATMENT WITH ORAL DOSES OF MEN15596 IN IRRITABLE BOWEL SYNDROME",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000214-71,0,0,0 2008-000217-30,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SENESE,Treatment with Oxaliplatin and Irinotecan in colorectal metastatic tumors with high expression of thymidilate synthase (TS).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000217-30,0,0,0 2008-000219-14,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,North Bristol NHS Trust,Efficacy of 8.4% sodium bicarbonate in adult patients with closed head injuries and intracranial hypertension.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000219-14,0,0,0 2008-000224-27,1,2011-07-31,2011-07-31,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Newcastle upon Tyne NHS Foundation Trust,Systemic sclerosis associated interstitial lung disease: A longitudinal observational study assessing optimum treatment regimens.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000224-27,0,0,0 2008-000225-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPO GETNE,"ENSAYO CLÍNICO DE FASE II, MULTICÉNTRICO, ABIERTO, NO CONTROLADO PARA EVALUAR LA EFICACIA DE LA COMBINACIÓN DE SORAFENIB Y BEVACIZUMAB EN EL TRATAMIENTO DE PACIENTES CON TUMOR NEUROENDOCRINO AVANZADO ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000225-19,0,0,0 2008-000227-25,1,2009-06-01,2009-06-01,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,Dept. Child & Adolescent Psychiatrie,"A single-center, single-blind, randomized, oral dose cross-over study in prepuberal boys with ADHD to investigate efficacy and bioequivalence of 20 mg Ritalin LA® compared to 20 mg Medikinet® retard a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000227-25,0,0,0 2008-000228-13,16,2009-01-27,2009-03-16,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & de'veloppement,"A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Primary Prevention of Venous Thromboembolism in Acutely Ill Medical Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000228-13,0,0,0 2008-000228-13,16,2009-01-27,2009-03-16,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,"A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Primary Prevention of Venous Thromboembolism in Acutely Ill Medical Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000228-13,0,0,0 2008-000230-53,1,2010-04-25,2010-04-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,The Medicines Company,The evaluation of patients with acute hypertension and intracerebral hemorrhage with intravenous clevidipine treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000230-53,0,0,0 2008-000239-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de NICE,Use of MEOPA by elderly with dementia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000239-17,0,0,0 2008-000243-33,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,ISTITUTO SUPERIORE DI SANITA',Alzheimer disease and antipsycotics: a long term multicenter randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000243-33,0,0,0 2008-000245-55,1,2011-11-24,2011-11-24,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,GYN Research GmbH,Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000245-55,0,0,0 2008-000247-34,1,2010-04-28,2010-04-28,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Charité – Universitätsmedizin Berlin,Prospektive randomisierte Phase II/III-Studie zur selektiven COX-2-Inhibition beim chronischen Subduralhämatom (Prospective randomized phase II/III study for the selective COX-2-inhibition in chronic ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000247-34,0,0,0 2008-000248-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Association pour la promotion de la réanimation médicale à Tours,Amikacine nébulisée à forte dose. Pharmacocinétique dans la pneumonie associée à la ventilation mécanique D’ARTAGNAN 3,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000248-15,0,0,0 2008-000252-28,1,2012-07-17,2012-07-17,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust,A Multi-Centre Prospective Controlled Trial Comparing Calcineurin Inhibitor Monotherapy With Sirolimus Monotherapy in Hepatitis C Infected Patients with Hepatic Fibrosis Following Liver Transplantatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000252-28,0,0,0 2008-000254-13,1,2010-08-06,2010-08-06,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Gwent Healthcare NHS Trust,A double blind randomised placebo controlled study assessing the effect of intra-operative local anaesthetic administration on postoperative pain in adolescent children undergoing oral surgery under g...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000254-13,0,0,0 2008-000256-26,1,2014-02-03,2014-02-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Queen Mary, University of London","An exploratory phase IIa study to evaluate the safety and immunological effects of intravenous interferonβ-1a (IFNβ-1a, Rebif®) therapy in the induction of tolerance to IFNβ in MS patients with neutra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000256-26,0,0,0 2008-000257-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,"Double blind, randomized, clinical trial to evaluate efficacy and safety of Phyllanthus amarus versus placebo in the treatment of patients with chronic hepatitis B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000257-36,0,0,0 2008-000264-17,1,2008-12-05,2008-12-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Aradigm Corporation,"A MULTI-CENTER, OPEN-LABEL, PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFECT ON SPUTUM PSEUDOMONAS AERUGINOSA DENSITY OF INHALED LIPOSOMAL CIPROFLOXACIN HYDROCHLORIDE IN ADULT S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000264-17,0,0,0 2008-000280-42,8,2017-08-24,2017-08-24,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered to Patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000280-42,0,0,0 2008-000280-42,8,2017-08-24,2017-08-24,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered to Patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000280-42,0,0,0 2008-000281-23,1,2013-03-31,2013-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Oxford,Melatonin in Acute Mania Investigation (MIAMI-UK),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000281-23,0,0,0 2008-000300-89,1,2010-06-01,2010-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust,The effects of sitagliptin (Januvia) on myocardial performance in patients with coronary artery disease and diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000300-89,0,0,0 2008-000301-11,5,2008-07-22,2008-07-22,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 12-week treatment, multi-center, randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 µg o.d.) in patients with chronic obstructiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000301-11,0,0,0 2008-000306-36,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Region Skåne,Nexavar in Relapsed Peripheral T-cell Non-Hodgkins Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000306-36,0,0,0 2008-000311-15,2,2009-07-20,2009-07-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Double-Blind, Placebo-Controlled, Randomised, Parallel Group Phase IIa Study to Evaluate the Histological Changes, Cellularity, Clinical Efficacy and Safety of AZD1981 in Patients with Moderate to S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000311-15,0,0,0 2008-000325-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Rééducation de l’héminégligence par adaptation prismatique. Intérêt de l’association d’un traitement par Méthilphénidate (RITALINE®). Etude des mécanismes de plasticité cérébrale impliqués.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000325-20,0,0,0 2008-000327-25,3,2009-02-03,2009-02-04,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc. 235 East 42nd Street NY10017,"""ESTUDIO DE FASE 2A ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS DE CE-224,535, UN ANTAGONISTA DEL RECEPTOR P2X7, EN EL TRATAMIENTO DE LOS SIGNOS Y SÍNTOMAS DE LA ARTRITIS R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000327-25,0,0,0 2008-000327-25,3,2009-02-03,2009-02-04,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER S.A.,"""ESTUDIO DE FASE 2A ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS DE CE-224,535, UN ANTAGONISTA DEL RECEPTOR P2X7, EN EL TRATAMIENTO DE LOS SIGNOS Y SÍNTOMAS DE LA ARTRITIS R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000327-25,0,0,0 2008-000328-16,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundacion Hospital Alcorcon,Efecto del tratamiento con dosis altas de Ribavirina frente a dosis estándar en pacientes infectados con el virus de la Hepatitis C Crónica genotipo 3 y carga viral alta sin respuesta en semana 4.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000328-16,0,0,0 2008-000330-50,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Organisation name was not entered,EFECTO DE SUPLEMENTACIÓN NUTRICIONAL ENRIQUECIDA CON ÁCIDOS GRASOS OMEGA-3 EN EL ESTRÉS OXIDATIVO Y METABOLISMO LIPÍDICO DE PACIENTES CON PROCESOS ONCOLÓGICOS DEL ÁREA OTORRINOLARINGOLÓGICA (ORL) SOM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000330-50,0,0,0 2008-000332-40,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,GRUPO ESPAÑOL DE TRATAMIENTO DE TUMORES DE CABEZA Y CUELLO (TTCC),ESTUDIO FASE II CON RADIOTERAPIA (RT) CONVENCIONAL + CETUXIMAB PARA EVALUAR LA SUPERVIVENCIA ESPECÍFICA LIBRE DE LARINGECTOMIA TOTAL EN PACIENTES AFECTOS DE UN CARCINOMA ESCAMOSO DE LARINGE LOCALMENTE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000332-40,0,0,0 2008-000333-22,1,2008-06-30,2008-06-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Dermal Laboratories Ltd,"A study to compare the effects on stratum corneum of two medical hand wash formulations, using non-invasive instrumental methods in human volunteers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000333-22,0,0,0 2008-000340-13,4,2008-02-27,2009-03-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 4 week double-blind, placebo-controlled, randomized, parallel group phase IIa study to assess the efficacy and safety of AZD1981 in patients with moderate to severe Chronic Obstructive Pulmonary Dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000340-13,0,0,0 2008-000341-64,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,"EVALUATION OF ACQUIRED OVEREXPRESSION OF HER2/neu ON CIRCULATING TUMOR CELLS IN PATIENTS WITH ADVANCED BREAST CANCER DURING CHEMOTHERAPY, AND ASSESSMENT OF ACTIVITY OF TRASTUZUMAB-BASED THERAPY: A PHA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000341-64,0,0,0 2008-000342-32,2,2009-08-14,2009-08-14,1,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Boehringer Ingelheim Pharmaceuticals, Inc.","An open-label, flexible dose, follow-up study to evaluate safety and efficacy of oral pramipexole (0.0625-0.5 mg/day) for 24 weeks in children and adolescents (age 6-17 years) diagnosed with Tourette ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000342-32,1,1,0 2008-000342-32,2,2009-08-14,2009-08-14,1,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An open-label, flexible dose, follow-up study to evaluate safety and efficacy of oral pramipexole (0.0625-0.5 mg/day) for 24 weeks in children and adolescents (age 6-17 years) diagnosed with Tourette ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000342-32,1,1,0 2008-000343-33,1,2009-08-07,2009-08-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase III double-blind, double-dummy, placebo-controlled, 8 week fixed dose trial with pramipexole IR (Mirapex®, Mirapexin®, Pexola®, Sifrol®) 0.125 and 0.5 mg/day administered orally to investigate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000343-33,0,0,0 2008-000345-55,12,2012-09-25,2012-09-25,8,1,0,0,2,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc 235 East 42nd Street New York, NY 10017","ESTUDIO DE FASE III, RANDOMIZADO Y ABIERTO DE CP-751.871 EN COMBINACIÓN CON PACLITAXEL Y CARBOPLATINO VERSUS PACLITAXEL Y CARBOPLATINO EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO. RANDOMIZED, OPE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000345-55,0,0,0 2008-000345-55,12,2012-09-25,2012-09-25,8,1,0,0,2,0,3,0,0,1,1,0,1,0,1,PFIZER,"ESTUDIO DE FASE III, RANDOMIZADO Y ABIERTO DE CP-751.871 EN COMBINACIÓN CON PACLITAXEL Y CARBOPLATINO VERSUS PACLITAXEL Y CARBOPLATINO EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO. RANDOMIZED, OPE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000345-55,0,0,0 2008-000345-55,12,2012-09-25,2012-09-25,8,1,0,0,2,0,3,0,0,1,1,0,1,0,1,Pfizer Inc.,"ESTUDIO DE FASE III, RANDOMIZADO Y ABIERTO DE CP-751.871 EN COMBINACIÓN CON PACLITAXEL Y CARBOPLATINO VERSUS PACLITAXEL Y CARBOPLATINO EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO. RANDOMIZED, OPE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000345-55,0,0,0 2008-000345-55,12,2012-09-25,2012-09-25,8,1,0,0,2,0,3,0,0,1,1,0,1,0,1,Pfizer España,"ESTUDIO DE FASE III, RANDOMIZADO Y ABIERTO DE CP-751.871 EN COMBINACIÓN CON PACLITAXEL Y CARBOPLATINO VERSUS PACLITAXEL Y CARBOPLATINO EN PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO. RANDOMIZED, OPE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000345-55,0,0,0 2008-000349-68,4,2010-12-17,2011-01-31,3,1,0,0,1,0,2,0,0,1,1,1,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York NY10017","A PHASE II PROSPECTIVE, RANDOMIZED, MULTI-CENTER, DIABETIC MACULAR EDEMA DOSE RANGING, COMPARATOR STUDY EVALUATING THE EFFICACY AND SAFETY OF PF-04523655 VERSUS LASER THERAPY (DEGAS) STUDIO PROS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000349-68,0,0,0 2008-000349-68,4,2010-12-17,2011-01-31,3,1,0,0,1,0,2,0,0,1,1,1,1,0,1,PFIZER,"A PHASE II PROSPECTIVE, RANDOMIZED, MULTI-CENTER, DIABETIC MACULAR EDEMA DOSE RANGING, COMPARATOR STUDY EVALUATING THE EFFICACY AND SAFETY OF PF-04523655 VERSUS LASER THERAPY (DEGAS) STUDIO PROS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000349-68,0,0,0 2008-000355-94,1,2008-11-21,2008-11-21,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Pfizer Inc.,"AN OPEN-LABEL, PARALLEL GROUP, SINGLE AND MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERATION OF MARAVIROC ADMINISTERED TO SUBJECTS WITH VARIOUS DEGREES OF RENAL IMPAIRED AND N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000355-94,0,0,0 2008-000357-35,3,2014-07-16,2014-08-13,2,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Novartis Pharma GmbH,"An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000357-35,0,0,0 2008-000357-35,3,2014-07-16,2014-08-13,2,1,0,0,0,2,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"An open-label, multi-center study to evaluate the efficacy of nilotinib in adult patients with gastrointestinal stromal tumors resistant to imatinib and sunitinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000357-35,0,0,0 2008-000358-11,5,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"""Estudio abierto, multicéntrico, con una sola rama de tratamiento, para evaluar la eficacia de nilotinib en pacientes adultos con tumores del estroma gastrointestinal metastásicos o irresecables en pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000358-11,0,0,0 2008-000358-11,5,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,NOVARTIS FARMA,"""Estudio abierto, multicéntrico, con una sola rama de tratamiento, para evaluar la eficacia de nilotinib en pacientes adultos con tumores del estroma gastrointestinal metastásicos o irresecables en pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000358-11,0,0,0 2008-000358-11,5,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,Novartis Pharma GmbH,"""Estudio abierto, multicéntrico, con una sola rama de tratamiento, para evaluar la eficacia de nilotinib en pacientes adultos con tumores del estroma gastrointestinal metastásicos o irresecables en pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000358-11,0,0,0 2008-000358-11,5,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A.,"""Estudio abierto, multicéntrico, con una sola rama de tratamiento, para evaluar la eficacia de nilotinib en pacientes adultos con tumores del estroma gastrointestinal metastásicos o irresecables en pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000358-11,0,0,0 2008-000360-16,1,,,0,1,0,0,1,0,3,0,0,1,1,1,0,1,0,"Medizinische Universität Innsbruck, Innere Medizin I",EFFECTS OF NIFEDIPINE ON IRON HOMEOSTASIS IN PATIENTS SUFFERING FROM IRONOVERLOAD DISEASES - Effekte von Nifedipin auf die Eisenhomeostase bei Patienten mit Eisenüberladungsstörungen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000360-16,0,0,0 2008-000364-16,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,FUNDACION PARA LA INVESTIGACION BIOMEDICA HOSPITAL UNIVERSITARIO NIÑO JESUS,Ensayo clínico abierto de fase I para evaluar la eficacia y seguridad del tratamiento con células mesenquimales autólogas infectadas con un nuevo adenovirus oncolítico en el tratamiento de pacientes p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000364-16,0,0,0 2008-000367-42,9,2015-04-16,2015-07-27,7,1,0,0,0,0,3,0,1,1,1,0,1,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals’ gE/AS01B vaccin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000367-42,0,0,0 2008-000367-42,9,2015-04-16,2015-07-27,7,1,0,0,0,0,3,0,1,1,1,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals’ gE/AS01B vaccin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000367-42,0,0,0 2008-000367-42,9,2015-04-16,2015-07-27,7,1,0,0,0,0,3,0,1,1,1,0,1,0,1,GlaxoSmithKline SA,"A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals’ gE/AS01B vaccin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000367-42,0,0,0 2008-000369-44,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first vacc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000369-44,0,0,0 2008-000370-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA PISANA,Evaluation of pharmacokinetic and pharmacodynamic interactions between escitalopram and drugs used for the treatment of bipolar disorders.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000370-20,0,0,0 2008-000380-42,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""",Radiotherapy and chemotherapy with cisplatin and temozolomide for patients affected by primary glioblastoma of new diagnosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000380-42,0,0,0 2008-000400-81,3,2011-05-23,2011-05-31,3,0,0,0,0,0,2,0,0,1,1,1,1,0,1,SOLVAY PHARMACEUTICALS B.V.,"A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000400-81,0,0,0 2008-000400-81,3,2011-05-23,2011-05-31,3,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Abbott Healthcare Products B.V.,"A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000400-81,0,0,0 2008-000400-81,3,2011-05-23,2011-05-31,3,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Solvay Pharmaceuticals BV,"A Multicenter, Randomized, Double Blind, Pramipexole Controlled Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients with Parkinson’s Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000400-81,0,0,0 2008-000401-11,4,2009-10-26,2009-10-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CHIESI Farmaceutici S.p.A,"A 12-week, multinational, randomised, double blind, double dummy, 4-arm parallel-group study comparing the efficacy and safety of CHF 1535 (fixed combination of beclomethasone dipropionate + formotero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000401-11,0,0,0 2008-000404-92,2,,,0,0,0,0,0,0,3,0,0,1,1,0,0,1,0,HOVON Foundation,Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000404-92,0,0,0 2008-000406-36,1,2008-10-30,2008-10-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double-blind, double-dummy, placebo-controlled, 3-way crossover study to evaluate potential next-day residual effects of a single evening dose of 3mg eszopiclone and 7.5mg zopiclone in h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000406-36,0,0,0 2008-000411-15,5,2010-07-02,2011-12-09,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A Phase Ib multicenter dose-determination study, with an adaptive, randomized, placebo-controlled, double-blind phase II, using various repeated IV doses of BHQ880 in combination with zoledronic acid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000411-15,0,0,0 2008-000411-15,5,2010-07-02,2011-12-09,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A","A Phase Ib multicenter dose-determination study, with an adaptive, randomized, placebo-controlled, double-blind phase II, using various repeated IV doses of BHQ880 in combination with zoledronic acid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000411-15,0,0,0 2008-000411-15,5,2010-07-02,2011-12-09,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A Phase Ib multicenter dose-determination study, with an adaptive, randomized, placebo-controlled, double-blind phase II, using various repeated IV doses of BHQ880 in combination with zoledronic acid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000411-15,0,0,0 2008-000412-33,4,2011-06-13,2011-07-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF TIGECYCLINE VERSUS IMIPENEM/CILASTATIN FOR THE TREATMENT OF SUBJECTS WITH HOSPITAL-ACQUIRED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000412-33,0,0,0 2008-000413-29,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,"GITMO GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO,CELLULE STAMINALI EMOPOIETICHE E TERAPIA CELLULARE - ONLUS",Randomized study with methylprednisolone 1mg/kg/day for treatment of grade I acute GvHD Studio randomizzato con methylprednisolone 1mg/kg/giorno per il trattamento della GvHD acuta di grado 1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000413-29,0,0,0 2008-000415-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Alba Therapeutics,"Ensayo de fase IIb, aleatorizado, doble ciego, controlado con placebo, para el tratamiento de la enfermedad celíaca activa con AT-1001",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000415-14,0,0,0 2008-000417-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,Randomized study for the treatment of primary Immune Thrombocytopenic Purpura (ITP) in newly diagnosed untreated adult patients. Comparison of standard dose prednisone versus high-dose Dexamethasone...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000417-30,0,0,0 2008-000422-39,9,2011-05-12,2011-05-12,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"MERCK & CO., INC.","""Ensayo clínico en fase II aleatorizado, doble ciego, controlado con placebo para estudiar la eficacia y la seguridad de bicalutamida con o sin deforolimus en varones con cáncer de próstata asintomáti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000422-39,0,0,0 2008-000422-39,9,2011-05-12,2011-05-12,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","""Ensayo clínico en fase II aleatorizado, doble ciego, controlado con placebo para estudiar la eficacia y la seguridad de bicalutamida con o sin deforolimus en varones con cáncer de próstata asintomáti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000422-39,0,0,0 2008-000422-39,9,2011-05-12,2011-05-12,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Europe) Inc.,"""Ensayo clínico en fase II aleatorizado, doble ciego, controlado con placebo para estudiar la eficacia y la seguridad de bicalutamida con o sin deforolimus en varones con cáncer de próstata asintomáti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000422-39,0,0,0 2008-000422-39,9,2011-05-12,2011-05-12,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Corp.,"""Ensayo clínico en fase II aleatorizado, doble ciego, controlado con placebo para estudiar la eficacia y la seguridad de bicalutamida con o sin deforolimus en varones con cáncer de próstata asintomáti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000422-39,0,0,0 2008-000422-39,9,2011-05-12,2011-05-12,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","""Ensayo clínico en fase II aleatorizado, doble ciego, controlado con placebo para estudiar la eficacia y la seguridad de bicalutamida con o sin deforolimus en varones con cáncer de próstata asintomáti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000422-39,0,0,0 2008-000422-39,9,2011-05-12,2011-05-12,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MSD,"""Ensayo clínico en fase II aleatorizado, doble ciego, controlado con placebo para estudiar la eficacia y la seguridad de bicalutamida con o sin deforolimus en varones con cáncer de próstata asintomáti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000422-39,0,0,0 2008-000422-39,9,2011-05-12,2011-05-12,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MSD Finland Oy,"""Ensayo clínico en fase II aleatorizado, doble ciego, controlado con placebo para estudiar la eficacia y la seguridad de bicalutamida con o sin deforolimus en varones con cáncer de próstata asintomáti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000422-39,0,0,0 2008-000422-39,9,2011-05-12,2011-05-12,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Shap @ Dohme,"""Ensayo clínico en fase II aleatorizado, doble ciego, controlado con placebo para estudiar la eficacia y la seguridad de bicalutamida con o sin deforolimus en varones con cáncer de próstata asintomáti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000422-39,0,0,0 2008-000424-86,1,,,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,Erasmus MC,Development and introduction of a pediatric liquid formulation of 6-mercaptopurine for treatment of leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000424-86,0,0,0 2008-000427-26,1,2011-03-02,2011-03-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Queen Victoria Hospital NHS Foundation Trust,A Comparison of Pre−Medication with Oral Paracetamol versus Intravenous Paracetamol Given at Time of Induction for Postoperative Analgesia Following Wisdom Tooth Extraction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000427-26,0,0,0 2008-000429-20,3,2009-12-18,2009-12-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Fresenius Kabi Deutschland GmbH,"A randomised, double-blind study evaluating the safety, tolerability, and amino acid plasma levels of Neoven compared to Vaminolact in infants after surgical interventions.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000429-20,0,0,0 2008-000433-21,1,2011-05-16,2011-05-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,High dose atorvastatin in acute ischemic stroke – Monocenter pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000433-21,0,0,0 2008-000434-47,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Immunomedics, Inc.",A Phase I/II Study of Immunotherapy with Subcutaneous Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lyphocytic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000434-47,0,0,0 2008-000441-58,1,2015-04-09,2015-04-09,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Belfast City Hospital,Investigation of the protective effects of keratinocyte growth factor (KGF) in a human lipopolysaccharide induced model of acute lung injury,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000441-58,0,0,0 2008-000444-13,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Finnish Defence Forces,Äkillisen akustisen vamman hoito ylipaineisella happihoidolla ja lääkkeillä: Prospektiivinen satunnaistettu ja kontrolloitu tutkimus vamman saaneilla varusmiehillä.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000444-13,0,0,0 2008-000451-97,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Janssen-Cilag International N.V.,"A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabeprazole in Pediatric Subjects with GERD 1 to 11 Years old, inclusive",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000451-97,0,0,0 2008-000452-27,2,2012-02-29,2012-02-29,2,1,1,0,0,0,1,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Pharmacokinetic, Pharmacodynamic and Safety Study of Single and Multiple Doses of Rabeprazole in Pediatric Subjects with GERD 1 to 11 Months old, Inclusive",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000452-27,0,0,0 2008-000453-35,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Max-Planck-Institute of Experimental Medicine,Open-label phase IIa pilot study exploring safety and potential efficacy of recombinant human erythropoietin in early mild Alzheimer Dementia and therapy-refractory Major Depression (“EPO-AD”),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000453-35,0,0,0 2008-000454-12,8,2010-07-30,2011-04-04,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schering Plough Research Institute, a Division of Schering Corporation",A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000454-12,0,0,0 2008-000459-88,1,2010-03-16,2010-03-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Univ.-Prof. Dr. Hans F. Merk, Dept. of Dermatology, University Hospital, RWTH Aachen University","Prospective, randomized study of the efficacy of photodynamic therapy in actinic keratosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000459-88,0,0,0 2008-000461-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska institutet,Effect of exercise or metformin on nocturnal blood pressure and other risk factors for cardiovascular heart disease among obese adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000461-28,0,0,0 2008-000465-37,4,2008-07-14,2008-07-14,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,MSD BV,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000465-37,0,0,0 2008-000465-37,4,2008-07-14,2008-07-14,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,Merck Sharp & Dohme GmbH,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000465-37,0,0,0 2008-000465-37,4,2008-07-14,2008-07-14,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme de España, S.A.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000465-37,0,0,0 2008-000465-37,4,2008-07-14,2008-07-14,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,Laboratoires Merck Sharp & Dohme - Chibret,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000465-37,0,0,0 2008-000470-21,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Groupe Francophone des Myélodysplasies,A Phase II study of Decitabine in patients with Chronic Myelomonocytic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000470-21,0,0,0 2008-000473-38,1,2011-12-28,2011-12-28,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Engelhard Arzneimittel GmbH & Co. KG,"Prospan® Hustenzäpfchen – Investigation on efficacy and tolerability in children: A double-blind, placebo controlled, randomised, multi-centre, comparative study with parallel groups for the symptomat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000473-38,0,0,0 2008-000474-20,1,2009-03-08,2009-03-08,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,Helperby Therapeutics Ltd,"Safety and Efficacy of HT61 (1%) gel applied once or three times for the eradication of nasal Staphylococcus aureus carriage in twelve subjects. A single- blinded, vehicle- controlled, single centre, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000474-20,0,0,0 2008-000475-25,1,2012-08-13,2012-08-13,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Cardiff University,"Randomised, controlled, double-blind, parallel group clinical trial evaluating the efficacies and safety of methyl-aminolevulinate photodynamic therapy and intense pulsed light, administered as place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000475-25,0,0,0 2008-000479-11,3,2009-02-06,2009-02-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A randomised, double-blind, parallel-group, active-controlled, flexible dose study exploring the efficacy and safety of 12 weeks treatment with Lu 31-130 in patients with schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000479-11,0,0,0 2008-000480-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,"Multicenter, randomised, double masked, controlled clinical trial on the safety and efficacy of Cyclosporine A eye drop treatment on patients with ocular cicatricial pemphigoid.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000480-41,0,0,0 2008-000486-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CONSORZIO ONCOTECH,A feasibility study of dose-dense FEC wiith G-CSF support followed by dose-dense Ixabepilone wiith G-CSF support as neoadjuvant chemotherapy in ER- negative breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000486-29,0,0,0 2008-000487-17,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,PIERRE FABRE PHARMA,"Clinical trial of the efficacy and tolerability of an immunostimulant drug, composed by ribosomal fractions, in socialized paediatric patients in order to prevent recurrent respiratory infections. A r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000487-17,0,0,0 2008-000488-41,1,2011-01-18,2011-01-18,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,"PULEVA BIOTECH, S.A.","Ensayo clínico, multicentrico, aleatorizado, doble ciego, de grupos paralelos, para evaluar la eficacia del extracto de valeriana Valexxol frente a placebo, en la mejora subjetiva de la calidad del su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000488-41,0,0,0 2008-000490-37,1,2011-03-21,2011-03-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,"Pharmacological treatment with memantine of oscilloscopy in patients suffering from multiple sclerosis: randomized,double blind placebo controlled study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000490-37,0,0,0 2008-000495-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,ViroLogik GmbH,"A Multicenter, Open-Label, Pilot Study to Explore the Safety and Efficacy of Intravenous Bortezomib in Patients with Hepatitis C",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000495-24,0,0,0 2008-000498-40,8,2016-06-10,2016-06-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000498-40,0,0,0 2008-000498-40,8,2016-06-10,2016-06-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000498-40,0,0,0 2008-000498-40,8,2016-06-10,2016-06-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000498-40,0,0,0 2008-000499-25,4,2009-02-20,2009-02-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SERONO SA,"International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmart suitability for selfinjection of Rebif New Formulation (RNF) in multidose cartridges in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000499-25,0,0,0 2008-000499-25,4,2009-02-20,2009-02-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Serono International S.A.,"International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmart suitability for selfinjection of Rebif New Formulation (RNF) in multidose cartridges in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000499-25,0,0,0 2008-000500-83,4,2009-02-24,2009-02-24,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,BEAUFOUR IPSEN PHARMA,"A PHASE II EXPLORATORY, ASCENDING DOSE, MULTICENTRE STUDY TO INVESTIGATE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERABILITY, OF BIM 23A760 IN ACROMEGALIC PATIENTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000500-83,0,0,0 2008-000500-83,4,2009-02-24,2009-02-24,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Ipsen Pharma SAS,"A PHASE II EXPLORATORY, ASCENDING DOSE, MULTICENTRE STUDY TO INVESTIGATE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERABILITY, OF BIM 23A760 IN ACROMEGALIC PATIENTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000500-83,0,0,0 2008-000500-83,4,2009-02-24,2009-02-24,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Ipsen Pharma,"A PHASE II EXPLORATORY, ASCENDING DOSE, MULTICENTRE STUDY TO INVESTIGATE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERABILITY, OF BIM 23A760 IN ACROMEGALIC PATIENTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000500-83,0,0,0 2008-000500-83,4,2009-02-24,2009-02-24,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Beaufour Ipsen Pharma,"A PHASE II EXPLORATORY, ASCENDING DOSE, MULTICENTRE STUDY TO INVESTIGATE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERABILITY, OF BIM 23A760 IN ACROMEGALIC PATIENTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000500-83,0,0,0 2008-000504-92,6,2011-07-26,2011-07-26,3,0,0,0,0,0,3,0,0,1,1,1,1,0,1,"Apex Bioscience, Inc.",PHP for the Treatment of Excess Nitric Oxide in Distributive Shock (PHOENIX),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000504-92,0,0,0 2008-000506-36,1,2009-12-18,2009-12-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose comparison study of escitalopram in combination with two fixed doses of gaboxadol to escitalopram in Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000506-36,0,0,0 2008-000511-16,1,2011-11-10,2011-11-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Keele University,Management of Asthma in School age Children On Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000511-16,0,0,0 2008-000511-16,1,2011-11-10,2011-11-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital of North Staffordshire NHS Trust,Management of Asthma in School age Children On Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000511-16,0,0,0 2008-000513-29,1,2009-12-02,2009-12-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROXALL Medizin GmbH,"Efficacy and safety of subcutaneous cluster immunotherapy with cluster-allergoid CLUSTOID® (glutaraldehyde-polymerized allergen extract of mixtures of grass and rye allergens – Holcus lanatus, Dactyli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000513-29,0,0,0 2008-000515-14,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA SANITARIA LOCALE 9 DI GROSSETO,Utility og GPIIb/IIIa inhibitor in patients with medium-low clinical risk but with high risk of periprocedural necrosis in coronary lesion.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000515-14,0,0,0 2008-000516-32,6,2011-07-20,2011-07-21,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,sanofi aventis Groupe,"Estudio de superioridad de insulina glargina frente a sitagliptina en pacientes con diabetes tipo 2, sin experiencia previa de insulinoterapia, que reciben tratamiento con metformina y no están sufici...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000516-32,0,0,0 2008-000517-30,1,2014-12-08,2014-12-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,The Royal Marsden Hospital NHS Trust,"A multicentre randomised phase II clinical study of UFT/leucovorin (LV), radiotherapy with or without cetuximab following induction gemcitabine plus capecitabine in patients with locally advanced panc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000517-30,0,0,0 2008-000521-19,5,2011-09-09,2011-09-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi aventis Groupe,Combination therapy of insulin glargine and sitagliptin in patients with type 2 diabetes not adequately controlled by a previous treatment with metformin and either insulin glargine or sitagliptin (Ex...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000521-19,0,0,0 2008-000524-82,1,2012-04-16,2012-04-16,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Royal Marsden Hospital,MESH: A Non-Randomised Phase II Trial of Methotrexate in Metastatic Colorectal Cancer with MSH2 Deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000524-82,0,0,0 2008-000526-39,2,2008-11-03,2008-11-03,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IV, open, multicentre, multicountry study to evaluate the immune response to a challenge dose of GSK Biologicals’ Twinrix™ vaccine versus monovalent hepatitis A and B vaccines from different m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000526-39,0,0,0 2008-000528-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA,Phase I/II study of Lapatinib in combination with Capecitabine and Vinorelbine for the second-line treatment of patients with refractory locally recurrent or metastatic breast cancer with ErbB2 overe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000528-22,0,0,0 2008-000529-20,1,2008-11-19,2008-11-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Janssen-Cilag Limited,"Comparison of Ionsys® and routine care with morphine IV PCA in the management of early post-operative mobilisation, ability to mobilise and in time to Fitness For Discharge (FFD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000529-20,0,0,0 2008-000531-18,9,2012-07-24,2012-07-30,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 12 to 36-month extension to a 12-month, open-label, randomised, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus Neoral in c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000531-18,0,0,0 2008-000531-18,9,2012-07-24,2012-07-30,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 12 to 36-month extension to a 12-month, open-label, randomised, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus Neoral in c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000531-18,0,0,0 2008-000531-18,9,2012-07-24,2012-07-30,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,"A 12 to 36-month extension to a 12-month, open-label, randomised, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus Neoral in c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000531-18,0,0,0 2008-000533-22,9,2010-07-16,2010-07-16,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec BVBA,"A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copeg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000533-22,0,0,0 2008-000533-22,9,2010-07-16,2010-07-16,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TIBOTEC BVBA,"A randomized, double-blind, placebo-controlled, Phase III trial of 2 regimens of telaprevir (with and without delayed start) combined with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copeg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000533-22,0,0,0 2008-000536-40,5,2009-01-15,2009-01-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Bayer HealthCare AG, D-51368 Leverkusen, Germany",Ensayo pivotal de fase III para determinar la eficacia y la seguridad del comprimido bucodispersable de vardenafilo comparado con placebo en el tratamiento de hombres con disfunción eréctil (DE) – ens...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000536-40,0,0,0 2008-000536-40,5,2009-01-15,2009-01-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,Ensayo pivotal de fase III para determinar la eficacia y la seguridad del comprimido bucodispersable de vardenafilo comparado con placebo en el tratamiento de hombres con disfunción eréctil (DE) – ens...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000536-40,0,0,0 2008-000537-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hopital Foch,"Anesthésie intraveineuse chez l’obèse : étude des posologies de propofol et de rémifentanil (étude multicentrique, prospective, ouverte comparant un groupe de patients obèses et un groupe de patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000537-22,0,0,0 2008-000540-14,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,ISTITUTO AUXOLOGICO ITALIANO,"Role of the renin-angiotensin system in the cardiovascular, metabolic, neurologic and respiratory response to hypobaric hypoxia during sustained exposure to high altitude.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000540-14,0,0,0 2008-000544-13,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Departamento de Oftalmología. Hospital Clínico San Carlos,Estudio sobre la eficacia y la seguridad del tratamiento combinado con ranibizumab (Lucentis®) y terapia fotodinámica con verteporfin (Visudyne®) versus monoterapia con ranibizumab (Lucentis®) en la N...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000544-13,0,0,0 2008-000546-31,1,2009-07-16,2009-07-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Ltd, Ramsgate Road,Sandwich,Kent CT13 9NJ","A RANDOMIZED, MULTICENTRE, DOUBLE BLIND, PLACEBO CONTROLLED STUDY EVALUATING THE EFFICACY OF VARENICLINE IN CESSATION OF ORAL TOBACCO USE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000546-31,0,0,0 2008-000547-34,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,ASSOCIAZIONE QOL-ONE,"Lenalidomide for Myelodysplastic Syndromes: Efficacy, Safety, Cardiac Changes, and Quality of Life (QoL-ESC RevMDS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000547-34,0,0,0 2008-000549-73,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Merz Pharmaceuticals GmbH,"A prospective, open-label, international, multicenter trial to investigate the efficacy and safety of NT 201, free of complexing proteins, in the treatment of glabellar frown lines",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000549-73,0,0,0 2008-000550-12,6,2009-11-30,2009-11-30,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Norgine Pharmaceuticals Ltd,"A Phase IIIb/IV, Multi-centre, Double-blind, Randomised, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of MOVICOL® with Placebo in Patients with Constipation Associated wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000550-12,0,0,0 2008-000551-10,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Institut Jules Bordet,Randomised Phase II study of biweekly versus fractionated triweekly combination Taxotere-Cisplatin-5FU in advanced gastric and gastro-esophageal junction cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000551-10,0,0,0 2008-000552-27,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,ACO HUD NORDIC AB,Effect of moisturizing creams on skin barrier function and prevention of Malassezia recurrence in patients with atopic eczema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000552-27,0,0,0 2008-000558-11,7,2010-10-01,2010-11-01,4,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Baxter Innovations GmbH,An Open-Label Phase III Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as well as in Specified Risk Groups,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000558-11,0,0,0 2008-000558-11,7,2010-10-01,2010-11-01,4,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Baxter AG,An Open-Label Phase III Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as well as in Specified Risk Groups,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000558-11,0,0,0 2008-000560-17,1,2011-04-28,2011-04-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"UMC Utrecht, Julius Center for Health Sciences and Primary Care",Prednisolone Rhinosinusitis Efficacy Trial (PRET) study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000560-17,0,0,0 2008-000561-28,1,2009-10-15,2009-10-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA` GRANDA (A.O. DI RILIEVO NAZIONALE),Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of bridging antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000561-28,0,0,0 2008-000562-23,2,2009-02-20,2009-02-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"Randomised, Double-Blind, Cross-over Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 2 Doses of Orally Inhaled BI 1744 CL, each in fixed dose combination (FDC) with 5μg T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000562-23,0,0,0 2008-000562-23,2,2009-02-20,2009-02-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co.KG,"Randomised, Double-Blind, Cross-over Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of 2 Doses of Orally Inhaled BI 1744 CL, each in fixed dose combination (FDC) with 5μg T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000562-23,0,0,0 2008-000564-16,3,2014-10-16,2014-10-16,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,MannKind Corporation,"A Phase 3, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects with Obstructive Pulmonary Disease...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000564-16,0,0,0 2008-000565-39,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,BEAUFOUR IPSEN PHARMA,"FOLLOW-UP OF THE PHASE III, MULTICENTRE, NON COMPARATIVE, ONE SINGLE GROUP, OPEN STUDY TO ASSESS THE LONG-TERM EFFICACY AND TOLERABILITY OF PAMOATE OF TRIPTORELIN 11.25 MG IN CHILDREN WITH PRECOCIOUS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000565-39,0,0,0 2008-000566-23,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"GeneCare Research Institute Co., Ltd.","A randomized phase 2 double-blind, placebo-controlled study of GK-001 in hepatocellular carcinoma (HCC) in chronic hepatitis C patients after prior curative HCC treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000566-23,0,0,0 2008-000569-50,3,2020-12-01,2020-12-01,3,0,0,0,0,1,0,0,0,1,1,0,1,0,0,St Anna Kinderkrebsforschung,"Allogeneic stem cell transplantation for children and adolescents with CML: Conditioning regimen, donor selection, supportive care and diagnostic procedures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000569-50,0,0,0 2008-000569-50,3,2020-12-01,2020-12-01,3,0,0,0,0,1,0,0,0,1,1,0,1,0,0,St. Anna Kinderkrebsforschung,"Allogeneic stem cell transplantation for children and adolescents with CML: Conditioning regimen, donor selection, supportive care and diagnostic procedures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000569-50,0,0,0 2008-000570-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO,Randomized phase II study of adjuvant chemotherapy with cisplatin + vinorelbine vs gemcitabine + vinorelbine in stage IB-IIIA radically resected non-small cell lung cancer (NSCLC) patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000570-21,0,0,0 2008-000579-12,1,2013-09-28,2013-09-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA,"A randomised, double-blind, parallel-group, multicentre, phase ii study to evaluate the safety and pharmacological activity of the combination of Vandetanib (100 or 300 mg/daily or placebo) with Fulve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000579-12,0,0,0 2008-000580-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Laboratoires THEA,Safety and Efficacy assessment of Geltim LP ® 1 mg/g (unpreserved Timolol gel – TG1030) in ocular hypertensive or glaucomatous patients stabilized by Xalatan® with ocular intolerance signs,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000580-41,0,0,0 2008-000581-23,1,2011-02-03,2011-02-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-masked, placebo-controlled add on study to assess the efficacy of oral aliskiren 300 mg once daily for diabetic macular edema Et randomiseret, dobbeltblindet placebo kontroller...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000581-23,0,0,0 2008-000582-39,6,2011-08-31,2011-08-31,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Genmab A/S,"An Open label single arm trial investifating zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000582-39,0,0,0 2008-000582-39,6,2011-08-31,2011-08-31,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GENMAB,"An Open label single arm trial investifating zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000582-39,0,0,0 2008-000583-16,6,2010-11-30,2010-12-31,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bayer Schering Pharma AG (BSP),"Multi-center, randomized comparison study to eVALUatE outcomes and resource needs of imaging and treatment following Primovist&#61666;-enhanced MRI of the liver in comparison to extra-cellular con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000583-16,0,0,0 2008-000583-16,6,2010-11-30,2010-12-31,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BAYER SCHERING PHARMA AG,"Multi-center, randomized comparison study to eVALUatE outcomes and resource needs of imaging and treatment following Primovist&#61666;-enhanced MRI of the liver in comparison to extra-cellular con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000583-16,0,0,0 2008-000584-42,1,2013-07-05,2013-07-05,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Universität Rostock, für diese handelnd Universitätsklinikum",Effekte von Zuclopenthixol auf aggressives Verhalten bei Kindern und Jugendlichen mit einer geistigen oder Lernbehinderung (unterdurchschnittlichen Intelligenz),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000584-42,0,0,0 2008-000585-22,1,2011-12-29,2011-12-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ferring Arzneimittel GmbH,"An Open-Label, Multi-Centre, Uncontrolled, Exploratory Study, Investigating Degarelix One-Month Dosing Regimen as Second-Line Hormonal Treatment after PSA-Failure in GnRH Agonist Treated Patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000585-22,0,0,0 2008-000586-26,1,2015-06-26,2015-06-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Oxford,Adjuvant Urokinase in the Treatment of Malignant Pleural Effusion: The Third Therapeutic Intervention in Maligant Effusion Trial (TIME3-UK). A Randomised Controlled Trial to evaluate whether use of in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000586-26,0,0,0 2008-000587-17,16,2010-03-29,2010-03-30,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann- La Roche Ltd,"Estudio abierto, multinacional para evaluar la seguridad, tolerabilidad y eficacia de tocilizumab en pacientes con artritis reumatoide activa en tratamiento con FAMEs no biológicos que tienen una resp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000587-17,0,0,0 2008-000587-17,16,2010-03-29,2010-03-30,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"Estudio abierto, multinacional para evaluar la seguridad, tolerabilidad y eficacia de tocilizumab en pacientes con artritis reumatoide activa en tratamiento con FAMEs no biológicos que tienen una resp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000587-17,0,0,0 2008-000587-17,16,2010-03-29,2010-03-30,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"Estudio abierto, multinacional para evaluar la seguridad, tolerabilidad y eficacia de tocilizumab en pacientes con artritis reumatoide activa en tratamiento con FAMEs no biológicos que tienen una resp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000587-17,0,0,0 2008-000588-41,1,2010-11-30,2010-11-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,Tranexamic acid efficacy reducing surgery bleding in patients undergoing surgery for complete prostatectomy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000588-41,0,0,0 2008-000592-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Berufsgenossenschaftliche Unfallklinik,A Randomized Open Clinical Study of Daily Subcutaneous Parathyroid Hormone (1-34) / Teriparatide Injection on the Consolidation of Regenerated Bone Formed after Distraction Osteogenesis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000592-24,0,0,0 2008-000597-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Kuopio University Hospital, Anesthesiology Clinic",Requirement of analgesics after two remifentanil dosing regimen in cardiac surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000597-21,0,0,0 2008-000599-25,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,TweeSteden Hospital,"Iron and Folic acid v.s. Iron solely in the treatment of post partum anaemia, effects on haemoglobin and health status",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000599-25,0,0,0 2008-000601-11,1,2010-11-01,2010-11-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien Univ. Klinik f. Innere Med. III, Abt. f. Gastroenterologie/Hepatologie",SORATACE: Sorafenib (Nexavar®) as inhibitor of collateral tumor vessel growth during transarterial chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC)- a pilot trial to evaluate safety and bio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000601-11,0,0,0 2008-000604-88,1,2010-07-12,2010-07-12,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,St Stephen's Aids Trust,"A phase IV, two-arm, open-label, single-centre randomised pilot study to assess the feasibility of immeidate or deferred switching of HIV-infected individuals intolerant of efavirenz, ritonavir-booste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000604-88,0,0,0 2008-000606-36,1,2011-01-25,2011-01-25,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,"Aarhus University Hospital, Dept of Endocrinology and Metabolism C",Treatment of hypoparathyroidism with subcutaneous PTH (1-84) injections: effects on muscle function and quality of life,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000606-36,0,0,0 2008-000609-12,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,University Hospital Antwerp; Department Respiratory Medicine,"Open, randomized, two-way crossover, pilot study to assess the effect of Salbutamol in comparison with Ipratropium bromide on central and peripheral airway dimensions in COPD patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000609-12,0,0,0 2008-000615-15,6,2013-07-23,2013-07-29,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MERCK KGAA,"Open-label, randomized, controlled Phase I/II study of cilengitide to evaluate the safety and efficacy of the combination of different regimens of cilengitide added to cisplatin, 5-FU, and cetuximab i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000615-15,0,0,0 2008-000615-15,6,2013-07-23,2013-07-29,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"Open-label, randomized, controlled Phase I/II study of cilengitide to evaluate the safety and efficacy of the combination of different regimens of cilengitide added to cisplatin, 5-FU, and cetuximab i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000615-15,0,0,0 2008-000617-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Klinik Loewenstein gGmbH,Randomized Phase III Multicenter Trial of RRM1 & ERCC1 Directed Customized Chemotherapy versus Standard of Care for 1st Line Treatment of Patients with Advanced Non-Small-Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000617-30,0,0,0 2008-000621-19,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Instituto Científico y Tecnológico de Navarra, S.A.",Nefropatía inducida por contraste intravenoso: Eficacia comparativa en la prevención de la aplicación de un protocolo de hidratación iv y oral; detección de marcadores precoces y profundización en el ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000621-19,0,0,0 2008-000622-40,7,2014-02-24,2014-07-07,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,H. Lundbeck A/S,"A randomised, double-blind, parallel-group, placebo-controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000622-40,0,0,0 2008-000623-25,1,2011-05-01,2011-05-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Nottingham,Ondansetron for the treatment of IBS with diarrhoea (IBS-D): Identifying the “responder”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000623-25,0,0,0 2008-000625-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"The use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: A multicenter, open-label randomized clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000625-19,0,0,0 2008-000626-39,1,2009-08-28,2009-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Graz,Calcipotriol zur Prävention der Polymorphen Lichtdermatose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000626-39,0,0,0 2008-000627-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,Conversion from cyclosporine to tacrolimus followed by randomized C0 or Bayesian monitoring using the C4 timepoint The effect on kidney function,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000627-26,0,0,0 2008-000628-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UMC Utrecht,"The effectiveness of intensive treatment on sympathetic hyperactivity. A randomized, cross-over trial in patients with chronic kidney disease and hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000628-25,0,0,0 2008-000634-53,6,2012-07-09,2012-07-09,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"ARIAD Pharmaceuticals, Inc.",A randomized phase II trial of deforolimus (AP23573; MK-8669) compared to progestin in female adult patients with advanced endometrial carcinoma following one line of chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000634-53,0,0,0 2008-000634-53,6,2012-07-09,2012-07-09,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp.,",A randomized phase II trial of deforolimus (AP23573; MK-8669) compared to progestin in female adult patients with advanced endometrial carcinoma following one line of chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000634-53,0,0,0 2008-000634-53,6,2012-07-09,2012-07-09,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck & Co, Inc.",A randomized phase II trial of deforolimus (AP23573; MK-8669) compared to progestin in female adult patients with advanced endometrial carcinoma following one line of chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000634-53,0,0,0 2008-000634-53,6,2012-07-09,2012-07-09,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"ARIAD PHARMACEUTICALS,INC.",A randomized phase II trial of deforolimus (AP23573; MK-8669) compared to progestin in female adult patients with advanced endometrial carcinoma following one line of chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000634-53,0,0,0 2008-000639-16,4,2010-06-22,2010-06-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients with Subjective Tinnitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000639-16,0,0,0 2008-000640-14,6,2009-10-01,2009-10-06,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (5mg, 10mg and 25mg) administered orally once daily over 12 weeks compared double blind to placebo, as m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000640-14,0,0,0 2008-000640-14,6,2009-10-01,2009-10-06,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer ingelheim Pharma GmbH & Co KG,"A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (5mg, 10mg and 25mg) administered orally once daily over 12 weeks compared double blind to placebo, as m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000640-14,0,0,0 2008-000640-14,6,2009-10-01,2009-10-06,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (5mg, 10mg and 25mg) administered orally once daily over 12 weeks compared double blind to placebo, as m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000640-14,0,0,0 2008-000640-14,6,2009-10-01,2009-10-06,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (5mg, 10mg and 25mg) administered orally once daily over 12 weeks compared double blind to placebo, as m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000640-14,0,0,0 2008-000641-54,10,2009-10-21,2009-10-31,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (1mg, 5mg, 10mg, 25mg, and 50mg) administered orally once daily over 12 weeks compared double blind to p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000641-54,0,0,0 2008-000641-54,10,2009-10-21,2009-10-31,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (1mg, 5mg, 10mg, 25mg, and 50mg) administered orally once daily over 12 weeks compared double blind to p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000641-54,0,0,0 2008-000641-54,10,2009-10-21,2009-10-31,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (1mg, 5mg, 10mg, 25mg, and 50mg) administered orally once daily over 12 weeks compared double blind to p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000641-54,0,0,0 2008-000641-54,10,2009-10-21,2009-10-31,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (1mg, 5mg, 10mg, 25mg, and 50mg) administered orally once daily over 12 weeks compared double blind to p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000641-54,0,0,0 2008-000641-54,10,2009-10-21,2009-10-31,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase II, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (1mg, 5mg, 10mg, 25mg, and 50mg) administered orally once daily over 12 weeks compared double blind to p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000641-54,0,0,0 2008-000643-34,1,2013-11-15,2013-11-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UZ Leuven,SOMATULINE Autogel 90 mg IN DUMPING SYNDROME,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000643-34,0,0,0 2008-000644-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,"A randomized, prospective trial of 2-6 weeks pre-operative hormonal treatment for hormone receptor positive breast cancer: Anastrozole +/- Fulvestrant or Tamoxifen Exposure - response in molecular pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000644-13,0,0,0 2008-000649-77,7,2010-12-09,2010-12-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Centocor BV,"A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects with Moderately to Severely Active Cr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000649-77,0,0,0 2008-000653-36,1,2010-07-08,2010-07-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Charité - Universitätsmedizin Berlin,Efficacy and tolerability of Docetaxel-Gemcitabin in patients with advanced non-small cell lung cancer and an ECOG-Performance-Index of 2. A multicenter phase II-trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000653-36,0,0,0 2008-000654-12,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Fachbereich Medizin der Johann Wolfgang Goethe-Universität Frankfurt/M.,PHARMACOKINETIC BERINERT P STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN SUBJECTS WITH MODERATE HEREDITARY ANGIOEDEMA - THE PASSION STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000654-12,0,0,0 2008-000657-35,1,2016-11-30,2016-11-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Greater Glasgow and Clyde Health Board (GGCHB)/University of Glasgow,"A multi-centre phase II trial to assess the efficacy of epirubicin, cisplatin and capecitabine incorporating the prospective validation of molecular classifiers and exploratory metabonomics.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000657-35,0,0,0 2008-000660-17,7,2013-02-28,2013-02-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"TPL108392: An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000660-17,0,0,0 2008-000660-17,7,2013-02-28,2013-02-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"TPL108392: An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000660-17,0,0,0 2008-000660-17,7,2013-02-28,2013-02-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline,"TPL108392: An open-label, multi-centre rollover study to assess the safety and efficacy of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000660-17,0,0,0 2008-000662-23,10,2012-06-30,2012-09-18,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann La-Roche Ltd,"A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000662-23,0,0,0 2008-000662-23,10,2012-06-30,2012-09-18,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"A randomized, multicenter phase II study to explore whether biomarkers correlate with treatment outcome in chemo-naive patients with advanced or recurrent non-squamous non-small cell lung cancer, who...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000662-23,0,0,0 2008-000663-42,4,2009-02-26,2009-02-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000663-42,0,0,0 2008-000663-42,4,2009-02-26,2009-02-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000663-42,0,0,0 2008-000663-42,4,2009-02-26,2009-02-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A 26-week extension to a 26-week treatment, multicenter, randomized, double-blind, placebo-controlled, adaptive, seamless, parallel-group study to assess safety, tolerability and efficacy of two do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000663-42,0,0,0 2008-000664-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,Clinical phase II trial to evaluate the safety and efficacy of treosulfan combined with cytarabine and fludarabine prior to autologous haematopoietic stem cell transplantation in elderly patients with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000664-16,0,0,0 2008-000668-18,1,2016-04-08,2016-04-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Hospices Civils de Lyon,A Randomized Phase II Study of Clofarabine / Intermediate-Dose Cytarabine (CLARA) versus High-Dose Cytarabine (HDAC) as Consolidation in Younger Patients with Newly-Diagnosed Acute Myeloid Leukem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000668-18,0,0,0 2008-000670-20,1,2010-08-31,2010-08-31,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Respitatory and Allergy Research Unit,Blood- and urinary concentrations of salbutamol in asthmatics and elite athletes with asthma; comparison between inhalation vs. oral administration.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000670-20,0,0,0 2008-000673-38,10,2012-06-21,2018-03-22,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in Patients with Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000673-38,0,0,0 2008-000673-38,10,2012-06-21,2018-03-22,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in Patients with Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000673-38,0,0,0 2008-000673-38,10,2012-06-21,2018-03-22,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline S.A.,"A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in Patients with Anthracycline- or Taxane-Exposed ErbB2-Positive Metastatic B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000673-38,0,0,0 2008-000674-20,1,2009-07-15,2009-07-15,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,St Stephen's Aids Trust,"A phase III, double blind, multi centre, randomised placebo controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing Central Nervous System (CNS) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000674-20,0,0,0 2008-000678-19,1,2011-02-03,2011-02-03,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,"Klinikum der Universität München, Klinikum Großhadern",Feasibility and efficacy of Lenalidomide maintenance after salvage immuno-chemotherapy induction in relapsed or refractory mantle cell lymphoma - a phase II study of the European MCL Network,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000678-19,0,0,0 2008-000679-90,9,2011-03-16,2011-03-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Shire Pharmaceutical Development Limited,"A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Ado...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000679-90,0,0,0 2008-000684-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Assistance Publique Hopitaux de marseille,ETUDE PILOTE POUR L’EVALUATION DE LA FAISABILITE ET LA VALIDATION D’UN PROTOCOLE SCINTIGRAPHIE DES RECEPTEURS DOPAMINERGIQUES (123I-IBZM) DANS LES PHEOCHROMOCYTOMES ET PARAGANGLIOMES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000684-42,0,0,0 2008-000686-30,1,2011-11-11,2011-11-11,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,Effect of glicemia normalization in fasting conditions by insulinic intensive treatment on frequency of restenosis after periferic angioplastic in patients affected by diabetes mellitus type II.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000686-30,0,0,0 2008-000688-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,IMATINIB MESYLATE IN ADVANCED LOW GRADE SOLID TUMORS EXPRESSING IMATINIB MESYLATE TARGETS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000688-41,0,0,0 2008-000689-21,6,2010-11-18,2010-11-18,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Genzyme Europe BV,"Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin’s Lymphoma (NHL), Hodgkin’s Disease (HD) or Multiple My...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000689-21,0,0,0 2008-000697-20,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,"PHASE II TRIAL TO EVALUATE EFFICACY AND SECURITY OF ACUTE INTAKE OF GLUTEN DERIVED FROM TRITICUM MONOCOCCUM IN PATIENTS AFFECTED BY CELIAC DISEASE: THE ""ANCIENT WHEAT"" PROJECT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000697-20,0,0,0 2008-000700-84,1,2009-02-09,2009-02-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UZ Leuven,"A single center trial with a randomized, double-blind, placebo-controlled phase to assess safety and efficacy of sc pasireotide in patients with dumping syndrome, followed by an open label phase on ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000700-84,0,0,0 2008-000701-11,10,2015-05-29,2015-07-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer Revised Protocol 03 incorporating Admini...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000701-11,0,0,0 2008-000706-36,1,2013-08-05,2013-08-05,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Hannover Medical School; Competence Network Viral Hepatitis (Hep-Net),Optimization of treatment for patients with chronic hepatitis C infected with HCV-genotype 2 or 3: 12 vs. 24 weeks of treatment extension for patients without rapid virological response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000706-36,0,0,0 2008-000707-28,1,2017-09-27,2017-09-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,The Institute of Cancer Research,"A Phase II Trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic carcinoma of the penis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000707-28,0,0,0 2008-000707-28,1,2017-09-27,2017-09-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Hospitals Bristol NHS Foundation Trust,"A Phase II Trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic carcinoma of the penis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000707-28,0,0,0 2008-000709-12,7,2015-09-17,2016-02-22,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Teva Branded Pharmeceutical Products R&D, Inc.","Estudio prospectivo, abierto, aleatorizado del tratamiento de combinación de MYOCET® más ciclofosfamida y trastuzumab frente a doxorubicina libre más ciclofosfamida sola, seguidos cada uno de docetaxe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000709-12,0,0,0 2008-000709-12,7,2015-09-17,2016-02-22,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cephalon France,"Estudio prospectivo, abierto, aleatorizado del tratamiento de combinación de MYOCET® más ciclofosfamida y trastuzumab frente a doxorubicina libre más ciclofosfamida sola, seguidos cada uno de docetaxe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000709-12,0,0,0 2008-000709-12,7,2015-09-17,2016-02-22,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","Estudio prospectivo, abierto, aleatorizado del tratamiento de combinación de MYOCET® más ciclofosfamida y trastuzumab frente a doxorubicina libre más ciclofosfamida sola, seguidos cada uno de docetaxe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000709-12,0,0,0 2008-000709-12,7,2015-09-17,2016-02-22,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CEPHALON FRANCE,"Estudio prospectivo, abierto, aleatorizado del tratamiento de combinación de MYOCET® más ciclofosfamida y trastuzumab frente a doxorubicina libre más ciclofosfamida sola, seguidos cada uno de docetaxe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000709-12,0,0,0 2008-000712-33,1,2008-07-24,2008-07-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Graz,Fentanyl for the treatment of dsypnea in patients with chronic heart failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000712-33,0,0,0 2008-000714-74,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Institution of Paediatric Anaesthesia and intensiv care, Astrid Lindgren Childrens Hospital, Karolin",Premedication in paediatric patients: Dose finding study of clonidine administrated as nasal aerosol.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000714-74,0,0,0 2008-000718-63,1,2009-06-29,2009-06-29,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Bayer Consumer Care AG,"An investigator-blinded, active-controlled phase 3 study to prove the non-inferior efficacy of a Clotrimazole ovule (500 mg) versus a Clotrimazole vaginal tablet (500 mg) in vaginal candidiasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000718-63,0,0,0 2008-000720-10,8,2011-10-26,2011-10-26,6,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Shire Pharmaceutical Development Limited,"A Phase III, Double- Blind, Placebo- Controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with Atte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000720-10,0,0,0 2008-000720-10,8,2011-10-26,2011-10-26,6,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Shire UK,"A Phase III, Double- Blind, Placebo- Controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with Atte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000720-10,0,0,0 2008-000724-12,1,2008-10-29,2008-10-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 2-week, randomised, double-blind, placebo-controlled, parallel group study to assess the tolerability and pharmacokinetics of orally administered AZD9668 in patients with COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000724-12,0,0,0 2008-000725-18,1,2008-10-19,2008-10-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Reaseach & Development,"A randomised, double-blind, crossover study to investigate the bronchodilatation post-inhalation of GSK961081 alone and with the addition of cumulative doses of short acting bronchodilators (salbutamo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000725-18,0,0,0 2008-000727-26,1,2009-02-25,2009-02-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"Study HZC111348, a repeat-dose study of GW685698/GW642444 Inhalation Powder versus placebo in the treatment of Chronic Obstructive Pulmonary Disease (COPD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000727-26,0,0,0 2008-000730-42,1,2011-02-02,2011-02-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma Corporation,"An open-label, multi-centre, clinical study to collect information on the clinical use of argatroban in patients with heparin induced thrombocytopenia (HIT) Type II who require parenteral antithrombot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000730-42,0,0,0 2008-000733-21,1,,,0,0,0,0,0,3,2,0,0,0,0,0,0,0,0,ANRS,"A randomized, double blind, multicenter study evaluating efficacy and safety of Clevudine monotherapy versus Tenofovir monotherapy versus combination therapy of Clevudine and Tenofovir for 96 weeks in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000733-21,0,0,0 2008-000738-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Societa' Italiana di Diabetologia,EFFECTS ON INCIDENCE OF CARDIOVASCULAR EVENTS OF THE ADDITION OF PIOGLITAZONE AS COMPARED WITH A SULFONYLUREA IN TYPE 2 DIABETIC PATIENTS INADEQUATELY CONTROLLED WITH METFORMIN Thiazolidinediones Or S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000738-39,0,0,0 2008-000741-55,1,2010-03-02,2010-03-02,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,Vasovist and Gadovist in comparison to Magnevist for detection of myocardial late enhancement in MR in different cardiac diseases using the technique of delayed enhancement,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000741-55,0,0,0 2008-000742-30,3,2009-06-01,2009-06-01,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Rigel Pharmaceuticals, Inc.","A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of Two Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000742-30,0,0,0 2008-000743-34,4,2009-06-09,2009-06-09,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,RIGEL PHARMACEUTICALS INC,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000743-34,0,0,0 2008-000743-34,4,2009-06-09,2009-06-09,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Rigel Pharmaceuticals, Inc.","A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000743-34,0,0,0 2008-000744-13,5,2013-06-28,2013-08-21,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,RIGEL PHARMACEUTICALS INC,"An Open-Label, Multicenter Extension Study to Evaluate the Safety of R935788 in Patients with Rheumatoid Arthritis Who Have Completed the Treatment Phase of a Rigel-Sponsored R935788 Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000744-13,0,0,0 2008-000744-13,5,2013-06-28,2013-08-21,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Rigel Pharmaceuticals, Inc","An Open-Label, Multicenter Extension Study to Evaluate the Safety of R935788 in Patients with Rheumatoid Arthritis Who Have Completed the Treatment Phase of a Rigel-Sponsored R935788 Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000744-13,0,0,0 2008-000744-13,5,2013-06-28,2013-08-21,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AstraZeneca AB,"An Open-Label, Multicenter Extension Study to Evaluate the Safety of R935788 in Patients with Rheumatoid Arthritis Who Have Completed the Treatment Phase of a Rigel-Sponsored R935788 Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000744-13,0,0,0 2008-000746-32,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Karolinska Institutet,"Validation of experimental pain models as translational for craniofacial myalgia with respect to the influence of 5-HT, glutamate, cortisol and estradiol level",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000746-32,0,0,0 2008-000748-14,1,2012-08-22,2012-08-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company limited,"An Open Label, Multicenter Phase 2 Study of Single-Agent Enzastaurin HCl in Previously Treated Waldenstrom’s Macroglobulinemia or Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000748-14,0,0,0 2008-000750-13,14,2010-12-29,2011-02-11,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Boehringer Ingelheim España, S.A.",A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000750-13,0,0,0 2008-000750-13,14,2010-12-29,2011-02-11,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000750-13,0,0,0 2008-000750-13,14,2010-12-29,2011-02-11,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Limited,A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000750-13,0,0,0 2008-000750-13,14,2010-12-29,2011-02-11,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Austria GmbH,A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000750-13,0,0,0 2008-000750-13,14,2010-12-29,2011-02-11,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim bv,A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000750-13,0,0,0 2008-000750-13,14,2010-12-29,2011-02-11,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Ellas AE,A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000750-13,0,0,0 2008-000750-13,14,2010-12-29,2011-02-11,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BOEHRINGER ING.,A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000750-13,0,0,0 2008-000750-13,14,2010-12-29,2011-02-11,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm.V,A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000750-13,0,0,0 2008-000750-13,14,2010-12-29,2011-02-11,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000750-13,0,0,0 2008-000750-13,14,2010-12-29,2011-02-11,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Finland Ky,A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000750-13,0,0,0 2008-000750-13,14,2010-12-29,2011-02-11,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim AB,A 78 week open label extension to trials assessing the safety and efficacy of BI 1356 (5 mg) as monotherapy or in combination with other antidiabetic medications in type 2 diabetic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000750-13,0,0,0 2008-000753-35,2,2009-04-20,2009-04-20,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Bronchiectasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000753-35,0,0,0 2008-000756-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZ Brussel,"Activity of sunitinib in esophageal cancer, melanoma and sarcoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000756-27,0,0,0 2008-000757-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Bordeaux,Lavage Bronchiolo-Alvéolaire sous ventilation non Invasive et sédation intra veineuse en objectif de concentration au Propofol chez le malade en insuffisance Respiratoire Aiguë. Etude Randomisée Contr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000757-35,0,0,0 2008-000759-91,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA S. LUIGI GONZAGA,Sorafenib plus paclitaxel metronomic chemotherapy in adreno-cortical-carcinoma patients progressing after 1st or snd line cytotoxic chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000759-91,0,0,0 2008-000761-32,3,2009-03-27,2009-03-27,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,PFIZER,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT OF G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000761-32,0,0,0 2008-000761-32,3,2009-03-27,2009-03-27,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Pfizer Inc,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT OF G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000761-32,0,0,0 2008-000761-32,3,2009-03-27,2009-03-27,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT OF G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000761-32,0,0,0 2008-000762-23,3,2009-03-27,2009-03-27,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK, PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT OF ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000762-23,0,0,0 2008-000762-23,3,2009-03-27,2009-03-27,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,PFIZER,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK, PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT OF ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000762-23,0,0,0 2008-000763-42,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 10-WEEK PLACEBO CONTROLLED FIXED DOSE STUDY OF PD 0332334 AND PAROXETINE EVALUATING THE EFFICACY AND SAFETY OF PD 0332334 FOR THE TREATMENT OF GENE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000763-42,0,0,0 2008-000765-33,1,2012-12-06,2012-12-06,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,AGMT gemeinnützige GmbH,"Phase II Study to Investigate the Treatment of Patients with NSCLC Stage IIIB and IV without the Option of Surgery with a Combination of Cisplatin, Docetaxel and Bevacizumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000765-33,0,0,0 2008-000766-23,1,2010-08-25,2010-08-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Medical School Hannover, Department of Psychiatry, Socialpsychiatry and Psychotherapy",Effects of QuetiapineXR in schizophrenic patients with cannabis abuse and/or cannabis induced psychosis -pilot study-,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000766-23,0,0,0 2008-000767-41,1,2011-09-30,2011-09-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH,Phase II Trial of Rituximab Plus 2CdA in Patients with Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000767-41,0,0,0 2008-000769-49,1,2011-08-22,2011-08-22,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Ghent,"Unicentrische vergelijkende studie van suctie curretage met standaard BOTOX injectie bij de behandeling van patiënten met essentiële axillaire hyperhidrosis: vergelijking van efficaciteit, duur van ef...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000769-49,0,0,0 2008-000771-17,1,2009-03-12,2009-03-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,RUNMC,"Hyperbilirubinemia, the favourable side effect of atazanavir? Influence of atazanavir treatment on endothelial dysfunction, vascular inflammation and heme oxygenase activity in type 2 diabetes mellitu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000771-17,0,0,0 2008-000780-42,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,PH&T SPA,Evaluation of the therapeutic equivalence of latanoprost PK and Xalatan. Double blind randomized clinical trial in subjects affected by open angle glaucoma or intraocular hypertension.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000780-42,0,0,0 2008-000781-23,3,2010-10-18,2011-07-11,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Genmab A/S,"An Open-label, International, Multi-Center, Phase I/II, Dose-escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000781-23,0,0,0 2008-000782-35,1,2011-04-07,2011-04-07,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,Verein fuer Krebsfoschung (Society for Cancer Research),Dose-escalating study to determine the maximum tolerated dose (MTD) of the mistletoe extract WEME 200 mg for intravesical instillation in patients with completely resected (R0) superficial bladder car...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000782-35,0,0,0 2008-000783-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ROCHE SAS,"Multicenter, phase II trial assessing the efficacy and safety of bevacizumab (Avastin®) combined to trastuzumab (Herceptin®) based chemotherapy in patients with primary inflammatory HER2+ breast cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000783-16,0,0,0 2008-000786-32,6,2008-12-12,2008-12-12,3,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Speedel Pharma Ltd,"A Randomised, Double-blind, Placebo-Controlled, Dose-ranging, Parallel Design Study to Evaluate the Efficacy and Safety of the Endothelin Antagonist Avosentan in Patients With Diabetic Kidney Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000786-32,0,0,0 2008-000787-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Inserm,Etude pilote ouverte de l'effet de la fluoxetine chez des patientes agées de 8 à 28 ans atteintes du Syndrôme de Rett Typique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000787-16,0,0,0 2008-000789-22,2,2011-09-06,2011-09-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R & D,"SAFE-AF: Safety of Fondaparinux in electric cardioversion of atrial fibrillation. An International, Multicentre, Randomised, Open, Controlled, Two-parallel Group, Phase II Study to Evaluate the Effic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000789-22,0,0,0 2008-000790-38,1,2009-06-17,2009-06-17,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of oral RSV604 in healthy adults experimentally infected with respiratory syncytial virus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000790-38,0,0,0 2008-000791-24,1,2009-11-30,2009-11-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Karolinska Institutet,The effect of anti-inflammatory analgesics on pain after Hallux Valgus surgery; a prospective randomised study comparing a weak opioid and a Coxib.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000791-24,0,0,0 2008-000793-20,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Erasmus MC,Sirolimus (Rapamune®) for the treatment of anti-Hu associated paraneoplastic neurological syndromes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000793-20,0,0,0 2008-000795-24,1,2017-10-16,2017-10-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Octapharma AG,Surveillance of results of long-term prophylactic treatment of von Willebrand disease with Wilate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000795-24,0,0,0 2008-000796-17,1,2008-08-11,2008-08-11,1,1,0,0,0,3,4,0,1,1,0,0,1,0,0,"Institut for Sundhedstjenesteforskning, Klinisk Farmakologi, Syddansk Universitet",Optagelse af svampemidlet miconazol og effekt på østrogenmetaboliserende enzymer i mennesker,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000796-17,0,0,0 2008-000799-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Assistance Publique Hopitaux de marseille,EVALUATION DU MEOPA DANS L'INTERRUPTION VOLONTAIRE DE GROSSESSE SOUS ANESTHESIE LOCALE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000799-25,0,0,0 2008-000803-26,1,2012-10-02,2012-10-02,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,AIO Studien gGmbH,A controlled randomized double-blind multi-center phase II study of FOLFOX6 or FOLFIRI combined with sorafenib versus placebo in second-line metastatic colorectal carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000803-26,0,0,0 2008-000804-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II,Valsartan 160 mg and hydrochlorothiazide 25 mg in subject suffering from arterial hypertension stage 1 or high normal with organ damage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000804-10,0,0,0 2008-000810-54,3,2010-11-10,2010-11-10,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,sanofi-aventis recherche et développement,"Multicenter, randomized, open label study evaluating an anti Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) monoclonal antibody, AVE1642, administered every 4 weeks in combination with fulvestra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000810-54,0,0,0 2008-000810-54,3,2010-11-10,2010-11-10,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,sanofi-aventis recherche et de'veloppement,"Multicenter, randomized, open label study evaluating an anti Insulin-like Growth Factor-1 Receptor (IGF-1R/CD221) monoclonal antibody, AVE1642, administered every 4 weeks in combination with fulvestra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000810-54,0,0,0 2008-000814-65,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE S. RAFFAELE DI MILANO,Maintenance therapy with Sunitinib in pancreatic adenocarcinoma metastatic: Phase II randomized trial. Terapia di mantenimento con Sunitinib nell'adenocarcinoma pancreatico metastatico: studio ran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000814-65,0,0,0 2008-000815-13,1,2010-12-01,2010-12-01,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Technical University Munich,"Analysis of cerebral, renal, peripheral, and retinal hemodynamics in adults with type 2 diabetes before, during, and after administration of pioglitazone or placebo.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000815-13,0,0,0 2008-000818-78,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO SAN DONATO IRCSS,Efficacy of fenoldopam mesilate in controlling splanchnic ischemia during cardiopulmonary bypass,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000818-78,0,0,0 2008-000822-38,1,2013-03-08,2013-03-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"A PROSPECTIVE, RANDOMIZED, OPEN LABEL BLINDED END POINT (PROBE), CROSS-OVER STUDY TO COMPARE THE EFFECTS OF TELMISARTAN AND LOSARTAN ON METABOLIC PROFILE OF RENAL TRANSPLANT PATIENTS Studio prospet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000822-38,0,0,0 2008-000824-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II,Effects of ezetimibe in association with statins on postprandial lipemia in type 2 diabetic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000824-20,0,0,0 2008-000826-37,5,2010-03-09,2010-03-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"Study AZ3110865, a study comparing SB-742457 or donepezil versus placebo in subjects with mild-to-moderate Alzheimer’s disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000826-37,0,0,0 2008-000827-25,4,2010-05-26,2010-11-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"Estudio AZ3110866: Estudio de dosis fija de SB-742457 frente a placebo, como tratamiento añadido a donepezilo, en sujetos con enfermedad de Alzheimer leve a moderada",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000827-25,0,0,0 2008-000827-25,4,2010-05-26,2010-11-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"Estudio AZ3110866: Estudio de dosis fija de SB-742457 frente a placebo, como tratamiento añadido a donepezilo, en sujetos con enfermedad de Alzheimer leve a moderada",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000827-25,0,0,0 2008-000830-30,5,2011-12-21,2011-12-21,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CSL Behring AG,"A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects with Primary Immunodeficiency (IgPro20 EU Extension Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000830-30,0,0,0 2008-000832-42,1,2012-09-13,2012-09-13,1,0,0,0,1,0,4,0,0,1,1,1,1,0,0,East Kent Hospital Trust,Effectiveness of Heliox in Hypercapnic Respiratory Failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000832-42,0,0,0 2008-000833-23,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA ISTITUTI CLINICI DI PERFEZIONAMENTO DI MILANO,Efficacy evaluation of oral baclofen treatment versus intrathecal baclofen in children with dystonic cerebral palsy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000833-23,0,0,0 2008-000837-23,4,2015-07-31,2015-07-31,2,1,0,0,0,0,3,0,0,1,1,0,1,0,0,University College London,A GCIG Intergroup multicentre trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000837-23,0,0,0 2008-000837-23,4,2015-07-31,2015-07-31,2,1,0,0,0,0,3,0,0,1,1,0,1,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,A GCIG Intergroup multicentre trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000837-23,0,0,0 2008-000844-15,8,2009-03-26,2009-03-26,4,1,1,0,0,0,1,0,0,2,0,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, NEW YORK, NY 10017. US","A PHASE 1, OPEN-LABEL STUDY OF LATANOPROST ACID PLASMA CONCENTRATIONS IN PEDIATRIC AND ADULT GLAUCOMA PATIENTS TREATED WITH LATANOPROST 0.005%",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000844-15,1,1,0 2008-000844-15,8,2009-03-26,2009-03-26,4,1,1,0,0,0,1,0,0,2,0,0,0,0,1,"PFIZER, S.A.","A PHASE 1, OPEN-LABEL STUDY OF LATANOPROST ACID PLASMA CONCENTRATIONS IN PEDIATRIC AND ADULT GLAUCOMA PATIENTS TREATED WITH LATANOPROST 0.005%",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000844-15,1,1,0 2008-000844-15,8,2009-03-26,2009-03-26,4,1,1,0,0,0,1,0,0,2,0,0,0,0,1,PFIZER,"A PHASE 1, OPEN-LABEL STUDY OF LATANOPROST ACID PLASMA CONCENTRATIONS IN PEDIATRIC AND ADULT GLAUCOMA PATIENTS TREATED WITH LATANOPROST 0.005%",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000844-15,1,1,0 2008-000846-30,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,IBSA,"Open-label, randomised, controlled, parallel group study for the evaluation of safety and efficacy of Diclofenac HPBCD 75 mg ampoules s.c. in comparison with Diclofenac HPBCD 75 mg ampoules i.m. and V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000846-30,0,0,0 2008-000853-37,1,2009-06-09,2009-06-09,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Sheffield Children's NHS Foundation Trust,Botulinum Toxin: an adjunct in limb reconstruction – can it reduce pain and joint complications in the lengthening phase?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000853-37,0,0,0 2008-000854-11,9,2010-06-09,2010-06-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Safety and Efficacy of Exenatide Once Weekly Injection versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000854-11,0,0,0 2008-000854-11,9,2010-06-09,2010-06-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"Safety and Efficacy of Exenatide Once Weekly Injection versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000854-11,0,0,0 2008-000859-10,1,2012-06-21,2012-06-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ANRS,"Etude pilote, multicentrique, évaluant l’efficacité d’un traitement anti VHC optimisé (induction par 360µg/S de PegIFN-alpha 2a + 18mg/kg/j de RBV pendant 6 mois puis en fonction de la réponse virolog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000859-10,0,0,0 2008-000862-21,2,2009-04-03,2009-04-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 12 week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and hydrochlorothiazide 25 mg compared to aliskiren ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000862-21,0,0,0 2008-000862-21,2,2009-04-03,2009-04-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12 week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and hydrochlorothiazide 25 mg compared to aliskiren ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000862-21,0,0,0 2008-000866-22,1,2010-11-02,2010-11-02,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,"University of Aarhus, School of Dentistry",Vurdering af det operative forløb i forbindelse med fjernelse af mandiblens 3. molar med særligt henblik på forekomsten af smerte og hævelse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000866-22,0,0,0 2008-000869-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Skaraborg Hospital,Impact of Losartan in hypertensive men with obstructive sleep apnea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000869-38,0,0,0 2008-000871-19,1,2009-06-17,2009-06-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pierre Fabre Médicament,"Comparative study of efficacy and safety of Structum® and Chondrosulf® in patients with symptomatic osteoarthritis of the knee.A Multicenter, Randomized, Double-Blind, Double Placebo-Controlled, Paral...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000871-19,0,0,0 2008-000872-25,7,2010-12-09,2010-12-09,6,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A randomized, observer-blind, active-controlled phase III study to demonstrate the superior efficacy of GSK Biologicals’ adjuvanted influenza candidate vaccine [GSK2186877A], administered intramuscula...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000872-25,0,0,0 2008-000873-40,5,2009-12-10,2009-12-11,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,Estudio de la combinación a dosis fija de comprimidos de Telmisartán 80 mg más Amlodipino 10 mg versus comprimidos sobreencapsulados de Amlodipino 10 mg o comprimidos de Telmisartán 80 mg como terapia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000873-40,0,0,0 2008-000873-40,5,2009-12-10,2009-12-11,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,Estudio de la combinación a dosis fija de comprimidos de Telmisartán 80 mg más Amlodipino 10 mg versus comprimidos sobreencapsulados de Amlodipino 10 mg o comprimidos de Telmisartán 80 mg como terapia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000873-40,0,0,0 2008-000873-40,5,2009-12-10,2009-12-11,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.",Estudio de la combinación a dosis fija de comprimidos de Telmisartán 80 mg más Amlodipino 10 mg versus comprimidos sobreencapsulados de Amlodipino 10 mg o comprimidos de Telmisartán 80 mg como terapia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000873-40,0,0,0 2008-000874-19,4,2010-05-18,2010-06-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim Esapaña, S.A.","A Phase III, eight week randomised double-blind, double-dummy, forced titration study to compare the fixed-dose combination tablet of telmisartan 80 mg plus amlodipine 10 mg versus amlodipine 10 mg ov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000874-19,0,0,0 2008-000874-19,4,2010-05-18,2010-06-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG C,"A Phase III, eight week randomised double-blind, double-dummy, forced titration study to compare the fixed-dose combination tablet of telmisartan 80 mg plus amlodipine 10 mg versus amlodipine 10 mg ov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000874-19,0,0,0 2008-000874-19,4,2010-05-18,2010-06-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A Phase III, eight week randomised double-blind, double-dummy, forced titration study to compare the fixed-dose combination tablet of telmisartan 80 mg plus amlodipine 10 mg versus amlodipine 10 mg ov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000874-19,0,0,0 2008-000874-19,4,2010-05-18,2010-06-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharmaceuticals. Inc.,"A Phase III, eight week randomised double-blind, double-dummy, forced titration study to compare the fixed-dose combination tablet of telmisartan 80 mg plus amlodipine 10 mg versus amlodipine 10 mg ov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000874-19,0,0,0 2008-000876-26,3,2009-03-09,2009-03-09,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,STEBA BIOTECH N.V.,"""VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCE""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000876-26,1,0,0 2008-000876-26,3,2009-03-09,2009-03-09,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,STEBA BIOTECH S.A.,"""VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCE""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000876-26,1,0,0 2008-000876-26,3,2009-03-09,2009-03-09,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,STEBA BIOTECH NV,"""VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCE""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000876-26,1,0,0 2008-000878-20,1,2015-08-04,2015-08-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Vejle Sygehus,Bevacizumab og Carboplatin til patienter med platinresistent epithelial ovariecancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000878-20,0,0,0 2008-000879-26,7,2010-08-05,2010-08-05,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,BAYER,"(REASON) double-blind, Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000879-26,0,0,0 2008-000879-26,7,2010-08-05,2010-08-05,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer Schering Pharma AG,"(REASON) double-blind, Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000879-26,0,0,0 2008-000880-40,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,ITALFARMACO,Paroxetine drops for the switch-therapy in patients chronic users of Benzodiazepines: an experience in Community Medicine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000880-40,0,0,0 2008-000881-22,3,2010-10-18,2010-10-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Randomized, Open-label, Study of Lopinavir/ritonavir 400/100 mg Tablet Twice-Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once-Daily Versus Lopinavir/ritonavir 400/10...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000881-22,0,0,0 2008-000885-21,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,TNO,The effect of betahistine 48 mg three times daily on motion sickness,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000885-21,0,0,0 2008-000887-18,1,2008-07-21,2008-07-21,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics GmbH & Co KG,"A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of Begrivac®, preservative free, inactivated split influenza vaccine, using the strain composition 2008/2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000887-18,0,0,0 2008-000889-22,1,2012-03-29,2012-03-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College Healthcare NHS Trust,A randomised controlled comparison of standard release Tacrolimus vs extended-release Tacrolimus as baseline maintenance monotherapy for kidney transplantation after induction with Campath 1-H.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000889-22,0,0,0 2008-000892-11,1,2014-07-25,2014-07-25,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,"Kirurginen sairaala, suu- ja leukakirurgian klinikka; Satu Yli-Petäys",Deksametasonin vaikutus postoperatiiviseen paranemiseen sekä elämänlaadun muuttuminen suusyöpäpotilaiden mikrovaskulaarisen rekonstruktioleikkauksen jälkeen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000892-11,0,0,0 2008-000893-19,1,2011-11-01,2011-11-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Whittington NHS Trust,"A randomised, double blind, placebo controlled, crossover trial of the adjuvant properties of imipramine for the overactive bladder.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000893-19,0,0,0 2008-000895-25,1,2009-11-05,2009-11-05,1,1,0,0,0,1,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics GmbH & Co. KG,"A Phase II, Open-label, multi center Study to Evaluate the Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000895-25,0,0,0 2008-000896-30,1,2012-06-21,2012-06-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Cologne,Surfactant application during spontaneous breathing with CPAP or during mechanical ventilation in the therapy of IRDS in premature infants <27 weeks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000896-30,0,0,0 2008-000901-13,3,2009-01-11,2009-06-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmaceutica S.A.,"A randomized, multi-center, double-blind, double-dummy, parallel-group, 8 week pilot study, to investigate the effect of QMF Twisthaler® (250/400 µg q.d. evening) compared to fluticasone propionate/sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000901-13,0,0,0 2008-000901-13,3,2009-01-11,2009-06-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, multi-center, double-blind, double-dummy, parallel-group, 8 week pilot study, to investigate the effect of QMF Twisthaler® (250/400 µg q.d. evening) compared to fluticasone propionate/sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000901-13,0,0,0 2008-000905-12,2,2009-11-09,2009-11-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CHIESI FARMACEUTICI S.p.A.,"A single dose, randomized, double blind, double dummy, placebo controlled, three-period crossover clinical study, comparing the onset of relief from methacholine induced bronchoconstriction with fix...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000905-12,0,0,0 2008-000905-12,2,2009-11-09,2009-11-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CHIESI,"A single dose, randomized, double blind, double dummy, placebo controlled, three-period crossover clinical study, comparing the onset of relief from methacholine induced bronchoconstriction with fix...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000905-12,0,0,0 2008-000906-35,11,2017-04-07,2017-11-10,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer AG,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000906-35,0,0,0 2008-000906-35,11,2017-04-07,2017-11-10,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer Healthcare AG,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000906-35,0,0,0 2008-000906-35,11,2017-04-07,2017-11-10,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer AG,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000906-35,0,0,0 2008-000906-35,11,2017-04-07,2017-11-10,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer Schering Pharma,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000906-35,0,0,0 2008-000906-35,11,2017-04-07,2017-11-10,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer Schering Pharma AG,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000906-35,0,0,0 2008-000907-27,3,2009-12-01,2010-02-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety and Pharmacokinetics of AZD4877 Administered Weekly in Patients with Recurrent Advanced Uroth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000907-27,0,0,0 2008-000908-91,10,2009-08-14,2009-08-17,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca AB,"A randomised, 6-week, multicentre, open-label, rater-blinded parallel group study comparing Quetiapine extended release monotherapy and augmentation with Lithium augmentation in patients with Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000908-91,0,0,0 2008-000908-91,10,2009-08-14,2009-08-17,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ASTRAZENECA,"A randomised, 6-week, multicentre, open-label, rater-blinded parallel group study comparing Quetiapine extended release monotherapy and augmentation with Lithium augmentation in patients with Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000908-91,0,0,0 2008-000912-34,2,2009-09-01,2009-09-01,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Protherics Medicines Development Ltd,A PHASE 2 STUDY OF THE ANTI-TUMOUR ACTIVITY AND SAFETY OF PROLARIX™ IN HEPATOCELLULAR CARCINOMA (HCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000912-34,0,0,0 2008-000912-34,2,2009-09-01,2009-09-01,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Protherics Development Medicines Ltd,A PHASE 2 STUDY OF THE ANTI-TUMOUR ACTIVITY AND SAFETY OF PROLARIX™ IN HEPATOCELLULAR CARCINOMA (HCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000912-34,0,0,0 2008-000913-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,NATHURA SRL,A symbiotic for the treatment of functional constipation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000913-30,0,0,0 2008-000926-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novosis AG,"An open label, parallel group, multiple dose Phase III clinical study in patients with prostate cancer to demonstrate the non-inferiority of a new Novosis Leuprorelin 3.57 mg implant versus the refere...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000926-38,0,0,0 2008-000928-71,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA,“TWIST”. RANDOMIZED PROSPECTIVE PHASE II STUDY OF TEMSIROLIMUS WITH OR WITHOUT LOW-DOSE INTERFERON ALPHA IN METASTATIC NON-CLEAR RENAL CELL CARCINOMA: GOIRC STUDY 02/2008,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000928-71,0,0,0 2008-000931-16,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Dr G I Hackett,"1054 -FINAL VERSION 30th Dec 2007 Clinical and biochemical improvement in Type 2 diabetic parameters in type 2 diabetic men with symptomatic testosterone deficiency syndrome (TDS). A double blind, p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000931-16,0,0,0 2008-000934-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",Activities of prolonged administration of vinorelbine or capecitabine oral to increase time to progression in patients with stable disease after the first line treatment with vinorelbine + xeloda. Ran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000934-35,0,0,0 2008-000936-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",DNA repair gene expression levels in NSCLC patients treated with platinum based chemotherapy: an open label randomized phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000936-42,0,0,0 2008-000938-49,1,2011-07-08,2011-07-08,1,0,0,0,1,1,2,0,0,1,0,0,1,0,1,Proteo Biotech AG,Placebo-controlled Randomized Trial to evaluate the Effect of Elafin on Cytokine Profiles after Major Surgery - Phase II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000938-49,0,0,0 2008-000939-17,1,2008-08-07,2008-08-07,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics Limited,"A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of FLUVIRIN® [Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur], Formulation 2008-2009, when Admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000939-17,0,0,0 2008-000942-29,1,2010-02-26,2010-02-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Medice Arnzneimittel Pütter GmbH & Co. KG,Quality assurance of methylphenidate administration in adults with ADHS Qualitätssicherung der Methylphendidatgabe bei Erwachsenen mit ADHS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000942-29,0,0,0 2008-000943-33,1,2008-07-23,2008-07-23,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation (Intramuscular Route)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000943-33,0,0,0 2008-000948-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Claudius Regaud,"Etude de phase II, multicentrique, en ouvert, évaluant l'efficacité d'un traitement par Sutent (sunitinib) chez des patients porteurs de métastases cérébrales d'origine rénale non traitées antérieurem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000948-13,0,0,0 2008-000952-28,4,2011-03-01,2011-03-21,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV (JCI),"An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE® in Subjects With Previously Treated Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000952-28,0,0,0 2008-000955-90,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,ISTITUTO C. MONDINO,"Randomized, single-blind, clinical and MRI study for evaluation of safety and efficacy of N-Acetyl Cysteine (NAC) associated with high-dose beta-Interferon in Relapsing-Remitting (RR) multiple sclero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000955-90,0,0,0 2008-000959-10,2,2010-08-30,2010-08-30,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Takeda Global Research & Development Centre (Europe) Limited,","A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Subjects with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000959-10,0,0,0 2008-000963-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,CELSION CORPORATION,"A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox (Thermally Sensitive Liposomal Doxorubicin) in Combination with Radiofrequency Ablation (RFA)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000963-41,0,0,0 2008-000967-40,3,2009-09-08,2009-09-08,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ActoGeniX NV.,"A Phase 2a Randomised, Placebo-Controlled, Double-Blind, Multi-Center Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects with Moderatley A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000967-40,1,0,0 2008-000967-40,3,2009-09-08,2009-09-08,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ActoGeniX N.V,"A Phase 2a Randomised, Placebo-Controlled, Double-Blind, Multi-Center Dose Escalation Study, to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011, in Subjects with Moderatley A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000967-40,1,0,0 2008-000968-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CeRePP,EFFICACY OF DULOXETINE IN THE TREATMENT OF URINARY INCONTINENCEAFTER PROSTATECTOMIE DUE TO CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000968-16,0,0,0 2008-000971-15,1,2009-08-26,2009-08-26,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Bristol,Evaluation of the effects of chronic treatment with venlafaxine (150 mg) and pregabalin (200 mg) on emotional indices of anxiety and panic induced by breathing carbon dioxide.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000971-15,0,0,0 2008-000972-25,12,2015-11-02,2018-06-18,9,1,0,0,0,1,3,0,0,2,0,0,0,0,1,AB Science,"A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase 3 study to compare efficacy and safety of ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000972-25,1,0,0 2008-000972-25,12,2015-11-02,2018-06-18,9,1,0,0,0,1,3,0,0,2,0,0,0,0,1,AB SCIENCE,"A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase 3 study to compare efficacy and safety of ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000972-25,1,0,0 2008-000972-25,12,2015-11-02,2018-06-18,9,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Ab Science,"A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase 3 study to compare efficacy and safety of ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000972-25,1,0,0 2008-000973-40,9,2018-05-30,2019-05-28,4,0,0,0,0,2,3,0,0,2,1,0,0,0,1,AB SCIENCE,"A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000973-40,1,0,0 2008-000973-40,9,2018-05-30,2019-05-28,4,0,0,0,0,2,3,0,0,2,1,0,0,0,1,AB Science,"A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000973-40,1,0,0 2008-000974-18,2,2012-03-26,2012-03-26,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AB SCIENCE,"A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, Phase III study to compare efficacy and safety of masitinib at 9 mg/kg/day in combination with gemcitabine, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000974-18,1,0,0 2008-000976-26,2,2009-02-27,2009-02-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A 4-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate The Efficacy and Safety of Saxagliptin in Comparison to Placebo as Add-on Treatment to Metformin XR in Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000976-26,0,0,0 2008-000976-26,2,2009-02-27,2009-02-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"A 4-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate The Efficacy and Safety of Saxagliptin in Comparison to Placebo as Add-on Treatment to Metformin XR in Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000976-26,0,0,0 2008-000977-39,4,2011-09-02,2011-09-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Subjects With Advanced Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000977-39,0,0,0 2008-000978-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Toulouse,Influence de la plasmaphérèse sur la pharmacocinétique du rituximab chez des patients traités pour des pathologies auto immunes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000978-20,0,0,0 2008-000982-51,6,2011-09-20,2011-11-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation",Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000982-51,0,0,0 2008-000983-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA,"Diagnostic procedure with 68Ga-labelled somatostatin analogues in tumours presumably expressing SSTR2 and/or 5 receptors, to be evaluated for treatment with the same analogues labelled with 90Y o 177L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000983-17,0,0,0 2008-000985-21,1,2013-11-22,2013-11-22,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Bayer HealthCare Pharmaceuticals Inc,"Randomized, controlled, parallel, prospective trial to evaluate the effect of secondary prophylaxis with rFVIII therapy in severe hemophilia A adult and/or adolescent subjects, as applicable, compared...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000985-21,0,0,0 2008-000986-42,3,2011-08-16,2011-08-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE DOSES OF PF-04360365 IN PATIENTS WITH MILD TO MODERATE ALZHEIMER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000986-42,0,0,0 2008-000987-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Netherlands Cancer Institute,Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000987-18,0,0,0 2008-000989-23,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,AstraZeneca AB,"A ROLLOVER PROTOCOL FOR PATIENTS WHO RECEIVED CP-675,206 IN OTHER PROTOCOLS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000989-23,0,0,0 2008-000989-23,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,PFIZER,"A ROLLOVER PROTOCOL FOR PATIENTS WHO RECEIVED CP-675,206 IN OTHER PROTOCOLS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000989-23,0,0,0 2008-000990-39,2,2008-12-12,2009-12-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"Reduction of the gingival inflammation by V0109 DI. Randomised, parallel groups, double blind study, V0109 DI versus placebo, in patients presenting gingivitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000990-39,0,0,0 2008-000991-26,2,2009-03-09,2009-03-09,2,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Dermatology, Bispebjerg Hospital","A RANDOMIZED, MULTICENTER STUDY OF DAYLIGHT MEDIATED PHOTODYNAMIC THERAPY WITH METVIX® CREAM 160 mg/g IN PATIENTS WITH MULTIPLE ACTINIC KERATOSIS ON THE FACE AND SCALP",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000991-26,0,0,0 2008-000992-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Center,Organ protection by noble gases – A clinical study to investigate Helium induced Pre- and Postconditioning in patients undergoing coronary artery bypass surgery (HIPP-CABG).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000992-12,0,0,0 2008-000994-39,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Nantes,Evaluation de l'intérêt d'un traitement par hydroquinidine pour la prise en charge des patients atteints d'un syndrome de Brugada à risque rythmique élevé et implantés d'un défibrillateur,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000994-39,0,0,0 2008-000996-57,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Centre,The effects of melatonin the occurence of on post-operative delirium in hip fracture patients – a randomized double-blind placebo controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-000996-57,0,0,0 2008-001001-41,1,2009-06-01,2009-06-01,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Protherics Medicines Development Ltd, a BTG plc company","A Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Patients With Mild to Moderate Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001001-41,0,0,0 2008-001002-16,5,2011-01-20,2011-09-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter, 24-week study followed by an extension assessing the efficacy and safety of AVE0010 in two titration regimens on top of met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001002-16,0,0,0 2008-001002-16,5,2011-01-20,2011-09-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & De'veloppement,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter, 24-week study followed by an extension assessing the efficacy and safety of AVE0010 in two titration regimens on top of met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001002-16,0,0,0 2008-001003-38,1,2008-11-17,2008-11-17,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,"The Royal Group of Hospitals, Belfast Trust",A study investigating rimonabant versus placebo in conjunction with a strict low-fat weight reduction diet in overweight and obese subjects: effects on glucose and lipid metabolism and cardiovascular ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001003-38,0,0,0 2008-001004-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre René Huguenin,A multicentre phase II trial to determine the efficacy of the anti-tyrosine kinase sunitinib (SUTENT®) as second line therapy in patients with transitional cell carcinoma (TCC) of the urothelium which...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001004-22,0,0,0 2008-001008-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"Effect of leukotriene gene polymorphisms on response to montelukast, a leukotriene receptor antagonist, in adults with asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001008-21,0,0,0 2008-001009-41,1,2018-03-27,2018-03-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College Healthcare NHS trust,mycophenylate mofetil and tacrolimus vs tacrolimus alone for the treatment of nephrotic syndrome secondary to idiopathic membranous glomerulonephritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001009-41,0,0,0 2008-001015-38,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,"LWL University Hospital Bochum, Ruhr-University Bochum","A randomized, placebo-controlled study of the central cannabinoid (CB1) receptor antagonist rimonabant as adjunctive therapy to improve cognition in schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001015-38,0,0,0 2008-001016-21,1,2012-03-01,2012-03-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH,Multizentrische Phase II Studie: Induktionschemotherapie und Chemoradiotherapie jeweils in Kombination mit Cetuximab bei Patienten mit nicht-metastasiertem Ösophaguskarzinom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001016-21,0,0,0 2008-001024-31,1,2015-04-22,2015-04-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford,A randomised controlled trial of iodide supplementation in preterm infants with follow-up at 2 years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001024-31,0,0,0 2008-001026-14,1,2012-01-23,2012-01-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Pharmaceuticals BV,An open study with OXN to evaluate the patient preference for pain treatment with respect to quality of life after WHO step I or step II analgesics for patients with moderate to severe non-malignant p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001026-14,0,0,0 2008-001026-14,1,2012-01-23,2012-01-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Comm VA,An open study with OXN to evaluate the patient preference for pain treatment with respect to quality of life after WHO step I or step II analgesics for patients with moderate to severe non-malignant p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001026-14,0,0,0 2008-001027-59,1,2010-04-02,2010-04-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Dundee,"A Randomised, Double-Blind, Double-Dummy Cross-Over Study to demonstrate Superiority of Fluticasone/ Salmeterol pMDI over double the dose of Fluticasone pMDI on Methacholine Hyper-Reactivity in Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001027-59,0,0,0 2008-001032-12,1,2013-05-15,2013-05-15,1,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Universitätsklinikum Schleswig-Holstein,"Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001032-12,0,0,0 2008-001035-35,1,2011-02-04,2011-02-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"a double blind, double dummy, randomized, multicenter, parallel group study to evaluate the Effects of aliSkiren, ramipril and combination treatment on plasma Concentration of Angiotensin II in Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001035-35,0,0,0 2008-001037-98,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,The minimum effect-site concentration of propofol that is able to prevent the responses to stimuli used to evoke cranial reflexes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001037-98,0,0,0 2008-001038-28,2,2008-07-17,2008-07-17,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Solvay Biologicals BV,"Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Season 2008/2009. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001038-28,0,0,0 2008-001043-19,3,2010-05-25,2010-05-25,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Genzyme Europe BV,"A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients 55 Years and Older with Acute Myelogenous Leukemia (AML) who have ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001043-19,0,0,0 2008-001047-19,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUad Surface Antigen, Inactivated, Adjuvanted with MF59C.1 Influenza Vaccine, Formulation 2008-2009, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001047-19,0,0,0 2008-001049-24,12,2015-03-02,2015-06-26,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"Efecto de liraglutida en el peso corporal en sujetos no diabéticos obesos o con sobrepeso y comorbilidad. Ensayo clínico aleatorizado, doble-ciego, controlado con placebo, grupos paralelos, multicéntr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001049-24,0,0,0 2008-001049-24,12,2015-03-02,2015-06-26,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Efecto de liraglutida en el peso corporal en sujetos no diabéticos obesos o con sobrepeso y comorbilidad. Ensayo clínico aleatorizado, doble-ciego, controlado con placebo, grupos paralelos, multicéntr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001049-24,0,0,0 2008-001050-40,4,2009-08-28,2009-08-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 26 week randomised, open labelled, parallel group, multi-national, treat-to-target trial comparing efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin ver...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001050-40,0,0,0 2008-001052-48,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Coombe Women and Infants University Hospital,A Comparison of the Post-operative analgesic effects of Propofol anaesthesia with Sevoflurane anaesthesia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001052-48,0,0,0 2008-001053-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INSTITUT CURIE,"Étude de phase II randomisée évaluant une irradiation pelvienne associée au Cisplatine seul ou au Cisplatine plus Cetuximab chez des patientes présentant un carcinome du col utérin de stade IB2, II et...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001053-18,0,0,0 2008-001055-21,4,2009-09-21,2009-09-21,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Lilly S.A.,A Comparison of Psychosocial Outcomes Following Tadalafil Once a Day or PDE5 Inhibitor As Needed in Men With Erectile Dysfunction.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001055-21,0,0,0 2008-001055-21,4,2009-09-21,2009-09-21,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ELI LILLY,A Comparison of Psychosocial Outcomes Following Tadalafil Once a Day or PDE5 Inhibitor As Needed in Men With Erectile Dysfunction.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001055-21,0,0,0 2008-001055-21,4,2009-09-21,2009-09-21,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,A Comparison of Psychosocial Outcomes Following Tadalafil Once a Day or PDE5 Inhibitor As Needed in Men With Erectile Dysfunction.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001055-21,0,0,0 2008-001055-21,4,2009-09-21,2009-09-21,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Lilly Deutschland GmbH,A Comparison of Psychosocial Outcomes Following Tadalafil Once a Day or PDE5 Inhibitor As Needed in Men With Erectile Dysfunction.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001055-21,0,0,0 2008-001060-36,4,2009-07-13,2009-07-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Acrux Pharma Pty Ltd,A Phase III open-label titration trial to evaluate the effectiveness and safety of different doses of a dermal application of Testosterone MD-Lotion® (cutaneous solution) in hypogonadal men,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001060-36,0,0,0 2008-001061-29,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Novo Nordisk A/S,"A randomised, double blind, placebo-controlled, multiple dose, dose-escalating, sequential dose group trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of pegylated long-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001061-29,0,0,0 2008-001062-93,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,"Perioperative treatment with COI-E (capecitabine, oxaliplatin, irinotecan and cetuximab) of liver metastasis of colorectal carcinoma potentially resectable although at high risk of recurrences",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001062-93,0,0,0 2008-001064-37,11,2011-03-21,2011-03-21,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Fournier Laboratories Ireland,Efecto del fenofibrato de colina (ABT-335/SLV348) sobre el edema macular medido por tomografía de coherencia óptica en sujetos con edema macular diabético - estudio aleatorizado y controlado con place...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001064-37,0,0,0 2008-001064-37,11,2011-03-21,2011-03-21,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Fournier Laboratories Ireland Ltd, a member of the Solvay group",Efecto del fenofibrato de colina (ABT-335/SLV348) sobre el edema macular medido por tomografía de coherencia óptica en sujetos con edema macular diabético - estudio aleatorizado y controlado con place...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001064-37,0,0,0 2008-001064-37,11,2011-03-21,2011-03-21,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Fournier Laboratories Ireland (FLI),Efecto del fenofibrato de colina (ABT-335/SLV348) sobre el edema macular medido por tomografía de coherencia óptica en sujetos con edema macular diabético - estudio aleatorizado y controlado con place...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001064-37,0,0,0 2008-001069-26,1,2013-08-31,2013-08-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Aberdeen,"Randomised controlled trial comparing foam sclerotherapy, alone or in combination with endovenous laser therapy, with conventional surgery as a treatment for varicose veins",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001069-26,0,0,0 2008-001071-30,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Medical University Vienna- Dept. of Pediatric Hemostaselology,Aspirin Resistance in Children after Interventional Cardiac Catheterization: The ARC Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001071-30,0,0,0 2008-001078-34,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Maastro Clinic,Phase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with radiotherapy and concomitant and adjuvant temozolomide,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001078-34,0,0,0 2008-001079-31,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009, when Administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001079-31,0,0,0 2008-001081-80,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Leiden University Medical Center,"Relevance of Biomarkers and Clinical Predictors of Outcome in Unselected Population with Febrile Urinary Tract Infection at Primary Care and Emergency Department in a Prospective, Randomized Cohort Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001081-80,0,0,0 2008-001084-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FNCLCC,A multicenter phase II clinical trial assessing the efficacy of the combination of lapatinib and capecitabine in patients with non pretreated brain metastasis from HER2 positive breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001084-10,0,0,0 2008-001087-36,11,2014-11-28,2014-11-28,9,1,0,0,0,1,3,0,0,1,0,0,1,0,2,Bayer Healthcare AG,"A Phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001087-36,0,0,0 2008-001087-36,11,2014-11-28,2014-11-28,9,1,0,0,0,1,3,0,0,1,0,0,1,0,2,BAYER HEALTHCARE AG,"A Phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001087-36,0,0,0 2008-001087-36,11,2014-11-28,2014-11-28,9,1,0,0,0,1,3,0,0,1,0,0,1,0,2,"Bayer Healthcare AG, D-51368 Leverkusen","A Phase III randomized, double-blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001087-36,0,0,0 2008-001089-10,4,2009-09-01,2010-11-08,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination with Metformin in Subjects with Typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001089-10,0,0,0 2008-001090-15,1,2013-12-31,2013-12-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Heidelberg,"Randomized, double-blind Phase II study of Docetaxel + Sorafenib (Nexavar®) versus Docetaxel + Placebo in First-Line treatment of patients with HER2-negative, metastatic breast cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001090-15,0,0,0 2008-001092-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital. Division of internal medi","""Effect of glimepiride on glycemic control in patients with typ 2 diabetes treated with insulin and metfromin""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001092-29,0,0,0 2008-001094-15,1,,,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""","SINGLE-BLIND, RANDOMIZED, PARALLEL GROUP, DOSE-FINDING TRIAL ON LITHIUM FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001094-15,0,0,0 2008-001095-77,1,2009-08-10,2009-08-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability and pharmacokinetics of once-daily inhaled doses of GSK573719 formula...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001095-77,0,0,0 2008-001098-13,1,2009-04-03,2009-04-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UZ Leuven,"Simultaneous administration of lorazepam and levetiracetam in non-convulsive status epilepticus, followed by IV valproate: a prospective, randomized, placebo-controled, double-blind pilot trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001098-13,0,0,0 2008-001104-23,1,2010-10-15,2010-10-15,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,CSL Behring GmbH,"A Phase II, multicentre, double-blinded, randomised, cross-over study to evaluate efficacy, safety and pharmacokinetics of Biostate® in subjects with Haemophilia A.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001104-23,0,0,0 2008-001105-42,5,2010-05-27,2010-05-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα Inhibitor ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001105-42,0,0,0 2008-001107-27,1,2015-11-20,2015-11-20,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Universität Leipzig,PHASE I-II MULTICENTER STUDY OF P210-B2A2 DERIVED PEPTIDE VACCINE IN CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITH PERSISTENT MOLECULAR RESIDUAL DISEASE DURING IMATINIB TREAT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001107-27,0,0,0 2008-001108-21,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación y desarrollo en el Área Cardiovascular,Estudio piloto comparativo del lansoprazol en formulación bucodispersable frente al omeprazol intravenoso en la evaluación del dolor torácico agudo de origen esofágico. Comparative study of oral spra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001108-21,0,0,0 2008-001122-13,2,2009-08-24,2009-08-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"Multi-center, randomized, double-blind, 5-arm parallel group, placebo controlled 4 week study to investigate the safety, tolerability and efficacy of two doses each (near to maximum tolerated dose and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001122-13,0,0,0 2008-001123-62,1,2011-10-26,2011-10-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chelsea Therapeutics Inc.,"A PHASE II, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RESPONSE, STUDY TO ASSESS THE CLINICAL BENEFIT OF DROXIDOPA AND DROXIDOPA/CARBIDOPA IN SUBJECTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001123-62,0,0,0 2008-001124-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UZ Leuven,Can the use of statin reduce the incidence of atrial flutter after major non-cardiac thoracic surgery ? A randomised double-blind study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001124-31,0,0,0 2008-001125-34,1,,,0,0,0,0,1,3,4,0,0,1,0,0,0,1,0,Arvi Yli-Hankala,Leikkauksen jälkeisen kivun voimakkuus propofoli- tai sevofluraanianestesian jälkeen.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001125-34,0,0,0 2008-001128-30,1,2011-10-19,2011-10-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,SE Dept. of Psychiatry and Psychotherapy,EFFICACY OF SERTINDOLE AS COMPARED TO OLANZAPINE OR RISPERIDONE ON PREATTENTIONAL AND ATTENTION-DEPENDENT FUNCTIONS IN PATIENTS WITH CHRONIC SCHIZOPHRENIA. A COGNITIVE AND FMRI STUDY.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001128-30,0,0,0 2008-001131-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Academic Medical Center, department of Gastroenterology and hepatology",Azathioprine maintenance treatment versus Infliximab maintenance treatment in Crohn's disease patients in remission: a randomized multicenter trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001131-35,0,0,0 2008-001135-35,4,2011-06-06,2011-06-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,The Medicines Company,Maintenance of platelet inhiBition with cangreloR after dIscontinuation of thienopyriDines in patients undergoing surGEry: The BRIDGE trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001135-35,0,0,0 2008-001136-12,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI,LONG-TERM OXYGEN THERAPY (LTOT) IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS WITH MODERATE CHRONIC HYPOXEMIA AND CHRONIC HEART FAILURE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001136-12,0,0,0 2008-001137-99,1,2019-05-30,2019-05-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Liverpool & Broadgreen University Hospitals Trust,CHANGE TO: A PILOT RANDOMISED STUDY TO COMPARE COMBINATION ANTIBIOTIC THERAPY (CIPROFLOXACIN AND DOXYCYCLINE) WITH STANDARD THERAPY (BUDESONIDE) IN THE TREATMENT OF ACTIVE CROHN'S DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001137-99,0,0,0 2008-001137-99,1,2019-05-30,2019-05-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Liverpool,CHANGE TO: A PILOT RANDOMISED STUDY TO COMPARE COMBINATION ANTIBIOTIC THERAPY (CIPROFLOXACIN AND DOXYCYCLINE) WITH STANDARD THERAPY (BUDESONIDE) IN THE TREATMENT OF ACTIVE CROHN'S DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001137-99,0,0,0 2008-001144-39,1,2011-09-07,2011-09-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Rigshospitalet,"A randomized phase II trial with bevacizumab, irinotecan and cerebral radiotherapy versus bevacizumab, temozolomide and cerebral radiotherapy as first line treatment for patients with glioblastoma mul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001144-39,0,0,0 2008-001149-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Besançon,"Fibrose hépatique sous Méthotrexate : Etude de la fréquence et facteurs associés au cours de trois affections distinctes (Psoriasis, Polyarthrite rhumatoïde et Maladie de Crohn)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001149-24,0,0,0 2008-001151-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II,ALEMTUZUMAB AND LOW-DOSE CYCLOSPORINE-A AS ALTERNATIVE IMMUNOSUPPRESSIVE TREATMENT FOR SEVERE APLASTIC ANEMIA (SAA) AND SINGLE-LINEAGE APLASTIC PATIENTS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001151-22,0,0,0 2008-001153-17,10,2010-06-20,2010-07-20,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,MSD ITALIA S.R.L.,"Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001153-17,0,0,0 2008-001153-17,10,2010-06-20,2010-07-20,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001153-17,0,0,0 2008-001153-17,10,2010-06-20,2010-07-20,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Europe) Inc.,"Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001153-17,0,0,0 2008-001153-17,10,2010-06-20,2010-07-20,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Merck & Co. Inc,"Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001153-17,0,0,0 2008-001153-17,10,2010-06-20,2010-07-20,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme de España, S.A.","Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001153-17,0,0,0 2008-001153-17,10,2010-06-20,2010-07-20,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., U.S.A.","Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001153-17,0,0,0 2008-001153-17,10,2010-06-20,2010-07-20,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,MSD,"Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001153-17,0,0,0 2008-001153-17,10,2010-06-20,2010-07-20,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Ireland (Human Health) Limited,"Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001153-17,0,0,0 2008-001153-17,10,2010-06-20,2010-07-20,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Laboratoires Merck Sharp & Dohme - Chibret,"Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001153-17,0,0,0 2008-001156-43,7,2010-03-31,2010-04-02,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 micrograms and 5 micrograms) administered once dail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001156-43,0,0,0 2008-001156-43,7,2010-03-31,2010-04-02,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 micrograms and 5 micrograms) administered once dail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001156-43,0,0,0 2008-001156-43,7,2010-03-31,2010-04-02,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim Pharmaceuticals, Inc.","A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 micrograms and 5 micrograms) administered once dail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001156-43,0,0,0 2008-001156-43,7,2010-03-31,2010-04-02,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 micrograms and 5 micrograms) administered once dail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001156-43,0,0,0 2008-001156-43,7,2010-03-31,2010-04-02,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co.KG,"A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 micrograms and 5 micrograms) administered once dail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001156-43,0,0,0 2008-001156-43,7,2010-03-31,2010-04-02,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 micrograms and 5 micrograms) administered once dail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001156-43,0,0,0 2008-001156-43,7,2010-03-31,2010-04-02,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 micrograms and 5 micrograms) administered once dail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001156-43,0,0,0 2008-001157-18,1,2009-01-06,2009-01-06,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Dermatologikum Hamburg,Proof-of-concept study: Prüfung der Wirksamkeit und der Verträglichkeit von Botulinum-Toxin (Xeomin®) bei der Behandlung von Krähenfüßen im Vergleich zu Dysport® im intraindividuellen Vergleich,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001157-18,0,0,0 2008-001158-42,1,2009-01-06,2009-01-06,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Dermatologikum Hamburg,Proof-of-concept study: Prüfung der Wirksamkeit und der Verträglichkeit von Botulinum-Toxin (Xeomin®) bei der Behandlung von Krähenfüßen im Vergleich zu Vistabel® im intraindividuellen Vergleich,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001158-42,0,0,0 2008-001159-23,9,2011-06-10,2011-07-26,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Limited,"A Randomized, Double-Blind Extension Study to Assess the Long-Term Safety and to Explore the Long-Term Efficacy of Zonisamide as Monotherapy in Newly Diagnosed Partial Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001159-23,0,0,0 2008-001160-36,1,2014-03-28,2014-03-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London,"A trial of Guanfacine, an alpha 2 adrenergic agonist, for Spatial Neglect and Impaired Vigilance following Stroke and Focal Brain Damage",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001160-36,0,0,0 2008-001168-35,12,2012-04-26,2012-04-26,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY 10017","ENSAYO ALEATORIZADO, ABIERTO, EN FASE 3 DE ERLOTINIB SOLO O EN COMBINACION CON CP-751,871 EN PACIENTES CON CANCER DE PULMON NO MICROCITICO AVANZADO DE HISTOLOGIA NO ADENOCARCINOMATOSA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001168-35,0,0,0 2008-001168-35,12,2012-04-26,2012-04-26,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"PFIZER, S.A.","ENSAYO ALEATORIZADO, ABIERTO, EN FASE 3 DE ERLOTINIB SOLO O EN COMBINACION CON CP-751,871 EN PACIENTES CON CANCER DE PULMON NO MICROCITICO AVANZADO DE HISTOLOGIA NO ADENOCARCINOMATOSA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001168-35,0,0,0 2008-001168-35,12,2012-04-26,2012-04-26,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"ENSAYO ALEATORIZADO, ABIERTO, EN FASE 3 DE ERLOTINIB SOLO O EN COMBINACION CON CP-751,871 EN PACIENTES CON CANCER DE PULMON NO MICROCITICO AVANZADO DE HISTOLOGIA NO ADENOCARCINOMATOSA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001168-35,0,0,0 2008-001168-35,12,2012-04-26,2012-04-26,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc.,"ENSAYO ALEATORIZADO, ABIERTO, EN FASE 3 DE ERLOTINIB SOLO O EN COMBINACION CON CP-751,871 EN PACIENTES CON CANCER DE PULMON NO MICROCITICO AVANZADO DE HISTOLOGIA NO ADENOCARCINOMATOSA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001168-35,0,0,0 2008-001170-32,9,2014-11-06,2014-11-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001170-32,0,0,0 2008-001170-32,9,2014-11-06,2014-11-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001170-32,0,0,0 2008-001170-32,9,2014-11-06,2014-11-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company limited,"Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001170-32,0,0,0 2008-001173-14,3,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Janssen Cilag International N.V.,",An Open-Label Evaluation of Safety of the IONSYS™ System [Fentanyl Iontophoretic Transdermal System (40 µg)] for Management of Acute Post- Operative Pain in Pediatric Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001173-14,0,0,0 2008-001174-33,5,2009-04-15,2009-04-15,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Merck Serono International S.A., A branch of Laboratoires Serono S.A.","A mulitnational, multicenter, exploratory pharmacogenomics trial to test the importance of identified genetic markers, and potentially identify new markers of various ovarian responses to GONAL-f® tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001174-33,0,0,0 2008-001174-33,5,2009-04-15,2009-04-15,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Merck Serono International, A branch of Laboratoires Serono S.A.","A mulitnational, multicenter, exploratory pharmacogenomics trial to test the importance of identified genetic markers, and potentially identify new markers of various ovarian responses to GONAL-f® tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001174-33,0,0,0 2008-001175-29,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,OSPEDALE POLICLINICO S. MATTEO,Phase II trial evaluating fotemustine (Muphoran) treatment in patients with refractory or relapsing multiple myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001175-29,0,0,0 2008-001176-67,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dr. Antonio Osuna Ortega,Biodisponibilidad de quercetina bajo distintas formas de administración y sus implicaciones sobre el efecto antihipertensivo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001176-67,0,0,0 2008-001177-15,1,2012-02-14,2012-02-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Instituto Científico y Tecnológico de Navarra,"ESTUDIO FASE II PARA EVALUAR LA EFICACIA DE CP-675,206 EN PACIENTES CON HEPATOCARCINOMA AVANZADO PHASE II STUDY TO ASSESS THE EFFICACY OF CP-675206 IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001177-15,0,0,0 2008-001179-30,1,2008-12-18,2008-12-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Orexo AB,"A double-blind, randomized, placebo-controlled, cross-over, allergen challenge study to evaluate the efficacy, safety and tolerability of BLX-028914 in subjects with allergic rhinitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001179-30,0,0,0 2008-001180-11,1,2014-02-20,2014-02-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche Pharma AG,"An Open-label, single-arm, Phase II study to evaluate the efficacy and the feasibility of bevacizumab (Avastin®) based on a FOLFOXIRI regimen until progression in patients with previously untreated me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001180-11,0,0,0 2008-001183-37,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Erasmus MC,PROSPECTIVE RANDOMIZED COMPARISON OF EMR VERSUS EMR FOLLOWED BY PHOTODYNAMIC THERAPY FOR THE TREATMENT OF EARLY BARRETT’S CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001183-37,0,0,0 2008-001184-11,1,2008-08-01,2008-08-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Biodel Inc,Effect of prandial treatment with insulin VIAjectTM compared to regular human insulin and insulin lispro on postprandial endothelial function and microvascular stress in type 2 diabetic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001184-11,0,0,0 2008-001185-91,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SENESE,"Central randomized, double-blind, crossover, multicenter clinical trial of Betametasone and placebo in children with ataxia teleangectasia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001185-91,0,0,0 2008-001191-68,1,2010-06-21,2010-06-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Institut de Terapia Regenerativa Tissular (ITRT),"“Regeneración del disco intervertebral lumbar mediante MSV*” *Células progenitoras de médula ósea autóloga, expandidas “Ex Vivo” con procedimiento GMP del Instituto de Biología y Genética Molecular d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001191-68,0,0,0 2008-001192-29,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Fundación Investigación y Desarrollo en el Area Cardiovascular,"“Evaluación mediante proteómica de biomarcadores proteicos asociados con el tratamiento con Eplerenona versus espironolactona en pacientes post-infarto agudo de miocardio, diabéticos con hipertensión ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001192-29,0,0,0 2008-001198-13,1,2009-02-19,2009-02-19,1,1,0,0,0,0,2,0,1,1,1,1,1,0,1,Bayer HealthCare AG/Bayer Schering Pharma AG,"Multicenter, open-label, randomized, uncontrolled study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gestoden...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001198-13,0,0,0 2008-001200-23,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,FONDAZIONE MONZINO CENTRO CARDIOLOGICO,A Study to Evaluate the Effectiveness of Induced Diuresis with Matched Hydration Therapy Compared to Standard Overnight Hydration in the Prevention of Contrast Induced Nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001200-23,0,0,0 2008-001201-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,POLICLINICO SAN DONATO IRCSS,Clinical trial on the use of ivabradine in patients with inappropriate sinus tachycardia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001201-42,0,0,0 2008-001204-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dra. Beatriz Sanchez Sobrino,Estudio comparativo de mupirocina versus acido fusidico tópico en la erradicación de portadores nasales de Staphylococcus aureus en pacientes con insuficiencia renal crónica en hemodiálisis por catete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001204-23,0,0,0 2008-001209-41,2,2009-01-15,2009-01-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"A multi-center, double-blind, placebo-controlled, randomized, multiple dose, 2-period cross-over, Phase IIa study to investigate the pharmacodynamics, tolerability and safety, and pharmacokinetics of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001209-41,0,0,0 2008-001210-25,1,2014-08-21,2014-08-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"National Institute of Allergy and Infectious Diseases (NIAID), NIH",Open Randomized Multi-Center Study to Evaluate Safety and Efficacy of Low Molecular Weight Sulfated Dextran in Islet Transplantation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001210-25,0,0,0 2008-001211-37,9,2011-03-01,2011-03-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A randomized, double-blind, parallel group, placebo controlled, multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and tam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001211-37,0,0,0 2008-001212-20,10,2011-12-13,2011-12-14,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"AN OPEN-LABEL, LONG TERM, MULTI-CENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF FIXED DOSE COMBINATIONS OF SOLIFENACIN SUCCINATE (6 MG AND 9 MG) WITH TAMSULOSIN HYDROCHLORIDE OCAS 0.4 MG, IN MALE SU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001212-20,0,0,0 2008-001218-26,1,2010-09-20,2010-09-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TROPHOS SA,"A double blind, placebo controlled study of the effect of 330mg QD of TRO19622 in the treatment of Chemotherapy Induced Peripheral Neuropathy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001218-26,0,0,0 2008-001219-39,1,2008-06-20,2008-06-20,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety of the Investigational Inactivated, Split-Virion Influenza Vaccine 15 µg Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001219-39,0,0,0 2008-001225-34,1,2020-10-12,2020-10-12,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Helsinki University Central Hospital,The influence of prime solution on the fluid balance after cardiac surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001225-34,0,0,0 2008-001226-14,4,2009-01-16,2009-01-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Merck & Co., Inc.","A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Dose-Finding Study of MK-3207 in the Treatment of Acute Migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001226-14,0,0,0 2008-001226-14,4,2009-01-16,2009-01-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"MERCK & CO., INC.","A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Dose-Finding Study of MK-3207 in the Treatment of Acute Migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001226-14,0,0,0 2008-001226-14,4,2009-01-16,2009-01-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Merck Sharp & Dohme (Sweden) AB,"A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Dose-Finding Study of MK-3207 in the Treatment of Acute Migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001226-14,0,0,0 2008-001226-14,4,2009-01-16,2009-01-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Merck Sharp & Dohme (Europe) Inc.,"A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Dose-Finding Study of MK-3207 in the Treatment of Acute Migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001226-14,0,0,0 2008-001231-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL UNIVERSITARIO RAMON Y CAJAL,Registro de cambios hemodinámicos retrobulbares mediante ecografía doppler color en pacientes con hipertensión ocular ( HTO ) tras tratamiento tópico con Ganfort® ( Bimatoprost / Timolol ).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001231-34,0,0,0 2008-001236-13,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,Sperimental controlled and randomized in singol blind study. Use of continuous epidural ketamina in patients submitted to toracotomy for pulmonary resection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001236-13,0,0,0 2008-001237-95,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. MARIA DI TERNI,Aprepitant in the prevention of delayed emesis induced by moderately emetogenic chemotherapy (cyclophosphamide + anthracycline) in breast cancer patients: a double-blind randomized study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001237-95,0,0,0 2008-001241-26,2,2011-04-01,2011-04-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biotest AG,"A randomized, placebo-controlled, double-blind, dose escalation study to evaluate the efficacy, safety and tolerability of the study drug BT971 in patients with rheumatoid arthritis receiving concomit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001241-26,0,0,0 2008-001242-10,4,2009-10-05,2009-10-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 28 to 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren / amlodipine / and hydrochlorothiazide in patients with essential hyperte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001242-10,0,0,0 2008-001242-10,4,2009-10-05,2009-10-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A 28 to 54-week, open-label, multicenter study to assess the long-term safety and tolerability of the combination of aliskiren / amlodipine / and hydrochlorothiazide in patients with essential hyperte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001242-10,0,0,0 2008-001243-18,5,2011-04-20,2011-04-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Services AG,"A 28 week extension to a 24 week multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of vildagliptin (50 mg qd) versus placebo in patients with type 2 diabete...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001243-18,0,0,0 2008-001243-18,5,2011-04-20,2011-04-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmaceutica,"A 28 week extension to a 24 week multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of vildagliptin (50 mg qd) versus placebo in patients with type 2 diabete...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001243-18,0,0,0 2008-001246-21,4,2010-02-10,2010-02-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, double-blind, randomized study to compare the efficacy of 24 weeks treatment with fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) versus metformin monotherapy (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001246-21,0,0,0 2008-001249-24,3,2009-10-28,2009-10-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A multi-center, double-blind, randomized, parallel group, placebo-controlled 12-week study to investigate glycemic parameters of efficacy, safety/ tolerability and pharmacokinetics of five dose levels...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001249-24,0,0,0 2008-001250-40,1,2019-11-21,2019-11-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Cancer Trials Ireland,"An open-label Phase II Study of the Efficacy and Safety of the Combination of Fludarabine, Cyclophosphamide, And Rituximab in Patients with Chronic Lymphocytic Leukaemia who are Newly Diagnosed, have ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001250-40,0,0,0 2008-001252-52,8,2018-03-05,2018-03-05,5,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, placebo controlled efficacy and safety trial of intravenous (i.v.) zoledronic acid, twice yearly compared to placebo in osteoporotic children treated with glu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001252-52,1,1,0 2008-001254-41,1,2009-08-19,2009-08-19,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A single-centre, single-blind, randomised, placebo-controlled phase IIa study to investigate the effect of AZD1305 given as an iv infusion on left ventricular performance in patients with left ventric...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001254-41,0,0,0 2008-001257-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Biomet Nederland BV,"Use of PRP to treat plantar fasciitis, blinded and randomized as a multi center study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001257-18,0,0,0 2008-001259-22,8,2010-04-23,2010-04-26,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Merck Serono S.A.,"?Ensayo clínico fase IV, prospectivo, multicéntrico, aleatorizado y abierto para evaluar la eficacia y seguridad de GONAL-f® a una dosis basada en las características iniciales de la paciente determi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001259-22,0,0,0 2008-001259-22,8,2010-04-23,2010-04-26,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Merck Serono International S.A.,"?Ensayo clínico fase IV, prospectivo, multicéntrico, aleatorizado y abierto para evaluar la eficacia y seguridad de GONAL-f® a una dosis basada en las características iniciales de la paciente determi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001259-22,0,0,0 2008-001259-22,8,2010-04-23,2010-04-26,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MERCK SERONO INTERNATIONAL SA,"?Ensayo clínico fase IV, prospectivo, multicéntrico, aleatorizado y abierto para evaluar la eficacia y seguridad de GONAL-f® a una dosis basada en las características iniciales de la paciente determi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001259-22,0,0,0 2008-001259-22,8,2010-04-23,2010-04-26,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Merck Serono S.A. Geneva,"?Ensayo clínico fase IV, prospectivo, multicéntrico, aleatorizado y abierto para evaluar la eficacia y seguridad de GONAL-f® a una dosis basada en las características iniciales de la paciente determi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001259-22,0,0,0 2008-001260-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,Terapia PEG-Interferone alfa 2B+Ribavirina versus terapia PEG-Interferone alfa 2B + Ribavirina+ Terapia ormonale sostitutiva (TOS) nella prevenzione della progressione della fibrosi epatica nell’epati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001260-36,0,0,0 2008-001262-87,4,2010-10-28,2010-12-15,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,FoldRx Pharmaceuticals Limited,An Open-Label Extension of Study Fx-005 Evaluating Long-Term Safety and Clinical Outcomes of Fx-1006A in Patients with Transthyretin Amyloid Polyneuropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001262-87,0,0,0 2008-001262-87,4,2010-10-28,2010-12-15,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"FoldRx Pharmaceuticals, Inc.",An Open-Label Extension of Study Fx-005 Evaluating Long-Term Safety and Clinical Outcomes of Fx-1006A in Patients with Transthyretin Amyloid Polyneuropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001262-87,0,0,0 2008-001264-37,1,2013-07-04,2013-07-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER ING.,A Phase II single-arm trial of BIBW 2992(Tovok) in EGFR FISH positive non-small cell lung cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001264-37,0,0,0 2008-001265-28,5,2010-11-04,2011-01-18,3,0,0,0,0,1,2,0,0,2,1,0,0,0,1,ISDIN S.A.,OFFENE (UNVERBLINDETE) VERLÄNGERUNGSTUDIE FÜR PATIENTEN AUS DER ISD002-P144-07 STUDIE MIT TOPISCH AUFGETRAGENEM P144 AUF HAUTFIBROSEN BEI PATIENTEN MIT SYSTEMISCHER SKLEROSE “Open Label Extension (OL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001265-28,1,0,0 2008-001265-28,5,2010-11-04,2011-01-18,3,0,0,0,0,1,2,0,0,2,1,0,0,0,1,ISDIN,OFFENE (UNVERBLINDETE) VERLÄNGERUNGSTUDIE FÜR PATIENTEN AUS DER ISD002-P144-07 STUDIE MIT TOPISCH AUFGETRAGENEM P144 AUF HAUTFIBROSEN BEI PATIENTEN MIT SYSTEMISCHER SKLEROSE “Open Label Extension (OL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001265-28,1,0,0 2008-001267-11,1,2012-12-18,2012-12-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Department of Nephrology,Saving residual kidney function among haemodialysis patients receiving irbesartan - a double blind randomised study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001267-11,0,0,0 2008-001281-86,3,2012-01-18,2012-01-18,1,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Janssen Biologics B.V.,"A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001281-86,0,0,0 2008-001281-86,3,2012-01-18,2012-01-18,1,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Centocor B.V.,"A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001281-86,0,0,0 2008-001282-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud University Nijmegen Medical Centre,"Influenza, pneumococcal and hepatitis B vaccination in patients with rheumatic autoimmune diseases treated with immunosuppressive therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001282-28,0,0,0 2008-001283-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,Chronic hepatitis C in illicit drug users and the role of antiviral therapy: the ARNICA project (Antiviral tReatment for chroNic hepatItis C in Active substance users),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001283-37,0,0,0 2008-001284-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ADELAIDA LAMAS FERREIRO,Estudio de la eficacia del tratamiento a largo plazo con suero salino hipertónico sobre las exacerbaciones pulmonares en pacientes con Fibrosis Quística,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001284-11,0,0,0 2008-001287-36,1,2010-06-08,2010-06-08,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Nitric BioTherapeutics, Inc",A Phase II Trial on the Reduction of Meticillin Resistant Staphylococcus Aureus in MRSA Positive Ulcers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001287-36,0,0,0 2008-001290-15,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HOVON Foundation,"Randomized maintenance therapy with Azacitidine (Vidaza) in older patients (≥ 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB, RAEB-t). A phase III...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001290-15,0,0,0 2008-001291-71,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,University of Wuerzburg,Electrophysiological correlates of putative endophenotypes of attention-deficit / hyperactivity disorder (ADHD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001291-71,0,0,0 2008-001293-32,1,,,0,0,0,0,0,3,2,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Besançon,Etude de l'échographie de contraste avec SonoVue chez les malades opérés d'une maladie de Crohn iléale: CROHN - SONOVUE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001293-32,0,0,0 2008-001298-13,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY10017","A RANDOMIZED PHASE 2, OPEN-LABEL STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL AND DOCETAXEL ALONE AS A FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001298-13,0,0,0 2008-001298-13,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,PFIZER,"A RANDOMIZED PHASE 2, OPEN-LABEL STUDY OF CP-751,871 IN COMBINATION WITH DOCETAXEL AND DOCETAXEL ALONE AS A FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001298-13,0,0,0 2008-001301-42,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"An open Phase II study to assess the clinical activity and safety of recMAGE-A3 + AS15 cancer immunotherapeutic in patients with metastatic cutaneous melanoma, and to explore its immunogenic propertie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001301-42,0,0,0 2008-001302-16,1,2010-07-01,2010-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical Faculty, Otto-von-Guericke University",Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of an esomeprazole therapy in patients with GERD -- a pilot study (phase IV-study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001302-16,0,0,0 2008-001303-34,1,2009-01-28,2009-01-28,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase I/II, randomized, single blind, controlled study in adults aged 18-60 years to evaluate the immunogenicity, safety and reactogenicity of an adjuvanted influenza vaccine candidate (GSK 2115160A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001303-34,0,0,0 2008-001305-42,6,2009-04-16,2009-04-16,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An eight-week double-blind, multi-center, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren 75mg, 150mg and 300mg in elderly patients with essent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001305-42,0,0,0 2008-001305-42,6,2009-04-16,2009-04-16,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An eight-week double-blind, multi-center, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren 75mg, 150mg and 300mg in elderly patients with essent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001305-42,0,0,0 2008-001306-16,10,2011-07-05,2011-07-07,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 2 year extension to a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001306-16,0,0,0 2008-001306-16,10,2011-07-05,2011-07-07,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 2 year extension to a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001306-16,0,0,0 2008-001306-16,10,2011-07-05,2011-07-07,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,"A 2 year extension to a 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001306-16,0,0,0 2008-001307-33,9,2012-08-20,2012-11-28,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GlaxoSmithkline Research & Development Ltd,A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001307-33,0,0,0 2008-001307-33,9,2012-08-20,2012-11-28,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001307-33,0,0,0 2008-001307-33,9,2012-08-20,2012-11-28,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.",A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001307-33,0,0,0 2008-001308-22,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Academic Medical Centre,Aspirin sensitivity in diabetes mellitus; the role of glycaemic control and dosing,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001308-22,0,0,0 2008-001309-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Linköping university,Pharmacogenetic of propofol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001309-40,0,0,0 2008-001310-24,1,2008-07-30,2008-07-30,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase III, open, non-randomized, multi-centric, single dose study to assess immunogenicity and safety of Fluarix™ / Influsplit SSW® 2008/2009 injected intramuscularly in young adults (18 to 60 years...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001310-24,0,0,0 2008-001314-24,4,2010-08-06,2010-11-30,4,1,0,0,0,2,2,0,0,1,1,0,1,0,1,BIOGEN IDEC LTD,"A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001314-24,0,0,0 2008-001314-24,4,2010-08-06,2010-11-30,4,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Biogen Idec Ltd,"A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001314-24,0,0,0 2008-001319-39,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,PROtection of coronary Microcirculation by Iloprost: Safety and Efficacy in Percutaneous Coronary Intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001319-39,0,0,0 2008-001323-64,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,PHASE III DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY ON THE EFFICACY OF URSODEOXYCHOLIC ACID FOR THE TREATMENT OF INTRAHEPATIC CHOLESTASIS OF PREGNANCY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001323-64,0,0,0 2008-001324-31,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Efficacy and security of oral supplementation with a probiotic (Lactobacillus reuteri) in newborns with birth weight < 1500 g: effects on necrotising enterocolitis (NEC) and gut colonization with gram...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001324-31,0,0,0 2008-001325-34,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,PROMISE AMI (PROtection of coronary Microcirculation by Iloprost: Safety and Efficacy evaluation in Acute Myocardial Infarction treated by primary PCI) Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001325-34,0,0,0 2008-001329-33,3,2010-10-18,2021-10-29,2,0,0,0,0,1,3,0,0,2,0,0,0,0,1,AbbVie Inc,Open-Label Continuation Treatment Study With Levodopa – Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Positiv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001329-33,1,0,0 2008-001335-36,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,HOSPICES CIVILS DE LYON,"Evaluation de la fonction rénale après introduction de l’évérolimus chez le transplanté cardiaque présentant une insuffisance rénale chronique : étude multicentrique, randomisée en ouvert",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001335-36,0,0,0 2008-001336-13,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Effet de la Nicotine transdermique sur les symptomes moteurs de la maladie de Parkinson avancée (une administration quotidienne) .Etude contrôlée, randomisée, en deux groupes parallèles et en simple i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001336-13,0,0,0 2008-001339-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. MARIA DI TERNI,Aprepitant in the prevention of cisplatin-induced delayed emesis: a double-blind randomized study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001339-37,0,0,0 2008-001340-39,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA,"Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001340-39,0,0,0 2008-001342-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Effectiveness on the clinical outcome of an oral enterovaccine (Colifagina) and evaluation of the role of the Astrovirus in the aetiology of the pathology of acute gastroenteritis in children.”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001342-13,0,0,0 2008-001346-92,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,No sponsor,Medical treatment with nitroglycerin for management of retained placenta - a multicentre trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001346-92,0,0,0 2008-001352-51,2,2010-04-02,2010-04-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Portola Pharmaceuticals Inc.,"A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, a Selective and Reversible P2Y12-Receptor Inhibitor, vs. Clopidogrel, as a Novel Antiplatelet Therapy in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001352-51,0,0,0 2008-001353-17,3,2008-11-07,2008-11-07,2,0,0,1,0,1,1,0,0,1,1,0,0,0,1,Santaris Pharma A/S,"A PHASE I/II, OPEN LABEL STUDY OF SPC2996 IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED FOLLICULAR OR LYMPHOPLASMACYTIC NON-HODGKIN’S LYMPHOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001353-17,0,0,0 2008-001354-41,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,"Cliniques Universitaires St Luc, Centre du Cancer",Neoadjuvant cetuximab monotherapy followed by surgery in squamous cell carcinoma of head and neck: phase I/II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001354-41,0,0,0 2008-001355-21,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY,"First Line UFT, OXALIPLATIN and ERBITUX combination (TEGAFOX-E) in Elderly (≥ 70 years) metastatic colorectal patients: a Phase II ITMO study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001355-21,0,0,0 2008-001361-29,3,2011-07-07,2011-07-07,2,0,0,0,0,0,2,0,0,1,1,0,1,0,0,EBMT (European group for Blood and Marrow Transplantation),Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001361-29,0,0,0 2008-001367-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIDAD HEPATICA. CIBERehd. HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE,"Estudio piloto, en fase IV para evaluar la influencia de la asociación de descontaminación intestinal selectiva (DIS) con norfloxacino a antibioterapia estándar sobre la traslocación bacteriana y la ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001367-11,0,0,0 2008-001368-35,1,,,0,0,0,0,0,3,4,0,0,1,0,0,0,1,0,Oulu University Hospital,Efficacy and Safety of Targeting Lower Arterial Oxygen Saturations to Reduce Oxygen Toxicity and Oxidative Stress in Very Preterm Infants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001368-35,0,0,0 2008-001369-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE,PHASE II STUDY OF LIPOSOME-ENCAPSULATED DOXORUBICIN PLUS PACLITAXEL AND TRASTUZUMAB AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY-ADVANCED BREAST CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001369-27,0,0,0 2008-001371-30,1,2011-03-02,2011-03-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Münster,Anxiolytic effects of single-dose quetiapine XR administration on clinical symptoms and amygdala activation during exposure in patients with simple phobia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001371-30,0,0,0 2008-001372-75,1,2010-08-06,2010-08-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Chorus, a Division of Eli Lilly and Company","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2245461 after Multiple Oral Administrations in Healthy Postmenopausal Women",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001372-75,0,0,0 2008-001376-73,1,2009-04-14,2009-04-14,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Innocoll Technologies,"A Randomized, Controlled, Open-Label Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge (Collatamp® G) in Combination With Antimicrobial Therapy Compared to Antimicro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001376-73,0,0,0 2008-001382-28,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Incyte Corporation,"A Phase 2, open label, dose regimen ranging clinical study to determine the safety and efficacy of INCB018424 in patients with advanced polycythemia vera or essential thrombocythemia refractory to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001382-28,0,0,0 2008-001384-11,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,3,,Catheter Ablation compared with Pharmacological Therapy for Atrial Fibrillation – the CAPTAF trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001384-11,0,0,0 2008-001394-15,1,2012-04-04,2012-04-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cardiff University,A multi-centre randomised phase II study of induction chemotherapy followed by gemcitabine or capecitabine based chemoradiotherapy (CRT) for locally advanced non-metastatic pancreatic cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001394-15,0,0,0 2008-001395-74,2,2009-04-30,2009-04-30,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Merrion Pharmaceuticals plc,"A multi-center Phase II study to compare MER-101 20mg tablets to intravenous Zometa® 4mg in male bisphosphonate-naïve, hormone-refractory prostate cancer patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001395-74,0,0,0 2008-001396-30,1,2009-03-02,2009-03-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Ltd, Ramsgate Road, Sandwich, Kent, UK","A PHASE 2A, DOUBLE BLIND (3RD PARTY OPEN), 4 WAY CROSS-OVER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, TOLERATION AND EFFICACY OF SINGLE INHALED DOSES OF PF-00610355 IN MOD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001396-30,0,0,0 2008-001397-32,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ASL 5 di PISA-ZONA VALDERA,"ARIPIPRAZOLE VERSUS ROPIRINOLE: A PILOT , OPEN-LABEL, PROSPECTIVE, RANDOMISED, CONTROLLED, MULTICENTRIC TRIAL, IN THERAPY WITH ROPIRINOLE OR ARIPIPRAZOLE FOR COCAINE DEPENDENCE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001397-32,0,0,0 2008-001401-42,1,2009-01-01,2009-01-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Medizinische Universität Wien, Univ. KlM III, Klinische Abt. f. Gastroenterologie/Hepatologie",Combination of Erlotonib plus Sorafenib in Patients with unresectable Hepatocellular Carcinoma; a randomized placebo controlled Phase II pilot trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001401-42,0,0,0 2008-001405-41,1,2013-02-28,2013-02-28,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,GMIHO mbH,A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001405-41,0,0,0 2008-001409-40,3,2010-08-16,2010-08-16,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Solvay Pharmaceuticals B.V.,"A Randomized, Double blind, Placebo-Controlled Dose Escalation Study to Investigate the Safety and Pharmacokinetics after Single and Multiple Doses of SLV334 in Sequential Cohorts of Patients with Mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001409-40,0,0,0 2008-001413-14,4,2011-07-22,2011-07-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 wee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001413-14,0,0,0 2008-001413-14,4,2011-07-22,2011-07-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 wee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001413-14,0,0,0 2008-001413-14,4,2011-07-22,2011-07-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 wee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001413-14,0,0,0 2008-001413-14,4,2011-07-22,2011-07-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat ® inhaler (5 μg/day) over 48 wee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001413-14,0,0,0 2008-001414-25,4,2011-07-22,2011-07-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat inhaler (5 mcg/day) over 48 week...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001414-25,0,0,0 2008-001414-25,4,2011-07-22,2011-07-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat inhaler (5 mcg/day) over 48 week...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001414-25,0,0,0 2008-001414-25,4,2011-07-22,2011-07-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat inhaler (5 mcg/day) over 48 week...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001414-25,0,0,0 2008-001414-25,4,2011-07-22,2011-07-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat inhaler (5 mcg/day) over 48 week...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001414-25,0,0,0 2008-001416-20,1,2009-11-11,2009-11-11,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,ITALFARMACO,Phase II High Pulse Dose Clinical Trial of Orally Administered ITF 2357 In Patients with Relapsed/Refractory Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001416-20,0,0,0 2008-001417-26,1,2011-11-22,2011-11-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Steigerwald Arzneimittelwerk GmbH,"Double blind, randomized, placebo-controlled, mulitcentric clinical trial to evaluate the relapse prevention of a hypericum extract in outdoor patients with moderate depressive episodes (major depress...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001417-26,0,0,0 2008-001421-34,2,2014-01-24,2014-05-29,2,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Universität zu Köln,"Phase II Trial of Combined Immunochemotherapy with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients with Previously Treated or Untreated T-Prolymphocytic Leuke...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001421-34,0,0,0 2008-001421-34,2,2014-01-24,2014-05-29,2,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"University of Cologne, Sponsor-Quality Management","Phase II Trial of Combined Immunochemotherapy with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients with Previously Treated or Untreated T-Prolymphocytic Leuke...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001421-34,0,0,0 2008-001422-14,1,2008-11-14,2008-11-14,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,CSL Limited,"A Single Centre, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira® vaccine in Healthy ‘Adults’ aged ≥ 18 to < 60 years and in Healthy ‘Older Adults’ aged ≥ 60 years for the 2008/20...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001422-14,0,0,0 2008-001426-14,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PROVINCIALE DI LECCO,a probiotic for the prevention of diarrhoea associated with antibiotics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001426-14,0,0,0 2008-001429-32,1,,,0,1,1,0,0,1,3,0,0,4,0,0,0,0,1,Novartis Pharma Services AG,"A multi-center, open label, 24-month treatment study to establish the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of canakinumab (anti-IL-1 beta antibody) in patients with NO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001429-32,0,1,1 2008-001430-27,1,2012-01-16,2012-01-16,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH,Fludarabine/Rituximab combined with escalating doses of Lenalidomide followed by Rituximab/Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with concomitant evaluati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001430-27,0,0,0 2008-001432-13,9,2011-10-12,2012-11-15,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merz Pharmaceuticals GmbH,"An Open-Label, Long-Term Treatment Study to assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001432-13,0,0,0 2008-001433-98,9,2017-03-20,2018-03-20,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,UCB Inc,"An open-label, multinational, multicenter, follow-up study to evaluate the long-term safety and efficacy of brivaracetam, used at a flexible dose up to a maximum of 150 mg/day, in subjects aged 16 yea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001433-98,0,0,0 2008-001433-98,9,2017-03-20,2018-03-20,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"UCB BioSciences, Inc","An open-label, multinational, multicenter, follow-up study to evaluate the long-term safety and efficacy of brivaracetam, used at a flexible dose up to a maximum of 150 mg/day, in subjects aged 16 yea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001433-98,0,0,0 2008-001436-12,4,2011-07-04,2011-07-04,1,0,0,0,0,2,2,0,0,2,0,0,0,0,0,FUNDACION PARA LA INVESTIGACION LA FE,"Estudio Fase II no aleatorizado de tratamiento con Temozolamida combinada con Topotecan para neuroblastoma y otros tumores sólidos pediátricos en situación de recaída o progresión. ""Phase 2 single-arm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001436-12,1,0,0 2008-001436-12,4,2011-07-04,2011-07-04,1,0,0,0,0,2,2,0,0,2,0,0,0,0,0,Institut Gustave Roussy,"Estudio Fase II no aleatorizado de tratamiento con Temozolamida combinada con Topotecan para neuroblastoma y otros tumores sólidos pediátricos en situación de recaída o progresión. ""Phase 2 single-arm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001436-12,1,0,0 2008-001438-29,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,NGF for visual blindness in patient affected by glioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001438-29,0,0,0 2008-001440-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Asociación de Investigación Hepatológica y Transplante Hepático Infantil,Estudio clinico intrapaciente de biodisponibilidad relativa de dos formulaciones de tacrolimus: Prograf (comprimidos de liberación normal) y Advagraf (comprimidos de liberación sostenida) en adolescen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001440-39,0,0,0 2008-001441-26,5,2009-03-12,2010-01-15,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A randomised, double-blind, parallel-group, fixed dose study exploring the efficacy and safety of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001441-26,0,0,0 2008-001443-19,4,2009-07-31,2020-07-31,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"Multicenter, randomized, double-blind, placebo-controlled, Phase IIa study to evaluate the efficacy, safety, and tolerability of ACT-128800, an S1P1 receptor agonist, administered for 6 weeks to subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001443-19,0,0,0 2008-001445-26,1,,,0,1,0,0,0,0,3,0,1,1,1,1,0,1,1,GlaxoSmithKline Biologicals,"A phase III, randomized, observer blind, multi-centre study to evaluate the immunogenicity, safety and reactogenicity of study vaccine GSK1557482A (FluLaval thiomersal-free), Fluarix and FluLaval thio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001445-26,0,0,0 2008-001447-19,1,2020-05-01,2020-05-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Leiden University Medical Center,Prophylactic infusion of CD4 positive donor lymphocytes early after T-cell depleted stem cell transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001447-19,0,0,0 2008-001449-25,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,SORIA NATURAL S.A.,EVALUACIÓN CLÍNICA DEL LEPISOR EN EL TRATAMIENTO DE LA HIPERPLASIA PROSTÁTICA BENIGNA LEVE Y MODERADA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001449-25,0,0,0 2008-001451-21,11,2009-02-25,2016-02-25,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc.,235 East 42nd Street,New York,NY 10017",AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001451-21,0,0,0 2008-001451-21,11,2009-02-25,2016-02-25,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer, S.A.",AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001451-21,0,0,0 2008-001451-21,11,2009-02-25,2016-02-25,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER INC.,AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001451-21,0,0,0 2008-001451-21,11,2009-02-25,2016-02-25,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc.,235 East 42nd Street,New York,NY 10017 US",AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001451-21,0,0,0 2008-001454-40,1,2009-11-16,2009-11-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,"A multi-step trial towards single donor islet transplantation in type I diabetic patients,using calcineurin inhibotor-free immunosuppression.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001454-40,0,0,0 2008-001457-18,1,,,0,1,0,0,1,0,2,0,1,1,1,1,0,1,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"Single-blind, Randomized, Phase 1/2 Trial of the Safety, Tolerability, and Immunogenicity of Meningococcal Group B rLP2086 Vaccine in Healthy Infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001457-18,0,0,0 2008-001459-23,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Nikolai Sleep Monitoring Clinic,Treatment of Testosterone deficiency in men with Sleep Apnoea Syndrome utilising Nebido therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001459-23,0,0,0 2008-001462-81,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,0,OSPEDALE POLICLINICO S. MATTEO,Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001462-81,0,0,0 2008-001464-36,8,2009-01-26,2015-02-09,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Science Incorporated,"A Phase 3b, Randomized, Double-Blind, Double-Dummy Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001464-36,0,0,0 2008-001464-36,8,2009-01-26,2015-02-09,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Incorporated,"A Phase 3b, Randomized, Double-Blind, Double-Dummy Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001464-36,0,0,0 2008-001464-36,8,2009-01-26,2015-02-09,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Inc,"A Phase 3b, Randomized, Double-Blind, Double-Dummy Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001464-36,0,0,0 2008-001466-93,1,2010-05-01,2010-05-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Imperial College London,Trial of adjuvant vitamin D with Infliximab in active Crohn's Disease (IBDVit2).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001466-93,0,0,0 2008-001467-10,1,2010-05-01,2010-05-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Imperial College London,Trial of Adjuvant Vitamin D with Standard Maintenance Therapy in Preventing Relapse of Inflammatory Bowel Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001467-10,0,0,0 2008-001468-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),Phase III clinical trial multicenter randomized for the evaluation of the safety and efficacy of the combined treatment of intravitreal triamcinolone and photodynamic therapy versus intravitreal Bevac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001468-34,0,0,0 2008-001469-28,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Dep. of Ophthalmology, Medical University of Vienna","A randomized, double-masked study with intraocular Bevacizumab (Avastin®) compared with intravitreal Ranibizumab (Lucentis®) in patients with persistent diabetic macular edema or persistent active neo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001469-28,0,0,0 2008-001472-69,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Luis F. Lopez-Cortes,Concentraciones intracelulares de Ribavirina trifosfato en pacientes coinfectados por el VHC/VIH. Influencia de Abacavir en la fosforilización intracelular de Ribavirina.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001472-69,0,0,0 2008-001486-28,4,2009-03-13,2009-03-13,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Avexa Limited,"A phase 3, open-label 96-week extension study of the safety of apricitabine in treatment-experienced HIV-1 infected patients who have completed protocol AVX-301 or AVX-302 or who have met the criteria...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001486-28,1,0,0 2008-001487-37,4,2011-04-08,2011-04-08,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Allergan UK Limited,"A Multicenter, Masked, Randomized, Sham-controlled, Paired-eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Brimo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001487-37,0,0,0 2008-001487-37,4,2011-04-08,2011-04-08,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Allergan Limited,"A Multicenter, Masked, Randomized, Sham-controlled, Paired-eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Brimo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001487-37,0,0,0 2008-001491-77,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Prof. Ola Winsö, Anesthesia and Intensive Care Medicine, Norrlands University Hospiatal",Randomized study comparing spinal anealgesia compared with epidural analgesia durinmg and postoperative nephrectomy dua to renal cell carcinoma Randomiserad studie av spinalbedövning jämfört med t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001491-77,0,0,0 2008-001492-30,4,2009-01-30,2009-01-30,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,"Comparación de la seguridad y eficacia de volinanserina y lormetazepam en el tratamiento del insomnio caracterizado por la dificultad para mantener el sueño. Estudio comparativo, aleatorizado, doble c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001492-30,0,0,0 2008-001493-32,1,2008-12-31,2008-12-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ISTITUTO PER L'INFANZIA BURLO GAROFOLO,Comparison between two different sedation strategies (propofol versus propofol plus ketamine) in deep sedation managed by non anesthesiologists.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001493-32,0,0,0 2008-001494-15,1,2008-12-04,2008-12-04,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Bayer Schering Pharma,"Phase I/II Study of Sagopilone in combination with carboplatin and bevacizumab in the first-line treatment of patients with stage IIIB/IV, non-squamous NSCLC.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001494-15,0,0,0 2008-001495-69,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Hospitalier Régional et Universitaire de Lille,"Réversibilité sous Tiotropium (SPIRIVA®) chez les patients BPCO : paramètres EFR, dyspnée et TDM",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001495-69,0,0,0 2008-001497-33,6,2009-07-30,2009-12-10,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","PHASE 4, PROSPECTIVE, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SMOKING CESSATION WITH VARENICLINE TARTRATE COMPARED WITH PLACEBO IN THE SETTING OF PATIENT SELF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001497-33,0,0,0 2008-001497-33,6,2009-07-30,2009-12-10,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,PFIZER,"PHASE 4, PROSPECTIVE, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SMOKING CESSATION WITH VARENICLINE TARTRATE COMPARED WITH PLACEBO IN THE SETTING OF PATIENT SELF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001497-33,0,0,0 2008-001499-55,1,2009-12-31,2009-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Turku PET Centre,Treatment Monitoring of Advanced Colorectal cancer with 18F-FDG PET/CT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001499-55,0,0,0 2008-001501-42,1,2014-08-04,2014-08-04,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,Jukka Sairanen,Tacrolimus in the treatment of Painful Bladder Syndrome / Interstitial Cystitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001501-42,0,0,0 2008-001502-17,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA MEYER,"MULTICENTRIC COMPARATIVE RANDOMIZED DOUBLE BLIND CROSS OVER STUDY WITH TACROLIMUS (FK506)0.1% EYEDROPS AND CYCLOSPORINE 1% EYEDROPS IN CHILDREN WITH SEVERE ACTIVE VERNAL KERATOCONJUNCTIVITIS, LASTING ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001502-17,0,0,0 2008-001503-26,3,2009-10-31,2009-10-31,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Vifor Pharma - Vifor (International) AG,EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac function in patients with iron deficiencY and chronic Heart Failure (EFFICACY-HF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001503-26,0,0,0 2008-001506-16,1,2017-12-20,2017-12-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Institut Bergonié,Diffuse large B cell non-hodgkin's lymphoma in the vulnerable/frail elderly. A multicentrix randomized phase II trial with emphasis on geritaric assesment and quality of life.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001506-16,0,0,0 2008-001507-39,6,2013-05-20,2013-06-20,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A single-arm, international, multi-center trial investigating the efficacy and safety of ofatumumab retreatment and maintenance treatment in patients with B-cell chronic lymphocytic leukemia who progr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001507-39,0,0,0 2008-001507-39,6,2013-05-20,2013-06-20,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A single-arm, international, multi-center trial investigating the efficacy and safety of ofatumumab retreatment and maintenance treatment in patients with B-cell chronic lymphocytic leukemia who progr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001507-39,0,0,0 2008-001509-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hungarian Kidney Foundation,Effects of beta blockers on central arterial pressure and vascular stiffness,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001509-40,0,0,0 2008-001515-37,1,2010-07-12,2010-07-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,CESAR Central European Society for Anticancer Drug Research,"A prospective angiogenic imaging study with DCE-MRI and DCE-USI in patients with colorectal cancer and liver metastases receiving sunitinib in addition to 5-FU, folinic acid and irinotecan (FOLFIRI) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001515-37,0,0,0 2008-001516-20,1,2008-12-17,2008-12-17,1,1,0,0,0,3,4,0,1,1,0,0,1,0,1,Institut of Public Health,Paroxetins effekt på tramadols metabolisme og farmakodynamik: et dosis respons studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001516-20,0,0,0 2008-001518-26,3,2009-09-10,2009-09-10,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,"Efficacy and safety of oral ataciguat (HMR1766) 200 mg administered once daily for 28 days on pain reduction in patients with Neuropathic Pain. A randomized, double-blind, placebo-controlled, cross-ov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001518-26,0,0,0 2008-001519-39,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Biologiske Stasjon Drøbak,Efficiency of a jellyfish sting inhibitor sun lotion and protocols for jellyfish sting pain relief,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001519-39,0,0,0 2008-001523-57,8,2011-10-28,2011-10-28,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,Estudio abierto y multicéntrico de evaluación de la respuesta temprana a abatacept con metotrexato de fondo mediante ecografía Power-Doppler en pacientes con artritis reumatoide activa y respuesta ins...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001523-57,0,0,0 2008-001523-57,8,2011-10-28,2011-10-28,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,Estudio abierto y multicéntrico de evaluación de la respuesta temprana a abatacept con metotrexato de fondo mediante ecografía Power-Doppler en pacientes con artritis reumatoide activa y respuesta ins...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001523-57,0,0,0 2008-001524-31,2,2010-07-14,2010-07-14,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, double-dummy, randomized, crossover, multicentre phase IV clinical study comparing the effect of Ursofalk® 500 mg tablets od versus Ursofalk® 250 mg capsules od on liver enzyme parameter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001524-31,0,0,0 2008-001525-34,1,2009-07-31,2009-07-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Derby Hospitals NHS Foundation Trust,THE ANALGESIC EFFICACY OF ULTRASOUND GUIDED TRANSVERSUS ABDOMINIS PLANE (TAP) BLOCK IN PATIENTS UNDERGOING OPEN APPENDICECTOMY: A PILOT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001525-34,0,0,0 2008-001526-13,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Efficacy of Gaviscon in the treatment of gastroesophageal reflux in preterm newborns,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001526-13,0,0,0 2008-001530-27,4,2009-08-04,2009-08-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28 Day Oral Administration of AZD9668 in Patients with Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001530-27,0,0,0 2008-001535-35,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Eli Lilly and Company,"A Phase 1b/2 Study of Gemcitabine-Cisplatin, With or Without LY2275796 Sodium, in Patients with Advanced Stage IIIB or IV Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001535-35,0,0,0 2008-001537-10,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST,A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001537-10,0,0,0 2008-001542-57,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Manuel García Medina,EFECTIVIDAD DE LA SUPLEMENTACIÓN ANTIOXIDANTE PARA PREVENIR LA PROGRESIÓN CLÍNICA EN EL GLAUCOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001542-57,0,0,0 2008-001546-67,2,2012-06-19,2012-06-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,A Phase II single-arm trial of BIBW 2992 in demographically and genotypically selected non-small cell lung cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001546-67,0,0,0 2008-001546-67,2,2012-06-19,2012-06-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim España S.A.,A Phase II single-arm trial of BIBW 2992 in demographically and genotypically selected non-small cell lung cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001546-67,0,0,0 2008-001550-41,11,2009-04-29,2009-06-17,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-Aventis Recherche & Développement,"A multicenter, double-blind, randomized, 12-month, placebo-controlled study to evaluate the lipid-lowering effect, safety and tolerability of AVE5530 25 mg/day and 50mg/day when added to ongoing stabl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001550-41,0,0,0 2008-001551-22,5,2014-11-07,2014-11-07,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cancer International Research Group,"A randomized, double-blind, placebo controlled, multicenter, phase II study of adding AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) to first li...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001551-22,0,0,0 2008-001551-22,5,2014-11-07,2014-11-07,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Translational Research in Oncology,"A randomized, double-blind, placebo controlled, multicenter, phase II study of adding AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) to first li...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001551-22,0,0,0 2008-001552-44,4,2012-12-04,2013-05-23,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Cancer International research Group,"A MULTICENTER OPEN LABEL PHASE II STUDY OF THE EFFICACY AND SAFETY OF AMG 479, A FULLY HUMAN MONOCLONAL ANTIBODY AGAINST INSULIN-LIKE GROWTH FACTOR TYPE 1 RECEPTOR (IGF-1R) AS SECOND LINE THERAPY IN P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001552-44,0,0,0 2008-001557-17,10,2011-04-26,2011-04-26,7,0,0,0,0,1,4,0,0,2,0,0,0,0,1,Fresenius Biotech GmbH,"Two-arm, randomized, open-label, phase IIIb study investigating the safety of a 3 hour i.p. infusion of catumaxomab with and without prednisolone premedication in patients with malignant ascites due t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001557-17,1,0,0 2008-001557-17,10,2011-04-26,2011-04-26,7,0,0,0,0,1,4,0,0,2,0,0,0,0,1,FRESENIUS BIOTECH GMBH,"Two-arm, randomized, open-label, phase IIIb study investigating the safety of a 3 hour i.p. infusion of catumaxomab with and without prednisolone premedication in patients with malignant ascites due t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001557-17,1,0,0 2008-001560-37,1,2012-07-30,2012-07-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Fakultät der TU-München, vertreten durch den Dekan",Sequentielle Kombination einer Chemotherapie mit Gemcitabine/Oxaliplatin und photodynamischen Therapie beim fortgeschrittenen Gallengangskarzinom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001560-37,0,0,0 2008-001561-28,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Klinik für Anästhesiologie und Operative Intensivmedizin Klinikum Ludwigshafen,Influence of perioperative HES 130/04 adminstration on postoperative complications: A prospective randomized trial in patients undergoing colorectal surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001561-28,0,0,0 2008-001563-11,2,2012-09-18,2012-09-18,2,1,1,0,0,0,2,1,0,1,0,0,1,0,1,Octapharma AG,"Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of human-cl rhFVIII, a Newly Developed Human Cell-Line Derived Recombinant FVIII Concentrate in Previously Treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001563-11,0,0,0 2008-001566-90,14,2010-05-13,2010-10-06,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent","A 6 MONTH, PROSPECTIVE, OPEN-LABEL MULTIPLE CENTER EXTENSION TRIAL TO EVALUATE THE LONG TERM SAFETY AND SUSTAINED EFFICACY OF FRAGMIN IN THE TREATMENT OF CHRONIC FOOT ULCERS IN DIABETIC PATIENTS WI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001566-90,0,0,0 2008-001566-90,14,2010-05-13,2010-10-06,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, new York, NY 10017","A 6 MONTH, PROSPECTIVE, OPEN-LABEL MULTIPLE CENTER EXTENSION TRIAL TO EVALUATE THE LONG TERM SAFETY AND SUSTAINED EFFICACY OF FRAGMIN IN THE TREATMENT OF CHRONIC FOOT ULCERS IN DIABETIC PATIENTS WI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001566-90,0,0,0 2008-001566-90,14,2010-05-13,2010-10-06,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent ,CT13 9NJ,UK","A 6 MONTH, PROSPECTIVE, OPEN-LABEL MULTIPLE CENTER EXTENSION TRIAL TO EVALUATE THE LONG TERM SAFETY AND SUSTAINED EFFICACY OF FRAGMIN IN THE TREATMENT OF CHRONIC FOOT ULCERS IN DIABETIC PATIENTS WI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001566-90,0,0,0 2008-001566-90,14,2010-05-13,2010-10-06,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"A 6 MONTH, PROSPECTIVE, OPEN-LABEL MULTIPLE CENTER EXTENSION TRIAL TO EVALUATE THE LONG TERM SAFETY AND SUSTAINED EFFICACY OF FRAGMIN IN THE TREATMENT OF CHRONIC FOOT ULCERS IN DIABETIC PATIENTS WI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001566-90,0,0,0 2008-001566-90,14,2010-05-13,2010-10-06,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer, S.A.","A 6 MONTH, PROSPECTIVE, OPEN-LABEL MULTIPLE CENTER EXTENSION TRIAL TO EVALUATE THE LONG TERM SAFETY AND SUSTAINED EFFICACY OF FRAGMIN IN THE TREATMENT OF CHRONIC FOOT ULCERS IN DIABETIC PATIENTS WI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001566-90,0,0,0 2008-001567-10,1,2008-08-28,2008-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A randomised, double-blind, placebo-controlled, 3-period crossover study to assess the efficacy and safety of single dose intranasal GSK1004723 compared with placebo in an allergen challenge chamber i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001567-10,0,0,0 2008-001568-35,1,2009-08-14,2009-08-14,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,BELFAST HEALTH & SOCIAL CARE TRUST,Comparison of fascia iliac compartment block with conventional sedation to facilitate the positioning of patients with fractured neck of femur for spinal anaesthesia and the effect of nerve blockade o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001568-35,0,0,0 2008-001575-30,1,2010-08-20,2010-08-20,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Nottingham,"A randomised, open-label, single-centre, pharmacokinetic study of a single dose of lorazepam administered by the intranasal and buccal route in healthy adult volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001575-30,0,0,0 2008-001579-32,1,2011-09-30,2011-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Hertfordshire,Erectile dysfunction:a randomised controlled trial of lipid lowering with simvastatin (EDS trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001579-32,0,0,0 2008-001580-11,7,2009-08-13,2009-08-13,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001580-11,0,0,0 2008-001581-91,6,2010-08-23,2010-08-23,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001581-91,0,0,0 2008-001583-36,2,2011-01-17,2011-01-17,2,1,0,0,1,0,4,0,0,1,0,0,1,0,1,Aesculap AG,Efficacy and Safety of Sangustop® as haemostatic agent versus a carrier-bound fibrin sealant during liver resection (ESSCALIVER),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001583-36,0,0,0 2008-001584-11,1,2008-12-31,2008-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,MedUni Innsbruck Klinik für Strahlentherapie,Hyperfraktioniert akzelerierte Strahlentherapie (HART) mit Mitomycin C / 5-Fluorouracil versus Cisplatin / 5-Fluorouracil bei lokal fortgeschrittenen Kopf-Hals-Tumoren,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001584-11,0,0,0 2008-001589-94,1,2013-10-25,2013-10-25,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Rigshospitalet,"En randomiseret, placebo-kontrolleret, dobbelt-blind afprøvning af intravenøs immunglobulin til kvinder med uforklarlig sekundær abortus habitualis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001589-94,0,0,0 2008-001591-80,1,2015-04-16,2015-04-16,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI,PHASE II STUDY OF LENALIDOMIDE IN COMBINATION WITH RITUXIMAB (R) FOR THE TREATMENT OF INDOLENT NON FOLLICULAR NON HODGKIN LYMPHOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001591-80,0,0,0 2008-001592-30,6,2010-07-02,2010-07-21,5,1,0,0,0,1,2,0,1,1,0,0,1,0,2,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered with or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001592-30,0,0,0 2008-001592-30,6,2010-07-02,2010-07-21,5,1,0,0,0,1,2,0,1,1,0,0,1,0,2,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered with or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001592-30,0,0,0 2008-001597-33,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,0,University Medical Center Utrecht,Development of chronic disease in newly diagnosed Idiopathic Thrombocytopenic Purpura of Childhood. A randomized controlled study on the influence of treatment with intravenous gammaglobulin on the co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001597-33,0,0,0 2008-001600-23,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),"Prospective, randomized, single masked pilot study on the variation of choroidal blood flow analyzed through the HRA dynamic angiography in patients treated with intravitreal injection of Selective ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001600-23,0,0,0 2008-001602-16,1,2009-12-21,2009-12-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,"Effects of Insulin Levemir and Insulin Insulatard on renal handling of sodium, fluid retention and weight in type 2 diabetic patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001602-16,0,0,0 2008-001603-30,1,2011-10-07,2011-10-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Galderma R&D,Gene expression in renal transplant patients with field Actinic Keratosis undergoing Metvix® PDT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001603-30,0,0,0 2008-001604-23,1,2012-11-08,2012-11-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's & St Thomas' NHS Foundation Trust,A double blind placebo controlled trial investigating the efficacy of Clopidogrel as prophylactic treatment for migrane.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001604-23,0,0,0 2008-001605-42,6,2013-06-19,2013-06-19,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Amgen Inc,"A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects with Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Effica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001605-42,0,0,0 2008-001606-16,10,2017-10-11,2018-05-17,8,1,1,0,0,2,2,0,0,2,0,0,0,0,1,Amgen Inc,"An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Tumor of Bone",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001606-16,1,1,0 2008-001606-16,10,2017-10-11,2018-05-17,8,1,1,0,0,2,2,0,0,2,0,0,0,0,1,Amgen Ltd,"An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Tumor of Bone",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001606-16,1,1,0 2008-001609-40,6,2009-05-26,2009-06-10,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001609-40,0,0,0 2008-001609-40,6,2009-05-26,2009-06-10,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001609-40,0,0,0 2008-001609-40,6,2009-05-26,2009-06-10,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","An 8-week double-blind, multicenter, randomized, multifactorial, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren administered alone and in combination with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001609-40,0,0,0 2008-001611-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Jose M Gatell - Hospital Clinic de Barcelona,Estudio piloto prospectivo de la farmacocinética y farmacodinamia de la interaciión entre tipranavir/ritonavir y raltegravir en pacientes infectados por el VIH-1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001611-38,0,0,0 2008-001612-20,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ROCHE,A study of chlorambucil plus MabThera as induction therapy followed in responders by maintenance therapy versus observation on response rate in patients ≥ 60 years with previously untreated chr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001612-20,0,0,0 2008-001620-31,1,2010-09-02,2010-09-02,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Highland,Glutathione Status in Platelets From Patients With Type 2 Diabetes: Therapeutic Potential of N-acetylcysteine to Help Prevent Platelet Hyperaggregability,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001620-31,0,0,0 2008-001632-13,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,LEGA ITALIANA PER LA LOTTA CONTRO I TUMORI,Continuous vs intermittent weekly docetaxel in the elderly patient with advanced and hormone-refractory prostate cancer: a randomized phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001632-13,0,0,0 2008-001634-28,1,2009-06-01,2009-06-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Dundee,Identification of genetic and functional biomarkers that predict PPAR-gamma-associated fluid retention and oedema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001634-28,0,0,0 2008-001635-34,4,2013-06-27,2013-06-27,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research & Development",A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Subjects With Indolent Non-Hodgkin’s Lymphoma (NHL) That is Refractory to or has Relapsed After Rituximab and Chemotherapy or Radioimmunotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001635-34,0,0,0 2008-001635-34,4,2013-06-27,2013-06-27,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Subjects With Indolent Non-Hodgkin’s Lymphoma (NHL) That is Refractory to or has Relapsed After Rituximab and Chemotherapy or Radioimmunotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001635-34,0,0,0 2008-001637-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"HUCH, Division of Cardiology",Acute heart failure in acute coronary syndrome: Double blind comparison of levosimendan and placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001637-10,0,0,0 2008-001640-40,6,2010-05-22,2010-06-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A phase III randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and safety of twice daily administration of the free combination of BI 1356 2.5 mg + metformin 500...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001640-40,0,0,0 2008-001640-40,6,2010-05-22,2010-06-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A phase III randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and safety of twice daily administration of the free combination of BI 1356 2.5 mg + metformin 500...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001640-40,0,0,0 2008-001640-40,6,2010-05-22,2010-06-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase III randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and safety of twice daily administration of the free combination of BI 1356 2.5 mg + metformin 500...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001640-40,0,0,0 2008-001640-40,6,2010-05-22,2010-06-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A phase III randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and safety of twice daily administration of the free combination of BI 1356 2.5 mg + metformin 500...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001640-40,0,0,0 2008-001642-19,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Umeå University,Perioperative pain management in children and adolscents undergoing scoliosis surgery. Intravenous analgesia with S-Ketamine and Morphine versus epidural analgesia with Fentanyl-Bupivacaine-Epinephrin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001642-19,0,0,0 2008-001645-26,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""",Phase II study: Systemic treatment with alternating weekly regimen of temozolomide and monthly fotemustine combination in recurrent glioblastoma patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001645-26,0,0,0 2008-001647-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud University Nijmegen Medical Center,Treatment with synthetic adrenocoticotropic hormone (ACTH) in patients with membranous nephropathy and high risk for renal failure. A pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001647-19,0,0,0 2008-001659-24,1,2008-07-07,2008-07-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Oxagen Ltd.,"A dose-finding study of the effects of OC000459 on responses to allergen challenge in the Vienna chamber in subjects known to suffer from grass pollen induced allergic rhinitis: a randomised, double-b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001659-24,0,0,0 2008-001662-85,2,2018-06-01,2018-06-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,A Phase 1/2 Open-label Study of Neratinib (HKI-272) in combination with Capecitabine in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or Locally advanced Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001662-85,0,0,0 2008-001663-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Diabeteszentrum Bad Lauterberg,Quantification of the DPP-4 inhibition-mediated enhancement of the activity of the entero-insular axis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001663-11,0,0,0 2008-001669-27,1,2011-07-20,2011-07-20,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Universitätsklinikum Heidelberg,A phase-III study on the value of allogeneic stem cell transplantation in poor-risk chronic lymphocytic leukemia by the German CLL Study Group (GCLLSG) and the German Cooperative Transplant Study Grou...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001669-27,0,0,0 2008-001670-32,1,2008-12-21,2008-12-21,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,Biodel Inc.,"A Single-Center, Double Blind Study Evaluating the Bioequivalence of the Pharmacokinetic and Pharmacodynamic Properties of Different Formulations of VIAject™ in Subjects with Type 1 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001670-32,0,0,0 2008-001672-70,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Heli Leppikangas,The effects of levosimendan on haemodynamics in patients undergoing elective aortic valve replacement (AVR) together with coronary artery bypass grafting (CABG) surgry,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001672-70,0,0,0 2008-001673-15,4,2010-05-11,2010-06-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with Lu AA21004 in patients with Generalised Anxiety Disorder (GAD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001673-15,0,0,0 2008-001674-32,1,2016-12-31,2016-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novo Nordisk Farma Oy,NordiNet International Outcome Study (NordiNet IOS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001674-32,0,0,0 2008-001677-15,1,2011-08-11,2011-08-11,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,King's College Hospital NHS Foundation Trust,The effect of intraoperative N-acetylcysteine on hepatocellular injury during laparoscopic bariatric surgery. A randomised controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001677-15,0,0,0 2008-001678-34,1,2008-11-25,2008-11-25,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Department of dermatology, Odense University Hospital","Examination of the efficacy of glycerol, two topical steroids and a topical immune modulator in experimentally induced skin irritation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001678-34,0,0,0 2008-001679-31,4,2010-04-26,2011-11-17,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Cephalon, Inc.","A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide with or without Obatoclax Administered Every 3 Weeks to Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001679-31,0,0,0 2008-001679-31,4,2010-04-26,2011-11-17,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Gemin X Pharmaceuticals US, Inc.","A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide with or without Obatoclax Administered Every 3 Weeks to Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001679-31,0,0,0 2008-001684-11,1,2010-07-31,2010-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Edinburgh,A Pilot Study into the Effect of Topical Menthol for Patients with Neuropathic-Type Pain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001684-11,0,0,0 2008-001685-87,5,2010-02-02,2010-02-02,4,1,0,0,0,0,2,0,2,1,0,0,1,0,2,"Maruho Co., Ltd","A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTRE PHASE IIB DOSE-FINDING STUDY OF M516102 IN THE TREATMENT OF PRURITUS ASSOCIATED WITH ATOPIC DERMATITIS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001685-87,0,0,0 2008-001686-28,2,2012-10-19,2012-10-19,2,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Universität Wuerzburg,Prospectively randomized phase III study of an individualized sensitivity-directed combination chemotherapy versus DTIC as first-line treatment in stage IV metastatic melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001686-28,0,0,0 2008-001687-37,1,2009-03-17,2009-03-17,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Novosis AG,"An open label, parallel group phase III clinical study in patients with prostate cancer to demonstrate the non-inferiority of a new Novosis Leuprorelin 10.72 mg implant versus the reference product Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001687-37,0,0,0 2008-001689-97,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Rennes,Etude de la relation dose-effet de la mélatonine dans l'autisme infantile.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001689-97,0,0,0 2008-001692-30,1,2010-09-14,2010-09-14,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Certmedica International GmbH,"monocentric randomised double-blind pilot trial, double dummy design for comparison of two therapy reginem formoline L112 vs. Orlistat 60 mg in patients with overweight or adipositas",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001692-30,0,0,0 2008-001694-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Afdeling for Traumatisk Hjerneskade,"En multicenter, randomiseret, placebo-kontrolleret studie af effekten af amantadin til fremme af bedring efter svær traumatisk hjerneskade: Amantadin-studiet",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001694-15,0,0,0 2008-001696-30,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Tibotec Pharmaceuticals Ltd.,"Ensayo fase II, abierto, de un solo brazo de tratamiento para evaluar la farmacocinética, seguridad, tolerabilidad y actividad antiviral de TMC278 en pacientes adolescentes de entre 12 y 18 años de ed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001696-30,0,0,0 2008-001698-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,service de santé des armées,Mannitol vs serum salé hypertonique en cas d'HTIC après traumatisme crânien grave: comparaison des effets sur la PtiO2 et le profil métabolique focal obtenu par microdialyse.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001698-14,0,0,0 2008-001700-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,None,Finding best practice: use of s-ketamine peroperatively and in patient controlled analgesia in the treatment of pain after major abdominal surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001700-23,0,0,0 2008-001703-32,1,2014-12-31,2014-12-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,2,Medical University of Vienna,Primary hyperparathyroidism: does a systematic treatment improve the calcium- and bone metabolism after successful surgery? – Part Systematic treatment of osteopenic and osteoporotic postmenopausal p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001703-32,0,0,0 2008-001703-32,1,2014-12-31,2014-12-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,2,Österreichische Nationalbank - Jubiläumsfonds,Primary hyperparathyroidism: does a systematic treatment improve the calcium- and bone metabolism after successful surgery? – Part Systematic treatment of osteopenic and osteoporotic postmenopausal p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001703-32,0,0,0 2008-001703-32,1,2014-12-31,2014-12-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,2,Servier,Primary hyperparathyroidism: does a systematic treatment improve the calcium- and bone metabolism after successful surgery? – Part Systematic treatment of osteopenic and osteoporotic postmenopausal p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001703-32,0,0,0 2008-001704-23,1,2016-12-31,2016-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Chirurgie",Primary hyperparathyroidism: does a systematic treatment improve the calcium and bone metabolism after successful surgery? – Part II Systematic treatment of patients with neither osteopenia nor osteo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001704-23,0,0,0 2008-001705-42,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,1,L'OREAL,ETUDE TRANSCRIPTOMIQUE DE LA REPONSE AU MINOXIDIL CHEZ L'HOMME ALOPECIQUE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001705-42,0,0,0 2008-001711-38,1,2011-05-01,2011-05-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Photocure ASA,An open dose-finding study of oral applied hexaminolevulinate (HAL) imaging in patients with suspicion or high risk of dysplasia or neoplasia in the colon,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001711-38,0,0,0 2008-001712-21,1,2010-05-03,2010-05-03,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,Delenex Therapeutics AG,"A double-blind, randomised placebo-controlled Phase I/IIa study to investigate the safety, tolerability and efficacy on pain of intra-articular ESBA105 applied to patients with severely painful osteo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001712-21,0,0,0 2008-001714-24,1,2009-06-10,2009-06-10,1,1,0,0,0,0,2,0,1,1,1,1,1,0,1,Biota Scientific Management Pty Ltd,"A Phase II, Double-Blind Placebo-Controlled Study to Determine the Prophylactic Efficacy of Oral BTA798 in an Experimental Rhinovirus Challenge Model",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001714-24,0,0,0 2008-001718-26,1,2010-02-16,2010-02-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & Développement,"An eight-week, multicenter, randomized, double-blind, placebo-controlled dose-finding study, with escitalopram (10mg daily) as active control, to evaluate the efficacy, safety and tolerability of thre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001718-26,0,0,0 2008-001719-39,1,2008-09-05,2008-09-05,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Innocoll Technologies,"A Phase II, Single Dose, Blinded, Prospective Study to Investigate the Efficacy and Safety of the CollaRx® Bupivacaine Implant in Women following Abdominal Hysterectomy or other Nonlaparoscopic Benign...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001719-39,0,0,0 2008-001721-34,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Amgen Inc,"A Phase 2, Randomised, Double-blind, Placebo-controlled, Dose-finding Study of Darbepoetin alfa for the Treatment of Anemia in Paediatric Subjects with Solid Tumours Receiving Cyclic Chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001721-34,0,0,0 2008-001724-32,3,2009-02-04,2009-02-04,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A phase II, double-blind, placebo-controlled, randomised, 6-way cross-over, single-dose study to investigate the local and systemic effects of 3 doses of inhaled AZD3199 (a β2-agonist) compared to for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001724-32,0,0,0 2008-001726-13,1,2011-11-30,2011-11-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York City, NY 10017",PHASE 2 TRIAL OF AG-013736 AS FIRST-LINE TREATMENT FOR PATIENTS WITH SQUAMOUS NON-SMALL CELL LUNG CANCER RECEIVING TREATMENT WITH CISPLATIN AND GEMCITABINE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001726-13,0,0,0 2008-001727-65,9,2009-04-30,2020-11-19,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ImClone Systems Incorporated,"A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients with HER2-Negative, Unresectable, Loc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001727-65,0,0,0 2008-001727-65,9,2009-04-30,2020-11-19,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ImClone LLC,"A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients with HER2-Negative, Unresectable, Loc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001727-65,0,0,0 2008-001728-30,2,2009-06-18,2009-09-22,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Mpex Pharmaceuticals, Inc.","A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP- 376 Solution for Inhalation Given for 28 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001728-30,0,0,0 2008-001732-13,1,2010-07-27,2010-07-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Edinburgh,Magnetic Resonance Imaging of Aortic Aneurysm Instability,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001732-13,0,0,0 2008-001736-12,8,2010-06-14,2011-07-25,6,1,0,0,2,0,2,0,0,1,1,0,1,0,1,ROCHE,"A Randomized, double blind study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva), on progression-free survival in patients with advanced...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001736-12,0,0,0 2008-001736-12,8,2010-06-14,2011-07-25,6,1,0,0,2,0,2,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Randomized, double blind study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva), on progression-free survival in patients with advanced...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001736-12,0,0,0 2008-001738-29,1,2011-08-03,2011-08-03,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Belfast Health and Social Care Trust,"Renin angiotensin Aldosterone (RAAS) axis, endothelial function and hypertension: diagnostic strategies and therapeutic role of potassium supplementation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001738-29,0,0,0 2008-001744-39,2,2010-03-22,2010-09-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche Ltd,"A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo, in patients with type 2 diabetes mell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001744-39,0,0,0 2008-001747-18,1,2011-07-20,2011-07-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,Etude multicentrique évaluant le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de C.E.R.A. (activateur continu du récepteur de l’érythropoïétine) chez des patients insu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001747-18,0,0,0 2008-001749-25,2,,,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,Matter Misericoridiae University Hospital. Dublín,An open label safety study of fosamprenavir/ritonavir (FPV/rtv (Telzir)) administered to HIV/HCV co-infected patients over 96 weeks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001749-25,0,0,0 2008-001749-25,2,,,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,Mater Misericordiae University Hospital,An open label safety study of fosamprenavir/ritonavir (FPV/rtv (Telzir)) administered to HIV/HCV co-infected patients over 96 weeks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001749-25,0,0,0 2008-001751-21,6,2013-10-31,2013-10-31,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Randomized, Phase 1b/2 Trial of AMG 102 or AMG 479 in Combination with Panitumumab versus Panitumumab Alone in Subjects with Wild-Type KRAS Metastatic Colorectal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001751-21,0,0,0 2008-001752-43,1,2011-11-23,2011-11-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,"CARDIAC PROTECTION WITH SEVOFLURANE IN PATIENTS WITH HIGH RISK UNDERGOING HEART SURGERY. RANDOMIZED, CONTROLLED STUDY.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001752-43,0,0,0 2008-001754-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",WEEKLY vs EVERY 3 WEEK CARBOPLATIN + PACLITAXEL IN PATIENTS WITH OVARIAN CANCER: RANDOMIZED MULTICENTER STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001754-40,0,0,0 2008-001755-22,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",STEALTH LIPOSOMAL DOXORUBICIN vs CARBOPLATIN/PACLITAXEL IN PATIENTS WITH OVARIAN CANCER RECURRENCE BETWEEN SIX AND TWELVE MONTHS AFTER PREVIOUS PLATINUM BASED CHEMOTHERAPY: PHASE III MULTICENTER RANDO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001755-22,0,0,0 2008-001755-22,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,"National Cancer Institute Naples, Italy",STEALTH LIPOSOMAL DOXORUBICIN vs CARBOPLATIN/PACLITAXEL IN PATIENTS WITH OVARIAN CANCER RECURRENCE BETWEEN SIX AND TWELVE MONTHS AFTER PREVIOUS PLATINUM BASED CHEMOTHERAPY: PHASE III MULTICENTER RANDO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001755-22,0,0,0 2008-001755-22,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Philipps-University Marburg,STEALTH LIPOSOMAL DOXORUBICIN vs CARBOPLATIN/PACLITAXEL IN PATIENTS WITH OVARIAN CANCER RECURRENCE BETWEEN SIX AND TWELVE MONTHS AFTER PREVIOUS PLATINUM BASED CHEMOTHERAPY: PHASE III MULTICENTER RANDO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001755-22,0,0,0 2008-001762-85,1,2013-04-26,2013-04-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,An open label study to determine the effect of R1507 (RO4858696) plus Tarceva (erlotinib) on progression-free survival in patients with stage IIIB/IV non-small cell lung cancer with progressive diseas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001762-85,0,0,0 2008-001763-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST,"LOW-DOSE METRONOMIC TEMOZOLOMIDE AND SORAFENIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME: A PHASE II CLINICAL TRIAL WITH EVALUATION OF CLINICAL, BIOLOGIC AND PHARMACODYNAMIC EFFECTS OF THE C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001763-11,0,0,0 2008-001764-36,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"University of Turin, Dept of Clinical & Biological Sciences",Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001764-36,0,0,0 2008-001764-36,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Azienda Ospedaliero Universitaria ''San Luigi Gonzaga'',Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001764-36,0,0,0 2008-001765-28,1,2010-05-17,2010-05-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche Ltd,"A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo in patients with type 2 diabetes melli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001765-28,0,0,0 2008-001766-90,6,2009-07-06,2009-07-07,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001766-90,0,0,0 2008-001767-11,3,2010-09-08,2010-10-14,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,"A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning compared with Fast Transitioning from a Stimulant Medication to Atomoxetine in Pediatric and Adol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001767-11,0,0,0 2008-001767-11,3,2010-09-08,2010-10-14,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning compared with Fast Transitioning from a Stimulant Medication to Atomoxetine in Pediatric and Adol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001767-11,0,0,0 2008-001769-27,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Southampton University Hospital Trust,Microbiological assessment of prophylactic ciprofloxacin therapy for children with cystic fibrosis during viral respiratory viral infection to prevent Pseudomonas aeruginosa colonisation – a randomise...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001769-27,0,0,0 2008-001770-33,1,2009-02-28,2009-02-28,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,"Charité-Universitätsmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie, CRC","INVESTIGATOR-INITIATED SINGLE BLIND, TWO-ARMED, RANDOMIZED PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM (5% MTF) ONCE DAILY VERSUS 2% MINOXIDIL TOPICAL SOLUTION (2% MTS) TWI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001770-33,0,0,0 2008-001773-15,1,2009-01-06,2009-01-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici SpA,"A single centre, randomised, double-blind, double-dummy, placebo-and active-controlled, 3-way cross-over study to evaluate the 24 hour FEV1 profile of a single dose of CHF 5188 pMDI (400/4 mcg QD) (fi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001773-15,0,0,0 2008-001774-32,3,2009-04-17,2009-04-17,2,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Baxter Innovations GmbH,"A BLINDED PHASE I/II DOSE ESCALATION STUDY TO ASSESS SAFETY AND IMMUNOGENICITY AND INVESTIGATE THE OPTIMAL DOSE LEVEL OF A FORMALIN-TREATED, UV-INACTIVATED, VERO CELL-DERIVED ROSS RIVER VIRUS (RRV) VA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001774-32,0,0,0 2008-001779-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI,Markers of hypercoagulability and risk of death and rehospitalization in heart failure patients: a pilot study on the effects of Fondaparinux,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001779-31,0,0,0 2008-001783-36,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"Soria Natural, S.A.","Estudio en fase II, doble ciego, comparado con placebo para evaluar la eficacia del Lepisor en pacientes con litiasis oxalocálcica de origen tubular.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001783-36,0,0,0 2008-001784-11,1,2009-03-17,2009-03-17,1,0,0,0,1,0,2,0,0,1,1,1,1,0,1,"Alita Pharmaceuticals, Inc.","A Phase 2, Double-Blind, Placebo-Controlled Study of Uro-Vaxom® for the Management of Uncomplicated Recurrent Urinary Tract Infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001784-11,0,0,0 2008-001786-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academical Medical Center,Innovative approaches for cocaine pharmacotherapy using fMRI: The case of varenicline,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001786-28,0,0,0 2008-001787-36,1,2011-02-28,2011-02-28,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Universitätsklinikum Mannheim, Universitätsklinik für Anästhesiologie und Operative Intensivmedizin",Verbessert die perioperative Applikation von Esketamin in subanästhetischer Dosierung die postoperative Analgesie?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001787-36,0,0,0 2008-001804-22,2,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,PregLem S.A.,"A Phase III, randomized, parallel group, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus placebo for pre-operative treatment of sy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001804-22,0,0,0 2008-001805-40,8,2010-08-27,2010-08-27,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,PREGLEM SA,"A Phase III, randomised, parallel group, double-blind, double-dummy, active comparator -controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus GnRH-agonist (le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001805-40,0,0,0 2008-001805-40,8,2010-08-27,2010-08-27,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,PregLem S.A.,"A Phase III, randomised, parallel group, double-blind, double-dummy, active comparator -controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus GnRH-agonist (le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001805-40,0,0,0 2008-001806-17,2,2009-08-07,2009-08-07,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Antisoma Research Limited,"A Phase II, Randomised, Open-Label, Multicentre Study of AS1402 in Combination with Letrozole as First Line Treatment in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001806-17,1,0,0 2008-001807-53,1,2019-09-26,2019-09-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Fédération Nationale des Centres de Lutte,Essai de phase II d’évaluation de l’efficacité et de la tolérance du bevacizumab (AVASTIN®) dans les cancers du sein inflammatoire HER2-.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001807-53,0,0,0 2008-001811-40,1,2010-07-09,2010-07-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The University of Dundee,A Proof of Concept Study to Evaluate the Additive Effects of HFA-BDP (Qvar) to fluticasone/salmeterol (Seretide) on Surrogate Markers of Small and Large Airway Inflammation in Refractory Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001811-40,0,0,0 2008-001823-71,1,2013-04-16,2013-04-16,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Associazione Malattie Sangue ONLUS,Phase II study of the combination of Lenalidomide and Alemtuzumab as consolidation in patients who responded to a previus chemotherapeutic regimen administered for relapsed or refractory Chronic Lymph...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001823-71,0,0,0 2008-001824-30,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Associazione Malattie Sangue Onlus,Phase II study of the combination Bendamustine and sc Alemtuzumab for patients with refractory or relapsed B-cell chronic lynphocytic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001824-30,0,0,0 2008-001825-32,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),"""Fase II Docetaxel-Oxiplatino-Capecitabina (DOX) a dosis ajustadas en pacientes con adenocarcinoma gástrico avanzado y estado general subóptimo""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001825-32,0,0,0 2008-001827-76,1,,,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,"Erasmusm MC, Rotterdam, The Netherlands","The role of TSH in the human immune system, a clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001827-76,0,0,0 2008-001829-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Eli Lilly and Company,Duloxetine Versus Placebo in the Long-Term Treatment of Patients with Late-Life Major Depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001829-33,0,0,0 2008-001833-87,1,2011-06-30,2011-06-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Medical Center Freiburg,"Use of Palifermin to reduce the duration, frequency and severity of oral mucositis after high dose therapy with BEAM and autologous peripheral blood stem cell transplantation in patients with malign l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001833-87,0,0,0 2008-001835-36,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Gedeon Richter Plc.,"Single center, exploratoric, open-label study to investigate the add-on effect of vinpocetin to the haemorheological effect of 100 mg acetyl-salicylicum in patients with chronic cerebrovascular diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001835-36,0,0,0 2008-001837-88,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Fundación Progreso y Salud,USO DE LAS CÉLULAS TRONCALES MESENQUIMALES DE TEJIDO ADIPOSO (CeTMAd) COMO TERAPIA DE REGENERACIÓN CELULAR EN EL SÍNDROME DE ISQUEMIA CRONICA CRÍTICA DE MIEMBROS INFERIORES EN PACIENTES DIABÉTICOS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001837-88,0,0,0 2008-001840-38,3,2009-04-21,2009-04-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,OBEcure,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight in Obese Female Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001840-38,0,0,0 2008-001840-38,3,2009-04-21,2009-04-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,OBEcure Ltd.,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Betahistine on Body Weight in Obese Female Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001840-38,0,0,0 2008-001841-24,7,2011-05-12,2011-05-17,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,CEPHALON FRANCE,A European Multicenter Open-Label Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001841-24,0,0,0 2008-001841-24,7,2011-05-12,2011-05-17,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Cephalon France,A European Multicenter Open-Label Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001841-24,0,0,0 2008-001842-19,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,ARCAGY,Etude de phase I / II de l’association carboplatine et topotecan oral hebdomadaire chez des patientes atteintes de cancer du col de l’utérus métastatique ou en rechute.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001842-19,0,0,0 2008-001843-20,1,2010-09-29,2010-09-29,1,0,0,0,1,0,4,0,0,1,1,1,1,0,0,Frimley Park Hospital,Prevention of pseudophakic cystoid macula oedema with pre- and postoperative ketorolac,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001843-20,0,0,0 2008-001847-20,11,2013-01-10,2013-01-10,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F Hoffmann-La Roche Ltd,"Estudio aleatorizado, controlado con placebo, para evaluar la seguridad y eficacia de añadir tocilizumab (TCZ) a metotrexato (MTX) frente al cambio a TCZ (controlado con placebo), con la posibilidad d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001847-20,0,0,0 2008-001847-20,11,2013-01-10,2013-01-10,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F Hoffmann-La Roche Ltd.,"Estudio aleatorizado, controlado con placebo, para evaluar la seguridad y eficacia de añadir tocilizumab (TCZ) a metotrexato (MTX) frente al cambio a TCZ (controlado con placebo), con la posibilidad d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001847-20,0,0,0 2008-001847-20,11,2013-01-10,2013-01-10,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"Estudio aleatorizado, controlado con placebo, para evaluar la seguridad y eficacia de añadir tocilizumab (TCZ) a metotrexato (MTX) frente al cambio a TCZ (controlado con placebo), con la posibilidad d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001847-20,0,0,0 2008-001849-26,1,2012-03-15,2012-03-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Charité - Universitätsmedizin Berlin,"Multicentre, open phase II trial to evaluate safety and efficacy of a perioperative chemotherapy with docetaxel, cisplatin and capecitabin in patients suffering from adenocarcinoma of the stomach, gas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001849-26,0,0,0 2008-001850-42,1,2014-04-07,2014-04-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"The Heart Centre, Rigshospitalet",Autolog mesenkymal stromal cellebehandling af patienter med hjertesvigt.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001850-42,0,0,0 2008-001853-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Ghent,Invloed van behandeling met infliximab op immuuncellen in het bloed van patiënten met spondyloartritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001853-17,0,0,0 2008-001854-42,8,2011-01-11,2011-03-02,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann- La Roche Ltd,"A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to sitagliptin and plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001854-42,0,0,0 2008-001854-42,8,2011-01-11,2011-03-02,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F.Hoffmann-La Roche Ltd,"A multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to sitagliptin and plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001854-42,0,0,0 2008-001855-23,12,2010-12-15,2011-03-21,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A multi-center, randomized, open-label, active-controlled study to compare the efficacy, safety and tolerability of taspoglutide (RO5073031) versus insulin glargine in insulin-naive type 2 diabetic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001855-23,0,0,0 2008-001855-23,12,2010-12-15,2011-03-21,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ROCHE,"A multi-center, randomized, open-label, active-controlled study to compare the efficacy, safety and tolerability of taspoglutide (RO5073031) versus insulin glargine in insulin-naive type 2 diabetic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001855-23,0,0,0 2008-001856-36,9,2010-12-13,2011-03-11,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann- La Roche Ltd,"A multicenter, randomized, open label, active-comparator controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to exenatide in patients with type 2 di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001856-36,0,0,0 2008-001856-36,9,2010-12-13,2011-03-11,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ROCHE,"A multicenter, randomized, open label, active-comparator controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to exenatide in patients with type 2 di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001856-36,0,0,0 2008-001856-36,9,2010-12-13,2011-03-11,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A multicenter, randomized, open label, active-comparator controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to exenatide in patients with type 2 di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001856-36,0,0,0 2008-001860-36,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Pierre Fabre Médicament,"EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CONTR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001860-36,0,0,0 2008-001865-28,1,2014-10-29,2014-10-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,The Relationship between Osteoporosis and Aortic Calcification in Postmenopausal Women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001865-28,0,0,0 2008-001865-28,1,2014-10-29,2014-10-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guys and St Thomas NHS Foundation Trust,The Relationship between Osteoporosis and Aortic Calcification in Postmenopausal Women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001865-28,0,0,0 2008-001869-29,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PISANA,Mechanism of action and metabolic effects of exenatide in obesity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001869-29,0,0,0 2008-001871-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region skåne- Hässleholms sjukvårdsorganisation,Local steroid injection in the treatment of idiopathic carpal tunnel syndrome: A randomized double-blind placebo-controlled trial among patients planned for surgical treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001871-31,0,0,0 2008-001872-54,3,2009-11-13,2009-11-13,3,0,0,0,0,1,2,0,0,1,1,1,1,0,1,Archemix Corp.,"A Randomized, Double-blind, Placebo-controlled, Clinical Outcome study of ARC1779 Injection in Patients with Thrombotic Microangiopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001872-54,0,0,0 2008-001872-54,3,2009-11-13,2009-11-13,3,0,0,0,0,1,2,0,0,1,1,1,1,0,1,Archemix Corp,"A Randomized, Double-blind, Placebo-controlled, Clinical Outcome study of ARC1779 Injection in Patients with Thrombotic Microangiopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001872-54,0,0,0 2008-001872-54,3,2009-11-13,2009-11-13,3,0,0,0,0,1,2,0,0,1,1,1,1,0,1,ARCHEMIX CORP,"A Randomized, Double-blind, Placebo-controlled, Clinical Outcome study of ARC1779 Injection in Patients with Thrombotic Microangiopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001872-54,0,0,0 2008-001875-32,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc.,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy, Safety And Tolerability Of Desvenlafaxine Succinate Sustained-release (DVS SR) In The Treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001875-32,0,1,1 2008-001876-67,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc.,"A 6-Month Open-Label, Multicenter, Flexible-Dose Extension Study to the B2061032 Study to Evaluate the Safety, Tolerability and Efficacy of Desvenlafaxine Succinate Sustained-Release (DVS SR) in the T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001876-67,0,1,1 2008-001881-10,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)",Raltegravir/Atazanavir pharmacokinetics and evaluation of lipids,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001881-10,0,0,0 2008-001885-96,1,2016-09-26,2016-09-26,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,University of Leipzig,"Treatment with Lenalidomide, Bendamustine and Prednisone (RBP) in Patients with Relapsed or Refractory Multiple Myeloma after Autologous Stem Cell Transplantation or Conventional Chemotherapy OSHO #07...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001885-96,0,0,0 2008-001886-26,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,GALENICA S.A.,"A multicenter, double-blind, randomized, placebo controlled phase III study of the efficacy and safety of Trimebutine 300 mg twice daily for the relief of functional dyspeptic patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001886-26,0,0,0 2008-001889-81,1,2009-04-08,2009-04-08,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Institute of Medicinal Molecular Design, Inc.","A Phase IIa, Proof of Concept Study to Evaluate the Reduction in Inflammatory Biomarkers and Assess Airway Function Following Administration of IMD-1041 in Patients with Chronic Obstructive Pulmonary ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001889-81,0,0,0 2008-001892-31,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Hospital Comarcal de Laredo. Sección de Digestivo,"Ensayo clínico unicéntrico, simple ciego y aleatorizado de comparación de la eficacia erradicadora de primera línea frente al Helicobacter pylori entre la triple terapia convencional oral con claritro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001892-31,0,0,0 2008-001903-42,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,An exploratory phase II dose escalation study of eltrombopag in MYH9 related disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001903-42,0,0,0 2008-001908-23,1,2011-03-28,2011-03-28,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,"Rigshospitalet, Department of Clinical Pharmacology","A randomised, double blinded, crossover study of the influence of Metoprolol on exercise induced elevation of catecholamines in healthy subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001908-23,0,0,0 2008-001909-41,1,2011-08-16,2011-08-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Stepani Bendel,Hydrokortisonihoito elinluovutuspotilailla (HYDRO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001909-41,0,0,0 2008-001910-25,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Octapharma AG,"Pharmacokinetics of WILATE® and Haemate® P in von Willebrand type 3 patients - a prospective, randomised, controlled, open-labelled, 2-arm cross-over study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001910-25,0,0,0 2008-001913-51,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO PER L'INFANZIA BURLO GAROFOLO,SYNERGIC EFFECTS OF OXYTOCIN AND PSYCHOTHERAPY IN POSTPARTUM DEPRESSION. RANDOMIZED CONTROLLED STUDY.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001913-51,0,0,0 2008-001916-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ORDINE MAURIZIANO,"A phase II, randomized trial with single agent trastuzumab or lapatinib in women with metastatic breast cancer iperexpressing HER2",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001916-18,0,0,0 2008-001917-12,1,2014-08-19,2014-08-19,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,helsinki University central Hospital,Jatkuvan haavapuudutuksen ja kertapuudutuksen vertailu laparotomian jälkeisen kivun hoidossa lapsipotilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001917-12,0,0,0 2008-001918-25,2,2014-11-17,2014-11-17,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,GlaxoSmithKline Biologicals,An open Phase I/II study of immunization with the recMAGE-A3 + AS15 Antigen Specific Cancer Immunotherapeutic in association with dacarbazine in patients with MAGE-A3 positive unresectable and progres...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001918-25,0,0,0 2008-001921-33,4,2011-06-01,2011-06-21,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase 2 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmacokinetics, and Pharmacodynamics of Dapagliflozin in S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001921-33,0,0,0 2008-001921-33,4,2011-06-01,2011-06-21,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase 2 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmacokinetics, and Pharmacodynamics of Dapagliflozin in S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001921-33,0,0,0 2008-001927-74,1,2010-11-18,2010-11-18,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University Hospitals Bristol NHS Foundation Trust,"A PHASE II, OPEN LABEL, RANDOMISED, TWO CENTRE STUDY TO EVALUATE THE IMPORTANCE OF NATURALLY INDUCED IMMUNE REGULATION ON THE MUCOSAL IMMUNE RESPONSE TO MENINGOCOCCAL SEROGROUP B OUTER MEMBRANE VESICL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001927-74,0,0,0 2008-001933-84,7,2010-12-02,2010-12-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001933-84,0,0,0 2008-001933-84,7,2010-12-02,2010-12-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001933-84,0,0,0 2008-001933-84,7,2010-12-02,2010-12-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001933-84,0,0,0 2008-001933-84,7,2010-12-02,2010-12-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001933-84,0,0,0 2008-001933-84,7,2010-12-02,2010-12-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001933-84,0,0,0 2008-001933-84,7,2010-12-02,2010-12-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Danmark A/S,"A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001933-84,0,0,0 2008-001933-84,7,2010-12-02,2010-12-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001933-84,0,0,0 2008-001934-28,6,2010-12-08,2010-12-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001934-28,0,0,0 2008-001934-28,6,2010-12-08,2010-12-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001934-28,0,0,0 2008-001934-28,6,2010-12-08,2010-12-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Denmark,"A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001934-28,0,0,0 2008-001934-28,6,2010-12-08,2010-12-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001934-28,0,0,0 2008-001934-28,6,2010-12-08,2010-12-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001934-28,0,0,0 2008-001934-28,6,2010-12-08,2010-12-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001934-28,0,0,0 2008-001936-11,4,2014-12-12,2014-12-12,3,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Wyeth Pharmaceuticals Inc., acting through its division Wyeth Research, a Pfizer Company","A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Tigecycline Versus Clindamycin for the Treatment of Complicated Skin and Skin Structure Infections, Includ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001936-11,1,1,0 2008-001936-11,4,2014-12-12,2014-12-12,3,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Wyeth Pharmaceuticals Inc., Acting through its division Wyeth Research, a Pfizer Company","A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Tigecycline Versus Clindamycin for the Treatment of Complicated Skin and Skin Structure Infections, Includ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001936-11,1,1,0 2008-001936-11,4,2014-12-12,2014-12-12,3,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Wyeth Pharmaceuticals Inc.,"A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Tigecycline Versus Clindamycin for the Treatment of Complicated Skin and Skin Structure Infections, Includ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001936-11,1,1,0 2008-001940-38,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,Functional RMN study to evaluate the prompt and middle term effect of the treatment with Donepezil in patients affected by multiple sclerosis and mild impairment of cognitive function.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001940-38,0,0,0 2008-001948-39,1,2014-09-15,2014-09-15,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,HANNU KOKKI,PAMOL F FARMAKOKINETIIKKA MAHAKIRURGISILLA POTILAILLA - 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001948-39,0,0,0 2008-001949-26,5,2016-09-04,2016-09-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,0,EORTC European Organisation for Research and Treatment of Cancer,A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001949-26,0,0,0 2008-001949-26,5,2016-09-04,2016-09-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001949-26,0,0,0 2008-001952-32,1,2010-10-16,2010-10-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre - Department of Dermatology,The effect of adalimumab on immune markers in lesional psoriatic skin.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001952-32,0,0,0 2008-001962-94,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Marc Miratvilles,Efecto antiinflamatorio bronquial del tratamiento sustitutivo en pacientes con déficit de alfa-1 antitripsina,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001962-94,0,0,0 2008-001965-27,2,2012-12-28,2012-12-28,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Shire Human Genetic Therapies, Inc.",An Open-Label Extension Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients with Type 1 Gaucher Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001965-27,0,0,0 2008-001966-10,5,2009-06-04,2011-07-18,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Serono SA - Geneva,"A phase III, double blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of safinamide (50 to 100 mg/day), as add on therapy, in subjects with idiopathic Parkinso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001966-10,0,0,0 2008-001968-36,1,2014-08-31,2014-08-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Swansea University,Comparison of infliximab and ciclosporin in steroid resistant ulcerative colitis: a Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001968-36,0,0,0 2008-001971-30,2,2011-05-10,2011-05-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck & Co, Inc.","A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination with Trastuzumab for Patients with HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001971-30,0,0,0 2008-001971-30,2,2011-05-10,2011-05-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ARIAD Pharmaceuticals, Inc.","A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination with Trastuzumab for Patients with HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001971-30,0,0,0 2008-001972-55,1,2013-01-01,2013-01-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,UMC St Radboud,"Efficacy of hyperbaric oxygen therapy in the treatment of late radiation damage, osteoradionecrosis, of the lower jaw.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001972-55,0,0,0 2008-001973-14,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Radboud University Nijmegen Medical Centre,TLR ligand matured dendritic cell vaccination in melanoma patients: the key towards a more potent immune induction?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001973-14,0,0,0 2008-001974-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Radboud University Nijmegen Medical Centre,mRNA-transfected dendritic cell vaccination in high risk uveal melanoma patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001974-33,0,0,0 2008-001974-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Rotterdam Eye Hospital,mRNA-transfected dendritic cell vaccination in high risk uveal melanoma patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001974-33,0,0,0 2008-001998-15,1,2013-03-29,2013-03-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SOPHARMA PLC,"A phase IV, 16 weeks, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to assess the efficacy and safety of oral Tribulus terrestris (Tribestan®) in men with erectile dysfuncti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001998-15,0,0,0 2008-001999-67,4,2010-03-02,2010-03-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis Recherche & Développement,"A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients with Multiple Scl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-001999-67,0,0,0 2008-002002-19,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,1,BIOCODEX,"Effets du moclobémide sur le profil d'activation cérébrale de patients dépressifs âgés lors de tâches cognitives et émotionnelles, en référence à des sujets témoins. Etude ouverte, multicentrique, che...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002002-19,0,0,0 2008-002003-75,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Maastricht University,Residual effects of zopiclone 7.5 mg on cognition and driving performance in insomnia patients chronically using hypnotics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002003-75,0,0,0 2008-002018-23,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,FONDAZIONE HUMANITAS PER LA RICERCA,MULTICENTRIC RANDOMIZED PHASE III STUDY COMPARING GEFITINIB VERSUS PLATINUM-BASED CHEMOTHERAPY IN EGFR FISH POSITIVE NSCLC PATIENTS (RANGE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002018-23,0,0,0 2008-002019-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE,Effet de l’association d’une statine au traitement antibiotique sur le pronostic des suspicions de pneumonies acquises sous ventilation mécanique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002019-42,0,0,0 2008-002022-10,5,2011-09-13,2012-03-23,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"An open-label, multicenter protocol providing pegylated interferon alfa-2a (PEGASYS) as monotherapy or in combination with ribavirin (COPEGUS) for patients with chronic hepatitis C who have participa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002022-10,0,0,0 2008-002022-10,5,2011-09-13,2012-03-23,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann - La Roche Ltd,"An open-label, multicenter protocol providing pegylated interferon alfa-2a (PEGASYS) as monotherapy or in combination with ribavirin (COPEGUS) for patients with chronic hepatitis C who have participa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002022-10,0,0,0 2008-002024-28,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO SAN DONATO IRCSS,QUIXIL VALIDATION IN HIP REPLACEMENT FIRST IMPLANT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002024-28,0,0,0 2008-002029-36,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,A.O. SAN GERARDO DI MONZA,Impact of intraperitonael nebulization of local anesthetic on postoperative pain associated with laparoscopic cholecystectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002029-36,0,0,0 2008-002030-30,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,A.O. SAN GERARDO DI MONZA,Impact of intraperitonael nebulization of local anesthetic on hypothermia and postoperative pain associated with laparoscopic surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002030-30,0,0,0 2008-002031-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. GERARDO DI MONZA,Phase III study protocol to compare conservative and active treatment during the third stage of labour in physiological childbirth Protocollo di studio di fase III sull'efficacia del trattamento pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002031-32,0,0,0 2008-002035-33,1,2014-09-29,2014-09-29,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Martha-Maria Krankenhaus Halle-Dölau gGmbH,Open-label study of Bevacizumab (AVASTIN®) in combination with Pemetrexed or Pemetrexed and Carboplatin as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002035-33,0,0,0 2008-002037-67,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Grifols Biologicals Inc.,EFFICACY AND SAFETY OF FACTOR IX (FIX) CONTAINED IN ALPHANINE® AND ITS PHARMACOKINETIC COMPARISON WITH BENEFIX® IN PATIENTS WITH SEVERE HEREDITARY HAEMOPHILIA B (Follow-up study of the trial IG404: E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002037-67,0,0,0 2008-002039-34,7,2010-12-03,2010-12-03,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002039-34,0,0,0 2008-002039-34,7,2010-12-03,2010-12-03,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002039-34,0,0,0 2008-002039-34,7,2010-12-03,2010-12-03,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmaceutica S.A.,"An open-label, randomized, multicenter, active-controlled, dose-ranging study to evaluate the safety and efficacy of albinterferon alfa-2b administered every 4 weeks plus ribavirin in interferon al...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002039-34,0,0,0 2008-002042-38,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Zakłady Farmaceutyczne ""UNIA"" Spółdzielnia Pracy","Multiple site, randomized, prospective, open comparison of new locally used benzydamine product efficacy with reference product in adult patients with acute pharyngitis or tonsillitis which do not req...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002042-38,0,0,0 2008-002043-16,4,2009-10-19,2009-10-19,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Gilead Sciences Europe Ltd.,"A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching a Stable HAART Regimen of fixed dose Abacavir/Lamivudine (Kivexa) Plus Lopinavir/Ritonavir (Kalet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002043-16,0,0,0 2008-002043-16,4,2009-10-19,2009-10-19,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Gilead Sciences Europe Ltd,"A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching a Stable HAART Regimen of fixed dose Abacavir/Lamivudine (Kivexa) Plus Lopinavir/Ritonavir (Kalet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002043-16,0,0,0 2008-002045-23,1,2008-10-28,2008-10-28,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Gilead Sciences Incorporated,"A Double-blind, Randomized, Placebo-controlled Phase 1/2 Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9131 in Antiretroviral-Naive, HIV-1 Infected Subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002045-23,0,0,0 2008-002046-27,4,2011-04-22,2011-04-22,2,1,0,1,1,0,1,0,0,1,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,Clinical phase I/IIA study of subcutaneous administration of Ofatumumab in Rheumatoid Arthritis patients on stable dose Methotrexate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002046-27,0,0,0 2008-002046-27,4,2011-04-22,2011-04-22,2,1,0,1,1,0,1,0,0,1,0,0,0,0,1,GlaxoSmithKline S.A.,Clinical phase I/IIA study of subcutaneous administration of Ofatumumab in Rheumatoid Arthritis patients on stable dose Methotrexate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002046-27,0,0,0 2008-002053-20,1,2008-10-13,2008-10-13,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Bayer Healthcare AG,"A 54 week treatment, randomized, multi center, double blind, placebo controlled study to assess the safety and efficacy of NEBIDO 1000 mg (4 ml) in elderly men with symptomatic late onset hypogonadism...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002053-20,0,0,0 2008-002060-34,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,"Medizinische Universität Wien; Univ.Klin.f.Innere Med. III, Abt.f.Gastroenterologie u. Hepatologie",Impact of Inhibition of Thrombocyte Activation on the course of chronic Hepatitis C,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002060-34,0,0,0 2008-002062-62,7,2010-07-19,2010-07-19,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Teva Pharmaceutical Industries, Ltd","A Multinational, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of talampanel in Subjects with Amyotrophic Lateral Sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002062-62,0,0,0 2008-002062-62,7,2010-07-19,2010-07-19,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Teva Pharmaceutical Industries,Ltd","A Multinational, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Study to Assess the Efficacy, Tolerability and Safety of talampanel in Subjects with Amyotrophic Lateral Sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002062-62,0,0,0 2008-002063-13,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Fluoxetine-Referenced Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Desvenlafaxine Succinate Sustained-Release ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002063-13,0,1,1 2008-002064-34,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc.,"A 6-MONTH, OPEN-LABEL, MULTI-CENTER, FLEXIBLE-DOSE EXTENSION STUDY TO THE B2061014 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF DESVENLAFAXINE SUCCINATE SUSTAINED-RELEASE (DVS SR) TABLET...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002064-34,0,1,1 2008-002066-57,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Wyeth Research,"Multicenter, Open-Label, Safety, Tolerability, and Pharmacokinetic Study to Evaluate Single Ascending Doses and Subsequent Short-Term Administration of Fixed Doses of Desvenlafaxine Succinate Sustaine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002066-57,0,1,1 2008-002067-14,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Wyeth Research,"6-Month, Multicenter, Open-Label, Flexible-Dose Study To Evaluate Safety, Efficacy, And Tolerability Of Desvenlafaxine Succinate Sustained-Release Tablets In The Treatment Of Child And Adolescent Outp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002067-14,0,1,1 2008-002069-30,1,2009-02-27,2009-02-27,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Bayer Vital GmbH,"A randomized, double-blind, single centre, placebo-controlled pilot study to assess on a molecular level the influence of a 5 % dexpanthenol ointment in subjects with previously injured skin by invest...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002069-30,0,0,0 2008-002070-35,1,2018-04-03,2018-04-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,MUC Research GmbH,"NEW ERA STUDY HIV and Eradication: A multicenter, open-label, non-randomized trial to evaluate treatment with multi-drug class (MDC) HAART and its impact on the decay rate of latently infected CD4+ ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002070-35,0,0,0 2008-002072-10,10,2015-12-08,2015-12-30,7,1,0,0,0,0,3,0,0,2,1,0,0,0,2,Boehringer Ingelheim International GmbH,"Multicenter, randomised, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard pemetrexed therapy compared to placebo plus standard pemetrexed therapy in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002072-10,1,0,0 2008-002074-35,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,Janssen-Cilag N.V./S.A.,Clinical outcome study in postoperative pain management to demonstrate the efficacy and safety of IONSYS (fentanyl ITS Iontophoretic Transdermal System) in daily clinical practice and to assess its co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002074-35,0,0,0 2008-002077-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PERUGIA,“Fenoldopam end Renal failure” (FENO-HSR) 'Fenoldopam e insufficienza renale acuta' (FENO-HSR),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002077-12,0,0,0 2008-002079-28,2,2008-11-06,2008-11-06,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Merck Sharp & Dohme GmbH,"A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002079-28,0,0,0 2008-002079-28,2,2008-11-06,2008-11-06,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merck & Co., Inc.","A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0724 Intravenous Infusion on the Amelioration of Neurological Damage and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002079-28,0,0,0 2008-002085-63,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""","TREATMENT OF CHRONIC PAIN BY NEUROMODULATION WITH LOCAL ANESTHETIC (NEURALTHERAPY) IN OPERATED AND / OR IRRADIATED PATIENTS FOR HEAD AND NECK, BREST AND, INTRATHROCIC NEOPLASM",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002085-63,0,0,0 2008-002086-31,1,2011-12-31,2011-12-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ISTITUTO PER L'INFANZIA BURLO GAROFOLO,"Randomized controlled Trial on the effectiveness of metoclopramide alone or in combination with ketoprofene, versus ketoprofene in acute migraine of child",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002086-31,0,0,0 2008-002089-74,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Semmelweis University,The investigation of the effect of dihydralazine (Depressan) on macular edema of type 2 diabetes patients and of inhibition of semicarbazide-sensitive amine oxidase (SSAO).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002089-74,0,0,0 2008-002090-12,1,2012-03-08,2012-03-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Hospital of the university of munich,Effect of Iloprost inhalation before and during extracorporeal circulation (ECC) on perioperative morbidity and outcome in high risk cardiac surgical patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002090-12,0,0,0 2008-002096-27,4,2011-06-21,2011-06-21,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 24-month double-blind, randomized, multicenter, placebocontrolled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily ver...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002096-27,0,0,0 2008-002098-11,1,2012-11-30,2012-11-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ISTITUTO PER L'INFANZIA BURLO GAROFOLO,Randomized Controlled Trial on the effectiveness of ketorolac and tramadole in not compound fractures of child.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002098-11,0,0,0 2008-002100-26,6,2010-11-18,2010-11-18,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Ferring Pharmaceuticals A/S,"PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002100-26,0,0,0 2008-002101-39,2,2009-09-09,2009-09-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKiline Research and Development,An extension study to protocol MD7108240; pazopanib eye drops in subjects with neovascolar age-related macular degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002101-39,0,0,0 2008-002101-39,2,2009-09-09,2009-09-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,An extension study to protocol MD7108240; pazopanib eye drops in subjects with neovascolar age-related macular degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002101-39,0,0,0 2008-002102-19,7,2016-04-26,2021-03-24,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,Estudio de pazopanib frente a sunitinib en el tratamiento de sujetos con carcinoma de células renales localmente avanzado y/o metastásico a Study of Pazopanib versus Sunitinib in the Treatment of Sub...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002102-19,0,0,0 2008-002102-19,7,2016-04-26,2021-03-24,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,Estudio de pazopanib frente a sunitinib en el tratamiento de sujetos con carcinoma de células renales localmente avanzado y/o metastásico a Study of Pazopanib versus Sunitinib in the Treatment of Sub...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002102-19,0,0,0 2008-002102-19,7,2016-04-26,2021-03-24,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,Estudio de pazopanib frente a sunitinib en el tratamiento de sujetos con carcinoma de células renales localmente avanzado y/o metastásico a Study of Pazopanib versus Sunitinib in the Treatment of Sub...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002102-19,0,0,0 2008-002105-39,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,Instituto Catalán de Oncología,"Estudio Piloto/Fase II aleatorizado, multicéntrico, doble ciego en neoadyuvancia de la combinación de exemestano y sunitinib en mujeres postmenopaúsicas con cáncer de mama primario, receptores hormona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002105-39,0,0,0 2008-002106-19,1,2010-03-17,2010-03-17,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Chelsea & Westminster NHS Foundation Trust,Remifentanil sedation for outpatient endoscopic procedures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002106-19,0,0,0 2008-002108-24,1,2009-09-09,2009-09-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Solace Pharmaceuticals Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent, Versus Placebo in the Treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002108-24,0,0,0 2008-002109-38,1,2011-01-07,2011-01-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"AVEO Pharmaceuticals, Inc.","A Phase 1b/2a, Open-Label, Multi-Center Study of AV-951 in Combination with Paclitaxel in Subjects with Advanced or Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002109-38,0,0,0 2008-002110-22,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,"Prof. dr L.H. van den Berg, UMC-Utrecht",A randomised sequential trial of Lithium in amyotrophic lateral sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002110-22,0,0,0 2008-002113-48,6,2015-09-03,2015-11-06,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized double-blind, placebo-controlled study of RAD001 in the treatment of Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002113-48,0,0,0 2008-002113-48,6,2015-09-03,2015-11-06,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized double-blind, placebo-controlled study of RAD001 in the treatment of Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002113-48,0,0,0 2008-002113-48,6,2015-09-03,2015-11-06,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized double-blind, placebo-controlled study of RAD001 in the treatment of Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002113-48,0,0,0 2008-002115-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Asociación Dr. Peset para el estudio de la Hematología (ADOPEH).,"Estudio fase II, multicéntrico para evaluar la eficacia y la seguridad de la administración del esquema COMP-14 (CICLOFOSFAMIDA, VINCRISTINA, DOXORUBICINA LIPOSÓMICA-MYOCET® Y PREDNISONA) combinado c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002115-41,0,0,0 2008-002117-46,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medizinische Klinik I, St. Josef-Hospital, Ruhr-Universität Bochum",Veränderungen der endogenen Insulin- und Glukagonsekretion während einer basalen Insulin-Substitution,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002117-46,0,0,0 2008-002119-42,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,"Merck& Co., Inc.",A Phase III Study to Assess the Tolerability and Efficacy of MK-0822 (Odanacatib) in Reducing the Risk of Bone Metastases and Prolonging Disease-Free Survival in Women with Breast Cancer Spanish titl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002119-42,0,0,0 2008-002120-29,1,2010-01-18,2010-01-18,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Merck&Co.,Inc","A Phase III Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Odanacatib) in Prolonging Bone Metastasis-Free Survival in Men with Castration-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002120-29,0,0,0 2008-002121-36,9,2010-03-02,2010-06-28,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme GmbH,"A 104-Week Extension to: A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002121-36,0,0,0 2008-002121-36,9,2010-03-02,2010-06-28,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","A 104-Week Extension to: A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002121-36,0,0,0 2008-002121-36,9,2010-03-02,2010-06-28,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MSD Finland Oy,"A 104-Week Extension to: A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002121-36,0,0,0 2008-002121-36,9,2010-03-02,2010-06-28,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck & Co. Inc.,"A 104-Week Extension to: A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002121-36,0,0,0 2008-002121-36,9,2010-03-02,2010-06-28,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A 104-Week Extension to: A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002121-36,0,0,0 2008-002121-36,9,2010-03-02,2010-06-28,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"MERCK & CO., INC.","A 104-Week Extension to: A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002121-36,0,0,0 2008-002121-36,9,2010-03-02,2010-06-28,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Laboratoires Merck Sharp & Dohme-Chibret,"A 104-Week Extension to: A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002121-36,0,0,0 2008-002121-36,9,2010-03-02,2010-06-28,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A 104-Week Extension to: A Phase IIb/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002121-36,0,0,0 2008-002122-10,4,2009-12-10,2009-12-10,3,0,0,0,1,0,3,0,0,1,1,0,1,0,1,RDR Pharma GmbH,"Comparison of the Clinical Efficacy and Tolerability of Latanoprost RDR 0.005% Eye Drops Test Formulation of RDR Pharma GmbH, Germany, for the Treatment of Ocular Hypertension and Primary Open Angle G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002122-10,0,0,0 2008-002123-93,1,2015-10-12,2015-10-12,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Johannes Gutenberg-Universität,Mycophenolate sodium in Graves’ orbitopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002123-93,0,0,0 2008-002124-28,8,2010-12-15,2011-01-30,7,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Renovo Ltd,"A double blind, within patient, placebo controlled trial to assess the efficacy of Juvista (avotermin) in conjunction with scar revision surgery for the improvement of disfiguring scars.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002124-28,0,0,0 2008-002124-28,8,2010-12-15,2011-01-30,7,0,0,0,0,0,3,0,0,1,0,0,1,0,1,RENOVO LTD,"A double blind, within patient, placebo controlled trial to assess the efficacy of Juvista (avotermin) in conjunction with scar revision surgery for the improvement of disfiguring scars.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002124-28,0,0,0 2008-002126-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO CLINICO HUMANITAS,A randomized phase II study of progression free survival comparing gemcitabine (1250 mg/m2 infusion) versus carboplatin (AUC5 infusion) plus alimta (500 mg/m2 infusion) as first-line chemotherapy in e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002126-12,0,0,0 2008-002130-30,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Technische Universität München Fakultät für Medizin,"Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT) Zielgerichtete, adjuvante Immunthe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002130-30,0,0,0 2008-002131-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSOCIAZIONE ITALIANA PER LO STUDIO DEL DOLORE,"A RANDOMIZED, OPEN COMPARISON BETWEEN PREGABALIN/TRANSDERMAL BUPRENORPHINE AND PREGABALIN/DICLOFENAC IN CHRONIC NEUROPATHIC PAIN PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002131-32,0,0,0 2008-002134-29,1,2009-09-23,2009-09-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,Rhodiola rosea Extract WS® 1375 in Subjects with Life Stress Symptoms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002134-29,0,0,0 2008-002135-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Antwerp,Is it possible to detect a fibrotic focus in a carcinoma with MR mammography with Gadovist 1.0 followed by core biopsy?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002135-33,0,0,0 2008-002136-15,1,2011-03-03,2011-03-03,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Ninewells Hospital and Medical School,A randomised single blind study comparing the molar ED50 of levobupivacaine and molar ED50 of ropivacaine when administered as a femoral perineural infusion for pain relief after total knee replacemen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002136-15,0,0,0 2008-002138-31,1,2010-01-31,2010-01-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,CENTRE LEON BERARD,"Evaluation de l'efficacité, de la tolérance et analyse médico-économique d'une administration unique de Pegfilgrastim dans les Autogreffes de cellules souches périphériques chez des patients atteints ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002138-31,0,0,0 2008-002139-34,1,2011-07-03,2011-07-03,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Imperial College London,The Pharmacokinetics of Inhaled Fluticasone Propionate delivered as Monodisperse Aerosols,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002139-34,0,0,0 2008-002140-41,1,2009-10-08,2009-10-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Double-blind, placebo controlled, randomized study of vardenafil to determine efficacy on Erectile Dysfunction (ED) in men with ED and Metabolic Syndrome (""ED-METABOLIC"")",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002140-41,0,0,0 2008-002141-24,1,2008-07-25,2008-07-25,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,"A phase II, single-center, randomized, controlled, observer-blind study to determine the non-inferiority of a topical mometasone formulation vs a marketed comparator by evaluation of the anti-psoriati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002141-24,0,0,0 2008-002142-38,1,2009-05-18,2009-05-18,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,NV Organon,"A phase I, single center, open-label parallel group trial to compare the pharmacokinetics of NOMAC between healthy female adolescents (aged 14-17 years) and healthy female adults (aged 18-50 years) af...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002142-38,0,0,0 2008-002143-16,1,2009-05-13,2009-05-13,1,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Clinuvel Pharmaceuticals Limited,"A Phase III, multicentre, double–blind, placebo controlled, cross over study to evaluate the safety and efficacy of subcutaneous bioresorbable implants of afamelanotide in the treatment of solar urtic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002143-16,0,0,0 2008-002144-42,8,2011-03-01,2011-03-01,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Limited,"A Phase II, randomised, multicentre study to evaluate the efficacy and safety of pazopanib in combination with pemetrexed versus cisplatin plus pemetrexed, as first-line therapy in subjects with stage...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002144-42,0,0,0 2008-002144-42,8,2011-03-01,2011-03-01,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A,"A Phase II, randomised, multicentre study to evaluate the efficacy and safety of pazopanib in combination with pemetrexed versus cisplatin plus pemetrexed, as first-line therapy in subjects with stage...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002144-42,0,0,0 2008-002144-42,8,2011-03-01,2011-03-01,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE R&D LIMITED,"A Phase II, randomised, multicentre study to evaluate the efficacy and safety of pazopanib in combination with pemetrexed versus cisplatin plus pemetrexed, as first-line therapy in subjects with stage...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002144-42,0,0,0 2008-002145-22,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,NeuroCode AG,"Klinische Untersuchung zur Verträglichkeit und Wirksamkeit nach Umstellung von Selegilin auf Rasagilin bei Patienten mit Morbus Parkinson und Schlafstörungen. Prospektive, offene, explorative Studie ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002145-22,0,0,0 2008-002151-25,3,2009-08-20,2009-08-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Multi-Centre Phase IIa Study to Assess the Effects on Biomarkers in Induced Sputum, Blood and Urine of AZD1236 Administered as Oral Table...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002151-25,0,0,0 2008-002152-26,1,2013-12-01,2013-12-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,The Royal Marsden Foundation Trust and The Institute of Cancer Research,Randomised double-blind controlled phase III trial of hyperbaric oxygen therapy in patients suffering long-term adverse effects of radiotherapy for pelvic cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002152-26,0,0,0 2008-002155-24,10,2012-03-05,2017-11-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Eli Lilly and Company Limited, UK","A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment with Pemetrexed + Cisplatin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002155-24,0,0,0 2008-002155-24,10,2012-03-05,2017-11-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment with Pemetrexed + Cisplatin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002155-24,0,0,0 2008-002155-24,10,2012-03-05,2017-11-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment with Pemetrexed + Cisplatin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002155-24,0,0,0 2008-002155-24,10,2012-03-05,2017-11-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,"A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment with Pemetrexed + Cisplatin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002155-24,0,0,0 2008-002156-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDATION OF EXPERIMENTAL AND CLINICAL ONCOLOGY,"A phase II non-randomised, open-label, single-arm study to assess the efficacy, safety and tolerability of Nexavar ® (Sorafenib) monotherapy as third line therapy in patients with progressed ovarian e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002156-14,0,0,0 2008-002157-21,1,2009-10-01,2009-10-01,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,NOVO NORDISK,"A Multi-Centre, Multi-National, Open-Label Sequential Trial Comparing Pharmacokinetics and Safety of N8 and Advate in Subjects with Haemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002157-21,0,0,0 2008-002158-40,12,2011-04-27,2011-12-21,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB PLUS PREDNISONE VERSUS PREDNISONE IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF A DO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002158-40,0,0,0 2008-002158-40,12,2011-04-27,2011-12-21,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB PLUS PREDNISONE VERSUS PREDNISONE IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF A DO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002158-40,0,0,0 2008-002158-40,12,2011-04-27,2011-12-21,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc.,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB PLUS PREDNISONE VERSUS PREDNISONE IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF A DO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002158-40,0,0,0 2008-002158-40,12,2011-04-27,2011-12-21,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA","A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB PLUS PREDNISONE VERSUS PREDNISONE IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF A DO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002158-40,0,0,0 2008-002158-40,12,2011-04-27,2011-12-21,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB PLUS PREDNISONE VERSUS PREDNISONE IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF A DO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002158-40,0,0,0 2008-002158-40,12,2011-04-27,2011-12-21,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer S.A.,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB PLUS PREDNISONE VERSUS PREDNISONE IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF A DO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002158-40,0,0,0 2008-002158-40,12,2011-04-27,2011-12-21,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017 USA","A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB PLUS PREDNISONE VERSUS PREDNISONE IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF A DO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002158-40,0,0,0 2008-002159-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut Gustave Roussy,"Etude randomisée, en double aveugle, contre placebo, de l’Efficacité de l’ Escitalopram dans le traitement de la détresse émotionnelle des sujets atteints de cancer ORL en cours de traitement",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002159-25,0,0,0 2008-002160-34,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,1,EleosInc Limited,Aezea™ (cenersen) in combination with chemotherapy for the treatment of refractory acute myelogenous leukemia subjects ≥ 55 years of age with inadequate response to a single frontline induction course...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002160-34,0,0,0 2008-002164-34,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,H. Lundbeck A/S,"Randomised, double-blind, 3-way crossover, single dose, placebo-controlled study investigating the effect on postural instability of melatonin and zolpidem in healthy elderly subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002164-34,0,0,0 2008-002169-30,1,2012-06-01,2012-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Greater Glasgow Health Board, Research and Development Department",A randomised placebo-controlled trial of metformin on progression of carotid atherosclerosis in non-diabetic patients with cardiovascular disease treated with conventional risk reducing agents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002169-30,0,0,0 2008-002169-30,1,2012-06-01,2012-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Senior Contracts Manager,Research and Enterprise,University of Glasgow",A randomised placebo-controlled trial of metformin on progression of carotid atherosclerosis in non-diabetic patients with cardiovascular disease treated with conventional risk reducing agents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002169-30,0,0,0 2008-002171-27,1,2016-04-07,2016-04-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Instituto Científico y Tecnológico de Navarra, SA. (ICT).","ENSAYO CLÍNICO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y MULTICÉNTRICO PARA EVALUAR LA EFICACIA DEL TRATAMIENTO PALIATIVO CON METILFENIDATO EN ASTENIA (DE PACIENTES CON CÁNCER AVANZADO).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002171-27,0,0,0 2008-002177-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Intérêt de la mesure de l’activité calcineurine dans le suivi thérapeutique du tacrolimus chez des patients transplantés rénaux,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002177-13,0,0,0 2008-002183-34,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,"Celtic Pharma Development Services Bermuda, Ltd.","Estudio Doble Ciego, Aleatorizado, Controlado con Placebo, Multicéntrico para evaluar la Eficacia Clínica, Seguridad e Inmunogenicidad de una Vacuna Humana para Cocaína (TA-CD) en el Tratamiento de l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002183-34,0,0,0 2008-002185-60,1,2011-06-29,2011-06-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Mundipharma Medical Company, Basel","RANDOMISED, CONTROLLED CLINICAL STUDY REGARDING THE FEASIBILITY OF CONVERTING OPIATE DEPENDENTS FROM METHADONE SUBSTITUTES TO SLOW RELEASE MORPHINE SULPHATE (SEVRE-LONG®)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002185-60,0,0,0 2008-002191-98,1,2013-11-28,2013-11-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Servicio de Nefrologia-Hospital Universitario Vall d'Hebron,"""Efecto del ARA-II Olmesartan sobre el metabolismo del potasio en pacientes con insuficiencia renal crónica""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002191-98,0,0,0 2008-002195-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,A Phase II randomized multicenter study to assess the efficacy of lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor in patients with low and intermediate-1 risk mye...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002195-10,0,0,0 2008-002197-35,1,2011-11-23,2011-11-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Krankenhaus Nordwest GmbH,Multizentrische randomisierte Phase II Studie zur Therapie des lokal fortgeschrittenen oder metastasierten NSCLC (Stadium IIIB/IV) mit Cisplatin/Docetaxel oder Oxaliplatin/Docetaxel A multicenter ra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002197-35,0,0,0 2008-002199-88,5,2013-01-25,2013-01-25,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Efecto de liraglutida en el peso corporal en sujetos con sobrepeso u obesos con diabetes tipo 2. Ensayo clínico de 1 año de duración, aleatorizado, doble-ciego, controlado con placebo, con tres grupos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002199-88,0,0,0 2008-002202-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,CALENDULA POMADE VERSUS PLACEBO CREAM/CORTISONE CREAM (FLUORCORTOLONE) IN THE PREVENTION OF CUTANEOUS ERYTHEMA DUE TO BREAST IRRADIATION. A RANDOMIZED STUDY ON 60 PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002202-18,0,0,0 2008-002204-25,4,2010-03-22,2010-03-31,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Biogen Idec Ltd,"A Phase 2, Randomized, Open-Label Study to Evaluate ECG Results and Pharmacokinetic Parameters for Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Combination with Lumiliximab Versus FCR Alone ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002204-25,0,0,0 2008-002205-40,6,2012-01-31,2012-01-31,6,1,0,0,0,2,3,0,0,1,0,0,1,0,2,GlaxoSmithKline,DEFEND-1: Durable Response Therapy Evaluation For Early Or New Onset Type 1 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002205-40,0,0,0 2008-002205-40,6,2012-01-31,2012-01-31,6,1,0,0,0,2,3,0,0,1,0,0,1,0,2,"TOLERX,INC.",DEFEND-1: Durable Response Therapy Evaluation For Early Or New Onset Type 1 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002205-40,0,0,0 2008-002205-40,6,2012-01-31,2012-01-31,6,1,0,0,0,2,3,0,0,1,0,0,1,0,2,"Tolerx, Inc.",DEFEND-1: Durable Response Therapy Evaluation For Early Or New Onset Type 1 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002205-40,0,0,0 2008-002205-40,6,2012-01-31,2012-01-31,6,1,0,0,0,2,3,0,0,1,0,0,1,0,2,GlaxoSmithKline UK Limited,DEFEND-1: Durable Response Therapy Evaluation For Early Or New Onset Type 1 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002205-40,0,0,0 2008-002206-20,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Impact de l'analgésie péridurale thoracique sur la récupération fonctionnelle des patients participant à un programme de réhabilitation précoce en chirurgie colo-rectale, Essai multicentrique, randomi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002206-20,0,0,0 2008-002208-24,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Pfizer Inc., 235 East 42nd Street,New York,NY 10017","A FOUR WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2A STUDY OF VARENICLINE TARTRATE (CP-526,555) IN THE TREATMENT OF POST-HERPETIC NEURALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002208-24,0,0,0 2008-002209-38,3,2009-03-06,2009-03-06,3,1,0,0,0,0,2,0,0,1,1,1,1,0,2,NovaCardia Inc.,"A multicenter, randomized, double-blind, placebo-controlled study of the hemodynamic effects of rolofylline injectable emulsion in the treatment of patients with heart failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002209-38,0,0,0 2008-002209-38,3,2009-03-06,2009-03-06,3,1,0,0,0,0,2,0,0,1,1,1,1,0,2,"NovaCardia, Inc. (A wholly owned subsidiary of Merck & Co., Inc.)","A multicenter, randomized, double-blind, placebo-controlled study of the hemodynamic effects of rolofylline injectable emulsion in the treatment of patients with heart failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002209-38,0,0,0 2008-002210-22,1,2012-08-02,2012-08-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Janssen Oncology, Inc.",An Extended Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy and Completed Clinical Study COU-AA-00...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002210-22,0,0,0 2008-002213-51,1,2014-12-06,2014-12-06,1,0,0,0,0,0,4,0,1,1,1,1,1,0,0,"Puolustusvoimat, Sotilaslääketieteen keskus","Typpihumalatesti sukeltajilla: Satunnaistettu nousu painekammiossa hengittämällä ilmaa, maskilla ilmaa tai maskilla happea.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002213-51,0,0,0 2008-002219-42,7,2010-09-14,2010-10-14,5,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Mundipharma Research Limited,A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children with Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin’s Lymphom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002219-42,0,0,0 2008-002219-42,7,2010-09-14,2010-10-14,5,1,0,1,0,1,1,0,0,1,1,0,0,0,1,MUNDIPHARMA RESEARCH LIMITED,A Phase I/II Pharmacokinetic Study of Intravenous and Oral Forodesine in Children with Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin’s Lymphom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002219-42,0,0,0 2008-002221-36,1,2008-11-20,2008-11-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Serono International, An affiliate of Merck KGaA, Darmstadt, Germany","A Phase II/III, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of atacicept in combination with corticosteroids and sequential therapy with cyclophosphamide and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002221-36,0,0,0 2008-002226-11,1,2020-10-23,2020-10-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Charité - Unversitätsmedizin Berlin,Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002226-11,0,0,0 2008-002230-30,5,2009-03-10,2009-07-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 6 Week Double-Blind, Placebo-controlled, Randomised, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of AZD1236 as an Oral Tablet in Patients with Moderate to Severe CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002230-30,0,0,0 2008-002231-32,13,2012-12-13,2013-01-04,11,1,0,0,0,0,0,0,0,1,1,0,1,0,2,Astellas Pharma Europe Ltd.,"A MULTICENTER, THREE ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED PO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002231-32,0,0,0 2008-002231-32,13,2012-12-13,2013-01-04,11,1,0,0,0,0,0,0,0,1,1,0,1,0,2,Service Desk,"A MULTICENTER, THREE ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED PO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002231-32,0,0,0 2008-002231-32,13,2012-12-13,2013-01-04,11,1,0,0,0,0,0,0,0,1,1,0,1,0,2,ASTELLAS PHARMA,"A MULTICENTER, THREE ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED PO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002231-32,0,0,0 2008-002231-32,13,2012-12-13,2013-01-04,11,1,0,0,0,0,0,0,0,1,1,0,1,0,2,"Astellas Pharma Europe, Ltd.","A MULTICENTER, THREE ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED PO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002231-32,0,0,0 2008-002236-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Center,A phase II study in patients with fludarabine refractory CLL: Dasatinib treatment combination for Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002236-15,0,0,0 2008-002237-73,1,2012-07-30,2012-07-30,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Dept. of Pharmacology, Aarhus University",Sildenafil Treatment of COPD associated Pulmonary Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002237-73,0,0,0 2008-002242-34,1,2009-07-01,2009-07-01,1,0,0,0,0,0,4,0,1,1,1,1,1,0,0,Center for neuropsykiatrisk Schrizofreniforskning,Antipsykotikas påvirkning af funktionelle kandidatendofænotyper for skizofreni: En prædiktor for outcome?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002242-34,0,0,0 2008-002244-42,1,2012-09-11,2012-09-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,"Does 1-alpha,25-dihydroxyvitamin D3 (calcitriol) enhance corticosteroid activity in steroid refractory asthma? A randomised control trial to test whether active vitamin D can improve the clinical res...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002244-42,0,0,0 2008-002244-42,1,2012-09-11,2012-09-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's and St Thomas' NHS Foundation Trust,"Does 1-alpha,25-dihydroxyvitamin D3 (calcitriol) enhance corticosteroid activity in steroid refractory asthma? A randomised control trial to test whether active vitamin D can improve the clinical res...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002244-42,0,0,0 2008-002246-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),"Local application of mitomicin C for the treatment of stricturing Crohn’s disease: a phase III, single-center, randomized clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002246-33,0,0,0 2008-002247-16,13,2013-02-27,2014-05-10,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002247-16,0,0,0 2008-002247-16,13,2013-02-27,2014-05-10,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002247-16,0,0,0 2008-002248-40,3,2009-07-06,2009-07-06,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Efecto de Duloxetina 60 mg, Administrado una Vez al Día, Frente a Placebo, en Pacientes con Lumbalgia Crónica Effect of Duloxetine 60 mg Once Daily versus Placebo in Patients with Chronic Low Back Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002248-40,0,0,0 2008-002248-40,3,2009-07-06,2009-07-06,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"Efecto de Duloxetina 60 mg, Administrado una Vez al Día, Frente a Placebo, en Pacientes con Lumbalgia Crónica Effect of Duloxetine 60 mg Once Daily versus Placebo in Patients with Chronic Low Back Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002248-40,0,0,0 2008-002260-33,7,,,0,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Bristol Myers Squibb International Corporation,A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or with Ph+ Leukemias Resistant or Intolerant to Imatinib Revised Pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002260-33,0,1,0 2008-002260-33,7,,,0,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb Internaltional Corporation,A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or with Ph+ Leukemias Resistant or Intolerant to Imatinib Revised Pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002260-33,0,1,0 2008-002263-13,5,2010-07-20,2010-07-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Multi-center, double-blind, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) compared to a monophasic contracepti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002263-13,0,0,0 2008-002263-13,5,2010-07-20,2010-07-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER HEALTHCARE AG,"Multi-center, double-blind, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) compared to a monophasic contracepti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002263-13,0,0,0 2008-002264-34,4,2010-10-05,2010-10-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LETI Pharma GmbH,"Randomised, double blinded, placebo controlled, parallel group study to evaluate efficacy and safety of Depigoid® Grass / Birch Mix in patients with allergic rhinitis and/or rhinoconjunctivitis with o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002264-34,0,0,0 2008-002269-29,1,2013-02-18,2013-02-18,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Universitätsklinikum Heidelberg,"A prospective, randomized, double-blind, multicenter, Phase III clinical study on transarterial chemoembolisation (TACE) combined with Sorafenib vs. TACE plus placebo in patients with hepatocellular c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002269-29,0,0,0 2008-002273-12,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,OSPEDALE POLICLINICO S. MATTEO,"Long term opioid administration in oncologic chronic pain: open label, prospective study on efficacy, safety and pharmacogenetic factors.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002273-12,0,0,0 2008-002277-13,1,2012-02-09,2012-02-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MCM Klosterfrau Vertriebs GmbH,"Double blind, randomized, placebo-controlled clinical trial to proof the efficacy and tolerability of the homeopathic medicinal product Klosterfrau Allergin Globuli in comparison to placebo in childre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002277-13,0,0,0 2008-002278-37,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Johann Wolfgang Goethe Universität,Auswirkungen von Pantoprazol auf die myokardiale Kontraktilität bei Patienten mit Herzinsuffizienz - influence of pantoprazole on human myocardial contractility at patients with congestive heart failu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002278-37,0,0,0 2008-002280-14,1,2009-01-13,2009-01-13,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Pierre Fabre Médicament,"Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002280-14,0,0,0 2008-002281-55,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Merck Farma y Química S.L,Estudio exploratorio para determinar el efecto de lutropina alfa en la calidad de los embriones y su implantación en mujeres de edad reproductiva avanzada,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002281-55,0,0,0 2008-002284-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"CombinatoRx, Incorporated","A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO ASSESS THE ANTI-INFLAMMATORY PROPERTIES OF TOPICAL CRX-197 IN LESIONAL SKIN OF ADULT SUBJECTS WITH MILD TO MODERATE ATOPIC DERMATITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002284-13,0,0,0 2008-002286-32,1,2014-10-03,2014-10-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Queen Mary Medical University of London,"Phase I/II Study combining humanised anti-CD20 (veltuzumab), anti-CD22 (epratuzumab) and both monoclonal antibodies with chemotherapy in adults with recurrent B precursor acute lymphoblastic leukaemia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002286-32,0,0,0 2008-002287-33,1,2011-11-15,2011-11-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Belfast Health and Social Care Trust,"Effect of HMG-Co A reductase inhibition on endothelial dysfunction, bioavailability of tetrahydrobiopterin (BH4) and functional regulation of endothelial nitric oxide synthase (eNOS) in human heart fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002287-33,0,0,0 2008-002287-33,1,2011-11-15,2011-11-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Queens University Belfast,"Effect of HMG-Co A reductase inhibition on endothelial dysfunction, bioavailability of tetrahydrobiopterin (BH4) and functional regulation of endothelial nitric oxide synthase (eNOS) in human heart fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002287-33,0,0,0 2008-002288-14,1,2011-06-30,2011-06-30,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,University of Birmingham,Phase I Dose Escalation Study of Clofarabine and Liposomal Daunorubicin in Childhood and Adolescent AML,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002288-14,0,0,0 2008-002292-27,1,2014-05-20,2014-05-20,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,OSPEDALE POLICLINICO S. MATTEO,"Long term opioid administration in no-oncologic chronic pain: open label, prospective study on efficacy, safety and pharmacokinetic factors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002292-27,0,0,0 2008-002295-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Role of immunosuppression with steroids in the outcome of fibrosis due to recurrent hepatitis C virus (HCV) infection after liver transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002295-10,0,0,0 2008-002298-11,1,2008-11-17,2008-11-17,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"Open-label, multicenter, dose-escalation Phase I/II study to evaluate safety, pharmacokinetics and activity of RO5126766, a dual Raf and MEK inhibitor, administered orally as monotherapy in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002298-11,0,0,0 2008-002299-92,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,METRONOMIC CAPECITABINE IN ADVANCED HEPATOCARCINOMA: A FASE II STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002299-92,0,0,0 2008-002301-38,2,2010-09-17,2010-09-17,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline S. A.,"A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study with a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA™ on Bone in Postmenopausal Women with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002301-38,0,0,0 2008-002301-38,2,2010-09-17,2010-09-17,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study with a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA™ on Bone in Postmenopausal Women with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002301-38,0,0,0 2008-002302-18,2,2009-11-09,2009-11-09,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Amicus Therapeutics, Inc.","An open-label, multicenter, study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of three dosing regimens of oral AT2220 in patients with Pompe disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002302-18,0,0,0 2008-002305-40,1,2013-05-03,2013-05-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Steigerwald Arzneimittelwerk GmbH,"A double-blind, randomised, placebo-controlled study on the Efficacy of Iberogast® (STW 5) in patients with functional dyspepsia and concomitant reflux symptoms measured with impedance and wireless pH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002305-40,0,0,0 2008-002306-19,1,2013-05-05,2013-05-05,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,University of Rochester,"Double-blind, placebo-controlled, parallel group, phase III study comparing dichlorphenamide vs. placebo for the treatment of periodic paralysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002306-19,0,0,0 2008-002308-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Centre Nijmegen St Radboud,A RANDOMISED STUDY OF DOCETAXEL/CISPLATIN/5-FLUOROURACIL (TPF) AS NEOADJUVANT CHEMOTHERAPY FOLLOWED BY CONCOMITANT CHEMORADIOTHERAPY (CRT) WITH CONVENTIONAL RADIOTHERAPY (RT) VERSUS CONCOMITANT CRT WI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002308-24,0,0,0 2008-002309-38,8,2010-12-20,2010-12-20,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with docetaxel in second-line treatment of patients with advanced or metastatic (stage IIIb/IV) no...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002309-38,0,0,0 2008-002309-38,8,2010-12-20,2010-12-20,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with docetaxel in second-line treatment of patients with advanced or metastatic (stage IIIb/IV) no...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002309-38,0,0,0 2008-002309-38,8,2010-12-20,2010-12-20,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with docetaxel in second-line treatment of patients with advanced or metastatic (stage IIIb/IV) no...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002309-38,0,0,0 2008-002310-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,A multicenter phase II trial of Recipient pre-treatment with Short-Term Rapamycin for the prevention of acute GVHD after hematopoietic stem cell transplantation in Elderly Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002310-22,0,0,0 2008-002311-40,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA,ICC APL STUDY 01 TREATMENT STUDY FOR CHILDREN AND ADOLESCENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002311-40,0,0,0 2008-002311-40,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA,ICC APL STUDY 01 TREATMENT STUDY FOR CHILDREN AND ADOLESCENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002311-40,0,0,0 2008-002314-21,1,2009-06-27,2009-06-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,A. MENARINI I.F.R.,VALUTAZIONE COMPARATIVA DEGLI EFFETTI SULLA FUNZIONE ENDOTELIALE DEL TRATTAMENTO CON NEBIVOLOLO E IDROCLOROTIAZIDE VS IRBESARTAN E IDROCLOROTIAZIDE IN PAZIENTI CON IPERTENSIONE ARTERIOSA NEO-DIAGNOSTI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002314-21,0,0,0 2008-002315-41,2,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Ardea Biosciences, Inc.","Estudio de dosis variables, controlado con placebo, multicéntrico, doble ciego y aleatorio para evaluar la eficacia y seguridad del RDEA806 en pacientes hiperuricémicos con gota sintomática Randomize...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002315-41,0,0,0 2008-002317-40,1,2009-04-30,2009-04-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Perrigo Israel Pharmaceuticals Ltd.,"A phase IIa, multi-center, randomized, double-blind, vehicle-controlled study to determine antipsoriatic efficacy and safety of topical CEP-701 (lestaurtinib) cream formulations in patients with psori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002317-40,0,0,0 2008-002318-22,4,2011-05-06,2011-05-06,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder from a Mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002318-22,0,0,0 2008-002319-42,9,2010-03-02,2010-05-03,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,Comparación de dos estrategias de tratamiento diferentes en pacientes con trastorno depresivo mayor en tratamiento con escitalopram que no presentan mejoría: Estrategia de intervención temprana versus...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002319-42,0,0,0 2008-002319-42,9,2010-03-02,2010-05-03,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Lilly S.A.,Comparación de dos estrategias de tratamiento diferentes en pacientes con trastorno depresivo mayor en tratamiento con escitalopram que no presentan mejoría: Estrategia de intervención temprana versus...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002319-42,0,0,0 2008-002320-29,12,2020-03-06,2020-03-06,9,0,0,0,0,2,3,0,0,2,0,0,0,0,1,"Exelixis, Inc.","An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002320-29,1,0,0 2008-002320-29,12,2020-03-06,2020-03-06,9,0,0,0,0,2,3,0,0,2,0,0,0,0,1,Exelixis Inc,"An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002320-29,1,0,0 2008-002322-11,1,2015-05-20,2015-05-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust,ARTemis : Avastin® Randomised Trial with nEo-adjuvant cheMotherapy for patients wIth early breaSt cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002322-11,0,0,0 2008-002322-11,1,2015-05-20,2015-05-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Cambridge,ARTemis : Avastin® Randomised Trial with nEo-adjuvant cheMotherapy for patients wIth early breaSt cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002322-11,0,0,0 2008-002325-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Medicine I, University Hospital St. Josef-Hospital, Ruhr University Bochum","Effects of Exenatide (Byetta®) on biochemical and histological parameters of liver function in patients with Nonalcoholic Steatohepatitis (NASH) – a randomized, placebo-controlled, parallel-group tria...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002325-37,0,0,0 2008-002326-11,5,2014-08-20,2014-08-20,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,PHARMA MAR,"A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS) STUDIO DI FA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002326-11,0,0,0 2008-002326-11,5,2014-08-20,2014-08-20,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Pharma Mar, S.A., Sociedad Unipersonal","A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS) STUDIO DI FA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002326-11,0,0,0 2008-002326-11,5,2014-08-20,2014-08-20,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Pharma Mar, S.A","A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS) STUDIO DI FA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002326-11,0,0,0 2008-002326-11,5,2014-08-20,2014-08-20,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Pharma Mar, S.A.","A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS) STUDIO DI FA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002326-11,0,0,0 2008-002332-15,1,2009-05-07,2009-05-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomised, double-blind, placebo-controlled study to evaluate the transthoracic Doppler echocardiography method as a non-invasive method for coronary function measurements; ability to detect short-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002332-15,0,0,0 2008-002333-75,8,2009-12-09,2009-12-10,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Vifor (International) Inc.,"A multi-centre, randomised, prospective, open-label study to investigate the efficacy and safety of a standardised correction dosage regimen of intravenous ferric carboxymaltose (FERINJECT®) versus ir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002333-75,0,0,0 2008-002335-32,1,2009-07-08,2009-07-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The University of Leeds,Does concentration affect the ED50 of bupivacaine for supraclavicular brachial plxus block?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002335-32,0,0,0 2008-002336-15,1,2017-09-20,2017-09-20,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,King's College London,The effect of prednisolone versus hydrocortisone as glucocorticoid replacement therapy on hypoglycaemia frequency in people with Type 1 diabetes and adrenal insufficiency: a pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002336-15,0,0,0 2008-002336-15,1,2017-09-20,2017-09-20,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,King's College Hospital NHS Foundation Trust,The effect of prednisolone versus hydrocortisone as glucocorticoid replacement therapy on hypoglycaemia frequency in people with Type 1 diabetes and adrenal insufficiency: a pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002336-15,0,0,0 2008-002338-31,1,2011-06-30,2011-06-30,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Hannover Medical School,Prospektive randomisierte Phase II Studie zur Behandlung von Patienten mit fortgeschrittenem hormonrefraktären Prostatakarzinom mittels LHRH-Analoga und Somatostatin-Analoga unter Berücksichtigung der...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002338-31,0,0,0 2008-002340-42,2,2009-11-09,2009-11-09,2,0,0,0,0,1,3,0,0,1,0,0,1,0,1,Biotec Pharmacon ASA,"A randomized, double-blind, placebo-controlled, parallel-group phase III clinical study to assess the efficacy and safety of soluble beta 1,3/1,6 glucan (SBG) on oral mucositis in head and neck cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002340-42,0,0,0 2008-002343-16,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Postoperative nausea and vomiting: acupuncture effect on postoperative prevention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002343-16,0,0,0 2008-002345-23,7,2015-06-09,2015-06-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,"A PHASE 2, MULTICENTER, OPEN-LABEL, ACTIVE COMPARATOR CONTROLLED, EXTENSION TRIAL TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CP-690,550 IN RENAL ALLOGRAFT RECIPIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002345-23,0,0,0 2008-002345-23,7,2015-06-09,2015-06-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY10017","A PHASE 2, MULTICENTER, OPEN-LABEL, ACTIVE COMPARATOR CONTROLLED, EXTENSION TRIAL TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CP-690,550 IN RENAL ALLOGRAFT RECIPIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002345-23,0,0,0 2008-002345-23,7,2015-06-09,2015-06-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 2, MULTICENTER, OPEN-LABEL, ACTIVE COMPARATOR CONTROLLED, EXTENSION TRIAL TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CP-690,550 IN RENAL ALLOGRAFT RECIPIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002345-23,0,0,0 2008-002345-23,7,2015-06-09,2015-06-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A","A PHASE 2, MULTICENTER, OPEN-LABEL, ACTIVE COMPARATOR CONTROLLED, EXTENSION TRIAL TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CP-690,550 IN RENAL ALLOGRAFT RECIPIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002345-23,0,0,0 2008-002345-23,7,2015-06-09,2015-06-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY10017, USA","A PHASE 2, MULTICENTER, OPEN-LABEL, ACTIVE COMPARATOR CONTROLLED, EXTENSION TRIAL TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CP-690,550 IN RENAL ALLOGRAFT RECIPIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002345-23,0,0,0 2008-002346-30,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Esko Kemppainen,SUPRAFYSIOLOGINEN HYDROKORTISONI VAIKEASSA AKUUTISSA HAIMATULEHDUKSESSA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002346-30,0,0,0 2008-002352-20,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Actelion Pharmaceuticals Ltd,"Single center, double-blind, randomized, placebo-controlled, two-period/two-treatment crossover study investigating the effect of miglustat on the nasal potential difference in patients with cystic fi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002352-20,0,0,0 2008-002354-38,1,2009-11-04,2009-11-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Merck Serono Ltd,"A Phase IV, prospective, open label multicentre study of Raptiva 1mg/kg/week by subcutaneous injection in adults with moderate to severe chronic plaque psoriasis who have failed previous biologic ther...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002354-38,0,0,0 2008-002356-18,6,2017-12-31,2018-01-25,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,medac Gesellschaft für klinische Spezialpräparate mbH,Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002356-18,0,0,0 2008-002356-18,6,2017-12-31,2018-01-25,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,MEDAC RESEARCH,Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002356-18,0,0,0 2008-002359-26,1,2009-04-28,2009-04-28,1,0,0,0,1,0,4,0,0,1,0,0,1,0,1,Stiefel Laboratories,"A multi-center, randomized, evaluator-blind, parallel group study evaluation of the efficacy, safety, and tolerability of DUAC® Akne Gel and Epiduo® Gel in the topical treatment of facial acne vulga...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002359-26,0,0,0 2008-002360-33,4,2009-05-15,2009-05-23,4,1,0,0,0,0,3,0,1,1,1,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, observer-blind, multicountry, multicentre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ GSK2186877A influenza vaccine administered to adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002360-33,0,0,0 2008-002361-31,1,2009-08-05,2009-08-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gilead Sciences Incorporated,"A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Activity of GS 9450 in Adults with Non-Alcoholic Steatohepat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002361-31,0,0,0 2008-002362-66,2,2009-12-15,2009-12-15,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, observer-blind, multi-country, multi-centre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals FLU NG vaccine compared to the reference v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002362-66,0,0,0 2008-002367-14,2,2016-03-31,2016-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Vejle Sygehus,Kombineret biologisk behandling og kemoterapi til patienter med inoperabelt cholangiocarcinom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002367-14,0,0,0 2008-002367-14,2,2016-03-31,2016-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Växjö Central Hospital,Kombineret biologisk behandling og kemoterapi til patienter med inoperabelt cholangiocarcinom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002367-14,0,0,0 2008-002369-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MSE Pharmazeutika GmbH,"Randomized, double-blind study of nanoquinone versus placebo in patients with tinnitus aurium and low baseline blood levels of Q10",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002369-29,0,0,0 2008-002373-12,1,2010-11-11,2010-11-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,Effect of Spironolactone on Exercise Capacity in functionally impaired older people without heart failure: a double blind placebo controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002373-12,0,0,0 2008-002376-95,1,2012-08-30,2012-08-30,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,University Hospital Birmingham NHS Foundation Trust,Myocardial protection with Perhexiline in Left Ventricular Hypertrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002376-95,0,0,0 2008-002378-37,1,2014-11-11,2014-11-11,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,National Institute of Health and the Environment (RIVM),The longitudinal kinetics of long term cellular memory immunity against Bordetella pertussis in Dutch 8-9 years old children after ACV booster vaccination.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002378-37,0,0,0 2008-002380-14,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Protocole n° 2 de thérapie génique du déficit immunitaire combiné sévère lié à l’X (DISC-X1) lié à l’X (DISC-X1) à l’aide d’un vecteur rétroviral sécurisé,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002380-14,0,0,0 2008-002381-55,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,"ROCHE FARMA, S.A.","Evaluación de la Eficacia de Rituximab en pacientes con Artritis Reumatoide a través de la medición, por Resonancia Magnética de Mano, de los parámetros clínicos de la enfermedad. Estudio RESONAR. Ef...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002381-55,0,0,0 2008-002383-34,1,2011-04-15,2011-04-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,JANSSEN-CILAG,"A randomised, controlled, open-label trial to compare brachial artery reactivity and cardiovascular risk of a treatment simplification by darunavir/ritonavir (DRV/r) 800/100 mg O.D. versus a triple co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002383-34,0,0,0 2008-002384-13,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,JANSSEN-CILAG,Efficacy and Tolerability of Flexible Doses of Paliperidone ER in Symptomatic Subjects with Schizophrenia with duration of illness < 10 years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002384-13,0,0,0 2008-002387-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hôpital Erasme,Impact of 25-hydroxy vitamin D deficiency and its correction on mineral and bone disorde among hemodialysis patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002387-33,0,0,0 2008-002390-13,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,University Hospital,Are cranberry capsules useful in preventing urinary tract infection in hip fracture patients with urinary tract catheter,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002390-13,0,0,0 2008-002391-97,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,University Hospital Antwerp; Department Respiratory Medicine,"Open-label, prospective study to assess the effects of formoterol and beclometasone dipropionate combination therapy on central and peripheral airway dimensions in asthmatic patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002391-97,0,0,0 2008-002392-27,7,2017-12-20,2017-12-20,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","""Estudio en fase 1/2, abierto y aleatorizado de la seguridad, eficacia y farmacocinética de letrozol más PD 0332991 (inhibidor oral de CDK 4/6) y letrozol en monoterapia, para el tratamiento en primer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002392-27,0,0,0 2008-002392-27,7,2017-12-20,2017-12-20,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Inc.,"""Estudio en fase 1/2, abierto y aleatorizado de la seguridad, eficacia y farmacocinética de letrozol más PD 0332991 (inhibidor oral de CDK 4/6) y letrozol en monoterapia, para el tratamiento en primer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002392-27,0,0,0 2008-002392-27,7,2017-12-20,2017-12-20,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Inc. 235 East 42nd Street New York NY 10017,"""Estudio en fase 1/2, abierto y aleatorizado de la seguridad, eficacia y farmacocinética de letrozol más PD 0332991 (inhibidor oral de CDK 4/6) y letrozol en monoterapia, para el tratamiento en primer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002392-27,0,0,0 2008-002392-27,7,2017-12-20,2017-12-20,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","""Estudio en fase 1/2, abierto y aleatorizado de la seguridad, eficacia y farmacocinética de letrozol más PD 0332991 (inhibidor oral de CDK 4/6) y letrozol en monoterapia, para el tratamiento en primer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002392-27,0,0,0 2008-002392-27,7,2017-12-20,2017-12-20,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,PFIZER,"""Estudio en fase 1/2, abierto y aleatorizado de la seguridad, eficacia y farmacocinética de letrozol más PD 0332991 (inhibidor oral de CDK 4/6) y letrozol en monoterapia, para el tratamiento en primer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002392-27,0,0,0 2008-002396-28,10,2009-04-15,2009-04-15,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Infinity Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002396-28,0,0,0 2008-002396-28,10,2009-04-15,2009-04-15,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,INFINITY PHARMACEUTICAL INC.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients with Metastatic and/or Unresectable Gastrointestinal Stromal Tumor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002396-28,0,0,0 2008-002399-92,1,2009-02-03,2009-02-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,MedPharm Ltd.,"A phase IIa randomised, observer-blind, comparative study of the efficacy, tolerability and consumer acceptability of topical MedSpray™ TP 1 % versus Lamisil® Once 1 % in the treatment of tinea pedis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002399-92,0,0,0 2008-002418-23,1,2010-02-19,2010-02-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Stiefel Laboratories Inc.,"A phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in subjects with distal subun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002418-23,0,0,0 2008-002421-37,4,2010-01-19,2010-01-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Ltd;Ramsgate Road,Sandwich,Kent CT13 9NJ","A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS AS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002421-37,0,0,0 2008-002421-37,4,2010-01-19,2010-01-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Ltd., Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK","A PHASE 2, 12 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL GROUP, PROOF OF CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF PD 0299685 FOR THE TREATMENT OF SYMPTOMS AS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002421-37,0,0,0 2008-002426-10,1,2010-03-24,2010-03-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Napp Pharmaceuticals Ltd,"A double-blind, double-dummy, parallel group, randomised study to compare the efficacy and tolerability of oxycodone/naloxone prolonged release (OXN PR) and codeine/paracetamol in the treatment of mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002426-10,0,0,0 2008-002427-90,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SUBSTIPHARM Développement,"Etude en double aveugle de l’équivalence clinique et mycologique du Locéryl® (Amorolfine, solution filmogène à 5%) et de son générique dans le traitement des onychomycoses sans atteinte de la matrice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002427-90,0,0,0 2008-002428-27,2,2012-11-22,2012-11-22,2,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Mundipharma Research Limited,"A multi-centre, open-label, single therapy, dose ranging study to characterise the pharmacokinetics and tolerability of BTDS 5-20 µg/h in children who require opioid analgesia for moderate to severe m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002428-27,0,0,0 2008-002439-33,3,2010-10-01,2010-10-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA,EFFICACY AND SAFETY OF ZOFENOPRIL + HYDROCHLOROTHIAZIDE COMBINATION VS IRBESARTAN + HYDROCHLOROTHIAZIDE COMBINATION IN ESSENTIAL HYPERTENSIVE PATIENTS NOT CONTROLLED BY PREVIOUS MONOTHERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002439-33,0,0,0 2008-002439-33,3,2010-10-01,2010-10-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.,EFFICACY AND SAFETY OF ZOFENOPRIL + HYDROCHLOROTHIAZIDE COMBINATION VS IRBESARTAN + HYDROCHLOROTHIAZIDE COMBINATION IN ESSENTIAL HYPERTENSIVE PATIENTS NOT CONTROLLED BY PREVIOUS MONOTHERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002439-33,0,0,0 2008-002446-39,1,2009-05-28,2009-05-28,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Clinuvel Pharmaceuticals Limited,"A Phase II, Multicentre, Double-blind, Placebo Controlled, Pilot Study to Evaluate the Safety and Efficacy of CUV1647 Administered as A Subcutaneous Bioresorbable 16mg Implant in Patients Undergoing P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002446-39,0,0,0 2008-002447-16,14,2015-09-08,2016-03-15,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Biologicals,A double-blind placebo-controlled Phase III study to assess the efficacy of MAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002447-16,0,0,0 2008-002447-16,14,2015-09-08,2016-03-15,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.",A double-blind placebo-controlled Phase III study to assess the efficacy of MAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002447-16,0,0,0 2008-002454-37,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,intrarterial chemotherapy with liposomial doxorubicin for recurrent glioblastoma affected patients. Phase II study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002454-37,0,0,0 2008-002455-25,7,2017-09-26,2018-05-16,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"BIAL - Portela & Cª, SA","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS ADJUNCTIVE THERAPY FOR REFRACTORY PARTIAL SEIZURES IN A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL&#8209;GROUP, MULTICENTR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002455-25,1,0,0 2008-002455-25,7,2017-09-26,2018-05-16,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"BIAL - PORTELA & Cª, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS ADJUNCTIVE THERAPY FOR REFRACTORY PARTIAL SEIZURES IN A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL&#8209;GROUP, MULTICENTR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002455-25,1,0,0 2008-002456-24,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,Wyeth Research,A Post Authorization Safety Surveillance Study of Xyntha in Usual Care Settings,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002456-24,0,1,1 2008-002457-20,5,2010-04-15,2010-05-31,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"""Estudio de fase 2, aleatorizado y abierto, de bosutinib administrado en combinación con exemestano frente a exemestano solo como tratamiento de segunda línea en mujeres posmenopáusicas con cáncer de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002457-20,0,0,0 2008-002467-13,1,2011-03-31,2011-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Northern Health and Social Care Trust,A non-inferiority study of the clinical effectiveness of anaesthesia obtained via application of Topical Anaesthetic Gel compared to infiltration of lidocaine for the treatment of lacerations in the E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002467-13,0,0,0 2008-002471-27,1,2013-04-22,2013-04-22,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Assistance Publique Hopitaux de marseille,Traitement de la Progéria de Hutchinson-Gilford par l’association de pravastatine (Vasten®) et d’acide zolédronique (Zométa®),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002471-27,0,0,0 2008-002472-99,1,2009-03-06,2009-03-06,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Evotec Neurosciences GmbH,"A phase II multicenter, randomised, double-blind, parallel group, placebo-controlled, study to evaluate the effectiveness of EVT 302 in smoking cessation, effect on its own and in combination with ope...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002472-99,0,0,0 2008-002498-11,1,2008-12-05,2008-12-05,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,McNeil AB,"PILOT STUDY ON USAGE PATTERNS OF A NOVEL NICOTINE REPLACEMENT THERAPY - A MULTI-CENTER, OPEN, 3-WEEK RANDOMIZED LOW INTERVENTION STUDY OF TWO DIFFERENT DIRECTIONS FOR USE IN SMOKERS MOTIVATED TO QUIT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002498-11,0,0,0 2008-002500-26,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,Sanofi-Aventis Recherche & Développement,"A multicenter, double blind, placebo controlled randomized study of the efficacy and safety of two rimonabant/metformin combinations for reducing A1C in the treatment of patients with type 2 diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002500-26,0,0,0 2008-002501-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,MedaPharma,Quality of life of patients with actinic keratoses and/or a superficial basal cell carcinoma treated with Imiquimod 5% cream.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002501-39,0,0,0 2008-002518-23,1,2009-06-12,2009-06-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"NV Organon, part of Schering-Plough Corporation","A randomized, safety-assessor blinded trial comparing 4.0 mg.kg-1 sugammadex with placebo in adult subjects scheduled for surgery requiring profound neuromuscular blockade",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002518-23,0,0,0 2008-002560-34,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Duloxetine HCl in Patients with Central Neuropathic Pain Due to Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002560-34,0,0,0 2008-002562-60,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,PIERRE FABRE MEDICAMENT,"Phase III, multicentre, double-blind, randomised, placebo-controlled, study to assess the efficacy of V0337 SO 01A suspension 10ml 4 times a day during 7 days on 2 parallel groups of patients sufferin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002562-60,0,0,0 2008-002578-36,1,2012-01-04,2012-01-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CHRU de LILLE,Etude d’efficacité et d’acceptabilité d’un traitement cholinergique dans l’apathie parkinsonienne “Cholinergic treatment in Parkinsonian Apathy: ChoPA - I”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002578-36,0,0,0 2008-002580-13,2,2009-09-03,2009-09-11,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with GSK2190915 on the allergen-induced asthmatic response in subjects with mild asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002580-13,0,0,0 2008-002580-13,2,2009-09-03,2009-09-11,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with GSK2190915 on the allergen-induced asthmatic response in subjects with mild asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002580-13,0,0,0 2008-002599-86,1,2013-03-22,2013-03-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's and St Thomas Foundation NHS Trust,A prospective open randomised controlled trial of women diagnosed with premature ovarian failure (POF) to investigate the effects of active treatment with HRT (hormone replacement therapy) or COCP (co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002599-86,0,0,0 2008-002599-86,1,2013-03-22,2013-03-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,A prospective open randomised controlled trial of women diagnosed with premature ovarian failure (POF) to investigate the effects of active treatment with HRT (hormone replacement therapy) or COCP (co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002599-86,0,0,0 2008-002601-40,1,2011-08-23,2011-08-23,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,LFB BIOTECHNOLOGIES,"Open, non-controlled, multicentre, first-in-man study using escalating doses of LFB-R603 in patients with advanced stage B-Chronic lymphocytic leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002601-40,0,0,0 2008-002602-20,2,2009-03-30,2009-03-30,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase Ib, Randomized, Observer-Blind, Multicenter, Factorial-Design Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Injections of Trivalent Inactivated Influenza Vaccine with or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002602-20,0,0,0 2008-002606-18,2,2010-11-29,2010-11-29,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Astrazeneca AB,"A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Tor Kinase Inhibitor AZD8055 Administered Orally to Patients with Adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002606-18,0,0,0 2008-002607-12,1,2011-04-23,2011-04-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Central Manchester& Manchester Children's University Hospitals NHS Trust,Sitagliptin vs sulphonylurea based treatments in Muslim patients with Type 2 diabetes during Ramadan,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002607-12,0,0,0 2008-002608-25,4,2009-11-09,2018-02-19,4,1,0,1,0,0,1,0,0,1,1,0,0,0,1,AstraZeneca AB,"A Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Tripl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002608-25,0,0,0 2008-002610-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Centre,Mechanisms of albuminuria in diabetes; reversal of injury to the glycocalyx by the ACE inhibitor lisinopril,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002610-21,0,0,0 2008-002623-85,8,2012-12-17,2012-12-17,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,A 3-PHASE STUDY TO EVALUATE SUSTAINED REMISSION AND PRODUCTIVITY OUTCOMES IN SUBJECTS WITH EARLY RHEUMATOID ARTHRITIS INITIATED ON TREATMENT WITH ETANERCEPT PLUS METHOTREXATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002623-85,0,0,0 2008-002623-85,8,2012-12-17,2012-12-17,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA",A 3-PHASE STUDY TO EVALUATE SUSTAINED REMISSION AND PRODUCTIVITY OUTCOMES IN SUBJECTS WITH EARLY RHEUMATOID ARTHRITIS INITIATED ON TREATMENT WITH ETANERCEPT PLUS METHOTREXATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002623-85,0,0,0 2008-002623-85,8,2012-12-17,2012-12-17,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company),A 3-PHASE STUDY TO EVALUATE SUSTAINED REMISSION AND PRODUCTIVITY OUTCOMES IN SUBJECTS WITH EARLY RHEUMATOID ARTHRITIS INITIATED ON TREATMENT WITH ETANERCEPT PLUS METHOTREXATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002623-85,0,0,0 2008-002623-85,8,2012-12-17,2012-12-17,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA",A 3-PHASE STUDY TO EVALUATE SUSTAINED REMISSION AND PRODUCTIVITY OUTCOMES IN SUBJECTS WITH EARLY RHEUMATOID ARTHRITIS INITIATED ON TREATMENT WITH ETANERCEPT PLUS METHOTREXATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002623-85,0,0,0 2008-002626-11,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Dept of Neurology,Intrathecal therapy with monoclonal antibodies in severe progressive multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002626-11,0,0,0 2008-002627-90,1,2012-02-29,2012-02-29,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Royal Liverpool and Broadgreen University Hospitals NHS Trust,Intracellular boosting of HIV protease inhibitors through inhibition of transport - a novel strategy for potentiating HIV therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002627-90,0,0,0 2008-002627-90,1,2012-02-29,2012-02-29,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Liverpool,Intracellular boosting of HIV protease inhibitors through inhibition of transport - a novel strategy for potentiating HIV therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002627-90,0,0,0 2008-002628-27,3,2010-12-22,2010-12-22,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"Randomized, double-blind, placebo-controlled, multi-center, proof-of-concept study to assess the efficacy of AIN457 in patients with psoriatic arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002628-27,0,0,0 2008-002631-33,3,2011-05-12,2011-05-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"Randomized, double-blind, placebo-controlled, multi-center, phase II, proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002631-33,0,0,0 2008-002632-15,1,2010-11-29,2010-11-29,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Birken GmbH,"Randomized, multicenter, double blind study to compare the efficacy and tolerability of Oleogel-S-10 for 3 months versus placebo only in patients with mild to moderate ac-tinic keratoses located at th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002632-15,0,0,0 2008-002636-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Uppsala University Children´s Hospital,"Study on the treatment of therapy-resistant enuresis with desmopressin and reboxetine; a randomised, placebo-controlled, double-blinded, cross-over study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002636-15,0,0,0 2008-002638-31,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,LUMC,"Contribution of norketamine to ketamine-induced antinociception, and cardiovascular and neurocognitive effects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002638-31,0,0,0 2008-002642-32,1,2009-06-04,2009-06-04,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,Warner Chilcott UK Limited,"A Placebo Controlled, Single-Blind, Pilot Clinical Evaluation of the Effect of a Novel Antibiotic Preparation on the Cutaneous Microflora and Clinical Signs in Acne Patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002642-32,0,0,0 2008-002644-42,1,2008-12-19,2008-12-19,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Pharmaxis Pharmaceuticals Limited,"A phase III multicenter, randomized, parallel, controlled, double blind study to investigate the safety and efficacy of inhaled mannitol over 12 months in the treatment of bronchiectasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002644-42,0,0,0 2008-002646-35,3,2008-11-19,2008-11-19,1,0,0,1,0,0,1,0,0,2,1,0,0,0,1,Movetis NV,"A prospective phase 1, single-dose, open-label, multi-centre clinical trial to evaluate the pharmacokinetics and safety of M0003 in young children aged between 1 and 36 months.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002646-35,1,0,0 2008-002647-16,1,2009-03-17,2009-03-17,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Institut de Recherches Internationales Servier,Assessment of blood glucose profile in type 2 diabetic patients after a one-week treatment with gliclazide 60 mg MR using both the glycaemic Holter method and multiple blood glucose samples. A double-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002647-16,0,0,0 2008-002649-22,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"AstraZeneca Farmacéutica Spain, S.A.",Efectividad de quetiapina de liberación prolongada vs sertralina como terapia co-adyuvante al tratamiento eutimizante previo en la depresión bipolar aguda: un estudio piloto,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002649-22,0,0,0 2008-002650-38,1,2014-11-25,2014-11-25,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,Organisation name was not entered,Vähentääkö pregabaliini opioidikipulääkityksen tarvetta ja kroonisen kivun esiintyvyyttä alle 65-vuotiailla potilailla sydänleikkauksen jälkeen?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002650-38,0,0,0 2008-002651-24,5,2012-08-23,2012-08-23,5,1,0,1,0,0,1,0,1,1,0,0,0,0,1,"MedImmune, LLC","A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002651-24,0,0,0 2008-002653-21,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium",Number of Doses and Time to Onset Of Pain Relief (Analgesic Effect) Using the IONSYS™ System [Fentanyl Iontophoretic Transdermal System (40 µg)],https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002653-21,0,0,0 2008-002655-24,3,2010-05-08,2010-08-05,3,0,0,0,0,0,2,0,0,1,1,0,1,0,1,SantoSolve A/S,"A randomised, double-blind, placebo (vehicle) controlled, parallel group study of the efficacy, safety and tolerability of topical 2PX (strontium chloride hexahydrate) in patients with chronic, modera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002655-24,0,0,0 2008-002661-30,1,2011-02-08,2011-02-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),Use of Maraviroc (MVC) in immunogical non-responder HIV-1-infected patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002661-30,0,0,0 2008-002662-56,1,2010-01-15,2010-01-15,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,AZIENDA OSPEDALIERA DI PARMA,Preoperative administration of controlled-release oxycodone vs morphine as transition oppioid for TIVA in pain control post VATS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002662-56,0,0,0 2008-002667-13,1,2013-09-10,2013-09-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Clinic of Heidelberg,A single-center controlled pilot study to investigate pre- and perioperative therapy with Sorafenib (Nexavar®) in patients who are candidates for a curative surgery of renal cell cancer (PREST = preop...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002667-13,0,0,0 2008-002668-32,10,2013-11-07,2013-11-07,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Oasmia Pharmaceutical AB,"An Open, Randomized, Multicenter Study in Patients with Recurrent Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficacy and Safety of paclitaxel (micell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002668-32,0,0,0 2008-002670-36,8,2010-07-09,2010-08-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"A randomised, double-blind, double-dummy, parallel-group multicentre study to demonstrate non-inferiority in pain and locomotor function and improvement in symptoms of constipation in subjects with mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002670-36,0,0,0 2008-002671-27,1,2010-04-30,2010-04-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Department of Medical Gastroenterology,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP CLINICAL AND EXPERIMENTAL PILOTSTUDY OF PREGABALIN IN PATIENTS WITH CHRONIC PANCREATITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002671-27,0,0,0 2008-002672-95,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Centre Nijmegen St Radboud,Studie naar de optimale therapieduur van orale angiogenese remmers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002672-95,0,0,0 2008-002673-13,1,2011-04-30,2011-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,PSKS,Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002673-13,0,0,0 2008-002675-27,2,2011-02-03,2011-02-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maint...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002675-27,0,0,0 2008-002676-10,7,2006-12-24,2012-08-31,6,1,0,0,0,0,3,0,0,1,1,0,1,0,2,OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALISATION INC,"A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Mainte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002676-10,0,0,0 2008-002676-10,7,2006-12-24,2012-08-31,6,1,0,0,0,0,3,0,0,1,1,0,1,0,2,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Mainte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002676-10,0,0,0 2008-002679-29,3,2008-12-01,2008-12-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GALDERMA R&D SNC,Plasma Pharmacokinetics study of CD5024 1% cream in subjects with papulopustular rosacea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002679-29,0,0,0 2008-002680-13,1,,,0,0,0,0,1,0,2,0,0,1,1,1,0,1,0,"Fundacion para la Investigación ""Hospital Universitario Doctor Peset""",“Antagonistas de GnRH en el manejo del cuerpo lúteo hemorrágico. Estudio clínico y ecográfico de la luteolisis mediada por el cetrorelix”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002680-13,0,0,0 2008-002681-63,1,2012-03-31,2012-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Research and Innovation Services, University of Dundee",DOES VITAMIN D REDUCE BLOOD PRESSURE AND LV MASS IN RESISTANT HYPERTENSIVE PATIENTS WITH VITAMIN D INSUFFICIENCY?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002681-63,0,0,0 2008-002684-14,1,2015-05-14,2015-05-14,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,IIL INTERGRUPPO ITALIANO LINFOMI ONLUS,Early salvage with high dose chemotherapy and stem cell transplantation in advanced stage Hodgkin’s lymphoma patients with positive positron emission tomography after two courses of ABVD (PET-2 positi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002684-14,0,0,0 2008-002686-30,1,2011-09-15,2011-09-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Christie Hospital NHS Foundation Trust,Assessment of the effects of the specific endothelin-A antagonist ZD4054 on prostate cancer biomarkers in patients with castrate-resistant metastatic disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002686-30,0,0,0 2008-002689-68,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Isala Klinieken, location Sophia",Cryo-thawed embryo transfer: natural versus artificial cycle. A non inferiority trial. cryo-thawed embryo transfer: natuurlijke versus artificiële cyclus. Een non-inferioriteitsstudie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002689-68,0,0,0 2008-002690-12,1,2011-07-03,2011-07-03,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Glostrup Hospital,"Sammenligning af to forskellige bedøvelser af børn til MR-scanning. Fordele, ulemper og tidsforbrug ved de to metoder.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002690-12,0,0,0 2008-002691-10,2,2010-05-20,2010-05-20,2,1,0,0,1,0,3,0,1,1,0,0,1,0,1,Baxter Innovations GmbH,"Single-Blind, randomized, Phase III B Study in children aged 1-11 years to investigate the immunogenicity, safety and interchangeability of two tick-borne encephalitis (TBE) vaccines administered acco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002691-10,0,0,0 2008-002693-35,13,2015-08-11,2015-10-20,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company Ltd,Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip Fracture,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002693-35,0,0,0 2008-002693-35,13,2015-08-11,2015-10-20,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Lilly S.A.,Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip Fracture,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002693-35,0,0,0 2008-002694-13,1,2010-10-19,2010-10-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Fundación Biomédica del CHUVI,"Estudio piloto, fase IV para analizar la seguridad de los combos Truvada vs Kivexa como parte de un TARGA basado en Kaletra. Estudio COMBOKA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002694-13,0,0,0 2008-002695-94,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Lluita contra la SIDA,CLINICAL TRIAL ASSESSING ONCE DAILY RALTEGRAVIR ADMINISTRATION (800 mg QD) IN HIV-1-INFECTED PATIENTS RECEIVING UNBOOSTED ATAZANAVIR (400 mg QD)-BASED ANTIRETROVIRAL THERAPY (ENSAYO CLÍNICO PARA EVALU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002695-94,0,0,0 2008-002696-27,5,2009-08-04,2009-08-04,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Hexal AG,"An open label, single-arm, baseline-controlled, multicenter study to evaluate the efficacy, safety and immunogenicity of subcutaneous HX575 administered once a week (qw) and once every two weeks (q2w)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002696-27,0,0,0 2008-002697-35,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI PARMA,"A dose-finding study of Docetaxel, Oxaliplatin and Capecitabine (TEX) as First-Line Treatment in Patients with Advanced Gastric Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002697-35,0,0,0 2008-002699-83,10,2013-10-07,2013-10-07,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia ""ASPIRE OPEN-LABEL"" (Aripiprazole In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002699-83,0,0,0 2008-002700-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Francisco Muñoz Negrete,Estudio del beneficio del tratamiento pautado con lágrimas artificiales en el ojo seco tras cirugía de catarata,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002700-25,0,0,0 2008-002701-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier Régional et Universitaire de Lille,"Recherche d’antagonisme entre antiémétiques (dropéridol, ondansétron, dexaméthasone) et paracétamol dans l’analgésie postopératoire des thyroïdectomies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002701-40,0,0,0 2008-002703-20,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,MOLMED,NGR014: Randomized phase II study of NGR-hTNF in combination with standard chemotherapy versus standard chemotherapy alone in previously untreated patients with advanced non-small cell lung cancer (NS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002703-20,0,0,0 2008-002705-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,HARRAS Pharma Curarina Arzneimittel GmbH,Double-randomized and controlled clinical trial in children to assess the efficacy and safety of Symphytum herb extract cream 10% against 1% in the acceleration of wound healing,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002705-38,0,0,0 2008-002707-10,6,2012-11-14,2012-11-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,POLICHEM S.A.,"MULTICENTRE, RANDOMIZED, DOUBLE BLIND WITHIN FREQUENCY OF ADMINISTRATION, PLACEBO CONTROLLED, DOSE-FINDING, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF 3 DOSES OF P-3058 NAIL LACQUER (5% o.d., 10% o....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002707-10,0,0,0 2008-002707-10,6,2012-11-14,2012-11-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Polichem SA,"MULTICENTRE, RANDOMIZED, DOUBLE BLIND WITHIN FREQUENCY OF ADMINISTRATION, PLACEBO CONTROLLED, DOSE-FINDING, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF 3 DOSES OF P-3058 NAIL LACQUER (5% o.d., 10% o....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002707-10,0,0,0 2008-002707-10,6,2012-11-14,2012-11-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,POLICHEM,"MULTICENTRE, RANDOMIZED, DOUBLE BLIND WITHIN FREQUENCY OF ADMINISTRATION, PLACEBO CONTROLLED, DOSE-FINDING, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF 3 DOSES OF P-3058 NAIL LACQUER (5% o.d., 10% o....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002707-10,0,0,0 2008-002708-25,17,2011-09-16,2011-12-20,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002708-25,0,0,0 2008-002711-41,1,2010-11-04,2010-11-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee (Research & Innovation Services),"“Tight glycaemic control” and the risk of hypoglycaemia: Is this different between multiple injections versus insulin pump therapy? A UK multi-centre, open randomised control trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002711-41,0,0,0 2008-002713-40,3,2009-05-30,2009-05-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"A prospective, multicenter, randomized, rater- and subject-blind, parallel group trial to investigate the non-inferiority of NT 201, free of complexing proteins, in comparison with Clostridium botulin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002713-40,0,0,0 2008-002714-22,1,2020-12-31,2020-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Innsbruck - Institut für gerichtliche Medizin,UNTERSUCHUNG DER GENETISCH BEDINGTEN VARIABILITÄT DES OPIOID- UND OPIATBEDARFS IM RAHMEN DES DROGENSUBSTITUTIONSPROGRAMMS und HÄUFIGKEITEN GENETISCHER POLYMORPHISMEN BEI POPULATIONEN MIT UND OHNE OPIO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002714-22,0,0,0 2008-002715-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO,"NEOADJUVANT EPIRUBICIN-OXALIPLATIN-XELODA AND OXALIPLATIN-XELODA-RADIOTHERAPY IN LOCALLY ADVANCED, RESECTABLE, GASTRIC CANCER. A PHASE II COLLABORATIVE STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002715-40,0,0,0 2008-002721-37,1,2013-02-25,2013-02-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Medizinische Fakultät der TU-München, vertreten durch den Dekan","An open-label, uncontrolled phase II trial of HDAC inhibitor LBH589 in patients with chemo-refractory metastatic gastric cancer overexpressing histone deacetylases - CLBH589BDE03T",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002721-37,0,0,0 2008-002723-85,2,2009-12-18,2009-12-18,2,1,0,0,0,2,3,0,0,1,1,1,1,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Initiated at 40,000 IU Every Week or 80,000 IU Every Week Versus Placebo in Subjects With IPSS Low- or Interme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002723-85,0,0,0 2008-002723-85,2,2009-12-18,2009-12-18,2,1,0,0,0,2,3,0,0,1,1,1,1,0,1,Janssen-Cilag International N.V,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Initiated at 40,000 IU Every Week or 80,000 IU Every Week Versus Placebo in Subjects With IPSS Low- or Interme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002723-85,0,0,0 2008-002724-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO PER L'INFANZIA BURLO GAROFOLO,"Continuous peritoneal infusion of ropivacaine following laparoscopy for postoperative analgesia in children: a randomized, double-blind, placebo-controlled study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002724-29,0,0,0 2008-002727-87,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,CHU TOULOUSE,Etude d’imagerie multimodale dans la maladie d’Alzheimer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002727-87,0,0,0 2008-002730-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Bergonié - Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-ouest,A PHASE II TRIAL TO ASSESS THE EFFICACY OF EFAVIRENZ IN METASTATIC PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002730-30,0,0,0 2008-002731-32,1,2010-06-23,2010-06-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,A 12 weeks open label two parallel groups study to assess the efficacy of orally administered duloxetine 60 mg and 120 mg per day on treatment outcomes in patients with diabetic peripheral neuropatic ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002731-32,0,0,0 2008-002733-70,8,2011-05-05,2011-05-16,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"MERCK & CO., INC.","""Ensayo clínico en fase III multicéntrico, doble ciego, aleatorizado y con control activo para evaluar la seguridad y la eficacia de raltegravir (MK-0518) administrado una vez al día frente a raltegra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002733-70,0,0,0 2008-002733-70,8,2011-05-05,2011-05-16,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","""Ensayo clínico en fase III multicéntrico, doble ciego, aleatorizado y con control activo para evaluar la seguridad y la eficacia de raltegravir (MK-0518) administrado una vez al día frente a raltegra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002733-70,0,0,0 2008-002733-70,8,2011-05-05,2011-05-16,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck & Co. Inc.,"""Ensayo clínico en fase III multicéntrico, doble ciego, aleatorizado y con control activo para evaluar la seguridad y la eficacia de raltegravir (MK-0518) administrado una vez al día frente a raltegra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002733-70,0,0,0 2008-002733-70,8,2011-05-05,2011-05-16,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Laboratoires Merck Sharp & Dhome-Chibret,"""Ensayo clínico en fase III multicéntrico, doble ciego, aleatorizado y con control activo para evaluar la seguridad y la eficacia de raltegravir (MK-0518) administrado una vez al día frente a raltegra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002733-70,0,0,0 2008-002733-70,8,2011-05-05,2011-05-16,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","""Ensayo clínico en fase III multicéntrico, doble ciego, aleatorizado y con control activo para evaluar la seguridad y la eficacia de raltegravir (MK-0518) administrado una vez al día frente a raltegra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002733-70,0,0,0 2008-002733-70,8,2011-05-05,2011-05-16,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MSD BV,"""Ensayo clínico en fase III multicéntrico, doble ciego, aleatorizado y con control activo para evaluar la seguridad y la eficacia de raltegravir (MK-0518) administrado una vez al día frente a raltegra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002733-70,0,0,0 2008-002733-70,8,2011-05-05,2011-05-16,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck & Co Inc.,","""Ensayo clínico en fase III multicéntrico, doble ciego, aleatorizado y con control activo para evaluar la seguridad y la eficacia de raltegravir (MK-0518) administrado una vez al día frente a raltegra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002733-70,0,0,0 2008-002735-32,1,,,0,1,0,0,0,0,2,0,1,1,1,1,0,1,1,Emotional Brain,"A double blind, randomized, placebo controlled cross-over study to investigate the subjective and physiological efficacy and safety of Lybrido and Lybridos in the domestic setting in healthy female su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002735-32,0,0,0 2008-002736-15,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE,"Phase II multicentric study to evaluate the efficacy and the safety of Bendamustine in adjunct to Etoposide, Aracytabin and Melphalan (BeEAM) as a preparative regimen for autologous stem cell transpla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002736-15,0,0,0 2008-002737-76,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Besançon,"Essai multicentrique, randomisé comparant deux stratégies thérapeutiques chez le cirrhotique classé Child-Pugh >8 ayant une infection bactérienne prouvée ou suspectée (à l’exclusion des ISLA) et un sy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002737-76,0,0,0 2008-002740-42,4,2010-10-25,2010-10-25,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Pharmaxis Pharmaceuticals Limited,Long Term Administration of Inahled Mannitol in Cystic Fibrosis - A Safety and Efficacy Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002740-42,0,0,0 2008-002741-23,1,2009-08-17,2009-08-17,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Berufsgenossenschaftliche Universitätsklinik Bergmannsheil GmbH,"Intra-individual, randomized comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in imaging the distal lower limb of patients with known or suspicion of osteomyelitis, evaluated in a bli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002741-23,0,0,0 2008-002747-16,10,2010-05-11,2010-05-11,10,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline R & D,FondaparinUx Trial with UFH during Revascularization in Acute Coronary Syndromes (FUTURA) A prospective study evaluating the safety of two regimens of adjunctive intravenous UFH during PCI in high ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002747-16,0,0,0 2008-002747-16,10,2010-05-11,2010-05-11,10,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,FondaparinUx Trial with UFH during Revascularization in Acute Coronary Syndromes (FUTURA) A prospective study evaluating the safety of two regimens of adjunctive intravenous UFH during PCI in high ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002747-16,0,0,0 2008-002747-16,10,2010-05-11,2010-05-11,10,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE R & D,FondaparinUx Trial with UFH during Revascularization in Acute Coronary Syndromes (FUTURA) A prospective study evaluating the safety of two regimens of adjunctive intravenous UFH during PCI in high ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002747-16,0,0,0 2008-002747-16,10,2010-05-11,2010-05-11,10,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline SA,FondaparinUx Trial with UFH during Revascularization in Acute Coronary Syndromes (FUTURA) A prospective study evaluating the safety of two regimens of adjunctive intravenous UFH during PCI in high ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002747-16,0,0,0 2008-002747-16,10,2010-05-11,2010-05-11,10,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D,FondaparinUx Trial with UFH during Revascularization in Acute Coronary Syndromes (FUTURA) A prospective study evaluating the safety of two regimens of adjunctive intravenous UFH during PCI in high ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002747-16,0,0,0 2008-002750-38,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Alcon Research Ltd,24-hour IOP control with Travoprost / Brinzolamide fixed combination once-daily (QD)in the evening vs TRAVATAN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002750-38,0,0,0 2008-002758-39,6,2011-04-11,2011-07-11,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"Effect of LY450139, a g-Secretase Inhibitor, on the Progression of Alzheimer’s Disease as Compared with Placebo.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002758-39,0,0,0 2008-002758-39,6,2011-04-11,2011-07-11,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ELI LILLY,"Effect of LY450139, a g-Secretase Inhibitor, on the Progression of Alzheimer’s Disease as Compared with Placebo.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002758-39,0,0,0 2008-002760-34,1,2009-09-17,2009-09-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.","A Multi-Center, Double-Masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN® in Patients with Open-Angle Glaucoma or Ocular Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002760-34,0,0,0 2008-002765-31,1,2008-12-05,2008-12-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Avontec GmbH,"A multicenter, randomized, double-blind, placebo-controlled, intraindividual-comparison phase IIa trial to evaluate the efficacy and safety of 2% AVT-02 UE ointment in an every other day treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002765-31,0,0,0 2008-002768-32,1,2020-07-03,2020-07-03,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,Freistaat Bayern,"A prospective phase I/II, one-arm, one-stage multi-center, open label study of lenalidomide in combination with pioglitazone, dexamethasone and metronomic low-dose chemotherapy with treosulfan in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002768-32,0,0,0 2008-002769-30,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,MERCK SERONO SA,"A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson�s diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002769-30,0,0,0 2008-002774-34,2,,,0,1,1,0,0,0,1,0,0,3,0,0,0,0,1,"Pfizer Inc,235 East 42nd Street,New York,NY 10017","A 8-WEEK, OPEN-LABEL, PHASE 1 STUDY TO EVALUATE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002774-34,0,1,0 2008-002774-34,2,,,0,1,1,0,0,0,1,0,0,3,0,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A 8-WEEK, OPEN-LABEL, PHASE 1 STUDY TO EVALUATE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002774-34,0,1,0 2008-002775-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Georges François Leclerc,Evaluation de l'association irinotécan/bévacizumab utilisée en néo-adjuvant et en adjuvant d'une radiochimiothérapie avec témozolomide concomitant pour les glioblastomes non résécables. Etude de phase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002775-28,0,0,0 2008-002780-13,13,2009-01-27,2009-02-17,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Alcon Research, Ltd.","A Three-Month, Multicenter, Double-Masked Study Comparing the Safety and Efficacy of the Fixed Combination Travoprost + Brinzolamide Eye Drops, Suspension vs Travatan vs Azopt in Patients with Open-An...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002780-13,0,0,0 2008-002780-13,13,2009-01-27,2009-02-17,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Alcon Research Limited,"A Three-Month, Multicenter, Double-Masked Study Comparing the Safety and Efficacy of the Fixed Combination Travoprost + Brinzolamide Eye Drops, Suspension vs Travatan vs Azopt in Patients with Open-An...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002780-13,0,0,0 2008-002780-13,13,2009-01-27,2009-02-17,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Alcon Hungary Ltd.,"A Three-Month, Multicenter, Double-Masked Study Comparing the Safety and Efficacy of the Fixed Combination Travoprost + Brinzolamide Eye Drops, Suspension vs Travatan vs Azopt in Patients with Open-An...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002780-13,0,0,0 2008-002781-66,8,2007-01-27,2009-01-27,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Alcon Research, Ltd.","A twelve-month, multicenter, double-masked study of Travoprost / Brinzolamide fixed combination QD AM and Travoprost / Brinzolamide fixed combination QD PM versus COSOPT BID in patients with open-angl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002781-66,0,0,0 2008-002781-66,8,2007-01-27,2009-01-27,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Alcon Research Ltd,"A twelve-month, multicenter, double-masked study of Travoprost / Brinzolamide fixed combination QD AM and Travoprost / Brinzolamide fixed combination QD PM versus COSOPT BID in patients with open-angl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002781-66,0,0,0 2008-002781-66,8,2007-01-27,2009-01-27,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Alcon Sverige AB,"A twelve-month, multicenter, double-masked study of Travoprost / Brinzolamide fixed combination QD AM and Travoprost / Brinzolamide fixed combination QD PM versus COSOPT BID in patients with open-angl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002781-66,0,0,0 2008-002782-32,19,2012-03-26,2013-12-09,14,1,0,0,2,0,3,0,0,1,1,0,1,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002782-32,0,0,0 2008-002782-32,19,2012-03-26,2013-12-09,14,1,0,0,2,0,3,0,0,1,1,0,1,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002782-32,0,0,0 2008-002783-33,21,2012-03-26,2014-02-19,18,1,0,0,2,0,3,0,0,1,1,0,1,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002783-33,0,0,0 2008-002783-33,21,2012-03-26,2014-02-19,18,1,0,0,2,0,3,0,0,1,1,0,1,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002783-33,0,0,0 2008-002784-14,20,2017-10-31,2017-10-31,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Development Centre Europe Ltd.,"A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn?s Disease Estudio abierto, de fase 3 para determinar la eficacia y ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002784-14,0,0,0 2008-002784-14,20,2017-10-31,2017-10-31,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn?s Disease Estudio abierto, de fase 3 para determinar la eficacia y ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002784-14,0,0,0 2008-002784-14,20,2017-10-31,2017-10-31,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn?s Disease Estudio abierto, de fase 3 para determinar la eficacia y ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002784-14,0,0,0 2008-002784-14,20,2017-10-31,2017-10-31,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Development Centre Europe Ltd,"A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn?s Disease Estudio abierto, de fase 3 para determinar la eficacia y ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002784-14,0,0,0 2008-002784-14,20,2017-10-31,2017-10-31,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Development Centre Europe ltd.,"A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohn?s Disease Estudio abierto, de fase 3 para determinar la eficacia y ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002784-14,0,0,0 2008-002791-10,1,2015-05-27,2015-05-27,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Hellenic Cooperative Oncology Group (HeCOG),GEMCITABINE COMBINED WITH THE mTOR INHIBITOR TEMSIROLIMUS (CCI-779) IN PATIENTS WITH INOPERABLE OR METASTATIC PANCREATIC CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002791-10,0,0,0 2008-002792-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Leiden University Medical Center,Differences in maternal temperature and saturation after administration of remifentanil PCA or epidural analgesia during labor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002792-28,0,0,0 2008-002794-13,1,2009-05-29,2009-05-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bionorica AG,"A multi-centre, double-blind, placebo-controlled, randomised, parallel group study to assess the efficacy and safety of two different dosages of a herbal medicinal product (dry extract BNO-1016) in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002794-13,0,0,0 2008-002795-96,1,2010-02-02,2010-02-02,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Novartis Pharma Services AG,"A single center, phase I, partially blinded, placebo-controlled, first-in-man study to evaluate the safety, tolerability and Proof of Mechanism (PoM) of a single administration of BFH772 in healthy vo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002795-96,0,0,0 2008-002797-36,3,2009-08-19,2009-08-19,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A twenty-four week, open-label, non-comparative, multicenter study to assess the efficacy and tolerability of an aliskiren-based treatment algorithm in patients with mild to moderate hypertension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002797-36,0,0,0 2008-002803-17,1,2012-05-16,2012-05-16,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Med. Univ. Wien, Klinik Innere Medizin I, Intensivstation","PROPHYLACTIC, DOUBLE BLIND, PLACEBO CONTROLLED RANDOMIZED USE OF HOMEOPATHY FOR PREVENTION OF ATRIAL FIBRILLATION IN PATIENTS WITH AORTOCORONARY BYPASS OR HEART VALVE SURGERY WITH HEART-LUNG MACHINE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002803-17,0,0,0 2008-002807-21,1,2014-07-07,2014-07-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"MUW, Universitätsklinik für Innere Medizin III, Abteilung für Nephrologie und Dialyse","VITA-D: Cholecalciferol substitution in vitamin D deficient kidney transplant recipients: A randomized, placebo-controlled study to evaluate the posttransplant outcome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002807-21,0,0,0 2008-002819-40,7,2011-12-28,2012-05-24,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F Hoffmann-La Roche Ltd,"A randomized, multicenter, Phase II study of the efficacy and safety of trastuzumab-MCC-DM1 vs. trastuzumab (Herceptin®) and docetaxel (Taxotere®) in patients with metastatic HER2-positive breast canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002819-40,0,0,0 2008-002819-40,7,2011-12-28,2012-05-24,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"A randomized, multicenter, Phase II study of the efficacy and safety of trastuzumab-MCC-DM1 vs. trastuzumab (Herceptin®) and docetaxel (Taxotere®) in patients with metastatic HER2-positive breast canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002819-40,0,0,0 2008-002819-40,7,2011-12-28,2012-05-24,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, multicenter, Phase II study of the efficacy and safety of trastuzumab-MCC-DM1 vs. trastuzumab (Herceptin®) and docetaxel (Taxotere®) in patients with metastatic HER2-positive breast canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002819-40,0,0,0 2008-002838-30,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,"Phase II, randomized, multicentric study of docetaxel and zoledronic acid versus zoledronic acid in patient with prostate cancer and bone metastase treated with LHRH",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002838-30,0,0,0 2008-002841-21,2,2009-11-09,2009-11-09,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men with Signs and Symptoms of Beni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002841-21,0,0,0 2008-002843-18,4,2013-01-10,2013-01-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Limited,"A 2-year, Randomized, Double-blind, Placebo-controlled, Multi-center, Phase II-III Study to Evaluate the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002843-18,0,0,0 2008-002844-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,"A DOUBLE BLIND, SINGLE DOSE, RANDOMIZED, 4-PERIOD CROSS-OVER, PLACEBO-CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE (CHF 1535) VERSUS SINGLE AGENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002844-40,0,0,0 2008-002846-51,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude de l'efficacité du Rituximab versus Azathioprine en traitement d'entretien au cours des vascularites associées aux ANCA : Etude prospective, multicentrique, contrôlée, randomisée",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002846-51,0,0,0 2008-002848-41,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled ascending dose study to evaluate the effect of APL180 on endothelial function in patients with familial hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002848-41,0,0,0 2008-002849-23,4,2009-06-05,2009-06-11,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-Aventis Recherche & Développement,"A multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and tolerability of AVE5530 when added to ongoing stable statin therapy at high doses in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002849-23,0,0,0 2008-002854-39,1,2009-11-24,2009-11-24,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Pharma Services AG,"A double blind, placebo controlled, parallel group study with an open label reference arm to assess the effects of intravenously administered AIN457 on ozone induced neutrophilia compared to placebo a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002854-39,0,0,0 2008-002855-26,4,2009-09-29,2010-07-28,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,CHELSEA THERAPEUTICS INC.,"A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED, PARALLEL-GROUP, INDUCTION-DESIGN STUDY TO ASSESS THE CLINICAL EFFECT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE BETA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002855-26,0,0,0 2008-002855-26,4,2009-09-29,2010-07-28,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Chelsea Therapeutics Inc,"A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED, PARALLEL-GROUP, INDUCTION-DESIGN STUDY TO ASSESS THE CLINICAL EFFECT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE BETA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002855-26,0,0,0 2008-002857-18,1,2011-03-02,2011-03-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment with LY2216684 in Adult Patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002857-18,0,0,0 2008-002878-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,The GAS study. A multi-site RCT comparing regional and general anaesthesia for effects on neurodevelopmental outcome and apnoea in infants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002878-35,0,0,0 2008-002898-12,3,2011-03-14,2012-03-14,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"An open label, Aclasta, re-treatment of relapsed patients with Paget´s disease of bone who participated in the CZOL446K2304 and CZOL446K2305 Core Registration studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002898-12,0,0,0 2008-002898-12,3,2011-03-14,2012-03-14,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open label, Aclasta, re-treatment of relapsed patients with Paget´s disease of bone who participated in the CZOL446K2304 and CZOL446K2305 Core Registration studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002898-12,0,0,0 2008-002901-38,5,2009-04-08,2010-02-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed dose study comparing the efficacy and safety of Lu AA21004 in acute treatment of major depressive disorder in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002901-38,0,0,0 2008-002902-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Onkološki inštitut Ljubljana,Preoperative Radiotherapy with Capecitabine and Bevacizumab in locally advanced rectal cancer: CRAB Phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002902-20,0,0,0 2008-002958-37,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,ISTITUTO EUROPEO DI ONCOLOGIA,Differences in dynamic contrast-enhanced (DCE) MRI measurements using Magnevist (Gd-DTPA) and Vas-ovist in patients with untreated squamous cell cervical carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002958-37,0,0,0 2008-002978-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),Intensification of HAART with Maraviroc (MVC) as first line therapy of HIV-1-infected patients to rapidly suppress viral replication and minimize the evolution of drug-resistant variants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002978-35,0,0,0 2008-002982-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Ghent,"A Prospective, randomized, clinical study on the effects of CPP-ACP paste on plaque, gingivitis and initial caries lesion development in orthodontic patients - part 2",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002982-30,0,0,0 2008-002983-32,7,2010-12-09,2012-02-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002983-32,0,0,0 2008-002983-32,7,2010-12-09,2012-02-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002983-32,0,0,0 2008-002983-32,7,2010-12-09,2012-02-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,A Phase II Study of Oral Single Agent Panobinostat in Patients with Refractory de novo or secondary Acute Myelogenous Leukemia (AML),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002983-32,0,0,0 2008-002985-70,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,3,University of Magdeburg,"Evaluation of the preventive effect of pentoxifylline and ursodeoxycholic acid to radiation induced liver toxicity after brachytherapy of liver metastases, assessed in a prospective randomised trial. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002985-70,0,0,0 2008-002986-30,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"A phase Ib, open-label, multi-center dose-finding study of oral panobinostat (LBH589) in combination with ara-C and mitoxantrone as salvage therapy for refractory or relapsed acute myeloid leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002986-30,0,0,0 2008-002999-98,1,2014-08-01,2014-08-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Helena Kallio,Artikaiinin ja lidokaiinin vertailu diodilaserpotilaiden paraokulaaripuudutuksessa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002999-98,0,0,0 2008-003003-31,8,2013-12-16,2014-03-03,6,1,0,0,0,1,2,0,0,1,0,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter a random...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003003-31,0,0,0 2008-003003-31,8,2013-12-16,2014-03-03,6,1,0,0,0,1,2,0,0,1,0,0,1,0,0,EORTC Headquarters,Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter a random...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003003-31,0,0,0 2008-003005-14,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ASSOCIAZIONE MALATTIE SANGUE,Antimicotyc prophylaxis with Amphotericina B in lypidic complex aerosol in GVHD patients under steroid treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003005-14,0,0,0 2008-003008-72,1,2009-06-12,2009-06-12,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l,"A Phase III, Randomized, Open-label, Single-center Study to Evaluate the Safety and Immunogenicity of a FLUAD-H5N1 Influenza Vaccine in Adult Subjects Using Four Different Vaccination Schedules",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003008-72,0,0,0 2008-003011-12,1,2012-12-27,2012-12-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Leeds,Prospective Randomised Double-Blind Placebo Controlled Study Assessing the Efficacy of Tocilizumab with Synovial Analysis in Patients with Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003011-12,0,0,0 2008-003012-35,1,2013-06-01,2013-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Leeds Teaching Hospitals NHS Trust,"CLARET: CLL Levels following Alemtuzumab in Responders to Early Therapy: A randomised, phase III trial to assess alemtuzumab consolidation therapy in patients with chronic lymphocytic leukaemia (CLL) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003012-35,0,0,0 2008-003015-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Unidad de Trasplantes y Terapia Celular del Hospital Universitario Central de Asturias,Estudio abierto de la eficacia de las células mononucleares autólogas de médula ósea en la regeneración celular en pacientes lesionados medulares con úlceras por presión y trayectos fistulosos.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003015-12,0,0,0 2008-003016-35,6,2013-08-12,2013-08-12,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,A Phase II Study of Oral Panobinostat in Adult Patients with Relapsed/Refractory Classical Hodgkin’s Lymphoma after high-dose chemotherapy with autologous stem cell transplant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003016-35,0,0,0 2008-003016-35,6,2013-08-12,2013-08-12,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A Phase II Study of Oral Panobinostat in Adult Patients with Relapsed/Refractory Classical Hodgkin’s Lymphoma after high-dose chemotherapy with autologous stem cell transplant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003016-35,0,0,0 2008-003016-35,6,2013-08-12,2013-08-12,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,A Phase II Study of Oral Panobinostat in Adult Patients with Relapsed/Refractory Classical Hodgkin’s Lymphoma after high-dose chemotherapy with autologous stem cell transplant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003016-35,0,0,0 2008-003059-56,1,2009-08-10,2009-08-10,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""",Phase II trial to assess safety and efficacy of Iron chelating agent Deferiprone in patients with Pantothenate Kinase-Associated Neurodegeneration – ICAND – Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003059-56,0,0,0 2008-003064-19,1,2016-07-07,2016-07-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universität Leipzig,"Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative Mammacarcinoma Phase-IIb-Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003064-19,0,0,0 2008-003079-32,13,2018-05-07,2018-09-05,12,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) VERSUS CHLORAMBUCIL AS FIRST-LINE THERAPY FOR PREVIOUSLY UNTREATED ELDERLY PA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003079-32,0,0,0 2008-003098-42,1,2009-02-17,2009-02-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biogen Idec Ltd,"A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003098-42,0,0,0 2008-003118-86,1,2010-01-14,2010-01-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 1356 (5 mg administered orally once daily) over 18 weeks in Type 2 diabetic patients with insufficient gly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003118-86,0,0,0 2008-003120-37,1,2022-04-03,2022-04-03,1,1,0,0,1,0,4,0,0,1,1,1,0,0,0,Medizinische Fakultät der Otto von Guericke Universität Magdeburg,"EV(E)A Studie Estriol versus Estradiol - Eine prospektive, randomisierte Multizenterstudie zur Evaluation der Wirkung einer lokalen Therapie auf urogenitale Beschwerden, Zytologie und Mammographiedic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003120-37,0,0,0 2008-003123-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Uppsala University,Neuroanatomical and functional abnormalities in patients with aversive effects from oral contraceptives.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003123-24,0,0,0 2008-003138-33,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Scandinavian Prostate Cancer Group (SPCG),"A Randomized, Open Label, Phase III, Multicenter, 2-Arm Study of Androgen deprivation +/- Taxotere (Docetaxel) for Non metastatic Prostate Cancer Patients with a Rising PSA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003138-33,0,0,0 2008-003139-19,4,2009-07-02,2009-07-29,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind, placebo and active controlled, parallel group, dose finding study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks treatment in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003139-19,0,0,0 2008-003140-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Cellerix, S.A.",Estudio prospectivo para la evaluación de la seguridad y eficacia a largo plazo de CX401 en pacientes que han participado en el ensayo FATT-1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003140-10,0,0,0 2008-003160-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST,CETUXIMAB PLUS IRINOTECAN IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS SELECTED ON THE BASIS OF KRAS MUTATION AND EGFR INTRON 1 CA TANDEM REPEATS: PHASE II PROSPECTIVE STUDY AND RETROSP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003160-19,0,0,0 2008-003167-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Cliniques Universitaires Saint Luc,Effet du fluconazole sur le taux d'anticorps anti-Saccharomyces cerevisiae (ASCSA) après résection chirurgicale pour maladie de Crohn.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003167-39,0,0,0 2008-003168-20,1,2011-06-14,2011-06-14,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,BELFAST HEALTH & SOCIAL CARE TRUST - BELFAST CITY HOSPITAL,"Comparison of the effect of transversus abdominis plane block or conventional analgesia on pain scores, patient satisfaction and incidence of chronic pelvic pain after total abdominal hysterectomy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003168-20,0,0,0 2008-003169-19,2,2011-10-07,2011-10-07,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Sigmoid Pharma Ltd,"A Randomized, Double-blind, Placebo-controlled Study of a Controlled Release Minicapusle Formulation of Ciclosporin (CyCol™) in the Treatment of Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003169-19,0,0,0 2008-003173-40,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ROCHE,"A single arm, open label study to assess the efficacy, safety and tolerability of once-monthly administration of subcutaneous C.E.R.A. for the maintenance of haemoglobin levels in pre-dialysis patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003173-40,0,0,0 2008-003174-18,1,2020-01-31,2020-01-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Heidelberg,"Open-labeled, randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003174-18,0,0,0 2008-003175-45,3,2010-03-22,2010-03-22,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Cancer International Research Group,"A randomized phase II, open-label multicenter trial of panobinostat monotherapy in women with HER2 positive locally recurrent or metastatic breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003175-45,0,0,0 2008-003176-21,4,2015-04-02,2015-04-02,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cancer International Research Group,"A phase II, open label multicenter trial of panobinostat (LBH589) monotherapy in women with HER2 negative locally recurrent or metastatic breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003176-21,0,0,0 2008-003178-17,3,2013-03-12,2013-03-12,2,1,1,0,0,0,1,0,0,2,0,0,0,0,2,,"A Multicenter, 2-Part Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aprepitant in Pediatric Patients Undergoing Surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003178-17,1,1,0 2008-003178-17,3,2013-03-12,2013-03-12,2,1,1,0,0,0,1,0,0,2,0,0,0,0,2,"Merck & Co., Inc.","A Multicenter, 2-Part Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aprepitant in Pediatric Patients Undergoing Surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003178-17,1,1,0 2008-003178-17,3,2013-03-12,2013-03-12,2,1,1,0,0,0,1,0,0,2,0,0,0,0,2,MSD Finland Oy,"A Multicenter, 2-Part Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aprepitant in Pediatric Patients Undergoing Surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003178-17,1,1,0 2008-003180-39,1,2011-07-23,2011-07-23,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Ortopædkirurgisk Afdeling Århus Universitetshospital,Undersøgelse af ketorolac i den postoperative smertebehandling efter total knæalloplastik,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003180-39,0,0,0 2008-003183-19,7,2012-12-14,2012-12-30,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Bristol Myers Squibb International Corporation,"A Randomized, Double-Blind, Multi-Center Phase 2 Trial of Exemestane (Aromasin) plus Dasatinib versus Exemestane plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer after Disease Progres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003183-19,0,0,0 2008-003185-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)",Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK) cells after allogeneic stem cell transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003185-26,0,0,0 2008-003189-25,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,"ASOCIACION PARA LA INVESTIGACION Y TRATAMIENTO DE ENFERMEDADES RENALES (AITER),","ensayo multicéntrico, aleatorizado, abierto que compara la eficacia y seguridad de un régimen inmunosupresor basado en basiliximab, introducción inmediata de dosis reducidas de tacrolimus de liberació...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003189-25,0,0,0 2008-003190-41,2,2010-05-06,2011-08-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Helsinn Healthcare SA,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Prospective Study to Assess the Efficacy, Safety and Tolerability of Three Oral Doses of Netupitant Given Once a Day (50, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003190-41,0,0,0 2008-003191-21,4,2010-09-29,2010-09-29,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Cardiokine Biopharma, LLC","Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects with Euvolemic Hyponatremia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003191-21,1,0,0 2008-003191-21,4,2010-09-29,2010-09-29,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"CARDIOKINE BIOPHARMA, LLC","Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects with Euvolemic Hyponatremia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003191-21,1,0,0 2008-003196-48,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,PIERRE FABRE MEDICAMENT,A phase II - III double-blind study of oral vinflunine plus best supportive care versus placebo plus best supportive care in patients with malignant pleural mesothelioma previously treated with system...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003196-48,0,0,0 2008-003199-23,6,2009-08-07,2009-08-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An 8 week, double-blind, randomized, parallel group, active-controlled study to evaluate the efficacy and safety of the combination of Aliskiren /Amlodipine / HCTZ in patients with moderate to seve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003199-23,0,0,0 2008-003199-23,6,2009-08-07,2009-08-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An 8 week, double-blind, randomized, parallel group, active-controlled study to evaluate the efficacy and safety of the combination of Aliskiren /Amlodipine / HCTZ in patients with moderate to seve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003199-23,0,0,0 2008-003202-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO CLINICO HUMANITAS,Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003202-33,0,0,0 2008-003203-32,5,2011-02-07,2011-02-07,5,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-AND ACTIVE-CONTROLLED EFFICACY AND SAFETY STUDY OF THE EFFECTS OF BAZEDOXIFENE/CONJUGATED ESTROGENS COMBINATIONS ON ENDOMETRIAL HYPERPLASIA AND PREVENTION OF OSTEOP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003203-32,0,0,0 2008-003207-30,1,,,0,1,0,0,0,1,4,0,0,1,0,0,0,1,1,NOVARTIS FARMACEUTICA S.A,"Ensayo abierto, no aleatorizado, multicéntrico, que evalúa la eficacia y seguridad de deferasirox (Exjade®) en pacientes con sobrecarga férrica después de un trasplante alogénico de progenitores hemat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003207-30,0,0,0 2008-003208-68,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Groupe d’Evaluation Français Avastin® versus Lucentis®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003208-68,0,0,0 2008-003209-16,1,2008-12-31,2008-12-31,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,ISTITUTO PER L'INFANZIA BURLO GAROFOLO,Randomised controlled trial on efficacy and safety of short term versus long term antibiotic therapy for pyelonephritis in childhood.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003209-16,0,0,0 2008-003210-10,4,2011-07-07,2011-07-07,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","""PHASE II MULTICENTER, PROSPECTIVE, RANDOMIZED, AGE RELATED MACULAR DEGENERATION, COMPARATOR CONTROLLED, DOSE RANGING STUDY EVALUATING PF-04523655 VERSUS RANIBIZUMAB IN THE TREATMENT OF SUBJECTS WITH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003210-10,0,0,0 2008-003210-10,4,2011-07-07,2011-07-07,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer S.A.,"""PHASE II MULTICENTER, PROSPECTIVE, RANDOMIZED, AGE RELATED MACULAR DEGENERATION, COMPARATOR CONTROLLED, DOSE RANGING STUDY EVALUATING PF-04523655 VERSUS RANIBIZUMAB IN THE TREATMENT OF SUBJECTS WITH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003210-10,0,0,0 2008-003213-27,1,2013-01-08,2013-01-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ORTHO BIOTECH, Division of JANSSEN-CILAG GmbH",Randomized Phase III Study on Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003213-27,0,0,0 2008-003214-94,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,OSPEDALE MAGGIORE DI MILANO (IRCCS),Tenofovir for the treatment of chronic hepatitis B: a study of efficacy and safety in clinical practice in NUC naive or IFN experienced patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003214-94,0,0,0 2008-003215-13,2,2010-01-21,2010-01-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Consumer Care AG,"A double-blind, randomized, multicenter, placebo-controlled phase 3 trial to prove the superiority of bifonazole vs. placebo after 4 weeks of onychomycosis treatment (as a follow-up of a 2 weeks treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003215-13,0,0,0 2008-003224-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,EFFECT OF SURFACTANT IN the CINETIC AND INFLAMMATION IN the NEW-BORN PRETERM WHIT RDS SINDROM.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003224-31,0,0,0 2008-003225-16,1,2014-09-12,2014-09-12,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Organisation name was not entered,Aivostimulaattorin ja levodopainfuusion vaikutus elämänlaatuun ja autonomisen hermoston toimintaan Parkinsonin tautia sairastavilla potilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003225-16,0,0,0 2008-003226-42,5,2010-12-28,2010-12-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A multicenter, randomized, double-blind, active-controlled, parallel group, 2-arm study to investigate the effect of estradiol valerate/dienogest compared to Microgynon on hormone withdrawal associate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003226-42,0,0,0 2008-003230-22,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"Multicenter, open label, prospective study to evaluate the efficacy and safety of deferasirox 30 mg/kg/day for 52 weeks, in transfusion-dependent &#946;-thalassemic patients with cardiac MRI T2*...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003230-22,0,0,0 2008-003231-20,1,2010-07-15,2010-07-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,KULeuven,Adherence Measurement in stable renal transplant patients following conversion form Prograft to advagraf,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003231-20,0,0,0 2008-003235-20,5,2016-03-01,2016-04-03,2,0,1,0,0,2,0,0,0,2,1,0,0,0,0,Landspítali Háskólasjúkrahús,NOPHO - ALL 2008,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003235-20,1,0,0 2008-003235-20,5,2016-03-01,2016-04-03,2,0,1,0,0,2,0,0,0,2,1,0,0,0,0,NOPHO,NOPHO - ALL 2008,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003235-20,1,0,0 2008-003235-20,5,2016-03-01,2016-04-03,2,0,1,0,0,2,0,0,0,2,1,0,0,0,0,Rigshospitalet,NOPHO - ALL 2008,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003235-20,1,0,0 2008-003240-11,4,2011-02-07,2011-02-07,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,LifeCycle Pharma A/S,"A Phase 3, Open-label, Multicenter, Prospective, Randomized Study of the Efficacy and Safety of Conversion from Prograf® Capsules Twice Daily to LCP-Tacro™ Tablets Once Daily for the Prevention of Acu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003240-11,0,0,0 2008-003241-89,5,2014-04-16,2014-04-16,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,LifeCycle Pharma A/S,"A Phase 3, Double-Blind, Double-Dummy, Multi-Center, Prospective, Randomized Study of the Efficacy and Safety of LCP-Tacro™ Tablets, Once Daily, Compared to Prograf Capsules, Twice Daily, in Combinati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003241-89,0,0,0 2008-003241-89,5,2014-04-16,2014-04-16,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Veloxis Pharmaceuticals A/S,"A Phase 3, Double-Blind, Double-Dummy, Multi-Center, Prospective, Randomized Study of the Efficacy and Safety of LCP-Tacro™ Tablets, Once Daily, Compared to Prograf Capsules, Twice Daily, in Combinati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003241-89,0,0,0 2008-003244-11,1,2009-12-31,2009-12-31,1,0,0,0,1,0,3,0,0,1,0,0,1,0,0,ISTITUTO PER L`INFANZIA BURLO GAROFOLO,"Evaluation of efficacy, acceptability and safety of two different solutions of PEG for colonoscopy in children: a prospective randomized trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003244-11,0,0,0 2008-003246-28,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CENTRO DI RIFERIMENTO ONCOLOGICO DI BASILICATA,A PILOT STUDY OF LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH PRIMARY PLASMA CELL LEUKEMIA STUDIO PILOTA DI LENALIDOMIDE IN ASSOCIAZIONE CON DEXAMETASONE IN PRIMA LINEA IN PAZIENTI CON LEUCEMIA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003246-28,0,0,0 2008-003249-10,1,2012-03-16,2012-03-16,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,University of the Saarland,"Olmesartan, Oxidant Stress and in Vivo Re-Endothelialization Capacity of Endothelial Progenitor Cells from Patients with Chronic Kidney Disease (OECD Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003249-10,0,0,0 2008-003250-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,SEQUENTIAL CHEMOTHERAPY WITH CISPLATIN PLUS VINORELBINE FOLLOWED BY WEEKLY DOCETAXEL IN LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003250-15,0,0,0 2008-003251-74,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,ROLE OF TESTOSTERONE AND ITS METABOLITE DIHYDROTESTOSTERONE ON METABOLISM AND ON MUSCLE STRENGTH IN SUBJECTS AFFECTED BY GENEDER IDENTITY DISORDER (GID) (FtM TRANSSEXUALS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003251-74,0,0,0 2008-003252-30,1,2009-01-30,2009-01-30,1,0,0,0,1,0,4,0,0,1,1,1,1,0,0,Aston University,Will the application of Morphine Gel to my leg ulcer ease the pain?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003252-30,0,0,0 2008-003253-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Nantes,"Anesthésie régionale pour chirurgie majeure du pied. Levobupivacaïne 0,5% versus Ropivacaïne 0,5% dans le bloc sciatique par voie médiofémorale.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003253-32,0,0,0 2008-003256-29,1,2012-11-24,2012-11-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité – Universitätsmedizin Berlin,Effect of Methylnaltrexone on Postoperative Analgesic Demands,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003256-29,0,0,0 2008-003258-14,3,2012-05-16,2012-05-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Phase 2, Randomized, Double-Blind, Placebo Controlled Study of AMG 386 in Combination with FOLFIRI in Subjects with Previously Treated Metastatic Colorectal Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003258-14,0,0,0 2008-003279-28,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Laboratoires Théa,"Efficacy and safety assessment of intracameral T2380 (Fixed combination of lidocaïne, phenylephrine and tropicamide) for anaesthesia and mydriasis in phacoemulsification cataract surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003279-28,0,0,0 2008-003280-40,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Public Health Service Amsterdam,Response to hepatitis A and B vaccine among children with immunesuppression due to either hiv or immunesuppressive medication,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003280-40,0,0,0 2008-003281-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE MAGGIORE DI MILANO (IRCCS),Efficacy of albumin administration for volume replacement in patients with severe sepsis or septic shock,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003281-25,0,0,0 2008-003283-20,5,2013-03-14,2013-03-14,3,1,0,0,0,0,2,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A single arm, open-label, phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of patients with HER2-positive locally recurrent or metastatic breast c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003283-20,1,0,0 2008-003284-39,1,2010-04-23,2010-04-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis France,"Etude nationale, multicentrique, non comparative, évaluant l’efficacité de l’association lévofloxacine (500 mg) et rifampicine (600 ou 900 mg selon le poids) administrée une fois par jour par voie ora...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003284-39,0,0,0 2008-003285-26,1,2014-12-31,2014-12-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Universität Mainz, Klinik und Poliklinik für Kinder- und Jugendpsychiatrie und -psychotherapie",Effect of methylphenidate formulation on ADHD-patients' adherence to medical treatment. A comparison of Medikinet retard® (ER) once daily and Medikinet® (IR) twice daily in children and adolescents di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003285-26,0,0,0 2008-003287-18,1,,,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,University Antwerp,Functional consequences of decreased RNA expression of certain GABA(A) receptor subunits in fragile X patients using Positron Emission Tomography and [11C]flumazenil.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003287-18,0,0,0 2008-003287-18,1,,,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,University Hospital Leuven gasthuisberg,Functional consequences of decreased RNA expression of certain GABA(A) receptor subunits in fragile X patients using Positron Emission Tomography and [11C]flumazenil.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003287-18,0,0,0 2008-003290-41,2,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,LungRx,"A Multi-center, open-label, multiple dose, dose finding study exploring the safety and tolerability of Beraprost Sodium Modified Release in PAH patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003290-41,0,0,0 2008-003290-41,2,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Lung Rx,"A Multi-center, open-label, multiple dose, dose finding study exploring the safety and tolerability of Beraprost Sodium Modified Release in PAH patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003290-41,0,0,0 2008-003292-42,7,2012-05-01,2013-02-28,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Amgen Inc,A Phase 1b/ 2 Trial of AMG 479 or AMG 102 in Combination with Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003292-42,0,0,0 2008-003293-18,1,2012-05-31,2012-05-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Belfast Health and Social Care Trust,Pharmacokinetics of ketamine in infants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003293-18,0,0,0 2008-003293-18,1,2012-05-31,2012-05-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Queen's University Belfast,Pharmacokinetics of ketamine in infants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003293-18,0,0,0 2008-003303-31,5,2011-06-26,2011-06-26,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer HealthCare AG,The Einstein CYP cohort study. Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism using a strong CYP 3A4 inducer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003303-31,0,0,0 2008-003314-97,13,2015-06-03,2015-07-03,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003314-97,0,0,0 2008-003314-97,13,2015-06-03,2015-07-03,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bristol Myers Squibb International Corporation,"A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003314-97,0,0,0 2008-003316-36,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO,NON PEGILATED LIPOSOMIAL DOXORUBICIN (TLC D-99) IN ASSOCIATION WITH IFOSFAMIDE IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003316-36,0,0,0 2008-003318-81,1,,,0,1,0,0,0,0,4,0,1,1,1,1,0,1,1,GlaxoSmithKline Biologicals,"A phase IV, open, randomized, controlled study to demonstrate the non-inferiority of co-administration of GSK Biologicals’ live attenuated measles-mumps-rubella-varicella vaccine and Baxter’s Neisseri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003318-81,0,0,0 2008-003322-42,3,2011-02-02,2011-02-02,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Tarsa Therapeutics, Inc.","A Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Parallel Group, 48 Week, Study of Oral Recombinant Calcitonin (rsCT) Compared to Calcitonin Nasal Spray in Postmenopausal Osteoporotic Wo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003322-42,0,0,0 2008-003325-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude ARCTIC Comparaison randomisée 1/ d'un traitement antiplaquettaire ajusté par monitoring à un traitement standard à dose fixe pour stenting coronaire avec DES, et 2/ d'un arrêt versus poursuite d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003325-17,0,0,0 2008-003327-23,6,2011-04-19,2011-05-22,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Endo Pharmaceuticals Solutions Inc,"ESTUDIO FASE III, ABIERTO, MULTICÉNTRICO E INTERNACIONAL PARA EVALUAR LA EFICACIA Y SEGURIDAD DE UN IMPLANTE DE OCTREÓTIDA FRENTE A UN DEPÓSITO DE SANDOSTATIN LAR® EN PACIENTES CON ACROMEGALIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003327-23,0,0,0 2008-003327-23,6,2011-04-19,2011-05-22,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Indevus Pharmaceuticals Incorporated,"ESTUDIO FASE III, ABIERTO, MULTICÉNTRICO E INTERNACIONAL PARA EVALUAR LA EFICACIA Y SEGURIDAD DE UN IMPLANTE DE OCTREÓTIDA FRENTE A UN DEPÓSITO DE SANDOSTATIN LAR® EN PACIENTES CON ACROMEGALIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003327-23,0,0,0 2008-003327-23,6,2011-04-19,2011-05-22,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Endo Pharmaceuticals Inc.,"ESTUDIO FASE III, ABIERTO, MULTICÉNTRICO E INTERNACIONAL PARA EVALUAR LA EFICACIA Y SEGURIDAD DE UN IMPLANTE DE OCTREÓTIDA FRENTE A UN DEPÓSITO DE SANDOSTATIN LAR® EN PACIENTES CON ACROMEGALIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003327-23,0,0,0 2008-003327-23,6,2011-04-19,2011-05-22,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Endo Pharmaceuticals Solutions Inc.,"ESTUDIO FASE III, ABIERTO, MULTICÉNTRICO E INTERNACIONAL PARA EVALUAR LA EFICACIA Y SEGURIDAD DE UN IMPLANTE DE OCTREÓTIDA FRENTE A UN DEPÓSITO DE SANDOSTATIN LAR® EN PACIENTES CON ACROMEGALIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003327-23,0,0,0 2008-003327-23,6,2011-04-19,2011-05-22,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Endo Pharmaceuticals Solutions,"ESTUDIO FASE III, ABIERTO, MULTICÉNTRICO E INTERNACIONAL PARA EVALUAR LA EFICACIA Y SEGURIDAD DE UN IMPLANTE DE OCTREÓTIDA FRENTE A UN DEPÓSITO DE SANDOSTATIN LAR® EN PACIENTES CON ACROMEGALIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003327-23,0,0,0 2008-003328-45,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Sahlgrenska Universitetssjukhuset,Klinisk utvecklingsarbete för utvärdering av molykulärt riktad behandling vid metastaserande njurcancer- PETTO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003328-45,0,0,0 2008-003331-20,1,2010-04-22,2010-04-22,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Technical University Munich, Klinikum rechts der Isar","Effect of quetiapine XR on sleep in patients with major depression, as compared with mirtazapine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003331-20,0,0,0 2008-003333-25,1,2010-11-29,2010-11-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Supernus Pharmaceuticals, Inc.","Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC XR) (1200 and 2400mg/day) as Adjun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003333-25,0,0,0 2008-003334-19,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Supernus Pharmaceuticals, Inc.","Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR) as Adjunctive Therapy in Subjects with Refractory Partial Epilepsy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003334-19,0,0,0 2008-003336-38,1,2010-07-27,2010-07-27,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Department of Medical Research,The effect of Amiloride and Spironolacton on renophysiological and cardiovascular parametres in healthy patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003336-38,0,0,0 2008-003337-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CENTRO DI RIFERIMENTO ONCOLOGICO DI BASILICATA,Diagnostic imaging in prostate cancer (as in tumours with accelerated menbrane turn-over)by F-18 Fluoro-metil-choline PET/CT Diagnostica per immagini nel carcinoma della prostata (con implementazio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003337-24,0,0,0 2008-003338-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Cristina Gómez Oliva,Estudio aleatorizado y doble ciego sobre la eficacia de la administración de somatostatina en bolus seguido de una perfusión corta endovenosa como profilaxis de pancreatitis aguda tras la realización ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003338-41,0,0,0 2008-003340-11,1,2010-01-13,2010-01-13,1,1,0,0,0,0,4,0,1,1,1,1,1,0,1,JANSSEN-CILAG GmbH,"The “therapeutic window” of the ""atypical” antipsychotic paliperidone ER - A Positron Emission Tomography study with [18F]fallypride as the radiotracer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003340-11,0,0,0 2008-003341-88,1,,,0,0,0,0,0,3,4,0,0,1,1,1,0,1,0,Klaus Olkkola,Interaction of rocuronium with sevoflurane as quantified by closed-loop feedback control ROCSEVO 1.0/ 2008-003341-88,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003341-88,0,0,0 2008-003342-29,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTI FISIOTERAPICI OSPITALIERI,Second line therapy with low dose fotemustine in progressive malignant gliomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003342-29,0,0,0 2008-003346-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Landstinget Västmanland, Division Kirurgi, Operationskliniken",Postoperative analgesia with wound catheter och Baxter Infusor after inguinalhernia operation ad modum Lichtenstein with net. Postoperativ smärtlindring med sårkateter och Baxter Infusor efter öppen l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003346-28,0,0,0 2008-003349-97,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Roessingh Research&Development,"Influence of a single dose of fluoxetine on brain activity during movement observation and execution, muscle activity and motor function in chronic stroke patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003349-97,0,0,0 2008-003359-58,1,2009-12-31,2009-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,CPS Research,A pilot study to examine the efficacy and safety of escitalopram in doses up to 50 mg for the treatment of patients with Major Depressive Disorder (MDD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003359-58,0,0,0 2008-003360-19,1,,,0,0,0,0,0,1,3,0,1,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude de l'effet de la pioglitazone dans l'ataxie de Friedreich : étude ""preuve de concept""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003360-19,0,0,0 2008-003362-26,1,2008-10-10,2008-10-10,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Almirall Hermal GmbH,"A phase IIa single-center, randomized, controlled, observer-blind study to investigate the antimicrobial efficacy of topical formulations containing octenidine and prednicarbate in an""expanded flora t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003362-26,0,0,0 2008-003364-19,1,2010-05-06,2010-05-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Open-Label, Active-Controlled Pilot Study to Evaluate the Safety and Antiretroviral Activity of Unboosted Atazanavir BID Plus Raltegravir BID and Boosted Atazanavir QD in Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003364-19,0,0,0 2008-003365-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo de Investigación en Oncología Médica del Hospital de Navarra,"Estudio fase II de quimioterapia de inducción con TPF seguido de radioterapia hiperfraccionada ""boost concomitante"" con cetuximab en pacientes con carcinoma localmente avanzado de laringe/hipofaringe",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003365-29,0,0,0 2008-003367-40,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,CHU de Rouen,"Pilot study of the effect of a substance P antagonist, aprepitant, on aldosterone and cortisol secretions in healthy volunteers ETUDE PILOTE DE L'EFFET D'UN ANTAGONISTE DE LA SUBSTANCE P, L'APREPIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003367-40,0,0,0 2008-003368-21,1,2009-12-31,2009-12-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ISTITUTO PER L`INFANZIA BURLO GAROFOLO,Pilot trial of CTLA4-Ig (Abatacept) in a child affected by a severe congenital autoimmune syndrome (IPEX),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003368-21,0,0,0 2008-003371-53,1,2011-12-16,2011-12-16,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Fakultní nemocnice u svaté Anny,Acute Stroke Study of Optimized tPA Dosing in Correlation with Artery Status,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003371-53,0,0,0 2008-003375-41,1,2009-06-16,2009-06-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis France,Etude de non-infériorité Bi-Profénid® 200 mg versus Bi-Profénid® 300 mg chez des patients présentant des douleurs liées à des affections aiguës bénignes fermées post-traumatiques de l'appareil locomot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003375-41,0,0,0 2008-003376-21,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Servicio Hepatología. Hospital Vall d'Hebron,EFECTOS DE LA ADMINISTRACIÓN DE ALBÚMINA EN PACIENTES CON CIRROSIS Y ENCEFALOPATIA HEPÁTICA AGUDA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003376-21,0,0,0 2008-003377-41,2,2010-04-14,2010-04-14,1,1,0,0,0,0,0,0,0,1,0,0,1,0,2,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial, with Placebo Run-In, and an Open-Label Treatment Period, to Evaluate the Performance of the Cogstate Computerized Neu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003377-41,0,0,0 2008-003379-28,7,2010-12-13,2010-12-14,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Merck & Co, Inc.","A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled, Multiple-Dose, Clinical Trial to Study the Safety and Efficacy of MK-0663/Etoricoxib and Ibuprofen in the Treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003379-28,0,0,0 2008-003379-28,7,2010-12-13,2010-12-14,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Merck & Co. Inc.,"A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled, Multiple-Dose, Clinical Trial to Study the Safety and Efficacy of MK-0663/Etoricoxib and Ibuprofen in the Treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003379-28,0,0,0 2008-003379-28,7,2010-12-13,2010-12-14,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Merck & Co., Inc.","A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled, Multiple-Dose, Clinical Trial to Study the Safety and Efficacy of MK-0663/Etoricoxib and Ibuprofen in the Treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003379-28,0,0,0 2008-003379-28,7,2010-12-13,2010-12-14,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., U.S.A.","A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled, Multiple-Dose, Clinical Trial to Study the Safety and Efficacy of MK-0663/Etoricoxib and Ibuprofen in the Treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003379-28,0,0,0 2008-003382-22,1,2011-01-28,2011-01-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Kade Pharmazeutische Fabrik GmbH,"Doppelblindstudie zur Wirksamkeit von Ovula mit 0,2 mg und 0,03 mg Estriol im Vergleich zu Placebo bei vaginaler Atrophie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003382-22,0,0,0 2008-003387-18,1,2011-02-28,2011-02-28,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,University of Dundee,The Effects of Oral Vitamin D Supplementation on Cardiovascular Disease Risk in UK South Asian Women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003387-18,0,0,0 2008-003389-25,10,2018-09-10,2018-10-09,8,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Celgene Corporation,"A PHASE 2, MULTICENTER, RANDOMIZED OPEN-LABEL STUDY TO DETERMINE THE EFFICACY OF LENALIDOMIDE (REVLIMID) VERSUS INVESTIGATOR’S CHOICE IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003389-25,0,0,0 2008-003392-40,1,2011-06-24,2011-06-24,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,Universität Marburg,Untersuchung des Einflusses von Carbamazepin auf die mittels transkranieller Magnetstimulation gemessene kortikale Exzitabilität des menschlichen Motorkortex in Abhängigkeit vom Polymorphismus für SCN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003392-40,0,0,0 2008-003395-22,1,2009-07-22,2009-07-22,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare,The Effects of Weight Reduction with Orlistat vs. Placebo on Changes in Body Composition,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003395-22,0,0,0 2008-003396-52,2,2019-11-29,2019-11-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,"Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003396-52,0,0,0 2008-003397-17,3,2010-11-05,2010-11-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma Corporation,"A Phase IIa, multi-centre, randomised, double-blind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of a n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003397-17,0,0,0 2008-003418-88,6,2014-03-03,2014-03-03,4,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Amgen Inc,"A Multicenter, Double-blind, Randomized Study Evaluating De Novo Weekly and Once Every 2 Week Darbepoetin alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease Rec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003418-88,1,1,0 2008-003421-17,2,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Institut de Recherches Internationales Servier,"Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment at 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, double...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003421-17,0,0,0 2008-003423-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude de phase II nationale multicentrique évaluant l’activité antitumorale du sunitinib (SUTENT) chez des patients atteints d’hépatocarcinomes fibrolamellaires inopérables d’emblée ou en rechute non ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003423-23,0,0,0 2008-003438-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación SEIMC-GESIDA,Ensayo Clínico aleatorizado para comparar la combinación ZDV + 3TC + ABC (Trizivir) frente a Lopinavir/R (Kaletra) en monoterapia en pacientes con supresión viral en tratamiento previo con ZDV + 3TC +...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003438-12,0,0,0 2008-003439-18,10,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,AstraZeneca AB,"Estudio en fase II aleatorizado, doble ciego y multicéntrico, para evaluar la eficacia de AZD2281 en el tratamiento de pacientes con cáncer de ovario seroso sensible al platino tras el tratamiento co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003439-18,0,0,0 2008-003458-13,3,2009-11-12,2010-05-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TAKEDA EUROPE RESEARCH & DEVELOPMENT CENTRE LTD,A Phase 2 Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Subjects Previously Treated With Epoetin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003458-13,0,0,0 2008-003458-13,3,2009-11-12,2010-05-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,A Phase 2 Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Subjects Previously Treated With Epoetin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003458-13,0,0,0 2008-003459-64,3,2009-06-27,2009-12-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TAKEDA EUROPE RESEARCH & DEVELOPMENT CENTRE LTD,A Phase 2 Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Subjects with Chronic Renal Failure Who Are on Hemodialysis or Do Not Require Dialysis and ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003459-64,0,0,0 2008-003459-64,3,2009-06-27,2009-12-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,A Phase 2 Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Subjects with Chronic Renal Failure Who Are on Hemodialysis or Do Not Require Dialysis and ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003459-64,0,0,0 2008-003460-19,7,2013-03-14,2013-03-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann - La Roche,"An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003460-19,0,0,0 2008-003460-19,7,2013-03-14,2013-03-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche,"An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003460-19,0,0,0 2008-003482-68,14,2012-05-14,2012-05-14,13,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"Ensayo clínico, multinacional, multicéntrico, aleatorizado ,doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de BAY 63-2521 (1 mg, 1.5 mg, 2mg, o 2.5 mg ,tid )administrado ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003482-68,0,0,0 2008-003482-68,14,2012-05-14,2012-05-14,13,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Bayer Healthcare AG,"Ensayo clínico, multinacional, multicéntrico, aleatorizado ,doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de BAY 63-2521 (1 mg, 1.5 mg, 2mg, o 2.5 mg ,tid )administrado ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003482-68,0,0,0 2008-003482-68,14,2012-05-14,2012-05-14,13,1,0,0,0,2,3,0,0,1,1,0,1,0,1,"Bayer HealthCare AG, D-51368 Leverkusen","Ensayo clínico, multinacional, multicéntrico, aleatorizado ,doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de BAY 63-2521 (1 mg, 1.5 mg, 2mg, o 2.5 mg ,tid )administrado ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003482-68,0,0,0 2008-003484-39,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,University Hospital Ghent,Farmacokinetische evaluatie van de eerste intraveneuze dosering van quinolones bij Intensieve Zorgen (IZ) patiënten met septische shock.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003484-39,0,0,0 2008-003485-25,7,2009-05-23,2009-05-23,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Pierre Fabre Médicament,"Impact of the V0034CR 01B emollient on atopic dermatitis symptoms in children. A randomised, placebo-controlled, parallel-groups, double-blind study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003485-25,0,0,0 2008-003485-25,7,2009-05-23,2009-05-23,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Pierre Fabre Medicament,"Impact of the V0034CR 01B emollient on atopic dermatitis symptoms in children. A randomised, placebo-controlled, parallel-groups, double-blind study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003485-25,0,0,0 2008-003486-58,1,2016-07-14,2016-07-14,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Intergroupe Francophone du Myélome,"Pharmacogenomic study to predict survival, best response and toxicity in newly diagnosed myeloma patients who are either 65 years of age or older treated with either a combination of melphalan-prednis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003486-58,0,0,0 2008-003525-16,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTI FISIOTERAPICI OSPITALIERI,Neoadjuvant chemotherapy with weekly docetaxel followed from concomitant docetaxel-RT in patients with high risk locally advanced prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003525-16,0,0,0 2008-003527-24,1,2016-03-08,2016-03-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Tampere University Hospital,Single arm study of the combination of biweekly Avastin and Docetaxel as the first line treatment for patients with locally recurrrent or metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003527-24,0,0,0 2008-003529-17,1,2016-04-27,2016-04-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"A PROSPECTIVE, RANDOMIZED, OPEN LABEL, BLINDED END-POINT (PROBE) TRIAL TO EVALUATE WHETHER, AT COMPARABLE BLOOD PRESSURE CONTROL, ACE INHIBITOR THERAPY MORE EFFECTIVELY THAN NON RAS INHIBITOR THERAPY ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003529-17,0,0,0 2008-003531-21,4,2009-09-03,2009-09-04,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Debiopharm S.A.,"A multicenter, randomized, double-blind, placebo-controlled parallel-group phase IIb study of the safety and efficacy of istaroxime over 24 hours at three doses in acute decompensated heart failure pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003531-21,0,0,0 2008-003531-21,4,2009-09-03,2009-09-04,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,DEBIOPHARM S.A.,"A multicenter, randomized, double-blind, placebo-controlled parallel-group phase IIb study of the safety and efficacy of istaroxime over 24 hours at three doses in acute decompensated heart failure pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003531-21,0,0,0 2008-003533-24,8,2013-09-26,2013-09-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (The BRISK FL Study) Pharmacogenetics ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003533-24,0,0,0 2008-003533-24,8,2013-09-26,2013-09-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (The BRISK FL Study) Pharmacogenetics ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003533-24,0,0,0 2008-003534-25,10,2011-01-04,2011-01-04,8,1,0,0,2,0,3,0,0,1,0,0,1,0,1,DAIICHI SANKYO EUROPE GMBH,"A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF CO ADMINISTRATION OF TRIPLE COMBINATIONS OF OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE, AND HYDROCHLOROTHIAZIDE CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003534-25,0,0,0 2008-003534-25,10,2011-01-04,2011-01-04,8,1,0,0,2,0,3,0,0,1,0,0,1,0,1,DAIICHI SANKYO EUROPE GmbH,"A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF CO ADMINISTRATION OF TRIPLE COMBINATIONS OF OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE, AND HYDROCHLOROTHIAZIDE CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003534-25,0,0,0 2008-003535-20,10,2010-09-07,2010-09-07,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Daiichi-Sankyo Europe GmbH,"A RANDOMISED, DOUBLE-BLIND, ADD-ON STUDY OF HYDROCHLOROTHIAZIDE IN SUBJECTS WITH MODERATE TO SEVERE HYPERTENSION NOT ACHIEVING TARGET BLOOD PRESSURE ON OLMESARTAN MEDOXOMIL/AMLODIPINE FIXED DOSE COMBI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003535-20,0,0,0 2008-003535-20,10,2010-09-07,2010-09-07,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,DAIICHI SANKYO EUROPE GmbH,"A RANDOMISED, DOUBLE-BLIND, ADD-ON STUDY OF HYDROCHLOROTHIAZIDE IN SUBJECTS WITH MODERATE TO SEVERE HYPERTENSION NOT ACHIEVING TARGET BLOOD PRESSURE ON OLMESARTAN MEDOXOMIL/AMLODIPINE FIXED DOSE COMBI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003535-20,0,0,0 2008-003537-25,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,University Medical Center Groningen,Can the steady-state hematopoiesis be improved post-ASCT by infusion of the autologous stem cell transplant directly in the bone marrow compartment.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003537-25,0,0,0 2008-003538-11,8,2011-10-31,2011-11-28,7,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co. KG,"Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive and treatment experienced patients for 24 weeks as combination therapy with pegyl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003538-11,0,0,0 2008-003538-11,8,2011-10-31,2011-11-28,7,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma RCV GmbH & Co. KG,"Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive and treatment experienced patients for 24 weeks as combination therapy with pegyl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003538-11,0,0,0 2008-003538-11,8,2011-10-31,2011-11-28,7,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Limited,"Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive and treatment experienced patients for 24 weeks as combination therapy with pegyl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003538-11,0,0,0 2008-003538-11,8,2011-10-31,2011-11-28,7,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive and treatment experienced patients for 24 weeks as combination therapy with pegyl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003538-11,0,0,0 2008-003538-11,8,2011-10-31,2011-11-28,7,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer-Ingelheim France,"Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive and treatment experienced patients for 24 weeks as combination therapy with pegyl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003538-11,0,0,0 2008-003538-11,8,2011-10-31,2011-11-28,7,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A.","Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive and treatment experienced patients for 24 weeks as combination therapy with pegyl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003538-11,0,0,0 2008-003538-11,8,2011-10-31,2011-11-28,7,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim bv,"Antiviral effect, safety and pharmacokinetics of BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naive and treatment experienced patients for 24 weeks as combination therapy with pegyl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003538-11,0,0,0 2008-003539-19,13,2019-08-19,2019-08-19,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Bayer AG,"Estudio de extensión a largo plazo, multicéntrico y multinacional, para evaluar la seguridad y tolerabilidad de BAY 63 2521 (1 mg, 1,5 mg, 2 mg o 2,5 mg tid) administrado por vía oral, en pacientes co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003539-19,0,0,0 2008-003539-19,13,2019-08-19,2019-08-19,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Bayer HealthCare AG, Bayer Vital GmbH, D-51368 Leverkusen","Estudio de extensión a largo plazo, multicéntrico y multinacional, para evaluar la seguridad y tolerabilidad de BAY 63 2521 (1 mg, 1,5 mg, 2 mg o 2,5 mg tid) administrado por vía oral, en pacientes co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003539-19,0,0,0 2008-003539-19,13,2019-08-19,2019-08-19,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"Estudio de extensión a largo plazo, multicéntrico y multinacional, para evaluar la seguridad y tolerabilidad de BAY 63 2521 (1 mg, 1,5 mg, 2 mg o 2,5 mg tid) administrado por vía oral, en pacientes co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003539-19,0,0,0 2008-003539-19,13,2019-08-19,2019-08-19,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Bayer AG,"Estudio de extensión a largo plazo, multicéntrico y multinacional, para evaluar la seguridad y tolerabilidad de BAY 63 2521 (1 mg, 1,5 mg, 2 mg o 2,5 mg tid) administrado por vía oral, en pacientes co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003539-19,0,0,0 2008-003539-19,13,2019-08-19,2019-08-19,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Bayer HealthCare AG,","Estudio de extensión a largo plazo, multicéntrico y multinacional, para evaluar la seguridad y tolerabilidad de BAY 63 2521 (1 mg, 1,5 mg, 2 mg o 2,5 mg tid) administrado por vía oral, en pacientes co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003539-19,0,0,0 2008-003540-11,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HOVON Foundation,"Prevention of severe GVHD after allogeneic hematopoietic stem cell transplantation, applied as consolidation immunotherapy in patients with hematological malignancies. A prospective randomized phase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003540-11,0,0,0 2008-003547-36,1,2011-09-30,2011-09-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Norgine Ltd,"An open study to investigate the effects of chronic hepatitis B or C on the pharmacokinetics of cholyl-lysyl-fluorescein (NRL972) before, during and after standard treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003547-36,0,0,0 2008-003552-29,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Johannes Förster, anest.lääkäri",Kloroprokaiini (40 mg) ja artikaiini (60 mg) päiväkirurgisina spinaalipuudutteina (Lyhenne: C40A60),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003552-29,0,0,0 2008-003554-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Tratamiento de Tumores Urológicos (SOGUG),"“Estudio Clínico en Fase II aleatorizado de radioterapia, hormonoterapia y quimioterapia con docetaxel versus radioterapia y hormonoterapia, en pacientes afectados de cáncer de próstata localizado de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003554-14,0,0,0 2008-003555-77,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Boiron,Evaluation de l'intérêt d'associer un traitement homéopathique à la prise en charge anti-émétique conventionnelle dans la prévention des nausées retardées lors des deux premières cures de chimiothéra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003555-77,0,0,0 2008-003557-32,12,2010-09-02,2010-09-02,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BIAL Portela & Ca, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE AS THERAPY IN PATIENTS WITH FIBROMYALGIA: A DOUBLE BLIND, RANDOMISED, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTRE CLINICAL TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003557-32,0,0,0 2008-003557-32,12,2010-09-02,2010-09-02,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BIAL - PORTELA & C, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE AS THERAPY IN PATIENTS WITH FIBROMYALGIA: A DOUBLE BLIND, RANDOMISED, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTRE CLINICAL TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003557-32,0,0,0 2008-003560-19,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,Laboratorios Novag S.A.,"""Estudio para la evaluación de la seguridad y la eficacia de la crema de ciclopirox olamina en niños de 3 meses a 10 años afectos de dermatomicosis"". ""Study for safety and efficacy evaluation of cicl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003560-19,0,0,0 2008-003564-19,1,2011-05-27,2011-05-27,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,CHU de Brest,Traitement de la péricardite aiguë bénigne : Aspirine en cure courte versus traitement prolongé. Essai contrôlé multicentrique en double aveugle de non-infériorité,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003564-19,0,0,0 2008-003566-26,1,2009-03-13,2009-03-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Mundipharma GmbH,"An exploratory, randomised, parallel-group, open-label, multicentre study to assess the post-operative management of moderate to severe pain in patients who underwent laparoscopic cholecystectomy, rec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003566-26,0,0,0 2008-003567-39,5,2011-02-28,2011-02-28,5,0,0,0,1,0,0,0,0,1,0,0,1,0,1,Laboratoires Théa,"Título completo del ensayo: Estudio de la eficacia clinica y de la seguridad de Azyter (azitromicina 1.5%) frente al uso de la tobramicina 0.3% en colirio, en el tratamiento de la conjuntivitis purule...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003567-39,0,0,0 2008-003567-39,5,2011-02-28,2011-02-28,5,0,0,0,1,0,0,0,0,1,0,0,1,0,1,Laboratoires Thea,"Título completo del ensayo: Estudio de la eficacia clinica y de la seguridad de Azyter (azitromicina 1.5%) frente al uso de la tobramicina 0.3% en colirio, en el tratamiento de la conjuntivitis purule...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003567-39,0,0,0 2008-003568-20,1,2011-06-07,2011-06-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Prof Alice Stanton,Renin Genotype and Response to Renin Angiotensin System Blockade.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003568-20,0,0,0 2008-003571-45,9,2009-09-18,2009-10-29,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Ltd, Ramsgate Road,Sandwich,Kent CT13 9NJ","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003571-45,0,0,0 2008-003571-45,9,2009-09-18,2009-10-29,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Limited, Ramsgate Road,Sandwich,Kent CT13 9NJ","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003571-45,0,0,0 2008-003571-45,9,2009-09-18,2009-10-29,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer S.A,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003571-45,0,0,0 2008-003571-45,9,2009-09-18,2009-10-29,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CROHN’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003571-45,0,0,0 2008-003572-21,4,2010-07-28,2010-07-28,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Pfizer, S.A.","A PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY INVESTIGATING THE DOSE-RESPONSE OF PF-00489791 ON ACUTE HEMODYNAMICS IN SUBJECTS WITH IDIOPATHIC AND FAMILIAL PULMONARY A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003572-21,0,0,0 2008-003572-21,4,2010-07-28,2010-07-28,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Pfizer Ltd,Ramsgate Road,Sandwich,Kent CT13 9NJ","A PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY INVESTIGATING THE DOSE-RESPONSE OF PF-00489791 ON ACUTE HEMODYNAMICS IN SUBJECTS WITH IDIOPATHIC AND FAMILIAL PULMONARY A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003572-21,0,0,0 2008-003572-21,4,2010-07-28,2010-07-28,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Pfizer Ltd.,"A PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY INVESTIGATING THE DOSE-RESPONSE OF PF-00489791 ON ACUTE HEMODYNAMICS IN SUBJECTS WITH IDIOPATHIC AND FAMILIAL PULMONARY A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003572-21,0,0,0 2008-003573-41,2,2009-04-03,2009-04-03,2,0,0,0,0,1,2,0,0,1,1,0,1,0,1,"TRF Pharma, Inc.","A randomised, double-blind, placebo-controlled study to assess the safety and activity of TRF-1101 on microvascular blood flow, vascular endothelial injury, and vasoocclusive pain in patients with sic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003573-41,0,0,0 2008-003575-47,2,2009-07-27,2009-07-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, double-blind, placebo controlled, parallel group study to investigate the effect of Taspoglutide on gastric emptying measured by a paracetamol test after single dose and after multiple d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003575-47,0,0,0 2008-003581-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dept of Neuroscience, Uppsala University",Pharmacokinetics of levodopa using duodenal levodopa/carbidopa infusion with and without oral COMT inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003581-26,0,0,0 2008-003586-45,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Anaesthesie, General Intensive Care and Pain Therapy",The precision of three pain scales as a function of sedation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003586-45,0,0,0 2008-003591-22,8,2010-08-10,2010-08-30,8,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Vifor (International) Inc.,"A multi-centre, randomised, prospective, single-blinded, controlled study to investigate the efficacy and safety of a standardised maintenance dosage regimen of intravenous ferric carboxymaltose (FERI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003591-22,0,0,0 2008-003592-48,1,2009-11-10,2009-11-10,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Novosis AG,"A double-blind, multi-centre, reference-controlled, randomised Phase III study to compare the analgesic efficacy and tolerability of a buprenorphine transdermal system in two different application int...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003592-48,0,0,0 2008-003593-18,1,2009-02-27,2009-02-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-Abelló A/S,A Phase III trial evaluating the tolerability of Grazax treatment in combination with antihistamine in subjects with seasonal grass pollen induced rhinoconjunctivitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003593-18,0,0,0 2008-003594-41,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"Uppsala University Hospital, Dept of Medical Scienses","An open label, multi-centre study of pasireotide LAR in addition to chemotherapy in patients with non-functioning, endocrine pancreatic tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003594-41,0,0,0 2008-003596-46,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"Multicenter, not-for-profit clinical study, in a open, controlled, randomized fashion to compare tolerability, safety and efficacy of two different treatment strategies for non malignant, persistent p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003596-46,0,0,0 2008-003597-18,1,2013-01-12,2013-01-12,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Avid Radiopharmaceuticals, Inc",A study evaluating the imaging characteristics of 18F-AV-45 in patients with frontotemporal dementia compared to patients with Alzheimer's disease and normal controls,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003597-18,0,0,0 2008-003600-55,1,2009-06-12,2009-06-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Alnylam Pharmaceuticals, Inc.","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003600-55,0,0,0 2008-003605-13,1,2010-11-30,2010-11-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Abteilung für Anaesthesie und Intensivmedizin, Medizinische Universität Wien",The effect of remifentanil on the reversal of established capsaicin-induced hyperalgesia in human volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003605-13,0,0,0 2008-003606-33,1,2015-05-13,2015-05-13,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,Pilot study to investigate the feasibility of 13-cis-Retinoic acid pharmacokinetic monitoring in high-risk neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003606-33,0,0,0 2008-003610-94,14,2019-08-19,2019-08-19,9,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"Estudio de extensión a largo plazo, multicéntrico y multinacional, para evaluar la seguridad y tolerabilidad de BAY 63 2521 (1 mg, 1,5 mg, 2 mg o 2,5 mg tid) administrado por vía oral, en pacientes co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003610-94,0,0,0 2008-003610-94,14,2019-08-19,2019-08-19,9,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Bayer AG,"Estudio de extensión a largo plazo, multicéntrico y multinacional, para evaluar la seguridad y tolerabilidad de BAY 63 2521 (1 mg, 1,5 mg, 2 mg o 2,5 mg tid) administrado por vía oral, en pacientes co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003610-94,0,0,0 2008-003617-27,3,2021-04-23,2021-04-23,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co. KG,"An open phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics, and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003617-27,0,0,0 2008-003617-27,3,2021-04-23,2021-04-23,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An open phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics, and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003617-27,0,0,0 2008-003617-27,3,2021-04-23,2021-04-23,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,SCS Boehringer Ingelheim Comm.V,"An open phase I/IIa trial to investigate the maximum tolerated dose, safety, pharmacokinetics, and efficacy of intraveneous BI 6727 as monotherapy or in combination with subcutaneous cytarabine in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003617-27,0,0,0 2008-003620-32,1,2012-04-11,2012-04-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Centre Oscar Lambret,Etude Prospective Randomisée Ouverte et Multicentrique évaluant les effets sur les fonctions cognitives de l’hormonothérapie adjuvante dans le cancer du sein de la femme ménopausée,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003620-32,0,0,0 2008-003621-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ERASME HOSPITAL,Utilisation du sufentanil en péridural lors du travail obstétrical: étude des répercussions sur le nouveau-né et l'allaitement maternel,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003621-16,0,0,0 2008-003623-23,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,"Academisch medisch centrum, department of psychiatry",Effect of different antipsychotic medication on craving related brain activity in patients with schizophrenia and cannabis abuse or dependence: a randomized controlled study comparing clozapine and ri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003623-23,0,0,0 2008-003625-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Traitement par Sandostatine LP remplaçant le traitement par Sandostatine SC chez les enfants présentant un hyperinsulinisme congénital résistant au diazoxide.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003625-16,0,0,0 2008-003630-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",Evaluation of the effacay of the intravesical thermochemotherapy with mitomycin C in intermediate risk superficial bladder tumors recurrent after BCG.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003630-17,0,0,0 2008-003631-21,1,2010-06-23,2010-06-23,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Phase 3, Open Label, Trial, Evaluating the safety, tolerability and Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Children Previously Partially Immunized with Preven...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003631-21,0,0,0 2008-003633-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,TB Investigation Unit of Barcelona,Evaluation of a rifapentine-containing regimen for intensive phase treatment of pulmonary tuberculosis Evaluación de una Pauta con Rifapentina para la Fase Intensiva del tratamiento de la Tuberc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003633-24,0,0,0 2008-003635-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitair Medisch Centrum Utrecht,"Maraviroc Immune Recovery Study (MIRS): A multicentre, randomized, placebo-controlled, exploratory mechanistic study into the role of Maraviroc on immune recovery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003635-20,0,0,0 2008-003636-38,2,2009-09-09,2009-09-09,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Biotec Pharmacon ASA,"A randomised, double-blind, placebo-controlled study to assess the efficacy and safety of soluble beta-1,3/1,6-glucan (SBG) in chronic foot ulcers in patients with diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003636-38,0,0,0 2008-003640-11,8,2011-03-25,2011-03-25,6,1,0,0,0,0,3,0,2,1,0,0,1,0,2,"Merck & Co., Inc","A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003640-11,0,0,0 2008-003640-11,8,2011-03-25,2011-03-25,6,1,0,0,0,0,3,0,2,1,0,0,1,0,2,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003640-11,0,0,0 2008-003640-11,8,2011-03-25,2011-03-25,6,1,0,0,0,0,3,0,2,1,0,0,1,0,2,"Merck & Co, Inc.","A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003640-11,0,0,0 2008-003640-11,8,2011-03-25,2011-03-25,6,1,0,0,0,0,3,0,2,1,0,0,1,0,2,"MERCK & CO., INC.","A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003640-11,0,0,0 2008-003640-11,8,2011-03-25,2011-03-25,6,1,0,0,0,0,3,0,2,1,0,0,1,0,2,Merck & Co. Inc,"A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003640-11,0,0,0 2008-003647-36,1,2010-09-21,2010-09-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5µg [2actuations of 2.5 µg] and 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003647-36,0,0,0 2008-003648-12,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Wyeth Pharmaceuticals Inc. (a Pfizer company),"A Phase 3, Open Label Trial Evaluating the Safety, Immunogenicity, and Impact of 13-valent Pneumococcal Conjugate Vaccine in Alaskan Native Children",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003648-12,0,1,1 2008-003649-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Effect of hyperbaric or isobaric bupivacaine on spinal block and on cardiac function in elderly patients undergoing transurethral procedures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003649-10,0,0,0 2008-003650-15,1,2009-07-13,2009-07-13,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Plethora Solutions Ltd,"A Phase II, multi-centre, double-blind, randomised, placebo-controlled, 4-way cross-over, dose-range finding study to evaluate efficacy and safety and tolerability of PSD502 in subjects with premature...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003650-15,0,0,0 2008-003654-15,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Karolinska University Hospital,Oral 1 mg oestradiol (E2) / 2 mg of drosperinone (DRSP) and 1 mg of oestradiol / 0.5 mg of norethisteroneacetate (NETA): effects on mammografic density and breast epithelial proliferation - an explora...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003654-15,0,0,0 2008-003655-74,1,2008-09-29,2008-09-29,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Omninvest Ltd.,FluvalAB Seasonal Influenza Vaccine Serologic Clinical Trial for 2008-2009 Influenza Season,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003655-74,0,0,0 2008-003657-32,1,2011-12-22,2011-12-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche Farma S.A.,Estudio abierto fase II de bevacizumab en combinación con paclitaxel y gemcitabina como tratamiento de primera línea en pacientes diagnosticados de carcinoma de mama metastasico o localmente avanzado ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003657-32,0,0,0 2008-003658-13,9,2019-06-30,2019-06-30,8,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Universitaetsklinikum Muenster,EWING 2008,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003658-13,0,0,0 2008-003659-63,1,2009-02-06,2009-02-06,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,BTG International Ltd,"A multicentre double-blind, placebo-controlled, randomised, parallel-group study to evaluate the safety and efficacy of BGC20-1259 in patients with mild to moderate probable Alzheimer’s Disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003659-63,0,0,0 2008-003661-19,1,2014-11-06,2014-11-06,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Ghent,Invloed van laag gedoseerde hormonale substitutie op insulinespiegels bij postmenopausale vrouwen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003661-19,0,0,0 2008-003662-25,3,2011-03-11,2011-03-11,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,H.Lundbeck A/S,"Randomised, double blind, placebo controlled study of Lu AA24493 in patients with Friedreich's Ataxia to evaluate safety and tolerability and to explore efficacy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003662-25,0,0,0 2008-003662-25,3,2011-03-11,2011-03-11,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Randomised, double blind, placebo controlled study of Lu AA24493 in patients with Friedreich's Ataxia to evaluate safety and tolerability and to explore efficacy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003662-25,0,0,0 2008-003665-12,1,2012-01-02,2012-01-02,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Centro Comunitario de Sangre y Tejidos de Asturias,"ENSAYO CLÍNICO MULTICÉNTRICO, ALEATORIZADO, ABIERTO PARA VALORAR LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO DE HERIDAS QUIRUGICAS DEL PIE DIABÉTICO CON INJERTOS CUTÁNEOS CULTIVADOS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003665-12,0,0,0 2008-003666-26,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA` GRANDA (A.O. DI RILIEVO NAZIONALE),"A double-blind, randomized trial of ARNICA comp.-Heel treatment in patients undergoing hemorrhoidectomy in day surgery: evaluation of postoperative pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003666-26,0,0,0 2008-003669-24,1,2011-04-30,2011-04-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Deutsches Krebsforschungszentrum,Intra-individual cross-over comparison of MultiHance® and Vasovist® enhanced MRA of the Carotids,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003669-24,0,0,0 2008-003670-18,1,2011-05-31,2011-05-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts,"Vasovist in MRI follow-up of embolized intracranial aneurysms at 3 Tesla – A prospective, multicenter, multinational, open-label, investigator initiated study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003670-18,0,0,0 2008-003676-22,1,2012-04-06,2012-04-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,The Medicines Company,A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure – A Pilot Study (PRONTO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003676-22,0,0,0 2008-003679-40,1,2010-03-03,2010-03-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Rigshospitalet,A phase II study of temsirolimus and bevacizumab in recurrent glioblastoma multiforme,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003679-40,0,0,0 2008-003680-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Servicio de Alergia. Hospital Civil. Málaga (Spain),"Valoración de la eficacia de un extracto de Dermatophagoides pteronyssinus, valorado en unidades de masa y administrado por vía subcutánea, en el tratamiento de la rinitis alérgica local. Estudio rand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003680-39,0,0,0 2008-003687-20,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003687-20,0,1,1 2008-003688-38,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of 3 Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003688-38,0,1,1 2008-003689-24,1,2010-06-28,2010-06-28,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Moorfields Eye Hospital NHS Foundation Trust,Lotemax in the treatment of chronic anterior uveitis: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003689-24,0,0,0 2008-003690-40,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Low-doses radiotherapy and concomitant chemotherapy with pemetrexed in progression desease NSCLC: a dose-descalation phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003690-40,0,0,0 2008-003693-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,"Treatment of Complex Regional Pain Syndrome type I: A randomised, double-blind, placebo-controlled study with multiple rounds of S(+)-ketamine infusions",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003693-17,0,0,0 2008-003694-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Universidad de Granada,"Ensayo clínico piloto aleatorizado, para evaluar la eficacia y tolerabilidad de quetiapina de liberación prolongada en comparación con la de amitriptilina en el tratamiento de pacientes con fibromial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003694-41,0,0,0 2008-003696-43,1,,,0,0,0,0,0,3,3,0,0,0,0,0,0,0,0,KWF Kankerbestrijding,Prevention of progression of duodenal adenomas to cancer in patients with familial adenomatous polyposis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003696-43,0,0,0 2008-003698-42,8,2013-08-13,2013-08-13,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AstraZeneca AB,"A controlled, randomised, double-blind, double-dummy, parallel-group, phase III, multicenter study to evaluate efficacy and safety of the oral direct thrombin inhibitor AZD0837 compared to warfarin fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003698-42,1,0,0 2008-003704-67,1,2010-09-27,2010-09-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5µg [2actuations of 2.5 µg] and 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003704-67,0,0,0 2008-003705-13,1,2014-07-23,2014-07-23,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Tuula Manner,"DOM- A comparative study with pre-emptive parenteral oxycodone, morphine and dexamethasone in the treatment of postoperative pain in paediatric patients 4 to 12 years of age.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003705-13,0,0,0 2008-003706-33,15,2011-10-24,2012-04-30,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Serono International,"A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003706-33,0,0,0 2008-003706-33,15,2011-10-24,2012-04-30,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Serono S.A. - Geneva,"A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003706-33,0,0,0 2008-003706-33,15,2011-10-24,2012-04-30,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MERCK SERONO SA,"A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003706-33,0,0,0 2008-003706-33,15,2011-10-24,2012-04-30,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Serono SA - Geneva,"A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003706-33,0,0,0 2008-003707-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude de l'effet du carbonate de lithium sur une population de patients atteints de SLA en ouvert en comparaison avec une population de référence. LISLA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003707-32,0,0,0 2008-003708-77,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Impact of a 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization With Vaccine Serotypes of Streptococcus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003708-77,0,1,1 2008-003712-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude de la réponse clinique et neurofonctionnelle à la fluoxétine dans l'autisme infantile,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003712-36,0,0,0 2008-003714-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Intensity Modulated Radiotherapy with Simultaneous Boost plus Temozolomide in high grade gliomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003714-10,0,0,0 2008-003727-23,1,2010-10-28,2010-10-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Birmingham NHS Foundation Trust,Does phosphate binding with sevelamer carbonate improve cardiovascular structure and function in patients with early chronic kidney disease?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003727-23,0,0,0 2008-003729-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,A phase II trial to evaluate the safety and activity of single-agent lenalidomide given as maintenance therapy after response to second-line therapy in patients with relapsed diffuse large B cell lymp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003729-18,0,0,0 2008-003731-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset,"Postoperative Hyperbaric Oxygen treatments to reduce complications in Diabetic patients undergoing Vascular Surgery (HODIVA) - A double blind, randomized controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003731-20,0,0,0 2008-003732-38,1,2008-12-08,2008-12-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios Almirall, S.A.","A PHASE IIa, RANDOMISED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO CONTROLLED, 3 PERIOD CROSS-OVER, ASCENDING DOSE CLINICAL TRIAL TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THREE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003732-38,0,0,0 2008-003733-24,1,2014-04-30,2014-04-30,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Abertawe Bro Morgannwg University NHS Trust,A randomised study to assess the effects of Epoetin Beta on renal function in patients with critical illness(with or without multi-organ failure),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003733-24,0,0,0 2008-003736-38,9,2010-06-14,2010-06-14,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BIAL-Portela & Ca, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE AS PREVENTIVE THERAPY FOR PATIENTS WITH MIGRAINE: A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003736-38,0,0,0 2008-003736-38,9,2010-06-14,2010-06-14,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BIAL - PORTELA & C, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE AS PREVENTIVE THERAPY FOR PATIENTS WITH MIGRAINE: A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE CLINICAL TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003736-38,0,0,0 2008-003737-25,3,2016-06-01,2016-06-01,1,0,0,0,0,0,4,0,0,2,0,0,0,0,1,SIRTEX TECHNOLOGY PTY LTD,"Estudio randomizado en el que se compara el uso de FOLFOX6m más microesferas SIR-Spheres® frente a FOLFOX6m, en pacientes con metástasis hepáticas no resecables debidas a carcinoma colorrectal primari...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003737-25,1,0,0 2008-003737-25,3,2016-06-01,2016-06-01,1,0,0,0,0,0,4,0,0,2,0,0,0,0,1,Sirtex Technology Pty Ltd,"Estudio randomizado en el que se compara el uso de FOLFOX6m más microesferas SIR-Spheres® frente a FOLFOX6m, en pacientes con metástasis hepáticas no resecables debidas a carcinoma colorrectal primari...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003737-25,1,0,0 2008-003739-19,1,2010-08-10,2010-08-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novo Nordisk Pharma S.A.,"Ensayo multicéntrico, abierto, aleatorizado, de dos grupos, paralelo para comparar el cambio en la distribución de grasa en sujetos con sobrepeso y obesos con diabetes tipo 2 tras 26 semanas de tratam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003739-19,0,0,0 2008-003740-11,4,2010-09-30,2010-09-30,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A PHASE 4, MULTINATIONAL, MULTICENTRE, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, PARALLEL GROUP, CONTROLLED CLINICAL STUDY OF FIXED COMBINATION BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003740-11,0,0,0 2008-003741-87,1,2010-12-09,2010-12-09,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, open-label, randomized, multicentre study to evaluate the feasibility of GSK Biologicals’ DTPa-IPV/Hib-MenC-TT vaccine co-administered with Prevenar compared with Pediacel co-administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003741-87,0,0,0 2008-003748-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación SEIMC-GESIDA,"“Estudio Fase IV-III, comparativo, aleatorizado y abierto para evaluar la eficacia para la recuperación de grasa periférica (o de extremidades) de lopinavir/ritonavir en monoterapia versus abacavir/la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003748-12,0,0,0 2008-003752-30,12,2015-06-30,2016-06-30,12,1,0,0,0,2,3,0,0,1,1,0,1,0,1,"Merck & Co., Inc","An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003752-30,0,0,0 2008-003752-30,12,2015-06-30,2016-06-30,12,1,0,0,0,2,3,0,0,1,1,0,1,0,1,"MERCK & CO., INC.","An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003752-30,0,0,0 2008-003753-33,6,2012-04-09,2012-04-09,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003753-33,0,0,0 2008-003753-33,6,2012-04-09,2012-04-09,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,"MERCK & CO., INC.","An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003753-33,0,0,0 2008-003766-26,1,2018-11-29,2018-11-29,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Southampton University Hospitals NHS Trust,The effects of purified n-3 fatty acids on serum biomarkers and cardiovascular risk markers in a randomized placebo controlled trial in patients with non alcoholic fatty liver disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003766-26,0,0,0 2008-003767-39,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Concomitant radiochemotherapy with Tegafur and Mitomycin in locally advanced anal canal cancer: Dose Escalation Study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003767-39,0,0,0 2008-003768-20,1,2016-09-16,2016-09-16,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Medizinische Universität Wien, Universitätsklinik f. Innere Med. III, Abt. f. Nephrologie u. Dialyse",Influence of mycophenolate mofetil (Cellcept) on the progression of diabetic nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003768-20,0,0,0 2008-003772-21,3,2014-12-05,2014-12-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER STUDY TO INVESTIGATE THE USE OF MEPOLIZUMAB (SB-240563) IN REDUCING THE NEED FOR SURGERY IN SUBJECTS WITH SEVERE BILATERAL NASAL POLYPOSIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003772-21,0,0,0 2008-003773-41,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Effect of heart rate and autonomic nervous system modulation on inflammatory state and peripheral vascular function in patients with type 2 diabetes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003773-41,0,0,0 2008-003774-17,1,2009-02-02,2009-02-02,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,Vantia Ltd,"A double-blind, placebo-controlled dose response study to investigate pharmacodynamics and pharmacokinetics of single and repeated oral doses of VA106483 in elderly male subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003774-17,0,0,0 2008-003779-37,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,iOMEDICO AG,Capecitabine and bevacizumab ± vinorelbine as 1st line treatment in HER2/neu-negative metastatic or locally advanced inoperable breast cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003779-37,0,0,0 2008-003780-38,7,2011-10-14,2011-11-11,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Schering-Plough Research Institute,"A 2-Year, Dose Range-Finding, Adaptive-Design Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003780-38,0,0,0 2008-003780-38,7,2011-10-14,2011-11-11,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Schering Plough Research Institute,"A 2-Year, Dose Range-Finding, Adaptive-Design Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003780-38,0,0,0 2008-003786-20,5,2010-01-04,2010-01-04,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Solvay Pharmaceuticals, Inc.","A Double-Blind, Placebo-Controlled, Randomized, Multi-Center, Dose-Finding Study of SLV320, a Selective A1 Adenosine Receptor Antagonist, to Evaluate the Effect on Renal Function and Safety in Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003786-20,0,0,0 2008-003786-20,5,2010-01-04,2010-01-04,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Solvay Pharmaceuticals Inc.,"A Double-Blind, Placebo-Controlled, Randomized, Multi-Center, Dose-Finding Study of SLV320, a Selective A1 Adenosine Receptor Antagonist, to Evaluate the Effect on Renal Function and Safety in Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003786-20,0,0,0 2008-003789-24,3,2010-09-23,2010-12-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF GDC-0449 AS MAINTENANCE THERAPY IN PATIENTS WITH OVARIAN CANCER IN A SECOND OR THIRD C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003789-24,0,0,0 2008-003791-22,5,2009-06-05,2009-06-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Recherche & Développement,"Efficacy and safety of eplivanserin 5mg/day in insomnia characterized by sleep maintenance difficulties: a 6-week, randomized, double-blind, placebo-controlled, polysomnography study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003791-22,0,0,0 2008-003792-52,1,2012-01-31,2012-01-31,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik fuer Dermatologie","Azelaic acid iontophoresis versus topical azelaic acid cream in the treatment of melasma – An open randomized, controlled, prospective, single blinded clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003792-52,0,0,0 2008-003800-73,6,2013-06-05,2013-07-05,3,1,0,0,0,1,0,0,0,1,1,1,1,0,1,PARI Pharma GmbH,"A phase II, multicentre, randomised, double-blind, placebo controlled clinical trial to investigate the efficacy and safety of 10 or 20 mg/day aerosolised liposomal ciclosporin A (L-CsA) versus aeroso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003800-73,0,0,0 2008-003800-73,6,2013-06-05,2013-07-05,3,1,0,0,0,1,0,0,0,1,1,1,1,0,1,Pari Pharma GmbH,"A phase II, multicentre, randomised, double-blind, placebo controlled clinical trial to investigate the efficacy and safety of 10 or 20 mg/day aerosolised liposomal ciclosporin A (L-CsA) versus aeroso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003800-73,0,0,0 2008-003801-15,2,2009-11-11,2009-11-11,1,0,0,0,0,1,2,0,0,1,1,0,1,0,1,PARIPharma GmbH,"A phase II, randomised, double-blind, placebo controlled, parallel group, dose-finding clinical trial to investigate the efficacy and safety of 10 and 20 mg/day aerosolised liposomal ciclosporin A (L-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003801-15,0,0,0 2008-003803-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA PISANA,Effects of the treatment with metformin and/or sitagliptin on β- cell function and insulin resistance in women with prior gestational diabetes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003803-30,0,0,0 2008-003824-51,1,2012-09-10,2012-09-10,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, open, multi-centre, controlled study to evaluate the long-term antibody persistence at 2 years, 3 years and 4 years after a single dose of GlaxoSmithKline (GSK) Biologicals’ meningococca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003824-51,0,0,0 2008-003828-38,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE,Yttrium Y90Ibritumomab Tiutexan (Zevalin)as a consolidation treatment for patients with high grade non-Hodgkin's lymphoma aged >60 years.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003828-38,0,0,0 2008-003829-16,1,2016-10-24,2016-10-24,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,GMIHO - Gesellschaft für medizinische Innovation Hämatologie und Onkologie mbH,"An open, randomized clinical phase I/II trial to investigate maximum tolerated dose, efficacy, and safety of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003829-16,0,0,0 2008-003831-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hopital Foch,Comparaison de l'effet de deux doses d'Acide Tranexamique sur les besoins transfusionnels en chirurgie cardiaque,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003831-20,0,0,0 2008-003832-40,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Hopital Foch,"Effet de la poursuite de la curarisation sur les besoins en hypnotique lors des interventions ne nécessitant pas une myorelaxation continue peropératoire (étude multicentrique, prospective et randomis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003832-40,0,0,0 2008-003833-25,1,2009-05-13,2009-05-13,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,Universitätskrankenhaus Schleswig-Holstein,"Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003833-25,0,0,0 2008-003835-18,2,2011-09-23,2011-09-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GE Healthcare Ltd,"A phase 2, open-label test-retest study to assess the reproducibility of quantitative measurements of 18F uptake by solid tumours using PET imaging following intravenous administration of AH111585 (18...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003835-18,0,0,0 2008-003836-39,2,2010-07-02,2010-07-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003836-39,0,0,0 2008-003839-20,1,2010-06-04,2010-06-04,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Gilead Sciences, Inc.","A Open-Label, Parallel-Group, Exploratory Study to Evaluate the Efficacy and Safety of 400 µg Regadenoson Bolus for Pharmacological Stress Echocardiography",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003839-20,0,0,0 2008-003840-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,UNITHER Pharmaceuticals,"Essai clinique comparant l'efficacité et la tolérance d'un comprimé à sucer contenant 14,63 mg d'Ibuprofène versus placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003840-13,0,0,0 2008-003842-27,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,CENTRO STUDI FADOI,"Randomized, single-blind, parallel groups, controlled study to compare levofloxacin and prulifloxacin in patients with exacerbations of COPD previously treated with different antibiotics and admitted ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003842-27,0,0,0 2008-003843-36,2,2010-01-04,2010-01-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Randomized Trial Comparing Exenatide with Placebo in Subjects with Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003843-36,0,0,0 2008-003854-13,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,GALDERMA R&D SNC,AN INVESTIGATOR BLIND PARALLEL GROUP VEHICLE CONTROL STUDY COMPARING THE EFFICACY AND SAFETY OF CD 5024 1% CREAM WITH METRONIDAZOLE 0.75% CREAM IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA OVER 16 W...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003854-13,0,0,0 2008-003855-65,4,2012-10-17,2017-10-17,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,"FEIBA NF: A PROSPECTIVE, OPEN-LABEL, RANDOMIZED, PARALLEL STUDY TO EVALUATE EFFICACY AND SAFETY OF PROPHYLACTIC VERSUS ON-DEMAND TREATMENT IN SUBJECTS WITH HEMOPHILIA A OR B AND A HIGH TITER INHIBITO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003855-65,0,0,0 2008-003855-65,4,2012-10-17,2017-10-17,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAXTER INNOVATIONS GMBH,"FEIBA NF: A PROSPECTIVE, OPEN-LABEL, RANDOMIZED, PARALLEL STUDY TO EVALUATE EFFICACY AND SAFETY OF PROPHYLACTIC VERSUS ON-DEMAND TREATMENT IN SUBJECTS WITH HEMOPHILIA A OR B AND A HIGH TITER INHIBITO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003855-65,0,0,0 2008-003856-32,1,2011-10-19,2011-10-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Evaluation de l’effet de la prise orale de perindopril orodispersible à la dose de 0,150 mg/kg/jour sur la fonction musculaire et myocardique dans la dystrophie musculaire de Duchenne à un stade préco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003856-32,0,0,0 2008-003861-17,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,Artu Biologicals Europe B.V.,"A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and tolerability of Oralgen Birch Pollen immunotherapy in patients with allergic rhinoconjun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003861-17,0,0,0 2008-003864-20,1,2011-05-20,2011-05-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Schering Plough Research Institute, a Division of Schering Corporation","A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long-Term Safety of Ragweed (Ambrosia artemisiifolia) Sublingual Tablet (SCH 39641) in Adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003864-20,0,0,0 2008-003865-23,1,2009-01-05,2009-01-05,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,Hyperion Therapeutics Limited,"A Phase 2, Switch-Over, Dose-Escalation Study of the Safety and Tolerability of HPN-100 (glyceryl tri-[4-phenylbutyrate]) Compared to Sodium Phenylbutyrate in Adult and Pediatric Subjects with Urea Cy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003865-23,0,0,0 2008-003869-72,1,2010-02-25,2010-02-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Bial - Portela & Cª, S.A.","A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE TOLERABILITY AND EFFECT OF THREE SINGLE-DOSE REGIMENS OF BIA 9-1067 ON THE LEVODOPA PHARMACOKINETICS, MOTOR RESPONSE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003869-72,0,0,0 2008-003870-16,1,2011-10-19,2011-10-19,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,"A PILOT STUDY OF SEQUENTIAL, NON-MYELOABLATIVE HLA-IDENTICAL SIBLING DONOR ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWED BY IV TEMSIROLIMUS IN PATIENTS WITH ADVANCED, TKI-REFRACTORY CLEAR-CELL RENAL C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003870-16,0,0,0 2008-003871-32,2,2009-11-23,2009-11-23,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase III, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of a Monovalent A/H5N1 Influenza Vaccine Adjuvanted with MF5...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003871-32,0,0,0 2008-003875-35,1,2009-11-17,2009-11-17,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Rottapharm SpA,Comparative study of efficacy and safety of GO-ON and Hyalgan in patients with symptomatic osteoarthritis of the knee.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003875-35,0,0,0 2008-003877-42,1,2012-11-29,2012-11-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Danish University Antidepressant Group (DUAG),Relapse prevention in patients with major depression treated with electroconvulsive therapy using a fixed dose range of escitalopram compared to a fixed dose of nortriptyline (DUAG-7) A randomised con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003877-42,0,0,0 2008-003879-49,1,2009-07-23,2009-07-23,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,Artu Biologicals Europe B.V.,"A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and the effect of different doses of Oralgen House Dust Mite in patients with house dust mit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003879-49,0,0,0 2008-003883-20,8,2012-04-16,2012-04-16,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003883-20,0,0,0 2008-003883-20,8,2012-04-16,2012-04-16,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"NOVARTIS FARMACEUTICA , S.A.","An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003883-20,0,0,0 2008-003883-20,8,2012-04-16,2012-04-16,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An open-label, multicenter, expanded access study of imatinib mesylate in adult patients with GIST in adjuvant setting after R0-resection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003883-20,0,0,0 2008-003886-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VieCuri Medisch Centrum voor Noord-Limburg,Effect of inhaled hypertonic saline solution to treat infants hospitalized with viral bronchiolitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003886-17,0,0,0 2008-003887-21,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Univ.-Doz. Dr. Karl-Heinz Smolle,Klinische Studie zur Überprüfung des Einflusses einer intradialytischen Verabreichung von Vitamin E und Vitamin C auf biochemische Indikatoren für die antioxidative Kapazität sowie auf Entzündungsmark...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003887-21,0,0,0 2008-003905-15,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""",Carmustine implant (Gliadel Wafer) plus adjuvant and concomitant Temozolomide in combination with radiotherapy in primary glioblastoma patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003905-15,0,0,0 2008-003906-32,5,2009-08-31,2009-08-31,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Stallergenes S.A.,"A randomised, double-blind, placebo-controlled, multi national, Phase III study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT), starting 2 months before the grass pollen season, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003906-32,0,0,0 2008-003906-32,5,2009-08-31,2009-08-31,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,STALLERGENES SA,"A randomised, double-blind, placebo-controlled, multi national, Phase III study of the efficacy and safety of 300 IR sublingual immunotherapy (SLIT), starting 2 months before the grass pollen season, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003906-32,0,0,0 2008-003908-61,2,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,0,University Medical Center Utrecht,"A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, 2-PERIOD, CROSSOVER STUDY TO COMPARE THE EFFECTS OF EZETIMIBE/SIMVASTATIN (10 MG/10 MG) COMBINATION TABLET VERSUS SIMVASTATIN 80 MG TABLET ON POSTPRANDIAL ARTE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003908-61,0,0,0 2008-003908-61,2,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,0,University Medical Center Ultrecht,"A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, 2-PERIOD, CROSSOVER STUDY TO COMPARE THE EFFECTS OF EZETIMIBE/SIMVASTATIN (10 MG/10 MG) COMBINATION TABLET VERSUS SIMVASTATIN 80 MG TABLET ON POSTPRANDIAL ARTE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003908-61,0,0,0 2008-003913-28,1,2011-05-16,2011-05-16,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,COSMO TECHNOLOGIES LTD,"Randomised, double-blind,multicentre,12 months extension study to evaluate the safety and the efficacy of daily Budesonide MMX 6mg vs placebo in the maintenance of remission in subjects with ulcerativ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003913-28,0,0,0 2008-003914-87,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,CHU de Nantes,Analyse de l’effet thérapeutique à trois mois des infiltrations du nerf pudendal dans les névralgies pudendales par syndrome canalaire.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003914-87,0,0,0 2008-003915-11,1,2011-11-19,2011-11-19,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Utah,Phase I/II Trial of Valproic Acid and Carnitine in Infants with Spinal Muscular Atrophy Type I (CARNI-VAL Type I),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003915-11,0,0,0 2008-003917-29,1,2010-07-02,2010-07-02,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Gilead Sciences Incorporated,"A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced Adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003917-29,0,0,0 2008-003920-40,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Instituto Grifols, S.A.","ESTUDIO CLÍNICO SOBRE LOS EFECTOS DE LA ADMINISTRACIÓN PROLONGADA DE ALBUMINA 20% SOBRE LA FUNCIÓN CARDIOCIRCULATORIA Y RENAL, Y LA HEMODINAMICA HEPATICA EN PACIENTES CON CIRROSIS AVANZADA Y ASCITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003920-40,0,0,0 2008-003923-21,3,2009-05-12,2009-06-08,3,1,0,0,0,0,3,0,0,1,1,0,1,0,2,"Merck & Co., Inc.","A Phase III, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0826/Ertapenem and Meropenem in Patients with Complicated Urinary Tract Infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003923-21,0,0,0 2008-003924-52,8,2011-11-12,2011-11-12,7,1,1,0,0,1,3,0,0,1,0,0,1,0,1,"PTC Therapeutics, Inc",A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003924-52,0,0,0 2008-003924-52,8,2011-11-12,2011-11-12,7,1,1,0,0,1,3,0,0,1,0,0,1,0,1,"PTC THERAPEUTICS, INC.",A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003924-52,0,0,0 2008-003925-17,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI PARMA,Immunotherapy by autologous peripheral blood mononuclear cells and GM-CSF for hepatocellular carcinoma undergoing radiofrequency thermal ablation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003925-17,0,0,0 2008-003930-19,1,2017-10-30,2017-10-30,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,CENTRE JEAN PERRIN,"Essai multicentrique randomisé de phase II comparant le Taxotère® en monothérapie à l’association Taxotère® plus curcumine en première ou deuxième ligne de traitement des cancers du sein inopérables, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003930-19,0,0,0 2008-003931-19,5,2013-07-09,2013-07-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One Cycle in Patients with Prostate Cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003931-19,0,0,0 2008-003932-40,1,2009-11-17,2009-11-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boerhinger Ingelheim Pharma GmbH & Co.KG,"A 12-week, double-blind, randomised, placebo-controlled, multicentre trial to evaluate efficacy and tolerability of Antistax® film-coated tablets, 720mg/day orally, in male and female patients sufferi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003932-40,0,0,0 2008-003936-38,1,2011-12-31,2011-12-31,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,"TAYS, Hematologian yksikkö",Bortetsomibi + Dexametasonihoidon hoitovasteen laadun selvitys aiemmin hoitamattomilla myeloomapotilailla.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003936-38,0,0,0 2008-003945-10,1,2014-04-04,2014-04-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre hospitalier universitaire de nice,ACTION OF THE AMANTADINE ON POST STROKE APHASIC PATIENTS LANGUAGE AND COMMUNICATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003945-10,0,0,0 2008-003946-28,1,2011-04-11,2011-04-11,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,ISTITUTO PER L`INFANZIA BURLO GAROFOLO,"Postoperative pain treatment following gynecologic surgery, using different doses of transdermal buprenorphine a double – blind, randomized study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003946-28,0,0,0 2008-003950-14,2,2009-07-02,2009-07-02,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,A phase III long-term follow-up study to assess the immune responses following vaccination at 36-46 months of age with a booster dose of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003950-14,0,0,0 2008-003952-31,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"Treatment of chronic rotator cuff tendinopathy with local steroid injection or hypertermia. A Randomized, prospective, clinical study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003952-31,0,0,0 2008-003953-34,1,2010-06-15,2010-06-15,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,D2 Derma Europe Ltd.,"A randomized, placebo-controlled, active comparator, observer-blinded multicentre phase II trial to evaluate the efficacy and safety of D2D001 in the treatment of HSV type 1 infection in the region of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003953-34,0,0,0 2008-003954-13,1,2010-06-11,2010-06-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Silkeborg Hospital,Vitamin D and type 2 diabetes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003954-13,0,0,0 2008-003960-20,5,2011-09-21,2011-09-21,3,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Prevention and Treatment of Bleeds in Previously Treated Subjects with Haemophilia A Sub-Trial: Safety and Efficacy of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003960-20,0,0,0 2008-003960-20,5,2011-09-21,2011-09-21,3,1,0,0,0,2,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Prevention and Treatment of Bleeds in Previously Treated Subjects with Haemophilia A Sub-Trial: Safety and Efficacy of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003960-20,0,0,0 2008-003962-24,1,2012-06-26,2012-06-26,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Fredericia hospital,visceral pain originating from the upper urinary tract - a randomised controlled trial on the effect of morphine and oxycodone in patients undergoing percutaneus nephrolithotomy (PCNL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003962-24,0,0,0 2008-003966-25,1,2010-12-10,2010-12-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Universität Mainz, Klinik und Poliklinik für Neurologie","Double-blind, placebo controlled, randomised, monocenter cross-over studie to evaluate the effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome compared to p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003966-25,0,0,0 2008-003967-37,1,2012-12-10,2012-12-10,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,CureVac GmbH,Safety and efficacy trial of a RNActive®-derived prostate cancer vaccine in hormone refractory disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003967-37,0,0,0 2008-003971-30,1,2011-11-30,2011-11-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Univ.-Prof. Dr. Karlheinz Tscheliessnigg,Klinische Studie zur Überprüfung der Auswirkungen einer präoperativen Verabreichung von Glutamin und/oder Omega-3-Fettsäuren auf das Inflammationsgeschehen nach aortokoronaren Bypassoperationen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003971-30,0,0,0 2008-003972-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,LUMC,"Hepatocellular carcinoma: vascular abnormalities prior to, during and following systemic anti-cancer treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003972-23,0,0,0 2008-003973-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,PC Pharma CVA : PostConditionnement pharmacologique au cours de la Chirurgie Valvulaire Aortique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003973-42,0,0,0 2008-003980-38,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Roche Slovensko s.r.o.,An open label study of the effect of Xeloda and radiotherapy on pathological response rate in patients with locally advanced rectal cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003980-38,0,0,0 2008-003982-21,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude des transporteurs de la dopamine et de la sérotonine en imagerie TEMP utilisant les radiopharmaceutiques 123I-FP-CIT (datscan) and 123 I-ADAM dans la sclérose latérale amyotrophique et dans une ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003982-21,0,0,0 2008-003984-38,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Dainippon Sumitomo Pharma America Ltd,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE COMPARATOR CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF TWO DOSES OF LURASIDONE IN ACUTELY PSYCHOTIC SUBJECTS WITH SCHIZOPHRENI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003984-38,0,0,0 2008-003988-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Centre Régional de Lutte contre le Cancer Val d'Aurelle- Paul Lamarque,Essai de phase I-II évaluant l’association de Cetuximab et de Trastuzumab chez des patients atteints de cancer pancréatique métastatique ayant progressé sous chimiothérapie à base de gemcitabine (Essa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003988-39,0,0,0 2008-003990-42,1,2014-01-27,2014-01-27,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,DuoCort Pharma AB,"An open, multi-centre, phase IIIb, long term follow-up study to assess the safety, tolerability and efficacy of once-daily oral modified-release hydrocortisone in patients with adrenal insufficiency.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003990-42,0,0,0 2008-003991-23,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,EFFECT OF ORAL ADMINISTRATION OF OLEASELECT TO HUMAN HEALTHY VOLUNTEERS ON METABOLIC AND INFLAMMATORY PATHWAYS RELATED TO THE RISK OF ISCHEMIC CARDIOVASCULAR DISEASE: A PILOT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003991-23,0,0,0 2008-003993-16,1,,,0,0,0,1,0,1,1,0,0,1,0,0,0,1,1,"Immunomedics, Inc.",A Phase Ib/II Study of Fractionated 90-Y-hPAM4 Plus Gemcitabine in Patients with Previously Untreated Advanced Pancreatic Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003993-16,0,0,0 2008-003995-23,1,2014-01-24,2014-01-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GBG Forschungs GmbH,An investigational randomized phase II-(III) study on epirubicin plus cyclophospamide (or CMF) vs nab-paclitaxel plus capecitabine as adjuvant chemotherapy for elderly non frail patients with an incre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003995-23,0,0,0 2008-003997-17,1,2012-10-05,2012-10-05,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,GBG Forschungs GmbH,A randomized phase III study to determine the efficacy of a taxane and bevacizumab with or without capecitabine as first line chemotherapy in patients with metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-003997-17,0,0,0 2008-004000-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,Servicio de Neumología del Hospital Valle Hebrón,"Ensayo Clínico Piloto, Aleatorizado, Paralelo, para Evaluar la Eficacia y Seguridad de dos Pautas de Tratamiento con Tobramicina Inhalada, en la Infección Bronquial Crónica por Pseudomonas aeruginosa,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004000-30,0,0,0 2008-004002-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,TREND,pharmacokinetic-pharmacodynamic modeling of S(+)-ketamine in fibromyalgia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004002-14,0,0,0 2008-004007-64,6,2015-04-01,2015-04-01,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Biologicals,"An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004007-64,0,0,0 2008-004007-64,6,2015-04-01,2015-04-01,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.","An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004007-64,0,0,0 2008-004008-30,4,2010-03-24,2010-03-24,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","RANDOMIZED, OPEN LABEL, PHASE 3 CLINICAL STUDY TO EVALUATE THE EFFECT OF THE ADDITION OF CP-751,871 TO GEMCITABINE AND CISPLATIN IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004008-30,0,0,0 2008-004009-32,3,2012-03-28,2012-03-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York City, NY 10017",Estudio en fase 2 aleatorizado de cisplatino/pemetrexed con o sin axitinib (AG-013736) para el tratamiento en primera línea de pacientes con cáncer de pulmón no microcítico no escamoso.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004009-32,0,0,0 2008-004009-32,3,2012-03-28,2012-03-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,Estudio en fase 2 aleatorizado de cisplatino/pemetrexed con o sin axitinib (AG-013736) para el tratamiento en primera línea de pacientes con cáncer de pulmón no microcítico no escamoso.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004009-32,0,0,0 2008-004009-32,3,2012-03-28,2012-03-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"PFIZER, S.A.",Estudio en fase 2 aleatorizado de cisplatino/pemetrexed con o sin axitinib (AG-013736) para el tratamiento en primera línea de pacientes con cáncer de pulmón no microcítico no escamoso.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004009-32,0,0,0 2008-004011-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Efficacité de l'infiltration tissulaire peropératoire par la ropivacaïne (Naropeine®) dans la chirurgie thyroïdienne : étude randomisée, en double aveugle versus placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004011-35,0,0,0 2008-004012-13,6,2010-11-19,2010-11-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"F.Hoffmann-La Roche Ltd - Pharmaceutical Division, PDR","A dose ranging, randomized, double blind, parallel-group placebo-controlled multi-center study of RO5313534 used as add-on to donepezil treatment in patients with mild to moderate symptoms of Alzh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004012-13,0,0,0 2008-004012-13,6,2010-11-19,2010-11-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A dose ranging, randomized, double blind, parallel-group placebo-controlled multi-center study of RO5313534 used as add-on to donepezil treatment in patients with mild to moderate symptoms of Alzh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004012-13,0,0,0 2008-004013-94,3,2013-02-18,2013-02-18,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,F. Hoffmann-La Roche Ltd.,A prospective Phase II study to evaluate alterations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression after initial expo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004013-94,0,0,0 2008-004014-27,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación Progreso y Salud,"Ensayo clínico multicéntrico fase I/II aleatorizado y controlado, para la evaluación de seguridad y factibilidad de la terapia con dos dosis distintas de células madre mesenquimales procedentes de tej...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004014-27,0,0,0 2008-004015-35,1,2011-06-28,2011-06-28,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Fundación Progreso y Salud,"ENSAYO CLÍNICO MULTICÉNTRICO FASE I/II ALEATORIZADO Y CONTROLADO CON PLACEBO, PARA EVALUACIÓN DE SEGURIDAD Y FACTIBILIDAD DE LA TERAPIA CON DOS DOSIS DISTINTAS DE CÉLULAS TRONCALES MESENQUIMALES AUTÓL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004015-35,0,0,0 2008-004016-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Lijf en Leven,Clopidogrel for the prevention of late cardiac events in patients with asymptomatic perioperative acute coronary syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004016-12,0,0,0 2008-004019-36,9,2015-12-04,2015-12-04,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,IPSEN PHARMA,"Estudio abierto, de extensión, con lanreotida autogel 120 mg en pacientes con tumor endocrino entero-pancreático no funcional. Open label extension study of lanreotide Autogel 120 mg in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004019-36,0,0,0 2008-004019-36,9,2015-12-04,2015-12-04,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,IPSEN PHARMA SAS,"Estudio abierto, de extensión, con lanreotida autogel 120 mg en pacientes con tumor endocrino entero-pancreático no funcional. Open label extension study of lanreotide Autogel 120 mg in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004019-36,0,0,0 2008-004019-36,9,2015-12-04,2015-12-04,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"IPSEN Research and Development, IPSEN PHARMA SAS","Estudio abierto, de extensión, con lanreotida autogel 120 mg en pacientes con tumor endocrino entero-pancreático no funcional. Open label extension study of lanreotide Autogel 120 mg in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004019-36,0,0,0 2008-004019-36,9,2015-12-04,2015-12-04,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"IPSEN Research and Development, BEAUFOUR IPSEN PHARMA","Estudio abierto, de extensión, con lanreotida autogel 120 mg en pacientes con tumor endocrino entero-pancreático no funcional. Open label extension study of lanreotide Autogel 120 mg in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004019-36,0,0,0 2008-004019-36,9,2015-12-04,2015-12-04,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,BEAUFOUR IPSEN PHARMA,"Estudio abierto, de extensión, con lanreotida autogel 120 mg en pacientes con tumor endocrino entero-pancreático no funcional. Open label extension study of lanreotide Autogel 120 mg in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004019-36,0,0,0 2008-004019-36,9,2015-12-04,2015-12-04,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Ipsen Pharma,"Estudio abierto, de extensión, con lanreotida autogel 120 mg en pacientes con tumor endocrino entero-pancreático no funcional. Open label extension study of lanreotide Autogel 120 mg in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004019-36,0,0,0 2008-004026-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"BIVIR : Essai randomisé en double insu comparant l'association oseltamivir et zanamivir à l'oseltamivir et placebo et au zanamivir et placebo dans le traitement curatif de la grippe, virologiquement s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004026-16,0,0,0 2008-004044-36,2,2015-02-01,2015-02-01,1,0,0,0,1,0,3,0,0,2,0,0,0,0,0,Bispebjerg Hospital,Behandling af præmaligne hudlæsioner med topikal imiquimod og fotodynamisk terapi hos organtransplanterede patienter - et randomiseret intraindividuelt forsøg med blindet effektvurdering,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004044-36,1,0,0 2008-004048-35,1,,,0,1,0,0,0,3,3,0,0,1,0,0,0,1,1,LABORATORI BALDACCI SPA,VALUTAZIONE DELL’EFFETTO DELL’AMINAFTONE NEL FENOMENO DI RAYNAUD SECONDARIO A SCLEROSI SISTEMICA: STUDIO RANDOMIZZATO IN DOPPIO CIECO CONTRO PLACEBO (VASC-1),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004048-35,0,0,0 2008-004049-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Karolinska Univsjukhuset,Vätskebehandling vid akut diabetessjukdom (Diabetes ketoacidos),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004049-27,0,0,0 2008-004064-39,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación Progreso y Salud,Estudio Clinico Fase II sobre la Angiogénesis terapéutica con Células Mononucleadas de Médula Ósea Autóloga en pacientes Diabéticos con Isquemia Crónica Crítica de miembros inferiores no revasculariza...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004064-39,0,0,0 2008-004083-39,1,2020-01-31,2020-01-31,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,GMIHO Gesellschaft für Medizinische Innovation – Hämatologie und Onkologie mbH,The combination of Lenalidomide and Dexamethasone with or without intensification by high-dose Melphalan in the treatment of multiple myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004083-39,0,0,0 2008-004087-40,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Prospect Therapeutics, Inc",A Phase 2 Study of GCS-100 in Combination with Chemo-immunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004087-40,0,0,0 2008-004088-21,1,2008-09-09,2008-09-09,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Pfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE EFFICACY AND SAFETY OF CP-945,598 IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004088-21,0,0,0 2008-004089-15,1,2011-09-30,2011-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Ghent,"The AZISAST Randomized Controlled Clinical Trial: Azithromycine as add-on therapy in Severe, Non-Eosinophilic Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004089-15,0,0,0 2008-004092-22,1,2008-11-27,2008-11-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxSmithKline Research & Development Limited,"A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the efficacy and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004092-22,0,0,0 2008-004093-40,6,2014-04-17,2014-12-12,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Nektar Therapeutics,"A Multicenter, Open-Label, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of NKTR-102 (PEG-Irinotecan) Versus Irinotecan in Patients with Second-Line, Irinotecan-Naïve, KRAS-Mutant, Col...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004093-40,0,0,0 2008-004095-43,5,2009-08-24,2009-08-24,5,1,0,0,0,0,2,0,1,1,0,0,1,0,2,"Merck & Co., Inc.","A Phase IIa Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled, Clinical Trial to Study the Efficacy and Safety of MK-0974 Co-administered with Ibuprofen or Acetaminophen in Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004095-43,0,0,0 2008-004095-43,5,2009-08-24,2009-08-24,5,1,0,0,0,0,2,0,1,1,0,0,1,0,2,MSD Finland Oy,"A Phase IIa Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled, Clinical Trial to Study the Efficacy and Safety of MK-0974 Co-administered with Ibuprofen or Acetaminophen in Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004095-43,0,0,0 2008-004095-43,5,2009-08-24,2009-08-24,5,1,0,0,0,0,2,0,1,1,0,0,1,0,2,Laboratoires Merck Sharp & Dohme-Chibret,"A Phase IIa Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled, Clinical Trial to Study the Efficacy and Safety of MK-0974 Co-administered with Ibuprofen or Acetaminophen in Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004095-43,0,0,0 2008-004095-43,5,2009-08-24,2009-08-24,5,1,0,0,0,0,2,0,1,1,0,0,1,0,2,"Merck & Co, Inc.","A Phase IIa Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled, Clinical Trial to Study the Efficacy and Safety of MK-0974 Co-administered with Ibuprofen or Acetaminophen in Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004095-43,0,0,0 2008-004096-21,2,2010-10-14,2010-10-14,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Novartis Pharma Services AG,"A phase 1 open label/phase 2 randomized, double-blind, multicenter study investigating the combination of RAD001 and sorafenib (Nexavar®) in patients with advanced hepatocellular carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004096-21,0,0,0 2008-004097-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,« OCTO : Quantification de l’impact des variations d’Observance d’une ChimioThérapie Orale par l’utilisation de piluliers électroniques et modélisation des marqueurs de toxicités»,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004097-41,0,0,0 2008-004098-17,1,2011-10-18,2011-10-18,1,0,0,0,0,0,4,0,0,1,1,1,1,0,1,East Tallinn Central Hospital,"Double-Blind, Randomized, Placebo -Controlled Study to Evaluate the Efficacy of Pre-operative Administration of Etoricoxib 120 mg, Etoricoxib 120 mg and Paracetamol 1 g Combination or Placebo in the T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004098-17,0,0,0 2008-004099-26,1,2015-12-01,2015-12-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Departmnet of nephrology,Randomised trial on combined effects of dual blockade of the renin angiotensin system and phosphate binding in diabetic and non-diabetic patients with impaired renal function.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004099-26,0,0,0 2008-004102-14,1,,,0,0,0,0,0,3,4,0,1,1,0,0,0,1,0,Kansanterveyslaitos,Rahapeliriippuvuuden hoitaminen kohdennetulla naltreksonilääkityksellä ja oppimismallilla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004102-14,0,0,0 2008-004104-31,20,2015-07-29,2015-10-05,19,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004104-31,0,0,0 2008-004104-31,20,2015-07-29,2015-10-05,19,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004104-31,0,0,0 2008-004104-31,20,2015-07-29,2015-10-05,19,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004104-31,0,0,0 2008-004104-31,20,2015-07-29,2015-10-05,19,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004104-31,0,0,0 2008-004106-13,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,"University of Trondheim, NTNU, Norway","An Open-Label, Randomized, Multicenter Phase II Trial Comparing the Depletion of Malignant Stem Cells with Dasatinib vs. Imatinib in Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004106-13,0,0,0 2008-004110-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II,UTILIZZO DEL QUIXIL NELL’INTERVENTO CHIRURGICO DI ERNIOPLASTICA INGUINALE: PROTOCOLLO PER ANALISI FARMACOECONOMICA MEDIANTE STUDIO MULTICENTRICO PROSPETTICO RANDOMIZZATO.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004110-26,0,0,0 2008-004112-13,1,2012-02-03,2012-02-03,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Nottingham University,PPAR-gamma: A noval therapeutic target for asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004112-13,0,0,0 2008-004113-96,1,2014-10-14,2014-10-14,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Ghent,"DRainage versus sEAlant in prospective, Monocentric, double blinded randomized trial to evaluate the effect of fibrin glue in surgical repair of incisional hernias (DREAM-trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004113-96,0,0,0 2008-004114-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medical Center; Department of general practice,Effectiveness of Diclofenac versus Paracetamol in primary care patients with knee osteoarthritis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004114-28,0,0,0 2008-004114-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fonds NutsOhra,Effectiveness of Diclofenac versus Paracetamol in primary care patients with knee osteoarthritis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004114-28,0,0,0 2008-004119-36,3,2010-01-09,2010-01-09,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Schering-Plough Research Institute,Proof-of-Concept and Dose Range-Finding Study of SCH 527123 in Subjects with Severe Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004119-36,0,0,0 2008-004122-17,1,2019-05-01,2019-05-01,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,BRC operations Pty. Ltd.,International Study to Predict Optimised Treatment - in Depression iSPOT-D,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004122-17,0,0,0 2008-004124-23,1,2010-01-14,2010-01-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Limited,"A 12 week, multicentre, open label study to evaluate the efficacy, tolerability and safety of a Fesoterodine flexible dose regimen in patients with overactive bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004124-23,0,0,0 2008-004126-16,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Roche Oy,Local Open-Label Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004126-16,0,0,0 2008-004128-22,1,2010-02-15,2010-02-15,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,F.Hoffmann-La Roche Ltd,"An exploratory study to evaluate the biological activity of R1507, a human monoclonal antibody, antagonist of the insulin-like growth factor receptor (IGF-1R) in women with operable breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004128-22,0,0,0 2008-004131-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,French Society of Cardiology,The ITALIC Study Is There A LIfe for DES after discontinuation of Clopidogrel : The ITALIC Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004131-38,0,0,0 2008-004132-20,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Air Liquide Santé International,This protocol describes a total of three studies that are intrinsically linked. It does therefore have three titels. 1. The effect of xenon and sevoflurane on depth of hypnosis monitors when titrated ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004132-20,0,0,0 2008-004134-25,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Asociación Andaluza de Hematología y Hemoterapia,Revlimid/dexametasona (RevDex) como tratamiento de inducción previo al trasplante de células progenitoras de sangre periférica para el tratamiento de pacientes con mieloma múltiple de nuevo diagnóstic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004134-25,0,0,0 2008-004136-20,1,2013-03-01,2013-03-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,CENTRE ANTOINE LACASSAGNE,ETUDE PILOTE DE DEPISTAGE DES SUJETS DEFICITAIRES EN DIHYDROPYRIMIDINE DESHYDROGENASE. APPLICATION AU CANCER DU SEIN TRAITE PAR FLUOROPYRIMIDINE ORALE.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004136-20,0,0,0 2008-004137-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CENTRE ANTOINE LACASSAGNE,EFFETS DU SUNITINIB DANS L'EXPRESSION DU VEGF ET DE L'INTERLEUKINE 8 : EXPLICATION DES EFFETS ANTI ANGIOGENIQUES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004137-21,0,0,0 2008-004138-26,1,2008-10-08,2008-10-08,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,AZIENDA OSPEDALIERA DI PARMA,USE OF ABATACEPT IN ANCA-ASSOCIATED VASCULITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004138-26,0,0,0 2008-004143-11,1,2013-01-23,2013-01-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,The University of Nottingham,Are macrolide antibiotics effective in chronic idiopathic cough?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004143-11,0,0,0 2008-004146-88,9,2012-06-18,2012-06-18,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Serono SA - Geneva,"A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004146-88,0,0,0 2008-004146-88,9,2012-06-18,2012-06-18,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Newron Pharmaceuticals,"A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004146-88,0,0,0 2008-004146-88,9,2012-06-18,2012-06-18,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SERONO SA,"A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004146-88,0,0,0 2008-004148-35,7,2013-07-29,2013-07-29,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"Cilengitide and cetuximab in combination with platinum-based chemotherapy as first-line treatment for subjects with advanced NSCLC Open-label, randomized, controlled, multicenter Phase II study invest...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004148-35,0,0,0 2008-004148-35,7,2013-07-29,2013-07-29,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MERCK KGAA,"Cilengitide and cetuximab in combination with platinum-based chemotherapy as first-line treatment for subjects with advanced NSCLC Open-label, randomized, controlled, multicenter Phase II study invest...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004148-35,0,0,0 2008-004149-27,4,2010-07-19,2010-08-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients with Severe Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004149-27,0,0,0 2008-004150-32,8,2018-02-14,2018-02-14,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PROSPECTIVE, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY & EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS, INCLUDING CANDIDEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004150-32,1,1,0 2008-004150-32,8,2018-02-14,2018-02-14,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,PFIZER,"A PROSPECTIVE, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY & EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS, INCLUDING CANDIDEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004150-32,1,1,0 2008-004150-32,8,2018-02-14,2018-02-14,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA","A PROSPECTIVE, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY & EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS, INCLUDING CANDIDEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004150-32,1,1,0 2008-004150-32,8,2018-02-14,2018-02-14,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer, Spain","A PROSPECTIVE, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY & EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS, INCLUDING CANDIDEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004150-32,1,1,0 2008-004152-71,1,2009-05-24,2009-05-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Icagen, Inc.","A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Assess the Safety and Efficacy of TWO Weeks of Oral Senicapoc Administration on Allergen challenge in Ato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004152-71,0,0,0 2008-004153-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Nantes,Intérêt d'utiliser des solutés de remplissage équilibrés à la phase précoce d'un traumatisme crânien grave pour limiter l'acidose hyperchlorémique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004153-15,0,0,0 2008-004158-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Nephrology and Renal Transplantation, KU Leuven",CYP3A4/5 and PGP activity in renal transplantation. A study assessing in vivo hepatic and intestinal CYP3A4/5 and PGP activity in kidney transplant recipients and its relationship with genetic and no...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004158-33,0,0,0 2008-004165-26,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,"A MULTICENTER, OPEN-LABEL, PHASE II STUDY OF DASATINIB IN COMBINATION WITH MELPHALAN AND PREDNISONE (D-MP) IN ADVANCED, RELAPSED / REFRACTORY MULTIPLE MYELOMA PATIENTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004165-26,0,0,0 2008-004167-19,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,GGz Nijmegen,"The effectiveness of antidepressants and psychological intervention in treating conversion disorder, motor type: a randomized placebo controlled clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004167-19,0,0,0 2008-004169-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Phase II study of Exemestane dose intensification (150 mg daily) in postmenopausal patients with advanced breast cancer progressing under standard dose Exe (25 mg daily) given as adjuvant or palliativ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004169-25,0,0,0 2008-004171-21,9,2015-02-18,2015-02-18,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PIERRE FABRE MEDICAMENT,A phase III trial of vinflunine + capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004171-21,0,0,0 2008-004171-21,9,2015-02-18,2015-02-18,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pierre Fabre Medicament,A phase III trial of vinflunine + capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004171-21,0,0,0 2008-004174-40,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Imagerie de la démyélinisation dans la sclérose en plaques : une étude en tomographie à émission de positons (TEP) avec le 11C-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (11C-PIB),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004174-40,0,0,0 2008-004175-22,1,2013-07-11,2013-07-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,B. Braun Melsungen AG,"PROSPECTIVE, CONTROLLED, DOUBLE-BLIND, RANDOMIZED MULTICENTRIC STUDY ON THE EFFICACY AND SAFETY OF A TARGET CONTROLLED PLASMA VOLUME REPLACEMENT THERAPY WITH A HYPER-ONCOTIC BALANCED HES 130/0.42 SO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004175-22,0,0,0 2008-004177-17,9,2018-12-26,2019-01-22,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Ritux...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004177-17,0,0,0 2008-004177-17,9,2018-12-26,2019-01-22,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Ritux...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004177-17,0,0,0 2008-004177-17,9,2018-12-26,2019-01-22,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Ritux...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004177-17,0,0,0 2008-004177-17,9,2018-12-26,2019-01-22,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Ritux...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004177-17,0,0,0 2008-004178-41,4,2012-01-11,2012-01-11,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis Recherche et Développement,"Estudio aleatorizado, multinacional de Aflibercept y FOLFOX6 modificado como tratamiento de primera línea para pacientes con cáncer colorrectal metastático",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004178-41,0,0,0 2008-004178-41,4,2012-01-11,2012-01-11,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche et développement,"Estudio aleatorizado, multinacional de Aflibercept y FOLFOX6 modificado como tratamiento de primera línea para pacientes con cáncer colorrectal metastático",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004178-41,0,0,0 2008-004178-41,4,2012-01-11,2012-01-11,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche et de`veloppement,"Estudio aleatorizado, multinacional de Aflibercept y FOLFOX6 modificado como tratamiento de primera línea para pacientes con cáncer colorrectal metastático",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004178-41,0,0,0 2008-004179-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU Montpellier,"Intérêt du bloc maxillaire suprazygomatique dans l’analgésie péri-opératoire, au cours de la chirurgie vélo-palatine sous anesthésie générale chez l'enfant : Etude multicentrique, prospective, randomi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004179-24,0,0,0 2008-004181-10,5,2010-02-17,2011-07-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D,"(FONDACAST, del inglés FONDAparinux in patients with a plaster CAST) Estudio Fase III, multicéntrico, aleatorizado, abierto, controlado, de dos grupos paralelos para evaluar la eficacia y seguridad de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004181-10,0,0,0 2008-004181-10,5,2010-02-17,2011-07-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline R & D,"(FONDACAST, del inglés FONDAparinux in patients with a plaster CAST) Estudio Fase III, multicéntrico, aleatorizado, abierto, controlado, de dos grupos paralelos para evaluar la eficacia y seguridad de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004181-10,0,0,0 2008-004181-10,5,2010-02-17,2011-07-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"(FONDACAST, del inglés FONDAparinux in patients with a plaster CAST) Estudio Fase III, multicéntrico, aleatorizado, abierto, controlado, de dos grupos paralelos para evaluar la eficacia y seguridad de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004181-10,0,0,0 2008-004181-10,5,2010-02-17,2011-07-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,*LOC to complete*,"(FONDACAST, del inglés FONDAparinux in patients with a plaster CAST) Estudio Fase III, multicéntrico, aleatorizado, abierto, controlado, de dos grupos paralelos para evaluar la eficacia y seguridad de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004181-10,0,0,0 2008-004182-26,1,2012-08-03,2012-08-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,"Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004182-26,0,0,0 2008-004183-38,1,2010-05-13,2010-05-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.","ENSAYO ALEATORIZADO, CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA, LA SEGURIDAD Y LA TOLERABILIDAD DE CP 533,536 EN PACIENTES CON FRACTURA CERRADA DE LA DIAFASIS TIBIAL A RANDOMIZED, PLACEBO-CONTRO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004183-38,0,0,0 2008-004207-63,4,2010-01-11,2010-01-12,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Eli Lilly and Company, Indianapolis","A 12-Week, Double-Blind, Placebo-Controlled Trial of LY2428757 in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004207-63,0,0,0 2008-004214-27,4,2011-09-21,2011-09-21,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Bayer HealthCare AG,"Estudio multicéntrico, abierto, no controlado para investigar la eficacia y seguridad del parche anticonceptivo transdérmico que contiene 0,55 mg de etinilestradiol y 2,1 mg de gestodeno (n.º de mater...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004214-27,0,0,0 2008-004214-27,4,2011-09-21,2011-09-21,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Bayer Healthcare AG,"Estudio multicéntrico, abierto, no controlado para investigar la eficacia y seguridad del parche anticonceptivo transdérmico que contiene 0,55 mg de etinilestradiol y 2,1 mg de gestodeno (n.º de mater...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004214-27,0,0,0 2008-004218-28,3,2010-07-09,2010-07-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Phase 3, Double-Blind, Randomized, Factorial, Efficacy and Safety Study of TAK 491 Plus Chlorthalidone Fixed-Dose Combination in Subjects with Moderate to Severe Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004218-28,0,0,0 2008-004220-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""","EFFECT OF SUPPLEMENTATION WITH CHOLECALCIFEROL ON GLUCOSE AND LIPID METABOLISM, BLOOD PRESSURE, BONE MASS, QUALITY OF LIFE, CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH ISCHAEMIC HEART DISE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004220-23,0,0,0 2008-004222-17,3,2010-01-15,2010-01-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized, Double-Blind, PLacebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naive to PDE5 Inhibito...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004222-17,0,0,0 2008-004222-17,3,2010-01-15,2010-01-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, PLacebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naive to PDE5 Inhibito...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004222-17,0,0,0 2008-004222-17,3,2010-01-15,2010-01-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,"A Randomized, Double-Blind, PLacebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naive to PDE5 Inhibito...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004222-17,0,0,0 2008-004223-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GEMCAD,"Estudio fase II, de la combinación de Oxaliplatino y Sorafenib en pacientes con Adenocarcinoma gástrico o de la unión gastroesofágica localmente avanzado o metastásico, en progresión tras un esquema ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004223-27,0,0,0 2008-004224-23,1,2013-04-15,2013-04-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Glasgow / NHS Greater Glasgow and Clyde,The effect of allopurinol on carotid ultrasound intima-media thickness and markers of endothelial function in patients with recent stroke - a pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004224-23,0,0,0 2008-004226-16,1,,,0,0,0,0,1,0,2,0,0,1,1,1,0,1,1,"Carbylan BioSurgery, Inc.","A prospective, multi-center, randomized, controlled, single-blinded study to evaluate the safety and efficacy of AdvaCoat Mx sinus gel for treatment of chronic rhinosinusitis without nasal polyps.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004226-16,0,0,0 2008-004228-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SOFAR SPA,Evaluation of the role of mesalazine in the treatment of diverticular disease of the colon and irritable colon syndrome: A randomised double blind placebo controlled clinical study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004228-22,0,0,0 2008-004229-40,1,2011-01-18,2011-01-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Ankylosing Spondylitis (AS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004229-40,0,0,0 2008-004231-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Medicine I, University Hospital St.Josef-Hospital, Ruhr University Bochum",Effects of vildagliptin (Galvus®) on beta-cell function and turnover in humans,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004231-38,0,0,0 2008-004236-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA,PET-CT DIAGNOSIS OF CARCINOMA PROSTATICO WITH ALTERNATIVE TO FLUORODESOSSIGLUCOSIO Radio: 18F-COLINA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004236-20,0,0,0 2008-004242-83,4,2009-05-13,2010-04-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, 32 week double-blind, parallel-group, multicenter study to compare the efficacy and safety of initiating treatment with combination (aliskiren/amlodipine) therapy in comparison with the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004242-83,0,0,0 2008-004245-29,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,"R&D Dept Raigmore Hospital, Inverness",Single Dose Dexamethasone following Aspiration of a Peri-tonsillar Abscess: A Randomised Placebo-Controlled Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004245-29,0,0,0 2008-004263-19,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Westdeutsche Studiengruppe GmbH,Randomized comparison of adjuvant Docetaxel / Cyclophosphamide with sequential adjuvant EC / Docetaxel chemotherapy in patients with HER2/neu negative early breast cancer – 6 x TC vs. 4 x EC -> 4 x Do...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004263-19,0,0,0 2008-004264-39,7,2014-04-30,2014-04-30,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag EMEA Medical Affairs,"A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE® on Myeloma related Bone Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004264-39,0,0,0 2008-004273-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Bergonié,A phase II trial to assess the efficacy of efavirenz as second-line monotherapy for the treatment of advanced pancreatic adenocarcinomas.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004273-18,0,0,0 2008-004276-49,6,2011-11-24,2011-11-24,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Teva Pharmaceutical Industries Ltd.,"A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohorts, Dose Range Finding Study to Evaluate the Safety, Tolerability and Clinical Effect of Escalating Doses of Laq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004276-49,0,0,0 2008-004277-17,1,2015-05-19,2015-05-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlobiFer International bvba,The effectiveness and tolerability of GlobiFer (haem iron) tablets compared to ferrous sulphate tablets in inflammatory bowel disease: a randomised-controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004277-17,0,0,0 2008-004278-41,1,2013-11-29,2013-11-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Institut Jules Bordet,"A phase II study of doxorubicin, cyclophosphamide and vindesine with valproic acid in patients with refractory or relapsing small cell lung cancer after platinum derivatives and etoposide.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004278-41,0,0,0 2008-004281-71,4,2016-07-16,2016-07-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004281-71,0,0,0 2008-004281-71,4,2016-07-16,2016-07-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004281-71,0,0,0 2008-004285-53,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Centre Régional de Lutte contre le Cancer Val d'Aurelle- Paul Lamarque,Etude de phase I-II évaluant l’association Sorafénib (NEXAVAR®) et Irinotecan en deuxième ligne ou plus de traitement des cancers colorectaux métastatiques avec une mutation de Kras – NEXIRI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004285-53,0,0,0 2008-004286-25,6,2010-02-24,2010-02-28,3,1,0,0,1,1,3,0,0,1,1,0,1,0,1,CELLERIX S.A.,"Estudio fase III, multicéntrico, simple ciego, randomizado, controlado con placebo, para evaluar la eficacia y seguridad de células madre expandidas derivadas de tejido adiposo autólogo (eASCs) (CX-40...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004286-25,0,0,0 2008-004303-59,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Örebro Läns Landsting,Blockad av femoralnerven till patienter med misstänkt höftfraktur – fungerar den i klinisk praxis? Eng: Blocking the femoral nerve on patients with suspected hip fracture - does it work in clinical p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004303-59,0,0,0 2008-004326-16,1,2008-11-26,2008-11-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GALENpharma GmbH,A prospective placebo-controlled intraindividual dose-finding study of Mometasone furoate cutaneous spray (solution) in patients with contact allergies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004326-16,0,0,0 2008-004330-24,6,2014-09-19,2014-11-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage II...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004330-24,0,0,0 2008-004330-24,6,2014-09-19,2014-11-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage II...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004330-24,0,0,0 2008-004331-38,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,MIPHARM,"Randomized study on the effectiveness, safety and acceptability 'of clobetasol propionate foam-cooled (OLUX) in comparison with cream aceponato methylprednisolone in the treatment of allergic contact ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004331-38,0,0,0 2008-004334-25,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA,Efficacy of folic acid at high doses in preventing congenital anomalies. Randomized clinical trial in fertile women who plan a pregnancy: folic acid 4mg vs 0.4mg.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004334-25,0,0,0 2008-004336-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Laboratoires Thea,"Azithromycin concentration into aqueous humor of patients undergoing cataract surgery, after 3 days of treatment by AZYTER ® Open randomised monocentre study with 2 groups of 15 patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004336-20,0,0,0 2008-004337-25,5,2010-07-07,2010-10-14,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil 2.5 and 5 mg Once Daily Dosing for 12 Weeks for the Treatment of E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004337-25,0,0,0 2008-004338-26,3,2010-03-03,2010-03-03,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Ferring Pharmaceuticals A/S,"A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of reduction in International Prostate Symptom Score (IPSS)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004338-26,0,0,0 2008-004340-37,5,2009-08-04,2012-07-02,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Hexal AG,"An open label, multinational, multicenter study to evaluate the safety of HX575 recombinant human erythropoietin alfa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004340-37,0,0,0 2008-004340-37,5,2009-08-04,2012-07-02,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Hexal Biotech ForschungsGmbH,"An open label, multinational, multicenter study to evaluate the safety of HX575 recombinant human erythropoietin alfa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004340-37,0,0,0 2008-004347-10,13,2014-01-09,2014-01-09,13,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Amgen Inc.,"A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated with Imm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004347-10,0,0,0 2008-004347-10,13,2014-01-09,2014-01-09,13,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Amgen Inc,"A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated with Imm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004347-10,0,0,0 2008-004351-29,1,2009-06-29,2009-06-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,HEXAL AG,"OPEN LABEL, MULTICENTER STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF GOSERELIN 10.8 mg IMPLANT HEXAL IN PATIENTS WITH ADVANCED HORMONE DEPENDENT PROSTATE CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004351-29,0,0,0 2008-004355-30,7,2012-02-20,2012-04-30,4,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Amgen Inc,A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination with Mitoxantrone and Prednisone in Subjects with Previously Treated Castrate Resistant Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004355-30,0,0,0 2008-004384-19,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,"Front-line treatment of Philadelphia positive (Ph pos), BCR-ABL positive, chronic myeloid leukemia (CML) with two tyrosine kinase inhibitors (TKI) (Nilotinib and Imatinib). A phase II exploratory mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004384-19,0,0,0 2008-004387-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Consejería de Sanidad de la Comunidad de Madrid,Ensayo clínico aleatorizado para evaluar la eficacia del ácido acetilsalicílico en la prevención primaria de la enfermedad cardiovascular en individuos mayores de 50 años con Diabetes Mellitus tipo 2....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004387-39,0,0,0 2008-004388-20,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"MONOCENTRIC, DOUBLE-BLIND, CASE-CONTROLLED STUDY FOR ASSESSMENT OF PRE-SEASONAL SUBLINGUAL SPECIFIC IMMUNOTHERAPY’S EFFECTIVENESS AS A TREATMENT OF GRASS-INDUCED ALLERGIC RHINOCONJUNCTIVITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004388-20,0,0,0 2008-004392-22,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Fundación MD Ánderson Internacional España,Estudio fase I/II de la seguridad y actividad de la combinación Lenalidomida y Rituximab (LenRtx) en pacientes con Leucemia Linfática Crónica (LLC) refractaria o en recidiva.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004392-22,0,0,0 2008-004393-40,6,2010-06-15,2010-06-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ThromboGenics NV,"A randomized, placebo controlled, double-masked, multicenter trial of microplasmin intravitreal injection for non-surgical treatment of focal vitreomacular adhesion.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004393-40,0,0,0 2008-004398-16,1,2012-09-19,2012-09-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Abbott Scandinavia AB,A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable RA Patients in Clinical remission,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004398-16,0,0,0 2008-004402-13,1,,,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,Inserm,"Etude en neuropsychologie, imagerie fonctionnelle et pharmacologie des effets cognitifs chez l'enfant épileptique traité par le topiramate ou le clobazam",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004402-13,0,0,0 2008-004405-34,10,2010-12-22,2011-02-28,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Gilead Sciences Incorporated,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004405-34,0,0,0 2008-004412-12,1,2010-10-18,2010-10-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as monotherapy in patients with type 2 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004412-12,0,0,0 2008-004416-13,15,2010-06-04,2010-10-20,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Compare YM150 bid and qd Doses and Enoxaparin for Prevention of Venous Thromboembolism in Subjects Undergoing Elective Hip Replacement...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004416-13,0,0,0 2008-004422-16,1,2009-10-23,2009-10-23,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Engelhard Arzneimittel GmbH & Co. KG,Investigation of local tolerability and efficacy of Muxan - a new topical treatment containing chloramine-T in 3 concentrations in comparison to Zovirax® in patients with Herpes simplex type 1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004422-16,0,0,0 2008-004425-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre for Human Drug Research,Neurocognitive testing in children with ADHD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004425-42,0,0,0 2008-004429-41,8,2012-12-12,2012-12-12,7,1,0,0,0,2,2,0,0,1,0,0,1,0,1,"Bayer Healthcare AG, D-51368 Leverkusen, Germany","A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a Com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004429-41,0,0,0 2008-004429-41,8,2012-12-12,2012-12-12,7,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Bayer Healthcare AG,"A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a Com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004429-41,0,0,0 2008-004431-38,1,2012-12-03,2012-12-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College,ACE inhibition and mechanisms of skeletal muscle weakness in COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004431-38,0,0,0 2008-004432-20,1,2009-07-09,2009-07-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ACE Aps,"Efficacy and tolerability of captopril oinment 0,1% og 0,3% in atopic dermatitis. A randomised, double-blind, placebocontrolled, doseescalating, intra-individual clinical study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004432-20,0,0,0 2008-004434-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Steno Diabetes Center,The Anti-Interleukin-1 in Diabetes Action trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004434-24,0,0,0 2008-004438-25,1,2019-12-09,2019-12-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004438-25,0,0,0 2008-004439-39,8,2013-04-23,2013-04-23,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA","Estudio abierto y aleatorizado, comparativo de dos estrategias diferentes en el tratamiento de sujetos con psoriasis en placas que han respondido a la administración de etanercept. Randomized Open-la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004439-39,0,0,0 2008-004439-39,8,2013-04-23,2013-04-23,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,"Estudio abierto y aleatorizado, comparativo de dos estrategias diferentes en el tratamiento de sujetos con psoriasis en placas que han respondido a la administración de etanercept. Randomized Open-la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004439-39,0,0,0 2008-004443-11,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",A 52-WEEK OPEN-LABEL SAFETY STUDY OF PD 0332334 IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004443-11,0,0,0 2008-004447-11,3,2010-07-15,2010-07-15,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Vectura Limited,"A Phase IIb Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy and Safety of Apomorphine Inhalation Powder in Patients With “On-Off” or “Wearing-Off” Effe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004447-11,0,0,0 2008-004447-11,3,2010-07-15,2010-07-15,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,VECTURA LIMITED,"A Phase IIb Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy and Safety of Apomorphine Inhalation Powder in Patients With “On-Off” or “Wearing-Off” Effe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004447-11,0,0,0 2008-004451-30,2,2010-06-03,2010-06-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study with and without Enzastaurin in Combination with Docetaxel and Prednisone, Followed by Enzastaurin Maintenance as First-Line Treatment in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004451-30,0,0,0 2008-004451-30,2,2010-06-03,2010-06-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ELI LILLY,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study with and without Enzastaurin in Combination with Docetaxel and Prednisone, Followed by Enzastaurin Maintenance as First-Line Treatment in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004451-30,0,0,0 2008-004454-33,14,2010-03-18,2013-06-24,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck KGaA,OPEN RANDOMIZED MULTINATIONALPHASE IIIB TRIAL EVALUATING THE ACTIVITY AND SAFETY OF CETUXIMAB AS 250MG/M2 WEEKLY AND 500 MG/M2 EVERY TWO WEEKS MAINTENANCE THERAPY AFTER PLATINUM-BASED CHEMOTEHRAPY IN ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004454-33,0,0,0 2008-004454-33,14,2010-03-18,2013-06-24,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MERCK KGAA,OPEN RANDOMIZED MULTINATIONALPHASE IIIB TRIAL EVALUATING THE ACTIVITY AND SAFETY OF CETUXIMAB AS 250MG/M2 WEEKLY AND 500 MG/M2 EVERY TWO WEEKS MAINTENANCE THERAPY AFTER PLATINUM-BASED CHEMOTEHRAPY IN ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004454-33,0,0,0 2008-004455-29,2,2011-07-14,2011-07-14,2,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, randomized, multicentre, observer-blind study to compare and characterize the immunoginicity and safety parameters induced by various GSK Biologicals’ Adjuvant Systems in combination with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004455-29,0,0,0 2008-004457-15,6,2013-07-01,2013-08-01,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,MERCK KGAA,"Cilengitide in subjects with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter - a multicenter, open-label Phase II study, investigating two cilengitide regimens in combinati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004457-15,0,0,0 2008-004457-15,6,2013-07-01,2013-08-01,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Merck KGaA,"Cilengitide in subjects with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter - a multicenter, open-label Phase II study, investigating two cilengitide regimens in combinati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004457-15,0,0,0 2008-004460-39,2,2009-06-23,2009-06-23,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"Boehringer Ingelheim Pharmaceuticals, Inc.","A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole IR (0.0625-0.5 mg/day) versus placebo for 6 weeks in children and adolescents (age 6-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004460-39,1,1,0 2008-004460-39,2,2009-06-23,2009-06-23,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomized, double-blind, placebo-controlled, flexible dose study to evaluate efficacy and safety of Pramipexole IR (0.0625-0.5 mg/day) versus placebo for 6 weeks in children and adolescents (age 6-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004460-39,1,1,0 2008-004467-19,1,,,0,1,0,0,0,1,4,0,0,1,1,1,0,1,1,Novartis Hungary Ltd,"An open-label, single center study of oral AMN 107 (nilotinib) in adult patients with imatinib - resistant or - intolerant chronic myeloid leukemia in chronic phase, accelerated phase or blast crisis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004467-19,0,0,0 2008-004471-22,1,,,0,0,0,0,1,0,2,0,0,1,0,0,0,1,0,ISTITUTO GIANNINA GASLINI,Minimum local anesthetic concentration of levobupivacaine and clonidine given for caudal anesthesia in children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004471-22,0,0,0 2008-004484-18,1,2014-09-15,2014-09-15,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Hannu Kokki,Suun kautta annosteltavan etorikoksibin ja laskimoon annosteltavan ketoprofeenin aivoselkäydinnestepitoisuudet ja niiden vaikutus prostaglandiini-E2-pitoisuuksiin aikuisten lonkan tekonivelleikkauksen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004484-18,0,0,0 2008-004485-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center of Groningen,Coronary versus Intravenous abCiximab administration during Emergency Reperfusion Of ST-segment elevation myocardial infarction – the CICERO trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004485-12,0,0,0 2008-004486-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,Efficacy of monoclonal anti CD 20 antibodies in steroid and cyclosporin dependent nephrotic syndrome in children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004486-26,0,0,0 2008-004487-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,Spontaneous monocentric study phase II: salvage therapy with clofarabine in combination with other cytotoxic agentsfor the treatment of resistent leukemia in children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004487-39,0,0,0 2008-004488-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE,"Ensayo clínico en fase IV, multicéntrico, controlado, aleatorizado, para evaluar la eficacia y seguridad de 3 pautas de administración de furosemida en pacientes con descompensación aguda moderada-sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004488-20,0,0,0 2008-004489-23,1,2009-07-08,2009-07-08,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Netherlands Vaccine Institute,Development of cellular immune response after infant pneumococcal conjugate vaccinations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004489-23,0,0,0 2008-004492-21,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación Hospital de Madrid,Estudio biológico del efecto de GW572016 (Lapatinib) en la apoptosis celular en el Carcinoma Ductal in Situ en pacientes con cáncer de mama HER2 positivo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004492-21,0,0,0 2008-004496-22,3,2015-01-27,2015-05-28,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bayer Health Care AG (study performed by Bayer Schering Pharma AG),"Prospective non-randomized (pharmacoepidemiologic) cohort study (open-label, multicenter) to assess the magnitude of potential risk with the administration of Gadovist® in patients with moderate to se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004496-22,0,0,0 2008-004496-22,3,2015-01-27,2015-05-28,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bayer Health Care AG,"Prospective non-randomized (pharmacoepidemiologic) cohort study (open-label, multicenter) to assess the magnitude of potential risk with the administration of Gadovist® in patients with moderate to se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004496-22,0,0,0 2008-004497-40,1,2009-05-27,2009-05-27,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Hull and East Yorkshire Hospitals NHS Trust,The effect of metformin on weight and cardiovascular risk markers in abdomenally obese subjects with impaired fasting glucose previously treated for 12 months with either rimonabant or placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004497-40,0,0,0 2008-004499-38,1,2014-07-09,2014-07-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Marsden NHS Foundation Trust,A randomised double-blind placebo-controlled trial of the safety and efficacy of ethosuximide 250mg capsules for the management of chemotherapy-induced painful peripheral neuropathy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004499-38,0,0,0 2008-004500-32,1,2014-01-16,2014-01-16,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Jesper Hastrup Svendsen,"""Effekten af Kortvarig Medicinsk Antiarytmisk Behandling på Succesraten og Qol efter Kateterablation for Atrieflimren"" ”The Effect of Short Term Amiodarone Treatment after Catheter Ablation for Atria...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004500-32,0,0,0 2008-004504-31,4,2011-03-21,2011-03-21,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Sharp & DOhme (Sweden) AB,"A Phase III Randomized, Placebo-Controlled Study to Evaluate the Effect of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety, and to Estimate the Effect of Odanacatib (MK-0822) on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004504-31,0,0,0 2008-004504-31,4,2011-03-21,2011-03-21,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","A Phase III Randomized, Placebo-Controlled Study to Evaluate the Effect of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety, and to Estimate the Effect of Odanacatib (MK-0822) on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004504-31,0,0,0 2008-004504-31,4,2011-03-21,2011-03-21,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Laboratoires Merck Sharp & Dhome-Chibret,"A Phase III Randomized, Placebo-Controlled Study to Evaluate the Effect of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety, and to Estimate the Effect of Odanacatib (MK-0822) on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004504-31,0,0,0 2008-004518-28,2,2010-06-17,2010-06-17,2,1,0,0,0,1,2,0,0,1,1,0,1,0,0,Radboud University Nijmegen Medical Centre,Investigation of posaconazole prophylaxis in children with chronic granulomatous disease (CGD): pharmacokinetics and tolerability (iPOD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004518-28,0,0,0 2008-004522-16,16,2013-05-24,2013-06-24,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Daiichi Sankyo Pharma Development,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR EVALUATION OF EFFICACY AND SAFETY OF DU-176B VERSUS WARFARIN IN SUBJECTS WITH ATRIAL FIBRILLAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004522-16,0,0,0 2008-004522-16,16,2013-05-24,2013-06-24,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,DAIICHI SANKIO DEVELOPMENT LIMITED,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR EVALUATION OF EFFICACY AND SAFETY OF DU-176B VERSUS WARFARIN IN SUBJECTS WITH ATRIAL FIBRILLAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004522-16,0,0,0 2008-004527-31,4,2013-09-05,2013-09-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gilead Sciences Incorporated,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS-9190, in Combination with Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and Ri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004527-31,0,0,0 2008-004529-41,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004529-41,0,0,0 2008-004530-25,1,2012-05-22,2012-05-22,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH,Lapatinib plus Caelyx in patients with advanced metastatic breast cancer following failure of Trastuzumab therapy – a Phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004530-25,0,0,0 2008-004531-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dr. Héctor Escobar Morreale,"PROTOCOLO DE INVESTIGACIÓN SOBRE EL PERFIL DE RIESGO CARDIOVASCULAR ASOCIADO A MUJERES CON SÍNDROME DE OVARIO POLIQUÍSTICO O HIPERANDROGENISMO OVULATORIO, Y EVOLUCIÓN DEL MISMO DURANTE EL TRATAMIENTO ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004531-38,0,0,0 2008-004533-21,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,ICIN,The role of Bosentan in fontan patients: improvement of aerobic capacity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004533-21,0,0,0 2008-004534-24,1,2012-05-08,2012-05-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,Can high-dose vitamin D supplementation reduce blood pressure and markers of cardiovascular risk in older people with isolated systolic hypertension?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004534-24,0,0,0 2008-004537-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset,Effekt av insulininfusion på sjukdomsförloppet vid infekterade fotsår samt vid thorax- och kärlkirurgi hos patienter med diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004537-19,0,0,0 2008-004539-39,2,2010-01-22,2010-01-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ThromboGenics N.V,"Single Intravenous Administration of TB-402 for the Prophylaxis of Venous hromboembolic Events (VTE) After Total Knee Replacement Surgery: A Dose-Escalating, Multicenter, Randomised, Active-Controlled...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004539-39,0,0,0 2008-004540-36,1,,,0,0,0,0,1,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Effetto della supplementazione dietetica con estratto di Crocus sativus (zafferano) sulla funzione retinica maculare nella degenerazione maculare legata all’eta’ (AMD) in fase iniziale (Protocollo Saf...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004540-36,0,0,0 2008-004541-29,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,Groupe Francophone des Myélodysplasies,"A phase II Study of Azacitidine (Vidaza®) combined to Epoetin beta (NeoRecormon®) in IPSS low-risk and intermediate-1 MDS Patients, resistant to ESA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004541-29,0,0,0 2008-004543-11,1,,,0,0,0,0,0,3,2,0,0,0,0,0,0,0,0,HOSPICES CIVILS DE LYON,COMBINA. Efficacité et tolérance des bithérapies oseltamivir + zanamivir ou oseltamivir + amantadine en comparaison avec la monothérapie oseltamivir dans le traitement de la grippe saisonnière A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004543-11,0,0,0 2008-004544-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CREPATS,"Etude ouverte, non comparative, évaluant chez des patients infectés par le VIH-1, ayant une charge virale indétectable avec un traitement comportant un inhibiteur de la protéase potentialisé par du ri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004544-37,0,0,0 2008-004548-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud university nijmegen medical centre,PHASE II STUDY OF LUTETIUM-177 LABELED CHIMERIC MONOCLONAL ANTIBODY cG250 (177Lu-DOTA-cG250) IN PATIENTS WITH ADVANCED RENAL CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004548-35,0,0,0 2008-004551-30,3,2016-02-15,2016-02-15,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ICORG,"A phase II multi-center, open-label, study of Nilotinib at a dose of 300mg twice daily in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004551-30,0,0,0 2008-004555-30,2,2009-09-21,2009-09-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MSD Finland Oy,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Lipid-Modifying Effect and Tolerability of MK-1903 in Patients with Dyslipidemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004555-30,0,0,0 2008-004555-30,2,2009-09-21,2009-09-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Lipid-Modifying Effect and Tolerability of MK-1903 in Patients with Dyslipidemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004555-30,0,0,0 2008-004556-71,5,2012-12-07,2012-12-07,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, A Division of Schering Corporation",A Single-Arm Study to Provide Boceprevir Treatment in Subjects with Chronic Hepatitis C Genotype 1 Deemed Nonresponders tPeginterferon/Ribavirin in Previous Schering-Plough Boceprevir Studies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004556-71,0,0,0 2008-004557-15,1,2008-11-28,2008-11-28,1,0,0,0,0,0,4,0,1,1,0,0,1,0,1,Merckle Recordati GmbH,"10 days clinical pilot study to investigate the wound healing efficacy of Mirfulan® ointment (containing zinc oxide and cod liver) in an intra-individual comparison with a placebo, zinc oxide and cod ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004557-15,0,0,0 2008-004558-34,10,2011-05-10,2012-12-21,10,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Amgen Limited,Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination with Low Dose Vitamin D for the Treatment of Subjects with Secondary Hyperparathyroidism (SHPT) Recently Ini...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004558-34,0,0,0 2008-004558-34,10,2011-05-10,2012-12-21,10,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Amgen Inc,Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination with Low Dose Vitamin D for the Treatment of Subjects with Secondary Hyperparathyroidism (SHPT) Recently Ini...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004558-34,0,0,0 2008-004560-39,1,2019-02-20,2019-02-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer),"Essai de phase III multicentrique randomisé, comparant l’effet d’une chimiothérapie adjuvante de 6 mois par gemcitabine-oxaliplatine à 85mg/m² (GEMOX 85) à une surveillance, chez des patients opérés ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004560-39,0,0,0 2008-004561-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Inner Retinal Dysfunction of the Cone System in Inherited Photoreceptor Degenerations: A Study of Disease Sequence and Assessment of Novel Therapeutic Strategies.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004561-26,0,0,0 2008-004562-10,6,2015-08-24,2015-08-24,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomised, placebo-controlled multicentre phase III clinical study followed by open-label phase on the efficacy and tolerability of budesonide 3 mg effervescent tablet in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004562-10,0,0,0 2008-004562-10,6,2015-08-24,2015-08-24,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,DR. FALK PHARMA GMBH,"Double-blind, randomised, placebo-controlled multicentre phase III clinical study followed by open-label phase on the efficacy and tolerability of budesonide 3 mg effervescent tablet in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004562-10,0,0,0 2008-004564-40,10,2010-09-06,2010-09-06,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004564-40,0,0,0 2008-004564-40,10,2010-09-06,2010-09-06,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer S.A,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004564-40,0,0,0 2008-004564-40,10,2010-09-06,2010-09-06,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004564-40,0,0,0 2008-004569-24,1,2010-03-23,2010-03-23,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Pantarhei Bioscience BV,"A double-blind, placebo-controlled, randomised, N=1 study to determine the effect of concomitant treatment with dehydroepiandrosterone (50 mg) on mood in women who experience mood disturbances during ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004569-24,0,0,0 2008-004571-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Durée de Traitement des Pyélonéphrites aiguës - Etude multicentrique, de non infériorité, randomisée évaluant deux durées de traitement antibiotique (5 versus 10 jours) dans les pyélonéphrites aiguës ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004571-22,0,0,0 2008-004575-21,2,2012-01-30,2012-01-30,1,1,0,0,0,0,2,0,0,1,1,0,1,0,0,Cliniques Universitaires St Luc,"A single arm, multicenter, phase II trial of RAD001 as monotherapy in the palliative treatment of patient with locally advanced or metastatic transitional cell carcinoma after failure of platinum-base...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004575-21,0,0,0 2008-004578-42,3,2014-11-11,2014-11-11,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","An Imaging Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopau...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004578-42,0,0,0 2008-004578-42,3,2014-11-11,2014-11-11,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck & Co. Inc.,"An Imaging Sub-Study of the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopau...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004578-42,0,0,0 2008-004579-22,2,2011-03-31,2011-03-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Octapharma AG,"A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg Assay Panel and the B-Cell /Antibody response panel to predict the clinical effect of Octagam 5% ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004579-22,0,0,0 2008-004580-19,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,CHU DE POITIERS,"PHARMACOKINETICS, SAFETY AND EFFICACY OF LENALIDOMIDE (REVLIMID®) IN COMBINATION WITH DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA AND IMPAIRED RENAL FONCTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004580-19,0,0,0 2008-004583-40,1,2012-12-08,2012-12-08,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Universitaetsklinikum Muenster,"A randomized, multi-center phase II trial to assess the efficay of 5-azacytidine added to standard primery therapy in elderly patients with newly diagnosed AML.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004583-40,0,0,0 2008-004584-19,1,2016-06-15,2016-06-15,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University hospital of Hvidovre,Skolioser hos cerebral parese patienter behandlet med Botulinum toxin A Injektioner.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004584-19,0,0,0 2008-004587-38,3,2010-01-19,2011-01-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Hidradenitis Suppurativa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004587-38,0,0,0 2008-004604-31,2,2012-01-10,2012-01-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Photocure ASA,A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low-grade cervical intraepithelial neoplasia (CIN1).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004604-31,0,0,0 2008-004605-34,6,2010-09-04,2010-09-06,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,DEBIOPHARM S.A.,"A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004605-34,0,0,0 2008-004605-34,6,2010-09-04,2010-09-06,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Debiopharm S.A.,"A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of Debio 025 combined with peg-IFNα2a and ribavirin in treatment naïve chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004605-34,0,0,0 2008-004610-27,4,2010-05-17,2010-05-17,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Palau Pharma S.A.,"A double-blind, randomised, placebo and mesalazine controlled phase II study to explore the safety and activity of dersalazine in patients with mild to moderate active colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004610-27,0,0,0 2008-004611-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,Phase I/II study: on the toxicity and effects of combining the p53 synthetic long peptides vaccine with either Imiquimod or Interferon-alfa to induce polarized p53-specific immunity in patients treate...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004611-35,0,0,0 2008-004612-12,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,CHU TOULOUSE,Existe t-il une sensibilité accrue à l’hormone de croissance chez les enfants présentant un syndrome de Prader-Willi ?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004612-12,0,0,0 2008-004613-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University College Hospital Galway,The role of the antioxidants ascorbic acid and n-acetylcysteine in the attenuation of ischaemia reperfusion injury in a human model,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004613-10,0,0,0 2008-004625-42,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Asklepios Kliniken Hamburg GmbH,Percutaneous Intramyocardial Cell Therapy After Acute Myocardial Infarction using Bone Marrow Mononuclear CellsT) WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL AND TRASTUZUMAB (HERCEPTIN®)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005127-29,0,0,0 2008-005127-29,2,2014-12-30,2014-12-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis groupe,MULTICENTER PHASE III RANDOMIZED TRIAL COMPARING DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL (AC->T) WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL AND TRASTUZUMAB (HERCEPTIN®)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005127-29,0,0,0 2008-005128-10,2,2010-01-25,2010-01-25,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly and Company - Indianapolis,Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients with Type 2 Diabetes Treated only with Lifestyle Interventions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005128-10,0,0,0 2008-005128-10,2,2010-01-25,2010-01-25,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Lilly S.A.,Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients with Type 2 Diabetes Treated only with Lifestyle Interventions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005128-10,0,0,0 2008-005131-15,1,2011-10-12,2011-10-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CHRU de Lille,ETUDE DE LA PHARMACOCINETIQUE DE L’ASSOCIATION PIPERACILLINE – TAZOBACTAM EN UTILISATION INTRA-VEINEUSE CONTINUE CHEZ L’ENFANT NEUTROPENIQUE FEBRILE .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005131-15,0,0,0 2008-005133-30,2,2011-01-17,2011-01-17,2,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Baxter Innovations GmbH,An Open Label Phase I/II Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule with a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy volunteers Ag...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005133-30,0,0,0 2008-005134-75,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HOSPICES CIVILS DE LYON,"Essai MANHYPIC. Essai prospectif randomisé en double aveugle comparant l’effet de perfusions iso-osmolaire et iso-volumique de 250 mL de MANnitol 20% versus Sérum salé HYpertonique 3,9%, sur la Press...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005134-75,0,0,0 2008-005135-15,1,2011-07-05,2011-07-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Nottingham,Do 100 kiloDaltons matter? A prospective randomised double-blind study on the blood volume expanding effects of two different colloids in patients undergoing laparoscopic cholecystectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005135-15,0,0,0 2008-005140-16,11,2011-05-25,2011-06-17,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"KAI Pharmaceuticals, Inc",Inhibición de la Delta-PROTEína cinasa C para la reducCCIÓN del tamaño del infarto en Infarto Agudo de Miocardio (PROTECCIÓN IAM) Inhibition of Delta-PROTEin kinase C for the reducTION of infarct size...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005140-16,0,0,0 2008-005140-16,11,2011-05-25,2011-06-17,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,KAI PHARMACEUTICALS INC,Inhibición de la Delta-PROTEína cinasa C para la reducCCIÓN del tamaño del infarto en Infarto Agudo de Miocardio (PROTECCIÓN IAM) Inhibition of Delta-PROTEin kinase C for the reducTION of infarct size...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005140-16,0,0,0 2008-005144-16,2,2009-11-11,2009-11-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"Open-label, single-arm, multi-center validation study of the ROSA-Scale (Relevant Outcome Scale for Alzheimer Patients) in patients with dementia of Alzheimer’s type (DAT) treated with memantine over ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005144-16,0,0,0 2008-005146-23,6,2009-10-09,2015-10-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12 week treatment, multi-center, randomized, parallel group, double blind, double dummy study to assess the superiority of indacaterol (150 μg o.d.) via a SDDPI in patients with moderate to severe C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005146-23,0,0,0 2008-005146-23,6,2009-10-09,2015-10-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica,"A 12 week treatment, multi-center, randomized, parallel group, double blind, double dummy study to assess the superiority of indacaterol (150 μg o.d.) via a SDDPI in patients with moderate to severe C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005146-23,0,0,0 2008-005147-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Mª Angeles Aguirre Zamorano,Arteriosclerosis y Lupus Eritematoso Sistémico: ¿Pueden las Estatinas detener este proceso?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005147-42,0,0,0 2008-005149-48,1,2013-10-05,2013-10-05,1,1,1,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III/IV, cluster-randomized, controlled study to evaluate the effectiveness of GlaxoSmithKline Biologicals’ 10-valent pneumococcal and non-typeable Haemophilus influenzae protein D conjugate va...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005149-48,0,0,0 2008-005166-31,5,2014-12-12,2014-12-12,3,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Wyeth Pharmaceuticals Inc., Acting through its division Wyeth Research, a Pfizer Company","A Phase 3, Multicenter, Randomized, and Double-blind Study to Evaluate the Safety of Tigecycline versus a Ceftriaxone Regimen in the Treatment of Complicated Intra-abdominal Infections and Community-a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005166-31,1,1,0 2008-005166-31,5,2014-12-12,2014-12-12,3,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Wyeth Pharmaceuticals Inc., acting through its division Wyeth Research, a Pfizer Company","A Phase 3, Multicenter, Randomized, and Double-blind Study to Evaluate the Safety of Tigecycline versus a Ceftriaxone Regimen in the Treatment of Complicated Intra-abdominal Infections and Community-a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005166-31,1,1,0 2008-005166-31,5,2014-12-12,2014-12-12,3,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Wyeth Pharmaceuticals, Inc.","A Phase 3, Multicenter, Randomized, and Double-blind Study to Evaluate the Safety of Tigecycline versus a Ceftriaxone Regimen in the Treatment of Complicated Intra-abdominal Infections and Community-a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005166-31,1,1,0 2008-005167-33,1,2016-03-31,2016-03-31,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Charité University Medicine Berlin,Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005167-33,0,0,0 2008-005168-15,1,2009-10-07,2009-10-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, two way cross-over, proof of concept study to compare the efficacy, safety, pharmacokinetics and pharmacodynamics of two-week oral administration of QAV680 versus placebo, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005168-15,0,0,0 2008-005169-78,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Traitement des récidives de glioblastomes par le SUTENT (SU11248) : essai de phase 2 avec étude translationnelle biologique et en imagerie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005169-78,0,0,0 2008-005171-95,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SENESE,"A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMANIZED ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005171-95,0,0,0 2008-005172-26,6,2012-03-12,2012-03-12,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,S.L.A. Pharma (UK) Ltd,"A Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Diltiazem Hydrochloride Cream in Subjects with Anal Fissure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005172-26,1,0,0 2008-005175-10,1,2011-03-09,2011-03-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guys and St Thomas' NHS Foudation Trust,Volume Expansion using a balanced gelatin solution in patients undergoing major abdominal surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005175-10,0,0,0 2008-005176-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,A PROSPECTIVE PHASE II MULTICENTRIC STUDY OF WEEKLY TOPOTECAN AND CISPLATIN (TOPOCIS) AS NEOADJUVANT TREATMENT IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CERVICAL CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005176-28,0,0,0 2008-005178-10,3,2011-05-10,2011-05-10,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Auris Medical AG,"Efficacy of AM 101 in Patients with Acute Inner Ear Tinnitus: A Multi-Centre, Double-Blind, randomised, Placebo-Controlled, Multiple Dose, Group Comparison Phase II Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005178-10,0,0,0 2008-005180-33,4,2011-04-11,2011-11-04,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Janssen Biologics B.V.,"A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-interleukin 6 (IL-6) Monoclonal Antibody, in Subjects with Solid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005180-33,0,0,0 2008-005180-33,4,2011-04-11,2011-11-04,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Centocor B.V.,"A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-interleukin 6 (IL-6) Monoclonal Antibody, in Subjects with Solid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005180-33,0,0,0 2008-005181-31,5,2012-02-07,2012-02-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF TANEZUMAB AS ADD-ON THERAPY TO OPIOID MEDICATION IN PATIENTS WITH PAIN DUE TO BONE METASTASES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005181-31,0,0,0 2008-005182-66,4,2013-02-14,2013-02-14,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc 235 East 42nd Street New York, NY 10017",PHASE II OPEN-LABEL SAFETY EXTENSION STUDY OF TANEZUMAB IN CANCER PATIENTS WITH PAIN DUE TO BONE METASTASES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005182-66,0,0,0 2008-005205-19,1,2009-07-28,2009-07-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A randomised, double-blind, placebo-controlled, 3-period cross-over study to evaluate the effect of two doses of GSK2190915 on the allergen-induced early asthmatic response in subjects with mild asthm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005205-19,0,0,0 2008-005206-39,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALI GALLIERA,Pilot Study: Iron-chelating treatment in patients with Neurodegeneration with Brain Iron Accumulation (NBIA).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005206-39,0,0,0 2008-005210-44,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Organisation name was not entered,Teofilina a dosis bajas como potenciador del tratamiento anti-inflamatorio en EPOC grave (Estudio ASSET),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005210-44,0,0,0 2008-005212-40,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Karolinska Institute,Pain mechanisms and fatigue in rheumatoid arthritis (RA) and healthy volunteers. Can antirheumatic and biological therapy affect pain processing and fatigue in RA?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005212-40,0,0,0 2008-005213-22,1,2016-02-29,2016-02-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charite Universitätsmedizin Berlin,SUPREMES - Sunphenon in progressive forms of multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005213-22,0,0,0 2008-005214-49,12,2012-05-03,2012-08-20,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd,"Estudio abierto, aleatorizado, de no inferioridad de Micafungina versus el tratamiento estándar para la prevención de la enfermedad fúngica invasiva en pacientes de alto riesgo receptores de un traspl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005214-49,0,0,0 2008-005214-49,12,2012-05-03,2012-08-20,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTELLAS PHARMA,"Estudio abierto, aleatorizado, de no inferioridad de Micafungina versus el tratamiento estándar para la prevención de la enfermedad fúngica invasiva en pacientes de alto riesgo receptores de un traspl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005214-49,0,0,0 2008-005215-17,12,2011-06-23,2011-06-23,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Astellas Pharma Europe Limited,A Study to Evaluate the Overall Effect of Solifenacin 5mg and 10mg on Bladder Wall Thickness and urinary Nerve Growth Factor in Female Subjects with Overactive Bladder and a Diagnosis of Detrusor Over...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005215-17,0,0,0 2008-005216-40,2,2009-09-09,2009-11-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An 8-week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and amlodipine 10 mg compared to amlodipine 10 mg in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005216-40,0,0,0 2008-005216-40,2,2009-09-09,2009-11-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmaceutica S.A.,"An 8-week, double-blind, randomized, parallel group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren 300 mg and amlodipine 10 mg compared to amlodipine 10 mg in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005216-40,0,0,0 2008-005217-22,2,2010-02-01,2010-02-01,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Galderma Research & Development,Efficacy and Safety of Clobetasol propionate shampoo 0.05% used in association with an antifungal shampoo in the treatment of moderate to severe Scalp Seborrheic Dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005217-22,0,0,0 2008-005219-16,1,2013-02-08,2013-02-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GE Healthcare Ltd,"A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis via the Expression of avb3 Integrin Receptors by [18F]AH111585 PET Imaging",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005219-16,0,0,0 2008-005221-11,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",New therapeutic approaches for anaplastic thyroid cancer: assessment of the benefit-risk profile of the combination valproic acid-paclitaxel.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005221-11,0,0,0 2008-005222-37,3,2016-01-21,2016-01-21,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Genzyme Europe B.V.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Confirming the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005222-37,0,0,0 2008-005223-28,7,2015-06-02,2015-06-02,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Genzyme Europe B.V.,"A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have been Stabi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005223-28,0,0,0 2008-005223-28,7,2015-06-02,2015-06-02,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Genzyme Europe BV,"A Phase 3, Randomized, Multi-Center, Multi-National, Open-Label, Active Comparator Study to Evaluate the Efficacy and Safety of Genz-112638 in Patients with Gaucher Disease Type 1 who have been Stabi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005223-28,0,0,0 2008-005224-91,1,2018-05-15,2018-05-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Ghent,Het gebruik van laag moleculair gewicht heparines (LMGH) tijdens hemodialyse.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005224-91,0,0,0 2008-005228-10,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ThromboGenics NV,"An Open Label, Single Center Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005228-10,0,0,0 2008-005232-33,6,2011-09-26,2011-09-26,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005232-33,0,0,0 2008-005234-79,1,2012-01-31,2012-01-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,DIPARTIMENTO DI MEDICINA CLINICA - UNIVERSITA` DEGLI STUDI DELL`INSUBRIA,Safety and efficacy of fondaparinux 1.5 mg in the prevention of venous thromboembolism in medical patients with severe renal insufficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005234-79,0,0,0 2008-005235-14,2,2012-01-08,2015-08-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER INC,A RANDOMIZED PHASE 2 TRIAL OF PF 00299804 VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005235-14,0,0,0 2008-005235-14,2,2012-01-08,2015-08-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.",A RANDOMIZED PHASE 2 TRIAL OF PF 00299804 VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005235-14,0,0,0 2008-005236-32,3,2012-03-15,2012-03-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eisai Inc,"Dalteparin Sodium Injection (Fragmin®), Multicenter, Open Label, Single-arm, Long Term (52 weeks) Study for Understanding Safety and Efficacy in Subjects with Malignancies and Symptomatic Venous Throm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005236-32,0,0,0 2008-005237-30,2,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,1,Janssen Biologics BV,"A Multicenter, Prospective, Long-term Registry of Pediatric Patients with Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005237-30,0,0,0 2008-005237-30,2,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,1,Janssen Biologics B.V.,"A Multicenter, Prospective, Long-term Registry of Pediatric Patients with Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005237-30,0,0,0 2008-005242-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Nicanor Vega Diaz. Hospital Universitario de Gran Canaria Dr Negrin,"ESTUDIO UNICENTRICO, PROSPECTIVO Y ALEATORIZADO DE COMPARACION DE LOS EFECTOS DE DIFERENTES SOLUCIONES DE DIALISIS PERITONEAL SOBRE LA FUNCIONALIDAD DE LA MEMBRANA PERITONEAL EN PACIENTES INCIDENTE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005242-23,0,0,0 2008-005244-16,1,2013-01-13,2013-01-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Wrightington, Wigan and Leigh NHS Trust","Probiotics for the prevention of Antibiotics associated diarrhoea and Clostridium difficile associated diarrhoea A multi-centre, double-blind, randomized placebo controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005244-16,0,0,0 2008-005246-23,1,2010-01-27,2010-01-27,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,Archemix Corp.,A Study of the Effect of ARC1779 Injection on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005246-23,0,0,0 2008-005248-17,17,2011-08-31,2013-03-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005248-17,0,0,0 2008-005248-17,17,2011-08-31,2013-03-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Inc.,RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005248-17,0,0,0 2008-005248-17,17,2011-08-31,2013-03-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005248-17,0,0,0 2008-005248-17,17,2011-08-31,2013-03-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005248-17,0,0,0 2008-005248-17,17,2011-08-31,2013-03-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005248-17,0,0,0 2008-005248-17,17,2011-08-31,2013-03-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005248-17,0,0,0 2008-005248-17,17,2011-08-31,2013-03-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005248-17,0,0,0 2008-005248-17,17,2011-08-31,2013-03-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005248-17,0,0,0 2008-005248-17,17,2011-08-31,2013-03-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005248-17,0,0,0 2008-005248-17,17,2011-08-31,2013-03-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005248-17,0,0,0 2008-005249-51,8,2010-12-20,2010-12-20,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent UK","A PHASE 2B, PARALLEL GROUP, PLACEBO AND ACTIVE COMPARATOR CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND EFFICACY OF 6-WEEK ONCE DAILY ADMINISTRATION OF INHALED PF-00610355 DRY POWDER IN P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005249-51,0,0,0 2008-005249-51,8,2010-12-20,2010-12-20,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"PFIZER, S.A.","A PHASE 2B, PARALLEL GROUP, PLACEBO AND ACTIVE COMPARATOR CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERATION AND EFFICACY OF 6-WEEK ONCE DAILY ADMINISTRATION OF INHALED PF-00610355 DRY POWDER IN P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005249-51,0,0,0 2008-005260-14,2,2012-01-17,2012-01-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AC Immune SA,"A double-blind placebo-controlled study of the safety, tolerability and efficacy of 12 months’ treatment with ACI 91 in patients with mild to moderate Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005260-14,0,0,0 2008-005262-31,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Effects of S 18886 on platelet function in type 2 diabetic patients treated by low-dose aspirin and with elevated levels of thromboxane A2. A multicentre, randomised, double-blind, cross-over study co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005262-31,0,0,0 2008-005263-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,The Mater Foundation/HRB Grant,"The effect of insulin therapy on beta-cell survival in patients with Maturity Onset Diabetes of the Young ( MODY) 3. A 2 year, single-centre, open-label, randomised, parallel-group trial comparing in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005263-34,0,0,0 2008-005266-31,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,CHU-Hôpitaux de Rouen,COMPARAISON D'UN TRAITEMENT PAR L'ANTICORPS MONOCLONAL ANTI-CD 20 : RITUXIMAB (MABTHERA®) ASSOCIE A UNE CORTICOTHERAPIE GENERALE COURTE PAR RAPPORT A UNE CORTICOTHERAPIE GENERALE DE LONGUE DUREE CHEZ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005266-31,0,0,0 2008-005275-10,7,2013-05-15,2013-07-08,3,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","""Estudio prospectivo, abierto, no aleatorizado y multicéntrico para investigar la seguridad y la tolerabilidad del voriconazol como tratamiento primario de la aspergilosis invasiva y de infecciones po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005275-10,1,1,0 2008-005275-10,7,2013-05-15,2013-07-08,3,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Pfizer Inc.,"""Estudio prospectivo, abierto, no aleatorizado y multicéntrico para investigar la seguridad y la tolerabilidad del voriconazol como tratamiento primario de la aspergilosis invasiva y de infecciones po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005275-10,1,1,0 2008-005275-10,7,2013-05-15,2013-07-08,3,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer, S.A.","""Estudio prospectivo, abierto, no aleatorizado y multicéntrico para investigar la seguridad y la tolerabilidad del voriconazol como tratamiento primario de la aspergilosis invasiva y de infecciones po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005275-10,1,1,0 2008-005276-27,7,2011-03-03,2011-03-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005276-27,0,0,0 2008-005277-35,6,2011-10-17,2012-05-18,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",EFFICACY AND SAFETY OF ERAXIS™/ECALTA (ANIDULAFUNGIN) COMPARED TO CANCIDAS (CASPOFUNGIN) IN NEUTROPENIC PATIENTS WITH INVASIVE CANDIDA INFECTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005277-35,0,0,0 2008-005277-35,6,2011-10-17,2012-05-18,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER,EFFICACY AND SAFETY OF ERAXIS™/ECALTA (ANIDULAFUNGIN) COMPARED TO CANCIDAS (CASPOFUNGIN) IN NEUTROPENIC PATIENTS WITH INVASIVE CANDIDA INFECTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005277-35,0,0,0 2008-005278-11,5,2012-06-08,2012-06-08,2,1,0,0,0,0,0,0,0,1,1,1,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN PATIENTS WITH CANDIDA DEEP TISSUE INFECTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005278-11,0,0,0 2008-005288-33,1,2009-10-29,2009-10-29,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"GlaxoSmithKline Research & Development, LtdD","Methodology Study to develop Sinerem enhanced 3T MR Imaging of Atherosclerotic Plaques within the Carotid Arteries, and to compare Sinerem MRI to contrast enhanced ultrasound",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005288-33,0,0,0 2008-005292-10,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación para la Investigación Biomédica Hospital Ramón y Cajal,ESTUDIO PILOTO DEL EFECTO DE UN INHIBIDOR DE LA INTEGRASA SOBRE LA LATENCIA Y EL RESERVORIO DEL VIH-1 EN PACIENTES QUE RECIBEN TRATAMIENTO ANTIRRETROVIRAL DE GRAN ACTIVIDAD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005292-10,0,0,0 2008-005294-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA USL 6 LIVORNO ZONA LIVORNESE,Multicenter Phase II study of Sequential Chemotherapy with Cisplatin/Gemcitabine Followed by Docetaxel in Elderly Advanced Non-Small-Cell Lung Cancer (NSCLC) patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005294-35,0,0,0 2008-005295-27,1,2010-09-01,2010-09-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Barts and The London NHS Trust,A NOVEL HYBRID PROTOCOL FOR RELAPSED GERM CELL TUMOURS WITH POOR PROGNOSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005295-27,0,0,0 2008-005301-19,4,2012-05-21,2012-06-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005301-19,0,0,0 2008-005301-19,4,2012-05-21,2012-06-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005301-19,0,0,0 2008-005304-93,1,2010-07-05,2010-07-05,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,North Bristol Trust,A Randomised Control Trial To Evaluate Whether Zoledronate Prevents Bone Loss In Acute Exacerbations Of Multiple Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005304-93,0,0,0 2008-005305-19,2,2009-04-20,2009-04-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Double-Blind, Outpatient, Crossover Study of the Anti-platelet Effects of AZD6140 Compared with Clopidogrel in Patients with Stable Coronary Artery Disease Previuosly Identified as Clopi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005305-19,0,0,0 2008-005306-39,1,2015-08-31,2015-08-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"RWTH Aachen University, represented by the rector, himself represented by Clinical Trial Center Aachen (CTC-A)",Food supplementation with Vitamin K for MGP-activation and inhibition of progression of aortic valve calcification NAHRUNGSERGÄNZUNG MIT VITAMIN K ZUR MGP-AKTIVIERUNG UND INHIBITION DER PROGRESSION...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005306-39,0,0,0 2008-005307-26,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",Intratecal Ziconotide in the treatment of neuropatic pain in cancer patients. A phase II study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005307-26,0,0,0 2008-005312-41,2,2015-02-24,2015-02-24,2,1,0,0,0,0,2,0,0,1,1,0,1,0,0,RWTH Aachen University,Perioperative chemotherapy with FOLFOX plus Cetuximab versus adjuvant FOLFOX plus Cetuximab for patients with resectable liver metastases of colorectal carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005312-41,0,0,0 2008-005313-21,1,2012-03-31,2012-03-31,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Sheffield Health and Social Research Consortium,The long term effectiveness of 40% salicylic acid plasters on corns,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005313-21,0,0,0 2008-005315-18,10,2012-01-05,2012-01-12,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"A confirmatory, placebo-controlled, randomised, double-blind, single-dummy, parallel group, ratio-finding study in constipated pain patients to establish an optimal hydromorphone – naloxone ratio with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005315-18,0,0,0 2008-005318-35,6,2010-06-25,2010-06-25,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ORGANON ITALIA,"A prospective, double-blind, placebo-controlled trial investigating the efficacy and safety of Org 25935 in relapse prevention in subjects with alcohol dependence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005318-35,0,0,0 2008-005318-35,6,2010-06-25,2010-06-25,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation","A prospective, double-blind, placebo-controlled trial investigating the efficacy and safety of Org 25935 in relapse prevention in subjects with alcohol dependence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005318-35,0,0,0 2008-005318-35,6,2010-06-25,2010-06-25,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NV Organon,"A prospective, double-blind, placebo-controlled trial investigating the efficacy and safety of Org 25935 in relapse prevention in subjects with alcohol dependence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005318-35,0,0,0 2008-005318-35,6,2010-06-25,2010-06-25,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Schering-Plough Research Institute,"A prospective, double-blind, placebo-controlled trial investigating the efficacy and safety of Org 25935 in relapse prevention in subjects with alcohol dependence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005318-35,0,0,0 2008-005319-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GLAXO SMITHKLINE,"``A double blind, parallel group, placebo controlled study to evaluate the effect of a single oral dose of GSK958108 on ejaculatory latency time (ELT) in male patients suffering from premature ejacula...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005319-16,0,0,0 2008-005320-81,4,2009-06-10,2009-06-15,2,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Novartis Pharma Services AG,"A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1β monoclonal antibody in patients with active rheumatoid arthr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005320-81,0,0,0 2008-005320-81,4,2009-06-10,2009-06-15,2,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Novartis Pharma Belgium,"A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1β monoclonal antibody in patients with active rheumatoid arthr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005320-81,0,0,0 2008-005320-81,4,2009-06-10,2009-06-15,2,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Novartis Farmacéutica S.A.,"A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1β monoclonal antibody in patients with active rheumatoid arthr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005320-81,0,0,0 2008-005324-93,1,2008-10-19,2008-10-19,1,1,0,0,0,3,4,0,1,1,0,0,1,0,1,CSL Limited,"A Single Centre, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira® vaccine in Healthy ‘Adults’ aged ≥ 18 to < 60 years and in Healthy ‘Older Adults’ aged ≥ 60 years for the 2008/20...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005324-93,0,0,0 2008-005325-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VU University Medical Center,The effect of exenatide compared to insulin glargine on cardiac function and metabolism in type 2 diabetic patients with congestive heart failure (NYHA II): a randomized-controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005325-10,0,0,0 2008-005326-36,6,2013-12-11,2014-11-27,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Kamada Limited,"A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin De...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005326-36,0,0,0 2008-005350-21,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK","A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED CROSSOVER STUDY OF THE EFFICACY OF FESOTERODINE IN INCREASING URETHRAL PRESSURE IN STRESS URINARY INCONTINENCE PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005350-21,0,0,0 2008-005351-14,1,2012-03-19,2012-03-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"University of Oulu, Department of Physical and Rehabilitation Medicine",Efficacy of zoledronic acid 5 mg for chronic low back pain due to Modic changes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005351-14,0,0,0 2008-005353-38,11,2022-01-21,2022-01-21,7,1,1,0,0,0,3,0,0,2,0,0,0,0,1,H. Lundbeck A/S,"Interventional, randomised, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 7 to 11 years, with Major depressive disorder ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005353-38,1,0,0 2008-005354-20,12,2019-07-30,2021-03-31,10,1,1,0,0,0,3,0,0,2,0,0,0,0,1,H. Lundbeck A/S,"Interventional, randomised, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 12 to 17 years, with Major depressive disorder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005354-20,1,0,0 2008-005356-25,8,2022-03-03,2022-04-19,5,1,1,0,0,0,3,0,0,2,1,0,0,0,1,H. Lundbeck A/S,"Long-term, open-label, flexible-dose, extension study of vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD) from 7 to 18 years of age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005356-25,1,0,0 2008-005360-14,1,2012-03-23,2012-03-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Elena Rubio. Consorcio Hospital General Universitario de Valencia,"Ensayo clínico aleatorizado, doble ciego con propionato de fluticasona tópico 2 veces por semana, como tratamiento de mantenimiento, para reducir el riesgo de recidivas de dermatitis atópica leve o mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005360-14,0,0,0 2008-005363-34,1,2012-01-17,2012-01-17,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,University of Surrey,Investigation to explore whether there is a synergistic effect between nicotine replacement therapy and guided bodyscanning on cigarette cravings and withdrawal symptoms in temporarily abstinent smoke...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005363-34,0,0,0 2008-005364-14,3,2012-01-02,2013-07-18,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,A phase I-II study of BIBF 1120 and Folfox compared to Bevacizumab and Folfox in first line metastatic colorectal cancer patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005364-14,0,0,0 2008-005364-14,3,2012-01-02,2013-07-18,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,SCS Boehringer Ingelheim Comm.V,A phase I-II study of BIBF 1120 and Folfox compared to Bevacizumab and Folfox in first line metastatic colorectal cancer patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005364-14,0,0,0 2008-005364-14,3,2012-01-02,2013-07-18,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Boehringer Ingelheim France,A phase I-II study of BIBF 1120 and Folfox compared to Bevacizumab and Folfox in first line metastatic colorectal cancer patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005364-14,0,0,0 2008-005365-61,1,2013-07-19,2013-07-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Med. Fakultaet der Friedrich-Alexander Universitaet Erlangen-Nuernberg,"A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005365-61,0,0,0 2008-005388-33,2,2013-03-07,2013-03-07,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Les Laboratoires CTRS,"A MULTICENTRE DOUBLE-BLIND RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF GS-101 EYE DROPS, AN ANTISENSE OLIGONUCLEOTIDE, VERSUS PLACEBO ON INHIBITION OF CORNEAL NEOVASCULARIZATION, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005388-33,0,0,0 2008-005392-10,2,2010-08-24,2010-08-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmaceutica SA,"A multi-centre, randomized, double-blind, parallel group, active and placebo controlled, Proof of Concept study in patients with acute migraine to assess the efficacy, safety and tolerability of singl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005392-10,0,0,0 2008-005392-10,2,2010-08-24,2010-08-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-centre, randomized, double-blind, parallel group, active and placebo controlled, Proof of Concept study in patients with acute migraine to assess the efficacy, safety and tolerability of singl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005392-10,0,0,0 2008-005394-35,1,,,0,0,0,0,0,1,3,0,0,1,0,0,0,1,0,Intituto Aragonés de Ciencias de la Salud,"Tratamiento de la hiperfenilalaninemia con dihidrocloruro de sapropterina (tetrahidrobiopterina, 6R-BH4) y su influencia en el patrón de aminoácidos y ácidos grasos desde la infancia hasta la edad adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005394-35,0,0,0 2008-005395-27,1,2011-02-07,2011-02-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,Inter-individual variability in response to warfarin in children: Analysis of environmental and pharmacogenetic factors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005395-27,0,0,0 2008-005405-20,1,2015-03-09,2015-03-09,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Medicine, Helsinki University Central Hospital",Bisfosfonaattien vaikutus luuntiheyteen ja luun uusiutumiseen leikkauksen jälkeen primaarissa hyperparatyreoosissa.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005405-20,0,0,0 2008-005424-85,6,2011-03-22,2011-03-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer company","A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of 50 mg/day of DVS SR in Adult Outpatients With Major Depressive Disor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005424-85,0,0,0 2008-005424-85,6,2011-03-22,2011-03-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals, Inc., acting through Wyeth Research, a Pfizer Company","A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of 50 mg/day of DVS SR in Adult Outpatients With Major Depressive Disor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005424-85,0,0,0 2008-005424-85,6,2011-03-22,2011-03-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals, Inc. Acting through its devision Wyeth Research, a Pfizer Company","A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of 50 mg/day of DVS SR in Adult Outpatients With Major Depressive Disor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005424-85,0,0,0 2008-005424-85,6,2011-03-22,2011-03-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals, Inc. Acting through its division Wyeth Research, a Pfizer Company","A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of 50 mg/day of DVS SR in Adult Outpatients With Major Depressive Disor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005424-85,0,0,0 2008-005424-85,6,2011-03-22,2011-03-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of 50 mg/day of DVS SR in Adult Outpatients With Major Depressive Disor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005424-85,0,0,0 2008-005424-85,6,2011-03-22,2011-03-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals, Inc.,Acting through its division Wyeth Research, a Pfizer Company","A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study to Evaluate the Efficacy and Safety of 50 mg/day of DVS SR in Adult Outpatients With Major Depressive Disor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005424-85,0,0,0 2008-005425-11,13,2018-06-20,2018-06-20,11,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Puma Biotechnology, Inc",A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005425-11,0,0,0 2008-005425-11,13,2018-06-20,2018-06-20,11,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Wyeth Research,A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005425-11,0,0,0 2008-005425-11,13,2018-06-20,2018-06-20,11,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals Inc., acting through its division Wyeth research, a Pfizer company",A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005425-11,0,0,0 2008-005425-11,13,2018-06-20,2018-06-20,11,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA",A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005425-11,0,0,0 2008-005425-11,13,2018-06-20,2018-06-20,11,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceutical Inc.,A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005425-11,0,0,0 2008-005425-11,13,2018-06-20,2018-06-20,11,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA",A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the Treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005425-11,0,0,0 2008-005426-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Utrecht,The effect of sevoflurane and isoflurane on vasopressor need,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005426-37,0,0,0 2008-005427-28,5,2011-03-08,2011-03-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma SA,"A Phase IIIb, multicenter study with a 12-week double-blind, placebo-controlled, randomized period followed by an open-label, extension phase to evaluate the safety and efficacy of certolizumab pegol ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005427-28,0,0,0 2008-005428-99,1,2016-10-07,2016-10-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University College London,A randomised controlled phase III trial comparing hyperthermia plus mitomycin to a second course of bacillus Calmette-Guerin or standard therapy in patients with recurrence of non-muscle invasive blad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005428-99,0,0,0 2008-005431-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ACHG-K.U.Leuven,PHASE III RANDOMIZED CHEMOPREVENTION STUDY OF SELENIUM ON THE RECURRENCE OF NON-INVASIVE BLADDER CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005431-15,0,0,0 2008-005432-32,1,2014-07-14,2014-07-14,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,St. George's University of London (SGUL),"Effects of an Angiotensin Receptor Antagonist Candesartan versus a calcium channel blocker Amlodipine on Microvascular Rarefaction, Endothelial Dysfunction and Microalbuminuria in Essential Hypertensi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005432-32,0,0,0 2008-005433-30,1,2011-03-28,2011-03-28,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Medizinische Hochschule Hannover, Klinik für Pneumologie",Taxotere-Enoxaparin-(ENOXA)-Studie: 1st-Line Docetaxel-Platin Chemotherapie alleine oder in Kombination mit Enoxaparin bei Patienten mit lokal fortgeschrittenem oder metastasiertem nicht-kleinzelligem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005433-30,0,0,0 2008-005436-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU de TOURS,Apport de l’échographie doppler avec injection de contraste pour la prise en charge des cancers du col de l’utérus de stade IB et II traités par radiochimiothérapie concomitante,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005436-33,0,0,0 2008-005438-57,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,Academic Medical Centre,"Predictive value of drug elimination gene polymorphisms on clearance and dose adjustment of sunitinib (Sutent, SU11248) in patients with cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005438-57,0,0,0 2008-005441-34,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Department of Anesthesia, University College Hospital Galway","Comparison of Transversus Abdominis Plane (TAP) block, Ilioinguinal Nerve Block and Surgical Infiltration for Orchidoplexy and Hydrocele Repair in Children.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005441-34,0,0,0 2008-005442-23,1,2009-05-21,2009-05-21,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Leyh Pharma GmbH,"Evaluation of the efficacy and safety of nose spray containing 3% silver protein diacetyl tannate (SEAT) in patients with uncomplicated viral rhinitis. A placebo-controlled, randomized, multicentric P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005442-23,0,0,0 2008-005448-18,3,2013-12-31,2013-12-31,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Morphotek, Inc.",An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005448-18,0,0,0 2008-005449-43,3,,,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,"Morphotek, Inc","A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory Rel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005449-43,0,0,0 2008-005450-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases","The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid artritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005450-20,0,0,0 2008-005451-23,1,2011-10-31,2011-10-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Charité - Universitätsmedizin Berlin, CharitéCentrum 3 für Zahn-, Mund- und Kieferheilkunde","Vergleichende, randomisierte, kontrollierte und doppelblinde In-situ-Studie zur Wirkung von Speichelersatzmitteln auf Schmelz und Dentin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005451-23,0,0,0 2008-005452-24,1,2015-12-18,2015-12-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Fertilitetsklinikken, Afsnit 455, Gynækologisk-Obstetrisk Afdeling, Hvidovre Hospital","Kort versus lang reagensglasbehandling. En prospektiv, konsekutiv og randomiseret sammenlignende undersøgelse.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005452-24,0,0,0 2008-005453-38,1,2017-03-31,2017-03-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Universitätsklinikum Ulm,"Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as well as Life Style Intervention Strategies SUCCESS C-Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005453-38,0,0,0 2008-005456-24,2,2012-10-15,2012-10-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharmaceuticals Products Ltd. A/S (LEO Pharma A/S),Safety and Efficacy of Calcipotriol plus Betamethasone Dipropionate Gel in Adolescent Patients (Aged 12 to 17 Years) with Scalp Psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005456-24,0,0,0 2008-005462-32,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,CHRU de TOURS,Effet de la rhDNase sur la biodistribution des protéases du neutrophile dans les expectorations des patients atteints de mucoviscidose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005462-32,0,0,0 2008-005464-14,1,2011-04-19,2011-04-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Prof. Salvatore Grisanti,"An open label, prospective, monocenter, prove of concept study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005464-14,0,0,0 2008-005466-30,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,2,University of Manchester,Effect of Perioperative AntiHER2 Therapy on Early Breast Cancer Study - Biological Phase,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005466-30,0,0,0 2008-005466-30,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,2,Institute of Cancer Research,Effect of Perioperative AntiHER2 Therapy on Early Breast Cancer Study - Biological Phase,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005466-30,0,0,0 2008-005466-30,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,2,University of South Manchester NHS Foundation Trust,Effect of Perioperative AntiHER2 Therapy on Early Breast Cancer Study - Biological Phase,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005466-30,0,0,0 2008-005469-67,1,2012-05-11,2012-05-11,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Thornton & Ross Limited,"A multi-centre, double-blind, vehicle-controlled, randomised group-comparative study to evaluate the efficacy and safety of Altoderm, a topically applied sodium cromoglicate lotion, in the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005469-67,0,0,0 2008-005470-12,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Medical University of Vienna,Calcitonin Prophylaxis in Phantom Limb Pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005470-12,0,0,0 2008-005471-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Nina Olofsson,Plasma concentration of Ropivacain and Ketorolac after local infiltration during surgery in hip replacement during the first 24 postoperative hours.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005471-10,0,0,0 2008-005472-27,1,2011-11-30,2011-11-30,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Innsbruck,"Die antidementive Therapie mit Acetylcholinesteraseinhibitoren: Untersuchung von Plasmakonzentrationen, Arzneimittelinteraktionen und Therapieeffekt in Abhängigkeit von genetischen Polymorphismen",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005472-27,0,0,0 2008-005473-35,1,2011-05-18,2011-05-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Lluita contra la SIDA,PILOT STUDY TO ASSESS THE ROLE OF IMMUNE ACTIVATION AND APOPTOSIS AS A MARKER FOR TREATMENT INTENSIFICATION WITH RALTEGRAVIR IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY WITH LONG-TERM VIRAL SUP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005473-35,0,0,0 2008-005476-27,12,2010-12-02,2010-12-02,8,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled, single-dose study to assess the initial efficacy of canakinumab (ACZ885) with respect to the adapted ACR Pediatric 30 criteria in patients with Systemic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005476-27,1,1,0 2008-005476-27,12,2010-12-02,2010-12-02,8,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A.,"A randomized, double-blind, placebo controlled, single-dose study to assess the initial efficacy of canakinumab (ACZ885) with respect to the adapted ACR Pediatric 30 criteria in patients with Systemic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005476-27,1,1,0 2008-005476-27,12,2010-12-02,2010-12-02,8,1,1,0,0,1,3,0,0,2,0,0,0,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo controlled, single-dose study to assess the initial efficacy of canakinumab (ACZ885) with respect to the adapted ACR Pediatric 30 criteria in patients with Systemic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005476-27,1,1,0 2008-005479-82,13,2011-09-12,2011-09-15,10,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled, withdrawal study of flare prevention of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manif...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005479-82,1,1,0 2008-005479-82,13,2011-09-12,2011-09-15,10,1,1,0,0,1,3,0,0,2,1,0,0,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo controlled, withdrawal study of flare prevention of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manif...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005479-82,1,1,0 2008-005479-82,13,2011-09-12,2011-09-15,10,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Novartis Farmacéutica S.A.,"A randomized, double-blind, placebo controlled, withdrawal study of flare prevention of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manif...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005479-82,1,1,0 2008-005481-30,5,2009-12-14,2009-12-14,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Addex Pharma SA,"A phase 2B, randomised, double-blind, placebo-controlled, parallel group, dose-ranging, multicentre study to investigate the efficacy, safety and tolerability of the mGluR5 negative allosteric modulat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005481-30,1,0,0 2008-005487-13,1,2009-03-02,2009-03-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharma A/S,A plaque test comparing 4 steroids with Daivobet® ointment and a vehicle control for the treatment of psoriasis vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005487-13,0,0,0 2008-005491-27,1,2010-02-28,2010-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UCR Uppsala Clinical Research Center,TAILORING OF PLATELET INHIBITION TO AVOID STENT THROMBOSIS TOPAS-1 A Pharmacodynamic Phase II Study of Clopidogrel P2Y12 Platelet Inhibition,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005491-27,0,0,0 2008-005492-94,15,2012-07-13,2012-07-13,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Newron Pharmaceuticals,OPEN LABEL TRIAL TO DETERMINE THE LONG TERM SAFETY OF SAFINAMIDE IN PARKINSON`S DISEASE PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005492-94,0,0,0 2008-005492-94,15,2012-07-13,2012-07-13,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Serono S.A. - Geneva,OPEN LABEL TRIAL TO DETERMINE THE LONG TERM SAFETY OF SAFINAMIDE IN PARKINSON`S DISEASE PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005492-94,0,0,0 2008-005492-94,15,2012-07-13,2012-07-13,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MERCK SERONO SA,OPEN LABEL TRIAL TO DETERMINE THE LONG TERM SAFETY OF SAFINAMIDE IN PARKINSON`S DISEASE PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005492-94,0,0,0 2008-005496-10,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Eli Lilly and Company,"An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin versus R-CHOP in the First-Line Treatment of Patients with Intermediate and High-Risk Diffuse Large B-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005496-10,0,0,0 2008-005500-10,3,2009-10-23,2009-10-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An eight-week, randomized, double-blind, parallel-group, pilot study to evaluate the efficacy and safety of aliskiren 300 mg in comparison with valsartan 320 mg in patients with mild to moderate hyper...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005500-10,0,0,0 2008-005503-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,José Such Ronda,"ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA DE NORFLOXACINO ORAL ASOCIADO A CEFOTAXIMA EN EL TRATAMIENTO DE LA PERITONITIS BACTERIANA ESPONTÁNEA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005503-26,0,0,0 2008-005506-40,1,2010-08-19,2010-08-19,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Novartis Pharma,"A double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study, to evaluate the safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administrations of LD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005506-40,0,0,0 2008-005508-14,1,2013-05-20,2013-05-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University College london,"A phase 3 randomized, placebo-controlled blinded investigation of six weeks vs. six months of oral valgancoclovir therapy in infants with symtomatic congenital cytomegalovirus infection. DMID # 06-004...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005508-14,0,0,0 2008-005514-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitätslehrkrankenhaus Hall in Tirol,"Endothelin Receptor Blockade in Heart Failure with Diastolic Dysfunction and Pulmonary Hypertension Randomisierte, placebokontrollierte, multizentrische, doppel- blinde Pilotstudie zur Untersuchung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005514-40,0,0,0 2008-005518-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Laboratoires GENEVRIER,"An exploratory, open-label, intra-individual,active- controlled study comparing the efficacy and safety of Betesil versus Daivobet for the treatment of chronic plaque psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005518-29,0,0,0 2008-005522-36,1,,,0,0,0,0,1,0,4,0,0,3,0,0,0,0,0,RUH (Bath) NHS Trust,Chewing gum and orthodontic pain relief,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005522-36,0,0,0 2008-005525-11,6,2013-03-13,2013-03-13,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F Hoffmann-La Roche Ltd,"A randomized, placebo controlled, double-blind, parallel group study to compare the safety and efficacy of the combination of rituximab (MabThera) and tocilizumab (Actemra) versus tocilizumab therapy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005525-11,0,0,0 2008-005532-32,1,2009-02-26,2009-02-26,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Kwizda Pharma,The bioavailability of nicorandil in humans: A pilot study to investigate the variability of its pharmacokinetic parameters in healthy volunteers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005532-32,0,0,0 2008-005536-32,2,2011-06-28,2011-06-28,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Cytavis Biopharma GmbH,Phase II double-blind placebo-controlled trial of CY-503 in patients with chemotherapy-refractory metastatic colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005536-32,0,0,0 2008-005538-59,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,ZonMw,"Impulsivity, a risk factor in relapse to substance use disorder: investigating neural substrates before and after pharmacological challenges",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005538-59,0,0,0 2008-005539-14,9,2014-07-07,2014-10-07,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,H. Lundbeck A/S,"A randomised, double-blind, parallel-group placebo-controlled phase lll study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005539-14,0,0,0 2008-005542-23,1,2019-08-30,2019-08-30,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Cancer Research UK,A CCLG/Cancer Research UK Phase I Trial of AT9283 (a selective inhibitor of Aurora kinases) given for 72 hours every 21 days via intravenous infusion in children and adolescents with relapsed and refr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005542-23,0,0,0 2008-005544-17,14,2010-07-29,2010-09-10,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck KGaA,"A randomized, double-blind, controlled phase III study of Stimuvax (L-BLP25 or BLP25 liposome vaccine) in combination with hormonal treatment versus hormonal treatment alone for first-line therapy of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005544-17,0,0,0 2008-005544-17,14,2010-07-29,2010-09-10,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MERCK KGAA,"A randomized, double-blind, controlled phase III study of Stimuvax (L-BLP25 or BLP25 liposome vaccine) in combination with hormonal treatment versus hormonal treatment alone for first-line therapy of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005544-17,0,0,0 2008-005544-17,14,2010-07-29,2010-09-10,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MMerck KGaA,"A randomized, double-blind, controlled phase III study of Stimuvax (L-BLP25 or BLP25 liposome vaccine) in combination with hormonal treatment versus hormonal treatment alone for first-line therapy of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005544-17,0,0,0 2008-005546-23,3,2015-09-01,2015-09-02,2,1,0,0,0,0,0,0,0,2,0,0,0,0,0,Yale University School of Medicine,Insulin Resistance Intervention after Stroke (IRIS) Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005546-23,1,0,0 2008-005546-23,3,2015-09-01,2015-09-02,2,1,0,0,0,0,0,0,0,2,0,0,0,0,0,YALE UNIVERSITY,Insulin Resistance Intervention after Stroke (IRIS) Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005546-23,1,0,0 2008-005549-46,1,2011-03-02,2011-03-02,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Hvidovre Hospital,"A randomised, controlled prospective open parallel groups clinical trial for the evaluation of efficacy and safety of TachoSil® in women undergoing hysterectomy. A pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005549-46,0,0,0 2008-005557-38,1,2010-11-29,2010-11-29,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,AstraZeneca GmbH,"Addition of vandetanib to standard therapy (pegliposomal doxorubicin) in patients with recurrent ovarian cancer. A multi-centre, non-randomized, open phase I/randomized phase II study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005557-38,0,0,0 2008-005558-19,2,2009-07-20,2010-01-10,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Idenix Pharmaceuticals, Inc.","A Phase I/II, Double-Blind, Dose-Escalation Study to Evaluate the Safety and Antiviral Activity of IDX184 in Treatment-Naïve Subjects Infected with Genotype 1 Chronic Hepatitis C",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005558-19,0,0,0 2008-005559-46,4,2012-10-03,2012-12-12,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec Ltd.,"A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005559-46,0,0,0 2008-005560-13,2,2017-08-02,2017-08-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Hochschule Hannover,A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The Hep...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005560-13,0,0,0 2008-005563-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ZonMw,Costs and effects of fibronectin as a triage in women with threatened preterm labour.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005563-33,0,0,0 2008-005565-54,1,2010-01-19,2010-01-19,1,0,0,0,0,1,3,0,0,1,0,0,1,0,1,Biotec Pharmacon ASA,"A randomized, double-blind, placebo-controlled, parallel-group phase III clinical study to assess the efficacy and safety of soluble beta 1,3/1,6 glucan (SBG) on oral mucositis in head and neck cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005565-54,0,0,0 2008-005570-12,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Geistlich Pharma AG,"Protocol Title: A multicentre, randomised placebo controlled, parallel group clinical trial to evaluate the anti-neoplastic effects of Taurolidine in patients undergoing curative surgery for non-meta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005570-12,0,0,0 2008-005571-10,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,Kennedy Krieger Inst. Johns Hopkins Medicine,DEXTROMETORPHAN IN RETT SYNDROME,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005571-10,0,0,0 2008-005575-96,16,2013-05-27,2013-10-17,15,1,0,0,2,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline Research & Development, Ltd",A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005575-96,0,0,0 2008-005575-96,16,2013-05-27,2013-10-17,15,1,0,0,2,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005575-96,0,0,0 2008-005576-26,2,2012-10-30,2012-10-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Nektar Therapeutics,"A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Unresectable Loca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005576-26,0,0,0 2008-005577-36,2,2011-10-06,2011-10-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Nektar Therapeutics,"A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic Breast Cancer Whose ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005577-36,0,0,0 2008-005578-12,1,2011-10-20,2011-10-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Nektar Therapeutics,"A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Locally Advanced ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005578-12,0,0,0 2008-005581-31,1,2011-12-12,2011-12-12,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Organisation name was not entered,Betydning af D-vitamin substitution hos overvægtige personer med lavt plasma D-vitamin niveau. Effekter på inflammatoriske markører samt fedt- og muskelmetabolisme.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005581-31,0,0,0 2008-005583-14,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA SENESE,NEW CONSERVATIVE THERAPIES IN RETINOBLASTOMA: DIRECT INTRAARTERIAL (OPHTALMIC ARTERY) CHEMOTHERAPY WITH MELPHALAN FOR INTRAOCULAR RETINOBLASTOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005583-14,0,0,0 2008-005584-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Radboud University Nijmegen Medical Centre,Dendritic cell vaccination in patients with Lynch Syndrome or colorectal cancer with MSI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005584-33,0,0,0 2008-005594-35,1,2021-08-23,2021-08-23,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,CHU Sart-Tilman,Randomized double-blind study of mesenchymal stem cells (MSC) in patients undergoing matched unrelated allogeneic bone marrow or peripheral blood stem cell transplantation- A European multicentre stud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005594-35,0,0,0 2008-005596-10,1,2009-02-20,2009-02-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Reckitt Benkiser Healthcare (UK) Ltd,"A multi centre, randomised, double blind, placebo-controlled, parallel group, single dose study of the efficacy of two flavour variants of Strepsils throat lozenges in the relief of sore throat due to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005596-10,0,0,0 2008-005598-36,1,2010-02-26,2010-02-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Acedemic Medical Centre Amsterdam,Optimal timing of rapid-acting insulin analogues administration before meal,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005598-36,0,0,0 2008-005604-54,1,2010-12-19,2010-12-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novexel, S.A.","A prospective, multicentre, double-blind, randomized, comparative study to estimate the safety, tolerability and efficacy of NXL104/ceftazidime plus metronidazole vs. meropenem in the treatment of com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005604-54,0,0,0 2008-005606-39,3,2015-04-06,2015-04-06,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"BIAL - PORTELA & C�, S.A.","EFFECTS OF ESLICARBAZEPINE ACETATE (BIA 2-093) ON COGNITIVE FUNCTION IN CHILDREN WITH PARTIAL ONSET SEIZURES: AN ADD-ON, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTRE CLINI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005606-39,1,0,0 2008-005606-39,3,2015-04-06,2015-04-06,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"BIAL - Portela & Cª, SA","EFFECTS OF ESLICARBAZEPINE ACETATE (BIA 2-093) ON COGNITIVE FUNCTION IN CHILDREN WITH PARTIAL ONSET SEIZURES: AN ADD-ON, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTRE CLINI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005606-39,1,0,0 2008-005606-39,3,2015-04-06,2015-04-06,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"BIAL-Portela & Ca, SA","EFFECTS OF ESLICARBAZEPINE ACETATE (BIA 2-093) ON COGNITIVE FUNCTION IN CHILDREN WITH PARTIAL ONSET SEIZURES: AN ADD-ON, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTRE CLINI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005606-39,1,0,0 2008-005609-21,1,2013-08-30,2013-08-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Faculty For Medicine, Otto-von-Guericke University Magdeburg",Exploratory study to assess the predictive value of 99mTc-labeled albumin spheres for the intrahepatic distribution of 90Y SIR Spheres in patients with liver metastases of colorectal tumors.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005609-21,0,0,0 2008-005612-40,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,FARMACEUTICI DAMOR,"Open-label, controlled, randomised, multicentre, parallel group clinical trial of efficacy and tolerability of heparan sulfate slow-release 120 mg tablets and defibrotide 400 mg capsules in the treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005612-40,0,0,0 2008-005615-18,8,2017-03-16,2017-03-16,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BOEHRINGER ING.,"LUX-Lung 3; A randomised, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005615-18,0,0,0 2008-005615-18,8,2017-03-16,2017-03-16,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim,"LUX-Lung 3; A randomised, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005615-18,0,0,0 2008-005615-18,8,2017-03-16,2017-03-16,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"LUX-Lung 3; A randomised, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005615-18,0,0,0 2008-005615-18,8,2017-03-16,2017-03-16,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"LUX-Lung 3; A randomised, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005615-18,0,0,0 2008-005615-18,8,2017-03-16,2017-03-16,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"LUX-Lung 3; A randomised, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005615-18,0,0,0 2008-005615-18,8,2017-03-16,2017-03-16,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim France,"LUX-Lung 3; A randomised, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005615-18,0,0,0 2008-005616-40,6,2010-01-08,2010-03-02,6,1,0,0,0,0,2,0,0,1,1,0,1,0,2,"Merck & Co., Inc.","A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK-0941 Compared to Sulfonylurea in Patients with Type 2 Diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005616-40,0,0,0 2008-005616-40,6,2010-01-08,2010-03-02,6,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Merck Sharp & Dohme (Sweden) AB,"A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK-0941 Compared to Sulfonylurea in Patients with Type 2 Diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005616-40,0,0,0 2008-005616-40,6,2010-01-08,2010-03-02,6,1,0,0,0,0,2,0,0,1,1,0,1,0,2,MSD Finland Oy,"A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK-0941 Compared to Sulfonylurea in Patients with Type 2 Diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005616-40,0,0,0 2008-005616-40,6,2010-01-08,2010-03-02,6,1,0,0,0,0,2,0,0,1,1,0,1,0,2,"MERCK & CO., INC.","A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK-0941 Compared to Sulfonylurea in Patients with Type 2 Diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005616-40,0,0,0 2008-005616-40,6,2010-01-08,2010-03-02,6,1,0,0,0,0,2,0,0,1,1,0,1,0,2,"Merck, sharp & Dohme (Human Health) Ltd","A Phase IIa, Multicenter, Double-Blind, Randomized, Active-Controlled, Parallel-Arm Clinical Trial to Study the Efficacy and Safety of MK-0941 Compared to Sulfonylurea in Patients with Type 2 Diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005616-40,0,0,0 2008-005617-22,1,,,0,1,0,0,0,0,4,0,0,3,0,0,0,0,0,Unidad de Investigación; Hospital Universitario de Canarias,"Inmunosupresión óptima en pacientes con alto riesgo de diabetes de novo tras el trasplante renal: Un estudio prospectivo, multicéntrico, controlado y randomizado",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005617-22,0,0,0 2008-005619-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medical Center,Impact of anti-tumor necrosis factors antibodies treatment on fertility of inflammatory bowel diseases male patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005619-16,0,0,0 2008-005625-11,2,2010-11-18,2010-11-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Healthcare AG,"A multi-center, double-blind, double-dummy, randomized, controlled, parallel-group study to assess efficacy and safety of SH T00658ID compared to SH D593B in the treatment of primary dysmenorrhea",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005625-11,0,0,0 2008-005632-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació privada de l'Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,INYECCIÓN FRECUENTE DE TOXINA BOTULÍNICA SIN PROTEÍNAS COMPLEJANTES: EVALUACIÓN DEL EFECTO SOBRE EL DOLOR EN DISTONÍA CERVICAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005632-32,0,0,0 2008-005638-56,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de TOULOUSE,Protocole IFM 2008 : Primo-traitement des patients de moins de 65 ans atteints de myélome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005638-56,0,0,0 2008-005644-17,1,2014-07-31,2014-07-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Hytönen Maija,Nenäpolyyppien hoito montelukastilla Montelukast treatment in nasal polyps,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005644-17,0,0,0 2008-005645-27,1,2012-06-30,2012-06-30,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Innsbruck, vertreten durch Univ. Prof. Dr. Martin Krismer",Vergleich von demineralisierter Knochenmatrix (DBM) und Knochenallograft bei der anterioren lumbale Wirbelkörperfusion (ALIF) mittels Synfix LR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005645-27,0,0,0 2008-005651-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Durée optimale du traitement double anti-plaquettaire après insertion d'un stent coronaire actif,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005651-24,0,0,0 2008-005653-37,2,2015-02-06,2015-02-06,1,1,0,0,0,0,4,0,0,2,1,0,0,0,0,Universityhospital of Heidelberg,"Multicenter, prospective randomized trial on the use of prothrombin complex and fresh frozen plasma in patients with intracerebral hemorrhage related to vitamin K antagonists (VKA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005653-37,1,0,0 2008-005654-21,1,2010-05-26,2010-05-26,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Bayer Consumer Care AG,"An investigator-blind, randomized, multicenter, 5-arm, placebo- and active controlled parallel group pilot trial to explore the efficacy and tolerability of topical bifonazole liquid spray in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005654-21,0,0,0 2008-005656-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dra. Rosario Blasco,ENSAYO CLÍNICO SOBRE LA EVOLUCIÓN Y EL IMPACTO DEL TRATAMIENTO FARMACOLÓGICO EN LA PERDIDA AXONAL PROGRESIVA EN PACIENTES QUE CON ESCLEROSIS MÚLTIPLE QUE HAN PRESENTADO UN PRIMER EPISODIO DESMIELINIZA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005656-24,0,0,0 2008-005657-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Royal College of Surgeons Ireland,Transversus Abdominis Plane Block for Analgesia in Renal Transplantation: A Randomised Controlled Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005657-38,0,0,0 2008-005659-83,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Erasmus MC,Second IVIg Dose in GBS patients with poor prognosis (SID-GBS trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005659-83,0,0,0 2008-005660-13,1,2009-12-01,2009-12-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,BOC Ltd.,COPD exacerbation - Heliox Therapy - Assessment Heliox vs. Medical Air in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Pilot Randomised Controlled Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005660-13,0,0,0 2008-005663-34,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Joseba Andoni Santamaría Zuazua,"Ensayo clínico sobre la eficacia de una pauta con amoxicilina/clavulánico 2000/125 mg (GE) cada doce horas, frente a placebo(GC) en la prevención de la infeccion postoperatoria tras la exodoncia de te...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005663-34,0,0,0 2008-005667-34,5,,,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,University of Edinburgh,Randomised Trial of Genetic Testing and Targeted Zoledronic acid Therapy to Prevent SQSTM1 Mediated Paget’s Disease Studio clinico randomizzato di analisi genetica e terapia mirata con acido zoledr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005667-34,0,0,0 2008-005667-34,5,,,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,NHS Lothian,Randomised Trial of Genetic Testing and Targeted Zoledronic acid Therapy to Prevent SQSTM1 Mediated Paget’s Disease Studio clinico randomizzato di analisi genetica e terapia mirata con acido zoledr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005667-34,0,0,0 2008-005667-34,5,,,0,0,0,0,0,0,0,0,1,3,0,0,0,0,0,AZIENDA OSPEDALIERA SENESE,Randomised Trial of Genetic Testing and Targeted Zoledronic acid Therapy to Prevent SQSTM1 Mediated Paget’s Disease Studio clinico randomizzato di analisi genetica e terapia mirata con acido zoledr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005667-34,0,0,0 2008-005687-13,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,GELTAMO (Grupo Español de Linfoma y Transplante Autólogo de Médula Ósea),"Estudio Fase II abierto prospectivo no aleatorizado para valorar la combinación de rituximab, bendamustina, mitoxantrone, dexametasona (R-BMD) en pacientes con Linfoma Folicular refractarios o en reca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005687-13,0,0,0 2008-005688-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Univeristy Hospital Na Bulovce,Biological therapy in the prevention of Crohn`s disease recurrence after resection in ileocecal region.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005688-32,0,0,0 2008-005691-27,1,2020-06-12,2020-06-12,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,INSTITUT CURIE,Etude de phase III randomisée comparant une chimiothérapie adjuvante par Fotémustine à une surveillance chez des patients présentant un mélanome de la choroïde à haut risque de rechute.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005691-27,0,0,0 2008-005692-10,2,2009-08-10,2009-08-10,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Randomized, Double-blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Subjects With Cancer-Relate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005692-10,0,0,0 2008-005695-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Eli Lilly Nederland,Comparing Problem Solving Treatment combined with duloxetine with Problem Solving Treatment alone for patients with major depressive disorder in primary care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005695-27,0,0,0 2008-005696-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Bordeaux,Evaluation de l’efficacité de l’infiltration continue d’anesthésiques locaux par un cathéter pariétal paravertébral pour l’analgésie postopératoire après arthrodèse lombaire,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005696-10,0,0,0 2008-005702-39,1,2013-01-31,2013-01-31,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,GERCOR,"Phase I/II study of Induction Chemotherapy with weekly RAD001, Carboplatine and Paclitaxel in Unresectable or Inoperable Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005702-39,0,0,0 2008-005705-19,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Multicentric trial of low molecular weight heparin (LMWH) plus low dose aspirin efficacy versus only low dose aspirin for prevention of recurrent preeclamsia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005705-19,0,0,0 2008-005707-26,1,2010-05-14,2010-05-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Chiesi Farmaceutici SpA,Effect of beclomethasone dipropionate/formoterol fumarate (BDP+FF) administered as a fixed pMDI combination on lung impedance and exhaled nitric oxide in comparison with the fixed combination of budes...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005707-26,0,0,0 2008-005708-18,1,2014-06-01,2014-06-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Queen Mary University of London,Prevention of metabolic complications of glucocorticoid excess,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005708-18,0,0,0 2008-005709-20,2,2009-11-18,2009-11-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"An open-label trial in genotype 2, 3, 4, 5 and 6 hepatitis C-infected subjects to evaluate the antiviral activity, safety, tolerability and pharmacokinetics of TMC435350 following 7 days once daily do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005709-20,0,0,0 2008-005710-48,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Étude randomisée contrôlée en double aveugle de l'effet des infiltrations du grand nerf occipital dans l'algie vasculaire de la face ""CHCI""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005710-48,0,0,0 2008-005712-40,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Evaluation of postoperative pain management with thoracic paravertebral block using levobupivacaine associated with sufentanil,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005712-40,0,0,0 2008-005713-22,11,2015-09-22,2015-11-03,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A RANDOMIZED, MULTICENTER, PHASE III OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB-MCC-DM1 VS. CAPECITABINE+LAPATINIB IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005713-22,0,0,0 2008-005713-22,11,2015-09-22,2015-11-03,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Hoffmann- La Roche Ltd,"A RANDOMIZED, MULTICENTER, PHASE III OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB-MCC-DM1 VS. CAPECITABINE+LAPATINIB IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005713-22,0,0,0 2008-005714-46,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,ISTITUTO CLINICO HUMANITAS,BIOLOGICALS SUPPORTS STUDY IN RESECTIVE SURGERY OF PANCREATIC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005714-46,0,0,0 2008-005727-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset,"BK viremi efter njurtransplantation: Screening, tidig diagnostik, tidig reduktion av immunhämning samt behandling med leflunomid (Arava®)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005727-28,0,0,0 2008-005744-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,PEDRO ACIEN ALVAREZ,INHIBIDORES DE LA AROMATASA (ANASTROZOL) ASOCIADOS A DISPOSITIVO INTRAUTERINO LIBERADOR DE LEVONORGESTREL (DIU-LNG) EN EL TRATAMIENTO DE LA ENDOMETRIOSIS MODERADA/SEVERA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005744-17,0,0,0 2008-005746-22,1,2010-04-28,2010-04-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Allergie-Centrum-Charite, Department of Dermatology, Charite - Universitätsmedizin Berlin","Multi-center, double blind, dose escalating study to compare the effects of 5 mg, 10mg and 20mg of Desloratadine in patients with acquired cold urticaria (ACU)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005746-22,0,0,0 2008-005747-42,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"Efficacy of a medical product containing sorbitol, simethicone and citrate potassium, in comparison with domperidone in patients affected by disfunctional dyspepsia: randomized monocentric cross-over ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005747-42,0,0,0 2008-005748-18,1,2010-01-26,2010-01-26,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Greater Glasgow and Clyde NHS Board and The University Of Glasgow,SAFETY AND TOLERABILITY OF ECULIZUMAB IN THE TREATMENT OF MULTIFOCAL MOTOR NEUROPATHY: AN OPEN LABEL STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005748-18,0,0,0 2008-005757-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,CORD BLOOD SERUM IN THE TREATMENT OF OCULAR SURFACE DISEASES (PILOT STUDY.),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005757-38,0,0,0 2008-005759-21,1,2013-01-14,2013-01-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Oxford,"Can atorvastatin improve vascular function in women with a history preeclampsia? A Randomised, double-blinded, placebo-controlled crossover trial of atorvastatin in women with a history of preeclampsi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005759-21,0,0,0 2008-005760-14,2,2018-11-06,2018-11-06,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,GORTEC,"Etude de phase III randomisée, multicentrique comparant une chimiothérapie d’induction par TPF suivie d’une association radiothérapie Erbitux® versus une radiochimiothérapie concomitante chez des pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005760-14,1,0,0 2008-005767-34,3,2010-10-25,2010-10-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A trial comparing efficacy and safety of NN5401 with insulin glargine, both in combination with oral antidiabetic drugs in subjects with type 2 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005767-34,0,0,0 2008-005768-15,2,2010-08-23,2010-08-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 26-week, randomised, open-labelled, two-arm, parallel-group, treat-to-target trial comparing efficacy and safety of soluble insulin analogue combination (SIAC) twice daily (BID) with biphasic insuli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005768-15,0,0,0 2008-005769-71,3,2010-05-31,2010-05-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 26-week, multinational, multi-centre, open-labelled, two-arm, parallel, randomised, treat-to-target trial comparing efficacy and safety of soluble insulin analogue combination (SIAC) once daily plus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005769-71,0,0,0 2008-005771-10,3,2010-09-05,2010-09-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 26 week randomised, controlled, open label, multicentre, multinational, three-arm, treat to target trial comparing efficacy and safety of three different dosing regimens of either Soluble Insulin Ba...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005771-10,0,0,0 2008-005773-35,1,,,0,0,0,1,0,0,1,0,0,4,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,AUTOLOUGUS STEM CELLS TRANSPLANTATION AFTER LINFOCYTE DEPLETION AS A NEW THERAPY FOR THE AGGRESSIVE AND DRUG RESISTANT FORMS OF MULTIPLE SLEROSIS IN THE ADULTS AND CHILDREN. TRAPIANTO DI CELLULE ST...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005773-35,0,0,0 2008-005774-13,3,2010-11-08,2010-12-08,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 52 week randomised, controlled, open label, multicentre, multinational, parallel, treat-to-target trial comparing efficacy and safety of SIBA and insulin glargine both administered once daily in a b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005774-13,0,0,0 2008-005776-27,9,2011-01-17,2011-01-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 52-week randomised, controlled, open label, multicentre, multinational treat-to-target trial comparing the efficacy and safety of SIBA and insulin glargine, both injected once daily in combination w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005776-27,0,0,0 2008-005777-35,5,2010-10-28,2010-11-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 52-week randomised, controlled, open label, multicentre, multinational treat-to-target trial comparing efficacy and safety of SIBA and insulin glargine both administered once daily in a basal-bol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005777-35,0,0,0 2008-005777-35,5,2010-10-28,2010-11-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"A 52-week randomised, controlled, open label, multicentre, multinational treat-to-target trial comparing efficacy and safety of SIBA and insulin glargine both administered once daily in a basal-bol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005777-35,0,0,0 2008-005778-11,2,2009-11-09,2009-11-09,1,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Noscira S.A.,"A 14 week double-blind, placebo-controlled, randomized, escalating dose study to evaluate the safety and tolerability of three oral doses of NP031112, a novel GSK3 inhibitor, in mild to moderate Alzhe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005778-11,0,0,0 2008-005779-86,1,2009-09-24,2009-09-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GENFIT,"A Pilot study to evaluate the Efficacy and Safety of GFT505 (80 mg) orally administered once daily for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005779-86,0,0,0 2008-005782-59,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University College London,ARISTOTLE - A phase III trial comparing standard versus novel CRT as pre-operative treatment for MRI defined locally advanced rectal cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005782-59,0,0,0 2008-005783-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Adj,Professor, Torsten Gordh",En proof of concept (POC) studie gällande guanethidines smärtlindrande effekt vid regional i.v administrering för behandling av komplext regional smärtsyndrom (CRP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005783-14,0,0,0 2008-005784-33,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Maternté Régionale Universitaire de Nancy,Effet du néfopam sur la montée laiteuse après césarienne ( étude randomisée en double insu),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005784-33,0,0,0 2008-005786-60,1,2018-11-20,2018-11-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Charité Universitaetsmedizin Berlin,"A prospective, multicentre trial on the value of 18F-FET PET in the post-therapeutic evaluation of childhood brain tumours",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005786-60,0,0,0 2008-005787-13,1,2009-05-04,2009-05-04,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Thornton & Ross Ltd,A proof of concept clinical investigation to evaluate the activity of Hedrin 4% lotion in the treatment of head lice using a 1 hour application time,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005787-13,0,0,0 2008-005789-30,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,María Isabel López Gálvez-Instituto Universitario de Oftalmobiología Aplicada-Universidad Valladolid,Estudio de la eficacia y seguridad de inyecciones intravítreas de bevacizumab en el edema macular secundario a oclusiones venosas retinianas (EBOVER),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005789-30,0,0,0 2008-005791-27,1,2010-01-18,2010-01-18,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in European Children",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005791-27,0,0,0 2008-005796-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St. Joseph-Hospital g GmbH,Untersuchung zum Effekt einer antibiotischen Therapie mit einem Chinolon der 4. Generation (Moxifloxacin) auf Metalloprotease 9 und Interleukin 6 im Wundsekret bei Patienten mit einem diabetischem Fuß...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005796-10,0,0,0 2008-005797-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,METFORMIN VS PLACEBO IN NEWLY DIAGNOSED TYPE 1 DIABETES MELLITUS: A RANDOMIZED CLINICAL TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005797-12,0,0,0 2008-005798-36,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005798-36,0,0,0 2008-005800-24,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,"Medizinische Universität Wien, Institut für Spezifische Prophylaxe und Tropenmedizin",Characterisation of humoral and cellular immunity of low- and high-responder after TBE vaccination,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005800-24,0,0,0 2008-005801-20,1,2011-12-31,2011-12-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Centre Hospitalier Régional et Universitaire de Lille,Etude d’efficacité et d’acceptabilité du méthylphénidate dans les troubles de la marche de la maladie de Parkinson : Etude multicentrique en double aveugle versus placebo.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005801-20,0,0,0 2008-005802-37,3,2010-01-08,2010-01-08,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"An 8 day open-label, multiple-dose, multi-center study to evaluate the safety/tolerability and pharmacokinetics of aliskiren in hypertensive pediatric and adolescent patients 6 – 17 years of age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005802-37,1,1,0 2008-005806-38,1,2013-06-06,2013-06-06,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F.Hoffmann-La Roche Ltd.,"A multiple ascending dose study to evaluate the safety, tolerability and effect on tumor response of the mTOR inhibitor (RAD001) in combination with the IGF-1R antagonist (R1507) in patients with adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005806-38,0,0,0 2008-005808-72,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Effect of preoperatively administered oxycontin and intraoperative nitrous oxide use on remifentanil-induced analgesia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005808-72,0,0,0 2008-005809-20,4,2010-05-19,2010-05-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo in obese patients with type 2 diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005809-20,0,0,0 2008-005809-20,4,2010-05-19,2010-05-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo in obese patients with type 2 diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005809-20,0,0,0 2008-005810-39,1,2009-08-26,2009-08-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the aliskiren 300 mg plus hydrochlorothiazide 25 mg in hypertensive patients not adequately responding to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005810-39,0,0,0 2008-005811-16,8,2017-10-25,2017-10-25,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005811-16,0,0,0 2008-005811-16,8,2017-10-25,2017-10-25,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005811-16,0,0,0 2008-005811-16,8,2017-10-25,2017-10-25,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GlaxoSmithKline SA,"A Phase III, Open Label, Randomized Trial of Ofatumumab Added to Fludarabine-Cyclophosphamide vs. Fludarabine-Cyclophosphamide Combination in Subjects with Relapsed Chronic Lymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005811-16,0,0,0 2008-005813-23,1,2009-05-24,2009-05-24,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"ASKA Pharmaceutical.Co., Ltd",Phase IIa study to evaluate the effects of GPD-1116 on late phase asthmatic response to allergen challenge in asthmatic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005813-23,0,0,0 2008-005814-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Cost-effectiveness of viscosupplementation therapy for patients with osteoarthritis of the knee: a randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005814-28,0,0,0 2008-005815-17,3,2010-03-26,2010-04-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"An exploratory, randomised, double-blind, single-dummy, placebo controlled, parallel group study to demonstrate the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) in addit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005815-17,0,0,0 2008-005817-23,2,2009-08-20,2009-08-20,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merck & Co., Inc.","A Phase IIA, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-8245 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005817-23,0,0,0 2008-005817-23,2,2009-08-20,2009-08-20,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merck & Co., Inc","A Phase IIA, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-8245 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005817-23,0,0,0 2008-005819-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Neuroscience, Uppsala University",A comparison of Dysport (100 U/ml) and Botox (100 U/ml) using dose conversion factor 3:1 and 1.7:1 in the treatment of cervical dystonia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005819-18,0,0,0 2008-005825-12,5,2013-01-14,2013-01-14,2,1,1,0,0,2,3,0,0,2,0,0,0,0,2,Protalix Biotherapeutics,": A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease Treated wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005825-12,1,1,0 2008-005825-12,5,2013-01-14,2013-01-14,2,1,1,0,0,2,3,0,0,2,0,0,0,0,2,PROTALIX BIOTHERAPEUTICS,": A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients with Gaucher Disease Treated wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005825-12,1,1,0 2008-005826-35,4,2013-02-14,2013-05-17,2,1,1,0,0,2,3,0,0,2,0,0,0,0,2,Protalix Biotherapeutics,"A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005826-35,1,1,0 2008-005826-35,4,2013-02-14,2013-05-17,2,1,1,0,0,2,3,0,0,2,0,0,0,0,2,PROTALIX BIOTHERAPEUTICS,"A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005826-35,1,1,0 2008-005828-84,1,2012-07-17,2012-07-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"ENT Hospital, Johannes-Gutenberg University, Mainz",Inflammatory mediators in nasal discharge of chronic rhinosinusitis patients treated with erythromycin.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005828-84,0,0,0 2008-005829-11,1,,,0,0,0,0,1,0,2,0,1,0,0,0,0,0,0,FUNDACION CV INVESTIGACION HOSPITAL DR PESET,Mifepristona en la prevención del síndrome de hiperestimulación ovárica en tratamientos de reproducción asistida,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005829-11,0,0,0 2008-005830-63,2,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,"Astellas Pharma Global Development, Inc. (APGD)","A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects with Moderate to Severe Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005830-63,0,0,0 2008-005831-13,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,NERVIANO MEDICAL SCIENCES,Phase II study of PHA-848125AC as second line-treatment in pemetrexed pre-treated malignant pleural mesothelioma patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005831-13,0,0,0 2008-005832-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,the role of antifungal prophylaxis with oral nystatin in critically ill patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005832-34,0,0,0 2008-005835-14,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,MIPHARM,"Efficacy and tolerability of a new topical formulation of Acyclovir gel (Acyclorir Liquipatch) given 3 times/day in the treatment of herpes simplex labialis. An open-label, blind controlled, randomise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005835-14,0,0,0 2008-005841-50,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Leids Universitair Medisch Centrum,Adjuvant zoledronic acid in ‘high risk’ Giant Cell Tumour of bone (GCT) - A randomized phase II study -,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005841-50,0,0,0 2008-005843-40,11,2014-10-27,2014-10-27,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,TopoTarget A/S,"A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005843-40,0,0,0 2008-005843-40,11,2014-10-27,2014-10-27,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Topotarget A/S,"A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005843-40,0,0,0 2008-005843-40,11,2014-10-27,2014-10-27,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,SPECTRUM Pharmaceuticals Inc.,"A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005843-40,0,0,0 2008-005843-40,11,2014-10-27,2014-10-27,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Spectrum Pharmaceuticals Inc.,"A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005843-40,0,0,0 2008-005843-40,11,2014-10-27,2014-10-27,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,TOPOTARGET A/S,"A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005843-40,0,0,0 2008-005843-40,11,2014-10-27,2014-10-27,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Spectrum Pharmaceuticals, Inc.","A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005843-40,0,0,0 2008-005848-16,4,2012-05-31,2012-05-31,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Daiichi Sankyo Development Ltd,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE 2 STUDY OF CS 7017 IN COLORECTAL CANCER PATIENTS WHO HAVE ACHIEVED DISEASE CONTROL FOLLOWING FIRST-LINE CHEMOTHERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005848-16,0,0,0 2008-005848-16,4,2012-05-31,2012-05-31,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,DAIICHI SANKIO DEVELOPMENT LIMITED,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED PHASE 2 STUDY OF CS 7017 IN COLORECTAL CANCER PATIENTS WHO HAVE ACHIEVED DISEASE CONTROL FOLLOWING FIRST-LINE CHEMOTHERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005848-16,0,0,0 2008-005855-61,2,2012-09-10,2012-09-10,1,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Boehringer Ingelheim (Pty) Ltd,"An open-label, multiple dose, cross-over study to evaluate the steady-state pharmacokinetic parameters of nevirapine extended release tablets in HIV-1 infected children, with an optional extension pha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005855-61,1,1,0 2008-005855-61,2,2012-09-10,2012-09-10,1,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An open-label, multiple dose, cross-over study to evaluate the steady-state pharmacokinetic parameters of nevirapine extended release tablets in HIV-1 infected children, with an optional extension pha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005855-61,1,1,0 2008-005859-16,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,StiL Forschungs-GmbH,Prospective randomized Multicenter study in first-line treatment of Advanced progredIeNT follicular And other IndoleNt and mantle cell lymphomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005859-16,0,0,0 2008-005861-80,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SCIOTEC DIAGNOSTIC TECHNOLOGIES GMBH,Efficacy of Fructose metabolizing enzymatic product Fructosin(R) with Fructose malabsorption ( Wirkamkeit des Fruktose-abbauenden Enzympräparates Fructosin® bei Fruktose-Malabsorption),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005861-80,0,0,0 2008-005862-30,1,2015-12-07,2015-12-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Hochschule Hannover,Pre-emptive therapy of acute graft versus host disease according to specific proteomic patterns after allogeneic hematopoietic stem cell transplantation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005862-30,0,0,0 2008-005863-32,1,2012-05-05,2012-05-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Department of Oncology,A Phase II Study of Neo-Adjuvant Statin Therapy in Postmenopausal Primary Breast Cancer - a Window-of Opportunity Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005863-32,0,0,0 2008-005865-67,3,2012-12-31,2012-12-31,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Topotarget A/S,An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005865-67,0,0,0 2008-005865-67,3,2012-12-31,2012-12-31,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,TopoTarget A/S,An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005865-67,0,0,0 2008-005867-33,3,2013-07-24,2013-07-24,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Prospective non-randomized (pharmacoepidemiologic) cohort study (open-label, multicenter) to assess the magnitude of potential risk with the administration of Primovist/Eovist in patients with moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005867-33,0,0,0 2008-005870-11,6,2012-04-04,2013-04-04,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Phase II multi-center, non-randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005870-11,0,0,0 2008-005870-11,6,2012-04-04,2013-04-04,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A Phase II multi-center, non-randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005870-11,0,0,0 2008-005870-11,6,2012-04-04,2013-04-04,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A Phase II multi-center, non-randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005870-11,0,0,0 2008-005871-92,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Sahlgrenska University Hospital,"En fas 1 studie av effekt av Tysabri (natalizumab), en IgG4 humaniserad monoklonal antikropp specifik mot VLA-4 (integrin alfa-4), administrerad som infusion 1 gång/månad under 3 månader hos patiente...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005871-92,0,0,0 2008-005872-29,11,2013-01-10,2013-01-25,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Eisai Limited,"A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005872-29,0,0,0 2008-005874-11,1,2012-10-18,2012-10-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratoires Merck Sharp & Dhome-Chibret,"A Substudy to Explore Biomarkers of Physical Function in the Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005874-11,0,0,0 2008-005876-28,8,2010-02-02,2010-02-04,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled study to evaluate canakinumab (ACZ885) for prophylaxis of signs and symptoms of acute flares in chronic gout patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005876-28,0,0,0 2008-005876-28,8,2010-02-02,2010-02-04,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled study to evaluate canakinumab (ACZ885) for prophylaxis of signs and symptoms of acute flares in chronic gout patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005876-28,0,0,0 2008-005885-30,3,2010-10-08,2011-01-31,3,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Pfizer Limited,"A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, SAFETY AND EFFICACY STUDY OF SITAXSENTAN SODIUM IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005885-30,0,0,0 2008-005885-30,3,2010-10-08,2011-01-31,3,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Pfizer Ltd,"A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, SAFETY AND EFFICACY STUDY OF SITAXSENTAN SODIUM IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005885-30,0,0,0 2008-005885-30,3,2010-10-08,2011-01-31,3,1,0,0,0,1,3,0,0,1,1,1,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, SAFETY AND EFFICACY STUDY OF SITAXSENTAN SODIUM IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005885-30,0,0,0 2008-005886-78,3,2010-12-08,2010-12-08,3,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Pfizer Ltd.,"A PHASE 3, MULTI-CENTER, OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF MONOTHERAPY SITAXSENTAN SODIUM AND COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PUL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005886-78,0,0,0 2008-005886-78,3,2010-12-08,2010-12-08,3,1,0,0,0,1,3,0,0,1,1,1,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, MULTI-CENTER, OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF MONOTHERAPY SITAXSENTAN SODIUM AND COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PUL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005886-78,0,0,0 2008-005886-78,3,2010-12-08,2010-12-08,3,1,0,0,0,1,3,0,0,1,1,1,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent UK","A PHASE 3, MULTI-CENTER, OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF MONOTHERAPY SITAXSENTAN SODIUM AND COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WITH PUL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005886-78,0,0,0 2008-005887-14,3,2010-12-08,2011-01-31,3,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Pfizer Ltd.,"A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005887-14,0,0,0 2008-005887-14,3,2010-12-08,2011-01-31,3,1,0,0,0,1,3,0,0,1,1,1,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent, UK","A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS WIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005887-14,0,0,0 2008-005889-32,8,2011-04-28,2011-04-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"RANDOMIZED DOUBLE-BLIND, 12-MONTH STUDY OF PREGABALINA IN SUBJECTS WITH RESTLESS LEGS SYNDROME. Estudio randomizado, doble ciego, de 12 meses de duración con pregabalina en pacientes con síndrome de p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005889-32,0,0,0 2008-005889-32,8,2011-04-28,2011-04-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","RANDOMIZED DOUBLE-BLIND, 12-MONTH STUDY OF PREGABALINA IN SUBJECTS WITH RESTLESS LEGS SYNDROME. Estudio randomizado, doble ciego, de 12 meses de duración con pregabalina en pacientes con síndrome de p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005889-32,0,0,0 2008-005890-37,1,2009-04-15,2009-04-15,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Moberg Derma AB,"Assessment of the effects on barrier impairment, clinical features and bacterial colonization of topical formulations in patients with atopic eczema; a phase IIa, single-center, randomized, observer-b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005890-37,0,0,0 2008-005891-28,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,Perspective evaluation on the role practiced by three different contraceptive hormonal on l I risk cardiovascular in young women: impact on the sensibility' insulinica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005891-28,0,0,0 2008-005892-83,1,2015-08-21,2015-08-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Epsom and St Helier University Hospitals NHS Trust,"Does metformin improve pregnancy outcomes [ incidence of LGA (≥90% birth weight centile) babies onset of maternal Gestational Diabetes, hypertension, PET, shoulder dystocia, admission to SCBU) in obes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005892-83,0,0,0 2008-005894-36,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,2,ZonMw,"A Phase 2B, Multi-Center, Randomized, Double-Blinded, Parallel-Arm Study to Assess Efficacy and Safety of 3’-aminomethylnicotine-P. aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX®) or placebo, co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005894-36,0,0,0 2008-005894-36,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,2,nabi biopharmaceuticals,"A Phase 2B, Multi-Center, Randomized, Double-Blinded, Parallel-Arm Study to Assess Efficacy and Safety of 3’-aminomethylnicotine-P. aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX®) or placebo, co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005894-36,0,0,0 2008-005903-25,2,2011-03-09,2011-03-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,4SC AG,"Exploratory, open-label study to demonstrate efficacy, safety and tolerability of SC12267 (35 mg) in patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005903-25,0,0,0 2008-005904-13,1,2009-09-06,2009-09-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Can-Fite BioPharma, Ltd.","A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients with Moderate-to-Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005904-13,0,0,0 2008-005905-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Nîmes,"Cinétique du taux de protéasome circulant au cours du traitement par inhibiteur du protéasome (bortézomib, Velcade®) au cours du myélome multiple",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005905-21,0,0,0 2008-005906-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Toulouse,Détermination de biomarqueurs associés à la réponse au Natalizumab dans la Sclérose en plaques,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005906-38,0,0,0 2008-005909-19,1,2011-10-11,2011-10-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The University of Dundee,Does extra fine HFA-BDP suppress small airways inflammation in COPD?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005909-19,0,0,0 2008-005910-37,1,2009-09-03,2009-09-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Memory Pharmaceuticals Corp,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of MEM 1414 (600 mg) on the Allergen-Induced Late Asthmatic Response in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005910-37,0,0,0 2008-005912-41,1,2012-10-23,2012-10-23,1,0,0,0,0,0,4,0,0,1,1,1,1,0,1,Belpharma SA/NV,Temocillin use in Complicated Urinary Tract Infections due to ESBL producing and AmpC hyperproducing Enterobacteriaceae in United Kingdom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005912-41,0,0,0 2008-005924-97,1,2009-11-19,2009-11-19,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Imperial College,"A 12 week observational study to evaluate the effects of the initiation of chemotherapy with anti-angiogenic activity on neovascularisation (as determined by contrast enhanced ultrasound, (CEUS)) with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005924-97,0,0,0 2008-005925-12,1,2020-07-23,2020-07-23,1,0,0,0,0,1,4,0,0,1,1,1,1,0,0,Medizinische Hochschule Hannover,Polyomavirus BK nephropathy after renal transplantation: Randomized clinical trial to demonstrate that switching to mTOR inhibitor is more effective than a reduction of immunosuppressive therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005925-12,0,0,0 2008-005929-11,3,2010-06-07,2010-06-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized Double-Blind Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Mild to Moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005929-11,0,0,0 2008-005934-59,1,2015-02-06,2015-02-06,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Kaija Puhakka,Pharmacokinetics of dexmedetomidine in paediatric intensive care patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005934-59,0,0,0 2008-005935-14,1,2010-09-20,2010-09-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,An Open-Label Study to Evaluate the Long-term Safety of Subcutaneous MOA-728 for Treatment of Opioid-Induced Constipation in Subjects With Nonmalignant Pain Estudio abierto para evaluar la seguridad a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005935-14,0,0,0 2008-005939-15,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"J. Uriach y Compañía, S.A.","Efficacy and safety of rupatadine in persistent allergic rhinitis and health-related quality of life in children age 6-11 years: A randomized, double blind, placebo-controlled clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005939-15,0,0,0 2008-005942-22,5,2012-08-29,2012-08-29,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck & Co.,A Randomized Discontinuation Phase II Trial of Deforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005942-22,0,0,0 2008-005942-22,5,2012-08-29,2012-08-29,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck & Co. Inc.,A Randomized Discontinuation Phase II Trial of Deforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005942-22,0,0,0 2008-005942-22,5,2012-08-29,2012-08-29,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc",A Randomized Discontinuation Phase II Trial of Deforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005942-22,0,0,0 2008-005942-22,5,2012-08-29,2012-08-29,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"MERCK & CO., INC.",A Randomized Discontinuation Phase II Trial of Deforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005942-22,0,0,0 2008-005945-46,7,2016-06-20,2016-06-30,5,1,1,0,0,2,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Safety and Efficacy of N8 in Prevention and On-demand Treatment of Bleeding Episodes in Subjects with Haemophilia A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005945-46,0,0,0 2008-005945-46,7,2016-06-20,2016-06-30,5,1,1,0,0,2,3,0,0,1,0,0,1,0,1,NOVO NORDISK,Safety and Efficacy of N8 in Prevention and On-demand Treatment of Bleeding Episodes in Subjects with Haemophilia A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005945-46,0,0,0 2008-005951-84,1,2011-09-30,2011-09-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, KIM III, Abteilung für Nephrologie",Treat-to-target trial of basal insulin in Post-Transplant Hyperglycemia (TIP): Efficacy and safety of a novel protocol in renal transplant recipients receiving a tacrolimus-based immunosupprerssion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005951-84,0,0,0 2008-005955-40,1,2012-04-26,2012-04-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Edinburgh,Induction of Heme Oxygenase-1: a therapeutic approach to reduce hepatic ischaemia-reperfusion injury in liver surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005955-40,0,0,0 2008-005955-40,1,2012-04-26,2012-04-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,NHS Lothian,Induction of Heme Oxygenase-1: a therapeutic approach to reduce hepatic ischaemia-reperfusion injury in liver surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005955-40,0,0,0 2008-005959-19,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Fédération Francophone de Cancérologie Digestive,Etude de phase II non contrôlée: traitement de première ligne par sunitinib plus folfiri pour les patients ayant un cancer du rectum avec des métastases synchrones résécables (SUREMETS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005959-19,0,0,0 2008-005960-14,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Departamento de Microbiología. Hospital Clinico San Carlos,"Estudio piloto comparativo post-autorización de efectividad y seguridad, entre vancomicina y daptomicina, en las bacteriemias por Staphylococcus sp oxacilin-resistentes de los pacientes hematológicos.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005960-14,0,0,0 2008-005961-77,1,2009-06-01,2009-06-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation Estudio multicéntrico, aleatorizado, en doble...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005961-77,0,0,0 2008-005964-15,5,2015-12-17,2015-12-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ImClone LLC,"""Estudio de fase 3, aleatorizado y doble ciego de IMC-1121B y el mejor tratamiento complementario (MTC) en comparación con placebo y MTC en el tratamiento del adenocarcinoma metastásico gástrico o de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005964-15,0,0,0 2008-005964-15,5,2015-12-17,2015-12-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,IMCLONE LLC,"""Estudio de fase 3, aleatorizado y doble ciego de IMC-1121B y el mejor tratamiento complementario (MTC) en comparación con placebo y MTC en el tratamiento del adenocarcinoma metastásico gástrico o de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005964-15,0,0,0 2008-005965-69,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Departamento de Microbiología. Hospital Clinico San Carlos,"Estudio piloto comparativo post-autorización de efectividad y seguridad, entre vancomicina y daptomicina, en las bacteriemias por Staphylococcus sp oxacilin-resistentes de los pacientes sometidos a he...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005965-69,0,0,0 2008-005967-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI,randomized phase II trial of two different sequences in first line chemotherapy of advanced non small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005967-33,0,0,0 2008-005969-55,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA CARDARELLI,Effetto dell`associazione tra un inibitore delle colinesterasi ed il precursore colinergico colina alfoscerato sui sintomi cognitivi e non della malattia di Alzheimer con danno vascolare associato,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005969-55,0,0,0 2008-005972-29,10,2010-03-06,2011-02-24,9,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in combination with Standard Treatment in Secondary Prevention of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005972-29,0,0,0 2008-005976-28,1,2015-10-26,2015-10-26,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Hannover Medical School,Prevention of HBV reinfection after liver transplantation using entecavir monotherapy after short-term HBIg administration: A pilot study Version 1.2 2008-09-11 Amendment 2 2009-07-07,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005976-28,0,0,0 2008-005977-37,1,2010-04-30,2010-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Portola Pharmaceuticals Inc.,"A PHASE 2, RANDOMIZED, PARALLEL GROUP, DOSE-FINDING, MULTICENTER, MULTINATIONAL STUDY OF THE SAFETY, TOLERABILITY AND PILOT EFFICACY OF THREE BLINDED DOSES OF THE ORAL FACTOR Xa INHIBITOR BETRIXABAN C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005977-37,0,0,0 2008-005978-13,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,CHU d'Angers,Analgésie péri-opératoire par cathéter fémoral pour fracture du col du fémur - Etude KTcol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005978-13,0,0,0 2008-005979-97,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Toulouse,EFFICACITE DU TRAITEMENT PAR POMPE A INSULINE EXTERNE CHEZ LE DIABETIQUE DE TYPE 2 : ETUDE RANDOMISEE EN PARALLELE SUR 1 AN VERSUS MULTI-INJECTIONS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005979-97,0,0,0 2008-005985-30,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Department of Pharmacology-Toxicology,Is augmentation of PORH by rosuvastatin adenosine-receptor mediated?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005985-30,0,0,0 2008-005987-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AMC Amsterdam,Preventing preterm birth: Costs and effects of screening of healthy women with a singleton pregnancy for a short cervical length.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005987-15,0,0,0 2008-005988-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Nantes,Comparaison du test au monoxyde d'azote aux épreuves pharmacologiques vasodiliatatrices et inotropes dans l'évaluation de la réversibilité de l'hypertension artérielle pulmonaire post-capillaire chez ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005988-33,0,0,0 2008-005989-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude multicentrique, randomisée en double-insu, contrôlée contre placebo évaluant les effets de la terlipressine chez les malades atteints de cirrhose avec une ascite récidivante traitée par paracent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005989-31,0,0,0 2008-005991-28,4,2016-02-03,2016-02-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women with Low Bone Mineral Density",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005991-28,0,0,0 2008-005992-81,1,2012-03-23,2012-03-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. F. Köhler Chemie GmbH,A Prospective Randomized Double Blind Multicenter Phase III Study Comparing two Methods of Cardioplegia in Coronary Artery Bypass Surgery Custodiol-N versus Custodiol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005992-81,0,0,0 2008-005993-12,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,Solvay Pharmaceutical GmbH,"A three month double-blind, randomized, placebo-controlled, parallel group, multi-center study with Creon® 25.000 MMS? in subjects after an attack of acute pancreatitis suffering from pancreatic exocr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005993-12,0,0,0 2008-005994-36,10,2016-03-10,2017-01-16,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,DR. FALK PHARMA GMBH,"Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with 9 mg budesonide vs. 3 g mesalazine vs. placebo in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005994-36,0,0,0 2008-005994-36,10,2016-03-10,2017-01-16,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, double-dummy, randomised, placebo-controlled, multi-centre phase III study on the efficacy and tolerability of a 8-week treatment with 9 mg budesonide vs. 3 g mesalazine vs. placebo in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005994-36,0,0,0 2008-005999-28,1,,,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,Groupe Francophone des Myélodysplasies (GFM),PHASE I-II TRIAL OF ERLOTINIB IN HIGHER RISK MYELODYSPLASTIC SYNDROME,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-005999-28,0,0,0 2008-006000-30,1,2014-10-06,2014-10-06,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Riika Merivirta,”Postoperative pain treatment with fentanyl patch after forefoot surgery/ Jalkateräleikkauksen jälkeinen kivunhoito kipulaastarilla”.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006000-30,0,0,0 2008-006001-16,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA UNITA` SANITARIA LOCALE LECCE,Efficacy of TachoSil on air leakage in chest surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006001-16,0,0,0 2008-006004-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ACE ApS,"Efficacy and tolerability of captopril ointment 0,1%, 0,3% and 1,0% in psoriasis vulgaris. A randomised, double-blind, placebocontrolled, doseescalating, intra-individual clinical study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006004-36,0,0,0 2008-006007-23,1,2019-01-08,2019-01-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,A clinicopathological phase II study of axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006007-23,0,0,0 2008-006009-18,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Tibotec Pharmaceuticals,"An open-label, Proof-of-Concept trial in treatment-naïve HIV-1- infected subjects to evaluate the antiviral activity of a single intramuscular dosing of TMC278LA as monotherapy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006009-18,0,0,0 2008-006012-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SAKK (Swiss Group for Clinical Cancer Research),"Neoadjuvant radiotherapy and capecitabine with or without panitumumab in patients with advanced, K-ras unmutated rectal cancer. A randomized multicenter phase II trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006012-38,0,0,0 2008-006013-24,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Oxagen Ltd.,"Dose Finding Study in Patients with Mild to Moderate Persistent Asthma: A Parallel Group, Randomised, Placebo Controlled, Double Blind Assessment of Oral OC000459 Dosed at Three Dose Schedules for Twe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006013-24,0,0,0 2008-006014-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CONSORZIO MARIO NEGRI SUD,Effects of the dose of erythropoiesis stimulating agents on cardiac-cerebrovascular outcomes and quality of life in hemodialysis patients. The DOSe of Erythropoietins (DOSE) trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006014-20,0,0,0 2008-006018-97,1,2009-12-26,2009-12-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merck & Co., Inc.","A Phase IIb, Multicenter, Randomized, Double-Blind Placebo-Controlled, 2-period adaptive Crossover Polysomnography Study to Evaluate the Safety and Efficacy of MK-4305 in Patients With Primary Insomni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006018-97,0,0,0 2008-006020-53,3,2010-10-14,2010-10-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme Europe B.V.,"A Prospective Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006020-53,0,0,0 2008-006021-14,9,2012-12-31,2018-05-23,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Bayer HealthCare AG, 51368 Leverkusen, Germany","A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006021-14,0,0,0 2008-006021-14,9,2012-12-31,2018-05-23,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Bayer AG, D-51368 Leverkusen, Germany","A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006021-14,0,0,0 2008-006021-14,9,2012-12-31,2018-05-23,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Bayer AG,"A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006021-14,0,0,0 2008-006021-14,9,2012-12-31,2018-05-23,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006021-14,0,0,0 2008-006022-34,1,2008-12-19,2008-12-19,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Bayer HealthCare AG,Randomized phase II study of sorafenib plus bicaluamide vs. placebo plus bicalutamide in castration-resistant asymptomatic or mildly symptomatic metastatic prostate cancer patients who had orchiectomy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006022-34,0,0,0 2008-006027-31,4,2010-01-28,2010-01-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Alcon Research Ltd,A Multi-Center Double-Masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN in Patients with Open-Angle Glaucoma or Ocular Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006027-31,0,0,0 2008-006027-31,4,2010-01-28,2010-01-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.",A Multi-Center Double-Masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN in Patients with Open-Angle Glaucoma or Ocular Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006027-31,0,0,0 2008-006032-36,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,Groupe Francophone des Myélodysplasies (GFM),A phase ii study of the efficacy and safety of lenalidomide combined to escalating doses of chemotherapy in intermediate-2-or high risk MDS and AML with del 5 q31,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006032-36,0,0,0 2008-006034-10,5,2015-05-14,2015-05-14,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,"Seattle Genetics, Inc.",A pivotal study of SGN-35 in treatment of patients with relapsed or refractory Hodgkin Lymphoma (HL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006034-10,0,0,0 2008-006034-10,5,2015-05-14,2015-05-14,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,SEATTLE GENETICS INC.,A pivotal study of SGN-35 in treatment of patients with relapsed or refractory Hodgkin Lymphoma (HL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006034-10,0,0,0 2008-006035-12,5,2010-05-31,2016-06-06,4,1,1,0,0,1,2,0,0,1,0,0,1,0,1,"Seattle Genetics, Inc.",A Phase 2 study of SGN-35 in treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006035-12,0,0,0 2008-006035-12,5,2010-05-31,2016-06-06,4,1,1,0,0,1,2,0,0,1,0,0,1,0,1,SEATTLE GENETICS INC.,A Phase 2 study of SGN-35 in treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006035-12,0,0,0 2008-006045-10,1,2014-07-02,2014-07-02,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Rennes,Effet de la stimulation dopaminergique continue par pompe à apomorphine sur les fluctuations cognitives et psychiques des patients parkinsoniens: étude clinique et métabolique cérébrale par TEP au 18F...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006045-10,0,0,0 2008-006049-26,6,2013-01-29,2013-07-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","""ESTUDIO DE CONTINUACIÓN ABIERTO, DE FASE 2B/3, PARA LOS SUJETOS QUE SE RETIREN DE LOS PROTOCOLOS UK 453,061 PARA EL TRATAMIENTO DE LA INFECCIÓN POR EL VIH 1"" ""A PHASE 2B/3 OPEN-LABEL ROLLOVER STUDY F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006049-26,0,0,0 2008-006049-26,6,2013-01-29,2013-07-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","""ESTUDIO DE CONTINUACIÓN ABIERTO, DE FASE 2B/3, PARA LOS SUJETOS QUE SE RETIREN DE LOS PROTOCOLOS UK 453,061 PARA EL TRATAMIENTO DE LA INFECCIÓN POR EL VIH 1"" ""A PHASE 2B/3 OPEN-LABEL ROLLOVER STUDY F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006049-26,0,0,0 2008-006049-26,6,2013-01-29,2013-07-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,PFIZER,"""ESTUDIO DE CONTINUACIÓN ABIERTO, DE FASE 2B/3, PARA LOS SUJETOS QUE SE RETIREN DE LOS PROTOCOLOS UK 453,061 PARA EL TRATAMIENTO DE LA INFECCIÓN POR EL VIH 1"" ""A PHASE 2B/3 OPEN-LABEL ROLLOVER STUDY F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006049-26,0,0,0 2008-006051-40,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SENESE,"A PHASE II STUDY: UNOPERABLE NON NON SQUAMOUS NON SMALL CELL LUNG CANCER METRONOMIC BIOCHEMOTHERAPY WITH WEEKLY CISPLATIN, DAILY ORAL ETOPOSIDE AND BEVACIZUMAB (mPEBev regimen)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006051-40,0,0,0 2008-006053-41,1,,,0,1,0,0,0,0,4,0,1,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"Estrogeni, fitoestrogeni o agopuntura nella terapia dei sintomi della menopausa fisiologica (versione del 18/9/2008 modificata in data 25/2/2009 in seguito ai chiarimenti richiesti dal CE Coordinatore...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006053-41,0,0,0 2008-006054-17,6,2011-05-31,2011-06-30,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006054-17,0,0,0 2008-006054-17,6,2011-05-31,2011-06-30,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Actelion Pharamceuticals Ltd,"A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006054-17,0,0,0 2008-006055-52,1,2014-11-04,2014-11-04,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,Charité - University Hospital of Berlin,Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006055-52,0,0,0 2008-006061-86,1,2011-01-18,2011-01-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Cassella-med,"Multizentrischer, randomisierter, doppelblinder, Placebo-kontrollierter Parallelgruppenvergleich zum Nachweis der Wirksamkeit und Unbedenklichkeit von Cineol im Rahmen der Therapie bei Patienten mit a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006061-86,0,0,0 2008-006064-11,2,2013-02-08,2013-02-08,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Centocor B.V.,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Rheumatoid Arthritis Despite Metho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006064-11,0,0,0 2008-006064-11,2,2013-02-08,2013-02-08,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Biologics B.V.,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Rheumatoid Arthritis Despite Metho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006064-11,0,0,0 2008-006065-87,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Fundació Lluita contra la SIDA,EFFICACY OF TREATMENT INTENSIFICATION WITH MARAVIROC ON HIV-1 VIRAL LATENCY IN RECENTLY INFECTED HIV-1 NAÏVE PATIENTS STARTING RALTEGRAVIR PLUS TENOFOVIR/EMTRICITABINE. (EFICACIA DE LA INTENSIFICACIÓN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006065-87,0,0,0 2008-006068-12,2,2011-07-13,2011-07-13,2,1,0,0,0,2,2,0,0,1,1,0,1,0,1,ASTRAZENECA,"A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 plus Carboplatin and Paclitaxel or Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006068-12,0,0,0 2008-006068-12,2,2011-07-13,2011-07-13,2,1,0,0,0,2,2,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 plus Carboplatin and Paclitaxel or Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006068-12,0,0,0 2008-006072-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Saint-Etienne,Mycophénolate sodic in graded increased doses in the first 3 months of renal transplantation _ Pharmacokinetic descriptive Pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006072-30,0,0,0 2008-006075-75,4,2009-12-11,2009-12-11,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Asahi Kasei Pharma Corporation,"A Phase IIa, Multi-Centre, Randomized, Double-Blind, Two-Part, Controlled, Repeated-Dose Study of AK106-001616 in Patients with Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006075-75,0,0,0 2008-006076-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASL 2 SAVONESE,"Multicenter, randomised, open-label, parallel group, controlled study to evaluate the efficacy, tollerability and safety of BioFOAM dressing containing larve of Lucilia sericata in patients with chron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006076-30,0,0,0 2008-006080-36,1,2015-05-01,2015-05-01,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Portsmouth Hospitals NHS Trust,Analgesic efficacy of ultrasound guided transversus abdominis plane block as part of a multimodal analgesic regime for post elective caesarean section pain – a comparative double-blinded placebo contr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006080-36,0,0,0 2008-006081-29,1,2009-10-14,2009-10-14,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,UZLeuven,INFLUENCE OF RIMONABANT ON LOWER ESOPHAGEAL FUNCTION IN HEALTHY VOLUNTEERS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006081-29,0,0,0 2008-006082-88,1,2009-06-23,2009-06-23,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,UZLeuven,INFLUENCE OF RIMONABANT ON GASTRIC SENSITIVITY AND ON THE GASTRIC RESPONSE TO A MEAL IN HEALTHY VOLUNTEERS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006082-88,0,0,0 2008-006083-11,2,2014-07-18,2014-07-18,2,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"An open multicentre, multicountry study to evaluate long-term antibody persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccinate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006083-11,0,0,0 2008-006095-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Lluis Mont-Girbau,Estudio de Ablación vs fármacos Antiarrítmicos en Fibrilacion Auricular Persistente (SARA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006095-30,0,0,0 2008-006097-15,5,2010-08-16,2010-08-16,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A double-blind, randomized, placebo- controlled multi-center trial to compare the phosphate lowering efficacy of different doses of SBR759 to placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006097-15,0,0,0 2008-006097-15,5,2010-08-16,2010-08-16,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A double-blind, randomized, placebo- controlled multi-center trial to compare the phosphate lowering efficacy of different doses of SBR759 to placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006097-15,0,0,0 2008-006124-64,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase IIIb, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ dTpa-IPV vaccine (Boostrix Polio) compared with Sano...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006124-64,0,0,0 2008-006128-79,1,2020-06-09,2020-06-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH,Phase II Study of Oxaliplatin / Irinotecan / Bevacizumab Followed by Docetaxel / Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006128-79,0,0,0 2008-006130-95,8,2013-10-08,2013-10-08,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017, USA","A THREE YEAR, PROSPECTIVE, OPEN-LABEL, STUDY TO EVALUATE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006130-95,1,1,0 2008-006130-95,8,2013-10-08,2013-10-08,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Pfizer Inc,"A THREE YEAR, PROSPECTIVE, OPEN-LABEL, STUDY TO EVALUATE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006130-95,1,1,0 2008-006130-95,8,2013-10-08,2013-10-08,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,PFIZER,"A THREE YEAR, PROSPECTIVE, OPEN-LABEL, STUDY TO EVALUATE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006130-95,1,1,0 2008-006135-12,1,2011-06-16,2011-06-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Charité- University Medicine Berlin,Balanced crystalloids versus balanced colloids within a goal-directed hemodynamic protocol in patients undergoing gynaecological tumor resection. Balancierte Kristalloide versus balancierte Kolloide ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006135-12,0,0,0 2008-006140-20,1,2014-08-08,2014-08-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BioVex Inc,A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEX GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients with Unresectable Stage III...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006140-20,0,0,0 2008-006141-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMCG,Arthrocentesis as initial treatment of arthropathy of the temporomandibular joint,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006141-12,0,0,0 2008-006143-40,1,2011-03-14,2011-03-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik Innere Medizin I",Assessment of platelet function in patients with chronic autoimmune thrombocytopenic purpura (cAITP) treated with the thrombopoietin receptor (MPL) agonist Eltrombopag,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006143-40,0,0,0 2008-006144-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Complejo Hospitalario Universitario de Albacete. Director Gerente Dr Jesús Martino Sánchez Martínez,Ensayo clínico aleatorizado doble ciego frente a placebo para evaluación del tratamiento con colistina inhalada en EPOC y/o bronquiectasias no fibrosis quística con infección bronquial crónica por Pse...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006144-18,0,0,0 2008-006145-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASONMEC (Asociación de Oncología Medica del Hospital de Cruces),"Estudio fase II, abierto, no aleatorizado, de bevacizumab, cisplatino y pemetrexed como primera línea de tratamiento de pacientes con cáncer de pulmón no microcítico (CPNM) y no epidermoide, en estadi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006145-13,0,0,0 2008-006146-26,12,2015-09-09,2015-09-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006146-26,0,0,0 2008-006146-26,12,2015-09-09,2015-09-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F.Hoffman-La Roche Ltd,"A randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006146-26,0,0,0 2008-006148-20,1,2009-04-11,2009-04-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GALENpharma GmbH,"A vehicle-controlled, investigator-blinded intraindividual comparison to evaluate the safety, tolerability and efficacy of Momegalen rich cream and ointment in patients with hand and foot eczema and m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006148-20,0,0,0 2008-006151-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Beaumont Hospital,A comparison of oral flucloxacillin alone with combined oral phenoxymethylpenicillin and flucloxacillin for the treatment of uncomplicated skin and soft tissue infections,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006151-42,0,0,0 2008-006153-41,1,2011-11-30,2011-11-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical university Graz, Department of Plastic Surgery",Target site pharmacokinetics of linezolid after repetitive doses in diabetic patients with bacterial foot infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006153-41,0,0,0 2008-006154-17,5,2012-05-03,2012-05-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Amgen Inc,"An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006154-17,0,0,0 2008-006156-22,2,2011-08-16,2011-08-16,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A single-blind, multiple dose, placebo-controlled, double dummy study to investigate the pharmacodynamic and pharmacokinetic interaction between aliskiren and furosemide in patients with heart failure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006156-22,0,0,0 2008-006158-16,6,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Radboud university medical center,Investigación sobre la concentración de medicamentos Anti-VIH en la sangre de mujeres embarazadas infectadas por el VIH (Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006158-16,0,0,0 2008-006158-16,6,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Radboud University Nijmegen Medical Centre,Investigación sobre la concentración de medicamentos Anti-VIH en la sangre de mujeres embarazadas infectadas por el VIH (Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006158-16,0,0,0 2008-006159-39,4,2010-05-10,2010-06-22,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Newron Pharmaceuticals S.p.A.,"A MULTICENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, EXTENSION STUDY TO ASSESS LONG-TERM SAFETY AND EFFICACY OF TWO FIXED DOSES OF RALFINAMIDE (160 OR 320 MG/DAY) IN PATIENTS WITH CHRONIC NEUR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006159-39,0,0,0 2008-006159-39,4,2010-05-10,2010-06-22,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,NEWRON PHARMACEUTICALS,"A MULTICENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, EXTENSION STUDY TO ASSESS LONG-TERM SAFETY AND EFFICACY OF TWO FIXED DOSES OF RALFINAMIDE (160 OR 320 MG/DAY) IN PATIENTS WITH CHRONIC NEUR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006159-39,0,0,0 2008-006161-84,1,2010-06-05,2010-06-05,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust,ARTiST - Aromasin Randomised Trial +/- Sutent as neoadjuvant Therapy for post-menopausal women with breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006161-84,0,0,0 2008-006168-12,1,2013-10-25,2013-10-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Odense University Hospital,Phase II trial with Cetuximab and Irinotecan (CetIri) for patients with platinum resistant esofagus- or gastric cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006168-12,0,0,0 2008-006173-33,5,2013-04-24,2013-04-24,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AIR LIQUIDE SANTE` INTERNATIONAL,An international Phase III randomised trial comparing in severe Exacerbations of Chronic obstructive pulmonary disease the efficacy of Helium/Oxygen versus Air/Oxygen administered during spontaneous b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006173-33,1,0,0 2008-006173-33,5,2013-04-24,2013-04-24,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Air Liquide Santé International,An international Phase III randomised trial comparing in severe Exacerbations of Chronic obstructive pulmonary disease the efficacy of Helium/Oxygen versus Air/Oxygen administered during spontaneous b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006173-33,1,0,0 2008-006173-33,5,2013-04-24,2013-04-24,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Air Liquide,An international Phase III randomised trial comparing in severe Exacerbations of Chronic obstructive pulmonary disease the efficacy of Helium/Oxygen versus Air/Oxygen administered during spontaneous b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006173-33,1,0,0 2008-006175-75,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Nantes,ETUDE DE PHASE II D’UN CONDITIONNEMENT SUB-MYELOABLATIF A TOXICITE REDUITE AVANT ALLOGREFFE DE CELLULES SOUCHES HEMATOPOÏETIQUES DANS LE TRAITEMENT DES HEMOPATHIES MALIGNES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006175-75,0,0,0 2008-006176-30,4,2010-03-11,2010-03-11,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Newron Pharmaceuticals S.p.A.,"EFFICACY AND SAFETY OF TWO FIXED DOSES (160 OR 320 MG/DAY) OF RALFINAMIDE IN PATIENTS WITH CHRONIC NEUROPATHIC LOW BACK PAIN. A MULTICENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED 12- WEEK STUDY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006176-30,0,0,0 2008-006176-30,4,2010-03-11,2010-03-11,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NEWRON PHARMACEUTICALS,"EFFICACY AND SAFETY OF TWO FIXED DOSES (160 OR 320 MG/DAY) OF RALFINAMIDE IN PATIENTS WITH CHRONIC NEUROPATHIC LOW BACK PAIN. A MULTICENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED 12- WEEK STUDY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006176-30,0,0,0 2008-006177-32,7,2011-03-02,2011-03-02,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Celgene Corporation,"A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, FIRST LINE MAINTENANCE STUDY OF LENALIDOMIDE (REVLIMID) IN PATIENTS WITH MANTLE-CELL LYMPHOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006177-32,0,0,0 2008-006180-36,2,2011-07-18,2011-07-18,1,1,0,0,0,0,3,0,0,1,1,0,1,0,0,EORTC - European Organisation for Research and Treatment of Cancer,Randomized Phase III trial on postoperative chemoradiation in combination with anti EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinomas (HNSCC) with high risk o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006180-36,0,0,0 2008-006181-28,6,2014-10-23,2014-12-09,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A single arm, multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006181-28,0,0,0 2008-006181-28,6,2014-10-23,2014-12-09,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Farmaceútica S.A.,"A single arm, multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006181-28,0,0,0 2008-006181-28,6,2014-10-23,2014-12-09,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A single arm, multicenter phase II trial of RAD001 as monotherapy in the treatment of advanced papillary renal cell cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006181-28,0,0,0 2008-006182-88,6,2016-11-07,2016-11-07,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006182-88,0,0,0 2008-006182-88,6,2016-11-07,2016-11-07,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006182-88,0,0,0 2008-006182-88,6,2016-11-07,2016-11-07,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006182-88,0,0,0 2008-006183-11,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II,"Multicenter, Open-Label, Single Arm Phase II Clinical Trial of Dasatinib in the Treatment of Systemic Mastocytosis (SM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006183-11,0,0,0 2008-006188-35,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SAN GERARDO DI MONZA,Immunological efficacy of efavirenz based treatment in HIV-positive naive patients (a pylot study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006188-35,0,0,0 2008-006191-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO DERMOPATICO IMMACOLATA,Biweekly Bevacizumab and weekly Carboplatin and Paclitaxel as II line therapy in advanced Malignant Melanoma patients: a phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006191-30,0,0,0 2008-006193-15,7,2011-01-04,2011-02-25,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"NPS Pharmaceuticals, Inc.",A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral Nutrition-Dependent Short Bowel Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006193-15,0,0,0 2008-006193-15,7,2011-01-04,2011-02-25,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NPS PHARMACEUTICALS,A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral Nutrition-Dependent Short Bowel Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006193-15,0,0,0 2008-006194-33,1,2009-12-16,2009-12-16,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,Revaccination with Pneumococcal Conjugate Vaccine - Characterization of the Immune Response after Polysaccharide (REPLAY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006194-33,0,0,0 2008-006208-52,1,2010-06-11,2010-06-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Helix BioPharma Cooperation,"Mono-centre, open-label study to investigate the multi-dose pharmacokinetics, efficacy and safety of Interferon alpha-2b Cream in women with a history of cytological diagnosed Pap IIID, with a confir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006208-52,0,0,0 2008-006209-17,4,2013-03-28,2013-12-09,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients with Pancreatic Cancer Studio di fase 1/fase 2 randomizzato per la valutazione di LY2603618 in c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006209-17,0,0,0 2008-006209-17,4,2013-03-28,2013-12-09,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ELI LILLY,A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients with Pancreatic Cancer Studio di fase 1/fase 2 randomizzato per la valutazione di LY2603618 in c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006209-17,0,0,0 2008-006210-14,2,2019-06-24,2019-06-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"Phase 2 Open-Label Single-Arm, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006210-14,0,0,0 2008-006211-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices civils de Lyon,Protection par la Ciclosporine A au cours de l’infarctus du myocarde thrombolysé : étude CICLADE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006211-21,0,0,0 2008-006212-38,2,2015-06-08,2015-06-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"Phase 2, Open-label Single-Arm, Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects with Advanced or Inoperable Hepatocellular Carcinoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006212-38,0,0,0 2008-006214-26,1,2011-04-04,2011-04-04,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Hoosier Oncology Group,"Phase II Trial of Neoadjuvent Cisplatin, Gemcitabine and Sunitinib Malate followed by radical cystectomy for transitional Cell Carcinoma (TCC) of the bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006214-26,0,0,0 2008-006215-20,4,2010-02-17,2010-05-26,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratoires MSD-Chibret,"A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Insulin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006215-20,0,0,0 2008-006215-20,4,2010-02-17,2010-05-26,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Insulin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006215-20,0,0,0 2008-006215-20,4,2010-02-17,2010-05-26,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MSD Finland Oy,"A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Insulin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006215-20,0,0,0 2008-006215-20,4,2010-02-17,2010-05-26,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of MK-0941 in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Insulin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006215-20,0,0,0 2008-006217-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,Utilizzo intraoperatorio del verde indocianina-pulsion quale test predittivo di insufficienza epatica dopo resezione epatica maggiore,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006217-25,0,0,0 2008-006221-14,1,2013-10-15,2013-10-15,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Company: Dr. Franz Köhler Chemie GmbH,"Wirksamkeit und Verträglichkeit von Physostigminsalicylat zur Behandlung des post-operativen Delirs nach Aorto-Koronarer-Bypass-Operation. Eine prospektive, doppelblinde, randomisierte, placebokontr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006221-14,0,0,0 2008-006224-61,1,,,0,0,0,0,0,1,4,0,0,1,1,1,0,1,0,Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,"Ensayo clínico multicéntrico, aleatorizado, controlado para evaluar la eficacia del tratamiento con carbonato de litio en pacientes con Esclerosis Lateral Amiotrófica",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006224-61,0,0,0 2008-006225-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ANRS,"Essai clinique multicentrique, randomisé et contrôlé comparant l’efficacité de la pioglitazone versus placebo chez les patients avec hépatite virale chronique C de génotype non-2, non-3, insulinorésis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006225-14,0,0,0 2008-006226-34,9,2015-05-13,2015-05-13,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et developpement,"A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006226-34,0,0,0 2008-006226-34,9,2015-05-13,2015-05-13,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Recherche & Dévelopment,"A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006226-34,0,0,0 2008-006226-34,9,2015-05-13,2015-05-13,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et development,"A multi-center, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006226-34,0,0,0 2008-006227-31,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Medical Faculty, Otto-von-Guericke-University Magdeburg",Inflammatory Topoproteome of Psoriasis under Etanercept Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006227-31,0,0,0 2008-006235-12,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,INTRATHECAL LEVOBUPIVACAINE USE IN CESAREAN SECTION : DETERMINATION OF �MINIMUM LOCAL ANESTHETIC DOSE (MLAD)�,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006235-12,0,0,0 2008-006237-27,2,2012-11-08,2012-11-08,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Torrent Pharmaceuticals Ltd.,Safety and efficacy of TRC4186 in the treatment of stable heart failure associated with HbA1c >= 6 % or type 2 diabetes receiving oral hypoglycaemic therapy (with or without additional insulin) as an ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006237-27,0,0,0 2008-006238-87,1,2012-11-15,2012-11-15,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,Improving the safety and efficacy of anticoagulation therapy for thromboembolic disease through vitamin K,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006238-87,0,0,0 2008-006239-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Stichting Lever Onderzoek,Augmenting response to entecavir using a temporary peginterferon alpha-2a add-on strategy for the treatment of HBeAg-positive chronic hepatitis B (ARES study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006239-11,0,0,0 2008-006242-26,1,2012-12-31,2012-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Würzburg,Genetic modulation of functional brain activity of attention-deficit/hyperactivity disorder-related working memory processes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006242-26,0,0,0 2008-006251-46,1,2012-11-30,2012-11-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Institute of Diabetes “Gerhardt Katsch”,Prediction of the efficacy of exenatide treatment in suboptimally controlled type 2 diabetic patients by “Metabolic Fingerprint” and evidence-based KADIS® decision support: a clinical pilot trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006251-46,0,0,0 2008-006252-21,4,2010-04-15,2010-05-31,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc,"A Phase 2, Randomized, Open-label Study of Bosutinib Administered in Combination With Letrozole Versus Letrozole Alone as First Line Therapy in Post-Menopausal Women With Locally Advanced or Metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006252-21,0,0,0 2008-006253-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"The Norwegian Radium Hospital, Oslo University Hospital","Phase I/II trial for vaccine therapy with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion in patients with metastatic malignant melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006253-41,0,0,0 2008-006256-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Saint-Etienne,Evaluation by high resolution micro computerized tomography of bone microarchitecture changes in patients with rheumatoid arthritis under anti-TNF therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006256-22,0,0,0 2008-006257-40,3,2018-10-16,2018-10-16,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,AC Immune SA,"A Phase I/II Double-Blind, Randomised, Placebo-Controlled, Adaptive Design Study of the Safety, Tolerability, Immunogenicity and Efficacy of ACI-24 in Patients with Mild to Moderate Alzheimer's Diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006257-40,0,0,0 2008-006258-16,1,2011-04-26,2011-04-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALLERGOPHARMA JOACHIM GANZER KG,A multicentre randomised placebo-controlled double-blind clinical trial for the immunological and histological evaluation of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hyp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006258-16,0,0,0 2008-006261-81,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,HAL Allergy,"Dose Tolerability Study with High Dose PURETHAL Mites in Allergic Rhinitis / Rhinoconjunctivitis Patients. An open study to assess tolerability, safety and short-term efficacy of high dose PURETHAL M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006261-81,0,0,0 2008-006262-28,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO EUROPEO DI ONCOLOGIA,Allogeneic Haematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Refractory “Triple Negative” Br...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006262-28,0,0,0 2008-006265-93,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,St Eriks Eye Hospital,"A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin®) for central retinal vein occlusion (CRVO).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006265-93,0,0,0 2008-006266-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA PISANA,Optimal Strategy for Coronary Artery Reperfusion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006266-29,0,0,0 2008-006268-12,1,2012-07-17,2012-07-17,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Friedrich-Alexander-Universitaet Erlangen-Nuernberg,Early treatment with deferasirox (Exjade®) in low risk MDS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006268-12,0,0,0 2008-006270-15,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Novartis Pharma AG,"A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy and tolerability of AFQ056 in reducing L-dopa induced dyskinesias in Parki...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006270-15,0,0,0 2008-006271-70,5,2012-04-13,2012-04-13,4,1,1,0,2,0,3,0,0,2,0,0,0,0,1,"Schering-Plough Research Institute, a division of Schering Corporation","A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy and Safety Study of Ezetimibe Monotherapy in Children (Ages 6 to 10 Years) With Primary Hypercholesterolemia (Heterozygous Fam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006271-70,1,1,0 2008-006271-70,5,2012-04-13,2012-04-13,4,1,1,0,2,0,3,0,0,2,0,0,0,0,1,"Schering-Plough Research Institute, A Division of Schering Corporation,","A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy and Safety Study of Ezetimibe Monotherapy in Children (Ages 6 to 10 Years) With Primary Hypercholesterolemia (Heterozygous Fam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006271-70,1,1,0 2008-006271-70,5,2012-04-13,2012-04-13,4,1,1,0,2,0,3,0,0,2,0,0,0,0,1,Schering-Plough Research Institute,"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy and Safety Study of Ezetimibe Monotherapy in Children (Ages 6 to 10 Years) With Primary Hypercholesterolemia (Heterozygous Fam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006271-70,1,1,0 2008-006271-70,5,2012-04-13,2012-04-13,4,1,1,0,2,0,3,0,0,2,0,0,0,0,1,"Schering-Plough Research Institute,divisione di Schering Corporation, per conto di MSP Singapore Co.","A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy and Safety Study of Ezetimibe Monotherapy in Children (Ages 6 to 10 Years) With Primary Hypercholesterolemia (Heterozygous Fam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006271-70,1,1,0 2008-006278-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMCG,"Motor function optimization in advanced Parkinson’s disease patients, combined with galantamine to prevent visual hallucinations.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006278-13,0,0,0 2008-006282-92,1,2010-12-31,2010-12-31,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Fundació Privada Institut d´Investigació Biomèdica de Girona Dr. Josep Trueta,Estudio piloto comparativo de la eficacia diagnóstica y caracterización del realce de las NEOplasias cerebrales con imágenes de RM contrastadas con medios de contraste intravascular (VASosvist®) y ex...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006282-92,0,0,0 2008-006286-80,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Daniel Podzamczer Palter,Evaluación de los niveles farmacológicos de Maraviroc en Líquido Cefalorraquídeo (LCR) y semen en sujetos infectados por el VIH.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006286-80,0,0,0 2008-006287-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,Virologic efficacy of Maraviroc in adult naive HIV patients with HIV-RNA>= 1000 copies/ml,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006287-11,0,0,0 2008-006288-36,1,2011-04-27,2011-04-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,Phase II open label trial to assess the efficacy and the impact on QTcF of continuous oral BIBW 2992 at a daily dose of 50 mg in patients with relapsed or refractory solid tumours including patients w...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006288-36,0,0,0 2008-006292-77,1,2010-03-02,2010-03-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,HAL Allergy,SUBLIVAC® Birch PROBE study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006292-77,0,0,0 2008-006295-29,1,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,0,The Institute of Cancer Research,"A single group trial evaluating one cycle of adjuvant BEP chemotherapy in high risk, stage 1 non-seminomatous germ cell tumours of the testis (NSGCTT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006295-29,0,0,0 2008-006295-29,1,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,0,University Hospital Birmingham NHS Foundation Trust,"A single group trial evaluating one cycle of adjuvant BEP chemotherapy in high risk, stage 1 non-seminomatous germ cell tumours of the testis (NSGCTT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006295-29,0,0,0 2008-006300-27,2,2011-02-23,2011-02-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,medac Gesellschaft für klinische Spezialpräparate mbH,Efficacy and safety of recombinant asparaginase in infants (< 1 year) with previously untreated acute lymphoblastic leukaemia - Phase II Clinical Trial -,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006300-27,0,0,0 2008-006301-17,5,2010-08-16,2010-08-16,3,1,0,0,2,0,3,0,1,1,0,0,1,0,2,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 3, Open label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006301-17,0,0,0 2008-006301-17,5,2010-08-16,2010-08-16,3,1,0,0,2,0,3,0,1,1,0,0,1,0,2,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase 3, Open label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006301-17,0,0,0 2008-006302-42,1,2015-05-27,2015-05-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The University of Oxford,A Phase II study in patients with locally advanced pancreatic carcinoma: ARC-II – Akt-inhibition by Nelfinavir plus chemoradiation with gemcitabine and cisplatin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006302-42,0,0,0 2008-006304-38,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Protocol for a study on male patients suffering from peripheral arterial disease with severe chronic limb ischemia during treatment with iloprost: assessment of oxidative stress and organic erectile d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006304-38,0,0,0 2008-006305-16,2,2009-05-06,2009-05-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, open-label, multicenter, two-period crossover study to evaluate the 24 hour bronchodilator profile of Tiotropium Bromide Respimat® administered once daily versus twice daily in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006305-16,0,0,0 2008-006309-17,1,2013-10-01,2013-10-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"KONSTANTINAS POVILAS VALUCKAS, INSTITUTE OF ONCOLOGY OF VILNIUS UNIVERSITY",Significance of prognostic and predictive factors for the efficacy and safety of neoadjuvant chemotherapy in combination with chemoradiation administered in patients with locally advanced cervical can...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006309-17,0,0,0 2008-006311-21,4,2011-12-31,2012-06-13,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis and dermatomyositis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006311-21,0,0,0 2008-006312-38,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,SAKK (Swiss Group for Clinical Cancer Research),"Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced, K-ras mutated rectal cancer. A randomized multicenter phase I/II trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006312-38,0,0,0 2008-006317-25,2,2010-04-12,2010-04-12,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Comparison of Adding Exenatide with Switching to Exenatide in Patients with Type 2 Diabetes Experiencing Inadequate Glycemic Control with Sitagliptin plus Metformin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006317-25,0,0,0 2008-006323-31,8,2011-09-22,2011-09-22,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Docetaxel, Compared with Docetaxel Alone, in 2nd Line Patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006323-31,0,0,0 2008-006323-31,8,2011-09-22,2011-09-22,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Docetaxel, Compared with Docetaxel Alone, in 2nd Line Patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006323-31,0,0,0 2008-006324-62,6,2011-02-23,2011-02-23,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novo Nordisk AS,"A Multi-Centre, Randomised, Double-Blind, Placebo Controlled Trial on Efficacy and Safety of FXIII Replenishment with two different Doses of Recombinant Factor XIII following Cardiopulmonary Bypass S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006324-62,0,0,0 2008-006324-62,6,2011-02-23,2011-02-23,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novo Nordisk A/S,"A Multi-Centre, Randomised, Double-Blind, Placebo Controlled Trial on Efficacy and Safety of FXIII Replenishment with two different Doses of Recombinant Factor XIII following Cardiopulmonary Bypass S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006324-62,0,0,0 2008-006328-75,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),NOCETER essai multicentrique randomisé en double aveugle contre placebo. Réduction du taux de CEsariennes chez les patientes dépassant le TERme: Impact d'une maturation cervicale ambulatoire par donne...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006328-75,0,0,0 2008-006333-27,10,2013-10-24,2013-10-24,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biogen Idec Limited,"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple Scl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006333-27,0,0,0 2008-006333-27,10,2013-10-24,2013-10-24,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biogen Idec LTD,"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects with Relapsing Multiple Scl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006333-27,0,0,0 2008-006334-10,2,2009-07-20,2009-07-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled BI 1744 CL, delivered with the Respimat® Inhaler, after 3 Weeks of Once Daily (5 µg [2 actuations ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006334-10,0,0,0 2008-006334-10,2,2009-07-20,2009-07-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim BV,"Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled BI 1744 CL, delivered with the Respimat® Inhaler, after 3 Weeks of Once Daily (5 µg [2 actuations ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006334-10,0,0,0 2008-006335-12,1,2009-10-07,2009-10-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Prof. Dr. med. Margitta Worm,Explorative analysis of the immunmodulatory capacities of apathogenic Escherichia coli Nissle 1917 in patients with rhinoconjunctivitis due to grass pollen allergy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006335-12,0,0,0 2008-006337-27,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"EPIX Pharmaceuticals, Inc.","A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PRX-03140 AS MONOTHERAPY IN SUBJECTS WITH ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006337-27,0,0,0 2008-006342-25,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Leeds Teaching Hospitals NHS Trust,"ADMIRE: Does the ADdition of Mitoxantrone Improve REsponse to FCR chemotherapy in patients with CLL: A randomised Phase II Trial of fludarabine, cyclophosphamide and rituximab (FCR) with or without m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006342-25,0,0,0 2008-006344-19,8,2011-11-20,2012-10-02,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Double-Blind, Randomised Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Dacarbazine Compared with Dacarbazine Alone in First Line Patients with BRAF Mutation Pos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006344-19,0,0,0 2008-006345-72,1,2009-09-21,2009-09-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A 28-Day, Polysomnographic and Subjective Assessment of Vestipitant (15mg/day) for the Treatment of Primary Insomnia in Adult Outpatients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006345-72,0,0,0 2008-006349-23,1,2014-11-21,2014-11-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The Leeds Teaching Hospitals NHS Trust,CMML201: A phase 2 study of azacitidine in chronic myelomonocytic leukaemia (CMML),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006349-23,0,0,0 2008-006352-22,5,2010-05-07,2010-10-06,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Medivation, Inc.",CONNECTION PLUS: An Open-Label Extension of the CONNECTION Protocol (DIM14) Evaluating Oral Dimebon in Patients with Alzheimer’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006352-22,0,0,0 2008-006365-91,1,2009-06-25,2009-06-25,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, open-label, randomised, multicentre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib-MenC-TT vaccine, when given in healthy infants at 3, 5 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006365-91,0,0,0 2008-006366-29,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,"IMMUNOTHERAPY OF MAINTENANCE IN THE PATIENTS WITH METASTATIC MELANOMA, CLINICAL BENEFIT AFTER CHEMOTHERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006366-29,0,0,0 2008-006369-10,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,BioTech Tools S.A.,"Preliminary assessment of the clinical tolerability, safety and immunogenicity of three different doses of grass pollen-derived peptides for oral use in antigen-specific immunotherapy of seasonal alle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006369-10,0,0,0 2008-006370-15,1,2016-02-09,2016-02-09,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,CHRU de Lille,A multicenter phase I/II dose excalation study of lenalidomide in relapse/refractory Waldenström macroglobulinemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006370-15,0,0,0 2008-006371-67,1,2012-12-14,2012-12-14,1,1,0,0,0,0,4,0,0,1,1,1,1,0,2,Royal Liverpool and Broadgreen University Hospital,EFFECT OF THIENOPYRIDINE DERIVATIVE (CLOPIDOGREL) ON THE DISPOSITION OF EFAVIRENZ AND NEVIRAPINE IN HIV POSITIVE PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006371-67,0,0,0 2008-006371-67,1,2012-12-14,2012-12-14,1,1,0,0,0,0,4,0,0,1,1,1,1,0,2,University of Liverpool,EFFECT OF THIENOPYRIDINE DERIVATIVE (CLOPIDOGREL) ON THE DISPOSITION OF EFAVIRENZ AND NEVIRAPINE IN HIV POSITIVE PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006371-67,0,0,0 2008-006372-29,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Blockeel Christophe,"Among non-IVF patients undergoing ovulation induction with clomiphene citrate (Clomid® 50 mg) and having no reaction at day 13 of the cycle, does administration of an increased dose of clomiphene citr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006372-29,0,0,0 2008-006373-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA,"Effect of montelukast on levels of metalloproteinase-9 (MMP-9), MMP-12, tissue inhibitor metalloproteinase-1 (TIMP-1), procollagen peptide type 1 C-terminal (PICP) and TGF-beta1 on induced sputum of c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006373-33,0,0,0 2008-006379-65,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ISTITUTO AUXOLOGICO ITALIANO,Evaluation of the benefit-risk profile of retinoic acid in the treatment of Cushing`s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006379-65,0,0,0 2008-006380-36,1,2012-07-23,2012-07-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"A PROSPECTIVE, PILOT, CROSS-OVER STUDY TO ASSESS THE EFFICACY OF PARICALCITOL IN REDUCING PARATHYROID HORMONE LEVELS AND AMELIORATING MARKERS OF BONE REMODELLING IN RENAL TRANSPLANT RECIPIENTS WITH SE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006380-36,0,0,0 2008-006381-29,1,2014-11-01,2014-11-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsmedizin Mainz,"Neoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene si...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006381-29,0,0,0 2008-006383-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,A phase II randomized study evaluating the role of 8 courses of primary chemotherapy versus 4 courses of primary chemotherapy in combination with endocrine therapy in locally advanced breast canc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006383-10,0,0,0 2008-006384-37,1,2010-08-16,2010-08-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,F. Hoffmann-La Roche Ltd,"A phase II study of orally administered RO4929097, a gamma-secretase inhibitor, as a single agent in patients with recurrent or refractory Non-Small Cell Lung Cancer (NSCLC).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006384-37,0,0,0 2008-006405-17,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Kuopio University Hospital,Finnish Dyspepsia Management -study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006405-17,0,0,0 2008-006409-18,12,2011-12-09,2012-08-23,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd.,"An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis versus Placebo in High Risk Surgical Subjects - A Multicentre, Randomized, Doub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006409-18,0,0,0 2008-006409-18,12,2011-12-09,2012-08-23,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTELLAS PHARMA EUROPE Ltd.,"An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis versus Placebo in High Risk Surgical Subjects - A Multicentre, Randomized, Doub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006409-18,0,0,0 2008-006409-18,12,2011-12-09,2012-08-23,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd,"An Exploratory Study to Compare the Efficacy and Safety of Micafungin as a Pre-emptive Treatment of Invasive Candidiasis versus Placebo in High Risk Surgical Subjects - A Multicentre, Randomized, Doub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006409-18,0,0,0 2008-006410-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institutionen för kirurgiska vetenskaper,Undersökning av en kväveoxidsyntashämmares effekt på smärta hos patienter med kronisk neuropatisk smärta. - Intravenös infusion med metylenblått,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006410-20,0,0,0 2008-006411-20,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,CHU de Bordeaux,EVALUATION PRONOSTIQUE DE LA TOMOGRAPHIE PAR EMISSION DE POSITONS COUPLEE AU SCANNER (TEP-TDM) AU FLUOROMISONIDAZOLE MARQUE AU FLUOR 18 (18F-FMISO) DANS LES CANCERS EPIDERMOIDES DES VOIES AERODIGESTIV...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006411-20,0,0,0 2008-006413-25,1,2009-02-09,2009-02-09,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Reckitt Benckiser Healthcare (UK) Limited,"A single-centre randomised, partially blind, single dose, crossover study investigating the onset of action of soothing and cooling after taking Gaviscon Peppermint liquid, Double Action Gaviscon liq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006413-25,0,0,0 2008-006414-19,1,2013-11-20,2013-11-20,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,East and North Hertfordhsire NHS Trust,Dynamic contrast enhanced MRI (DCE-MRI) assessment of the vascular changes induced with bevacizumab alone and in combination with interferon-α in patients with advanced renal cell carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006414-19,0,0,0 2008-006420-65,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,ESPECIALIDADES FARMACÉUTICAS CENTRUM S.A.,"Ensayo clínico piloto, fase IV, unicéntrico, controlado, doble ciego, sobre los efectos del extracto de curcuma centrum estandarizado al 12% en curcumina + fototerapia local con luz visible en adultos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006420-65,0,0,0 2008-006421-13,2,2013-12-17,2013-12-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Wilhelminen Krebsforschung GmbH,Multicenter Phase II Study: Bendamustine plus Bortezomib plus Dexamethasone in the treatment of stage II/III relapsed or refractory multiple myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006421-13,0,0,0 2008-006422-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"Especialidades Farmacéuticas Centrum, S.A","Ensayo clínico, aleatorizado, doble ciego, controlado con placebo, de la eficacia de Anapsos® en la reducción del empleo de corticosteroides tópicos en el tratamiento de la dermatitis atópica moderada...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006422-33,0,0,0 2008-006424-54,3,2011-03-29,2011-03-29,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"An Exploratory Multi-Centre, Multi-National, Randomised, Double Blinded, Parallel Arm Trial Evaluating Safety, Pharmacokinetics and Dose-finding of prophylactic administration of Long Acting rFVIIa (L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006424-54,0,0,0 2008-006425-14,3,2012-04-23,2012-04-23,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Allos Therapeutics, Inc",Phase 1/2 Study of Pralatrexate in Female Patients with Previously-treated Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006425-14,1,0,0 2008-006426-34,1,2010-12-02,2010-12-02,1,0,0,0,0,0,3,0,1,1,0,0,1,0,0,Pulmonary dept. Gentofte Hospital,"Varenicline for long-term nicotine replacement therapy (NRT) users A double blind, placebo controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006426-34,0,0,0 2008-006430-10,5,2011-03-02,2011-03-02,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A multi-center, open label Phase II trial of TKI258 in FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006430-10,0,0,0 2008-006430-10,5,2011-03-02,2011-03-02,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multi-center, open label Phase II trial of TKI258 in FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006430-10,0,0,0 2008-006430-10,5,2011-03-02,2011-03-02,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmaceútica S.A.,"A multi-center, open label Phase II trial of TKI258 in FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006430-10,0,0,0 2008-006433-28,1,2012-08-31,2012-08-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Birmingham,Rapid reduction versus abrupt quitting for smokers who want to stop soon: a randomised controlled non-inferiority trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006433-28,0,0,0 2008-006435-13,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,University of Southampton,GRACE (Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe).Workpackage 10: Antibiotic Trial One,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006435-13,0,0,0 2008-006437-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA,Effect of montelukast on lung function in children younger than 2 years with wheezing.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006437-26,0,0,0 2008-006438-82,1,2009-11-25,2009-11-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Odense Universitetshospital, Nyremedicinsk Afd. Y",Vitamin D og kronisk nyreinsufficiens,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006438-82,0,0,0 2008-006439-12,14,2022-03-21,2022-03-31,5,0,0,0,0,0,0,0,0,2,0,0,0,0,0,Regents of the University of Minnesota,Momento Estratégico para el Inicio de la Terapia Antiretroviral Strategic Timing of AntiRetroviral Treatment (START),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006439-12,1,0,0 2008-006441-10,4,2021-04-09,2021-04-09,2,1,0,0,0,1,3,0,0,1,1,0,1,0,2,MRN-Medical Research Network GmbH,A double blind controlled clinical study to investigate the efficacy and tolerability of subcutaneous Treprostinil sodium in patients with severe non-operable Chronic Thromboembolic Pulmonary Hyperten...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006441-10,0,0,0 2008-006441-10,4,2021-04-09,2021-04-09,2,1,0,0,0,1,3,0,0,1,1,0,1,0,2,SCIPHARM SáRL,A double blind controlled clinical study to investigate the efficacy and tolerability of subcutaneous Treprostinil sodium in patients with severe non-operable Chronic Thromboembolic Pulmonary Hyperten...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006441-10,0,0,0 2008-006443-39,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Roche Farma, S.A.","Estudio piloto de fase II multicéntrico, aleatorizado, en grupos paralelos para comparar la incidencia de las reacciones a la infusión de Tocilizumab en pacientes con AR moderada a grave cuando la inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006443-39,0,0,0 2008-006444-19,8,2011-11-02,2011-12-08,7,0,0,0,0,0,2,0,0,1,1,0,1,0,1,SYGNIS Bioscience GmbH & Co. KG,"AXIS 2: AX200 for the treatment of ischemic stroke A multinational, multicenter, randomized, doubleblind, placebo-controlled, phase II trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006444-19,0,0,0 2008-006445-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Paravertebral block: influence of Body Mass Index on the dosage of local anaesthetic.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006445-18,0,0,0 2008-006446-25,3,2009-12-08,2009-12-08,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A randomized, double-blind, placebo-controlled, multiple dose study of VX-809 to evaluate safety, pharmacokinetics, and pharmacodynamics of VX-809 in cystic fibrosis subjects homozygous for the deltaF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006446-25,0,0,0 2008-006447-40,5,2013-01-31,2013-01-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 104 week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy of aliskiren on the progression of atherosclerosis in patients with coronary art...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006447-40,0,0,0 2008-006447-40,5,2013-01-31,2013-01-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 104 week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy of aliskiren on the progression of atherosclerosis in patients with coronary art...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006447-40,0,0,0 2008-006447-40,5,2013-01-31,2013-01-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica,"A 104 week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy of aliskiren on the progression of atherosclerosis in patients with coronary art...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006447-40,0,0,0 2008-006449-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,Evaluation méthodologique de la tomographie par émission de positons couplée au scanner (TEP-TDM) au Fluoromisonidazole marqué au fluor 18 ([18F]-FMISO) dans l’évaluation de la réponse au traitement d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006449-14,0,0,0 2008-006451-52,1,2012-03-14,2012-03-14,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,"An investigation of the association between vitamin K intake, vitamin K epoxide reductase subunit (VKORC1) genotype and anticoagulation response to warfarin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006451-52,0,0,0 2008-006452-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Centre,The effects of melatonin in the treatment of delirium,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006452-22,0,0,0 2008-006453-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Karolinska University hospital Huddinge,"Peg-INF alfa-2a plus ribavirin treatment of liver transplant patients with hepatitis C relaps on protocol liver biopsies - a Nordic study on rapid viral response, early viral response, end of treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006453-40,0,0,0 2008-006465-85,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI,Pharmacokinetic evaluation of a new formulation of recombinant factor IX (BeneFIX) in the italian population with severe or moderate B haemophilia previously treated.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006465-85,0,0,0 2008-006484-36,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,MULTICENTER COMPARATIVE STUDY BETWEEN NUTRITIONAL THERAPY ALONE AND ANTI-TNF-alpha MONOCLONAL ANTIBODY IN INDUCING AND MAINTAINING REMISSION IN PEDIATRIC CROHN`S DISEASE: A RANDOMIZED CONTROLLED TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006484-36,0,0,0 2008-006486-88,1,2012-06-11,2012-06-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford,"Modafinil for the treatment of fatigue in lung cancer: a multicentre, randomised, double-blinded, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006486-88,0,0,0 2008-006489-27,1,2016-09-15,2016-09-15,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Prévention par une héparine de bas poids moléculaire, l'enoxaparine, des complications maternelles et périnatale chez les patientes ayant un antécédent de prééclampsie sévère avant 34 semaines d'améno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006489-27,0,0,0 2008-006491-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Henri Becquerel,"Etude prospective, multicentrique, de phase II testant la faisabilité d’un traitement d’entretien par l’alemtuzumab chez des patients porteurs de leucémie lymphoïde chronique, traités et répondant à l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006491-30,0,0,0 2008-006492-71,5,2011-10-13,2011-10-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A double-blind, efficacy and safety study of duloxetine versus placebo in the treatment of children and adolescents with major depressive disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006492-71,0,0,0 2008-006497-15,4,2012-12-31,2014-09-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Wilhelminen Krebsforschung GmbH,Lenalidomide and Dexamethasone for treatment of patients with acute myeloma (light chain)-induced renal failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006497-15,0,0,0 2008-006502-42,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA MEYER,Early antibiotic treatment in pseudomonas aeruginosa eradication in cystic fibrosis patients: a randomised policentric study on two different protocols,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006502-42,0,0,0 2008-006504-33,1,2012-10-17,2012-10-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"Etude multicentrique, en ouvert, non randomisée de phase II évaluant l’efficacité de bevacizumab (Avastin®) associé à paclitaxel/carboplatine en première ligne ou à erlotinib en deuxième ligne de trai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006504-33,0,0,0 2008-006525-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,CISPLATIN AND DOCETAXEL FOLLOWED BY SHORT-COURSE OF RADIOTHERAPY AND CONSOLIDATION CHEMOTHERAPY WITH CIPLATIN AND DOCETAXEL IN INOPERABLE NON SMALL CELL LUNG CANCER (NSCLC-STAGE III).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006525-14,0,0,0 2008-006526-34,1,2012-02-29,2012-02-29,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Gynækologisk-obstetrisk afd. G, Glostrup Hospital",Intravesikal instillation af Botulinum toxin type A til patienter med urge urininkontinens,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006526-34,0,0,0 2008-006527-30,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,"Preventing Breast cancer through Assumption of Metformin, Diet and Physical Activity",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006527-30,0,0,0 2008-006528-67,1,2011-01-13,2011-01-13,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Hvidovre Hospital, Anæstesiologisk afdeling 532","Den perioperative effekt af methylprednisolon ved hoftealloplastik: et prospektivt, dobbeltblindet, placebokontrolleret studie.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006528-67,0,0,0 2008-006544-20,7,2014-01-30,2014-01-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A","A randomized, double-blind, multi-center phase III study comparing everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in patients with advanced gastric cancer after...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006544-20,0,0,0 2008-006544-20,7,2014-01-30,2014-01-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, multi-center phase III study comparing everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in patients with advanced gastric cancer after...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006544-20,0,0,0 2008-006544-20,7,2014-01-30,2014-01-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, multi-center phase III study comparing everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in patients with advanced gastric cancer after...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006544-20,0,0,0 2008-006551-51,1,2011-12-22,2011-12-22,1,1,1,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III double-blind, cluster-randomized, controlled study to evaluate the impact on nasopharyngeal carriage, acute otitis media, immunogenicity and safety of GSK Biologicals’ 10-valent pneumococc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006551-51,0,0,0 2008-006556-21,7,2017-01-23,2017-10-23,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Novartis Pharma Service AG,"A randomized phase III, double-blind, placebo-controlled multicenter trial of Everolimus in combination with Trastuzumab and Paclitaxel, as first line therapy in women with HER2 positive locally advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006556-21,0,0,0 2008-006556-21,7,2017-01-23,2017-10-23,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized phase III, double-blind, placebo-controlled multicenter trial of Everolimus in combination with Trastuzumab and Paclitaxel, as first line therapy in women with HER2 positive locally advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006556-21,0,0,0 2008-006558-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,cliniques universitaire de mont godinne,None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006558-17,0,0,0 2008-006559-27,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,Exploratory study on Omalizumab in patients affected by Painful Bladder Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006559-27,0,0,0 2008-006560-11,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,Prevention of human cytomegalovirus (HCMV) mother-to-fetus transmission by administration of virus-specific hyperimmune globulin to pregnant women with primary HCMV infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006560-11,0,0,0 2008-006561-89,2,2011-10-17,2011-10-17,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol Myers Squibb International Corporation,"A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) versus Bevacizumab plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006561-89,0,0,0 2008-006625-14,4,2011-12-19,2011-12-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, delivered with the Respimat® Inhaler, after 3 Weeks of Olodaterol Once Daily...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006625-14,0,0,0 2008-006625-14,4,2011-12-19,2011-12-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Phase II, Randomised, Double-Blind, Cross-over Study to Compare the 24-hour FEV1-time Profile of Orally Inhaled Olodaterol, delivered with the Respimat® Inhaler, after 3 Weeks of Olodaterol Once Daily...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006625-14,0,0,0 2008-006644-19,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SAN GERARDO DI MONZA,Evaluation of inflammatory immune parameters predicting cardiovascular risk in HIV-1-infected antiretroviral therapy naive patients treated with atazanavir/ritonavir versus lopinavir/ritonavir based r...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006644-19,0,0,0 2008-006649-18,1,2018-12-11,2018-12-11,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,University College London,"CMV TCR Gene Therapy: A Phase I Safety, Toxicity and Feasibility Study of Adoptive Immunotherapy with CMV TCR-transduced Donor-derived T cells for Recipients of Allogeneic Haematopoietic Stem Cell Tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006649-18,0,0,0 2008-006652-22,1,2009-09-21,2009-09-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Leeds Teaching Hospital NHS Trust,"A multicentre, randomised, double blind, evaluative comparison trial of Rapydan® patch and Ametop® gel for topical anaesthesia during venous cannulation in adults admitted to hospital for day-case sur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006652-22,0,0,0 2008-006666-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA PISANA,Myocardial Dyssynchrony and Sympathetic activity by cardiac gated-SPECT in patients with heart failure treated with cardiac resynchronyzation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006666-28,0,0,0 2008-006704-27,1,2013-03-10,2013-03-10,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,"Neuromuscular Research Unit, Copenhagen University Hospital Rigshopspitalet",Effect of Bezafibrate on muscle metabolism during exercise in patients with fat metabolic disorders in skeletal muscle,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006704-27,0,0,0 2008-006709-18,2,2011-06-10,2011-06-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,"An exploratory, prospective phase II study to investigate progression-free survival, response and overall survival seen with pemetrexed/cisplatin and the role of thymidylate synthase expression.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006709-18,0,0,0 2008-006710-23,1,,,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,Blood Transfusion Centre of Slovenia,Modulation of the immune response in patients with pancreatic tubular carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006710-23,0,0,0 2008-006713-25,1,2011-01-31,2011-01-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,OSPEDALE MAGGIORE DI MILANO (IRCCS),A SINGLE-ARM PILOT STUDY WITH LOW-DOSE RITUXIMAB PLUS STANDARD ORAL PREDNISONE IN IDIOPATHIC AUTOIMMUNE HEMOLYTIC ANEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006713-25,0,0,0 2008-006714-15,1,2014-04-01,2014-04-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Psykiatrisk Center Gentofte,The effect of treatment of traumatised refugees with Traume-Focused Cognitive Behavioural Therapy and antidepressants - a randomised controlled clinical trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006714-15,0,0,0 2008-006716-38,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,CHU de Toulouse,Etude observationnelle des évènements indésirables graves survenant chez les patients traités par rituximab pour maladie dysimmunitaire hors polyarthrite rhumatoïde .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006716-38,0,0,0 2008-006718-10,1,2010-03-02,2010-03-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Alcon Laboratories, Inc.",The Efficacy and Safety of Travoprost 0.004% versus Tafluprost 0.005% in Primary Open-Angle Glaucoma or Ocular Hypertensive Patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006718-10,0,0,0 2008-006719-20,17,2015-03-30,2015-03-30,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.","TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006719-20,0,0,0 2008-006719-20,17,2015-03-30,2015-03-30,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"MERCK & CO., INC.","TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006719-20,0,0,0 2008-006719-20,17,2015-03-30,2015-03-30,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006719-20,0,0,0 2008-006719-20,17,2015-03-30,2015-03-30,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,","TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006719-20,0,0,0 2008-006719-20,17,2015-03-30,2015-03-30,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.","TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006719-20,0,0,0 2008-006719-20,17,2015-03-30,2015-03-30,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006719-20,0,0,0 2008-006720-62,3,2010-11-10,2010-11-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"MERCK & CO., INC.","A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glyc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006720-62,0,0,0 2008-006720-62,3,2010-11-10,2010-11-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glyc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006720-62,0,0,0 2008-006720-62,3,2010-11-10,2010-11-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck & Co Inc,"A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glyc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006720-62,0,0,0 2008-006722-34,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,0,ISTITUTO SUPERIORE DI SANITA`,Multicentric randomized placebo controlled trial of Lithium carbonate combined with Riluzole in patients with ALS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006722-34,0,0,0 2008-006726-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,Anti-TNF monoclonal antibody to treat acute GvHD refractary to the first line therapy with steroids,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006726-34,0,0,0 2008-006728-73,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,GRUPO ESPAÑOL DE NEUROONCOLOGIA MEDICA,"Ensayo Clínico abierto, fase II, de tratamiento neo-adyuvante de Sunitinib (SU11248) previo al tratamiento con irradiación y concomitante a la misma, en pacientes con Glioblastoma RPA-V-VI y sólo biop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006728-73,0,0,0 2008-006729-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,"OPEN PILOT STUDY, TWO ARMS, WITH HISTORIC CONTROL, MULTICENTRIC TO EVALUATE SAFETY AND EFFICACY OF ASSOCIATION WITH EVEROLIMUS AND LOW DOSES OF CYCLOSPORIN AND STEROIDS AFTER INDUCTION WITH MONOCLONAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006729-15,0,0,0 2008-006732-35,5,2013-01-31,2013-12-06,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,"A Single-Arm, Phase 2 Trial of Pemetrexed, Cisplatin, and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Treatment of Nonsquamous Advanced NSCLC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006732-35,0,0,0 2008-006732-35,5,2013-01-31,2013-12-06,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,"A Single-Arm, Phase 2 Trial of Pemetrexed, Cisplatin, and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Treatment of Nonsquamous Advanced NSCLC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006732-35,0,0,0 2008-006732-35,5,2013-01-31,2013-12-06,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ELI LILLY,"A Single-Arm, Phase 2 Trial of Pemetrexed, Cisplatin, and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Treatment of Nonsquamous Advanced NSCLC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006732-35,0,0,0 2008-006738-85,1,2008-12-09,2008-12-09,1,0,0,0,0,0,4,0,1,1,0,0,1,0,1,"Azur Pharma, Ltd.","A Single Dose, Open-Label, Randomized, Two-Way Crossover Food Effect Study Comparing 12.5 mg FazaClo™ (clozapine) ODT under Fasted and Fed Conditions in Healthy Male Volunteers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006738-85,0,0,0 2008-006741-70,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,"Comparison of the efficacy of intrarticular corticosteroid therapy administered alone or in combination with methotrexate in children with juvenile idiopatic arthritis: a phase II, randomized acticely...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006741-70,0,0,0 2008-006742-26,2,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,1,ASTRAZENECA,Evaluation Study of a New Management Strategy for Gastroesophageal Reflux Disease (GERD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006742-26,0,0,0 2008-006742-26,2,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,1,AstraZeneca AS,Evaluation Study of a New Management Strategy for Gastroesophageal Reflux Disease (GERD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006742-26,0,0,0 2008-006749-18,2,2010-08-05,2010-08-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Fresenius Kabi Deutschland GmbH,Efficacy and safety of 6 % hydroxyethyl starch 130/0.4 (Voluven®) vs. 5% HSA in volume replacement therapy during elective open-heart surgery in paediatric patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006749-18,0,0,0 2008-006750-17,1,2012-07-16,2012-07-16,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"A prospective, sequential study to assess the efficacy of rituximab therapy in maintaining remission of nephrotic syndrome after steroid and immunosuppressive therapy withdrawal in patients with stero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006750-17,0,0,0 2008-006751-48,1,2019-01-24,2019-01-24,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University College London,PHASE II STUDY OF BORTEZOMIB CONSOLIDATION AFTER HIGH DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006751-48,0,0,0 2008-006751-48,1,2019-01-24,2019-01-24,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,CR UK and UCL Cancer Trials Centre,PHASE II STUDY OF BORTEZOMIB CONSOLIDATION AFTER HIGH DOSE THERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006751-48,0,0,0 2008-006755-44,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,HOSPICES CIVILS DE LYON,METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006755-44,0,0,0 2008-006756-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Neocutis,VVS study: the efficacy and safety of Bio-restorative Skin Cream in the local treatment of vulvar vestibulitis syndrome (VVS) compared with placebo.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006756-22,0,0,0 2008-006760-10,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,"Pfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ UK","A 6-MONTH, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, PARALLEL GROUP, MAINTENANCE OF EFFECT STUDY OF ESREBOXETINE (PNU-165442G) ADMINISTERED ONCE DAILY (QD) IN PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006760-10,0,0,0 2008-006762-29,1,2009-07-16,2009-07-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare (UK) Ltd,"A double-blind, randomised, crossover, single dose, single centre, study examining the analgesic efficacy and tolerability of fixed-dose combinations of ibuprofen 200mg and acetaminophen 500mg, ibupro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006762-29,0,0,0 2008-006763-36,2,2011-12-22,2013-01-31,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Marvel Life Sciences Limited,"Randomized, double-blind study comparing the immunogenicity of two different brands of human insulin for the treatment of diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006763-36,0,0,0 2008-006765-82,1,2014-01-29,2014-01-29,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI,Preventive therapy for multidrug-resistant tuberculosis: a multicentre clincal trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006765-82,0,0,0 2008-006766-28,1,2015-03-31,2015-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo de Tratamiento de los Tumores Digestivos - TTD,"Estudio de fase II exploratorio, abierto, aleatorizado, multicéntrico para evaluar la eficacia y seguridad de la combinación de panitumumab con quimioterapia FOLFOX 4 o panitumumab con quimioterapia F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006766-28,0,0,0 2008-006768-13,1,2010-04-22,2010-04-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline AB,Follow-up survey for comparing stable dosing with a symptom based “as needed-regimen” in moderate and severe persitent asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006768-13,0,0,0 2008-006769-95,1,2011-06-02,2011-06-02,1,0,0,0,0,0,4,0,1,1,1,1,1,0,0,St Stephen's Aids Trust,"A Randomised, Placebo Controlled, Phase IV, Safety and Exploratory Immunogenicity Study into the Impact of Maraviroc, an Orally Administered CCR5 Inhibitor, on the Intensification of Immune Function i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006769-95,0,0,0 2008-006772-30,1,2010-12-31,2010-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical University of Graz,Evaluation of HCV clearance by hemodialysis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006772-30,0,0,0 2008-006773-32,1,2015-10-23,2015-10-23,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,Health Protection Agency,"A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006773-32,0,0,0 2008-006775-67,6,2010-07-16,2011-11-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A randomised, open-label, assessor-blind, parallel groups, multicentre trial comparing the efficacy of MENOPUR versus recombinant FSH in controlled ovarian stimulation following a GnRH antagonist prot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006775-67,0,0,0 2008-006776-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska Institutet,NO som behandling vid knäproteskirurgi. Studie med avseende på anti-inflammatorisk modulation hos patienter som genomgår operation med ryggbedövning.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006776-29,0,0,0 2008-006778-14,1,2015-03-08,2015-03-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Biothera,"A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG® Injection in Combination with Cetuximab and Concomitant Paclitaxel and Carboplatin Therapy in Patients with Previously Untreated Advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006778-14,0,0,0 2008-006780-37,1,2016-03-08,2016-03-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Biothera,"A Phase 2, Randomized, Efficacy and Safety Study of Imprime PGG® Injection in Combination with Bevacizumab and Concomitant Paclitaxel and Carboplatin Therapy in Patients with Previously Untreated Adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006780-37,0,0,0 2008-006782-83,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospital Universitario Virgen de las Nieves,Prevention MODS by modulating the inflammatory response through melatonin administration in surgical patients with severe sepsis. Prevención del MODS mediante la modulación de la respuesta inflamat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006782-83,0,0,0 2008-006785-29,12,2010-10-14,2011-01-26,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Actelion Pharmaceuticals Ltd.,"A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006785-29,0,0,0 2008-006785-29,12,2010-10-14,2011-01-26,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Actelion Pharmaceuticals Ltd,"A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006785-29,0,0,0 2008-006786-92,13,2011-06-17,2011-06-17,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"Estudio multicéntrico, aleatorizado, de grupos paralelos, doble ciego, controlado con placebo, de búsqueda de dosis para evaluar la eficacia, seguridad y tolerabilidad de tres dosis de ACT-128800, un ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006786-92,0,0,0 2008-006786-92,13,2011-06-17,2011-06-17,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"Estudio multicéntrico, aleatorizado, de grupos paralelos, doble ciego, controlado con placebo, de búsqueda de dosis para evaluar la eficacia, seguridad y tolerabilidad de tres dosis de ACT-128800, un ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006786-92,0,0,0 2008-006787-11,1,2009-05-30,2009-05-30,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Shionogi & Co., Ltd.","A randomized, double blind, placebo-controlled, 2-period cross over study to evaluate effects of S-555739 on prostaglandin D2 (PGD2) induced nasal airway resistance in healthy adult volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006787-11,0,0,0 2008-006788-35,1,2009-07-17,2009-07-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Shionogi & Co., Ltd.","A randomised, double-blind, placebo-controlled, 2-period crossover study to evaluate effects of multiple oral doses of S-555739 on nasal allergen challenge in subjects with intermittent grass pollen s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006788-35,0,0,0 2008-006790-33,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA CARDARELLI,A Phase II Study of Low dose ARA-C + Lenalidomide for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) without Deletion 5q in Patients Age 70 Years or Older Who Decline Remission Induction Che...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006790-33,0,0,0 2008-006792-68,5,2010-04-15,2010-05-01,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GALDERMA R & D SNC,Efficacy and Safety comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel associated with Lymecycline 300mg Capsules versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Vehicle Gel associated with Lymecy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006792-68,0,0,0 2008-006792-68,5,2010-04-15,2010-05-01,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Galderma Research & Development,Efficacy and Safety comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel associated with Lymecycline 300mg Capsules versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Vehicle Gel associated with Lymecy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006792-68,0,0,0 2008-006794-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude Randomisée, de non Infériorité comparant Amoxicilline en traitement Court per os à un des traitements usuels (Amoxicilline IV relais per os) de l'érysipèle. = Short course of Amoxicilline for eR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006794-32,0,0,0 2008-006795-30,1,2010-06-30,2010-06-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,"Institute of Clinical Medicine, Family Medicine, University of Turku","Controlled-release melatonin in fast withdrawal of temazepam, zopiclone or zolpidem in elderly persons with insomnia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006795-30,0,0,0 2008-006796-80,4,2010-11-08,2010-11-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & De`veloppement,"The QUTIE Study: A Randomized, Double-Blind, Placebo-controlled Study Comparing Aflibercept Versus Placebo on the QTc interval in Cancer Patients treated with Docetaxel",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006796-80,0,0,0 2008-006796-80,4,2010-11-08,2010-11-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & Développement,"The QUTIE Study: A Randomized, Double-Blind, Placebo-controlled Study Comparing Aflibercept Versus Placebo on the QTc interval in Cancer Patients treated with Docetaxel",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006796-80,0,0,0 2008-006798-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CONSORZIO ONCOTECH,"Medical optimization of TORisel (MoTOR): MULTICENTER, PHASE II EVALUATION OF TORISEL AS II-LINE TREATMENT FOR METASTATIC RCC PATIENTS PROGRESSING AFTER CYTOKINE THERAPY, TYROSINE KINASE, OR ANGIOGENES...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006798-33,0,0,0 2008-006799-32,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Chroma Therapeutics Ltd,"The OPAL Study: A Phase II Single Arm Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006799-32,0,0,0 2008-006801-17,11,2017-08-07,2017-08-07,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine, with or without pertuzumab, in patients with HER2-positive metastatic breast cancer that have progres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006801-17,0,0,0 2008-006801-17,11,2017-08-07,2017-08-07,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,F. Hoffmann - La Roche Ltd.,"A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine, with or without pertuzumab, in patients with HER2-positive metastatic breast cancer that have progres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006801-17,0,0,0 2008-006801-17,11,2017-08-07,2017-08-07,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Head, EU/ROW Regulatory Affairs","A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine, with or without pertuzumab, in patients with HER2-positive metastatic breast cancer that have progres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006801-17,0,0,0 2008-006802-40,3,2017-06-15,2017-06-15,1,0,0,0,0,1,2,0,0,2,1,0,0,0,0,Akademiska University Hospital,"A PHASE II STUDY WITH OXALIPLATIN + 5FU + CETUXIMAB AND RADIOTHERAPY FOR TREATMENT OF NON-RESECTABLE, LOCALLY ADVANCED BUT NOT METASTATIC CANCER OF OESOPHAGUS OR THE CARDIA REGION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006802-40,1,0,0 2008-006802-40,3,2017-06-15,2017-06-15,1,0,0,0,0,1,2,0,0,2,1,0,0,0,0,Uppsala University Hospital,"A PHASE II STUDY WITH OXALIPLATIN + 5FU + CETUXIMAB AND RADIOTHERAPY FOR TREATMENT OF NON-RESECTABLE, LOCALLY ADVANCED BUT NOT METASTATIC CANCER OF OESOPHAGUS OR THE CARDIA REGION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006802-40,1,0,0 2008-006802-40,3,2017-06-15,2017-06-15,1,0,0,0,0,1,2,0,0,2,1,0,0,0,0,Karolinska University Hospital,"A PHASE II STUDY WITH OXALIPLATIN + 5FU + CETUXIMAB AND RADIOTHERAPY FOR TREATMENT OF NON-RESECTABLE, LOCALLY ADVANCED BUT NOT METASTATIC CANCER OF OESOPHAGUS OR THE CARDIA REGION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006802-40,1,0,0 2008-006804-46,1,2011-02-28,2011-02-28,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Oxford,Assessment of protection against malaria by sporozoite challenge of healthy adults vaccinated with AdCh63 ME-TRAP and MVA ME-TRAP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006804-46,0,0,0 2008-006825-15,1,2011-05-13,2011-05-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Ghent,Extended infusie van betalactam en carbapenem antibiotica: farmakokinetische aspecten in patienten met verschillende gradaties in nierfunctie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006825-15,0,0,0 2008-006826-33,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,CHU d'Angers,"Effet d’une prémédication sur la douleur, en IRM fonctionnelle, chez des volontaires sains.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006826-33,0,0,0 2008-006827-29,8,2011-11-29,2011-11-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FERRING SPA,"A Phase 3b, Non-randomized, Open-label, Multi-Centre, Follow-on Safety Trial of Monthly Doses of Degarelix in Patients with Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006827-29,0,0,0 2008-006827-29,8,2011-11-29,2011-11-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A Phase 3b, Non-randomized, Open-label, Multi-Centre, Follow-on Safety Trial of Monthly Doses of Degarelix in Patients with Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006827-29,0,0,0 2008-006831-10,16,2016-08-18,2016-09-26,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006831-10,0,0,0 2008-006831-10,16,2016-08-18,2016-09-26,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006831-10,0,0,0 2008-006831-10,16,2016-08-18,2016-09-26,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG q,"Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006831-10,0,0,0 2008-006831-10,16,2016-08-18,2016-09-26,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006831-10,0,0,0 2008-006831-10,16,2016-08-18,2016-09-26,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006831-10,0,0,0 2008-006831-10,16,2016-08-18,2016-09-26,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Unilfarma, Lda.","Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006831-10,0,0,0 2008-006831-10,16,2016-08-18,2016-09-26,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006831-10,0,0,0 2008-006831-10,16,2016-08-18,2016-09-26,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006831-10,0,0,0 2008-006831-10,16,2016-08-18,2016-09-26,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006831-10,0,0,0 2008-006831-10,16,2016-08-18,2016-09-26,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Hellas,"Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006831-10,0,0,0 2008-006831-10,16,2016-08-18,2016-09-26,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006831-10,0,0,0 2008-006833-29,2,2013-11-26,2013-11-26,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Lung LLC,An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006833-29,0,0,0 2008-006837-28,1,2011-04-27,2011-04-27,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Antwerp; Department Respiratory Medicine,"Double blind, randomized, placebo-controlled, two-way crossover, pilot study to assess the effect of high dose N-acetylcysteine on small airways and on inflammation and oxidative stress in COPD patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006837-28,0,0,0 2008-006840-20,3,2013-07-31,2013-08-07,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Wyeth, a Pfizer Company",Planned Transition to Sirolimus-based Therapy Versus Continued Tacrolimus-based Therapy in Renal Allograft Recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006840-20,0,0,0 2008-006840-20,3,2013-07-31,2013-08-07,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals Inc.,Planned Transition to Sirolimus-based Therapy Versus Continued Tacrolimus-based Therapy in Renal Allograft Recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006840-20,0,0,0 2008-006840-20,3,2013-07-31,2013-08-07,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Wyeth Pharmaceuticals Inc,Planned Transition to Sirolimus-based Therapy Versus Continued Tacrolimus-based Therapy in Renal Allograft Recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006840-20,0,0,0 2008-006841-25,1,2010-01-30,2010-01-30,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Oncology Institute of Southern Switzerland,Phase II study of the combination of RAD001 and Letrozole in patients with recurrent endometrial cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006841-25,0,0,0 2008-006842-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHRU de Lille,Etude monocentrique randomisée en double aveugle versus placebo avec deux groupes parallèles d’efficacité et de tolérance de la défériprone (traitement chélateur de fer) sur la surcharge cérébrale en ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006842-25,0,0,0 2008-006844-21,1,2010-02-04,2010-02-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Dermal Laboratories Ltd,Evaluation of a developmental ‘long lasting’ emollient in subjects with dry skin.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006844-21,0,0,0 2008-006845-13,2,2010-06-16,2010-06-16,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"McNeil AB (Johnson & Johnson Consumer and Personal Products Worldwide, J&J CPPW)","Efficacy and safety following use of a novel nicotine replacement therapy. A multicenter, randomized, double blind, placebo-controlled, parallel group, 52-week study in smokers motivated to quit.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006845-13,0,0,0 2008-006846-24,1,2012-11-05,2012-11-05,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,North West London Hospitals NHS Trust,An Evaluation of the Effectiveness of Ibuprofen and Morphine for Acute Pain in Sickle Cell Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006846-24,0,0,0 2008-006849-28,1,2009-05-07,2009-05-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, multi-center, two-period crossover study to investigate the bronchodilatory effect of 50µg NVA237 inhaled once daily in patients with Chronic Obstructiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006849-28,0,0,0 2008-006854-17,1,2020-07-30,2020-07-30,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,CH-Versailles,A PROSPECTIVE RANDOMIZED PHASE II STUDY EVALUATING THE OPTIMIZATION OF THE RESIDUAL PLASMATIC LEVEL OF DASATINIB (SPRYCEL®) IN PATIENTS NEWLY DIAGNOSED WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006854-17,0,0,0 2008-006857-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Blocage des effets létaux de l'aldostérone dans l'infarctus du myocarde traité ou non par la reperfusion pour améliorer le pronostic et la survie à six mois : Etude randomisée comparant un blocage spé...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006857-42,0,0,0 2008-006860-12,1,2011-08-01,2011-08-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,GWT-TUD GmbH,Comparative investigation of Insuline glargine versus Metformin as first line drug in treat-ment of early Type 2 Diabetes (GLORY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006860-12,0,0,0 2008-006862-27,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)",Infusion of Cytokine Induced Killer (CIK) cells in patients relapsing after allogeneic stem cell transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006862-27,0,0,0 2008-006863-35,1,2022-03-01,2022-03-01,1,0,0,0,1,0,4,0,0,1,0,0,0,0,0,Bispebjerg Hospital,"Prophylactic photodynamic therapy for organ transplant patients – a randomised, intra-individual trial with blinded outcome evaluation. Profylaktisk fotodynamisk terapi för organtransplanterade pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006863-35,0,0,0 2008-006866-27,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,Boehringer Ingelheim (Canada) Ltd./Ltée,Open-label safety and tolerability study of dabigatran etexilate given for 3 days at the end of standard anticoagulant therapy in children aged 12 years to less than 18 years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006866-27,0,1,1 2008-006868-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Asociación Andaluza de Hematología,Estudio Fase II de Combinación de Lenalidomida/Ciclofosfamida a dosis metronómicas/Prednisona para el tratamiento de pacientes mayores de 75 años con mieloma múltiple de nuevo diagnóstico,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006868-11,0,0,0 2008-006869-86,1,2011-02-23,2011-02-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A comparison of Symbicort® Maintenance and Reliever Therapy (Symbicort Turbuhaler® 160/4.5 mg, one inhalation bid plus as-needed) and Symbicort Turbuhaler 160/4.5 mg, one inhalation bid plus terbutali...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006869-86,0,0,0 2008-006871-60,2,2013-06-30,2013-06-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"University Hospital Heidelberg, Ruprechts-Karl-University Heidelberg","Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006871-60,0,0,0 2008-006871-60,2,2013-06-30,2013-06-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"University Hospital Heidelberg, Ruprecht-Karls-University Heidelberg","Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006871-60,0,0,0 2008-006872-31,3,2014-06-12,2014-06-14,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann - La Roche Ltd,A randomized phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed duri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006872-31,1,0,0 2008-006872-31,3,2014-06-12,2014-06-14,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,A randomized phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed duri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006872-31,1,0,0 2008-006873-33,6,,,0,1,1,0,0,0,0,0,0,2,1,0,0,0,1,Viiv Healthcare UK Limited,"AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC AND 48-WEEK SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006873-33,0,1,0 2008-006873-33,6,,,0,1,1,0,0,0,0,0,0,2,1,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC AND 48-WEEK SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006873-33,0,1,0 2008-006873-33,6,,,0,1,1,0,0,0,0,0,0,2,1,0,0,0,1,Pfizer Inc,"AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC AND 48-WEEK SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006873-33,0,1,0 2008-006873-33,6,,,0,1,1,0,0,0,0,0,0,2,1,0,0,0,1,ViiV Healthcare UK Limited,"AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC AND 48-WEEK SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006873-33,0,1,0 2008-006873-33,6,,,0,1,1,0,0,0,0,0,0,2,1,0,0,0,1,"Pfizer, S.A.","AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC AND 48-WEEK SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006873-33,0,1,0 2008-006874-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Nîmes,"Aspects Pharmacogénétiques et Pharmacocinétiques de la réponse à la CHimiothérapie d’induction par Docetaxel, Cisplatine et 5-Fluorouracile (TPF), des cancers ORL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006874-14,0,0,0 2008-006879-71,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOSPITAL SAN PEDRO,Tratamiento del edema de macula diabético clinicamente significativo con Ranibizumab (LUCENTIS) intravitreo. TREATMENT OF DIABETIC CLINICALLY SIGNIFICANT MACULAR EDEMA WITH INTRAVITREOUS RANIBIZUMAB (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006879-71,0,0,0 2008-006885-27,1,2012-02-08,2012-02-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Clinical Immunology and Rheumatology,EFFICACY AND SAFETY OF ADALIMUMAB (HUMIRA®) IN PATIENTS WITH PERIPHERAL SPONDYLOARTHRITIS WITHOUT ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006885-27,0,0,0 2008-006886-10,1,2009-07-01,2009-07-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios Almirall, S.A.","A multiple dose, double blind, double-dummy, two-week 3 way cross-over, placebo-controlled clinical trial to assess the efficacy and safety of twice daily inhaled Aclidinium-bromide 400 µg compared to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006886-10,0,0,0 2008-006887-12,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Institut de Recerca HSCSP,Randomized controlled trial to compare treatment with oral anticoagulation with vitamin K antagonists versus low molecular weight heparin (bemiparin) in patients with anticoagulation criteria and have...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006887-12,0,0,0 2008-006889-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ErasmusMC,A pilotstudy comparing systemic versus locoregional injection of radiolabelled somatostatin analogues in patients with neuroendocrine Gastro-Entero_Pancreatic (GEP) tumors.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006889-29,0,0,0 2008-006891-31,1,2012-02-08,2012-02-08,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,King's College London,A randomised placebo-controlled trial of Lithium carbonate in Amyotrophic Lateral Sclerosis (LiCALS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006891-31,0,0,0 2008-006899-30,1,2011-03-04,2011-03-04,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,ISTITUTI FISIOTERAPICI OSPITALIERI,PHASE II STUDY OF 90Y-IBRITUMOMAB TIUXETAN AND FOTEMUSTINE ASSOCIATED WITH CYTARABINE ETOPOSIDE MELPHALAN AS CONDITIONING CHEMORADIOIMMUNOTHERAPY IN PATIENTS AFFECTED BY LYMPHOMA (HODGKIN AND NON-HODG...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006899-30,0,0,0 2008-006903-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Center,Narrow band UV-B phototherapy and fluticasone proprionate versus narrow band UV-B phototherapy and placebo for the treatment of active vitiligo: a randomized double blind controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006903-22,0,0,0 2008-006905-18,1,2019-09-30,2019-09-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,RWTH Aachen University,Pharmakotherapie kognitiver Defizite bei schizophrenen Störungen – Randomisierte placebokontrollierte Doppelblindstudie mit Pergolid versus Tolcapon TOCTAP (Treatment of Cognitive Deficits in Schizop...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006905-18,0,0,0 2008-006906-41,7,2010-05-18,2010-05-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd,A Modified Case Control Study To Identify Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure To Lapaquistat Acetate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006906-41,0,0,0 2008-006907-22,1,2010-08-11,2010-08-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ICORG - the All-Ireland Cooperative Oncology Research Group,A Phase II study of lapatanib and capecitabine in the treatment of metastatic pancreatic cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006907-22,0,0,0 2008-006909-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ACROSS:Associació Catalana per a la Recerca Oncològica i les seves implicacions sanitàries i Socials,"Ensayo clínico fase II con cetuximab bisemanal en combinación con oxaliplatino, 5-fluorouracilo y ácido folínico (folfox-4) en el tratamiento de primera linea del cáncer colorectal metastásico kras ti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006909-16,0,0,0 2008-006912-39,1,,,0,0,0,0,1,0,2,0,0,1,0,0,0,1,1,"VIROSTATICS, SRL","ANTIRETROVIRAL-SPARING CONCEPT: AN EXPLORATORY PHASE II, RANDOMIZED, SINGLE BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF THERAPEUTIC IMMUNIZATION ON THE QUANTITY OF HIV-SPECIFIC T CELL ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006912-39,0,0,0 2008-006913-26,1,2012-11-14,2012-11-14,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Departement of orthopaedic surgery, Århus Sygehus","Postoperative smerter efter bækkenosteotomi med lokal infiltrationsanalgesi hos børn med cerebral parese. Et prospektivt, randomiseret og dobbeltblindet studie.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006913-26,0,0,0 2008-006914-62,12,2013-04-02,2013-04-02,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Bayer HealthCare AG, 51368 Leverkusen, Germany","A Phase III, multi-center, placebo controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2 or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006914-62,0,0,0 2008-006914-62,12,2013-04-02,2013-04-02,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A Phase III, multi-center, placebo controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2 or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006914-62,0,0,0 2008-006916-39,3,2016-02-05,2016-05-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Johns Hopkins University,CLEAR III. Clot lysis: evaluating accelerated resolution of intraventricular hemorrhage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006916-39,0,0,0 2008-006917-25,5,2010-09-16,2010-09-23,5,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Nuon Therapeutics, Inc.","A Phase II, Randomized Multi-Center, Double-Blind Study of Tranilast with Concomitant Methotrexate (MTX) Compared to MTX Alone in Patients with Active Rheumatoid Arthritis (RA).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006917-25,0,0,0 2008-006919-20,1,2012-10-22,2012-10-22,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH,Phase I/II Trial of Lenalidomide in Combination with Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients with Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006919-20,0,0,0 2008-006921-14,1,2009-06-19,2009-06-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALK-Abelló Arzneimittel GmbH,A multicentre randomised Phase II clinical trial to demonstrate equivalent pharmacodynamic efficacy and tolerability of two updosing schedules for ALK-Flex SQ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006921-14,0,0,0 2008-006922-32,1,,,0,1,0,0,0,0,2,0,1,1,1,1,0,1,0,RUNMC,Heme oxygenase (HO) activity in humans. Effects of heme arginate (Normosang®) on parameters of HO activity and on adenosine induced vasodilation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006922-32,0,0,0 2008-006924-68,10,2012-04-18,2012-04-27,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"Extension Phase of the Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006924-68,0,0,0 2008-006924-68,10,2012-04-18,2012-04-27,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche,"Extension Phase of the Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006924-68,0,0,0 2008-006927-29,1,2010-04-09,2010-04-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Cytos Biotechnology AG,"A Double-blind, Placebo-controlled Study to Assess Pharmacodynamic and Clinical Efficacy of CYT003-QbG10 in Patients with Persistent Allergic Asthma Bronchiale",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006927-29,0,0,0 2008-006928-55,1,2011-02-08,2011-02-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hull and East Yorkshire NHS Trust,Are early and late cardiovascular risk markers in women with Polycystic Ovary Syndrome increased with concomitant Nonalcoholic Steatohepatitis and can this be modified with Exenatide?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006928-55,0,0,0 2008-006930-92,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Arana Therapeutics Ltd,"A multi-centre randomised, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of ART621 following multiple dose ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006930-92,0,0,0 2008-006931-11,4,2014-10-21,2014-10-21,1,1,0,1,0,2,1,0,0,1,1,0,0,0,1,Novartis Pharma Services AG,"A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of twice daily oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006931-11,0,0,0 2008-006931-11,4,2014-10-21,2014-10-21,1,1,0,1,0,2,1,0,0,1,1,0,0,0,1,NOVARTIS FARMA,"A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of twice daily oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006931-11,0,0,0 2008-006932-36,1,2014-11-25,2014-11-25,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Martin Maaroos,Comparison of biatrial pacing an intravenous metoprolol infusion in prediction of postoperative atrial fibrillation after coronary artery bypass grafting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006932-36,0,0,0 2008-006936-37,4,2011-02-18,2011-02-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development","A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis on a Stable Backg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006936-37,0,0,0 2008-006936-37,4,2011-02-18,2011-02-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc., acting through its division Wyeth Research, a Pfizer company","A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ILV-094 Administered Subcutaneously to Subjects with Active Rheumatoid Arthritis on a Stable Backg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006936-37,0,0,0 2008-006937-28,1,2012-01-12,2012-01-12,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Universitätsklinik für Klinische Pharmakologie,Effect of Rosuvastatin on endothelial function in patients with diabetes and glaucoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006937-28,0,0,0 2008-006938-94,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Dra Maria José Colomina Soler,"Ensayo clínico multicéntrico, aleatorizado y controlado con placebo para evaluar la eficacia de la utilización perioperatoria de ácido tranexámico sobre la hemorragia quirúrgica en la cirugía compleja...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006938-94,0,0,0 2008-006939-13,2,2012-01-23,2012-01-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND ACTIVITY OF MetMAb, A MONOVALENT ANTAGONIST ANTIBODY TO THE RECEPTOR MET, ADMINISTERED TO PATIENTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006939-13,0,0,0 2008-006946-24,4,2011-09-06,2013-09-17,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high gr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006946-24,0,0,0 2008-006947-38,1,2012-12-13,2012-12-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London (Institute of Pyschiatry),A randomised double-blind placebo-controlled pilot study of D-cycloserine-augmented exposure therapy in adolescents with obsessive-compulsive disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006947-38,0,0,0 2008-006949-75,1,2009-08-14,2009-08-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical University Graz, Department for Plastic Surgery",Tissue pharmacokinetics of daptomycin measured by in vivo microdialysis in patients with diabetic foot infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006949-75,0,0,0 2008-006952-23,8,2011-10-17,2013-03-05,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"ALEXION PHARMACEUTICALS, INC.","AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006952-23,0,0,0 2008-006952-23,8,2011-10-17,2013-03-05,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,ALEXION PHARMACEUTICALS,"AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006952-23,0,0,0 2008-006953-41,6,2011-10-17,2011-10-17,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"ALEXION PHARMACEUTICALS, INC.","AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006953-41,0,0,0 2008-006953-41,6,2011-10-17,2011-10-17,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ALEXION PHARMACEUTICALS,"AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006953-41,0,0,0 2008-006954-17,8,2013-10-09,2013-10-10,7,1,0,0,0,1,2,0,0,1,1,0,1,0,1,ALEXION PHARMACEUTICALS,"AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006954-17,0,0,0 2008-006954-17,8,2013-10-09,2013-10-10,7,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"ALEXION PHARMACEUTICALS, INC.","AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006954-17,0,0,0 2008-006955-28,7,2012-10-29,2013-02-13,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"ALEXION PHARMACEUTICALS, INC.","AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006955-28,0,0,0 2008-006955-28,7,2012-10-29,2013-02-13,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,ALEXION PHARMACEUTICALS,"AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006955-28,0,0,0 2008-006957-42,7,2012-05-10,2012-05-10,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, double-dummy, randomised, comparative, multi-centre phase III study on the efficacy and tolerability of an 8-week oral treatment with 9 mg budesonide once daily vs. 3 mg budesonide three...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006957-42,0,0,0 2008-006967-35,1,2010-09-13,2010-09-13,1,1,0,0,1,0,2,0,1,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für klinische Pharmakologie",The effects of intravenous heme arginate on functional magnetic resonance imaging during ischemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006967-35,0,0,0 2008-006968-11,1,2010-06-25,2010-06-25,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Action Pharma A/S,"Pharmacokinectics of AP214 Acetate in patients undergoing cardiac surgery. A randomized, double-blind, placebo-controlled sequential ascending dose trial investigating pharmacokinetics, as well as sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006968-11,0,0,0 2008-006972-31,1,2015-02-19,2015-02-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,Clinical phase II trial to evaluate the safety and efficacy of clofarabine and treosulfan conditioning prior to peripheral blood stem cells transplantation in paediatric and adult patients with advanc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006972-31,0,0,0 2008-006976-31,4,2010-03-17,2010-03-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmaceutica S.A,"A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006976-31,0,0,0 2008-006976-31,4,2010-03-17,2010-03-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006976-31,0,0,0 2008-006977-34,1,2011-07-04,2011-07-04,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients with Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006977-34,0,0,0 2008-006978-15,1,2011-09-13,2011-09-13,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,United Therapeutics Corporation,DISTOL-EXT:Digital Ischaemic Lesions in Scleroderma treated with Oral Treprostinil Diethanolamine: An open-label multicenter extension study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006978-15,0,0,0 2008-006979-72,2,2011-01-27,2011-01-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc","A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients with Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006979-72,0,0,0 2008-006980-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Efficacy and safety of anti-cytomegalovirus prophylaxis versus pre-emptive approaches with valganciclovir in heart transplant recipients treated with everolimus or mycophenolate. A randomized open-lab...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006980-35,0,0,0 2008-006981-27,1,2014-04-25,2014-04-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc","A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006981-27,0,0,0 2008-006986-10,1,2009-03-31,2009-03-31,1,1,0,0,0,0,3,1,1,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare,A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006986-10,0,0,0 2008-006989-28,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,"HUCH, Hospital for Children and Adolescents",EXTENDED ANGIOCOMB Antiangiogenetic therapy for pediatric malignancies with no conventional treatment modalities left,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006989-28,0,0,0 2008-006991-31,1,,,0,1,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Effect of the combined treatment with myo-inositol and metformin on the phenotype of the polycystic ovary syndrome: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006991-31,0,0,0 2008-006992-57,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,sanna kivivuori,Antiangiogenetic therapy for pediatric patients with inoperable benign tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-006992-57,0,0,0 2008-007004-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,Maraviroc in HIV Acute INfection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007004-29,0,0,0 2008-007008-27,7,2011-05-02,2012-05-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,Estudio abierto de terapia de mantenimiento con bevacizumab (AVASTIN) con o sin pemetrexed tras una quimioterapia de primera línea con bevacizumab-cisplatino-pemetrexed en pacientes con cáncer de pulm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007008-27,0,0,0 2008-007008-27,7,2011-05-02,2012-05-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann - La Roche Ltd.,Estudio abierto de terapia de mantenimiento con bevacizumab (AVASTIN) con o sin pemetrexed tras una quimioterapia de primera línea con bevacizumab-cisplatino-pemetrexed en pacientes con cáncer de pulm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007008-27,0,0,0 2008-007012-15,1,2011-11-09,2011-11-09,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Cytos Biotechnology AG,"A Two-Stage Randomized Placebo-controlled Ascending Dose Phase I/ IIa Study to Evaluate Safety, Tolerability, Pharmacodynamic Effects and Preliminary Efficacy of an Anti-Interleukin 1 beta Vaccine (CY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007012-15,0,0,0 2008-007015-32,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma GmbH,"A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with multip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007015-32,0,0,0 2008-007016-15,3,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,0,University of Milan,RANDOMISED STUDY OF FIRST CHOICE IMMUNOTOLERANCE INDUCTION IN PATIENTS WITH SEVERE TYPE A HAEMOPHILIA WITH INHIBITOR AT HIGH RISK OF FAILURE: COMPARISON OF INDUCTION OF IMMUNE TOLERANCE WITH FVIII CON...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007016-15,0,0,0 2008-007016-15,3,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,0,FONDAZIONE CHARTA,RANDOMISED STUDY OF FIRST CHOICE IMMUNOTOLERANCE INDUCTION IN PATIENTS WITH SEVERE TYPE A HAEMOPHILIA WITH INHIBITOR AT HIGH RISK OF FAILURE: COMPARISON OF INDUCTION OF IMMUNE TOLERANCE WITH FVIII CON...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007016-15,0,0,0 2008-007016-15,3,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,0,FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI,RANDOMISED STUDY OF FIRST CHOICE IMMUNOTOLERANCE INDUCTION IN PATIENTS WITH SEVERE TYPE A HAEMOPHILIA WITH INHIBITOR AT HIGH RISK OF FAILURE: COMPARISON OF INDUCTION OF IMMUNE TOLERANCE WITH FVIII CON...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007016-15,0,0,0 2008-007017-76,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Josep M Cruzado,"Estudio prospectivo, randomizado para comparar paratiroidectomía subtotal versus cinacalcet en el tratamiento del hiperparatiroidismo secundario persistente post trasplante renal.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007017-76,0,0,0 2008-007019-33,3,,,0,0,0,0,0,1,0,0,0,2,1,0,0,0,0,University of Milan,IMMUNE TOLERANCE INDUCTION STUDY IN PATIENTS WITH SEVERE TYPE A HAEMOPHILIA WITH INHIBITOR AFTER FAILURE OF A PREVIOUS INDUCTION OF IMMUNE TOLERANCE WITH FVIII CONCENTRATES WITHOUT VON WILLEBRAND FACT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007019-33,0,0,0 2008-007019-33,3,,,0,0,0,0,0,1,0,0,0,2,1,0,0,0,0,FONDAZIONE CHARTA,IMMUNE TOLERANCE INDUCTION STUDY IN PATIENTS WITH SEVERE TYPE A HAEMOPHILIA WITH INHIBITOR AFTER FAILURE OF A PREVIOUS INDUCTION OF IMMUNE TOLERANCE WITH FVIII CONCENTRATES WITHOUT VON WILLEBRAND FACT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007019-33,0,0,0 2008-007019-33,3,,,0,0,0,0,0,1,0,0,0,2,1,0,0,0,0,FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI,IMMUNE TOLERANCE INDUCTION STUDY IN PATIENTS WITH SEVERE TYPE A HAEMOPHILIA WITH INHIBITOR AFTER FAILURE OF A PREVIOUS INDUCTION OF IMMUNE TOLERANCE WITH FVIII CONCENTRATES WITHOUT VON WILLEBRAND FACT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007019-33,0,0,0 2008-007020-25,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AMC,Glucose lowering by continuous tube feeding and Vildagliptin in addition to insulin in hyperglycemic acute stroke patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007020-25,0,0,0 2008-007023-26,4,2012-02-10,2012-02-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007023-26,0,0,0 2008-007023-26,4,2012-02-10,2012-02-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"PHASE 3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007023-26,0,0,0 2008-007024-26,1,2011-05-09,2011-05-09,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Bayer Healthcare AG,"A single-center, open-label, crossover, randomized study to investigate the impact of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestogene (material no. 8087639...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007024-26,0,0,0 2008-007026-19,1,2012-12-20,2012-12-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Aventis Pharma Ltd trading as sanofi-aventis,COMPARISON OF A BASAL PLUS ONE INSULIN REGIMEN (INSULIN GLARGINE/INSULIN GLULISINE) WITH A BIPHASIC INSULIN REGIMEN (INSULIN ASPART/INSULIN ASPART PROTAMINE 30/70) IN TYPE 2 DIABETES PATIENTS FOLLOWIN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007026-19,0,0,0 2008-007027-11,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA CARDARELLI,OTTIMIZZAZIONE DELLA PROFILASSI CON IMMUNOGLOBULINE ANTIEPATITE B (HBIG) IN PAZIENTI SOTTOPOSTI A TRAPIANTO DI FEGATO PER EPATOPATIA CORRELATA AL VIRUS DELL`EPATITE B (HBV),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007027-11,0,0,0 2008-007028-25,1,2013-09-05,2013-09-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospitals Bristol NHS Foundation Trust,A Randomised Controlled Trial to Determine the Effect of Decapeptyl on Reduction of Prostate Volume Pre-Radiotherapy Compared with Standard Therapy (Zoladex),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007028-25,0,0,0 2008-007031-41,1,2012-08-31,2012-08-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Center for Stroke Research Berlin - Charité Universitätsmedizin Berlin,"Beta-Blocker in Acute Ischemic Stroke – a prospective, randomized, double-blinded, placebo-controlled safety and efficacy trial of early treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007031-41,0,0,0 2008-007033-41,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Hephata-Klinik,Pilot study on therapeutic efficacy of modafinil in idiopathic hypersomnie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007033-41,0,0,0 2008-007038-24,3,2011-07-21,2011-07-22,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ViiV Healthcare UK Limited,"""Estudio piloto de una nueva combinación de maraviroc + atazanavir/ritonavir frente a atazanavir/ritonavir + emtricitabina/tenofovir para el tratamiento de pacientes con infección por VIH del tipo VIH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007038-24,0,0,0 2008-007038-24,3,2011-07-21,2011-07-22,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer. S.A.,"""Estudio piloto de una nueva combinación de maraviroc + atazanavir/ritonavir frente a atazanavir/ritonavir + emtricitabina/tenofovir para el tratamiento de pacientes con infección por VIH del tipo VIH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007038-24,0,0,0 2008-007038-24,3,2011-07-21,2011-07-22,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","""Estudio piloto de una nueva combinación de maraviroc + atazanavir/ritonavir frente a atazanavir/ritonavir + emtricitabina/tenofovir para el tratamiento de pacientes con infección por VIH del tipo VIH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007038-24,0,0,0 2008-007043-14,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University Hospital Southampton NHS Foundation Trust,A Pilot Study of Clofarabine Pre-Conditioning Prior to Full or Reduced Intensity Allogeneic Transplantation in the Treatment of High Risk Acute Myeloid Leukaemia and Myelodysplasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007043-14,0,0,0 2008-007047-13,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,Prevention and treatment of kidney transplantation rejection by means of innovative therapeutic apheresis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007047-13,0,0,0 2008-007053-13,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,"Grachtenhaus-Apotheke, Inh. Klaus Stegemann e. K.","Doppelblinde, randomisierte, Placebo-kontrollierte Studie der Phase III zur Bestimmung der Wirksamkeit, Verträglichkeit und Sicherheit von intravesikal verabreichter Oxybutynin-Lösung bei Kindern/Juge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007053-13,0,0,0 2008-007054-35,2,2011-05-24,2014-07-25,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A RANDOMIZED PHASE III STUDY OF IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007054-35,0,0,0 2008-007055-28,5,2010-03-26,2010-03-26,5,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Ferrer International, SA","GF-001001-00 cream. A multicentre, randomised, double-blind, parallel, placebo-controlled phase II study to assess the efficacy and safety of 3 different doses of GF-001001-00 cream versus placebo cr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007055-28,0,0,0 2008-007055-28,5,2010-03-26,2010-03-26,5,0,0,0,0,0,2,0,0,1,0,0,1,0,1,FERRER INTERNACIONAL S.A.,"GF-001001-00 cream. A multicentre, randomised, double-blind, parallel, placebo-controlled phase II study to assess the efficacy and safety of 3 different doses of GF-001001-00 cream versus placebo cr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007055-28,0,0,0 2008-007057-12,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,ROCHE,A Randomized open label study of the effect of first line combination treatment with Avastin (bevacizumab) plus paclitaxel and gemcitabine Compared With Avastin (bevacizumab) plus paclitaxel on ob...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007057-12,0,0,0 2008-007058-36,1,2011-10-13,2011-10-13,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Aegerion Pharmaceuticals,A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients with Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007058-36,0,0,0 2008-007067-16,1,2009-12-10,2009-12-10,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,JELFA SA,"Randomised, double-blind, parallel-group, comparative study of two terbinafine products",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007067-16,0,0,0 2008-007086-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,OSPEDALE POLICLINICO S. MATTEO,Whole lung lavage followed by inhaled Sargramostim in the treatment of autoimmune pulmonary alveolar proteinosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007086-23,0,0,0 2008-007087-42,9,2010-03-30,2010-04-27,9,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Sym...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007087-42,0,0,0 2008-007090-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Nîmes,Analgésie post-opératoire après prothèse totale de hanche : Intérêt de l’infiltration péri articulaire d’anesthésiques locaux,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007090-20,0,0,0 2008-007093-37,5,2011-10-11,2011-10-11,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Actavis Deutschland GmbH & Co.Kg,"CLEOPATRA: Eficacia clínica de Pentalong® en pacientes con angina de pecho estable después de 12 semanas de administración sistemática: ensayo aleatorizado, doble ciego, controlado con placebo. Clini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007093-37,1,0,0 2008-007093-37,5,2011-10-11,2011-10-11,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Actavis Deutschland GmbH & Co. KG,"CLEOPATRA: Eficacia clínica de Pentalong® en pacientes con angina de pecho estable después de 12 semanas de administración sistemática: ensayo aleatorizado, doble ciego, controlado con placebo. Clini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007093-37,1,0,0 2008-007094-20,1,2017-03-06,2017-03-06,1,1,0,0,1,0,3,0,0,1,1,1,1,0,0,Institut Bergonié,Étude multicentrique de phase III évaluant L’efficacité d’une stratégie d’adaptation de dose de l’imatinib mésylate sur la réponse moléculaire chez des patients présentant une leucémie myéloïde chroni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007094-20,0,0,0 2008-007097-38,3,2013-07-26,2013-07-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer-Ingelheim France,"A randomized, open-label Phase II study of BIBW 2992 versus cetuximab (Erbitux®) in patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) after failure of platinum-contai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007097-38,0,0,0 2008-007097-38,3,2013-07-26,2013-07-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim España S.A.,"A randomized, open-label Phase II study of BIBW 2992 versus cetuximab (Erbitux®) in patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) after failure of platinum-contai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007097-38,0,0,0 2008-007097-38,3,2013-07-26,2013-07-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A randomized, open-label Phase II study of BIBW 2992 versus cetuximab (Erbitux®) in patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) after failure of platinum-contai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007097-38,0,0,0 2008-007104-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset,Multiferon treatment of non-responders to peg-IFN alfa plus ribavirin standard of care treatment - a study of the early viral kinetics during the initial 12 weeks treatment.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007104-28,0,0,0 2008-007105-36,3,2010-09-02,2010-09-02,1,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Chelsea Therapeutics Inc.,"A MULTI-CENTER, ONE-YEAR OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE BETA HYDROXYLASE DEFICIENCY OR NON-DIABETIC NEUROPATHY AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007105-36,0,0,0 2008-007105-36,3,2010-09-02,2010-09-02,1,1,0,0,0,1,3,0,0,1,1,1,1,0,1,CHELSEA THERAPEUTICS INC.,"A MULTI-CENTER, ONE-YEAR OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE BETA HYDROXYLASE DEFICIENCY OR NON-DIABETIC NEUROPATHY AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007105-36,0,0,0 2008-007110-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,LFB BIOTECHNOLOGIES,"An international randomised, double-blind, placebo-controlled study to assess the efficacy and safety of 2 dosing regimens of FIBRINOGENE T1 in the treatment of peri-operative bleeding associated with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007110-29,0,0,0 2008-007125-39,1,2018-09-30,2018-09-30,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,"Klinik f. Innere Med., Fachabteilung Hämatologie","A phase I-II trial of lenalidomide, bendamustin and dexamethasone in the treatment of patients with systemic AL-amyloidosis and ineligible for stem cell transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007125-39,0,0,0 2008-007144-33,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,1,PROMEFARM,"Evaluation of a new reduced volume bowel preparation before colonoscopy Multicentre, randomised, observer-blind, parallel group,comparative study with a reference formulation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007144-33,0,0,0 2008-007147-13,6,2011-04-27,2011-04-30,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"A Phase IIb, randomized, double-blind, placebo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including peginterferon ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007147-13,0,0,0 2008-007149-30,1,2015-06-26,2015-06-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,Optimal Treatment of Drug Resistant Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007149-30,0,0,0 2008-007149-30,1,2015-06-26,2015-06-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cambridge Clinical Trials Unit,Optimal Treatment of Drug Resistant Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007149-30,0,0,0 2008-007152-94,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY,Efficacy and Safety of RAD001 (Everolimus) in Patients Affected by Biliary Tract Cancer Progressing After Prior Chemotherapy: a Phase II I.T.M.O. Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007152-94,0,0,0 2008-007153-13,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY,"An open label, single arm, phase II study of combination RAD001 and octreotide LAR in patients with advanced neuroendocrine tumors as first line treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007153-13,0,0,0 2008-007155-27,3,2012-04-18,2012-04-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ARQULE,A Randomized Controlled Phase 2 Trial of ARQ 197 in Patients with Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007155-27,0,0,0 2008-007155-27,3,2012-04-18,2012-04-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ArQule, Inc.",A Randomized Controlled Phase 2 Trial of ARQ 197 in Patients with Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007155-27,0,0,0 2008-007157-12,3,2013-03-14,2013-04-11,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,CENTOCOR,"A Randomized, Open label, Phase 2 Study of CNTO 328 (Anti IL 6 Monoclonal Antibody) and VELCADE Melphalan Prednisone Compared With VELCADE-Melphalan-Prednisone for the Treatment of Previously Untreate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007157-12,0,0,0 2008-007157-12,3,2013-03-14,2013-04-11,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Centocor BV,"A Randomized, Open label, Phase 2 Study of CNTO 328 (Anti IL 6 Monoclonal Antibody) and VELCADE Melphalan Prednisone Compared With VELCADE-Melphalan-Prednisone for the Treatment of Previously Untreate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007157-12,0,0,0 2008-007158-36,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,"Amicus Therapeutics, Inc.","An open-label, multicentre, long-term extension study to assess the safety, efficacy and pharmacodynamics of AT2101 in adult patients with Type I Gaucher disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007158-36,0,0,0 2008-007161-23,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,CHU de Nîmes,Etude comparative de l’efficacité articulaire et fonctionnelle du Mélange Equimoléculaire Oxygène-Protoxyde d’Azote (MEOPA) dans la rééducation des capsulites rétractiles d'épaule.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007161-23,0,0,0 2008-007162-32,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,ISTITUTO C. MONDINO,ADVANCED MRI STUDY ON INFLAMMATORY AND DEGENRATIVE DAMAGE IN MULTIPLE SCLEROSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007162-32,0,0,0 2008-007163-16,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,CHU de Nîmes,"La TEP-TDM au 18F-FDG : permet-elle d’optimiser les résultats de la scintigraphie à la I123-MIBG dans la recherche d’éléments discriminants pour l’implantation d’un défibrillateur implantable, en prév...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007163-16,0,0,0 2008-007167-16,11,2013-12-08,2014-02-24,9,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007167-16,1,0,0 2008-007168-40,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Use of 68Ga-DOTA-NOC for the evaluation of patients with Idiopathic pulmonary fibrosis STUDY CODE: 68Ga-DOTA-NOC/ILD 01/2008,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007168-40,0,0,0 2008-007173-20,1,2009-04-16,2009-04-16,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Pierre Fabre Dermatologie represented by Institut de Recherche Pierre Fabre,"Assessment of the activity of a new cream containing betamethasone dipropionate at 0.010%, 0.025% and 0.050% versus reference products using a vasoconstriction assay in healthy subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007173-20,0,0,0 2008-007175-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University of Pécs, Medical School, Department of Ophthalmology","A randomized, controlled, two-center phase II. study assessing the efficacy and safety of intravitreal Lucentis injections in patients with clinically significant macular edema secondary to central re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007175-24,0,0,0 2008-007176-22,1,2010-06-26,2010-06-26,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Department of Medicine M, Aarhus University Hospital","A comparison of pharmacodynamics and pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 70 and 50 & Fast-acting Human Insulin in patients with Type 1 diabetes, A randomised, quadruple cross-o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007176-22,0,0,0 2008-007177-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospital Clinic Barcelona,EFECTO DEL SIROLIMUS SOBRE LOS BIOMARCADORES RELACIONADOS CON LA TOLERANCIA EN RECEPTORES DE TRASPLANTE HEPÁTICO ESTABLES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007177-20,0,0,0 2008-007178-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Center for Biomedical Research of La Rioja (CIBIR),"Estudio unicéntrico de fase II, doble ciego, randomizado, comparando doxiciclina administrada oralmente frente a placebo en pacientes con pterigión. Single center, double blind, randomized clinical t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007178-39,0,0,0 2008-007179-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hopital Foch,"Evaluation de l’effet anesthésique de la dexmédétomidine dans une population d’opérés recevant une anesthésie totale intraveineuse en « boucle » guidée par l’index bispectral (Etude monocentrique, pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007179-26,0,0,0 2008-007180-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,LUMC,INFLUENCE OF B CELL DEPLETION BY MONOCLONAL ANTI-CD20 ANTIBODIES IN SYSTEMIC SCLERODERMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007180-16,0,0,0 2008-007182-23,1,2011-03-08,2011-03-08,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Health Protection Agency,"A phase 2, open-label study of the safety, tolerability and immunogenicity of a Novartis meningococcal B vaccine when administered at a 0, 2, 6 month schedule and of a single dose of Novartis meningoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007182-23,0,0,0 2008-007183-42,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Pfizer Ltd.,"A PHASE IIb RANDOMISED DOUBLE BLIND, PLACEBO CONTROLLED PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-00610355 OVER 4 WEEKS IN MODERATE ASTHMATIC SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007183-42,0,0,0 2008-007185-33,5,2010-10-15,2011-01-12,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company","A Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103 Administered to Subjects With Active Rheumatoid Arthritis on a Background of Methotrexate",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007185-33,0,0,0 2008-007185-33,5,2010-10-15,2011-01-12,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103 Administered to Subjects With Active Rheumatoid Arthritis on a Background of Methotrexate",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007185-33,0,0,0 2008-007185-33,5,2010-10-15,2011-01-12,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Wyeth Pharmaceuticals Inc., Acting through its division Wyeth Research, a Pfizer Company","A Seamless, Phase 1/2, Multiple Ascending Dose, Proof of Concept Study of ATN-103 Administered to Subjects With Active Rheumatoid Arthritis on a Background of Methotrexate",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007185-33,0,0,0 2008-007190-20,3,2010-11-17,2010-11-17,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca AB,"An International, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase IV Study of the Safety and Efficacy of Lithium versus Placebo as an add on to SEROQUEL XR™ (Quetiapine Fumarate) in A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007190-20,0,0,0 2008-007205-36,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,DETERMINATION DE LA DOSE MINIMALE EFFICACE DE ROPIVACAINE POUR RACHIANESTHÉSIE UNILATÉRALE HYPOBARE AU COURS DE LA CHIRURGIE TRAUMATIQUE DU COL FÉMORAL CHEZ LA PERSONNE ÂGÉE : ÉTUDE PROSPECTIVE COMPAR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007205-36,0,0,0 2008-007208-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Asociación para el Estudio de las Enfermedades Infecciosas,Estudio comparativo de dos métodos para predecir el uso de co-receptores por el virus de la inmunodeficiencia 1 (HIV-1): el ensayo fenotípico (Trofile ESTA®) y la respuesta virológica a corto plazo a ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007208-28,0,0,0 2008-007225-39,1,2016-11-21,2016-11-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Leuven,A 2 year prospective multicentre randomised controlled trial comparing effectiveness in daily practice of different treatment strategies for early RA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007225-39,0,0,0 2008-007226-19,4,2010-05-27,2010-05-27,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Tranzyme Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic Ga...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007226-19,0,0,0 2008-007232-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"University of Szeged, Medical and Pharmaceutical Center, Department of Ophthalmology","Comparison of the effect of intravitreal ranibizumab injections compared to macular grid-pattern laser therapy for the symptomatic treatment of diabetic macular edema (a randomized, controlled, phase ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007232-18,0,0,0 2008-007232-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Semmelweis University Department of Ophthalmology,"Comparison of the effect of intravitreal ranibizumab injections compared to macular grid-pattern laser therapy for the symptomatic treatment of diabetic macular edema (a randomized, controlled, phase ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007232-18,0,0,0 2008-007232-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Cholnoky F. County Hospital Veszprém Department of Ophthalmology,"Comparison of the effect of intravitreal ranibizumab injections compared to macular grid-pattern laser therapy for the symptomatic treatment of diabetic macular edema (a randomized, controlled, phase ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007232-18,0,0,0 2008-007235-40,1,2010-07-10,2010-07-10,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Department für Pädiatrie, Medizinische Universität Innsbruck",Development of Varicella-zoster virus (VZV)-specific CD4+ T cells on primary VZV infection or vaccination in renal transplant (RTX) recipients and healthy donors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007235-40,0,0,0 2008-007236-18,1,2013-06-20,2013-06-20,1,0,0,0,0,1,4,0,0,1,1,1,1,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"Effects of cardioprotective therapy, carvedilol vs ramipril, in patients affected by Duchenne and Becker muscular dystrophy. Clinical significance and prognostic value of Cardiac Magnetic Resonance st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007236-18,0,0,0 2008-007237-47,1,2017-10-19,2017-10-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Charité - Universitätsmedizin Berlin,Perioperative physostigmine prophylaxis for liver resection patients at risk for delirium and postoperative cognitive dysfunction Perioperative Gabe von Physostigmin bei Leberteilresktion zur Prophyl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007237-47,0,0,0 2008-007238-23,1,2009-06-14,2009-06-14,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Niconovum AB,"Anopen label, randomised, two-way crossover bioequivalence study in healthy sokers of Zonnic 1,5 mg nicotine gum versus Nicorette 4 mg nicotine chewing gum Classic flavour",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007238-23,0,0,0 2008-007240-34,1,2011-08-03,2011-08-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,NHS Greater Glasgow & Clyde Hospitals & University of Glasgow,"Effect of macrolides on asthma control, airway inflammation and bacterial colonisation in smokers with asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007240-34,0,0,0 2008-007244-33,1,2010-06-02,2010-06-02,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline Research & Development Limited,The efficacy of orally administered GSK2190915 as an add-on to current therapy in subjects with moderate to severe asthma who have elevated sputum neutrophils,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007244-33,0,0,0 2008-007246-60,3,2016-09-02,2017-06-30,3,1,0,1,0,1,1,0,0,1,0,0,0,0,0,Nordic Lymphoma Group,"Lenalidomide, bendamustine and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007246-60,0,0,0 2008-007264-41,1,,,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,"Iho-ja allergiasairaala, HUS","Keuhkoputkien supistumistaipumus 3-6-vuotiailla, hengitystieoireisilla lapsilla",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007264-41,0,0,0 2008-007285-29,1,2014-08-20,2014-08-20,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,HUS,Tehoaako haavapuudutepumppu sektion jälkeisessä kivunhoidossa?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007285-29,0,0,0 2008-007287-42,1,2010-09-30,2010-09-30,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA DI PARMA,Ivabradine in multislice CT: comparison with metoprolol in the reduction of motion artefacts and in the improvement of diagnostic care.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007287-42,0,0,0 2008-007290-20,10,2014-08-01,2014-12-20,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,The Medicines Company UK Ltd,Ensayo europeo en ambulancias para tratar el síndrome coronario agudo: EUROMAX,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007290-20,0,0,0 2008-007290-20,10,2014-08-01,2014-12-20,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,THE MEDICINES COMPANY UK,Ensayo europeo en ambulancias para tratar el síndrome coronario agudo: EUROMAX,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007290-20,0,0,0 2008-007290-20,10,2014-08-01,2014-12-20,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,The Medicines Company UK Ltd.,Ensayo europeo en ambulancias para tratar el síndrome coronario agudo: EUROMAX,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007290-20,0,0,0 2008-007292-25,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,GIULIANI,"AN OPEN, PILOT PHASE III, RANDOMIZED CLINICAL TRIAL TO ASSESS THE TISSUTAL PHARMAKINETICS OF MESALAZINE TABLETS IN PATIENTS WITH MILD TO MODERATE LEFT-SIDED ULCERATIVE COLITIS IN ACTIVE PHASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007292-25,0,0,0 2008-007295-14,4,,,0,0,0,0,0,2,3,0,0,2,1,0,0,0,0,EORTC,Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007295-14,0,0,0 2008-007295-14,4,,,0,0,0,0,0,2,3,0,0,2,1,0,0,0,0,European Organization for Research and Treatment of Cancer (EORTC),Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007295-14,0,0,0 2008-007296-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AISF - ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO,"Multicenter open-label, phase IIB study with 0.5 mg / day Entecavir (BARACLUDE ) in patients with positive HBsAg solid or hematologic malignancies undergoing chemotherapy (ChemET) (ChemET)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007296-24,0,0,0 2008-007297-38,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Effects of Atorvastatin on Number and Function of Pro-inflammatory CD4+CD28null T-cells and Defective Treg in Patients with Acute Coronary Syndromes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007297-38,0,0,0 2008-007299-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Juan Pasquau Liñao,Intervención sobre los profesionales sanitarios para reducir la duración del tratamiento antibiótico en el ámbito Hospitalario,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007299-20,0,0,0 2008-007305-36,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,GELTAMO (Grupo Español de Linfoma y Transplante Autólogo de Médula Ósea),"Estudio fase II prospectivo, abierto, multicéntrico de Gemcitabina, Oxaliplatino y Dexametasona + Rituximab en pacientes con linfomas agresivos (difuso de céluls grandes B y del manto) en recaída o re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007305-36,0,0,0 2008-007307-91,1,2010-12-21,2010-12-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Long-Term, Phase 2, Multicenter, Randomized, Open-Label, Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007307-91,0,0,0 2008-007308-27,3,2010-09-03,2010-09-03,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Bayer HealthCare AG,"Multi-center, open-label, randomized, parallel-group comparison of cycle control, bleeding pattern, lipid and carbohydrate metabolism of the transdermal contraceptive patch containing 0.55 mg ethinyle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007308-27,0,0,0 2008-007309-35,1,,,0,1,0,0,1,0,4,0,0,1,1,1,0,1,0,Barts and The London NHS Trust,The Cerebrospinal Fluid (CSF) pharmacokinetics of a single pre-operative intravenous bolus dose of diclofenac (Dyloject) in comparison of diclofenac infusion (Voltarol),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007309-35,0,0,0 2008-007313-68,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,1,GRIFOLS ITALIA,A Prospective Randomized Pilot study to evaluate the effect of preoperative antithrombin supplementation on postoperative levels of antithrombin in patients undergoing cardiac surgery with cardiopulmo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007313-68,0,0,0 2008-007315-32,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University Hospitals Bristol NHS Foundation Trust,CIRCADIAN VARIATIONS IN CYTOKINES AND THE EFFECT OF TIMED RELEASE TABLET PREDNISONE IN POLYMYALGIA RHEUMATICA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007315-32,0,0,0 2008-007319-33,1,2011-07-22,2011-07-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Leeds Teaching Hospitals NHS Trust,Do genes predict response to treatment in age-related macular degeneration?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007319-33,0,0,0 2008-007320-25,5,2011-09-15,2011-09-15,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,TROPHOS,"Phase II/III, multicenter, randomized, parallel group, double-blind, placebo controlled study to assess safety and efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with ril...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007320-25,0,0,0 2008-007320-25,5,2011-09-15,2011-09-15,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,TROPHOS SA,"Phase II/III, multicenter, randomized, parallel group, double-blind, placebo controlled study to assess safety and efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with ril...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007320-25,0,0,0 2008-007322-19,1,2012-04-10,2012-04-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Queen Victoria Hospital NHS Foundation Trust,A Comparison of Remifentanil Patient-Controlled Analgesia vs. Oral Morphine Analgesia for Dressing Changes in Burns Patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007322-19,0,0,0 2008-007323-64,3,2009-07-07,2009-08-10,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Serentis Limited,"A phase II, double-blind, vehicle controlled study to determine the efficacy, safety and toleration of SRD441 ointment in patients with atopic dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007323-64,0,0,0 2008-007326-19,10,2017-01-24,2017-01-24,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007326-19,0,0,0 2008-007326-19,10,2017-01-24,2017-01-24,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann - La Roche Ltd,"A phase III, randomized, open-label study to compare pharmacokinetics, efficacy and safety of subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with HER2 positive e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007326-19,0,0,0 2008-007329-38,2,2011-12-30,2011-12-30,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,ERYDEL S.P.A.,"Estudio multicéntrico, aleatorizado, con doble enmascaramiento en grupos paralelos, sobre la dexametasona intraeritrocitaria comparada con un placebo en pacientes con enfermedad de Crohn dependiente d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007329-38,0,0,0 2008-007334-22,1,2011-03-21,2011-03-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, double-blind, double-dummy, 2-arm parallel-group, multicenter 24-week study comparing the efficacy and safety of AVE0010 to sitagliptin as add-on to metformin in obese type 2 diabetic pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007334-22,0,0,0 2008-007335-40,11,2011-08-01,2011-08-01,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week double-blind treatment period assessing the efficacy and safety of lixisenatide in patients with Type 2 diabet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007335-40,0,0,0 2008-007335-40,11,2011-08-01,2011-08-01,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & De`veloppement,"A randomized, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week double-blind treatment period assessing the efficacy and safety of lixisenatide in patients with Type 2 diabet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007335-40,0,0,0 2008-007336-17,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,"Medizinische Universität Wien, Uni. Klinik für Neurologie","Blockade of the greater occipital nerve in frequent migraine and medication-overuse headache - a double-blinded, randomized, controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007336-17,0,0,0 2008-007337-49,1,2009-08-12,2009-08-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase II, randomized, double-blind, placebo controlled, multi-center study to evaluate the effects of LCI699 on cortisol in patients with hypertension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007337-49,0,0,0 2008-007338-23,1,2009-10-13,2009-10-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase II, randomized, double-blind, placebo and active controlled, parallel group, multi-center, dose ranging study to evaluate the efficacy and safety of LCI699 compared to placebo after 8 weeks tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007338-23,0,0,0 2008-007344-34,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Academic Medical Centre,"External Cephalic Version with uterine relaxation: atosiban versus fenoterol, a multi-centre trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007344-34,0,0,0 2008-007345-31,17,2011-10-17,2019-10-04,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc., acting through its division of Wyeth Research",A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007345-31,0,0,0 2008-007345-31,17,2011-10-17,2019-10-04,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Research, Division of Wyeth Pharmaceuticals, Inc.",A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007345-31,0,0,0 2008-007345-31,17,2011-10-17,2019-10-04,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Puma Biotechnology, Inc",A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007345-31,0,0,0 2008-007345-31,17,2011-10-17,2019-10-04,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc., acting through its division of Wyeth Research, a Pfizer company",A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007345-31,0,0,0 2008-007346-63,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Alloksys Life Sciences B.V.,"Reumap: An Open Label phase II study of Bovine Intestinal Alkaline Phosphatase (bIAP), An Inflammation modulating moiety, in RA patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007346-63,0,0,0 2008-007347-13,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Baxter Innovations GmbH,Advate (rAHF-PFM): Pharmacokinetic comparison of 3000 IU Advate (rAHF-PFM) (using one 3000 IU potency vial) with 3000 IU Advate (rAHF-PFM) (using two 1500 IU potency vials) in previously treated patie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007347-13,0,0,0 2008-007348-32,4,2015-06-10,2015-06-10,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007348-32,0,0,0 2008-007348-32,4,2015-06-10,2015-06-10,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Farmaceútica S.A.,"An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007348-32,0,0,0 2008-007348-32,4,2015-06-10,2015-06-10,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007348-32,0,0,0 2008-007349-30,1,2011-02-11,2011-02-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"Open-label, phase II, randomized, comparative, multicentre trial of concurrent Whole Brain Radiation Therapy (WBRT) and capecitabine (Xeloda®) followed by maintenance capecitabine compared with standa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007349-30,0,0,0 2008-007350-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ROCHE,"A single arm, open-label trial assessing the effect of Capecitabine (Xeloda®) on progression-free survival rate at four months in breast cancer patients with CNS progression after whole brain radiothe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007350-35,0,0,0 2008-007353-12,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,0,UNIVERSITA` DEGLI STUDI DI PARMA,METHOTREXATE AS STEROID-SPARING AGENT IN IDIOPATHIC RETROPERITONEAL FIBROSIS: A MULTICENTRE RANDOMISED CONTROLLED TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007353-12,0,0,0 2008-007365-23,1,2011-02-09,2011-02-09,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of BMN 110 in Subjects with Mucopolysaccharidosis IVA (Morquio Syndrome)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007365-23,0,0,0 2008-007384-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Sten Walther,"A prospective, multi-centre, randomised, double-blind, placebo-controlled comparison of intravenous dexmedetomidine with haloperidol in treatment of hyperactive delirium after heart surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007384-17,0,0,0 2008-007404-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",Role of Estrogens in osteoclastogenesis and immunomodulation of T cells.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007404-28,0,0,0 2008-007405-37,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"Multicenter, not-for-profit study to evaluate tolerability, safety of tramadol once-a-day in older patients with dementia and difficulty to verbalize",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007405-37,0,0,0 2008-007406-11,1,2010-05-21,2010-05-21,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Enobia Canada Limited Partnership,"A Multicenter, Open-Label Study of the Safety, Tolerability and Pharmacology of ENB-0040 (Enobia’s human recombinant tissue non-specific alkaline phosphatase fusion protein) in up to 6 Severely Affect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007406-11,0,0,0 2008-007407-86,3,2013-01-23,2013-01-31,2,1,0,0,0,0,0,0,0,1,0,0,1,0,0,Medizinische Universität Innsbruck - Universitätsklinik für Innere Medizin III,Efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007407-86,0,0,0 2008-007412-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut Gustave Roussy,"Essai de phase III comparant la perfusion isolée pelvienne (PIP) avec du TNF-α 0,3 mg et du melphalan 1,5 mg/kg versus traitement standard dans les tumeurs pelviennes localement évoluées d’origine gyn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007412-15,0,0,0 2008-007413-76,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Pertti Suominen,Metyyliprednisolonin farmakokinetiikka ja -dynamiikka lasten avosydänleikkausten yhteydessä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007413-76,0,0,0 2008-007416-15,5,2012-11-29,2013-11-29,5,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX 770 in Subjects with Cystic Fibrosis and the G551D Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007416-15,0,0,0 2008-007420-26,2,2011-01-12,2011-01-12,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AstraZeneca AB,"A phase IIa, double-blind, randomized, 2-way cross-over study to evaluate the effect of a single dose of AZD1386 95 mg compared to placebo in a multimodal experimental pain model on esophageal sensiti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007420-26,0,0,0 2008-007444-34,8,2012-10-17,2012-10-17,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination with Metformin in Su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007444-34,0,0,0 2008-007444-34,8,2012-10-17,2012-10-17,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd,"A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination with Metformin in Su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007444-34,0,0,0 2008-007445-31,1,2010-09-30,2010-09-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Cellerix, S.A",Estudio multicéntrico fase I-IIa para evaluar la seguridad y eficacia de células madre expandidas derivadas de tejido adiposo alogénico (eASCs) (Cx601) para el tratamiento de las fístulas perianales c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007445-31,0,0,0 2008-007446-54,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,"Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam",LOWERING VIRAL LOAD WITH NUCLEOS(T)IDE ANALOGUES PRIOR TO PEG-INTERFERON ALFA-2B TREATMENT TO INCREASE SUSTAINED RESPONSE IN HBEAG-POSITIVE CHRONIC HEPATITIS B (PADD-STUDY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007446-54,0,0,0 2008-007447-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II,GH-IGF-I status and Multiple Sclerosis: clinical implications (a prevalence study). Asse GH-IGF-1 e Sclerosi Multipla: implicazioni cliniche (studio di prevalenza),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007447-14,0,0,0 2008-007455-26,5,2012-01-05,2012-01-05,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007455-26,0,0,0 2008-007456-96,2,2010-04-20,2010-07-20,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc","A Phase 2b, Double blind, Randomized, Parallel Group, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS 9450 in Adults with Chronic Hepatitis C Virus Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007456-96,0,0,0 2008-007457-13,3,2012-02-01,2012-02-14,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dainippon Sumitomo Pharma America Inc.,"A Randomized, 6-Week, Double-Blind, Placebo-controlled, Fixed-Flexible-Dose, Parallel-Group Study of Lurasidone in the Treatment of Bipolar I Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007457-13,0,0,0 2008-007457-13,3,2012-02-01,2012-02-14,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Sunovion Pharmaceuticals, Inc.","A Randomized, 6-Week, Double-Blind, Placebo-controlled, Fixed-Flexible-Dose, Parallel-Group Study of Lurasidone in the Treatment of Bipolar I Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007457-13,0,0,0 2008-007458-37,2,2011-05-23,2011-05-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biotest AG,"A randomized, placebo-controlled, double-blind, multicentre, multiple dose, cohort study with escalating doses to evaluate the safety and efficacy of the humanized monoclonal antibody (mab) BT061 admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007458-37,0,0,0 2008-007459-28,8,2012-06-13,2012-06-13,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly and Company,"Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007459-28,0,0,0 2008-007467-17,8,2012-01-19,2012-01-19,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label, multi-center, 24-month extension study to evaluate the safety of ranibizumab as symptomatic treatment for visual impairment due to diabetic macular edema in patients who have complet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007467-17,0,0,0 2008-007467-17,8,2012-01-19,2012-01-19,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An open-label, multi-center, 24-month extension study to evaluate the safety of ranibizumab as symptomatic treatment for visual impairment due to diabetic macular edema in patients who have complet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007467-17,0,0,0 2008-007467-17,8,2012-01-19,2012-01-19,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","An open-label, multi-center, 24-month extension study to evaluate the safety of ranibizumab as symptomatic treatment for visual impairment due to diabetic macular edema in patients who have complet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007467-17,0,0,0 2008-007468-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,LUMC,STUDY ON PLEIOTROPE EFFECTS OF HIGH DOSE STATIN IN THE COMMENCEMENT OF INFLAMMATORY PROCESSES IN THE ABDOMINAL AORTIC ANEURYSM WALL.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007468-41,0,0,0 2008-007470-38,1,2011-04-30,2011-04-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Mikko Pitkänen,LIA (Local infiltration analgesia) vs intrathecal morphine for postoperative pain relief after hip arthroplasty,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007470-38,0,0,0 2008-007474-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,GREEN LIGHT: Intra-operative fluorescent imaging of sentinel lymph nodes in breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007474-38,0,0,0 2008-007476-19,1,2013-02-27,2013-02-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospitals Bristol NHS Trust,A prospective case series of Ranibizumab for the treatment of inflammatory and idiopathic choroidal neovascular membranes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007476-19,0,0,0 2008-007478-39,3,2010-12-23,2010-12-23,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Janssen Cilag International, N.V.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Postherpetic Neuralgia and Post-Trau...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007478-39,0,0,0 2008-007478-39,3,2010-12-23,2010-12-23,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Janssen Cilag International, NV","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Postherpetic Neuralgia and Post-Trau...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007478-39,0,0,0 2008-007479-26,4,2011-04-28,2011-10-14,4,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, 2 Part, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX 770 in Subjects Aged 6 to 11 Years with Cystic Fibrosi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007479-26,0,0,0 2008-007482-23,3,2011-12-01,2012-01-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dainippon Sumitomo Pharma America Inc.,"A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel- Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007482-23,0,0,0 2008-007482-23,3,2011-12-01,2012-01-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Sunovion Pharmaceuticals, Inc.","A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel- Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007482-23,0,0,0 2008-007482-23,3,2011-12-01,2012-01-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sunovion Pharmaceuticals Inc.,"A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel- Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007482-23,0,0,0 2008-007483-42,5,2013-02-01,2013-02-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dainippon Sumitomo Pharma America Inc.,"A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007483-42,0,0,0 2008-007483-42,5,2013-02-01,2013-02-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Sunovion, Inc.","A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007483-42,0,0,0 2008-007483-42,5,2013-02-01,2013-02-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sunovion Pharmaceuticals Inc,"A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007483-42,0,0,0 2008-007483-42,5,2013-02-01,2013-02-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sunovion Pharmaceuticals Inc.,"A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007483-42,0,0,0 2008-007484-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Helena Elding Larsson,"DIAPREV-IT Diabetes Prevention Immune Tolerance. A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd® on the progression to type 1 diabetes in chil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007484-16,0,0,0 2008-007492-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Center,An independent prospective randomised controlled trial comparing the efficacy and cost effectiveness of infliximab and etanercept in 'high need' patients with moderate to severe chronic plaque type ps...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007492-24,0,0,0 2008-007495-20,1,2011-06-06,2011-06-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche Austria GmbH,"A single arm, open-label, multicentre, phase II study to evaluate the efficacy and safety of bevacizumab and trastuzumab combination and sequential capecitabine in patients with HER2-positive locally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007495-20,0,0,0 2008-007497-37,1,2016-07-21,2016-07-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ARCAGY,ESSAI EN DEUX ETAPES DE L’EVALUATION DE LA LENALIDOMIDE (REVLIMID®) DANS LE CANCER DE L’OVAIRE EN RECHUTE TARDIVE (> 6 MOIS): - EN MONOTHERAPIE CHEZ DES PATIENTES ASYMPTOMATIQUES AVEC UNE ELEVATION D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007497-37,0,0,0 2008-007498-19,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,"Columbia Laboratories, Inc","The Effect of Vaginal Progesterone Administration in the prevention of Preterm Birth in Women with Short Cervix, [also Known as: Vaginal progesterone bioadhesive gel (Prochieve)® Extending Gestation A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007498-19,0,0,0 2008-007504-28,6,2015-01-29,2015-01-29,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co. Inc.","12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007504-28,0,0,0 2008-007504-28,6,2015-01-29,2015-01-29,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation","12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007504-28,0,0,0 2008-007504-28,6,2015-01-29,2015-01-29,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007504-28,0,0,0 2008-007504-28,6,2015-01-29,2015-01-29,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.","12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007504-28,0,0,0 2008-007504-28,6,2015-01-29,2015-01-29,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007504-28,0,0,0 2008-007504-28,6,2015-01-29,2015-01-29,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc","12-Week, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Mometasone Furoate Metered Dose Inhaler in the Treatment of Children Ages 5 to 11 Years With Persistent Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007504-28,0,0,0 2008-007507-83,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"Once-a-day regimen or Steroid withdrawal in de novo kidney transplant recipients treated with everolimus, cyclosporin and steroids: a 12-month, prospective, randomized, multicenter, open-label study. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007507-83,0,0,0 2008-007510-30,2,2009-07-08,2009-07-08,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Array BioPharma Inc.,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF 12 WEEKS OF TREATMENT WITH ARR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007510-30,0,0,0 2008-007515-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SentoClone AB,"A multi-centre, two-arm, randomized, open, phase II study of adaptive design investigating SentoClone® compared to reference treatment in advanced malignant melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007515-33,0,0,0 2008-007516-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Laboratoires NEGMA,Comparaison des effets du nébivolol et de l'aténolol sur la fonction endothéliale vasomotrice des artères de conductance lors de l'hypertension artérielle essentielle,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007516-15,0,0,0 2008-007519-34,1,2009-09-01,2009-09-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"University of Leuven Hospitals, Division of Gastroenterology",Feasibility of Accelerated infliximab infusions - Safety and Tolerability in patients wit IBD. FAST,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007519-34,0,0,0 2008-007520-26,1,2012-06-14,2012-06-14,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Klinikum der Universität München,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007520-26,0,0,0 2008-007524-25,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,REGIONE LOMBARDIA - DIREZIONE GENERALE SANITA`,Predictive factors for the optimization of cetuximab in the treatment of patients with advanced colorectal cancer. an italian randomised trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007524-25,0,0,0 2008-007525-39,3,2010-12-16,2010-12-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled, multicenter regimen finding study of subcutaneously administered AIN457, assessing Psoriasis Area and Severity Index (PASI) response in patients with mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007525-39,0,0,0 2008-007526-19,2,2013-12-05,2013-12-05,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Fondazione Evidence,"Doble tratamiento antiplaquetario durante 6 versus 12 meses tras implante de stents recubiertos ""de segunda generación""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007526-19,0,0,0 2008-007526-19,2,2013-12-05,2013-12-05,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,FONDAZIONE EVIDENCE,"Doble tratamiento antiplaquetario durante 6 versus 12 meses tras implante de stents recubiertos ""de segunda generación""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007526-19,0,0,0 2008-007546-56,1,2014-07-01,2014-07-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Klinikum der Universität München, Campus Großhadern",A Phase II Multicentre Study of perioperative Chemotherapy for resectable Adenocarcinoma of the Gastroesophageal Junction and of the Stomach,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007546-56,0,0,0 2008-007549-29,1,2011-01-21,2011-01-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Danish Multiple Sclerosis Research Center,Trichuris suis Ova Therapy for Relapsing Multiple Sclerosis - a safety study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007549-29,0,0,0 2008-007605-37,1,2009-10-09,2009-10-09,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, open, multicentre, extension study to assess the immune response following administration of an additional dose of GSK Biologicals’ 10-valent conjugate pneumococcal vaccine or Prevenar™ a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007605-37,0,0,0 2008-007609-36,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,University of Essen,Prospektiv randomisierte multizentrische Phase II-Studie zur Metastasenresektion von Lungenfiliae (poor-prognosis) beim klarzelligen Nierenzellkarzinom +/- adjuvante Sunitinibtherapie über 1 Jahr - SM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007609-36,0,0,0 2008-007625-39,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Biotest AG,"An open, prospective, single-arm study investigating safety and efficacy of the human hepatitis B immunoglobulin BT088 after subcutaneous application in liver transplanted patients Clinical Phase: III",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007625-39,0,0,0 2008-007626-19,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,CHU Clermont-Ferrand,Traitement par la toxine botulinique de la dystonie en griffe des orteils chez les patients parkinsoniens : Comparaison de l’efficacité d’injections effectuées dans la musculature extrinsèque (le lon...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007626-19,0,0,0 2008-007627-40,1,2010-06-17,2010-06-17,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Wien,Evaluation of Local Anaesthetic Volumes for Caudal Blocks in Children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007627-40,0,0,0 2008-007644-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Asociación Terapeutica en Hematologia y Oncología Médicas,"Estudio de fase II, multicéntrico, abierto, aleatorizado, de tratamiento secuencial con docetaxel y erlotinib intermitente frente a erlotinib en pacientes con carcinoma no microcítico de pulmón localm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007644-34,0,0,0 2008-007645-31,1,2015-03-02,2015-03-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Medical Center Freiburg,Freiburger Studie zur Behandlung von Primären ZNS-Lymphomen bei Patienten über 65 Jahre: Methotrexat-basierte Chemo-Immuntherapie mit anschließender Erhaltungstherapie - PRIMAIN-Studie -,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007645-31,0,0,0 2008-007647-14,1,2014-08-18,2014-08-18,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Turku University Hospital,The effect of fluvoxamine and ciprofloxacin on the pharmacokinetics and pharmacodynamics of nabumetone: A three-phase double-blind placebo-controlled cross-over study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007647-14,0,0,0 2008-007648-32,7,2009-01-31,2010-03-18,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"PTC Therapeutics, Inc.",A Phase 2b Extension Study of PTC124 in Subjects with Nonsense Mutation Mediated Duchenne and Becker Muscular Dystrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007648-32,0,0,0 2008-007648-32,7,2009-01-31,2010-03-18,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"PTC THERAPEUTICS, INC.",A Phase 2b Extension Study of PTC124 in Subjects with Nonsense Mutation Mediated Duchenne and Becker Muscular Dystrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007648-32,0,0,0 2008-007649-30,3,2010-11-18,2010-11-18,2,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Biolex Therapeutics Inc.,"SELECT-2: Phase 2B, Partially Blinded, Randomized Study In Treatment Naïve Subjects With HCV Genotype 1 To Compare The Efficacy, Safety, And Tolerability Of Three Doses of Locteron™ Plus Ribavirin Giv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007649-30,0,0,0 2008-007650-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOTEL (Grupo Oncológico para el Tratamiento de las Enfermedades Linfoides),"Estudio Fase II abierto prospectivo no aleatorizado para valorar la combinación de rituximab, bendamustina (R-B) en pacientes con Linfoma Folicular refractarios o en recaída tras tratamiento con R-qu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007650-35,0,0,0 2008-007652-10,1,2017-01-09,2017-01-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre René Gauducheau,"Etude de phase II ouverte évaluant en fonction du polymorphisme du CYP2D6, le taux de réponse biologique au traitement par tamoxifène (TAM) administré en situation pré-opératoire chez des patientes pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007652-10,0,0,0 2008-007653-12,1,2009-10-06,2009-10-06,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Sverige AB,Determination of ( 11 C) miglustat uptake in bone tissue and brain using Positron Emission Tomography (PET).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007653-12,0,0,0 2008-007657-12,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,LOFARMA,"Evaluating the efficacy, safety, tolerability of use and treatment adherence in two different dosing schedules, pre-costagionale and costagionale, of a sublingual allergoid (Lais Parietaria)administer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007657-12,0,0,0 2008-007660-41,3,2013-03-21,2013-04-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline LLC,"A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007660-41,0,0,0 2008-007660-41,3,2013-03-21,2013-04-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd.,"A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007660-41,0,0,0 2008-007661-24,2,2013-03-08,2013-03-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline LLC,"A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Long-Term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007661-24,0,0,0 2008-007661-24,2,2013-03-08,2013-03-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd.,"A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Long-Term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007661-24,0,0,0 2008-007662-37,2,2013-01-18,2013-01-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metform...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007662-37,0,0,0 2008-007662-37,2,2013-01-18,2013-01-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline LLC,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metform...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007662-37,0,0,0 2008-007664-42,3,2013-03-25,2013-04-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd.,"A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007664-42,0,0,0 2008-007664-42,3,2013-03-25,2013-04-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline LLC,"A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007664-42,0,0,0 2008-007665-22,1,2011-02-03,2011-02-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Vejle Sygehus,En fase II undersøgelse af Temsirolimus og Irinotecan til behandlingsresistente patienter med metastaserende colorectal cancer og KRAS mutationer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007665-22,0,0,0 2008-007667-17,1,2013-03-22,2013-03-22,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Dekan des Fachbereichs Medizin der Johann Wolfgang Goethe-Universität Frankfurt/M.,"Doppelblinde, randomisierte Placebo-kontrollierte crossover-Studie zur Erfassung des Effektes einer DPP-IV-Hemmung auf die Zahl und Funktion von Progenitorzellen sowie die Endothelfunktion von Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007667-17,0,0,0 2008-007669-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU of Liège,Effectiveness of prophylactic antibiotic intervention (fosfomycin trometamol) to prevent urinary tract infections due to urodynamic studies in women with urine incontinence or prolapsed: a randomized...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007669-21,0,0,0 2008-007670-37,3,2010-09-13,2010-09-13,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Exploratory study of S 38093 versus placebo in patients with mild to moderate Alzheimer’s Disease. An international, multi-centre, randomised, double-blind, placebo-controlled phase IIa study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007670-37,0,0,0 2008-007681-30,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,LUSOFARMACO,EFFICACY AND SAFETY OF ZOFENOPRIL + HYDROCHLOROTHIAZIDE COMBINATION VS. IRBESARTAN + HYDROCHLOROTHIAZIDE COMBINATION IN ESSENTIAL HYPERTENSIVE PATIENTS NOT CONTROLLED BY PREVIOUS MONOTHERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007681-30,0,0,0 2008-007686-24,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,3,,"A phase I/ II, non-randomized, feasibility/ safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with metastatic pancreatic cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007686-24,0,0,0 2008-007687-41,1,2009-11-23,2009-11-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen Cilag International, NV","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007687-41,0,0,0 2008-007688-17,1,2010-08-31,2010-08-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen Cilag International, NV","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007688-17,0,0,0 2008-007689-52,10,2011-03-02,2011-03-02,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled with Simvastatin 20 mg or Atorvastatin 10 mg: A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007689-52,0,0,0 2008-007689-52,10,2011-03-02,2011-03-02,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"MERCK & CO., INC.","A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled with Simvastatin 20 mg or Atorvastatin 10 mg: A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007689-52,0,0,0 2008-007689-52,10,2011-03-02,2011-03-02,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck & Co. Inc.,"A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled with Simvastatin 20 mg or Atorvastatin 10 mg: A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007689-52,0,0,0 2008-007689-52,10,2011-03-02,2011-03-02,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., N.J., USA","A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled with Simvastatin 20 mg or Atorvastatin 10 mg: A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007689-52,0,0,0 2008-007689-52,10,2011-03-02,2011-03-02,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck & Co. Inc,"A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled with Simvastatin 20 mg or Atorvastatin 10 mg: A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007689-52,0,0,0 2008-007689-52,10,2011-03-02,2011-03-02,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled with Simvastatin 20 mg or Atorvastatin 10 mg: A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007689-52,0,0,0 2008-007690-21,5,2015-01-19,2015-01-19,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Janssen Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Cancer-Related Pain, Follo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007690-21,0,0,0 2008-007690-21,5,2015-01-19,2015-01-19,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Janssen Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Cancer-Related Pain, Follo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007690-21,0,0,0 2008-007690-21,5,2015-01-19,2015-01-19,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Cancer-Related Pain, Follo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007690-21,0,0,0 2008-007704-28,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Emotional Brain,"Lybridos PoC: A double blind, randomized, cross-over placebo controlled pilot study to investigate the subjective and physiological efficacy and safety of Lybridos in healthy female subjects with Fema...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007704-28,0,0,0 2008-007705-37,7,2012-04-11,2012-05-31,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Alcon Research, Ltd",The Safety and Efficacy of AL-8309B Ophtalmic Solution for the treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007705-37,0,0,0 2008-007711-32,2,2010-04-23,2010-04-23,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A randomised, double-blind, double dummy, active controlled, parallel group, forced titration study to compare the fixed-dose combination of Telmisartan 80mg plus Hydrochlorothiazide 25mg (T80/HCTZ25)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007711-32,0,0,0 2008-007711-32,2,2010-04-23,2010-04-23,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH&Co KG,"A randomised, double-blind, double dummy, active controlled, parallel group, forced titration study to compare the fixed-dose combination of Telmisartan 80mg plus Hydrochlorothiazide 25mg (T80/HCTZ25)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007711-32,0,0,0 2008-007712-14,1,2010-08-31,2010-08-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Erasme Hospital,Monitoring of serum concentrations of posaconazole given as prophylaxis or therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007712-14,0,0,0 2008-007725-39,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,Fundación GEL/TAMO,"ESTUDIO MULTICENTRICO FASE II, NO ALEATORIZADO, DE RITUXIMAB EN COMBINACIÓN CON BENDAMUSTINA COMO PRIMER TRATAMIENTO SISTÉMICO EN LINFOMA DE CÉLULAS B DE LA ZONA MARGINAL EXTRAGANGLIONAR DEL TEJIDO L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007725-39,0,0,0 2008-007748-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Foreest Medical School,Dipeptide Alanyl Glutamine Prevents Postoperative Insulin Resistance in Colon Carcinoma Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007748-33,0,0,0 2008-007749-29,1,2015-01-31,2015-01-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,2,"R&D Department,",Monotherapy vs Dual Therapy for Initial Treatment for hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007749-29,0,0,0 2008-007749-29,1,2015-01-31,2015-01-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Cambridge Clinical Trials Unit,Monotherapy vs Dual Therapy for Initial Treatment for hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007749-29,0,0,0 2008-007753-12,1,2010-03-15,2010-03-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"MUW, Universitätsklinik für Innere Medizin I, Abteilung für Infektionskrankheiten und Tropenmedizin",The pharmacokinetics of anidulafungin during continuous venovenous hemofiltration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007753-12,0,0,0 2008-007758-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Besançon,Intérêt du rémifentanil dans l’anesthésie pour triple endoscopie en ventilation spontanée : étude randomisée contrôlée contre placebo Etude ENDOTANIL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007758-36,0,0,0 2008-007762-39,1,2011-02-09,2011-02-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Regeneron Pharmaceuticals Inc.,"A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007762-39,0,0,0 2008-007763-16,1,2013-02-05,2013-02-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Gynäkologie und Gyn.Onkologie",Topical Imiquimod in Treating Patients with Grade 2/3 Cervical Intraepithelial Neoplasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007763-16,0,0,0 2008-007765-23,1,2013-06-03,2013-06-03,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,SIMIT sezione Regione Lombardia,MoLO study - Evaluation of cost/efficacy ratio of monotherapy with lopinavir/ritonavir versus standard in patients treated with protesi inhibotors in virologic suppressison.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007765-23,0,0,0 2008-007768-41,2,2013-08-28,2013-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007768-41,0,0,0 2008-007769-21,1,2011-07-14,2011-07-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Lilly Deutschland GmbH,"A Randomized, Open-label Study on the Effects of Insulin Pen Devices on Glycemic Control in Children, Adolescents and Adults with Type 1 Diabetes: Novel Pen with Memory Function (HumaPen® Memoir) vs. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007769-21,0,0,0 2008-007770-37,2,2009-10-28,2009-10-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Acacia Pharma Ltd.,"Randomised, double-blind, placebo-controlled, Phase II study to assess the safety and efficacy of different doses of intravenous APD405 (buspirone for IV injection) for the prevention of post-operativ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007770-37,0,0,0 2008-007784-16,1,2011-02-16,2011-02-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Regeneron Pharmaceuticals Inc.,"A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate Lowering Therapy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007784-16,0,0,0 2008-007785-39,1,2014-02-25,2014-02-25,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,CureVac GmbH,Safety and efficacy phase I/IIa trial of an RNActive®-derived cancer vaccine in stage IIIB/IV non small cell lung cancer (NSCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007785-39,0,0,0 2008-007786-23,3,2016-02-29,2016-02-29,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.","ESTUDIO EN FASE 2 ALEATORIZADO Y DOBLE CIEGO DE AXITINIB (AG-013736) CON O SIN AJUSTE DE LA DOSIS EN PACIENTES CON CANCER DE CELULAS RENALES METASTASICO RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007786-23,0,0,0 2008-007786-23,3,2016-02-29,2016-02-29,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017","ESTUDIO EN FASE 2 ALEATORIZADO Y DOBLE CIEGO DE AXITINIB (AG-013736) CON O SIN AJUSTE DE LA DOSIS EN PACIENTES CON CANCER DE CELULAS RENALES METASTASICO RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007786-23,0,0,0 2008-007786-23,3,2016-02-29,2016-02-29,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017 US","ESTUDIO EN FASE 2 ALEATORIZADO Y DOBLE CIEGO DE AXITINIB (AG-013736) CON O SIN AJUSTE DE LA DOSIS EN PACIENTES CON CANCER DE CELULAS RENALES METASTASICO RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007786-23,0,0,0 2008-007788-17,3,2010-06-23,2010-06-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007788-17,0,0,0 2008-007788-17,3,2010-06-23,2010-06-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007788-17,0,0,0 2008-007789-51,3,2014-03-27,2014-03-27,1,1,1,0,1,0,2,0,1,2,0,0,0,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 µg, 120 µg, and 200 µg i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007789-51,1,1,0 2008-007789-51,3,2014-03-27,2014-03-27,1,1,1,0,1,0,2,0,1,2,0,0,0,0,1,Pfizer Inc,"A Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 µg, 120 µg, and 200 µg i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007789-51,1,1,0 2008-007792-24,1,2009-06-03,2009-06-03,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Medical University of Graz, Department of Internal Medicine, Div. Endocrinology and Nuclear Medicine","Effects of vitamin D supplementation in healthy women and men on immunological, endocrine and metabolic parameters",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007792-24,0,0,0 2008-007794-20,2,2012-09-30,2012-09-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"AKH Wien, Klinik für Innere Medizin I, Onkologie",A randomized controlled open-label multicenter phase II study for initial treatment of acute graft-versus-host disease with extracorporeal photopheresis and corticosteroids or corticosteroids alone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007794-20,0,0,0 2008-007795-23,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,Instituto Cientifico y Tecnologico de Navarra,ESTUDIO FASE II ALEATORIO CON INMUNOTERAPIA MEDIANTE CÉLULAS DENDRÍTICAS EN PACIENTES CON METÁSTASIS HEPÁTICAS RESECADAS DE CARCINOMA COLORRECTAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007795-23,0,0,0 2008-007797-37,3,2000-07-14,2009-07-14,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Phase II Randomised, Double-blind, Parallel Group, 4-week treatment, Adaptive Dose Finding, Multi-centre study evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to three diffe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007797-37,0,0,0 2008-007798-18,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AIO-Studien-gGmbH,"An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination with Epirubicin, Cisplatin and Capecitabine (ECX) versus ECX Chemotherapy alone in Subjects with Locally Advanced Gastr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007798-18,0,0,0 2008-007799-13,4,2012-08-30,2012-10-31,2,0,0,0,0,0,2,0,0,2,0,0,0,0,0,vejle Sygehus,Panitumumab (Vectibix) and Pegylated Liposomal Doxorubicin (Caelyx) to platinum-resistant epithelial ovarian cancer with KRAS wild-type.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007799-13,1,0,0 2008-007799-13,4,2012-08-30,2012-10-31,2,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Vejle Hospital,Panitumumab (Vectibix) and Pegylated Liposomal Doxorubicin (Caelyx) to platinum-resistant epithelial ovarian cancer with KRAS wild-type.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007799-13,1,0,0 2008-007799-13,4,2012-08-30,2012-10-31,2,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Vejle Sygehus,Panitumumab (Vectibix) and Pegylated Liposomal Doxorubicin (Caelyx) to platinum-resistant epithelial ovarian cancer with KRAS wild-type.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007799-13,1,0,0 2008-007800-27,2,2010-02-05,2010-02-05,1,1,0,0,1,0,3,0,0,1,1,1,1,0,1,Janssen-Cilag International NV,"A Prospective, Randomized, Active-controlled, Rater-blinded Study of the Prevention of Relapse Comparing Paliperidone Palmitate with Oral Risperidone in Adults with Recently-Diagnosed Schizophrenia Wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007800-27,0,0,0 2008-007802-12,3,2010-09-23,2012-10-31,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc., Acting through its division Wyeth Research, a Pfizer Company","An Open-label, Single-Arm, Phase 2 Study of Inotuzumab Ozogamicin Plus Rituximab in Subjects With Relapsed/Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible for Autologous Stem Cell Tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007802-12,0,0,0 2008-007802-12,3,2010-09-23,2012-10-31,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company","An Open-label, Single-Arm, Phase 2 Study of Inotuzumab Ozogamicin Plus Rituximab in Subjects With Relapsed/Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible for Autologous Stem Cell Tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007802-12,0,0,0 2008-007802-12,3,2010-09-23,2012-10-31,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,"An Open-label, Single-Arm, Phase 2 Study of Inotuzumab Ozogamicin Plus Rituximab in Subjects With Relapsed/Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible for Autologous Stem Cell Tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007802-12,0,0,0 2008-007803-10,14,2018-06-28,2018-06-29,13,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Puma Biotechnology, Inc","A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007803-10,0,0,0 2008-007803-10,14,2018-06-28,2018-06-29,13,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc., acting through its division Wyeth research, a Pfizer company","A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007803-10,0,0,0 2008-007803-10,14,2018-06-28,2018-06-29,13,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Wyeth Research, Division of Wyeth Pharmaceuticals, Inc.","A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007803-10,0,0,0 2008-007803-10,14,2018-06-28,2018-06-29,13,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc., a wholly owened subsidiary of Pfizer Inc, 500 Arcola Road, collegeville, PA 19426 USA","A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007803-10,0,0,0 2008-007803-10,14,2018-06-28,2018-06-29,13,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Puma Biotechnology, Inc.","A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007803-10,0,0,0 2008-007803-10,14,2018-06-28,2018-06-29,13,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Wyeth Research, Division on Wyeth Pharmaceuticals, Inc.","A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007803-10,0,0,0 2008-007803-10,14,2018-06-28,2018-06-29,13,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc., acting through its division of Wyeth Research, a Pfizer company","A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007803-10,0,0,0 2008-007827-14,3,2011-03-10,2011-04-30,2,1,0,0,0,0,4,0,0,1,1,0,1,0,1,HELSINN HEALTHCARE SA,"Multicenter, Phase IV, Open-Label, Uncontrolled Study to Assess the Efficacy and Safety of a Single Intravenous Dose of Palonosetron 0.25 mg (Aloxi, Onicit, Paloxi) in the Prevention of Chemotherapy-I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007827-14,0,0,0 2008-007827-14,3,2011-03-10,2011-04-30,2,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Helsinn Healthcare SA,"Multicenter, Phase IV, Open-Label, Uncontrolled Study to Assess the Efficacy and Safety of a Single Intravenous Dose of Palonosetron 0.25 mg (Aloxi, Onicit, Paloxi) in the Prevention of Chemotherapy-I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007827-14,0,0,0 2008-007829-40,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,FARMACEUTICI DAMOR,"Open-label, controlled, randomised, single centre, parallel group clinical trial of efficacy and tolerability of Clarema 1% cream and Hirudoid 40000 U.APTT gel in the topical treatment of haematomas a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007829-40,0,0,0 2008-007831-41,5,2010-06-21,2010-06-21,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A twelve-week, randomized, double-blind, parallel group study to evaluate the prolonged efficacy and safety of aliskiren 300 mg compared to telmisartan 80 mg in mild to moderate hypertensive patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007831-41,0,0,0 2008-007831-41,5,2010-06-21,2010-06-21,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A twelve-week, randomized, double-blind, parallel group study to evaluate the prolonged efficacy and safety of aliskiren 300 mg compared to telmisartan 80 mg in mild to moderate hypertensive patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007831-41,0,0,0 2008-007844-33,3,2010-08-03,2010-08-03,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MedImmune Limited,"A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study to Evaluate the Efficacy and Safety of CAT-354, a Fully Human Monoclonal Antibody Directed Against Interleukin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007844-33,0,0,0 2008-007845-29,4,2010-06-28,2010-07-03,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Bioprojet,"Essai multicentrique prospectif randomisé en double aveugle et en groupes parallèles, destiné à évaluer les effets de doses ascendantes de BF2.649 et de BF2.649 combiné à du modafinil dans le traiteme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007845-29,0,0,0 2008-007846-69,2,2012-11-21,2012-11-21,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline S.A.,"Estudio en fase III, abierto, multicéntrico para evaluar la persistencia de anticuerpos a a largo plazo en niños hasta los 6 años de edad, tras una pauta completa de vacunación (primaria y de recuerdo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007846-69,0,0,0 2008-007846-69,2,2012-11-21,2012-11-21,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"Estudio en fase III, abierto, multicéntrico para evaluar la persistencia de anticuerpos a a largo plazo en niños hasta los 6 años de edad, tras una pauta completa de vacunación (primaria y de recuerdo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007846-69,0,0,0 2008-007866-46,4,2010-06-30,2010-07-07,3,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Bioprojet,"Essai multicentrique prospectif randomisé en double aveugle contre placebo et en groupes parallèles, destiné à évaluer les effets du BF2.649 dans le traitement de la somnolence diurne excessive associ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007866-46,0,0,0 2008-007869-23,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SAN GERARDO DI MONZA,Mesenchymal Stromal Cells (MSC) for the treatment of severe (grade II-IV) steroid-resistant Graft Versus Host Disease (GVHD): a phase I trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007869-23,0,0,0 2008-007871-26,1,2014-03-17,2014-03-17,1,0,0,0,0,0,2,0,0,1,0,0,1,0,3,,None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007871-26,0,0,0 2008-007872-99,4,2013-04-09,2013-04-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Auxilium UK Limited,"Long term follow up of subjects treated with AA4500 in studies AUX-CC-854, AUX-CC-856, AUX-CC-857/AUX-CC-858 and AUX-CC-859",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007872-99,0,0,0 2008-007874-39,1,2009-11-14,2009-11-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Innotech international,Etude multicentrique en ouvert sur l'efficacité et la tolérance d'un traitement local avec polygynax au cours des vaginites mycosiques et/ou bactériennes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007874-39,0,0,0 2008-007875-26,1,2012-12-31,2012-12-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Leeds,Modulation of Clot Structure and Platelet Function by Aspirin in Individuals with Diabetes: the role of aspirin dose and Glycaemic control,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007875-26,0,0,0 2008-007877-19,1,2012-04-19,2012-04-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Jena,Nasale Inhalation von Colistin mit dem Pari-Sinus-Vernebler bei Patienten mit Mukoviszidose und Pseudomonasnachweis im Nasen-Nasennebenhöhlenbereich. Nasal inhalation of colistin by the Pari Sinus ne...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007877-19,0,0,0 2008-007881-45,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,"A double-blind, placebo-controlled, randomized trial investigating the safety and efficacy of Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007881-45,0,0,0 2008-007883-41,7,2015-10-20,2015-10-20,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Subjects with Congenital Factor XIII Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007883-41,0,0,0 2008-007883-41,7,2015-10-20,2015-10-20,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Subjects with Congenital Factor XIII Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007883-41,0,0,0 2008-007925-38,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Hellenic Cooperative Oncology Group,STUDY OF THE mTOR INHIBITOR TEMSIROLIMUS (CCI-779) IN PATIENTS WITH CA125 ONLY RELAPSE OF OVARIAN CANCER A phase II study by the Hellenic Cooperative Oncology Group,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007925-38,0,0,0 2008-007926-21,5,2012-06-20,2012-08-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,Effect of Passive Immunization on the Progression of Alzheimer`s Disease: LY2062430 versus Placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007926-21,0,0,0 2008-007926-21,5,2012-06-20,2012-08-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,Effect of Passive Immunization on the Progression of Alzheimer`s Disease: LY2062430 versus Placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007926-21,0,0,0 2008-007928-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fédération Francophone de Cancérologie Digestive - FFCD,ESSAI DE PHASE II RANDOMISE EVALUANT L’EFFICACITE DE SEQUENCES THERAPEUTIQUES ASSOCIANT FOLFIRI + BEVACIZUMAB ASSOCIEES OU NON AU MAINTIEN DU BEVACIZUMAB PENDANT LES INTERVALLES LIBRES DE CHIMIOTHERAP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007928-25,0,0,0 2008-007938-21,13,2011-04-07,2011-06-16,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim GmbH&Co KG,A 78 week open label extension to trials assessing the safety and efficacy of BI 10773 as monotherapy or in combination with Metformin in type 2 diabetic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007938-21,0,0,0 2008-007938-21,13,2011-04-07,2011-06-16,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV & Co. KG,A 78 week open label extension to trials assessing the safety and efficacy of BI 10773 as monotherapy or in combination with Metformin in type 2 diabetic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007938-21,0,0,0 2008-007938-21,13,2011-04-07,2011-06-16,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH&Co KG,A 78 week open label extension to trials assessing the safety and efficacy of BI 10773 as monotherapy or in combination with Metformin in type 2 diabetic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007938-21,0,0,0 2008-007938-21,13,2011-04-07,2011-06-16,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,A 78 week open label extension to trials assessing the safety and efficacy of BI 10773 as monotherapy or in combination with Metformin in type 2 diabetic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007938-21,0,0,0 2008-007938-21,13,2011-04-07,2011-06-16,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,A 78 week open label extension to trials assessing the safety and efficacy of BI 10773 as monotherapy or in combination with Metformin in type 2 diabetic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007938-21,0,0,0 2008-007938-21,13,2011-04-07,2011-06-16,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim España S.A.,A 78 week open label extension to trials assessing the safety and efficacy of BI 10773 as monotherapy or in combination with Metformin in type 2 diabetic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007938-21,0,0,0 2008-007938-21,13,2011-04-07,2011-06-16,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,A 78 week open label extension to trials assessing the safety and efficacy of BI 10773 as monotherapy or in combination with Metformin in type 2 diabetic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007938-21,0,0,0 2008-007938-21,13,2011-04-07,2011-06-16,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,A 78 week open label extension to trials assessing the safety and efficacy of BI 10773 as monotherapy or in combination with Metformin in type 2 diabetic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007938-21,0,0,0 2008-007938-21,13,2011-04-07,2011-06-16,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER ING.,A 78 week open label extension to trials assessing the safety and efficacy of BI 10773 as monotherapy or in combination with Metformin in type 2 diabetic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007938-21,0,0,0 2008-007939-41,1,2011-09-12,2011-09-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Biologische Heilmittel Heel GmbH,","ESTUDIO DOBLE CIEGO, ALEATORIZADO, MULTICÉNTRICO SOBRE LA EFICACIA DE TRAUMEEL® S (POMADA Y GEL), EN TÉRMINOS DE DOLOR Y FUNCIÓN, COMPARADO CON UN AINE TÓPICO EN DEPORTISTAS CON ESGUINCE DE TOBILLO AG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007939-41,0,0,0 2008-007944-33,20,2012-01-26,2012-12-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase IIIb multicenter, 52 week treatment, randomized, blinded, double dummy, parallel group efficacy study comparing the effect of inhaled indacaterol 150 &#956;g o.d. vs inhaled tiotropium ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007944-33,0,0,0 2008-007944-33,20,2012-01-26,2012-12-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A phase IIIb multicenter, 52 week treatment, randomized, blinded, double dummy, parallel group efficacy study comparing the effect of inhaled indacaterol 150 &#956;g o.d. vs inhaled tiotropium ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007944-33,0,0,0 2008-007944-33,20,2012-01-26,2012-12-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica,"A phase IIIb multicenter, 52 week treatment, randomized, blinded, double dummy, parallel group efficacy study comparing the effect of inhaled indacaterol 150 &#956;g o.d. vs inhaled tiotropium ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007944-33,0,0,0 2008-007945-29,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Institute of Cancer research and molecular medicine.,Treatment of LADA .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007945-29,0,0,0 2008-007948-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Agence nationale de recherches sur le sida et les hépatites virales. ANRS.,Essai randomisé en double insu comparant l’efficacité et la tolérance du tartrate de varénicline versus placebo dans l’aide à l’arrêt de la consommation de tabac chez les patients infectes infectés pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007948-34,0,0,0 2008-007951-29,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Herlev Hospital, Onkologisk Afd. R",Et fase II forsøg af neoadjuverende behandling med pegyleret liposomal doxorubicin (Caelyx®) og cyklofosfamid +/- trastuzumab med efterfølgende docetaxel til patienter med primær inoperabel og lokoreg...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007951-29,0,0,0 2008-007952-90,2,2010-12-14,2010-12-14,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Lipid Therapeutics GmbH,"A randomized, multi-center, doubleblind, parallel group, placebocontrolled, phase IIb, dose ranging study to investigate the efficacy and safety of LT-02 in patients with mesalazine-refractory ulcerat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007952-90,0,0,0 2008-007964-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AKELA Pharma Inc.,"A Multicenter, Multinational, Randomized, Open-Label, Parallel-Group 12-Week Trial to Evaluate the Safety of Fentanyl TAIFUN® Treatment after Titrated Dose Administration and the Current Breakthrough ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007964-40,0,0,0 2008-007965-22,1,2013-06-18,2013-06-18,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Nuclear Medicine UZ Gasthuisberg,Evaluating diagnostic challenges in the management of neuroendocrine tumours with peptide receptor radionuclide therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007965-22,0,0,0 2008-007965-22,1,2013-06-18,2013-06-18,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Gastroenterology UZ Gasthuisberg,Evaluating diagnostic challenges in the management of neuroendocrine tumours with peptide receptor radionuclide therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007965-22,0,0,0 2008-007965-22,1,2013-06-18,2013-06-18,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Hepatology UZ Gasthuisberg,Evaluating diagnostic challenges in the management of neuroendocrine tumours with peptide receptor radionuclide therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007965-22,0,0,0 2008-007965-22,1,2013-06-18,2013-06-18,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,General Medical Oncology UZ Gasthuisberg,Evaluating diagnostic challenges in the management of neuroendocrine tumours with peptide receptor radionuclide therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007965-22,0,0,0 2008-007965-22,1,2013-06-18,2013-06-18,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Radiopharmacy,Evaluating diagnostic challenges in the management of neuroendocrine tumours with peptide receptor radionuclide therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007965-22,0,0,0 2008-007965-22,1,2013-06-18,2013-06-18,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Radiotherapy UZ Gasthuisberg,Evaluating diagnostic challenges in the management of neuroendocrine tumours with peptide receptor radionuclide therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007965-22,0,0,0 2008-007967-18,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CASA DI CURA PRIVATA S.RAFFAELE - PISANA,"A Double-Blind, Placebo Crontrolled, Prallel Group Study to Compare the Efficacy of Rizatriptan 10 mg Iyophilized wafer in the Acute Treatment of Migraine in Patients with Unilateral Trigeminal Autono...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007967-18,0,0,0 2008-007968-42,1,2014-09-16,2014-09-16,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Helsinki University Central Hospital,Patient-controlled sedation vs propofol infusion for ERCP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007968-42,0,0,0 2008-007969-23,12,2016-11-28,2016-11-28,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Celgene Corporation,A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007969-23,0,0,0 2008-007972-70,1,2010-03-31,2010-03-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital Leuven,Transplacentar pharmacokinetics of remifentanil,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007972-70,0,0,0 2008-007973-19,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Pharmacologic optimization of voriconazole - a prospective clustered group-randomized cross-over trial of therapeutic drug monitoring,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007973-19,0,0,0 2008-007974-39,1,2015-08-14,2015-08-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,AIO-Studien-gGmbH,"Randomized three arm phase III trial on induction treatment with a fluoropyrimidine-, oxaliplatin- and bevacizumab-based chemotherapy for 24 weeks followed by maintenance treatment with a fluoropyrimi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007974-39,0,0,0 2008-007978-38,2,2009-12-30,2009-12-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Vernalis (R & D) Limited,"A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Parallel Group Study of the Safety, Tolerability and Efficacy of V3381 for Up to 13 Weeks in Patients with Diabetic Peripheral Neuropathic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007978-38,0,0,0 2008-007981-44,1,2009-03-12,2009-03-12,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GALDERMA R&D SNC,EXPLORATORY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CD5789 IN SUBJECTS WITH ACNE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007981-44,0,0,0 2008-007984-17,1,2014-01-20,2014-01-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Moorfields Eye Hospital NHS Foundation Trust,Pilot randomised placebo-controlled double-masked clinical trial of subconjunctival Bevacizumab on eyes with recent onset of corneal neovascularisation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007984-17,0,0,0 2008-007987-40,1,2009-10-14,2009-10-14,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA` DI NOVARA,Low dose intravenous ketamine (S) associated to thoracic epidural analgesia: effects on the “post-thoracotomy pain syndrome” (PTPS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007987-40,0,0,0 2008-007988-16,1,2013-03-12,2013-03-12,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,OSPEDALE S. RAFFAELE,Imatinib piu` idrossiurea nel trattamento dei meningiomi recidivati o in progressione: studio randomizzato di fase II.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007988-16,0,0,0 2008-007989-34,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,Use of policlonal immunoglobulins (Pentaglobin) in the treatment of sepsis in cirrhotic patients awaiting for liver transplantation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007989-34,0,0,0 2008-007995-81,3,2012-03-02,2012-03-02,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2a, 2-Part, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study of Telaprevir in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007995-81,0,0,0 2008-007996-26,1,2011-12-31,2011-12-31,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,ISTITUTO PER L`INFANZIA BURLO GAROFOLO,"Comparison between wound infiltration with different ropivacaine concentrations following inguinal herniotomy for postoperative analgesia in children: a randomized, double-blind, placebo-controlled s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007996-26,0,0,0 2008-007997-39,15,2013-03-28,2013-03-28,12,1,0,0,0,1,4,0,0,1,1,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,A Postauthorization Safety Surveillance Study of Patients Switching to ReFacto AF From ReFacto or Other Factor VIII Products in Usual Care Settings,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007997-39,0,0,0 2008-007997-39,15,2013-03-28,2013-03-28,12,1,0,0,0,1,4,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals, Inc. Acting through its division Wyeth Research, a Pfizer Company",A Postauthorization Safety Surveillance Study of Patients Switching to ReFacto AF From ReFacto or Other Factor VIII Products in Usual Care Settings,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-007997-39,0,0,0 2008-008004-41,9,2017-05-01,2017-05-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Cougar Biotechnology Inc,"A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prosta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008004-41,0,0,0 2008-008004-41,9,2017-05-01,2017-05-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prosta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008004-41,0,0,0 2008-008004-41,9,2017-05-01,2017-05-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prosta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008004-41,0,0,0 2008-008005-21,7,2011-12-08,2012-01-12,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Medivation, Inc.","CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer s Disease on Donepezi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008005-21,0,0,0 2008-008005-21,7,2011-12-08,2012-01-12,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"MEDIVATION, INC.","CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer s Disease on Donepezi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008005-21,0,0,0 2008-008006-46,2,2010-10-22,2010-10-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"MERCK & CO., INC.",A Randomized Clinical Trial to Evaluate the Effects of High Dose Statin and Niacin Therapy on Excised Plaque Biomarkers in Patients Undergoing Carotid Endarterectomy (CEA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008006-46,0,0,0 2008-008006-46,2,2010-10-22,2010-10-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Merck & Co., Inc.",A Randomized Clinical Trial to Evaluate the Effects of High Dose Statin and Niacin Therapy on Excised Plaque Biomarkers in Patients Undergoing Carotid Endarterectomy (CEA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008006-46,0,0,0 2008-008008-42,14,2014-12-10,2015-01-21,9,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Novartis PharmaServices AG,An open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008008-42,1,1,0 2008-008008-42,14,2014-12-10,2015-01-21,9,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,An open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008008-42,1,1,0 2008-008008-42,14,2014-12-10,2015-01-21,9,1,1,0,0,1,3,0,0,2,1,0,0,0,1,NOVARTIS FARMA,An open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008008-42,1,1,0 2008-008008-42,14,2014-12-10,2015-01-21,9,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Novartis Farmacéutica S.A.,An open-label extension study of canakinumab (ACZ885) in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) and active systemic manifestations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008008-42,1,1,0 2008-008009-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Anestesia-Reanimación,"Estudio aleatorizado, doble ciego y controlado sobre la eficacia de la albúmina y manitol en el cebado del sistema de circulación extracorpórea en cirugía cardiaca para reducir el sangrado postoperato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008009-23,0,0,0 2008-008010-39,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,1,INFAI Institut für biomedizinische Analytik und NMR Imaging GmbH,The Sensivity and Specificity of the Modified Helicobacter Test INFAI Using New Test Meal with 13C-Urea Breath Test in Helicobacter Pylori Positive and Negative Patients with Dyspepsia Taking Proton P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008010-39,0,0,0 2008-008012-98,1,2012-03-25,2012-03-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Stefan Lundeberg,Pharmacokinetic study of the opioid ketobemidone in neonates after an intravenous administration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008012-98,0,0,0 2008-008013-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Joan Xavier Fontdevila Font,Estudio aleatorizado para determinar la utilidad de la teicoplanina en la reducción de la colonización bacteriana de la superficie del expansor mamario en cirugía reconstructiva de mama,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008013-19,0,0,0 2008-008045-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. MARIA DELLA MISERICORDIA,"A Phase 2, proof of concept, 52-Week Open Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with primary Sjögren...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008045-38,0,0,0 2008-008046-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Départemental Vendée,"Etude randomisée, contrôlée, en double insu, prospective, comparant différentes doses de neostigmine lors de la décurarisation avancée; NEODEC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008046-21,0,0,0 2008-008065-35,1,2011-06-30,2011-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BiogenIdec A/S,A multi-centre and prospective trial to evaluate the effects on mul-tiple sclerosis related fatigue during treatment with Tysabri® in patients with relapsing remitting multiple sclerosis over the cour...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008065-35,0,0,0 2008-008104-41,1,2010-10-27,2010-10-27,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III long-term follow-up study to assess immunological memory induced following primary and booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn-PD-DiT), thr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008104-41,0,0,0 2008-008124-33,4,2014-01-20,2014-01-20,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, open, multi centre gynaecological extension study for follow-up of a subset of 580299/008 study subjects who were either cervical cytology negative and oncogenic HPV positive or pregnant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008124-33,0,0,0 2008-008124-33,4,2014-01-20,2014-01-20,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A phase IIIb, open, multi centre gynaecological extension study for follow-up of a subset of 580299/008 study subjects who were either cervical cytology negative and oncogenic HPV positive or pregnant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008124-33,0,0,0 2008-008127-15,5,2013-02-11,2013-02-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with piog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008127-15,0,0,0 2008-008127-15,5,2013-02-11,2013-02-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with piog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008127-15,0,0,0 2008-008127-15,5,2013-02-11,2013-02-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV Gmbh,"A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with piog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008127-15,0,0,0 2008-008127-15,5,2013-02-11,2013-02-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind parallel group study to compare the efficacy and safety of initial combination therapy with linagliptin 5 mg + pioglitazone 15 mg, 30 mg, or 45 mg, vs. monotherapy with piog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008127-15,0,0,0 2008-008129-31,1,,,0,0,0,0,0,3,4,0,0,1,0,0,0,1,0,Organisation name was not entered,Anestesian aikaisen lihassähkökäyrän (EMG) havaitseminen leikkausmonitorilla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008129-31,0,0,0 2008-008135-28,1,2011-04-13,2011-04-13,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Hull and East Yorkshire NHS Hospitals Trust,Effect of Sildenafil on Pulmonary Artery Pressure during hypoxia and exercise in Chronic Heart Failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008135-28,0,0,0 2008-008137-11,2,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,0,CHU de Limoges,"""Adaptation Bayésienne de posologie des immunosuppresseurs chez les patients transplantés pulmonaires, atteints ou non de mucoviscidose"" “Bayesian dose Adjustment of immunoSuppressants After Lung Tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008137-11,0,0,0 2008-008140-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation de l'effet d'une infiltration péri-cicatricielle continue d'anesthésique local sur la zone d'hyperalgésie secondaire liée à la cicatrice d'extraction de pièce opératoire après colectomie co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008140-25,0,0,0 2008-008141-37,1,,,0,0,0,0,1,0,4,0,0,3,0,0,0,0,0,Sherwood Forest Hospitals Foundation Trust,"Effects of Exenatide on excess daytime sleepiness (EDS), wakefulness and driving performance in obese type-2 diabetes patients without sleep apnea – proof of concept study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008141-37,0,0,0 2008-008143-24,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SAN GERARDO DI MONZA,Inhalatorial sedation in patient with SAH versus conventional intravenus sedation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008143-24,0,0,0 2008-008144-24,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Pharmazeutische Fabrik Montavit Ges.m.b.H.,Tussavit®in the treatment of couch due to respiratory system disease of different etiology,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008144-24,0,0,0 2008-008167-99,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,FNCLCC,Etude randomisée de phase III comparant l’Exemestane à un placebo chez des femmes ménopausées à risque élevé de cancer du sein.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008167-99,0,0,0 2008-008169-36,1,,,0,0,0,0,0,1,4,0,1,1,1,1,0,1,0,University Medical Center Utrecht,Immune response after Human Papillomavirus vaccination in patients with auto-immune disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008169-36,0,0,0 2008-008171-34,17,2011-08-17,2011-08-17,16,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,AN EXPLORATORY TRIAL TO ASSESS NATURALISTIC SAFETY AND EFFICACY OUTCOMES IN PATIENTS TRANSITIONED TO USTEKINUMAB FROM PREVIOUS METHOTREXATE THERAPY (TRANSIT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008171-34,0,0,0 2008-008171-34,17,2011-08-17,2011-08-17,16,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Janssen-Cilag International,AN EXPLORATORY TRIAL TO ASSESS NATURALISTIC SAFETY AND EFFICACY OUTCOMES IN PATIENTS TRANSITIONED TO USTEKINUMAB FROM PREVIOUS METHOTREXATE THERAPY (TRANSIT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008171-34,0,0,0 2008-008171-34,17,2011-08-17,2011-08-17,16,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,AN EXPLORATORY TRIAL TO ASSESS NATURALISTIC SAFETY AND EFFICACY OUTCOMES IN PATIENTS TRANSITIONED TO USTEKINUMAB FROM PREVIOUS METHOTREXATE THERAPY (TRANSIT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008171-34,0,0,0 2008-008171-34,17,2011-08-17,2011-08-17,16,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Janssen-Cilag EMEA Medical Affairs,AN EXPLORATORY TRIAL TO ASSESS NATURALISTIC SAFETY AND EFFICACY OUTCOMES IN PATIENTS TRANSITIONED TO USTEKINUMAB FROM PREVIOUS METHOTREXATE THERAPY (TRANSIT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008171-34,0,0,0 2008-008175-34,2,2010-11-19,2010-11-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Single Doses of the Oral Motilin Receptor Agon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008175-34,0,0,0 2008-008177-57,1,2010-12-02,2010-12-02,1,1,0,0,0,3,4,0,0,1,0,0,1,0,0,University of Leeds,“What is the ED95 dose of Prilocaine for femoral nerve block using ultrasound?”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008177-57,0,0,0 2008-008190-58,1,2011-02-21,2011-02-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"A Phase IIa, open-label, randomized trial in treatment-naïve HIV-1-infected subjects to determine the antiviral activity of 14 days of monotherapy with 4 different dose regimens of TMC310911 co-admini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008190-58,0,0,0 2008-008192-34,8,2012-04-18,2014-02-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Edmond Pharma S.r.l.,"THE EFFICACY AND SAFETY OF ERDOSTEINE IN THE LONG-TERM THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). A 12-month, randomised, double-blind, placebo-controlled, parallel group, multicenter st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008192-34,0,0,0 2008-008192-34,8,2012-04-18,2014-02-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,EDMOND PHARMA S.r.l.,"THE EFFICACY AND SAFETY OF ERDOSTEINE IN THE LONG-TERM THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). A 12-month, randomised, double-blind, placebo-controlled, parallel group, multicenter st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008192-34,0,0,0 2008-008192-34,8,2012-04-18,2014-02-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,EDMOND PHARMA S.R.L.,"THE EFFICACY AND SAFETY OF ERDOSTEINE IN THE LONG-TERM THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). A 12-month, randomised, double-blind, placebo-controlled, parallel group, multicenter st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008192-34,0,0,0 2008-008192-34,8,2012-04-18,2014-02-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Edmond Pharma,"THE EFFICACY AND SAFETY OF ERDOSTEINE IN THE LONG-TERM THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). A 12-month, randomised, double-blind, placebo-controlled, parallel group, multicenter st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008192-34,0,0,0 2008-008193-31,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Hopital Foch,Impact des facteurs chronologiques et démographiques sur les posologies per-opératoires des agents anesthésiques (Etude prospective multicentrique),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008193-31,0,0,0 2008-008195-13,1,2009-10-08,2009-10-08,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Swedish Institute for Infectious Disease Control (SMI),"An immunogenicity and safety study of combined adsorbed tetanus, low dose diphtheria and acellular pertussis vaccine (Td5ap and Td1aP) given as a school-leaving booster to 14-15-year-old children prim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008195-13,0,0,0 2008-008198-73,4,2012-02-07,2012-02-07,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Kiadis Pharma Netherlands B.V.,"An open label, uncontrolled, multicentre, multinational study on the efficacy and safety of administration of donor lymphocytes depleted of alloreactive T-cells (ATIR), through the use of TH9402 and l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008198-73,0,0,0 2008-008199-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie,Circadiane Ritme in Anti-Epileptische Medicatie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008199-15,0,0,0 2008-008200-40,1,2010-09-07,2010-09-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc","A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema (DME)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008200-40,0,0,0 2008-008202-52,6,2019-09-30,2019-09-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,0,LYSARC,DOUBLE BLIND RANDOMIZED PHASE III STUDY OF LENALIDOMIDE (REVLIMID®) MAINTENANCE VERSUS PLACEBO IN RESPONDING ELDERLY PATIENTS WITH DLBCL AND TREATED WITH R-CHOP IN FIRST LINE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008202-52,0,0,0 2008-008202-52,6,2019-09-30,2019-09-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,0,GELARC,DOUBLE BLIND RANDOMIZED PHASE III STUDY OF LENALIDOMIDE (REVLIMID®) MAINTENANCE VERSUS PLACEBO IN RESPONDING ELDERLY PATIENTS WITH DLBCL AND TREATED WITH R-CHOP IN FIRST LINE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008202-52,0,0,0 2008-008203-17,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,CHU Clermont-Ferrand,Effets de l’injection per-opératoire d’anesthésiques locaux et d’adrénaline au cours d’une Arthroplastie Totale de Hanche sur les pertes sanguines per et post opératoires.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008203-17,0,0,0 2008-008208-42,1,2012-05-01,2012-05-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,UCL - The Joint UCLH/UCL Comprehensive Biomedical Research Unit,"A Randomised, Double-Blind Placebo-Controlled Pilot Study Assessing the Safety and Tolerability of Arimoclomol in Adult with Sporadic Inclusion Body Myositis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008208-42,0,0,0 2008-008209-22,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Academic Medical Center,Chemoradiation combined with panitumumab followed by surgery for patients with operable esophageal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008209-22,0,0,0 2008-008210-38,1,2010-12-08,2010-12-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Chru de Lille,Effet d’un traitement anti-glutamatergique sur les troubles de la marche avec freezing et sur l’attention dans la maladie de Parkinson: “freezing of gait and glutamate: FOGG-I”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008210-38,0,0,0 2008-008211-26,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO SUPERIORE DI SANITA`,Peptide-based vaccine in combination or not with chemotherapy in melanoma patients: a phase II randomized clinical study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008211-26,0,0,0 2008-008215-25,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Walter Fischer,Behandling ved intraventrikulær blødning: Et pilotstudie af virkningen med tidlig intraventrikulær actilysebehandling.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008215-25,0,0,0 2008-008220-32,1,2010-08-04,2010-08-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,EUTHERAPIE pour le compte du promoteur Les Laboratoires Servier,"Efficacité clinique de VALDOXAN dans les conditions de pratique quotidienne (efficience) chez des patients déprimés, en switch ou naïfs de traitement Etude clinique interventionelle de phase IV, mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008220-32,0,0,0 2008-008228-34,1,2009-12-08,2009-12-08,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Pharmaxis Ltd,Determination of the pharmacokinetics of inhaled mannitol after single and multiple dosing in cystic fibrosis patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008228-34,0,0,0 2008-008232-87,1,2011-07-30,2011-07-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Charite Universitätsmedizin Berlin- Campus Virchow-Klinikum,Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008232-87,0,0,0 2008-008235-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Vesa Pakanen,Parasetamolin käyttö oheiskipulääkkeenä oksikodonin kanssa ohitusleikkauksen jälkeisen kivun hoidossa Paracetamol as Adjuctive Treatment for Postoperative Pain after Off-Pump Bypass Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008235-28,0,0,0 2008-008237-11,1,2011-02-09,2011-02-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leeds,An open label study to assess the effectiveness of oral methotrexate in reducing pain in knee osteoarthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008237-11,0,0,0 2008-008238-35,2,2015-11-30,2015-11-30,2,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Universitätsklinikum Ulm,"Open-Label, Multicenter Phase II Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Core-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008238-35,0,0,0 2008-008239-27,1,2009-07-11,2009-07-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Technische Universität München,Dosisfindungsstudie Sugammadex und Neostigmin bei geringer neuromuskulärer Restblockade (Sugammadex and Neostigmine dose finding study for reversal of residual neuromuscular blockade),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008239-27,0,0,0 2008-008240-25,6,2010-07-17,2010-07-18,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A randomised, open-labelled, single dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of pegylated long-acting human growth hormone (NNC126-0083) co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008240-25,0,0,0 2008-008246-20,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,"Radboud University Nijmegen Medical Center, Department of Anaesthesiology, Pain and Palliative Medic",Evaluation of the efficacy and safety of sugammadex (Bridion) in children with renal failure.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008246-20,0,0,0 2008-008251-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC,Clinical and immunological effects of imiquimod and HPV-vaccination compared to imiquimod alone in female patients with Usual type VIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008251-42,0,0,0 2008-008254-23,1,2009-12-18,2009-12-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A randomised, double-blind, placebo-controlled, 2-way crossover study to determine the efficacy of repeat inhaled doses of GW870086X on FEV1 in mild to moderate asthmatics",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008254-23,0,0,0 2008-008257-30,5,2011-09-15,2011-09-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Merck & Co. Inc,"A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Pos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008257-30,0,0,0 2008-008257-30,5,2011-09-15,2011-09-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Merck Sharp & Dohme (Europe) Inc.,"A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Pos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008257-30,0,0,0 2008-008257-30,5,2011-09-15,2011-09-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Pos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008257-30,0,0,0 2008-008257-30,5,2011-09-15,2011-09-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.","A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Pos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008257-30,0,0,0 2008-008257-30,5,2011-09-15,2011-09-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Merck & Co., Inc.","A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Pos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008257-30,0,0,0 2008-008258-21,6,2012-01-23,2012-01-23,5,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"F. Hoffmann - La Roche Ltd - Pharmaceutical Division, PDR","A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008258-21,0,0,0 2008-008258-21,6,2012-01-23,2012-01-23,5,0,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008258-21,0,0,0 2008-008259-41,1,2011-08-26,2011-08-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Rotterdam Eye Hospital,"Anti-VEGF (bevacizumab/ranibizumab) versus RPE-choroid graft in the treatment of 1) non-responders to 3 intravitreal anti-VEGF injections, or 2) patients with AMD and pigment epithelium rip, or 3) pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008259-41,0,0,0 2008-008260-28,3,2011-11-17,2011-11-17,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008260-28,0,0,0 2008-008262-12,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,Groupe Francophone des Myélodysplasies,A phase II study evaluating the efficacy and safety of Lenalidomide (Revlimid®) with or without Epoetin beta (NeoRecormon®) in transfusion-dependent ESA-resistant patients with IPSS low- and intermedi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008262-12,0,0,0 2008-008265-36,4,2010-04-27,2010-04-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-AVENTIS GROUPE,"?Estudio aleatorizado, con doble enmascaramiento, controlado con placebo y de grupos paralelos de la eficacia y la seguridad de dos dosis de comprimidos para chupar de lisinato de ketoprofeno (6,25 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008265-36,0,0,0 2008-008274-31,1,2011-12-31,2011-12-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Fakultní Thomayerova nemocnice s poliklinikou,Establishing a new method of heliox administration in the management of acute exacerbation of chronic obstructive lung disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008274-31,0,0,0 2008-008275-34,1,2012-08-21,2012-08-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,NHS Lothian,The Effect of Omega-3 Fatty Acids on Non-Alcoholic Fatty Liver Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008275-34,0,0,0 2008-008275-34,1,2012-08-21,2012-08-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Edinburgh,The Effect of Omega-3 Fatty Acids on Non-Alcoholic Fatty Liver Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008275-34,0,0,0 2008-008276-14,3,2011-07-25,2011-08-11,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F. Hoffmann-la Roche Ltd,"A Phase Ib/II, open-label study of the safety, tolerability, and efficacy of trastuzumab-MCC-DM1 in combination with pertuzumab administered intravenously to patients with HER2-positive locally advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008276-14,0,0,0 2008-008276-14,3,2011-07-25,2011-08-11,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A Phase Ib/II, open-label study of the safety, tolerability, and efficacy of trastuzumab-MCC-DM1 in combination with pertuzumab administered intravenously to patients with HER2-positive locally advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008276-14,0,0,0 2008-008278-29,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Is early revaccination after ALL therapy feasible ? Evaluation of loss of antibodies and responsiveness to (re)vaccination in children after treatment for acute lymphocytic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008278-29,0,0,0 2008-008280-96,1,2014-04-30,2014-04-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Psychiatry and Psychotherapy, University of Mainz",Randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder – the EMC trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008280-96,0,0,0 2008-008282-36,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Grupo de Investigação do Cancro Digestivo,"Randomized, open-label phase II study evaluating the safety and efficacy of Cetuximab plus modified FOLFOX - 6 versus modified FOLFOX - 6 alone as 2nd line therapy after progression on the 1st line tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008282-36,0,0,0 2008-008283-26,3,2009-10-22,2009-10-22,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg ODT for the Treatment of Acute Migraine in Patients on Topira...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008283-26,0,0,0 2008-008283-26,3,2009-10-22,2009-10-22,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"MERCK & CO., INC.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg ODT for the Treatment of Acute Migraine in Patients on Topira...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008283-26,0,0,0 2008-008285-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,PROSPECTIVE STUDY “IBDISC”: Regeneration and Immunity in patients affected by IBD undergoing immunomodulatory treatment and adjuvant role of G-CSF and/or plasmapheresis (Inflammatory Bowel Diseases I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008285-12,0,0,0 2008-008287-28,1,2014-03-18,2014-03-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Erlangen,Effect of direct renin-inhibition aliskiren on renal haemodynamic and metabolic parameters in patients with prediabetes Effekt des direkten Renin-Inhbitor Aliskiren auf die renale Hämodynamik und a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008287-28,0,0,0 2008-008288-92,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Grupo de Reproducción Asistida HSP/FP,Estudio clínico inicial para determinar las ventajas de emplear un preparado de FSH y LH recombinantes en proporción 2:1 frente a la pauta habitual con menotropina (proporción: 1:1),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008288-92,0,0,0 2008-008291-14,2,2013-04-17,2013-04-17,2,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Nottingham University Hospitals NHS Trust,Study of treatments in Pyoderma Gangrenosum patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008291-14,0,0,0 2008-008293-31,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Erasmus MC Sophia,Early introduction in the Netherlands of alglucosidase alfa manufactured in a 4000 liter bioreactor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008293-31,0,0,0 2008-008296-33,10,2011-09-17,2011-10-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A Phase III randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of Linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008296-33,0,0,0 2008-008296-33,10,2011-09-17,2011-10-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer-Ingelheim Pharma GmbH & Co. KG,"A Phase III randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of Linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008296-33,0,0,0 2008-008296-33,10,2011-09-17,2011-10-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas AE,"A Phase III randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of Linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008296-33,0,0,0 2008-008296-33,10,2011-09-17,2011-10-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelehim AB,"A Phase III randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of Linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008296-33,0,0,0 2008-008296-33,10,2011-09-17,2011-10-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Phase III randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of Linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008296-33,0,0,0 2008-008296-33,10,2011-09-17,2011-10-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A Phase III randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of Linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008296-33,0,0,0 2008-008296-33,10,2011-09-17,2011-10-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A Phase III randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of Linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008296-33,0,0,0 2008-008296-33,10,2011-09-17,2011-10-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A Phase III randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of Linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008296-33,0,0,0 2008-008296-33,10,2011-09-17,2011-10-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim España S.A.,"A Phase III randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of Linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008296-33,0,0,0 2008-008298-77,16,2010-11-18,2011-03-04,13,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008298-77,0,0,0 2008-008298-77,16,2010-11-18,2011-03-04,13,1,0,0,0,0,3,0,0,1,1,0,1,0,2,BRISTOL-M.SQUIBB,"A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008298-77,0,0,0 2008-008299-14,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,Hypogonadotropic hypogonadism in male newborn,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008299-14,0,0,0 2008-008301-22,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,PHASE II CLINICAL STUDY OF THE DIAGNOSTIC EFFICACY OF [18F]FLUOROETHYILCHOLINE ([18F]FECh) IN PATIENTS WITH PROSTATE CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008301-22,0,0,0 2008-008306-43,1,2010-05-03,2010-05-03,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novo Nordisk A/S,"A Trial Investigating the Pharmacokinetic Properties of NN1250 in Children, Adolescents and Adults with Type 1 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008306-43,0,0,0 2008-008309-23,1,2011-10-04,2011-10-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ROCHE,Etude clinique comparative en double aveugle versus placebo sur la rapidité d’action du tocilizumab sur le soulagement des patients atteints de polyarthrite rhumatoïde active avec réponse inadéquate a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008309-23,0,0,0 2008-008314-40,4,2011-01-26,2011-01-26,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bayer Healthcare AG,"Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008314-40,0,0,0 2008-008314-40,4,2011-01-26,2011-01-26,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008314-40,0,0,0 2008-008317-20,1,,,0,0,0,0,1,1,4,0,0,1,0,0,0,1,0,University Hospital Ghent,The effect of inhaled N-Acetylcysteine compared to normal saline on sputum rheology and lung function,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008317-20,0,0,0 2008-008319-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,University Hospital Ghent,"A single-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of Somatostatin used as inflow modulator in liver transplantation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008319-24,0,0,0 2008-008323-15,1,2014-08-28,2014-08-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical Research Council,"FOCUS 3 A study to determine the feasibility of molecular selection of therapy using KRAS, BRAF and topo-1 in patients with metastatic or locally advanced colorectal cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008323-15,0,0,0 2008-008324-33,1,2009-05-22,2009-05-22,1,0,0,0,0,3,4,0,1,1,0,0,1,0,0,Sanna Vilo,Bioavailability of dexmedetomidine after intranasal administration in healthy subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008324-33,0,0,0 2008-008332-90,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,BioCis Pharma Oy,"Double-blind, vehicle-controlled, single centre Phase I/IIa study with topical twice daily doses of 5% cis-urocanic acid to investigate pharmacokinetics, safety, tolerability, and efficacy for up to 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008332-90,0,0,0 2008-008336-85,5,2013-06-14,2013-07-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"F. Hoffmann-La Roche Ltd, Pharmaceuticals Division, PDR",A single-arm Phase II clinical study investigating the addition of bevacizumab to carboplatin and weekly paclitaxel as first-line treatment in patients with epithelial ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008336-85,0,0,0 2008-008336-85,5,2013-06-14,2013-07-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"F. Hoffmann-La Roche Ltd.,Pharmaceuticals Division, PDR",A single-arm Phase II clinical study investigating the addition of bevacizumab to carboplatin and weekly paclitaxel as first-line treatment in patients with epithelial ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008336-85,0,0,0 2008-008336-85,5,2013-06-14,2013-07-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffman - La Roche Ltd.,A single-arm Phase II clinical study investigating the addition of bevacizumab to carboplatin and weekly paclitaxel as first-line treatment in patients with epithelial ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008336-85,0,0,0 2008-008336-85,5,2013-06-14,2013-07-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,A single-arm Phase II clinical study investigating the addition of bevacizumab to carboplatin and weekly paclitaxel as first-line treatment in patients with epithelial ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008336-85,0,0,0 2008-008337-11,9,2011-01-17,2011-01-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"Estudio de fase III, aleatorizado, doble ciego y controlado con placebo de la seguridad y la eficacia de dos dosis de CP 690,550 en pacientes con artritis reumatoide activa que reciben tratamiento de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008337-11,0,0,0 2008-008337-11,9,2011-01-17,2011-01-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","Estudio de fase III, aleatorizado, doble ciego y controlado con placebo de la seguridad y la eficacia de dos dosis de CP 690,550 en pacientes con artritis reumatoide activa que reciben tratamiento de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008337-11,0,0,0 2008-008337-11,9,2011-01-17,2011-01-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","Estudio de fase III, aleatorizado, doble ciego y controlado con placebo de la seguridad y la eficacia de dos dosis de CP 690,550 en pacientes con artritis reumatoide activa que reciben tratamiento de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008337-11,0,0,0 2008-008337-11,9,2011-01-17,2011-01-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer, S.A.","Estudio de fase III, aleatorizado, doble ciego y controlado con placebo de la seguridad y la eficacia de dos dosis de CP 690,550 en pacientes con artritis reumatoide activa que reciben tratamiento de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008337-11,0,0,0 2008-008337-11,9,2011-01-17,2011-01-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA","Estudio de fase III, aleatorizado, doble ciego y controlado con placebo de la seguridad y la eficacia de dos dosis de CP 690,550 en pacientes con artritis reumatoide activa que reciben tratamiento de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008337-11,0,0,0 2008-008338-35,8,2011-03-10,2012-09-14,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008338-35,0,0,0 2008-008338-35,8,2011-03-10,2012-09-14,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer, S.A","PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008338-35,0,0,0 2008-008338-35,8,2011-03-10,2012-09-14,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE COMPARATOR, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008338-35,0,0,0 2008-008339-27,1,2011-02-28,2011-02-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY10017","A 17-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER TRIAL OF PREGABALIN FOR THE TREATMENT OF CHRONIC CENTRAL NEUROPATHIC PAIN AFTER SPINAL CORD INJURY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008339-27,0,0,0 2008-008342-20,1,2011-12-31,2011-12-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,King's College London,"Genetically determined brain abnormalities in Down’s Syndrome.- towards a treatment: A randomised, single-blind, placebo-controlled trial of lithium carbonate in Down’s Syndrome (DownsLit).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008342-20,0,0,0 2008-008353-35,1,2009-12-14,2009-12-14,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE DERMATOLOGIE REPRESENTED BY INSTITUT DE RECHERCHE PIERRE FABRE,EFFICACY STUDY OF A CICLOPIROXOLAMINE 1% FOAM (DC115 GM 02A) VERSUS CICLOPIROXOLAMINE 1.5% SHAMPOO (SEBIPROX®) IN THE TREATMENT OF MODERATE SEBORRHEIC DERMATITIS OF THE SCALP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008353-35,0,0,0 2008-008354-23,2,2010-05-31,2010-05-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Cubist Pharmaceuticals,INC",CONSERV TM – 2 (Clinical Outcomes and Safety Trial to Investigate Ecallantide’s Effect on Reducing Surgical Blood Loss Volume) – A Phase 2 Randomized Double-Blind Active-Controlled Study in Subjects E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008354-23,0,0,0 2008-008354-23,2,2010-05-31,2010-05-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cubist Pharmaceuticals,CONSERV TM – 2 (Clinical Outcomes and Safety Trial to Investigate Ecallantide’s Effect on Reducing Surgical Blood Loss Volume) – A Phase 2 Randomized Double-Blind Active-Controlled Study in Subjects E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008354-23,0,0,0 2008-008355-42,1,2010-08-01,2010-08-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Fertilitetsklinikken,"Supplering med hCG ved kontrolleret ovariel stimulering med rekombinant FSH for in vitro fertilisering Et randomiseret kontrolleret klinisk studie Kliniske, embryonale, endokrine og genetiske aspekter",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008355-42,0,0,0 2008-008359-40,3,2010-08-31,2010-08-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomised, double-blind, placebo-controlled, parallel-group proof- of-concept study to assess the efficacy, safety and tolerability of two single i.v. infusions of AIN457 10 mg/kg (ant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008359-40,0,0,0 2008-008361-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTI ORTOPEDICI RIZZOLI,PHASE III TRIAL ON THE EFFICACY OF DOSE`S INTENSIFICATION IN PATIENTS WITH NON METASTATIC EWING`S SARCOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008361-35,0,0,0 2008-008366-13,2,2012-02-22,2012-03-31,2,0,0,0,0,0,4,0,0,1,1,0,1,0,0,Unit for Psychiatric Research,Comparison of the effects of Sertindole and Olanzapine on Cognition,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008366-13,0,0,0 2008-008367-95,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Karolinska Institutet, Inst för kliniska vetenskaper, Danderyds sjukhus",Effect of exenatid on microcirculation in patients with type 2 diabetes mellitus and coronary artery disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008367-95,0,0,0 2008-008369-37,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,INSERM,Un placebo peut il améliorer l'apprentissage d'une habileté motrice manuelle du sujet sain? Comparaison avec la paroxétine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008369-37,0,0,0 2008-008372-13,2,2013-04-25,2013-04-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Hospital Universitario de Rennes,"Ensayo de fase III, aleatorizado y multicéntrico, en sujetos mayores de 70 años con cáncer de pulmón de célula no pequeña en estadio IV, comparativo de una estrategia ""clásica"" de asignación al tratam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008372-13,0,0,0 2008-008372-13,2,2013-04-25,2013-04-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Rennes,"Ensayo de fase III, aleatorizado y multicéntrico, en sujetos mayores de 70 años con cáncer de pulmón de célula no pequeña en estadio IV, comparativo de una estrategia ""clásica"" de asignación al tratam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008372-13,0,0,0 2008-008376-14,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA ASL BRESCIA,"A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF COMBINED TREATMENT OF GUGGULU AND TRIPHALA FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND OVERWEIGHT IN SUBJEC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008376-14,0,0,0 2008-008377-56,1,2013-03-27,2013-03-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Palliativ medicinsk afdeling, Bispebjerg Hospital",Melatonin for træthed og andre symptomer hos patienter med fremskreden kræft,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008377-56,0,0,0 2008-008378-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Saint-Etienne,A survey on the success of inhibitor elimination using individualized concentrate selection and controlled immune tolerance induction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008378-29,0,0,0 2008-008380-94,1,2014-10-07,2014-10-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Helsinki University Central Hospital,Jatkuvan haavapuudutuksen vaikutukset tavanomaiseen kipulääkitykseen lapsipotilailla sydänleikkauksen jälkeen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008380-94,0,0,0 2008-008382-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Azienda Ospedaliera di Perugia,"Open , multicenter, randomized trial comparing two therapeutic approaches for the treatment of invasive fungal infections in neutropenic onco-hematologic patients.Empiric vs. ``presumptive`` (preempt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008382-35,0,0,0 2008-008384-10,1,2010-10-14,2010-10-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Nile Therapeutics, Inc.","A MULTI CENTER, SINGLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF INTRAVENOUS CD‐NP IN THE TREATMENT OF PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE (ADHF)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008384-10,0,0,0 2008-008387-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA,Phase II study of cetuximab in combination with cisplatin-docetaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a biomarker-based assessment of activity.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008387-27,0,0,0 2008-008392-34,12,2012-09-14,2013-07-11,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008392-34,0,0,0 2008-008392-34,12,2012-09-14,2013-07-11,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008392-34,0,0,0 2008-008394-63,5,2011-04-21,2011-04-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 52-week treatment, randomized, double-blind, placebo-controlled, with open label tiotropium, parallel-group study to assess the efficacy, safety and tolerability of NVA237 in patients with chronic o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008394-63,0,0,0 2008-008394-63,5,2011-04-21,2011-04-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Service AG,"A 52-week treatment, randomized, double-blind, placebo-controlled, with open label tiotropium, parallel-group study to assess the efficacy, safety and tolerability of NVA237 in patients with chronic o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008394-63,0,0,0 2008-008412-47,14,2011-05-12,2011-05-12,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis Recherche & Développement,"Double blind placebo controlled dose ranging study of the efficacy and safety of celivarone at 50, 100 or 300 mg OD with Amiodarone as calibrator for the prevention of ICD interventions or death",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008412-47,0,0,0 2008-008412-47,14,2011-05-12,2011-05-12,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis Recherche & De`veloppement,"Double blind placebo controlled dose ranging study of the efficacy and safety of celivarone at 50, 100 or 300 mg OD with Amiodarone as calibrator for the prevention of ICD interventions or death",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008412-47,0,0,0 2008-008432-82,6,2010-11-23,2010-11-23,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"MacroGenics, Inc.","A Multicenter, Multinational Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Childr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008432-82,1,0,0 2008-008434-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Marc Van de Velde,Een gecombineerde spinale epidurale anesthesie bij arbeid : positieve invloed op kwaliteit van analgesie door epiduraal clonidine en neostigmine bij doorbraakpijn?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008434-36,0,0,0 2008-008435-29,9,2016-04-04,2016-04-05,8,1,0,0,0,1,4,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc.Acting through its division Wyeth Research, a Pfizer Company","A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia A ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008435-29,0,0,0 2008-008435-29,9,2016-04-04,2016-04-05,8,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research & Development,"A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia A ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008435-29,0,0,0 2008-008435-29,9,2016-04-04,2016-04-05,8,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,"A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia A ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008435-29,0,0,0 2008-008435-29,9,2016-04-04,2016-04-05,8,1,0,0,0,1,4,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company","A Non-Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of ReFacto AF in Previously Treated Pediatric Subjects Less Than Twelve Years of Age With Severe Hemophilia A ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008435-29,0,0,0 2008-008436-93,8,2016-11-24,2017-01-02,7,1,0,0,0,1,4,0,0,1,0,0,1,0,1,"Wyeth Pharmaceutical Inc. acting through its division Wyeth Research, a Pfizer Company",An Open-Label Study of the Safety and Efficacy of ReFacto AF in Previously Untreated Patients in Usual Care Settings,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008436-93,0,0,0 2008-008436-93,8,2016-11-24,2017-01-02,7,1,0,0,0,1,4,0,0,1,0,0,1,0,1,"Wyeth Pharmaceutical Inc. Acting through its division Wyeth Research, a Pfizer Company",An Open-Label Study of the Safety and Efficacy of ReFacto AF in Previously Untreated Patients in Usual Care Settings,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008436-93,0,0,0 2008-008436-93,8,2016-11-24,2017-01-02,7,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research & Development,An Open-Label Study of the Safety and Efficacy of ReFacto AF in Previously Untreated Patients in Usual Care Settings,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008436-93,0,0,0 2008-008436-93,8,2016-11-24,2017-01-02,7,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development,An Open-Label Study of the Safety and Efficacy of ReFacto AF in Previously Untreated Patients in Usual Care Settings,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008436-93,0,0,0 2008-008439-28,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Effects of the addition of haloperidol on propofol requirements during sedation with propofol and remifentanil,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008439-28,0,0,0 2008-008441-38,1,2016-07-06,2016-07-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,London School Of Hygiene and Tropical Medicine,"Tranexamic acid for the treatment of postpartum haemorrhage: An international randomised, double blind, placebo controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008441-38,0,0,0 2008-008442-21,1,2009-12-21,2009-12-21,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Maastricht University,The effect of Spironolactone on memory performance under stressful circumstances.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008442-21,0,0,0 2008-008444-25,2,2013-01-24,2013-01-24,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Janssen Infectious Diseases BVBA,"A Phase II, open-label trial with TMC207 as part of a multi-drug resistant tuberculosis (MDR-TB) treatment regimen in subjects with sputum smear-positive pulmonary infection with MDR-TB.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008444-25,0,0,0 2008-008447-26,5,2010-02-08,2010-02-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008447-26,0,0,0 2008-008447-26,5,2010-02-08,2010-02-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A randomized, double-blind, controlled, parallel group, 12-week treatment study to compare the efficacy and safety of the combination of indacaterol 150 μg once daily with open label tiotropium 18 μg ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008447-26,0,0,0 2008-008448-26,2,2011-03-24,2011-03-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LETI Pharma GmbH,"Randomized, double-blind, parallel group, multicenter study to evaluate the efficacy and safety of four doses of depigmented glutaraldehyde polymerized birch pollen allergenic extract (Depigoid® Birch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008448-26,0,0,0 2008-008452-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Cirugía General y Digestiva Hospital Universitario de Bellvitge,Ensayo clínico comparativo aleatorizado entre dos estrategias de tratamiento en pacientes con diverticulitis aguda. Hospitalización versus tratamiento domiciliario.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008452-17,0,0,0 2008-008474-31,1,2014-03-16,2014-03-16,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Charité Berlin,Nutzen des Placeboeffektes bei atopischer Dermatitis - Steigerung der pharmakologischen Wirkung bei Juckreiz durch Klassische Konditionierung und Erwartungsprozesse: Eine randomisierte kontrollierte S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008474-31,0,0,0 2008-008475-34,1,2010-11-30,2010-11-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Abteilung für Anaesthesie und Intensivmedizin, Medizinische Universität Wien",The effect of remifentanil on the reversal of established sunburn-induced hyperalgesia in human volunteers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008475-34,0,0,0 2008-008476-14,1,2012-08-16,2012-08-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust,A Pharmacokinetic Study of Adjuvant Capecitabine in Patients who have undergone Proximal Pancreatico-Duodenectomy for Resection of Pancreatic Adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008476-14,0,0,0 2008-008478-30,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Lukaskrankenhaus GmbH,[Targetspezifische Second-line-Therapie des metastasierten Urothelkarzinoms mit Temsirolimus] Target-specific therapy of metastatic urothelial carcinoma with temsirolimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008478-30,0,0,0 2008-008479-32,1,2011-02-14,2011-02-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,Do xanthine oxidase inhibitors reduce left ventricular hypertrophy and endothelial dysfunction in normotensive patients with chronic stable angina?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008479-32,0,0,0 2008-008481-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Marcelo L. Berthier Torres,Tratamiento de la Afasia Post-ictus con Donepezilo y Rehabilitación Grupal Intensiva de la Afasia: Análisis de la Reorganización Funcional de la Redes del Lenguaje con Neuroimagen Estructural y Funcio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008481-12,0,0,0 2008-008485-12,1,2011-01-27,2011-01-27,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Dundee,Do Xanthine Oxidase Inhibitors Regress Left ventricular Hypertrophy in Diabetes?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008485-12,0,0,0 2008-008486-35,1,2010-12-28,2010-12-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Graz, Klinische Abteilung für Endokrinologie und Nuklearmedizin","Comparison of the impact of biphasic insulin aspart 30(BiAsp30), biphasic insulin aspart 70 (BiAsp 70) and insulin aspart on postprandial glucose and lipid metabolism during two consecutive meals in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008486-35,0,0,0 2008-008489-11,1,2016-07-11,2016-07-11,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHRU de TOURS,Placenta accreta : analyse en échographie de contraste en population à haut risque,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008489-11,0,0,0 2008-008491-13,1,2010-04-21,2010-04-21,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,AZIENDA USL 8 AREZZO,A Multicentric randomized comparison between iso-osmolar and ipo-osmolar contrast agents in STEMI patients undergoing primary PCI. Assessment of contrast-induced nephropathy incidence and myocardial t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008491-13,0,0,0 2008-008494-59,6,2010-06-16,2011-06-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A phase III randomised, double-blind parallel group extension study to investigate the safety and efficacy of twice daily administration of the free combination of linagliptin 2.5 mg + metformin 500 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008494-59,0,0,0 2008-008494-59,6,2010-06-16,2011-06-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A phase III randomised, double-blind parallel group extension study to investigate the safety and efficacy of twice daily administration of the free combination of linagliptin 2.5 mg + metformin 500 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008494-59,0,0,0 2008-008494-59,6,2010-06-16,2011-06-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase III randomised, double-blind parallel group extension study to investigate the safety and efficacy of twice daily administration of the free combination of linagliptin 2.5 mg + metformin 500 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008494-59,0,0,0 2008-008494-59,6,2010-06-16,2011-06-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A phase III randomised, double-blind parallel group extension study to investigate the safety and efficacy of twice daily administration of the free combination of linagliptin 2.5 mg + metformin 500 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008494-59,0,0,0 2008-008494-59,6,2010-06-16,2011-06-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A phase III randomised, double-blind parallel group extension study to investigate the safety and efficacy of twice daily administration of the free combination of linagliptin 2.5 mg + metformin 500 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008494-59,0,0,0 2008-008512-51,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,onepharm Research & Development GmbH,"A double blind, randomized, placebo-controlled, three-arm, phase II study to investigate the safety and efficacy of oral glycyrrhizin (Glycyron® tablets) for the treatment of gingivitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008512-51,0,0,0 2008-008513-19,1,2013-09-13,2013-09-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Heidelberg,"Phase II Studie zur Wirksamkeit und Verträglichkeit von Vorinostat bei Patienten mit fortgeschrittenen, metastasierten Weichteilsarkomen. English title: A Phase II Study to Investigate the Efficacy an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008513-19,0,0,0 2008-008517-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CONSORCI SANITARI DEL MARESME,Estudio multicéntrico controlado y aleatorizado sobre la eficacia de los ácidos grasos poliinsaturados (Omacor R) en la mejoría clínica y la prevención del síndrome metabólico en pacientes con esquizo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008517-19,0,0,0 2008-008518-38,2,2013-05-07,2013-05-07,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Clavis Pharma ASA,A Phase II Study of CP-4055 plus Idarubicin as Second Course Remission-Induction Therapy in Patients with Acute Myeloid Leukaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008518-38,1,0,0 2008-008527-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Witten/Herdecke,"A Randomized, Double-Blind, Active Controlled Study Comparing the Intravenous Dose of Morphine and Oxycodone Combined in a Ratio of 1:1 Versus Morphine Alone Required to Achieve Effective Pain Control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008527-14,0,0,0 2008-008529-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,U.O.PNEUMOLOGIA- AZ. USL1 DI MASSA E CARRARA,Evaluation of erdosteine effect on systemic inflamation biomarkers during COPD exacerbations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008529-32,0,0,0 2008-008532-82,1,2009-08-07,2009-08-07,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Medical University of Vienna, Dept. of Clinical Pharmacology","A Study of the Pharmacodynamics, Pharmacokinetics, and Safety & Efficacy of ARC1779 Injection in Patients with von Willebrand Disease Type 2B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008532-82,0,0,0 2008-008553-27,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Oxford,"Open-label, randomised multicentre study of CAMPATH-1H versus basiliximab induction treatment and sirolimus versus tacrolimus maintenance treatment for the preservation of renal function in patients r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008553-27,0,0,0 2008-008554-23,1,2011-12-31,2011-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"The Multiple Sclerosis Research Group, Department of Clinical Neuroscience",Neutralizing Antibodies to Interferon beta in patients treated with Rebif New Formulation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008554-23,0,0,0 2008-008555-41,1,2015-03-02,2015-03-02,1,0,0,0,0,0,2,0,1,1,1,1,1,0,0,Universitätsklinikum Essen,Comparative study of the effect of intranasal insulin on memory deficits in type 2 diabetes and early Alzheimer´s dementia (INSULA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008555-41,0,0,0 2008-008556-16,2,2010-11-22,2010-11-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,Pharmacokinetic and safety pilotstudy of RAltegravir and atazanavir in a once DAily dose regimen in HIV-1 in-fected patients (PRADA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008556-16,0,0,0 2008-008593-31,2,2010-05-06,2010-05-06,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,SantoSolve A/S,"A 26 week placebo-controlled, randomised, double-blind, parallel group study of the efficacy and safety of 2PX (topical strontium chloride hexahydrate) in patients with pain due to osteoarthritis of t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008593-31,0,0,0 2008-008594-58,1,2010-06-07,2010-06-07,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GABA International AG,In situ mineral change and fluoride retention of sound and demineralized enamel in high cariogenic milieus following the single application of a 1.25%- fluoride or a placebo gel.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008594-58,0,0,0 2008-008597-31,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Malmoe University Hospital,"Comparative study to evaluate the effects of racemic ketamin versus s-ketamine on cerebral blood flow, blood volume and metabolism",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008597-31,0,0,0 2008-008598-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Hospitalier Régional et Universitaire de Lille,«Effet de la posologie de remifentanil associé au propofol en AIVOC (anesthésie intra-veineuse à objectif de concentration) sur la variabilité sinusale chez l’enfant »,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008598-72,0,0,0 2008-008599-15,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,"A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF CYCLOPHOSPHAMIDE, LENALIDOMIDE AND DEXAMETHASONE (CRD) versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008599-15,0,0,0 2008-008604-40,6,2011-03-03,2011-03-03,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of volume reduction of the prostate in patients with prosta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008604-40,0,0,0 2008-008605-22,1,2010-06-01,2010-06-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik für Dermatologie",Determination of the human papillomavirus (HPV)-specific antibody status in oral fluids of individuals vaccinated with a quadrivalent HPV vaccine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008605-22,0,0,0 2008-008606-52,2,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,"A PHASE 3, INTERGROUP MULTICENTRE, RANDOMIZED, CONTROLLED 3 ARM PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE (Rd) VERSUS MELPHALAN, PREDN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008606-52,0,0,0 2008-008652-16,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,BRACCO IMAGING,"QUANTITATIVE EVALUATION OF SONOVUE ENHANCED ULTRASONOGRAPHY FOR EARLY IDENTIFICATION OF SUBJECTS WITH HEPATOCELLULAR CARCINOMA REFRACTORY TO SORAFENIB THERAPY : A PHASE II EXPLORATIVE, INTRA-PATIENT C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008652-16,0,0,0 2008-008655-42,8,2011-01-12,2011-01-12,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen Cilag International,"A Phase IIb, multi-centre, randomised, double-blind, active-controlled, trial comparing the neuropsychiatric adverse event profile of etravirine 400 mg q.d. versus efavirenz 600 mg q.d. in combination...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008655-42,0,0,0 2008-008655-42,8,2011-01-12,2011-01-12,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase IIb, multi-centre, randomised, double-blind, active-controlled, trial comparing the neuropsychiatric adverse event profile of etravirine 400 mg q.d. versus efavirenz 600 mg q.d. in combination...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008655-42,0,0,0 2008-008656-16,1,2012-09-17,2012-09-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Chiesi Farmaceutici SpA,"A Single-centre, Double-blind, Double-dummy, Randomised, Crossover Study to investigate the effect of Formoterol HFA-pMDI versus Salmeterol HFA-pMDI on small airways physiological parameters in COPD p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008656-16,0,0,0 2008-008676-13,1,2015-07-24,2015-07-24,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,A Phase II Study Of Sunitinib And Low Dose Metronomic Cyclophosphamide In Advanced Renal Cell Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008676-13,0,0,0 2008-008683-28,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Privada Clínic per a la Recerca Biomèdica,Evaluación de la eficacia y la seguridad de la combinación de fosfomicina (F) e imipenem (I) para el tratamiento de la endocarditis infecciosa (EI) sobre válvula nativa o protésica por S. Aureus resis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008683-28,0,0,0 2008-008688-80,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,FUNDACION PARA LA INVESTIGACION BIOMEDICA HOSPITAL UNIVERSITARIO INFANTIL NIÑO JESUS,Ensayo clínico en fase I para evaluar el tratamiento de tumores infantiles del sistema nervioso central refractarios o recurrentes con ICOVIR5,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008688-80,0,0,0 2008-008689-11,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Children's Memorial Health Institute,Efficacy and safety of omega – 3 based lipid solution (Omegaven) in comparison with Lipofundin LCT/MCT in reducing cholestasis in children on parenteral nutrition – randomized double – blind clinical ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008689-11,0,0,0 2008-008692-33,1,2014-09-03,2014-09-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Urology, Herlev Hospital",Evaluation of cytotoxicity and genetic changes of high dose vitamin C infusions in castration resistant metastatic human prostate cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008692-33,0,0,0 2008-008697-31,10,2015-05-27,2015-06-11,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized Phase III, double-blind, placebo-controlled multicenter trial of daily everolimus in combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over-expressing loca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008697-31,0,0,0 2008-008697-31,10,2015-05-27,2015-06-11,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized Phase III, double-blind, placebo-controlled multicenter trial of daily everolimus in combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over-expressing loca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008697-31,0,0,0 2008-008697-31,10,2015-05-27,2015-06-11,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmaceutica S.A,"A randomized Phase III, double-blind, placebo-controlled multicenter trial of daily everolimus in combination with trastuzumab and vinorelbine, in pretreated women with HER2/neu over-expressing loca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008697-31,0,0,0 2008-008698-69,11,2014-12-04,2014-12-04,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008698-69,0,0,0 2008-008698-69,11,2014-12-04,2014-12-04,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008698-69,0,0,0 2008-008698-69,11,2014-12-04,2014-12-04,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008698-69,0,0,0 2008-008712-98,5,2010-12-03,2010-12-03,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008712-98,0,0,0 2008-008712-98,5,2010-12-03,2010-12-03,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008712-98,0,0,0 2008-008712-98,5,2010-12-03,2010-12-03,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008712-98,0,0,0 2008-008713-20,1,2010-04-29,2010-04-29,1,1,0,0,0,3,2,0,1,1,1,1,1,0,0,Danish Headache Center,EP4 receptor antagonism and PGE2 in a human headache model,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008713-20,0,0,0 2008-008715-26,3,2012-08-28,2018-01-26,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bristol Myers Squibb International Corporation,"A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carcinom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008715-26,0,0,0 2008-008719-25,5,2011-02-16,2011-05-04,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008719-25,0,0,0 2008-008719-25,5,2011-02-16,2011-05-04,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A","A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008719-25,0,0,0 2008-008719-25,5,2011-02-16,2011-05-04,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008719-25,0,0,0 2008-008720-33,1,,,0,0,0,0,0,1,3,0,0,1,0,0,0,1,0,Cliniques Universitaires St Luc,"A one year, open, prospective study on the role of quarterly intravitreal injections of Lucentis 0,5 mg (ranibizumab) in preventing of delaying progression of radiation retinopathy in eyes treated wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008720-33,0,0,0 2008-008721-29,1,2011-05-04,2011-05-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Selbstmedikation GmbH,"Double-blind, randomised, multi-centre, placebo-controlled clinical trail to investigate the efficacy and safety of a combination of comfrey root extract plus methyl nicotinate versus a preparation co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008721-29,0,0,0 2008-008722-73,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA PISANA,ROLE OF PAROXETINE AS ADD-ON THERAPY TO GNRH AGONIST IN THE TREATMENT OF ENDOMETRIOSIS-RELATED CHRONIC PELVIC PAIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008722-73,0,0,0 2008-008723-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Örebro University Hospital,Postoperative Pain Relief following Total Hip Arthroplasty. A comparison between Intrathecal morphine (IM) and Local Infiltration Analgesia (LIA).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008723-15,0,0,0 2008-008724-32,2,2009-12-08,2010-03-19,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD S.N.C.,"A randomised, comparative, multicentre clinical trial of the immunogenicity and safety of Tdap-IPV vaccine (REPEVAX) and a tetanus monovalent vaccine in healthy adults 18 years of age and older",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008724-32,0,0,0 2008-008726-75,2,2011-04-12,2011-04-12,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Intercell USA, Inc. (Intercell)","A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers’ Diarrhea Vaccine System",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008726-75,0,0,0 2008-008731-28,4,2013-02-28,2013-02-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharmaxis Ltd.,"A phase III multicenter, randomized, parallel, controlled, double blind study to investigate the safety and efficacy of inhaled mannitol over 12 months in the treatment of bronchiectasis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008731-28,0,0,0 2008-008731-28,4,2013-02-28,2013-02-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharmaxis Pharmaceuticals Limited,"A phase III multicenter, randomized, parallel, controlled, double blind study to investigate the safety and efficacy of inhaled mannitol over 12 months in the treatment of bronchiectasis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008731-28,0,0,0 2008-008732-84,5,2011-04-14,2011-04-14,5,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma Corporation,"A Phase IIb, double-blind, parallel group, multi-centre, dose-finding study to investigate the efficacy and safety of 4 doses of MP-513 when added to ongoing metformin monotherapy in subjects with Typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008732-84,0,0,0 2008-008734-36,8,2009-05-19,2009-05-19,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PIERRE FABRE MEDICAMENT,"EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CONTR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008734-36,0,0,0 2008-008739-27,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ROCHE,"Randomised phase II trial of bevacizumab (AVASTIN) in combination with gemcitabine or attenuated doses of cisplatin and gemcitabine as first-line treatment of elderly patients with advanced, metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008739-27,0,0,0 2008-008745-38,1,2010-09-30,2010-09-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Barts and the London NHS Trust,THE EFFECT OF VITAMIN D ON THE MICROCIRCULATION OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND VITAMIN D DEFICIENCY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008745-38,0,0,0 2008-008746-20,1,2011-12-07,2011-12-07,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Studienzentrale AGO Austria,Randomized Phase II AGO-Study comparing combined liposomal doxorubicin (Myocet) and gemcitabine (Gemzar) with liposomal doxorubicin (Myocet) monotherapy in platinum-refractory and platinum-resistant e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008746-20,0,0,0 2008-008748-26,3,2009-07-08,2010-01-14,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A phase IIIb randomized, double-blind, placebo controlled, 2 period crossover, multicenter study to assess the effect of indacaterol (150 μg o.d.) on exercise endurance in patients with moderate to se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008748-26,0,0,0 2008-008748-26,3,2009-07-08,2010-01-14,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,"A phase IIIb randomized, double-blind, placebo controlled, 2 period crossover, multicenter study to assess the effect of indacaterol (150 μg o.d.) on exercise endurance in patients with moderate to se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008748-26,0,0,0 2008-008749-39,1,2014-03-06,2014-03-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY,"Capecitabine in combination with Oxaliplatin, Irinotecan and Bevacizumab (COI-B regimen) as First-Line therapy for metastatic colorectal cancer: a Phase II I.T.M.O. study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008749-39,0,0,0 2008-008753-33,5,2010-12-09,2010-12-09,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Janssen Cilag International NV,"A Randomized, Double-Blind, Placebo- and Active-Controlled Study of Carisbamate in the Treatment of Neuropathic Pain in Diabetic Peripheral Neuropathy Followed by a Blinded Extension Phase",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008753-33,0,0,0 2008-008754-23,1,2012-05-31,2012-05-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Medical Center Göttingen,A Therapeutic Exploratory Study to Determine the Efficacy and Safety of Calcineurin-Inhibitor-Free de-novo Immunosuppression after Liver Transplantation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008754-23,0,0,0 2008-008794-55,1,2014-02-15,2014-02-15,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,The Clatterbridge Cancer Centre NHS Foundation Trust,A randomised phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008794-55,0,0,0 2008-008852-18,1,2014-10-04,2014-10-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Innsbruck Innere Medizin V,Profile of soluble and cellular biomarkers and of functional imaging during antiangiogenic therapies in cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008852-18,0,0,0 2008-008854-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic,Estudio aleatorizado y abierto para determinar si la administración de un antibiótico puede reducir la incidencia de infección en pacientes con cultivos positivos durante una artroplastia de cadera.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008854-22,0,0,0 2008-008857-53,1,2011-11-03,2011-11-03,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Acacia Pharma Ltd,"Open-Label, Pilot Phase I/II Study of the Efficacy and Safety of Concomitant Megestrol + Formoterol in Patients with Cachexia and Advanced Malignancy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008857-53,0,0,0 2008-008895-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Influence de l'introduction du sirolimus sur la balance inflammatoire chez le transplanté rénal,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008895-15,0,0,0 2008-008896-32,1,2014-05-07,2014-05-07,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Cologne,"Memory, Ageing, and the Cholinergic System a combined fMRI and PET study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008896-32,0,0,0 2008-008899-14,1,2012-09-21,2012-09-21,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Liverpool Women's NHS Foundation Trust,"Standardised, Concentrated, Additional Macronutrients, Parenteral (SCAMP) nutrition in very preterm infants: a phase IV randomised controlled study of macronutrient intake, growth and implications for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008899-14,0,0,0 2008-008900-42,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,MUMC,The DIEP flap as a model of ischemia-reperfusion: an intervention study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008900-42,0,0,0 2008-008918-39,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",BRAIN DERIVED NEUROTROPHIC FACTOR AND MAJOR DEPRESSIVE DISORDER TREATMENT: CLINICAL PSYCHOLOGICAL AND PSYCHOPHARMACOTHERAPIC EVALUATIONS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008918-39,0,0,0 2008-008919-26,1,2011-05-01,2011-05-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Orthopaedic research unit. Odense University Hospital,Postoperative Analgesia With Local Infiltration After Periacetabular Osteotomy For The Treatment Of Dysplasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008919-26,0,0,0 2008-008920-34,1,2017-07-21,2017-07-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Odense University Hospital,Induction chemotherapy with Carboplatin and Navelbine Oral® followed by concomitant Navelbine Oral® and irradiation in local-regionally advanced non-small cell lung cancer. A randomized phase II stud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008920-34,0,0,0 2008-008921-30,1,2017-02-04,2017-02-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Odense University Hospital,Concomitant Tarceva® and irradiation in patients in local-regionally advanced non-small cell lung cancer. A phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008921-30,0,0,0 2008-008922-55,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,Grupo Español de Investigación en Sarcomas,"ENSAYO FASE II ALEATORIZADO, ABIERTO, MULTICÉNTRICO Y PROSPECTIVO DE DOXORRUBICINA vs TRABECTEDINA Y DOXORRUBICINA EN PRIMERA LÍNEA DE PACIENTES CON SARCOMA DE PARTES BLANDAS AVANZADOS NO OPERABLES Y/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008922-55,0,0,0 2008-008934-35,1,2015-12-31,2015-12-31,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Dr Josep Ordi-Ros. Hospital Universitario Vall d'Hebron,ENSAYO CLÍNICO ALEATORIZADO Y CONTROLADO PARA EVALUAR LA EFICACIA DE LA AZATIOPRINA VS. MICOFENOLATO SÓDICO PARA EL TRATAMIENTO DE LA FASE DE INDUCCIÓN Y MANTENIMIENTO DE LA REMISIÓN DE LOS BROTES EXT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008934-35,0,0,0 2008-008936-10,1,2011-10-09,2011-10-09,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Division of Cardiology, Robert-Bosch-Krankenhaus",Comparative evaluation of different CMR pulse-sequences with respect to their practicability and diagnostic performance in diagnosing the inflamed myocardium in patients with acute myocardial infarcti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008936-10,0,0,0 2008-008954-22,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,Medisch Spectrum Twente,Non Steroidal Anti-Inflammatory Drugs and the antiplatelet effects of acetylsalicylic acid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008954-22,0,0,0 2008-008974-30,1,2010-06-25,2010-06-25,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Phenomix Corporation,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-008974-30,0,0,0 2009-009014-40,1,2015-01-30,2015-01-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Karolinska Institutet,Pre-treatment with Mifepristone prior to Mirena insertion for optimizing bleeding pattern in pre-menopausal women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009014-40,0,0,0 2009-009034-32,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,R788 as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009034-32,0,0,0 2009-009035-30,1,2012-05-28,2012-05-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ImClone LLC,Randomized Phase 2 Trial Investigating Liposomal Doxorubicin With or Without Anti Platelet Derived Growth Factor Receptor-Alpha (PDGFRα) Monoclonal Antibody IMC-3G3 in Patients With Platinum-Refractor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009035-30,0,0,0 2009-009036-77,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Section of dental pharmacology and pharmacotherapy, ICO, University of Oslo",THE EFFECT OF IBUPROFEN AND PARACETAMOL ON REACTIVE OXYGEN SPECIES (ROS) IN LEUKOCYTES.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009036-77,0,0,0 2009-009037-14,1,2010-05-17,2010-05-17,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Auris ehf.,"A randomised, blinded, phase IIa, placebo controlled, parallel group study to assess the efficacy, safety and tolerability of repeat doses of thymol solution 4% administered to the outer ear canal of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009037-14,0,0,0 2009-009039-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sahlgrenska University Hospital,Abciximab versus Eptifibatide versus Bivalirudin during PCI in patients with acute coronary syndromes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009039-32,0,0,0 2009-009056-20,1,2013-05-11,2013-05-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"MUW, Department of Clinical Pharmacology",Does staphylothrombin enhance coagulation activation in staphylococcus aureus bacteremia?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009056-20,0,0,0 2009-009074-27,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,PROF. ALFREDO CHETTA,Effect of an ACE inhibitor on the exercise capacity of COPD patients. A randomized double-blind placebo-controlled study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009074-27,0,0,0 2009-009096-35,1,2009-11-16,2009-11-16,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Activus Pharma Co., Ltd","An open-label, 28-day multiple dose pilot study to evaluate the effects on lung oxidative stress, safety and pharmacokinetics of TA-270 in patients with chronic obstructive pulmonary disease (COPD).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009096-35,0,0,0 2009-009114-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hopital Foch,Impact de la technique anesthésique et analgésique sur le risque de récidive biologique de cancer de la prostate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009114-40,0,0,0 2009-009115-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,Fenoldopam mesilate efficacy to control splancnic ischemia during cardiopulmonary bypass in pediatric patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009115-22,0,0,0 2009-009116-49,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,Study on efficacy of Tetraspan on children aged less than 36 months undergoing major surgery Valutazione dell’efficacia del Tetraspan al 6% nei pazienti di eta' inferiore a 36 mesi sottoposti a chi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009116-49,0,0,0 2009-009134-32,1,2013-07-02,2013-07-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,North Bristol NHS Trust,Bristol Randomised Controlled Trial of Zoledronic Acid in Malignant Pleural disease(Pilot Study).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009134-32,0,0,0 2009-009154-25,1,2013-07-12,2013-07-12,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,King's College London,The effect of a humanised monoclonal anti-IgE antibody (omalizumab) on disease control and bronchial mucosal inflammation in non-atopic (“intrinsic”) asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009154-25,0,0,0 2009-009154-25,1,2013-07-12,2013-07-12,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Guy's and St.Thomas' NHS Foundation Trust,The effect of a humanised monoclonal anti-IgE antibody (omalizumab) on disease control and bronchial mucosal inflammation in non-atopic (“intrinsic”) asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009154-25,0,0,0 2009-009155-37,1,2016-01-13,2016-01-13,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU-HOPITAUX DE ROUEN,Evaluation of the impact of physical reconditioning associated with specific nutritional supplementation in obese patients suffering of metabolic syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009155-37,0,0,0 2009-009157-24,7,2010-11-23,2011-01-31,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A multicenter, randomized, double blind (double dummy), active comparator controlled study to compare the efficacy, safety and tolerability of taspoglutide versus pioglitazone in type 2 diabetes patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009157-24,0,0,0 2009-009157-24,7,2010-11-23,2011-01-31,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann - La Roche Ltd,"A multicenter, randomized, double blind (double dummy), active comparator controlled study to compare the efficacy, safety and tolerability of taspoglutide versus pioglitazone in type 2 diabetes patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009157-24,0,0,0 2009-009177-10,1,2011-08-23,2011-08-23,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Bayer HealthCare AG,"Multicenter, open-label, randomized study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gestodene in healthy y...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009177-10,0,0,0 2009-009178-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"CHRU Montpellier- Direction de la Recherche, Partenariats et Réseaux, Relations avec l'Université","Etude ouverte, randomisée, comparant l'efficacité du retraitement par etanercept ou par rituximab, après insuffisance d'efficacité du rituximab, chez les patients atteints de polyarthrite rhumatoïde a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009178-28,0,0,0 2009-009182-34,1,2010-01-29,2010-01-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALFRED E. TIEFENBACHER (GMBH & CO. KG),"RANDOMIZED, DOUBLE MASKED; ACTIVE CONTROLLED, CROSSOVER PHASE III EQUIVALENCE STUDY OF DORZOLAMIDE 2 % EYE DROPS SOLUTION IN SUBJECTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009182-34,0,0,0 2009-009194-99,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,Agensys Inc,"A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects with Metastatic Pancreatic Cancer ?Estudio global, multicéntrico, abierto, de fase II ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009194-99,0,0,0 2009-009214-40,5,2012-01-27,2012-01-27,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA","A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INFECT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009214-40,0,0,0 2009-009214-40,5,2012-01-27,2012-01-27,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INFECT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009214-40,0,0,0 2009-009214-40,5,2012-01-27,2012-01-27,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INFECT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009214-40,0,0,0 2009-009215-22,1,2017-02-24,2017-02-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Aalborg Psychiatric Hospital, Centre for Skizophrenia",“Treating clozapine-induced sinustachycardia (BISCLOZ).” Frekvensregulering af clozapin-induceret sinustakykardi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009215-22,0,0,0 2009-009216-53,11,2013-09-04,2013-09-04,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd,"""Estudio multicéntrico de seguimiento a largo plazo de la seguridad y eficacia de dos niveles de dosis del complejo de neurotoxina purificada BOTOX® (toxina botulínica tipo A) en pacientes con inconti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009216-53,0,0,0 2009-009235-30,1,2014-12-08,2014-12-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London,Antidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009235-30,0,0,0 2009-009256-20,15,2014-11-21,2015-11-21,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Limited,Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009256-20,0,0,0 2009-009256-20,15,2014-11-21,2015-11-21,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline S.A.,Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009256-20,0,0,0 2009-009277-10,1,2012-08-16,2012-08-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Hospital Heidelberg,Neoadjuvant Radiochemotherapy Combined with Panitumumab in Locally Advanced KRAS wild-type Rectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009277-10,0,0,0 2009-009278-29,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,UZ Leuven,Follow-up studie: Metformin therapie bij kinderen en adolescenten met neurogene of neuromusculaire aandoeningen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009278-29,0,0,0 2009-009315-22,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,NVALT,A randomized phase II study of erlotinib compared to single agent chemotherapy-erlotinib combination in pretreated patients with advanced NSCLC (NVALT10 study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009315-22,0,0,0 2009-009316-50,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier de Toulouse,Diagnostic et traitement de l'asthme chez le sportif : la frontière entre la pathologie et le dopage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009316-50,0,0,0 2009-009318-41,6,2010-11-11,2010-11-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED, MULTI-CENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ADDED ON TO DICLOFENAC SR IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009318-41,0,0,0 2009-009318-41,6,2010-11-11,2010-11-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED, MULTI-CENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ADDED ON TO DICLOFENAC SR IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009318-41,0,0,0 2009-009320-36,6,2013-01-21,2013-01-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Cilag International NV,"A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 100 mg and JNJ-28431754 300 mg Compared With G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009320-36,0,0,0 2009-009323-11,1,2013-05-14,2013-05-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford,A randomised controlled trial of natural versus hormone replacement therapy cycles in frozen embryo replacement IVF: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009323-11,0,0,0 2009-009324-36,3,2017-05-10,2017-05-10,3,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",OPEN-LABEL PHASE IV STUDY TO INVESTIGATE THE SEROPERSISTENCE OF TICK-BORNE ENCEPHALITIS (TBE) VIRUS ANTIBODIES AFTER THE FIRST BOOSTER AND THE RESPONSE TO A SECOND BOOSTER VACCINATION WITH FSME-IMMUN ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009324-36,0,0,0 2009-009334-32,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,University medical center Utrecht,Effect of Statins on Sympathetic Activity in Hypertensive Patients with Chronic Kidney Disease: a Randomized trial in Hypertensive Patients with Chronic Kidney Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009334-32,0,0,0 2009-009356-20,1,2012-08-09,2012-08-09,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,IPSEN NV,"A PHASE II/III, MULTI-CENTRE, PROSPECTIVE, EXPLORATORY, OPEN LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 MG IN THE SYMPTOMATIC TREATMENT OF PATIENTS WITH REFRACTORY DIARRHE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009356-20,0,0,0 2009-009357-22,1,2014-04-22,2014-04-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University College London,"A phase IV randomised, placebo controlled, double-blind, single centre, out-patient trial to investigate the functional benefit of botulinum toxin injections combined with physiotherapy treatment for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009357-22,0,0,0 2009-009366-13,10,2011-07-01,2012-02-07,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,United Therapeutics Corporation,"A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009366-13,0,0,0 2009-009366-13,10,2011-07-01,2012-02-07,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,UNITED THERAPEUTICS,"A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hypert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009366-13,0,0,0 2009-009367-64,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,PREEMPTIVE ANALGESIA DURING A SPRING FINGER INTERVENTION UNDER LOCAL ANAESTHESIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009367-64,0,0,0 2009-009369-32,1,2017-02-07,2017-02-07,1,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Alexion Pharma GmbH,Extension Study of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Severely Affected Infants and Young Children with Hypophosphatasia (HPP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009369-32,0,0,0 2009-009372-13,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Institut de Cancérologie de la Loire,"A phase II, multi-center, open-label, repeat-dose study of Lenalidomide (Revlimid ®) plus low-dose Dexamethasone in patients with refractory B-cell lineage acute lymphoblastic leukemia or in relapse a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009372-13,0,0,0 2009-009374-27,2,2012-02-28,2012-04-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects with Advanced Cancer or Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009374-27,0,0,0 2009-009375-35,1,2012-07-01,2012-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Regionshospital skive,Den endokrine effekt af enten r-LH eller lav dosis r-hCG tilskud til r-FSH stimulering hos normogonadotrope kvinder som gennemgår IVF/ICSI behandling efter en lang GnRH agonist nedreguleringsprotocol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009375-35,0,0,0 2009-009377-10,2,2012-01-10,2012-01-10,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,SLA Pharma (UK) Ltd,"A Multicenter, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability and Efficacy Study of Naloxone SR capsules in Subjects with Constipation due to Opioids taken...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009377-10,0,0,0 2009-009379-36,1,2009-05-16,2009-05-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Marinomed Biotechnologie GmbH,"A phase II, single-center, randomized, controlled, observer-blind study with intra-individual comparisons within two parallel groups to assess the efficacy of a topical Aescin formulation in the treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009379-36,0,0,0 2009-009418-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,"Phase II study evaluating efficacy and tolerability of Sorafenib in the treatment of iatrogenic lymphedema occurring in breast cancer patients following surgical dissection of, and/or radiotherapy on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009418-42,0,0,0 2009-009421-29,1,2012-03-18,2012-03-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust,Non - invasive assessment of inflammatory burden in small abdominal aortic aneurysms: A USPIO - enhanced Magnetic Resonance Imaging (MRI) study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009421-29,0,0,0 2009-009422-92,1,2012-07-31,2012-07-31,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Fundación PETHEMA,"Ensayo clínico multicéntrico, prospectivo, abierto y con control histórico para determinar la eficacia y seguridad de la administración de DepoCyte (citarabina liposómica inyectable) como profilaxis d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009422-92,0,0,0 2009-009426-81,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Heidelberg,Contrast-enhanced Imaging of the Abdomen: Gadovist® vs. Dotarem® – Intraindividual comparison of 0.1mmol/kg bw gadoterate meglumine with 0.1mmol/kg bw gadobutrol for dynamic abdominal imaging in patie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009426-81,0,0,0 2009-009427-11,1,2012-12-27,2012-12-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Fresenius Medical Care Deutschland GmbH,Efecto de la solución de diálisis peritoneal balance sobre la membrana peritoneal de pacientes tratados con diálisis peritoneal automatizada (DPA) (The effect of balance peritoneal dialysis solution o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009427-11,0,0,0 2009-009428-36,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,CHU de Bordeaux,Imagerie moléculaire in vivo des transmissions cholinergique et dopaminergique dans les démences à corps de Lewy par tomographie d’émission monophotonique : Applications au diagnostic et à l’identific...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009428-36,0,0,0 2009-009429-26,1,2012-01-13,2012-01-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,FREE UNIVERSITY OF BRUSSELS,A PILOT STUDY TO EVALUATE THE EFFECT OF TRIGGERING FINAL OOCYTE MATURATION WITH GnRHa OR hCG ON ENDOMETRIAL RECEPTIVITY PARAMETERS AND THE LUTEAL PHASE IN OOCYTE DONORS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009429-26,0,0,0 2009-009431-30,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI,PHASE III STUDY COMPARING RITUXIMAB-SUPPLEMENTED ABVD (R-ABVD) WITH ABVD FOLLOWED BY INVOLVED-FIELD RADIOTHERAPY (ABVD-RT) IN LIMITED-STAGE (STAGE I-IIA WITH NO AREAS OF BULK) HODGKIN’S LYMPHOMA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009431-30,0,0,0 2009-009436-69,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Danderyds sjukhus AB,Effekt av domperidon på p-glukosnivåerna och glukosvariabiliteten över dygnet hos personer med typ-1 diabetes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009436-69,0,0,0 2009-009438-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Luis Fernando López Cortés,"Eficacia de dosis altas de interferón pegilado alfa-2a y ribavirina en el retratamiento de pacientes con cirrosis hepática por virus C (genotipos 1 o 4), coinfectados por el VIH, no respondedores a un...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009438-34,0,0,0 2009-009457-13,5,2015-03-09,2015-04-02,4,1,0,1,0,1,1,0,0,1,0,0,0,0,0,Erasmus MC,A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009457-13,0,0,0 2009-009457-13,5,2015-03-09,2015-04-02,4,1,0,1,0,1,1,0,0,1,0,0,0,0,0,Hospices Civils de Lyon,A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009457-13,0,0,0 2009-009461-33,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,AISAR ASSOCIAZIONE ITALIANA PER LO STUDIO DEGLI ANTIMICROBICI E DELLE RESISTENZE,"A Phase IIa, Open-Label, Dose-Escalating Study to Evaluate the Safety of AV-951 in Combination with Everolimus in Subjects with Metastatic Renal Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009461-33,0,0,0 2009-009463-61,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Sanquin Plasma Products,"Controlled trail of immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial parvovirus B19 persistence - - a prospective, double-blind, randomized, placebo-controlled cl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009463-61,0,0,0 2009-009467-59,1,2015-09-27,2015-09-27,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Institut Jules Bordet,Feasibility study of hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with stage III or only pleural stage IV ovarian carcinoma in first line therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009467-59,0,0,0 2009-009470-27,1,2014-06-13,2014-06-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospitals of Leicester NHS Trust,PHASE II TRIAL OF THE EFFECT OF GEMCITABINE WITH INTRAVENOUS OMEGA 3 FISH OIL INFUSION IN PATIENTS WITH UNRESECTABLE PANCREATIC ADENOCARCINOMA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009470-27,0,0,0 2009-009475-35,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,KARAKTER universitair centrum voor kinder- en jeudpsychiatrie,Lack of Empathy as a Symptom in various Psychiatric Disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009475-35,0,0,0 2009-009476-12,1,2011-01-20,2011-01-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Charité Campus Mitte, Instituts für Radiologie",Non-invasive detection of prostate cancer using functional MRI in patients with histopathologically confirmed prostate cancer before prostatectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009476-12,0,0,0 2009-009498-87,1,2010-01-07,2010-01-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study Of Xolair (Omaluzimab) In Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Anithist...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009498-87,0,0,0 2009-009500-39,12,2012-08-20,2012-08-20,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,"A Randomized Trial Comparing either Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects with Type 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009500-39,0,0,0 2009-009500-39,12,2012-08-20,2012-08-20,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,"A Randomized Trial Comparing either Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects with Type 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009500-39,0,0,0 2009-009500-39,12,2012-08-20,2012-08-20,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A,"A Randomized Trial Comparing either Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects with Type 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009500-39,0,0,0 2009-009502-79,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI,"open, non comparative, prospectic, phase IV clinical study to evaluate the activity and tolerance of Cinacalcet-HCl (drug name Mimpara) in patients affected by MEN1-associated primary hyperparathyroid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009502-79,0,0,0 2009-009503-19,1,2012-06-26,2012-06-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Biogen Idec International GmbH,"A prospective, open label, non-randomised, clinical trial to determine if natalizumab (Tysabri) improves ambulatory measures in relapsing remitting multiple sclerosis (RRMS) patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009503-19,0,0,0 2009-009505-25,1,2014-09-30,2014-09-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Timo Laitio,"Effect of Xenon, in Combination with Therapeutic Hypothermia, on the Brain and on Neurological Outcome following Brain Ischemia in Cardiac Arrest Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009505-25,0,0,0 2009-009516-44,2,2020-06-19,2020-06-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A randomised, open label, parallel group Phase II study comparing the efficacy and tolerability of BIBF 1120 versus sunitinib in previously untreated patients with Renal Cell Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009516-44,0,0,0 2009-009516-44,2,2020-06-19,2020-06-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, open label, parallel group Phase II study comparing the efficacy and tolerability of BIBF 1120 versus sunitinib in previously untreated patients with Renal Cell Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009516-44,0,0,0 2009-009517-18,5,2010-07-12,2010-07-12,5,1,0,0,0,0,2,0,0,1,1,0,1,0,2,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase IIa, Multicenter, Randomized, Placebo- and Active- Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus Who Ha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009517-18,0,0,0 2009-009517-18,5,2010-07-12,2010-07-12,5,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Merck and Co. Inc.,"A Phase IIa, Multicenter, Randomized, Placebo- and Active- Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus Who Ha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009517-18,0,0,0 2009-009517-18,5,2010-07-12,2010-07-12,5,1,0,0,0,0,2,0,0,1,1,0,1,0,2,"MERCK & CO., INC.","A Phase IIa, Multicenter, Randomized, Placebo- and Active- Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus Who Ha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009517-18,0,0,0 2009-009517-18,5,2010-07-12,2010-07-12,5,1,0,0,0,0,2,0,0,1,1,0,1,0,2,"Merck & Co., Inc.","A Phase IIa, Multicenter, Randomized, Placebo- and Active- Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus Who Ha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009517-18,0,0,0 2009-009517-18,5,2010-07-12,2010-07-12,5,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Merck & co.Inc,"A Phase IIa, Multicenter, Randomized, Placebo- and Active- Comparator Controlled, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus Who Ha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009517-18,0,0,0 2009-009556-21,1,2014-09-14,2014-09-14,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Heikki Koskela,Saline challenge in monitoring asthma control,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009556-21,0,0,0 2009-009579-36,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,3,,Effectiveness of inhaled corticosteroids in preschool children following hospital admission for acute dyspnea and wheeze,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009579-36,0,0,0 2009-009596-35,1,2013-05-28,2013-05-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Queen Mary's, University of London",Optimisation of Peri-operative Cardiovascular Management to Improve Surgical Outcome (Optimise Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009596-35,0,0,0 2009-009597-27,3,2012-03-16,2012-03-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"An open label, multi-center, phase 3 study with corresponding blinded image reading to determine the efficacy and safety of a single intravenous injection of 0.1 mmol/kg body weight of gadobutrol 1.0 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009597-27,0,0,0 2009-009597-27,3,2012-03-16,2012-03-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Health Care AG (study performed by Bayer Schering Pharma AG),"An open label, multi-center, phase 3 study with corresponding blinded image reading to determine the efficacy and safety of a single intravenous injection of 0.1 mmol/kg body weight of gadobutrol 1.0 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009597-27,0,0,0 2009-009598-90,3,2013-09-28,2013-09-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Health Care AG (study performed by Bayer Schering Pharma AG),"An open label, multi-center, phase 3 study with corresponding blinded image reading to determine the efficacy and safety of a single intravenous injection of 0.1 mmol/kg body weight of gadobutrol 1.0 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009598-90,0,0,0 2009-009598-90,3,2013-09-28,2013-09-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Health Care AG,"An open label, multi-center, phase 3 study with corresponding blinded image reading to determine the efficacy and safety of a single intravenous injection of 0.1 mmol/kg body weight of gadobutrol 1.0 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009598-90,0,0,0 2009-009599-11,1,2014-02-13,2014-02-13,1,0,0,0,1,0,4,0,0,1,1,1,1,0,0,Joint UCLH/UCL/Royal Free Biomedical Research Unit,Prospective randomised cross over comparison on the physiological response to non-invasive ventilation using either Air O2 or Heliox21,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009599-11,0,0,0 2009-009602-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),MICIVAX : Essai randomisé contrôlé contre placebo évaluant l’efficacité et la tolérance de la vaccination anti-grippale chez des patients traités par immunosuppresseurs pour une Maladie Inflammatoire ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009602-10,0,0,0 2009-009605-25,1,2014-11-17,2014-11-17,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,Hanna Illman,""" Reversal of neuromuscular blockade by sugammadex during propofol-remifentanil anaesthesia: Does reversal change bispectral index and entropy levels?""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009605-25,0,0,0 2009-009608-38,4,2011-07-04,2012-01-02,4,1,0,0,0,2,2,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche,"A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in Combination with Pegasys and Copeg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009608-38,0,0,0 2009-009656-20,1,2015-02-13,2015-02-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Charite Universitaetsmedizin Berlin,Sunphenon EGCg (Epigallocatechin-Gallat) in the early stage of Alzheimer´s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009656-20,0,0,0 2009-009657-19,1,2009-12-17,2009-12-17,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Ikaria, Inc.","A randomized, double-blind, placebo-controlled, multi-center study of IK-1001 to evaluate safety, population pharmacokinetics and proof-of-concept efficacy for reduction of ischemia-reperfusion mediat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009657-19,0,0,0 2009-009696-34,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Eli Lilly and Company,A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients with Active Rheumatoid Arthritis on Concomitant DMARD Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009696-34,0,0,0 2009-009756-21,3,2013-08-21,2013-08-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects with Elevated Serum Calcium Despite Recent Treatment with IV Bisphosphonate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009756-21,0,0,0 2009-009776-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Agence nationale de recherches sur le sida et les hépatites virales. ANRS.,Essai clinique comparant l’efficacité et la tolérance de deux stratégies thérapeutiques de maintenance: monothérapie par lopinavir/ritonavir ou trithérapie en comprimé unique quotidien par efavirenz/e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009776-13,0,0,0 2009-009836-54,6,2017-09-05,2017-09-05,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Celgene Corporation,"A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY OF THE SAFETY AND EFFICACY OF DIFFERENT LENALIDOMIDE (REVLIMID®) DOSE REGIMENS IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL CH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009836-54,0,0,0 2009-009837-14,1,2015-01-07,2015-01-07,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,"Seinäjoen keskussairaala, Fysiatrian ja kuntoutuksen tulosyksikkö",Aktiivinen harjoittelu verrattuna botuliinitoksiiniin kroonisen tenniskyynärpään hoidossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009837-14,0,0,0 2009-009856-19,1,2010-12-23,2010-12-23,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Moderate to Severe Knee or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009856-19,0,0,0 2009-009857-17,2,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,Janssen-Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Loading Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Inadequately ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009857-17,0,0,0 2009-009858-24,9,2015-03-04,2015-03-04,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Incyte Corporation,"A Randomized Study of the JAK Inhibitor INCB018424 Tablets Compared to Best Available Therapy in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009858-24,0,0,0 2009-009858-24,9,2015-03-04,2015-03-04,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Sevices AG,"A Randomized Study of the JAK Inhibitor INCB018424 Tablets Compared to Best Available Therapy in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009858-24,0,0,0 2009-009858-24,9,2015-03-04,2015-03-04,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Randomized Study of the JAK Inhibitor INCB018424 Tablets Compared to Best Available Therapy in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009858-24,0,0,0 2009-009862-15,5,2009-11-20,2009-11-20,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"AstraZeneca AB, European Regulatory Affairs","A double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose-Escalating Study of AZD1305 Given Intravenoulsy for Cardioversion of Atrial Fibrillation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009862-15,0,0,0 2009-009862-15,5,2009-11-20,2009-11-20,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AstraZeneca AB,"A double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose-Escalating Study of AZD1305 Given Intravenoulsy for Cardioversion of Atrial Fibrillation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009862-15,0,0,0 2009-009863-75,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Karolinska Institutet/ Hospital,El-porCEA: Assessment of safety and immunogenicity of intradermal electroporation of tetwtCEA DNA in patients with colorectal cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009863-75,0,0,0 2009-009867-70,1,2014-04-10,2014-04-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CENTRE LEON BERARD,"Evaluation, chez des femmes atteintes d’un cancer du sein non métastatique recevant un traitement antihormonal adjuvant, de l’efficacité d’un traitement homéopathique par BRN-01 versus placebo dans le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009867-70,0,0,0 2009-009868-31,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,ZonMW,"Quality of life, gross motor function, and actual everyday physical activity level in children with spastic Cerebral Palsy: (cost)effectiveness of combined treatment with multilevel botulinum-toxin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009868-31,0,0,0 2009-009869-34,4,2010-09-17,2010-09-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Randomized, placebo-controlled, double-blind, multi center study to evaluate the safety and efficacy of ciprofloxacin inhale compared to placebo in patients with non-cystic fibrosis bronchiectasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009869-34,0,0,0 2009-009871-36,1,2016-01-18,2016-01-18,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Friedrich- Alexander- Universität Erlangen Nürnberg,"Effect and Safety of preventive Treatment with ACE-Inhibitor and Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy Placebokontrollierte, doppelblinde, random...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009871-36,0,0,0 2009-009873-87,1,2010-07-14,2010-07-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mundipharma Research Ltd.,"A double-blind, randomised, incomplete block, crossover, placebo-controlled, dose-response study to assess bronchial hyperresponsiveness and airway inflammation effects of FlutiForm® pMDI low and high...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009873-87,0,0,0 2009-009874-28,1,2010-03-16,2010-03-16,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,ABCSG - Austrian Breast & Colorectal Cancer Study Group,Epirubicine plus Cyclophosphamid followed by Docetaxel +/- Sunitinib before surgery for the treatment of patients with HER2neu-negative operable breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009874-28,0,0,0 2009-009875-37,1,,,0,0,0,0,0,1,4,0,0,1,1,1,0,1,0,Staf Longziekten,A placebo-controlled trial of insulin therapy with or without adjuvant metformin in patients with cystic fibrosis-related diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009875-37,0,0,0 2009-009877-85,1,2011-02-14,2011-02-14,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,Immunogenicity of the Purified Vero Rabies Vaccine – Serum Free in Comparison with the Reference Purified Vero Rabies Vaccine in Pre-exposure Use in Healthy Adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009877-85,0,0,0 2009-009879-35,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Instituto Científico y Tecnológico de Navarra, S.A.",Estudio prospectivo en fase II de la eficacia y seguridad de la vacunación con células dendríticas autólogas en pacientes con glioblastoma multiforme tras resección quirúrgica completa con microscopio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009879-35,0,0,0 2009-009882-33,1,2017-10-13,2017-10-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,St Bartholomew's and The London NHS Trust,A multi-centre phase II study using Carboplatin AUC-10 for metastatic seminoma with IGCCCG good prognosis disease - therapy directed by initial metabolic response on PET-CT [CAR-PET],https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009882-33,0,0,0 2009-009885-15,6,2016-03-01,2016-03-01,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009885-15,0,0,0 2009-009885-15,6,2016-03-01,2016-03-01,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline SA,"A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009885-15,0,0,0 2009-009885-15,6,2016-03-01,2016-03-01,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase II, Randomised, Multi-Centre Study Evaluating Lapatinib in Combination with Vinorelbine or Capecitabine in Women with ErbB2 Overexpressing Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009885-15,0,0,0 2009-009888-60,7,2010-06-21,2010-06-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5, 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009888-60,0,0,0 2009-009888-60,7,2010-06-21,2010-06-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5, 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009888-60,0,0,0 2009-009888-60,7,2010-06-21,2010-06-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the efficacy on blood glucose control and safety of five doses of LCQ908 (2, 5, 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009888-60,0,0,0 2009-009889-13,4,2010-09-30,2010-09-30,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration for the Treatment of Hyperglycemia in Metformin Monotherapy Treated Type 2 Diabetic Patients: a Randomized, Double-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009889-13,0,0,0 2009-009893-28,1,2013-09-23,2013-09-23,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"HUCH, ATEK, TÖÖLÖN SAIRAALA, NEUROKIRURGIAN KLINIKKA",Tavoite-ohjattu nestehoito vatsa-asennon neurokirurgisen potilaan anestesiassa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009893-28,0,0,0 2009-009894-88,1,2013-04-24,2013-04-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital of Heidelberg,Lapatinib versus Lapatinib with Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A randomized phase II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009894-88,0,0,0 2009-009899-12,1,2018-10-17,2018-10-17,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,CENTRE LEON BERARD,Evaluation chez l’enfant et l’adulte présentant une rechute d’ostéosarcome de l’efficacité et de la tolérance d’un traitement adjuvant par Thiotépa® haute dose associé à une chimiothérapie conventionn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009899-12,0,0,0 2009-009908-39,1,2013-10-23,2013-10-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust,A pharmacokinetic study of capecitabine in patients undergoing peri-operative chemotherapy and a total gastrectomy for adenocarcinoma of the stomach,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009908-39,0,0,0 2009-009909-25,1,2011-10-24,2011-10-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Johann Wolfgang Goethe-Universität Frankfurt,"Evaluation of the efficacy and safety of a Macugen monotherapy versus Combined Therapies in the Treatment of Diabetic Retinopathy – a single centre, randomized, prospective Phase II trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009909-25,0,0,0 2009-009916-33,1,2016-07-13,2016-07-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Medical Center Freiburg,Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic ac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009916-33,0,0,0 2009-009917-16,1,2012-01-17,2012-01-17,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,"Odontologisk Institut, Aarhus Universitet",Kvælstofforiltes smertestillende effekt ved tandbehandling af børn,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009917-16,0,0,0 2009-009918-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"LABORATORIOS GRIFOLS, S.A.","Ensayo Clínico fase IV, prospectivo, aleatorizado, doble ciego, de grupos paralelos y unicéntrico, para evaluar el efecto de la taurina en Nutrición Parenteral Total sobre la función hepática en pacie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009918-40,0,0,0 2009-009919-21,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO DERMOPATICO IMMACOLATA,Antiangiogenic activity of metronomic therapy with capecitabine in metastatic solid tumors of gastrointestinal tract: a phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009919-21,0,0,0 2009-009921-28,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,ISTITUTI FISIOTERAPICI OSPITALIERI,"The Effect of Metformin, an insulin-sensitizing drug, on Breast Cancer Primary Prevention: The Plotina Breast Cancer Prevention Randomized, Placebo Controlled Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009921-28,0,0,0 2009-009926-94,1,2012-04-04,2012-04-04,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Department of medical gastroenterology, Herlev Hospital",Use of combined measurements of serum infliximab and anti-infliximab antibodies in the treatment of patients with Crohns disease failing infliximab therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009926-94,0,0,0 2009-009928-37,1,2011-12-31,2011-12-31,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Charite Universitätsmedizin Berlin,Phase 1/2 Studie: CONKO-008 Oxaliplatin/Folinsäure/5-Fluorouracil (24h) in Kombination mit Lapatinib in der Zweitlinientherapie des Pankreaskarzinoms nach Progress unter Gemcitabin-Monotherapie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009928-37,0,0,0 2009-009936-56,1,2009-10-26,2009-10-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche et développement,"Randomized, double-blind, placebo and active controlled study of the activity of SAR407899A single-dose on the ability to increase duration of penile rigidity, under experimental condition, in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009936-56,0,0,0 2009-009937-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Metronomic Capecitabine plus Docetaxel as first line treatment for metastatic breast cancer patients: a phase II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009937-14,0,0,0 2009-009938-33,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,ISTITUTO EUROPEO DI ONCOLOGIA,Temozolomide in the chemo-immuno-therapy of refractory acute leukaemia of adult patients: The TRIAC protocol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009938-33,0,0,0 2009-009944-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOSPITAL SANT JOAN DE DÉU,"EFECTOS ENDOCRINO-METABÓLICOS Y SOBRE LA ADIPOSIDAD VISCERAL DE LA ADMINISTRACIÓN DE METFORMINA EN NIÑOS PREPUBERALES CON BAJO PESO AL NACER PARA LA EDAD GESTACIONAL, RECUPERACIÓN POSTNATAL ESPONTÁNEA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009944-21,0,0,0 2009-009948-23,1,2009-06-10,2009-06-10,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Almirall Hermal GmbH,"A phase IIa single-center, randomized, controlled, observer-blind study to investigate the antimicrobial efficacy of topical formulations containing octenidine and prednicarbate in an ""expanded flora ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009948-23,0,0,0 2009-009952-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Intérêt des inhibiteurs de l'enzyme de conversion dans l'atteinte rénale précoce des enfants drépanocytaires : Etude randomisée en double aveugle énalapril versus placebo.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009952-18,0,0,0 2009-009956-20,1,2011-04-29,2011-04-29,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,"Free State of Bavaria rep. by the Univ. of Regensburg, rep. by the Regensburg Univ. Hospital","Prospective, randomized, controlled, mono-centric, two-armed, single-blinded pilot study for the treatment of venous and capillary vascular malformations by Indocyanine Green-augmented laser therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009956-20,0,0,0 2009-009977-85,1,2009-06-18,2009-06-18,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intradermal Route)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009977-85,0,0,0 2009-009983-29,2,2010-01-12,2010-01-12,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Relypsa, Inc.","A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Study to Evaluate the Effects of RLY5016 in Heart Failure Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009983-29,0,0,0 2009-009986-32,1,2011-01-20,2011-01-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Rotterdam Eye Hospital,"Continuation of platelet inhibiting drugs in eyelid surgery. A randomized, double-masked, placebo-controlled clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009986-32,0,0,0 2009-009990-84,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Laboratoires NEGMA,"Étude comparative, randomisée, en double-insu, en groupes parallèles, évaluant la tolérance digestive d’ART44 versus ART®50 chez des patients présentant une gonarthrose.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009990-84,0,0,0 2009-009992-36,4,2018-07-09,2018-07-09,2,1,0,0,0,0,2,0,0,1,1,0,1,0,0,University Hospital Leuven,A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment of K-Ras wild type metastatic colorectal cancer: Everest 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009992-36,0,0,0 2009-009992-36,4,2018-07-09,2018-07-09,2,1,0,0,0,0,2,0,0,1,1,0,1,0,0,Hospital Universitario de Lovaina,A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment of K-Ras wild type metastatic colorectal cancer: Everest 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009992-36,0,0,0 2009-009995-11,5,2011-04-27,2011-04-27,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, adaptive-design dose finding study to assess the antiviral efficacy and safety of NIM811 administered in combination with Standard of Care (SOC) for 12 weeks in relapsed HCV-1 infecte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009995-11,0,0,0 2009-009995-11,5,2011-04-27,2011-04-27,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A randomized, adaptive-design dose finding study to assess the antiviral efficacy and safety of NIM811 administered in combination with Standard of Care (SOC) for 12 weeks in relapsed HCV-1 infecte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009995-11,0,0,0 2009-009995-11,5,2011-04-27,2011-04-27,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmaceutica, S.A.","A randomized, adaptive-design dose finding study to assess the antiviral efficacy and safety of NIM811 administered in combination with Standard of Care (SOC) for 12 weeks in relapsed HCV-1 infecte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009995-11,0,0,0 2009-009998-10,1,2015-10-12,2015-10-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Centre for Ophthalmology, University of Tuebingen","Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009998-10,0,0,0 2009-009999-12,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,1,ISOFOL Medical AB,"An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate and Pemetrexed Single Agent, given as Neoadjuvant Treatment in Patients with Resectable Rectal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-009999-12,0,0,0 2009-010000-28,2,2013-10-24,2013-10-24,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"An open-label, multi-center study of the safety and tolerability of the combination of Trastuzumab-MCC-DM1 (T-DM1) with docetaxel, and potentially pertuzumab, for treatment for patients with advanced ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010000-28,0,0,0 2009-010002-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de BREST,"Etude de l'intérêt du bloc paravertébral continu, dans la prise en charge de la chirurgie rénale et/ou surrénalienne par laparotomie chez l'adulte",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010002-11,0,0,0 2009-010004-28,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,COG,ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010004-28,0,0,0 2009-010008-27,4,2010-05-20,2010-05-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Duloxetine 60 mg Once Daily Versus Placebo in the Treatment of Patients with Osteoarthritis Knee Pain Duloxetina 60 mg, Administrado una Vez al Día, Frente a Placebo en el Tratamiento de Pacientes co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010008-27,0,0,0 2009-010008-27,4,2010-05-20,2010-05-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"Duloxetine 60 mg Once Daily Versus Placebo in the Treatment of Patients with Osteoarthritis Knee Pain Duloxetina 60 mg, Administrado una Vez al Día, Frente a Placebo en el Tratamiento de Pacientes co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010008-27,0,0,0 2009-010017-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOELAMS,Bendamustine in patients with refractory or relapsed T-cell lymphoma. A phase II multicenter study “BENTLY”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010017-72,0,0,0 2009-010058-37,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Odense University Hospital,Chronic subdural hematome - reduction of risc of recurrence by treatment with ACE inhibitors (in Danish: Kronisk subduralt hæmatom – reduktion af recidiv risiko ved behandling med ACE hæmmere),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010058-37,0,0,0 2009-010059-28,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,VVOG,"Addition to main protocol Leiden CYPTAM for Belgian centres only Protocol outline – CYP-TAMBRUT-3 Prevalence of genetic polymorphisms in genes coding for tamoxifen metabolising enzymes, in postmenopau...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010059-28,0,0,0 2009-010060-41,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PISANA,Evaluation of efficacy of lithium salts therapy in patients with Amyotrophic Lateral Sclerosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010060-41,0,0,0 2009-010062-33,5,2011-06-09,2011-06-09,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Advanced BioHealing Inc,"A Prospective, Multi-center, Randomized, Controlled Clinical Investigation of Dermagraft® in Subjects with Venous Leg Ulcers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010062-33,0,0,0 2009-010063-16,8,2011-11-11,2011-11-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,Use of Duloxetine or Pregabalin in Monotherapy versus Combination Therapy of Both Drugs in Patients with Painful Diabetic Neuropathy The COMBO (COmbination vs Monotherapy of pregaBalin and dulOxetine...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010063-16,0,0,0 2009-010063-16,8,2011-11-11,2011-11-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Ltd.,Use of Duloxetine or Pregabalin in Monotherapy versus Combination Therapy of Both Drugs in Patients with Painful Diabetic Neuropathy The COMBO (COmbination vs Monotherapy of pregaBalin and dulOxetine...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010063-16,0,0,0 2009-010063-16,8,2011-11-11,2011-11-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,Use of Duloxetine or Pregabalin in Monotherapy versus Combination Therapy of Both Drugs in Patients with Painful Diabetic Neuropathy The COMBO (COmbination vs Monotherapy of pregaBalin and dulOxetine...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010063-16,0,0,0 2009-010063-16,8,2011-11-11,2011-11-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,Use of Duloxetine or Pregabalin in Monotherapy versus Combination Therapy of Both Drugs in Patients with Painful Diabetic Neuropathy The COMBO (COmbination vs Monotherapy of pregaBalin and dulOxetine...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010063-16,0,0,0 2009-010064-42,1,2009-10-16,2009-10-16,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA` DI NOVARA,The effects of peritonsillar infiltration of tramadol versus tramadol plus magnesium on post-tonsillectomy pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010064-42,0,0,0 2009-010065-23,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Essex Pharma GmbH,"Conventional Step-Up versus Infliximab Monotherapy in Patients with Active Moderate to Severe Ulcerative Colitis. A Randomized, Open Label, Prospective, Multicenter Study (Phase 3, Protocol No. P05553...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010065-23,0,0,0 2009-010067-16,5,2013-07-09,2013-07-09,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal Alz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010067-16,0,0,0 2009-010076-17,1,2010-02-17,2010-02-17,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,"CBLAYA&HUGET, S.L.","Ensayo clínico unicéntrico, aleatorizado, doble-ciego, controlado con placebo, de busqueda de dosis, para evaluar la eficacia analgésica, seguridad y tolerabilidad de una solución glucosada (painoff) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010076-17,0,0,0 2009-010078-39,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Academic Medical Center,The effect of helium on the immune system ex vivo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010078-39,0,0,0 2009-010079-25,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,LIDDS AB,"An open, single and multiple dose, efficacy and safety Proof of Principle study of Liproca® Depot, a controlled release formulation of 2-hydroxyflutamide, injected into the prostate in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010079-25,0,0,0 2009-010082-23,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Fundació Clínic per a la Recerca Biomèdica,"Eficacia del ARIpiprazol en el tratamiento de la Anorexia NErviosa en población infanto-juvenil: ensayo clínico piloto, aleatorizado, doble ciego, controlado con placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010082-23,0,0,0 2009-010083-42,1,2013-07-17,2013-07-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Barts Health NHS Trust,"RANDOMISED, MULTI-CENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF VITAMIN D SUPPLEMENTATION IN ADULT AND ADOLESCENT PATIENTS WITH ASTHMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010083-42,0,0,0 2009-010084-16,1,2013-07-02,2013-07-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Barts Health NHS Trust,"Randomised, Multi-Centre, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation in Patients with Chronic Obstructive Pulmonary Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010084-16,0,0,0 2009-010085-35,1,2013-04-05,2013-04-05,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Barts Health NHS Trust,"Cluster-randomised, Double-Blind, Placebo-Controlled Trial of Vitamin D Supplementation for the Prevention of Influenza and other Respiratory Infections in Sheltered Accommodation (ViDiFlu)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010085-35,0,0,0 2009-010088-17,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALI GALLIERA,Whole liver iron overload measured by the biosusceptometer Magnetic Iron Detector (MID) in thalassemia and MDS patients treated with deferasirox,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010088-17,0,0,0 2009-010091-17,4,2010-07-19,2010-07-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from peripheral nerve injury",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010091-17,0,0,0 2009-010093-38,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Dekan of the Medical Faculty of the University Erlangen-Nuremberg; Prof. Dr. Dr. h. c. Jürgen Schüttler,Multi-institutional Phase I/II Study: Neoadjuvant chemoradiation with 5-FU (or capecitabine) and oxaliplatin combined with deep regional hyperthermia in locally advanced or recurrent rectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010093-38,0,0,0 2009-010095-23,1,2009-12-30,2009-12-30,1,0,0,0,1,0,3,0,0,1,1,1,1,0,1,Omrix Biopharmaceuticals Ltd,"A prospective, controlled, randomized, multi-center, pivotal study evaluating the safety and efficacy of ADHEXIL in prevention and/or reduction of adhesions in gynecology surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010095-23,0,0,0 2009-010099-74,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""","A RANDOMIZED PHASE II STUDY OF CARBOPLATIN AND PACLITAXEL +/- CETUXIMAB, IN ADVANCED AND/OR RECURRENT CERVICAL CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010099-74,0,0,0 2009-010101-36,1,2010-08-27,2010-08-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Alcon Laboratories, Inc.",The Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (Azarga®) to Prostaglandin Monotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010101-36,0,0,0 2009-010104-28,3,2012-02-14,2012-02-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Dept. of Intensive Care, Rigshospitalet",Effects of hydroxyethyl starch 130/0.4 compared to a balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010104-28,0,0,0 2009-010104-28,3,2012-02-14,2012-02-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Dept. of Intensive Care, Rigshopitalet",Effects of hydroxyethyl starch 130/0.4 compared to a balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010104-28,0,0,0 2009-010106-11,3,2011-12-12,2011-12-12,3,1,0,0,0,0,2,0,1,1,0,0,1,0,2,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase 2 Observer-Blind Randomized Controlled Multicenter Dose-Ranging and Formulation-Finding Study of a new Novartis Meningococcal B Recombinant Vaccine evaluating the immunogenicity, tolerability ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010106-11,0,0,0 2009-010106-11,3,2011-12-12,2011-12-12,3,1,0,0,0,0,2,0,1,1,0,0,1,0,2,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 2 Observer-Blind Randomized Controlled Multicenter Dose-Ranging and Formulation-Finding Study of a new Novartis Meningococcal B Recombinant Vaccine evaluating the immunogenicity, tolerability ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010106-11,0,0,0 2009-010108-27,2,2012-11-20,2012-11-20,1,1,1,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Six-week Evaluator-Blind, Randomized, Active-Controlled Evaluation of the Effects of Three Doses of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI), Montelukast, and Beclome...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010108-27,0,0,0 2009-010110-30,4,2017-12-04,2017-12-04,3,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Active-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Long-Term Safety of Mometasone Furoate / Formoterol Fumarate (MF/F, MK-0887A [SCH418131]), Compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010110-30,1,1,0 2009-010112-15,1,2010-10-13,2010-10-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,EUTHERAPIE pour le compte du promoteur Les Laboratoires Servier,"Effets cliniques de VALDOXAN® (25 ou 50mg) à long terme chez des patients déprimés - Etude clinique, nationale, interventionnelle de phase IV, multicentrique, réalisée en ouvert. Etude Valdoxan D - EX...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010112-15,0,0,0 2009-010114-30,5,2011-06-30,2012-04-26,5,1,0,0,0,2,2,0,0,1,1,0,1,0,1,AstraZeneca AB,"A randomised, open-label, multi-centre, 2-stage, parallel group study to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010114-30,0,0,0 2009-010114-30,5,2011-06-30,2012-04-26,5,1,0,0,0,2,2,0,0,1,1,0,1,0,1,ASTRAZENECA,"A randomised, open-label, multi-centre, 2-stage, parallel group study to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010114-30,0,0,0 2009-010116-15,1,2012-05-22,2012-05-22,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,RIEMSER Arzneimittel AG,A multicentre double blind placebo controlled clinical dose- finding study for three doses of Antiadipositum X 112 T® (Cathine-hydrochloride) vs. placebo in 240 patients with a body mass index (BMI) b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010116-15,0,0,0 2009-010138-22,1,2013-06-13,2013-06-13,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Universitätsklinik für Klinische Pharmakologie,Effect of antioxidants on oxygen induced vasoconstriction in LPS induced inflammatory model in humans,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010138-22,0,0,0 2009-010140-33,1,2016-09-05,2016-09-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cardiff University,A randomised phase II Trial of carboplatin and gemcitabine +/- vandetanib in first line treatment Of advanced Urothelial cell Cancer in patients who are not suitable to receive cisplatin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010140-33,0,0,0 2009-010143-13,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,0,CESAR Central European Society for Anticancer Drug Research-EWIV,Prospective randomized phase-II trial with Temsirolimus versus Sunitinib in previously untreated patients with advanced or metastatic non-clear cell renal carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010143-13,0,0,0 2009-010145-31,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,Novartis Vaccines and Diagnostics GmbH & Co. KG,"A phase IV, open-label, multi-center follow-up study to determine the persistence of tick-borne encephalitis (TBE)-specific antibody responses among children and adolescents previously immunized again...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010145-31,0,0,0 2009-010147-14,5,2010-12-31,2010-12-31,4,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Bayer Healthcare AG,"A diagnostic interventional, controlled, cross-sectional evaluation of joint status using MRI in subjects with severe hemophilia A treated with primary prophylaxis, secondary prophylaxis, or on-demand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010147-14,0,0,0 2009-010149-29,1,2011-01-24,2011-01-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Phase 2a Study of BMS-790052 in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects with Chronic Hepatitis C Virus Genotype 1 Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010149-29,0,0,0 2009-010163-16,1,2012-04-25,2012-04-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University College London,Bile salt manipulation as a novel treatment for Crohn’s disease: a single centre open label pilot study of atorvastatin and colesevalam in patients with active ileal Crohn’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010163-16,0,0,0 2009-010164-42,1,2016-07-20,2016-07-20,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Oulun yliopisto,Ahtaan esinahan (fimoosin) hoito 0.1 % mometasonifuroaattivoiteella yli 6-v pojilla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010164-42,0,0,0 2009-010170-38,7,2012-11-02,2012-11-02,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People Aliskiren Prevention Of Later Life Outcomes (APOLLO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010170-38,0,0,0 2009-010170-38,7,2012-11-02,2012-11-02,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.",A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People Aliskiren Prevention Of Later Life Outcomes (APOLLO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010170-38,0,0,0 2009-010172-21,5,2013-03-21,2013-07-04,2,0,0,0,0,2,2,0,0,2,1,0,0,0,0,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",An Investigator-initiated study on rFVIIa prophylaxis in children with haemophilia A and inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010172-21,1,0,0 2009-010172-21,5,2013-03-21,2013-07-04,2,0,0,0,0,2,2,0,0,2,1,0,0,0,0,Dott.ssa Elena Santagostino,An Investigator-initiated study on rFVIIa prophylaxis in children with haemophilia A and inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010172-21,1,0,0 2009-010172-21,5,2013-03-21,2013-07-04,2,0,0,0,0,2,2,0,0,2,1,0,0,0,0,Elena Santagostino,An Investigator-initiated study on rFVIIa prophylaxis in children with haemophilia A and inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010172-21,1,0,0 2009-010173-20,2,2010-07-29,2010-07-29,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK","A MULTICENTER, OPEN LABEL STUDY TO INVESTIGATE THE FEASIBILITY AND EFFICACY OF A SMOKING CESSATION PROGRAM WITH VARENICLINE IN PATIENTS UNDERGOING ELECTIVE SURGERY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010173-20,0,0,0 2009-010186-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica Hospital Universitario Niño Jesús,TRASPLANTE HAPLOIDÉNTICO E INFUSIÓN DE CÉLULAS NK ESTIMULADAS CON IL-15 EN PACIENTES CON TUMORES SÓLIDOS REFRACTARIOS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010186-23,0,0,0 2009-010187-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,IFCT,"Etude de phase II-III randomisée comparant bevacizumab 7,5 mg/kg en association avec la chimiothérapie versus la chimiothérapie seule dans les cancers bronchiques à petites cellules étendus et chimios...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010187-42,0,0,0 2009-010188-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Eli Lilly Nederland,Effectiveness of Transmural Collaborative care and Duloxetine for major depressive disorder and (sub)chronic pain: a randomized placebo-controlled Multi-Centre trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010188-18,0,0,0 2009-010189-48,1,2012-05-28,2012-05-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE,Randomised trial comparing the introduction of an immediate or deferred new HAART regimen in failing HIV infected patients: the role of lamivudine monotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010189-48,0,0,0 2009-010190-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Saint-Etienne,DETECTION OF ACUTE RENAL FAILURE IN CRITICALLY ILL PATIENTS: A prospective evaluation of cystatin C diagnostic performance,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010190-20,0,0,0 2009-010191-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Alloksys Life Sciences BV,"A randomized, double-blind, placebo-controlled phase IIIa study on bIAP, an anti-inflammatory moiety, in patients undergoing combined aortic valve replacement and coronary artery bypass grafting.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010191-19,0,0,0 2009-010192-24,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),Estudio fase II randomizado de Capecitabina + Bevacizumab versus Capecitabina + Oxaliplatino + Bevacizumab en combinación con radioterapia externa como tratamiento preoperatorio en pacientes con cánce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010192-24,0,0,0 2009-010193-38,3,2010-09-28,2010-09-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"IMPAX Laboratories, Inc.",A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010193-38,0,0,0 2009-010193-38,3,2010-09-28,2010-09-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.",A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010193-38,0,0,0 2009-010196-25,8,2013-10-08,2013-10-15,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Service AG,"A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced Hepatocellular Carcinoma after ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010196-25,0,0,0 2009-010196-25,8,2013-10-08,2013-10-15,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced Hepatocellular Carcinoma after ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010196-25,0,0,0 2009-010196-25,8,2013-10-08,2013-10-15,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmaceutica S.A.,"A randomized phase III, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of everolimus (RAD001) in adult patients with advanced Hepatocellular Carcinoma after ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010196-25,0,0,0 2009-010198-19,4,2009-05-06,2010-09-03,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A Phase 2 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ for weight reduction and reduced LDL chole...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010198-19,0,0,0 2009-010198-19,4,2009-05-06,2010-09-03,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmaceutica SA,"A Phase 2 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ for weight reduction and reduced LDL chole...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010198-19,0,0,0 2009-010205-37,4,2012-05-15,2012-05-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Compare the Efficacy and Safety of Denosumab versus Placebo in Males with Low Bone Mineral Density",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010205-37,0,0,0 2009-010207-83,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Lehrstuhl für Klinisch-Experimentelle Medizin, Universitaet des Saarlandes","Effect of Omega-3 Fatty Acids (n3-PUFA, Zodin®) on Post-Prandial Triglyceride Tolerance",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010207-83,0,0,0 2009-010208-27,5,2011-12-22,2011-12-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 36-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic he...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010208-27,0,0,0 2009-010208-27,5,2011-12-22,2011-12-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A 36-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic he...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010208-27,0,0,0 2009-010208-27,5,2011-12-22,2011-12-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 36-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the efficacy, safety and tolerability of LCZ696 compared to valsartan in patients with chronic he...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010208-27,0,0,0 2009-010221-39,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Bristol Myers Squibb International Corporation,An Exploratory Phase 2 Study to Assess the Effect of Dapagliflozin on Glomerular Filtration Rate (GFR) in Subjects with Type 2 Diabetes who have Inadequate Glycemic and Blood Pressure (BP) Control Ph...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010221-39,0,0,0 2009-010224-25,2,2010-02-24,2010-02-24,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2.5 mg Saxagliptin, PO, BID, in Combination with Metformin in Subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010224-25,0,0,0 2009-010225-39,1,2012-02-28,2012-02-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Fundación para la Investigación Biomédica del Hospital Universitario La Paz,Ensayo clínico en Fase I-IIa para conocer la factibilidad y seguridad del uso alogénico de células madre expandidas (e-ASC) derivadas de la grasa en el tratamiento local de fístulas recto-vaginales de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010225-39,0,0,0 2009-010227-62,1,2014-01-16,2014-01-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GE Healthcare Ltd and its Affiliates,A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (F18) Injection for Identifying Subjects with Amnestic Mild Cognitive Impairment who will Convert to Probable Alzheimer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010227-62,0,0,0 2009-010236-18,11,2012-05-14,2012-08-06,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the 6 months efficacy and safety of aliskiren therapy on top of standard therapy, on morbidity and mort...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010236-18,0,0,0 2009-010236-18,11,2012-05-14,2012-08-06,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the 6 months efficacy and safety of aliskiren therapy on top of standard therapy, on morbidity and mort...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010236-18,0,0,0 2009-010236-18,11,2012-05-14,2012-08-06,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the 6 months efficacy and safety of aliskiren therapy on top of standard therapy, on morbidity and mort...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010236-18,0,0,0 2009-010260-41,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Breast cancer prevention with fenretinide in young women at genetic and familial risk. A phase III randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010260-41,0,0,0 2009-010261-23,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of VX-770 in Subjects Aged 12 Years and Older With Cystic Fibrosis who are Homozygous ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010261-23,0,1,1 2009-010265-23,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Gastrocentrum kirurgi,"A prospective, randomized, blinded, placebo-controlled study of the value of preoperative treatment with Tazocin on bacterial contamination and infectious complications in patients with acute cholecys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010265-23,0,0,0 2009-010266-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Afdeling heelkunde, Universitair Medisch Centrum Sint Radboud","Een gerandomiseerde dubbelblinde, placebogecontroleerde, klinische parallelle groep studie van pregabaline in patiënten met chronische pancreatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010266-28,0,0,0 2009-010267-17,1,2010-10-06,2010-10-06,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Chiesi Farmaceutici S.p.A.,"IN-VIVO DEPOSITION MEASUREMENT OF BECLOMETASONE AND FORMOTEROL AFTER INHALATION OF A SINGLE DOSE OF THE COMBINATION BDP PLUS FORMOTEROL NEXT (TM) DPI IN HEALTHY VOLUNTEERS, ASTHMATIC AND COPD PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010267-17,0,0,0 2009-010269-21,4,2016-12-22,2016-12-22,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ViiV Healthcare UK Ltd,A Phase IIb study to select a once daily oral dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naïve adult subjects.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010269-21,0,0,0 2009-010269-21,4,2016-12-22,2016-12-22,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,A Phase IIb study to select a once daily oral dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naïve adult subjects.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010269-21,0,0,0 2009-010269-21,4,2016-12-22,2016-12-22,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline S. A,A Phase IIb study to select a once daily oral dose of GSK1349572 administered with either abacavir/lamivudine or tenofovir/emtricitabine in HIV-1 infected antiretroviral therapy naïve adult subjects.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010269-21,0,0,0 2009-010270-37,3,2015-01-23,2015-01-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A Phase IIb pilot study to assess the antiviral activity of GSK1349572 containing regimen in antiretroviral therapy (ART)-experienced, HIV-1-infected adult subjects with raltegravir resistance",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010270-37,0,0,0 2009-010270-37,3,2015-01-23,2015-01-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Phase IIb pilot study to assess the antiviral activity of GSK1349572 containing regimen in antiretroviral therapy (ART)-experienced, HIV-1-infected adult subjects with raltegravir resistance",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010270-37,0,0,0 2009-010273-20,11,2019-07-11,2020-07-11,10,1,0,0,0,0,3,0,0,1,0,0,1,0,0,European organisation for research and treatment of Cancer,Adjuvant peginterferon alda-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. Pegint...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010273-20,0,0,0 2009-010273-20,11,2019-07-11,2020-07-11,10,1,0,0,0,0,3,0,0,1,0,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Adjuvant peginterferon alda-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group. Pegint...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010273-20,0,0,0 2009-010276-16,1,2013-05-07,2013-05-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly,"A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010276-16,0,0,0 2009-010277-21,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Calthorpe Clinic,A Randomised Controlled Trial on Efficacy of mifepristone followed by 6-8 hours versus 24 hours vaginal misoprostol in Early Pregnancy Abortions (< 63 days gestations),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010277-21,0,0,0 2009-010280-17,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Organisation name was not entered,TS HYPE - Turner syndrome and Hypertension; a double-blinded randomised interventional trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010280-17,0,0,0 2009-010282-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Tandvården SU/Mölndal,"A randomized, open-label, cross-over study to explore a potential involvement of a dopamine related dysfunction as a mechanism behind bruxism",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010282-23,0,0,0 2009-010288-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Hospital,Breast cell turnover and mammographic density in women with Polycystic Ovary Syndrome (PCOS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010288-17,0,0,0 2009-010290-21,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University Medical Centre Nijmegen St Radboud,"A phase Ib study of combination of temsirolimus (Torisel®) and pegylated liposomal doxorubicin (PLD, Doxil®/ Caelyx®) in advanced or recurrent breast, endometrial and ovarian cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010290-21,0,0,0 2009-010292-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,"Evaluation of Metformin effect on left ventricular function and on energetic metabolism, in patients affected by heart failure and glucidic intolerance.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010292-24,0,0,0 2009-010295-23,1,2011-07-25,2011-07-25,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,AZIENDA USL 8 AREZZO,"Load & Go trial: Safety and effectiveness of three different clopidogrel loading doses, administered at first medical contact in patients with acute myocardial infarction undergoing primary angioplast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010295-23,0,0,0 2009-010319-34,4,2014-03-01,2014-03-01,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Astellas Pharma Global Development, Inc.",A Phase 1/2 Study Evaluating Intermittent and Continuous OSI 906 and Weekly Paclitaxel in Patients with Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) Studio di fase I/II per la valut...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010319-34,0,0,0 2009-010319-34,4,2014-03-01,2014-03-01,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.",A Phase 1/2 Study Evaluating Intermittent and Continuous OSI 906 and Weekly Paclitaxel in Patients with Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) Studio di fase I/II per la valut...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010319-34,0,0,0 2009-010327-41,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Fundació Privada Clínic per a la Recerca Biomèdica,"Estudio aleatorizado y abierto de la eficacia, seguridad y tolerabilidad de dosis repetidas de bevacizumab intravítreo en pacientes con edema macular uveítico",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010327-41,0,0,0 2009-010334-21,1,2010-10-26,2010-10-26,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,Oxford University,A phase IIa study to assess the safety and efficacy of a new influenza vaccine candidate MVA-NP+M1 in healthy adults.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010334-21,0,0,0 2009-010335-41,1,2016-02-18,2016-02-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Birmingham,"A MULTICENTRE, PHASE II, OPEN LABEL, RANDOMISED CONTROLLED TRIAL OF REPEATED AUTOLOGOUS INFUSIONS OF G-CSF MOBILISED CD133+ BONE MARROW STEM CELLS IN PATIENTS WITH CIRRHOSIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010335-41,0,0,0 2009-010336-18,1,,,0,0,0,0,1,0,3,0,0,1,1,1,0,1,0,Maria Antonia Saornil Alvarez,Influencia del acetónido de triamcinolona y del ranibizumab en la retinopatía post irradiación en el melanoma de úvea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010336-18,0,0,0 2009-010337-45,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,GRUPO ESPAÑOL DE NEUROONCOLOGIA MEDICA,"Ensayo Clínico, fase II aleatorizado de tratamiento neo-adyuvante con 2 ciclos de temozolomida a dosis extendidas, previos al tratamiento con temozolomida más irradiación y posterior adyuvancia con te...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010337-45,0,0,0 2009-010338-23,1,2010-05-18,2010-05-18,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GALDERMA Research & Development,Intra-individual randomized comparison of the efficacy of two botulinum toxins type A on moderate to severe forehead wrinkles after one injection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010338-23,0,0,0 2009-010339-42,8,2011-03-14,2011-03-14,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & Développement,"An eight-week, multinational, multicenter, double-blind, active- and placebo-controlled clinical trial evaluating the efficacy and tolerability of three fixed doses of SSR125543 (20 mg daily, 50 mg da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010339-42,0,0,0 2009-010357-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Hypothalamus-Pituitary-Adrenal Axis function in the topical management with clobetasol propionate of oral lichen planus (OLP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010357-12,0,0,0 2009-010359-28,2,2010-09-10,2010-09-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc","A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF LEBRIKIZUMAB (MILR1444A)IN ADULT PATIENTS WITH ASTHMA WHO ARE INADEQUATELY CONTROLLE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010359-28,0,0,0 2009-010360-41,1,2012-04-02,2012-04-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare (UK) Limited,"A multicentre, randomised, open-label, active-controlled trial of the effectiveness of buprenorphine/naloxone in reducing intravenous buprenorphine misuse in France",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010360-41,0,0,0 2009-010366-28,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Effects of different doses of remifentanil in patients ventilated in Pressure Support Ventilation (PSV) vs Neurally Adjusted Ventilatory Assist (NAVA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010366-28,0,0,0 2009-010367-17,1,2011-02-28,2011-02-28,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Dundee,None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010367-17,0,0,0 2009-010381-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Isala klinieken,Aerosolised salbutamol in two doses as a treatment for preterm infants with developing bronchopulmonary dysplasia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010381-30,0,0,0 2009-010383-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,Comparison between two different dosages of remifentanil administered by a patient controlled tecnique (PCSA) for diagnostic and andoscopich procedures.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010383-42,0,0,0 2009-010384-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,GERCOR,A Phase III randomized trial investigating the duration of adjuvant therapy with the modified FOLFOX 6 regimen (3 versus 6 months) for patients with stage III colon cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010384-16,0,0,0 2009-010387-41,1,2010-02-24,2010-02-24,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,CSL Behring LLC,"A 12-week, Multicenter, Pharmacokinetic and Safety Study of Human Plasma-Derived Factor XIII Concentrate in Subjects with Congential Factor XIII Deficiency Estudio de 12 semanas, multicéntrico, de fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010387-41,0,0,0 2009-010390-21,1,2014-08-30,2014-08-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche Pharma AG,"A randomized, open-label, multi-center Phase II trial of bevacizumab and radiotherapy fol-lowed by bevacizumab and irinotecan vs. temozolomide and radiotherapy followed by temo-zolomide monotherapy in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010390-21,0,0,0 2009-010393-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de BREST,ETUDE DE L’EFFICACITE D’UN TRAITEMENT PAR BUMETANIDE DANS UNE POPULATION D’ENFANTS AUTISTES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010393-38,0,0,0 2009-010396-25,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Càndid Villanueva,"Estudio multicéntrico, aleatorizado, doble-ciego, controlado con placebo, sobre la eficacia del tratamiento con beta-bloqueantes pra aprevenir la descompenzación de la cirrosis con hipertensión porta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010396-25,0,0,0 2009-010399-10,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,OSPEDALE G.PASQUINUCCI-FONDAZIONE G.MONASTERIO,STANDARD VERSUS TAILORED ANTI-PLATELET THERAPY IN ACS PATIENTS UNDERGOING PERCUTANEOUS CORONARY ANGIOPLASTY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010399-10,0,0,0 2009-010402-11,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,"ALEXION PHARMACEUTICALS, INC.",AN OPEN-LABEL MULTI-CENTER STUDY OF ECULIZUMAB IN CHILDREN AND ADOLESCENTS WITH A DIAGNOSIS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010402-11,0,1,1 2009-010403-84,1,2012-07-18,2012-07-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A one year, open label, multicenter trial of LBH589 alone or in combination with ESA in red blood cell transfusion-dependent LOW and INT-1 MDS patients being either refractory to ESA or with a low pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010403-84,0,0,0 2009-010404-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Fundación de Investigación Biomédica del Hospital Universitario La Paz, Madrid",PREVENCIÓN DEL SÍNDROME DE BAJO GASTO POSTOPERATORIO EN RECIÉN NACIDOS SOMETIDOS A CIRUGÍA CARDIOVASCULAR: ESTUDIO PILOTO SOBRE LA FARMACOCINÉTICA Y FARMACODINAMIA DOSIS-DEPENDIENTE DE DOS INODILATAD...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010404-28,0,0,0 2009-010417-73,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Cooperativo GEMCAD (Grupo Español Multidisciplinar en Cáncer Digestivo),"Estudio abierto, no aleatorizado, multicéntrico, en fase II, para evaluar la eficacia y seguridad de Bevacizumab en combinación con Capecitabina y Oxaliplatino, como primera línea de tratamiento en pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010417-73,0,0,0 2009-010418-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",Effects of the prolonged administration of N-acetylcysteine on tissutal oxigenation and healing of foot ulcers in diabetic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010418-31,0,0,0 2009-010421-39,5,2014-05-06,2014-05-06,4,1,0,0,0,1,4,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A longitudinal 2-year bone marrow study of eltrombopag olamine (SB-497115-GR) in previously treated adults, with chronic immune (idiopathic) thrombocytopenic purpura (ITP).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010421-39,0,0,0 2009-010421-39,5,2014-05-06,2014-05-06,4,1,0,0,0,1,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A longitudinal 2-year bone marrow study of eltrombopag olamine (SB-497115-GR) in previously treated adults, with chronic immune (idiopathic) thrombocytopenic purpura (ITP).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010421-39,0,0,0 2009-010422-20,1,2010-05-02,2010-05-02,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,CMC Contrast AB,"Evaluation of the imaging quality of CMC-001(manganese chloride tetrahydrate) in liver Magnetic Resonance Imaging (MRI) in healthy volunteers. A double-blind, randomized cross-over, dose-response stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010422-20,0,0,0 2009-010423-58,4,2010-09-02,2010-09-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,"An evaluation of the effectiveness and tolerability of tapentadol hydrochloride prolonged release, and tapentadol hydrochloride immediate release on demand, in subjects with uncontrolled severe chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010423-58,0,0,0 2009-010425-39,4,2010-06-18,2010-08-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,"An evaluation of the effectiveness and tolerability of tapentadol hydrochloride prolonged release, and tapentadol hydrochloride immediate release on demand, in subjects with severe chronic pain due to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010425-39,0,0,0 2009-010427-12,7,2010-07-06,2010-07-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,"An evaluation of the effectiveness and tolerability of tapentadol hydrochloride prolonged release, and tapentadol hydrochloride immediate release on demand, in subjects with uncontrolled severe chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010427-12,0,0,0 2009-010428-25,6,2011-01-21,2011-01-21,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,"An evaluation of the effectiveness and tolerability of tapentadol hydrochloride prolonged release, and tapentadol hydrochloride immediate release on demand, in subjects with severe chronic nociceptive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010428-25,0,0,0 2009-010434-22,1,2010-12-07,2010-12-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A SINGLE-DOSE, OPEN-LABEL, 2-WAY CROSS-OVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 50/6 HFA pMDI (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 50µg PLUS FORMOTEROL FUMARATE 6 µg ) USING THE AERO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010434-22,0,0,0 2009-010435-40,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,"Infinity Pharmaceuticals, Inc.","Un estudio de fase 2 multicéntrico para evaluar la eficacia y seguridad del IPI-504 en combinación con trastuzumab en pacientes con cáncer de mama pretratado, localmente avanzado o metastásico, positi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010435-40,0,0,0 2009-010436-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASOCIACION TERAPEUTICA EN HEMATOLOGIA Y ONCOLOGIA MEDICAS DEL HOSPITAL ARNAU DE VILANOVA DE VALENCIA,"Ensayo clínico en fase II de la combinación de vinorelbina oral y cisplatino, administrada en inducción y concomitante con radioterapia, en pcaientes con cácner de pulmón no microcítico (CPNM) localme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010436-17,0,0,0 2009-010437-50,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF DIFFERENT GABAPENTIN DOSES IN HAEMODIALYSIS PATIENTS WITH UREMIC PRURITUS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010437-50,0,0,0 2009-010498-19,2,2009-11-16,2009-11-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galderma R&D SNC,"A MULTICENTER, RANDOMIZED, INTRA-INDIVIDUAL, DOUBLE BLIND, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CD2027 OINTMENT 9µG/G APPLIED TWICE DAILY OVER 4 WEEKS IN THE TREATMENT OF TA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010498-19,0,0,0 2009-010516-15,4,2013-07-25,2013-07-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"Ensayo aleatorizado, de grupos paralelos, en doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de SBI-087 en sujetos seropositivos con artritis reumatoide activa en tratamie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010516-15,0,0,0 2009-010516-15,4,2013-07-25,2013-07-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company","Ensayo aleatorizado, de grupos paralelos, en doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de SBI-087 en sujetos seropositivos con artritis reumatoide activa en tratamie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010516-15,0,0,0 2009-010520-25,5,2011-07-19,2011-08-19,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amarin Pharma Inc.,"A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension to Evaluate the Efficacy and Safety of AMR101 in Patients With Fasting Triglyceride...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010520-25,0,0,0 2009-010520-25,5,2011-07-19,2011-08-19,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AMARIN PHARMA INC.,"A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension to Evaluate the Efficacy and Safety of AMR101 in Patients With Fasting Triglyceride...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010520-25,0,0,0 2009-010536-17,8,2011-08-10,2011-11-04,5,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Alcon Research LTD,A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010536-17,0,0,0 2009-010536-17,8,2011-08-10,2011-11-04,5,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"ALCON RESEARCH, LTD.",A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010536-17,0,0,0 2009-010536-17,8,2011-08-10,2011-11-04,5,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Alcon Research Ltd.,A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle Following Cataract Surgery in Diabetic Retinopathy Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010536-17,0,0,0 2009-010539-41,1,2013-05-01,2013-05-01,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Vejle Sygehus,"Norspan versus Oxycontin som postoperativ smertebehandling til ekstracapsulære femurfraktur. Et randomiseret, dobbelt-blindet og placebo-kontrolleret pilotstudium.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010539-41,0,0,0 2009-010541-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio Nefrología Hospital Universitario de Bellvitge,Efecto de la inhibición de la diana de rapamicina (mTor) sobre el metabolismo y rendimiento en el ejercicio físico,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010541-31,0,0,0 2009-010547-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UZLeuven,Amisulpride versus Placebo in Functional Dyspespia with delayed gastric emptying,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010547-13,0,0,0 2009-010548-32,8,2019-04-29,2019-04-29,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A phase Ib/IIb, open-label, multi-center study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza) in adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010548-32,0,0,0 2009-010548-32,8,2019-04-29,2019-04-29,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A phase Ib/IIb, open-label, multi-center study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza) in adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010548-32,0,0,0 2009-010548-32,8,2019-04-29,2019-04-29,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A phase Ib/IIb, open-label, multi-center study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza) in adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010548-32,0,0,0 2009-010549-30,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"PRAMIPEXOLE IN THE MALE LIBIDO FAILURE : A PHASE II, off-label, pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010549-30,0,0,0 2009-010551-26,8,2015-02-05,2015-02-05,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase I/II Multi-centre Study of AZD8931 in Combination with Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumours and in a Sele...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010551-26,0,0,0 2009-010551-26,8,2015-02-05,2015-02-05,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Phase I/II Multi-centre Study of AZD8931 in Combination with Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumours and in a Sele...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010551-26,0,0,0 2009-010555-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),NICOREA : Evaluation multicentrique d'une stratégie de substitution nicotinique par timbre transdermique lors du sevrage de la ventilation mécanique de patients fumeurs hospitalisés en réanimation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010555-28,0,0,0 2009-010557-12,1,2012-09-24,2012-09-24,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,The Pennine Acute Hospitals NHS Trust,"A Single Blind, Randomised, Cross-over Study to Compare the Efficacy of Lidocaine 5% Plasters(Versatis) versus Pregabalin (Lyrica) in the Treatment of Complex Regional Pain Syndrome, Type 1.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010557-12,0,0,0 2009-010562-31,4,2010-10-18,2010-10-18,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,TEVA Pharmaceuticals Europe,Comparative bioavailability of Myfenax® (Teva) and CellCept® (Roche) in stable patients after renal transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010562-31,0,0,0 2009-010563-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Stichting Pediatrisch Onderzoek Enschede,The protective effect of a nasal corticosteroid (Avamys) on exercise induced airway obstruction in cold air.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010563-17,0,0,0 2009-010565-23,1,2009-06-24,2009-06-24,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics GmbH & Co. KG,"A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of Begrivac®, preservative free, inactivated split influenza vaccine, using the strain composition 2009/2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010565-23,0,0,0 2009-010571-24,1,2012-10-25,2012-10-25,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"An open label, multicenter, Phase I/II study of pazopanib in combination with paclitaxel in first line treatment of subjects with stage IIIBwet/IV non-small cell lung cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010571-24,0,0,0 2009-010572-20,1,2010-08-04,2010-08-04,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects with Advanced and/or Metastatic Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010572-20,0,0,0 2009-010576-21,6,2011-03-31,2011-05-24,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol Myers Squibb International Corporation,Randomized phase II of CCNU versus CCNU-dasatinib in patients with recurrent glioblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010576-21,0,0,0 2009-010579-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Julio A Virseda Rodriguez,"TRATAMIENTO INTRAVESICAL, EFECTO TERAPÉUTICO Y PREVENTIVO CON FÁRMACOS ANTINEOPLÁSICOS, MITOMICINA C EN UNA SOLA DOSIS ADMINISTRADOS EN LAS PRIMERAS 24 HORAS DE RESECCIÓN TRANSURETRAL DE VEJIGA SUPERF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010579-26,0,0,0 2009-010582-23,7,2013-10-03,2013-10-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Biologics B.V.,"A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept (EN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010582-23,0,0,0 2009-010582-23,7,2013-10-03,2013-10-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CENTOCOR,"A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept (EN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010582-23,0,0,0 2009-010582-23,7,2013-10-03,2013-10-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Centocor BV,"A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept (EN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010582-23,0,0,0 2009-010584-16,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ZonMw,New pharmacotherapeutic treatment options for crack-cocaine dependent people in the Netherlands.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010584-16,0,0,0 2009-010586-23,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, Adjuvanted with MF59C.1 Influenza Vaccine, Formulation 2009-2010, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010586-23,0,0,0 2009-010587-42,11,2011-12-21,2012-01-17,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Monthly Actonel Therapies in Postmenopausal Women Transitioned from Weekly or Daily Alendronate Therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010587-42,0,0,0 2009-010589-46,3,2009-11-03,2009-11-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-centre, randomized, double-blind, placebo controlled, multiple-dose, 4-way cross-over study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010589-46,0,0,0 2009-010589-46,3,2009-11-03,2009-11-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multi-centre, randomized, double-blind, placebo controlled, multiple-dose, 4-way cross-over study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010589-46,0,0,0 2009-010590-20,6,2011-08-17,2011-08-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"A Phase IIb, randomized, double-blind, placebo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including PegIFNα-2a and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010590-20,0,0,0 2009-010594-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,LUMC,Thoracic epidural anesthesia with ropivacaine: effects of age on neural blockade and cardiovascular parameters,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010594-20,0,0,0 2009-010598-19,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2009-2010, when Administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010598-19,0,0,0 2009-010599-45,1,2011-06-28,2011-06-28,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Bayer HealthCare AG,"Single-center, open-label, uncontrolled study to investigate the effects of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestodene (material no. 80876395) on the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010599-45,0,0,0 2009-010604-29,8,2011-02-21,2011-05-18,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Alcon Research Ltd,An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using DuoTrav APS Eye Drops Solution Versus XALACOM® Eye Drops Solution,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010604-29,0,0,0 2009-010604-29,8,2011-02-21,2011-05-18,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Alcon Research, Ltd.",An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using DuoTrav APS Eye Drops Solution Versus XALACOM® Eye Drops Solution,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010604-29,0,0,0 2009-010604-29,8,2011-02-21,2011-05-18,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Alcon Hungary Ltd.,An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using DuoTrav APS Eye Drops Solution Versus XALACOM® Eye Drops Solution,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010604-29,0,0,0 2009-010606-10,7,2011-05-25,2011-05-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.",An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using Travoprost APS Eye Drops Solution Versus XALATAN Eye Drops Solution,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010606-10,0,0,0 2009-010606-10,7,2011-05-25,2011-05-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Alcon Hungary Ltd.,An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using Travoprost APS Eye Drops Solution Versus XALATAN Eye Drops Solution,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010606-10,0,0,0 2009-010606-10,7,2011-05-25,2011-05-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Alcon Research Ltd.,An Evaluation of Patient Reported Outcomes and Ocular Surface Health in Patients Using Travoprost APS Eye Drops Solution Versus XALATAN Eye Drops Solution,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010606-10,0,0,0 2009-010608-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,MUMC+,A prospective cohort study to investigate the use of alfa V beta 3 integrin scintigraphic imaging with 99mTC-NC100692 to predict scar formation and heart failure after myocardial infarction in patient...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010608-27,0,0,0 2009-010609-35,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Department of Medical Sciences, Dermatology and venerology, Uppsala University, Uppsala Sweden","Is treatment with emollients always beneficial? Comparative biophysical and molecularbiological studies of the skinbarrier function in patients with atopic dermatitis, ichtyosis vulgaris and x-linke...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010609-35,0,0,0 2009-010611-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació clinic per a la Recerca biomèdica,Ensayo clínico para evaluar el efecto sobre la grasa subcutánea del cambio de EFV por LPV/r en pacientes infectados por VIH que desarrollaron lipoatrofia que sigue siendo clínicamente evidente a pesar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010611-33,0,0,0 2009-010613-68,9,2013-07-10,2013-07-10,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Ipsen Pharma,"""Estudio en fase II, internacional, multicéntrico, aleatorizado, abierto, de BN83495, un inhibidor oral de la esteroide sulfatasa, frente a acetato de megestrol (AM) en mujeres con cáncer endometrial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010613-68,0,0,0 2009-010614-30,1,,,0,1,0,0,1,0,0,0,0,3,0,0,0,0,0,University Hospitals Bristol,Randomised cross-over pilot study to determine the effects of isoflurane and propofol on pulmonary vascular resistance in children with pulmoanry hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010614-30,0,0,0 2009-010615-32,4,2011-05-11,2012-03-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Ltd,"A randomized, double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010615-32,0,0,0 2009-010615-32,4,2011-05-11,2012-03-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A randomized, double-blind, placebo-controlled study to evaluate the safety of 12 weeks of dosing with GW856553 and its effects on inflammatory markers, infarct size, and cardiac function in subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010615-32,0,0,0 2009-010621-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Comité Départemental d’Hygiène Social,Apport de l’Hélium dans le réentraînement à l’effort des patients atteints de broncho-pneumopathie chronique obstructive sévère. Etude prospective en double aveugle randomisée. Mélange hélium-oxygène ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010621-39,0,0,0 2009-010623-64,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,1,Renapharma AB,"A clinical open, randomised study of oral iron (Duroferon®) vs. intravenous iron (Ferinject®) for iron substitution in blood donors.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010623-64,0,0,0 2009-010625-39,1,2012-02-28,2012-02-28,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Prague Psychiatric Center,QEEG cordance and EEG connectivity changes after administration of subanesthetic ketamine doses in depressive disorder patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010625-39,0,0,0 2009-010632-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO,EFFECT OF ORAL OR INTRAVENOUS STEROID PROPHYLAXIS ON THE OCCURRENCE OF GRAVES’ ORBITOPATHY IN PATIENTS WITH GRAVES’ DISEASE AFTER TREATMENT WITH RADIOACTIVE IODINE EFFETTO DELLA PROFILASSI CON STER...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010632-18,0,0,0 2009-010640-34,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,INDUCTION OF DONOR-SPECIFIC TOLERANCE IN PATIENTS WITH LIVER TRANSPLANTATION WITH RECIPIENT PRE-TREATMENT WITH THYMOGLOBULINE AND MINIMAL POST-TRANSPLANT IMMUNOSUPPRESSION.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010640-34,0,0,0 2009-010642-57,1,2010-09-01,2010-09-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Servier Slovensko, spol. s.r.o.","“Efficacy and safety of ValdoxanR given orally once a day for 24 weeks in patients with Major Depressive Disorder.” Open, national, multicentric clinical trial for the evaluation of the antidepressant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010642-57,0,0,0 2009-010643-14,7,2013-08-08,2013-08-08,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Axial Spondyloarthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010643-14,0,0,0 2009-010643-14,7,2013-08-08,2013-08-08,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Abbott GmbH & Co. KG,A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Axial Spondyloarthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010643-14,0,0,0 2009-010656-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE,Preclinical and clinical evaluation of the activity of Docetaxel and Gemcitabine in chemonaive ERCC1-positive locally advanced or metastatic Non-Small Cell Lung Cancer patients (PLP-09),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010656-10,0,0,0 2009-010660-42,1,2010-06-21,2010-06-21,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,BOWS Pharmaceuticals AG,A double-blind two part placebo-controlled study consisting of a single ascending and multiple-dose tolerance study of peroral insulin in patients with Type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010660-42,0,0,0 2009-010661-23,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI,MITOXANTRONE/GLATIRAMER ACETATE COMBINED TREATMENT IN THE THERAPY OF SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010661-23,0,0,0 2009-010662-28,3,2010-11-26,2010-11-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,A trial comparing efficacy and safety of NN1250 and insulin glargine in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010662-28,0,0,0 2009-010665-23,13,2010-03-19,2010-03-25,10,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-week treatment, multi-center, randomized, parallel group, blinded, double dummy study to compare the efficacy and safety of Indacaterol (150 &#956;g o.d.) delivered via a SDDPI with Tiotro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010665-23,0,0,0 2009-010665-23,13,2010-03-19,2010-03-25,10,1,0,0,2,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 12-week treatment, multi-center, randomized, parallel group, blinded, double dummy study to compare the efficacy and safety of Indacaterol (150 &#956;g o.d.) delivered via a SDDPI with Tiotro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010665-23,0,0,0 2009-010665-23,13,2010-03-19,2010-03-25,10,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A 12-week treatment, multi-center, randomized, parallel group, blinded, double dummy study to compare the efficacy and safety of Indacaterol (150 &#956;g o.d.) delivered via a SDDPI with Tiotro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010665-23,0,0,0 2009-010668-40,10,2013-09-12,2013-12-26,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 microgram...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010668-40,0,0,0 2009-010668-40,10,2013-09-12,2013-12-26,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Lda.,"A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 microgram...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010668-40,0,0,0 2009-010668-40,10,2013-09-12,2013-12-26,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 microgram...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010668-40,0,0,0 2009-010668-40,10,2013-09-12,2013-12-26,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 microgram...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010668-40,0,0,0 2009-010668-40,10,2013-09-12,2013-12-26,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 microgram...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010668-40,0,0,0 2009-010668-40,10,2013-09-12,2013-12-26,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 microgram...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010668-40,0,0,0 2009-010669-22,10,2013-11-11,2013-12-09,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Limited,"A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 μg / 5 μg; ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010669-22,0,0,0 2009-010669-22,10,2013-11-11,2013-12-09,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 μg / 5 μg; ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010669-22,0,0,0 2009-010669-22,10,2013-11-11,2013-12-09,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim AB,"A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 μg / 5 μg; ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010669-22,0,0,0 2009-010669-22,10,2013-11-11,2013-12-09,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A.","A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 μg / 5 μg; ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010669-22,0,0,0 2009-010669-22,10,2013-11-11,2013-12-09,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,,"A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 μg / 5 μg; ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010669-22,0,0,0 2009-010669-22,10,2013-11-11,2013-12-09,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Norway KS,"A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 μg / 5 μg; ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010669-22,0,0,0 2009-010669-22,10,2013-11-11,2013-12-09,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 μg / 5 μg; ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010669-22,0,0,0 2009-010669-22,10,2013-11-11,2013-12-09,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,SCS Boehringer Ingelheim Comm.V,"A randomised, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 μg / 5 μg; ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010669-22,0,0,0 2009-010672-16,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO CLINICO HUMANITAS,PHASE II STUDY OF SUNITINIB IN METASTATIC RENAL CANCER WITH NON-CLEAR CELL HISTOLOGY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010672-16,0,0,0 2009-010696-24,1,2014-10-15,2014-10-15,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,Helsinki University Central Hospital,Artikaiinin ja fentanyyli-artikaiinin vertailu päiväkirurgisten alaraajaleikkauspotilaiden spinaalipuudutteena,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010696-24,0,0,0 2009-010700-28,1,2015-12-02,2015-12-02,1,1,0,0,0,0,3,0,1,1,1,1,1,0,0,University of Cologne,GRANITE-1 - Granulocyte-transfusions for patients with febrile neutropenia Granulozytentransfusionen bei Patienten mit febriler Neutropenie (GRANITE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010700-28,0,0,0 2009-010703-80,2,2009-08-31,2009-08-31,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients with Symptomatic Pulmonary Ar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010703-80,0,0,0 2009-010707-92,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,HOSPITAL SANT JOAN DE DÉU,EMPLEO DE METFORMINA EN NIÑOS Y ADOLESCENTES CON DIABETES MELLITUS TIPO 1 USE OF METFORMIN IN CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010707-92,0,0,0 2009-010708-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Department of Anaesthesia,Does the stellate ganglion block improve postoperative analgesia following upper limb trauma?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010708-28,0,0,0 2009-010713-69,1,2010-03-08,2010-03-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Lek Pharmaceuticals d.d.,"Randomized, placebo controlled, double-blind, parallel group, multicentric Phase IV study on the clinical efficacy of lactic acid bacteria in form of hard capsules (capsule contains not less than 2 x ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010713-69,0,0,0 2009-010714-30,7,2012-08-17,2012-08-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Centocor BV,"A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010714-30,0,0,0 2009-010714-30,7,2012-08-17,2012-08-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CENTOCOR,"A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010714-30,0,0,0 2009-010714-30,7,2012-08-17,2012-08-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen Biologics B.V.,"A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010714-30,0,0,0 2009-010715-32,11,2017-03-03,2017-07-22,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects with Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010715-32,0,0,0 2009-010719-33,1,2012-06-06,2012-06-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gebro Pharma GmbH,"Prospective, clinical trial to investigate safety, tolerability and efficacy of Dexibuprofen Gebro 400 mg powder for oral suspension (test) compared to Ibuprofen 400 mg powder for oral suspension (ref...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010719-33,0,0,0 2009-010720-26,5,2010-10-25,2010-10-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Sirtris Pharmaceuticals, Inc.","A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010720-26,0,0,0 2009-010721-39,1,2011-04-28,2011-04-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Peer Tfelt-Hansen,A phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks with Aura,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010721-39,0,0,0 2009-010722-19,1,2011-06-16,2011-06-16,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,CSL Behring LLC,"A Prospective, Multicenter, Open-label, Phase 3b Study of Human Plasma-Derived Factor XIII Concentrate in Subjects with Congenital Factor XIII Deficiency Estudio prospectivo, multicéntrico, con etiqu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010722-19,0,0,0 2009-010725-39,1,2015-06-16,2015-06-16,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,The University of Manchester,A randomised controlled trial to measure the effects and costs of a dental caries prevention regime for young children attending primary care dental services,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010725-39,0,0,0 2009-010725-39,1,2015-06-16,2015-06-16,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Belfast Health and Social Care Trust,A randomised controlled trial to measure the effects and costs of a dental caries prevention regime for young children attending primary care dental services,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010725-39,0,0,0 2009-010726-19,4,2011-11-09,2011-11-09,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc,A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010726-19,0,0,0 2009-010726-19,4,2011-11-09,2011-11-09,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc.,A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010726-19,0,0,0 2009-010727-91,1,2013-02-28,2013-02-28,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"LMU München, Campus Großhadern",Colesevelam for the treatment of bile acid malabsorption in patients with Crohn’s disease (Colesevelam für die Therapie der Gallensäuren-Malabsorption bei M. Crohn-Patienten),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010727-91,0,0,0 2009-010730-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"ACT BIOTECH, Inc","A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination with Chemotherapy as First-line Therapy in Subjects with Advanced Gastric Cancer Estudio de fase 2, abierto, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010730-21,0,0,0 2009-010736-18,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Pharming Technologies B.V.,An open-label exploratory Phase II study of the safety and prophylactic effect of a weekly 50 U/kg rC1INH treatment in asymptomatic patients with hereditary C1INH deficiency (HAE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010736-18,0,0,0 2009-010737-47,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,HOSPITAL SANT JOAN DE DÉU,"Ensayo de fase II, no randomizado, abierto, unicéntrico, de quimioterapia intraarterial con melfalán para el tratamiento del retinoblastoma (RTB) en fase intraocular avanzada. Phase II trial, no ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010737-47,0,0,0 2009-010738-23,1,2016-09-14,2016-09-14,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Universitätsklinikum Ulm,Multi-Center Phase II Study with Pomalidomide in Patients with Myeloproliferative Neoplasms in Fibrotic Stage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010738-23,0,0,0 2009-010739-42,7,2011-01-27,2011-01-27,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men with Signs and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010739-42,0,0,0 2009-010739-42,7,2011-01-27,2011-01-27,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men with Signs and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010739-42,0,0,0 2009-010742-59,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,HOSPITAL SANT JOAN DE DÉU,"ENSAYO DE FASE IV-II, BRAZO ÚNICO, ABIERTO, CON IRINOTECAN EN COMBINACIÓN CON CIS-PLATINO EN PACIENTES PEDIÁTRICOS CON GLIOMAS DE MAL PRONÓSTICO. PHASE IV-II SINGLE-ARM, OPEN LABEL STUDY OF IRINOTECAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010742-59,0,0,0 2009-010756-10,1,2011-05-27,2011-05-27,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,InDex Pharmaceuticals AB,Effect of an additional single dose of Kappaproct to corticosteroid treated patients with brain edema caused by brain tumor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010756-10,0,0,0 2009-010758-36,1,2011-04-28,2011-04-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,VU University Medical Center,Pyridostigmine: using a cholinesterase inhibitor to activate the cholinergic anti-inflammatory pathway in patients with CRPS-1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010758-36,0,0,0 2009-010759-29,1,2016-07-26,2016-07-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cliniques Universitaires Saint-Luc,"étude clinique sur l’administration de 3 doses de betaméthasone (12mg) à 18 heures d’intervalle lors d’une menace d’accouchement prématuré dans les grossesses gémellaires traitées par Atosiban, plutôt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010759-29,0,0,0 2009-010760-42,2,2013-06-18,2016-04-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,4SC AG,"A proof-of-concept Phase II study to evaluate efficacy, safety and pharmacokinetics of 4SC-201 and the treatment combination of Sorafenib plus 4SC-201 in patients with hepatocellular carcinoma exh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010760-42,0,0,0 2009-010761-22,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,ECG changes and C-protein level variations during and after treatment with atorvastatin at different dosages in the secondary prevention of stroke.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010761-22,0,0,0 2009-010763-17,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Sophiahemmet,Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia congenita-a double-blind placebo-controlled phase II proof of concept study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010763-17,0,0,0 2009-010777-20,3,2015-06-23,2015-06-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Astellas Pharma Global Development, Inc. (APGD)","A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin’s Lymphoma Who Are Ineligible For Or Have Previously Received An ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010777-20,0,0,0 2009-010783-41,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,Uppsala University,Population pharmacokinetic and pharmacodynamic modeling of gabapentin in neuropathic pain - Effect of adjuvant pharmacotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010783-41,0,0,0 2009-010786-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO,"Open label, phase III, multicentric randomised trial, comparing five years of treatment with a non steroidal aromatase inhibitor, either anastrozole or letrozole, versus switching after 2-3 years to t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010786-22,0,0,0 2009-010787-42,11,2010-12-15,2011-02-11,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Ipsen Pharma,"PHASE II, OPEN, RANDOMISED, PARALLEL GROUP, NONCOMPARATIVE MULTICENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPEATED SUBCUTANEOUS (S.C.) ADMINISTRATION OF DIFFERENT DOSES OF BIM 23A760 IN ACROME...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010787-42,0,0,0 2009-010787-42,11,2010-12-15,2011-02-11,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,BEAUFOUR IPSEN PHARMA,"PHASE II, OPEN, RANDOMISED, PARALLEL GROUP, NONCOMPARATIVE MULTICENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF REPEATED SUBCUTANEOUS (S.C.) ADMINISTRATION OF DIFFERENT DOSES OF BIM 23A760 IN ACROME...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010787-42,0,0,0 2009-010788-18,11,2016-02-16,2016-02-16,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme Corporation,An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010788-18,0,0,0 2009-010798-19,2,2011-09-14,2011-09-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A randomized, double-blind, placebo-controlled, infusion proof-of-concept trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ascending doses of FE 202158 in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010798-19,0,0,0 2009-010802-12,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Clinique Mutualiste Chirurgicale,Etude de l’impact d’une colle biologique sur le saignement péri-opératoire lors d’une chirurgie pour pose de Prothèse Totale de Genou (PTG). Etude EVICEL®.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010802-12,0,0,0 2009-010804-27,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,ROLE OF NITRIC OXIDE IN LUNG INFLAMMATION OF COPD PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010804-27,0,0,0 2009-010805-35,3,2010-03-08,2010-03-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Maruho Co.,Ltd.","A randomised, placebo-controlled, double-blind, left-right comparison, multi centre phase IIa study to investigate the efficacy and safety of M518101 in plaque psoriasis patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010805-35,0,0,0 2009-010806-12,8,2013-05-01,2013-05-01,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, open label, controlled study to compare the Sustained Virological Response during treatment with Neoral or tacrolimus in maintenance liver transplant recipients treated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010806-12,0,0,0 2009-010806-12,8,2013-05-01,2013-05-01,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multi-center, randomized, open label, controlled study to compare the Sustained Virological Response during treatment with Neoral or tacrolimus in maintenance liver transplant recipients treated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010806-12,0,0,0 2009-010806-12,8,2013-05-01,2013-05-01,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A multi-center, randomized, open label, controlled study to compare the Sustained Virological Response during treatment with Neoral or tacrolimus in maintenance liver transplant recipients treated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010806-12,0,0,0 2009-010807-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,"Study on spinal anestesiology whitbupivacaine, levobupivacaine e ropivacaine.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010807-10,0,0,0 2009-010808-28,1,2013-02-07,2013-02-07,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Kings College Hospital NHS Foundation Trust,Role of Non-invasive test in detecting fibrosis in chronic hepatitis B patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010808-28,0,0,0 2009-010808-28,1,2013-02-07,2013-02-07,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,King's College London,Role of Non-invasive test in detecting fibrosis in chronic hepatitis B patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010808-28,0,0,0 2009-010810-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,"UTILIDAD DEL TRATAMIENTO ANTIBIÓTICO EN LAS AGUDIZACIONES DE LA ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA (EPOC) SIN PURULENCIA EN EL ESPUTO: ENSAYO CLINICO, ALEATORIZADO, CONTROLADO Y DOBLE CIEGO DE EF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010810-31,0,0,0 2009-010811-34,1,2009-07-08,2009-07-08,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase III, open, non-randomized, multi-centric, single dose study to assess mmunogenicity and safety of Fluarix / Influsplit SSW® 2009/2010 injected intramuscularly in young adults (18 to 60 years) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010811-34,0,0,0 2009-010813-57,1,2010-09-20,2010-09-20,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,UCB Celltech,"A multicenter, randomized, double-blind, placebo-controlled, single dose study to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of intravenous and subcutaneous CDP6038 in ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010813-57,0,0,0 2009-010821-38,1,2009-07-14,2009-07-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Elevation Pharmaceuticals, Inc","Single-Dose, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Bronchodilatory Effects of Glycopyrrolate Inhalation Solution (GIS) Using a High Efficiency Nebulizer in Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010821-38,0,0,0 2009-010824-25,1,2015-04-28,2015-04-28,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,GMIHO Gesellschaft für Medizinische Innovation-Hämatologie und Onkologie mbH,"Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) with Rituximab, Dexamethason, High-dose...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010824-25,0,0,0 2009-010825-37,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Novartis Farmaceutica S.A,"Ensayo clínico de fase II, controlado, abierto, aleatorizado y multicéntrico, para comparar la eficacia y la seguridad de ranibizumab (inyección intravítrea) frente a fotocoagulación láser en paciente...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010825-37,0,0,0 2009-010826-20,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Centre Hospitalier Régional et Universitaire de Lille,A phase I dose escalation study of clofarabine given in combination with multi-agent therapy for remission induction in pediatric patients with acute lymphoblastic leukemia in first relapse or refract...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010826-20,0,0,0 2009-010827-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación PETHEMA,"Estudio nacuinal, multicéntrico, abierto, de tratamiento de inducción con VELCADE y Dexametasona en pacientes con mieloma múltiple e insuficiencia renal no tratados previamente",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010827-23,0,0,0 2009-010830-23,2,2011-12-29,2011-12-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,Efficacy of Once-Weekly Exenatide versus Once or Twice Daily Insulin Detemir in Patients with Type 2 Diabetes Treated with Metformin Alone or in Combination with Sulphonylurea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010830-23,0,0,0 2009-010832-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Francisco Bosa Ojeda,"Ensayo clínico, randomizado, doble ciego y controlado con placebo de la ivabradina en pacientes con síndrome coronario agudo: Efectos de la ivabradina en la reducción del estrés oxidativo y de marcad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010832-17,0,0,0 2009-010833-27,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo de Tratamiento de los Tumores Digestivos - TTD,"Estudio de fase II, abierto y multicéntrico para evaluar la eficacia y seguridad de la combinación de panitumumab con irinotecán en pacientes con cáncer colorrectal metastásico con KRAS no mutado y re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010833-27,0,0,0 2009-010834-23,1,2009-05-01,2009-05-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.","A multi-center, double-masked study of the safety and efficacy of DuoTrav APS compared to DuoTrav in patients with open-angle glaucoma or ocular hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010834-23,0,0,0 2009-010840-33,1,2010-03-19,2010-03-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,BELFAST HEALTH & SOCIAL CARE TRUST,Time to resumption of spontaneous respiration in patients administered either suxamethonium or rocuronium followed by sugammadex,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010840-33,0,0,0 2009-010842-67,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,OSPEDALE G.PASQUINUCCI-FONDAZIONE TOSCANA GABRIELE MONASTERIO,Effects of periprocedural atorvastatin therapy on patients undergoing percutaneous coronary intervention (PCI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010842-67,0,0,0 2009-010843-15,2,,,0,1,0,0,0,0,3,0,0,1,1,0,0,1,1,Clinuvel Pharmaceuticals Limited,"A Phase III, randomised, double blind, placebo controlled study to evaluate the safety and efficacy of subcutaneous implants of afamelanotide (16 mg) in patients suffering from polymorphic light erupt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010843-15,0,0,0 2009-010857-10,1,2014-02-28,2014-02-28,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,"Universitätsklinik für Kinder- und Jugendheilkunde, Medizinsiche Universität Wien",Proteinuria in patients with bevacizumab (Avastin®): Identification of potential protein biomarker candidates for monitoring treatment side-effects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010857-10,0,0,0 2009-010861-21,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PISANA,Evaluation of the bilo-enteric anastomoses with contrast-enhanced MR-cholangiopancreatography (MRCP) with PRIMOVIST (Gd-EOB-DTPA-enhanced MRCP): comparison with conventional T2-weighted MRCP.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010861-21,0,0,0 2009-010862-43,2,2010-06-30,2010-06-30,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,BTG International Ltd,"A multinational, multi-centre, randomised, double-blind, placebo-controlled, 3-way crossover study in migraine patients, treated with two doses of BGC20-1531 and placebo.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010862-43,0,0,0 2009-010863-18,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Amphia ziekenhuis,The additive effect of short contact tar-derivates to UVB therapy in “en plaque” psoriasis: a prospective single blind unicenter randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010863-18,0,0,0 2009-010864-40,2,2009-11-26,2009-11-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A double-blind, double-dummy, placebo-controlled, randomised, multi-centre, 5-way cross-over, single-dose study to investigate the local and systemic effects of inhaled AZD9164 compared to tiotropium ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010864-40,0,0,0 2009-010865-22,4,2011-03-02,2011-03-02,2,0,0,0,0,1,2,0,0,2,0,0,0,0,1,ApoPharma Incorporated,"An open-label, single treatment, safety and efficacy, long-term study of deferiprone in subjects with Friedreich's ataxia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010865-22,1,0,0 2009-010865-22,4,2011-03-02,2011-03-02,2,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"APOPHARMA INC., TORONTO, ONTARIO","An open-label, single treatment, safety and efficacy, long-term study of deferiprone in subjects with Friedreich's ataxia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010865-22,1,0,0 2009-010866-49,1,2012-12-01,2012-12-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Merck Serono S.A. - Geneva,Phase II Trial with Safety Run-in of MEK Inhibitor AS703026 in Subjects with Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010866-49,0,0,0 2009-010869-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE G.PASQUINUCCI-FONDAZIONE TOSCANA GABRIELE MONASTERIO/CNR,Acute and long term effects of thyroid hormone replacement therapy in patients with ST-Elevation Myocardial Infarction (STEMI) and borderline/reduced triiodothyronine levels.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010869-23,0,0,0 2009-010875-26,2,2013-05-02,2013-05-02,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A double-blind, placebo-controlled, randomized Phase 2 study of BHQ880, an anti-Dickkopf1 (DKK1) monoclonal antibody (mAb), in patients with untreated multiple myeloma and renal insufficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010875-26,0,0,0 2009-010875-26,2,2013-05-02,2013-05-02,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A double-blind, placebo-controlled, randomized Phase 2 study of BHQ880, an anti-Dickkopf1 (DKK1) monoclonal antibody (mAb), in patients with untreated multiple myeloma and renal insufficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010875-26,0,0,0 2009-010883-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IMAS,Efecto de la administración endovenosa combinada de metadona y ketamina en PCA sobre la analgesia postoperatoria de pacientes intervenidos de artrodesis lumbar.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010883-40,0,0,0 2009-010886-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Universitetssjukhuset Örebro,En dubbel-blind randomiserad studie i postoperativ smärtlindring och mobilisering efter att intrathekal morfin- eller lokal infiltrativ analgesi (LIA)-teknik används vid total knäproteskirurgi.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010886-22,0,0,0 2009-010887-41,1,2012-04-10,2012-04-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"A randomized, exploratory, open-label 48-week trial with a 2-week Pre-Treatment Phase to investigate the pharmacokinetics, safety, tolerability and antiviral activity of etravirine (ETR) in combinatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010887-41,0,0,0 2009-010895-64,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Eisai s.r.l.,"A superiority, randomized, open-label, multi-center study to compare the efficacy and safety of adjunctive zonisamide vs replacement with zonisamide of the last added antiepileptic drug in patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010895-64,0,0,0 2009-010900-27,2,2009-07-09,2009-07-09,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Solvay Biologicals BV,"Immunogenicity, reactogenicity and safety of the trivalent influenza subunit vaccine Influvac® for the season 2009/2010. An open-label, baseline-controlled multi-center study in two groups: adult subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010900-27,0,0,0 2009-010901-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación de Investigación Biomédica Hospital La Paz,ESTUDIO ALEATORIZADO Y DOBLE CIEGO CON DOBUTAMINA VERSUS PLACEBO PARA EL TRATAMIENTO DEL BAJO FLUJO EN VENA CAVA SUPERIOR EN RECIÉN NACIDOS DE BAJO PESO: EVALUACIÓN SISTEMÁTICA DE LOS EFECTOS SOBRE LA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010901-35,0,0,0 2009-010902-13,4,2012-07-05,2012-07-21,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company,Duloxetina versus placebo en el tratamiento de pacientes de avanzada edad con trastorno de ansiedad generalizada Duloxetine versus Placebo in the Treatment of Elderly Patients with Generalized Anxiet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010902-13,0,0,0 2009-010902-13,4,2012-07-05,2012-07-21,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,LILLY S.A.,Duloxetina versus placebo en el tratamiento de pacientes de avanzada edad con trastorno de ansiedad generalizada Duloxetine versus Placebo in the Treatment of Elderly Patients with Generalized Anxiet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010902-13,0,0,0 2009-010903-98,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"Canyon Pharmaceuticals, Inc.",A dose-ranging study of bolus-only Desirudin in patients undergoing PCI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010903-98,0,0,0 2009-010904-27,2,2010-05-26,2010-05-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merck & Co., Inc","A Phase II Randomized, Open-Label, Multiple-Rising Dose Clinical Trial to Study the Efficacy and Safety of MK-2578 for the Maintenance of Anemia Treatment in Patients With Chronic Kidney Disease Wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010904-27,0,0,0 2009-010904-27,2,2010-05-26,2010-05-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"MERCK & CO., INC.","A Phase II Randomized, Open-Label, Multiple-Rising Dose Clinical Trial to Study the Efficacy and Safety of MK-2578 for the Maintenance of Anemia Treatment in Patients With Chronic Kidney Disease Wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010904-27,0,0,0 2009-010912-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,MAraviroc In HIV/ HCV Coinfection and Liver fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010912-14,0,0,0 2009-010913-59,1,2012-10-16,2012-10-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Sanofi-Aventis Deutschland GmbH,"Health Assessment, Patient treatment satisfaction and Quality-of-Life in insulin-naive type 2 diabetes Patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glarg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010913-59,0,0,0 2009-010914-31,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Dr. Christian Domingo,Eficacia clínica y cambios histológicos secundarios al tratamiento con omalizumab en asmáticos alérgicos en estadio V de la gina,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010914-31,0,0,0 2009-010916-14,1,2011-09-26,2011-09-26,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,Antti Aho,Sugammadeksin vaikutus anestesiasyvyyden mittaamiseen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010916-14,0,0,0 2009-010917-61,1,2012-12-06,2012-12-06,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Haukeland University hospital,Glucocorticoid Replacement in Addison's disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010917-61,0,0,0 2009-010918-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Amar Agha, Beaumont Hospital",Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010918-30,0,0,0 2009-010920-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Universitario La Paz,Estudio para evaluar la eficacia de Rapamicina en pacientes con Poliquistosis Renal Autosómica Dominante (PQRAD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010920-24,0,0,0 2009-010921-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UMC Utrecht,"Chemopreventive effects of 5-ASA and UDCA in Ulcerative Colitis: A Double-blind, Randomized Placebo-controlled Pilot Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010921-38,0,0,0 2009-010922-21,3,2013-07-12,2013-12-17,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals France, Wyeth Research Division","A phase II a , Multicenter, Randomized , Third -party Unblinded , Long- term Extension study to Determine Safety, Tolerability and Immunogenicity of ACC-001 with QS-21 Adjuvant in Subjects with Mild t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010922-21,0,0,0 2009-010922-21,3,2013-07-12,2013-12-17,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA","A phase II a , Multicenter, Randomized , Third -party Unblinded , Long- term Extension study to Determine Safety, Tolerability and Immunogenicity of ACC-001 with QS-21 Adjuvant in Subjects with Mild t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010922-21,0,0,0 2009-010937-38,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma S.A.S.,"A 16-week treatment, multicenter, randomized, double blind, placebo-controlled, parallel-group study to assess the effect of omalizumab on the expression of FcεRI receptors of blood basophils and dend...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010937-38,0,0,0 2009-010939-40,1,2013-01-01,2013-01-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,UMCN St Radboud,"PLEASE Persistent Lyme Empiric Antibiotic Study Europe. A prospective, randomised study comparing two prolonged oral antibiotic strategies after initial intravenous ceftriaxone therapy for patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010939-40,0,0,0 2009-010943-15,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,"Intensive Care Unit, The Adelaide and Meath Hospital Incorporating the National Children's Hospital",Determination of Pharmacokinetic Parameters of Amphotericin B in critically ill patients during continuous veno-venous haemodiafiltration.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010943-15,0,0,0 2009-010945-30,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II,"Prospective, Randomized, Controlled, Double Blind Study on the Effectiveness of Movicol (PEG 3350) versus SedaStip (acacia fiber, psyllium fiber (Plantago ovata), fructose) in the Treatment of Chronic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010945-30,0,0,0 2009-010947-15,1,2011-07-26,2011-07-26,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"MUW, Klinik für Innere Med. I, Onkologie",PHASE II TRIAL OF LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010947-15,0,0,0 2009-010951-28,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Celator Pharmaceuticals, Inc","Phase IIB, multicenter, randomized, open-label trial of CPX-351 (Cytarabine:Daunorubicin) liposome injection versus intensive salvage therapy in adult patients ≤ 60 years old with AML in first relapse...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010951-28,0,0,0 2009-010952-81,1,2014-08-28,2014-08-28,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Leeds Teaching Hospitals NHS Trust,The use of Metformin and Gonadotrophin Releasing Hormone Antagonist for the treatment of women with Polycystic Ovary Syndrome undergoing In-vitro Fertilisation-Embryo Transfer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010952-81,0,0,0 2009-010955-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Division of Clinically Immunology and Rheumatology, AMC",Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010955-29,0,0,0 2009-010956-93,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Leeds,"Randomised comparisons, in myeloma patients of all ages, of thalidomide, lenalidomide, carfilzomib and bortezomib induction combinations, and of lenalidomide and combination lenalidomide vorinostat as...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010956-93,0,0,0 2009-010963-18,2,2010-06-08,2010-06-08,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S),"A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g (LEO 80190 ointment) with hydrocortisone 10 mg/g ointment, both applied once daily in the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010963-18,0,0,0 2009-010965-22,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Erasmus MC - Department of Pediatrics,The effect of long-term simvastatin treatment on cognitive function and daily life in children with Neurofibromatosis 1: a one year randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010965-22,0,0,0 2009-010966-47,1,2014-03-31,2014-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Universität Bremen,"Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010966-47,0,0,0 2009-010967-18,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,University Medical Centre Utrecht,Effect of adding vildagliptin to start of insulin treatment in combination with metformin in patients with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010967-18,0,0,0 2009-010968-42,5,2012-01-07,2012-01-07,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GUERBET,Efficacy evaluation of DOTAREM-enhanced MRA compared to GADOVIST-enhanced MRA in the diagnosis of clinical significant abdominal or lower limb arterial diseases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010968-42,0,0,0 2009-010971-26,3,2010-12-01,2010-12-01,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,MENARINI RICERCHE S.P.A.,A Phase II trial comparing Brivudin 0.1% ophthalmic solution with Aciclovir 3 % ophthalmic ointment in the treatment of patients with herpetic dendritic keratitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010971-26,0,0,0 2009-010971-26,3,2010-12-01,2010-12-01,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Menarini Ricerche S.p.A.,A Phase II trial comparing Brivudin 0.1% ophthalmic solution with Aciclovir 3 % ophthalmic ointment in the treatment of patients with herpetic dendritic keratitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010971-26,0,0,0 2009-010973-19,6,2012-02-01,2012-02-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010973-19,0,0,0 2009-010975-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Associació Catalana per a la Recerca Oncológica i les seves implicacions Sanitáries i Socials,Estudio clínico abierto de fase II de panitumumab en combinación con quimioterapia FOLFIRI como tratamiento de segunda línea en sujetos con cáncer colorrectal metastásico que expresa KRAS no mutado y ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010975-26,0,0,0 2009-010976-94,1,2017-01-11,2017-01-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,herlev hospital,"behandling af patienter med avanceret rectumcancer med capecitabin og oxaliplatin før under og efter kurativt intenderet strålebehandling, samt tillæg af cetuximab til patienter der er K-RAS vild-type",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010976-94,0,0,0 2009-010980-18,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Pharma Mar, S.A.","Efficacité et Tolérance de la Plitidepsine chez les patients souffrant d’un liposarcome dédifférencié (DLPS) avancé, non opérable ou métastatique, en rechute/réfractaire : Une étude exploratoire multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010980-18,0,0,0 2009-010982-22,1,2011-07-07,2011-07-07,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ITALFARMACO,Phase II study of the histone-deacetylase inhibitor GIVINOSTAT (ITF2357) in combination with hydroxyurea in patients with JAK2V617F positive Polycythemia Vera non-responder to hydroxyurea monotherapy ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010982-22,0,0,0 2009-010998-20,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Leeds Teaching Hospitals NHS Trust,"Attenuated dose Rituximab with ChemoTherapy In CLL: A randomised, phase IIB trial in previously untreated patients with Chronic Lymphocytic Leukaemia (CLL) to compare fludarabine, cyclophosphamide and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010998-20,0,0,0 2009-010999-19,1,,,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,Erasmus MC - Sophia Children's Hospital,Protein and Energy Interactions in Critically Ill Children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010999-19,0,0,0 2009-011000-34,5,2011-03-04,2011-03-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 16-week multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of subcutaneous AIN457 followed by an extensio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011000-34,0,0,0 2009-011002-42,1,2010-07-12,2010-07-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GUERBET,Intra-individual efficacy evaluation of DOTAREM®-enhanced MRA compared to GADOVIST®–enhanced MRA in the diagnosis of clinically significant abdominal or limb arterial diseases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011002-42,0,0,0 2009-011003-23,1,2009-12-14,2009-12-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GENFIT,A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 35 days in patients presenting with impaired glucose tolerance and abdominal obesity. A double bli...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011003-23,0,0,0 2009-011004-33,1,2009-07-30,2009-07-30,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics GmbH & Co. KG,"A Phase II, single center, uncontrolled, open label study to evaluate safety and immunogenicity of FLUVIRIN® [Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur], Formulation 2009/2010, when Admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011004-33,0,0,0 2009-011006-42,1,2012-07-31,2012-07-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Rigshospitalet, Hjertemedicinsk afd. B",Sildenafil and diastolic dysfunction after AMI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011006-42,0,0,0 2009-011007-23,6,2010-08-16,2010-08-23,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A facilitated access open-label, non-randomized, multicenter, long-term safety and efficacy study in Chronic Kidney Disease patients treated with SBR759 who have completed previous SBR759 studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011007-23,0,0,0 2009-011007-23,6,2010-08-16,2010-08-23,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma,"A facilitated access open-label, non-randomized, multicenter, long-term safety and efficacy study in Chronic Kidney Disease patients treated with SBR759 who have completed previous SBR759 studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011007-23,0,0,0 2009-011007-23,6,2010-08-16,2010-08-23,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A facilitated access open-label, non-randomized, multicenter, long-term safety and efficacy study in Chronic Kidney Disease patients treated with SBR759 who have completed previous SBR759 studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011007-23,0,0,0 2009-011008-43,1,2014-01-27,2014-01-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,Early vs.delayed EVERolimus in de novo HEART transplant recipients: optimozation of the safety/efficacy profile (EVERHEART Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011008-43,0,0,0 2009-011009-18,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI,Pilot study on the efficacy of IV haloperidol in the treatment of chronic migraine with and without medication overuse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011009-18,0,0,0 2009-011010-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Assistance Publique Hopitaux de marseille,Evaluation de l’efficacité de l’anesthésie locale lors de la réalisation d’une laryngoscopie indirecte au naso-fibroscope souple en consultation d’ORL pédiatrique.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011010-23,0,0,0 2009-011013-24,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,3,Actelion Pharmaceuticals Ltd.,"A Multicenter, Double-blind, Randomized Study comparing the Safety and Tolerability of Iloprost inhalation solution delivered by I-neb utilizing Power disc-15 and Power disc-6 in Patients with Symptom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011013-24,0,0,0 2009-011014-17,1,2010-06-03,2010-06-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, US",EFFECTS OF PREGABALIN ON SLEEP MAINTENANCE IN SUBJECTS WITH FIBROMYALGIA SYNDROME AND SLEEP MAINTENANCE DISTURBANCE: A RANDOMIZED PLACEBO-CONTROLLED 2-WAY CROSSOVER POLYSOMNOGRAPHY STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011014-17,0,0,0 2009-011017-24,1,2011-07-15,2011-07-15,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,LFB Biotechnologies,"A Phase II, open-label, randomised, dose-finding study to compare the efficacy (in terms of clearance of RhD-positive RBCs) and safety of LFB-R593, a monoclonal anti-RhD antibody, vs Rhophylac®, a pol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011017-24,0,0,0 2009-011018-51,4,2011-05-09,2011-05-09,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Clinuvel Pharmaceuticals Limited,"A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Erythropoietic Pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011018-51,0,0,0 2009-011020-65,9,2013-09-02,2014-06-03,6,1,0,0,0,1,3,0,0,1,1,0,1,0,0,European Organisation for Research and Treatment of Cancer,A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011020-65,0,0,0 2009-011022-33,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase II, double-blind study to evaluate the safety, reactogenicity and immunogenicity of two different formulations of GSK Biologicals’ pneumococcal protein candidate vaccine, when given as a boos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011022-33,0,0,0 2009-011036-36,1,2012-05-30,2012-05-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,"Alcon Research, Ltd.","Estudio multicéntrico de la pigmentación en la red trabecular después de dos años de tratamiento con TRAVATAN 0,004% solución oftálmica. A multicenter study of the pigmentation in the trabecular meshw...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011036-36,0,0,0 2009-011037-27,1,2012-07-31,2012-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Instituto Científico Tecnológico de Navarra (ICTN),"Estudio fase II, multicéntrico, para evaluar los marcadores predictores de respuesta en cáncer de mama localmente avanzado, tratado con bevacizumab en combinación con quimioterapia neoadyuvante.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011037-27,0,0,0 2009-011038-82,1,2014-03-13,2014-03-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinsche Universität Wien, Univ.Klinik f. Anästhesie u. Allgem. Intensivmedizin",Postoperative pain after anesthesia: propofol vs. sevoflurane,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011038-82,0,0,0 2009-011039-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,EFICACIA DEL TRATAMIENTO CON CONDROITIN SULFATO EN LA RIZARTROSIS. MEDICION CON TESTS SENSORIALES Y FUNCIONALES CUANTITATIVOS Y ANALISIS DE CONCORDANCIA CON ESCALAS SUBJETIVAS DE DOLOR.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011039-11,0,0,0 2009-011041-12,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Pharma Mar S.A.,Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis®) en association avec l’oxaliplatine chez des patientes atteintes d’un cancer de l’ovaire avancé prétraité.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011041-12,0,0,0 2009-011042-26,1,2012-03-05,2012-03-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik f.Neurologie",Botulinumtoxin type B for plantar hyperhidrosis: a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011042-26,0,0,0 2009-011044-20,1,2009-07-01,2009-07-01,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,AstraZeneca AB,"A Single-Centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four Period Crossover Study to Assess the Effect of Single Oral Doses of AZD5672 (600mg and 150mg) on QT/QTc Interval, Comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011044-20,0,0,0 2009-011049-15,1,2015-08-15,2015-08-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Institut Bergonié - Département d’Oncologie Médicale,Evaluation de l’efficacité du temsirolimus chez des patients récidivant d’un cancer de la vessie après une première ligne de chimiothérapie. Essai clinique de phase II multicentrique.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011049-15,0,0,0 2009-011051-51,1,2009-10-05,2009-10-05,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, double-blind, randomized study to demonstrate the non-inferiority of an aged lot of GlaxoSmithKline Biologicals' FLU NG vaccine in adults aged 65 years and above compared to a fresh lot o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011051-51,0,0,0 2009-011055-43,3,2012-01-31,2012-01-31,3,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Octapharma AG,"Clinical Study to Investigate the Efficacy, Safety, and Immunogenicity of human-cl rhFVIII in Previously Treated Patients With Severe Haemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011055-43,0,0,0 2009-011056-21,7,2015-05-20,2015-05-29,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011056-21,0,0,0 2009-011056-21,7,2015-05-20,2015-05-29,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011056-21,0,0,0 2009-011056-21,7,2015-05-20,2015-05-29,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A","An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011056-21,0,0,0 2009-011059-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Clermont-Ferrand,"Etude des effets de l’adjonction de clonidine au mélange anesthésique local + opiacé destiné à l’infusion péridurale autocontrôlée pour l’analgésie du travail obstétrical (lévobupivacaïne 0,568 mg/ml ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011059-27,0,0,0 2009-011078-14,1,2011-11-24,2011-11-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,The Christie NHS Foundation Trust,A single arm phase II study to investigate the use of Lenalidomide in the treatment of patients with early stage CLL associated with poor prognostic factors.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011078-14,0,0,0 2009-011079-57,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen,Evaluation of Indocyanine Green (ICG) enhanced Near-InfraRed Fluorescence (NIRF) Imaging for Intra-Operative Sentinel Lymph Node (SLN) detection in Breast Surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011079-57,0,0,0 2009-011088-35,1,2015-02-10,2015-02-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Philipps-Universität Marburg,Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011088-35,0,0,0 2009-011090-33,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Fundación PETHEMA,"ESTUDIO PILOTO FASE II, MULTICÉNTRICO, NO ALEATORIZADO, PARA VALORAR LA EFICACIA Y LA SEGURIDAD DE LENALIDOMIDA EN INDUCCIÓN Y POST-INDUCCIÓN EN PACIENTES CON LEUCEMIA MIELOIDE AGUDA DE NOVO (LMA) CON...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011090-33,0,0,0 2009-011093-15,1,2014-03-22,2014-03-22,1,1,0,0,1,0,2,0,1,1,0,0,1,0,0,"Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology",The role of the neurotransmitters dopamine and acetylcholine in the interaction of selective attention and working memory.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011093-15,0,0,0 2009-011095-30,1,2013-08-08,2013-08-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Fakultät Mannheim, Ruprecht-Karls-Universität Heidelberg",Intra-individual comparison of Gd-EOB-DTPA disodium (Primovist) and Gadobutrol (Gadovist) in patients with suspicion of hepatocellular carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011095-30,0,0,0 2009-011097-15,1,2011-03-04,2011-03-04,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie",Effect of atypical antipsychotics on gene expression in soft tissues of healthy subjects. A placebo controlled randomised pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011097-15,0,0,0 2009-011098-34,4,2011-03-30,2011-04-30,3,0,0,0,0,0,2,0,0,1,1,0,1,0,1,JSW Lifesciences GmbH,"A multicentre double-blind, placebo-controlled, randomised, parallel-group study to evaluate the efficacy and safety of Lornoxicam in patients with mild to moderate probable Alzheimer’s Disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011098-34,0,0,0 2009-011099-31,1,2011-01-14,2011-01-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Idera Pharmaceuticals, Inc.","A Multi-center, Randomized, Double-blind, Comparator-controlled, Dose-escalation Safety Assessment Study of Combination Treatment with IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011099-31,0,0,0 2009-011101-16,2,2011-06-07,2011-06-07,2,1,0,1,0,0,1,0,0,1,1,1,0,0,1,"Schering-Plough Research Institute, A Division of Schering Corporation",Dose-Escalation Study to Evaluate the Safety and Tolerability of SCH 717454 in Combination with Different Treatment Regimens in Subjects with Advanced Solid Tumors (Phase 1b/2; Protocol No. P04722),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011101-16,0,0,0 2009-011105-17,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ROCHE,"A single-arm, open-label study of early improvement of anemia and fatigue during treatment with tocilizumab (TCZ) in combination with non biologic DMARDs, in adult patients with moderate to severe act...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011105-17,0,0,0 2009-011106-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institute for Clinical and Experimental Medicine,Aditive effects of omega-3 polyunsaturated fatty acids and pioglitazone in the treatment of type 2 diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011106-42,0,0,0 2009-011107-23,3,2012-04-04,2012-04-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"A randomised, double-blind, placebo-controlled, parallel-group, multicenter study to demonstrate improvement of symptoms of RLS in subjects with moderate to severe idiopathic RLS with daytime symptoms...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011107-23,0,0,0 2009-011108-46,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Instituto Universitario IVI Valencia,Utilidad de los antagonistas de la GnRH en el tratamiento del síndrome de hiperestimulación ovárica precoz.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011108-46,0,0,0 2009-011109-18,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,FUNDACION PARA LA INVESTIGACION BIOMEDICA HOSPITAL UNIVERSITARIO 12 DE OCTUBRE,Valoración de la eficacia de los corticoides epidurales en el tratamiento del dolor postoperatorio y la prevención del dolor neuropático persistente en cirugía protésica de rodilla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011109-18,0,0,0 2009-011112-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dept. of Anaesthesia, Oslo University Hospital, Ullevål",Dexmedetomidine versus midazolam til sedasjon av pediatriske intensivpasienter ved Oslo Universitetssykehus.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011112-37,0,0,0 2009-011113-25,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Per Honore,"Populationsbaseret farmakokinetisk og farmakodynamisk doseringsmodel af epirubicin, cyklofosfamid og docetaxel til brystkræft",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011113-25,0,0,0 2009-011115-20,3,2017-06-27,2017-06-27,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,"The Centre for Child and Adolescent Mental Health, Eastern and Southern Norway (R.BUP)","Nordic Longterm OCD treatment Study: A Nordic Multicenter treatment study evaluating a stepped care model based on the ""Expert Clinical Guidelines"". The study is performed with no sponsor from pharmac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011115-20,1,0,0 2009-011115-20,3,2017-06-27,2017-06-27,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,"The Centre for Child and Adolescent Mental Health, Eastern and Southern","Nordic Longterm OCD treatment Study: A Nordic Multicenter treatment study evaluating a stepped care model based on the ""Expert Clinical Guidelines"". The study is performed with no sponsor from pharmac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011115-20,1,0,0 2009-011116-38,1,2012-10-02,2012-10-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,Efficacy of nebulised beclometasone versus placebo in preventing viral wheezing in pre-school children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011116-38,0,0,0 2009-011118-47,10,2014-01-17,2014-02-28,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"A phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011118-47,0,0,0 2009-011118-47,10,2014-01-17,2014-02-28,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pierre Fabre Medicament,"A phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011118-47,0,0,0 2009-011118-47,10,2014-01-17,2014-02-28,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pierre Fabre Medicament/Institut de Recherche Pierre Fabre,"A phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011118-47,0,0,0 2009-011121-13,3,2012-10-31,2012-10-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TRANSGENE S.A.,"A phase II randomized, multicenter, open-label study of TG4040 (MVA-HCV) in combination with pegylated interferon alfa-2a and ribavirin versus pegylated interferon alfa-2a and ribavirin in treatment-n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011121-13,0,0,0 2009-011122-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FUNDACION PARA LA INVESTIGACION BIOMEDICA HOSPITAL 12 DE OCTUBRE,"LA ANALGESIA DEL PARACETAMOL,¿DISMINUYE CUANDO SE ADMINISTRAN ANTIEMÉTICOS ANTISEROTONINÉRGICOS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011122-33,0,0,0 2009-011123-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FUNDACION PARA LA INVESTIGACION BIOMEDICA HOSPITAL UNIVERSITARIO 12 DE OCTUBRE,PERFUSIÓN DE LEVOBUPIVACAINA VERSUS FENTANILO A NIVEL DE PLEXO AXILAR EN EL TRATAMIENTO DEL SÍNDROME DOLOROSO REGIONAL COMPLEJO TIPO I,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011123-31,0,0,0 2009-011125-14,1,2011-08-29,2011-08-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pierre Fabre Dermatologie,"A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011125-14,0,0,0 2009-011128-70,7,2016-12-21,2016-12-21,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, multicenter, phase III study to evaluate the efficacy and safety of pasireotide LAR in patients with Cushing's disease Studio multicentrico, randomizzato, in doppio ciec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011128-70,0,0,0 2009-011128-70,7,2016-12-21,2016-12-21,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, multicenter, phase III study to evaluate the efficacy and safety of pasireotide LAR in patients with Cushing's disease Studio multicentrico, randomizzato, in doppio ciec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011128-70,0,0,0 2009-011128-70,7,2016-12-21,2016-12-21,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, multicenter, phase III study to evaluate the efficacy and safety of pasireotide LAR in patients with Cushing's disease Studio multicentrico, randomizzato, in doppio ciec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011128-70,0,0,0 2009-011132-34,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,"Academic Medical Center, Department of dermatology",A 24 week multinational multi-center study consisting of a 12-week single blind study to evaluate the efficacy and safety of methotrexate versus Azathioprin treatment in adult patients with chronic se...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011132-34,0,0,0 2009-011135-13,16,2016-09-08,2016-09-08,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"BIAL - Portela & Ca, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS MONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSET SEIZURES: A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011135-13,0,0,0 2009-011135-13,16,2016-09-08,2016-09-08,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"BIAL - PORTELA & C�, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS MONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSET SEIZURES: A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011135-13,0,0,0 2009-011137-26,17,2012-02-02,2012-02-02,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, A Division of Schering Corporation",An open-label study assessing the addition of subcutaneous golimumab (GLM) to conventional disease-modifying antirheumatic drug (DMARD) therapy in biologic-na�ve subjects with rheumatoid arthritis (P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011137-26,0,0,0 2009-011137-26,17,2012-02-02,2012-02-02,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",An open-label study assessing the addition of subcutaneous golimumab (GLM) to conventional disease-modifying antirheumatic drug (DMARD) therapy in biologic-na�ve subjects with rheumatoid arthritis (P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011137-26,0,0,0 2009-011137-26,17,2012-02-02,2012-02-02,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Shering Plough Research Institute, A division of Schering Plough Corporation",An open-label study assessing the addition of subcutaneous golimumab (GLM) to conventional disease-modifying antirheumatic drug (DMARD) therapy in biologic-na�ve subjects with rheumatoid arthritis (P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011137-26,0,0,0 2009-011144-19,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,LUNDBECK ITALIA,"A randomised, double-blind, placebo-controlled study to evaluate if rasagiline can improve depressive symptoms and cognitive function in non-demented, idiopathic Parkinson s disease patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011144-19,0,0,0 2009-011145-18,3,2013-10-30,2013-11-08,3,1,1,0,0,1,3,0,0,1,0,0,1,0,2,Bio Products Laboratory,"A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011145-18,0,0,0 2009-011145-18,3,2013-10-30,2013-11-08,3,1,1,0,0,1,3,0,0,1,0,0,1,0,2,Bio Products Laboratory Ltd,"A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011145-18,0,0,0 2009-011145-18,3,2013-10-30,2013-11-08,3,1,1,0,0,1,3,0,0,1,0,0,1,0,2,Bio Products Laboratory Limited,"A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011145-18,0,0,0 2009-011148-21,2,2010-08-05,2010-08-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 12-week, randomised, double-blind, placebo-controlled, parallel group, multinational, phase IIb dose range finding study to evaluate the efficacy and safety of AZD9668 administered orally at 3 dose ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011148-21,0,0,0 2009-011149-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Gastroenterología del Hospital Universitario Mútua de Terrassa,Estudio multicéntrico doble ciego controlado con placebo para valorar la eficacia de la colestiramina en el tratamiento de la diarrea crónica acuosa atribuida a la malabsorción de ácidos biliares,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011149-14,0,0,0 2009-011150-17,10,2014-07-31,2014-09-11,8,1,0,0,0,1,0,0,0,1,0,0,1,0,1,"GlaxoSmithKline,S.A.","AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011150-17,0,0,0 2009-011150-17,10,2014-07-31,2014-09-11,8,1,0,0,0,1,0,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Ltd,"AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011150-17,0,0,0 2009-011150-17,10,2014-07-31,2014-09-11,8,1,0,0,0,1,0,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011150-17,0,0,0 2009-011152-22,1,2017-01-09,2017-01-09,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,GENETHON,Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011152-22,0,0,0 2009-011156-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE MONZINO CENTRO CARDIOLOGICO,Effects of beta-blockers on exercise performance in uncomplicated hypertension Valutazione degli effetti della terapia beta-bloccante sulla tolleranza allo sforzo nell'ipertensione arteriosa non co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011156-21,0,0,0 2009-011157-41,5,2010-12-13,2010-12-13,4,0,0,0,2,0,3,0,0,1,0,0,1,0,1,LABORATORIES THEA,"Efficacy and Safety assessment of LT2345 unpreserved eye drops versus Xalatan in ocular hypertensive ou glaucomatous patients. PHase III study, international, multicentre, randomised, investigator mas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011157-41,0,0,0 2009-011157-41,5,2010-12-13,2010-12-13,4,0,0,0,2,0,3,0,0,1,0,0,1,0,1,Laboratoires Thea,"Efficacy and Safety assessment of LT2345 unpreserved eye drops versus Xalatan in ocular hypertensive ou glaucomatous patients. PHase III study, international, multicentre, randomised, investigator mas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011157-41,0,0,0 2009-011157-41,5,2010-12-13,2010-12-13,4,0,0,0,2,0,3,0,0,1,0,0,1,0,1,Laboratoires Théa,"Efficacy and Safety assessment of LT2345 unpreserved eye drops versus Xalatan in ocular hypertensive ou glaucomatous patients. PHase III study, international, multicentre, randomised, investigator mas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011157-41,0,0,0 2009-011157-41,5,2010-12-13,2010-12-13,4,0,0,0,2,0,3,0,0,1,0,0,1,0,1,laboratoires théa,"Efficacy and Safety assessment of LT2345 unpreserved eye drops versus Xalatan in ocular hypertensive ou glaucomatous patients. PHase III study, international, multicentre, randomised, investigator mas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011157-41,0,0,0 2009-011158-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Additional treatment to primary PCI: effects of ischemic postconditioning and Exenatide.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011158-17,0,0,0 2009-011159-29,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Institut de Recerca de l?Hospital de la Santa Creu i Sant Pau,Ensayo clínico sobre la evaluación de las estrategias de tratamiento diferido con antibióticos en las infecciones respiratorias agudas no complicadas en atención primaria (Estudio PDA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011159-29,0,0,0 2009-011160-11,1,2016-07-25,2016-07-25,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Groupe Francophone des Myélodysplasies (GFM),A phase II study of the efficacy and safety of lenalidomide combined to azacitidine in intermediate-2 or high risk MDS AND AML with del 5q,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011160-11,0,0,0 2009-011161-87,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Groupe Francophone des Myélodysplasies,Treatment of anemia in myelodysplastic syndromes low risk with epoetin beta with Analysis of impact on quality of life and functional capacity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011161-87,0,0,0 2009-011162-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION PARA LA INVESTIGACION BIOMEDICA HOSPITAL GREGORIO MARAÑON,Tratamiento de la carcinomatosis peritoneal del cáncer gástrico mediante quimioterapia neoadyuvante+QT preoperatoria intraperitoneal y sistémica simultáneas + citorreducción y quimioterapia intraperit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011162-29,0,0,0 2009-011163-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FUNDACION PARA LA INVESTIGACION BIOMEDICA HOSPITAL GREGORIO MARAÑON,Ablación de sustrato de las taquicardias ventriculares monomórficas versus fármacos antiarrítmicos en pacientes con descargas apropiadas de desfibrilador automático implantable,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011163-36,0,0,0 2009-011164-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica Hospital Gregorio Marañón,"ENSAYO CLINICO FASE II, UNICENTRICO, PROSPECTIVO, PILOTO, DE UNA SOLA COHORTE, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LAS CELULAS MADRE MESENQUIMALES EN EL TRATAMIENTO DE LA ENFERMEDAD INJERTO CONTRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011164-11,0,0,0 2009-011165-85,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION PARA LA INVESTIGACION BIOMEDICA HOSPITAL GREGORIO MARAÑON,EFICACIA DE LA GAMMAGLOBULINA INTRAVENOSA PARA LA PREVENCIÓN DE INFECCIONES EN PACIENTES CON HIPOGAMMAGLOBULINEMIA TRAS EL TRASPLANTE CARDIACO.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011165-85,0,0,0 2009-011169-98,5,2010-01-06,2011-01-06,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011169-98,0,0,0 2009-011169-98,5,2010-01-06,2011-01-06,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Gilead Sciences Incorporated,"A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011169-98,0,0,0 2009-011169-98,5,2010-01-06,2011-01-06,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Gilead Sciences, Inc","A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011169-98,0,0,0 2009-011170-15,1,2015-09-21,2015-09-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Evaluation de l'efficacité d'une corticothérapie à faible dose, associée à l'acide mycophénolique (Myfortic) dans le traitement d'attaque du syndrome néphrotique à lésions glomérulaires minimes de l'a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011170-15,0,0,0 2009-011171-76,1,2011-01-31,2011-01-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Agence nationale de recherches sur le sida et les hépatites virales. ANRS.,Etude pilote évaluant l’intérêt d’une intensification par maraviroc (Celsentri®) chez des patients infectés par le VIH-1 présentant une restauration immunitaire insuffisante malgré une charge virale c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011171-76,0,0,0 2009-011172-30,1,2011-06-01,2011-06-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 2 DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS/ PHARMACODYNAMICS OF PF-04360365 IN MILD TO MODERATE ALZHEIMER’S DI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011172-30,0,0,0 2009-011173-32,1,2010-11-23,2010-11-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leeds,Treating painful hand osteoarthritis using low dose oral prednisolone- assessing short-term pain and imaging outcomes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011173-32,0,0,0 2009-011174-15,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA PISANA,PRE-OPERATIVE CHEMO-RADIOTHERAPIC TREATMENT IN ESOPHAGEAL AND GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011174-15,0,0,0 2009-011175-70,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Liverpool Heart and Chest Hospital,A randomised factorial trial of N-acetylcysteine prophylaxis and iso-osmolar versus low-osmolar contrast media on kidney function in patients at risk of contrast induced nephropathy following cardiac ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011175-70,0,0,0 2009-011181-28,14,2013-08-09,2013-08-09,11,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Schwartz Biosciences, INC - UCB Group","AN OPEN-LABEL, MULTICENTER, MULTINATIONAL STUDY OF LACOSAMIDE AS FIRST ADD-ON ANTIEPILEPTIC DRUG (AED) TREATMENT IN SUBJECTS WITH PARTIAL-ONSET SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011181-28,1,0,0 2009-011181-28,14,2013-08-09,2013-08-09,11,1,0,0,0,0,3,0,0,2,1,0,0,0,1,UCB Biosciences Inc.,"AN OPEN-LABEL, MULTICENTER, MULTINATIONAL STUDY OF LACOSAMIDE AS FIRST ADD-ON ANTIEPILEPTIC DRUG (AED) TREATMENT IN SUBJECTS WITH PARTIAL-ONSET SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011181-28,1,0,0 2009-011181-28,14,2013-08-09,2013-08-09,11,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Schwarz Biosciences, INC - UCB Group","AN OPEN-LABEL, MULTICENTER, MULTINATIONAL STUDY OF LACOSAMIDE AS FIRST ADD-ON ANTIEPILEPTIC DRUG (AED) TREATMENT IN SUBJECTS WITH PARTIAL-ONSET SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011181-28,1,0,0 2009-011182-86,1,2010-05-04,2010-05-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Biolex Therapeutics, Inc","480 Study: Phase 2b Open-label, Randomized Study in Treatment Naïve Subjects with HCV Genotype 1 to Compare the Efficacy, Safety, and Tolerability of the 480 µg Dose of Locteron™ Plus Ribavirin Giv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011182-86,0,0,0 2009-011184-36,2,2010-12-31,2011-03-29,2,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Dept. of Neurology - Univ. of Kansas Medical Center,"A Phase II Randomised, Double-Blind, Placebo Controlled, Cross-Over Study to Investigate the Efficacy of Mexiletine in Patients with Non-Dystrophic Myotonia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011184-36,0,0,0 2009-011184-36,2,2010-12-31,2011-03-29,2,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University College London-Joint UCLH/UCL Biomedical (R&D) Unit,"A Phase II Randomised, Double-Blind, Placebo Controlled, Cross-Over Study to Investigate the Efficacy of Mexiletine in Patients with Non-Dystrophic Myotonia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011184-36,0,0,0 2009-011186-88,10,2015-05-07,2015-05-07,2,0,0,0,0,2,4,0,0,2,1,0,0,0,0,FONDAZIONE ANGELO BIANCHI BONOMI,Desarrollo de inhibidores en pacientes no tratados previamente (PUP) o en pacientes mínimamente tratados con componentes sanguíneos (MBCTP) al ser expuestos a concentrados de derivados plasmáticos con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011186-88,1,0,0 2009-011186-88,10,2015-05-07,2015-05-07,2,0,0,0,0,2,4,0,0,2,1,0,0,0,0,FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI,Desarrollo de inhibidores en pacientes no tratados previamente (PUP) o en pacientes mínimamente tratados con componentes sanguíneos (MBCTP) al ser expuestos a concentrados de derivados plasmáticos con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011186-88,1,0,0 2009-011187-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ACROSS,"“Estudio fase III multicéntrico, aleatorizado y abierto de dos pautas de hierro intravenoso en combinación con epoetina beta para el tratamiento de la anemia inducida por quimioterapia en pacientes co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011187-11,0,0,0 2009-011189-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTI FISIOTERAPICI OSPITALIERI,Phase III prospective clinical trial: 18F-FCH/PET evaluation in early diagnosis of disease recurrence in prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011189-27,0,0,0 2009-011200-39,3,2010-07-07,2010-07-07,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A six week randomized, double-blind, multi-center, placebocontrolled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011200-39,0,0,0 2009-011206-42,1,2010-07-01,2010-07-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Incyte Corporation,"A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011206-42,0,0,0 2009-011207-23,1,2015-07-27,2015-07-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hull and east Yorkshire Hospital NHS Trust,A study to Investigate the Effect of Intraperitoneal Levobupivacaine on Post Operative Laparoscopic Pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011207-23,0,0,0 2009-011207-23,1,2015-07-27,2015-07-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,,A study to Investigate the Effect of Intraperitoneal Levobupivacaine on Post Operative Laparoscopic Pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011207-23,0,0,0 2009-011208-42,2,2014-09-01,2015-10-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Imperial College, London","First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: A randomised, double-blind, placebo-controlled, multi-centre trial [The PROMISE (PROgesterone in rec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011208-42,0,0,0 2009-011208-42,2,2014-09-01,2015-10-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Academic Medical Center Amsterdam,"First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: A randomised, double-blind, placebo-controlled, multi-centre trial [The PROMISE (PROgesterone in rec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011208-42,0,0,0 2009-011212-37,1,2010-08-23,2010-08-23,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,Galderma research & Development,Anti P. acnes activity of Epiduo® Gel compared to Benzoyl Peroxide 2.5% Gel in the treatment of subjects with acne vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011212-37,0,0,0 2009-011216-38,7,2016-09-20,2017-09-21,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Medtronic International Trading,"A randomized, controlled, open-label, parallel-group, multicenter study to compare the effect of Intrathecal Baclofen Therapy (ITB Therapy) versus Best Medical Treatment (BMT) on severe spasticity ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011216-38,0,0,0 2009-011216-38,7,2016-09-20,2017-09-21,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Medtronic International trading,"A randomized, controlled, open-label, parallel-group, multicenter study to compare the effect of Intrathecal Baclofen Therapy (ITB Therapy) versus Best Medical Treatment (BMT) on severe spasticity ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011216-38,0,0,0 2009-011216-38,7,2016-09-20,2017-09-21,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MEDTRONIC,"A randomized, controlled, open-label, parallel-group, multicenter study to compare the effect of Intrathecal Baclofen Therapy (ITB Therapy) versus Best Medical Treatment (BMT) on severe spasticity ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011216-38,0,0,0 2009-011216-38,7,2016-09-20,2017-09-21,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Medtronic International Trading Sarl,"A randomized, controlled, open-label, parallel-group, multicenter study to compare the effect of Intrathecal Baclofen Therapy (ITB Therapy) versus Best Medical Treatment (BMT) on severe spasticity ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011216-38,0,0,0 2009-011217-24,2,2015-03-17,2015-10-13,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Eisai Ltd,"A Phase 1b/2, Multicenter, Open-label, Dose-escalation and Confirmation Study of Eribulin in Combination with Capecitabine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011217-24,0,0,0 2009-011217-24,2,2015-03-17,2015-10-13,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Eisai Limited,"A Phase 1b/2, Multicenter, Open-label, Dose-escalation and Confirmation Study of Eribulin in Combination with Capecitabine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011217-24,0,0,0 2009-011219-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hopital Foch,Comparison between two methods of post-operative analgesia after thoracotomy: epidural administration of sufentanil and levobupivacaine and epidural administration of levobupivacaine associated with i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011219-20,0,0,0 2009-011220-62,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,University Medical Center Utrecht,A randomized controlled withdrawal trial in Crohn's disease patients in long-term remission on mesalazine: the CROWN study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011220-62,0,0,0 2009-011221-13,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Takeda Global Research & Development Center, Inc.","A Comparative, Randomized, Open-Label, Multi-Center, Single Dose Pharmacokinetic, Pharmacodynamic and Safety Study of Alogliptin (12.5 mg and 25 mg) Between Children, Adolescents, and Adults with Type...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011221-13,0,1,1 2009-011222-34,18,2013-04-10,2013-06-18,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011222-34,0,0,0 2009-011222-34,18,2013-04-10,2013-06-18,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Development Centre Europe Ltd.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011222-34,0,0,0 2009-011225-14,1,2012-07-16,2012-07-16,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,"A PROSPECTIVE, MULTICENTER PHASE II STUDY EVALUATING PREDICTIVE FACTORS FOR LENALIDOMIDE TREATMENT RESPONSE IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011225-14,0,0,0 2009-011228-73,1,2014-12-31,2014-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford,A pilot study of Aripiprazole treatment for antipsychotic induced hyperprolactinaemia in young patients with severe mental illness and learning disabilities.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011228-73,0,0,0 2009-011228-73,1,2014-12-31,2014-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,,A pilot study of Aripiprazole treatment for antipsychotic induced hyperprolactinaemia in young patients with severe mental illness and learning disabilities.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011228-73,0,0,0 2009-011231-12,6,2011-03-30,2011-03-30,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,sanofi-aventis recherche & développement,"A 24-week, randomized, open-label, parallel group multinational comparison of Lantus® (insulin glargine) given in the morning as once-a-day basal insulin versus Neutral Protamine Hagedorn (NPH) insuli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011231-12,1,1,0 2009-011233-27,1,2011-12-20,2011-12-20,1,0,0,0,1,0,4,0,0,1,1,1,1,0,0,North Wales NHS Trust,Comparison of efficacy of concentration with volume of local anaesthetics in femoral-sciatic blocks for total knee replacement,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011233-27,0,0,0 2009-011235-12,8,2015-09-30,2015-09-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-Abelló A/S,"A Randomised,parallel-group,double-blind,placebo-controlled,multi-national,Phase III trial investigating the asthma preventing effect of Grazax compared to placebo in children with grass pollen induce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011235-12,0,0,0 2009-011236-35,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,GE Healthcare Limited and its Affiliates,A post-marketing safety study in patients with moderate renal insufficiency who receive Omniscan (Gadodiamide Injection) for contrast enhanced magnetic resonance imaging (MRI) Estudio de seguridad po...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011236-35,0,0,0 2009-011237-27,7,2010-07-26,2010-09-08,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Beh�ets patients with posterior or panuveitis treated w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011237-27,0,0,0 2009-011237-27,7,2010-07-26,2010-09-08,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma Services Ag,"A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Beh�ets patients with posterior or panuveitis treated w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011237-27,0,0,0 2009-011237-27,7,2010-07-26,2010-09-08,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Beh�ets patients with posterior or panuveitis treated w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011237-27,0,0,0 2009-011237-27,7,2010-07-26,2010-09-08,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Beh�ets patients with posterior or panuveitis treated w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011237-27,0,0,0 2009-011238-84,3,2012-05-11,2012-05-11,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Efficacy and safety of 3 dose regimens of agomelatine (10, 25, 25-50 mg) versus placebo given once a day for 6 weeks in out-patients suffering from moderate to severe Major Depressive Disorder. A 6-we...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011238-84,0,0,0 2009-011244-19,1,2012-04-10,2012-04-10,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Fundación para la Investigación Biomédica del Hospital Universitario La Paz-Sección Cirugía Torácica,"Ensayo clínico en Fase I-IIa para comprobar la factibilidad y seguridad del uso autólogo de células madre derivadas de la grasa expandidas ""in vitro"" para el tratamiento local de fístulas traqueo-esof...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011244-19,0,0,0 2009-011245-55,2,2010-09-01,2010-09-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Active Biotech Research AB,An Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During Treatment With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE). Final Protocol dated 2009-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011245-55,0,0,0 2009-011246-25,2,2011-06-03,2011-06-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"MRZ 92579/TI/3003: A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients with Subjective Tinnitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011246-25,0,0,0 2009-011248-21,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,3,,"het optimaliseren van de voorbereiding voor sigmoidoscopie in de regio; Moviprep versus Bisacodyl/klysma, een enkelblind gerandomiseerd onderzoek",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011248-21,0,0,0 2009-011250-17,2,2010-07-14,2010-07-14,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Centocor B.V.,"An Open-label, Multicenter, Phase 2 Study of Single-agent CNTO 888 (an anti- CCL2 Monoclonal Antibody) for the Treatment of Subjects with Recurrent Ovarian Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011250-17,0,0,0 2009-011251-48,2,2011-07-06,2011-07-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen Biologics B.V.,"An Open-label, Multicenter, Phase 2 Study of Single-agent CNTO 888 (an anti-CCL2 Monoclonal Antibody) for the Treatment of Subjects with Metastatic Castrate-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011251-48,0,0,0 2009-011252-22,1,2017-04-06,2017-04-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Medical Faculty, University of Bonn",Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients (CeTeG),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011252-22,0,0,0 2009-011253-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",Paroxetine or Quetiapine in Addition to Mood Stabilizers in Bipolar Depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011253-40,0,0,0 2009-011254-18,1,2009-12-29,2009-12-29,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Aegera Therapeutics Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 versus Placebo in Patients with Painful Diabetic Peripheral Neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011254-18,0,0,0 2009-011255-44,1,2012-04-11,2012-04-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Steno Diabetes Center,The effect of paricalcitol versus placebo on plasma NT-proBNP in patients with type 1 diabetes mellitus and diabetic nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011255-44,0,0,0 2009-011257-40,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA S. LUIGI GONZAGA,Sospension of androgen hormonal deprivation in patients with high levels of CgA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011257-40,0,0,0 2009-011258-16,1,2013-12-31,2013-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Dr. Jaime Sagrista Sauleda,Eficacia de la colchicina administrada en el primer brote de pericarditis para evitar la aparición de recidivas.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011258-16,0,0,0 2009-011264-11,1,2013-02-01,2013-02-01,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Queen Mary University of London,"A randomized, double blind, placebo controlled, phase II, multi-centre pilot study to investigate the effects of vitamin D2 or D3 supplementation on metabolic parameters in people at risk of type 2 di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011264-11,0,0,0 2009-011264-11,1,2013-02-01,2013-02-01,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Medical Research Council,"A randomized, double blind, placebo controlled, phase II, multi-centre pilot study to investigate the effects of vitamin D2 or D3 supplementation on metabolic parameters in people at risk of type 2 di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011264-11,0,0,0 2009-011265-82,1,2010-03-19,2010-03-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 4-week, phase-II, double-blind, placebo-controlled, randomized, parallel group, multi-centre study to assess the efficacy and tolerability/safety of inhaled AZD3199 once daily compared to 9 μg formo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011265-82,0,0,0 2009-011268-13,1,2015-02-11,2015-02-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Greater Glasgow and Clyde,Optimal management of rheumatoid arthritis patients who require biologic therapy (ORBIT study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011268-13,0,0,0 2009-011268-13,1,2015-02-11,2015-02-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Glasgow,Optimal management of rheumatoid arthritis patients who require biologic therapy (ORBIT study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011268-13,0,0,0 2009-011271-78,2,2010-10-26,2010-10-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,A trial comparing efficacy and safety of NN5401 with insulin glargine in insulin naive subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011271-78,0,0,0 2009-011273-32,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Pilot study for the evaluation of the safety and the feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in patients on stable treatment with two NRTIs + atazanavir/ritonavir ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011273-32,0,0,0 2009-011276-29,1,2010-06-30,2010-06-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ORFAGEN,"Systemic and local diffusion of ethanol after administration of ethanol 96% formulated in a gel (L0122 Gel) and ethanol 98% solution (absolute ethanol) by the percutaneous route, in patients with cong...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011276-29,0,0,0 2009-011277-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Charité - University Hospital of Berlin,A therapy and pharmacokinetics study of temsirolimus in patients with refractory and recidivated primary CNS lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011277-33,0,0,0 2009-011279-56,1,2011-03-02,2011-03-02,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Orphan Europe Recordati,"Multicenter open-label pilot study to evaluate the safety, pharmacology and efficacy of a new dose regimen (i.e. 20-10-10 mg/kg) of Pedea (intravenous ibuprofen) in preterm newborn infants of less tha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011279-56,0,0,0 2009-011280-37,1,2012-09-27,2012-09-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Centre Léon Bérard,"Efficacy and safety assessment of oral LBH589 in adult patients with advanced soft tissue sarcoma after doxorubicin failure: an open-label, multi-centric phase II study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011280-37,0,0,0 2009-011281-28,1,2010-03-31,2010-03-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospitals Leuven,"Randomised, placebo controlled clinical trial to evaluate remifentanil as maternal sedation and fetal immobilisation during diagnostic prenatal MRI.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011281-28,0,0,0 2009-011283-11,1,2009-07-20,2009-07-20,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Baxter Innovations GmbH,"AN OPEN-LABEL PHASE 3 STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF A VERO CELL-DERIVED TRIVALENT SEASONAL INFLUENZA VACCINE, STRAIN COMPOSITION 2009/2010, IN AN ADULT AND ELDERLY POPULATION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011283-11,0,0,0 2009-011289-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II,Probiotics in Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011289-27,0,0,0 2009-011291-29,2,2021-01-31,2021-01-31,1,0,0,0,0,0,4,0,0,2,0,0,0,0,2,Interuniversity Cardiology Institute of the Netherlands (ICIN),Routine versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure: RACE 3,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011291-29,1,0,0 2009-011291-29,2,2021-01-31,2021-01-31,1,0,0,0,0,0,4,0,0,2,0,0,0,0,2,Interuniversity Cardiology Institute Netherlands,Routine versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure: RACE 3,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011291-29,1,0,0 2009-011296-80,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Novartis Pharma S.A.S,Efficacy of Rasilez® (Aliskiren) compared to ramipril in the treatment of moderate systolic hypertensive patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011296-80,0,0,0 2009-011299-32,17,2018-03-25,2018-03-26,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011299-32,0,0,0 2009-011299-32,17,2018-03-25,2018-03-26,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011299-32,0,0,0 2009-011299-32,17,2018-03-25,2018-03-26,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Limited,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011299-32,0,0,0 2009-011302-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Bordeaux,METHODE D’EVALUATION DE L’APTITUDE A LA CONDUITE CHEZ DES PATIENTS SOUFFRANT DE PATHOLOGIES DE L’EVEIL AutoSoP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011302-41,0,0,0 2009-011305-17,5,2013-04-01,2013-04-01,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,ABRAXIS BIOSCIENCE LLC AN INDIRECT SUBSIDIARY OF CELGENE CORPORATION,A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011305-17,0,0,0 2009-011305-17,5,2013-04-01,2013-04-01,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Abraxis BioScience, LLC, a wholly owned subsidiary of Celgene Corporation",A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011305-17,0,0,0 2009-011305-17,5,2013-04-01,2013-04-01,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Abraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation",A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011305-17,0,0,0 2009-011305-17,5,2013-04-01,2013-04-01,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Abraxis BioScience, LLC, an indirect subsidiary of Celgene Corporation",A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine versus Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011305-17,0,0,0 2009-011307-22,1,,,0,1,0,0,0,3,4,0,0,1,0,0,0,1,0,Niuvanniemen sairaala,Klotsapiiniresistentin skitsofrenian polyfarmasiatutkimus: satunnaistettu kaksoissokkotutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011307-22,0,0,0 2009-011309-18,1,2012-08-31,2012-08-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A Prospective, Observational Study of Men With Premature Ejaculation Who Are Treated With PRILIGY™ or Alternate Care",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011309-18,0,0,0 2009-011316-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,GETAID,"ESSAI MULTICENTRIQUE RANDOMISE CONTROLE, AVEC DEUX GROUPES PARALLELES, EN DOUBLE AVEUGLE, COMPARANT LE FERRISAT®AU PLACEBO DANS L’ANEMIE ASSOCIEE AUX MICI AU COURS DU TRAITEMENT PAR ANTI-TNF ALPHA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011316-38,0,0,0 2009-011318-22,6,2011-06-15,2011-06-15,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,Efectos de la administración de tadalafilo (LY450190) una vez al día o a demanda en comparación con la administración de citrato de sildenafilo a demanda sobre la discontinuación del tratamiento en pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011318-22,0,0,0 2009-011318-22,6,2011-06-15,2011-06-15,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,LILLY S.A.,Efectos de la administración de tadalafilo (LY450190) una vez al día o a demanda en comparación con la administración de citrato de sildenafilo a demanda sobre la discontinuación del tratamiento en pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011318-22,0,0,0 2009-011322-34,1,2014-10-21,2014-10-21,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Martina Bachmann,Päiväkirurginen spinaalipuudutus artikaiinilla verrattuna artikaiini-fentanyyliin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011322-34,0,0,0 2009-011324-60,1,2012-07-02,2012-07-02,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Hannover Medical School,Prospective randomized trial to compare a twice daily to a once daily administration of the Tacrolimus in lung transplanted patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011324-60,0,0,0 2009-011325-14,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Cliniques Universitaires Saint-Luc,Phase II Study of Preoperative Panitumumab and External Beam Radiotherapy in Patients with Locally Advanced Rectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011325-14,0,0,0 2009-011327-31,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Grupo Español de Cáncer de Pulmón,"Estudio de pemetrexed y cisplatino como tratamiento de primera línea en pacientes con cáncer de pulmón no escamoso, avanzado: estudio farmacogenómico en fase IIA (Study of pemetrexed disodium plus ci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011327-31,0,0,0 2009-011337-27,1,2012-06-04,2012-06-04,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,AGMT,"A two-stage multicenter phase II trial of concurrent induction chemoimmunotherapy with epirubicine, oxaliplatin, capecitabine and panitumumab in KRAS wild-type, resectable type II gastric adenocarci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011337-27,0,0,0 2009-011339-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,daniel pacha vicente,Estudio clínico prospectivo y randomizado comparando la inyección subacromial de plasma rico en plaquetas o de betametasona y bupivacaina en la tendinosis del manguito rotador del hombro.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011339-11,0,0,0 2009-011342-26,1,2013-09-27,2013-09-27,1,0,0,0,1,0,4,0,0,1,0,0,1,0,3,"Great Western Hospital, Swindon",The use of prophylactic antibiotics for percutaneous K-wires in orthopaedic surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011342-26,0,0,0 2009-011343-39,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Janssen-Cilag AB,Patient and physician preferences and satisfaction with oral and long-acting injectable long-term antipsychotic treatment for psychotic disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011343-39,0,0,0 2009-011345-43,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,CHU de GRENOBLE,"« Etude contrôlée randomisée versus placebo évaluant l’efficacité de Gelsemium sempervirens (5CH et 15CH) sur l’anxiété anticipatoire provoquée, chez des volontaires sains. »",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011345-43,0,0,0 2009-011346-26,4,2011-01-10,2011-01-20,4,0,0,0,0,1,0,0,0,1,0,0,1,0,1,BIOSYNEXUS INC,"A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight (VLBW) Neonates for the Preventi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011346-26,0,0,0 2009-011346-26,4,2011-01-10,2011-01-20,4,0,0,0,0,1,0,0,0,1,0,0,1,0,1,Biosynexus Incorporated,"A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight (VLBW) Neonates for the Preventi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011346-26,0,0,0 2009-011348-20,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ISTITUTI CLINICI DI PERFEZIONAMENTO DI MILANO,COMPARISON BETWEEN DIFFERENT DOSES OF OPIATE ADMINISTERED IN SPINAL WAY IN LABOUR: CHANGES IN CARDIOTOCOGRAPHIC TRACE.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011348-20,0,0,0 2009-011354-18,1,2012-12-31,2012-12-31,1,0,0,0,0,0,4,1,0,1,0,0,1,0,0,Universitätsklinikum Essen,"Randomised, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable ren...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011354-18,0,0,0 2009-011355-46,1,2012-03-26,2012-03-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Consumer Care AG,"A double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of acetylsalicylic acid combined with pseudoephedrine, compared with acetylsalicylic acid alone, and pseud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011355-46,0,0,0 2009-011357-41,2,2015-02-03,2015-02-03,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A long-term, open, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in healthy female subjects up to 10 years after administration of the first ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011357-41,0,0,0 2009-011360-10,23,2014-01-24,2014-01-24,22,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Efectos de ivabradina en pacientes con arteriopatía coronaria estable sin insuficiencia cardíaca clínica. Estudio multicéntrico, internacional, aleatorizado, doble ciego, controlado con placebo Study...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011360-10,0,0,0 2009-011360-10,23,2014-01-24,2014-01-24,22,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Efectos de ivabradina en pacientes con arteriopatía coronaria estable sin insuficiencia cardíaca clínica. Estudio multicéntrico, internacional, aleatorizado, doble ciego, controlado con placebo Study...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011360-10,0,0,0 2009-011360-10,23,2014-01-24,2014-01-24,22,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut Recherches Internationales Servier,"Efectos de ivabradina en pacientes con arteriopatía coronaria estable sin insuficiencia cardíaca clínica. Estudio multicéntrico, internacional, aleatorizado, doble ciego, controlado con placebo Study...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011360-10,0,0,0 2009-011377-33,1,2015-09-26,2015-09-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,The Christie NHS Foundation Trust,AN ASSESSMENT OF IMAGING AND CIRCULATING BIOMARKERS IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA TREATED WITH THE ANTI-VEGF MONOCLONAL ANTIBODY BEVACIZUMAB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011377-33,0,0,0 2009-011378-14,10,2011-06-17,2011-06-21,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH with Paricalcitol-centered Therapy vs. Cinacalcet Therapy with Low-dose Vitamin D in Hemodialysis Patients with Secondary Hype...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011378-14,0,0,0 2009-011378-14,10,2011-06-17,2011-06-21,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH with Paricalcitol-centered Therapy vs. Cinacalcet Therapy with Low-dose Vitamin D in Hemodialysis Patients with Secondary Hype...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011378-14,0,0,0 2009-011380-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA,Clinical use of 18F-Choline in glial brain tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011380-37,0,0,0 2009-011382-80,1,2012-03-20,2012-03-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Nottingham University Hospital,Intravenous Iron: biomarkers and treatment strategies in anaemic Colorectal cancer patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011382-80,0,0,0 2009-011384-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,"Randomized, controlled, trial, phase III, pregabalin vs placebo on postoperative morphine request after pectus escavatum surgery in children",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011384-36,0,0,0 2009-011386-92,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,"Efficacité et tolérance de la toxine botulique dans le traitement du Syndrome des Jambes Sans Repos : étude non comparative sans insu de phase II selon un schéma ""optimal en 2 étapes""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011386-92,0,0,0 2009-011396-77,4,2013-03-28,2013-03-28,2,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Wyeth Research Division on Wyeth Pharmaceuticals Inc.,"A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011396-77,1,1,0 2009-011396-77,4,2013-03-28,2013-03-28,2,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011396-77,1,1,0 2009-011396-77,4,2013-03-28,2013-03-28,2,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Wyeth Pharmaceuticals Inc. (a Pfizer Company),"A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011396-77,1,1,0 2009-011397-14,1,2015-01-23,2015-01-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Technical University of Dresden,Effect of anti-TNF-alpha therapy on endothelial progenitor cells and endothelial dysfunction in patients with psoriasis without risk factors for atherosclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011397-14,0,0,0 2009-011398-33,3,2010-11-18,2010-11-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,BEGIN™: EASY AM A trial comparing efficacy and safety of NN1250 and insulin glargine in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011398-33,0,0,0 2009-011399-31,4,2010-12-01,2010-12-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,BEGIN™: EASY PM A trial comparing the efficacy and safety of NN1250 and insulin glargine in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011399-31,0,0,0 2009-011400-33,11,2014-07-09,2014-08-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011400-33,0,0,0 2009-011400-33,11,2014-07-09,2014-08-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann - La Roche Ltd,"A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011400-33,0,0,0 2009-011401-16,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,CHu - Hôpitaux de Rouen,"Evaluation de la réponse Immunitaire contre la souche de Neisseria meningitidis B:14,P1-7,16 chez les sujets amenés à être vaccinés par MenBVac®",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011401-16,0,0,0 2009-011403-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Intercommunal de Créteil,ETUDE PILOTE SUR L’EFFICACITE ET LA TOLERANCE DES INJECTIONS INTRA-VITREENNES DE LUCENTIS (RANIBIZUMABÒ) A LA PHASE INITIALE DES OCCLUSIONS DE LA VEINE CENTRALE DE LA RETINE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011403-23,0,0,0 2009-011404-34,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Traitement par forte dose d'érythropoïétine après arrêt cardiaque : essai multicentrique contrôlé randomisé EPO-ACR 02,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011404-34,0,0,0 2009-011405-16,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación Hospital de Madrid,"BEVACIZUMAB Y TRASTUZUMAB PREOPERATORIO JUNTO CON PACLITAXEL SEMANAL SEGUIDO, TRAS CIRUGÍA, DE DOXORUBICINA LIPOSOMAL ENCAPSULADA, CICLOFOSFAMIDA Y TRASTUZUMAB EN MUJERES CON CÁNCER DE MAMA HER2 +",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011405-16,0,0,0 2009-011406-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude randomisée prospective comparant l'effet du cyclophosphamide et du mycophénolate chez les enfants atteints de néphrose corticodépendante,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011406-42,0,0,0 2009-011409-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA,"Randomized evaluation of the effectiveness of lithium in subjects with treatment-resistant depression and suicide risk. An independent, pragmatic, multicentre, parallel-group, superiority trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011409-17,0,0,0 2009-011410-18,8,2010-07-02,2010-09-09,4,0,0,0,0,0,3,0,0,1,1,0,1,0,1,"Biovail Laboratories International SRL, c/o Biovail Technologies Ltd","A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects with Premat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011410-18,0,0,0 2009-011411-21,3,2010-07-02,2010-07-02,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,"Biovail Laboratories International SRL, c/o Biovail Technologies Ltd","A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Two Doses of Tramadol Hydrochloride Orally Disintegrating Tablets in Male Subjects with Premat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011411-21,0,0,0 2009-011418-68,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,GlaxoSmithKline Consumer Healthcare GmbH & Co. KG,"Pilotstudie zur Anwendung eines pflanzlichen Kombinationspräparats bei Frauen mit Reizblase (""Overactive Bladder""-Syndrom). (Translation: Pilot-Study with a herbal combination in women suffering from...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011418-68,0,0,0 2009-011423-31,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,CENTRE JEAN PERRIN,Essai pilote de phase II évaluant l'association Taxotère® plus curcumine en première ligne de traitement des cancers de la prostate métastatiques hormono-résistants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011423-31,0,0,0 2009-011424-64,4,2010-12-12,2010-12-13,4,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Abbott GmbH&Co.KG,"A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011424-64,0,0,0 2009-011424-64,4,2010-12-12,2010-12-13,4,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Abbott GmbH & Co. KG,"A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011424-64,0,0,0 2009-011426-33,3,2011-05-03,2011-05-03,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Lilly S.A.,Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Stu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011426-33,0,0,0 2009-011426-33,3,2011-05-03,2011-05-03,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Eli Lilly and Company Ltd,Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Stu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011426-33,0,0,0 2009-011428-79,1,2017-07-19,2017-07-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc","Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritonea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011428-79,0,0,0 2009-011433-27,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Roche Romania SRL,A phase II multicenter open-label study of MabThera (Rituximab) addition to regularly prescribed chemotherapy in patients with untreated Mantle Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011433-27,0,0,0 2009-011434-10,2,,,0,1,1,0,0,2,3,0,0,2,0,0,0,0,1,OCTAPHARMA AG,"CLINICAL STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS AND SAFETY OF IMMUNOGLOBULIN INTRAVENOUS (HUMAN) 10% (NEWGAM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011434-10,0,1,0 2009-011437-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Clínic,EFECTO DE LA ADMINISTRACIÓN DE ALBÚMINA INTRAVENOSA Y MIDODRINA ORAL SOBRE LA FUNCIÓN RENAL DE LOS PACIENTES CON CIRROSIS HEPÁTICA Y INSUFICIENCIA RENAL FUNCIONAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011437-27,0,0,0 2009-011441-11,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Dr. Francisco Marrero Rodríguez. Hospital Universitario de Canarias,Estudio Randomizado Doble Ciego y Controlado con Placebo Para Evaluar la Eficacia y Seguridad de la Administración Intermitente y a Largo Plazo de Levosimendan en Pacientes con Insuficiencia Cardiaca ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011441-11,0,0,0 2009-011445-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Jules Bordet-Université Libre de Bruxelles,Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011445-13,0,0,0 2009-011446-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Uppsala University,"A randomized, placebo-controlled, double blind, parallel group phase II study of anti-ESBL IgY for the eradication of ESBL Klebsiella pneumoniae and Escherichia coli in faeces in carriers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011446-26,0,0,0 2009-011448-20,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Dutch Diabetes Research Foundation,"Hyperoxic exercise training as an innovative therapy to improve metabolic control, endothelial dysfunction and physical fitness in deconditioned type 2 diabetes patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011448-20,0,0,0 2009-011450-18,1,2009-05-28,2009-05-28,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,CSL Limited,"A Phase IV, Single-centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2009/2010 Formulation of the Enzira® Vaccine in Two Groups of Healthy Volunteers: ‘Adults’ (aged ≥ 18 to < ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011450-18,0,0,0 2009-011452-21,1,2012-08-17,2012-08-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals of Leicester NHS trust,Study of the effectiveness of Voriconazole in the treatment of Aspergillus fumigatus associated asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011452-21,0,0,0 2009-011453-41,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,ALK-Abelló S.A.,"Mecanismos moleculares y celulares de rinitis alérgica en pacientes tratados con GRAZAX® -""Molecular and cellular mechanism in rhinitis allergic patients treated with GRAZAX®""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011453-41,0,0,0 2009-011454-17,3,2013-05-29,2013-05-29,2,1,0,0,0,2,2,0,0,1,0,0,1,0,0,Universitatsklinikum Munster,Etude pharmacocinétique de la doxorubicine en fonction de l'âge chez des enfants atteints de tumeurs ou leucémies.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011454-17,0,0,0 2009-011454-17,3,2013-05-29,2013-05-29,2,1,0,0,0,2,2,0,0,1,0,0,1,0,0,Hôpital Universitaire de Münster,Etude pharmacocinétique de la doxorubicine en fonction de l'âge chez des enfants atteints de tumeurs ou leucémies.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011454-17,0,0,0 2009-011454-17,3,2013-05-29,2013-05-29,2,1,0,0,0,2,2,0,0,1,0,0,1,0,0,Universitätsklinikum Münster,Etude pharmacocinétique de la doxorubicine en fonction de l'âge chez des enfants atteints de tumeurs ou leucémies.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011454-17,0,0,0 2009-011455-51,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,"Department of Oncology, University Hospital Herlev",Palliative treatment of ulcerated cutaneous metastases: Randomised trial between electrochemotherapy and radiotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011455-51,0,0,0 2009-011458-16,1,2011-12-20,2011-12-20,1,0,0,0,1,0,4,0,0,1,1,1,1,0,0,North Wales NHS Trust,Comparison of efficacy and side effects of intrathecal fentanyl with intrathecal morphine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011458-16,0,0,0 2009-011459-39,1,2009-08-14,2009-08-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double-blind, placebo-controlled 4-period crossover study to assess the efficacy and safety of repeat dose intranasal GSK1004723 (1000μg), oral GSK835726 (10mg) and cetirizine (10mg) in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011459-39,0,0,0 2009-011461-84,2,2011-09-15,2011-09-15,1,1,1,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once- Daily in Subjects with Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011461-84,1,1,0 2009-011464-11,2,2013-12-23,2013-12-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Vertex Pharamceuticals, Inc.","EXTEND: A 3-Year, Virology, Follow-up Study in Subjects Previously Treated With Telaprevir in Select Clinical Studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011464-11,0,0,0 2009-011466-29,4,2010-03-11,2010-03-15,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Calixa Therapeutics Inc,"A Multicenter, Double-blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA 101 and Intravenous Ceftazidime in Complicated Urinary Tract Infection, Including Pyeloneph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011466-29,0,0,0 2009-011470-15,12,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Actelion Pharmaceuticals Ltd,"Estudio de extensión del estudio AC-058B201, multicéntrico, aleatorizado, de grupos paralelos, doble ciego, para evaluar la seguridad, tolerabilidad, y eficacia a largo plazo de 10, 20, y 40 mg/día ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011470-15,0,0,0 2009-011470-15,12,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ACTELION Pharmaceuticals Ltd,"Estudio de extensión del estudio AC-058B201, multicéntrico, aleatorizado, de grupos paralelos, doble ciego, para evaluar la seguridad, tolerabilidad, y eficacia a largo plazo de 10, 20, y 40 mg/día ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011470-15,0,0,0 2009-011470-15,12,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ACTELION Pharmaceuticals Ltd.,"Estudio de extensión del estudio AC-058B201, multicéntrico, aleatorizado, de grupos paralelos, doble ciego, para evaluar la seguridad, tolerabilidad, y eficacia a largo plazo de 10, 20, y 40 mg/día ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011470-15,0,0,0 2009-011473-33,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma S.A.S.,"Etude prospective, multicentrique, randomisée, en ouvert, évaluant la progression de la fibrose rénale selon le profil de transition épithélio-mésenchymateuse chez des patients adultes transplantés ré...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011473-33,0,0,0 2009-011479-62,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,Visualizing VEGF producing lesions in Von Hippel-Lindau disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011479-62,0,0,0 2009-011483-11,2,2012-07-12,2012-07-12,2,0,0,0,0,1,2,0,0,1,0,0,1,0,0,NMDSG,"Clinical and biological evaluation of azacitidine in transfusion-dependent patients with Low and intermediate-1 risk MDS, and low-risk CMML, who are either refractory to or not eligible for treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011483-11,0,0,0 2009-011485-28,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,1,PledPharma AB,A local feasibility study of mangafodipir as an adjunct to percutaneous coronary intervention in patients with acute myocardial infarction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011485-28,0,0,0 2009-011492-73,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Swindon and Marlborough NHS Foundation Trust,Analysis of Blood Loss With the Use of Fibrin Sealant in Total Knee Replacement Surgery – A Randomised Controlled Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011492-73,0,0,0 2009-011497-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",PILOT CLINICAL TRIAL WITH MIRCERA (methoxy polyethylene glycol-epoetin beta) IN DIALYSIS UNIT OF A.O. SAN GIOVANNI BATTISTA DI TORINO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011497-15,0,0,0 2009-011498-34,2,2012-08-20,2012-08-20,2,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Ergomed Clinical Research Limited,"An Open-Label, Multi-Center Phase I/II Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Oral Tasidotin HCL in Patients with Advanced Solid Tumors (part A), and com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011498-34,0,0,0 2009-011499-31,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,SOCIETA` ITALIANA DI ANDROLOGIA,STUDIO PROSPETTICO RANDOMIZZATO DI VALUTAZIONE DEI DIFFERENTI APPROCCI TERAPEUTICI AL DISAGIO SESSUALE AD ESPRESSIONE SULLA SFERA ERETTILE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011499-31,0,0,0 2009-011504-36,5,2013-08-09,2013-10-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergopharma Joachim Ganzer KG,Randomised double blind placebo controlled pivotal study to evaluate efficacy and safety of rPhleum in adult and adolescent patients suffering from rhinoconjunctivitis +/- controlled Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011504-36,0,0,0 2009-011504-36,5,2013-08-09,2013-10-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergopharma GmbH & Co. KG,Randomised double blind placebo controlled pivotal study to evaluate efficacy and safety of rPhleum in adult and adolescent patients suffering from rhinoconjunctivitis +/- controlled Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011504-36,0,0,0 2009-011505-16,1,2012-12-05,2012-12-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien,KIM I,Klinische Abteilung für Infektionen u.Tropenmedizin",Pharmacokinetics of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without peritonitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011505-16,0,0,0 2009-011513-24,10,2018-05-09,2018-05-09,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) VERSUS PLACEBO IN SUBJECTS WITH TRANSFUSION-DE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011513-24,0,0,0 2009-011516-37,1,2013-05-28,2013-05-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Danish Multiple Sclerosis Research Centre,"Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multiple s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011516-37,0,0,0 2009-011520-53,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Roche Slovensko s.r.o.,Evaluation of Adherence and Persistence to Tocilizumab in combination with Methotrexate or Tocilizumab Monotherapy in patients with moderate to severe active rheumatoid arthritis in local environment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011520-53,0,0,0 2009-011523-31,1,2011-07-28,2011-07-28,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"R & D, Cambridge University Hospitals",A study of the immune response to vaccination in MS patients treated with alemtuzumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011523-31,0,0,0 2009-011525-13,1,2010-08-02,2010-08-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Vernalis (R&D) Limited,"Phase II Open-label Pilot Study of V3381, a Novel N-Methyl-D-Aspartate Receptor Antagonist, in Chronic Cough Patients attending a Specialist Clinic",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011525-13,0,0,0 2009-011527-31,1,2012-06-01,2012-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik KIM II, Abteilung für Kardiologie",Effect of Nebivolol on climacteric disorders in postmenopausal women: A pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011527-31,0,0,0 2009-011529-15,1,2010-10-15,2010-10-15,1,0,0,0,0,0,2,0,1,1,1,1,1,0,1,AVIR Green Hills Biotechnology Research Development Trade AG,"A Phase II Prospective, Randomised, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of the Influenza Vaccine GHB11L1 Administered Intranasally Against a Controlled Influenza Virus Challe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011529-15,0,0,0 2009-011531-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",Relative adrenal insufficiency in cirrhosis: relevance in patients with ascites and treatment with hydrocortisone in refractory ascites,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011531-13,0,0,0 2009-011534-10,1,2011-09-01,2011-09-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Karolinska University Hospital,Effects on insulin sensitivity and body composition of combination therapy with growth hormone (GH) and insulin-like growth factor-I (IGF-I) in growth hormone deficient adults with impaired glucose to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011534-10,0,0,0 2009-011535-12,5,2020-07-08,2020-07-08,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"FOLDRX PHARMACEUTICALS, INC.",Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011535-12,0,0,0 2009-011535-12,5,2020-07-08,2020-07-08,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Pfizer Inc.,Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011535-12,0,0,0 2009-011535-12,5,2020-07-08,2020-07-08,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"FoldRx Pharmaceuticals, Ltd.",Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011535-12,0,0,0 2009-011538-93,2,2013-01-31,2013-01-31,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London,"A prospective, randomised study to access safety, changes in platelet reactivity, plasma cardiac biomarkers and metabolic parameters over 48 weeks in HIV-1 infected subjects undergoing a switch in an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011538-93,0,0,0 2009-011539-10,3,2011-05-06,2011-05-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, multi-center, parallel group, double blind, study to assess the safety of QMF Twisthaler® (500/400μg) and mometasone furoate Twisthaler® (400μg) in adolescent and adult patients with per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011539-10,0,0,0 2009-011541-24,8,2013-02-28,2013-02-28,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Teva Pharmaceutical Industries Ltd,"An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011541-24,0,0,0 2009-011542-25,1,2015-04-30,2015-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,NHS Greater Glasgow and Clyde,CIRCCa(Cediranib In Recurrent Cervical Cancer) A Randomised Double Blind Phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cerv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011542-25,0,0,0 2009-011542-25,1,2015-04-30,2015-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Glasgow,CIRCCa(Cediranib In Recurrent Cervical Cancer) A Randomised Double Blind Phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cerv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011542-25,0,0,0 2009-011543-40,1,2010-01-29,2010-01-29,1,0,0,0,1,0,4,0,0,1,1,1,1,0,0,Papworth Hospital,Assessment of platelet inhibitory response to clopidogrel when coadministered with a proton pump inhibitor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011543-40,0,0,0 2009-011546-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,LABORATORIOS CASEN FLEET S.L.U,"ENSAYO CLÍNICO ALEATORIZADO, DOBLE-CIEGO Y CONTROLADO CON PLACEBO, PARA EVALUAR LA EFICACIA Y TOLERABILIDAD DE LA COMBINACIÓN DE ISOFLAVONAS DE SOJA Y EXTRACTO DE TRÉBOL ROJO (FITOGYN) EN EL TRATAMIEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011546-26,0,0,0 2009-011556-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS OSPEDALE MAGGIORE POLICLINICO MANGIAGALLI E REGINA ELENA,Treatment of sudden idiopathic deafness with hyperbaric oxygen-therapy and intramuscular injection of CDP-choline.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011556-22,0,0,0 2009-011558-16,5,2011-03-31,2011-03-31,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Evaluación de los efectos de 4 dosis orales de S44121 versus placebo sobre la función cardiaca y el NT-proBNP en pacientes con insuficiencia cardiaca crónica y disfunción ventricular izquierda.Estudio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011558-16,0,0,0 2009-011558-16,5,2011-03-31,2011-03-31,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Evaluación de los efectos de 4 dosis orales de S44121 versus placebo sobre la función cardiaca y el NT-proBNP en pacientes con insuficiencia cardiaca crónica y disfunción ventricular izquierda.Estudio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011558-16,0,0,0 2009-011558-16,5,2011-03-31,2011-03-31,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratorios Servier SL,Evaluación de los efectos de 4 dosis orales de S44121 versus placebo sobre la función cardiaca y el NT-proBNP en pacientes con insuficiencia cardiaca crónica y disfunción ventricular izquierda.Estudio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011558-16,0,0,0 2009-011559-38,7,2012-12-28,2012-12-28,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Evaluación de los efectos de 4 dosis orales de S44121 versus placebo sobre la función cardiaca y el NT-proBNP en pacientes con insuficiencia cardiaca crónica y disfunción ventricular izquierda no trat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011559-38,0,0,0 2009-011559-38,7,2012-12-28,2012-12-28,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Evaluación de los efectos de 4 dosis orales de S44121 versus placebo sobre la función cardiaca y el NT-proBNP en pacientes con insuficiencia cardiaca crónica y disfunción ventricular izquierda no trat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011559-38,0,0,0 2009-011559-38,7,2012-12-28,2012-12-28,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratorios Servier SL,Evaluación de los efectos de 4 dosis orales de S44121 versus placebo sobre la función cardiaca y el NT-proBNP en pacientes con insuficiencia cardiaca crónica y disfunción ventricular izquierda no trat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011559-38,0,0,0 2009-011560-11,3,2011-01-21,2011-01-21,3,1,0,0,2,1,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Effects of three oral dosage of S 44121 on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1. A 3-days, single-blind, internation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011560-11,0,0,0 2009-011560-11,3,2011-01-21,2011-01-21,3,1,0,0,2,1,2,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Effects of three oral dosage of S 44121 on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1. A 3-days, single-blind, internation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011560-11,0,0,0 2009-011564-11,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Wyeth Pharmaceuticals Inc. (a Pfizer Company),"A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 2 and 3 Doses of 13-valent Pneumococcal Conjugate Vaccine in Human Immunodeficiency Virus-Infected S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011564-11,0,1,1 2009-011571-71,1,2009-12-14,2009-12-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Consumer Health SA,"A randomized, double-blind, multi-center, placebo-controlled, 3-treatment arm, parallel group study to evaluate the efficacy and safety of diclofenac diethylamine 2.32% gel applied twice or three time...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011571-71,0,0,0 2009-011577-32,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,LUSOFARMACO,Comparison between frovatriptan plus different treatment regimens of dexketoprofen (25 mg and 37.5 mg) and frovatriptan alone in the acute treatment of migraine without aura and migraine with aura att...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011577-32,0,0,0 2009-011580-36,4,2014-03-04,2014-03-04,3,1,0,0,0,0,2,0,0,1,1,0,1,0,0,EORTC - European Organisation for Research and Treatment of Cancer,Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction (metastatic or not amenable to curative surgery) a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011580-36,0,0,0 2009-011582-88,1,,,0,0,0,0,0,0,2,0,1,1,1,1,0,1,0,St James Hospital,The differential effects of donepezil and placebo on EEG/ ERP measures and fMRI in mild cognitive impairment and elderly controls,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011582-88,0,0,0 2009-011585-28,4,2011-10-05,2011-10-05,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,BTG International Ltd,A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011585-28,1,0,0 2009-011587-11,1,2015-08-14,2015-08-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Southampton NHS Foundation Trust,INVESTIGATING THE CLINICAL USE OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PREVENAR)IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011587-11,0,0,0 2009-011589-27,2,2010-12-02,2010-12-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratoires Fournier S.A. A Solvay Pharmaceuticals company,"A Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV337 in Patients with Type 2 Diabetes on Metformin Monot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011589-27,0,0,0 2009-011590-32,3,2012-04-04,2012-04-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Multi-Center, Randomized, Double Blind, Placebo-Controlled, ‘add-on’ study to investigate the efficacy and safety of 24 weeks intravenous treatment with QAX576 in patients (≥18-75 years) with persis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011590-32,0,0,0 2009-011591-30,3,2012-12-05,2012-12-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,An open-label non-randomized extension study to evaluate the safety and tolerability of AIN457 (anti interleukin-17 monoclonal antibody) in patients with moderate to severe ankylosing spondylitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011591-30,0,0,0 2009-011593-15,7,2013-01-28,2013-08-02,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A 24 week randomized double-blind, placebo controlled withdrawal trial with a 16 week open label lead-in phase, and 64 week open label follow-up, to evaluate the efficacy and safety of tocilizumab in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011593-15,1,0,0 2009-011594-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"LWL University Hospital Bochum, Ruhr-University Bochum","A randomized, double-blind, placebo-controlled study of tetrabenazine as adjunctive therapy to risperidone in first-episode schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011594-33,0,0,0 2009-011599-31,1,2010-11-30,2010-11-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Abteilung für Anaesthesie und Intensivmedizin, Medizinische Universität Wien",The effect of high-dose remifentanil on the reversal of established capsaicin-induced hyperalgesia in human volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011599-31,0,0,0 2009-011600-27,7,2010-11-08,2010-11-08,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Laboratorios Almirall, S.A.",Efficacia e sicurezza di aclidinio bromuro a due livelli di dose rispetto a placebo per il trattamento di pazienti con broncopneumopatia cronica ostruttiva (BPCO) da moderata a grave,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011600-27,0,0,0 2009-011603-23,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,KEDRION,"Evaluation of Haemostatic Efficacy, Tolerability and Safety of Kedrion Fibrin Sealant in patients undergoing major or minor Liver Surgery. Multicenter, Controlled, Open Label Randomised Phase II/III...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011603-23,0,0,0 2009-011606-41,10,2012-07-31,2012-07-31,7,0,1,0,0,0,3,0,0,2,1,0,0,0,1,"MacroGenics, Inc.","A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Chil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011606-41,1,0,0 2009-011606-41,10,2012-07-31,2012-07-31,7,0,1,0,0,0,3,0,0,2,1,0,0,0,1,"MACROGENICS, INC.","A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Chil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011606-41,1,0,0 2009-011608-51,3,2012-07-31,2012-07-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd.,"A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients with M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011608-51,0,0,0 2009-011608-51,3,2012-07-31,2012-07-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Inflammatory Effects of GSK1399686 in Patients with M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011608-51,0,0,0 2009-011611-21,5,2012-02-28,2012-10-31,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company Ltd.,Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011611-21,0,0,0 2009-011613-24,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously unt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011613-24,0,0,0 2009-011617-25,6,2013-05-02,2021-08-31,6,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Merck & Co., Inc.","A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered in Pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011617-25,0,0,0 2009-011617-25,6,2013-05-02,2021-08-31,6,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,","A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered in Pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011617-25,0,0,0 2009-011617-25,6,2013-05-02,2021-08-31,6,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered in Pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011617-25,0,0,0 2009-011617-25,6,2013-05-02,2021-08-31,6,1,0,0,0,0,3,0,1,1,0,0,1,0,1,MSD Finland Oy,"A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered in Pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011617-25,0,0,0 2009-011618-12,1,2014-11-18,2014-11-18,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Helsinki Central university Hospital,Pharyngeal anaestesia with articaine:does it reduce surgical stress in gastroscopy?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011618-12,0,0,0 2009-011621-14,2,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,A 52-week open label extension study to evaluate the safety and tolerability of AIN457 (anti IL-17 monoclonal antibody) in patients with moderate to severe Crohn’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011621-14,0,0,0 2009-011622-34,2,2012-11-07,2012-11-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,An open label non-randomized extension study to evaluate the safety and tolerability of AIN457 (anti interleukin-17 monoclonal antibody) in patients with psoriatic arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011622-34,0,0,0 2009-011623-31,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,University Hospital Ghent,Individually adapted immunosuppression in de novo renal transplantation based on immune function monitoring: a prospective randomised study Extension study: The impact of magnesium supplementation on ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011623-31,0,0,0 2009-011625-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Abbott,"""PSOGEN:Effect adalimumab op zelfbeeld en seksueel functioneren bij matige en ernstige psoriasis van de anogenitale regio; prospectief, open label pilot onderzoek""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011625-13,0,0,0 2009-011626-34,2,2012-04-26,2012-04-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, multi-center, double-blind, proof-of-concept study to assess the effect of multiple infusions of AIN457 (10 mg/kg) versus placebo on disease activity as measured by MRI scans over a 24 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011626-34,0,0,0 2009-011637-27,1,2013-09-12,2013-09-12,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Hull and East Yorkshire NHS Hospital Trust,Clopidogrel versus Aspirin in Chronic Heart Failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011637-27,0,0,0 2009-011638-90,1,2011-08-19,2011-08-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Belfast Health and Social Care Trust,Targeting microvascular dysfunction in young hypertensive patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011638-90,0,0,0 2009-011662-28,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SAN GERARDO DI MONZA,Exploratory study on inflammatory immune response related to endothelial dysfunction in HIV-infected na�ve patients treated with abacavir compared to tenofovir-based regimens.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011662-28,0,0,0 2009-011663-37,1,2010-01-16,2010-01-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"IBSA, Institut Biochimique SA","Multicentre, randomized, double-blind, active comparator-and placebo-controlled, parallel-group phase III clinical study for the evaluation of Diclofenac HPBCD 25, 50 mg/ml administered as a single s....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011663-37,0,0,0 2009-011669-10,1,2010-12-17,2010-12-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ArQule, Inc.",A Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Associated Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011669-10,0,0,0 2009-011672-29,3,2010-12-08,2011-01-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,A trial investigating the efficacy and safety of NN1250 compared to insulin detemir in subjects with type 1 diabetes mellitus in a basal/bolus treatment regimen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011672-29,0,0,0 2009-011672-29,3,2010-12-08,2011-01-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,A trial investigating the efficacy and safety of NN1250 compared to insulin detemir in subjects with type 1 diabetes mellitus in a basal/bolus treatment regimen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011672-29,0,0,0 2009-011675-79,1,2015-12-17,2015-12-17,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,CH-Versailles,A PHASE II STUDY TO ASSESS EFFICACY AND SAFETY OF PIOGLITAZONE (ACTOS®) AS ADD-ON THERAPY TO IMATINIB MESYLATE (GLEEVEC®) IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN MAJOR MO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011675-79,0,0,0 2009-011676-30,6,2012-01-09,2012-01-09,6,1,0,0,0,2,0,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 2b, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis Meningococcal B Recombinant Vaccine Administered at 12, 18 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011676-30,0,0,0 2009-011676-30,6,2012-01-09,2012-01-09,6,1,0,0,0,2,0,0,1,1,0,0,1,0,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase 2b, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis Meningococcal B Recombinant Vaccine Administered at 12, 18 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011676-30,0,0,0 2009-011679-65,6,2013-01-24,2013-02-11,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"NPS Pharmaceuticals, Inc.","A Long Term, Open Label Study with Teduglutide for Subjects with Parenteral Nutrition Dependent Short Bowel Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011679-65,0,0,0 2009-011679-65,6,2013-01-24,2013-02-11,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NPS Pharmaceuticals,"A Long Term, Open Label Study with Teduglutide for Subjects with Parenteral Nutrition Dependent Short Bowel Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011679-65,0,0,0 2009-011679-65,6,2013-01-24,2013-02-11,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NPS PHARMACEUTICALS,"A Long Term, Open Label Study with Teduglutide for Subjects with Parenteral Nutrition Dependent Short Bowel Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011679-65,0,0,0 2009-011682-91,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Role of 64Cu-ATSM PET/CT for the localization of hypoxic areas in uterine cervical cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011682-91,0,0,0 2009-011696-68,1,2010-08-01,2010-08-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Nottingham,The effect of drugs used to reverse neuromuscular blockade on intra-cranial pressure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011696-68,0,0,0 2009-011719-19,8,2015-06-23,2015-08-18,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB BioSciences GmbH,"PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXIAL SPA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011719-19,0,0,0 2009-011719-19,8,2015-06-23,2015-08-18,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schwarz Biosciences, GmbH","PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXIAL SPA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011719-19,0,0,0 2009-011719-19,8,2015-06-23,2015-08-18,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies","PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS (AXIAL SPA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011719-19,0,0,0 2009-011720-59,10,2015-08-24,2015-08-24,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB BioSciences GmbH,"Estudio de fase III, multicéntrico, aleatorizado, doble ciego, en grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de certolizumab pegol en sujetos con artritis psoriá...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011720-59,0,0,0 2009-011720-59,10,2015-08-24,2015-08-24,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schwarz Biosciences, GmbH","Estudio de fase III, multicéntrico, aleatorizado, doble ciego, en grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de certolizumab pegol en sujetos con artritis psoriá...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011720-59,0,0,0 2009-011720-59,10,2015-08-24,2015-08-24,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies","Estudio de fase III, multicéntrico, aleatorizado, doble ciego, en grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de certolizumab pegol en sujetos con artritis psoriá...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011720-59,0,0,0 2009-011720-59,10,2015-08-24,2015-08-24,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"SCHWARZ BIOSCIENCES, GmbH, Miembro del Grupo UCB","Estudio de fase III, multicéntrico, aleatorizado, doble ciego, en grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de certolizumab pegol en sujetos con artritis psoriá...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011720-59,0,0,0 2009-011723-31,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Västra Götalandsregionen,Effects of valproic acid on fibrinolysis in man,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011723-31,0,0,0 2009-011725-14,2,2013-03-13,2013-05-01,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG),IELSG 34: A Multicenter Phase II study to evaluate the clinical activity and the safety profile of everolimus (RAD001) in marginal zone B-cell lymphomas (MZL) EudraCT Number 2009-011725-14,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011725-14,0,0,0 2009-011736-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,"Etude pilote de phase II, N=1 en crossover répétés, en double aveugle, randomisée versus placebo, multicentrique, évaluant l’efficacité de la SIMVAstatine sur les DYSkinésies induites par la L-Dopa ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011736-35,0,0,0 2009-011737-27,1,2014-07-18,2014-07-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Leipzig,A multi centre randomised placebo-controlled double-blind clinical trial for the evaluation of efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic deriva...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011737-27,0,0,0 2009-011739-11,4,2013-07-23,2013-07-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,"Estudio fase 2 de Pemetrexed y Cisplatino como tratamiento de inducción, seguido de Pemetrexed y Cisplatino en combinación con radioterapia, en pacientes con cáncer de pulmón no microcítico, localment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011739-11,0,0,0 2009-011739-11,4,2013-07-23,2013-07-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,"Estudio fase 2 de Pemetrexed y Cisplatino como tratamiento de inducción, seguido de Pemetrexed y Cisplatino en combinación con radioterapia, en pacientes con cáncer de pulmón no microcítico, localment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011739-11,0,0,0 2009-011740-19,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,"Gilead Sciences, Inc.","Phase 3b Randomized, Double-Blind, Placebo-Controlled Two-Part Trial to Assess the Safety and Efficacy of Continuous Aztreonam for Inhalation Solution (AZLI) in Subjects with Cystic Fibrosis (CF) and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011740-19,0,1,1 2009-011742-26,1,2010-12-22,2010-12-22,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Institute for Biomedical Aging Research,Humoral and cellular immune response against tetanus and diphtheria following booster vaccination,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011742-26,0,0,0 2009-011743-39,2,2011-08-23,2011-08-26,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safety a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011743-39,0,0,0 2009-011745-94,9,2012-07-17,2012-07-19,8,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Shire Pharmaceutical Development Limited,"A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel group Study to Assess the Time to Response to Lisdexamfetamine Dimesylate and Atomoxetine Hydrochloride in Children and Adolescents ag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011745-94,1,0,0 2009-011745-94,9,2012-07-17,2012-07-19,8,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Shire Pharmaceutical Development LtD,"A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel group Study to Assess the Time to Response to Lisdexamfetamine Dimesylate and Atomoxetine Hydrochloride in Children and Adolescents ag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011745-94,1,0,0 2009-011745-94,9,2012-07-17,2012-07-19,8,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Shire Pharmaceutical Development Ltd.,"A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel group Study to Assess the Time to Response to Lisdexamfetamine Dimesylate and Atomoxetine Hydrochloride in Children and Adolescents ag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011745-94,1,0,0 2009-011751-46,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INSTITUT CURIE,Etude de phase II monocentrique associant Bevacizumab et Temozolomide chez des patients atteints de mélanome uvéal en première ligne métastatique.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011751-46,0,0,0 2009-011752-21,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Praxis Pharmaceutical S.A.,"Estudio de búsqueda de dosis de Nepidermina (Factor de Crecimiento Epidérmico humano recombinante), administrada intralesionalmente para el tratamiento de pacientes con úlceras de pie diabético no isq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011752-21,0,0,0 2009-011753-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Neonatal intensive care unit, VU medical center Amsterdam","Pain treatment of newborns: paracetamol rectal versus intraveneous administration, an open randomised clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011753-41,0,0,0 2009-011755-47,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Vivostat A/S,A feasibility study to evaluate the effect of Vivostat® Platelet Rich Fibrin (PRF®) in the treatment of diabetic foot ulcers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-011755-47,0,0,0 2009-011756-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI,"Reinduction with liposomal anthracyclines and Capecitabine in patients with breast cancer, locally advanced (IIIA-IIIB-IIIC) HER2 negative, not obtaining a pathological complete response ( or =65 years) with multiple myeloma in 1st relapse or refractory to 1st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012359-91,0,0,0 2009-012367-34,9,2011-01-10,2012-11-16,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"BioCryst Pharmaceuticals, Inc.","A Phase 3, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard of C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012367-34,1,0,0 2009-012370-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Nantes,"Pharmacocinétique de l’ertapénème chez des patients brûlés sous ventilation mécanique. Étude monocentrique de médicament, de phase IV, ouverte, prospective.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012370-12,0,0,0 2009-012372-27,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,LUMC,"The Sevoflurane study, understanding the effects of Sevoflurane to improve safety and outcome of cardiac surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012372-27,0,0,0 2009-012376-27,1,2010-12-01,2010-12-01,1,1,0,0,1,0,3,0,0,1,1,1,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,EFFECTS OF LONG-ACTING SOMATOSTATIN ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE/SEVERE RENAL INSUFFICIENCY(ALADIN II STUDY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012376-27,0,0,0 2009-012380-34,7,2012-02-03,2017-03-01,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Janssen Biologics BV,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012380-34,0,0,0 2009-012380-34,7,2012-02-03,2017-03-01,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Janssen Biologics B.V.,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012380-34,0,0,0 2009-012380-34,7,2012-02-03,2017-03-01,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Centocor BV,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012380-34,0,0,0 2009-012380-34,7,2012-02-03,2017-03-01,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012380-34,0,0,0 2009-012380-34,7,2012-02-03,2017-03-01,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012380-34,0,0,0 2009-012385-31,1,2009-12-17,2009-12-17,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase II, Randomized, Controlled, Double-blind, Multi-center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adjuva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012385-31,0,0,0 2009-012387-13,1,2010-06-29,2010-06-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,McMaster University,PROTECT - Prophylaxis of ThromboEmbolism in Critical Care Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012387-13,0,0,0 2009-012389-30,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"University Medical Centre Ljubljana, Department of Gynaecology",Transurethral ultrasound-directed injection of autologous myoblasts in combination with functional electrical stimulation in patients with intrinsic urinary sphincter deficiency.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012389-30,0,0,0 2009-012393-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Laboratoires IPRAD,"Essai comparatif, multicentrique, prospectif, randomisé, en double insu, d’efficacité et de tolérance de Météoxane® versus placebo dans la poussée douloureuse du syndrome de l'intestin irritable",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012393-12,0,0,0 2009-012394-35,6,2012-12-18,2012-12-28,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 90-week, multi-center, randomized, double-blind, placebo-controlled study in patients with mild Alzheimer s Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody respon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012394-35,0,0,0 2009-012394-35,6,2012-12-18,2012-12-28,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 90-week, multi-center, randomized, double-blind, placebo-controlled study in patients with mild Alzheimer s Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody respon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012394-35,0,0,0 2009-012394-35,6,2012-12-18,2012-12-28,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A 90-week, multi-center, randomized, double-blind, placebo-controlled study in patients with mild Alzheimer s Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody respon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012394-35,0,0,0 2009-012395-27,3,2011-06-21,2011-06-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label extension to a 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s Disease (AD) to investigate the safety and tole...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012395-27,0,0,0 2009-012397-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",Energy metabolism and the skeleton: reciprocal interplay.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012397-12,0,0,0 2009-012398-36,1,2014-11-18,2014-11-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Helsinki University Hospital,Patient-controlled sedation with propofol in ERCP:alfentanyl vs remifentanyl,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012398-36,0,0,0 2009-012405-18,1,2013-12-03,2013-12-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,"Single site, phase II, double blind, randomised, placebo controlled study of the effect of dutasteride (Avodart)0.5 mg on the volume and characteristics of prostate cancer, as assessed by multifunctio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012405-18,0,0,0 2009-012412-41,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,IFCT,Etude de phase II évaluant l’association de cetuximab à une radiothérapie et chimiothérapie concomitante par cisplatine et pemetrexed dans le traitement des cancers bronchiques non à petites cellules ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012412-41,0,0,0 2009-012413-21,1,2015-02-17,2015-02-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU Limoges,Etude de phase II évaluant un traitement par cisplatine et vinorelbine orale administrés de façon hebdomadaire et radiothérapie concomitante chez le sujet âgé indépendant atteint de cancer broncho-pul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012413-21,0,0,0 2009-012417-22,4,2013-02-12,2013-02-12,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,"A phase II, multi-center, non-randomized, open-label study of TKI258 in patients with relapsed or refractory multiple myeloma, who are with or without t(4;14) translocation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012417-22,0,0,0 2009-012417-22,4,2013-02-12,2013-02-12,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A phase II, multi-center, non-randomized, open-label study of TKI258 in patients with relapsed or refractory multiple myeloma, who are with or without t(4;14) translocation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012417-22,0,0,0 2009-012418-38,8,2018-02-27,2018-02-27,6,1,0,0,0,1,0,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload (TELESTO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012418-38,0,0,0 2009-012418-38,8,2018-02-27,2018-02-27,6,1,0,0,0,1,0,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload (TELESTO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012418-38,0,0,0 2009-012419-16,1,2011-12-07,2011-12-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Desitin Arzneimittel GmbH,Influence of the Non-Ergot Dopamine agonist Piribedil on vigilance and cognitive function in patients with Parkinson's disease compared to other oral Non-Ergot Dopamine agonists,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012419-16,0,0,0 2009-012424-87,1,2012-12-21,2012-12-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London South Kensington London,T cells and TNF: The impct of TNF blockade on effector T cell populations in rheumatoid arthritis and other conditions treated with anti-TNF-alpha agents.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012424-87,0,0,0 2009-012428-10,1,,,0,1,0,0,1,0,3,0,0,3,0,0,0,0,0,University of Exeter,Preventing depression relapse / recurrence in NHS settings through mindfulness-based cognitive therapy (MBCT).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012428-10,0,0,0 2009-012430-70,1,2016-10-12,2016-10-12,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Institut Gustave Roussy,Etude de phase II multicentrique étudiant l’efficacité de la doxorubicine associée à de la trabectedine (Yondelis) en première ligne dans le traitement des patients présentant un léiomyosarcome métas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012430-70,0,0,0 2009-012431-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Krajská nemocnice Liberec, a.s.","Možnosti terapeutického ovlivnění neurogenního hyperaktivního detruzoru u pacientů po spinálním poranění a s roztroušenou sklerózou aplikací botulinumtoxinu A. Prospektivní, otevřená studie porovnávaj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012431-15,0,0,0 2009-012432-32,4,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,2,"University Medical Center Freiburg Dept. Klinikum Stuttgart, Stuttgart Cancer Center","RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE AND HIGH-DOSE CYTARABINE WITH OR WITHOUT THIOTEPA, AND WITH OR WITHOUT RITUXIMAB, FOLLOWED BY BRAIN IRRADIATION vs. HIGH-D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012432-32,0,0,0 2009-012432-32,4,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,2,University Hospital Southampton NHS Foundation Trust,"RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE AND HIGH-DOSE CYTARABINE WITH OR WITHOUT THIOTEPA, AND WITH OR WITHOUT RITUXIMAB, FOLLOWED BY BRAIN IRRADIATION vs. HIGH-D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012432-32,0,0,0 2009-012432-32,4,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,2,International Extranodal Lymphoma Srudy Group IELSG,"RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE AND HIGH-DOSE CYTARABINE WITH OR WITHOUT THIOTEPA, AND WITH OR WITHOUT RITUXIMAB, FOLLOWED BY BRAIN IRRADIATION vs. HIGH-D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012432-32,0,0,0 2009-012432-32,4,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,2,IELSG-International Extranodal Lymphoma Study Group,"RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE AND HIGH-DOSE CYTARABINE WITH OR WITHOUT THIOTEPA, AND WITH OR WITHOUT RITUXIMAB, FOLLOWED BY BRAIN IRRADIATION vs. HIGH-D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012432-32,0,0,0 2009-012433-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Reanal Pte. Ltd.,"Open, self-controlled phase IV. clinical study of the Nicoflex ointment on patients with knee arthrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012433-30,0,0,0 2009-012436-32,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Medizinische Hochschule Hannover,"A multicenter, randomized, open-labeled study to steer immunsuppressive and antiviral therapy by measurement of virus- (CMV, ADV, HSV) specific T cells in addition to determination of trough levels of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012436-32,0,0,0 2009-012437-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Skånes University Hospital,Clofarabine based remission induction followed by haploidentical stem cell transplantation in children with refractory hematological malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012437-30,0,0,0 2009-012439-14,5,2013-06-27,2013-06-27,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Astellas Pharma Global Development, Inc. (APGD)","A Phase II, Multicenter, Open-Label, Randomized Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects with HER2 Negative Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012439-14,0,0,0 2009-012442-23,1,2013-07-23,2013-07-23,1,0,0,0,1,0,4,0,0,1,1,1,1,0,0,Dorset County Hospital NHS foundation trust,Intraarticular injections for hip osteoarthritis: Steroid versus Hyaluronic acid: randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012442-23,0,0,0 2009-012444-16,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Janssen-Cilag International NV,"A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Exploratory Study of the Safety and Efficacy of JNJ-39758979 in the Treatment of Adults with Persistent Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012444-16,0,0,0 2009-012445-35,1,2012-01-27,2012-01-27,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Herlev Hospital,Aldosterone receptor blockade in patients with chronic kidney disease. Influence on arterial stiffness and kidney function.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012445-35,0,0,0 2009-012446-23,6,2011-01-26,2011-07-29,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Allergan Limited,"A MULTICENTER, RANDOMIZED, DOUBLE MASKED, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF CYCLOSPORINE OPHTHALMIC SOLUTION 0,010% COMPARED WITH ITS VEHICLE ADMINISTRATED QID FOR 3 MONTHS F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012446-23,0,0,0 2009-012446-23,6,2011-01-26,2011-07-29,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Allergan Ltd,"A MULTICENTER, RANDOMIZED, DOUBLE MASKED, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF CYCLOSPORINE OPHTHALMIC SOLUTION 0,010% COMPARED WITH ITS VEHICLE ADMINISTRATED QID FOR 3 MONTHS F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012446-23,0,0,0 2009-012446-23,6,2011-01-26,2011-07-29,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ALLERGAN INC,"A MULTICENTER, RANDOMIZED, DOUBLE MASKED, PARALLEL GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF CYCLOSPORINE OPHTHALMIC SOLUTION 0,010% COMPARED WITH ITS VEHICLE ADMINISTRATED QID FOR 3 MONTHS F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012446-23,0,0,0 2009-012449-48,1,2010-02-01,2010-02-01,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Air Liquide Santé International,„Sympathetic neural outflow during Xenon anesthesia in humans“,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012449-48,0,0,0 2009-012450-20,1,2011-05-10,2011-05-10,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"Multicenter, open-label, non-comparative, proof-of-concept, phase 2a study to evaluate the effect of a single infusion of tezosentan on pulmonary vascular resistance in patients with stable, chronic p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012450-20,0,0,0 2009-012451-18,3,2011-07-31,2011-07-31,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London,"""EUROACTION PLUS con intervención intensiva sobre el tabaco (vareniclina) durante un programa de cardiología preventiva para pacientes con enfermedad aterosclerosa establecida, individuos con alto rie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012451-18,0,0,0 2009-012453-38,1,2011-12-22,2011-12-22,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Studienzentrale AGO Austria,"A two-stage multicenter phase II trial of concurrent panitumumab immunotherapy, cisplatin chemotherapy and pelvic radiotherapy for primary cancer of the uterine cervix stage Ib-IIIb",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012453-38,0,0,0 2009-012456-25,6,2010-05-07,2010-05-07,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Pfizer Inc.,"A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 26-WEEK TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DIMEBON (LATREPIRDINE, PF-01913539) IN PATIENTS WITH MODERATE-TO-SEVERE ALZHE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012456-25,0,0,0 2009-012456-25,6,2010-05-07,2010-05-07,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"PFIZER, S.A.","A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 26-WEEK TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DIMEBON (LATREPIRDINE, PF-01913539) IN PATIENTS WITH MODERATE-TO-SEVERE ALZHE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012456-25,0,0,0 2009-012456-25,6,2010-05-07,2010-05-07,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 26-WEEK TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DIMEBON (LATREPIRDINE, PF-01913539) IN PATIENTS WITH MODERATE-TO-SEVERE ALZHE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012456-25,0,0,0 2009-012457-37,1,2010-09-22,2010-09-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vantia Ltd,"A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Cross-Over Proof of Concept Study to Investigate the Efficacy and Safety of Pre-Emptive Administration of Repeated, Oral Doses of VA111913 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012457-37,0,0,0 2009-012458-19,2,2012-10-15,2013-04-24,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD S.N.C.,"An open-label, randomised, comparative, multicentre study of the immunogenicity and safety of ZOSTAVAX® when administered by intramuscular route or subcutaneous route to subjects ≥50 years of age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012458-19,0,0,0 2009-012459-96,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr Calleja Panero,VALORACIÓN INTENSIVA DE LA CINÉTICA DEL RNA DEL VIRUS DE LA HEPATITIS C COMO PREDICTOR PRECOZ DE AUSENCIA DE RESPUESTA VIROLÓGICA SOSTENIDA EN PACIENTES CON HEPATITIS CRÓNICA POR VHC TRATADOS CON INTE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012459-96,0,0,0 2009-012460-14,3,2010-04-23,2012-08-26,2,1,0,0,0,0,2,0,1,1,1,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, open-label, randomised study to assess the safety and immunogenicity of a birth dose of GSK Biologicals’ reduced-antigen-content tri-component pertussis vaccine followed by routine paediat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012460-14,0,0,0 2009-012461-54,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sörmlands läns landsting,"Långverkande opioidantagonistbehandling för opioidberoende patienter, effekter på missbruk och kriminalitet Treatment of opioid dependency with long acting opioid antagonist, effect on the substance a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012461-54,0,0,0 2009-012476-28,13,2017-08-01,2017-08-23,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche,"An open-label, multi-center, three arm randomized, phase III study to compare the efficacy and safety of RO5072759 + chlorambucil (GClb), rituximab + chlorambucil (RClb)or chlorambucil (Clb) alone in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012476-28,0,0,0 2009-012476-28,13,2017-08-01,2017-08-23,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche Ltd,"An open-label, multi-center, three arm randomized, phase III study to compare the efficacy and safety of RO5072759 + chlorambucil (GClb), rituximab + chlorambucil (RClb)or chlorambucil (Clb) alone in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012476-28,0,0,0 2009-012479-93,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Nina Olofsson,Multimodal drug infiltration during bone marrow aspiration. A randomized dubble blind controlled study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012479-93,0,0,0 2009-012499-28,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),Efficacy of the treatment with hydroxychloroquine in non responders HIV-infected HAART-treated patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012499-28,0,0,0 2009-012500-11,13,2014-03-05,2014-07-28,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biogen Idec Ltd,"Estudio multicéntrico, doble ciego, aleatorizado, en grupos paralelos, en monoterapia, controlado con fármaco activo, para determinar la eficacia y la seguridad de daclizumab obtenido mediante un proc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012500-11,0,0,0 2009-012500-11,13,2014-03-05,2014-07-28,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BIOGEN IDEC LTD,"Estudio multicéntrico, doble ciego, aleatorizado, en grupos paralelos, en monoterapia, controlado con fármaco activo, para determinar la eficacia y la seguridad de daclizumab obtenido mediante un proc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012500-11,0,0,0 2009-012504-13,12,2015-12-29,2015-12-29,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017","PHASE 2, OPEN-LABEL SINGLE ARM STUDY OF THE EFFICACY AND SAFETY OF PF-02341066 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION INVOLVING THE ANAP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012504-13,0,0,0 2009-012504-13,12,2015-12-29,2015-12-29,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.","PHASE 2, OPEN-LABEL SINGLE ARM STUDY OF THE EFFICACY AND SAFETY OF PF-02341066 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION INVOLVING THE ANAP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012504-13,0,0,0 2009-012504-13,12,2015-12-29,2015-12-29,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017 US","PHASE 2, OPEN-LABEL SINGLE ARM STUDY OF THE EFFICACY AND SAFETY OF PF-02341066 IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION INVOLVING THE ANAP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012504-13,0,0,0 2009-012505-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UZLeuven,A randomized double-blind placebo controlled trial evaluating the effect of esomeprazole (nexiam) 40 mg twice daily in subjects with chronic unexplained cough,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012505-18,0,0,0 2009-012509-20,1,2015-03-10,2015-03-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,A randomised controlled trial of epimacular brachytherapy versus ranibizumab monotherapy for the treatment of subfoveal choroidal neovascularisation associated with wet age-related macular degeneratio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012509-20,0,0,0 2009-012512-41,1,2010-10-07,2010-10-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Grampian,The pharmacokinetics of single and multiple doses of intravenous ketorolac in children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012512-41,0,0,0 2009-012518-39,12,2018-01-31,2018-06-26,10,1,0,0,0,2,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012518-39,0,0,0 2009-012518-39,12,2018-01-31,2018-06-26,10,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012518-39,0,0,0 2009-012518-39,12,2018-01-31,2018-06-26,10,1,0,0,0,2,3,0,0,1,1,0,1,0,1,GlaxoSmithKline S.A,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012518-39,0,0,0 2009-012518-39,12,2018-01-31,2018-06-26,10,1,0,0,0,2,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development,"A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012518-39,0,0,0 2009-012520-84,16,2013-01-30,2013-01-30,11,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012520-84,1,1,0 2009-012520-84,16,2013-01-30,2013-01-30,11,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Wyeth Pharmaceuticals Inc, (a Pfizer Company) 500 Arcola Road, Collegeville, PA 19426 USA","A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012520-84,1,1,0 2009-012520-84,16,2013-01-30,2013-01-30,11,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company, Philadelphia, PA-19101, USA","A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012520-84,1,1,0 2009-012520-84,16,2013-01-30,2013-01-30,11,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA","A 2-Part Open-label Study to Assess the Clinical Benefit and Long-term Safety of Etanercept in Children and Adolescents With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012520-84,1,1,0 2009-012529-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Toulouse,"A randomised, REQUIP® IR-controlled, n-of-1, multiple crossover, pilot trial of the effect of REQUIP®CR on abnormal daytime somnolence in patients with Parkinson’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012529-12,0,0,0 2009-012541-33,3,2010-05-05,2010-05-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomised, placebo-controlled, double-blind (double-dummy technique), crossover, multi-centre study, to evaluate onset of effect in patients with Chronic Obstructive Pulmonary Disease (COPD) treate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012541-33,0,0,0 2009-012541-33,3,2010-05-05,2010-05-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA,"A randomised, placebo-controlled, double-blind (double-dummy technique), crossover, multi-centre study, to evaluate onset of effect in patients with Chronic Obstructive Pulmonary Disease (COPD) treate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012541-33,0,0,0 2009-012543-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic,Efecto del maraviroc (MVC) en la recuperación inmunológica de pacientes infectados por el VIH-1 con respuesta discordante y una cifra de linfocitos CD4 inferior a las 200 células/mm3,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012543-42,0,0,0 2009-012544-16,4,2012-07-30,2012-07-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Pharmacosmos A/S,"A phase III, randomized, comparative, open-label study of intravenous iron oligosaccharide (Monofer®) administered by infusions or repeated bolus injections in comparison with oral iron sulphate in in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012544-16,0,0,0 2009-012546-23,12,2012-02-23,2012-03-06,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A 48-WEEK, DOUBLE BLIND, RANDOMIZED, MULTINATIONAL, MULTICENTRE, 2-ARM PARALLEL GROUP, REFERENCE TREATMENT CONTROLLED CLINICAL TRIAL OF “FIXED COMBINATION” BECLOMETHASONE DIPROPIONATE PLUS FORMOTERO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012546-23,0,0,0 2009-012546-23,12,2012-02-23,2012-03-06,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CHIESI,"A 48-WEEK, DOUBLE BLIND, RANDOMIZED, MULTINATIONAL, MULTICENTRE, 2-ARM PARALLEL GROUP, REFERENCE TREATMENT CONTROLLED CLINICAL TRIAL OF “FIXED COMBINATION” BECLOMETHASONE DIPROPIONATE PLUS FORMOTERO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012546-23,0,0,0 2009-012555-22,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,Omninvest Ltd.,"Serologic Study of FluvalAB Influenza Vaccine (Trivalent, Seasonal) intended to Use in the 2009-2010 Vaccination Season",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012555-22,0,0,0 2009-012560-14,1,2010-09-07,2010-09-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,EUTHERAPIE / Les Laboratoires Servier,"Réponse au VALDOXAN® et restauration des rythmes de vie dans la dépression unipolaire : Etude VALDOXAN® D-Rhythm. Etude clinique interventionnelle de phase IV, multicentrique",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012560-14,0,0,0 2009-012561-56,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Role of 18F-FLT PET/CT for evaluating suspect lesions in patients with malignant lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012561-56,0,0,0 2009-012562-31,1,2013-11-07,2013-11-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),Tratamiento selectivo en cáncer colorrectal: selección de capecitabina o 5-fluorouracilo para ser combinados con oxaliplatino o irinotecan como quimioterapia en combinación con bevacizumab en primera...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012562-31,0,0,0 2009-012564-13,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,Orphan Europe SARL,"Cysteamine Hydrochloride for nephropathic Cystinosis, open-label Phase III pivotal study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012564-13,0,0,0 2009-012566-32,6,2011-02-11,2011-02-11,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Rheumatoid Arthritis and an Inadequate Response to Me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012566-32,0,0,0 2009-012567-33,2,2010-09-16,2010-09-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 2, 6-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for Treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012567-33,0,0,0 2009-012568-14,2,2011-09-15,2012-03-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Otsuka Pharmaceutical Development & Commercialization,"A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Monotherapy in Adult Patients with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012568-14,0,0,0 2009-012569-79,2,2013-12-24,2014-09-18,2,1,0,0,0,0,3,0,1,1,1,0,1,0,1,Bayer HealthCare AG,"An open-label, non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral ß-amyloid when compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012569-79,0,0,0 2009-012569-79,2,2013-12-24,2014-09-18,2,1,0,0,0,0,3,0,1,1,1,0,1,0,1,Bayer AG,"An open-label, non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral ß-amyloid when compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012569-79,0,0,0 2009-012570-13,3,2013-03-13,2013-03-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Bayer HealthCare AG, D51368 Leverkusen",An uncontrolled open label multicenter phase II safety study of BAY 73-4506 in patients with hepatocellular carcinoma (HCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012570-13,0,0,0 2009-012570-13,3,2013-03-13,2013-03-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,An uncontrolled open label multicenter phase II safety study of BAY 73-4506 in patients with hepatocellular carcinoma (HCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012570-13,0,0,0 2009-012574-12,11,2020-12-23,2020-12-23,9,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ImClone LLC,"""Estudio en fase 3 aleatorizado, multicéntrico y abierto de quimioterapia con pemetrexed-cisplatino más IMC-11F8 en comparación con quimioterapia con pemetrexed-cisplatino sola en el tratamiento de pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012574-12,1,0,0 2009-012575-10,3,2018-04-10,2018-04-10,1,1,0,0,0,0,4,0,0,2,1,0,0,0,0,UNIVERSITY OF LIVERPOOL,Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012575-10,1,0,0 2009-012575-10,3,2018-04-10,2018-04-10,1,1,0,0,0,0,4,0,0,2,1,0,0,0,0,University Hospitals Bristol NHS Foundation Trust,Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012575-10,1,0,0 2009-012575-10,3,2018-04-10,2018-04-10,1,1,0,0,0,0,4,0,0,2,1,0,0,0,0,University of Liverpool,Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012575-10,1,0,0 2009-012576-27,9,2018-12-31,2019-01-30,8,0,0,0,0,0,2,0,0,2,0,0,0,0,0,"Medical Faculty, University Magdeburg",Evaluación de Sorafenib en combinación con microterapia local guiada por RM con contraste Gd-EOB-DTPA en pacientes con carcinoma hepatocelular inoperable Evaluation of Sorafenib in combination with l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012576-27,1,0,0 2009-012576-27,9,2018-12-31,2019-01-30,8,0,0,0,0,0,2,0,0,2,0,0,0,0,0,"UNIVERSITAT MAGDEBURG, MEDIZINISCHE FAKULTAT",Evaluación de Sorafenib en combinación con microterapia local guiada por RM con contraste Gd-EOB-DTPA en pacientes con carcinoma hepatocelular inoperable Evaluation of Sorafenib in combination with l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012576-27,1,0,0 2009-012579-90,3,2011-04-11,2011-04-11,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,Antiviral effect and safety of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-α 2a and ri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012579-90,0,0,0 2009-012579-90,3,2011-04-11,2011-04-11,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,Antiviral effect and safety of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-α 2a and ri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012579-90,0,0,0 2009-012579-90,3,2011-04-11,2011-04-11,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co. KG,Antiviral effect and safety of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-α 2a and ri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012579-90,0,0,0 2009-012581-32,13,2013-12-06,2014-04-24,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline Research & Development, Ltd",A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). (Short title: The Stabiliz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012581-32,0,0,0 2009-012582-64,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Treatment with bevacizumab and irinotecan in patients with recurrent or refractory high grade glioma after conventional treatment.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012582-64,0,0,0 2009-012583-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA PISANA,Phase II study of interleukin-2 and zoledronic acid as maintenance therapy in patients with multiple myeloma having undergone autograft,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012583-13,0,0,0 2009-012584-34,2,2016-09-06,2016-09-06,1,1,1,0,0,1,2,0,0,1,1,0,1,0,1,ERYTECH Pharma,"A multicentre, open, randomized, Phase II/III study, evaluating efficacy and safety of erythrocytes encapsulating L-Asparaginase (GRASPA®) versus reference L-asparaginase treatment in combination with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012584-34,0,0,0 2009-012585-30,1,2010-02-16,2010-02-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Grampian Research and Development,The pharmacokinetics of single and multiple doses of intravenous paracetamol in children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012585-30,0,0,0 2009-012586-55,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Leiden University Medical Center,"Influence of S(+)-ketamine on Diffuse Noxious Inhibitory Control (DNIC) and offset analgesia (OA) in chronic pain patients (neuropathic pain, complex regional pain syndrome type 1, fibromyalgia) and h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012586-55,0,0,0 2009-012587-14,6,2013-10-08,2013-10-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"BIAL - Portela & Ca, S.A.",SAFETY AND EFFICACY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY FOR PARTIAL SEIZURES IN ELDERLY PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012587-14,0,0,0 2009-012590-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Rôle neuroprotecteur de la Ciclosporine A dans l’infarctus cérébral traité par thrombolyse intraveineuse. Etude pilote monocentrique randomisée contrôlée versus placebo.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012590-35,0,0,0 2009-012591-27,1,2010-09-22,2010-09-22,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,University of Oxford,A phase I/IIa study to assess the safety and immunogenicity of new malaria vaccine candidates AdCh63 MSP1 alone and with MVA MSP1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012591-27,0,0,0 2009-012592-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Caen,"Méthode d’évaluation de l’aptitude à la conduite chez des patients souffrant de pathologies de l’éveil: cirrhose avec ou sans encéphalopathie (AutoSoP ""foie"").",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012592-10,0,0,0 2009-012595-27,12,2016-01-05,2016-01-05,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF-02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER (N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012595-27,0,0,0 2009-012595-27,12,2016-01-05,2016-01-05,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer, S.A.","PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF-02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER (N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012595-27,0,0,0 2009-012595-27,12,2016-01-05,2016-01-05,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017 US","PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF-02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER (N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012595-27,0,0,0 2009-012596-94,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación para la Investigación Biomédica del Hospital Gregorio Marañón,Estudio clínico aleatorizado comparativo entre angioplastia primaria y angioplastia postfibrinolisis como estrategias de reperfusión en pacientes con infarto agudo de miocardio con elevación del segme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012596-94,0,0,0 2009-012597-13,2,2010-06-24,2010-07-23,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Forest Research Institute, Inc.","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients with Type 2 Diabetes Mellitus on Background Treatment with G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012597-13,0,0,0 2009-012598-37,2,2010-08-12,2010-08-12,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Forest Research Institute, Inc.","A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DUTOGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ON BACKGROUND TREATMENT WITH P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012598-37,0,0,0 2009-012600-48,3,2010-02-12,2010-03-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Novartis Pharma AG,"A randomized, partially-blinded, single-dose, 4-way crossover study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol maleate administered via the Conce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012600-48,0,0,0 2009-012600-48,3,2010-02-12,2010-03-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Novartis Pharma Services AG,"A randomized, partially-blinded, single-dose, 4-way crossover study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally inhaled indacaterol maleate administered via the Conce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012600-48,0,0,0 2009-012602-39,2,2011-03-15,2011-03-15,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Fresenius Kabi Deutschland GmbH,"A randomised, double-blind study evaluating the safety, tolerability, protein accretion, amino acid plasma levels and long-term outcome of Neoven compared to Vaminolact(R) in premature very low birth ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012602-39,0,0,0 2009-012603-26,3,2011-03-18,2011-03-18,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Fresenius Kabi Deutschland GmbH,"A randomised, double-blind study evaluating the safety, tolerability and clinical outcome of Neoven compared to Vaminolact in premature ELBW infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012603-26,0,0,0 2009-012604-92,1,2011-03-18,2011-03-18,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Fresenius Kabi Deutschland GmbH,"A randomised, double-blind study of the safety and efficacy of Neoven compared to Vaminolact in infants and children requiring long-term parenteral nutrition",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012604-92,0,0,0 2009-012607-26,1,2013-12-13,2013-12-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Cologne,MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Advanc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012607-26,0,0,0 2009-012608-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,An-Institut für Qualitätssicherung in der operativen Medizin gGmbH,Phase II-Studie zur Erfassung der Wirksamkeit einer neoadjuvanten Chemotherapie mit 5-FU/ Leucovorin/ Oxaliplatin/ Docetaxel beim lokal fortgeschrittenen Adenokarzinom des Magens oder des gastroösoph...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012608-20,0,0,0 2009-012609-20,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,INTRAVITREAL BEVACIZUMAB INJECTION VS. CONVENTIONAL LASER SURGERY FOR VISION-THREATENING RETINOPATHY OF PREMATURITY.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012609-20,0,0,0 2009-012612-41,6,2011-02-01,2011-02-01,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 4-month, Randomized, Double-blind, Placebo- and Active-Controlled, Multi-centre, Parallel-Group Study, with an Optional 2-Month Extension to Evaluate Efficacy, Safety and Tolerability of AZD1656 as ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012612-41,0,0,0 2009-012613-21,10,2012-05-08,2012-05-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec BVBA,"An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) for subjects from the control group of the VX-950-TiDP24-C21...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012613-21,0,0,0 2009-012613-21,10,2012-05-08,2012-05-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Infectious Diseases BVBA,"An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) for subjects from the control group of the VX-950-TiDP24-C21...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012613-21,0,0,0 2009-012613-21,10,2012-05-08,2012-05-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TIBOTEC BVBA,"An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) for subjects from the control group of the VX-950-TiDP24-C21...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012613-21,0,0,0 2009-012613-21,10,2012-05-08,2012-05-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Infectious Dieseases-Diagnostic BVBA,"An open-label, single-arm, roll-over trial of telaprevir in combination with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) for subjects from the control group of the VX-950-TiDP24-C21...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012613-21,0,0,0 2009-012614-48,5,2010-11-08,2010-11-08,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of the H3 receptor antagonist, GSK239512 in subjects with mild to moderate Alzheimer’s disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012614-48,0,0,0 2009-012615-18,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CHU de Clermont-Ferrand,Efficacy and safety of cholecalciferol on rheumatoid arthritis activity in patients with vitamin D deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012615-18,0,0,0 2009-012616-40,3,2015-07-03,2015-07-03,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients with Evidence of Persistent Leukemia by RQ-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012616-40,0,0,0 2009-012616-40,3,2015-07-03,2015-07-03,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients with Evidence of Persistent Leukemia by RQ-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012616-40,0,0,0 2009-012621-12,1,2012-06-26,2012-06-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,Maximising physical function in later life: a 2 centre randomised trial of progressive resistance exercise training in combination with ACE inhibition,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012621-12,0,0,0 2009-012623-28,2,2012-11-26,2012-11-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Syndax Pharmaceuticals Inc,"A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012623-28,0,0,0 2009-012624-93,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE,“Esmolol in cardiac surgery. A randomized controlled trial with clinical relevant endpoints.”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012624-93,0,0,0 2009-012639-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Meander Medical Centre,Combined intracutaneous and intraperitoneal anaesthesia for postoperative pain reduction after laparoscopic cholecystectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012639-13,0,0,0 2009-012640-17,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,Swedish Herbal Institute,"A randomized, controlled, parallel-group, double-blind study of the proprietary Kan Jang Oral Solution versus placebo in patients with non complicated respiratory tract infections (common cold).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012640-17,0,0,0 2009-012642-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Swedish CLL-group,A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic L...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012642-22,0,0,0 2009-012643-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Freezing of gait in Parkinson's disease: in search of the underlying mechanism and the application of a new treatment option,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012643-42,0,0,0 2009-012644-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,PHASE 2 SINGLE- ARM STUDIES OF TEMOZOLOMIDE IN COMBINATION WITH TOPOTECAN IN REFRACTORY AND RELAPSED NEUROBLASTOMA AND OTHER PAEDIATRIC SOLID TUMOURS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012644-16,0,0,0 2009-012652-24,4,2011-06-30,2011-06-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global Research and Development Centre (Europe) Ltd.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin Plus Metformin, Alogliptin Alone, or Metformin Alone in Subjects with Type 2 Diabet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012652-24,0,0,0 2009-012654-20,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,sistemic thrombolysis with Alteplase between 3-4.5 hours in acute ischaemic stroke. Evaluation of clinical efficacy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012654-20,0,0,0 2009-012655-26,1,2014-08-26,2014-08-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Hellenic Cooperative Oncology Group,"A SINGLE-ARM, MULTICENTER, PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH CAPECITABINE / OXALIPLATIN IN FIRST-LINE, WILD-TYPE K-RAS METASTATIC COLORECTAL CANCER PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012655-26,0,0,0 2009-012658-19,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,Leiden University Medical Center,None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012658-19,0,0,0 2009-012663-34,1,2010-06-25,2010-06-25,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Phenomix Corporation,"A Phase 3, Randomized, Double-Blind, Active-Controlled, Multi-Center Extension Study to Evaluate Safety and Efficacy of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012663-34,0,0,0 2009-012665-61,6,2011-01-25,2011-01-25,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Celgene Corporation,"A PHASE 2, OPEN-LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN COMBINATION WITH CETUXIMAB IN PRETREATED SUBJECTS WITH KRAS MUTANT METASTATIC COLORECTAL CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012665-61,0,0,0 2009-012666-31,1,2012-12-03,2012-12-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Leeds Teaching Hospitals and University of Leeds,The role of progesterone support and genetic polymorphisms for inflammatory cytokines on the risk of developing ovarian hyperstimulation syndrome (OHSS) in women undergoing In-Vitro fertilisation/Intr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012666-31,0,0,0 2009-012667-34,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,Oslo University Hospital - Ullevål,"BRONCHIOLITIS, OPTIMAL TREATMENT IN INFANTS AND PROGNOSIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012667-34,0,0,0 2009-012672-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ApaTech Limited,"""A prospective, randomised study comparing the use of Actifuse™ ABX synthetic bone substitute with INFUSE® in patients requiring posterolateral instrumented lumbar fusion with interbody fusion"" also r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012672-27,0,0,0 2009-012673-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHRU de TOURS,Etude pharmacocinétique et pharmacodynamique comparant deux posologies différentes de la Thymoglobuline® en transplantation rénale.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012673-35,0,0,0 2009-012675-10,1,2010-06-11,2010-06-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dainippon Sumitomo Pharma Europe Ltd.,"An exploratory, randomised, double blind, placebo controlled, 14 day, two-way crossover, inhaled allergen challenge study to evaluate the effects of SMP-028 in subjects with mild to moderate asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012675-10,0,0,0 2009-012676-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Wallenberg laboratory,Femoral-Express-I,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012676-27,0,0,0 2009-012696-97,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,Management of children following acute pyelonefritis or recurrent urinary tract infection episodes and prevention of renal scarring: a prospective randomised controlled clinical trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012696-97,0,0,0 2009-012701-19,1,2011-03-02,2011-03-02,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, randomized, controlled, observer-blind study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ Streptococcus pneumoniae protein containing vacci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012701-19,0,0,0 2009-012703-25,3,2012-11-02,2013-02-15,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Pergamum AB,"A prospective double-blind, randomised concept study of PXL01 versus placebo in flexor tendon surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012703-25,0,0,0 2009-012705-19,3,2010-09-30,2010-09-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects with Active Rheumatoid A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012705-19,0,0,0 2009-012706-39,1,2013-11-26,2013-11-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Klinikum der Otto-von-Guericke Universität Magdeburg,"Multicentric, open-label, single-arm phase II study with oral lapatinib in combination with oral capecitabine plus intrathecally administered liposomal cytarabine (DepoCyte®) for the treatment of meni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012706-39,0,0,0 2009-012707-26,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA SENESE,THERAPEUTIC EFFECTIIVENESS OF N-ACETYL-CYSTEINE AND ASCORBIC ACID IN PATIENTS WITH ALKAPTONURIA-OCHRONOSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012707-26,0,0,0 2009-012709-20,10,2012-08-06,2012-08-08,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AGENNIX INC.,"A Phase 3, randomized, double-blind, placebo-controlled study of oral talactoferrin in addition to best supportive care in patients with non-small cell lung cancer who have failed two or more prior tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012709-20,1,0,0 2009-012709-20,10,2012-08-06,2012-08-08,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Agennix Incorporated,"A Phase 3, randomized, double-blind, placebo-controlled study of oral talactoferrin in addition to best supportive care in patients with non-small cell lung cancer who have failed two or more prior tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012709-20,1,0,0 2009-012712-40,1,2010-11-03,2010-11-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik Innere Medizin III, Abt.für Nephrologie u.Dialyse",Improving Secretion of Insulin in New Onset Diabetes after Renal Transplantation (ISINODAT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012712-40,0,0,0 2009-012713-22,1,2013-05-31,2013-05-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ. Klinik für Anästhesie, Allg. Intensivmedizin u Schmerztherapie",Randomized Double-blind Study Comparing the Efficacy of Duloxetine with Placebo in Patients with Chronic Low Back Pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012713-22,0,0,0 2009-012714-49,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,Pilot study of Lapatinib (Tyverb®) in néoadjuvant treatment for patients with locally bladder carcinoma before cystectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012714-49,0,0,0 2009-012716-40,7,2011-06-30,2011-06-30,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Peptimmune Inc.,"The Effect of the Dose of PI-2301 on Efficacy, Safety, and Tolerability, in Subjects with the Relapsing Remitting Form of Multiple Sclerosis: A Phase 2 Randomized, double-blind, four–arm, parallel, pl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012716-40,1,0,0 2009-012717-22,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University College London,UKALL14 - A randomized trial for adults with newly diagnosed acute lymphoblastic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012717-22,0,0,0 2009-012718-35,3,2013-02-27,2013-02-27,1,0,0,1,0,1,1,0,0,2,1,0,0,0,1,Only For Children Pharmaceuticals,"An open-label, randomised crossover pharmacokinetic, palatability and safety study to assess the bioavailability of 5ml of a new 6MP oral liquid formulation by comparison to a currently registered 6MP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012718-35,1,0,0 2009-012738-65,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA USL 4 PRATO,CLINICAL ACTIVITY OF DNA DAMAGING AND NON-DAMAGING CHEMIOTHERAPY REGIMENS IN ADVANCED BREAST CANCER PATIENTS WITH DIFFERENT BIOLOGICAL SUB-TYPES DEFINED BY BIOMARKERS EVALUATION ON CIRCULATING TUMOR C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012738-65,0,0,0 2009-012740-17,1,,,0,0,0,0,0,1,3,0,0,1,0,0,0,1,0,MUMC,Topical rapamycin to treat fibrofolliculomas in Birt-Hogg-Dubé syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012740-17,0,0,0 2009-012741-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Caen,SUPPLEMENTATION EN VITAMINE D CHEZ LES FEMMES MENOPAUSEES OSTEOPOROTIQUES: EVALUATION D’UN SCHEMA THERAPEUTIQUE DE NORMALISATION BIOLOGIQUE DU TAUX SERIQUE DE 25OHVITAMINE D,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012741-27,0,0,0 2009-012746-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,"pilot study of second line therapy for AAA Acquired Aplastic Anemia with antithymocyte globulin, cyclosporin and etanercept",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012746-23,0,0,0 2009-012748-17,2,2012-06-05,2012-06-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Alzheimer Immunotherapy,"A phase 3, multicenter, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in subjects with mild to moderate Alzheimer's disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012748-17,0,0,0 2009-012750-21,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CHU de NICE,Traitement des épidermolyses bulleuses dystrophiques héréditaires par l’épigallocatéchine-3-gallate oral (Polyphenon E®),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012750-21,0,0,0 2009-012752-24,1,2011-08-17,2011-08-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Birmingham,High or Low Dose Syntocinon (Oxytocin) for delay in labour,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012752-24,0,0,0 2009-012752-24,1,2011-08-17,2011-08-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Birmingham Women's Hospital,High or Low Dose Syntocinon (Oxytocin) for delay in labour,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012752-24,0,0,0 2009-012758-18,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Universitätsklinikum Hamburg-Eppendorf,A randomized multi-center treatment study (COALL 08-09) to improve the survival of children with acute lymphoblastic leukemia on behalf of the German Society of Pediatric Hematology and Oncology,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012758-18,0,0,0 2009-012759-12,14,2012-05-31,2013-07-15,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A multi-center, randomized, double-blind, parallel group study of the safety, disease remission and prevention of structural joint damage during treatment with tocilizumab (TCZ), as a monotherapy and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012759-12,0,0,0 2009-012763-34,1,2010-12-31,2010-12-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Medizinische Universität Wien, Univ. Klinik für Anästhesie, Allg. Intensivmedizin u Schmerztherapie",Reversal of neuromuscular blockage in Patients with End Stage Hepatic Failure (listed for Liver Transplantation),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012763-34,0,0,0 2009-012769-74,1,2012-10-23,2012-10-23,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 110017",PHASE 1 SAFETY AND TOLERABILITY STUDY OF FIGITUMUMAB COMBINED WITH PEGVISOMANT IN PATIENTS WITH ADVANCED SOLID TUMORS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012769-74,0,0,0 2009-012772-27,7,2011-01-14,2011-06-14,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","""Estudio internacional, multicéntrico, doble ciego, aleatorizado, de grupos paralelos y controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad a largo plazo de la niacina de libera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012772-27,0,0,0 2009-012772-27,7,2011-01-14,2011-06-14,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,MSD Finland Oy,"""Estudio internacional, multicéntrico, doble ciego, aleatorizado, de grupos paralelos y controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad a largo plazo de la niacina de libera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012772-27,0,0,0 2009-012772-27,7,2011-01-14,2011-06-14,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","""Estudio internacional, multicéntrico, doble ciego, aleatorizado, de grupos paralelos y controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad a largo plazo de la niacina de libera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012772-27,0,0,0 2009-012775-10,6,2010-12-01,2010-12-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 24-Week, Randomised, Double-Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Add-On Compared to Uptitration of Metformin in Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012775-10,0,0,0 2009-012775-10,6,2010-12-01,2010-12-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A 24-Week, Randomised, Double-Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Add-On Compared to Uptitration of Metformin in Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012775-10,0,0,0 2009-012776-27,1,2013-03-20,2013-03-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,3,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,The effect of sitagliptin on myocardial performance in patients with type 2 diabetes and coronary artery disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012776-27,0,0,0 2009-012782-63,4,2011-10-26,2011-10-26,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Schering-Plough Research Institution, A Division of Schering Corporation",Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Versus Ribavirin Dose Reduction for the Management of Anem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012782-63,0,0,0 2009-012782-63,4,2011-10-26,2011-10-26,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Schering-Plough Research Institution, a division of Schering Corporation",Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Versus Ribavirin Dose Reduction for the Management of Anem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012782-63,0,0,0 2009-012784-34,1,2013-06-06,2013-06-06,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,STUDY OF HYDROXYUREA MECHANISMS OF ACTION ON LEUKOCYTE ACTIVATION IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE SYNDROMES.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012784-34,0,0,0 2009-012786-58,8,2011-11-02,2013-06-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ipsen Pharma S.A.S.,PROSTATE CANCER ANTIGEN-3 (PCA-3) AND TMPRSS2-ERG (T2-ERG) SCORE CHANGES DURING INITIATION OF ANDROGEN DEPRIVATION THERAPY (ADT) WITH TRIPTORELIN 22.5MG IN PATIENTS WITH ADVANCED PROSTATE CANCER (PCA)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012786-58,0,0,0 2009-012786-58,8,2011-11-02,2013-06-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ipsen Pharma SAS,PROSTATE CANCER ANTIGEN-3 (PCA-3) AND TMPRSS2-ERG (T2-ERG) SCORE CHANGES DURING INITIATION OF ANDROGEN DEPRIVATION THERAPY (ADT) WITH TRIPTORELIN 22.5MG IN PATIENTS WITH ADVANCED PROSTATE CANCER (PCA)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012786-58,0,0,0 2009-012786-58,8,2011-11-02,2013-06-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ipsen Pharma,PROSTATE CANCER ANTIGEN-3 (PCA-3) AND TMPRSS2-ERG (T2-ERG) SCORE CHANGES DURING INITIATION OF ANDROGEN DEPRIVATION THERAPY (ADT) WITH TRIPTORELIN 22.5MG IN PATIENTS WITH ADVANCED PROSTATE CANCER (PCA)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012786-58,0,0,0 2009-012787-14,9,2014-01-22,2014-01-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, double-blind, placebo-controlled phase III study of regorafenib plus BSC versus placebo plus BSC in patients with metastatic colorectal cancer (CRC) who have progressed after standard t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012787-14,0,0,0 2009-012797-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC),Essai de phase II randomisé multicentrique évaluant l’efficacité d’une chimiothérapie seule ou combinée à l’AMG 102 ou au panitumumab en traitement de première ligne chez des patients atteints d’adéno...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012797-12,0,0,0 2009-012799-28,2,2012-02-14,2012-02-14,2,1,0,0,1,0,4,0,0,1,0,0,1,0,1,Allergan,"A 3-Month, Multicenter, Investigator masked, Pilot Study to Evaluate the Efficacy and Safety of Bimatoprost/Timolol Fixed Combination vs Latanoprost in treatment Naïve Patients with Open Angle Glaucom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012799-28,0,0,0 2009-012802-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Centre Nijmegen St Radboud,Evaluation of the activity of temsirolimus with FLT-PET in patients with renal cell cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012802-38,0,0,0 2009-012803-24,3,2010-12-21,2011-01-31,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Regado Biosciences, Inc","A RANDOMIZED, PARTIALLY-BLINDED, MULTI-CENTER, ACTIVE-CONTROLLED, DOSE RANGING STUDY ASSESSING THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF THE REG1 ANTICOAGULATION SYSTEM COMPARED TO UNFRACTIONATED ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012803-24,0,0,0 2009-012805-20,1,2010-07-19,2010-07-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomised, double blind, placebo controlled, parallel-group study with use of budesonide/formoterol “as-needed”, or terbutaline “as-needed” or regular use of budesonide + terbutaline “as-needed”, i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012805-20,0,0,0 2009-012806-37,3,2011-09-26,2011-09-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study with a 24-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012806-37,0,0,0 2009-012807-25,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IIL INTERGRUPPO ITALIANO LINFOMI ONLUS,"A PHASE III MULTICENTER, RANDOMIZED STUDY WITH LENALIDOMIDE (Revlimid) MAINTENANCE VERSUS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY AND ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012807-25,0,0,0 2009-012808-11,1,2010-04-28,2010-04-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Therakind Limited,"An open label, single dose, pharmacokinetic study of oromucosal midazolam administered to children from 3 months to less than 18 years undergoing routine elective surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012808-11,0,0,0 2009-012809-19,3,2011-12-15,2011-12-15,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,STEBA BIOTECH SA,VASCULAR-TARGETED PHOTODYNAMIC THERAPY USING WST11 IN PATIENTS WITH LOCALISED PROSTATE CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012809-19,1,0,0 2009-012810-29,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Air Liquide Santé International,STABILITE HEMODYNAMIQUE LORS D’UNE ENDARTERIECTOMIE CAROTIDIENNE SOUS ANESTHESIE GENERALE CHEZ LE SUJET AGE : COMPARAISON LENOXe™ (xénon 100% v/v) versus SEVOFLURANE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012810-29,0,0,0 2009-012813-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC),"Essai de phase II, randomisé multicentrique, évaluant le meilleur protocole de chimiothérapie associée à une thérapie ciblée choisie selon le statut KRAS dans les métastases hépatiques initialement no...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012813-22,0,0,0 2009-012814-36,1,2014-11-10,2014-11-10,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Helsingin Diakonissalaitos,Buprenorfiini-naloksoni ja metadoni erilaisissa psykososiaalisissa hoito-ohjelmissa buprenorfiiniriippuvaisten korvaushoidossa. Satunnaistettu kontrolloitu tutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012814-36,0,0,0 2009-012815-16,1,2013-02-28,2013-02-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Technische Universität München,Dosis-Wirkungsstudie von Rocuronium unter Propofol-Anästhesie (Rocuronium Dose Finding Study after single shot or steady state propofol anesthesia),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012815-16,0,0,0 2009-012816-41,12,2012-06-14,2012-06-14,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 52-Week, Randomised, Double Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Compared to Glimepiride in Elderly Patients with Typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012816-41,0,0,0 2009-012816-41,12,2012-06-14,2012-06-14,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,ASTRAZENECA,"A 52-Week, Randomised, Double Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Compared to Glimepiride in Elderly Patients with Typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012816-41,0,0,0 2009-012817-23,1,2020-05-20,2020-05-20,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Maternite Regionale Universitaire de Nancy,Utilisation d’un surfactant exogène chez des nouveau-nés grands prématurés présentant une détresse respiratoire sévère en prévention de la dysplasie bronchopulmonaire,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012817-23,0,0,0 2009-012820-97,5,2012-07-11,2012-10-08,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,OSI PHARMACEUTICALS INC,"A Randomized, Double-Blind Placebo-Controlled Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012820-97,0,0,0 2009-012820-97,5,2012-07-11,2012-10-08,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Astellas Pharma Global Development, Inc.","A Randomized, Double-Blind Placebo-Controlled Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012820-97,0,0,0 2009-012820-97,5,2012-07-11,2012-10-08,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"OSI Pharmaceuticals, Inc.","A Randomized, Double-Blind Placebo-Controlled Phase 3 Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012820-97,0,0,0 2009-012836-33,4,2010-08-23,2019-08-23,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A randomised, double blind study to evaluate the safety and efficacy of the p38 kinase inhibitor, GW856553, in subjects with neuropathic pain from lumbosacral radiculopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012836-33,0,0,0 2009-012842-21,6,2014-01-03,2014-01-03,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Aptalis Pharma US Inc.,"A randomised, double blind, active-controlled, two-treatment, crossover multinational, multicentre trial to compare two pancreatic enzyme products in the treatment of exocrine pancreatic insufficiency...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012842-21,0,0,0 2009-012842-21,6,2014-01-03,2014-01-03,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,EURAND SPA,"A randomised, double blind, active-controlled, two-treatment, crossover multinational, multicentre trial to compare two pancreatic enzyme products in the treatment of exocrine pancreatic insufficiency...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012842-21,0,0,0 2009-012847-40,1,2014-11-05,2014-11-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,2,NHS Lothian,A Randomised Study Comparing Two Different Regimens of Ovarian Stimulation Using Pergoveris and Cetrorelix for Controlled Ovarian Superovulation in Assisted Conception Treatment.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012847-40,0,0,0 2009-012847-40,1,2014-11-05,2014-11-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,2,The University of Edinburgh,A Randomised Study Comparing Two Different Regimens of Ovarian Stimulation Using Pergoveris and Cetrorelix for Controlled Ovarian Superovulation in Assisted Conception Treatment.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012847-40,0,0,0 2009-012848-16,7,2013-06-13,2014-06-13,5,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPHAGE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012848-16,1,1,0 2009-012848-16,7,2013-06-13,2014-06-13,5,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Pfizer Inc.,"A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPHAGE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012848-16,1,1,0 2009-012848-16,7,2013-06-13,2014-06-13,5,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA","A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPHAGE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012848-16,1,1,0 2009-012850-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA SANITARIA LOCALE DI BARI,Statins IN TREATMENT OF ACUTE coronary syndrome. COMPARISON OF EFFICACY BETWEEN Atorvastatin and Rosuvastatin IN PATIENTS UNDERGO A PTCA THROUGH THE MONITORING OF C REACTIVE PROTEIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012850-19,0,0,0 2009-012852-26,17,2014-12-23,2015-02-11,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Recherche & Développement,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate cardiovascular outcomes during treatment with lixisenatide in type 2 diabetic patients after an Acute Coro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012852-26,0,0,0 2009-012852-26,17,2014-12-23,2015-02-11,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Recherche & D�veloppement,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate cardiovascular outcomes during treatment with lixisenatide in type 2 diabetic patients after an Acute Coro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012852-26,0,0,0 2009-012853-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Jean Perrin,"Phase II trial assessing neoadjuvant therapy with FEC 100 followed by Taxotere® (docetaxel) plus Vectibix® (panitumumab) in patients with operable, HR and Her-2 negative breast cancer. TVA study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012853-39,0,0,0 2009-012855-90,1,2010-12-02,2010-12-02,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Jelfa SA,"Randomised, placebo-controlled, double-blind, parallel-group, comparative study of two topical products for the treatment of psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012855-90,0,0,0 2009-012857-39,4,2011-10-11,2011-10-11,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, OPEN LABEL STUDY OF FIGITUMUMAB (CP 751,871) PLUS CISPLATIN (OR CARBOPLATIN) AND ETOPOSIDE, VERSUS CISPLATIN (OR CARBOPLATIN) AND ETOPOSIDE ALONE, AS FIRST LINE TREATMENT IN PAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012857-39,0,0,0 2009-012857-39,4,2011-10-11,2011-10-11,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"PFIZER, S.A.","A PHASE 2, RANDOMIZED, OPEN LABEL STUDY OF FIGITUMUMAB (CP 751,871) PLUS CISPLATIN (OR CARBOPLATIN) AND ETOPOSIDE, VERSUS CISPLATIN (OR CARBOPLATIN) AND ETOPOSIDE ALONE, AS FIRST LINE TREATMENT IN PAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012857-39,0,0,0 2009-012859-21,2,2016-07-11,2016-07-11,1,0,0,0,0,0,2,0,0,1,1,0,1,0,0,NCIC Clinical Trial Group (NCIC CTG),A PHASE II/III STUDY OF INTRAPERITONEAL (IP) PLUS INTRAVENOUS (IV) CHEMOTHERAPY VERSUS IV CARBOPLATIN PLUS PACLITAXEL IN PATIENTS WITH EPITHELIAL OVARIAN CANCER OPTIMALLY DEBULKED AT SURGERY FOLLOWING...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012859-21,0,0,0 2009-012859-21,2,2016-07-11,2016-07-11,1,0,0,0,0,0,2,0,0,1,1,0,1,0,0,GRUPO ESPAÑOL DE INVESTIGACIÓN EN CANCER DE OVARIO (GEICO),A PHASE II/III STUDY OF INTRAPERITONEAL (IP) PLUS INTRAVENOUS (IV) CHEMOTHERAPY VERSUS IV CARBOPLATIN PLUS PACLITAXEL IN PATIENTS WITH EPITHELIAL OVARIAN CANCER OPTIMALLY DEBULKED AT SURGERY FOLLOWING...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012859-21,0,0,0 2009-012876-29,1,2011-03-31,2011-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Leicester,A prospective study to assess emergence and transmissibility of drug resistance to neuraminidase inhibitor following treatment of children and adults with acute pandemic influenza,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012876-29,0,0,0 2009-012897-12,1,2010-06-24,2010-06-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BIAL-Portela & Ca, SA","A double-blind, randomised, placebo-controlled study to investigate the tolerability and the effect of three multiple-dose regimens of BIA 9-1067 on the levodopa pharmacokinetics, catechol-0-methyltra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012897-12,0,0,0 2009-012898-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hopital Foch,Relation dose-effet du propofol : comparaison en double aveugle des différentes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012898-36,0,0,0 2009-012916-41,1,2012-03-13,2012-03-13,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,CROLLL GmbH,The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NASH) - a prospective open-label phase I/II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012916-41,0,0,0 2009-012919-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude multicentrique randomisée en double insu des effets de l'administration de norfloxacine ou d'un placebo sur la survie des malades atteints de cirrhose avec une insuffisance hépatocellulaire,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012919-17,0,0,0 2009-012923-27,4,2011-05-23,2011-05-23,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Begin™: Flex T1. A 26-week trial investigating the dosing flexibility, efficacy and safety of NN1250 in subjects with type 1 diabetes with a 26-week extension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012923-27,0,0,0 2009-012926-35,2,2010-10-20,2010-10-20,1,1,0,0,0,0,2,0,1,1,1,1,1,0,1,"Merck & Co, Inc.","A Phase IIb, Randomized, Placebo-Controlled, Dose-Ranging Study of MK-5442 in the Treatment of Postmenopausal Women with Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012926-35,0,0,0 2009-012928-89,1,2011-06-14,2011-06-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,South Tees NHS Trust,Intrathecal injection of a single dose of Ziconotide (Prialt®) to evaluate the option of continuous administration via implanted pump. A Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012928-89,0,0,0 2009-012929-11,3,2018-11-08,2019-03-13,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Bone Therapeutics S.A.,"Phase III, pivotal, multicentre, randomised, double-blind controlled Study to evaluate the Efficacy and Safety of Autologous Osteoblastic Cells (PREOB®) Implantation in Early Stage Non Traumatic Osteo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012929-11,0,0,0 2009-012931-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Landstinget Gävleborg,Smärtlindring efter Abdominell Hysterektomi - Är Blockad av Plexus Hypogastricus Superior en Effektiv Metod?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012931-14,0,0,0 2009-012934-63,4,2013-01-31,2013-01-31,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AstraZeneca AB,"A Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of AZD8931 In Combination with Anastrozole, Compared to Anastrozole alone, in Post-menopa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012934-63,0,0,0 2009-012935-13,4,2010-07-01,2010-07-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomized, double-blind, placebo controlled, multi-centre phase IIb dose finding study to assess the effect on GERD symptoms, safety and tolerability during four weeks treatment with AZD3355 in dos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012935-13,0,0,0 2009-012941-45,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Glostrup Hospital,LuRVO: Classification of Central Retinal Vein Occlusion and Management with Lucentis (Ranibizumab) - a randomised clinical trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012941-45,0,0,0 2009-012942-22,1,2019-02-20,2019-02-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC),"Essai de phase II, randomisé multicentrique, évaluant l'efficacité d'une chimiothérapie standard à base de fluoropyrimidine associée au cétuximab ou au bévacizumab, chez des patients kras sauvage, att...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012942-22,0,0,0 2009-012943-41,1,2012-12-21,2012-12-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012943-41,0,0,0 2009-012944-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VUMC,Effect of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan (“Zevalin”) following first-line R-CVP therapy in patients with follicular lymphoma on conversion rate assessed by FDG-PET ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012944-17,0,0,0 2009-012945-49,1,2016-12-12,2016-12-12,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Royal Marsden Hosptial Foundation Trust,A Phase II Trial of Nilotinib in the Treatment of Patients with c-KIT Mutated Advanced Acral and Mucosal Melanoma (NICAM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012945-49,0,0,0 2009-012945-49,1,2016-12-12,2016-12-12,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,The Institute of Cancer Research,A Phase II Trial of Nilotinib in the Treatment of Patients with c-KIT Mutated Advanced Acral and Mucosal Melanoma (NICAM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012945-49,0,0,0 2009-012947-40,6,2016-09-13,2016-09-13,5,1,0,0,0,0,2,0,0,1,0,0,1,0,0,PENTA Foundation,BREATHER (PENTA 16): Short-Cycle Therapy (SCT) (5 days on/2 days off) in young people with chronic HIV,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012947-40,0,0,0 2009-012947-40,6,2016-09-13,2016-09-13,5,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical Research Council,BREATHER (PENTA 16): Short-Cycle Therapy (SCT) (5 days on/2 days off) in young people with chronic HIV,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012947-40,0,0,0 2009-012949-33,1,2013-08-12,2013-08-12,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Helsinki University Central Hospital,Cross-reactive immunity elicited by oral and parenteral typhoid vaccines against non-typhoid Salmonellae,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012949-33,0,0,0 2009-012950-19,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,NILG (Northern Italy Leukemia Group),Multicentre study to optimize therapy of B-ALL and high grade non-Hodgkin Lymphoma in Adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012950-19,0,0,0 2009-012953-39,3,2011-04-19,2011-04-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,4SC AG,"A Randomized, Double Blind, Placebo-controlled, Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of SC12267 (35 mg) in Combination with Methotrexate compared to Methotrexate Alone in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012953-39,0,0,0 2009-012956-26,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA,Randomized clinical trial on efficacy and tolerability of intra-articular clodronate compared to placebo in knee osteoarthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012956-26,0,0,0 2009-012957-39,1,2015-02-12,2015-02-12,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,University of Cologne,"A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) in patients with relapsed or refractory chronic lymphocytic leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012957-39,0,0,0 2009-012963-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ALFREDO TAGARRO GARCIA,"ENSAYO CLINICO FASE II CORTICOIDES PARA EL EMPIEMA Y EL DERRAME PLEURAL PARANEUMÓNICO EN NIÑOS MULTICENTRIC, PHASE II, CLINICAL TRIAL CORTICOIDS FOR EMPYEMA AND PLEURAL EFFUSION IN CHILDREN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012963-33,0,0,0 2009-012964-14,2,2014-06-23,2014-06-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Exelixis Inc,A randomized discontinuation study of XL184 in subjects with advanced solid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012964-14,0,0,0 2009-012966-30,1,2012-11-05,2012-11-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,DAIICHI SANKYO EUROPE GmbH,"“Eficacia de Sevikar® comparado con la combinación de Perindoprilo/Amlodipino sobre la Presión Arterial Central, en Pacientes con Hipertensión moderada a severa - SEVITENSION”",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012966-30,0,0,0 2009-012968-13,1,2014-09-09,2014-09-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,"A Proof of Principle, Double-Blind, Randomised Placebo-Controlled,Multi-centre Trial of pravaStatin to Ameliorate Early Onset Pre-eclampsia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012968-13,0,0,0 2009-012973-37,9,2019-11-30,2019-11-30,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,MolMed S.pA.,"TK008: Estudio aleatorizado de fase III sobre el trasplante de células hematopoyéticas haploidéntico con o sin una estrategia de apoyo con linfocitos HSV-TK donados, en pacientes con leucemia aguda de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012973-37,0,0,0 2009-012973-37,9,2019-11-30,2019-11-30,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,MolMed S.p.A.,"TK008: Estudio aleatorizado de fase III sobre el trasplante de células hematopoyéticas haploidéntico con o sin una estrategia de apoyo con linfocitos HSV-TK donados, en pacientes con leucemia aguda de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012973-37,0,0,0 2009-012973-37,9,2019-11-30,2019-11-30,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,MOLMED,"TK008: Estudio aleatorizado de fase III sobre el trasplante de células hematopoyéticas haploidéntico con o sin una estrategia de apoyo con linfocitos HSV-TK donados, en pacientes con leucemia aguda de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012973-37,0,0,0 2009-012978-12,1,,,0,0,0,0,0,1,4,0,0,1,1,1,0,1,0,"Merck Serono, an affiliate of E. Merck AB","A Phase IV, prospective, open-label, uncontrolled, single-centre cohort trial to be conducted in Norway to assess the responsiveness of subjects with phenylketonuria (PKU) to treatment with Kuvan® 20 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012978-12,0,0,0 2009-012981-30,1,2011-08-18,2011-08-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Ghent,Prospective study to assess the efficacy and safety of lanreotide 120 mg as treatment of clinical symptoms associated with inoperable intestinal obstruction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012981-30,0,0,0 2009-012983-14,2,2013-04-22,2013-04-22,2,0,0,0,0,0,3,0,0,1,1,1,1,0,1,"BioNumerik Pharmaceuticals, Inc.","Randomized, multicenter, double-blind, phase 3 trial of Tavocept versus Placebo in patients with newly diagnosed or relapsed advanced (stage IIIB/IV) primary adenocarcinoma of the lung treated with do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012983-14,0,0,0 2009-012985-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,SU/Mölndal Sjukhus,"Kortisondroppar, dexametason 0,1 %, jämfört med kortisondroppar i kombination med nepafenac 0.1% som behandling vid gråstarrskirurgi. En prospektiv, randomiserad, dubbel - maskerad studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012985-29,0,0,0 2009-012986-67,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU DE POITIERS,Evaluation of the efficacy of Tamsulosine (alpha blockers) compared to phloroglucinol in improving JJ ureteral stent tolerance. A randomized controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012986-67,0,0,0 2009-012988-34,3,2009-10-26,2009-10-26,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,NovImmune SA,"A multicenter, randomized, double-blind, placebo-controlled clinical trial investigating the safety and efficacy of NI-0401 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012988-34,0,0,0 2009-012989-30,13,2017-05-09,2017-05-09,5,1,0,0,0,0,3,0,2,1,1,0,1,0,1,Teva Pharmaceutical Industries Ltd,"A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laqui...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012989-30,0,0,0 2009-012993-10,1,2012-01-24,2012-01-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,A. MENARINI I.F.R.,EFFICACY AND SAFETY OF ZOFENOPRIL+HYDROCHLOROTHIAZIDE COMBINATION VS. IRBESARTAN+HYDROCHLOROTHIAZIDE COMBINATION IN METABOLIC SYNDROME PATIENTS WITH ESSENTIAL HYPERTENSION NOT CONTROLLED BY PREVIOUS M...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012993-10,0,0,0 2009-012994-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA` CAMPUS BIOMEDICO,RANDOMISED PROSPECTIVE TRIAL: PREVENTION OF PANCREATIC FISTULA AFTER PANCREATICO-DUODENECTOMY USING BIOLOGICAL SEALANT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012994-37,0,0,0 2009-012997-11,5,2014-05-12,2014-07-02,5,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"An Open-Label, Rollover Study to Evaluate the Long Term Safety and Efficacy of VX 770 in Subjects with Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-012997-11,0,0,0 2009-013002-13,2,2012-10-01,2012-10-01,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Philogen S.p.A,A prospective non-randomized study of 131I-L19SIP Radioimmunotherapy (RIT) in combination with Whole Brain Radiation Therapy (WBRT) in patients with multiple brain metastases from solid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013002-13,0,0,0 2009-013002-13,2,2012-10-01,2012-10-01,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,PHILOGEN S.P.A.,A prospective non-randomized study of 131I-L19SIP Radioimmunotherapy (RIT) in combination with Whole Brain Radiation Therapy (WBRT) in patients with multiple brain metastases from solid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013002-13,0,0,0 2009-013004-31,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,0,UNIVERSITA` DEGLI STUDI DI PARMA,"Early combined prolonged release ropinirole and rasagiline therapy in newly diagnosed patients with Parkinsons disease. A prospective, randomized, parallel groups, long-term follow-up study includ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013004-31,0,0,0 2009-013020-23,1,2012-10-29,2012-10-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,A Pilot study of cognitive enhancer and cognitive training combination – Testing a therapeutic paradigm for cognitive impairment in schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013020-23,0,0,0 2009-013022-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Effecten en bijwerkingen van opioïden: een studie naar de rol van farmacokinetische en farmacogenetische heterogeniteit.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013022-16,0,0,0 2009-013022-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ZonMw,Effecten en bijwerkingen van opioïden: een studie naar de rol van farmacokinetische en farmacogenetische heterogeniteit.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013022-16,0,0,0 2009-013024-23,1,2022-03-01,2022-03-01,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,"Universitätsklinik für Kinder- und Jugendheilkunde, Medizinische Universität Wien",Comparative analysis of bevacizumab levels in serum and cerebrospinal fluid in children with recurrent malignant brain tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013024-23,0,0,0 2009-013027-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,Seton or glue for transfinteric anal fistulas? Prospective randomised trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013027-31,0,0,0 2009-013028-21,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,USE OF CLINICAL AND INTERMEDIATE PHENOTYPES TO ASSESS RESPONSE TO QUETIAPINE: THE ROLE OF PUTATIVE CAUSATIVE GENES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013028-21,0,0,0 2009-013029-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,"Proteomic profile analysis to classify advanced pancreatic adenocarcinoma patients for clinical outcome after treatment with PDXG (cisplatin, docetaxel, capecitabine, gemcitabine) or PEXG (cisplatin, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013029-41,0,0,0 2009-013030-25,3,2011-11-23,2011-11-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GE Healthcare Ltd,A PRINCIPAL OPEN-LABEL STUDY TO COMPARE THE BRAIN UPTAKE OF [18F]FLUTEMETAMOL WITH BRAIN FIBRILLAR AB LEVELS DETERMINED POST-MORTEM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013030-25,0,0,0 2009-013030-25,3,2011-11-23,2011-11-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GE Healthcare Ltd and its Affiliates,A PRINCIPAL OPEN-LABEL STUDY TO COMPARE THE BRAIN UPTAKE OF [18F]FLUTEMETAMOL WITH BRAIN FIBRILLAR AB LEVELS DETERMINED POST-MORTEM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013030-25,0,0,0 2009-013030-25,3,2011-11-23,2011-11-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GE Healthcare Ltd. and its Affiliates,A PRINCIPAL OPEN-LABEL STUDY TO COMPARE THE BRAIN UPTAKE OF [18F]FLUTEMETAMOL WITH BRAIN FIBRILLAR AB LEVELS DETERMINED POST-MORTEM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013030-25,0,0,0 2009-013036-20,1,,,0,0,0,0,1,0,4,0,0,1,1,1,0,1,0,Rigshospital,Effekten af Gabapentin på urin kateter gener hos patienter med et abdominalt aorta aneurisme som behandles med en endovaskulær stent,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013036-20,0,0,0 2009-013037-19,1,2011-10-06,2011-10-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vascular Biogenics Ltd.,"A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013037-19,0,0,0 2009-013049-27,1,2011-10-06,2011-10-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MAYOLY-SPINDLER,Evaluation de l’intérêt thérapeutique de MeteoSpasmyl ® administré à la demande dans la prise en charge du syndrome de l’intestin irritable.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013049-27,0,0,0 2009-013052-76,1,2011-03-28,2011-03-28,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,ARTIC (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie),"A single-arm, phase II study of SU11248 (sunitinib) in patients with von Hippel-Lindau (VHL) disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013052-76,0,0,0 2009-013053-15,9,2013-05-29,2013-05-29,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc.","""Estudio de fase II abierto de MK 7009 administrado de forma concomitante con interferón alfa 2a pegilado y ribavirina a pacientes con hepatitis C crónica después de participar en otros ensayos clínic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013053-15,0,0,0 2009-013053-15,9,2013-05-29,2013-05-29,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","""Estudio de fase II abierto de MK 7009 administrado de forma concomitante con interferón alfa 2a pegilado y ribavirina a pacientes con hepatitis C crónica después de participar en otros ensayos clínic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013053-15,0,0,0 2009-013053-15,9,2013-05-29,2013-05-29,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.","""Estudio de fase II abierto de MK 7009 administrado de forma concomitante con interferón alfa 2a pegilado y ribavirina a pacientes con hepatitis C crónica después de participar en otros ensayos clínic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013053-15,0,0,0 2009-013053-15,9,2013-05-29,2013-05-29,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","""Estudio de fase II abierto de MK 7009 administrado de forma concomitante con interferón alfa 2a pegilado y ribavirina a pacientes con hepatitis C crónica después de participar en otros ensayos clínic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013053-15,0,0,0 2009-013053-15,9,2013-05-29,2013-05-29,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Europe) Inc.,"""Estudio de fase II abierto de MK 7009 administrado de forma concomitante con interferón alfa 2a pegilado y ribavirina a pacientes con hepatitis C crónica después de participar en otros ensayos clínic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013053-15,0,0,0 2009-013053-15,9,2013-05-29,2013-05-29,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"""Estudio de fase II abierto de MK 7009 administrado de forma concomitante con interferón alfa 2a pegilado y ribavirina a pacientes con hepatitis C crónica después de participar en otros ensayos clínic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013053-15,0,0,0 2009-013054-33,1,2012-05-22,2012-05-22,1,1,0,0,0,1,0,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics Srl.,"A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence compared to Naïve Children and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013054-33,0,0,0 2009-013055-30,5,2011-09-06,2012-08-10,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Ardea Biosciences, Inc.","Randomized, Double-Blind, Multicenter, Placebo-Controlled, Safety and Efficacy Study of RDEA594 Versus Placebo in the Treatment of Hyperuricemia in Patients with Gout",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013055-30,0,0,0 2009-013056-71,10,2013-06-27,2013-09-06,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Pharma A/S,"Ensayo abierto, aleatorizado, multicentrico, controlado con grupo paralelo para evaluar la eficacia y seguridad de TachoSilâ frente a la práctica habitual en técnicas de sellado de duramadre para la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013056-71,0,0,0 2009-013056-71,10,2013-06-27,2013-09-06,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Nycomed Danmark ApS,"Ensayo abierto, aleatorizado, multicentrico, controlado con grupo paralelo para evaluar la eficacia y seguridad de TachoSilâ frente a la práctica habitual en técnicas de sellado de duramadre para la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013056-71,0,0,0 2009-013061-26,1,2011-09-19,2011-09-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Turku,"Efficacy, safety, tolerability and pharmacokinetics of concomitant administration of tramadol with duloxetine or pregabalin: a randomized controlled flexible-dose study in patients with neuropathic pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013061-26,0,0,0 2009-013062-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA USL 8 AREZZO,"BEVACIZUMAB COMBINED WITH PDT, VERSUS RANIBIZUMAB AND PEGAPTANIB BOTH COMBINED WITH PDT FOR NEOVACULAR AGE RELATED MACULAR DEGENERATION CLINICAL TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013062-11,0,0,0 2009-013063-19,6,2011-10-24,2011-10-31,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013063-19,0,0,0 2009-013064-40,7,2011-10-07,2011-10-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013064-40,0,0,0 2009-013064-40,7,2011-10-07,2011-10-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013064-40,0,0,0 2009-013065-25,2,2011-02-02,2011-02-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013065-25,0,0,0 2009-013066-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,“Levosimendan to reduce mortality in high risk cardiac surgery patients. A multicentre randomized controlled trial.”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013066-31,0,0,0 2009-013067-19,2,2011-02-08,2011-03-08,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013067-19,0,0,0 2009-013069-24,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,AZIENDA OSPEDALIERA - CENTRO RICERCHE CLINICHE DI VERONA,"A double blind, single dose, randomized, 2-way crossover, placebo controlled study to set-up the resting state test in 10 healthy subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013069-24,0,0,0 2009-013072-52,8,2014-12-01,2015-02-03,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Abbott GmbH & Co. KG,"A Multi-centre, Randomised, Double-Dummy, Double-Blind Study Evaluating Two Doses of Adalimumab versus Methotrexate (MTX) in Paediatric Subjects with Chronic Plaque Psoriasis (Ps)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013072-52,1,1,0 2009-013072-52,8,2014-12-01,2015-02-03,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Abbott GmBH & Co KG,"A Multi-centre, Randomised, Double-Dummy, Double-Blind Study Evaluating Two Doses of Adalimumab versus Methotrexate (MTX) in Paediatric Subjects with Chronic Plaque Psoriasis (Ps)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013072-52,1,1,0 2009-013072-52,8,2014-12-01,2015-02-03,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multi-centre, Randomised, Double-Dummy, Double-Blind Study Evaluating Two Doses of Adalimumab versus Methotrexate (MTX) in Paediatric Subjects with Chronic Plaque Psoriasis (Ps)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013072-52,1,1,0 2009-013072-52,8,2014-12-01,2015-02-03,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie DeutschlandGmbH & Co. KG,"A Multi-centre, Randomised, Double-Dummy, Double-Blind Study Evaluating Two Doses of Adalimumab versus Methotrexate (MTX) in Paediatric Subjects with Chronic Plaque Psoriasis (Ps)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013072-52,1,1,0 2009-013074-41,3,2014-11-17,2014-11-17,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Norge AS,A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican®) and early elimination of cyclosporine (Sandimmun Neoral®) in de novo heart transplant reci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013074-41,0,0,0 2009-013074-41,3,2014-11-17,2014-11-17,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Healthcare A/S,A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican®) and early elimination of cyclosporine (Sandimmun Neoral®) in de novo heart transplant reci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013074-41,0,0,0 2009-013075-21,1,2012-05-23,2012-05-23,1,1,0,0,0,1,0,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics Srl.,"A Phase 2, Open-Label, Single-Center, Extension Study Evaluating Antibody Persistence compared to Naïve Children and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013075-21,0,0,0 2009-013080-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AMC,Prokinetics to alter the position of the gastric acid pocket in Gastro Esophageal Reflux Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013080-19,0,0,0 2009-013081-17,1,2010-09-09,2010-09-09,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Bayer HealthCare Pharmaceuticals, Inc.","Open-label, multi-center, two-stage, age stratified, pharmacokinetic, safety, and efficacy study in children 2 month to < 2 years of age undergoing Magnevist Injection enhanced MRI",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013081-17,0,0,0 2009-013088-20,6,2011-08-17,2011-08-17,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Allergan Ltd,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex Follow...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013088-20,0,0,0 2009-013089-26,5,2014-08-05,2014-08-05,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd,"A Multicenter, Long-term Follow-up Study of the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Idiopathic Overactive Bladder with Urinary Incontine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013089-26,0,0,0 2009-013090-18,2,2013-05-10,2013-05-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novo Nordisk A/S,"A 52-Week Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Multinational Exploratory Trial In Islet Cell Transplant Subjects With Type 1 Diabetes Mellitus To Evaluate The Ea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013090-18,0,0,0 2009-013091-40,7,2013-03-21,2013-03-21,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Abbott GmbH & Co. KG,Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg with Active Juvenile Idiopathic Arthritis (JIA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013091-40,1,1,0 2009-013091-40,7,2013-03-21,2013-03-21,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg with Active Juvenile Idiopathic Arthritis (JIA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013091-40,1,1,0 2009-013093-41,7,2014-12-31,2015-03-23,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,AMBIT BIOSCIENCES CORPORATION,"A PHASE 2 OPEN-LABEL, AC220 MONOTHERAPY EFFICACY (ACE) STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH FLT3-ITD ACTIVATING MUTATIONS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013093-41,0,0,0 2009-013093-41,7,2014-12-31,2015-03-23,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Ambit Biosciences Corporation,"A PHASE 2 OPEN-LABEL, AC220 MONOTHERAPY EFFICACY (ACE) STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH FLT3-ITD ACTIVATING MUTATIONS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013093-41,0,0,0 2009-013094-17,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013094-17,0,0,0 2009-013094-17,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Haukeland University Hospital, Helse Bergen",A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013094-17,0,0,0 2009-013097-40,3,2011-11-10,2011-11-10,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Noscira S.A.,"A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013097-40,0,0,0 2009-013099-38,1,2019-06-26,2019-06-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Klinikum der Universität München, Anstalt des öffentlichen Rechts vertreten durch den Vorstand","Sequential first-line therapy in metastatic colorectal cancer with Capecitabine/FUFA, Irinotecan and Bevacizumab - Capecitabine/FUFA plus Bevacizumab versus Capecitabine/FUFA plus Irinotecan plus Bev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013099-38,0,0,0 2009-013100-32,1,2012-06-15,2012-06-15,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Exeter,"Does modulating the gut hormones, incretins, modify vascular function, thereby reducing the risk of vascular complications in insulin resistant individuals?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013100-32,0,0,0 2009-013100-32,1,2012-06-15,2012-06-15,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Royal Devon and Exeter NHS Foundation Trust,"Does modulating the gut hormones, incretins, modify vascular function, thereby reducing the risk of vascular complications in insulin resistant individuals?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013100-32,0,0,0 2009-013103-63,1,,,0,1,0,1,1,0,1,0,0,1,1,1,0,1,0,Asklepios Kliniken Hamburg GmbH,Pilot study investigating the effect of intra-coronary and intra-myocardial application of enriched CD133pos autologous bone marrow derived stem cells for improving left ventricular function in chroni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013103-63,0,0,0 2009-013105-34,3,2012-05-24,2012-05-24,1,1,1,0,0,0,2,0,1,2,0,0,0,0,1,Baxter Innovations GmbH,"A PHASE I/II STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF A VERO CELL-DERIVED WHOLE VIRUS H5N1 INFLUENZA VACCINE IN HEALTHY INFANTS, CHILDREN AND ADOLESCENTS AGED 6 MONTHS TO 17 YEARS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013105-34,1,1,0 2009-013107-56,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Phase II trial with intranasal Midazolam delivered using a MAD (Mucosal Atomizer Device) for paediatric painful procedures.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013107-56,0,0,0 2009-013110-27,1,2011-03-17,2011-03-17,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,AstraZeneca AB,"A phase I, multi-centre, double-blind, placebo-controlled parallel group study to assess the pharmacoMRI effects of AZD6765 in male and female patients fulfilling the criteria for Major Depressive Dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013110-27,0,0,0 2009-013111-35,1,2010-06-07,2010-06-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galderma R&D SNC,"EFFECT OF CD08514 VERSUS PLACEBO, IN PATIENTS PRESENTING WITH TYPE 1 ROSACEA, OVER AN 8-WEEK TREATMENT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013111-35,0,0,0 2009-013112-12,1,2013-07-09,2013-07-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Barts & the London NHS Trust,Randomised Controlled Trial To Compare The effects of G-CSF(Granocyte™) And Autologous Bone Marrow Progenitor Cells On Quality Of Life And Left Ventricular Function In Patients with Idiopathic Dilated...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013112-12,0,0,0 2009-013115-35,3,2010-07-16,2010-07-16,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Sangart, Inc.","A multi-center, randomized, double-blind, controlled dose-finding study to evaluate the safety and efficacy of MP4OX treatment plus standard of care in severely injured trauma patients with lactic aci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013115-35,0,0,0 2009-013118-28,1,2014-10-31,2014-10-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Tarja Heiskanen,Bukkaalinen fentanyyli syöpäpotilaiden toimenpidekivun hoidossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013118-28,0,0,0 2009-013120-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,LABCATAL,Efficacité et tolérance du LBC 45 dans la dermite séborrhéique du cuir chevelu,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013120-23,0,0,0 2009-013123-33,1,2012-12-15,2012-12-15,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,Tays,THE USE OF DEXMEDETOMIDINE IN THE POSTOPERATIVE SEDATION OF HEAD AND NECK CANCER SURGERY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013123-33,0,0,0 2009-013126-16,4,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,TIBOTEC PHARMACEUTICALS LTD.,Acceso continuado de etravirina en niños y adolescentes infectados por VIH-1 previamente tratados. Continued access to etravirine in treatment experienced HIV-1 infected children and adolescents.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013126-16,0,0,0 2009-013126-16,4,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,Tibotec Pharmaceuticals c/o Tibotec BVBA,Acceso continuado de etravirina en niños y adolescentes infectados por VIH-1 previamente tratados. Continued access to etravirine in treatment experienced HIV-1 infected children and adolescents.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013126-16,0,0,0 2009-013126-16,4,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,Tibotec Pharmaceuticals,Acceso continuado de etravirina en niños y adolescentes infectados por VIH-1 previamente tratados. Continued access to etravirine in treatment experienced HIV-1 infected children and adolescents.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013126-16,0,0,0 2009-013128-22,1,2014-08-04,2014-08-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Hellenic Cooperative Oncology Group,Lapatinib and Whole Brain Radiotherapy for patients with brain metastases from lung and breast tumors. A phase II study of the Hellenic Cooperative Oncology Group (HeCOG).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013128-22,0,0,0 2009-013129-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amphia Ziekenhuis,"A multicenter open label randomized pilot study, to compare retinal nerve fiber layer thickness measured by Optical Coherence Tomography after treatment with daily 20 mg glatiramer acetate subcutaneou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013129-41,0,0,0 2009-013131-38,2,2010-12-16,2010-12-16,2,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Baxter Innovations GmbH,"An open label phase 1/2 study to assess the immunogenicity and safety of two different dose levels of H1N1 pandemic infuenza vaccine in healthy infants, children and adolescents aged 6 months to 17 ye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013131-38,0,0,0 2009-013133-22,1,2011-06-04,2011-06-04,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Belfast Health & Social Care Trust,Comparison of the effects of single shot or continuous popliteal nerve block on postoperative outcome measures in patients undergoing operative repair of ankle fracture.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013133-22,0,0,0 2009-013134-24,1,2011-06-04,2011-06-04,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Belfast Health & Social Care Trust,Comparison of fascia iliaca compartment block or femoral nerve block using levobupivacaine for postoperative analgesia after operative repair of femoral neck fracture: a dose response study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013134-24,0,0,0 2009-013156-72,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,IMAS,Farmacocinética en la obesidad mórbida: estudio de la influencia de dos técnicas de cirugía bariátrica (bypass Gástrico y Sleeve Gastrectomy) en el metabolismo de fármacos.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013156-72,0,0,0 2009-013157-15,14,2018-08-21,2018-08-21,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013157-15,0,0,0 2009-013157-15,14,2018-08-21,2018-08-21,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013157-15,0,0,0 2009-013157-15,14,2018-08-21,2018-08-21,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd,"A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013157-15,0,0,0 2009-013157-15,14,2018-08-21,2018-08-21,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013157-15,0,0,0 2009-013157-15,14,2018-08-21,2018-08-21,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013157-15,0,0,0 2009-013157-15,14,2018-08-21,2018-08-21,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.","A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013157-15,0,0,0 2009-013157-15,14,2018-08-21,2018-08-21,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013157-15,0,0,0 2009-013157-15,14,2018-08-21,2018-08-21,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas,"A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013157-15,0,0,0 2009-013157-15,14,2018-08-21,2018-08-21,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013157-15,0,0,0 2009-013157-15,14,2018-08-21,2018-08-21,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013157-15,0,0,0 2009-013157-15,14,2018-08-21,2018-08-21,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013157-15,0,0,0 2009-013157-15,14,2018-08-21,2018-08-21,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co. KG,"A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013157-15,0,0,0 2009-013159-31,1,2019-08-23,2019-08-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Bristol NHS Foundation Trust,Preoperative volume replacement vs. usual care in diabetic patients having CABG surgery: a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013159-31,0,0,0 2009-013163-18,1,2009-12-17,2009-12-17,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,REVOTAR Biopharmaceuticals AG,"A double-blind, placebo controlled, randomized, cross-over Phase IIa study to evaluate the effect of Bimosiamose on ozone induced sputum neutrophilia in healthy subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013163-18,0,0,0 2009-013165-25,2,2013-09-09,2013-09-09,1,1,1,0,0,0,1,0,1,2,1,0,0,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Comparative Single-Dose Pharmacokinetic and Safety Study of TAK-491 Between Infants, Children, and Adolescents with Hypertension and Healthy Adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013165-25,1,1,0 2009-013165-25,2,2013-09-09,2013-09-09,1,1,1,0,0,0,1,0,1,2,1,0,0,0,1,Takeda Development Centre Europe Ltd.,"A Comparative Single-Dose Pharmacokinetic and Safety Study of TAK-491 Between Infants, Children, and Adolescents with Hypertension and Healthy Adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013165-25,1,1,0 2009-013169-24,1,2010-03-03,2010-03-03,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,PTC Therapeutics Inc,A Phase 2a Study of Ataluren (PTC124) in Nonambulatory Patients with Nonsense–Mutation-Mediated Duchenne/Becker Muscular Dystrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013169-24,0,0,0 2009-013174-41,7,2017-11-02,2017-11-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Medivation, Inc.","AFFIRM: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients with Progressive Castration-Resistant Prostate Cancer Previously Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013174-41,0,0,0 2009-013177-18,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Protocole CYTOCINON : Evaluation de l'efficacité de l'association oxytocine-misoprostol dans la prévention de l'hémorragie du postpartum,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013177-18,0,0,0 2009-013178-42,3,2010-11-01,2010-11-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.",A Twelve-Month Open-Label Safety Study of Polyquaternium-Preserved DuoTrav APS Dosed Once Daily in Patients with Open-Angle Glaucoma or Ocular Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013178-42,0,0,0 2009-013198-16,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,UNIVERSITA` DEGLI STUDI DI PARMA,Acute Myocardial Infarction and endothelial function. Assessment with a non invasive ultrasonographic computerized method during oral vitamin C supplementation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013198-16,0,0,0 2009-013201-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Propofol and Tiopentone in paediatric sedation for fRMI study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013201-33,0,0,0 2009-013219-37,7,2013-06-10,2013-09-06,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"AVEO Pharmaceuticals, Inc.","A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013219-37,1,0,0 2009-013219-37,7,2013-06-10,2013-09-06,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"AVEO PHARMACEUTICALS, INC.","A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013219-37,1,0,0 2009-013220-24,7,2017-07-31,2017-07-31,6,1,0,0,0,1,0,0,0,1,1,0,1,0,0,Uniwersytet Jagielloński – Collegium Medicum,Intercambio plasmático y dosificación de glucocorticoides en el tratamiento de la vasculitis asociada a anticuerpos anticitoplasma de neutrófilos (ANCA): estudio multicéntrico aleatorizado y controlad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013220-24,0,0,0 2009-013220-24,7,2017-07-31,2017-07-31,6,1,0,0,0,1,0,0,0,1,1,0,1,0,0,Cambridge University Hospitals NHS Trust,Intercambio plasmático y dosificación de glucocorticoides en el tratamiento de la vasculitis asociada a anticuerpos anticitoplasma de neutrófilos (ANCA): estudio multicéntrico aleatorizado y controlad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013220-24,0,0,0 2009-013220-24,7,2017-07-31,2017-07-31,6,1,0,0,0,1,0,0,0,1,1,0,1,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,Intercambio plasmático y dosificación de glucocorticoides en el tratamiento de la vasculitis asociada a anticuerpos anticitoplasma de neutrófilos (ANCA): estudio multicéntrico aleatorizado y controlad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013220-24,0,0,0 2009-013220-24,7,2017-07-31,2017-07-31,6,1,0,0,0,1,0,0,0,1,1,0,1,0,0,Addenbrooke's Hospital,Intercambio plasmático y dosificación de glucocorticoides en el tratamiento de la vasculitis asociada a anticuerpos anticitoplasma de neutrófilos (ANCA): estudio multicéntrico aleatorizado y controlad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013220-24,0,0,0 2009-013222-16,14,2010-01-31,2011-01-31,8,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Ipsen Pharma,"ESTUDIO EN FASE II ABIERTO, ADAPTATIVO, MULTICÉNTRICO, CON AUMENTO Y AJUSTE DE LA DOSIS PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE LA ADMINISTRACIÓN SUBCUTÁNEA REPETIDA DE DISTINTAS DOSIS DE BIM 23A76...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013222-16,0,0,0 2009-013222-16,14,2010-01-31,2011-01-31,8,1,0,0,0,1,2,0,0,1,1,0,1,0,1,IPSEN PHARMA SAS,"ESTUDIO EN FASE II ABIERTO, ADAPTATIVO, MULTICÉNTRICO, CON AUMENTO Y AJUSTE DE LA DOSIS PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE LA ADMINISTRACIÓN SUBCUTÁNEA REPETIDA DE DISTINTAS DOSIS DE BIM 23A76...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013222-16,0,0,0 2009-013223-37,3,2010-07-29,2010-07-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"""Estudio en fase 2a, aleatorizado, doble ciego, controlado con un fármaco activo y con placebo, de PF-04171327 en el tratamiento de los signos y síntomas de la artritis reumatoide"" A PHASE 2A, RANDOM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013223-37,0,0,0 2009-013223-37,3,2010-07-29,2010-07-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer S.A.,"""Estudio en fase 2a, aleatorizado, doble ciego, controlado con un fármaco activo y con placebo, de PF-04171327 en el tratamiento de los signos y síntomas de la artritis reumatoide"" A PHASE 2A, RANDOM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013223-37,0,0,0 2009-013223-37,3,2010-07-29,2010-07-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","""Estudio en fase 2a, aleatorizado, doble ciego, controlado con un fármaco activo y con placebo, de PF-04171327 en el tratamiento de los signos y síntomas de la artritis reumatoide"" A PHASE 2A, RANDOM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013223-37,0,0,0 2009-013226-17,1,2015-04-14,2015-04-14,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Plymouth Hospitals NHS Trust,The ENIGMA-II Trial. Nitrous oxide anaesthesia and cardiac morbidity after major surgery: a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013226-17,0,0,0 2009-013227-28,1,2010-11-25,2010-11-25,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,LFB BIOTECHNOLOGIES,"A Double-Blind, Randomized, Crossover Study of the Recovery of FACTANE 100 versus 200 IU/ml followed by an Open-Label Safety Study of FACTANE 200 IU/ml in Previously Treated Patients With Severe (FVI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013227-28,0,0,0 2009-013228-21,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Oxford,Prevention of atrial oxidative stress and electrical remodelling in patients undergoing cardiac surgery: randomised placebo-controlled trial of perioperative high-dose atorvastatin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013228-21,0,0,0 2009-013232-20,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Dept of Urology Aarhus Universityhospital,"An Open Phase II, Two-centre, 1-Arm Safety Study of Once-daily Orally Administered 10 mg ZD4054 in Prior Chemotherapy Treated Patients with Metastatic Hormone-resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013232-20,0,0,0 2009-013235-38,4,2011-12-01,2011-12-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A multicenter, randomized, double-blind, placebocontrolled study, to assess the long term safety of 52 weeks treatment with QVA149 (110μg indacaterol / 50μg glycopyrrolate) in patients with moderate t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013235-38,0,0,0 2009-013235-38,4,2011-12-01,2011-12-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, placebocontrolled study, to assess the long term safety of 52 weeks treatment with QVA149 (110μg indacaterol / 50μg glycopyrrolate) in patients with moderate t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013235-38,0,0,0 2009-013256-69,16,2012-06-26,2012-08-11,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 52-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013256-69,0,0,0 2009-013256-69,16,2012-06-26,2012-08-11,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 52-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013256-69,0,0,0 2009-013256-69,16,2012-06-26,2012-08-11,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 52-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013256-69,0,0,0 2009-013256-69,16,2012-06-26,2012-08-11,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmaceutica, S.A.","A 52-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013256-69,0,0,0 2009-013259-31,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,UMC Utrecht,A multicenter double blind placebo-controlled randomised trial for benign esophageal anastomotic strictures: Savary dilation vs savary dilation with Triamcinolon,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013259-31,0,0,0 2009-013261-26,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,Moberg Derma AB,"A double-blind, randomized, multi-centre, placebo-controlled study of efficacy and safety of topical K101 in twelve months treatment of distal subungual onychomycosis (DSO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013261-26,0,0,0 2009-013262-84,8,2013-11-05,2013-11-05,8,1,1,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE DERMATOLOGIE,"A randomised, controlled, multidose, multicentre, adaptive phase II/III study in infants with proliferating infantile hemangiomas requiring systemic therapy to compare four regimens of propranolol (1 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013262-84,0,0,0 2009-013264-39,1,2009-11-13,2009-11-13,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,BIODEL inc.,"A Single-Center, Double Blind, Randomized Crossover Study Evaluating Injection Site Toleration of VIAject® 7, VIAject® 25 and Insulin Lispro in Subjects with Type 1 or Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013264-39,0,0,0 2009-013265-26,1,2010-04-30,2010-04-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Lluita contra la Sida,INTERACCIONES FARMACOLÓGICAS ENTRE ECHINACEA PURPUREA Y DARUNAVIR/RITONAVIR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013265-26,0,0,0 2009-013267-19,1,2011-02-21,2011-02-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GENENTECH, Inc.","A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY TO EVALUATE LEBRIKIZUMAB (MILR1444A) IN ADULT PATIENTS WITH ASTHMA WHO ARE NOT TAKING INHALED CORTICOSTEROIDS (MOLLY)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013267-19,0,0,0 2009-013268-38,1,2011-04-26,2011-04-26,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,AWD.pharma GmbH & Co KG,"A multicentre, double-blind, randomised, active- and placebo-controlled clinical trial on the pain relieving effects of the modfied-release formulation of flupirtine in patients suffering from moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013268-38,0,0,0 2009-013269-24,1,2010-04-22,2010-04-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Randomised, double-blind, triple dummy, partial cross-over (each active treatment with placebo) study using an Environmental Challenge Chamber (ECC) to assess the safety and efficacy of 2 weeks of ora...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013269-24,0,0,0 2009-013271-22,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL`ADULTO,Front-line treatment of Ph positive (Ph+)/Bcr-Abl positive Acute Lymphoblastic Leukemia (ALL) with two tyrosine kinase inhibitors (TKI) (Imatinib and Nilotinib). A phase II exploratory multicentric ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013271-22,0,0,0 2009-013272-47,1,2019-05-01,2019-05-01,1,1,0,0,0,0,4,0,1,1,1,1,1,0,1,BRC operations Pty. Ltd,International Study to Predict Optimized Treatment - in Attention-Deficit and Hyperactivity Disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013272-47,0,0,0 2009-013273-17,2,2011-02-03,2011-02-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Ichthyol-Gesellschaft Cordes, Hermanni & Co. (GmbH & Co.) KG","Double-blind, randomized, vehicle-controlled, multi-centric trial to prove the therapeutic efficacy and tolerability of a liquid acne topical containing Clindamycin phosphate and Sodiumbituminosulfona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013273-17,0,0,0 2009-013274-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SOCIETA` PRODOTTI ANTIBIOTICI,"Multicenter, randomized, parallel group open study to compare, in patients with postmenopausal osteoporosis, the effects of clodronate (Difosfonal) administered either intramuscularly at a dose of 10...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013274-41,0,0,0 2009-013275-21,1,2012-02-07,2012-02-07,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Imperial College Healthcare NHS Trust,"Pilot Study: Evaluating the effect of 300microgram testosterone patches in addition to Hormone Replacement Therapy on arterial compliance, insulin resistance and sexual desire",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013275-21,0,0,0 2009-013276-46,1,2012-05-01,2012-05-01,1,0,0,0,1,0,4,0,0,1,1,1,1,0,0,Queen Victoria Hospital,The effect of oral Ivermectin on Demodex associated blepharitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013276-46,0,0,0 2009-013279-23,1,2016-12-21,2016-12-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital of Heidelberg,In vivo response monitoring of treatment with the EGFR-monoclonal-antibody Cetuximab in metastatic colorectal cancer – a single center phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013279-23,0,0,0 2009-013283-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Assistance publique hôpitaux de marseille,sevofluorane versus propofol pour l'intubation des nouveau-nés en réanimation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013283-39,0,0,0 2009-013284-19,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Medical University Innsbruck,Immune tolerance induction in MS patients with neutralizing antibodies against interferon-beta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013284-19,0,0,0 2009-013286-26,1,2010-06-02,2010-06-02,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merck & Co., Inc.","A Phase IIb, Randomized, Active Comparator-Controlled, Open-Label Clinical Trial to Study the Efficacy and Safety of MK-2578 for the Treatment of Anemia in ESA (Erythropoiesis-Stimulating Agent)-Naive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013286-26,0,0,0 2009-013287-39,1,2012-10-25,2012-10-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Lluita contra la SIDA,RANDOMISED AND PROSPECTIVE CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOPINAVIR/RITONAVIR MONOTHERAPY VS DARUNAVIR/RITONAVIR MONOTHERAPIES AS SIMPLIFICATION SWITCHING STRATEGIES OF PI/NNRTI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013287-39,0,0,0 2009-013289-20,1,2012-05-14,2012-05-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A Phase III, randomised, double-blind, placebo-controlled parallel group efficacy and safety study of linagliptin 5 mg administered orally once daily over 24 weeks in type 2 diabetic patients with ins...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013289-20,0,0,0 2009-013291-46,7,2014-05-08,2014-05-29,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,"Ensayo clínico de Fase III abierto, de un solo grupo y con dosificación flexible de tapentadol LP oral en pacientes con dolor tumoral crónico que hayan completado el Periodo de Mantenimiento del estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013291-46,0,0,0 2009-013293-41,1,2016-01-11,2016-01-11,1,1,0,0,0,0,4,0,0,1,1,1,1,0,3,Joint UCLH/UCH Biomedical Research Unit,"Randomised, double blind, phase IV study to compare the incidence of ECG changes during elective caesarean section under spinal anaesthesia when using phenylephrine or ephedrine infusion to maintain b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013293-41,0,0,0 2009-013294-18,2,2020-08-31,2020-08-31,1,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Universitätsklinikum Greifswald der Ernst-Moritz-Arndt Universität Greifswald AöR,"Magnesiumsulfate in the prevention of post-ERCP pancreatitis – a prospective randomized, placebo-controlled multicenter study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013294-18,1,0,0 2009-013294-18,2,2020-08-31,2020-08-31,1,0,0,0,0,0,3,0,0,2,1,0,0,0,0,"University of Szeged, First Department of Internal Medicine","Magnesiumsulfate in the prevention of post-ERCP pancreatitis – a prospective randomized, placebo-controlled multicenter study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013294-18,1,0,0 2009-013295-48,1,2011-03-01,2011-03-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Århus University Hospital, Department of Dermatology",Treatment of patients with Nephrogenic Systemic Fibrosis(NSF) with Imatinib Mesylate(Glivec). An open label clinical trial among patients with moderate to severe NSF.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013295-48,0,0,0 2009-013316-12,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Roche Nederland B.V.,"A multi-center, randomized, double blind, placebo controlled study to evaluate remission in DMARD and biological naïve early reumatoid arthritis (RA) subjects treated with tocilizumab (TCZ) plus tigh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013316-12,0,0,0 2009-013317-10,4,2011-10-31,2011-10-31,2,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Genmab A/S,"An Open-label, Multi-Center, Phase I/II Trial Investigating the Pharmacokinetic profile of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in non-curable patients with SCCHN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013317-10,0,0,0 2009-013319-36,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Lille,"« Etude Multicentrique Randomisée En-Ouvert de Phase II du Pomalidomide avec la Dexaméthasone dans le Myélome Multiple en rechute ou réfractaire, en progression, n’ayant préalablement pas obtenu au mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013319-36,0,0,0 2009-013320-23,1,2010-04-14,2010-04-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ANGELINI,"A randomized, double-blind, placebo-controlled trial of benzydamine hydrochloride cream in the treatment of plaque psoriasis: a proof-of-concept and dose-finding study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013320-23,0,0,0 2009-013326-17,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,"MedImmune, LLC","A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Children",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013326-17,0,1,1 2009-013328-21,1,2013-05-13,2013-05-13,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"N-GENE Research Laboratories, Inc.","A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multiple Dose, Multicenter Study to Assess the Safety and Efficacy of BGP-15 when Administered Orally Once or Twice Daily as Add-on Ther...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013328-21,0,0,0 2009-013329-41,6,2010-12-13,2011-02-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A Phase 3 Randomized, Double-Blind, Placebo- and Oxycodone-Controlled, Multicenter Study of the Efficacy and Safety of Tanezumab in Patients with Osteoarthritis of the Knee or Hip",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013329-41,0,0,0 2009-013331-37,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,WSG GmbH,GALADON - Molecular Imaging Response Assessment of Bevacizumab+Docetaxel as Neoadjuvant Chemotherapy in Primary Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013331-37,0,0,0 2009-013333-24,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,MERCK SERONO SPA,"Multicenter, open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from other injectable DMDs using ReBiSmart to self-inject ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013333-24,0,0,0 2009-013334-24,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,KeyNeurotek Pharma GmbH,"Double-blind placebo-controlled proof of concept study with the µ-receptor agonist KN203 in patients with overactive bladder syndrome Double-blind, randomized, parallel groups prospective phase II-a s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013334-24,0,0,0 2009-013340-36,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,PREVENTION OF REPERFUSION INJURY IN HUMAN LUNG TRANSPLANTATION FOR CYSTIC FIBROSIS BY TARGETING IL-8 ACTIVITY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013340-36,0,0,0 2009-013342-92,5,2011-07-04,2011-09-30,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,DAIICHI SANKYO EUROPE GmbH,EFFECTS OF ANGIOTENSIN-RECEPTOR BLOCKADE WITH OLMESARTAN ON CAROTID ATHEROSCLEROSIS IN PATIENTS WITH HYPERTENSION: THE CONFIRMATORY OLMESARTAN PLAQUE REGRESSION STUDY (CONFIRM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013342-92,0,0,0 2009-013342-92,5,2011-07-04,2011-09-30,4,1,0,0,0,0,4,0,0,1,1,0,1,0,1,DAIICHI SANKYO EUROPE GMBH,EFFECTS OF ANGIOTENSIN-RECEPTOR BLOCKADE WITH OLMESARTAN ON CAROTID ATHEROSCLEROSIS IN PATIENTS WITH HYPERTENSION: THE CONFIRMATORY OLMESARTAN PLAQUE REGRESSION STUDY (CONFIRM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013342-92,0,0,0 2009-013344-37,1,2010-10-08,2010-10-08,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-Origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Adult and Elderly s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013344-37,0,0,0 2009-013346-83,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Sanofi Pasteur SA,"Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 3 to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013346-83,0,0,0 2009-013348-35,1,,,0,0,0,0,0,0,3,0,1,1,1,1,0,1,0,University Medical Center Utrecht,(Patho)Physiological aspects of the bile salt-FXR-FGF19-axis: potential consequences in Crohn's disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013348-35,0,0,0 2009-013351-30,1,2017-04-05,2017-04-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsmedizin der Johannes Gutenberg-Universität Mainz,"A phase I/II trail to evaluate the safety, feasibility and efficacy of the addition of temsirolimus (Torisel™) to a regimen of bendamustine and rituximab for the treatment of patients with follicular ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013351-30,0,0,0 2009-013355-29,1,2012-07-05,2012-07-05,1,0,0,1,0,0,1,1,1,1,1,1,0,0,0,Sheffield Children's NHS Foundation Hospital,A multi-stage clinical study to develop a non-invasive Short Synacthen Test (SST) with nasally administered synacthen and salivary cortisol. The validated non-invasive SST will be used to establish no...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013355-29,0,0,0 2009-013378-42,5,2011-10-17,2011-10-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,OM PHARMA,"Double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom drops in children suffering from recurrent respiratory tract infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013378-42,0,0,0 2009-013378-42,5,2011-10-17,2011-10-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,OM PHARMA SA,"Double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom drops in children suffering from recurrent respiratory tract infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013378-42,0,0,0 2009-013391-44,4,2012-05-18,2013-09-05,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,OM PHARMA,"Multicentre, double blind, placebo-controlled, randomised clinical study to assess the efficacy and safety of Doxium® 500 three times daily in patients suffering from chronic venous insufficiency (CVI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013391-44,0,0,0 2009-013391-44,4,2012-05-18,2013-09-05,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,OM PHARMA SA,"Multicentre, double blind, placebo-controlled, randomised clinical study to assess the efficacy and safety of Doxium® 500 three times daily in patients suffering from chronic venous insufficiency (CVI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013391-44,0,0,0 2009-013395-48,4,2011-01-14,2011-02-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Randomised, Double-Blind, Placebo- and Active-Controlled, Incomplete Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Once Daily Treatment of 4 Doses of BI 1744 CL Inhalation ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013395-48,0,0,0 2009-013395-48,4,2011-01-14,2011-02-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Randomised, Double-Blind, Placebo- and Active-Controlled, Incomplete Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Once Daily Treatment of 4 Doses of BI 1744 CL Inhalation ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013395-48,0,0,0 2009-013396-22,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Odense Universitetshospital/Syddansk Universitet,None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013396-22,0,0,0 2009-013397-40,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,maternite régionale de nancy,Intérêt du bloc au triangle de Petit pour la prise en charge de l'analgésie de la chirurgie gynécologique lourde,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013397-40,0,0,0 2009-013398-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Rafael Selgas,ACONDICIONAMIENTO DEL DONANTE CADÁVER MEDIANTE LA ADMINISTRACIÓN DE TIMOGLOBULINA PARA DISMINUIR EL ESTADO PRO-INFLAMATORIO TRAS LA MUERTE CEREBRAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013398-16,0,0,0 2009-013400-31,1,2013-08-30,2013-08-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Southampton,"A phase 2, double-blind, placebo-controlled study of the safety and tolerability of etanercept in patients with Alzheimer’s disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013400-31,0,0,0 2009-013402-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST,INduction chemoThERapy followed by CEtuximab Plus definiTive radiOtheRapy versus radiation plus cisplatin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013402-14,0,0,0 2009-013403-55,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,VU university medical center,Early recognition and optimal treatment of delirium in patients with advanced cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013403-55,0,0,0 2009-013404-32,1,,,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,Groupe Francophone des Myélodysplasies (GFM),A Phase I/II Multicenter Study of IV Clofarabine In Patients with High-Risk Myelodysplastic Syndrome who have failed Therapy with Azacitidine: the NIDEVOL study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013404-32,0,0,0 2009-013406-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Masaryk University,"First Line Therapy of Glioblastoma Multiforme with Surgical Resection, Irradiation Therapy, Temozolomide and Additional Tumour-Lysate Pulsed Dendritic Cell Vaccination. A Feasibility Phase II Study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013406-13,0,0,0 2009-013407-66,9,2015-04-28,2015-06-23,6,1,0,0,0,2,0,0,0,2,0,0,0,0,1,"AVEO Pharmaceuticals, Inc.",A Rollover Protocol to Allow Continued Access to Tivozanib (AV-951) for Subjects Enrolled in Other Tivozanib Protocols Protocollo roll-over per l'accesso continuato a tivozanib (AV-951) per i sogg...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013407-66,1,0,0 2009-013407-66,9,2015-04-28,2015-06-23,6,1,0,0,0,2,0,0,0,2,0,0,0,0,1,"AVEO PHARMACEUTICALS, INC.",A Rollover Protocol to Allow Continued Access to Tivozanib (AV-951) for Subjects Enrolled in Other Tivozanib Protocols Protocollo roll-over per l'accesso continuato a tivozanib (AV-951) per i sogg...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013407-66,1,0,0 2009-013408-30,1,2014-09-26,2014-09-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,Randomised phase II trial of cediranib (AZD2171) vs. placebo in addition to cisplatin / gemcitabine chemotherapy for patients with advanced biliary tract cancers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013408-30,0,0,0 2009-013410-26,1,2017-12-13,2017-12-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,3,ROCHE SAS,"An open-label, randomized, multicenter, phase II, comparative, exploratory study on neoadjuvant treatment with trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus bevacizumab according t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013410-26,0,0,0 2009-013411-36,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Statens Serum Institut,"Immunogenicity and safety of a tetanus, diphtheria and mono component acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as a booster vaccination to a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013411-36,0,0,0 2009-013412-13,3,2010-12-02,2010-12-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,An extension trial comparing safety and efficacy of NN5401 plus meal-time insulin aspart for the remaining meals with insulin detemir plus meal-time insulin aspart in type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013412-13,0,0,0 2009-013420-23,1,2013-03-05,2013-03-05,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Eli Lilly and Company,Neurobiological Correlates of Antidepressant Response After Duloxetine Hydrochloride Treatment in Subjects with Major Depressive Disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013420-23,0,0,0 2009-013421-42,2,2014-09-05,2014-10-09,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Apogenix GmbH,"A phase II, randomized, open-label, multi-centre study of weekly APG101 + reirradiation versus reirradiation in the treatment of patients with first or second progression of glioblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013421-42,0,0,0 2009-013422-17,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,CHU de Bordeaux,Etude de l’efficacité et de la toxicité d’une stratégie d’allogreffe de cellules souches hématopoïétiques à conditionnement atténué dans le lymphome folliculaire en rechute chimiosensible.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013422-17,0,0,0 2009-013423-31,1,2012-07-25,2012-07-25,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,"Medizinische Universität Innsbruck, Universitätsklinik für Innere Medizin I",Phase I/II study of lenalidomide and Cetuximab in patients with advanced solid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013423-31,0,0,0 2009-013425-42,4,2012-11-28,2012-12-28,4,0,0,0,1,0,0,0,0,1,0,0,1,0,2,Atrium Medical Corporation,"A 2x2 Factorial, Randomized, Multicenter, Single-Blind Evaluation of Intracoronary Abciximab Infusion and Aspiration Thrombectomy in Patients Undergoing Percutaneous Coronary Intervention for Anterior...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013425-42,0,0,0 2009-013425-42,4,2012-11-28,2012-12-28,4,0,0,0,1,0,0,0,0,1,0,0,1,0,2,Cardiovascular Research Foundation,"A 2x2 Factorial, Randomized, Multicenter, Single-Blind Evaluation of Intracoronary Abciximab Infusion and Aspiration Thrombectomy in Patients Undergoing Percutaneous Coronary Intervention for Anterior...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013425-42,0,0,0 2009-013426-16,1,2011-10-01,2011-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Southampton,"Management of Irritable Bowel Syndrome in Primary Care: Feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy webs...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013426-16,0,0,0 2009-013429-40,1,2011-10-20,2011-10-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"Randomized, double-blind, placebo-controlled trial to determine the capacity of VAK694 to elicit long term immune tolerance when combined with subcutaneous allergen immunotherapy for the treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013429-40,0,0,0 2009-013431-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU Montpellier,Etude ouverte prospective randomisée sur l’utilisation du Flammacérium® dans les nécroses cutanées ischémiques du pied,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013431-38,0,0,0 2009-013432-20,1,2010-07-30,2010-07-30,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,Charité Campus Mitte,"Intra-individual, randomized comparison of the MRI contrast agents gadobutrol versus gadoterate meglumine in breast MR imaging",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013432-20,0,0,0 2009-013435-38,10,2011-12-16,2012-07-30,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Abbott GmbH & Co. KG,"An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013435-38,0,0,0 2009-013435-38,10,2011-12-16,2012-07-30,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Abbott GmBH & Co.KG,"An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013435-38,0,0,0 2009-013437-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,José Luño Fernandez,Efecto del ácido acetilsalicílico en la prevención primaria del riesgo cardiovascular en paciente con enfermedad renal crónica (Estudio AASER),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013437-21,0,0,0 2009-013438-26,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Karolinska University Hospital,"A multicentre, open label, randomised phase II study with docetaxel (Taxotere®), cisplatin and 5-fluorouracil as induction chemotherapy, combined with hyperfractionated radiotherapy and cetuximab (Er...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013438-26,0,0,0 2009-013441-28,1,2013-04-16,2013-04-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Copenhagen University Hospital, Rigshospitalet","POMEVAR : PreOperative Methylprednisolone in EndoVascular Aortic Repair - a randomized, double-blind, placebocontrolled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013441-28,0,0,0 2009-013442-86,3,2010-12-31,2010-12-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Inc,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of 48 Weeks of GS-9190 in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Previously Untreated Subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013442-86,0,0,0 2009-013455-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,EFFICACY OF ELETTROPORATION COMBINED WITH BLEOMYCIN IN THE TREATMENT OF KELOIDS AND HYPERTROPHIC SCARS: A PILOT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013455-30,0,0,0 2009-013456-76,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Pharmakokinetics and Pharmacodynamics of Acetaminophen( paracetamol i.v) in Neonates,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013456-76,0,0,0 2009-013458-33,1,2010-12-31,2010-12-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Charité Universitätsmedizin Berlin,Modulation of Cytochrome-P450 dependent eicosanoid formation by treatment with omega-3 PUFA (Omacor®),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013458-33,0,0,0 2009-013459-31,8,2014-01-29,2014-01-29,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Amicus Therapeutics, Inc.","A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013459-31,0,0,0 2009-013459-31,8,2014-01-29,2014-01-29,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"AMICUS THERAPEUTICS, INC","A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013459-31,0,0,0 2009-013461-25,1,2014-06-16,2014-06-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"St. George's, University of London",The influence of CYP3A5 and ABCB1 genotype on the pharmacokinetics of twice daily Tacrolimus and Advagraf,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013461-25,0,0,0 2009-013462-25,1,2011-03-28,2011-03-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Greater Glasgow and Clyde Health Board,A dose finding study for ultrasound guided anterior psoas compartment blocks in patients with a fractured neck of femur,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013462-25,0,0,0 2009-013468-37,1,2012-03-01,2012-03-01,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Royal National Hospital for Rheumatic Disease,A short-term open-label single site pilot study evaluating the use of asasantin retard therapy in the management of Raynaud’s phenomenon.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013468-37,0,0,0 2009-013469-25,1,2014-10-17,2014-10-17,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Kuopio University Hospital,"LASKIMOON ANNETUN OKSIKODONIN TEHO, TURVALLISUUS JA PLASMAPITOISUUDET ENSISYNNYTTÄJIEN SYNNYTYSKIVUN HOIDOSSA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013469-25,0,0,0 2009-013470-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU d'Amiens,Place de l’antibiothérapie postopératoire dans la cholécystite aiguë lithiasique. Antibiothérapie postopératoire de courte durée versus absence d’antibiothérapie postopératoire,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013470-41,0,0,0 2009-013472-41,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA,A GOIRC Phase II randomized trial of an oral chemotherapy combination of Capecitabine plus Vinorelbine and their sequential single agent use in Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013472-41,0,0,0 2009-013473-18,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,CHU Clermont-Ferrand,Reconnaissance des émotions et neurones miroirs dans la maladie de Parkinson,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013473-18,0,0,0 2009-013476-53,1,2016-03-31,2016-03-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Nîmes,Evaluation des performances de l’imagerie cérébrale isotopique du métabolisme glucidique en TEP (18F-FDG) et de la perfusion en TEMP (99mTc-ECD) pour le diagnostic de maladie d’Alzheimer au stade prod...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013476-53,0,0,0 2009-013480-18,1,2011-12-21,2011-12-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Evaluation of tissue with low level of oxygene in patients affected by neck and brain cancer by PET/TC with Cu-ATSM (PET-ATSM-1).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013480-18,0,0,0 2009-013481-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sint Maartenskliniek,Pharmacokinetics of high dose Ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013481-10,0,0,0 2009-013482-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hôpitaux Universitaires de Strasbourg,« Rotation ou Changement de biothérapie dans la polyarthrite rhumatoïde en cas d’échec à un anti-TNF »,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013482-26,0,0,0 2009-013483-38,7,2018-04-05,2018-04-05,6,1,0,0,0,2,0,0,0,1,0,0,1,0,1,Celgene Corporation,"A PHASE 2/3 MULTICENTER, RANDOMIZED OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) VERSUS INVESTIGATOR?S CHOICE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013483-38,0,0,0 2009-013484-19,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,OSPEDALE POLICLINICO S. MATTEO,Clinical trial on use of Saquinavir in patients affected by primitive glomerulonephritis associated to resistant nephrotic syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013484-19,0,0,0 2009-013485-23,3,2011-03-31,2011-03-31,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,OM PHARMA,"A Multicentre, Double-blind, Placebo-Controlled, Parallel Group Study of the Effect of Oral Etamsylate (Dicynone®) in Patients with Menorrhagia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013485-23,0,0,0 2009-013498-17,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Cardiologia - Azienda Ospedaliero Universitaria di Modena,IntraCoronary Abciximab with the ClearWay Catheter To Improve Outcomes with Lysis (IC ClearLy) Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013498-17,0,0,0 2009-013499-29,1,2011-11-30,2011-11-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Technische Universität München,"Dosisfindungsstudie für Sugammadex und Neostigmin zur Reversierung einer geringen neuromuskulären Restblockade (train of four ratio 0,2) [Sugammadex and Neostigmine dose finding study for reversal of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013499-29,0,0,0 2009-013504-32,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"A 26-week treatment, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety and tolerability of NVA237 in patients with chronic obstructive pulmonary disease...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013504-32,0,0,0 2009-013504-32,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Novartis Farmaceutica, S.A.","A 26-week treatment, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety and tolerability of NVA237 in patients with chronic obstructive pulmonary disease...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013504-32,0,0,0 2009-013537-22,1,2014-10-04,2014-10-04,1,0,0,0,0,3,3,0,0,1,0,0,1,0,0,Klaus Olkkola,Clinical safety of neostigmine or sugammadex to reverse rocuronium-induced neuromuscular block Rokuronilla aikaansaadun lihasrelaksaation kumoaminen neostigmiinilla tai sugammadeksilla: kliininen turv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013537-22,0,0,0 2009-013538-26,5,2010-12-13,2010-12-13,5,1,0,0,0,0,2,0,2,1,0,0,1,0,1,Amgen Inc,"A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 853 in Subjects with Inadequately Controlled Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013538-26,0,0,0 2009-013538-26,5,2010-12-13,2010-12-13,5,1,0,0,0,0,2,0,2,1,0,0,1,0,1,Amgen Inc.,"A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 853 in Subjects with Inadequately Controlled Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013538-26,0,0,0 2009-013539-39,2,2010-09-27,2010-09-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013539-39,0,0,0 2009-013540-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",The MILES-3 randomized phase III study assessing the efficacy of cisplatin combined with gemcitabine as first-line therapy of elderly patients with advanced non small cell lung cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013540-36,0,0,0 2009-013541-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Brest,Intérêt de l’utilisation d’un inhibiteur de la mTor (everolimus) pour la minimisation des anticalcineurines dans les transplantations rénales de type « old for old » (receveur > 60 ans recevant un gre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013541-28,0,0,0 2009-013543-11,1,2010-07-30,2010-07-30,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,James Cook University Hospital,A comparison of nausea with two routine ways of managing low blood pressure after delivery of the baby during spinal anaesthesia for Caesarean section.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013543-11,0,0,0 2009-013547-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leids Universitair Medisch Centrum,Sodium Bicarbonate for the prevention of Contrast Induced Nephropathy in patients undergoing CTPA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013547-11,0,0,0 2009-013549-27,5,2010-09-22,2010-09-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A.","A randomised double-blind, placebo-controlled, 3 parallel group study investigating the efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013549-27,0,0,0 2009-013549-27,5,2010-09-22,2010-09-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,BOEHRINGER ING.,"A randomised double-blind, placebo-controlled, 3 parallel group study investigating the efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013549-27,0,0,0 2009-013549-27,5,2010-09-22,2010-09-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,,"A randomised double-blind, placebo-controlled, 3 parallel group study investigating the efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013549-27,0,0,0 2009-013549-27,5,2010-09-22,2010-09-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,SCS Boehringer Ingelheim Comm.V,"A randomised double-blind, placebo-controlled, 3 parallel group study investigating the efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013549-27,0,0,0 2009-013549-27,5,2010-09-22,2010-09-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim France,"A randomised double-blind, placebo-controlled, 3 parallel group study investigating the efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013549-27,0,0,0 2009-013552-72,10,2013-05-23,2013-07-16,9,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson’s Disease (Phase 3 Protocol No. P0566...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013552-72,0,0,0 2009-013552-72,10,2013-05-23,2013-07-16,9,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Schering-Plough Research Institute, a division of Schering Corporation","A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson’s Disease (Phase 3 Protocol No. P0566...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013552-72,0,0,0 2009-013552-72,10,2013-05-23,2013-07-16,9,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Schering Corporation, división Schering-Plough Research","A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson’s Disease (Phase 3 Protocol No. P0566...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013552-72,0,0,0 2009-013552-72,10,2013-05-23,2013-07-16,9,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson’s Disease (Phase 3 Protocol No. P0566...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013552-72,0,0,0 2009-013554-32,1,2013-07-18,2013-07-18,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Fundación Progreso y Salud,"ENSAYO CLÍNICO FASE I/II MULTICÉNTRICO, ABIERTO Y ALEATORIZADO PARA EL ESTUDIO DEL USO DE LAS CÉLULAS TRONCALES MESENQUIMALES DE TEJIDO ADIPOSO (CeTMAd) COMO TERAPIA DE REGENERACIÓN CELULAR EN EL SÍND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013554-32,0,0,0 2009-013616-12,3,2011-08-31,2011-09-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Dapoxetine in Men With Premature Ejaculation and Concomitant Erectile Dysfu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013616-12,0,0,0 2009-013618-29,10,2016-02-18,2016-02-18,6,1,1,0,0,0,0,0,0,2,1,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,Open-label safety and tolerability study of dabigatran etexilate mesilate given for 3 days at the end of standard anticoagulant therapy in successive groups of children aged 2 years to less than 12 y...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013618-29,1,1,0 2009-013618-29,10,2016-02-18,2016-02-18,6,1,1,0,0,0,0,0,0,2,1,0,0,0,1,Boehringer Ingelheim France,Open-label safety and tolerability study of dabigatran etexilate mesilate given for 3 days at the end of standard anticoagulant therapy in successive groups of children aged 2 years to less than 12 y...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013618-29,1,1,0 2009-013618-29,10,2016-02-18,2016-02-18,6,1,1,0,0,0,0,0,0,2,1,0,0,0,1,Boehringer Ingelheim (Canada) Ltd/Ltée,Open-label safety and tolerability study of dabigatran etexilate mesilate given for 3 days at the end of standard anticoagulant therapy in successive groups of children aged 2 years to less than 12 y...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013618-29,1,1,0 2009-013618-29,10,2016-02-18,2016-02-18,6,1,1,0,0,0,0,0,0,2,1,0,0,0,1,BOEHRINGER ING.,Open-label safety and tolerability study of dabigatran etexilate mesilate given for 3 days at the end of standard anticoagulant therapy in successive groups of children aged 2 years to less than 12 y...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013618-29,1,1,0 2009-013618-29,10,2016-02-18,2016-02-18,6,1,1,0,0,0,0,0,0,2,1,0,0,0,1,SCS Boehringer Ingelheim Comm.V,Open-label safety and tolerability study of dabigatran etexilate mesilate given for 3 days at the end of standard anticoagulant therapy in successive groups of children aged 2 years to less than 12 y...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013618-29,1,1,0 2009-013618-29,10,2016-02-18,2016-02-18,6,1,1,0,0,0,0,0,0,2,1,0,0,0,1,"Boehringer Ingelheim España, S.A.",Open-label safety and tolerability study of dabigatran etexilate mesilate given for 3 days at the end of standard anticoagulant therapy in successive groups of children aged 2 years to less than 12 y...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013618-29,1,1,0 2009-013618-29,10,2016-02-18,2016-02-18,6,1,1,0,0,0,0,0,0,2,1,0,0,0,1,Boehringer Ingelheim,Open-label safety and tolerability study of dabigatran etexilate mesilate given for 3 days at the end of standard anticoagulant therapy in successive groups of children aged 2 years to less than 12 y...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013618-29,1,1,0 2009-013619-36,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Fundación General de la Universidad de Salamanca,"Estudio, multicéntrico, aleatorizado, doble ciego, fase III de Revlimid (Lenalidomida) versus placebo en pacientes con Síndrome Mielodisplasico de bajo riesgo (IPSS bajo e intermedio-1) con alteración...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013619-36,0,0,0 2009-013620-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA SANITARIA LOCALE BI DI BIELLA,Multicenter randomized open clinical trial for `lock` efficacy assessment of totally implantable vascular access device with saline solution vs heparin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013620-22,0,0,0 2009-013622-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CARDIOLOGIA UNIVERSITARIA - OSPEDALE CLINICIZZATO SS. ANNUNZIATA - VIA DEI VESTINI - 66013 CHIETI,ROSUVASTATIN FOR REDUCTION OF MYOCARDIAL DAMAGE AND SYSTEMIC INFLAMMATION DURING CORONARY ANGIOPLASTY - The REMEDY Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013622-17,0,0,0 2009-013636-20,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Fundación Progreso y Salud,"ENSAYO CLINICO FASE II MULTICENTRICO, ABIERTO Y ALEATORIZADO SOBRE EL USO TERAPEUTICO DE LA INFUSION INTRAARTERIAL DE CÉLULAS MONONUCLEADAS DE MÉDULA ÓSEA AUTÓLOGA EN PACIENTES NO DIABÉTICOS CON ISQUE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013636-20,0,0,0 2009-013638-26,1,2011-08-22,2011-08-22,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,University College London,"A phase I/II study of first line Vorinostat with pemetrexed-cisplatin, in patients with malignant pleural mesothelioma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013638-26,0,0,0 2009-013639-39,2,2011-03-11,2011-03-11,1,1,0,0,1,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Cell-Derived, Inactivated Novel Swine Ori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013639-39,0,0,0 2009-013640-37,3,2011-08-10,2011-08-10,3,1,0,0,1,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Cell-derived, Inactivated Novel Swine Orig...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013640-37,0,0,0 2009-013642-80,1,2013-07-01,2013-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Neurology, Odense University Hospital","Randomised, double-blind, placebo-controlled trial of the effect of the combination of imipramine and pregabalin for the treatment of painful polyneuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013642-80,0,0,0 2009-013643-11,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""",Neuroprotective effects of palmitoylethanolamide in diabetic neuropathy: a pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013643-11,0,0,0 2009-013645-29,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Epsom & St Helier's University Hospital NHS Trust,A Two Phase Prospective Randomized Control Trial of Infiltrated Periarticular Multimodal Analgesia following Primary Total Hip Replacement,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013645-29,0,0,0 2009-013647-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,National Institute on Drug Abuse (NIDA),Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013647-10,0,0,0 2009-013648-35,8,2013-08-08,2014-06-06,7,1,0,0,0,0,2,2,0,2,0,0,0,0,0,PENTA FOUNDATION,"A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013648-35,1,0,0 2009-013648-35,8,2013-08-08,2014-06-06,7,1,0,0,0,0,2,2,0,2,0,0,0,0,0,Fundación Penta,"A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013648-35,1,0,0 2009-013648-35,8,2013-08-08,2014-06-06,7,1,0,0,0,0,2,2,0,2,0,0,0,0,0,PENTA Foundation,"A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013648-35,1,0,0 2009-013648-35,8,2013-08-08,2014-06-06,7,1,0,0,0,0,2,2,0,2,0,0,0,0,0,"Medical Research Council, Clinical Trials Unit","A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013648-35,1,0,0 2009-013648-35,8,2013-08-08,2014-06-06,7,1,0,0,0,0,2,2,0,2,0,0,0,0,0,Paediatric European Network for Treatment of AIDS (PENTA) Foundation,"A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013648-35,1,0,0 2009-013648-35,8,2013-08-08,2014-06-06,7,1,0,0,0,0,2,2,0,2,0,0,0,0,0,Medical Research Council,"A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antiretroviral t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013648-35,1,0,0 2009-013651-29,4,2017-11-28,2017-11-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,0,AGMT,"MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation alone in Patients with Chronic Lymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013651-29,0,0,0 2009-013652-69,6,2012-10-16,2012-10-23,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Phase 2a/2b study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013652-69,0,0,0 2009-013656-77,1,,,0,1,0,0,1,1,3,0,0,0,0,0,0,0,0,Nice University Hospital,Traitment of recessive nonbullous congenital ichthyosis with topic Epigallocatechin.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013656-77,0,0,0 2009-013657-14,1,2010-06-22,2010-06-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Randomized, Open label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013657-14,0,0,0 2009-013660-39,1,,,0,0,0,1,0,1,1,1,0,0,0,0,0,0,1,Erempharma SAS,Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré par Aeroneb® Idehaler® et Tobi® 300mg/5ml administré par Pari LC Plus ®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013660-39,0,0,0 2009-013662-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,PROSPECTIVE EVALUATION OF SERUM MALDI TOF MS PROTEOMIC PROFILE PREDICTIVE OF OUTCOME IN PATIENTS WITH GLIOBLASTOMA MULTIFORME TREATED WITH STANDARD TREATMENT STRATIFIED ACCORDING TO MGMT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013662-33,0,0,0 2009-013665-26,2,2011-05-10,2011-05-10,2,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Novartis Pharma,"A double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study to evaluate the efficacy, safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administrati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013665-26,0,0,0 2009-013665-26,2,2011-05-10,2011-05-10,2,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Novartis Pharma Services AG,"A double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study to evaluate the efficacy, safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administrati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013665-26,0,0,0 2009-013667-19,5,2013-08-14,2013-08-14,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate AFQ056 in adult patients with Fragile X Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013667-19,0,0,0 2009-013667-19,5,2013-08-14,2013-08-14,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate AFQ056 in adult patients with Fragile X Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013667-19,0,0,0 2009-013667-19,5,2013-08-14,2013-08-14,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate AFQ056 in adult patients with Fragile X Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013667-19,0,0,0 2009-013668-38,5,2012-05-09,2012-05-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A phase IIb, randomised, double-blind, placebo-controlled, parallel group, safety and efficacy study of BI 10773 (10 mg and 25 mg) administered orally, once daily over 78 weeks in type 2 diabetic pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013668-38,0,0,0 2009-013668-38,5,2012-05-09,2012-05-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Danmark A/S,"A phase IIb, randomised, double-blind, placebo-controlled, parallel group, safety and efficacy study of BI 10773 (10 mg and 25 mg) administered orally, once daily over 78 weeks in type 2 diabetic pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013668-38,0,0,0 2009-013668-38,5,2012-05-09,2012-05-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A phase IIb, randomised, double-blind, placebo-controlled, parallel group, safety and efficacy study of BI 10773 (10 mg and 25 mg) administered orally, once daily over 78 weeks in type 2 diabetic pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013668-38,0,0,0 2009-013668-38,5,2012-05-09,2012-05-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim, Lda","A phase IIb, randomised, double-blind, placebo-controlled, parallel group, safety and efficacy study of BI 10773 (10 mg and 25 mg) administered orally, once daily over 78 weeks in type 2 diabetic pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013668-38,0,0,0 2009-013668-38,5,2012-05-09,2012-05-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd,"A phase IIb, randomised, double-blind, placebo-controlled, parallel group, safety and efficacy study of BI 10773 (10 mg and 25 mg) administered orally, once daily over 78 weeks in type 2 diabetic pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013668-38,0,0,0 2009-013669-25,1,2010-05-18,2010-05-18,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Aegera Therapeutics Inc.,An Open-Label Randomized Phase 2 Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with High-dose Cytarabine and Idarubicin in AML Following Failure of a Sing...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013669-25,0,0,0 2009-013670-41,2,2010-10-07,2010-10-07,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Synosia Therapeutics AG,"A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Two-arm Safety and Efficacy Study of SYN118 as Adjunctive Therapy in Subjects with Parkinson‟s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013670-41,0,0,0 2009-013671-21,3,2011-04-01,2011-04-01,1,1,0,0,1,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Egg-Derived, Inactivated Novel Swine Orig...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013671-21,0,0,0 2009-013672-45,3,2011-07-01,2011-07-01,3,1,0,0,1,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and non-Adjuvanted Egg-derived, Inactivated Novel Swine Or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013672-45,0,0,0 2009-013679-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,STOP SIDA,étude cas-témoins comparant l'efficacité d’une combinaison thérapeutique contenant l'inhibiteur de l'intégrase raltégravir (400 mg x 2) ou une combinaison thérapeutique ne contenant pas le raltégravir...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013679-23,0,0,0 2009-013680-19,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"Phase II, Open, Monocenter Study to investigate the efficacy of Propionyl-L-carnitine (ST 261) Colon Release Tablets in Patients Affected by Inflammatory Bowel Disease (IBD) under Oral Stable Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013680-19,0,0,0 2009-013681-92,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA` DI NOVARA,PRevEntion of cardiac and Vascular pEriprocedural complications in patients undergoiNg coronary angiography or angioplasTy: IntraCoronary Adenosine administration to prevent peRiprocedUral myonecrosiS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013681-92,0,0,0 2009-013683-39,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Fundación para la Investigación Biomédica del Hospital Gregorio Marañón,"?Ensayo clínico de factibilidad, seguridad y eficacia de la terapia de resincronización cardiaca y del transplante intracoronario de células madre mononucleares de medula ósea en pacientes con infarto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013683-39,0,0,0 2009-013684-19,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Uppsala läns landsting,Studie av botulinumtoxiners anhidrotiska (svettreducerande) effekt beroende på använd koncentration.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013684-19,0,0,0 2009-013686-26,1,2011-01-19,2011-01-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, double-blind, placebo controlled, multicenter, 3-period crossover study to compare the effect of indacaterol (150μg o.d.) on inspiratory capacity to placebo in patients with moderate COP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013686-26,0,0,0 2009-013687-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,Effets du système AnaConDa sur les paramètres respiratoires en ventilation mécanique spontanée avec aide inspiratoire: étude physiologique.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013687-39,0,0,0 2009-013689-18,1,2011-06-28,2011-06-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Janssen-Cilag S.A.,ESTUDIO FASE IV PARA LA EVALUACIÓN DEL EFECTO MODULADOR DE LA GALANTAMINA (REMINYL CLP®) SOBRE EL RITMO CIRCADIANO DE PACIENTES CON ENFERMEDAD DE ALZHEIMER MODERADA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013689-18,0,0,0 2009-013690-18,4,2012-01-30,2012-01-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Gilead Sciences Inc,"A Phase 2, Randomized, Open-Label trial of GS-9256 plus GS-9190 alone and in combination with Ribavirin for 28 days in Treatment Naive Subjects with Chronic Genotype 1 Hepatitis C Virus Infection.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013690-18,0,0,0 2009-013691-47,4,2016-11-23,2016-11-23,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Institut de Recherches Internationales Servier,"Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin’s Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013691-47,0,0,0 2009-013691-47,4,2016-11-23,2016-11-23,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Pharmacyclics LLC,"Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin’s Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013691-47,0,0,0 2009-013691-47,4,2016-11-23,2016-11-23,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Pharmacyclics. LLC,"Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin’s Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013691-47,0,0,0 2009-013695-46,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,MERCK SERONO s.a.s,"ETUDE MULTICENTRIQUE, RANDOMISEE EN DOUBLE AVEUGLE VERSUS PLACEBO EVALUANT L’EFFICACITE D’UN TRAITEMENT ADDITIONNEL PAR CHOLECALCIFEROL (VITAMINE D3) CHEZ DES PATIENTS ATTEINTS DE SCLEROSE EN PLAQUES ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013695-46,0,0,0 2009-013701-34,1,2018-01-03,2018-01-03,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Hospital of the University of Munich,"Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo- controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013701-34,0,0,0 2009-013702-14,1,2016-06-10,2016-06-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Hospital of the University of Munich,"Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013702-14,0,0,0 2009-013704-31,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,"Oulu University Hospital, Department of Internal Medicine","PXR-agonisti rifampisiinin vaikutukset glukoosi-, lipidi- ja hormonihomeostaasiin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013704-31,0,0,0 2009-013705-34,1,2011-12-05,2011-12-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A double-blind, placebo controlled, randomised, parallel group, single centre, phase IIa study to investigate the efficacy, tolerability and safety of 8 doses of AZD8848 administered intranasally once...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013705-34,0,0,0 2009-013706-13,1,2014-06-01,2014-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Wilhelminenspital der Stadt Wien,ANALGESIC RESPONSE TO TRANSDERMAL LIDOCAINE IN PATIENTS WITH PAINFUL PERIPHERAL DIABETIC NEUROPATHY UNDERLYING DIFFERENT SENSORY PATTERNS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013706-13,0,0,0 2009-013707-63,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,C.U.B ERASME HOSPITAL,POSTOPERATIVE ANALGESIA USING PREPERITONEAL CONTINUOUS INFUSIONS OF ROPIVACAINE IN PATIENTS UNDERGOING LIVER SURGERY -CONSEQUENCES ON ROPIVACAINE METABOLISM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013707-63,0,0,0 2009-013710-27,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase III, observer-blind, randomized trial to evaluate the safety and immunogenicity of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuvan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013710-27,0,0,0 2009-013713-99,3,2017-06-28,2017-06-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Hospices Civils de Lyon,Does Cyclosporine ImpRove Clinical oUtcome in ST elevation myocardial infarction patients (CIRCUS study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013713-99,0,0,0 2009-013737-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL UNIVERSITARIO SON DURETA. UNIDAD DE INVESTIGACIÓN,"TRATAMIENTO MULTIDISCIPLINARIO DE LA OBESIDAD MÓRBIDA: MEDICAMENTOS, TERAPIA DE COMPORTAMIENTO, APOYO NUTRICIONAL Y ACTIVIDAD FÍSICA. ESTDIO TRAMOMTANA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013737-24,0,0,0 2009-013756-79,1,2011-12-20,2011-12-20,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Anticancer Informing ""Me Gnosi Nika""",VECTIBIX PLUS OXALIPLATIN-BASED ADJUVANT TREATMENT OF RECTAL CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013756-79,0,0,0 2009-013758-33,3,2013-05-02,2013-05-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma S.A.,"MULTICENTER STUDY WITH A 16-WEEK DOUBLE-BLIND, PLACEBO-CONTROLLED (DURING THE INITIAL 2 WEEKS) RANDOMIZED PERIOD, FOLLOWED BY A 24-WEEK OPEN LABEL EXTENSION TO ASSESS MAGNETIC RESONANCE IMAGE-VERIFIED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013758-33,0,0,0 2009-013759-32,2,2010-06-23,2010-06-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED, 3 WAY CROSS-OVER STUDY TO EVALUATE THE EFFECT ON TROUGH FEV1 AFTER 4 WEEKS TREATMENT WITH CHF 5188 pMDI QD (FIXED COMBINATION BUDESONIDE / CARMOTEROL) IN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013759-32,0,0,0 2009-013762-63,4,2013-05-27,2013-07-30,3,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Prosensa Therapeutics B.V,"A phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous and intravenous doses of PRO044 in patients with Duchen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013762-63,0,0,0 2009-013762-63,4,2013-05-27,2013-07-30,3,1,0,1,0,1,1,0,0,1,0,0,0,0,1,PROSENSA THERAPEUTICS BV,"A phase I/IIa, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous and intravenous doses of PRO044 in patients with Duchen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013762-63,0,0,0 2009-013763-19,1,,,0,1,0,0,1,0,3,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"Multicenter, randomized, blinded, placebo controlled, cross over, single dose study to assess the effect of indacaterol (150 �g) versus tiotropium (18 �g) on Inspiratory Capacity in moderate COPD pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013763-19,0,0,0 2009-013766-78,4,2011-12-13,2012-02-13,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase I/II Trial of BMS-754807 in Combination with Trastuzumab (Herceptin®) in Subjects with Advanced or Metastatic Her-2-positive Breast Cancer Revised Protocol Number 01 (version 2.0, dated 01-J...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013766-78,0,0,0 2009-013777-17,1,2012-03-05,2012-03-05,1,1,0,0,0,0,2,0,0,1,1,1,1,0,3,Central Manchester and Manchester University Children's Hospital NHS Trust.,The effect of pamidronate treatment on bone health in patients with neuromuscular disease undergoing hip surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013777-17,0,0,0 2009-013778-41,2,2012-11-14,2012-11-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Cephalon, Inc.","""Estudio abierto para determinar la dosis máxima tolerada y evaluar la eficacia y seguridad de CEP-18770 en pacientes con mieloma múltiple recidivante y resistente al tratamiento más reciente""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013778-41,0,0,0 2009-013780-19,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,NOVARTIS FARMACÉUTICA S.A,"Estudio multicéntrico, aleatorizado, abierto, de 24 meses de duración, con dos grupos paralelos, para comparar la eficacia de everolimus en la mejora del perfil cardiovascular en el régimen con AMF vs...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013780-19,0,0,0 2009-013783-39,1,2010-11-24,2010-11-24,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline SA,"Estudio fase II, aleatorizado, abierto, multicéntrico para evaluar la seguridad e inmunogenicidad de la vacuna experimental adyuvada de gripe pandémica H1N1 administrada como primovacunación y booste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013783-39,0,0,0 2009-013785-52,1,2010-11-27,2010-11-27,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline S.A.,"Estudio fase III, no aleatorizado, abierto para evaluar la seguridad e inmunogenicidad de la vacuna H1N1 adyuvada con AS03A administrada como primovacunación y booster en sujetos entre 3 y 17 años de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013785-52,0,0,0 2009-013786-25,1,,,0,0,0,0,1,0,4,0,0,3,0,0,0,0,0,Northumbria Healthcare NHS Foundation Trust,Comparison of the effect of Etoricoxib and Diclofenac on early morning activity in RA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013786-25,0,0,0 2009-013787-39,1,2015-12-03,2015-12-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and company,A Phase 2 Study to Evaluate LY2603618 in Combination with Pemetrexed in Patients with Advanced or Metastatic Non-small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013787-39,0,0,0 2009-013788-21,12,2016-09-26,2016-09-26,8,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013788-21,0,0,0 2009-013788-21,12,2016-09-26,2016-09-26,8,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmBH & Co KG,"A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013788-21,0,0,0 2009-013788-21,12,2016-09-26,2016-09-26,8,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013788-21,0,0,0 2009-013788-21,12,2016-09-26,2016-09-26,8,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013788-21,0,0,0 2009-013788-21,12,2016-09-26,2016-09-26,8,1,0,0,0,2,2,0,0,1,0,0,1,0,1,"Unilfarma, Lda.","A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013788-21,0,0,0 2009-013788-21,12,2016-09-26,2016-09-26,8,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013788-21,0,0,0 2009-013788-21,12,2016-09-26,2016-09-26,8,1,0,0,0,2,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013788-21,0,0,0 2009-013788-21,12,2016-09-26,2016-09-26,8,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim España S.A.,"A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013788-21,0,0,0 2009-013788-21,12,2016-09-26,2016-09-26,8,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas AE,"A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013788-21,0,0,0 2009-013788-21,12,2016-09-26,2016-09-26,8,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd,"A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013788-21,0,0,0 2009-013788-21,12,2016-09-26,2016-09-26,8,1,0,0,0,2,2,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013788-21,0,0,0 2009-013789-17,3,2011-07-20,2011-07-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, double...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013789-17,0,0,0 2009-013791-49,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Southampton Universities Hospital Trust,Safety and Efficacy of parenteral KGF in moderate asthma subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013791-49,0,0,0 2009-013792-22,2,2010-06-30,2010-06-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharma A/S,"A Phase 2, proof of concept and dose finding study, investigating treatment efficacy of LEO 29102 cream (2.5 mg/g, 1.0 mg/g, 0.3 mg/g, 0.1 mg/g, 0.03 mg/g), LEO 29102 cream vehicle, and Elidel (Pimecr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013792-22,0,0,0 2009-013795-44,2,2014-03-14,2014-03-31,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"The Kirby Institute (formerly National Centre in HIV Epidemiology and Clinical Research (NCHECR)), University of New Sou","A randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV plus two nucleotide reverse transcriptase inhib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013795-44,0,0,0 2009-013795-44,2,2014-03-14,2014-03-31,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,National Centre in HIV Epidemiology and Clinical Research,"A randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV plus two nucleotide reverse transcriptase inhib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013795-44,0,0,0 2009-013796-22,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Servicio de Neurología. Hospital Universitari de Bellvitge.,Estatus epilépticos refractarios: utilidad de la monitorización de niveles plasmáticos.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013796-22,0,0,0 2009-013798-16,1,2013-09-12,2013-09-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Liverpool and Broadgreen University Hospitals NHS Trust,A comparison of plerixafor/G-CSF with chemotherapy/G-CSF for stem cell transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013798-16,0,0,0 2009-013801-33,1,2013-02-07,2013-02-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Steen W. Henneberg, Børnesmerteenheden, Anæstesi afd. 4013, Juliane Marie Centeret, Rigshospitalet",Nasal administration af sufentanil+ketamin til procedure-relaterede smerter hos børn.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013801-33,0,0,0 2009-013803-70,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Splošna bolnišnica Celje,Modified PCA regimen of remifentanil delivery for labour pain Prilagojeno od porodnice vodeno lajšanje porodne bolečine z remifentanilom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013803-70,0,0,0 2009-013817-93,1,2013-03-31,2013-03-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"North Bristol NHS Trust, Research and Development",Arthroplasty Pain Experience Study (APEX): A randomised controlled trial to determine if local wound infiltration reduces chronic pain after lower limb arthroplasty.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013817-93,0,0,0 2009-013837-92,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase III, open, randomized, trial to evaluate the immunogenicity and safety of a single or two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013837-92,0,0,0 2009-013838-25,10,2016-04-20,2016-04-20,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ImClone LLC,"""Estudio en fase 3 aleatorizado, multicéntrico y abierto de quimioterapia con gemcitabina-cisplatino más IMC-11F8 en comparación con quimioterapia con gemcitabina-cisplatino sola en el tratamiento de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013838-25,1,0,0 2009-013838-25,10,2016-04-20,2016-04-20,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"""Estudio en fase 3 aleatorizado, multicéntrico y abierto de quimioterapia con gemcitabina-cisplatino más IMC-11F8 en comparación con quimioterapia con gemcitabina-cisplatino sola en el tratamiento de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013838-25,1,0,0 2009-013839-37,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,IIL INTERGRUPPO ITALIANO LINFOMI ONLUS,A phase II multi-centre study of MBVD in elderly and/or cardiopathic patients affected by Hodgkin s lymphoma (HL).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013839-37,0,0,0 2009-013841-27,1,2011-08-11,2011-08-11,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,"A Randomized, Double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Multofocl Motor Neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013841-27,0,0,0 2009-013856-61,1,2017-06-30,2017-06-30,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,University Hospital Heidelberg,"A phase III national, multicentre, randomized open-label study with Lenalidomide/Dexamethasone versus Lenalidomide/Dexamethasone and autologous stem cell transplantation followed by Lenalidomide maint...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013856-61,0,0,0 2009-013858-32,1,2011-01-05,2011-01-05,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 6 to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013858-32,0,0,0 2009-013864-37,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Gedeon Richter Plc.,"A randomized, multicenter, double-blind, parallel study to compare the efficacy and safety profile of RGH-507 (tolperisone-containing) gel versus a ketoprofen-containing gel in the treatment of patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013864-37,0,0,0 2009-013869-26,1,2012-02-09,2012-02-09,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Associação para Desenvolvimento da Dermatologia do Hospital de Santa Maria,"""Influence of Remicade (infliximab) in the skin proteome of psoriatic patients""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013869-26,0,0,0 2009-013870-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",Sorafenib in the first line treatment of advanced hepatocellular carcinoma with ChildPugh liver function class B. Multicentre phase 3 randomized trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013870-42,0,0,0 2009-013872-29,1,2012-09-30,2012-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,York Hospitals NHS Foundation Trust,"COLLOID OR CRYSTALLOID FOR GOAL DIRECTED FLUID THERAPY IN PATIENTS UNDERGOING ELECTIVE COLORECTAL SURGERY: A RANDOMISED, DOUBLE-BLIND CONTROLLED TRIAL.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013872-29,0,0,0 2009-013877-16,1,2014-01-09,2014-01-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospitals Bristol NHS Foundation Trust,Oesophageal squamous cell cancer: chemoradiotherapy versus chemotherapy and surgery - a feasibility study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013877-16,0,0,0 2009-013878-40,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Odense University Hospital,Phase II trial of Cetuximab in combination with chemotherapy (Carboplatinum and Navelbine) for patients with platinum-resistant head- and neckcancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013878-40,0,0,0 2009-013881-25,4,2011-04-01,2011-04-01,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12-Week Treatment with ASP1941 in Combina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013881-25,0,0,0 2009-013884-21,3,2011-11-21,2011-11-21,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Enceladus Pharmaceuticals BV,"A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013884-21,0,0,0 2009-013885-14,2,2012-08-09,2012-08-09,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BIOPROJET,"A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson?s disease followed by a 38-Week open-l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013885-14,0,0,0 2009-013886-24,3,2012-08-10,2012-08-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BIOPROJET,"A Randomized, Multicenter, 12-Week, Double-blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson Disease, followed by a 9-mon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013886-24,0,0,0 2009-013889-30,1,2014-10-20,2014-10-20,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Karin Blomgren,"Metronidatsoli ja penisilliini nielupaiseen hoidossa: Satunnaistettu, kaksoissokko, lumekontrolloitu lääketutkimus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013889-30,0,0,0 2009-013890-16,1,2012-11-02,2012-11-02,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,GEDII - Grupo de Estudo da Doença inflamatória Intestinal,Herica - Histological and Endoscopic evaluation of Remission induced by Infliximab in moderately to severely active ulcerative Colitis Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013890-16,0,0,0 2009-013892-23,1,2011-01-30,2011-01-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,”Akut indledning” med Rocuronium-Sugammadex sammenlignet med Suxamethon,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013892-23,0,0,0 2009-013897-42,1,2014-02-28,2014-02-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Southampton University Hospitals NHS Trust R&D department,STOPAH: STeroids Or Pentoxifylline for Alcoholic Hepatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013897-42,0,0,0 2009-013901-33,5,2010-10-07,2011-01-13,3,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013901-33,0,0,0 2009-013901-33,5,2010-10-07,2011-01-13,3,1,0,0,0,1,3,0,0,1,1,1,1,0,1,"Novartis Farmacéutica, S.A.","A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet’s patients with posterior or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013901-33,0,0,0 2009-013904-30,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase II, Open Label Study to Evaluate the Immunogenicity, Tolerability and Safety of a MF59-Adjuvanted, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013904-30,0,0,0 2009-013917-91,1,2011-10-17,2011-10-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AiCuris GmbH & Co. KG,"A randomized, double-blind, placebo controlled trial to evaluate the safety, tolerability and antiviral activity of 12 weeks’ treatment with a new antiviral HCMV drug",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013917-91,0,0,0 2009-013923-43,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,LOFARMA,Studio in doppio cieco controllato con placebo sulla efficacia e tollerabilita' della terapia desensibilizzante con nichel in pazienti affetti da sindrome sistemica da allergia al nichel,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013923-43,0,0,0 2009-013928-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Luis Bujanda Fernández de Piérola,Estudio controlado y randomizado para evaluar la eficacia de la pravastatina en la supervivencia y recidiva del cáncer gastroesofágico avanzado,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013928-23,0,0,0 2009-013929-42,3,2011-09-05,2011-11-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL NV,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JNJ-39588146 in Subjects with Heart Failure ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013929-42,0,0,0 2009-013929-42,3,2011-09-05,2011-11-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JNJ-39588146 in Subjects with Heart Failure ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013929-42,0,0,0 2009-013930-25,1,2011-09-20,2011-09-20,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,"Aarhus University Hospital, Department of Neurology","Randomiseret, dobbelt blindet placebokontrolleret undersøgelse af subkutan immunglobulinbehandling af kronisk inflammatorisk demyeliniserende polyradikuloneuropati (English: A randomized, double-bli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013930-25,0,0,0 2009-013931-39,1,2010-09-23,2010-09-23,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, observer-blind, randomized study to assess the immunogenicity, safety and reactogenicity of a two-dose schedule with GSK Biologicals’ A/California/7/2009 (H1N1)v-like vaccine containing th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013931-39,0,0,0 2009-013935-39,12,2011-06-27,2011-07-01,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,"""Eficacia y seguridad de la administración oral diaria de S06911 (combinación fija de ranelato de estroncio 2g / vitamina D3 1000 UI) en la insuficiencia de vitamina D para el tratamiento de la osteop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013935-39,0,0,0 2009-013935-39,12,2011-06-27,2011-07-01,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Laboratorios Servier SL,"""Eficacia y seguridad de la administración oral diaria de S06911 (combinación fija de ranelato de estroncio 2g / vitamina D3 1000 UI) en la insuficiencia de vitamina D para el tratamiento de la osteop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013935-39,0,0,0 2009-013956-62,1,2012-08-29,2012-08-29,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,University Medical Center of the University Ulm,"Preparation of Neuroplant® 300mg N in film-coated tablets (St. John´s wort, SJW) in the treatment of mild to moderate Major Depressive Disorder (MDD) in adolescents from 12 to 17 years (inclusive): a ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013956-62,0,0,0 2009-013957-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Central Hospital,The effect of levosimendan on blood coagulation after cardiac surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013957-13,0,0,0 2009-013976-38,1,2014-10-28,2014-10-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Charité Berlin, Department of rheumatology",Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013976-38,0,0,0 2009-013976-38,1,2014-10-28,2014-10-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Charité Berlin, department of rheumatology",Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013976-38,0,0,0 2009-014016-35,1,2013-04-03,2013-04-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Afdeling V, Aarhus Sygehus",Jernsubstitution efter øvre mavetarmblødning Undersøgelse af effekten af jernbehandling peroralt (Ferro Duretter® ) eller Intravenøst (Ferinject®) i 3 måneder efter udskrivelse versus ingen jernbehan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014016-35,0,0,0 2009-014036-37,3,2010-06-24,2010-11-04,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Allergopharma Joachim Ganzer KG,A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of safety and efficacy of a specific immunotherapy with an aluminium hydroxide adsorbed allergoid preparation of ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014036-37,0,0,0 2009-014037-25,6,2014-10-21,2015-10-21,6,1,0,0,0,2,2,0,0,1,1,0,1,0,0,OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA,Bortezomib (Velcade): A feasibility and phase II study in childhood relapsed acute lymphoblastic leukemia Bortezomib (Velcade): Studio di fattibilita' e di fase II nella recidiva di leucemia lin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014037-25,0,0,0 2009-014037-25,6,2014-10-21,2015-10-21,6,1,0,0,0,2,2,0,0,1,1,0,1,0,0,Erasmus MC,Bortezomib (Velcade): A feasibility and phase II study in childhood relapsed acute lymphoblastic leukemia Bortezomib (Velcade): Studio di fattibilita' e di fase II nella recidiva di leucemia lin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014037-25,0,0,0 2009-014037-25,6,2014-10-21,2015-10-21,6,1,0,0,0,2,2,0,0,1,1,0,1,0,0,University Hospital Ghent,Bortezomib (Velcade): A feasibility and phase II study in childhood relapsed acute lymphoblastic leukemia Bortezomib (Velcade): Studio di fattibilita' e di fase II nella recidiva di leucemia lin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014037-25,0,0,0 2009-014038-11,4,2010-12-10,2010-12-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, 2-period, cross-over study to assess the efficacy and safety of differing doses of NVA237 administered either once daily or twice daily, in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014038-11,0,0,0 2009-014038-11,4,2010-12-10,2010-12-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, 2-period, cross-over study to assess the efficacy and safety of differing doses of NVA237 administered either once daily or twice daily, in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014038-11,0,0,0 2009-014038-11,4,2010-12-10,2010-12-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S. A,"A randomized, double-blind, placebo-controlled, 2-period, cross-over study to assess the efficacy and safety of differing doses of NVA237 administered either once daily or twice daily, in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014038-11,0,0,0 2009-014040-11,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,University of Regensburg,"Multimodality treatment including pre- and postoperative systemic chemotherapy plus cetuximab, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with perito...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014040-11,0,0,0 2009-014041-81,1,2015-05-31,2015-05-31,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,GOIM GRUPPO ONCOLOGICO MERIDIONALE,Optimal strategy in K-ras wild type metastatic colorectal cancer patients: cetuximab plus FOLFIRI followed by FOLFOX+/- cetuximab (GOIM multicenter program),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014041-81,0,0,0 2009-014042-28,1,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,0,"Imperial College, London",What duration of intravenous antibiotic therapy should be used in the treatment of infective exacerbations of cystic fibrosis in patients chronically colonised with Pseudomonas aeruginosa?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014042-28,0,0,0 2009-014045-92,5,2011-08-30,2011-09-01,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder. An 8-week randomised, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014045-92,0,0,0 2009-014049-10,1,2010-07-12,2010-07-12,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Institut de Recherche Pierre Fabre,Exploratory study of besipirdine efficacy and safety in male patients with persistent stress urinary incontinence after radical prostatectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014049-10,0,0,0 2009-014050-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hopital Erasme - Chest service,Conversion from a twice-daily tacrolimus (tac) regimen to a once-daily tacorlimus exended-release formulation (TacXL) regimen : Pharamcokinetic studies in stable cystic fibrosis (CF) and non-CF patien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014050-15,0,0,0 2009-014054-14,1,2012-02-03,2012-02-03,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Guys' and St Thomas' NHS Foundation Trust, Joint Clinical Trials Office",Comparison of the Safety of Intracameral Levofloxacin to intracameral Cefuroxime for the prevention of endophthalmitis in cataract surgery (SILC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014054-14,0,0,0 2009-014056-30,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,CHU Clermont-Ferrand,Reconnaissance des expressons faciales émotionnelles chez les patients présentant un épisode dépressif magnétique transcranienne répétée du cortex préfrontal dorsolatéral droit à basse fréquence et/ou...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014056-30,0,0,0 2009-014076-22,6,2011-05-10,2011-05-10,4,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Fresenius Biotech GmbH,"Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014076-22,1,0,0 2009-014076-22,6,2011-05-10,2011-05-10,4,0,0,0,0,1,2,0,0,2,0,0,0,0,1,FRESENIUS BIOTECH GMBH,"Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014076-22,1,0,0 2009-014096-46,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Essai thérapeutique de phase IIa ouvert, multicentrique, évaluant l'intérêt du Pazopanib dans les dermatofibrosarcomes de Darier-ferrand (DFSP) inopérables ou localement avancés (intervention mutilant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014096-46,0,0,0 2009-014136-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Washington,"A pilot study on the safety and efficacy of haemopoietic stem cell mobilization (CD34+ cells) with MOZOBIL ± G-CSF, in adult patients diagnosed with beta-thalassaemia major.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014136-37,0,0,0 2009-014137-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Unita` Operativa di Endocrinologia e Malattie del Metabolismo,"Monitoring of endothelial dysfunction during chronic administration of vardenafil in patients with type 2 diabetes mellitus: A longitudinal, randomised, placebo-controlled, double blind, phase II b, c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014137-25,0,0,0 2009-014176-22,16,2013-02-18,2013-02-18,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly,A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention (PCI) Or as Pre-treatment At the Time of Diagnosis in Patients with Non-ST-Elevation Myocardial Infarction (NSTEMI) - The ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014176-22,0,0,0 2009-014176-22,16,2013-02-18,2013-02-18,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention (PCI) Or as Pre-treatment At the Time of Diagnosis in Patients with Non-ST-Elevation Myocardial Infarction (NSTEMI) - The ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014176-22,0,0,0 2009-014176-22,16,2013-02-18,2013-02-18,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly & Company,A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention (PCI) Or as Pre-treatment At the Time of Diagnosis in Patients with Non-ST-Elevation Myocardial Infarction (NSTEMI) - The ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014176-22,0,0,0 2009-014216-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA SANITARIA LOCALE 4 DI TORINO,"REYAGEN study. Optimization of unboosted atazanavir dosing, when associated with tenofovir, guided by pharmacogenetics profile of HIV-patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014216-35,0,0,0 2009-014242-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CONSORCI MAR PARC DE SALUT BARCELONA,"Estudio en fase IV, multicéntrico, doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y seguridad de la administración por vía intravenosa de dosis intermitentes de levosimen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014242-28,0,0,0 2009-014246-29,4,2011-09-13,2011-12-12,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Lung Rx Inc,"A 12-week, double-blind, international, multicenter, dose-response study of the safety and efficacy of Beraprost Sodium Modified Release (BPS-MR) in patients with pulmonary arterial hypertension (PAH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014246-29,0,0,0 2009-014246-29,4,2011-09-13,2011-12-12,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Lung Rx,"A 12-week, double-blind, international, multicenter, dose-response study of the safety and efficacy of Beraprost Sodium Modified Release (BPS-MR) in patients with pulmonary arterial hypertension (PAH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014246-29,0,0,0 2009-014249-10,4,2015-11-23,2015-11-23,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014249-10,0,0,0 2009-014249-10,4,2015-11-23,2015-11-23,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GlaxoSmithkline Research & Development Ltd,A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014249-10,0,0,0 2009-014256-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hôpital Universitaire Des Enfants Reine Fabiola,Une analgésie de choix pour l'intubation des nouveau-nés : Etude multicentrique randomisée comparant le rémifentanil à l'association morphine-midazolam,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014256-30,0,0,0 2009-014260-19,1,2013-07-03,2013-07-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Bristol NHS Foundation Trust,A feasibility study of adding xenon to cooling therapy in babies at high risk of brain injury following poor condition at birth,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014260-19,0,0,0 2009-014263-40,1,2010-10-13,2010-10-13,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,Penwest Pharmaceuticals Co.,"A Phase 2a, Double Blind, Randomized, Placebo-controlled, 28 day, Two-arm, Parallel Group Study of A0001 in Patients with the A3243G Mitochondrial DNA Point Mutation and Evidence of Impaired Mitochond...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014263-40,0,0,0 2009-014264-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Clinique Mutualiste Chirurgicale,Prospective multicentric evaluation of a bladder preservation strategy using a combination of neoadjuvant chemotherapy with intensified MVAC (Méthotrexate + vinblastine + adriamicine + Cisplatine) and...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014264-19,0,0,0 2009-014268-20,1,,,0,0,0,0,0,0,4,0,1,1,1,1,0,1,0,Erasmus MC,VZV vaccination to prevent herpes zoster after transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014268-20,0,0,0 2009-014269-25,4,2020-08-28,2020-08-28,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street New York, NY 10017",PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014269-25,0,0,0 2009-014269-25,4,2020-08-28,2020-08-28,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Inc,PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014269-25,0,0,0 2009-014270-18,5,2011-06-22,2011-06-22,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,"""Eficacia y seguridad de una administración oral diaria de S06911 (combinación fija de ranelato de estroncio 2g / vitamina D3 1000UI) en la deficiencia de vitamina D para el tratamiento de la osteopor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014270-18,0,0,0 2009-014270-18,5,2011-06-22,2011-06-22,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Laboratorios Servier S.L.,"""Eficacia y seguridad de una administración oral diaria de S06911 (combinación fija de ranelato de estroncio 2g / vitamina D3 1000UI) en la deficiencia de vitamina D para el tratamiento de la osteopor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014270-18,0,0,0 2009-014271-41,6,2011-12-22,2012-03-21,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"A multicenter, prospective, randomized, double-blind, placebo-controlled, international study to assess the effects of 2g per day of strontium ranelate versus placebo on the time to fracture healing i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014271-41,0,0,0 2009-014271-41,6,2011-12-22,2012-03-21,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"A multicenter, prospective, randomized, double-blind, placebo-controlled, international study to assess the effects of 2g per day of strontium ranelate versus placebo on the time to fracture healing i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014271-41,0,0,0 2009-014272-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU University Medical Center,Effect of additional treatment with exenatide in patients with an acute myocardial infarction: the EXAMI trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014272-21,0,0,0 2009-014275-53,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"An open, single centre study to evaluate the long-term antibody persistence and immune memory between 16 and 20 years after the primary study HAB-028 (208127/021) in which healthy adults were vaccina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014275-53,0,0,0 2009-014276-22,2,2011-05-11,2011-05-11,2,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Laboratoires Genevrier,"Prospective, randomised, multi-centre, blind-observer, controlled, parallel-group study comparing the efficacy and the safety of DERMAGEN® versus conventionnal treatment in the treatment of diabetic n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014276-22,0,0,0 2009-014279-37,1,2015-11-27,2015-11-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Roche Products Limited,Open-Label study of bevacizumab (Avastin®) and taxane monotherapy for the first-line treatment of patients with advanced triple-negative breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014279-37,0,0,0 2009-014280-38,1,2017-03-31,2017-03-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Nottingham University Hospitals NHS Trust,A randomised controlled trial of standard and low dose Avastin® for Neovascular Macular Degeneration in the East Midlands,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014280-38,0,0,0 2009-014283-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Effect of remifentanil on postoperative cognitive function in patients undergoing major abdominal surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014283-19,0,0,0 2009-014286-20,1,2011-01-25,2011-01-25,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Applied Genetic Technologies Corporation,"A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha 1 Antitrypsin (rAAV1-CB-hAAT) in Patients with Alpha 1 Antitrypsin Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014286-20,0,0,0 2009-014290-40,12,2013-04-27,2013-04-30,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Daiichi Sankyo Development Limited,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP,MULTI-CENTER, MULTI-NATIONAL STUDY FOR THE EVALUATION OF EFFICACY AND SAFETY OF (LMW) HEPARIN/EDOXABAN VERSUS (LMW)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014290-40,0,0,0 2009-014290-40,12,2013-04-27,2013-04-30,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,DAIICHI SANKIO DEVELOPMENT LIMITED,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP,MULTI-CENTER, MULTI-NATIONAL STUDY FOR THE EVALUATION OF EFFICACY AND SAFETY OF (LMW) HEPARIN/EDOXABAN VERSUS (LMW)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014290-40,0,0,0 2009-014292-52,1,2019-10-11,2019-10-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College NHS trust,Tacrolimus vs prednisolone for the treatment of nephrotic syndrome secondary to minimal change disease: A Randomised Control Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014292-52,0,0,0 2009-014293-17,2,2015-02-13,2015-02-13,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Atrium MC Parkstad,Phase II study of cetuximab combined with cisplatin or carboplatin/pemetrexed as first line treatment in patients with malignant pleural mesothelioma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014293-17,1,0,0 2009-014293-17,2,2015-02-13,2015-02-13,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,University Hospital Ghent,Phase II study of cetuximab combined with cisplatin or carboplatin/pemetrexed as first line treatment in patients with malignant pleural mesothelioma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014293-17,1,0,0 2009-014295-21,8,2012-07-27,2012-07-29,7,1,1,0,0,1,1,0,0,2,0,0,0,0,1,"Biogen Idec, Inc.","B-LONG: An Open-label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc fusion (rFIXFc) in the Prevention and Treatment of Ble...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014295-21,1,0,0 2009-014295-21,8,2012-07-27,2012-07-29,7,1,1,0,0,1,1,0,0,2,0,0,0,0,1,"Biogen Idec Inc., 9 Fourth Avenue,Waltham, MA 02451, USA","B-LONG: An Open-label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc fusion (rFIXFc) in the Prevention and Treatment of Ble...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014295-21,1,0,0 2009-014295-21,8,2012-07-27,2012-07-29,7,1,1,0,0,1,1,0,0,2,0,0,0,0,1,Biogen Idec Hemophilia Inc.,"B-LONG: An Open-label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc fusion (rFIXFc) in the Prevention and Treatment of Ble...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014295-21,1,0,0 2009-014295-21,8,2012-07-27,2012-07-29,7,1,1,0,0,1,1,0,0,2,0,0,0,0,1,Biogen Idec Inc.,"B-LONG: An Open-label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc fusion (rFIXFc) in the Prevention and Treatment of Ble...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014295-21,1,0,0 2009-014296-40,8,2011-03-17,2011-05-17,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUATE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014296-40,0,0,0 2009-014296-40,8,2011-03-17,2011-05-17,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUATE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014296-40,0,0,0 2009-014296-40,8,2011-03-17,2011-05-17,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer S.A.,"PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF 2 DOSES OF CP-690,550 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON BACKGROUND METHOTREXATE WITH INADEQUATE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014296-40,0,0,0 2009-014300-55,1,2012-03-02,2012-03-02,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Charité-Universitätsmedizin Berlin,"Phase II study on the combined systemic and intrathecal chemotherapy with methotrexate, ifosfamide and liposomal cytarabine (DepoCyte®) in patients with HER-2/neu-negative breast cancer and leptomenin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014300-55,0,0,0 2009-014301-14,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Farmacologic prevention with Varenicline in heavy smokers undergoing early detection lung cancer screening,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014301-14,0,0,0 2009-014302-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Prophylaxis of hypotension in Caesarean Section: comparison between plasma expander hydroxyethyl starch and isotonic polyelectrolytic balanced solution.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014302-34,0,0,0 2009-014310-94,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dr. Xavier Serra Aracil, Corporació Sanitaria Parc Taulí","Ensayo clínico prospectivo controlado y aleatorizado de no inferioridad del tratamiento del cancer de recto T2-T3s (superficial) N0, M0 mediante quimiorradioterapia preoperatoria y microcirugía endosc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014310-94,0,0,0 2009-014313-27,1,2009-12-15,2009-12-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Lluita contra la SIDA,ESTUDIO PILOTO PARA COMPARAR LOS PARÁMETROS FARMACOCINÉTICOS EN PLASMA E INTRACELULARES DE RALTEGRAVIR ADMINISTRADO UNA VEZ AL DÍA EN PACIENTES ADULTOS INFECTADOS POR EL VIH.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014313-27,0,0,0 2009-014315-12,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,CIB/RIVM,Immunogenicity of alternate and reduced immunization schedules using the regular thirteen-valent polysaccharide conjugate vaccine against infection with Streptococcus pneumoniae,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014315-12,0,0,0 2009-014316-35,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Phase IIb pilot study for the evaluation of the safety and the feasibility of treatment simplification to tenofovir+emtricitabina+raltegravir or to lamivudine+abacavir+raltegravir in patients with opt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014316-35,0,0,0 2009-014336-38,1,2013-07-01,2013-07-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsmedizin der Johannes Gutenberg-University Mainz,"A randomized, placebo-controlled phase II trial investigating SUNITINIB versus placebo in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus treated with chemother...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014336-38,0,0,0 2009-014338-79,2,2018-12-17,2018-12-17,1,1,0,0,0,1,2,0,0,1,1,0,1,0,1,NERVIANO MEDICAL SCIENCES,PHASE II STUDY OF ORAL PHA-848125AC IN PATIENTS WITH THYMIC CARCINOMA PREVIOUSLY TREATED WITH CHEMOTHERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014338-79,0,0,0 2009-014338-79,2,2018-12-17,2018-12-17,1,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Nerviano Medical Sciences S.r.l.,PHASE II STUDY OF ORAL PHA-848125AC IN PATIENTS WITH THYMIC CARCINOMA PREVIOUSLY TREATED WITH CHEMOTHERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014338-79,0,0,0 2009-014339-19,4,2011-11-29,2011-11-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ONO Pharmaceutical Co., Ltd.","A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014339-19,0,0,0 2009-014341-84,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"Schwarz Pharma Deutschland GmbH, UCB Group","Non-GI: A multi site, open-label, interventional Pilot study assessing the switch from oral treatment to rotigotine transdermal patch (Neupro) in Parkinson's disease patients with identified gastroint...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014341-84,0,0,0 2009-014343-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Deutsches Herzzentrum,RANDOMIZED TRIAL OF PRASUGREL PLUS BIVALIRUDIN VERSUS CLOPIDOGREL PLUS HEPARIN IN PATIENTS WITH ACUTE STEMI BAVARIAN REPERFUSION ALTERNATIVES EVALUATION [BRAVE-4] TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014343-36,0,0,0 2009-014344-11,1,2014-09-30,2014-09-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London,Neuroprotective effects of hypothermia combined with inhaled xenon following perinatal asphyxia - the TOBY Xe trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014344-11,0,0,0 2009-014346-28,1,2009-12-31,2009-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Erasme hospital,Timing of intubation in a modified rapid sequence induction with remifentanil,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014346-28,0,0,0 2009-014348-12,1,2014-08-15,2014-08-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Mikkel Østergaard,"Helkrops MR, MR af sacroiliacaled og columna totalis og cirkulerende biomarkører hos patienter med spondylartritis i behandling med adalimumab (ASIM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014348-12,0,0,0 2009-014349-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació institut d'investigació Biomèdica de Girona (IdibGi),Reducción de la excreción urinaria de albumina y mejora de la rigidez vascular. Efectos del Olmesartan a dosis media y altas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014349-10,0,0,0 2009-014350-15,1,2015-01-16,2015-01-16,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Tecnimede, Sociedade Técnico-Medicinal, S.A.","Estudo clínico exploratório para avaliar a eficácia e a segurança do Metabol-MG como terapêutica adjuvante em doentes com diabetes mellitus de tipo 2 e hipomagnesemia, sob tratamento com antidiabético...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014350-15,0,0,0 2009-014351-72,2,2011-08-09,2011-08-09,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Serumwerk Bernburg,"A single-center, randomized, single-blind study in parallel groups to evaluate the efficacy and safety of a new intravenous iron HES preparation as compared to intravenous iron dextran (Cosmofer) in a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014351-72,0,0,0 2009-014359-63,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Novartis Pharma Services AG,"A double blind, randomized, parallel study to assess the effects of aliskiren/amlodipine and amlodipine monotherapy on ankle foot volume (AFV) in patients naïve to trial drugs with mild to moderate hy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014359-63,0,0,0 2009-014361-14,1,2013-06-19,2013-06-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,EVALUATION OF FEASIBILITY OF RITUXIMAB BY INTRALESIONAL INJECTION IN PATIENTS WITH GRAVES OPHTALMOPATHY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014361-14,0,0,0 2009-014362-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Marc Van de Velde,Onderhoud van de analgesie tijdens de arbeid na gecombineerde spinale epidurale anesthesie: ”positieve invloed op kwaliteit van analgesie door patient-controlled epidural analgesia met clonidine en ne...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014362-25,0,0,0 2009-014364-18,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,PSORIASIS AND CARDIOVASCULAR DISEASE: IMMUNOMODULATOR ROLE OF THE TREATMENT WITH ROSUVASTATIN IN PATIENTS WITH PSORIASIS OF MILD OR OF MODERATE-SEVERE SKIN DISEASE.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014364-18,0,0,0 2009-014365-12,7,2012-04-04,2014-06-04,6,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F.Hoffmann-La Roche,"An open label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir (Tamiflu) in the treatment of infants 0 to < 12 months of age with confirmed influenza infection.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014365-12,0,0,0 2009-014365-12,7,2012-04-04,2014-06-04,6,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F.Hoffmann-La Roche Ltd.,"An open label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation of oseltamivir (Tamiflu) in the treatment of infants 0 to < 12 months of age with confirmed influenza infection.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014365-12,0,0,0 2009-014368-20,9,2014-01-03,2014-01-04,7,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Janssen Biologics B.V.,"A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects With Moderate to Severe Plaque-type ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014368-20,1,1,0 2009-014368-20,9,2014-01-03,2014-01-04,7,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects With Moderate to Severe Plaque-type ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014368-20,1,1,0 2009-014368-20,9,2014-01-03,2014-01-04,7,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Centocor BV,"A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Adolescent Subjects With Moderate to Severe Plaque-type ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014368-20,1,1,0 2009-014373-41,3,2016-12-14,2017-06-27,3,1,0,0,0,2,2,0,0,1,0,0,1,0,0,NHS Greater Glasgow and Clyde,A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and IM for patients with Chronic Myeloid Leukaemia (CML) in Major Cytogenetic Response (MCyR) with residual disease detecta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014373-41,0,0,0 2009-014373-41,3,2016-12-14,2017-06-27,3,1,0,0,0,2,2,0,0,1,0,0,1,0,0,Clinical Trial Center Aachen,A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and IM for patients with Chronic Myeloid Leukaemia (CML) in Major Cytogenetic Response (MCyR) with residual disease detecta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014373-41,0,0,0 2009-014375-50,1,2011-07-21,2011-07-21,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Yeovil District Hospital,Comparison of the Efficacy of Thoracic Epidural Analgesia and a Local Anaesthetic Wound Infusion Catheter after Laparoscopic Colectomy within the Enhanced Recovery Programme : a pilot RCT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014375-50,0,0,0 2009-014376-22,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,CHIESI,"MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, TWO-ARM PARALLEL GROUPS STUDY DESIGN TO DEMONSTRATE THE EFFICACY AND TOLERABILITY OF A SINGLE DOSE OF BDP SUSPENSION FOR NEBULISATION 1600 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014376-22,0,0,0 2009-014377-40,7,2011-02-04,2011-02-04,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Bayer Healthcare AG,"A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014377-40,0,0,0 2009-014378-16,5,2011-02-04,2011-03-01,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer Healthcare AG,"A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of Low Dose BAY 58-2667 (25 μg/h, 10 μg/h) Given Intravenously to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014378-16,0,0,0 2009-014382-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut d'Anesthésiologie des Alpes Maritimes,ImpImpact du remplissage vasculaire par des solutés équilibrés sur la morbidité des patients de réanimation (IRVASE) : étude randomisée contrôlée monocentrique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014382-12,0,0,0 2009-014383-18,1,2014-03-14,2014-03-14,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Medizinische Hochschule Hannover,"A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014383-18,0,0,0 2009-014387-20,3,2012-04-30,2012-04-30,2,1,1,0,0,0,1,0,0,2,0,0,0,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants (Term and Preterm), Less Than 12 Weeks Chronological Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014387-20,1,1,0 2009-014388-38,1,2012-06-11,2012-06-11,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Neurim Pharmaceuticals Ltd,"A double-blind, parallel group, randomized, placebo controlled study of the efficacy of Circadin® 2mg in alleviating sleep disturbances in patients with mild to moderate Alzheimer Disease (AD) treate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014388-38,0,0,0 2009-014391-22,4,2011-03-24,2011-03-24,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Pharma AG,"An open label, multi-center, randomized, comparative Phase IIIb study to compare efficacy and safety of intravenous (i.v.) daptomycin with that of Semi-synthetic Penicillins (SSPs) or vancomycin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014391-22,0,0,0 2009-014391-22,4,2011-03-24,2011-03-24,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"An open label, multi-center, randomized, comparative Phase IIIb study to compare efficacy and safety of intravenous (i.v.) daptomycin with that of Semi-synthetic Penicillins (SSPs) or vancomycin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014391-22,0,0,0 2009-014391-22,4,2011-03-24,2011-03-24,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open label, multi-center, randomized, comparative Phase IIIb study to compare efficacy and safety of intravenous (i.v.) daptomycin with that of Semi-synthetic Penicillins (SSPs) or vancomycin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014391-22,0,0,0 2009-014392-51,6,2016-02-04,2016-10-10,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A dose blinded extension study to the CBAF312A2201 study to evaluate long-term safety, tolerability and efficacy of BAF312 given orally once daily in patients with relapsing multiple sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014392-51,0,0,0 2009-014392-51,6,2016-02-04,2016-10-10,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A dose blinded extension study to the CBAF312A2201 study to evaluate long-term safety, tolerability and efficacy of BAF312 given orally once daily in patients with relapsing multiple sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014392-51,0,0,0 2009-014392-51,6,2016-02-04,2016-10-10,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,"A dose blinded extension study to the CBAF312A2201 study to evaluate long-term safety, tolerability and efficacy of BAF312 given orally once daily in patients with relapsing multiple sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014392-51,0,0,0 2009-014394-41,1,2013-06-17,2013-06-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hvidovre Hospital,"Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of the hand, and solu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014394-41,0,0,0 2009-014395-21,3,2011-04-16,2011-04-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Randomised, double-blind, placebo-controlled, 3-way cross-over study to determine the effect of 6 weeks treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014395-21,0,0,0 2009-014395-21,3,2011-04-16,2011-04-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer-Inglheim RCV GmbH & Co KG,"Randomised, double-blind, placebo-controlled, 3-way cross-over study to determine the effect of 6 weeks treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014395-21,0,0,0 2009-014395-21,3,2011-04-16,2011-04-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"Randomised, double-blind, placebo-controlled, 3-way cross-over study to determine the effect of 6 weeks treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014395-21,0,0,0 2009-014396-43,1,2012-03-12,2012-03-12,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Medical School Hannover,"A single arm, open-label multicenter phase II trial of temsirolimus in patients with relapsed/ recurrent squamous cell cancer of the Head and Neck (HNSCC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014396-43,0,0,0 2009-014401-13,5,2011-10-21,2011-10-21,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,A.C.R.A.F. S.p.A.,"Efficacy and safety of an alcohol-free formulation of 0.15% benzydamine spray in children with sore throat. Randomized, double blind, placebo-controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014401-13,0,0,0 2009-014401-13,5,2011-10-21,2011-10-21,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,ANGELINI,"Efficacy and safety of an alcohol-free formulation of 0.15% benzydamine spray in children with sore throat. Randomized, double blind, placebo-controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014401-13,0,0,0 2009-014402-33,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,European Commission,"Effects of dronabinol (Marinol(R)) on actual driving, simulated driving and Standardized Field Sobriety Test",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014402-33,0,0,0 2009-014403-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Rôle de l'axe CXCR4/CXCL12 dans le contrôle de l'immunité humorale et de l'auto-immunité chez les patients lupiques après vaccination anti-grippale- GRIPLUP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014403-31,0,0,0 2009-014405-14,1,2013-01-01,2013-01-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik Innere Medizin III, Abt.für Nephrologie u.Dialyse","Vildagliptin in New Onset Diabetes After Transplantation (ViNODAT). A double-blind, randomized, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014405-14,0,0,0 2009-014406-34,3,2015-04-10,2015-04-10,1,0,0,0,0,0,2,0,0,2,0,0,0,0,2,ORVACS,"International, multicenter, randomized, non-comparative controlled study of therapeutic intensification plus immunomodulation in HIV patients with long-term viral suppression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014406-34,1,0,0 2009-014406-34,3,2015-04-10,2015-04-10,1,0,0,0,0,0,2,0,0,2,0,0,0,0,2,KEYRUS BIOPHARMA,"International, multicenter, randomized, non-comparative controlled study of therapeutic intensification plus immunomodulation in HIV patients with long-term viral suppression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014406-34,1,0,0 2009-014407-31,1,2012-12-15,2012-12-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Odense Universitetshospital,"Randomiseret fase II forsøg med irinotecan, cetuximab og everolimus (ICE) sammenlignet med capecitabin og oxaliplatin (CapOx) til patienter med gemcitabin resistent pancreascancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014407-31,0,0,0 2009-014408-71,1,2015-01-26,2015-01-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,UHL NHS Trust,Biomarkers to target antibiotic and systemic corticosteroid therapy in COPD exacerbations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014408-71,0,0,0 2009-014409-15,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AIBILI - Association for Innovation and Biomedical Research on Light and Image,"Prospective, randomized, multicenter, open label phase II study to access efficacy and safety of Lucentis monotherapy (ranibizumab 0.5 mg intravitreal injections) compared with Lucentis plus panretina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014409-15,0,0,0 2009-014410-10,8,2012-03-12,2012-04-13,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CHIESI,"A 12-week, multicentre, multinational, randomized, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster 100/6 (beclomethasone dipropionate 100 �g plus for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014410-10,0,0,0 2009-014410-10,8,2012-03-12,2012-04-13,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici SpA,"A 12-week, multicentre, multinational, randomized, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster 100/6 (beclomethasone dipropionate 100 �g plus for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014410-10,0,0,0 2009-014412-35,2,2011-06-06,2011-06-06,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Aradigm Corporation,"An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Administration of Two Strengths of Ciprofloxacin for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014412-35,1,0,0 2009-014414-98,1,2015-07-30,2015-07-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Department of Orthopaedic Surgery University Hospital Linköping,The impact of local bisphosphonate treatment on prosthetic fixation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014414-98,0,0,0 2009-014415-12,4,2012-03-16,2012-03-23,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refrac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014415-12,0,0,0 2009-014415-12,4,2012-03-16,2012-03-23,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refrac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014415-12,0,0,0 2009-014416-35,3,2011-04-05,2011-04-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer-Inglheim RCV GmbH & Co KG,"Randomised, double-blind, placebo-controlled, 3-way cross-over study to determine the effect of 6 weeks treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5µg] and 10 µg [2 actuations of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014416-35,0,0,0 2009-014416-35,3,2011-04-05,2011-04-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"Randomised, double-blind, placebo-controlled, 3-way cross-over study to determine the effect of 6 weeks treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5µg] and 10 µg [2 actuations of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014416-35,0,0,0 2009-014416-35,3,2011-04-05,2011-04-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Randomised, double-blind, placebo-controlled, 3-way cross-over study to determine the effect of 6 weeks treatment of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5µg] and 10 µg [2 actuations of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014416-35,0,0,0 2009-014417-27,4,2011-01-04,2011-01-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Randomised, double-blind, double-dummy, placebo-controlled, 4-way cross-over study to characterise the 24-hour FEV1-time profiles of BI 1744 CL 5µg and 10µg (oral inhalation, delivered by the Respimat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014417-27,0,0,0 2009-014417-27,4,2011-01-04,2011-01-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"Randomised, double-blind, double-dummy, placebo-controlled, 4-way cross-over study to characterise the 24-hour FEV1-time profiles of BI 1744 CL 5µg and 10µg (oral inhalation, delivered by the Respimat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014417-27,0,0,0 2009-014417-27,4,2011-01-04,2011-01-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Danmark A/S,"Randomised, double-blind, double-dummy, placebo-controlled, 4-way cross-over study to characterise the 24-hour FEV1-time profiles of BI 1744 CL 5µg and 10µg (oral inhalation, delivered by the Respimat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014417-27,0,0,0 2009-014417-27,4,2011-01-04,2011-01-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co. KG,"Randomised, double-blind, double-dummy, placebo-controlled, 4-way cross-over study to characterise the 24-hour FEV1-time profiles of BI 1744 CL 5µg and 10µg (oral inhalation, delivered by the Respimat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014417-27,0,0,0 2009-014418-86,2,2011-01-10,2011-01-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Randomised, double-blind, double-dummy, placebo-controlled, 4-way cross-over study to characterise the 24-hour FEV1-time profiles of BI 1744 CL 5µg and 10µg (oral inhalation, delivered by the Respimat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014418-86,0,0,0 2009-014418-86,2,2011-01-10,2011-01-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"Randomised, double-blind, double-dummy, placebo-controlled, 4-way cross-over study to characterise the 24-hour FEV1-time profiles of BI 1744 CL 5µg and 10µg (oral inhalation, delivered by the Respimat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014418-86,0,0,0 2009-014419-11,2,2010-11-04,2010-11-04,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, observer-blind, randomized, study in adults aged between 18 and 60 years to assess the immunological equivalence of the Quebec-manufactured A/California/7/2009 (H1N1)v-like antigen adjuva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014419-11,0,0,0 2009-014420-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ISTITUTI CLINICI DI PERFEZIONAMENTO DI MILANO,PEDIATRIC INTENSIVE CARE C PROTEIN HEMOSTASIS STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014420-37,0,0,0 2009-014421-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ZAMBON France,ETUDE DE L'EFFICACITE ET DE LA TOLERANCE DE RHINOMAXIL (BECLOMETASONE) DANS LE TRAITEMENT DE LA RHINOSINUSITE INFECTIEUSE AIGUË DE L'ADULTE NE RELEVANT PAS D'UN TRAITEMENT ANTIBIOTIQUE. ETUDE MULTICEN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014421-16,0,0,0 2009-014424-29,7,2011-04-11,2011-04-15,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,Estudio de extensión abierto para pacientes con enfermedad de Alzheimer que hayan completado uno de los dos estudios fase 3 doble ciego con Semagacestat (H6L-MC-LFAN o H6L-MC-LFBC). Open-Label Exten...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014424-29,0,0,0 2009-014430-25,1,2013-02-15,2013-02-15,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Sociedad Andaluza de Enfermedades Infecciosas SAEI,"Ensayo clínico abierto, aleatorizado, para comparar la calidad de vida de los pacientes VIH+ que inician monoterapia con comprimidos de LPV/r vs triple terapia que contengan un IP potenciado",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014430-25,0,0,0 2009-014431-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Andrés Íñiguez Romo,Contribución de la administración precoz de GH a la regeneración y remodelado favorable del miocardio ventricular izquierdo en pacientes con infarto agudo de miocardio,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014431-20,0,0,0 2009-014436-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMCG,"A prospective, open, randomized, single center study comparing the effects of duo therapy with Everolimus and steroids versus triple treatment of low dose calcineurin inhibitor, low-dose MMF and stero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014436-38,0,0,0 2009-014437-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Essai randomisé d'immunonutrition par L-arginine guidée en réanimation non chirurgicale,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014437-24,0,0,0 2009-014440-10,7,2012-01-11,2013-07-23,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck KGaA,"A Phase II, Open-label, 1:1 Randomized, Controlled Trial Exploring the Efficacy of EMD 1201081 in Combination with Cetuximab in Second-Line Cetuximab-Naïve Subjects with Recurrent or Metastatic Squamo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014440-10,0,0,0 2009-014441-93,2,2017-01-18,2017-01-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MEDA Pharma GmbH & Co. KG,"Clinical trial to assess the efficacy of the fixed combination product Tepilta® in the treatment of radiation-induced oesophagitis compared to its active ingredients oxetacaine and antacids, and to p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014441-93,0,0,0 2009-014443-36,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Francophone de Cancérologie Digestive (FFCD),Carcinome hépatocellulaire avancé sur cirrhose Child B : étude de tolérance et d’efficacité du Torisel® (Temsirolimus),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014443-36,0,0,0 2009-014444-11,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS,Functional and morphological retinal changes in diabetic macular edema treated with pegaptanib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014444-11,0,0,0 2009-014445-80,8,2013-05-17,2013-05-17,5,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Clavis Pharma,A Randomised Phase III Study of Elacytarabine vs. Investigator´s Choice in Patients with Late Stage Acute Myeloid Leukaemia Estudio aleatorizado fase III de elacitarabina comparada con la elección de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014445-80,1,0,0 2009-014445-80,8,2013-05-17,2013-05-17,5,0,0,0,0,1,3,0,0,2,0,0,0,0,1,CLAVIS PHARMA ASA,A Randomised Phase III Study of Elacytarabine vs. Investigator´s Choice in Patients with Late Stage Acute Myeloid Leukaemia Estudio aleatorizado fase III de elacitarabina comparada con la elección de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014445-80,1,0,0 2009-014446-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITA` CAMPUS BIOMEDICO,A PHASE II TRANSLATIONAL STUDY INVESTIGATING THE BIOLOGICAL EFFECTS OF THE ZOLEDRONIC ACID AS NEOADJUVANT THERAPY ON INVASIVE PROSTATE CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014446-28,0,0,0 2009-014448-13,1,,,0,1,0,0,1,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase III, randomised, single-blind study to evaluate the immunogenicity and safety of sequential administration of a licensed seasonal trivalent vaccine and the pandemic H1N1 influenza candidate va...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014448-13,0,0,0 2009-014449-96,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase II, observer-blind, randomized trial to evaluate the safety and immunogenicity of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuvant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014449-96,0,0,0 2009-014452-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academisch ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum,"Safety and efficacy of the addition of simvastatin to panitumumab in k-ras mutant advanced or metastatic colorectal cancer patients. A single-arm, multicenter, phase II study using a Simon two stage d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014452-30,0,0,0 2009-014453-32,4,2013-11-26,2013-11-26,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Lung RX,An open-label extension of BPS-MR-PAH-203 in pulmonary arterial hypertension (PAH) patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014453-32,0,0,0 2009-014453-32,4,2013-11-26,2013-11-26,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Lung LLC,An open-label extension of BPS-MR-PAH-203 in pulmonary arterial hypertension (PAH) patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014453-32,0,0,0 2009-014453-32,4,2013-11-26,2013-11-26,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Lung LLC Inc,An open-label extension of BPS-MR-PAH-203 in pulmonary arterial hypertension (PAH) patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014453-32,0,0,0 2009-014455-68,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Haukeland University Hospital, Helse Bergen",A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral tosedostat to standard induction therapy in AML and RAEB ≥ 66 years and ver...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014455-68,0,0,0 2009-014455-68,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,HOVON Foundation,A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral tosedostat to standard induction therapy in AML and RAEB ≥ 66 years and ver...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014455-68,0,0,0 2009-014456-29,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,PHASE II STUDY OF LAPATINIB IN EGFR/HER2NEU POSITIVE ADVANCED CHORDOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014456-29,0,0,0 2009-014457-33,1,2015-09-24,2015-09-24,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,"An Open Label, Longitudinal Study of the Effects of Subcutaneous Acute and Chronic Pasireotide (SOM230) Therapy on Adrenocorticotrophic Hormone and Tumour Volume in Patients with Nelson's Syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014457-33,0,0,0 2009-014462-26,1,2021-11-11,2021-11-11,1,0,0,0,0,1,3,0,0,1,0,0,0,0,0,Ghent University Hospital,"Dutch-Belgian pediatric AML protocol for children with newly diagnosed acute myeloid leukemia, based on the NOPHO-AML 2004 study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014462-26,0,0,0 2009-014463-39,3,,,0,0,0,1,0,0,1,2,0,2,0,0,0,0,1,"Celltrion, Inc.","A Double-blind Randomised, Parallel Phase I/IIb Study to Evaluate Initial Safety and Efficacy, Comparative Pharmacokinetics and Immunogenicity for CT-P6 and Herceptin in Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014463-39,0,0,0 2009-014468-20,1,2013-12-01,2013-12-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik für Chirurgie, Abt.für Allgemeinchirurgie",A prospective comparison of vitamin B12 supplementation after gastric bypass surgery( sublingual vs. intramuscular),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014468-20,0,0,0 2009-014469-19,3,2013-09-05,2014-08-18,3,1,0,0,0,0,0,0,0,1,1,0,1,0,0,Oxford University,Evaluation of Mirtazapine and Folic Acid for Schizophrenia: A Large Simple 2x2 Factorial Trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014469-19,0,0,0 2009-014469-19,3,2013-09-05,2014-08-18,3,1,0,0,0,0,0,0,0,1,1,0,1,0,0,UNIVERSITY OF OXFORD,Evaluation of Mirtazapine and Folic Acid for Schizophrenia: A Large Simple 2x2 Factorial Trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014469-19,0,0,0 2009-014469-19,3,2013-09-05,2014-08-18,3,1,0,0,0,0,0,0,0,1,1,0,1,0,0,University of Oxford,Evaluation of Mirtazapine and Folic Acid for Schizophrenia: A Large Simple 2x2 Factorial Trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014469-19,0,0,0 2009-014476-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dekan of the Medical Faculty of the University Erlangen-Nuremberg; Prof. Dr. Dr. h. c. Jürgen Schüttler,"Chemoradiation following induction chemotherapy in locally advanced, unresectable pancreatic cancer -a randomised phase 3 trial: Chemoradiation following induction chemotherapy compared with chemothe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014476-21,0,0,0 2009-014480-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Luis Fernando López Cortés,"Concentraciones plasmáticas e intracelulares de Raltegravir y Etravirina administrados una vez al día (800 mg y 400 mg, respectivamente) comparado con su dosificación estándard (400 mg y 200 mg/12 h) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014480-39,0,0,0 2009-014481-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE,Treatment of brain metastases (MTSC) by Whole Brain Radiotherapy (WBRT) and temozolomide (TMZ) concomitant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014481-26,0,0,0 2009-014490-41,15,2014-04-27,2014-04-27,12,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"A multicenter, double-blind, placebo-controlled Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension Studio multicentrico, in doppio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014490-41,0,0,0 2009-014490-41,15,2014-04-27,2014-04-27,12,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"A multicenter, double-blind, placebo-controlled Phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension Studio multicentrico, in doppio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014490-41,0,0,0 2009-014491-21,1,2013-06-06,2013-06-06,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Cambridge University Hospitals NHS Trust,Neoadjuvant docetaxel prior to radical prostatectomy for high risk localised prostate cancer. Evaluation of biological and functional imaging surrogates of therapy efficacy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014491-21,0,0,0 2009-014492-46,4,2015-02-13,2015-02-13,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED, TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BIVALENT rLP2086 VACCINE WHEN ADMINISTERED AS A 3-DOSE REGIMEN IN HEALTHY Y...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014492-46,0,0,0 2009-014493-18,7,2012-09-18,2013-05-16,6,1,1,0,1,0,2,0,2,1,0,0,1,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017","A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in He...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014493-18,0,0,0 2009-014493-18,7,2012-09-18,2013-05-16,6,1,1,0,1,0,2,0,2,1,0,0,1,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017 US","A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in He...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014493-18,0,0,0 2009-014493-18,7,2012-09-18,2013-05-16,6,1,1,0,1,0,2,0,2,1,0,0,1,0,1,PFIZER S.L.U.,"A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in He...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014493-18,0,0,0 2009-014493-18,7,2012-09-18,2013-05-16,6,1,1,0,1,0,2,0,2,1,0,0,1,0,1,Pfizer Inc.,"A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in He...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014493-18,0,0,0 2009-014494-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU TOULOUSE,Douleur aiguë modérée en préhospitalier : Etude prospective randomisée en double aveugle comparant le mélange équimolaire oxygène protoxyde d’azote au placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014494-40,0,0,0 2009-014497-18,4,2015-06-17,2015-06-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,Estudio en fase II que evalúa vinorelbina oral como agente único en pacientes con cáncer de mama con receptores hormonales positivos y metástasis óseas y que han recibido tratamiento hormonal previo. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014497-18,0,0,0 2009-014501-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Determination De La Dose Efficace De L-Bupivacaine Pour Rachianesthésie En Chirurgie Proctologique : Étude Comparative Prospective Randomisée En Double Aveugle.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014501-13,0,0,0 2009-014516-35,5,2011-07-04,2011-07-04,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"EFFICACY AND TOLERABILITY OF CHONDROITIN SULPHATE 1000MG, TWICE DAILY IN PATIENTS WITH SYMPTOMATIC KNEE OSTEOARTHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014516-35,0,0,0 2009-014518-83,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Acino Supply AG,"A double blind, two-period cross-over study to compare the analgesic efficacy and tolerability of a new modified release formulation of hydromorphone (Hydromorphone hydrochloride 8 mg, 16 mg, and 24 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014518-83,0,0,0 2009-014522-41,3,2013-07-02,2013-07-02,3,1,0,0,0,0,4,0,0,1,0,0,1,0,2,ALK-Abelló A/S,An interventional trial assessing the tolerability and safety of GRAZAX® in adults with grass pollen allergy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014522-41,0,0,0 2009-014523-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Stichting longgeneeskunde Fryslan,The effect of treatment with high dose vitamin D on airway inflammation in non-atopic asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014523-23,0,0,0 2009-014527-23,1,2011-09-30,2011-09-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"KH der Elisabethinen Linz GmbH, I. Interne Abteilung","Anidulafungin in patients with hematologic malignancies - An open-label, prospective study to evaluate the safety profile at prophylactic and therapeutic dosages",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014527-23,0,0,0 2009-014532-37,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Universitätsklinikum Schleswig-Holstein,"Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014532-37,0,0,0 2009-014534-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""",EFFECT OF ACUTE ADMINISTRATION OF N-ACETYLCYSTEINE ON BLOOD PRESSURE OF PULMONARY ARTERIAL IN PRIMARY PULMONARY HYPERTENSION.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014534-15,0,0,0 2009-014539-20,1,2011-09-21,2011-09-21,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Ostrava,The Position of Outpatient 24-Hour Dual-Probe pH-metry in the Diagnostics of Extraosophageal Reflux,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014539-20,0,0,0 2009-014540-11,1,2010-06-15,2010-06-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK","A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE DOSE, 5-WAY CROSSOVER STUDY ASSESSING THE PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY PROFILES OF ORAL INHALED PF-03635659 IN PATIENTS WITH MODERAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014540-11,0,0,0 2009-014542-29,1,2014-10-09,2014-10-09,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Kari T. Kivistö,"BISOPROLOLIN VAIKUTUS HEMODYNAMIIKKAAN LIEVÄSTI TAI KOHTALAISESTI HYPERTENSIIVISILLÄ MIEHILLÄ: KAKSOISSOKKO, VAIHTOVUOROINEN LUMEKONTROLLOITU TUTKIMUS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014542-29,0,0,0 2009-014543-36,1,2010-03-11,2010-03-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,"A Randomized, Double-Blind, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of GSK573719 Administered Once- and Twice-Daily in Subjects with COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014543-36,0,0,0 2009-014544-11,2,2010-10-28,2010-10-28,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Cephalon Inc,"A 12-Month, open-label Study to evaluate the Safety, Tolerability, and Efficacy of Armodafinil (150 and 250 mg/day) as Treatment for Patients with excessive Sleepiness associated with mild or moderte ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014544-11,0,0,0 2009-014545-83,4,2010-10-28,2011-01-06,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Cephalon Inc.,"A 12-week, randomized, double-blind, placebo-controlled, parallel-group. fixed-dosage study to evaluate the efficacy and safety of armodafinil (50, 150, and 250 mg/day) as treatment for patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014545-83,0,0,0 2009-014548-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""","Evaluation of chemopreventive effect of a galenic preparation, comparable to a food integrator, composed by seleniomethionine, lycopene and polyphenols (green tea epigallocatechingallate and catechins...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014548-13,0,0,0 2009-014550-14,1,2010-02-01,2010-02-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"Dow Pharmaceutical Sciences, Inc on behalf of Coria Laboratories","A single center, randomized, controlled study to determine the irritant potential of topical acne formulations on intact healthy skin on the back following repeated application during a 21-day treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014550-14,0,0,0 2009-014551-80,5,2011-08-09,2011-08-09,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH Co KG,"Randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 6 weeks of oral BI 671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., or placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014551-80,0,0,0 2009-014551-80,5,2011-08-09,2011-08-09,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"Randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 6 weeks of oral BI 671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., or placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014551-80,0,0,0 2009-014551-80,5,2011-08-09,2011-08-09,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"Randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 6 weeks of oral BI 671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., or placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014551-80,0,0,0 2009-014551-80,5,2011-08-09,2011-08-09,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"Randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 6 weeks of oral BI 671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., or placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014551-80,0,0,0 2009-014551-80,5,2011-08-09,2011-08-09,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Randomised, double-blind, double-dummy, placebo-controlled, parallel group study to assess the efficacy and safety of 6 weeks of oral BI 671800 ED 400 mg b.i.d., Montelukast 10 mg q.d., or placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014551-80,0,0,0 2009-014552-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de salut MAR),"Ensayo clínico exploratorio, prospectivo, aleatorizado, comparativo, para determinar la eficacia y seguridad de dos protocolos para hiperestimulación ovárica controlada en mujeres que van a ser tratad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014552-30,0,0,0 2009-014556-29,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST,PHASE II TRIAL OF FOLFOXIRI PLUS PANITUMUMAB AS FIRST-LINE TREATMENT FOR KRAS AND BRAF WILD-TYPE METASTATIC COLORECTAL CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014556-29,0,0,0 2009-014561-77,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AISSM ONLUS,Phase III multicentric open label study to assess the effectiveness of decitabine in the treatment of chronic myelomonocytic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014561-77,0,0,0 2009-014562-26,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Novartis Farmacéuitica S.A,"“Estudio multicéntrico, aleatorizado, abierto de maximización de micofenolato sódico (MFS) versus micofenolato mofetilo (MMF) para minimizar la dosis de tacrolimus en pacientes trasplantados renales e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014562-26,0,0,0 2009-014563-39,9,2016-01-07,2016-01-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,BOEHRINGER ING.,"Ensayo clínico de fase III, aleatorizado, con BIBW 2992 en combinación con paclitaxel semanal frente al tratamiento quimioterápico de elección del investigador, después de la administración de BIBW 29...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014563-39,0,0,0 2009-014563-39,9,2016-01-07,2016-01-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Limited,"Ensayo clínico de fase III, aleatorizado, con BIBW 2992 en combinación con paclitaxel semanal frente al tratamiento quimioterápico de elección del investigador, después de la administración de BIBW 29...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014563-39,0,0,0 2009-014563-39,9,2016-01-07,2016-01-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim France,"Ensayo clínico de fase III, aleatorizado, con BIBW 2992 en combinación con paclitaxel semanal frente al tratamiento quimioterápico de elección del investigador, después de la administración de BIBW 29...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014563-39,0,0,0 2009-014563-39,9,2016-01-07,2016-01-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co. KG,"Ensayo clínico de fase III, aleatorizado, con BIBW 2992 en combinación con paclitaxel semanal frente al tratamiento quimioterápico de elección del investigador, después de la administración de BIBW 29...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014563-39,0,0,0 2009-014563-39,9,2016-01-07,2016-01-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"Ensayo clínico de fase III, aleatorizado, con BIBW 2992 en combinación con paclitaxel semanal frente al tratamiento quimioterápico de elección del investigador, después de la administración de BIBW 29...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014563-39,0,0,0 2009-014563-39,9,2016-01-07,2016-01-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Finland Ky,"Ensayo clínico de fase III, aleatorizado, con BIBW 2992 en combinación con paclitaxel semanal frente al tratamiento quimioterápico de elección del investigador, después de la administración de BIBW 29...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014563-39,0,0,0 2009-014563-39,9,2016-01-07,2016-01-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelhein España S.A.,"Ensayo clínico de fase III, aleatorizado, con BIBW 2992 en combinación con paclitaxel semanal frente al tratamiento quimioterápico de elección del investigador, después de la administración de BIBW 29...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014563-39,0,0,0 2009-014563-39,9,2016-01-07,2016-01-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,SCS Boehringer Ingelheim Comm. V,"Ensayo clínico de fase III, aleatorizado, con BIBW 2992 en combinación con paclitaxel semanal frente al tratamiento quimioterápico de elección del investigador, después de la administración de BIBW 29...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014563-39,0,0,0 2009-014567-39,8,2014-05-12,2014-07-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Peripheral Spondyloarthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014567-39,0,0,0 2009-014567-39,8,2014-05-12,2014-07-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Peripheral Spondyloarthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014567-39,0,0,0 2009-014568-21,1,2013-01-13,2013-01-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Greater Glasgow & Clyde,VALIDATION OF AN EFFECT-SITE TARGETED PROPOFOL INFUSION FOR ANAESTHESIA IN CHILDREN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014568-21,0,0,0 2009-014568-21,1,2013-01-13,2013-01-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Glasgow,VALIDATION OF AN EFFECT-SITE TARGETED PROPOFOL INFUSION FOR ANAESTHESIA IN CHILDREN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014568-21,0,0,0 2009-014571-49,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,The use of systemic propranolol in congenital hemangiomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014571-49,0,0,0 2009-014572-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,The use of topical propranolol in pyogenic granulomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014572-22,0,0,0 2009-014580-39,1,2010-12-21,2010-12-21,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,ALK-Abelló Arzneimittel GmbH,A multicentre randomised Phase II clinical pilot study to compare the pharmacodynamic efficacy and tolerability of the sublingual and the vestibular administration route for SLITonePLUS® Birch,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014580-39,0,0,0 2009-014582-51,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Faculty of Medicine, Technische Universität München",Pilot study - sequential combination therapy using selective immunoglobulin apheresis and omalizumab in patients with severe atopic dermatitis and elevated total IgE levels,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014582-51,0,0,0 2009-014586-75,4,2010-08-18,2010-08-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multinational, Phase IIb Study to Evaluate the Efficacy and Safety of 60 mg AZD9668 Administered Orally Twice Daily to Subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014586-75,0,0,0 2009-014589-24,4,2013-07-22,2014-01-29,3,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Octapharma AG,"Prospective, Open-label, Non-controlled, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NEWGAM) in Primary Immune Thrombocytopenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014589-24,0,0,0 2009-014591-21,11,2011-02-10,2011-03-18,7,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014591-21,0,0,0 2009-014591-21,11,2011-02-10,2011-03-18,7,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Lilly S.A.,A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014591-21,0,0,0 2009-014593-18,1,2012-07-19,2012-07-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,CureTech,"CT-2008-01: Phase II study to evaluate the safety, tolerability and efficacy of FOLFOX + CT-011 versus FOLFOX alone administered intravenously to patients with colorectal adenocarcinoma previously unt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014593-18,0,0,0 2009-014594-40,2,2010-11-17,2010-11-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 12-week, Phase-II, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multi-Centre Study to Assess the Effect of 60 mg AZD9668 Administered Orally Twice Daily on Structural Changes in the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014594-40,0,0,0 2009-014597-17,6,2010-10-04,2011-01-21,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014597-17,0,0,0 2009-014597-17,6,2010-10-04,2011-01-21,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer, S.A.","A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014597-17,0,0,0 2009-014598-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Chimiothérapie par temozolomide-bevacizumab dans les glioblastomes supratentoriels des sujets de 70 ans et plus présentant un état fonctionnel altéré (IK < 70),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014598-42,0,0,0 2009-014600-66,1,2013-01-01,2013-01-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Medical Center Nijmegen,"A multicentre, prospective, randomized open-label pilot study to assess the feasibility and preliminary efficacy of interferon gamma in combination with Anidulafungin for the treatment of candidemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014600-66,0,0,0 2009-014601-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Fertility preservation in patients with breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014601-13,0,0,0 2009-014602-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Intercommunal de Toulon - La Seyne sur Mer,IMPACT D’UNE INTENSIFICATION THERAPEUTIQUE PAR INHIBITEUR D’INTEGRASE +/- INHIBITEUR DE CCR5 SUR LE RESERVOIR LYMPHOÏDE DU VIH-1 CHEZ DES PATIENTS AU STADE CHRONIQUE DE L’INFECTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014602-33,0,0,0 2009-014605-14,3,2010-10-26,2010-10-26,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Phase 4, 8-Week, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily in Outpatients with Major Depressive Disorder and Associated Painful Physic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014605-14,0,0,0 2009-014612-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AIBILI - Association for Innovation and Biomedical Research on Light and Image,"Prospective, multicenter, open-label study to evaluate the safety and efficacy of intravitreal ranibizumab in patients with subfoveal or juxtafoveal choroidal neovascularization (CNV) secondary to oth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014612-34,0,0,0 2009-014616-36,1,2013-05-05,2013-05-05,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Agence nationale de recherches sur le sida et les hépatites virales. ANRS.,"Etude pilote de la pharmacocinétique, de la tolérance et de l’efficacité du raltégravir associé à deux molécules actives parmi les analogues nucléosi(ti)diques et l’enfuvirtide, avant et après transpl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014616-36,0,0,0 2009-014618-80,2,2014-02-05,2014-02-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi center, randomized, double blind, placebo-controlled, study of the safety, tolerability, and the effects on arterial structure and function of ACZ885 in patients with clinically evident athero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014618-80,0,0,0 2009-014619-11,1,2011-02-09,2011-02-09,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Pirkanmaan sairaanhoitopiiri,The effect of dexmedetomidine on reactivity of a propofol-anaesthetized patient,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014619-11,0,0,0 2009-014620-36,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Tampere University Hospital,Electroencephalogram during increasing and decreasing desflurane concentration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014620-36,0,0,0 2009-014637-24,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,0,AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA,"On field immunization with a novel influenza vaccine administered via intradermic route (Intanza): tolerability, safety, immunogenicity and acceptability study in subjects ≥ 60 years and evaluation of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014637-24,0,0,0 2009-014640-11,2,2011-08-15,2011-08-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Activaero GmbH,"A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate Tolerability, Safety and Efficacy of AKITA Inhaled Steroid Suspension for Inhalation (AICS) in Subjects with Asthma Requiring Chronic O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014640-11,0,0,0 2009-014641-88,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,Medizinische Fakultaet der Technischen Universitaet Muenchen,Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in combination with donor lymphocyte infusion (DLI) in patients with CD20 positive...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014641-88,0,0,0 2009-014643-36,1,2011-03-16,2011-03-16,1,1,0,0,0,0,4,0,1,1,1,1,1,0,1,MENARINI Benelux NV/SA,"Effects Of The Administration Of Nebivolol Versus Carvedilol On Microcirculatory Endothelial Function, Arterial Stiffness And Wave Reflection In Healthy Volunteers” (NeCaMic-study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014643-36,0,0,0 2009-014644-11,9,2011-10-19,2011-10-19,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Teva Pharmaceutical Industries Ltd,"A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014644-11,0,0,0 2009-014652-30,1,2013-08-06,2013-08-06,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,PRO APARTS SRL,"Efficacy, safety and pharmacokinetics of SPK-843 in the treatment of pulmonary mycosis.Phase III Open clinical study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014652-30,0,0,0 2009-014654-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Alicia Pareja Ríos,"Ensayo clínico multicéntrico aleatorizado de tres grupos paralelos para estimar la seguridad y eficacia de la Triamcinolona acetónido asociada a láser, el Bevacizumab asociado a láser frente a láser e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014654-15,0,0,0 2009-014656-30,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)",Combination of Atazanavir and Raltegravir as Dual Strategy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014656-30,0,0,0 2009-014657-32,1,2010-02-25,2010-02-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merck & Co., Inc.","""A Phase IIa Randomized, Placebo-Controlled, Parallel Group, Clinical Trial to Study the Efficacy and Safety of MK-2866 in Women with Moderate to Severe Chronic Obstructive Pulmonary Disease Participa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014657-32,0,0,0 2009-014659-59,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,U.O. Terapia Intensiva,MANAGEMENT OF THE PATIENT WITH ACUTE Abdomen abdominal SURGERY UNDER URGENT: Multicentre randomized PILOT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014659-59,0,0,0 2009-014660-19,3,2011-07-11,2016-09-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Ardea Biosciences, Inc.","Estudio Multicéntrico, Aleatorizado, Doble Ciego, Controlado con Placebo, de Combinación, para Evaluar la Seguridad, Eficacia y la Posible Interacción Farmacocinética de RDEA594 y Alopurinol en Pacien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014660-19,0,0,0 2009-014662-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,Phase II comparative study of Myocet plus Cyclophosphamide plus metformin versus Myocet plus Cyclophosphamide in first line treatment of HER2 negative metastatic breast cancer patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014662-26,0,0,0 2009-014666-25,1,2014-04-10,2014-04-10,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,FONDAZIONE FRANCO E PIERA CUTINO,SEQUENTIAL DEFERASIROX-DEFERIPRONE VERSUS DEFERASIROX OR DEFERIPRONE MULTICENTRE RANDOMIZED TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014666-25,0,0,0 2009-014669-13,1,2011-03-16,2011-03-16,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Alexion Pharmaceuticals Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Multi-Center Study of Eculizumab in Patients with Generalized Myasthenia Gravis (gMG) Who Have Moderate to Severe Muscle Weakness Despite Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014669-13,0,0,0 2009-014670-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,H.-Hartziekenhuis Roeselare-Menen vzw,Controlled study on the Relative Pharmacokinetics of Advagraf versus Prograft in Kidney transplant patients with severe Diarrhoea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014670-17,0,0,0 2009-014675-41,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Hospices Civils de Lyon,Efficacité de la Fluoxétine dans la prévention des apnées centrales compliquant les crises d’épilepsie. Etude randomisée en double aveugle contre placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014675-41,0,0,0 2009-014677-41,1,2013-11-05,2013-11-05,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH,"CHAMP – An open-label, randomised, multicentre, phase II clinical study of panitumumab plus pemetrexed and cisplatin (PemCisP) versus PemCis in the first-line treatment of patients with stage IIIB or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014677-41,0,0,0 2009-014681-25,3,2010-11-09,2010-11-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"Pharmacodynamic and clinical assessment of DC 982 GE (2,4 or 6 capsules per day) in patients with chronic venous disorders : randomised, placebo-controlled, dose effect, double blind, parallel group ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014681-25,0,0,0 2009-014681-25,3,2010-11-09,2010-11-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT-IRPF-IDPF,"Pharmacodynamic and clinical assessment of DC 982 GE (2,4 or 6 capsules per day) in patients with chronic venous disorders : randomised, placebo-controlled, dose effect, double blind, parallel group ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014681-25,0,0,0 2009-014688-37,4,2011-01-19,2011-01-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Impax Laboratories, Inc.",A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014688-37,0,0,0 2009-014690-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Saint-Etienne,Comparison of the protective effect of two cardioplegic solutions Custodiol versus St Thomas on the cardiac metabolism assessed by microdialysis in coronary surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014690-41,0,0,0 2009-014691-21,2,2015-04-24,2015-04-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Odense University Hospital,"GAND-emesis A multinational, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and tolerability of palonosetron and dexamethasone plus the neurokinin1-rece...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014691-21,0,0,0 2009-014694-40,1,2012-02-20,2012-02-20,1,0,0,0,0,0,4,0,0,1,0,0,1,0,3,,"A pilot evaluation of the pharmacokinetics, efficacy and safety of switching from efavirenz to maraviroc administered at 600mg then 300mg twice-daily in patients suppressed on an efavirenz-containing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014694-40,0,0,0 2009-014696-52,5,2018-10-08,2018-11-08,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,KV Pharmaceutical Co.,"A PHASE 3B, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF HYDROXYPROGESTERONE CAPROATE INJECTION, 250 MG/ML, VERSUS VEHICLE FOR THE PREVENTION OF PRETERM BIRTH IN WOMEN WITH A PREVIOUS SINGLETON SPO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014696-52,0,0,0 2009-014696-52,5,2018-10-08,2018-11-08,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,AMAG Pharma USA Inc.,"A PHASE 3B, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF HYDROXYPROGESTERONE CAPROATE INJECTION, 250 MG/ML, VERSUS VEHICLE FOR THE PREVENTION OF PRETERM BIRTH IN WOMEN WITH A PREVIOUS SINGLETON SPO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014696-52,0,0,0 2009-014696-52,5,2018-10-08,2018-11-08,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"AMAG Pharma USA, Inc","A PHASE 3B, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF HYDROXYPROGESTERONE CAPROATE INJECTION, 250 MG/ML, VERSUS VEHICLE FOR THE PREVENTION OF PRETERM BIRTH IN WOMEN WITH A PREVIOUS SINGLETON SPO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014696-52,0,0,0 2009-014696-52,5,2018-10-08,2018-11-08,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"HOLOGIC, INC.","A PHASE 3B, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF HYDROXYPROGESTERONE CAPROATE INJECTION, 250 MG/ML, VERSUS VEHICLE FOR THE PREVENTION OF PRETERM BIRTH IN WOMEN WITH A PREVIOUS SINGLETON SPO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014696-52,0,0,0 2009-014696-52,5,2018-10-08,2018-11-08,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Hologic, Inc.","A PHASE 3B, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF HYDROXYPROGESTERONE CAPROATE INJECTION, 250 MG/ML, VERSUS VEHICLE FOR THE PREVENTION OF PRETERM BIRTH IN WOMEN WITH A PREVIOUS SINGLETON SPO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014696-52,0,0,0 2009-014698-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Rennes,Effet de la vaccination du grand prématuré sur les régulations cardio-respiratoires par étude en polysomnographie des variabilités,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014698-41,0,0,0 2009-014699-24,1,2013-03-14,2013-03-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,4SC AG,"A Phase 2 Proof of Concept Study to Evaluate the Efficacy, Safety and Pharmacokinetics of the HDAC Inhibitor 4SC-201 in Patients with Relapsed or Refractory Hodgkin’s Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014699-24,0,0,0 2009-014717-27,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Karolinska Institutet/Södersjukhuset,Betametasone as postoperative pain treatment for knee arthroscopies at a day surgical center,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014717-27,0,0,0 2009-014719-11,1,2011-05-24,2011-05-24,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Oxford,"Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Baxter H1N1 vaccine and GlaxoSmithKline H1N1 vaccine in children 6 months to 12 ye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014719-11,0,0,0 2009-014721-16,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE,Controlled randomized pilot study for characterization and identification of CD34+ stem cells in the splancnic distrect after GCSF stimolation in cirrhotic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014721-16,0,0,0 2009-014722-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HOVON Foundation,Rituximab in Primary Central Nervous system Lymphoma. A randomized HOVON / ALLG intergroup study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014722-42,0,0,0 2009-014724-32,1,2017-03-07,2017-03-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Medical Center Eppendorf,"SAFETY, TOLERABILITY AND MECHANISM OF ACTION OF BOSWELLIC ACIDS (BA) IN MULTIPLE SCLEROSIS (MS) AND CLINICALLY ISOLATED SYNDROME (CIS): A MRI-CONTROLLED, MULTICENTER, BASELINE-TO-TREATMENT, 32-WEEKS, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014724-32,0,0,0 2009-014725-16,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,AIO Studien gGmbH,"Double-blind, placebo-controlled, randomized phase II-study investigating the efficacy of Bevacizumab for symptom control in patients with malignant ascites due to advanced-stage gastrointestinal canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014725-16,0,0,0 2009-014727-23,1,2012-11-15,2012-11-15,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Prof. Ivana Zavaroni,"Multi-center, randomized, open-label, two-parallel arm, intervention trial comparing DPP-IV inhibitor Vildagliptin with Glibenclamide (Glyburide) in achieving and maintaining good blood glucose contro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014727-23,0,0,0 2009-014728-44,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,Martin Luther Universität Halle-Wittenberg,A randomized phase II trial of irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX) versus systemic treatment with intravenous cetuximab and i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014728-44,0,0,0 2009-014729-18,6,2011-06-16,2011-06-16,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck & Co. Inc.,"""A Phase IIb, Randomized, Double-Blind, Placebo- and Active-Controlled, Dose-Range-Finding Study to Evaluate the Effects of MK-5442 on Bone Mineral Density (BMD) in the Treatment of Osteoporosis in Po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014729-18,0,0,0 2009-014729-18,6,2011-06-16,2011-06-16,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","""A Phase IIb, Randomized, Double-Blind, Placebo- and Active-Controlled, Dose-Range-Finding Study to Evaluate the Effects of MK-5442 on Bone Mineral Density (BMD) in the Treatment of Osteoporosis in Po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014729-18,0,0,0 2009-014729-18,6,2011-06-16,2011-06-16,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merc & Co. Inc,"""A Phase IIb, Randomized, Double-Blind, Placebo- and Active-Controlled, Dose-Range-Finding Study to Evaluate the Effects of MK-5442 on Bone Mineral Density (BMD) in the Treatment of Osteoporosis in Po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014729-18,0,0,0 2009-014729-18,6,2011-06-16,2011-06-16,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & dohme Corp. a Subsidiary of Merck & Co., Inc.","""A Phase IIb, Randomized, Double-Blind, Placebo- and Active-Controlled, Dose-Range-Finding Study to Evaluate the Effects of MK-5442 on Bone Mineral Density (BMD) in the Treatment of Osteoporosis in Po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014729-18,0,0,0 2009-014730-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE,SO03-01 - EVALUATION OF THE EFFECT OF N-3 SUPPLEMENTATION ON FUNCTIONAL IMPROVEMENT IN POSTSTROKE PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014730-22,0,0,0 2009-014732-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,SOGUG,"Ensayo clínico fase IV.II para el análisis de los factores moleculares de pronóstico de respuesta y beneficio clínico en pacientes con cáncer renal metastásico o avanzado, tratados con bevacizumab e i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014732-38,0,0,0 2009-014734-16,1,2010-05-13,2010-05-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ","A PHASE 2A RANDOMIZED, DOUBLE-BLINDED, DOUBLE DUMMY, PLACEBO AND ACTIVE CONTROLLED, TWO-WAY CROSS-OVER, FLARE-ENRICHED MULTI-CENTRE CLINICAL TRIAL TO EXAMINE THE PAIN RELIEF PRODUCED BY 2 WEEKS OF DAI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014734-16,0,0,0 2009-014735-20,7,2012-07-27,2012-07-27,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MedImmune Ltd,"A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Efficacy and Safety of CAM-3001 in Subjects with Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014735-20,0,0,0 2009-014737-24,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Medizinische Universität Innsbruck,Vergleichende Studie zur Darstellung der Somatostatinrezeptoren bei Kopf-Hals-Tumoren mit Immunhistochemie und PET (68Ga-DOTA-Tyr3-Octreotid),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014737-24,0,0,0 2009-014739-19,2,2011-01-01,2011-01-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Phase 2 Study of LY2605541 Compared with Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014739-19,0,0,0 2009-014739-19,2,2011-01-01,2011-01-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,A Phase 2 Study of LY2605541 Compared with Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014739-19,0,0,0 2009-014741-89,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier de Toulouse,Recherche de la DE90 d'un bolus de sufentanil pour l'analgésie des soins douloureux de nursing des malades intubés de réanimation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014741-89,0,0,0 2009-014742-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Agence nationale de recherches sur le sida et les hépatites virales ANRS,Essai randomisé multicentrique de phase III évaluant chez des patients en primo-infection VIH-1 l’impact sur les réservoirs (par quantification de l’ADN-VIH-1 dans les PBMC) d’une combinaison comprena...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014742-28,0,0,0 2009-014758-14,1,2010-12-31,2010-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,West Middlesex University Hospital,Does nebulised hypertonic (3%) saline reduce the duration of hospital admission in infants with bronchiolitis?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014758-14,0,0,0 2009-014762-26,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Ardea Biosciences, Inc.","A Phase 2, Multiple-Dose, Pharmacokinetic and Pharmacodynamic Study of RDEA594 in Gout Patients with Hyperuricemia and Gout with Renal Insufficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014762-26,0,0,0 2009-014765-74,1,2010-06-03,2010-06-03,1,1,0,0,0,0,0,0,1,1,0,0,1,0,1,Omninvest Ltd.,Tolerability and Safety Study of Fluval P Monovalent Influenza Vaccine in Children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014765-74,0,0,0 2009-014767-40,3,2011-04-28,2011-06-22,3,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Abbott Biologicals B.V.,"Randomized, Double-Blind, Active-Controlled Trial to Assess the Safety and Immunogenicity of Solvay's Cell-Derived Influenza Vaccine, Including Revaccination, in Elderly subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014767-40,0,0,0 2009-014768-21,1,2013-06-14,2013-06-14,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Dresden Technical University,Treatment of MDS patients with single agent temsirolimus – a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014768-21,0,0,0 2009-014769-16,1,2013-06-20,2013-06-20,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA` GRANDA (A.O. DI RILIEVO NAZIONALE),REWORD-HF REverse WOrsening Renal function in Decompensated Heart Failure Impact of different therapeutic approaches in patients with cardiorenal syndrome in the setting of acute decompensated cong...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014769-16,0,0,0 2009-014770-17,1,2011-04-12,2011-04-12,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,Netherlands Vaccine Institute,New influenza A (H1N1) disease incidence and immunogenicity of the pandemic influenza A (H1N1) vaccine in healthy adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014770-17,0,0,0 2009-014772-22,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,MAASTRO Clinic,Chloroquine as an anti-autophagy drug in small cell lung cancer (SCLC) patients: A phase I trial to be followed by a phase II trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014772-22,0,0,0 2009-014773-40,1,2017-10-06,2017-10-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Institut Paoli-Calmettes,Essai de phase II de preuve du concept : Evaluation de l’activité anti-cellules souches cancéreuses du bevacizumab administré en combinaison à la chimiothérapie néoadjuvante dans les cancers du sein,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014773-40,0,0,0 2009-014774-18,1,2011-03-31,2011-03-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Nottingham,"The effects of balanced and unbalanced crystalloids and colloids on serum biochemistry and visceral blood flow: A two-phase, double-blind, randomised cross-over study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014774-18,0,0,0 2009-014775-42,1,,,0,0,0,0,0,1,3,0,0,1,0,0,0,1,1,CELLERIX S.A.,Estudio prospectivo para la evaluación de la seguridad y eficacia a largo plazo de Cx401 en pacientes que hayan participado en el ensayo clínico FATT2. A prospective study for the assessment of the l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014775-42,0,0,0 2009-014796-51,1,2011-10-31,2011-10-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec Ltd.,"Phase 2a, open-label, randomized, noncomparative study of BIIB021 in combination with exemestane in women with hormone receptor-positive, advanced metatatic breast cancer who have progressed on a nons...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014796-51,0,0,0 2009-014799-23,3,2013-08-28,2013-08-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Philogen S.p.A,A phase II study of intratumoral application of L19IL2 in patients with stage III/IV melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014799-23,0,0,0 2009-014799-23,3,2013-08-28,2013-08-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,PHILOGEN S.P.A.,A phase II study of intratumoral application of L19IL2 in patients with stage III/IV melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014799-23,0,0,0 2009-014803-30,9,2012-11-23,2012-11-23,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,"A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes on Stable Doses of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014803-30,0,0,0 2009-014803-30,9,2012-11-23,2012-11-23,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly & Company - Indianapolis,"A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes on Stable Doses of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014803-30,0,0,0 2009-014803-30,9,2012-11-23,2012-11-23,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes on Stable Doses of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014803-30,0,0,0 2009-014803-30,9,2012-11-23,2012-11-23,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly & Company,"A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes on Stable Doses of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014803-30,0,0,0 2009-014807-30,1,2010-06-03,2010-06-03,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,Omninvest Ltd.,Tolerability and Immunogenicity Study of Fluval P Monovalent Influenza Vaccine in Children and Adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014807-30,0,0,0 2009-014810-87,1,,,0,1,0,0,0,0,2,0,1,1,1,1,0,1,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Effect of Memantine 20 mg (Ebixa) and Donepezil 5 mg (Aricept) on motor cortex plasticity induced by paired associative stimulation using transcranial magnetic stimulation (TMS) in patients suffering ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014810-87,0,0,0 2009-014811-11,4,2012-06-11,2012-06-11,2,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Multicenter, Double-Blind, Active-Controlled, Flexible-Dose, Parallel-Group Study of the Efficacy and Safety of Prolonged Release Paliperidone for the Treatment of Symptoms of Schizophre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014811-11,1,1,0 2009-014815-11,1,2010-12-11,2010-12-11,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Eisai Limited,"A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects with Psoriasis Vulgaris",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014815-11,0,0,0 2009-014816-37,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,NAMED SRL,"Open prospective, uncontrolled pilot study to assess the tolerability and efficacy of Lymdiaral injektopas (Pascoe-Named) in the treatment of pannicolopatia-edema-fibrosclerotic (PEFS) and venous-ly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014816-37,0,0,0 2009-014821-17,1,2017-05-01,2017-05-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Herlev Hospital,Intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tumour in combination with trastuzumab (Herceptin®) in pati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014821-17,0,0,0 2009-014823-22,1,2013-05-06,2013-05-06,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,AZIENDA USL DI FORLI`,Second biopsy of axillary sentinel node in the local recurrence of breast cancer after mastectomy and first negative sentinel node. Studio LiSeR - M,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014823-22,0,0,0 2009-014824-40,1,2009-11-12,2009-11-12,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Arana Therapeutics Ltd,"An open label follow on study to evaluate the long-term safety, tolerability and efficacy of ART621 following fortnightly administration for 48 weeks in patients with rheumatoid arthritis concomitantl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014824-40,0,0,0 2009-014825-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude prospective multicentrique ouverte évaluant l'efficacité immunologique et la tolérance de la vaccination grippale chez des patients suivis pour une maladie inflammatoire chronique intestinale( M...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014825-18,0,0,0 2009-014827-21,1,2015-08-05,2015-08-05,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Derby Hospitals NHS Foundation Trust,A single centre double blind randomised controlled trial investigating the use of dexamethasone in the treatment of acute tonsillitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014827-21,0,0,0 2009-014827-21,1,2015-08-05,2015-08-05,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Derby Hospitals NHS Foundations Trust,A single centre double blind randomised controlled trial investigating the use of dexamethasone in the treatment of acute tonsillitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014827-21,0,0,0 2009-014830-10,1,2011-11-15,2011-11-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik Innere Medizin III, Abt.für Nephrologie u.Dialyse",Glucose Control in Pre-Diabetic Renal Transplant Patients: Efficacy and Safety of Vildagliptin and Pioglitazone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014830-10,0,0,0 2009-014831-18,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,RUNMC,Short term statin treatment and endothelial dysfunction due to ischemia and reperfusion injury,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014831-18,0,0,0 2009-014832-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Analgésie par Bloc Paravertébral après Vidéothoracoscopie. Etude comparative : Ropivacaïne versus Ropivacaïne et Sufentanil,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014832-38,0,0,0 2009-014833-26,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO EUROPEO DI ONCOLOGIA,"Phase IIB Randomized, Placebo Controlled Trial of Pioglitazone for Oral Premalignant Lesions. An Inter-Consortium Collaborative Study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014833-26,0,0,0 2009-014834-22,7,2010-10-27,2011-02-24,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with activ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014834-22,0,0,0 2009-014834-22,7,2010-10-27,2011-02-24,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with activ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014834-22,0,0,0 2009-014834-22,7,2010-10-27,2011-02-24,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with activ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014834-22,0,0,0 2009-014835-19,4,2011-03-28,2011-06-27,3,1,0,0,0,2,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 24-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppressio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014835-19,0,0,0 2009-014835-19,4,2011-03-28,2011-06-27,3,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 24-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppressio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014835-19,0,0,0 2009-014835-19,4,2011-03-28,2011-06-27,3,1,0,0,0,2,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A 24-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppressio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014835-19,0,0,0 2009-014839-21,2,2013-06-30,2013-06-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"CIS bio international, member of IBA group",Diagnostic value of 18F-choline PET/CT for the detection of systemic prostate cancer disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014839-21,0,0,0 2009-014841-10,7,2012-06-19,2012-07-19,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly & Company - Indianapolis,Impacto de LY2189265 en comparación con el de metformina en el control glucémico en la Diabetes Mellitus de Tipo 2 Inicial (AWARD-3: Evaluación de la Administración Semanal de LY2189265 en Diabetes – ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014841-10,0,0,0 2009-014841-10,7,2012-06-19,2012-07-19,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,Impacto de LY2189265 en comparación con el de metformina en el control glucémico en la Diabetes Mellitus de Tipo 2 Inicial (AWARD-3: Evaluación de la Administración Semanal de LY2189265 en Diabetes – ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014841-10,0,0,0 2009-014841-10,7,2012-06-19,2012-07-19,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly & Company,Impacto de LY2189265 en comparación con el de metformina en el control glucémico en la Diabetes Mellitus de Tipo 2 Inicial (AWARD-3: Evaluación de la Administración Semanal de LY2189265 en Diabetes – ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014841-10,0,0,0 2009-014842-28,3,2014-01-29,2014-01-29,3,0,0,0,0,1,2,0,0,1,0,0,1,0,1,SuppreMol GmbH,"A Randomised, Multi-centre, Double-Blind, Placebo-Controlled, Single/Multiple Dose Escalation Phase Ib/IIa Clinical Trial to Investigate the Safety and Efficacy of Recombinant Human Soluble Fc-gamma R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014842-28,0,0,0 2009-014844-13,1,2011-03-17,2011-03-17,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,Charité Universitätsmedizin Berlin,Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantation...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014844-13,0,0,0 2009-014845-95,1,2010-08-24,2010-08-24,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Norgine Ltd.,"Open study to assess the tolerability, safety and efficacy of an adapted 2 litre gut cleansing solution (NRL0706) in routine colon cleansing prior to colonoscopies for colon tumour screening",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014845-95,0,0,0 2009-014846-26,7,2012-05-14,2012-05-14,4,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A Phase III randomized, double blind, placebo controlled, multicenter study of panobinostat for maintenance of response in patients with Hodgkin’s lymphoma who are at risk for relapse after high dose ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014846-26,0,0,0 2009-014846-26,7,2012-05-14,2012-05-14,4,1,0,0,0,2,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A Phase III randomized, double blind, placebo controlled, multicenter study of panobinostat for maintenance of response in patients with Hodgkin’s lymphoma who are at risk for relapse after high dose ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014846-26,0,0,0 2009-014846-26,7,2012-05-14,2012-05-14,4,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Novartis Farmacéutica SA,"A Phase III randomized, double blind, placebo controlled, multicenter study of panobinostat for maintenance of response in patients with Hodgkin’s lymphoma who are at risk for relapse after high dose ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014846-26,0,0,0 2009-014853-33,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,An open single centre study to evaluate the long-term antibody persistence and immune memory between 16 and 20 years after the primary study HAB-032 (208127/022) in which healthy adults were vaccinate...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014853-33,0,0,0 2009-014854-14,1,2012-04-20,2012-04-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"A phase II, open-label, multicentre, 12 month study to evaluate the efficacy and safety of ranibizumab (0.5 mg) in patients with choroidal neovascularization secondary to pathological myopia (PM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014854-14,0,0,0 2009-014857-34,1,2011-01-01,2011-01-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsklinikum Erlangen,"Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014857-34,0,0,0 2009-014858-15,7,2015-03-16,2015-03-16,5,1,0,0,2,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014858-15,0,0,0 2009-014858-15,7,2015-03-16,2015-03-16,5,1,0,0,2,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014858-15,0,0,0 2009-014862-25,1,2014-11-18,2014-11-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Helsinki University Central Hospital,Dexmedetomidine vs placebo in ERCP sedation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014862-25,0,0,0 2009-014863-37,1,2017-05-01,2017-05-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Herlev hospital,"Intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic capecitabine and in patients with a HER2-positive tu,our in combination with trastuzumab (Herceptin (R)) in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014863-37,0,0,0 2009-014868-19,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,"Australian Kidney Trials Network, University of Queensland","A randomised, double-blind, placebo-controlled, factorial-design trial to assess the effect of aspirin & fish oil in the prevention of early thrombosis in arterio-venous fistulae in patients with Stag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014868-19,0,0,0 2009-014869-43,1,,,0,0,0,0,0,1,3,0,0,1,0,0,0,1,0,Centre Hospitalier Régional et Universitaire,Influence des acides gras polyinsaturés à longue chaîne n-3 sur l'expression des mucines dans la muqueuse nasale de patients atteints de mucoviscidose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014869-43,0,0,0 2009-014870-16,4,2014-08-20,2014-08-20,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,BioAlliance Pharma,"A phase II, multicentre, randomised, double-blind, placebo-controlled study comparing the efficacy and safety of Clonidine Lauriad™ 50 μg and 100 μg mucoadhesive buccal tablet (MBT) applied once daily...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014870-16,0,0,0 2009-014870-16,4,2014-08-20,2014-08-20,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Onxeo,"A phase II, multicentre, randomised, double-blind, placebo-controlled study comparing the efficacy and safety of Clonidine Lauriad™ 50 μg and 100 μg mucoadhesive buccal tablet (MBT) applied once daily...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014870-16,0,0,0 2009-014876-23,2,2012-04-26,2012-04-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Enzon Pharmaceuticals, Inc.",A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients with Metastatic Colorectal Carcinoma (mCRC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014876-23,0,0,0 2009-014876-23,2,2012-04-26,2012-04-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Enzon Pharmaceuticals, Inc",A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients with Metastatic Colorectal Carcinoma (mCRC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014876-23,0,0,0 2009-014880-38,3,2011-02-03,2011-02-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A randomised, double-blind, 8 treatments, 4 periods, incomplete crossover study to determine the optimal free dose combination of BI 1744 CL and tiotropium bromide (both delivered by the Respimat® Inh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014880-38,0,0,0 2009-014880-38,3,2011-02-03,2011-02-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A randomised, double-blind, 8 treatments, 4 periods, incomplete crossover study to determine the optimal free dose combination of BI 1744 CL and tiotropium bromide (both delivered by the Respimat® Inh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014880-38,0,0,0 2009-014880-38,3,2011-02-03,2011-02-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, 8 treatments, 4 periods, incomplete crossover study to determine the optimal free dose combination of BI 1744 CL and tiotropium bromide (both delivered by the Respimat® Inh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014880-38,0,0,0 2009-014885-25,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,0,Centre Hospitalier Intercommunal de Créteil,PRETTINEO PREmedication Trial for Tracheal Intubation of the NEOnate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014885-25,0,0,0 2009-014886-21,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,University Medical Centre Groningen,Intraoperative bile duct visualisation in children with biliary atresia using a fluorescence camera system: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014886-21,0,0,0 2009-014889-26,10,2016-04-16,2017-04-17,8,1,0,0,0,1,2,0,0,1,0,0,1,0,0,EORTC (European Organisation for Research and Treatment of Cancer),TRUSTS: A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Tissu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014889-26,0,0,0 2009-014892-31,1,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,ErasmusMC - Sophia,Morphine intravenous vs. Paracetamol intravenous in children on ECMO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014892-31,0,0,0 2009-014894-42,4,2011-11-14,2011-11-14,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 26-week randomised, controlled, open label, multicentre, multinational, treat to target trial investigating the impact of dietary intervention on weight change and the relationship between weight ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014894-42,0,0,0 2009-014895-23,1,2018-04-30,2018-04-30,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Universitätsklinikum Erlangen,Phase II clinical trial of a sequential therapy involving the FLOT regiment in palliative first-line treatment followed by AIO plus irinotecan in second-line treatment combined with supportive parente...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014895-23,0,0,0 2009-014904-73,1,2010-12-31,2010-12-31,1,0,0,0,0,0,4,0,0,1,1,1,1,0,1,Cassella-med GmbH & Co. KG,Open label clinical trial to determine the blood ethanol concentration following repeated administration of Bronchicum Elixir to children (1 to 12 years) with acute bronchitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014904-73,0,0,0 2009-014906-33,1,2014-12-18,2014-12-18,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,University College London,A Pilot study of Response to Velcade combination chemotherapy in AL amyloidosis (REVEAL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014906-33,0,0,0 2009-014907-29,1,2019-05-08,2019-05-08,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,University College London,A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tiss...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014907-29,0,0,0 2009-014908-57,1,,,0,0,0,1,0,0,1,0,1,1,1,1,0,1,1,Purdue Pharma L.P.,CAPSAICIN CHALLENGE STUDY TO INVESTIGATE THE POTENTIAL ANALGESIC EFFECTS OF V113741 IN HEALTHY MALE SUBJECTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014908-57,0,0,0 2009-014909-14,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Max-Planck-Institut für Psychiatrie,Neuropsychological effects of hydrocortisone substitution in patients with partial adrenal insufficiency after traumatic brain injury or subarachnoidal haemorrhage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014909-14,0,0,0 2009-014911-11,5,2011-01-28,2011-10-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A multi-centre, randomized, double-blind, active control, parallel-group, 2-arm study to investigate the effect of ethinylestradiol / drospirenone / (0.02 mg/3 mg) oral contraception in a 24/4 regimen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014911-11,0,0,0 2009-014911-11,5,2011-01-28,2011-10-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Healthcare AG,"A multi-centre, randomized, double-blind, active control, parallel-group, 2-arm study to investigate the effect of ethinylestradiol / drospirenone / (0.02 mg/3 mg) oral contraception in a 24/4 regimen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014911-11,0,0,0 2009-014912-36,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Karolinska Institutet,Behandling vid Langerhans cellhistiocytos (LCH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014912-36,0,0,0 2009-014913-28,1,2013-11-01,2013-11-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,London School of Hygiene & Tropical Medicine,RETRO-PRO: The effectiveness of simvastatin compared to atorvastatin: an e-clinical randomised trial within a research database in routine clinical practice - a feasibility study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014913-28,0,0,0 2009-014916-37,3,2012-06-13,2012-06-13,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","""Estudio de fase 4, doble ciego, controlado con placebo, multicéntrico y de 12 semanas de duración para evaluar la seguridad y la eficacia del tartrato de Vareniclina (CP-526,555) 1 mg dos veces al d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014916-37,0,0,0 2009-014916-37,3,2012-06-13,2012-06-13,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017 US","""Estudio de fase 4, doble ciego, controlado con placebo, multicéntrico y de 12 semanas de duración para evaluar la seguridad y la eficacia del tartrato de Vareniclina (CP-526,555) 1 mg dos veces al d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014916-37,0,0,0 2009-014916-37,3,2012-06-13,2012-06-13,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,PFIZER,"""Estudio de fase 4, doble ciego, controlado con placebo, multicéntrico y de 12 semanas de duración para evaluar la seguridad y la eficacia del tartrato de Vareniclina (CP-526,555) 1 mg dos veces al d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014916-37,0,0,0 2009-014918-99,3,2011-03-02,2011-05-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MENARINI RICERCHE S.P.A.,"Intra-articular treatment with MEN16132 in patients with symptomatic primary osteoarthritis of the knee: A randomised, multi-centre, double blind, placebo controlled, five parallel group, dose finding...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014918-99,0,0,0 2009-014918-99,3,2011-03-02,2011-05-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Menarini Ricerche, S.p.A","Intra-articular treatment with MEN16132 in patients with symptomatic primary osteoarthritis of the knee: A randomised, multi-centre, double blind, placebo controlled, five parallel group, dose finding...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014918-99,0,0,0 2009-014922-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC,Carfilzomib in combination with Thalidomide and Dexamethasone for remission induction and consolidation of Multiple Myeloma at first presentation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014922-40,0,0,0 2009-014923-22,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ALK-ABELLO`,"A phase IIIB trial investigating 3-year treatment efficacy, tolerability and safety of Grazax in children aged 5-18 years with grass pollen induced rhinoconjunctivitis with/without controlled contro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014923-22,0,0,0 2009-014940-12,9,2013-01-14,2015-03-16,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"""Evaluación de los efectos antiarritmicos de 3 dosis orales de S44121 versus placebo en pacientes con insuficiencia cardiaca crónica, disfunción ventricular izquierda sistólica y riesgo de presentar a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014940-12,0,0,0 2009-014940-12,9,2013-01-14,2015-03-16,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratorios Servier S.L.,"""Evaluación de los efectos antiarritmicos de 3 dosis orales de S44121 versus placebo en pacientes con insuficiencia cardiaca crónica, disfunción ventricular izquierda sistólica y riesgo de presentar a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014940-12,0,0,0 2009-014944-13,2,2011-05-12,2011-05-12,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 2, Multi-center, Non-controlled, Open-label Dose Escalation Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Orally Administered OPC-67683 Two Times Daily to Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014944-13,0,0,0 2009-014958-16,1,2010-07-01,2010-07-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,"A 12-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2599506 in Patients with Type 2 Diabetes Mellitus Treated with Diet and Exercise, with or without Metformin Estudio de fase ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014958-16,0,0,0 2009-014980-38,1,2021-08-23,2021-08-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU de Liège,Co-transplantation of mesenchymal stem cells and HLA-mismatched allogeneic hematopoietic cells after reduced-intensity conditioning: a phase II randomized double-blind study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014980-38,0,0,0 2009-014982-16,1,2011-09-25,2011-09-25,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Wockhardt UK Limited,"An open label, single dose safety study of Diamorphine Hydrochloride Nasal Spray (0.1mg/kg) in children",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014982-16,0,0,0 2009-014983-20,1,2011-07-04,2011-07-04,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Wockhardt UK Limited,An open label single dose pharmacokinetic study of Diamorphine Hydrochloride Nasal Spray (0.06mg/kg) in children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014983-20,0,0,0 2009-014986-22,10,2010-12-13,2011-01-31,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in patients with inadequately controlled type 2 diabetes and e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014986-22,0,0,0 2009-014992-31,16,2021-09-29,2021-09-29,12,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Actelion Pharmaceuticals Ltd,"Estudio de extensión abierta, de grupo único de tratamiento y a largo plazo, para evaluar la seguridad y tolerabilidad de ACT-293987 en pacientes con hipertensión arterial pulmonar",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014992-31,1,0,0 2009-014997-16,1,2017-12-31,2017-12-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Medizinische Universität Wien, Abteilung für Nephrologie und Dialyse",Identification of patients with high probability of not or poorly responding to therapy with mycophenolic acid pro-drugs.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-014997-16,0,0,0 2009-015002-19,2,2011-05-13,2011-05-13,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,VITAL THERAPIES INCORPORATED,EFFICACY AND SAFETY OF ELAD IN SUBJECTS WITH ACUTE ON CHRONIC HEPATITIS (AOCH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015002-19,0,0,0 2009-015005-39,1,2011-06-27,2011-06-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,Monocentric prospective randomized controlled open phase IV study to explorate the mechanismen of the synergetic effect of the Crateagus -Extract WS® 1442 in addition to endurance training related to ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015005-39,0,0,0 2009-015007-97,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,DR. ENRICO MONTANARI,Retinal Nerve Fiber Layer (RNFL) as measured by Optical Coherence Tomography (OCT) to Depict axonal loss in Early RRMS treated with difFEreNt dosage of subCutaneous IFN bEta 1a,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015007-97,0,0,0 2009-015008-25,1,2010-04-30,2010-04-30,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, open, non-randomized, trial to evaluate the immunogenicity and safety of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuvanted w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015008-25,0,0,0 2009-015011-41,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"Phase III, non-randomised, open-label study to evaluate the safety and immunogenicity of a prime-boost schedule of the H1N1 candidate vaccine adjuvanted with AS03B administered to subjects aged 3 to 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015011-41,0,0,0 2009-015012-18,1,2010-08-24,2010-08-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,HAL Allergy BV,"A prospective, randomized, open, multi-centre study to assess safety of PURETHAL Grasses given with a rush induction schedule to patients with allergic rhinoconjunctivitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015012-18,0,0,0 2009-015013-46,2,2010-10-26,2010-10-26,1,0,0,0,0,0,0,0,0,1,0,0,1,0,2,Alfred Health,Aspirin and Tranexamic Acid for Coronary Artery Surgery Trial ATACAS (ASA e acido tranexamico nell'intervento di by-pass aorto coronarico CABG),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015013-46,0,0,0 2009-015013-46,2,2010-10-26,2010-10-26,1,0,0,0,0,0,0,0,0,1,0,0,1,0,2,ALFRED HEALTH,Aspirin and Tranexamic Acid for Coronary Artery Surgery Trial ATACAS (ASA e acido tranexamico nell'intervento di by-pass aorto coronarico CABG),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015013-46,0,0,0 2009-015014-22,9,2010-07-16,2010-07-16,8,1,0,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A randomized, double-blind, placebo controlled, parallel group, multi-centre, 2-week treatment study to evaluate the safety and efficacy of fluticasone furoate nasal spray (FFNS) 110 mcg, administered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015014-22,1,0,0 2009-015014-22,9,2010-07-16,2010-07-16,8,1,0,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline S.A.,"A randomized, double-blind, placebo controlled, parallel group, multi-centre, 2-week treatment study to evaluate the safety and efficacy of fluticasone furoate nasal spray (FFNS) 110 mcg, administered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015014-22,1,0,0 2009-015017-48,4,2011-07-28,2011-07-28,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double blind, placebo and Naproxen controlled, multi-center, study to determine the safety, tolerability, pharmacokinetics and effect on pain of a single intra-articular administration o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015017-48,0,0,0 2009-015018-23,7,2010-07-19,2010-07-26,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated, not tolera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015018-23,0,0,0 2009-015019-42,6,2014-05-27,2014-06-27,5,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Janssen Biologics B.V.,"A Multicenter, Double Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects with Active Polyarticular Course Juvenile Idiopathic Arthritis (JI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015019-42,1,1,0 2009-015036-15,1,2015-06-12,2015-06-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Innsbruck - Universitätsklinik für Neurologie,Avastin / Irinotecan in patients with recurrent or progressive malignant glioma An academic prospective single-arm phase II clinical trial for evaluation of advanced functional neuroimaging technique...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015036-15,0,0,0 2009-015037-78,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,DR. PAOLO MORA,"PERI-OPERATIVE PROPHYLAXIS FOR CATARCT SURGERY IN UVEITIC PATIENTS: A MULTICENTRIC, PROSPECTIVE, RANDOMISED STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015037-78,0,0,0 2009-015058-38,1,2014-02-05,2014-02-05,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,University of Leeds,Improving the outcome for patients after osteoporotic femoral fractures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015058-38,0,0,0 2009-015059-26,1,2011-10-11,2011-10-11,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Actavis GmbH & Co. KG,Efficacy of 12 weeks oral Pentalong® on Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension Short title: CAESAR Clinical efficacy study o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015059-26,0,0,0 2009-015066-61,3,2010-01-15,2013-07-20,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Sanofi-Aventis Recherche & Développement,"Efficacy and safety of SAR407899A in patients with painful diabetic neuropathy. A 28-day, randomized, double-blind, placebo-controlled, parallel-group study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015066-61,0,0,0 2009-015068-32,1,2013-11-15,2013-11-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Vejle Hospital,"”Et fase II-forsøg med standardkemoterapi og panitumumab til pati-enter med metastaserende NSCL udvalgt på basis af mutationsstatus"" Phase II trial with standard chemotherapi and panutimumab to patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015068-32,0,0,0 2009-015070-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU de BREST,Evaluation de l'intérêt d'une préparation de l'intestin Grèle par polyéthylèneglycol pour l'exploration par vidéocapsule endoscopique des saignements digestifs inexpliqués,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015070-35,0,0,0 2009-015071-27,1,2011-01-19,2011-01-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ActivX Biosciences, Inc.","A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Once-Daily KRP-104 in Patients with Type 2 Diabetes with Inadequate Glycemic Control on Metformin Alo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015071-27,0,0,0 2009-015077-12,1,2014-09-30,2014-09-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Birmingham NHS Foundation Trust,The use of corticosteroids (Budenofalk) as a chemopreventative agent in ulcerative colitis associated neoplasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015077-12,0,0,0 2009-015079-29,12,2012-08-06,2012-11-01,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA","A Phase 3 Extension, Multicenter, Double-blind, Parallel-Group, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015079-29,0,0,0 2009-015079-29,12,2012-08-06,2012-11-01,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A Phase 3 Extension, Multicenter, Double-blind, Parallel-Group, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015079-29,0,0,0 2009-015080-13,12,2012-08-06,2012-11-01,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA","A Phase 3 Extension, Multicenter, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Carriers and Participated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015080-13,0,0,0 2009-015080-13,12,2012-08-06,2012-11-01,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical and Development","A Phase 3 Extension, Multicenter, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Carriers and Participated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015080-13,0,0,0 2009-015080-13,12,2012-08-06,2012-11-01,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development","A Phase 3 Extension, Multicenter, Long-term Safety and Tolerability Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Carriers and Participated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015080-13,0,0,0 2009-015082-31,2,2013-06-25,2013-06-25,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,A Phase 2 Randomized Clinical Trial of ABT-888 in Combination with Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects with Recurrent High Grade Serous Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015082-31,0,0,0 2009-015086-31,2,2014-01-08,2014-01-08,1,1,1,0,0,1,3,0,0,1,1,1,1,0,1,Bio Products Laboratory Limited,"Ten03: A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL’s High Purity Factor X in the treatment of the Factor X Deficient Subjects Undergoing Surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015086-31,0,0,0 2009-015090-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Association of Dutch Burn Centres,Standard Treatment Or topical doxepin against Pruritus in burn patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015090-12,0,0,0 2009-015099-86,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud University Nijmegen Medical Centre,"Comparison of efficacy, safety and costs of outpatient biological treatment for psoriasis in daily clinical practice.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015099-86,0,0,0 2009-015100-25,1,,,0,1,0,0,0,0,4,0,0,0,0,0,0,0,0,INSERM,Cohorte multicentrique nationale de patients atteints de grippe pandémique (nouveau virus A/H1N1v d’origine porcine),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015100-25,0,0,0 2009-015103-58,1,2011-01-05,2011-01-05,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,MSD Finland Oy,"A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar™ in Healthy Adults and Toddlers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015103-58,0,0,0 2009-015105-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Hospitalier Universiatire de Lille,"Etude de phase II évaluant une chimiothérapie combinant doxorubicine, cyclophosphamide, vindésine et acide valproïque dans les cancers bronchiques à petites cellules réfractaires ou récidivant après u...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015105-39,0,0,0 2009-015106-19,5,2012-10-05,2012-10-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development,A Phase 2b Dose-Evaluation Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015106-19,0,0,0 2009-015112-18,1,2014-07-01,2014-07-01,1,1,1,0,0,0,3,0,0,1,0,0,1,0,1,CSL Behring GmbH,"A Phase III, Open-Label, Multicentre Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Biostate® in Paediatric Subjects with Haemophilia A.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015112-18,0,0,0 2009-015113-44,15,2013-10-14,2014-11-18,14,0,0,0,0,0,3,0,0,1,0,0,1,0,0,INSERM-ANRS,An open label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naive subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015113-44,0,0,0 2009-015113-44,15,2013-10-14,2014-11-18,14,0,0,0,0,0,3,0,0,1,0,0,1,0,0,European AIDS treatment network (NEAT),An open label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naive subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015113-44,0,0,0 2009-015113-44,15,2013-10-14,2014-11-18,14,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Inserm-ANRS (Agence nationale de recherches sur le sida et les hépatites virales),An open label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naive subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015113-44,0,0,0 2009-015113-44,15,2013-10-14,2014-11-18,14,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ANSR,An open label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naive subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015113-44,0,0,0 2009-015113-44,15,2013-10-14,2014-11-18,14,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Inserm- ANRS (Agence nationale de recherches sur le sida et les hépatites virales),An open label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naive subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015113-44,0,0,0 2009-015113-44,15,2013-10-14,2014-11-18,14,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Agence nationale de recherches sur le sida et les h�patites virales ANRS,An open label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naive subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015113-44,0,0,0 2009-015113-44,15,2013-10-14,2014-11-18,14,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Agence nationale de recherches sur le sida et les hépatites virales ANRS,An open label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naive subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015113-44,0,0,0 2009-015113-44,15,2013-10-14,2014-11-18,14,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Agence nationale de recherches sur le sida et les hépatites virales (National Agency for AIDS-ANRS),An open label randomised two-year trial comparing two first-line regimens in HIV-infected antiretroviral naive subjects: darunavir/r + tenofovir/emtricitabine vs. darunavir/r + raltegravir,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015113-44,0,0,0 2009-015114-22,1,2015-03-30,2015-03-30,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Roche Pharma AG,"A randomized controlled, single-blind, proof- of- concept-study to investigate the protective effects of early treatment with C.E.R.A. in patients with chronic kidney disease on renal disease progress...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015114-22,0,0,0 2009-015116-17,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ARCO,Phase II study with pharmacokinetic and pharmacodynamic evaluations of metronomic chemotherapy with oral Vinorelbine and Dexamethasone in advanced castraction-resistant prostate cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015116-17,0,0,0 2009-015118-23,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,GETH,"ESTUDIO PILOTO FASE II MULTICÉNTRICO, NO ALEATORIZADO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE DASATINIB TRAS TRASPLANTE ALOGÉNICO DE PROGENITORES HEMOPOYÉTICOS EN PACIENTES CON LEUCEMIA AGUDA LINFOBLÁ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015118-23,0,0,0 2009-015119-42,1,2012-03-28,2012-03-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH,"An open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015119-42,0,0,0 2009-015120-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CENTRE ANTOINE LACASSAGNE,"Etude d’un traitement préopératoire par Cisplatine-Docétaxel et radiothérapie dans le cancer bronchique non à petites cellules de stade IIIA/IIIB (T1-4, N2): Etude de phase II",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015120-28,0,0,0 2009-015121-37,1,2013-06-26,2013-06-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ANRS,Etude multicentrique randomisée ouverte comparant la réduction virale et la tolérance de l’association IFN alpha-2b XL + ribavirine versus IFN peg alpha-2b + ribavirine chez des patients atteints d’hé...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015121-37,0,0,0 2009-015122-11,1,2018-06-12,2018-06-12,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,GBG Forschungs GmbH,"A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015122-11,0,0,0 2009-015125-36,1,2011-12-31,2011-12-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medical School Hannover. Department of Psychiatry, Social Psychiatry and Psychotherapy","Clostridium botulinum Typ A Neurotoxinkomplex zur adjuvanten Behandlung von depressiven Störungen – Eine randomisierte, kontrollierte Pilotstudie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015125-36,0,0,0 2009-015136-14,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,1,FORMAC Pharmaceuticals NV,Modified release metronidazole for the treatment of pouchitis after colectomy with ileo-anal pouch anastomosis for ulcerative colitis: a pharmacokinetic study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015136-14,0,0,0 2009-015158-39,6,2013-01-29,2013-01-29,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, dose-response, randomised, placebo-controlled, parallel group, multicentre phase III clinical study on the efficacy and tolerability of mesalazine granules vs. placebo for the prevention...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015158-39,0,0,0 2009-015159-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitaetsklinikum Wuerzburg,"UKW-Inf-001: Prospective trial to evaluate pharmacokinetic, safety and efficacy of intermittent application of increased doses of caspofungin for antifungal prophylaxis in high risk patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015159-26,0,0,0 2009-015160-34,1,,,0,1,0,0,0,0,4,0,1,0,0,0,0,0,0,INSERM,"""COhort on FLU during PREGnancy"" Etude de cohorte évaluant l'expression clinique et le retentissement materno-foetal de la grippe survenant au cours de la grossesse.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015160-34,0,0,0 2009-015161-31,13,2012-12-20,2012-12-20,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015161-31,0,0,0 2009-015161-31,13,2012-12-20,2012-12-20,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015161-31,0,0,0 2009-015161-31,13,2012-12-20,2012-12-20,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a division of Schering Corporation","A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015161-31,0,0,0 2009-015161-31,13,2012-12-20,2012-12-20,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.","A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015161-31,0,0,0 2009-015161-31,13,2012-12-20,2012-12-20,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering Corporation, división Schering-Plough Research Institute","A Phase 3, 12-Week, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3; Protocol No. P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015161-31,0,0,0 2009-015162-57,13,2013-05-23,2013-07-16,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme corp.,"A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015162-57,0,0,0 2009-015162-57,13,2013-05-23,2013-07-16,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015162-57,0,0,0 2009-015162-57,13,2013-05-23,2013-07-16,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schering-Plough Research Institute, a division of Schering Corporation","A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015162-57,0,0,0 2009-015162-57,13,2013-05-23,2013-07-16,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schering-Plough Research Institute, division of Schering Corporation","A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015162-57,0,0,0 2009-015162-57,13,2013-05-23,2013-07-16,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of Preladenant in Subjects With Moderate to Severe Parkinson’s Disease (Phase 3, Protocol No. P06153)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015162-57,0,0,0 2009-015163-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Department of Pediatrics Aarhus University Hospital Skejby,Reduction of hypertrophic scars and keloid by use of corticosteroid cream after removal of a tunneled central venous catheter in childhood cancer survivors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015163-14,0,0,0 2009-015165-31,1,2013-06-30,2013-06-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Northumberland, Tyne and Wear NHS Foundation Trust","Antiglucocorticoid augmentation of antiDepressants in Depression: a double-blind, randomised, placebo-controlled, parallel-group trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015165-31,0,0,0 2009-015166-62,1,2014-12-31,2014-12-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,A randomised controlled trial of Losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015166-62,0,0,0 2009-015168-32,5,2012-05-25,2012-05-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicentre, Randomised, Double Blind, Placebo controlled Phase IIb Study to compare the Efficacy and Safety of Two Dosing Regimens of Intravenous Infusions of CytoFabTM (AZD9773) in Adult Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015168-32,0,0,0 2009-015170-35,1,2014-09-01,2014-09-01,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,The Newcastle upon Tyne Hospitals NHS Foundation Trust,Multicentre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated with Parkinson's Disease (MUSTARDD-PD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015170-35,0,0,0 2009-015174-35,1,2010-03-25,2010-03-25,1,1,0,0,0,0,2,0,1,1,1,1,1,0,1,GlaxoSmithKline Biologicals,"A phase II, randomised, open-label study to evaluate the safety and immunogenicity of the adjuvanted pandemic H1N1 influenza candidate vaccine following a 0-28 day or 0-4 month vaccination schedule in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015174-35,0,0,0 2009-015175-27,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,0,Netherlands Vaccine Institute,Immunogenicity and safety of intradermal injection of reduced dose Inactivated Poliovirus vaccine (IPV) with a jet injector in healthy adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015175-27,0,0,0 2009-015176-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CHU de Nantes,CLOFARABINE/ARA-C TREATMENT COMBINED WITH REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTEMYELOID LEUKEMIA IN PRIMARY TREATMENT FAILURE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015176-10,0,0,0 2009-015198-11,9,2014-09-26,2014-09-26,7,1,1,0,1,0,3,0,1,2,0,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A Phase 3, Randomized, Active-Controlled, Observer-Blinded Trial to Assess the Safety and Tolerability of a Meningococcal Serogroup B Bivalent Recombinant Lipoprotein (rLP2086) Vaccine Given in Healt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015198-11,1,1,0 2009-015198-11,9,2014-09-26,2014-09-26,7,1,1,0,1,0,3,0,1,2,0,0,0,0,1,Pfizer Inc.,"A Phase 3, Randomized, Active-Controlled, Observer-Blinded Trial to Assess the Safety and Tolerability of a Meningococcal Serogroup B Bivalent Recombinant Lipoprotein (rLP2086) Vaccine Given in Healt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015198-11,1,1,0 2009-015217-52,1,2012-09-19,2012-09-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Cologne,Pilotstudie zur Pyridoxalphosphattherapie bei Patienten mit primärer Hyperoxalurie Typ I - Pilot trial on treatment of patients with primary hyperoxaluria type I with pyridoxal-phosphate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015217-52,0,0,0 2009-015236-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Surgery, National University of Ireland","NEBULISED INTRAPERITONEAL LOCAL ANAESTHETIC (NILA) FOR LAPAROSCOPIC SURGERY: A PROSPECTIVE, RANDOMISED, DOUBLE BLINDED, PLACEBO CONTROLLED CLINICAL TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015236-15,0,0,0 2009-015237-76,1,2017-01-17,2017-01-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre du Cancer des Cliniques Universitaires Saint-Luc,An open label multicentric phase II study of Panitumumab (Vectibix®) in cutaneous squamous cell carcinoma (SCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015237-76,0,0,0 2009-015238-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,RANDOMIZED PHASE II/III STUDY OF INDIVIDUALIZED NEOADJUVANT CHEMOTHERAPY IN ‘TRIPLE-NEGATIVE’ BREAST TUMORS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015238-31,0,0,0 2009-015242-30,1,2011-11-07,2011-11-07,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,The Walton Centre for Neurology and Neurosurgery NHS Trust,An open study to compare the efficacy of immunoglobulin administered subcutaneoulsy (SCIG) with current best practice in patients with Complex Regional Pain Syndrome (CRPS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015242-30,0,0,0 2009-015247-16,19,2012-10-18,2012-10-18,19,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"MERCK & CO., INC.","A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled with Atorvastatin 10 mg: A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015247-16,0,0,0 2009-015247-16,19,2012-10-18,2012-10-18,19,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled with Atorvastatin 10 mg: A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015247-16,0,0,0 2009-015247-16,19,2012-10-18,2012-10-18,19,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled with Atorvastatin 10 mg: A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015247-16,0,0,0 2009-015247-16,19,2012-10-18,2012-10-18,19,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc.","A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled with Atorvastatin 10 mg: A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015247-16,0,0,0 2009-015255-25,3,2011-06-21,2011-07-21,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of linagliptin (5 mg), administered orally once daily over 24 weeks in type 2 diabetic patients (age...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015255-25,0,0,0 2009-015255-25,3,2011-06-21,2011-07-21,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of linagliptin (5 mg), administered orally once daily over 24 weeks in type 2 diabetic patients (age...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015255-25,0,0,0 2009-015255-25,3,2011-06-21,2011-07-21,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of linagliptin (5 mg), administered orally once daily over 24 weeks in type 2 diabetic patients (age...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015255-25,0,0,0 2009-015276-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,,The effect of nebulisation of ipratropiumbromide on oxygenation and end-expiratory lung volume in mechanically ventilated children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015276-10,0,0,0 2009-015296-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA USL 6 LIVORNO ZONA LIVORNESE,MULTICENTRIC PROSPECTIVE DOSE-FINDING AND PHASE II STUDY WITH ORAL TOPOTECAN IN ADVANCED SMALL-CELL LUNG CANCER (SCLC) PATIENTS RECURRENT AFTER A FIRST LINE THERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015296-26,0,0,0 2009-015297-36,3,2016-06-17,2016-06-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, Research and Development Ltd","A Phase II (BRF113710) single-arm, open-label study of GSK2118436 in previously treated BRAF mutant metastatic melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015297-36,0,0,0 2009-015297-36,3,2016-06-17,2016-06-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Phase II (BRF113710) single-arm, open-label study of GSK2118436 in previously treated BRAF mutant metastatic melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015297-36,0,0,0 2009-015297-36,3,2016-06-17,2016-06-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXOSMITHLINE RESEARCH AND DEVELOPMENT LIMITED,"A Phase II (BRF113710) single-arm, open-label study of GSK2118436 in previously treated BRAF mutant metastatic melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015297-36,0,0,0 2009-015298-11,6,2016-09-16,2016-09-16,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A Phase III randomized, open-label Study comparing GSK2118436 to DTIC in previously untreated subjects with BRAF mutation positive advanced (Stage III) or metastatic (Stage IV) melanoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015298-11,0,0,0 2009-015298-11,6,2016-09-16,2016-09-16,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A Phase III randomized, open-label Study comparing GSK2118436 to DTIC in previously untreated subjects with BRAF mutation positive advanced (Stage III) or metastatic (Stage IV) melanoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015298-11,0,0,0 2009-015316-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oslo Universitetssykehus - Rikshospitalet,Perioperativ administrasjon av pregabalin ved laparoskopisk living donor nefrektomi (L-LDN) - et adjuvans til peroral analgetisk behandling - en randomisert kontrollert studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015316-17,0,0,0 2009-015318-23,4,2016-08-30,2016-08-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec Ltd.,"A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects with Multiple Sclerosis Who Have Completed T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015318-23,0,0,0 2009-015318-23,4,2016-08-30,2016-08-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen,"A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects with Multiple Sclerosis Who Have Completed T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015318-23,0,0,0 2009-015319-41,1,2016-03-02,2016-03-02,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Charite Universitätsmedizin Berlin,Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS) Trichuris suis Oozyten (TSO®) bei schubförmig remittierender MS und CIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015319-41,0,0,0 2009-015321-37,1,2010-11-17,2010-11-17,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Phase 3, Open-label Study to Evaluate Persistence of the Antibody Response Elicited by Pneumococcal Conjugate Vaccine in Healthy Children Who Have Been Previously Immunized With a 4-Dose Series of a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015321-37,0,0,0 2009-015336-15,3,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"UNIVERSITA` DEGLI STUDI ""G. D`ANNUNZIO"" CHIETI",Long-term treatment for cancer patients with deep vein thrombosis or pulmonary embolism - a randomized open label study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015336-15,0,0,0 2009-015336-15,3,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Department of Vascular Medicine of the Academic Medical Center,Long-term treatment for cancer patients with deep vein thrombosis or pulmonary embolism - a randomized open label study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015336-15,0,0,0 2009-015378-36,1,2010-09-30,2010-09-30,1,1,0,0,0,0,3,0,1,1,1,1,1,0,0,Queen Mary University of London,Effect of anastrozole on arthralgia and the effect of glucosamine sulphate supplementation in postmenopausal women with arthralgia in the IBIS-II breast cancer prevention trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015378-36,0,0,0 2009-015381-64,1,2010-01-05,2010-01-05,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Clinical Research International Ltd.,"""3D-Visualization of the anti-obstructive effect of Levocetirizine""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015381-64,0,0,0 2009-015383-33,1,2014-04-08,2014-04-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Freistaat Bayern, vertreten durch die Universität Regensburg","Die perioperative Anwendung von Etoricoxib verglichen mit Diclofenac bei Patienten nach Implantation einer Hüftgelenkstotalendoprothese, prospektive, doppelt blinde Phase IIIb Studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015383-33,0,0,0 2009-015386-30,4,2011-09-29,2011-12-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SmithKline Beecham Corporation (doing business as GlaxoSmithKline),"A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015386-30,0,0,0 2009-015386-30,4,2011-09-29,2011-12-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline LLC,"A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015386-30,0,0,0 2009-015396-27,1,2013-10-03,2013-10-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,Prevention of Recurrent Severe Hypoglycaemia: a Definitive RCT Comparing Optimised MDI and CSII with or without Adjunctive Real-time Continuous Glucose Monitoring.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015396-27,0,0,0 2009-015397-35,1,2010-09-03,2010-09-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,"A multicenter, open-label trial to assess cognitive and psychomotor performance as surrogate parameters for driving ability under stable long term treatment with tapentadol hydrochloride prolonged-rel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015397-35,0,0,0 2009-015398-11,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Radboud University Nijmegen Medical Centre,Pharmacokinetic and pharmacodynamic profile of rapid-acting insulin injected by needle-free jet-injection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015398-11,0,0,0 2009-015400-26,3,2011-12-01,2011-12-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Daiichi Sankyo Pharma Development,MULTICENTER PHASE 2 TRIAL OF ARQ 197 FOR SUBJECTS WITH RELAPSED OR REFRACTORY GERM CELL TUMORS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015400-26,0,0,0 2009-015402-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ULB Erasme,"Chimiothérapie d’induction suivie d’une radiochimiothérapie préopératoire à base de cisplatine, 5FU et panitumumab dans le traitement des cancers oesogastriques avancés et opérables",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015402-19,0,0,0 2009-015403-95,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Faculty Hospital Hradec Králové,A pilot trial of noninvasive assessment of methotrexate hepatotoxicity in the course of pharmacokinetically guided pharmacotherapy of psoriasis with methotrexate and folic acid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015403-95,0,0,0 2009-015404-26,1,2012-01-03,2012-01-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Spectrum Pharmaceuticals, Inc.","A Multicenter, Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial of Single-Dose Intravesical EOquinâ as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015404-26,0,0,0 2009-015407-47,5,2012-03-19,2012-03-19,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015407-47,0,0,0 2009-015407-47,5,2012-03-19,2012-03-19,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,NOVARTIS FARMA,"A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015407-47,0,0,0 2009-015407-47,5,2012-03-19,2012-03-19,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015407-47,0,0,0 2009-015410-22,1,2011-12-01,2011-12-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Fakultaet der Technischen Universitaet Muenchen,"A multicenter, randomized, double-blind study with 2 groups as prove of concept for the treatment of ACE induced angioedema with subcutaneous Icatibant",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015410-22,0,0,0 2009-015415-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitair Ziekenhuis Antwerpen (UZA) - Multidisciplinair Pijncentrum,"Lidocaine patches in postoperative and posttraumatic neuropathic chronic skin pain - A prospective, randomized, double-blinded, placebo-controlled, parrallel, multicentre, investigator initiated study...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015415-41,0,0,0 2009-015417-46,2,2014-04-07,2014-04-07,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A Phase Ib/II, open label, multi-center study evaluating the safety and efficacy of BKM120 in combination with trastuzumab in patients with relapsing HER2 overexpressing breast cancer who have previou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015417-46,0,0,0 2009-015456-14,8,2012-08-02,2012-08-02,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A partially blinded, prospective, randomized multicenter study evaluating efficacy, safety and tolerability of oral sotrastaurin plus standard or reduced exposure tacrolimus vs. myfortic plus tacrolim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015456-14,0,0,0 2009-015457-21,1,2016-07-05,2016-07-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GORTEC,"Etude de phase II, multicentrique, évaluant l’efficacité et la tolérance d’une association Réirradiation-Erbitux chez des patients précédemment irradiés et présentant une récidive locale inopérable d’...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015457-21,0,0,0 2009-015459-25,13,2014-06-30,2014-07-01,11,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015459-25,0,0,0 2009-015459-25,13,2014-06-30,2014-07-01,11,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015459-25,0,0,0 2009-015459-25,13,2014-06-30,2014-07-01,11,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMACEUTICA S.A.,"An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015459-25,0,0,0 2009-015476-98,17,2018-07-06,2018-07-26,12,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim Norway KS,"LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015476-98,0,0,0 2009-015476-98,17,2018-07-06,2018-07-26,12,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Boehringer-Ingelheim RCV GmbH & Co KG,"LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015476-98,0,0,0 2009-015476-98,17,2018-07-06,2018-07-26,12,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim RCV Gmbh & Co KG,"LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015476-98,0,0,0 2009-015476-98,17,2018-07-06,2018-07-26,12,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim,"LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015476-98,0,0,0 2009-015476-98,17,2018-07-06,2018-07-26,12,1,0,0,0,0,3,0,0,1,1,0,1,0,2,"Boehringer Ingelheim España, S.A.","LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015476-98,0,0,0 2009-015476-98,17,2018-07-06,2018-07-26,12,1,0,0,0,0,3,0,0,1,1,0,1,0,2,BOEHRINGER INGELHEIM FRANCE,"LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015476-98,0,0,0 2009-015476-98,17,2018-07-06,2018-07-26,12,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015476-98,0,0,0 2009-015476-98,17,2018-07-06,2018-07-26,12,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015476-98,0,0,0 2009-015476-98,17,2018-07-06,2018-07-26,12,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim Limited,"LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015476-98,0,0,0 2009-015476-98,17,2018-07-06,2018-07-26,12,1,0,0,0,0,3,0,0,1,1,0,1,0,2,"Unilfarma, Lda.","LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015476-98,0,0,0 2009-015476-98,17,2018-07-06,2018-07-26,12,1,0,0,0,0,3,0,0,1,1,0,1,0,2,SCS Boehringer Ingelheim Comm. V,"LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015476-98,0,0,0 2009-015476-98,17,2018-07-06,2018-07-26,12,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co. KG,"LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015476-98,0,0,0 2009-015476-98,17,2018-07-06,2018-07-26,12,1,0,0,0,0,3,0,0,1,1,0,1,0,2,BOEHRINGER ING.,"LUX-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015476-98,0,0,0 2009-015496-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,BG university hospital Bergmannsheil GmbH,Wirksamkeit von Etoricoxib bei Patienten mit neuropathischen Schmerzen mit und ohne peripherer Hyperalgesie (Efficacy of etoricoxibe in patients with neuropathic pain with and without peripheral hyper...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015496-27,0,0,0 2009-015498-11,7,2018-06-28,2018-06-28,6,1,0,0,0,1,4,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals Inc, a wholled owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA","A Randomized Phase 4 Study Comparing 2 Intravenous Temsirolimus (TEMSR) Regimens in Subjects With Relapsed, Refractory Mantle Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015498-11,0,0,0 2009-015498-11,7,2018-06-28,2018-06-28,6,1,0,0,0,1,4,0,0,1,1,0,1,0,1,"Wyeth Pharmaceuticals, Inc. Acting through its division Wyeth Research, a Pfizer Company","A Randomized Phase 4 Study Comparing 2 Intravenous Temsirolimus (TEMSR) Regimens in Subjects With Relapsed, Refractory Mantle Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015498-11,0,0,0 2009-015499-88,1,2012-11-05,2012-11-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Martin-Luther-Universität Halle-Wittenberg,Senkung einer erhöhten Herzfrequenz durch Ivabradin bei Patienten mit Multiorgandysfunktionssyndrom.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015499-88,0,0,0 2009-015500-26,3,2011-11-17,2015-11-30,2,1,0,0,0,0,3,0,1,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","""A Phase III Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015500-26,1,1,0 2009-015500-26,3,2011-11-17,2015-11-30,2,1,0,0,0,0,3,0,1,2,0,0,0,0,1,Merck Sharp & Dohme Corp.,"""A Phase III Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015500-26,1,1,0 2009-015500-26,3,2011-11-17,2015-11-30,2,1,0,0,0,0,3,0,1,2,0,0,0,0,1,"Merck & Co., Inc.","""A Phase III Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015500-26,1,1,0 2009-015502-19,5,2011-03-31,2011-03-31,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Merck Serono SA – Geneva,"A multinational, multicenter, single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015502-19,0,0,0 2009-015504-25,10,2018-11-30,2018-11-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GENENTECH, Inc","An Open Label, Multicenter, randomized, phase III study to investigate the efficacy and safety of Bendamustine compared with Bendamustine + RO5072759 (GA101) in patients with Rituximabrefractory, in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015504-25,0,0,0 2009-015507-52,14,2015-07-30,2015-07-30,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015507-52,0,0,0 2009-015507-52,14,2015-07-30,2015-07-30,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015507-52,0,0,0 2009-015507-52,14,2015-07-30,2015-07-30,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015507-52,0,0,0 2009-015508-24,4,2011-03-28,2011-07-15,3,1,0,0,0,2,3,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A 38-week extension to a 24-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintaining uveitis suppression when reducing sys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015508-24,0,0,0 2009-015508-24,4,2011-03-28,2011-07-15,3,1,0,0,0,2,3,0,0,1,1,1,1,0,1,NOVARTIS FARMA,"A 38-week extension to a 24-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintaining uveitis suppression when reducing sys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015508-24,0,0,0 2009-015508-24,4,2011-03-28,2011-07-15,3,1,0,0,0,2,3,0,0,1,1,1,1,0,1,"Novartis Farmacéutica, S.A.","A 38-week extension to a 24-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintaining uveitis suppression when reducing sys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015508-24,0,0,0 2009-015509-38,5,2011-02-10,2011-02-24,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 34-week extension to a 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppressio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015509-38,0,0,0 2009-015509-38,5,2011-02-10,2011-02-24,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A 34-week extension to a 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppressio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015509-38,0,0,0 2009-015511-40,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Miguel Giovanni Uriol Rivera,ESTUDIO MIR-EPO EVALUACIÓN DE LA EFICACIA DE LA DOSIS EQUIVALENTE DE MIRCERA EN PACIENTES EN HEMODIÁLISIS CRÓNICA PREVIAMENTE TRATADOS CON ERITROPOYETINA RECOMBINANTE HUMANA Y ANÁLISIS DE LOS FACTORES...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015511-40,0,0,0 2009-015512-17,4,2013-12-05,2013-12-05,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline,"Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS (sAML/MDS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015512-17,0,0,0 2009-015512-17,4,2013-12-05,2013-12-05,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS (sAML/MDS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015512-17,0,0,0 2009-015514-21,6,2014-12-31,2014-12-31,5,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"Ensayo TEAM (eficacia de Tasigna en melanoma avanzado): Un estudio fase III, aleatorizado, abierto, multicéntrico, con dos grupos de tratamiento para comparar la eficacia de Tasigna® frente a dacarbaz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015514-21,0,0,0 2009-015514-21,6,2014-12-31,2014-12-31,5,1,0,0,0,1,0,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A","Ensayo TEAM (eficacia de Tasigna en melanoma avanzado): Un estudio fase III, aleatorizado, abierto, multicéntrico, con dos grupos de tratamiento para comparar la eficacia de Tasigna® frente a dacarbaz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015514-21,0,0,0 2009-015514-21,6,2014-12-31,2014-12-31,5,1,0,0,0,1,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"Ensayo TEAM (eficacia de Tasigna en melanoma avanzado): Un estudio fase III, aleatorizado, abierto, multicéntrico, con dos grupos de tratamiento para comparar la eficacia de Tasigna® frente a dacarbaz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015514-21,0,0,0 2009-015515-40,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Wyeth Pharmaceuticals B.V.,PREVENTION OF THE PROGRESSION OF VERY EARLY SYMPTOMS INTO ANKYLOSING SPONDYLITIS: A PLACEBO CONTROLLED TRIAL WITH ETANERCEPT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015515-40,0,0,0 2009-015516-18,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Univ.-Klinik für Augenheilkunde und Optometrie, Medizinische Universität Wien",Microstructural morphological changes of the macula after intravitreal microplasmin for non-surgical treatment of vitreomacular traction syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015516-18,0,0,0 2009-015523-91,1,2010-05-25,2010-05-25,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Medizinische Universiätsklinik Graz, Abteilung für Endokrinologie und Nuklearmedizin","Placebo controlled study on effects of vitamin D supplementation in healthy women and men on immunological, endocrine and metabolic parameters",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015523-91,0,0,0 2009-015525-37,3,2010-07-29,2010-07-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"Safety, Tolerability and Pharmacokinetics of 3 Dose regimens of AZD1446 vs. Placebo as an Add-on Treatment to Donepezil: A Multi-centre, Double-blind, Randomised, Placebo controlled, Parallel group Ph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015525-37,0,0,0 2009-015527-82,1,2011-12-14,2011-12-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grünenthal Pharma S.A.,Estudio abierto de extensión para los pacientes con lumbalgia crónica severa o dolor crónico severo debido a artrosis de rodilla que han completado alguno de los ensayos clínicos previos de fase IIIb ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015527-82,0,0,0 2009-015529-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU TOULOUSE,Prise en charge pharmacologique de l’anxiété et de la douleur chez les patients qui souffrent en situation d’urgence traumatique préhospitalière : étude randomisée contrôlée en double-aveugle.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015529-35,0,0,0 2009-015532-14,5,2013-05-21,2013-05-21,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Serono S.A. - Geneva,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II trial to investigate the efficacy and safety of weekly intra-articular (i.a.) injections of 10, 30, and 100 µg of A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015532-14,0,0,0 2009-015533-79,1,2017-11-19,2017-11-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Oxford Radcliffe Hospitals NHS Trust,An assessment of the effects of pressors on graft blood flow after free tissue transfer surgery: A randomised study – Part II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015533-79,0,0,0 2009-015537-67,1,2013-10-04,2013-10-04,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Universitätsmedizin der Johannes Gutenberg-Universität Mainz,"Untersuchung der Wirksamkeit und Sicherheit von Vareniclin in der Postakutbehandlung der Alkoholabhängigkeit - eine prospektive, bizentrische, doppelblinde, placebokontrollierte, randomisierte Phase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015537-67,0,0,0 2009-015538-30,1,2011-12-15,2011-12-15,1,1,0,0,0,1,4,0,1,1,0,0,1,0,0,Rheinisch-Westfälisch Technische Hochschule Aachen,Effect of intranasal oxytocin on social approach in patients with social phobia and healthy control,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015538-30,0,0,0 2009-015543-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Caen,Evaluation diagnostique et pronostique de l’hypoxie dans les tumeurs cérébrales par le F-MISO en imagerie TEP et par des marqueurs biologiques en vue d'une meilleure orientation thérapeutique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015543-16,0,0,0 2009-015556-15,15,2011-02-02,2011-12-30,6,1,0,0,2,0,3,0,0,1,1,0,1,0,1,Biogen Idec Limited,"A Multicenter, Randomized, Open-Label, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects with Rel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015556-15,0,0,0 2009-015556-15,15,2011-02-02,2011-12-30,6,1,0,0,2,0,3,0,0,1,1,0,1,0,1,BIOGEN IDEC LTD,"A Multicenter, Randomized, Open-Label, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects with Rel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015556-15,0,0,0 2009-015558-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,Abatacept treatment in patients with primary Sjögren’s syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015558-40,0,0,0 2009-015559-25,1,2015-10-20,2015-10-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,"Preoperative intravitreal ranibizumab for persistent diabetic vitreous haemorrhage: A randomized, double-masked, controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015559-25,0,0,0 2009-015564-34,1,2014-11-18,2014-11-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Helsinki University Central hospital,Target-controlled infusion vs patient-controlled sedation with propofol in ERCP.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015564-34,0,0,0 2009-015565-31,9,2011-08-01,2011-08-01,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients with Primary Insomnia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015565-31,0,0,0 2009-015565-31,9,2011-08-01,2011-08-01,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Europe) Inc.,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients with Primary Insomnia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015565-31,0,0,0 2009-015565-31,9,2011-08-01,2011-08-01,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MSD Finland,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients with Primary Insomnia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015565-31,0,0,0 2009-015565-31,9,2011-08-01,2011-08-01,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients with Primary Insomnia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015565-31,0,0,0 2009-015565-31,9,2011-08-01,2011-08-01,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & CO., Inc.","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients with Primary Insomnia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015565-31,0,0,0 2009-015565-31,9,2011-08-01,2011-08-01,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Long Term Safety Study of MK-4305 in Patients with Primary Insomnia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015565-31,0,0,0 2009-015578-37,10,2015-01-21,2015-01-21,8,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Bayer HealthCare AG,"A randomized, double-blind, multicenter trial to evaluate the safety and efficacy of sequential (intravenous, oral) moxifloxacin versus comparator in pediatric subjects with complicated intra-abdomina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015578-37,1,1,0 2009-015579-28,13,2013-02-12,2013-02-12,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Vifor Pharma Inc.,"An Open-label, Multicentre, Randomised, 3-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject High- and Low-dosage Regimens) versus Oral Iron f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015579-28,0,0,0 2009-015579-28,13,2013-02-12,2013-02-12,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,VIFOR PHARMA INC.,"An Open-label, Multicentre, Randomised, 3-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject High- and Low-dosage Regimens) versus Oral Iron f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015579-28,0,0,0 2009-015584-13,1,2010-03-08,2010-03-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,Onset-tid samt hæmodynamisk respons på anæstesi indledning hos ældre ved sammenligning af thiopental og propofol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015584-13,0,0,0 2009-015586-31,1,2011-07-18,2011-07-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergan Limited,"A Multicenter, Masked, Randomized, Sham-Controlled, Parallel-Group, 3 Month Study with a 9-Month Safety Extension to Evaluate the Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Del...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015586-31,0,0,0 2009-015587-34,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,CHU de RENNES,"Etude d'impact à 3 ans sur l'état de santé, la qualité de vie et les coûts, de deux stratégies thérapeutiques (Natalizumab en perfusions mensuelles pendant 3 ans versus Mitoxantrone en induction penda...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015587-34,0,0,0 2009-015588-15,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Intercell AG,"SAFETY AND IMMUNOGENICITY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®) IN A PEDIATRIC POPULATION. OPEN LABEL, RANDOMIZED, ACTIVE CONTROLLED, PHASE 3 STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015588-15,0,1,1 2009-015589-74,2,2010-03-29,2010-03-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nycomed Sweden Holding 2 AB,"A controlled, randomized, double-blind, cross-over study of the onset of analgesic effect of two formulations of ibuprofen for the treatment of pain after oral surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015589-74,0,0,0 2009-015595-10,3,2013-08-09,2013-08-09,3,1,1,0,0,0,3,0,1,1,1,0,1,0,1,Intercell AG,"IMMUNOGENICITY AND SAFETY OF THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®, JESPECT®) IN A PEDIATRIC POPULATION IN NON‐ENDEMIC COUNTRIES. UNCONTROLLED, OPEN‐LABEL PHASE 3 STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015595-10,0,0,0 2009-015598-11,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Institut Gustave Roussy,"Essai de phase III multicentrique comparant la surveillance simple (standard) à la laparotomie exploratrice plus chimio-hyperthermie intrapéritonéale (CHIP), chez des patients atteints d’un cancer col...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015598-11,0,0,0 2009-015600-26,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Universitätsklinikum Würzburg,An open label prospective pilot-study to determine the improvement of impaired endothelial function and endothelial progenitor cell numbers following treatment with Aliskiren 300 mg in patients with c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015600-26,0,0,0 2009-015602-18,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Actelion Pharmaceuticals,Diabetes and vascular complications: the role of endothelin and physical inactivity’,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015602-18,0,0,0 2009-015603-10,2,2010-12-16,2010-12-16,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Intercell USA, Inc","A Phase Two, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System in Travelers to Asia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015603-10,0,0,0 2009-015606-19,2,2012-06-12,2012-07-11,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Jerini US Inc,"A Phase III Randomized Double-blind, Placebo-controlled Multicenter Study of Icatibant for Subcutaneous Injection in Patients with Acute Attacks of Hereditary Angioedema (HAE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015606-19,0,0,0 2009-015614-21,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""",Stereotactic accelerated radiotherapy concurrent with Temozolomide chemotherapy in newly diagnosed glioblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015614-21,0,0,0 2009-015619-42,1,,,0,0,0,0,1,1,2,0,0,1,1,1,0,1,1,Xenon Pharmaceuticals Inc.,"Phase 2a, Single-Blind, Placebo-Controlled, 3-Period, 2-Treatment, Crossover Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Oral Doses of XPF-001 in Patients with Inherited Er...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015619-42,0,0,0 2009-015620-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,The efficacy of the Botulinum toxin-A on the manual abilities in children with congenital spastic hemiplegia. Interest of the measure of the bimanual task performance.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015620-29,0,0,0 2009-015621-36,3,2012-04-25,2012-05-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MERCK SERONO SA,"A double-blind, randomized, comparative, multicenter, exploratory, and placebo-controlled Phase II trial of FOLFIRI plus MSC1936369B or placebo with a safety run-in part as second-line treatment of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015621-36,0,0,0 2009-015621-36,3,2012-04-25,2012-05-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Serona S.A., Geneva, Switzerland","A double-blind, randomized, comparative, multicenter, exploratory, and placebo-controlled Phase II trial of FOLFIRI plus MSC1936369B or placebo with a safety run-in part as second-line treatment of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015621-36,0,0,0 2009-015621-36,3,2012-04-25,2012-05-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Serono S.A., Geneva","A double-blind, randomized, comparative, multicenter, exploratory, and placebo-controlled Phase II trial of FOLFIRI plus MSC1936369B or placebo with a safety run-in part as second-line treatment of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015621-36,0,0,0 2009-015624-28,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Héctor Guiral Torner,"Estudio doble ciego, aleatorizado, controlado con placebo, multicéntrico, de grupos paralelos para evaluar la eficacia de Lymphomyosot en la reducción de la incidencia de amigdalectomía en pacientes c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015624-28,0,0,0 2009-015626-11,1,2014-10-31,2014-10-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Queen Mary University London,Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate-5-lipoxygenase (ALOX5) promoter genotype.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015626-11,0,0,0 2009-015628-27,5,2013-09-11,2013-09-11,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A phase Ib/II, multi-center, open-label study to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer, that has p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015628-27,0,0,0 2009-015629-35,1,2011-12-19,2011-12-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Janssen-Cilag NV/SA,"Open-label, single arm, interventional study to explore the efficacy and safety of paliperidone ER in the management of patients with acute agitation and/or aggression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015629-35,0,0,0 2009-015630-30,3,2011-07-19,2011-07-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"AMAG Pharmaceuticals, Inc.","Ferumoxytol Compared to Iron Sucrose Trial (FIRST): A Randomized, Multicenter, Trial of Ferumoxytol Compared to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects with Chronic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015630-30,0,0,0 2009-015632-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Essai en double aveugle contre placebo d'un traitement par inhibiteur de l'acétyl cholinesterase sur l'évolution d'un syndrome confusionnel chez les plus de 75 ans et évolution vers un syndrome dément...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015632-15,0,0,0 2009-015636-15,1,2012-02-08,2012-02-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company",An Open-label Extension Study to Assess the Long-term Safety and Tolerability of ATN-103 in Subjects With Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015636-15,0,0,0 2009-015638-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,"An open-label, blinded-endpoint, randomized, prospective trial investigating the effects of vitamin D administration on plasma renin activity in patients with stable chronic heart failure.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015638-31,0,0,0 2009-015640-42,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,3,,Etude de l’efficacité thérapeutique de la photothérapie dynamique (PDT) dans le lichen scléreux génital et les dysplasies génitales résistantes aux traitements conventionnels.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015640-42,0,0,0 2009-015642-35,1,,,0,0,0,0,0,0,2,0,1,1,1,1,0,1,1,medphano Arzneimittel GmbH,"Doppelblinde, randomisierte, kontrollierte, klinisch-experimentelle Studie der Phase II zum Nachweis der Wirksamkeit mittels Vasokonstriktionstest von Polcortolon® N Spray gegenüber Volonimat® Salbe N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015642-35,0,0,0 2009-015647-16,1,2011-06-27,2011-06-27,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"GUIDE Clinic, St James's Hospital",The pharmacokinetics of once daily Kaletra and methadone in a population of HIV positiive drug users.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015647-16,0,0,0 2009-015649-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medical clinic, University Hospital of North Norway",Immunmodulating and clinical effect of vitamin D onthe induction of remission in the patients with moderate to severe ulcerative colitis under the treatment with Infliximab.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015649-21,0,0,0 2009-015652-20,10,2012-08-13,2012-08-23,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Shire-Movetis NV,"A 12-week, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of prucalopride in subjects with chronic non-cancer pain suffering from opioid induced constipation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015652-20,0,0,0 2009-015652-20,10,2012-08-13,2012-08-23,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Movetis NV,"A 12-week, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of prucalopride in subjects with chronic non-cancer pain suffering from opioid induced constipation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015652-20,0,0,0 2009-015653-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Prospective study on the effects of etanercept treatment in patients with rheumatoid arthritis who are naïve for TNF-alpha blocking therapy and patients who do not respond (anymore) to prior treatment...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015653-20,0,0,0 2009-015658-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA USL 4 PRATO,A PILOT STUDY TESTING THE FEASIBILITY OF TWO DIFFERENTS REGIMENS INCORPORATING DOSE-DENSE DOCETAXEL AND CAPECITABINE-ORAL VINORELBINE IN THE ADJUVANT TREATMENT OF EARLY BREAST CANCER PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015658-39,0,0,0 2009-015659-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Institutet,Cortical and hormonal stress responses to pain management with morphine in standard clinical dosage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015659-26,0,0,0 2009-015679-28,1,2014-03-06,2014-03-06,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Southampton University Hospitals Trust,PRIMARY PREVENTION OF ATOPY AND ASTHMA WITH ALLERGEN SUBLINGUAL IMMUNOTHERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015679-28,0,0,0 2009-015680-14,1,2014-12-17,2014-12-17,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Leiden University Medical Center,Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients with Refractory Perianal Crohn’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015680-14,0,0,0 2009-015681-55,2,2011-06-20,2011-06-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.",A Dose-Escalation Study of AL-39324 Suspension versus Lucentis™ for the Treatment of Exudative Age-Related Macular Degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015681-55,0,0,0 2009-015700-26,1,2010-04-30,2010-04-30,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,National Institute for Health and Welfare,Evaluation of a vaccination campaign with A(H1N1)v pandemic vaccines: a prospective cohort study. A(H1N1)v-pandemiarokotuskampanjan vaikutukset,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015700-26,0,0,0 2009-015703-13,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Klinik für Innere Medizin II der Klinikum Chemnitz gGmbH,The influence of Telmisartan on insulin resistance and fatty liver in patients suffer from hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015703-13,0,0,0 2009-015705-40,4,2014-02-18,2014-02-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,A Study of the Safety and Efficacy of Entecavir plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015705-40,0,0,0 2009-015705-40,4,2014-02-18,2014-02-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Study of the Safety and Efficacy of Entecavir plus Tenofovir in Adults with Chronic Hepatitis B Virus Infection with Previous Nucleoside/Nucleotide Treatment Failure.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015705-40,0,0,0 2009-015712-17,5,2014-04-14,2014-05-08,5,0,0,0,0,0,4,0,0,1,0,0,1,0,0,HCRI,"A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous corona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015712-17,0,0,0 2009-015713-51,19,2012-03-07,2013-06-22,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram Tiotropium Inhalation Solut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015713-51,0,0,0 2009-015713-51,19,2012-03-07,2013-06-22,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas AE,"A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram Tiotropium Inhalation Solut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015713-51,0,0,0 2009-015713-51,19,2012-03-07,2013-06-22,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim International GmbH,"A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram Tiotropium Inhalation Solut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015713-51,0,0,0 2009-015713-51,19,2012-03-07,2013-06-22,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A","A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram Tiotropium Inhalation Solut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015713-51,0,0,0 2009-015713-51,19,2012-03-07,2013-06-22,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehrringer Ingelheim Finland Ky,"A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram Tiotropium Inhalation Solut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015713-51,0,0,0 2009-015713-51,19,2012-03-07,2013-06-22,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram Tiotropium Inhalation Solut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015713-51,0,0,0 2009-015713-51,19,2012-03-07,2013-06-22,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim Pharmaceuticals, Inc","A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram Tiotropium Inhalation Solut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015713-51,0,0,0 2009-015713-51,19,2012-03-07,2013-06-22,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram Tiotropium Inhalation Solut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015713-51,0,0,0 2009-015713-51,19,2012-03-07,2013-06-22,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram Tiotropium Inhalation Solut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015713-51,0,0,0 2009-015713-51,19,2012-03-07,2013-06-22,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram Tiotropium Inhalation Solut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015713-51,0,0,0 2009-015713-51,19,2012-03-07,2013-06-22,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Norway KS,"A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram Tiotropium Inhalation Solut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015713-51,0,0,0 2009-015713-51,19,2012-03-07,2013-06-22,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram Tiotropium Inhalation Solut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015713-51,0,0,0 2009-015713-51,19,2012-03-07,2013-06-22,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim Pharma GmbH & Co. KG, Medical Affairs Germany","A randomised, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 microgram and 5 microgram Tiotropium Inhalation Solut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015713-51,0,0,0 2009-015716-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospitals Leuven,A comparative trial between the analgesic efficacy of a standard postoperative analgesic regimen and TAP- block in addition to a standard postoperative regimen after inguinal hernia repair in a surgi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015716-18,0,0,0 2009-015719-42,8,2013-10-17,2013-10-25,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shire-Movetis NV,"A 12-week, randomised, double-blind, placebo controlled trial to evaluate the efficacy, quality of life, safety and tolerability of prucalopride in male subjects with chronic constipation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015719-42,0,0,0 2009-015719-42,8,2013-10-17,2013-10-25,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Movetis NV,"A 12-week, randomised, double-blind, placebo controlled trial to evaluate the efficacy, quality of life, safety and tolerability of prucalopride in male subjects with chronic constipation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015719-42,0,0,0 2009-015720-28,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Antwerp University Hospital,Therapeutic efficacy of Wilms tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with myeloid malignancies and multiple myeloma: a phase II trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015720-28,0,0,0 2009-015721-36,3,2011-06-16,2011-06-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,An extension trial to NN1250-3585 investigating safety and efficacy of NN1250 compared to insulin detemir in subjects with type 1 diabetes mellitus in a basal/bolus treatment regimen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015721-36,0,0,0 2009-015721-36,3,2011-06-16,2011-06-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,An extension trial to NN1250-3585 investigating safety and efficacy of NN1250 compared to insulin detemir in subjects with type 1 diabetes mellitus in a basal/bolus treatment regimen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015721-36,0,0,0 2009-015722-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BOIRON,ONCOMEO : Etude pilote évaluant la réponse tumorale chez des patients en échappement thérapeutique et traités par Ruta graveolens 9 CH ou Phenacetinum 4 CH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015722-11,0,0,0 2009-015723-90,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA PISANA,VARIATION OF PARATHYROID GLAND FOLLOWING CINACALCET USE IN DIALISYS PATIENTS WITH SONOGRAPHIC EVIDENCE OF SECONDARY HYPERPLASIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015723-90,0,0,0 2009-015725-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Protection cellulaire par la ciclosporine A dans l’arrêt cardiaque,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015725-37,0,0,0 2009-015728-27,1,2012-07-18,2012-07-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Alimentary Health Ltd,"A Double Blind, Randomised, placebo-contoled Trial to establish teh safety and efficacy of a probiotic in subjects with Irritable Bowel Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015728-27,0,0,0 2009-015729-35,1,2012-05-18,2012-05-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hull and East Yorkshire Hospitals NHS Trust,TO DETERMINE IF CARDIOVASCULAR RISK INDICES INCLUDING POSTPRANDIAL HYPERTRIGLYCERIDAEMIA ARE MODIFIED FAVOURABLY BY NICOTINIC ACID (NIACIN) IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME (PCOS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015729-35,0,0,0 2009-015730-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE,OPTIMISATION DE L’EVALUATION DE LA FONCTION SURRENALIENNE APRES ARRET D’UNE CORTICOTHERAPIE PROLONGEE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015730-30,0,0,0 2009-015737-73,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Radboud University Nijmegen Medical Centre,Single-step antigen loading and TLR activation of dendritic cells by mRNA electroporation for vaccination in stage III and IV melanoma patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015737-73,0,0,0 2009-015738-31,1,2012-08-14,2012-08-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Astellas Pharma Global Development, Inc. (APGD)","A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects with Stage III (Unresectable) or Stage IV Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015738-31,0,0,0 2009-015739-34,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Goethe-Universität Frankfurt/Main,"Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015739-34,0,0,0 2009-015740-42,1,2021-07-13,2021-07-13,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Universitätsklinkum Erlangen,"A PHASE 3, MULTICENTER, RANDOMIZED, OPEN, PROSPECTIVE, CONTROLLED, PARALLEL-GROUP STUDY OF REDUCTION OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ONGOING REMISSION RETRO – REduction of Therapy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015740-42,0,0,0 2009-015742-34,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,sanofi-aventis,Better Accepance of a Singe injection Apidra (insulin glulisine) Added to once daily Lantus (insulin glargine) versus twice daily Premixed insulin in a real Life Use Setting.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015742-34,0,0,0 2009-015743-16,1,2010-10-01,2010-10-01,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,University Hospitals of Leicester NHS Trust,"A randomised, partially observer-blind, multi-centre, head-to-head comparison of a two dose regimen of Baxter and GSK H1N1 pandemic vaccines, administered 21 days apart",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015743-16,0,0,0 2009-015744-42,1,2013-04-11,2013-04-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Oxford Radcliffe Hospitals Trust,Randomized open label study of oral versus intravenous antibiotic treatment for bone and joint infections requiring prolonged antibiotic treatment: Preliminary study in a single centre.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015744-42,0,0,0 2009-015749-22,1,2012-11-30,2012-11-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Leipzig,"A prospective, monocentric clinical trial with adalimumab for topical treatment in chronic wounds",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015749-22,0,0,0 2009-015752-22,1,2012-10-25,2012-10-25,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Bent Gymoese Jørgensen,Tilsætning af sufentanil til interskalenerblokade ved skulderoperation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015752-22,0,0,0 2009-015754-38,8,2011-12-20,2011-12-20,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,An extension trial to NN1250-3579 comparing safety and efficacy of NN1250 plus OAD(s) with insulin glargine plus OAD(s) in type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015754-38,0,0,0 2009-015755-24,3,2011-11-15,2011-12-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"An extension trial to trial NN1250-3583 comparing safety and efficacy of NN1250 with insulin glargine, both with insulin aspart as meal-time insulin, in type 1 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015755-24,0,0,0 2009-015758-39,1,2015-12-12,2015-12-12,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Hellenic Oncology Research Group (HORG),"Phase I/II, Multicenter, Single-Arm Clinical Trial of Panitumumab in Combination with Cisplatin, Fluourouracil and Docetaxel (DCF) in Locally Advanced or Metastatic Cancer of the Stomach and Gastro-oe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015758-39,0,0,0 2009-015760-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Effet de différents schémas d'insulinothérapie sur la compliance artérielle, la fonction endothéliale et la fonction autonome cardiaque de patients diabétiques de type 2 mal équilibrés sous traitement...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015760-33,0,0,0 2009-015766-56,3,2011-06-01,2011-06-01,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Vifor (International) AG,A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with multiple myeloma and iron-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015766-56,0,0,0 2009-015766-56,3,2011-06-01,2011-06-01,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Vifor Pharma Inc.,A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with multiple myeloma and iron-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015766-56,0,0,0 2009-015767-14,3,2012-11-09,2012-11-09,3,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Vifor (International) AG,A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with lymphoid malignancies and ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015767-14,0,0,0 2009-015768-33,9,2017-02-17,2017-02-17,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,BioMarin International Ltd.,"A Phase IIIb, Multicenter, Open-Label, Randomized, Controlled Study of the Efficacy, Safety, and Population Pharmacokinetics of Sapropterin Dihydrochloride (Kuvan) in Phenylketonuria (PKU) Patients <4...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015768-33,0,0,0 2009-015768-33,9,2017-02-17,2017-02-17,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,MERCK SERONO SA,"A Phase IIIb, Multicenter, Open-Label, Randomized, Controlled Study of the Efficacy, Safety, and Population Pharmacokinetics of Sapropterin Dihydrochloride (Kuvan) in Phenylketonuria (PKU) Patients <4...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015768-33,0,0,0 2009-015768-33,9,2017-02-17,2017-02-17,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Merck Serono S.A. - Geneva,"A Phase IIIb, Multicenter, Open-Label, Randomized, Controlled Study of the Efficacy, Safety, and Population Pharmacokinetics of Sapropterin Dihydrochloride (Kuvan) in Phenylketonuria (PKU) Patients <4...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015768-33,0,0,0 2009-015768-33,9,2017-02-17,2017-02-17,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,BioMarin International Ltd,"A Phase IIIb, Multicenter, Open-Label, Randomized, Controlled Study of the Efficacy, Safety, and Population Pharmacokinetics of Sapropterin Dihydrochloride (Kuvan) in Phenylketonuria (PKU) Patients <4...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015768-33,0,0,0 2009-015770-35,5,2014-06-03,2014-06-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,Phase II randomized trial of the Polo-like kinase 1 inhibitor BI 6727 monotherapy versus investigator’s choice chemotherapy in ovarian cancer patients resistant or refractory to platinum-based cytotox...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015770-35,0,0,0 2009-015770-35,5,2014-06-03,2014-06-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,Phase II randomized trial of the Polo-like kinase 1 inhibitor BI 6727 monotherapy versus investigator’s choice chemotherapy in ovarian cancer patients resistant or refractory to platinum-based cytotox...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015770-35,0,0,0 2009-015770-35,5,2014-06-03,2014-06-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,Phase II randomized trial of the Polo-like kinase 1 inhibitor BI 6727 monotherapy versus investigator’s choice chemotherapy in ovarian cancer patients resistant or refractory to platinum-based cytotox...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015770-35,0,0,0 2009-015770-35,5,2014-06-03,2014-06-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.",Phase II randomized trial of the Polo-like kinase 1 inhibitor BI 6727 monotherapy versus investigator’s choice chemotherapy in ovarian cancer patients resistant or refractory to platinum-based cytotox...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015770-35,0,0,0 2009-015770-35,5,2014-06-03,2014-06-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,Phase II randomized trial of the Polo-like kinase 1 inhibitor BI 6727 monotherapy versus investigator’s choice chemotherapy in ovarian cancer patients resistant or refractory to platinum-based cytotox...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015770-35,0,0,0 2009-015771-27,1,2014-12-12,2014-12-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik für Notfallmedizin",Requirement of Skeletal Muscle Paralysis in Hypothermic Patients after Cardiac Arrest. A pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015771-27,0,0,0 2009-015773-12,4,2011-02-01,2011-02-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","""Estudio polisomnográfico de fase IIb, multicéntrico, aleatorizado, doble ciego, controlado con placebo, cruzado, adaptativo de dos periodos para evaluar la seguridad y la eficacia de MK-6096 en pacie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015773-12,0,0,0 2009-015773-12,4,2011-02-01,2011-02-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MSD Finland Oy,"""Estudio polisomnográfico de fase IIb, multicéntrico, aleatorizado, doble ciego, controlado con placebo, cruzado, adaptativo de dos periodos para evaluar la seguridad y la eficacia de MK-6096 en pacie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015773-12,0,0,0 2009-015773-12,4,2011-02-01,2011-02-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","""Estudio polisomnográfico de fase IIb, multicéntrico, aleatorizado, doble ciego, controlado con placebo, cruzado, adaptativo de dos periodos para evaluar la seguridad y la eficacia de MK-6096 en pacie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015773-12,0,0,0 2009-015773-12,4,2011-02-01,2011-02-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck & Co. Inc.,"""Estudio polisomnográfico de fase IIb, multicéntrico, aleatorizado, doble ciego, controlado con placebo, cruzado, adaptativo de dos periodos para evaluar la seguridad y la eficacia de MK-6096 en pacie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015773-12,0,0,0 2009-015776-95,1,2012-09-06,2012-09-06,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Universitätsklinik für Innere Medizin, Klinische Abteilung für Endokrinologie und Nuklearmedizin",Effects of vitamin D supplementation in coronary artery disease patients with postchallenge hyperglycemia and vitamin D deficiency on endothelial function and insulin sensivitivity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015776-95,0,0,0 2009-015779-28,1,2016-12-31,2016-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Bristol NHS Foundation Trust,A single-centre randomised controlled trial of propofol cardioplegia on blood and myocardial biomarkers of stress and injury in patients having isolated coronary artery bypass grafting (CABG) or aorti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015779-28,0,0,0 2009-015780-14,1,2010-11-30,2010-11-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Abteilung für Anästhesie und Intensivmedizin, Medizinische Universität Wien",The effect of high dose remifentanil on the reversal of established sunburn-induced hyperalgesia in human volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015780-14,0,0,0 2009-015782-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Centre,Nifedipine versus Atosiban in the treatment of threatened preterm labour,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015782-30,0,0,0 2009-015783-34,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA,Effects of Magnesium on Blood Pressure in Patients with familiarity for Metabolic Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015783-34,0,0,0 2009-015784-13,1,2013-12-30,2013-12-30,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Teemu Luostarinen,"Mannitolin ja hypertonisen keittosuolan vaikutus hemodynamiikkaan, happoemästasapainoon ja veren hyytymi-seen tavoiteohjatun nestehoidon aikana subaraknoidaalivuotopotilailla.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015784-13,0,0,0 2009-015785-64,2,2019-07-02,2019-07-02,1,0,0,0,0,0,3,0,0,1,1,0,1,0,0,CHU de DIJON - Délégation à la recherche clinique et à l’innovation,ESSAI RANDOMISE - SORAFENIB-PRAVASTATINE VERSUS SORAFENIB SEUL POUR LE TRAITEMENT PALLIATIF DU CARCINOME HEPATOCELLULAIRE CHILD-PUGH A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015785-64,0,0,0 2009-015791-94,9,2015-04-16,2015-07-27,7,1,0,0,0,0,3,0,1,1,1,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety and immunogenicity of GSK Biologicals’ gE/AS01B vaccine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015791-94,0,0,0 2009-015791-94,9,2015-04-16,2015-07-27,7,1,0,0,0,0,3,0,1,1,1,0,1,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety and immunogenicity of GSK Biologicals’ gE/AS01B vaccine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015791-94,0,0,0 2009-015791-94,9,2015-04-16,2015-07-27,7,1,0,0,0,0,3,0,1,1,1,0,1,0,1,GlaxoSmithKline SA,"A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety and immunogenicity of GSK Biologicals’ gE/AS01B vaccine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015791-94,0,0,0 2009-015795-10,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Alcon d.o.o.,"Assessing the safety and efficacy of switching to Azarga (Brinzolamide/Timolol Fixed Combination), as replacement therapy in patients with uncontrolled intraocular pressure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015795-10,0,0,0 2009-015796-27,1,2011-05-20,2011-05-20,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,Alcon d.o.o.,"Patient Preference Comparison of Azarga versus Cosopt, after Single Doses in Patients with Open-Angled Glaucoma or Ocular Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015796-27,0,0,0 2009-015798-11,1,2010-09-17,2010-09-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","“Ensayo de fase III, aleatorizado, controlado con un fármaco de comparación activo, con doble enmascaramiento, de doce semanas de duración, para comparar la eficacia y la seguridad de MK-2452 (0,0015%...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015798-11,0,0,0 2009-015799-92,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Universitätspital Zürich Anästhesie,Intravenous ferric carboxymaltose (Ferinject®) with or without Erythropoietin for the correction of preoperative anaemia in patients undergoing orthopaedic surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015799-92,0,0,0 2009-015800-25,1,2011-07-31,2011-07-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Liverpool Heart & Chest Hospital NHS Trust,"A pilot randomised control trial, in intensive care patients, comparing seven days versus two days treatment with empirical antibiotics to treat hospital acquired infection of unknown origin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015800-25,0,0,0 2009-015804-24,1,2014-08-01,2014-08-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,URSAPHARM Arzneimittel GmbH,Perioperative Ödemtherapie mit Bromelain nach Weisheitszahnosteotomien – Überprüfung der Wirksamkeit in Abhängigkeit von unterschiedlichen Dosierungen (Dosisfindungsstudie),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015804-24,0,0,0 2009-015810-23,1,2011-06-30,2011-06-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Leeds,Intra-articular and intravenous infliximab in the treatment of resistant seronegative oligoarthritis of the knee,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015810-23,0,0,0 2009-015811-42,4,2015-09-25,2015-10-06,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Genzyme Europe B.V.,"A Phase 3, Randomized, Multi-Center, Multi-National, Double-Blind Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once Daily versus Twice Daily Dosing of Genz-112638 in Patients with G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015811-42,0,0,0 2009-015815-42,9,2017-05-09,2017-05-09,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Teva Pharmaceutical Industries Ltd,"A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-302 (BRAVO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015815-42,0,0,0 2009-015816-17,6,2011-05-10,2011-05-31,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"An extension trial to NN1250-3582 comparing safety and efficacy of NN1250 and insulin glargine, both with insulin aspart as meal-time insulin � OADs in type 2 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015816-17,0,0,0 2009-015816-17,6,2011-05-10,2011-05-31,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"An extension trial to NN1250-3582 comparing safety and efficacy of NN1250 and insulin glargine, both with insulin aspart as meal-time insulin � OADs in type 2 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015816-17,0,0,0 2009-015817-31,2,2011-01-14,2011-01-14,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,OxThera IP AB,"A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, Study to Evaluate the Efficacy and Safety of Oxabact(TM) to Reduce Urinary Oxalate in Subjects with Primary Hyperoxaluria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015817-31,0,0,0 2009-015821-34,1,2011-06-24,2011-06-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MEDICE Arzneimittel GmbH & Co. KG,Dosisfindungsstudie zu Nicotinamid bei dialysepflichtigen Patienten mit Hyperphosphatämie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015821-34,0,0,0 2009-015824-27,1,2011-08-16,2011-08-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MENARINI Benelux NV/SA,"The effects of Nebivolol/HCTZ on Central Arterial Pressure, a randomised double-blind cross-over trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015824-27,0,0,0 2009-015825-36,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,"Morphotek, Inc.",An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects with Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015825-36,0,0,0 2009-015826-13,1,2014-04-20,2014-04-20,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,PROF. TIZIANO GHERLI,THE USE OF COENZYME Q 10 BEFORE HEART SURGERY IN ELDERLY PATIENTS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015826-13,0,0,0 2009-015828-28,1,2010-09-30,2010-09-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Wien,Iloprost in der Behandlung der Präeklampsie – klinische Pilotstudie engl.: oral Iloprost in pre-eclampsia treatment - a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015828-28,0,0,0 2009-015833-66,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,CASA DI CURA PRIVATA S.RAFFAELE - PISANA,Ropinirole 24h prolonged release and motor fluctuations: a study to control the wearing-off induced by dopamine agonists immediate release Ropinirolo a rilascio prolungato e fluttuazioni motorie: s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015833-66,0,0,0 2009-015834-31,20,2014-05-19,2015-05-21,19,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015834-31,0,0,0 2009-015834-31,20,2014-05-19,2015-05-21,19,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Farmacéutica SA,"A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015834-31,0,0,0 2009-015834-31,20,2014-05-19,2015-05-21,19,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015834-31,0,0,0 2009-015835-34,1,,,0,0,0,0,0,1,3,0,1,1,0,0,0,1,0,AZIENDA OSPEDALIERA ORDINE MAURIZIANO,VITAMIN D EFFECT ON T LYMPHOCYTES AND OSTEOCLASTOGENESIS IN RHEUMAOID ARTHRITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015835-34,0,0,0 2009-015837-55,1,2016-06-24,2016-06-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Kings College London,"Double-blind, 36 month, placebo-controlled trial of mifepristone on cognition in alcoholics",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015837-55,0,0,0 2009-015837-55,1,2016-06-24,2016-06-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,South London and Maudsley NHS Foundation Trust,"Double-blind, 36 month, placebo-controlled trial of mifepristone on cognition in alcoholics",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015837-55,0,0,0 2009-015839-33,2,2011-05-04,2011-05-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,An extension trial comparing safety and efficacy of NN5401 with insulin glargine in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015839-33,0,0,0 2009-015840-40,1,2011-07-20,2011-07-20,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Belfast Health and Social Care Trust,Chronic pain and mobility outcomes following primary hip arthroplasty. A comparison of intravenous morphine with lumbar plexus levobupivacaine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015840-40,0,0,0 2009-015844-41,4,2016-01-26,2016-01-26,1,0,0,0,0,1,4,0,0,2,0,0,0,0,1,Merck KGaA,"A Phase IV Open-Label, Single-Cohort Study of the Long-Term Neurocognitive Outcomes in 4 to 5 Year-Old Children with Phenylketonuria Treated with Sapropterin Dihydrochloride (Kuvan®) for 7 Years.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015844-41,1,0,0 2009-015844-41,4,2016-01-26,2016-01-26,1,0,0,0,0,1,4,0,0,2,0,0,0,0,1,BioMarin International Ltd.,"A Phase IV Open-Label, Single-Cohort Study of the Long-Term Neurocognitive Outcomes in 4 to 5 Year-Old Children with Phenylketonuria Treated with Sapropterin Dihydrochloride (Kuvan®) for 7 Years.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015844-41,1,0,0 2009-015845-21,9,2012-01-31,2012-01-31,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015845-21,0,0,0 2009-015849-22,1,2014-12-15,2014-12-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Salford Royal Foundation NHS Trust,An open label study of intra-articular steroid injection in the management of symptomatic knee OA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015849-22,0,0,0 2009-015850-39,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,"Adamas Pharmaceuticals, Inc","A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin with Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015850-39,0,0,0 2009-015852-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospital Universitario Dr. Negrin,18F-FMISO-PET in High Grade Gliomas: Assessment of Tumor Hypoxia and Effect of Spinal Cord Stimulation Ensayo Clínico con FMISO-PET en gliomas de alto grado de malignidad: Valoración de la hipoxi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015852-11,0,0,0 2009-015858-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dr. Antonio Javier Trujillo Santos,Comparación de la adición de bajas dosis de vitamina K al tratamiento con acenocumarol frente al tratamiento tradicional con acenocumarol sobre la estabilidad del efecto anticoagulante y sus complicac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015858-38,0,0,0 2009-015859-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"The Sahlgrenska Academy, University of Gothenburg",None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015859-24,0,0,0 2009-015863-15,1,2011-08-29,2011-08-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Dr. Antonio Román Broto,"ENSAYO CLÍNICO DE FASE II, ABIERTO, UNICÉNTRICO, PILOTO PARA EVALUAR LAS CARACTERÍSTICAS FARMACOCINÉTICAS, SEGURIDAD Y TOLERABILIDAD, TRAS LA CONVERSIÓN DE UN RÉGIMEN INMUNOSUPRESOR CON PROGRAF® A TAC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015863-15,0,0,0 2009-015864-32,3,2013-08-05,2013-08-05,2,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Meropenem in Hospitalized Children With Complicated Intra-Abdominal Infec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015864-32,1,1,0 2009-015865-30,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Máximo Bernabeu Wittel,ENSAYO CLINICO RANDOMIZADO DOBLE CIEGO DE HIERRO CARBOXIMALTOSA INTRAVENOSO CON O SIN ERITOPOYETINA PARA LA PREVENCIÓN DE TRANSFUSIONES DE CONCENTRADOS DE HEMATÍES EN EL PERIOPERATORIO DE FRACTURA DE ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015865-30,0,0,0 2009-015866-71,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska University Hospital Huddinge,Fast detoxification of opioid addiction in patients suffering from opioids induced hyperalgesi (OIH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015866-71,0,0,0 2009-015867-15,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA SAN GERARDO DI MONZA,Different Anesthesiological Strategies Evaluation in Deep Brain Stimulation Neurosurgeries,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015867-15,0,0,0 2009-015868-34,6,2014-04-15,2014-05-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ipsen Pharma SAS,"A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED STUDY, ASSESSING THE EFFICACY AND SAFETY OF DYSPORT USED FOR THE TREATMENT OF LOWER LIMB SPASTICITY IN ADULT SUBJECT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015868-34,0,0,0 2009-015870-36,1,2010-05-19,2010-05-19,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,McNeil AB,Nicotine pharmacodynamics with a new oral nicotine replacement product and NiQuitin Lozenge. A study in healthy smokers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015870-36,0,0,0 2009-015875-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II,Modulation of intestinal and extraintestinal inflammation in infants with Cystic Fibrosis by early modification of intestinal microflora,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015875-28,0,0,0 2009-015876-86,1,,,0,0,0,0,0,0,4,0,1,3,0,0,0,0,0,Southampton University Hospitals,"An investigation into the mechanisms of action of a combined long acting beta agonist/inhaled corticosteroid (Seretide 500 accuhaler) on the bacterial colonisation, immunology and inflammation of pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015876-86,0,0,0 2009-015877-11,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Dynavax Technologies Corporation,"An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Licensed Vaccine (Engerix-B®) among Adults (18 to 75 Years of Age) with Chronic Kidney Disease (CKD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015877-11,0,0,0 2009-015878-35,10,2016-05-27,2016-05-27,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bayer AG,"Randomized, double blind, placebo controlled, parallel group, multi-center study to evaluate the hemodynamic effects of Riociguat (BAY 63-2521) as well as safety and kinetics in patients with pulmonar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015878-35,1,0,0 2009-015878-35,10,2016-05-27,2016-05-27,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bayer Healthcare AG,"Randomized, double blind, placebo controlled, parallel group, multi-center study to evaluate the hemodynamic effects of Riociguat (BAY 63-2521) as well as safety and kinetics in patients with pulmonar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015878-35,1,0,0 2009-015881-71,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AMW GmbH,"An open label, parallel group, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of two new GnRH implants (AMW Goserelin 3.6 mg Im...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015881-71,0,0,0 2009-015883-32,6,2012-03-20,2012-03-20,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Janssen Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Multicenter Study with a 26 Week Extension to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 as Monotherapy in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015883-32,0,0,0 2009-015883-32,6,2012-03-20,2012-03-20,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Janssen-Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Multicenter Study with a 26 Week Extension to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 as Monotherapy in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015883-32,0,0,0 2009-015884-15,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,0,The National Institute of Allergy and Infectious Diseases (NIAID) and The Eunice Kennedy Shriver NICHD,"A Phase I/II, Multicenter, Open-Label, Non comparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015884-15,0,1,1 2009-015885-75,2,2012-01-11,2012-01-11,2,1,1,0,0,0,1,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Pharmacokinetic, Pharmacodynamic and Short-term Safety Study of Single and Multiple Day Doses of Rabeprazole Sodium in Neonates and Pre-term Infants with a Corrected Age of Less than 44 Weeks with a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015885-75,0,0,0 2009-015888-14,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,Fa.Elexxion,Micro-biological and clinical evaluation of the results after adjuvanter laser therapy with 810nm diode laser in frame the parodontologic basis therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015888-14,0,0,0 2009-015890-11,1,2012-07-18,2012-07-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Ghent,Conditioning with volatile anesthetics in liver transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015890-11,0,0,0 2009-015895-87,1,2013-01-01,2013-01-01,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,UMC St Radboud,Application of zileuton (Zyflo CR) in patients with Sjögren Larsson Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015895-87,0,0,0 2009-015898-12,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Galápagos NV,"Randomized, Double-Blind, Placebo-Controlled, Multicenter, Exploratory Phase II Study to Compare Three Dose Regimens of GLPG0259 vs Placebo, in Combination with Methotrexate, Administered for 12 Weeks...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015898-12,0,0,0 2009-015901-38,4,2010-09-23,2010-10-22,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ALMIRALL, S.A.","Efficacy, safety and tolerability of two Fixed-Dose Combinations of Aclidinium bromide with two doses of Formoterol fumarate compared with Aclidinium bromide, Formoterol fumarate and placebo all admin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015901-38,0,0,0 2009-015902-20,1,2010-04-06,2010-04-06,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,AVIR Green Hills Biotechnology Research Development Trade AG,"Randomized, double-blind, placebo-controlled, Phase IIa dose finding study of single dose GHB11L1 in healthy adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015902-20,0,0,0 2009-015903-22,1,2011-10-12,2011-10-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Leeds,THE EFFECT OF EICOSAPENTAENOIC ACID (EPA) ON BIOMARKERS OF GROWTH AND VASCULARITY IN HUMAN COLORECTAL CANCER LIVER METASTASES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015903-22,0,0,0 2009-015904-24,1,2012-07-27,2012-07-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Rheinische Friedrich-Wilhelms-Universität Bonn,"An open, prospective study to compare the safety and efficacy of raltegravir vs. atazanavir / ritonavir, both in combination with tenofovir DF and emtricitabine, in the treatment of HIV-infection in A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015904-24,0,0,0 2009-015909-39,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,"Phase I/II trial of dexamethasone, ofatumumab and bendamustine [Treanda] (DOT) as first-line treatment of mantle-cell lymphoma (MCL) in the elderly",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015909-39,0,0,0 2009-015911-42,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Boehringer Ingelheim bv,A phase Ib open label clinical trial of continuous once daily oral treatment using BIBW 2992 plus cetuximab (Erbitux®) in patients with non-small cell lung cancer with progression following prior erlo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015911-42,0,0,0 2009-015914-23,1,2010-05-18,2010-05-18,1,1,0,0,1,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare (GSKCH),Clinical efficacy of an experimental toothpaste,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015914-23,0,0,0 2009-015916-16,1,2011-08-24,2011-08-24,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust,A Comparison of Postural and Ibopamine Challenges between Progressive and Non-Progressive Glaucoma Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015916-16,0,0,0 2009-015918-22,10,2014-10-30,2014-10-30,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 24 months, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015918-22,0,0,0 2009-015918-22,10,2014-10-30,2014-10-30,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A 24 months, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015918-22,0,0,0 2009-015918-22,10,2014-10-30,2014-10-30,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 24 months, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015918-22,0,0,0 2009-015918-22,10,2014-10-30,2014-10-30,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A 24 months, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015918-22,0,0,0 2009-015926-13,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,Sahlgrenska University Hospital,Treatment of Huntington´s disease with OSU 6162 - a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015926-13,0,0,0 2009-015927-94,1,2013-01-04,2013-01-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hull and East Yorkshire NHS Trust,Are early and late cardiovascular risk markers in women with Polycystic Ovary Syndrome increased with concomitant Nonalcoholic Steatohepatitis and can this be modified with Liraglutide?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015927-94,0,0,0 2009-015928-28,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,PsychoGenics Inc,"A double-blind, randomized, placebo controlled, dose finding study of oral eltoprazine for treatment of levodopa-induced dyskinesias (LID) in a levodopa challenge-dose setting in Parkinsons Disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015928-28,0,0,0 2009-015929-37,8,2014-10-28,2014-10-28,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Andromeda Biotech Ltd,"A PHASE III, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF DIAPEP277 IN NEWLY DIAGNOSED TYPE 1 DIABETES SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015929-37,0,0,0 2009-015929-37,8,2014-10-28,2014-10-28,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Andromeda Biotech Ltd, 42 Hayarkon st, Yavne, 81227, Israel","A PHASE III, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF DIAPEP277 IN NEWLY DIAGNOSED TYPE 1 DIABETES SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015929-37,0,0,0 2009-015929-37,8,2014-10-28,2014-10-28,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Andromeda Biotech Ltd, 42 Hayarkon st, Yavne 81227, Israel","A PHASE III, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF DIAPEP277 IN NEWLY DIAGNOSED TYPE 1 DIABETES SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015929-37,0,0,0 2009-015929-37,8,2014-10-28,2014-10-28,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ANDROMEDA BIOTECH LTD.,"A PHASE III, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF DIAPEP277 IN NEWLY DIAGNOSED TYPE 1 DIABETES SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015929-37,0,0,0 2009-015931-33,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,JANSSEN-CILAG,"An open label, prospective, multicenter, single-arm clinical trial to investigate the safety and the analgesic effectiveness of a low dose (4 mg) OROS hydromorphone hydrochloride as starting dose in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015931-33,0,0,0 2009-015934-30,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CHU de Bordeaux,étude randomisée en double insu et crossover comparant l’efficacité de la L-carnitine à un placebo dans le traitement de la fatigue dans la sclérose en plaques,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015934-30,0,0,0 2009-015936-14,2,2019-06-27,2020-06-18,2,0,0,0,0,1,2,0,0,1,0,0,1,0,0,"University Children´s Hospital Tübingen,",PHASE II FEASIBILITY STUDY USING CH14.18/CHO ANTIBODY AND SUBCUTANEOUS INTERLEUKIN 2 AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CHILDREN WITH RELAPSED NEUROBLASTOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015936-14,0,0,0 2009-015939-33,17,2013-01-31,2013-05-20,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy, Safety, and Tolerability of AMG 785 in Adults with Fresh Unilateral Intertrochanteric Fracture of the Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015939-33,0,0,0 2009-015939-33,17,2013-01-31,2013-05-20,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy, Safety, and Tolerability of AMG 785 in Adults with Fresh Unilateral Intertrochanteric Fracture of the Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015939-33,0,0,0 2009-015940-40,1,2014-11-05,2014-11-05,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Helsingin ja uudenmaan sairaanhoitopiiri,Vitamin-D intervention pilotti,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015940-40,0,0,0 2009-015941-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,"A phase 1b/2 study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with cisplatin and radiotherapy as a first line therapy in patients with advanced cervical cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015941-22,0,0,0 2009-015943-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,SEQUENTIAL STUDY ON THE INCIDENCE AND INTENSITY OF INTESTINAL CONSTIPATION ASSOCIATED TO OXYCODONE (OXYCONTIN) AND THE COMBINATION OF OXYCODONE/NALOXONE (TARGIN) FOR CHRONIC ONCOLOGIC PAIN TREATMENT (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015943-17,0,0,0 2009-015944-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Interaction médicamenteuse entre la Colchicine et les inhibiteurs de calcineurine chez les patients transplantés rénaux,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015944-41,0,0,0 2009-015948-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University of Tartu, Faculty of Medicine",Pharmacokinetics of ertapenem in patients with severe sepsis and intraabdominal infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015948-42,0,0,0 2009-015950-39,1,2015-12-17,2015-12-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Johann Wolfgang Goethe-Universität Frankfurt/M.,Addition of Rituximab to Leflunomide in patients with active rheumatoid arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015950-39,0,0,0 2009-015952-11,1,2011-06-24,2011-06-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Department of OncologyHerlev University Hospital,"Phase Fase II examination of irinotecan, cetuximab and everolimus for patients resistente to chemoptherapy with metastatic colorectal cancer and KRAS mutation or with KRAS wildtype after progression o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015952-11,0,0,0 2009-015953-18,6,2013-06-26,2013-08-05,4,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infectio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015953-18,1,1,0 2009-015955-25,1,2011-07-05,2011-07-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital,INDIVIDUAL 5-FLUOROURACIL DOSE INDIVIDUALIZATION IN PATIENTS WITH COLORECTAL CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015955-25,0,0,0 2009-015957-20,3,2013-11-28,2013-11-28,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,Karolinska University Hospital,Abatacept Treatment in Polymyositis and Dermatomyositis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015957-20,1,0,0 2009-015958-38,1,2013-03-28,2013-03-28,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Effect of xantina oxidasi inhibition on left ventricular function and on energetic stores of the haert in patients affected by chronic cardiac insufficiency.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015958-38,0,0,0 2009-015960-32,1,2011-01-14,2011-01-14,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, randomised, observer-blind, multicentre study to evaluate the immunogenicity and safety of a 2-dose vaccination with the new process manufactured adjuvanted pandemic H1N1 influenza candid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015960-32,0,0,0 2009-015965-29,3,2011-12-16,2012-05-10,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Pierrel Research Europe GmbH,"Multicenter, randomized study comparing oral valganciclovir versus intravenous ganciclovir in patients following allogeneic stem cell transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015965-29,0,0,0 2009-015968-34,1,2020-07-28,2020-07-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,FRED HUTCHINSON CANCER RESEARCH CENTER,Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia:...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015968-34,0,0,0 2009-015970-36,7,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase II, Open-Label, Randomised, Comparative, Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination with Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015970-36,0,0,0 2009-015970-36,7,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,ASTRAZENECA,"A Phase II, Open-Label, Randomised, Comparative, Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination with Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015970-36,0,0,0 2009-015974-36,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI,"Phase II prospective study on high dose myeloablative therapy, with peripheral stem cell support, in elderly patients (>=65 e <76 years) with aggressive relapsed or refractory non Hodgkin lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015974-36,0,0,0 2009-015978-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude ouverte de phase 2 de 52 semaines visant à établir l'efficacité et la tolérance du Belimumab (HGS1006, LymphoStat-B), un anticorps monoclonal humanisé anti-BLys (BAFF), chez des patients atteint...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015978-35,0,0,0 2009-015979-27,1,2015-05-25,2015-05-25,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Activartis Biotech GmbH,"First line standard therapy of glioblastoma multiforme with or without add-on treatment with Trivax, an anti-tumour immune therapy based on tumour-lysate charged dendritic cells",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015979-27,0,0,0 2009-015981-73,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer),Phase II study evaluating the toxicity and activity of the combination lapatinib + capecitabine in elderly patients aged 70 and over with metastatic breast cancer over expressing HER2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015981-73,0,0,0 2009-015982-29,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,University Medical Center Utrecht,"A randomized, placebo-controlled, double blind, 4-period, cross-over trial, to study the effects of aliskiren, hydrochlorothiazide and moxonidine on endothelial dysfunction in obesity related hyperten...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015982-29,0,0,0 2009-015984-15,1,2012-09-10,2012-09-10,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"Shire Human Genetic Therapies, Inc. (Shire HGT)","A Phase I/II Safety, Tolerability, Ascending Dose and Dose Frequency Study of Recombinant Human Heparan-N-sulfatase (rhHNS) Intrathecal Administration via an Intrathecal Drug Delivery Device in Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015984-15,0,0,0 2009-015985-75,5,2013-07-08,2013-07-24,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Shire Human Genetic Therapies (HGT), Inc.",An Open-label Extension of Study TKT028 Evaluating Safety and Clinical Outcomes of Replagal Enzyme Replacement Therapy Administered to Adult Patients with Fabry Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015985-75,0,0,0 2009-015987-32,7,2014-07-04,2015-02-24,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"AVEO Pharmaceuticals, Inc.",An Extension Treatment Protocol for Subjects who have Participated in a Phase 3 Study of Tivozanib Hydrochloride vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015987-32,0,0,0 2009-015987-32,7,2014-07-04,2015-02-24,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"AVEO PHARMACEUTICALS, INC.",An Extension Treatment Protocol for Subjects who have Participated in a Phase 3 Study of Tivozanib Hydrochloride vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015987-32,0,0,0 2009-015988-13,5,2011-03-02,2011-03-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Recordati S.p.A.,","AN INTERNATIONAL MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND TRIAL TO EVALUATE DIFFERENT DOSE COMBINATIONS OF LERCANIDIPINE AND ENALAPRIL IN COMPARISON WITH EACH COMPONENT ADMINISTERED AL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015988-13,0,0,0 2009-015988-13,5,2011-03-02,2011-03-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,RECORDATI,"AN INTERNATIONAL MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND TRIAL TO EVALUATE DIFFERENT DOSE COMBINATIONS OF LERCANIDIPINE AND ENALAPRIL IN COMPARISON WITH EACH COMPONENT ADMINISTERED AL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015988-13,0,0,0 2009-015989-62,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Amgen Research (Munich) GmbH,"An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015989-62,0,0,0 2009-015993-37,1,2010-07-19,2010-07-19,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Institut für Klinische Forschung und Entwicklung (ikfe) GmbH,Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients – Investigation on Postprandial Excursions of Proinsulin and PAI-1 Levels,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015993-37,0,0,0 2009-015997-36,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase III, double-blind, randomized, study in adults aged between 18 and 60 years to assess the immunological non-inferiority of two manufacturing processes of the A/California/7/2009 (H1N1)v-like a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015997-36,0,0,0 2009-015999-10,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,BioGeneriX AG,"Efficacy and Safety of XM22 compared to pegfilgrastim in patients with breast cancer receiving chemotherapy. A multinational, multicentre, randomised, double-blind controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-015999-10,0,0,0 2009-016000-22,1,2011-12-19,2011-12-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BioGeneriX AG,"Efficacy and safety of XM22 in patients with non small cell lung cancer receiving cisplatin / etoposide chemotherapy. A multinational, multicentre, randomised, double-blind placebo-controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016000-22,0,0,0 2009-016003-26,1,2012-10-02,2012-10-02,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,UHB NHS Foundation Trust,RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016003-26,0,0,0 2009-016007-39,4,2010-06-03,2010-06-14,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2599506 Given as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016007-39,0,0,0 2009-016007-39,4,2010-06-03,2010-06-14,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Lilly S.A.,"A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2599506 Given as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016007-39,0,0,0 2009-016008-22,12,2013-12-02,2015-05-14,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016008-22,0,0,0 2009-016008-22,12,2013-12-02,2015-05-14,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016008-22,0,0,0 2009-016008-22,12,2013-12-02,2015-05-14,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG.,"A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Inactive Non-infectious Intermediate-, Posterior-, or Pan-uveitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016008-22,0,0,0 2009-016012-21,1,2012-05-08,2012-05-08,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IV, open, non-randomized, multicentre study to assess the reactogenicity and immunogenicity of a booster dose of GSK Biologicals’ combined reduced-antigen-content diphtheria, tetanus and acell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016012-21,0,0,0 2009-016017-24,1,,,0,1,0,0,0,1,2,0,0,0,0,0,0,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,A PHASE II RANDOMIZED NON COMPARATIVE STUDY ON THE ACTIVITY OF TRABECTEDIN OR GEMCITABINE + DOCETAXEL IN METASTATIC OR LOCALLY RELAPSED UTERINE LEIOMYOSARCOMA PRETREATED WITH CONVENTIONAL CHEMOTHER...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016017-24,0,0,0 2009-016019-39,10,2014-08-15,2017-01-19,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Taiho Oncology, Inc.","AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF S-1 AND CISPLATIN COMPARED WITH 5-FU AND CISPLATIN IN PATIENTS WITH METASTATIC DIFFUSE GASTRIC CANCER PREVIOUSLY UNTREATED WITH CHEMOTHERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016019-39,0,0,0 2009-016019-39,10,2014-08-15,2017-01-19,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"TAIHO PHARMA USA, INC","AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF S-1 AND CISPLATIN COMPARED WITH 5-FU AND CISPLATIN IN PATIENTS WITH METASTATIC DIFFUSE GASTRIC CANCER PREVIOUSLY UNTREATED WITH CHEMOTHERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016019-39,0,0,0 2009-016019-39,10,2014-08-15,2017-01-19,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Taiho Pharma USA, Inc.","AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF S-1 AND CISPLATIN COMPARED WITH 5-FU AND CISPLATIN IN PATIENTS WITH METASTATIC DIFFUSE GASTRIC CANCER PREVIOUSLY UNTREATED WITH CHEMOTHERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016019-39,0,0,0 2009-016022-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITA` CAMPUS BIOMEDICO,Studio aperto per la valutazione dell efficacia dell insulina spray buccale sul controllo glicometabolico in soggetti con ridotta tolleranza ai carboidrati (studio PREVORAL 2).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016022-14,0,0,0 2009-016025-34,2,2014-12-16,2014-12-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Daiichi Sankyo Pharma Development,"A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 1/2 STUDY OF ARQ 197 IN COMBINATION WITH IRINOTECAN AND CETUXIMAB IN SUBJECTS WITH METASTATIC COLORECTAL CANCER WITH WILD-TYPE KRAS WHO HAVE RECEIVED FRONT-LINE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016025-34,0,0,0 2009-016026-13,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,FUNDACION GELTAMO,Estudio de fase II de uso de anticuerpo monoclonal anti-CD20 (ofatumumab) más ESHAP seguido de trasplante autólogo de progenitores hemopoyéticos para el tratamiento de linfoma de Hodgkin clásico en re...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016026-13,0,0,0 2009-016027-62,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,GRUPO ESPAÑOL DE INVESTIGACION EN SARCOMAS,"ENSAYO CLÍNICO, FASE II, ABIERTO, NO CONTROLADO, MULTICÉNTRICO Y PROSPECTIVO, DE QUIMIOTERAPIA INTENSIVA, CIRUGÍA Y RADIOTERAPIA EN SARCOMA DE EWING DE NIÑOS Y ADULTOS JÓVENES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016027-62,0,0,0 2009-016029-32,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,STRUTTURA SEMPLICE GESTIONE-ORG.-FUNZ. HUB EMOFILIA,MECHANISM OF ACTION AND EFFICACY OF AN ALTERNATIVE IMMUNOTOLERANCE REGIMEN BASED ON MODULATION OF IMMUNE RESPONSES: A NEW CHANCE FOR HAEMOPHILIA PATIENTS WITH REFRACTORY INHIBITORS ?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016029-32,0,0,0 2009-016035-35,5,2010-03-03,2015-02-13,4,1,1,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"An Open-Label, Multi-Center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects with Confirmed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016035-35,1,1,0 2009-016035-35,5,2010-03-03,2015-02-13,4,1,1,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline S. A,"An Open-Label, Multi-Center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects with Confirmed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016035-35,1,1,0 2009-016038-29,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Danish Pain Research Center,Topical lidocaine: Predictors of response in peripheral nerve damage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016038-29,0,0,0 2009-016041-25,3,2012-02-27,2012-02-27,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Forest Research Institute, Inc.",A Long-Term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016041-25,0,0,0 2009-016042-57,1,,,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,Jose Carlos Flores González,"ENSAYO CLÍNICO ALEATORIZADO, DOBLE CIEGO, CONTROLADO Y PARALELO PARA COMPARAR LA EFICACIA DE LA NEBULIZACIÓN DE SUERO SALINO HIPERTÓNICO AL 3% CON ADRENALINA FRENTE A NEBULIZACIÓN DE SUERO SALINO HIP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016042-57,0,0,0 2009-016043-19,1,2011-11-14,2011-11-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Charité – University Medicine Berlin,Impact of a balanced infusion solution compound of 50% cristalloid and 50% colloid versus a unbalanced infusion solution of 100% cristalloid within a goal-directed hemodynamic protocol on acid-base ba...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016043-19,0,0,0 2009-016047-19,2,2015-03-18,2015-05-18,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Eisai Inc.,"An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination with Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients with Advanced Non-S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016047-19,0,0,0 2009-016050-41,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,1,Eisai Inc.,"An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Carboplatin + Gemcitabine versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients with Platinum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016050-41,0,0,0 2009-016051-22,3,2010-11-24,2010-11-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ChemoCentryx, Inc.","A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016051-22,0,0,0 2009-016053-18,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,UMC St Radboud,"The effect of vildagliptin on endothelium-dependent vasodilatation. A double blind, cross-over study in type 2 diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016053-18,0,0,0 2009-016054-40,1,2013-07-30,2013-07-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,PharmaMar S.A.,"Ensayo clínico de fase II, de optimización de dosis, abierto, de Zalypsis® (PM00104) en pacientes con mieloma múltiple recaído/refractario",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016054-40,0,0,0 2009-016055-22,2,,,0,0,0,0,0,0,4,0,1,2,0,0,0,0,0,"HY, HUS",Hepatitis A vaccine in patients with immunomodulative drugs,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016055-22,0,0,0 2009-016057-17,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Gentofte Hospital,"Behandling med nerveaktiverende medicin efter apopleksi - måling af genoptræningseffekt, patologisk træthed, muskelstyrke og knogleafkalkning",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016057-17,0,0,0 2009-016062-82,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SOUTH EASTERN EUROPEAN RESEARCH ONCOLOGY GROUP,Phase II clinical study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016062-82,0,0,0 2009-016064-36,11,2015-07-02,2015-07-02,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GW Pharma Ltd,"A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016064-36,0,0,0 2009-016064-36,11,2015-07-02,2015-07-02,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GW Pharma Ltd.,"A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016064-36,0,0,0 2009-016065-29,7,2014-11-24,2014-11-24,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GW Pharma Ltd.,"A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016065-29,0,0,0 2009-016065-29,7,2014-11-24,2014-11-24,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GW Pharma Ltd,"A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016065-29,0,0,0 2009-016066-91,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""","SAFETY AND EFFICACY OF ERYTHROPOIETIN IN AMYOTROPHIC LATERAL SCLEROSIS: A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016066-91,0,0,0 2009-016068-35,9,2011-06-21,2011-06-21,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis Recherche & Développement,A randomized double blind-placebo controlled dose ranging study to evaluate the efficacy and safety of SAR153191 in patients with Ankylosing Spondylitis (AS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016068-35,0,0,0 2009-016069-27,3,2013-08-05,2013-08-05,2,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium","A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016069-27,1,1,0 2009-016070-33,4,2010-07-30,2010-08-24,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase IIa, Randomized, Double-Blind, Placebo- and Active- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal Wom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016070-33,0,0,0 2009-016070-33,4,2010-07-30,2010-08-24,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Phase IIa, Randomized, Double-Blind, Placebo- and Active- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal Wom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016070-33,0,0,0 2009-016070-33,4,2010-07-30,2010-08-24,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Europe) Inc.,"A Phase IIa, Randomized, Double-Blind, Placebo- and Active- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal Wom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016070-33,0,0,0 2009-016070-33,4,2010-07-30,2010-08-24,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","A Phase IIa, Randomized, Double-Blind, Placebo- and Active- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of MK-6913 for the Treatment of Vasomotor Symptoms in Postmenopausal Wom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016070-33,0,0,0 2009-016075-30,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL`ADULTO,Therapy of the Young Adult Acute Lymphoblastic Leukemia (ALL): treatment intensification of the pediatric protocol AIEOP LLA-2000,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016075-30,0,0,0 2009-016077-14,1,2017-01-31,2017-01-31,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Mika Lehto,"Role of ALiskiren, a direct renin inhibitor, in preventing atrial Fibrillation in patients with a pacemaker; RALF Eteisvärinäkuorman määritys sydämentahdistimella aliskireenihoidossa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016077-14,0,0,0 2009-016078-33,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase III, observer-blind, randomised trial to evaluate the safety and immunogenicity of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuvan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016078-33,0,0,0 2009-016079-32,1,2012-08-31,2012-08-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsklinik für Psychiatrie - Spezialambulanz für Abhangigkeitserkrankungen,Auswirkungen der Substitutionstherapie mit Methadon und Buprenorphin auf die kognitiven Funktionen.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016079-32,0,0,0 2009-016080-11,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,VU University Medical Center,A COMPREHENSIVE AND TARGETED THERAPY APPROACH IN PEDIATRIC MALIGNANT PONTINE GLIOMAS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016080-11,0,0,0 2009-016082-29,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Erasme hospital,Role of Lanreotide in the Management of Paraduodenal Pancreatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016082-29,0,0,0 2009-016083-36,1,2013-04-23,2013-04-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Daiichi Sankyo Pharma Development,Phase 2 Study of CS-7017 and Erlotinib in Subjects with Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016083-36,0,0,0 2009-016086-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude de cohorte prospective ouverte, monocentrique, évaluant l'efficacité immunologique et la tolérance de la vaccination anti-grippale (saisonnière et H1N1) chez des patients suivis pour une maladie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016086-28,0,0,0 2009-016087-37,5,2011-01-26,2011-01-26,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MERCK SERONO SA,"A multinational, multicenter, single blood sampling exploratory pharmacogenetic study of the REGARD (the REbif vs Glatiramer Acetate in Relapsing MS Disease) trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016087-37,0,0,0 2009-016087-37,5,2011-01-26,2011-01-26,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Merck Serono S.A. - Geneva,"A multinational, multicenter, single blood sampling exploratory pharmacogenetic study of the REGARD (the REbif vs Glatiramer Acetate in Relapsing MS Disease) trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016087-37,0,0,0 2009-016088-13,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Kirurgisen sairaalan munuaisensiirtoihin liittyvän kivun hoidon tutkimusryhmä,Pregabaliinin vaikutus leikkauskipuun ja toipumiseen munuaisensiirtopotilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016088-13,0,0,0 2009-016090-14,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Dr. Vicente Estrada,"Análisis de los cambios en el tejido adiposo de pacientes con infección VIH y lipoatrofia en tratamiento con análogos de nucleósidos timidínicos, tras el cambio a monoterapia con Lopinavir/ritonavir",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016090-14,0,0,0 2009-016091-80,5,2012-11-08,2013-05-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"Estudio multicentrico, randomizado, abierto, para evaluar el inhibidor de la poli (ADP-ribosa) polimerasa 1 (PARP-1), BSI-201, administrado una o dos veces por semana, en combinación con gemcitabina/c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016091-80,0,0,0 2009-016091-80,5,2012-11-08,2013-05-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & de`veloppement,"Estudio multicentrico, randomizado, abierto, para evaluar el inhibidor de la poli (ADP-ribosa) polimerasa 1 (PARP-1), BSI-201, administrado una o dos veces por semana, en combinación con gemcitabina/c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016091-80,0,0,0 2009-016092-30,1,2011-01-15,2011-01-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik f.Innere Medizin I,Abt. f. Infektionen u.Tropenmedizin",THE PHARMACOKINETICS OF DAPTOMYCIN DURING CONTINUOUS VENOVENOUS HEMOFILTRATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016092-30,0,0,0 2009-016094-16,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,University Hospital Ghent,"Sevoflurane-Remifentanil interaction: Multiple response surfaces, validation of calibration stimuli, validation of the intraoperative isobole concept and investigating remifentanil induced opioid tole...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016094-16,0,0,0 2009-016095-68,12,2014-08-21,2014-08-29,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non infectious In...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016095-68,0,0,0 2009-016095-68,12,2014-08-21,2014-08-29,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non infectious In...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016095-68,0,0,0 2009-016096-29,1,2010-09-28,2010-09-28,1,1,0,0,0,1,2,0,0,1,0,0,1,0,3,University College London,Pilot of oral Sildenafil for the treatment of Pulmonary Hypertension in Thalassaemia with comparison to controls.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016096-29,0,0,0 2009-016119-38,5,2011-04-06,2011-04-06,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Amgen Inc,A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Rheumatoid Arthritis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016119-38,0,0,0 2009-016136-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Czech Lymphoma Research Organization s.r.o. (CLRO),"PET-RIMCEB: Early PET adjusted rituximab-based intensified immunochemotherapy in young poor risk DLBCL patients A phase III study A randomized, open-label trial comparing intensified immunochemotherap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016136-12,0,0,0 2009-016137-10,1,2014-10-03,2014-10-03,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Anne Vakkuri,"Lonkan ja polven tekonivelleikkausten yhteydessä käytettävien kipulääkkeiden (Oxycontin, Targiniq) vertailu leikkauksenjälkeisen pahoinvoinnin suhteen",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016137-10,0,0,0 2009-016138-29,13,2017-11-20,2017-11-20,13,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Pharma Mar, S.A.","Estudio de Fase III, Aleatorizado, Multicéntrico y Abierto de Plitidepsina en combinación con Dexametasona vs. Dexametasona sola en pacientes con Mieloma Múltiple Refractario o en Recaída.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016138-29,0,0,0 2009-016138-29,13,2017-11-20,2017-11-20,13,1,0,0,0,1,3,0,0,1,0,0,1,0,1,PHARMA MAR,"Estudio de Fase III, Aleatorizado, Multicéntrico y Abierto de Plitidepsina en combinación con Dexametasona vs. Dexametasona sola en pacientes con Mieloma Múltiple Refractario o en Recaída.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016138-29,0,0,0 2009-016139-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Medizinische Universität Wien, Univ.Klinik für Kinder-und Jugendheilkunde",The AT1 receptor antagonist losartan for the prevention of excessive aortic root dilatation in children and adolescents with Marfan syndrom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016139-36,0,0,0 2009-016140-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut Diagnostic per la Imatge,MRI in Clinically Isolated Syndromes and relapsing multiple sclerosis after single dose (0.1 mmol/kg) and cumulative dose (0.1 + 0.1 mmol/kg) of GADOVIST at 3.0T Estudio de resonancia magnética 3.0T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016140-39,0,0,0 2009-016142-44,2,2016-10-02,2016-10-02,2,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Hospital Ulm,Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016142-44,0,0,0 2009-016143-19,2,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,0,CHU de Toulouse,VALIDATION OF DYSKINESIA RATING SCALES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016143-19,0,0,0 2009-016143-19,2,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,0,Michael J. Fox Foundation for Parkinson’s Research,VALIDATION OF DYSKINESIA RATING SCALES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016143-19,0,0,0 2009-016151-21,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",A randomized multicentre phase II trial with pazopanib and weekly paclitaxel vs weekly paclitaxel in platinum resistant or refractory ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016151-21,0,0,0 2009-016154-40,1,2012-05-24,2012-05-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas AE,"A randomised, double-blind, placebo-controlled parallel group efficacy and safety trial of BI 10773 (10 and 25 mg administered orally once daily) over 24 weeks in patients with type 2 diabetes mellitu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016154-40,0,0,0 2009-016158-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,U.L.S.S. 16,Efficacy of intravitreal bevacizumab for exudative age-related macular degeneration.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016158-42,0,0,0 2009-016159-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen (UMCG),Vitamin D in addition to RAAS blockade and dietary sodium for the Treatment of Urinary Excretion of albumin: the ViRTUE-study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016159-23,0,0,0 2009-016163-12,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Amgen Inc,A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Psoriasis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016163-12,0,0,0 2009-016164-36,1,2010-02-10,2010-02-10,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Becton, Dickinson and Company, BD Technologies","A mono-center, open label, randomised 2-period crossover study to compare the pharmacokinetics and pharmacodynamics of continuous insulin infusion administered either intradermally or subcutaneously i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016164-36,0,0,0 2009-016176-78,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,Terapy with everolimus in liver transplant.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016176-78,0,0,0 2009-016178-33,14,2015-04-13,2015-09-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Unilfarma, Lda.","A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016178-33,0,0,0 2009-016178-33,14,2015-04-13,2015-09-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016178-33,0,0,0 2009-016178-33,14,2015-04-13,2015-09-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016178-33,0,0,0 2009-016178-33,14,2015-04-13,2015-09-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim B.V.,"A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016178-33,0,0,0 2009-016178-33,14,2015-04-13,2015-09-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim Pharmaceuticals, Inc.","A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016178-33,0,0,0 2009-016178-33,14,2015-04-13,2015-09-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co. KG,"A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016178-33,0,0,0 2009-016178-33,14,2015-04-13,2015-09-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas AE,"A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016178-33,0,0,0 2009-016178-33,14,2015-04-13,2015-09-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016178-33,0,0,0 2009-016178-33,14,2015-04-13,2015-09-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016178-33,0,0,0 2009-016178-33,14,2015-04-13,2015-09-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016178-33,0,0,0 2009-016178-33,14,2015-04-13,2015-09-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim Pharmaceuticals, España S.A.","A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016178-33,0,0,0 2009-016179-31,6,2012-07-26,2012-08-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A phase III, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg and 25 mg administered once daily) as add on to pre-existing antidiabetic therap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016179-31,0,0,0 2009-016179-31,6,2012-07-26,2012-08-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A phase III, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg and 25 mg administered once daily) as add on to pre-existing antidiabetic therap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016179-31,0,0,0 2009-016179-31,6,2012-07-26,2012-08-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim, Lda.","A phase III, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg and 25 mg administered once daily) as add on to pre-existing antidiabetic therap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016179-31,0,0,0 2009-016179-31,6,2012-07-26,2012-08-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A phase III, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg and 25 mg administered once daily) as add on to pre-existing antidiabetic therap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016179-31,0,0,0 2009-016179-31,6,2012-07-26,2012-08-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A phase III, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg and 25 mg administered once daily) as add on to pre-existing antidiabetic therap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016179-31,0,0,0 2009-016179-31,6,2012-07-26,2012-08-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A phase III, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg and 25 mg administered once daily) as add on to pre-existing antidiabetic therap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016179-31,0,0,0 2009-016196-29,11,2018-05-21,2018-05-25,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Non-infectious Intermediate-, Posterior-, or Pan-uveitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016196-29,0,0,0 2009-016196-29,11,2018-05-21,2018-05-25,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Non-infectious Intermediate-, Posterior-, or Pan-uveitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016196-29,0,0,0 2009-016196-29,11,2018-05-21,2018-05-25,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbvie Deutschland GmbH & Co. KG,"A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Non-infectious Intermediate-, Posterior-, or Pan-uveitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016196-29,0,0,0 2009-016197-33,3,2015-03-16,2015-03-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Celltrion, Inc.","A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination with Paclitaxel, in Patients with Metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016197-33,0,0,0 2009-016200-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Acino Supply AG,"An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (ACINO Goserelin 10.8 mg Implant) applied e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016200-23,0,0,0 2009-016203-32,2,2017-01-12,2017-01-12,1,1,1,0,0,2,3,0,0,2,0,0,0,0,1,Amgen Inc.,An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016203-32,1,1,0 2009-016203-32,2,2017-01-12,2017-01-12,1,1,1,0,0,2,3,0,0,2,0,0,0,0,1,Amgen Inc,An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016203-32,1,1,0 2009-016217-23,10,2015-07-17,2015-09-28,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prost...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016217-23,0,0,0 2009-016218-26,5,2011-06-16,2011-06-16,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016218-26,0,0,0 2009-016218-26,5,2011-06-16,2011-06-16,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.","A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016218-26,0,0,0 2009-016218-26,5,2011-06-16,2011-06-16,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Merck Sharp & Dohme (Europe) Inc.,"A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016218-26,0,0,0 2009-016218-26,5,2011-06-16,2011-06-16,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016218-26,0,0,0 2009-016218-26,5,2011-06-16,2011-06-16,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,MSD Finland Oy,"A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016218-26,0,0,0 2009-016223-56,1,2013-10-21,2013-10-21,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Kyowa Hakko Kirin Pharma, Inc.","An Open-Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination with Bortezomib in Subjects with Relapsed and/or Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016223-56,0,0,0 2009-016226-13,1,2010-12-16,2010-12-16,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Agence nationale de recherches sur le sida et les hépatites virales,Etude de phase II randomisée évaluant l'immunogénicité et la tolérance du vaccin antigrippal A(H1N1)v adjuvanté comparativement au vaccin antigrippal A(H1N1)v non adjuvanté chez des patients infectés ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016226-13,0,0,0 2009-016240-40,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,"VERISFIELD (UK) LTD, GREEK BRANCH","MULTICENTER, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE WITH THE REFERENCE PRODUCT CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE THERAPY WITH THE COMBINATION OF BENZOYL PEROXIDE-ERYTHROMYCIN/VE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016240-40,0,0,0 2009-016241-25,1,2012-10-29,2012-10-29,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"VERISFIELD (UK) LTD, GREEK BRANCH","MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARATIVE WITH THE REFERENCE PRODUCT CLINICAL STUDY TO DEMONSTRATE THE SAFETY AND EFFICACY OF THE THERAPY WITH THE COMBINATION ERYTHROMYCIN-ISOTRETINOIN/VERISF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016241-25,0,0,0 2009-016243-20,2,2012-03-19,2012-03-19,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A phase III randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 10773 and sitagliptin administered orally over 24 weeks, in drug naïve patients with type 2 diab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016243-20,0,0,0 2009-016243-20,2,2012-03-19,2012-03-19,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A phase III randomised, double-blind, placebo-controlled parallel group efficacy and safety study of BI 10773 and sitagliptin administered orally over 24 weeks, in drug naïve patients with type 2 diab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016243-20,0,0,0 2009-016244-39,10,2015-08-28,2015-08-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,BOEHRINGER ING.,"A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016244-39,0,0,0 2009-016244-39,10,2015-08-28,2015-08-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Unilfarma, Lda.","A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016244-39,0,0,0 2009-016244-39,10,2015-08-28,2015-08-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Limited,"A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016244-39,0,0,0 2009-016244-39,10,2015-08-28,2015-08-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim AB,"A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016244-39,0,0,0 2009-016244-39,10,2015-08-28,2015-08-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Norway KS,"A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016244-39,0,0,0 2009-016244-39,10,2015-08-28,2015-08-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim B.V.,"A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016244-39,0,0,0 2009-016244-39,10,2015-08-28,2015-08-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim RCV & Co KG,"A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016244-39,0,0,0 2009-016244-39,10,2015-08-28,2015-08-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,,"A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016244-39,0,0,0 2009-016244-39,10,2015-08-28,2015-08-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim España S.A,"A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016244-39,0,0,0 2009-016244-39,10,2015-08-28,2015-08-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Finland Ky,"A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks with a 104-week extension per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016244-39,0,0,0 2009-016245-26,2,2012-06-28,2012-06-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A,"Estudio de Fase 2, de 17 Semanas, Multicéntrico, Aleatorizado y Doble Ciego, Sobre la Eficacia de LY2140023 Combinado con Tratamiento Clínico Habitual Comparado con Placebo Combinado con Tratamiento C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016245-26,0,0,0 2009-016245-26,2,2012-06-28,2012-06-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ELI LILLY,"Estudio de Fase 2, de 17 Semanas, Multicéntrico, Aleatorizado y Doble Ciego, Sobre la Eficacia de LY2140023 Combinado con Tratamiento Clínico Habitual Comparado con Placebo Combinado con Tratamiento C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016245-26,0,0,0 2009-016246-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOSPITAL SANT JOAN DE DÉU,Efectos Sobre Marcadores de Riesgo Cardiovascular de la Adición de Metformina al Tratamiento con Hormona de Crecimiento en Pacientes Prepuberales con Antecedentes de Peso Bajo al Nacer para la Edad Ge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016246-12,0,0,0 2009-016248-37,1,2012-06-18,2012-06-18,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Pfizer Ltd., Ramsgate Road, Sandwich, Kent. CT13 9NJ UNITED KINGDOM",A SINGLE ARM SINGLE CENTRE STUDY TO INVESTIGATE SAFETY AND EFFICACY OF SILDENAFIL IN NEAR TERM AND TERM NEWBORNS WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016248-37,0,0,0 2009-016251-21,5,2011-11-15,2011-11-16,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A multicentre, randomised, placebo- and active-controlled, 5-way crossover trial to characterise the pharmacokinetics and evaluate the bronchodilator efficacy and safety of once-daily tiotropium deliv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016251-21,0,0,0 2009-016251-21,5,2011-11-15,2011-11-16,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim (UK) Ltd,"A multicentre, randomised, placebo- and active-controlled, 5-way crossover trial to characterise the pharmacokinetics and evaluate the bronchodilator efficacy and safety of once-daily tiotropium deliv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016251-21,0,0,0 2009-016251-21,5,2011-11-15,2011-11-16,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A multicentre, randomised, placebo- and active-controlled, 5-way crossover trial to characterise the pharmacokinetics and evaluate the bronchodilator efficacy and safety of once-daily tiotropium deliv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016251-21,0,0,0 2009-016251-21,5,2011-11-15,2011-11-16,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A multicentre, randomised, placebo- and active-controlled, 5-way crossover trial to characterise the pharmacokinetics and evaluate the bronchodilator efficacy and safety of once-daily tiotropium deliv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016251-21,0,0,0 2009-016251-21,5,2011-11-15,2011-11-16,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"A multicentre, randomised, placebo- and active-controlled, 5-way crossover trial to characterise the pharmacokinetics and evaluate the bronchodilator efficacy and safety of once-daily tiotropium deliv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016251-21,0,0,0 2009-016258-41,4,2012-02-03,2012-02-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 24 weeks in patients with typ 2 dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016258-41,0,0,0 2009-016258-41,4,2012-02-03,2012-02-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 24 weeks in patients with typ 2 dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016258-41,0,0,0 2009-016258-41,4,2012-02-03,2012-02-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOehringer Ingelheim RCV GmbH&Co KG,"A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 24 weeks in patients with typ 2 dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016258-41,0,0,0 2009-016258-41,4,2012-02-03,2012-02-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 24 weeks in patients with typ 2 dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016258-41,0,0,0 2009-016261-28,1,2010-04-19,2010-04-19,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,"Randomized, observer-blind, multi-center, reference-controlled phase IIb study to evaluate the efficacy of topically applied LAS41002 lotion in the treatment of scalp psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016261-28,0,0,0 2009-016266-90,13,2009-10-08,2013-10-08,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A randomized, double-blind, placebo-controlled, multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of SAR153191 on top of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016266-90,0,0,0 2009-016266-90,13,2009-10-08,2013-10-08,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis Recherche & Développement,"A randomized, double-blind, placebo-controlled, multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of SAR153191 on top of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016266-90,0,0,0 2009-016267-11,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Inserm,Etude des réponses immunitaires après vaccination anit-influenza saisonnier et anti-H1N1 variant pandémique dans une population de personnel soignant.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016267-11,0,0,0 2009-016268-35,2,2011-03-30,2011-05-10,2,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, randomized, observer blind study to evaluate the safety and immunogenicity of three different vaccination schedules employing two formulations of the monovalent A/California/7/2009 (H1N1)v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016268-35,0,0,0 2009-016278-34,3,2012-07-31,2012-07-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Imperial College London,UMPIRE - Use of a Multidrug Pill In Reducing cv Events - a randomised controlled trial of fixed dose combination medication and usual care in those at high risk of cardiovascular disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016278-34,0,0,0 2009-016278-34,3,2012-07-31,2012-07-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Universitair Medisch Centrum Utrecht,UMPIRE - Use of a Multidrug Pill In Reducing cv Events - a randomised controlled trial of fixed dose combination medication and usual care in those at high risk of cardiovascular disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016278-34,0,0,0 2009-016298-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Fundación para la Investigación Biomédica del Hospital Universitario La Paz,",Ensayo clínico individual en fase I-IIa para conocer la factibilidad y seguridad del uso autólogo de células madre expandidas (e-ASC) derivadas de la grasa en el tratamiento local de la incontinencia ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016298-14,0,0,0 2009-016300-23,1,2011-06-16,2011-06-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,Pilot double blind randomised placebo controlled crossover trial of Hyoscine for the treatment of Clozapine induced nocturnal sialorrhoea.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016300-23,0,0,0 2009-016302-16,1,2010-11-02,2010-11-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dow Pharmaceutical Sciences Inc.,"A Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of IDP-109 Solution in the Treatment of Patients with Verrucae Vulgares",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016302-16,0,0,0 2009-016317-20,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II,PILOT STUDY TO ASSESS SAFETY AND TOLERABILITY OF LITHIUM ON SPINOCEREBELLAR ATAXIA OF TYPE 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016317-20,0,0,0 2009-016337-10,1,2012-11-27,2012-11-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Grünenthal GmbH,Lidocaine 5% medicated plaster for the topical treatment of localized chronic postoperative neuropathic pain after total knee replacement or thoracotomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016337-10,0,0,0 2009-016338-29,1,2018-09-18,2018-09-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,ARCAGY,Essai randomisé multicentrique de phase III comparant la poursuite du traitement d’entretien par l’association bevacizumab + taxane versus remplacement par bevacizumab + exemestane chez des patientes ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016338-29,0,0,0 2009-016357-17,5,2018-04-03,2018-04-03,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) versus Placebo in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-Positive,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016357-17,1,1,0 2009-016360-37,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,0,Björn Holmberg,TREATMENT OF DYSKINESIAS IN PARKINSON’S DISEASE WITH OSU6162 – A PILOT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016360-37,0,0,0 2009-016361-28,3,2017-09-11,2017-09-11,1,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted with Ritonavir (RTV) Liquid with an Opti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016361-28,1,1,0 2009-016362-85,1,2010-11-04,2010-11-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,SIGMA-TAU,"A PILOT, RANDOMIZED, SINGLE SITE, 3 PARALLEL ARMS, OPEN-LABEL STUDY IN PATIENTS ON CHRONIC DIALYSIS WITH END STAGE RENAL DISEASE (ESRD) TO EVALUATE THE ENHANCING EFFECT OF TWO DOSES OF THYMOSIN ALPHA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016362-85,0,0,0 2009-016364-36,1,2015-06-30,2015-06-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,3,,Injection of Autologous Bone Marrow Cells into Damaged Myocardium of No-option Patients with Ischemic Heart Failure: a randomized placebo controlled trail.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016364-36,0,0,0 2009-016365-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,MIGUEL CASARES FERNÁNDEZ-ALVÉS,"Aplicación de células madre mesenquimales obtenidas de tejido adiposo del paciente quemado, para el tratamiento de la quemadura. Application of Mesenchymal Stem Cells in the management of the burn wou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016365-29,0,0,0 2009-016366-88,6,2012-04-17,2012-04-17,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study, to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016366-88,0,0,0 2009-016371-30,3,2011-06-07,2011-06-07,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Cardiokine Biopharma LLC,"International, multi-center, study of a twenty-eight week, open-label, titrated oral lixivaptan administration in patients with chronic hyponatremia: extension to studies CK-LX3401, 3405, and 3430",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016371-30,0,0,0 2009-016374-32,13,2011-05-06,2011-05-06,12,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Merck Sharp & Dohme Corp.,"""Ensayo Clínico Mundial, Aleatorizado, Doble Ciego, Controlado con Placebo, con Grupos Paralelos para Evaluar la Seguridad y Eficacia de Rizatriptán en el Tratamiento de las Crisis de Migraña en Niños...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016374-32,1,1,0 2009-016374-32,13,2011-05-06,2011-05-06,12,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"MERCK & CO., INC.","""Ensayo Clínico Mundial, Aleatorizado, Doble Ciego, Controlado con Placebo, con Grupos Paralelos para Evaluar la Seguridad y Eficacia de Rizatriptán en el Tratamiento de las Crisis de Migraña en Niños...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016374-32,1,1,0 2009-016374-32,13,2011-05-06,2011-05-06,12,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Merck & Co., Inc.","""Ensayo Clínico Mundial, Aleatorizado, Doble Ciego, Controlado con Placebo, con Grupos Paralelos para Evaluar la Seguridad y Eficacia de Rizatriptán en el Tratamiento de las Crisis de Migraña en Niños...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016374-32,1,1,0 2009-016374-32,13,2011-05-06,2011-05-06,12,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Merck Sharp & Dohme Corp,"""Ensayo Clínico Mundial, Aleatorizado, Doble Ciego, Controlado con Placebo, con Grupos Paralelos para Evaluar la Seguridad y Eficacia de Rizatriptán en el Tratamiento de las Crisis de Migraña en Niños...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016374-32,1,1,0 2009-016375-30,14,2011-04-18,2011-04-29,13,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Merck & Co., Inc., One Merck Drive, P.O. Box 100, Whitehouse Station, NJ, 08889-0100, USA","""Ensayo clínico mundial, abierto, para analizar la seguridad y tolerabilidad a largo plazo de rizatriptán en el tratamiento de la migraña, con o sin aura, de niños migrañosos."" // ""A Worldwide, Open L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016375-30,1,1,0 2009-016375-30,14,2011-04-18,2011-04-29,13,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Merck Sharp & Dohme Corp.,"""Ensayo clínico mundial, abierto, para analizar la seguridad y tolerabilidad a largo plazo de rizatriptán en el tratamiento de la migraña, con o sin aura, de niños migrañosos."" // ""A Worldwide, Open L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016375-30,1,1,0 2009-016375-30,14,2011-04-18,2011-04-29,13,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Merck & Co., Inc.","""Ensayo clínico mundial, abierto, para analizar la seguridad y tolerabilidad a largo plazo de rizatriptán en el tratamiento de la migraña, con o sin aura, de niños migrañosos."" // ""A Worldwide, Open L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016375-30,1,1,0 2009-016376-76,1,2010-04-01,2010-04-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merck & Co., Inc","A Phase II Extension of a Randomized, Open-Label, Multiple-Rising Dose Clinical Trial to Study the Efficacy and Safety of MK-2578 for the Maintenance of Anemia Treatment in Patients with Chronic Kidne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016376-76,0,0,0 2009-016377-15,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II,"DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO TEST THE EFFICACY, SAFETY AND TOLERABILITY OF LITHIUM IN MULTIPLE SYSTEM ATROPHY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016377-15,0,0,0 2009-016378-34,2,2019-03-06,2019-03-06,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"MedImmune, LLC","An Open Label, Phase 1/2 Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016378-34,0,0,0 2009-016378-34,2,2019-03-06,2019-03-06,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,MedImmune LLC,"An Open Label, Phase 1/2 Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016378-34,0,0,0 2009-016381-88,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FUNDACIÓ PRIVADA CLÍNIC PER A LA RECERCA BIOMÈDICA,ESTUDIO PARA VALORAR LA SEGURIDAD Y LA EFICACIA DEL HIERRO ENDOVENOSO EN PACIENTES CON FRACTURAS DE CADERA EN LA PREVENCIÓN DE LA ANEMIA PERIOPERATORIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016381-88,0,0,0 2009-016382-29,3,2010-09-10,2011-01-31,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Piramal Life Sciences Limited,"A Phase II, 12-Week Randomised, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate Safety, Tolerability, Pharmacokinetics and Effect On Glycemic Control of P1736-05 in Subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016382-29,0,0,0 2009-016383-36,2,2011-11-21,2011-11-21,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients with Haemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016383-36,0,0,0 2009-016383-36,2,2011-11-21,2011-11-21,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients with Haemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016383-36,0,0,0 2009-016384-11,1,2018-08-06,2018-08-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU Caen,Effects of EXEnatide on Glycemic Control and Weight over 26 weeks in Continuous Subcutaneous Insulin Infusion (CSII) Treated Patients with Type 2 Diabetes : a phase 2/3 doUble blind randoMized Placebo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016384-11,0,0,0 2009-016386-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Pharmacokinetics of critically ill patients with invasive candidiasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016386-28,0,0,0 2009-016417-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de SAINT-ETIENNE,Fondaparinux population pharmacokinetic to morbid obese patients in post-operatory bariatric surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016417-15,0,0,0 2009-016442-74,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,"Trasplante autólogo de células madre mesenquimales en esclerosis múltiple: ensayo clínico fase II aleatorizado, enmascarado y cruzado con placebo.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016442-74,0,0,0 2009-016443-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Poitiers,Etude prospective du rôle prédictif du polymorphisme fonctionnel 5-HTTLPR sur la réponse au traitement par l’escitalopram des patients souffrant d’un trouble obsessionnel compulsif,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016443-19,0,0,0 2009-016445-25,1,2011-10-07,2011-10-07,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Ortopædkirurgisk Afd. E, Århus Universitetshospital",Undersøgelse af postoperative bolus infusioner ved primær hoftealloplastik,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016445-25,0,0,0 2009-016446-50,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Maastricht University - CAPHRI School for Public Health and Primary Care,Helping more smokers to quit by combining varenicline with counselling for smoking cessation. The COVACO randomized controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016446-50,0,0,0 2009-016448-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Curie,Traitement adjuvant dans les rétinoblastomes unilatéraux étendus énucléés d’emblée.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016448-38,0,0,0 2009-016449-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Banc de Sang i Teixits (BST),"Regeneración del cartílago articular en gonartrosis de IIº y IIIer grados mediante infiltración articular de Xcel-m-condro-alfa* *Células progenitoras mesenquimales de médula ósea autóloga, expandida...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016449-24,0,0,0 2009-016453-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,"Phase II study of preoperative bevacizumab plus weekly paclitaxel, carboplatin and metronomic cyclophosphamide � trastuzumab and endocrine therapy for inflammatory breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016453-17,0,0,0 2009-016455-21,1,2011-12-01,2011-12-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Fundació Lluita contra la SIDA,PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SWITCHING PROTEASE INHIBITOR TO ETRAVIRINE IN HIV-1-INFECTED SUBJECTS WITH VIREMIA SUPPRESSION (ESTUDIO PILOTO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016455-21,0,0,0 2009-016457-18,15,2013-09-26,2013-09-26,15,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd,"A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016457-18,0,0,0 2009-016457-18,15,2013-09-26,2013-09-26,15,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ASTELLAS PHARMA EUROPE Ltd,"A Multicentre, Single-Arm, Open-Label Study Of The Repeated Administration Of QUTENZA For The Treatment Of Peripheral Neuropathic Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016457-18,0,0,0 2009-016458-42,8,2014-02-27,2014-02-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Randomized, Controlled, Long-term Safety Study Evaluating the Effect of Repeated Applications of QUTENZA plus Standard of Care versus Standard of Care alone in Subjects with Painful Diabetic Perip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016458-42,0,0,0 2009-016458-42,8,2014-02-27,2014-02-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe R&D,"A Randomized, Controlled, Long-term Safety Study Evaluating the Effect of Repeated Applications of QUTENZA plus Standard of Care versus Standard of Care alone in Subjects with Painful Diabetic Perip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016458-42,0,0,0 2009-016458-42,8,2014-02-27,2014-02-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTELLAS PHARMA,"A Randomized, Controlled, Long-term Safety Study Evaluating the Effect of Repeated Applications of QUTENZA plus Standard of Care versus Standard of Care alone in Subjects with Painful Diabetic Perip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016458-42,0,0,0 2009-016459-23,1,2016-04-19,2016-04-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Oxford,Single arm NCRI feasibility study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016459-23,0,0,0 2009-016463-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,LWL University Hospital Bochum,Antidepressive response to add-on occupational therapy in patients with major depression: A randomized controlled multicentre trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016463-10,0,0,0 2009-016466-82,2,2020-02-28,2020-02-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CO.DON AG,"Prospective, randomised, open label, multicentre Phase-III clinical trial to compare the efficacy and safety of the treatment with the autologous chondrocyte transplantation product co.don chondrosphe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016466-82,0,0,0 2009-016468-35,2,,,0,1,0,0,0,0,3,0,0,1,1,0,0,1,1,AstraZeneca AB,"A randomised, double-blind, phase III efficacy and safety study of cediranib (RECENTIN™ ) when added to cisplatin plus a fluoropyrimidine, compared with cisplatin plus a fluoropyrimidine alone, in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016468-35,0,0,0 2009-016475-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Treatment of advanced hepatocellular carcinoma (HCC) with portal vein thrombosis by hepatic intra-arterial injection of microspheres loaded with Yttrium-90 (Thera-Sphere),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016475-29,0,0,0 2009-016476-67,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,"treatment of healthcare-associated pneumonia: a prospective, multicenter study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016476-67,0,0,0 2009-016480-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,P Pierre Dellamonica,"“No Nuc, No Boost” : A phase 2 pilot study of simplification by Maraviroc-Raltegravir following 6 months of treatment with Maraviroc-Raltegravir-Tenofovir-Emtricitabine in naive patients infected by C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016480-11,0,0,0 2009-016482-28,1,2018-09-06,2018-09-06,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Charite Universitätsmedizin Berlin,SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy Sunphenon EGCg (Epigallocatechin-Gallat) in der Muskeldystrophie vom Typ Duchenne,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016482-28,0,0,0 2009-016487-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOIM GRUPPO ONCOLOGICO MERIDIONALE,Phase II multicenter study with Fotemustine and Temozolomide modulation in patients with metastatic melanoma (MM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016487-36,0,0,0 2009-016488-12,8,2014-01-30,2014-01-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016488-12,0,0,0 2009-016488-12,8,2014-01-30,2014-01-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016488-12,0,0,0 2009-016489-10,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,University of Heidelberg,Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016489-10,0,0,0 2009-016490-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,Medicina Regenerativa en la Superficie Ocular: Aplicación de terapia celular para la reparación de la superficie ocular mediante amplificación ex vivo de células progenitoras autólogas del limbo escle...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016490-16,0,0,0 2009-016492-29,3,2013-02-08,2013-02-12,2,1,1,0,0,0,3,0,2,2,0,0,0,0,1,AstraZeneca AB,An Efficacy and 2-Year Safety Study of Open-label Rosuvastatin in Children and Adolescents (aged from 6 to less than 18 years) with Familial Hypercholesterolaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016492-29,1,1,0 2009-016498-13,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación para la Formación en Investigación Sanitarias de la Región de Murcia,Estudio aleatorizado y doble-ciego para valorar el beneficio del tratamiento con testosterona en pacientes deficientes con IC avanzada (TIC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016498-13,0,0,0 2009-016500-24,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Fundació Clinic per a la Recerca Biomèdica,"Estudio multicéntrico, aleatorizado, doble-ciego, controlado con placebo, sobre la eficacia de la asociación de simvastatina al tratamiento estándar en la prevención de la recidiva hemorrágica en paci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016500-24,0,0,0 2009-016501-41,5,2011-10-25,2011-10-25,5,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Omrix Biopharmaceuticals Ltd,"A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Evicel as an Adjunct to Sutured Dural Repair",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016501-41,0,0,0 2009-016502-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Antwerp : Department Respiratory Medicine,"A randomized, double-blind, placebo-controlled, two way cross-over study to assess the particle deposition and acute effects of formoterol and budesonide combination therapy (Symbicort® forte Turbohal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016502-16,0,0,0 2009-016504-22,5,2013-12-06,2013-12-06,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AFFiRiS AG,"A randomised, controlled, parallel group, double-blind, multi-center, phase II study to assess the clinical- and immunological activity as well as the safety and tolerability of different doses/formul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016504-22,1,0,0 2009-016506-17,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,U.O. Terapia intensiva,RIGOROUS NORMOXYA MAINTENANCE IN INTENSIVE CARE UNIT: RANDOMIZED CONTROLLED TRIAL.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016506-17,0,0,0 2009-016508-21,1,2010-10-31,2010-10-31,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Hospital Universitario Vall D'Hebron. Departamento de Medicina Interna,ESTUDIO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LA LENALIDOMIDA EN EL TRATAMIENTO DEL LUPUS ERITEMATOSO CUTÁNEO.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016508-21,0,0,0 2009-016509-41,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"WWCR, WORLDWIDE CLINICAL RESEARCH",A double-blind placebo controlled randomized trial of PF-804 in patients with incurable stage IIIB/IV non-small cell lung cancer after failure of standard therapy for advanced or metastatic disease. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016509-41,0,0,0 2009-016513-26,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Centre Hospitalier Universitaire de Besançon,Etude pilote multicentrique randomisée en double aveugle des effets de la toxine botulique dans le traitement des vestibulodynies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016513-26,0,0,0 2009-016516-21,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,CHU de BREST,"Comparaison de l’anesthésie par bloc axillaire sous échographie avec 40 ou 25 ml de xylocaine 1,5% adrénalinée dans la prise en charge de la chirurgie de l’avant-bras et de la main.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016516-21,0,0,0 2009-016517-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Javier Pérez Gisbert,"ESTUDIO FASE IV, PROSPECTIVO, ALEATORIZADO Y COMPARATIVO ENTRE LA TERAPIA “SECUENCIAL” Y “CONCOMITANTE” PARA LA ERRADICACIÓN DE Helicobacter pylori EN LA PRÁCTICA CLÍNICA HABITUAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016517-14,0,0,0 2009-016522-14,7,2017-09-14,2017-09-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin alfa for the Treatment of Anaemic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Studio mul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016522-14,0,0,0 2009-016522-14,7,2017-09-14,2017-09-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN INC.,"A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin alfa for the Treatment of Anaemic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Studio mul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016522-14,0,0,0 2009-016523-61,1,2012-02-15,2012-02-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King’s College London,18F-fluoride PET for Early Non-invasive Assessment of Cortical Bone Formation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016523-61,0,0,0 2009-016523-61,1,2012-02-15,2012-02-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's & St Thomas NHS Trust,18F-fluoride PET for Early Non-invasive Assessment of Cortical Bone Formation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016523-61,0,0,0 2009-016525-34,10,2012-05-29,2012-05-29,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 (Canagliflozin) Compared with Si...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016525-34,0,0,0 2009-016528-30,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,CHU DIJON,"Etude multicentrique, randomisée de non infériorité de deux stratégies thérapeutiques chez des enfants atteints de toxoplasmose congénitale",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016528-30,0,0,0 2009-016529-32,13,2016-01-27,2017-01-27,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GW PHARMA LTD,"A multicenter, non-comparative, open-label extension study to assess the long term safety of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in patients with uncontrolled persist...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016529-32,0,0,0 2009-016529-32,13,2016-01-27,2017-01-27,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GW Pharma Ltd,"A multicenter, non-comparative, open-label extension study to assess the long term safety of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in patients with uncontrolled persist...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016529-32,0,0,0 2009-016529-32,13,2016-01-27,2017-01-27,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GW Pharma Ltd.,"A multicenter, non-comparative, open-label extension study to assess the long term safety of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctive therapy in patients with uncontrolled persist...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016529-32,0,0,0 2009-016531-35,1,2012-04-16,2012-04-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Shire Pharmaceutical Development Ltd,"A Proof of Concept, Phase 2a, Double-blind, Parallel Group, Randomised, Placebo controlled Study to Assess the Effect of Lanthanum Carbonate on intact FGF23 in Normo-phosphataemic Subjects with Stage ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016531-35,0,0,0 2009-016532-12,1,2012-12-31,2012-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical University of Vienna,Target tissue concentration of standard antibiotic treatment in coronary artery bypass grafting using left internal mammary artery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016532-12,0,0,0 2009-016537-98,1,2010-12-22,2010-12-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sirtris Pharmaceuticals Inc.,"A Phase IIa, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Assess the Safety, Tolerability and Activity of Oral SRT2104 Capsules Administered for 28 days to Subjects with Type 2 Diabe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016537-98,0,0,0 2009-016560-36,6,2015-03-17,2015-03-31,5,0,0,0,0,0,2,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,A LONG-TERM MONITORING STUDY TO EVALUATE THE PERSISTENCE OF DIRECT ACTING ANTIVIRAL (DAA) TREATMENT-RESISTANT MUTATIONS OR THE DURABILITY OF SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PATIENTS TREATED WI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016560-36,1,0,0 2009-016566-82,1,2014-07-07,2014-07-07,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Belfast Health and Social Care Trust,Skin bacteria as a source of surgical infections: molecular epidemiology and prevention of wound contaimination,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016566-82,0,0,0 2009-016566-82,1,2014-07-07,2014-07-07,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Queen's University Belfast,Skin bacteria as a source of surgical infections: molecular epidemiology and prevention of wound contaimination,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016566-82,0,0,0 2009-016568-36,17,2013-05-06,2013-05-07,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"Estudio aleatorizado, doble ciego y con triple simulación para comparar la eficacia de otamixabán con la de heparina no fraccionada más eptifibatida en pacientes con angina inestable/infarto de miocar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016568-36,0,0,0 2009-016568-36,17,2013-05-06,2013-05-07,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & de`veloppement,"Estudio aleatorizado, doble ciego y con triple simulación para comparar la eficacia de otamixabán con la de heparina no fraccionada más eptifibatida en pacientes con angina inestable/infarto de miocar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016568-36,0,0,0 2009-016571-30,1,2010-03-12,2010-03-12,1,1,0,0,1,0,3,0,1,1,0,0,1,0,1,Dermal Laboratories Ltd,"A study to determine the effects on stratum corneum of a clinical hand cleansing protocol comparing two antiseptic hand washes, using non-invasive instrumental methods in human volunteers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016571-30,0,0,0 2009-016572-78,1,2010-06-28,2010-06-28,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,Dermal Laboratories Ltd,Arm immersion test to compare the skin effects of routine bathing with and without the use of an emollient bath additive.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016572-78,0,0,0 2009-016579-31,1,2014-10-13,2014-10-13,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Oxford,An open label randomised controlled study to evaluate the induction of immune memory following infant vaccination with a glyco-conjugate Neisseria meningitidis serogroup C vaccine and to assess the im...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016579-31,0,0,0 2009-016581-80,2,2010-10-12,2010-10-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double-blind, placebo-controlled, three-way crossover, repeat dose pilot study comparing the effect of inhaled fluticasone furoate/GW642444M combination and fluticasone furoate on the al...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016581-80,0,0,0 2009-016584-10,3,2018-12-09,2018-12-09,2,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung SAKK,Multimodal therapy with and without cetuximab in patients with locally advanced esophageal carcinoma. An open-label phase III trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016584-10,1,0,0 2009-016587-36,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,"Schering Plough, S.A",Artritis de cadera asociada a la EA. Eficacia y Seguridad del tratamiento precoz con Infliximab (Remicade®),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016587-36,0,0,0 2009-016588-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Grupo Oncológico para el Tratamiento y Estudio de los Linfomas (GOTEL),ENSAYO FASE II PARA VALORAR LA COMBINACIÓN DE LENALIDOMIDA CON DOSIS METRONÓMICAS DE CICLOFOSFAMIDA EN PACIENTES CON LINFOMA DE HODGKIN CLÁSICO REFRACTARIO O EN RECAÍDA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016588-12,0,0,0 2009-016590-15,6,2015-06-24,2015-06-24,6,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016590-15,0,0,0 2009-016590-15,6,2015-06-24,2015-06-24,6,1,1,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016590-15,0,0,0 2009-016591-68,1,2012-07-31,2012-07-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Odense University Hospital,Placebo-controlled trial investigating the effect of Vitamin K3-lotion for the treatment of cetuximab induced folliculitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016591-68,0,0,0 2009-016592-29,1,2010-09-16,2010-09-16,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Dundee,Reversibility of Acute β-Blocker Induced Bronchoconstriction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016592-29,0,0,0 2009-016595-77,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Juan Francisco Navarro González,Efecto de la combinación estatinas-aspirina versus estatinas-pentoxifilina sobre la lesión aterosclerótica en pacientes con enfermedad renal crónica.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016595-77,0,0,0 2009-016596-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Gregorio Marañón,CORTICOIDES PARA LA PREVENCIÓN DE LAS COMPLICACIONES DE LA VIA AÉREA POSTEXTUBACIÓN EN NIÑOS CRÍTICOS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016596-30,0,0,0 2009-016597-32,4,2012-03-13,2012-03-13,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Innovacell Biotechnologie AG,Skeletal muscle-derived cell implantation in female patients with stress urinary incontinence: a multinational and multicenter open follow-up study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016597-32,1,0,0 2009-016599-66,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Progreso y Salud,Ensayo Clínico Fase II sobre el Efecto de la Infusión Intracoronaria de Células Mononucleadas de Médula Ósea Sobre la Recuperación Funcional en Pacientes con Infarto Crónico Anterior y Depresión Sever...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016599-66,0,0,0 2009-016600-23,1,2012-06-02,2012-06-02,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Hull and East Yorkshire Hospitals NHS Trust,"A double blind, randomised, placebo controlled trial to study the clinical effectiveness of Angiotensin Converting Enzyme (ACE) inhibitors, ramipril,in patients with intermittent claudication",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016600-23,0,0,0 2009-016601-42,3,2014-06-19,2014-06-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016601-42,0,0,0 2009-016601-42,3,2014-06-19,2014-06-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Medicament,A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016601-42,0,0,0 2009-016604-23,3,2010-08-06,2010-08-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multi-center, double-blind, placebo-controlled, randomized study to compare the effect of a subcutaneous canakinumab administration to placebo in patients with Impaired Glucose Tolerance or patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016604-23,0,0,0 2009-016604-23,3,2010-08-06,2010-08-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, double-blind, placebo-controlled, randomized study to compare the effect of a subcutaneous canakinumab administration to placebo in patients with Impaired Glucose Tolerance or patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016604-23,0,0,0 2009-016607-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU Amiens,Traitement des leucémies primitives à plasmocytes du sujets de moins de 70 ans,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016607-33,0,0,0 2009-016608-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU AMIENS,Administration de Surfactant précoce : Evaluation chez le Nouveau-né ≥ 35 semaines d’aménorrhée présentant une détresse respiratoire,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016608-22,0,0,0 2009-016610-24,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,"Bortezomib, Desametasone e Doxorubicina liposomiale peghilata come terapia di induzione prima di ASCT (autologous stem cell transplantation) ad intensita` ridotta in pazienti anziani affetti da mielom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016610-24,0,0,0 2009-016613-22,2,2011-06-16,2011-06-16,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,PeP-Tonic Medical AB,"A double-blind, placebo controlled multi-centre study to evaluate the effects of topical Oxytocin on vaginal atrophy in postmenopausal women.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016613-22,0,0,0 2009-016616-21,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Wuerzburg University Hospital,"Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma followed by Response-adapted Consolidation and Lena...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016616-21,0,0,0 2009-016620-32,1,,,0,1,0,0,0,1,2,0,0,0,0,0,0,0,0,"Dept. of Neurological Surgery, Medical University of Vienna",Intravenous application of milrinone for the treatment and prophylaxis of SAB induced vasospasm Intravenöse Applikation von Milrinone zur Therapie und Prophylaxe eines SAB induzierten Vasospasmus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016620-32,0,0,0 2009-016622-13,2,2010-12-16,2010-12-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"An Open-Label Randomized, Parallel, Two-Arm Phase II Study Comparing BMS-690514 + Letrozole with Lapatinib + Letrozole in Recurrent or Metastatic Breast Cancer Patients Who Are Hormone Receptor Positi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016622-13,0,0,0 2009-016626-14,1,2010-06-16,2010-06-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,"A Phase IIa, two-center, randomized, double-blind study with parallel groups to evaluate the anti-mycotic and anti-inflammatory efficacy of topical combinational product LAS 41003 versus corresponding...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016626-14,0,0,0 2009-016627-56,1,2011-07-08,2011-07-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,"A phase IIa, multi-center, randomized, double-blind study to evaluate the anti-mycotic and anti-inflammatory efficacy of topical combinational product LAS 41003 versus corresponding mono-substances in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016627-56,0,0,0 2009-016628-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP),Ensayo clínico comparativo para la reparación de defectos condrales de rodilla: trasplante autólogo de condrocitos cultivados vs. células troncales mesenquimales autólogas procedentes de tejido adipos...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016628-29,0,0,0 2009-016629-33,1,2010-03-05,2010-03-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,"A 12 day placebo- and reference-controlled, double-blind, single center, randomized, phase II clinical study with an intraindividual comparison, investigating the anti-psoriatic efficacy and the toler...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016629-33,0,0,0 2009-016631-35,1,2016-06-03,2016-06-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Heidelberg,Phase II Trial of Ipilimumab in Patients with advanced melanoma and spontaneous preexisting immune response to NY-ESO-1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016631-35,0,0,0 2009-016634-27,3,2012-11-21,2012-11-21,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cephalon, Inc.","A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major Depr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016634-27,0,0,0 2009-016635-36,2,2011-10-11,2011-10-11,2,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, open-label, randomised, multicentre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib-MenC-TT vaccine, when given to healthy infants at 2, 4 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016635-36,0,0,0 2009-016636-13,3,2016-12-19,2016-12-19,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"An open, dose-escalation Phase I/II study to assess the safety, immunogenicity and clinical activity of recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016636-13,0,0,0 2009-016640-39,1,2012-07-01,2012-07-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,Everolimus added to long acting octreotide as a volume reducing treatment of polycystic livers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016640-39,0,0,0 2009-016641-26,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,ZARI - Univeristätsmedizin Göttingen,The influence of propofol and inhalational anesthetics on postoperative pain perception,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016641-26,0,0,0 2009-016643-18,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Universitario de La Paz,Ensayo clínico randomizado para evaluar la eficiencia y efectividad de la dosificación individualizada de acenocumarol mediante un algoritmo farmacogenético versus ajuste estándar en pacientes que in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016643-18,0,0,0 2009-016648-38,8,2013-09-03,2013-10-09,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Cephalon, Inc.","A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016648-38,0,0,0 2009-016648-38,8,2013-09-03,2013-10-09,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,CEPHALON FRANCE,"A 6-Month, Open-Label, Flexible-Dosage (150 to 200 mg/day) Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016648-38,0,0,0 2009-016650-40,1,2013-05-08,2013-05-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Herlev Hospital,Kan injektion af Methylprednisolonacetat (Depo-Medrol) 80 mg i mastektomikaviteten ved drænfjernelsen efter operation for primær mammakancer virke profylaktisk mod seromdannelse ? Et randomiseret pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016650-40,0,0,0 2009-016653-17,1,2013-04-29,2013-04-29,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,AZIENDA UNITA` SANITARIA LOCALE N 12 DI VIAREGGIO,TREATMENT OF HYPOTENSION IN EXTREMELY PRETERM INFANTS: A MULTICENTER RANDOMIZED CONTROLLED TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016653-17,0,0,0 2009-016654-41,4,2011-11-03,2014-04-22,3,1,1,0,0,1,2,0,0,1,1,0,1,0,1,"PTC Therapeutics, Inc.",A Phase 2 Study of Ataluren (PTC124) as an Oral Treatment for Nonsense Mutation Methylmalonic Acidemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016654-41,0,0,0 2009-016654-41,4,2011-11-03,2014-04-22,3,1,1,0,0,1,2,0,0,1,1,0,1,0,1,"PTC THERAPEUTICS, INC.",A Phase 2 Study of Ataluren (PTC124) as an Oral Treatment for Nonsense Mutation Methylmalonic Acidemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016654-41,0,0,0 2009-016655-21,4,2010-11-15,2010-11-15,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Ferrer Internacional, S.A","A Multi-Centre, Randomized, Placebo-controlled, Parallel-Group, Double-Blinded Study to Compare the Therapeutic Efficacy, Safety and Tolerability of 3 Single Vaginal Doses of Arasertaconazole Nitrate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016655-21,0,0,0 2009-016659-23,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,Inserm,Etude de phase II évaluant l'immunogénicité et la tolérance d'un vaccin inactivé non adjuvanté contre la grippe A (H1N1) après transplantation rénale,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016659-23,0,0,0 2009-016660-36,1,,,0,1,0,0,0,0,2,0,1,0,0,0,0,0,0,Inserm,Etude de phase II évaluant l'immunogénicité et la tolérance d'un vaccin inactivé non adjuvanté contre la grippe A/H1N1v chez la femme enceinte,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016660-36,0,0,0 2009-016661-28,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo Español de Tratamiento de Tumores Digestivos-TTD,Estudio de fase II de panitumumab como agente único de primera línea en pacientes ancianos frágiles con cáncer colorrectal avanzado con KRAS no mutado,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016661-28,0,0,0 2009-016662-90,1,,,0,1,0,0,0,1,4,0,0,0,0,0,0,0,0,Inserm,"Etude de cohorte évaluant l'efficacité cliique, la tolérance et l'immunogénicité à la vaccination antigrippale pandémique chez les patients atteints de mucoviscidose et, le cas échéant, l'expression c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016662-90,0,0,0 2009-016663-11,1,2011-05-27,2011-05-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A 35-Day, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate the Effects of GSK1521498 on Body Weight and Composition, Eating Behaviour an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016663-11,0,0,0 2009-016667-11,3,2012-03-16,2012-03-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cephalon, Inc.","A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults With Major Depr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016667-11,0,0,0 2009-016668-35,1,2015-09-25,2015-09-25,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Copenhagen University Hospital,Hyperbaric Oxygen - a new treatment modality in patients with salivary gland radiation injury,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016668-35,0,0,0 2009-016669-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,"A phase II study to investigate the efficacy of RAD001 (Afinitor®, everolimus) in patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016669-27,0,0,0 2009-016675-29,1,2015-12-09,2015-12-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Queen Mary university of London,A Phase II Study Investigating Upfront Pazopanib in Metastatic Clear Cell Renal Cancer [PANTHER],https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016675-29,0,0,0 2009-016678-34,1,2009-12-01,2009-12-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,3,Imperial College London,Exploring the Relationship Between Insulin Resistance and Interferon Resistance: Options to Overcome HCV Non-Response to Pegylated Interferon,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016678-34,0,0,0 2009-016679-31,1,2010-06-22,2010-06-22,1,1,0,0,1,0,2,0,1,1,0,0,1,0,1,Fertin Pharma A/S,Sammenligning af effekten af 3 slags nikotintyggegummi til at lindre trangen til at ryge (nikotintrangen),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016679-31,0,0,0 2009-016682-28,1,2010-04-12,2010-04-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bionorica AG,"A multi-centre, double-blind, placebo-controlled, randomised, parallel group study to assess the efficacy and safety of a herbal medicinal product (dry extract BNO-1016) in patients with acute rhinos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016682-28,0,0,0 2009-016684-11,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,ISTITUTI ORTOPEDICI RIZZOLI,Meloxicam periradicular injection in physiological solution vs physiological solution in the treatment of lumbar and/or sacral radiculite: single blind randomized study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016684-11,0,0,0 2009-016686-28,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI PARMA,Evaluation of [18F]Fluorocholine PET/CT imaging for staging and restaging of prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016686-28,0,0,0 2009-016690-15,3,2010-07-05,2010-07-05,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development LTD,"A randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of GSK573719 delivered once-daily over 28 days in subjects with COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016690-15,0,0,0 2009-016692-29,1,2013-04-08,2013-04-08,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, double-dummy, randomized, placebo-controlled, phase IIa study on the efficacy and tolerability of a 14-day treatment with budesonide effervescent tablets vs. viscous budesonide suspensio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016692-29,0,0,0 2009-016693-33,1,2010-10-26,2010-10-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the single pill (SPC) combination of Aliskiren 300 mg / Amlodipine 10 mg in hypertensive patients not adeq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016693-33,0,0,0 2009-016697-32,1,2014-10-27,2014-10-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI,PRotease-Inhibitors MOnotherapy Strategies as maintenance therapy in persons with fully suppressed HIV replication: results from an open-label randomized comparative trial (PRIMO Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016697-32,0,0,0 2009-016701-42,1,2016-03-22,2016-03-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU Limoges,Techniques anesthésiques locorégionales et qualité de vie en soins palliatifs,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016701-42,0,0,0 2009-016703-35,1,2012-01-26,2012-01-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Dansk Multipel Sclerose Center,Natalizumabbehandling af progressiv multipel sklerose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016703-35,0,0,0 2009-016705-42,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI,Pilot study on efficacy of a simplification strategy from DRV/r 600/100 mg BID to DRV/r 800/100mg QD + OBT in HIV-positive patients HAART-experienced with virological response.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016705-42,0,0,0 2009-016707-30,2,2013-03-06,2013-03-06,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Exelixis, Inc.",A Phase 2 Study of XL147 in Subjects with Advanced or Recurrent Endometrial Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016707-30,0,0,0 2009-016707-30,2,2013-03-06,2013-03-06,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Sanofi-aventis US Inc.,A Phase 2 Study of XL147 in Subjects with Advanced or Recurrent Endometrial Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016707-30,0,0,0 2009-016708-21,1,2016-02-03,2016-02-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ARCAGY,"Essai multicentrique de phase II évaluant l'efficcacité et la tolérance de l'association de bevacizumab, paclitaxel et capecitabine en première ligne chez des patientes atteintes de cancer du sein mé...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016708-21,0,0,0 2009-016709-41,1,2014-12-31,2014-12-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,2,NHS Lothian,Coagulopathy during surgery for the repair of Extent 4 Thoraco-Abdominal Aortic Aneurysms - feasibility study of the use of Fibrinogen Concentrate by infusion in place of Fresh Frozen Plasma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016709-41,0,0,0 2009-016709-41,1,2014-12-31,2014-12-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,2,University of Edinburgh,Coagulopathy during surgery for the repair of Extent 4 Thoraco-Abdominal Aortic Aneurysms - feasibility study of the use of Fibrinogen Concentrate by infusion in place of Fresh Frozen Plasma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016709-41,0,0,0 2009-016713-20,4,2013-04-25,2014-04-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of treatment) given orally during 16 weeks in patients with Obsessive-Compulsive Disorder. A randomised, double-bli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016713-20,0,0,0 2009-016713-20,4,2013-04-25,2014-04-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de recherches Internationales Servier,"Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of treatment) given orally during 16 weeks in patients with Obsessive-Compulsive Disorder. A randomised, double-bli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016713-20,0,0,0 2009-016713-20,4,2013-04-25,2014-04-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratorios Servier S.L.,"Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of treatment) given orally during 16 weeks in patients with Obsessive-Compulsive Disorder. A randomised, double-bli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016713-20,0,0,0 2009-016715-38,1,2015-06-12,2015-06-12,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Copenhagen,"The TEA Trial- Tolerance and Effect of Antipsychotics in children and adolescents with psychosis An investigator-initiated, phase IV, randomised double-blind multi-centre trial of the benefits and ha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016715-38,0,0,0 2009-016716-20,1,2013-10-15,2013-10-15,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Brighton and Sussex University Hospitals NHS Trust,Better targeting of antidepressants in older people: the influence of age and genetic background on serotonin signalling,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016716-20,0,0,0 2009-016719-39,3,2012-08-28,2012-09-28,3,1,0,0,0,2,4,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,"IMMUNINE – Purified Factor IX Concentrate Virus-Inactivated: A Phase IV, Prospective, Open-label Multicenter Study to Prospectively Document the Exposure of IMMUNINE and to Monitor FIX Inhibitors in P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016719-39,0,0,0 2009-016720-31,6,2012-05-03,2012-05-03,5,1,0,1,0,2,1,0,0,1,0,0,0,0,1,Baxter Innovations GmbH,"BAX 326 (Factor IX recombinante): Estudio en fase I/III prospectivo, controlado, multicéntrico que evalúa la farmacocinética, eficacia, seguridad e inmunogenicidad en pacientes con hemofilia B grave (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016720-31,0,0,0 2009-016720-31,6,2012-05-03,2012-05-03,5,1,0,1,0,2,1,0,0,1,0,0,0,0,1,Baxter Healthcare Corporation,"BAX 326 (Factor IX recombinante): Estudio en fase I/III prospectivo, controlado, multicéntrico que evalúa la farmacocinética, eficacia, seguridad e inmunogenicidad en pacientes con hemofilia B grave (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016720-31,0,0,0 2009-016721-33,3,2011-04-12,2011-04-12,3,1,0,0,0,0,3,0,2,1,0,0,1,0,1,Sanofi Pasteur MSD S.N.C,A Study to Estimate the Immune Response Following a Challenge Dose in Adults (≥ 50 years old) Vaccinated With a Primary Series of an Hepatitis B Vaccine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016721-33,0,0,0 2009-016722-13,8,2017-02-28,2017-02-28,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase III, multicenter, randomized, parallel-group study to assess the efficacy and safety of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open-label octreotide LAR or lanreo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016722-13,0,0,0 2009-016722-13,8,2017-02-28,2017-02-28,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A phase III, multicenter, randomized, parallel-group study to assess the efficacy and safety of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open-label octreotide LAR or lanreo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016722-13,0,0,0 2009-016722-13,8,2017-02-28,2017-02-28,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A phase III, multicenter, randomized, parallel-group study to assess the efficacy and safety of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open-label octreotide LAR or lanreo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016722-13,0,0,0 2009-016725-34,1,2011-10-03,2011-10-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Cephalon, Inc.",An Open-Label Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016725-34,0,0,0 2009-016727-53,5,2014-04-23,2014-04-23,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharmacosmos A/S,"A phase III, randomized, open-label study of intravenous iron isomaltoside 1000 (Monofer®) as mono therapy (without erythropoeisis stimulating agents) in comparison with oral iron sulfate in subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016727-53,0,0,0 2009-016728-29,7,2014-04-23,2014-04-25,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharmacosmos A/S,"A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) administered by Infusions or Repeated Bolus Injections in Comparison with Oral Iron Sulphate in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016728-29,0,0,0 2009-016731-34,1,2013-12-23,2013-12-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College,Amino acid regimen and intravenous lipid composition in preterm parenteral nutrition: a randomised double blind controlled trial of Nutritional Evaluation and Optimisation in Neonates.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016731-34,0,0,0 2009-016732-12,1,2010-04-16,2010-04-16,1,1,0,0,0,0,2,0,1,1,1,1,1,0,1,"MAP Pharmaceuticals, Inc.","An Open-Label, 2-Period, Crossover Phase 2 Study Comparing the Pharmacokinetics and Tolerability of Dihydroergotamine Mesylate (DHE) Delivered Intravenously (DHE 45) and by Oral Inhalation (MAP0004) i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016732-12,0,0,0 2009-016733-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Essai de phase II non contrôlé multicentrique (national) évaluant l’intérêt du Nilotinib en première ou seconde ligne dans le traitement des mélanomes primitifs ou stade III inopérables et stade IV a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016733-10,0,0,0 2009-016734-26,4,2012-03-19,2012-03-19,3,1,0,0,0,1,3,0,2,1,0,0,1,0,1,Novartis Pharma Services AG,A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder after Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Patients Who success...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016734-26,0,0,0 2009-016735-36,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Novartis Farmacéutica S.A.,Estudio de los efectos de ALiskiren o Losartán sobre los bioMARKadores del remodelado miocárdico. Estudio ALLMARK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016735-36,0,0,0 2009-016737-95,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,ROSuvastatin Pretreatment to Reduce Embolization during Carotid Artery Stenting Pretrattamento con Rosuvastatina per Ridurre l'Embolizzazione durante Angioplastica Carotidea con Impianto di Stent,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016737-95,0,0,0 2009-016738-28,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA PISANA,"Phase IV prospective, randomized, open with blind endpoints, parallel group study to evaluate the effect of Aliskiren on endothelial dysfunction in patients with essential hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016738-28,0,0,0 2009-016743-18,1,2012-03-14,2012-03-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust,A feasibility study of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016743-18,0,0,0 2009-016745-25,1,2011-03-11,2011-03-11,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,ikfe GmbH,Investigation of a switch from Insulin Therapy to a metformin & saxagliptin combination in patients with type 2 diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016745-25,0,0,0 2009-016748-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Free State of Bavaria rep. by the Univ. of Regensburg, rep. by the Regensburg Univ. Hospital","Prospective, randomized, placebo-controlled, monocentric, two-armed, observer-blinded and within-patient study for Photodynamic Therapy (PDT) with MAL in the treatment of actinic keratoses (AK) and ph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016748-38,0,0,0 2009-016751-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AMC, divisie Psychiatrie","A double blind, placebo controlled study of memantine in patients with obsessive-compulsive disorder.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016751-22,0,0,0 2009-016752-52,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,BGP Kranj,"Intravensko lajšanje porodnih bolečin z remifentanilom, ki si ga uravnava porodnica sama – primerjava protokola brez uporabe bazalne infuzije in protokola z uporabo bazalne infuzije glede kvalitete la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016752-52,0,0,0 2009-016752-52,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Katedra za biofarmacijo in farmakokinetiko, Fakulteta za farmacijo","Intravensko lajšanje porodnih bolečin z remifentanilom, ki si ga uravnava porodnica sama – primerjava protokola brez uporabe bazalne infuzije in protokola z uporabo bazalne infuzije glede kvalitete la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016752-52,0,0,0 2009-016757-18,8,2012-09-28,2012-10-31,6,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Chiesi Farmaceutici SpA,"A phase III, 12-week, multicentre, multinational, randomised, double-blind, double-dummy, 3 arm-parallel group study to test the efficacy of CHF 1535 50/6 ?g (fixed combination of beclomethasone dipro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016757-18,1,1,0 2009-016757-18,8,2012-09-28,2012-10-31,6,1,1,0,0,0,3,0,0,2,1,0,0,0,1,CHIESI,"A phase III, 12-week, multicentre, multinational, randomised, double-blind, double-dummy, 3 arm-parallel group study to test the efficacy of CHF 1535 50/6 ?g (fixed combination of beclomethasone dipro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016757-18,1,1,0 2009-016757-18,8,2012-09-28,2012-10-31,6,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Chesi Farmaceutici SpA,"A phase III, 12-week, multicentre, multinational, randomised, double-blind, double-dummy, 3 arm-parallel group study to test the efficacy of CHF 1535 50/6 ?g (fixed combination of beclomethasone dipro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016757-18,1,1,0 2009-016758-42,11,2014-09-18,2014-10-28,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Gilead Sciences Incorporated,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016758-42,0,0,0 2009-016759-22,11,2015-04-16,2015-04-17,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Incorporated,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoprox...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016759-22,0,0,0 2009-016760-36,1,2012-10-31,2012-10-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AIBILI,"Prospective, randomized, open label phase II study to assess efficacy and safety of Macugen® (pegaptanib 0.3 mg intravitreal injections) plus panretinal photocoagulation (PRP) and PRP (monotherapy) in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016760-36,0,0,0 2009-016761-29,1,2014-07-02,2014-07-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Birmingham,"A 48-WEEK PHASE II, RANDOMISED, DOUBLE BLINDED PLACEBO CONTROLLED, PARALLEL-GROUP, MULTI-CENTRE TRIAL ON LIRAGLUTIDE’S SAFETY, EFFICACY AND ACTION ON LIVER HISTOLOGY AND METABOLISM IN OVERWEIGHT PATIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016761-29,0,0,0 2009-016762-87,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,OSPEDALE MAGGIORE DI MILANO (IRCCS),"a randomized, open-label study to evaluate the safety and efficacy of delayed introduction of sirolimus and concomitant tacrolimus elimination in de novo renal allograft recipients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016762-87,0,0,0 2009-016766-86,9,2014-09-03,2014-09-03,9,1,0,0,2,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, SAFETY AND EFFICACY STUDY OF ONCE DAILY CONTROLLED RELEASE PREGABALIN IN THE TREATMENT OF PATIENTS WITH POSTHERPETIC NEURALGIA (PROTOCOL A008122...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016766-86,0,0,0 2009-016766-86,9,2014-09-03,2014-09-03,9,1,0,0,2,0,3,0,0,1,1,0,1,0,1,Pfizer Inc.,"A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, SAFETY AND EFFICACY STUDY OF ONCE DAILY CONTROLLED RELEASE PREGABALIN IN THE TREATMENT OF PATIENTS WITH POSTHERPETIC NEURALGIA (PROTOCOL A008122...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016766-86,0,0,0 2009-016773-15,1,,,0,0,0,0,0,0,4,0,1,1,1,1,0,1,0,Matti Ristola,"A Randomized, Controlled, Open-label Study of Comparing Immunogenicity of Sequential Hepatitis B and Hepatitis A Vaccination vs Vaccination with a Dual Hepatitis B and Hepatitis A Vaccine among HIV-1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016773-15,0,0,0 2009-016775-30,5,2012-11-06,2012-11-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Helsinn Healthcare SA,"A phase III multicenter, randomized, double-blind, double-dummy, active-controlled, parallel group study of the efficacy and safety of oral netupitant administered in combination with palonosetron and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016775-30,0,0,0 2009-016778-34,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,1,THERABEL LUCIEN PHARMA,Evaluation de la non-infériorité de l’efficacité d’Helicidine® versus Sirop à base de dextromethorphane sur la toux sèche des patients pris en charge en médecine générale.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016778-34,0,0,0 2009-016779-31,1,2010-11-12,2010-11-12,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novo Nordisk A/S,"A Trial Investigating the Pharmacokinetic Properties of NN5401 in Children, Adolescents and Adults with Type 1 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016779-31,0,0,0 2009-016782-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH,Panitumimab in combination with radiotherapy in patients with locally advanced RAS wildtype rectal cancer (clinical stages II and III),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016782-28,0,0,0 2009-016783-37,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Sahlgrenska University Hospital,"The Effects of 18-Month Replacement with a Very Low Fixed Dose vs. Standard Dose of Growth Hormone (GH) on Insulin Sensitivity, Body Composition, Bone Mass, Lipids, Muscle Strength and Quality of Life...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016783-37,0,0,0 2009-016784-11,3,2018-04-19,2018-04-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ImClone LLC,"An Open-label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-based Chemotherapy versus Platinum-based Chemother...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016784-11,0,0,0 2009-016785-88,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,University Hospital Ghent,Dexmedetomidine pharmacokinetics-pharmacodynamics in mechanically ventilated children with single-organ respiratory failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016785-88,0,0,0 2009-016789-10,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Div KIR AMC,Efficacy of the H1N1 Flu (swine flu) vaccination in patients with Rheumatoid Arthritis treated with rituximab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016789-10,0,0,0 2009-016790-15,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Emotional Brain,"A double blind, randomized, cross-over placebo controlled study to investigate the subjective and physiological efficacy and safety of Lybrido and Lybridos in the domestic setting in healthy female su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016790-15,0,0,0 2009-016791-71,3,2012-12-06,2012-12-06,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 24-week, multicentre, randomised, double-blind, age-stratified, placebo controlled phase III study with an 80-week extension period to evaluate the efficacy and safety of dapagliflozin 10 mg once da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016791-71,0,0,0 2009-016797-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,"Phase 2/3, twelve-month, multicenter, intra-subjectcontrolled (retrospective-prospective), open-label, active-treatment study to evaluate the efficacy, safety, tolerability and pharmacokinetics of cin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016797-32,0,0,0 2009-016800-22,4,2011-08-30,2011-10-18,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly and Company Limited,A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016800-22,0,0,0 2009-016801-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,IPERBOREAL PHARMA,"Efficacy and Safety assessments of a peritoneal dialysis solution containing Glucose, Xylitol and L-Carnitine compared to standard PD solutions in Continuous Ambulatory Peritoneal Dialysis (CAPD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016801-40,0,0,0 2009-016804-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Accelerator Advanced Application,Intérêt de la Tomographie par Émission de Positons avec la 3’-désoxy-3’-[18F]-fluoro-thymidine (18F-FLT) pour l’obtention d’une cartographie de l’activité mitotique myéloïde corps entier dans les syn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016804-21,0,0,0 2009-016806-18,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Klinik Löwenstein gGmbH,"Multizentrische, randomisierte Phase II-Studie zur Therapie des lokal fortgeschrittenen oder metastasierten NSCLC im Stadium IV UICC 7 mit zwei unterschiedlichen Regimen von Cisplatin / Carboplatin un...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016806-18,0,0,0 2009-016807-42,3,2011-02-14,2011-02-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled, multicenter dose ranging study of subcutaneously administered AIN457, assessing Psoriasis Area and Severity Index (PASI) response in patients with moder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016807-42,0,0,0 2009-016811-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CESAR AUGUSTO VALERO MARTINEZ,"Remifentanilo frente a paracetamol para el tratamiento del dolor de las versiones externas. Ensayo clínico aleatorizado, controlado y enmascarado",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016811-39,0,0,0 2009-016812-18,5,2012-03-09,2012-05-15,5,0,0,0,0,0,3,0,0,1,1,0,1,0,1,"Anthera Pharmaceuticals, Inc.",Evaluacion de la seguridad y eficacia del tratamiento a corto plazo con A-002 en sujetos con sindromes coronarios agudos Evaluation of the safety and efficacy of short-term A-002 treatment in subjects...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016812-18,0,0,0 2009-016812-18,5,2012-03-09,2012-05-15,5,0,0,0,0,0,3,0,0,1,1,0,1,0,1,ANTHERA PHARMACEUTICALS,Evaluacion de la seguridad y eficacia del tratamiento a corto plazo con A-002 en sujetos con sindromes coronarios agudos Evaluation of the safety and efficacy of short-term A-002 treatment in subjects...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016812-18,0,0,0 2009-016813-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,Randomized prospectic clinical trial Phase II in patients affected by prognostic class RPA V and VI glioblastoma: comparison between hypofractionated radiotherapy (RT) 30 Gy (6 fractions in two weeks)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016813-11,0,0,0 2009-016814-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica Hospital Gregorio Marañón,"Estudio abierto, comparativo, aleatorizado, del uso de TachoSil en pacientes con riesgo de sangrado sometidas a cirugía mamaria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016814-25,0,0,0 2009-016815-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Allergy Unit Department of Oto-rhino-Laryngology Lund/Malmö University Hospital,Is Intralymphatic Allergen Immunotherapy effective and safe: A human randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016815-39,0,0,0 2009-016816-20,1,2018-03-31,2018-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,co.don AG,"Prospective, randomised, open label, multicentre Phase II clinical trial to investigate the efficacy and safety of the treatment of large defects (4-10 cm2) with 3 different doses of the autologous ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016816-20,0,0,0 2009-016818-24,12,2011-10-13,2012-12-14,7,1,0,0,0,0,4,0,0,1,1,0,1,0,1,SANOFI AVENTIS GROUPE,"A Randomized, international, multi-center, open-label study to document optimal timing of initiation of dronedarone TreatmEnt after conversion with loading dose of aMIodarone in patients with perSiste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016818-24,0,0,0 2009-016818-24,12,2011-10-13,2012-12-14,7,1,0,0,0,0,4,0,0,1,1,0,1,0,1,sanofi aventis,"A Randomized, international, multi-center, open-label study to document optimal timing of initiation of dronedarone TreatmEnt after conversion with loading dose of aMIodarone in patients with perSiste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016818-24,0,0,0 2009-016818-24,12,2011-10-13,2012-12-14,7,1,0,0,0,0,4,0,0,1,1,0,1,0,1,sanofi aventis groupe,"A Randomized, international, multi-center, open-label study to document optimal timing of initiation of dronedarone TreatmEnt after conversion with loading dose of aMIodarone in patients with perSiste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016818-24,0,0,0 2009-016823-74,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Cardoz AB,An open pilot study to assess the effects of pemirolast on C-reactive protein levels in subjects with coronary artery disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016823-74,0,0,0 2009-016824-29,1,2011-06-07,2011-06-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Dansk Multipel Sclerose Center,REsPons på interferon-Alfa hos InterfeRon-β-neutraliserende antistof-positive patienter med multipel sklerose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016824-29,0,0,0 2009-016826-15,3,2014-04-09,2014-04-09,2,0,0,0,0,0,2,0,0,2,0,0,0,0,0,CECOG,A phase II study evaluating the efficacy and safety of lapatinib + vinorelbine in ErbB2 positive metastatic breast cancer patients after progression of chemotherapy or hormonal treatment in combinatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016826-15,1,0,0 2009-016827-72,1,2010-06-09,2010-06-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Galenica AB,"A multicentre, randomized, double-blind, safety and efficacy non-inferiority, intra-individual study, comparing Mometasone furoate Galenica 0.1% cream with Elocon 0.1% cream and placebo in patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016827-72,0,0,0 2009-016829-34,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,"Medizinische Universität Graz, Klinische Abteilung für Thorax -u. Hyperbare Chirurgie",Influence of perioperative administration of diclovenac-natrium/orfendadrincitrate on the recurrence rate of surgically treated spontaneous pneumothorax,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016829-34,0,0,0 2009-016834-28,1,2010-05-14,2010-05-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label, multi-center, continued access trial of investigational drug ASA404 for patients in previous ASA404 clinical trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016834-28,0,0,0 2009-016835-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación Investigación Biomédica Hospital Príncipe de Asturias,"ESTUDIO CLÍNICO MULTICÉNTRICO, PROSPECTIVO, ALEATORIZADO, ABIERTO Y CONTROLADO, PARA LA PREVENCIÓN DE LA INFECCIÓN DEL ORIFICIO EXTERNO (IOE) DEL CATÉTER PERITONEAL CON UNA PASTA ANTIBIÓTICA TÓPICA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016835-36,0,0,0 2009-016836-11,1,2012-12-20,2012-12-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,OSI Pharmaceuticals LLC,"A Randomized, Phase 2 Study of Single-agent Erlotinib versus Oral Etoposide in Patients with Recurrent or Refractory Pediatric Ependymoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016836-11,0,0,0 2009-016839-35,13,2017-12-05,2017-12-05,13,1,0,0,0,1,3,0,0,1,0,0,1,0,2,"Onyx Therapeutics, Inc.","A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016839-35,0,0,0 2009-016839-35,13,2017-12-05,2017-12-05,13,1,0,0,0,1,3,0,0,1,0,0,1,0,2,"Onyx Pharmaceuticals, Inc.","A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016839-35,0,0,0 2009-016840-38,11,2015-09-04,2015-09-04,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Onyx Therapeutics, Inc.","A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects with Relapsed and Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016840-38,0,0,0 2009-016841-24,3,2013-09-10,2013-09-10,3,1,1,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIB open, multicountry, randomized, controlled study to demonstrate the non-inferiority of the immune response of GSK Biologicals’ meningococcal serogroup A, C, W-135 and Y conjugate vaccine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016841-24,0,0,0 2009-016841-24,3,2013-09-10,2013-09-10,3,1,1,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A phase IIIB open, multicountry, randomized, controlled study to demonstrate the non-inferiority of the immune response of GSK Biologicals’ meningococcal serogroup A, C, W-135 and Y conjugate vaccine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016841-24,0,0,0 2009-016842-22,1,2012-12-20,2012-12-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,photonamic GmbH & Co. KG,Evaluation of the suitability of PD L 506 for intraoperative visualisation of palpable and nonpalpable breast cancer tissue,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016842-22,0,0,0 2009-016846-16,1,2017-02-16,2017-02-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Oxford,Phase II Clinical Trial of 6-Mercaptopurine(6MP)and low-dose Methotrexate In Patients With Known BRCA Defective Tumours.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016846-16,0,0,0 2009-016847-20,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,FUNDACION PARA LA INVESTIGACIÓN LA FE,Optimización del tratamiento de la anemia ferropénica secundaria a hemorragia digestiva aguda. Comparación de dos estrategias (hierro intravenoso vs oral).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016847-20,0,0,0 2009-016848-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Toulouse,Evaluation en TEP des modifications du métabolisme cérébral induit par la chimiothérapie RCHOP chez des malades porteurs de lymphome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016848-39,0,0,0 2009-016849-25,1,2011-09-07,2011-09-07,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Pfizer Inc,"A DOUBLE-BLIND, RANDOMIZED, MULTICENTER EFFICACY AND SAFETY STUDY OF PREGABALIN (LYRICA) AS MONOTHERAPY IN PATIENTS WITH PARTIAL SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016849-25,0,0,0 2009-016850-42,1,2011-12-26,2011-12-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,AN OPEN-LABEL MULTICENTER EXTENSION STUDY TO DETERMINE LONG TERM SAFETY AND EFFICACY OF PREGABALIN (LYRICA) AS MONOTHERAPY IN PATIENTS WITH PARTIAL SEIZURES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016850-42,0,0,0 2009-016853-16,1,,,0,0,0,1,0,1,1,0,0,1,0,0,0,1,1,MOLOGEN AG,"A Phase I/II, Proof-of-Principle, Multi-Center, Open-Label, Single-Arm, Non-randomized Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine Consisting of Genetically Modified Allogeneic (Hu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016853-16,0,0,0 2009-016855-23,1,2013-08-05,2013-08-05,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,University of Leeds,Targeting systemic inflammation to improve endothelial function in obesity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016855-23,0,0,0 2009-016857-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Ghent,Dose finding study for effective reversal of a moderate rocuronium-induced neuromuscular block with sugammadex in morbidly obese patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016857-16,0,0,0 2009-016858-41,3,2015-10-10,2015-10-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Ltd.,"An Open-Label, Single-Arm, Multicenter Phase 2 Study of E7080 in Subjects with Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016858-41,0,0,0 2009-016859-22,7,2014-11-19,2014-11-19,5,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A one-year open-label, multicenter trial to assess efficacy, safety and tolerability of canakinumab (ACZ885) and the efficacy and safety of childhood vaccinations in patients aged 4 years or younger w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016859-22,1,1,0 2009-016859-22,7,2014-11-19,2014-11-19,5,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A,"A one-year open-label, multicenter trial to assess efficacy, safety and tolerability of canakinumab (ACZ885) and the efficacy and safety of childhood vaccinations in patients aged 4 years or younger w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016859-22,1,1,0 2009-016862-10,1,2012-12-03,2012-12-03,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Exelixis INC.,A Phase 1/2 Study of XL147 Administered in Combination with Trastuzumab or Paclitaxel and Trastuzumab in Subjects with Metastatic Breast Cancer who have Progressed on a Previous Trastuzumab- Based Reg...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016862-10,0,0,0 2009-016869-28,1,2011-10-07,2011-10-07,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to less than 6 Years Old) Subjects with Congenital FXIII A-subunit Defici...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016869-28,0,0,0 2009-016870-33,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Centre Oscar Lambret,Cilengitide (EMD121974) in combination with irradiation in children and young adults with newly diagnosed diffuse intrinsic pontine glioma : Phase I study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016870-33,0,0,0 2009-016871-32,2,2016-11-30,2016-11-30,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de TOULOUSE,"A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016871-32,0,0,0 2009-016873-13,1,2014-07-25,2014-07-25,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,King’s College Hospital NHS Foundation Trust,A novel therapy using recombinant human PTH 1-84 to stimulate bone repair and enhance fracture healing in the acute Charcot foot: a double blind placebo controlled phase IV trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016873-13,0,0,0 2009-016874-34,1,2010-12-29,2010-12-29,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,Plymouth Hospitals NHS Trust,A Study into the Effect of Mechanical Bowel Preparation on Aerobic Exercise Capacity as Measured by Cardiopulmonary Exercise Testing.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016874-34,0,0,0 2009-016875-30,1,2016-01-19,2016-01-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CRLC VAL D’AURELLE,"Essai de phase II évaluant l’association de gemcitabine, trastuzumab et erlotinib en 1ère ligne de traitement par chimiothérapie des patients atteints d’un adénocarcinome du pancréas métastatique",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016875-30,0,0,0 2009-016877-14,1,2011-12-14,2011-12-14,1,0,0,0,0,0,3,0,1,1,0,0,1,0,0,COPSAC,H1N1v Vaccination of Pregnant Women: A Longitudinal Cohort Study Characterizing Influenza A-H1N1v Vaccination in Pregnant Women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016877-14,0,0,0 2009-016879-29,8,2012-02-15,2017-12-18,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,MOLMED,NGR015: Randomised double-blind phase III study of NGR-hTNF plus best investigator's choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (M...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016879-29,0,0,0 2009-016880-13,1,2017-03-01,2017-03-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST,RANDOMIZED CONTROLLED TRIAL OF THE EFFECTS OF PARENTERAL FISH OIL EMULSION IN CRITICALLY ILL SEPTIC PATIENTS IN THE INTENSIVE CARE UNIT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016880-13,0,0,0 2009-016898-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Nantes,"Phase II study of first line treatment of chronic graft versus host disease with the association of ciclosporine, corticosteroids and Rituximab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016898-14,0,0,0 2009-016902-17,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI,Direct renin inhibitor (aliskiren)and carotid plaques instability markers in hypertensive patients requiring carotid endoarterectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016902-17,0,0,0 2009-016904-21,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Medisch Spectrum Twente,The predictive value of the acute effect of montelukast on an exercise challenge test for the outcome of longterm treatment with montelukast,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016904-21,0,0,0 2009-016907-41,1,2013-08-19,2013-08-19,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Charité, Universitätsmedizin Berlin","Investigation of nociceptive and antinociceptive mechanisms under anesthesia using fMRI, EEG and noxious reflexes Untersuchung von nozizeptiven und antinozizeptiven Mechanismen unter Narkose mittel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016907-41,0,0,0 2009-016909-42,1,2012-03-19,2012-03-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,3,University Hospitals Birmingham NHS Foundation Trust,Effect of topical imiquimod on lentigo maligna.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016909-42,0,0,0 2009-016911-39,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"An open, phase IV, multicentre, study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B vaccine challenge in healthy children aged 11-12 ye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016911-39,0,0,0 2009-016914-25,1,2014-09-12,2014-09-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Deutsches Herzzentrum Berlin,CEDRIC: Clopidogrel- Effects on Diameter Reduction and Intimal Hyperplasia in Long-term Follow up after Cardiac Transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016914-25,0,0,0 2009-016920-30,1,2018-05-11,2018-05-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universitaet Wien, Universitaetsklinik für Radiologie und Nuklearmedizin",Non invasive imaging of human cartilage by scintigraphy using novel radiopharmaceutical 99mTcCS(chondroitin sulfate) to prove cartilage degeneration (osteoarthritis)in comparision with proteoglycan sp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016920-30,0,0,0 2009-016921-32,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundació Sant Joan de Déu,"A phase II, randomized, double-blind, placebo-controlled, in parallel groups clinical trial to assess the safety and efficacy of dietary supplementation with tryptophan to achieve weight loss, and its...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016921-32,0,0,0 2009-016922-15,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,HOSPITAL SANT JOAN DE DÉU,ENSAYO PILOTO CON IMATINIB PARA PACIENTES CON NEUROFIBROMA PLEXIFORME ASOCIADO A LA NEUROFIBROMATOSIS TIPO I. PILOT STUDY WITH IMATINIB FOR PLEXIFORM NEUROFIBROMA IN NEUROFIBROMATOSIS TYPE I PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016922-15,0,0,0 2009-016923-77,5,2014-05-21,2014-10-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Alfa Wassermann SpA,"Multicentre, randomised, double blind, placebo controlled study on long-term treatment with Sulodexide for prevention of recurrent DVT in patients with venous thromboembolism",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016923-77,0,0,0 2009-016923-77,5,2014-05-21,2014-10-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALFA WASSERMANN SPA,"Multicentre, randomised, double blind, placebo controlled study on long-term treatment with Sulodexide for prevention of recurrent DVT in patients with venous thromboembolism",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016923-77,0,0,0 2009-016923-77,5,2014-05-21,2014-10-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALFA WASSERMANN,"Multicentre, randomised, double blind, placebo controlled study on long-term treatment with Sulodexide for prevention of recurrent DVT in patients with venous thromboembolism",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016923-77,0,0,0 2009-016924-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Division of Paediatrics, Rikshospitalet University Hospital",NorCAPITAL The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016924-30,0,0,0 2009-016925-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospital Sant Joan de Déu,"""CAFEÍNA COMO TRATAMIENTO DE LAS APNEAS EN PACIENTES CON BRONQUIOLITIS AGUDA""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016925-32,0,0,0 2009-016926-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Intravitreal Bevacizumab associated with epiretinal brachitherapy as a treatment for Coroidal Neovascularization (CNV) secondary to exudative Age Related Macular Degeneration (AMD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016926-15,0,0,0 2009-016930-29,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.,Ranolazine to treat early cardiotoxicity induced by antitumor drugs,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016930-29,0,0,0 2009-016932-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,BOOG Study Center B.V,Phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016932-11,0,0,0 2009-016936-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Farmacia. Hospital Universitario de Bellvitge.,Estudio farmacocinético-farmacodinámico poblacional tras la administración oral o intravenosa de voriconazol en paciente crítico (fase IV),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016936-11,0,0,0 2009-016940-38,9,2014-05-08,2014-05-08,6,1,0,0,2,0,3,0,0,1,1,0,1,0,1,Oncolytics Biotech Inc.,"Randomized, Double-blind, Multicenter Phase 3 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus the Chemotherapy Alone in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016940-38,0,0,0 2009-016940-38,9,2014-05-08,2014-05-08,6,1,0,0,2,0,3,0,0,1,1,0,1,0,1,ONCOLYTICS,"Randomized, Double-blind, Multicenter Phase 3 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Paclitaxel and Carboplatin versus the Chemotherapy Alone in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016940-38,0,0,0 2009-016945-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude prospective, multicentrique contrôlée vs. placebo, randomisée, en double Insu, évaluant les bénéfices et risques d'un traitement précoce par faibles doses de corticoïdes, des pneumonies graves d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016945-24,0,0,0 2009-016947-20,8,2020-04-27,2020-05-06,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Seattle Genetics, Inc.","A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016947-20,0,0,0 2009-016947-20,8,2020-04-27,2020-05-06,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,SEATTLE GENETICS INC.,"A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016947-20,0,0,0 2009-016948-39,1,2011-12-29,2011-12-29,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Sinikka Oksa,Toremifeenihoidon vaikutus rintojen 3D-ultraäänilöydökseen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016948-39,0,0,0 2009-016950-42,5,2011-01-25,2011-01-25,4,0,0,0,0,0,2,0,0,1,1,0,1,0,1,"Shionogi USA, Inc.","A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of S 888711 tablets administered once-daily for 42 days to adult subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016950-42,0,0,0 2009-016950-42,5,2011-01-25,2011-01-25,4,0,0,0,0,0,2,0,0,1,1,0,1,0,1,"SHIONOGI USA, INC","A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of S 888711 tablets administered once-daily for 42 days to adult subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016950-42,0,0,0 2009-016951-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA` DI NOVARA,Thoracic epidural L-Bupivacaine and onset of symptomatic supraventricular tachy-arrhythmias after thoracotomy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016951-23,0,0,0 2009-016952-36,1,2014-07-01,2014-07-01,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,Cancer Research UK,A Cancer Research UK Phase I trial of AT9283 (a selective inhibitor of aurora kinases) given over 72 hrs every 21 days via intravenous infusion in children and adolescents aged 6 months to 18 years wi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016952-36,0,0,0 2009-016953-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Inn-Salzach-Klinikum gGmbH,Depressions-Spektrums-Störung und differenzielle Effekte neuerer Antidepressiva auf die Verkehrssicherheit,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016953-16,0,0,0 2009-016954-42,1,,,0,1,0,0,1,0,3,0,0,1,0,0,0,1,1,Swiss Cardio Technologies AG,Randomized Clinical Safety and Efficacy Investigation of the Swiss Cardio Technologies Cardioplexol Solution in comparison with Buckberg Solution,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016954-42,0,0,0 2009-016955-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA USL 2 DI LUCCA,Assessment of association efficacy of colinergic precursor and cholinesterasic inhibitor somministered transdermal in patient with Alzheimer`s disease and severe behavioural disturbances,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016955-23,0,0,0 2009-016957-17,1,2010-10-17,2010-10-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Mundipharma Oy,"A randomised, double-blind, parallel group multicenter study to demonstrate non-inferiority of the analgesic efficacy of oxycodone/naloxone 10/5 or 20/10 mg prolonged release tablets (OXN PR) BID comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016957-17,0,0,0 2009-016958-41,1,2014-05-31,2014-05-31,1,0,0,0,1,0,3,0,0,1,1,1,1,0,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA` GRANDA (A.O. DI RILIEVO NAZIONALE),Early LEvosimendan Vs usual care in Advanced chronic hearT failurE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016958-41,0,0,0 2009-016959-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,LABORATOIRES BOIRON,"Etude contrôlée, randomisée en double aveugle versus placebo de l’efficacité de la spécialité homéopathique BRN-01 dans le traitement des bouffées de chaleur de la femme ménopausée",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016959-21,0,0,0 2009-016962-10,1,2014-09-08,2014-09-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA,"First Line Dose-Dense Chemotherapy With Docetaxel, Cisplatin, Folinic Acid and 5- Fluorouracil plus Panitumumab in Patients With Locally Advanced or Metastatic Cancer of the Stomach or Gastro-Esophage...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016962-10,0,0,0 2009-016965-26,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Centro Comunitario de Sangre y Tejidos de Asturias,"Ensayo clínico multicéntrico, aleatorizado, abierto para valorar la eficacia y seguridad del tratamiento de úlceras venosas crónicas con injertos cutáneos cultivados",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016965-26,0,0,0 2009-016966-97,1,2014-09-30,2014-09-30,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Universitätsklinikum Essen,"Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized, Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients with Cold Agglutinin Disease Usi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016966-97,0,0,0 2009-016968-37,1,2013-05-29,2013-05-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre Francois Baclesse,Evaluation de l’intérêt d’un dosage des anticorps anti-cetuximab dans la prise en charge thérapeutique des patients présentant un cancer colique ou des voies aéro-digestives supérieures et candidats à...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016968-37,0,0,0 2009-016969-28,2,2011-01-25,2011-01-27,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,IBSA INSTITUT BIOCHIMIQUE SA,"Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil, IBSA-Institut Bioch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016969-28,0,0,0 2009-016969-28,2,2011-01-25,2011-01-27,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"IBSA, Institut Biochimique SA","Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil, IBSA-Institut Bioch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016969-28,0,0,0 2009-016970-33,5,2015-03-18,2015-03-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme Europe,"An Extension Protocol for Participants of Genzyme-Sponsored Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of Matrix-Induced Autologous Chondrocyte Implantation (MACI® implant)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016970-33,0,0,0 2009-016970-33,5,2015-03-18,2015-03-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Vericel Corporation,"An Extension Protocol for Participants of Genzyme-Sponsored Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of Matrix-Induced Autologous Chondrocyte Implantation (MACI® implant)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016970-33,0,0,0 2009-016970-33,5,2015-03-18,2015-03-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme Europe BV,"An Extension Protocol for Participants of Genzyme-Sponsored Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of Matrix-Induced Autologous Chondrocyte Implantation (MACI® implant)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016970-33,0,0,0 2009-016971-31,3,2012-05-17,2012-07-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,,"A phase III, randomised, double-blind, placebo-controlled parallel group safety and efficacy study of linagliptin (5 mg administered orally once daily) over 12 weeks followed by a 40 week double-blind...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016971-31,0,0,0 2009-016971-31,3,2012-05-17,2012-07-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim,"A phase III, randomised, double-blind, placebo-controlled parallel group safety and efficacy study of linagliptin (5 mg administered orally once daily) over 12 weeks followed by a 40 week double-blind...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016971-31,0,0,0 2009-016971-31,3,2012-05-17,2012-07-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim AB,"A phase III, randomised, double-blind, placebo-controlled parallel group safety and efficacy study of linagliptin (5 mg administered orally once daily) over 12 weeks followed by a 40 week double-blind...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016971-31,0,0,0 2009-016973-13,2,2014-02-12,2014-02-12,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Lexicon Pharmaceuticals, Inc","A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects with Symptomatic Carcinoid Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016973-13,0,0,0 2009-016982-26,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,1,SIGMA-TAU,Neuronal conduction along the visual patways after oral treatment with Acetyl-L-carnitine in patients with Leber’s Hereditary Optic Neuropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016982-26,0,0,0 2009-016987-34,9,2013-03-13,2013-03-13,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA","""Estudio de fase 3 aleatorizado y doble ciego de la eficacia y la seguridad de 2 dosis de CP-690,550 en comparación con metotrexato en pacientes con artritis reumatoide no tratados previamente con met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016987-34,0,0,0 2009-016987-34,9,2013-03-13,2013-03-13,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER,"""Estudio de fase 3 aleatorizado y doble ciego de la eficacia y la seguridad de 2 dosis de CP-690,550 en comparación con metotrexato en pacientes con artritis reumatoide no tratados previamente con met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016987-34,0,0,0 2009-016987-34,9,2013-03-13,2013-03-13,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","""Estudio de fase 3 aleatorizado y doble ciego de la eficacia y la seguridad de 2 dosis de CP-690,550 en comparación con metotrexato en pacientes con artritis reumatoide no tratados previamente con met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016987-34,0,0,0 2009-016992-31,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Democritus Universityof Thrace Medical School,EUropean Pharmacogenetics of AntiCoagulation Therapy trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016992-31,0,0,0 2009-016992-31,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,University Utrecht,EUropean Pharmacogenetics of AntiCoagulation Therapy trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016992-31,0,0,0 2009-016992-31,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Fundacion Marques de Valdecilla,EUropean Pharmacogenetics of AntiCoagulation Therapy trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016992-31,0,0,0 2009-016993-34,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Uppsala University Hospital,EUropean Pharmacogenetics of AntiCoagulation Therapy trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016993-34,0,0,0 2009-016994-13,3,2013-03-25,2013-03-25,3,0,0,0,1,0,4,0,0,1,0,0,1,0,0,University Utrecht,EUropean Pharmacogenetics of AntiCoagulation Therapy trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016994-13,0,0,0 2009-016994-13,3,2013-03-25,2013-03-25,3,0,0,0,1,0,4,0,0,1,0,0,1,0,0,"Prof. Dr. R Marre, University Hospital Ulm",EUropean Pharmacogenetics of AntiCoagulation Therapy trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016994-13,0,0,0 2009-016994-13,3,2013-03-25,2013-03-25,3,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Elisabethinen Hospital Linz,EUropean Pharmacogenetics of AntiCoagulation Therapy trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016994-13,0,0,0 2009-016996-31,5,2012-11-20,2012-12-18,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Upsher-Smith Laboratories, Inc.","A Randomized, Multicenter, Double-Blind, Placebo–Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-Onse...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016996-31,0,0,0 2009-016998-15,1,2014-10-04,2014-10-04,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,University of Turku,Effect of terbinafine and itraconazole on the pharmacokinetics and pharmacodynamics of oral tramadol: A three-phase randomized balanced cross-over study in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016998-15,0,0,0 2009-017000-83,1,2018-04-18,2018-04-18,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Institut Gustave Roussy,Essai de phase II évaluant l’effet curatif de la pravastatine chez des patients présentant une fibrose cutanée et sous-cutanée radio-induite établie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017000-83,0,0,0 2009-017003-28,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,BIOGEN-DOMPE` SRL,Relationship between IL-6 and TNF-α polymorphism and flu-like syndrome development in multiple sclerosis patients treated with Interferon-beta 1a i.m. Open label multicentre study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017003-28,0,0,0 2009-017004-91,4,2016-02-11,2016-02-11,3,1,1,0,0,0,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim France,"A randomised, double-blind, placebo-controlled parallel group dose finding study of linagliptin (1 mg or 5 mg administered orally once daily) over 12 weeks in children and adolescents, from 10 to 17 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017004-91,1,1,0 2009-017004-91,4,2016-02-11,2016-02-11,3,1,1,0,0,0,2,0,0,2,0,0,0,0,1,BOEHRINGER ING.,"A randomised, double-blind, placebo-controlled parallel group dose finding study of linagliptin (1 mg or 5 mg administered orally once daily) over 12 weeks in children and adolescents, from 10 to 17 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017004-91,1,1,0 2009-017004-91,4,2016-02-11,2016-02-11,3,1,1,0,0,0,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, placebo-controlled parallel group dose finding study of linagliptin (1 mg or 5 mg administered orally once daily) over 12 weeks in children and adolescents, from 10 to 17 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017004-91,1,1,0 2009-017010-68,1,2011-08-29,2011-08-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsmedizin der Johannes Gutenberg-Universität Mainz,A TElmisartan and AMlodipine STudy to Assess the cardiovascular PROTECTive effects as measured by endothelial dysfunction in hypertensive at risk patients beyond blood pressure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017010-68,0,0,0 2009-017011-16,1,2012-02-08,2012-02-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,3,University Federico II,"Treatment of the low IGF-1 syndrome associated with Chronic Heart Failure: A Randomized, Placebo-Controlled, Double-Blind Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017011-16,0,0,0 2009-017013-29,4,2015-02-25,2017-11-23,4,1,1,0,0,0,0,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,Acceso continuado a darunavir/ritonavir (DRV/rtv) de niños y adolescentes de 3 o más años de edad infectados por el VIH-1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017013-29,0,0,0 2009-017013-29,4,2015-02-25,2017-11-23,4,1,1,0,0,0,0,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,Acceso continuado a darunavir/ritonavir (DRV/rtv) de niños y adolescentes de 3 o más años de edad infectados por el VIH-1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017013-29,0,0,0 2009-017013-29,4,2015-02-25,2017-11-23,4,1,1,0,0,0,0,0,0,1,0,0,1,0,1,Janssen R&D Ireland,Acceso continuado a darunavir/ritonavir (DRV/rtv) de niños y adolescentes de 3 o más años de edad infectados por el VIH-1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017013-29,0,0,0 2009-017014-80,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Academical Medical Center, University of Amsterdam",The effect of helium inhalation on the coronary circulation and vessel diameter,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017014-80,0,0,0 2009-017024-82,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,FUNDACIÓN SANT JOAN DE DEU,Clinical and neuropsychological factors associated with second generation antipsychotic response in patients diagnosed with first episode of early onset schizophrenia spectrum disorders Factores cl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017024-82,0,0,0 2009-017026-39,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Aldagen, Inc",A PHASE III TRIAL OF ALD-101 ADUVANT THERAPY of UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT) IN PATIENTS WITH INBORN ERRORS OF METABOLISM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017026-39,0,0,0 2009-017028-22,7,2014-08-14,2014-08-14,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, 8 week study to evaluate the dose response, efficacy and safety of aliskiren in pediatric hypertensive patients 6-17 years of age.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017028-22,1,1,0 2009-017029-20,7,2015-08-13,2015-08-13,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A multicenter, double-blind, randomized, 52 week extension study to evaluate the long term safety, tolerability and efficacy of aliskiren compared to enalapril in pediatric hypertensive patients 6-17 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017029-20,1,1,0 2009-017031-18,1,2015-06-08,2015-06-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Rotterdam Eye Hospital,"Treatment of Cystoid Macular Edema following cataract surgery. A randomized, double-masked, placebo-controlled, clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017031-18,0,0,0 2009-017032-41,5,2014-02-18,2014-02-18,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017032-41,0,0,0 2009-017032-41,5,2014-02-18,2014-02-18,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017032-41,0,0,0 2009-017033-22,1,2012-05-30,2012-05-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Odense University Hospital,"Syd Dansk Hypertensions- og Diabetes Studie Et prospektivt, dobbeltblindet, randomiseret multicenterstudie af effekten af spironolakton på blodtrykket hos type 2 diabetikere med behandlingsresistent ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017033-22,0,0,0 2009-017039-16,5,2013-04-04,2013-04-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Effect of strontium ranelate (2g per day) in the management of long bone fractures with delayed-union or non union: an international open label study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017039-16,0,0,0 2009-017039-16,5,2013-04-04,2013-04-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Effect of strontium ranelate (2g per day) in the management of long bone fractures with delayed-union or non union: an international open label study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017039-16,0,0,0 2009-017041-58,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Sanitari del Maresme,Ensayo clínico exploratorio sobre la eficacia y la seguridad de la osteopatia en el tratamiento preventivo de la migraña,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017041-58,0,0,0 2009-017044-13,8,2012-12-14,2012-12-14,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Shire Development Inc,"A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017044-13,0,0,0 2009-017044-13,8,2012-12-14,2012-12-14,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Shire Development LLC,"A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017044-13,0,0,0 2009-017044-13,8,2012-12-14,2012-12-14,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Shire Development Inc.,"A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017044-13,0,0,0 2009-017047-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Gustave Roussy,"Essai de phase 2-3 randomisé, comparant deux modalités de réirradiation après chirurgie en territoire irradié des carcinomes des voies aéro-digestives supérieures : - radiothérapie monofractionnée av...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017047-34,0,0,0 2009-017048-15,1,2013-08-13,2013-08-13,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsmedizin Göttingen,Botulinum Neurotoxin Typ A (Xeomin®) als Therapieoption der allergischen und intrinsischen Rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017048-15,0,0,0 2009-017050-12,1,2013-09-10,2013-09-10,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Sektion Chirurgische Forschung,Improving wound healing in chronic ulcus cruris venosum with native fibrin enriched with endogenous platelets and vagal stimulation with p-Stim (a pilot study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017050-12,0,0,0 2009-017051-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMC Utrecht,Metabolic adverse events before and after glucocorticoid pulse therapy in rheumatoid arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017051-10,0,0,0 2009-017052-27,1,2011-04-30,2011-04-30,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Medizinische Hochschule Hannover,"A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017052-27,0,0,0 2009-017054-12,1,2011-06-13,2011-06-13,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Merck & Co., Inc.","A Two Part, Phase I-IIa Study Evaluating MK-1775 in Combination With Topotecan/Cisplatin in Adult Patients With Cervical Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017054-12,0,0,0 2009-017060-17,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Academic Medical Center,STIMULATE study: Statins influence on Minrin upregulation of von Willebrand factor and factor VIII,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017060-17,0,0,0 2009-017061-28,5,2012-12-18,2013-01-18,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 24-week, multicentre, randomised, double-blind, age-stratified, placebo controlled phase III study with a 28-week extension period to evaluate the efficacy and safety of dapagliflozin 10 mg once dai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017061-28,0,0,0 2009-017063-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Roche Romania SRL,Biomarkers Impact On the response to Treatment with Erlotinib in first line non-small cell lung Cancer with EGFR activating mutations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017063-42,0,0,0 2009-017064-16,1,2021-06-18,2021-06-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Fédération Francophone de Cancérologie Digestive,Essai randomisé en double aveugle de phase II/III évaluant la chimioembolisation combinée au sunitinib ou à un placebo chez des patients atteints de carcinome hépatocellulaire (SATURNE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017064-16,0,0,0 2009-017066-23,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Guys and St Thomas Foundation Trust,A randomized trial of Rituximab in induction therapy for living donor renal transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017066-23,0,0,0 2009-017075-24,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Natural Pharma International Npi AB,Delayed sleep phase in adolescents - effects of melatonin treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017075-24,0,0,0 2009-017077-37,5,2012-05-29,2012-05-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A Multicenter, Multifactorial, Randomized, Double-Blind, Placebo-Controlled Dose- Finding Study of Nifedipine GITS and Candesartan in Combination Compared to Monotherapy in Adult Patients with Essenti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017077-37,0,0,0 2009-017080-41,1,2012-07-13,2012-07-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GW Pharma Ltd.,"A randomised, partially-blind, placebo-controlled, pilot, dose-ranging study to assess the effect of cannabidiol (CBD) on liver fat levels in subjects with fatty liver disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017080-41,0,0,0 2009-017081-23,1,2016-02-10,2016-02-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Centre Hospitalier Universitaire de Nancy,Optimisation du traitement du choc cardiogénique. Etude pilote physiopathologique ouverte multicentrique comparant l’efficacité et la tolérance de l’adrénaline et la noradrénaline (Optima CC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017081-23,0,0,0 2009-017082-39,9,2011-02-04,2012-01-12,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer Healthcare AG,"A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 µg/h, 100 µg/h, 150 µg/h) Given Intravenously t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017082-39,0,0,0 2009-017082-39,9,2011-02-04,2012-01-12,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 µg/h, 100 µg/h, 150 µg/h) Given Intravenously t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017082-39,0,0,0 2009-017082-39,9,2011-02-04,2012-01-12,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Bayer Healthcare AG, D-51368, Leverkusen","A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 µg/h, 100 µg/h, 150 µg/h) Given Intravenously t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017082-39,0,0,0 2009-017083-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOIM GRUPPO ONCOLOGICO MERIDIONALE,A phase II study of metronomic oral chemoterapy with Cyclophosphamide plus Capecitabine combined with Trastuzumab in advanced breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017083-16,0,0,0 2009-017085-22,1,2011-10-31,2011-10-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Technische Universität München,Sugammadex improves muscle function after standard neuromuscular recovery (SIMAR) [Verbesserung der Muskelfunktion durch Sugammadex nach normaler neuromuskulärer Erholung],https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017085-22,0,0,0 2009-017087-17,1,2018-05-29,2018-05-29,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Addenbrooke's Hospital,Alemtuzumab for ANCA-Associated Refractory Vasculitis - A study of safety and efficacy (ALEVIATE).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017087-17,0,0,0 2009-017091-25,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Quantification de la régression de l'albuminurie et de l'atteinte endothéliale dans une population de patients drépanocytaires homozygotes hyperfiltrants traités par inhibiteurs du système rénine-ang...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017091-25,0,0,0 2009-017092-24,1,2013-06-20,2013-06-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer),Etude de phase II randomisée d’évaluation de la faisabilité d’une chimiothérapie par docetaxel prednisone sur un mode hebdomadaire ou toutes les 3 semaines dans une population de patients âgés (+75ans...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017092-24,0,0,0 2009-017093-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Phase 2 study with the multi-targeted tyrosine-kinase inhibitor Pazopanib (GW786034) for patients with relapsed or refractory urothelial cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017093-20,0,0,0 2009-017094-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA,Gene expression as predictive markers of outcome in non-small cell lung cancer patients (stage IIIB with pleural effusion and stage IV) treated with chemotherapy. Phase II trial of GOIRC.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017094-38,0,0,0 2009-017095-24,5,2015-01-12,2015-01-12,3,1,0,0,1,1,3,0,0,1,0,0,1,0,1,AOP Orphan Pharmaceuticals AG,"A phase III, randomized, multicenter, subject- and sponsor-blinded, placebo controlled study to compare the efficacy and safety of “Anagrelide retard” versus placebo in “at risk” subjects with Essenti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017095-24,0,0,0 2009-017098-40,1,2014-08-14,2014-08-14,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,King's College London,Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure (DEC-MDS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017098-40,0,0,0 2009-017098-40,1,2014-08-14,2014-08-14,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,King's College Hospital NHS Foundation Trust,Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure (DEC-MDS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017098-40,0,0,0 2009-017099-25,1,2010-10-31,2010-10-31,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Oriel Therapeutics Inc,A Pilot Pharmacodynamic/Pharmacokinetic Study of Fluticasone Propionate Administered as a Dry Powder in Patients with Asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017099-25,0,0,0 2009-017101-11,1,2013-10-23,2013-10-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"MUW, Klinik für Innere Medizin I, Onkologie",A Pilot Study of Erlotinib and Temsirolimus in Patients with Advanced Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017101-11,0,0,0 2009-017122-39,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Wyeth Research Division of Wyeth Pharmaceuticals Inc.,"A Phase 3, Open Label, Single Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017122-39,0,1,1 2009-017126-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Nîmes,Qualité du réveil après chirurgie bariatrique : Xénon versus desflurane,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017126-39,0,0,0 2009-017134-47,1,2014-09-22,2014-09-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Edinburgh,"Efficacy of Metformin in Pregnant Obese Women, a Randomised Controlled Trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017134-47,0,0,0 2009-017134-47,1,2014-09-22,2014-09-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,NHS Lothian,"Efficacy of Metformin in Pregnant Obese Women, a Randomised Controlled Trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017134-47,0,0,0 2009-017136-40,7,2012-07-23,2012-08-02,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017136-40,0,0,0 2009-017136-40,7,2012-07-23,2012-08-02,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen Cilag international NV,"A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017136-40,0,0,0 2009-017136-40,7,2012-07-23,2012-08-02,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen - Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017136-40,0,0,0 2009-017136-40,7,2012-07-23,2012-08-02,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,JASSEN-CILAG INTERNATIONAL NV,"A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017136-40,0,0,0 2009-017137-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Klinische Abteilung für Thorax -u. Hyperbare Chirurgie, Medizinische Universität Graz","Clinical course after substitution of Vitamin-D deficiency in patients with lung cancer or oesophageal carcinoma. Double blind randomised prospective, placebo-controlled study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017137-22,0,0,0 2009-017138-36,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,St Elisabeth Hospital,Influenza H1N1 Immunogenicity study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017138-36,0,0,0 2009-017139-16,1,2011-07-06,2011-07-06,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Bayer HealthCare AG,"Effect of exercise alone or in combination with testosterone replacement on muscle strength and quality of life in older men with low testosterone concentrations: a randomized double-blind, placebo co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017139-16,0,0,0 2009-017141-58,1,,,0,0,0,0,0,0,4,0,1,1,1,1,0,1,1,OPERA SRL,"An Open-Label Exploratory Clinical Study to Evaluate the Antibody and Cell Mediated Immunity of One Intramuscular Dose of MF59-Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017141-58,0,0,0 2009-017144-14,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Centre Hospitalier de Toulouse,Effets du traitement hormonal substitutif et du raloxifène sur les cellules dendritiques plasmacytoïdes et les lymphocytes B chez les femmes ménopausées,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017144-14,0,0,0 2009-017147-33,1,2016-02-08,2016-02-08,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,AGMT gemeinnützige GmbH,A Phase I/II Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017147-33,0,0,0 2009-017148-15,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"A retrospective pharmacogenetic analysis of patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN) in clinical studies CCOX189A0117, CCOX189A2332, CCOX189A2369, CCOX189A0126, CC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017148-15,0,0,0 2009-017151-97,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO,PHASE II STUDY OF SECOND LINE TREATMENT WITH WEEKLY NON-PEGILATE LIPOSOMIAL DOXORUBICIN IN METASTATIC GASTRIC CARCINOMA STUDIO DI FASE II SUL TRATTAMENTO DI SECONDA LINEA CON DOXORUBICINA LIPOSOMIA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017151-97,0,0,0 2009-017153-35,6,2014-10-28,2014-10-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AIR LIQUIDE SANTE INTERNATIONAL,"An international, multi-center, randomized, controlled trial evaluating the effect of xenon on post-operative delirium in elderly patients undergoing hip fracture surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017153-35,0,0,0 2009-017153-35,6,2014-10-28,2014-10-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AIR LIQUIDE SANTE` INTERNATIONAL,"An international, multi-center, randomized, controlled trial evaluating the effect of xenon on post-operative delirium in elderly patients undergoing hip fracture surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017153-35,0,0,0 2009-017155-10,1,,,0,0,0,0,0,1,3,0,0,1,0,0,0,1,0,CASA DI CURA PRIVATA S.RAFFAELE - PISANA,Evaluation of tolerability and efficacy of the combination Sildenafil/Bosentan in patients with severe pulmonary hypertension. Valutazione dell`efficacia e della tollerabilita` della terapia combin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017155-10,0,0,0 2009-017160-17,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTI ORTOPEDICI RIZZOLI,"NSAID USED IN MESOTHERAPY VS NSAID INTRAMUSCOLAR INJECTION IN algodistrophy TREATMENT: A RANDOMIZED, CONTROLLED STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017160-17,0,0,0 2009-017161-28,1,2014-11-14,2014-11-14,1,0,0,0,0,3,4,0,0,1,1,1,1,0,0,Juha Holopainen,VEGF-estäjä bevasitsumabi sarveiskalvon uudissuonituksen hoidossa.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017161-28,0,0,0 2009-017163-42,1,2017-03-22,2017-03-22,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Karolinska Institute,"Pain modulation in RA – Influence of adalimumab. A randomized, placebo-controlled study using functional magnetic resonance imaging",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017163-42,0,0,0 2009-017168-17,1,2011-02-08,2011-02-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients with Heart Failure with Preserved Ejection Fraction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017168-17,0,0,0 2009-017169-53,6,2013-06-02,2014-06-02,5,1,1,0,0,0,0,0,0,1,0,0,1,0,1,"Bayer HealthCare AG, Leverkusen, D-51368 Germany","A multi-center, open label, single-arm study to investigate the safety and efficacy of daily oral administration of 2 mg dienogest tablets for the treatment of endometriosis in adolescents over a tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017169-53,0,0,0 2009-017169-53,6,2013-06-02,2014-06-02,5,1,1,0,0,0,0,0,0,1,0,0,1,0,1,Bayer HelathCare AG,"A multi-center, open label, single-arm study to investigate the safety and efficacy of daily oral administration of 2 mg dienogest tablets for the treatment of endometriosis in adolescents over a tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017169-53,0,0,0 2009-017169-53,6,2013-06-02,2014-06-02,5,1,1,0,0,0,0,0,0,1,0,0,1,0,1,"Bayer HelathCare AG, Leverkusen, D-51368 Germany","A multi-center, open label, single-arm study to investigate the safety and efficacy of daily oral administration of 2 mg dienogest tablets for the treatment of endometriosis in adolescents over a tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017169-53,0,0,0 2009-017169-53,6,2013-06-02,2014-06-02,5,1,1,0,0,0,0,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A multi-center, open label, single-arm study to investigate the safety and efficacy of daily oral administration of 2 mg dienogest tablets for the treatment of endometriosis in adolescents over a tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017169-53,0,0,0 2009-017171-13,1,2014-01-12,2014-01-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,"A randomised placebo-controlled trial of saracatinib (AZD0530) plus weekly paclitaxel in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017171-13,0,0,0 2009-017174-20,3,2011-11-21,2012-01-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Serono S.A. - Geneva,"A double-blind, randomized, placebo-controlled, parallel-group, dose escalation trial to explore the potential antidyskinetic properties of safinamide in patients with Parkinson's disease suffering fr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017174-20,0,0,0 2009-017176-25,1,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,0,Sandwell and West Birmingham NHS Trust,Aspirin resistance and heart disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017176-25,0,0,0 2009-017178-19,1,2016-05-09,2016-05-09,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,Groupe Francophone des Myélodysplasies,A phase I-II study of the efficacy and safety of Idarubicin combined to Azacitidine in int-2 or high risk myelodysplastic syndromes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017178-19,0,0,0 2009-017182-38,6,2011-10-19,2011-10-21,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division",An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson’s Disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017182-38,0,0,0 2009-017182-38,6,2011-10-19,2011-10-21,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)",An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson’s Disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017182-38,0,0,0 2009-017182-38,6,2011-10-19,2011-10-21,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Impax Laboratories, Inc.",An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson’s Disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017182-38,0,0,0 2009-017192-26,1,2015-05-28,2015-05-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Free State of Bavaria represented by Regensburg University represented by Regensburg University Hospital represented by,"A 3-Armed Prospective Randomized Controlled, Open-Labeled Phase III Trial to Evaluate Late Introduction of Cyclosporine or Everolimus versus a 5-day Delay of Cyclosporine in Combination with MMF in Li...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017192-26,0,0,0 2009-017193-20,1,2010-05-11,2010-05-11,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,UZLeuven,"Effect of naloxone and methylnaltrexone on satiety, gastric sensitivity, and accommodation to food in healthy volunteers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017193-20,0,0,0 2009-017194-38,1,2015-05-28,2015-05-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GRUPO DE TRATAMIENTO DE LOS TUMORES DIGESTIVOS (TTD),"Estudio piloto fase II aleatorizado, multicentrico para evaluar la seguridad y eficacia del tratamiento de mFOLFOX-6 mas cetuximab frente a un tratamiento inicial con mFOLFOX-6 mas cetuximab (por 8 ci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017194-38,0,0,0 2009-017197-21,6,2011-08-14,2011-08-14,6,1,1,0,0,0,1,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A multicenter, open-label, single ascending dose study to evaluate pharmacokinetics, safety and tolerability of solifenacin succinate suspension in pediatric patients aged 5 to 17 years (inclusive) wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017197-21,0,0,0 2009-017201-11,1,2011-11-14,2011-11-14,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"VERISFIELD (UK) LTD, GREEK BRANCH","MULTICENTER, RANDOMIZED, DOUBLE-BLIND COMPARATIVE STUDY WITH THE REFERENCE PRODUCTS, FOR ASSESSMENT OF THERAPEUTIC SUPERIORITY OF THE COMBINATION CLINDAMYCIN-TRETINOIN/VERISFIELD, GEL, (1.0+0.025)%, (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017201-11,0,0,0 2009-017222-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Laboratorios Litaphar S.A.,"Ensayo clínico aleatorizado, doble ciego, doble enmascarado, multicéntrico para evaluar la eficacia y seguridad de 5 mg de mifepristona oral comparado con triptorelina IM administrados durante 4 meses...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017222-39,0,0,0 2009-017223-25,3,2010-11-15,2010-11-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research Ltd,"A double blind, double dummy, randomised, multicentre, two arm parallel group study to assess the efficacy and safety of FlutiForm® pMDI 125/5 µg (2 puffs bid) vs Symbicort® Turbohaler® 200/6 µg (2 pu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017223-25,0,0,0 2009-017228-24,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Instituto Científico y Tecnológico de Navarra,Ensayo clínico de tratamiento de la Diabetes Mellitus tipo 1 autoinmune con células madre mesenquimales autólogas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017228-24,0,0,0 2009-017229-20,1,2013-02-01,2013-02-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,KRKA-POLSKA Sp. z o.o.,Efficacy and safety of PANtoprazole in the treatment and SympTom relief in patients with gAstRoesophageal reflux disease (GERD) – PAN-STAR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017229-20,0,0,0 2009-017234-51,4,2016-10-18,2016-12-22,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A multicenter extension trial of subcutaneously administered AIN457 in patients with moderate to severe chronic plaque-type psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017234-51,0,0,0 2009-017237-22,8,2011-09-08,2011-09-15,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen Biologics B.V.,"A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refract...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017237-22,0,0,0 2009-017237-22,8,2011-09-08,2011-09-15,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,JANSSEN BIOLOGICS B.V.,"A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refract...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017237-22,0,0,0 2009-017237-22,8,2011-09-08,2011-09-15,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen Biologics B.V. (formerly known as Centocor B.V.),"A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refract...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017237-22,0,0,0 2009-017237-22,8,2011-09-08,2011-09-15,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Centocor B.V. (Janssen Biologics),"A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refract...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017237-22,0,0,0 2009-017237-22,8,2011-09-08,2011-09-15,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Centocor B.V.,"A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refract...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017237-22,0,0,0 2009-017238-39,4,2012-01-12,2012-01-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)",A Study to Compare IPX066 and Carbidopa / Levodopa / Entacapone (CLE) in Advanced Parkinson’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017238-39,0,0,0 2009-017238-39,4,2012-01-12,2012-01-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"IMPAX LABORATORIES, INC.",A Study to Compare IPX066 and Carbidopa / Levodopa / Entacapone (CLE) in Advanced Parkinson’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017238-39,0,0,0 2009-017240-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASOCIACIÓN GALLEGA DE ENFERMEDAD INFLAMATORIA INTESTITAL (E.I.G.A.),EFFICACY OF BECOMETASONE DIPROPIONATE ON MICROSCOPIC COLITIS EFICACIA DEL DIPROPIONATO DE BECLOMETASONA EN LA COLITIS MICROSCOPICA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017240-14,0,0,0 2009-017241-55,1,2010-06-10,2010-06-10,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,ISTITUTO PER L`INFANZIA BURLO GAROFOLO,Open randomized study on propranolol vs prednisone for haemangioma in patients younger than 18 months of age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017241-55,0,0,0 2009-017242-30,14,2014-12-02,2014-12-03,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicyl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017242-30,0,0,0 2009-017242-30,14,2014-12-02,2014-12-03,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicyl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017242-30,0,0,0 2009-017245-64,1,2013-05-14,2013-05-14,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Leeds Teaching Hospitals NHS Trust,The effect of metformin co-treatment in hormone-replacement frozen embryo replacement cycles in women with polycystic ovary syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017245-64,0,0,0 2009-017247-33,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,FUNDACIÓ PRIVADA CLINIC PER A LA RECERCA BIOMÈDICA,"Estudio fase II aleatorizado en pacientes con cáncer colorrectal en estadio IV progresivo a dos líneas de quimioterapia, comparando el mejor tratamiento de soporte frente a tratamiento con células den...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017247-33,0,0,0 2009-017248-14,7,2014-03-22,2014-03-22,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BIOPROJET,BF2.649 en pacientes con síndrome de apnea obstructiva del sueño (SAOS) tratados con presión positiva continua nasal de las vías respiratorias (nCPAP) que todavía refieren somnolencia diurna excesiva ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017248-14,0,0,0 2009-017251-94,7,2014-05-07,2014-05-14,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bioprojet,"Efficacy and safety of BF2.649 in the treatment of Excessive Daytime Sleepiness in patients with Obstructive Sleep Apnoea syndrome (OSA), refusing the nasal continuous positive airway pressure (nCPAP)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017251-94,0,0,0 2009-017253-35,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Oxford BioMedica (UK) Ltd,"A multicentre, open-label extension study to determine the long term safety, tolerability and efficacy of ProSavin® in patients with bilateral, idiopathic Parkinson’s disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017253-35,0,0,0 2009-017256-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Cardiología. Hospital Universitario Vall d'Hebron,Ensayo de eficacia y seguridad de la doble antiagregación comparada con la combinación de anticoagulación oral + doble antiagregación en pacientes con fibrilación auricular de bajo-moderado riesgo som...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017256-27,0,0,0 2009-017257-35,1,2010-12-17,2010-12-17,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Revotar Biopharmaceuticals AG,"Multi-center, randomized, double-blind, placebo-controlled, cross-over Phase II study to evaluate the safety and efficacy of inhaled Bimosiamose for the treatment of patients with moderate to severe C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017257-35,0,0,0 2009-017259-91,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,University Hospital Motol,Phase I/II clinical trial: Immunotherapy of prostate cancer patients in biochemical relapse with dendritic cell-based vaccine Fáze I/II klinické studie imunoterapie karcinomu prostaty ve stádiu bio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017259-91,0,0,0 2009-017260-16,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Consorci Mar Parc de salut de Barcelona (Parc de salut MAR),CITICOLINA EN LA EVOLUCIÓN DE LA LEUCOARAIOSIS A MEDIO-LARGO PLAZO. ESTUDIO ALEATORIZADO Y CONTROLADO CON PLACEBO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017260-16,0,0,0 2009-017261-32,1,2016-05-10,2016-05-10,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Martin-Luther-Universität Halle-Wittenberg,Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017261-32,0,0,0 2009-017265-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Hospital Ghent,Invloed van voeding op farmacokinetiek en -dynamiek van desmopressine tablet in vergelijking met desmopressine MELT-vorm,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017265-33,0,0,0 2009-017266-23,3,2010-06-03,2010-06-03,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Forest Research Institute, Inc.","A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled, Safety Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus Treated With Dutogliptin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017266-23,0,0,0 2009-017267-41,1,2010-09-02,2010-09-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, parallel group study to compare the pharmacodynamics/efficacy, safety and pharmacokinetics of QAV680 versus placebo in patients with moderate persistent asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017267-41,0,0,0 2009-017269-49,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INSTITUT CURIE,Etude de phase II d’évaluation de la toxicité et de l’efficacité d’un traitement par Tacrolimus (Prograf®) chez des patients atteints d’un lymphome diffus à grandes cellules B ou T.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017269-49,0,0,0 2009-017270-21,5,2011-12-12,2011-12-12,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"Estudio aleatorizado de fase II de gemcitabina/cisplatino con o sin SAR240550 (BSI-201), un inhibidor de PARP1, en pacientes con cáncer de pulmón no microcítico en estadio IV _________________________...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017270-21,0,0,0 2009-017270-21,5,2011-12-12,2011-12-12,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & de'veloppement,"Estudio aleatorizado de fase II de gemcitabina/cisplatino con o sin SAR240550 (BSI-201), un inhibidor de PARP1, en pacientes con cáncer de pulmón no microcítico en estadio IV _________________________...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017270-21,0,0,0 2009-017271-17,1,2013-10-22,2013-10-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017271-17,0,0,0 2009-017272-24,7,2012-10-24,2012-10-24,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation","Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous SCH 900222 in Subjects with Moderate-to-Severe Chronic Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017272-24,0,0,0 2009-017273-38,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Manuel Praga Terente,"Estudio fase III, multicéntrico, aleatorizado, abierto de grupos paralelos para comparar la eficacia y seguridad de la pauta Prednisona-Ac Micofenólico-Ciclosporina a Prednisona-Ac Micofenólico en el ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017273-38,0,0,0 2009-017274-20,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,0,Centre Hospitalier Universitaire de GRENOBLE,Evaluation de l’efficacité de l’Alfentanil chez l’enfant en réanimation infantile par rapport au Sufentanil - traitement de référence - sur le confort du patient lors de l’aspiration trachéale,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017274-20,0,0,0 2009-017279-77,2,2020-05-23,2020-05-23,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,GELARC,"Randomized Phase III study evaluating the non-inferiority of a treatment adapted to the early response evaluated with 18F-FDG PET compared to a standard treatment, for patients aged from 18 to 80 year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017279-77,0,0,0 2009-017279-77,2,2020-05-23,2020-05-23,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,LYSARC,"Randomized Phase III study evaluating the non-inferiority of a treatment adapted to the early response evaluated with 18F-FDG PET compared to a standard treatment, for patients aged from 18 to 80 year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017279-77,0,0,0 2009-017282-35,3,2017-09-20,2017-09-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017282-35,0,0,0 2009-017288-40,1,,,0,1,0,0,0,0,3,0,1,1,1,1,0,1,1,"Schering-Plough Research Institute, a Division of Schering Corporation","A Randomized, Open-Label, Comparative, Multicenter Trial to Compare the Effects on Metabolic Parameters of Two NOMAC-E2 Batches (Pivotal Phase III and Commercial Batch) and a Monophasic COC Containing...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017288-40,0,0,0 2009-017293-20,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Vomissements Post-OPératoires chez l'enfant: Evaluation de l'adjonction du Dropéridol à une bi-prophylaxie classique.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017293-20,0,0,0 2009-017295-24,1,2014-03-31,2014-03-31,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,University Hospital Motol,Phase I/II clinical trial:Immunotherapy of hormone-refractory prostate cancer patients with dendritic cell-based vaccine (Fáze I/II klinické studie imunoterapie hormonálně refrakterního karcinomu pros...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017295-24,0,0,0 2009-017296-17,1,2012-04-30,2012-04-30,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Statens Serum Institut,"A phase IIa specificity trial of the diagnostic agent C-Tb, when given intradermally by the Mantoux technique to healthy volunteers previously vaccinated with BCG",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017296-17,0,0,0 2009-017301-11,3,2014-03-28,2014-03-28,3,1,1,0,0,0,3,0,0,1,0,0,1,0,1,CSL Behring GmbH,"An Open-Label, Multi-Centre Extension Study to Assess the Efficacy and Safety of Biostate® in Paediatric, Adolescent, and Adult Subjects with Von Willebrand Disease who Completed Clinical Studies CSLC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017301-11,0,0,0 2009-017304-88,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Wyeth Research division of Wyeth Pharmaceuticals Inc.,"A Phase 3, Open Label Trial Evaluating the Safety,Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Healthy Children Aged 15 Months to 17 Years in the United States",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017304-88,0,1,1 2009-017306-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Leiden University Medical Center, Department of Rheumatology",ANTI-IGE THERAPY (OMALIZUMAB) IN IGE-ACPA POSITIVE RA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017306-36,0,0,0 2009-017308-10,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,Heli Sätilä,”Lasten idiopaattisen varvaskävelyn botuliinihoito – satunnaistettu kontrolloitu arvioijasokkoutettu tutkimus”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017308-10,0,0,0 2009-017309-12,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,FUNDACIÓN ESPAÑOLA DE REUMATOLOGÍA (FER),Evaluación de la respuesta a etoricoxib en pacientes con Espondilitis Anquilosante (EA) e inadecuada respuesta > o = a 2 AINES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017309-12,0,0,0 2009-017311-15,11,2013-04-18,2013-05-03,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"Estudio de extensión al estudio multicéntrico, aleatorizado, abierto y controlado CRAD001H2304, para evaluar la eficacia y seguridad a largo plazo de everolimus con control de la concentración en rece...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017311-15,0,0,0 2009-017311-15,11,2013-04-18,2013-05-03,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"Estudio de extensión al estudio multicéntrico, aleatorizado, abierto y controlado CRAD001H2304, para evaluar la eficacia y seguridad a largo plazo de everolimus con control de la concentración en rece...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017311-15,0,0,0 2009-017311-15,11,2013-04-18,2013-05-03,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"Estudio de extensión al estudio multicéntrico, aleatorizado, abierto y controlado CRAD001H2304, para evaluar la eficacia y seguridad a largo plazo de everolimus con control de la concentración en rece...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017311-15,0,0,0 2009-017313-30,5,2015-07-07,2015-07-07,5,1,1,0,0,0,1,0,0,1,0,0,1,0,1,Bayer HealthCare AG,Single-dose pilot study of oral rivaroxaban in pediatric subjects with venous thromboembolism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017313-30,0,0,0 2009-017314-76,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut de Cardiologie de Montréal,Etude de recherche sur l'élimination de la conduction dormante guidée par l'adénosine lors des procédures d'isolation des veines pulmonaires pour le traitement d'ablation par cathéter de la fibrillati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017314-76,0,0,0 2009-017315-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Erasmus MC Rotterdam,Multi Center Clinical trial of endovascular treatment of acute ischemic stroke in the Netherlands. Multi Center Clinical trial of endovascular treatment of acute ischemic stroke in the Netherlands...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017315-15,0,0,0 2009-017317-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE SANTA LUCIA,Investigating the neuroprotective effect of Donepezil in patients affected by Alzheimer disease: a 12 month longitudinal analysis of the peripheral levels of neurotrophins and inflammatory factors in ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017317-30,0,0,0 2009-017319-13,4,2011-10-14,2011-10-14,2,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Alcon Research Ltd.,Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Acute Otitis Media with Otorrhea in Tympanostomy Tubes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017319-13,1,0,0 2009-017320-29,1,2013-06-10,2013-06-10,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Department of Orthopaedics IKE,Does teriparatide accelerate early callus formation in proximal humeral fractures?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017320-29,0,0,0 2009-017324-11,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Universitätsmedizin Göttingen,"Wirksamkeit von Ranibizumab bei Patienten mit CHORIOIDALER NEOVASKULARISATION (CNV), als Folge einer altersbedingten Makuladegeneration (AMD), bei einer Gabe alle zwei Monate gegenüber der Behandlung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017324-11,0,0,0 2009-017325-19,1,2014-10-29,2014-10-29,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,Helsingin reumakeskus,“The effect of Six months Adalimumab Treatment on Sick Leaves and retirement in Patients with rheumatoid Arthritis who are at risk of losing their ability to work”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017325-19,0,0,0 2009-017326-39,1,,,0,1,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospitals Leuven,Vergelijkende studie tussen PCEA en TAP-block als postoperatieve pijnstilling bij setio-patiënten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017326-39,0,0,0 2009-017328-25,1,2015-10-15,2015-10-15,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,University Hospital Heidelberg,"A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017328-25,0,0,0 2009-017329-20,1,2016-05-31,2016-05-31,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,"Melbourne Health, Royal Melbourne Hospital","A randomised, double-blind, placebo-controlled trial of intranasal insulin (440IU) in children and young adults at risk of type 1 diabetes: INTRANASAL INSULIN TRIAL II",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017329-20,0,0,0 2009-017331-18,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo Español Multidisciplinar en Cáncer Digestivo-GEMCAD,Estudio abierto de fase II para evaluar los posibles marcadores tumorales predictivos en pacientes con cáncer colorrectal metastásico y tumor con KRAS no mutado tratados con FOLFOX6m y panitumumab com...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017331-18,0,0,0 2009-017332-41,2,2014-01-23,2014-01-23,2,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York NY10017","A Phase 4, Open-label Trial Describing the Safety, Tolerability, and Immunogenicity of the 13 valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017332-41,0,0,0 2009-017332-41,2,2014-01-23,2014-01-23,2,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Wyeth LLC,"A Phase 4, Open-label Trial Describing the Safety, Tolerability, and Immunogenicity of the 13 valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017332-41,0,0,0 2009-017336-40,3,2011-05-30,2011-07-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Prospective, open label TElmisartan/AMlodipine single pill STudy to Assess the efficacy in patients with essential hypertension who are not controlled on RAASi mono-therapy being switched",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017336-40,0,0,0 2009-017336-40,3,2011-05-30,2011-07-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"Prospective, open label TElmisartan/AMlodipine single pill STudy to Assess the efficacy in patients with essential hypertension who are not controlled on RAASi mono-therapy being switched",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017336-40,0,0,0 2009-017336-40,3,2011-05-30,2011-07-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim BV,"Prospective, open label TElmisartan/AMlodipine single pill STudy to Assess the efficacy in patients with essential hypertension who are not controlled on RAASi mono-therapy being switched",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017336-40,0,0,0 2009-017340-14,1,2014-03-25,2014-03-25,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,University Hospital Southampton NHS Foundation Trust,WT1 Immunity via DNA fusion Gene Vaccination in Haematological Malignancies by intramuscular injection followed by intramuscular electroporation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017340-14,0,0,0 2009-017346-32,1,,,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,Orchard Therapeutics (Europe) Ltd,A PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME Studio clinico di fase I/II: terapia genica con cellule staminali ematopoietiche per il trattam...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017346-32,0,0,0 2009-017347-33,1,2013-08-24,2013-08-24,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,University of Leipzig,A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients ≥60 years with AML not eligible for conventional Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017347-33,0,0,0 2009-017349-77,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,A Phase I/II clinical trial of hematopoietic stem cell gene therapy for the treatment of Metachromatic Leukodystrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017349-77,0,0,0 2009-017350-13,1,2013-07-15,2013-07-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Erasme Hospital,Pharmacokinetics of oseltamivir in patients with infection due to influenza A H1N1 2009 admitted in intensive care unit.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017350-13,0,0,0 2009-017351-96,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UZleuven,A placebo controlled trial with Baclofen for the treatment of GERD patients with incomplete PPI response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017351-96,0,0,0 2009-017353-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jon Perez Barcena,"Eficacia del dipéptido N(2)-L-Alanil-L-glutamina en los pacientes traumáticos ingresados en la UCI: estudio piloto, prospectivo, aleatorizado y doble ciego",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017353-36,0,0,0 2009-017354-12,6,2011-10-26,2011-10-26,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK","A MULTICENTER, OPEN-LABEL, RANDOMIZED, TWO ARM CROSS-OVER STUDY ASSESSING DYAD (SUBJECT AND CAREGIVER) AND ADULT SUBJECT PERCEPTION OF CONVENIENCE AND PREFERENCE OF THE NEWLY DEVELOPED GENOTROPIN MARK...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017354-12,1,0,0 2009-017356-28,1,2012-02-16,2012-02-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Dundee,Evaluation of Beta Blockers for the Treatment of Asthma. A randomised controlled trial of propranolol.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017356-28,0,0,0 2009-017357-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE PAOLO PROCACCI ONLUS,OPIOIDS IN THE ELDERLY PATIENT: OSTEOARTHRITIC PAIN VERSUS CANCER RELATED PAIN.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017357-35,0,0,0 2009-017358-10,9,2013-05-16,2013-05-16,9,1,0,0,0,0,0,0,0,1,0,0,1,0,1,AstraZeneca AB,"SAVOR Evaluación de saxagliptina a partir de los resultados vasculares registrados en pacientes con diabetes mellitus Ensayo clínico fase IV, multicéntrico, aleatorizado, doble ciego, controlado con p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017358-10,0,0,0 2009-017358-10,9,2013-05-16,2013-05-16,9,1,0,0,0,0,0,0,0,1,0,0,1,0,1,ASTRAZENECA,"SAVOR Evaluación de saxagliptina a partir de los resultados vasculares registrados en pacientes con diabetes mellitus Ensayo clínico fase IV, multicéntrico, aleatorizado, doble ciego, controlado con p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017358-10,0,0,0 2009-017359-92,3,2010-12-08,2010-12-08,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Clinuvel Pharmaceuticals Limited,"A Phase III, randomised, double blind, placebo controlled, parallel group study, to evaluate the safety and efficacy of subcutaneous implants of afamelanotide (16 mg) in patients suffering from polymo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017359-92,0,0,0 2009-017363-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IMETISA,Tratamiento de la fibrosis inducida por radioterapia en tumores de vías aerodigestivas superiores mediante la combinación de pentoxifilina-tocoferol y oxigenoterapia hiperbárica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017363-42,0,0,0 2009-017365-36,6,2015-08-13,2015-08-13,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GANYMED Pharmaceuticals AG,"International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esophagu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017365-36,0,0,0 2009-017369-47,1,2013-01-31,2013-01-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,2,Research and Development Office Cardiff and Vale NHS Trust,An in-vitro observational pilot study of the role of gamma delta T cells in the acute phase reaction to intravenous bisphosphonate; in blood samples donated by patients receiving intravenous bisphosph...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017369-47,0,0,0 2009-017374-20,1,2012-11-01,2012-11-01,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Bernhard-Nocht-Institute for Tropical Medicine,"Probiotic Saccharomyces boulardii for the prevention of antibiotic-associated diarrhoea – randomised, double-blind, placebo-controlled trial Saccharomyces boulardii zur Prävention der Antibiotika-a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017374-20,0,0,0 2009-017376-25,2,2013-04-27,2013-04-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refrac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017376-25,0,0,0 2009-017378-19,1,,,0,0,0,0,1,0,2,0,0,1,1,1,0,1,0,Dr. Antonio Mari Roig,Estudio prospectivo controlado sobre el efecto protector de la toxina botulínica tipo a en la sialoadenitis radioinducida,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017378-19,0,0,0 2009-017379-90,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SENESE,Characterization of the secondary failure to TNF-blockers monoclonal antibodies. Receptor as a rescue therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017379-90,0,0,0 2009-017380-42,2,2010-08-20,2010-08-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ALMIRALL, S.A.",Efficacy and safety of three doses of aclidinium bromide compared to placebo and to an active comparator all administered twice daily by inhalation in patients with stable moderate and severe chronic ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017380-42,0,0,0 2009-017384-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academisch ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum,"Safety and efficacy of the addition of simvastatin to cetuximab in k-ras mutant advanced or metastatic colorectal cancer patients. A single-arm, multicenter, phase II study using a Simon two stage des...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017384-42,0,0,0 2009-017387-16,1,2011-04-18,2011-04-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novo Nordisk Pharmaceutique S.A.S,"To assess ease of use, acceptability and preference of Norditropin NordiFlex® in subjects on prescribed growth hormone therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017387-16,0,0,0 2009-017388-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Laboratoires Théa,Efficacy and Safety Assessment of Azyter® eye drops (T1225) in patients with blepharitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017388-41,0,0,0 2009-017396-19,13,2016-12-14,2017-08-22,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017396-19,0,0,0 2009-017396-19,13,2016-12-14,2017-08-22,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017396-19,0,0,0 2009-017398-39,1,2010-06-10,2010-06-10,1,0,0,0,0,0,3,0,1,1,1,1,1,0,1,Helperby Thearapeutics Ltd,"Randomised double-blind, vehicle controlled dosing frequency study of HT61 1% gel applied to the anterior nares plus chlorhexidine body and hair washes in subjects with nasal carriage of Staphylococcu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017398-39,0,0,0 2009-017400-91,1,2012-01-10,2012-01-10,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Renovo,"An exploratory, single centre, randomized, placebo controlled, assessor blind clinical trial to assess the effects of intradermal administrations of Prevascar on scarring in human subjects of African ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017400-91,0,0,0 2009-017401-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Reims,Comparaison de la radiothérapie multichamps et du rituximab IV dans le traitement des lymphomes B cutanés indolents à lésions multiples ou récidivantes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017401-11,0,0,0 2009-017402-36,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Instituto Científico y Tecnológico de Navarra,Estudio prospectivo fase II de la vacunación con células dendríticas autólogas en pacientes con cáncer de mama triple negativo en estadios II-III,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017402-36,0,0,0 2009-017405-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Teknon,"Regeneración del cartílago articular en gonartrosis de IIº, IIIº y IVº grados mediante infiltración articular de MSV* *Células progenitoras de médula ósea autóloga, expandidas “Ex Vivo” con procedimi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017405-11,0,0,0 2009-017407-28,1,2010-03-29,2010-03-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,"A phase II, single-center, randomized, controlled, double-blind study to assess effects on skin conditions and patient reported outcome of a topical formulation containing LAS41002 on lesional skin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017407-28,0,0,0 2009-017409-13,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,Sanquin Blood Supply Foundation,"Dose escalating study to evaluate pharmacokinetics, efficacy and safety of apotransferrin in atransferrinemia patients Dosis eskalierende Studie zur Bewertung de Pharmakokinetik, Wirksamkeit und Si...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017409-13,0,0,0 2009-017409-13,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,Prothya Biosolutions Netherlands B.V.,"Dose escalating study to evaluate pharmacokinetics, efficacy and safety of apotransferrin in atransferrinemia patients Dosis eskalierende Studie zur Bewertung de Pharmakokinetik, Wirksamkeit und Si...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017409-13,0,0,0 2009-017409-13,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,Sanquin Plasma Products,"Dose escalating study to evaluate pharmacokinetics, efficacy and safety of apotransferrin in atransferrinemia patients Dosis eskalierende Studie zur Bewertung de Pharmakokinetik, Wirksamkeit und Si...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017409-13,0,0,0 2009-017412-32,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI,RANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXIN TYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSON DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017412-32,0,0,0 2009-017415-16,1,2011-04-29,2011-04-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. August Wolff GmbH & Co KG Arzneimittel,"A Phase III, single-center, randomized, double-blind, parallel group, placebo-controlled study of Alpicort F in the treatment of chemotherapy induced alopecia in women",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017415-16,0,0,0 2009-017416-33,1,2012-06-30,2012-06-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University",Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017416-33,0,0,0 2009-017418-56,1,2010-09-09,2010-09-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Birken GmbH,"Open, Prospective, Controlled, Randomised, Multicenter Phase II Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Moist Wound Healing Dressing alone in Acce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017418-56,0,0,0 2009-017420-75,1,2011-02-16,2011-02-16,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Joergen B Dahl,"Effekten af transversus abdominis plane (TAP) blok på patienter, der får foretaget laparoskopisk cholcystektomi i dagkirurgisk regi",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017420-75,0,0,0 2009-017422-39,6,2017-09-24,2017-09-27,5,1,0,0,0,1,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer (EORTC),Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017422-39,0,0,0 2009-017422-39,6,2017-09-24,2017-09-27,5,1,0,0,0,1,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017422-39,0,0,0 2009-017422-39,6,2017-09-24,2017-09-27,5,1,0,0,0,1,2,0,0,1,0,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017422-39,0,0,0 2009-017425-19,1,2015-09-15,2015-09-15,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,University Hospital Ghent,Vitiligo en het Koebnerfenomeen. (Vitiligo inductie- en therapie model : klinische en immunologische analyse),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017425-19,0,0,0 2009-017428-17,1,2015-05-31,2015-05-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA ORDINE MAURIZIANO,A Phase II Randomized Clinical Trial of Panitumumab plus Gemcitabine and Oxaliplatin (GEMOX) versus GEMOX alone as First Line Treatment in Advanced Biliary Tract Adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017428-17,0,0,0 2009-017429-21,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Miguel Ángel Zapata. Oftalmología. Hospital vall d'Hebron,"ENSAYO CLÍNICO, ABIERTO, DE SEGURIDAD Y EFICACIA DE ADALIMUMAB INTRAVÍTREO EN PACIENTES CON NEOVASCULARIZACIÓN COROIDEA SECUNDARIA A DEGENERACIÓN MACULAR ASOCIADA A LA EDAD EN PACIENTES NO RESPONDEDOR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017429-21,0,0,0 2009-017430-49,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Dr Miguel Santín Cerezales,"Ensayo clínico de dos estrategias para la toma de decisiones terapéuticas en el estudo de contactos de tuberculosis: estrategia estándar, basada en la prueba de la tuberculina (PT) sola frente a la co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017430-49,0,0,0 2009-017432-40,4,2012-07-23,2020-04-01,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MOLOGEN AG,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-Center Clinical Study to Evaluate Efficacy and Safety of a Maintenance Therapy with Immunomodulator MGN1703 in Patients with Advanced Col...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017432-40,0,0,0 2009-017434-45,2,2011-08-16,2011-08-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,InfaCare Pharmaceutical Corporation,"A Phase 2b, Multicenter, Single-dose, Blinded, Randomized, Placebo-controlled, Dose-escalation, Safety and Efficacy Trial of Stannsoporfin in Neonates with Hyperbilirubinemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017434-45,0,0,0 2009-017435-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Steba Biotech S.A.,"A Phase IIa, Safety and Preliminary Effects Study of WST11 (Stakel®)-Mediated Vascular-Targeted Photodynamic (VTP) Therapy in Subjects with Choroidal Neovasularization (CNV) Associated with Age-Relate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017435-18,0,0,0 2009-017437-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PERUGIA,"MANAGEMENT OF PRIMARY AND SECUNDARY PERITONEAL CARCINOMATOSIS FROM COLO-RECTAL CANCER, RECURRENT OVARIAN CANCER AND ABDOMINAL SARCOMATOSIS BY CYTOREDUCTIVE SURGERY PLUS HYPERTHERMIC INTRAPERITONEAL CH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017437-22,0,0,0 2009-017438-32,4,2011-07-11,2011-07-11,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A 12-week, double-blind, randomized, parallel-group, placebo-controlled study of 4 doses of VX-509 in subjects with active rheumatoid arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017438-32,0,0,0 2009-017440-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación PETHEMA,EVALUACIÓN DEL EFECTO ANTITUMORAL DEL ÁCIDO ZOLEDRÓNICO EN PACIENTES CON MIELOMA MÚLTIPLE Y RECAÍDA BIOQUÍMICA ASINTOMÁTICA: ENSAYO CLÍNICO PROSPECTIVO DEL GRUPO GEM/PETHEMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017440-13,0,0,0 2009-017441-63,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,U.O. Ginecologia e Ostetricia,EVALUATION OF PROGESTERONE-RELATED COMPOUNDS FOR THE TERZIARY PROPHILAXYS OF PRETERM DELIVERY: A MULTICENTRE RANDOMIZED CONTROLLED TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017441-63,0,0,0 2009-017443-34,9,2011-07-15,2011-10-12,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A Ph II/III seamless, multi-center, randomized, double-blind, placebo-controlled study of the reduction in signs and symptoms and inhibition of structural damage during treatment with tocilizumab v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017443-34,0,0,0 2009-017448-15,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO NEUROLOGICO MEDITERRANEO NEUROMED,"A multicenter, open label, hystorical Group controlled study by evaluate the effectivness and sAfety in the use of INfliximab (Tumor necrosis factor - alfa antibody) in preventing or reducing cerebral...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017448-15,0,0,0 2009-017449-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FRED HUTCHINSON CANCER RESEARCH CENTER UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE SEATTLE CHILDREN,Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia:...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017449-72,0,0,0 2009-017454-12,3,2013-06-17,2013-06-17,1,0,0,0,0,0,3,0,0,2,1,0,0,0,0,University of Cincinnati - Academic Medical Center -Department of Neurology,"INTERVENTIONAL MANAGEMENT OF STROKE TRIAL CLINICAL PROTOCOL A phase III, randomized, multi-center, open label, 900 subject clinical trial that will examine whether a combined intravenous (IV) and intr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017454-12,1,0,0 2009-017458-11,1,2011-07-22,2011-07-22,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,"Institute for Social Medicine, Epidemiology, and Health Economics, Charité Berlin","Homeopathy for Depression: a randomized, four-armed, partial double-blind study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017458-11,0,0,0 2009-017463-41,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,CHU de Rouen,Etude pilote d'évaluation du test du freination de la sécrétion de l'hormone parathyroïdienne par le Cinacalcet (MIMPARA). Comparaisons : 1/ avec les résultats du test de charge calcique intra-veineux...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017463-41,0,0,0 2009-017464-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA,Arterial Hypertension in patients with elevated aldosterone to renin ratio but negative confirmatory test for Primary Aldosteronism: comparison between anti-hypertensive efficacy of potassium canrenoa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017464-17,0,0,0 2009-017467-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Servicio Enfermedades Infecciosas,"- ENSAYO CLÍNICO DE FASE II, ALEATORIZADO Y ABIERTO PARA EL TRATAMIENTO ETIOLÓGICO DE LA ENFERMEDAD DE CHAGAS CRÓNICA CON POSACONAZOL y BENZNIDAZOL - PHASE II CLINICAL TRIAL, RANDOMIZED AND OPEN FOR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017467-42,0,0,0 2009-017468-18,1,2013-01-07,2013-01-07,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Bioibérica S.A.,"Ensayo clínico aleatorizado, doble ciego, controlado con placebo para valorar el efecto de condroitín sulfato sobre el dolor en pacientes afectos de artrosis de rodilla mediante Resonancia Magnética f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017468-18,0,0,0 2009-017470-20,1,2014-02-23,2014-02-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratoires Grünenthal,An open-label extension study for patients with severe chronic low back pain or severe chronic pain due to knee osteoarthritis who have completed any of the previous phase IIIb trials with tapentadol ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017470-20,0,0,0 2009-017472-25,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Universitätsklinikum Schleswig-Holstein, Campus Lübeck","„Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“ (“Catheter-directed foam sclerotherapy of varicose veins und...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017472-25,0,0,0 2009-017477-38,2,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,GlaxoSmithKline S.A.,"An Open-Label, Dose-Escalation, Phase IB/ II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination with Oral Everolim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017477-38,0,0,0 2009-017477-38,2,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,GlaxoSmithKline Research & Development Ltd,"An Open-Label, Dose-Escalation, Phase IB/ II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Combination with Oral Everolim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017477-38,0,0,0 2009-017479-29,3,2011-06-28,2011-06-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination with Atorvastatin, Simvastatin, and Rosuvastatin in Patients with Hypercholesterolemia or Low HDL-C",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017479-29,0,0,0 2009-017480-42,1,2012-01-16,2012-01-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Synairgen Research Ltd,"A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to asthmatic subjects after the onset of a respiratory viral ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017480-42,0,0,0 2009-017481-23,1,2011-08-29,2011-08-29,1,1,0,0,0,0,2,1,0,1,0,0,1,0,1,SmartPractice,Clinical Evaluation of T.R.U.E. TEST® Neomycin Sulfate and Potassium Dichromate Allergens: Bioequivalence of Vehicle Formulations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017481-23,0,0,0 2009-017485-23,6,2018-08-22,2018-08-22,6,1,0,0,0,0,2,0,0,1,0,0,1,0,0,EORTC,"TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (""Treat CTC"" trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017485-23,0,0,0 2009-017487-16,3,2012-01-31,2012-04-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Alnylam Pharmaceuticals, Inc.","A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017487-16,0,0,0 2009-017488-40,10,2011-07-15,2011-12-28,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomized, double-blind, parallel-group placebo-controlled study of the safety and reduction of signs and symptoms during treatment with tocilizumab (TCZ) versus placebo in patients with ankylos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017488-40,0,0,0 2009-017490-38,2,2011-11-02,2011-11-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec Ltd,"""Estudio aleatorizado de interrrupción de tratamiento con Natalizumab"" ""Randomized Treatment Interruption of Natalizumab""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017490-38,0,0,0 2009-017490-38,2,2011-11-02,2011-11-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec,"""Estudio aleatorizado de interrrupción de tratamiento con Natalizumab"" ""Randomized Treatment Interruption of Natalizumab""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017490-38,0,0,0 2009-017498-39,1,2012-12-10,2012-12-10,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Oxford,"A follow-on, multi-centre, open-label, clinical, phase 3 trial to investigate the persistence of serotype-specific antibodies at 40 months of age in children who have received either the 7-valent or t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017498-39,0,0,0 2009-017499-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Academical Medical Center, University of Amsterdam",The use of Helium after Resuscitation: a safety and feasibility study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017499-26,0,0,0 2009-017503-29,6,2010-10-12,2010-10-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, controlled extension study of CACZ885H2356 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017503-29,0,0,0 2009-017520-88,1,2012-03-22,2012-03-22,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Medical Faculty, TU Dresden",Ciclosporin vs. Alitretinoin for severe atopic hand dermatitis. A randomized controlled investigator-initiated double-blind trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017520-88,0,0,0 2009-017523-26,8,2011-08-22,2011-12-12,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017523-26,0,0,0 2009-017524-36,1,2010-06-23,2010-06-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Forest Research Institute, Inc.","A Phase III, Multicenter, Double-blind, Active-Controlled, 52-Week Extension Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017524-36,0,0,0 2009-017525-19,1,2014-08-11,2014-08-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"St. Vincents University Hospital, Department of Rheumatology.","Abatacept in Psoriasis and Psoriatic Arthritis: a single centre, placebo-controlled, crossover study in 15 patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017525-19,0,0,0 2009-017537-21,1,2011-07-04,2011-07-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Portsmouth Hospitals NHS Trust,"Oral thiamine (Vitamin B1) supplementation in subjects with type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled crossover trial assessing biophysical markers of endothelial functi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017537-21,0,0,0 2009-017540-13,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Clinical Trials and Research Governance,A Phase IV Open-Labelled Prospective Pilot Study of Intravitreal Macugen (pegaptanib) for Ischaemic Diabetic Macular Oedema (MIDME study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017540-13,0,0,0 2009-017581-22,1,2013-12-31,2013-12-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Department of Psychiatry and Psychotherapy, Charity University Medicine",Cognitive impairment in bipolar disorder treated with aripiprazole Kognitive Beeinträchtigung bei bipolarer Störung unter Behandlung von Aripiprazol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017581-22,0,0,0 2009-017582-29,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CONSORZIO MARIO NEGRI SUD,Omega-3 fatty acids for Prevention of post-opERative Atrial fibrillation (OPERA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017582-29,0,0,0 2009-017587-16,1,2012-09-07,2012-09-07,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Barts Health NHS Trust,Treatment monitoring using FDG-PET/CT and FLT-PET/CT in patients with Hodgkin Lymphoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017587-16,0,0,0 2009-017589-22,1,2011-10-21,2011-10-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Ghent,Interacties tussen hart en nieren tijdens de behandeling van gedecompenseerd hartfalen: diuretica versus ultrafiltratie (CRUF Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017589-22,0,0,0 2009-017591-24,4,2012-06-29,2012-06-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Randomized Phase 2 Study of LY2181308 in Combination with Docetaxel versus Docetaxel in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who Were Previously Treated with Fir...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017591-24,0,0,0 2009-017591-24,4,2012-06-29,2012-06-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Eli Lilly and Company, Limited",A Randomized Phase 2 Study of LY2181308 in Combination with Docetaxel versus Docetaxel in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who Were Previously Treated with Fir...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017591-24,0,0,0 2009-017594-37,3,2015-09-10,2015-09-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, open-label 18 month study to evaluate the long-term safety and tolerability of valsartan in children 6 to 17 years of age with hypertension and with or without chronic kidney disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017594-37,0,0,0 2009-017595-25,1,2015-03-23,2015-03-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital Muenster,Balanced 6 % HES 130/0.4 vs. balanced crystalloid-based infusion in patients undergoing colorectal surgery Balancierte 6% HES 130/0.4-Lösung vs. balancierte Kristalloid-Lösung bei Patienten mit kol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017595-25,0,0,0 2009-017596-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST,Terapia di II linea con Docetaxel + Lanreotide in pazienti con carcinoma prostatico metastatico ormonorefrattario e in progressione in corso di chemioterapia di I linea con Docetaxel. Studio di fase I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017596-26,0,0,0 2009-017599-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CENTRO PER LA PREVENZIONE E CURA DEL TABAGISMO,"EFFICACY AND SAFETY OF SMOKING CESSATION WITH VARENICLINE TARTRATE IN DIBETIC SMOKERS: A DOUBLE-BLIND,PLACEBO-CONTROLLED, RANDOMIZED, TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017599-26,0,0,0 2009-017600-89,1,,,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,Asociación para la investigación de Nefrología Infantil,Ensayo intrapaciente de biodisponibilidad relativa de dos formulaciones de tacrolimus: Prograf (comprimidos de liberación normal) y Advagraf (comprimidos de liberación sostenida) en niños trasplantado...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017600-89,0,0,0 2009-017603-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PERUGIA,"Aprepitant for prevention of acute and delayed nausea and vomiting: a phase III, double-blind, randomized, palcebo-controlled trial in patients receiving a high-emetogenic dose of cyclophosphamide for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017603-28,0,0,0 2009-017619-14,1,2011-12-16,2011-12-16,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medicinsk Forskningsafsnit, Holstebro",RENO- OG KREDSLØBSPROTEKTIV EFFEKT AF VITAMIN-D-ANALOG (PARICALCITOL) HOS PATIENTER MED MODERAT TIL SVÆR KRONISK NYREINSUFFICIENS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017619-14,0,0,0 2009-017620-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Scheper Ziekenhuis,Onderzoek naar de farmacokinetiek van uracil na orale toediening bij patiënten met colorectaal carcinoom.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017620-11,0,0,0 2009-017622-39,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Clinical Center Ljubljana,"A double blind, randomized study to compare influence of niacin/laropiprant on functional and morphological characteristics of arterial wall and parameters of inflammation in subjects with CHD already...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017622-39,0,0,0 2009-017624-72,1,2014-11-13,2014-11-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Instituto Científico y Tecnológico de Navarra,Tratamiento de la Artrosis mediante la inyección intra-articular de Células Madre Mesenquimales de Médula Ósea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017624-72,0,0,0 2009-017625-20,1,2019-09-23,2019-09-23,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Pawel Florkiewicz,Continuous ropivacaine infusion in treatment of postoperative pain in cardiac surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017625-20,0,0,0 2009-017626-39,1,2012-06-30,2012-06-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,The Hospital District of Southwest Finland,Akuutin appendisiitin hoito: leikkaus- vs. antibioottihoito,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017626-39,0,0,0 2009-017636-41,1,2012-05-30,2012-05-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College,Vasopressin and Corticosteroids in Septic Shock,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017636-41,0,0,0 2009-017640-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ISTITUTI ORTOPEDICI RIZZOLI,Continuous peripheral block in the pain and ischemic ulcer treatment in arteriopathy patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017640-13,0,0,0 2009-017642-32,1,2012-04-10,2012-04-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Odense University Hospital,Nyreprofylakse ved ST-segment elevation myokardie infarkt og primær PCI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017642-32,0,0,0 2009-017647-34,1,2011-12-22,2011-12-22,1,0,0,0,0,0,4,0,1,1,0,0,1,0,1,Helperby Therapeutics,"Effect of minocycline and amoxicillin administration on the prevalence of antibiotic resistant bacteria and on the indigenous oral, faecal, cutaneous and nasal microbiotas.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017647-34,0,0,0 2009-017649-67,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,The Central Remedial Clinic and The Children's University Hospital,Bone Health in Duchenne Muscular Dystrophy- a case controlled study of Risedronate use,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017649-67,0,0,0 2009-017658-11,2,2014-05-16,2014-05-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Vifor Pharma,"An open-label, multicentre, randomised, 2-arm study to investigate the comparative efficacy and safety of intravenous ferric carboxymaltose versus oral iron for the treatment of iron deficiency anaemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017658-11,0,0,0 2009-017659-83,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,BGP Kranj,"Intravensko lajšanje porodnih bolečin z remifentanilom, ki si ga uravnava porodnica sama – vpliv hitrosti dovajanja posameznih odmerkov na kvaliteto lajšanja porodnih bolečin in varnost uporabe Int...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017659-83,0,0,0 2009-017661-34,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,An open label trial of afatinib (Giotrif) in treatment-naive (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017661-34,0,0,0 2009-017661-34,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim,An open label trial of afatinib (Giotrif) in treatment-naive (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017661-34,0,0,0 2009-017661-34,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda",An open label trial of afatinib (Giotrif) in treatment-naive (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017661-34,0,0,0 2009-017661-34,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim Ellas SA,An open label trial of afatinib (Giotrif) in treatment-naive (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017661-34,0,0,0 2009-017661-34,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Boehringer Ingelheim España, S.A.",An open label trial of afatinib (Giotrif) in treatment-naive (1st line) or chemotherapy pre-treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017661-34,0,0,0 2009-017663-42,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,"A Single-Arm Multi-Center Trial of Bendamustine given with Ofatumumab (BendOfa) in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL) Studio multicentrico, a braccio singolo, d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017663-42,0,0,0 2009-017664-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,BIOTRONIK France,GIANT Study - Genotyping Infarct patients to Adjust and Normalize Thienopyridine treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017664-16,0,0,0 2009-017665-31,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA` DI NOVARA,Effect on mother and fetus of epidural and combined spinal-epidural techniques for labour analgesia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017665-31,0,0,0 2009-017666-23,1,2010-11-18,2010-11-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis,"An open-label, randomized, two-arm parallel group study to compare the effects of 4-week QD treatment with lixisenatide or liraglutide on the postprandial plasma glucose in patients with type 2 diabet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017666-23,0,0,0 2009-017668-18,2,2011-09-09,2011-09-09,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 1/2, Open-Label Study in Men with Prostate Cancer to Assess the Safety, Pharmacokinetics, and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1 Month Depot, Including a Randomized...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017668-18,0,0,0 2009-017669-44,2,2010-09-24,2010-09-24,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,A study of the Effects of Inhaled Fliticasone Furotate/GW642444 versus Placebo on HPA Axis of Adolescent and Adult Asthmatics.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017669-44,0,0,0 2009-017669-44,2,2010-09-24,2010-09-24,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline,A study of the Effects of Inhaled Fliticasone Furotate/GW642444 versus Placebo on HPA Axis of Adolescent and Adult Asthmatics.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017669-44,0,0,0 2009-017671-22,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Eisai Limited,"An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Commercially Available Therapies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017671-22,0,0,0 2009-017672-24,2,2011-11-29,2011-11-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CSL Behring GmbH,A single-arm study to demonstrate the efficacy and safety of Privigen in the treatment of subjects with chronic inflammatory demyelinating polyneuropathy (CIDP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017672-24,0,0,0 2009-017673-38,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,QUALISSIMA,Comparaison des effets de l’aripiprazole et de la rispéridone sur le profil d’activation cérébrale chez des patients schizophrènes lors de tâches émotionnelles et en référence à des sujets témoins,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017673-38,0,0,0 2009-017674-20,5,2011-09-18,2011-09-18,5,1,0,0,1,0,3,2,0,1,0,0,1,0,1,BioGeneriX AG,"Efficacy, safety and tolerability of XM17 compared to Gonal-f® in women undergoing assisted reproductive technologies. A multi-national, multi-centre, randomised, controlled, assessor-blind, parallel ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017674-20,0,0,0 2009-017675-16,1,2013-02-25,2013-02-25,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Plymouth Hospitals NHS Trust,Phase II Trial of Single Agent Ofatumumab in Relapsed / Refractory Mantle Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017675-16,0,0,0 2009-017676-24,1,2012-07-31,2012-07-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Erlangen,"Randomized, double blind, active-controlled, parallel study to analyse effects of the combination of aliskiren and valsartan on the vascular structure and function of retinal vessels",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017676-24,0,0,0 2009-017682-33,1,2017-02-03,2017-02-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHRU de Lille,L’intérêt de la Xylocaine® et de la kétamine per et postopératoire sur la prise en charge de la douleur postopératoire aigue et chronique après colectomie par Laparoscopie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017682-33,0,0,0 2009-017686-34,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,UROLOGY ASSOCIATES S.L.,"ENSAYO CLÍNICO, FASE IIIb, MULTICÉNTRICO, DOBLE CIEGO, PARA EVALUAR LA EFICACIA DE VARDENAFILO BUCODISPERSABLE vs PLACEBO, EN PACIENTES CON DISFUNCIÓN ERÉCTIL MAS COMORBILIDAD Y EL IMPACTO EN LA CALID...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017686-34,0,0,0 2009-017688-40,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Sanofi Pasteur SA,"Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intradermal Route)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017688-40,0,0,0 2009-017689-22,1,2013-03-14,2013-03-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Nottingham,The Cardiovascular and Inflammatory Effects of Statin Therapy in Patients with COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017689-22,0,0,0 2009-017690-38,1,2010-05-27,2010-05-27,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017690-38,0,0,0 2009-017692-18,1,2010-05-14,2010-05-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Valderm ApS,"A phase IIa, single-center, randomized, observer-blind, placebo- and reference-controlled proof of concept study with intraindividual comparison of treatments to investigate the safety and antipsoriat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017692-18,0,0,0 2009-017696-22,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,ISTITUTO NAZIONALE DI RICOVERO E CURA PER ANZIANI IRCCS,Multicentered study to investigate reproducibility of OGTT following the recommendations of the Italian joint SIBioC-SIMeL Study Group on Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017696-22,0,0,0 2009-017704-86,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,OSPEDALE POLICLINICO S. MATTEO,Phase II clinical trial for the Staph. Aureus spondylodiscitis treatmen with daptomycin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017704-86,0,0,0 2009-017707-28,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación Pethema,"Ensayo multicéntrico, fase II de Lenalidomida, Ciclofosfamida y Dexametasona en pacientes con amiloidosis sistémica primaria (AL) de nuevo diagnóstico no candidatos a trasplante.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017707-28,0,0,0 2009-017709-12,2,2014-06-25,2014-06-25,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Ipsen Pharma SAS,"A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN CHILDREN WITH D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017709-12,1,0,0 2009-017711-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Martini Ziekenhuis Groningen,SYMPTOMATIC IMPROVEMENT BY PERITONEAL DIALYSIS IN PATIENTS WITH END STAGE CONGESTIVE HEART FAILURE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017711-15,0,0,0 2009-017716-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Center,"A phase II, randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib and metformin in patients with locally advanced and metastastatic pancreatic canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017716-32,0,0,0 2009-017723-26,6,2015-04-14,2015-04-14,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ipsen Pharma SAS,"A phase III, prospective, multicentre, open label, extension study, to assess the long term safety and efficacy of repeated treatment of Dysport intramuscular injection in the treatment of lower limb ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017723-26,0,0,0 2009-017723-26,6,2015-04-14,2015-04-14,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,IPSEN PHARMA SAS,"A phase III, prospective, multicentre, open label, extension study, to assess the long term safety and efficacy of repeated treatment of Dysport intramuscular injection in the treatment of lower limb ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017723-26,0,0,0 2009-017725-19,1,2012-05-07,2012-05-07,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,F. Hoffmann-La Roche AG,"A Phase IIIB multicenter, double-blind, randomized, placebocontrolled study, evaluating the effect of treatment with dalcetrapib 600 mg on Atherosclerotic Disease as measured by I. Coronary Intravascu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017725-19,0,0,0 2009-017728-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZLeuven,A randomized controlled trial comparing pregabalin and placebo in patients with persistent globus sensation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017728-13,0,0,0 2009-017731-17,1,2022-01-20,2022-01-20,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,AIO-Studien-gGmbh,An open-label 2:1 randomized phase II study of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as first-line treatment of patients with non-resectable metastatic colorectal cancer and RAS wild-type,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017731-17,0,0,0 2009-017735-18,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,CHRU Montpellier - Direction de la Recherche,"Etude prospective, contrôlée, randomisée du traitement de l’occlusion sévère de la veine centrale de la rétine à sa phase précoce par injection intra-vitréenne de Bevacizumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017735-18,0,0,0 2009-017736-41,1,2013-05-29,2013-05-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Anæstesiologisk Afd. Herlev Hospital,"""Fibrinogen-koncentrat som initial behandling ved postpartum blødning""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017736-41,0,0,0 2009-017737-21,3,2011-11-08,2011-11-08,3,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Vifor Pharma,"A Multicentre Randomised Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose (1,000 mg iron) in Improving Fatigue Symptoms in Iron-deficient ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017737-21,0,0,0 2009-017739-17,1,2010-12-09,2010-12-09,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Charité,Assessment of myocardial viability in MRI: Comparison of Late Gadolinium Enhancement with Gadovist vs. Magnevist vs. Dotarem,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017739-17,0,0,0 2009-017740-13,1,2012-09-11,2012-09-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PHF SA,"Pilot study to evaluate the efficacy, safety and tolerability of ammonium chloride in terms of protection from hepatotoxic effect of Hep C infection and normalisation of altered liver parameters, in a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017740-13,0,0,0 2009-017742-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Groupe d’étude sur le risque d’exposition des soignants aux agents infectieux (GERES),ISENTRESS® + TRUVADA® : Etude multicentrique relative à la tolérance d’une nouvelle trithérapie antirétrovirale prescrite dans le cadre de la prophylaxie post-exposition de personnes récemment soumise...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017742-31,0,0,0 2009-017744-14,9,2012-12-04,2013-04-12,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research anda Development,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults with Partial-Onset Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017744-14,0,0,0 2009-017744-14,9,2012-12-04,2013-04-12,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults with Partial-Onset Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017744-14,0,0,0 2009-017744-14,9,2012-12-04,2013-04-12,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults with Partial-Onset Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017744-14,0,0,0 2009-017744-14,9,2012-12-04,2013-04-12,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"An Open-Label, Flexible-Dose Study of Retigabine Immediate Release (IR) as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults with Partial-Onset Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017744-14,0,0,0 2009-017745-55,4,2011-04-11,2011-05-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase II randomised, double-blind, placebo-controlled, incomplete crossover trial with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses of 1.25μg, 2....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017745-55,0,0,0 2009-017752-28,1,2017-01-03,2017-01-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Cardiovascular laboratory 2014, The Heart Centre, Rigshospitalet",Stamcellebehandling af patienter med kronisk kranspulsåresygdom MesenchYmal STROMAL CELL therapy in patients with chronic myocardial ischemia (MyStromalCell Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017752-28,0,0,0 2009-017753-34,2,2013-08-27,2013-08-27,1,1,1,0,0,0,3,0,0,1,0,0,1,0,1,CSL Behring GmbH,"A Phase III Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy, and Safety of Biostate® in Paediatric Subjects with von Willebrand Disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017753-34,0,0,0 2009-017757-36,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,0,Instituto Científico y Tecnológico de Navarra,"Ensayo clínico fase I-II, controlado intraindividualmente para evaluar la eficacia del trasplante de melanocitos autólogos en monocapa sobre un soporte de membrana amniótica en el tratamiento del vití...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017757-36,0,0,0 2009-017765-31,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Mikko Pitkänen,Local infiltration analgesia for pain relief after lumbar fusion surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017765-31,0,0,0 2009-017768-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Saint-Etienne,Analgésie par bloc continu du plan transverse de l’abdomen en chirurgie d’exérèse hépatique : efficacité et influence sur la réhabilitation précoce.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017768-18,0,0,0 2009-017772-25,9,2012-02-10,2012-02-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 26-week treatment multi-center, randomized, doubleblind, parallel-group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 μg q.d.) i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017772-25,0,0,0 2009-017772-25,9,2012-02-10,2012-02-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A 26-week treatment multi-center, randomized, doubleblind, parallel-group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 μg q.d.) i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017772-25,0,0,0 2009-017772-25,9,2012-02-10,2012-02-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 26-week treatment multi-center, randomized, doubleblind, parallel-group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 μg q.d.) i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017772-25,0,0,0 2009-017775-19,21,2014-06-30,2014-07-07,19,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017775-19,0,0,0 2009-017775-19,21,2014-06-30,2014-07-07,19,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017775-19,0,0,0 2009-017775-19,21,2014-06-30,2014-07-07,19,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017775-19,0,0,0 2009-017776-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,,"A pilot study evaluating response to induction chemotherapy with oxaliplatin, capecitabine and bevacizumab in patients with extensive peritoneal carcinomatosis of colorectal origin.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017776-24,0,0,0 2009-017781-23,2,2010-06-10,2010-06-10,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Baxter Innovations GmbH,"An Open Label Phase 3 Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Trivalent Seasonal Influenza Vaccine, Strain Composition 2009/2010, in an Adult Population",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017781-23,0,0,0 2009-017782-30,1,2016-06-15,2016-06-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Medizinische Universität Graz, Universitäts-Augenklinik",Treatment of macular edema due to central retinal vein occlusion with ranibizumab (Lucentis®).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017782-30,0,0,0 2009-017788-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CRLCC Alexis Vautrin,Etude de phase II randomisée multicentrique évaluant l'efficacité d’estramustine phosphate (Estracyt ®) chez des patientes présentant un cancer du sein métastatique HER2- / RH+ ayant déjà reçu un trai...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017788-40,0,0,0 2009-017789-22,1,2011-03-29,2011-03-29,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Ursapharm Arzneimittel GmbH,"A randomized, placebo-controlled study investigating the effects of moxaverine on ocular blood flow after oral administration in healthy subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017789-22,0,0,0 2009-017793-20,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación Progreso y Salud,"ENSAYO CLINICO FASE II MULTICÉNTRICO, ABIERTO Y ALEATORIZADO SOBRE EL USO TERAPEUTICO DE LA INFUSION INTRAPORTAL DE CÉLULAS MONONUCLEADAS DE MÉDULA ÓSEA AUTÓLOGA COMO POTENCIADOR DE LA REGENERACIÓN HE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017793-20,0,0,0 2009-017794-37,1,2011-03-08,2011-03-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Professor Jørgen Berg Dahl,"Effekten af Adductor-Kanal-Blokade på morfinforbrug, smerter og gangfunktion efter knæalloplastik",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017794-37,0,0,0 2009-017798-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,"An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017798-39,0,0,0 2009-017799-26,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Instituto Aragonés de Ciencias de la Salud,Estudio de los indicadores de eficacia y seguridad de dos quelantes del hierro en pacientes con sobrecarga férrica.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017799-26,0,0,0 2009-017800-10,1,2012-12-31,2012-12-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,3,NHS Lothian,Scottish and Newcastle Anti-emetic Pre-treatment for Paracetamol Poisoning study (SNAP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017800-10,0,0,0 2009-017800-10,1,2012-12-31,2012-12-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,3,University of Edinburgh,Scottish and Newcastle Anti-emetic Pre-treatment for Paracetamol Poisoning study (SNAP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017800-10,0,0,0 2009-017801-12,2,2011-07-06,2011-07-06,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Abbott Laboratories,"A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-384 in Subjects with Mild-to-Moderate Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017801-12,0,0,0 2009-017801-12,2,2011-07-06,2011-07-06,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Abbott GmbH & Co. KG,"A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-384 in Subjects with Mild-to-Moderate Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017801-12,0,0,0 2009-017802-35,3,,,0,1,0,0,0,0,3,0,0,1,1,0,0,1,1,Novartis Pharma Services AG,"A randomized, controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not toler...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017802-35,0,0,0 2009-017803-27,1,,,0,0,0,1,0,0,1,0,0,4,0,0,0,0,0,CHU DE NANCY,ESSAI DE PHASE I DE MYOCET® CHEZ DES ENFANTS AYANT UN GLIOME MALIN REFRACTAIRE OU EN RECHUTE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017803-27,0,0,0 2009-017804-95,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Institut de Recerca de l?Hospital de la Santa Creu i Sant Pau,"Prevención del sangrado postoperatorio: Ensayo clínico unicéntrico, aleatorizado, paralelo y controlado que evalúa la eficacia de la cola de fibrina y el ácido tranexámico en pacientes intervenidos de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017804-95,0,0,0 2009-017805-13,3,2011-11-07,2011-11-07,1,1,1,0,0,0,2,0,0,1,1,1,1,0,1,Octapharma AG,"""PROSPECTIVE, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED, MULTICENTRE, ADAPTIVE, TWO-STAGE PHASE II/III STUDY EVALUATING SAFETY AND EFFICACY OF THREE DIFFERENT DOSAGES OF NEWGAM IN P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017805-13,0,0,0 2009-017806-36,1,2011-07-26,2011-07-26,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Surrey,Effect of Vitano® on physiological and psychological responses to psychological stress assessed under laboratory conditions and in everyday life.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017806-36,0,0,0 2009-017807-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Instituto Valenciano de Infertilidad (IVI) de Valencia,Comparación entre ciclo natural y artificial en receptoras de ovocitos.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017807-27,0,0,0 2009-017809-11,2,2013-05-14,2013-05-14,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase I/IIa randomized, observer-blind, placebo-controlled, multicenter study to evaluate the safety and immunogenicity of the GSK Biologicals’ herpes zoster vaccine, gE/AS01B in comparison to place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017809-11,0,0,0 2009-017814-56,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novo Nordisk A/S,"A 26-week, randomised, open-label, multinational, treat-to-target trial comparing efficacy and safety of insulin degludec/insulin aspart once daily (OD) and insulin glargine OD both in combination wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017814-56,0,0,0 2009-017819-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Juan Cordoba,"Efectos de la administración de ornitina-fenilacetato (OCR-002) en pacientes con cirrosis y hemorragia digestiva alta. Effects of the administration of ornithine phenylacetate (OP, OCR-002) in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017819-16,0,0,0 2009-017823-24,1,2011-02-01,2011-02-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Tartu University Hospital,Meropenem pharmacokinetics in very low birth weight neonates,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017823-24,0,0,0 2009-017825-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD,"Prospective, randomised, double-blind study to evaluate the efficacy of treatment with melatonin in adult patients with severe sepsis or septic shock. Estudio prospectivo, aleatorizado, doble-ciego...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017825-21,0,0,0 2009-017827-24,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,José Luis Vázquez Martínez,Eficacia y seguridad del levosimendan en el fallo cardiaco agudo grave en niños críticos,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017827-24,0,0,0 2009-017828-54,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Cross-reactivity and tolerability of ertapenem in patients with IgE-mediated allergy to -lactams.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017828-54,0,0,0 2009-017829-19,1,2020-11-30,2020-11-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Instituto Científico y Tecnológico de Navarra,Ensayo clínico fase II controlado de inmunoterapia combinada con linfocitos efectores autólogos en pacientes con linfoma no Hodgkin folicular en tratamiento de mantenimiento con rituximab tras respues...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017829-19,0,0,0 2009-017831-16,1,2012-04-01,2012-04-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Institute of pharmacology, Aarhus university",Effects of 6 months intensive vasodilating treatment on vascular resistance and coronary flow reserve in hypertensive patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017831-16,0,0,0 2009-017837-23,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,Yolanda de Diego Otero,"Ensayo piloto fase II de tratamiento doble ciego, aleatorizado, de una vía cruzada, para investigar la efectividad y seguridad de la combinación de Ácido Ascórbico (vitamina C) y Tocoferol (vitamina E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017837-23,0,0,0 2009-017838-44,3,2011-03-16,2011-03-16,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Sequel Pharmaceuticals, Inc.","A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary Efficacy Study of K201 Oral for the Prevention of Atrial Fibrillation (AF) Recurrence...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017838-44,0,0,0 2009-017839-18,1,2011-12-14,2011-12-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PurGenesis Techonologies Inc.,"A 2-WEEK EXPLORATORY RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, DOSE-RANGING, PLACEBO-CONTROLLED SAFETY, TOLERABILITY, BIOMARKER AND EFFICACY CLINICAL STUDY OF PUR 0110 RECTAL ENEMA IN MILD-TO-MODERATE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017839-18,0,0,0 2009-017840-15,1,2012-11-30,2012-11-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"DSC Services, s.r.o.",Srovnání účinnosti kapecitabinu (Xeloda) s kontinuálním podáním 5-fluorouracilu v předoperační konkomitantní léčbě s radioterapií u karcinomu rekta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017840-15,0,0,0 2009-017842-30,1,2013-05-09,2013-05-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,West Hertfordshire Hospitals NHS Trust,"A randomised, double-blind, placebo-controlled trial to compare the early administration of intravenous haloperidol versus placebo in the prevention and treatment of delirium in critically ill ventila...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017842-30,0,0,0 2009-017843-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Foundation of Liver Research (SLO),"A multi-center randomized, open label, controlled study in primary liver transplantation comparing long term renal function and development of de novo malignancy in recipients treated with standard do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017843-32,0,0,0 2009-017848-14,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Roche Farma, S.A.","Estudio fase II de capecitabina- oxaliplatino-trastuzumab (XELOX-trastuzumab) como tratamiento perioperatorio de pacientes con adenocarcinoma gástrico o de la unión gastroesofágica, resecable (estadio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017848-14,0,0,0 2009-017849-57,1,2014-06-01,2014-06-01,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,Somatostatin analogues as a volume reducing treatment of polycystic livers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017849-57,0,0,0 2009-017852-28,1,2012-05-24,2012-05-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 versus Placebo in Patients with DSM-IVTR Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017852-28,0,0,0 2009-017853-36,1,2012-10-10,2012-10-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017853-36,0,0,0 2009-017854-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Gregorio Marañón,Efecto de la dosis de FSH recombinante en el resultado de la estimulación ovárica para fecundación in vitro en pacientes con baja reserva ovárica. Estudio aleatorizado y abierto de no inferioridad.(Ve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017854-11,0,0,0 2009-017858-12,1,2011-07-25,2011-07-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharma A/S,A phase 2a proof of concept study comparing three doses of an oral solution of LEO 22811 with a placebo oral solution for the treatment of psoriasis vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017858-12,0,0,0 2009-017859-98,4,2012-11-14,2012-12-14,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Promedior Inc,"A Randomized, Double-Masked, Placebo-Controlled Study of PRM-151 in the Prevention of Postoperative Scarring in Glaucoma Patients Following Primary Trabeculectomy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017859-98,0,0,0 2009-017860-17,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Société Française de Cardiologie,Evaluation du bénéfice thérapeutique du post-conditionnement par la morphine dans l’infarctus du myocarde,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017860-17,0,0,0 2009-017862-22,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,ZonMw,The effectiveness of Nicotine Replacement Therapy for young people aged 12 to 18 years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017862-22,0,0,0 2009-017869-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Hospital Zurich,"A dual-center, open-label Proof of Concept study to evaluate the efficacy of Terguride for the treatment of fibrosis in patients with systemic sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017869-27,0,0,0 2009-017871-13,1,2012-12-03,2012-12-03,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,New Medical Enzymes AG,A multicenter phase II study to evaluate safety and efficacy of glutadon once weekly (GDO) in patients with metastatic colorectal cancer resistant or intolerable to approved chemo- and molecular-targe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017871-13,0,0,0 2009-017872-26,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Role and pharmacological modulation of lug inflammation in chronic obstructive pulmonary disease (COPD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017872-26,0,0,0 2009-017874-20,2,2011-09-12,2011-09-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AXCAN PHARMA INC,Treatment of Diarrhea-predominant Irritable Bowel Syndrome with LACTEOL 340 mg : a pilot study evaluating safety and efficacy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017874-20,0,0,0 2009-017874-20,2,2011-09-12,2011-09-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AXCAN PHARMA SAS,Treatment of Diarrhea-predominant Irritable Bowel Syndrome with LACTEOL 340 mg : a pilot study evaluating safety and efficacy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017874-20,0,0,0 2009-017878-21,1,2010-08-27,2010-08-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Albireo AB,"A Phase IIa, Double-blind, Randomised, Placebo-controlled, Dose-finding Efficacy and Safety Study of A3309 in Patients with Dyslipidemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017878-21,0,0,0 2009-017882-42,2,2011-06-03,2011-06-03,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Raptor Therapeutics Inc.,"A Randomized, Crossover, Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017882-42,0,0,0 2009-017885-22,3,2013-06-24,2013-06-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Ludwig Institute For Cancer Research,Phase II Study of ADI-PEG 20 in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017885-22,0,0,0 2009-017885-22,3,2013-06-24,2013-06-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Ludwig Institute for Cancer Research, Ltd",Phase II Study of ADI-PEG 20 in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017885-22,0,0,0 2009-017901-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,LYOCENTRE,Etude de l’efficacité et de la tolérance du traitement par la culture totale lyophilisée de lactobacillus casei variété rhamnosus (Lcr35 Lc) administré par voie vaginale dans la prévention de récidiv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017901-12,0,0,0 2009-017903-28,14,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,2,HOVON Foundation,"A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide mainte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017903-28,0,0,0 2009-017903-28,14,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,2,Nordic Myeloma Study Group,"A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide mainte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017903-28,0,0,0 2009-017904-95,5,2014-02-18,2014-03-13,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Upsher-Smith Laboratories, Inc.","Estudio abierto de extensión para evaluar la seguridad de USL255 como terapia adyuvante en pacientes con crisis de inicio parcial refractarias que habían participado en el P09-004, un estudio en fase ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017904-95,0,0,0 2009-017905-13,13,2016-09-16,2016-09-16,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017905-13,0,0,0 2009-017918-69,9,2018-04-19,2018-04-19,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AB Science,"A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017918-69,1,0,0 2009-017918-69,9,2018-04-19,2018-04-19,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AB SCIENCE,"A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017918-69,1,0,0 2009-017921-20,1,2011-05-06,2011-05-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Univ. Klinik für Anästhesiologie,Influence of Gender on the Plasma-Effect site equilibration time of propofol anesthetic and Cisatracurium Besylate neuromuscular blocking agent. A pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017921-20,0,0,0 2009-017923-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Clermont-Ferrand,Effet d'une infiltration cicatricielle de ropivacaine sur l'anagésie post-opératoire après endarteriectomie carotidienne.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017923-25,0,0,0 2009-017924-18,1,2014-03-28,2014-03-28,1,0,0,0,0,0,3,0,0,1,0,0,1,0,3,,Efficacy assessment of repeat intramyocardial injection of autologous bone marrow cells in previously responding no-option patients with residual refractory angina pectoris and documented ischemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017924-18,0,0,0 2009-017925-20,1,2015-03-27,2015-03-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Leeds,"Does Cocareldopa treatment in combination with routine NHS occupational and physical therapy, delivered early after stroke within a stroke service, improve functional recovery including walking and ar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017925-20,0,0,0 2009-017926-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Traitement de la nephropathie à cylindres myelomateux. MYRE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017926-38,0,0,0 2009-017930-35,10,2016-07-18,2017-02-01,7,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AB Science,"A prospective, multicenter, randomised, double-blind, placebocontrolled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 6 mg/kg/day in combination with bortezomib and d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017930-35,1,0,0 2009-017930-35,10,2016-07-18,2017-02-01,7,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AB SCIENCE,"A prospective, multicenter, randomised, double-blind, placebocontrolled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 6 mg/kg/day in combination with bortezomib and d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017930-35,1,0,0 2009-017938-46,7,2015-12-30,2015-12-30,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG (Abbott),"A Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects with Enthesitis Related Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017938-46,1,1,0 2009-017938-46,7,2015-12-30,2015-12-30,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects with Enthesitis Related Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017938-46,1,1,0 2009-017938-46,7,2015-12-30,2015-12-30,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Abbott GmbH & Co. KG,"A Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects with Enthesitis Related Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017938-46,1,1,0 2009-017938-46,7,2015-12-30,2015-12-30,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Abbott GmbH & Co. KG (Abbott),"A Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects with Enthesitis Related Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017938-46,1,1,0 2009-017939-18,1,2014-10-20,2014-10-20,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University College London,"A Phase 4 randomised, double-blind, placebo controlled, crossover trial Nitrofurantoin Macrocrystals 100 mg twice daily for six weeks in the treatment of overactive bladder symptoms associated with a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017939-18,0,0,0 2009-017940-15,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Devenir de la spermatogénèse chez les hommes drépanocytaires traités médicalement (HYDREP).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017940-15,0,0,0 2009-017942-30,5,2011-01-25,2011-01-25,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Shionogi USA, Inc.",An open-label safety study of S-888711 in adult subjects with relapsed persistent or chronic immune thrombocytopenia with or without prior splenectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017942-30,1,0,0 2009-017942-30,5,2011-01-25,2011-01-25,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"SHIONOGI USA, INC",An open-label safety study of S-888711 in adult subjects with relapsed persistent or chronic immune thrombocytopenia with or without prior splenectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017942-30,1,0,0 2009-017943-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Antwerp University Hospital,"Study of the combination of gemcitabine, cetuximab and radiotherapy in patients with head and neck cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017943-32,0,0,0 2009-017946-30,13,2017-04-14,2017-04-19,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc.,"A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017946-30,0,0,0 2009-017950-11,5,2016-12-27,2016-12-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ViiV Healthcare UK Ltd,"A Phase III, randomized, double blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered with fixed-dose dual nucleoside reverse transc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017950-11,0,0,0 2009-017950-11,5,2016-12-27,2016-12-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ViiV Healthcare S.L,"A Phase III, randomized, double blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered with fixed-dose dual nucleoside reverse transc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017950-11,0,0,0 2009-017951-87,4,2015-05-25,2015-05-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ViiV Healthcare, S. L.",A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1-infected adult subjects with treatment failure on an integrase inhibitor containing regimen.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017951-87,0,0,0 2009-017951-87,4,2015-05-25,2015-05-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Viiv Healthcare,A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1-infected adult subjects with treatment failure on an integrase inhibitor containing regimen.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017951-87,0,0,0 2009-017951-87,4,2015-05-25,2015-05-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GLAXO SMITHKLINE,A Phase III study to demonstrate the antiviral activity and safety of dolutegravir in HIV-1-infected adult subjects with treatment failure on an integrase inhibitor containing regimen.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017951-87,0,0,0 2009-017957-37,9,2019-04-15,2019-04-15,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017957-37,0,0,0 2009-017957-37,9,2019-04-15,2019-04-15,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017957-37,0,0,0 2009-017959-98,1,2018-07-04,2018-07-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Rotterdam Eye Hospital,Early treatment of patients with central serous retinopathy: A randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017959-98,0,0,0 2009-017961-52,4,2011-09-26,2011-09-26,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-week, multi-center, randomized, double-blind, placebo-controlled efficacy and safety study examining seizure frequency of BGG492 capsules administrated orally three times daily (TID) as adjunc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017961-52,0,0,0 2009-017961-52,4,2011-09-26,2011-09-26,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 12-week, multi-center, randomized, double-blind, placebo-controlled efficacy and safety study examining seizure frequency of BGG492 capsules administrated orally three times daily (TID) as adjunc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017961-52,0,0,0 2009-017966-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dr. Guillermo Reyes Copa,"ENSAYO CLÍNICO PROSPECTIVO, CONTROLADO Y ALEATORIZADO DE REGENERACIÓN CELULAR CARDIACA CON LÁSER Y CÉLULAS MADRES AUTÓLOGAS DE MÉDULA ÓSEA, EN PACIENTES CON ENFERMEDAD CORONARIA Y ANGINA REFRACTARIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017966-21,0,0,0 2009-017971-10,2,2013-04-01,2013-04-01,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation","An 8-Week, Placebo-Controlled, Double-Blind, Randomized, Fixed- Dose Efficacy and Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017971-10,1,1,0 2009-017978-21,17,2018-10-25,2019-11-28,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Serono S.A. - Geneva,Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE). Registro prospettico osservazionale sulla sicurez...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017978-21,0,0,0 2009-017978-21,17,2018-10-25,2019-11-28,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SERONO SA,Prospective observational long-term safety registry of Multiple Sclerosis patients who have participated in cladribine clinical trials (PREMIERE). Registro prospettico osservazionale sulla sicurez...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017978-21,0,0,0 2009-017995-26,3,2014-04-15,2014-04-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GELARC,PHASE II STUDY OF MINI-CHOP PLUS OFATUMUMAB (O) IN NON PREVIOULSY TREATED PATIENTS AGED OVER 80 YEARS WITH CD 20+ DIFFUSE LARGE B-CELL LYMPHOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017995-26,0,0,0 2009-017995-26,3,2014-04-15,2014-04-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,LYSARC,PHASE II STUDY OF MINI-CHOP PLUS OFATUMUMAB (O) IN NON PREVIOULSY TREATED PATIENTS AGED OVER 80 YEARS WITH CD 20+ DIFFUSE LARGE B-CELL LYMPHOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017995-26,0,0,0 2009-017996-11,1,2019-03-19,2019-03-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Fédération Francophone de Cancérologie Digestive,ESSAI DE PHASE II RANDOMISE EVALUANT L’EFFICACITE DE SEQUENCES THERAPEUTIQUES ASSOCIANT FOLFIRI + BEVACIZUMAB ASSOCIEES OU NON AU MAINTIEN DU BEVACIZUMAB PENDANT LES INTERVALLES LIBRES DE CHIMIOTHERAP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017996-11,0,0,0 2009-017997-19,1,2016-10-06,2016-10-06,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Ghent University Hospital,Influence of oral doxycycline on wound healing after endonasal endoscopic sinus surgery for chronic rhinosinusitis with and without nasal polyposis: a double-blind randomized placebo-controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017997-19,0,0,0 2009-017998-37,1,2019-03-26,2019-03-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Ghent University Hospital,Scintigraphic detection of tumor necrosis factor with radioactive labeled TNFα-blocker in patients with active rheumatoid arthritis and active axial and peripheric spondyloarthropathy. Scintigrafis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017998-37,0,0,0 2009-017999-25,4,2015-09-23,2015-09-23,2,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Amgen Inc,"An Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cinacalcet HCl in Pediatric Subjects Aged 28 Days to < 6 Years with Chronic Kidney Disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-017999-25,1,1,0 2009-018001-51,9,2021-02-02,2021-02-02,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Viiv Healthcare,"A Phase III Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator-selected Background R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018001-51,1,0,0 2009-018001-51,9,2021-02-02,2021-02-02,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Viiv Healthcare UK Limited,"A Phase III Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator-selected Background R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018001-51,1,0,0 2009-018001-51,9,2021-02-02,2021-02-02,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Viiv Healthcare S. L,"A Phase III Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator-selected Background R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018001-51,1,0,0 2009-018004-18,1,2012-11-13,2012-11-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH&Co KG,"A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 μg once dail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018004-18,0,0,0 2009-018005-43,2,2012-11-07,2012-11-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 μg once dai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018005-43,0,0,0 2009-018005-43,2,2012-11-07,2012-11-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH&Co KG,"A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 μg once dai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018005-43,0,0,0 2009-018006-21,5,2011-08-19,2011-08-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & CoKG,"A Phase II, randomised, double- blind, placebo controlled, cross-over efficacy and safety comparison of tiotropium 5 μg administered once daily (in the evening) and tiotropium 2.5 μg administered twic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018006-21,0,0,0 2009-018006-21,5,2011-08-19,2011-08-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase II, randomised, double- blind, placebo controlled, cross-over efficacy and safety comparison of tiotropium 5 μg administered once daily (in the evening) and tiotropium 2.5 μg administered twic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018006-21,0,0,0 2009-018009-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION PARA LA INVESTIGACIÓN LA FE,"PREPARACIÓN DE FOLICULOS ANTRALES, PREVIA FECUNDACION IN VITRO TIPO ICSI, EN PACIENTES CON BAJA RESPUESTA OVÁRICA. ENSAYO CLÍNICO PROSPECTIVO, ALEATORIZADO, CONTROLADO.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018009-26,0,0,0 2009-018010-18,1,2014-02-01,2014-02-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik f.Innere Medizin I,Abt. f. Infektionen u.Tropenmedizin",Multiple-dose Pharmacokinetics of Doripenem during continuous venovenous hemodiafiltration and molecular adsorbent recirculating system in ICU patients and during hemodialysis in longterm hemodialysis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018010-18,0,0,0 2009-018014-20,1,2014-12-12,2014-12-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Common Services Agency,A Randomised Phase II Study Evaluating Cediranib vs. Cediranib and Saracatanib in patients with relapsed metastatic clear cell renal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018014-20,0,0,0 2009-018015-11,6,2013-10-01,2013-10-01,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ImClone LLC,"""Estudio de fase 2, aleatorizado, de IMC-3G3, un anticuerpo monoclonal anti-PDGFRalfa humano, más mitoxantrona y prednisona frente a mitoxantrona más prednisona en el cáncer de próstata metastásico re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018015-11,0,0,0 2009-018015-11,6,2013-10-01,2013-10-01,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,IMCLONE LLC,"""Estudio de fase 2, aleatorizado, de IMC-3G3, un anticuerpo monoclonal anti-PDGFRalfa humano, más mitoxantrona y prednisona frente a mitoxantrona más prednisona en el cáncer de próstata metastásico re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018015-11,0,0,0 2009-018016-25,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,0,Academic Medical Center,Dopamine-serotonin dysbalance in patients with dystonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018016-25,0,0,0 2009-018017-40,1,2012-06-27,2012-06-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare UK Ltd,"A randomised, double-blind, multi-centre, placebo controlled parallel group study to evaluate the efficacy and tolerability of a new Ibuprofen gel in patients with acute sports-related traumatic blunt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018017-40,0,0,0 2009-018018-21,1,2010-12-14,2010-12-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare UK,"A randomised, double-blind, multi-centre, placebo controlled parallel group study to evaluate the efficacy and tolerability of a new Ibuprofen patch in patients with acute sports related traumatic blu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018018-21,0,0,0 2009-018022-30,14,2013-11-09,2013-11-29,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A 6-month, open label, prospective, multicenter, international, exploratory study of a transition to flexibly dosed paliperidone palmitate in patients with schizophrenia previously unsuccessfully tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018022-30,0,0,0 2009-018022-30,14,2013-11-09,2013-11-29,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"A 6-month, open label, prospective, multicenter, international, exploratory study of a transition to flexibly dosed paliperidone palmitate in patients with schizophrenia previously unsuccessfully tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018022-30,0,0,0 2009-018024-15,1,2010-12-08,2010-12-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Clinuvel Pharmaceuticals Limited,"A Phase II, Randomised, Open Label Pilot Study to Evaluate the Efficacy and Safety of Two Dosage Regimens of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Mild to Moderate Acne Vu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018024-15,0,0,0 2009-018025-73,1,2014-07-19,2014-07-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GMIHO mbH,Randomised phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- or third-line treatment of patients with metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018025-73,0,0,0 2009-018029-57,1,2010-12-08,2010-12-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Logical Therapeutics Inc.,"A Double-Blind, Double-Dummy, Randomized, Active-Comparator, Arthritis Non-Inferiority Study of LT-NS001 versus Naprosyn® for Twelve Weeks in Osteoarthritis Patients to Compare Endoscopic Gastric Ulce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018029-57,0,0,0 2009-018031-90,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,3,,Antibiotic treatment in nasal septal surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018031-90,0,0,0 2009-018034-11,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Karolinska Institutet,Open pilot study of treatment with vancomycin to children and adolescents with primary sclerosing cholangitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018034-11,0,0,0 2009-018038-12,2,2013-10-07,2013-10-07,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation","A 26-Week, Multi-Center, Open-Label, Flexible Dose, Long-Term Safety Trial of Asenapine in Adolescent Subjects With Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018038-12,1,1,0 2009-018044-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Meander MC,A randomised phase II study of repeated Rhenium-188 HEDP combined with Docetaxel versus Docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone’,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018044-18,0,0,0 2009-018046-38,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Phafag AG,"Double blind, placebo-controlled randomized clinical trial to evaluate the efficacy and safety of a transtympanic treatment of tinnitus with caroverine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018046-38,0,0,0 2009-018049-19,1,2013-08-20,2013-08-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten",A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018049-19,0,0,0 2009-018050-34,1,2013-02-10,2013-02-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien,Univ.Klinik f.Anästhesie, Intensivmedizin und Schmerztherapie",Perioperative fluid management in patients receiving cadaveric renal transplants – Effects of normal saline versus balanced infusates on the incidence of electrolyte and acid-base disturbances,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018050-34,0,0,0 2009-018054-33,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Faculty of Pharmacy, University of Ljubljana",Efficacy of vitamin E and omega-3 unsaturated fatty acid in prevention of damage induced by oxidative stress in patients with schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018054-33,0,0,0 2009-018056-42,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,AZIENDA OSPEDALIERA G. BROTZU,A phase IV single-centre study to evaluate the topical administration of capsaicin cream (0.075%) as a healthy volunteer model of neuropathic pain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018056-42,0,0,0 2009-018058-44,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GERCOR,Proof-of-concept phase II study to evaluate the anti-tumoractivity of sorafenib along with pathological and molecularchanges in tumor samples from patients with resectable hepatocellular carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018058-44,0,0,0 2009-018059-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,futurum,Behandling av akuta hudförändringar hos bröstcancerpatienter som genomgår strålterapi - är en steroidkräm (Betnovat) mer effektiv än mjukgörande krämer mot strålinducerade hudbiverkningar ?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018059-18,0,0,0 2009-018064-95,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,University of Leuven,Amyloid imaging in late life depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018064-95,0,0,0 2009-018066-36,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,Glaukos Corporation,Evaluación aleatorizada prospectiva en abierto del iStent® (GTS400)frente a dos agentes hipotensores oculares en pacientes con glaucoma primario de ángulo abierto,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018066-36,0,0,0 2009-018067-27,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,Glaukos Corporation,Evaluación cruzada prospectiva en abierto del iStent® (GTS400) en pacientes con glaucoma primario de ángulo abierto (Synergy Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018067-27,0,0,0 2009-018070-64,8,2012-06-29,2012-07-03,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26 Week Multicenter Study with a 26-Week Extension to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 (Canagliflo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018070-64,0,0,0 2009-018070-64,8,2012-06-29,2012-07-03,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26 Week Multicenter Study with a 26-Week Extension to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 (Canagliflo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018070-64,0,0,0 2009-018072-33,7,2020-06-30,2020-06-30,5,1,0,0,0,2,0,0,0,2,0,0,0,0,0,Universitätsklinikum Münster,"Prospective Trial for the diagnosis and treatment of children, adolescents and young adults with Intracranial Germ Cell Tumours",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018072-33,1,0,0 2009-018072-33,7,2020-06-30,2020-06-30,5,1,0,0,0,2,0,0,0,2,0,0,0,0,0,University of Münster,"Prospective Trial for the diagnosis and treatment of children, adolescents and young adults with Intracranial Germ Cell Tumours",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018072-33,1,0,0 2009-018074-56,1,2012-09-14,2012-09-14,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,Revival of autochthonous adrenocortical stem cells in autoimmune Addison’s disease (RoSA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018074-56,0,0,0 2009-018077-31,8,,,0,0,1,0,0,2,0,0,0,2,0,0,0,0,0,Universitätsmedizin Greifswald,A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018077-31,0,0,0 2009-018077-31,8,,,0,0,1,0,0,2,0,0,0,2,0,0,0,0,0,St. Anna Kinderkrebsforschung/CCRI,A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018077-31,0,0,0 2009-018077-31,8,,,0,0,1,0,0,2,0,0,0,2,0,0,0,0,0,Jagiellonian University Medical College,A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018077-31,0,0,0 2009-018077-31,8,,,0,0,1,0,0,2,0,0,0,2,0,0,0,0,0,St. Anna Kinderkrebsforchung Children's Cancer Research Institute,A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018077-31,0,0,0 2009-018077-31,8,,,0,0,1,0,0,2,0,0,0,2,0,0,0,0,0,St. Anna Kinderkrebsforschung,A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018077-31,0,0,0 2009-018077-31,8,,,0,0,1,0,0,2,0,0,0,2,0,0,0,0,0,INSTITUTO DE INVESTIGACIÓN SANITARIA LA FE DE VALENCIA,A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018077-31,0,0,0 2009-018079-15,2,2010-08-30,2010-08-30,2,1,0,1,0,0,1,0,2,1,0,0,0,0,1,"Idenix Pharmaceuticals, Inc",A Phase I/IIa Study Assessing Single and Multiple Doses of HCV Protease Inhibitor IDX320 in Healthy and Genotype 1 HCV-Infected Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018079-15,0,0,0 2009-018079-15,2,2010-08-30,2010-08-30,2,1,0,1,0,0,1,0,2,1,0,0,0,0,1,"Idenix Pharmaceuticals, Inc.",A Phase I/IIa Study Assessing Single and Multiple Doses of HCV Protease Inhibitor IDX320 in Healthy and Genotype 1 HCV-Infected Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018079-15,0,0,0 2009-018083-94,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,"Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients with High-Risk Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018083-94,0,0,0 2009-018084-27,8,2017-05-12,2017-05-12,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Pharmaceutical Industries, Ltd.","A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018084-27,0,0,0 2009-018084-27,8,2017-05-12,2017-05-12,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Teva Pharmaceutical Industries Ltd.,"A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018084-27,0,0,0 2009-018085-35,1,2014-03-11,2014-03-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Regionalhospital Silkeborg,"Intestinal Inflammation in Ankylosing Spondylitis assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the effects of Adalimumab on mucosal healing INTestinal inflammation ved Ank...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018085-35,0,0,0 2009-018086-12,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Athena Care/ Isala Klinieken,Efficacy and safety of Haemocomplettan® P in patients experiencing microvascular bleeding while undergoing elective complex cardiac surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018086-12,0,0,0 2009-018087-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska University Hospital Huddinge,Goal Directed fluid substitution at patients with proximal femoral fracture. Evaluation of costs and consequences of alternative strategies of intra -opertaive fluid substitution- randomised clinical ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018087-10,0,0,0 2009-018090-30,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Institut Claudius Regaud,"Hormonothérapie adjuvante du cancer du sein : Pharmacocinétique du tamoxifène et des anti-aromatases, corrélation avec les caractéristiques pharmacogénétiques Protocole PHACS (Pharmacologie de l’Hormo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018090-30,0,0,0 2009-018091-34,1,2014-06-06,2014-06-06,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis (Hellas) S.A.C.I,A multicenter open label phase II study to evaluate the safety and efficacy of deferasirox in combination with deferioxamine followed by transitioning to deferasirox monotherapy in β-thalassemia patie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018091-34,0,0,0 2009-018092-14,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Krankenhaus Nordwest GmbH,"A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric carcinoma who have progressed after therapy with a fluoropyrimidine/plat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018092-14,0,0,0 2009-018095-33,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Institut Pasteur,Evaluation d’outils de diagnostic sérologique discriminant une infection naturelle par le virus amaril d’une vaccination anti-amarile,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018095-33,0,0,0 2009-018097-64,1,2014-05-19,2014-05-19,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,GlaxoSmithKline Biologicals,Long-term follow-up of study participants from GlaxoSmithKline (GSK) Biologicals’-sponsored clinical trials evaluating Human Immunodeficiency Virus vaccine [F4co (p24-RT-Nef-p17)/AS01B vaccine] (73246...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018097-64,0,0,0 2009-018101-52,2,2011-09-20,2011-09-20,1,1,0,0,0,0,3,0,1,1,0,0,1,0,2,Novartis Vaccines and Diagnostics S.r.l,"Title of the trial: A Phase 3, Open-Label, Multi-Center, Extension Study of V72P13E1 to Assess Antibody Persistence at One Year After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018101-52,0,0,0 2009-018102-22,1,2011-06-07,2011-06-07,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,PIERRE FABRE DERMATOLOGIE,"A multicentre, open-label, repeated-dose, pharmacokinetic study of Propranolol in infants treated for proliferating infantile hemangiomas (IHs) requiring systemic therapy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018102-22,0,0,0 2009-018103-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,David López Vaquero,"ENSAYO CLÍNICO ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA EVALUAR EL USO DE LA GLUTAMINA COMO AGENTE PROTECTOR EN LA MUCOSITIS ORAL Y LA RADIODERMITIS INDUCIDA POR LA RADIOTERAPIA Y/O QUI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018103-40,0,0,0 2009-018108-17,1,2010-11-30,2010-11-30,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Medizinische Universität Graz,Kann der antiaggregatorische Effekt von Clopidogrel und Acetylsalicylsäure durch die Gabe von Thrombozytenkonzentraten aufgehoben werden?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018108-17,0,0,0 2009-018109-29,3,2012-02-13,2012-02-15,3,1,0,0,1,0,3,0,0,1,0,0,1,0,1,"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.",A PHASE 3 MULTI-CENTER PARALLEL DESIGN CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF 5% MINOXIDIL FOAM VS. 2% MINOXIDIL SOLUTION IN FEMALES FOR THE TREATMENT OF FEMALE PATTERN HAIR LOSS (ANDROG...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018109-29,0,0,0 2009-018112-26,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Weleda AG,"Efficacy and tolerability of Citrus/Cydonia comp.® 1% solution for injection in patients with grass pollen seasonal allergic rhinitis: A randomised, double-blind, placebo-controlled clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018112-26,0,0,0 2009-018117-40,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Novartis Pharma S.A.S,"Etude prospective, randomisée, comparant les profils glycémiques sur 72 hr obtenus par enregistrement continu du glucose (CSGM) chez des patients diabétiques de type 2 insuffisamment contrôlés par la ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018117-40,0,0,0 2009-018118-21,4,2013-03-25,2013-03-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to placebo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018118-21,0,0,0 2009-018119-14,1,2015-06-30,2015-06-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,Huntington's Disease Rilmenidine Safety Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018119-14,0,0,0 2009-018121-75,6,2012-04-20,2012-04-20,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"MEDIVATION, INC.",CONCERT PLUS: An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Latrepirdine) in Patients with Alzheimer's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018121-75,0,0,0 2009-018121-75,6,2012-04-20,2012-04-20,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Medivation, Inc.",CONCERT PLUS: An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Latrepirdine) in Patients with Alzheimer's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018121-75,0,0,0 2009-018123-32,6,2011-06-17,2011-06-17,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Medivation, Inc",HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018123-32,0,0,0 2009-018123-32,6,2011-06-17,2011-06-17,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"MEDIVATION, INC.",HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018123-32,0,0,0 2009-018125-70,1,2014-08-21,2014-08-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Graz,"Styrian Vitamin D Hypertension Trial: A randomized, double-blind, placebo controlled trial to study the effects of vitamin D supplementation on systolic blood pressure in vitamin D deficient hypertens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018125-70,0,0,0 2009-018137-37,1,2013-04-03,2013-04-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,"An open label, single site, 12 month, Phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018137-37,0,0,0 2009-018139-98,1,2014-11-26,2014-11-26,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Ville-Valtteri Välimäki,"Satunnaistettu, sokkoutettu, lumekontrolloitu tutkimus D-vitamiinin suurannoshoidosta – 100 000 tai 200 000 yksikköä D3-vitamiinia suun kautta kolmen kuukauden välein",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018139-98,0,0,0 2009-018141-20,11,2014-05-31,2014-06-25,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharma A/S,"A Phase 3 Study of Subcutaneous Innohep 20,000 anti-Xa IU/ml for the Treatment of Venous Thromboembolism (VTE) in Cancer Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018141-20,0,0,0 2009-018141-20,11,2014-05-31,2014-06-25,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO PHARMA A/S,"A Phase 3 Study of Subcutaneous Innohep 20,000 anti-Xa IU/ml for the Treatment of Venous Thromboembolism (VTE) in Cancer Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018141-20,0,0,0 2009-018143-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Västra Götalandsregionen,"An open label, historical control, study to assess the impact on bacteriological healing of Prednisolone in patients with neuroborreliosis-caused peripheral facial palsy receiving treatment with Doxyc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018143-25,0,0,0 2009-018146-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Swedish Orphan International AB,Multicenter randomized controlled study comparing the efficacy and safety of natural Multi-subtype interferon alpha (Multiferon) in association with ribavirin versus retreatment with pegylated interfe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018146-38,0,0,0 2009-018148-45,1,2016-04-05,2016-04-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,An exploratory Phase 2 study of Pemetrexed and Cisplatin as Preoperative chemotherapy in the treatment of Stage IIIAN2 nonsquamous non-Small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018148-45,0,0,0 2009-018153-23,1,2020-02-20,2020-02-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Oxford,A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018153-23,0,0,0 2009-018155-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,STALLERGENES IBÉRICA S.A.,"Estudio multicéntrico, aleatorizado, abierto, para evaluar la eficacia del tratamiento con inmunoterapia subcutánea con ácaros (Alustal Rapid) mediante rinometría acústica tras provocación nasal en pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018155-16,0,0,0 2009-018157-23,3,2010-12-16,2010-12-16,2,0,0,0,0,1,2,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD3241 in Patients with Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018157-23,0,0,0 2009-018161-12,7,2013-06-03,2013-07-09,5,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Shire Development Inc.,"A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolesc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018161-12,0,0,0 2009-018161-12,7,2013-06-03,2013-07-09,5,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Shire Development Inc,"A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolesc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018161-12,0,0,0 2009-018162-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Thorax Center, Univeristy Medical Center Groningen, Groningen, The Netherlands",Metabolic modulation with metformin to reduce heart failure after acute myocardial infarction: Glycometabolic Intervention as adjunct to Primary percutaneous coronary intervention in ST elevation myoc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018162-34,0,0,0 2009-018166-36,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,CHU de Poitiers,"Evaluation de l’entretien de l’anesthésie générale sous Xénon comparé au Desflurane au cours de l’endartérectomie carotidienne, étude prospective, randomisée et comparative.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018166-36,0,0,0 2009-018167-26,7,2014-04-16,2014-04-16,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension: IMPRES Extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018167-26,0,0,0 2009-018167-26,7,2014-04-16,2014-04-16,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension: IMPRES Extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018167-26,0,0,0 2009-018167-26,7,2014-04-16,2014-04-16,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension: IMPRES Extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018167-26,0,0,0 2009-018167-26,7,2014-04-16,2014-04-16,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica SA,"An extension study to QTI571A2301 to evaluate the longterm safety, tolerability and efficacy of oral QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension: IMPRES Extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018167-26,0,0,0 2009-018168-81,2,2012-05-02,2012-05-02,1,1,0,0,0,1,4,0,0,2,0,0,0,0,1,Merck Serono Norway,"ENDURE: A Phase IV, prospective, open-label, uncontrolled, multi-centre cohort trial to assess the responsiveness of subjects with phenylketonuria (PKU) to treatment with Kuvan® 20 mg/kg/day for 28 da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018168-81,1,0,0 2009-018169-12,1,2015-03-24,2015-03-24,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Nîmes,"Etude randomisée évaluant l’efficacité et la tolérance du rémifentanil lors d’une induction en séquence rapide, chez des sujets fragiles",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018169-12,0,0,0 2009-018171-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ONCOSUR,"Estudio clínico de fase IIa, del tratamiento con heparina topica en pacientes con sindrome eritrodisestesico palmo-plantar asociado a capecitabina",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018171-13,0,0,0 2009-018172-33,5,2012-02-27,2012-02-27,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SANOFI AVENTIS GROUPE,"A 24-week, open, multicenter, comparative study of 2 strategies (including insulin glargine versus premixed insulin) for the therapeutic management of patients with type 2 diabetes failing oral agents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018172-33,0,0,0 2009-018173-31,7,2013-12-19,2015-03-17,5,0,0,0,0,0,0,0,0,2,0,0,0,0,0,Population Health Research Institute,"A large, international, placebo-controlled, factorial trial to assess the impact of clonidine and acetyl-salicylic acid (ASA) in patients undergoing noncardiac surgery who are at risk of a perioperati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018173-31,1,0,0 2009-018173-31,7,2013-12-19,2015-03-17,5,0,0,0,0,0,0,0,0,2,0,0,0,0,0,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,"A large, international, placebo-controlled, factorial trial to assess the impact of clonidine and acetyl-salicylic acid (ASA) in patients undergoing noncardiac surgery who are at risk of a perioperati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018173-31,1,0,0 2009-018173-31,7,2013-12-19,2015-03-17,5,0,0,0,0,0,0,0,0,2,0,0,0,0,0,POPULATION HEART RESEARCH INSTITUTE (PHRI),"A large, international, placebo-controlled, factorial trial to assess the impact of clonidine and acetyl-salicylic acid (ASA) in patients undergoing noncardiac surgery who are at risk of a perioperati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018173-31,1,0,0 2009-018174-54,4,2010-06-15,2010-07-06,3,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Novartis Services AG,"MERIDIAN: A 12-month prospective, open-label, randomized, multicenter, parallel-group study to evaluate the efficacy, safety and tolerability of a Myfortic®-based regimen in the conversion from a CNI ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018174-54,0,0,0 2009-018174-54,4,2010-06-15,2010-07-06,3,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"MERIDIAN: A 12-month prospective, open-label, randomized, multicenter, parallel-group study to evaluate the efficacy, safety and tolerability of a Myfortic®-based regimen in the conversion from a CNI ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018174-54,0,0,0 2009-018174-54,4,2010-06-15,2010-07-06,3,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","MERIDIAN: A 12-month prospective, open-label, randomized, multicenter, parallel-group study to evaluate the efficacy, safety and tolerability of a Myfortic®-based regimen in the conversion from a CNI ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018174-54,0,0,0 2009-018175-14,1,2012-06-06,2012-06-06,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Effects of ivabradine IV versus placebo on haemodynamic parameters in patients with a low cardiac output syndrome following planned coronary artery bypass surgery and requiring positive inotropic trea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018175-14,0,0,0 2009-018181-36,1,2010-08-11,2010-08-11,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Nottingham,"Nitrous Oxide and Functional Magnetic Resonance Imaging to investigate cerebral regional blood flow, cerebral metabolism and neuronal activity.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018181-36,0,0,0 2009-018182-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Ainara Aguirre Caballero,Efectividad del magnesio epidural para reducir las necesidades de analgesia postoperatoria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018182-13,0,0,0 2009-018187-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ziekenhuisgroep Twente,Double dose treatment: Corticosteroid injection therapy in arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018187-10,0,0,0 2009-018188-29,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Dept of Oncology,Randomised blinded trial of Calendula Officinalis compared with aqueos cream for the prevention of acute skin toxicity in relation to radiotherapy for breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018188-29,0,0,0 2009-018189-36,2,2020-02-24,2020-02-24,2,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU de Saint-Étienne,Prevención en receptor con nefropatía por IgA (NIgA) de la Recurrencia completa trAs primer Trasplante renal: ATG-F versus Basiliximab como tratamientos inmunosupresores de inducción,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018189-36,0,0,0 2009-018189-36,2,2020-02-24,2020-02-24,2,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU Saint-Etienne,Prevención en receptor con nefropatía por IgA (NIgA) de la Recurrencia completa trAs primer Trasplante renal: ATG-F versus Basiliximab como tratamientos inmunosupresores de inducción,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018189-36,0,0,0 2009-018190-31,1,2013-11-01,2013-11-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik f.Innere Medizin II, Abt.f.Angiologie","OMEGA-3-POLYUNSATURATED FATTY-ACIDS (n3-PUFA) IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE: EFFECTS ON ENDOTHELIAL FUNCTION – A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018190-31,0,0,0 2009-018191-34,1,2011-07-22,2011-07-22,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Follica Inc.,A Study to Explore the Effect of Controlled Cutaneous Perturbation and Pharmacologic Modulation for Inducing Follicular Neogenesis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018191-34,0,0,0 2009-018194-31,1,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,1,Pharmarama International Limited,Topical Amlodipine in Raynaud's Phenomenon,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018194-31,0,0,0 2009-018195-33,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Centro de Investigación Biomédica en Red en el Área de Salud Mental (CIBERSAM),Eficacia de quetiapina de liberación prolongada vs. placebo como terapia coadyuvante al tratamiento eutimizante en el control de los síntomas subsindrómicos del trastorno bipolar,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018195-33,0,0,0 2009-018197-66,5,2014-10-30,2014-10-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"Ensayo clínico de seguridad, efecto antiviral y farmacocinética de BI 207127 en combinación con BI 201335 y con Ribavirina durante 4 semanas (Parte 1) y con o sin ribavirina durante 24-48 semanas (Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018197-66,0,0,0 2009-018197-66,5,2014-10-30,2014-10-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"Ensayo clínico de seguridad, efecto antiviral y farmacocinética de BI 207127 en combinación con BI 201335 y con Ribavirina durante 4 semanas (Parte 1) y con o sin ribavirina durante 24-48 semanas (Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018197-66,0,0,0 2009-018197-66,5,2014-10-30,2014-10-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","Ensayo clínico de seguridad, efecto antiviral y farmacocinética de BI 207127 en combinación con BI 201335 y con Ribavirina durante 4 semanas (Parte 1) y con o sin ribavirina durante 24-48 semanas (Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018197-66,0,0,0 2009-018197-66,5,2014-10-30,2014-10-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Ensayo clínico de seguridad, efecto antiviral y farmacocinética de BI 207127 en combinación con BI 201335 y con Ribavirina durante 4 semanas (Parte 1) y con o sin ribavirina durante 24-48 semanas (Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018197-66,0,0,0 2009-018197-66,5,2014-10-30,2014-10-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Unilfarma, Lda.","Ensayo clínico de seguridad, efecto antiviral y farmacocinética de BI 207127 en combinación con BI 201335 y con Ribavirina durante 4 semanas (Parte 1) y con o sin ribavirina durante 24-48 semanas (Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018197-66,0,0,0 2009-018200-17,1,2011-02-08,2011-02-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,3,University Hospitals of Leicester NHS Trust,"Plasma Levels of Oseltamivir in critically ill, suspected or confirmed H1N1 infected patients on Extra Corporeal membrane Oxygenation (ECMO)support.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018200-17,0,0,0 2009-018205-43,1,2011-07-12,2011-07-12,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,Oncology Department,A clinical phase I / II trial of Belinostat in combination with Erlotinib in patients with non-small cell lung cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018205-43,0,0,0 2009-018209-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AZIENDA SANITARIA OSPEDALIERA ""S. GIOVANNI BATTISTA DI TORINO""","EFFECTS OF DHEA TREATMENT ON ANTHROPOMETRIC AND METABOLIC PARAMETERS, AND ON QUALITY OF LIFE (QOL) IN PATIENTS WITH ADDISON S DISEASE UNDER GLUCORTICOID-MINERALCORTICOID SUBSTITUTIVE TREATMENT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018209-32,0,0,0 2009-018212-26,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,Centre Hospitalier Universitaire de Besançon,Etude de la diffusion de la daptomycine dans le tissu osseux et le liquide synovial chez le volontaire sain après injection unique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018212-26,0,0,0 2009-018214-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire DE NANCY,Étude sur la relation dose-effet de la néostigmine pour l’antagonisation des faibles niveaux de curarisations résiduelles induites par l’atracurium,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018214-19,0,0,0 2009-018215-53,1,2011-10-03,2011-10-03,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,sanofi-aventis Netherlands,"The effect of the addition of dronedarone to, versus increase of, existing conventional rate control medication on ventricular rate during paroxysmal or persistent atrial fibrillation (AFRODITE study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018215-53,0,0,0 2009-018218-21,2,2013-12-28,2013-12-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Menarini Ricerche S.p.A.,"Double-blind, randomised, placebo-controlled, parallel group study to evaluate the efficacy and safety of oral administration of Nepadutant in infant colic",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018218-21,0,0,0 2009-018226-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,3,,The effect of botulinum toxin type A injections in the m. rectus femoris in stroke patients presenting with a stiff knee gait.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018226-29,0,0,0 2009-018228-14,1,2015-09-30,2015-09-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Hospital Leuven,"HGG-2010. AS phase IIb prospective placebo-controlled double blind randomized clinical trial for the treatment of patients with newly diagnosed glioblastoma multiforme with tumor vaccination as ""add-o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018228-14,0,0,0 2009-018240-23,8,2013-04-21,2013-06-17,6,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Clovis Oncology Inc.,"A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018240-23,0,0,0 2009-018240-23,8,2013-04-21,2013-06-17,6,1,0,0,0,2,2,0,0,1,1,0,1,0,1,"CLOVIS ONCOLOGY, INC.","A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018240-23,0,0,0 2009-018240-23,8,2013-04-21,2013-06-17,6,1,0,0,0,2,2,0,0,1,1,0,1,0,1,"Clovis Oncology, Inc.","A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018240-23,0,0,0 2009-018240-23,8,2013-04-21,2013-06-17,6,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Clovis Oncology Inc,"A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018240-23,0,0,0 2009-018245-21,1,2012-05-05,2012-05-05,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Rigshospitalet,"Fibrinklæber ved bilateral knæalloplastik – et prospektivt randomiseret studie med fokus på: blodtab, smerte, ROM, hævelse og styrke",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018245-21,0,0,0 2009-018246-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Antoni van Leeuwenhoek Ziekenhuis,Phase II trial evaluating combined image guided radiotherapy with Panitumumab (Vectibix®) in patients with muscle invasive transitional cell carcinoma of the bladder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018246-38,0,0,0 2009-018247-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SAN GERARDO DI MONZA,"Peritoneal nebulization of Ropivacaine for postoperative pain control after laparoscopic cholecystectomy A multicentre, randomized, controlled, double blinded, phase III clinical trial; comparing pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018247-24,0,0,0 2009-018258-43,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI,"SIB-GBM trial (Simultaneous Integrated Boost in Glioblastoma multiforme: hyprofractionated radiotherapy with concomitant boost and temozolomide, in glioblastoma RPA III and IV patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018258-43,0,0,0 2009-018266-35,2,2014-06-23,2014-06-23,2,1,0,0,0,1,3,0,0,1,0,0,1,0,0,CHU de LIMOGES,Efficacité du Rituximab au cours du syndrome néphrotique idiopathique ciclosporinodépendant de l'enfant.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018266-35,0,0,0 2009-018267-27,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,InfaCare Pharmaceutical Corporation,"A 5-Year, Extension, Follow-up, Blinded-Outcomes Trial of Subjects Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-202 ""Un estudio ciego de seguimiento y ampliación de 5 años de dur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018267-27,0,0,0 2009-018269-11,1,2014-09-03,2014-09-03,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Pohjois-Karjalan keskussairaala,"Haavan puuduteinfuusio keisarinleikkauksen jälkeisen kivun hoitona. Prospektiivinen , satunnaistettu, kontrolloitu tutkimus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018269-11,0,0,0 2009-018277-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Nîmes,"EVALUATION DU RETENTISSEMENT PSYCHIATRIQUE, CARDIOVASCULAIRE ET SUR LA QUALITE DE VIE DE L’ HORMONOTHERAPIE FREINATRICE DANS UNE COHORTE DE PATIENTS THYROIDECTOMISES POUR CARCINOME THYROIDIEN PAPILLA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-018277-31,0,0,0 2010-018233-21,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Leiden University Medical Centre,Modeling the respiratory effects of subanesthetic doses of propofol under closed-loop or non-steady-state conditions without and with a remifentanil background infusion in healthy volunteers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018233-21,0,0,0 2010-018235-17,1,2012-08-31,2012-08-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,TAILOR Trombocytes And IndividuaLization of ORal antiplatelet treatment after percutaneous coronary intervention (Trombocytter og individualiseret oral antitrombotisk behandling efter perkutan koronar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018235-17,0,0,0 2010-018249-78,1,2013-10-23,2013-10-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Nottingham,Small Particle Inhaled Steroids in Refractory Steroid-responsive Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018249-78,0,0,0 2010-018254-12,1,2012-04-03,2012-04-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer, Inc","A LOCAL, MULTICENTRE, OPEN-LABEL, EXTENSION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE FLEXIBLE DOSE REGIMEN IN ELDERLY PATIENTS WITH OVERACTIVE BLADDER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018254-12,0,0,0 2010-018270-20,1,,,0,0,0,0,0,1,4,0,0,1,0,0,0,1,0,Asociación Andaluza de Hematología y Hemoterapia.,"“Estudio, multicéntrico, aleatorizado, abierto, fase II de Vidaza (Azacitidina) versus tratamiento de soporte en pacientes con síndrome mielodisplásico de bajo riesgo (IPSS bajo e intermedio-1) sin de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018270-20,0,0,0 2010-018273-38,1,2011-03-01,2011-03-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effect of Single and Multiple Oral Doses of AZD1446/ Placebo and a Single Dose o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018273-38,0,0,0 2010-018275-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Centre Nijmegen St Radboud,A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018275-20,0,0,0 2010-018276-25,1,2011-07-15,2011-07-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Wien,Effects of intravenous Lidocaine on MAC of Sevoflurane,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018276-25,0,0,0 2010-018279-99,1,2012-06-22,2012-06-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Faculty of Medicine, Otto-von-Guericke-University Magdeburg",Skin Topoproteome under Adalimumab (Humira®) Treatment in Patients with Moderate to Severe Psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018279-99,0,0,0 2010-018283-16,10,2014-03-06,2014-03-06,7,0,0,0,0,2,3,0,0,1,0,0,1,0,1,"BHR PHARMA, LLC","A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients with Severe Traumatic Brain Injury",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018283-16,0,0,0 2010-018283-16,10,2014-03-06,2014-03-06,7,0,0,0,0,2,3,0,0,1,0,0,1,0,1,"BHR Pharma, LLC","A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients with Severe Traumatic Brain Injury",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018283-16,0,0,0 2010-018284-42,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,University Medical Centre Groningen,"Double-blind randomized trial comparing efficacy, safety and tolerance between Levetiracetam monotherapy and Valproic acid monotherapy in children with newly diagnosed epilepsy Een dubbelblind gera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018284-42,0,0,0 2010-018285-23,1,2018-04-01,2018-04-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,Effect of active vitamin D treatment on arterial stiffness and albuminuria in patients with type 2 diabetes and stage 3 chronic kidney disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018285-23,0,0,0 2010-018285-23,1,2018-04-01,2018-04-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's and St.Thomas' NHS Foundation Trust,Effect of active vitamin D treatment on arterial stiffness and albuminuria in patients with type 2 diabetes and stage 3 chronic kidney disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018285-23,0,0,0 2010-018289-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Insitute of Endocrinology,"Clinical, laboratory and ultrasound markers for the prediction of the response on the pulse-dose treatment by intravenous glucocorticoids in patients with endocrine orbitopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018289-21,0,0,0 2010-018291-25,1,2013-03-18,2013-03-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Charité-Universitätsmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie, CRC","INVESTIGATOR-INITIATED, DOUBLE BLIND, TWO-ARMED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL WITH AN OPEN-LABEL EXTENSION PHASE, TO INVESTIGATE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM TWICE DAILY IN M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018291-25,0,0,0 2010-018295-24,5,2012-08-29,2012-08-29,4,1,0,0,2,0,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection Revised Protocol Number 03, inc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018295-24,0,0,0 2010-018295-24,5,2012-08-29,2012-08-29,4,1,0,0,2,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection Revised Protocol Number 03, inc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018295-24,0,0,0 2010-018296-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,María del Pino Alberiche Ruano,"EFECTOS DEL TRATAMIENTO CON L-TIROXINA SOBRE LA TENSIÓN ARTERIAL, LA FUNCIÓN MIOCÁRDICA Y EL GROSOR DE LA ÍNTIMA MEDIA CAROTÍDEA EN PACIENTES CON HIPOTIROIDISMO SUBCLÍNICO LEVE Y RIESGO CARDIOVASCULAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018296-19,0,0,0 2010-018298-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UZLeuven,Prospective Randomised Double-blind Sham Study on the Use of Botox for the Treatment of Diffuse esophageal spasm,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018298-39,0,0,0 2010-018300-85,7,2012-05-11,2012-05-11,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Menarini Ricerche S.p.A.,"Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D) - The Iris-2 Study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018300-85,0,0,0 2010-018300-85,7,2012-05-11,2012-05-11,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MENARINI RICERCHE S.P.A.,"Double-blind, randomised, placebo-controlled, parallel-group phase II study to evaluate the effect of oral ibodutant in irritable bowel syndrome with diarrhoea (IBS-D) - The Iris-2 Study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018300-85,0,0,0 2010-018301-11,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,Centre chirurgical Marie Lannelongue,STUDY OF TRANAXAMIC ACID DOSAGE IN PEDIATRIC CARDIAC SURGERY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018301-11,0,0,0 2010-018309-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Association REDAR, Hôpital Ambroise Paré, Service d'Anesthésie et de Réanimation","Etude bi-centrique, randomisée, en groupes parallèles et double aveugle contre placebo pour évaluer l’efficacité et la sécurité à long terme de la toxine botulique en deux administrations répétées sur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018309-12,0,0,0 2010-018311-15,3,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,GE Healthcare Limited,"A Phase 2, Open-label Study to Assess the Uptake and Retention and Safety of GE 148 (18F) Injection in Subjects with Biopsy-proven Prostate Cancer who are Scheduled for Radical Prostatectomy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018311-15,0,0,0 2010-018313-29,1,2010-11-22,2010-11-22,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Photopharmica,"Open-label, within-subject controlled, Phase IIa study to investigate repeat dose antimicrobial photodynamic therapy in patients with acne vulgaris.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018313-29,0,0,0 2010-018314-75,10,2019-01-07,2019-01-07,9,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Micromet AG,"A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018314-75,0,0,0 2010-018314-75,10,2019-01-07,2019-01-07,9,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Amgen Research (Munich) GmbH,"A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018314-75,0,0,0 2010-018314-75,10,2019-01-07,2019-01-07,9,1,0,0,0,1,2,0,0,1,0,0,1,0,1,MICROMET AG,"A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018314-75,0,0,0 2010-018315-15,5,2013-04-05,2013-04-05,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 μg bid with placebo, a 6-week efficacy and safety study in children aged 6 to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018315-15,0,0,0 2010-018316-32,1,2012-10-16,2012-10-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase 2, randomized, blinded, 5-period cross-over, placebo and activecontrolled, multicenter, dose-finding study of single doses of formoterol 2.25 μg, 4.5 μg, and 9 μg delivered via Symbicort pMDI ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018316-32,0,0,0 2010-018318-62,1,2012-01-19,2012-01-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Phase III, Randomized, Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on a Sulfonylu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018318-62,0,0,0 2010-018319-13,6,2011-05-02,2011-05-02,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GALDERMA R&D SNC,"A DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE ACTIVITY OF CD5024 1% CREAM IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA OVER 12 WEEKS TREATMENT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018319-13,0,0,0 2010-018320-10,4,2015-06-15,2015-06-24,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,An open-label extension of study AC-066A301 investigating the safety and tolerability of ACT-385781A in patients with pulmonary arterial hypertension (PAH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018320-10,0,0,0 2010-018320-10,4,2015-06-15,2015-06-24,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ACTELION Pharmaceuticals Ltd,An open-label extension of study AC-066A301 investigating the safety and tolerability of ACT-385781A in patients with pulmonary arterial hypertension (PAH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018320-10,0,0,0 2010-018321-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,"Transversus abdominis plane block, intravenous lignocaine or placebo for postoperative analgesia after open prostate surgery: a randomized controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018321-20,0,0,0 2010-018322-40,5,2012-02-02,2012-02-02,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ACTELION Pharmaceuticals Ltd,"A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018322-40,0,0,0 2010-018322-40,5,2012-02-02,2012-02-02,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018322-40,0,0,0 2010-018322-40,5,2012-02-02,2012-02-02,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018322-40,0,0,0 2010-018324-13,1,2013-01-31,2013-01-31,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,CONSORZIO PER LA RICERCA ONCOLOGICA,"Open phase II randomized study to assess safety, tolerability and efficacy of trastuzumab combined with vinorelbine in patients with HER2 positive metastatic breast cancer and cardiac diseases",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018324-13,0,0,0 2010-018326-39,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Department of Genito-Urinary Medicine and Infectious Diseases,"An open-label, randomised pilot study comparing the efficacy, safety and tolerability of raltegravir with protease inhibitor-based therapy in treatment-naïve, HIV/Hepatitis C co-infected injecting dru...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018326-39,0,0,0 2010-018327-26,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,VU University Medical Center,Chemoradiation with gemcitabine in combination with panitumumab for patients with locally advanced pancreatic cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018327-26,0,0,0 2010-018329-20,2,2012-10-24,2012-10-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Teva Pharmaceutical Industries Ltd.,"A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018329-20,0,0,0 2010-018331-18,1,2012-03-06,2012-03-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A 52 week, Single center, Open-label Study to Evaluate Neutrophil function and survival effects of Tocilizumab (TCZ) in Patients with Active Rheumatoid Arthritis (RA) on Background Non-biologic DMARDs...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018331-18,0,0,0 2010-018332-41,2,2012-07-31,2012-07-31,2,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Helsinki University Central Hospital,"A Randomized, Open-label, Parallel Group, Multicenter Pilot Study Evaluating the Efficacy and Safety of Alternative Dosing of Ribavirin vs. Standard of Care Dosing in Combination with Peginterferon al...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018332-41,0,0,0 2010-018332-41,2,2012-07-31,2012-07-31,2,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Dept. of Infectious diseases / virology University of Gothenburg,"A Randomized, Open-label, Parallel Group, Multicenter Pilot Study Evaluating the Efficacy and Safety of Alternative Dosing of Ribavirin vs. Standard of Care Dosing in Combination with Peginterferon al...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018332-41,0,0,0 2010-018333-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,Receptorial radiotherapy with 177Lu-DOTA-Tyr3-Octreotate as Maintaining Therapy in Extended Small Cell Lung Cancer (SCLC) after a first standard chemotherapy line,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018333-21,0,0,0 2010-018334-51,1,,,0,0,0,0,0,1,2,0,1,1,1,1,0,1,1,Bavarian Nordic A/S,"An open-label, non-controlled study to immunize healthy volunteers actively working with or in the vicinity of replicating Vaccinia virus with IMVAMUNE® (MVA-BN®)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018334-51,0,0,0 2010-018335-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación de la Universidad de Salamanca,"Ensayo clínico en fase I/II prospectivo, abierto, no aleatorizado para el tratamiento de la discopatía degenerativa intervertebral lumbar mediante artrodesis posterolateral instrumentada y células mad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018335-17,0,0,0 2010-018339-16,1,2013-07-03,2013-07-03,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,GMIHO mbH,"CRESCENDO (Compliance: Role Emerges for Success in CML: Evaluation aND Optimisation): A prospective, multi-center, phase IV study to assess the compliance in patients with Philadelphia chromosome-posi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018339-16,0,0,0 2010-018340-14,1,2014-12-08,2014-12-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Nottingham,Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018340-14,0,0,0 2010-018341-56,1,2011-03-15,2011-03-15,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Oxford,"A phase I/IIa sporozoite challenge study to assess the safety, immunogenicity and protective efficacy of new malaria vaccine candidates; AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018341-56,0,0,0 2010-018342-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI,PRE-EMPTIVE ANALGESIA E SURGICAL STRESS RESONSE WITH SUB-LINGUAL MORPHINE PRE-EMPTIVE ANALGESIA E RISPOSTA ALLO STRESS CHIRURGICO CON MORFINA SUB-LINGUALE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018342-31,0,0,0 2010-018343-34,1,2015-05-13,2015-05-13,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Ludwigs Maximilians University,Comparison of 6% Hydroxyethyl Starch and 5% Albumin for Volume Replacement Therapy in Patients Undergoing Cystectomy (CHART study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018343-34,0,0,0 2010-018345-64,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Evaluation of the efficacy of Xeomin in the treatment of cervical dystonia (CD) and blepharospasmus (BS) in patients who did not respond to treatment with Botox.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018345-64,0,0,0 2010-018350-13,2,2010-07-01,2010-07-01,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Abbott Biologicals B.V.,"Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Season 2010/2011. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018350-13,0,0,0 2010-018353-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA` GRANDA (A.O. DI RILIEVO NAZIONALE),"BeTACTIC Study. Best Therapy After Cardiac Transplantation, the Italian Challenge. A multicenter, prospective, randomized, open-label study to compare the efficacy and safety of Everolimus and Mycoph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018353-36,0,0,0 2010-018354-12,3,2012-07-14,2012-07-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biocon S.A.,"A Randomized, Active Controlled, Parallel Group, Multicentre, Two-Phase, Open-Label Study Comparing the Safety and Immunogenicity of Insugen R and Insugen N with Actrapid and Insulatard in Patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018354-12,0,0,0 2010-018354-12,3,2012-07-14,2012-07-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BIOCON S A,"A Randomized, Active Controlled, Parallel Group, Multicentre, Two-Phase, Open-Label Study Comparing the Safety and Immunogenicity of Insugen R and Insugen N with Actrapid and Insulatard in Patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018354-12,0,0,0 2010-018355-10,1,2010-09-06,2010-09-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,"An Investigator-blind, Controlled Study to Assess the Efficacy of Five Distinct Combinations of LAS 41004 in Different Concentrations Compared to Placebo and to Two Active Controls in a Psoriasis-Plaq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018355-10,0,0,0 2010-018361-33,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Arrow Therapeutics Ltd. (a member of the AstraZeneca group of companies),"A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AZD7295 in Combination with Pegylated Interferon alpha-2a and Ribavirin in Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018361-33,0,0,0 2010-018363-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""","A phase II dose finding study of induction cisplatin, docetaxel and escalating doses of capecitabine followed by concurrent cetuximab and radiotherapy in locally advanced inoperable head and neck squa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018363-42,0,0,0 2010-018365-34,2,,,0,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Raptor Therapeutics Inc.,"A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Nephropathic Cystinosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018365-34,0,0,0 2010-018365-34,2,,,0,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Horizon Pharma USA, Inc.","A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Nephropathic Cystinosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018365-34,0,0,0 2010-018369-48,1,2014-06-01,2014-06-01,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,Medizinische Universität Wien,Der Einfluss von Adalimumab auf kardiovaskuläre und metabolische Risikofaktoren in der Therapie von Patienten mit mittelschwerer bis schwerer Psoriasis vulgaris im Vergleich zu einer Standardtherapie ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018369-48,0,0,0 2010-018370-21,1,2014-09-25,2014-09-25,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,CESAR Central European Society for Anticancer Drug Research EWIV,Phase I/II study with Temsirolimus versus no add-on in patients with castration resistant prostate cancer (CRPC) receiving first-line Docetaxel chemotherapy CESAR Study in Prostrate Cancer with Tem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018370-21,0,0,0 2010-018371-18,1,2010-07-08,2010-07-08,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics GmbH,"A Phase III, multicenter, uncontrolled, open-label study to evaluate safety and immunogenicity of Begrivac®, preservative free, inactivated split influenza vaccine, using the strain composition 2010/2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018371-18,0,0,0 2010-018373-38,2,2011-01-19,2011-01-19,1,1,0,1,0,0,1,0,0,2,0,0,0,0,0,University of Birmingham,"A Phase I trial of figitumumab, an IGF-1R antibody, in children aged 1-12 years old with relapsed/refractory Solid Tumours",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018373-38,1,0,0 2010-018374-20,1,2012-02-20,2012-02-20,1,0,0,0,0,0,3,0,0,1,0,0,1,0,3,Cardiome UK Limited,"A Phase 3b Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients with Recent Onset Symptomatic Atria...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018374-20,0,0,0 2010-018375-22,6,2013-08-19,2013-08-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, double-blind, parallel group study of the safety and effect on clinical outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease modifying anti-rheumatoid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018375-22,0,0,0 2010-018375-22,6,2013-08-19,2013-08-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomized, double-blind, parallel group study of the safety and effect on clinical outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease modifying anti-rheumatoid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018375-22,0,0,0 2010-018377-38,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Leiden University Medical Centre,Immune respons after inactivated oral cholera vaccin (Dukoral) in renal transplant recipients Mucosal response in ImmunoCompromised Host (MICH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018377-38,0,0,0 2010-018379-70,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación PETHEMA,"Estudio Fase IIb Nacional, Abierto, Multicéntrico, Randomizado, Comparativo de tratamiento con un esquema secuencial Melfalán/Prednisona/Bortezomib (Velcade®) (MPV) seguido de Lenalidomida (Revlimid®)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018379-70,0,0,0 2010-018383-16,7,2012-01-31,2012-01-31,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Cephalon, Inc.","A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018383-16,0,0,0 2010-018385-23,6,2016-10-28,2017-01-13,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects with Active Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018385-23,0,0,0 2010-018386-32,10,2017-01-25,2017-01-27,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF TWO DOSES OF APREMILAST (CC-10004) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018386-32,0,0,0 2010-018389-22,6,2010-12-16,2011-01-20,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomized, multicentre, open-label, Phase II study of the efficacy and safety of lapatinib plus epirubicin and cyclophosphamide (EC90-L) followed by weekly paclitaxel and lapatinib (PX-L) compared...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018389-22,0,0,0 2010-018389-22,6,2010-12-16,2011-01-20,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.","A randomized, multicentre, open-label, Phase II study of the efficacy and safety of lapatinib plus epirubicin and cyclophosphamide (EC90-L) followed by weekly paclitaxel and lapatinib (PX-L) compared...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018389-22,0,0,0 2010-018392-22,1,2010-12-13,2010-12-13,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,GlaxoSmithKline S.A.,"Estudio fase I, abierto, multicéntrico para evaluar la seguridad e inmunogenicidad de la vacuna antigripal estacional trivalente (GSK2186877A) adyuvada con varias dosis de AS03, administrada en niños ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018392-22,0,0,0 2010-018399-25,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,"Medizinische Universität Wien, Univ.Klinik für Zahn-,Mund-u.Kieferheilkunde,Klin.Abt.f.orale Chirurg",A randomized controlled trial: Photodynamic Treatment for the therapy of premalignant mucosal oral lesions.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018399-25,0,0,0 2010-018401-10,6,2016-02-29,2016-02-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Otsuka Pharmaceutical Development & Commercialization, Inc","A Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018401-10,0,0,0 2010-018401-10,6,2016-02-29,2016-02-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,2,OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALISATION INC,"A Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018401-10,0,0,0 2010-018403-29,1,2011-11-09,2011-11-09,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Jørgen B. Dahl,"Effekten af Transversus abdominis plane (TAP) block versus sårinfiltration versus placebo på patienter, der får foretaget åben operation for lyskebrok i dagkirurgisk regi",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018403-29,0,0,0 2010-018405-12,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,"Forest Research Institute, Inc.","Evaluation of the Long-Term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018405-12,0,0,0 2010-018407-28,1,2014-09-09,2014-09-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering","A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine as an Active Control in Subjects With an Acute Exacerba...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018407-28,0,0,0 2010-018408-96,1,2015-03-06,2015-03-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering","A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine using Olanzapine as an Active Control in Subjects Diagnosed with Schizophrenia who Completed Protocol P056...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018408-96,0,0,0 2010-018409-13,1,2014-05-28,2014-05-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering","A Phase 3b, Multicenter, Double-Blind, Fixed-Dose, Parallel-Group, Three Week Placebo Controlled Trial Evaluating the Safety and Efficacy of Asenapine in Subjects With Bipolar 1 Disorder Experiencing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018409-13,0,0,0 2010-018410-78,1,2014-11-21,2014-11-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering","A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed with Bipolar 1 Disorder who Completed Protocol P05691 (formerly 041044) (Phase3B, Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018410-78,0,0,0 2010-018411-15,6,2013-05-23,2013-05-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018411-15,0,0,0 2010-018412-32,7,2012-09-12,2012-09-12,4,1,1,0,0,1,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research and Development LTD,"A phase II, double blind, exploratory, parallel-group, placebo-controlled clinical study to assess two dosing regimens of GSK2402968 for efficacy, safety, tolerability and pharmacokinetics in ambulant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018412-32,1,1,0 2010-018413-30,7,2011-09-09,2011-12-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MSD,"""Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario- Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018413-30,0,0,0 2010-018413-30,7,2011-09-09,2011-12-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"""Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario- Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018413-30,0,0,0 2010-018413-30,7,2011-09-09,2011-12-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MSD Finland Oy,"""Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario- Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018413-30,0,0,0 2010-018413-30,7,2011-09-09,2011-12-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","""Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario- Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018413-30,0,0,0 2010-018413-30,7,2011-09-09,2011-12-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","""Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario- Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018413-30,0,0,0 2010-018414-69,7,2011-11-08,2011-11-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"MERCK & CO., INC.","""Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario -Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018414-69,0,0,0 2010-018414-69,7,2011-11-08,2011-11-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"""Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario -Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018414-69,0,0,0 2010-018414-69,7,2011-11-08,2011-11-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"""Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario -Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018414-69,0,0,0 2010-018414-69,7,2011-11-08,2011-11-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MDS Finland Oy,"""Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario -Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018414-69,0,0,0 2010-018414-69,7,2011-11-08,2011-11-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","""Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario -Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018414-69,0,0,0 2010-018414-69,7,2011-11-08,2011-11-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","""Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario -Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018414-69,0,0,0 2010-018416-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Régional et Universitaire de Lille,Effets du Fénofibrate durant la première année de schizophrénie (effects of Fenofibrate® in first year of schizophrenia),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018416-33,0,0,0 2010-018418-53,4,2011-05-07,2011-05-20,2,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Novartis Pharma Service AG,"A non-randomized, open-label study to characterize the pharmacokinetics of Glivec/Gleevec® (imatinib mesylate) in pediatric (age range 1 to less than 4 years) patients with chronic myeloid leukemia (C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018418-53,0,0,0 2010-018419-14,5,2015-07-01,2015-07-01,3,1,1,0,0,1,1,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec® (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with ref...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018419-14,0,0,0 2010-018419-14,5,2015-07-01,2015-07-01,3,1,1,0,0,1,1,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec® (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with ref...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018419-14,0,0,0 2010-018421-19,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AMC,Preventive Antibiotics in Stroke Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018421-19,0,0,0 2010-018426-39,1,,,0,1,1,0,0,1,3,0,0,4,0,0,0,0,1,Amgen Inc.,"A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects with Immune Thrombocytopenia (ITP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018426-39,0,1,1 2010-018430-48,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo Español Multidisciplinar en cáncer Digestivo-GEMCAD,"Estudio de fase II para evaluar la eficacia y la seguridad de la quimiorradioterapia con 5-fluorouracilo, mitomicina C y panitumumab como tratamiento del carcinoma anal de células escamosas",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018430-48,0,0,0 2010-018431-18,9,2014-12-12,2014-12-12,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Biologics B.V.,"Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (infliximab) and Placebo in the Prevention of Recurrence in Crohn’s Disease Patients Undergoing Surgic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018431-18,0,0,0 2010-018431-18,9,2014-12-12,2014-12-12,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CENTOCOR,"Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (infliximab) and Placebo in the Prevention of Recurrence in Crohn’s Disease Patients Undergoing Surgic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018431-18,0,0,0 2010-018431-18,9,2014-12-12,2014-12-12,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Centocor BV,"Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (infliximab) and Placebo in the Prevention of Recurrence in Crohn’s Disease Patients Undergoing Surgic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018431-18,0,0,0 2010-018435-18,1,2012-09-03,2012-09-03,1,0,0,0,1,0,4,0,0,1,1,1,1,0,0,Papworth Hospital NHS Foundation Trust,"Assessing Platelet Inhibitory Response to Clopidogrel – Feasibility, Safety and Cost Analysis of a Tailored Platelet Inhibition Strategy for Elective PCI Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018435-18,0,0,0 2010-018436-41,3,2012-10-15,2012-10-19,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"Acute hemoDynamic effects of RIociguat (BAY 63-2521) in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE 1): A randomized, double-blind, placebo-controlled, single...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018436-41,0,0,0 2010-018437-21,10,2013-03-06,2013-03-06,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SANOFI AVENTIS GROUPE,"A 24-week, multicenter, international, randomized (1:1), parallel-group, open-label, comparative study of insulin glargine versus liraglutide in insulin-naïve patients with Type 2 diabetes treated wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018437-21,0,0,0 2010-018441-61,2,2011-06-10,2011-06-10,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Dr. Gerhard Mann chem.-pharm. Fabrik GmbH/ Bausch & Lomb Incorporated,"A Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Multicenter, Exploratory Study Assessing Safety and Efficacy of BOL-303242-X",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018441-61,0,0,0 2010-018447-34,1,2014-07-09,2014-07-09,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,Great Ormond Street Hospital for Children NHS Trust,Investigation of dendritic cell vaccine immunotherapy in paediatric high grade glioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018447-34,0,0,0 2010-018448-15,1,2011-10-03,2011-10-03,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Obstetrisk afd., Hvidovre Hospital","Effekten af præoperativ enkeltdosis methylprednisolon på det postoperative forløb efter abdominal hysterektomi: Et prospektivt, dobbeltblindet, placebo-kontrolleret studie.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018448-15,0,0,0 2010-018450-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Agneta Blanck Olerup,Optimising pain control after caesarean section - an evaluation if oxycodone can replace morphine and low potency opioids postoperatively.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018450-12,0,0,0 2010-018454-13,9,2010-10-15,2015-10-15,7,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Laboratoires SMB S.A.,"A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018454-13,0,0,0 2010-018454-13,9,2010-10-15,2015-10-15,7,1,0,0,0,1,3,0,0,1,1,1,1,0,1,LABORATOIRES SMB S.A.,"A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018454-13,0,0,0 2010-018456-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALI GALLIERA,Efficacia diagnostica della metodica 18F-DOPA-PET/TC nello studio del Neuroblastoma: confronto con scintigrafia 123I-MIBG.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018456-27,0,0,0 2010-018466-22,1,2018-05-14,2018-05-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leeds,ED95 doses of commonly used local anaesthetic agents for ultrasound guided brachial plexus blocks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018466-22,0,0,0 2010-018467-42,1,2019-01-31,2019-01-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Medical Center Hamburg-Eppendorf,Comparison between 5 – azacytidine treatment and 5 – azacytidine followed by allogeneic stem cell transplantation in elderly patients with advanced MDS according to donor availability Vergleich zwi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018467-42,0,0,0 2010-018471-26,2,2012-01-09,2012-01-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase II randomised, double-blind, placebo controlled, cross-over efficacy and safety comparison of three doses of tiotropium inhalation solution delivered via Respimat® inhaler (1.25, 2.5 and 5.0 μ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018471-26,0,0,0 2010-018471-26,2,2012-01-09,2012-01-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Phase II randomised, double-blind, placebo controlled, cross-over efficacy and safety comparison of three doses of tiotropium inhalation solution delivered via Respimat® inhaler (1.25, 2.5 and 5.0 μ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018471-26,0,0,0 2010-018476-24,4,2014-02-07,2014-02-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,A prospective double-blind randomized Phase III study of 300 mg vs. 150 mg erlotinib in current smokers with locally advanced or metastatic NSCLC in second-line setting after failure on chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018476-24,0,0,0 2010-018477-38,6,2011-07-18,2011-07-22,5,1,0,1,0,0,1,0,0,2,0,0,0,0,1,CSL Behring GmbH,"An Open-label, Multicenter, Dose-Escalation Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018477-38,1,0,0 2010-018477-38,6,2011-07-18,2011-07-22,5,1,0,1,0,0,1,0,0,2,0,0,0,0,1,CSL BEHRING GmbH,"An Open-label, Multicenter, Dose-Escalation Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018477-38,1,0,0 2010-018478-19,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo Español de Investigación en Cáncer de Ovario - GEICO,Ensayo fase II para evaluar la eficacia y seguridad de catumaxomab como tratamiento de consolidación en pacientes con un cáncer epitelial de ovario en una segunda o tercera remisión completa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018478-19,0,0,0 2010-018480-42,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,1,Baxter Innovations GmbH,"A RANDOMIZED, CONTROLLED, MULTICENTER PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FIBRIN SEALANT VH S/D 500 S-APR (TISSEEL) FOR HEMOSTASIS IN SUBJECTS UNDERGOING HEPATIC RESECTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018480-42,0,0,0 2010-018481-22,4,2010-07-12,2010-07-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind, placebo-controlled, parallel group, repeated-dose study to evaluate the efficacy, safety, tolerability and pharmacokinetics of three different dosing regimens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018481-22,0,0,0 2010-018485-24,5,2013-08-05,2013-10-16,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biotest AG,"A multi-center, double-blind, randomized, placebo-controlled, dose-finding study in patients with active rheumatoid arthritis incompletely controlled on stable MTX doses to investigate efficacy and sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018485-24,0,0,0 2010-018486-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Kris-och Traumacentrum,"Treatment of exacerbations of post-traumatic stress disorder by short-term dexamethasone, a pilot study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018486-37,0,0,0 2010-018487-16,2,2011-05-01,2011-07-04,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Laboratorios ViiV Healthcare SL,"Estudio de fase IIb para seleccionar una dosis oral diaria de GSK2248761 en combinación con tenofovir/emtricitabina o abacavir/lamivudina, en sujetos adultos infectados por el VIH-1 que no han recibid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018487-16,0,0,0 2010-018487-16,2,2011-05-01,2011-07-04,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ViiV Healthcare UK Ltd,"Estudio de fase IIb para seleccionar una dosis oral diaria de GSK2248761 en combinación con tenofovir/emtricitabina o abacavir/lamivudina, en sujetos adultos infectados por el VIH-1 que no han recibid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018487-16,0,0,0 2010-018490-38,1,2012-07-04,2012-07-04,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Anæstesiologisk Afd. I, Skejby Sygehus",Effekten af levosimendan på systolisk deformation og diastolisk funktion hos patienter med operationskrævende aortastenose og svær hypertrofi af venstre ventrikel,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018490-38,0,0,0 2010-018491-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Vrije Universiteit Medical Center,Effect of aminobisphosphonates and statins on circulating Vy9Vd2-T cells,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018491-24,0,0,0 2010-018494-37,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,HOVON Foundation,A randomized phase II study for evaluation of T cell depleted non myeloablative allogeneic stem cell transplantation followed by early consolidation with lenalidomide or lenalidomide combined with bor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018494-37,0,0,0 2010-018495-25,1,2011-02-07,2011-02-07,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Medicinsk Forskning,Effekten af atorvastatin på NO-systemet hos raske kontrol personer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018495-25,0,0,0 2010-018498-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Erasmus Medical Center,VItamin D treatment Effect on retinal nerve fiber loss after Optic neuritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018498-39,0,0,0 2010-018501-10,11,2017-10-20,2018-10-20,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A Phase III Randomized, Double blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018501-10,0,0,0 2010-018501-10,11,2017-10-20,2018-10-20,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"A Phase III Randomized, Double blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018501-10,0,0,0 2010-018506-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Mª Isabel Fernández García,"Ensayo clínico randomizado, de grupos paralelos para estudiar la eficacia y seguridad de diltiazem frente a nitroglicerina en pacientes con fisura anal.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018506-37,0,0,0 2010-018517-29,1,2011-09-07,2011-09-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical Faculty, Otto-von-Guericke-University Magdeburg",Topoproteome-Analysis of Psoriasis under Fumarate-Treatment.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018517-29,0,0,0 2010-018518-56,5,2014-09-01,2014-09-01,3,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Limited,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018518-56,0,0,0 2010-018519-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Rituximab-2cda + Rituximab maintenance in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018519-14,0,0,0 2010-018523-26,1,2013-04-30,2013-04-30,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,Immediate versus delayed treatment with Entecavir in patients with active chronic hepatitis B (CHB): impact on liver fibrosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018523-26,0,0,0 2010-018524-58,1,2013-01-18,2013-01-18,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,B. Braun Melsungen AG,Prospective controlled double-blind phase III bicentre study on the efficacy and safety of a balanced gelatine solution in combination with a balanced electrolyte solution versus a standard gelatine s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018524-58,0,0,0 2010-018529-21,1,2010-12-23,2010-12-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Karolinska Institutet, Institution CLINTEC, enheten för anestesi",Albuminkinetik vid generell inflammation en explorativ studie på patienter vid stor bukkirurgi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018529-21,0,0,0 2010-018531-17,1,2012-01-16,2012-01-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Central Manchester University Hospitals NHS Foundation Trust,"Effect of Tredaptive on serum lipoproteins, lipoproteins metabolism, oxidative stress and HDL antioxidant function.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018531-17,0,0,0 2010-018532-40,3,2011-07-19,2011-07-19,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ViiV Healthcare UK Ltd,A Phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018532-40,0,0,0 2010-018532-40,3,2011-07-19,2011-07-19,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Laboratorios ViiV Healthcare SL,A Phase 2b study to select a once daily oral dose of GSK2248761 in HIV-1 infected antiretroviral therapy experienced adults with non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018532-40,0,0,0 2010-018534-44,4,2012-12-05,2012-12-05,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Phytopharm plc,"A Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and tolerability of Cogane™ (PYM50028), a novel, orally active neurotro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018534-44,0,0,0 2010-018539-16,2,2018-10-31,2018-10-31,2,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Philipps-Universität Marburg,"A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib-maintenance therapy in Flt3-ITD positive AML in complete hematological remission after a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018539-16,0,0,0 2010-018543-34,1,2016-06-20,2016-06-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Orthopaedic Syrgery Unit Northern Jytland,NSAIDs INFLUENCE ON HEAL OF COLLES FRACTURE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018543-34,0,0,0 2010-018548-15,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,"Anestesicentrum, Sundsvalls Sjukhus, Landstinget Västernorrland",Spinal vs intercostal block for analgesia after open cholecystectomy - differences in postoperative pain? Spinalbedövning jämfört med interkostalbedövning för smärtlindring efter öppen gallkirurgi ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018548-15,0,0,0 2010-018553-35,1,2012-05-22,2012-05-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gambro Lundia AB,SMARTCIT - A NOVEL CITRATE BASED ANTICOAGULATION Smartcit - en ny citratbaserad antikoagulationsstrategi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018553-35,0,0,0 2010-018557-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Desensitisation of ulcerative colitis patients intolerant for mesalazine treatment.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018557-35,0,0,0 2010-018559-84,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Medizinische Fakultät der technischen Universität Muenchen,AMBITIOUS Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage Single- arm trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment in a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018559-84,0,0,0 2010-018560-16,1,2021-03-05,2021-03-05,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Ralentissement sévère de la croissance staturale chez les enfants avec anorexie mentale. Essai thérapeutique par l'hormone de croissance.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018560-16,0,0,0 2010-018562-23,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Laboratorios Leti, S.L.U.","A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients with Allergic Rhinitis and/or Rhinoconjunctivitis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018562-23,0,0,0 2010-018562-23,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,LETI Pharma GmbH,"A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients with Allergic Rhinitis and/or Rhinoconjunctivitis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018562-23,0,0,0 2010-018563-41,9,2015-05-15,2015-05-15,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Inc.,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FOUR 12-WEEK TREATMENT CYCLES (48 WEEKS TOTAL) OF EPRATUZUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018563-41,0,0,0 2010-018564-17,2,2011-04-13,2011-04-13,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Farmak International Holding GmbH,"A Phase II, multicenter, multinational, randomized, double-blinded, placebo-controlled dose-finding study to evaluate the efficacy and safety of carbabenzpyride in the treatment of uncomplicated influ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018564-17,0,0,0 2010-018565-26,5,2015-06-03,2015-06-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Inc.,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FOUR 12-WEEK TREATMENT CYCLES (48 WEEKS TOTAL) OF EPRATUZUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018565-26,0,0,0 2010-018566-23,6,2015-06-26,2015-06-26,4,1,0,0,0,0,3,0,0,1,1,0,1,0,0,European Organisation for Research and Treatment of Cancer,"Double blind randomized phase III study of maintenance Pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy. MAPPING, an EORTC Lung group study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018566-23,0,0,0 2010-018568-18,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Institut de Recerca de l'Hospital de la Santa Creu i Sant Paui,Ensayo clínico aleatorizado doble ciego y controlado con placebo para evaluar la eficacia y seguridad de la administración de agentes opioides como tratamiento preventivo del dolor asociado a los cuid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018568-18,0,0,0 2010-018579-12,10,2013-05-01,2013-06-24,6,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Shire Pharmaceutical Development ltd,"A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018579-12,1,0,0 2010-018579-12,10,2013-05-01,2013-06-24,6,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Shire Pharmaceutical Development Ltd,"A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018579-12,1,0,0 2010-018580-42,2,2011-07-14,2011-07-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Poxel,"Randomized, double-blind, placebo-controlled, parallel-group study of the safety and efficacy of imeglimin or placebo add-on therapy in type 2 diabetic subjects not adequately controlled by metformin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018580-42,0,0,0 2010-018581-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",CONSERVATIVE MANAGEMENT OF ENDOMETRIAL CANCER AND ATYPICAL HYPERPLASIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018581-23,0,0,0 2010-018583-17,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2010-2011, when Administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018583-17,0,0,0 2010-018584-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,LUMC,A phase II study of ARA290 as therapeutic strategy in no-option critical limb ischemia patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018584-41,0,0,0 2010-018585-23,1,2021-04-29,2021-04-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017",AG-013736 (axitinib) for the treatment of metastatic renal cell cancer (mRCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018585-23,0,0,0 2010-018586-39,1,2011-12-12,2011-12-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical Department M (Endocrinology & Diabetes),Diurnal variation of exogenous peptides,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018586-39,0,0,0 2010-018590-38,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,LUMC,The thrombogenicity of the dienogest/estradiol valerate containing oral contraceptive (Qlaira),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018590-38,0,0,0 2010-018592-16,1,2014-07-22,2014-07-22,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,COPSAC,"Antibiotics as a treatment of repeated asthmatic symptoms in children. A randomized, controlled study within the ABC-cohort (Asthma Begins in Childhood)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018592-16,0,0,0 2010-018594-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,European Myeloma Network,European Myeloma Network sequential phase I / phase II trial on RIC allogeneic transplantation: an optimized program for high risk relapsed patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018594-37,0,0,0 2010-018596-24,1,,,0,1,0,0,0,1,4,0,1,3,0,0,0,0,0,Oxford Radcliffe Hospital NHS Trust,Assessment of Salmonella Typhim Vi(TM) vaccine (Sanofi Pasteur MSD) for the investigation of selective antibody deficiency to polysaccharide.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018596-24,0,0,0 2010-018597-20,3,2011-02-08,2011-03-08,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multi-center, randomized, double-blind, placebo- controlled, two-period cross-over study to assess the effect of 50µg inhaled NVA237 on exercise endurance in patients with moderate to severe COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018597-20,0,0,0 2010-018597-20,3,2011-02-08,2011-03-08,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A multi-center, randomized, double-blind, placebo- controlled, two-period cross-over study to assess the effect of 50µg inhaled NVA237 on exercise endurance in patients with moderate to severe COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018597-20,0,0,0 2010-018597-20,3,2011-02-08,2011-03-08,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind, placebo- controlled, two-period cross-over study to assess the effect of 50µg inhaled NVA237 on exercise endurance in patients with moderate to severe COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018597-20,0,0,0 2010-018600-87,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA` DI NOVARA,POST-OPERATIVE PAIN CONTROL OF PEDIATRIC PATIENTS UNDERWENT ORTHOPEDIC SURGERY: COMPARISON OF INTRAVENOUS ANALGESIA AND ONE-SHOT EPIDURAL LUMBAR NERVE BLOCK.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018600-87,0,0,0 2010-018603-29,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, Adjuvanted with MF59C.1 Influenza Vaccine, Formulation 2010-2011, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018603-29,0,0,0 2010-018604-85,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Lund University,Randomized study of yohimbine treatment for type 2 diabetes patients carrying a specific genetic risk variant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018604-85,0,0,0 2010-018604-85,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region Skåne,Randomized study of yohimbine treatment for type 2 diabetes patients carrying a specific genetic risk variant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018604-85,0,0,0 2010-018608-98,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,AstraZeneca AB,"A double-blind, randomized, placebo-controlled, two-centre, phase IIa pharmacodynamic cross-over study to assess the effect of AZD2516 on the total number of reflux episodes in healthy male volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018608-98,0,0,0 2010-018611-15,1,2013-02-28,2013-02-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Abertawe Bro Morgannwg University LHB,A study to compare the effectiveness and morbidity of Alkalinized Intravesical Lidocaine Vs Lidocaine gel in achieving anaesthesia prior to intravesical Botulinum Toxin (BTX) injections,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018611-15,0,0,0 2010-018614-70,9,2016-06-06,2016-06-06,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca AB,"An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA?) as First line Treatment in Caucasian Patients, who have Epidermal Growt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018614-70,0,0,0 2010-018614-70,9,2016-06-06,2016-06-06,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ASTRAZENECA,"An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA?) as First line Treatment in Caucasian Patients, who have Epidermal Growt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018614-70,0,0,0 2010-018619-14,1,2010-11-05,2010-11-05,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,ikfe GmbH,Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018619-14,0,0,0 2010-018621-19,9,2013-06-25,2013-06-25,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-Abelló A/S,Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018621-19,0,0,0 2010-018621-19,9,2013-06-25,2013-06-25,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-Abello A/S,Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018621-19,0,0,0 2010-018624-20,1,2011-01-17,2011-01-17,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University Medical Center Freiburg,Tolerance of virucidal alcohol-based hand rubs - healthy volunteer trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018624-20,0,0,0 2010-018627-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA MEYER,PHARMACOLOGY STUDY FOR EFFICACY OF TOPIRAMATE ASSOCIATED WITH HYPOTHERIMIA TREATMENT IN NEWBORNS WITH HYPOXIC ISCHEMIC ENCEPHALOPATY: A PILOT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018627-25,0,0,0 2010-018628-14,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University Ghent,Pharmacokinetic evaluation of moxifloxacin administered intravenously and orally in healthy volunteers who have had a gastric bypass.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018628-14,0,0,0 2010-018630-52,2,2011-10-11,2011-10-11,2,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Intercell AG,"AN OPEN-LABEL, UNCONTROLLED PHASE 4 STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF THE JAPANESE ENCEPHALITIS (JE) VACCINE IXIARO® (IC51) IN AN ELDERLY POPULATION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018630-52,0,0,0 2010-018637-21,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Universitätsklinikum Schleswig-Holstein UKSH,Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018637-21,0,0,0 2010-018638-29,1,2016-03-01,2016-03-01,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Centre du Cancer des Cliniques Universitaires Saint-Luc,"Phase I/II study of peptide vaccination associated with GM-CT-01, a galactomannan oligomer that inhibits galestin-3, in patients with advanced metastatic melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018638-29,0,0,0 2010-018639-17,1,2012-08-31,2012-08-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Erlangen,Prospective and open label study with blind end point evaluation on the effect of mineralcorticoid receptor inhibition on endothelial function of the micro- and macrovasculature in patient with metabo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018639-17,0,0,0 2010-018640-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,GUNA S.P.A.,"""Evaluation of Clinical Immunology of a long-term treatment with Physiological Regulating Medicine in a Pediatric Population suffering from chronic atopic dermatitis. Experimental study randomized dou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018640-13,0,0,0 2010-018644-14,4,2012-11-06,2012-11-06,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Octapharma AG,"PROSPECTIVE CLINICAL STUDY IN CHILDREN WITH SEVERE HAEMOPHILIA A TO INVESTIGATE CLINICAL EFFICACY, IMMUNOGENICITY, PHARMACOKINETICS, AND SAFETY OF HUMAN-CL RHFVIII",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018644-14,0,0,0 2010-018646-31,9,2012-07-10,2012-07-10,8,1,0,0,0,0,3,2,0,1,0,0,1,0,1,"CELLTRION, Inc","A Randomized, Double Blind, Parallel-Group, Phase 3 Study to Demonstrate Equivalence in Efficacy and Safety of CT-P13 Compared With Remicade When Co-administered With Methotrexate in Patients With Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018646-31,0,0,0 2010-018650-12,1,2015-11-06,2015-11-06,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Toulouse,Evaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient Parkinsonien,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018650-12,0,0,0 2010-018658-12,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación Rafael Clavijo,Efecto del anticuerpo monoclonal anti-IL6 (tocilizumab) en el riesgo cardiovascular de los pacientes con artritis reumatoide.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018658-12,0,0,0 2010-018660-16,1,2012-02-03,2012-02-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospitals of leicester NHS Trust,Randomised controlled trial on the effects of parenteral fish oil emulsion in patients with severe acute pancreatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018660-16,0,0,0 2010-018661-35,22,2016-04-07,2016-04-07,20,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018661-35,0,0,0 2010-018662-23,18,2016-02-29,2016-02-29,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK 700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018662-23,0,0,0 2010-018663-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,BRACCO,"Substitutive therapy of hypothyroid patients with L-thyroxine (T4) plus T3 sulfate (T3S). A Phase II, open-label, single centre, parallel group study on therapeutic efficacy and tolerability",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018663-42,0,0,0 2010-018664-16,4,2011-12-07,2011-12-07,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Double-Blind, Randomized, Crossover Trial of CSII Reservoir In-use Comparing Insulin Lispro Formulation to Insulin Aspart in Patients with Type 1 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018664-16,0,0,0 2010-018665-30,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Martin-Luther University Halle-Wittenberg,COMFORT-study Comparison of Olanzapin and Metoclopramide For treatment Of bReakThrough emesis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018665-30,0,0,0 2010-018668-18,2,2011-08-10,2011-08-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE BRONCHODILATOR EFFICACY AND SAFETY AFTER SINGLE AND REPEATED ADMINISTRATIONS OF DIFFERENT DOSES OF GLYCOPYRROLATE VIA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018668-18,0,0,0 2010-018671-20,1,2015-04-30,2015-04-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Forest Research Institute Inc., a wholly owned subsidiary of Forest Laboratories, LLC","A Double-Blind, Placebo-Controlled Trial of Asenapine in the Prevention of Recurrence of a Mood Episode After Stabilization of an Acute Manic/Mixed Episode in Subjects With Bipolar 1 Disorder (Phase 3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018671-20,0,0,0 2010-018673-37,1,2017-04-12,2017-04-12,1,1,0,0,0,0,4,0,0,1,1,1,1,0,3,University of Nottingham,The use of Ranibizumab (Lucentis ®) for the treatment of corneal neovascularisation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018673-37,0,0,0 2010-018674-20,7,2014-10-27,2014-12-18,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination with Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018674-20,0,0,0 2010-018684-42,3,2012-11-27,2012-11-27,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sunovion Pharmaceuticals Inc.,"Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drug...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018684-42,0,0,0 2010-018684-42,3,2012-11-27,2012-11-27,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sunovion Pharmaceuticals Inc,"Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drug...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018684-42,0,0,0 2010-018686-36,1,2011-03-02,2011-03-02,1,0,0,0,1,0,3,0,1,1,0,0,1,0,1,Madaus GmbH,"Agio-Prep 3g versus Agio-Prep 6g versus Moviprep® - a prospective, randomised, controlled evaluation of bowel cleansing for colonoscopy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018686-36,0,0,0 2010-018688-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,A.U.S.L. RIMINI,A randomized blinded study for the use of foley catheter plus placebo versus foley catheter plus misoprostol in the induction of labor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018688-40,0,0,0 2010-018693-20,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SAN GERARDO DI MONZA,"Do peritoneal nebulization of Ropivacaine reduce the use of morphine after short gynecologic laparoscopic surgery? A multicentre, randomized, controlled, double blinded, phase III clinical trial; com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018693-20,0,0,0 2010-018695-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ADRFARCP,Etude prospective de la prescripion d'anidulafungine pour infections intra-abdominales graves hospitalisées en réanimation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018695-25,0,0,0 2010-018696-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU DIJON,Etude de l’évolution de la réponse immunitaire Th17 chez des patients atteints de polyarthrite rhumatoïde et traités par tocilizumab après échec des autres thérapies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018696-21,0,0,0 2010-018699-26,1,2020-06-19,2020-06-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Goethe Universität Frankfurt,Phase I/II study with oral panobinostat maintenance therapy following allogeneic stem cell transplantation in patients with high risk MDS or AML (PANOBEST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018699-26,0,0,0 2010-018700-90,1,2011-08-16,2011-08-16,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Vejle Hospital,En fase II undersøgelse af pemetrexed og gemcitabin til behandlingsresistente patienter med KRAS muteret metastaserende colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018700-90,0,0,0 2010-018705-11,5,2015-01-30,2015-01-30,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"ONO Pharmaceutical Co., Ltd.",A SAFETY AND EFFICACY EXTENSION STUDY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018705-11,0,0,0 2010-018705-11,5,2015-01-30,2015-01-30,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck KGaA,A SAFETY AND EFFICACY EXTENSION STUDY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018705-11,0,0,0 2010-018705-11,5,2015-01-30,2015-01-30,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Serono S.A. - Geneva,A SAFETY AND EFFICACY EXTENSION STUDY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018705-11,0,0,0 2010-018708-99,3,2013-07-08,2013-07-08,3,1,0,0,0,0,2,0,2,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An open-label, phase II study to determine acute (after the first dose administration) and chronic (after 28 days of treatment) effects of the sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018708-99,0,0,0 2010-018708-99,3,2013-07-08,2013-07-08,3,1,0,0,0,0,2,0,2,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"An open-label, phase II study to determine acute (after the first dose administration) and chronic (after 28 days of treatment) effects of the sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018708-99,0,0,0 2010-018708-99,3,2013-07-08,2013-07-08,3,1,0,0,0,0,2,0,2,1,0,0,1,0,1,BOEHRINGER ING.,"An open-label, phase II study to determine acute (after the first dose administration) and chronic (after 28 days of treatment) effects of the sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018708-99,0,0,0 2010-018709-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Optimizing Susceptibility to CCR5 Antagonist Response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018709-12,0,0,0 2010-018712-32,1,2010-09-30,2010-09-30,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Oriel Therapeutics Inc,A Pilot Pharmacodynamic/Pharmacokinetic Study of SalmeterolXinofoate as a Dry Powder in Combination with Fluticasone in Patients with Asthma for Dose-Scale Bronchodilator Model Development.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018712-32,0,0,0 2010-018714-73,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,GE Healthcare Ltd. and its Affiliates,"A Principal, Open-Label, Single Center Study to Validate the Detection of Cerebral Cortical Amyloid with Flutemetamol (18F) Injection in Subjects Previously Biopsied",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018714-73,0,0,0 2010-018715-15,1,2011-01-19,2011-01-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GE Healthcare Ltd. and its Affiliates,"A principal, prospective, open-label biopsy study to validate detection of cerebral cortical amyloid with Flutemetamol (18F) Injection in NPH subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018715-15,0,0,0 2010-018716-33,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,CHRU de TOURS,Etude de l'efficacité du méthotrexate en adjonction d'un anti-histaminique H1 dans le traitement de l'urticaire chronique idiopathique sévère réfractaire aux anti-H1 seuls : essai randomisé.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018716-33,0,0,0 2010-018718-57,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA UNITA` SANITARIA LOCALE N 12 DI VIAREGGIO,Role of on-line hemodiafiltration (HDF) in the modulation of resistance to erythropoiesis stimulating agents (REDERT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018718-57,0,0,0 2010-018720-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Swedish Pituitary Study group,Behandling med kabergolin hos patienter med ACTH-beroende Cushing´s syndrom (treatment with cabergoline in patients with ACTH-dependent Cushing´s syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018720-12,0,0,0 2010-018723-26,4,2013-02-15,2013-05-22,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"An open label, non-comparative, pharmacokinetic and pharmacodynamic study to evaluate the effect of Dabigatran Etexilate on coagulation parameters including a calibrated thrombin time test in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018723-26,0,0,0 2010-018723-26,4,2013-02-15,2013-05-22,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"An open label, non-comparative, pharmacokinetic and pharmacodynamic study to evaluate the effect of Dabigatran Etexilate on coagulation parameters including a calibrated thrombin time test in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018723-26,0,0,0 2010-018723-26,4,2013-02-15,2013-05-22,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"An open label, non-comparative, pharmacokinetic and pharmacodynamic study to evaluate the effect of Dabigatran Etexilate on coagulation parameters including a calibrated thrombin time test in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018723-26,0,0,0 2010-018724-16,1,2012-12-10,2012-12-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group),"A prospective, open-label, pilot-study of azithromycin for lymphocytic bronchi(oli)tis after lung transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018724-16,0,0,0 2010-018730-51,2,2014-05-17,2014-05-17,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, open, multi-centre, controlled study to assess the long-term persistence of antibodies after a single dose of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroup ACWY tetanus-toxo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018730-51,0,0,0 2010-018735-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AMW GmbH,"An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (AMW Goserelin 10.8 mg Implant) applied eve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018735-18,0,0,0 2010-018737-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA MEYER,Safety and efficacy of treatment with propranolol in newborns suffering from rethinopathy of the preterm: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018737-21,0,0,0 2010-018738-27,1,2010-12-29,2010-12-29,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients with Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018738-27,0,0,0 2010-018739-17,4,2011-11-04,2011-11-29,2,1,0,0,0,2,2,0,0,1,1,0,1,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.","A Randomized, Placebo-controlled, Double-blind Phase 2 Study of Second-line Treatment with OSI-906 in Patients with Advanced Hepatocellular Carcinoma (HCC) after Failure of First-line Treatment with S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018739-17,0,0,0 2010-018739-17,4,2011-11-04,2011-11-29,2,1,0,0,0,2,2,0,0,1,1,0,1,0,1,"OSI Pharmaceuticals, Inc.","A Randomized, Placebo-controlled, Double-blind Phase 2 Study of Second-line Treatment with OSI-906 in Patients with Advanced Hepatocellular Carcinoma (HCC) after Failure of First-line Treatment with S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018739-17,0,0,0 2010-018739-17,4,2011-11-04,2011-11-29,2,1,0,0,0,2,2,0,0,1,1,0,1,0,1,"Astellas Pharma Global Development, Inc.","A Randomized, Placebo-controlled, Double-blind Phase 2 Study of Second-line Treatment with OSI-906 in Patients with Advanced Hepatocellular Carcinoma (HCC) after Failure of First-line Treatment with S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018739-17,0,0,0 2010-018740-13,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University Medical Center Groningen,Short- and long-term effects of oxytocin on empathy and social behaviour in autistic and antisocial male adults.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018740-13,0,0,0 2010-018741-65,8,2012-01-17,2012-01-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,OPHTHOTECH CORPORATION,"A PHASE 2, RANDOMIZED, DOUBLE-MASKED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREOUS INJECTIONS OF E10030 (ANTI-PDGF PEGYLATED APTAMER) GIVEN IN COMBINATION WITH LUCENTIS® IN S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018741-65,0,0,0 2010-018751-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Clermont-Ferrand,Analgésie opiacée per-opératoire en chirurgie ambulatoire : comparaison sufentanil-rémifentanil en chirurgie pour avulsions des dents de sagesse.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018751-10,0,0,0 2010-018752-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud University Nijmegen Medical Centre,Pharmacokinetics of anidulafungin (Ecalta ®) given intravenously as antifungal prophylaxis to recipients of an allogeneic haematopoietic stem cell transplant following myeloablative chemotherapy or pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018752-27,0,0,0 2010-018754-13,1,2019-05-15,2019-05-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Krankenhaus Nordwest GmbH,"A randomized multicenter Phase II/III Study comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) versus Epirubicin, Cisplatin and 5-FU (ECF) in patients with locally advanced resectable adeno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018754-13,0,0,0 2010-018759-82,1,2013-02-28,2013-02-28,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Eli Lilly and Company,The Effect of Postprandial Hyperglycemia on Arterial Stiffness in Patients with Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018759-82,0,0,0 2010-018761-35,1,2011-12-15,2011-12-15,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,Lipid Pharmaceuticals ehf,Lýsi sem hægðalyf,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018761-35,0,0,0 2010-018761-35,1,2011-12-15,2011-12-15,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,Lýsi hf,Lýsi sem hægðalyf,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018761-35,0,0,0 2010-018762-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA UNITA` SANITARIA LOCALE N 12 DI VIAREGGIO,METRONOMIC ORAL VINORELBINE IN ADVANCED (STAGE IIIB-IV) NON-SMALL CELL LUNG CANCER PATIENTS: A PHASE II TRIAL (MOVE Trial � ASL1209/001),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018762-23,0,0,0 2010-018763-42,1,2012-09-20,2012-09-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Dundee,Do Phosphodiesterase 5 Inhibitors Improve Exercise Capacity in COPD Patients with Pulmonary Hypertension?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018763-42,0,0,0 2010-018766-23,6,2010-11-08,2011-01-31,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"Estudio aleatorizado, a doble ciego, controlado con placebo, exploratorio, con ajuste de dosis, de 12 semanas de seguimiento para evaluar la actividad antiepiléptica de BGG492 administrado por vía or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018766-23,0,0,0 2010-018766-23,6,2010-11-08,2011-01-31,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A,"Estudio aleatorizado, a doble ciego, controlado con placebo, exploratorio, con ajuste de dosis, de 12 semanas de seguimiento para evaluar la actividad antiepiléptica de BGG492 administrado por vía or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018766-23,0,0,0 2010-018767-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,The use of Contrast Enhanced Transesophageal Echocardiography in thoracic endovascular aortic repair (TEVAR). Feasibility and safety of a new tool for intraoperative monitoring and follow up.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018767-42,0,0,0 2010-018768-18,1,2018-01-25,2018-01-25,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,AOP Orphan Pharmaceuticals AG,"An open-label, prospective, multicentre, phase I/II dose escalation study to determine the maximum tolerated dose and to assess the safety and efficacy of P1101, PEG-Proline-Interferon alpha-2b for pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018768-18,0,0,0 2010-018770-20,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Oslo University Hospital,"Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018770-20,0,0,0 2010-018771-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA ""S. CROCE E CARLE""",Therapy of patency of ductus arteriosus (PDA) in very low birth weight (VLBW)preterm infants: oral ibuprofen versus intravenous ibuprofen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018771-23,0,0,0 2010-018774-21,5,2012-11-09,2014-05-15,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA,OLMESARTAN +AMLOIPINE TREATMENT IN DIABETIC PATIENTS: EVALUATING BLOOD PRESSURE CONTROL AFTER 48 HOURS FROM THE LAST ADMINISTRATION (MISSED DOSE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018774-21,0,0,0 2010-018774-21,5,2012-11-09,2014-05-15,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.,OLMESARTAN +AMLOIPINE TREATMENT IN DIABETIC PATIENTS: EVALUATING BLOOD PRESSURE CONTROL AFTER 48 HOURS FROM THE LAST ADMINISTRATION (MISSED DOSE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018774-21,0,0,0 2010-018775-17,9,2012-03-09,2012-03-31,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline,DEFEND 2: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018775-17,0,0,0 2010-018775-17,9,2012-03-09,2012-03-31,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Tolerx, Inc.",DEFEND 2: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018775-17,0,0,0 2010-018776-24,1,2012-08-09,2012-08-09,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust,Proof of mechanism study of an oral hedgehog inhibitor (GDC-0449) in patients with resectable pancreatic ductal adenocarcinoma in the pre-operative window period.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018776-24,0,0,0 2010-018780-42,6,2016-12-19,2017-01-19,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Releapsed After Rituximab-Containing Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018780-42,0,0,0 2010-018780-42,6,2016-12-19,2017-01-19,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Releapsed After Rituximab-Containing Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018780-42,0,0,0 2010-018780-42,6,2016-12-19,2017-01-19,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Releapsed After Rituximab-Containing Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018780-42,0,0,0 2010-018781-23,1,,,0,0,0,0,1,0,0,0,0,4,0,0,0,0,1,Top Institute Food and Nutrition,Diagnose of GH-deficiency: comparing the dietary-protein test with conventional Growth Hormone Stimulation Tests,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018781-23,0,0,0 2010-018786-33,1,2011-01-04,2011-01-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bionorica SE,"A randomized, double-blind, placebo-controlled, cross-over phase IIa/b study to assess the efficacy and safety of 2 dosages of a herbal medicinal product (dry extract BNO-1355) in patients with season...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018786-33,0,0,0 2010-018791-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Kliniken der Stadt Koeln gGmbH, Klinikum Merheim","Single-center, single-armed, open-label, prospective study assessing efficacy and safety of a conversion of stable kidney allograft recipients to an Everolimus-based regimen to prevent the development...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018791-24,0,0,0 2010-018792-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Kliniken der Stadt Koeln gGmbH, Klinikum Merheim","Single-center, single-armed, open-label, prospective study assessing efficacy and safety of a conversion of kidney allograft recipients suffering from Chronic Allograft Nephropathy (CAN) assessed by ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018792-17,0,0,0 2010-018793-21,2,2012-01-13,2012-01-13,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Celtic Pharma Development Services Bermuda Limited,"A Randomized, Double-blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients with Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability, and S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018793-21,0,0,0 2010-018794-38,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO,EVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018794-38,0,0,0 2010-018795-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Alliance pour la recherche en cancérologie,Evaluation of the effect of pasireotide LAR administration in the lymphocele prevention after axillary node dissection for breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018795-24,0,0,0 2010-018796-21,4,2011-07-12,2011-07-12,4,1,0,0,0,0,3,0,0,1,1,1,1,0,2,OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALISATION INC,"A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018796-21,0,0,0 2010-018796-21,4,2011-07-12,2011-07-12,4,1,0,0,0,0,3,0,0,1,1,1,1,0,2,"Otsuka Pharmaceutical Development & Commercialization, Inc","A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018796-21,0,0,0 2010-018798-39,1,2014-03-28,2014-03-28,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Abteilung für Endokrinologie","Correction of vitamin D deficiency in critically ill patients: a randomized, doulbe-blind, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018798-39,0,0,0 2010-018837-23,1,2011-08-09,2011-08-09,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cardiff University,A randomised Phase II study of carboplatin with or without the addition of the ETAR inhibitor ZD4054 as treatment for patients with metastatic breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018837-23,0,0,0 2010-018838-45,1,2010-11-05,2010-11-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Relypsa, Inc.","A Multicenter, Open-Label, Single-Arm Study to Evaluate a Titration Regimen for RLY5016 in Heart Failure Patients with Chronic Kidney Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018838-45,0,0,0 2010-018849-59,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH,A randomized phase II trial of standard carboplatin-based chemotherapy with or without panitumumab in platinum-sensitive recurrent ovarian cancer Eine randomisierte Phase II-Studie zu einer Stan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018849-59,0,0,0 2010-018850-11,1,2015-12-15,2015-12-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Hochschule Hannover (MHH),Panitumumab in combination with cisplatin/gemcitabine chemotherapy in patients with cholangiocarcinomas - a randomized clinical phase II study - PiCCA Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018850-11,0,0,0 2010-018851-88,2,2016-05-09,2016-05-09,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,MOLMED,NGR016: Randomized phase II study evaluating two doses of NGR-hTNF administered either as single agent or in combination with doxorubicin in patients with advanced soft-tissue sarcoma (STS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018851-88,0,0,0 2010-018852-29,1,2011-05-20,2011-05-20,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Novartis Pharma GmbH,"A 12-month, two-armed, randomized, double-masked, multicenter, Phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to Ranibizumab intravitreal injections vs. las...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018852-29,0,0,0 2010-018853-36,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,0,Prof. Stefano Gandolfi-Universita` degli studi di Parma,"Switching from beta blocker monotherapy to either ganfort � or cosopt �. A three months, single-blind , parallel group, randomized clinical trial in ocular hypertension/primary open angle glaucoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018853-36,0,0,0 2010-018858-12,3,2011-07-12,2011-09-13,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc","A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018858-12,0,0,0 2010-018859-97,4,2011-07-12,2011-09-01,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc","A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018859-97,0,0,0 2010-018860-17,9,2011-07-12,2011-07-12,7,1,0,0,0,0,3,0,0,1,1,0,1,0,2,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Multicenter, 52-week, Open-label Study to Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018860-17,0,0,0 2010-018860-17,9,2011-07-12,2011-07-12,7,1,0,0,0,0,3,0,0,1,1,0,1,0,2,OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALISATION INC,"A Multicenter, 52-week, Open-label Study to Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018860-17,0,0,0 2010-018861-53,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,Efficacy and safety of the calcimimetic Cinacalcet in the management of patients with Primary Hyperparathyroidism due to a MEN-1 mutation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018861-53,0,0,0 2010-018862-22,1,2012-01-05,2012-01-05,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,Kliniken Essen-Mitte,Exploratory study to evaluate different MRI-contrast-agent-application-schemes using Gadovist to optimize contrast enhancement for longer lasting breast examination,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018862-22,0,0,0 2010-018863-40,7,2013-05-14,2013-05-14,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"An interaction study to evaluate changes in blood pressure following 1, 1.5, 2, and 2.5 mg riociguat tid (dose titration) compared to placebo treatment on the background of stable sildenafil pretreatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018863-40,0,0,0 2010-018863-40,7,2013-05-14,2013-05-14,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Bayer Health Care AG,"An interaction study to evaluate changes in blood pressure following 1, 1.5, 2, and 2.5 mg riociguat tid (dose titration) compared to placebo treatment on the background of stable sildenafil pretreatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018863-40,0,0,0 2010-018866-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"A.I.L. (ASSOCIAZIONE ITALIANA CONTRO LE LEUCEMIE, LINFOMI E MIELOMI",Intensified program including Bendamustine followed by PBSC mobilization and high dose therapy and autograft for patients with relapsed or resistant CD 20+ Follicular Non Hodgkin Lymphoma: a multicen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018866-21,0,0,0 2010-018869-29,4,2012-04-17,2013-10-04,4,1,0,0,0,2,2,0,0,1,0,0,1,0,0,Centre Leon-Berard,PHASE II STUDY OF NILOTINIB EFFICACY IN PIGMENTED VILLO-NODULAR SYNOVITIS/ TENOSYNOVIAL GIANT CELL TUMOUR (PVNS/TGCT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018869-29,0,0,0 2010-018869-29,4,2012-04-17,2013-10-04,4,1,0,0,0,2,2,0,0,1,0,0,1,0,0,CENTRE LEON BERARD,PHASE II STUDY OF NILOTINIB EFFICACY IN PIGMENTED VILLO-NODULAR SYNOVITIS/ TENOSYNOVIAL GIANT CELL TUMOUR (PVNS/TGCT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018869-29,0,0,0 2010-018869-29,4,2012-04-17,2013-10-04,4,1,0,0,0,2,2,0,0,1,0,0,1,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,PHASE II STUDY OF NILOTINIB EFFICACY IN PIGMENTED VILLO-NODULAR SYNOVITIS/ TENOSYNOVIAL GIANT CELL TUMOUR (PVNS/TGCT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018869-29,0,0,0 2010-018870-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,randomized study for hcv recurrence treatment in liver transplant patients with ribavirin pre-treatment for 8 weeks follwed by stadard therapy (48 weeks) with interferon pegylated and ribavirin vs sta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018870-19,0,0,0 2010-018873-39,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Dutch-Belgian Cooperative Trial Group for Hematology Oncology,A multicenter phase II study of subcutaneous Velcade plus oral Melphalna and Prednisone or plus Oral cyclophosphamide and Prednisone or plus Prednisone in newly diagnosed elderly multiple myeloma pati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018873-39,0,0,0 2010-018874-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Siemens Molecular Imaging,"A phase II, open label, non-randomized, multi-center, pilot, efficacy study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a tool to monitor response to an anti-angiogenic drug.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018874-19,0,0,0 2010-018875-30,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,CHU de Nantes,Comparaison de l’effet antisécrétoire d’une dose unique de rabeprazole 20 mg et d’omeprazole 20 mg chez des sujets obèses,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018875-30,0,0,0 2010-018878-21,1,2013-05-13,2013-05-13,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,St Stephen's AIDS Trust,"A phase III, open-label, single centre, single-arm, pilot study to assess the feasibility of switching, individuals receiving efavirenz with continuing Central Nervous System (CNS) toxicity, to ralteg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018878-21,0,0,0 2010-018880-41,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,EFFECTS OF LOSARTAN ON AORTIC ROOT AND ASCENDING AORTA REMODELING IN PATIENTS WITH BICUSPID AORTIC VALVE.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018880-41,0,0,0 2010-018892-20,1,2014-09-30,2014-09-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Herz- & Diabeteszentrum NRW,Pathophysiologie der Cheyne-Stokes Atmung: Senkung des pulmonalkapillären Wedge-Drucks als kausaler Therapieansatz,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018892-20,0,0,0 2010-018893-19,4,2013-03-11,2013-03-11,2,0,0,0,0,1,3,0,0,1,1,1,1,0,1,"AOI Pharmaceuticals, Inc.",A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018893-19,0,0,0 2010-018893-19,4,2013-03-11,2013-03-11,2,0,0,0,0,1,3,0,0,1,1,1,1,0,1,Aeterna Zentaris GmbH,A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018893-19,0,0,0 2010-018898-37,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC),Estudio de fase II de la combinación de panitumumab con paclitaxel como tratamiento de primera línea de sujetos con cáncer de cabeza y cuello recurrente o metastásico,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018898-37,0,0,0 2010-018900-10,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Laboratoires Mayoly Spindler,Safety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018900-10,0,0,0 2010-018901-12,1,2014-01-27,2014-01-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical University Graz, Department of Internal Medicine, Div. Endocrinology and Metabolism","Placebo controlled study on effects of vitamin D supplementation in type 1 diabetic subjects on immunological, endocrine and metabolic parameters: Step 2 of the Austrian Diabetes Prevention Programme ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018901-12,0,0,0 2010-018902-35,1,2010-11-02,2010-11-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Targacept Inc,"A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Proof of Principle Study to Evaluate the Safety, Tolerability, and Efficacy of TC-6499-12 in the Treatment of Constipation Predominant I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018902-35,0,0,0 2010-018904-94,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE,EFFICACY AND SAFETY OF INTRAMUSCULAR NERIDRONATE IN OSTEOPOROTIC PATIENTS AFFECTED BY PARKINSON'S DISEASE EFFICACIA E SICUREZZA DEL NERIDRONATO INTRAMUSCOLARE NEL TRATTAMENTO DELL OSTEOPORO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018904-94,0,0,0 2010-018911-13,3,2014-04-25,2014-07-09,3,1,1,0,0,1,3,0,0,1,1,1,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Long-term, Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Flexible-Dose Oral Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patients with Schizophrenia or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018911-13,0,0,0 2010-018913-32,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"A controlled extension study of CACZ885H2357 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018913-32,0,0,0 2010-018917-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medical Center,A SINGLE-CENTER PHARMACOGENETIC STUDY OF DONOR AND RECIPIENT TO IMPROVE THE EFFICACY AND REDUCE THE NEPHROTOXICITY OF TACROLIMUS AFTER KIDNEY TRANSPLANTATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018917-30,0,0,0 2010-018919-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ThromboGenics NV,"An Open-Label, Ascending- Exposure-Time, Single Center Trial to Evaluate the Pharmacokinetic Properties of Ocriplasmin (Generic Name of the Molecule Microplasmin) Intravitreal Injection in Subjects Sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018919-16,0,0,0 2010-018920-21,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Landstinget i Östergötland,Evaluation of a Structured Algorithm for Intrathecal Bolus Doses of Ziconotide(Prialt®) - The Swedish Ziconotide Bolus Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018920-21,0,0,0 2010-018937-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medisch Spectrum Twente,The predictive value of the acute effect of beclomethasone on a mannitol challenge test for the outcome of lomgterm treatment with beclomethasone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018937-23,0,0,0 2010-018940-15,1,2013-11-28,2013-11-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SALUS Haus GmbH & Co. KG,"A Phase IV, multi-centre, randomized, open label study to investigate the efficacy and safety of Floradix® mit Eisen and ferro sanol® duodenal mite 50 mg in pregnant women with diagnosed iron deficien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018940-15,0,0,0 2010-018945-72,3,2013-07-30,2013-07-30,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F.Hoffmann-La Roche,"A randomized, multicenter, open-label phase Ib/II study of RO5083945 in combination with cisplatin and gemcitabine/pemetrexed versus cisplatin and gemcitabine/pemetrexed in patients with advanced or r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018945-72,0,0,0 2010-018947-33,2,2011-09-25,2011-12-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A MULTICENTER, MULTINATIONAL, SINGLE-DOSE, OPEN LABEL, RANDOMIZED, 2-WAY CROSSOVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 100/6 NEXT DPI® (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100 µg PLU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018947-33,0,0,0 2010-018948-14,1,2016-08-02,2016-08-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Dose-Ranging And Efficacy Study of LY2439821 (an Anti-IL-17 Antibody) in Patients With Moderate-To-Severe Psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018948-14,0,0,0 2010-018960-17,3,2017-02-28,2017-02-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"""Estudio de fase II, abierto, aleatorizado para evaluar la eficacia y seguridad de paclitaxel administrado semanalmente como agente único y dos regímenes diferentes de SAR240550 (BSI-201), un inhibido...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018960-17,0,0,0 2010-018961-50,9,2011-11-09,2011-11-16,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"AMAG Pharmaceuticals, Inc.","A Phase III, Randomized, Open-label, Active-Controlled Trial Comparing Ferumoxytol with Iron Sucrose for the Treatment of Iron Deficiency Anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018961-50,0,0,0 2010-018961-50,9,2011-11-09,2011-11-16,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"AMAG PHARMACEUTICALS, INC","A Phase III, Randomized, Open-label, Active-Controlled Trial Comparing Ferumoxytol with Iron Sucrose for the Treatment of Iron Deficiency Anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018961-50,0,0,0 2010-018963-40,1,2015-03-25,2015-03-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London,"A multi-centre, double-blind, individually randomised, placebo-controlled, parallel arm RCT with 12-week follow-up to establish the clinical and cost effectiveness of amisulpride augmentation of cloza...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018963-40,0,0,0 2010-018965-42,9,2018-05-15,2018-05-15,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A PHASE-3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO COMPARE EFFICACY AND SAFETY OF POMALIDOMIDE IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM -ASSOCIATED MYEL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018965-42,0,0,0 2010-018974-19,2,2012-04-25,2012-04-25,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A randomised, controlled, open label, multicentre, multinational, treat-to-target trial investigating the efficacy and safety of intensification with addition of bolus insulin aspart in subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018974-19,0,0,0 2010-018975-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO ORTOPEDICO RIZZOLI,EFFICACY OF ROSE HIP IN TREATMENT OF PAIN IN PATIENTS WITH COXARTHROSIS EFFICACIA DELL'ESTRATTO DI ROSA CANINA NEL TRATTAMENTO COMPLEMENTARE DEL DOLORE NEL PAZIENTE AFFETTO DA ARTROSI SEVERA DELL'A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018975-13,0,0,0 2010-018976-25,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,sanofi-aventis Belgium,"An open label non-controlled trial to evaluate the effect of dronedarone (Multaq® 400 mg BID) on the quality of life in patiënts with a history of, or current non-permanent atrial fibrillation (AF)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018976-25,0,0,0 2010-018979-16,1,2012-04-04,2012-04-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Erlangen,EFFECTS OF SAXAGLITPIN ON ENDOTHELIAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018979-16,0,0,0 2010-018980-41,8,2020-01-08,2020-08-01,3,0,0,0,0,1,3,0,0,2,1,0,0,0,0,German Society of Pediatric Hematology and Oncology gGmbH (GPOH gGmbH),International randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018980-41,1,0,0 2010-018980-41,8,2020-01-08,2020-08-01,3,0,0,0,0,1,3,0,0,2,1,0,0,0,0,Hannover Medical School,International randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018980-41,1,0,0 2010-018982-43,1,2013-11-05,2013-11-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,AB SCIENCE,"A prospective, multicenter, open-label, uncontrolled, two-parallel group, phase 1/2 study to evaluate safety and efficacy of masitinib at 9 mg/kg/day in monotherapy and in combination with dacarbazine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018982-43,0,0,0 2010-018987-17,1,2010-11-23,2010-11-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Elevation Pharmaceuticals, Inc.","Randomized, Placebo-Controlled, Double-Blind, Dose Ranging, Single Dose, 6-Way Crossover Study to Assess the Safety, Efficacy and Pharmacokinetics of EP-101 Using eFlow Nebulizer in Patients with COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018987-17,0,0,0 2010-018991-25,1,2010-09-21,2010-09-21,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Immunogenicity of the Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine Without Adjuvant in Healthy Adult Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018991-25,0,0,0 2010-018992-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre hospitalier universitaire d'Amiens,"Evaluation pharmacocinétique de MDZ028 après administration unique d'une forme orale nouvelle, lors de la prémédication anesthésique chez l'enfant.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018992-16,0,0,0 2010-018993-20,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,"Universitätsklinikum Schleswig-Holstein, Campus Kiel","Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018993-20,0,0,0 2010-018999-25,4,2012-02-02,2012-02-02,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,PregLem S.A.,"A Phase III, multicentre, clinical study investigating the efficacy and safety of 3-months open-label treatment with PGL4001, followed by a randomised, double-blind placebo controlled period of 10 day...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018999-25,0,0,0 2010-019000-22,3,2017-04-15,2017-04-25,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sunovion Pharmaceuticals Inc.,Long-Term Eslicarbazepine Acetate Extension Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019000-22,0,0,0 2010-019000-22,3,2017-04-15,2017-04-25,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sepracor Inc.,Long-Term Eslicarbazepine Acetate Extension Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019000-22,0,0,0 2010-019001-42,1,2012-02-23,2012-02-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Teva Pharmaceutical Works Private Limited Company,"A Randomized, Double-Blind, Active Comparator, Non-Inferiority Study of Subcutaneously Administered Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) or Pegfilgrastim i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019001-42,0,0,0 2010-019004-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. LUIGI GONZAGA,ANDROGEN DEPRIVATION THERAPY WITHDRAWAL VERSUS MAINTENANCE AND INTERMITTENT DOCETAXEL THERAPY VERSUS CONTINUOUS ADMINISTRATION IN PATIENTS WITH PROSTATE CANCER RESISTANT TO CHEMICAL CASTRATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019004-24,0,0,0 2010-019009-40,5,2011-05-31,2011-05-31,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK","A PHASE 2A RANDOMIZED DOUBLE-BLINDED, PLACEBO AND ACTIVE CONTROLLED TWO COHORT TWO DOSES CROSS-OVER MULTI-CENTER CLINICAL STUDY TO ASSESS EFFICACY OF A ONCE DAILY ADMINISTRATION OF A PHOSPHODIESTERASE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019009-40,0,0,0 2010-019009-40,5,2011-05-31,2011-05-31,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.A.","A PHASE 2A RANDOMIZED DOUBLE-BLINDED, PLACEBO AND ACTIVE CONTROLLED TWO COHORT TWO DOSES CROSS-OVER MULTI-CENTER CLINICAL STUDY TO ASSESS EFFICACY OF A ONCE DAILY ADMINISTRATION OF A PHOSPHODIESTERASE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019009-40,0,0,0 2010-019013-13,1,2013-02-09,2013-02-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BRACCO IMAGING,A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase- Associated Lipocalin (NGAL) as a New Bio-Marker in Patients with Normal eGFR Undergoing Percutaneous Coronary Inte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019013-13,0,0,0 2010-019014-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,Karolinska University Hospital,"A PROSPECTIVE, RANDOMISED, OPEN, BLINDED EVALUATION, ASCENDING-DOSE, PILOT TRIAL OF IMATINIB IN ACUTE ISCHAEMIC STROKE (I-STROKE/pilot)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019014-25,0,0,0 2010-019017-25,1,2015-10-30,2015-10-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Freistaat Bayern, represented by Universität Regensburg",Efficacy of medical treatment with SOM230 LAR in patients with primary inoperable thymoma and/or with local recurrent thymoma to reduce tumor size,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019017-25,0,0,0 2010-019019-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,'Delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) as an outcome measure to evaluate the effectiveness of intra-articular hyaluronic acid for knee osteoarthritis’,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019019-39,0,0,0 2010-019025-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Otsuka Pharmaceutical Development Commercialization, Inc.","A Phase IIa, Single-Center Study, Investigating the Short-Term Renal Hemodynamic Effects, Safety and Pharmacokinetics/Pharmacodynamics of Oral Tolvaptan (OPC-41061) in Subjects with Autosomal Dominant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019025-33,0,0,0 2010-019026-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University of Liège,"TADAM, a Belgian project of Heroin-Assisted Treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019026-13,0,0,0 2010-019028-30,5,2011-05-17,2011-05-17,5,1,0,0,1,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 3-month blinded, randomized, multicenter, placebo controlled study to evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus tox...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019028-30,0,0,0 2010-019028-30,5,2011-05-17,2011-05-17,5,1,0,0,1,0,0,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A 3-month blinded, randomized, multicenter, placebo controlled study to evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus tox...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019028-30,0,0,0 2010-019029-32,16,2011-07-29,2011-10-13,15,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019029-32,0,0,0 2010-019029-32,16,2011-07-29,2011-10-13,15,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019029-32,0,0,0 2010-019029-32,16,2011-07-29,2011-10-13,15,1,0,0,0,0,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019029-32,0,0,0 2010-019033-98,1,2015-06-23,2015-06-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Clinical Center of Tuebingen,A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019033-98,0,0,0 2010-019035-35,4,2012-08-01,2012-08-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN CONTROLLED RELEASE FORMULATION AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL ONSET SEIZURES - PROTOCOL A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019035-35,0,0,0 2010-019035-35,4,2012-08-01,2012-08-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017 USA","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN CONTROLLED RELEASE FORMULATION AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL ONSET SEIZURES - PROTOCOL A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019035-35,0,0,0 2010-019035-35,4,2012-08-01,2012-08-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN CONTROLLED RELEASE FORMULATION AS ADJUNCTIVE THERAPY IN ADULTS WITH PARTIAL ONSET SEIZURES - PROTOCOL A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019035-35,0,0,0 2010-019037-10,1,,,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),IcatibaNt In Treatment of Idiopathic Angio Edema.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019037-10,0,0,0 2010-019040-39,1,2010-07-27,2010-07-27,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics GmbH,"A Phase III, multicenter, uncontrolled, open label study to evaluate safety and immunogenicity of FLUVIRIN® [Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur], Formulation 2010/2011, when admin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019040-39,0,0,0 2010-019047-19,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Pneumologia c/o Villa Pineta,ADDITIONAL EFFECT OF TIOTROPIUM BROMIDE ON EXERCISE TOLERANCE IN COPD PATIENTS. PILOT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019047-19,0,0,0 2010-019051-21,1,2013-05-31,2013-05-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farma, S.A.","Estudio de un único brazo, fase II de bevacizumab en combinación con temozolomida en pacientes con glioblastoma multiforme recurrente",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019051-21,0,0,0 2010-019057-17,4,2011-09-20,2011-11-16,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Santaris Pharma A/S,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Antiviral Activity of SPC3649 (miravirsen) Administered to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019057-17,0,0,0 2010-019058-42,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI,"Safety of sumatriptan in combination with lithium for treatment of cluster headache, Pilot Study,Phase II",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019058-42,0,0,0 2010-019060-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Clinical prospective study to evaluate the efficacy of hygienical therapy and metronidazole in addition to antibiotic therapy in patients affected by bisphosponate-associated osteonecrosis of the jaws,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019060-37,0,0,0 2010-019061-28,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Grupo Español de Tratamiento de Tumores de Cabeza y Cuello,"Estudio fase II, aleatorizado, para valorar la eficacia de paclitaxel en monoterapia vs paclitaxel + cetuximab (ERBITAX) en pacientes con carcinoma escamoso de cabeza y cuello recurrente y/o metastási...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019061-28,0,0,0 2010-019064-36,3,2013-01-18,2013-01-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Aptalis Pharma Canada Inc.,"Efficacy and Safety of PYLERA™ (Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride) With Omeprazole Given x 10 Days in Subjects Who Failed Treatment for Eradication of Helic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019064-36,0,0,0 2010-019064-36,3,2013-01-18,2013-01-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Axcan Pharma INC,"Efficacy and Safety of PYLERA™ (Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride) With Omeprazole Given x 10 Days in Subjects Who Failed Treatment for Eradication of Helic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019064-36,0,0,0 2010-019064-36,3,2013-01-18,2013-01-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,APTALIS PHARMA CANADA INC.,"Efficacy and Safety of PYLERA™ (Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride) With Omeprazole Given x 10 Days in Subjects Who Failed Treatment for Eradication of Helic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019064-36,0,0,0 2010-019066-92,3,2015-12-15,2015-12-15,3,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Ipsen Pharma SAS,"A double-blind, randomized placebo-controlled clinical trial investigating the efficacy and safety of Somatuline Depot (lanreotide) Injection in the treatment of carcinoid syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019066-92,0,0,0 2010-019069-28,6,2012-09-04,2013-09-04,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ipsen Innovation,"A phase III, multicentre, prospective, double blind, randomised, placebo controlled study, assessing the efficacy and safety of Dysport intramuscular injections used for the treatment of upper limb sp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019069-28,0,0,0 2010-019069-28,6,2012-09-04,2013-09-04,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,IPSEN PHARMA SAS,"A phase III, multicentre, prospective, double blind, randomised, placebo controlled study, assessing the efficacy and safety of Dysport intramuscular injections used for the treatment of upper limb sp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019069-28,0,0,0 2010-019071-29,1,2011-07-29,2011-07-29,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"BioVex, Inc.",A Phase 3 Randomized Trial of Concurrent Cisplatin And Radiotherapy With or Without OncoVEXGM-CSF in Previously Untreated Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019071-29,0,0,0 2010-019072-68,1,2011-09-28,2011-09-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's & St Thomas' NHS Foundation Trust,"A randomised, double blind, crossover study to determine the mechanism of action of Gaviscon Advance in Gastro-Oesophageal Reflux Disease (GORD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019072-68,0,0,0 2010-019075-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION HOSPITAL DE MADRID,Determinación de la respuesta del estroma a nab-paclitaxel en combinación con gemcitabina en cáncer de páncreas. Assessment of tumor stroma response to nab-placlitaxel (Abraxane) in combination with ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019075-30,0,0,0 2010-019079-32,5,2014-02-05,2014-02-05,5,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Allergan Limited,"A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019079-32,0,0,0 2010-019082-29,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A double-blind, double-dummy, randomized, placebo- and active-controlled, three-way crossover study to evaluate the effect of Budesonide/Formoterol Spiromax® 80/4.5 mcg Inhalation Powder and Symbicort...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019082-29,0,0,0 2010-019083-36,1,2012-06-05,2012-06-05,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,U.O. Tossicologia,"Evaluation of the effectiveness and the tollerability of paracetamol 1000 mgs + caffeine 130 mgs in the treatment of the migraine. I study randomizzato, double blind, double dummy, vs. sumatriptan 50 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019083-36,0,0,0 2010-019085-82,1,2011-09-27,2011-09-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ipsen Innovation,"A PHASE II, DOUBLE BLIND, RANDOMISED, PLACEBO AND ACTIVE COMPARATOR CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF THREE DOSES OF DYSPORT RU (20 U, 50 U AND 75 U) ADMINISTERED AS A SINGLE TREAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019085-82,0,0,0 2010-019086-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"UO Divisione Nefrologia, Dialisi e Trapianto renale","Multicenter, no-profit, open, single sequence cross-over study on effectiveness and safety of anti-rejection therapy based on modified release Tacrolimus(Advagraf)and on patients quality of life and a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019086-28,0,0,0 2010-019091-78,1,2011-05-16,2011-05-16,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Oxford,An observational study into the maintenance of seroprotection against Meningococcal serogroup C disease throughout childhood following a single dose of a conjugated Meningococcal serogroup C vaccine a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019091-78,0,0,0 2010-019094-15,5,2012-06-01,2012-06-01,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Italfarmaco S.p.A.,"A multicenter, open label dose finding study to evaluate preliminary efficacy and safety profile of Givinostat in subjects with polyarticular course Juvenile Idiopathic Arthritis (poly JIA) not adequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019094-15,0,0,0 2010-019094-15,5,2012-06-01,2012-06-01,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ITALFARMACO,"A multicenter, open label dose finding study to evaluate preliminary efficacy and safety profile of Givinostat in subjects with polyarticular course Juvenile Idiopathic Arthritis (poly JIA) not adequa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019094-15,0,0,0 2010-019095-70,2,2011-10-06,2011-10-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Dai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019095-70,0,0,0 2010-019096-29,1,2012-10-05,2012-10-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,The effects of oral vitamin D supplementation on cardiovascular disease risk in patients with Myalgic Encephalomyelitis /Chronic Fatigue Syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019096-29,0,0,0 2010-019096-29,1,2012-10-05,2012-10-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Tayside,The effects of oral vitamin D supplementation on cardiovascular disease risk in patients with Myalgic Encephalomyelitis /Chronic Fatigue Syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019096-29,0,0,0 2010-019100-23,3,2012-04-23,2012-04-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"BIAL – PORTELA & Ca, S.A.","A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Diabetic Neuropathic Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019100-23,0,0,0 2010-019101-42,4,2012-04-23,2012-04-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"BIAL – PORTELA & Ca, S.A.","A Phase 3, Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter Clinical Study of Eslicarbazepine Acetate in Post-Herpetic Neuralgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019101-42,0,0,0 2010-019102-17,2,2015-01-14,2015-01-14,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Ipsen Pharma SAS,"A PHASE III, PROSPECTIVE, MULTICENTRE, OPEN LABEL, EXTENSION STUDY ASSESSING THE LONG TERM SAFETY AND EFFICACY OF REPEATED TREATMENT WITH DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN CHIL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019102-17,1,0,0 2010-019104-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,THT Research sprl,Etude prospective de l'efficacité d'un mélange probiotique dans le syndrome du colon irritable.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019104-23,0,0,0 2010-019106-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Netherlands Cancer Institute (NKI),Phase II and Pharmacological Study with Wee-1 Inhibitor AZD1775 Combined with Carboplatin in Patients with p53 Mutated Epithelial Ovarian Cancer that Show Early Relapse (< 3 months) or Progression du...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019106-16,0,0,0 2010-019108-22,1,2015-05-19,2015-05-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"MUW, Klinik f. Mund-, Kiefer, und Gesichtschirurgie",NEOADJUVANTE RADIOIMMUNTHERAPIE MIT CETUXIMAB IN PATIENTEN MIT FORTGESCHRITTENEN TUMOREN DER KOPF-HALSREGION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019108-22,0,0,0 2010-019109-40,1,2012-08-01,2012-08-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Xenome Ltd,"A multicenter, randomized, observer-blinded, single-dose, placebo-controlled, sequential cohort study of the efficacy and safety of Xen2174 in subjects following bunionectomy surgery 3 años) con Lopinavir/riton...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019446-38,0,0,0 2010-019447-19,1,2011-10-24,2011-10-24,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar),Estudio comparativo de efectividad y tolerancia de haloperidol y risperidona en el delirium en la enfermedad oncológica avanzada y terminal,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019447-19,0,0,0 2010-019448-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar),"Ensayo clínico, prospectivo, aleatorizado, comparativo, para determinar la eficacia y seguridad de dos protocolos para preparación endometrial en mujeres subsidiarias de transferencia de embriones.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019448-38,0,0,0 2010-019454-41,7,2013-07-22,2013-07-22,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohm Corp.,"A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) in the Treatment of Men with Osteoporosis Treated with Vitamin D and Calcium 1",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019454-41,0,0,0 2010-019454-41,7,2013-07-22,2013-07-22,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"MERCK & CO., INC.","A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) in the Treatment of Men with Osteoporosis Treated with Vitamin D and Calcium 1",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019454-41,0,0,0 2010-019454-41,7,2013-07-22,2013-07-22,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) in the Treatment of Men with Osteoporosis Treated with Vitamin D and Calcium 1",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019454-41,0,0,0 2010-019454-41,7,2013-07-22,2013-07-22,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme B.V.,"A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) in the Treatment of Men with Osteoporosis Treated with Vitamin D and Calcium 1",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019454-41,0,0,0 2010-019454-41,7,2013-07-22,2013-07-22,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) in the Treatment of Men with Osteoporosis Treated with Vitamin D and Calcium 1",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019454-41,0,0,0 2010-019459-23,7,2014-05-13,2014-05-13,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,"A CLINICAL STUDY OF IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN) (IGSC), 20% FOR THE EVALUATION OF EFFICACY, SAFETY, AND PHARMACOKINETICS IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019459-23,0,0,0 2010-019461-29,1,2013-05-29,2013-05-29,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Stiftung Institut für Herzinfarktforschung,ETAMI-Study: Early Thienopyridine treatment to improve primary PCI in Patients with Acute Myocardial Infarction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019461-29,0,0,0 2010-019462-92,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,CHU de Nantes,Phase I/II trial of Carfilzomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019462-92,0,0,0 2010-019463-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. CARLO,"MULTICENTER PHASE II STUDY FOR THE EVALUATION OF BEVACIZUMAB, OXALIPLATIN AND CAPECITABINE IN THE TREATMENT OF ELDERLY PATIENTS WITH ADVANCED COLORECTAL CANCER STUDIO MULTICENTRICO DI FASE II PER L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019463-10,0,0,0 2010-019464-37,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,FONDAZIONE TOSCANA GABRIELE MONASTERIO,effects of dynamic co2 therapy in periodic breathing in heart failure patients Effetti della somministrazione dinamica di anidride carbonica nella sindrome delle apnee centrali in pazienti con scom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019464-37,0,0,0 2010-019465-28,1,2011-05-31,2011-05-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double-blind, placebo-controlled, four-way crossover, repeat dose study comparing the effect of inhaled fluticasone furoate/GW642444M combination, GW642444M and fluticasone furoate on th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019465-28,0,0,0 2010-019466-81,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development,"A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Four 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 100 mg, GSK2190915 300 mg, M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019466-81,0,1,1 2010-019469-26,1,2014-04-24,2014-04-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Aberdeen,Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre placebo controlled randomised trial of a calcium channel blocker(nifedipine)and an alpha bloc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019469-26,0,0,0 2010-019469-26,1,2014-04-24,2014-04-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Grampian,Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre placebo controlled randomised trial of a calcium channel blocker(nifedipine)and an alpha bloc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019469-26,0,0,0 2010-019483-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska University Hospital,Vitamin D supplementation for prevention of placenta mediated pregnancy complications.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019483-37,0,0,0 2010-019484-10,4,2018-02-08,2018-02-08,4,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Eisai Ltd,"An open-label, multicenter Phase Ib/2 study of E7080 alone, and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-target...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019484-10,0,0,0 2010-019488-12,1,2012-12-20,2012-12-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Joint Research Office, Barts and The London NHS Trust",A Single Centre Prospective Randomised Study to Investigate the Metabolism of Intravenous Paracetamol in Humans,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019488-12,0,0,0 2010-019497-32,4,2013-02-27,2013-02-27,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,PregLem S.A.,"A Phase III, multicentre, clinical study investigating the efficacy and safety of three successive periods of 3-month open-label PGL4001 treatment, each followed by ten days of double-blind treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019497-32,1,0,0 2010-019500-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CONSORZIO MARIO NEGRI SUD,Single Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High Risk Polycythemia Vera or High Risk Essential Thrombocythemia who are Either Hydroxyurea Resistant or Intolerant Or ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019500-23,0,0,0 2010-019501-41,4,2015-08-27,2019-01-01,2,0,0,0,0,2,3,0,0,2,1,0,0,0,0,CONSORZIO MARIO NEGRI SUD,Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019501-41,1,0,0 2010-019501-41,4,2015-08-27,2019-01-01,2,0,0,0,0,2,3,0,0,2,1,0,0,0,0,Myeloproliferative Disease Research Consortium (MPD-RC),Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019501-41,1,0,0 2010-019501-41,4,2015-08-27,2019-01-01,2,0,0,0,0,2,3,0,0,2,1,0,0,0,0,Consorzio Mario Negri Sud,Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019501-41,1,0,0 2010-019505-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Rottapharm SpA,"ESTUDIO ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LEGALON SIL EN EL TRATAMIENTO DE LA RECURRENCIA DE VHC EN EL INJERTO DE PACIENTES SOMETIDOS A UN TRAS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019505-42,0,0,0 2010-019507-28,3,2011-05-25,2011-05-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.","Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and Treatment of Ocular Inflammation and Pain after Cataract Surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019507-28,0,0,0 2010-019511-37,3,2011-08-25,2011-08-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 16-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Safety and Efficacy of Dapagliflozin 2.5 mg BID, 5 mg BID and 10 mg QD Versus Placebo in Patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019511-37,0,0,0 2010-019513-24,1,2013-12-31,2013-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,London School of Hygiene & Tropical Medicine,Antibiotics for exacerbations of chronic obstructive pulmonary disease: a pilot randomised trial within the General Practice Research Database,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019513-24,0,0,0 2010-019514-24,5,2012-10-10,2012-11-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Double-Blind, Randomized, Parallel-Arm, Multi-Center Study to Determine the Dose Response of Methotrexate (MTX) in Combination Therapy with Adalimumab in Subjects with Early Rheumatoid Arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019514-24,0,0,0 2010-019514-24,5,2012-10-10,2012-11-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Double-Blind, Randomized, Parallel-Arm, Multi-Center Study to Determine the Dose Response of Methotrexate (MTX) in Combination Therapy with Adalimumab in Subjects with Early Rheumatoid Arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019514-24,0,0,0 2010-019517-16,1,2012-03-27,2012-03-27,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Professor Jørgen B. Dahl,Effekten af Adductor-Kanal-Blokade (AKB) på patienter efter rekonstruktion af forreste korsbånd (ACL) i dagkirurgisk regi (The Effect of Adductor-Channel Blockade (ACB) in Patients After Anterior Cr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019517-16,0,0,0 2010-019518-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)",(Maraviroc ENHancement of Immunological Response): A pilot study of maraviroc as an add-on in patients with reduced CD4 cell count despite full viral suppression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019518-25,0,0,0 2010-019519-39,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Erasmus MC - Department of Neurology,Efficacy of RAD001/everolimus in Autism and NeuroPsychological deficits in children with TSC (RAPIT-trial) Onderzoek naar behandeling van leer- en gedragsproblemen bij kinderen met Tubereuze Sclero...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019519-39,0,0,0 2010-019521-34,1,2014-12-08,2014-12-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Inc.,"A 15 WEEK, RANDOMIZED, DOUBLE BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, FLEXIBLE-DOSE, SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12-17 YEARS OLD) WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019521-34,0,0,0 2010-019522-13,13,2018-01-22,2018-01-22,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,HEXAL AG (a Sandoz company),"A randomized, controlled, double-blind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus Cyclophosphamide, Vincristine, Prednisone vs. MabThera® plus Cyclophosphamide...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019522-13,0,0,0 2010-019522-13,13,2018-01-22,2018-01-22,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,HEXAL AG,"A randomized, controlled, double-blind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus Cyclophosphamide, Vincristine, Prednisone vs. MabThera® plus Cyclophosphamide...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019522-13,0,0,0 2010-019524-31,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,RECORDATI,Safety of an ACE-I/CCB fixed combination (Lercanidipine/Enalapril) in elderly hypertensive patients not adequately controlled by CCB monotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019524-31,0,0,0 2010-019525-34,18,2015-03-18,2015-03-18,18,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019525-34,0,0,0 2010-019526-14,2,2014-12-01,2014-12-01,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Ltd,"An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019526-14,0,0,0 2010-019527-58,1,2013-09-26,2013-09-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,NHS Lothian,EMPIRE-Elafin Myocardial Protection from Ischaemia RepErfusion injury,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019527-58,0,0,0 2010-019527-58,1,2013-09-26,2013-09-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Edinburgh,EMPIRE-Elafin Myocardial Protection from Ischaemia RepErfusion injury,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019527-58,0,0,0 2010-019529-33,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,UMCU,A Phase l/ll study to assess safety of co-infusion of haematopoietic stem cells from a haplo-identical donor and a single unit unrelated cord blood in high risk patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019529-33,0,0,0 2010-019532-12,1,2011-05-27,2011-05-27,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,CSL Limited,"A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2010/2011 Formulation of the Enzira® vaccine in Two Groups of Healthy Volunteers: ‘Adults’ (aged 18 to 59 y...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019532-12,0,0,0 2010-019540-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Emotional Brain,"A double blind, randomized, cross-over placebo controlled study to investigate the efficacy of sublingual testosterone solution on physiological and subjective arousal in healthy, sexually dysfunction...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019540-39,0,0,0 2010-019541-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Protocole pilote d'étude de l'efficacité et de la sécurité d'un traitement de l'allergie à l'arachide par immunothérapie épicutanée (EPIT) chez des enfants allergiques : étude multicentrique randomisé...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019541-26,0,0,0 2010-019543-19,6,2011-12-21,2011-12-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Limited,"A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Determine the Safety and Efficacy of AMG 827 in Subjects wth Inadequately Controlled Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019543-19,0,0,0 2010-019543-19,6,2011-12-21,2011-12-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Determine the Safety and Efficacy of AMG 827 in Subjects wth Inadequately Controlled Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019543-19,0,0,0 2010-019544-39,4,2011-10-15,2011-10-15,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Amgen Inc,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Moderate to Severe Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019544-39,0,0,0 2010-019547-19,8,2013-11-12,2019-04-24,5,1,1,0,0,1,2,0,0,2,1,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A randomized, open label study comparing safety and efficacy parameters for a high and a low dose of ambrisentan (adjusted for body weight) for the treatment of pulmonary arterial hypertension in pae...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019547-19,1,1,0 2010-019547-19,8,2013-11-12,2019-04-24,5,1,1,0,0,1,2,0,0,2,1,0,0,0,1,"GlaxoSmithKline Research & Development, Ltd","A randomized, open label study comparing safety and efficacy parameters for a high and a low dose of ambrisentan (adjusted for body weight) for the treatment of pulmonary arterial hypertension in pae...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019547-19,1,1,0 2010-019547-19,8,2013-11-12,2019-04-24,5,1,1,0,0,1,2,0,0,2,1,0,0,0,1,"GlaxoSmithKline, S.A.","A randomized, open label study comparing safety and efficacy parameters for a high and a low dose of ambrisentan (adjusted for body weight) for the treatment of pulmonary arterial hypertension in pae...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019547-19,1,1,0 2010-019550-40,7,2015-04-17,2015-04-24,4,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"AMAG Pharmaceuticals, Inc.",An Open-Label Extension Study of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects with Chronic Kidney Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019550-40,1,0,0 2010-019552-50,1,2013-11-14,2013-11-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Glycotope GmbH,"Dose-escalation-, PK- and safety study with single agent CetuGEXTM in patients with EGFR positive locally advanced and/or metastatic cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019552-50,0,0,0 2010-019554-41,3,2014-12-11,2014-12-11,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,"Emergent Product Development Seattle, LLC",A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Bendamustine vs. Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019554-41,0,0,0 2010-019554-41,3,2014-12-11,2014-12-11,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Trubion Pharmaceuticals,A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Bendamustine vs. Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019554-41,0,0,0 2010-019556-44,7,2011-12-21,2011-12-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Initiation of agomelatine after antidepressant treatment by SSRI or SNRI in outpatients suffering Major Depressive Disorder. A 3-week, randomised, double then single-blind, controlled, parallel groups...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019556-44,0,0,0 2010-019556-44,7,2011-12-21,2011-12-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Initiation of agomelatine after antidepressant treatment by SSRI or SNRI in outpatients suffering Major Depressive Disorder. A 3-week, randomised, double then single-blind, controlled, parallel groups...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019556-44,0,0,0 2010-019556-44,7,2011-12-21,2011-12-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratorios Servier S.L.,"Initiation of agomelatine after antidepressant treatment by SSRI or SNRI in outpatients suffering Major Depressive Disorder. A 3-week, randomised, double then single-blind, controlled, parallel groups...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019556-44,0,0,0 2010-019558-42,4,2011-03-17,2011-03-17,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Biogen Idec Ltd.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety, and Tolerability of Baminercept in Subjects With Moderate to Severe Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019558-42,0,0,0 2010-019559-23,6,2011-09-26,2011-09-27,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label extension study of CACZ885H2356E1 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019559-23,0,0,0 2010-019562-91,7,2014-01-29,2014-01-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences International Ltd,"A Phase 3, Double-Blind, Multicenter, Randomized, Placebo Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome) for the Prevention of Inv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019562-91,0,0,0 2010-019563-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,RECKITT BENCKISER HEALTHCARE,Etude de non-infériorité de l’efficacité de Gaviscon suspension buvable en flacon versus Oméprazole 20mg sur le pyrosis chez des patients ayant un RGO dont l’épisode actuel n’est pas traité.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019563-11,0,0,0 2010-019564-37,1,2013-05-14,2013-05-14,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GMIHO Gesellschaft für Medizinische Innovation – Hämatologie und Onkologie mbH,"A Double-blind Placebo-controlled Randomized Multicenter Phase II Trial of Skin Toxicity Treatment in Subjects with Metastatic Colorectal Carcinoma Receiving Panitumumab Eine doppelblinde, placebo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019564-37,0,0,0 2010-019568-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CH VERSAILLES,A prospective randomized phase II study evaluating the monitoring of imatinib mesylate (Gliveec®) plasmatic through level in patients newly diagnosed with chronic phase chronic myelogenous leukaemia (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019568-35,0,0,0 2010-019574-33,1,2015-05-20,2015-05-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Nantes,"Etude prospective, multicentrique, randomisée, en double-aveugle, contrôlée à groupes parallèles, visant à évaluer la balance bénéfice-risque du sevrage progressif d'un inhibiteur de la calcineurine (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019574-33,0,0,0 2010-019575-29,1,2017-04-07,2017-04-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Liverpool,"Phase II trial of ofatumumab, dexamethasone and lenalidomide for high-risk CLL (NCRI CLL210)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019575-29,0,0,0 2010-019575-29,1,2017-04-07,2017-04-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Liverpool and Broadgreen University Hospital NHS Trust,"Phase II trial of ofatumumab, dexamethasone and lenalidomide for high-risk CLL (NCRI CLL210)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019575-29,0,0,0 2010-019577-16,13,2016-09-20,2022-06-06,8,0,0,0,0,0,3,0,0,2,1,0,0,0,1,GlaxoSmithKline Research & Development Ltd,A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first- or second-line...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019577-16,1,0,0 2010-019577-16,13,2016-09-20,2022-06-06,8,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first- or second-line...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019577-16,1,0,0 2010-019577-16,13,2016-09-20,2022-06-06,8,0,0,0,0,0,3,0,0,2,1,0,0,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first- or second-line...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019577-16,1,0,0 2010-019578-34,3,2013-02-15,2013-02-25,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK inhibitor GSK1120212 plus Gemcitabine vs. Placebo plus Gemcitabine in Subjects with Metastatic Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019578-34,0,0,0 2010-019578-34,3,2013-02-15,2013-02-25,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK inhibitor GSK1120212 plus Gemcitabine vs. Placebo plus Gemcitabine in Subjects with Metastatic Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019578-34,0,0,0 2010-019581-82,3,2012-01-04,2012-01-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly & Company,"The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019581-82,0,0,0 2010-019584-10,6,2012-12-03,2013-01-16,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche,"A Randomized, Open label, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591) Boosted with Low Dose Ritonavir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019584-10,0,0,0 2010-019584-10,6,2012-12-03,2013-01-16,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Hoffmann-La Roche,"A Randomized, Open label, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591) Boosted with Low Dose Ritonavir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019584-10,0,0,0 2010-019585-90,5,2013-01-25,2013-01-29,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche,"A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir (Danoprevir/r) and Copegus, in Combina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019585-90,0,0,0 2010-019587-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Universität des Saarlandes,"Improvement of outcome and reduction of toxicity in elderly patients with CD20+ aggressive B-cell lymphoma by an optimised schedule of the monoclonal antibody rituximab, substitution of conventional b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019587-36,0,0,0 2010-019588-12,5,2013-08-01,2013-08-01,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A multi-center, phase I/II study of BAY 86-9766 in combination with gemcitabine in patients with locally advanced inoperable or metastatic pancreatic cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019588-12,0,0,0 2010-019588-12,5,2013-08-01,2013-08-01,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Bayer HealthCare AG, D-51368 Leverkusen, Germany","A multi-center, phase I/II study of BAY 86-9766 in combination with gemcitabine in patients with locally advanced inoperable or metastatic pancreatic cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019588-12,0,0,0 2010-019588-12,5,2013-08-01,2013-08-01,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Bayer HealthCare AG, Germany","A multi-center, phase I/II study of BAY 86-9766 in combination with gemcitabine in patients with locally advanced inoperable or metastatic pancreatic cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019588-12,0,0,0 2010-019589-10,1,2011-07-27,2011-07-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Multicentre Study to assess efficacy and safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and Fluticasone Propionate FP)/Salmete...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019589-10,0,0,0 2010-019590-15,3,2011-10-18,2011-10-19,2,1,1,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"HZA106827: A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019590-15,1,1,0 2010-019591-67,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,CHU de SAINT-ETIENNE,Pain assessment during general anesthesia : DOLANS Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019591-67,0,0,0 2010-019594-14,3,2011-10-18,2011-10-18,2,1,1,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double-blind, parallel group, multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder alone, and Fluticasone Propionate alone in the t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019594-14,1,1,0 2010-019594-14,3,2011-10-18,2011-10-18,2,1,1,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline,"A randomised, double-blind, parallel group, multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder alone, and Fluticasone Propionate alone in the t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019594-14,1,1,0 2010-019595-79,1,2013-01-01,2013-01-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Medical Centre Nijmegen,A randomised phase II study of radio-chemotherapy with or without panitumumab (Vectibix®) in irresectable squamous cell carcinoma or adenocarcinoma of the oesophagus (Panoramic),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019595-79,0,0,0 2010-019598-13,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,MOLTENI,"A randomised, double-blind, dose-response, placebo-controlled, multicenter, phase IIA clinical study to evaluate the efficacy and safety of topical application of G.68.y/EtOH in patients with type 1 o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019598-13,0,0,0 2010-019599-64,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU Toulouse,Effet d'un inhibiteur de la DPP-IV sur la sécrétion de glucagon au cours du diabète de type 1 avec ou sans neuropathie autonome végétative,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019599-64,0,0,0 2010-019600-23,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A Phase III, open, non-randomized, multi-centric, single dose study to assess immunogenicity and safety of Fluarix™ / Influsplit SSW® 2010/2011 injected intramuscularly in young adults (18 to 60 years...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019600-23,0,0,0 2010-019602-16,1,2013-10-16,2013-10-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust,A study of lapatinib in combination with oxaliplatin and capecitabine in early HER-2 overexpressing oesophageal and gastric cancers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019602-16,0,0,0 2010-019622-13,1,2017-11-29,2017-11-29,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,CHU de Clermont-Ferrand,Etude de la Cinétique IntraMonocytaire de l’Imiglucérase (CIMI) et de sa corrélation avec l’évolution clinique et biologique de la maladie de Gaucher,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019622-13,0,0,0 2010-019626-14,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,CHU de Nantes,ROLE DES NEO-ARTICULATIONS TRANSVERSO-SACREES OU TRANSVERSO-ILIAQUES (ATLS) DANS LES LOMBALGIES CHRONIQUES : ETUDE PROSPECTIVE MULTICENTRIQUE RANDOMISEE EN DOUBLE AVEUGLE DE L’EFFICACITE DES INFILTR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019626-14,0,0,0 2010-019630-28,7,2015-11-13,2015-11-13,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Alexion Pharmaceuticals, Inc.","A RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL TO DETERMINE SAFETY AND EFFICACY OF ECULIZUMAB IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION (AMR) IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS REQUIRING...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019630-28,0,0,0 2010-019630-28,7,2015-11-13,2015-11-13,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,ALEXION PHARMACEUTICALS,"A RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL TO DETERMINE SAFETY AND EFFICACY OF ECULIZUMAB IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION (AMR) IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS REQUIRING...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019630-28,0,0,0 2010-019631-35,4,2017-05-22,2017-05-24,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,"Alexion Pharmaceuticals, Inc.","AN OPEN-LABEL, SINGLE-ARM, MULTICENTER TRIAL TO DETERMINE SAFETY AND EFFICACY OF ECULIZUMAB IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION (AMR) IN SENSITIZED RECIPIENTS OF A KIDNEY TRANSPLANT FROM ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019631-35,0,0,0 2010-019631-35,4,2017-05-22,2017-05-24,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,ALEXION PHARMACEUTICALS,"AN OPEN-LABEL, SINGLE-ARM, MULTICENTER TRIAL TO DETERMINE SAFETY AND EFFICACY OF ECULIZUMAB IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION (AMR) IN SENSITIZED RECIPIENTS OF A KIDNEY TRANSPLANT FROM ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019631-35,0,0,0 2010-019632-12,1,2012-05-07,2012-05-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,IPSEN Pharma GmbH,"A phase II, multicentre, open, prospective, randomised, parallel-group, pharmacodynamic equivalence study on intramuscular versus subcutaneous applications of Triptorelin pamoate (Pamorelin® LA 11.25 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019632-12,0,0,0 2010-019633-10,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Dynavax Technologies Corporation,"An Open-Label, Randomized, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Engerix-B® and Fendrix® in Adults on Hemodialysis Who Have Previously Received Hepatitis B Vaccina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019633-10,0,0,0 2010-019634-26,4,2013-01-16,2013-01-16,3,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Mpex Pharmaceuticals, Inc.","A Phase 3, Open-Label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin™) versus Tobramycin Inhalation Solution (TIS) in Stable Cystic Fibrosis Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019634-26,1,0,0 2010-019635-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Aker BioMarine Antarctic AS,"A Single Centre, Open-Label, Randomised Multi-Dose Study to Assess Changes in the Brain Metabolism of Juvenile ADHD Patients After Thirteen Weeks of Daily Intake of 4 g Superba Krill Oil or 4 g omega-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019635-36,0,0,0 2010-019637-96,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,YMBiosciences INC,"A Randomized, Phase II, Double-Blind Study of Nimotuzumab Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019637-96,0,0,0 2010-019638-28,16,2013-02-28,2013-05-22,15,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd.,"INVESTIGATING NEW ONSET DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT CORTICOSTEROIDS ? A MULTICENTER, TWO ARM, RANDOMIZED, O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019638-28,0,0,0 2010-019638-28,16,2013-02-28,2013-05-22,15,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ASTELLAS PHARMA,"INVESTIGATING NEW ONSET DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT CORTICOSTEROIDS ? A MULTICENTER, TWO ARM, RANDOMIZED, O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019638-28,0,0,0 2010-019639-37,8,2013-09-12,2013-09-18,7,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Astellas Pharma Europe Ltd.,"A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING RENAL FUNCTION IN AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT SIROLIMUS IN KIDNEY TRANSPLANT SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019639-37,0,0,0 2010-019639-37,8,2013-09-12,2013-09-18,7,1,0,0,0,0,4,0,0,1,1,0,1,0,1,ASTELLAS PHARMA,"A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING RENAL FUNCTION IN AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT SIROLIMUS IN KIDNEY TRANSPLANT SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019639-37,0,0,0 2010-019643-19,1,2014-04-30,2014-04-30,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik f.Innere Medizin I, Abt.f.Hämatologie u.Hämostaseologie",The effect of clopidogrel and prasugrel with and without acetylsalicylic acid (ASA) on hemostatic system activation at the site of plug formation in vivo in man,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019643-19,0,0,0 2010-019645-25,2,2013-01-08,2013-01-08,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,FERROKIN BIOSCIENCES INC.,"A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of FBS0701 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019645-25,0,0,0 2010-019645-25,2,2013-01-08,2013-01-08,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Shire Development LLC,"A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of FBS0701 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019645-25,0,0,0 2010-019647-19,1,2012-10-23,2012-10-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford,A double blind randomised placebo controlled trial of montelukast in the treatment of acute persistent cough in young people and adults (aged 16-49) in primary care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019647-19,0,0,0 2010-019649-24,1,2013-02-15,2013-02-15,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Ann Merete Møller,Effekten af Transversus Abdominis Plane (TAP) blok som postoperativ smertebehandling efter laparoskopisk kolonkirurgi.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019649-24,0,0,0 2010-019656-41,1,2014-10-21,2014-10-21,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,King’s College London,"Effects of Zoledronic Acid on arterial calcification and arterial stiffness in women – a co-twin randomised double blind, placebo-controlled parallel group, clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019656-41,0,0,0 2010-019656-41,1,2014-10-21,2014-10-21,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,Guy’s and St Thomas’ NHS Foundation Trust,"Effects of Zoledronic Acid on arterial calcification and arterial stiffness in women – a co-twin randomised double blind, placebo-controlled parallel group, clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019656-41,0,0,0 2010-019657-18,1,2016-08-28,2016-08-28,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Gynäkologie und Gyn.Onkologie",Topical Imiquimod in Treating Patients with Persistent HPV-Infection after Surgical or Radiation Treatment of Cervical Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019657-18,0,0,0 2010-019660-36,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,0,UMC St Radboud,The effect of interleukin-1 receptor antagonist on insulin secretion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019660-36,0,0,0 2010-019665-28,1,2011-04-22,2011-04-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Hanmi Pharmaceutical Company Limited,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF SINGLE SUBCUTANEOUS DOSES OF HM11260C IN ADULT PA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019665-28,0,0,0 2010-019668-35,1,2011-02-11,2011-02-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,SagaMedica ehf.,"A parallel, randomised, double blind, placebo controlled study to investigate the effect of SagaPro on nocturia in men",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019668-35,0,0,0 2010-019669-27,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,University of Tartu,Hypobaric vs hyperbaric bupivacaine for spinal anaesthesia in total knee arthroplasty,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019669-27,0,0,0 2010-019670-32,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),Pharmacokinetics and Safety of Human Pasteurised C1-Inhibitor Concentrate (Berinert/CE1145) in Subjects with Congenital C1-INH Deficiency and Frequent Hereditary Angioedema (HAE) Attacks. Studio d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019670-32,0,0,0 2010-019672-76,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,Impact de la correction du déficit en vitamine D chez les patients porteurs de syndrome d’apnées- hypopnées obstructives du sommeil.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019672-76,0,0,0 2010-019673-15,1,2015-10-31,2015-10-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Universit� Cattolica del Sacro Cuore,"A open label, phase 2, non randomized, multicentre trial to assess the feasibility of induction treatment with 5-azacitidine (5-AZA) followed by allogeneic stem cell transplantation (allo-SCT) or con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019673-15,0,0,0 2010-019678-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Paracetamol intravenously in neonates with a gestational age of less than 32 weeks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019678-34,0,0,0 2010-019683-37,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO CLINICO HUMANITAS,PHASE II STUDY OF EVEROLIMUS IN PATIENTS WITH THYMOMA AND THYMIC CARCINOMA PREVIOUSLY TREATED WITH CHEMOTHERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019683-37,0,0,0 2010-019684-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Maasstad Hospital,Pharmacological Treatment in Osteoarthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019684-11,0,0,0 2010-019685-87,11,2014-07-30,2014-07-31,8,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Takeda Pharma A/S,"Effect of roflumilast on exacerbation rate in patients with COPD treated with fixed combinations of LABA and ICS. A 52-week, randomised double-blind trial with roflumilast 500 ?g versus placebo Efe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019685-87,0,0,0 2010-019685-87,11,2014-07-30,2014-07-31,8,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Nycomed GmbH,"Effect of roflumilast on exacerbation rate in patients with COPD treated with fixed combinations of LABA and ICS. A 52-week, randomised double-blind trial with roflumilast 500 ?g versus placebo Efe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019685-87,0,0,0 2010-019687-36,7,2012-07-24,2012-07-24,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Bioprojet,"ENSAYO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y COMPARADOR, DE GRUPOS PARALELOS, PARA VALORAR LA EFICACIA DE BF2.649 EN EL TRATAMIENTO DE LA SOMNOLENCIA DIURNA EXCESIVA EN NA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019687-36,0,0,0 2010-019687-36,7,2012-07-24,2012-07-24,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,BIOPROJET,"ENSAYO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y COMPARADOR, DE GRUPOS PARALELOS, PARA VALORAR LA EFICACIA DE BF2.649 EN EL TRATAMIENTO DE LA SOMNOLENCIA DIURNA EXCESIVA EN NA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019687-36,0,0,0 2010-019688-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Friedrich-Schiller University Jena, Clinic for Internal Medicine I",Prospective placebo controlled trial: Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjuncti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019688-12,0,0,0 2010-019689-10,3,2013-02-21,2013-02-21,1,1,0,0,0,2,2,0,0,1,1,1,1,0,1,Novartis Services AG,"A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019689-10,0,0,0 2010-019689-10,3,2013-02-21,2013-02-21,1,1,0,0,0,2,2,0,0,1,1,1,1,0,1,NOVARTIS FARMA,"A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019689-10,0,0,0 2010-019689-10,3,2013-02-21,2013-02-21,1,1,0,0,0,2,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A multi-center, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and tolerability of KRP203 in patients with active subacute cutaneous lupus erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019689-10,0,0,0 2010-019690-15,2,2011-09-27,2011-09-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline LLC,"A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019690-15,0,0,0 2010-019691-70,1,2013-12-01,2013-12-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Ghent University,Pharmacokinetic evaluation of fluoroquinolone antibiotics administered intravenously in intensive care patients with normal renal function and with renal hyperfiltration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019691-70,0,0,0 2010-019692-30,8,2013-12-02,2013-12-02,8,1,1,0,0,1,3,0,0,1,0,0,1,0,1,"PTC Therapeutics, Inc",A Phase 3 Extension Study of Ataluren (PTC124) in Subjects with Nonsense-Mutation-Mediated Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019692-30,0,0,0 2010-019692-30,8,2013-12-02,2013-12-02,8,1,1,0,0,1,3,0,0,1,0,0,1,0,1,"PTC THERAPEUTICS, INC.",A Phase 3 Extension Study of Ataluren (PTC124) in Subjects with Nonsense-Mutation-Mediated Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019692-30,0,0,0 2010-019694-15,1,2013-03-05,2013-03-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,N.V. Roche S.A.,"Act-Alone : An open-label, single-arm study to describe glucocorticoid use in rheumatoid arthritis patients treated with Tocilizumab in daily clinical practice and to evaluate systematic glucocorticoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019694-15,0,0,0 2010-019695-76,3,2011-12-21,2011-12-22,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets Administered Twice Daily compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019695-76,0,0,0 2010-019706-16,2,2013-02-06,2013-02-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Polichem SA,"A randomized, double blind, placebo controlled, parallel groups, pilot study to assess the effects of two new nail lacquers, cyclosporine 5% and calcipotriol 0.005%, in the treatment of nail psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019706-16,0,0,0 2010-019706-16,2,2013-02-06,2013-02-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,POLICHEM,"A randomized, double blind, placebo controlled, parallel groups, pilot study to assess the effects of two new nail lacquers, cyclosporine 5% and calcipotriol 0.005%, in the treatment of nail psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019706-16,0,0,0 2010-019707-32,5,2013-11-07,2017-06-19,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Boehringer Ingelheim España, S.A",LUME-Lung 3. A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019707-32,0,0,0 2010-019707-32,5,2013-11-07,2017-06-19,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,LUME-Lung 3. A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019707-32,0,0,0 2010-019707-32,5,2013-11-07,2017-06-19,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim,LUME-Lung 3. A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019707-32,0,0,0 2010-019707-32,5,2013-11-07,2017-06-19,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim bv,LUME-Lung 3. A Phase I/II study of continuous oral treatment with BIBF 1120 added to standard gemcitabine/cisplatin therapy in first line NSCLC patients with squamous cell histology.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019707-32,0,0,0 2010-019709-41,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Groupe Francophone des Myélodysplasies,A phase I study of azacitidine with Ceplene/interleukin-2 followed by a randomized phase II study of the efficacy and safety of maintenance treatment with azacitidine with or without Ceplene/interleuk...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019709-41,0,0,0 2010-019710-24,1,,,0,0,0,0,1,1,3,0,0,1,1,1,0,1,0,ASSOCIAZIONE QOL-ONE,A Randomized Study to Evaluate the Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QoLESS AZA-AMLE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019710-24,0,0,0 2010-019712-20,1,,,0,0,0,0,0,0,4,0,1,4,0,0,0,0,0,"University of Oslo, Institute of Clinical Dentistry",D-CYCLOSERINE ENHANCEMENT OF EXPOSURE TREATMENT OF DENTALLY FEARFUL AND AVOIDANT CHILDREN. A PILOT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019712-20,0,0,0 2010-019713-21,1,2015-06-05,2015-06-05,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,University Hospitals Bristol NHS Foundation Trust,A RANDOMISED CONTROLLED TRIAL TO COMPARE NORMOXIC VERSUS STANDARD CARDIOPULMONARY BYPASS IN CYANOTIC CHILDREN UNDERGOING CARDIAC SURGERY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019713-21,0,0,0 2010-019714-24,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Research & Development Department,"A phase II, open label, single site light dose escalation trial of single dose Verteporfin Photodynamic Therapy (PDT) in primary soft tissue sarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019714-24,0,0,0 2010-019715-38,1,2010-10-20,2010-10-20,1,0,0,0,1,0,2,0,1,1,0,0,1,0,0,Universitätsmedizin der Johannes Gutenberg-Universität Mainz,"Placebokontrollierte, prospektive Beobachtung des Schmerzempfindens bei Probanden während der mechanischen Epilation mit dem Braun Expressive Epilationsgerät nach Auftragen von Lokaltherapeutika (Emla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019715-38,0,0,0 2010-019718-25,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,Fundación PETHEMA,"Ensayo clínico multicéntrico, prospectivo, abierto, de un solo grupo, de fase II para analizar la terapia de inducción con una combinación de clofarabina y dosis bajas de citarabina seguido de terapia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019718-25,0,0,0 2010-019720-32,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,"Ferrer Internacional, S.A.","Cardiovascular Fixed Combination Pill ASR: ensayo clínico farmacodinámico de la combinación a dosis fijas de ácido acetilsalicílico, simvastatina, y ramipril (Cardiovascular Polypill); Colesterol LDL ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019720-32,0,0,0 2010-019724-30,1,2012-11-14,2012-11-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Lilly S.A.,"Comparación de insulina lispro premezclada (proporción baja) dos veces al día frente a insulina glargina una vez al día e insulina lispro prandial una vez al día, como estrategias de intensificación d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019724-30,0,0,0 2010-019726-14,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO,SORAFENIB IN ELDERLY PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (SERCC STIDY). IMPACT OF ADVERSE EVENTS MANAGEMENT IN ELDERLY mRCC PATIENTS TREATED WITH SORAFENIB.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019726-14,0,0,0 2010-019727-55,1,2015-06-01,2015-06-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,3,,Eradikeringsbehandling av MRSA- en jämförelse av kombinerad systemisk antibiotikabehandling och lokal mupirocinbehandling med enbart mupirocin för att eradikera MRSA vid svalgbärarskap,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019727-55,0,0,0 2010-019730-27,4,2012-10-01,2012-10-01,4,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, randomized, controlled, observer-blind study to assess the safety, reactogenicity and immunogenicity of two formulations of GlaxoSmithKline (GSK) Biologicals’ Streptococcus pneumoniae prot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019730-27,0,0,0 2010-019735-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Amiens,Effets du traitement substitutif par hormone de croissance chez les patients présentant un déficit somatotrope sévère secondaire à un traumatisme crânien,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019735-35,0,0,0 2010-019737-94,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,FIBHULP,"ESTUDIO ABIERTO, DE EFICACIA, TOLERANCIA Y SEGURIDAD DEL TRATAMIENTO CON EL FACTOR TRÓFICO IGF-I EN LA ATAXIA CEREBELOSA DEGENERATIVA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019737-94,0,0,0 2010-019740-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTI FISIOTERAPICI OSPITALIERI,Isotonic contrast (iodixanol) administration vs. low osmolar contrast (iopromide) use: evaluating risk of contrast-induced nephropathy in cancer patients at very low risk,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019740-39,0,0,0 2010-019742-12,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,A Phase II study with a sequential clofarabine-cyclophosphamide combination schedule as salvage therapy for refractory and relapsed acute lymphoblastic leukemia (ALL) in adult patients Studio di ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019742-12,0,0,0 2010-019745-25,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,CRUCELL SWITZERLAND AG,"A Phase III open, randomized, parallel, multi-center study in children aged 6 - 35 months to compare the immunogenicity and safety of a single 0.5 mL dose of Inflexal V with a 0.25 mL 2-dose regimen o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019745-25,0,0,0 2010-019748-38,1,2015-11-04,2015-11-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Heidelberg,Hautveränderungen bei Patienten mit Kopf- und Halstumor unter kombinierter RadioImmuno-(chemo)-therapie mit Erbitux®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019748-38,0,0,0 2010-019752-50,5,2013-06-12,2013-06-26,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A multicenter, multinational phase II study to assess the clinical safety and feasibility of T-DM1 sequentially with anthracyline-based chemotherapy, as adjuvant or neoadjuvant therapy for patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019752-50,0,0,0 2010-019754-41,1,2011-09-15,2011-09-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,InfectoPharm Arzneimittel und Consilium GmbH,"Multizentrische, prospektive, einarmige Phase III-Studie zur Wirksamkeit und Sicherheit einer oralen Therapie mit Propranolol (ProAngiol Saft; 2 mg/kg KG/d mit fakultativer Dosiserhöhung auf 3 mg/kg K...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019754-41,0,0,0 2010-019755-21,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Onconova Therapeutics Inc.,"A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019755-21,0,0,0 2010-019755-21,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ONCONOVA THERAPEUTICS,"A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019755-21,0,0,0 2010-019755-21,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Onconova Therapeutics Inc,"A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019755-21,0,0,0 2010-019756-42,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA SENESE,Sequential first line chemotherapy ECF (epirubicin + cisplatin + 5-fluoruracil) followed by DCF (docetaxel + cisplatin + 5-fluoruracil) in advanced/metastatic gastric cancer HER-2 negative: a phase II...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019756-42,0,0,0 2010-019758-42,3,2013-02-22,2013-02-22,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Phase 2 Randomized Study of LY2541546 Versus Placebo in Postmenopausal Women with Low Bone Mineral Density: An Evaluation of the Dose Response Relationship using Bone Mineral Density,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019758-42,0,0,0 2010-019759-23,1,2014-01-09,2014-01-09,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Guys' and St. Thomas' NHS Foundation Trust,Evaluation of [11C]-methionine positron emission computerised tomography (PET CT) in diagnosing neurofibromatosis 1(NF1) - malignant peripheral nerve sheath tumours (MPNST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019759-23,0,0,0 2010-019760-36,7,2014-09-03,2014-09-03,2,1,0,0,0,2,2,0,0,1,1,0,1,0,1,"Grifols Therapeutics, Incorporated","A Phase 2, Randomized, Open-label (with Blinded Plasminogen Activator and Placebo Control Groups) Study to Evaluate the Effects of Different Intra-thrombus Infusion Regimens of Plasmin (Human) Compare...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019760-36,0,0,0 2010-019760-36,7,2014-09-03,2014-09-03,2,1,0,0,0,2,2,0,0,1,1,0,1,0,1,"Talecris Biotherapeutics, Incorporated","A Phase 2, Randomized, Open-label (with Blinded Plasminogen Activator and Placebo Control Groups) Study to Evaluate the Effects of Different Intra-thrombus Infusion Regimens of Plasmin (Human) Compare...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019760-36,0,0,0 2010-019764-36,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,0,JOSEP ORDI-ROS,"RIVAROXABAN VERSUS ACENOCUMAROL EN LA PROFILAXIS SECUNDARIA DEL SÍNDROME ANTIFOSFOLÍPIDO:UN ESTUDIO MULTICÉNTRICO, PROSPECTIVO Y RANDOMIZADO.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019764-36,0,0,0 2010-019765-28,17,2015-08-07,2015-08-07,14,1,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB BIOSCIENCES GMBH,"A MULTICENTER, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, POSITIVE CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LACOSAMIDE (200 TO 600MG/DAY) TO CONTROLLED RELEASE CARBAMAZEPINE (400 TO 1200MG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019765-28,1,1,0 2010-019765-28,17,2015-08-07,2015-08-07,14,1,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB BIOSCIENCES GmbH,"A MULTICENTER, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, POSITIVE CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LACOSAMIDE (200 TO 600MG/DAY) TO CONTROLLED RELEASE CARBAMAZEPINE (400 TO 1200MG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019765-28,1,1,0 2010-019765-28,17,2015-08-07,2015-08-07,14,1,0,0,0,0,3,0,0,2,0,0,0,0,1,SCHWARZ BIOSCIENCES GmbH,"A MULTICENTER, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, POSITIVE CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LACOSAMIDE (200 TO 600MG/DAY) TO CONTROLLED RELEASE CARBAMAZEPINE (400 TO 1200MG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019765-28,1,1,0 2010-019767-11,1,,,0,0,0,0,0,1,4,0,0,1,0,0,0,1,0,Graz Medical University,Ö-PKU 1 – Evaluation of a Test for the identication of BH4 responsive PKU patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019767-11,0,0,0 2010-019768-35,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,3,,Intrathecal baclofen treatment in dystonic cerebral palsy: a randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019768-35,0,0,0 2010-019773-15,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,CYTHERIS,"A multicenter, open-labeled, controlled, randomized study of recombinant Interleukin-7 (CYT107) treatment to restore and maintain CD4 T-lymphocyte counts above 500 cells/�L in HIV-infected patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019773-15,0,0,0 2010-019774-33,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Fundación progreso y Salud,"Clinical trial phase I/II multicentric, open, randomized and controlled for the study of stem cells as therapy critical ischemia in low limbs in insulinized type 2 diabetic patients: study of the insu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019774-33,0,0,0 2010-019774-33,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,fundacion progreso y salud,"Clinical trial phase I/II multicentric, open, randomized and controlled for the study of stem cells as therapy critical ischemia in low limbs in insulinized type 2 diabetic patients: study of the insu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019774-33,0,0,0 2010-019775-29,3,2012-07-31,2012-07-31,3,1,0,0,0,0,2,0,1,1,0,0,1,0,1,MSD Finland Oy,"""Estudio multicéntrico y doble ciego de la seguridad, la tolerabilidad y la inmunogenicidad de una vacuna antineumocócica conjugada (V114) en comparación con Prevenar 13™ en lactantes sanos"";""A Multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019775-29,0,0,0 2010-019775-29,3,2012-07-31,2012-07-31,3,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","""Estudio multicéntrico y doble ciego de la seguridad, la tolerabilidad y la inmunogenicidad de una vacuna antineumocócica conjugada (V114) en comparación con Prevenar 13™ en lactantes sanos"";""A Multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019775-29,0,0,0 2010-019777-15,3,2012-05-30,2012-05-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline LLC,"A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Sitagliptin in Subjects With Type 2 Diabetes Melli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019777-15,0,0,0 2010-019778-34,3,2012-08-07,2012-08-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sunovion Pharmaceuticals Inc.,"A RANDOMIZED, 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, FLEXIBLE-DOSE, PARALLEL-GROUP STUDY OF LURASIDONE ADJUNCTIVE TO LITHIUM OR DIVALPROEX FOR THE TREATMENT OF BIPOLAR I DEPRESSION IN SUBJECTS DEMO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019778-34,0,0,0 2010-019778-34,3,2012-08-07,2012-08-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Sunovion, Inc.","A RANDOMIZED, 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, FLEXIBLE-DOSE, PARALLEL-GROUP STUDY OF LURASIDONE ADJUNCTIVE TO LITHIUM OR DIVALPROEX FOR THE TREATMENT OF BIPOLAR I DEPRESSION IN SUBJECTS DEMO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019778-34,0,0,0 2010-019783-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospital Trebic,Two doses of albumin after large paracentesis in cirrhotics with refractory ascites: a randomized study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019783-37,0,0,0 2010-019785-90,6,2012-04-01,2012-04-03,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase IIa, Double-blind, Randomised, Parallel-group, Multi-centre Study to Evaluate the Analgesic Efficacy of 28 Days Oral Administration of AZD2423 Compared to Placebo in Patients with Posttraumati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019785-90,0,0,0 2010-019787-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO PER L`INFANZIA BURLO GAROFOLO,ORAL ONDANSETRON VS DOMPERIDONE FOR SYMPTOMATIC TREATMENT OF VOMITING DURING ACUTE GASTROENTERITIS IN CHILDREN: MULTICENTRE RANDOMIZED CONTROLLED TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019787-36,0,0,0 2010-019788-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Laboratoire BIODERMA,Evaluation de la tolérance d'un produit cosmétique dans les suites de séances de photothérapie dynamique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019788-12,0,0,0 2010-019790-15,1,2011-03-04,2011-03-04,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,PHARMA MAR,"Open-label, Phase II Clinical Trial of Aplidin (Plitidepsin) in Patients with Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia (Post-PV/ET) Myelofibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019790-15,0,0,0 2010-019791-73,17,2011-07-06,2011-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-aventis recherche & développement,"A Randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019791-73,0,0,0 2010-019791-73,17,2011-07-06,2011-11-21,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-aventis recherche & d�veloppement,"A Randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019791-73,0,0,0 2010-019795-74,11,2013-04-17,2013-06-28,9,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"""Estudio Fase IIIb aleatorizado de dos años, simple ciego, multicéntrico y controlado, para evaluar la eficacia y seguridad de 0,5 mg de ranibizumab en dos algoritmos de tratamiento de tipo ""tratar y ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019795-74,0,0,0 2010-019795-74,11,2013-04-17,2013-06-28,9,1,0,0,1,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"""Estudio Fase IIIb aleatorizado de dos años, simple ciego, multicéntrico y controlado, para evaluar la eficacia y seguridad de 0,5 mg de ranibizumab en dos algoritmos de tratamiento de tipo ""tratar y ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019795-74,0,0,0 2010-019795-74,11,2013-04-17,2013-06-28,9,1,0,0,1,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","""Estudio Fase IIIb aleatorizado de dos años, simple ciego, multicéntrico y controlado, para evaluar la eficacia y seguridad de 0,5 mg de ranibizumab en dos algoritmos de tratamiento de tipo ""tratar y ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019795-74,0,0,0 2010-019797-32,6,2013-02-14,2013-06-14,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with inadequately contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019797-32,0,0,0 2010-019798-13,7,2013-02-07,2013-02-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with Inadequately Contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019798-13,0,0,0 2010-019802-17,12,2012-03-05,2012-03-07,10,1,1,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 micrograms administered once daily via the Respimat device in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019802-17,0,0,0 2010-019802-17,12,2012-03-05,2012-03-07,10,1,1,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 micrograms administered once daily via the Respimat device in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019802-17,0,0,0 2010-019802-17,12,2012-03-05,2012-03-07,10,1,1,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 micrograms administered once daily via the Respimat device in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019802-17,0,0,0 2010-019802-17,12,2012-03-05,2012-03-07,10,1,1,0,0,2,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A","A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 micrograms administered once daily via the Respimat device in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019802-17,0,0,0 2010-019802-17,12,2012-03-05,2012-03-07,10,1,1,0,0,2,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim RCV GmbH & Co KG,","A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 micrograms administered once daily via the Respimat device in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019802-17,0,0,0 2010-019802-17,12,2012-03-05,2012-03-07,10,1,1,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 micrograms administered once daily via the Respimat device in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019802-17,0,0,0 2010-019802-17,12,2012-03-05,2012-03-07,10,1,1,0,0,2,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 micrograms administered once daily via the Respimat device in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019802-17,0,0,0 2010-019802-17,12,2012-03-05,2012-03-07,10,1,1,0,0,2,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 micrograms administered once daily via the Respimat device in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019802-17,0,0,0 2010-019802-17,12,2012-03-05,2012-03-07,10,1,1,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH&Co KG,"A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 micrograms administered once daily via the Respimat device in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019802-17,0,0,0 2010-019802-17,12,2012-03-05,2012-03-07,10,1,1,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A randomised, double-blind, placebo-controlled parallel-group trial to confirm the efficacy after 12 weeks and the safety of tiotropium 5 micrograms administered once daily via the Respimat device in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019802-17,0,0,0 2010-019804-21,1,2010-12-08,2010-12-08,1,0,0,0,1,0,4,0,0,1,0,0,1,0,1,Wepa Apothekenbedarf GmbH & Co KG,"A randomised, controlled, assessor-blind, clinical investigation of the activity of mosquito® LäuseShampoo compared with Infectopedicul® permethrin 0.5% lotion in the treatment of head lice",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019804-21,0,0,0 2010-019805-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,Pharmacogenomics in optimizing the chemotherapy in the treatment of colorectal carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019805-41,0,0,0 2010-019809-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II,Efficacy of methylergometrine daily administration in puerperium,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019809-42,0,0,0 2010-019810-26,1,2019-09-05,2019-09-05,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,King's College Hospital Foundtion NHS Trust,"A randomised controlled trial to investigate the effects of the use of pre-operative GnRH analogue and intra-operative mechanical tourniquet for myomectomy on surgical blood loss, future fertility and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019810-26,0,0,0 2010-019815-40,1,2014-05-07,2014-05-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Skåne University Hospital, Department of Oncology",Avastin and chemotherapy followed by a KRAS stratified randomization to maintenance treatment for first line treatment of metastatic colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019815-40,0,0,0 2010-019817-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Bergonié,A phase II study of GDC-0449 in patients with advanced chondrosarcomas.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019817-20,0,0,0 2010-019820-30,10,2017-08-29,2017-08-29,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination with Low-Dose Dexamethasone versus High-Dose Dexamethasone in Subjects with Ref...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019820-30,0,0,0 2010-019821-32,13,2016-12-16,2016-12-16,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc.,"A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019821-32,0,0,0 2010-019825-32,2,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Novartis Pharma Service AG,"An exploratory, open label, non-randomized, within-patient multiple dose-escalation safety, tolerability, PK and efficacy trial of RAD001 (everolimus) in patients with Lymphangioleiomyomatosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019825-32,0,0,0 2010-019825-32,2,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"An exploratory, open label, non-randomized, within-patient multiple dose-escalation safety, tolerability, PK and efficacy trial of RAD001 (everolimus) in patients with Lymphangioleiomyomatosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019825-32,0,0,0 2010-019829-34,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,AN OPEN LABEL EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF DIFLUNISAL IN TRANSTHYRETIN HEREDITARY AMYLOIDOSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019829-34,0,0,0 2010-019830-29,1,2011-09-21,2011-09-21,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Hopitaux Universitaires de Strasbourg,Evaluation of the effects of CO2 insufflation on central body temperature and on postoperative pain in laparoscopic surgery VALUTAZIONE DEGLI EFFETTI DEL CONDIZIONAMENTO DELLA CO2 INSUFFLATA SULLA ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019830-29,0,0,0 2010-019831-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI,A phase III randomized trial comparing two regimens for treatment of cancer anorexia / cachexia syndrome(CACS).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019831-36,0,0,0 2010-019832-11,1,2012-02-06,2012-02-06,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline Research and Development Ltd,An open-label study to evaluate the utility of the apoptosis imaging biomarker [18F]ML-10 to assess the response to chemotherapy in patients with non Hodgkin's lymphoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019832-11,0,0,0 2010-019835-37,3,2010-12-07,2010-12-07,2,1,0,0,0,0,3,0,1,1,1,0,1,0,1,Sanofi Pasteur SA,"Safety and Immunogenicity of an Intramuscular H5N1 Inactivated, Split Virion Influenza Vaccine Adjuvanted with AF03 in Adults and Elderly subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019835-37,0,0,0 2010-019837-85,1,2016-03-11,2016-03-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU de Poitiers,Étude de la toxicité cutanée du cétuximab (anti-Epidermal Growth Factor Receptor): recherche d’un lien entre la réponse inflammatoire cutanée et la réponse radiologique.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019837-85,0,0,0 2010-019841-25,1,2014-07-15,2014-07-15,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,A Phase II Study to evaluate activity and toxicity of Gemcitabine in Combination with Pemetrexed long term infusion in the Treatment of pretreated Metastatic Colorectal Cancer Patients Studio di fa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019841-25,0,0,0 2010-019843-20,2,2016-01-05,2016-01-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen R&D Ireland,A Prospective 3-Year Follow-up Study in Subjects Previously Treated in a Phase IIb or Phase III Study With a TMC435-Containing Regimen for the Treatment of Hepatitis C Virus (HCV) infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019843-20,0,0,0 2010-019844-38,8,2012-10-29,2012-10-29,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF EARLY TREATMENT WITH EPLERENONE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019844-38,0,0,0 2010-019844-38,8,2012-10-29,2012-10-29,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Inc.,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF EARLY TREATMENT WITH EPLERENONE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019844-38,0,0,0 2010-019844-38,8,2012-10-29,2012-10-29,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA","A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF EARLY TREATMENT WITH EPLERENONE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019844-38,0,0,0 2010-019844-38,8,2012-10-29,2012-10-29,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer, S.A","A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF EARLY TREATMENT WITH EPLERENONE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019844-38,0,0,0 2010-019850-42,5,2017-04-26,2017-04-26,2,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Alexion Pharma International Sàrl,"An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase alfa (human recombinant tissue nonspecific alkaline phosphatase fusion protein) in Infants and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019850-42,1,0,0 2010-019850-42,5,2017-04-26,2017-04-26,2,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Alexion Pharma GmbH,"An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase alfa (human recombinant tissue nonspecific alkaline phosphatase fusion protein) in Infants and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019850-42,1,0,0 2010-019850-42,5,2017-04-26,2017-04-26,2,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Alexion Pharma GmbH,"An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase alfa (human recombinant tissue nonspecific alkaline phosphatase fusion protein) in Infants and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019850-42,1,0,0 2010-019856-30,1,2010-07-22,2010-07-22,1,1,0,0,0,1,3,0,0,1,1,1,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, vehicle-controlled, multicenter trial of topically administered LDE225 cream [0.75% bid] to evaluate clearance of Basal Cell Carcinoma in adult patients with Nevoid Basa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019856-30,0,0,0 2010-019858-41,3,2012-12-20,2012-12-20,3,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Avraham Pharmaceuticals Ltd.,"A 6-month prospective, multi-center, double-blind, placebo-controlled, randomized, adaptive-trial-design study to evaluate the safety and efficacy of 80mg b.i.d. ladostigil in patients with mild to mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019858-41,0,0,0 2010-019859-21,4,2013-11-15,2013-11-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd.,"A PHASE II, OPEN LABEL, PARALLEL GROUP, MULTI-CENTER STUDY TO COMPARE THE PHARMACOKINETICS OF TACROLIMUS IN ADULT SUBJECTS UNDERGOING PRIMARY ALLOGRAFT TRANSPLANTATION RECEIVING AN ADVAGRAF OR PROGRAF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019859-21,0,0,0 2010-019859-21,4,2013-11-15,2013-11-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTELLAS PHARMA,"A PHASE II, OPEN LABEL, PARALLEL GROUP, MULTI-CENTER STUDY TO COMPARE THE PHARMACOKINETICS OF TACROLIMUS IN ADULT SUBJECTS UNDERGOING PRIMARY ALLOGRAFT TRANSPLANTATION RECEIVING AN ADVAGRAF OR PROGRAF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019859-21,0,0,0 2010-019862-10,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,IPSEN,"Randomised, phase III multicenter, open study of lanreotide in non metastatic castration-resistant prostate cancer patients presenting elevated Chromogranin A levels",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019862-10,0,0,0 2010-019863-12,1,,,0,0,0,0,1,3,3,0,1,4,0,0,0,0,0,Paris Descartes - Laboratoire Psychologie Clinique et Psychopathologie,"Analyse du mouvement rythmique spontané, mesure de la cohérence cardiaque et appréciation des conduites cliniques et langagières chez des enfants hyperactifs en situation d'examen psychométrique et de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019863-12,0,0,0 2010-019864-36,1,2012-02-10,2012-02-10,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"University Hospital of Antwerp, Department of Respiratory Medicine","Open-label, prospective exploratory study to assess the effects of formoterol and beclometasone dipropionate combination therapy on central and peripheral airway dimensions in COPD patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019864-36,0,0,0 2010-019865-26,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Estetra S.A.,"A randomised, open-label, multi-centre, dose-finding study to evaluate cycle control of 15 mg or 20 mg estetrol combined with either 150 μg levonorgestrel or 3 mg drospirenone, compared to a combined ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019865-26,0,0,0 2010-019866-96,4,2013-03-26,2013-03-26,2,0,0,0,0,1,3,0,0,2,1,0,0,0,1,ZIOPHARM Oncology Inc,"A Phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus placebo in patients with front-line metastatic s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019866-96,1,0,0 2010-019867-13,9,2013-10-14,2013-10-15,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp.,","""A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019867-13,0,0,0 2010-019867-13,9,2013-10-14,2013-10-15,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"MERCK & CO., INC.","""A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019867-13,0,0,0 2010-019867-13,9,2013-10-14,2013-10-15,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"""A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019867-13,0,0,0 2010-019867-13,9,2013-10-14,2013-10-15,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Corp.,"""A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019867-13,0,0,0 2010-019867-13,9,2013-10-14,2013-10-15,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohm Corp, a subsidiary of Merck Co., Inc","""A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019867-13,0,0,0 2010-019867-13,9,2013-10-14,2013-10-15,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.","""A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019867-13,0,0,0 2010-019867-13,9,2013-10-14,2013-10-15,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","""A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019867-13,0,0,0 2010-019867-13,9,2013-10-14,2013-10-15,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","""A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019867-13,0,0,0 2010-019871-31,8,2014-08-07,2014-08-07,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,","A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK- 0663/Etoricoxib in Patients with R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019871-31,0,0,0 2010-019871-31,8,2014-08-07,2014-08-07,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK- 0663/Etoricoxib in Patients with R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019871-31,0,0,0 2010-019872-65,10,2014-11-12,2014-11-12,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019872-65,0,0,0 2010-019872-65,10,2014-11-12,2014-11-12,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,","A Phase III, Two-Part, Randomized, Double-Blind, Active Comparator-Controlled, Multicenter Clinical Trial to Study the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019872-65,0,0,0 2010-019873-13,1,2013-09-16,2013-09-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UCL Cliniques Universitaires Saint Luc,Comparative study of the clinical response and cardiorespiratory endurance in early rheumatoid arthritis patients treated with Tociluzimab or Methotrexate Addendum protocol : Global gene expression pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019873-13,0,0,0 2010-019874-34,1,2015-06-22,2015-06-22,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,Queen Mary University of London,"A randomised, placebo controlled, double-blind, cross-over trial of the Polypill on risk factor reduction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019874-34,0,0,0 2010-019879-29,1,2012-06-06,2012-06-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Fundació Lluita contra la SIDA,MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM TENOFOVIR TO ABACAVIR IN HIV-1-INFECTED SUBJECTS WITH LOSS OF BONE MINERAL DENSITY (ESTUDIO MULTICÉNTRICO PARA EVALUAR LO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019879-29,0,0,0 2010-019881-96,2,2011-08-30,2011-08-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.",A PHASE 3 MULTI-CENTER PARALLEL DESIGN CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF 5% MINOXIDIL FOAM VS. VEHICLE IN FEMALES FOR THE TREATMENT OF FEMALE PATTERN HAIR LOSS (ANDROGENETIC ALOPECI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019881-96,0,0,0 2010-019883-36,3,2012-12-06,2013-01-22,2,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019883-36,0,0,0 2010-019883-36,3,2012-12-06,2013-01-22,2,1,0,0,0,2,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019883-36,0,0,0 2010-019883-36,3,2012-12-06,2013-01-22,2,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019883-36,0,0,0 2010-019884-12,1,2013-11-30,2013-11-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Universitätsklinikum Aachen,Induction of Fibrosis Regression regarding Chronic Hepatitis B Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019884-12,0,0,0 2010-019885-10,1,2017-07-09,2017-07-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsmedizin Mainz (vertreten durch den wissenschaftlichen Vorstand),Non-randomized phase-IV-study to investigate the efficacy of FOLFIRI in combination with cetuximab in the first-line treatment of metastatic colorectal cancer inculding a regular dermal prophylaxis to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019885-10,0,0,0 2010-019887-35,3,2012-06-20,2013-06-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Advanced BioHealing Inc,"A Prospective, Multi-center, Longitudinal Cohort Study of Dermagraft® in Subjects with Venous Leg Ulcers: A Long-term Follow-up to the DEVO-Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019887-35,0,0,0 2010-019887-35,3,2012-06-20,2013-06-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Shire Regenerative Medicine, Inc.","A Prospective, Multi-center, Longitudinal Cohort Study of Dermagraft® in Subjects with Venous Leg Ulcers: A Long-term Follow-up to the DEVO-Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019887-35,0,0,0 2010-019888-10,7,2012-10-31,2012-10-31,6,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",PROSPECTIVE OPEN-LABEL INVESTIGATION OF THE NON-SURGICAL TREATMENT WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (XIAPEX®),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019888-10,0,0,0 2010-019888-10,7,2012-10-31,2012-10-31,6,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017 US",PROSPECTIVE OPEN-LABEL INVESTIGATION OF THE NON-SURGICAL TREATMENT WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM (XIAPEX®),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019888-10,0,0,0 2010-019891-54,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,VU University Medical Center,Effects of oral corticosteroids and DMSO on inflammatory signs and symptoms in Complex Regional Pain Syndrome type 1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019891-54,0,0,0 2010-019892-31,1,2012-03-30,2012-03-30,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Lightlake Sinclair Oy,Hoitotutkimus BED-syömishäiriöstä ja sen taustatekijöistä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019892-31,0,0,0 2010-019894-13,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH,The Parkinson's Progression Markers Initiative (PPMI) I Marcatori di Progressione della Malattia di Parkinson,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019894-13,0,0,0 2010-019895-66,11,2020-09-10,2020-09-10,10,1,0,0,0,0,0,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"Estudio multicéntrico, randomizado, doble ciego, controlado con placebo, con grupos de tratamiento paralelos, de dos años de duración, para evaluar el efecto de RO4909832 administrado por vía subcután...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019895-66,0,0,0 2010-019897-33,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,erasmus mc,Selective D1 activation by addition of L-Dopa to antipsychotic treatment in patients with schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019897-33,0,0,0 2010-019899-77,1,2012-07-30,2012-07-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Mette Astrup Madsen,Can preoperative Dexamethasone optimise surgical outcomes after laparoscopic inguinal hernia repair.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019899-77,0,0,0 2010-019902-17,4,2012-08-06,2012-08-06,4,1,0,0,0,0,3,0,2,1,0,0,1,0,1,Bayer HealthCare AG,"A multicenter, open-label, randomized, controlled, two-arm study to assess compliance with daily tablet intake of women on treatment with the oral contraceptive SH T00186D/BAY 86-5300 (0.02 mg ethinyl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019902-17,0,0,0 2010-019907-43,6,2013-06-04,2013-06-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ipsen Innovation,"A phase III, randomised, double blind and open label phase, active and placebo controlled study comparing the short term efficacy of two formulations of clostridium botulinum type A toxin (Dysport and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019907-43,0,0,0 2010-019909-42,4,2014-07-18,2014-11-14,2,1,0,1,0,0,1,0,0,1,1,1,0,0,2,GlaxoSmithKline Biologicals,"A double-blind, randomized, placebo-controlled, Phase I/II Study evaluating the safety, immunogenicity and clinical activity of neoadjuvant treatment with WT1-A10 + AS15 Antigen-Specific Cancer Immuno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019909-42,0,0,0 2010-019912-18,4,2013-11-07,2013-11-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomized, double-blind, parallel-group study of safety and the effect on clinical outcome of tocilizumab SC versus placebo SC in combination with traditional disease modifying anti-rheumatic drugs...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019912-18,0,0,0 2010-019913-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ISTITUTO GIANNINA GASLINI,"Sterofundin vs Normale Saline for intraoperative fluid therapy in children aged under 36 months, undergoing surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019913-12,0,0,0 2010-019920-30,1,2011-05-14,2011-05-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Rigshospitalet,Cardiology Laboratory 2013","A Single center, open, randomized, placebo-controlled study investigating the safety of administration of Ilomedin® in addition to standard treatment in patients having undergone percutaneous coronary...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019920-30,0,0,0 2010-019925-33,9,2011-09-01,2011-09-27,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019925-33,0,0,0 2010-019926-15,1,2012-09-10,2012-09-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Celgene Corporation,"A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, TO COMPARE THE EFFICACY AND SAFETY OF TWO DOSES OF APREMILAST (CC-10004) IN SUBJECTS WITH ACTIVE RHEUMATOID ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019926-15,0,0,0 2010-019930-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Accare,The effectiveness of Parent-Child Interaction Therapy versus methylphenidate in preschool children with ADHD and disruptive behavior problems with insufficient improvement through Parent Management Tr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019930-28,0,0,0 2010-019932-11,1,2013-03-01,2013-03-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Seattle Genetics, Inc.",Treatment with SGN-35 in patients with CD30-positive hematologic malignancies who have previously participated in an SGN-35 study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019932-11,0,0,0 2010-019933-89,1,2012-10-01,2012-10-01,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,"St. George's, University of London",Investigation of a low dose Iohexol infusion for the measurement of Glomerular Filtration Rate (GFR) in adult volunteers and patients with Chronic Kidney Disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019933-89,0,0,0 2010-019935-37,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Roche Oy,"A pragmatic, randomized, parallel group study of the effect on disease remission, work productivity, and tolerability of tocilizumab in combination with DMARDs and individually designed best practice ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019935-37,0,0,0 2010-019937-85,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Dr. Luis Serra Majem,"Dieta Mediterránea, Ejercicio y Estatinas en el Tratamiento de la Dislipemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019937-85,0,0,0 2010-019938-27,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Input of tact and kinestesia in strength perception.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019938-27,0,0,0 2010-019939-35,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,CNIC Centro Nacional de Investigaciones Cardiológicas,Daño por isquémia-reperfusión: nuevos datos en el conocimiento de los mecanismos de acción responsables de la cardioprotección conferida por el B-bloqueo en el infarto agudo de miocardio.Traslación de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019939-35,0,0,0 2010-019941-24,7,2016-04-20,2017-02-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis and a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019941-24,0,0,0 2010-019942-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,"Randomized, fase II-III study of peri and post surgery chemiotherapy in removable pancreas carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019942-23,0,0,0 2010-019945-24,1,2011-06-14,2011-06-14,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Birken GmbH,"Open, Prospective, Controlled Case series Documentation to Compare Intra-individually the Efficacy and Tolerance of Sericare versus Non-adhesive Wound Dressing alone in Accelerating the Epithelializat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019945-24,0,0,0 2010-019947-21,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,CAIBER,"Phase III study, multicenter, randomized, double-blind, parallel group measuring the efficacy and safety of flunarizine in the prevention of migraine in the pediatric population. Estudio de Fase II...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019947-21,0,0,0 2010-019950-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Essai randomisé multicentrique d’efficacité et de tolérance dans le traitement de l’accès palustre simple d’importation par Riamet® versus Malarone®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019950-42,0,0,0 2010-019952-35,8,2020-12-04,2020-12-04,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,CEL-SCI Corporation,"A Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection [Multikine] Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemoradiot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019952-35,1,0,0 2010-019953-16,1,2013-09-16,2013-09-16,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Royal Devon & Exeter Foundation Trust,A Preliminary Randomised Controlled Trial using Standard Therapy Vs Mugard,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019953-16,0,0,0 2010-019954-42,1,2013-01-18,2013-01-18,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Med. Klinik II, Klinikum der Universität München Grosshadern",Effect of Niacin/ Laropiprant on postprandial lipoprotein and glucose metabolism in patients with severe dyslipoproteinemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019954-42,0,0,0 2010-019955-23,1,2012-11-13,2012-11-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Liverpool Women's NHS Foundation Trust,"To evaluate the pharmakcokinetics, tolerability and short term safety of ciprofloxacin in neonates and infants with suspected (or proven) Gram Negative Infection Open Label pilot PK study - TINN Trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019955-23,0,0,0 2010-019955-23,1,2012-11-13,2012-11-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Liverpoool Womens NHS Foundation Trust,"To evaluate the pharmakcokinetics, tolerability and short term safety of ciprofloxacin in neonates and infants with suspected (or proven) Gram Negative Infection Open Label pilot PK study - TINN Trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019955-23,0,0,0 2010-019956-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Allan Vaag, Steno Diabetes Center",Safety and efficacy of liraglutide as add-on to insulin and metformin therapy in type 2 diabetes patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019956-32,0,0,0 2010-019962-10,1,2013-05-30,2013-05-30,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,SANFILIPPO Therapeutics SAS,"AN OPEN-LABEL, SINGLE ARM, MONOCENTRIC, PHASE I/II CLINICAL STUDY OF INTRACEREBRAL ADMINISTRATION OF ADENO-ASSOCIATED VIRAL VECTORS SEROTYPE 10 CARRYING THE HUMAN SGSH AND SUMF1 cDNAS FOR THE TREATMEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019962-10,0,0,0 2010-019964-36,4,2011-07-07,2011-07-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ChemoCentryx, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects with Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019964-36,0,0,0 2010-019965-27,1,2016-09-15,2016-09-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Swiss Group for Clinical Cancer Research,"Fulvestrant with or without AZD6244, a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor: a randomized placebo-controll...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019965-27,0,0,0 2010-019966-95,1,2015-07-14,2015-07-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Duke University,A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019966-95,0,0,0 2010-019968-37,6,2013-04-18,2013-04-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH&CoKG,"A phase III, randomized, double-blind, placebo-controlled, parallel group safety and efficacy study of BI 10773 (10 mg and 25 mg administered orally once daily) during 52 weeks in patients with type 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019968-37,0,0,0 2010-019968-37,6,2013-04-18,2013-04-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A phase III, randomized, double-blind, placebo-controlled, parallel group safety and efficacy study of BI 10773 (10 mg and 25 mg administered orally once daily) during 52 weeks in patients with type 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019968-37,0,0,0 2010-019968-37,6,2013-04-18,2013-04-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase III, randomized, double-blind, placebo-controlled, parallel group safety and efficacy study of BI 10773 (10 mg and 25 mg administered orally once daily) during 52 weeks in patients with type 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019968-37,0,0,0 2010-019968-37,6,2013-04-18,2013-04-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A phase III, randomized, double-blind, placebo-controlled, parallel group safety and efficacy study of BI 10773 (10 mg and 25 mg administered orally once daily) during 52 weeks in patients with type 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019968-37,0,0,0 2010-019968-37,6,2013-04-18,2013-04-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A phase III, randomized, double-blind, placebo-controlled, parallel group safety and efficacy study of BI 10773 (10 mg and 25 mg administered orally once daily) during 52 weeks in patients with type 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019968-37,0,0,0 2010-019970-33,5,2012-05-02,2012-05-15,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Services AG,"A multi-centre, double-blind, placebo controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of KRP203 in subjects with moderately active refractory ulcer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019970-33,0,0,0 2010-019972-65,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Essai clinique, randomisé, multicentrique comparant l’efficacité et la tolérance d’un traitement prénatal par l’association pyriméthamine et sulfadiazine vs spiramycine pour réduire la transmission ve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019972-65,0,0,0 2010-019973-13,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Novartis Pharma AG,"A multi-center, randomized, double-blind, active controlled study to assess efficacy, safety and tolerability of the anti-IL13 monoclonal antibody QAX576 in the treatment of perianal fistulas in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019973-13,0,0,0 2010-019975-30,1,2014-04-23,2014-04-23,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"University Medical Center, Johannes Gutenberg-University Mainz","Investigation of the efficacy and safety of preoperative IOP reduction with preservative-free COSOPT-S® (dorzolamide/timolol, MSD) eye drops versus oral acetazolamide and dexamethasone eye drops and a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019975-30,0,0,0 2010-019977-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA,Efficacy of Cilostazol for the treatment of Raynaud’s Phenomenon in patients affected by Systemic Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019977-14,0,0,0 2010-019980-13,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,Ipsen Farmaceutica b.v.,Predictive value of baseline and stimulated serum IGF-I and IGFBP-3 during a dose-escalation IGF-I generation test with NutropinAq for the 1 year growth response to growth hormone (GH) therapy in shor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019980-13,0,0,0 2010-019981-94,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,HUS/ Neuropsykiatrian poliklinikka,"Attention Deficit Hyperactivity Disorder (ADHD) and opioid maintenance therapy. A randomized, placebo-controlled study of the efficacy of atomoxetine for treating adult ADHD in patients receiving opio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019981-94,0,0,0 2010-019982-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU medical center,"Targeted therapy selection based on tumor tissue kinase activity profiles for patients with advanced solid malignancies, an exploratory study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019982-27,0,0,0 2010-019983-35,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Cliniques universitaires Saint Luc,Phase I-II study of low dose CdA combined with valproic acid (VPA) in previously treated B-cell chronic lymphocytic leukemia (CLL) patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019983-35,0,0,0 2010-019984-12,1,2012-09-24,2012-09-24,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Adelaide & Meath Hospital, incorporating The National Children's Hospital","A multicentre randomised trial comparing the effects of 2% chlorhexidine gluconate in 70% isopropyl alcohol as a skin, exit site and catheter hub cleansing agent versus other forms of chlorhexidine gl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019984-12,0,0,0 2010-019986-27,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,ISTITUTO AUXOLOGICO ITALIANO,"Breathing disorders in heart failure: high altitude hypoxia as a model to define diagnostic tools, therapeutic strategies and gender related differences.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019986-27,0,0,0 2010-019987-35,6,2013-12-26,2013-12-26,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Phase 2, Interventional, Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects with Immune Thrombocytopenia Purpura Receiving Romiplostim.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019987-35,0,0,0 2010-019988-10,2,2013-04-17,2013-04-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, 10017","A PHASE 3, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019988-10,0,0,0 2010-019989-91,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Exploratory Study to Evaluate the Effect of Adding GSK2190915 300mg Tablets ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019989-91,0,0,0 2010-019991-55,4,2016-11-22,2016-11-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Celgene Corporation Headquarters,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS Studio di fase 3, m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019991-55,0,0,0 2010-019991-55,4,2016-11-22,2016-11-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS Studio di fase 3, m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019991-55,0,0,0 2010-019992-30,5,2016-11-30,2016-11-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis Studio di fase 3, mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019992-30,0,0,0 2010-019994-13,1,2011-05-09,2011-05-09,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GALDERMA R&D,EXPLORATORY STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CD07387 SOLUTION IN PATIENTS WITH VITILIGO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019994-13,0,0,0 2010-019996-32,6,2014-04-21,2014-05-21,5,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Neovacs SA,"A phase II, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety and immunogenicity of Neovacs’ TNFα-Kinoid in adult subjects with Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019996-32,0,0,0 2010-019997-33,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Leiden University Medical Center,Responsiveness to botulinum toxinum type A in complex regional pain syndrome related fixed dystonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019997-33,0,0,0 2010-019998-14,6,2012-01-17,2012-01-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,"Evaluación de la efectividad, seguridad y tolerabilidad de tapentadol de liberación prolongada frente a una combinación de tapentadol de liberación prolongada y pregabalina en pacientes con lumbalgia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019998-14,0,0,0 2010-020002-15,14,2016-03-08,2016-06-22,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 3, MULTI-SITE, OPEN-LABEL STUDY OF THE LONG TERM SAFETY AND TOLERABILITY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020002-15,0,0,0 2010-020002-15,14,2016-03-08,2016-06-22,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"PFIZER, S.A.","A PHASE 3, MULTI-SITE, OPEN-LABEL STUDY OF THE LONG TERM SAFETY AND TOLERABILITY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020002-15,0,0,0 2010-020002-15,14,2016-03-08,2016-06-22,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New york, NY 10017","A PHASE 3, MULTI-SITE, OPEN-LABEL STUDY OF THE LONG TERM SAFETY AND TOLERABILITY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020002-15,0,0,0 2010-020003-73,2,2013-04-24,2013-04-24,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, 10017","A PHASE 3, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020003-73,0,0,0 2010-020003-73,2,2013-04-24,2013-04-24,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, 10017 USA","A PHASE 3, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020003-73,0,0,0 2010-020004-30,14,2013-01-29,2013-01-29,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","""Estudio en fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo y con grupos paralelos para evaluar la eficacia y la seguridad de 2 dosis orales de CP 690,550 y 1 dosis subcutánea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020004-30,0,0,0 2010-020004-30,14,2013-01-29,2013-01-29,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,PFIZER INC.,"""Estudio en fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo y con grupos paralelos para evaluar la eficacia y la seguridad de 2 dosis orales de CP 690,550 y 1 dosis subcutánea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020004-30,0,0,0 2010-020004-30,14,2013-01-29,2013-01-29,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Pfizer Inc,"""Estudio en fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo y con grupos paralelos para evaluar la eficacia y la seguridad de 2 dosis orales de CP 690,550 y 1 dosis subcutánea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020004-30,0,0,0 2010-020004-30,14,2013-01-29,2013-01-29,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,PFIZER S.A.,"""Estudio en fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo y con grupos paralelos para evaluar la eficacia y la seguridad de 2 dosis orales de CP 690,550 y 1 dosis subcutánea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020004-30,0,0,0 2010-020004-30,14,2013-01-29,2013-01-29,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA","""Estudio en fase 3, multicéntrico, aleatorizado, doble ciego, controlado con placebo y con grupos paralelos para evaluar la eficacia y la seguridad de 2 dosis orales de CP 690,550 y 1 dosis subcutánea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020004-30,0,0,0 2010-020005-32,7,2013-01-31,2013-01-31,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","A PHASE 3, MULTI-SITE, RANDOMIZED, MIXED-BLIND, PARALLEL-GROUP TREATMENT WITHDRAWAL AND RE-TREATMENT STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020005-32,0,0,0 2010-020008-31,1,2016-10-27,2016-10-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ACADIA Pharmaceuticals Inc,"A Single center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020008-31,0,0,0 2010-020010-28,1,,,0,0,0,0,0,1,4,0,0,1,1,1,0,1,0,Dr.ssa Marina Aiello-Universit� degli studi di Parma,EVALUATION OF RESPIRATORY MUSCLES` FUNCTION IN PATIENTS AFFECTED BY ALS WITH HEAVY METAL POISONING,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020010-28,0,0,0 2010-020014-28,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Centre for Human Drug Research,Pharmacokinetics in Plasma and Saliva of a Single Dose Immediate- or Extended Release Methylphenidate in Healthy Volunteers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020014-28,0,0,0 2010-020015-36,1,2012-03-31,2012-03-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Diabeteszentrum Bad Lauterberg,„Feed-Back“-Suppression der Nahrungs-induzierten GLP-1-Sekretion durch Erhöhung des intakten GLP-1 unter DPP-4-Inhibition: Ein Vergleich von Vildagliptin und Sitagliptin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020015-36,0,0,0 2010-020018-27,1,2014-09-12,2014-09-12,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Tameside Hospital NHS Foundation Trust,Effect of Testosterone on endothelial function and Microcirculation in Type 2 Diabetic patients with Hypoganadism.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020018-27,0,0,0 2010-020020-21,1,2016-04-14,2016-04-14,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Leeds Teaching Hospitals Trust,Comparison of the ED95 dose of 0.075% and 0.1% bupivacaine for labour analgesia in primigravida,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020020-21,0,0,0 2010-020023-43,2,2015-11-04,2015-11-04,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Bioven (Europe) Ltd.,"A Phase III, open-label, multicentre, randomised trial to establish safety and efficacy of an EGF cancer vaccine in inoperable, late stage (IIIb/IV) NSCLC patients eligible to receive standard treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020023-43,0,0,0 2010-020026-17,2,2010-08-06,2010-08-06,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Baxter Innovations GmbH,"AN OPEN-LABEL PHASE 3 STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF A VERO CELL-DERIVED TRIVALENT SEASONAL INFLUENZA VACCINE, STRAIN COMPOSITION 2010/2011, IN AN ADULT AND ELDERLY POPULATION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020026-17,0,0,0 2010-020030-25,1,2013-11-13,2013-11-13,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"ACCESS Pharmaceuticals, Inc",A Phase II Trial of ProLindac™ and Paclitaxel Combination as Second Line-Treatment in Platinum Pretreated Patients with Advanced Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020030-25,0,0,0 2010-020033-14,8,2013-05-09,2013-05-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicentre, randomized, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of DEB025 combined with peg-IFN alfa-2a and ribavirin in chronic hepatitis C genot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020033-14,0,0,0 2010-020033-14,8,2013-05-09,2013-05-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multicentre, randomized, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of DEB025 combined with peg-IFN alfa-2a and ribavirin in chronic hepatitis C genot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020033-14,0,0,0 2010-020033-14,8,2013-05-09,2013-05-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A multicentre, randomized, double-blind, placebo-controlled, parallel-group phase II study on the efficacy and safety of DEB025 combined with peg-IFN alfa-2a and ribavirin in chronic hepatitis C genot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020033-14,0,0,0 2010-020034-26,5,2012-05-15,2012-05-15,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, open label, parallel-group phase IIB study on the efficacy and safety of oral regimens of DEB025 alone or in combination with ribavirin versus Standard of Care (peg-IFNα2a p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020034-26,0,0,0 2010-020034-26,5,2012-05-15,2012-05-15,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multicenter, randomized, open label, parallel-group phase IIB study on the efficacy and safety of oral regimens of DEB025 alone or in combination with ribavirin versus Standard of Care (peg-IFNα2a p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020034-26,0,0,0 2010-020040-35,1,2011-06-17,2011-06-17,1,0,0,0,0,0,4,0,1,1,0,0,1,0,1,MicroCHIPS,Pharmacokinetics of hPTH (1-34) delivery with MicroCHIPS’ implantable reservoir array device.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020040-35,0,0,0 2010-020041-27,1,2013-10-14,2013-10-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Dept of Endocrinology O106, Herlev Hospital",Liothyronin (T3) og hjertesvigt,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020041-27,0,0,0 2010-020042-94,1,2013-04-01,2013-04-01,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin",The Effect of High-dose Remifentanil on the Reversal of Neuropathic Pain in Postherpetic Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020042-94,0,0,0 2010-020043-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,Analgésie post-opératoire en chirurgie cardiaque:effet de l'administration continue de ropivacaine par cathéter multiperforé bi-latérosternal après sternotomie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020043-13,0,0,0 2010-020044-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Clermont-Ferrand,PHARMACOCINETIQUE DU SEVOFLURANE LORS D’UNE SEDATION SUR 48H EN REANIMATION AVEC LE SYSTEME ANACONDA : EVALUATION CHEZ LE PATIENT OBESE.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020044-35,0,0,0 2010-020047-12,1,2021-07-20,2021-07-20,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude de l'effet d'un traitement préventif par Nebivolol sur l'apparition et la progression de la dysfonction cardiaque chez les enfants atteints de dystrophie de Duchenne,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020047-12,0,0,0 2010-020048-36,1,2012-10-29,2012-10-29,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"Shire HGT, Inc","A Phase I/II, Randomized, Safety and Ascending Dose Ranging Study of Intrathecal Idursulfase-IT administered in conjunction with intravenous Elaprase in Pediatric Patients with Hunter Syndrome and Cog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020048-36,0,0,0 2010-020053-14,5,2012-03-09,2012-03-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diabete...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020053-14,0,0,0 2010-020053-14,5,2012-03-09,2012-03-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Research & Development,"A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diabete...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020053-14,0,0,0 2010-020057-13,1,2012-01-05,2012-01-05,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Dermatologikum Hamburg,Proof-of-concept-study to Evaluate the Efficacy and Tolerability of Repeated Versus Single Treatment with Botulinum-Toxin (Vistabel®) Treatment in Combination with a Hyaluronic Acid (Juvederm-Ultra® 2...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020057-13,0,0,0 2010-020060-38,1,2013-05-22,2013-05-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label extension study of CACZ885H2357E1 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020060-38,0,0,0 2010-020061-24,3,2014-06-20,2014-06-20,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 5-month follow-up and long term treatment period in patients with active recurrent or chronic TNF-receptor a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020061-24,0,0,0 2010-020061-24,3,2014-06-20,2014-06-20,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 5-month follow-up and long term treatment period in patients with active recurrent or chronic TNF-receptor a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020061-24,0,0,0 2010-020063-21,1,2010-07-27,2010-07-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Charité-Universitätsmedizin,"“A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis”",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020063-21,0,0,0 2010-020065-24,12,2016-03-23,2016-03-23,10,1,0,0,0,0,4,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020065-24,0,0,0 2010-020065-24,12,2016-03-23,2016-03-23,10,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ROCHE,A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020065-24,0,0,0 2010-020067-20,1,2014-10-30,2014-10-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Hôpital FOCH,"A multicentre phase II trial to determine the efficacy of RAD 001 (everolimus, Afinitor®) as second line therapy in patients with transitional cell carcinoma (TCC) of the urothelium which failed or pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020067-20,0,0,0 2010-020069-26,12,2013-06-28,2013-08-28,10,1,1,0,0,1,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research and Development LTD,"A phase III, randomized, double blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in subjects with Duchenne muscular dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020069-26,1,1,0 2010-020069-26,12,2013-06-28,2013-08-28,10,1,1,0,0,1,3,0,0,2,0,0,0,0,1,GlaxoSmithKline.S.A.,"A phase III, randomized, double blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in subjects with Duchenne muscular dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020069-26,1,1,0 2010-020072-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI,"Bendamustine, Bortezomib and Dexamethasone (BVD) in the treatment of relapsed or refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020072-33,0,0,0 2010-020077-16,9,2014-10-03,2016-03-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH A 92 W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020077-16,0,0,0 2010-020077-16,9,2014-10-03,2016-03-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Ltd., Ramsgate Road, Sandwich, kent, CT13 9NJ, United Kingdom","A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH A 92 W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020077-16,0,0,0 2010-020077-16,9,2014-10-03,2016-03-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer, S.A","A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH A 92 W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020077-16,0,0,0 2010-020077-16,9,2014-10-03,2016-03-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc,"A MULTICENTRE, 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ETANERCEPT ON A BACKGROUND NSAID IN THE TREATMENT OF ADULT SUBJECTS WITH NON RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH A 92 W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020077-16,0,0,0 2010-020079-22,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,STALLERGENES S.A.,"Determination of sensitivity and specificity of five solutions of allergen extract (5 grasses, birch, ragweed pollens and Dermatophagoides pteronyssinus and Dermatophagoides farinae mites) for diagnos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020079-22,0,0,0 2010-020081-22,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,North Bristol NHS Trust,The administration of Parathyroid hormone affects functional recovery from pertrochanteric fractured neck of femur: A prospective randomised comparative pilot study with blinded objective functional o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020081-22,0,0,0 2010-020083-38,8,2012-09-14,2012-09-14,6,1,0,0,0,0,2,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A Multicenter, Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged ≥ 13 Years.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020083-38,1,0,0 2010-020083-38,8,2012-09-14,2012-09-14,6,1,0,0,0,0,2,0,0,2,1,0,0,0,1,F.Hoffmann-La Roche Ltd,"A Multicenter, Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged ≥ 13 Years.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020083-38,1,0,0 2010-020087-38,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,South Tees Hospitals NHS Foundation Trust,Comparison of the Effects of Intermittent Boluses to Simple Continuous Infusion on Patient Global Perceived Effect in Intrathecal Therapy for Pain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020087-38,0,0,0 2010-020097-42,1,2010-07-22,2010-07-22,1,0,0,0,0,0,4,0,1,1,1,1,1,0,1,Baxter Innovations GmbH,Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule with FSME-IMMUN 0.25ml JUNIOR in Healthy Children aged 1 to below 15 Years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020097-42,0,0,0 2010-020098-18,1,,,0,0,0,0,0,1,2,0,1,0,0,0,0,0,0,HOSPICES CIVILS DE LYON,CrYSTobs A cohort of patients with cystinosis : compliance to cysteamine and neurological complications An auxiliary study to Raptor RP103 03 and RP103 04,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020098-18,0,0,0 2010-020101-32,5,2016-02-11,2016-03-08,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GENENTECH, Inc.","A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF METMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB IN PATIENTS WITH METASTATIC, TRI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020101-32,0,0,0 2010-020103-70,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Tartu,Pharmacokinetics of intravenous phenobarbital and lidocaine in the treatment of neonatal seizures of term neonates requireing therapeutic hypothermia Intravenoosse fenobarbitaali ja lidokaiini far...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020103-70,0,0,0 2010-020106-15,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Clinic per la Recerca Biomédica,Estudio español de fibrilación auricular y resincronización,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020106-15,0,0,0 2010-020109-34,2,2012-04-05,2012-04-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MERCK SERONO SA,"A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020109-34,0,0,0 2010-020109-34,2,2012-04-05,2012-04-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Serono S.A. - Geneva,"A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020109-34,0,0,0 2010-020112-11,2,2013-04-16,2013-04-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a division of Schering Corporation","A Phase 3, 12-Week, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Preladenant in Subjects with Moderate to Severe Parkinson’s Disease. (Phase 3; Protocol No. P07037)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020112-11,0,0,0 2010-020113-85,5,2013-12-10,2014-03-07,4,1,1,0,0,0,3,0,0,1,1,0,1,0,1,CSL Behring GmbH,"A Multi-center, Interventional, Non-randomized, Open-label, Single-group Phase III Study to evaluate Plasma-Derived Antihemophilic Factor/von Willebrand Factor Concentrate (Biostate®) for Immune Tol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020113-85,0,0,0 2010-020113-85,5,2013-12-10,2014-03-07,4,1,1,0,0,0,3,0,0,1,1,0,1,0,1,CSL BEHRING S.P.A.,"A Multi-center, Interventional, Non-randomized, Open-label, Single-group Phase III Study to evaluate Plasma-Derived Antihemophilic Factor/von Willebrand Factor Concentrate (Biostate®) for Immune Tol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020113-85,0,0,0 2010-020114-29,1,2011-07-08,2011-07-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Department of Nephrology,Insulin-like growth factor in hemodialysis patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020114-29,0,0,0 2010-020116-11,4,2014-07-13,2014-07-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,NOVARTIS FARMACEUTICA S.A,"A phase II, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in patients with advanced non-small-cell lung cancer who have received at least two lines of prior chemot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020116-11,0,0,0 2010-020116-11,4,2014-07-13,2014-07-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A phase II, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in patients with advanced non-small-cell lung cancer who have received at least two lines of prior chemot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020116-11,0,0,0 2010-020117-87,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE,REACT ON (REscuing ACTivity Of Na-channels) STUDY Study and correction of abnormalities of nonsense mutations in Brugada Syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020117-87,0,0,0 2010-020121-41,5,2014-06-30,2014-06-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"An uncontrolled, open-label, phase II study in subjects with metastatic adenocarcinoma of the colon or rectum who are receiving first line chemotherapy with mFOLFOX6 (oxaliplatin/ folinic acid/5-fluor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020121-41,0,0,0 2010-020121-41,5,2014-06-30,2014-06-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Bayer Health Care AG, D-51368 Leverkusen","An uncontrolled, open-label, phase II study in subjects with metastatic adenocarcinoma of the colon or rectum who are receiving first line chemotherapy with mFOLFOX6 (oxaliplatin/ folinic acid/5-fluor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020121-41,0,0,0 2010-020122-18,7,2011-05-04,2011-05-31,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A prospective, randomized, double-blind, double-dummy, placebo- and active controlled, multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to varde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020122-18,0,0,0 2010-020126-17,1,2013-08-15,2013-08-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase 2b, dose-ranging study to evaluate the efficacy and safety of MEDI-563 in adults with uncontrolled asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020126-17,0,0,0 2010-020127-52,4,2010-08-12,2013-07-11,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophilia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020127-52,0,0,0 2010-020137-10,12,2017-01-05,2017-01-05,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects with Moderate to Severe Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020137-10,0,0,0 2010-020137-10,12,2017-01-05,2017-01-05,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmBH & Co. KG,"An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects with Moderate to Severe Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020137-10,0,0,0 2010-020137-10,12,2017-01-05,2017-01-05,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"An Open-Label, Multicenter, Efficacy and Safety Study to Evaluate Two Treatment Algorithms in Subjects with Moderate to Severe Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020137-10,0,0,0 2010-020140-36,6,2012-01-01,2012-01-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020140-36,0,0,0 2010-020141-26,1,2011-07-28,2011-07-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an oral tablet in Subjects with Mild COPD Following Segmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020141-26,0,0,0 2010-020144-34,3,2012-01-16,2012-01-16,2,1,1,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of fluticasone furoate inhalation powder in the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020144-34,1,1,0 2010-020146-10,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,ROTTAPHARM S.P.A.,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LEGALON SIL FOR THE TREATMENT OF HCV RECURRENCE IN STABLE LIVER TRANSPLANTED PATIENTS. STUDIO RANDOMIZ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020146-10,0,0,0 2010-020147-12,12,2014-03-28,2014-03-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017","AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN ADMINISTERED IN COMBINATION WITH RITUXIMAB COMPARED TO DEFINED INVESTIGATOR’S CHOICE THERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020147-12,0,0,0 2010-020147-12,12,2014-03-28,2014-03-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer, S.A.","AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN ADMINISTERED IN COMBINATION WITH RITUXIMAB COMPARED TO DEFINED INVESTIGATOR’S CHOICE THERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020147-12,0,0,0 2010-020147-12,12,2014-03-28,2014-03-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc,"AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN ADMINISTERED IN COMBINATION WITH RITUXIMAB COMPARED TO DEFINED INVESTIGATOR’S CHOICE THERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020147-12,0,0,0 2010-020150-34,10,2015-10-13,2015-12-23,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"""A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020150-34,0,0,0 2010-020150-34,10,2015-10-13,2015-12-23,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"MERCK & CO., INC.","""A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020150-34,0,0,0 2010-020150-34,10,2015-10-13,2015-12-23,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp,"""A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020150-34,0,0,0 2010-020150-34,10,2015-10-13,2015-12-23,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","""A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020150-34,0,0,0 2010-020150-34,10,2015-10-13,2015-12-23,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc","""A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020150-34,0,0,0 2010-020151-31,3,2019-01-14,2019-01-14,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"ArQule, Inc.",An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020151-31,0,0,0 2010-020151-31,3,2019-01-14,2019-01-14,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ARQULE,An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020151-31,0,0,0 2010-020152-54,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,MOLTENI,Pilot double blind study to assess the efficacy and tolerability of morphine sulphate oral solution (Oramorph) given as add-on therapy in the preventive analgesia (pre-medication) in patients undergoi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020152-54,0,0,0 2010-020153-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,Effects of Sildenafil on pulmonary artery pressure in patients with heart failure with preserved ejection fraction and pulmonary hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020153-14,0,0,0 2010-020154-33,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline R&D Limited,"RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects with Partial Onset Seizures(≥12 years old) and Subjects with Lennox-Gastaut Syndrome (≥12 years ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020154-33,0,1,1 2010-020155-31,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Sergio Hernández Expósito,EVALUACIÓN NEUROPSICOLÓGICA DE LA EFICACIA DE LA ATOMOXETINA EN EL TRASTORNO POR DÉFICIT DE ATENCIÓN CON HIPERACTIVIDAD.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020155-31,0,0,0 2010-020157-13,2,2011-07-15,2011-07-15,2,1,0,0,0,0,2,0,1,1,1,1,1,0,1,GlaxoSmithKline Research & Development Ltd,"An open-label, non-randomized, pharmacokinetic and safety study of repeat doses of fluticasone furoate and GW642444M combination in healthy subjects and in subjects with mild, moderate or severe hepat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020157-13,0,0,0 2010-020166-20,2,2011-06-02,2011-06-03,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, multiple-dose, placebo-controlled, parallel group study to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of ACZ885 in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020166-20,0,0,0 2010-020167-20,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,KEDRION,"Pharmacokinetics, efficacy, tolerability and safety evaluation of the therapy with subcutaneous immunoglobulin in the treatment of hypo or agammaglobulinaemic patients. Open label phase II/III study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020167-20,0,0,0 2010-020168-39,1,2012-01-09,2012-01-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Forward Pharma GmbH,"A randomised, double blind, placebo controlled efficacy and safety trial of different doses/dose regimens of FP187 compared to placebo in moderate to severe plaque psoriasis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020168-39,0,0,0 2010-020169-26,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,3,,INFLUENCE OF NALOXONE AND METHYLNALTREXONE ON INTERDIGESTIVE GASTROINTESTINAL MOTILITY AND HUNGER SCORES IN MAN.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020169-26,0,0,0 2010-020170-42,1,2014-12-10,2014-12-10,1,1,1,0,0,0,1,0,0,1,0,0,1,0,1,H. Lundbeck A/S,An open-label study evaluating the Pharmacokinetics and Tolerability of Lu AA21004 in connection with multiple oral dosing of Lu AA21004 in child and adolescent patients with a DSM-IV-TRTM diagnosis o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020170-42,0,0,0 2010-020171-23,1,2015-02-28,2015-02-28,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,4SC AG,"A phase I/II study to evaluate safety, tolerability, pharmacokinetics and efficacy of resminostat (4SC-201) in combination with a second-line treatment in patients with k-ras mutated advanced colorect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020171-23,0,0,0 2010-020172-30,5,2012-06-08,2012-06-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergan Limited,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Intraprostatic Administration of BOTOX® 200 U (Botulinum Toxin Type A) Purified Neuroto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020172-30,0,0,0 2010-020174-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ZonMw,Dexamethasone for the prevention of a pain flare after palliative radiotherapy for painful bone metastases: a multicenter double-blind placebo-controlled randomized study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020174-42,0,0,0 2010-020177-16,5,2011-09-20,2011-09-26,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS PHARMA SERVICES AG,"A randomized, placebo- controlled, parallel group study to assess the efficacy, safety, and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020177-16,0,0,0 2010-020179-22,1,2012-08-30,2012-08-30,1,0,0,0,1,0,3,0,0,1,0,0,1,0,0,Department of Dermatology,Konventionel vs. fraktioneret CO2 laser-assisteret fotodynamisk terapi af non melanom hudcancer og forstadier hertil,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020179-22,0,0,0 2010-020181-21,3,2014-05-28,2014-05-28,2,1,0,0,0,0,3,0,1,1,0,0,1,0,2,Bayer HealthCare AG,"Multicenter, randomized, open-label, parallel-group study to evaluate user satisfaction with and tolerability of the low-dose levonorgestrel (LNG) intrauterine delivery system (IUS) with 12 µg LNG/day...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020181-21,0,0,0 2010-020185-19,11,2016-10-04,2017-11-01,6,1,0,0,2,0,0,0,2,2,1,0,0,0,0,University Medical Center Utrecht,Optimization of Treatment and Management of Schizophrenia in Europe,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020185-19,1,0,0 2010-020185-19,11,2016-10-04,2017-11-01,6,1,0,0,2,0,0,0,2,2,1,0,0,0,0,University Medical Centre Utrecht,Optimization of Treatment and Management of Schizophrenia in Europe,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020185-19,1,0,0 2010-020185-19,11,2016-10-04,2017-11-01,6,1,0,0,2,0,0,0,2,2,1,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA' DEGLI STUDI DI NAPOLI,Optimization of Treatment and Management of Schizophrenia in Europe,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020185-19,1,0,0 2010-020188-19,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Oncology Department,Intra-hepatic chemotherapy with oxaliplatin every second week in combination with systemic gemcitabine and capecitabine and in patients with a KRAS-wild type tumour in combination with cetuximab in pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020188-19,0,0,0 2010-020189-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,"A randomised phase II study of pre-operative or peri-operative docetaxel, oxaliplatin, capecitabine (DOX) regimen in patients with locally advanced resectable gastric cancer STUDIO DI FASE II RANDO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020189-37,0,0,0 2010-020192-23,1,2015-03-29,2015-03-29,1,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A Multi-Centre, Multinational, Open-Label, Single-Arm and Multiple Dosing Trial on Safety and Efficacy of Monthly Replacement Therapy with Recombinant Factor XIII (rFXIII) in Paediatric Subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020192-23,0,0,0 2010-020193-42,1,2015-01-29,2015-01-29,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Hywel DdA Health Borad,"A comparative study of the effects of Liraglutide and Acarbose on glycaemic control, weight and Health-Related Quality-of-life(HRQOL) in Overweight type 2 Diabetic patients on Oral Hypoglycemic Agents...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020193-42,0,0,0 2010-020196-23,1,2013-02-28,2013-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MERCK SERONO SPA,"A phase II, multicentre, open label, prospective, interventional study to evaluate the sperm DNA fragmentation in idiopathic male infertility before and after treatment with Gonal-f PEN 900 IU.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020196-23,0,0,0 2010-020198-18,8,2012-08-23,2012-08-23,6,1,1,0,0,1,3,0,0,2,0,0,0,0,1,BioMarin Pharmaceutical Inc,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/week and 2.0 mg/kg/every other week BMN 110 in Patients with Muco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020198-18,1,0,0 2010-020198-18,8,2012-08-23,2012-08-23,6,1,1,0,0,1,3,0,0,2,0,0,0,0,1,BIOMARIN PHARMACEUTICAL INC.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/week and 2.0 mg/kg/every other week BMN 110 in Patients with Muco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020198-18,1,0,0 2010-020199-45,6,2016-06-16,2016-06-16,5,1,0,0,0,1,0,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc.,"A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) Studio di estensione multicent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020199-45,0,0,0 2010-020199-45,6,2016-06-16,2016-06-16,5,1,0,0,0,1,0,0,0,1,0,0,1,0,1,BIOMARIN PHARMACEUTICAL INC.,"A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) Studio di estensione multicent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020199-45,0,0,0 2010-020202-16,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,1,ProFibrix BV,"A Phase 2, Randomized, Single-Blind, Controlled, Comparative Efficacy and Safety and Study of Topical Fibrocaps™ and Gelatin Sponge (USP) in Surgical Hemostasis in the Netherlands",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020202-16,0,0,0 2010-020204-30,1,2011-02-09,2011-02-09,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,Eisai Limited,"A Multicenter, Open-label, Sequential, Multiple-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Efficacy or Eritoran in Descending Age Groups of Pediatric Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020204-30,0,0,0 2010-020204-30,1,2011-02-09,2011-02-09,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,Eisai Inc.,"A Multicenter, Open-label, Sequential, Multiple-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Efficacy or Eritoran in Descending Age Groups of Pediatric Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020204-30,0,0,0 2010-020206-14,1,2012-11-07,2012-11-07,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,St George's University of London,"Evaluation study of Meticillin Resistant Staphylococcus aureus (MRSA) during routine nasal decolonisation programmes with Bactroban Nasal® ointment, Chlorhexidine Gluconate 4% body and hair wash, and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020206-14,0,0,0 2010-020209-33,1,2013-07-20,2013-07-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Leuven,"BOsentan for Mild Pulmonary vascular disease in Asd patients (the BOMPA trial): a double-blind, randomized controlled, pilot trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020209-33,0,0,0 2010-020212-11,1,2011-08-31,2011-08-31,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Overlæge dr.med. Frederik Grønhøj,"Enkelt dosis (single dosis) farmakokinetik af 9-cis-retinoic acid (Alitretinoin, Toctino®) hos patienter med moderat til svær lever insufficiens.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020212-11,0,0,0 2010-020213-82,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS,Comparison of Incidence and Severity of conjunctival hyperemia associated with use of topical Bimatoprost 0.01% and latanoprost 0.005% in Glaucoma or Ocular Hypertensive patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020213-82,0,0,0 2010-020215-36,4,2013-04-26,2013-04-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"A prospective, controlled, double blind, international study to assess the effects of strontium ranelate vs. placebo on the reduction of periprosthetic bone loss in patients with total hip arthroplast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020215-36,0,0,0 2010-020215-36,4,2013-04-26,2013-04-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratorios Servier S.L.,"A prospective, controlled, double blind, international study to assess the effects of strontium ranelate vs. placebo on the reduction of periprosthetic bone loss in patients with total hip arthroplast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020215-36,0,0,0 2010-020215-36,4,2013-04-26,2013-04-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"A prospective, controlled, double blind, international study to assess the effects of strontium ranelate vs. placebo on the reduction of periprosthetic bone loss in patients with total hip arthroplast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020215-36,0,0,0 2010-020219-35,2,2013-10-17,2013-10-17,2,1,0,0,0,0,4,0,0,1,1,0,1,0,0,Royal Brompton & Harefield NHS Foundation Trust,Evaluating the benefit of additional platelet inhibition in acute coronary syndrome patients with high platelet reactivity undergoing PCI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020219-35,0,0,0 2010-020220-22,3,2012-07-23,2012-09-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men with Signs and Symptoms of Benig...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020220-22,0,0,0 2010-020223-44,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,"Medizinische Universität Wien, Univ.Klinik f.Radiodiagnostik","(18)F-FDG PET/CT in patients with idiopathic interstitial pneumonias: correlation of tracer uptake and histological findings, and texture-based recognition of usual interstitial pneumonia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020223-44,0,0,0 2010-020224-22,1,2011-08-30,2011-08-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"PTC Therapeutics, Inc",A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020224-22,0,0,0 2010-020226-17,1,2015-04-14,2015-04-14,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Imperial College,An evaluation of the effect of an angiotensin-converting enzyme (ACE) inhibitor on the growth rate of small abdominal aortic aneurysms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020226-17,0,0,0 2010-020227-48,1,2017-01-10,2017-01-10,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, open-label, multi-centre immunization study to evaluate the safety of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly according to a 0, 1, 6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020227-48,0,0,0 2010-020228-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud University Nijmegen Medical Centre,Immunochemotherapy: Do platin-based chemotherapeutics enhance dendritic cell vaccine efficay in melanoma patients?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020228-23,0,0,0 2010-020229-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ROCHE,A randomized phase II trial of erlotinib (TARCEVA) or intermittent dosing of erlotinib and docetaxel in male former smokers with locally advanced or metastatic squamous nonsmall cell lung cancer (N...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020229-42,0,0,0 2010-020233-56,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Oslo University Hospital,"PHASE I/II TRIAL OF VACCINE THERAPY IN RELAPSED AND PLATINUM RESISTANT EPITHELIAL OVARIAN CANCER PATIENTS USING AUTOLOGOUS DENDRITIC CELLS LOADED WITH AMPLIFIED OVARIAN CANCER STEM CELL mRNA, hTERT ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020233-56,0,0,0 2010-020234-26,3,2012-10-31,2012-10-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Patients With Type 2 Diabetes Mellit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020234-26,0,0,0 2010-020239-38,1,2012-05-09,2012-05-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Orexo AB,Conversion of fast acting oral opioids to Abstral (SL fentanyl) in opioid tolerant cancer patients with breakthrough pain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020239-38,0,0,0 2010-020240-35,2,2015-03-24,2015-04-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Modena and Reggio Emilia,Significance of the FSH receptor polymorphism p.N680S for the efficacy of FSH therapy of idiopathic male infertility: a pharmacogenetic approach.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020240-35,0,0,0 2010-020240-35,2,2015-03-24,2015-04-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,Significance of the FSH receptor polymorphism p.N680S for the efficacy of FSH therapy of idiopathic male infertility: a pharmacogenetic approach.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020240-35,0,0,0 2010-020257-13,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERO-UNIVERSITARIA,"A pilot, prospective, randomized, open, blinded end point, phase II study of tolerability and efficacy of Eperisone in Amyotrophic Lateral Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020257-13,0,0,0 2010-020299-42,1,2017-02-15,2017-02-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Philipps-University Marburg,"A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020299-42,0,0,0 2010-020300-29,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Pfizer Inc.,"A 6-MONTH, OPEN-LABEL, SAFETY TRIAL OF PREGABALIN IN ADOLESCENT PATIENTS WITH FIBROMYALGIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020300-29,0,0,0 2010-020302-15,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,IMM - Instituto de Medicina Molecular,"Ensaio clínico multicêntrico, prospectivo, aleatorizado e aberto com endpoint em dupla ocultação para determinar a eficácia do Tratamento Trombolítico Endovascular comparativamente ao tratamento padrã...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020302-15,0,0,0 2010-020303-69,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Enzyme substitution in exocrine pancreatic insufficiency; Self administration against a fixed dose regimen.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020303-69,0,0,0 2010-020305-32,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,"A phase II, open label study to evaluate the activity and safety of Everolimus in association to Imatinib in PDGFRA-D842V unresectable or metastatic gastrointestinal stromal tumours (GISTs)as fi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020305-32,0,0,0 2010-020310-28,8,2013-01-08,2014-01-08,7,1,1,0,0,1,2,0,0,1,0,0,1,0,1,ALEXION PHARMACEUTICALS,"AN OPEN-LABEL, MULTI-CENTER CLINICAL TRIAL OF ECULIZUMAB IN PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC-UREMIC SYNDROME (aHUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020310-28,0,0,0 2010-020310-28,8,2013-01-08,2014-01-08,7,1,1,0,0,1,2,0,0,1,0,0,1,0,1,"ALEXION PHARMACEUTICALS, INC.","AN OPEN-LABEL, MULTI-CENTER CLINICAL TRIAL OF ECULIZUMAB IN PEDIATRIC PATIENTS WITH ATYPICAL HEMOLYTIC-UREMIC SYNDROME (aHUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020310-28,0,0,0 2010-020312-12,2,2012-11-27,2012-11-27,1,1,0,0,0,0,2,0,1,1,1,1,1,0,1,GlaxoSmithKline Biologicals,"A phase IIa, observer-blind, multi-country, multicentre, randomised study to evaluate the immunogenicity, safety and reactogenicity of the GlaxoSmithKline Biologicals’ quadrivalent influenza vaccine (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020312-12,0,0,0 2010-020312-12,2,2012-11-27,2012-11-27,1,1,0,0,0,0,2,0,1,1,1,1,1,0,1,GlaxoSmithKline S.A.,"A phase IIa, observer-blind, multi-country, multicentre, randomised study to evaluate the immunogenicity, safety and reactogenicity of the GlaxoSmithKline Biologicals’ quadrivalent influenza vaccine (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020312-12,0,0,0 2010-020313-81,1,,,0,1,0,0,0,0,3,0,1,1,1,1,0,1,1,GlaxoSmithKline Biologicals,"A Phase IIIA, open, randomized study to assess immunogenicity and safety of Fluarix™/Influsplit SSW® 2010/2011 or Pandemrix™ vaccination in adults aged 18 years and above previously vaccinated with on...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020313-81,0,0,0 2010-020315-36,11,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F.Hoffmann-La Roche,"A Randomized, Double-Blind, Double Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif) In Patients With Relapsing Multiple Sclero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020315-36,0,0,0 2010-020315-36,11,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ROCHE,"A Randomized, Double-Blind, Double Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif) In Patients With Relapsing Multiple Sclero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020315-36,0,0,0 2010-020319-34,5,2011-11-16,2011-11-16,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GUERBET,Evaluación de la seguridad y la eficacia de Dotarem en resonancia magnética (RM) en pacientes con lesiones del sistema nervioso central (SNC) SAFETY AND EFFICACY EVALUATION OF DOTAREM® IN MAGNETIC RE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020319-34,0,0,0 2010-020319-34,5,2011-11-16,2011-11-16,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Guerbet Laboratories Ltd.,Evaluación de la seguridad y la eficacia de Dotarem en resonancia magnética (RM) en pacientes con lesiones del sistema nervioso central (SNC) SAFETY AND EFFICACY EVALUATION OF DOTAREM® IN MAGNETIC RE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020319-34,0,0,0 2010-020324-22,9,2017-08-16,2017-08-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020324-22,0,0,0 2010-020325-40,2,2012-05-04,2012-05-04,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pharma Mar, S.A. Sociedad Unipersonal","Phase Ib/II, Multicenter, Open-Label, Randomized, Clinical Study with Dose Optimization of Two Different Schedules of Elisidepsin Trifluoroacetate (Irvalec®) as a Single Agent in Patients with Unresec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020325-40,0,0,0 2010-020326-18,7,2013-10-31,2013-10-31,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"ALEXION PHARMACEUTICALS, INC.","AN OPEN-LABEL, MULTI-CENTER CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH ATYPICAL HEMOLYTIC-UREMIC SYNDROME",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020326-18,0,0,0 2010-020326-18,7,2013-10-31,2013-10-31,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ALEXION PHARMACEUTICALS,"AN OPEN-LABEL, MULTI-CENTER CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH ATYPICAL HEMOLYTIC-UREMIC SYNDROME",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020326-18,0,0,0 2010-020328-23,11,2015-03-05,2015-05-25,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Serono,"A THREE-ARM, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER, PHASE II STUDY TO EVALUATE THE EFFICACY OF VIGANTOL OIL AS ADD-ON THERAPY IN SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020328-23,0,0,0 2010-020328-23,11,2015-03-05,2015-05-25,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Serono SA-Geneva an affiliate of Merck KgaA, Darmstadt","A THREE-ARM, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER, PHASE II STUDY TO EVALUATE THE EFFICACY OF VIGANTOL OIL AS ADD-ON THERAPY IN SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020328-23,0,0,0 2010-020328-23,11,2015-03-05,2015-05-25,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Serono The Netherlands - a division of Merck B.V.,"A THREE-ARM, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER, PHASE II STUDY TO EVALUATE THE EFFICACY OF VIGANTOL OIL AS ADD-ON THERAPY IN SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020328-23,0,0,0 2010-020328-23,11,2015-03-05,2015-05-25,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Serono SA - Geneva, an affiliate of Merck KGaA,","A THREE-ARM, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER, PHASE II STUDY TO EVALUATE THE EFFICACY OF VIGANTOL OIL AS ADD-ON THERAPY IN SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020328-23,0,0,0 2010-020328-23,11,2015-03-05,2015-05-25,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MERCK SERONO SA,"A THREE-ARM, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER, PHASE II STUDY TO EVALUATE THE EFFICACY OF VIGANTOL OIL AS ADD-ON THERAPY IN SUBJECTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020328-23,0,0,0 2010-020329-42,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,EFFECTS OF PREVENTIVE TREATMENT WITH STEROIDS ON COAGULATION DYSFUNCTION INDUCED BY EXTRACORPOREAL CIRCULATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020329-42,0,0,0 2010-020330-26,2,2011-05-26,2011-05-26,1,1,0,0,0,0,4,0,1,1,1,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IV, open label, randomized, multicountry study to evaluate immunogenicity and safety of GSK Biologicals' seasonal (2010-2011) influenza vaccine FluarixTM in children previously vaccinated with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020330-26,0,0,0 2010-020331-39,1,2011-07-07,2011-07-07,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase IV, open label, randomized, monocentric study to evaluate immunogenicity and safety of GSK Biologicals' seasonal (2010-2011) influenza vaccine FluarixTM in adolescents previously vaccinated wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020331-39,0,0,0 2010-020332-19,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,"ERASMUS MC, Dept Anesthesiology",Putting Resistance under the Microscope. (Weerstand onder de Loep),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020332-19,0,0,0 2010-020337-99,17,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F.Hoffmann-La Roche,"A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif) In Patients With Relapsing Multiple Sclero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020337-99,0,0,0 2010-020337-99,17,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ROCHE,"A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif) In Patients With Relapsing Multiple Sclero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020337-99,0,0,0 2010-020338-25,16,,,0,1,0,0,0,0,3,0,2,2,1,0,0,0,1,F.Hoffmann-La Roche,"A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020338-25,0,0,0 2010-020338-25,16,,,0,1,0,0,0,0,3,0,2,2,1,0,0,0,1,F. Hoffmann - La Roche,"A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020338-25,0,0,0 2010-020341-27,1,,,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,Groupe Francophone des Myélodysplasies,A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine (Vidaza®) in intermediate-2 and high risk MDS patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020341-27,0,0,0 2010-020342-98,3,2011-09-22,2011-10-21,2,0,0,0,0,0,2,0,0,1,1,0,1,0,1,"Unigene Laboratories, Inc.","A Double-Blind, Randomized, Repeat Dose, Parallel Group Study of Recombinant Human Parathyroid Hormone (rhPTH(1-31)NH2) tablets, or Placebo tablets, Compared to Open Label Forsteo in Postmenopausal Wo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020342-98,0,0,0 2010-020343-13,1,2010-08-12,2010-08-12,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Laboratorios del Dr Esteve S.A,"A double-blind, randomised, placebo-controlled, 4‑way cross-over Phase I study to investigate the pharmacokinetics, pharmacodynamics and safety of escalating single doses of E‑52862 in young healthy m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020343-13,0,0,0 2010-020345-27,16,2018-04-18,2019-04-19,14,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"SCHWARZ BIOSCIENCES, INC. A Member of the UCB Group of Companies","AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020345-27,1,0,0 2010-020345-27,16,2018-04-18,2019-04-19,14,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"UCB BIOSCIENCES, INC.","AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020345-27,1,0,0 2010-020345-27,16,2018-04-18,2019-04-19,14,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"SCHWARZ BIOSCIENCES, INC A member of the UCB Group of Companies","AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020345-27,1,0,0 2010-020345-27,16,2018-04-18,2019-04-19,14,1,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB Biosciences Inc.,"AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020345-27,1,0,0 2010-020345-27,16,2018-04-18,2019-04-19,14,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"UCB Biosciences, Inc.","AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020345-27,1,0,0 2010-020345-27,16,2018-04-18,2019-04-19,14,1,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB BioSciences INC.,"AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020345-27,1,0,0 2010-020347-12,13,2021-04-21,2021-04-21,11,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma Protocollo CA204004: Studio di fase 3, randomizzato, in a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020347-12,1,0,0 2010-020347-12,13,2021-04-21,2021-04-21,11,1,0,0,0,1,3,0,0,2,0,0,0,0,1,BRISTOL-M.SQUIBB,"A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma Protocollo CA204004: Studio di fase 3, randomizzato, in a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020347-12,1,0,0 2010-020347-12,13,2021-04-21,2021-04-21,11,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Bristol Myers Squibb International Corporation,"A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma Protocollo CA204004: Studio di fase 3, randomizzato, in a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020347-12,1,0,0 2010-020348-36,2,2015-04-15,2015-04-15,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Alchemia Oncology Pty Ltd,Randomized double-blind Phase III trial of FOLF(HA)iri vs FOLFIRI for second or third line therapy in irinotecan-naïve patients with metastatic colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020348-36,0,0,0 2010-020352-59,1,2012-09-18,2012-09-18,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A multi-center, placebo-controlled study to evaluate the safety of GSK716155 and its effects on myocardial metabolism, myocardial function, and exercise capacity in patients with NYHA Class II/III con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020352-59,0,0,0 2010-020357-14,1,,,0,0,0,0,1,0,3,0,1,0,0,0,0,0,0,FONDAZIONE MONZINO CENTRO CARDIOLOGICO,EFFECTS OF BETA 2 RECEPTOR BLOCKADE ON PULMONARY FUNCTION IN A HUMAN MODEL OF ACUTE HYDRIC OVERLOAD EFFETTI DEL BLOCCO BETA 2 RECETTORIALE SULLA FUNZIONE POLMONARE IN UN MODELLO UMANO DI SOVRACCARI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020357-14,0,0,0 2010-020359-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de nantes,Etude pilote prospective multicentrique évaluant l’effet antalgique d’une injection de toxine botulique type A au niveau du ganglion Impar chez des patients présentant des proctalgies chroniques au se...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020359-30,0,0,0 2010-020360-38,3,2016-04-22,2016-04-22,1,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Bristol Myers Squibb International Corporation,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin (BMS-477118) as Monotherapy in Pediatric Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020360-38,1,1,0 2010-020360-38,3,2016-04-22,2016-04-22,1,1,0,0,0,0,3,0,0,2,1,0,0,0,1,BRISTOL-M.SQUIBB,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin (BMS-477118) as Monotherapy in Pediatric Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020360-38,1,1,0 2010-020363-21,9,2013-01-14,2020-08-21,6,1,0,0,0,1,0,0,0,2,0,0,0,0,1,"Seattle Genetics, Inc.","An open-label, phase 2/3, treatment-option protocol of brentuximab vedotin in patients with progression of Hodgkin lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020363-21,1,0,0 2010-020363-21,9,2013-01-14,2020-08-21,6,1,0,0,0,1,0,0,0,2,0,0,0,0,1,SEATTLE GENETICS INC.,"An open-label, phase 2/3, treatment-option protocol of brentuximab vedotin in patients with progression of Hodgkin lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020363-21,1,0,0 2010-020369-26,1,2012-01-20,2012-01-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Biogen Idec,High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020369-26,0,0,0 2010-020370-42,4,2014-02-27,2014-02-27,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,F. Hoffmann-La Roche Ltd,"A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant nega...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020370-42,0,0,0 2010-020371-22,2,2014-01-08,2014-06-24,2,1,0,0,0,0,2,0,0,1,1,0,1,0,0,Radboud University Nijmegen Medical Centre,Achieving appropriate exposuRe to RIBAvirin after a dose advise based on an abbreviated AUC of a first dose of ribavirin (ARRIBA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020371-22,0,0,0 2010-020372-30,1,,,0,0,0,0,0,0,4,0,1,1,1,1,0,1,0,Tommi Vimpeli,Raskauden ehkäisyn vaikutukset kohdun ja munasarjojen verenkiertoon,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020372-30,0,0,0 2010-020375-24,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Sorafenib in recurrent and/or metastatic salivary gland carcinomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020375-24,0,0,0 2010-020376-37,1,2012-04-06,2012-04-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Trevena, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Adaptive, Ascending Dose-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Invasive Hemodynamics of TRV120027 in Patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020376-37,0,0,0 2010-020377-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,EFFECTS OF THE ADMINISTRATION OF ANTITHROMBIN ON THE EMOCOAGULATIVE STATE AND ON THE INFLAMMATORY RESPONSE IN PATIENT WITH LOW PLASMATIC LEVELS OF ANTITHROMBIN AFTER CARDIAC INTERVENTIONS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020377-16,0,0,0 2010-020379-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,Phase II study of hypofractionated radio-chemotherapy with gemcitabine plus oxaliplatin for unresectable nonmetastatic locally advanced pancreatic cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020379-22,0,0,0 2010-020380-20,2,2013-03-23,2013-03-23,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"Janssen Research & Development, L.L.C.",Open-Label Evaluation of the Pharmacokinetic Profile and Safety of Tapentadol Oral Solution for the Treatment of Postsurgical Pain in Children and Adolescents Aged From 6 to Less Than 18 Years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020380-20,1,1,0 2010-020385-13,2,2016-03-31,2016-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Vejle Hospital,Randomized phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable cholangiocarcinoma without KRAS mutations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020385-13,0,0,0 2010-020386-24,6,2013-10-09,2013-10-09,4,1,0,0,0,1,2,0,0,2,0,0,0,0,1,TROPHOS SA,"Phase II, multicenter, randomized, adaptive, double-blind, placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020386-24,1,0,0 2010-020386-24,6,2013-10-09,2013-10-09,4,1,0,0,0,1,2,0,0,2,0,0,0,0,1,TROPHOS,"Phase II, multicenter, randomized, adaptive, double-blind, placebo controlled study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old Spinal Muscular Atrophy (SMA) patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020386-24,1,0,0 2010-020387-38,3,2013-12-13,2013-12-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus Infection w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020387-38,0,0,0 2010-020394-17,2,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,MERRIMACK PHARMACEUTICALS,A Phase 1-2 trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020394-17,0,0,0 2010-020395-28,3,2014-06-25,2014-06-25,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MERRIMACK PHARMACEUTICALS,"A Randomized, Double-Blind Phase 2 trial of Exemestane +/- MM-121 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive (ER+) and/or Progesterone Receptor Positive (P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020395-28,0,0,0 2010-020396-22,1,,,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,Trimel Biopharma SRL,"Two-Center, Randomized, Placebo and Active Comparator Evaluation of the Pharmacokinetics (PK) and Safety, Along with Initial Pharmacodynamic (PD) Efficacy of Three Dose Levels of TBS-2 Intranasal Gel ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020396-22,0,0,0 2010-020397-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,VUmc Dept Urology,"The efficacy of an antigenic marker lesion for the therapeutic effect in patients with multiple, Ta/T1, G1/G2, non-muscle invasive bladder cancer (NMIBC) treated with TUR followed by IL-2 instillation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020397-42,0,0,0 2010-020398-18,18,2012-08-08,2012-12-12,13,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Amgen Inc.,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Metastatic Adenocarcinoma of the Pancreas",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020398-18,0,0,0 2010-020399-41,2,2019-02-27,2019-02-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 1-year, multicenter, open-label extension to CZOL446H2337 to evaluate safety and efficacy of zoledronic acid twice yearly in osteoporotic children treated with glucocorticoids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020399-41,0,0,0 2010-020401-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,IDENTIFICATION OF OXIDATIVE-STRESS AND MICROINFLAMMATION GENES MODULATED BY ERYTHROPOIETIN ADMINISTRATION IN PATIENTS WITH RENAL TRANSPLANT AND CHRONIC RENAL FAILURE. PERSPECTIVES FOR ERYTHROPOITIN PH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020401-32,0,0,0 2010-020402-15,2,2012-02-07,2012-02-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Develco Pharma Schweiz AG,"Randomised, double-blind, cross-over Phase III study to investigate the efficacy and safety of oxycodone after once daily administration of Oxycodone HCl XL tablets in comparison to twice daily admini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020402-15,0,0,0 2010-020403-75,1,2016-01-17,2016-01-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universität Leipzig,ACE inhibitor for lung protection during mechanical Ventilation for acute lung injury - pilot trial ACE-Hemmer zur Lungenprotektion bei beatmeten Patienten mit akutem Lungenversagen - Pilotstudie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020403-75,0,0,0 2010-020404-29,2,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,"Eli Lilly and Company Limited, Indianapolis","A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients with Diabetic Kidney Disease due to Type 1 or Type 2 Diab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020404-29,0,0,0 2010-020407-73,1,2012-02-16,2012-02-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A double-blind, placebo-controlled, randomised, parallel-group, phase-II, multi-centre study to assess the efficacy, safety and tolerability of 4 twice daily doses and 2 once daily doses of AZD1981 gi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020407-73,0,0,0 2010-020408-31,1,2014-09-04,2014-09-04,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Eli Lilly and Company,A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Pemetrexed and Cisplatin in Patients with Stage IV Non-small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020408-31,0,0,0 2010-020412-11,2,2011-08-26,2011-08-26,1,1,1,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A randomized, double-blind, double-dummy, parallel-group, placebo controlled (on inhaled corticosteroid medication), multicenter study to evaluate the efficacy and safety of vilanterol inhalation powd...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020412-11,1,1,0 2010-020412-11,2,2011-08-26,2011-08-26,1,1,1,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A randomized, double-blind, double-dummy, parallel-group, placebo controlled (on inhaled corticosteroid medication), multicenter study to evaluate the efficacy and safety of vilanterol inhalation powd...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020412-11,1,1,0 2010-020413-90,4,2014-04-29,2014-06-17,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and Luma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020413-90,0,0,0 2010-020414-28,8,2019-01-17,2019-01-17,8,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"ARIAD Pharmaceuticals, Inc.",A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020414-28,0,0,0 2010-020414-28,8,2019-01-17,2019-01-17,8,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"ARIAD PHARMACEUTICALS,INC.",A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020414-28,0,0,0 2010-020415-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Stavanger University Hospital,"En åpen, randomisert cross over studie av fosfatbinder (sevelamer) eller aktivt vitamin D hos pasienter med kronisk nyresvikt i stadium 3b (eGFR 30-45 ml/min/1,73 m2) for evaluering av fibroblast like...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020415-36,0,0,0 2010-020422-17,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,"A single center, twelve-month, open-label, prospective study followed by a six-month withdrawal period to evaluate the efficacy, tolerability, safety and pharmacokinetics (PK) of doxycycline in comb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020422-17,0,0,0 2010-020423-51,1,2014-09-22,2014-09-22,1,1,1,0,0,1,3,0,0,1,0,0,1,0,0,Asklepios Klinik Sankt Augustin,Remission Induction by Etanercept in Enthesitis related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy) Remissionsstudie mit Etanercept bei Kindern mit Enthesitis-assoziierte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020423-51,0,0,0 2010-020424-21,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,VU medical center,Betablocker Therapy in Pulmonary Arterial Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020424-21,0,0,0 2010-020426-18,13,2013-07-12,2017-02-20,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ImClone LLC,"A Randomized, Multicenter, Double-Bind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020426-18,0,0,0 2010-020426-18,13,2013-07-12,2017-02-20,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,IMCLONE LLC,"A Randomized, Multicenter, Double-Bind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020426-18,0,0,0 2010-020427-43,1,2010-10-28,2010-10-28,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","A PHASE 2 MULTICENTER, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF 04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE ON STABLE DONEPEZIL THERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020427-43,0,0,0 2010-020428-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ANA M,Efectividad de una aproximación farmacogenética en la individualización de la terapia analgésica con opioides,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020428-23,0,0,0 2010-020432-18,1,2019-01-28,2019-01-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ASOCIACION ANDALUZA DE HEMATOLOGIA Y HEMOTERAPIA,TRATAMIENTO DE MANTENIMIENTO CON 5-AZACITIDINA EN PACIENTES CON LEUCEMIA MIELOBLÁSTICA AGUDA NO ELEGIBLES PARA TRATAMIENTO INTENSIVO Y CON RESPUESTA PARCIAL O COMPLETA TRAS QUIMIOTERAPIA DE INDUCCIÓN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020432-18,0,0,0 2010-020433-13,1,2012-04-02,2012-04-02,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Charité-Universitätsmedizin Berlin,"Eine 8-wöchige, monozentrische, baseline-kontrollierte offene Studie zur Evaluierung des Einflusses einer “Single pill combination” auf die Blutdrucksenkung bei Patienten mit nicht-kontrolliertem Blut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020433-13,0,0,0 2010-020435-40,1,2015-07-20,2015-07-20,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Centre du Cancer,Phase I/II study of peptide vaccination associated with tumoral immunomodulation with proinflammatory cytokines and imiquimod in patients with advanced metastatic melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020435-40,0,0,0 2010-020437-12,3,2012-07-05,2012-07-05,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,DermaTools Biotech GmbH,"A multicentric, double blind, randomized, comparative Phase II b study of the efficacy of a wound healing solution in patients with diabetic foot ulcer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020437-12,0,0,0 2010-020439-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Cáncer de Ovario (GEICO),"Ensayo clínico fase II no controlado, multicéntrico y prospectivo para determinar el beneficio clínico y toxicidad de Pazopanib, inhibidor multidiana de receptores con actividad tirosin-quinasa (VEGFR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020439-38,0,0,0 2010-020440-35,1,2014-08-18,2014-08-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London,"GR activity in induced sputum macrophages, and a change in inflammatory biomarkers 2-hours after a single dose of either Symbicort®/Budesonide/Formoterol or placebo in Chronic Obstructive Pulmonary Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020440-35,0,0,0 2010-020441-27,1,2012-09-25,2012-09-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"University of Leipzig Ritterstr. 26, 04109 Leipzig","Ranibizumab combined with selective peripheral laser photocoagulation for treatment of central retinal vein occlusion A randomized, controlled interventional phase 2b (proof of concept) study of of t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020441-27,0,0,0 2010-020442-10,1,2015-06-24,2015-06-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,"Efficacy of atazanavir/ritonavir monotherapy as maintenance in patients with viral suppression. Randomized, open label non inferiority trial. (MODAt STUDY)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020442-10,0,0,0 2010-020444-36,4,2013-01-29,2013-01-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020444-36,0,0,0 2010-020444-36,4,2013-01-29,2013-01-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,"A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020444-36,0,0,0 2010-020444-36,4,2013-01-29,2013-01-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen R&D Ireland,"A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020444-36,0,0,0 2010-020447-13,1,2015-05-05,2015-05-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label, multicenter phase II study to examine the efficacy and safety of everolimus as second-line therapy in the treatment of patients with metastatic renal cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020447-13,0,0,0 2010-020448-37,2,2015-04-02,2015-04-02,1,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Enceladus Pharmaceuticals,Randomized placebo-controlled multicenter exploratory Phase IIA study to assess the safety and efficacy of PEG-liposomal prednisolone sodium phosphate (Nanocort) in subjects with active ulcerative col...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020448-37,0,0,0 2010-020450-33,1,2018-08-12,2018-08-12,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Institute of Specific Prophylaxis and Tropical Medicine,Characterization of cellular and humoral immunity in the elderly upon vaccination with the purified inactivated Japanese Encephalitis Vaccine IXIARO® Charakterisierung der zellulären und humoralen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020450-33,0,0,0 2010-020451-32,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Academic Medical Center Amsterdam,Pilot study of everolimus in the treatment of advanced malignancies in patients with Peutz-Jeghers syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020451-32,0,0,0 2010-020452-64,1,2019-03-08,2019-03-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hull and East Yorkshire Hospitals NHS Trust,A prospective randomisd open label study to determine the effects of intravenous iron administration on markers of acute kidney injury in chronic kidney disease (CKD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020452-64,0,0,0 2010-020454-34,13,2019-03-29,2019-03-29,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma Studio multicent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020454-34,0,0,0 2010-020454-34,13,2019-03-29,2019-03-29,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN INC.,"A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma Studio multicent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020454-34,0,0,0 2010-020455-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHRU de Tours,Imagerie moléculaire de l’activation microgliale dans l’infarctus cérébral: validation d’un nouveau radiopharmaceutique le [18F]-DPA-714.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020455-31,0,0,0 2010-020458-33,1,2012-02-07,2012-02-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GW Pharma Ltd.,"A randomised, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GW42003: GW42004 plus GW42003 and GW42004 alone in the treatment of dyslipidaemia in sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020458-33,0,0,0 2010-020460-38,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Novartis Pharma S.A.S,"Etude prospective, randomisée, en ouvert évaluant le bénéfice clinique sur les hypoglycémies après 6 mois de l’addition de la vildagliptine versus celle d’un autre antidiabétique oral, chez des patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020460-38,0,0,0 2010-020464-38,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,University of Oslo,"Nutrition, growth and development among very preterm infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020464-38,0,0,0 2010-020467-21,6,2014-02-27,2014-06-09,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,F. Hoffmann-La Roche Ltd,"A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant nega...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020467-21,0,0,0 2010-020470-42,3,2014-04-14,2014-04-14,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,F. Hoffmann-La Roche Ltd,"A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant nega...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020470-42,0,0,0 2010-020470-42,3,2014-04-14,2014-04-14,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,F. Hoffmann - La Roche Ltd.,"A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant nega...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020470-42,0,0,0 2010-020471-23,12,2012-02-24,2014-07-29,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Purdue Pharma L.P.,"An Open-label, Multicentre Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children from Ages 6 to 16 Years Old, Inclusive, with Moderate to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020471-23,0,0,0 2010-020472-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,18F-Fluorothymidine Positron Emission Tomography as an early predictor of response to neoadjuvant therapy in patients with locally advanced breast carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020472-34,0,0,0 2010-020475-23,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","A PHASE 2 RANDOMIZED, DOUBLE-BLINDED, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED TWO COHORT TWO-WAY CROSS-OVER, MULTI-CENTRE CLINICAL TRIAL TO EXAMINE THE PAIN RELIEF PRODUCED BY 2 WEEKS OF DAILY OR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020475-23,0,0,0 2010-020480-21,1,2021-04-21,2021-04-21,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Universitätsmedizin Charite,Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020480-21,0,0,0 2010-020482-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Endocrinology, Sahlgrenska University Hospital",Ga-68-DOTATOC -PET in the management of pituitary tumours (PA) and Thyroid associated ophtalmopathy (TAO) Ga-68-DOTATOC PET i handläggningen av hypofystumörer (PA) och thyroidea associerad oftalmop...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020482-24,0,0,0 2010-020484-20,3,2013-06-11,2013-06-11,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ViroPharma Incorporated,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO ASSESS THE SAFETY AND EFFICACY OF VP 20621 FOR PREVENTION OF RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) IN ADULT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020484-20,0,0,0 2010-020489-82,1,2011-04-14,2011-04-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Fidia Farmaceutici S.p.A.,"Randomised, double-blind, placebo-controlled, parallel-groups, multi-centre clinical trial Phase III with Diclofenac Sodium 140 mg medicated plaster in patients with fresh impact injuries of the limbs...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020489-82,0,0,0 2010-020492-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sint Franciscus Gasthuis,Pharmacokinetics of ertapenem in a three-weekly dosing regime in patients with end stage renal disease depending on hemodialysis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020492-23,0,0,0 2010-020493-42,3,2022-04-28,2022-04-28,2,1,1,0,0,0,3,0,0,2,1,0,0,0,1,H. Lundbeck A/S,"A Double-blind, Randomized, Placebo-controlled, Multicentre, Relapse-prevention Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020493-42,1,0,0 2010-020497-41,11,2021-04-06,2021-04-06,4,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Mesoblast, Inc.","A prospective, double blind, randomized, placebo-controlled clinical trial of intracoronary infusion of immunoselected, bone marrow-derived Stro3 mesenchymal precursor cells (MPC) in the treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020497-41,1,0,0 2010-020499-50,1,2013-08-30,2013-08-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,South Tees Hospitals NHS Foundation Trust,"Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, a B cell depleting monoclonal antibody. An investigator-led, industry supported, multicentre, op...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020499-50,0,0,0 2010-020501-32,1,2015-10-12,2015-10-12,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Merja Kokki,"NENÄN LIMAKALVOLLE ANNETUN FENTANYYLIN TEHO, TURVALLISUUS JA PLASMAPITOISUUDET SYNNYTTÄJIEN SYNNYTYSKIVUN HOIDOSSA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020501-32,0,0,0 2010-020504-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"GATAC: Asian ginseng (Panax Ginseng) for the treatment of Cancer-Related Fatigue: a randomized, double-blind controlled study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020504-30,0,0,0 2010-020508-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ZonMw zorg voor jeugd-effecten en kosten,Hersengymnastiek? Sport en neurofeedback als behandeling voor ADHD.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020508-31,0,0,0 2010-020509-34,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,CHU de Clermont-Ferrand,"Etude comparative de l'influence de deux antagonistes du récepteur 5-HT3, le tropisétron et le granisétron, sur l'effet analgésique du paracétamol.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020509-34,0,0,0 2010-020510-29,2,2011-08-16,2011-08-16,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Purdue Pharma L.P.,"An Open-label Study to Characterise the Pharmacokinetics and Safety of Oxycodone Hydrochloride q12h Controlled-Release Tablets (ORF) in Paediatric Patients Aged 6 to 16 Years Inclusive, Who Require Op...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020510-29,0,0,0 2010-020513-87,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,FIDIA,"A randomized, placebo-controlled, double-blind study on the intensity and duration of efficacy of sodium hyaluronate therapy (500-730 KDa) (HYALGAN) in the conservative treatment of Achilles tendinopa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020513-87,0,0,0 2010-020515-37,19,2018-10-19,2018-10-19,18,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020515-37,0,0,0 2010-020515-37,19,2018-10-19,2018-10-19,18,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020515-37,0,0,0 2010-020515-37,19,2018-10-19,2018-10-19,18,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020515-37,0,0,0 2010-020516-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA,"EXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020516-11,0,0,0 2010-020520-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Gregorio Marañón,ESTUDIO PILOTO RANDOMIZADO ABIERTO DE AHORRO DE MEDIDAS RECTALES EN ESTREÑIMIENTO OPIOIDE EN POBLACIÓN EN FASE TERMINAL MEDIANTE EL EMPLEO DE METILNALTREXONA SUBCUTANEA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020520-22,0,0,0 2010-020521-40,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,EPIFARMA S.R.L.,"Evaluation of therapeutic equivalence of diclofenac gel 1% formulation compared to Voltaren emulGel 1% gel in subjects with traumatic pathology: a double blind, randomized, phase III multicentre study...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020521-40,0,0,0 2010-020538-24,1,2013-09-30,2013-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GABA International AG,White spot lesion development in post-orthodontic patients following weekly application of a 1.25% fluoride gel compared to placebo over 6 months,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020538-24,0,0,0 2010-020540-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,Single centre randomized study to evaluate the effect of Levothyroxine on cardiac function in patients with chronic heart failure and subclinical hypothyroidism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020540-34,0,0,0 2010-020545-26,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,"BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020545-26,0,0,0 2010-020546-96,1,2011-11-30,2011-11-30,1,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of VX-770 on Lung Clearance Index in Subjects with Cystic Fibrosis, the G551D Mutation, and FEV1 >90% Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020546-96,0,0,0 2010-020547-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Foot and Ankle Surgical center,A randomized study comparing etoricoxib and diclofenac sodium in post hallux valgus surgery pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020547-13,0,0,0 2010-020551-31,1,2018-05-29,2018-05-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Nordic Bone and Marrow Transplantation Group,Randomized study of oral ganciclovir versus i.v. ganciclovir for preemptive therapy of cytomegalovirus infection after stem cell transplantation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020551-31,0,0,0 2010-020558-33,9,2012-08-01,2012-09-27,8,1,1,0,0,1,0,0,0,2,0,0,0,0,1,"Biogen Idec Hemophilia, Inc.","A-LONG: An Open-label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding in Pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020558-33,1,0,0 2010-020558-33,9,2012-08-01,2012-09-27,8,1,1,0,0,1,0,0,0,2,0,0,0,0,1,BIOGEN IDEC LTD,"A-LONG: An Open-label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding in Pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020558-33,1,0,0 2010-020559-29,1,2011-01-03,2011-01-03,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Pantec Biosolutions AG,"Proof of concept study to investigate the efficacy, safety and tolerability as well as the pharmacokinetics and pharmacodynamics of a newly developed patch containing follicle-stimulating hormone appl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020559-29,0,0,0 2010-020579-21,5,2011-08-01,2011-08-03,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase IV Prospective, Double-blind, Double-dummy, Randomised, Crossover Study to Assess the Impact on Daily Cognitive Functioning of Quetiapine Fumarate Immediate Release (Seroquel IR) Dosed twice D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020579-21,0,0,0 2010-020579-21,5,2011-08-01,2011-08-03,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Phase IV Prospective, Double-blind, Double-dummy, Randomised, Crossover Study to Assess the Impact on Daily Cognitive Functioning of Quetiapine Fumarate Immediate Release (Seroquel IR) Dosed twice D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020579-21,0,0,0 2010-020597-42,1,,,0,0,0,0,0,1,3,0,1,0,0,0,0,0,0,Fundación Hospital Nacional de Parapléjicos,Eficacia y seguridad de la hormona del crecimiento (GH) en sujetos con lesión medular: ensayo clínico aleatorio triple ciego y controlado con grupo placebo. Effects and Safety of GH treatment in SCI: ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020597-42,0,0,0 2010-020599-47,1,2012-02-03,2012-02-03,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Departments of Medical Research and Medicine,The effect of Amiloride and Spironolacton on renophysiological and cardiovascular parametres in patients with hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020599-47,0,0,0 2010-020601-32,13,2012-06-25,2012-06-28,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe BV,"A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solif...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020601-32,0,0,0 2010-020602-14,7,2012-11-29,2012-11-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A 12-WEEK, MULTINATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, 2-ARM PARALLEL GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF CHF 1535 200/6µg (FIXED COMBINATION BECLOMETHASONE DIPROP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020602-14,0,0,0 2010-020602-14,7,2012-11-29,2012-11-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CHIESI,"A 12-WEEK, MULTINATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, 2-ARM PARALLEL GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF CHF 1535 200/6µg (FIXED COMBINATION BECLOMETHASONE DIPROP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020602-14,0,0,0 2010-020603-79,2,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,AB Science,"A prospective, multicentre, randomised, double-blind, placebo-controlled, 3-parallel groups, phase 2 study to evaluate efficacy and safety of 12 weeks treatment with masitinib versus placebo in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020603-79,0,0,0 2010-020604-29,5,2012-05-10,2012-05-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,"A Phase 3b, randomized, double-blind, placebo-controlled parallel-design study to evaluate the efficacy and safety of tadalafil co-administered with finasteride for 6 months in men with lower urinary ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020604-29,0,0,0 2010-020606-15,4,2015-05-27,2015-05-27,1,1,0,0,0,0,3,0,0,1,1,0,1,0,0,AIO-Studien-gGmbH,"An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced or metastatic esophageal squamous cell cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020606-15,0,0,0 2010-020611-36,3,2013-12-19,2013-12-19,2,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Genzyme Europe B.V.,"A Phase 4 Prospective Exploratory Muscle Biopsy, Biomarker, and Imaging Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020611-36,0,0,0 2010-020613-91,1,2013-05-21,2013-05-21,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,medac Gesellschaft für klinische Spezialpräparate mbH,"A randomized, multi-centre, parallel-group, open label, Oncaspar® controlled dose ranging trial of three doses of pegylated recombinant asparaginase in adult patients with newly diagnosed acute lympho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020613-91,0,0,0 2010-020616-11,6,2014-04-14,2014-09-06,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"Estudio en fase III, multicéntrico, aleatorizado, de 12 semanas, doble ciego, con grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de RO4917838 en pacientes con síntom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020616-11,0,0,0 2010-020617-82,1,2014-10-24,2014-10-24,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,University of Turku,Effect of itraconazole and ticlopidine on the pharmacokinetics and pharmacodynamics of oral tramadol: A three-phase randomized balanced cross-over study in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020617-82,0,0,0 2010-020620-22,6,2013-02-21,2013-02-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,Estudio en fase II aleatorizado para evaluar la combinación de vinflunina con gemcitabina y vinflunina con carboplatino en pacientes no elegibles para cisplatino con cáncer avanzado o metastásico de c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020620-22,0,0,0 2010-020621-40,1,2014-01-07,2014-01-07,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,The University of Oxford,SONATINA: A Phase II Multi-Centre Randomised Controlled Study of Nelfinavir Addition to Radiotherapy Treatment in Neo-Adjuvant Therapy for Rectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020621-40,0,0,0 2010-020657-14,1,2013-04-24,2013-04-24,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Alfact Innovation,"A multicentre, double-blind, randomized, placebo-controlled study to evaluate the efficacy and the safety of ALF-5755 in patients with nonacetaminophen severe acute hepatitis and early stage acute liv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020657-14,0,0,0 2010-020659-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,"COMBINED THERAPY WITH PEG-INTERFERON-α, RIBAVIRIN AND RITUXIMAB OF HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020659-30,0,0,0 2010-020660-37,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,ROTTAPHARM S.P.A.,"A Multicenter, randomized, double blind, double dummy, placebo controlled, parallel group, phase II study on the prevention of mucositis by CR3294, orally administered for 5 days in haematological pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020660-37,0,0,0 2010-020662-23,1,2012-06-13,2012-06-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,Allopurinol as a possible oxygen sparing agent during exercise in peripheral arterial disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020662-23,0,0,0 2010-020662-23,1,2012-06-13,2012-06-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Tayside,Allopurinol as a possible oxygen sparing agent during exercise in peripheral arterial disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020662-23,0,0,0 2010-020664-38,1,2015-07-24,2015-07-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Hellenic Cooperative Oncology Group,Efficacy and safety of Bevacizumab/Temsirolimus combination after first-line Bevacizumab/IFN combination in advanced renal cell carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020664-38,0,0,0 2010-020677-17,2,2014-04-05,2014-04-05,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Air Liquide Santé International,"Efficacy and safety of xenon anaesthesia compared to sevoflurane anaesthesia and total intravenous anaesthesia for on-pump coronary artery bypass graft surgery: a randomised, three-arm, single-blind, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020677-17,0,0,0 2010-020678-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,USE OF SORAFENIB IN THE PREVENTION OF RELAPSE OF RESECTED/ABLATED HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH HEPATITIS C VIRUS CHRONIC INFECTION.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020678-41,0,0,0 2010-020679-21,1,2015-03-31,2015-03-31,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Max-Planck-Institut für Psychiatrie,"Growth hormone and gonadotropin deficiency after brain injury (traumatic brain injury, subarachnoidal hemorrhage, ischemic stroke): the effects of hormone replacement on cognition,quality of life and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020679-21,0,0,0 2010-020681-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Lunamed Operations AG,"A PILOT STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND EFFICACY OF A DAILY DOSE OF 500MG. LU901 (4PHENYL-BUTYRATE, CONTROLLED RELEASE TABLETS) IN ADDITION TO STANDARD HORMONAL TREATMENT IN PATIENTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020681-16,0,0,0 2010-020683-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,Injection sous-conjonctivale de ranibizumab (Lucentis®) dans le traitement de la néovascularisation cornéenne : étude pilote de phase I/II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020683-38,0,0,0 2010-020684-20,6,2011-10-24,2011-10-24,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin, with or without ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020684-20,0,0,0 2010-020688-18,1,2013-04-26,2013-04-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, multipledose, exploratory proof of concept study to assess the safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of QAX576 in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020688-18,0,0,0 2010-020690-17,4,2012-01-09,2012-01-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Kythera Biopharmaceuticals, Inc.","ESTUDIO DE FASE 3, MULTICÉNTRICO, ALEATORIZADO, EN DOBLE CIEGO Y CONTROLADO CON PLACEBO DE ATX-101 (INYECCIÓN DE DESOXICOLATO DE SODIO) FRENTE PLACEBO EN LA REDUCCIÓN DEL TEJIDO ADIPOSO SUBCUTÁNEO LOC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020690-17,0,0,0 2010-020691-28,5,2012-02-01,2012-02-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Kythera Biopharmaceuticals, Inc.","ESTUDIO DE FASE 3, MULTICÉNTRICO, ALEATORIZADO, EN DOBLE CIEGO Y CONTROLADO CON PLACEBO DE ATX-101 (INYECCIÓN DE DESOXICOLATO DE SODIO) FRENTE PLACEBO EN LA REDUCCIÓN DEL TEJIDO ADIPOSO SUBCUTÁNEO LOC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020691-28,0,0,0 2010-020691-28,5,2012-02-01,2012-02-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Kythera Biopharmaceuticals Inc.,"ESTUDIO DE FASE 3, MULTICÉNTRICO, ALEATORIZADO, EN DOBLE CIEGO Y CONTROLADO CON PLACEBO DE ATX-101 (INYECCIÓN DE DESOXICOLATO DE SODIO) FRENTE PLACEBO EN LA REDUCCIÓN DEL TEJIDO ADIPOSO SUBCUTÁNEO LOC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020691-28,0,0,0 2010-020693-42,9,2012-07-05,2012-07-05,8,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Stallergenes S.A.,"A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract sol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020693-42,0,0,0 2010-020693-42,9,2012-07-05,2012-07-05,8,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Stallergenes SA,"A randomised, double-blind, placebo-controlled, multi-national, Phase IIIb study to assess the sustained clinical effect and safety of sublingual immunotherapy administered as birch pollen extract sol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020693-42,0,0,0 2010-020696-23,4,2014-04-14,2014-06-09,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,F. Hoffmann-La Roche Ltd,"Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020696-23,0,0,0 2010-020698-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Antwerp University Hospital : Department Respiratory Medicine,Study of the vascular wall with functional imaging in OSA patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020698-17,0,0,0 2010-020718-26,3,2014-09-17,2014-11-12,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020718-26,0,0,0 2010-020722-18,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,1-DEAMINO 8-D-ARGININA VASOPRESSIN IN PERCUTANEOUS ULTRASOUND-GUIDED RENAL BIOPSY: A RANDOMIZED CONTROLLED TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020722-18,0,0,0 2010-020724-21,1,2012-02-28,2012-02-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Universitätsklinik für Neurologie, Medizinische Universität Wien",Amyloid Imaging with [11C]PIB PET and MRI in MCI – a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020724-21,0,0,0 2010-020726-18,4,2012-12-27,2012-12-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,Estudio Abierto de Seguridad a Largo Plazo de LY2216684 12 a 18 mg Una Vez al Día como Tratamiento Adyuvante para Pacientes con Trastorno Depresivo Mayor con Respuesta Parcial al Tratamiento con un In...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020726-18,0,0,0 2010-020726-18,4,2012-12-27,2012-12-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,Estudio Abierto de Seguridad a Largo Plazo de LY2216684 12 a 18 mg Una Vez al Día como Tratamiento Adyuvante para Pacientes con Trastorno Depresivo Mayor con Respuesta Parcial al Tratamiento con un In...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020726-18,0,0,0 2010-020730-26,1,2012-11-13,2012-11-13,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","A PLACEBO-CONTROLLED, ESCALATING DOSE, MULTIPLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PREGABALIN IN PEDIATRIC PATIENTS WITH PARTIAL ONSET SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020730-26,0,0,0 2010-020731-39,1,2013-10-09,2013-10-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017",A 12-MONTH OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF FLEXIBLE DOSES OF PREGABALIN IN PEDIATRIC PATIENTS WITH PARTIAL ONSET SEIZURES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020731-39,0,0,0 2010-020737-50,2,2011-09-12,2011-09-12,2,1,0,0,0,0,2,0,2,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of 10mg memantine in the treatment of memory, concentration or attention problems (s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020737-50,0,0,0 2010-020738-24,1,2014-07-07,2014-07-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,Optimising Treatment With Tumour Necrosis Factor Inhibitors In Rheumatoid Arthritis: Is Dose Tapering Practical In Good Responders? A “Proof Of Principle” And Exploratory Trial. (OPTTIRA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020738-24,0,0,0 2010-020742-10,4,2011-06-30,2011-06-30,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Ipsen Pharma,Recombinant Human Insulin-like Growth Factor (rhIGF-1) and Growth Hormone (rhGH) Combination Therapy of Pre-Pubertal Children with Idiopathic Growth Hormone Deficiency and Poor Response to First Year ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020742-10,0,0,0 2010-020743-12,9,2012-11-26,2012-11-26,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Respon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020743-12,0,0,0 2010-020743-12,9,2012-11-26,2012-11-26,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astra Zeneca AB,"A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Respon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020743-12,0,0,0 2010-020744-35,8,2013-03-19,2013-03-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Respo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020744-35,0,0,0 2010-020744-35,8,2013-03-19,2013-03-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Respo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020744-35,0,0,0 2010-020745-27,9,2013-02-11,2013-02-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase III, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with Inadequate Response ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020745-27,0,0,0 2010-020745-27,9,2013-02-11,2013-02-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Phase III, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with Inadequate Response ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020745-27,0,0,0 2010-020746-98,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Santen Oy,An open-label phase IV study on the changes in ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switched from preserved travoprost 0.004% eye drops to preservative...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020746-98,0,0,0 2010-020747-13,1,2012-02-10,2012-02-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A double-blind, placebo controlled, randomised, parallel group phase IIa study to investigate the efficacy, tolerability, and safety of different dosing regimens of AZD8848 administered intranasally t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020747-13,0,0,0 2010-020748-37,1,2012-08-20,2012-08-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Mundipharma AB,"An open label, multi-centre, prospective age-group-controlled study to evaluate efficacy and safety of buprenorphine transdermal patches in subjects with chronic, moderate to severe osteoarthritis pai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020748-37,0,0,0 2010-020749-28,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo Español de Tumores Neuroendocrinos (GETNE),"Ensayo clínico fase II, abierto, no controlado, multicéntrico de pazopanib en monoterapia para la determinación de actividad, seguridad y biomarcadores predictivos en pacientes con progresión de tumo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020749-28,0,0,0 2010-020757-14,1,2016-07-01,2016-07-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,LYSARC,A multicentric phase II study evaluating the benefit of a short induction treatment by Bendamustine and Rituximab followed by maintenance therapy with rituximab In Elderly (≥ 60 years old) patients wi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020757-14,0,0,0 2010-020759-30,1,2013-12-09,2013-12-09,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Medizinische Universität Wien,A pilot study to assess [11C]elacridar and [11C]tariquidar as two positron emission tomography radiotracers for visualization of P-glycoprotein in humans.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020759-30,0,0,0 2010-020763-20,2,2015-05-12,2015-05-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"National University of Ireland, Galway",Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP 2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020763-20,0,0,0 2010-020763-20,2,2015-05-12,2015-05-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Belfast Health & Social Care Trust,Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP 2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020763-20,0,0,0 2010-020764-38,1,2011-08-04,2011-08-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, US","PHASE 2, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, 4-WEEK INPATIENT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TWO FIXED DOSES OF PF-02545920 COMPARED TO PLACEBO IN THE TREATMENT OF ACU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020764-38,0,0,0 2010-020769-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Poitiers,Evaluation médico-économique de l’infusion continue intra-duodénale d’une forme gélifiée de levodopa dans le traitement des formes avancées et sévères de maladie de parkinson par l’intermédiaire d’un ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020769-25,0,0,0 2010-020772-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,"A Phase II Study of Dose Density Regimen with Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days with Filgrastim Support followed by Weekly Paclitaxel in Women with Primary Breas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020772-38,0,0,0 2010-020775-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ClinTrio Ltd.,Assessment of myocardial viability using reduced doses of contrast agent (GV Via),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020775-22,0,0,0 2010-020780-21,1,2015-04-30,2015-04-30,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,"Department of Obstetrics and Gynaecology, Karolinska Institutet, Stockholm",Paracervical block (PCB) during II-trimester abortion – a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020780-21,0,0,0 2010-020782-24,1,2019-09-09,2019-09-09,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Helsinki University Central Hospital,The effects of dexmedetomidine on cardiac electrophysiology in adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020782-24,0,0,0 2010-020783-38,1,2011-10-27,2011-10-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vascular Biogenics Ltd,"A Phase II, Randomised, Double blind, Placebo-Controlled, Dose-Ranging Study to Assess the Effect of Multiple Doses of VB-201 on Biomarkers of Inflammation, Safety and Pharmacokinetics in Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020783-38,0,0,0 2010-020787-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitair Medisch Centrum Groningen,"Neo-adjuvant chemotherapy, cytoreductive surgery with hyperthermic intra-peritoneal chemotherapy for peritoneal carcinomatosis of colorectal origin (NACHO-trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020787-37,0,0,0 2010-020793-42,1,2016-12-31,2016-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Clinic for Thoracic and Cardiovascular Surgery, Heart Centre North Rhine-Westfalia",The effect of vitamin D on all-cause mortality in congestive heart failure patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020793-42,0,0,0 2010-020794-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Laboratoires SMB S.A.,"A phase II, randomised, partially-blinded, cross over study to evaluate the systemic effect of two doses of the SMB BUDESONIDE-SALMETEROL DPI fixed-dose combination capsule (300/25 µg BID and 150/25 µ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020794-16,0,0,0 2010-020796-24,1,2011-08-29,2011-08-29,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,"Dow Pharmaceutical Sciences, Inc","A multi-center, randomized, observer-blind trial to compare the irritant potential of the two topical acne formulations Acanya® Gel and Epiduo® Gel on acneic skin in a split-face assessment during a 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020796-24,0,0,0 2010-020797-41,6,2012-11-13,2012-11-13,2,0,0,1,0,0,1,0,0,2,1,0,0,0,2,Only for Children Pharmaceuticals,NEMO-1: An open label exploratory dose finding and pharmacokinetic clinical trial of bumetanide for the treatment of NEonatal seizure using Medication Off-patent.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020797-41,1,0,0 2010-020797-41,6,2012-11-13,2012-11-13,2,0,0,1,0,0,1,0,0,2,1,0,0,0,2,Great Ormond Street Hospital for Children NHS Trust,NEMO-1: An open label exploratory dose finding and pharmacokinetic clinical trial of bumetanide for the treatment of NEonatal seizure using Medication Off-patent.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020797-41,1,0,0 2010-020797-41,6,2012-11-13,2012-11-13,2,0,0,1,0,0,1,0,0,2,1,0,0,0,2,Only For Children Pharmaceuticals,NEMO-1: An open label exploratory dose finding and pharmacokinetic clinical trial of bumetanide for the treatment of NEonatal seizure using Medication Off-patent.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020797-41,1,0,0 2010-020798-17,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)","A Randomized, Multi-Center, Blinded, Placebo-Controlled Study of Mapatumumab ([HGS1012], a Fully Human Monoclonal Antibody to TRAIL-R1) in Combination with Sorafenib as a First-Line Therapy in Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020798-17,0,0,0 2010-020802-13,2,2012-11-12,2012-11-12,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"OncoGenex Technologies, Inc.","A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Clinical Benefit of Adding Custirsen to Docetaxel Retreatment/Prednisone as an Option for Secondline Therapy in Men with Ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020802-13,1,0,0 2010-020803-63,7,2015-02-04,2018-02-01,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AB Science,"A prospective, multicenter, randomised, double-blind, placebo-controlled, 2-parallel groups, Phase 3 study to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020803-63,1,0,0 2010-020807-57,7,2018-02-09,2018-02-09,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"Estudio Fase III, aleatorizado, multicéntrico y abierto, para evaluar eficacia y de seguridad del inhibidor de JAK INC424 (comprimidos), frente al mejor tratamiento de soporte en pacientes con policit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020807-57,0,0,0 2010-020807-57,7,2018-02-09,2018-02-09,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"Estudio Fase III, aleatorizado, multicéntrico y abierto, para evaluar eficacia y de seguridad del inhibidor de JAK INC424 (comprimidos), frente al mejor tratamiento de soporte en pacientes con policit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020807-57,0,0,0 2010-020807-57,7,2018-02-09,2018-02-09,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","Estudio Fase III, aleatorizado, multicéntrico y abierto, para evaluar eficacia y de seguridad del inhibidor de JAK INC424 (comprimidos), frente al mejor tratamiento de soporte en pacientes con policit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020807-57,0,0,0 2010-020809-33,1,2010-10-08,2010-10-08,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Engelhard Arzneimittel GmbH & Co.KG,"A phase IIa, single-center, randomized, observer-blind trial with intraindividual comparison of treated versus untreated to assess the wound healing efficacy of topical Tyrosur® Gel after experimental...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020809-33,0,0,0 2010-020810-27,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,Laboratoires BOIRON,"Essai clinique contrôlé randomisé, multicentrique, évaluant l'efficacité de deux médicaments homéopathiques (Dopamine 5 CH et Serotoninum muriaticum 5 CH) chez l'enfant TDAH âgé de 3 à 7 ans (6 ans et...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020810-27,0,0,0 2010-020814-27,5,2019-04-04,2019-04-04,5,1,0,0,0,2,3,0,0,1,0,0,1,0,0,EORTC,Empirical versus pre-emptive (diagnostic-driven) antifungal therapy of patients treated for haematological malignancies or receiving an allogeneic stem cell transplant. A therapeutic open label phase ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020814-27,0,0,0 2010-020818-28,1,2014-03-31,2014-03-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"St George's, University of London","A randomised, double-blind, placebo-controlled trial of metformin in chronic obstructive pulmonary disease (COPD) exacerbations: a pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020818-28,0,0,0 2010-020820-23,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,1,MedImmune,A Phase 1/2 Study of CAT-8015 in Adult Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020820-23,0,0,0 2010-020821-41,12,2019-02-08,2019-02-14,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Medivation, Inc.","A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Na�ve Patients with Progressive Metastatic Prostate Cancer Who Have Fail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020821-41,0,0,0 2010-020821-41,12,2019-02-08,2019-02-14,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.","A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Na�ve Patients with Progressive Metastatic Prostate Cancer Who Have Fail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020821-41,0,0,0 2010-020821-41,12,2019-02-08,2019-02-14,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Medivation, Inc., a wholly owned subsidiary of Pfizer","A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Na�ve Patients with Progressive Metastatic Prostate Cancer Who Have Fail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020821-41,0,0,0 2010-020824-23,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Karolinska University Hospital,P-piller och ekonomiskt beteende,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020824-23,0,0,0 2010-020825-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Radiation Therapy Oncology Group,A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020825-42,0,0,0 2010-020826-17,1,2011-03-22,2011-03-22,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"An open-label, non-randomized pharmacokinetic and safety study of repeat doses of fluticasone furoate and GW642444M combination in healthy subjects and in subjects with severe renal impairment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020826-17,0,0,0 2010-020827-28,2,2011-07-16,2011-07-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Single Treatment Cycle Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Lateral Cantha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020827-28,0,0,0 2010-020828-21,1,2011-09-13,2011-09-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020828-21,0,0,0 2010-020832-20,1,2011-05-23,2011-05-23,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation - for Global trials","An Evaluation of the Safety and Pharmacokinetics of Posaconazole (POS, SCH 56592) IV Solution via Peripheral Administration in Healthy Volunteers (P06356)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020832-20,0,0,0 2010-020835-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,"“A phase II study of cisplatin plus cyclophospamide for patients with previously treated, advanced, triple receptor negative breast cancer” Studio di fase II con cisplatino e ciclofosfamide metrono...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020835-38,0,0,0 2010-020836-21,3,2013-05-23,2013-05-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A randomised, double-blind, parallel-group, placebo-controlled, induction trial to assess the clinical efficacy and safety of NNC0142-0000-0002 in subjects with moderately to severely active Crohn’s d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020836-21,0,0,0 2010-020839-39,2,2012-06-29,2012-06-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"UCB Biosciences, Inc. A Member of the UCB Group of Companies","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY WITH AN ACTIVE COMPARATOR TO EVALUATE THE EFFICACY AND SAFETY OF CDP6038 ADMINISTERED SUBCUTANEOUSLY FOR 12 WEEKS TO SUBJECTS WITH AC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020839-39,0,0,0 2010-020839-39,2,2012-06-29,2012-06-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"UCB Biosciences, Inc","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY WITH AN ACTIVE COMPARATOR TO EVALUATE THE EFFICACY AND SAFETY OF CDP6038 ADMINISTERED SUBCUTANEOUSLY FOR 12 WEEKS TO SUBJECTS WITH AC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020839-39,0,0,0 2010-020840-36,2,2013-10-17,2013-10-17,1,1,0,0,0,0,2,0,1,2,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A Phase II Randomized, Observer-Blind, Multi-Center, Controlled Study of a Trivalent Group B strep. Vaccine in Healthy Pregnant Women.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020840-36,1,1,0 2010-020840-36,2,2013-10-17,2013-10-17,1,1,0,0,0,0,2,0,1,2,0,0,0,0,1,Novartis Vaccines and Diagnostics GmbH,"A Phase II Randomized, Observer-Blind, Multi-Center, Controlled Study of a Trivalent Group B strep. Vaccine in Healthy Pregnant Women.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020840-36,1,1,0 2010-020841-29,1,2017-08-31,2017-08-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King`s College London,The role of anti-IgE (omalizumab) in the management of severe recalcitrant paediatric atopic eczema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020841-29,0,0,0 2010-020841-29,1,2017-08-31,2017-08-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy`s & St Thomas` NHS Foundation Trust,The role of anti-IgE (omalizumab) in the management of severe recalcitrant paediatric atopic eczema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020841-29,0,0,0 2010-020852-79,14,2016-08-10,2016-08-10,13,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN AS ADJUNCTIVE THERAPY IN CHILDREN 4 -16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020852-79,1,0,0 2010-020852-79,14,2016-08-10,2016-08-10,13,1,0,0,0,0,3,0,0,2,1,0,0,0,1,PFIZER INC.,"A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN AS ADJUNCTIVE THERAPY IN CHILDREN 4 -16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020852-79,1,0,0 2010-020855-29,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,UNIVERSITA' DEGLI STUDI DI MESSINA,Radioiodine ablation of post-surgical thyroid remnants by recombinant human TSH (rhTSH) in patients with moderately severe and severe Graves' orbithopathy (GO) Ablazione radiometabolica del residuo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020855-29,0,0,0 2010-020859-30,10,2015-09-10,2016-02-19,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,UCB Inc.,"A phase 3, multicenter, open-label, extension study to assess the safety and tolerability of Epratuzumab treatment in systemic lupus erythematosus subjects (EMBODY 4)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020859-30,0,0,0 2010-020860-39,3,2013-01-29,2013-04-30,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",A LONG-TERM OPEN-LABEL EXTENSION STUDY OF LERSIVIRINE FOR THE TREATMENT OF HIV-1 INFECTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020860-39,0,0,0 2010-020861-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire,Etude de l’efficacité de l’analgésie par infiltration continue cicatricielle dans la chirurgie du rachis lombaire ou thoracique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020861-26,0,0,0 2010-020868-38,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,U.O.C. EMATOLOGIA - OSP. S. EUGENIO - ASL RM C,"(A Phase 2) STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE (Rd) FOLLOWED BY RITUXIMAB, AUTOGRAFT AND LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED WALDESTROM MACRO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020868-38,0,0,0 2010-020871-22,1,2014-05-30,2014-05-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,West-ward Pharmaceutical Corporation,"An international, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of phenobarbital as adjunctive therapy in participants (≥ 17 to 70 years old...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020871-22,0,0,0 2010-020872-49,1,2013-03-12,2013-03-12,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU Amiens,"Étude randomisée, en double aveugle, versus placebo, évaluant chez des patients porteurs d'une MRC, non dialysés, l'effet du traitement par carbonate de sevelamer sur le contrôle des taux sériques de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020872-49,0,0,0 2010-020875-22,1,2013-01-01,2013-01-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,RUNMC,"In vivo induction of heme oxygenase-1 (HO-1) in the metabolic syndrome (MetS). Influence of heme arginate (Normosang) infusion on heme oxygenase-1 activity, endothelial dysfunction, insulin resistance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020875-22,0,0,0 2010-020881-53,3,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Amgen Inc,A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020881-53,0,0,0 2010-020882-25,1,2015-03-19,2015-03-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Strathmann GmbH & Co. KG,Prospective Multicentre Randomized Double-Blind Placebo-Controlled Parallel Group Study on the Efficacy and Tolerability of StroVac® in Patients With Recurrent Symptomatic Bacterial Urinary Tract Infe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020882-25,0,0,0 2010-020886-26,4,2014-09-12,2014-12-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"Prospective, open-label, non-randomized, single-arm, multi-center dose titration study to investigate the safety and efficacy of NT 201 in subjects deemed to require total body doses of 800 U of NT 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020886-26,0,0,0 2010-020886-26,4,2014-09-12,2014-12-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERZ PHARMACEUTICALS GMBH,"Prospective, open-label, non-randomized, single-arm, multi-center dose titration study to investigate the safety and efficacy of NT 201 in subjects deemed to require total body doses of 800 U of NT 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020886-26,0,0,0 2010-020888-20,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,Merja Kokki,"LASKIMOON ANNETUN FENTANYYLIN TEHO, TURVALLISUUS JA PITOISUUDET PLASMASSA KEISARILEIKKAUKSEN YHTEYDESSÄ",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020888-20,0,0,0 2010-020890-18,2,2013-11-05,2013-11-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","AN EXPLORATORY PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO ASSESS THE EFFECTS OF TOFACITINIB (CP-690,550) ON MAGNETIC RESONANCE IMAGING ENDPOINTS, IN METHOTREXATE NAÏVE SUBJECTS WITH EARLY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020890-18,0,0,0 2010-020890-18,2,2013-11-05,2013-11-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"AN EXPLORATORY PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO ASSESS THE EFFECTS OF TOFACITINIB (CP-690,550) ON MAGNETIC RESONANCE IMAGING ENDPOINTS, IN METHOTREXATE NAÏVE SUBJECTS WITH EARLY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020890-18,0,0,0 2010-020891-43,2,2011-03-08,2011-03-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 4-week, Double-Blind, Placebo-Controlled, Randomised, Parallel group, Multi-Centre, Phase IIa Study to Investigate the Tolerability and Safety of 100 mg Oral AZD2423 in Patients with Moderate to Sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020891-43,0,0,0 2010-020892-22,14,2013-06-28,2013-06-28,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca AB,A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020892-22,0,0,0 2010-020892-22,14,2013-06-28,2013-06-28,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ASTRAZENECA,A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium (FosD) in the Treatment of Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020892-22,0,0,0 2010-020902-13,1,2014-09-04,2014-09-04,1,1,0,0,1,0,2,0,0,1,1,1,1,0,0,"Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Innsbruck","Intravitreal Lucentis (Ranibizumab) in acute central serous Chrioretinopathy - a prospective, randomized, single blind monocentric study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020902-13,0,0,0 2010-020904-31,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Novartis Farmacéutica S.A.,"Estudio piloto, abierto, multicéntrico, de eficacia y seguridad del tratamiento con canakinumab durante 6 meses y seguimiento de hasta 6 meses, en pacientes con síndrome de Hiper-IgD activo.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020904-31,0,0,0 2010-020906-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,MUMC,Randomized controlled trial of escitalopram versus placebo for patients with irritable bowel syndrome and panic disorder.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020906-14,0,0,0 2010-020911-35,7,2013-08-13,2013-09-19,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Gilead Sciences Inc.,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus) and Peginterferon Alfa 2a (Pegasys) in T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020911-35,0,0,0 2010-020911-35,7,2013-08-13,2013-09-19,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus) and Peginterferon Alfa 2a (Pegasys) in T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020911-35,0,0,0 2010-020912-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Vanda Pharmaceuticals Inc.,Open-label safety study of a 1-year 20 mg dose regimen of tasimelteon for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD) in blind individuals with no light perception.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020912-12,0,0,0 2010-020913-10,1,2013-08-19,2013-08-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Norfolk & Norwich University Hospitals NHS Foundation Trust,"An open label, pilot, multi-centre, step-down, randomised controlled trial to examine whether Etanercept 25mg once weekly is effective in maintaining a clinical response in patients with Ankylosing Sp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020913-10,0,0,0 2010-020916-12,2,2013-10-31,2013-10-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Astellas Pharma Global Development, Inc.","A Randomized, Double-Blind, Placebo-controlled Phase 2 Study of Maintenance OSI 906 plus Erlotinib (Tarceva®), or Erlotinib plus Placebo in Patients with Nonprogression Following Four Cycles of 1st-li...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020916-12,0,0,0 2010-020917-97,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,0,ASSOCIAZIONE ITALIANA PNEUMOLOGI OSPEDALIERI,"SPHERIC-1 (Sildenafil in the Chronic Obstructive Pulmonary Disease associated to Chronic Pulmonary Hypertension. Sixteen weeks long, multicentre, randomized, double blind study, in comparison with pla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020917-97,0,0,0 2010-020919-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospitals Leuven,None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020919-37,0,0,0 2010-020920-24,1,2014-10-31,2014-10-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik f.Innere Medizin I,Abt. f. Infektionen u.Tropenmedizin",Concentrations of doripenem in the cerebrospinal fluid of neurointensive care patients with extraventricular drainage due to secondary obstructive hydrocephalus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020920-24,0,0,0 2010-020922-16,2,2011-12-22,2011-12-22,2,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Bayer Healthcare AG,"International, prospective, double-blind, 3-arm comparative, randomized, placebo controlled phase IV study on the effect of counseling and either tranexamic acid or mefenamic acid or placebo, on the m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020922-16,0,0,0 2010-020923-37,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude de l'efficacité et de la tolérance de la mexiletine dans les myotonies non dystrophiques,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020923-37,0,0,0 2010-020924-22,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Birmingham,United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020924-22,0,0,0 2010-020925-42,7,2016-10-28,2016-10-28,3,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Astellas Pharma Europe Ltd.,"A Phase II, Open-Label, Multi-Center Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted from a Prograf® Based Immunosuppressive Regimen to a Tacroli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020925-42,1,0,0 2010-020926-17,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación GEL/TAMO (Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea),"Bendamustina, Citarabina, Etopósido y Melfalán como régimen de acondicionamiento para el transplante autólogo de progenitores hematopoyéticos en pacientes con linfoma agresivo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020926-17,0,0,0 2010-020931-37,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,GRIFOLS S.A.,EFFICACY AND SAFETY OF NIULIVA FOR THE PREVENTION OF HEPATITIS B VIRUS RECURRENCE IN NEWLY ORTHOTOPIC LIVER TRANSPLANT RECIPIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020931-37,0,0,0 2010-020932-20,2,2012-11-30,2012-11-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Double Masked, Placebo Controlled, Randomised, Parallel Group Phase IIa Study to assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-Ocular Pressure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020932-20,0,0,0 2010-020933-25,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Bispebjerg Hospital,Fraktioneret CO2 laser-assisteret fotodynamisk terapi versus keratolytisk behandling af terapiresistente fodvorter,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020933-25,0,0,0 2010-020935-38,1,2011-08-22,2011-08-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Consumer Health,"A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of diclofenac sodium topical gel 1% applied four times daily in subjects with acu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020935-38,0,0,0 2010-020936-21,1,2011-07-24,2011-07-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Consumer Health S.A.,"A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of diclofenac sodium topical gel 1% applied four times daily in subjects with acu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020936-21,0,0,0 2010-020939-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medizinische Universität Wien,Univ.Klinik f.Kinder-u.Jugendheilkunde",Pilot Trial: Feasibility of Microdialysis for Pharmacokinetic Studies in Neonatal Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020939-40,0,0,0 2010-020941-29,4,2011-11-12,2012-11-12,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Actelion Pharmaceuticals Ltd.,"A multi-center, double-blind, randomized, active reference, parallel group study to evaluate the efficacy, safety and tolerability of a 10-day twice daily oral administration of 3 doses of ACT-179811 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020941-29,0,0,0 2010-020941-29,4,2011-11-12,2012-11-12,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Actelion Pharmaceuticals Ltd,"A multi-center, double-blind, randomized, active reference, parallel group study to evaluate the efficacy, safety and tolerability of a 10-day twice daily oral administration of 3 doses of ACT-179811 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020941-29,0,0,0 2010-020943-10,1,2017-06-12,2017-06-12,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University of Leeds,A randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp) prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme: T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020943-10,0,0,0 2010-020944-37,1,2015-05-14,2015-05-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University College London,"Pilot study to establish laboratory methods for urine Nerve Growth Factor (NGF) and immunohistochemical staining of the vanilloid receptor (TRPV1) in bladder biopsies, following open label treatment w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020944-37,0,0,0 2010-020945-28,9,2013-01-11,2013-01-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Perindopril arginine/Amlodipine versus Valsartan/Amlodipine antihypertensive strategies: Efficacy and safety in mild to moderate hypertensive patients. A randomised, double blind 6-month study follo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020945-28,0,0,0 2010-020945-28,9,2013-01-11,2013-01-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Perindopril arginine/Amlodipine versus Valsartan/Amlodipine antihypertensive strategies: Efficacy and safety in mild to moderate hypertensive patients. A randomised, double blind 6-month study follo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020945-28,0,0,0 2010-020945-28,9,2013-01-11,2013-01-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Itziar Fernandez Gonzalez,"Perindopril arginine/Amlodipine versus Valsartan/Amlodipine antihypertensive strategies: Efficacy and safety in mild to moderate hypertensive patients. A randomised, double blind 6-month study follo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020945-28,0,0,0 2010-020946-80,8,2012-06-28,2012-07-12,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA","A PHASE IIIB, ONE YEAR, OPEN LABEL, MULTICENTRE, NONCOMPARATIVE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF INTRAVITREAL PEGAPTANIB SODIUM INJECTION IN SUBJECTS WITH DIABETIC MACULAR EDEMA (DME)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020946-80,0,0,0 2010-020946-80,8,2012-06-28,2012-07-12,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc,"A PHASE IIIB, ONE YEAR, OPEN LABEL, MULTICENTRE, NONCOMPARATIVE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF INTRAVITREAL PEGAPTANIB SODIUM INJECTION IN SUBJECTS WITH DIABETIC MACULAR EDEMA (DME)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020946-80,0,0,0 2010-020946-80,8,2012-06-28,2012-07-12,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer, S.A.","A PHASE IIIB, ONE YEAR, OPEN LABEL, MULTICENTRE, NONCOMPARATIVE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF INTRAVITREAL PEGAPTANIB SODIUM INJECTION IN SUBJECTS WITH DIABETIC MACULAR EDEMA (DME)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020946-80,0,0,0 2010-020949-26,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Dr. Miguel Blanca Gómez,Valoración de la eficacia de un extracto despigmentado de gramíneas en el tratamiento de la rinitis alérgica local,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020949-26,0,0,0 2010-020951-30,9,2014-09-30,2014-10-17,7,1,1,0,0,0,0,0,0,1,0,0,1,0,1,Shire Pharmaceutical Development Ltd,"A Phase 3, Open-label, Multicentre, 2-Year Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents Aged 6-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020951-30,0,0,0 2010-020951-30,9,2014-09-30,2014-10-17,7,1,1,0,0,0,0,0,0,1,0,0,1,0,1,Shire Pharmaceutical Development Ltd.,"A Phase 3, Open-label, Multicentre, 2-Year Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents Aged 6-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020951-30,0,0,0 2010-020953-14,1,2014-11-13,2014-11-13,1,0,0,0,1,3,4,0,1,1,0,0,1,0,0,"Derartment of Anaesthesiology and Intensive Care, Turku University Hospital",Effects of posaconazole and voriconazole on the pharmacokinetics and pharmacodynamics of sublingual buprenorphine: A three-phase double-blind cross-over study in healthy subjects.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020953-14,0,0,0 2010-020956-69,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Universitätsklinikum Freiburg,Effekte von Oxytocin bei Patientinnen und Patienten mit Borderline-Persönlichkeitsstörung,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020956-69,0,0,0 2010-020965-26,13,2019-04-01,2019-04-15,12,1,0,0,0,2,3,0,0,1,0,0,1,0,2,GlaxoSmithkline Research & Development,"A randomized, double blind, placebo controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020965-26,0,0,0 2010-020965-26,13,2019-04-01,2019-04-15,12,1,0,0,0,2,3,0,0,1,0,0,1,0,2,Novartis Pharma Services AG,"A randomized, double blind, placebo controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020965-26,0,0,0 2010-020965-26,13,2019-04-01,2019-04-15,12,1,0,0,0,2,3,0,0,1,0,0,1,0,2,GlaxoSmithKline R&D Ltd,"A randomized, double blind, placebo controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020965-26,0,0,0 2010-020965-26,13,2019-04-01,2019-04-15,12,1,0,0,0,2,3,0,0,1,0,0,1,0,2,"GlaxoSmithKline, S.A.","A randomized, double blind, placebo controlled phase III study to evaluate the efficacy and safety of pazopanib as adjuvant therapy for subjects with localized or locally advanced RCC following nephre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020965-26,0,0,0 2010-020966-34,1,2018-05-22,2018-05-22,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ICORG,"A phase II neoadjuvant study assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Traztuzumab and Lapatinib) in Erb B2 positive breast cancer patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020966-34,0,0,0 2010-020968-38,2,2013-09-24,2013-09-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment with CNTO 136 Administered Intravenously in Subjects with Active Lupus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020968-38,0,0,0 2010-020973-18,1,2012-06-20,2012-06-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"“Effect of treatment with ossein-hydroxyapatite compound on the time of fracture-healing”. A prospective, multicenter, double-blind, randomised, placebo controlled clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020973-18,0,0,0 2010-020977-18,2,2012-01-19,2012-01-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergan Ltd,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Repeat Treatment (two cycle) Study of the Safety and Efficacy of AGN-214868 in Patients with Postherpetic Neuralgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020977-18,0,0,0 2010-020979-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Randomized fase II study using chemiotherapy with metformine in patients affected by pancreas metastatic cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020979-23,0,0,0 2010-020983-39,8,2015-12-03,2015-12-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ViiV Healthcare UK Limited,"A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020983-39,0,0,0 2010-020983-39,8,2015-12-03,2015-12-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ViiV Healthcare S. L.,"A Phase 3, randomized, double-blind study of the safety and efficacy of GSK1349572 plus abacavir/lamivudine fixed-dose combination therapy administered once daily compared to Atripla over 96 weeks in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020983-39,0,0,0 2010-020985-94,1,2011-02-25,2011-02-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare (UK) Ltd,"A randomised, double blind, placebo-controlled, parallel group, single dose study of the efficacy of a flavoured variant of Strepsils Throat Lozenge in the relief of dry and irritated sore throat due ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020985-94,0,0,0 2010-020987-39,1,,,0,1,1,0,0,1,3,0,0,4,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Long-Term Multicenter, Randomized, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC-14597) as Maintenance Treatment in Adolescent Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020987-39,0,1,1 2010-020988-20,1,,,0,0,1,0,0,0,2,0,0,4,0,0,0,0,0,DAIDS,"A 48 week PhI/II multicentre open-label non-comparative study to evaluate PK, safety, tolerability & antiviral activity of DTG in HIV-1 infected children and adolescents of 6 weeks to <18 years of age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020988-20,0,1,1 2010-020989-20,2,2015-01-26,2015-01-26,1,0,0,0,0,1,2,0,0,1,1,0,1,0,1,"Quark Pharmaceuticals, Inc.","Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020989-20,0,0,0 2010-020992-21,5,2015-09-15,2017-03-10,3,0,0,0,0,0,3,0,0,1,1,1,1,0,1,AB Science,"A 24-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 3-parallel groups, Phase 2b/3 study to compare efficacy and safety of masitinib at 3 and 4.5 mg/kg/da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020992-21,0,0,0 2010-020993-41,5,2013-02-18,2013-02-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXO SMITH KLINE RESEARCH & DEVELOPMENT LTD,A phase 2a study to evaluate the effect of rilapladib (SB-659032) on biomarkers related to the pathogenesis and progression of Alzheimer’s disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020993-41,0,0,0 2010-020993-41,5,2013-02-18,2013-02-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,A phase 2a study to evaluate the effect of rilapladib (SB-659032) on biomarkers related to the pathogenesis and progression of Alzheimer’s disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020993-41,0,0,0 2010-020993-41,5,2013-02-18,2013-02-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmtihKline, S.A.",A phase 2a study to evaluate the effect of rilapladib (SB-659032) on biomarkers related to the pathogenesis and progression of Alzheimer’s disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020993-41,0,0,0 2010-020994-18,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Pharma Mar, S.A. Sociedad Unipersonal",Estudio Clínico y Farmacocinético en Fase II de PM00104 (Zalypsis®) en Pacientes con Carcinoma Urotelial Avanzado y/o Metastático que Progresa Después de una Primera Línea de Tratamiento Basado en Pla...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020994-18,0,0,0 2010-020998-16,7,2015-03-30,2015-03-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,A Phase III randomized study evaluating the efficacy and safety of continued and re-induced bevacizumab in combination with chemotherapy for patients with locally recurrent or metastatic breast cancer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-020998-16,0,0,0 2010-021001-21,1,2011-10-01,2011-10-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Allergie-Centrum-Charité,"An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021001-21,0,0,0 2010-021002-38,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Clínic per a la Recerca Biomèdica,Estudio sobre los efectos metabólicos de atazanavir/ritonavir versus darunavir/ritonavir en combinación con tenofovir/emtricitabina en pacientes infectados por el VIH-1 sin tratamiento previo: ensayo ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021002-38,0,0,0 2010-021003-24,12,2013-04-02,2013-04-18,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Amgen Inc,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021003-24,0,0,0 2010-021008-77,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,"Göteborgs Universitet, Göteborg Sweden",A MULTI - CENTER OPEN LABEL PHASE II (B) STUDY TO ASSESS EFFECTS OF SOM230 ON CARDIOVASCULAR PARAMETERS IN ACROMEGALIC PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021008-77,0,0,0 2010-021009-19,1,2015-08-21,2015-08-21,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action. A two year open label single arm study of teriparatide in secondary care.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021009-19,0,0,0 2010-021011-16,8,2014-06-30,2014-06-30,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Pharamceutical Industries, Ltd",A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021011-16,0,0,0 2010-021011-16,8,2014-06-30,2014-06-30,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Pharmaceutical Industries, Ltd",A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination with Custirsen (OGX-011) in Men with Metastatic Castrate Resistant Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021011-16,0,0,0 2010-021014-33,4,2013-02-06,2013-02-06,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Olympus Biotech Europe SAS,"A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment with Trafermin 0.01% Spray in Patients with Diabetic Foot Ulcer of Neuropathic Ori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021014-33,0,0,0 2010-021014-33,4,2013-02-06,2013-02-06,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Olympus France SAS,"A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment with Trafermin 0.01% Spray in Patients with Diabetic Foot Ulcer of Neuropathic Ori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021014-33,0,0,0 2010-021014-33,4,2013-02-06,2013-02-06,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,OLYMPUS FRANCE,"A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment with Trafermin 0.01% Spray in Patients with Diabetic Foot Ulcer of Neuropathic Ori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021014-33,0,0,0 2010-021015-16,9,2013-03-27,2013-03-27,7,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Olympus France SAS,"A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment with Trafermin 0.01% Spray in Patients with Diabetic Foot Ulcer of Neuropathic Ori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021015-16,0,0,0 2010-021015-16,9,2013-03-27,2013-03-27,7,0,0,0,0,0,3,0,0,1,1,0,1,0,1,Olympus Biotech Europe SAS,"A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment with Trafermin 0.01% Spray in Patients with Diabetic Foot Ulcer of Neuropathic Ori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021015-16,0,0,0 2010-021016-41,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Odense University Hospital,"Dose determination of Taxotere®, Eloxatin® and Xeloda® (TEX) in combination with Herpectin® as first line treatment to patients with HER2-positive non-resectable esophagus, cardia or gastric cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021016-41,0,0,0 2010-021017-23,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"RCT comparing the analgesic efficacy of 4 therapeutic strategies based on 4 different major opioids (fentanyl, oxycodone, buprenorphine vs morphine) in cancer patients with moderate/severe pain, at th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021017-23,0,0,0 2010-021018-49,1,2017-12-15,2017-12-15,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,GWT-TUD GmbH,Fish OIL optimal dosE Determination Study Findungsstudie für die Optimaldosierung von Fischöl,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021018-49,0,0,0 2010-021020-94,5,2011-05-20,2011-09-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Sanofi-aventis Recherche & Développement,"A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate (MTX) in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021020-94,0,0,0 2010-021020-94,5,2011-05-20,2011-09-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Sanofi-aventis Recherche & D�veloppement,"A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate (MTX) in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021020-94,0,0,0 2010-021021-13,3,2013-04-10,2013-04-10,3,1,0,0,1,0,3,0,0,1,0,0,1,0,1,"IBSA, Institut Biochimique S.A.",Safety and efficacy study comparing a new hMG formulation (hMG-IBSA) to a reference product (Menopur®) in patients undergoing ovarian stimulation for in vitro fertilisation (IVF).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021021-13,0,0,0 2010-021022-35,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,CHU de Saint-Etienne,Effet of curarization under general anaesthesia on eye movements in non-strabismus children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021022-35,0,0,0 2010-021024-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Organisation name was not entered,Anit-Inflammatory treatment to decrease suicidality in patients with a recent suicide attempt and a depressive disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021024-10,0,0,0 2010-021032-34,4,2011-06-15,2011-06-15,3,1,1,0,0,0,3,0,1,2,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, double-blind, randomized study to evaluate the immunogenicity and safety of GSK Biologicals’ quadrivalent influenza vaccine compared to GSK Biologicals’ trivalent influenza vaccine admin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021032-34,1,1,0 2010-021033-30,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,National Institute for Health and Welfare,Evaluation of the effectiveness of vaccination with 2009 H1N1 vaccines during influenza season 2010-11 2009 H1N1-influenssarokotteiden tehokkuus influenssakaudella 2010-11,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021033-30,0,0,0 2010-021034-63,2,2011-06-06,2011-06-06,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A phase III randomized, partially-blind, controlled, multi-country, multi-centre study to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals’ quadrivalent influenza vaccine D-QI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021034-63,0,0,0 2010-021034-63,2,2011-06-06,2011-06-06,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III randomized, partially-blind, controlled, multi-country, multi-centre study to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals’ quadrivalent influenza vaccine D-QI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021034-63,0,0,0 2010-021036-33,1,2012-01-10,2012-01-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bionorica SE,Double-blind comparison of VAC BNO 1095 FCT with placebo to identify dose dependent effects in patients suffering from cyclic mastodynia and PMS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021036-33,0,0,0 2010-021037-32,14,2016-06-20,2016-08-01,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Eli Lilly and Company Limited, Indianapolis","A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021037-32,0,0,0 2010-021037-32,14,2016-06-20,2016-08-01,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021037-32,0,0,0 2010-021039-14,1,2012-06-14,2012-06-14,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Tampere University, Faculty of Medicine, Department of Ophthalmology","An open-label, phase IV, pilot study, to evaluate confocal microscopic findings of cornea, ocular signs and symptoms in patients with ocular hypertension or open-angle glaucoma switching from latanopr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021039-14,0,0,0 2010-021041-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,Use of Calcimimetics vs oral Paricalcitol in Renal transplant Patients affected with Persistent Secondary Hyperparathyroidism. A pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021041-42,0,0,0 2010-021044-17,1,2011-11-04,2011-11-04,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,Medizinische Universität Wien,The effect of agomelatine on CLOCK gene expression in patients with major depressive disorder and healthy controls: an exploratory study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021044-17,0,0,0 2010-021048-16,1,2014-07-11,2014-07-11,1,1,1,0,0,1,0,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc.,"A Multicenter, Multinational, Open-Label, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021048-16,0,0,0 2010-021050-20,1,2012-11-16,2012-11-16,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Ghent University Hospital,Assessment of the optimal dosing of piperacillin-tazobactam in intensive care unit patients: extended versus continuous infusion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021050-20,0,0,0 2010-021052-25,1,2013-12-31,2013-12-31,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,ITACA-S 2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach): comparison of the efficacy of a peri-operative versus a post-operative chemotherapy treatment in patients wi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021052-25,0,0,0 2010-021057-39,3,2011-09-30,2011-09-30,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novo Nordisk A/S,"A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Paediatric (10 – 17 years old) Subjects with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021057-39,0,0,0 2010-021059-25,4,2011-10-19,2011-10-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,A 12-Week Study to Evaluate the 24 Hour Pulmonary Function of Fluticasone Furoate (FF)/Vilanterol (VI) Inhalation Powder (FF/VI Inhalation Powder) Once Daily Compared with Salmeterol/Fluticasone Propi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021059-25,0,0,0 2010-021059-25,4,2011-10-19,2011-10-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.",A 12-Week Study to Evaluate the 24 Hour Pulmonary Function of Fluticasone Furoate (FF)/Vilanterol (VI) Inhalation Powder (FF/VI Inhalation Powder) Once Daily Compared with Salmeterol/Fluticasone Propi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021059-25,0,0,0 2010-021061-72,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Ögonkliniken, Akademiska sjukhuset i Uppsala",To evaluate the safety and efficacy of a single subconjunctival injection of methylprednisolone versus standard postoperative steroid regiment in terms of intraocular inflammation and intraocular pres...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021061-72,0,0,0 2010-021062-29,3,2013-11-18,2013-11-18,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021062-29,0,0,0 2010-021062-29,3,2013-11-18,2013-11-18,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021062-29,0,0,0 2010-021067-32,16,2011-05-15,2013-05-07,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"AN OPEN LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB-MCC-DM1 (T-DM1) ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI CANCER THERAPIES IN PATIENTS PREVIOUSLY TREATED WITH THE EQUI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021067-32,0,0,0 2010-021067-32,16,2011-05-15,2013-05-07,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"AN OPEN LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB-MCC-DM1 (T-DM1) ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI CANCER THERAPIES IN PATIENTS PREVIOUSLY TREATED WITH THE EQUI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021067-32,0,0,0 2010-021068-13,2,2011-08-29,2011-08-29,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD S.N.C.,"An open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis adsorbed vaccine (RE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021068-13,0,0,0 2010-021069-63,13,2017-04-24,2017-04-24,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Amylin Pharmaceuticals, LLC","A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with exenatide once weekly in Patients with Type 2 Diabetes Mellitus” (EXSCEL: EXenatide Study of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021069-63,0,0,0 2010-021069-63,13,2017-04-24,2017-04-24,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,"A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with exenatide once weekly in Patients with Type 2 Diabetes Mellitus” (EXSCEL: EXenatide Study of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021069-63,0,0,0 2010-021069-63,13,2017-04-24,2017-04-24,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Amylin Pharmaceuticals, LCC","A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with exenatide once weekly in Patients with Type 2 Diabetes Mellitus” (EXSCEL: EXenatide Study of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021069-63,0,0,0 2010-021070-11,1,2014-05-01,2014-05-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BioVex Inc,An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment with OncoVEX GM-CSF or GM-CSF for Eligible Melanoma Patients Participating in Study 005/05,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021070-11,0,0,0 2010-021071-83,1,2010-10-26,2010-10-26,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Omninvest Ltd.,"Tolerability and Immunogenicity Study of FluvalAB Influenza Vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/strain/0.5 mL) in Adults and Elderly Person",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021071-83,0,0,0 2010-021073-36,1,2011-08-17,2011-08-17,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline,"Estudio fase III, doble ciego aleatorizado para evaluar la inmunogenicidad y seguridad de la vacuna antigripal tetravalente de GSK Biologicals GSK2282512A (FLU Q-QIV) comparada con la vacuna antigripa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021073-36,0,0,0 2010-021075-89,1,2013-01-04,2013-01-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd.,"A MULTICENTER, THREE ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS RECEIVING AN IMMUNOSUPPRESSIVE REGIMEN OF ADVAGRAF® (IMMEDIATELY OR DELAYED PO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021075-89,0,0,0 2010-021082-74,9,2012-12-06,2013-12-06,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,DAIICHI SANKYO DEVELOPMENT LTD.,"RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 1B/2 STUDY OF U3-1287 (AMG 888) IN COMBINATION WITH ERLOTINIB IN EGFR TREATMENT NAÏVE SUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WHO H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021082-74,0,0,0 2010-021082-74,9,2012-12-06,2013-12-06,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,DAIICHI SANKYO PHARMA DEVELOPMENT,"RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 1B/2 STUDY OF U3-1287 (AMG 888) IN COMBINATION WITH ERLOTINIB IN EGFR TREATMENT NAÏVE SUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WHO H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021082-74,0,0,0 2010-021086-73,1,2018-12-31,2018-12-31,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,University of Cologne,"HD-R3i - A prospective, randomized, placebo-controlled, international, multicenter phase I/II trial of RAD001 (everolimus) in combination with DHAP as induction therapy in patients with relapsed or re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021086-73,0,0,0 2010-021090-36,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,LAPATINIB plus LETROZOLE or CAPECITABINE AS FIRST LINE TREATMENT OF ER+/HER2+ METASTIC BREAST CANCER– A phase IIb randomized study with built-in crossover,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021090-36,0,0,0 2010-021091-28,6,2018-06-06,2018-06-06,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,AB Science,"A multicenter, randomised, open-label, three-parallel groups, phase 2-3 study to evaluate the efficacy and safety of masitinib with dexamethasone, gemcitabine with dexamethasone and the combination of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021091-28,1,0,0 2010-021092-89,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,SOUTHERN ITALY COOPERATIVE ONCOLOGY GROUP,"Cisplatin and Alimta with panitumumaB for Advanced non-squamous Lung cAncer (CABALA Trial): a SICOG multicenter, phase II trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021092-89,0,0,0 2010-021093-11,8,2013-12-27,2013-12-27,5,1,1,0,0,0,3,0,0,2,1,0,0,0,2,Boehringer Ingelheim Norway KS,"A Phase III randomised, double blind, placebo-controlled, parallel group study to assess the efficacy and safety over 48 weeks of orally inhaled Tiotropium bromide (2.5 µg and 5 µg once daily ) delive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021093-11,1,1,0 2010-021093-11,8,2013-12-27,2013-12-27,5,1,1,0,0,0,3,0,0,2,1,0,0,0,2,BOEHRINGER ING.,"A Phase III randomised, double blind, placebo-controlled, parallel group study to assess the efficacy and safety over 48 weeks of orally inhaled Tiotropium bromide (2.5 µg and 5 µg once daily ) delive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021093-11,1,1,0 2010-021093-11,8,2013-12-27,2013-12-27,5,1,1,0,0,0,3,0,0,2,1,0,0,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"A Phase III randomised, double blind, placebo-controlled, parallel group study to assess the efficacy and safety over 48 weeks of orally inhaled Tiotropium bromide (2.5 µg and 5 µg once daily ) delive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021093-11,1,1,0 2010-021093-11,8,2013-12-27,2013-12-27,5,1,1,0,0,0,3,0,0,2,1,0,0,0,2,Boehringer Ingelheim RCV GmbH,"A Phase III randomised, double blind, placebo-controlled, parallel group study to assess the efficacy and safety over 48 weeks of orally inhaled Tiotropium bromide (2.5 µg and 5 µg once daily ) delive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021093-11,1,1,0 2010-021093-11,8,2013-12-27,2013-12-27,5,1,1,0,0,0,3,0,0,2,1,0,0,0,2,"Boehringer Ingelheim España, S.A","A Phase III randomised, double blind, placebo-controlled, parallel group study to assess the efficacy and safety over 48 weeks of orally inhaled Tiotropium bromide (2.5 µg and 5 µg once daily ) delive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021093-11,1,1,0 2010-021093-11,8,2013-12-27,2013-12-27,5,1,1,0,0,0,3,0,0,2,1,0,0,0,2,Boehringer Ingelheim Pharma GmbH & Co.KG,"A Phase III randomised, double blind, placebo-controlled, parallel group study to assess the efficacy and safety over 48 weeks of orally inhaled Tiotropium bromide (2.5 µg and 5 µg once daily ) delive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021093-11,1,1,0 2010-021093-11,8,2013-12-27,2013-12-27,5,1,1,0,0,0,3,0,0,2,1,0,0,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase III randomised, double blind, placebo-controlled, parallel group study to assess the efficacy and safety over 48 weeks of orally inhaled Tiotropium bromide (2.5 µg and 5 µg once daily ) delive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021093-11,1,1,0 2010-021096-85,1,2013-01-02,2013-01-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nycomed,"A dose titrated clinical trial with a placebo-controlled, double-blind, randomised, cross-over phase to demonstrate the efficacy of 400 μg Intranasal fentanyl (INFS) dose strength, and to evaluate 12 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021096-85,0,0,0 2010-021097-11,4,2011-11-21,2011-11-21,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind placebo controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021097-11,0,0,0 2010-021097-11,4,2011-11-21,2011-11-21,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multi-center, randomized, double-blind placebo controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021097-11,0,0,0 2010-021111-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,"A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021111-17,0,0,0 2010-021113-23,7,2013-02-04,2013-02-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,"""""Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de una pauta con peginterfe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021113-23,0,0,0 2010-021113-23,7,2013-02-04,2013-02-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"""""Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de una pauta con peginterfe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021113-23,0,0,0 2010-021113-23,7,2013-02-04,2013-02-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen R&D Ireland,"""""Estudio en fase III, aleatorizado, doble ciego y controlado con placebo para investigar la eficacia, la seguridad y la tolerabilidad de TMC435 frente a placebo como parte de una pauta con peginterfe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021113-23,0,0,0 2010-021116-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Instituto Aragonés de Ciencias de la Salud,Estudio y resultados de una modalidad de derivación biliopancreática laparoscópica para el tratamiento definitivo de la diabetes tipo 2 en pacientes con IMC entre 30 y 35.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021116-42,0,0,0 2010-021118-47,1,2011-12-13,2011-12-13,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Fundación Hospital de Madrid,"Estudio fase II, abierto, multicéntrico, no aleatorizado para evaluar la eficacia y la seguridad de la combinación de lapatinib, oxaliplatino y capecitabina como tratamiento neoadyuvante en pacientes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021118-47,0,0,0 2010-021120-96,1,2014-04-24,2014-04-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche Products Limited,A study to assess the incidence of mutations in the tyrosine kinase domain of the epidermal growth factor receptor in UK patients with newly diagnosed locally advanced or metastatic non-small cell lu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021120-96,0,0,0 2010-021123-26,1,,,0,0,0,0,0,0,3,0,1,1,0,0,0,1,0,National Institute for Health and Welfare,Kaksoissokkoutettu kliininen hoitotutkimus: Rahapeliriippuvuuden hoitaminen opiaattisalpaaja naltreksonilla ja oppimismallilla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021123-26,0,0,0 2010-021125-12,1,2016-12-01,2016-12-01,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Janssen Infectious Diseases BVBA,Early access of TMC207 in combination with other anti-tuberculosis (TB) drugs in subjects with extensively drug resistant (XDR) or pre-XDR pulmonary TB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021125-12,0,0,0 2010-021128-92,14,2014-12-21,2015-12-21,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi aventis groupe,"Ensayo clínico multicéntrico, abierto y de un solo grupo para proporcionar acceso previo a la comercialización de cabazitaxel a los pacientes con cáncer de próstata metastásico hormono-resistente trat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021128-92,0,0,0 2010-021128-92,14,2014-12-21,2015-12-21,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis groupe,"Ensayo clínico multicéntrico, abierto y de un solo grupo para proporcionar acceso previo a la comercialización de cabazitaxel a los pacientes con cáncer de próstata metastásico hormono-resistente trat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021128-92,0,0,0 2010-021128-92,14,2014-12-21,2015-12-21,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Groupe,"Ensayo clínico multicéntrico, abierto y de un solo grupo para proporcionar acceso previo a la comercialización de cabazitaxel a los pacientes con cáncer de próstata metastásico hormono-resistente trat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021128-92,0,0,0 2010-021134-66,1,2017-12-14,2017-12-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Institut Jerome Lejeune,Efficacy assessment of systematic treatment with folinic acid and thyroid hormone on psychomotor development of Down Syndrome young children Evaluation de l'efficacité d'un traitement systématique ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021134-66,0,0,0 2010-021137-32,2,2012-09-26,2012-09-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A multi-center, double-blind, randomized, placebocontrolled, cross-over study to evaluate the efficacy, safety and tolerability of SAF312 in subjects with neurogenic detrusor overactivity due to spina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021137-32,0,0,0 2010-021139-15,1,,,0,1,0,0,1,0,3,0,0,1,1,1,0,1,0,Technische Universität München Fakultät für Medizin,Do Selective Radiation Dose Escalation and Tumor Hypoxia Status Impact the Locoregional Tumor Control after Radiochemotherapy of Head & Neck Tumors?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021139-15,0,0,0 2010-021141-41,1,2017-08-02,2017-08-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospitals Bristol NHS Foundation Trust,"Randomised Control Trial of the Clinical Effectiveness, Safety and Cost Effectiveness of Adalimumab in Combination with Methotrexate for the Treatment of Juvenile Idiopathic Arthritis Associated Uveit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021141-41,0,0,0 2010-021142-21,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Fundación Institut de Recerca de l' Hospital de la Santa Creu i Sant Pau,"?Alteraciones del sueño en pacientes con depresión mayor resistente al tratamiento con inhibidores selectivos de la recaptación de serotonina: ensayo clínico, aleatorizado, abierto, de grupos paralelo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021142-21,0,0,0 2010-021143-41,6,2018-12-06,2018-12-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development and Commercialization, Inc.","An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021143-41,0,0,0 2010-021144-17,1,2010-07-06,2010-07-06,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Engelhard Arzneimittel GmbH & Co. KG,"A phase III, multi-center, double-blind, randomized, vehicle controlled trial in a parallel-group design to evaluate the efficacy and safety of two formulations of Muxan containing 0.5 % or 1 % chlora...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021144-17,0,0,0 2010-021146-22,1,2014-11-20,2014-11-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Newcastle upon Tyne Hospitals NHS Foundation Trust,Alemtuzumab and rheumatoid arthritis - an immunisation study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021146-22,0,0,0 2010-021150-19,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,"Academical medical Center, Department of dermatology",Doxycycline versus minocycline in the treatment of rosacea: a randomised controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021150-19,0,0,0 2010-021155-11,5,2017-02-17,2017-02-17,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid B Antibody in Patients with Alzheimer's Disease. Monitorización continua de la eficacia y la seguridad de solanezumab, un antic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021155-11,0,0,0 2010-021155-11,5,2017-02-17,2017-02-17,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly & Company,"Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid B Antibody in Patients with Alzheimer's Disease. Monitorización continua de la eficacia y la seguridad de solanezumab, un antic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021155-11,0,0,0 2010-021156-26,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,Vertex Pharmaceuticals Inc.,"A Phase 1, Randomized, Open-label, Single-Dose, Crossover, Relative Bioavailability, and Food-Effect Study of a Pediatric Chewable Tablet Formulation Relative to a 375-mg Core Tablet Formulation of Te...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021156-26,0,1,1 2010-021159-25,1,2011-07-20,2011-07-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Lluita contra la Sida,INTERACCIONES FARMACOLÓGICAS ENTRE LA SILIMARINA Y DARUNAVIR/RITONAVIR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021159-25,0,0,0 2010-021161-71,1,2013-03-18,2013-03-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Professor Jørgen Berg Dahl,Effekten af Adductor-Kanal-Blokade på smerter og morfinforbrug efter revisions knæalloplastik,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021161-71,0,0,0 2010-021162-30,2,2014-04-08,2014-04-08,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Octapharma AG,"Prospective, Open-Label, Multi-Center, Phase III Clinical Study To Investigate The Efficacy And Safety Of Human Factor VWF/VIII Concentrate (Wilate) In Subjects With Inherited Type 3 Von Willebrand Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021162-30,0,0,0 2010-021162-30,2,2014-04-08,2014-04-08,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,OCTAPHARMA AG,"Prospective, Open-Label, Multi-Center, Phase III Clinical Study To Investigate The Efficacy And Safety Of Human Factor VWF/VIII Concentrate (Wilate) In Subjects With Inherited Type 3 Von Willebrand Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021162-30,0,0,0 2010-021163-33,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,The Institute of Cancer Research,A Phase II Trial of Cediranib in the Treatment of Patients with Alveolar Soft Part Sarcoma (CASPS) Ensayo fase II de Cediranib en el tratamiento de pacientes con sarcoma de partes blandas alveolar ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021163-33,0,0,0 2010-021163-33,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,The Royal Marsden Hospital NHS Foundation Trust,A Phase II Trial of Cediranib in the Treatment of Patients with Alveolar Soft Part Sarcoma (CASPS) Ensayo fase II de Cediranib en el tratamiento de pacientes con sarcoma de partes blandas alveolar ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021163-33,0,0,0 2010-021163-33,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,The Institute of Cancer Research / The Royal Marsden NHS Foundation Trust,A Phase II Trial of Cediranib in the Treatment of Patients with Alveolar Soft Part Sarcoma (CASPS) Ensayo fase II de Cediranib en el tratamiento de pacientes con sarcoma de partes blandas alveolar ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021163-33,0,0,0 2010-021165-76,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,"STOMP: Small cell lung cancer Trial of Olaparib (AZD2281) as Maintenance Programme: a randomised, double blind, multicentre phase II trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021165-76,0,0,0 2010-021166-30,1,2013-01-01,2013-01-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,Efficacy and safety of canakinumab in Schnitzler syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021166-30,0,0,0 2010-021170-11,1,2012-01-05,2012-01-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GENENTECH, Inc.","A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF INTRAVENOUS MEMP1972A IN THE PREVENTION OF ALLERGEN-IN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021170-11,0,0,0 2010-021172-28,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,1,F. Hoffmann-La Roche Ltd,"Farmacocinética y seguridad de valganciclovir en pacientes pediátricos < 4 meses de edad, receptores de trasplante cardíaco. Pharmacokinetics and safety of valganciclovir in pediatric heart transplant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021172-28,0,0,0 2010-021174-11,8,2013-01-23,2013-02-05,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen R&D Ireland,"A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon α-2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021174-11,0,0,0 2010-021174-11,8,2013-01-23,2013-02-05,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon α-2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021174-11,0,0,0 2010-021179-10,4,2012-04-19,2012-04-19,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,TROPHOS SA,"""An Open Label safety Extension study of olesoxime (TRO19622) in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole.""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021179-10,0,0,0 2010-021179-10,4,2012-04-19,2012-04-19,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,TROPHOS,"""An Open Label safety Extension study of olesoxime (TRO19622) in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole.""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021179-10,0,0,0 2010-021184-32,11,2016-11-10,2016-11-10,9,1,0,0,0,0,2,2,0,1,1,0,1,0,1,Hexal AG,"A randomized, double-blind, controlled study to evaluate pharmacokinetics, pharmacodynamics, safety and efficacy of GP2013 and rituximab in patients with rheumatoid arthritis refractory or intolerant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021184-32,0,0,0 2010-021186-70,1,2014-03-26,2014-03-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Belfast Health and Social Care Trust,Keratinocyte growth factor in Acute lung injury to REduce pulmonary dysfunction – a randomised placebo controlled trial (KARE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021186-70,0,0,0 2010-021188-34,7,2013-02-19,2013-09-05,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,LABORATORIES THEA,"Efficacy and safety assessment of intracameral T2380 (Fixed combination of lidocaine, phenylephrine and tropicamide) for mydriasis and anaesthesia in phacoemulsification cataract surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021188-34,1,0,0 2010-021188-34,7,2013-02-19,2013-09-05,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Laboratoires Théa,"Efficacy and safety assessment of intracameral T2380 (Fixed combination of lidocaine, phenylephrine and tropicamide) for mydriasis and anaesthesia in phacoemulsification cataract surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021188-34,1,0,0 2010-021191-29,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,ROCHE,"A multicenter, open label study to assess the effect of trastuzumab + Whole Brain Radiotherapy (WBRT) on brain metastases from HER-2 positive breast cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021191-29,0,0,0 2010-021192-87,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo Gallego de Investigación en Oncología - GGIO,Ensayo de fase II para evaluar la eficacia y la seguridad de panitumumab combinado con docetaxel y cisplatino como tratamiento de primera línea del adenocarcinoma gástrico o de la unión gastroesofágic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021192-87,0,0,0 2010-021193-11,1,2011-07-05,2011-07-05,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Helperby Thearapeutics Ltd,"A randomised, open-labelled, multiple dose study of HT61 formulations applied to the anterior nares plus chlorhexidine body and hair washes in subjects with nasal carriage of Staphylococcus aureus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021193-11,0,0,0 2010-021195-28,1,2012-05-29,2012-05-29,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Bayer HealthCare AG,"Single-center, randomized, placebo-controlled, double-blind, parallel group study to evaluate whether a single-dose of either 20 mg piroxicam, 40 mg piroxicam or 80 mg piroxicam shows an effect on ov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021195-28,0,0,0 2010-021196-85,9,2017-09-25,2017-10-02,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Bavarian Nordic, Inc.","A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021196-85,0,0,0 2010-021196-85,9,2017-09-25,2017-10-02,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Bavarian Nordic, Inc","A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021196-85,0,0,0 2010-021196-85,9,2017-09-25,2017-10-02,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"BN ImmunoTherapeutics, Inc.","A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021196-85,0,0,0 2010-021198-35,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,University Utrecht,D-cycloserine (DCS) enhancement of exposure therapy in panic disorder with agoraphobia: a randomized controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021198-35,0,0,0 2010-021207-25,1,2011-01-11,2011-01-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Creabilis Sàrl,"CT 327 in the treatment of psoriasis vulgaris: A Randomized, Double-Blind, Placebo Controlled Phase II, Multi-Centre, Study of the Efficacy and Safety of CT 327, a topical cream formulation of Pegylat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021207-25,0,0,0 2010-021209-18,9,2020-02-19,2020-02-28,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen R&D Ireland,"""Ensayo abierto con TMC278 25 mg al día en combinación con una pauta de base con dos inhibidores de la transcriptasa inversa nucleosídicos/nucleotídicos en pacientes infectados por el VIH-1 que partic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021209-18,0,0,0 2010-021209-18,9,2020-02-19,2020-02-28,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TIBOTEC PHARMACEUTICALS LTD.,"""Ensayo abierto con TMC278 25 mg al día en combinación con una pauta de base con dos inhibidores de la transcriptasa inversa nucleosídicos/nucleotídicos en pacientes infectados por el VIH-1 que partic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021209-18,0,0,0 2010-021209-18,9,2020-02-19,2020-02-28,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"""Ensayo abierto con TMC278 25 mg al día en combinación con una pauta de base con dos inhibidores de la transcriptasa inversa nucleosídicos/nucleotídicos en pacientes infectados por el VIH-1 que partic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021209-18,0,0,0 2010-021214-39,1,2013-10-07,2013-10-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Placebo-controlled, Double-blind Study of LY2216684 Fixed-dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021214-39,0,0,0 2010-021215-16,4,2013-08-13,2013-08-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 mg to 18 mg Once Daily and LY2216684 Fixed-Dose 6 mg Once Daily as Adjunctive Treatment for Patients with Major Depre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021215-16,0,0,0 2010-021216-41,5,2013-04-29,2013-04-30,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021216-41,0,0,0 2010-021217-23,3,2011-03-22,2011-03-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients with Moderate to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021217-23,0,0,0 2010-021218-50,7,2019-03-14,2019-03-14,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AB Science,"A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021218-50,1,0,0 2010-021219-17,5,2019-02-11,2019-02-11,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,AB Science,"A 96-week, prospective, multicenter, randomised, double-blind, placebo-controlled, 2-parallel groups, Phase 3 study to compare efficacy and safety of masitinib 4.5 mg/kg/day versus placebo in the trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021219-17,1,0,0 2010-021220-10,6,2014-10-21,2014-10-21,4,1,0,0,0,0,2,0,0,1,1,0,1,0,2,ASTRAZENECA,A Randomised Double-blind Phase IIa Study (with Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination with Exemestane vs. Exemestane Alone in ER+ Breast Cancer Patien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021220-10,0,0,0 2010-021220-10,6,2014-10-21,2014-10-21,4,1,0,0,0,0,2,0,0,1,1,0,1,0,2,AstraZeneca AB,A Randomised Double-blind Phase IIa Study (with Combination Safety Run-in) to Assess the Safety and Efficacy of AZD4547 in Combination with Exemestane vs. Exemestane Alone in ER+ Breast Cancer Patien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021220-10,0,0,0 2010-021221-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UMCU,A phase I/ II study Efficacy and safety of alpha/beta T- /CD19B-cell depleted allogeneic haematopoietic stem cells transplantation in high risk or relapsed acute leukaemia / MDS followed by an innate...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021221-12,0,0,0 2010-021224-10,1,2011-07-01,2011-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Universitätsklinik für Anästhesie,Intesivmedizin und Schmerztherapie,Mediniz.Universität Wien",The Impact of Interscalene Brachial Plexus Blockade on Postoperative Function after Shoulder Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021224-10,0,0,0 2010-021228-89,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Effect of L-Thyroxine supplementation in the first weeks of life on long-term neurodevelopmental outcome in infants with transient hypothyroxinemia born at or less than 28 weeks’ gestation Suppleme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021228-89,0,0,0 2010-021231-14,9,2012-03-26,2012-03-26,5,0,1,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE SAFETY, TOLERABILITY, AND EFFICACY OF VORICONAZOLE AND ANIDULAFUNGIN IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF INVASIV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021231-14,1,1,0 2010-021231-14,9,2012-03-26,2012-03-26,5,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Pfizer Inc.,"A PROSPECTIVE, RANDOMIZED TRIAL COMPARING THE SAFETY, TOLERABILITY, AND EFFICACY OF VORICONAZOLE AND ANIDULAFUNGIN IN COMBINATION TO THAT OF VORICONAZOLE ALONE WHEN USED FOR PRIMARY THERAPY OF INVASIV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021231-14,1,1,0 2010-021235-13,2,2013-05-15,2013-06-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,HAL Allergy B.V.,"A randomized, double-blind, placebo-controlled study to determine safety, tolerability and the optimal effective dose of SUBLIVAC FIX Phleum pratense in patients with allergic rhinitis/rhinoconjunctiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021235-13,0,0,0 2010-021236-34,1,2011-03-18,2011-03-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,Pilot study to assess the difference in glycemic profiles between vildagliptin and glimepiride using CGM device,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021236-34,0,0,0 2010-021238-74,17,2016-12-20,2017-01-03,15,1,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB BIOSCIENCES GmbH,"A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, FOLLOW UP STUDY EVALUATING THE LONG TERM SAFETY OF LACOSAMIDE (200 TO 600MG/DAY) IN COMPARISON WITH CARBAMAZEPINE (400 TO 1200MG/DAY), USED AS MONOTHERAPY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021238-74,1,1,0 2010-021238-74,17,2016-12-20,2017-01-03,15,1,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB BIOSCIENCES GMBH,"A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, FOLLOW UP STUDY EVALUATING THE LONG TERM SAFETY OF LACOSAMIDE (200 TO 600MG/DAY) IN COMPARISON WITH CARBAMAZEPINE (400 TO 1200MG/DAY), USED AS MONOTHERAPY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021238-74,1,1,0 2010-021238-74,17,2016-12-20,2017-01-03,15,1,0,0,0,0,3,0,0,2,0,0,0,0,1,SCHWARZ BIOSCIENCES GmbH,"A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, FOLLOW UP STUDY EVALUATING THE LONG TERM SAFETY OF LACOSAMIDE (200 TO 600MG/DAY) IN COMPARISON WITH CARBAMAZEPINE (400 TO 1200MG/DAY), USED AS MONOTHERAPY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021238-74,1,1,0 2010-021239-15,1,2011-03-28,2011-03-28,1,1,0,0,0,1,3,0,0,1,1,1,1,0,1,"Novartis Farmacéutica, S.A.","Estudio multicéntrico, abierto para evaluar el uso clínico a largo plazo del tratamiento con AIN457 en pacientes que finalicen los ensayos clínicos en los que se investiga AIN457 para el tratamiento d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021239-15,0,0,0 2010-021240-18,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA S. GERARDO DI MONZA,Peritoneal nebulization of Ropivacaine for pain control after laparoscopic colectomy Nebulizzazione peritoneale di Ropivacaina per il controllo del dolore dopo colectomia laparoscopica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021240-18,0,0,0 2010-021241-44,1,2016-01-26,2016-01-26,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHRU de TOURS,"Etude multicentrique, randomisée en groupes parallèles, évaluant l’efficacité et la tolérance d’un antibiocycle hebdomadaire dans la prévention des infections urinaires sur vessie neurologique.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021241-44,0,0,0 2010-021242-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHRU de Tours,"Etude multicentrique, de non infériorité, randomisée, ouverte, évaluant l’efficacité de deux Durées d’Antibiothérapie (6 semaines versus 12 semaines) dans le Traitement des Infections sur Prothèses Os...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021242-22,0,0,0 2010-021248-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,ANGIOGENESIS IMAGING WITH CONTRAST-ENHANCED ULTRASOUND (CEUS) IN COLORECTAL CANCER PATIENTS WITH LIVER METASTASES TREATED WITH BEVACIZUMAB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021248-16,0,0,0 2010-021253-39,4,2019-11-15,2019-11-15,1,0,0,0,0,1,2,0,0,2,0,0,0,0,0,Swiss Group for Clinical Cancer Research SAKK,"Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy. A randomized, open-label, multicentre phase II trial Studio open label, di ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021253-39,1,0,0 2010-021253-39,4,2019-11-15,2019-11-15,1,0,0,0,0,1,2,0,0,2,0,0,0,0,0,SAKK - GRUPPO SVIZZERO DI RICERCA CLINICA SUL CANCRO,"Rituximab plus lenalidomide or rituximab monotherapy for untreated patients with follicular lymphoma in need of therapy. A randomized, open-label, multicentre phase II trial Studio open label, di ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021253-39,1,0,0 2010-021255-81,2,2011-08-29,2011-10-06,2,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Bayer HealthCare AG,"Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021255-81,0,0,0 2010-021257-39,1,2014-05-28,2014-05-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,2,SWBH NHS Trust,"Is it clinically effective to treat arm flexor spasticity, with Botulinum toxin – type A (BoNTA) and physiotherapy, as soon as signs of abnormal muscle activity are observed? (A phase II study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021257-39,0,0,0 2010-021257-39,1,2014-05-28,2014-05-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Keele University,"Is it clinically effective to treat arm flexor spasticity, with Botulinum toxin – type A (BoNTA) and physiotherapy, as soon as signs of abnormal muscle activity are observed? (A phase II study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021257-39,0,0,0 2010-021258-20,8,2020-05-29,2020-05-29,7,1,0,0,0,0,4,0,0,2,0,0,0,0,0,KOMPETENZNETZ VORHOFFLIMMERN E.V. (AFNET),Early treatment of Atrial fibrillation for Stroke prevention Trial (EAST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021258-20,1,0,0 2010-021258-20,8,2020-05-29,2020-05-29,7,1,0,0,0,0,4,0,0,2,0,0,0,0,0,Kompetenznetz Vorhofflimmern e.V. (AFNET),Early treatment of Atrial fibrillation for Stroke prevention Trial (EAST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021258-20,1,0,0 2010-021258-20,8,2020-05-29,2020-05-29,7,1,0,0,0,0,4,0,0,2,0,0,0,0,0,Kompetenznetz Vorhofflimmern e.V. (AFNET e.V.),Early treatment of Atrial fibrillation for Stroke prevention Trial (EAST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021258-20,1,0,0 2010-021259-22,6,2011-06-08,2014-03-25,3,0,0,0,0,0,3,0,0,1,1,1,1,0,1,"TolerX, Inc.",DEFEND-1 Long Term Follow Up: Durable-Response Therapy Evaluation for Early or New Onset Type 1 Diabetes Extension Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021259-22,0,0,0 2010-021263-33,1,2013-03-08,2013-03-08,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Sykehuset i Vestfold HF,"PERIOPERATIVE LEVOSIMENDAN INFUSION IN PATIENTS WITH HEART FAILURE UNDERGOING NON-CARDIAC SURGERY: A PROSPECTIVE, RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021263-33,0,0,0 2010-021264-14,2,2020-07-17,2020-07-17,2,1,0,0,0,0,0,0,0,1,1,0,1,0,0,RWTH Aachen University,"Vitamin K1 to slow vascular calcification in hemodialysis patients. Multicenter, multinational, randomized controlled clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021264-14,0,0,0 2010-021264-14,2,2020-07-17,2020-07-17,2,1,0,0,0,0,0,0,0,1,1,0,1,0,0,"RWTH Aachen University represented by the rector, himself represented by the dean of the Medical Faculty","Vitamin K1 to slow vascular calcification in hemodialysis patients. Multicenter, multinational, randomized controlled clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021264-14,0,0,0 2010-021265-80,1,2016-05-30,2016-05-30,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Centre Hospitalier Universitaire de Reims,Injections intradétrusoriennes de toxine botulique A chez l'enfant présentant un syndrome d'hyperactivité vésicale neurogène : essai thérapeutique contrôlé multicentrique de non infériorité entre deux...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021265-80,0,0,0 2010-021266-30,1,2014-01-14,2014-01-14,1,1,1,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",A FOLLOW UP INVESTIGATION FOR PATIENTS COMPLETING STUDY A1481276 TO INVESTIGATE DEVELOPMENTAL PROGRESS 12 AND 24 MONTHS FOLLOWING COMPLETION OF SILDENAFIL TREATMENT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021266-30,0,0,0 2010-021268-13,1,2019-09-04,2019-09-04,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University College Dublin,The Effects of Normalising Sex Hormone Levels in Obese Hypogonadal Men: A Prospective Randomized Comparator Controlled Parallel Arm Clinical Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021268-13,0,0,0 2010-021270-11,1,2014-06-30,2014-06-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Impact of Daflon 500 mg on the progression of chronic venous disease and symptoms in patients operated on for varicose veins with conservation of the great saphenous vein. A multicentre, double blind...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021270-11,0,0,0 2010-021271-83,1,2012-02-08,2012-02-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Extension Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021271-83,0,0,0 2010-021275-92,1,2013-03-13,2013-03-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Charité – Universitätsmedizin Berlin,"Single center, open-label, cross-over study in maintenace kidney allograft recipients to evaluate the bioavailability of CellCept® (Mycophenolate mofetil) in comparison to Myfortic® (Enteric- coated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021275-92,0,0,0 2010-021277-36,1,2017-09-08,2017-09-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Queen Mary, University of London",REGENERATE – AMI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021277-36,0,0,0 2010-021283-14,6,2012-01-03,2012-03-12,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novo Nordisk A/S,"A randomised, double blind, placebo-controlled, multiple dose trial of Anti-IL-20 (109-0012) in subjects with rheumatoid arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021283-14,0,0,0 2010-021283-14,6,2012-01-03,2012-03-12,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVO NORDISK,"A randomised, double blind, placebo-controlled, multiple dose trial of Anti-IL-20 (109-0012) in subjects with rheumatoid arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021283-14,0,0,0 2010-021284-33,1,2013-03-31,2013-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Research and Development Department, John Radcliffe Hospital",Proof of concept study of combined allergen immunotherapy and antibiotics for the treatment of chronic atopic eczema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021284-33,0,0,0 2010-021287-16,4,2017-05-02,2017-05-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe BV (APEB),"A phase 2, open-label, single-arm, efficacy and safety study of MDV3100 in patients with hormone-naïve prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021287-16,0,0,0 2010-021287-16,4,2017-05-02,2017-05-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A phase 2, open-label, single-arm, efficacy and safety study of MDV3100 in patients with hormone-naïve prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021287-16,0,0,0 2010-021287-16,4,2017-05-02,2017-05-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe,"A phase 2, open-label, single-arm, efficacy and safety study of MDV3100 in patients with hormone-naïve prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021287-16,0,0,0 2010-021287-16,4,2017-05-02,2017-05-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V. (APEB),"A phase 2, open-label, single-arm, efficacy and safety study of MDV3100 in patients with hormone-naïve prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021287-16,0,0,0 2010-021291-29,5,2012-06-17,2012-09-17,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,FOVEA PHARMACEUTICALS,"A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (1% ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021291-29,1,0,0 2010-021291-29,5,2012-06-17,2012-09-17,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Fovea Pharmaceuticals SA,"A 6-month, Phase II, Double-masked, Multicenter, Randomized, Placebo controlled, Parallel Group Study to Assess the Safety and Efficacy of Topical Administration of Two Concentrations of FOV2304 (1% ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021291-29,1,0,0 2010-021295-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA` DI NOVARA,therapy antiedemigena through administration of corticosteroidi after surgical extraction of the teeth of the judgment.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021295-28,0,0,0 2010-021297-11,10,2016-08-01,2016-08-10,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Eli Lilly and Company Limited, Indianapolis","A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Pri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021297-11,0,0,0 2010-021297-11,10,2016-08-01,2016-08-10,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Lilly, S.A.","A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Pri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021297-11,0,0,0 2010-021333-31,1,2013-08-16,2013-08-16,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Klinikum der Universität München,Reduktion des Ischämie-Reperfusionsschadens durch ex-vivo Tacrolimus-Perfusion marginaler Organe vor Lebertransplantation (Tacrolimus-Organ-Perfusion TOP-Studie),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021333-31,0,0,0 2010-021336-33,12,2016-11-30,2016-11-30,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017","PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021336-33,0,0,0 2010-021336-33,12,2016-11-30,2016-11-30,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY10017","PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021336-33,0,0,0 2010-021336-33,12,2016-11-30,2016-11-30,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer, S.A.","PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021336-33,0,0,0 2010-021336-33,12,2016-11-30,2016-11-30,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017 US","PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021336-33,0,0,0 2010-021337-31,3,2013-08-28,2013-08-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen R&D Ireland,"A Phase III open-label study to evaluate the safety, tolerability and efficacy of TMC435 plus PegIFN?-2a (Pegasys)® and ribavirin (Copegus)® triple therapy in chronic hepatitis C genotype-1 infected s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021337-31,0,0,0 2010-021337-31,3,2013-08-28,2013-08-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"A Phase III open-label study to evaluate the safety, tolerability and efficacy of TMC435 plus PegIFN?-2a (Pegasys)® and ribavirin (Copegus)® triple therapy in chronic hepatitis C genotype-1 infected s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021337-31,0,0,0 2010-021343-41,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Effect of sapropterin on variations of blood phenylalanine and tyrosine over 24 hours and from day to day in children with phenylketonuria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021343-41,0,0,0 2010-021344-17,1,2012-12-24,2012-12-24,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A non-randomized, multiple dose, three treatment period, open-label, single sequence, single group study to evaluate the pharmacokinetic effect of two doses of QTI571 (imatinib) on the co-administe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021344-17,0,0,0 2010-021348-16,2,2016-08-11,2019-02-28,2,1,0,1,0,1,1,0,0,1,1,0,0,0,1,"Shire Human Genetic Therapies, Inc",An Open-Label Extension of Study HGT-SAN-055 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Administration of rhHNS in Patients with Sanfilippo Syndrome Type A (MPS IIIA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021348-16,0,0,0 2010-021349-36,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,Verona Pharma plc,"Randomised, Double-Blind, Placebo-Controlled Evaluation of the Safety and Duration of Action of 2 Single Inhaled Doses, 0.036 mg/kg (12X) and 0.072 mg/kg (24X), of RPL554, a Dual PDE 3/4 Inhibitor, in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021349-36,0,0,0 2010-021355-85,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU AMIENS,"Etude nationale, multicentrique, prospective, évaluant la correction et le maintien du taux d’hémoglobine avec une administration sous-cutanée mensuelle de Mircera® chez des patients transplantés réna...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021355-85,0,0,0 2010-021356-26,2,2012-10-11,2012-11-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A Phase IIb, randomized, observer-blind, placebo controlled, multicenter primary/booster therapeutic vaccination study to determine efficacy and safety of F4co/ AS01B vaccine, administered intramuscul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021356-26,0,0,0 2010-021356-26,2,2012-10-11,2012-11-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase IIb, randomized, observer-blind, placebo controlled, multicenter primary/booster therapeutic vaccination study to determine efficacy and safety of F4co/ AS01B vaccine, administered intramuscul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021356-26,0,0,0 2010-021358-20,5,2013-08-12,2013-08-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A PHOSPHODIESTERASE 5 INHIBITOR (PF-0048...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021358-20,0,0,0 2010-021358-20,5,2013-08-12,2013-08-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 east 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A PHOSPHODIESTERASE 5 INHIBITOR (PF-0048...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021358-20,0,0,0 2010-021360-15,1,2013-09-17,2013-09-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Instituto Grifols S.A.,"""EFECTOS DEL RECAMBIO PLASMÁTICO SOBRE LA CAPACIDAD FUNCIONAL DE LA ALBÚMINA SÉRICA, LA DISFUNCIÓN CIRCULATORIA, LA FUNCION RENAL Y CEREBRAL EN PACIENTES CIRRÓTICOS CON “ACUTE-ON-CHRONIC LIVER FAILURE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021360-15,0,0,0 2010-021361-69,1,2011-03-30,2011-03-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"J. Uriach y Compañía, S.A.","A multicenter, open-label study to assess pharmacokinetics, efficacy, tolerability and safety of Rupatadine in paediatrics patients (2-5 years old) with allergic rhinitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021361-69,0,0,0 2010-021362-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Helsingin Lääkärikeskus Oy, Graviditas Lapsettomuusklinikka",Ovarian stimulation with delayed start of r-hFSH in IVF treatment in subjects at increased risk of OHSS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021362-29,0,0,0 2010-021367-32,1,2011-11-23,2011-11-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Schering-Plough HealthCare Products, Inc","A Randomized, Open-Label, Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021367-32,0,0,0 2010-021368-13,1,2011-05-22,2011-05-22,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Antipodean Pharmaceuticals,A Double-blind Randomised Placebo-controlled Multicentre Study of 40mg MitoQ and Placebo for the Treatment of Participants with Raised Liver Enzymes due to Non-Alcoholic Fatty Liver Disease (NAFLD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021368-13,0,0,0 2010-021369-66,1,2012-12-18,2012-12-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Department of Pharmacy Universitaetsmedizin Mainz,Investigation of pharmacokinetics of Ciprofloxacin and Piperacillin/Tazobactam in Patients receiving continuous renal replacement therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021369-66,0,0,0 2010-021370-11,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,iOMEDICO AG,"An open label, single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021370-11,0,0,0 2010-021373-37,4,2018-02-01,2018-02-01,4,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche et Développement,Evaluation of Insuman Implantable 400 IU/ml in patients with Type 1 diabetes treated with the Medtronic MiniMed Implantable Pump System using Insuplant 400 IU/mL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021373-37,0,0,0 2010-021375-92,4,2014-12-01,2014-12-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A 24-week phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of twice daily oral administration of empagliflozin + metformin compared with the individual comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021375-92,0,0,0 2010-021375-92,4,2014-12-01,2014-12-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A 24-week phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of twice daily oral administration of empagliflozin + metformin compared with the individual comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021375-92,0,0,0 2010-021375-92,4,2014-12-01,2014-12-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A 24-week phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of twice daily oral administration of empagliflozin + metformin compared with the individual comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021375-92,0,0,0 2010-021375-92,4,2014-12-01,2014-12-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A 24-week phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of twice daily oral administration of empagliflozin + metformin compared with the individual comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021375-92,0,0,0 2010-021377-36,11,2017-10-23,2017-10-31,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A two stage phase III, international, multi center, randomized, controlled, open-label study to investigate the pharmacokinetics, efficacy and safety of rituximab SC in combination with CHOP or CVP ve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021377-36,0,0,0 2010-021382-78,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR),Ensayo fase I/II de escalada de dosis de radioterapia sobre regiones hipóxicas determinadas con F18-fluoromisonidazol (FMISO)-PET/TC en cáncer de pulmón.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021382-78,0,0,0 2010-021384-33,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Beroendecentrum Stockholm,The Effect of Naltrexone on Amphetamine Cue Reactivity: An fMRI Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021384-33,0,0,0 2010-021390-36,1,2013-02-19,2013-02-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,uzleuven,"The Effect of Acute Intake of Oral Buspirone Hydrochloride on Esophageal Motility, Bolus Transit and Symptoms of Dysphagia, in Patients with Ineffective Esophageal Motility: A Pilot, Open-label, Singl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021390-36,0,0,0 2010-021394-37,9,2012-08-29,2013-01-25,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,UCB Pharma SA,"Estudio multicéntrico, doble ciego, controlado con placebo, de grupos paralelos, fase IV para evaluar el efecto de rotigotina sobre los síntomas no motores en pacientes con enfermedad de Parkinson idi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021394-37,0,0,0 2010-021395-28,8,2013-12-04,2014-02-04,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,Effect of Teriparatide on Femoral Neck Fracture Healing,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021395-28,0,0,0 2010-021395-28,8,2013-12-04,2014-02-04,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,Effect of Teriparatide on Femoral Neck Fracture Healing,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021395-28,0,0,0 2010-021396-81,12,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,Instituto de Investigación Sanitaria La Fe de Valencia,European Low and Intermediate Risk Neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021396-81,0,0,0 2010-021396-81,12,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,INSTITUTO DE INVESTIGACIÓN SANITARIA LA FE DE VALENCIA,European Low and Intermediate Risk Neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021396-81,0,0,0 2010-021396-81,12,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,INSTITUTO DE INVESTIGACIÓN SANITARIA LA FE DE,European Low and Intermediate Risk Neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021396-81,0,0,0 2010-021396-81,12,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,INSTITUTO DE INVESTIGACION SANITARIA LA FE DE VALENCIA,European Low and Intermediate Risk Neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021396-81,0,0,0 2010-021396-81,12,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,FUNDACION PARA LA INVESTIGACION HOSPITAL UNIVERSITARIO LA FE.,European Low and Intermediate Risk Neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021396-81,0,0,0 2010-021396-81,12,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA,European Low and Intermediate Risk Neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021396-81,0,0,0 2010-021397-12,5,2012-05-29,2012-05-29,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Shire-Movetis NV,"An explorative, randomized, placebo-controlled, double-blind, parallel-group trial, to evaluate the pharmacodynamic effect of M0003 on reflux parameters in subjects with gastroesophageal reflux diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021397-12,0,0,0 2010-021397-12,5,2012-05-29,2012-05-29,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Movetis NV,"An explorative, randomized, placebo-controlled, double-blind, parallel-group trial, to evaluate the pharmacodynamic effect of M0003 on reflux parameters in subjects with gastroesophageal reflux diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021397-12,0,0,0 2010-021399-26,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación para la Formación y la Investigación de los profesionales de la Salud (FUNDESALUD),ENSAYO CLÍNICO CRUZADO PARA EVALUAR LA EFICACIA DEL TRATAMIENTO CON CITRATO DE FENTANILO ORAL TRANSMUCOSA DE LA DISNEA DE ESFUERZO EN PACIENTES CON CÁNCER AVANZADO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021399-26,0,0,0 2010-021401-20,1,2011-04-04,2011-04-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Allergan Pharmaceuticals Ireland,"A Multicenter, Randomised, Double-Blind Study to Evaluate the Efficacy of VISTABEL® (20 units) in the Treatment of Glabellar Lines, When Compared to BOCOUTURE® (30 units)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021401-20,0,0,0 2010-021403-24,1,2013-05-29,2013-05-29,1,0,0,0,0,0,4,0,1,1,1,1,1,0,0,North Lincolnshire and Goole NHS Foundation Trust,A Prospective Pilot Study to Investigate the Effectiveness of Quinagolide in the Improvement of Psychological Symptoms Associated with Hyperprolactinaemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021403-24,0,0,0 2010-021406-38,1,,,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,Mariefreds Vårdcentral,EMLA CREAM AS PAIN RELIEF DURING PNEUMOCOCCAL VACCINATION EMLA KRÄM SOM SMÄRTLINDRING VID PNEUMOKOCKVACCINATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021406-38,0,0,0 2010-021407-24,1,2012-08-28,2012-08-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Rigshospitalet,Phase II study of BIBF 1120 in recurrent Glioblastoma multiforme,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021407-24,0,0,0 2010-021410-34,1,,,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,Medical Centre Haaglanden,A double blind randomized study on the efficacy of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021410-34,0,0,0 2010-021412-42,1,2016-09-30,2016-09-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Royal Marsden Hospital,Prospective randomised controlled trial to investigate the effectiveness of inhalers for the relief of breathlessness in patients with lung cancer and COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021412-42,0,0,0 2010-021413-23,1,2014-08-01,2014-08-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"University of Athens, Medical School",Optimizing Dosing of Colistin for Infections Resistant to all Other Antibiotics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021413-23,0,0,0 2010-021414-32,4,2013-11-05,2013-11-05,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Pfizer Limited,"A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF PF-03049423 IN SUBJECTS WITH ISCHEMIC STROKE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021414-32,0,0,0 2010-021414-32,4,2013-11-05,2013-11-05,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK","A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF PF-03049423 IN SUBJECTS WITH ISCHEMIC STROKE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021414-32,0,0,0 2010-021415-16,4,2014-08-26,2014-08-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER ING.,Randomised phase II study of afatinib alone or in combination with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021415-16,0,0,0 2010-021415-16,4,2014-08-26,2014-08-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim,Randomised phase II study of afatinib alone or in combination with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021415-16,0,0,0 2010-021415-16,4,2014-08-26,2014-08-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.",Randomised phase II study of afatinib alone or in combination with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021415-16,0,0,0 2010-021415-16,4,2014-08-26,2014-08-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,Randomised phase II study of afatinib alone or in combination with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021415-16,0,0,0 2010-021422-35,1,2011-07-04,2011-07-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Deutsche Homöopathie-Union, DHU-Arzneimittel GmbH & Co. KG","Efficacy, safety and tolerability of Influcid tablets in patients (1 to 65 years old) suffering from upper respiratory tract infections with flu-like symptoms. A randomized, international, multicenter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021422-35,0,0,0 2010-021424-94,4,2012-11-30,2012-11-30,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,The Medicines Company,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin versus IV Vancomycin for the Treatment of Patients with Acute Bacterial Skin and Skin St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021424-94,0,0,0 2010-021425-13,7,2015-10-19,2015-10-19,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021425-13,0,0,0 2010-021425-13,7,2015-10-19,2015-10-19,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,JANSSEN-CILAG INTERNATIONAL NV,An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021425-13,0,0,0 2010-021430-64,1,2015-01-16,2015-01-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Leeds,A randomised double blind placebo controlled clinical trial of anti B-cell therapy in patients with primary Sjögren’s syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021430-64,0,0,0 2010-021433-32,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE(IDIBELL),Individualización de las dosis de Ganciclovir/Valganciclovir por predicción bayesiana en pacientes trasplantados de órgano sólido infectados por citomegalovirus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021433-32,0,0,0 2010-021434-55,7,2011-10-17,2011-10-17,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Ferring Pharmaceuticals A/S,"An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021434-55,0,0,0 2010-021435-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academisch Medisch Centrum Amsterdam,Effects of abatacept (Orencia®) on biomarkers in synovial tissue in patients with rheumatoid arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021435-14,0,0,0 2010-021437-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ErasmusMC,"Paracetamol (Acetaminophen) in Stroke 2 (PAIS 2): A randomized, placebo-controlled clinical trial of high-dose paracetamol in patients with acute stroke and a body temperature of 36.5°C or above P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021437-30,0,0,0 2010-021438-68,1,2011-02-01,2011-02-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lytix Biopharma AS,"A randomised, double-blind, placebo-controlled, Phase IIa pilot study to evaluate the safety, tolerability and efficacy of Lytixar™ (LTX-109) in patients with uncomplicated, Gram-positive, skin infect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021438-68,0,0,0 2010-021439-16,1,2016-01-12,2016-01-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre Oscar Lambret,Etude de phase II randomisée chez des patients porteurs d’un cancer épidermoïde métastatique de l’œsophage évaluant l’intérêt de la poursuite ou non d’un traitement cytotoxique chez des patients non p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021439-16,0,0,0 2010-021444-18,1,2014-10-31,2014-10-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Cardiff University,"TO ESTABLISH THE FEASIBILITY OF COMBINING EITHER THE TYROSINE KINASE INHIBITOR AC220 OR THE CXCR4 INHIBITOR PLERIXAFOR OR THE HSP90 INHIBITOR, GANETESPIB, WITH CHEMOTHERAPY IN OLDER PATIENTS WITH ACUT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021444-18,0,0,0 2010-021445-42,3,2021-01-29,2021-01-29,3,1,0,0,0,0,0,0,0,1,0,0,1,0,0,HOVON Foundation,"A multicenter, phase II study of bortezomib and dexamethasone as induction treatment followed by high dose melphalan (HDM) and autologous stem cell transplantation (SCT) in patients with de novo amylo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021445-42,0,0,0 2010-021446-21,1,2014-10-21,2014-10-21,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Per Rosenberg,Laskimonsisäisesti annetun rasvaemulsion kyky sitoa bupivakaiinia verenkierrossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021446-21,0,0,0 2010-021447-41,1,2017-12-31,2017-12-31,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,NHS Greater Glasgow Health Board,"SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic, castrate-refractory prostate cancer: a phase I/randomised phase II study by the UK NCRI Prostate Clinical Studies Group",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021447-41,0,0,0 2010-021447-41,1,2017-12-31,2017-12-31,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Glasgow University,"SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic, castrate-refractory prostate cancer: a phase I/randomised phase II study by the UK NCRI Prostate Clinical Studies Group",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021447-41,0,0,0 2010-021448-17,3,2012-07-04,2012-07-04,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, open-label, follow-up study to evaluate the long-term safety and tolerability of BGG492 TID as adjunctive therapy in patients with partial onset seizures completing double-blind, placeb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021448-17,0,0,0 2010-021449-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHRU de TOURS,Valeur prédictive de la concentration sérique d’Adalimumab (Humira) sur la réponse clinique dans la polyarthrite rhumatoïde,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021449-28,0,0,0 2010-021451-12,1,2014-02-04,2014-02-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Leeds,"An open label, multi-centre, randomised, parallel group phase II selection trial to identify the optimal starting dose of bendamustine (60 vs 100 mg/m2) when given in combination with thalidomide and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021451-12,0,0,0 2010-021452-26,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Crise Rénale sclérodermique : amélioration du pronostic par adjonction de Bosentan au traitement de référence de la maladie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021452-26,0,0,0 2010-021456-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Laboratorios SOPHIA, S.A. de C.V.","“ESTUDIO CLÍNICO DE SEGURIDAD PARA COMPARAR UNA SOLUCIÓN TÓPICA OFTÁLMICA DE GAAP OFTENO® (LATANOPROST AL 0.005%) FRENTE A XALATAN® (LATANOPROST AL 0.005%) COMO PRODUCTO DE REFERENCIA, EN PACIENTES CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021456-25,0,0,0 2010-021463-32,7,2017-08-04,2017-08-21,6,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Innovacell Biotechnologie AG,"Skeletal muscle-derived cell implantation for the treatment of fecal incontinence: a multicenter, randomized, double-blind, placebocontrolled, parallel-group, dose-finding clinical study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021463-32,0,0,0 2010-021465-72,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dra. Mª Dolores Arenas,"Ensayo clínico unicéntrico, abierto, no controlado, para determinar la variación en la concentración plasmática de hormona paratiroidea (PTH) en las 48 horas subsiguientes a la administración de cinac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021465-72,0,0,0 2010-021472-28,2,2012-02-10,2012-02-10,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AstraZeneca AB,"A Phase II Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the efficacy of 28-Day Oral Administration of AZD5069 Twice Daily in Patients with Bronchiectasis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021472-28,0,0,0 2010-021473-36,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,KEDRION,"Efficacy and Safety evaluation of Kedrion Human Hepatitis B Immunoglobulin for intramuscular use in the prevention of hepatitis B in the newborns of Hepatitis B Virus carrier-mothers: multi-centre, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021473-36,0,0,0 2010-021474-11,3,2012-10-08,2012-10-08,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GE Healthcare Srl,"A Multicentre, Randomised, Open-label, Comparative Phase IV Trial To Assess Changes in Dementia Diagnostic Category and Diagnostic Confidence After DaTSCAN Imaging in Subjects with an Uncertain Diagno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021474-11,0,0,0 2010-021474-11,3,2012-10-08,2012-10-08,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GE Healthcare Ltd. and its Affiliates,"A Multicentre, Randomised, Open-label, Comparative Phase IV Trial To Assess Changes in Dementia Diagnostic Category and Diagnostic Confidence After DaTSCAN Imaging in Subjects with an Uncertain Diagno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021474-11,0,0,0 2010-021477-36,2,2017-12-15,2017-12-15,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Zurich,Adjuvant chemotherapy versus NEOadjuvant gemcitabine/ oxaliplatin plus adjuvant gemcitabine in resectable PAncreatic Cancer: a randomized multicenter phase III study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021477-36,0,0,0 2010-021477-36,2,2017-12-15,2017-12-15,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Gesellschaft für Studienmanagement und Onkologie mbH,Adjuvant chemotherapy versus NEOadjuvant gemcitabine/ oxaliplatin plus adjuvant gemcitabine in resectable PAncreatic Cancer: a randomized multicenter phase III study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021477-36,0,0,0 2010-021490-37,3,2013-03-13,2013-03-13,3,1,1,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD,"A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4, and 12 Months.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021490-37,0,0,0 2010-021491-28,3,2013-10-09,2013-10-09,2,1,1,0,0,0,3,0,1,1,0,0,1,0,1,SANOFI PASTEUR MSD S.N.C.,"A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021491-28,0,0,0 2010-021491-28,3,2013-10-09,2013-10-09,2,1,1,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD S.N.C.,"A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021491-28,0,0,0 2010-021495-29,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,AB Science,"A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib at 6 mg/kg/day versus placebo in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021495-29,0,0,0 2010-021497-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FRANCISCO BORJA BARRACHINA LARRAZA,ACIDO TRANEXAMICO FRENTE A PLACEBO PARA LA REDUCCION DE LAS PERDIDAS SANGUINEAS EN LA CIRUGIA DE REEMPLAZO TOTAL DE CADERA: ENSAYO CLINICO ALEATORIZADO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021497-11,0,0,0 2010-021499-27,1,2011-05-19,2011-05-19,1,0,0,0,0,0,4,0,0,1,1,1,1,0,1,Chemische Fabrik Kreussler & Co. GmbH,"A Prospective, Randomized, Multi-centre, Placebo-controlled, Double blind, Comparative Study To Evaluate the Efficacy and Safety of Dynexan® Mundgel in Subjects with Acute Teething Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021499-27,0,0,0 2010-021501-20,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,ISTITUTO NEUROLOGICO MEDITERRANEO NEUROMED,study for evaluation of 18F-choline PET/CT efficacy in patients with prostate carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021501-20,0,0,0 2010-021502-38,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Christine Fromer Stiftung,STUDIE ZUR MESSUNG DER VAGINALEN INTERLEUKINE BEI PATIENTINNEN MIT ZERVIKALEN NEOPLASIEN (CIN 1-3) ODER CHRONISCHER CANDIDIASIS VAGINALIS UNTER BEHANDLUNG MIT 4PHENYL-BUTYRATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021502-38,0,0,0 2010-021507-24,5,2012-02-20,2012-02-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,"A Multicenter, Double-masked, Randomized, Parallel Study of the Safety and Efficacy of Bimatoprost 0.03%/Timolol 0.5% Preservative freeOphthalmic Solution Compared with GANFORT® (bimatoprost 0.03%/tim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021507-24,0,0,0 2010-021515-17,1,2012-09-24,2012-09-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Imperial College London,RiFL: Rifaxamin in Fatty Liver Disease. Does Modulation of Gut Microbiota Reduce Hepatic Inflammation in Non-Alcoholic Steatohepatitis (NASH)?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021515-17,0,0,0 2010-021516-42,4,2013-01-14,2013-01-14,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company,Two Approaches to Escalate Lispro Therapy in Patients with Type 2 Diabetes Mellitus Not Achieving Adequate Glycemic Control on Basal Insulin Therapy and Oral Agents Alone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021516-42,0,0,0 2010-021518-45,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,A pilot study on the effect of ARA290 on pain and pain responses and retinal edema in patients with diabetes mellitus and neuropathic pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021518-45,0,0,0 2010-021520-10,1,2011-02-02,2011-02-02,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,AstraZeneca AB,"An open, single centre, phase I study in male adolescents with asthma, aged 12 to 17 years, to assess pharmacokinetics of orally administered AZD1981 tablets 100mg twice daily for 6½ days",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021520-10,0,0,0 2010-021523-28,5,2011-05-24,2011-09-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ascendis Pharma A/S,"A Phase 2, Multiple Dose, Open-Label, Parallel-Group, Active Controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACP-001 in Adult Patients with Growth Hormone Deficiency (AG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021523-28,0,0,0 2010-021523-28,5,2011-05-24,2011-09-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASCENDIS PHARMA A/S,"A Phase 2, Multiple Dose, Open-Label, Parallel-Group, Active Controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACP-001 in Adult Patients with Growth Hormone Deficiency (AG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021523-28,0,0,0 2010-021526-36,1,2013-12-01,2013-12-01,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,Klinikum der Universität München,Dynamic and high-resolution MR angiography of the supraaortic vessels at 3 Tesla: Performance of Gadobutrol (Gadovist) in comparison to Gedobenate Dimeglumine (Multihance) and Gadoterate Meglumine (Do...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021526-36,0,0,0 2010-021528-81,2,2015-07-01,2015-07-01,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics s.r.l.,"A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021528-81,0,0,0 2010-021529-11,5,2014-07-08,2014-07-08,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck KGaA,"A randomized, double-blind, placebo-controlled, multicenter Phase II trial investigating two doses of EMD 525797 in subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant prost...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021529-11,0,0,0 2010-021531-13,1,2014-01-23,2014-01-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Joint UCLH and UCL Biomedical Research Unit,"Multi-centre, randomised, double-blind phase II study comparing cediranib (AZD2171) plus gefitinib (Iressa, ZD1839) with cediranib plus placebo in subjects with recurrent/progressive glioblastoma (DOR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021531-13,0,0,0 2010-021533-31,5,2012-08-07,2012-08-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021533-31,0,0,0 2010-021534-55,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Luis Carlos Imaz Navarro,"Comparación analgésica de bupivacaína, a diferentes dosis por catéter paravertebral torácico, y su implicación en la función pulmonar en pacientes intervenidos de toracotomía para cirugía de resección...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021534-55,0,0,0 2010-021556-25,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,IBSA,"Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial cys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021556-25,0,0,0 2010-021557-40,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,"A phase III trial comparing bortezomib, cyclophosphamide and dexamethasone versus lenalinomide cyclophosphamide and dexamethasone in patients with multiple myeloma at first relapse STUDIO DI FASE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021557-40,0,0,0 2010-021558-21,5,2012-01-25,2012-01-25,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Asahi Kasei Pharma Corporation,"A Phase IIa, Multi-Centre, Randomised, Double-Blind, Comparator Controlled, Repeated-Dose Study of 2 Dose Levels of AK106 001616 in Patients with Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021558-21,0,0,0 2010-021560-15,8,2012-11-19,2012-11-22,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 26 week randomised, parallel three-arm, open-label, multi-centre, multinational treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide versus insulin degludec ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021560-15,0,0,0 2010-021560-15,8,2012-11-19,2012-11-22,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"A 26 week randomised, parallel three-arm, open-label, multi-centre, multinational treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide versus insulin degludec ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021560-15,0,0,0 2010-021568-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"ISDIN, S.A.",Estudio clínico para evaluar la eficacia y tolerabilidad de Denutraxan® sobre el alivio del prurito asociado a dermatitis atópica en niños.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021568-14,0,0,0 2010-021569-58,1,2012-01-05,2012-01-05,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase I/II, double-blind, randomized, multicentre study to evaluate the safety and immunogenicity of new formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine when administered to he...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021569-58,0,0,0 2010-021571-88,1,2013-05-08,2013-05-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bioforce AG Roggwil TG,Echinaforce Hotdrink versus Oseltamivir in the Treatment of acute uncomplicated Flu,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021571-88,0,0,0 2010-021572-29,7,2022-06-09,2022-06-09,3,0,1,0,0,1,0,0,0,2,1,0,0,0,1,"GlaxoSmithKline Research & Development, Ltd","An open-label, long term extension study for treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up to 18 years who have participated in AMB112529 and in whom continued tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021572-29,1,0,0 2010-021572-29,7,2022-06-09,2022-06-09,3,0,1,0,0,1,0,0,0,2,1,0,0,0,1,"GlaxoSmithKline, S.A","An open-label, long term extension study for treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up to 18 years who have participated in AMB112529 and in whom continued tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021572-29,1,0,0 2010-021572-29,7,2022-06-09,2022-06-09,3,0,1,0,0,1,0,0,0,2,1,0,0,0,1,GlaxoSmithKline Research & Development Limited,"An open-label, long term extension study for treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up to 18 years who have participated in AMB112529 and in whom continued tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021572-29,1,0,0 2010-021574-11,2,2011-10-11,2011-10-11,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Furiex Pharmaceuticals, Inc","A Randomized, Controlled, Double-Blind, Multicenter, Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitaliz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021574-11,0,0,0 2010-021576-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitätsklinikum Tuebingen,Effects of transfusion thresholds on neurocognitive outcome of extremely low birth weight infants (ETTNO) a blinded randomized controlled multicenter trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021576-28,0,0,0 2010-021577-37,4,2012-07-31,2012-09-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GENENTECH, Inc","A PHASE II, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MLTA3698A IN COMBINATION WITH A DISEASE-MODIFYING ANTI-RHEUMATIC DRUG (DMARD) COMPARED WITH ADALIMUMAB...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021577-37,0,0,0 2010-021587-15,1,2018-02-28,2018-02-28,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ICORG,"A Phase III Clinical Trial Comparing TC to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021587-15,0,0,0 2010-021590-37,6,2016-12-20,2017-01-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017","A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAILUR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021590-37,0,0,0 2010-021590-37,6,2016-12-20,2017-01-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER INC.,"A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAILUR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021590-37,0,0,0 2010-021590-37,6,2016-12-20,2017-01-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY10017,USA","A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAILUR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021590-37,0,0,0 2010-021591-28,5,2012-11-14,2012-11-14,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,The Medicines Company,A clinical trial comparing cangrelor to clopidogrel standard of care therapy in subjects who require percutaneous coronary intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021591-28,0,0,0 2010-021591-28,5,2012-11-14,2012-11-14,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,THE MEDICINES COMPANY,A clinical trial comparing cangrelor to clopidogrel standard of care therapy in subjects who require percutaneous coronary intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021591-28,0,0,0 2010-021593-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,INSTITUT DE RESERCA.HSCSP,"Prevención de la progresión de la hipertensión portal en la cirrosis compensada mediante el uso de vasodilatadores hepáticos selectivos. Estudio multicéntrico, aleatorizado y doble-ciego",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021593-11,0,0,0 2010-021598-35,1,2019-09-09,2019-09-09,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University College London,"Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021598-35,0,0,0 2010-021600-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO,FEC neo-adjuvant chemotherapy followed by weekly Taxol administration combined with Trastuzumab in II-III stage HER2 positive breast cancer patients.Fase II trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021600-24,0,0,0 2010-021604-16,1,2014-04-25,2014-04-25,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Charité Universitätsmedizin Berlin,"A double-blind, randomized, placebo controlled study to evaluate the effectiveness of etoricoxib as an additive analgesic to epidural analgesia in colon or rectum fast-track surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021604-16,0,0,0 2010-021613-23,1,2014-09-25,2014-09-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,HYPAZ: An open-label investigation into hypertension induced by pazopanib therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021613-23,0,0,0 2010-021615-17,1,2012-03-01,2012-03-01,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Lars H. Rasmussen,"Randomized trial comparing endovascular laser, foam sclerotherapy and stripping in patients with varicose veins due to incompetent small saphenous vein",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021615-17,0,0,0 2010-021618-42,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Vejle Hospital,En fase II undersøgelse af oral vinorelbin i kombination med trastuzumab til 1. og 2. linie behandling af kvinder med metastaserende HER2 positiv brystkræft,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021618-42,0,0,0 2010-021621-12,14,2015-03-18,2015-03-18,11,1,1,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021621-12,1,1,0 2010-021621-12,14,2015-03-18,2015-03-18,11,1,1,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021621-12,1,1,0 2010-021621-12,14,2015-03-18,2015-03-18,11,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"GlaxoSmithKline, S.A.","A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021621-12,1,1,0 2010-021622-35,1,2014-05-07,2014-05-07,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Dean of Medical Faculty of Goethe University Frankfurt,"A monocenter, non-controlled, non-randomized IST to compare bioavailability of Kaletra softgelcapsules or -suspension to Kaletra tablets in pediatric patients – C2T Eine monozentrische, nicht kon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021622-35,0,0,0 2010-021624-99,1,2022-05-09,2022-05-09,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Decan of Medical Faculty of Goethe University Frankfurt,"A multi-centre, non-controlled, non-randomised IST to evaluate the plasma level of antiretroviral substances, the viral resistance profile and their impact on the clinical response in HIV infected ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021624-99,0,0,0 2010-021627-27,7,2013-01-11,2013-01-11,7,1,0,0,0,0,3,0,0,1,1,1,1,0,1,MERCK SHARP & DOHME CORP.,"A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021627-27,0,0,0 2010-021627-27,7,2013-01-11,2013-01-11,7,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021627-27,0,0,0 2010-021628-84,9,2012-11-08,2012-11-28,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec BVBA,"A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-na�ve subjects with genoty...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021628-84,0,0,0 2010-021628-84,9,2012-11-08,2012-11-28,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TIBOTEC BVBA,"A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-na�ve subjects with genoty...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021628-84,0,0,0 2010-021628-84,9,2012-11-08,2012-11-28,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Infectious Diseases BVBA,"A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-na�ve subjects with genoty...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021628-84,0,0,0 2010-021630-63,1,2011-11-08,2011-11-08,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Reckitt Benckiser,"A randomised, double blind placebo controlled study in patients with reflux symptoms to assess suppression of gastro-oesophageal reflux by ‘Gaviscon Double Action Peppermint liquid’ using the BRAVO sy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021630-63,0,0,0 2010-021638-72,14,2015-07-15,2015-07-15,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021638-72,0,0,0 2010-021638-72,14,2015-07-15,2015-07-15,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GLAXO SMITH KLINE RESEARCH & DEVELOPMENT LTD,A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021638-72,0,0,0 2010-021639-15,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,Guiding GC1008 treatment of primary brain tumors by 89Zr-GC1008 PET imaging.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021639-15,0,0,0 2010-021642-22,1,2012-01-19,2012-01-19,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A two part study to investigate the pharmacokinetics and pharmacodynamics of SB705498, a TRPV1 antagonist, in cough. Part A: an open label study in healthy subjects to determine the exposure to SB-705...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021642-22,0,0,0 2010-021644-18,1,2011-12-22,2011-12-22,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase IIIB, observer-blind, randomized, parallel groups, extension study to evaluate the immunogenicity and safety following a single intramuscular dose of FLUAD or Agrippal S1 influenza vaccines in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021644-18,0,0,0 2010-021651-79,1,2012-01-06,2012-01-06,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Studio degli effetti immuno-virologici dell’interruzione di Maraviroc nei pazienti che stanno fallendo un regime contenente Maraviroc Viro-Immunologic Effects of Interrupting Maraviroc in Patients ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021651-79,0,0,0 2010-021653-39,1,2011-06-30,2011-06-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Consumer Health S.A.,"A randomized, double-blind, parallel group, single-dose study of the efficacy of lidocaine 8 mg + cetylpyridinium chloride (CPC) 2 mg fixed combination lozenges on sore throat pain intensity compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021653-39,0,0,0 2010-021658-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Phase II study of preoperative TPF chemotherapy in locally advanced resectable oral cavity squamous cell cancer in order to improve the rate of pathological complete response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021658-21,0,0,0 2010-021659-17,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación Pública Andaluza Progreso y Salud,"Phase I / II, multicenter, double blind, randomized, comparison of two groups and two doses, to evaluate the safety and efficacy of autologous ASCs in the treatment of fecal incontinence. ESTUDIO F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021659-17,0,0,0 2010-021662-30,11,2012-07-23,2012-08-17,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 12 month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PDT i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021662-30,0,0,0 2010-021662-30,11,2012-07-23,2012-08-17,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12 month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PDT i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021662-30,0,0,0 2010-021662-30,11,2012-07-23,2012-08-17,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A 12 month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PDT i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021662-30,0,0,0 2010-021664-16,1,2013-11-25,2013-11-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Solvotrin Innovations Ltd,The role of doxycycline in the management of diastolic dysfunction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021664-16,0,0,0 2010-021665-68,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Antwerp,Comparison of Slow Efficiency dialysis (SLEDD) with Unfractionated Heparin versus Citrasate in Critically Ill Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021665-68,0,0,0 2010-021691-28,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Hospital Vall d'Hebron,PILOT CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF BOTULINUM NEUROTOXIN TYPE- A IN SALIVARY GLANDS IN THE TREATMENT OF CHRONIC DROOLING IN PATIENTS WITH CEREBRAL PALSY: A CONTROLLED CLINICAL ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021691-28,0,0,0 2010-021715-17,6,2014-04-21,2014-05-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A","A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genotype...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021715-17,0,0,0 2010-021715-17,6,2014-04-21,2014-05-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genotype...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021715-17,0,0,0 2010-021715-17,6,2014-04-21,2014-05-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genotype...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021715-17,0,0,0 2010-021715-17,6,2014-04-21,2014-05-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim International GmbH,"A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genotype...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021715-17,0,0,0 2010-021715-17,6,2014-04-21,2014-05-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genotype...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021715-17,0,0,0 2010-021715-17,6,2014-04-21,2014-05-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genotype...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021715-17,0,0,0 2010-021716-42,6,2014-03-12,2014-03-12,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH,"A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and rib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021716-42,0,0,0 2010-021716-42,6,2014-03-12,2014-03-12,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and rib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021716-42,0,0,0 2010-021716-42,6,2014-03-12,2014-03-12,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A","A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and rib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021716-42,0,0,0 2010-021716-42,6,2014-03-12,2014-03-12,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim International GmbH,"A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and rib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021716-42,0,0,0 2010-021716-42,6,2014-03-12,2014-03-12,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and rib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021716-42,0,0,0 2010-021716-42,6,2014-03-12,2014-03-12,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 12 or 24 weeks or BI 201335 240 mg for 12 weeks in combination with pegylated interferon-α and rib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021716-42,0,0,0 2010-021718-41,2,2013-05-03,2013-05-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergan Ltd,"A Pilot, Multicenter, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety and Efficacy of AGN-214868 in Patients with Idiopathic Overactive Bladder and Urinary Incontinence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021718-41,0,0,0 2010-021719-18,1,2016-02-23,2016-02-23,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Hannover Medical School,Phase I/II study on cytarabine and idarubicine combined with escalating doses of clofarabine as induction therapy in patients with acute myeloid leukemia and high risk for induction failure (CIARA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021719-18,0,0,0 2010-021720-10,3,2013-06-04,2013-06-20,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,The Medicines Company,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin versus IV Vancomycin for the Treatment of Patients with Acute Bacterial Skin and Skin St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021720-10,0,0,0 2010-021722-35,1,2012-07-16,2012-07-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Moorfields Eye Hospital,Diabetic macula oedema: A prospective randomised study comparing the detailed functional and anatomical changes of repeated pan anti-VEGF therapy with ranibizumab versus conventional macular laser the...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021722-35,0,0,0 2010-021723-27,1,2013-05-14,2013-05-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An exploratory, randomized, double-blind, placebo controlled, multi-center study to assess the efficacy, safety and tolerability of a single and a repeated dose of oral BCT197 in patients with an acut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021723-27,0,0,0 2010-021734-59,4,2014-06-10,2014-06-19,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Limited,Safety and Efficacy of 120 mg and 240 mg BI 201335 once daily in combination with pegylated interferon alpha 2a and ribavirin for treatment of chronic Hepatitis C (HCV) genotype 1 infection in HIV/HCV...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021734-59,0,0,0 2010-021734-59,4,2014-06-10,2014-06-19,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BOEHRINGER ING.,Safety and Efficacy of 120 mg and 240 mg BI 201335 once daily in combination with pegylated interferon alpha 2a and ribavirin for treatment of chronic Hepatitis C (HCV) genotype 1 infection in HIV/HCV...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021734-59,0,0,0 2010-021734-59,4,2014-06-10,2014-06-19,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,Safety and Efficacy of 120 mg and 240 mg BI 201335 once daily in combination with pegylated interferon alpha 2a and ribavirin for treatment of chronic Hepatitis C (HCV) genotype 1 infection in HIV/HCV...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021734-59,0,0,0 2010-021734-59,4,2014-06-10,2014-06-19,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Boehringer Ingelheim España, S.A.",Safety and Efficacy of 120 mg and 240 mg BI 201335 once daily in combination with pegylated interferon alpha 2a and ribavirin for treatment of chronic Hepatitis C (HCV) genotype 1 infection in HIV/HCV...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021734-59,0,0,0 2010-021738-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GEMCAD,"Estudio fase II abierto, no aleatorizado, para evaluar la eficacia y seguridad del tratamiento neoadyuvante concomitante de Gemcitabina y Erlotinib seguido de Gemcitabina, Erlotinib y radioterapia en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021738-72,0,0,0 2010-021755-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Phase II study on imatinib in combination with RAD001 in advanced chordoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021755-34,0,0,0 2010-021756-26,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"VG Region, Sahlgrenska sjukhuset, Hudkliniken, Göteborg",Behandlingseffekt av UV ljus jämfört med peroralt D vitamin på D-vitaminnivån hos somaliska kvinnor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021756-26,0,0,0 2010-021775-80,1,2015-01-13,2015-01-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,Explorative Untersuchung zum Einfluss der Vitamin D-vermitteltenr Modulation der initialen subkutanen Gräserpollen-spezifischen Immuntherapie bei Allergikern mit Gräserpollen-induzierter Rhinokonjunkt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021775-80,0,0,0 2010-021777-37,1,2013-03-28,2013-03-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsklinikum Schleswig-Holstein (UK-SH),"""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021777-37,0,0,0 2010-021778-13,7,2013-10-14,2013-11-12,5,1,1,0,0,0,3,0,0,2,1,0,0,0,1,BOEHRINGER ING.,"A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat inhaler (2.5 micrograms and 5 micrograms...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021778-13,1,1,0 2010-021778-13,7,2013-10-14,2013-11-12,5,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co. KG,"A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat inhaler (2.5 micrograms and 5 micrograms...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021778-13,1,1,0 2010-021778-13,7,2013-10-14,2013-11-12,5,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat inhaler (2.5 micrograms and 5 micrograms...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021778-13,1,1,0 2010-021778-13,7,2013-10-14,2013-11-12,5,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Boehringer Ingelheim, Lda","A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat inhaler (2.5 micrograms and 5 micrograms...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021778-13,1,1,0 2010-021778-13,7,2013-10-14,2013-11-12,5,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Boehringer Ingelheim RCV Gmb & Co KG,"A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat inhaler (2.5 micrograms and 5 micrograms...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021778-13,1,1,0 2010-021778-13,7,2013-10-14,2013-11-12,5,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat inhaler (2.5 micrograms and 5 micrograms...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021778-13,1,1,0 2010-021781-29,13,2016-06-30,2020-10-27,11,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Bayer AG,A multicenter Phase III uncontrolled open-label trial to evaluate safety and efficacy of BAY 81-8973 in children with severe haemophilia A under prophylaxis therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021781-29,0,0,0 2010-021781-29,13,2016-06-30,2020-10-27,11,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,A multicenter Phase III uncontrolled open-label trial to evaluate safety and efficacy of BAY 81-8973 in children with severe haemophilia A under prophylaxis therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021781-29,0,0,0 2010-021782-70,1,2014-11-07,2014-11-07,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Universitätsmedizin der Johannes Gutenberg-Universität Mainz,"Open monocentric clinical pilot study in COPD und Asthma patients to investigate static as well as dynamic ventilation, intrapulmonary ADC and pO2 using helium-3-MRI after inhalation of hyperpolarise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021782-70,0,0,0 2010-021783-15,1,2011-10-14,2011-10-14,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Guys and St Thomas' NHS Foundation Trust,Ropivacaine 0.75% versus Levobupivacaine 0.5% for conversion of labour epidural to surgical anaesthesia for emergency Caesarean section. (RoLe Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021783-15,0,0,0 2010-021785-30,13,2012-08-09,2014-01-28,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ViiV Healthcare UK Limited,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021785-30,0,0,0 2010-021785-30,13,2012-08-09,2014-01-28,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,VIIV HEALTHCARE UK LIMITED,"A MULTICENTER, RANDOMIZED, DOUBLE BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV INFECTE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021785-30,0,0,0 2010-021786-78,1,2015-04-18,2015-04-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Wien,Treatment of chronic lymphocytic leukemia with the use of an antiviral compound - a proof of principle study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021786-78,0,0,0 2010-021787-15,4,2013-02-18,2013-02-18,4,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Laboratorios León Farma S.A.,"A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety and Tolerability of Drospirenone as LF111 During 13 Cycles",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021787-15,0,0,0 2010-021788-33,3,2013-07-12,2013-07-12,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017 US","A PHASE 4, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VARENICLINE COMPARED TO PLACEBO FOR SMOKING CESSATION THROUGH REDUCTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021788-33,0,0,0 2010-021788-33,3,2013-07-12,2013-07-12,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","A PHASE 4, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VARENICLINE COMPARED TO PLACEBO FOR SMOKING CESSATION THROUGH REDUCTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021788-33,0,0,0 2010-021789-31,4,2012-11-02,2012-11-02,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","A PHASE 4 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF RE-TREATMENT WITH VARENICLINE IN SUBJECTS WHO ARE CURRENTLY SMOKING, AND WHO HAVE PREVIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021789-31,0,0,0 2010-021789-31,4,2012-11-02,2012-11-02,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 4 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF RE-TREATMENT WITH VARENICLINE IN SUBJECTS WHO ARE CURRENTLY SMOKING, AND WHO HAVE PREVIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021789-31,0,0,0 2010-021789-31,4,2012-11-02,2012-11-02,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017 US","A PHASE 4 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF RE-TREATMENT WITH VARENICLINE IN SUBJECTS WHO ARE CURRENTLY SMOKING, AND WHO HAVE PREVIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021789-31,0,0,0 2010-021790-37,1,2016-08-16,2016-08-16,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,"Universitätsklinikum Schleswig-Holstein, Campus Lübeck","Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021790-37,0,0,0 2010-021792-81,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE,SFCE-Metro 01 : Etude de phase II de chimiothérapie métronomique associant celecoxib-methotrexate-vinblastine-cyclophosphamide chez les enfants porteurs d’une tumeur solide en rechute ou en progressi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021792-81,0,0,0 2010-021793-12,9,2014-08-13,2014-08-13,6,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Actelion Pharmaceuticals Ltd,"A prospective, multicenter, open-label extension of FUTURE 3 to assess the safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with pul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021793-12,1,1,0 2010-021793-12,9,2014-08-13,2014-08-13,6,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Actelion Pharmaceuticals Ltd.,"A prospective, multicenter, open-label extension of FUTURE 3 to assess the safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with pul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021793-12,1,1,0 2010-021797-10,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,VU university medical center,A phase II randomized multicenter study on efficacy and safety of cultured autologous skin (Tiscover®) and acellular dermal matrix (AS210) in chronic (arterio-)venous ulcers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021797-10,0,0,0 2010-021798-34,1,2010-12-08,2010-12-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare (GSKCH),To assess the subjective effect of two paracetamol preparations on the feeling of breathing in subjects with the common cold.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021798-34,0,0,0 2010-021800-72,3,2012-04-17,2012-04-24,3,1,0,0,2,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GW642444 and with tiotropium over 24 weeks in subjects with COPD. Studio multicentrico per confrontare l'efficacia e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021800-72,0,0,0 2010-021800-72,3,2012-04-17,2012-04-24,3,1,0,0,2,0,3,0,0,1,0,0,1,0,1,GLAXO SMITH KLINE RESEARCH & DEVELOPMENT LTD,A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GW642444 and with tiotropium over 24 weeks in subjects with COPD. Studio multicentrico per confrontare l'efficacia e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021800-72,0,0,0 2010-021802-39,1,2012-04-10,2012-04-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GSK573719 with tiotropium over 24 weeks in subjects with COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021802-39,0,0,0 2010-021811-17,1,2014-10-20,2014-10-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Helsingin yliopisto,Suun limakalvolle annosteltu fentanyyli luuydinaspiraatioon ja -biopsiaan liittyvän kivun hoidossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021811-17,0,0,0 2010-021813-22,1,2012-10-01,2012-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Central Manchester University Hospitals NHS Foundation Trust,The Anticoagulation of Calf Thrombosis (ACT) Study: A randomised controlled trial comparing standardised anticoagulation versus conservative therapy in the treatment of below knee deep vein thrombosis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021813-22,0,0,0 2010-021814-43,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Ulrich Tacke,The Safety and Tolerability of Methadone/Naloxone Combination in Opioid Substitution Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021814-43,0,0,0 2010-021815-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,- Identification of the sentinel node in breast cancer with fluorescence lymphography using indocyanine green dye (ICG): pilot study. - Identificazione del linfonodo sentinella nel carcinoma mammar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021815-18,0,0,0 2010-021817-22,5,2018-09-04,2018-09-04,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Ipsen Innovation,"A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, CONTROLLED, MULTIPLE TREATMENT STUDY ASSESSING EFFICACY AND SAFETY OF DYSPORT USED IN THE TREATMENT OF OF UPPER LIMB SPASTICITY IN CHIL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021817-22,1,1,0 2010-021817-22,5,2018-09-04,2018-09-04,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,IPSEN INNOVATION,"A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, CONTROLLED, MULTIPLE TREATMENT STUDY ASSESSING EFFICACY AND SAFETY OF DYSPORT USED IN THE TREATMENT OF OF UPPER LIMB SPASTICITY IN CHIL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021817-22,1,1,0 2010-021821-10,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,1,apceth GmbH & Co. KG,"Open, Randomized, Mono-centre, Two-Parallel Group Clinical Phase I/II Trial on the Evaluation of Tolerability and Efficacy of an Intravenous In-fusion of Human Bone-Marrow Derived Autologous, CD34-Neg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021821-10,0,0,0 2010-021825-11,9,2013-08-26,2013-08-26,5,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Actelion Pharmaceuticals Ltd,"An open label, prospective multicenter study to assess the pharmacokinetics, tolerability, safety and efficacy of the pediatric formulation of bosentan two versus three times a day in children with pu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021825-11,1,1,0 2010-021825-11,9,2013-08-26,2013-08-26,5,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Actelion Pharmaceuticals Ltd.,"An open label, prospective multicenter study to assess the pharmacokinetics, tolerability, safety and efficacy of the pediatric formulation of bosentan two versus three times a day in children with pu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021825-11,1,1,0 2010-021826-37,4,2012-09-17,2012-09-17,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GUERBET,Xenetix 350 : Evaluación comparativa de la calidad de imagen en la angiografía de las arterias coronarias mediante escáner Xenetix 350 : comparative assessment of image quality for coronary CT angiog...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021826-37,0,0,0 2010-021841-38,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase II Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Adjuvanted with MF59C.1 Influenza Vaccine (Fluad), Formulation 2011/20...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021841-38,0,0,0 2010-021842-23,1,2011-05-16,2011-05-16,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Iceland,A randomized clinical trial of the effects of Tea tree essential oil on adult leg cellulitis of class II in the Eron/Dall classification system for cellulitis: Pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021842-23,0,0,0 2010-021844-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medical Centre,Perioperative esmolol infusion for haemodynamic stability during major vascular surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021844-17,0,0,0 2010-021846-23,2,2014-02-21,2014-02-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab for Prolonging Bone Metastasis-Free Survival in Men with Hormone-Refractory Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021846-23,0,0,0 2010-021850-20,6,2016-07-06,2016-07-06,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Catalyst Pharmaceutical Partners, Inc.","A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Discontinuation Study Followed by an Open-label Extension Period to Evaluate the Efficacy and Safety of Amifampridine Phosphate (3,4...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021850-20,0,0,0 2010-021850-20,6,2016-07-06,2016-07-06,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,BIOMARIN PHARMACEUTICAL INC.,"A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Discontinuation Study Followed by an Open-label Extension Period to Evaluate the Efficacy and Safety of Amifampridine Phosphate (3,4...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021850-20,0,0,0 2010-021850-20,6,2016-07-06,2016-07-06,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"BioMarin Pharmaceutical, Inc","A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Discontinuation Study Followed by an Open-label Extension Period to Evaluate the Efficacy and Safety of Amifampridine Phosphate (3,4...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021850-20,0,0,0 2010-021851-23,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA S. GERARDO DI MONZA,analgesic effectiveness of ultrasound-guided ilioinguinal iliohypogastric and genitofemoral nerve block after inguinal herniorrhaphy EFFICACIA ANALGESICA DEL BLOCCO ECOGUIDATO DEI NERVI ILEOIPOGAST...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021851-23,0,0,0 2010-021857-38,2,2015-11-20,2015-11-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Karolinska University Hospital/Huddinge,Randomized phase II Trial comparing Lenalidomide with lowdose dexamethasone versus Lenalidomide in Second Line Multiple Myeloma (MM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021857-38,0,0,0 2010-021857-38,2,2015-11-20,2015-11-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Karolinska University Hospital,Randomized phase II Trial comparing Lenalidomide with lowdose dexamethasone versus Lenalidomide in Second Line Multiple Myeloma (MM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021857-38,0,0,0 2010-021858-20,1,2011-03-30,2011-03-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"PALAU PHARMA, S.A.","DOUBLE BLIND RANDOMISED, PLACEBO AND ACTIVE CONTROLLED, PROOF OF ACTIVITY STUDY OF UR-63325 IN ALLERGIC RHINITIS INDUCED BY NASAL CHALLENGE TO ALLERGIC PATIENTS OTHERWISE HEALTHY.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021858-20,0,0,0 2010-021860-13,12,2014-12-01,2014-12-17,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"BIAL - Portela & Ca, S.A.","EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON'S DISEASE PATIENTS WITH 'WEARING-OFF' PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021860-13,0,0,0 2010-021860-13,12,2014-12-01,2014-12-17,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"BIAL - PORTELA & Cª, S.A.","EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON'S DISEASE PATIENTS WITH 'WEARING-OFF' PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMISED,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021860-13,0,0,0 2010-021861-62,1,2014-05-20,2014-05-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,Baclofen for the Treatment of Alcohol Dependence,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021861-62,0,0,0 2010-021863-34,1,2015-09-30,2015-09-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Southampton NHS Foundation Trust,A phase II trial of the addition of ipilumimab to carboplatin and etoposide chemotherapy for the first line treatment of extensive small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021863-34,0,0,0 2010-021867-34,1,2015-08-10,2015-08-10,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Innovacell Biotechnologie AG - Life Science Center Innsbruck,"An open, multicenter study to evaluate the urodynamic properties of a local implantation of autologous skeletal muscle-derived cells (SMDCs) in female patients with stress urinary incontinence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021867-34,0,0,0 2010-021868-15,4,2017-11-08,2017-11-08,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Astellas Pharma Global Development, Inc. (APGD)","A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021868-15,0,0,0 2010-021869-73,1,2014-05-14,2014-05-14,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,OrthoCell Pty Ltd,The value of Autologous Tenocyte Implantation in patients with chronic Achilles tendinopathy: a double-blind randomised clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021869-73,0,0,0 2010-021870-12,14,2015-04-16,2015-08-07,12,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Active Biotech AB,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021870-12,0,0,0 2010-021871-10,6,2015-09-09,2015-09-09,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,INNOVACELL BIOTECNOLOGIE,"A multicenter, randomized, double-blinded, parallel-group, placebo controlled study to assess the efficacy and safety of skeletal muscle-derived cell implantation in female patients with stress urin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021871-10,0,0,0 2010-021871-10,6,2015-09-09,2015-09-09,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Innovacell Biotechnologie AG - Life Science Center Innsbruck,"A multicenter, randomized, double-blinded, parallel-group, placebo controlled study to assess the efficacy and safety of skeletal muscle-derived cell implantation in female patients with stress urin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021871-10,0,0,0 2010-021871-10,6,2015-09-09,2015-09-09,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Innovacell Biotechnologie AG,"A multicenter, randomized, double-blinded, parallel-group, placebo controlled study to assess the efficacy and safety of skeletal muscle-derived cell implantation in female patients with stress urin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021871-10,0,0,0 2010-021872-27,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Institut Català d’Oncologia (ICO),"“Estudio de fase II de tratamiento neoadyuvante con gemcitabina, Tarceva® y oxaliplatino, seguido de quimiorradioterapia con Tarceva® y gemcitabina en pacientes con adenocarcinoma pancreático de resec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021872-27,0,0,0 2010-021874-12,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Novartis Vaccines Institute for Global Health (NVGH),"A Phase 2, Randomized, Observer–blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of Three Formulations of the NVGH Glycoconjugate Vaccine against S. Typhi in Adult Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021874-12,0,0,0 2010-021879-85,1,2014-04-11,2014-04-11,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Nottingham,Mode of action of Moviprep:impact on distribution of intestinal fluid and colonic microbiota,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021879-85,0,0,0 2010-021884-34,3,2013-01-01,2013-01-01,1,0,1,0,0,0,0,0,0,2,0,0,0,0,0,Radboud University Medical Centre Nijmegen,"Relapse prevention in children and adolescents with DSM-IV Conduct Disorder treated with Risperidone: a Randomized Double blind, Placebo-Controlled, Discontinuation Study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021884-34,1,0,0 2010-021884-34,3,2013-01-01,2013-01-01,1,0,1,0,0,0,0,0,0,2,0,0,0,0,0,Radboud University,"Relapse prevention in children and adolescents with DSM-IV Conduct Disorder treated with Risperidone: a Randomized Double blind, Placebo-Controlled, Discontinuation Study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021884-34,1,0,0 2010-021885-31,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,NKI-AVL,Randomized Phase II Study Using a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Infiltrating Lymphocytes and Interleukin-2 in Metastatic Melanoma’,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021885-31,0,0,0 2010-021886-63,1,2017-08-08,2017-08-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,East and North Hertfordshire NHS Trust,A trial of Prostate Radiotherapy in Conjunction with Carbogen and Nicotinamide (PROCON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021886-63,0,0,0 2010-021887-13,1,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Isala Clinics Zwolle,Detection of stress in newborns during intubation by means of skin conductance measurements.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021887-13,0,0,0 2010-021898-36,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Tandem high-dose chemotherapy (HDCT) with peripheral-blood stem-cell rescue for patients with metastatic germ-cell tumors failing first-line treatment.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021898-36,0,0,0 2010-021900-93,10,2015-06-25,2020-06-30,9,0,0,0,0,0,3,0,0,1,0,0,1,0,2,STEBA BIOTECH SA,A European Randomised Phase 3 Study to Assess the Efficacy and Safety of TOOKAD Soluble for Localised Prostate Cancer Compared to Active Surveillance Studio europeo randomizzato di Fase 3 eseguit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021900-93,0,0,0 2010-021900-93,10,2015-06-25,2020-06-30,9,0,0,0,0,0,3,0,0,1,0,0,1,0,2,STEBA BIOTECH,A European Randomised Phase 3 Study to Assess the Efficacy and Safety of TOOKAD Soluble for Localised Prostate Cancer Compared to Active Surveillance Studio europeo randomizzato di Fase 3 eseguit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021900-93,0,0,0 2010-021901-19,1,2011-12-01,2011-12-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Med Uni Graz, Univ. Klinik für Anästhesiologie und Intensivmedizin","Reduzierter Opioidverbrauch durch Physostigmin als Dauertropf zur postoperativen PCA – PHANOS (PHysostigmine-enhANced Opioid analgeSia). prospektive, doppelblinde, randomisierte, placebokontrollierte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021901-19,0,0,0 2010-021918-30,1,2011-08-15,2011-08-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Professor Jørgen Berg Dahl,Effekten af Adductor-Kanal-Blokade på smerter og morfinforbrug efter knæalloplastik,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021918-30,0,0,0 2010-021922-36,1,2013-09-19,2013-09-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Nephrology, Rigshospitalet, University of Copenhagen",Safety and effect of liraglutide in patients with type 2 diabetes and severe renal insufficiency.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021922-36,0,0,0 2010-021923-29,1,2013-11-28,2013-11-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Universitätsklinik für Augenheilkunden und Optometrie, Medizinische Universität Wien","Management of recurrent or persistent choroidal neovascularization secondary to age-related macular degeneration A prospective, randomized, clinical study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021923-29,0,0,0 2010-021924-81,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital General de Granollers,Eficacia Analgésica del Transversus Abdomini Plane (TAP) Block en cirugía de Cesárea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021924-81,0,0,0 2010-021925-12,1,2016-08-23,2016-08-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Gilead Sciences International Ltd.,FINITE CHB - First investigation in stopping TDF treatment after long term virologic suppression in HBeAg-negative Chronic Hepatitis B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021925-12,0,0,0 2010-021926-37,3,2014-02-18,2014-02-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Genentech Inc,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MABT5102A IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021926-37,0,0,0 2010-021928-96,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ISDIN S.A.,"Ensayo clínico multicéntrico, doble ciego, para evaluar la eficacia y seguridad de lambdalina vs placebo como anestésico en fotodepilación con láser",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021928-96,0,0,0 2010-021933-30,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Maastricht University,"Effects of treated and untreated Allergic Rhinitis on Mood, Cognitive functions and Actual Driving Performance",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021933-30,0,0,0 2010-021936-33,2,2012-05-02,2012-05-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Galderma R&D SNC,"A multi-center randomized, double-blind, placebo controlled, parallel-group study of CD 07743 for the improvement of Lateral Canthal Lines (crow’s feet)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021936-33,0,0,0 2010-021941-38,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,LEO Pharma A/S,LEO 90110 ointment in the treatment of psoriasis vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021941-38,0,0,0 2010-021943-41,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,VU Medical Center,Treatment optimization of cetuximab in patients with metastatic colorectal cancer based on tumour uptake of 89Zr-labeled cetuximab assessed by PET,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021943-41,0,0,0 2010-021944-17,1,2017-05-15,2017-05-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Hannover Medical School,"Randomized, Multi-centre, Phase II Trial to compare the Event-Free Survival of Clofarabine / Ara-C (ClAraC) or of FLAMSA Treatment in Patients with High Risk AML or Advanced MDS scheduled for Allogene...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021944-17,0,0,0 2010-021945-29,1,2017-03-13,2017-03-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"LUX-Breast 2;An open label, phase II trial of BIBW 2992 (afatinib) in patients with metastatic HER2-overexpressing breast cancer failing HER2-targeted treatment in the neoadjuvant and/or adjuvant trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021945-29,0,0,0 2010-021946-22,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,University Hospital Essen,THE IPI – MULTIBASKET TRIAL IN ADVANCED OCULAR MELANOMA: PROSPECTIVE CLINICAL PHASE II MULTIBASKET STUDY IN OCULAR MELANOMA PATIENTS WITH ADVANCED DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021946-22,0,0,0 2010-021951-26,1,2018-09-05,2018-09-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Liverpool,"VIP: A prospective, phase II, double blinded, multicentre, randomised clinical trial comparing combination gemcitabine and vandetanib therapy with gemcitabine therapy alone in locally advanced or meta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021951-26,0,0,0 2010-021951-26,1,2018-09-05,2018-09-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Liverpool and Broadgreen University Hospitals Trust,"VIP: A prospective, phase II, double blinded, multicentre, randomised clinical trial comparing combination gemcitabine and vandetanib therapy with gemcitabine therapy alone in locally advanced or meta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021951-26,0,0,0 2010-021955-14,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Purdue Pharma L.P.,"A Multicenter, Inpatient, Open-label Study to Characterize the Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Aged from Birth to 6 Years of Age (in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021955-14,0,0,0 2010-021957-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Liège - Physical Medicine Service,Contribution à l’optimalisation du traitement des tendinopathies chroniques : injection de concentrés plaquettaires chez des patients présentant une tendinopathie rotulienne supérieure Optimization o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021957-38,0,0,0 2010-021960-14,2,2014-03-27,2014-03-27,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"An open-label extension study to CQTI571A2102 to evaluate the long-term safety, tolerability and efficacy of QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021960-14,0,0,0 2010-021960-14,2,2014-03-27,2014-03-27,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma AG,"An open-label extension study to CQTI571A2102 to evaluate the long-term safety, tolerability and efficacy of QTI571 (imatinib) in the treatment of severe pulmonary arterial hypertension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021960-14,0,0,0 2010-021961-61,8,2017-02-01,2017-02-01,4,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Sunesis Pharmaceuticals, Inc.","A Phase 3, Randomized, Controlled, Double Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021961-61,1,0,0 2010-021961-61,8,2017-02-01,2017-02-01,4,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"SUNESIS PHARMACEUTICALS, INC.","A Phase 3, Randomized, Controlled, Double Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021961-61,1,0,0 2010-021962-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Bo Lennernäs,"KEES- A single arm phase II trial of the peroral regimen KEES (Ketokonazole, Etoposide, Estramustine, Sendoxan) in patients with Castration Resistant Prostate Cancer (CRPC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021962-31,0,0,0 2010-021963-34,2,2010-12-23,2011-02-04,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Idera Pharmaceuticals, Inc.","A Phase 2, Randomized, Double-Blind, Comparator-Controlled, 12-week Trial of IMO-2125 plus Ribavirin in Patients Infected with Hepatitis C Virus who were Nonresponders to Pegylated-Interferon plus Rib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021963-34,0,0,0 2010-021967-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ANRS,"Essai clinique multicentrique, ouvert, prospectif évaluant l’efficacité d’une supplémentation par vitamine D en association à une bithérapie par interféron alpha pégylé plus ribavirine chez les patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021967-34,0,0,0 2010-021968-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA,"NOT RANDOMISED OPEN LABEL STUDY TO COMPARE EFFICACY OF BEVACIZUMAB (AVASTIN, ROCHE) VERSUS RANIBIZUMAB (LUCENTIS, NOVARTIS) ADMINISTERED BY INTRAVITREAL INJECTION IN PATIENTS WITH EXUDATIVE AGE RELATE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021968-15,0,0,0 2010-021973-35,3,2011-02-17,2011-03-31,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.","Assessing the Safety and Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% Fixed Combination), as Replacement Therapy in Patients Uncontrolled on Bimatoprost 0.03%/Timolol 0.5% Therapy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021973-35,0,0,0 2010-021977-35,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,"ARAFARMA GROUP, S.A.","ENSAYO CLÍNICO DE EFICACIA Y NO INFERIORIDAD, CRUZADO, ALEATORIZADO Y MULTICÉNTRICO ENTRE DOS FORMULACIONES TÓPICAS DE CAPSAICINA PARA EL ALIVIO DEL DOLOR MODERADO A SEVERO EN LA NEUROPATÍA DIABÉTICA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021977-35,0,0,0 2010-021978-11,11,2015-10-21,2016-04-13,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biogen Idec Limited,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis A Mul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021978-11,0,0,0 2010-021978-11,11,2015-10-21,2016-04-13,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BIOGEN IDEC LTD,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis A Mul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021978-11,0,0,0 2010-021979-85,1,2015-02-06,2015-02-06,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,"The Pediatric Clinics, The Juliane Marie Center, The Danish National Hospital ""Rigshospitalet""","Danish: BCG vaccination og sygelighed blandt danske småbørn. En prospektivt, randomiseret, klinisk lægemiddelafprøvning. English: Bacille Calmette Guérin immunisation at birth and childhood morbidity ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021979-85,0,0,0 2010-021983-14,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,UZ Gasthuisberg,A randomized placebo-controlled double blind study to treat BOS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021983-14,0,0,0 2010-021984-33,1,2012-09-10,2012-09-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A phase II/III, multi-center, randomized, 4-week, double-blind, parallel group, placebo and active-controlled trial of the safety and efficacy of RO4917838 vs. placebo in patients with an acute exacer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021984-33,0,0,0 2010-021986-60,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GENFIT,"A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 12 weeks in patients with Type 2 Diabetes mellitus. A Multicentre, Randomised, Double Blind, Place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021986-60,0,0,0 2010-021987-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen,Renal Hemodynamic Effects of ALiskiren (rasilez) in comparison to ramipril (Tritrace) in patients with overweigHt/obeSiTy and UntreateD hYpertension: The renal HEALTH-STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021987-13,0,0,0 2010-021988-32,1,2013-07-26,2013-07-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LUSOFARMACO,"A multicentre, multinational, randomised, double-blind, pilot, ascending dose for non responder, parallel group study on the therapeutic efficacy and safety of o.d. Zofenopril 30 mg plus HCTZ 12.5 mg ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021988-32,0,0,0 2010-021994-35,5,2015-03-24,2015-03-24,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ViiV Healthcare UK Limited,"""Estudio multicéntrico, aleatorizado, enmascarado y controlado con placebo para evaluar la seguridad de maraviroc en combinación con otros antirretrovirales en sujetos infectados por el VIH-1 y por el...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021994-35,0,0,0 2010-021995-27,6,2014-08-18,2014-08-18,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"A randomised, double-blind, double-dummy, parallel-group multicenter study to demonstrate improvement in symptoms of constipation and noninferiority in analgesic efficacy in subjects with non-malignan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-021995-27,0,0,0 2010-022001-18,1,2012-07-13,2012-07-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University College Dublin Clinical Research Centre,A Randomised Trial of Single Dose Oral Dexamethasone versus Multi-Dose Prednisolone in the Treatment of Acute Exacerbations of Asthma in children who attend the Emergency Department,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022001-18,0,0,0 2010-022009-16,1,2012-05-28,2012-05-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Nottingham,A randomised controlled trial of Tranexamic acid in Intracerebral Haemorrhage (TICH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022009-16,0,0,0 2010-022010-32,1,2012-05-02,2012-05-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Barts and The London NHS Trust,"A phase II single arm, multi-centre trial of triamcinolone with a GnRH analog for castration resistant prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022010-32,0,0,0 2010-022011-19,8,2012-04-09,2012-04-09,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Vifor (International) Inc.,"An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared with Sevelamer Carbonate Followed by a Randomised Compa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022011-19,0,0,0 2010-022012-40,8,2012-10-25,2012-10-25,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Vifor (International) Inc.,"An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Phase 3 Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21 Compared with Sevelamer Carbonate in Dial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022012-40,0,0,0 2010-022015-19,4,2014-02-13,2014-02-14,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A","A Phase II, single-arm study of orally administered BKM120 as second-line therapy in patients with advanced endometrial carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022015-19,0,0,0 2010-022015-19,4,2014-02-13,2014-02-14,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A Phase II, single-arm study of orally administered BKM120 as second-line therapy in patients with advanced endometrial carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022015-19,0,0,0 2010-022015-19,4,2014-02-13,2014-02-14,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A Phase II, single-arm study of orally administered BKM120 as second-line therapy in patients with advanced endometrial carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022015-19,0,0,0 2010-022017-26,1,2014-03-11,2014-03-11,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Central Manchester University Hospitals Foundation Trust,A pilot study on the effects of an alternate-day corticosteroid regimen in children with active crohn’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022017-26,0,0,0 2010-022021-15,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III, SUPERIORITY TRIAL TO ASSESS THE EFFICACY AND SAFETY OF ACETYL-L-CARNITINE IN COMBINATION WITH A C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022021-15,0,0,0 2010-022025-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,MUMC,Intradiscal Methylene Blue Injection Treatment for Chronic Discogenic Low back pain A prospective Clinical Series followed by a Randomised Placebo-Controlled Clinical Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022025-15,0,0,0 2010-022027-30,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,UZ Gasthuisberg,A randomized placebo-controlled double blind study to prevent BOS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022027-30,0,0,0 2010-022029-13,1,,,0,1,0,0,0,3,2,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with intravenous BHQ880, a fully human, anti-Dickkopf1 (DKK1) neutralizing antibody in previously untre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022029-13,0,0,0 2010-022032-37,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CASA DI CURA ABANO TERME POLISPECIALISTICA E TERMALE,"Randomized, open-label, single centre study on ovarian stimulation in ART poor responders treated with recombinant FSH in association with recombinant LH. Randomized, open-label, single centre stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022032-37,0,0,0 2010-022033-28,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Echo Pharmaceuticals B.V.,"A two-phased, randomized, double blind, placebo-controlled study of ECP002A (Δ9-THC) to determine safety, tolerability and efficacy in Multiple Sclerosis patients suffering from spasticity and pain.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022033-28,0,0,0 2010-022034-88,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Odense University Hospital,Evaluation of the optimal dose of prophylactic anticoagulation with low- molecular- weight heparin administered subcutaneously to critically ill patients – part 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022034-88,0,0,0 2010-022036-36,1,2016-11-22,2016-11-22,1,1,0,1,0,1,1,0,0,1,1,1,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",A Phase 1 trial of pf‑03084014 in patients with advanced solid tumor malignancy and t‑cell acute lymphoblastic leukemia/lymphoblastic lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022036-36,0,0,0 2010-022037-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNICANCER,Phase III randomised trial to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of recu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022037-29,0,0,0 2010-022040-20,1,2013-01-31,2013-01-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Lothian,A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022040-20,0,0,0 2010-022040-20,1,2013-01-31,2013-01-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Edinburgh,A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022040-20,0,0,0 2010-022041-19,1,2012-10-16,2012-10-16,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,RostaQuo S.p.A.,Effects of L-carnitine administration in patients with elevated Lp(a)levels.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022041-19,0,0,0 2010-022042-24,1,2017-05-31,2017-05-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,NHS Lothian,A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis in patients with Pseudomonas Aeruginosa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022042-24,0,0,0 2010-022042-24,1,2017-05-31,2017-05-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,University of Edinburgh,A Randomised Controlled Trial of Atorvastatin as an Anti-Inflammatory Agent in Non-Cystic Fibrosis Bronchiectasis in patients with Pseudomonas Aeruginosa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022042-24,0,0,0 2010-022044-20,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,María de los Ángeles Álvarez López,"Ensayo aleatorizado, doble ciego y controlado con placebo de doxiciclina en la prevención de la erupción acneiforme por cetuximab.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022044-20,0,0,0 2010-022046-25,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,"Department of Pediatric Gastroenterology, Academic Medical Centre",Cholic acid treatment in Peroxisomal Biogenesis Disorders (Zellweger spectrum): biochemical and clinical effects.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022046-25,0,0,0 2010-022049-88,1,2014-02-19,2014-02-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche Pharma AG,"""Efficacy and safety study of a sequential therapy of tocilizumab (TCZ) and, if initially inade-quately responded to tocilizumab (TCZ), followed by rituximab (RTX) in DMARD-IR patients with rheumatoid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022049-88,0,0,0 2010-022052-23,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"GITMO GRUPPO ITALIANO TRAPIANTO DI MIDOLLO OSSEO,CELLULE STAMINALI EMOPOIETICHE E TERAPIA CELLULARE - ONLUS","Prospective, phase II randomized study to compare busulfan-fludarabine reduced-intensity conditioning (RIC) with thiotepa-fludarabine RIC regimen prior to allogeneic transplantation of hematopoietic c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022052-23,0,0,0 2010-022054-16,2,2015-03-27,2015-03-27,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MEDA Pharma GmbH & Co. KG,Long-term effects of Aldara® 5% cream and Solaraze® 3% gel in the treatment of actinic keratoses on the face or scalp with respect to the risk of progression to in-situ and invasive squamous cell carc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022054-16,0,0,0 2010-022055-36,1,2010-11-15,2010-11-15,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,UZLeuven,Intragastric pressure as a determinant of satiation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022055-36,0,0,0 2010-022057-42,1,2013-12-23,2013-12-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universität Leipzig,Pilot study to optimise the use and to evaluate the diagnostic value of intraoperative contrast-enhanced 3D-ultrasound with SonoVue® for imaging of intracranial tumors Pilotstudie zur Optimierung d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022057-42,0,0,0 2010-022058-18,1,2013-11-18,2013-11-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Cologne,A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF CYCLOPHOSPHAMIDE AS SOLE GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-CY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022058-18,0,0,0 2010-022060-13,3,2013-03-04,2013-03-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CHIESI,"MULTICENTRE, RANDOMIZED, OPEN-LABEL, TWO-ARM PARALLEL GROUPS, ACTIVE CONTROLLED STUDY DESIGN TO DEMONSTRATE EFFICACY AND TOLERABILITY OF CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022060-13,0,0,0 2010-022060-13,3,2013-03-04,2013-03-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"MULTICENTRE, RANDOMIZED, OPEN-LABEL, TWO-ARM PARALLEL GROUPS, ACTIVE CONTROLLED STUDY DESIGN TO DEMONSTRATE EFFICACY AND TOLERABILITY OF CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022060-13,0,0,0 2010-022064-12,9,2018-05-23,2018-05-23,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis R&D,"Estudio aleatorizado, abierto y multicéntrico de comparación de cabazitaxel a dosis de 25 mg/m2 y 20 mg/m2, administrado en combinación con prednisona cada 3 semanas, con docetaxel administrado en com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022064-12,0,0,0 2010-022065-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Sahlgrenska University Hospital,Effect of angiogenesis inhibiting therapy in patients progressing on endocrine treatment and patients with triple negative breast cancer - a translational phase II study within the Swedish Association...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022065-10,0,0,0 2010-022066-28,1,2012-07-11,2012-07-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 6-month multicenter, single-arm, open-label study to investigate changes in biomarkers after initiation of treatment with 0.5 mg fingolimod (FTY720) in patients with relapsing-remitting multiple scl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022066-28,0,0,0 2010-022067-35,1,2012-10-16,2012-10-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment with a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir boosted HCV Protease Inhibitor (RO5190591/r, DNV/r) w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022067-35,0,0,0 2010-022072-31,1,,,0,0,0,0,1,0,2,0,0,3,0,0,0,0,0,RJAH Orthopaedic Hospital,Autologous Cell Therapy for Osteoarthritis: An evaluation of the safety and efficacy of autologous transplantation of articular chondrocytes and/or bone marrow-derived stromal cells to repair chondral...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022072-31,0,0,0 2010-022073-34,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,CVIE THERAPEUTICS COMPANY LIMITED,"Antihypertensive effect of different doses of Rostafuroxin in comparison with Losartan, assessed by office and ambulatory blood pressure monitoring in a hypertensive population selected according to a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022073-34,0,0,0 2010-022075-66,1,2012-01-19,2012-01-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Cardif and Vale University Local Health Board,A Single Centre Physiological Study of Glucose Metabolism Before and After Tacrolimus Withdrawal For Deteriorating Kidney Function In Renal Transplant Recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022075-66,0,0,0 2010-022077-33,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,"Phase II, open label, study of primary chemotherapy with Bevacizumab in association with carboplatin, paclitaxel in early and locally advanced triple negative (ER, PgR and HER2 negative) breast cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022077-33,0,0,0 2010-022082-10,4,2011-09-08,2011-09-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Norgine Ltd,"A Phase III, Multi-centre, Double-blind, Double-dummy, Randomised, Study to Assess the Superiority of Zegerid® 20 mg vs. Losec® 20 mg in the Rapid Relief of Heartburn Associated with GERD as on Demand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022082-10,0,0,0 2010-022083-12,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ROXALL Medizin GmbH,Evaluation of tolerability and efficacy of subcutaneous cluster-immunotherapy in patients with allergic rhinitis / rhino-conjunctivitis due to grass pollen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022083-12,0,0,0 2010-022084-36,1,2011-02-28,2011-02-28,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Zymenex A/S,"A single center, open-label, dose escalation study of the safety and pharmacokinetics of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) for the treatment of patients with alpha-mannosidosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022084-36,0,0,0 2010-022085-26,1,2012-01-21,2012-01-21,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Zymenex A/S,"A single center, randomized, open-label, multiple-dose study of the efficacy and long-term safety of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) for the treatment of patients with alpha-m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022085-26,0,0,0 2010-022091-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOIM GRUPPO ONCOLOGICO MERIDIONALE,Bevacizumab + Folfox4 or Xelox2 as first- line treatment in colorectal cancer. Randomized phase II study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022091-31,0,0,0 2010-022092-65,2,2013-04-30,2013-04-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Achillion Pharmaceuticals, Inc.","A phase IIa, randomized, double-blind (subject and investigator blind, sponsor open) placebo-controlled trial to evaluate the safety, tolerability and antiviral activity of oral ACH-0141625 in combina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022092-65,0,0,0 2010-022095-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut de Recerca HSCSP,Estudio doble ciego de tratatmiento preventivo con alopurinol 3% crema vs placebo de la eritrodisestesia palmoplantar secundaria al tratamiento con capecitabina,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022095-31,0,0,0 2010-022096-54,1,2013-06-05,2013-06-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Repha GmbH,"Randomised, prospective, double-dummy double-blinded study to evaluate safety and efficacy of Angocin Anti-Infekt N versus standard antibiotics in the treatment of acute uncomplicated cystitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022096-54,0,0,0 2010-022099-29,4,2014-12-10,2014-12-10,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022099-29,0,0,0 2010-022099-29,4,2014-12-10,2014-12-10,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ELI LILLY,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022099-29,0,0,0 2010-022100-42,4,2014-12-10,2014-12-10,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022100-42,0,0,0 2010-022101-18,9,2014-12-10,2015-01-12,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) Studio di fase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022101-18,0,0,0 2010-022101-18,9,2014-12-10,2015-01-12,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ELI LILLY AND COMPANY,"A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) Studio di fase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022101-18,0,0,0 2010-022102-41,5,2018-07-17,2018-07-31,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Mundipharma Research Ltd.,"A randomised, open label, multi-centre, Phase III study to investigate the efficacy of bendamustine compared to treatment of physician's choice in the treatment of subjects with indolent Non-Hodgkin's...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022102-41,0,0,0 2010-022102-41,5,2018-07-17,2018-07-31,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MUNDIPHARMA RESEARCH LIMITED,"A randomised, open label, multi-centre, Phase III study to investigate the efficacy of bendamustine compared to treatment of physician's choice in the treatment of subjects with indolent Non-Hodgkin's...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022102-41,0,0,0 2010-022103-21,1,2013-03-31,2013-03-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Hospital Tübingen,Neoadjuvant treatment of locoregional metastases in malignant melanoma (AJCC stage IIIB/C) with Multiferon: a phase IIa DeCOG trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022103-21,0,0,0 2010-022104-50,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Stichting NVALT Studies,A randomized phase II study of paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV non-squamous-non-small cell lung cancer: NVALT12,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022104-50,0,0,0 2010-022106-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Longterm Effects of Intraarticular Hyaluronan vs Corticosteroid in Osteoarthritis of the Hip: A Randomized Controlled Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022106-40,0,0,0 2010-022110-29,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Synairgen Research Limited,"A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to COPD patients after the onset of a respiratory viral infec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022110-29,0,0,0 2010-022111-19,7,2013-10-17,2014-01-16,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,Comparative efficacy of DUODART tm plus lifestyle advice versus watchful waiting plus lifestyle advice with step-up therapy to tamsulosin in the management of treatment naive men with moderately sympt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022111-19,0,0,0 2010-022111-19,7,2013-10-17,2014-01-16,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.",Comparative efficacy of DUODART tm plus lifestyle advice versus watchful waiting plus lifestyle advice with step-up therapy to tamsulosin in the management of treatment naive men with moderately sympt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022111-19,0,0,0 2010-022113-25,1,2010-11-29,2010-11-29,1,1,0,0,1,0,2,0,1,1,0,0,1,0,1,RespiVert Ltd,"A two day, randomised, single blind, parallel group trial of repeat doses of intranasal RV568 in the Vienna Challenge Chamber in subjects with seasonal allergic rhinitis (SAR)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022113-25,0,0,0 2010-022114-12,1,2011-07-19,2011-07-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,Multizentrische prospektive randomisierte kontrollierte offene Phase IV Studie zur Evaluation von Synergien zwischen WS® 1070 und strukturiertem Stressmanagement bei Patienten mit nachlassender Leistu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022114-12,0,0,0 2010-022119-20,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,The University of Birmingham,A randomised controlled trial of extended warfarin treatment versus routine warfarin treatment for the prevention of recurrent venous thromboembolism and post thrombotic syndrome in patients being tre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022119-20,0,0,0 2010-022120-72,1,2013-09-17,2013-09-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's & St. Thomas' NHS Foundation Trust,The metabolic impact of Darunavir/ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1-infected patients (MIDAs).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022120-72,0,0,0 2010-022121-15,8,2012-10-16,2013-10-10,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MERCK SHARP & DOHME CORP.,"A 52 Week extension to: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022121-15,0,0,0 2010-022121-15,8,2012-10-16,2013-10-10,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc.","A 52 Week extension to: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022121-15,0,0,0 2010-022121-15,8,2012-10-16,2013-10-10,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A 52 Week extension to: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022121-15,0,0,0 2010-022121-15,8,2012-10-16,2013-10-10,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A 52 Week extension to: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022121-15,0,0,0 2010-022121-15,8,2012-10-16,2013-10-10,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A 52 Week extension to: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022121-15,0,0,0 2010-022121-15,8,2012-10-16,2013-10-10,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA","A 52 Week extension to: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022121-15,0,0,0 2010-022121-15,8,2012-10-16,2013-10-10,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A 52 Week extension to: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022121-15,0,0,0 2010-022123-29,1,2014-02-25,2014-02-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Medical University of Vienna, Department of Clinical Pharmacology","Acetylic salicylic acid for the treatment of Chronic Obstructive Pulmonary Disease (COPD). A randomized, double-blind, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022123-29,0,0,0 2010-022128-63,6,2012-11-28,2012-12-14,5,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Lux Biosciences, Inc.","A Multi-Center, Double-Masked, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Noninfectious Uveitis Involving the Intermed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022128-63,1,0,0 2010-022128-63,6,2012-11-28,2012-12-14,5,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"LUX BIOSCIENCES, INC.","A Multi-Center, Double-Masked, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Noninfectious Uveitis Involving the Intermed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022128-63,1,0,0 2010-022131-11,1,2012-01-20,2012-01-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Whipps Cross University Hospital,A phase 4 pilot study to establish if an intramuscular steroid injection is as effective as an intralesional steroid injection in the treatment of tennis elbow?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022131-11,0,0,0 2010-022133-28,1,2016-02-24,2016-02-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"AMAG Pharmaceuticals, Inc.","Ferumoxytol for Anemia of CKD Trial (FACT): A Phase IV, Open-Label, Multicenter Trial, with MRI Substudy, of Repeated Doses of Ferumoxytol Compared with Iron Sucrose for the Treatment of Iron Deficien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022133-28,0,0,0 2010-022134-89,16,2019-12-13,2019-12-13,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,I.R.I.S.,"The efficAcy and safety of Trimetazidine in Patients with angina pectoris having been treated by percutaneous Coronary Intervention. ATPCI study An international, multicentre, randomised, double-blin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022134-89,0,0,0 2010-022134-89,16,2019-12-13,2019-12-13,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Servier Portugal - Especialidades Farmacêuticas Lda.,"The efficAcy and safety of Trimetazidine in Patients with angina pectoris having been treated by percutaneous Coronary Intervention. ATPCI study An international, multicentre, randomised, double-blin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022134-89,0,0,0 2010-022138-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI,"A SINGLE-CENTRE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF COMBINATION THERAPY WITH VARDENAFIL 10 mg AND TAMSULOSIN 0,4 mg IN THE TREATMENT OF MEN WITH PERSIS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022138-10,0,0,0 2010-022150-16,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,"Medizinische Universität Wien, Univ.Klinik f.klinische Pharmakologie",Determination of Moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients including a pilot phase,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022150-16,0,0,0 2010-022151-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION SANTIAGO DEXEUS FONT,Ensayo clínico fase II aleatorizado de cotratamiento con hormona de crecimiento recombinante humana dentro de un protocolo largo de estimulación ovárica bajo agonista de GnRH en mujeres con pobre resp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022151-32,0,0,0 2010-022153-42,2,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,"Cytori Therapeutics, Inc",A phase II trial of safety and efficacy of ADRCs delivered via the intracoronary route in the treatment of patients with ST-elevation acute myocardial infarction – The ADVANCE Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022153-42,0,0,0 2010-022155-33,3,2018-05-16,2018-05-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"CALISTOGA PHARMACEUTICALS, INC.",A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non- Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents Studio di fase 2 per valutare l'ef...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022155-33,0,0,0 2010-022155-33,3,2018-05-16,2018-05-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.",A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non- Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents Studio di fase 2 per valutare l'ef...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022155-33,0,0,0 2010-022160-13,1,2016-11-23,2016-11-23,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Eli Lilly and Company,Phase 1b/2a Study Combining LY2157299 with Standard Temozolomide-based Radiochemotherapy in Patients with Newly Diagnosed Malignant Glioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022160-13,0,0,0 2010-022162-27,1,2018-08-31,2018-08-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Martin-Luther-Universität Halle-Wittenberg,FOLFOX/bevacizumab with or without irinotecan in first-line treatment for metastatic colorectal cancer. A randomized phase II study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022162-27,0,0,0 2010-022163-35,8,2015-08-19,2015-08-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis R&D,"Estudio aleatorizado, abierto y multicéntrico de comparación de cabazitaxel a dosis de 20 mg/m2 y 25 mg/m2 administrado cada 3 semanas en combinación con prednisona para el tratamiento del cáncer de p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022163-35,0,0,0 2010-022163-35,8,2015-08-19,2015-08-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Recherche et Developpement,"Estudio aleatorizado, abierto y multicéntrico de comparación de cabazitaxel a dosis de 20 mg/m2 y 25 mg/m2 administrado cada 3 semanas en combinación con prednisona para el tratamiento del cáncer de p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022163-35,0,0,0 2010-022164-12,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Genta Incorporated,"A randomized, double-blind study of capecitabine plus tesetaxel versus capecitabine plus placebo as second-line therapy in subjects with gastric cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022164-12,0,0,0 2010-022165-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Prim. Univ.-Prof. Dr. Günter Janetschek c/o Universitätsklinik für Urologie und Andrologie,Klinische Studie zur Induktion einer Apoptose von Prostatazellen durch die Injektion von Botulinumtoxin A bei Patienten mit benigner Prostatahyperplasie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022165-10,0,0,0 2010-022166-27,2,2012-01-31,2012-01-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, placebo- controlled, cross-over, proof of concept study comparing the effects of both single dose and repeated dosing treatment for 2 weeks of BGG492 in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022166-27,0,0,0 2010-022168-11,5,2011-09-30,2011-09-30,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Trius Therapeutics, Inc.","A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-Day Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Stru...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022168-11,0,0,0 2010-022169-91,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO CLINICO HUMANITAS,PHASE II STUDY WITH BENDAMUSTINE GEMCITABINE AND VINORELBINE (BeGEV) AS INDUCTION THERAPY IN RELAPSED/REFRACTORY HODGKIN’S LYMPHOMA PATIENTS BEFORE HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022169-91,0,0,0 2010-022170-14,2,2012-07-10,2012-07-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Acacia Pharma Ltd,"Open-label, ascending-dose, Phase II study to determine the minimum effective dose of APD421 (intravenous amisulpride) in the prevention of cisplatin-induced nausea and vomiting",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022170-14,0,0,0 2010-022172-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Faculty of pharmacy, University of Ljubljana",ODNOS MED FARMAKOKINETIKO IN FARMAKODINAMIKO FENTANILA PRI OTROCIH (Pharmacokinetics and pharmcodynamics of fentanyl in pediatric population),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022172-30,0,0,0 2010-022178-14,3,2011-12-20,2011-12-20,3,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Dr. Gerhard Mann Chem.-Pharm. Fabrik GmbH/Bausch & Lomb,"A Randomized, Multicenter, Single-Masked, Parallel-Group Dose Finding Study Comparing the Safety and Efficacy of BOL-303259-X (0.006%, 0.012%, 0.024% and 0.040%) to Latanoprost 0.005% in Subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022178-14,0,0,0 2010-022180-35,1,2015-04-22,2015-04-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Cologne,Ofatumumab in relapsed nodular lymphocyte predominant Hodgkin Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022180-35,0,0,0 2010-022181-28,4,2012-09-12,2012-10-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A 6-month, randomised, double-blind, parallel-group, risperidone-controlled, fixed-dose study evaluating the safety and efficacy of zicronapine in patients with schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022181-28,0,0,0 2010-022183-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Phase II study of metronomic oral Vinorelbine plus Bevacizumab as first line treatment for metastatic breast cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022183-12,0,0,0 2010-022184-35,1,2016-12-14,2016-12-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,A pragmatic randomised double-blind trial of Antipsychotic Treatment of very LAte-onset Schizophrenia-like psychosis: The ATLAS Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022184-35,0,0,0 2010-022184-35,1,2016-12-14,2016-12-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,South London and Maudsley NHS Foundation Trust,A pragmatic randomised double-blind trial of Antipsychotic Treatment of very LAte-onset Schizophrenia-like psychosis: The ATLAS Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022184-35,0,0,0 2010-022188-37,1,2014-12-16,2014-12-16,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Pirkanmaan sairaanhoitopiiri,A comparative study between the Relieva Stratus MicroFlow Spacer drug eluting ethmoid sinus stent therapy and the intranasal corticoid steroid therapy in the treatment of patients with chronic rhinosi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022188-37,0,0,0 2010-022189-28,15,2014-05-20,2020-01-29,10,1,1,0,0,0,2,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II OPEN-LABEL, RANDOMIZED, MULTI- CENTRE COMPARATIVE STUDY OF BEVACIZUMAB-BASED THERAPY IN PAEDIATRIC PATIENTS WITH NEWLY DIAGNOSED SUPRATENTORIAL, INFRATENTORIAL CEREBELLAR, OR PEDUNCULAR HIG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022189-28,1,1,0 2010-022189-28,15,2014-05-20,2020-01-29,10,1,1,0,0,0,2,0,0,2,1,0,0,0,1,ROCHE,"A PHASE II OPEN-LABEL, RANDOMIZED, MULTI- CENTRE COMPARATIVE STUDY OF BEVACIZUMAB-BASED THERAPY IN PAEDIATRIC PATIENTS WITH NEWLY DIAGNOSED SUPRATENTORIAL, INFRATENTORIAL CEREBELLAR, OR PEDUNCULAR HIG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022189-28,1,1,0 2010-022193-13,8,2012-01-03,2013-04-01,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp. a subsidiary of Merck &Co., Inc","""Ensayo clínico en fase IIb, aleatorizado, controlado con placebo, de búsqueda de dosis para estudiar la seguridad y la eficacia de de MK-3102 en pacientes con diabetes mellitus de tipo 2 y un control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022193-13,0,0,0 2010-022193-13,8,2012-01-03,2013-04-01,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","""Ensayo clínico en fase IIb, aleatorizado, controlado con placebo, de búsqueda de dosis para estudiar la seguridad y la eficacia de de MK-3102 en pacientes con diabetes mellitus de tipo 2 y un control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022193-13,0,0,0 2010-022193-13,8,2012-01-03,2013-04-01,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"""Ensayo clínico en fase IIb, aleatorizado, controlado con placebo, de búsqueda de dosis para estudiar la seguridad y la eficacia de de MK-3102 en pacientes con diabetes mellitus de tipo 2 y un control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022193-13,0,0,0 2010-022193-13,8,2012-01-03,2013-04-01,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc","""Ensayo clínico en fase IIb, aleatorizado, controlado con placebo, de búsqueda de dosis para estudiar la seguridad y la eficacia de de MK-3102 en pacientes con diabetes mellitus de tipo 2 y un control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022193-13,0,0,0 2010-022193-13,8,2012-01-03,2013-04-01,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","""Ensayo clínico en fase IIb, aleatorizado, controlado con placebo, de búsqueda de dosis para estudiar la seguridad y la eficacia de de MK-3102 en pacientes con diabetes mellitus de tipo 2 y un control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022193-13,0,0,0 2010-022193-13,8,2012-01-03,2013-04-01,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MSD Finland Oy,"""Ensayo clínico en fase IIb, aleatorizado, controlado con placebo, de búsqueda de dosis para estudiar la seguridad y la eficacia de de MK-3102 en pacientes con diabetes mellitus de tipo 2 y un control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022193-13,0,0,0 2010-022200-46,4,2012-08-07,2012-08-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Orion Corporation,"Efficacy and safety of ODM-101 compared to a standard combination (Stalevo®); a randomised, double-blind, crossover, proof of concept study in patients with Parkinson's disease and end-of-dose motor f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022200-46,0,0,0 2010-022201-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Daniel Podzamczer,EVALUACIÓN DE LOS NIVELES DE ETRAVIRINA EN LÍQUIDO CEFALORAQUÍDEO (LCR) EN SUJETOS INFECTADOS POR EL VIH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022201-18,0,0,0 2010-022202-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Daniel Podzamczer,ESTUDIO PILOTO DEL CAMBIO EN LA ACTIVIDAD ANTIRRETROVIRAL EN SISTEMA NERVIOSO CENTRAL TRAS LA SUSTITUCIÓN DE TDF/FTC/EFV POR ABC/3TC/MVC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022202-41,0,0,0 2010-022205-17,4,2013-02-07,2014-01-21,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Ina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022205-17,0,0,0 2010-022206-40,5,2013-07-23,2013-07-23,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022206-40,0,0,0 2010-022207-22,5,2013-02-07,2014-01-06,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Ina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022207-22,0,0,0 2010-022208-36,8,2013-02-07,2014-03-24,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022208-36,0,0,0 2010-022209-16,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University College London,"ICON8 Trials Programme ICON8: An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022209-16,0,0,0 2010-022211-19,3,2011-06-24,2011-06-24,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GALDERMA R&D,PILOT STUDY TO EXPLORE EFFICACY AND SAFETY OF DIFFERENT DOSE REGIMENS OF CD5789 IN SUBJECTS WITH ACNE VULGARIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022211-19,0,0,0 2010-022215-19,1,2016-05-26,2016-05-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Greater Glasgow & Clyde NHS,A Pharmacokinetic Study Of The Combined Use Of Recombinant Human GH And IGF-1 In Children With Inflammatory Bowel (Crohn’s) Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022215-19,0,0,0 2010-022216-39,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,INSTITUTO DE INVESTIGACIÓN SANITARIA LA FE,"ESTUDIO COMPARATIVO, RANDOMIZADO, CIEGO, DEL EFECTO DEL PRETRATAMIENTO CON ANÁLOGOS DE GNRH FRENTE A PLACEBO EN PACIENTES ESTÉRILES DIAGNOSTICADAS DE ENDOMETRIOSIS QUE REALIZAN TRATAMIENTO DE FECUNDAC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022216-39,0,0,0 2010-022221-15,2,2012-04-24,2012-04-24,1,1,0,0,0,1,2,0,0,2,0,0,0,0,1,PHARMA MAR,"Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis(PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022221-15,1,0,0 2010-022221-15,2,2012-04-24,2012-04-24,1,1,0,0,0,1,2,0,0,2,0,0,0,0,1,"Pharma Mar S.A., Sociedad Unipersonal","Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis(PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022221-15,1,0,0 2010-022223-29,5,2012-11-14,2012-11-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Helsinn Healthcare SA,"Single-dose, multicenter, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of oral palonosetron 0.50 mg compared to I.V. palonosetron 0.25 mg administere...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022223-29,0,0,0 2010-022224-77,2,2013-07-31,2013-07-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"UCB Biosciences, Inc.","A PHASE 2 MULTI-CENTER, OPEN-LABEL, FOLLOW-UP STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF CDP6038 ADMINISTERED SUBCUTANEOUSLY TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO COMPLETED STUDY ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022224-77,0,0,0 2010-022224-77,2,2013-07-31,2013-07-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,UCB Biosciences Inc,"A PHASE 2 MULTI-CENTER, OPEN-LABEL, FOLLOW-UP STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF CDP6038 ADMINISTERED SUBCUTANEOUSLY TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO COMPLETED STUDY ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022224-77,0,0,0 2010-022228-66,10,2013-06-18,2013-07-07,9,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, double-dummy, placebo controlled, multicenter study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, compared to placebo and etanerce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022228-66,0,0,0 2010-022228-66,10,2013-06-18,2013-07-07,9,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, double-dummy, placebo controlled, multicenter study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, compared to placebo and etanerce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022228-66,0,0,0 2010-022228-66,10,2013-06-18,2013-07-07,9,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S. A,"A randomized, double-blind, double-dummy, placebo controlled, multicenter study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, compared to placebo and etanerce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022228-66,0,0,0 2010-022228-66,10,2013-06-18,2013-07-07,9,1,0,0,2,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, double-dummy, placebo controlled, multicenter study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, compared to placebo and etanerce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022228-66,0,0,0 2010-022229-13,3,2013-10-31,2013-11-01,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Morphotek Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in combination with Carboplatin and Paclitaxel or Docetaxel Followed by Pemetrexed in Chemotherapy na...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022229-13,0,0,0 2010-022229-13,3,2013-10-31,2013-11-01,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MORPHOTEK INC,"A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in combination with Carboplatin and Paclitaxel or Docetaxel Followed by Pemetrexed in Chemotherapy na...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022229-13,0,0,0 2010-022230-81,6,2015-05-07,2015-05-07,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Allos Therapeutics, Inc.","A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Follo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022230-81,0,0,0 2010-022230-81,6,2015-05-07,2015-05-07,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ALLOS,"A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients with Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Follo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022230-81,0,0,0 2010-022231-11,2,2020-11-18,2020-11-18,1,1,0,0,0,1,4,0,0,2,0,0,0,0,1,Genzyme Corporation,A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients Aged 8 Years of Age and Older,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022231-11,1,0,0 2010-022232-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,Effects of a combination treatment with lercanidipine + enalapril vs. lercanidipine + hydrochlorothiazide on blood pressure and endothelial function in essential hypertensive patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022232-37,0,0,0 2010-022233-28,1,,,0,0,0,0,0,1,3,0,1,0,0,0,0,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,Fatal familial insomnia: preventive treatment with doxycycline of at risk individuals Insonnia Fatale Familiare: trattamento preventivo con doxiciclina in soggetti a rischio,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022233-28,0,0,0 2010-022235-10,8,2020-02-12,2020-02-12,5,1,0,0,0,1,2,0,0,1,1,0,1,0,0,Erasmus MC,A Phase I/II study of Azacitidine (Vidaza®) in pediatric patients with newly diagnosed or relapsed high-grade pediatric MDS or JMML,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022235-10,0,0,0 2010-022239-12,1,2013-11-15,2013-11-15,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Isis Pharmaceuticals, Inc.","A Phase 1b/2 Study of Docetaxel and Prednisone, with or without ISIS 183750 (an eIF4E Inhibitor), inPatients with Castrate-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022239-12,0,0,0 2010-022240-21,1,2012-12-14,2012-12-14,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Isis Pharmaceuticals Inc.,"A Phase 1b/2 Study of Carboplatin-Paclitaxel, with or without ISIS 183750 (an eIF4E Inhibitor), in Patients with Stage IV Non-Small Cell Lung Cancer IV stádiumú, nem kissejtes tüdőrákos, carboplati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022240-21,0,0,0 2010-022242-24,2,2016-12-06,2016-12-06,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022242-24,0,0,0 2010-022243-38,9,2016-01-12,2016-01-12,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022243-38,0,0,0 2010-022243-38,9,2016-01-12,2016-01-12,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022243-38,0,0,0 2010-022244-20,2,2012-07-16,2012-07-16,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Almirall S.A.,"Double-blind, randomized, vehicle- and comparator-controlled, multicenter trial to evaluate the efficacy and safety of LAS41007 in the treatment of actinic keratosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022244-20,0,0,0 2010-022246-25,1,2016-07-27,2016-07-27,1,0,0,0,0,0,3,0,0,1,0,0,1,0,3,,Diagnostic clinique et mécanismes physiopathologiques de l'allergie à l'insuline.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022246-25,0,0,0 2010-022247-37,2,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Soligenix, Inc.","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF ORBEC® (ORAL BECLOMETHASONE 17,21-DIPROPIONATE) IN CONJUNCTION WITH TEN DAYS OF HIGH-DOSE PRED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022247-37,0,0,0 2010-022248-19,4,2013-06-20,2013-06-20,3,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals’ candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022248-19,0,0,0 2010-022253-42,1,2015-12-25,2015-12-25,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Kantonsspital St. Gallen,"An open, multicentric phase II trial to evaluate the efficacy and safety of Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line therapy for patients with relapsed or refractory ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022253-42,0,0,0 2010-022255-37,1,2015-04-28,2015-04-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU de Bordeaux,"Etude de l’efficacité et de la tolérance, de l’injection intra prostatique de toxine botulique A, chez l’homme, dans le traitement de l’hyperplasie bénigne de prostate symptomatique.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022255-37,0,0,0 2010-022257-41,4,2012-03-28,2012-04-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Global Research and Development Centre (Europe) Ltd.,"A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022257-41,0,0,0 2010-022258-17,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Instituto Aragonés de Ciencias de la Salud,Efecto de niacina/laropiprant en la concentración de lipoproteína (A) en relación a las concentraciones basales y al tamaño de lipoproteína (A).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022258-17,0,0,0 2010-022260-12,1,2016-03-21,2016-03-21,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,A Phase II trial of broad spectrum antibiotic therapy for early stage chronic lymphocytic leukaemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022260-12,0,0,0 2010-022265-10,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Intercell AG,LONG TERM IMMUNITY AND SAFETY WITH OR WITHOUT A BOOSTER DOSE FOLLOWING PRIMARY VACCINATION WITH THE JAPANESE ENCEPHALITIS VACCINE IC51 (IXIARO®) IN A PEDIATRIC POPULATION IN A JEV-ENDEMIC COUNTRY. OP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022265-10,0,1,1 2010-022266-27,1,2014-09-15,2014-09-15,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Valneva Austria GmbH,"Long term immunity and safety following vaccination with the Japanese Encephalitis vaccine IC51 (IXIARO®, JESPECT®) in a pediatric population in non-endemic countries. Uncontrolled, Phase 3 Follow-up ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022266-27,0,0,0 2010-022270-14,1,2020-02-05,2020-02-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,Estudio abierto de extensión de fase 2 con conatumumab . A Phase 2 Open Label Extension Study of Conatumumab.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022270-14,0,0,0 2010-022271-59,3,2016-07-04,2016-07-04,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid (OPC-67683) Administered Orally as 200 mg Total Daily Dose f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022271-59,0,0,0 2010-022273-34,1,2015-03-13,2015-03-13,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A multi-centric, open-label, phase II study investigating the combination of Afinitor with paclitaxel and carboplatin in first line treatment of patients with advanced (stage IV) large cell lung cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022273-34,0,0,0 2010-022278-15,3,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy And Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have A Confirmed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022278-15,0,0,0 2010-022279-77,2,2011-07-29,2011-08-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study to determine the efficacy and dose response of repeat inhaled doses of GW870086X on FEV1 in adults with Persi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022279-77,0,0,0 2010-022280-35,1,2011-04-14,2011-04-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A randomised, double-blind, placebo-controlled study of topical GW870086X formulation in subjects with moderate or severe atopic dermatitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022280-35,0,0,0 2010-022281-27,1,2011-02-28,2011-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,"An Investigator-blind, Controlled Study to Assess the Efficacy and Safety of different formulations of LAS 41004 Compared to Placebo and to Active Control in a Psoriasis-Plaque-Test",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022281-27,0,0,0 2010-022284-35,5,2013-12-03,2013-12-03,4,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Orfagen,CLINICAL EFFICACY AND SAFETY OF TAZAROTENE CREAM 0.05% IN THE INITIAL AND MAINTENANCE THERAPIES OF LAMELLAR ICHTHYOSIS (LI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022284-35,1,0,0 2010-022284-35,5,2013-12-03,2013-12-03,4,1,1,0,0,1,3,0,0,2,0,0,0,0,1,ORFAGEN,CLINICAL EFFICACY AND SAFETY OF TAZAROTENE CREAM 0.05% IN THE INITIAL AND MAINTENANCE THERAPIES OF LAMELLAR ICHTHYOSIS (LI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022284-35,1,0,0 2010-022290-34,1,2014-03-04,2014-03-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Pharmecosse,An investigation of the efficacy of a single dose of insulin in the prevention of excessive cutaneous scarring in breast surgery patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022290-34,0,0,0 2010-022293-14,2,2016-03-31,2016-03-31,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,Inserm-ANRS,"Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-definin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022293-14,0,0,0 2010-022293-14,2,2016-03-31,2016-03-31,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,Inserm - ANRS,"Optimized Phase III Trial of Immuno-stimulation with Maraviroc, a CCR5 antagonist, combined with Anti Retroviral Therapy (cART) in advanced, Late diagnosed HIV-1 infected patients with an AIDS-definin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022293-14,0,0,0 2010-022297-14,8,2012-10-17,2012-12-19,6,0,0,0,0,0,3,0,0,1,1,1,1,0,1,"Reata Pharmaceuticals, Inc",Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurence of Renal Events (BEACON) Valutazione del bardoxolone metile in pazienti con insufficienza r...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022297-14,0,0,0 2010-022297-14,8,2012-10-17,2012-12-19,6,0,0,0,0,0,3,0,0,1,1,1,1,0,1,REATA PHARMACEUTICALS INC,Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurence of Renal Events (BEACON) Valutazione del bardoxolone metile in pazienti con insufficienza r...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022297-14,0,0,0 2010-022302-41,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Consorcio de Apoyo a la Investigación Biomédica en Red (CAIBER),"Ensayo clínico prospectivo, aleatorizado, comparativo de la eficacia y seguridad del levofloxacino versus isoniazida en el tratamiento de la infección latente tuberculosa del trasplante hepático",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022302-41,0,0,0 2010-022303-22,1,2013-01-16,2013-01-16,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 4, RANDOMIZED, OPEN-LABEL TRIAL TO ASSESS THE IMPACT OF PROPHYLACTIC ANTIPYRETIC MEDICATION ON THE IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN WITH ROUTINE PEDIATRIC VACCI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022303-22,0,0,0 2010-022304-50,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novo Nordisk A/S,A trial comparing the efficacy and safety of insulin degludec three times weekly in insulin naïve subjects with type 2 diabetes mellitus when titrated using two different titration algorithms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022304-50,0,0,0 2010-022307-22,2,2017-12-20,2017-12-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Haukeland University Hospital, Division of Psychiatry",The Bergen Psychosis Project 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022307-22,0,0,0 2010-022308-34,1,2012-11-08,2012-11-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Central Manchester Foundation Hospitals Trust,Eplerenone in Metabolic Syndrome: An investigation into the effects of Eplerenone on perivascular adipose tissue and small artery tone in obesity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022308-34,0,0,0 2010-022313-25,15,2016-01-20,2016-03-04,13,1,0,0,0,1,3,0,0,1,0,0,1,0,1,C.T. Development Switzerland SARL,"Estudio internacional, aleatorizado, doble ciego, controlado con placebo fase 3 para evaluar la eficacia y la seguridad de KIACTA^TM en la prevención de la disminución de la función renal en pacientes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022313-25,0,0,0 2010-022313-25,15,2016-01-20,2016-03-04,13,1,0,0,0,1,3,0,0,1,0,0,1,0,1,A.T. Development Switzerland SARL,"Estudio internacional, aleatorizado, doble ciego, controlado con placebo fase 3 para evaluar la eficacia y la seguridad de KIACTA^TM en la prevención de la disminución de la función renal en pacientes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022313-25,0,0,0 2010-022315-19,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,ERYDEL S.P.A.,Valutazione degli effetti del Desametasone Sodio Fosfato Intra-Eritrocitario sui Sintomi Neurologici in Pazienti con Atassia Teleangectasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022315-19,0,0,0 2010-022318-22,1,2019-09-24,2019-09-24,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Maarit Valkealahti / University hospital of Oulu,Tsoledronaatti hoito paikallista kiihtynyttä luunvaihdunta- oireyhtymää sairastavilla potilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022318-22,0,0,0 2010-022319-20,1,2015-06-30,2015-06-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Odense University Hospital,"The effect of antidepressant therapy on quality of life, physical and menthal health and cortisole metabolism in PCOS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022319-20,0,0,0 2010-022320-67,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA` DI NOVARA,USE OF TOLVAPTAN IN CLINICAL SYNDROMES CHARACTERIZED BY INAPPROPRIATE SECRETION OF ADH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022320-67,0,0,0 2010-022326-32,3,2011-12-03,2011-12-03,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind, placebo and active controlled, parallel group study to evaluate the dose response of AHU377 in combination with valsartan 320 mg after 8 week treatment in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022326-32,0,0,0 2010-022326-32,3,2011-12-03,2011-12-03,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A multi-center, randomized, double-blind, placebo and active controlled, parallel group study to evaluate the dose response of AHU377 in combination with valsartan 320 mg after 8 week treatment in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022326-32,0,0,0 2010-022329-13,1,2013-02-20,2013-02-20,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Hôpitaux Universitaires de Strasbourg,Etude de phase I associant la rapamycine et l’irinotecan dans toutes tumeurs solides réfractaires de l’enfant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022329-13,0,0,0 2010-022332-37,1,2015-11-18,2015-11-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA` GRANDA (A.O. DI RILIEVO NAZIONALE),A SINGLE-ARM MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022332-37,0,0,0 2010-022334-92,1,2011-10-17,2011-10-17,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,"Barts and the London School of Medicine and Dentistry, Queen Mary University of London",Effects of a combination of varenicline and transdermal nicotine patch on post-quitting urges to smoke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022334-92,0,0,0 2010-022335-11,1,2013-02-13,2013-02-13,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,"Barts and the London School of Medicine and Dentistry, Queen Mary University of London",Effects of a tailored dose of varenicline on post-quitting urges to smoke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022335-11,0,0,0 2010-022336-36,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,Place de la Kétamine à dose anti-hyperalgésique dans l'épargne morphinique en réanimation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022336-36,0,0,0 2010-022337-29,3,2011-12-20,2011-12-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,A trial comparing the efficacy and safety of insulin degludec once daily in insulin naïve subjects with type 2 diabetes mellitus when titrated using two different titration algorithms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022337-29,0,0,0 2010-022338-10,3,2019-12-24,2019-12-24,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022338-10,0,0,0 2010-022338-10,3,2019-12-24,2019-12-24,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Lilly S.A.,Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022338-10,0,0,0 2010-022348-18,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Heart- and Diabetescenter NRW,Application of Daptomycin in MRSA infected diabetic foot in comparison to vancomycin treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022348-18,0,0,0 2010-022351-28,1,2016-01-15,2016-01-15,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Hôpital FOCH,"Essai prospectif randomisé, en double aveugle, comparant la Nalbuphine à l'association Hydroxyzine-Salbutamol dans la dystocie de démarrage.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022351-28,0,0,0 2010-022363-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University","Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson's Disease: A randomised, placebo-controlled double-blind trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022363-35,0,0,0 2010-022364-12,7,2015-03-30,2015-03-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022364-12,0,0,0 2010-022365-10,10,2016-10-06,2016-10-06,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Daiichi Sankyo Development Limited,"A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squamous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022365-10,0,0,0 2010-022365-10,10,2016-10-06,2016-10-06,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,DAIICHI SANKIO DEVELOPMENT LIMITED,"A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squamous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022365-10,0,0,0 2010-022366-27,4,2013-06-13,2013-06-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"BIAL Portela & Cª, S.A.","Efficacy and safety of BIA 9-1067 in idiopathic Parkinson’s disease patients with “wearing-off” phenomenon treated with levodopa plus a dopa decarboxylase inhibitor (DDCI): a double-blind, randomised,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022366-27,0,0,0 2010-022370-14,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,Centre Hospitalier de Toulouse,Evaluation de la tolérance d'une administration intra-nasale d'ocytocine chez des nourrissons présentant un syndrome de Prader-Willi et de son effet sur la succion et la prise alimentaire.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022370-14,0,0,0 2010-022372-31,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Dynavax Technologies Corporation,An Observational Study Evaluating the Long-Term Safety and Immunogenicity of HEPLISAV™ Compared with Engerix-B® in Adults With Chronic Kidney Disease Who Have Previously Received a Hepatitis B Vaccine...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022372-31,0,0,0 2010-022378-15,5,2012-10-01,2012-10-01,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Nycomed GmbH,"VELVET (Veltuzumab various doses exploratory trial), a randomized, double blind, placebo controlled, multicentre, multinational phase II dose range finding trial in subjects with moderate to severe rh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022378-15,0,0,0 2010-022380-35,4,2015-02-25,2015-02-25,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biotest AG,"A randomized, double-blind, placebo-controlled, multicenter, parallel-group, adaptive group-sequential phase II study, to determine the efficacy and safety of BT086 as an adjunctive treatment in sever...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022380-35,0,0,0 2010-022382-10,13,2013-07-09,2013-09-04,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohn's Disease Studio ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022382-10,0,0,0 2010-022382-10,13,2013-07-09,2013-09-04,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohn's Disease Studio ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022382-10,0,0,0 2010-022382-10,13,2013-07-09,2013-09-04,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to Severely Active Crohn's Disease Studio ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022382-10,0,0,0 2010-022383-12,18,2013-09-04,2013-10-23,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A 52 week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects with Crohn's Disease Studio di 52 sett...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022383-12,0,0,0 2010-022383-12,18,2013-09-04,2013-10-23,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A 52 week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects with Crohn's Disease Studio di 52 sett...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022383-12,0,0,0 2010-022383-12,18,2013-09-04,2013-10-23,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"A 52 week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects with Crohn's Disease Studio di 52 sett...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022383-12,0,0,0 2010-022384-35,16,2013-09-04,2013-11-14,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn's Disease Studio di estensione in aperto per valutare la sicurezza di GSK1605786A in soggetti affetti da mor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022384-35,0,0,0 2010-022384-35,16,2013-09-04,2013-11-14,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn's Disease Studio di estensione in aperto per valutare la sicurezza di GSK1605786A in soggetti affetti da mor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022384-35,0,0,0 2010-022388-37,1,2021-02-10,2021-02-10,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Technische Universität Dresden,Treatment of patients with MDS or AML with an impending hematological relapse with Azacitidin (Vidaza) Behandlung des drohenden hämatologischen Rezidivs von Patienten mit MDS oder AML mit Azacitidi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022388-37,0,0,0 2010-022389-28,1,2013-03-05,2013-03-05,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Lars Søndergaard,"Treatment with Endothelinantagonist to tcpc patients; a multicenter, randomized, Prospective study measuring maximal O2 uptake in ergometer bicycle test. [TEMPO-study].",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022389-28,0,0,0 2010-022393-13,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,"Academical Medical Center, University of Amsterdam",Does helium protect the heart against ischaemia-reperfusion damage in patients with acute myocardial infarction?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022393-13,0,0,0 2010-022394-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Institut d'Investigació Biomèdica de Girona (IdibGi),"Estudio piloto fase IV, aleatorizado, doble ciego y de grupos paralelos, en el que se pretende estudiar el imapcto de la metformina sobre la flora intestinal en pacientes diabéticos de reciente diagnó...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022394-34,0,0,0 2010-022395-31,8,2016-03-10,2018-02-15,2,0,0,0,0,2,3,0,0,2,0,0,0,0,0,European Myeloma Network,"A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022395-31,1,0,0 2010-022395-31,8,2016-03-10,2018-02-15,2,0,0,0,0,2,3,0,0,2,0,0,0,0,0,European Myeloma Network Datacenter,"A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022395-31,1,0,0 2010-022395-31,8,2016-03-10,2018-02-15,2,0,0,0,0,2,3,0,0,2,0,0,0,0,0,E.M.N. - EUROPEAN MYELOMA NETWORK,"A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022395-31,1,0,0 2010-022397-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Helsinki - Erkki Isometsä,Sequence Towards Recovery in Depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022397-14,0,0,0 2010-022400-53,1,2016-06-28,2016-06-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Køge Hospital,Intracoronary administration of melatonin for patients with acute myocardial infarction: a placebo controlled randomized study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022400-53,0,0,0 2010-022402-40,8,2013-03-01,2013-03-01,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Shire-Movetis NV,"Trial consisting of an 8-week double-blind placebo-controlled part to evaluate efficacy, safety, tolerability and pharmacokinetics of prucalopride in paediatric subjects with functional constipation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022402-40,1,0,0 2010-022402-40,8,2013-03-01,2013-03-01,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,SHIRE-MOVETIS NV,"Trial consisting of an 8-week double-blind placebo-controlled part to evaluate efficacy, safety, tolerability and pharmacokinetics of prucalopride in paediatric subjects with functional constipation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022402-40,1,0,0 2010-022403-22,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"A proof-of concept, open-label, forced titration, multicenter study to assess the safety/tolerability and efficacy of 10-weeks treatment of LCI699 in patients with Cushing’s disease Studio multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022403-22,0,0,0 2010-022406-41,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Novartis Pharma Services AG,"A 3-month, exploratory, non-randomized, multi-center, open label study to evaluate the reliability, safety and usability of the Transplantation Sensor System combined with Myfortic in adult kidney tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022406-41,0,0,0 2010-022408-28,2,2012-09-13,2012-09-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 2 or 3 Infection + ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022408-28,0,0,0 2010-022410-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,MUMC,Topical Diclofenac and Vitamin D3 to treat Basal Cell Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022410-11,0,0,0 2010-022413-26,1,2015-04-28,2015-04-28,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Medical Center Hamburg-Eppendorf,Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (IDEAL-Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022413-26,0,0,0 2010-022416-40,1,2013-04-25,2013-04-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,The Royal Marsden NHS Foundation Trust,"A Translational, proof of the concept, study Of Pre-operative Pazopanib in treatment-naive patients with resectable soft tissue Sarcomas (TOPPS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022416-40,0,0,0 2010-022417-25,1,,,0,0,0,0,0,1,4,0,0,1,0,0,0,1,0,University Medical Center Groningen,Pheochromocytoma RandomisEd Study Comparing adRenoreceptor Inhibiting agents for Preoperative Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022417-25,0,0,0 2010-022422-32,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University Hospital Southampton NHS Foundation Trust,A randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with Bortezomib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022422-32,0,0,0 2010-022425-15,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,0,Universitätsklinikum Heidelberg,"ACCEPT - (ACC, Erbitux® and particle therapy) - Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost (Phase I/II feasibility study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022425-15,0,0,0 2010-022428-58,1,2014-12-31,2014-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Aarhus University Hospital, Skejby",PRECON 2 – Fast-track cardiac surgery (kvalitetssikringsprojekt). Remifentanyl anæstesi til koronar bypass (CABG) med eller uden samtidig udskiftning af aortaklappen (AVR) bedømt ved opvågningsforløb ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022428-58,0,0,0 2010-022433-29,1,2014-12-09,2014-12-09,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,"Aarhus University Hospital, Department of Ophthalmology",Pharmacological intervention on diabetic retinopathy with PGF,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022433-29,0,0,0 2010-022437-28,2,2011-06-06,2011-06-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Efficacy of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022437-28,0,0,0 2010-022439-12,4,2013-08-14,2013-08-14,3,0,0,0,0,0,2,0,0,2,0,0,0,0,2,ADVANCELL,"A Phase II Placebo Controlled, Multicenter Study to Investigate the Safety and Efficacy of ATH008 cream in Patients with Palmar-Plantar Erythrodysesthesia Syndrome (PPES) secondary to capecitabine the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022439-12,1,0,0 2010-022439-12,4,2013-08-14,2013-08-14,3,0,0,0,0,0,2,0,0,2,0,0,0,0,2,"Advancell Advanced In Vitro Cell Technologies, S.A","A Phase II Placebo Controlled, Multicenter Study to Investigate the Safety and Efficacy of ATH008 cream in Patients with Palmar-Plantar Erythrodysesthesia Syndrome (PPES) secondary to capecitabine the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022439-12,1,0,0 2010-022440-20,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,0,CHU de Nice,"Traitements of angioma plans of the child by laser to pulsed colouring agent and Timolol (Néogel 0,1%).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022440-20,0,0,0 2010-022441-21,1,2013-08-22,2013-08-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,"EPs® 7630 film-coated tablets in subjects (≥18 years old) suffering from common cold A prospective, multi-center, single-arm, open-label, phase IV clinical post-marketing safety study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022441-21,0,0,0 2010-022444-20,1,,,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,ZonMW,PHASE I-II STUDY OF GEMCITABINE AND VALPROIC ACID PLUS VALGANCICLOVIR IN PATIENTS WITH ADVANCED NASOPHARYNGEAL CARCINOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022444-20,0,0,0 2010-022445-20,11,2021-09-03,2021-09-04,8,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma. Ensayo de fase 3, aleatorizado y abierto, d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022445-20,1,0,0 2010-022445-20,11,2021-09-03,2021-09-04,8,1,0,0,0,1,3,0,0,2,0,0,0,0,1,BRISTOL-M.SQUIBB,"A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma. Ensayo de fase 3, aleatorizado y abierto, d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022445-20,1,0,0 2010-022446-24,1,,,0,1,0,1,0,1,1,0,0,1,1,1,0,1,0,Hospital of the Ludwig Maximilians University Munich,Active immunotherapy of patients with acute myeloid leukemia using autologous dendritic cells transfected with RNA encoding leukemia-associated antigens,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022446-24,0,0,0 2010-022449-38,2,2013-02-19,2013-06-26,2,1,1,0,1,0,2,0,1,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-BLIND TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF REPEVAX AND BIVALENT rLP2086 VACCINE WHEN ADMINISTERED CONCOMITANTLY IN HEALTHY ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022449-38,0,0,0 2010-022454-17,1,2011-06-09,2011-06-09,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Liège- Dpt de Médecine Générale,"A double-blind, placebo controlled, randomized, comparative, mono-centre trial to assess the impact of a monthly administration of 50.000 IU of Vitamin D during 6 months on Vitamin D level in healt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022454-17,0,0,0 2010-022455-31,2,2013-09-19,2013-09-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 with Ritonavir (ABT 450/r) in Combination with ABT-267 and/or ABT 333 With and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022455-31,0,0,0 2010-022455-31,2,2013-09-19,2013-09-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 with Ritonavir (ABT 450/r) in Combination with ABT-267 and/or ABT 333 With and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022455-31,0,0,0 2010-022458-18,4,2012-09-25,2012-10-29,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase II randomised, double-blind, placebo-controlled incomplete cross-over trial with 4-week treatment periods to evaluate efficacy and safety of tiotropium inhalation solution (doses of 1.25 μg, 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022458-18,0,0,0 2010-022459-45,5,2015-07-28,2015-07-31,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,IMMATICS BIOTECHNOLOGIES GMBH,"A randomized, controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022459-45,0,0,0 2010-022459-45,5,2015-07-28,2015-07-31,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,immatics biotechnologies GmbH,"A randomized, controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022459-45,0,0,0 2010-022460-12,1,2012-12-10,2012-12-10,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Herlev Hospital,"The effect of melatonin on depression, anxiety, cogntive function and sleep disturbances in breast cancer patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022460-12,0,0,0 2010-022461-10,1,2012-03-05,2012-03-05,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Southampton University Hospitals NHS Trust,A pilot study investigating the antiplatelet effect of generic clopidogrel versus Plavix™ – is there any difference in platelet reactivity in healthy subjects?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022461-10,0,0,0 2010-022463-35,1,2016-09-30,2016-09-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Manchester Mental Health and Social Care Trust,The Benefit of Minocycline on Negative Symptoms in Psychosis: Extent and Mechanisms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022463-35,0,0,0 2010-022467-36,1,2015-02-20,2015-02-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Freistaat Bayern,A phase II study about interferon gamma 1b to therapy the steroid-refractory bronchiolitis obliterans after allogenic stem cell therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022467-36,0,0,0 2010-022468-11,1,2013-04-12,2013-04-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,EKOS Corporation,Ultrasound Accelerated Thombolysis of Pulmonary Embolism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022468-11,0,0,0 2010-022472-31,1,2011-05-21,2011-05-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital of South Manchester,The effect of Lidocaine and its Delivery in Patients with Chronic Cough,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022472-31,0,0,0 2010-022473-33,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,"Department of Ophthalmology, Hietzing Hospital",Short term effect of Lucentis® (Ranibizumab) as pretreatment to laser photocoagulation versus Lucentis® (Ranibizumab) combined with laser photocoagulation in the treatment of diabetic macular edema. A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022473-33,0,0,0 2010-022475-55,14,2020-02-13,2020-02-13,12,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","A 12-WEEK RANDOMIZED, OPEN-LABEL, ACTIVE COMPARATOR PERIOD FOLLOWED BY A 12-WEEK SAFETY EXTENSION PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 16 YEARS AND >25 KG W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022475-55,1,0,0 2010-022475-55,14,2020-02-13,2020-02-13,12,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer, S.L.U.","A 12-WEEK RANDOMIZED, OPEN-LABEL, ACTIVE COMPARATOR PERIOD FOLLOWED BY A 12-WEEK SAFETY EXTENSION PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF FESOTERODINE IN SUBJECTS AGED 6 TO 16 YEARS AND >25 KG W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022475-55,1,0,0 2010-022482-95,1,2018-08-14,2018-08-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Belgian Gynaecological Oncolgy Group,BGOG-OV5:Phase II study of weekly Paclitaxel/Carboplatin in combination with prophylactic G-CSF in the treatment of gynaecological cancers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022482-95,0,0,0 2010-022486-10,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Psioxus Therapeutics Limited,"A multicentre, randomised, double-blind, placebo-controlled, dose-finding phase II clinical study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022486-10,0,0,0 2010-022486-10,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Myotec Therapeutics Limited,"A multicentre, randomised, double-blind, placebo-controlled, dose-finding phase II clinical study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022486-10,0,0,0 2010-022487-12,1,2012-08-03,2012-08-03,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,"Cerexa, Inc","A Phase 2, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Coadministered Ceftaroline fosamil and NXL104 Versus Intravenous Doripenem in Adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022487-12,0,0,0 2010-022489-29,1,2017-04-07,2017-04-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,The University of Birmingham,Long-term tapering versus standard prednisolone (steroid) therapy for the treatment of the initial episode of childhood nephrotic syndrome: national multicentre randomised double blind trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022489-29,0,0,0 2010-022489-29,1,2017-04-07,2017-04-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Central Manchester University Hospitals NHS Foundation Trust,Long-term tapering versus standard prednisolone (steroid) therapy for the treatment of the initial episode of childhood nephrotic syndrome: national multicentre randomised double blind trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022489-29,0,0,0 2010-022492-54,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Centro Nacional de Investigaciones Cardiovasculares (CNIC),"Efecto de un fármaco a dosis fija incluyendo ácido acetilsalicílico, una estatina y un inhibidor de enzima convertidora de angiotensina en la adherencia al tratamiento y el control de los factores de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022492-54,0,0,0 2010-022492-54,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,CNIC,"Efecto de un fármaco a dosis fija incluyendo ácido acetilsalicílico, una estatina y un inhibidor de enzima convertidora de angiotensina en la adherencia al tratamiento y el control de los factores de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022492-54,0,0,0 2010-022496-66,1,2014-03-07,2014-03-07,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Joint UCLH and UCL Biomedical Research Unit,An Evaluation of the Tolerability and Feasibility of combining 5-Amino-Levulinic Acid (5-ALA) with Carmustine Wafers (Gliadel) in the Surgical Management of Primary Glioblastoma (GALA-5 Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022496-66,0,0,0 2010-022500-50,1,,,0,1,0,0,1,0,4,0,0,1,0,0,0,1,0,Ortopædkirurgisk afdeling,Pain treatment after anterior cruciate ligament reconstruction - Comparison of infiltration analgesia with femoral nerve block after hamstrings anterior cruciate ligament reconstruction.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022500-50,0,0,0 2010-022502-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Pantec Biosolution AG,"Prospektive, randomisierte, klinische 4-Arm Pilotstudie zur Dosisfin-dung der kombinierten Anwendung von P.L.E.A.S.E. mit 5% topischen Imiquimod versus Standardapplikation von 5% topischem Imiquimod ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022502-40,0,0,0 2010-022504-42,2,2014-03-31,2014-03-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients with Active Rheumatoid Arthritis on background Methotrexate Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022504-42,0,0,0 2010-022505-18,1,2012-11-30,2012-11-30,1,1,0,0,1,0,2,0,1,1,0,0,1,0,0,Health Protection Agency,"A Phase II/III Open Label, Randomised Study of the Safety, Reactogenicity and Immunogenicity of a Single Dose of Novartis Meningococcal ACWY Conjugate Vaccine (Menveo) or Glaxosmithkline Meningococcal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022505-18,0,0,0 2010-022506-41,6,2015-01-05,2015-03-02,4,1,0,0,2,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase IIb Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in Subjects with Active Ulcerative Colitis (UC) S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022506-41,0,0,0 2010-022509-17,1,2017-09-29,2017-09-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farmacêutica Química, Lda","Phase II, open-label study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lung cancer who present activating mutations in the tyrosine kinase domain o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022509-17,0,0,0 2010-022510-11,2,2012-03-07,2012-03-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A multicenter, open-label, dose ranging study to determine the pharmacokinetics and pharmacodynamics of mepolizumab administered intravenously or subcutaneously to adult asthmatic subjects with elevat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022510-11,0,0,0 2010-022511-18,1,2019-12-31,2019-12-31,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,"Albert-Ludwig University Freiburg, Laboratory for Biological and Personality Psychology",Behavioral effects and neural correlates of oxytocin on social attention [Verhaltenseffekte und neuronales Korrelat von Oxytocin im Kontext sozialer Aufmerksamkeit],https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022511-18,0,0,0 2010-022513-26,1,2011-05-06,2011-05-06,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,SkyePharma AG,"Randomised, single-blind, placebo controlled, four-period four-treatment cross-over design, proof of concept study to compare the pharmacodynamic, safety and pharmacokinetics of one single administrat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022513-26,0,0,0 2010-022514-47,5,2013-05-23,2013-05-23,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022514-47,1,0,0 2010-022515-20,2,2013-06-06,2013-06-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017, USA",PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF PD 0332991 IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022515-20,0,0,0 2010-022516-39,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Institut de Recerca HSCSP,Estudio aleatorizado sobre el efecto hemodinámico de la asociación de simvastatina con betabloqueantes no cardioselectivos en pacientes con cirrosis hepática e hipertensión portal clínicamente sig...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022516-39,0,0,0 2010-022517-25,2,2012-02-14,2012-09-17,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Addex Pharma SA,"Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety, tolerability and efficacy of ADX48621 in the treatment of levodopa induced dyskinesia i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022517-25,0,0,0 2010-022518-16,1,2019-08-13,2019-08-13,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,King's College Hospital NHS Foundation Trust,A prospective single blind randomised controlled study to compare the outcomes of patients with diabetes and clinically non-infected ischaemic and neuropathic foot ulcers treated with and without ora...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022518-16,0,0,0 2010-022520-73,1,2015-12-17,2015-12-17,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Hellenic Oncology Research Group,"Phase II, open-label non-randomized trial to investigate the efficacy of Bevacizumab in combination with dose dense sequential chemotherapy in the neo-adjuvant setting for HER2 negative breast cancer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022520-73,0,0,0 2010-022521-15,1,2012-07-20,2012-07-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Pantec Biosolutions AG,"Prospektive, klinische 4-Arm Pilotstudie zur Dosisfindung der kombi-nierten Anwendung von P.L.E.A.S.E. mit 5% topischen Imiquimod ver-sus Standardapplikation von 5% topischem Imiquimod bei Basaliomen",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022521-15,0,0,0 2010-022529-14,3,2012-03-26,2012-03-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F.Hoffmann-La Roche,"A phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of dalcetrapib on lipids, lipoproteins, apolipoproteins and markers of CV risk in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022529-14,0,0,0 2010-022534-84,3,2013-03-01,2013-12-03,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,UCB Pharma SA,"A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE HORMONE AND LIPID LEVELS IN MALE SUBJECTS WITH PARTIAL-ONSET SEIZURES AFTER A SWITCH OF TREATMENT FROM CARBAMAZEPINE AS ADJUNCTIVE TREATMENT TO ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022534-84,0,0,0 2010-022538-10,1,2011-09-28,2011-09-28,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"An open, phase IV, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a hepatitis B (Engerix-B™ Kinder) vaccine challenge in children ag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022538-10,0,0,0 2010-022548-19,3,2012-05-28,2012-05-28,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Tetraphase Pharmaceuticals, Inc.","A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of 2 Dose Regimens of TP-434 Compared with Ertapenem in Adult Comm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022548-19,1,0,0 2010-022549-59,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Tolerx, Inc.",DEFEND 2A: Durable-Response Therapy Evaluation For Early- or New-Onset Type 1 Diabetes in Adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022549-59,0,0,0 2010-022556-23,2,2011-12-15,2011-12-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Grünenthal GmbH,"A randomized 4 week Phase IIa trial evaluating the efficacy, safety, and tolerability of GRT6005, a new centrally acting analgesic in subjects with moderate to severe pain due to osteoarthritis (OA) o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022556-23,0,0,0 2010-022557-42,2,2012-01-05,2012-01-05,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Grünenthal GmbH,"A randomized 4-week Phase IIa trial evaluating the efficacy, safety, and tolerability of GRT6005, a new centrally acting analgesic, in subjects with pain due to diabetic polyneuropathy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022557-42,0,0,0 2010-022558-18,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,A pilot trial with clenbuterol in spinal and bulbar muscular atrophy (SBMA). Studio pilota con il clenbuterolo nella atrofia muscolare spinale bulbare (SBMA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022558-18,0,0,0 2010-022560-12,5,2012-11-13,2012-12-19,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,IMCLONE LLC,A Phase 2 Study of a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in Previously Treated Patients with Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022560-12,0,0,0 2010-022560-12,5,2012-11-13,2012-12-19,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ImClone LLC,A Phase 2 Study of a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in Previously Treated Patients with Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022560-12,0,0,0 2010-022568-11,3,2014-09-01,2014-09-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-65003...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022568-11,0,0,0 2010-022568-11,3,2014-09-01,2014-09-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-65003...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022568-11,0,0,0 2010-022570-13,1,2013-06-13,2013-06-13,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Medizinsiche Fakultät der Technischen Universität München,Gadovit-Studie Intraindividueller Vergleich der diagnostischen Wertigkeit von delayed-enhancement imaging mit Gadobutrol (Gadovist®) versus Gadobenat Dimeglumin (Multihance®) mittels einer MRT Bildge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022570-13,0,0,0 2010-022572-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Ghent University Hospital,Invloed van Somatuline® autogel 120mg op post-operatieve drainage na rectumresectie voor rectumcarcinoom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022572-32,0,0,0 2010-022576-30,5,2014-10-07,2014-10-07,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Radius Health, Inc.","A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022576-30,0,0,0 2010-022579-68,1,2013-08-28,2013-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Corimmun GmbH,"COR-1, an anti-ß1 receptor antibody cyclopeptide in heart failure: a phase II, multicentre, randomised, double-blind and placebo-controlled study with parallel groups",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022579-68,0,0,0 2010-022583-13,8,2014-03-11,2014-03-11,6,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"An open-label, multi-center, expanded access study of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC). The EFFECTS STUDY: Everolimu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022583-13,1,0,0 2010-022583-13,8,2014-03-11,2014-03-11,6,1,0,0,0,1,3,0,0,2,0,0,0,0,1,NOVARTIS FARMA,"An open-label, multi-center, expanded access study of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC). The EFFECTS STUDY: Everolimu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022583-13,1,0,0 2010-022583-13,8,2014-03-11,2014-03-11,6,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Farmaceútica S.A.,"An open-label, multi-center, expanded access study of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC). The EFFECTS STUDY: Everolimu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022583-13,1,0,0 2010-022584-35,1,2013-08-23,2013-08-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Dresden Universtity of Technology,Clofarabine salvage therapy in patients with relapsed or refractory AML The BRIDGE Trial (Therapie mit Clofarabin bei rezidivierter oder refraktärer akuter myeloischer Leukämie (Bridge-Studie)),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022584-35,0,0,0 2010-022586-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Alfred E. Tiefenbacher (GmbH & Co. KG),"Randomized, Double-Masked, Active Controlled, Crossover Phase III Equivalence Study of Travoprost Eye Drops Solution in Subjects with Open Angle Glaucoma or Ocular Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022586-10,0,0,0 2010-022587-12,1,2020-08-12,2020-08-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Guy's and St. Thomas' NHS Foundation Trust,The Additive effect of Vitamin K Supplementation and Bisphosphonate on Fracture Risk in Post-menopausal Osteoporosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022587-12,0,0,0 2010-022589-29,1,2012-10-04,2012-10-04,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Oxford,Investigation of pathways regulating cell survival and early antiangiogenic response to single agent Everolimus or Rapamycin in renal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022589-29,0,0,0 2010-022596-64,4,2013-01-09,2013-01-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & d�veloppement,"A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022596-64,0,0,0 2010-022596-64,4,2013-01-09,2013-01-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022596-64,0,0,0 2010-022598-32,1,2014-04-17,2014-04-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Genentech Inc,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE II STUDY TO EVALUATE THE IMPACT OF MABT5102A ON BRAIN AMYLOID LOAD AND RELATED BIOMARKERS IN PATIENTS WITH MILD TO MO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022598-32,0,0,0 2010-022599-30,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo de Tratamiento de los Tumores Digestivos(TTD),ENSAYO fase IIb randomizado para evaluar la eficacia de Gemcitabina-Erlotinib vs Gemcitabina- Erlotinib-Capecitabina en pacientes con cáncer de páncreas metastásico.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022599-30,0,0,0 2010-022604-45,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Odense Universitetshospital,EFFEKTEN AF EZETIMIBE SOM TILLÆG TIL OPTIMAL STATINBEHANDLING PÅ PLAQUE-KOMPOSITIONEN HOS PATIENTER MED AKUT MYOKARDIEINFARKT - VURDERET MED OPTICAL COHERENCE TOMOGRAPHY OG INTRAVASKULÆR ULTRALYD (OCT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022604-45,0,0,0 2010-022606-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Fort-de-France,L'Analgésie Péridurale permet une distraction épiphysaire précoce dans le traitement de la Maladie de Blount par fixateur externe spécifique sous couvert du monitorage des pressions des loges musculai...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022606-41,0,0,0 2010-022611-19,3,2011-10-20,2011-10-20,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Xention Limited,"A Phase 2a, multicentre, parallel-group, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of 2 doses of XEN-D0501 in the treatment of idiopathic overactive bladde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022611-19,0,0,0 2010-022615-19,1,2011-06-28,2011-06-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"Pilot, Open-Label, Randomised, Repeated Dose, 4-Way Cross-Over, Clinical Pharmacology Study of Beclomethasone Dipropionate (Clenil® Modulite®) 250 µg HFA PMDI using the Aerochamber Plus™ Spacer Device...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022615-19,0,0,0 2010-022616-39,1,2013-04-15,2013-04-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"RELIGHT - Ranibizumab treatment of diabetic macular oEdema with bimonthLy monItorinG after a pHase of initial Treatment. A UK, 18-month, prospective, open-label, multicenter, single-arm Phase IIIb stu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022616-39,0,0,0 2010-022620-77,5,2017-08-28,2018-08-28,3,0,0,1,0,0,1,0,0,2,0,0,0,0,1,AB Science,"A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination with etoposide, or masitinib in combination with irinoteca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022620-77,1,0,0 2010-022622-32,1,2012-10-22,2012-10-22,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Moberg Derma AB,"An open, multi-centre trial comparing the efficacy and safety of two different treatment regimens of topical MOB015 treatment of distal subungual onychomycosis (DSO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022622-32,0,0,0 2010-022625-15,2,2013-09-19,2013-09-19,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratoires ELERTE,EVALUATION OF THE EFFICACY OF IBUPROFEN WITH CODEINE VERSUS IBUPROFEN IN THE TREATMENT OF FEMOROTIBIAL OSTEOARTHRITIS OF THE KNEE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022625-15,0,0,0 2010-022627-29,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,OSPEDALE POLICLINICO S. MATTEO,Innate immune responses in patients with chronic hepatitis B treated with Sebivo (telbivudine),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022627-29,0,0,0 2010-022629-14,8,2018-06-29,2019-01-17,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A phase II, randomized double-blind study of efficacy and safety of two dose levels of LDE225 in patients with locally advanced or metastatic basal cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022629-14,0,0,0 2010-022629-14,8,2018-06-29,2019-01-17,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A phase II, randomized double-blind study of efficacy and safety of two dose levels of LDE225 in patients with locally advanced or metastatic basal cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022629-14,0,0,0 2010-022629-14,8,2018-06-29,2019-01-17,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis farmacéutica S.A.,"A phase II, randomized double-blind study of efficacy and safety of two dose levels of LDE225 in patients with locally advanced or metastatic basal cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022629-14,0,0,0 2010-022630-92,1,2011-08-31,2011-08-31,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Action Pharma A/S,"An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022630-92,0,0,0 2010-022636-37,7,2015-05-28,2015-05-28,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Amicus Therapeutics, Inc.","A RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF AT1001 AND ENZYME REPLACEMENT THERAPY (ERT) IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS, WHO WERE PREVIOUSLY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022636-37,0,0,0 2010-022636-37,7,2015-05-28,2015-05-28,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"AMICUS THERAPEUTICS, INC","A RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF AT1001 AND ENZYME REPLACEMENT THERAPY (ERT) IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS, WHO WERE PREVIOUSLY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022636-37,0,0,0 2010-022638-96,10,2014-01-06,2014-01-06,6,1,1,0,2,1,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome Studio randomizzato, in doppio ci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022638-96,1,1,0 2010-022638-96,10,2014-01-06,2014-01-06,6,1,1,0,2,1,2,0,0,2,0,0,0,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome Studio randomizzato, in doppio ci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022638-96,1,1,0 2010-022638-96,10,2014-01-06,2014-01-06,6,1,1,0,2,1,2,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome Studio randomizzato, in doppio ci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022638-96,1,1,0 2010-022640-20,1,2017-01-31,2017-01-31,1,0,0,0,0,3,4,0,0,1,0,0,1,0,0,Johanna Laukkarinen,Cortisone treatment for the prevention of postoperative pancreatitis and pancreatitis-induced complications after pancreaticoduodenectomy (Whipple operation).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022640-20,0,0,0 2010-022641-25,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,University Medical Center Utrecht,Maraviroc Abacavir STudy – effect on Endothelial Recovery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022641-25,0,0,0 2010-022644-21,1,2012-04-17,2012-04-17,1,1,0,0,0,0,4,1,0,1,0,0,1,0,0,Plymouth Hospitals NHS Trust,A study to assess the equivalence in efficacy of anesthesia using topical Proxymetacaine 0.5% drops versus sub-conjunctival Lignocaine 2% (without adrenaline) for subsequent Intravitreal Injections of...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022644-21,0,0,0 2010-022645-14,9,2016-06-21,2016-06-24,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of standard of care +/- continuous bevacizumab treatment beyond progression of disease (PD) in patients with advanced no...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022645-14,0,0,0 2010-022646-24,3,2016-05-05,2017-02-11,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AB Science,"A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination with gemcitabine or carboplatin or capecitabine in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022646-24,1,0,0 2010-022647-38,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation",Efficacy and Safety of 3-Week Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated with Bipolar I Disorder (Protocol No. P06107),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022647-38,0,1,1 2010-022648-19,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation","A 26-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed episodes Associated With Bipolar I Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022648-19,0,1,1 2010-022653-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Phase II study of neoadjuvant cisplatin and gemcitabine plus sorafenib for patients with transitional cell carcinoma of the bladder.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022653-41,0,0,0 2010-022655-29,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Erasmus MC,Randomised open label cross-over study into the efficacy of RApamycin in children with Tuberous sclerosis complex with intractable Epilepsy (RATE-trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022655-29,0,0,0 2010-022656-22,13,2015-09-14,2015-09-14,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022656-22,0,0,0 2010-022656-22,13,2015-09-14,2015-09-14,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA","A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022656-22,0,0,0 2010-022656-22,13,2015-09-14,2015-09-14,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer, S.L.U.","A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF PF-00299804 VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER FOLLOWING PROGRESSION AFTER, OR INTOLERANCE TO, AT ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022656-22,0,0,0 2010-022658-18,7,2012-03-14,2012-03-14,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin in type 2 diabetes mellitus patients ≥ 70 years (drug-nai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022658-18,0,0,0 2010-022658-18,7,2012-03-14,2012-03-14,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin in type 2 diabetes mellitus patients ≥ 70 years (drug-nai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022658-18,0,0,0 2010-022660-12,1,2014-12-11,2014-12-11,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Friedrich Schiller University,"A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of Iloprost in the early postoperative period after liver transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022660-12,0,0,0 2010-022673-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Psykiatri Nordväst, Karolinska Universitetssjukhuset Solna",The Dexametasone-CRH-test as a potential predictor of treatment effect in depression: a pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022673-33,0,0,0 2010-022674-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Lilly S.A.,"Estudio en fase 2, abierto, multicéntrico y aleatorizado para evaluar la seguridad y la eficacia de cisplatino y pemetrexed con o sin cixutumumab como tratamiento de primera línea en pacientes con car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022674-14,0,0,0 2010-022677-34,1,2013-12-13,2013-12-13,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Dekan des Fachbereichs Humanmedizin,Influence of high dose vitamin D substitution on humoral immunity and lymphocyte function in patients with type 1 diabetes mellitus or Addison´s disease (ViDDA1),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022677-34,0,0,0 2010-022678-15,1,2011-03-12,2011-03-12,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Dow Pharmaceutical Sciences, Inc.",A Phase 4 Open-Label Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-110 Gel (ACANYA™ Gel) in Subjects with Acne Vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022678-15,0,0,0 2010-022679-71,1,2014-12-31,2014-12-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Clinical Trials Center Aachen, University of Aachen",Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary Resuscitation Xenon und milde therapeutische Hypothermie nach kardiopulmonaler Reanimation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022679-71,0,0,0 2010-022681-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Brno,Ofatumumab Added to Dexamethasone in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022681-27,0,0,0 2010-022682-98,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Julius Center for Health Sciences and Primary Care, UMC Utrecht","Monitoring of influenza-like symptoms among elderly, an observational study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022682-98,0,0,0 2010-022685-27,7,2013-06-03,2013-06-03,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Randomised, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022685-27,0,0,0 2010-022685-27,7,2013-06-03,2013-06-03,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Randomised, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022685-27,0,0,0 2010-022685-27,7,2013-06-03,2013-06-03,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Norway KS,"A Randomised, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022685-27,0,0,0 2010-022685-27,7,2013-06-03,2013-06-03,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A Randomised, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022685-27,0,0,0 2010-022685-27,7,2013-06-03,2013-06-03,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim bv,"A Randomised, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022685-27,0,0,0 2010-022685-27,7,2013-06-03,2013-06-03,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim AB,"A Randomised, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022685-27,0,0,0 2010-022686-10,1,2015-01-31,2015-01-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Dr. W. Schwabe GmbH & Co. KG,"Multi-centre, open-label clinical trial to evaluate the efficacy and safety of Rhodiola rosea extract WS® 1375 in Subjects with Burnout Symptoms",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022686-10,0,0,0 2010-022687-12,1,2016-12-16,2016-12-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Essen,"A Randomized Discontinuation, Blinded, Placebo-Controlled, Phase II Study of Sorafenib in Patients with Chemonaïve Metastatic Uveal Melanoma (Sorafenib Treatment of Metastatic Uveal Melanoma)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022687-12,0,0,0 2010-022689-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FUNDACIÓN GRUPO ESPAÑOL DE INVESTIGACIÓN EN CÁNCER DE MAMA,"Ensayo prospectivo, abierto, no comparativo para determinar la incidencia de náuseas y vómitos inducidos por la quimioterapia (NVIQT) asociada al régimen docetaxel-ciclofosfamida en pacientes con cánc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022689-29,0,0,0 2010-022693-14,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,university medical centre groningen,A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022693-14,0,0,0 2010-022695-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Karolinska Institute, Södersjukhuset AB",Effects on subclinical heartfailure in type 2 diabetic subjects on liraglutide treatment versus glimepiride both in combination with metformin.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022695-31,0,0,0 2010-022699-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Nederlands Kanker Instutuut-Antonie van Leeuwenhoek Ziekenhuis,"Phase II Study of Docetaxel, Oxaliplatin, Capecitabine with Bevacizumab and Trastuzumab in case of human epidermal growth factor receptor 2 (HER2)-positivity in Patients with Locally Advanced or Metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022699-30,0,0,0 2010-022701-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Isala,"Reduction of surgical-site infection in hip and knee arthroplasty: the influence of perioperative mupirocin nasal ointment and chlorhexidine soap in a double-blind, randomized, multicentre, placebo-co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022701-17,0,0,0 2010-022703-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,Local immunotherapy by the synergism of monobenzone and imiquimod cream (MI) for cutanous metastases in stage III-IV melanoma patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022703-22,0,0,0 2010-022705-18,1,2014-11-22,2014-11-22,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Overlæge, dr.med. Claus Zachariae",Behandling af refraktær urticaria med adalimumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022705-18,0,0,0 2010-022706-41,1,2012-10-15,2012-10-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,MENARINI RICERCHE S.P.A.,"Double-blind, randomised, placebo-controlled, parallel group pilot study to evaluate the efficacy and safety of oral administration of Nepadutant in infant colic babies not responder to conventional t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022706-41,0,0,0 2010-022709-16,2,2012-10-09,2012-10-09,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Amicus Therapeutics, Inc.",AN OPEN-LABEL PHASE 2A STUDY TO INVESTIGATE DRUG-DRUG INTERACTIONS BETWEEN AT1001 (MIGALASTAT HYDROCHLORIDE) AND AGALSIDASE IN SUBJECTS WITH FABRY DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022709-16,0,0,0 2010-022710-77,8,2013-11-29,2013-11-29,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Actelion Pharmaceuticals Ltd,"Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of macitentan in patients with ischemic digital ulcers as...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022710-77,0,0,0 2010-022710-77,8,2013-11-29,2013-11-29,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,ACTELION PHARMACEUTICALS LTD.,"Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of macitentan in patients with ischemic digital ulcers as...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022710-77,0,0,0 2010-022713-26,1,2011-05-02,2011-05-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"Localized gastrointestinal stromal tumors (GIST): an exploratory open-label, multicenter, single-arm phase II study to evaluate the efficacy of 2 years of adjuvant nilotinib treatment following at lea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022713-26,0,0,0 2010-022715-19,1,2016-07-27,2016-07-27,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitetssjukhuset Linköping,Inflammation och koagulation vid habituell abort,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022715-19,0,0,0 2010-022716-39,1,,,0,1,0,0,0,1,2,0,0,4,0,0,0,0,1,Dyax Corp.,"A 3-Part Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Subcutaneous Ecallantide in Prepubertal Paediatric Patients Experiencing Acute Attacks of Hereditary Angioedema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022716-39,0,0,0 2010-022718-17,6,2013-05-17,2013-05-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH&Co KG,"A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (inc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022718-17,0,0,0 2010-022718-17,6,2013-05-17,2013-05-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (inc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022718-17,0,0,0 2010-022718-17,6,2013-05-17,2013-05-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma Ellas AE,"A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (inc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022718-17,0,0,0 2010-022718-17,6,2013-05-17,2013-05-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (inc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022718-17,0,0,0 2010-022718-17,6,2013-05-17,2013-05-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (inc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022718-17,0,0,0 2010-022718-17,6,2013-05-17,2013-05-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A phase III double-blind, extension, placebo-controlled parallel group safety and efficacy trial of BI 10773 (10 and 25mg once daily) and sitagliptin (100mg once daily) given for minimum 76 weeks (inc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022718-17,0,0,0 2010-022721-14,2,2011-11-30,2011-11-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, blinded, double-dummy, multi-center, placebo controlled, 3 period, cross-over study to assess the effect of QVA149 (110/50 µg o.d.) on exercise endurance in patients with moderate to sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022721-14,0,0,0 2010-022721-14,2,2011-11-30,2011-11-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmaceutica, S.A.","A randomized, blinded, double-dummy, multi-center, placebo controlled, 3 period, cross-over study to assess the effect of QVA149 (110/50 µg o.d.) on exercise endurance in patients with moderate to sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022721-14,0,0,0 2010-022725-16,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,FRANCISCO JOSE MORALES PONCE,INTRACORONARY ADMINISTRATION OF TENECTEPLASE VERSUS ABCIXIMAB AS ADJUNCTIVE TREATMENT DURING PRIMARY ANGIOPLASTY IN ACUTE MYOCARDIAL INFARCTION OF ANTERIOR LOCATION ADMINISTRACION INTRACORONARIA DE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022725-16,0,0,0 2010-022726-33,9,2015-12-31,2017-06-29,8,1,1,0,0,1,3,0,0,1,1,0,1,0,1,Baxter Innovations GmbH,"BAX 326 (factor IX recombinante): Estudio de continuación sobre la evaluación de seguridad, inmunogenicidad y eficacia hemostática en pacientes tratados previamente portadores de hemofilia B grave (ni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022726-33,0,0,0 2010-022726-33,9,2015-12-31,2017-06-29,8,1,1,0,0,1,3,0,0,1,1,0,1,0,1,Baxalta Innovations GmbH,"BAX 326 (factor IX recombinante): Estudio de continuación sobre la evaluación de seguridad, inmunogenicidad y eficacia hemostática en pacientes tratados previamente portadores de hemofilia B grave (ni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022726-33,0,0,0 2010-022730-91,1,2013-07-29,2013-07-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bracco Imaging S.p.A.,"Characterization of focal liver lesions with Sonovue(R)-enhanced ultrasound imaging: a phase III, intrapatient comparative study versus unenhanced ultrasound imaging using histology or combined imagin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022730-91,0,0,0 2010-022736-37,3,2011-10-07,2011-10-07,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Zambon S.p.A.,"Efficacy, tolerability and safety of Z7202, a once daily Diclofenac Diethylamine (DEA) medicated plaster in comparison with Flector®, a twice daily Diclofenac Hydroxyethylpyrrolidine medicated plaster...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022736-37,0,0,0 2010-022737-28,1,2014-05-09,2014-05-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Leeds Teaching Hospitals NHS Trust,A randomised phase II screening trial with functional imaging and patient reported toxicity sub-studies comparing LApatiNib plus capecitabine versus continued Trastuzumab plus capecitabine after local...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022737-28,0,0,0 2010-022739-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut de Recerca HSCSP,Estudio comparativo de 2 pautas anestésicas en TEC: Repercusión hemodinámica y duración de la convulsión.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022739-13,0,0,0 2010-022742-25,7,2014-03-20,2014-05-21,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Tesaro, Inc.","A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Rec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022742-25,0,0,0 2010-022743-37,6,2014-02-24,2014-02-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Tesaro, Inc.","A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Rec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022743-37,0,0,0 2010-022743-37,6,2014-02-24,2014-02-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"TESARO, INC.","A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Rec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022743-37,0,0,0 2010-022744-21,1,2018-05-08,2018-05-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AB Science,"A 12-week, proof of concept prospective, randomized, double blind, phase 2a study to compare safety and efficacy of masitinib to placebo in the treatment of mood disorders in patients with antidepress...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022744-21,0,0,0 2010-022746-24,10,2014-02-19,2014-02-20,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Tesaro, Inc.","A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy- Induced Nausea and Vomiting (CINV) in Subjects Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022746-24,0,0,0 2010-022746-24,10,2014-02-19,2014-02-20,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"TESARO, INC.","A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy- Induced Nausea and Vomiting (CINV) in Subjects Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022746-24,0,0,0 2010-022749-74,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CAROLINA IBAÑEZ LOPEZ,ANALGESIA POSTOPERATORIA MEDIANTE LA INFUSIÓN DE UN ANESTESICO LOCAL EN EL LECHO QUIRURGICO TRAS MASTECTOMÍA RADICAL MODIFICADA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022749-74,0,0,0 2010-022750-16,1,2015-12-31,2015-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Marjo Renko,Magnesiumsulfaatti-infuusio lasten äkillisen bronkusobstruktion hoidossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022750-16,0,0,0 2010-022754-17,1,2019-02-14,2019-02-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,"Bevacizumab And Combination Chemotherapy in rectal cancer Until Surgery: A Phase II, Multicentre, Open-label, Randomised Study of Neoadjuvant Chemotherapy and Bevacizumab in Patients with MRI defined ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022754-17,0,0,0 2010-022757-42,4,2016-01-14,2016-01-14,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Immodulon Therapeutics Limited,"A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022757-42,0,0,0 2010-022757-42,4,2016-01-14,2016-01-14,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,IMMODULON THERAPEUTICS LTD,"A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022757-42,0,0,0 2010-022758-18,11,2013-07-03,2013-07-16,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022758-18,0,0,0 2010-022758-18,11,2013-07-03,2013-07-16,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022758-18,0,0,0 2010-022759-42,8,2014-10-25,2014-10-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022759-42,0,0,0 2010-022759-42,8,2014-10-25,2014-10-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022759-42,0,0,0 2010-022760-12,14,2019-10-01,2019-10-01,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022760-12,0,0,0 2010-022762-27,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,"Klinisk Farmakologisk Afdeling, Bispebjerg","Studiets formål er, at undersøge hvorvidt v-penicillin og trimethoprim inducerer oxidativt stress i raske frivillige forsøgsdeltagere. En eventuel induktion vurderes ud fra målinger på 8-oxoGuo- og 8-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022762-27,0,0,0 2010-022763-35,1,2013-08-01,2013-08-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Medical University of Graz,"Vitamin D supplementation in chronic heart failure: a randomized, double-blind, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022763-35,0,0,0 2010-022766-27,5,2014-11-19,2014-11-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK","A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF MULTISTEM (PF-05285401) IN SUBJECTS WITH MODERATE TO SEVERE ULCERAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022766-27,0,0,0 2010-022766-27,5,2014-11-19,2014-11-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER LIMITED,"A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF MULTISTEM (PF-05285401) IN SUBJECTS WITH MODERATE TO SEVERE ULCERAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022766-27,0,0,0 2010-022770-13,2,2020-07-15,2020-07-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cancer Trials Ireland,A phase II study of pazopanib in patients with metastatic or unresectable renal cell carcinoma (RCC) who have failed prior sunitinib therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022770-13,0,0,0 2010-022770-13,2,2020-07-15,2020-07-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ICORG- All Ireland Co-operative Oncology Research Group,A phase II study of pazopanib in patients with metastatic or unresectable renal cell carcinoma (RCC) who have failed prior sunitinib therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022770-13,0,0,0 2010-022772-31,1,2014-09-17,2014-09-17,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Psychiatrie und Psychotherapie",Brain Network Dysfunction as a Model for Schizophrenia: Connectivity Alterations using Ketamine and pharmacological Magnetic Resonance Imaging,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022772-31,0,0,0 2010-022775-57,1,2014-04-10,2014-04-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's and St Thomas' NHS Foundation Trust,Effects of Vitamin D supplementation on Vitamin D levels and immune activation in HIV infected individuals on antiretroviral therapy-A pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022775-57,0,0,0 2010-022777-34,7,2012-05-09,2017-09-13,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults with Partial-Onset Seizures (Extension of Study RGB113905).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022777-34,0,0,0 2010-022777-34,7,2012-05-09,2017-09-13,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S. A.","A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults with Partial-Onset Seizures (Extension of Study RGB113905).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022777-34,0,0,0 2010-022780-35,6,2017-03-16,2017-03-19,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"THERAKOS, Inc.",A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX TM for the Treatment of Patients with Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD). Estudio c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022780-35,0,0,0 2010-022780-35,6,2017-03-16,2017-03-19,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,THERAKOS,A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX TM for the Treatment of Patients with Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD). Estudio c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022780-35,0,0,0 2010-022782-99,5,2012-10-17,2012-10-17,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Genentech, Inc.","A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA (CIU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022782-99,1,0,0 2010-022782-99,5,2012-10-17,2012-10-17,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"GENENTECH , INC","A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA (CIU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022782-99,1,0,0 2010-022784-35,2,2012-11-22,2012-11-22,2,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Genentech, Inc.","A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY STUDY OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC IDIOPATHIC URTICARIA (CIU) WHO REMAIN SYMPTOMATIC DESPITE TREATMENT ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022784-35,0,0,0 2010-022785-27,5,2012-06-27,2012-06-27,2,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"GENENTECH , INC","A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, RESPONSE DURATION AND SAFETY OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022785-27,1,0,0 2010-022785-27,5,2012-06-27,2012-06-27,2,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Genentech, Inc.","A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, RESPONSE DURATION AND SAFETY OF XOLAIR (OMALIZUMAB) IN PATIENTS WITH CHRONIC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022785-27,1,0,0 2010-022791-31,1,,,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,University Erlangen-Nuremberg,Contrast sensitivity of patients with normal tension glaucoma by application of Azarga®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022791-31,0,0,0 2010-022792-57,1,2015-01-15,2015-01-15,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE,Effet d’un agoniste du récepteur au GLP1 (Exenatide) sur le contenu en triglycérides intramyocardique chez le patient obèse diabétique.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022792-57,0,0,0 2010-022793-14,1,2015-11-02,2015-11-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,AB Science,"A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate the efficacy and safety of masitinib in combination with 5-fluorouracil (5-FU) or capecitabine, or masitin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022793-14,0,0,0 2010-022794-34,1,2011-07-18,2011-07-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Consumer Health,"A randomized, double-blind, placebo-controlled, multi-center parallel group phase IV study to evaluate the efficacy and safety of Voltaren® Schmerzgel 1.16% gel in subjects with acute neck pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022794-34,0,0,0 2010-022795-31,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Barts and the London NHS Trust,A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours with Poor Prognosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022795-31,0,0,0 2010-022796-62,5,2011-09-02,2011-09-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022796-62,0,0,0 2010-022798-32,6,2011-10-14,2011-11-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Menarini Ricerche S.p.A.,"""Estudio doble ciego, aleatorizado, controlado con placebo y con comparador activo, de grupos paralelos, para evaluar el efecto analgésico de una única administración oral de cuatro diferentes combina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022798-32,0,0,0 2010-022798-32,6,2011-10-14,2011-11-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MENARINI RICERCHE S.P.A.,"""Estudio doble ciego, aleatorizado, controlado con placebo y con comparador activo, de grupos paralelos, para evaluar el efecto analgésico de una única administración oral de cuatro diferentes combina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022798-32,0,0,0 2010-022802-41,4,2013-07-09,2013-07-09,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Orion Corporation Orion Pharma,"SAFETY AND PHARMACOKINETICS OF ODM-201 IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER: OPEN, NON-RANDOMISED, UNCONTROLLED, MULTICENTRE, MULTIPLE DOSE ESCALATION STUDY WITH A RANDOMISED PHASE II E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022802-41,0,0,0 2010-022803-24,4,2015-10-21,2015-10-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Orion Corporation Orion Pharma,"SAFETY AND TOLERABILITY OF ODM-201 IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER: OPEN, NON-RANDOMISED, UNCONTROLLED, MULTICENTRE, EXTENSION STUDY TO STUDY 3104001",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022803-24,0,0,0 2010-022808-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,"A fase II, randomized, Double-Blind, Placebo-Controlled, Multicentre Study for the Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022808-40,0,0,0 2010-022809-18,1,2014-03-04,2014-03-04,1,1,0,0,0,0,4,0,0,1,1,1,1,0,3,Hywel Dda Health Board,"Effectiveness of Glucophage® SR as an adjunct to insulin in improving glycaemic control, without increasing the episodes of hypoglycaemia, in non-overweight patients with type-1 Diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022809-18,0,0,0 2010-022810-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Witten/Herdecke,"MULTICENTER, OPEN-LABEL PHASE II STUDY TO EVALUATE THE EFFICACY OF A 2-CYCLE IMMUNOTHERAPY WITH THE TRI FUNCTIONAL BISPECIFIC ANTIBODY CATUMAXOMAB (ANTI EPCAM X ANTI-CD3) IN ADDITION TO SYSTEMIC CHEMO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022810-26,0,0,0 2010-022812-37,1,2013-09-09,2013-09-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Oxford University Hospitals NHS Trust,A phase 2 trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022812-37,0,0,0 2010-022815-21,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,UNIVERSITA` DI TORINO,Use of metformin in obese adolescent patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022815-21,0,0,0 2010-022816-38,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Department of Anesthesiology & Intensive Care,Preoperative Optimization of the High-Risk Patient undergoing Hip Fracture Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022816-38,0,0,0 2010-022817-24,1,2011-08-05,2011-08-05,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Oxford,"A multi-centre, open-label, clinical, phase 4 trial, following on from a head-to-head comparison study of two H1N1 influenza vaccines in children, to compare firstly, the persistence of antibody again...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022817-24,0,0,0 2010-022818-19,7,2012-11-16,2012-11-16,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Biogen Idec Limited,"A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022818-19,0,0,0 2010-022819-19,1,2011-05-29,2011-05-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,G. Pohl-Boskamp GmbH & Co. KG,"Efficacy, safety and tolerability of two weeks treatment with SIA capsules in acute bronchitis - A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial -",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022819-19,0,0,0 2010-022820-61,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,PHASE CONTRAST MAGNETIC RESONANCE (MR) IMAGING IN MONITORING THE EFFECTS OF TADALAFIL IN PATIENTS WITH OUT-OF-PROPORTION PULMONARY HYPERTENSION AND LEFT VENTRICULAR DYSFUNCTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022820-61,0,0,0 2010-022821-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,Cardiovascular Outcomes of Replacement with Testosterone. Role of testosterone replacement therapy in patients with heart failure.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022821-14,0,0,0 2010-022822-34,1,2012-07-01,2012-07-01,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,"Lipidklinikken, Aalborg Sygehus",Additiv kolesterolsænkende effekt ved kombinationsbehandling med psyllium frøskaller og sojaproteinisolat i tillæg til hjerterigtig kost hos hyperkolesterolæmipatienter,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022822-34,0,0,0 2010-022826-34,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,3,,Randomised trial to investigate possible differences in biological availability and effectiveness between vitamin K solution in oil and vitamin K tablets.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022826-34,0,0,0 2010-022831-12,1,2012-05-30,2012-05-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma S.A.S.,Etude de la valeur prédictive de la réversibilité de l’obstruction bronchique sur l’efficacité d’un traitement d’un mois par indacatérol (Onbrez Breezhaler) 150 µg une fois par jour chez des patients ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022831-12,0,0,0 2010-022835-13,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,UNIVERSITA` DEGLI STUDI DI FIRENZE - DIPARTIMENTO DI PSICOLOGIA,"The Effects of Nicotine withdrawal on Panic-like Response to Breath Holding: A Placebo-Controlled, Double-Blind, Cross-Over Patch Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022835-13,0,0,0 2010-022837-27,4,2017-03-01,2017-03-01,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022837-27,0,0,0 2010-022838-85,9,2016-12-16,2016-12-16,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithkline Research and Development Ltd,"A Phase III randomized, open-label study comparing GSK1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022838-85,0,0,0 2010-022838-85,9,2016-12-16,2016-12-16,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A Phase III randomized, open-label study comparing GSK1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022838-85,0,0,0 2010-022838-85,9,2016-12-16,2016-12-16,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Phase III randomized, open-label study comparing GSK1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022838-85,0,0,0 2010-022840-19,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Universitätsmedizin Mainz,"A monocentric, randomized, placebo-controlled double-blind clinical trial to assess the efficacy of Selenium in Morbus Basedow",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022840-19,0,0,0 2010-022841-93,2,2013-01-28,2013-01-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Double-blind, Active-Controlled Study of the Efficacy and Safety of Flexibly-Dosed BMS-820836 in Patients with Treatment Resistant Major Depression Revised protocol 03(da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022841-93,0,0,0 2010-022842-26,1,2013-01-01,2013-01-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Medical Centre Nijmegen,Autophagy inhibition using hydrochloroquine in breast cancer patients: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022842-26,0,0,0 2010-022843-39,3,2014-04-16,2014-04-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Ltd,Efficacy of oral alitretinoin treatment in patients with palmo-plantar pustulosis (PPP) inadequately responding to standard topical treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022843-39,0,0,0 2010-022844-19,2,2019-09-30,2019-09-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Dijon,Randomized phase III study of a treatment driven by early PET response compared to a treatment not monitored by early PET in patients with Ann Arbor Stage III-IV or high risk IIB Hodgkin lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022844-19,0,0,0 2010-022846-26,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University Hospital of Grenoble,Réversion de l'effet anticoagulant des nouveaux antithrombotiques anti Xa et anti IIa par des médicaments hémostatiques spécifiques ou non spécifiques : étude ex vivo chez le volontaire sain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022846-26,0,0,0 2010-022849-19,1,2011-08-26,2011-08-26,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Professor Jørgen B. Dahl,"""Effekten af Adductor-Kanal-Blokade (AKB) hos patienter efter knæ-artroskopi"" ""The Effect of Adductor-Canal-Blockade (ACB) in Patients After Knee Arthroscopy""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022849-19,0,0,0 2010-022850-18,1,2013-01-31,2013-01-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Nottingham University Hospitals NHS Trust,A Study of the the antiviral activity of Metformin as an anti-Hepatitis C virus agent in patients with chronic Hepatitis C virus infection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022850-18,0,0,0 2010-022854-18,1,2015-09-30,2015-09-30,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,"Dekan des Fachbereichs Medizin der Goethe Universität, represented by the Coordinating Investigator",OPEN LABEL PHASE II STUDY TO EVALUATE THE SAFETY OF STANDARD INDUCTION AND CONSOLIDATION THERAPY IN COMBINATION WITH DASATINIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022854-18,0,0,0 2010-022855-46,3,2020-03-10,2020-03-10,2,1,0,0,0,1,2,0,0,1,1,0,1,0,0,"Dekan des Fachbereichs Medizin der Goethe Universität, represented by the Coordinating Investigator",AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH NILOTINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHILADEL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022855-46,0,0,0 2010-022855-46,3,2020-03-10,2020-03-10,2,1,0,0,0,1,2,0,0,1,1,0,1,0,0,Fundación PETHEMA,AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH NILOTINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHILADEL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022855-46,0,0,0 2010-022855-46,3,2020-03-10,2020-03-10,2,1,0,0,0,1,2,0,0,1,1,0,1,0,0,Azienda ULSS 12 veneziana,AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH NILOTINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHILADEL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022855-46,0,0,0 2010-022857-41,1,2011-04-12,2011-04-12,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare,Effects of a common cold treatment on cognitive function,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022857-41,0,0,0 2010-022858-16,1,2018-04-13,2018-04-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Limoges,EFFECT OF BEVACIZUMAB SUBCONJUNCTIVAL INJECTIONS ON CORNEAL NEWVESSELS INTERET DES INJECTIONS SOUS-CONJONCTIVALES DE BEVACIZUMAB COMME TRAITEMENT DES NEOVAISSEAUX CORNEENS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022858-16,0,0,0 2010-022859-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE,Evaluation de l’arrêt du traitement immunosuppresseur d’entretien après 2 ans dans les glomérulonéphrites lupiques prolifératives,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022859-30,0,0,0 2010-022861-93,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,Laboratoire LABCATAL,Confirmation de l'efficacité et de la tolérance du LBC 45 dans la dermite séborrhéique du cuir chevelu,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022861-93,0,0,0 2010-022863-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital,"Phase IV, randomized and controlled study about efficacy an safety of the use of continuous pressure airway CPAP Bussignac in the immediate postoperative period of patients undergoing lung resection s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022863-36,0,0,0 2010-022864-12,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Medical Faculty, Otto-von-Guericke-University Magdeburg",Effect of Omalizumab (Xolair) on the threshold of degranulation and the composition of intracellular granules in skin mast cells and peripheral basophilic granulocytes before and during omalizumab the...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022864-12,0,0,0 2010-022865-81,2,2012-10-02,2012-10-02,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Ablynx NV,"A phase I/II, multi-center, randomized, double-blind, placebo controlled study, with a single ascending dose part followed by a multiple ascending dose part, evaluating the safety, pharmacokinetics, p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022865-81,0,0,0 2010-022866-28,1,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,0,Hospices Civils de Lyon,VEDROP: Etude de l’absorption de la Vitamine E sous une forme hydrosoluble (pégylée) dans les hypocholestérolémies familiales par retention de chylomicrons,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022866-28,0,0,0 2010-022867-37,7,2013-08-13,2013-08-13,5,1,0,0,2,0,0,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with standard of care in hepatitis C genotype 1 treatmentnaïve patients Studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022867-37,0,0,0 2010-022867-37,7,2013-08-13,2013-08-13,5,1,0,0,2,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with standard of care in hepatitis C genotype 1 treatmentnaïve patients Studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022867-37,0,0,0 2010-022867-37,7,2013-08-13,2013-08-13,5,1,0,0,2,0,0,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A randomized, double-blind, placebo-controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with standard of care in hepatitis C genotype 1 treatmentnaïve patients Studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022867-37,0,0,0 2010-022871-78,1,2012-03-06,2012-03-06,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Medizinische Hochschule Hannover,"A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a Seasonal Influenza Vaccine including H1N1 in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022871-78,0,0,0 2010-022872-30,8,2012-10-25,2012-10-25,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Helsinn Healthcare SA,"A multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022872-30,1,0,0 2010-022873-32,1,2012-07-24,2012-07-24,1,0,0,0,0,0,4,0,0,1,1,1,1,0,1,Analgesic Solutions,"An Enriched Enrollment, Double Blind, Placebo-Controlled, Parallel Group, Randomized Withdrawal Trial to Evaluate the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients with Moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022873-32,0,0,0 2010-022874-15,1,2012-08-29,2012-08-29,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Nottingham,Comparison of 30% nitrous oxide with therapeutic dose nimodipine on cerebral and systemic vascular physiology,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022874-15,0,0,0 2010-022881-28,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,CHU Toulouse,Etude de l'influence sur la récupération motrice du traitement précoce de la spasticité après AVC : comparaison en double aveugle contre placebo Toxine Botulique A versus baclofène.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022881-28,0,0,0 2010-022882-80,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Hospices Civils de Lyon,EXPAND ID. Analyse de la réponse immunitaire à la vaccination anti-grippe chez les sujets âgés de 65 ans et plus.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022882-80,0,0,0 2010-022884-36,3,2015-01-06,2016-01-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Versus Placebo in Anemic Patients With IPSS Low- or Intermediate 1 Risk Myelodysplastic Syndromes Uno studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022884-36,0,0,0 2010-022884-36,3,2015-01-06,2016-01-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Versus Placebo in Anemic Patients With IPSS Low- or Intermediate 1 Risk Myelodysplastic Syndromes Uno studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022884-36,0,0,0 2010-022886-92,1,2014-10-08,2014-10-08,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Nottingham University Hospital NHS Trust,The effect of probiotics on the incidence of spontaneous bacterial peritonitis in patients with cirrhosis and ascites.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022886-92,0,0,0 2010-022890-33,3,,,0,0,0,0,1,1,2,0,0,2,0,0,0,0,0,ASSOCIAZIONE QOL-ONE,Eltrombopag for the treatment of thrombocytopenia due to low- and intermediate risk myelodysplastic syndromes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022890-33,0,0,0 2010-022894-32,1,2015-02-16,2015-02-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Birmingham,"Dexamethasone Reduces Emesis After Major gastrointestinal Surgery (DREAMS trial) - A prospective, double-blind, multicentre, randomised control trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022894-32,0,0,0 2010-022895-30,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Chiesi Farmaceutici S.p.A.,"A 12-week, multicentre, randomised, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster® 100/6 (beclomethasone dipropionate 100 µg plus formoterol 6 µg/a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022895-30,0,0,0 2010-022897-14,3,2014-05-15,2014-09-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Dep. of Cancer Research and Molecular medicine, Norwegian University of Science and Technology",A feasibility study of Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia - the pre-MENAC study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022897-14,0,0,0 2010-022897-14,3,2014-05-15,2014-09-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,St. Olavs University Hospital,A feasibility study of Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia - the pre-MENAC study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022897-14,0,0,0 2010-022897-14,3,2014-05-15,2014-09-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Greater Glasgow Health Board,A feasibility study of Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia - the pre-MENAC study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022897-14,0,0,0 2010-022899-32,1,2011-03-10,2011-03-10,1,1,0,0,0,0,2,1,1,1,0,0,1,0,1,Celerion,"An open label, randomised, single dose, 5 way cross over study to compare the rate and extent of absorption of a 8.75mg Flurbiprofen lozenge with flavour and excipient base variants of a 8.75mg Flurb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022899-32,0,0,0 2010-022901-16,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Gemma Rialp,Estudio multicéntrico sobre el efecto del tratamiento de la alcalosis metabólica con acetazolamida en la duración de la ventilación mecánica.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022901-16,0,0,0 2010-022902-41,15,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,"A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022902-41,0,0,0 2010-022902-41,15,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ROCHE,"A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022902-41,0,0,0 2010-022905-17,9,2015-07-10,2015-12-28,7,1,0,0,2,0,3,0,0,1,0,0,1,0,1,GW Pharma Ltd.,"A two-part, placebo-controlled, study of the safety and efficacy of Sativex oromucosal spray (Sativex; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022905-17,0,0,0 2010-022905-17,9,2015-07-10,2015-12-28,7,1,0,0,2,0,3,0,0,1,0,0,1,0,1,GW PHARMA LTD,"A two-part, placebo-controlled, study of the safety and efficacy of Sativex oromucosal spray (Sativex; Nabiximols) as adjunctive therapy in relieving uncontrolled persistent chronic pain in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022905-17,0,0,0 2010-022909-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospital General de L’Hospitalet,Ensayo clínico Fase II para evaluar la eficacia y seguridad de la aplicación de Células Progenitoras de Médula Ósea Autóloga expandidas en el tratamiento quirúrgico de pseudoartrosis no hipertróficas ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022909-18,0,0,0 2010-022911-20,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Dow Pharmaceutical Sciences,"A Multi-Center, Phase 3, Randomized, Double-Blind, 4-Arm Clinical Trial to Compare the Safety and Efficacy of Clin-RA Gel vs. Clindamycin Phosphate 1.2% Gel vs. Tretinoin 0.025% Gel vs. Clin-RA Gel Ve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022911-20,0,1,1 2010-022912-37,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Medicis Pharmaceutical Corporation,"Multi-centre, open-label, long-term safety trial to assess the long-term safety of tretinoin clindamycin phosphate gel in patients from 12 to less than 18 years of age with acne vulgaris.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022912-37,0,1,1 2010-022912-37,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Dow Pharmaceutical Sciences,"Multi-centre, open-label, long-term safety trial to assess the long-term safety of tretinoin clindamycin phosphate gel in patients from 12 to less than 18 years of age with acne vulgaris.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022912-37,0,1,1 2010-022913-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,"A prospective randomised open label study to determine the best dose escalation sceme of dipyridamol added to acetylsalicylic acid, based on the side-effect headache, in patients starting secondary pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022913-25,0,0,0 2010-022914-15,6,2015-01-07,2015-01-13,5,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 4, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO -CONTROLLED, MULTICENTER STUDY EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF 12 WEEKS VARENICLINE TARTRATE 1MG BID AND BUPROPION HYDROC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022914-15,0,0,0 2010-022914-15,6,2015-01-07,2015-01-13,5,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017 US","A PHASE 4, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO -CONTROLLED, MULTICENTER STUDY EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF 12 WEEKS VARENICLINE TARTRATE 1MG BID AND BUPROPION HYDROC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022914-15,0,0,0 2010-022914-15,6,2015-01-07,2015-01-13,5,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"Pfizer, S.L.U.","A PHASE 4, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO -CONTROLLED, MULTICENTER STUDY EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF 12 WEEKS VARENICLINE TARTRATE 1MG BID AND BUPROPION HYDROC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022914-15,0,0,0 2010-022915-21,2,2011-07-25,2011-07-25,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Orion Corporation,"Duration of motor response after administration of experimental levodopa/carbidopa/entacapone treatment regimens compared to standard treatment (Stalevo®); a randomised, double-blind, crossover, multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022915-21,0,0,0 2010-022918-15,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Dow Pharmaceutical Sciences,"Multi-centre, randomized, double-blind, active- and vehicle-controlled trial to compare the efficacy and safety of tretinoin clindamycin phosphate gel to clindamycin phosphate gel alone, tretinoin gel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022918-15,0,1,1 2010-022919-20,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Dow Pharmaceutical Sciences,"Multi-centre, randomized, double-blind trial to compare the efficacy and safety of tretinoin clindamycin phosphate gel to clindamycin phosphate gel alone in the treatment of acne vulgaris in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022919-20,0,1,1 2010-022919-20,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Medicis Pharmaceutical Corporation,"Multi-centre, randomized, double-blind trial to compare the efficacy and safety of tretinoin clindamycin phosphate gel to clindamycin phosphate gel alone in the treatment of acne vulgaris in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022919-20,0,1,1 2010-022921-13,7,2012-08-10,2012-08-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Auxilium UK Limited,"A PHASE 3, OPEN-LABEL STUDY OF THE SAFETY AND EFFECTIVENESS OF AA4500 ADMINISTERED TWICE PER TREATMENT CYCLE FOR UP TO FOUR TREATMENT CYCLES (2 x 4) IN MEN WITH PEYRONIE?S DISEASE Estudio en fase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022921-13,0,0,0 2010-022921-13,7,2012-08-10,2012-08-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AUXILIUM UK LIMITED,"A PHASE 3, OPEN-LABEL STUDY OF THE SAFETY AND EFFECTIVENESS OF AA4500 ADMINISTERED TWICE PER TREATMENT CYCLE FOR UP TO FOUR TREATMENT CYCLES (2 x 4) IN MEN WITH PEYRONIE?S DISEASE Estudio en fase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022921-13,0,0,0 2010-022922-34,2,2012-09-21,2012-09-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Orion Corporation,"Safety and efficacy of ORM-12741 on cognitive and behavioural symptoms in patients with Alzheimer’s disease: A randomised, double-blind, placebo-controlled, parallel group, multicentre study of 12 wee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022922-34,0,0,0 2010-022922-34,2,2012-09-21,2012-09-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Orion Corporation Orion Pharma,"Safety and efficacy of ORM-12741 on cognitive and behavioural symptoms in patients with Alzheimer’s disease: A randomised, double-blind, placebo-controlled, parallel group, multicentre study of 12 wee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022922-34,0,0,0 2010-022923-31,3,2015-11-08,2015-11-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical University Innsbruck / Department for General and Surgical Intensive Care Medicine,"A multicenter double-blind, placebo controlled, randomized, pilot trial to assess the efficacy of pre-hospital administration of Fibrinogen Concentrate (FGTW) in trauma patients, presumed to bleed (FI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022923-31,0,0,0 2010-022923-31,3,2015-11-08,2015-11-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Innsbruck / Univ.-Klinik für Allgem. u. Chirurg. Intensivmedizin,"A multicenter double-blind, placebo controlled, randomized, pilot trial to assess the efficacy of pre-hospital administration of Fibrinogen Concentrate (FGTW) in trauma patients, presumed to bleed (FI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022923-31,0,0,0 2010-022924-57,2,2020-07-01,2021-01-31,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden",Randomised phase II study with cetuximab (Erbitux®) in combination with 5-FU and cisplatin or carboplatin versus CETuximab (Erbitux®) in combination with paclitaxel and carboplatin for treatment of pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022924-57,0,0,0 2010-022924-57,2,2020-07-01,2021-01-31,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Radiumhemmet Karolinska University Hospital,Randomised phase II study with cetuximab (Erbitux®) in combination with 5-FU and cisplatin or carboplatin versus CETuximab (Erbitux®) in combination with paclitaxel and carboplatin for treatment of pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022924-57,0,0,0 2010-022924-57,2,2020-07-01,2021-01-31,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Radiumhemmet,Randomised phase II study with cetuximab (Erbitux®) in combination with 5-FU and cisplatin or carboplatin versus CETuximab (Erbitux®) in combination with paclitaxel and carboplatin for treatment of pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022924-57,0,0,0 2010-022927-31,1,2017-04-16,2017-04-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Grupo Español de Cáncer de Pulmón,Ensayo clínico fase II aleatorizado de vinorelbina oral y cisplatino como tratamiento de inducción y después con radioterapia concomitante frente a cisplatino y etopósido con radioterapia concomitante...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022927-31,0,0,0 2010-022938-85,1,2016-03-01,2016-03-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,AIO-Studien-gGmbH,Comparison of two preemptive treatment strategies of panitumumab mediated skin toxicity and assessment of quality of life in patients with Ras-wildtype colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022938-85,0,0,0 2010-022939-11,3,2014-01-14,2014-01-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pharmacyclics, Incorporated","Multicenter phase 2 study of Bruton’s tyrosine kinase (Btk) inhibitor, PCI-32765, in relapsed or refractory mantle cell lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022939-11,0,0,0 2010-022941-72,4,2012-10-08,2012-10-08,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Astellas Pharma Europe Ltd.,"A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN STABLE HEART TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF® BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT EVE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022941-72,0,0,0 2010-022945-52,1,,,0,1,1,0,0,1,1,0,0,4,0,0,0,0,0,Children’s Oncology Group,A Phase 1 Study of BMS-354825 (Dasatinib) in Children with Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022945-52,0,1,1 2010-022946-25,1,,,0,1,1,0,0,1,3,0,0,4,0,0,0,0,0,Children's Oncology Group,"Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib: IND# 73969, NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022946-25,0,1,1 2010-022947-39,1,2012-06-13,2012-06-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Randomized, Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Safety, Tolerability and Effect on Atrial Fibrillation Burden of BMS-914392 in Patients with Paroxysmal Atrial Fibri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022947-39,0,0,0 2010-022948-21,2,2013-04-08,2013-04-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.",Efficacy and Safety of Adding the Brinzolamide/Timolol Maleate Fixed Combination (Azarga®) in Ocular Hypertensive or Glaucoma Patients Uncontrolled on Prostaglandin Monotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022948-21,0,0,0 2010-022949-17,10,2020-12-17,2020-12-17,4,1,0,0,0,2,3,0,0,2,0,0,0,0,0,Mario Negri Gynecology Oncology Group - MaNGO,"A Phase III international, randomized study with Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022949-17,1,0,0 2010-022949-17,10,2020-12-17,2020-12-17,4,1,0,0,0,2,3,0,0,2,0,0,0,0,0,Mario Negri Gynecologic Oncology Group,"A Phase III international, randomized study with Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022949-17,1,0,0 2010-022949-17,10,2020-12-17,2020-12-17,4,1,0,0,0,2,3,0,0,2,0,0,0,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"A Phase III international, randomized study with Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022949-17,1,0,0 2010-022950-17,1,2015-05-12,2015-05-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ImmunoGen, Inc",A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine (IMGN901) in Combination with Carboplatin/Etoposide in Patients with Advanced Solid Tumors including Extensive Stage Smal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022950-17,0,0,0 2010-022951-49,4,2016-08-11,2016-11-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefractory ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022951-49,0,0,0 2010-022952-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA` DI NOVARA,N-Acetytilcysteine Versus placebo for the prevention of Acute Reduction in Renal function after primary Angioplasty (NoVARA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022952-22,0,0,0 2010-022955-43,2,2012-04-04,2012-04-04,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, UK",OPEN LABEL EUROPEAN STUDY TO SUPPORT THE EARLY IDENTIFICATION OF PATIENTS WITH CHRONIC NEUROPATHIC LOW BACK PAIN IN PRIMARY CARE AND TO ASSESS THE EFFECTIVENESS AND TOLERABILITY OF PREGABALIN IN THIS ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022955-43,0,0,0 2010-022960-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ChronTech Pharma AB,"A Phase II Open-Label, Randomized, Parallel group, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C in Combination with Electroporation followed by Standard of Care in Chronic H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022960-10,0,0,0 2010-022965-82,8,2012-09-24,2012-09-24,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Santen Oy,"A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to tho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022965-82,0,0,0 2010-022965-82,8,2012-09-24,2012-09-24,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANTEN OY,"A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to tho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022965-82,0,0,0 2010-022967-37,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,ISTITUTO EUROPEO DI ONCOLOGIA,Bowel cleansing for colonoscopy: comparison between a same day low-volume preparation and a conventional split one. Pulizia intestinale per colonscopia: confronto tra una preparazione a volume rido...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022967-37,0,0,0 2010-022968-13,2,2012-08-25,2012-08-25,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PharmaMar S.A. Sociedad Unipersonal,"""Estudio clínico de fase II, multicéntrico, abierto de trabectedina (Yondelis®) en pacientes con cáncer de mama avanzado, HER2 negativo, positivo para receptores hormonales, con sobreexpresión o subex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022968-13,0,0,0 2010-022968-13,2,2012-08-25,2012-08-25,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pharma Mar, S.A. Sociedad Unipersonal","""Estudio clínico de fase II, multicéntrico, abierto de trabectedina (Yondelis®) en pacientes con cáncer de mama avanzado, HER2 negativo, positivo para receptores hormonales, con sobreexpresión o subex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022968-13,0,0,0 2010-022969-95,9,2013-12-02,2014-02-06,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Actelion Pharmaceuticals Ltd,"Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel group study to assess the efficacy, safety and tolerability of macitentan in patients with ischemic digital ulcers asso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022969-95,0,0,0 2010-022970-14,18,2018-12-11,2019-04-14,17,1,0,0,2,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022970-14,0,0,0 2010-022970-14,18,2018-12-11,2019-04-14,17,1,0,0,2,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022970-14,0,0,0 2010-022970-14,18,2018-12-11,2019-04-14,17,1,0,0,2,0,3,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022970-14,0,0,0 2010-022971-79,3,2012-03-27,2012-03-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Helsinn Healthcare SA,"A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondanset...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022971-79,0,0,0 2010-022975-67,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA U.L.S.S. N.8 DI ASOLO,68Ga-DOTANOC as a PET tool to diagnose nueroendocrine tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022975-67,0,0,0 2010-022976-29,2,2012-03-07,2012-03-07,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Flexion Therapeutics, Inc.","A Double-Blind, Randomised, Placebo-Controlled, Two-Phase Study (a Single Ascending Dose Phase Followed by a Proof of Concept Phase) to Assess the Safety, Efficacy and Pharmacokinetics of FX005 (50:50...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022976-29,0,0,0 2010-022978-14,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",PHASE 1B OPEN-LABEL STUDY OF THE SAFETY AND CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066) IN TUMORS WITH GENETIC EVENTS INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK ) GENE LOCUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022978-14,0,0,0 2010-022980-37,1,2012-08-20,2012-08-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,A prospective comparator controlled randomized exploratory study on the efficacy of LAS 41005 compared to cryotherapy in subjects with hyperkeratotic actinic keratosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022980-37,0,0,0 2010-022983-11,6,2013-12-19,2013-12-19,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomized, multicenter, open-label phase II study of RO5083945 in combination with FOLFIRI versus FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with KRAS wild-type...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022983-11,0,0,0 2010-022983-11,6,2013-12-19,2013-12-19,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F.Hoffmann-La Roche Ltd.,"A randomized, multicenter, open-label phase II study of RO5083945 in combination with FOLFIRI versus FOLFIRI plus cetuximab or FOLFIRI alone as second line treatment in patients with KRAS wild-type...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022983-11,0,0,0 2010-022984-36,7,2012-05-03,2012-05-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Santen Oy,"A phase III, randomized, double-masked 6-month clinical study to compare the efficacy and safety of the preservative-free fixed dose combination of tafluprost 0.0015% and timolol 0.5% eye drops to tho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022984-36,0,0,0 2010-022987-11,1,2016-09-15,2016-09-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Fédération Francophone de Cancérologie Digestive (FFCD),PHARMACOGENETIQUE DE LA GEMCITABINE : ETUDE DE L’IMPACT DU POLYMORPHISME GENETIQUE DE LA CYTIDINE DEAMINASE (CDA) SUR LA TOXICITE ET L’EFFICACITE THERAPEUTIQUE DANS LES ADENOCARCINOMES PANCREATIQUES R...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022987-11,0,0,0 2010-022988-35,1,2015-07-31,2015-07-31,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Fundación para la Investigación Biomédica del Hospital Gregorio Marañón,TRATAMIENTO DE LA CISTITIS HEMORRÁGICA SEVERA POST-TRASPLANTE ALOGÉNICO CON CÉLULAS MESENQUIMALES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022988-35,0,0,0 2010-022991-29,5,2011-11-18,2011-11-18,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Sucampo Pharma Americas, Inc.","A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of Lubiprostone in Patients with Opioid-induced Bowel Dysfunction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022991-29,0,0,0 2010-022994-32,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,UMC Utrecht,Effect of N-acetylcysteine on hydrogen sulfide in chronic kidney disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022994-32,0,0,0 2010-022996-79,1,2013-10-14,2013-10-14,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,"On demand versus daily sildenafil for patients undergoing bilateral nerve sparing radical prostatectomy: a randomized, open label, parallel group trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022996-79,0,0,0 2010-022998-33,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundació Clínic recerca Biomèdica,Evaluación de la utilidad de la indometacina como tratamiento de soporte en mujeres con amenaza de parto pretérmino y alto riesgo de inflamación intraamniótica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022998-33,0,0,0 2010-023001-36,7,2014-05-28,2014-05-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer Health Care AG,"Multicenter, open-label study to evaluate the safety and efficacy (by blinded reading) of contrast-enhanced magnetic resonance angiography (MRA) after a single intravenous injection of 0.1 mmol/kg gad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023001-36,0,0,0 2010-023001-36,7,2014-05-28,2014-05-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Multicenter, open-label study to evaluate the safety and efficacy (by blinded reading) of contrast-enhanced magnetic resonance angiography (MRA) after a single intravenous injection of 0.1 mmol/kg gad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023001-36,0,0,0 2010-023002-13,3,2012-07-12,2012-07-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Multicenter, open-label study to evaluate the safety and efficacy (by blinded reading) of Gadobutrol-enhanced magnetic resonance angiography (MRA) after a single injection of 0.1 mmol/kg of Gadobutrol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023002-13,0,0,0 2010-023003-96,1,2013-12-17,2013-12-17,1,1,1,0,0,0,1,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Open-label, multicenter, pharmacokinetic, and safety study in children (term newborn infants to 23 months of age) undergoing a contrast-enhanced MRI with an intravenous injection of 0.1 mmol/kg BW gad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023003-96,0,0,0 2010-023006-12,1,2017-12-01,2017-12-01,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Professor Krzysztof Tadeusz Drzewiecki,"Lipofilling with MSC enriched fat, a permanent autologous filler?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023006-12,0,0,0 2010-023007-10,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Uppsala university,"A neuroscience perspective on anxiety proneness - Sex differences, monoaminergic pathways and treatment response",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023007-10,0,0,0 2010-023008-29,1,2014-06-26,2014-06-26,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Fundación Huésped,"Estudio Fase 3, Aleatorizado, Abierto, Controlado de Lopinavir/Ritonavir y Lamivudina versus terapia estándar en Pacientes Infectados con HIV-1 Naïve.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023008-29,0,0,0 2010-023015-33,6,2018-01-18,2018-01-23,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development LtdŒÚ°,MEK114375: A Rollover Study to Provide Continued Treatment with GSK1120212 to Subjects with Solid Tumors and Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023015-33,0,0,0 2010-023017-65,10,2014-08-29,2014-10-29,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, CLINICAL ACTIVITY AND PHARMACOKINETICS OF BOSUTINIB (PF-05208763) VERSUS PLACEBO IN SUBJECTS WITH AUTOSOMAL DO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023017-65,0,0,0 2010-023017-65,10,2014-08-29,2014-10-29,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,PFIZER INC.,"A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, CLINICAL ACTIVITY AND PHARMACOKINETICS OF BOSUTINIB (PF-05208763) VERSUS PLACEBO IN SUBJECTS WITH AUTOSOMAL DO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023017-65,0,0,0 2010-023017-65,10,2014-08-29,2014-10-29,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Inc.,"A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, CLINICAL ACTIVITY AND PHARMACOKINETICS OF BOSUTINIB (PF-05208763) VERSUS PLACEBO IN SUBJECTS WITH AUTOSOMAL DO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023017-65,0,0,0 2010-023017-65,10,2014-08-29,2014-10-29,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"PFIZER, S.L.U.","A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, CLINICAL ACTIVITY AND PHARMACOKINETICS OF BOSUTINIB (PF-05208763) VERSUS PLACEBO IN SUBJECTS WITH AUTOSOMAL DO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023017-65,0,0,0 2010-023020-24,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Helsinki University Central Hospital,Dexmedetomidin compared with placebo in sedation during radiofrequency catheter ablation of atrial fibrillation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023020-24,0,0,0 2010-023021-38,1,2015-04-30,2015-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Västerbottens läns landsting,Switch To RItuXimab in MS A phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy approach,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023021-38,0,0,0 2010-023022-20,2,2013-11-06,2013-11-06,2,1,0,1,0,0,1,0,0,1,1,0,0,0,0,Universitätsklinikum Ulm,"A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agents ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023022-20,0,0,0 2010-023023-19,2,2015-09-01,2015-09-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farma S.p.A.,"A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta-1b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023023-19,0,0,0 2010-023023-19,2,2015-09-01,2015-09-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta-1b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023023-19,0,0,0 2010-023025-37,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Heart Center co.,Oksikodoni-naloksoni kombinaation käyttö sydänleikkauspotilaiden postoperatiivisen kivun hoidossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023025-37,0,0,0 2010-023029-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Plerixafor MM02 - Plerixafor plus G-CSF after chemotherapy for the mobilization of Peripheral Blood Stem Cells (PBSCs) in Multiple Myeloma (MM) patients undergoing Autologous Stem Cell Transplantatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023029-39,0,0,0 2010-023030-23,1,2012-12-30,2012-12-30,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,The Univeristy of Nottingham,Circadian Rhythm In Tobramycin Elimination in Cystic Fibrosis (CRITIC) - a Randomised Pharmacokinetic Comparison of Tobramycin in CF,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023030-23,0,0,0 2010-023032-17,9,2012-07-27,2012-07-27,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023032-17,0,0,0 2010-023032-17,9,2012-07-27,2012-07-27,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"An open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023032-17,0,0,0 2010-023034-23,11,2014-04-03,2015-02-26,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04236921 IN SUBJECTS WITH CROHN’S DISEASE WHO ARE ANTI-TNF INADEQUATE RESPONDERS (ANDANTE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023034-23,0,0,0 2010-023034-23,11,2014-04-03,2015-02-26,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04236921 IN SUBJECTS WITH CROHN’S DISEASE WHO ARE ANTI-TNF INADEQUATE RESPONDERS (ANDANTE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023034-23,0,0,0 2010-023034-23,11,2014-04-03,2015-02-26,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER INC.,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04236921 IN SUBJECTS WITH CROHN’S DISEASE WHO ARE ANTI-TNF INADEQUATE RESPONDERS (ANDANTE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023034-23,0,0,0 2010-023035-42,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNICANCER,Randomized phase III study evaluating hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023035-42,0,0,0 2010-023035-42,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Unicancer,Randomized phase III study evaluating hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023035-42,0,0,0 2010-023037-35,1,2012-07-25,2012-07-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,York Teaching Hospital NHS Foundation Trust,Short-term intraocular pressure trends in high risk patients following intravitreal Ranibizumab (Lucentis) injections for Wet Age Related Macular Degeneration - Is there a role for systemic Acetazolam...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023037-35,0,0,0 2010-023038-22,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar),Eficacia del hierro intravenoso carboximaltosa para la mejoría de la anemia postoperatoria en pacientes de prótesis de rodilla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023038-22,0,0,0 2010-023040-32,2,2013-02-28,2013-02-28,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,Celgene Corporation,"A phase IV, Open-Label, Single-Arm ROLLOVER STUDY FOR SUBJECTS WHO PARTICIPATED IN OTHER ROMIDEPSIN PROTOCOLS. Estudio de extensión de fase IV, abierto, de un solo brazo para pacientes que hayan part...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023040-32,0,0,0 2010-023043-15,3,2014-02-13,2014-02-13,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"Prospective, double-blind, placebo-controlled, randomized, multi-center study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of post-stroke spast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023043-15,0,0,0 2010-023044-32,1,2014-03-31,2014-03-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Charité Universitaetsmedizin Berlin,Mechanisms of action in exposure therapy: Decoding the neural basis of fear extinction and its pharmacological modulation in patients with panic disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023044-32,0,0,0 2010-023047-15,5,2016-11-03,2016-11-03,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Celgene Corporation,"A Phase 2 Proof-of-Concept, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-40...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023047-15,0,0,0 2010-023047-15,5,2016-11-03,2016-11-03,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,CELGENE CORPORATION,"A Phase 2 Proof-of-Concept, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-40...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023047-15,0,0,0 2010-023048-34,2,2014-02-17,2014-02-17,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"NEUROTEC PHARMA, S.L",A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of low doses of oral Diazoxide for the treatment of Multiple Sclerosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023048-34,1,0,0 2010-023050-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Martin-Luther-Universität Halle-Wittenberg,"A multicenter, randomized, phase II trial: BIBF 1120 vs. placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023050-37,0,0,0 2010-023057-11,1,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,"J. Uriach y Compañía, S.A.",Efficacy and safety of rupatadine solution in the treatment of Chronic Spontaneous Urticaria (CSU) in paediatric patients (2-11 years old).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023057-11,0,0,0 2010-023058-35,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,UZ BRUSSEL,A Two-Stage Phase II Study of Autologous TriMix-DC Therapeutic Vaccine in Combination with Ipilimumab in Patients with Previously Treated Unresectable Stage III or IV Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023058-35,0,0,0 2010-023061-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ramón Cañete Estrada,"ensayo clínico sobre efectos de la metformina en la obesidad pediátrica: efectos en el peso corporal, perfil de biomarcadores inflamatorios y de riesgo cardiovascular, e impacto en factores relacionad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023061-21,0,0,0 2010-023062-40,1,2017-01-30,2017-01-30,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"Medivation, Inc.","A Phase 1/2, First in Human, Single-arm, Open-label Study of Once a Day, Orally Administered Talazoparib (BMN 673) in Patients with Advanced or Recurrent Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023062-40,0,0,0 2010-023066-52,11,2017-04-24,2017-04-27,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An Open Label, Multicenter Study Investigating the Safety and Efficacy of Ofatumumab Therapy versus Physicians` Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukaemia (C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023066-52,0,0,0 2010-023066-52,11,2017-04-24,2017-04-27,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"An Open Label, Multicenter Study Investigating the Safety and Efficacy of Ofatumumab Therapy versus Physicians` Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukaemia (C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023066-52,0,0,0 2010-023066-52,11,2017-04-24,2017-04-27,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"An Open Label, Multicenter Study Investigating the Safety and Efficacy of Ofatumumab Therapy versus Physicians` Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukaemia (C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023066-52,0,0,0 2010-023069-24,5,2013-04-02,2013-05-16,3,1,0,0,1,1,3,0,0,2,0,0,0,0,1,Novo Nordisk A/S,"A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC 0156 0000 0009 when used for Treatment and Prophylaxis of Bleeding Episodes in Patients with Haemo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023069-24,1,0,0 2010-023069-24,5,2013-04-02,2013-05-16,3,1,0,0,1,1,3,0,0,2,0,0,0,0,1,NOVO NORDISK,"A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC 0156 0000 0009 when used for Treatment and Prophylaxis of Bleeding Episodes in Patients with Haemo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023069-24,1,0,0 2010-023070-40,8,2013-12-02,2013-12-02,4,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Novo Nordisk A/S,"An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 during Surgical Procedures in Patients with Haemophilia B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023070-40,1,0,0 2010-023070-40,8,2013-12-02,2013-12-02,4,1,1,0,0,1,3,0,0,2,1,0,0,0,1,NOVO NORDISK,"An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 during Surgical Procedures in Patients with Haemophilia B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023070-40,1,0,0 2010-023071-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Daniel Podzamczer Palter,cambios en la densitometría mineral ósea en pacientes infectados por VIH. Estudio aleatorizado con ácidos grasos poliinsaturados n-3. changes in bone mineral densitometry HIV-infected patients. Random...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023071-25,0,0,0 2010-023072-17,8,2014-03-31,2014-03-31,4,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Novo Nordisk A/S,Safety and Efficacy of NNC-0156-0000-0009 after Long-Term Exposure in Patients with Haemophilia B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023072-17,1,0,0 2010-023072-17,8,2014-03-31,2014-03-31,4,1,1,0,0,1,3,0,0,2,1,0,0,0,1,NOVO NORDISK,Safety and Efficacy of NNC-0156-0000-0009 after Long-Term Exposure in Patients with Haemophilia B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023072-17,1,0,0 2010-023076-10,1,2015-01-06,2015-01-06,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Geron Corporation,"A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients with Essential Thrombocythemia who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or who Ref...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023076-10,0,0,0 2010-023077-19,1,2013-07-08,2013-07-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Geron Corporation,A Randomized Phase II Study of Imetelstat as Maintenance Therapy after Initial Induction Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023077-19,0,0,0 2010-023081-52,10,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Danish Gynaecological Cancer Group,A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023081-52,0,0,0 2010-023083-40,1,2015-04-14,2015-04-14,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cardiff University,A Phase II study of neoadjuvant chemotherapy given before SCPRT as treatment for patients with MRI-staged operable rectal cancer at high risk of metastatic relapse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023083-40,0,0,0 2010-023086-21,1,2012-05-24,2012-05-24,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD S.N.C.,"An open-label, multicentre study to evaluate the immunogenicity and safety of one dose of a diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (REPEVAX®) followed by 2 doses of a dipht...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023086-21,0,0,0 2010-023090-19,2,2013-11-05,2013-11-05,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,AlgiPharma AS,"A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (OligoG) administered for 28 days in subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023090-19,0,0,0 2010-023091-10,2,2014-11-04,2014-11-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,A 24-week study to evaluate the effect of fluticasone furoate/ vilanterol 100/25 mcg Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler on arterial stiffness compared with placebo a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023091-10,0,0,0 2010-023093-39,3,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,Institut de Recerca Hospital Sant Pau,"Ensayo clínico aleatorizado y doble ciego, controlado con placebo, de esteroides perioperatorios en pacientes adultos de alto riesgo sometidos a cirugía cardiaca con circulación extracorpórea (CEC) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023093-39,0,0,0 2010-023093-39,3,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,Population Health Research Institute (PHRI),"Ensayo clínico aleatorizado y doble ciego, controlado con placebo, de esteroides perioperatorios en pacientes adultos de alto riesgo sometidos a cirugía cardiaca con circulación extracorpórea (CEC) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023093-39,0,0,0 2010-023093-39,3,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE,"Ensayo clínico aleatorizado y doble ciego, controlado con placebo, de esteroides perioperatorios en pacientes adultos de alto riesgo sometidos a cirugía cardiaca con circulación extracorpórea (CEC) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023093-39,0,0,0 2010-023095-31,1,2015-09-01,2015-09-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Humedics GmbH,"Prospektive, randomisierte, kontrollierte, multizentrische Phase III Studie zur schnellen Identifizierung risikoarmer Patienten nach chirurgischer Leberteilresektion durch Anwendung des LiMAx-Tests",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023095-31,0,0,0 2010-023097-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Pharnext,"A Phase II, Randomised, Placebo-Controlled Trial of the Safety, Efficacy, Pharmacodynamics of PTX3003 in Patients with Charcot-Marie-Tooth Disease Type 1A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023097-40,0,0,0 2010-023098-21,6,2012-10-11,2012-10-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023098-21,0,0,0 2010-023099-13,5,2012-04-30,2012-04-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"Eficacia y tolerancia de la suspensión oral V0251 en neuritis vestibular. Estudio aleatorizado, doble ciego y controlado con placebo.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023099-13,0,0,0 2010-023099-13,5,2012-04-30,2012-04-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT -IRPF- PIERRE FABRE INNOVATION,"Eficacia y tolerancia de la suspensión oral V0251 en neuritis vestibular. Estudio aleatorizado, doble ciego y controlado con placebo.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023099-13,0,0,0 2010-023101-35,1,2011-05-03,2011-05-03,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Sequel Pharmaceuticals Inc.,"TUNDRA-AF: A mulTi-center, randomized, doUble-bliNded, placebo-controlled Dose-escalating study of the effects of K201 on the RestorAtion of sinus rhythm in subjects with symptomatic Atrial Fibrilla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023101-35,0,0,0 2010-023103-94,1,2016-01-28,2016-01-28,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Uppsala University,PHASE I/IIa AdCD40L IMMUNOGENE THERAPY FOR MALIGNANT MELANOMA PATIENTS WITH DISSEMINATED DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023103-94,0,0,0 2010-023104-28,2,2013-07-04,2013-07-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Menarini International Operations Luxembourg S.A.,"A multicentre randomised, double blind, active controlled, parallel group comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the treatment of isolated systolic hypertension in elderly patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023104-28,0,0,0 2010-023105-35,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Cantacuzino National Institute of Research and Development for Microbiology and Immunology,"The Study of the Immunogenity and Reactogenity of Trivalent, Purified, Inactivated Influenza Vaccine for Parenteral Administration in Adults, for the 2010-2011 Season, Produced by Cantacuzino National...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023105-35,0,0,0 2010-023107-10,1,2014-04-30,2014-04-30,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"St. Josef-Hospital, Ruhr University, Bochum",The influence of liraglutide on hypoglycaemia counterregulation and pulsatile insulin secretion in type 2 diabetics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023107-10,0,0,0 2010-023110-30,1,2012-12-21,2012-12-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,An exploratory phase III prospective open-label clinical study on monthly OCT monitoring of the effects of Ozurdex for macular oedema related to retinal vascular diseases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023110-30,0,0,0 2010-023111-34,4,2019-08-16,2019-08-16,1,1,1,0,0,1,1,0,0,2,1,0,0,0,1,Oxford BioMedica (UK) Ltd,"A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR422459, Administered to Patients with Stargardt's Macular Degeneration.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023111-34,1,1,0 2010-023111-34,4,2019-08-16,2019-08-16,1,1,1,0,0,1,1,0,0,2,1,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR422459, Administered to Patients with Stargardt's Macular Degeneration.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023111-34,1,1,0 2010-023111-34,4,2019-08-16,2019-08-16,1,1,1,0,0,1,1,0,0,2,1,0,0,0,1,sanofi-aventis recherche et développement,"A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR422459, Administered to Patients with Stargardt's Macular Degeneration.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023111-34,1,1,0 2010-023112-14,7,2012-04-19,2012-04-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & CoKG,"A Phase III, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 µg and 5 µg once...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023112-14,0,0,0 2010-023112-14,7,2012-04-19,2012-04-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A Phase III, randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 µg and 5 µg once...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023112-14,0,0,0 2010-023115-33,1,2019-11-04,2019-11-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Fédération Francophone de Cancérologie Digestive,"Essai évaluant l'efficacité et la tolérance d'une chimiothérapie péri-opératoire par 5FU-Cisplatine-Cetuximab dans les adénocarcinomes de l'estomac et de la jonction oesogastrique. Phase II monobras, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023115-33,0,0,0 2010-023119-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Gregorio Marañón,"Estudio en fase 4, aleatorizado, controlado de eficacia y seguridad del uso de la presión continua de la vía aérea CPAP en el periodo postoperatorio inmediato de los pacientes sometidos a cirugía de r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023119-32,0,0,0 2010-023120-24,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,MAASTRO clinic,"Nitroglycerin's effect on perfusion and hypoxia in human non small cell lung cancer: proof of principle, a phase II trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023120-24,0,0,0 2010-023121-38,1,2012-09-20,2012-09-20,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Intercytex Ltd,A prospective placebo controlled phase II study to evaluate the use of allogeneic fibroblasts for the treatment of skin erosions in recessive dystrophic epidermolysis bulllosa.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023121-38,0,0,0 2010-023122-21,1,2014-05-09,2014-05-09,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,King's College London,Pro-Bono 2- A prospective study of loss of bone mineral density in patients with HIV over time: implications for clinical practice and therapeutic options: Vitamin D sub study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023122-21,0,0,0 2010-023122-21,1,2014-05-09,2014-05-09,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Guy's and St. Thomas' NHS Foundation Trust,Pro-Bono 2- A prospective study of loss of bone mineral density in patients with HIV over time: implications for clinical practice and therapeutic options: Vitamin D sub study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023122-21,0,0,0 2010-023124-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Academisch Ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum,"Chemo-Immunotherapy, gemcitabine with pegylated interferon alpha-2b (Peg-Intron) with and without p53 synthetic long peptide (p53 SLP) vaccine, for patients with platinum resistant ovarian cancer. CHI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023124-24,0,0,0 2010-023125-38,4,2020-02-17,2020-02-17,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Nordic Lymphoma Group,Dose densified chemoimmunotherapy with early CNS prophylaxis in patients less than 65 years with high risk (aaIPI≥2) Diffuse Large B-Cell Lymphoma (NLG-LBC05),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023125-38,1,0,0 2010-023127-23,1,2011-06-16,2011-06-16,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Alvine Pharmaceuticals, Inc.","A Phase 2a, Double-Blind, Placebo Controlled Trial of the Efficacy, Safety and Tolerability of 6-Weeks Treatment With Varying Methods of ALV003 Administration in Patients With Well-Controlled Celiac D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023127-23,0,0,0 2010-023129-39,7,2012-10-29,2012-10-29,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Sangart, Inc.","A multi-center, randomized, double-blind, controlled study to evaluate the safety and efficacy of MP4OX treatment, in addition to standard treatment, in severely injured trauma patients with lactic ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023129-39,1,0,0 2010-023129-39,7,2012-10-29,2012-10-29,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,SANGART,"A multi-center, randomized, double-blind, controlled study to evaluate the safety and efficacy of MP4OX treatment, in addition to standard treatment, in severely injured trauma patients with lactic ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023129-39,1,0,0 2010-023135-42,5,2019-05-03,2019-05-03,1,0,0,0,0,2,2,0,0,2,0,0,0,0,0,Centre Oscar Lambret,INTERNATIONAL RANDOMIZED PHASE II TRIAL OF THE COMBINATION OF VINCRISTINE AND IRINOTECAN WITH OR WITHOUT TEMOZOLOMIDE (VI OR VIT) IN CHILDREN AND ADULTS WITH REFRACTORY OR RELAPSED RHABDOMYOSARCOMA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023135-42,1,0,0 2010-023135-42,5,2019-05-03,2019-05-03,1,0,0,0,0,2,2,0,0,2,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,INTERNATIONAL RANDOMIZED PHASE II TRIAL OF THE COMBINATION OF VINCRISTINE AND IRINOTECAN WITH OR WITHOUT TEMOZOLOMIDE (VI OR VIT) IN CHILDREN AND ADULTS WITH REFRACTORY OR RELAPSED RHABDOMYOSARCOMA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023135-42,1,0,0 2010-023139-40,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Instituto Científico y Tecnológico de Navarra,Estudio fase II con inmunoterapia mediante células dendríticas e Hiltonol en pacientes con tumores sólidos.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023139-40,0,0,0 2010-023150-37,6,2014-02-14,2014-02-14,4,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Amgen Inc,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023150-37,1,1,0 2010-023155-28,1,2016-09-22,2016-09-22,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Ghent University Hospital,Dexmedetomidine pharmacokinetics-pharmacodynamics in mechanically ventilated neonates with single-organ respiratory failure (NEODEX),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023155-28,0,0,0 2010-023156-89,12,2017-04-11,2017-04-11,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP & DOHME CORP.,"A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy. Sperimentazione clinica di Fase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023156-89,0,0,0 2010-023156-89,12,2017-04-11,2017-04-11,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy. Sperimentazione clinica di Fase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023156-89,0,0,0 2010-023156-89,12,2017-04-11,2017-04-11,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp.a subsidiary of Merck & Co., Inc., USA","A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy. Sperimentazione clinica di Fase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023156-89,0,0,0 2010-023156-89,12,2017-04-11,2017-04-11,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co, Inc.","A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy. Sperimentazione clinica di Fase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023156-89,0,0,0 2010-023156-89,12,2017-04-11,2017-04-11,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co, Inc.","A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy. Sperimentazione clinica di Fase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023156-89,0,0,0 2010-023156-89,12,2017-04-11,2017-04-11,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.","A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy. Sperimentazione clinica di Fase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023156-89,0,0,0 2010-023156-89,12,2017-04-11,2017-04-11,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck & Co., Inc.","A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy. Sperimentazione clinica di Fase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023156-89,0,0,0 2010-023156-89,12,2017-04-11,2017-04-11,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc","A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy. Sperimentazione clinica di Fase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023156-89,0,0,0 2010-023156-89,12,2017-04-11,2017-04-11,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy. Sperimentazione clinica di Fase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023156-89,0,0,0 2010-023156-89,12,2017-04-11,2017-04-11,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy. Sperimentazione clinica di Fase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023156-89,0,0,0 2010-023159-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,MANUEL ÁNGEL GÓMEZ RÍOS,EFICACIA DE LA INFUSIÓN CONTINUA DE LEVOBUPIVACAINA EN LA HERIDA QUIRÚRGICA TRAS CESÁREA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023159-27,0,0,0 2010-023161-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Evaluation de la toxine botulinique dans le traitement du trouble salivaire chez le patient atteint de sclérose latérale amyotrophique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023161-21,0,0,0 2010-023167-17,4,,,0,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Boehringer Ingelheim Pharma GmbH & Co. KG,","A randomised, double-blind, double-dummy, placebo-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 22.7, 45.5, and 90.9 µg b....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023167-17,0,0,0 2010-023168-41,4,2011-12-23,2011-12-23,1,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Boehringer Ingelheim Pharma GmbH & Co. KG,","A randomised, double-blind, double-dummy, placebo-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 45.5, 90.9 and 181.8 μg b....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023168-41,1,0,0 2010-023169-23,4,2011-11-11,2011-11-11,1,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, double-dummy, active-controlled, parallel-group study to assess and compare efficacy and safety of an 8-week treatment with BI 54903 at doses of 90.9 181.8 and 363.6 μg b.i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023169-23,1,0,0 2010-023172-12,17,2012-12-10,2013-04-24,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche et development,A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023172-12,0,0,0 2010-023172-12,17,2012-12-10,2013-04-24,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis group,A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023172-12,0,0,0 2010-023175-26,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Leiden University Medical Center,Influence of Tapentadol on endogenous modulation of pain in chronic neuropathic pain patients and healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023175-26,0,0,0 2010-023176-12,1,2012-01-04,2012-01-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Biotech Tools sa,"Clinical efficacy, immunogenicity, clinical tolerability and assessment of safety of gpASIT+TM administered orally, according to two administration schedules, for the prophylaxis of seasonal grass pol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023176-12,0,0,0 2010-023178-37,6,2014-10-28,2014-12-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Ril...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023178-37,0,0,0 2010-023178-37,6,2014-10-28,2014-12-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Inc.,"A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Ril...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023178-37,0,0,0 2010-023179-25,1,,,0,0,0,0,0,1,2,0,1,3,0,0,0,0,0,Aintree University Hospital NHS Foundation Trust,Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023179-25,0,0,0 2010-023179-25,1,,,0,0,0,0,0,1,2,0,1,3,0,0,0,0,0,UNIVERSITY OF LIVERPOOL,Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023179-25,0,0,0 2010-023182-22,1,2011-05-04,2011-05-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Prosidion Ltd,"A Phase 2, Double-Blind, Placebo-Controlled, Randomised, Single Dose, Crossover Study to Investigate the Glucose Lowering of PSN821 in Patients with Type 2 Diabetes (T2DM) after an Ensure Plus challen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023182-22,0,0,0 2010-023183-40,9,2015-02-19,2015-02-19,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A randomized, open-label phase II multicenter study evaluating the efficacy of oral Everolimus alone or in combination with Pasireotide LAR i.m. in advanced progressive pancreatic neuroendocrine tumor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023183-40,0,0,0 2010-023183-40,9,2015-02-19,2015-02-19,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,"A randomized, open-label phase II multicenter study evaluating the efficacy of oral Everolimus alone or in combination with Pasireotide LAR i.m. in advanced progressive pancreatic neuroendocrine tumor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023183-40,0,0,0 2010-023183-40,9,2015-02-19,2015-02-19,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, open-label phase II multicenter study evaluating the efficacy of oral Everolimus alone or in combination with Pasireotide LAR i.m. in advanced progressive pancreatic neuroendocrine tumor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023183-40,0,0,0 2010-023184-18,2,,,0,1,0,0,0,1,3,0,0,1,1,1,0,1,0,Inserm,PRE clinical mutation CARriers from families with DIlated cardiomyopathy and ACE inhibitors (PRECARDIA-INHERITANCE study) Preventive effect of ACE inhibitor (perindopril) on the onset or progression ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023184-18,0,0,0 2010-023185-42,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"Academic Medical Center, Division of Clinical Immunology and Rheumatology","Proof-of-concept double-blind, placebo-controlled, randomized clinical trial with nilotinib in spondyloarthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023185-42,0,0,0 2010-023186-21,3,2013-02-26,2013-02-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023186-21,0,0,0 2010-023189-27,1,2012-11-28,2012-11-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Birmingham,The pharmacogenetics of vitamin D response in tuberculosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023189-27,0,0,0 2010-023192-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,mib Dienstleistungsgesellschaft mbH,EFFECT OF SWITCHING FROM NRTIS TO MARAVIROC ON NRTI-ASSOCIATED MITCHONDRIAL TOXICITY AND IMMUNE ACTIVATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023192-26,0,0,0 2010-023193-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Institut de Recerca de l'Hospital de la Sta Creu i Sant Pau,"""Ensayo clínico aleatorizado, doble ciego, de grupos paralelos, controlado con placebo para la valoración de la eficacia del zoledronato endovenoso para disminución de la resorción periprotésica en pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023193-39,0,0,0 2010-023195-22,1,2019-05-09,2019-05-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Liverpool,"Randomised controlled open-label trial of TPF induction chemotherapy in the surgical management of locally advanced head and neck cancer (T = taxane, P = cisplatin, F = 5-fluorouracil)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023195-22,0,0,0 2010-023195-22,1,2019-05-09,2019-05-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Aintree University Hospitals NHS Foundation Trust,"Randomised controlled open-label trial of TPF induction chemotherapy in the surgical management of locally advanced head and neck cancer (T = taxane, P = cisplatin, F = 5-fluorouracil)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023195-22,0,0,0 2010-023198-21,1,2015-06-25,2015-06-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,The Relative Effectiveness of Pumps Over MDI and Structured Education.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023198-21,0,0,0 2010-023205-35,1,2016-01-06,2016-01-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Vilnius University Hospital Santariskiu Clinics,Study of Rituximab in Addition to Glucocorticoid in Pretreated Elderly or Unfit Patients with Chronic B Lymphocytic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023205-35,0,0,0 2010-023206-12,1,,,0,0,0,0,1,1,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA VINCENZO MONALDI DI NAPOLI,Arterial Hypertension After Successful Aortic Decoarctation: Atenolol vs Enalapril Comparison of Efficacy and Tolerability in Pediatric Age.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023206-12,0,0,0 2010-023207-10,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,hameln rds a.s.,"A multicentre, randomized, open label, parallel group pilot study comparing efficacy and safety of sufentanil transdermal delivery system (TDS) to oral sustained release morphine sulphate in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023207-10,0,0,0 2010-023208-29,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Rheinische Friedrich-Wilhelms-University of Bonn,Effects of Oxytocin on opioide withdrawal symptoms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023208-29,0,0,0 2010-023210-31,5,2013-03-21,2013-03-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ipsen Innovation,"A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNITS O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023210-31,0,0,0 2010-023210-31,5,2013-03-21,2013-03-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,IPSEN INNOVATION,"A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNITS O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023210-31,0,0,0 2010-023211-34,1,2015-01-23,2015-01-23,1,1,0,0,0,0,3,0,0,1,1,1,1,0,3,University Hospitals of Leicester NHS Trust,Randomized Controlled Trial Comparing Intracoronary Administration of Adenosine or Sodium Nitroprusside to Control for Attenuation of Microvascular Obstruction During Primary Percutaneous Coronary Int...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023211-34,0,0,0 2010-023215-34,1,2011-12-02,2011-12-02,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Teva Women`s Health Research,"A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of a 91-day Extended Cycle Oral Contraceptive Regimen, Compared to two 28-day Standard Oral Contraceptive Regimens, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023215-34,0,0,0 2010-023216-14,2,2013-04-23,2013-04-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Hermo Pharma Ltd,"A Phase II, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study of 10 Weeks Treatment with Fluoxetine 20 mg and Computer Software-Based Training in Adult Patients with Amblyopia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023216-14,0,0,0 2010-023217-61,1,2012-07-16,2012-07-16,1,1,0,0,0,1,4,0,0,1,1,1,1,0,0,University College London,"A phase IV, open-label, partial cross-over partial parallel, randomized, multi-centre study to compare the gastrointestinal tolerability of once daily oral deferasirox, when administered before or aft...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023217-61,0,0,0 2010-023218-30,4,2018-02-10,2018-02-10,2,1,0,0,0,0,0,0,0,1,0,0,1,0,0,EORTC,Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023218-30,0,0,0 2010-023218-30,4,2018-02-10,2018-02-10,2,1,0,0,0,0,0,0,0,1,0,0,1,0,0,European Organization for Research and Treatment of Cancer (EORTC),Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023218-30,0,0,0 2010-023219-32,1,2011-11-21,2011-11-21,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GENFIT,A Pilot study to evaluate the Efficacy of GFT505 (80mg) orally administered once daily for 8 weeks on insulin sensitivity and hepatic glucose production using a glucose clamp technique and Safety in p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023219-32,0,0,0 2010-023226-20,1,2011-04-28,2011-04-28,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,KULeuven,Effect of the GLP-1 analogue liraglutide on intragastric pressure and satiation during nutrient drink infusion.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023226-20,0,0,0 2010-023227-26,1,2011-05-02,2011-05-02,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Repha GmbH,"Randomized, prospective double-blinded study to evaluate safety and efficacy of Angocin Anti-Infekt N versus placebo in the prophylaxis of respiratory tract infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023227-26,0,0,0 2010-023228-26,3,2012-01-04,2012-01-09,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,TRANZYME.INC.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023228-26,0,0,0 2010-023228-26,3,2012-01-04,2012-01-09,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Tranzyme, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023228-26,0,0,0 2010-023229-38,6,2012-03-29,2012-03-29,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Tranzyme, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023229-38,1,0,0 2010-023229-38,6,2012-03-29,2012-03-29,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Tranzyme, Inc","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023229-38,1,0,0 2010-023230-22,1,2016-05-04,2016-05-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Velindre NHS Trust,"A phase II trial to assess the safety, immunological activity of Trovax plus Pemetrexed/ Cisplatin in patients with malignant pleural mesothelioma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023230-22,0,0,0 2010-023231-42,4,2012-03-19,2012-03-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study of LY2409021 in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023231-42,0,0,0 2010-023231-42,4,2012-03-19,2012-03-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study of LY2409021 in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023231-42,0,0,0 2010-023231-42,4,2012-03-19,2012-03-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ELI LILLY,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study of LY2409021 in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023231-42,0,0,0 2010-023233-30,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,VU university medical center,‘Intravenous iron treatment in iron deficient patients with pulmonary arterial hypertension',https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023233-30,0,0,0 2010-023235-41,1,2012-06-26,2012-06-26,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,PARI Pharma GmbH,"A comparative, randomised, two period, multi-center, cross-over 14 weeks bioequivalence study of Tobramycin PARI (T100) versus TOBI® (Novartis) in cystic fibrosis patients with bronchopulmonary chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023235-41,0,0,0 2010-023237-37,1,2015-03-31,2015-03-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,GBG Forschungs GmbH (German Breast Group),A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with HER2-positive metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023237-37,0,0,0 2010-023238-22,5,2014-06-23,2014-09-18,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Laboratorios SALVAT, S.A.","A Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of Ciprofloxacin 0.3% plus Fluocinolone Acetonide 0.025% Otic Solution Compared to Ciprofloxacin 0.3% Otic solu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023238-22,0,0,0 2010-023239-40,5,2013-05-29,2013-05-29,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Laboratorios SALVAT, S.A.","A Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of Ciprofloxacin 0.3% plus Fluocinolone Acetonide 0.025% Otic Solution Compared to Ciprofloxacin 0.3% Otic solu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023239-40,0,0,0 2010-023240-33,1,2015-01-07,2015-01-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guys and St Thomas' NHS Foundation Trust,Post-operative pain in children with cerebral palsy following major hip surgery: a double blind randomised placebo controlled trial of pre-operative Botulinum toxin type A. [The Post-Operative Pain in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023240-33,0,0,0 2010-023241-29,3,2014-01-20,2014-02-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Intercept Pharmaceuticals Inc,"A Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Obeticholic Acid (INT-747) for the Treatment of Portal Hypertension (PESTO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023241-29,0,0,0 2010-023242-69,2,2012-08-30,2012-08-30,1,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Octapharma AG,"Clinical Study to Investigate the Long-Term Efficacy, Safety, and Immunogenicity of human-cl rhFVIII in Previously Treated Patients with Severe Haemophilia A – Extension Study to GENA-01",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023242-69,0,0,0 2010-023245-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI,"Treatment with Peg-interferon alfa-2a and ribavirin in patients with hepatitis HCV-related, with or without HIV co-infection, and end stage renal disease on dialysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023245-30,0,0,0 2010-023254-36,1,2015-09-11,2015-09-11,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Brighton and Sussex University Hospitals NHS Trust,Is a short course of azithromycin effective in the treatment of mild to moderate pelvic inflammatory disease (PID)?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023254-36,0,0,0 2010-023258-34,6,2012-04-24,2012-04-25,5,1,0,0,1,0,4,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd.,"Tolerability of QUTENZA(TM) when applied after pre-treatment with lidocaine or tramadol in subjects with peripheral neuropathic pain – A randomized, multi-center, assessor-blinded study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023258-34,0,0,0 2010-023262-46,1,2014-08-14,2014-08-14,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Royal Devon & exeter Foundation trust,A Randomised Prospective Pilot Study Comparing the Outcomes of Patients with Lumbar Nerve Root Pain Secondary to Lumbar Disc Prolapse Treated by Nerve Root Block with or without the Addition of Clonid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023262-46,0,0,0 2010-023263-18,17,2019-02-20,2019-02-20,15,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017 US","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC AND ADULT SUBJECTS WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023263-18,1,0,0 2010-023263-18,17,2019-02-20,2019-02-20,15,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Pfizer Inc.,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC AND ADULT SUBJECTS WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023263-18,1,0,0 2010-023264-40,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA S. GERARDO DI MONZA,Efficacy in the central nervous system (CNS) of two combination regimens with different penetration rank in HIV-positive na�ve patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023264-40,0,0,0 2010-023265-22,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CENTRE LEON BERARD,"A randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy of afatinib (BIBW 2992) in maintenance therapy after postoperative concurrent radiotherapy and chemotherapy for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023265-22,0,0,0 2010-023268-42,1,2011-08-25,2011-08-25,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,McNeil AB,NICOTINE PHARMACODYNAMICS WITH A NEW ORAL NICOTINE REPLACEMENT PRODUCT AND NICOTINE GUM 4 MG. A STUDY IN HEALTHY SMOKERS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023268-42,0,0,0 2010-023271-26,1,2014-02-26,2014-02-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mithra Pharmaceuticals SA,"A randomized, double-blind, multi-centre, placebo controlled phase II clinical study to evaluate the efficacy, tolerance and safety of an aqueous gel containing 2% (w/w) of cidofovir, directly applied...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023271-26,0,0,0 2010-023277-19,1,2015-01-28,2015-01-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Med. Univ. Wien, Univ. Klinik für Dermatologie","CD20-Immunotargeting in Stage IV Melanoma Patients- A Prospective, Open Label, Two-Period Pilot Study to Evaluate Overall Tumor Responsive Rate",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023277-19,0,0,0 2010-023279-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,José Antonio Pérez Simón,Efecto inmunomodulador de la vitamina D postrasplante alogénico: Ensayo clínico fase I-II multicéntrico,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023279-25,0,0,0 2010-023280-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Mercedes Loscertales Abril,Ensayo clínico para demostrar la eficacia de suero isotónico frente a suero hipotónico y relación con los niveles de sodio plasmático durante el postoperatorio de cirugía general en pacientes pediátri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023280-17,0,0,0 2010-023281-47,4,2011-08-29,2011-08-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici SpA,"A phase III, 8-week, multinational, multicentre, randomized, double-blind, triple-dummy, active controlled, 3-arm parallel-group clinical trial to test the efficacy of CHF 1535 (fixed combination of b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023281-47,0,0,0 2010-023293-39,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,"Västra Götalandsregionen, Shalgrenska University Hospital Östra",Tryckkammarbehandling vid besvär från urinblåsan som uppkommit efter strålbehandling mot cancer i bäckenregionen.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023293-39,0,0,0 2010-023297-39,5,2012-09-13,2012-09-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Helsinn Healthcare SA,"A phase III, multicenter, randomized, double-blind, unbalanced (3:1) active control study to assess the safety and describe the efficacy of netupitant and palonosetron for the prevention of chemothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023297-39,0,0,0 2010-023300-27,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,Helsinki University Central Hospital,Ability of the new Vero-cell-derived inactivated Japanese encephalitis vaccine (IXIARO) to elicit a booster response in travellers previously vaccinated with traditional mouse-brain derived vaccine (J...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023300-27,0,0,0 2010-023310-31,3,2015-12-23,2015-12-31,2,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CONSORCIO DE APOYO A LA INVESTIGACION BIOMEDICA EN RED (CAIBER),"Ensayo clínico en fase IV aleatorizado, abierto, multicéntrico y de no inferioridad para comparar la seguridad y la eficacia de colistina iv. con meropenem iv. en el tratamiento de la neumonía asociad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023310-31,0,0,0 2010-023310-31,3,2015-12-23,2015-12-31,2,0,0,0,0,0,4,0,0,1,0,0,1,0,0,FISEVI,"Ensayo clínico en fase IV aleatorizado, abierto, multicéntrico y de no inferioridad para comparar la seguridad y la eficacia de colistina iv. con meropenem iv. en el tratamiento de la neumonía asociad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023310-31,0,0,0 2010-023310-31,3,2015-12-23,2015-12-31,2,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Consorcio de apoyo a la Investigación Biomédica en Red (CAIBER),"Ensayo clínico en fase IV aleatorizado, abierto, multicéntrico y de no inferioridad para comparar la seguridad y la eficacia de colistina iv. con meropenem iv. en el tratamiento de la neumonía asociad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023310-31,0,0,0 2010-023311-34,1,2012-02-05,2012-02-05,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,AOP Orphan Pharmaceuticals AG,"A prospective, randomized, double blinded, crossover, two-treatment, two-sequence, short term pharmacokinetic, pharmacodynamic and tolerability, single centre study to compare AOP200704 vs. Esmolol in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023311-34,0,0,0 2010-023313-57,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Helsinki University Central Hospital,Homing potential of the antigen specific B cell and antibody mediated immune response after vaccination Spesifisten B solujen kotiutumispotentiaali ja vasta-aine vaste rokotetuilla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023313-57,0,0,0 2010-023315-34,1,2012-09-10,2012-09-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma S.A.S.,"Etude ouverte, multicentrique, évaluant l’efficacité et la sécurité d’emploi clinique du Lucentis® (ranibizumab 0,5 mg) chez des patients Diabétiques présentant une atteinte visuelle due à un œdème ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023315-34,0,0,0 2010-023316-13,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Randomized multicenter study on security and efficacy of therapeutic switch to maraviroc + darunavir/ritonavir once daily in patients who are in triple antiretroviral regimen with three drugs belongi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023316-13,0,0,0 2010-023322-21,4,2012-07-13,2012-07-13,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Noscira S.A,"A multicenter, Randomized, Double-blind, Placebo-controlled, 4-arm, 26 week Parallel-Group Study to evaluate the Efficacy, Safety and Tolerability of Two Oral Doses and Two Regimes of Tideglusib vs Pl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023322-21,0,0,0 2010-023324-25,1,2014-04-16,2014-04-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ABCSG (Austrian Breast & Colorectal Cancer Study Group),Multicentre randomized phase II study of neoadjuvant trastuzumab plus docetaxel with and without bevacizumab and trastuzumab plus docetaxel plus non-pegylated liposome-encapsulated doxorubicin (NPLD) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023324-25,0,0,0 2010-023325-37,1,2013-01-01,2013-01-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Imperial College,UMPIRE Trial sub-study - Polypill Effects on Sub Clinical Atherosclerosis (PESCA): A randomised controlled trial of a cardiovascular polypill treatment strategy compared with usual care on carotid int...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023325-37,0,0,0 2010-023326-20,2,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomized, double blind, placebo and active controlled, parallel group study to evaluate the safety and efficacy of 6-week treatment with oral doses of 50 mg b.i.d., 200 mg b.i.d., and 400 mg b.i.d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023326-20,0,0,0 2010-023331-42,1,2013-07-31,2013-07-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Neurology, Odense University Hospital","Oxcarbazepine for the treatment of chronic peripheral neuropathic pain: predictors of response - a randomised, double-blind, placebo-controlled clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023331-42,0,0,0 2010-023335-41,1,2012-02-28,2012-02-28,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Abbott,A Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed Indolent Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023335-41,0,0,0 2010-023342-67,5,2013-09-12,2013-09-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) with E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023342-67,0,0,0 2010-023343-16,10,2014-07-31,2014-07-31,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Celgene Corporation,"Open-label, multi-center, single-arm study for the safety and efficacy of Pomalidomide (CC-4047) monotherapy for subjects with refractory or relapsed and refractory multiple myeloma: a companion study...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023343-16,0,0,0 2010-023345-30,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,U.L.S.S. 9 DI TREVISO,Prospective spontaneous cross-over study on pancreatic T1/T2 enhancement in patients with IPMT: comparison Omniscan-Dotarem,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023345-30,0,0,0 2010-023346-78,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Respiratory and Allergy research unit,Blod and urine concentrations of Procaterol in persons with asthma and elite athletes with asthma: a comparison of inhalation vs. oral administration.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023346-78,0,0,0 2010-023347-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Gastroenterology CHC Liege,Treatment of Crohn’s disease-associated refractory diarrhoea with octreotide LAR An open pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023347-14,0,0,0 2010-023348-33,8,2012-04-20,2012-04-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Nove...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023348-33,0,0,0 2010-023349-32,5,2012-04-05,2012-05-04,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Nove...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023349-32,0,0,0 2010-023349-32,5,2012-04-05,2012-05-04,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Nove...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023349-32,0,0,0 2010-023349-32,5,2012-04-05,2012-05-04,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily via a Nove...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023349-32,0,0,0 2010-023350-37,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,South Warwickshire NHS Foundation Trust,Does intravenous lidocaine reduce opioid requirements after day case gynaecological laparoscopy?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023350-37,0,0,0 2010-023355-29,1,2016-02-09,2016-02-09,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Papworth Hospital NHS Foundation Trust,Tyrosine kinase Inhibitors in DysplAsia of Lung epithelium Study 1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023355-29,0,0,0 2010-023356-90,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,0,Oncology Department,Electrochemotherapy as a palliative treatment for brain metastases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023356-90,0,0,0 2010-023362-44,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institute of oncology Ljubljana,ITAC 2 TRIAL: INTERMITTENT TKI AND CHEMOTHERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023362-44,0,0,0 2010-023366-49,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,"Med. Univ. Wien, Univ. Klinikum für Interne Medizin III",Bosentan for treatment ofhepatopulmonary syndrome in patients with liver cirrhosis - a prospective double blind randomized controlled clinical study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023366-49,0,0,0 2010-023369-23,5,2012-12-04,2012-12-05,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,FIRST-IN-PATIENT STUDY TO ASSESS THE SAFETY AND TOLERABILITY AND TO EXPLORE THE POTENTIAL THERAPEUTIC EFFICACY OF A NOVEL GLUTAMATE MODULATOR AS MONOTHERAPY AND AS ADD-ON THERAPY IN PATIENTS WITH SCHI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023369-23,0,0,0 2010-023375-26,1,2015-12-31,2015-12-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Medizinische Universität Wien, Klinik für Innere Medizin II, Abteilung für Kardiologie","Effects of Sildenafil on Signs and SYmptoms of Ischemia, Myocardial BlooD Flow, and Markers of ANgiogenesis in Patients with REfractory CoronarY Artery Disease (SYDNEY) A Randomized, Double-Blind, Pl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023375-26,0,0,0 2010-023377-19,8,2015-02-11,2015-02-11,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA,A Randomised Open-Label Phase II Study to Assess the Efficacy & Safety of AZD4547 Monotherapy versus Paclitaxel in Patients with Advanced Gastric Adenocarcinoma (inc. Adenocarcinoma of the Lower Third...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023377-19,0,0,0 2010-023377-19,8,2015-02-11,2015-02-11,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca,A Randomised Open-Label Phase II Study to Assess the Efficacy & Safety of AZD4547 Monotherapy versus Paclitaxel in Patients with Advanced Gastric Adenocarcinoma (inc. Adenocarcinoma of the Lower Third...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023377-19,0,0,0 2010-023382-22,4,2012-10-03,2012-10-03,2,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Astellas Pharma Europe B.V. (APEB),"Phase I/II, multi-center, open label study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of ASP9521 in patients with metastatic castrate-resistant pros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023382-22,0,0,0 2010-023383-40,7,2012-03-07,2013-03-07,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ThromboGenics N.V,"Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery: A Phase IIb, Multicentre, Randomised, Active-Controlled, Doub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023383-40,0,0,0 2010-023384-18,2,2014-02-28,2014-02-28,2,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Baxter Innovations GmbH,"Randomized, double-blind, phase I/II clinical study to investigate the safety and immunogenicity of a multivalent recombinant OspA Lyme Borreliosis vaccine (mv rOspA LB Vaccine) in healthy subjects ag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023384-18,0,0,0 2010-023388-16,5,2012-07-19,2012-07-19,3,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Santhera Pharmaceuticals (Switzerland) Limited,"A Phase IIIb Double-Blind, Randomised, Placebo-Controlled Study of Patient Reported Outcomes in Friedreich’s Ataxia Patients after withdrawal from Treatment with Idebenone (PROTI Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023388-16,1,0,0 2010-023393-39,6,2011-12-20,2011-12-20,6,1,1,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD S.N.C,"A Randomized, Double-Blinded, Controlled with GARDASIL (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Tolerabil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023393-39,0,0,0 2010-023393-39,6,2011-12-20,2011-12-20,6,1,1,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD S.N.C.,"A Randomized, Double-Blinded, Controlled with GARDASIL (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Tolerabil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023393-39,0,0,0 2010-023394-19,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Maatschap Cardiologie Isala klinieken,Early Beta blocker Administration before reperfusion in patients with ST-Elevation Myocardial Infarction who are planned to undergo primary PCI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023394-19,0,0,0 2010-023394-19,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Maatschap Cardiologie Isala,Early Beta blocker Administration before reperfusion in patients with ST-Elevation Myocardial Infarction who are planned to undergo primary PCI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023394-19,0,0,0 2010-023395-61,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Isidre Vilacosta,Estudio de la eficacia de los corticoides en la prevención de la fibrilación auricular tras cirugía cardiaca Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023395-61,0,0,0 2010-023396-25,7,2013-10-16,2013-10-16,6,0,0,0,0,1,2,0,0,2,0,0,0,0,1,SuppreMol GmbH,"Ensayo clínico multicéntrico, de grupos paralelos, controlado por placebo, doble ciego, randomizado 2:2:1, de fase IIa, para investigar la seguridad, eficacia y farmacocinética del receptor Fc-gamma I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023396-25,1,0,0 2010-023400-28,1,2013-07-20,2013-07-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi aventis groupe,"ENSAYO CLÍNICO RANDOMIZADO FASE II DE DOCETAXEL-CARBOPLATINO EN COMBINACIÓN CON INIPARIB (BSI-201), Y DOCETAXEL-CARBOPLATINO COMO TRATAMIENTO NEOADYUVANTE DE PACIENTES CON CÁNCER DE MAMA ESTADIO TEMP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023400-28,0,0,0 2010-023406-13,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Städtische Kliniken Neuss, Lukaskrankenhaus GmbH",Target-spezifische Therapie mit Pazopanib zusätzlich zu Vinflunin bei Patienten mit fortgeschrittenem oder metastasiertem Urothelkarzinom nach Versagen einer platinhaltigen Therapie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023406-13,0,0,0 2010-023407-95,12,2018-06-02,2018-06-20,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin's lym...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023407-95,0,0,0 2010-023407-95,12,2018-06-02,2018-06-20,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin's lym...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023407-95,0,0,0 2010-023409-37,2,2018-07-13,2018-07-13,2,1,0,0,0,1,3,0,0,1,0,0,1,0,0,University Hospital Ulm,Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM1 M...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023409-37,0,0,0 2010-023410-31,1,,,0,0,0,0,0,0,2,0,1,4,0,0,0,0,0,CHU DE POITIERS,Simplification du test de sensibilité au sel : étude préalable chez l'enfant et l'adulte,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023410-31,0,0,0 2010-023411-33,1,2013-05-07,2013-05-07,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,ISTITUTO CLINICO HUMANITAS,"A phase II, randomized, double-blind, placebo controlled trial of Sorafenib as adjuvant treatment for hepatocellular carcinoma after TACE-based treatments. Studio di Fase II, randomizzato, in doppi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023411-33,0,0,0 2010-023412-13,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Array BioPharma Inc.,"A Phase II, open-label study to assess the safety and efficacy of oral MEK162 in adults with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600 or NRAS mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023412-13,0,0,0 2010-023412-13,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,NOVARTIS FARMA,"A Phase II, open-label study to assess the safety and efficacy of oral MEK162 in adults with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600 or NRAS mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023412-13,0,0,0 2010-023414-31,1,2016-04-22,2016-04-22,1,1,0,0,0,0,2,0,1,1,0,0,1,0,3,Medizinische Fakultät. Otto von Guericke Universität,Ketamine in treatment resistant major depression (TRD) Ketamine in behandlungsresistenter Depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023414-31,0,0,0 2010-023417-54,1,2012-07-23,2012-07-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Ltd,"A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719 125mcg once-daily alone and in combination with GW642444...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023417-54,0,0,0 2010-023418-29,3,2011-12-13,2011-12-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,HZC113109: A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared with Fluticasone Propionate/Sal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023418-29,0,0,0 2010-023419-33,3,2012-01-24,2012-01-24,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development,HZC112352: A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared with Fluticasone Propionate/Sal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023419-33,0,0,0 2010-023419-33,3,2012-01-24,2012-01-24,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline S.A.,HZC112352: A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared with Fluticasone Propionate/Sal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023419-33,0,0,0 2010-023420-25,1,2017-12-31,2017-12-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Med. Univ. Wien, Univ. Klinik für Innere Medizin III, Abt. Gastroenterologie und Hepatologie",Safety and efficacy of vardenafil in patients with liver cirrhosis. A randomized controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023420-25,0,0,0 2010-023422-20,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo Español de Tumores Neuroendocrinos (GETNE),"Estudio en fase II de everolimus, un inhibidor mTOR (de formulación oral), junto con OcteotrideLAR®, en pacientes adultos con tumores neuroendocrinos gastrointestinales avanzados no funcionales y bien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023422-20,0,0,0 2010-023426-20,1,2012-11-22,2012-11-22,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,GWT-TUD GmbH,"Low dose Urokinase therapy in patients with diabetic foot syndrome, critical limb ischemia as well as rest ischemia or missing of option revascularisation in comparison to the standard therapy - rando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023426-20,0,0,0 2010-023427-18,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,"University Hospital Schleswig-Holstein, Campus Luebeck",Definitive radiochemotherapy with 5-FU / cisplatin plus/minus cetuximab in unresectable locally advanced esophageal cancer: a phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023427-18,0,0,0 2010-023428-26,10,2013-04-26,2016-05-13,2,0,0,0,0,1,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medulla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023428-26,1,0,0 2010-023428-26,10,2013-04-26,2016-05-13,2,0,0,0,0,1,3,0,0,2,0,0,0,0,1,ASTRAZENECA,"A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medulla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023428-26,1,0,0 2010-023428-26,10,2013-04-26,2016-05-13,2,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Genzyme Corporation,"A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medulla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023428-26,1,0,0 2010-023430-23,3,2011-12-19,2011-12-19,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Serono S.A.,"A phase IIIb, open-label, single-arm, multicenter study to assess the immunogenicity of the r-hGH liquid multidose formulation (Saizen solution for injection) when administered to male and female adul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023430-23,0,0,0 2010-023433-35,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Hospices Civils de Lyon,Implication des radicaux libres produits par la xanthine oxydase dans les altérations mitochondriales du muscle squelettique de patients diabétiques,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023433-35,0,0,0 2010-023436-16,2,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,HOVON Foundation,The feasibility and efficacy of subcutaneous Plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: a prospective phase II study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023436-16,0,0,0 2010-023437-30,11,2015-10-09,2015-12-09,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","""Estudio doble ciego, aleatorizado, controlado con placebo, de búsqueda de dosis para evaluar la eficacia y la seguridad de PF-00547659 en sujetos con enfermedad de Crohn que no responden adecuadament...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023437-30,0,0,0 2010-023437-30,11,2015-10-09,2015-12-09,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,PFIZER SLU,"""Estudio doble ciego, aleatorizado, controlado con placebo, de búsqueda de dosis para evaluar la eficacia y la seguridad de PF-00547659 en sujetos con enfermedad de Crohn que no responden adecuadament...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023437-30,0,0,0 2010-023439-41,1,2012-05-03,2012-05-03,1,0,0,0,0,0,4,0,0,1,1,1,1,0,1,Dermal Laboratories,"An emollient gel for the management of atopic dermatitis - an open, uncontrolled study in general practice in children over 2 years, adults and the elderly.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023439-41,0,0,0 2010-023442-75,4,2012-06-14,2012-06-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline,An exercise endurance study to evaluate the effects of treatment of COPD patients with a dual bronchodilator: GSK573719/GW642444,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023442-75,0,0,0 2010-023444-32,3,2012-04-05,2012-07-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline,An exercise endurance study to evaluate the effects of treatment of COPD patients with a dual bronchodilator: GSK573719/GW642444.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023444-32,0,0,0 2010-023446-70,1,2015-03-28,2015-03-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Med. Univ. Wien, Univ. Klinik für Psychiatrie und Psychotherapie","Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023446-70,0,0,0 2010-023452-87,6,2013-09-04,2013-09-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cubist Pharmaceuticals, Inc.","A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE SAFETY AND EFFICACY OF INTRAVENOUS CXA 201 AND INTRAVENOUS LEVOFLOXACIN IN COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023452-87,0,0,0 2010-023453-11,6,2013-05-29,2013-05-29,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Cubist Pharmaceuticals, Inc.","A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE SAFETY AND EFFICACY OF INTRAVENOUS CXA 201 AND INTRAVENOUS LEVOFLOXACIN IN COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023453-11,0,0,0 2010-023455-28,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Maija Kaukonen,Dexmedetomidine pharmacokinetics during continuous venovenous hemofiltration and hemodiafiltration in critically ill patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023455-28,0,0,0 2010-023457-11,1,2012-02-08,2012-02-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UZ Leuven,Immune regulation and timing of chemotherapy in advanced/recurrent ovarian and endometrial cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023457-11,0,0,0 2010-023461-22,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,0,CENTRE LEON BERARD,"Efficacité et tolérance d’emplâtres de lidocaïne à 5% (Versatis® 5%) dans les douleurs neuropathiques et dans les douleurs de crises vaso-occlusives drépanocytaires de l’enfant, de l’adolescent et du ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023461-22,0,0,0 2010-023467-18,6,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,0,"CLINICAL TRIAL SERVICE UNIT, UNIVERSITY OF OXFORD","HPS 3 / TIMI 55: REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid-modification): A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib amo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023467-18,0,0,0 2010-023467-18,6,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,0,University of Oxford,"HPS 3 / TIMI 55: REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid-modification): A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib amo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023467-18,0,0,0 2010-023469-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,LUMC,A phase II study of ARA 290 as therapeutic strategy in rheumatoid arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023469-22,0,0,0 2010-023471-26,4,2013-10-28,2013-10-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharmacosmos A/S,"A Phase III, Randomized, Comparative, Open-label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison with In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023471-26,0,0,0 2010-023473-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Inn-Salzach-Klinikum gGmbH,Verkehrssicherheit unter Agomelatin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023473-18,0,0,0 2010-023476-23,1,2015-12-21,2015-12-21,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Cardiff University,Seal or Varnish? A Randomised Trial To Determine The Relative Cost And Effectiveness Of Pit And Fissure Sealants And Fluoride Varnish In Preventing Dental Decay,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023476-23,0,0,0 2010-023478-38,1,2012-12-20,2012-12-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,OSI Pharmaceuticals LLC,"Open-label, Phase 2 Study of Single-agent Erlotinib for Patients with Pediatric Ependymoma Previously Treated with Oral Etoposide in Protocol OSI-774-205",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023478-38,0,0,0 2010-023479-24,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Radboud University Nijmegen Medical Centre,Effect of Interleukin-1 receptor antagonist on insulin sensitivity in subjects with type 1 diabetes mellitus.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023479-24,0,0,0 2010-023481-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II,"Evaluation of long term risk-benefit profile of levothyroxin treatment in children with congenital hypothyroidism:influence of initial levothyroxine dose on neurodevelopment, growth, cardiovascular an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023481-41,0,0,0 2010-023482-21,3,2012-02-01,2012-02-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PLIVA HRVATSKA d.o.o.,"A Multicentre, Randomised, Double-Blind, Parallel-Group Study of the Efficacy and Safety of a PLIVA Ointment (Calcipotriol + Betamethasone 50 µg/g + 0.5 mg/g ointment) versus Vehicle and Dovobet® in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023482-21,0,0,0 2010-023483-41,3,2013-03-27,2013-03-27,2,1,1,0,0,2,3,0,0,2,0,0,0,0,1,LFB BIOTECHNOLOGIES,"A MULTICENTER STUDY ON THE EFFICACY, SAFETY AND PHARMACOKINETICS OF I10E IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023483-41,1,1,0 2010-023484-17,3,2016-05-26,2016-05-26,1,0,0,0,0,2,3,0,0,2,1,0,0,0,0,Grupo Español de Investigación en Sarcomas,LOCALIZED HIGH-RISK SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL IN ADULTS: AN INTEGRATING APPROACH COMPRISING STANDARD VS HISTOTYPE-TAILORED NEOADJUVANT CHEMOTHERAPY (ISG-STS 10-01),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023484-17,1,0,0 2010-023484-17,3,2016-05-26,2016-05-26,1,0,0,0,0,2,3,0,0,2,1,0,0,0,0,Italian Sarcoma Group,LOCALIZED HIGH-RISK SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL IN ADULTS: AN INTEGRATING APPROACH COMPRISING STANDARD VS HISTOTYPE-TAILORED NEOADJUVANT CHEMOTHERAPY (ISG-STS 10-01),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023484-17,1,0,0 2010-023484-17,3,2016-05-26,2016-05-26,1,0,0,0,0,2,3,0,0,2,1,0,0,0,0,ITALIAN SARCOMA GROUP,LOCALIZED HIGH-RISK SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL IN ADULTS: AN INTEGRATING APPROACH COMPRISING STANDARD VS HISTOTYPE-TAILORED NEOADJUVANT CHEMOTHERAPY (ISG-STS 10-01),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023484-17,1,0,0 2010-023485-53,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,IDIAP JORDI GOL I GURINA,Evaluation of the relationship between effervescent acetaminophen and blood pressure. A clinical trial. EVALUACION DE LA RELACIÓN ENTRE PARACETAMOL EFERVESCENTE Y PRESIÓN ARTERIAL. ENSAYO CLÍNICO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023485-53,0,0,0 2010-023488-16,1,2013-12-12,2013-12-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE DERMATOLOGIE represented by INSTITUT DE RECHERCHE PIERRE FABRE,"A multicentre, open-label study of propranolol in infants with proliferating infantile hemangioma requiring systemic therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023488-16,0,0,0 2010-023491-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Pharmacokinetics and safety of moxifloxacin; a dose escalation in patients with tuberculosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023491-25,0,0,0 2010-023494-19,1,2011-08-07,2011-08-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dr. August Wolff GmbH & Co. KG Arzneimittel,"A Phase IIa, Multi-Centre, Double-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of K(D)PT after Multiple Ascending Doses in Patients with Active M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023494-19,0,0,0 2010-023495-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,Esmolol to treat tachicardia in septic shock,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023495-11,0,0,0 2010-023498-20,5,2014-01-21,2014-01-21,4,1,1,0,0,0,1,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects with Chronic Hepatitis C Genotype 1 (Phase 1b),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023498-20,1,1,0 2010-023498-20,5,2014-01-21,2014-01-21,4,1,1,0,0,0,1,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck and Co., Inc.",Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects with Chronic Hepatitis C Genotype 1 (Phase 1b),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023498-20,1,1,0 2010-023498-20,5,2014-01-21,2014-01-21,4,1,1,0,0,0,1,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.",Assessment of the Pharmacokinetics of Boceprevir in Pediatric Subjects with Chronic Hepatitis C Genotype 1 (Phase 1b),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023498-20,1,1,0 2010-023499-25,7,2011-09-30,2011-09-30,1,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Boehringer Ingelheim Finland Ky,"A phase II/III randomized, open-label study to compare the efficacy and safety of intravenous volasertib in combination with subcutaneous cytarabine versus investigator’s choice of anti-leukemic trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023499-25,0,0,0 2010-023499-25,7,2011-09-30,2011-09-30,1,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Boehringer Ingelheim bv,"A phase II/III randomized, open-label study to compare the efficacy and safety of intravenous volasertib in combination with subcutaneous cytarabine versus investigator’s choice of anti-leukemic trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023499-25,0,0,0 2010-023499-25,7,2011-09-30,2011-09-30,1,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase II/III randomized, open-label study to compare the efficacy and safety of intravenous volasertib in combination with subcutaneous cytarabine versus investigator’s choice of anti-leukemic trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023499-25,0,0,0 2010-023499-25,7,2011-09-30,2011-09-30,1,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"A phase II/III randomized, open-label study to compare the efficacy and safety of intravenous volasertib in combination with subcutaneous cytarabine versus investigator’s choice of anti-leukemic trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023499-25,0,0,0 2010-023499-25,7,2011-09-30,2011-09-30,1,1,0,0,0,0,2,0,0,1,1,0,1,0,2,,"A phase II/III randomized, open-label study to compare the efficacy and safety of intravenous volasertib in combination with subcutaneous cytarabine versus investigator’s choice of anti-leukemic trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023499-25,0,0,0 2010-023499-25,7,2011-09-30,2011-09-30,1,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Boehringer Ingelheim AB,"A phase II/III randomized, open-label study to compare the efficacy and safety of intravenous volasertib in combination with subcutaneous cytarabine versus investigator’s choice of anti-leukemic trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023499-25,0,0,0 2010-023499-25,7,2011-09-30,2011-09-30,1,1,0,0,0,0,2,0,0,1,1,0,1,0,2,SCS Boehringer Ingelheim Comm.V,"A phase II/III randomized, open-label study to compare the efficacy and safety of intravenous volasertib in combination with subcutaneous cytarabine versus investigator’s choice of anti-leukemic trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023499-25,0,0,0 2010-023502-12,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,University College London,"A Proof of Principle, Double-Blind, Randomised Placebo-Controlled,Multi-centre Trial of pravaStatin to Ameliorate Early Onset Pre-eclampsia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023502-12,0,0,0 2010-023503-10,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,FUNDACION SEIMC-GESIDA,"Ensayo clínico piloto, abierto, controlado y aleatorizado para evaluar la actividad de fosamprenavir frente al virus de la hepatitis C (VHC) genotipo 1 en pacientes coinfectados por el virus de la inm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023503-10,0,0,0 2010-023505-36,4,2015-11-02,2015-11-02,2,1,1,0,0,1,3,0,0,2,0,0,0,0,1,EISAI LTD UK,"A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023505-36,1,1,0 2010-023505-36,4,2015-11-02,2015-11-02,2,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Eisai Ltd,"A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023505-36,1,1,0 2010-023507-95,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,BASICS Study Group,BASICS Trial (Basilar Artery International Cooperation Study Research Protocol) BASICS Trial (Basilar Artery International Cooperation Study Research Protocol): Studio randomizzato di sicurezza e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023507-95,0,0,0 2010-023507-95,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,St. Antonius Hospital,BASICS Trial (Basilar Artery International Cooperation Study Research Protocol) BASICS Trial (Basilar Artery International Cooperation Study Research Protocol): Studio randomizzato di sicurezza e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023507-95,0,0,0 2010-023508-28,1,2016-03-01,2016-03-01,1,1,0,0,0,1,4,0,0,1,1,1,1,0,0,Plymouth Hospital NHS Trust,A CLINICAL TRIAL OF THE INTRA-TUMOURAL CONCENTRATION AND ACTIVITY OF NILOTINIB IN INTRA-CUTANEOUS SCHWANNOMAS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023508-28,0,0,0 2010-023509-37,1,2013-08-09,2013-08-09,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Institut für klinische Forschung und Entwicklung Berlin GmbH am St. Hedwig Krankenhaus,"A prospective, randomized, single-blind, placebo-controlled, two-armed, phase IV study in patients with subclinical hypothyroidism treated over 52 weeks either with levothyroxine in adjusted dosing to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023509-37,0,0,0 2010-023510-32,1,2011-07-22,2011-07-22,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Laboratoires SMB S.A.,"A phase IV, randomised, double-blinded, placebo-controlled, parallel study to estimate the influence of vitamin D (D-CURE®) supplementation on the 25-hydroxyvitamin D serum concentration in patients a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023510-32,0,0,0 2010-023512-13,4,2013-04-24,2013-04-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, multi-center study of subcutaneous secukinumab to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolerability and long-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023512-13,0,0,0 2010-023513-64,3,2011-02-26,2011-03-17,2,1,0,0,0,0,3,0,1,1,1,0,1,0,1,GE Healthcare Ltd and its Affiliates,A Single-Arm Open-Label Multi-Center Study to Determine the Specificity of Flutemetamol (18F) Injection for Excluding the Presence of Brain Amyloid in Healthy Young Adult Subjects Aged 18 to 40,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023513-64,0,0,0 2010-023513-64,3,2011-02-26,2011-03-17,2,1,0,0,0,0,3,0,1,1,1,0,1,0,1,GE Healthcare Ltd. and its Affiliates,A Single-Arm Open-Label Multi-Center Study to Determine the Specificity of Flutemetamol (18F) Injection for Excluding the Presence of Brain Amyloid in Healthy Young Adult Subjects Aged 18 to 40,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023513-64,0,0,0 2010-023523-23,1,2012-09-12,2012-09-12,1,1,0,0,1,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents and Young Adults to Evaluate Safety and Immunogenicity of Two Different rMenB with OMV + MenACWY Combination Vaccina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023523-23,0,0,0 2010-023525-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Cáncer de Ovario,"ENSAYO EN FASE III ALEATORIZADO DE CISPLATINO MÁS PACLITAXEL CON Y SIN BEVACIZUMAB FRENTE AL DOBLETE SIN PLATINO, TOPOTECAN MÁS PACLITAXEL, CON Y SIN BEVACIZUMAB, EN CARCINOMA DE CÉRVIX EN ESTADIO IVB...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023525-38,0,0,0 2010-023526-21,22,2016-02-24,2017-02-24,20,1,1,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"An open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023526-21,0,0,0 2010-023528-25,1,2011-08-05,2011-08-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU Brugmann,Etude clinique prospective randomisée en double aveugle de phase 4 comparant la durée d'analgésie postopératoire du fentanyl et du sufentanil administrés comme adjuvant en rachianesthésie dans le cadr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023528-25,0,0,0 2010-023529-39,1,2012-09-26,2012-09-26,1,1,0,0,1,1,2,0,0,1,1,1,1,0,0,Southampton University Hopsitals NHS Trust,Reducing antibiotic tolerance using low dose nitric oxide in cystic fibrosis – a phase 2 pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023529-39,0,0,0 2010-023531-42,1,2014-07-01,2014-07-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Psykiatrien i Region Syddanmark,The role of vitamin D supplementation on symptoms in patients treated for depression. A double-blind randomized trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023531-42,0,0,0 2010-023532-16,1,2013-11-11,2013-11-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Janssen R&D Ireland,"An open-label study to evaluate the safety, tolerability and pharmacokinetics of etravirine (ETR) in combination with other antiretrovirals (ARVs) in antiretroviral treatment-experienced HIV-1 infecte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023532-16,0,0,0 2010-023533-34,1,,,0,0,0,1,0,1,1,1,0,4,0,0,0,0,1,EREMPHARMA SAS,Etude pharmacocinétique de l’équivalence de la biodisponibilité entre Nebcinal® 150mg/3ml administré par Aeroneb® Idehaler® et Tobi® 300mg/5ml administré par Pari LC Plus ® /Pulmoaid ® chez des patien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023533-34,0,0,0 2010-023534-23,8,2012-09-26,2012-09-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SERONO SA,"A phase IIIB, multicentre, multinational, randomized, open-label trial to compare the efficacy and safety of ovarian stimulation with GONAL-f day 1 to day 5 followed by Pergoveris starting day 6 to P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023534-23,0,0,0 2010-023534-23,8,2012-09-26,2012-09-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Serono S.A. - Geneva,"A phase IIIB, multicentre, multinational, randomized, open-label trial to compare the efficacy and safety of ovarian stimulation with GONAL-f day 1 to day 5 followed by Pergoveris starting day 6 to P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023534-23,0,0,0 2010-023536-16,1,2017-03-28,2017-03-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"University of California, San Francisco, Immune Tolerance Network","A Randomised, Double-blind, Single-centre, Placebo controlled Study of Sublingual Immunotherapy and Subcutaneous Immunotherapy in Adults with Seasonal Allergic Rhinitis (ITN043AD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023536-16,0,0,0 2010-023538-22,1,2012-07-20,2012-07-20,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,Lipid Pharmaceuticals,Lýsi sem hægðalyf fyrir börn,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023538-22,0,0,0 2010-023543-15,1,2012-06-07,2012-06-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,BioCis Pharma Oy,"Double-blind, placebo-controlled, multi-centre Phase II study to investigate dose response, safety, tolerability and efficacy of topical twice daily doses of 2.5% and 5% cis-urocanic acid in compariso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023543-15,0,0,0 2010-023550-36,4,2012-08-29,2012-10-12,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients with DSM-IV-TR Schizophrenia Followed by Open-Label Treatment with LY2140023",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023550-36,0,0,0 2010-023550-36,4,2012-08-29,2012-10-12,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Lilly S.A.,"A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients with DSM-IV-TR Schizophrenia Followed by Open-Label Treatment with LY2140023",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023550-36,0,0,0 2010-023552-90,1,2015-10-15,2015-10-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Medizinische Universität Wien, Abteilung für Herzchirurgie",Short-term endothelin A receptor blockade in patients with on-pump coronary artery bypass grafting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023552-90,0,0,0 2010-023560-40,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Uppsala l�ns landsting,Haematopoetic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023560-40,0,0,0 2010-023561-22,2,2013-03-05,2013-04-04,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,BioMarin Pharmaceutical Inc,"A Phase 1/2 Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic and Preliminary Efficacy of BMN 701 (GILT-tagged Recombinant human GAA) in Patients with Late-onset Pompe Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023561-22,0,0,0 2010-023562-51,1,2016-08-08,2016-08-08,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Biothera,"A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbitux®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer Eine offene, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023562-51,0,0,0 2010-023566-43,1,2013-02-27,2013-02-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INFECTOPHARM Arzneimittel GmbH,"Multizentrische, randomisierte, doppelblinde, kontrollierte Phase III-Studie zur Behandlung der papulopustulären Rosazea mit Permethrin Creme 5 % (InfectoScab®) versus Permethrin Creme 2,5 % versus Me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023566-43,0,0,0 2010-023571-26,1,2014-02-04,2014-02-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Aberdeen,Does nitrite reduce ischaemia-reperfusion injury in patients with acute ST segment elevation myocaridal infarction?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023571-26,0,0,0 2010-023571-26,1,2014-02-04,2014-02-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,NHS Grampian,Does nitrite reduce ischaemia-reperfusion injury in patients with acute ST segment elevation myocaridal infarction?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023571-26,0,0,0 2010-023575-25,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Universität Regensburg,Perioperative FOLFOXIRI and bevacizumab compared with postoperative FOLFOX in patients with resectable liver metastases from colorectal cancer (PERIMAX).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023575-25,0,0,0 2010-023576-10,1,2013-04-26,2013-04-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Early effect of agomelatine on general interest in outpatients with Major Depressive Disorder. A 12-week, randomized, double-blind, multicentre study with parallel groups: agomelatine (25mg/day given ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023576-10,0,0,0 2010-023577-20,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,VU University Medical Center,"Revlimid, Endoxan, Prednisone Evaluation After prior revlimid Treatment (REPEAT): A phase 1 and phase 2 study of lenalidomide (Revlimid) in combination with cyclophosphamide (endoxan) and prednisone (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023577-20,0,0,0 2010-023580-18,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Merck, S.L","Ensayo clínico fase II, de cetuximab en cáncer colorrectal metastático refractario con K-RAS mutado y genotipos FcyRII/IIIa favorables Phase II clinical study of cetuximab in refractory colorectal can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023580-18,0,0,0 2010-023584-17,1,2018-05-25,2018-05-25,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,Universität Leipzig,Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicentre ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023584-17,0,0,0 2010-023586-22,1,2018-03-28,2018-03-28,1,1,0,0,0,3,4,0,0,1,0,0,1,0,1,Bayer AG,Prospective Case Crossover Study to Assess Whether PDE5 Inhibitor Exposure in Men Increases the Risk for the Development of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023586-22,0,0,0 2010-023587-40,8,2012-08-30,2012-08-30,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomized, double-blind, parallel-group study of the reduction of signs and symptoms during treatment with tocilizumab versus adalimumab, both in combination with MTX, in patients with moderate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023587-40,0,0,0 2010-023588-16,4,2014-10-14,2014-10-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Iron Therapeutics (Switzerland) AG,"A prospective, multicentre, randomised, double-blind, placebo controlled study with oral ST10-021 for the treatment of iron deficiency anaemia in subjects with quiescent ulcerative colitis where oral ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023588-16,0,0,0 2010-023589-39,4,2014-10-14,2014-10-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Iron Therapeutics (Switzerland) AG,"A prospective, multicentre, randomised, double-blind, placebo controlled study with oral ST10-021 for the treatment of iron deficiency anaemia in subjects with quiescent Crohn's Disease where oral fer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023589-39,0,0,0 2010-023594-18,1,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"Semmelweis University, 2nd Department of Pediatrics","CPT-SIOP-2009 Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients with Choroid Plexus Tumors. CPT-SIOP-2009 Nemzetközi, kezelés optimalizáló vizsgálat plexus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023594-18,0,0,0 2010-023597-39,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Lluís Cabero Roura,HEPARINA DE BAJO PESO MOLECULAR (HBPM) para la prevención de complicaciones derivadas de la insuficiencia placentaria en las pacientes de riesgo sin trombofilia: ensayo clínico multicéntrico randomiza...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023597-39,0,0,0 2010-023600-27,4,2013-07-10,2013-07-10,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.",A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Subje...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023600-27,0,0,0 2010-023601-35,8,2013-10-09,2013-10-10,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.",A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Orally Twice Daily compared with Placebo in Adolescent and Adul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023601-35,0,0,0 2010-023602-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO,A FEASIBILITY STUDY EVALUATING THE EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR (HCC) CARCINOMA AND HIV INFECTION TREATED WITH HAART REGIMENS Studio di fattibilita' che...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023602-12,0,0,0 2010-023603-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,UZ Leuven,Ilaris (Canakinumab) in the Schnitzler syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023603-10,0,0,0 2010-023606-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,GIENNE PHARMA S.P.A.,Efficacy and safety of Canrenone Add on in patients with Essential Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023606-13,0,0,0 2010-023611-34,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Cerenis Therapeutics,"A Phase II Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects with Acute Coronary Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023611-34,0,0,0 2010-023612-14,1,2019-04-02,2019-04-02,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Clinical Trials and Research Governance,"A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic resonan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023612-14,0,0,0 2010-023613-61,2,2016-12-23,2016-12-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MOLMED,NGR018: Randomized phase II study of NGR-hTNF plus an anthracycline versus an anthracycline alone in platinum-resistant ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023613-61,0,0,0 2010-023614-31,2,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,MOLMED,NGR019: Randomized double-blind phase II study of NGR-hTNF versus placebo as maintenance treatment in advanced malignant pleural mesothelioma (MPM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023614-31,0,0,0 2010-023621-37,7,2012-02-29,2012-03-13,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 26-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023621-37,0,0,0 2010-023621-37,7,2012-02-29,2012-03-13,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S. A,"A 26-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023621-37,0,0,0 2010-023623-26,6,2013-07-29,2013-07-29,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CEPHALON FRANCE,"A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Depression...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023623-26,0,0,0 2010-023623-26,6,2013-07-29,2013-07-29,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cephalon, Inc.","A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Depression...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023623-26,0,0,0 2010-023625-38,1,2014-10-01,2014-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's and St Thomas' NHS Foundation Trust,Investigating the effect of Maraviroc on microbial translocation in HIV-1 infected individuals who are receiving antiretroviral therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023625-38,0,0,0 2010-023627-14,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Santen Oy,Cross-sectional study to investigate the occurence and severity of signs and symptoms of ocular surface disease in patients with ongoing chronic topical treatment for glaucoma or ocular hypertension.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023627-14,0,0,0 2010-023630-24,1,2017-05-03,2017-05-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GMIHO mbH,Phase II open-label pilot study evaluating the safety and efficacy of Certican ® (everolimus) in the prevention of chronic graft-versus-host disease and late pulmonary complications after allogeneic h...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023630-24,0,0,0 2010-023636-17,1,2014-03-19,2014-03-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The Rotterdam Eye Hospital,Intravitreal versus submacular injection of rtPA for acute submacular haemorrhages.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023636-17,0,0,0 2010-023637-29,1,2014-04-29,2014-04-29,1,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A SINGLE CENTRE, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, 2-WAY CROSS OVER STUDY TO COMPARE SAFETY ASSESSED BY KNEMOMETRY AND URINARY CORTISOL MEASUREMENTS OF CHF1535 50/6 pMDI (FIXED COMBINATION OF BE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023637-29,0,0,0 2010-023643-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Deventer Hospital,The influence of hyoscine N-butylbromide on colonoscopic polyp detection ratio,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023643-15,0,0,0 2010-023645-29,1,2014-02-12,2014-02-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Münster,"Efficacy and safety of fumaric acid esters in the treatment of patients with cutaneous lupus erythematosus: A monocentre, open-label, prospective pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023645-29,0,0,0 2010-023648-34,9,2014-03-19,2014-10-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Helsinn Therapeutics (U.S.), Inc.","Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Effic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023648-34,0,0,0 2010-023648-34,9,2014-03-19,2014-10-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"HELSINN THERAPEUTICS (U.S), INC","Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Effic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023648-34,0,0,0 2010-023649-31,3,2014-10-10,2014-10-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Helsinn Therapeutics (U.S.), Inc.","Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023649-31,0,0,0 2010-023650-36,10,2014-04-22,2014-06-12,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Helsinn Therapeutics (U.S.), Inc.",Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer ? Cachexia (NSCLC-C): An Extension Study (ROMANA-3). HCl de Anamorelina en el tratamiento de caquexia asociada al carcinoma broncopulmo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023650-36,0,0,0 2010-023650-36,10,2014-04-22,2014-06-12,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"HELSINN THERAPEUTICS (U.S), INC",Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer ? Cachexia (NSCLC-C): An Extension Study (ROMANA-3). HCl de Anamorelina en el tratamiento de caquexia asociada al carcinoma broncopulmo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023650-36,0,0,0 2010-023654-37,1,2015-06-17,2015-06-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Academic Medical Center,Effects of methylphenidate on the development of the dopaminergic system in the brain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023654-37,0,0,0 2010-023662-47,1,2011-10-31,2011-10-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Oulu University Hospital, Department of Internal Medicine","PXR-aktivaation vaikutukset sokeri-, kolesteroli- ja hormonitasapainoon",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023662-47,0,0,0 2010-023666-46,1,2012-07-12,2012-07-12,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,LFB BIOTECHNOLOGIES,EFFICACY AND SAFETY STUDY OF FACTANE 200 IU/ml ADMINISTERED BY CONTINUOUS INFUSION IN SEVERE HAEMOPHILIA A PATIENTS DURING MAJOR SURGICAL PROCEDURES Ocena skuteczności i bezpieczeństwa preparatu FA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023666-46,0,0,0 2010-023668-42,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Southampton University Hospital NHS Trust,Pulmonary surfactant (S) biology in ventilated children on a paediatric intensive care unit with acute (A) hypoxic respiratory (R) failure- a pilot (P) study (S): (SARPS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023668-42,0,0,0 2010-023669-23,7,2014-05-30,2014-05-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"Multicenter, Open-Label, Early Access Program of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirrhos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023669-23,0,0,0 2010-023669-23,7,2014-05-30,2014-05-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V,"Multicenter, Open-Label, Early Access Program of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirrhos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023669-23,0,0,0 2010-023671-26,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Klinikum der Universität München-Großhadern,Panitumumab after Resection of Liver Metastases from Colorectal Cancer in RAS Wild-type Patients -PARLIM- Panitumumab nach Resektion von Lebermetastasen des kolorektalen Karzinoms bei Patienten mi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023671-26,0,0,0 2010-023674-39,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Österreichisches Akromegalie Register,Evaluation of a standardized treatment regimen for acromegaly: A multi centre intervention study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023674-39,0,0,0 2010-023677-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. LUIGI GONZAGA,Bio-molecular effects of interferon-beta and d-vitamin association,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023677-19,0,0,0 2010-023678-38,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023678-38,0,0,0 2010-023681-45,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Verksamhetsområde Geriatrik, Lungmedicin och Allergologi vid Sahlgrenska Universitetssjukhuset",Endotoxin-induced immune response in the lower respiratory tract in smokers with and without chronic bronchitis (CB) and / or chronic obstructive pulmonary disease (COPD) Endotoxin-inducerad immun...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023681-45,0,0,0 2010-023683-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Pk/Pd aspects of linezolid in critically ill patients with late onset Ventilator-Associated Pneumonia. Intermittent versus Continuous Infusion Introduction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023683-41,0,0,0 2010-023686-22,1,2017-09-18,2017-09-18,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Hospices Civils de Lyon,Traitement préopératoire des hypospades sévères par oestrogènes locaux versus placebo : effet sur les défauts de cicatrisation post opératoires,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023686-22,0,0,0 2010-023688-16,1,2014-12-25,2014-12-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CESAR Central European Society for Anticancer Drug Research-EWIV,"An Open-Label, Randomized, Parallel Group Study of Patients Treated with Paclitaxel with Standard Dosing versus Pharmacokinetic Guided Dose Adjustment in Patients with Advanced NSCLC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023688-16,0,0,0 2010-023691-33,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde",A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma Metronomická a cílená antiangiogenní terapie pro děti s recidivujícím/p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023691-33,0,0,0 2010-023691-33,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde",A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma Metronomická a cílená antiangiogenní terapie pro děti s recidivujícím/p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023691-33,0,0,0 2010-023692-26,6,2013-07-08,2013-07-17,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AstraZeneca AB,"(OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared with Adalimumab Mono...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023692-26,0,0,0 2010-023695-91,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Institut Jules Bordet,Sorafenib plus capecitabine activity assesment in patients with advanced pre-treated colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023695-91,0,0,0 2010-023697-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,Evaluation de l'efficacité et de la tolérance d'un traitement court de 7 jours par ceftriaxone intraveineux le 1er jour puis par cefixime per os du 2éme au 7éme jours dans la prise en charge aux urgen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023697-39,0,0,0 2010-023740-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Haukeland University Hospital,Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023740-32,0,0,0 2010-023742-79,1,2015-02-10,2015-02-10,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,AEGERION PHARMACEUTICALS,"A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor ‘lomitapide’ (AEGR-733) in Patients with Homozygous Familial Hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023742-79,0,0,0 2010-023744-33,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,Duchenne muscular dystrophy: double-blind randomized trial to find optimum steroid regimen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023744-33,0,0,0 2010-023744-33,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,University of Rochester,Duchenne muscular dystrophy: double-blind randomized trial to find optimum steroid regimen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023744-33,0,0,0 2010-023746-67,1,2016-12-30,2016-12-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Dr Daniel Serón. Servicio de Nefrología. Hospital Universitario Vall d'Hebron,"Tratamiento con inmunoglobulinas y rituximab en el rechazo crónico humoral en el trasplante renal: estudio multicéntrico, prospectivo, randomizado y controlado con placebo. Treatment with intravenous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023746-67,0,0,0 2010-023747-15,1,2014-11-27,2014-11-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oslo,"Tick borne diseases in norwegian general practice. A randomized, controlled trial for treatment of erythema migrans in norwegian general practice. A comparison of phneoxymetylpenicillin, amoxicillin a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023747-15,0,0,0 2010-023749-30,1,2012-12-31,2012-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Studio PKCT - Pharmacokinetics of chemotherapy when given concurrently with antiretroviral (Protocol no. CSL01). Studio PKCT – Farmacocinetica dei chemioterapici antitumorali quando somministrati i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023749-30,0,0,0 2010-023754-37,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Ashford and St Peters Hospitals NHS Trust,Local Anaesthetic Infusion for Laparoscopic Hysterectomy: A Randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023754-37,0,0,0 2010-023755-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITA` CAMPUS BIOMEDICO,Use of doxorubicin liposomiale not peghilata (MYOCET) as second-line chemotherapy in epithelial ovarian carcinoma: Carboplatin + Myocet in patients Platinum sensitive or Myocet as single agent in pati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023755-28,0,0,0 2010-023756-82,1,2015-04-30,2015-04-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Dresden University of Technology,Rasagiline treatment for Sleep disorders in Parkinson´s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023756-82,0,0,0 2010-023757-11,1,2021-04-14,2021-04-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,Myeloid and plasmacytoid blood dendritic cells for immunotherapy of stage III melanoma patients scheduled for radical lymph node dissection Myeloide en plasmacytoide dendritische cel vaccinaties vo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023757-11,0,0,0 2010-023759-27,14,2012-02-29,2012-04-30,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023759-27,0,0,0 2010-023759-27,14,2012-02-29,2012-04-30,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023759-27,0,0,0 2010-023759-27,14,2012-02-29,2012-04-30,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023759-27,0,0,0 2010-023759-27,14,2012-02-29,2012-04-30,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MERCK SHARP & DOHME CORP.,"A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023759-27,0,0,0 2010-023759-27,14,2012-02-29,2012-04-30,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Corp,"A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023759-27,0,0,0 2010-023759-27,14,2012-02-29,2012-04-30,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023759-27,0,0,0 2010-023759-27,14,2012-02-29,2012-04-30,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MSD Finland Oy,"A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023759-27,0,0,0 2010-023759-27,14,2012-02-29,2012-04-30,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme (Sweden) AB,"A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023759-27,0,0,0 2010-023762-49,6,2013-04-22,2013-04-22,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF ANRUKINZUMAB IN PATIENTS WITH ACTIVE U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023762-49,0,0,0 2010-023762-49,6,2013-04-22,2013-04-22,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA","A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF ANRUKINZUMAB IN PATIENTS WITH ACTIVE U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023762-49,0,0,0 2010-023762-49,6,2013-04-22,2013-04-22,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.L.U.","A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR UNBLINDED, PLACEBO-CONTROLLED, MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF ANRUKINZUMAB IN PATIENTS WITH ACTIVE U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023762-49,0,0,0 2010-023763-17,7,2015-05-13,2016-04-07,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Genentech, Inc.",A phase II double-blind placebo-controlled randomized study of GDC- 0941 or GDC-0980 with Fulvestrant versus Fulvestrant in advanced or metastatic breast cancer in patients resistant to aromatase in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023763-17,0,0,0 2010-023763-17,7,2015-05-13,2016-04-07,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ROCHE,A phase II double-blind placebo-controlled randomized study of GDC- 0941 or GDC-0980 with Fulvestrant versus Fulvestrant in advanced or metastatic breast cancer in patients resistant to aromatase in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023763-17,0,0,0 2010-023767-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Medisch Centrum Leeuwarden,Evaluatie van het effect van ketanserin i.v. op de sublinguale microcirculatie middels SDF-imaging bij septische patienten op de Intensive Care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023767-18,0,0,0 2010-023769-23,8,2013-09-04,2013-09-04,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both plus Mealtime Insulin in Patients with Ty...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023769-23,0,0,0 2010-023770-39,5,2013-11-22,2013-11-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® both in combination with oral antihyperglycemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023770-39,0,0,0 2010-023772-71,4,2014-06-10,2016-12-30,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination with a Standard Care Regimen of Melphalan and Prednis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023772-71,0,0,0 2010-023772-71,4,2014-06-10,2016-12-30,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Millennium Pharmaceuticals, Inc","An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination with a Standard Care Regimen of Melphalan and Prednis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023772-71,0,0,0 2010-023775-25,7,2013-02-06,2013-02-26,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023775-25,0,0,0 2010-023776-52,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,"Optimizing tamoxifen therapy through the induction of CYP3A4, CYP2C and CYP2D6 mediated metabolism",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023776-52,0,0,0 2010-023777-19,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,UZ Brussel,Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants: the SToP-BPD study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023777-19,0,0,0 2010-023777-19,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Academic Medical Center,Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants: the SToP-BPD study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023777-19,0,0,0 2010-023779-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Stichting Toegepast Caridologisch Onderzoek,A Comparison of Drug Eluting and Bare Metal Stents with Bivalirudin during PCI or Bivalirudin for 4 hours in Acute Coronary Syndromes. The Eindhoven Reperfusion Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023779-24,0,0,0 2010-023782-22,6,2014-06-09,2014-06-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEUMAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023782-22,0,0,0 2010-023782-22,6,2014-06-09,2014-06-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA","A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEUMAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023782-22,0,0,0 2010-023782-22,6,2014-06-09,2014-06-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEUMAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023782-22,0,0,0 2010-023782-22,6,2014-06-09,2014-06-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.L.U.","A PHASE 2, RANDOMIZED, DOUBLE-BLIND ASSESSMENT OF EFFICACY AND SAFETY OF PF-04171327(1, 5, 10, 15 MG DOSE, DAILY) COMPARED TO 5 MG AND 10 MG PREDNISONE DAILY AND PLACEBO DAILY IN SUBJECTS WITH RHEUMAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023782-22,0,0,0 2010-023783-41,11,2019-03-14,2019-03-14,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Eisai Limited,"A Multicenter, Randomized, Double- Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I- Refractory Differentiated Thyroid Cancer Studio di Fase 3, multicentrico, randomizzato, in doppio ciec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023783-41,0,0,0 2010-023783-41,11,2019-03-14,2019-03-14,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,EISAI LTD UK,"A Multicenter, Randomized, Double- Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I- Refractory Differentiated Thyroid Cancer Studio di Fase 3, multicentrico, randomizzato, in doppio ciec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023783-41,0,0,0 2010-023783-41,11,2019-03-14,2019-03-14,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Eisai Ltd,"A Multicenter, Randomized, Double- Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I- Refractory Differentiated Thyroid Cancer Studio di Fase 3, multicentrico, randomizzato, in doppio ciec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023783-41,0,0,0 2010-023788-16,1,2013-08-02,2013-08-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharmacosmos A/S,"A Randomized, Prospective, Double-Blind, Comparative Placebo-Controlled Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-anemic Patients Undergoing Elective or S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023788-16,0,0,0 2010-023789-33,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Valderm ApS,"A phase IIa, multicenter, randomized, two-arm, observer-blind, vehicle and reference controlled proof of concept trial to investigate intra-individually (left/ right) the antipsoriatic efficacy and sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023789-33,0,0,0 2010-023790-19,1,2012-03-19,2012-03-19,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,"Rigshospitalet, afd. 2034","Et randomiseret, prospektivt, dobbeltblindt, komparativt, placebokontrolleret forsøg med intravenøs indgift af jernisomaltosid 1000 (Monofer®) via infusioner til bloddonorer med jernmangel",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023790-19,0,0,0 2010-023791-63,2,2012-02-14,2012-02-14,2,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase II, Randomized, Controlled, Observer-Blind, Clinical Study to Evaluate the Humoral and Cell Mediated Immunity and Safety of Two Intramuscular Doses of Fluad® or Agrippal® in Previously Unvacci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023791-63,0,0,0 2010-023792-25,1,2017-01-30,2017-01-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Alder Hey Children's NHS Foundation Trust,A randomised controlled trial of continuous subcutaneous insulin infusion(CSII) compared to multiple daily injection(MDI) regimens on insulin in children and young people at diagnosis of type I diabet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023792-25,0,0,0 2010-023794-19,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA S. GERARDO DI MONZA,"II Phase Study for the evaluation of Full-oral, metronomic schedule of Vinorelbine (VNB) and Capecitabine (CAPE) in locally advanced or metastatic breast cancer (BC) patients (pts) Studio di Fase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023794-19,0,0,0 2010-023797-39,1,2015-08-20,2015-08-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Barts Health NHS Trust,"TREATMENT OF IRON DEFICIENCY ANAEMIA IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE USING FERROUS SULPHATE OR COSMOFER: TOLERANCE AND EFFECTS ON HAEMOGLOBIN, DISEASE ACTIVITY, MOOD, QUALITY OF LIFE AN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023797-39,0,0,0 2010-023798-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundacion para la Investigacion Biomedica Hospital Universitario La Paz,A PHASE I/IIA CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS (ASC) ON INDUCTION TO REMISSION IN ULCERATIVE COLITIS ENSAYO CLÍNICO EN FASE I/IIA PARA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023798-20,0,0,0 2010-023799-21,10,2018-08-21,2018-08-21,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023799-21,0,0,0 2010-023799-21,10,2018-08-21,2018-08-21,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly & Company,The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023799-21,0,0,0 2010-023801-36,3,2013-05-16,2013-05-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Resverlogix Corp.,"Phase IIb multi-center, double-blind, randomized, parallel group, placebo-controlled clinical trial for the assessment of coronary plaque changes with RVX000222, as determined by intravascular ultraso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023801-36,0,0,0 2010-023802-10,15,2021-02-04,2021-02-04,11,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","AN OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG TERM SAFETY AND CLINICAL BENEFIT OF ETANERCEPT IN CHILDREN AND ADOLESCENTS WITH EXTENDED OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS RELAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023802-10,1,1,0 2010-023802-10,15,2021-02-04,2021-02-04,11,1,1,0,0,0,3,0,0,2,0,0,0,0,1,PFIZER INC.,"AN OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG TERM SAFETY AND CLINICAL BENEFIT OF ETANERCEPT IN CHILDREN AND ADOLESCENTS WITH EXTENDED OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS RELAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023802-10,1,1,0 2010-023802-10,15,2021-02-04,2021-02-04,11,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States","AN OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG TERM SAFETY AND CLINICAL BENEFIT OF ETANERCEPT IN CHILDREN AND ADOLESCENTS WITH EXTENDED OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS RELAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023802-10,1,1,0 2010-023802-10,15,2021-02-04,2021-02-04,11,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"PFIZER, S.L.U.","AN OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG TERM SAFETY AND CLINICAL BENEFIT OF ETANERCEPT IN CHILDREN AND ADOLESCENTS WITH EXTENDED OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS RELAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023802-10,1,1,0 2010-023803-92,7,2012-08-13,2012-08-13,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novo Nordisk A/S,Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients with Congenital Haemophilia and Inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023803-92,0,0,0 2010-023803-92,7,2012-08-13,2012-08-13,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,NOVO NORDISK,Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients with Congenital Haemophilia and Inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023803-92,0,0,0 2010-023804-28,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Bioprojet,An open-label naturalistic pragmatic study to assess the long term safety of BF2.649 (Pitolisant) in the treatment of Excessive Daytime Sleepiness (EDS) in narcolepsy (12 months follow-up).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023804-28,0,0,0 2010-023809-36,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,"Risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023809-36,0,0,0 2010-023814-29,1,2015-01-28,2015-01-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Instituto Científico y Tecnológico de Navarra,Concentración y actividad antibiótica en soluciones de sellado,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023814-29,0,0,0 2010-023815-33,1,2011-08-25,2011-08-25,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,AVIR Green Hills Biotechnology Research Development Trade AG,"Randomised, double-blind, placebo-controlled, phase I/II study of single dose GHB16L2 trivalent influenza vaccine in healthy adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023815-33,0,0,0 2010-023816-15,2,2012-03-20,2012-03-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AstraZeneca AB,"A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Active Controlled, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of 2 Fixed Dose Groups of TC-5214 (S-mecamylamine) as...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023816-15,0,0,0 2010-023819-34,3,2012-10-04,2012-10-26,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A Phase II, double-blind, randomized, Proof-of-Concept, dose-ranging trial evaluating the efficacy, safety and pharmacokinetics of oral LDE225 in treatment of adult patients with Nevoid Basal Cell Car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023819-34,0,0,0 2010-023822-19,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Juan Pedro Barret Nerín,ESTUDIO DE LA EFICACIA DE BOSENTAN EN LA MODULACIÓN DE LA RESPUESTA INFLAMATORIA Y DE LA CICATRIZACIÓN EN PACIENTES QUEMADOS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023822-19,0,0,0 2010-023827-34,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,PHASE III CLINICAL TRIAL TO ASSESS THE ADDED ROLE OF 68Ga-DOTANOC PET-CT IN PATIENTS WITH NEUROENDOCRINE TUMORS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023827-34,0,0,0 2010-023828-24,1,2013-02-28,2013-02-28,1,1,0,0,0,0,3,0,0,1,1,1,1,0,3,University of Nottingham,The effect of Thalidomide on sputum biomarkers in IPF cough.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023828-24,0,0,0 2010-023830-22,2,2021-05-28,2021-05-28,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,TETEC AG,NDisc Study: A Prospective Randomized Multicentre Phase I / II Clinical Trial to Evaluate Safety and Efficacy of NOVOCART® Disc plus Autologous Disc Chondrocyte Transplantation (ADCT) in the Treatment...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023830-22,0,0,0 2010-023831-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO,"Study for metastatic thyroid cancer using 124i and [18F] FDG PET / CT in patients with elevated values of Tg and / or AbTg with negative ultrasonography of the neck, previously treated with thyroidect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023831-40,0,0,0 2010-023837-45,2,2013-04-08,2013-06-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A Phase II Open-Label, Two-Cohort, Multicentre Study of GSK2118436 as a Single Agent in Treatment Na�ve and Previously Treated Subjects with BRAF Mutation-Positive Metastatic Melanoma to the Brain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023837-45,0,0,0 2010-023839-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,General University Hospital in Prague,EXEnatide in patients undergoing Coronary artery bypass grafting for improved glUcose conTrol and hemodynamIc ValuEs,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023839-42,0,0,0 2010-023841-31,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Dr. Juan Jesús Gómez-Reino Carnota,"Ensayo clínico fase III, de grupos paralelos, randomizado, controlado con placebo, doble ciego y multicéntrico, para evaluar la eficacia y seguridad de la administración de tocilizumab en pacientes di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023841-31,0,0,0 2010-023843-13,1,2013-06-30,2013-06-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Hospitalsenheden Horsens,Dyb sedation med spontan respiration kombineret med lokalanæstesi kontra generel anæstesi til gynækologiske patienter på Dagkirurgisk Center på Regionshospital Horsens.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023843-13,0,0,0 2010-023844-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sint Maartenskliniek,Effectiveness and safety of parecoxib in children undergoing scoliosis surgery compared to placebo: a double-blinded randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023844-34,0,0,0 2010-023849-30,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University of Amsterdam,The effects of MR and GR blockade on the reconsolidation and extinction of fear memories,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023849-30,0,0,0 2010-023851-27,1,2017-02-17,2017-02-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Kings College Hospital NHS Foundation Trust,"A 12 week, multi centre, open label study to evaluate the effect of fesoterodine flexible dosing regimen on the sexual function of women with overactive bladder.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023851-27,0,0,0 2010-023852-10,1,2014-01-08,2014-01-08,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Avid Radiopharmaceuticals, Inc.",18F-AV-45 Amyloid PET Imaging in Primary Progressive Aphasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023852-10,0,0,0 2010-023854-35,3,2013-09-04,2013-09-04,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"MedImmune, LLC","A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023854-35,0,0,0 2010-023856-97,3,2016-01-26,2016-01-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biogen Idec Limited,"A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Immunogenicity and Pharmacokinetics of BIIB019, Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Inj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023856-97,0,0,0 2010-023858-37,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023858-37,0,0,0 2010-023861-23,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Maastricht University,The effect of P-glycoprotein transport inhibition on brainmechanisms of sedation and cognitive impairment following antihistamines in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023861-23,0,0,0 2010-023865-22,1,2013-06-30,2013-06-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Health Protection Agency,A prospective study to evaluate the immune response of UK infants receiving the 13-valent pneumococcal conjugate vaccine as part of their routine primary immunisation schedule at 2 and 4 months (code:...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023865-22,0,0,0 2010-023866-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD,"Predicción de la hipotensión del bloqueo espinal de las cesáreas mediante análisis de la actividad del SNA, y efectos de la profilaxis farmacológica de la hipotensión sobre el bienestar fetal",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023866-29,0,0,0 2010-023867-17,1,2015-10-22,2015-10-22,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital Leuven,Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in IUI cycles stimulated with gonadotrophins: a prospective randomized multicentre study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023867-17,0,0,0 2010-023869-21,1,2013-10-11,2013-10-11,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Roche Oy,A study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lunf cancer who present activating mutations in the tyrosine kinase domain of the epidermal gro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023869-21,0,0,0 2010-023871-25,1,2015-01-05,2015-01-05,1,1,0,0,1,0,4,0,0,1,0,0,1,0,3,Nottingham University Hospitals NHS Trust,The FINOF(Femoral Nerve-Block Intervention in Neck Of Femur Fracture) Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023871-25,0,0,0 2010-023873-20,9,2015-04-10,2015-04-14,8,1,1,0,1,0,3,0,1,2,0,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE LOT CONSISTENCY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MENINGOCOCCAL SEROGROUP B BIVALENT rLP2086 VACCINE IN HEAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023873-20,1,1,0 2010-023873-20,9,2015-04-10,2015-04-14,8,1,1,0,1,0,3,0,1,2,0,0,0,0,1,PFIZER INC.,"A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE LOT CONSISTENCY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MENINGOCOCCAL SEROGROUP B BIVALENT rLP2086 VACCINE IN HEAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023873-20,1,1,0 2010-023873-20,9,2015-04-10,2015-04-14,8,1,1,0,1,0,3,0,1,2,0,0,0,0,1,Pfizer Inc.,"A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE LOT CONSISTENCY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MENINGOCOCCAL SEROGROUP B BIVALENT rLP2086 VACCINE IN HEAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023873-20,1,1,0 2010-023875-24,1,2015-05-30,2015-05-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,3,"AHSC Joint Research Office, Imperial College",Anglo-Scandinavian Cardiac Outcomes Trial; Post Trial Follow-Up Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023875-24,0,0,0 2010-023878-40,1,2019-12-10,2019-12-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical University Vienna,"Influence of intra-arterial cerebral Papaverine Hydrochloride on cerebral glucose, lactate, pyruvate, glycerol, and glutamate concentrations, cerebral oxygenation, angiographic vasospasm, delayed stro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023878-40,0,0,0 2010-023880-17,1,2015-11-23,2015-11-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leeds,SWITCH: Randomised-controlled trial of switching to alternative tumour-necrosis factor (TNF)-blocking drugs or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023880-17,0,0,0 2010-023883-42,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE),"Randomized, double-blind, placebo controlled trial to evaluate the efficacy of high dose intravenous immunoglobulins in diabetic painful polyneuropaty (DPNP)resistant to conventional therapies Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023883-42,0,0,0 2010-023888-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Omeros Corporation,"A Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Men...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023888-17,0,0,0 2010-023889-52,1,2012-05-10,2012-05-10,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Karolinska Universitetssjukhuset,"Effects of Clindamycin and Ciprofloxacin administration on the emergence, prevalence and persistence of antibiotic-resistant bacteria in humans",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023889-52,0,0,0 2010-023892-24,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ROCHE,"Phase II, open-label study of erlotinib (Tarceva) treatment In patients with locally advanced or metastatic non-small-cell lung cancer who present activating mutations in the tyrosine kinase domain of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023892-24,0,0,0 2010-023895-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Chiasma, Inc.",Estudio de prueba de concepto diseñado para evaluar los efectos de Octreolin sobre el gradiente de presión venosa hepática en sujetos con cirrosis e hipertensión portal,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023895-26,0,0,0 2010-023900-29,4,2014-11-04,2014-11-04,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Allergan Pharmaceuticals Ireland,"A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex Versus Lucentis in Patients with Branch Retinal Vein Occlusion Studio multicentrico, randomiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023900-29,0,0,0 2010-023900-29,4,2014-11-04,2014-11-04,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ALLERGAN PHARMACEUTICALS IRELAND,"A 12-Month, Multicentre, Randomised, Parallel Group Study to Compare the Efficacy and Safety of Ozurdex Versus Lucentis in Patients with Branch Retinal Vein Occlusion Studio multicentrico, randomiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023900-29,0,0,0 2010-023901-36,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Faculty of Medicine, Otto-von-Guericke-University, Magdeburg",Psoriasis-topoproteome under ustekinumab treatment (PIROUETTE-Study) - as an interventional observation study (phase IV) within approved label and indication and with minimal invasive taking of skin b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023901-36,0,0,0 2010-023903-91,3,2012-11-23,2012-11-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Photocure ASA,A randomized phase II dose-finding study of hexaminolevulinate (HAL) photodynamic therapy (PDT) in patients with low/moderate-grade cervical intraepithelial neoplasia (CIN1 or 2).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023903-91,0,0,0 2010-023908-27,1,2012-11-28,2012-11-28,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Nederland bv,Effects of bosentan in a HOMogenEous population of SSc subjects with a predefined restriction of blood flow in the hands (HOME),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023908-27,0,0,0 2010-023909-35,11,2014-05-15,2014-08-20,6,1,1,0,0,2,3,0,0,2,1,0,0,0,1,Swedish Orphan Biovitrum AB (publ),"A Prospective, Randomized, Double-Blind, Phase 3 Study Comparing rhBSSL and Placebo Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants Born Before Week 3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023909-35,1,1,0 2010-023910-30,1,2019-02-25,2019-02-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leeds,"A Prospective, Single-centre, Randomised Study Evaluating the Clinical, Imaging and Immunological Depth of Remission Achieved by Very Early versus Delayed Etanercept in patients with Rheumatoid Arthri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023910-30,0,0,0 2010-023911-32,4,2015-04-30,2015-04-30,4,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Bayer HealthCare AG,"Multicenter, open-label, randomized, controlled parallel-group study to assess discontinuation rates, bleeding patterns, user satisfaction and adverse event profile of LCS12 in comparison to etonogest...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023911-32,0,0,0 2010-023912-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Canaria de Investigación y Salud,Evaluación de la eficacia de una herramienta de ayuda para la toma de decisiones (ELECCIÓN DE ESTATINAS) para personas con diabetes tipo 2 Evaluation of the efficacy of a decision aid (STATIN CHOICE) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023912-14,0,0,0 2010-023915-33,3,2012-06-14,2012-06-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,POXEL S.A.,"Randomized, double-blind, placebo-controlled, parallel-group study of the safety and efficacy of imeglimin or placebo add-on therapy in type 2 diabetic subjects not adequately controlled by sitaglipti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023915-33,0,0,0 2010-023917-68,7,2016-12-06,2016-12-06,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ALLERGAN LTD,"A 2-year, multicenter, double-masked, randomized, parallel study of the safety of LUMIGAN 0.1 mg/mL compared with LUMIGAN 0.3 mg/mL in patients with glaucoma or ocular hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023917-68,0,0,0 2010-023917-68,7,2016-12-06,2016-12-06,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Allergan Limited,"A 2-year, multicenter, double-masked, randomized, parallel study of the safety of LUMIGAN 0.1 mg/mL compared with LUMIGAN 0.3 mg/mL in patients with glaucoma or ocular hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023917-68,0,0,0 2010-023918-30,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,SOCIETA' ITALO BRITANNICA L. MANETTI - H.ROBERTS & C. PER AZIONI,Pilot clinical study on the systemic bioavailability of l-thyroxine in healthy female volunteers after four weeks of topical treatment with a new formulation based on l-thyroxine Studio clinico pil...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023918-30,0,0,0 2010-023919-34,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,María Carmen Cabellos Mínguez,"Estudio de la eficacia de la fenitoína en la profilaxis de las convulsiones en los pacientes con meningitis neumocócica de 50 años o más. Ensayo clínico comparativo, multicéntrico, controlado con plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023919-34,0,0,0 2010-023920-26,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación para la Investigación Biomédica Hospital Universitario Ramón y Cajal,Eficacia y seguridad del bicarbonato en el tratamiento de la alteración renal aguda asociada a la cirugía cardiaca,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023920-26,0,0,0 2010-023921-39,1,2011-09-25,2011-09-25,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Novo Nordisk A/S,"Multi-Centre, Open-Label, Randomised Trial Investigating the Pharmacokinetics of a Single Dose of NNC 0155-0000-0004 (N8) in Patients with Haemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023921-39,0,0,0 2010-023923-78,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Forsight Vision 4, Inc.",“ A prospective clinical trial to evaluate the V4 Drug delivery device for long term delivery of Ranibizumab for the Treatment of Choroidal Neovascularization”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023923-78,0,0,0 2010-023935-41,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Consorcio de Apoyo a la Investigación Biomédica en Red (CAIBER),PILOT STUDY ASSESSING THE EFFECTIVENESS OF 18FDG PET-CT IN THE EARLY DIAGNOSIS OF BREAST CANCER AND / OR OVARIAN CANCER IN WOMEN BRCA1 or BRCA 2 MUTATION CARRIERS ESTUDIO PILOTO PARA LA VALORACION ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023935-41,0,0,0 2010-023938-23,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,BRACCO,Effect of Mesalazine plus nifedipine suppositoires (Antrorect) in functional ano-rectal pain disorders: a pilot randomized double-blind placebo-controlled study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023938-23,0,0,0 2010-023939-42,5,2011-11-14,2011-11-14,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablet in Patients with Prim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023939-42,0,0,0 2010-023939-42,5,2011-11-14,2011-11-14,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"MERCK & CO., INC.","A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablet in Patients with Prim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023939-42,0,0,0 2010-023941-31,1,2015-04-09,2015-04-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité Universitätsmedizin Berlin,Effects of EGCG (Epigallocatechin Gallate) in Chorea Huntington,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023941-31,0,0,0 2010-023942-63,1,2011-12-04,2011-12-04,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Clinical Trials Center Aachen, University of Aachen",The safety and feasibility of delivering xenon to patients before and after coronary artery bypass graft implantation: a pilot study Abbreviated study title: A pre- and post-Coronary Artery bypass gr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023942-63,0,0,0 2010-023945-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. PAOLO (A.O. DI RILIEVO NAZIONALE),Effect of Prasugrel sull'iperreattivita' bronchial and markers of airway inflammation in patients with chronic asthma: randomized crossover pilot study (Study PRINA). Effetto del Prasugrel sull'ipe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023945-31,0,0,0 2010-023946-58,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ErasmusMC,Immunogenicity and safety of an adjuvant hepatitis B vaccine (fendrix) compared to Engerix in non-responding HIV-infected patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023946-58,0,0,0 2010-023947-14,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Hospital Universitario La Princesa,"Prospective, Randomized and Comparative Study to evaluate the efficacy of two vaccines against Hepatitis B virus in inflammatory bowel disease patients ENSAYO CLÍNICO MULTICÉNTRICO, PROSPECTIVO, AL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023947-14,0,0,0 2010-023948-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"LABORATORIOS LETI, S.L. UNIPERSONAL",Estandarización biológica del extracto alergénico de Dactylis glomerata para determinar la actividad biológica en unidades equivalentes de Histamina (HEP).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023948-33,0,0,0 2010-023949-29,1,2011-11-10,2011-11-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios LETI, S.L.Unipersonal",Estandarización biológica del extracto alergénico de Lolium perenne para determinar la actividad biológica en unidades equivalentes de Histamina(HEP).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023949-29,0,0,0 2010-023950-35,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Laboratorios Leti, S.L.Unipersonal",Biological standardization of Poa pratensis allergen extract to determine the biological activity in HEP units. Estandarización biológica del extracto alergénico de Poa pratensis para determinar la...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023950-35,0,0,0 2010-023951-27,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Laboratorios LETI, S.L.Unipersonal",Estandarización biológica del extracto alergénico de Secale cereale para determinar la actividad biológica en unidades equivalentes de Histamina (HEP).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023951-27,0,0,0 2010-023952-10,4,2013-08-15,2013-08-15,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Gilead Sciences, Inc.","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023952-10,0,0,0 2010-023953-12,3,2015-03-31,2015-03-31,1,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Genzyme Corporation,"A Phase 2, Multi-Center, Randomized, Open-Label, Repeat Dose, Dose-Comparison Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Human Acid Sphingomyelinase in Patients With A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023953-12,1,0,0 2010-023955-27,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Leiden University Medical Center,Randomized controlled trial on the use of rhEPO to reduce top-up transfusions in neonates with red blood cell alloimmunization,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023955-27,0,0,0 2010-023956-99,7,2015-01-04,2015-06-10,4,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023956-99,1,0,0 2010-023956-99,7,2015-01-04,2015-06-10,4,0,0,0,0,0,2,0,0,2,1,0,0,0,1,BRISTOL-M.SQUIBB,"A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023956-99,1,0,0 2010-023957-12,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institute of Oncology Ljubljana,Randomized Multicentre Phase III study of short course radiation therapy followed by prolonged pre-operative chemotherapy and surgery in primary high risk rectal cancer compared to standard chemoradi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023957-12,0,0,0 2010-023957-12,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen (UMCG),Randomized Multicentre Phase III study of short course radiation therapy followed by prolonged pre-operative chemotherapy and surgery in primary high risk rectal cancer compared to standard chemoradi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023957-12,0,0,0 2010-023957-12,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UMC Groningen,Randomized Multicentre Phase III study of short course radiation therapy followed by prolonged pre-operative chemotherapy and surgery in primary high risk rectal cancer compared to standard chemoradi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023957-12,0,0,0 2010-023957-12,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dutch Colorectal Cancer Group,Randomized Multicentre Phase III study of short course radiation therapy followed by prolonged pre-operative chemotherapy and surgery in primary high risk rectal cancer compared to standard chemoradi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023957-12,0,0,0 2010-023957-12,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,,Randomized Multicentre Phase III study of short course radiation therapy followed by prolonged pre-operative chemotherapy and surgery in primary high risk rectal cancer compared to standard chemoradi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023957-12,0,0,0 2010-023958-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Mª Antònia Perelló Juan,"Ensayo clínico aleatorizado de fase IV, en secuencia cruzada, doble ciego, comparando la influencia de la flora intestinal productora del gas metano en la respuesta al tratamiento del estreñimiento cr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023958-36,0,0,0 2010-023959-28,6,2013-07-01,2013-07-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023959-28,0,0,0 2010-023959-28,6,2013-07-01,2013-07-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GILEAD SCIENCES INC.,"A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023959-28,0,0,0 2010-023962-39,3,2012-06-04,2012-06-04,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Convergence Pharmaceuticals Ltd,"A randomized, double blind, cross-over study to evaluate the safety and efficacy of CNV1014802 in subjects with neuropathic pain from lumbosacral radiculopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023962-39,0,0,0 2010-023963-16,8,2014-02-26,2014-02-26,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Convergence Pharmaceuticals Ltd,"A Phase IIa Placebo-Controlled, Double-Blind Randomised Withdrawal Study to Evaluate the Safety and Efficacy of CNV1014802 in Patients with Trigeminal Neuralgia. Estudio de fase IIa, controlado con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023963-16,0,0,0 2010-023963-16,8,2014-02-26,2014-02-26,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CONVERGENCE PHARMACEUTICALS LTD.,"A Phase IIa Placebo-Controlled, Double-Blind Randomised Withdrawal Study to Evaluate the Safety and Efficacy of CNV1014802 in Patients with Trigeminal Neuralgia. Estudio de fase IIa, controlado con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023963-16,0,0,0 2010-023969-21,1,2014-04-15,2014-04-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Gateshead Health NHS Foundation Trust,Vascular Augmentation of Late-life Unremitted Depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023969-21,0,0,0 2010-023971-25,1,2019-04-10,2019-04-10,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Essai randomisé de phase II d’évaluation immunologique d’une stratégie vaccinale de « prime-boost » anti-pneumococcique associant un vaccin conjugué (Prevenar) et le vaccin polysaccharidique (Pneumo2...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023971-25,0,0,0 2010-023976-16,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University of Antwerp,Maternal antibodies against pertussis in neonates .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023976-16,0,0,0 2010-023977-21,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Nayana Joshi Jubert,"Ensayo clínico aleatorizado, doble ciego, de grupos paralelos, de la inyección intra-articular de plasma rico en plaquetas frente a la inyección intra-articular de betametasona y bupivacaína en la art...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023977-21,0,0,0 2010-023978-39,11,2012-08-08,2012-12-12,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Amgen Inc,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Locally Advanced Unresectable Adenocarcinoma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023978-39,0,0,0 2010-023979-25,1,2013-09-18,2013-09-18,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Department of Nephrology,Role of renal and systemic vascular resistance for progression of chronic kidney disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023979-25,0,0,0 2010-023980-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,St. Antonius Hospital,"An efficacy, safety and pharmacokinetic study on the short-term and long-term use of METFORMIN in obese children and adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023980-17,0,0,0 2010-023981-27,1,2012-02-10,2012-02-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Activaero GmbH,"An Open-Label Randomized Pilot Trial to Evaluate Tolerability, Safety and Applicability of AKITA Inhaled Budesonide Suspension in Children aged 3-11 years with Mild to Moderate Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023981-27,0,0,0 2010-023982-23,1,2012-05-21,2012-05-21,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,The Stanley Medical Research Institute,"A randomized trial administering Minocycline, Acetylsalicylic acid or Pramipexole vs Placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffecive disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023982-23,0,0,0 2010-023983-42,1,2013-01-08,2013-01-08,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,The Stanley Medical Research Institute,A randomized trial administering Raloxifene vs. Placebo as add-on to antipsychotics in post menopausal patients with schizophrenia or schizoaffecive disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023983-42,0,0,0 2010-023986-23,6,2012-02-01,2012-06-07,4,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Agennix Incorporated,"OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023986-23,1,0,0 2010-023987-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,In vivo imaging of the effect of fulvestrant on availability of estrogen receptor binding sites in metastatic breast tumor lesions using [18F]FES-PET,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023987-41,0,0,0 2010-023988-17,4,2020-12-31,2020-12-31,1,0,1,0,0,0,3,0,0,2,1,0,0,0,2,BrepCo Biopharma Limited,"Management of Hypotension In the Preterm: A multi centre, randomised, controlled trial of hypotension management in the extremely low gestational age newborn",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023988-17,1,0,0 2010-023991-15,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,1,KEDRION,"Efficay and Safety Evaluation of Kedrion Fibrin Sealant, in middle ear microsurgery. Monocenter, controlled, single blind, randomised, two parallel arms, phase II/III study Valutazione dell’efficac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023991-15,0,0,0 2010-023992-24,4,2016-02-08,2016-02-08,4,1,0,0,0,0,0,0,0,1,1,0,1,0,0,University of Leipzig,International randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023992-24,0,0,0 2010-023992-24,4,2016-02-08,2016-02-08,4,1,0,0,0,0,0,0,0,1,1,0,1,0,0,Universidad de Leipzig,International randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023992-24,0,0,0 2010-023996-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-023996-25,0,0,0 2010-024000-10,4,2014-07-18,2014-07-18,3,1,0,0,1,0,2,0,0,1,0,0,1,0,1,BIOGEN IDEC LTD,"A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis Studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024000-10,0,0,0 2010-024000-10,4,2014-07-18,2014-07-18,3,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Biogen Idec Limited,"A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis Studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024000-10,0,0,0 2010-024001-12,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,TYKS,The effect of bevacizumab treatment on reading ability in age related macular degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024001-12,0,0,0 2010-024004-98,1,2018-07-02,2018-07-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Medicine Göttingen Dept. Hematology and Oncology,"Subcutaneous Rituximab and Intravenous Bendamustine in very Elderly Patients or Elderly Medically Non Fit Patients(""slow go"") with Aggressive CD-20-positive B-cell Lymphoma Short tiltle: BRENDA Su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024004-98,0,0,0 2010-024005-13,1,2011-12-14,2011-12-14,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Orion Corporation Orion Pharma,"Efficacy of ORM-12741 for prevention of cold-induced vasospasm; a randomised, double-blind, placebo-controlled, single centre crossover study in patient with Raynaud's phenomenon secondary to systemic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024005-13,0,0,0 2010-024006-35,3,2014-04-03,2014-04-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Cephalon Inc.,"A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations in Patients (12-75 ye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024006-35,0,0,0 2010-024006-35,3,2014-04-03,2014-04-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products, R&D, Inc.","A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations in Patients (12-75 ye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024006-35,0,0,0 2010-024006-35,3,2014-04-03,2014-04-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations in Patients (12-75 ye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024006-35,0,0,0 2010-024007-27,7,2013-08-19,2014-02-04,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3B, Randomized, Open-label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared with a Single Tablet Regimen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024007-27,0,0,0 2010-024010-61,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,BIOIBÉRICA S.A.,Ensayo clínico de no inferioridad para evaluar la eficacia y seguridad de la combinación de Condroitín sulfato e Hidrocloruro de glucosamina frente a Celecoxib en pacientes afectos de artrosis de rodi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024010-61,0,0,0 2010-024011-14,7,2014-09-30,2015-06-01,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A",An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024011-14,0,0,0 2010-024011-14,7,2014-09-30,2015-06-01,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024011-14,0,0,0 2010-024011-14,7,2014-09-30,2015-06-01,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,An open label two-stage study of orally administered BKM120 in patients with metastatic non-small cell lung cancer with activated PI3K pathway,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024011-14,0,0,0 2010-024013-31,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"An open-label, intra-patient dose-escalation study to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of multiple infusions of BPS804 in adults with h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024013-31,0,0,0 2010-024014-60,3,2016-06-10,2016-06-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Eli Lilly and Company Limited, Indianapolis","An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed with or without Cixutumumab as First-Line Therapy in Patients with Advanced Nonsqua...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024014-60,0,0,0 2010-024017-31,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024017-31,0,0,0 2010-024018-71,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,PREMEDICATION IN CHILDREN: CLONIDINE VERSUS MELATONIN PREMEDICAZIONE IN ETA PEDIATRICA: CLONIDINA VERSUS MELATONINA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024018-71,0,0,0 2010-024020-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Sanitari de Terrassa,Evaluación de la efectividad analgésica del euthetic mixture of local anesthetic (EMLA) en la práctica de la histerosalpingografia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024020-26,0,0,0 2010-024023-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Lorenzo Victor, PhD","An open label, parallel groups, phase III, clinical trial to assess the antiproteinuric effects of the vitamin D derivates in patients with chronic kidney disease and vitamin D insufficiency.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024023-25,0,0,0 2010-024024-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CAIBER,"INVESTIGACION DE LA OBESIDAD EN LAS INCRETINAS:EVALUACIÓN DE NUEVOS TRATAMIENTOS DE DIABETES. EFECTO DE LOS TRATAMIENTOS CON INSULINA, LIRAGLUTIDE Y CIRUGÍA BARIÁTRICA EN LA MEJORIA DE LA DIABETES TIP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024024-14,0,0,0 2010-024026-38,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Radboud University Nijmegen Medical Center,Combining N-of-1 trials to estimate population clinical effectiveness of drugs using Bayesian hierarchical modeling. The case of Mexilitin for patients with Non-Dystrophic Myotonia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024026-38,0,0,0 2010-024028-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospital Universitario de Canarias,EFFECT OF PENTOXIFYLLINE ON THE TIGHT JUNCTIONS (TJs) OF THE INTESTINAL MUCOSA IN PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS). EFECTO DE LA PENTOXIFILINA EN LAS UNIONES ESTRECHAS (TJs) DE LA MUCOS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024028-24,0,0,0 2010-024033-24,1,2013-10-15,2013-10-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dermapharm AG,"Doppelblinde, randomisierte klinische Studie zum Vergleich der Wirksamkeit und Verträglichkeit von Betamethason 0,05%_Salicylsäure 2% Lösung vs. Diprosalic Lösung vs. Grundlage bei Patienten mit Psori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024033-24,0,0,0 2010-024042-30,1,2012-11-07,2012-11-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Durata Therapeutics, Inc","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO COMPARE THE EFFICACY AND SAFETY OF DALBAVANCIN TO A COMPARATOR REGIMEN (VANCOMYCIN AND LINEZOLID) FOR THE TREATMENT OF ACUTE BACTERIAL SKIN A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024042-30,0,0,0 2010-024044-15,1,2013-08-15,2013-08-15,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Lantheus Medical Imaging, Inc.","A Phase 3, Open-Label, Multicenter Study for the Assessment of Myocardial Perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in Patients with Suspected or Known C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024044-15,0,0,0 2010-024045-69,1,2011-04-01,2011-04-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare,"A multi centre, randomised, double blind, single dose parallel group, placebo controlled study to investigate the efficacy of Strepsils Plus and Strepsils Extra in the treatment of sore throat due to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024045-69,0,0,0 2010-024046-29,1,2016-01-06,2016-01-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,FNCLCC,"Etude de phase II, randomisée, multicentrique, de l’Afatinib (BIBW2992) administré en pré-opératoire, chez des patients ayant un carcinome épidermoïde des voies aérodigestives supérieures non métastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024046-29,0,0,0 2010-024048-14,1,2015-01-01,2015-01-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Imperial College London,A randomised-controlled trial of donepezil for motor recovery in acute stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024048-14,0,0,0 2010-024049-53,7,2015-06-11,2015-06-11,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and Safety of FIAsp compared to insulin aspart both in Combination with insulin detemir in Adults with Type 1 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024049-53,0,0,0 2010-024050-10,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Middelfart Rygsektor,Vertebroplasty versus periost infiltration with lidocain as pain treatment in osteoporotic fractures in the thoracic and lumbar spine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024050-10,0,0,0 2010-024051-93,2,2014-12-22,2015-01-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination with Insulin Glargine and Metformin in Adults with Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024051-93,0,0,0 2010-024054-11,6,2017-07-21,2017-07-21,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid® in Adults with Type 1 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024054-11,0,0,0 2010-024061-48,1,2014-01-10,2014-01-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche Bulgaria EOOD,"Phase II, open-label study of erlotinib (Tarceva®) treatment in patients with locally advanced, metastatic or recurrent non-small cell lung cancer who present activating mutations in the tyrosine kina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024061-48,0,0,0 2010-024062-22,1,2013-11-01,2013-11-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Moorfields Eye Hospital,"A prospective, randomised controlled trial of Ranibizumab pre-treatment in Diabetic Vitrectomy – a pilot study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024062-22,0,0,0 2010-024064-18,2,2012-02-06,2012-02-08,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Omthera Pharmaceutical Inc.,Efficacy and Safety of Epanova® in Severe Hypertriglyceridemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024064-18,0,0,0 2010-024065-46,1,2014-06-09,2014-06-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Lone Baandrup,Melatonin vs. placebo til nedtrapning af benzodiazepiner hos patienter med skizofreni: et randomiseret klinisk forsøg (SMART),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024065-46,0,0,0 2010-024068-16,2,2012-01-06,2012-01-06,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Synageva Biopharma Corp.,"An open label multicenter study to evaluate the safety, tolerability and pharmacokinetics of SBC-102 in adult patients with liver dysfunction due to lysosomal acid lipase deficiency.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024068-16,0,0,0 2010-024069-30,7,2014-04-17,2014-08-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus Erythematosus Studio di fase IIb, per valutare l'™efficacia e la sicurezza di Sifali...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024069-30,0,0,0 2010-024069-30,7,2014-04-17,2014-08-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus Erythematosus Studio di fase IIb, per valutare l'™efficacia e la sicurezza di Sifali...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024069-30,0,0,0 2010-024077-39,3,2020-07-13,2020-07-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,"Phase IB-II, open label, multicentre feasibility study of pazopanib in combination with Paclitaxel and Carboplatin in patients with platinumrefractory/ resistant ovarian, fallopian tube or peritoneal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024077-39,0,0,0 2010-024078-20,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,0,Instituto Científico y Tecnológico de Navarra,"Ensayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pulsa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024078-20,0,0,0 2010-024084-40,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,0,Aurora Pujol Onofre,"Ensayo clínico en adrenomieloneuropatía (AMN): validación de biomarcadores de estrés oxidativo, eficacia y tolerancia de la combinación de antioxidantes N-acetilcisteína, ácido lipoico y vitamina E",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024084-40,0,0,0 2010-024087-17,6,2012-02-21,2012-02-21,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024087-17,0,0,0 2010-024087-17,6,2012-02-21,2012-02-21,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024087-17,0,0,0 2010-024092-39,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,0,JESUS GONZALEZ BARBOTEO,Ensayo clínico multicéntrico aleatorizado simple ciego comparativo entre dos ratios de conversión de metadona parenteral a metadona oral en pacientes con cáncer avanzado y dolor oncológico.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024092-39,0,0,0 2010-024094-39,1,2015-07-01,2015-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"University of Ulm, University Hospital Ulm","Offene, monozentrische, nicht kontrollierte und nicht randomisierte Phase IV-Studie zur Bestimmung der Pharmakokinetik von Carbapenemen in adipösen Patienten.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024094-39,0,0,0 2010-024096-87,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Sebastiano Biondo Aglio,ESTUDIO CLÍNICO PROSPECTIVO ALEATORIZADO DOBLE CIEGO SOBRE LA UTILIDAD TERAPÉUTICA DEL GASTROGRAFÍN EN ÍLEO PARALÍTICO EN EL POSTOPERATORIO DE CIRUGÍA COLORRECTAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024096-87,0,0,0 2010-024099-25,6,2013-05-23,2015-12-07,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, multi-center cross-over study to evaluate patient preference and Health Care Professional (HCP) satisfaction with subcutaneous (SC) administration of trastuzumab in HER2-positive early...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024099-25,0,0,0 2010-024099-25,6,2013-05-23,2015-12-07,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"A randomized, multi-center cross-over study to evaluate patient preference and Health Care Professional (HCP) satisfaction with subcutaneous (SC) administration of trastuzumab in HER2-positive early...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024099-25,0,0,0 2010-024100-10,1,2013-05-03,2013-05-03,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,The Rotterdam Eye Hospital,"Clonidine as an adjuvant to prolong local anaesthesia in ophthalmic surgery with cryocoagulation. A randomized, controlled, patient-masked trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024100-10,0,0,0 2010-024107-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Zentrum für Neuro-Onkologie,"Monozentrische Randomisierte Phase III Studie zum Vergleich von hoch dosiertem Bevacizumab plus Irinotecan, niedrig dosiertem Bevacizumab plus Irinotecan und CCNU/Procarbacin bei Patienten mit fortsch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024107-27,0,0,0 2010-024108-84,9,2014-02-15,2014-02-15,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,"A PHASE 3 CLINICAL STUDY TO DETERMINE THE PHARMACOKINETICS, SAFETY AND EFFICACY OF rVWF:rFVIII and rVWF IN THE TREATMENT OF BLEEDING EPISODES IN SUBJECTS DIAGNOSED WITH VON WILLEBRAND DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024108-84,0,0,0 2010-024108-84,9,2014-02-15,2014-02-15,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,BAXTER INNOVATIONS GMBH,"A PHASE 3 CLINICAL STUDY TO DETERMINE THE PHARMACOKINETICS, SAFETY AND EFFICACY OF rVWF:rFVIII and rVWF IN THE TREATMENT OF BLEEDING EPISODES IN SUBJECTS DIAGNOSED WITH VON WILLEBRAND DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024108-84,0,0,0 2010-024111-13,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AIO-Studien-gGmbH,Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas prior to gastrectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024111-13,0,0,0 2010-024113-31,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Instituto Científico y Tecnológico de Navarra,"Ensayo clínico multicéntrico, doble ciego, controlado con placebo, cruzado (2x2) con aleatorización de la secuencia, para evaluar la eficacia y seguridad de Omalizumab (Xolair®, Novartis) en una nueva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024113-31,0,0,0 2010-024115-14,1,2013-04-09,2013-04-09,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital Muenster,Preoperative Intravenous Ferric Carboxymaltose (Ferinject) in Patients with Orthopaedic Surgery and High Risk of Blood Loss Intravenöse Gabe von Eisen-Carboxymaltose (Ferinject) zur präoperativen T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024115-14,0,0,0 2010-024117-31,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Instituto Científico y Tecnológico de Navarra,Estudio de la eficacia de la administración prolongada de antibióticos betalactámicos frente a la administración intermitente en el tratamiento de la infección causada por microorganismo sensibles per...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024117-31,0,0,0 2010-024118-73,1,2019-05-21,2019-05-21,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Instituto Científico y Tecnológico de Navarra,ESTUDIO PROSPECTIVO EN FASE II DE LA EFICACIA Y SEGURIDAD DE LA VACUNACIÓN CON CÉLULAS DENDRÍTICAS AUTÓLOGAS EN PACIENTES CON ADENOCARCINOMA DE COLON LOCALMENTE AVANZADO DE ALTO RIESGO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024118-73,0,0,0 2010-024119-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Clínica Universidad de Navarra/Universidad de Navarra,"EVALUATION OF THE EFFICACY OF TOLCAPONE AS A GENOTYPE-BASED TARGETED COGNITIVE ENHANCER IN SCHIZOPHRENIA, BASED ON THE POLYMORPHISM RS4680 EVALUACIÓN DE TOLCAPONA COMO POTENCIADOR COGNITIVO EN LA E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024119-15,0,0,0 2010-024129-20,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Consorcio de Apoyo a la Investigación Biomédica en red (CAIBER),"Oral Versus Intramuscular Cobalamin to treat Cobalamin Deficiency: Noninferiority randomised controlled trial, pragmatic and multi-center in the primary healthcare setting (OB12 project). Admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024129-20,0,0,0 2010-024131-16,1,2014-04-30,2014-04-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Universitätsklinikum Münster,"Efficacy and Safety of oral Alitretinoin (Toctino®) in the Treatment of Patients with Cutaneous Lupus Erythematosus: A Multicentre, Open-Label, Prospective Pilot Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024131-16,0,0,0 2010-024132-41,10,2021-07-30,2021-08-30,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,"A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA EVALUATING THE BENEFIT OF GA101 (RO5072759) PLUS CHEMOTHERAPY COMP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024132-41,1,0,0 2010-024132-41,10,2021-07-30,2021-08-30,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ROCHE,"A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED INDOLENT NON-HODGKIN'S LYMPHOMA EVALUATING THE BENEFIT OF GA101 (RO5072759) PLUS CHEMOTHERAPY COMP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024132-41,1,0,0 2010-024133-23,2,2015-05-29,2015-05-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffman-La Roche Ltd.,"An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor RO5185426 in Patients with Metastatic or Unresectable Papillary Thyroid Cancer (PTC) positive for the BRAF V600 Mutation and Resistant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024133-23,0,0,0 2010-024137-22,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,AstraZeneca AB,"A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024137-22,0,0,0 2010-024138-43,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Javier Pascual Ramírez,Protocolo de suero salino hipertónico y terlipresina en la mejora funcional del shock séptico,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024138-43,0,0,0 2010-024150-10,2,2012-07-27,2012-08-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Teva Pharmaceutical Industries Ltd.,"A 15-week, double-blind, randomized, active-controlled, multicenter study to evaluate the efficiency and safety of Alendronate plus Vitamin D3 in the prevention of Vitamin D3 insufficiency and deficie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024150-10,0,0,0 2010-024152-29,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,University Hospital of Tübingen,Canakinumab for Behçet`s Disease Resistant to Standard Treatment (CanBeDisT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024152-29,0,0,0 2010-024153-36,1,2012-02-02,2012-02-02,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Professor Jørgen Berg Dahl,"Effekten af Transversus Abdominis Plane (TAP) blok versus sårinfiltration versus placebo på smerter efter åben prostatektomi, et dobbeltblindt randomiseret forsøg",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024153-36,0,0,0 2010-024156-28,1,2017-12-21,2017-12-21,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Charité - University Hospital of Berlin,"A multi-center, double-blind, placebo-controlled phase II study of the efficacy and safety of canakinumab in subjects with Schnitzler syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024156-28,0,0,0 2010-024158-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Especialidades Farmaceúticas Centrum S.A.,"ENSAYO CLÍNICO PILOTO, FASE IV, UNICÉNTRICO, CONTROLADO, ABIERTO CON EVALUACIÓN CIEGA POR TERCEROS, DE 12 SEMANAS DE DURACIÓN PARA EVALUAR LA EFICACIA Y SEGURIDAD DE EXTRACTO DE CÚRCUMA CENTRUM® ESTAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024158-13,0,0,0 2010-024162-22,1,,,0,1,0,1,0,0,1,0,0,3,0,0,0,0,1,Azellon Ltd,A Prospective Open-Label Study to Evaluate the Safety of Cell Bandage (Mesenchymal Stem Cells) in the Treatment of Meniscal Tears,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024162-22,0,0,0 2010-024164-18,1,2012-11-08,2012-11-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Medical Center Hamburg-Eppendorf,"Single-arm, open-label, monocentric Phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) for the treatment of patients with HER2-positive, hormone-refractory prostate cancer after...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024164-18,0,0,0 2010-024165-44,5,2017-01-26,2017-01-26,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushing’s disease (Seascape)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024165-44,0,0,0 2010-024165-44,5,2017-01-26,2017-01-26,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,NOVARTIS FARMACEUTICA S.A.,"An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushing’s disease (Seascape)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024165-44,0,0,0 2010-024168-16,1,2015-12-14,2015-12-14,1,0,0,0,1,0,2,0,0,1,1,1,1,0,0,CASA DI CURA PRIVATA S.RAFFAELE - PISANA,A TRIAL OF INHALED NEBULISED UNFRACTIONATED HEPARIN SODIUM IN PATIENTS WITH STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE STUDIO CLINICO SULLA SOMMINISTRAZIONE DI EPARINA SODICA NON FRAZIONATA NEBUL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024168-16,0,0,0 2010-024169-33,1,2011-12-01,2011-12-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Sucampo Pharma Americas, Inc.","A Single-center, Double-masked, Randomized, Pharmacodynamic Crossover Study of Ocular Blood Flow Effects of Topically-administered Unoprostone in Adults with Age-related Macular Degeneration (AMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024169-33,0,0,0 2010-024172-26,1,2015-05-19,2015-05-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, double-dummy, active controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares, for whom NSAIDs and/or colchi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024172-26,0,0,0 2010-024173-39,4,2012-09-10,2012-09-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Service AG,"A randomized, double-blind, active-controlled study of canakinumab (ACZ885) pre-filled syringes or reconstituted lyophilizate versus triamcinolone acetonide for treating acute gouty arthritis flares ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024173-39,0,0,0 2010-024173-39,4,2012-09-10,2012-09-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, active-controlled study of canakinumab (ACZ885) pre-filled syringes or reconstituted lyophilizate versus triamcinolone acetonide for treating acute gouty arthritis flares ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024173-39,0,0,0 2010-024175-58,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IKEM,Comparison of two treatment options for hypertension in heart transplant recipients Srovnání dvou způsobů léčby hypertenze u pacientů po transplantaci srdce,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024175-58,0,0,0 2010-024177-39,1,,,0,1,0,0,0,0,2,0,1,1,1,1,0,1,1,ALFA WASSERMANN,Prospective microbiological study on patients with non-constipation IBS treated with rifaximin 550 mg tablets.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024177-39,0,0,0 2010-024179-18,9,2012-05-25,2012-05-25,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017",A 14 WEEK RANDOMIZED PARALLEL GROUP PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTRE STUDY OF FESOTERODINE 8 MG IN OVERACTIVE BLADDER PATIENTS WITH SUB-OPTIMAL RESPONSE TO TOLTERODINE 4 MG ER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024179-18,0,0,0 2010-024179-18,9,2012-05-25,2012-05-25,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017 US",A 14 WEEK RANDOMIZED PARALLEL GROUP PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTRE STUDY OF FESOTERODINE 8 MG IN OVERACTIVE BLADDER PATIENTS WITH SUB-OPTIMAL RESPONSE TO TOLTERODINE 4 MG ER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024179-18,0,0,0 2010-024179-18,9,2012-05-25,2012-05-25,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,PFIZER INC.,A 14 WEEK RANDOMIZED PARALLEL GROUP PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTRE STUDY OF FESOTERODINE 8 MG IN OVERACTIVE BLADDER PATIENTS WITH SUB-OPTIMAL RESPONSE TO TOLTERODINE 4 MG ER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024179-18,0,0,0 2010-024179-18,9,2012-05-25,2012-05-25,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Inc.,A 14 WEEK RANDOMIZED PARALLEL GROUP PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTRE STUDY OF FESOTERODINE 8 MG IN OVERACTIVE BLADDER PATIENTS WITH SUB-OPTIMAL RESPONSE TO TOLTERODINE 4 MG ER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024179-18,0,0,0 2010-024181-22,14,2012-11-04,2012-11-19,14,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","A 12-WEEK, PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL IN OVERACTIVE BLADDER SUBJECTS TO CONFIRM THE EFFICACY OF 8 MG FESOTERODINE COMPARED TO 4 MG FESOTER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024181-22,0,0,0 2010-024181-22,14,2012-11-04,2012-11-19,14,1,0,0,0,0,4,0,0,1,1,0,1,0,1,PFIZER INC.,"A 12-WEEK, PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL IN OVERACTIVE BLADDER SUBJECTS TO CONFIRM THE EFFICACY OF 8 MG FESOTERODINE COMPARED TO 4 MG FESOTER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024181-22,0,0,0 2010-024181-22,14,2012-11-04,2012-11-19,14,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Pfizer Inc.,"A 12-WEEK, PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL IN OVERACTIVE BLADDER SUBJECTS TO CONFIRM THE EFFICACY OF 8 MG FESOTERODINE COMPARED TO 4 MG FESOTER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024181-22,0,0,0 2010-024181-22,14,2012-11-04,2012-11-19,14,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Pfizer Inc,"A 12-WEEK, PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL IN OVERACTIVE BLADDER SUBJECTS TO CONFIRM THE EFFICACY OF 8 MG FESOTERODINE COMPARED TO 4 MG FESOTER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024181-22,0,0,0 2010-024181-22,14,2012-11-04,2012-11-19,14,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017 US","A 12-WEEK, PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL IN OVERACTIVE BLADDER SUBJECTS TO CONFIRM THE EFFICACY OF 8 MG FESOTERODINE COMPARED TO 4 MG FESOTER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024181-22,0,0,0 2010-024182-44,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,3,,Pilot study: Leucocyte actIvation and endothelial function after oral fat loading combined with VITamin D,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024182-44,0,0,0 2010-024185-22,1,2011-06-10,2011-06-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Med. Univ. Wien, Klinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie","Prospective, Randomized Clinical Pilot Study: Use of Lidocaine/Tetracaine Patch (Rapydan®) for Topical Anesthesia before Aterial Access",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024185-22,0,0,0 2010-024189-23,1,2012-09-09,2012-09-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Weleda AG,"Efficacy and safety of Neurodoron in patients with nervous exhaustion - a randomized, double-blind, placebo-controlled clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024189-23,0,0,0 2010-024190-39,1,2016-12-31,2016-12-31,1,0,1,0,0,1,3,0,0,1,0,0,1,0,1,Aptevo Europe Limited,"Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects with Hemophilia B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024190-39,0,0,0 2010-024191-25,2,2014-07-25,2014-07-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Effects of agomelatine (25 to 50 mg/day) on circadian rhythms in patients with Major Depressive Disorder. An exploratory 6-week open, flexible dose, international multicentre, non comparative study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024191-25,0,0,0 2010-024194-39,10,2018-01-31,2018-01-31,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED TRIAL COMPARING THE EFFICACY OF GA101 (RO5072759) IN COMBINATION WITH CHOP (G-CHOP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024194-39,0,0,0 2010-024194-39,10,2018-01-31,2018-01-31,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann - La Roche Ltd.,"A PHASE III, MULTICENTER, OPEN-LABEL, RANDOMIZED TRIAL COMPARING THE EFFICACY OF GA101 (RO5072759) IN COMBINATION WITH CHOP (G-CHOP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024194-39,0,0,0 2010-024196-83,1,2015-02-03,2015-02-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Can-Fite BioPharma, Ltd.","A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients with Moderate-to-Severe Plaque Psoriasis CF 10...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024196-83,0,0,0 2010-024198-38,6,2012-09-28,2012-09-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 (15 and 20 mg/day) in patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024198-38,0,0,0 2010-024201-12,1,2012-05-15,2012-05-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Med. Uni. Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie",Klinische Pilotstudie Zum Prospektiven Vergleich der Analgetischen Wirksamkeit Eines Oralen Und Eines Invasiven Opiat-Regimes Nach Herzchirurgischen Operationen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024201-12,0,0,0 2010-024202-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"UNIVERSITÄTSMEDIZIN GÖTTINGEN, GEORG-AUGUST-UNIVERSITÄT,Klinik für Kinder- und Jugendpsychiatrie/Psychotherapie",Effect of oxytocin on therapy results of a group based social skill training in adolescents with Autism Spectrum Disorder Effekt von Oxytocin auf den Therapieerfolg eines sozialen Kompetenztraini...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024202-34,0,0,0 2010-024208-81,1,2013-05-14,2013-05-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Christian Westergaard,Smoking young asthmatics: Change of inflammation and quitting cessation rate – effect of Champix,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024208-81,0,0,0 2010-024210-65,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Evaluation of antiplatelet drug response after load of statins in patients undergoing coronary angioplasty with stenting. Valutazione della risposta farmacologica antipiastrinica dopo carico di sta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024210-65,0,0,0 2010-024211-13,4,2012-02-17,2012-02-17,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,ACTELION Pharmaceuticals Ltd.,"Long term, single-arm, open-label extension study of the MUSIC study to assess the safety and tolerability of macitentan in patients with idiopathic pulmonary fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024211-13,0,0,0 2010-024212-33,1,,,0,0,0,0,0,0,0,0,0,4,0,0,0,0,0,CHU de BORDEAUX,"Pharmacocinétique de population des anti-infectieux (Ceftazidime, Ciprofloxacine et Voriconazole) chez l’enfant âgé de 1 mois à 5 ans.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024212-33,0,0,0 2010-024213-31,1,2014-01-08,2014-01-08,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Leicester,Can Vitamin D Replacement Reduce Insulin resistance In South Asians with Vitamin D Deficiency?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024213-31,0,0,0 2010-024214-54,2,2011-07-25,2011-07-25,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GALDERMA R&D SNC,Exploratory study to assess facial tolerability after daily application of several concentrations and formulations containing CD5789 in acne subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024214-54,0,0,0 2010-024215-14,7,2018-07-06,2018-07-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Sperimentazio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024215-14,0,0,0 2010-024215-14,7,2018-07-06,2018-07-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc","A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Sperimentazio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024215-14,0,0,0 2010-024216-34,1,2012-03-13,2012-03-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,ABCSG (Austrian Breast & Colorectal Cancer Study Group),"Neoadjuvant Endocrine Treatment +/- Bevacizumab in postmenopausal Patients with Operable Primary, HER2-neu negative Breast Cancer (including Lobular Cancer) (I) not suitable for Chemotherapy or (II) u...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024216-34,0,0,0 2010-024219-15,7,2012-06-25,2012-06-25,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK","A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED PH-797804 FOR 12 WEEKS IN ADULTS WITH MODERATE TO S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024219-15,0,0,0 2010-024225-20,1,2020-03-26,2020-03-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"University Hospital Munich, Germany",The impact of phosphate balanced cristalloid infusion on acid-base homeostastis Auswirkungen einer balancierten Infusionslösung mit Phosphatzusatz auf den Säure-Basen-Haushalt,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024225-20,0,0,0 2010-024227-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación para la Investigación Biomédica del Hospital Ramón y Cajal,Ensayo clínico en fase II sobre neuroprotección por cannabinoides en enfermedad de Huntington,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024227-24,0,0,0 2010-024230-35,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Fundacion par la investigación biomédica del Hospital Universitario La Paz,Effectiveness of hipertonic saline serum 3% nebulized in bronchiolitis Eficacia del suero salino hipertónico al 3% nebulizado en el tratamiento de la bronquiolitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024230-35,0,0,0 2010-024231-16,1,2013-03-21,2013-03-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma S.A.S,"Etude prospective, multicentrique, randomisée, en ouvert, de phase 2, d'une durée de 12 semaines, évaluant la pharmacodynamie, l’efficacité et la tolérance de Simulect® chez des patients adultes trans...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024231-16,0,0,0 2010-024237-23,1,2016-04-06,2016-04-06,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Basilea Pharmaceutica International Ltd.,An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients with Advanced Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024237-23,0,0,0 2010-024238-46,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Universitätsklinikum Ulm,"DETECT III – A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus Lapatinib in patients with initially HER2-negative metastatic breast cancer and H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024238-46,0,0,0 2010-024242-30,3,2014-10-17,2014-11-14,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,CSL Behring GmbH,Prospective open-label uncontrolled multi-center post-marketing study to assess inhibitory antibody formation in subjects with congenital C1-INH deficiency and acute hereditary angioedema (HAE) attack...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024242-30,0,0,0 2010-024244-15,3,2012-10-13,2012-10-13,3,1,0,0,2,0,4,0,0,1,0,0,1,0,1,ALCON Research Ltd,"""Patient Preference Comparison of Azarga versus Cosopt, in Patients with Open-Angle Glaucoma or Ocular Hypertension.""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024244-15,0,0,0 2010-024244-15,3,2012-10-13,2012-10-13,3,1,0,0,2,0,4,0,0,1,0,0,1,0,1,"ALCON RESEARCH, LTD.","""Patient Preference Comparison of Azarga versus Cosopt, in Patients with Open-Angle Glaucoma or Ocular Hypertension.""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024244-15,0,0,0 2010-024247-32,6,2014-07-25,2014-07-25,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SHIRE VIROPHARMA INCORPORATED,"A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WHO D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024247-32,0,0,0 2010-024247-32,6,2014-07-25,2014-07-25,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,VIROPHARMA INCORPORATED,"A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WHO D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024247-32,0,0,0 2010-024247-32,6,2014-07-25,2014-07-25,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Shire ViroPharma Incorporated,"A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WHO D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024247-32,0,0,0 2010-024249-59,13,2015-12-18,2016-02-03,8,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Cardiorentis Ltd.,"Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering from Acute Decompens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024249-59,1,0,0 2010-024249-59,13,2015-12-18,2016-02-03,8,0,0,0,0,0,3,0,0,2,1,0,0,0,1,CARDIORENTIS LTD,"Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering from Acute Decompens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024249-59,1,0,0 2010-024251-87,6,2013-10-09,2013-10-09,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmBH & Co KG,"A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024251-87,0,0,0 2010-024251-87,6,2013-10-09,2013-10-09,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024251-87,0,0,0 2010-024251-87,6,2013-10-09,2013-10-09,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024251-87,0,0,0 2010-024251-87,6,2013-10-09,2013-10-09,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024251-87,0,0,0 2010-024251-87,6,2013-10-09,2013-10-09,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024251-87,0,0,0 2010-024252-29,6,2003-10-15,2013-11-18,6,1,0,0,0,1,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim,"A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024252-29,0,0,0 2010-024252-29,6,2003-10-15,2013-11-18,6,1,0,0,0,1,3,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A.","A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024252-29,0,0,0 2010-024252-29,6,2003-10-15,2013-11-18,6,1,0,0,0,1,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim France,"A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024252-29,0,0,0 2010-024252-29,6,2003-10-15,2013-11-18,6,1,0,0,0,1,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024252-29,0,0,0 2010-024253-36,1,2019-12-23,2019-12-23,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,Great Ormond Street Hospital for Children NHS Trust,"Phase I/II, historical controlled, open-label, non-randomised, single-centre trial to assess the safety and efficacy of EF1αS-ADA lentiviral vector mediated gene modification of autologus CD34+ cells ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024253-36,0,0,0 2010-024254-11,1,2013-09-26,2013-09-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Can-Fite BioPharma, Ltd","A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients with Moderate-to-Severe Dry Eye D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024254-11,0,0,0 2010-024256-28,2,2012-04-20,2012-04-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen Cilag International NV,"A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024256-28,0,0,0 2010-024260-17,10,2014-01-21,2014-01-21,4,1,1,0,0,0,3,0,0,1,1,1,1,0,1,"Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1. Studio di Fase ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024260-17,0,0,0 2010-024260-17,10,2014-01-21,2014-01-21,4,1,1,0,0,0,3,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1. Studio di Fase ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024260-17,0,0,0 2010-024260-17,10,2014-01-21,2014-01-21,4,1,1,0,0,0,3,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc",A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1. Studio di Fase ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024260-17,0,0,0 2010-024260-17,10,2014-01-21,2014-01-21,4,1,1,0,0,0,3,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc",A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination with Peginterferon alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1. Studio di Fase ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024260-17,0,0,0 2010-024262-22,2,2022-05-31,2022-05-31,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Friedrich-Schiller-Universität Jena,Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotinib o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024262-22,1,0,0 2010-024263-40,1,2019-03-28,2019-03-28,1,1,0,0,0,1,3,0,0,1,1,1,1,0,0,"Medizinische Universität Wien, Univ. Klinik f. Klinische Pharmakologie",Plasma exchange as therapy for disseminated intrevascular coagulation (DIC)- a randomized-controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024263-40,0,0,0 2010-024264-18,6,2016-05-24,2016-06-20,4,1,1,0,0,1,1,0,0,2,0,0,0,0,1,Amgen Research (Munich) GmbH,"A Single-Arm Multicenter Phase II Study preceded by Dose Evalua-tion to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024264-18,1,1,0 2010-024264-18,6,2016-05-24,2016-06-20,4,1,1,0,0,1,1,0,0,2,0,0,0,0,1,MICROMET GMBH,"A Single-Arm Multicenter Phase II Study preceded by Dose Evalua-tion to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024264-18,1,1,0 2010-024265-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HOSPITAL UNIVERSITARI DE BELLVITGE,Perineural vs systemic N-methyl-D-aspartate (NMDA) receptors antagonism with ketamine as a reverser of peripheral and central sensitization in phantom limb pain ANTAGONISMO DE LOS RECEPTORES N-MET...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024265-40,0,0,0 2010-024266-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine and vinorelbine in metastatic breast cancer patients Studio di fase II di terapia orale metronomica con Vin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024266-21,0,0,0 2010-024270-19,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,CHIESI,"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/day for up to 12 Weeks) and to Explore the Effect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024270-19,0,0,0 2010-024271-10,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,PIERRE FABRE MEDICAMENT,Urodynamic effect of one single vaginal application of 2 mL of V0162 gel (0.8%) in post-menopausal women with overactive bladder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024271-10,0,0,0 2010-024272-26,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS,Comparison of the effects of Bimatoprost 0.01% and Timolol 0.5% on circadian intraocular pressure Confronto tra gli effetti del Bimatoprost 0.01% e Timololo 0.5% sulla pressione intraoculare circa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024272-26,0,0,0 2010-024273-38,3,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University Hospitals of Leuven,Supplemental COrTicosteroids in Cirrhotic Hypotensive patients with suspicion of SepsIS. The SCOTCHIS trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024273-38,0,0,0 2010-024273-38,3,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University Hospitals Leuven,Supplemental COrTicosteroids in Cirrhotic Hypotensive patients with suspicion of SepsIS. The SCOTCHIS trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024273-38,0,0,0 2010-024279-14,4,2011-09-28,2011-10-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Intendis GmbH,"Double-blind, randomized, vehicle-controlled, multicenter, multinational, parallel-group study of the efficacy and safety of mapracorat ointment in concentrations of 0.01%, 0.03% and 0.1% over max. 4 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024279-14,0,0,0 2010-024282-41,1,2018-06-19,2018-06-19,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Hospices Civils de Lyon,TRAITEMENT DE LA DYSPLASIE FIBREUSE DES OS CHEZ LES PATIENTS NON REPONDEURS AUX BISPHOSPHONATES PAR LE TOCILIZUMAB. L’ESSAI TOCIDYS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024282-41,0,0,0 2010-024283-18,1,2013-02-21,2013-02-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Afferent Pharmaceuticals, Inc.","A Study to Assess the Efficacy of AF-219, a P2X3 Receptor Antagonist, in Subjects with Chronic Cough",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024283-18,0,0,0 2010-024287-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Salvage therapy with trabectidin in metastatic pancreatic adenocarcinoma: a single-arm phase II trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024287-17,0,0,0 2010-024289-24,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Helse Bergen HF, Haukeland Unversity Hospital",TREATMENT OF PANCREATIC ADENOCARCINOMA BY COMBINING CONTRAST AGENT AND GEMCITABINE UNDER SONICATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024289-24,0,0,0 2010-024290-40,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,FUNDACIÓN PROGRESO Y SALUD,Multicenter clinical trial to evaluate the safety and feasibility of allogeneic tissue engineered product (human nanostructured artificial cornea) in patients with advanced corneal trophic ulcers refr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024290-40,0,0,0 2010-024292-30,2,2013-11-28,2013-11-28,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Pharma Mar, S.A. Sociedad Unipersonal",A Phase II Study of PM01183 as Second-line Treatment in Patients with Metastatic Pancreatic Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024292-30,0,0,0 2010-024297-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Liege,Allogeneic hematopoietic cell transplantation from HLA-matched donors after reduced-intensity conditioning: a phase II randomized study comparing 2 GVHD prophylaxis regimen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024297-19,0,0,0 2010-024298-37,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Dipartimento Integrato di Oncologia, Ematologia e Patologie dell'Apparato Respiratorio",Early strong opiod treatment in cancer pain -Morphine vs weak opiods Studio ESOT-M - Valutazione comparativa di strategie farmacologiche per la gestione del dolore nel paziente oncologico,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024298-37,0,0,0 2010-024300-10,1,2019-03-26,2019-03-26,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,University Medical Center Göttingen,Early prospective therapy trial to delay renal failure in children with Alport syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024300-10,0,0,0 2010-024303-27,2,2012-07-13,2012-07-13,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 20 weeks randomised, multinational, open labelled, 2 armed, parallel group comparison of twice daily subject-driven titration of biphasic insulin aspart (BIAsp) 30 versus twice daily investigator-dr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024303-27,0,0,0 2010-024305-13,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,QUEST PHARMATECH INC.,A RANDOMIZED CONTROLLED STUDY ON THE EFFECTIVENESS OF FIRST-LINE CHEMOTHERAPY (CARBOPLATIN AND PACLITAXEL) VERSUS CHEMO-IMMUNOTHERAPY (CARBOPLATIN-PACLITAXEL-OREGOVOMAB) IN PATIENTS WITH ADVANCED EPIT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024305-13,0,0,0 2010-024306-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Västra Götalandsregionen,An exploratory study of sorafenib for patients listed for transplantation due to HCC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024306-36,0,0,0 2010-024307-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,TREATMENT WITH CMV PP65-SPECIFIC T CELLS GENERATED BY USE OF A CMV PP65 PROTEIN-SPANNING PEPTIDE POOL IN PATIENTS WITH CMV REACTIVATION OR CMV DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024307-27,0,0,0 2010-024309-11,1,,,0,0,0,0,1,0,3,0,0,1,1,1,0,1,0,JOSEP MARIA BOTARGUES BOTÉ,Eritromicina versus lavados por sonda nasogástrica para mejorar la calidad visual de la endoscopia digestiva en pacientes con hemorragia digestiva alta. Ensayo clínico aleatorizado,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024309-11,0,0,0 2010-024311-13,5,,,0,1,0,0,0,1,2,0,0,1,1,0,0,1,1,Merck KGaA,"A Multicenter, Double-Blind, Placebo Controlled, Randomized, 2-Arm Phase IIa Pilot Trial Assessing the Effect of Sapropterin on Cognitive Abilities in Young Adults with Phenylketonuria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024311-13,0,0,0 2010-024315-14,1,2014-10-21,2014-10-21,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Tekonivelsairaala Coxa,Paikallispuudutus polven tekonivelleikkauksen yhteydessä - vähentynyt opiaattien kulutus leikkauksen jälkeen ja nopeampi liikeharjoituksen aloitus - kaksoissokkotutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024315-14,0,0,0 2010-024320-23,1,2011-09-13,2011-09-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Chorus, Eli Lilly and Company",A Proof-of-Concept Study of the Effects of LY2828360 in the Treatment of Patients with Osteoarthritic Knee Pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024320-23,0,0,0 2010-024327-24,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,University Medical Centre Utrecht,Effect of C1-esterase inhibitor on systemic inflammation in trauma patients with a femur fracture.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024327-24,0,0,0 2010-024328-53,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación para la Investigación Biomédica del Hospital Universitario La Paz,Phase IIa clinical trial to determine the feasibility and safety of using autologous expanded stem cell (ASC) from fat in the treatment of keratopathy associated with bilateral limbic insufficiency ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024328-53,0,0,0 2010-024329-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Fundación para la Investigación Biomédica del Hospital Universitario La Paz, Sección de Cirugía Colorrectal del Hospital","ENSAYO CLINICO FASE IIa PARA EL TRATAMIENTO DE LA FISTULA PERIANAL EXTREMADAMENTE COMPLEJA Y RESISTENTE AL TRATAMIENTO CONVENCIONAL, CON CELULAS MADRE AUTOLOGAS OBTENIDAS DE LIPOASPIRADO ENSAYO CLI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024329-19,0,0,0 2010-024331-16,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación para la Investigación Biomédica del Hospital Universitario La Paz,Clinical trial phase II to determine the feasibility and safety of using autologous mesenchymal stem cells derived from autologous expanded adipose tissue (ASC) in the local treatment of female urinar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024331-16,0,0,0 2010-024332-42,8,2016-09-14,2016-09-14,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer AG,"A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024332-42,0,0,0 2010-024332-42,8,2016-09-14,2016-09-14,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024332-42,0,0,0 2010-024332-42,8,2016-09-14,2016-09-14,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer AG,"A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024332-42,0,0,0 2010-024336-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,JUAN MACIAS SANCHEZ,"ENSAYO CLÍNICO PILOTO, FASE II PARA EVALUAR LA ACTIVIDAD ANTIVÍRICA DE LA COMBINACIÓN DE INTERFERÓN PEGILADO MÁS RIBAVIRINA MÁS NITAZOXANIDA EN INDIVIDUOS CON HEPATITIS CRÓNICA DEBIDA A GENOTIPO 4 DEL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024336-42,0,0,0 2010-024342-30,2,2014-04-24,2014-04-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled multi-center study of BYM338 for treatment of cachexia in patients with stage IV non-small cell lung cancer or stage III/IV adenocarcinoma of the pancrea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024342-30,0,0,0 2010-024354-11,1,2013-08-26,2013-08-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ABCSG (Austrian Breast & Colorectal Cancer Study Group),Preoperative induction chemotherapy in combination with Bevacizumab followed by combined chemoradiotherapy in locally advanced rectal cancer with high risk of recurrence- phase II pilot study with pre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024354-11,0,0,0 2010-024355-85,5,2016-12-09,2016-12-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,EAU Research Foundation,"A randomized, double blind, placebo controlled phase II trial to evaluate the safety and efficacy of recMAGE-A3 + AS15 ASCI in patients with MAGE-A3 positive muscle invasive bladder cancer after cys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024355-85,0,0,0 2010-024355-85,5,2016-12-09,2016-12-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,EAU EUROPEAN ASSOCIATION OF UROLOGY,"A randomized, double blind, placebo controlled phase II trial to evaluate the safety and efficacy of recMAGE-A3 + AS15 ASCI in patients with MAGE-A3 positive muscle invasive bladder cancer after cys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024355-85,0,0,0 2010-024359-99,3,2011-10-26,2011-10-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-639 to Placebo in Subjects with Diabetic Neuropathic Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024359-99,0,0,0 2010-024364-18,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Leiden University,The effects of ARA290 on the cognitive and neural processing of emotions in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024364-18,0,0,0 2010-024364-18,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Leiden University Medical Center,The effects of ARA290 on the cognitive and neural processing of emotions in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024364-18,0,0,0 2010-024371-12,6,2013-02-07,2013-10-22,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Double-Blind, 58 week Rollover Study to assess the Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression. Revised Protocol 01 Incorporating Protoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024371-12,1,0,0 2010-024371-12,6,2013-02-07,2013-10-22,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,BRISTOL-M.SQUIBB,"A Multicenter, Double-Blind, 58 week Rollover Study to assess the Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression. Revised Protocol 01 Incorporating Protoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024371-12,1,0,0 2010-024377-40,1,2017-04-24,2017-04-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Medizinische Universität Wien, UniKlinik für Klinische Pharmakologie","A randomized phase II pilot - trial, examining the safety, pharmacokinetics, pharmacodynamics, and clinical efficacy of escalating doses of alteplase in patients with acute lung injury / acute respira...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024377-40,0,0,0 2010-024379-15,1,2015-11-19,2015-11-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,"Pazopanib with 5-Flourouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line treatment in advanced gastric cancer; a randomized Phase II study. - The PaFLO study. Pazopanib mit 5-FU, Leukovorin und ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024379-15,0,0,0 2010-024380-41,1,2016-06-23,2016-06-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cardiff University,A pilot study to assess the effect of regulatory T-cell depletion on 5T4-containing MVA(TroVax®)vaccination in patients with inoperable metastatic colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024380-41,0,0,0 2010-024381-21,10,2018-09-24,2018-09-24,9,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A 12-month, multicenter, open label, randomized, controlled study to evaluate the efficacy, tolerability and safety of early introduction of everolimus, reduced CNI, and early steroid elimination c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024381-21,1,1,0 2010-024381-21,10,2018-09-24,2018-09-24,9,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A 12-month, multicenter, open label, randomized, controlled study to evaluate the efficacy, tolerability and safety of early introduction of everolimus, reduced CNI, and early steroid elimination c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024381-21,1,1,0 2010-024381-21,10,2018-09-24,2018-09-24,9,1,1,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS FARMA,"A 12-month, multicenter, open label, randomized, controlled study to evaluate the efficacy, tolerability and safety of early introduction of everolimus, reduced CNI, and early steroid elimination c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024381-21,1,1,0 2010-024384-40,1,2011-06-09,2011-06-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A single-dose, open-label, randomized, 2-way crossover, clinical pharmacology study of four inhalations of CHF 1535 100/6 NEXT DPI® (fixed combination of beclomethasone dipropionate 100μg plus formote...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024384-40,0,0,0 2010-024387-17,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,Cumberland Pharmaceuticals Inc.,"A Multi-center, Randomized, Open-Label, Parallel, Active-Comparator, Multiple Dose Trial to Determine the Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Pediatric Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024387-17,0,0,0 2010-024389-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Department of Hematology,A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024389-23,0,0,0 2010-024391-25,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,1,XCell-Center GmbH,"A Multi-centre, double blind, randomized placebo controlled phase II study to assess the efficacy and safety of ASCT01 in Critical limb Ischemia Patients - SCILI",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024391-25,0,0,0 2010-024393-19,9,2017-06-29,2017-06-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Amgen, Inc.","A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024393-19,0,0,0 2010-024394-39,4,2011-12-19,2011-12-19,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,"A Phase II study of orally administered BEZ235 monotherapy in patients with hormone receptor positive, HER2 negative, metastatic breast cancer, with or without PI3K activated pathway",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024394-39,0,0,0 2010-024394-39,4,2011-12-19,2011-12-19,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A Phase II study of orally administered BEZ235 monotherapy in patients with hormone receptor positive, HER2 negative, metastatic breast cancer, with or without PI3K activated pathway",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024394-39,0,0,0 2010-024396-12,3,2011-12-16,2011-12-16,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024396-12,0,0,0 2010-024396-12,3,2011-12-16,2011-12-16,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,NOVARTIS FARMA,"A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024396-12,0,0,0 2010-024400-98,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2011-2012, when Administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024400-98,0,0,0 2010-024402-35,1,2012-03-29,2012-03-29,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Sussex NHS Research Consortium,Clinical effectiveness of Transversus Abdominis Plane (TAP) block as postoperative analgesic in patients undergoing laparoscopic colorectal surgery: a double blinded randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024402-35,0,0,0 2010-024409-11,1,2016-03-14,2016-03-14,1,1,0,0,1,0,2,0,0,1,1,1,1,0,0,Scottish National Blood Transfusion Service,Pilot Clinical Assessment of Ex Vivo Expanded Corneal Limbal Stem Cell Transplantation in Patients with Severe Ocular Surface Disease (OSD) Arising from Limbal Stem Cell Deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024409-11,0,0,0 2010-024409-11,1,2016-03-14,2016-03-14,1,1,0,0,1,0,2,0,0,1,1,1,1,0,0,NHS Lothian,Pilot Clinical Assessment of Ex Vivo Expanded Corneal Limbal Stem Cell Transplantation in Patients with Severe Ocular Surface Disease (OSD) Arising from Limbal Stem Cell Deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024409-11,0,0,0 2010-024414-61,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital de Girona Dr Josep Trueta,"Efectos endocrino-metabólicos, sobre la adiposidad visceral y parámetros de riesgo cardiovascular de la administración de metformina en niños prepuberales con obesidad y marcadores de riesgo para el s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024414-61,0,0,0 2010-024415-14,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,Institut Català d’Oncologia (ICO),"Ensayo clínico fase II, no randomizado, para evaluar el papel de Ipilimumab en monoterapia, administrado en primera línea en pacientes afectos de melanoma uveal metastásico. ""Phase II multi-center, n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024415-14,0,0,0 2010-024417-31,1,2012-11-26,2012-11-26,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Beaumont Hospital/RCSI,The effect of vitamin D replacement on arterial stiffness in an elderly community based population.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024417-31,0,0,0 2010-024421-21,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,JUAN IGNACIO ARENAS RUIZ-TAPIADOR,"Estudio fase II, multicéntrico, aleatorizado, doble ciego, de grupos paralelos para comparar la eficacia y seguridad de sorafenib más pravastatina frente a sorafenib más placebo en pacientes con hepat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024421-21,0,0,0 2010-024423-24,8,2017-10-30,2018-03-05,4,1,0,0,0,2,2,0,0,2,0,0,0,0,1,ABScience,"A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2/3 Study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024423-24,1,0,0 2010-024423-24,8,2017-10-30,2018-03-05,4,1,0,0,0,2,2,0,0,2,0,0,0,0,1,AB Science,"A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2/3 Study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024423-24,1,0,0 2010-024423-24,8,2017-10-30,2018-03-05,4,1,0,0,0,2,2,0,0,2,0,0,0,0,1,AB SCIENCE,"A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 2/3 Study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024423-24,1,0,0 2010-024424-26,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,AB Science,"A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo on cognitive impairment associate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024424-26,0,0,0 2010-024425-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Leiden University Medical Centre,"Phase III Randomized Double-blind Cross-over trial of Supersaturated Calcium-phosphate rinse (Caphosol®) versus NaCl 0.9% in the relief of Oral Mucositis in renal cell carcinoma, hepatocellular carcin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024425-20,0,0,0 2010-024428-10,1,,,0,1,0,0,0,1,2,0,0,4,0,0,0,0,0,CHU de NICE,Traitement des épidermolyses bulleuses simples de type Dowling Maera par l'érythromicine orale,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024428-10,0,0,0 2010-024431-17,1,2012-07-26,2012-07-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,A PILOT STUDY TO EVALUATE THE INCIDENCE OF HYPONATREMIA IN A MEDICAL-SURGICAL HOSPITAL AND TO EXPLORE THE EFFICACY AND SAFETY OF TOLVAPTAN IN THE CLINICAL PRACTICE STUDIO PILOTA PER VALUTARE L'IN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024431-17,0,0,0 2010-024435-16,2,2012-08-06,2012-08-06,2,1,0,0,2,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A 12-week study to evaluate the effect of fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI) on arteri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024435-16,0,0,0 2010-024438-52,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fakultní nemocnice v Motole,Impaired sense of smell and its conservative tratment in patients with chronic rhinosinusitis Hodnocení poruchy čichu a její medikamentózní léčba u pacientů s chronickou polypózní rinosinusitidou,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024438-52,0,0,0 2010-024440-15,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,DIATER Laboratorio de Diagnostico y Aplicaciones Terapéuticas S.A.,"Multicentre, double-blind, randomized, placebo-controlled, parallel-group, clinical trial to evaluates the clinical efficacy and safety of immunotherapy with purified major allergen Alt a 1 in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024440-15,0,0,0 2010-024445-78,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Magle AB,Nicotine plasma concentrations and subjective effects of a single dose of Nicachet 4 mg nicotine oromucosal powder in pouch compared with 4mg Nicorette chewing gum and 1mg Nicorette nasal spray.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024445-78,0,0,0 2010-024446-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA CARDINALE G.PANICO-TRICASE (LECCE),"A PHASE II STUDY OF CHEMOTHERAPY, MOZOBIL AND G-CSF AS MOBILIZING THERAPY FOR DOUBLE AUTOLOGOUS TRANSPLANTATION (ASCT) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL NON HODGKIN LYMPHOMA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024446-30,0,0,0 2010-024448-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Netherlands Heart Foundation,Effects of low-dose aspirin taken at bedtime on blood pressure of subjects with who use aspirin for prevention of recurrent cardiovascular events: the Aspirin In Reduction of Tension II (ASPIRETENSION...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024448-13,0,0,0 2010-024449-65,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Västerbottens läns landsting,Will there be lipid changes during dialysis with Citrasate as dialysate compared to conventional dialysis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024449-65,0,0,0 2010-024454-10,1,2014-11-18,2014-11-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"An open label, phase II trial of afatinib with or without vinorelbine for the treatment of HER2-overexpressing Inflammatory Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024454-10,0,0,0 2010-024457-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr.Gerardo Aguilar Dr.Francisco Martí Hospital Clínico de Valencia Ser. Anestesiología y Reanimación,Farmacocinética de anidulafungina en pacientes sometidos a hemodiafiltración.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024457-36,0,0,0 2010-024460-18,1,2012-06-01,2012-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Umeå Universitet,Vitamin-D-deficiency in imigrants. Treatment study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024460-18,0,0,0 2010-024462-21,1,2013-03-07,2013-03-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Research and Development, Barts and The London NHS Trust","Prospective, double-blinded, randomised, placebo controlled trial of pre-emptive analgesia to prevent pain following sternotomy for cardiac surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024462-21,0,0,0 2010-024467-40,1,2021-12-31,2021-12-31,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,GRUPO ESPAÑOL DE TRASPLANTE HEMATOPOYÉTICO Y TERAPIA CELULAR (GETH),OFATUMUMAB COMO PARTE DEL RÉGIMEN DE ACONDICIONAMIENTO DE INTENSIDAD REDUCIDA PARA PACIENTES CON LEUCEMIA lINFÁTICA CRÓNICA DE ALTO RIESGO QUE RECIBEN UN TRASPLANTE ALOGÉNICO DE PROGENITORES HEMATOPOY...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024467-40,0,0,0 2010-024468-16,9,2016-01-22,2016-01-22,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A randomized, double-blind, placebo-controlled Phase III study of first-line maintenance Tarceva vs Tarceva at the time of disease progression in patients with advanced non-small cell lung cancer (NSC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024468-16,0,0,0 2010-024468-16,9,2016-01-22,2016-01-22,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, double-blind, placebo-controlled Phase III study of first-line maintenance Tarceva vs Tarceva at the time of disease progression in patients with advanced non-small cell lung cancer (NSC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024468-16,0,0,0 2010-024473-39,12,2017-01-26,2017-02-09,12,1,0,0,0,1,3,0,0,1,0,0,1,0,2,"Novartis Farmacéutica, S.A.","An open-label, multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024473-39,0,0,0 2010-024473-39,12,2017-01-26,2017-02-09,12,1,0,0,0,1,3,0,0,1,0,0,1,0,2,Novartis Pharma Services AG,"An open-label, multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024473-39,0,0,0 2010-024473-39,12,2017-01-26,2017-02-09,12,1,0,0,0,1,3,0,0,1,0,0,1,0,2,Novartis Ireland Limited,"An open-label, multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024473-39,0,0,0 2010-024473-39,12,2017-01-26,2017-02-09,12,1,0,0,0,1,3,0,0,1,0,0,1,0,2,NOVARTIS FARMA,"An open-label, multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) of post polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024473-39,0,0,0 2010-024477-39,9,2015-10-01,2015-10-01,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biogen Idec Limited,"A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024477-39,0,0,0 2010-024479-20,2,2014-06-27,2014-06-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Limited,"A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study, with an Open-Label Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of E5501 in Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024479-20,0,0,0 2010-024481-22,5,2013-06-17,2013-06-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sandoz GmbH,"A randomized, double-blind, parallel-group, multi-center Phase III study comparing the efficacy and safety of EP2006 and Neupogen® in breast cancer patients treated with myelosuppressive chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024481-22,0,0,0 2010-024483-17,8,2016-08-10,2016-08-10,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Eisai Ltd,"A Randomised, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024483-17,0,0,0 2010-024483-17,8,2016-08-10,2016-08-10,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,EISAI LTD UK,"A Randomised, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024483-17,0,0,0 2010-024485-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE TOSCANA GABRIELE MONASTERIO,Dipyridamole versus Adenosine infusion in the physiologic assessment of Intermediate coronary Stenoses in the cardiac catheterization laboratorY Infusione di dipiridamolo contro adenosina nella val...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024485-21,0,0,0 2010-024487-18,1,2013-06-30,2013-06-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Dept. of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital",Effects of vitamin D on beta cell function and insulin sensitivity in pre-diabetes and diabetes mellitus type 2 - EVIDENS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024487-18,0,0,0 2010-024488-42,1,2016-08-15,2016-08-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Aalborg University Hospital, Aalborg Psychiatric Hospital, Centre for Psychosisresearch",Pregabalin for anxiety comorbidity in patients with schizophrenia (PACS) - A Double-blinded Randomized Placebo Controlled Trial Pregabalin til behandling af komorbid angst ved skizofreni - Et dobbe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024488-42,0,0,0 2010-024490-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",A phase 2 study of panitumumab in patients with cetuximab-refractory metastatic colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024490-39,0,0,0 2010-024496-37,1,2016-11-14,2016-11-14,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Virttu Biologics Limited,"A PHASE I/IIa STUDY OF THE SAFETY, TOLERABILITY AND BIOLOGICAL EFFECT OF SINGLE AND REPEAT ADMINISTRATION OF THE SELECTIVELY REPLICATION-COMPETENT HERPES SIMPLEX VIRUS HSV1716 INTO THE TUMOUR-BEARING...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024496-37,0,0,0 2010-024503-27,1,2011-11-29,2011-11-29,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Noora Kaartinen,Fertiliteetin säilyttäminen GnRH-agonistilla sytostaattihoitoa saavilla premenopausaalisilla rintasyöpäpotilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024503-27,0,0,0 2010-024510-57,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Lluita contra la SIDA,"Estudio Randomizado, Prospectivo, Controlado, para Comparar la Eficacia y Seguridad de Dos Estrategias Farmacológicas Diferentes sobre la Alteración Neurocognitiva en la Infección por VIH. Estudio TRI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024510-57,0,0,0 2010-024512-34,8,2013-01-18,2013-01-18,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.","Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024512-34,0,0,0 2010-024512-34,8,2013-01-18,2013-01-18,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ALCON RESEARCH, LTD.","Safety and IOP-Lowering Efficacy of Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL Fixed Combination Eye Drops, Suspension compared to Brinzolamide 10 mg/mL Eye Drops, Suspension and Brimonidine 2 mg/mL ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024512-34,0,0,0 2010-024513-31,12,2013-01-15,2013-01-29,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Alcon Research, Ltd.","Efficacy and Safety of Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension plus Brimonidine 2 mg/mL Eye Drops, Solution in Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024513-31,0,0,0 2010-024513-31,12,2013-01-15,2013-01-29,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"ALCON RESEARCH, LTD.","Efficacy and Safety of Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension plus Brimonidine 2 mg/mL Eye Drops, Solution in Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024513-31,0,0,0 2010-024515-13,1,,,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,VU University Medical Center,Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024515-13,0,0,0 2010-024516-34,4,2013-12-30,2013-12-30,4,1,0,0,2,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled regimen finding study of efficacy, safety and tolerability of secukinumab at 12 weeks administered with an i.v. or s.c. loading regimen compared to place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024516-34,0,0,0 2010-024516-34,4,2013-12-30,2013-12-30,4,1,0,0,2,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled regimen finding study of efficacy, safety and tolerability of secukinumab at 12 weeks administered with an i.v. or s.c. loading regimen compared to place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024516-34,0,0,0 2010-024517-31,1,2012-10-05,2012-10-05,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Hans Christian Wulf,BEHANDLING AF BASALCELLE KARCINOMER MED METHYL AMINOLEVULINAT OG DAGSLYS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024517-31,0,0,0 2010-024518-74,8,2012-06-18,2013-10-15,7,1,0,0,2,1,2,0,0,1,1,0,1,0,1,"Infinity Pharmaceuticals, Inc","A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients with Metastatic or Locally Advanced (Unresectable) Chondrosarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024518-74,0,0,0 2010-024518-74,8,2012-06-18,2013-10-15,7,1,0,0,2,1,2,0,0,1,1,0,1,0,1,INFINITY PHARMACEUTICAL INC.,"A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients with Metastatic or Locally Advanced (Unresectable) Chondrosarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024518-74,0,0,0 2010-024520-15,1,2016-02-01,2016-02-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,A pilot study to establish the safety and efficacy of a combination of dexamethasone and lenalidomide in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024520-15,0,0,0 2010-024527-25,2,2017-10-10,2017-10-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farma SpA,"A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living don...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024527-25,0,0,0 2010-024527-25,2,2017-10-10,2017-10-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living don...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024527-25,0,0,0 2010-024528-12,1,2011-09-27,2011-09-27,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Henning Glerup,Kontrast UltraLydsskanning af Tyndtarmen hos patienter med Crohns sygdom – et pilotstudie (KULT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024528-12,0,0,0 2010-024529-18,5,2014-12-17,2014-12-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024529-18,0,0,0 2010-024529-18,5,2014-12-17,2014-12-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024529-18,0,0,0 2010-024532-42,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,María José Linares Gil,"Ensayo multicéntrico aleatorizado a doble ciego, para evaluar la eficacia analgésica y la seguridad del gel de Lidocaína+Diclofenaco tópico (300mg+90mg)frente la lidocaina sóla (300mg) en la Cirugía ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024532-42,0,0,0 2010-024534-38,1,2016-04-20,2016-04-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Medizinische Universität Wien, Abteilung für Herzchirurgie",Pilot-Trial: Dabigatran as an alternative anticoagulant in patients with left ventricular assist device,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024534-38,0,0,0 2010-024537-23,4,2018-01-22,2018-01-22,3,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Bristol Myers Squibb International Corporation,"A Prospective Single Arm, Open-Label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder boosted with Ritonavir (RTV) Liquid with an Opti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024537-23,1,1,0 2010-024538-51,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Silvia Gil Trujillo,"Study of the effects of pregabalin in postoperative pain control in general total intravenous anesthesia, general inhalation anesthesia and combined anesthesia after abdominal hysterectomy. ESTUDIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024538-51,0,0,0 2010-024540-15,10,2015-01-16,2015-01-16,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Teva Branded Pharmaceutical Product R&D, Inc.",An Open-Label Extension Study to evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients with Eosinophilic Asthma who completed a prior Cephalon-sponsored Study ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024540-15,0,0,0 2010-024540-15,10,2015-01-16,2015-01-16,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.",An Open-Label Extension Study to evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients with Eosinophilic Asthma who completed a prior Cephalon-sponsored Study ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024540-15,0,0,0 2010-024540-15,10,2015-01-16,2015-01-16,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Cephalon Inc.,An Open-Label Extension Study to evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients with Eosinophilic Asthma who completed a prior Cephalon-sponsored Study ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024540-15,0,0,0 2010-024540-15,10,2015-01-16,2015-01-16,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Teva Branded Pharmaceutical Producs R&D, Inc.",An Open-Label Extension Study to evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients with Eosinophilic Asthma who completed a prior Cephalon-sponsored Study ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024540-15,0,0,0 2010-024541-67,1,2013-12-10,2013-12-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,NHS Greater Glasgow & Clyde R&D Office,Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis – pilot phase,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024541-67,0,0,0 2010-024541-67,1,2013-12-10,2013-12-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The University of Glasgow,Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis – pilot phase,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024541-67,0,0,0 2010-024543-33,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,Maastricht University,Can memantine prevent memory impairment induced by MDMA in humans,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024543-33,0,0,0 2010-024546-30,1,2012-09-24,2012-09-24,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Laboratories León Farma S.A.,"Randomized, Open-Label Study to Evaluate the Influence on the Ovarian Activity, and the Cervix Score Over Two Treatment Cycles of 4.0 mg Drospirenone Daily for 24 Days as Compared to 0.075 mg Desogest...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024546-30,0,0,0 2010-024547-32,1,2013-03-15,2013-03-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU Clermont-Ferrand,Effets potentiels d’une supplémentation en oméga 3 sur la membrane des cardiomyocytes de patients atteints d’athérosclérose coronaire ?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024547-32,0,0,0 2010-024549-65,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,CHU Clermont-Ferrand,Impact du remplissage vasculaire sur l’œdème pulmonaire mesuré par la clairance alvéolaire chez des patients atteints de SDRA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024549-65,0,0,0 2010-024551-82,1,2013-03-22,2013-03-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,OPEN LABEL TRIAL OF ATOMOXETINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN WITH 22q11.2 DELETION SYNDROME (22qDS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024551-82,0,0,0 2010-024551-82,1,2013-03-22,2013-03-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,South London and Maudsley NHS Foundation Trust,OPEN LABEL TRIAL OF ATOMOXETINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN WITH 22q11.2 DELETION SYNDROME (22qDS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024551-82,0,0,0 2010-024552-28,1,2013-03-04,2013-03-04,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Oxford Radcliffe Hospitals NHS Trust,BRUISE CONTROL : BRidge or continUe coumadIn for device SurgEry randomized CONTROLled Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024552-28,0,0,0 2010-024557-36,3,2015-10-20,2015-10-20,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Kirby Institute,"A phase IV open-label multicentre, international trial of response guided treatment with directly observed pegylated interferon alfa 2b and self-administered ribavirin for patients with chronic HCV ge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024557-36,0,0,0 2010-024558-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aalto-yliopiston Kylmälaboratorion Aivotutkimusyksikkö,CRPS-potilaiden aivomuutosten korjaantuminen hoidon myötä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024558-12,0,0,0 2010-024561-43,1,2013-07-10,2013-07-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Scleroseklinikken, Rigshospitalet",Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024561-43,0,0,0 2010-024566-22,2,,,0,1,1,0,0,1,1,0,0,4,0,0,0,0,1,GlaxoSmithKline Research and Development LTD,"A double-blind, escalating dose, randomized, placebo-controlled study to assess the pharmacokinetics, safety and tolerability of single subcutaneous injections of GSK2402968 in non-ambulant subjects w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024566-22,0,1,0 2010-024568-16,4,2016-04-22,2016-04-22,2,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Bristol Myers Squibb International Corporation,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin IR or Metformin XR in Pediatric Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024568-16,1,1,0 2010-024568-16,4,2016-04-22,2016-04-22,2,1,1,0,0,0,3,0,0,2,1,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin IR or Metformin XR in Pediatric Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024568-16,1,1,0 2010-024572-25,1,2011-05-31,2011-05-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Dr. August Wolff GmbH & Co. KG Arzneimittel,Local antibacterial efficacy of a gel containing 0.1 % octenidine dihydrochloride on pre-damaged skin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024572-25,0,0,0 2010-024579-23,7,2013-06-26,2015-05-06,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merz Pharmaceuticals GmbH,"Prospective, double-blind, placebo-controlled, randomized, multi-center study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of post-stroke spast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024579-23,0,0,0 2010-024579-23,7,2013-06-26,2015-05-06,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MERZ PHARMACEUTICALS GMBH,"Prospective, double-blind, placebo-controlled, randomized, multi-center study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of post-stroke spast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024579-23,0,0,0 2010-024584-41,1,2015-01-15,2015-01-15,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Hospital Universitari de Bellvitge,"Ensayo clínico, multicéntrico, aleatorio y controlado con placebo para evaluar la eficacia de la administración de concentrado de fibrinógeno sobre los requerimientos de derivados sanguíneos en la cir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024584-41,0,0,0 2010-024585-22,2,2017-12-22,2017-12-22,1,1,0,0,0,1,2,0,0,1,1,0,1,0,0,Imperial College Academic Healthsciences Centre,"What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024585-22,0,0,0 2010-024586-45,9,2015-07-17,2015-07-17,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Gilead Sciences Inc.,"A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon ?-2a (Pegasys®) ver...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024586-45,0,0,0 2010-024586-45,9,2015-07-17,2015-07-17,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GILEAD SCIENCE INC.,"A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination with Peginterferon ?-2a (Pegasys®) ver...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024586-45,0,0,0 2010-024588-42,1,2015-01-22,2015-01-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,Vitamin D supplementation and male infertility: a randomized double blinded clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024588-42,0,0,0 2010-024595-26,8,2015-04-21,2015-06-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Phase 2 Placebo-controlled Double-Blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-Advanced Pancreatic Cancer Studio di fase 2, controllato con placebo, in doppio cieco, su d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024595-26,0,0,0 2010-024595-26,8,2015-04-21,2015-06-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALISATION INC,"Phase 2 Placebo-controlled Double-Blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-Advanced Pancreatic Cancer Studio di fase 2, controllato con placebo, in doppio cieco, su d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024595-26,0,0,0 2010-024597-19,3,2012-10-05,2012-10-05,1,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,Multiple-Dose Study Apixaban in Pediatric Subjects with an Indwelling Central Venous Catheter,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024597-19,1,1,0 2010-024603-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,A phase II study of low-dose vaginal estrogens in pre and postmenopausal breast cancer patients with urogenital atrophy Studio di fase II con estrogeno topico a basse dosi in pazienti con carcinoma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024603-26,0,0,0 2010-024606-34,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Mª Victoria Gil Navarro,Eficacia y seguridad de Piperacilina/Tazobactam administrada en perfusión continua versus infusión intermitente en pacientes con infección complicada o nosocomial con sospecha o aislamiento de Pseudom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024606-34,0,0,0 2010-024613-31,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Novartis Vaccines and Diagnostics GmbH,"A Phase III Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture (Optaflu®), Form...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024613-31,0,0,0 2010-024614-66,6,2014-03-04,2014-03-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc","A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations and Change in Lung Fu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024614-66,0,0,0 2010-024614-66,6,2014-03-04,2014-03-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products, R&D, Inc.","A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations and Change in Lung Fu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024614-66,0,0,0 2010-024614-66,6,2014-03-04,2014-03-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products, R&D, Inc","A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the reduction of Clinical Asthma Exacerbations and Change in Lung Fu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024614-66,0,0,0 2010-024616-33,2,2013-09-26,2013-09-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,TROPHOS SA,"Phase II, multicenter, randomized, double-blind, placebo controlled study to assess safety and efficacy of TRO40303 for reduction of reperfusion injury in patients undergoing Percutaneous Coronary Int...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024616-33,0,0,0 2010-024621-20,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Gustave Roussy,First International Randomized Study in MAlignant Progressive Pheochromocytoma and Paraganglioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024621-20,0,0,0 2010-024623-24,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Medizinische Universität Wien, Univ. Klinik f. Dermatologie",Topical imiquimod 5% cream therapy versus photodynamic therapy with methyl-aminolaevulinate 16% cream of actinic keratoses in organ transplant recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024623-24,0,0,0 2010-024624-20,1,2015-05-20,2015-05-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,A Pilot Study Investigating the Sensitivity of 18F-labelled Sodium Fluoride PET-CT for Detecting Skeletal Metastases in Renal Cell Carcinoma compared to Planar Bone Scintigraphy and Multidetector CT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024624-20,0,0,0 2010-024625-20,1,2018-08-29,2018-08-29,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Leiden University Medical Center,ADMINISTRATION OF HA-1 TCR TRANSDUCED VIRUS-SPECIFIC T-CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH-RISK LEUKEMIA (LUMC 2010-02),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024625-20,0,0,0 2010-024626-37,5,2014-03-21,2014-03-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo in patients with mild to moderate Alzheimer’s disease. A 24- week international, multi-centre, randomised, double-blind, p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024626-37,0,0,0 2010-024631-16,5,2013-01-02,2014-07-09,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,"A Phase 2, Multi-Center, Double-Blind, placebo controlled, Randomized Study of Ombrabulin in Patients with Platinum-Sensitive Recurrent Ovarian Cancer treated with Carboplatin/Paclitaxel",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024631-16,0,0,0 2010-024631-16,5,2013-01-02,2014-07-09,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SANOFI-AVENTIS S.P.A,"A Phase 2, Multi-Center, Double-Blind, placebo controlled, Randomized Study of Ombrabulin in Patients with Platinum-Sensitive Recurrent Ovarian Cancer treated with Carboplatin/Paclitaxel",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024631-16,0,0,0 2010-024632-42,6,2013-11-11,2013-11-14,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Reemergence in Major Depressive Disorder LY2216684 comparado frente a placebo como tratamiento combinado con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024632-42,0,0,0 2010-024632-42,6,2013-11-11,2013-11-14,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Reemergence in Major Depressive Disorder LY2216684 comparado frente a placebo como tratamiento combinado con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024632-42,0,0,0 2010-024632-42,6,2013-11-11,2013-11-14,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Reemergence in Major Depressive Disorder LY2216684 comparado frente a placebo como tratamiento combinado con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024632-42,0,0,0 2010-024635-16,4,2013-09-19,2013-09-19,4,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research Limited,"A double-blind, double dummy randomised, parallel group, multicentre study to compare the efficacy and safety of Flutiform pMDI with fluticasone pMDI and with Seretide pMDI in paediatric subjects aged...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024635-16,0,0,0 2010-024638-48,12,2016-07-27,2016-07-27,8,1,1,0,0,0,0,0,0,2,1,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",A MULTICENTER OPEN-LABEL EXTENSION STUDY TO ASSESS LONG-TERM SAFETY OF PF-00547659 IN SUBJECTS WITH CROHN’S DISEASE (OPERA II),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024638-48,1,1,0 2010-024638-48,12,2016-07-27,2016-07-27,8,1,1,0,0,0,0,0,0,2,1,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States",A MULTICENTER OPEN-LABEL EXTENSION STUDY TO ASSESS LONG-TERM SAFETY OF PF-00547659 IN SUBJECTS WITH CROHN’S DISEASE (OPERA II),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024638-48,1,1,0 2010-024638-48,12,2016-07-27,2016-07-27,8,1,1,0,0,0,0,0,0,2,1,0,0,0,1,"PFIZER, S.L.U.",A MULTICENTER OPEN-LABEL EXTENSION STUDY TO ASSESS LONG-TERM SAFETY OF PF-00547659 IN SUBJECTS WITH CROHN’S DISEASE (OPERA II),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024638-48,1,1,0 2010-024638-48,12,2016-07-27,2016-07-27,8,1,1,0,0,0,0,0,0,2,1,0,0,0,1,Pfizer Inc.,A MULTICENTER OPEN-LABEL EXTENSION STUDY TO ASSESS LONG-TERM SAFETY OF PF-00547659 IN SUBJECTS WITH CROHN’S DISEASE (OPERA II),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024638-48,1,1,0 2010-024639-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,SERVICIO DIGESTIVO,INFUSIÓN DE PANTOMICINA ENDOVENOSA PREVIAMENTE A LA REALIZACIÓN DE UNA GASTROSCOPIA EN UN EPISODIO DE HEMORRAGIA DIGESTIVA ALTA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024639-18,0,0,0 2010-024640-15,3,2012-09-30,2013-09-27,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Ranbaxy Laboratories Limited,"A randomized, double-blind, placebo-controlled ‘Proof of Concept’ study of 12 week treatment with RBx 10017609 in subjects with moderate to severe chronic obstructive pulmonary disease (COPD).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024640-15,1,0,0 2010-024641-71,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,ANGELINI,"A randomized, multicenter, double-blind study assessing the efficacy and safety of two topical 10% naproxen gel formulations in the treatment of benign soft-tissue injuries.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024641-71,0,0,0 2010-024644-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA' DEGLI STUDI DI NAPOLI,Concomitant therapy with levofloxacyn versus sequential therapy with levofloxacin for eradication of H. pylori infection Terapia concomitante con levofloxacina verso terapia sequenziale con levof...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024644-15,0,0,0 2010-024646-30,1,2017-01-19,2017-01-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospitals Birmingham NHS Foundation Trust,Anti-viral prophylaxis for prevention of cytomegalovirus (CMV) reactivation in immunocompetent patients in critical care.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024646-30,0,0,0 2010-024647-32,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II,Combined enzyme enhancement therapy (EET) and enzyme replacement therapy (ERT) in patients with Pompe disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024647-32,0,0,0 2010-024649-61,1,2011-06-10,2011-06-10,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,Pilot study: performance of the Progensa PCA3 test in post-oxytocin urine specimens,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024649-61,0,0,0 2010-024651-86,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,"Randomized Trial, Masked, and Placebo Controlled to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension Estudio aleatoriz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024651-86,0,0,0 2010-024652-28,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Fundació Clínic per a la Recerca Biomèdica,Estudio para evaluar la actividad y la tolerabilidad de la biterapia con lopinavir/ritonavir y 3TC en sustitución de una triple terapia que incluya lopinavir/ritonavir y 3TC ó FTC en pacientes con inf...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024652-28,0,0,0 2010-024657-36,1,2013-06-24,2013-06-24,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Statens Serum Institut,"Metronidazol for the treatment of dientamoebiasis in children in Denmark – A randomized, placebo-controlled, double-blinded clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024657-36,0,0,0 2010-024659-10,1,2013-01-17,2013-01-17,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Rigshospitalet,Can stimulation of the nNOS system in muscle disease with nNOS insufficiency improve heart and skeletal muscle function and cognition?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024659-10,0,0,0 2010-024664-17,1,2015-11-18,2015-11-18,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Bioinova, s.r.o.","Utilization of Autologous Mesenchymal Cells to Enhance Rotator Cuff Repair - a Prospective Non-randomized, Open-Label Study to Assess the Safety and the Efficacy. Využití autologních mesenchymální...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024664-17,0,0,0 2010-024665-52,1,2016-12-14,2016-12-14,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Bioinova, s.r.o.","Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease: a Prospective, Non-randomized, Open-Label Study to Assess the Safety and the Efficacy. Vyu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024665-52,0,0,0 2010-024667-40,1,2019-04-04,2019-04-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,St. Antonius Hospital,Cost-effectiveness of CYP2C19 guided treatment with antiplatelet drugs in patients with ST-segment-elevation myocardial infarction undergoing immediate percutaneous coronary intervention with stent im...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-024667-40,0,0,0 2011-000022-29,1,2013-03-11,2013-03-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Wien,The interaction of intravenous lidocaine on the Cp50 of propofol for skin incision Effekt von intravenösem Lidocain auf den Cp50-Wert von Propofol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000022-29,0,0,0 2011-000023-33,1,2015-11-28,2015-11-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,S.P.A. ITALIANA LABORATORI BOUTY,"Clinical trial to evaluate, in patient suffering of neck pain the therapeutic equivalence, tolerability and satisfaction of subjects treated by medicated plaster containing piroxicam or diclofenac. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000023-33,0,0,0 2011-000026-30,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Academic medical centre,Induction of Labour with a Foley catheter or oral Misoprostol at Term,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000026-30,0,0,0 2011-000030-11,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,INSTITUTO DE INVESTIGACIÓN SANITARIA LA FE,EFICACIA DE N-ACETILCISTEINA EN EL LÍQUIDO DE PRESERVACIÓN DURANTE EL TRASPLANTE HEPÁTICO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000030-11,0,0,0 2011-000032-28,5,2018-01-03,2018-01-03,3,1,0,0,0,1,0,0,0,1,1,0,1,0,1,Synageva Biopharma Corp.,"AN OPEN LABEL, MULTICENTER, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SBC-102 IN CHILDREN WITH GROWTH FAILURE DUE TO LYSOSOMAL ACI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000032-28,0,0,0 2011-000032-28,5,2018-01-03,2018-01-03,3,1,0,0,0,1,0,0,0,1,1,0,1,0,1,SYNAGEVA BIOPHARMA CORP.,"AN OPEN LABEL, MULTICENTER, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SBC-102 IN CHILDREN WITH GROWTH FAILURE DUE TO LYSOSOMAL ACI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000032-28,0,0,0 2011-000032-28,5,2018-01-03,2018-01-03,3,1,0,0,0,1,0,0,0,1,1,0,1,0,1,Alexion Pharmaceuticals Inc.,"AN OPEN LABEL, MULTICENTER, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SBC-102 IN CHILDREN WITH GROWTH FAILURE DUE TO LYSOSOMAL ACI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000032-28,0,0,0 2011-000033-36,15,2022-07-05,2022-07-05,2,0,0,1,0,1,1,0,0,2,1,0,0,0,1,Nordic Nanovector ASA,A phase I/II study of 177Lu-HH1 (BetalutinTM) radioimmunotherapy for treatment of relapsed CD37+ non-Hodgkin lymphoma Studio di Fase I/II di terapia radioimmunologica con 177Lu-DOTA-HH1 (Betalutin™...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000033-36,1,0,0 2011-000033-36,15,2022-07-05,2022-07-05,2,0,0,1,0,1,1,0,0,2,1,0,0,0,1,Nordic Nanovector AS,A phase I/II study of 177Lu-HH1 (BetalutinTM) radioimmunotherapy for treatment of relapsed CD37+ non-Hodgkin lymphoma Studio di Fase I/II di terapia radioimmunologica con 177Lu-DOTA-HH1 (Betalutin™...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000033-36,1,0,0 2011-000035-89,1,2012-12-22,2012-12-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Med. Univ. Wien, Klinik für klinische Pharmakologie",Target site pharmacokinetics of doripenem at steady state in intubated intensive care patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000035-89,0,0,0 2011-000037-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,MCM Klosterfrau GmbH & Co. KG,Open label clinical trial to investigate the physiological effects on sleep of Nervenruh Baldrian Forte 600 in patients with primary insomnia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000037-36,0,0,0 2011-000038-12,1,2015-04-30,2015-04-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University College London (UCL),"A Phase 2b randomised, double blind, placebo-controlled trial of trimetazidine therapy in patients with non-obstructive hypertrophic cardiomyopathy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000038-12,0,0,0 2011-000045-20,8,2013-07-17,2013-07-17,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,RECORDATI S.p.A,EFFECTIVENESS AND SAFETY OF SILODOSIN IN THE TREATMENT OF LUTS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA: A EUROPEAN PHASE IV CLINICAL STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000045-20,0,0,0 2011-000045-20,8,2013-07-17,2013-07-17,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,RECORDATI,EFFECTIVENESS AND SAFETY OF SILODOSIN IN THE TREATMENT OF LUTS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA: A EUROPEAN PHASE IV CLINICAL STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000045-20,0,0,0 2011-000049-19,2,2013-03-07,2013-03-07,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,PHARMING TECHNOLOGIES B.V.,"A Phase III randomized, double-blind, placebocontrolled study with an open-label extension evaluating the efficacy, safety and immunogenicity of recombinant human C1 inhibitor for the treatment of ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000049-19,0,0,0 2011-000049-19,2,2013-03-07,2013-03-07,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Pharming Technologies B.V.,"A Phase III randomized, double-blind, placebocontrolled study with an open-label extension evaluating the efficacy, safety and immunogenicity of recombinant human C1 inhibitor for the treatment of ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000049-19,0,0,0 2011-000050-32,2,2011-10-06,2011-10-27,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GE Healthcare Ltd. and its affiliates,"A phase 4 randomized, double-blind study comparing patient comfort and safety between iodixanol 320 mg I/ml and iopamidol 370 mg I/ml in patients undergoing contrast-enhanced computed tomographic (CEC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000050-32,0,0,0 2011-000051-16,3,2013-10-01,2013-10-01,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"JENNEREX, INC.",A Phase 2b Randomized Open-Label Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma Who H...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000051-16,1,0,0 2011-000051-16,3,2013-10-01,2013-10-01,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"Jennerex, Inc",A Phase 2b Randomized Open-Label Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma Who H...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000051-16,1,0,0 2011-000053-23,1,2012-06-21,2012-06-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,UCB Biosciences GmbH,"Multicenter, double-blind, placebo-controlled, two-arm, randomized, parallel, treatment intervention, sleep lab phase 4 study to assess the effect of rotigotine on nocturnal blood pressure in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000053-23,0,0,0 2011-000056-42,1,2012-11-21,2012-11-21,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,"UCB Celltech, UK - Registered Branch of UCB Pharma SA","A MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECTS OF ROTIGOTINE ON SLEEP EFFICIENCY IN PATIENTS WITH ADVANCED PARKINSON’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000056-42,0,0,0 2011-000057-23,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ALK-Abello S.A.,Estudio abierto para valorar la tolerabilidad de la inmunoterapia con AVANZ Phleum pratense,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000057-23,0,0,0 2011-000059-17,1,2013-09-24,2013-09-24,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Koege Hospital,The clinical significance of acid rebound: Symptoms of reflux after 8 weeks of PPI treatment in patients with functional dyspepsia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000059-17,0,0,0 2011-000062-35,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Mikko Pitkänen, MD, PhD",Artikaiini 40mg ja kloroprokaiini 40 mg päiväkirurgisina spinaalipuudutteina (Lyhenne: A40C40),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000062-35,0,0,0 2011-000064-10,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,"Med. Univ. Wien, Klinik für klinische Pharmakologie",Target site pharmacokinetics of linezolid or tigecycline in patients with severe skin and skin structure infections (SSSI) associated with chronic fistulas.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000064-10,0,0,0 2011-000069-11,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,FERNADO PEREZ RUIZ,"ENSAYO CLINICO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, DE GRUPOS PARALELOS,, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE TETRACOSÁCTIDO FRENTE A FOSFATO-ACETATO DE BETAMETASONA Y FRENTE A LA COMBINACIÓN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000069-11,0,0,0 2011-000075-13,1,2013-09-20,2013-09-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GBG Forschungs GmbH,A multicenter non-randomized phase II study to evaluate nab-paclitaxel in metastatic breast cancer patients failing a solvent based taxane as (neo-)adjuvant treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000075-13,0,0,0 2011-000076-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Centre Nijmegen,Efficacy and Cost Efficacy of Prophylactic treatment with Antibiotics during concomitant chemoradiotherapy in patients with locally advanced head and neck cancer to prevent Aspiration Pneumonia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000076-33,0,0,0 2011-000078-80,6,2021-04-21,2021-04-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd.,"A Phase II, Parallel Group, Randomized, Multicentre, Open Label Study to Compare the Pharmacokinetics of Tacrolimus in De Novo Pediatric Allograft Recipients Treated with an Advagraf or Prograf Based ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000078-80,0,0,0 2011-000078-80,6,2021-04-21,2021-04-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTELLAS PHARMA,"A Phase II, Parallel Group, Randomized, Multicentre, Open Label Study to Compare the Pharmacokinetics of Tacrolimus in De Novo Pediatric Allograft Recipients Treated with an Advagraf or Prograf Based ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000078-80,0,0,0 2011-000083-10,4,2016-01-25,2016-01-25,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL®) vs. Dasatinib plus Smoothen Antagonist (BMS-833923) in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philade...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000083-10,0,0,0 2011-000084-27,3,2014-08-12,2014-08-12,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Bioprojet,DOUBLE BLIND RANDOMIZED STUDY TO ASSESS THE EFFICACY OF BF2.649 COMPARED TO PLACEBO IN ADD-ON TO SODIUM OXYBATE IN THE TREATMENT OF NARCOLEPTIC PATIENTS WITH RESIDUAL EXCESSIVE DAYTIME SLEEPINESS (E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000084-27,0,0,0 2011-000087-95,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,"Agile Therapeutics, Inc","AN OPEN-LABEL, PHASE 3 STUDY OF THE CONTRACEPTIVE EFFICACY AND SAFETY OF AGILE TRANSDERMAL CONTRACEPTIVE DELIVERY SYSTEM (TCDS) IN SEXUALLY ACTIVE WOMEN REQUESTING CONTRACEPTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000087-95,0,0,0 2011-000088-28,2,2016-07-27,2016-07-27,1,1,0,0,0,1,3,0,0,1,1,0,1,0,0,Fred Hutchinson Cancer Research Center,A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000088-28,0,0,0 2011-000090-32,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Bridge BioResearch Rights (Jersey) Ltd,"A Randomised, Double-Blind, Repeat-Dose, Placebo-Controlled Phase IIa Proof of Concept Study to Investigate the Safety and Efficacy of Oral BBR-012 in Combination With Standard Medical Care in Diabeti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000090-32,0,0,0 2011-000091-33,1,2012-01-20,2012-01-20,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Idera Pharmaceuticals, Inc.","A Phase 2, Randomized, Double-Blind, Comparator-Controlled, 12-week Trial of IMO-2125 plus Ribavirin in Treatment-Naive Patients Infected with Hepatitis C Virus, Genotype 1",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000091-33,0,0,0 2011-000092-13,1,2016-03-21,2016-03-21,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,,A trial aimed at enhancing immunity to Influenza in elderly individuals through reversal of immune senescence mediated by herpes virus infection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000092-13,0,0,0 2011-000097-56,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,HOVON Foundation,ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma A HOVON/GLSG/NCRI study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000097-56,0,0,0 2011-000102-21,7,2015-02-03,2015-02-03,6,1,0,0,2,0,3,0,0,1,0,0,1,0,2,NOVARTIS FARMA,"A randomized, double-blind, placebo- and active-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 1 year in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000102-21,0,0,0 2011-000102-21,7,2015-02-03,2015-02-03,6,1,0,0,2,0,3,0,0,1,0,0,1,0,2,Novartis Pharma Services AG,"A randomized, double-blind, placebo- and active-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 1 year in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000102-21,0,0,0 2011-000102-21,7,2015-02-03,2015-02-03,6,1,0,0,2,0,3,0,0,1,0,0,1,0,2,Novartis Farmacéutica S.A.,"A randomized, double-blind, placebo- and active-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 1 year in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000102-21,0,0,0 2011-000102-21,7,2015-02-03,2015-02-03,6,1,0,0,2,0,3,0,0,1,0,0,1,0,2,Novartis Pharma AG,"A randomized, double-blind, placebo- and active-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 1 year in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000102-21,0,0,0 2011-000105-53,2,,,0,0,0,0,0,0,3,0,2,0,0,0,0,0,1,KV Pharmaceutical Co.,"A Prospective Follow-Up Study of Children Aged 23 to 25 months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000105-53,0,0,0 2011-000105-53,2,,,0,0,0,0,0,0,3,0,2,0,0,0,0,0,1,"Hologic, Inc.","A Prospective Follow-Up Study of Children Aged 23 to 25 months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000105-53,0,0,0 2011-000106-22,3,2013-02-06,2013-02-06,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GE Healthcare Ltd. and its affiliates,"A Phase 4 Randomized, Double-blind Study Comparing Patient Comfort and Safety between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000106-22,0,0,0 2011-000107-40,1,2012-12-20,2012-12-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Glenmark Pharmaceuticals SA,"A Phase IIb, 12 week Randomized, Double-Blind, Parallel Group, Placebo-Controlled study to evaluate Efficacy, Safety and Tolerability of 2, 4 and 6 mg of Revamilast in patients with Active Rheumatoid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000107-40,0,0,0 2011-000110-19,1,2016-12-18,2016-12-18,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Assistance Publique – Hôpitaux de Paris (AP-HP),Closure of patent foramen ovale or anticoagulants versus antiplatelet therapy to prevent stroke recurrence,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000110-19,0,0,0 2011-000111-26,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"A. MENARINI PHARMA U.K.,",Effect of late sodium current inhibition on MRI measured diastolic dysfunction and myocardial perfusion reserve in aortic stenosis - a proof of concept study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000111-26,0,0,0 2011-000114-19,10,2015-12-21,2015-12-21,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension). A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000114-19,0,0,0 2011-000114-19,10,2015-12-21,2015-12-21,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension). A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000114-19,0,0,0 2011-000114-19,10,2015-12-21,2015-12-21,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension). A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000114-19,0,0,0 2011-000115-11,1,2011-07-07,2011-07-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A randomized, double-blind, placebo controlled, incomplete block, 3 way cross over study in subjects with allergic rhinitis to assess the effect of intranasal repeat doses of SB-705498 when administer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000115-11,0,0,0 2011-000117-39,2,2012-12-03,2012-12-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ixodes AG.,"A Phase 3 randomized, double-blind, placebo-controlled study of SHB004 (10% topical azithromycin) administered locally twice daily for three consecutive days for the prevention of Borreliosis in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000117-39,0,0,0 2011-000120-15,3,2012-12-21,2012-12-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALK-Abelló A/S,AVANZ Phleum pratense maintenance dose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000120-15,0,0,0 2011-000120-15,3,2012-12-21,2012-12-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALK-Abello A/S,AVANZ Phleum pratense maintenance dose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000120-15,0,0,0 2011-000123-33,1,2014-04-04,2014-04-04,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,King's College Hospital NHS Foundation Trust,Evaluation of the feasibility of modulating and measuring endogenous neurogenesis with erythropoietin (rhEPOα) to expedite recovery after stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000123-33,0,0,0 2011-000123-33,1,2014-04-04,2014-04-04,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,King's College London,Evaluation of the feasibility of modulating and measuring endogenous neurogenesis with erythropoietin (rhEPOα) to expedite recovery after stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000123-33,0,0,0 2011-000124-15,1,2013-10-31,2013-10-31,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,Ergomed Clinical Research Limited,"An Open-Label, Multi-Center Phase I/IIa Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Oral Tasidotin HCL in Patients with Relapsed/Refractory Aggressive Non-Hod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000124-15,0,0,0 2011-000125-76,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Hannu Kokki,OKSIKODONIN KESKUSHERMOSTOPENETRAATIO EPIDURAALISEN ANNOSTELUN JÄLKEEN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000125-76,0,0,0 2011-000126-30,1,2011-12-08,2011-12-08,1,1,0,0,1,0,2,0,0,1,1,1,1,0,1,Pharmaxis Ltd,"A phase II, multi-centre, single blind study to evaluate the safety, tolerability and explore the efficacy of 8.0 mg ASM8 inhaled daily for 14 days in adult subjects with moderate to severe asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000126-30,0,0,0 2011-000127-32,1,2019-04-15,2019-04-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Werkgroep Immunotherapie Nederland voor Oncologie,A randomized phase II study to explore the efficacy and feasibility of upfront bi-monthly rotations between Everolimus and Pazopanib with sequential treatment of first line Pazopanib and second line E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000127-32,0,0,0 2011-000129-61,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AMC Amsterdam,ASB treat study: Preventing preterm birth with nitrofurantoin: Costs and effects of screening and treating healthy women for asymptomatic bacteriuria’,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000129-61,0,0,0 2011-000130-11,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,Clinical trials in rare diseases: therapeutic alternative to the use of oral corticosteroids in patients with cystic fibrosis underwent double lung transplantation. Sperimentazione clinica in malat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000130-11,0,0,0 2011-000133-37,1,2012-02-27,2012-02-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicentre, 6-way Crossover, Single-dose, Phase IIa study to Evaluate the Pharmacokinetics and Pharmacodynamics of different Dry Powder I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000133-37,0,0,0 2011-000137-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITA` CAMPUS BIOMEDICO,USE OF TRABECTEDIN IN PATIENTS WITH RELAPSED/PROGRESSION OF EPITHELIAL CARCINOMA OVARY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000137-36,0,0,0 2011-000138-12,1,2017-10-18,2017-10-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"A prospective, randomized, double-blind, placebo controlled clinical trial to assess the effects of long-acting somatostatin (Octreotide LAR)therapy on disease progression in patients with Autosomal D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000138-12,0,0,0 2011-000141-20,6,2014-06-10,2014-06-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-alpha (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000141-20,0,0,0 2011-000141-20,6,2014-06-10,2014-06-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-alpha (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000141-20,0,0,0 2011-000141-20,6,2014-06-10,2014-06-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-alpha (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000141-20,0,0,0 2011-000141-20,6,2014-06-10,2014-06-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim International GmbH,"A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-alpha (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000141-20,0,0,0 2011-000141-20,6,2014-06-10,2014-06-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-alpha (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000141-20,0,0,0 2011-000141-20,6,2014-06-10,2014-06-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-alpha (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000141-20,0,0,0 2011-000143-24,1,2017-12-18,2017-12-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD),"Phase IV, multicentric study to evaluate correlation between global objectives response according RECIST v1.1 criteria evaluated by conventional images tecniques with morfologic response by TAC and pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000143-24,0,0,0 2011-000144-21,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University College London,ION– Is ablative radiOiodine Necessary for low risk differentiated thyroid cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000144-21,0,0,0 2011-000150-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE DON CARLO GNOCCHI ONLUS,"EFFECTS OF GLATIRAMER ACETATE ON TISSUE DAMAGE, CORTICAL FUNCTIONS AND FATIGUE IN MULTIPLE SCLEROSIS: A MORPHO-FUNCTIONAL MRI STUDY. Effetti della terapia con Glatiramer Acetato (Copaxone)sul danno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000150-31,0,0,0 2011-000152-42,1,2012-10-15,2012-10-15,1,1,0,0,1,0,4,0,0,1,0,0,1,0,3,"Medical Faculty, University Magdeburg",An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren 15% gel and Differin 0.1 % gel for the treatment and maintenance treatment of facial acne vulgaris and late...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000152-42,0,0,0 2011-000155-16,1,2014-01-31,2014-01-31,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI,"Modulation of response to hormonal therapy with lapatinib and/or metformin in patients with HER2-negative, ER and/or PgR positive metastatic breast cancer with progressive disease after first-line hor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000155-16,0,0,0 2011-000156-42,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Amphia Hospital,Effect of the plasma substitutes Gelofusine and Hydroxyethyl Starch 130/0.4 combined with lactated ringer's solution on the coagulation system,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000156-42,0,0,0 2011-000157-23,1,2012-12-23,2012-12-23,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,UMC St Radboud,Street Fitness In surgical patieNts undergoing general anesthesia after reversal of neuromuscular rest blockade with sugammadeX (SFINX study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000157-23,0,0,0 2011-000158-47,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Klin. Abtlg. für Thorax- & Hyperbare Chirurgi,Assessment of extracellular concentrations of linezolid and other currently approved antibiotics in patients presenting with severe bacterial lung infection Messung extrazellulärer Konzentrationen ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000158-47,0,0,0 2011-000160-97,8,2013-02-13,2013-02-13,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVAGALI Pharma S.A.,"A MULTICENTER, RANDOMIZED, DOUBLE-MASKED, 2 PARALLEL ARM, VEHICLE CONTROLLED, 6-MONTH PHASE III TRIAL WITH A 6 MONTH OPEN LABEL TREATMENT SAFETY FOLLOW-UP PERIOD TO EVALUATE THE EFFICACY AND SAFETY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000160-97,1,0,0 2011-000160-97,8,2013-02-13,2013-02-13,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVAGALI PHARMA S.A.,"A MULTICENTER, RANDOMIZED, DOUBLE-MASKED, 2 PARALLEL ARM, VEHICLE CONTROLLED, 6-MONTH PHASE III TRIAL WITH A 6 MONTH OPEN LABEL TREATMENT SAFETY FOLLOW-UP PERIOD TO EVALUATE THE EFFICACY AND SAFETY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000160-97,1,0,0 2011-000161-13,1,2012-11-19,2012-11-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Alcon Research Ltd,"Assessing the Efficacy and Tolerability of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination), as Replacement Therapy in Patients Previously on Bimatoprost 0.03%/Timolol ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000161-13,0,0,0 2011-000164-10,2,2013-06-27,2013-06-27,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Shire Development Inc,"A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000164-10,0,0,0 2011-000164-10,2,2013-06-27,2013-06-27,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Shire Development LLC,"A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000164-10,0,0,0 2011-000165-12,4,2013-06-17,2013-06-17,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Relypsa, Inc.","A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of RLY5016 in the Treatment of Hyperkalemia in Patients with Hypertension and Diabetic Nephropathy Receivi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000165-12,0,0,0 2011-000169-10,1,2012-12-05,2012-12-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CLINUVEL PHARMACUETICALS LTD.,"A Phase II, Randomised Pilot Study to Evaluate the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000169-10,0,0,0 2011-000174-66,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Academic Medical Centre,Assessment of Perinatal Outcome by uSe of Tocolysis in Early Labour (APOSTEL IV); Nifedipine versus placebo in the treatment of preterm premature rupture of membranes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000174-66,0,0,0 2011-000175-13,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,FONDAZIONE ITALIANA LINFOMI ONLUS,A phase II study of oral Panobinostat in adult patients with relapsed/refractory diffuse large B-cell lymphoma after high-dose chemotherapy with autologous stem cell transfusion (ASCT) or in adult pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000175-13,0,0,0 2011-000176-33,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Cell Therapy Of Duchenne Muscular Dystrophy by intra-arterial delivery of HLA-identical allogeneic mesoangioblasts,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000176-33,0,0,0 2011-000177-31,6,2015-02-28,2015-02-28,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Prima BioMed Ltd,CANVAS: A Randomized Trial of Cvac (Autologous Dendritic Cells Pulsed with Recombinant Human Fusion Protein [Mucin 1-Glutathione S Transferase] Coupled to Oxidized Polymannose) as Maintenance Treatmen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000177-31,0,0,0 2011-000177-31,6,2015-02-28,2015-02-28,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Prima BioMed,CANVAS: A Randomized Trial of Cvac (Autologous Dendritic Cells Pulsed with Recombinant Human Fusion Protein [Mucin 1-Glutathione S Transferase] Coupled to Oxidized Polymannose) as Maintenance Treatmen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000177-31,0,0,0 2011-000180-28,1,2012-10-01,2012-10-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GW Pharma Ltd,"A randomised, double-blind, placebo-controlled parallel group, pilot study of 40:1 ratio of formulated GWP42003 : GWP42004 in the treatment of iatrogenic weight gain and dyslipidaemia associated with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000180-28,0,0,0 2011-000181-34,5,2013-09-19,2014-01-28,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000181-34,0,0,0 2011-000181-34,5,2013-09-19,2014-01-28,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,INSPIRATION BIOPHARMACEUTICALS,Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000181-34,0,0,0 2011-000186-13,1,2011-07-11,2011-07-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,"An Investigator-blind, Controlled Exploratory Study to Assess the Efficacy and Safety of Different Concentrations of Active Ingredients in the project Formulations of LAS 41004 Compared to a Bland Oin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000186-13,0,0,0 2011-000190-31,1,2013-11-29,2013-11-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Therabel Pharmaceuticals Ltd,Double-blind parallel placebo-controlled study to evaluate the effect of Molsidomine on the Endothelial Dysfunction in patients with stable angina pectoris undergoing a percutaneous CORonary intervent...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000190-31,0,0,0 2011-000192-13,3,2012-04-23,2012-04-23,3,0,0,1,0,1,1,0,0,1,0,0,0,0,1,Forest Laboratories UK Ltd.,A 7-day open-label pharmacokinetic study to investigate the systemic absorption of colistimethate sodium after inhalation of dry powder colistimethate sodium for inhalation (Colobreathe® 125mg) in adu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000192-13,0,0,0 2011-000194-31,1,2014-06-30,2014-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Plymouth Hospitals NHS Trust,An open randomised trial of patient controlled analgesia (PCA) versus routine care in the Emergency Department,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000194-31,0,0,0 2011-000195-34,22,2017-06-14,2017-07-14,20,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A single arm, open-label, phase II, multicentre study to assess the safety of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC). Studio multicentrico...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000195-34,0,0,0 2011-000195-34,22,2017-06-14,2017-07-14,20,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"A single arm, open-label, phase II, multicentre study to assess the safety of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC). Studio multicentrico...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000195-34,0,0,0 2011-000197-53,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,"Effects of Potassium Sparing Diuretics on Potassium Urinary Output, Plasma Levels and Cardiac Arrhythmias in Neurocritical Care Patients Receiving Mannitol Therapy for Cerebral Edema: double blind, pl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000197-53,0,0,0 2011-000198-29,5,2019-06-28,2019-06-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MedImmune, LLC",A Phase 1b/2 Randomized Study of MEDI-573 in Combination with an Aromatase Inhibitor (AI) Versus AI Alone in Women with Metastatic Breast Cancer (MBC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000198-29,0,0,0 2011-000201-44,1,2014-03-05,2014-03-05,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Infinity Pharmaceuticals, Inc","A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated patients with Stage IIIB or IV Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000201-44,0,0,0 2011-000203-41,8,2013-12-01,2014-01-27,3,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Actelion Pharmaceuticals Ltd,"Multicenter, double-blind, placebo-controlled, randomized, prospective study of bosentan as adjunctive therapy to inhaled nitric oxide in the management of persistent pulmonary hypertension of the new...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000203-41,1,1,0 2011-000203-41,8,2013-12-01,2014-01-27,3,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Actelion Pharmaceuticals Ltd.,"Multicenter, double-blind, placebo-controlled, randomized, prospective study of bosentan as adjunctive therapy to inhaled nitric oxide in the management of persistent pulmonary hypertension of the new...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000203-41,1,1,0 2011-000206-22,1,2014-10-23,2014-10-23,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,"Helsingin Yliopisto, Kemian laitos",Elimination kinetics of HCN after inhaled exposure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000206-22,0,0,0 2011-000207-40,1,,,0,0,0,0,1,0,3,0,0,1,1,1,0,1,0,FUNDACION PARA LA INVESTIGACION CV HOSPITAL DR. PESET,ANALOGOS DE GNRH Y PROTECCION OVARICA FRENTE A AGENTES GONADOTOXICOS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000207-40,0,0,0 2011-000210-19,4,2013-02-05,2013-02-05,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000210-19,0,0,0 2011-000211-64,4,2016-12-26,2016-12-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Phase 1b/2 Study with Gemcitabine and LY2157299 for Patients with Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2) Studio di fase 1b/2 sull'™uso...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000211-64,0,0,0 2011-000211-64,4,2016-12-26,2016-12-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ELI LILLY AND COMPANY,A Phase 1b/2 Study with Gemcitabine and LY2157299 for Patients with Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2) Studio di fase 1b/2 sull'™uso...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000211-64,0,0,0 2011-000212-25,2,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,Shire HGT Inc,An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction with Intravenous Elaprase® in Pediatric Patient...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000212-25,0,1,0 2011-000213-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Intramuscular corticosteroid injections in hip osteoarthritis: a double-blinded randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000213-39,0,0,0 2011-000214-19,9,2013-11-14,2013-11-14,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,AstraZeneca,"A 30 day international, randomized, parallel-group, double-blind, placebo-controlled phase IV study to evaluate efficacy and safety of pre-hospital vs. in-hospital initiation of ticagrelor therapy in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000214-19,0,0,0 2011-000214-19,9,2013-11-14,2013-11-14,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,ASTRAZENECA,"A 30 day international, randomized, parallel-group, double-blind, placebo-controlled phase IV study to evaluate efficacy and safety of pre-hospital vs. in-hospital initiation of ticagrelor therapy in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000214-19,0,0,0 2011-000215-79,1,2015-07-30,2015-07-30,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,CHU de Clermont Ferrand,Tociluzimab effect on Endothelial function in patients with Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000215-79,0,0,0 2011-000218-20,3,2018-01-24,2018-01-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsmedizin Mainz,"LICC: L-BLP25 in Patients with Colorectal Carcinoma after curative resection of hepatic metastases – a randomized, placebo-controlled, multicenter, multinational, double blinded phase II trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000218-20,0,0,0 2011-000220-16,11,2013-01-07,2013-01-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essential H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000220-16,0,0,0 2011-000220-16,11,2013-01-07,2013-01-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TAKEDA EUROPE RESEARCH & DEVELOPMENT CENTRE LTD,"A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essential H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000220-16,0,0,0 2011-000221-68,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude multicentrique randomisée évaluant l’intérêt du Rituximab pour le traitement des glomérulonéphrites extra membraneuses idiopathiques,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000221-68,0,0,0 2011-000229-63,4,2012-08-29,2012-08-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Novartis Pharma Services AG,"A multicenter, randomized, blinded, double-dummy, placebo controlled, 3-period cross-over study to evaluate the effect of QVA149 on patient reported dyspnea in moderate to severe chronic obstructive p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000229-63,0,0,0 2011-000229-63,4,2012-08-29,2012-08-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Novartis Farmacéutica S.A.,"A multicenter, randomized, blinded, double-dummy, placebo controlled, 3-period cross-over study to evaluate the effect of QVA149 on patient reported dyspnea in moderate to severe chronic obstructive p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000229-63,0,0,0 2011-000233-37,1,2011-09-19,2011-09-19,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,"Stockholm Läns Landsting, Karolinska University Hospital","Insulin-like Growth Factor (IGF-I) induced muscle glucose uptake and interstitial IGF-1 concentrations. Placebo controlled, crossover study of the effect of sc rhIGF-I(Increlex) administration on gluc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000233-37,0,0,0 2011-000237-36,1,2013-05-25,2013-05-25,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,University of Nottingham,Predicting Response to Azithromycin Therapy in Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000237-36,0,0,0 2011-000240-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Skånes Onkologiska Klinik, Skåne University Hospital, Lund",A MULTICENTER PHASE II STUDY EVALUATING EFFICACY AND SAFETY OF 177Lu-DOTA-TATE BASED ON KIDNEY-DOSIMETRY IN PATIENTS WITH DISSEMINATED NEUROENDOCRINE TUMORS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000240-16,0,0,0 2011-000241-21,2,2013-03-07,2013-03-07,2,1,0,0,1,1,2,0,0,1,1,1,1,0,1,GlaxoSmithKline Research & Development Limited,A clinical and mechanistic proof of efficacy study with belimumab in chronic immune thrombocytopenia (ITP) patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000241-21,0,0,0 2011-000242-38,5,2013-10-23,2013-10-23,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy Studio di 2 anni sull'efficacia e la sicurezza di belimumab per via...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000242-38,0,0,0 2011-000242-38,5,2013-10-23,2013-10-23,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy Studio di 2 anni sull'efficacia e la sicurezza di belimumab per via...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000242-38,0,0,0 2011-000242-38,5,2013-10-23,2013-10-23,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.",A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy Studio di 2 anni sull'efficacia e la sicurezza di belimumab per via...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000242-38,0,0,0 2011-000243-24,1,2012-04-16,2012-04-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd.,"An open-label, phase 2a study to evaluate pazopanib eye drops administered for 12 weeks to patients with neovascular agerelated macular degeneration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000243-24,0,0,0 2011-000245-20,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,FUNDACIÓ SANT JOAN DE DEU,"ENSAYO CLÍNICO DOBLE CIEGO A SEIS MESES, CONTROLADO CON PLACEBO, DE LA EFICACIA DE RALOXIFENO COMO TRATAMIENTO ADYUVANTE DE LOS SÍNTOMAS NEGATIVOS DE LA ESQUIZOFRENIA, EN MUJERES POSTMENOPÁUSICAS ""A ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000245-20,0,0,0 2011-000249-18,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,RICARDO MOUZO MIRCO,ACCIÓN DEL PARICALCITOL SOBRE PARÁMETROS DE INFLAMACIÓN Y ESTRÉS OXIDATIVO EN PACIENTES CON ENFERMEDAD RENAL CRÓNICA ESTADIO Vd PORTADORES DE CATÉTERES TUNELIZADOS PARA HEMODIÁLISIS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000249-18,0,0,0 2011-000250-28,3,2012-08-13,2012-08-13,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Astellas Pharma Europe B.V.,"A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with Ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000250-28,0,0,0 2011-000254-39,1,2015-10-14,2015-10-14,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Anestesi och Operationskliniken,Perioperative Goal Directed Fluid Therapy during Esophageal Resection. A prospective randomized controlled open multi-centre trial to study the effect on postoperative complications,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000254-39,0,0,0 2011-000257-23,1,2011-11-04,2011-11-04,1,0,0,0,1,0,4,0,0,1,0,0,1,0,1,Thornton & Ross Ltd,"A randomised, controlled, assessor-blind, clinical trial to demonstrate superiority of Hedrin® Once liquid gel compared with Lyclear 1% permethrin crème rinse in the treatment of head lice",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000257-23,0,0,0 2011-000259-17,1,2018-06-30,2018-06-30,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Charité - Universitätsmedizin Berlin,A phase I/II study of Pazopanib and weekly Topotecan in patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000259-17,0,0,0 2011-000260-99,1,2013-03-11,2013-03-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Department of Genitourinary medicine and Infectious Diseases, St James's Hospital, Dublin 8",Immunogenicity of pneumococcal vaccination after prime boosting in HIV-Infected Adults: A Randomised Controlled Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000260-99,0,0,0 2011-000261-12,4,2012-09-13,2012-09-13,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Subjects with International Pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000261-12,0,0,0 2011-000263-27,2,2014-09-17,2014-09-17,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,CSL Behring GmbH,"An open-label, prospective, multicenter study to investigate the specificity of in vivo antibody binding to red blood cells in subjects with chronic immune thrombocytopenic purpura (ITP) treated with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000263-27,0,0,0 2011-000263-27,2,2014-09-17,2014-09-17,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,CSL Behring LLC,"An open-label, prospective, multicenter study to investigate the specificity of in vivo antibody binding to red blood cells in subjects with chronic immune thrombocytopenic purpura (ITP) treated with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000263-27,0,0,0 2011-000264-10,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Instituto Aragonés de Ciencias de la Salud,Melatonina asociada a inhibición ácida como estrategia de quimioprevención en esófago de Barrett. Estudio piloto,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000264-10,0,0,0 2011-000265-12,9,2015-10-16,2015-10-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Limited,"A Double-blind, Randomized, Placebo-controlled, Multicenter, Parallel-group Study with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Adjunctive Perampanel in Primary Generalized...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000265-12,0,0,0 2011-000266-35,3,2014-03-26,2014-06-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services,"A phase II, open-label, single-arm, non-randomized, multi-center study to evaluate the efficacy of oral TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000266-35,0,0,0 2011-000266-35,3,2014-03-26,2014-06-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A phase II, open-label, single-arm, non-randomized, multi-center study to evaluate the efficacy of oral TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000266-35,0,0,0 2011-000266-35,3,2014-03-26,2014-06-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A phase II, open-label, single-arm, non-randomized, multi-center study to evaluate the efficacy of oral TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000266-35,0,0,0 2011-000270-57,2,2013-04-08,2013-04-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Glenmark Pharmaceuticals SA,"A phase II, 12-week randomized, double-blind, triple dummy, parallel group, placebo-controlled, dose range finding study to evaluate safety, tolerability and efficacy of revamilast in patients with c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000270-57,0,0,0 2011-000272-34,3,2015-02-14,2015-03-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,Phase II study assessing the maintenance treatment with Vinflunine after first-line therapy with gemcitabine and cisplatin in patients with advanced or metastatic transitional cell carcinoma of the ur...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000272-34,0,0,0 2011-000273-31,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Herlev University Hospital,Intra-hepatic and systemic chemotherapy with or without antibody for patients with non-resectable liver metastasis from solid tumours,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000273-31,0,0,0 2011-000275-13,4,2015-05-27,2015-06-11,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000275-13,0,0,0 2011-000275-13,4,2015-05-27,2015-06-11,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the safety, tolerability and long term efficacy up to 2 years in patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000275-13,0,0,0 2011-000276-34,8,2014-10-21,2014-10-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000276-34,0,0,0 2011-000276-34,8,2014-10-21,2014-10-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000276-34,0,0,0 2011-000276-34,8,2014-10-21,2014-10-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 24 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000276-34,0,0,0 2011-000278-74,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"KRKA, tovarna zdravil, d. d., Novo mesto",A COMPARATIVE EFFICACY AND SAFETY OF CETYLPYRIDINIUM CHLORIDE 1.0 mg/BENZYDAMINE HYDROCHLORIDE 3 mg FIXED COMBINATION LOZENGES IN SUBJECTS WITH SORE THROAT ASSOCIATED WITH UPPER RESPIRATORY TRACT INFE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000278-74,0,0,0 2011-000281-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Vanda Pharmaceuticals Inc.,"A Multicenter, Randomized, Double-Mask, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of 20 mg Tasimelteon versus Placebo in Totally Blind Subjects with N24HSWD followed by...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000281-35,0,0,0 2011-000284-27,1,2012-12-06,2012-12-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leicester,A Randomised Controlled Trial for People with Established Type 2 Diabetes during Ramadan: Liraglutide versus a Sulphonylurea and/or Pioglitazone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000284-27,0,0,0 2011-000285-35,3,2012-10-11,2012-10-11,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cardoz AB,"An international, multi-centre, randomised, stratified, double-blinded, placebo-controlled, 4-parallel group trial investigating the efficacy and safety of three different dose levels of CRD007 admini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000285-35,0,0,0 2011-000290-31,1,2013-03-08,2013-03-08,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Evangelisches Krankenhaus Lutherhaus gGmbH,Comparison of the effect of an ongoing treatment with alendronate or a drug holiday on the fracture risk in osteoporotic patients with a bisphosphonate long term therapy Vergleich einer Weiterbehan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000290-31,0,0,0 2011-000291-34,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,3,,Direct effect of four different compounds on experimental pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000291-34,0,0,0 2011-000293-62,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación PETHEMA,"Phase II, Open, National, Multicenter Study of Bendamustine, Bortezomib (Velcade) and prednisone (BVP) in patients with newly diagnosed multiple myeloma (BenVelPres) Estudio de Fase II Abierto, Nac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000293-62,0,0,0 2011-000299-33,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AGO Research GmbH,"Efficacy, tolerability and safety of Temsirolimus in women with platinum-refractory ovarian carcinoma or advanced endometrial carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000299-33,0,0,0 2011-000300-18,3,2017-02-17,2017-02-17,3,1,0,0,2,0,0,0,0,1,0,0,1,0,0,NHS Greater Glasgow and Clyde Board,REducing with MetfOrmin Vascular Adverse Lesions in T1DM Vermindering van vaatschade met metformine in type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000300-18,0,0,0 2011-000300-18,3,2017-02-17,2017-02-17,3,1,0,0,2,0,0,0,0,1,0,0,1,0,0,University of Glasgow,REducing with MetfOrmin Vascular Adverse Lesions in T1DM Vermindering van vaatschade met metformine in type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000300-18,0,0,0 2011-000300-18,3,2017-02-17,2017-02-17,3,1,0,0,2,0,0,0,0,1,0,0,1,0,0,NHS Greater Glasgow and Clyde,REducing with MetfOrmin Vascular Adverse Lesions in T1DM Vermindering van vaatschade met metformine in type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000300-18,0,0,0 2011-000300-18,3,2017-02-17,2017-02-17,3,1,0,0,2,0,0,0,0,1,0,0,1,0,0,Maastricht University Medical Centre,REducing with MetfOrmin Vascular Adverse Lesions in T1DM Vermindering van vaatschade met metformine in type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000300-18,0,0,0 2011-000301-45,7,2012-06-12,2012-06-12,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, double-blind, multi-center study to assess safety and tolerability of different oral doses of BAY 94-8862 in subjects with stable chronic heart failure with left ventricular systolic dys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000301-45,0,0,0 2011-000308-16,1,2013-12-10,2013-12-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UZ Leuven,Prucalopride versus Placebo in Idiopathic and Diabetic Gastroparesis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000308-16,0,0,0 2011-000310-19,2,2015-01-31,2019-02-05,2,0,1,0,0,0,2,0,0,1,0,0,1,0,0,Lund University,"Fentanyl treatment in newborn infants: A Pharmacokinetic, Pharmacodynamic, and Pharmacogenetic Study (PK/PD model)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000310-19,0,0,0 2011-000311-34,5,2015-01-15,2015-01-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"SCHERING PLOUGH RESEARCH INSTITUTE, A DIVISION OF SCHERING CORPORATION","A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects with Active Axial Spondyloarthritis (Phase 3b, Protocol No. P07642,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000311-34,0,0,0 2011-000311-34,5,2015-01-15,2015-01-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation","A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects with Active Axial Spondyloarthritis (Phase 3b, Protocol No. P07642,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000311-34,0,0,0 2011-000323-33,5,2013-04-30,2013-04-30,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"A Phase 2/3, multicenter, open-label clinical study to assess the safety and efficacy of BAY86-6150 in subjects with hemophilia A or B with inhibitors, composed of 2 Parts (A & B). Part A: Sequential ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000323-33,0,0,0 2011-000328-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Miguel Yebra Bango,Ensayo clínico exploratorio del efecto de atorvastatina en la modulación de la rigidez arterial y de los marcadores biológicos implicados en la arteriosclerosis en pacientes con lupus eritematoso sist...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000328-13,0,0,0 2011-000329-66,1,,,0,0,0,0,1,0,4,0,0,1,1,1,0,1,0,Ana Vallejo de la Cueva,?ENSAYO CLÍNICO ALEATORIZADO: SEDACIÓN EN PROCEDIMIENTOS ENDOSCÓPICOS KETAMINA VERSUS PROPOFOL?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000329-66,0,0,0 2011-000330-11,7,2016-04-28,2016-06-28,5,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Astellas Pharma Europe B.V.,"A Phase 3, Open-Label, Baseline-controlled, Multicenter, Sequential Dose Titration Study to Assess the Long-Term Efficacy and Safety, and the Pharmacokinetics of Solifenacin Succinate Suspension in Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000330-11,1,0,0 2011-000337-36,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,FUNDACIÓ SANT JOAN DE DÉU,IMPACT OF THE ADMINISTRATION OF SYSTEMIC GLUCOCORTICOIDS ON INFLAMMATORY RESPONSE AND CLINICAL EVOLUTION OF PATIENTS DIAGNOSED WITH MODERATE-SEVERE BRONCHIOLITIS IMPACTO DE LA ADMINISTRACIÓN DE GLU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000337-36,0,0,0 2011-000338-12,1,2012-08-17,2012-08-17,1,0,1,0,0,0,3,0,0,1,0,0,1,0,1,Medical Developments International Limited,"A randomised, double blind, multi-centre, placebo controlled study to evaluate the efficacy and safety of methoxyflurane (Penthrox(TM)) for the treatment of acute pain in patients presenting to an Eme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000338-12,0,0,0 2011-000347-25,8,2012-07-13,2012-07-31,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 12 weeks in hypertensive patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000347-25,0,0,0 2011-000347-25,8,2012-07-13,2012-07-31,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim AB,"A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 12 weeks in hypertensive patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000347-25,0,0,0 2011-000347-25,8,2012-07-13,2012-07-31,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 12 weeks in hypertensive patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000347-25,0,0,0 2011-000347-25,8,2012-07-13,2012-07-31,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Danmark A/S,"A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 12 weeks in hypertensive patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000347-25,0,0,0 2011-000347-25,8,2012-07-13,2012-07-31,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim B.V.,"A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 12 weeks in hypertensive patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000347-25,0,0,0 2011-000347-25,8,2012-07-13,2012-07-31,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Finland KY,"A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 12 weeks in hypertensive patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000347-25,0,0,0 2011-000347-25,8,2012-07-13,2012-07-31,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Noway KS,"A phase III randomised, double-blind, placebo-controlled, parallel group, efficacy and safety study of BI 10773 (10 mg, 25 mg) administered orally, once daily over 12 weeks in hypertensive patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000347-25,0,0,0 2011-000348-11,6,2014-06-09,2015-10-17,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Endocyte, Inc.",A RANDOMIZED DOUBLE-BLIND PHASE 3 TRIAL COMPARING EC145 AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD/DOXIL®/CAELYX®) IN COMBINATION VERSUS PLD IN PARTICIPANTS WITH PLATINUM-RESISTANT OVARIAN CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000348-11,0,0,0 2011-000362-35,1,2017-08-18,2017-08-18,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,"Bioinova, s.r.o.","A Prospective, Non-randomized, Open Label Study to Assess the Safety and the Efficacy of Autologous Multipotent Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis. Bezpečnost ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000362-35,0,0,0 2011-000365-12,1,2011-07-05,2011-07-05,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, open-label, five period, crossover study to evaluate the single dose pharmacokinetics and food effect of two pediatric AFQ056 formulations in healthy adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000365-12,0,0,0 2011-000366-35,1,2018-04-06,2018-04-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Birmingham,Tackling Early Morbidity and Mortality in myeloma: assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000366-35,0,0,0 2011-000366-35,1,2018-04-06,2018-04-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Warwick,Tackling Early Morbidity and Mortality in myeloma: assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000366-35,0,0,0 2011-000368-88,6,,,0,1,1,0,0,0,2,0,0,2,1,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000368-88,0,1,0 2011-000368-88,6,,,0,1,1,0,0,0,2,0,0,2,1,0,0,0,1,"GlaxoSmithKline, S.A.","A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000368-88,0,1,0 2011-000368-88,6,,,0,1,1,0,0,0,2,0,0,2,1,0,0,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"A Multi-center, Randomized Parallel Group, Placebo-Controlled Double-Blind Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000368-88,0,1,0 2011-000369-11,2,2013-06-30,2013-06-30,2,1,1,0,0,1,2,0,0,1,0,0,1,0,1,ViroPharma Incorporated,Open-label single-dose study to evaluate the response and pharmacokinetics/pharmacodynamics of different doses of Cinryze® [C1 Inhibitor (human)] for treatment of acute angioedema attacks in children ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000369-11,0,0,0 2011-000374-60,11,2022-02-03,2022-02-03,8,1,1,0,0,0,3,0,0,2,0,0,0,0,1,UCB Pharma SA,"Estudio de seguimiento, multicéntrico, abierto, a largo plazo, para evaluar la seguridad y la eficacia de brivaracetam como tratamiento adyuvante en pacientes pediátricos con epilepsia Open-label, si...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000374-60,1,0,0 2011-000374-60,11,2022-02-03,2022-02-03,8,1,1,0,0,0,3,0,0,2,0,0,0,0,1,UCB PHARMA S.A.,"Estudio de seguimiento, multicéntrico, abierto, a largo plazo, para evaluar la seguridad y la eficacia de brivaracetam como tratamiento adyuvante en pacientes pediátricos con epilepsia Open-label, si...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000374-60,1,0,0 2011-000375-13,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,"National Institute of Public Health and Environment (RIVM, the Netherlands)",Study to determine the appropriate age for a second immunization with the Meningococcal C conjugated vaccine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000375-13,0,0,0 2011-000379-15,1,2012-09-10,2012-09-10,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Allergan Ltd.,"A Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of Bimatoprost Solution 0.03%, 0.1%, and 0.3% Compared with Vehicle in Men with Androgenic Alopecia wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000379-15,0,0,0 2011-000380-27,1,2012-09-10,2012-09-10,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Allergan Ltd.,"A Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety and Efficacy of Bimatoprost Solution 0.03%, 0.1%, and 0.3% Compared with Vehicle in Women with Female Pattern Hair ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000380-27,0,0,0 2011-000381-35,1,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,University of Oxford,"Understanding typhoid disease after vaccination: a single centre, randomised, double-blind, placebo-controlled study to evaluate M01ZH09 in a healthy adult challenge model, using Ty21a vaccine as a po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000381-35,0,0,0 2011-000383-10,7,2013-09-10,2013-09-10,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim RCV GmBH & Co KG,"A phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of linagliptin 5 mg/BI 10773 25 mg and linagliptin 5 mg/BI 10773 10 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000383-10,0,0,0 2011-000383-10,7,2013-09-10,2013-09-10,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Danmark A/S,"A phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of linagliptin 5 mg/BI 10773 25 mg and linagliptin 5 mg/BI 10773 10 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000383-10,0,0,0 2011-000383-10,7,2013-09-10,2013-09-10,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,,"A phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of linagliptin 5 mg/BI 10773 25 mg and linagliptin 5 mg/BI 10773 10 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000383-10,0,0,0 2011-000383-10,7,2013-09-10,2013-09-10,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim AB,"A phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of linagliptin 5 mg/BI 10773 25 mg and linagliptin 5 mg/BI 10773 10 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000383-10,0,0,0 2011-000383-10,7,2013-09-10,2013-09-10,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A.","A phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of linagliptin 5 mg/BI 10773 25 mg and linagliptin 5 mg/BI 10773 10 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000383-10,0,0,0 2011-000383-10,7,2013-09-10,2013-09-10,5,1,0,0,0,0,3,0,0,1,0,0,1,0,2,BOEHRINGER ING.,"A phase III randomized, double-blind, parallel group study to evaluate the efficacy and safety of once daily oral administration of linagliptin 5 mg/BI 10773 25 mg and linagliptin 5 mg/BI 10773 10 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000383-10,0,0,0 2011-000385-35,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,UCB PHARMA,"MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE PREDICTABILITY OF EARLY RESPONSE TO CERTOLIZUMAB PEGOL (IN COMBINATION WITH METHOTREXATE) AS CONFIRMED AT WEEK 52 IN SUBJECTS WITH MODERATE-SEVERE RHEUMAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000385-35,0,0,0 2011-000388-28,1,2015-12-01,2015-12-01,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,University Medical Center Freiburg,"Safety of Vorinostat in combination with Bortezomib, Doxorubicin and Dexamethasone (VBDD) in patients with refractory or relapsed multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000388-28,0,0,0 2011-000391-34,10,2016-12-06,2016-12-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,BOEHRINGER ING.,"A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000391-34,0,0,0 2011-000391-34,10,2016-12-06,2016-12-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000391-34,0,0,0 2011-000391-34,10,2016-12-06,2016-12-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,,"A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000391-34,0,0,0 2011-000391-34,10,2016-12-06,2016-12-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Boehringer Ingelheim Hellas, S.A.","A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000391-34,0,0,0 2011-000391-34,10,2016-12-06,2016-12-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A.","A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000391-34,0,0,0 2011-000391-34,10,2016-12-06,2016-12-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer-Ingelheim Danmark A/S,"A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000391-34,0,0,0 2011-000391-34,10,2016-12-06,2016-12-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim France,"A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000391-34,0,0,0 2011-000391-34,10,2016-12-06,2016-12-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000391-34,0,0,0 2011-000391-34,10,2016-12-06,2016-12-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim,"A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000391-34,0,0,0 2011-000392-14,16,2016-06-21,2016-09-12,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000392-14,0,0,0 2011-000392-14,16,2016-06-21,2016-09-12,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim,"A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000392-14,0,0,0 2011-000392-14,16,2016-06-21,2016-09-12,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,,"A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000392-14,0,0,0 2011-000392-14,16,2016-06-21,2016-09-12,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,BOEHRINGER ING.,"A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000392-14,0,0,0 2011-000392-14,16,2016-06-21,2016-09-12,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim AB,"A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000392-14,0,0,0 2011-000392-14,16,2016-06-21,2016-09-12,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,SCS Boehringer Ingelheim Comm.V,"A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000392-14,0,0,0 2011-000392-14,16,2016-06-21,2016-09-12,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim France,"A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000392-14,0,0,0 2011-000392-14,16,2016-06-21,2016-09-12,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000392-14,0,0,0 2011-000392-14,16,2016-06-21,2016-09-12,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim Limited,"A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000392-14,0,0,0 2011-000392-14,16,2016-06-21,2016-09-12,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim bv,"A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000392-14,0,0,0 2011-000392-14,16,2016-06-21,2016-09-12,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,"Boehringer Ingelheim Hellas, S.A.","A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000392-14,0,0,0 2011-000392-14,16,2016-06-21,2016-09-12,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,"Unilfarma, Lda.","A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000392-14,0,0,0 2011-000392-14,16,2016-06-21,2016-09-12,9,1,0,0,0,0,3,0,0,1,1,0,1,0,2,"Boehringer Ingelheim España, S.A.","A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemoradiotherapy in primary unresected patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000392-14,0,0,0 2011-000393-61,5,2013-05-15,2013-05-15,5,1,1,0,0,0,2,0,0,1,0,0,1,0,1,HAL Allergy B.V.,"A multi-centre, randomized, double-blind, placebo-controlled, dose range finding study to identify the optimal (i.e. safe and effective) dose of PURETHAL® Mites SCIT in patients with house dust mites-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000393-61,0,0,0 2011-000395-34,1,2012-11-02,2012-11-02,1,1,0,0,1,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 2, randomized, comparative, multicenter study evaluating the safety and immunogenicity of a new liquid formulation of adsorbed meningococcal C vaccine (conjugate CRM-197), a lyophilized mening...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000395-34,0,0,0 2011-000396-14,1,2014-05-22,2014-05-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Aberdeen,The use of Ketamine as an anaesthetic during electroconvulsive therapy (ECT) for depression: does it improve treatment outcome?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000396-14,0,0,0 2011-000396-14,1,2014-05-22,2014-05-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Grampian,The use of Ketamine as an anaesthetic during electroconvulsive therapy (ECT) for depression: does it improve treatment outcome?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000396-14,0,0,0 2011-000397-59,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,3,,"Prevention of post-ERCP acute pancreatitis by heme-oxygenase activation through the administration of hemin: a prospective, randomized double blind controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000397-59,0,0,0 2011-000400-17,3,2014-12-02,2014-12-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000400-17,0,0,0 2011-000401-50,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación para la Formación e Investigación Sanitarias de la Región de Murcia,Efficacy and safety of reversal with Sugammadex (BRIDION®) from deep Neuromuscular Blockade induced by rocuronium in children Eficacia y seguridad de la reversión con Sugammadex (BRIDION®) del bloq...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000401-50,0,0,0 2011-000407-41,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,FUNDACIÓ SANT JOAN DE DEU,ASSESSMENT OF THE ANALGESIC EFFICACY AND TOLERABILITY OF THE PERIOPERATIVE ASSOCIATION OF KETAMINE WITH OPIATES AFTER POSTERIOR VERTEBRAL FUSION SURGERY IN CHILDREN WITH IDIOPATHIC SCOLIOSIS EVALUA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000407-41,0,0,0 2011-000408-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CRLC Val d’Aurelle – Paul Lamarque,Etude de phase II randomisée évaluant la chimioradiothérapie (RT + cisplatine vs. RT + cisplatine + gemcitabine) comme traitement conservateur des cancers infiltrants de vessie opérables d’emblée : Et...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000408-17,0,0,0 2011-000410-18,15,2012-10-19,2012-11-16,11,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Baxter Innovations GmbH,A PHASE 3b CLINICAL STUDY TO ASSESS WHETHER REGULAR ADMINISTRATION OF ADVATE IN THE ABSENCE OF IMMUNOLOGICAL DANGER SIGNALS REDUCES THE INCIDENCE RATE OF INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS WI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000410-18,0,0,0 2011-000411-12,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,UMC St Radboud,The effect of Liraglutide on insulin-associated weight gain in patients with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000411-12,0,0,0 2011-000413-39,5,2014-05-15,2014-05-27,5,1,1,0,0,2,3,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,"BAX 326 (recombinant factor IX): A Phase 3 Prospective, Multicenter Study Evaluating Efficacy and Safety in Previously Treated Patients With Severe (FIX level < 1%) or Moderately Severe (FIX level ≤ 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000413-39,0,0,0 2011-000414-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorcio de Apoyo a la Investigacion Biomedica en Red (CAIBER),Ensayo aleatorizado controlado sobre la terapia guiada por el antígeno carbohidrato 125 en los pacientes dados de alta por insuficiencia cardiaca aguda: efecto sobre la mortalidad a 1 año.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000414-20,0,0,0 2011-000416-25,9,2015-03-31,2015-03-31,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen R&D Ireland,"A Phase III, open-label trial of TMC435 in combination with peginterferon alpha-2a and ribavirin for HCV genotype-1 infected subjects who participated in the placebo group of a Phase II/III TMC435 stu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000416-25,0,0,0 2011-000416-25,9,2015-03-31,2015-03-31,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Tibotec Pharmaceuticals,"A Phase III, open-label trial of TMC435 in combination with peginterferon alpha-2a and ribavirin for HCV genotype-1 infected subjects who participated in the placebo group of a Phase II/III TMC435 stu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000416-25,0,0,0 2011-000420-15,2,2014-03-26,2014-03-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04236921 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000420-15,0,0,0 2011-000425-72,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS,Treatment of macular edema secondary to central or branch vein occlusion by dexamethazone intravitreal injection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000425-72,0,0,0 2011-000426-29,8,2014-02-19,2014-02-19,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty (eTHA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000426-29,0,0,0 2011-000426-29,8,2014-02-19,2014-02-19,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty (eTHA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000426-29,0,0,0 2011-000428-14,2,2012-01-23,2012-01-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Almirall S.A.,"A PHASE IIA, RANDOMISED, SINGLE DOSE, DOUBLE-BLIND, DOUBLE-DUMMY, 6 WAY COMPLETE CROSS-OVER, PLACEBO CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF 4 DOSES OF LAS100977 Q...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000428-14,0,0,0 2011-000429-58,1,2011-12-27,2011-12-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Almirall S.A.,"A PHASE IIA, RANDOMISED, SINGLE DOSE, DOUBLE-BLIND, DOUBLE-DUMMY, 6 WAY COMPLETE CROSS-OVER, PLACEBO CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF 4 STRENGTHS OF LAS1009...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000429-58,0,0,0 2011-000430-11,4,2015-10-16,2015-10-16,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Società Italian di Cardiologia Invasiva GISE,Minimizing Adverse haemmhorragic events by TRansradial access site and systemic Implementation of angioX (MATRIX) Accesso Radiale versus Femorale e bivalirudina versus eparina non frazionata con o ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000430-11,1,0,0 2011-000430-11,4,2015-10-16,2015-10-16,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,G.I.S.E. - SOCIETA'' ITALIANA CARDIOLOGIA INVASIVA,Minimizing Adverse haemmhorragic events by TRansradial access site and systemic Implementation of angioX (MATRIX) Accesso Radiale versus Femorale e bivalirudina versus eparina non frazionata con o ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000430-11,1,0,0 2011-000436-28,3,2012-08-14,2012-08-14,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Zalicus, Inc.","A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, RANDOMIZED WITHDRAWAL DESIGN TRIAL USING ADAPTIVE RANDOMIZATION COMPARING Z102 WITH PLACEBO IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000436-28,1,0,0 2011-000437-36,2,2017-05-12,2017-05-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-response of BMS-663068/GSK3684934 in Treatment-experienced HIV-1 Subjects, Followed by an Open-labe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000437-36,0,0,0 2011-000437-36,2,2017-05-12,2017-05-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ViiV Healthcare UK Limited,"A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-response of BMS-663068/GSK3684934 in Treatment-experienced HIV-1 Subjects, Followed by an Open-labe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000437-36,0,0,0 2011-000439-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Effect of metformin and clomiphene in obese hypogonadal men with or without type 2 diabetes on plasma levels of testosterone and metabolic parameters Effetto della terapia con metformina e clomifen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000439-10,0,0,0 2011-000440-22,9,2015-01-08,2017-11-20,2,0,0,0,0,2,0,0,0,2,1,0,0,0,0,University of Heidelberg,MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000440-22,1,0,0 2011-000440-22,9,2015-01-08,2017-11-20,2,0,0,0,0,2,0,0,0,2,1,0,0,0,0,"European LeukemiaNet, Ruprecht-Karls-Universität Heidelberg",MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000440-22,1,0,0 2011-000440-22,9,2015-01-08,2017-11-20,2,0,0,0,0,2,0,0,0,2,1,0,0,0,0,VU University Medical Center,MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000440-22,1,0,0 2011-000440-22,9,2015-01-08,2017-11-20,2,0,0,0,0,2,0,0,0,2,1,0,0,0,0,Fakultní nemocnice Brno,MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000440-22,1,0,0 2011-000441-20,13,2013-03-11,2013-09-18,12,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Insmed Incorporated,"ESTUDIO ALEATORIZADO, ABIERTO, CONTROLADO CON MEDICAMENTO ACTIVO Y MULTICÉNTRICO PARA EVALUAR LA EFICACIA, SEGURIDAD Y TOLERABILIDAD DE ARIKACE EN PACIENTES CON FIBROSIS QUÍSTICA CON INFECCIÓN CRÓNICA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000441-20,0,0,0 2011-000441-20,13,2013-03-11,2013-09-18,12,1,1,0,0,1,3,0,0,1,0,0,1,0,1,INSMED INCORPORATED,"ESTUDIO ALEATORIZADO, ABIERTO, CONTROLADO CON MEDICAMENTO ACTIVO Y MULTICÉNTRICO PARA EVALUAR LA EFICACIA, SEGURIDAD Y TOLERABILIDAD DE ARIKACE EN PACIENTES CON FIBROSIS QUÍSTICA CON INFECCIÓN CRÓNICA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000441-20,0,0,0 2011-000442-38,3,2014-08-14,2014-08-21,2,0,1,0,0,1,3,0,0,1,1,1,1,0,1,Insmed Incorporated,"Randomized, placebo-controlled, double-blind, multicenter study to assess the efficacy, safety and tolerability of Arikace™ in Cystic Fibrosis patients with chronic infection due to Pseudomonas Aerugi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000442-38,0,0,0 2011-000443-24,16,2015-07-15,2015-07-17,14,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Insmed Incorporated,Estudio de seguridad y tolerabilidad a largo plazo de la administración abierta de amicacina liposomal para inhalación (Arikace) en pacientes con fibrosis quística con infección crónica por Pseudomona...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000443-24,0,0,0 2011-000443-24,16,2015-07-15,2015-07-17,14,1,1,0,0,1,3,0,0,1,0,0,1,0,1,INSMED INCORPORATED,Estudio de seguridad y tolerabilidad a largo plazo de la administración abierta de amicacina liposomal para inhalación (Arikace) en pacientes con fibrosis quística con infección crónica por Pseudomona...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000443-24,0,0,0 2011-000454-32,1,2018-08-14,2018-08-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London,A single arm phase IIa study (with combination safety run-in) to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients who...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000454-32,0,0,0 2011-000455-16,1,2014-04-10,2014-04-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CYATHUS EXQUIRERE PharmaforschungsGmbH,"Efficacy and local tolerability of topically applied heparin (Heparin 2,400 IU/ml Cutaneous Spray) on the suitability of newly constructed primary arteriovenous Fistulas in haemodialysed patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000455-16,0,0,0 2011-000456-42,6,2013-06-14,2013-06-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GILEAD SCIENCE INC.,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS 5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000456-42,0,0,0 2011-000456-42,6,2013-06-14,2013-06-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gilead Sciences Inc.,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS 5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000456-42,0,0,0 2011-000460-10,4,2012-10-03,2012-10-03,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Merck Serono S.A. Geneva,First year growth response associated genetic markers validation Phase IV open-label study in Growth Hormone Deficient and Turner Syndrome pre-pubertal children : the PREDICT Pharmacogenetics Validati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000460-10,0,0,0 2011-000460-10,4,2012-10-03,2012-10-03,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MERCK SERONO SA,First year growth response associated genetic markers validation Phase IV open-label study in Growth Hormone Deficient and Turner Syndrome pre-pubertal children : the PREDICT Pharmacogenetics Validati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000460-10,0,0,0 2011-000460-10,4,2012-10-03,2012-10-03,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Merck Serono SA,First year growth response associated genetic markers validation Phase IV open-label study in Growth Hormone Deficient and Turner Syndrome pre-pubertal children : the PREDICT Pharmacogenetics Validati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000460-10,0,0,0 2011-000461-12,2,2014-12-03,2014-12-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double blind, placebo controlled, multi-centre study to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in chronic obstructive pulmonary disease patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000461-12,0,0,0 2011-000467-27,1,2013-11-06,2013-11-06,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Flexible-Dose Once-weekly Oral Aripiprazole in Children and Adolescents with Tourette's Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000467-27,0,0,0 2011-000468-83,2,,,0,1,0,0,0,1,3,0,0,1,1,1,0,1,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-weekly Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000468-83,0,0,0 2011-000469-11,4,2014-03-13,2014-03-14,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-weekly Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000469-11,0,0,0 2011-000475-14,2,2012-04-24,2012-04-24,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines when Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine in Healt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000475-14,0,0,0 2011-000476-34,1,2012-12-20,2012-12-20,1,1,0,0,1,0,4,0,1,1,0,0,1,0,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase IV,PlaceboControlled,Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix) and Quadrivalent ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000476-34,0,0,0 2011-000480-27,2,2012-02-01,2016-12-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College Cork,A Randomised Trial Evaluating the Safety and Efficacy of a Single Low Dose of Intracoronary Insulin-like Growth Factor-1 Following Percutaneous Coronary Intervention for ST-Elevation Acute Myocardial ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000480-27,0,0,0 2011-000483-94,2,2012-09-17,2012-09-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Ltd,"A multicenter, two-part, randomized, parallel group, placebo and sitagliptin-controlled study to evaluate the safety and efficacy of GSK256073 administered once or twice daily for 12 weeks in subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000483-94,0,0,0 2011-000483-94,2,2012-09-17,2012-09-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A multicenter, two-part, randomized, parallel group, placebo and sitagliptin-controlled study to evaluate the safety and efficacy of GSK256073 administered once or twice daily for 12 weeks in subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000483-94,0,0,0 2011-000484-28,5,2012-03-05,2012-03-05,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A randomised, double-blind, dose-finding, multicenter study of the safety, tolerability, and efficacy of GSK2251052 therapy compared to imipenem-cilastatin in the treatment of adult subjects with fe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000484-28,0,0,0 2011-000484-28,5,2012-03-05,2012-03-05,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A randomised, double-blind, dose-finding, multicenter study of the safety, tolerability, and efficacy of GSK2251052 therapy compared to imipenem-cilastatin in the treatment of adult subjects with fe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000484-28,0,0,0 2011-000484-28,5,2012-03-05,2012-03-05,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.","A randomised, double-blind, dose-finding, multicenter study of the safety, tolerability, and efficacy of GSK2251052 therapy compared to imipenem-cilastatin in the treatment of adult subjects with fe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000484-28,0,0,0 2011-000484-28,5,2012-03-05,2012-03-05,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GLAXO SMITHKLINE,"A randomised, double-blind, dose-finding, multicenter study of the safety, tolerability, and efficacy of GSK2251052 therapy compared to imipenem-cilastatin in the treatment of adult subjects with fe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000484-28,0,0,0 2011-000485-35,4,2012-03-05,2012-03-05,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"GlaxoSmithKline, S.A.","A Study to Assess the Safety, Tolerability and Preliminary Efficacy of GSK2251052 in the treatment of complicated intra-abdominal infection in adults. Estudio para evaluar la seguridad, tolerabilid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000485-35,0,0,0 2011-000485-35,4,2012-03-05,2012-03-05,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline Research & Development Limited,"A Study to Assess the Safety, Tolerability and Preliminary Efficacy of GSK2251052 in the treatment of complicated intra-abdominal infection in adults. Estudio para evaluar la seguridad, tolerabilid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000485-35,0,0,0 2011-000485-35,4,2012-03-05,2012-03-05,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Study to Assess the Safety, Tolerability and Preliminary Efficacy of GSK2251052 in the treatment of complicated intra-abdominal infection in adults. Estudio para evaluar la seguridad, tolerabilid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000485-35,0,0,0 2011-000485-35,4,2012-03-05,2012-03-05,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"A Study to Assess the Safety, Tolerability and Preliminary Efficacy of GSK2251052 in the treatment of complicated intra-abdominal infection in adults. Estudio para evaluar la seguridad, tolerabilid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000485-35,0,0,0 2011-000487-10,2,2014-05-27,2014-05-27,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Targacept, Inc.","A Double-Blind, Positive Comparator, Randomized, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients with Mild to Mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000487-10,0,0,0 2011-000488-29,2,2015-02-16,2015-02-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.",A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients with Mild to Moderate Renal Impairment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000488-29,0,0,0 2011-000490-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Català d'Oncologia,"Phase II randomised, open-label, multicentric clinical trial of neoadjuvant treatment comprising chemotherapy and trastuzumab with or without metformin, in women with HER2/ErbB2 positive primary breas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000490-30,0,0,0 2011-000493-56,3,2015-06-23,2015-06-23,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"GENENTECH, Inc.","A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF GDC-0980 VERSUS EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO HAVE PROGRESSED ON OR FOLLOWING VEGF-TARGETED THERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000493-56,0,0,0 2011-000499-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACIÓ SANT JOAN DE DEU,A PHASE II CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF AMPHOTERICIN B LIPID COMPLEX (ABELCET®) FOR THE PROPHYLAXIS OF INVASIVE PULMONARY ASPERGILLOSIS DURING PROLONGED NEUTROPENIA IN PAE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000499-32,0,0,0 2011-000501-52,1,2020-04-30,2020-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Greater Glasgow and Clyde,PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000501-52,0,0,0 2011-000501-52,1,2020-04-30,2020-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Glasgow,PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000501-52,0,0,0 2011-000503-40,1,2012-09-19,2012-09-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen",DABI-ADP-1: IMPACT OF DABIGATRAN AND PHENPROCOUMON ON ADP INDUCED PLATELET AGGREGATION IN PATIENTS WITH ATRIAL FIBRILLATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000503-40,0,0,0 2011-000504-18,1,2014-05-01,2014-05-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen",DABI-ADP-2: IMPACT OF DABIGATRAN AND PHENPROCOUMON ON CLOPIDOGREL MEDIATED ADP INDUCED PLATELET AGGREGATION IN PATIENTS WITH ATRIAL FIBRILLATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000504-18,0,0,0 2011-000506-21,1,2015-07-09,2015-07-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,3,Imperial College Healthcare NHS Trust,"A double-blind, randomised placebo-controlled trial to determine whether low-dose intravenous ketamine peri-operatively can prevent chronic post-surgical pain, in patients undergoing thoracotomy or vi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000506-21,0,0,0 2011-000509-29,10,2015-08-31,2015-08-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Phase III randomized, multicenter, two-arm, open-label trial to evaluate the efficacy of T-DM1 compared with treatment of physician's choice in patients with HER2-positive metastatic breast cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000509-29,0,0,0 2011-000509-29,10,2015-08-31,2015-08-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE,"A Phase III randomized, multicenter, two-arm, open-label trial to evaluate the efficacy of T-DM1 compared with treatment of physician's choice in patients with HER2-positive metastatic breast cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000509-29,0,0,0 2011-000512-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Seksjon for odontologisk farmakologi og farmakoterapi. UiO,Blokkering av analgetiske doser av pentazocine med naloxon,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000512-26,0,0,0 2011-000513-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University Medical Center Groningen,The pharmacokinetic effect of clarithromycin on the AUC0-12h of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000513-39,0,0,0 2011-000518-21,1,2012-06-06,2012-06-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,Cross-over study to assess the difference in fasting plasma glucose (FPG) between vildagliptin (Galvus®/Eucreas®) and sitagliptin (Januvia®/Janumet®) after two weeks (FPG-VISIT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000518-21,0,0,0 2011-000520-15,4,2014-04-23,2014-04-24,3,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A MULTICENTER, OPEN LABEL STUDY TO COMPARE ON DEMAND TREATMENT TO A PROPHYLAXIS REGIMEN OF NONACOG ALFA (BENEFIX) IN SUBJECTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B (FIX:C ≤2%)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000520-15,1,1,0 2011-000527-33,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Ghent University Hospital,Characteristics of adult patients with nocturia and nocturnal polyuria and analysis of pharmacokinetic and –dynamic characteristics of desmopressin Melt in this population,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000527-33,0,0,0 2011-000531-88,1,2012-05-30,2012-05-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,FONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO,"Ceftidoren versus levofloxacin in the treatment of patients with Acute Exacerbations of Chronic Bronchitis (AECB). Multi-centre, open-label, randomised, levofloxacin-controlled, parallel groups stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000531-88,0,0,0 2011-000533-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Trasplante Hematopoyético (GETH),"Estudio prospectivo, abierto, multicéntrico, de brazo único para evaluar la farmacocinética/farmacodinamia, factibilidad y seguridad de Doripenem como monoterapia en infusión prolongada (1000 mg en 4 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000533-36,0,0,0 2011-000535-86,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,CHU AMBROISE PARE,A PHASE IIb STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ROPIVACAINE COMPARED TO ADRENALINE-LIDOCAINE TO REDUCE PAIN IN PATIENT UNDERGOING SURGERY FOR THIRD MOLAR TEETH EXTRACTION.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000535-86,0,0,0 2011-000536-28,2,2013-03-29,2013-03-29,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Alcon Research Ltd.,Safety and efficacy study with ESBA1008 versus Lucentis for the treatment of exudative age-related macular degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000536-28,0,0,0 2011-000538-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VU University Medical Center,An exploratory open-label PET-observer-blinded pilot study to evaluate the effect of 3 and 12 months treatment with Aliskeren-based versus amlodipin-based antihypertensive treatment in patients with a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000538-12,0,0,0 2011-000541-20,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,Effect of Denosumab on Osteolytic Lesion Activity in Total Hip Arthroplasty (THA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000541-20,0,0,0 2011-000547-24,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Antwerp University Hospital,Therapeutic efficacy of Wilms' tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with solid tumors: a phase I/feasibility study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000547-24,0,0,0 2011-000553-23,1,2013-07-30,2013-07-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,German Breast Group GBG Forschungsgesellschaft mbH (Sponsor nach GCP),A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000553-23,0,0,0 2011-000554-31,2,2013-06-28,2013-06-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Ustekinumab in Subjects with Primary Biliary Cirrhosis Who had an Inad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000554-31,0,0,0 2011-000561-12,1,2015-06-19,2015-06-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,ITALIAN SARCOMA GROUP,"A phase II, open label, non-randomized study of second or third line treatment with the combination of sorafenib and everolimus in patients affected by relapsed and non-resectable high-grade osteos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000561-12,0,0,0 2011-000563-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),Randomized prospectic clinical trial for delivery induction in patients with unfavoreable obstetric conditions. STUDIO CLINICO PROSPETTICO RANDOMIZZATO MULTICENTRICO PER L'INDUZIONE DEL TRAVAGLIO D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000563-28,0,0,0 2011-000566-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hannu Kokki,Laskimoon annetun ketoprofeenin ja deksketoprofeenin aiheuttama kirvely,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000566-36,0,0,0 2011-000567-26,5,2013-01-01,2013-01-01,1,0,1,0,0,0,0,0,0,2,0,0,0,0,0,Radboud University Medical Centre Nijmegen,"A randomised double-blind, placebo-controlled study of risperidone in the treatment of DSM-IV-TR conduct disorder in children and adolescents.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000567-26,1,0,0 2011-000571-13,1,2013-03-15,2013-03-15,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Gentofte Hospital,The effect of GLP-1 in psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000571-13,0,0,0 2011-000572-33,1,2015-05-08,2015-05-08,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Oryx GmbH und Co. KG,Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of PArvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000572-33,0,0,0 2011-000575-14,8,2014-03-10,2014-03-10,7,0,0,0,0,0,2,0,0,1,0,0,1,0,1,D&A PHARMA,"Randomized, multicenter, double-blind, placebo-controlled study of the safety and efficacy of 4 dose regimens of SMO.IR, an oral solid formulation of sodium oxybate, in the maintenance of alcohol ab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000575-14,0,0,0 2011-000579-15,6,2013-10-18,2013-10-18,4,1,0,0,2,1,2,0,0,1,1,1,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000579-15,0,0,0 2011-000579-15,6,2013-10-18,2013-10-18,4,1,0,0,2,1,2,0,0,1,1,1,1,0,1,Institut de Recherches Internationales Servier,Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000579-15,0,0,0 2011-000582-13,5,2016-02-11,2016-02-11,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Development Centre Europe Ltd.,"A 16-week, randomized, placebo-controlled, double blind, and parallel group trial to assess the anti-inflammatory effects of Roflumilast in chronic obstructive pulmonary disease The ROBERT study (Rofl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000582-13,0,0,0 2011-000583-96,1,2013-10-01,2013-10-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Aarhus University Hospital, Skejby",Undersøgelse af 6-uger versus 6-måneders clopidogrel behandling hos patienter med samtidig aspirin og oral angikoagulans behandling efter implantation af en drug-eluting stent,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000583-96,0,0,0 2011-000586-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Center,The efficacy of mepolizumab treatment on rhinovirus induced asthma exacerbations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000586-12,0,0,0 2011-000587-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",SODIUM PICOSULPHATE AND MAGNESIUM CITRATE VERSUS POLYETHYLENE GLYCOLE (PEG) AS EVACUATING TREATMENT PRIOR TO COLONOSCOPY: PHASE IV RANDOMIZED TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000587-10,0,0,0 2011-000591-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Mater University Hospital,SIRS Steroids In caRdiac Surgery Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000591-34,0,0,0 2011-000593-54,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),"Effect of Vitamin D supplementation in HIV-infected children, adolescents and young adults with hypovitaminosis D. Effetto della supplementazione con Vitamina D in bambini, adolescenti e giovani ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000593-54,0,0,0 2011-000595-33,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Goethe University Frankfurt,Randomized controlled trial to compare the effects of single versus repeated intracoronary application of autologous bone marrow-derived mononuclear cells on total and SHFM-predicted mortality in pati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000595-33,0,0,0 2011-000598-30,4,2014-08-08,2014-09-08,2,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Cellseed France S.A.R.L.,MULTICENTER STUDY OF CULTURED AUTOLOGOUS ORAL MUCOSAL EPITHELIAL CELL-SHEET (CAOMECS) TRANSPLANTATION TO PATIENTS WITH TOTAL LIMBAL STEM CELL DEFICIENCY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000598-30,1,0,0 2011-000601-49,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Institute of Cancer Research,TOPARP: Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000601-49,0,0,0 2011-000601-49,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Royal Marsden NHS Foundation Trust,TOPARP: Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000601-49,0,0,0 2011-000602-22,2,2012-03-15,2012-03-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc,"A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF-04991532 AND SITAGLIPTIN IN ADULT PATIENTS WIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000602-22,0,0,0 2011-000603-40,5,2016-05-18,2016-05-18,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Vifor (International) Inc.,"Multicentre, prospective, randomised, 2-arm study to assess the impact of ferric carboxymaltose on exercise capacity in chronic heart failure patients with iron deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000603-40,0,0,0 2011-000603-40,5,2016-05-18,2016-05-18,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,VIFOR (INTERNATIONAL) INC.,"Multicentre, prospective, randomised, 2-arm study to assess the impact of ferric carboxymaltose on exercise capacity in chronic heart failure patients with iron deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000603-40,0,0,0 2011-000607-41,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Centre Hospitalier de Jolimont-Lobbes-Tubize-Nivelles,A phase I/II multicentric Belgian prospective novel sequential chemo-immunotherapy regimen for adjuvant treatment in non-muscle invasive bladder cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000607-41,0,0,0 2011-000608-16,1,2018-02-09,2018-02-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,2,The Newcastle upon Tyne Hospitals NHS Foundation Trust,To evaluate the safety and effectiveness of human ex vivo expanded autologous limbal stem cells for the treatment of unilateral total limbal stem cell deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000608-16,0,0,0 2011-000609-32,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Millennium Pharmaceuticals, Inc","A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab and Vincristine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000609-32,0,0,0 2011-000612-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI,Open-label study on the use of Finasteride in prolonged treatment (4 years) of tics in Tourette's disease and Parkinson's disease in the pounding Studio in aperto sull`™utilizzo della Finasteride ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000612-26,0,0,0 2011-000618-20,2,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,European Organization for the Research and Treatment of Cancer (EORTC),A PHASE II-R and A PHASE III TRIAL EVALUATING BOTH *ERLOTINIB (PH II-R) AND CHEMORADIATION (PH III) AS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTED HEAD OF PANCREAS ADENOCARCINOMA Essai de Phase I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000618-20,0,0,0 2011-000618-20,2,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,EORTC,A PHASE II-R and A PHASE III TRIAL EVALUATING BOTH *ERLOTINIB (PH II-R) AND CHEMORADIATION (PH III) AS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTED HEAD OF PANCREAS ADENOCARCINOMA Essai de Phase I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000618-20,0,0,0 2011-000619-16,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Fundación Investigación Biomedica. Hospital Clinico San Carlos,Identification of the effect of allopurinol treatment on platelets from diabetic patients with stable coronary ischemic disease and aspirin resistance. XUE Study. Estudio cruzado para valorar el efec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000619-16,0,0,0 2011-000620-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI,Effects of short term Erdosteine treatment on chronic cough on bronchitis phenotypes of COPD Effetti del trattamento a breve termine con Erdosteina sulla tosse cronica del fenotipo bronchitico dell...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000620-14,0,0,0 2011-000621-80,8,2018-08-08,2018-09-20,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"Randomized, Open-Label Study of Abiraterone Acetate (JNJ 212082) plus Prednisone/ Prednisolone with or without Exemestane in Postmenopausal Women with ER+ Metastatic Breast Cancer Progressing after Le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000621-80,0,0,0 2011-000621-80,8,2018-08-08,2018-09-20,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"Randomized, Open-Label Study of Abiraterone Acetate (JNJ 212082) plus Prednisone/ Prednisolone with or without Exemestane in Postmenopausal Women with ER+ Metastatic Breast Cancer Progressing after Le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000621-80,0,0,0 2011-000624-16,1,2014-06-03,2014-06-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Justus Liebig Universität Gießen,Infertility and inflammatory urogenital diseases as a result of the metabolic syndrome Male infertility with infection and inflammation -MIBIE- Projekt B4: Infertilität und inflammatorische Urogen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000624-16,0,0,0 2011-000626-29,1,2013-11-13,2013-11-13,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,QUEEN MARY UNIVERSITY OF LONDON,Keloid Scars: A randomised clinical and laboratory based study on the treatment and differentiation factors of the local disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000626-29,0,0,0 2011-000628-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,"Denosumab in enhancement of bone bonding of hip prosthesis in postmenopausal women: a randomized, double-blind, placebo-controlled study Satunnaistettu, kaksoissokkoutettu, lumekontrolloitu kliini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000628-14,0,0,0 2011-000629-55,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Manuel Rodríguez García,CLINICAL TRIAL WITH TENOFOVIR VERSUS LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL IN LAMIVUDINE-RESISTANT CHRONIC HEPATITIS-B PATIENTS WITH UNDETECTABLE VIRAL LOAD ENSAYO CLÍNICO DE SIMPLIFICACIÓN CON TENOFO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000629-55,0,0,0 2011-000631-92,3,2012-06-13,2012-06-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A phase II, randomized, double-blind, placebo controlled, parallel design, dose ranging, multi-center trial of four levels of exposure of QGE031 s.c. for 16 weeks in subjects aged 18 years and older w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000631-92,0,0,0 2011-000631-92,3,2012-06-13,2012-06-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma AG,"A phase II, randomized, double-blind, placebo controlled, parallel design, dose ranging, multi-center trial of four levels of exposure of QGE031 s.c. for 16 weeks in subjects aged 18 years and older w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000631-92,0,0,0 2011-000633-36,4,2013-03-25,2013-03-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A randomised, controlled, assessor-blind, parallel groups, multinational, multicentre trial assessing the dose-response relationship of FE 999049 in controlled ovarian stimulation in women undergoing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000633-36,0,0,0 2011-000634-11,5,2013-09-24,2013-09-24,2,1,0,0,0,0,2,0,0,2,1,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared with Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000634-11,1,0,0 2011-000634-11,5,2013-09-24,2013-09-24,2,1,0,0,0,0,2,0,0,2,1,0,0,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared with Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000634-11,1,0,0 2011-000634-11,5,2013-09-24,2013-09-24,2,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"GlaxoSmithKline, S.A.","A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared with Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000634-11,1,0,0 2011-000637-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE,“AN OBSERVATIONAL STUDY ON THE MOLECULES INVOLVED IN THE INTRACELLULAR UPTAKE IN PATIENTS AFFECTED FROM CHRONIC MYELOID LEUKEMIA RECEIVING TIROSINE-KINASE INHIBITORS.” STUDIO DELLE MOLECOLE COINVOL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000637-37,0,0,0 2011-000640-24,2,2011-12-08,2011-12-08,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A Multi-Center, Randomized, Double-Blind, Multiple Ascending Dose, Placebo-Controlled, Parallel Group 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of the HCV N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000640-24,0,0,0 2011-000642-37,1,2015-01-12,2015-01-12,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,Greater Glasgow Health Board,A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000642-37,0,0,0 2011-000642-37,1,2015-01-12,2015-01-12,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,University of Glasgow,A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000642-37,0,0,0 2011-000643-25,1,2015-09-10,2015-09-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,The Qure study: Q-fever fatigue syndrome - response to treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000643-25,0,0,0 2011-000644-16,1,2014-06-25,2014-06-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"University of Tartu, Clinic of Anaesthesiology and Intensive Care",High volume haemodiafiltration in treatment of severe sepsis -- impact on pharmacokinetics of doripenem and piperacillin tazobactam and inflammatory response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000644-16,0,0,0 2011-000647-24,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Radboud University Nijmegen Medical Centre,"The safety, tolerability, and analgesic efficacy of Δ9-THC (Namisol®) in chronic pancreatitis patients suffering from persistent abdominal pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000647-24,0,0,0 2011-000649-20,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,FONDAZIONE DELL'ISTITUTO TOSCANO TUMORI,Phase II study of pre-operative treatment with external radiotherapy plus panitumumab in operable locally advanced rectal cancer (favourable and intermediate prognostic group) (RaP Study/STAR-03) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000649-20,0,0,0 2011-000651-16,12,2013-08-16,2013-08-16,9,1,1,0,0,0,3,0,0,2,0,0,0,0,2,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000651-16,1,1,0 2011-000651-16,12,2013-08-16,2013-08-16,9,1,1,0,0,0,3,0,0,2,0,0,0,0,2,Merck Sharp & Dohme Corp,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000651-16,1,1,0 2011-000651-16,12,2013-08-16,2013-08-16,9,1,1,0,0,0,3,0,0,2,0,0,0,0,2,"Merck Sharp & Dohme a subsidiary of Merck Co., Inc","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000651-16,1,1,0 2011-000651-16,12,2013-08-16,2013-08-16,9,1,1,0,0,0,3,0,0,2,0,0,0,0,2,Merck Sharp & Dohme Corp.,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000651-16,1,1,0 2011-000651-16,12,2013-08-16,2013-08-16,9,1,1,0,0,0,3,0,0,2,0,0,0,0,2,Merck Sharp & Dohme (Sweden) AB,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000651-16,1,1,0 2011-000651-16,12,2013-08-16,2013-08-16,9,1,1,0,0,0,3,0,0,2,0,0,0,0,2,"MERCK & CO., INC.","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000651-16,1,1,0 2011-000651-16,12,2013-08-16,2013-08-16,9,1,1,0,0,0,3,0,0,2,0,0,0,0,2,,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000651-16,1,1,0 2011-000653-23,2,2013-12-19,2013-12-19,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Janssen Infectious Diseases BVBA,"A Phase III placebo-controlled, double-blind, randomized trial to evaluate the efficacy and safety of TMC207 in subjects with sputum smear-positive pulmonary infection with multi-drug resistant Mycoba...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000653-23,0,0,0 2011-000656-42,2,2013-04-01,2013-04-01,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MSD Finland Oy,"A 66-Week Extension to: A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding, Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients with Type 2 Diabetes Mellitus and Inadeq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000656-42,0,0,0 2011-000656-42,2,2013-04-01,2013-04-01,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A 66-Week Extension to: A Phase IIb, Randomized, Placebo-Controlled, Dose-Range Finding, Clinical Trial to Study the Safety and Efficacy of MK-3102 in Patients with Type 2 Diabetes Mellitus and Inadeq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000656-42,0,0,0 2011-000659-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Tübingen,"Treatment of therapy resistant Alopecia areata with fumaric acid esters (Fumaderm® and Fumaderm initial®) – an open, single center, non-randomized, pilot study with 40 patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000659-18,0,0,0 2011-000661-12,1,2014-11-28,2014-11-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Oxford,A randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000661-12,0,0,0 2011-000666-35,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Ghent University Hospital,Analysis of the effect and side effects of desmopressin melt in patients with nocturnal polyuria.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000666-35,0,0,0 2011-000670-62,7,2012-12-19,2012-12-19,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Shire-Movetis NV,"A randomised, double-blind, placebo-controlled trial to evaluate the efficacy, quality of life, safety and tolerability of long-term treatment (24 weeks) with prucalopride in subjects aged ≥ 18 year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000670-62,0,0,0 2011-000670-62,7,2012-12-19,2012-12-19,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SHIRE-MOVETIS NV,"A randomised, double-blind, placebo-controlled trial to evaluate the efficacy, quality of life, safety and tolerability of long-term treatment (24 weeks) with prucalopride in subjects aged ≥ 18 year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000670-62,0,0,0 2011-000672-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,Antagonistes NMDA en relais de la kétamine dans la douleur neuropathique.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000672-34,0,0,0 2011-000674-58,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Allergopharma Joachim Ganzer KG,"Double-blind, placebo controlled study to investigate the dose response of an allergoid preparation of Phleum pratense in adult patients with IgE mediated allergic Rhinitis / Rhinoconjunctivitis with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000674-58,0,0,0 2011-000677-31,1,2015-12-06,2015-12-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,Testosterone Replacement in Young Male cancer Survivors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000677-31,0,0,0 2011-000682-12,3,2014-01-16,2014-03-03,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sunovion Pharmaceuticals Inc.,"A Long-term, Multicenter, Open-Label, Flexible Dose Continuation Study in Subjects Who Have Completed a Prior Lurasidone Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000682-12,0,0,0 2011-000683-99,1,2014-11-17,2014-11-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Takeda Development Centre Europe Ltd.,"Control of moderate or severe asthma with 160, 320 and 640μg ciclesonide/day. A one-year randomised, double-blind, multicenter trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000683-99,0,0,0 2011-000691-34,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Dra Itxarone Bilbao. Servicio de Cirugía Hepatobiliopancreatica y Trasplantes. HUVH.,"Single-center pilot study, prospective, open-label, to evaluate the efficacy and safety of immunosuppression low nephrotoxicity, based on the use of ATeGe-Fresenius in patients with renal insufficienc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000691-34,0,0,0 2011-000692-14,1,2016-08-29,2016-08-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Hannu Kokki,Buprenorfiini-hoidon vaikutus lonkka- ja polviproteesileikkauksen jälkeiseen toipumiseen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000692-14,0,0,0 2011-000693-57,1,2018-01-23,2018-01-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Håkan Ledin (investigator initiated trial),"A Randomized, Placebo-controlled, Double-blind, Two-center Study with Denosumab in Subjects Undergoing Elective Total Knee Replacement Surgery En randomiserad, placebokontrollerad, dubbelblind, två...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000693-57,0,0,0 2011-000695-34,1,2015-05-12,2015-05-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.-Klinik für Notfallmedizin",Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000695-34,0,0,0 2011-000698-30,1,2012-08-30,2012-08-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Henrik Kehlet,Postoperative søvnforstyrrelser efter Zolpidem behandling ved fast-track hofte- eller knæalloplastik,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000698-30,0,0,0 2011-000699-32,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"UZ KULeuven, service of Rheumatology",Nail involvement in psoriatic arthritis: a cross-sectional and observational prospective study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000699-32,0,0,0 2011-000703-40,1,2018-02-28,2018-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Odense University Hospital,"Clinical trial with chemotherapy for patients with non-resectable, locally advanced pancreatic cancer and addition of chemo-radiotherapy for patients with borderline resectable pancreatic cancer. DPS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000703-40,0,0,0 2011-000708-17,4,2014-06-26,2014-06-26,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,"A 24 months, prospective, randomized, double-blind study to assess the effect of daily oral administration of 2 g of strontium ranelate versus placebo on bone mineral density in postmenopausal osteopo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000708-17,0,0,0 2011-000711-85,2,2013-06-07,2013-06-07,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Genentech, Inc","A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF MEGF0444A IN COMBINATION WITH CARBOPLATIN, PACLITAXEL AND BEVACIZUMAB IN PATIENTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000711-85,0,0,0 2011-000719-19,1,2018-10-30,2018-10-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Birmingham,A Randomised Controlled Trial of the Efficacy and Mechanism of Levothyroxine Treatment on Pregnancy and Neonatal Outcomes in Women with Thyroid Antibodies. (TABLET: Thyroid AntiBodies and LEvoThyroxin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000719-19,0,0,0 2011-000721-77,1,2016-09-29,2016-09-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Barts Health NHS Trust,"A randomised, double-blind, placebo-controlled trial assessing the safety and efficacy of intracoronary nitrite infusion during acute myocardial infarction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000721-77,0,0,0 2011-000722-30,10,2016-03-01,2016-03-01,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",A MULTICENTER OPEN-LABEL EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN STUDY B0151003 (ANDANTE II) STUDIO DI ESTENSIONE MULTICENTRICO IN APERTO SUI SOGGETTI CHE HANNO PARTECIPATO ALLO STUDIO B0...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000722-30,0,0,0 2011-000722-30,10,2016-03-01,2016-03-01,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Inc.,A MULTICENTER OPEN-LABEL EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN STUDY B0151003 (ANDANTE II) STUDIO DI ESTENSIONE MULTICENTRICO IN APERTO SUI SOGGETTI CHE HANNO PARTECIPATO ALLO STUDIO B0...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000722-30,0,0,0 2011-000722-30,10,2016-03-01,2016-03-01,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,PFIZER INC.,A MULTICENTER OPEN-LABEL EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN STUDY B0151003 (ANDANTE II) STUDIO DI ESTENSIONE MULTICENTRICO IN APERTO SUI SOGGETTI CHE HANNO PARTECIPATO ALLO STUDIO B0...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000722-30,0,0,0 2011-000723-32,2,2012-03-27,2012-03-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc,"A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF-04991532 AND ONCE DAILY SITAGLIPTIN IN ADULT ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000723-32,0,0,0 2011-000724-15,5,2016-05-02,2016-05-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,EISAI LTD UK,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Treatment of Physician's Choice in Subjects with Advanced Non-Small Cell Lung Cancer. Studio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000724-15,0,0,0 2011-000724-15,5,2016-05-02,2016-05-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Ltd,"A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Treatment of Physician's Choice in Subjects with Advanced Non-Small Cell Lung Cancer. Studio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000724-15,0,0,0 2011-000725-69,3,2012-09-07,2012-09-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Zambon S.p.A.,"Efficacy, tolerability and safety of Z7202, a once daily diclofenac diethylamine medicated plaster in the local treatment of painful conditions. Multi-centre, multinational, placebo- controlled, doubl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000725-69,0,0,0 2011-000728-14,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"Anadys Development, LTD","A Phase 2a, Randomized, Open-Label Study in Patients with Chronic Hepatitis C Viral Infection to Assess the Safety, Tolerability, Pharmacodynamics, and Antiviral Activity of ANA773 Tosylate Administer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000728-14,0,0,0 2011-000729-55,3,2018-05-25,2018-05-25,2,1,1,0,0,2,1,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase I Study of Ridaforolimus in Paediatric Patients with Advanced Solid Tumours,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000729-55,1,1,0 2011-000732-29,5,2012-03-01,2013-02-25,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab versus Pemetrexed in Subjects with Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000732-29,0,0,0 2011-000732-29,5,2012-03-01,2013-02-25,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab versus Pemetrexed in Subjects with Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000732-29,0,0,0 2011-000735-80,1,2019-08-19,2019-08-19,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Lene Drasbek Huusom,Administration of antenatal magnesium sulphate for prevention of cerebral palsy in preterm infants (MASP-STUDY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000735-80,0,0,0 2011-000739-97,1,2014-07-20,2014-07-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Med. Univ. Wien,"Prospective, randomized, controlled, open-label study evaluating quality of life in patients with advanced malignant tumors with and without “add-on” homeopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000739-97,0,0,0 2011-000745-21,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Schriners Hospitals for Children,"An international, multicenter, open-label, efficacy and safety trial of intravenous zoledronic acid in infants less than one year of age, with severe osteogenesis imperfecta Une étude clinique mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000745-21,0,0,0 2011-000749-19,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,3,Cardiff University,Bloodwise and NCRI Working Group Pick a Winner Programme (LI-1) Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000749-19,0,0,0 2011-000750-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Isala Klinieken,A randomised clinical trial on the effectiveness of Emla and Rapydan for prevention of vena punction-induced pain in children.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000750-37,0,0,0 2011-000752-41,4,2015-04-30,2015-06-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,EISAI LTD UK,"An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Sorafenib versus Sorafenib Alone as First Line Therapy in Patients with Hepatocellular Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000752-41,0,0,0 2011-000752-41,4,2015-04-30,2015-06-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Inc.,"An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Sorafenib versus Sorafenib Alone as First Line Therapy in Patients with Hepatocellular Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000752-41,0,0,0 2011-000753-24,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,VU University Medical Center,Central effects of endogenous GLP-1 and the GLP-1 analog liraglutide on brain satiety and reward circuits and feeding behavior in diabetes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000753-24,0,0,0 2011-000755-17,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Xavier Pintó Sala,Effect of nicotinic adic on the composition of high density lipoprotein (HDL) and endothelial function in patients with premature coronary heart disease and elevated HDL-cholesterol. Efecto del áci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000755-17,0,0,0 2011-000756-42,2,2012-07-11,2012-07-11,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Dompé s.p.a.,"A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. Pilotstudie der Phase 2, multize...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000756-42,0,0,0 2011-000756-42,2,2012-07-11,2012-07-11,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,DOMPE' s.p.a.,"A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. Pilotstudie der Phase 2, multize...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000756-42,0,0,0 2011-000757-22,2,2014-11-13,2014-11-13,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GLAXO SMITHKLINE,"A Phase IIIb open-label, randomised, multi-centre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000757-22,0,0,0 2011-000757-22,2,2014-11-13,2014-11-13,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase IIIb open-label, randomised, multi-centre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000757-22,0,0,0 2011-000758-41,6,2014-12-31,2014-12-31,4,1,1,0,2,0,3,0,1,2,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, observer-blind, randomized, multi-country, non-influenza vaccine comparator-controlled study to demonstrate the efficacy of GlaxoSmithKline Biologicals’ quadrivalent seasonal influenza ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000758-41,1,1,0 2011-000758-41,6,2014-12-31,2014-12-31,4,1,1,0,2,0,3,0,1,2,0,0,0,0,1,GlaxoSmithKline S.A.,"A phase III, observer-blind, randomized, multi-country, non-influenza vaccine comparator-controlled study to demonstrate the efficacy of GlaxoSmithKline Biologicals’ quadrivalent seasonal influenza ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000758-41,1,1,0 2011-000759-18,3,2015-03-10,2015-03-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA","A Randomized, Active-Controlled Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon alf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000759-18,0,0,0 2011-000759-18,3,2015-03-10,2015-03-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MERCK SHARP & DOHME CORP.,"A Randomized, Active-Controlled Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon alf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000759-18,0,0,0 2011-000759-18,3,2015-03-10,2015-03-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp.,a subsidiary of Merck&Co.,Inc.","A Randomized, Active-Controlled Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon alf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000759-18,0,0,0 2011-000762-35,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,A.O. UNIVERSITARIA INTEGRATA DI VERONA,EFFECTS OF THE VITAMIN D ADMINISTRATION ON RESPIRATORY FUNCTIONS IN PAEDIATRIC PATIENTS SUFFERING FROM EFFORT ASTHMA EFFETTI DELLA SOMMINISTRAZIONE DI VITAMINA D SULLA FUNZIONALITA' RESPIRATORIA DI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000762-35,0,0,0 2011-000765-12,1,2015-05-30,2015-05-30,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Oryx GmbH & Co. KG,Phase I/IIa study of immunization with frameshift peptides administered with Montanide ISA-51 VG in patients with advanced MSI-H colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000765-12,0,0,0 2011-000766-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,"Prevención del sangrado postoperatorio en artroplastia total de rodilla: Ensayo clínico multicéntrico, aleatorizado, abierto, paralelo de tres brazos de tratamiento, que evalúa la eficacia del ácido t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000766-35,0,0,0 2011-000767-27,8,2013-04-08,2013-05-04,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to sever...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000767-27,0,0,0 2011-000767-27,8,2013-04-08,2013-05-04,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, multicenter study of subcutaneous secukinumab, assessing Psoriasis Area and Severity Index (PASI) response and maintenance of response in subjects with moderate to sever...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000767-27,0,0,0 2011-000770-60,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"“An open-label, multi-center, expanded access study with fingolimod in patients with relapsing-remitting multiple sclerosis for whom no suitable therapy exists” Studio in aperto, multicentrico, di ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000770-60,0,0,0 2011-000773-31,1,2017-09-04,2017-09-04,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Eisai Inc.,"An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Cetuximab versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000773-31,0,0,0 2011-000774-58,1,2012-06-07,2012-06-07,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Eisai Inc.,"An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination with Cisplatin and Capecitabine versus Cisplatin and Capecitabine Alone in Patients with Advanced or Metastatic Solid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000774-58,0,0,0 2011-000776-34,1,,,0,1,0,0,0,1,4,0,0,1,0,0,0,1,0,Umea University,"THE EFFECT OF DIFLUNISAL ON FAMILIAL TRANSTHYRETIN AMYLOIDOSIS: An open label extension study of ”the diflunisal trial” (IND 68092), and an open label observational study on previously untreated patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000776-34,0,0,0 2011-000778-71,4,2013-05-13,2013-07-23,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depressi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000778-71,0,0,0 2011-000778-71,4,2013-05-13,2013-07-23,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depressi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000778-71,0,0,0 2011-000780-27,1,2013-09-10,2013-09-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Graz,"A single-center, randomized, controlled, 2-period cross-over, open-labelled trial to evaluate the impact of different application volumes on pharmacokinetic and pharmacodynamic properties of insulin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000780-27,0,0,0 2011-000783-98,1,2014-08-13,2014-08-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Effects of oral administration of ivabradine (7.5 mg bid) on post-ischaemic stunning induced by exercise stress in patients with coronary artery disease and exercise inducible ischaemia. Effects of...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000783-98,0,0,0 2011-000785-35,1,2012-03-21,2012-03-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,A PROSPECTIVE STUDY TO ASSESS THE INTERACTION BETWEEN PATIENT GENOTYPE AND ROSTAFUROXIN EFFECTS ON ARTERIAL BLOOD PRESSURE AND KIDNEY FUNCTION IN NEVER-TREATED HYPERTENSIVE TYPE 2 DIABETES PATIENTS (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000785-35,0,0,0 2011-000790-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,Propofol-based or Sevoflurane-based Anesthesia Induction in Patients Undergoing Fiberoptic Tracheal Intubation for Cervical Spine Surgery: Effects on Systemic Hemodynamics and Respiratory Drive- the B...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000790-31,0,0,0 2011-000792-14,1,2020-07-22,2020-07-22,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Institut Paoli-Calmettes,Etude de phase II évaluant la tolérance et l’efficacité d’un traitement de consolidation par Rituximab sous-cutané à faibles doses chez des patients présentant une leucémie lymphoïde chronique en répo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000792-14,0,0,0 2011-000794-31,1,2013-04-11,2013-04-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Dept. of Pharmacology,Neurodegenerative Changes in Alzheimer’s Disease: Identifying potential effects of Victoza® on degenerative changes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000794-31,0,0,0 2011-000796-14,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Leeds Teaching Hospitals NHS Trust,Chemotherapy plus Ofatumumab at Standard or Mega dose In CLL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000796-14,0,0,0 2011-000799-32,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Lluita contra la SIDA,Use of genotypic HIV-1 tropism testing in proviral DNA to guide CCR5 antagonist treatment in subjects with undetectable HIV-1 viremia USO DEL TROPISMO GENOTÍPICO DEL VIH-1 A PARTIR DE ADN PROVIRAL ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000799-32,0,0,0 2011-000801-39,8,2017-06-27,2017-06-27,7,1,0,0,2,1,3,0,0,1,0,0,1,0,0,Mukoviszidose Institute gGmbH,"Prospective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000801-39,0,0,0 2011-000801-39,8,2017-06-27,2017-06-27,7,1,0,0,2,1,3,0,0,1,0,0,1,0,0,MUKOVISZIDOSE E.V.,"Prospective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000801-39,0,0,0 2011-000802-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Javier García Campayo,"Efficacy of memantine in the treatment of fibromyalgia: an open, uncontrolled, exploratory 3-months follow-up study Evaluación de la eficacia de memantina en el tratamiento de la fibromialgia: un ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000802-23,0,0,0 2011-000804-17,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,FUNDACION SEIMC-GESIDA,"Randomized, multicentric, open label comparative trial to assess safety of Anidulafungina versus Anfotericina B Liposomal for antifungic profilaxis in high risk hepatic transplanted patients. AVALTRA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000804-17,0,0,0 2011-000805-27,3,2013-12-16,2013-12-16,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.,Effect of Ranolazine in Heart Failure Patients with Preserved Ejection Fraction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000805-27,0,0,0 2011-000805-27,3,2013-12-16,2013-12-16,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Menarini International Operations Luxembourg S.A., Avenue de la Gare, 1611 Luxembourg, Luxembourg",Effect of Ranolazine in Heart Failure Patients with Preserved Ejection Fraction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000805-27,0,0,0 2011-000808-18,1,2013-12-31,2013-12-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Aalborg Universitetshospital,"Et randomiseret, dobbelt blindet, placebo kontrolleret, parallel gruppe klinisk studie af azithromycin hos patienter med Campylobacter concisus og diarré",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000808-18,0,0,0 2011-000809-42,1,2013-02-23,2013-02-23,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Ann Merete Møller,Effekten af Transversus Abdominis Plane (TAP) blok som postoperativ smertebehandling efter åben abdominal hysterektomi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000809-42,0,0,0 2011-000811-23,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University Hospital Southampton NHS Foundation Trust,"Treatment of neonatal chronic lung disease (nCLD). The Surfactant, Nutrition and Microorganism Interactions study in infants at risk of developing chronic lung disease - 2 (TSuNaMI-II)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000811-23,0,0,0 2011-000813-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Sahlgrenska Academy,Effects of obeticholic acid on hepatic fatty acid/triglyceride metabolism and hepatobiliary detoxification/elimination in morbidly obese and gallstone patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000813-37,0,0,0 2011-000814-21,2,2013-04-22,2013-04-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BIAL INDUSTRIAL FARMACEUTICA, S.A.","A phase II, multicentre, randomized, double-blind study with subcutaneous immunotherapy at different doses, in parallel groups and placebo controlled in patients with rhinoconjunctivitis ± asthma sens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000814-21,0,0,0 2011-000815-15,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,3,Medizinische Fakultät der technischen Universität Muenchen,BOSTRIP (Investigator Initiated Trial) (Biomarkers of systemic treatment response in Psoriasis) Differential analysis of metabolomic profiles in patients with chronic plaque psoriasis undergoing sys...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000815-15,0,0,0 2011-000818-20,1,2017-08-31,2017-08-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Klinisk Biokemisk Afdeling, Aarhus Universitetshospital, Skejby",Kan behandling med lavmolekylært heparin under graviditet med intrauterin væksthæmning øge fostervæksten?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000818-20,0,0,0 2011-000821-62,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Consorci Sanitari Terrassa,"Comparación de la efectividad analgésica del bloqueo femoral, la infiltración intraarticular o la combinación de ambas en el control del dolor en la artroplastia total de rodilla.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000821-62,0,0,0 2011-000824-14,1,,,0,1,0,0,1,0,2,0,1,1,0,0,0,1,1,BRACCO,"Pharmacokinetics of orally aministered single doses (40-60-80 mcg) of T3 sulfate (T3S)-sodium salt. A single blind, randomized, placebo-controlled clinical study in healthy subjects Farmacocinetica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000824-14,0,0,0 2011-000826-31,3,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,Novo Nordisk,"Safety, Efficacy and Pharmacokinetics of NNC-0156- 0000-0009 (N9-GP) in Previously Treated Children with Haemophilia B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000826-31,0,0,0 2011-000826-31,3,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,NOVO NORDISK,"Safety, Efficacy and Pharmacokinetics of NNC-0156- 0000-0009 (N9-GP) in Previously Treated Children with Haemophilia B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000826-31,0,0,0 2011-000828-15,8,2012-09-17,2012-09-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A ProspEctive, Randomized, DoubLE-Blind CoMparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult PatiENTs with Type 2 Diabetes Mellitus: The ELEMENT 2 Study Estudio prospectiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000828-15,0,0,0 2011-000828-15,8,2012-09-17,2012-09-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,"A ProspEctive, Randomized, DoubLE-Blind CoMparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult PatiENTs with Type 2 Diabetes Mellitus: The ELEMENT 2 Study Estudio prospectiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000828-15,0,0,0 2011-000828-15,8,2012-09-17,2012-09-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A ProspEctive, Randomized, DoubLE-Blind CoMparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult PatiENTs with Type 2 Diabetes Mellitus: The ELEMENT 2 Study Estudio prospectiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000828-15,0,0,0 2011-000829-73,4,2013-03-25,2013-03-25,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Combination with Mealtime Insulin Lispro in Adult Patients with Type 1 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000829-73,0,0,0 2011-000830-12,7,2015-04-09,2015-04-09,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Eisai Limited,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Plus Standard of Care fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000830-12,0,0,0 2011-000831-10,6,2013-01-22,2013-01-22,3,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Eisai Limited,"A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 versus Eltrombopag, in Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000831-10,0,0,0 2011-000833-35,4,2013-01-17,2013-01-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, double blind, randomized, parallel group, placebo-controlled study to evaluate the hemodynamic responses to intravenous RLX030 infusion in subjects with acute heart failure.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000833-35,0,0,0 2011-000833-35,4,2013-01-17,2013-01-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS PHARMA AG,"A multicenter, double blind, randomized, parallel group, placebo-controlled study to evaluate the hemodynamic responses to intravenous RLX030 infusion in subjects with acute heart failure.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000833-35,0,0,0 2011-000834-12,4,2012-03-14,2012-03-15,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Almirall S.A.,"A MULTIPLE DOSE, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL CLINICAL TRIAL TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY INHALED ACLIDINIUM BROMIDE 400 μg COMPARED TO PLACEBO AND TO T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000834-12,0,0,0 2011-000836-27,9,2014-09-23,2015-01-12,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol Myers Squibb International Corporation,"An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C. Studio di ri-trattamento in aperto con Peg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000836-27,0,0,0 2011-000836-27,9,2014-09-23,2015-01-12,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRISTOL-M.SQUIBB,"An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C. Studio di ri-trattamento in aperto con Peg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000836-27,0,0,0 2011-000839-84,1,2014-06-20,2014-06-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,RadioMedic s.r.o.,"Clinical assessment of the tissue distribution of [18F]FMISO, INJ SOL after intravenous injection in patiens with malignancy Klinické hodnocení farmakodistribuce intravenózně aplikovaného [18F]FMIS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000839-84,0,0,0 2011-000840-70,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST,INDUCTION CHEMOTHERAPY WITH FOLFOXIRI PLUS CETUXIMAB AND MAINTENANCE WITH CETUXIMAB OR BEVACIZUMAB THERAPY IN UNRESECTABLE KRAS WILD-TYPE METASTATIC COLORECTAL CANCER PATIENTS STUDIO DI FASE II RAN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000840-70,0,0,0 2011-000841-19,2,2013-09-23,2013-09-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,Home Delivery of Pemetrexed as Maintenance Treatment in Patients Who Have Not Progressed after Induction Therapy for Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Feasibility Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000841-19,0,0,0 2011-000842-39,10,2014-01-16,2014-01-24,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Comparison of LY2605541 versus Insulin Glargine as Basal Insulin Treatment in Combination with Oral Anti-Hyperglycemia Medications in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: A Doub...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000842-39,0,0,0 2011-000842-39,10,2014-01-16,2014-01-24,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,A Comparison of LY2605541 versus Insulin Glargine as Basal Insulin Treatment in Combination with Oral Anti-Hyperglycemia Medications in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: A Doub...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000842-39,0,0,0 2011-000842-39,10,2014-01-16,2014-01-24,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,A Comparison of LY2605541 versus Insulin Glargine as Basal Insulin Treatment in Combination with Oral Anti-Hyperglycemia Medications in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: A Doub...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000842-39,0,0,0 2011-000843-26,1,2013-03-31,2013-03-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University Medical Center Goettingen,Veränderungen im autonomen Nervensystem während der Tabakentwöhnung – Mögliche Effekte pharmakologischer Interventionen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000843-26,0,0,0 2011-000844-56,1,2013-05-07,2013-05-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité Universitätsmedizin Berlin,"UsTekinumab for the treatment Of Patients with active Ankylosing Spondylitis (TOPAS) – a 28-week, prospective, open-label, proof-of-concept study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000844-56,0,0,0 2011-000847-25,5,2014-06-12,2014-06-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"A multi-center, randomized, open-label, mechanism of action trial on the biological effects of the therapeutic cancer vaccine Stimuvax® (L-BLP25) in rectal cancer subjects undergoing neoadjuvant chemo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000847-25,0,0,0 2011-000850-48,14,2017-02-03,2017-08-04,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Sma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000850-48,0,0,0 2011-000850-48,14,2017-02-03,2017-08-04,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease Sma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000850-48,0,0,0 2011-000852-40,1,2013-05-14,2013-05-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dermal Laboratories,"A double-blind, placebo-controlled study determining the efficacy of terbinafine shampoo in the treatment of pityriasis capitis and seborrhoeic dermatitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000852-40,0,0,0 2011-000853-22,3,2015-04-02,2015-04-02,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab versus best supportive care following first-line chemotherapy in subjects with unresectable locally ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000853-22,0,0,0 2011-000853-22,3,2015-04-02,2015-04-02,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab versus best supportive care following first-line chemotherapy in subjects with unresectable locally ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000853-22,0,0,0 2011-000854-44,9,2013-11-15,2014-04-16,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Toray Industries Inc,"A Two Part, Multi Centre, Randomized, Placebo Controlled, Double Blind Study of TRK 170 for the Treatment of Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000854-44,0,0,0 2011-000854-44,9,2013-11-15,2014-04-16,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Toray Industries, Inc.","A Two Part, Multi Centre, Randomized, Placebo Controlled, Double Blind Study of TRK 170 for the Treatment of Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000854-44,0,0,0 2011-000860-90,10,2017-10-25,2017-10-25,9,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000860-90,0,0,0 2011-000860-90,10,2017-10-25,2017-10-25,9,1,1,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000860-90,0,0,0 2011-000860-90,10,2017-10-25,2017-10-25,9,1,1,0,0,1,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC) wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000860-90,0,0,0 2011-000864-82,1,2013-06-12,2013-06-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Medical Center Groningen,"A randomized double blind cross-over study of the effects of low dose and high dose hydrocortisone replacement therapy on cognition, quality of life, metabolic profile and somatosensation in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000864-82,0,0,0 2011-000868-95,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Hvidovre Hospital,"Vitamin D and COPD A randomised, doubble-blind, placebo-controlled trial of the effect of vitamin D on withdrawal from pulmonary rehabilitation and exercise endurance",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000868-95,0,0,0 2011-000870-79,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,"Laboratorios LETI, S.L.U.",Prospective study to evaluate the safety of a 4-month treatment with Depigoid® Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml) in patie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000870-79,0,0,0 2011-000874-67,6,2015-12-18,2015-12-18,6,1,1,0,0,0,1,0,0,1,1,0,1,0,1,F. Hoffman-La Roche Ltd.,"An open-label, multicenter, single-arm, Phase I dose-escalation with efficacy tail extension study of RO5185426 in pediatric patients with surgically incurable and unresectable Stage IIIC or Stage IV ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000874-67,0,0,0 2011-000874-67,6,2015-12-18,2015-12-18,6,1,1,0,0,0,1,0,0,1,1,0,1,0,1,ROCHE,"An open-label, multicenter, single-arm, Phase I dose-escalation with efficacy tail extension study of RO5185426 in pediatric patients with surgically incurable and unresectable Stage IIIC or Stage IV ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000874-67,0,0,0 2011-000876-33,2,2012-11-14,2012-11-14,1,1,0,0,0,0,2,0,1,2,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase II, double-blind, multicentre study to evaluate the safety and immunogenicity of a booster dose of new formulations of GlaxoSmithKline Biologicals’ combined DTPa-HBV-IPV/Hib vaccine in healthy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000876-33,1,1,0 2011-000877-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Grupo de Estudos Oncológicos,Phase III clinical trial for evaluation of prophylactic treatment with minocycline versus reactive treatment of dermatological toxicity secondary to cetuximab in patients with metastatic colorectal ca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000877-29,0,0,0 2011-000879-14,1,2015-12-10,2015-12-10,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Hellenic Oncology Research Group (H.O.R.G.),"A Phase II Trial of Pazopanib, in Relapsed and Refractory Small Cell Lung Cancer (SCLC).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000879-14,0,0,0 2011-000880-28,1,2020-12-30,2020-12-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG),Bendamustine and Rituximab for the treatment of Splenic Marginal Zone Lymphoma. The IELSG-36 phase II prospective study. Bendamustina e Rituximab per il trattamento del Linfoma zona marginale sple...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000880-28,0,0,0 2011-000882-11,1,2015-06-23,2015-06-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,A.R.T.I.C. (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie ),A comparison of blood and tissue biomarkers before and after nephrectomy in the firstline setting with everolimus in patients with locally advanced or metastatic renal cell carcinoma Etude des marq...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000882-11,0,0,0 2011-000885-36,1,,,0,1,0,0,1,0,3,0,0,1,0,0,0,1,0,GETECCU,"Multicentric, randomized double blind clinical trial and paralell groups to compare Adalimub vs Azatioprina efficacy prevention in Crhon disease post-surgical recurrency after 52 weeks of treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000885-36,0,0,0 2011-000888-27,8,2015-01-20,2015-07-16,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SYNTHON BV,"Multi-centre, randomized, double-blind, placebo-controlled, parallel-group, 9 month, equivalence trial comparing the efficacy and safety and tolerability of GTR (Synthon BV) to Copaxone® (Teva) in sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000888-27,0,0,0 2011-000888-27,8,2015-01-20,2015-07-16,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Synthon BV,"Multi-centre, randomized, double-blind, placebo-controlled, parallel-group, 9 month, equivalence trial comparing the efficacy and safety and tolerability of GTR (Synthon BV) to Copaxone® (Teva) in sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000888-27,0,0,0 2011-000890-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Instrumental and clinical effects of withdrawal of beta blockers therapy in patients with heart failure and right ventricular dysfunction'' Effetti clinici e strumentali della sospensione della ter...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000890-29,0,0,0 2011-000893-68,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Fundació Clinic per a la Recerca Biomèdica,"Differences in endothelial function amongst Sitagliptin and Liraglutide Users: A randomized, open-label, parallel-group and active controlled trial Diferencias en la función endotelial entre pacien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000893-68,0,0,0 2011-000897-80,6,2013-03-14,2013-03-20,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Genentech, Inc.",PHASE II RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF rhuMAb BETA7 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000897-80,0,0,0 2011-000899-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Endocrinology, Sahlgrenska University Hospital",Rituximab (RTX) therapy in steroid resistant patients or patients relapsing after intravenous steroids with active TAO Rescue RTX,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000899-33,0,0,0 2011-000900-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZ BRUSSEL,AA randomized phase II clinical trial on the efficacy of axitinib as a monotherapy or in combination with lomustine for the treatment of patients with recurrent glioblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000900-16,0,0,0 2011-000901-37,1,2021-01-28,2021-01-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"SK Life Science, Inc","A PHASE 2, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, ADJUNCTIVE PLACEBO-CONTROLLED TRIAL WITH AN OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF YKP3089 IN SUBJECTS WITH TREATMENT RESISTANT P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000901-37,0,0,0 2011-000902-24,2,2012-10-08,2012-10-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Symphogen A/S,"An open-label, single arm, phase II trial to investigate the safety and efficacy of Sym004 in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000902-24,0,0,0 2011-000903-41,5,2012-07-04,2012-07-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.L.U.","AN OBSERVATIONAL STUDY TO COLLECT FOLLOW-UP CLINICAL DATA FROM KIDNEY TRANSPLANT RECIPIENTS WHO RECEIVED TOFACITINIB (CP-690,550) IN COMPLETED PHASE 2 STUDIES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000903-41,0,0,0 2011-000903-41,5,2012-07-04,2012-07-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017, USA","AN OBSERVATIONAL STUDY TO COLLECT FOLLOW-UP CLINICAL DATA FROM KIDNEY TRANSPLANT RECIPIENTS WHO RECEIVED TOFACITINIB (CP-690,550) IN COMPLETED PHASE 2 STUDIES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000903-41,0,0,0 2011-000903-41,5,2012-07-04,2012-07-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"AN OBSERVATIONAL STUDY TO COLLECT FOLLOW-UP CLINICAL DATA FROM KIDNEY TRANSPLANT RECIPIENTS WHO RECEIVED TOFACITINIB (CP-690,550) IN COMPLETED PHASE 2 STUDIES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000903-41,0,0,0 2011-000903-41,5,2012-07-04,2012-07-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","AN OBSERVATIONAL STUDY TO COLLECT FOLLOW-UP CLINICAL DATA FROM KIDNEY TRANSPLANT RECIPIENTS WHO RECEIVED TOFACITINIB (CP-690,550) IN COMPLETED PHASE 2 STUDIES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000903-41,0,0,0 2011-000903-41,5,2012-07-04,2012-07-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER INC.,"AN OBSERVATIONAL STUDY TO COLLECT FOLLOW-UP CLINICAL DATA FROM KIDNEY TRANSPLANT RECIPIENTS WHO RECEIVED TOFACITINIB (CP-690,550) IN COMPLETED PHASE 2 STUDIES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000903-41,0,0,0 2011-000905-30,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Rafael Esteban Mur,CLINICAL TRIAL WITH PROPHYLACTIC TENOFOVIR FOR HAEMATOLOGICAL CANCER PATIENTS SHOWING A HBc-Ab POSITIVE AND HBs-Ag PATTERN AND TO BE TREATED WITH RITUXIMAB (PREBLIN STUDY) ENSAYO CLÍNICO DE TENOFOV...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000905-30,0,0,0 2011-000908-18,1,2016-04-21,2016-04-21,1,0,0,0,0,1,3,0,0,1,1,1,1,0,0,Vilnius University Hospital Santariskiu Clinics,Treatment Protocol for young adults (18-45 years of age) with Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000908-18,0,0,0 2011-000911-26,1,2014-02-24,2014-02-24,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,University of Cologne,Heart rate control after acute myocardial infarct,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000911-26,0,0,0 2011-000914-21,5,2013-05-07,2013-05-07,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Baxter Innovations GmbH,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFECTIVENESS OF IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% SOLUTION (IGIV, 10%) FOR THE TREATMENT OF MILD TO MODERATE ALZH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000914-21,0,0,0 2011-000915-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Julian Taylor,Evaluation of the efficacy of Pregabalin for the treatment of evoked and non-evoked neuropathic pain at the level of the spinal cord injury during the early and late sub-acute phase of the spinal cord...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000915-14,0,0,0 2011-000917-38,2,2014-02-13,2014-02-13,1,1,0,1,0,1,1,0,1,1,1,0,0,0,1,Novartis Pharma Services AG,"A first–in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multiple ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000917-38,0,0,0 2011-000919-22,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Liverpool,RIAltO: A Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with CLL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000919-22,0,0,0 2011-000919-22,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,"Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trus",RIAltO: A Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with CLL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000919-22,0,0,0 2011-000921-61,1,2017-09-30,2017-09-30,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,"Ruprecht-Karls-University Heidelberg, Medical Faculty","A phase I/II, randomized, open-label, multi-centre study of BIBF1120 + reirradiation (R-RT) versus reirradiation in the treatment of patients with first or second progression of glioblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000921-61,0,0,0 2011-000922-31,1,2013-05-30,2013-05-30,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Karolinska Institutet,Patients´ recovery day 0-3 after short-stay elective surgery – a pilot study comparing desflurane and propofol TCI as main anaesthetics.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000922-31,0,0,0 2011-000923-33,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Rijksinstituut voor Volksgezondheid en Milieu (RIVM),Effects of paracetamol use on the immune response after hepatitis B vaccination,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000923-33,0,0,0 2011-000924-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,KU Leuven LRD,Development and validation of a sputum biomarker mRNA panel for the diagnostic work-up of asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000924-14,0,0,0 2011-000925-60,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Kungälv Hospital,Effect of treatment with methylphenidate on mental fatigue (“brain fatigue”) and pain on persons who have suffered a traumatic brain injury or whip lash injury – a pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000925-60,0,0,0 2011-000926-31,1,2013-05-13,2013-05-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GW Pharma Ltd.,"A Multicentre, Double-blind, Randomised Parallel Group, Placebo- controlled Study of the Effect of long-term treatment with Sativex on Cognitive Function and Mood of Patients with Spasticity due to Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000926-31,0,0,0 2011-000931-10,1,2012-08-08,2012-08-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gedeon Richter Plc.,"An Exploratory, Double-Blind, Randomized, Placebo and Active-Controlled Study to Assess the Safety and Efficacy of RGH-478 for the Treatment of Moderate to Severe Pain in Osteoarthritis of the Knee",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000931-10,0,0,0 2011-000933-35,1,,,0,0,0,0,1,0,2,0,0,1,0,0,0,1,0,CHU Toulouse,LE MISOPROSTOL 25µg PAR VOIE VAGINALE PEUT-IL ETRE UTILISE EN PREMIERE INTENTION DANS LA MATURATION CERVICALE? UN ESSAI RANDOMISE VERSUS DINOPROSTONE A LIBERATION CONTINUE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000933-35,0,0,0 2011-000935-98,1,2011-11-11,2011-11-11,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A single dose, placebo-controlled, randomised, double-blind double dummy, 5-way crossover (7 treatments, 5 periods incomplete block), including 24-h pulmonary function tests, pharmacodynamic compariso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000935-98,0,0,0 2011-000939-86,1,2012-04-17,2012-04-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Mundipharma AB,An open-label single site single dose pilotstudy using mannitol challenge test with the purpose to explore treatment with fixed dose combinations in adult subjects with asthma in primary care in Swede...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000939-86,0,0,0 2011-000942-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"CTMM, the Center for Translational Molecular Medicine","Effects of thyroid hormone treatment on mitochondrial function, ectopic fat accumulation, insulin sensitivity and brown adipose tissue in type 2 diabetes mellitus.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000942-39,0,0,0 2011-000943-26,2,2011-07-15,2011-07-15,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IV, open-label, study to assess the antibody persistence in healthy 5-year-old children, previously vaccinated at 3, 5 and 11months of age with GSK Biologicals’ DTPa-HBV-IPV/Hib or DTPa-IPV/Hi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000943-26,0,0,0 2011-000944-43,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Gilead Sciences Inc.,"A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly with GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects with Chronic Genotype 1 HCV Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000944-43,0,0,0 2011-000945-19,13,2012-07-20,2017-11-30,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Gilead Sciences Inc.,A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000945-19,0,0,0 2011-000945-19,13,2012-07-20,2017-11-30,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GILEAD SCIENCE INC.,A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000945-19,0,0,0 2011-000945-19,13,2012-07-20,2017-11-30,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.",A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000945-19,0,0,0 2011-000946-39,13,2012-07-20,2018-04-09,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Gilead Sciences Inc.,A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000946-39,0,0,0 2011-000946-39,13,2012-07-20,2018-04-09,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GILEAD SCIENCE INC.,A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000946-39,0,0,0 2011-000946-39,13,2012-07-20,2018-04-09,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.",A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000946-39,0,0,0 2011-000947-26,2,2013-08-29,2013-08-29,1,1,0,0,2,0,2,0,0,1,1,1,1,0,1,Novartis Pharma AG,"Multi-center, randomized, evaluator-blind, active-controlled, parallel-group design to determine safety, tolerability, and efficacy of multiple daily administration of LFF571 for 10 days in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000947-26,0,0,0 2011-000947-26,2,2013-08-29,2013-08-29,1,1,0,0,2,0,2,0,0,1,1,1,1,0,1,Novartis Farmacéutica S.A,"Multi-center, randomized, evaluator-blind, active-controlled, parallel-group design to determine safety, tolerability, and efficacy of multiple daily administration of LFF571 for 10 days in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000947-26,0,0,0 2011-000948-18,1,2015-05-30,2015-05-30,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Oryx GmbH & Co. KG,Phase I/IIa study of immunization with a p16INK4a peptide combined with MONTANIDE ISA-51 VG in patients with advanced HPV-associated cancers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000948-18,0,0,0 2011-000954-46,4,2015-07-21,2015-07-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"An open-label, single-arm, phase II, multicenter study to evaluate the efficacy of vemurafenib in metastatic melanoma patients with brain metastases",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000954-46,0,0,0 2011-000954-46,4,2015-07-21,2015-07-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffman-La Roche Ltd.,"An open-label, single-arm, phase II, multicenter study to evaluate the efficacy of vemurafenib in metastatic melanoma patients with brain metastases",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000954-46,0,0,0 2011-000954-46,4,2015-07-21,2015-07-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"An open-label, single-arm, phase II, multicenter study to evaluate the efficacy of vemurafenib in metastatic melanoma patients with brain metastases",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000954-46,0,0,0 2011-000960-93,5,2013-01-17,2013-01-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-week treatment, randomized, blinded, double-dummy, parallel-group study to assess the efficacy, safety, and tolerability of NVA237 (50 μg o.d.) compared to tiotropium (18 μg o.d.) in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000960-93,0,0,0 2011-000961-10,1,2014-10-17,2014-10-17,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Royal Liverpool and Broadgreen University Hospitals Trust,Neoadjuvant IntraviTreal Ranibizumab treatment in high risk Ocular melanoma patients: A two stage single centre Phase II single arm study (NITRO Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000961-10,0,0,0 2011-000971-15,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,PETHEMA,"Multicentric, prospective, open-label, of one group and phase I-II clinical trial to analyze induction treatment with a combination of fludarabine, idarubicin, cytarabine, G-CSF and plerixafor for the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000971-15,0,0,0 2011-000972-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"FERRER INTERNACIONAL, S.A","Estudio randomizado, abierto, con endpoint enmascarado, cruzado, de dosis única para comparar la farmacodinamia de TORASEMIDA- LP 10 mg, TORASEMIDA-LI 10 mg y FUROSEMIDA-LI 40 mg en pacientes con insu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000972-32,0,0,0 2011-000973-30,1,2012-09-30,2012-09-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,PLERIXAFOR MOBILIZED STEM CELLS AS SOURCE FOR GENE THERAPY OF BETA-THALASSEMIA AMD-THAL . Cellule staminali mobilizzate mediante Plerixafor come fonte per la terapia genica della beta-talassemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000973-30,0,0,0 2011-000977-29,2,2012-07-11,2012-07-11,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Spinifex Pharmaceuticals Pty Ltd,"A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the safety, tolerability and pharmacokinetic profile of EMA401 (angiotensin II type 2 receptor an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000977-29,0,0,0 2011-000978-53,2,2012-12-20,2012-12-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Acacia Pharma Ltd,"Randomised, double-blind, placebo-controlled Phase II proof-of-concept study of APD515 solution for oromucosal and oral administration for relief of xerostomia in patients with cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000978-53,0,0,0 2011-000984-29,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Ghent University Hospital,Prospectieve vergelijkende studie tussen verschillende tumescentie technieken bij endoveneuze ablatie behandeling voor varices,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000984-29,0,0,0 2011-000985-36,1,,,0,1,0,0,1,0,4,0,0,1,0,0,0,1,0,JOSE MANUEL GARCIA DOMINGUEZ,"Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as ""responders"" and ""not responders"" under trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000985-36,0,0,0 2011-000986-10,4,2015-04-04,2015-04-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sunovion Pharmaceuticals Inc.,"A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, FLEXIBLE-DOSE, PARALLEL-GROUP STUDY OF LURASIDONE ADJUNCTIVE TO LITHIUM OR DIVALPROEX FOR THE PREVENTION OF RECURRENCE IN SUBJECTS WITH BIPOLAR I DISORDE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000986-10,0,0,0 2011-000987-92,5,2017-05-18,2017-07-17,4,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Pharming Technologies B.V.,"Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000987-92,0,0,0 2011-000987-92,5,2017-05-18,2017-07-17,4,1,1,0,0,1,2,0,0,1,0,0,1,0,1,PHARMING TECHNOLOGIES B.V.,"Open-label, phase II, single arm study to evaluate the safety, immunogenicity, pharmacokinetics and efficacy of recombinant human C1 inhibitor for the treatment of acute attacks in pediatric patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000987-92,0,0,0 2011-000988-28,1,2015-11-03,2015-11-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Edinburgh,"Fractures and Bisphosphonates: A double-blind, randomised controlled trial on the effect of alendronic acid on healing and clinical outcomes of wrist fractures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000988-28,0,0,0 2011-000988-28,1,2015-11-03,2015-11-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Lothian,"Fractures and Bisphosphonates: A double-blind, randomised controlled trial on the effect of alendronic acid on healing and clinical outcomes of wrist fractures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000988-28,0,0,0 2011-000989-35,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation du desogestrel pour la restauration pharmacologique d'une activité ventilatoire au cours du syndrome d'hypoventilation alvéolaire centrale congénitale (Syndrome d'Ondine),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000989-35,0,0,0 2011-000990-29,7,,,0,0,0,0,0,2,0,0,0,3,0,0,0,0,0,INSTITUT CURIE,Multinational European Trial for Children with the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome OMS/DES Ensayo Multinacional Europeo para niños con el Síndrome de Opsoclono Mioclono/ Síndr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000990-29,0,0,0 2011-000990-29,7,,,0,0,0,0,0,2,0,0,0,3,0,0,0,0,0,Institut Curie,Multinational European Trial for Children with the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome OMS/DES Ensayo Multinacional Europeo para niños con el Síndrome de Opsoclono Mioclono/ Síndr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000990-29,0,0,0 2011-000990-29,7,,,0,0,0,0,0,2,0,0,0,3,0,0,0,0,0,Oxford University Hospitals NHS Trust,Multinational European Trial for Children with the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome OMS/DES Ensayo Multinacional Europeo para niños con el Síndrome de Opsoclono Mioclono/ Síndr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000990-29,0,0,0 2011-000990-29,7,,,0,0,0,0,0,2,0,0,0,3,0,0,0,0,0,A.I.E.O.P.,Multinational European Trial for Children with the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome OMS/DES Ensayo Multinacional Europeo para niños con el Síndrome de Opsoclono Mioclono/ Síndr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000990-29,0,0,0 2011-000991-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Instituto Aragonés de Ciencias de la Salud,"Impact of melatonin in the pretreatment of organ donor and the influence in the evolution of liver transplant: a prospective, randomised double-blind study. Impacto de la melatonina en el pretratam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000991-33,0,0,0 2011-000994-30,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Medizinische Universität Graz,"A randomized, double‐blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on metabolic and fertility parameters in PCOS women Einfluss einer Vitamin D-Supplementieru...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000994-30,0,0,0 2011-000997-77,4,2013-08-28,2013-08-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Glimepiride in Subjects with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-000997-77,0,0,0 2011-001005-27,1,2012-10-15,2012-10-15,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Department of Anaesthesiology, University Hospital of Skejby",The effect of dobtutamin on postoperative systolic deformation and diastolic function in patients with concentric hypertrophy of the left ventricle,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001005-27,0,0,0 2011-001006-10,2,2019-09-23,2019-09-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,advanceCOR GmbH,"REVACEPT, AN INHIBITOR OF PLATELET ADHESION IN SYMPTOMATIC CAROTID STENOSIS: A PHASE II, MULTICENTRE; RANDOMISED, DOSE-FINDING, DOUBLE-BLIND AND PLACEBO-CONTROLLED SUPERIORITY STUDY WITH PARALLEL GROU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001006-10,0,0,0 2011-001007-12,8,2011-11-14,2011-11-14,6,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of 1 g/10 mg Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablets in Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001007-12,0,0,0 2011-001010-34,1,2013-11-05,2013-11-05,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,ABCSG (Austrian Breast & Colorectal Cancer Study Group),"A randomized, placebo-controlled, double-blind multicenter phase II study to investigate the protectivity and efficacy of Metformin against steatosis in combination with FOLFIRI and Cetuximab in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001010-34,0,0,0 2011-001012-56,5,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,Eli Lilly and Company,A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001012-56,0,0,0 2011-001012-56,5,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,ELI LILLY AND COMPANY,A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001012-56,0,0,0 2011-001012-56,5,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,Lilly S.A,A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001012-56,0,0,0 2011-001015-32,6,2020-11-26,2020-11-26,5,1,0,0,0,0,3,0,0,1,0,0,1,0,0,AGO Research GmbH,"A multi-centre, open-label, randomised, twoarm Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001015-32,0,0,0 2011-001015-32,6,2020-11-26,2020-11-26,5,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"AGO Research GmbH, AGO Study Group","A multi-centre, open-label, randomised, twoarm Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001015-32,0,0,0 2011-001015-32,6,2020-11-26,2020-11-26,5,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Johanna Mäenpää,"A multi-centre, open-label, randomised, twoarm Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001015-32,0,0,0 2011-001017-13,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS,Phase II trial of individualized selection of chemotherapy in patients with advanced pancreatic carcinoma based on the identification of therapeutic targets in tumor tissue Ensayo fase II de selecc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001017-13,0,0,0 2011-001019-30,5,2013-06-19,2013-06-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmBH,"A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001019-30,0,0,0 2011-001019-30,5,2013-06-19,2013-06-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001019-30,0,0,0 2011-001019-30,5,2013-06-19,2013-06-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Arzneimittel GmbH,"A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001019-30,0,0,0 2011-001020-38,5,2014-01-21,2014-01-21,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001020-38,0,0,0 2011-001023-21,1,2012-04-10,2012-04-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,DR. REDDY'S LABORATORIES LIMITED,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of DRL-17822 in Patients with Type II Hyperlipidemia Studio randomizzato, in doppi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001023-21,0,0,0 2011-001024-38,1,2016-10-31,2016-10-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AIO-Studien-gGmbH,Randomisierte Phase II Studie zum Vergleich der Therapie Vinorelbin in Kombination mit dem mTOR-Inhibitor Everolimus vs. Vinorelbin Monotherapie in der Zweitlinienbehandlung von Patientinnen mit metas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001024-38,0,0,0 2011-001027-20,1,2018-05-04,2018-05-04,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Charité - Universitätsmedizin Berlin,"A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension. Eine multizentrische, Plazebo-k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001027-20,0,0,0 2011-001033-16,9,2011-12-15,2018-12-05,8,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Novo Nordisk A/S,Safety and Efficacy of NNC 0155-0000-0004 in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients with Haemophilia A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001033-16,0,0,0 2011-001034-42,1,2011-12-05,2011-12-05,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Santhera Pharmaceuticals (Switzerland) Limited,"A single visit, observational, follow-up study of Patients with Leber’s Hereditary Optic Neuropathy following participation in SNT-II-003 trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001034-42,0,0,0 2011-001055-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Eduardo García Díaz,Ensayo clínico aleatorizado controlado en fase IV para validar una herramienta costo-efectiva que OPTImice el tratamiento con ESTatinas de la dislipemia diabética en Atención Primaria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001055-36,0,0,0 2011-001060-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Safety and efficacy of switching a stable combined antiretroviral therapeutic regimen to atazanavir with ritonavir plus lamivudine in treatment experienced HIV positive patients with full and stable v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001060-21,0,0,0 2011-001062-18,8,2013-11-12,2013-11-12,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, placebo-controlled, dose-ranging, multi-centre trial of QAW039 (1-450 mg p.o.), to investigate the effect on FEV1 and ACQ in patients with moderate-to-severe, persistent, allergic asthma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001062-18,0,0,0 2011-001062-18,8,2013-11-12,2013-11-12,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, placebo-controlled, dose-ranging, multi-centre trial of QAW039 (1-450 mg p.o.), to investigate the effect on FEV1 and ACQ in patients with moderate-to-severe, persistent, allergic asthma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001062-18,0,0,0 2011-001063-43,1,2013-07-04,2013-07-04,1,1,0,0,1,0,3,0,0,1,1,1,1,0,0,University College London (UCL),"A Phase III single-blind, randomised, placebo controlled trial of long term therapy in patients with stable COPD using Moxifloxacin, Azithromycin, and Doxycycline: a Bayesian decision analysis, includ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001063-43,0,0,0 2011-001066-17,2,2013-08-05,2013-08-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis (X-PL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001066-17,0,0,0 2011-001067-51,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Alberto Capelastegui Sainz,UTILIZACION ADECUADA DEL TRATAMIENTO ANTIBIOTICO EN LAS NEUMONIAS ADQUIRIDAS EN LA COMUNIDAD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001067-51,0,0,0 2011-001068-23,2,2012-09-25,2012-09-25,1,0,0,0,0,0,4,0,0,2,0,0,0,0,1,ACO Hud Nordic AB,"Comparison of Moisturisers for the Prevention of Atopic Dermatitis Relapse– a Randomised, Double Blind Controlled Study (COMPADRE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001068-23,1,0,0 2011-001071-40,2,2012-03-19,2013-02-28,2,0,0,0,2,0,2,0,0,1,0,0,1,0,1,InSpira Medical AB,"A Phase IIa Safety study of oral administration of anti-CD3 monoclonal antibody in non-responder genotype-I chronic Hepatitis C subjects, a single-blind, randomized, controlled single-center study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001071-40,0,0,0 2011-001074-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Medizinische Universität Graz, Universitätsklinik für Innere Medizin","Effect of High Dose Selenium on Inflammation and Neurological Outcome after Cardiac Arrest: A randomized, double blind placebo controlled phase 2a study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001074-26,0,0,0 2011-001076-18,5,2016-07-22,2016-07-22,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"A Phase 2, Randomized, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 at Two Dose Levels in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001076-18,0,0,0 2011-001076-18,5,2016-07-22,2016-07-22,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase 2, Randomized, Open-label, Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 at Two Dose Levels in Subjects With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001076-18,0,0,0 2011-001077-13,2,2012-09-14,2012-09-14,2,1,0,0,0,1,4,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,"A multicenter, randomized, comparative study of different deferasirox administration regimens on gastrointestinal (GI) tolerability in low or intermediate (int-1) risk myelodysplastic syndrome (MDS) p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001077-13,0,0,0 2011-001077-13,2,2012-09-14,2012-09-14,2,1,0,0,0,1,4,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A multicenter, randomized, comparative study of different deferasirox administration regimens on gastrointestinal (GI) tolerability in low or intermediate (int-1) risk myelodysplastic syndrome (MDS) p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001077-13,0,0,0 2011-001078-25,1,2016-12-31,2016-12-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"National Institute of Health, National Eye Institute",Long-term Follow-up of Patients Who Participated in the Multicenter Uveitis Steroid Treatment Trial (MUST Trial Follow-up Study).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001078-25,0,0,0 2011-001084-42,7,2015-11-04,2015-11-04,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Synta Pharmaceutical Corp.,"A Randomized, Phase IIb/III Study of Ganetespib (STA-9090) in Combination with Docetaxel versus Docetaxel alone in Subjects with Stage IIIb or IV Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001084-42,0,0,0 2011-001084-42,7,2015-11-04,2015-11-04,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Synta Pharmaceuticals Corp.,"A Randomized, Phase IIb/III Study of Ganetespib (STA-9090) in Combination with Docetaxel versus Docetaxel alone in Subjects with Stage IIIb or IV Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001084-42,0,0,0 2011-001086-41,1,2021-07-27,2021-07-27,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,University Hospital of Muenster,"A randomized, placebo-controlled, multi-center phase I/II trial to assess the safety and efficacy of nintedanib (BIBF 1120) added to low-dose cytarabine in elderly patients with AML unfit for an inten...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001086-41,0,0,0 2011-001088-28,1,2020-01-10,2020-01-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,South London and Maudsley NHS Foundation Trust,"Feasibility, efficacy and acceptability of injected buprenorphine as treatment for opiate users who persist in injecting illicit heroin through opiate maintenance treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001088-28,0,0,0 2011-001088-28,1,2020-01-10,2020-01-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,King's College London,"Feasibility, efficacy and acceptability of injected buprenorphine as treatment for opiate users who persist in injecting illicit heroin through opiate maintenance treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001088-28,0,0,0 2011-001091-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Gregorio Marañón,"Comparative, randomized, double-blind clinical trial on 50 effective plasma concentration of propofol required for insertion of the Supreme Laryngeal Mask with or without association of remifentanil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001091-18,0,0,0 2011-001092-39,2,2013-02-21,2013-02-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001092-39,0,0,0 2011-001092-39,2,2013-02-21,2013-02-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose study to assess the efficacy, safety and tolerability of AQW051 in reducing L-dopa induced dyskinesias ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001092-39,0,0,0 2011-001093-26,1,2014-06-30,2014-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Imperial College, London","A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Oral Azithromycin (500 Mg OD) as a Supplement to Standard Care for Adult Patients with Acute Exacerbations of Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001093-26,0,0,0 2011-001094-58,2,2013-03-04,2013-03-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Prospective, multi-center, randomized, heparin-controlled dose-finding trial to evaluate the efficacy and safety of rivaroxaban, a direct factor Xa inhibitor, on the background of standard dual antipl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001094-58,0,0,0 2011-001096-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,F.Hoffmann-La Roche Ltd.,"An International, Multi-Center Study Evaluating the Correlation of IL28B Genotypes with Chronic Hepatitis C Disease Characteristics and Patient Demographics Medzinárodné, multicentrické klinické sk...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001096-39,0,0,0 2011-001097-25,1,,,0,1,1,0,0,0,3,0,0,1,0,0,0,1,1,Roche Pharma AG,"Long-term, interventional, open label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Germany who completed the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001097-25,0,0,0 2011-001098-16,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Leeds,"STAR: A Randomised Multi-Stage Phase II/III trial of Sunitinib comparing Temporary cessation with Allowing continuation, at the time of maximal radiological response, in the first-line treatment of lo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001098-16,0,0,0 2011-001099-21,1,2015-07-01,2015-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Population Health Research Institute,SIRS Steroids In caRdiac Surgery Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001099-21,0,0,0 2011-001105-28,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,Eisai Inc.,"An Open-label Pilot Study With an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, and Efficacy of Perampanel (E2007) Oral Suspension When Given as a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001105-28,0,1,1 2011-001107-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación SEIMC-GESIDA,"Ensayo Clínico aleatorizado, abierto, de no inferioridad y con seguimiento a 96 semanas sobre la eficacia de azatanavir / ritonavir + lamivudina como tratamiento de mantenimiento en pacientes con sup...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001107-12,0,0,0 2011-001111-31,3,2015-11-18,2015-11-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001111-31,0,0,0 2011-001112-53,8,2016-12-05,2016-12-05,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Amgen Inc.,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Prim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001112-53,0,0,0 2011-001112-53,8,2016-12-05,2016-12-05,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,AMGEN INC.,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Prim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001112-53,0,0,0 2011-001113-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Hospital Clinic i Provincial,Pharmakokynetic and Pharmacodynamic study of Temsirolimus in Renal Cell Carcinoma Patients Estudio farmacocinético y farmacodinámico de temsirolimus en pacientes con carcinoma de células renales.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001113-14,0,0,0 2011-001114-33,2,2013-07-01,2013-07-01,2,1,0,1,0,0,1,0,0,1,1,0,0,0,1,"Janssen-Cilag International NV,",An Open-Label Study to Evaluate the Penetration of Doripenem in Cerebrospinal Fluid After Doripenem Administration in Pediatric Subjects Less Than 1 Year Chronological Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001114-33,0,0,0 2011-001116-65,6,2013-11-20,2013-12-04,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,Second study of the Effect of Teriparatide on Femoral Neck Fracture Healing,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001116-65,0,0,0 2011-001117-13,11,2017-08-10,2017-08-10,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Cardio3 BioSciences SA,Congestive Heart Failure Cardiopoietic Regenerative Therpapy CHART-1 Trial Efficacy and Safety of Bone Marrow-Derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001117-13,0,0,0 2011-001117-13,11,2017-08-10,2017-08-10,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Celyad SA,Congestive Heart Failure Cardiopoietic Regenerative Therpapy CHART-1 Trial Efficacy and Safety of Bone Marrow-Derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001117-13,0,0,0 2011-001118-32,2,2015-09-25,2015-09-25,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,Sandoz GmbH,"Twelve-month study on the immunogenicity, safety, and efficacy of Zarzio®/Filgrastim HEXAL® in patients with severe chronic neutropenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001118-32,0,0,0 2011-001119-30,2,2014-09-25,2014-09-25,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,to-BBB technologies B.V.,"An open-label, Phase I/IIa, dose escalating study of 2B3-101 in patients with solid tumors and brain metastases or recurrent malignant glioma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001119-30,0,0,0 2011-001121-24,1,2013-05-02,2013-05-02,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,Papworth Hospital NHS Trust,Prospective randomised controlled trial of video assisted thorascopic (VATS) cytoreductive pleurectomy compared to talc pleurodesis in patients with suspected or proven malignant mesothelioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001121-24,0,0,0 2011-001122-18,3,2014-05-05,2014-05-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy and Safety of Ustekinumab (STELARA®) and CNTO 1959 Administered Subcutaneously in Su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001122-18,0,0,0 2011-001123-20,3,,,0,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2 Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001123-20,0,1,0 2011-001123-20,3,,,0,1,1,0,0,1,2,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 2 Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001123-20,0,1,0 2011-001131-23,3,2012-09-18,2012-09-18,3,0,0,0,0,1,2,0,0,1,0,0,1,0,1,SIENA BIOTECH SPA,"A double-blind, placebo-controlled study in Huntington's Disease patients to determine the safety and tolerability of SEN0014196 Studio in doppio cieco, controllato con placebo in pazienti affetti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001131-23,0,0,0 2011-001131-23,3,2012-09-18,2012-09-18,3,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Siena Biotech SpA,"A double-blind, placebo-controlled study in Huntington's Disease patients to determine the safety and tolerability of SEN0014196 Studio in doppio cieco, controllato con placebo in pazienti affetti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001131-23,0,0,0 2011-001132-30,1,2014-12-31,2014-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Všeobecná fakultní nemocnice v Praze,Non-invasive parameters in the evaluation of portal hypertension in patients with liver cirrhosis and their significance for the evolution of cardial complications.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001132-30,0,0,0 2011-001134-42,3,2014-03-10,2014-03-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc","A phase 2, proof of concept, randomised, placebo-controlled, parallel group study to evaluate the effect of ranolazine and dronedarone when given alone and in combination on atrial fibrillation burden...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001134-42,0,0,0 2011-001137-16,2,2015-06-01,2015-06-01,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,LIDDS AB,"An open, single dose, antitumor effect study of 2-hydroxyflutamide as a controlled release product (Liproca® Depot), injected into the prostate in patients with localized prostate cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001137-16,0,0,0 2011-001138-40,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,iOMEDICO AG,"First Line Pazopanib in Poor Risk Patients with Metastatic Renal Cell Carcinoma Einarmige, multizentrische Studie zur Bewertung von Pazopanib als Erstlinientherapie in Hochrisikopatienten mit fortg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001138-40,0,0,0 2011-001139-22,1,2015-07-21,2015-07-21,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,"Medizinische Universität Graz, Klin. Abteilung für Gastroenterologie und Hepatologie",AMBRISENTAN FOR TREATMENT OF PORTOPULMONARY HYPERTENSION (POPH): A PILOT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001139-22,0,0,0 2011-001140-30,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Laboratoires Ethypharm,"Randomized, placebo-controlled study of Fentanyl Ethypharm for breakthrough pain in opioid-treated patients with cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001140-30,0,0,0 2011-001141-32,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Isala klinieken department Cardiology,Catheter ablation versus Amiodarone to pRevent Future ventricular tachycardia Episodes in patients with a defibrillator and a history of a myocardial infarction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001141-32,0,0,0 2011-001142-15,10,2018-12-10,2018-12-10,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A Multi-national Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC 0129-0000-1003 when Administered for Treatment and Prophylaxis of Bleeding in Patients with Haemophilia A ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001142-15,0,0,0 2011-001142-15,10,2018-12-10,2018-12-10,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"A Multi-national Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC 0129-0000-1003 when Administered for Treatment and Prophylaxis of Bleeding in Patients with Haemophilia A ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001142-15,0,0,0 2011-001142-15,10,2018-12-10,2018-12-10,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novo Nordisk A/s,"A Multi-national Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC 0129-0000-1003 when Administered for Treatment and Prophylaxis of Bleeding in Patients with Haemophilia A ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001142-15,0,0,0 2011-001143-70,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Breno Moreno de Gusmao,"Estudio clínico fase II para tratamiento de los Síndromes Mielodisplásicos comparativo entre hidralazina/Ac.valproico y tratamiento de soporte en pacientes no candidatos, refractarios y/o intolerante ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001143-70,0,0,0 2011-001144-30,9,2018-12-10,2018-12-10,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and Safety of NNC 0129-0000-1003 (N8-GP) during Surgical Procedures in Patients with Haemophilia A Efficacia e sicurezza di NNC 0129-0000-1003 nel corso di interventi chirurgici in pazie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001144-30,0,0,0 2011-001144-30,9,2018-12-10,2018-12-10,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVO NORDISK,Efficacy and Safety of NNC 0129-0000-1003 (N8-GP) during Surgical Procedures in Patients with Haemophilia A Efficacia e sicurezza di NNC 0129-0000-1003 nel corso di interventi chirurgici in pazie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001144-30,0,0,0 2011-001148-31,1,2014-12-04,2014-12-04,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Imperial College London,A pilot clinical trial with the iron chelator Deferiprone in Parkinson's disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001148-31,0,0,0 2011-001160-21,2,2012-01-23,2012-01-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & developpement,Study to investigate the immune response to influenza vaccine in patients with multiple sclerosis on teriflunomide treatment and using a population of patients with multiple sclerosis as a reference,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001160-21,0,0,0 2011-001161-41,6,2016-04-26,2021-01-07,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001161-41,0,0,0 2011-001161-41,6,2016-04-26,2021-01-07,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001161-41,0,0,0 2011-001161-41,6,2016-04-26,2021-01-07,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.",A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001161-41,0,0,0 2011-001173-24,1,2012-01-16,2012-01-16,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,COSMO TECHNOLOGIES LTD,Colon staining efficacy of single oral doses of methylene blue MMX modified release tablets administered to patients undergoing colonoscopy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001173-24,0,0,0 2011-001175-38,1,2012-03-26,2012-03-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MEDICE Arzneimittel Pütter GmbH & CO.KG,"A multi-center, randomized, double-blind,phase II trial with intraindividual comparison to assess superiority of Soventol HydroCort 0.5 % Cremogel vs vehicle on lesional skin in patients with mild ato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001175-38,0,0,0 2011-001180-53,15,2014-03-31,2014-04-28,15,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Janssen R&D Ireland,"A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C genoty...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001180-53,0,0,0 2011-001180-53,15,2014-03-31,2014-04-28,15,1,0,0,0,0,3,0,0,1,0,0,1,0,2,JANSSEN R&D IRELAND,"A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C genoty...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001180-53,0,0,0 2011-001180-53,15,2014-03-31,2014-04-28,15,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Tibotec Pharmaceuticals,"A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C genoty...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001180-53,0,0,0 2011-001180-53,15,2014-03-31,2014-04-28,15,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Janssen-Cilag Polska Sp z o.o,"A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C genoty...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001180-53,0,0,0 2011-001187-21,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,University of Zurich,"A Phase I/II, Open Monocentric Study To Evaluate The Safety And Efficacy Of An Autologous Tissue-Engineered Vascular Graft In Peadiatric Patients Requiring Reconstruction Of Right Ventricle Outflow Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001187-21,0,0,0 2011-001191-19,1,2014-04-15,2014-04-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Hjertemedicinsk klinik B, 2142, Rigshospitalet",Cardiac effects of inhibition of the renin angiotensin system with losartan in patients with hypertrophic cardiomyopathy. Inhibering af renin angiotensin systemet med losartan hos patienter med hyp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001191-19,0,0,0 2011-001192-39,3,2014-06-10,2014-06-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dendreon Corporation,"AN OPEN-LABEL STUDY OF SIPULEUCEL-T IN EUROPEAN MEN WITH METASTATIC, CASTRATE RESISTANT PROSTATE CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001192-39,0,0,0 2011-001193-26,3,2015-07-15,2015-07-15,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Acino Supply AG,"An open label, one-arm, multiple dose study in patients with prostate cancer to demonstrate efficacy of a one month goserelin 3.6 mg implant in a two months treatment (2 application periods) and PK/PD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001193-26,0,0,0 2011-001201-27,4,2012-09-26,2012-09-26,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation","A randomized, controlled, parallel-group, double-blind trial of sugammadex or usual care (neostigmine or spontaneous recovery) for reversal of rocuronium- or vecuronium-induced neuromuscular blockade ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001201-27,0,0,0 2011-001201-27,4,2012-09-26,2012-09-26,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A randomized, controlled, parallel-group, double-blind trial of sugammadex or usual care (neostigmine or spontaneous recovery) for reversal of rocuronium- or vecuronium-induced neuromuscular blockade ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001201-27,0,0,0 2011-001201-27,4,2012-09-26,2012-09-26,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co, Inc.","A randomized, controlled, parallel-group, double-blind trial of sugammadex or usual care (neostigmine or spontaneous recovery) for reversal of rocuronium- or vecuronium-induced neuromuscular blockade ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001201-27,0,0,0 2011-001201-27,4,2012-09-26,2012-09-26,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA","A randomized, controlled, parallel-group, double-blind trial of sugammadex or usual care (neostigmine or spontaneous recovery) for reversal of rocuronium- or vecuronium-induced neuromuscular blockade ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001201-27,0,0,0 2011-001202-99,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"Relevare Pharmaceuticals, Ltd.","A Phase IIb/III, Double-Blind, Placebo-Controlled, Randomized Study Investigating the Safety, Tolerability and Efficacy of Flupirtine as Adjunct to Opioids When Administered to Cancer Subjects Who Are...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001202-99,0,0,0 2011-001205-27,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,3,,The effect of fibrate therapy in two patients with neutral lipid storage disease with myopathy (NLSDM).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001205-27,0,0,0 2011-001208-36,1,,,0,1,1,0,0,0,2,0,0,1,0,0,0,1,1,Chiesi Farmaceutici S.p.A,"A SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSS-OVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 50/6 NEXT DPI® (FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE 50 µg PLUS FORMOTEROL FUMARATE 6 µg ) V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001208-36,0,0,0 2011-001209-28,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Buckinghamshire Healthcare NHS Trust,Impact of insulin detemir versus insulin glargine on glycaemic control and metabolism during exercise in Type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001209-28,0,0,0 2011-001211-31,1,2019-06-30,2019-06-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Birmingham,A study of pazopanib efficacy and safety in patients with advanced clear-cell renal cell carcinoma and ECOG Performance Status 2 (PaZ02),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001211-31,0,0,0 2011-001218-32,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Rafael López López,Randomized phase II b study of Cabazitaxel in metastatic Colorectal Cancer resistant to standard treatment Estudio aleatorizado fase II-b de Cabazitaxel en Cáncer Colorrectal Metastásico resistente...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001218-32,0,0,0 2011-001219-30,6,2012-08-28,2014-10-13,4,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Nordic Pharma France,"Randomised, Evaluator-Blinded, Multicentre, International, Parallel-Group, Active-Controlled Clinical Trial of Gusperimus versus Conventional Therapy in Relapse of Granulomatosis with Polyangiitis (We...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001219-30,1,0,0 2011-001219-30,6,2012-08-28,2014-10-13,4,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Nordic Pharma SAS,"Randomised, Evaluator-Blinded, Multicentre, International, Parallel-Group, Active-Controlled Clinical Trial of Gusperimus versus Conventional Therapy in Relapse of Granulomatosis with Polyangiitis (We...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001219-30,1,0,0 2011-001220-38,3,2012-10-26,2014-02-13,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multicenter, 12 week, randomized, double-blind, placebo-controlled biomarker study of secukinumab (AIN457) in rheumatoid arthritis patients followed by an open label extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001220-38,0,0,0 2011-001221-24,1,2020-07-02,2020-07-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical University of Vienna,Specific immunotherapy of birch pollen-related food allergy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001221-24,0,0,0 2011-001222-15,11,2016-01-18,2016-02-23,9,0,0,0,0,1,2,0,0,1,0,0,1,0,1,"ChemoCentryx, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with Anti- Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Backg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001222-15,0,0,0 2011-001224-37,1,2017-12-04,2017-12-04,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"Research, Enterprise & Development (UOB)",Mistletoe in early Breast Cancer (MBC): A pilot study for a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001224-37,0,0,0 2011-001230-42,7,2015-01-13,2015-04-03,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services,"A multicenter, randomized, double blind, placebo controlled, phase II trial evaluating the safety and efficacy of TKI258 combined with fulvestrant, in postmenopausal patients with HER2- and HR+ breas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001230-42,0,0,0 2011-001230-42,7,2015-01-13,2015-04-03,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double blind, placebo controlled, phase II trial evaluating the safety and efficacy of TKI258 combined with fulvestrant, in postmenopausal patients with HER2- and HR+ breas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001230-42,0,0,0 2011-001230-42,7,2015-01-13,2015-04-03,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multicenter, randomized, double blind, placebo controlled, phase II trial evaluating the safety and efficacy of TKI258 combined with fulvestrant, in postmenopausal patients with HER2- and HR+ breas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001230-42,0,0,0 2011-001230-42,7,2015-01-13,2015-04-03,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A multicenter, randomized, double blind, placebo controlled, phase II trial evaluating the safety and efficacy of TKI258 combined with fulvestrant, in postmenopausal patients with HER2- and HR+ breas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001230-42,0,0,0 2011-001231-23,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación para el Progreso de la Oncología en Cantabria,Estudio fase II para evaluar la eficacia y seguridad de Trastuzumab en combinación con XELOX como primera línea de tratamiento para el cáncer gástrico avanzado o metastásico en pacientes con tumores H...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001231-23,0,0,0 2011-001232-27,1,2015-06-30,2015-06-30,1,1,0,0,0,0,2,0,1,1,0,0,1,0,3,Charité Universitaetsmedizin Berlin,Characterization of human peripheral and intestinal T-cell responses after mucosal antigen exposure: induction of tolerance vs. immunization by oral administration of KLH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001232-27,0,0,0 2011-001240-29,5,2018-04-12,2018-04-12,3,1,1,0,0,1,1,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc.",A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001240-29,0,0,0 2011-001240-29,5,2018-04-12,2018-04-12,3,1,1,0,0,1,1,0,0,1,0,0,1,0,1,"MILLENNIUM PHARMACEUTICALS, INC.",A Phase 1/2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001240-29,0,0,0 2011-001243-67,1,2013-09-12,2013-09-12,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label proof-of-concept study with a double-masked, dose-ranging component to assess the effects of AIN457 in patients with noninfectious uveitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001243-67,0,0,0 2011-001245-32,2,2012-04-18,2012-04-18,1,1,0,0,0,0,3,0,0,1,1,0,1,0,2,"Forest Laboratories, Inc.","A Phase 3, Randomized, Double-Blind Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001245-32,0,0,0 2011-001246-14,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE,"Phase II multicentric study to evaluate the efficacy and the safety of Bendamustine in adjunct to Etoposide, Aracytabin and Melphalan (BeEAM) as a preparative regimen for autologous stem cell transpla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001246-14,0,0,0 2011-001250-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,Etude de la cinétique de la céfazoline et de la clindamycine dans l’antibioprophylaxie pour césarienne programmée avec une injection avant l’incision.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001250-28,0,0,0 2011-001251-37,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Vu Medical center,"Exploring alternative wound care treatment for percutanous gastrostomy site infection: a prospective, randomized, open, blinded end-point (PROBE) design.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001251-37,0,0,0 2011-001253-82,10,2014-02-03,2014-02-03,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Protocol I2R-MC-BIAO The Impact of LY2605541 versus Insulin Glargine for Patients with Type 1 Diabetes Mellitus Treated with Preprandial Insulin Lispro: a Double-Blind, Randomized, 52 Week Study The ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001253-82,0,0,0 2011-001253-82,10,2014-02-03,2014-02-03,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"Protocol I2R-MC-BIAO The Impact of LY2605541 versus Insulin Glargine for Patients with Type 1 Diabetes Mellitus Treated with Preprandial Insulin Lispro: a Double-Blind, Randomized, 52 Week Study The ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001253-82,0,0,0 2011-001254-29,13,2013-08-13,2013-08-13,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Protocol I2R-MC-BIAM The Impact of LY2605541 versus Insulin Glargine for Patients with Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin with Insulin Lispro: a Double-Blind, Rando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001254-29,0,0,0 2011-001254-29,13,2013-08-13,2013-08-13,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,"Protocol I2R-MC-BIAM The Impact of LY2605541 versus Insulin Glargine for Patients with Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin with Insulin Lispro: a Double-Blind, Rando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001254-29,0,0,0 2011-001254-29,13,2013-08-13,2013-08-13,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"Protocol I2R-MC-BIAM The Impact of LY2605541 versus Insulin Glargine for Patients with Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin with Insulin Lispro: a Double-Blind, Rando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001254-29,0,0,0 2011-001255-36,9,2013-05-29,2013-06-20,6,1,1,0,0,1,2,0,0,2,0,0,0,0,1,GILEAD SCIENCES INC.,Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Pediatric Patients with Cystic Fib...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001255-36,1,1,0 2011-001255-36,9,2013-05-29,2013-06-20,6,1,1,0,0,1,2,0,0,2,0,0,0,0,1,"Gilead Sciences, Inc.",Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Pediatric Patients with Cystic Fib...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001255-36,1,1,0 2011-001256-10,1,2014-01-22,2014-01-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Roche s.r.o.,"Open-label, multicenter phase IV study of ribavirin (Copegus®) combined with standard treatment to assess correlation between hemoglobin decrease and rate of sustained virological response in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001256-10,0,0,0 2011-001258-27,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Mads Werner,Lidokainplaster til behandling af kroniske smerter efter lyskebrokkirurgi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001258-27,0,0,0 2011-001261-40,3,2014-06-06,2014-06-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Protocol I2R-MC-BIAN (a) Study: The Impact of LY2605541 versus Insulin Glargine for Patients with Type 1 Diabetes Mellitus Treated with Preprandial Insulin Lispro: an Open-Label, Randomized, 78 week ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001261-40,0,0,0 2011-001261-40,3,2014-06-06,2014-06-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY,"Protocol I2R-MC-BIAN (a) Study: The Impact of LY2605541 versus Insulin Glargine for Patients with Type 1 Diabetes Mellitus Treated with Preprandial Insulin Lispro: an Open-Label, Randomized, 78 week ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001261-40,0,0,0 2011-001264-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region Skåne,Eplerenone and spironolactone in male patients with ascites due to liver cirrhosis. A Swedish prospective randomized multicenter study of efficacy and endocrinologic side effects. Eplerenon versus ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001264-22,0,0,0 2011-001265-40,1,2012-09-10,2012-09-10,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"NPS Pharmaceuticals, Inc.","A 6-Month Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults with Hypoparathyroidism - A Clinica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001265-40,0,0,0 2011-001266-17,12,2014-02-08,2014-03-17,9,1,1,0,0,1,0,0,0,2,1,0,0,0,1,GlaxoSmithKline Research and Development LTD,"An open-label extension study of the long-term safety, tolerability and efficacy of GSK2402968 in subjects with Duchenne Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001266-17,1,1,0 2011-001266-17,12,2014-02-08,2014-03-17,9,1,1,0,0,1,0,0,0,2,1,0,0,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"An open-label extension study of the long-term safety, tolerability and efficacy of GSK2402968 in subjects with Duchenne Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001266-17,1,1,0 2011-001266-17,12,2014-02-08,2014-03-17,9,1,1,0,0,1,0,0,0,2,1,0,0,0,1,"GlaxoSmithKline, S.A.","An open-label extension study of the long-term safety, tolerability and efficacy of GSK2402968 in subjects with Duchenne Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001266-17,1,1,0 2011-001267-49,5,2014-08-04,2014-08-04,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"ChemoCentryx, Inc","A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Diabetic Nephropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001267-49,0,0,0 2011-001271-39,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Spanish Oncology Genito-Urinary Group (SOGUG),Estudio en fase II aleatorizado de vinflunina en monoterapia como terapia de mantenimiento en pacientes con cáncer avanzado o metastásico de células de transición del urotelio que obtengan beneficio c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001271-39,0,0,0 2011-001278-24,8,2016-01-06,2016-04-01,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Menarini International Operations Luxembourg SA,EFFICACY OF RANOLAZINE IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001278-24,0,0,0 2011-001278-24,8,2016-01-06,2016-04-01,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.,EFFICACY OF RANOLAZINE IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001278-24,0,0,0 2011-001280-49,1,2013-06-29,2013-06-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma S.A.S,"« GRACE : Gilenya® - Réponse Au Coping - Evaluation » Etude multicentrique de phase IV, prospective, en ouvert, d'une durée de 4 mois, visant à comparer la réponse à l’initiation du fingolimod (Gileny...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001280-49,0,0,0 2011-001282-40,2,2021-02-25,2021-02-25,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Morphotek Inc,A Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects with Metastatic Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001282-40,1,0,0 2011-001283-22,2,2012-03-31,2013-04-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier (I.R.I.S.),"International follow-up study, after the investigational drug exposure in diabetic patients previously included in the REGULATE trial (benfluorex versus pioglitazone).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001283-22,0,0,0 2011-001284-44,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"MAGGOT 2006 Egészségügyi, Kereskedelmi és Szolgáltató Ltd.","A RANDOMIZED, OPEN, SELF-CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF LARVAL THERAPY IN PATIENTS WITH LEG ULCERS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001284-44,0,0,0 2011-001287-22,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE,"A Prospective Randomized Crossover trial of Oral Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia Studio prospettico, randomizzato, crossover sulla somministrazione orale di Fle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001287-22,0,0,0 2011-001288-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE,A Pilot Study to Evaluate the Safety and Tolerability of the combination ot Trabectidin and Indole-3-Carbinol in refractory ER-positive metastatic breast cancer Studio pilota per valutare la sicure...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001288-32,0,0,0 2011-001290-78,1,2018-12-06,2018-12-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Barts Health NHS Trust,"Diagnostic accuracy of MRI, diffusion-weighted MRI, FDG-PET/CT and Fluoro-ethyl-choline PET/CT in the detection of lymph node metastases in surgically staged endometrial and cervical carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001290-78,0,0,0 2011-001291-19,1,2011-07-26,2011-07-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Adocia SA,"A phase IIa, double-blinded, randomized trial comparing the pharmacokinetics, pharmacodynamics and safety of BioChaperone® rhInsulin to fast-acting insulin analog in patients with Type 1 Diabetes mell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001291-19,0,0,0 2011-001292-39,11,2014-02-26,2014-02-26,11,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Lab Servier,Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years. A rand...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001292-39,0,0,0 2011-001292-39,11,2014-02-26,2014-02-26,11,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years. A rand...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001292-39,0,0,0 2011-001292-39,11,2014-02-26,2014-02-26,11,1,1,0,0,0,2,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years. A rand...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001292-39,0,0,0 2011-001298-17,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Phase II study on ET-743 in BRCA1 and BRCA2 mutation carrie and BRCAness phenotype advanced ovarian cancer patients. Studio di fase II su ET-743 (Yondelis) in pazienti con carcinoma ovarico avanzat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001298-17,0,0,0 2011-001300-35,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University College London,A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001300-35,0,0,0 2011-001300-35,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,UNIVERSITY COLLEGE LONDON,A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001300-35,0,0,0 2011-001303-13,1,2013-09-28,2013-09-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Cilag,HIV postexposure prophylaxis with Darunavir/r (PEPDar),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001303-13,0,0,0 2011-001308-36,1,2019-05-28,2019-05-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,FNCLCC,Etude de phase II multicentrique évaluant l’efficacité de la Gemcitabine en association avec le Pazopanib en traitement de seconde ligne des léiomyosarcomes utérins ou des tissus mous métastatiques ou...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001308-36,0,0,0 2011-001309-29,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,"Allos Therapeutics, Inc.","A Multi-center, Open-label, Extension Study to Allow Continued Treatment of Patients Who Have Participated in Allos-sponsored Pralatrexate Studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001309-29,0,0,0 2011-001310-34,1,2013-11-25,2013-11-25,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Med. Univ. Wien, Univ. Klinik für Innere Med. III",Female Sexual Dysfunction in the Peri and Postmenopause: Effect of intranasal Oxytocin administration on sexual function and activity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001310-34,0,0,0 2011-001312-59,1,2012-07-24,2012-07-24,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Imperial College London,"A double-blinded, randomized, crossover clinical study to assess the efficacy of Qutenza (capsaicin 8% patches) for the reduction of site pain caused by continuous subcutaneous infusion of Remodulin (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001312-59,0,0,0 2011-001313-14,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Dutch growth research foundation,Young adult Prader-Willi Study Effects of Growth Hormone after final height: A clinical care study to the optimal dosage of growth hormone in young adults with PWS. Jong volwassenen Prader Willy s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001313-14,0,0,0 2011-001314-34,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,MedPointe Pharmaceuticals,"Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Astelin Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Subjects with Seasonal Allergic Rhinitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001314-34,0,1,1 2011-001315-31,1,2015-06-01,2015-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Leuven,analgesia with continuous IV-infusion of lidocain during the perioperative period in patients undergoin laparoscopic sterilization.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001315-31,0,0,0 2011-001318-32,5,2017-02-22,2017-03-20,4,1,0,0,2,0,3,0,0,1,1,1,1,0,1,"Upsher-Smith Laboratories, Inc.","A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects with Seizure Clusters ARTEMIS-1: Acute Rescue T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001318-32,0,0,0 2011-001318-32,5,2017-02-22,2017-03-20,4,1,0,0,2,0,3,0,0,1,1,1,1,0,1,UPSHER-SMITH LABORATORIES,"A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects with Seizure Clusters ARTEMIS-1: Acute Rescue T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001318-32,0,0,0 2011-001319-30,1,2017-02-28,2017-02-28,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,University Hospitals Bristol NHS Foundation Trust,"A randomized, double-blind, parallel group, placebo-controlled trial of metformin in tuberous sclerosis complex.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001319-30,0,0,0 2011-001323-21,3,2014-01-13,2014-01-13,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Ge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001323-21,0,0,0 2011-001326-26,2,2012-10-10,2012-10-10,2,0,0,0,0,1,2,0,0,1,1,1,1,0,1,NOVIMMUNE BV,"PIANO. Primary Biliary Cirrhosis: Investigating A New Treatment Option using NI-0801, a fully human anti-CXCL10 monoclonal antibody. An open label single arm study to investigate the safety and effica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001326-26,0,0,0 2011-001326-26,2,2012-10-10,2012-10-10,2,0,0,0,0,1,2,0,0,1,1,1,1,0,1,NovImmune S.A.,"PIANO. Primary Biliary Cirrhosis: Investigating A New Treatment Option using NI-0801, a fully human anti-CXCL10 monoclonal antibody. An open label single arm study to investigate the safety and effica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001326-26,0,0,0 2011-001329-26,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""",ErythroPOietin in ALS: a Study of dose-finding and Safety Eritropoietina nella SLA: uno studio di identificazione della dose e sicurezza,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001329-26,0,0,0 2011-001331-22,3,2015-01-23,2015-01-23,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Chiesi Farmaceutici S.p.A.,A FIRST IN HUMAN CLINICAL STUDY ON THE SAFETY AND TOLERABILITY OF TWO ESCALATING SINGLE DOSES OF CHF 5633 (SYNTHETIC SURFACTANT) IN PRETERM NEONATES WITH RESPIRATORY DISTRESS SYNDROME,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001331-22,0,0,0 2011-001332-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie",Pharmacokinetics of Infliximab Pharmakokinetic von Infliximab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001332-29,0,0,0 2011-001333-17,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine when Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001333-17,0,0,0 2011-001340-29,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Institut de Recerca del Hospital de la Santa Creu i Sant Pau,Effectiveness of Added blocking of radial and median nerves with levobupivacaine in the control of postoperative pain in the rhizarthrosis ambulatory surgery Eficacia del bloqueo añadido de los ne...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001340-29,0,0,0 2011-001342-15,3,2013-05-09,2013-05-09,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Services AG,A 36-week open-label extension study of CACZ885H2361 on the safety and tolerability of canakinumab 150 mg s.c. pre-filled syringe (PFS) in treating acute gouty arthritis flares in frequently flaring p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001342-15,0,0,0 2011-001342-15,3,2013-05-09,2013-05-09,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,A 36-week open-label extension study of CACZ885H2361 on the safety and tolerability of canakinumab 150 mg s.c. pre-filled syringe (PFS) in treating acute gouty arthritis flares in frequently flaring p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001342-15,0,0,0 2011-001345-32,12,2015-05-19,2015-06-08,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001345-32,0,0,0 2011-001345-32,12,2015-05-19,2015-06-08,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.","A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001345-32,0,0,0 2011-001345-32,12,2015-05-19,2015-06-08,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp, a Subsidiary of Merck & Co., Inc.","A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001345-32,0,0,0 2011-001345-32,12,2015-05-19,2015-06-08,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck & Co., Inc.","A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001345-32,0,0,0 2011-001345-32,12,2015-05-19,2015-06-08,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schering Corporation, a Subsidiary of Merck & Co., Inc.","A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001345-32,0,0,0 2011-001345-32,12,2015-05-19,2015-06-08,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Schering-Plough Corporation, a Subsidiary of Merck & Co.,Inc.","A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001345-32,0,0,0 2011-001348-31,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Mälarsjukhuset,Can the dosage of vaccine against TBE is optimized by means of changes in dosing interval for those over 50 years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001348-31,0,0,0 2011-001349-33,2,2013-09-12,2013-09-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults with Major Depres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001349-33,0,0,0 2011-001350-28,1,2013-05-02,2013-05-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed-dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001350-28,0,0,0 2011-001351-37,3,2017-05-18,2017-05-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults with Major Depressive Disorder, the Orion Trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001351-37,0,0,0 2011-001354-29,4,2013-05-03,2013-05-07,3,1,1,0,0,1,3,0,0,1,0,0,1,0,1,LFB BIOTECHNOLOGIES,"An open-label, multicentre efficacy and safety study of I10E in patients with primary Immune ThrombocytoPenia (ITP) Studio multicentrico, in aperto, sull`™efficacia e la sicurezza di I10E in pazie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001354-29,0,0,0 2011-001356-10,1,2019-03-21,2019-03-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,LYSARC,STUDY OF THE EFFICACY AND SAFETY OF FIRST LINE TREATMENT WITH CHOP AND LENALIDOMIDE (Rev-CHOP) IN PATIENTS AGED FROM 60 TO 80 YEARS WITH PREVIOUSLY UNTREATED ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001356-10,0,0,0 2011-001360-21,5,2014-02-22,2014-02-22,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults with Uncontrolled, Severe Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001360-21,0,0,0 2011-001360-21,5,2014-02-22,2014-02-22,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB R&D Mölndal,"A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults with Uncontrolled, Severe Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001360-21,0,0,0 2011-001362-18,5,2013-04-03,2013-04-03,3,1,1,0,0,2,3,0,0,2,0,0,0,0,1,"Gilead Sciences, Inc.",Open-Label Phase 3 Trial to Evaluate the Safety of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Children with Cystic Fibrosis (CF) and Chroni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001362-18,1,1,0 2011-001362-18,5,2013-04-03,2013-04-03,3,1,1,0,0,2,3,0,0,2,0,0,0,0,1,GILEAD SCIENCES INC.,Open-Label Phase 3 Trial to Evaluate the Safety of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Children with Cystic Fibrosis (CF) and Chroni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001362-18,1,1,0 2011-001362-18,5,2013-04-03,2013-04-03,3,1,1,0,0,2,3,0,0,2,0,0,0,0,1,"Gilead Sciences, Inc.",Open-Label Phase 3 Trial to Evaluate the Safety of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Children with Cystic Fibrosis (CF) and Chroni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001362-18,1,1,0 2011-001363-46,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ROCHE,"RANDOMIZED, NON COMPARATIVE PHASE II TRIAL WITH BEVACIZUMAB AND FOTEMUSTINE IN THE TREATMENT OF RECURRENT GLIOBLASTOMA. STUDIO RANDOMIZZATO, NON COMPARATIVO DI FASE II CON BEVACIZUMAB E FOTEMUSTINA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001363-46,0,0,0 2011-001364-22,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ROCHE,"A multi-center, open-label clinical trial to evaluate the objective response rate of bevacizumab in combination with modified FOLFOX-6 followed by one year of maintenance with bevacizumab alone in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001364-22,0,0,0 2011-001365-40,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,F.Hoffmann-La Roche,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of 2 Doses of RO4905417 (R1512) Administered to Patients with Non ST-Elevation Myocardial Infarcti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001365-40,0,0,0 2011-001368-23,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,MedPointe Pharmaceuticals,Active-Controlled Trial of the Safety and Tolerability of MP29-02 in Subjects with Chronic Allergic or Nonallergic Rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001368-23,0,1,1 2011-001369-42,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Meda Pharmaceuticals Inc.,"Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients with Seasonal Aller...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001369-42,0,1,1 2011-001370-26,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Meda Pharmaceuticals Inc.,"Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients with Seasonal Aller...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001370-26,0,1,1 2011-001371-39,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Meda Pharmaceuticals Inc.,"Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray and Fluticasone Propionate Nasal Spray in the Treatment of Patients with Seasonal Allerg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001371-39,0,1,1 2011-001382-40,1,2015-06-30,2015-06-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Central Manchester University Hospitals NHS Foundation Trust,Proof of mechanism pre-surgical window trial of metformin in non-diabetic women with endometrial carcinoma: a feasibility study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001382-40,0,0,0 2011-001384-45,1,2011-08-12,2011-08-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,"A 22 day bland ointment and reference-controlled, investigator-blind, single center, randomized, proof of concept clinical study with an intraindividual comparison investigating the anti-psoriatic eff...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001384-45,0,0,0 2011-001386-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Role of PET/CT with 124I for dosimetry of thyroid carcinoma before radioisotopic treatment Ruolo della PET/TC con 124I per la valutazione dosimetrica pre-trattamento dei carcinomi della tiroide,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001386-41,0,0,0 2011-001393-26,1,,,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Clínico San Carlos,Phase II clinical trial to evaluate the feasibility and safety of human adipose derived mesenchymal stem cells on chronic ischaemic stroke. Ensayo Clínico en fase IIa para conocer la factibilidad y...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001393-26,0,0,0 2011-001396-39,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Glostrup Hospital,"Effekten af relaksation på placering af larynxmaske hos patienter, der i bugleje, skal opereres for discusprolaps eller forsnævring i lænderyggen.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001396-39,0,0,0 2011-001398-19,1,2014-04-25,2014-04-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité Universitätsmedizin Berlin,D-cycloserine augmented exposure therapy in patients with agoraphobia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001398-19,0,0,0 2011-001403-12,1,2015-06-30,2015-06-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Charite Universitaetsmedizin Berlin,Carbon Dioxide for the Treatment of Febrile Seizures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001403-12,0,0,0 2011-001407-13,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Maastricht Universitary Medical Centre,NasuMel® Gel - a Medical Grade Honey Product for the Treatment of Chronically Infected Radical Mastoid Cavities,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001407-13,0,0,0 2011-001408-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,"Effects of Liraglutide on left ventricular (LV) morphology, function and energy metabolism in patients with type 2 diabetes and heart failure : an in vivo cardiac Magnetic Resonance Imaging and 31P Sp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001408-37,0,0,0 2011-001410-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZ BRUSSEL,Randomized phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III/IV melanoma in patients who are free from measurable tumor lesions following the local treatment of m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001410-33,0,0,0 2011-001412-65,21,2016-02-02,2019-08-22,20,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",A 12-MONTH OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS 1 MONTH TO 16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES AND PEDIATRIC AND A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001412-65,1,0,0 2011-001412-65,21,2016-02-02,2019-08-22,20,1,0,0,0,0,3,0,0,2,0,0,0,0,1,PFIZER INC.,A 12-MONTH OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS 1 MONTH TO 16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES AND PEDIATRIC AND A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001412-65,1,0,0 2011-001412-65,21,2016-02-02,2019-08-22,20,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Pfizer Inc.,A 12-MONTH OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS 1 MONTH TO 16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES AND PEDIATRIC AND A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001412-65,1,0,0 2011-001419-29,1,2014-01-13,2014-01-13,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Universitätsklinik für Radiodiagnostik,Influence of iodinated contrast agents on heart rate variation and diagnostic image quality during CT angiography of the coronary arteries Bestimmung des Einflusses von iodhältigen Kontrastmitteln...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001419-29,0,0,0 2011-001421-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,Rituximab plus Bendamustine as front line treatment in frail elderly (≥70 years) patients with diffuse large B-cell non-Hodgkin’s lymphoma: a phase II multicenter study of the Fondazione Italiana Linf...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001421-24,0,0,0 2011-001422-23,1,2018-09-30,2018-09-30,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Genentech Inc,"A PHASE I, OPEN LABEL, DOSE ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB (MPDL3280A) ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT TO PATIENTS WITH LOCALLY ADVANCED OR METASTATIC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001422-23,0,0,0 2011-001424-38,3,2013-07-09,2013-07-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Recherche & Développement,"A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 over 24 weeks in Patients with Hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001424-38,0,0,0 2011-001429-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,Feasibility Study: FES-PET to determine ER-expression in epithelial ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001429-25,0,0,0 2011-001436-33,1,2013-11-22,2013-11-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, double-blind, parallel-group study of the safety and efficacy of RO4917523 versus placebo, as adjunctive therapy in patients with major depressive disorder with inadequate response to on...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001436-33,0,0,0 2011-001437-16,1,2017-08-07,2017-08-07,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Pharma Services AG,"A 3-year, multi-center study to evaluate optical coherence tomography as an outcome measure in patients with multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001437-16,0,0,0 2011-001442-15,10,2012-11-29,2012-11-29,9,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 32-week, patient- and rater-blinded, randomized, multi-center, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001442-15,0,0,0 2011-001442-15,10,2012-11-29,2012-11-29,9,1,0,0,0,0,0,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A 32-week, patient- and rater-blinded, randomized, multi-center, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001442-15,0,0,0 2011-001442-15,10,2012-11-29,2012-11-29,9,1,0,0,0,0,0,0,0,1,1,0,1,0,1,,"A 32-week, patient- and rater-blinded, randomized, multi-center, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001442-15,0,0,0 2011-001442-15,10,2012-11-29,2012-11-29,9,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A 32-week, patient- and rater-blinded, randomized, multi-center, parallel-group study to evaluate disease control and safety in patients with relapsing remitting multiple sclerosis transferred from pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001442-15,0,0,0 2011-001448-31,1,2011-12-13,2011-12-13,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines Institute for Global Health (NVGH),"A Phase 2, open-label, single-center, extension study to evaluate the booster response induced by Vi-CRM197 after priming with either Vi-CRM197 or Typherix administered in adult subjects in H01_04TP s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001448-31,0,0,0 2011-001449-34,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,FUNDACION INVESTIGACION HOSPITAL CLINICO DE VALENCIA-INSTITUTO DE INVESTIGACION SANITARIA INCLIVA,"Phase II study, multicenter, prospective, open label, preemptive treatment of cytomegalovirus (CMV) infection driven by virologic monitoring and quantification of T CD8pp65/IE-1-IFNgamma+ lymphocytes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001449-34,0,0,0 2011-001452-11,1,2016-02-15,2016-02-15,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Skånes Universitetssjukhus Lund,Supplemental Oxygen in Catherized Coronary Emergency Reperfusion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001452-11,0,0,0 2011-001455-37,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,"Department of Radiology, Oslo University Hospital, Norway",Prospective randomized interventional study. Compare the effect of bleomycin and Tetradecyl Sodium Sulphate (Fibrovein) in the treatment of venous malformations. Clinical neurological and neurophysiol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001455-37,0,0,0 2011-001456-11,11,2016-12-23,2016-12-28,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Multicenter, International, Randomized, Double-blind, Placebo controlled, Parallel-group Study to Assess the Efficacy and Safety of AMG 785 Treatment in Postmenopausal Women With Osteoporosis Est...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001456-11,0,0,0 2011-001459-35,1,2014-04-24,2014-04-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CHIESI,"MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY ON THE THERAPEUTIC EFFICACY AND SAFETY OF BECLOMETHASONE DIPROPIONATE SUSPENSION FOR INHALATION 800 micrograms TWICE DA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001459-35,0,0,0 2011-001460-22,2,2015-06-16,2015-06-16,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A Phase II/III, Multicenter, Randomized, Double Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001460-22,0,0,0 2011-001461-40,1,2012-05-10,2012-05-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Hull and East Yorkshire Acute Hospitals NHS Trust,A comparison of Mirena use in women with and without fibroids,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001461-40,0,0,0 2011-001462-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Westdeutsche Studiengruppe GmbH,Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001462-17,0,0,0 2011-001463-51,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Enfermedades Infecciosas. Unidad VIH. Hospital Universitari de Bellvitge,EVALUACIÓN DE LOS NIVELES DE ETRAVIRINA EN PLASMA SEMINAL EN SUJETOS INFECTADOS POR EL VIH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001463-51,0,0,0 2011-001465-41,2,2012-12-04,2012-12-04,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A randomized, open label intra-patient dose escalation study with an untreated reference group to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of multiple infusions of BPS8...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001465-41,0,0,0 2011-001468-23,7,2015-07-06,2016-07-05,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,TRANSGENE S.A,"A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001468-23,0,0,0 2011-001468-23,7,2015-07-06,2016-07-05,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Transgene S.A.,"A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001468-23,0,0,0 2011-001469-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Deventer Ziekenhuis,A randomised clinical trial on the effectiveness of MediHoney barrier cream versus the standard therapy with zinc oxide in the treatment of intertrigo.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001469-42,0,0,0 2011-001472-18,1,2013-04-26,2013-04-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,STZ 1172 Gesundheitsförderung und Stoffwechselforschung,"Double-Blind, Randomised, Cross-Over, Placebo-Controlled, Single-Centre Phase IIa Clinical Study on the Influence of Udenafil on the Portal Flow in Cirrhotic Patients with Portal Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001472-18,0,0,0 2011-001474-25,1,2019-12-31,2019-12-31,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,"Klinik für Dermatologie, Venerologie und Allergologie; Charité - Universitätsmedizin Berlin","A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node dissecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001474-25,0,0,0 2011-001477-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"MERIT MEDICAL SYSTEMS, INC.","Phase 3 Prospective,Randomized, blinded and controlled investigation of Hepasphere/Quadrasphere microspheres for delivery of doxorubicin for the treatment of hepatocellular cancer. This Study is Phase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001477-14,0,0,0 2011-001480-42,14,2016-02-15,2016-03-15,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme Corporation and its Affiliates,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Continuation Period to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001480-42,0,0,0 2011-001480-42,14,2016-02-15,2016-03-15,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GENZYME EUROPE BV,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Continuation Period to Assess the Safety and Efficacy of Two Different Regimens of Mipomersen in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001480-42,0,0,0 2011-001481-18,1,2017-03-30,2017-03-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Uppsala University Hospital,Uncemented total hip implant and subcutaneous injection of Denosumab for patients with osteoarthritis of the hip. A randomised double blind placebo controlled study on the effects on bone evaluated wi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001481-18,0,0,0 2011-001483-21,6,2012-02-14,2012-07-11,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Karo Bio AB,"A Placebo-controlled, Double-blind, Randomised, Parallel-group, Long-term Phase III Trial Assessing the Safety and Efficacy of 50 µg and 100 µg/day of eprotirome in Patients with Heterozygous Familial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001483-21,0,0,0 2011-001488-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE MONZINO CENTRO CARDIOLOGICO,Antiplatelet effect of low doses of aspirin taken every 12 hours in patients undergoing coronary artery bypass graft and / or aortic valve replacement surgery with bioprostheses Effetto antipiastri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001488-40,0,0,0 2011-001490-40,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ORION CORPORATION ORION PHARMA,"Comparative evaluation of the effects of dexmedetomidine and propofol on patient/ventilator interaction in difficult-to-wean mechanically ventilated patients; a prospective, open, randomised, multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001490-40,0,0,0 2011-001491-20,1,2018-11-01,2018-11-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Ruprecht-Karls University Heidelberg, Medical Faculty","A phase II trial to evaluate the safety, feasibility and efficacy of a salvage therapy consisting of the mTOR inhibitor Temsirolimus (Torisel™) added to the standard therapy of Rituximab and DHAP for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001491-20,0,0,0 2011-001492-39,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Vl-Medi Oy, Väestöliitto",A randomized study to evaluate the predictive impact of using Cerazette progestin only pill before Nexplanon implant insertion regarding bleeding control,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001492-39,0,0,0 2011-001493-25,7,2012-07-09,2012-07-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A trial comparing the efficacy and safety of adding liraglutide versus addition of insulin aspart with the largest meal to insulin degludec, both in combination with metformin, in subjects with type 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001493-25,0,0,0 2011-001495-18,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Population health Research Institute,Steroids in Cardiac Surgery (SIRS) trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001495-18,0,0,0 2011-001499-20,1,2016-07-26,2016-07-26,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Meletios-Athanasios Dimopoulos,"A phase II open label, non comparative, non randomized study for the assessment of the efficacy and safety of lenalidomide + adriamycine and low dose dexamethasone combination (RAD) in newly diagnosed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001499-20,0,0,0 2011-001502-10,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,National Cancer Institute,Phase II study of Everolimus in refractory testicular germ cell cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001502-10,0,0,0 2011-001505-26,1,2019-10-30,2019-10-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Karolinska Institutet,Repeated doses of misoprostol for medical treatment of missed abortion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001505-26,0,0,0 2011-001506-96,1,2014-12-09,2014-12-09,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,sanofi-aventis recherche et développement,A Phase I/II Study of Cabazitaxel Combined with Abiraterone Acetate and Prednisone in Patients with Metastatic Castrate-Resistant Prostate Cancer (CRPC) whose Disease has Progressed after Docetaxel C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001506-96,0,0,0 2011-001507-13,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AIO-Studien-gGmbH,"Multicenter, explorative phase II study of perioperative 5-FU, leucovorin, docetaxel, and oxaliplatin (FLOT) in combination with Trastuzumab in patients with HER2-positive, locally advanced resectable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001507-13,0,0,0 2011-001508-37,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"Phase III randomized, open, controlled study to evaluate the immune response to the hepatitis B antigen of the RTS,S/AS01E candidate vaccine, when administered as primary vaccination integrated into a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001508-37,0,1,1 2011-001509-28,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,Efficacy and mechanisms of a short course of intensified insulin treatment on remission or responsiveness to oral therapy in type 2 diabetes Efficacia e meccanismi di un trattamento insulinico inte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001509-28,0,0,0 2011-001510-33,1,2015-08-26,2015-08-26,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Leeds Teaching Hospitals R and D department,The Efficacy of Continuous Intra-articular Infusion of Local Anaesthetic Agent following Elective Primary Hip Arthroplasty,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001510-33,0,0,0 2011-001512-65,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Masaryk University,A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma Metronomická a cílená antiangiogenní terapie pro děti s recidivujícím/p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001512-65,0,0,0 2011-001513-13,2,2017-07-10,2017-07-10,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Synageva Biopharma Corp.,"AN OPEN LABEL MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF SBC-102 IN ADULT SUBJECTS WITH LIVER DYSFUNCTION DUE TO LYSOSOMAL ACID LIPASE DEFICIENCY WHO P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001513-13,0,0,0 2011-001514-34,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Leiden University Medical Center,Infusion of IL-15 activated NK cells after allogeneic stem cell transplantation in children transplanted for relapsed/refractory leukemia: a feasibility study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001514-34,0,0,0 2011-001515-31,4,2014-12-17,2014-12-17,3,1,1,0,0,0,3,0,0,1,0,0,1,0,0,PENTA Foundation Onlus,"EFFICACY, PHARMACOKINETICS AND SAFETY OF MEROPENEM IN INFANTS BELOW 90 DAYS OF AGE (INCLUSIVE) WITH CLINICAL OR CONFIRMED LATE-ONSET SEPSIS: A EUROPEAN MULTICENTER RANDOMISED PHASE III TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001515-31,0,0,0 2011-001515-31,4,2014-12-17,2014-12-17,3,1,1,0,0,0,3,0,0,1,0,0,1,0,0,FONDAZIONE PENTA ONLUS,"EFFICACY, PHARMACOKINETICS AND SAFETY OF MEROPENEM IN INFANTS BELOW 90 DAYS OF AGE (INCLUSIVE) WITH CLINICAL OR CONFIRMED LATE-ONSET SEPSIS: A EUROPEAN MULTICENTER RANDOMISED PHASE III TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001515-31,0,0,0 2011-001516-54,4,2012-09-27,2012-09-27,3,1,0,0,2,0,4,0,0,1,0,0,1,0,1,GILEAD SCIENCE INC.,"A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001516-54,0,0,0 2011-001516-54,4,2012-09-27,2012-09-27,3,1,0,0,2,0,4,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001516-54,0,0,0 2011-001518-33,1,2012-12-04,2012-12-04,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Hospital of South Manchester NHS Foundation Trust,A signal seeking window trial of AZD8931 in patients with resectable non-small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001518-33,0,0,0 2011-001520-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Skåne University Hospital, Malmö",Ketamine as an alternative to electroconvulsive therapy for treatment of major depressive disorder Ketamin som alternativ till ECT vid egentlig depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001520-37,0,0,0 2011-001521-25,6,2014-12-10,2014-12-12,4,0,1,0,0,0,2,0,0,1,0,0,1,0,0,PENTA Foundation Onlus,: NEOMERO 2: FARMACOCINÉTICA Y SEGURIDAD DE MEROPENEM EN NIÑOS DE EDADES HASTA 90 DÍAS (INCLUSIVE) CON MENINGITIS PROBABLE O CONFIRMADA: ENSAYO MULTICÉNTRICO EUROPEO DE FASE I-II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001521-25,0,0,0 2011-001521-25,6,2014-12-10,2014-12-12,4,0,1,0,0,0,2,0,0,1,0,0,1,0,0,FONDAZIONE PENTA ONLUS,: NEOMERO 2: FARMACOCINÉTICA Y SEGURIDAD DE MEROPENEM EN NIÑOS DE EDADES HASTA 90 DÍAS (INCLUSIVE) CON MENINGITIS PROBABLE O CONFIRMADA: ENSAYO MULTICÉNTRICO EUROPEO DE FASE I-II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001521-25,0,0,0 2011-001521-25,6,2014-12-10,2014-12-12,4,0,1,0,0,0,2,0,0,1,0,0,1,0,0,PENTA Foundation (Fondazione Penta Onlus),: NEOMERO 2: FARMACOCINÉTICA Y SEGURIDAD DE MEROPENEM EN NIÑOS DE EDADES HASTA 90 DÍAS (INCLUSIVE) CON MENINGITIS PROBABLE O CONFIRMADA: ENSAYO MULTICÉNTRICO EUROPEO DE FASE I-II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001521-25,0,0,0 2011-001521-25,6,2014-12-10,2014-12-12,4,0,1,0,0,0,2,0,0,1,0,0,1,0,0,FONDAZIONE PENTA,: NEOMERO 2: FARMACOCINÉTICA Y SEGURIDAD DE MEROPENEM EN NIÑOS DE EDADES HASTA 90 DÍAS (INCLUSIVE) CON MENINGITIS PROBABLE O CONFIRMADA: ENSAYO MULTICÉNTRICO EUROPEO DE FASE I-II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001521-25,0,0,0 2011-001521-25,6,2014-12-10,2014-12-12,4,0,1,0,0,0,2,0,0,1,0,0,1,0,0,St George's University of London,: NEOMERO 2: FARMACOCINÉTICA Y SEGURIDAD DE MEROPENEM EN NIÑOS DE EDADES HASTA 90 DÍAS (INCLUSIVE) CON MENINGITIS PROBABLE O CONFIRMADA: ENSAYO MULTICÉNTRICO EUROPEO DE FASE I-II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001521-25,0,0,0 2011-001524-38,13,2012-01-04,2013-01-04,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ALMIRALL, S. A.",EFFICACY AND SAFETY OF ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE FIXED-DOSE COMBINATIONS COMPARED WITH INDIVIDUAL COMPONENTS AND PLACEBO WHEN ADMINISTERED TO PATIENTS WITH STABLE CHRONIC OBSTRUCTIVE PULM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001524-38,0,0,0 2011-001524-38,13,2012-01-04,2013-01-04,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALMIRALL SA,EFFICACY AND SAFETY OF ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE FIXED-DOSE COMBINATIONS COMPARED WITH INDIVIDUAL COMPONENTS AND PLACEBO WHEN ADMINISTERED TO PATIENTS WITH STABLE CHRONIC OBSTRUCTIVE PULM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001524-38,0,0,0 2011-001526-19,8,2015-08-25,2015-08-25,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,F.Hoffmann-La Roche Ltd,"A randomized, open-label, multicenter Phase IIIb study comparing two trastuzumab dosing regimens, each in combination with cisplatin/ capecitabine chemotherapy, as first-line therapy in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001526-19,0,0,0 2011-001526-19,8,2015-08-25,2015-08-25,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,ROCHE,"A randomized, open-label, multicenter Phase IIIb study comparing two trastuzumab dosing regimens, each in combination with cisplatin/ capecitabine chemotherapy, as first-line therapy in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001526-19,0,0,0 2011-001527-20,3,2012-03-14,2012-04-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"TIMI 57 - A Double-Blind, Randomized, Placebo-controlled, Multicenter, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Combination with HMG-CoA Reductase Inhibitors in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001527-20,0,0,0 2011-001528-39,4,2012-03-14,2012-05-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"""A Double-blind, Radomized, Placebo-comtrolled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia"" ""Estudio mul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001528-39,0,0,0 2011-001529-26,5,2012-05-08,2012-05-08,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C, Compared with Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001529-26,0,0,0 2011-001534-42,1,2016-06-16,2016-06-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Treosulfan and 4 Gy TBI based conditioning with Rapamycin-based GvHD prophylaxis for allogeneic stem cell transplantation in patients with haematological malignancies Condizionamento a base di Tr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001534-42,0,0,0 2011-001538-41,1,2014-06-04,2014-06-04,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University of Birmingham,The impact of the combination of the GLP-1 analogue liraglutide (Victoza) and laparoscopic adjustable gastric banding (LAGB) on diabetes control,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001538-41,0,0,0 2011-001539-21,1,2017-01-05,2017-01-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 2-arm, prospective, randomized, controlled, open-label, 12 month Phase III trial to evaluate the efficacy of Everolimus in combination with a centre specific standard immunosuppressive regimen consi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001539-21,0,0,0 2011-001544-30,1,2012-03-02,2012-03-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Placebo and Ezetimibe Controlled, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Hypercholesterolemic Subjects With a 10 Year Framingham Risk Score of 10...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001544-30,0,0,0 2011-001550-29,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Tumores Neuroendocrinos,A Phase II randomized double-blind study of Santostatin LAR in combination with Axitinib versus Placebo in patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pancr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001550-29,0,0,0 2011-001550-29,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GETNE (GRUPO ESPAñOL DE TUMORES NEUROENDOCRINOS),A Phase II randomized double-blind study of Santostatin LAR in combination with Axitinib versus Placebo in patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pancr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001550-29,0,0,0 2011-001555-37,13,2018-10-25,2018-10-25,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of apremilast (CC-10004) in the treatment of active ankylosing spondyliti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001555-37,0,0,0 2011-001556-11,1,,,0,0,0,0,1,1,4,0,0,1,0,0,0,1,0,IRCCS FONDAZIONE STELLA MARIS,Decline of mentale functions in adults with Down Syndrome: clinical and experimental study on the effects of treatment with fluoxetine and of cognitive and physical training. Declino delle funzioni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001556-11,0,0,0 2011-001557-85,3,,,0,0,0,0,0,2,2,0,0,2,1,0,0,0,0,Nordic Lymphoma Group,"NLG-MCL5 (MARiT) Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 years A Nordic Lymphoma Group and British Lymphoma Group Phase-II Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001557-85,0,0,0 2011-001558-27,2,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"UCB BIOSCIENCES, Inc","A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF LACOSAMIDE (LCM) ORAL SOLUTION (SYRUP) AS ADJUNCTIVE THERAPY IN CHILDREN WITH PARTIAL ONSET SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001558-27,0,1,0 2011-001559-35,6,2021-05-18,2021-05-18,6,1,1,0,0,0,2,0,0,1,0,0,1,0,1,"UCB BIOSCIENCES, Inc","AN OPEN-LABEL STUDY TO DETERMINE SAFETY, TOLERABILITY, AND EFFICACY OF LONG-TERM ORAL LACOSAMIDE (LCM) AS ADJUNCTIVE THERAPY IN CHILDREN WITH EPILEPSY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001559-35,0,0,0 2011-001564-21,1,2014-09-14,2014-09-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,NHS Greater Glasgow and Clyde,Towards Onset Prevention of COGnitive decline in adults with Down syndrome (the TOP-COG study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001564-21,0,0,0 2011-001564-21,1,2014-09-14,2014-09-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Glasgow,Towards Onset Prevention of COGnitive decline in adults with Down syndrome (the TOP-COG study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001564-21,0,0,0 2011-001568-22,3,2013-07-10,2013-07-10,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novo Nordisk A/S,"A multicenter, randomised, double-blind, placebo-controlled, multiple-dose trial with rFXIII administered to subjects with mild to moderate active ulcerative colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001568-22,0,0,0 2011-001571-39,1,2014-11-21,2014-11-21,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Bristol,Investigating the relationship between sleep disturbance and learning in children with Benign Epilepsy of Childhood with Centrotemporal Spikes (BECCTS): A Randomised Double-Blind Placebo-Controlled Cr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001571-39,0,0,0 2011-001572-19,4,2013-05-20,2013-05-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Randomised, double-blind, parallel-group, placebo-controlled, fixed dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult patients with Major Depressive Disorder (MDD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001572-19,0,0,0 2011-001573-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hôpital Erasme,optimization of doses of broad spectrum B-lactames (ceftazidim and meropenem) and vancomycin in septic patient traeted with chronic hemodialysis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001573-10,0,0,0 2011-001581-18,1,2012-11-30,2012-11-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline GmbH & Co. KG,Effects of bronchodilatation with salmeterol on the autonomic nervous system,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001581-18,0,0,0 2011-001588-37,3,2012-12-20,2012-12-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the renal hemodynamic effects of RLX030 at a dose of 30 μg/kg/day or placebo infused for 24 hours in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001588-37,0,0,0 2011-001589-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HUCH Eye Hospital,"MINOPTIC - A prospective, double-masked, placebo-controlled study on efficacy and safety of minicycline in the treatment of optic neuritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001589-16,0,0,0 2011-001593-25,2,2013-07-11,2013-07-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharmacosmos A/S,"An Open-label, Multi-Centre, Non-Randomised Extension Study to Assess the Ability to Maintain a Stable Haemoglobin and to Assess Safety of Iron Isomaltoside 1000 (Monofer®) in Subjects with Inflammato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001593-25,0,0,0 2011-001595-19,5,2016-09-30,2016-09-30,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,SANTEN INCORPORATED,"A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE- 109 (three doses) for the Treatment of active, Non-Infec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001595-19,0,0,0 2011-001598-25,1,2018-03-06,2018-03-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"INSTITUTO GRIFOLS, S.A.","A multicenter, randomized, controlled study to evaluate the efficacy and safety of short-term plasma exchange followed by long-term plasmaphereses with infusion of human albumin combined with intraven...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001598-25,0,0,0 2011-001602-10,1,2016-02-11,2016-02-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Center for Cancer Immunotherapy (CCIT) / Department of Oncology, Herlev Hospital",Dendritic cell vaccination in combination with Docetaxel for patients with prostata cancer - a randomized phase II trial Dendritcellevaccination i kombination med Docetaxel til patienter med cancer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001602-10,0,0,0 2011-001608-37,1,2014-03-31,2014-03-31,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GLAXOSMITHKLINE BIOLOGICALS SA,"Open, randomised, controlled, multicenter Phase IIIb study to evaluate the immune response and safety, after the administration of GlaxoSmithKline Biologicals live attenuated measles mumps rubella ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001608-37,0,0,0 2011-001612-62,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,0,Institute of Tropical Medicine Antwerp,Simplifying the Rabies Pre-exposure Vaccination,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001612-62,0,0,0 2011-001616-57,2,2014-09-12,2014-09-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A Phase 2 study of SAR245409 in patients with relapsed or refractory mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma or diffuse large B-cell lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001616-57,0,0,0 2011-001617-14,2,2014-06-06,2014-08-13,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"An adaptive multicentre, randomized, partially doubleblind, placebo controlled study to assess the safety, PK and PD/efficacy of RLX030 in women with pre-eclampsia Studio adattativo, multicentric...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001617-14,0,0,0 2011-001617-14,2,2014-06-06,2014-08-13,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,NOVARTIS FARMA,"An adaptive multicentre, randomized, partially doubleblind, placebo controlled study to assess the safety, PK and PD/efficacy of RLX030 in women with pre-eclampsia Studio adattativo, multicentric...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001617-14,0,0,0 2011-001626-15,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Roche Farma, S.A.","A multi-centre, randomized, double-blind study of the safety and efficacy of tocilizumab (TCZ) in combination with methotrexate (MTX), versus TCZ (placebo controlled) in patients with active rheumatoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001626-15,0,0,0 2011-001629-25,1,2014-01-22,2014-01-22,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"An open label extension study to evaluate the safety, tolerability and efficacy of AIN457 in patients with relapsing-remitting multiple sclerosis Otevřené prodloužení klinické studie hodnotící bezp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001629-25,0,0,0 2011-001635-23,11,2015-03-18,2015-03-18,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Cilag International N.V.,PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects Inibitore della PROTEAsi (DRV/rtv) in mono o triplice terapia in soggetti con infezione da HIV-1 virol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001635-23,0,0,0 2011-001635-23,11,2015-03-18,2015-03-18,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,PROTEAse inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects Inibitore della PROTEAsi (DRV/rtv) in mono o triplice terapia in soggetti con infezione da HIV-1 virol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001635-23,0,0,0 2011-001638-41,2,2012-06-08,2013-04-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"CLARUS THERAPEUTICS, INC.","PHASE III, ACTIVE-CONTROLLED, SAFETY AND EFFICACY TRIAL OF ORAL TESTOSTERONE UNDECANOATE (TU) IN HYPOGONADAL MEN.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001638-41,0,0,0 2011-001639-21,4,2020-08-29,2020-08-29,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,NMDSG Nordics Myeloplastics Syndrom Study Group,A multicenter open randomized phase II study of efficacy and safety of azacitidine alone or in combination with lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype inclu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001639-21,1,0,0 2011-001639-21,4,2020-08-29,2020-08-29,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,NMDSG Nordic Myelodysplastic Syndrom Group,A multicenter open randomized phase II study of efficacy and safety of azacitidine alone or in combination with lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype inclu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001639-21,1,0,0 2011-001642-14,1,2012-04-02,2012-04-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Surrey,"The effects of subcutaneous insulin detemir on glucose flux, pharmacokinetics and brain function in type one diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001642-14,0,0,0 2011-001643-79,16,2015-11-03,2015-11-03,14,1,0,0,0,0,4,0,0,2,1,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with pers...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001643-79,1,0,0 2011-001643-79,16,2015-11-03,2015-11-03,14,1,0,0,0,0,4,0,0,2,1,0,0,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 pediatric subjects 4-11 years old with pers...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001643-79,1,0,0 2011-001644-29,17,2015-06-04,2015-06-23,14,1,0,0,0,0,4,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,A Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma. Klinické ho...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001644-29,0,0,0 2011-001644-29,17,2015-06-04,2015-06-23,14,1,0,0,0,0,4,0,0,1,1,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,A Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma. Klinické ho...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001644-29,0,0,0 2011-001645-33,1,2012-02-13,2012-02-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"AC4115408: A12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK573719 Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001645-33,0,0,0 2011-001646-16,3,2016-09-23,2016-09-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ViiV Healthcare UK Limited,"A Dolutegravir Open Label Protocol for HIV infected, Adult and Adolescents Patients with Integrase Resistance",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001646-16,0,0,0 2011-001646-16,3,2016-09-23,2016-09-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,VIIV HEALTHCARE UK LIMITED,"A Dolutegravir Open Label Protocol for HIV infected, Adult and Adolescents Patients with Integrase Resistance",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001646-16,0,0,0 2011-001649-34,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,CNIO - Centro Nacional de Investigaciones Oncológicas,"Ensayo clínico de fase I/II, aleatorizado, de paclitaxel neoadyuvante frente a imprimación con BIBF 1120 seguida por BIBF 1120 más paclitaxel en cáncer de mama HER-2 negativo con estudios correlativos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001649-34,0,0,0 2011-001650-29,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,A. Carlsson Research AB,"TREATMENT OF MENTAL FATIGUE (""BRAIN FATIGUE"") WITH THE DOPAMINERGIC STABILIZER OSU6162 AFTER STROKE AND MILD/MODERATE TRAUMATIC BRAIN INJURY– INCREASE OF PATIENT NUMBER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001650-29,0,0,0 2011-001659-36,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ITALIAN SARCOMA GROUP,ABCB1/P-glycoprotein as biological marker for treatment of patient with high grade osteosarcoma Espressione di ABCB1/P-glycoprotein come fattore per la stratificazione biologica dell'osteosarcoma ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001659-36,0,0,0 2011-001661-40,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Abbott Laboratories,"A Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Juvenile Rheumatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001661-40,0,1,1 2011-001664-22,1,2014-12-31,2014-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Wien - Universitätsklinik für Frauenheilkunde,"A prospective, randomized, multicenter study to evaluate the impact of Darbepoetin alfa in combination with Ferric(III)-Carboxymaltose in comparison to Darbepoetin alfa and Ferric(III)-Carboxymaltose ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001664-22,0,0,0 2011-001667-44,2,2013-02-15,2013-02-15,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Active Biotech AB,An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with ABR-215757 (paquinimod),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001667-44,0,0,0 2011-001673-70,1,2013-01-03,2013-01-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Skånes Universitetssjukhus,EPO to protect renal function after cardiac surgery. EPRICS. A phase II double blind randomized controlled study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001673-70,0,0,0 2011-001674-25,1,2013-07-12,2013-07-12,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Francisco J. González Vílchez,"Evaluation of the efficacy of sildenafil on the functional capacity of patients with heart failure with preserved ejection fraction. A randomized, double blind, parallel group and placebo-controlled c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001674-25,0,0,0 2011-001680-44,1,,,0,0,1,0,0,0,1,0,0,4,0,0,0,0,0,The National Institute of Allergy and Infectious Diseases (NIAID),"A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Rilpivirine in Antiretroviral Naive HIV-1 Infected Children, < 12 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001680-44,0,1,1 2011-001682-41,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),Comparison of the efficacy and the safety of different schedules of administration of sub-lingual immunotherapy in patients with ragweed pollinosis: a phase III randomized and controlled clinical stud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001682-41,0,0,0 2011-001683-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University of Debrecen, Medical and Health Science Center, Department of Anaesthesiology and Intensive Therapy","Reversal of residual rocuronium neuromuscular block using sugammadex: a prospective, dobule-blind, randomized, controlled, dose-finding study A reziduális rocuroniumblokád felfüggesztése sugammadex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001683-22,0,0,0 2011-001684-50,1,2014-04-29,2014-04-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Nottingham,'Stem cell Trial of recovery EnhanceMent after Stroke 3’ (STEMS 3)- a pilot randomised controlled trial of G-CSF and therapy in chronic stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001684-50,0,0,0 2011-001686-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"German Heart Centre Munich, Department of Cardiovascular Diseases","INTRACORONARY STENTING AND ANTITHROMBOTIC REGIMEN: ADJUSTING ANTIPLATELET TREATMENT IN PATIENTS BASED ON PLATELET FUNCTION TESTING - ISAR ADAPT-PF PROSPEKTIVE, RANDOMISIERTE STUDIE ZUR ANTITHROMBOZ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001686-40,0,0,0 2011-001689-16,1,2018-07-05,2018-07-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,"Prospective randomized, double-blind, and placebo-controlled clinical trial with hydroxychloroquine (HCQ) in patients with erosive-inflammatory osteoarthritis (OA) of the finger joints (acronym: OA TR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001689-16,0,0,0 2011-001690-62,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Birmingham,A randomised phase II clinical trial of conditioning cyclophosphamide and chemoembolisation with or without vaccination with dendritic cells pulsed with HepG2 lysate ex vivo in patients with Hepatocel...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001690-62,0,0,0 2011-001692-39,1,2013-09-02,2013-09-02,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Novartis Pharma GmbH,"A 21-week, multicenter, open label study to evaluate the safety and tolerability profile of the combination of a SSRI or SNRI antidepressive therapy with oral fingolimod in the treatment of RRMS patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001692-39,0,0,0 2011-001695-19,8,2014-02-13,2014-02-13,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Vifor (International) Inc.,"A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose with Placebo in Patients with Chronic Heart Failure and Iron Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001695-19,0,0,0 2011-001695-19,8,2014-02-13,2014-02-13,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,VIFOR (INTERNATIONAL) INC.,"A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose with Placebo in Patients with Chronic Heart Failure and Iron Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001695-19,0,0,0 2011-001696-39,1,2012-12-31,2012-12-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"University of Southern Denmark, Clinical Pharmacology",The inhibitory effect of metformin on gluconeogenesis in relation to polymorphisms in Organic Cation Transporter 1 (OCT1) in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001696-39,0,0,0 2011-001697-26,7,2014-06-25,2014-06-25,5,0,0,0,0,0,4,0,0,2,0,0,0,0,2,Professor Reich,Optimisinf outpatient care in mild to moderate psoriasis by a newly developed ''Topical Treatment Optimising Programme'' - an international study using Daivobet/Dovobet Gel (PSO-TOP) Ottimizzazione...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001697-26,1,0,0 2011-001697-26,7,2014-06-25,2014-06-25,5,0,0,0,0,0,4,0,0,2,0,0,0,0,2,SCIDERM GMBH,Optimisinf outpatient care in mild to moderate psoriasis by a newly developed ''Topical Treatment Optimising Programme'' - an international study using Daivobet/Dovobet Gel (PSO-TOP) Ottimizzazione...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001697-26,1,0,0 2011-001698-22,1,,,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,Verona Pharma plc,EVALUATION OF THE EFFICACY AND SAFETY OF 6 REPEATED DAILY DOSES OF NEBULISED RPL554 0.018 mg/kg (6X) IN ALLERGIC ASTHMATICS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001698-22,0,0,0 2011-001699-20,12,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,St. Anna Kinderkrebsforschung,International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis Protocolo internacional colaborativo de tratamiento para niños y adolescentes con hist...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001699-20,0,0,0 2011-001711-31,2,2013-08-06,2013-08-06,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sunovion Pharmaceuticals Inc.,"A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance treatment of subjects with schizophrenia Studio di sospensione randomizzato, in doppio cieco, cont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001711-31,0,0,0 2011-001711-31,2,2013-08-06,2013-08-06,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SUNOVION PHARMACEUTICALS INC.,"A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance treatment of subjects with schizophrenia Studio di sospensione randomizzato, in doppio cieco, cont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001711-31,0,0,0 2011-001712-61,5,2012-11-19,2012-11-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 26-week, randomised, open-label, multinational, treat-to-target trial comparing efficacy and safety of insulin degludec/insulin aspart (IDegAsp) twice daily (BID) and BIAsp 30 BID both with metformi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001712-61,0,0,0 2011-001713-14,1,2015-05-29,2015-05-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"A PROSPECTIVE, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE ANTIPROTEINURIC EFFECT OF SELECTIVE VITAMIN D RECEPTOR ACTIVATION BY PARICALCITOL IN TYPE 2 DIABETES PATIENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001713-14,0,0,0 2011-001715-31,1,2018-11-30,2018-11-30,1,0,0,0,1,0,3,0,0,1,1,1,1,0,0,Fundación para la Formación e Investigación Sanitaria de la Región de Murcia,"Cytoreduction with or without intraoperative intraperitoneal hyperthermic chemotherapy (HIPEC) in patients with peritoneal carcinomatosis from ovarian cancer , fallopian tube or primary peritoneal car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001715-31,0,0,0 2011-001716-59,1,2011-12-22,2011-12-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness of an Intravenous Infusion of AZD2927 in Patients Undergoing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001716-59,0,0,0 2011-001718-32,1,2014-05-13,2014-05-13,1,1,1,0,0,1,2,0,0,1,1,1,1,0,1,FERROKIN BIOSCIENCES INC.,"A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of FBS0701 in a Pediatric Population with Transfusional Iron Overloa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001718-32,0,0,0 2011-001720-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO,"Multi-centre, phase II, single arm study of the docetaxel, oxaliplatin, capecitabine (DOC) combination in untreated patients with advanced or metastatic gastric cancer Studio di fase II della combi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001720-37,0,0,0 2011-001724-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE SACRO CUORE-DON CALABRIA,Use of 68-Ga-DOTANOC for the assessment of human neuroendocrine tumors by imaging with Positron Emission Tomography (PET) Impiego del 68-Ga-DOTANOC nella diagnostica per immagini mediante Tomografi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001724-38,0,0,0 2011-001725-24,5,2014-07-31,2014-07-31,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,DOVIGIST: Phase II trial to evaluate the efficacy and safety of Dovitinib (TKI258) in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001725-24,0,0,0 2011-001725-24,5,2014-07-31,2014-07-31,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services,DOVIGIST: Phase II trial to evaluate the efficacy and safety of Dovitinib (TKI258) in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001725-24,0,0,0 2011-001725-24,5,2014-07-31,2014-07-31,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,DOVIGIST: Phase II trial to evaluate the efficacy and safety of Dovitinib (TKI258) in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001725-24,0,0,0 2011-001726-14,1,,,0,0,0,0,1,0,2,0,0,1,0,0,0,1,0,AUSL DI MODENA,Supplementetion with vitamin D in patients with chronic heart failure and hypovitaminosis D Effetti della supplementazione di vitamina D in pazienti con ipovitaminosi D e insufficienza cardiaca cro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001726-14,0,0,0 2011-001729-25,10,2015-09-10,2015-09-10,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma SA,"A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol in combination with methotrexate for inducing and sustaining clinical respo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001729-25,0,0,0 2011-001729-25,10,2015-09-10,2015-09-10,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB PHARMA SA/NV.,"A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol in combination with methotrexate for inducing and sustaining clinical respo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001729-25,0,0,0 2011-001731-24,6,2013-12-27,2014-04-24,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Glimepiride When Used in Combination with Metformin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001731-24,0,0,0 2011-001731-24,6,2013-12-27,2014-04-24,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Development Centre Europe Ltd.,"A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Glimepiride When Used in Combination with Metformin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001731-24,0,0,0 2011-001732-37,11,2013-12-27,2014-05-05,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Development Centre Europe Ltd.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001732-37,0,0,0 2011-001732-37,11,2013-12-27,2014-05-05,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001732-37,0,0,0 2011-001732-37,11,2013-12-27,2014-05-05,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,TAKEDA EUROPE RESEARCH & DEVELOPMENT CENTRE LTD,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001732-37,0,0,0 2011-001733-16,10,2015-02-23,2015-03-17,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 FOR INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE CROHN’...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001733-16,0,0,0 2011-001733-16,10,2015-02-23,2015-03-17,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Inc.,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 FOR INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE CROHN’...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001733-16,0,0,0 2011-001733-16,10,2015-02-23,2015-03-17,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017, USA","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 FOR INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE CROHN’...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001733-16,0,0,0 2011-001735-22,7,2019-08-21,2019-08-21,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects with High-risk Smoldering Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001735-22,0,0,0 2011-001736-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Med. Univ. Wien, Klinik für Dermatologie",BOSENTAN FOR THE TREATMENT OF SKIN ULCERS IN DIABETIC MICROANGIOPATHY Bosentan zur Behandlung von Hautulzera bei diabetischer Mikroangiopahtie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001736-30,0,0,0 2011-001739-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",A study of Sativex for pain Relief and appetite stimulation in Patients with advanced malignancy. Phase II Studio monocentrico di fase II per la valutazione degli effetti clinici ed immunologici de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001739-21,0,0,0 2011-001743-78,1,2016-04-06,2016-04-06,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Laves-Arzneimittel GmbH,"MULTICENTRIC RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND 3-ARM PIVOTAL STUDY ON EFFICACY AND SAFETY OF COLIBIOGEN® ORAL IN PATIENS WITH PROVEN DIAGNOSIS OF IRRITABLE BOWEL SYNDROME MULTIZENTRISCHE, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001743-78,0,0,0 2011-001747-69,1,2016-06-01,2016-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Monash University,Combination gefitinib and methotrexate to treat ectopic pregnancies II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001747-69,0,0,0 2011-001747-69,1,2016-06-01,2016-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,2,NHS Lothian,Combination gefitinib and methotrexate to treat ectopic pregnancies II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001747-69,0,0,0 2011-001752-10,5,2013-12-27,2013-12-27,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,TAKEDA EUROPE RESEARCH & DEVELOPMENT CENTRE LTD,"A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Placebo and Sitagliptin 100 mg When Us...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001752-10,0,0,0 2011-001752-10,5,2013-12-27,2013-12-27,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Placebo and Sitagliptin 100 mg When Us...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001752-10,0,0,0 2011-001752-10,5,2013-12-27,2013-12-27,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Takeda Development Centre Europe Ltd.,"A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Placebo and Sitagliptin 100 mg When Us...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001752-10,0,0,0 2011-001754-28,10,2015-07-29,2015-07-29,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 FOR MAINTENANCE THERAPY IN SUBJECTS WITH MODERATE TO SEVERE CROH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001754-28,0,0,0 2011-001754-28,10,2015-07-29,2015-07-29,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc.235 East 42nd Street, New York, NY 10017, USA","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 FOR MAINTENANCE THERAPY IN SUBJECTS WITH MODERATE TO SEVERE CROH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001754-28,0,0,0 2011-001754-28,10,2015-07-29,2015-07-29,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Inc.,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 FOR MAINTENANCE THERAPY IN SUBJECTS WITH MODERATE TO SEVERE CROH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001754-28,0,0,0 2011-001756-12,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Cliniques Universitaires Saint Luc - UCL,Surrogate markers evaluation in pre-demented Alzheimer’s disease patients and healthy elderly controls,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001756-12,0,0,0 2011-001758-26,8,2015-12-08,2015-12-08,8,1,1,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Limited,"A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001758-26,0,0,0 2011-001758-26,8,2015-12-08,2015-12-08,8,1,1,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001758-26,0,0,0 2011-001758-26,8,2015-12-08,2015-12-08,8,1,1,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelehim AB,"A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001758-26,0,0,0 2011-001758-26,8,2015-12-08,2015-12-08,8,1,1,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co. KG,"A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001758-26,0,0,0 2011-001758-26,8,2015-12-08,2015-12-08,8,1,1,0,0,0,3,0,0,1,0,0,1,0,2,"Unilfarma, Lda.","A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001758-26,0,0,0 2011-001758-26,8,2015-12-08,2015-12-08,8,1,1,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer,"A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001758-26,0,0,0 2011-001758-26,8,2015-12-08,2015-12-08,8,1,1,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co.KG,"A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001758-26,0,0,0 2011-001764-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Magle AB,The effect of 6 weeks’ use of the Nicachet 4 mg nicotine powder in pouch on the oral mucosa. A short-term smoking cessation and tolerability study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001764-21,0,0,0 2011-001765-41,1,2013-09-25,2013-09-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Medizinische Fakultät der Otto-von-Guericke Universität Magdeburg Universitätsklinikum Magdeburg A.ö.R.,"Single-arm, open-label, multicentre phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) in combination with vinorelbine for the treatment of patients with metastatic breast cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001765-41,0,0,0 2011-001772-19,1,2013-05-09,2013-05-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vectura Limited,"A randomised, double-blind, placebo controlled, parallel group, study to evaluate the efficacy and safety of VR506 inhalation powder from a new dry powder inhaler in adolescent and adult subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001772-19,0,0,0 2011-001775-39,1,2017-04-08,2017-04-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA SANITARIA DELL'ALTO ADIGE - COMPRENSORIO SANITARIO DI BOLZANO,"PHASE II MULTICENTER CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001775-39,0,0,0 2011-001776-19,1,2013-09-05,2013-09-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bombastus-Werke AG,"MULTICENTRIC RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND 2-ARM PIVOTAL STUDY ON EFFICACY AND SAFETY OF ARHAMA®-TINKTUR N IN PATIENS WITH ACUTE DIARRHEA MULTIZENTRISCHE, RANDOMISIERTE, PLAZEBO-KONTRO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001776-19,0,0,0 2011-001777-43,10,2015-05-18,2015-05-18,8,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001777-43,0,0,0 2011-001777-43,10,2015-05-18,2015-05-18,8,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer,"A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001777-43,0,0,0 2011-001777-43,10,2015-05-18,2015-05-18,8,1,1,0,0,0,3,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm. V,"A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001777-43,0,0,0 2011-001777-43,10,2015-05-18,2015-05-18,8,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution (2.5 µg and 5 µg) delivered via Respimat® inhaler once daily in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001777-43,0,0,0 2011-001779-38,1,2012-11-13,2012-11-13,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"Prospective, randomized, double-blind, placebo-controlled, parallel-group, 3-stage dose-finding study to identify a safe and effective dose of NT 201 for unilateral injection into the soft palate for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001779-38,0,0,0 2011-001783-21,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Childrens's Research Institute,Optimizing Pain Treatment in Pre-Term Neonates Optimale behandeling van pijn bij te vroeg geboren kinderen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001783-21,0,0,0 2011-001785-17,5,2016-05-13,2016-05-13,4,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Octapharma AG,"Clinical Study in Previously Treated Children with Severe Haemophilia A to Investigate the Long-Term Immunogenicity, Tolerability and Efficacy of Human-cl rhFVIII",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001785-17,0,0,0 2011-001787-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,OSPEDALE POLICLINICO S. MATTEO,"An open-label, phase II study of Pomalidomide and Dexamethasone (PDex) for previously treated patients with AL amyloidosis Studio in aperto di fase II con pomalidomide e desametasone (PDex) per paz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001787-22,0,0,0 2011-001788-36,1,2016-12-31,2016-12-31,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Cell Medica Ltd.,A Phase I/II study to investigate the safety of Adenovirus specific T cells given to high-risk paediatric patients post allogeneic haematopoietic stem cell transplant (allo-HSCT) to treat reactivation...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001788-36,0,0,0 2011-001789-16,1,2017-04-05,2017-04-05,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Plymouth Hospital NHS Trust,Investigation of the intra-tumoural concentration and activity of sorafenib in cutaneous schwannomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001789-16,0,0,0 2011-001790-41,9,2019-05-31,2019-05-31,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AB Science,"A prospective, multicenter, randomised, open-label, active controlled, 2 parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001790-41,1,0,0 2011-001791-19,1,2014-06-25,2014-06-25,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"GTx, Inc.","Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients with Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001791-19,0,0,0 2011-001792-39,2,2013-05-16,2014-06-25,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"GTx, Inc.","Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients with Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001792-39,0,0,0 2011-001793-26,1,2015-07-29,2015-07-29,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Royal Marsden Hospital,A Phase II Trial of Metformin and Axitinib in BRAF Mutated Advanced Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001793-26,0,0,0 2011-001794-85,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,University Medical Center Utrecht,Transarterial RAdioembolization versus ChemoEmbolization for the treatment of HCC: A multicenter randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001794-85,0,0,0 2011-001795-19,1,2020-04-27,2020-04-27,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Cologne,STATIN RECAPTURE THERAPY BEFORE CORONARY ARTERY BYPASS GRAFTING (ACRONYM: START-CABG TRIAL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001795-19,0,0,0 2011-001801-29,1,2011-11-11,2011-11-11,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Boehringer Ingelheim,"A single dose, randomised, placebo-controlled, double-blind, 5-way crossover (employing an incomplete block design), efficacy (including 24-h pulmonary function tests) and safety comparison of Tiotr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001801-29,0,0,0 2011-001805-28,2,2016-06-22,2016-09-12,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc,A Long-Term Study for Extended BMN 701Treatment of Patients with Pompe Disease who have Participated in a BMN 701 Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001805-28,0,0,0 2011-001810-32,1,2011-12-19,2011-12-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Elevation Pharmaceuticals, Inc","A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Seven Arm, Four-Period Cross-over, Incomplete Block Design, 7-Day Dosing Study to Assess the Dose-Response, Safety, and Efficacy of EP-101...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001810-32,0,0,0 2011-001812-80,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Maastro Clinic,Non invasive imaging of [18F]HX4 with Positron-Emission-Tomography (PET) in Head and Neck Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001812-80,0,0,0 2011-001814-33,6,2019-04-11,2019-04-12,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Limited,"LUX-Lung 7: A randomised, open-label Phase IIb Trial of afatinib versus gefitinib as first-line treatment of patients with EGFR mutation positive advanced adenocarcinoma of the lung",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001814-33,0,0,0 2011-001814-33,6,2019-04-11,2019-04-12,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim,"LUX-Lung 7: A randomised, open-label Phase IIb Trial of afatinib versus gefitinib as first-line treatment of patients with EGFR mutation positive advanced adenocarcinoma of the lung",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001814-33,0,0,0 2011-001814-33,6,2019-04-11,2019-04-12,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Norway KS,"LUX-Lung 7: A randomised, open-label Phase IIb Trial of afatinib versus gefitinib as first-line treatment of patients with EGFR mutation positive advanced adenocarcinoma of the lung",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001814-33,0,0,0 2011-001814-33,6,2019-04-11,2019-04-12,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"LUX-Lung 7: A randomised, open-label Phase IIb Trial of afatinib versus gefitinib as first-line treatment of patients with EGFR mutation positive advanced adenocarcinoma of the lung",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001814-33,0,0,0 2011-001814-33,6,2019-04-11,2019-04-12,6,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A","LUX-Lung 7: A randomised, open-label Phase IIb Trial of afatinib versus gefitinib as first-line treatment of patients with EGFR mutation positive advanced adenocarcinoma of the lung",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001814-33,0,0,0 2011-001815-29,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,UMC Utrecht,Chemopreventive effects of mesalazine in patients at high risk of recurrent (nonfamilial) colorectal adenomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001815-29,0,0,0 2011-001819-30,2,2014-07-19,2014-07-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanochemia Pharmazeutika AG,Detection of non-muscle invasive bladder cancer using PVP-Hypericin (Vidon®) fluorescence cystoscopy (Hypericin PDD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001819-30,0,0,0 2011-001820-39,1,2021-07-30,2021-07-30,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Academic medical centre,Levothyroxine for euthyroid women with recurrent miscarriage and thyroid autoimmunity : a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001820-39,0,0,0 2011-001821-26,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO,Aerosol Tobramycin 300 mg single dose in adult patient with cystic fibrosis: pilot study of antimicrobial activity Tobramicina 300 mg aerosol in monosomministrazione in pazienti adulti con Fibrosi ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001821-26,0,0,0 2011-001822-81,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU-Ulg,"Infusion of third-party mesenchymal stem cells after renal or liver transplantation: a phase I-II, open-label, clinical study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001822-81,0,0,0 2011-001824-39,1,2013-06-10,2013-06-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, double-dummy, placebo-controlled, 3-period crossover study to evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of orally inhaled indacaterol adminis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001824-39,0,0,0 2011-001825-25,2,2012-05-22,2012-05-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-centre, randomized, double-blind, double-dummy, multiple-dose, crossover study to evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of orally inhaled indacaterol adminis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001825-25,0,0,0 2011-001826-61,3,2015-06-29,2015-06-29,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Hanmi Pharmaceutical Co., Ltd.","A phase II, randomized, active controlled, open label study of safety and efficacy of HM10560A a Long-acting rhGH-HMC001 conjugate in treatment of subjects suffering from adult growth hormone deficien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001826-61,0,0,0 2011-001836-44,1,2019-04-19,2019-04-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,"A Phase II Trial to Assess the Activity of TroVax® (MVA-5T4) Versus Placebo in Patients with Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001836-44,0,0,0 2011-001839-23,1,2013-09-12,2013-09-12,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,H. Lundbeck A/S,"Interventional randomised, double-blind, parallel-group, placebo-controlled, exploratory study investigating the effects of Lu AA21004 on cognition and BOLD fMRI signals in subjects remitted from depr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001839-23,0,0,0 2011-001841-34,1,2015-09-01,2015-09-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,NHS Greater Glasgow Health Board,A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001841-34,0,0,0 2011-001841-34,1,2015-09-01,2015-09-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Glasgow,A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001841-34,0,0,0 2011-001845-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,LIPOSOMAL AMPHOTERICIN B (AMBISOME) 10 mg/kg once a week for 10 weeks as maintenance antifungal therapy for Proven/Probable Invasive Fungal Infection in hematologic patients with Acute Myeloid Leukaem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001845-34,0,0,0 2011-001847-58,4,2014-05-19,2014-05-19,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT,"A Randomized Phase II, Open-Label study of the Efficacy and Safety of Orally Administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or intol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001847-58,0,0,0 2011-001847-58,4,2014-05-19,2014-05-19,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,"A Randomized Phase II, Open-Label study of the Efficacy and Safety of Orally Administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or intol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001847-58,0,0,0 2011-001849-33,3,2013-04-30,2013-04-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sylentis S.A.U.,DOSE FINDING CLINICAL TRIAL WITH SYL040012 TO EVALUATE THE TOLERABILITY AND EFFECT ON INTRAOCULAR PRESSURE IN SUBJECTS WITH OCULAR HYPERTENSION OR OPEN-ANGLE GLAUCOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001849-33,0,0,0 2011-001855-35,1,2015-10-01,2015-10-01,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Salford Royal NHS Foundation Trust,Does subcutaneous interleukin-1 receptor antagonist reduce inflammation following subarachnoid haemorrhage?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001855-35,0,0,0 2011-001856-12,1,,,0,0,0,0,0,1,4,0,0,1,0,0,0,1,0,The Motol University Hospital,Early assessment of effectivness of neoadjuvant chemotherapy for carcinoma of the esophagus and esophago-gastric junction using FDG-PET/CT.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001856-12,0,0,0 2011-001858-28,5,2020-08-12,2022-08-04,4,0,0,0,0,0,3,0,0,2,0,0,0,0,0,ICORG,Neo-AEGIS (NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study): Randomised Clinical Trial of neoadjuvant and adjuvant chemotherapy (Investigator’s ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001858-28,1,0,0 2011-001858-28,5,2020-08-12,2022-08-04,4,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Cancer Trials Ireland,Neo-AEGIS (NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study): Randomised Clinical Trial of neoadjuvant and adjuvant chemotherapy (Investigator’s ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001858-28,1,0,0 2011-001858-28,5,2020-08-12,2022-08-04,4,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Cancer Trials Ireland Company Limited By Guarantee,Neo-AEGIS (NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study): Randomised Clinical Trial of neoadjuvant and adjuvant chemotherapy (Investigator’s ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001858-28,1,0,0 2011-001859-36,1,2011-09-26,2011-09-26,1,0,0,1,1,0,1,0,1,1,0,0,0,0,1,Meditop Pharmaceuticals Co. Ltd.,Clinical study on the insulin sensitizing effect of multiple administration of Vition (Meditop) in healthy human volunteers (Pilot study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001859-36,0,0,0 2011-001862-16,1,,,0,1,0,0,1,0,2,0,0,3,0,0,0,0,0,University Hospitals Bristol NHS Foundation Trust,Randomised controlled pilot study: Does intraoperative clonidine reduce the incidence of post-hospitalisation negative behaviour changes in children who are distressed during the induction of general ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001862-16,0,0,0 2011-001863-39,1,2014-02-13,2014-02-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche Austria GmbH,A multi-center study of the safety and effect on disease activity of Tocilizumab (TCZ) in combination with Methotrexate (MTX) versus Tocilizumab monotheraphy in patients with mild to moderate rheumato...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001863-39,0,0,0 2011-001865-42,3,2012-02-27,2012-02-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"AMAG Pharmaceuticals, Inc.","A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001865-42,0,0,0 2011-001866-17,2,2013-04-23,2013-04-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"AMAG Pharmaceuticals, Inc.","A Phase III, Open-Label Extension Trial of the Safety and Efficacy of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001866-17,0,0,0 2011-001867-28,3,2014-02-24,2014-02-24,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Genentech, Inc","A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MEGF0444A DOSED TO PROGRESSION IN COMBINATION WITH BEVACIZUMAB AND FOLFOX IN PATIENTS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001867-28,0,0,0 2011-001869-41,1,2014-06-18,2014-06-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Moorfields Eye Hospital NHS Foundation Trust,An exploratory study of ranibizumab (Lucentis) for treatment of uveitic patients with refractory cystoid macular oedema. 'The LIMO study',https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001869-41,0,0,0 2011-001871-37,1,2012-12-03,2012-12-03,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Department of Infectious Diseases - Aarhus University Hospital,Immune Response to Bivalent or Tetravalent Human Papillomavirus Vaccine in HIV infected Adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001871-37,0,0,0 2011-001873-24,3,2019-04-03,2019-04-03,2,1,1,0,0,1,1,0,0,1,0,0,1,0,1,Eli Lilly and Company,A multiple ascending dose study of Tadalafil to assess the pharmacokinetics and safety in a pediatric population with Pulmonary Arterial Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001873-24,0,0,0 2011-001876-21,3,2013-05-09,2013-05-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche et développement,"MULTINATIONAL, MULTICENTER, RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF EFFICACY AND SAFETY OF SAR292833 ADMINISTRATION FOR 4 WEEKS IN PATIENTS WITH CHRONIC PERIPHERAL NEUROPA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001876-21,0,0,0 2011-001878-25,1,2014-10-31,2014-10-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Idenix Pharmaceuticals, Inc.","A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination with Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects with Genotype 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001878-25,0,0,0 2011-001883-23,4,2020-06-30,2020-08-31,3,1,0,0,0,0,4,0,0,1,1,0,1,0,2,University of Dundee,"FAST- Febuxostat versus Allopurinol Streamlined Trial A prospective, randomised, open-label, blinded endpoint (PROBE) clinical trial evaluating long term cardiovascular safety of febuxostat in compa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001883-23,0,0,0 2011-001884-39,4,2013-04-24,2013-04-24,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,A phase II study of orally administered BEZ235 monotherapy in patients with metastatic or unresectable malignant PEComa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001884-39,0,0,0 2011-001884-39,4,2013-04-24,2013-04-24,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,NOVARTIS FARMA,A phase II study of orally administered BEZ235 monotherapy in patients with metastatic or unresectable malignant PEComa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001884-39,0,0,0 2011-001884-39,4,2013-04-24,2013-04-24,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Novartis Farmaceutica S.A.,A phase II study of orally administered BEZ235 monotherapy in patients with metastatic or unresectable malignant PEComa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001884-39,0,0,0 2011-001888-51,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,Inpharm,"Jednoduse zaslepena klinicka studie ke zhodnoceni ucinnosti a bezpecnosti pripravku MD-Lumbar, MD-Neural a MD-Muscle v porovnani s trimecainem (Mesocainem) v subkutanni aplikaci u pacientu s akutni bo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001888-51,0,0,0 2011-001889-17,1,2011-11-22,2011-11-22,1,0,1,0,0,1,3,0,0,1,0,0,1,0,1,"MediWound, Ltd.",Scar Formation and Quality of Life assessment in subjects (adults & children) following treatment with Debrase compared to Standard of Care (SOC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001889-17,0,0,0 2011-001891-21,9,2012-05-06,2012-05-07,4,0,1,0,0,0,3,0,0,1,1,1,1,0,1,F.Hoffmann-La Roche Ltd,"A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients with Stable Coronary Hear...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001891-21,0,0,0 2011-001892-38,1,2012-02-01,2012-02-01,1,0,0,0,1,0,4,0,0,1,0,0,1,0,1,Panin S.r.l.,"A randomised, controlled, assessor-blind, clinical trial to compare Liceko ® with NIX/Lyclear 1% permethrin crème rinse in the treatment of head lice.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001892-38,0,0,0 2011-001893-24,1,2012-05-12,2012-05-12,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,Bayer HealthCare AG,Relative bioavailability and food effect study of two oral liquid formulations in comparison to a 1mg tablet of riociguat to characterize its pharmacokinetic properties in healthy male and female adul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001893-24,0,0,0 2011-001897-25,12,2014-06-02,2014-07-04,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001897-25,0,0,0 2011-001897-25,12,2014-06-02,2014-07-04,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001897-25,0,0,0 2011-001899-18,1,2013-07-29,2013-07-29,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Patients with Congenital Hemophilia A With Factor VIII Inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001899-18,0,0,0 2011-001900-36,2,2012-09-26,2012-09-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"FFA115285: A randomised, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate inhal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001900-36,0,0,0 2011-001903-10,4,2013-06-04,2013-06-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Orexo AB,"A randomized, double-blind, placebo-controlled, dose finding trial using sublingual alfentanil to alleviate pain associated with a prostate biopsy procedure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001903-10,0,0,0 2011-001913-14,1,2012-03-14,2012-03-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,St Stephen's Aids Trust,A randomized crossover study of the effects of zinc sulphate supplementation on atazanavir/ritonavir-associated hyperbilirubinemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001913-14,0,0,0 2011-001914-33,1,2017-10-30,2017-10-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Leeds,"A phase 1/2a, dose escalation study of CHR-3996 in combination with tosedostat in subjects with relapsed, refractory multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001914-33,0,0,0 2011-001915-29,11,2018-06-20,2018-06-20,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,A Multicenter Controlled Open-Label Extension (OLE) Study To Assess the Long-Term Safety and Efficacy of AMG 145 Estudio de extensión abierto (OLE) controlado y multicéntrico para evaluar la seguri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001915-29,0,0,0 2011-001916-69,1,,,0,0,0,0,0,1,4,0,0,1,1,1,0,1,0,"HagaZiekenhuis, pulmonary department",insulin therapy in non-diabetic adults with cystic fibrosis insuline therapie in cystic fibrosis patienten zonder diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001916-69,0,0,0 2011-001918-34,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Medizinische Universität Graz,"An open, single-centre, controlled trial to investigate the efficacy and usability of published best practice to control glycaemia in hospitalised patients with type 2 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001918-34,0,0,0 2011-001919-31,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Roskilde sygehus,"DALIAH A Danish Study of Low-dose Interferon Alpha Versus Hydroxyurea in the Treatment of Ph-negative Chronic Myeloid Neoplasias - A National Randomized Prospective Study With Focus on Efficacy, Toxi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001919-31,0,0,0 2011-001929-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital 12 de Octubre,"Randomised, open-label, crossover clinical trial to evaluate the antiproteinuric effect of three different types of diuretics (hydrochlorothiazide, amiloride and spironolactone) in patients with chron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001929-24,0,0,0 2011-001935-21,1,2011-12-21,2011-12-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,IPSEN PHARMA SAS,An interventional non-therapeutic study to assess ex vivo basophil activation in response to various preparations of taspoglutide and related items in blood samples from subjects who previously receiv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001935-21,0,0,0 2011-001936-45,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,3,,Pertussis vaccination in pregnancy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001936-45,0,0,0 2011-001938-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Cliniques universitaires Saint-Luc,Randomized Phase II Study of CABAZITAXEL versus METHOTREXATE in patients with recurrent or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based therapy Etu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001938-42,0,0,0 2011-001943-60,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Lars Jørgen Østergaard,Cellular immunity in adult Hepatitis B-vaccinated serologic non-responders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001943-60,0,0,0 2011-001952-12,6,2014-04-10,2014-09-10,5,1,0,0,0,2,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"An open-label study to evaluate the long-term safety, tolerability and efficacy of AFQ056 in adult patients with Fragile X Syndrome Studio in aperto per valutare la sicurezza, la tollerabilita' e ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001952-12,0,0,0 2011-001952-12,6,2014-04-10,2014-09-10,5,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A,"An open-label study to evaluate the long-term safety, tolerability and efficacy of AFQ056 in adult patients with Fragile X Syndrome Studio in aperto per valutare la sicurezza, la tollerabilita' e ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001952-12,0,0,0 2011-001952-12,6,2014-04-10,2014-09-10,5,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An open-label study to evaluate the long-term safety, tolerability and efficacy of AFQ056 in adult patients with Fragile X Syndrome Studio in aperto per valutare la sicurezza, la tollerabilita' e ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001952-12,0,0,0 2011-001953-10,4,2021-03-26,2021-03-26,2,1,1,0,0,1,2,0,0,2,0,0,0,0,1,"bluebird bio, Inc.",A phase 2/3 study of the efficacy and safety of hematopoietic stem cells transduced with Lenti D lentiviral vector for the treatment of cerebral adrenoleukodystrophy (CALD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001953-10,1,1,0 2011-001955-35,1,2014-08-31,2014-08-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Birmingham,"Single Arm Phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) as non-toxic therapy against myeloid and lymphoid cancers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001955-35,0,0,0 2011-001956-12,1,2015-01-19,2015-01-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,3,University Hospital Motol,Monitoring of MxA mRNA Expression as a Marker of Rresponse to Interferon ß Therapy in Patients with Multiple Sclerosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001956-12,0,0,0 2011-001959-37,1,2015-07-14,2015-07-14,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Eisai Limited,"An open label, multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects with Advanced Solid Tumours or with B-cell Malignancies and in Combination...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001959-37,0,0,0 2011-001963-37,1,2017-07-07,2017-07-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Essen,Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell lung cancer (NSCLC) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001963-37,0,0,0 2011-001965-42,9,2018-08-03,2018-08-03,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MYLAN GmbH,"A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP, PHASE III STUDY OF THE EFFICACY AND SAFETY OF HERCULES PLUS TAXANE VERSUS HERCEPTIN® PLUS TAXANE AS FIRST LINE THERAPY IN PATIENTS WITH HER2-PO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001965-42,0,0,0 2011-001976-21,1,2012-06-11,2012-06-11,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur,Safety and Immunogenicity of a Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Adult and Elderly Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001976-21,0,0,0 2011-001977-13,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Northwest Biotherapeutics Inc,"A Phase III clinical trial evaluating DCVax®-L, autologous dendritic cells (DC) pulsed with tumor lysate antigen for the treatment of glioblastoma multiforme (GBM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001977-13,0,0,0 2011-001977-13,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Northwest Biotherapeutics, Inc","A Phase III clinical trial evaluating DCVax®-L, autologous dendritic cells (DC) pulsed with tumor lysate antigen for the treatment of glioblastoma multiforme (GBM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001977-13,0,0,0 2011-001982-42,1,2015-03-30,2015-03-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's & St. Thomas' NHS Foundation Trust,Investigation of a novel intervention in Acute HIV infection (AHI) on long term latent HIV reservoir size: A pilot study of antiretroviral therapy plus immunoglobulin in AHI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001982-42,0,0,0 2011-001985-16,7,2012-09-19,2012-09-20,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Relieving Opioid-Induced Constipation (OIC) in Patients with Cancer-Related Pain.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001985-16,0,0,0 2011-001986-41,6,2012-09-20,2012-09-21,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001986-41,0,0,0 2011-001987-24,2,2012-08-16,2012-08-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001987-24,0,0,0 2011-001988-52,11,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,0,EORTC,Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001988-52,0,0,0 2011-001988-52,11,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001988-52,0,0,0 2011-001988-52,11,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001988-52,0,0,0 2011-001995-20,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA DI PADOVA,A pilot study on educational aproach to improve compliance to medical precriptions in transplantation recipients. Progetto Pilota d'Intervento Educativo per Migliorare l'Aderenza alle Prescrizioni ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001995-20,0,0,0 2011-001998-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Department of Oncology University Hospital Uppsala,An International Randomized Phase II Study Comparing Early Electrochemotherapy to Delayed or No Electrochemotherapy in Patients with Cutaneous Breast Cancer Metastases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-001998-10,0,0,0 2011-002000-32,5,2014-01-13,2014-01-13,3,1,0,0,0,1,4,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A single arm, open-label, multicenter, Phase IV trial to assess long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002000-32,1,0,0 2011-002000-32,5,2014-01-13,2014-01-13,3,1,0,0,0,1,4,0,0,2,0,0,0,0,1,NOVARTIS FARMA,"A single arm, open-label, multicenter, Phase IV trial to assess long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002000-32,1,0,0 2011-002000-32,5,2014-01-13,2014-01-13,3,1,0,0,0,1,4,0,0,2,0,0,0,0,1,Novartis Farmaceutica S. A,"A single arm, open-label, multicenter, Phase IV trial to assess long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002000-32,1,0,0 2011-002001-30,1,2012-06-07,2012-06-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INFECTOPHARM Arzneimittel und Consilium GmbH,"Multicenter, prospective, double-blind, two-armed phase III study for efficacy and safety of the topic impetigo therapy of two 2 % mupirocin ointments Multizentrische, prospektive, doppelblinde, z...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002001-30,0,0,0 2011-002002-70,1,2015-05-06,2015-05-06,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,A RANDOMISED PHASE II TRIAL OF SECOND LINE THERAPY IN ADVANCED BILIARY TRACT CANCER: CAPECITABINE OR CAPECITABINE PLUS MITOMYCIN C (BIT-2) STUDIO RANDOMIZZATO DI FASE II DI CHEMIOTERAPIA DI SECONDA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002002-70,0,0,0 2011-002004-32,2,2013-12-10,2013-12-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects with Mild to Moderate Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002004-32,0,0,0 2011-002007-15,1,2014-11-11,2014-11-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Axelar AB,"Phase II, randomized, open-label study of the IGF-1R inhibitor AXL1717 compared to docetaxel in patients with previously treated, locally advanced, or metastatic squamous cell carcinoma or adenocarcin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002007-15,0,0,0 2011-002008-33,12,2017-08-21,2017-08-21,9,1,1,0,0,1,1,0,0,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002008-33,1,1,0 2011-002008-33,12,2017-08-21,2017-08-21,9,1,1,0,0,1,1,0,0,2,0,0,0,0,1,PFIZER INC.,A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002008-33,1,1,0 2011-002008-33,12,2017-08-21,2017-08-21,9,1,1,0,0,1,1,0,0,2,0,0,0,0,1,"Pfizer, S.L.U.",A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002008-33,1,1,0 2011-002008-33,12,2017-08-21,2017-08-21,9,1,1,0,0,1,1,0,0,2,0,0,0,0,1,Pfizer Inc.,A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002008-33,1,1,0 2011-002009-31,14,2017-11-22,2019-09-27,13,1,0,0,0,0,4,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,A single arm open label multicentre extension study of bevacizumab in patients with solid tumours on study treatment with bevacizumab at the end of a F. Hoffmann-La Roche and/or Genentech sponsored ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002009-31,0,0,0 2011-002009-31,14,2017-11-22,2019-09-27,13,1,0,0,0,0,4,0,0,1,1,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,A single arm open label multicentre extension study of bevacizumab in patients with solid tumours on study treatment with bevacizumab at the end of a F. Hoffmann-La Roche and/or Genentech sponsored ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002009-31,0,0,0 2011-002010-37,1,2019-10-28,2019-10-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Foundation for Liver research,"A Multi-center, Randomized, Open-label study for Induction of HBsAg decline using an add-on treatment of peginterferon alfa-2a in HBeAg-negative chronic hepatitis B patients treated with nucleos(t)ide...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002010-37,0,0,0 2011-002017-11,1,2012-07-16,2012-07-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALK-Abelló S. A.,Estudio abierto para evaluar la tolerabilidad de la inmunoterapia con AVANZ Dermatophagoides mezcla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002017-11,0,0,0 2011-002018-35,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,0,ASSOCIAZIONE ITALIANA PNEUMOLOGI OSPEDALIERI,"SPHERIC-1OE (Sildenafil and Pulmonary HypERtension In COPD – Open Extension) - A multicenter, longitudinal, 12 months open-label study, for the observation of the use of sildenafil in the treatment of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002018-35,0,0,0 2011-002022-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Ramón y Cajal,"Assessment of Therapeutic Response to Benznidazole in patients with Chronic Chagas Disease by Measuring Plasma Parasite Load and the Specific Immune Response against Trypanosoma cruzi. A Randomized, o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002022-41,0,0,0 2011-002024-40,1,2013-02-13,2013-02-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults with Active, Moderate to Severe Rheumatoid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002024-40,0,0,0 2011-002026-52,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC),"Essai de phase III randomisé multicentrique comparant une chimiothérapie adjuvante de 6 mois par gemcitabine versus une association de 5-fluorouracile et acide folinique, irinotécan et oxaliplatine (m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002026-52,0,0,0 2011-002028-41,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,Oxford University Hospitals NHS Trust,A study to determine regional lung function in patients with Non-small cell lung cancer (NSCLC) undegoing radiotherapy using hyperpolarised xenon gas MR imaging,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002028-41,0,0,0 2011-002029-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,MULTICENTER SECOND LINE STUDY OF AXITINIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) PROGRESSED WITH SORAFENIB STUDIO CLINICO MULTICENTRICO DI SECONDA LINEA DI AXITINIB IN PAZIENTI CO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002029-24,0,0,0 2011-002034-38,1,2013-06-03,2013-06-03,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Rgshospitalet,"Analgetisk effekt af perioperativ Escitalopram til patienter med højt præoperativt catastrophising-niveau ved total knæalloplastik: Et randomiseret, dobbeltblindet, placebokontrolleret studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002034-38,0,0,0 2011-002035-26,2,2015-10-26,2015-10-27,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase IIIb observer-blind, randomized, multicentre primary immunization study to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine and Merck's Quadrivalent Hum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002035-26,0,0,0 2011-002038-37,1,2017-08-23,2017-08-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Oxford,Hyperpolarised xenon magnetic resonance imaging (Xe-129 MRI) lung imaging in COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002038-37,0,0,0 2011-002041-36,2,2016-02-10,2016-02-10,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,POLARIS GROUP,"A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002041-36,1,0,0 2011-002041-36,2,2016-02-10,2016-02-10,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Polaris Group,"A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002041-36,1,0,0 2011-002044-28,2,2017-01-20,2017-01-20,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Shire Human Genetics Therapies Inc,"A Phase I/II, Multicenter, Open-label, Dose Escalation Study of HGT-1110 Administered Intrathecally in Children with Metachromatic Leukodystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002044-28,0,0,0 2011-002047-10,8,2014-10-04,2014-10-24,5,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Astellas Pharma Europe B.V.,"An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects with Overactive Bladder (OAB)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002047-10,1,0,0 2011-002047-10,8,2014-10-04,2014-10-24,5,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Astellas Europe Pharma B.V.,"An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects with Overactive Bladder (OAB)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002047-10,1,0,0 2011-002048-29,2,2014-08-27,2014-09-03,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Forest Research Institute, Inc","A randomized, double-blind, placebo-controlled, parallel-group study of cariprazine (RGH-188) in the prevention of relapse in patients with schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002048-29,0,0,0 2011-002052-14,3,2016-02-23,2016-02-23,2,0,0,0,0,1,0,0,0,1,1,0,1,0,0,AZIENDA OSPEDALIERA MEYER,EURO-HIT-HLH European cooperative pilot study for testing Hybrid ImmunoTherapy for Hemophagocytic LymphoHistiocytosis EURO-HIT-HLH Studio cooperativo pilota per la valutazione della terapia i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002052-14,0,0,0 2011-002057-65,1,2011-12-23,2011-12-23,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Galderma R&D SNC,Effect of CD08100/02 3% gel versus placebo in subjects presenting with erythematotelangiectatic rosacea over a 4 week treatment period.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002057-65,0,0,0 2011-002058-30,1,2012-03-23,2012-03-23,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Galderma R&D SNC,Effect of CD08100/02 3% gel versus placebo gel in subjects presenting with papulopustular rosacea over a 6-week treatment period.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002058-30,0,0,0 2011-002060-24,2,2013-02-19,2013-02-19,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,Chiesi Farmaceutici SpA,"A phase II, multinational, multicentre, double blind, double dummy, randomised, cross-over, active - and placebo-controlled clinical study to compare the bronchodilator effect of single administration...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002060-24,1,1,0 2011-002061-38,1,2013-05-01,2013-05-01,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Katholieke Universiteit Leuven,A randomised prospective trough level monitoring study with real-time therapeutic adaptations: Trough level Adapted infliXImab Treatment scheme (TAXIT).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002061-38,0,0,0 2011-002065-37,8,2015-05-28,2015-05-28,5,1,1,0,0,0,3,0,1,1,0,0,1,0,1,Bayer HealthCare AG,"Multi-center, single-arm study to assess the safety, efficacy, discontinuation rate and pharmacokinetics of the low-dose levonorgestrel intrauterine contraceptive system (LCS12) in post-menarcheal fem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002065-37,0,0,0 2011-002066-20,7,2014-01-02,2014-01-02,6,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Phase 3, Double-Blind, Randomized, Multi-center, Placebo-Controlled Sequential Dose Titration Study to Assess Efficacy, Safety and Population Pharmacokinetics of Solifenacin Succinate Suspension in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002066-20,0,0,0 2011-002066-20,7,2014-01-02,2014-01-02,6,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Europe Pharma B.V.,"A Phase 3, Double-Blind, Randomized, Multi-center, Placebo-Controlled Sequential Dose Titration Study to Assess Efficacy, Safety and Population Pharmacokinetics of Solifenacin Succinate Suspension in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002066-20,0,0,0 2011-002067-20,12,2016-01-13,2016-01-13,10,1,0,0,1,0,4,0,0,1,1,0,1,0,1,UCB Pharma SA,"A multicenter, single blind, randomized parallel group study to assess the short and long term efficacy of certolizumab pegol plus methotrexate compared with adalimumab plus methotrexate in subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002067-20,0,0,0 2011-002067-20,12,2016-01-13,2016-01-13,10,1,0,0,1,0,4,0,0,1,1,0,1,0,1,UCB PHARMA SA/NV.,"A multicenter, single blind, randomized parallel group study to assess the short and long term efficacy of certolizumab pegol plus methotrexate compared with adalimumab plus methotrexate in subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002067-20,0,0,0 2011-002068-26,2,2015-10-27,2015-10-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Subjects with Generalized Myasthenia Gravis (MG) Studio ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002068-26,0,0,0 2011-002068-26,2,2015-10-27,2015-10-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Subjects with Generalized Myasthenia Gravis (MG) Studio ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002068-26,0,0,0 2011-002069-39,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Clínic per a la Recerca Biomèdica,Comparación de dos combinaciones de antirretrovirales en la Profilaxis Post-Exposición al VIH-1: TDF-FTC (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs TDF-FTC (Truvada ®) + Maraviroc (Celsentri ®)....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002069-39,0,0,0 2011-002070-23,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Maastricht University Medical Center,Effects of roflumilast on cognition in healthy adults: a behaviour-EEG study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002070-23,0,0,0 2011-002071-42,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Clínic de Recerca Biomèdica,"Effects of losartan and antiretroviral regimen containing raltegravir in fibrosis inflammation mediators, cardiovascular risk and neurocognitive disorders in HIV infected patients previously effect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002071-42,0,0,0 2011-002073-30,3,2012-09-14,2012-09-14,2,1,0,0,2,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"12-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Park...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002073-30,0,0,0 2011-002073-30,3,2012-09-14,2012-09-14,2,1,0,0,2,0,2,0,0,1,0,0,1,0,1,"Novartis Farmaceutica, S.A.","12-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Park...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002073-30,0,0,0 2011-002073-30,3,2012-09-14,2012-09-14,2,1,0,0,2,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"12-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Park...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002073-30,0,0,0 2011-002074-23,6,2013-04-24,2013-04-24,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe Ldopa induced dyskinesias in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002074-23,0,0,0 2011-002074-23,6,2013-04-24,2013-04-24,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe Ldopa induced dyskinesias in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002074-23,0,0,0 2011-002074-23,6,2013-04-24,2013-04-24,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","13-week, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of modified release AFQ056 in reducing moderate to severe Ldopa induced dyskinesias in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002074-23,0,0,0 2011-002076-16,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"Clinical Otitis Media and Pneumonia Study (COMPAS): a phase III , double-blind, randomized, controlled, multicentre study to demonstrate the efficacy of GlaxoSmithKline (GSK) Biologicals’ 10-valent pn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002076-16,0,1,1 2011-002077-35,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, open, controlled study in South Africa to assess the immunogenicity, safety and reactogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine administered as a 3-dose (6, 10...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002077-35,0,1,1 2011-002080-21,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE),Open-label phase 2 study of dacarbazine in patients with metastatic colorectal carcinoma based on expression of O6-methylguanine-DNA-methyltransferase (MGMT) Studio aperto di fase II sull'attivita...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002080-21,0,0,0 2011-002081-20,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CENTRE HOSPITALIER UNIVERSITAIRE DE LILLE,A Multicenter Open label Phase II study of Pomalidomide and Dexamethasone in Progressive Relapsed or Refractory Multiple Myeloma patients with deletion 17p or translocation (4;14) Adverse Karyotypic A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002081-20,0,0,0 2011-002082-38,1,2013-09-01,2013-09-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Birmingham,A study of the effects of Simvastatin on neutrophil function in elderly subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002082-38,0,0,0 2011-002083-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,BG University Hospital Bergmannsheil GmbH,Is there a correlation between the pain relief and the A-delta- and C-fiber function after topical application of lidocaine (5%) in patients with peripheral neuropathic pain? Korreliert die Schmerz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002083-25,0,0,0 2011-002084-20,1,,,0,1,0,0,0,0,4,0,1,1,1,1,0,1,0,Medizinische Universität Wien; Universitätsklinik für Klinische Pharmakologie,"A prospective, randomized, controlled open-label trial to investigate the effects of 10mg rivaroxaban or 110mg dabigatran on microparticle formation in critically ill patients compared to age-& sex-ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002084-20,0,0,0 2011-002087-24,1,2015-10-30,2015-10-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Hellenic Oncology Research Group (HORG),A phase II study of Temsirolimus in patients with advanced hormone - and chemotherapy - resistant prostate cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002087-24,0,0,0 2011-002090-36,8,2012-12-17,2012-12-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis Recherche et Développement,"A randomized, 24-week, open-label, 2-arm parallel-group, multicenter study comparing the efficacy and safety of insulin glargine/lixisenatide fixed ratio combination versus insulin glargine on top of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002090-36,0,0,0 2011-002092-42,4,2013-01-18,2013-01-18,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Grünenthal GmbH,"Evaluation of the efficacy, tolerability, and safety of 7 days of treatment with GRT6010 or pregabalin in comparison to placebo in subjects with peripheral neuropathic pain.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002092-42,0,0,0 2011-002093-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Tartu,Bioavailability of oral N-acetylcysteine in different intensive care unit patient groups Suukaudselt manustatud N-atsetüültsüsteiini biosaadavus erineva hospitaliseerimis-näidustusega intensiivravi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002093-23,0,0,0 2011-002095-17,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Anna Suy Franch,Sulfato de magnesio en pauta continua versus discontinua en la conducta expectante de la preeclampsia grave: ensayo clínico aleatorizado,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002095-17,0,0,0 2011-002096-42,1,2013-12-17,2013-12-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LETI Pharma GmbH,Biological Standardization of Ambrosia elatior Allergen Extract Determination of the Biological Activity in HEP units. An Open Monocenter Study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002096-42,0,0,0 2011-002099-18,1,2016-01-29,2016-01-29,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Vejle Hospital,Veliparib (ABT888) Monotherapy for Patients with BRCA germline mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002099-18,0,0,0 2011-002101-29,2,2012-01-26,2012-01-26,2,0,0,0,1,0,2,0,0,1,1,1,1,0,1,Nycomed GmbH,"A randomised, double-blind, 4-weeks cross-over trial to investigate the effect of 500 µg roflumilast tablets once-daily versus placebo on pulmonary function, asthma symptoms and inflammatory markers i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002101-29,0,0,0 2011-002102-73,1,2013-11-05,2013-11-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Endokrinologisk afd. M,Testosterone therapy of patients with type 2 diabetes mellitus Testosterone therapy of patients with type 2 diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002102-73,0,0,0 2011-002103-15,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,RIVM,Development of humoral and cellular immune response in infants after pneumococcal conjugate vaccinations with Synflorix® or Prevenar-13®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002103-15,0,0,0 2011-002104-32,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Novo Nordisk A/S,"A trial investigating the pharmacokinetic properties of FIAsp in children, adolescents and adults with type 1 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002104-32,0,0,0 2011-002107-15,5,2015-12-19,2016-04-19,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Kirby Institute, University of New South Wa","A randomised, open label study to evaluate the efficacy and safety of maraviroc(MVC) as a switch for N(t)RTI or PI/r in HIV1 infected individuals with stable, well controlled plasma HIV RNA while taki...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002107-15,0,0,0 2011-002107-15,5,2015-12-19,2016-04-19,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of New South Wales,"A randomised, open label study to evaluate the efficacy and safety of maraviroc(MVC) as a switch for N(t)RTI or PI/r in HIV1 infected individuals with stable, well controlled plasma HIV RNA while taki...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002107-15,0,0,0 2011-002112-84,3,2013-08-28,2013-08-28,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled, parallel group, proof of concept study evaluating the efficacy,safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002112-84,0,0,0 2011-002114-36,10,2018-08-10,2018-08-10,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,Open-Label Access Protocol of Denosumab for Subjects with Advanced Cancer. Protocollo con accesso `œin aperto` su denosumab nei pazienti con carcinoma in stadio avanzato.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002114-36,0,0,0 2011-002114-36,10,2018-08-10,2018-08-10,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN INC.,Open-Label Access Protocol of Denosumab for Subjects with Advanced Cancer. Protocollo con accesso `œin aperto` su denosumab nei pazienti con carcinoma in stadio avanzato.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002114-36,0,0,0 2011-002119-27,7,2013-09-10,2013-09-10,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cubist Pharmaceuticals, Inc.","A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF INTRAVENOUS CXA-201 WITH THAT OF MEROPENEM IN COMPLICATED INTRAABDOMINAL INFECTIONS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002119-27,0,0,0 2011-002120-41,7,2013-10-14,2013-10-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cubist Pharmaceuticals, Inc.","A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF INTRAVENOUS CXA-201 WITH THAT OF MEROPENEM IN COMPLICATED INTRAABDOMINAL INFECTIONS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002120-41,0,0,0 2011-002122-43,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,ISTITUTO CLINICO HUMANITAS,Iron therapy in IBD patients with normal levels of haemoglobin and chronic fatigue Effetti della terapia marziale in pazienti con fatica cronica e IBD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002122-43,0,0,0 2011-002128-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Accumulation of Nadroparin Used in Renal Insufficiency Assessed by anti-Xa levels,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002128-41,0,0,0 2011-002130-40,5,2013-01-04,2013-01-11,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Durata Therapeutics, Inc","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO COMPARE THE EFFICACY AND SAFETY OF DALBAVANCIN TO A COMPARATOR REGIMEN (VANCOMYCIN AND LINEZOLID) FOR THE TREATMENT OF ACUTE BACTERIAL SKIN A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002130-40,0,0,0 2011-002132-10,4,2019-11-14,2019-11-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomized, two-arm, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first line patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002132-10,0,0,0 2011-002132-10,4,2019-11-14,2019-11-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"A randomized, two-arm, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first line patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002132-10,0,0,0 2011-002133-20,2,2012-09-30,2012-09-30,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen Alzheimer Immunotherapy,"A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Alzheimer's Disease Who Participated in Study EL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002133-20,0,0,0 2011-002135-26,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,AESCULAPIUS FARMACEUTICI S.R.L.,"Efficacy and Safety of Acyclovir 5 Lipstick (Contra) in Treatment of Skin Infections Provoked by Herpes Simplex. A Randomised, Double-blind, Placebo Controlled, Parallel Group Study. Efficacia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002135-26,0,0,0 2011-002140-27,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, open study in children previously enrolled in study 10PN-PD-DIT-037 (111188) to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002140-27,0,1,1 2011-002142-13,13,2016-10-11,2016-10-11,12,1,1,0,0,0,0,0,0,2,0,0,0,0,1,Merck Sharp & Dohme Corp,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002142-13,1,1,0 2011-002142-13,13,2016-10-11,2016-10-11,12,1,1,0,0,0,0,0,0,2,0,0,0,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation","A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002142-13,1,1,0 2011-002142-13,13,2016-10-11,2016-10-11,12,1,1,0,0,0,0,0,0,2,0,0,0,0,1,Merck Sharp & Dohme Corp.,"A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002142-13,1,1,0 2011-002142-13,13,2016-10-11,2016-10-11,12,1,1,0,0,0,0,0,0,2,0,0,0,0,1,"SCHERING PLOUGH RESEARCH INSTITUTE, A DIVISION OF SCHERING CORPORATION","A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002142-13,1,1,0 2011-002143-95,4,2012-12-13,2013-01-31,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-blind, Placebo- and Active-Controlled Study Comparing the Safety and Analgesic Efficacy of ABT-110 to Placebo in Subjects with Chronic Low Back Pain Sperimentazi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002143-95,0,0,0 2011-002143-95,4,2012-12-13,2013-01-31,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,ABBOTT GMBH & Co. KG,"A Multicenter, Randomized, Double-blind, Placebo- and Active-Controlled Study Comparing the Safety and Analgesic Efficacy of ABT-110 to Placebo in Subjects with Chronic Low Back Pain Sperimentazi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002143-95,0,0,0 2011-002143-95,4,2012-12-13,2013-01-31,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Abbott GmbH & Co. KG,"A Multicenter, Randomized, Double-blind, Placebo- and Active-Controlled Study Comparing the Safety and Analgesic Efficacy of ABT-110 to Placebo in Subjects with Chronic Low Back Pain Sperimentazi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002143-95,0,0,0 2011-002144-27,4,2012-12-13,2013-01-31,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Study Comparing the Safety and Analgesic Efficacy of ABT-110 to Placebo in Subjects with Pain from Osteoarthritis of the Knee ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002144-27,0,0,0 2011-002144-27,4,2012-12-13,2013-01-31,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,ABBOTT GMBH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Study Comparing the Safety and Analgesic Efficacy of ABT-110 to Placebo in Subjects with Pain from Osteoarthritis of the Knee ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002144-27,0,0,0 2011-002144-27,4,2012-12-13,2013-01-31,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Abbott GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Study Comparing the Safety and Analgesic Efficacy of ABT-110 to Placebo in Subjects with Pain from Osteoarthritis of the Knee ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002144-27,0,0,0 2011-002145-35,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Aktion Bronchialkarzinom (ABC) e.V.,SELECT-A: TS stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002145-35,0,0,0 2011-002147-10,1,,,0,0,0,0,0,0,4,0,1,1,1,1,0,1,0,Institute for Biomedical Aging Research,Influenza vaccination in old age: Immunological and biogerontological characterization of responders and non-responders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002147-10,0,0,0 2011-002149-36,1,2013-08-19,2013-08-19,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"GenSpera, Inc.","An Open-Label, Single-Arm, Phase 2 Study of G-202 in Patients with Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002149-36,0,0,0 2011-002150-31,2,2021-05-20,2021-05-20,2,1,1,0,0,0,1,0,0,1,1,1,1,0,1,Amgen Inc,"An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Darbepoetin alfa in Paediatric Subjects From Birth to Less than 1 Year of Age With Anem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002150-31,0,0,0 2011-002154-32,1,2013-01-04,2013-01-04,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Amicus Therapeutics, Inc.","AN OPEN-LABEL MULTI-CENTER, INTERNATIONAL STUDY TO INVESTIGATE DRUG-DRUG INTERACTIONS BETWEEN AT2220 AND ALGLUCOSIDASE ALFA IN PATIENTS WITH POMPE DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002154-32,0,0,0 2011-002157-64,1,2017-04-30,2017-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Common Services Agency,ARomatase Inhibition plus minus SaracaTinib as Advanced breast CAncer Therapy: a randomised phase II study of aromatase inhibition plus/minus the src-inhibitor AZD0530 in post-menopausal women with ad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002157-64,0,0,0 2011-002158-30,1,2011-08-24,2011-08-24,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Omninvest Ltd.,"Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/strain/0.5 mL) in Adults and Elderly Persons",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002158-30,0,0,0 2011-002159-32,7,2015-10-08,2015-12-28,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,BIOGEN IDEC LTD,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis Studio multicentrico, randomizzato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002159-32,0,0,0 2011-002159-32,7,2015-10-08,2015-12-28,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Biogen Idec Research Limited,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis Studio multicentrico, randomizzato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002159-32,0,0,0 2011-002160-24,3,2014-06-04,2014-06-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in Patients with Major Depr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002160-24,0,0,0 2011-002162-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,José Esteban Castelao Fernández,"A phase II randomized, prospective, multicenter, placebo-controlled clinical trial to evaluate the chemopreventive effect of vitamin D in women at high risk of breast cancer. Ensayo clínico en fase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002162-21,0,0,0 2011-002166-20,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Clinic per a la Recerca Biomèdica,Treatment of hepatorenal syndrome with terlipressin infusion adjusted to hemodynamic response TrAtaMiEnto deL sIndrOme hepatoRrenAl con TErlipresina en infusión ajustada a la respuesta hemodinámica...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002166-20,0,0,0 2011-002167-23,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,Institut Paoli-Calmettes,"A phase Ib/II open-label study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2+/PI3K-activated, trastuzumab-resistant locally advanced, recurrent and metastatic bre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002167-23,0,0,0 2011-002168-26,2,2015-01-30,2015-01-30,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Roche (Magyarország) Kft.,OPEN LABEL STUDY OF ERLOTINIB (TARCEVA®) AS SINGLE AGENT FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC LUNG ADENOCARCINOMA WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002168-26,0,0,0 2011-002169-39,8,2019-05-15,2019-05-20,8,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002169-39,0,0,0 2011-002169-39,8,2019-05-15,2019-05-20,8,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002169-39,0,0,0 2011-002172-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Pharma Mar S.A. Sociedad Unipersonal,A phase II Controlled Study of PM01183 in Platinum-Resistant / Refractory Advanced Ovarian Cancer Patients. Estudio controlado de fase II de PM01183 en pacientes con cáncer de ovario avanzado resis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002172-16,0,0,0 2011-002173-33,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Fundació Privada EUGIN,Impact of clomiphene citrate administration during the early luteal phase on endocrine profile in agonist triggered GnRH antagonist in vitro fertilization cycles Impacto de la administración de cit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002173-33,0,0,0 2011-002174-23,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Lofarma S.p.A.,A dose Finding Study of the Efficacy of LAIS Grass tablets in patients suffering from grass pollen-induced allergic rhinoconjunctivitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002174-23,0,0,0 2011-002175-42,1,2012-11-28,2012-11-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Paracelsus Medizinische Universität - Universitätsklinik für Anästhesie,The effect and safety of dexmedetomidine as an additive to ropivacaine for interscalene brachial plexus blocks for shoulder surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002175-42,0,0,0 2011-002177-34,1,2014-09-12,2014-09-12,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU de Toulouse,Population pharmacokinetics of levofloxacin in intensive care patients with severe community-acquired pneumonia Pharmacocinétique de population de la lévofloxacine chez des patients de réanimation ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002177-34,0,0,0 2011-002178-22,4,2013-09-26,2013-09-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Avanir Pharmaceuticals, Inc.","A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002178-22,0,0,0 2011-002181-20,1,2012-01-31,2012-01-31,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Oslo University Hospital,Naltrexone Implants for Alcoholism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002181-20,0,0,0 2011-002184-17,6,2014-01-02,2014-01-02,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"A two part, double-blind, randomized, placebo-controlled and open-label study to investigate the efficacy, safety and tolerability of eltrombopag, a thrombopoietin receptor agonist, in pediatric pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002184-17,0,0,0 2011-002184-17,6,2014-01-02,2014-01-02,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Glaxosmithkline Research and Development Ltd,"A two part, double-blind, randomized, placebo-controlled and open-label study to investigate the efficacy, safety and tolerability of eltrombopag, a thrombopoietin receptor agonist, in pediatric pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002184-17,0,0,0 2011-002184-17,6,2014-01-02,2014-01-02,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Glaxosmithkline, S.A.","A two part, double-blind, randomized, placebo-controlled and open-label study to investigate the efficacy, safety and tolerability of eltrombopag, a thrombopoietin receptor agonist, in pediatric pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002184-17,0,0,0 2011-002185-21,1,2014-10-20,2014-10-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Research and Development Nottingham University Hospital,"An open label study to determine the efficacy of ferric carboxymaltose in preoperative colorectal cancer related anaemia, and to develop biomarkers to predict response to this treatment strategy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002185-21,0,0,0 2011-002187-24,1,2012-09-13,2012-09-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomized, Double-Blind, Placebo-Controlled 12-Week Extension Study to Assess the Safety and Tolerability of NKTR-118 in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002187-24,0,0,0 2011-002188-58,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,1,PROMEFARM,Low volume PEG-CS in combination with bisacodyl in high risk patients for inadequate bowel preparation Volumi ridotti di una soluzione a base di PEG-CS in associazione a bisacodile in pazienti ad a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002188-58,0,0,0 2011-002190-33,7,2014-03-27,2014-03-27,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA","A PHASE II TRIAL OF PF-04856884 (CVX-060), A SELECTIVE ANGIOPOIETIN 2 (ANG-2) INHIBITOR IN COMBINATION WITH AG-013736 (AXITINIB) IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC RENAL CELL CARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002190-33,0,0,0 2011-002190-33,7,2014-03-27,2014-03-27,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,PFIZER INC.,"A PHASE II TRIAL OF PF-04856884 (CVX-060), A SELECTIVE ANGIOPOIETIN 2 (ANG-2) INHIBITOR IN COMBINATION WITH AG-013736 (AXITINIB) IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC RENAL CELL CARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002190-33,0,0,0 2011-002190-33,7,2014-03-27,2014-03-27,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"PFIZER, S.L.U.","A PHASE II TRIAL OF PF-04856884 (CVX-060), A SELECTIVE ANGIOPOIETIN 2 (ANG-2) INHIBITOR IN COMBINATION WITH AG-013736 (AXITINIB) IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC RENAL CELL CARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002190-33,0,0,0 2011-002191-16,1,2017-08-31,2017-08-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klink f. Innere Medizin I",A Phase II pilot study to assess efficacy and safety of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients with ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002191-16,0,0,0 2011-002192-41,1,2016-08-17,2016-08-17,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Hospital Tübingen,"Multicenter phase II study of peritransplantation immunosuppression using ATG, rituximab, sirolimus and mycophenolate mofetil in patient receiving mismatched hematopoietic cell transplantation after r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002192-41,0,0,0 2011-002193-23,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),Long term Immunogenicity of Quadrivalent Human Papillomavirus vaccine (Gardasil) in HIV-infected adolescents and young adults vs. healthy adolescents and young adults: non-randomized controlled clinic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002193-23,0,0,0 2011-002195-16,1,2015-05-19,2015-05-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"MUW, Klinik für Mund-, Kiefer-und Gesichtschirurgie",NEOADJUVANTE RADIOTHERAPIE MIT CETUXIMAB BEI PATIENT/INNEN MIT FORTGESCHRITTENEN TUMOREN DER KOPF-HALSREGION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002195-16,0,0,0 2011-002198-44,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Cerexa, Inc. (subsidary of Forest Laboratories)",Pharmacokinetics of a Single Dose of Ceftaroline fosamil in Children Ages Birth to Younger Than 12 Years With Suspected or Confirmed Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002198-44,0,1,1 2011-002202-70,1,2013-07-04,2013-07-04,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsklinikum Schleswig-Holstein (UK-SH),"A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002202-70,0,0,0 2011-002203-15,3,2017-10-02,2017-10-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"NTNU, Norwegian University of Science and Technology",Metformin treatment of pregnant PCOS women and prevention of late miscarriages and preterm birth The PregMet 2 Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002203-15,0,0,0 2011-002207-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO,A prospective study with beta-blockers and ACE-inhibitors in patients operable breast cancer experiencing mild cardiac toxicity during treatment with anthracycline and/or trastuzumab Studio prospe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002207-15,0,0,0 2011-002211-28,1,2020-03-25,2020-03-25,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,VU medical center,Perioperative selective decontamination of the digestive tract (SDD) in elective colorectal cancer patients: a multicenter randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002211-28,0,0,0 2011-002212-81,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,"Klinik für Physikalische Medizin und Rehabilitation, Medizinische Universität Wien",Efficacy of Lidocaine medicated plaster in patients with CRPS: a pilot-study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002212-81,0,0,0 2011-002213-12,1,,,0,1,0,0,1,0,4,0,0,4,0,0,0,0,0,CHU de Limoges,Paracetamol and setrons : drug interactions in the management of pain after tonsillectomy in children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002213-12,0,0,0 2011-002219-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,Effect of pharmacological prophylaxis with low molecular weight heparin on implantation in women undergoing assisted reproductive procedures to prevent implant failure: a prospective randomized study....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002219-28,0,0,0 2011-002221-21,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Shire Development Inc,"A Phase 3, Double-blind, Randomized, Multi-center, Placebo controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once daily Dosing with Extended-release Guanfacine H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002221-21,0,1,1 2011-002222-46,1,2013-10-31,2013-10-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,In vivo effects of C1-esterase inhibitor on innate immune response during endotoxemia in human - VECTOR-II study A randomized controlled pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002222-46,0,0,0 2011-002224-40,9,2016-01-28,2016-01-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Genentech, Inc.","A randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MetMAb in Combination with Tarceva(erlotinib) in Patients with Met Diagnostic-Posit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002224-40,0,0,0 2011-002224-40,9,2016-01-28,2016-01-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GENENTECH , INC","A randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MetMAb in Combination with Tarceva(erlotinib) in Patients with Met Diagnostic-Posit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002224-40,0,0,0 2011-002225-22,1,,,0,1,0,1,0,0,1,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase I, randomized, controlled, double-blind study to assess safety, reactogenicity and immunogenicity of GSK Biologicals’ pneumococcal vaccine 2830930A when administered as a single dose in health...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002225-22,0,0,0 2011-002228-42,1,2016-04-15,2016-04-15,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation de l'efficacité de RAD001 sur la croissance des schwannomes vestibulaires chez des patients souffrant de neurofibromatose de type 2.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002228-42,0,0,0 2011-002229-23,1,2013-10-30,2013-10-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,RB Pharmaceuticals Inc.,"A randomised, double blind, placebo controlled, cross over study of the effects of Buprenorphine Hemiadipate Hydrochloride/Naloxone Hydrochloride Dihydrate intravenous challenges in opioid dependent s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002229-23,0,0,0 2011-002231-26,4,2013-08-12,2013-08-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study with a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg once daily...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002231-26,0,0,0 2011-002233-19,1,2015-07-01,2015-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Karolinska Institute,Antiplatelet effects of once versus twice daily dosing of aspirin after coronary artery bypass grafting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002233-19,0,0,0 2011-002234-39,10,2014-01-24,2014-01-24,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral rivaroxaban (BAY 59-7939) compared with that of dose-ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002234-39,0,0,0 2011-002234-39,10,2014-01-24,2014-01-24,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER HEALTHCARE AG,"A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral rivaroxaban (BAY 59-7939) compared with that of dose-ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002234-39,0,0,0 2011-002235-26,11,2013-12-09,2013-12-31,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Purdue Pharma L.P.,"An Open-label, Extension Study to Assess the Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children Who Completed the OTR3001 Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002235-26,0,0,0 2011-002236-92,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Maatschap cardiologie Isala klinieken Zwolle,"Dopamine on top of standard treatment for patients with exacerbation of Heart Failure, at home situation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002236-92,0,0,0 2011-002243-98,1,2021-04-08,2021-04-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Nephrology, OUH, Odense, DK",The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity Effekten af spironolakton på calcineurinhæmmer inducerede nefrotoksitet.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002243-98,0,0,0 2011-002248-29,2,2015-05-21,2015-05-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergopharma Joachim Ganzer KG,A multicentre randomised placebo-controlled double-blind clinical trial for evaluation of the optimal dose for safety and efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed Allerg...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002248-29,0,0,0 2011-002254-31,2,2013-06-06,2013-06-06,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Rigshospitalet, ITA 4131, Department of Intensive care","Double-blinded, randomized trial in severe pneumonia patients with severe sepsis investigating the safety and efficacy of co-administration of iloprost and ascending doses of eptifibatide compared to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002254-31,0,0,0 2011-002257-61,4,2017-01-03,2017-01-03,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Amgen Research (Munich) GmbH,"An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002257-61,0,0,0 2011-002257-61,4,2017-01-03,2017-01-03,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,MICROMET AG,"An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002257-61,0,0,0 2011-002257-61,4,2017-01-03,2017-01-03,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Micromet AG,"An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002257-61,0,0,0 2011-002258-30,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ALMIRALL PRODESFARMA,NEUROPHYSIOLOGIC STUDY AIMED AT EVALUATING ON EFFECT OF SATIVEX® ON SPASTICITY IN PROGRESSIVE MULTIPLE SCLEROSIS studio neurofisiologico per valutare l'effetto del sativex sulla spasticita' in scl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002258-30,0,0,0 2011-002259-32,4,2013-06-14,2013-06-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Anergis SA,"A multicentre, double-blind, placebo-controlled, randomized trial to assess the efficacy and tolerability of two dosing regimens of AllerT, a combination of contiguous overlapping peptides derived fro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002259-32,0,0,0 2011-002261-38,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude de la dose-réponse au bronchodilatateur puis recherche de dose du bronchodilatateur par la technique de l'interruption du débit chez l'enfant siffleur âgé de 2,5 à 6 ans - Etude DORESI.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002261-38,0,0,0 2011-002264-25,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Medizinische Universität Wien,Univ.Klinik f.Anästhesie,Allgemeine Intensivmedizin u.Schmerztherapie",Vergleich von topischer Lokalanästhesie gegenüber Kühlung zur Reduktion des Applikationsschmerzes bei topischer Exposition mit Capsaicin 8%,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002264-25,0,0,0 2011-002267-26,1,2017-02-01,2017-02-01,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Medizinische Universität Wien,"Hepatitis C in renal transplant recipients – Safety and efficacy of a conversion of immunosuppression to high-dose cyclosporine A and its impact on HCV-replication, parameters of liver function and gl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002267-26,0,0,0 2011-002268-26,1,2016-12-12,2016-12-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"University Health Network, Toronto General Hospital",Valacyclovir in Delaying Antiretroviral Treatment Entry (VALIDATE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002268-26,0,0,0 2011-002271-42,1,2014-07-14,2014-07-14,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Medical Center Goettingen,Sofortige versus bedarfsangepasste Antibiotikatherapie beim unkomplizierten Harnwegsinfekt – eine vergleichende Effektivitätsstudie in hausärztlichen Praxen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002271-42,0,0,0 2011-002273-29,5,2012-10-24,2012-10-25,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3b, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of Ranolazine in Subjects with Chronic Stable Angina and Coronary Artery Disease with a History of Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002273-29,0,0,0 2011-002275-41,2,2013-01-18,2013-01-18,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Multicenter, Randomized, Single-Blind Crossover Study of the Safety and Tolerability of Two Adalimumab Formulations in Adult Subjects with Rheumatoid Arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002275-41,0,0,0 2011-002276-16,3,2013-03-05,2013-03-05,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A randomised, double-blind, double dummy study investigating the efficacy and safety of Linagliptin co-administered with metformin QD at evening time versus metformin bid over 14 weeks in treament nai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002276-16,0,0,0 2011-002276-16,3,2013-03-05,2013-03-05,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A randomised, double-blind, double dummy study investigating the efficacy and safety of Linagliptin co-administered with metformin QD at evening time versus metformin bid over 14 weeks in treament nai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002276-16,0,0,0 2011-002276-16,3,2013-03-05,2013-03-05,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, double dummy study investigating the efficacy and safety of Linagliptin co-administered with metformin QD at evening time versus metformin bid over 14 weeks in treament nai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002276-16,0,0,0 2011-002277-38,5,2013-04-04,2013-08-04,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-Abelló A/S,A one-year trial evaluating the efficacy and safety of the ALK house dust mite allergy immunotherapy tablet in adult subjects with house dust mite allergic rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002277-38,0,0,0 2011-002279-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Med Uni Graz, Abt. für NEURO- u. GESICHTSCHIRURGISCHE ANÄSTHESIE u. INTENSIVMEDIZIN",Comparative study of the hypnosedative management during video sleep endoscopy in patients with obstructive sleep apnoe syndrome Vergleichende Untersuchung für hypnosedatives Management im Rahmen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002279-40,0,0,0 2011-002281-20,1,,,0,0,0,0,0,0,3,0,1,1,1,1,0,1,0,Niels Jørgen Secher,Modning af de cervikale forhold med Misoprostol. En prospektiv randomiseret dobbelt-blindet undersøgelse ved igangsættelse efter terminen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002281-20,0,0,0 2011-002284-14,1,2012-03-26,2012-03-26,1,0,0,0,0,0,4,0,1,1,0,0,1,0,1,Schur Pharmazeutika GmbH & Co. KG,"Subacute local tolerance of an ointment containing 0.5% neomycin sulfate (Myacyne Salbe) Subakute lokale Verträglichkeit einer Neomycinsulfat 0,5% Salbe (Myacyne Salbe)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002284-14,0,0,0 2011-002285-21,5,2013-06-07,2013-06-07,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,Evaluation of the long term safety of the use of dabigatran etexilate in patients with a bileaflet mechanical heart valve,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002285-21,0,0,0 2011-002285-21,5,2013-06-07,2013-06-07,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co.KG,Evaluation of the long term safety of the use of dabigatran etexilate in patients with a bileaflet mechanical heart valve,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002285-21,0,0,0 2011-002285-21,5,2013-06-07,2013-06-07,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm.V,Evaluation of the long term safety of the use of dabigatran etexilate in patients with a bileaflet mechanical heart valve,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002285-21,0,0,0 2011-002285-21,5,2013-06-07,2013-06-07,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim bv,Evaluation of the long term safety of the use of dabigatran etexilate in patients with a bileaflet mechanical heart valve,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002285-21,0,0,0 2011-002285-21,5,2013-06-07,2013-06-07,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Ltd,Evaluation of the long term safety of the use of dabigatran etexilate in patients with a bileaflet mechanical heart valve,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002285-21,0,0,0 2011-002287-24,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,0,Erasmus MC,"Massive blood loss in children during multiple trauma or major surgery: Fibrinogen therapy for massive blood loss during elective surgery for craniosynostosis repair, a double blinded randomized contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002287-24,0,0,0 2011-002288-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,New frontiers in breast imaging: contrast enhanced digital mammography. - Clinical performance of contrast-enhanced spectral mammography (CESM - SenoBright) in pre-surgical evaluation of extent of m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002288-29,0,0,0 2011-002290-36,1,2012-09-30,2012-09-30,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,"Multidisciplinary Pain Center 7612, Rigshospitalet",Hyperbaric Oxygen effect on inflammation by a heat injury model in healthy male volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002290-36,0,0,0 2011-002292-41,1,2012-09-18,2012-09-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Phase 3, Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of LY2140023 Monohydrate in Patients with DSM-IV-TR Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002292-41,0,0,0 2011-002294-29,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación para la Investigación Biomédica del Hospital Gregorio Marañon,STUDY OF PULMONARY AND SYSTEMIC INFLAMMATORY RESPONSE SECONDARY TO PULMONARY RESECTION SURGERY USING INTRAVENOUS ANESTHESIA VERSUS INHALATION ANESTHESIA WITH HALOGENATED AGENTS ESTUDIO DE LA RESPU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002294-29,0,0,0 2011-002296-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ROXALL Medizin GmbH,"Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from birch pollen allergy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002296-42,0,0,0 2011-002301-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ROXALL Medicina España S.A.,"PHASE II STUDY TO ASSESS THE TOLERABILITY, SAFETY AND EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN PATIENTS SUFFERING FROM GRASS POLLEN ALLERGY Estudio de fase II para evaluar la tolerabilidad, segurida...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002301-29,0,0,0 2011-002307-14,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Groupe Est Ouest des Leucémies et Autres Maladies du Sang,"ICLL01 BOMP Study Phase II salvage treatment with Bendamustine, Ofatumumab and MethylPrednisolone (BOMP) in relapsed B-cell chronic lymphocytic leukemia (B-CLL).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002307-14,0,0,0 2011-002313-11,6,2013-02-26,2013-02-26,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients with Autoimmune Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002313-11,0,0,0 2011-002313-11,6,2013-02-26,2013-02-26,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients with Autoimmune Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002313-11,0,0,0 2011-002317-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ROXALL Medizin GmbH,"Phase II study to assess the tolerability, safety and efficacy of subcutaneous cluster-immunotherapy in patients suffering from house dust mite allergy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002317-10,0,0,0 2011-002319-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ROXALL Medizin GmbH,"Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from birch pollen allergy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002319-27,0,0,0 2011-002321-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Roxall Medicina España S.A.,"PHASE II STUDY TO ASSESS THE TOLERABILITY, SAFETY AND EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN PATIENTS SUFFERING FROM HOUSE DUST MITE ALLERGY Estudio de fase II para evaluar la tolerabilidad, segur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002321-22,0,0,0 2011-002325-22,5,2013-12-09,2013-12-15,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Eli Lilly & Company,"A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients with Active Ankylosin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002325-22,1,0,0 2011-002326-49,7,2017-09-22,2017-09-22,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly & Company,"A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Ant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002326-49,0,0,0 2011-002328-42,5,2019-06-26,2019-06-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Protocol I1F-MC-RHBE A Multicenter, Randomized, Double-Blind, Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002328-42,0,0,0 2011-002329-23,2,2015-06-16,2015-06-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Genzyme Corporation and its Affiliates,"A 2-Week, Randomized, Placebo-Controlled, Fixed Dose Period Followed by a 6-Month, Single-Arm, Open-Label, Dose Titration Period Study to Investigate the Efficacy and Safety of Sevelamer Carbonate in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002329-23,0,0,0 2011-002331-25,6,2017-10-31,2017-10-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"An Open-Label, Randomized, Multicenter Phase IIa Study Evaluating Pertuzumab in Combination with Trastuzumab and Chemotherapy in Patients with HER2-Positive Advanced Gastric Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002331-25,0,0,0 2011-002331-25,6,2017-10-31,2017-10-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"An Open-Label, Randomized, Multicenter Phase IIa Study Evaluating Pertuzumab in Combination with Trastuzumab and Chemotherapy in Patients with HER2-Positive Advanced Gastric Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002331-25,0,0,0 2011-002333-19,6,2015-03-23,2015-06-10,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"A Randomized, Double-blind, Placebo controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months? administration of Ofatumumab in Subjects with Relapsing-Rem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002333-19,0,0,0 2011-002333-19,6,2015-03-23,2015-06-10,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A Randomized, Double-blind, Placebo controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months? administration of Ofatumumab in Subjects with Relapsing-Rem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002333-19,0,0,0 2011-002333-19,6,2015-03-23,2015-06-10,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline SA,"A Randomized, Double-blind, Placebo controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months? administration of Ofatumumab in Subjects with Relapsing-Rem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002333-19,0,0,0 2011-002334-39,1,2014-01-10,2014-01-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Forest Research Institute, Inc","A Double-blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002334-39,0,0,0 2011-002336-72,4,2012-10-04,2012-10-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 26-weeks randomised, parallel two-arm, double-blind, multi-centre, multinational, treat-to-target trial comparing fixed ratio combination of insulin degludec and liraglutide with insulin degludec in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002336-72,0,0,0 2011-002337-19,1,2014-03-13,2014-03-13,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,AZIENDA UNITA' SANITARIA LOCALE DI PARMA,A PHASE II EXPLORATIVE STUDY EVALUATING ACTIVITY AND SAFETY OF HOMEOPATHIC MEDICINE ON CANCER RELATED FATIGUE (CRF) AND QUALITY OF LIFE IN ONCOLOGIC PATIENTS UNDER CHEMOTHERAPY IN DAY HOSPITAL AT FID...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002337-19,0,0,0 2011-002339-24,1,2016-02-09,2016-02-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Barts and the London NHS Trust,"Open label, single-centre study to evaluate the efficacy of the bradykinin (BK) B2 receptor antagonist, Icatibant, in the relief of symptoms resulting from moderate to severe angioedema unresponsive t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002339-24,0,0,0 2011-002341-35,1,2011-12-19,2011-12-19,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Reckitt Benckiser Healthcare (UK) Ltd,A randomised single dose two cohort study comparing the speed of raft formation assessed by gamma scintigraphy in healthy volunteers following administration of a single dose of Gaviscon® Strawberry F...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002341-35,0,0,0 2011-002343-99,1,2014-06-13,2014-06-13,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Heart of England NHS Foundation Trust,An Open-label Study into the Efficacy and Dosing of Probiotic Escherichia coli Nissle 1917 for Prevention of Gram-negative Gastric Colonisation in Ventilated Intensive Care Patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002343-99,0,0,0 2011-002346-12,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Sint Antonius Ziekenhuis,Oral Versus Intravenous Dexamethasone study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002346-12,0,0,0 2011-002347-10,5,2015-06-27,2015-06-27,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Inc.,"A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) versus BSC Alone in Patients with Locally Advanced or Metastatic Non-Squamous Non...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002347-10,0,0,0 2011-002347-10,5,2015-06-27,2015-06-27,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,EISAI INC.,"A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) versus BSC Alone in Patients with Locally Advanced or Metastatic Non-Squamous Non...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002347-10,0,0,0 2011-002348-28,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Merck & Co., Inc.","A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Single-Dose Pharmacokinetics of MK-0462 in Migraineurs Aged 6 to 17 Years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002348-28,0,1,1 2011-002349-36,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Merck & Co., Inc.",An Open-Label Single-Dose Study to Evaluate the Pediatric Palatability of Maxalt Oral Disintegrating Tablets,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002349-36,0,1,1 2011-002350-31,14,2015-03-27,2015-04-23,12,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002350-31,0,0,0 2011-002350-31,14,2015-03-27,2015-04-23,12,1,0,0,0,0,0,0,0,1,0,0,1,0,1,NOVARTIS PHARMA AG,"A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab intr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002350-31,0,0,0 2011-002351-34,1,2014-07-01,2014-07-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Medizinische Universitaet Wien, Univ.Klinik f.Innere Medizin III, Abteilung fuer Gastroenterologie und Hepatologie",Effects of oral and intravenous lipid load on Hepatitis C virus concentrations in serum and lipoprotein subfractions Effekte von oraler und intravenoeser Fettbelastung auf die Hepatitis C Virus Ko...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002351-34,0,0,0 2011-002353-57,7,2014-02-18,2014-03-25,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Mundipharma Research Limited,"A randomised, multi-centre, double-blind, active-controlled, parallel group study to assess the efficacy and safety of modified release prednisone (Lodotra®) compared to immediate release prednisone (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002353-57,0,0,0 2011-002362-21,12,2012-12-20,2012-12-20,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A randomised, double-blind, parallel-group, active-controlled, flexible dose study evaluating the effects of Lu AA21004 versus agomelatine in adult patients suffering from major depressive disorder ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002362-21,0,0,0 2011-002362-21,12,2012-12-20,2012-12-20,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H.LUNDBECK A/S,"A randomised, double-blind, parallel-group, active-controlled, flexible dose study evaluating the effects of Lu AA21004 versus agomelatine in adult patients suffering from major depressive disorder ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002362-21,0,0,0 2011-002363-15,2,2013-09-02,2013-09-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Roche a/s,"Multicenter, randomized, parallel group study to compare the incidence of Tocilizumab related infusion reactions in patients with moderate to severe active RA, when infusion is given over 31 minutes c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002363-15,0,0,0 2011-002364-25,1,2012-12-18,2012-12-18,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,Norgine Limited,"A multi-centre, randomised, investigator-blinded study comparing the polyp detection rate of two different types of bowel preparation: a 2-litre solution (MOVIPREP®) versus a hyperosmotic and stimulan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002364-25,0,0,0 2011-002365-37,1,2017-04-26,2017-04-26,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,J.W. Goethe-University,"A double-blind, placebo-controlled, randomized, multicenter phase II trial to assess the efficacy of temsirolimus added to standard primary therapy in elderly patients with newly diagnosed AML",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002365-37,0,0,0 2011-002370-23,2,2013-05-16,2013-05-24,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Institut de Recherches Internationales Servier,"A double-blind, multicenter, international randomised study to assess the effects of 4 month-oral administration of 2g per day of strontium ranelate versus placebo on the bone quality and remodelling,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002370-23,0,0,0 2011-002370-23,2,2013-05-16,2013-05-24,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"A double-blind, multicenter, international randomised study to assess the effects of 4 month-oral administration of 2g per day of strontium ranelate versus placebo on the bone quality and remodelling,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002370-23,0,0,0 2011-002379-40,10,2014-04-10,2014-09-17,4,1,1,0,0,1,2,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome Studio in aperto per valutare la sicurezza e la tollerabilita' a lun...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002379-40,1,1,0 2011-002379-40,10,2014-04-10,2014-09-17,4,1,1,0,0,1,2,0,0,2,1,0,0,0,1,NOVARTIS FARMA,An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome Studio in aperto per valutare la sicurezza e la tollerabilita' a lun...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002379-40,1,1,0 2011-002379-40,10,2014-04-10,2014-09-17,4,1,1,0,0,1,2,0,0,2,1,0,0,0,1,Novartis Farmacéutica S.A,An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome Studio in aperto per valutare la sicurezza e la tollerabilita' a lun...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002379-40,1,1,0 2011-002380-24,11,2017-05-01,2017-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim,"LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002380-24,0,0,0 2011-002380-24,11,2017-05-01,2017-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Ltd,"LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002380-24,0,0,0 2011-002380-24,11,2017-05-01,2017-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer-Ingelheim Ellas A.E.,"LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002380-24,0,0,0 2011-002380-24,11,2017-05-01,2017-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Unilfarma, Lda.","LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002380-24,0,0,0 2011-002380-24,11,2017-05-01,2017-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A","LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002380-24,0,0,0 2011-002380-24,11,2017-05-01,2017-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002380-24,0,0,0 2011-002380-24,11,2017-05-01,2017-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer-Ingelheim B.V,"LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002380-24,0,0,0 2011-002380-24,11,2017-05-01,2017-12-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,2,BOEHRINGER ING.,"LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002380-24,0,0,0 2011-002382-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Virgilio Hernando Requejo,Riboflavina como tratamiento profiláctico de la migraña.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002382-37,0,0,0 2011-002384-16,1,2015-09-30,2015-09-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),A Phase II study of Axitinib as maintenance for patients with advanced colorectal carcinoma. Estudio Fase II con Axitinib como tratamiento de mantenimiento en pacientes con Carcinoma Colorrectal Me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002384-16,0,0,0 2011-002386-38,1,2015-10-19,2015-10-19,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,VERISFIELD (UK) LTD,"Μονοκεντρική, τυχαιοποιημένη, διπλή-τυφλή, συγκριτική με πρωτότυπο φάρμακο κλινική μελέτη για την αξιολόγηση της αποτελεσματικότητας και της ασφάλειας της θεραπείας με Clindamycin vaginal suppositorie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002386-38,0,0,0 2011-002387-24,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,CHU Angers,Dyva-AAGG: Dysfonction vasculaire micro et macro vasculaire induite par les traitements anti-angiogéniques : Identification de nouveaux marqueurs pronostics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002387-24,0,0,0 2011-002392-41,2,2012-10-08,2012-10-08,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Zalicus, Inc.","A PHASE II, DOUBLE-BLIND, CONTROLLED, MULTI-CENTER, RANDOMIZED, LONG TERM SAFETY TRIAL OF Z102 AND PREDNISONE (5 MG OR 7.5 MG) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002392-41,0,0,0 2011-002393-23,10,2014-12-12,2015-01-30,9,1,1,0,0,0,0,0,0,1,0,0,1,0,1,CSL Behring GmbH,"A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002393-23,0,0,0 2011-002393-23,10,2014-12-12,2015-01-30,9,1,1,0,0,0,0,0,0,1,0,0,1,0,1,CSL BEHRING GMBH,"A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002393-23,0,0,0 2011-002396-42,6,2014-01-21,2014-01-27,6,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Laboratorios León Farma S.A.,"A Pivotal, Multicentre, Double-Blind, Double-Dummy, Randomised Trial on the Contraceptive Efficacy, Tolerability and Safety of LF111 (Drospirenone) Over 9 Cycles in Comparison With Desogestrel 0.075 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002396-42,0,0,0 2011-002400-32,2,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"A dose-finding phase Ib study followed by an open-label, randomized phase II study of BEZ235 plus paclitaxel in patients with HER2 negative, inoperable locally advanced or metastatic breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002400-32,0,0,0 2011-002400-32,2,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,"Novartis Farmacéutica, S.A.","A dose-finding phase Ib study followed by an open-label, randomized phase II study of BEZ235 plus paclitaxel in patients with HER2 negative, inoperable locally advanced or metastatic breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002400-32,0,0,0 2011-002403-15,3,2013-11-28,2015-01-19,3,1,1,0,0,1,0,2,0,1,1,0,1,0,1,OCTAPHARMA AG,"A prospective, controlled, randomised, cross-over study investigating the pharmacokinetic properties, surrogate efficacy and safety of Octafibrin compared to Haemocomplettan® P/ RiaSTAPTM in subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002403-15,0,0,0 2011-002408-34,1,2014-10-23,2014-10-23,1,1,0,0,0,3,4,0,0,1,0,0,1,0,0,Matti Ristikankare,Hyoskiinibutyylibromidin hyöty kolonoskopiassa.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002408-34,0,0,0 2011-002410-36,2,,,0,1,1,0,0,1,3,0,1,2,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, open, controlled study to evaluate immunogenicity of GSK Biologicals’ MenACWY-TT conjugate vaccine administered intramuscularly to at risk subjects from 1 to less than 18 years and to an ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002410-36,0,1,0 2011-002411-29,15,2015-05-28,2015-05-28,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"An Open-Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting. S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002411-29,0,0,0 2011-002411-29,15,2015-05-28,2015-05-28,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ABBOTT GMBH & Co. KG,"An Open-Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting. S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002411-29,0,0,0 2011-002411-29,15,2015-05-28,2015-05-28,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"An Open-Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting. S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002411-29,0,0,0 2011-002411-29,15,2015-05-28,2015-05-28,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbvie Deutschland GmbH & Co. KG,"An Open-Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting. S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002411-29,0,0,0 2011-002413-11,1,2014-03-03,2014-03-03,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD S.N.C,"A phase III open-label randomised study, to evaluate the immunogenicity and safety of the concomitant administration of V419 (PR5I) given at 2, 3 and 4 months of age with two types of meningococcal se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002413-11,0,0,0 2011-002415-28,5,2014-07-21,2014-07-21,4,1,1,0,0,0,3,0,0,1,0,0,1,0,1,CSL BEHRING GMBH,"A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B Studio di fase II/III, multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002415-28,0,0,0 2011-002415-28,5,2014-07-21,2014-07-21,4,1,1,0,0,0,3,0,0,1,0,0,1,0,1,CSL Behring GmbH,"A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B Studio di fase II/III, multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002415-28,0,0,0 2011-002416-85,4,2013-05-14,2013-05-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Recherche et Développement,"A 24-week, open-label, randomized, 2-arm parallel group, multinational, multi-center clinical trial to compare the efficacy and safety of lixisenatide injected prior to the main meal of the day versus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002416-85,0,0,0 2011-002419-27,2,2018-01-23,2018-01-28,2,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Octapharma AG,"Prospective, open-label, uncontrolled, Phase III study to assess the efficacy and safety of Octafibrin for on-demand treatment of acute bleeding and to prevent bleeding during and after surgery in sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002419-27,0,0,0 2011-002424-41,3,2014-11-20,2014-12-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ONCOGENEX TECHNOLOGIES INC,"A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination with OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma Studio randomizzato, in d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002424-41,0,0,0 2011-002424-41,3,2014-11-20,2014-12-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"OncoGenex Technologies, Inc.","A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination with OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma Studio randomizzato, in d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002424-41,0,0,0 2011-002424-41,3,2014-11-20,2014-12-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,OncoGenex Technologies Inc.,"A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination with OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma Studio randomizzato, in d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002424-41,0,0,0 2011-002425-21,1,2014-11-30,2014-11-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Nottingham,Efficacy of Dehydroepiandrosterone to overcome the effect of ovarian aging,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002425-21,0,0,0 2011-002434-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Hospital Tuebingen,Highdose Chemotherapy and transplantation of 34+ selected stem cell for progressive systemic sclerosis Modification according to manifestation Hochdosis-Chemotherapie und autologe Retransfusion C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002434-40,0,0,0 2011-002437-19,2,2013-05-14,2013-05-14,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,"BAX326 (RECOMBINANT FACTOR IX): A PHASE 2/3 PROSPECTIVE, UNCONTROLLED, MULTICENTER STUDY EVALUATING PHARMACOKINETICS, EFFICACY, SAFETY, AND IMMUNOGENICITY IN PREVIOUSLY TREATED PEDIATRIC PATIENTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002437-19,0,0,0 2011-002438-38,1,2014-01-30,2014-01-30,1,0,0,0,1,0,2,0,1,1,1,1,1,0,1,Helperby Therapeutics Limited,"An open-label, multiple dose, efficacy study of HT61 in combination with marketed antibiotics, applied to the anterior nares in subjects with nasal carriage of Staphylococcus aureus (S. aureus).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002438-38,0,0,0 2011-002441-34,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Associació Per la Recerca Oncològica (APRO),"Ensayo clínico fase II, abierto, no controlado y multicéntrico de pazopanib en monoterapia para determinar la eficacia y la seguridad en segunda línea de tratamiento en pacientes con carcinoma de célu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002441-34,0,0,0 2011-002443-10,1,2012-03-21,2012-03-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Procter & Gamble Technical Centres Ltd., UK","A Randomized, Open-Label, Single-Dose, Parallel Group Study to Evaluate the Utility of Magnetic Resonance Imaging (MRI) in Demonstrating the Nasal Decongestant Efficacy of an Active Control (Vicks® Si...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002443-10,0,0,0 2011-002445-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Clinical Oncology, Leiden University Medical Center",Neo-adjuvant dovitinib in patients with hepatocellular carcinoma prior to local treatment: a phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002445-36,0,0,0 2011-002451-33,2,2012-12-21,2012-12-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily via a Novel Dry Powder Inhaler Compared with Tiotro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002451-33,0,0,0 2011-002452-13,1,2015-11-24,2015-11-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002452-13,0,0,0 2011-002453-65,2,2013-01-07,2013-01-07,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Ardea Biosciences, Inc.",Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002453-65,0,0,0 2011-002456-14,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Oasmia Pharmaceutical AB,"A follow-up study exploring number of cycles for weekly treatment with Paclical® in patients with metastatic breast cancer, previously treated in study OAS-11PAC-W",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002456-14,0,0,0 2011-002459-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,"Boceprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Difficult-to-Treat Menopausal Women With Chronic Hepatitis C Genotype 1, either deemed Nonresponders to Peginterferon/Ribavirin or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002459-33,0,0,0 2011-002461-37,8,2014-01-10,2014-01-10,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,UCB BIOSCIENCES Inc,"A PROSPECTIVE, MULTINATIONAL, OPEN-LABEL, SINGLE-ARM, EXPLORATIVE STUDY TO EVALUATE THE TOLERABILITY AND EFFICACY OF LACOSAMIDE WHEN ADDED TO LEVETIRACETAM WITH WITHDRAWAL OF THE CONCOMITANT SODIUM CH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002461-37,0,0,0 2011-002462-20,6,2013-04-03,2013-04-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,DR. AUGUST WOLFF GMBH & CO. KG,"Randomised, double-blind, placebo-controlled prospective clinical trial to evaluate the efficacy and safety of K(D)PT in patients with mild to moderate ulcerative colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002462-20,0,0,0 2011-002462-20,6,2013-04-03,2013-04-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dr August Wolff GmbH & Co KG Arzneimittel,"Randomised, double-blind, placebo-controlled prospective clinical trial to evaluate the efficacy and safety of K(D)PT in patients with mild to moderate ulcerative colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002462-20,0,0,0 2011-002464-24,1,2011-12-14,2011-12-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dr. August Wolff GmbH & Co. KG Arzneimittel,Clinical study to investigate the efficacy and safety of an estradiol containing cream (0.01 % estradiol) in patients with dermatoporosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002464-24,0,0,0 2011-002466-20,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Royal Liverpool And Broadgreen University Hospitals NHS Trust,"An exploratory, randomised, 3-way crossover study to determine the effect of paracetamol on urinary cystine excretion in cystinuria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002466-20,0,0,0 2011-002468-26,1,2015-09-01,2015-09-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Allan Flyvbjerg,"Liraglutide in chronic heart failure. A randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002468-26,0,0,0 2011-002469-39,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Isala Klinieken,DIAbetes-PREvention Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002469-39,0,0,0 2011-002470-23,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO NEUROLOGICO MEDITERRANEO NEUROMED,"Evaluation of diagnosic accuracy of 18F-choline PET/CT in examination of patients qith prostate cancer, in relation to PSA value and its derivatives. Valutazione della performance diagnostica della...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002470-23,0,0,0 2011-002472-16,1,2012-07-06,2012-07-06,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,Cytonet GmbH & Co KG,"Open, prospective, diagnostic, multicentre study in healthy subjects, patients with urea cycle disorders (UCD), and carriers of UCD mutations, to evaluate in vivo ureagenesis measured after a single a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002472-16,0,0,0 2011-002480-19,2,2013-07-22,2013-07-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER INC.,"A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, 2-WAY CROSSOVER STUDY OF PREGABALIN IN THE TREATMENT OF FIBROMYALGIA WITH CONCURRENT ANTIDEPRESSANT THERAPY FOR COMORBID DEPRESSIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002480-19,0,0,0 2011-002480-19,2,2013-07-22,2013-07-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"PFIZER, SLU","A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, 2-WAY CROSSOVER STUDY OF PREGABALIN IN THE TREATMENT OF FIBROMYALGIA WITH CONCURRENT ANTIDEPRESSANT THERAPY FOR COMORBID DEPRESSIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002480-19,0,0,0 2011-002484-21,1,2012-08-31,2012-08-31,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Universitätsklinik für Anästhesie - Paracelsus Medizinische Universität Salzburg,"Comparison of ultrasound guided interscalene brachial plexus block with 10 ml vs 20 ml ropivacaine 0.5% Dosisvergleich der ultraschallgezielten, interskalenären brachialen Plexusblockade mit 10 ml ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002484-21,0,0,0 2011-002502-74,2,,,0,1,1,0,0,1,2,0,0,2,1,0,0,0,1,Neurophyxia B.V.,"A multi-centre, randomised, double-blind, placebo-controlled Phase II study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of 2-iminobiotin (2-IB) in neonates with gestational ag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002502-74,0,1,0 2011-002507-15,9,2014-12-23,2015-02-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002507-15,0,0,0 2011-002507-15,9,2014-12-23,2015-02-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GILEAD SCIENCE INC.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002507-15,0,0,0 2011-002508-34,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,"MERCK, S.L.","Evaluate adherence to treatment with Glucophage sachets versus tablets in diabetes type 2 patients, previously treated with metformin tablets Evaluar la adherencia al tratamiento con Dianben sobres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002508-34,0,0,0 2011-002510-36,7,2012-04-24,2013-04-24,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, double dummy, multicenter study to assess the safety, tolerability and long-term efficacy of intravenous (10 mg/kg) and subcutaneous (300 mg) secukinumab in subjects with m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002510-36,0,0,0 2011-002512-89,1,2013-05-25,2013-05-25,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Tayside Clinical Trials Unit, University of Dundee","Evaluation of any steroid sparing effect of beta blocker therapy on airway hyper-responsiveness in stable, mild to moderate, asthmatics.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002512-89,0,0,0 2011-002513-11,1,2014-01-29,2014-01-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Fixed dose OPC-34712 (4, 2, and 1 mg/day) in the Treatment of Adults With Acute Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002513-11,0,0,0 2011-002514-37,3,2016-02-25,2016-02-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002514-37,0,0,0 2011-002516-85,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,A.O. UNIVERSITARIA INTEGRATA DI VERONA,Open-label study to evaluate the efficacy and tolerability of orally administered rosiglitazone in patients with progressive bone Fibrodysplasia (FOP) Studio in aperto per valutare l'efficacia e la...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002516-85,0,0,0 2011-002517-11,4,2012-10-18,2012-10-18,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,UCB BIOSCIENCES GmbH,"A multi-centre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetic of olokizumab administered subcutaneously to subjects with modera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002517-11,0,0,0 2011-002518-35,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Karl Emil Kristensen,The effect of aldosterone on the development of chronic allograft nephropathy after kidney transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002518-35,0,0,0 2011-002520-40,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,CASA DI CURA PRIVATA S.RAFFAELE - PISANA,"Carvedilol, ivabradine and their combination in patients with heart failure - the CARVIVA-HF study Effetto delle differenti modalita' di riduzione della frequenza cardiaca sulla capacita' funzional...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002520-40,0,0,0 2011-002523-17,2,2012-08-27,2012-08-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 12-week, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy, Safety, and Patient Use (User Study) of Symbicort® (Budesonide/Formoterol) Breath Actuated Metered Dose...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002523-17,0,0,0 2011-002526-43,3,2014-04-09,2014-04-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALLERGAN LIMITED,Single and Repeat Dose Study of the Safety and Efficacy of AGN-150998 in Patients with Exudative Age-related Macular Degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002526-43,0,0,0 2011-002526-43,3,2014-04-09,2014-04-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergan Limited,Single and Repeat Dose Study of the Safety and Efficacy of AGN-150998 in Patients with Exudative Age-related Macular Degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002526-43,0,0,0 2011-002527-18,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""","Phase II, open label, monocentric, uncontrolled, non randomized clinical trial on Sodium Fluorescein for Surgery of High Grade Gliomas. Studio clinico di Fase II, in aperto, monocentrico, non contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002527-18,0,0,0 2011-002528-42,15,2019-10-09,2019-10-09,12,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the SPONSOR or Merck)","A Phase III, Multicenter, Double-Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadeq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002528-42,1,1,0 2011-002528-42,15,2019-10-09,2019-10-09,12,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc","A Phase III, Multicenter, Double-Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadeq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002528-42,1,1,0 2011-002528-42,15,2019-10-09,2019-10-09,12,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Double-Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadeq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002528-42,1,1,0 2011-002528-42,15,2019-10-09,2019-10-09,12,1,1,0,0,0,3,0,0,2,1,0,0,0,1,MERCK SHARP & DOHME CORP.,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadeq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002528-42,1,1,0 2011-002528-42,15,2019-10-09,2019-10-09,12,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Merck Sharp & Dhome Corp., a subsidiary of Merck & Co., Inc (hereafter referred to as Sopnsor or Merck)","A Phase III, Multicenter, Double-Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadeq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002528-42,1,1,0 2011-002528-42,15,2019-10-09,2019-10-09,12,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Merck Sharp & Dohme Corp. A subsidiary of Merck & Co. Inc,"A Phase III, Multicenter, Double-Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadeq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002528-42,1,1,0 2011-002529-23,6,2019-09-17,2019-10-17,5,1,1,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc","""A Phase III, Multicenter, Double-Blind, Randomized, Placebo- Controlled Clinical Trial to Evaluate the Safety and Efficacy MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002529-23,0,0,0 2011-002529-23,6,2019-09-17,2019-10-17,5,1,1,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","""A Phase III, Multicenter, Double-Blind, Randomized, Placebo- Controlled Clinical Trial to Evaluate the Safety and Efficacy MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002529-23,0,0,0 2011-002529-23,6,2019-09-17,2019-10-17,5,1,1,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co. Inc.","""A Phase III, Multicenter, Double-Blind, Randomized, Placebo- Controlled Clinical Trial to Evaluate the Safety and Efficacy MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002529-23,0,0,0 2011-002529-23,6,2019-09-17,2019-10-17,5,1,1,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co.","""A Phase III, Multicenter, Double-Blind, Randomized, Placebo- Controlled Clinical Trial to Evaluate the Safety and Efficacy MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002529-23,0,0,0 2011-002529-23,6,2019-09-17,2019-10-17,5,1,1,0,0,0,3,0,0,1,1,0,1,0,1,MERCK SHARP & DOHME CORP.,"""A Phase III, Multicenter, Double-Blind, Randomized, Placebo- Controlled Clinical Trial to Evaluate the Safety and Efficacy MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002529-23,0,0,0 2011-002532-12,2,2017-12-31,2017-12-31,2,0,0,0,0,0,4,0,0,1,0,0,1,0,0,MAYO CLINIC,Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002532-12,0,0,0 2011-002532-12,2,2017-12-31,2017-12-31,2,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Mayo Clinic,Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002532-12,0,0,0 2011-002533-18,3,2013-10-10,2013-10-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","52 Week Extension: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002533-18,0,0,0 2011-002533-18,3,2013-10-10,2013-10-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA","52 Week Extension: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002533-18,0,0,0 2011-002538-38,2,2013-12-05,2013-12-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002538-38,0,0,0 2011-002539-24,1,2015-05-15,2015-05-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Hospital of the University of Munich,Effect of Mipomersen on LDL-Cholesterol Levels in Patients with Severe LDL-Hypercholesterolemia and Atherosclerosis Treated by Regular LDL-Apheresis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002539-24,0,0,0 2011-002542-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Lymphatic mapping in oropharyngeal neoplasms: comparison between Dynamic Lymphoscintigrafy and Fluorescence Lymphografy using indocyanine green dye (ICG). Validation study. Mapping linfatico nelle...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002542-12,0,0,0 2011-002544-27,1,2015-10-14,2015-10-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Technische Universitaet Muenchen Fakultaet fuer Medizin,"Prospective, explorative trial for the detection of circulating cell-free tumor DNA in the plasma of patients with gastrointestinal stromal tumors (GIST) harboring activating mutations of CKIT or PDGF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002544-27,0,0,0 2011-002545-35,2,2016-12-31,2016-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Oxford,A randomised phase 2 study of paclitaxel with or without GSK1120212 in advanced wt BRAF melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002545-35,0,0,0 2011-002547-94,1,2016-10-15,2016-10-15,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Dept. of Intensive Care 4131, Rigshospitalet",Early Goal-Directed Nutrition in ICU Patients – EAT-ICU Trial Tidlig målrettet ernæring til intensivpatienter - EAT-ICU Forsøget,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002547-94,0,0,0 2011-002550-32,3,2014-07-31,2014-07-31,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,DBV Technologies,"A double-blind, placebo-controlled, randomized trial to study the Viaskin® Peanut’s Efficacy and Safety for treating peanut allergy in children and adults.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002550-32,0,0,0 2011-002550-32,3,2014-07-31,2014-07-31,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,DBV Technologies SA,"A double-blind, placebo-controlled, randomized trial to study the Viaskin® Peanut’s Efficacy and Safety for treating peanut allergy in children and adults.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002550-32,0,0,0 2011-002554-30,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Fundación Renal Jaume Arnó,Effect of Paricalcitol on blood vessels: an investigation over pleotropic analogues of vitamin-D. EFECTO DEL PARICALCITOL SOBRE LA PARED VASCULAR: INVESTIGACIÓN SOBRE LOS EFECTOS PLEOTRÓPICOS DE AN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002554-30,0,0,0 2011-002555-34,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,FRANCISCO JAVIER BELDA,"Study on the safety of administration of sevoflurane for long-term sedation in critical patients on assisted ventilation. A multicentric, randomised, controlled, prospective clinical trial. Estudio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002555-34,0,0,0 2011-002557-56,4,2012-03-27,2012-03-27,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT,"A randomized, double-blind, parallel-group, placebo-controlled study to assess the clinical benefit of SSR411298 as adjunctive treatment for persistent cancer pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002557-56,0,0,0 2011-002557-56,4,2012-03-27,2012-03-27,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,sanofi-aventis,"A randomized, double-blind, parallel-group, placebo-controlled study to assess the clinical benefit of SSR411298 as adjunctive treatment for persistent cancer pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002557-56,0,0,0 2011-002561-38,1,2016-02-16,2016-02-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,St. Vincent's University Hospital,"A double blind, randomized, placebo controlled, crossover study of the effectiveness of oral fampridine in improving upper limb function in progressive multiple sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002561-38,0,0,0 2011-002563-23,6,2014-02-18,2014-02-18,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MedImmune Limited,"A Phase 2 Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002563-23,0,0,0 2011-002564-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer Cetuximab e Cisplatino con o senza Paclitaxel nel tumore testa-collo ricorrente o metastatico,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002564-24,0,0,0 2011-002565-38,6,2016-06-17,2016-07-17,4,1,0,0,0,2,2,0,0,2,1,0,0,0,1,"MedImmune, LLC",A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL Studio in aperto randomizzato di fase 2 su MEDI-551 in adulti con LDGCB recidivante o refrattario,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002565-38,1,0,0 2011-002565-38,6,2016-06-17,2016-07-17,4,1,0,0,0,2,2,0,0,2,1,0,0,0,1,MEDIMMUNE ONCOLOGY INC,A Phase 2 Randomized Open-label Study of MEDI-551 in Adults With Relapsed or Refractory DLBCL Studio in aperto randomizzato di fase 2 su MEDI-551 in adulti con LDGCB recidivante o refrattario,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002565-38,1,0,0 2011-002566-21,4,2016-01-08,2016-01-08,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,"MedImmune, LLC",A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL Studio in aperto di fase 2 su MEDI-551 e bendamustina rispetto a rit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002566-21,0,0,0 2011-002566-21,4,2016-01-08,2016-01-08,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,MEDIMMUNE ONCOLOGY INC,A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL Studio in aperto di fase 2 su MEDI-551 e bendamustina rispetto a rit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002566-21,0,0,0 2011-002567-17,1,2019-10-30,2019-10-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Technische Universität Dresden,A single-arm phase II trial to assess the efficacy of Midostaurin (PKC412) added to standard primary therapy in patients with newly diagnosed c-KIT or FLT3-ITD mutated t(8;21) AML,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002567-17,0,0,0 2011-002569-39,6,2020-05-27,2020-05-27,4,1,0,1,0,2,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A phase IB/II, open label, multicenter study of INC280 administered orally in combination with gefitinib in adult patients with EGFR mutated, c-MET-amplified non-small cell lung cancer who have progre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002569-39,0,0,0 2011-002569-39,6,2020-05-27,2020-05-27,4,1,0,1,0,2,1,0,0,1,0,0,0,0,1,Novartis Farmacéutica S.A.,"A phase IB/II, open label, multicenter study of INC280 administered orally in combination with gefitinib in adult patients with EGFR mutated, c-MET-amplified non-small cell lung cancer who have progre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002569-39,0,0,0 2011-002569-39,6,2020-05-27,2020-05-27,4,1,0,1,0,2,1,0,0,1,0,0,0,0,1,Novartis Farma,"A phase IB/II, open label, multicenter study of INC280 administered orally in combination with gefitinib in adult patients with EGFR mutated, c-MET-amplified non-small cell lung cancer who have progre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002569-39,0,0,0 2011-002570-23,4,2013-05-29,2013-05-29,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"An open-label, single-arm, multi-center phase II study to evaluate the efficacy and safety of AUY922 in combination with trastuzumab standard therapy as second-line treatment in patients with HER2-pos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002570-23,0,0,0 2011-002570-23,4,2013-05-29,2013-05-29,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmaceutica S.A.,"An open-label, single-arm, multi-center phase II study to evaluate the efficacy and safety of AUY922 in combination with trastuzumab standard therapy as second-line treatment in patients with HER2-pos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002570-23,0,0,0 2011-002570-23,4,2013-05-29,2013-05-29,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An open-label, single-arm, multi-center phase II study to evaluate the efficacy and safety of AUY922 in combination with trastuzumab standard therapy as second-line treatment in patients with HER2-pos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002570-23,0,0,0 2011-002571-42,1,2012-04-19,2012-04-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GALENpharma GmbH,"Phase IIa, multi-center, randomized, double-blind, vehicle-controlled study for assessment of clinical skin condition and effects on barrier impairment of a topical formulation containing tarenflurbil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002571-42,0,0,0 2011-002576-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,ARCAGY,Phase 2 multicenter study to assess the safety and efficacy of BKM120 as monotherapy in the treatment of initial or recurrent metastatic endometrial cancer after first line therapy in patients who can...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002576-16,0,0,0 2011-002577-33,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Institute of Cancer Research,A Phase III randomised trial of Peri-Operative chemotherapy versus sUrveillance in upper Tract urothelial cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002577-33,0,0,0 2011-002585-20,1,2012-05-01,2012-05-01,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Psykiatrien i Region Syddanmark,The role of vitamin D supplementation on well-being and symptoms of depression during the Winter season in health service staff.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002585-20,0,0,0 2011-002586-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Renapharma AB,"A 12-week clinical double-blind, randomised study of cholecalciferol versus placebo in patients with chronic kidney disease stage 3-4 (CHICK). En 12-veckors clinisk, dubbel-blind, randomiserad stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002586-38,0,0,0 2011-002587-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Effects of Aliskiren on microcirculation dysfunction in patients affected by hypertension Effetti del farmaco Aliskiren sulla disfunzione del microcircolo nei pazienti con ipertensione arteriosa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002587-24,0,0,0 2011-002594-33,6,2012-11-16,2012-11-19,6,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Tranzyme, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of Once-Daily Administrations of TZP 102 for the Treatment of Symptoms Associated with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002594-33,0,0,0 2011-002598-49,1,2018-12-01,2018-12-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College Joint Research Office,The AXitinib MicroBubble UltraSound in metastatic Colorectal cancer trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002598-49,0,0,0 2011-002600-32,1,2014-08-07,2014-08-07,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Universitätsklinik für Radiodiagnostik, Abteilung für Neuroradiologie, Medizinische Universität Wien",OLFACTORY NEURAL REPSONSES AS A MEASURE OF THERAPEUTIC SUCCESS IN PERSONS WITH OLFACTORY ANOSMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002600-32,0,0,0 2011-002601-30,1,2013-06-04,2013-06-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,OMNIVISION GmbH,"A COMPARISON OF LATANOPROST 50µg/ml EYE DROPS vs. XALATAN EYE DROPS IN THE TREATMENT OF OPEN ANGLE GLAUCOMA: AN OPEN, RANDOMIZED, CLINICAL TRIAL COMPARACION DE LATANOPROST 50μg/ml COLIRIO vs. XALA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002601-30,0,0,0 2011-002602-78,3,2012-07-13,2012-09-06,3,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Teva Women's Health Research&Development, a division of Teva Branded Pharmaceutical Products R&D, Inc.","A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of DR-102 Compared to a 28-day Standard Oral Contraceptive Regimen, on Hemostatic Parameters in Healthy Women",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002602-78,0,0,0 2011-002602-78,3,2012-07-13,2012-09-06,3,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"TEVA WOMEN'S HEALTH RESEARCH&DEVELOPMENT, A DIVISION OF TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.","A Multinational, Multicenter, Randomized, Open-Label Study to Evaluate the Impact of DR-102 Compared to a 28-day Standard Oral Contraceptive Regimen, on Hemostatic Parameters in Healthy Women",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002602-78,0,0,0 2011-002603-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION INVESTIGACION HOSPITAL CLINICO DE VALENCIA-INSTITUTO DE INVESTIGACION SANITARIA INCLIVA,Early treatment with ganciclovir of active infection by cytomegalovirus (CMV) in critically ill patients on mechanical ventilation with severe sepsis or septic shock Tratamiento anticipado con ganc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002603-15,0,0,0 2011-002605-29,14,2018-05-23,2020-05-20,11,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Novo Nordisk A/S,Efficacy and safety of liraglutide in combination with metformin versus metformin monotherapy on glycaemic control in children and adolescents with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002605-29,1,0,0 2011-002608-34,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Paula Diéguez García,Comparation of the efficacy and onset of the distribution circumferencial va not ircumferencial of local anesthetic in the median and ulnar nerves for surgery of carpal tunnel COMPARACIÓN DE LA EFI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002608-34,0,0,0 2011-002609-31,2,2014-09-17,2015-12-18,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Guerbet,Diagnostic contribution of XENETIX® CT PERFUSION in pre-therapeutical assessment of hepatocellular carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002609-31,0,0,0 2011-002611-29,1,2021-06-26,2021-06-26,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,Freistaat Bayern,"A prospective phase I and consecutive phase II, twoarm, randomized multi-center trial of temsirolimus in combination with pioglitazone, etoricoxib and metronomic low-dose trofosfamide versus dacarbazi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002611-29,0,0,0 2011-002613-10,1,2017-10-25,2017-10-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Steigerwald Arzneimittelwerk GmbH,"A double-blind, randomised, placebo-controlled study on the efficacy of Iberogast® (STW 5) in patients with irritable bowel syndrome Randomisierte, doppelblinde, placebokontrollierte Studie zur Wir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002613-10,0,0,0 2011-002629-23,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,Immunogenicity and protective efficacy of GlaxoSmithKline Biologicals’ rec-Hepatitis B vaccine (10 µg) in newborns of Hepa-titis B envelope antigen positive (HBeAg+) and Hepatitis B surface antigen po...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002629-23,0,1,1 2011-002630-39,1,2016-06-09,2016-06-09,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Oslo University Hospital Rikshospitalet,MICROVASCULAR RESISTANCE IN WOMEN WITH CHEST PAIN AND NO OR MINIMAL CORONARY ARTERY DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002630-39,0,0,0 2011-002632-99,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,SUTNET Trial: Biological and Clinical Phase II study of Sunitinib in patients with unresectable and/or metastatic pheochromocytoma/paraganglioma SUTNET Trial: Studio Clinico-Biologico Di Fase II Co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002632-99,0,0,0 2011-002633-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Rheumazentrum Ruhrgebiet,Diagnostic value of oral prednisolone test for rheumatoid arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002633-19,0,0,0 2011-002640-27,2,2013-09-30,2013-09-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GIULIANI,"A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn‟s disease (Ileo-Colitis) Multizentr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002640-27,0,0,0 2011-002643-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Heart Center Co. Tampere University Hospital,Intracoronary administration of levosimendan in cardiac surgery patients Sepelvaltimoihin annetun levosimendaanin vaikutuksia sydänleikkauspotilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002643-10,0,0,0 2011-002652-14,1,2013-03-25,2013-03-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,Safety and tolerability of Pelargonium sidoides extract EPs®7630 in children (1 to 5 years old) suffering from acute bronchitis Sicherheit und Verträglichkeit von Pelargonium sidoides-Extrakt EPs®7...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002652-14,0,0,0 2011-002656-14,1,2015-10-20,2015-10-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College,"A randomised, prospective study, assessing changes in cerebral function in treatment naive HIV-1 infected subjects commencing either boosted atazanavir with Truvada or boosted darunavir with maraviroc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002656-14,0,0,0 2011-002657-60,1,2014-01-15,2014-01-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Klinikum der Universität,THE EFFECT OF NEU-P11 ON SYMPTOMS IN PATIENTS WITH D-IBS THE EFFECT OF NEU-P11 ON SYMPTOMS IN PATIENTS WITH D-IBS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002657-60,0,0,0 2011-002665-38,3,2012-06-04,2012-06-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Almirall S.A.,"A MULTIPLE DOSE, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, 2 PERIOD CROSSOVER CLINICAL TRIAL TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE 400 MCG BID ON EXERCISE ENDURANCE IN PATIENTS WITH STABLE MO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002665-38,0,0,0 2011-002667-14,1,2018-12-31,2018-12-31,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,Institute of Hematology and Blood Transfusion,Effect of vaccination in patients with recurrent respiratory papillomatosis– can we improve the quality of life of these patients? Očkování proti HPV u pacientů s rekurentní laryngální papillomatóz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002667-14,0,0,0 2011-002668-25,2,2014-02-04,2014-02-04,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Vertex Pharmaceuticals Incorporated,"An Open-Label, Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodefici...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002668-25,0,0,0 2011-002669-40,3,2013-02-08,2013-02-08,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Alder BioPharmaceuticals, Inc.","A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALD518 in the Reduction of Oral Mucositis in Subjects With Head and Neck Can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002669-40,0,0,0 2011-002669-40,3,2013-02-08,2013-02-08,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,ALDER BIOPHARMACEUTICALS INC,"A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALD518 in the Reduction of Oral Mucositis in Subjects With Head and Neck Can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002669-40,0,0,0 2011-002677-30,1,2018-06-15,2018-06-15,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,"Professor Hans Erik Johnsen, MD, DMSc, Department of Haematology, Aalborg Hospital",Preclinical phase 0 micro dose study to evaluate the effekt of R-CHOP chemotherapy on cellular gene-expression. - Establisment of a preclinical model for in vivo evaluation of molecular biological efe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002677-30,0,0,0 2011-002678-21,5,2014-05-30,2014-05-30,5,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Apotex Inc,"A PHASE III, RANDOMIZED, ACTIVE CONTROLLED, ASSESSORBLINDED STUDY OF SAFETY AND EFFICACY OF PEGYLATED APOFILGRASTIM VERSUS US AND EU LICENSED NEULASTA® IN SUBJECTS WITH STAGE IIA, IIB OR IIIA BREAST C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002678-21,0,0,0 2011-002683-24,4,2014-06-10,2014-06-10,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Nuron Biotech, Inc.","A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002683-24,1,0,0 2011-002683-24,4,2014-06-10,2014-06-10,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,NURON BIOTECH INC.,"A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and efficacy of NU100 in patients with relapsing forms of multiple sclerosis Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002683-24,1,0,0 2011-002684-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Antwerp University Hospital,Efficacy and safety of a 4 year pubertal therapy with growth hormone (somatropine Omnitrope) or an aromatase inhibitor (letrozole Femara) or the combination of both in boys with a short predicted heig...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002684-25,0,0,0 2011-002685-20,8,2014-09-11,2014-09-14,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CSL Behring GmbH,"REPLACE (Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery): a prospective, multinational, multicenter, randomized, double-blind, placebo-controlled, phase III study...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002685-20,0,0,0 2011-002685-20,8,2014-09-11,2014-09-14,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CSL BEHRING GMBH,"REPLACE (Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery): a prospective, multinational, multicenter, randomized, double-blind, placebo-controlled, phase III study...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002685-20,0,0,0 2011-002687-25,1,2012-07-13,2012-07-13,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Hospital of Wuerzburg,Pharmacokinetics of Hydrocortisone after Subcutaneous Administration Compared with Intramuscular Injection in Chronic Adrenal Insufficiency (PHYSCA-Trial) Pharmakokinetik der subkutanen Hydrocortis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002687-25,0,0,0 2011-002689-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,Haukeland University Hospital,"TREATMENT OF RELAPSED ACUTE LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: DISEASE STABILIZATION THROUGH CHEMOTHERAPY, IMMUNOMODULATORY TREATMENT AND IMMUNOTHERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002689-19,0,0,0 2011-002691-17,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,ALEXION PHARMA INTERNATIONAL SARL,"An open label, multi-center trial of eculizumab in patients with Shiga-toxin producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002691-17,0,0,0 2011-002692-42,1,2016-10-01,2016-10-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"MUW-Medical University of Vienna,Medizinische Universität Wien","Characterization of myeloma bone lesions - before and during anti-cancer therapy - using 18F-FDG-, 18F-fluoride PET/CT and MRI- a pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002692-42,0,0,0 2011-002695-16,2,2017-04-21,2017-04-21,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 2, Randomized Study of Bortezomib/dexamethasone With or Without Elotuzumab in Subjects with Relapsed/Refractory Multiple Myeloma. Studio di fase 2 randomizzato su bortezomib/desametasone co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002695-16,0,0,0 2011-002695-16,2,2017-04-21,2017-04-21,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2, Randomized Study of Bortezomib/dexamethasone With or Without Elotuzumab in Subjects with Relapsed/Refractory Multiple Myeloma. Studio di fase 2 randomizzato su bortezomib/desametasone co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002695-16,0,0,0 2011-002696-41,3,2013-10-22,2013-10-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,The effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002696-41,0,0,0 2011-002707-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundacion para la investigación Biomédica del hospital Gregorio Marañón,""" SILDENAFIL IN THE POST-CARDIAC SURGERY IN CHILDREN: IVORY STUDY"" ?SILDENAFILO EN EL POSTOPERATORIO DE CIRUGÍA CARDIACA EN NIÑOS: ESTUDIO IVORY?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002707-16,0,0,0 2011-002714-37,3,2014-02-04,2014-02-04,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002714-37,0,0,0 2011-002714-37,3,2014-02-04,2014-02-04,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ROCHE,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002714-37,0,0,0 2011-002715-28,4,2014-01-30,2014-01-30,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002715-28,0,0,0 2011-002715-28,4,2014-01-30,2014-01-30,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ROCHE,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SUSTAINED VIROLOGIC RESPONSE OF THE HCV POLYMERASE INHIBITOR PRODRUG RO5024048 IN COMBINATION...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002715-28,0,0,0 2011-002719-27,1,2013-11-15,2013-11-15,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,AZIENDA OSPEDALIERA DI PARMA,GLUCOSE METABOLISM AND INFLAMMATORY PARAMETERS UNDER IGF-I TREATMENT IN CYSTIC FIBROSIS METABOLISMO GLUCIDICO E PARAMETRI INFIAMMATORI DURANTE TRATTAMENTO CON RHIGF-I NELLA FIBROSI CISTICA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002719-27,0,0,0 2011-002723-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitetssjukhuset Örebro,Postoperativ smärtlindring efter abdominell hysterektomi. En jämförelse mellan intermittent infusion av lokalanestesimedel i buken och intravenös infusion.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002723-17,0,0,0 2011-002727-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,The effects of switching antidepressants on endoxifen exposure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002727-18,0,0,0 2011-002731-26,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"An open-label, multi-center, expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist. Programma i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002731-26,0,0,0 2011-002732-70,6,2020-11-15,2021-12-18,5,1,1,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children with HBeAg Positive Chronic Hepatitis B in the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002732-70,1,0,0 2011-002732-70,6,2020-11-15,2021-12-18,5,1,1,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control in Children with HBeAg Positive Chronic Hepatitis B in the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002732-70,1,0,0 2011-002734-39,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Oslo University Hospital,Opioid Induced Hyperalgesia: possible to avoid by gradual reduction compared to acute withdrawal from remifentanil?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002734-39,0,0,0 2011-002739-24,1,2013-12-31,2013-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Dr. med. Tina Vilsbøll,Does the GLP-1 receptor agonist (Victoza®) improve the metabolic response to physical training in patients with type 2 diabetes?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002739-24,0,0,0 2011-002741-35,3,2013-07-05,2013-07-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared with Placebo in Subjects with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002741-35,0,0,0 2011-002743-10,3,2013-11-22,2013-11-22,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",A STUDY OF PREGABALIN IN THE TREATMENT OF SUBJECTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY WITH BACKGROUND TREATMENT OF NSAID FOR OTHER PAIN CONDITIONS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002743-10,0,0,0 2011-002743-10,3,2013-11-22,2013-11-22,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,A STUDY OF PREGABALIN IN THE TREATMENT OF SUBJECTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY WITH BACKGROUND TREATMENT OF NSAID FOR OTHER PAIN CONDITIONS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002743-10,0,0,0 2011-002743-10,3,2013-11-22,2013-11-22,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER INC.,A STUDY OF PREGABALIN IN THE TREATMENT OF SUBJECTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY WITH BACKGROUND TREATMENT OF NSAID FOR OTHER PAIN CONDITIONS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002743-10,0,0,0 2011-002744-27,1,,,0,1,0,0,0,1,2,0,0,3,0,0,0,0,3,Imperial College,Pharmacodynamic Studies of a Histone Deacetylase Inhibitor in FRDA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002744-27,0,0,0 2011-002745-35,1,2016-06-30,2016-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,UZLeuven,A placebo controlled trial with Baclofen for the treatment of patients with clinical suspicion of rumination syndrome or esophageal belching,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002745-35,0,0,0 2011-002748-28,1,2013-07-29,2013-07-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gilead Sciences Inc.,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002748-28,0,0,0 2011-002749-37,4,2018-11-28,2018-11-28,1,0,0,0,0,1,4,0,0,2,0,0,0,0,0,Univeristy of Milano-Bicocca,Validation of digital-PCR analysis through programmed imatinib interruption in PCR negative chronic myeloid leukemia patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002749-37,1,0,0 2011-002749-37,4,2018-11-28,2018-11-28,1,0,0,0,0,1,4,0,0,2,0,0,0,0,0,UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA,Validation of digital-PCR analysis through programmed imatinib interruption in PCR negative chronic myeloid leukemia patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002749-37,1,0,0 2011-002750-31,9,2015-12-16,2018-12-11,7,1,1,0,0,1,3,0,0,1,0,0,1,0,1,"Alexion Pharmaceuticals, Inc.","A multicenter, randomized, placebo-controlled study of SBC-102 in patients with lysosomal acid lipase deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002750-31,0,0,0 2011-002750-31,9,2015-12-16,2018-12-11,7,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Synageva BioPharma Corporation,"A multicenter, randomized, placebo-controlled study of SBC-102 in patients with lysosomal acid lipase deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002750-31,0,0,0 2011-002751-34,1,2017-09-28,2017-09-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Vejle Hospital,"An Open-Label Phase II Study of the Safety and Efficacy of Doxorubicin and Cyclophosphamide in Combination with Bortezomib, Lenalidomide, and Dexamethasone for Treatment of Patients with Newly Diagn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002751-34,0,0,0 2011-002754-31,12,2015-10-22,2015-10-22,8,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002754-31,0,0,0 2011-002755-34,1,2014-11-03,2014-11-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Serumwerk Bernburg AG,Open clinical study to determine the compatibility of Pyolysin®-Salbe in children aged between 0 and 17 years during the dermatological treatment of superficial wounds Offene klinische Studie zur ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002755-34,0,0,0 2011-002758-29,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Med. Univ. Wien, Uk für Innere Medizin I",Cerebral microdialysis in neurointensive care patients to determine brain penetration of antibiotics. An open label explorative study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002758-29,0,0,0 2011-002766-21,10,2021-02-01,2021-02-01,5,1,0,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim,An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) Studio clinico di estensione in aperto per la valutazione della sicurez...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002766-21,1,0,0 2011-002766-21,10,2021-02-01,2021-02-01,5,1,0,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim Limited,An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) Studio clinico di estensione in aperto per la valutazione della sicurez...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002766-21,1,0,0 2011-002766-21,10,2021-02-01,2021-02-01,5,1,0,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim España S.A,An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) Studio clinico di estensione in aperto per la valutazione della sicurez...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002766-21,1,0,0 2011-002766-21,10,2021-02-01,2021-02-01,5,1,0,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) Studio clinico di estensione in aperto per la valutazione della sicurez...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002766-21,1,0,0 2011-002766-21,10,2021-02-01,2021-02-01,5,1,0,0,0,2,3,0,0,2,0,0,0,0,1,SCS Boehringer Ingelheim Ingelheim Comm.V,An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) Studio clinico di estensione in aperto per la valutazione della sicurez...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002766-21,1,0,0 2011-002766-21,10,2021-02-01,2021-02-01,5,1,0,0,0,2,3,0,0,2,0,0,0,0,1,BOEHRINGER ING.,An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) Studio clinico di estensione in aperto per la valutazione della sicurez...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002766-21,1,0,0 2011-002766-21,10,2021-02-01,2021-02-01,5,1,0,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) Studio clinico di estensione in aperto per la valutazione della sicurez...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002766-21,1,0,0 2011-002766-21,10,2021-02-01,2021-02-01,5,1,0,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim Hellas,An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) Studio clinico di estensione in aperto per la valutazione della sicurez...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002766-21,1,0,0 2011-002766-21,10,2021-02-01,2021-02-01,5,1,0,0,0,2,3,0,0,2,0,0,0,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda",An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) Studio clinico di estensione in aperto per la valutazione della sicurez...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002766-21,1,0,0 2011-002768-25,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Allergan Limited,"A Single Center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Osteoarth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002768-25,0,0,0 2011-002770-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Emotional Brain BV,"A double-blind, randomized, placebo-controlled, proof of concept study to investigate the safety and efficacy of the combined administration of 0.5 mg sublingual testosterone and 10 mg tadalafil in wo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002770-23,0,0,0 2011-002773-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitetssjukhuset Örebro,Effekt av aldosteronblockad på hjärtrytmrubbningar hos dialysbehandlade.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002773-39,0,0,0 2011-002774-23,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Boehringer Ingelheim Pharmaceuticals, Inc.","An open-label clinical study to investigate pharmacokinetics (PK) of different doses (0.125 mg, 0.25 mg, 0.5 mg) of pramipexole administered once daily orally in pediatric patients who are individuall...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002774-23,0,1,1 2011-002775-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Med. Uni. Wien, UK für Neurologie",Vienna Interventional Management of Stroke Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002775-42,0,0,0 2011-002777-27,1,2016-02-22,2016-02-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Can-Fite BioPharma Ltd.,"A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Subjects with Elevated Intraocular Pressure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002777-27,0,0,0 2011-002778-21,1,2013-02-13,2013-02-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios del Dr. Esteve, S.A","A randomized, double-blind, controlled with active treatment (tramadol 100 mg) and placebo, parallel groups, Phase II clinical trial to establish the effective dose between 4 strengths of E-58425 for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002778-21,0,0,0 2011-002780-16,1,2018-05-31,2018-05-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Karolinska Institutet,PROLOGUES - Prehospital lowering of glucose in Stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002780-16,0,0,0 2011-002781-21,1,2014-04-24,2014-04-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Leeds Teaching Hospitals,A clinical study to evaluate the biological effects of administering rimantadine in patients with hepatitis C virus (HCV) infection alongside standard combination therapy with pegylated interferon and...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002781-21,0,0,0 2011-002782-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,INFAI GmbH,Gastromotal 13C-octanoic acid breath test in the diagnosis and evaluation of therapeutic outcome in patients with dyspeptic symptoms and delayed gastric emptying,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002782-38,0,0,0 2011-002784-24,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Sacro Cuore - Don Calabria Hospital,"Randomized, Open-label, Multi Centre Phase III Clinical Trial on Multiple versus Single Dose of Ivermectin for the Treatment of Strongyloides",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002784-24,0,0,0 2011-002785-20,1,2017-06-26,2017-06-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Charité - Universitätsmedizin Berlin,Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002785-20,0,0,0 2011-002787-25,1,2017-11-30,2017-11-30,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,"The protein tyrosine kinase inhibitor nilotinib as first-line treatment of Ph+, BCR-ABL+ chronic myeloid leukemia (CML) in early chronic phase: a phase IIIb, multicenter study of complete molecular re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002787-25,0,0,0 2011-002789-18,4,2013-09-30,2013-09-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Menarini Ricerche S.p.A,"A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING PHASE II STUDY ASSESSING RANOLAZINE IN THE MAINTENANCE OF SINUS RHYTHM AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH NON-PE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002789-18,0,0,0 2011-002789-18,4,2013-09-30,2013-09-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MENARINI RICERCHE S.P.A,"A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING PHASE II STUDY ASSESSING RANOLAZINE IN THE MAINTENANCE OF SINUS RHYTHM AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH NON-PE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002789-18,0,0,0 2011-002789-18,4,2013-09-30,2013-09-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MENARINI RICERCHE S.P.A.,"A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING PHASE II STUDY ASSESSING RANOLAZINE IN THE MAINTENANCE OF SINUS RHYTHM AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH NON-PE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002789-18,0,0,0 2011-002790-28,7,2015-10-13,2015-10-13,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A 26 week, randomized, double-blind, parallel-group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma-related events during treatment with Symbicort®,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002790-28,0,0,0 2011-002790-28,7,2015-10-13,2015-10-13,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 26 week, randomized, double-blind, parallel-group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma-related events during treatment with Symbicort®,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002790-28,0,0,0 2011-002792-42,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,LYSARC,A phase 3 open label randomized study to compare the efficacy and safety of rituximab plus lenalidomide ( CC-5013) versus rituximab plus chemotherapy followed by rituximab in subjects with previously ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002792-42,0,0,0 2011-002793-23,4,2014-01-23,2014-01-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Phase 3 Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotypes 1 and 4 Studio di Fase 3 per la valutazi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002793-23,0,0,0 2011-002793-23,4,2014-01-23,2014-01-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Phase 3 Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects with Chronic Hepatitis C Genotypes 1 and 4 Studio di Fase 3 per la valutazi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002793-23,0,0,0 2011-002796-41,1,2011-12-14,2011-12-14,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,McNeil AB,A PROOF OF CONCEPT WITH A NEW NICOTINE INHALER IN COMPARISON WITH NICOTINE INHALER 10 MG - AN EXPLORATORY STUDY IN ADULT HEALTHY SMOKERS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002796-41,0,0,0 2011-002797-23,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Nektar Therapeutics,"AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY OF NKTR-102 IN SUBJECTS PREVIOUSLY ENROLLED IN NKTR-102 STUDIES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002797-23,0,0,0 2011-002798-50,1,2014-05-26,2014-05-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Rune Rasmussen,Effect of prostacyclin infusion on cerebral vessels and metabolism in patients with subarachnoid haemorrhage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002798-50,0,0,0 2011-002803-13,4,2016-08-05,2016-08-08,4,1,0,0,0,2,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomised, Phase II Study Evaluating MK-1775 in Combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin Alone in Adult Patients with Platinum Sensitive p53 Mutant Ovarian Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002803-13,0,0,0 2011-002806-59,14,2014-11-19,2015-01-16,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Recherche & Développement,"Long-term Safety and Tolerability of REGN727/SAR236553 in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy: A Randomized, Double...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002806-59,0,0,0 2011-002806-59,14,2014-11-19,2015-01-16,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT,"Long-term Safety and Tolerability of REGN727/SAR236553 in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy: A Randomized, Double...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002806-59,0,0,0 2011-002810-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",A Phase 1/2 Study of Lenalidomide in combination with Bendamustine (LEBEN) in relapsed and primary refractory Hodgkin Lymphoma Studio di Fase 1/2 sull'utilizzo di Lenalidomide in combinazione con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002810-35,0,0,0 2011-002811-27,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,0,"Bente Langdahl, consultant, ass. professor, PhD, DMSc",The Effect of Treatment with PTH and Zoledronic acid in Patients with Osteogenesis Imperfecta Effekten af behandling af patienter med osteogenesis imperfecta med zoledronsyre og PTH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002811-27,0,0,0 2011-002812-10,1,2017-08-28,2017-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Medical Center of the Johannes Gutenberg University Mainz,"A prospective, randomised, open-label phase IIb clinical trial assessing the effect of pegylated Interferon alfa-2a (Pegasys®) 180 µg once weekly for 48 weeks in addition to an ongoing nucelos(t)ide b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002812-10,0,0,0 2011-002813-12,4,2013-03-19,2013-03-19,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,"CELLTRION, Inc","A Phase 3, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study to Compare the Efficacy and Safety of CT-P10 With MabThera, Each Administered in Combination With Cyclophosphamide, Vincris...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002813-12,0,0,0 2011-002816-97,1,2012-02-15,2012-02-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Pulmagen Therapeutics LLP,"A Randomised, Placebo-Controlled, Double-Blind, Parallel Group Phase II Study to Assess the Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects with Partly Controlled Atopic Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002816-97,0,0,0 2011-002817-12,10,2013-09-04,2013-10-17,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or Remission with GSK1605786A in Subjects with Moderately-to-Severely Active Crohn's Disease Estudio de tratamien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002817-12,0,0,0 2011-002818-37,3,2013-01-17,2013-01-17,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A phase II, 20-week, multi-centre, randomised, double-blind, placebo-controlled, parallel group proof of concept study to investigate the efficacy and safety of GSK1605786 for treatment of patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002818-37,0,0,0 2011-002819-28,1,2016-12-09,2016-12-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Stockholms Läns Landsting,Internet-based cognitive behavior therapy in combination with D-Cycloserine for Obsessive Compulsive Disorder: A double blinded randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002819-28,0,0,0 2011-002821-24,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,ALFA WASSERMANN,"Prospective pharmacodynamic study on patients with moderate, active Crohn’s disease treated with Rifaximin-EIR 400 mg tablets. Studio prospettico di farmacodinamica in pazienti con morbo di Crohn d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002821-24,0,0,0 2011-002823-16,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,0,A.O. UNIVERSITARIA INTEGRATA DI VERONA,Effects of Vitamin D in patients affected by heart failure Effetti della vitamina D in pazienti affetti da scompenso cardiaco,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002823-16,0,0,0 2011-002824-42,1,2015-02-10,2015-02-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Stealth Peptides Inc.,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia™ (MTP-131) on Reperfusion Injury in Patients Treated with Stand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002824-42,0,0,0 2011-002825-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospital General Universitario de Alicante,"Pilot, placebo-controlled, double-blind, randomized, parallel propofol effective in preventing refractory chronic migraine Estudio piloto, controlado con placebo, doble ciego, aleatorizado y parale...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002825-22,0,0,0 2011-002827-17,2,2014-04-30,2014-04-30,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson’s Disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002827-17,0,0,0 2011-002828-41,2,2014-11-17,2015-03-17,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A fixed dose, dose-response study of ropinirole prolonged release (PR) as adjunctive treatment to L-dopa in patients with advanced Parkinson's disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002828-41,0,0,0 2011-002829-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Stavanger Helseforskning AS,Sildenafil in Chronic Heart Failure; An investigator initiated multi-national clinical research study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002829-21,0,0,0 2011-002833-20,1,2015-11-03,2015-11-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Oxford University Hospitals NHS Trust,Prospective study of 18F-RGD PET-CT in assessment of response to antiangiogenic treatment in patients with renal cancer and comparison with perfusion CT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002833-20,0,0,0 2011-002840-29,4,2014-07-03,2014-07-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Dose Range Finding Study of JNJ–38518168 in Subjects with Active Rheumatoid Arthritis Despite Concomitant Methotre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002840-29,0,0,0 2011-002843-92,6,2019-02-25,2019-02-25,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Onxeo,"Multicentre, randomised, controlled, open-label, study comparing the efficacy and safety of slow repeated intravenous infusions of 2 doses of Doxorubicin TransdrugTM (DT) (20 mg/m² or 30 mg/m²) to th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002843-92,0,0,0 2011-002843-92,6,2019-02-25,2019-02-25,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,BioAlliance Pharma,"Multicentre, randomised, controlled, open-label, study comparing the efficacy and safety of slow repeated intravenous infusions of 2 doses of Doxorubicin TransdrugTM (DT) (20 mg/m² or 30 mg/m²) to th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002843-92,0,0,0 2011-002849-36,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Janssen-Cilag International NV,"A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Dose Range Finding Study of JNJ-39758979 in Subjects with Active Rheumatoid Arthritis Despite Concomitant Methotre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002849-36,0,0,0 2011-002853-77,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Lluita contra la SIDA,"PROSPECTIVE, RANDOMISED, CROSSOVER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE LIPID-LOWERING EFFECT OF ADDING TENOFOVIR/EMTRICITABINE CO-FORMULATION VS PLACEBO TO HIV-1-INFECTED SUBJECTS WI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002853-77,0,0,0 2011-002859-34,14,2015-05-27,2015-06-25,12,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 24-month, phase IIIb, open-label, randomized, activecontrolled, 3- arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002859-34,0,0,0 2011-002859-34,14,2015-05-27,2015-06-25,12,1,0,0,0,0,0,0,0,1,0,0,1,0,1,NOVARTIS PHARMA AG,"A 24-month, phase IIIb, open-label, randomized, activecontrolled, 3- arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002859-34,0,0,0 2011-002860-26,2,2013-01-10,2013-01-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Trius Therapeutics, Inc.","A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous to Oral 6-Day TR-701 Free Acid and Intravenous to Oral 10-Day Linezolid for the Treatment of Acut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002860-26,0,0,0 2011-002863-84,1,2012-11-30,2012-11-30,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,"Medizinische Universitaet Wien, AKH Wien, Innere Medizin III, klin.Abteilung fuer Nephrologie und Dialyse","Calcitonin stimulation: pentagastrin vs. calcium gluconate - potency, feasibility and tolerance in chronic kidney disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002863-84,0,0,0 2011-002865-39,3,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,sanofi-aventis recherche et développement,"An open label, multicenter phase II study of intravenous SAR3419, an anti-CD19 antibody-maytansine conjugate, in combination with rituximab in patients with relapsed or refractory Diffuse Large B Cell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002865-39,0,0,0 2011-002866-19,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"A 3-month, multicenter, randomized, open label study to evaluate the impact of early vs delayed introductioN of EVERolimus on WOUND healing in de novo kidney transplant recipients (NEVERWOUND study) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002866-19,0,0,0 2011-002867-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Department of Anaesthesia,Comparsion of continuous paravertebral blockade and continuous wound catheter infiltration for analgesia following mastectomy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002867-40,0,0,0 2011-002871-40,2,2014-10-31,2014-10-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Hexal AG,"Open label, single arm, multicenter study to evaluate the safety and immunogenicity of HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in pre-dialysis and dialysis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002871-40,0,0,0 2011-002872-17,9,2019-05-22,2020-02-10,6,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002872-17,0,0,0 2011-002872-17,9,2019-05-22,2020-02-10,6,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002872-17,0,0,0 2011-002872-17,9,2019-05-22,2020-02-10,6,1,0,0,0,2,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and thymu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002872-17,0,0,0 2011-002873-47,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,Grupo Español de Oncología Genitourinaria (SOGUG),PHASE II CLINICAL TRIAL OF DOVITINIB (TKI-258) IN FIRST-LINE METASTATIC OR LOCALLY ADVANCED NON-RESECTABLE ADRENOCORTICAL CARCINOMA ENSAYO CLÍNICO FASE II DE DOVITINIB (TKI-258) EN PRIMERA LINEA DE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002873-47,0,0,0 2011-002876-18,1,2014-11-17,2014-11-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,CYCLosporinE A in reperfused acute myocardial infarction (CYCLE-Trial) Ciclosporina A nell'infarto miocardico acuto riperfuso (studio CYCLE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002876-18,0,0,0 2011-002877-46,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Fundación Renal Iñigo Álvarez de Toledo,"Paricalcitol effect vs Albumine, inflammation and Fibrosis in Chronic proteinuric kidney disease patients (PALIFE trial) Randomized, controlled trial. Efecto de Paricalcitol sobre la Albuminuria, L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002877-46,0,0,0 2011-002880-42,2,2012-11-30,2012-11-30,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Synageva Biopharma Corp.,An Open Label Multicenter Extension Study to Evaluate the Long-Term Efficacy and Safety of SBC 102 in Children with Lysosomal Acid Lipase Deficiency Who Previously Received Treatment with SBC-102,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002880-42,1,0,0 2011-002887-26,13,2020-08-07,2020-08-07,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002887-26,0,0,0 2011-002887-26,13,2020-08-07,2020-08-07,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002887-26,0,0,0 2011-002887-26,13,2020-08-07,2020-08-07,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002887-26,0,0,0 2011-002891-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,"Receptorial radiotherapy with 177Lu DOTATATE in somatostatine receptors positive tumours, a phase II study. Radioterapia recettoriale con 177Lu-DOTATATE in tumori con recettori positivi per la soma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002891-18,0,0,0 2011-002893-21,6,2015-05-18,2016-03-30,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Genentech, Inc.","A PHASE II, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF CARBOPLATIN/PACLITAXEL AND CARBOPLATIN/PACLITAXEL/BEVACIZUMAB WITH AND WITHOUT GDC-0941 IN PATIENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002893-21,0,0,0 2011-002893-21,6,2015-05-18,2016-03-30,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GENENTECH , INC","A PHASE II, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF CARBOPLATIN/PACLITAXEL AND CARBOPLATIN/PACLITAXEL/BEVACIZUMAB WITH AND WITHOUT GDC-0941 IN PATIENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002893-21,0,0,0 2011-002894-48,11,2015-09-03,2016-10-28,7,1,0,0,0,0,3,2,0,1,1,0,1,0,1,Boehringer Ingelheim International GmbH,"Efficacy, pharmacokinetics, and safety of BI 695500 versus rituximab in patients with moderately to severely active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, activ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002894-48,0,0,0 2011-002896-40,4,2014-05-07,2014-05-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017 US","A RANDOMIZED, DOUBLE-BLIND, STUDY COMPARING THE PHARMACOKINETICS AND PHARMACODYNAMICS, AND ASSESSING THE SAFETY OF PF-05280586 AND RITUXIMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS ON A BACKGROUN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002896-40,0,0,0 2011-002896-40,4,2014-05-07,2014-05-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A RANDOMIZED, DOUBLE-BLIND, STUDY COMPARING THE PHARMACOKINETICS AND PHARMACODYNAMICS, AND ASSESSING THE SAFETY OF PF-05280586 AND RITUXIMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS ON A BACKGROUN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002896-40,0,0,0 2011-002900-34,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,CRESIB- International Research Center in Health of Barcelona,Population Pharmacokinetics in Benznidazol-treated adults with Chronic Chagas Disease. Benznidazol Pharmacokinetics and adverse reactions relationship. Estudio de Farmacocinética Poblacional de Ben...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002900-34,0,0,0 2011-002901-31,5,2013-11-05,2013-11-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002901-31,0,0,0 2011-002905-31,1,2014-04-14,2014-04-14,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Nycomed GmbH,"Effect of roflumilast 500 μg tablets once daily at acute COPD exacerbations treated with standard therapy of oral steroids and antibiotics. A randomised, double-blind, placebo-controlled, parallel-gro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002905-31,0,0,0 2011-002908-33,5,2014-07-02,2014-09-09,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim International GmbH,"A randomized, double-blind, multi-center, multi-national Phase III trial to compare efficacy and safety of BI 695500 plus chemotherapy versus rituximab plus chemotherapy in patients with untreated fol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002908-33,0,0,0 2011-002908-33,5,2014-07-02,2014-09-09,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BOEHRINGER INGELHEIM INTERNATIONAL GMBH,"A randomized, double-blind, multi-center, multi-national Phase III trial to compare efficacy and safety of BI 695500 plus chemotherapy versus rituximab plus chemotherapy in patients with untreated fol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002908-33,0,0,0 2011-002911-27,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA DI PARMA,Effect of boceprevir therapy on HCV-specific T cell responses: perspectives of immune monitoring and immune therapy Effetto della terapia con boceprevir sulle risposte T linfocitarie di HCV-specifi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002911-27,0,0,0 2011-002912-10,9,2014-05-30,2014-12-05,7,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Chiasma, Inc.",EFFICACY AND SAFETY OF ORAL OCTREOLIN™ IN PATIENTS WITH ACROMEGALY WHO ARE CURRENTLY RECEIVING PARENTERAL SOMATOSTATIN ANALOGS Efficacia e sicurezza di Octreolin™ orale in pazienti con acromegali...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002912-10,0,0,0 2011-002912-10,9,2014-05-30,2014-12-05,7,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Chiasma, Inc",EFFICACY AND SAFETY OF ORAL OCTREOLIN™ IN PATIENTS WITH ACROMEGALY WHO ARE CURRENTLY RECEIVING PARENTERAL SOMATOSTATIN ANALOGS Efficacia e sicurezza di Octreolin™ orale in pazienti con acromegali...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002912-10,0,0,0 2011-002912-10,9,2014-05-30,2014-12-05,7,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"CHIASMA, INC.",EFFICACY AND SAFETY OF ORAL OCTREOLIN™ IN PATIENTS WITH ACROMEGALY WHO ARE CURRENTLY RECEIVING PARENTERAL SOMATOSTATIN ANALOGS Efficacia e sicurezza di Octreolin™ orale in pazienti con acromegali...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002912-10,0,0,0 2011-002913-12,9,2020-09-02,2020-09-02,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002913-12,0,0,0 2011-002913-12,9,2020-09-02,2020-09-02,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KGKG,"A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002913-12,0,0,0 2011-002913-12,9,2020-09-02,2020-09-02,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002913-12,0,0,0 2011-002917-12,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Department of Orthopaedics IKE,Does PTH enhance healing after spinal fusion? Förbättrar PTH postero-lateral fusionsläkning vid ryggkirurgi?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002917-12,0,0,0 2011-002919-28,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO,Antenatal corticosteroids and respiratory distress syndrome in late preterm infants born by elective cesarean section. Multicentric randomized controlled clinical trial CORTICOSTEROIDI PRENATALI ED...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002919-28,0,0,0 2011-002920-41,1,2014-01-17,2014-01-17,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Hospital Tübingen,"Open-label Trial of Stelara® (Ustekinumab) In Patients with Pyoderma gangrenosum – an open, non-placebo controlled pilot study with 10 patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002920-41,0,0,0 2011-002921-23,1,2014-03-27,2014-03-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH,Pharmacokinetics and metabolic activation of capecitabine when given concomitantly with oxaliplatin and the monoclonal antibody cetuximab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002921-23,0,0,0 2011-002928-41,1,2018-10-28,2018-10-28,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Med. Uni. Wien, Klinik für Innere I",Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002928-41,0,0,0 2011-002931-25,4,2013-10-21,2013-10-21,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine Monotherapy in Subjects with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002931-25,0,0,0 2011-002935-24,1,,,0,0,0,0,1,0,4,0,0,3,0,0,0,0,0,The Princess Alexandra Hospital NHS Trust,A pilot study comparing the effectiveness of peripheral nerve block in forefoot surgery for post-operative pain relief when administered at the beginning rather than at the end of surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002935-24,0,0,0 2011-002941-36,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,NKI-AVL,Multicenter phase 1/2a study using T-cell receptor gene therapy in metastatic melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002941-36,0,0,0 2011-002943-92,1,,,0,1,0,0,0,1,4,0,0,1,1,1,0,1,1,GlaxoSmithKline Research and Development Limited,"A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation of FLOLAN™ in Subjects with Pulmonary Arterial Hypertension (PAH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002943-92,0,0,0 2011-002944-28,4,2013-02-21,2013-06-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A phase 2, multi-national, multi-centre, double masked, randomised, placebo controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002944-28,0,0,0 2011-002944-28,4,2013-02-21,2013-06-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"A phase 2, multi-national, multi-centre, double masked, randomised, placebo controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002944-28,0,0,0 2011-002946-11,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, open label, randomized, multicenter study of the im-munogenicity and safety of a booster dose of Kinrix when co-administered with varicella vaccine (Varivax®, Merck and Company) and MMR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002946-11,0,1,1 2011-002947-83,5,2016-11-22,2016-11-22,3,1,0,0,0,0,2,0,0,1,1,0,1,0,0,European Organisation for Research and Treatment of Cancer,Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geriatri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002947-83,0,0,0 2011-002949-35,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,Novo Nordisk A/S,"This trial is a randomized, single-centre, double-blind, two-period cross-over glucose clamp trial to test for bioequivalence between two SIBA (IDeg) formulations in healthy subjects. This trial is p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002949-35,0,1,1 2011-002955-33,1,2013-05-10,2013-05-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Aziende Chimiche Riunite Angelini Francesco S.p.A,Clinical and microbiological assessment of prulifloxacin in patients with Acute Bacterial Rhinosinusitis (ABRS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002955-33,0,0,0 2011-002957-67,2,2021-04-26,2021-04-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects With Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Ther...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002957-67,0,0,0 2011-002957-67,2,2021-04-26,2021-04-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX-1106) in Subjects With Progressive Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Ther...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002957-67,0,0,0 2011-002959-34,1,2015-06-01,2015-06-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Sønderjylland Hospital, department of neurology","RETRAP - A double blind, randomized, placebo controlled study of the effect of the combination of resistance training and prolonged release fampridine on muscle strength in the lower extremities, walk...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002959-34,0,0,0 2011-002962-19,1,2014-12-19,2014-12-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University College Dublin,CHLORHEXIDINE VERSUS POVIDONE-IODINE FOR SKIN ANITSEPSIS PRIOR TO CENTRAL VENOUS CATHETER INSERTION IN PRETERM INFANTS: PROTOCOL FOR A RANDOMISED TRIAL (THE SKA TRIAL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002962-19,0,0,0 2011-002965-39,1,2016-07-20,2016-07-20,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Swiss Group for Clinical Cancer Research (SAKK),Orteronel maintenance therapy in patients with metastatic castration resistant prostate cancer and non-progressive disease after first-line docetaxel therapy: A multicenter randomized double-blind pla...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002965-39,0,0,0 2011-002968-24,2,2013-08-20,2013-08-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and safety of liraglutide versus placebo as add-on to existing diabetes medication in subjects with type 2 diabetes and moderate renal impairment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002968-24,0,0,0 2011-002969-38,1,2014-07-14,2014-07-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 6-month, multicenter, randomized, controlled parallel group study to evaluate the effect of physical training on fatigue in patients with relapsing-remitting multiple sclerosis treated with fingolim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002969-38,0,0,0 2011-002970-22,6,2018-09-20,2018-09-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY AND COMPANY,"A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Eff...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002970-22,0,0,0 2011-002970-22,6,2018-09-20,2018-09-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Eff...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002970-22,0,0,0 2011-002977-44,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)","Antibiotics vs Surgery in Acute Appendicitis: an intention to treat prospective randomised controlled study, The ASAA-Study Antibiotics vs Surgery in Acute Appendicitis: an intention to treat prosp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002977-44,0,0,0 2011-002981-19,3,2014-12-29,2014-12-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in Subjects with Active Crohn's Diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002981-19,0,0,0 2011-002985-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jules Bordet Institute,An open-label phase II trial evaluating the efficacy and safety of neoadjuvant EndoTAGTM-1 in combination with paclitaxel in patients with Her2-negative high risk breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002985-19,0,0,0 2011-002986-39,1,2012-05-23,2012-05-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Profil Institut für Stoffwechselforschung GmbH,"A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Fourfold Cross-Over Study to Investigate the Glucose Lowering Effects of Dextromethorphan and Amantadine in Subjects with Type 2 Diabetes Mel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002986-39,0,0,0 2011-002987-26,1,2012-07-03,2012-07-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Bispebjerg Hospital,Effects of high dose terbutaline on physical performance in patients with chronic obstructive pulmonary disease and acute inflammatory response after exercise,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002987-26,0,0,0 2011-002992-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA' DEGLI STUDI DI PERUGIA,PREvention of VENous Thromboembolism In Hemorrhagic Stroke patients PREvention of VENous Thromboembolism In Hemorrhagic Stroke patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002992-40,0,0,0 2011-002995-17,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,3,,Treatment trial of stiff skin syndrome with Losartan,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002995-17,0,0,0 2011-003006-25,7,2013-12-10,2013-12-10,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Shire Development LLC,"Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003006-25,0,0,0 2011-003006-25,7,2013-12-10,2013-12-10,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SHIRE PHARMACEUTICALS LTD,"Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003006-25,0,0,0 2011-003006-25,7,2013-12-10,2013-12-10,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Shire Development Inc,"Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003006-25,0,0,0 2011-003006-25,7,2013-12-10,2013-12-10,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Shire Development LLC.,"Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003006-25,0,0,0 2011-003006-25,7,2013-12-10,2013-12-10,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Shire Development Inc.,"Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003006-25,0,0,0 2011-003010-17,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,Randomized double-blind intervention trial to assess the efficacy of vitamin D3 supplementation vs placebo in reducing hepatic steato-inflammation and cardio-metabolic risk profile in patients affecte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003010-17,0,0,0 2011-003012-23,1,2012-04-13,2012-04-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AQUINOX PHARMACEUTICALS INC,"A phase IIa single-centre, randomised, double-blind, placebo-controlled, two-way cross-over allergen challenge study to evaluate the effect of treatment with once daily AQX-1125 on the late asthmatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003012-23,0,0,0 2011-003016-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,GUNA SPA,Controlled randomized study on maintenance to low activity disease with low doses of SKA citokines compared with standard therapy (DMARDS)of arthritis management Studio controllato randomizzato sul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003016-23,0,0,0 2011-003018-17,1,2013-12-23,2013-12-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shire Development LLC,"The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003018-17,0,0,0 2011-003019-47,10,2014-02-10,2014-03-27,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Shire Development Inc.,"A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Resi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003019-47,0,0,0 2011-003019-47,10,2014-02-10,2014-03-27,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Shire Development LLC,"A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Resi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003019-47,0,0,0 2011-003019-47,10,2014-02-10,2014-03-27,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Shire Development Inc,"A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Resi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003019-47,0,0,0 2011-003025-10,1,2020-05-29,2020-05-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,Effect of active vitamin-D treatment on left ventricular hypertrophy in patients with type-2 diabetes and stage-3 chronic kidney disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003025-10,0,0,0 2011-003025-10,1,2020-05-29,2020-05-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's and St Thomas NHS Foundation Trust,Effect of active vitamin-D treatment on left ventricular hypertrophy in patients with type-2 diabetes and stage-3 chronic kidney disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003025-10,0,0,0 2011-003030-14,1,2014-06-30,2014-06-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Nerve Growth Factor (NGF) eye drop administration as visual rescue treatment in visual loss-associated optic gliomas. Effetti neurali della somministrazione topica di un collirio a base di Nerve Gr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003030-14,0,0,0 2011-003032-31,1,2012-12-28,2012-12-28,1,0,1,0,0,0,3,0,0,1,0,0,1,0,1,"Ferrer Internacional, S.A.","A phase III 3 arms, multicenter, randomised, investigator-blind study to assess the efficacy and safety of ozenoxacin 1% cream applied twice daily for 5 days versus placebo in the treatment of patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003032-31,0,0,0 2011-003036-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI,Ministry of health integrated oncological program n°5/2006: 18F-Fluorometilcholine (18FFCH) PET/CT sensibility in diagnosis of breast cancer metastasis Programma integrato di oncologia n. 5/2006 d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003036-31,0,0,0 2011-003038-14,2,,,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,GETAID,"A RANDOMIZED CONTROLLED TRIAL INVESTIGATING TAILORED TREATMENT WITH INFLIXIMAB FOR ACTIVE LUMINAL CROHN'S DISEASE Een gerandomiseerd, gecontroleerd onderzoek naar een passende behandeling met Infli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003038-14,0,0,0 2011-003044-53,5,2012-10-09,2012-12-10,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","AN OPEN-LABEL, RANDOMISED PHASE 1B/2 STUDY OF PF-04691502 IN COMBINATION WITH LETROZOLE COMPARED WITH LETROZOLE ALONE IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003044-53,0,0,0 2011-003044-53,5,2012-10-09,2012-12-10,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017 US","AN OPEN-LABEL, RANDOMISED PHASE 1B/2 STUDY OF PF-04691502 IN COMBINATION WITH LETROZOLE COMPARED WITH LETROZOLE ALONE IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003044-53,0,0,0 2011-003044-53,5,2012-10-09,2012-12-10,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer, S.L.U.","AN OPEN-LABEL, RANDOMISED PHASE 1B/2 STUDY OF PF-04691502 IN COMBINATION WITH LETROZOLE COMPARED WITH LETROZOLE ALONE IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER-2 NEGATIVE EARLY BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003044-53,0,0,0 2011-003047-22,4,2012-11-29,2012-12-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Reckitt Benckiser Pharmaceuticals,"A Randomised, Double-Blind, Double-Dummy, Active-Drug-Controlled, Parallel-Group, Multicentre Acceptability and Safety Study of the Transfer from Subutex®/Suboxone® to RBP-6300 in Opioid-Dependent Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003047-22,0,0,0 2011-003049-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"ChemoCentryx, Inc","A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Effect of CCX140-B on Albuminuria in Subjects with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003049-16,0,0,0 2011-003051-19,1,,,0,1,0,0,1,0,4,0,0,1,1,1,0,1,1,ZAMBON S.p.A.,Evaluation of the speed of action of Ibuprofen Arginine in comparison to Ibuprofen in the acute pain relief after mini invasive orthopaedic arthroscopic knee surgery in adults. Valutazione della ve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003051-19,0,0,0 2011-003052-40,1,2014-06-17,2014-06-17,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Southampton University Hospital NHS Trust,An exploratory study to investigate the optimal scheduling of chemotherapy in patients with operable colorectal liver metastases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003052-40,0,0,0 2011-003053-25,1,2015-09-10,2015-09-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Research and Enterprise Department,"A randomised, double blind, placebo controlled trial to evaluate the effect of Rivastigmine on gait in people with Parkinson’s disease who have fallen.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003053-25,0,0,0 2011-003059-20,4,2019-05-07,2019-05-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of different intra-articular (i.a.) dosages of sprifermin in subjects with prim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003059-20,0,0,0 2011-003062-32,5,2015-11-26,2015-12-25,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",A RANDOMIZED PHASE 2 NON-COMPARATIVE STUDY OF THE EFFICACY OF PF-04691502 AND PF-05212384 IN PATIENTS WITH RECURRENT ENDOMETRIAL CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003062-32,0,0,0 2011-003062-32,5,2015-11-26,2015-12-25,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,PFIZER SLU,A RANDOMIZED PHASE 2 NON-COMPARATIVE STUDY OF THE EFFICACY OF PF-04691502 AND PF-05212384 IN PATIENTS WITH RECURRENT ENDOMETRIAL CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003062-32,0,0,0 2011-003062-32,5,2015-11-26,2015-12-25,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017 US",A RANDOMIZED PHASE 2 NON-COMPARATIVE STUDY OF THE EFFICACY OF PF-04691502 AND PF-05212384 IN PATIENTS WITH RECURRENT ENDOMETRIAL CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003062-32,0,0,0 2011-003063-30,1,2019-06-21,2019-06-21,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,CHU Nantes,Traitement Ciblé et Précoce du Canal Artériel du Prématuré par Ibuprofène (TRIOCAPI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003063-30,0,0,0 2011-003065-15,1,2017-07-03,2017-07-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients with Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003065-15,0,0,0 2011-003066-32,2,2015-02-27,2015-02-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A randomized double-blind multiple-dose placebo-controlled trial to establish the efficacy of QBX258 (combination of VAK694 and QAX576) in asthma that is inadequately controlled with inhaled corticost...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003066-32,0,0,0 2011-003067-30,5,2014-09-10,2014-09-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Open Label Study of Safety and Efficacy with BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with Human Immunodeficiency Virus (HIV) a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003067-30,0,0,0 2011-003067-30,5,2014-09-10,2014-09-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Open Label Study of Safety and Efficacy with BMS-790052 plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with Human Immunodeficiency Virus (HIV) a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003067-30,0,0,0 2011-003069-14,9,2016-06-01,2016-06-01,8,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A 24-month, multi-center, single arm, prospective study to evaluate renal function, efficacy, safety and tolerability of everolimus in combination with reduced exposure cyclosporine or tacrolimus i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003069-14,1,0,0 2011-003069-14,9,2016-06-01,2016-06-01,8,1,1,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS FARMA,"A 24-month, multi-center, single arm, prospective study to evaluate renal function, efficacy, safety and tolerability of everolimus in combination with reduced exposure cyclosporine or tacrolimus i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003069-14,1,0,0 2011-003069-14,9,2016-06-01,2016-06-01,8,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A,"A 24-month, multi-center, single arm, prospective study to evaluate renal function, efficacy, safety and tolerability of everolimus in combination with reduced exposure cyclosporine or tacrolimus i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003069-14,1,0,0 2011-003071-11,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Ghent University,Cognitieve en emotionele controle: gelijkenissen en verschillen in neuraal substraat - 11C-Raclopride,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003071-11,0,0,0 2011-003072-37,10,2017-10-18,2017-10-18,8,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Biogen Idec Research Ltd,"An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003072-37,0,0,0 2011-003072-37,10,2017-10-18,2017-10-18,8,1,1,0,0,1,3,0,0,1,0,0,1,0,1,BIOGEN IDEC RESEARCH LTD,"An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003072-37,0,0,0 2011-003073-28,4,2013-12-05,2013-12-05,4,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Biogen Idec Research Ltd,"An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003073-28,0,0,0 2011-003075-11,8,2017-11-01,2017-11-01,6,1,1,0,0,1,3,0,0,1,0,0,1,0,1,BIOGEN IDEC RESEARCH LTD,"An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant, Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003075-11,0,0,0 2011-003075-11,8,2017-11-01,2017-11-01,6,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Biogen Idec Research Ltd,"An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant, Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003075-11,0,0,0 2011-003076-36,3,2014-11-24,2014-11-24,2,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Biogen Idec Research Ltd,"Open-label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in the Prevention and Treatment of Bleeding Episodes in Pe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003076-36,0,0,0 2011-003078-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,SPCG,SPCG 16 Sensi-cab Randomized phase III trial comparing cabazitaxel in combination with hormone therapy to hormone therapy alone in metastatic prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003078-10,0,0,0 2011-003080-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO CLINICO HUMANITAS,WEIGHT-ADJUSTED LOW MOLECOLAR WEIGHT HEPARIN IN RECURRENT IMPLANTATION FAILURE: A RANDOMIZED OPEN LABELED TRIAL Eparina a basso Peso Molecolare a dosaggio aggiustato per il peso corporeo in fallime...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003080-30,0,0,0 2011-003081-32,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Boehringer Ingelheim bv,An exploratory study to investigate the pharmacokinetics and effects of DABIgatran etexilate in patients with stable severe RENAL disease: DabiRenal Een studie naar de farmacokinetiek en effecten v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003081-32,0,0,0 2011-003082-15,1,2013-06-01,2013-06-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Karen Toftdahl Bjørnholdt,High dose dexamethasone for pain following arthroscopic shoulder surgery: A randomised blinded clinical trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003082-15,0,0,0 2011-003084-30,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,PROTOCOL OF POST-THYROIDECTOMY PAIN MANAGEMENT GESTIONE DEL DOLORE POST-TIROIDECTOMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003084-30,0,0,0 2011-003087-70,1,2014-05-27,2014-05-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Polichem SA,"Randomized, open-label, controlled study on the efficacy of Ciclopoli® (ciclopirox 8% nail lacquer) versus Loceryl® (amorolfine 5% nail lacquer) on the culture conversion to negative in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003087-70,0,0,0 2011-003089-34,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,Chr. Hansen A/S,"The effect for Lactobacillus paracasei subsp. paracasei, L. casei 431® on immune response to influenza vaccination in healthy adult volunteers - a multi-center, randomized, placebo-controlled, parall...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003089-34,0,0,0 2011-003099-35,1,2018-06-30,2018-06-30,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,Phase I/II study of oral MEK inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination with Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposi’s sarcoma (KS).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003099-35,0,0,0 2011-003100-21,13,2017-05-10,2019-06-05,11,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"UCB BIOSCIENCES, Inc.","A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003100-21,1,1,0 2011-003100-21,13,2017-05-10,2019-06-05,11,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"UCB BIOSCIENCES, INC.","A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003100-21,1,1,0 2011-003104-20,1,2021-03-03,2021-03-03,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,UZLeuven,"The effect of Acomplia® (rimonabant) on esophageal sensitivity and gastric accommodation during food intake in healthy volunteers: a single-blind, placebo-controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003104-20,0,0,0 2011-003105-22,1,2013-11-19,2013-11-19,1,0,0,0,0,0,3,0,0,1,0,0,1,0,3,Rigshospitalet,"Analgetisk effekt af perioperativ Gabapentin ved total knæalloplastik: Et randomiseret, dobbeltblindet, placebokontrolleret dosis-respons studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003105-22,0,0,0 2011-003106-24,1,2014-09-09,2014-09-09,1,0,0,0,0,0,4,0,0,1,1,1,1,0,1,Baxter Innovations GmbH,Effectiveness of PREFLUCEL vaccination against infection with seasonal influenza virus in an adult and elderly population aged 50 years and older,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003106-24,0,0,0 2011-003115-34,1,2016-12-31,2016-12-31,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,Medizinische Universität Wien,A Collagen-Fibrin Patch (Tachosil®) for the Prevention of Symptomatic Lymphoceles after Pelvic Lymphadenectomy in Women with Gynecologic Malignancies: a Randomized Clinical Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003115-34,0,0,0 2011-003117-41,3,2015-01-30,2015-01-30,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled, multiple dose study to evaluate the safety, tolerability, and efficacy of intravenous administration of secukinumab (AIN457) in patients with asthma not...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003117-41,0,0,0 2011-003118-17,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma GmbH,"A 12 month, multi-center, open-label, randomized, controlled study to evaluate efficacy/safety and evolution of renal function of everolimus in co-exposure with tacrolimus in de novo liver transplant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003118-17,0,0,0 2011-003119-50,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Vesa Kontinen,Topical anaesthesia for postoperative pain in adult patients undergoing tonsillectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003119-50,0,0,0 2011-003121-94,3,2014-11-27,2014-11-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharmacosmos A/S,"A Prospective, Non-controlled, Safety Study of Intravenous Iron Isomaltoside 1000 (Monofer®) administered by a High Dosing Regimen in Subjects with Inflammatory Bowel Disease (PROMISE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003121-94,0,0,0 2011-003122-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Assessment of aspirin response in patients with Type 1 diabetes mellitus: a pilot study Valutazione della risposta all`™aspirina in pazienti con Diabete Mellito di tipo 1: studio pilota.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003122-27,0,0,0 2011-003123-35,1,2013-01-18,2013-01-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford,"The impact of single versus double dose acetylsalicylic acid on platelet function in patients with type 2 diabetes (the ""ASP Study"").",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003123-35,0,0,0 2011-003124-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Cliniques Universitaires Saint Luc,A prospective phase II study on dose escalation using PET based adaptive IMRT stage II-III non small lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003124-12,0,0,0 2011-003128-11,3,2014-07-23,2014-07-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,Phase II trial of dasatinib in subjects with advanced cancers harboring DDR2 mutation or inactivating B-RAF mutation Pharmacogenetics Blood Amendment 1; Revised Protocol 02 incorporating amendment 05,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003128-11,0,0,0 2011-003129-92,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,MUMC+,"The Orange III trial: Optimised recovery with Movicol preoperatively within an enhanced recovery programme, a randomised controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003129-92,0,0,0 2011-003130-14,6,2014-03-25,2014-04-30,6,0,0,0,0,1,3,0,0,1,0,0,1,0,1,InDex Pharmaceuticals AB,"A placebo-controlled, double-blind, randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003130-14,0,0,0 2011-003130-14,6,2014-03-25,2014-04-30,6,0,0,0,0,1,3,0,0,1,0,0,1,0,1,INDEX PHARMACEUTICALS,"A placebo-controlled, double-blind, randomised study to assess the efficacy and safety of Kappaproct as an add-on to current practice in chronic active treatment refractory ulcerative colitis patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003130-14,0,0,0 2011-003132-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Svettmottagningen Hidroskliniken, Stockholm","Botulinum toxin treatment in craniofacial, inguinal, palmar, plantar and truncal hyperhidrosis, a randomized, double blind, placebo controlled study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003132-30,0,0,0 2011-003133-34,1,2013-12-03,2013-12-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,A. Carlsson Research AB,The Effects of the Dopamine Stabilizer (-)-OSU6162 on Craving and Impulsivity in Alcohol Dependent Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003133-34,0,0,0 2011-003134-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC,5-Aminolevulinic Acid PhotoDynamic Therapy for the treatment of premalignant disorders of the vulva. 5-Aminolevulinic acid fotodynamische therapie voor behandeling van premaligne aandoeningen van d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003134-13,0,0,0 2011-003137-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Pia österlund and Helena Isoniemi,"Open-label, single-arm, phase II study of bevacizumab (AVASTIN) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer II vaiheen avo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003137-33,0,0,0 2011-003142-41,21,2017-06-22,2018-02-28,19,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Amgen, Inc.","A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003142-41,0,0,0 2011-003142-41,21,2017-06-22,2018-02-28,19,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN INC.,"A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003142-41,0,0,0 2011-003142-41,21,2017-06-22,2018-02-28,19,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,"A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003142-41,0,0,0 2011-003144-50,3,2013-05-09,2013-05-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pierre Fabre Dermatologie, Represented by Institut de Recherche Pierre Fabre","A randomised, double blind, controlled, multicentre study in infants with infantile hemangioma to compare propranolol gel to placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003144-50,0,0,0 2011-003145-17,8,2015-10-19,2016-05-10,7,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Threshold Pharmaceuticals, Inc.","A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003145-17,0,0,0 2011-003145-17,8,2015-10-19,2016-05-10,7,1,0,0,0,1,3,0,0,1,1,0,1,0,1,THRESHOLD PHARMACEUTICALS INC.,"A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003145-17,0,0,0 2011-003147-22,1,2012-08-31,2012-08-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Glenmark Farmaceutica LTDA,"A Multicenter, Open-Label, Comparator-Controlled, Parallel Group, Phase 3 Study to Assess the Efficacy and Safety of Clotrimazole/Clindamycin (200 mg/100 mg FDC) Ovules Compared with Metronidazole (50...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003147-22,0,0,0 2011-003148-39,6,2013-07-30,2013-07-30,4,1,1,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"A 26-week, Multinational, Multi-centre, Open-Labelled, Randomised, Parallel, Efficacy and Safety Comparison of Insulin Degludec and Insulin Detemir in children and adolescents 1 to less than 18 year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003148-39,0,0,0 2011-003148-39,6,2013-07-30,2013-07-30,4,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 26-week, Multinational, Multi-centre, Open-Labelled, Randomised, Parallel, Efficacy and Safety Comparison of Insulin Degludec and Insulin Detemir in children and adolescents 1 to less than 18 year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003148-39,0,0,0 2011-003151-20,10,2017-02-14,2017-04-14,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomised, Placebo-Controlled, Parellel-Group, Double-Blind Efficacy and Safety Trial of MK-8931 with a long term double-blind extension in Subjects with Mild to Moderate Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003151-20,0,0,0 2011-003151-20,10,2017-02-14,2017-04-14,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.","A Randomised, Placebo-Controlled, Parellel-Group, Double-Blind Efficacy and Safety Trial of MK-8931 with a long term double-blind extension in Subjects with Mild to Moderate Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003151-20,0,0,0 2011-003151-20,10,2017-02-14,2017-04-14,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidary of Merck & Co., Inc","A Randomised, Placebo-Controlled, Parellel-Group, Double-Blind Efficacy and Safety Trial of MK-8931 with a long term double-blind extension in Subjects with Mild to Moderate Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003151-20,0,0,0 2011-003154-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Privatärztliche urologische Partnerschaft GbR, EuromedClinic",Circulating Tumor Cells in Patients with Castration Resistant Metastatic Prostate Cancer Undergoing Zoledronate Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003154-12,0,0,0 2011-003156-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Tampere University Hospital,"OPEN, SINGLE-ARM, MULTICENTER, PHASE II TRIAL INVESTIGATING THE SAFETY OF BIWEEKLY CABAZITAXEL IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH A DOCETAXEL-CONTAINI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003156-39,0,0,0 2011-003158-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Pia Österlund and Helena Isoniemi,"A population-based prospective study to evaluate clinical behaviour, resectability and survival in metastatic colorectal cancer patients in Finland",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003158-24,0,0,0 2011-003163-29,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,SNIPP study - A investigator initiated phase II study of Sunitinib in patients with recurrent paraganglioma/pheochromocytoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003163-29,0,0,0 2011-003166-32,1,2011-10-17,2011-10-17,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Omninvest Ltd.,"A Randomized, Double-blind, Multi-Center Study to Evaluate Safety and Immunogenicity of One Dose of Four FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) Influenza Vaccines ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003166-32,0,0,0 2011-003167-30,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A randomised, open-label study to assess the immunogenicity and reactogenicity of GSK Biologicals’ IPV vaccine administered as a three-dose primary vaccination course at 2-3-4 months of age in healthy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003167-30,0,1,1 2011-003168-63,2,2020-02-26,2020-02-26,2,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Hospital Ulm,"Phase-II study evaluating midostaurin in induction, consolidation and maintenance therapy also after allogeneic blood stem cell transplantation in patients with newly diagnosed acute myeloid leukemia ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003168-63,0,0,0 2011-003172-36,1,2014-12-04,2014-12-04,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Department of Anaesthesia, Tampere University Hospital",Arousal reaction during desflurane anaesthesia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003172-36,0,0,0 2011-003173-28,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Helsinki University Hospital,Volume replacement therapy in cardiac surgery: effect on renal function. Nestehoito sydänkirurgiassa: vaikutus munuaisten toimintaan.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003173-28,0,0,0 2011-003174-89,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Enrique De Madaria Pascual,Ursodeoxycholic acid in the secondary prophylaxis of acute biliary pancreatitis: pilot clinical trial randomized double-blind. Ácido ursodeoxicólico en la profilaxis secundaria de pancreatitis agud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003174-89,0,0,0 2011-003176-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO,"Individualizing duration of antibiotic therapy in hospitalized patients with community-acquired pneumonia: a non-inferiority, randomized, controlled trial. Individualizzazione della durata della te...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003176-36,0,0,0 2011-003179-12,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"University Hospital of Wuerzburg, Medical Director",Mineralocorticoid Receptor antagonists in End stage reNal DiseAse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003179-12,0,0,0 2011-003181-32,1,2015-06-25,2015-06-25,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Karolinska University Hospital,In vivo expansion and efficacy of adoptive natural killer cell-based immunotherapy for high-risk myeloid diseases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003181-32,0,0,0 2011-003183-75,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,the role of vitamin D supplementation in the prevention of cardiovascular risk factors Il ruolo della supplementazione con Vitamina D nella prevenzione dei fattori di rischio cardiovascolare,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003183-75,0,0,0 2011-003184-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHRU de Tours,Impact sur l’efficacité et la tolérance entre 4 mois et 12 mois post-transplantation de 2 valeurs de concentrations résiduelles cibles d’Advagraf® chez des patients transplantés rénaux de novo.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003184-29,0,0,0 2011-003185-33,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE DI RICOVERO E CURA PER ANZIANI IRCCS,"Prospective, controlled, randomized, blind study to evaluate the effects of intramuscular-paravertebral injections of an oxygen-ozone (O2-O3) mixture in patients with lumbar pain aged 65 or older S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003185-33,0,0,0 2011-003188-31,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,CRUCELL SWITZERLAND AG,"A Phase IV, open label study to evaluate the immune response against homogenous and heterogenous circulating strains in elderly subjects after vaccination with Inflexal V Uno studio di Fase IV in a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003188-31,0,0,0 2011-003190-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,HolsboerMaschmeyer NeuroChemie (HMNC) GmbH,Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication according to the the ABCB1 Gene Optimierung der Depressionsbehandlung durch genotypabhängige Medikationsanpassunge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003190-29,0,0,0 2011-003191-36,1,2017-04-29,2017-04-29,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,"Dose-dense ABVD as first line therapy in early stage unfavorable Hodgkin’s Lymphoma: a phase II, prospective, multi-center study Studio prospettico, multicentrico, di fase II non randomizzato per v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003191-36,0,0,0 2011-003192-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,University of Sydney,Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003192-11,0,0,0 2011-003194-28,1,2013-01-12,2013-01-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,PULSION Medical Systems SE,"Determination of the sensitivity of ICG fluorescence technique for the detection of Sentinel Lymph Nodes in breast cancer – a monocenter, prospective open-label clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003194-28,0,0,0 2011-003197-84,2,2016-02-03,2016-02-03,1,1,1,0,0,1,2,0,0,1,0,0,1,0,1,BIOMARIN PHARMACEUTICAL INC.,"A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age with Mucopolysaccharidosis IVA (Morquio A Syndrome) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003197-84,0,0,0 2011-003197-84,2,2016-02-03,2016-02-03,1,1,1,0,0,1,2,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc.,"A Phase 2, Open-label, Multinational Clinical Study to Evaluate the Safety and Efficacy of BMN 110 in Pediatric Patients Less Than 5 Years of Age with Mucopolysaccharidosis IVA (Morquio A Syndrome) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003197-84,0,0,0 2011-003201-14,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,Krankenhaus Nordwest GmbH,"Phase I/II, Open Label, Dose Escalating Study To Investigate Safety, Tolerability, And Preliminary Efficacy Of The Trifunctional Anti-HER-2/neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-2/n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003201-14,0,0,0 2011-003202-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,MULTICENTER ITALIAN STUDY ON THE CEUS ASSESSMENT OF RESPONSE OF COLORECTAL CANCER METASTASIS TREATED WITH AVASTIN. STUDIO MULTICENTRICO ITALIANO PER VALUTARE LA RISPOSTA ALLA TERAPIA CON AVASTIN DE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003202-24,0,0,0 2011-003206-25,7,2013-12-30,2013-12-30,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Norgine Ltd,"A multi-centre, phase II, double-blind, randomised, placebo-controlled, parallel group, dose-ranging study in patients with faecal incontinence; to evaluate the efficacy, safety and tolerability of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003206-25,0,0,0 2011-003206-25,7,2013-12-30,2013-12-30,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NORGINE LIMITED,"A multi-centre, phase II, double-blind, randomised, placebo-controlled, parallel group, dose-ranging study in patients with faecal incontinence; to evaluate the efficacy, safety and tolerability of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003206-25,0,0,0 2011-003207-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,COMPARISON BETWEEN INTRA-ARTICULAR INJECTION OF CORTICOSTEROIDS AND INTRA-ARTICULAR INJECTION OF HYALURONIC ACID IN THE TREATMENT OF ROTATOR CUFF TENDINOPATHY. A PROSPECTIVE CLINICAL TRIAL. CONFRON...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003207-37,0,0,0 2011-003208-19,2,2014-08-04,2014-08-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GW Pharma Ltd.,"A randomised, double-blind, placebo-controlled parallel group, pilot study of GWP42003 in the symptomatic treatment of ulcerative colitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003208-19,0,0,0 2011-003212-22,1,2017-09-30,2017-09-30,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,GOSH/ICH Joint Research & Development Office,Phase I study of ex-vivo lentiviral gene therapy for the inherited skin disease Netherton Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003212-22,0,0,0 2011-003216-23,1,2017-02-02,2017-02-02,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHRU MONTPELLIER,Intranasal Midazolam versus intranasal Ketamine to sedate newborns for intubation in delivery room Anesthésie par kétamine versus midazolam intranasal pour l'intubation des nouveau-nés en salle de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003216-23,0,0,0 2011-003217-41,1,2020-07-03,2020-07-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH,Biomarker directed treatment in metastatic colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003217-41,0,0,0 2011-003218-17,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Hospital Universitario La Paz,"Efficacy of topical tranexamic acid versus intravenous administration to reduce blood transfussion rate in total knee arthroplasty surgery: phase III, unicentric, controlled,double blind, randomized ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003218-17,0,0,0 2011-003221-97,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Fundacio Sant Joan de Deu,BENEFICIOS DEL CONTROL GLICÉMICO ESTRICTO SOBRE EL PRONÓSTICO DEL PACIENTE PEDIÁTRICO CRÍTICAMENTE ENFERMO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003221-97,0,0,0 2011-003226-27,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Birmingham,A Phase II Study of Pazopanib in Metastatic Merkel Cell Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003226-27,0,0,0 2011-003227-35,1,2013-12-17,2013-12-17,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,18F-FECh-PET in patients with brain tumors Utilizzo della PET (Tomografia ad Emissione di Positroni) con 18FluoroetilColina (18F-FECh) per lo studio dei pazienti con tumore cerebrale,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003227-35,0,0,0 2011-003232-31,1,2013-05-02,2013-05-02,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,sanofi-aventis recherche et développement,"A two part protocol to assess, using double blind placebo control, the safety, tolerability, and pharmacokinetics of ascending single doses of a new intra-articular administration formulation of SAR11...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003232-31,0,0,0 2011-003233-34,1,2017-12-01,2017-12-01,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,University of Nottingham,The effect of intravenous iron on postoperative transfusion requirements in hip fracture patients – a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003233-34,0,0,0 2011-003237-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HOVON Foundation,Treatment of severe GVHD after allogeneic hematopoietic stem cell transplanatation with MSCs and steroid versus steroids alone. A prospective double-blind placebo-controlled randomized phase III trial...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003237-33,0,0,0 2011-003238-15,1,2015-05-22,2015-05-22,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,KKRN Katholisches Klinikum Ruhrgebiet Nord GmbH,Quality of analgesia and side effect incidence and severity during postoperative pain management with Palexia® compared to Targin® Klinische Prüfung zum Vergleich Tapentadol (Palexia®) und Oxycodo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003238-15,0,0,0 2011-003239-76,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,BRUSCHETTINI SRL,"Efficacy and tolerability clinical trial of Lantigen B (A bacterial lysate having immunostimulating activity) in the prophylaxis of respiratory infections, with special reference to patients with alle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003239-76,0,0,0 2011-003243-21,1,2016-07-28,2016-07-28,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,Fundación Pública Andaluza Progreso y Salud,"Randomized, comparative and prospective clinical trial evaluating efficacy and safety of a dose of seasonal flu vaccine compared to two doses of vaccine for prevention of influenza in solid organ tran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003243-21,0,0,0 2011-003248-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Central Military Hospital,"The clinical significance of epigenetic factors research to refine the diagnosis, estimate prognosis and risk of recurrence after curative pancreatic cancer resection.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003248-36,0,0,0 2011-003249-16,1,2013-06-18,2013-06-18,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital of Antwerp,"OPEN-LABEL, PROSPECTIVE EXPLORATORY STUDY TO ASSESS THE EFFECTS OF FORMOTEROL AND BECLOMETASONE DIPROPIONATE COMBINATION THERAPY USING A DPI DEVICE ON CENTRAL AND PERIPHERAL AIRWAY DIMENSIONS IN ASTHM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003249-16,0,0,0 2011-003250-34,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,IVI Madrid,Endometrial receptivity with different support protocols for the luteal phase in ovarian stimulation cycles in which final oocyte maturation is carried out with GnRH analogues. Analysis by endometrial...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003250-34,0,0,0 2011-003254-90,1,2017-08-24,2017-08-24,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomised, active-controlled, open-label, multiple-dose, proof-of-concept study of intravitreal LFG316 in patients with active non-infectious intermediate-, posterior-, or panuveitis requiring syst...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003254-90,0,0,0 2011-003255-19,1,2016-09-30,2016-09-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals SA,"A phase IV, open-label, single-center study to evaluate long term immunogenicity up to 10 years after the first booster immunization with Tick Borne Encephalitis vaccine in adults who received 1 of 3 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003255-19,0,0,0 2011-003259-20,1,2014-10-24,2014-10-24,1,0,0,0,1,0,4,0,1,1,0,0,1,0,0,University of Turku,Effect of duloxetine and venlafaxine on the pharmacokinetics and pharmacodynamics of oral tramadol: A three-phase randomized balanced cross-over study in healthy volunteers Duloksetiinin ja venlaf...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003259-20,0,0,0 2011-003264-77,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Erasmus MC,A prospective trial with ketoconazole and octreotide combination therapy for treatment of Cushing’s disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003264-77,0,0,0 2011-003266-32,2,2013-07-02,2013-07-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CROSS-OVER EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY AND PAI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003266-32,0,0,0 2011-003266-32,2,2013-07-02,2013-07-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CROSS-OVER EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY AND PAI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003266-32,0,0,0 2011-003270-80,1,2012-08-27,2012-08-27,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Kirsten Rasmussen,Effect of colloid versus crystalloid on coagulation in elective urological surgery. A randomised clinical trial. Effekt af kolloid versus krystalloid på koagulation ved elektiv urologisk kirurgi. E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003270-80,0,0,0 2011-003273-28,1,2015-03-25,2015-03-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Ruprecht-Karls-University Heidelberg, Med Faculty represented by Universitätsklinikum Heidelberg and its Commercial D",Treatment of patients with metastatic melanoma (AJCC stage IV or III unresectable) with the PDE-inhibitor Tadalafil: A Pilot Trial for “Proof of Principle” Pilot-Studie zur Behandlung von Patiente...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003273-28,0,0,0 2011-003278-10,3,2014-09-30,2014-09-30,1,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Allergan Ltd.,"A Multicenter, Double-masked, Randomized, Active-controlled, Parallel Study of the Safety and Efficacy of Once-daily Bimatoprost Preservative-free Ophthalmic Solution Compared to Twice-daily Timolol O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003278-10,1,0,0 2011-003283-78,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GIULIANI,"A PROOF-OF-CONCEPT CLINICAL STUDY, TO ASSESS THE EFFECT OF GED-0507-34-Levo 80 mg Tablets IN INDUCTION OF REMISSION OF ACTIVE ULCERATIVE COLITIS STUDIO CLINICO PER LA VERIFICA DELL`™EFFETTO DI GED-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003283-78,0,0,0 2011-003285-33,4,2016-03-04,2016-03-04,2,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Akinion Pharmaceuticals AB,"A Phase 1/2, Open-Label, Multi-Center Dose Escalation, Safety and Tolerability Study of AKN-028 in Patients with Acute Myelogenous Leukemia (AML)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003285-33,0,0,0 2011-003288-31,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Technical University Dresden,"Open, randomized, multicenter phase II trial with cetuximab /5-FU/FA/irinotecan or cetuximab/5-FU/FA /irinotecan/oxaliplatin in ras wild type patients or with irinotecan/oxaliplatin/5-FU/FA with or wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003288-31,0,0,0 2011-003293-93,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sint Antonius Ziekenhuis,"Cyp3A4 metabolism before and after surgery induced weight loss in morbidly obese patients, using midazolam as a model drug",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003293-93,0,0,0 2011-003295-37,4,2012-05-24,2012-05-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"Efficacy of the V0034CR01B emollient on xerosis in children with atopic dermatitis. Randomised, vehicle-controlled, parallel-groups, double-blind study with an open label extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003295-37,0,0,0 2011-003297-81,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,St Eriks Eye Hospital,"A prospective, randomized study on intravitreal Ozurdex for preventing recurrent vitreous hemorrhage following pars plana vitrectomy for proliferative diabetic retinopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003297-81,0,0,0 2011-003298-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Utrecht,"A phase IV, randomized, open label, cross-over, intervention trial to investigate the effect of the switch of lopinavir-ritonavir to raltegravir on endothelial function, chronic inflammation, immune a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003298-26,0,0,0 2011-003299-36,1,2012-05-01,2012-05-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,MERCK SHARP & DOHME CORP.,"A Randomized, Partially Double-Blind, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomita...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003299-36,0,0,0 2011-003300-21,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Bristol-Myers Squibb Company,"A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety of Atazanavir (ATV) Capsule Boosted with Ritonavir (RTV) with an Optimized NRTI Background Therapy, in HIV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003300-21,0,1,1 2011-003301-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,A Randomized Phase II Trial of Carboplatin-Paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced (stage III-IV) or recurrent endometrial cancer. Studio randomizzato di fase II di c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003301-16,0,0,0 2011-003302-24,1,2013-09-26,2013-09-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratorios Dr. Esteve S.A. (ESTEVE),"An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, as part of an analgesic the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003302-24,0,0,0 2011-003303-38,1,2013-02-19,2013-02-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ViiV Healthcare UK Limited,Observational Drug Exposure Registry for Long-Term Follow-Up of Subjects Exposed to GSK2248761,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003303-38,0,0,0 2011-003304-20,1,2012-10-15,2012-10-15,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Moorfields Eye Hospital NHS Foundation Trust,Randomised Controlled Trial of Intravitreal therapy with Avastin compared to Observation in Patients with Diabetic Ischaemic Macular Oedema ‘The DIME study’,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003304-20,0,0,0 2011-003308-18,4,2015-10-15,2015-10-15,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"A two-cohort, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab and vinorelbine in first line patients with HER2-positive adv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003308-18,0,0,0 2011-003308-18,4,2015-10-15,2015-10-15,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A two-cohort, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab and vinorelbine in first line patients with HER2-positive adv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003308-18,0,0,0 2011-003309-12,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Efficacité et tolérance d’un traitement par inhibiteur de l’aromatase (Anastrozole) pour limiter l’avance de maturation osseuse liée à une adrénarche pathologique chez des enfants ayant un syndrome de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003309-12,0,0,0 2011-003310-17,1,2012-11-30,2012-11-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"""Estudio fase II, multicentrico, doble ciego, randomizado, controlado con placebo para evaluar los efectos de IIoprost inhalado en una prueba de resistencia durante un test de ejercicio cardiopulmonar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003310-17,0,0,0 2011-003311-27,1,2016-09-09,2016-09-09,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Oxford,Vascular Targeted Photodynamic therapy with WST11 for T1a Renal Tumours. PHASE IIa histological follow up trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003311-27,0,0,0 2011-003313-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospital General Universitario de Alicante,Efficacy of agomelatine on sleep disturbance in Autism Spectrum Disorder (ASD) Eficacia de agomelatina en la alteración del sueño en el Trastorno del Espectro Autista (TEA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003313-42,0,0,0 2011-003314-16,1,2012-03-21,2012-03-21,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Omninvest Ltd.,"A Randomized, Active Controlled, Double-blind, Multi-Centre Study to Evaluate Safety and Immunogenicity of One Dose of FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) Influ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003314-16,0,0,0 2011-003317-41,1,2013-03-22,2013-03-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dermapharm AG,"Double-blind, randomized, clinical trial to compare the efficacy and safety of diclofenc 3% gel vs. Solaraze 3% gel vs. vehicle for the treatment of patients with actinic keratosis. Doppelblinde, r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003317-41,0,0,0 2011-003320-12,1,2013-03-31,2013-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,Study of the effect of morphine on prasugrel absorption in patients with prior history of ST elevation myocardial infarction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003320-12,0,0,0 2011-003321-99,1,,,0,1,0,0,1,0,4,0,0,1,0,0,0,1,0,UZ Brussels,Comparison of Volulyte® versus Tetraspan® in patients undergoing cardiopulmonary bypass.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003321-99,0,0,0 2011-003325-10,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,VU University Medical Center,A randomized controlled trail on the effects of periconceptional and prenatal folic acid supplementation on congenital anomalies and preterm birth,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003325-10,0,0,0 2011-003326-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Landstinget i Värmland,Is regional anaethesia of the hip preferable over traditional analgesia in the acute stage of the management of patients with a fracture of the hip? Är regional bedövning av höften att föredra fram...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003326-27,0,0,0 2011-003328-11,1,2014-04-28,2014-04-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Servier International / Les Laboratoires Servier,"Patient pREference and satisFaction for pErindopril oRodispersible vs convENtional tablets in daily Clinical practicE PREFERENCE Étude clinique interventionnelle, menée en ouvert et en consultation de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003328-11,0,0,0 2011-003329-89,4,2014-07-08,2014-08-05,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol Myers Squibb International Corporation,"A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-lab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003329-89,0,0,0 2011-003335-63,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,"Effects of liraglutide on β-cell function in type 2 diabetic patients with secondary failure to oral hypoglycemic agents. A randomized, controlled, parallel groups, open-label, phase II study. Effe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003335-63,0,0,0 2011-003337-34,4,2014-04-28,2014-04-28,3,1,1,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research and Development Ltd,HZA106853: A dose-ranging study of Vilanterol (VI) inhalation powder in children aged 5-11 years with asthma on a background of inhaled corticosteroid therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003337-34,1,1,0 2011-003338-15,5,2014-09-24,2019-09-24,4,1,1,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research and Development Limited,HZA106855: A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003338-15,1,1,0 2011-003339-74,1,2013-10-22,2013-10-22,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,Moorfields Eye Hospital R&D Department,A Prospective Randomised Controlled Trial of Intravitreal Ozurdex and Macular Laser Therapy versus Macular Laser Therapy only in Diabetic Macular Oedema (OZLASE study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003339-74,0,0,0 2011-003340-45,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ARCO,"OPEN-LABEL PHASE II STUDY OF INDUCTION TREATMENT WITH FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY PREOPERATIVE CHEMORADIOTHERAPY PLUS BEVACIZUMAB IN PATIENTS WITH LOCALLY ADVANCED, RESECTABLE RECTAL CANCER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003340-45,0,0,0 2011-003341-18,1,2014-01-27,2014-01-27,1,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Italfarmaco S.p.A.,An Open-Label Extension of the Dose Finding study (DSC/08/2357/36) in patients with polyarticular course Juvenile Idiopathic Arthritis (poly JIA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003341-18,0,0,0 2011-003346-40,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Erasmus MC-Daniël den Hoed,"A phase II study in mCRPC on the pharmacodynamic effects of budesonide on cabazitaxel (Jevtana®): A randomised, open-label multicenter study: CABARESC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003346-40,0,0,0 2011-003368-64,1,2012-04-19,2012-04-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biomay AG,"Safety and dose finding study based on the effects of three subcutaneous injections of BM32, a recombinant hypoallergenic grass pollen vaccine, on responses to allergen challenge by skin testing and i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003368-64,0,0,0 2011-003372-37,1,2019-03-04,2019-03-04,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,CENTRE LEON BERARD,"An international, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003372-37,0,0,0 2011-003390-29,1,2014-10-10,2014-10-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Orthopedic Research Group,Undersøgelse af LIA (lokal infiltrationsanalgesi) kontra femoralisblokade som smertebehandling til open-wedge høj tibia osteotomi.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003390-29,0,0,0 2011-003392-10,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,Novartis Pharma Services AG,"An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 in Noonan syndrome hypertrophic cardiomyopathy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003392-10,0,0,0 2011-003397-82,1,2015-05-27,2015-05-27,1,0,0,0,0,0,4,0,0,1,1,1,1,0,1,B. Braun Melsungen AG,"Prospective, randomized, controlled, double-blind, parallel-group, mono-centre, explorative Phase IV trial on the efficacy and safety of a fish oil containing lipid emulsion versus a standard soybean ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003397-82,0,0,0 2011-003399-36,1,2012-01-26,2012-01-26,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Randomized, Double-Blind, Active-Controlled Clinical Trial to Study the Efficacy and Safety of MK-4214 (filgrastim) and Neupogen™ as an Adjunct to Combination Chemotherapy with Doxorubicin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003399-36,0,0,0 2011-003400-20,3,2013-12-27,2014-03-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003400-20,0,0,0 2011-003401-21,1,2015-08-31,2015-08-31,1,1,0,1,0,1,1,0,1,1,0,0,0,0,0,CHU GRENOBLE,Treprostinil Iontophoresis : a Pharmacodynamic and Pharmacokinetic Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003401-21,0,0,0 2011-003402-25,1,2013-06-19,2013-06-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Schülke & Mayr GmbH,"Randomized, Double-blind, Single-center, Placebo-controlled Study to evaluate the Efficacy of octenisept® in Patients with Chronic Wounds.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003402-25,0,0,0 2011-003406-24,4,2014-07-07,2014-07-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003406-24,0,0,0 2011-003406-24,4,2014-07-07,2014-07-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003406-24,0,0,0 2011-003407-38,2,2013-09-25,2013-09-25,2,1,0,1,0,2,1,0,0,1,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Paediatric Patients with Advanced Solid Tumours,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003407-38,0,0,0 2011-003408-19,1,2014-03-28,2014-03-28,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,WILEX AG,"A Phase I/II, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of the MEK inhibitor WX-554 in patients with solid tumours",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003408-19,0,0,0 2011-003409-36,5,2016-08-08,2016-08-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Genentech, Inc.",A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients with Moderate to Severe Ulcerative Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003409-36,0,0,0 2011-003412-23,5,2013-04-15,2013-04-15,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Médicament - IRPF,EFFECT OF V0251 IN ACUTE VERTIGO. A RANDOMISED DOUBLE-BLIND PLACEBO CONTROLLED STUDY.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003412-23,0,0,0 2011-003414-17,4,2013-05-21,2013-05-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,An open-label extension study of CACZ885H2356E2 and CACZ885H2357E2 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/or colchicine are contraindicated...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003414-17,0,0,0 2011-003415-31,8,2014-03-13,2014-04-02,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis Recherche & Développement,Randomized Phase II Study of Cabazitaxel versus Topotecan in Small Cell Lung Cancer Patients with Progressive Disease during or after a First Line Platinum Based Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003415-31,0,0,0 2011-003415-31,8,2014-03-13,2014-04-02,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT,Randomized Phase II Study of Cabazitaxel versus Topotecan in Small Cell Lung Cancer Patients with Progressive Disease during or after a First Line Platinum Based Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003415-31,0,0,0 2011-003416-23,1,2016-04-01,2016-04-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"An open label, single arm trial to evaluate patients with metastatic renal cell carcinoma treated with everolimus after failure of first line therapy with sunitinib or pazopanib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003416-23,0,0,0 2011-003418-18,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Sahlgrenska University Hospital,"A Randomised, Double Blind, Placebo Controlled, Multi-centre, Parallel Group, Interventional Study of Mesalazine (Asacol®) Treatment in IBS and the Evaluation of Rectal Inflammatory Status using the M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003418-18,0,0,0 2011-003425-96,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Nottingham,Helicobacter eradication to prevent ulcer bleeding in aspirin users: a large simple randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003425-96,0,0,0 2011-003427-36,4,2014-09-30,2014-09-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003427-36,0,0,0 2011-003427-36,4,2014-09-30,2014-09-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbvie Deutschland GmbH & Co. KG,"Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003427-36,0,0,0 2011-003427-36,4,2014-09-30,2014-09-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003427-36,0,0,0 2011-003430-13,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Children's Oncology Group,Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003430-13,0,0,0 2011-003432-32,1,2015-11-12,2015-11-12,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude randomisée en double aveugle de l’efficacité du topiramate sur les symptômes d’irritabilité - impulsivité, d’hyperphagie et d’automutilation dans une population de patients atteints du Syndrome ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003432-32,0,0,0 2011-003433-33,1,,,0,1,1,0,0,1,1,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Single Dose Biocomparison Study to Assess two Pediatric Formulations of MK-8669 to the Provisional Market Formulation in Healthy Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003433-33,0,1,1 2011-003447-21,1,2015-04-24,2015-04-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Camden Provider Services,Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra© in combination with Truvada© for HIV post-exposure prophylaxis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003447-21,0,0,0 2011-003448-28,12,2016-09-20,2016-09-20,8,1,0,0,0,2,3,0,0,1,1,0,1,0,1,CSL Behring GmbH,"Randomized, multicenter, double-blind, placebo-controlled, parallel-group phase III study to investigate the efficacy, safety, and tolerability of 2 different doses of IgPro20 (subcutaneous immunoglob...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003448-28,0,0,0 2011-003448-28,12,2016-09-20,2016-09-20,8,1,0,0,0,2,3,0,0,1,1,0,1,0,1,CSL BEHRING GMBH,"Randomized, multicenter, double-blind, placebo-controlled, parallel-group phase III study to investigate the efficacy, safety, and tolerability of 2 different doses of IgPro20 (subcutaneous immunoglob...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003448-28,0,0,0 2011-003449-17,1,2014-10-30,2014-10-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CHIESI,"A 12-week, multicenter, randomized, double-blind, double-dummy, 2-arm parallel group study comparing the efficacy and safety of Foster NEXThaler (beclomethasone dipropionate 100 µg plus formoterol 6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003449-17,0,0,0 2011-003466-33,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Mental Health Services North Holland North,Memantine Add-On Therapy to Clozapine Memantine als additietherapie bij clozapine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003466-33,0,0,0 2011-003470-88,1,2013-09-19,2013-09-19,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,"University Medical Center Utrecht, The Netherlands",Phenylephrine versus EPhedrine on cerebral Perfusion during carotid EndarteRectomy: PEPPER study De invloed van fenylefrine en efedrine op de cerebrale perfusie tijdens carotisendarteriectomie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003470-88,0,0,0 2011-003473-29,1,2015-07-09,2015-07-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Cologne,Trial on treatment with inhaled furosemide of preterm and term neonates with transient tachypnoea Inhalatives Furosemid bei Frühgeborenen und Neugeborenen mit Transitorischer Tachypnoe,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003473-29,0,0,0 2011-003474-86,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Myron D. Ginsberg,Albumin in Acute Stroke (ALIAS) Trial-Part 2: A Phase III Randomized Multicenter Clinical Trial of High-Dose Human Albumin Therapy for Neuroprotection in Acute Ischemic Stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003474-86,0,0,0 2011-003475-11,1,2014-12-06,2014-12-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London (UCL),"A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003475-11,0,0,0 2011-003478-98,7,2016-08-12,2016-08-12,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,A Phase 3 Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003478-98,0,0,0 2011-003478-98,7,2016-08-12,2016-08-12,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 3 Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003478-98,0,0,0 2011-003484-30,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Farmacéutica S.A.,"A multi-centre, open-label, non-randomised, parallel group clinical trial to assess the efficacy of fingolimod in naïve patients versus fingolimod in patients previously treated with interferons or gl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003484-30,0,0,0 2011-003486-15,4,2013-10-29,2013-10-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB BIOSCIENCES GMBH,"A multi-center, randomized, double-blind, placebo-controlled, parallel group, polysomnography study to investigate safety and efficacy of the rotigotine transdermal patch in subjects with Restless L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003486-15,0,0,0 2011-003486-15,4,2013-10-29,2013-10-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB BIOSCIENCES GmbH,"A multi-center, randomized, double-blind, placebo-controlled, parallel group, polysomnography study to investigate safety and efficacy of the rotigotine transdermal patch in subjects with Restless L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003486-15,0,0,0 2011-003487-75,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Phase II trial on safety and activity of intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt's lymphoma. Studio di fase II sulla sicurezza ed attivita' di una combinazione...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003487-75,0,0,0 2011-003494-29,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Stanford University School of Medicine,FLT-PET vs FDG-PET Response Assessment in Diffuse Large B-cell Lymphoma FLT-PET/CT vs. FDG-PET/CT zur Therapiekontrolle beim DLBCL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003494-29,0,0,0 2011-003495-36,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,SENDO TECH,"A multicenter pilot phase II study for the preliminary evaluation of feasibility, activity and safety of the administration of Bendamustine and Ofatumumab in combination in marginal zone B-cell lympho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003495-36,0,0,0 2011-003496-11,4,2012-11-02,2013-03-06,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Endo Pharmaceuticals Inc.,"A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared with Mitomycin C in the Intravesical Treatment of Subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003496-11,0,0,0 2011-003498-27,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Grupo Español de Tratamiento de Tumores Genitourinarios (SOGUG)-Spanish Genitourinary Oncologic Group,A phase II open label study of cabazitaxel in patients with advanced or metastatic transitional cell carcinoma of the urothelium who have progressed ?12 months after a previous platinum based chemothe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003498-27,0,0,0 2011-003502-24,9,2015-01-07,2015-01-07,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Astellas Pharma Global Development, Inc.","A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination with mFOLFOX6 with Bevacizumab in Combination with mFOLFOX6 in Stage IV Metastatic Corectal Cancer (mCRC) Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003502-24,0,0,0 2011-003502-24,9,2015-01-07,2015-01-07,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.","A Phase 2, Open Label, Multicenter, Randomized Trial Comparing Tivozanib in Combination with mFOLFOX6 with Bevacizumab in Combination with mFOLFOX6 in Stage IV Metastatic Corectal Cancer (mCRC) Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003502-24,0,0,0 2011-003507-38,6,2013-07-12,2013-08-19,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BIOGEN IDEC RESEARCH LTD,"An Open-Label, Multicenter, Multinational Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Quality of Life as Reported by Subjects with Multiple Scle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003507-38,0,0,0 2011-003507-38,6,2013-07-12,2013-08-19,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Biogen Idec Research Limited,"An Open-Label, Multicenter, Multinational Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Quality of Life as Reported by Subjects with Multiple Scle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003507-38,0,0,0 2011-003509-65,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO ONCOLOGICO VENETO,Weekly therapy with Carboplatin and Docetaxel in patients with head-neck cancer with important comorbidity TERAPIA SETTIMANALE CON CARBOPLATINO E DOCETAXEL IN PAZIENTI CON TUMORI CAPO-COLLO CON IMP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003509-65,0,0,0 2011-003512-23,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase II, randomized, observer blind, multicenter study to evaluate the safety and immunogenicity of a single low dose of AS03-adjuvanted, Quebec- or Dresden- manufactured monovalent A/California/7/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003512-23,0,1,1 2011-003513-41,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,Danish Headache Center,A study of the farmacokinetic effect of telmisartan on the serum concentration of verapamil and the prophylactic effect of verapamil on clusterheadache.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003513-41,0,0,0 2011-003517-42,4,2013-02-20,2013-02-21,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Spectrum Pharmaceuticals, Inc","A Phase 3 International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003517-42,0,0,0 2011-003523-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Department of Anaesthesia,A comparison of interscalene brachial plexus block combined with stellate ganglion block versus interscalene brachial plexus block for postoperative analgesia in major orthopaedic surgery of the upper...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003523-35,0,0,0 2011-003530-13,1,2015-11-09,2015-11-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Brighton & Sussex University Hospitals NHS Trust,Randomised phase II window study of short-term preoperative treatment with the PI3K inhibitor GDC-0941 plus Anastrozole versus Anastrozole alone in patients with ER-positive primary breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003530-13,0,0,0 2011-003532-32,2,2013-09-03,2013-09-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","Phase 2 Assessment of the Relationship between Serotonin and Efficacy in Ulcerative Colitis: A Multi-Center Randomized, Double Blind, Placebo-Controlled, Pilot Study to Evaluate Safety and Preliminar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003532-32,0,0,0 2011-003536-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHRU de TOURS,Prévention de la pré-éclampsie et du retard de croissance intra utérin par l'aspirine à faible dose chez les primipares ayant des notch utérins bilatéraux au premier trimestre. Etude randomisée pragma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003536-30,0,0,0 2011-003538-16,11,2015-03-17,2015-03-23,11,1,0,0,0,0,3,0,2,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inadequate Responders...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003538-16,0,0,0 2011-003538-16,11,2015-03-17,2015-03-23,11,1,0,0,0,0,3,0,2,1,0,0,1,0,1,SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT,"A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing The Efficacy and Safety of Sarilumab Added To DMARD Therapy In Patients With Rheumatoid Arthritis Who Are Inadequate Responders...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003538-16,0,0,0 2011-003539-68,1,,,0,0,0,0,0,1,3,0,0,1,0,0,0,1,0,CHU-HOPITAUX DE ROUEN,ETUDE PROSPECTIVE RANDOMISEE COMPARATIVE PREDNISONE/ CYCLOPHOSPHAMIDE VERSUS PREDNISONE/ RITUXIMAB AU COURS DE L'HEMOPHILIE ACQUISE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003539-68,0,0,0 2011-003541-17,1,2016-08-31,2016-08-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Instituo de Investigacion Sanitaria La Fe,EFFECT OF THE ADMINISTRATION OF ALLOPURINOL ON THE PREVENTION OF MUSCLE MASS LOSS IN IMMOBILIZED SUBJECTS. EFECTO DE LA ADMINISTRACIÓN DE ALOPURINOL SOBRE LA PREVENCIÓN DE LA PÉRDIDA DE MASA MUSCU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003541-17,0,0,0 2011-003544-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Department of Neurosurgery, PMU","DRES - A prospective, multi-center, double blind, randomized, placebo controlled study to assess the efficacy of Dexamethason in reducing the reoperation rate in patients with chronic subdural hematom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003544-42,0,0,0 2011-003545-18,13,2017-12-18,2018-04-16,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc","A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Periphera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003545-18,0,0,0 2011-003545-18,13,2017-12-18,2018-04-16,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Periphera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003545-18,0,0,0 2011-003547-21,1,2014-12-31,2014-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Renal Clinic Heidelberg,A randomized open-label trial to evaluate the cardiovascular risk in stable renal allograft recipients on a ciclosporin A (CsA) based regimen monitored either by residual expression of nuclear factor ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003547-21,0,0,0 2011-003551-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FIBHULP,"Reparative Therapy In Acute Ischemic Stroke With Alogeneic Mesenchymal Stem Cells From Adipose Tissue. Safety Assessment. A Randomised, Double Blind Placebo? Controlled Single Center Pilot Clinical Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003551-18,0,0,0 2011-003553-26,1,2014-09-17,2014-09-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,CESAR Central European Society for Anticancer Drug Research-EWIV,A single arm study in metastatic colorectal cancer patients treated with pharmacokinetically (PK) dose adjusted weekly or biweekly 5-fluorouracil (5-FU) regimes. Eine einarmige Studie bei Patienten...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003553-26,0,0,0 2011-003556-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Martini Hospital Groningen,A randomized pilot study comparing the safety of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after knee arthroplasty surgery. DARINA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003556-39,0,0,0 2011-003559-21,4,2012-11-07,2012-11-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A Retrospective Pharmacogenetic Analysis of Hepatitis C Patients treated with Alisporivir (DEB025) Alone or in Combination with Peg-IFN2a and/or Ribavirin Analisi Farmacogenetica Retrospettiva de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003559-21,0,0,0 2011-003559-21,4,2012-11-07,2012-11-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,A Retrospective Pharmacogenetic Analysis of Hepatitis C Patients treated with Alisporivir (DEB025) Alone or in Combination with Peg-IFN2a and/or Ribavirin Analisi Farmacogenetica Retrospettiva de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003559-21,0,0,0 2011-003559-21,4,2012-11-07,2012-11-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmaceutica S.A,A Retrospective Pharmacogenetic Analysis of Hepatitis C Patients treated with Alisporivir (DEB025) Alone or in Combination with Peg-IFN2a and/or Ribavirin Analisi Farmacogenetica Retrospettiva de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003559-21,0,0,0 2011-003560-74,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,"Effectiveness of Clonidine for the treatment of radicular pain: A randomized, double-blind and prospective study. (EFFOC study) Effectiviteit van Clonidine ter behandeling van radiculaire pijn: Een...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003560-74,0,0,0 2011-003564-72,1,2019-12-11,2019-12-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Aarhus University Hospital,A Randomised phase II study with the combination of Xeloda (Capecitabine) plus Navelbine Oral ( Vinorelbine) day 1 and day 8 every 3. week versus Xeloda plus Navelbine Oral given metronimic as 1. or 2...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003564-72,0,0,0 2011-003570-89,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,VU University Medical Center,The effect of interferon beta-1a treatment on functional adaptation in Multiple Sclerosis (MS) Het effect van interferon beta-1a behandeling op functionele adaptatie in Muliple Sclerose (MS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003570-89,0,0,0 2011-003572-36,1,2014-12-16,2014-12-16,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Royal Devon & Exeter NHS Foundation Trust,The role of GLP-1 analogues in reducing reperfusion injury after acute stroke in patients with impaired swallowing.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003572-36,0,0,0 2011-003572-36,1,2014-12-16,2014-12-16,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Exeter,The role of GLP-1 analogues in reducing reperfusion injury after acute stroke in patients with impaired swallowing.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003572-36,0,0,0 2011-003573-28,1,2015-05-04,2015-05-04,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase III Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 when Administered to Adult and Elderly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003573-28,0,0,0 2011-003574-84,5,2015-08-20,2015-08-20,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE,"A Randomized, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients with Unresectable Advanced or Metastatic Hepatocellular Car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003574-84,0,0,0 2011-003574-84,5,2015-08-20,2015-08-20,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A Randomized, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients with Unresectable Advanced or Metastatic Hepatocellular Car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003574-84,0,0,0 2011-003575-11,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,"Medizinische Universität Graz, Innere Medizin","A randomized, double-blind, placebo controlled trial to evaluate the effects of vitamin D supplementation on androgen levels in hypogonadal men",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003575-11,0,0,0 2011-003576-36,7,2015-02-13,2015-02-13,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"MERRIMACK PHARMACEUTICALS, INC.",A Phase II Randomized Open Label Study of MM-121 in combination with Paclitaxel versus Paclitaxel alone in patient with Platinum Resistant/Refractory Advanced Ovarian Cancers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003576-36,1,0,0 2011-003576-36,7,2015-02-13,2015-02-13,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,MERRIMACK PHARMACEUTICALS,A Phase II Randomized Open Label Study of MM-121 in combination with Paclitaxel versus Paclitaxel alone in patient with Platinum Resistant/Refractory Advanced Ovarian Cancers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003576-36,1,0,0 2011-003576-36,7,2015-02-13,2015-02-13,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT,A Phase II Randomized Open Label Study of MM-121 in combination with Paclitaxel versus Paclitaxel alone in patient with Platinum Resistant/Refractory Advanced Ovarian Cancers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003576-36,1,0,0 2011-003588-31,5,2012-09-28,2012-09-28,5,1,0,0,0,0,2,0,2,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A multicentre, randomised, double-blind, active-controlled, 4-way cross-over study to evaluate the efficacy and safety of a free combination of 3 doses of Glycopyrrolate with fixed combination Beclome...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003588-31,0,0,0 2011-003588-31,5,2012-09-28,2012-09-28,5,1,0,0,0,0,2,0,2,1,0,0,1,0,1,CHIESI,"A multicentre, randomised, double-blind, active-controlled, 4-way cross-over study to evaluate the efficacy and safety of a free combination of 3 doses of Glycopyrrolate with fixed combination Beclome...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003588-31,0,0,0 2011-003591-37,1,2015-03-25,2015-03-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cardiff University,Children with Eczema Antibiotic Management Study (CREAM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003591-37,0,0,0 2011-003593-85,8,2014-08-26,2014-08-26,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"Multicenter, Open-Label Study of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Human Immunodeficiency Virus/Genotype 1 Chronic Hepatitis C Coinfected Subjects With Severe Fibrosis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003593-85,0,0,0 2011-003593-85,8,2014-08-26,2014-08-26,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"Multicenter, Open-Label Study of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Human Immunodeficiency Virus/Genotype 1 Chronic Hepatitis C Coinfected Subjects With Severe Fibrosis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003593-85,0,0,0 2011-003594-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,BioTissue Technologies GmbH,A Comparative Observational Prospective Randomized Open-Label Study on Efficacy of BioSeed®-C and chondrotissue® Treatment of Local Femoral Cartilage Defects in the Knee. Eine offene vergleichende ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003594-28,0,0,0 2011-003595-36,1,2014-12-15,2014-12-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Birmingham,Can muscle dysfunction in COPD be altered by oxygenation in patients with intermittent hypoxia on exertion?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003595-36,0,0,0 2011-003599-35,4,2016-01-29,2017-01-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cook Myosite, Incorporated","A Double blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Effectiveness of Cook MyoSite Incorporated AMDC in Female Patients with Stress Urinary Incontinence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003599-35,0,0,0 2011-003599-35,4,2016-01-29,2017-01-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cook MyoSite, Incorporated","A Double blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Effectiveness of Cook MyoSite Incorporated AMDC in Female Patients with Stress Urinary Incontinence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003599-35,0,0,0 2011-003600-20,3,2012-12-04,2012-12-04,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-Administration of Sitagliptin and Atorvastatin in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Contr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003600-20,0,0,0 2011-003601-25,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Regulon AE,"Randomised, Multicenter Phase III Clinical Study of Lipoplatin plus Gemcitabine Versus Gemcitabine as First-Line Treatment in Inoperable, Locally Advanced or Metastatic Pancreatic Cancer Πολυκεντρι...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003601-25,0,0,0 2011-003602-25,2,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,A Phase Ib/randomized phase II study of BEZ235 and trastuzumab versus lapatinib and capecitabine in patients with HER2-positive locally advanced or metastatic breast cancer who failed prior to trastuz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003602-25,0,0,0 2011-003602-25,2,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Novartis Farmaceutica S.A.,A Phase Ib/randomized phase II study of BEZ235 and trastuzumab versus lapatinib and capecitabine in patients with HER2-positive locally advanced or metastatic breast cancer who failed prior to trastuz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003602-25,0,0,0 2011-003603-37,1,2015-04-02,2015-04-02,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Pharma Services AG,"Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 when Administered to Adult and Elderly S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003603-37,0,0,0 2011-003604-21,1,2011-09-04,2011-09-04,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Universitätsklinik für Innere Medizin IV, Medizinische Universität Innsbruck",The role of immunosuppressives in immunosenescence and immunotolerance in renal transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003604-21,0,0,0 2011-003606-24,2,2015-11-24,2015-11-24,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,FOREST RESEARCH INSTITUTE,"A 52-week, Double-Blind, Randomized, Placebo Controlled Parallel Group Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects with Chronic Obstructive Pulmonary Disease (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003606-24,0,0,0 2011-003606-24,2,2015-11-24,2015-11-24,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Forest Research Institute, Inc","A 52-week, Double-Blind, Randomized, Placebo Controlled Parallel Group Study to Evaluate the Effect of Roflumilast 500 μg on Exacerbation Rate in Subjects with Chronic Obstructive Pulmonary Disease (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003606-24,0,0,0 2011-003608-19,1,2018-11-30,2018-11-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,Trial of afatinib (BIBW 2992) in suspected or confirmed mutant EGFR lung cancer patients unfit for chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003608-19,0,0,0 2011-003611-37,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA' DI NOVARA,PRevEntion of cardiac and Vascular pEriprocedural complications in patients undergoiNg coronary angiography or angioplasTy: hydratation vs carbonates to prevent Contrast-Induced Nephropathy in patient...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003611-37,0,0,0 2011-003614-17,1,2016-04-01,2016-04-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Medical Center Hamburg-Eppendorf,Pretreatment of patients expecting bariatric surgery with GLP-1 analog Liraglutide,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003614-17,0,0,0 2011-003615-28,1,2014-01-17,2014-01-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Shire Development LLC,"A Phase 2, Multicenter, Double-blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003615-28,0,0,0 2011-003617-42,3,2012-11-19,2012-11-19,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,F. Hoffmann-La Roche Ltd.,"An adaptive, multi-center, randomized, investigator-masked, subject-masked, multiple-dose, placebo-controlled, parallel study to investigate efficacy, safety, tolerability and pharmacokinetics of RO50...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003617-42,0,0,0 2011-003618-18,6,2015-01-22,2015-01-22,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003618-18,0,0,0 2011-003618-18,6,2015-01-22,2015-01-22,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003618-18,0,0,0 2011-003621-10,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,INSTITUT CURIE,CONSERVATIVE TREATMENT OF PATIENTS WITH RETINOBLASTOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003621-10,0,0,0 2011-003622-27,10,2016-07-25,2016-07-25,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Inc,"A OPEN-LABEL EXTENSION STUDY OF CP-690,550 AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN?S DISEASE ""Estudio de Extensión abierto de CP-690,550 como tratamiento de mantenimiento en pacientes con enf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003622-27,0,0,0 2011-003622-27,10,2016-07-25,2016-07-25,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA","A OPEN-LABEL EXTENSION STUDY OF CP-690,550 AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN?S DISEASE ""Estudio de Extensión abierto de CP-690,550 como tratamiento de mantenimiento en pacientes con enf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003622-27,0,0,0 2011-003622-27,10,2016-07-25,2016-07-25,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, New York 10017","A OPEN-LABEL EXTENSION STUDY OF CP-690,550 AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN?S DISEASE ""Estudio de Extensión abierto de CP-690,550 como tratamiento de mantenimiento en pacientes con enf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003622-27,0,0,0 2011-003623-35,4,2014-04-03,2014-04-03,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Bionorica SE,"A multicentre, randomized, double-blind, placebo-controlled, parallel group study to assess efficacy and safety of two dosages of a herbal medicinal product (dry extract BNO 1016) in patients with chr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003623-35,0,0,0 2011-003625-97,1,2017-07-20,2017-07-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Hellenic Cooperative Oncology Group,Phase II study of cabazitaxel as 2nd-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes Κλινική δοκιμή φάσης II χορήγησης cabazitaxel ως θεραπεί...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003625-97,0,0,0 2011-003628-11,1,2013-11-25,2013-11-25,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"University Hospital Schleswig Holstein Kiel, Clinic of Neurology",Tapentadol PR vs Oxycodon CR A pilotstudiy for a mechanism-orientated Therapy of peripheral chronic neuropathic pain syndrom Tapentadol PR vs. Oxycodon CR - Eine Pilotstudie für eine mechanismen-or...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003628-11,0,0,0 2011-003629-86,2,2016-12-26,2016-12-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Viiv Healthcare,"A Phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each admini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003629-86,0,0,0 2011-003629-86,2,2016-12-26,2016-12-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,VIIV HEALTHCARE UK LIMITED,"A Phase IIIb, randomized, open-label study of the safety and efficacy of GSK1349572 (dolutegravir, DTG) 50 mg once daily compared to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily each admini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003629-86,0,0,0 2011-003630-13,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Sint Antonius Hospital,99mTc labelled anti-TNF-alpha for the imaging of disease activity in pulmonary sarcoidosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003630-13,0,0,0 2011-003633-33,1,2012-11-05,2012-11-05,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Central Manchester University Hospitals NHS Foundation Trust,The effect of purified fish oils on glucose regulation in Congenital Hyperinsulinism of Infancy (CHI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003633-33,0,0,0 2011-003634-14,1,2012-09-28,2012-09-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios Leti, S.L.Unipersonal",Estandarización biológica del extracto alergénico de Blomia tropicalis para determinar la actividad biológica en unidades equivalentes de Histamina (HEP).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003634-14,0,0,0 2011-003646-41,1,2016-08-11,2016-08-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Oliver Ploder MD, DDS, PhD","Pilotstudy: randomized, open label, single-center study to investigate the efficacy and safety of NT 201 for the prophylaxis of relapse after advancement of the mandible",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003646-41,0,0,0 2011-003648-31,1,2012-09-10,2012-09-10,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Universitätsklinikum Erlangen,"Pharmacokinetic-pharmacodynamic modeling of the postoperative pain sensation during patient-controlled analgesia with target-controlled infusion of Hydromorphone, taking into account the interaction w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003648-31,0,0,0 2011-003652-39,1,2020-05-13,2020-05-13,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Karen Schow Jensen,Exercise induced bronchoconstriction in children – a single dose of montelukast as alternative to regular daily doses. Anstrengelsesudløst astma hos børn – enkeltdosering af montelukast som alterna...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003652-39,0,0,0 2011-003653-26,1,2011-12-13,2011-12-13,1,0,0,0,1,0,2,0,1,1,1,1,1,0,0,Clinical Trials and Research Governance,"A phase II, single-centre, randomised, single-blind, study to evaluate Vi-CRM197 against historical unvaccinated controls in a healthy adult challenge model, with a Vi-PS vaccine control arm.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003653-26,0,0,0 2011-003654-40,1,2012-03-23,2012-03-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Department of Psychiatry,A Preliminary Study of Intravenous Ketamine in Selective Serotonin Reuptake Inhibitor (SSRI)-Resistant Depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003654-40,0,0,0 2011-003657-26,5,2016-10-04,2016-10-04,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi aventis recherche et développement,"An open label non-randomized phase 2 study evaluating SAR3419, an anti-CD19 antibody ? maytansine conjugate, administered as single agent by intravenous infusion to patients with relapsed or refractor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003657-26,0,0,0 2011-003657-26,5,2016-10-04,2016-10-04,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT,"An open label non-randomized phase 2 study evaluating SAR3419, an anti-CD19 antibody ? maytansine conjugate, administered as single agent by intravenous infusion to patients with relapsed or refractor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003657-26,0,0,0 2011-003668-55,8,2015-12-04,2015-12-18,8,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) OR ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS. Paediatric i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003668-55,0,0,0 2011-003668-55,8,2015-12-04,2015-12-18,8,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) OR ADALIMUMAB IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS. Paediatric i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003668-55,0,0,0 2011-003669-14,5,2019-02-28,2019-02-28,4,1,0,0,0,1,3,0,0,1,0,0,1,0,0,London School Of Hygiene and Tropical Medicine,"Tranexamic Acid for the treatment of significant traumatic brain injury: an international, randomised, double blind, placebo controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003669-14,0,0,0 2011-003672-36,2,2015-09-17,2015-09-18,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase IIIA, observer-blind, randomized study to evaluate non-inferiority of a second dose of GSK Biologicals’ measles-mumps-rubella vaccine vs. a second dose of Merck & Co., Inc.’s MMR vaccine when ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003672-36,0,0,0 2011-003672-36,2,2015-09-17,2015-09-18,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals S.A.,"A Phase IIIA, observer-blind, randomized study to evaluate non-inferiority of a second dose of GSK Biologicals’ measles-mumps-rubella vaccine vs. a second dose of Merck & Co., Inc.’s MMR vaccine when ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003672-36,0,0,0 2011-003675-11,1,2014-07-28,2014-07-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Leuven,"Comparison of 2-chloroprocaïne, bupivacaïne and lidocaïne for spinal anesthesia in knee artroscopy in an outpatient setting: a double blind randomised trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003675-11,0,0,0 2011-003676-37,1,2013-07-07,2013-07-07,1,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Protalix Biotherapeutics,A Multicenter Extension Study of Taliglucerase alfa in Pediatric Subjects with Gaucher Disease Un estudio de Extensión Multicéntrica de Taliglucerasa alfa en sujetos pediátricos con la enfermedad d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003676-37,0,0,0 2011-003678-97,1,2019-04-30,2019-04-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Ghent University Hospital,Exploration of TNF-alpha Blockade with golimumab in the Induction of Clinical Remission in Patients with Early peripheral SpondyloArthritis (SpA) according to ASAS-criteria (‘CRESPA’). Exploratie v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003678-97,0,0,0 2011-003685-32,1,2013-07-08,2013-07-08,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Protalix Biotherapeutics,A Multicenter Extension Study of Taliglucerase alfa in Adult Subjects with Gaucher Disease Un estudio de Extensión Multicéntrica de Taliglucerasa alfa en sujetos adultos con la enfermedad de Gauche...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003685-32,0,0,0 2011-003687-78,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) LANREOTIDE AUTOGEL NELTRATTAMENTO DEI PAZIENTI CON FIBROSI POLMONARE IDIOPATICA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003687-78,0,0,0 2011-003692-12,1,2013-03-11,2013-03-11,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,AZAD Pharma AG,"A phase III , multicentre, randomised, investigator-masked, cross-over, comparative efficacy study of a generic Brinzolamide 10 mg/ml ophthalmic suspension (Azad Pharma AG) and Brinzolamide 10 mg/ml o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003692-12,0,0,0 2011-003694-29,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase 3b, Multi-Center, Open-label Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy at-risk Adults Studio di Fase 3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003694-29,0,0,0 2011-003695-36,1,2019-05-16,2019-05-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Brighton & Sussex University Hospitals NHS Trust,Is intravenous iron and darbepoetin more effective than oral iron in reducing blood transfusion requirements for patients undergoing cardiac surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003695-36,0,0,0 2011-003697-93,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospital Universitario de Canarias,"Effectiveness of hyperbaric oxygen therapy in the treatment of the open tibial fractures. Open clinical trial, randomized, prospective and controlled. Efectividad de la oxigenoterapia hiperbárica e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003697-93,0,0,0 2011-003699-34,1,2017-03-31,2017-03-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,London School of Hygiene & Tropical Medicine,Feasibility study including a double blind (C)controlled study and an open label (C) controlled study for a larger randomised trial measuring the effect of oral vitamin D (I) on morbidity and mortalit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003699-34,0,0,0 2011-003710-16,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, randomized, open, controlled study in healthy Japanese children to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ 10-valent pneumococcal conjugate va...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003710-16,0,1,1 2011-003711-39,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, open, single centre study to assess the safety, reac-togenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate (10Pn-PD-DiT) vaccine (GSK 102485...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003711-39,0,1,1 2011-003712-23,14,2019-03-11,2019-04-04,14,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A 5-year study to compare the durability of glycemic control of a combination regimen with vildagliptin & metformin versus standard-of-care monotherapy with metformin, initiated in treatment-naive pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003712-23,0,0,0 2011-003712-23,14,2019-03-11,2019-04-04,14,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 5-year study to compare the durability of glycemic control of a combination regimen with vildagliptin & metformin versus standard-of-care monotherapy with metformin, initiated in treatment-naive pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003712-23,0,0,0 2011-003712-23,14,2019-03-11,2019-04-04,14,1,0,0,0,0,4,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 5-year study to compare the durability of glycemic control of a combination regimen with vildagliptin & metformin versus standard-of-care monotherapy with metformin, initiated in treatment-naive pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003712-23,0,0,0 2011-003715-28,3,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,1,"Halozyme, Inc.","A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined with PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Compared to Gemcitabine Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003715-28,0,0,0 2011-003718-18,1,2017-11-30,2017-11-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Marsden Hospital NHS Foundation Trust,Proof-of-concept study of AZD 4547 in patients with FGFR1 or FGFR2 amplified tumours,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003718-18,0,0,0 2011-003719-42,5,2015-11-03,2015-11-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MetMAb IN COMBINATION WITH EITHER BEVACIZUMAB + PLATINUM + PACLITAXEL OR PEMETREXED + ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003719-42,0,0,0 2011-003719-42,5,2015-11-03,2015-11-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MetMAb IN COMBINATION WITH EITHER BEVACIZUMAB + PLATINUM + PACLITAXEL OR PEMETREXED + ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003719-42,0,0,0 2011-003719-42,5,2015-11-03,2015-11-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc","A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MetMAb IN COMBINATION WITH EITHER BEVACIZUMAB + PLATINUM + PACLITAXEL OR PEMETREXED + ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003719-42,0,0,0 2011-003719-42,5,2015-11-03,2015-11-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Genentech Inc.,"A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MetMAb IN COMBINATION WITH EITHER BEVACIZUMAB + PLATINUM + PACLITAXEL OR PEMETREXED + ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003719-42,0,0,0 2011-003720-12,5,2015-09-02,2015-09-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MetMAb IN COMBINATION WITH PACLITAXEL + CISPLATIN OR CARBOPLATIN AS FIRST-LINE TREATME...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003720-12,0,0,0 2011-003720-12,5,2015-09-02,2015-09-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF MetMAb IN COMBINATION WITH PACLITAXEL + CISPLATIN OR CARBOPLATIN AS FIRST-LINE TREATME...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003720-12,0,0,0 2011-003730-13,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Effects of plasma expanders administration in pregnancies complicated by intra uterine growth restriction Effetti della somministrazione di espansori del volume plasmatico materno in gravidanze com...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003730-13,0,0,0 2011-003731-63,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IV, open, multi-centre study to assess the immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy Taiwanese in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003731-63,0,1,1 2011-003732-31,4,2014-02-13,2014-02-13,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, parallel-group, 26-week study comparing the efficacy and safety of indacaterol (Onbrez Breezhaler 150 μg o.d.) with salmeterol/fluticasone propionate (Seretide Accuhaler 50...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003732-31,0,0,0 2011-003732-31,4,2014-02-13,2014-02-13,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, parallel-group, 26-week study comparing the efficacy and safety of indacaterol (Onbrez Breezhaler 150 μg o.d.) with salmeterol/fluticasone propionate (Seretide Accuhaler 50...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003732-31,0,0,0 2011-003732-31,4,2014-02-13,2014-02-13,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Farmacéutica SA,"A randomized, double-blind, parallel-group, 26-week study comparing the efficacy and safety of indacaterol (Onbrez Breezhaler 150 μg o.d.) with salmeterol/fluticasone propionate (Seretide Accuhaler 50...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003732-31,0,0,0 2011-003733-34,1,2012-05-25,2012-05-25,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,ikfe – Institute for Clinical Research and Development,Human Insulin Analogs: Evaluation of inflammatory mRNA expression of Macrophages and Endothelial function of Short-acting insulin – HERMES Pilot Study Humaninsulin-Analoga: Evaluation der inflammat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003733-34,0,0,0 2011-003741-17,1,,,0,0,0,0,1,0,2,0,0,1,1,1,0,1,1,PolyMedix Inc.,"Randomized, Dose Ranging, Active Controlled Efficacy and Safety Evaluation of PMX-30063 As Initial Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Staphylococcus au...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003741-17,0,0,0 2011-003742-40,1,2014-02-13,2014-02-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort™ EC as a Maintenance Treatment for Crohn’s Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003742-40,0,0,0 2011-003743-22,2,2014-09-10,2014-09-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort EC for the Treatment of Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive Studio non compara...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003743-22,0,0,0 2011-003743-22,2,2014-09-10,2014-09-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Multicenter, Open label, Non-Comparative Study to Evaluate the Safety of Entocort EC for the Treatment of Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive Studio non compara...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003743-22,0,0,0 2011-003745-18,1,2016-12-31,2016-12-31,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,University of Heidelberg,A PHASE II WINDOW-OF-OPPORTUNITY STUDY OF PREOPERATIVE THERAPY WITH PAZOPANIB (VOTRIENT®) IN HIGH-RISK SOFT TISSUE SARCOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003745-18,0,0,0 2011-003746-41,1,2015-02-11,2015-02-11,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin","A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihistamine-resistant cold contact urticaria (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003746-41,0,0,0 2011-003751-19,5,2015-08-27,2015-08-27,3,1,0,0,0,1,2,0,0,1,1,1,1,0,1,PCI Biotech AS,"An open-label, single arm, multi-centre, Phase II study to evaluate the safety and efficacy of PC-A11 with superficial and interstitial laser light application in patients with recurrent head and neck...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003751-19,0,0,0 2011-003753-26,2,2015-02-11,2015-02-11,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003753-26,0,0,0 2011-003754-61,4,2015-01-05,2015-01-22,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GILEAD SCIENCE INC.,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenoca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003754-61,0,0,0 2011-003754-61,4,2015-01-05,2015-01-22,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Gilead Sciences, Inc.","A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenoca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003754-61,0,0,0 2011-003756-39,2,2013-10-23,2013-10-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Ardea Biosciences, Inc.","A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects with Gout and an Intolerance or Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003756-39,0,0,0 2011-003767-29,4,2014-05-14,2014-05-14,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Ardea Biosciences, Inc.","A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003767-29,0,0,0 2011-003768-55,2,2014-04-16,2014-04-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Ardea Biosciences, Inc.","A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering Serum U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003768-55,0,0,0 2011-003769-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione Italiana Linfomi ONLUS,R-CHOP-14 or R-CHOP-21 & consolidation PET–oriented radiotherapy (RT) in diffuse large B cell lymphoma (DLBCL) patients with low risk profile according to age-adjusted IPI (0 with bulky or 1) St...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003769-14,0,0,0 2011-003775-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Fluoxetine therapy for multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003775-11,0,0,0 2011-003777-28,1,2014-02-10,2014-02-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London and Imperial College Healthcare NHS Trust,"Obeticholic acid treatment in patients with bile acid diarrhoea: an open-label, pilot study of mechanisms, safety and symptom response.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003777-28,0,0,0 2011-003784-30,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,CHU de bordeaux,Rubinstein-Taybi syndrome: approach to functional imaging and therapeutic trial SYNDROME DE RUBINSTEIN-TAYBI : APPROCHE EN IMAGERIE FONCTIONNELLE ET ESSAI THERAPEUTIQUE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003784-30,0,0,0 2011-003786-14,1,2014-03-30,2014-03-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Ghent University Hospital,Heeft het toedienen van ketamine of sevoflurane bij kinderen van 0 tot 14 jaar een meerwaarde tijdens het verwijderen van chirurgische thoraxdrains?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003786-14,0,0,0 2011-003791-37,1,2015-12-31,2015-12-31,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,"Department of Haematology, Aalborg University Hospital","Pre-Clinical Phase 0 Microdose Study to evaluate the effect of Melphalan, Bortezomib and Dexamethasone on cellular gene-expression. Præklinisk fase 0 mikrodosisstudie til vurdering af Melphalans, B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003791-37,0,0,0 2011-003795-36,1,2015-08-20,2015-08-20,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Novartis Pharma GmbH,"Multi-center, open-label, prospective, randomized, parallel group study investigating a tacrolimus Hexal® based regimen versus a Prograf® based regimen in de novo renal transplant recipients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003795-36,0,0,0 2011-003799-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,"Comparison of two antiretroviral regimens in HIV Post-exposure Prophylaxis: TDF-FTC (Truvada®) + Lopinavir/ritonavir (kaletra®) versus TDF-FTC (Truvada®) + raltegravir (Isentress®). A prospective, ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003799-35,0,0,0 2011-003803-39,1,2016-10-27,2016-10-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,St George's University of London,Pain management in osteoarthritis using the centrally acting analgesics duloxetine and pregabalin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003803-39,0,0,0 2011-003807-39,1,2011-11-25,2011-11-25,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GALENpharma,"A phase II, single-center, randomized, observer-blind, vehicle-controlled trial to determine clinical equivalence of MomeGalen Cream (mometasone furoate 0.1 %) to Ecural® Fettcreme (reference drug) an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003807-39,0,0,0 2011-003808-20,1,2012-05-22,2012-05-22,1,0,0,0,0,0,2,0,1,1,1,1,1,0,1,Evolva SA,"A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077-3201-2TBS in Healthy Subjects and Type 2 Diabetic Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003808-20,0,0,0 2011-003810-18,6,2013-11-25,2013-11-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly & Company,"A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Once-Daily Liraglutide in Patients with Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003810-18,0,0,0 2011-003810-18,6,2013-11-25,2013-11-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Once-Daily Liraglutide in Patients with Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003810-18,0,0,0 2011-003812-22,5,2014-05-13,2014-05-13,3,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"Cerexa, Inc. (subsidary of Forest Laboratories)","A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftaroline Versus Comparator in Pediatric Subjects With Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003812-22,1,1,0 2011-003814-18,13,2015-10-01,2015-10-01,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Human Genome Sciences, Inc.","A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Syst...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003814-18,0,0,0 2011-003814-18,13,2015-10-01,2015-10-01,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)","A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Syst...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003814-18,0,0,0 2011-003814-18,13,2015-10-01,2015-10-01,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,HUMAN GENOME SCIENCES INC,"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Syst...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003814-18,0,0,0 2011-003814-18,13,2015-10-01,2015-10-01,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Human Genome Sciences, a wholly owned subsidiary of GlaxoSmithKline, Plc","A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Syst...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003814-18,0,0,0 2011-003814-18,13,2015-10-01,2015-10-01,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Human Genome Sciences, Inc. (a wholy owned subsidiary of GlaxoSmithKline PLC)","A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Syst...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003814-18,0,0,0 2011-003814-18,13,2015-10-01,2015-10-01,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC),"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Syst...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003814-18,0,0,0 2011-003815-46,1,2015-03-30,2015-03-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Erasmus MC,Double blind placebo controlled randomized intervention study aiming at reducing dexamethasone related side effects in children with acute lymphoblastic leukemia (ALL).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003815-46,0,0,0 2011-003816-21,4,2013-02-12,2013-02-12,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"ALCON RESEARCH, LTD.","Multi-Center Study Assessing Efficacy and Tolerability of TRAVATAN Solution without BAK, containing Polyquad Preservative (0.004 travoprost) in Patients Previously on latanoprost 0.005 or bimatopros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003816-21,0,0,0 2011-003816-21,4,2013-02-12,2013-02-12,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Alcon Research, Ltd","Multi-Center Study Assessing Efficacy and Tolerability of TRAVATAN Solution without BAK, containing Polyquad Preservative (0.004 travoprost) in Patients Previously on latanoprost 0.005 or bimatopros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003816-21,0,0,0 2011-003816-21,4,2013-02-12,2013-02-12,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,S.A. Alcon-Couvreur N.V,"Multi-Center Study Assessing Efficacy and Tolerability of TRAVATAN Solution without BAK, containing Polyquad Preservative (0.004 travoprost) in Patients Previously on latanoprost 0.005 or bimatopros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003816-21,0,0,0 2011-003818-16,1,2012-10-17,2012-10-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, open-label, cross-over study to evaluate patient preferences for Eucreas® versus Victoza® as add-on to Metformin in Type 2 Diabetes mellitus patients who did not have adequate glycaemic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003818-16,0,0,0 2011-003821-93,2,2014-04-14,2014-04-14,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, Multicenter, Double Blinded, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/Ivacaftor Cotherapy in Subjects w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003821-93,0,0,0 2011-003822-29,3,2015-12-28,2016-02-04,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003822-29,0,0,0 2011-003823-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSOCIAZIONE SALENTINA ANGELA SERRA ONLUS,Phase II randomized multicenter study of multiple doses of palonosetron plus aprepitant versus multiple doses of palonosetron alone in preventing chemotherapy-induced nausea and vomiting in patients w...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003823-36,0,0,0 2011-003824-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Pilot phase II trial on safety and activity of secondary prophylaxis with Romiplostim in patients with non-Hodgkin lymphoma and chemotherapy-induced throm-bocytopenia Studio pilota di fase II sulla...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003824-12,0,0,0 2011-003825-81,5,2018-03-12,2018-03-12,2,1,1,0,0,1,0,0,0,1,1,0,1,0,1,"Shire Orphan Therapies, Inc","A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents with Heredit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003825-81,0,0,0 2011-003825-81,5,2018-03-12,2018-03-12,2,1,1,0,0,1,0,0,0,1,1,0,1,0,1,"Shire Orphan Therapies, LLC","A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents with Heredit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003825-81,0,0,0 2011-003825-81,5,2018-03-12,2018-03-12,2,1,1,0,0,1,0,0,0,1,1,0,1,0,1,"SHIRE HUMAN GENETIC THERAPIES, INC.","A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents with Heredit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003825-81,0,0,0 2011-003826-28,1,2013-12-02,2013-12-02,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,ZAMBON S.p.A.,Evaluation of efficacy and safety of Ibuprofen Arginine 600 mg tid vs. Ibuprofen 600 mg tid in the treatment of pain and inflammation in Osteoarthritis (OA) patients with hypertension pharmacologicall...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003826-28,0,0,0 2011-003827-37,5,2013-10-14,2013-10-14,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Amgen Inc,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-term Tolerability and Durable Efficacy of AMG 145 on LDL-C in Hyperlipidemic Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003827-37,0,0,0 2011-003832-30,6,2016-04-08,2016-04-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nektar Therapeutics,"The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Locally Recurre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003832-30,0,0,0 2011-003832-30,6,2016-04-08,2016-04-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NEKTAR THERAPEUTICS,"The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Locally Recurre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003832-30,0,0,0 2011-003836-29,3,2013-06-25,2013-06-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A randomized, double-blind, placebo-controlled, repeat-dose study of the efficacy, safety, tolerability, and pharmacodynamics of subcutaneously-administered REGN668 in adult patients with extrinsic mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003836-29,0,0,0 2011-003847-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ICORG,"ECOG 2809: Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003847-22,0,0,0 2011-003849-18,1,2016-03-22,2016-03-22,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,LYSARC,"A MULTI-CENTER, PHASE IB/II, OPEN LABEL, SINGLE ARM STUDY OF INOTUZUMAB OZOGAMICIN PLUS RITUXIMAB (R-CMC544) ALTERNATING WITH GEMCITABINE-OXALIPLATIN PLUS RITUXIMAB (R-GEMOX) IN PATIENTS AGED FROM 18 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003849-18,0,0,0 2011-003850-26,5,2012-05-24,2012-05-24,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Multicenter, Open-label Study to Assess Hospitalization Rates in Adult Subjects with Schizophrenia Treated Prospectively for 6 Months with Aripiprazole IM Depot Compared with 6-month Retrospective T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003850-26,0,0,0 2011-003850-26,5,2012-05-24,2012-05-24,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALISATION INC,"A Multicenter, Open-label Study to Assess Hospitalization Rates in Adult Subjects with Schizophrenia Treated Prospectively for 6 Months with Aripiprazole IM Depot Compared with 6-month Retrospective T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003850-26,0,0,0 2011-003851-20,1,2012-02-02,2012-02-02,1,1,0,0,1,0,3,0,0,1,1,1,1,0,1,"Alcon Research, Ltd.","A Multicente, Observer-Masked Study of the Safety and Efficacy of MDPF Travoprost, 0.004% Compared to TRAVATAN in Patients with Open-Angle Glaucoma or Ocular Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003851-20,0,0,0 2011-003866-34,1,2016-04-28,2016-04-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,North Bristol NHS Trust (NBT),"A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administere...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003866-34,0,0,0 2011-003890-27,1,2013-04-19,2013-04-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A multi-centre, double-blind, randomised, parallel group study to assess the efficacy and safety of multiple doses of topically applied hyperemisation-inducing ointment (2 cm ointment line per applica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003890-27,0,0,0 2011-003893-97,9,2014-04-05,2014-04-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ104) Plus Metronida...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003893-97,0,0,0 2011-003894-27,1,2013-05-08,2013-05-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Technische Universität Dresden,Tolerance and effect of an add-on therapy with an ivy leaves dry extract syrup on lung function in children with asthma. Verträglichkeit und Einfluss einer zusätzlichen Behandlung mit einem Efeubl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003894-27,0,0,0 2011-003895-35,8,2014-04-07,2014-04-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ104) Plus Metronid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003895-35,0,0,0 2011-003895-35,8,2014-04-07,2014-04-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA AB,"A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ104) Plus Metronid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003895-35,0,0,0 2011-003933-32,1,2012-01-31,2012-01-31,1,1,0,0,1,0,2,0,1,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge,"A randomised, blind, placebo controlled crossover study of the influence of the HCN channel-blocker ivabradine on the symptoms of neuropathic pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003933-32,0,0,0 2011-003934-16,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Pluristem Ltd.,"A Phase I/II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Regeneration of Injured Gluteal Muscu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003934-16,0,0,0 2011-003938-14,15,2019-09-10,2019-09-10,14,1,1,0,0,0,0,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults (Phase 3; Protocol No. MK- 5592-069),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003938-14,0,0,0 2011-003938-14,15,2019-09-10,2019-09-10,14,1,1,0,0,0,0,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Ltd,A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults (Phase 3; Protocol No. MK- 5592-069),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003938-14,0,0,0 2011-003938-14,15,2019-09-10,2019-09-10,14,1,1,0,0,0,0,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Corp.,A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults (Phase 3; Protocol No. MK- 5592-069),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003938-14,0,0,0 2011-003943-23,1,2013-11-25,2013-11-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Spirig Pharma AG,"Prospective, randomized, partly blinded, in part placebo-controlled, multicenter, dose-finding trial exploring safety, tolerability and efficacy of a topical resiquimod gel in patients with multiple a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003943-23,0,0,0 2011-003950-24,1,2015-08-17,2015-08-17,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Hospitals of Leicester NHS Trust,"PHASE II TRIAL OF PALLIATIVE EPIRUBICIN, OXALIPLATIN & CAPECITABINE (EOX) CHEMOTHERAPY COMBINED WITH OMEGA-3 FISH OIL INFUSION (OMEGAVEN) IN PATIENTS WITH OESOPHAGO-GASTRIC CARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003950-24,0,0,0 2011-003952-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,LUIS FERNÁNDEZ- LLEBREZ DEL REY,"Open randomized controlled trial to evaluate the efficacy and safety of remifentanil versus nitrous oxide in the external cephalic version at term in singleton pregnancy in breech presentation, COD: R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003952-37,0,0,0 2011-003953-25,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,1,Abbott GmbH & Co. KG,"A Multicenter, Randomized, Single-Blind Crossover Study of the Safety and Tolerability of Two Adalimumab Formulations in Adult Subjects with Rheumatoid Arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003953-25,0,0,0 2011-003958-85,1,2014-08-27,2014-08-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Immodulon Therapeutics Ltd,"A Phase II, Single Arm, Investigative Study of IMM-101 in Combination with Radiation Induced Tumour Necrosis in Patients with Previously Treated Colorectal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003958-85,0,0,0 2011-003966-34,2,2014-02-12,2014-02-12,1,0,0,0,0,0,3,0,0,1,1,0,1,0,0,Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU),The ADACAL Study: cAlprotectin and hsCRP as markers of a new Diagnostic-therapeutic strAtegy that assesses muCosal Activity to individuaLize treatment and improve the prognosis of patients with Crohn?...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003966-34,0,0,0 2011-003971-12,1,2015-11-18,2015-11-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus? in Subjects With Type 1 Diabetes Mellitus. Estudio clínico de fase III para estudiar la seguridad y eficac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003971-12,0,0,0 2011-003997-10,4,2014-10-15,2014-10-15,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GENENTECH, Inc.","A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND DOSING REGIMENS OF MEMP1972A IN ADULTS WITH ALLERGIC ASTHMA WHO ARE INADEQUATELY CONTROLLED ON INH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003997-10,0,0,0 2011-003998-28,3,2014-07-08,2014-07-08,3,0,0,0,0,2,2,0,0,1,0,0,1,0,1,Cerenis Therapeutics,"Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-Label Study of the Effects of CER-001 on Plaque Volume in Subjects with Homozygous Familial Hypercholesterolemia (HoFH) Studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003998-28,0,0,0 2011-003998-28,3,2014-07-08,2014-07-08,3,0,0,0,0,2,2,0,0,1,0,0,1,0,1,CERENIS THERAPEUTICS SA,"Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-Label Study of the Effects of CER-001 on Plaque Volume in Subjects with Homozygous Familial Hypercholesterolemia (HoFH) Studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-003998-28,0,0,0 2011-004002-25,2,2013-01-24,2013-01-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-04937319 AND SITAGLIPTIN ON GLYCEMIC CONTROL IN ADULT PATIENTS WITH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004002-25,0,0,0 2011-004005-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Complejo Hospitalario Torrecárdenas,Sulfato de magnesio y ketamina como coadyuvantes anestésicos en artroplastia de rodilla: efectos sobre los requerimientos analgésicos periperatorios.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004005-24,0,0,0 2011-004011-24,14,2018-07-13,2018-07-13,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffman-La Roche Ltd.,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB (RO5185426) ADJUVANT THERAPY IN PATIENTS WITH SURGICALLY RESECTED, CUTANEOUS BRAF-MUTANT MELANOMA AT HIGH RISK FOR RECU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004011-24,0,0,0 2011-004011-24,14,2018-07-13,2018-07-13,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB (RO5185426) ADJUVANT THERAPY IN PATIENTS WITH SURGICALLY RESECTED, CUTANEOUS BRAF-MUTANT MELANOMA AT HIGH RISK FOR RECU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004011-24,0,0,0 2011-004013-16,11,2015-01-02,2015-01-02,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600mg every 8 hours) Versus Vancomycin Plus Aztreonam in the Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004013-16,0,0,0 2011-004013-16,11,2015-01-02,2015-01-02,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA AB,"A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600mg every 8 hours) Versus Vancomycin Plus Aztreonam in the Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004013-16,0,0,0 2011-004016-29,5,2015-01-04,2015-06-18,4,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Multi-Center Study to Evaluate the Efficacy and Safety of BMS- 945429 Subcutaneous Injection in Adults with Active Psoriatic Art...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004016-29,1,0,0 2011-004016-29,5,2015-01-04,2015-06-18,4,0,0,0,0,0,2,0,0,2,1,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Multi-Center Study to Evaluate the Efficacy and Safety of BMS- 945429 Subcutaneous Injection in Adults with Active Psoriatic Art...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004016-29,1,0,0 2011-004017-17,1,2016-03-29,2016-03-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The University of Leeds,"Prospective, Single-centre, Open-Label, Randomised, Pilot Study Assessing the changes in expression of JAK-STAT and Speed & Depth of Remission Induced by Tocilizumab & Methotrexate Combination and Toc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004017-17,0,0,0 2011-004025-27,3,2015-04-14,2015-04-14,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,HENNIG ARZNEIMITTEL GmbH & Co. KG,"Efficacy and safety of a fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg vs betahistine dihydrochloride 16 mg in patients with vertigo of peripheral origin. A multi-centre, double-blin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004025-27,0,0,0 2011-004029-28,13,2017-08-15,2017-08-17,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg vs at 10 mg/kg in Subjects with Previously Treated or Untreated Unresectable or Metastatic Melanoma. Studio di fase I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004029-28,0,0,0 2011-004029-28,13,2017-08-15,2017-08-17,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg vs at 10 mg/kg in Subjects with Previously Treated or Untreated Unresectable or Metastatic Melanoma. Studio di fase I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004029-28,0,0,0 2011-004030-33,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,CHU de Clermont-Ferrand,Prévention du développement de douleur neuropathique post-mastectomie / tumorectomie par l’administration de mémantine en pré et post-chirurgie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004030-33,0,0,0 2011-004031-31,1,2012-04-24,2012-04-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,RespiVert Ltd,"A randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability of treatment with repeat doses of inhaled RV568 in patients with COPD.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004031-31,0,0,0 2011-004033-13,1,2014-07-21,2014-07-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Spinifex Pharmaceuticals Pty Ltd,A Phase 2 open label biomarker study of angiotensin II type 2 receptor antagonist EMA401 for the treatment of pain in patients with chemotherapy-induced peripheral neuropathy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004033-13,0,0,0 2011-004038-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI,"Non-inferiority,randomized clinical trial to evaluate the efficacy and the safety of the use of fixed-dose combination efavirenz/tenofovir/emtricitabine (Atripla) administered in alternate days versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004038-33,0,0,0 2011-004039-30,1,2012-10-07,2012-10-07,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,PLymouth Hospitals NHS Trust,"Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 Years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004039-30,0,0,0 2011-004046-18,10,2014-03-18,2014-06-30,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,Knee joint replacement over 5 years in patients with knee osteoarthritis. A long term follow up study in patients of the CL3-12911-018 study. Studio di follow up a lungo termine per pazienti che h...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004046-18,0,0,0 2011-004046-18,10,2014-03-18,2014-06-30,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Knee joint replacement over 5 years in patients with knee osteoarthritis. A long term follow up study in patients of the CL3-12911-018 study. Studio di follow up a lungo termine per pazienti che h...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004046-18,0,0,0 2011-004046-18,10,2014-03-18,2014-06-30,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Laboratorios Servier,Knee joint replacement over 5 years in patients with knee osteoarthritis. A long term follow up study in patients of the CL3-12911-018 study. Studio di follow up a lungo termine per pazienti che h...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004046-18,0,0,0 2011-004062-15,2,2022-04-16,2022-04-16,2,0,0,0,0,1,2,0,0,1,0,0,0,0,0,University Hospital of Regensburg,"Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high risk neuroblastoma Pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004062-15,0,0,0 2011-004063-77,1,2018-02-02,2018-02-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Klinikum der Universität München, Anstalt des öffentlichen Rechts",Gemcitabine in Combination with the Oral Irreversible ErbB Inhibitor Afatinib versus Gemcitabine Alone in Patients with Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial Gemcit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004063-77,0,0,0 2011-004064-29,1,2013-02-13,2013-02-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Daiichi Sankyo, Inc.",A PHARMACODYNAMIC EVALUATION OF SWITCHING FROM TICAGRELOR TO PRASUGREL IN SUBJECTS WITH STABLE CORONARY ARTERY DISEASE: 2ND SWITCHING ANTIPLATELET AGENTS (SWAP 2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004064-29,0,0,0 2011-004070-29,1,2013-07-12,2013-07-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hopital Erasme,What are the optimal doses of cephalosporins of first and second generation to manage obese patients? Quelles sont les doses optimales de céphalosporines de premières et deuxième génération à admin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004070-29,0,0,0 2011-004072-10,1,2017-10-24,2017-10-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Leeds,FGFR Inhibition for Epithelial Solid Tumours: a Phase Ib trial of AZD4547 in combination with gemcitabine and cisplatin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004072-10,0,0,0 2011-004074-28,3,2014-11-04,2014-11-04,2,1,1,0,0,1,1,0,0,1,0,0,1,0,1,Promethera Biosciences,"A prospective, open label, multicenter, partially randomized, safety study of one cycle of Promethera HepaStem in Urea Cycle Disorders and Crigler-Najjar Syndrome Patients Uno studio sperimentale p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004074-28,0,0,0 2011-004074-28,3,2014-11-04,2014-11-04,2,1,1,0,0,1,1,0,0,1,0,0,1,0,1,PROMETHERA BIOSCIENCES,"A prospective, open label, multicenter, partially randomized, safety study of one cycle of Promethera HepaStem in Urea Cycle Disorders and Crigler-Najjar Syndrome Patients Uno studio sperimentale p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004074-28,0,0,0 2011-004078-26,1,2017-01-31,2017-01-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Brighton & Sussex University Hospitals NHS Trust,A double blind placebo controlled randomised trial to study the effects of birch pollen specific immunotherapy (BP-SIT) on the symptoms of the oral allergy syndrome in adult patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004078-26,0,0,0 2011-004080-70,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Med. Univ. Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie",Preoperative parenteral thiamine supplementation in patients undergoing heart surgery – a pilot study Präoperativ parenterale Thiamin Supplementierung bei Patienten/innen mit Herz Operation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004080-70,0,0,0 2011-004082-33,1,2014-08-25,2014-08-25,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,UZLeuven,The role of induced phase 3 contractions in the control of hunger and food intake,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004082-33,0,0,0 2011-004085-15,1,2012-04-17,2012-04-17,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Laboratories León Farma S.A,"Open-Label, Randomized Study to Evaluate the Influence on the Hormonal and Ovarian Activity of Two Different Dosages of Drospirenone (either 4.0 mg for 24 Days or 2.8 mg Daily for 28 Days) Over Two Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004085-15,0,0,0 2011-004086-32,1,2013-05-23,2013-05-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,POXEL,Étude randomisée en double-aveugle versus placebo des effets de l’iméglimine sur la sécrétion d’insuline au cours d’un clamp hyperglycémique chez le sujet diabétique de type,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004086-32,0,0,0 2011-004087-30,1,2012-04-30,2012-04-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Tartu University Department of Sports Medicine and Rehabilitation,Effect of 12 weeks rehabilitation (aspect of neuromuscular physical therapy) in middle-aged patients in post-atroscopic period 12 nädalat kestva taastusravi (neuromuskulaarse liikumisravi aspekt) m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004087-30,0,0,0 2011-004089-13,1,2012-12-20,2012-12-20,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Cassella-med GmbH & Co. KG,"Placebo-controlled exploratory pilot study to investigate the effect and onset of action of Traumaplant® for delayed onset muscle soreness. Placebo-kontrollierte, explorative Pilotstudie zur Unters...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004089-13,0,0,0 2011-004090-82,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospitals Bristol NHS Foundation Trust Research and Innovation Department,A Phase II Trial of Combination Cabazitaxel and Cisplatin Chemotherapy in the Neoadjuvant Treatment of Transitional Cell Carcinoma of the Urinary Bladder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004090-82,0,0,0 2011-004091-12,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Pluristem Ltd.,"A Phase II, Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled, Parallel-Groups Study to Evaluate the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004091-12,0,0,0 2011-004094-93,2,2013-07-02,2013-07-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Allergie-Centrum Charité,"Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40 mg in cold contact urticaria (CCU) Función de la li...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004094-93,0,0,0 2011-004094-93,2,2013-07-02,2013-07-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Consorci Mar Parc de Salut de Barcelona,"Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40 mg in cold contact urticaria (CCU) Función de la li...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004094-93,0,0,0 2011-004094-93,2,2013-07-02,2013-07-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Department of Dermatology and Allergy Charité- Universitätsmedizin Berlin,"Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40 mg in cold contact urticaria (CCU) Función de la li...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004094-93,0,0,0 2011-004095-10,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur Limited,"A Phase III Randomized, Open-Label, Active-Comparator Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Infants When Given at 2, 4, and 6 Months Concomitant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004095-10,0,1,1 2011-004096-36,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,0,OSPEDALE POLICLINICO S. MATTEO,Efficacy of thalidomide in the treatment of severe recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT) Efficacia di talidomide nel trattamento dell'epistassi severa ricorrente nella ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004096-36,0,0,0 2011-004097-29,1,2014-02-20,2014-02-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen R&D Ireland,"An Open-Label, Single-Arm Phase III Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004097-29,0,0,0 2011-004103-20,2,2019-01-23,2019-01-23,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Viamet Pharmaceuticals, Inc.","A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects with Castration-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004103-20,0,0,0 2011-004103-20,2,2019-01-23,2019-01-23,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Innocrin Pharmaceuticals, Inc.","A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects with Castration-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004103-20,0,0,0 2011-004104-38,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,FIBHULP,"ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO, DE EFICACIA, TOLERANCIA Y SEGURIDAD DEL TRATAMIENTO CON EL FACTOR TRÓFICO IGF-I EN LA ATAXIA DE FRIEDREICH",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004104-38,0,0,0 2011-004106-16,4,2012-06-01,2012-06-01,1,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Actelion pharmaceuticals Ltd,"A randomized, prospective, double-blind, placebo-controlled, group sequential multicenter study to assess efficacy, safety, and tolerability of the pediatric formulation of bosentan in children with p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004106-16,1,0,0 2011-004108-39,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur Limited,"A Phase III Randomized, Partially Double-Blind, Active- Comparator-Controlled, Lot-to-Lot Consistency Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004108-39,0,1,1 2011-004109-25,5,2017-02-22,2017-02-22,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Upsher-Smith Laboratories, Inc.",An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects with Seizure Clusters,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004109-25,0,0,0 2011-004114-42,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,University Hospital Antwerp,Fenfluramine as anti-epilepticum in Dravet syndrome. Fenfluramine als anti-epilepticum bij Dravet syndroom.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004114-42,0,0,0 2011-004126-10,7,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Genentech Inc.,A PHASE Ib/II STUDY OF GDC-0068 OR GDC-0980 WITH ABIRATERONE ACETATE VERSUS ABIRATERONE ACETATE IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL-BASED CHEMOTHERA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004126-10,0,0,0 2011-004129-28,1,2013-08-28,2013-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche,"Study To Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted DANOPREVIR in Combination With Peginterferon Alfa-2a Plus Ribavirin in Treatment-naive Patients and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004129-28,0,0,0 2011-004130-34,3,2015-07-28,2015-07-28,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis Recherche & Développement,"A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 Versus Ezetimibe in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004130-34,0,0,0 2011-004138-33,1,2019-05-06,2019-05-06,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,Søren Rittig,The effect of melatonin on nocturnal enuresis Melatonins effekt på enuresis nocturna,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004138-33,0,0,0 2011-004139-29,1,2016-02-20,2016-02-20,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Medizinische Universität Innsbruck / UK für Anästhesie und Intensivmedizin & UK für Allgem. u. Chirurg. Intensivmedizin,RETIC trial: Reversal of Trauma Induced Coagulopathy by using Coagulation factor concentrates or Fresh frozen Plasma Reversierung einer Trauma induzierten Koagulopathie mittels Frischplasma oder Ge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004139-29,0,0,0 2011-004144-22,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Institut Jules Bordet - Université Libre de Bruxelles,A Phase I/II study to assess the safety and immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) combined with infusions of ex vivo regulatory T cells depleted T lymphocy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004144-22,0,0,0 2011-004145-41,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,UH Montpellier,Efficacy and safety of acebutolol versus propranolol in the proliferative phase of infantile hemangiomas Efficacité et tolérance de l'acébutolol versus propranolol sur la phase proliférative des h...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004145-41,0,0,0 2011-004146-18,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,"Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment Of T-cell Lymphoma, a multicentre randomis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004146-18,0,0,0 2011-004148-23,10,2018-01-18,2018-01-18,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim International GmbH,"A multicenter, international, randomized, parallel group, double blind,placebo-controlled CArdiovascular Safety & Renal Microvascular outcomE with LINAgliptin, 5 mg once daily in patients with type 2 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004148-23,0,0,0 2011-004150-26,3,2014-01-15,2014-01-15,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Vertex Pharmaceuticals,"A Multicenter, Open-Label, Phase 2b Pilot Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2 and Ribavirin) in Subjects With Genotype 1 Chronic He...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004150-26,0,0,0 2011-004151-39,5,2015-06-01,2015-07-22,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Kyowa Hakko Kirin Pharma, Inc.","Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) in Subjects with Previously Treated Peripheral T-cell Lymphoma (PTCL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004151-39,0,0,0 2011-004152-19,1,2016-01-18,2016-01-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Ludwig Boltzmann institute for COPD and Respiratory Epidemiology,Effects of ROFLUMILAST on markers of subclinical atherosclerosis In stable COPD; the ELASTIC-trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004152-19,0,0,0 2011-004154-25,3,2019-09-11,2020-05-15,2,1,1,0,0,1,1,0,0,1,1,0,1,0,1,Biotest AG,"A prospective, open-label, phase I/II study investigating pharmacokinetic properties of BT524 and efficacy and safety of BT524 in the treatment and prophylaxis of bleeding in patients with congenital ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004154-25,0,0,0 2011-004155-39,1,2016-03-08,2016-03-08,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bayer Healthcare AG,Phase Ib / II study of BAY 1000394 in combination with cisplatin / etoposide or carboplatin / etoposide as first-line therapy in subjects with extensive disease small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004155-39,0,0,0 2011-004156-19,6,2012-09-25,2013-09-24,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2b, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment Resistant Partial Epilepsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004156-19,0,0,0 2011-004157-66,4,2013-09-13,2013-09-13,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Quark Pharmaceuticals, Inc.","An Open-Label Dose Escalation Study of PF-04523655 (Stratum I) Combined With A Prospective, Randomized, Double-Masked, Multi-Center, Controlled Study (Stratum II) Evaluating The Efficacy and Safety of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004157-66,0,0,0 2011-004158-24,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Boehringer Ingelheim RCV GmbH & Co KG,"A 24-week, randomized, double-blind, active-controlled, parallel group trial to assess the superiority of oral linagliptin and metformin compared to linagliptin monotherapy in newly diagnosed, treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004158-24,0,0,0 2011-004160-30,2,2013-11-15,2014-10-10,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, active-controlled study to assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004160-30,0,0,0 2011-004160-30,2,2013-11-15,2014-10-10,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Service AG,"A multicenter, randomized, active-controlled study to assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004160-30,0,0,0 2011-004166-16,1,2018-10-10,2018-10-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Abteilung für Pulmologie, Landesklinikum Thermenregion Hochegg","Does simvastatin treatment affect COPD exacerbations? - Evaluation in a randomized controlled trial Kann Simvastatin Exazerbationen bei COPD beeinflussen? - Evaluierung in einem randomisierten, dop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004166-16,0,0,0 2011-004167-68,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,MARIA TERESA PARRAS MALDONADO,"Comparación de bloqueo TAP (abordaje cuadrado lumbar) versus bloqueo femoral para analgesia postoperatoria de artroplastia parcial de cadera, ambos guiados con ultrasonidos",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004167-68,0,0,0 2011-004168-30,2,2017-03-10,2017-03-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Hannover Medical School,A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004168-30,0,0,0 2011-004169-34,1,2014-07-01,2014-07-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Bristol,Effects of Varenicline and Cognitive Bias Modification on Neural Response to Smoking Cues,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004169-34,0,0,0 2011-004171-36,1,2013-06-30,2013-06-30,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,Samsung Electronics Co. Ltd.,"A Randomized, Double-blind, Parallel Group, Multicenter Trial to Compare the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of SAIT101 to MabThera® in Subjects with Severe Rheumatoid Arthriti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004171-36,0,0,0 2011-004172-11,1,2013-03-22,2013-03-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Laboratorios SALVAT, S.A.","Ensayo Clínico multicéntrico, aleatorizado, paralelo, doble ciego, para evaluar la eficacia y seguridad de Fluocinolona Acetónido 0.025% gotas óticas en solución en comparación con placebo en paciente...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004172-11,0,0,0 2011-004177-83,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Academic Medical Center,Boosting the oxytocin system in acute trauma: The effectiveness of intranasal oxytocin treatments and stimulation of social support on preventing trauma related psychopathology Versterken van het ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004177-83,0,0,0 2011-004178-27,1,2012-02-24,2012-02-24,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Karolinska University Hospital,"A Randomized, Open Label, Multicenter, Phase II, 2-Arm Study comparing the conventional 3 weekly schedule of Jevtana (Cabazitaxel) with a weekly regimen in patients with Metastastic Castration Resista...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004178-27,0,0,0 2011-004179-35,1,2013-07-09,2013-07-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,C4Pain ApS,"A single center, randomized, double-blind, placebo-controlled 2-way crossover study to investigate the mechanism of action of etoricoxib in subjects with osteoarthritis knee pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004179-35,0,0,0 2011-004182-33,1,2012-05-30,2012-05-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Vejle Hospital,Phase II Study of gemcitabin and capecitabine in Chemotherapy Refractory Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004182-33,0,0,0 2011-004183-29,1,2015-04-21,2015-04-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Dermal Laboratories,"A randomised, placebo-controlled trial to investigate the effectiveness of an antimicrobial product in the elimination of Staphylococcus aureus colonisation from the anterior nares of adult subjects w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004183-29,0,0,0 2011-004184-79,1,2014-04-08,2014-04-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dermal Laboratories Limited,A placebo controlled evaluation of a developmental gel for the treatment of atopic eczema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004184-79,0,0,0 2011-004185-14,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma GmbH,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of intraseasonal specific short-term immunotherapy with depigmented glutaraldehyde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004185-14,0,0,0 2011-004187-30,2,2016-07-26,2016-07-26,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Avraham Pharmaceuticals Ltd.,"A 36-month, multi-centre, randomized double-blind placebo-controlled study to evaluate the safety and efficacy of low dose Ladostigil in patients with Mild Cognitive Impairment (MCI)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004187-30,0,0,0 2011-004188-65,2,2019-03-01,2019-05-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Odense University Hospital,FOLFIRI + Erbitux versus alternating FOLFIRI + Erbitux/FOLFOX + Erbitux to patients with RAS wild type metastatic colorectalcancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004188-65,0,0,0 2011-004189-13,1,2016-08-31,2016-08-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Wien,ASSESSMENT OF MULTIDRUG RESISTANCE IN BREAST CANCER AND LOW GRADE GLIOMA PATIENTS WITH [11C]TARIQUIDAR PET. A PILOT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004189-13,0,0,0 2011-004192-37,1,2015-07-30,2015-07-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Joint Research Compliance Office, Imperial College",Hellenic Anglo Research into Morning Or Night antihypertensive drug deliverY trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004192-37,0,0,0 2011-004198-10,1,2015-08-03,2015-08-03,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Swiss Cardio Technologies AG,"A Single-Centre, Single Blind, Randomized, Active-Controlled Phase III Non-Inferiority Study to Investigate the Safety and Efficacy of the Cardioplegic Solution Cardioplexol when used during a Cardi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004198-10,0,0,0 2011-004199-12,1,2014-04-09,2014-04-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Birmingham,An open label dose ranging study to optimise vitamin D levels prior to oesophagectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004199-12,0,0,0 2011-004200-38,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,NKI-AVL,Phase II study exploring safety and efficacy of the combination of ipilimumab with radiofrequency ablation (RFA) in patients with unresectable uveal melanoma liver metastasis (SECIRA-UM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004200-38,0,0,0 2011-004201-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,The BOKITO-1B Study: Tenofovir DF Bone and Kidney Toxicity. Pharmacology in HBV monoinfected patients. De BOKITO-1B studie: Tenofovir DF bot- en niertoxiciteit. Farmacologie bij patiënten met hepa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004201-25,0,0,0 2011-004205-24,5,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,F. Hoffmann-La Roche Ltd,"A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of LEBRIKIZUMAB in patients with uncontrolled asthma who are on inhaled corticosteroids and second c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004205-24,0,0,0 2011-004205-24,5,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,F. HOFFMANN - LA ROCHE LTD.,"A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of LEBRIKIZUMAB in patients with uncontrolled asthma who are on inhaled corticosteroids and second c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004205-24,0,0,0 2011-004206-19,1,2013-04-26,2013-04-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,AMC,Patient and Endoscopist Satisfaction with DEXmedetomidine versus Propofol/Alfentanil sedation during oesophagus interventions (PESDEX). Ondervindingen van patiënten en endoscopist met dexmedetomidi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004206-19,0,0,0 2011-004208-39,8,2016-03-09,2016-03-09,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Randomized, double-blind, placebo-controlled, multicEnter Study comParing CIprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004208-39,0,0,0 2011-004208-39,8,2016-03-09,2016-03-09,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,BAYER HEALTHCARE AG,"Randomized, double-blind, placebo-controlled, multicEnter Study comParing CIprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004208-39,0,0,0 2011-004211-23,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CHU Amiens,Etude d’efficacité et d’acceptabilité de la Tétrabénazine dans le syndrome tardif aux neuroleptiques : Etude randomisée multicentrique en groupes parallèles en double aveugle versus placebo «XELADYS»,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004211-23,0,0,0 2011-004213-16,1,2014-02-16,2014-02-16,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Ipsen Ltd,"A PHASE IV, RANDOMISED, OPEN-LABEL, MULTI-CENTRE STUDY TO ASSESS THE IMPACT ON DISEASE CONTROL, SAFETY, PATIENT AND CLINICIAN EXPERIENCE OF CHANGING PATIENTS WITH ADVANCED PROSTATE CANCER FROM A 3-MON...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004213-16,0,0,0 2011-004214-42,3,2014-05-15,2014-05-16,2,0,0,1,0,1,1,0,0,1,0,0,0,0,1,QLT Inc.,An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and Vision Outcome in Subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004214-42,0,0,0 2011-004216-31,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Novartis Pharma Services AG,"A phase II, multi-centre, randomized, double blind, placebo-controlled study to determine the mode of action of omalizumab in patients with chronic idiopathic urticaria (CIU) who remain symptomatic wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004216-31,0,0,0 2011-004217-17,1,,,0,1,1,0,0,0,4,0,0,4,0,0,0,0,1,Novartis Pharmaceuticals Corporation,"A single-arm, open-label study of the Palatability and Tolerability of Exjade Taken with Meals, with Different Liquids or Crushed and Added to Food",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004217-17,0,1,1 2011-004218-41,4,2012-10-01,2012-10-01,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of LEBRIKIZUMAB in patients with uncontrolled asthma who are on inhaled corticosteroids and second co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004218-41,0,0,0 2011-004218-41,4,2012-10-01,2012-10-01,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of LEBRIKIZUMAB in patients with uncontrolled asthma who are on inhaled corticosteroids and second co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004218-41,0,0,0 2011-004220-34,1,2017-08-23,2017-08-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,King's College London,A randomised phase II trial of [18F]fluorothymidine and the standard tracer [18F]Fluorodeoxyglucose in the assessment of systemic therapy response in triple negative breast cancer and their utility co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004220-34,0,0,0 2011-004220-34,1,2017-08-23,2017-08-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Guy's and St Thomas' NHS Foundation Trust,A randomised phase II trial of [18F]fluorothymidine and the standard tracer [18F]Fluorodeoxyglucose in the assessment of systemic therapy response in triple negative breast cancer and their utility co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004220-34,0,0,0 2011-004221-28,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Comparaison Glibenclamide/Insuline dans le traitement du diabète gestationnel. Essai randomisé multicentrique de non infériorité,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004221-28,0,0,0 2011-004223-12,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,1,Digna Biotech S.L.,"A pilot, randomised, double blind, placebo-controlled, parallel groups, clinical trial to investigate the efficacy and safety of Cardiotrophin-1 (CT-1) in kidney transplantation. Ensayo clínico, pi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004223-12,0,0,0 2011-004228-37,1,2021-03-08,2021-03-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsmedizin Goettingen,Translational Validation Trial-B (add-on phase I/II study to the Clinical Research Unit (Klinische Forschergruppe) KFO179-2 Translatorische Validierungsstudie-B der Phase I/II (add-on Studie zur Kl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004228-37,0,0,0 2011-004231-31,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Erasmus University Medical Centre Rotterdam,Randomized double blind multi-centre study of the effects on low-dose pegvisomant treatment in acromegalic subjects in whom the IGF1 levels has been normalized by long-acting somatostatin analogues ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004231-31,0,0,0 2011-004232-66,1,2017-08-28,2017-08-28,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Clermont-Ferrand,Influence d’une stratégie de prévention des hypotensions artérielles peropératoires chez les patients à risques élevés de complications postopératoires : étude multicentique prospective randomisée con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004232-66,0,0,0 2011-004235-31,1,2012-09-24,2012-09-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,IPPMed GmbH,SEVICONTROL-1: Efficacy and safety of a fixed combination of olmesartan 40 mg/amlodipin 10 mg in patients with moderate essential hypertension not sufficiently controlled under monotherapy with candes...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004235-31,0,0,0 2011-004237-14,6,2014-03-20,2014-03-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C Studio di fas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004237-14,0,0,0 2011-004237-14,6,2014-03-20,2014-03-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C Studio di fas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004237-14,0,0,0 2011-004239-29,1,2012-09-28,2012-09-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hopital Erasme,what are the optimal doses of broad spectrum B-lactams to administer to obese patients if infected?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004239-29,0,0,0 2011-004245-41,1,2014-06-24,2014-06-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Hywel Dda Health Board,"Safety, Tolerability and Effectiveness of Glocophage®SR in patients with type-2 Diabetes and Chronic Kidney Disease (eGFR 30 to 45mL/minute/1.73m2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004245-41,0,0,0 2011-004249-42,1,2012-12-13,2012-12-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,IPPMed GmbH,SEVICONTROL-2: Efficacy and Safety of a sequential therapy change from Candesartan 32 mg to the fixed combination of olmesartan 40 mg/amlodipine 10 mg in patients with poorly controlled moderate hyper...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004249-42,0,0,0 2011-004250-26,3,2019-03-27,2019-03-27,2,1,0,1,0,2,1,0,0,1,1,0,0,0,1,Clovis Oncology Inc.,"A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients with gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004250-26,0,0,0 2011-004253-11,7,2013-09-26,2013-09-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A randomised, double-blind, placebo-controlled, parallel group study to determine the effect of 12 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 μg, 5/5 μg)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004253-11,0,0,0 2011-004253-11,7,2013-09-26,2013-09-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, placebo-controlled, parallel group study to determine the effect of 12 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 μg, 5/5 μg)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004253-11,0,0,0 2011-004253-11,7,2013-09-26,2013-09-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A randomised, double-blind, placebo-controlled, parallel group study to determine the effect of 12 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 μg, 5/5 μg)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004253-11,0,0,0 2011-004253-11,7,2013-09-26,2013-09-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, placebo-controlled, parallel group study to determine the effect of 12 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 μg, 5/5 μg)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004253-11,0,0,0 2011-004253-11,7,2013-09-26,2013-09-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A randomised, double-blind, placebo-controlled, parallel group study to determine the effect of 12 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 μg, 5/5 μg)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004253-11,0,0,0 2011-004253-11,7,2013-09-26,2013-09-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A randomised, double-blind, placebo-controlled, parallel group study to determine the effect of 12 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 μg, 5/5 μg)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004253-11,0,0,0 2011-004254-25,1,2014-05-09,2014-05-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, double-blind, placebo-controlled, multicenter, 28-week treatment study with an 8 week follow-up period to investigate the impact of subcutaneous Omalizumab on quality of life measures as...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004254-25,0,0,0 2011-004257-29,2,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,0,National Cancer Institute,A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High Risk Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004257-29,0,1,0 2011-004257-29,2,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,0,All Ireland Cooperative Oncology Research Group ( ICORG),A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High Dose Interferon a-2b for Resected High Risk Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004257-29,0,1,0 2011-004258-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,Clinical trial to study application of MESNA for infiltration into the epidural ''Failed Back Syndrome'' (FBS) Protocollo di studio spontaneo per applicazione di MESNA per l'infiltrazione epidura...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004258-24,0,0,0 2011-004259-38,1,,,0,0,1,0,0,1,3,0,0,4,0,0,0,0,1,"Asklepion Pharmaceuticals, LLC",Investigation in the Pathogenesis of Liver Disease in Patients with Inborn Errors of bile Acid Metabolism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004259-38,0,1,1 2011-004265-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Center,Left Ventricular Thrombus Formation after Acute Myocardial Infarction - a randomized multi-center trial comparing 2 different anti-thrombotic regimens Linker Ventrikel Thrombus Formatie na het Acu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004265-32,0,0,0 2011-004266-15,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital of North Norway,"Androgen replacement in young hypogonadal men: a 2 year randomized, double-blind placebo controlled study Testosteron substitutionsbehandling till unga hypogonadala män: 2 års randomiserad, dubbe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004266-15,0,0,0 2011-004266-15,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"RMC, Skåne University Hospital","Androgen replacement in young hypogonadal men: a 2 year randomized, double-blind placebo controlled study Testosteron substitutionsbehandling till unga hypogonadala män: 2 års randomiserad, dubbe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004266-15,0,0,0 2011-004267-71,1,2012-04-25,2012-04-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Acacia Pharma Ltd,"Randomised, double-blind, placebo-controlled, dose-ranging Phase II study of APD421 (amisulpride for IV injection) for the prevention of post-operative nausea and vomiting",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004267-71,0,0,0 2011-004268-31,1,2015-06-30,2015-06-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Odense University Hospital,Adalimumab (Humira) in the treatment of chronic pouchitis Adalimumab (Humira) til behandling af kronisk pouchitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004268-31,0,0,0 2011-004269-34,1,2012-05-30,2012-05-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Photocure ASA,"An open, prospective, within-patient, controlled, multi-center phase IIa study of Hexvix flexible fluorescence cystoscopy and white light flexible cystoscopy in the detection of bladder cancer after 3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004269-34,0,0,0 2011-004271-36,1,2013-04-16,2013-04-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,FluidDA nv,"Analysis of airway responses in severe COPD patients to Daxas®, using CT based functional respiratory imaging. Analyse van de luchtweg respons na behandeling met Daxas® bij patiënten met ernstige C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004271-36,0,0,0 2011-004272-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,The BOKITO-2B Study: Tenofovir DF Bone and Kidney Toxicity. Incidence and reversibility in HBV-monoinfected patients. De BOKITO-2B studie: Tenofovir bot- en niertoxiciteit. Incidentie en reversib...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004272-11,0,0,0 2011-004273-88,1,2014-09-29,2014-09-29,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Erling Bjerregaard Pedersen, Medicinsk forskningsafsnit, Regionshospitalet Holstebro","Effect of hydroxyethyl starch on renal handling of sodium and water, vasoactive hormones,biomarkers and the circulatory system in patients undergoing laparoscopic nephrectomy Effekten af hydroxyeth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004273-88,0,0,0 2011-004274-28,1,2013-06-04,2013-06-04,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Erling Bjerregaard Pedersen, Medicinsk forskningsafsnit, Regionshospitalet Holstebro","Effect of hydroxyethyl starch on renal handling of sodium and water, vasoactive hormones,biomarkers and the circulatory system in patients undergoing radical prostatectomy Effekten af hydroxyethyl ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004274-28,0,0,0 2011-004285-15,1,2011-11-14,2011-11-14,1,1,0,0,0,1,4,0,1,1,0,0,1,0,0,Professor Jørgen Berg Dahl,A comparison of the efficacy of the Adductor-Canal-Blockade vs. the femoral nerve block on muscle strength and mobilization in healthy volunteers: a randomized study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004285-15,0,0,0 2011-004286-32,1,2012-08-07,2012-08-07,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,ikfe GmbH,Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients with moderate Metabolic Control during Metformin Monotherapy Untersuchung des Effektes der zusätzlich...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004286-32,0,0,0 2011-004287-30,8,2017-04-03,2017-12-28,7,1,1,0,0,1,2,0,0,1,1,0,1,0,1,Alexion Pharmaceuticals Inc,"A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004287-30,0,0,0 2011-004287-30,8,2017-04-03,2017-12-28,7,1,1,0,0,1,2,0,0,1,1,0,1,0,1,Alexion Pharmaceuitcals Inc,"A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004287-30,0,0,0 2011-004287-30,8,2017-04-03,2017-12-28,7,1,1,0,0,1,2,0,0,1,1,0,1,0,1,Synageva BioPharma Corp.,"A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004287-30,0,0,0 2011-004287-30,8,2017-04-03,2017-12-28,7,1,1,0,0,1,2,0,0,1,1,0,1,0,1,Alexion Pharmaceuticals inc,"A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004287-30,0,0,0 2011-004294-87,1,2015-05-01,2015-05-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Per Klausen Fink,Treatment of multi-organ bodily distress syndrome. A double-blinded placebo controlled trial of the effect of Imipramine (STreSS-3) Behandling af multi-organ bodily distress syndrome. Et dobbelt-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004294-87,0,0,0 2011-004295-11,6,2016-12-19,2016-12-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis- Associated Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004295-11,0,0,0 2011-004296-36,3,2015-04-08,2015-04-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MedImmune, LLC,","A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects with Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004296-36,0,0,0 2011-004300-38,1,2016-10-18,2016-10-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Leeds,"HERO:Hydroxychloroquine Effectiveness in Reducing Symptoms of hand OA, a randomised, double-blind, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004300-38,0,0,0 2011-004301-24,3,2015-12-29,2015-12-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Free State of Bavaria, represented by the University of Regensburg, represented by the University Hospital Regensburg",The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Reference Group Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004301-24,0,0,0 2011-004301-24,3,2015-12-29,2015-12-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Free State of Bavaria, represented by the University of Regensburg, represented by Prof. Edward K. Geissler",The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Reference Group Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004301-24,0,0,0 2011-004301-24,3,2015-12-29,2015-12-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Free State of Bavaria, represented by the University of Regensburg, represented by Prof. Edward K. Gessler",The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Reference Group Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004301-24,0,0,0 2011-004304-38,6,2013-06-05,2013-06-26,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,PARI Pharma GmbH,A long-term safety follow-up study of L-CsA therapy for patients who participated in study 12011.201 and volunteered to continue or to cross-over to L-CsA inhalation therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004304-38,0,0,0 2011-004305-24,1,2012-09-26,2012-09-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Med Uni Graz, Univ. Klinik Dermatologie,Abteilung für Allgemeine Dermatologie",Inhibition of the Hedgehog Pathway in Basal Cell Carcinomas of Patients treated with Itraconazole for Onychomycosis Inhibierung des Hedgehog Pathways in Basalzellkarzinomen bei Patienten/-innen mit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004305-24,0,0,0 2011-004307-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Reino Pöyhiä,Comparison of periosteal and subcutaneous infusions of articaine and bupivacaine in treatment of acute pain after sternotomy Artikaiini ja bupivakaiini periostaalisena ja subkutaanisena infuusiona ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004307-20,0,0,0 2011-004308-39,1,2017-07-28,2017-07-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.",A Phase 2 Pilot Study with a Randomized Double-Blind Treatment Phase to Evaluate the Pharmacodynamics and Safety of REGN727 in Patients with Autosomal Dominant Hypercholesterolemia and Gain-of-Functio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004308-39,0,0,0 2011-004311-23,1,2013-08-27,2013-08-27,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,University of Edinburgh,"A randomised, placebo controlled trial to study the effect of heme-arginate on heme-oxygenase-1 induction and renal function in recipients of deceased donor renal transplants.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004311-23,0,0,0 2011-004311-23,1,2013-08-27,2013-08-27,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,NHS Lothian,"A randomised, placebo controlled trial to study the effect of heme-arginate on heme-oxygenase-1 induction and renal function in recipients of deceased donor renal transplants.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004311-23,0,0,0 2011-004327-13,6,2012-08-29,2012-10-19,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,Long-Term Open-Label Safety Study of LY2140023 in Patients with Schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004327-13,0,0,0 2011-004327-13,6,2012-08-29,2012-10-19,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Lilly S.A.,Long-Term Open-Label Safety Study of LY2140023 in Patients with Schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004327-13,0,0,0 2011-004349-42,3,2014-04-04,2014-04-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomized, double-blind, 12- week, parallel group, placebo-controlled study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004349-42,0,0,0 2011-004350-26,7,2019-06-18,2019-07-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004350-26,0,0,0 2011-004351-39,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,"Phase II, randomized, double arm, multi-center study evaluating the efficacy and safety of azithromycin for the long term prophylactic treatment of COPD in primary antibody deficiency patients with cl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004351-39,0,0,0 2011-004354-25,2,2014-04-15,2014-04-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A 28-day randomised, placebo-controlled, double-blind parallel group phase IIa trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of once daily oral doses of 2.5 mg, 10 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004354-25,0,0,0 2011-004354-25,2,2014-04-15,2014-04-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A 28-day randomised, placebo-controlled, double-blind parallel group phase IIa trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of once daily oral doses of 2.5 mg, 10 mg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004354-25,0,0,0 2011-004355-40,5,2013-09-20,2013-09-20,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Zymenex A/S,"A multi-center, open-label trial of the long-term efficacy and safety of Lamazym for the treatment of patients with alpha-Mannosidosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004355-40,0,0,0 2011-004356-20,1,2012-11-02,2012-11-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Pergamum AB,"A randomised, parallel-group, double-blind, placebo-controlled study of DPK-060 to investigate clinical safety and efficacy in patients with acute external otitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004356-20,0,0,0 2011-004357-82,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,A. Carlsson Research AB,A randomized controlled trial of OSU6162 in treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004357-82,0,0,0 2011-004361-32,1,2016-02-02,2016-02-02,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Philipps-Universität Marburg,Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid A prospective multi-centre randomised double-blind placebo-controlled pilot study Wirksamkeit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004361-32,0,0,0 2011-004363-74,10,2018-07-26,2018-07-26,9,1,0,0,0,1,4,0,0,1,0,0,1,0,1,PFIZER INC.,"A SINGLE ARM OPEN LABEL INTERNATIONAL MULTI CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT®) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL DIFFERENTIATED UNRESEC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004363-74,0,0,0 2011-004363-74,10,2018-07-26,2018-07-26,9,1,0,0,0,1,4,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Road, New York, NY 10017","A SINGLE ARM OPEN LABEL INTERNATIONAL MULTI CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT®) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL DIFFERENTIATED UNRESEC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004363-74,0,0,0 2011-004363-74,10,2018-07-26,2018-07-26,9,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Pfizer S.L.U.,"A SINGLE ARM OPEN LABEL INTERNATIONAL MULTI CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT®) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL DIFFERENTIATED UNRESEC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004363-74,0,0,0 2011-004363-74,10,2018-07-26,2018-07-26,9,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Pfizer Inc.,"A SINGLE ARM OPEN LABEL INTERNATIONAL MULTI CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT®) IN PATIENTS WITH PROGRESSIVE ADVANCED METASTATIC WELL DIFFERENTIATED UNRESEC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004363-74,0,0,0 2011-004368-31,4,2019-07-22,2019-07-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A 12-Week Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004368-31,0,0,0 2011-004369-34,1,2018-01-17,2018-01-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universtiy Medical Center Utrecht,"SPACE trial SMA and Pyridostigmine in Adults and Children; Efficacy trial Phase II, mono-center, doubleblind, placebo-controlled, crossover trial to assess efficacy of pyridostigmine in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004369-34,0,0,0 2011-004370-28,1,2014-08-22,2014-08-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dermapharm AG,"Double-blind, randomized clinical trial to compare the efficacy and safety of fusidic acid 2% betamethasone 0,1% cream vs. Fucicort cream vs. vehicle for patients with bacterial infected eczemas. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004370-28,0,0,0 2011-004371-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Instituto de Investigaciones del Sueño,Effects of pregabalin on slow wave sleep and glucose tolerance in patients with diabetic polyneuropathy. An exploratory study. Efecto de la pregabalina sobre el sueño de ondas lentas y sobre la tol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004371-36,0,0,0 2011-004372-11,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Efficacité de l’ondansetron sur les vomissements dus aux gastroentérites aiguës pédiatriques en période hivernale,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004372-11,0,0,0 2011-004376-11,8,2013-06-14,2013-06-14,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Forest Research Institute, Inc.","A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004376-11,0,0,0 2011-004376-11,8,2013-06-14,2013-06-14,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,FOREST RESEARCH INSTITUTE,"A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004376-11,0,0,0 2011-004377-84,4,2019-02-07,2019-02-07,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY AND ACTIVITY OF DCDT2980S IN COMBINATION WITH RITUXIMAB OR DCDS4501A IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004377-84,0,0,0 2011-004377-84,4,2019-02-07,2019-02-07,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Genentech Inc,"A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY AND ACTIVITY OF DCDT2980S IN COMBINATION WITH RITUXIMAB OR DCDS4501A IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004377-84,0,0,0 2011-004378-27,6,2013-09-02,2013-11-04,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson's patients with L-dopa induced dyskinesias Studio in aperto per valutare la sicurezza, la to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004378-27,0,0,0 2011-004378-27,6,2013-09-02,2013-11-04,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson's patients with L-dopa induced dyskinesias Studio in aperto per valutare la sicurezza, la to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004378-27,0,0,0 2011-004378-27,6,2013-09-02,2013-11-04,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","An open-label treatment study to evaluate the safety, tolerability and efficacy of AFQ056 in Parkinson's patients with L-dopa induced dyskinesias Studio in aperto per valutare la sicurezza, la to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004378-27,0,0,0 2011-004384-75,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,3,,"Randomized controlled trial: Picoprep versus Moviprep for efficacy, safety and patient tolerability in colonoscopy bowel preparation. Gerandomiseerd onderzoek naar de werkzaamheid, veiligheid en pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004384-75,0,0,0 2011-004388-62,6,2013-05-14,2013-05-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Shire-Movetis NV,"A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate Efficacy of a Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in subjects with Gastroesophage...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004388-62,0,0,0 2011-004391-11,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Masaryk University,Treatment of metastatic renal cell carcinoma using interleukin-12 secreting dendritic cells. Phase I/II clinical trial. Léčba metastázujícího renálního karcinomu s využitím dendritických buněk pro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004391-11,0,0,0 2011-004393-28,1,2017-12-31,2017-12-31,1,0,0,0,1,0,3,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,"""Effectiveness of leech therapy in treatment of chronic low back pain - a randomised controlled clinical study"" „Randomisierte kontrollierte Studie zur Wirksamkeit der Blutegeltherapie (Hirudo ve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004393-28,0,0,0 2011-004394-90,1,2012-11-12,2012-11-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Abteilung für Gastroenterologie und Hepatologie",Keyhole Limpet Hemocyanin in Chronic Hepatitis C and Compensated Cirrhosis - IM1 Keyhole Limpet Hemocyanin bei chronischer Hepatitis C und kompensierter Leberzirrhose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004394-90,0,0,0 2011-004395-11,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,Fundación para la Formación e Investigación Sanitarias de la Región de Murcia,PHASE I/II CLINICAL TRIAL ON THE USE OF THE AMNIOTIC MEMBRANE FOR LARGE WOUND EPITHELIZATION ENSAYO CLÍNICO EN FASE I/II DE UTILIZACIÓN DE MEMBRANA AMNIÓTICA PARA LA EPITELIZACIÓN DE GRANDES HERIDA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004395-11,0,0,0 2011-004396-36,3,2015-03-24,2016-11-14,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Fakultät für Medizin der Technischen Universität München,Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004396-36,0,0,0 2011-004397-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de salut MAR),"Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study. Eficacia de la pregabalina en el tratamiento del dolor en el cáncer de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004397-28,0,0,0 2011-004400-38,3,2020-03-17,2020-03-17,2,1,1,0,0,0,2,0,1,1,1,0,1,0,1,Pfizer Inc,"A Phase 2, Randomized, Controlled, Observer-blinded Study, Conducted to Describe the Immunogenicity, Safety, and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004400-38,0,0,0 2011-004400-38,3,2020-03-17,2020-03-17,2,1,1,0,0,0,2,0,1,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A Phase 2, Randomized, Controlled, Observer-blinded Study, Conducted to Describe the Immunogenicity, Safety, and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004400-38,0,0,0 2011-004404-37,5,2015-01-07,2015-01-14,5,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Scandinavian Sarcoma Group,Pazopanib in advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib . A non-comparative phase II multicenter study by the Scandinavian Sarcoma Group,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004404-37,0,0,0 2011-004405-25,1,2015-06-09,2015-06-09,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital Tübingen,Study for prevention of peritoneal carcinomatosis in patients with stomach cancer Studie zur Verhinderung der Peritonealkarzinose beim Magenkarzinom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004405-25,0,0,0 2011-004406-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNICANCER,Etude randomisée de phase III comparant une radiochimiothérapie préopératoire à une chimiothérapie néoadjuvante Folfirinox suivie de radiochimiothérapie préopératoire pour les patients atteints de can...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004406-25,0,0,0 2011-004410-42,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Inserm,"A phase I/II, open labeled, monocentric study of direct intracranial administration of a replication deficient adeno-associated virus gene transfer vector serotype rh.10 expressing the human ARSA cDNA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004410-42,0,0,0 2011-004411-22,3,2017-08-03,2017-08-03,2,1,1,0,0,0,0,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A multicenter, 52 to 104 week extension study to evaluate the long term growth and development of pediatric hypertensive patients 6 – 17 years of age treated previously with aliskiren",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004411-22,1,1,0 2011-004415-24,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,IRCCS CENTRO SAN GIOVANNI DI DIO,Molecular imaging for the early diagnosis and monitoring of Alzheimer’s disease in old individuals with cognitive disturbances: an ADNI-compatible prospective study Immagine molecolare per la diagn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004415-24,0,0,0 2011-004417-16,1,,,0,0,0,0,1,0,4,0,0,4,0,0,0,0,0,St. Elisabeth Hospital,CEFTRIAXONE NEONATAL THERAPY: A RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE EFFECT OF CEFTRIAXONE ON HYPERBILIRUBINEMIA Ceftriaxon therapie bij neonaten (cefsint): een gerandomiseerd gecontroleer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004417-16,0,0,0 2011-004418-40,6,,,0,0,0,0,2,1,2,0,0,2,0,0,0,0,1,Eli Lilly and Company,A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate plus Lomustine Therapy compared to Lomustine Monotherapy in Patients with Recurrent Glioblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004418-40,0,0,0 2011-004418-40,6,,,0,0,0,0,2,1,2,0,0,2,0,0,0,0,1,ELI LILLY,A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate plus Lomustine Therapy compared to Lomustine Monotherapy in Patients with Recurrent Glioblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004418-40,0,0,0 2011-004418-40,6,,,0,0,0,0,2,1,2,0,0,2,0,0,0,0,1,"Lilly S.A,",A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate plus Lomustine Therapy compared to Lomustine Monotherapy in Patients with Recurrent Glioblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004418-40,0,0,0 2011-004419-22,6,2014-07-31,2014-07-31,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004419-22,0,0,0 2011-004420-35,9,2014-10-06,2014-10-06,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.",A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004420-35,0,0,0 2011-004421-27,1,2014-05-30,2014-05-30,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics s.r.l,"A Phase 3b, Randomized, Open-label, Multi-Center Study Assessing Immunogenicity, Safety and 1 Year Persistence of Antibodies after One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine, ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004421-27,0,0,0 2011-004425-27,1,2014-10-15,2014-10-15,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Newcastle Upon Tyne Hospitals NHS Foundation Trust,Study of Optimal Replacement of Thyroxine in the ElDerly (SORTED) SORTED 1 – a Randomised Controlled Trial (Pilot study) SORTED 2 – Qualitative Interviews SORTED 3 – Retrospective Cohort,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004425-27,0,0,0 2011-004426-10,3,2016-10-27,2016-10-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffman-La Roche Ltd.,"An open-label, phase II study of vemurafenib in patients with BRAF V600 mutation-positive cancers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004426-10,0,0,0 2011-004428-36,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur S.A,"Phase III, A3L24 extension protocol, randomized, blind-observer, multi-center booster vaccination study in toddlers who completed a three-dose primary series of DTaP-IPV-Hep B-PRP-T combined vaccine o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004428-36,0,1,1 2011-004431-31,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,"Phase III, randomized, blind-observer, multi-center, four-arm, parallel-group trial in 2133 infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004431-31,0,1,1 2011-004432-58,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,"Phase III, open-label, and mono-center booster vaccination study in toddlers who completed a three-dose primary series of DTaP-IPV-Hep B-PRP-T combined vaccine or of Pentaxim™ and Engerix™ B in Study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004432-58,0,1,1 2011-004433-14,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,"Randomized, open, controlled, multicenter, Phase III trial in infants who will receive DTaP-IPV-Hep B-PRP-T (Group 1, N=286), CombAct-Hib™ and Engerix B™ Pediatric with OPV (Group 2, N=286), or DTaP-I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004433-14,0,1,1 2011-004434-33,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur S.A,"Phase III, randomized, blind-observer, single-center, controlled trial of the DTaP-IPV-Hep B-PRP-T vaccine in 266 healthy Peruvian infants.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004434-33,0,1,1 2011-004435-31,3,2016-05-31,2016-08-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ViiV Healthcare UK Limited,An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004435-31,0,0,0 2011-004435-31,3,2016-05-31,2016-08-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,VIIV HEALTHCARE UK LIMITED,An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004435-31,0,0,0 2011-004436-61,1,2012-11-15,2012-11-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A Four-Part, Open-Label Study to Evaluate the Effects of Repeat Dose GSK2118436 on the Single Dose Pharmacokinetics of Warfarin, the Effects of Repeat Dose Oral Ketoconazole and Oral Gemfibrozil on th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004436-61,0,0,0 2011-004438-32,3,2014-05-01,2014-05-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the effect of repeat doses of GSK962040 on the pharmacokinetics of levodopa in subjects with Parkinson’s di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004438-32,0,0,0 2011-004446-17,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,VU University Medical Center Amsterdam,"Metoclopramide, dexamethasone or Aloxi for the prevention of delayed chemotherapy-induced nausea and vomiting in moderately emetogenic non-AC-based chemotherapy: the MEDEA trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004446-17,0,0,0 2011-004449-42,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur S.A,"Multi-center, randomized, observer blinded, Phase III trial in 1,376 infants, using Infanrix hexa™ as the control vaccine. Four-arm trial with subjects randomly allocated to receive 1 of 3 lots of DTa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004449-42,0,1,1 2011-004450-26,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,"Phase III, multi-center study in children fully vaccinated with a three-dose primary and the booster dose of the DTaP-IPV-Hep B-PRP-T combined vaccine or CombAct-Hib™ and OPV and Engerix™ B in Study A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004450-26,0,1,1 2011-004451-39,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc.,Evaluation of Antibody Persistence at 3.5 and 4.5 Years of Age in Healthy Children After Primary Series and Booster Vaccination with Investigational (DTaP-IPV-HB-Hib) or Infanrix™ hexa vaccines in Lat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004451-39,0,1,1 2011-004454-26,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,"Mono-center, open-label, randomized, active-controlled trial in 310 infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004454-26,0,1,1 2011-004455-39,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur S.A,"Phase III, randomized, blind-observer, multicenter, four-arm study of three batches of the DTaP-IPV-Hep B-PRP-T vaccine and one arm receiving Infanrix hexa™.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004455-39,0,1,1 2011-004456-19,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur S.A,"Phase III, open-label, multi-center booster vaccination study in toddlers who completed a three-dose primary series of the DTaP-IPV-Hep B-PRP-T combined vaccine or Infanrix hexa™ in Study A3L11.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004456-19,0,1,1 2011-004457-87,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur S.A,"A Phase III, randomized, blind-observer, controlled, multicenter trial in 412 infants in Thailand.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004457-87,0,1,1 2011-004458-25,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Sanofi Pasteur MSD,"Antibody persistence in 11 to 13-year-old children previously vaccinated at 6 years old with either REVAXIS or DT Polio, and immune response to a booster dose of TETRAVAC-ACELLULAIRE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004458-25,0,0,0 2011-004463-69,1,2016-12-02,2016-12-02,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Charité – University Medicine Berlin,Investigation of Radiation Retinopathy (RadiRet Study) Subtitle: Influence of Lucentis® on radiation retinopathy after irradiation of choroidal melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004463-69,0,0,0 2011-004464-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut de Recerca e la SIDA - IrsiCaixa-,"Impact of Raltegravir Intensification on HIV-1-infected Subjects with Complete Viral Suppression under Monotherapy with Protease Inhibitors. A 24-week controlled, open-label, proof-of-concept pilot cl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004464-30,0,0,0 2011-004465-32,1,2014-03-26,2014-03-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Dept. of Cardiothoracic & Vascular Surgery, Aarhus University Hospital, Skejby",Can post-operative treatment with parathyroid hormone enhance bone healing and quality of newly formed bone after sternotomy in cardiac surgery patients? Kan postoperativ behandling med parathyroid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004465-32,0,0,0 2011-004466-14,1,2012-10-31,2012-10-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare,Effects of two doses of a common cold treatment on cognitive function,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004466-14,0,0,0 2011-004468-31,8,2013-07-12,2014-06-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"CELLTRION, INC.","An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patients With Rheumatoid Arthritis Who Were Treated With I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004468-31,0,0,0 2011-004468-31,8,2013-07-12,2014-06-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"CELLTRION, Inc","An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patients With Rheumatoid Arthritis Who Were Treated With I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004468-31,0,0,0 2011-004470-28,1,2013-07-31,2013-07-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital of South Manchester,Plasma and intrapulmonary population pharmacokinetics of piperacillin/tazobactam in critically ill patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004470-28,0,0,0 2011-004471-37,3,2012-08-31,2012-08-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Develco Pharma Schweiz AG,"Randomised, double-blind, cross-over Phase III study to investigate the efficacy and safety of hydromorphone after once daily administration of Hydromorphone HCl PR tablets XL in comparison to twice d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004471-37,0,0,0 2011-004474-29,3,2012-05-28,2012-05-28,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Norgine Ltd.,"A Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of TZP-101 (IV Ulimorelin) Administered Post-Operatively in Patients Who Have Undergone Partial Bowel Resection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004474-29,0,0,0 2011-004475-36,1,2014-06-18,2014-06-18,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Delta Crystallon B.V.,"A Phase IIa, randomized, double-blind, placebo-controlled, exploratory, dose-ranging study to evaluate the safety, effectiveness and pharmacokinetics of three courses of DC-TAB treatment in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004475-36,0,0,0 2011-004476-10,1,2019-09-16,2019-09-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Fundación Grupo Español de Investigación en Cáncer de Mama (Fundación GEICAM),"Phase II, open-label, non-randomized study of nab-paclitaxel for the neoadjuvant treatment of patients with stage II and III luminal breast cancer. Estudio Fase II, abierto, no randomizado con nab-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004476-10,0,0,0 2011-004481-15,7,2018-10-31,2018-10-31,6,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ETOP (European Thoracic Oncology Platform),An open-label phase II trial of erlotinib and bevacizumab in patients with advanced non-small cell lung cancer and activating EGFR mutations Studio in aperto di fase II su erlotinib e bevacizumab ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004481-15,0,0,0 2011-004481-15,7,2018-10-31,2018-10-31,6,1,0,0,0,0,2,0,0,1,0,0,1,0,0,IBCSG,An open-label phase II trial of erlotinib and bevacizumab in patients with advanced non-small cell lung cancer and activating EGFR mutations Studio in aperto di fase II su erlotinib e bevacizumab ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004481-15,0,0,0 2011-004482-32,1,2016-04-28,2016-04-28,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Universitätsklinikum Ulm,"Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients with Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole) Studie zur Wirksamkeit, Sicherheit und Verträgl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004482-32,0,0,0 2011-004483-30,7,2014-12-09,2014-12-16,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004483-30,0,0,0 2011-004483-30,7,2014-12-09,2014-12-16,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GILEAD SCIENCE INC.,"A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004483-30,0,0,0 2011-004485-15,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase IIIb, open, randomized study to evaluate non-inferiority of GSK Biologicals’ measles-mumps-rubella-varicella vaccine versus co-administration of GSK Biologicals’ Priorix™ and Varilrix™ in heal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004485-15,0,1,1 2011-004486-33,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,BioTech Tools S.A.,"Safety, clinical tolerability and immunogenicity of gpASIT+TM administered subcutaneously to hay fever patients either alone or in presence of DnaK immunoregulating adjuvant.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004486-33,0,0,0 2011-004491-10,1,,,0,1,1,0,0,1,3,0,0,4,0,0,0,0,1,"Asklepion Pharmaceuticals, LLC","An Open-Label, Single-Center, Nonrandomized Study to Compare the Therapeutic Efficacy of To Be Marketed (TBM) Cholic Acid Capsules with that of the Currently Used (CU) Formulation of Cholic Acid Capsu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004491-10,0,1,1 2011-004494-81,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Pharmaneuroboost N.V.,"Proof-of-Concept Study of Pipamperone 15mg added to Stable Treatment with Risperidone or Paliperidone in Chronic Schizophrenic and Schizoaffective Patients with Residual Symptoms: a phase I/IIa, rand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004494-81,0,0,0 2011-004495-12,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,VU University Medical center,Antibiotic treatment alone for children with acute appendicitis; a prospective cohort study part of the Antibiotic versus Primary Appendectomy for Children with acute appendicitis; the APAC trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004495-12,0,0,0 2011-004496-37,2,2012-10-05,2012-10-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Orion Pharma,"A RANDOMISED, MULTICENTRE, TWO-ARM, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, COMPARATIVE EFFICACY AND SAFETY CLINICAL STUDY OF IBUPROFEN 5% GEL IN ADULT HUMAN PATIENTS WITH PAIN RELATED TO UN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004496-37,0,0,0 2011-004497-28,3,2012-10-05,2012-10-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Orion Pharma,"A RANDOMISED, MULTICENTRE, TWO-ARM, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, COMPARATIVE EFFICACY AND SAFETY CLINICAL STUDY OF IBUPROFEN 5% ROLL-ON GEL IN ADULT HUMAN PATIENTS WITH PAIN RELAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004497-28,0,0,0 2011-004498-96,1,2015-02-17,2015-02-17,1,1,0,0,1,1,3,0,0,1,0,0,1,0,0,Moorfields Eye Hospital,Ozurdex in proliferative vitreoretinopathy; a randomised control trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004498-96,0,0,0 2011-004501-24,1,2012-03-12,2012-03-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,CureTech Ltd.,"Phase II study to evaluate the safety, tolerability and efficacy of CT-011 administered intravenously to patients with metastatic melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004501-24,0,0,0 2011-004507-20,3,2014-11-14,2014-11-14,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.,"RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS RANOLAZINA EN PACIENTES CON ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004507-20,0,0,0 2011-004507-20,3,2014-11-14,2014-11-14,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Menarini International Operations Luxembourg S.A.,"RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS RANOLAZINA EN PACIENTES CON ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004507-20,0,0,0 2011-004518-40,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SENESE,Serological response to antipneumococcal vaccination and consequent impact on Streptococcus pneumoniae nasal carriage in HIV positive adults: a prospective study using 13-valent conjugate vaccine R...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004518-40,0,0,0 2011-004520-35,1,2015-01-30,2015-01-30,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Vanda Pharmaceuticals Inc.,AN EXTENSION OPEN-LABEL SAFETY STUDY OF A 24-MONTH 20MG DOSE REGIMEN OF TASIMELTEON FOR THE TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER (N24HSWD) IN BLIND INDIVIDUALS WITH NO LIGHT PERCEPTION WHO HAV...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004520-35,0,0,0 2011-004522-10,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,LOFARMA,Study on the efficacy and safety of three different doses of Lais Ambrosia tablets in patients with allergic rhinoconjunctivitis to pollen of Ambrosia Studio sull'efficacia e la sicurezza di tre d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004522-10,0,0,0 2011-004525-27,5,2018-11-13,2018-11-13,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Witho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004525-27,0,0,0 2011-004528-36,1,,,0,0,1,0,0,1,3,0,0,4,0,0,0,0,1,"Asklepion Pharmaceuticals, LLC","An open-label, single center, non-randomized, continuation study of cholic acid capsules in subjects with inborn errors of bile acid synthesis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004528-36,0,1,1 2011-004529-28,4,2013-03-25,2013-03-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of JNJ-40346527 in Subjects with Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004529-28,0,0,0 2011-004532-58,1,2014-02-07,2014-02-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sandoz GmbH,"A randomized, double-blind, parallel-group, multi-center Phase 3 comparative study investigating efficacy and safety of LA-EP2006 and Neulasta® in breast cancer patients treated with myelosuppressive ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004532-58,0,0,0 2011-004538-32,1,2013-01-18,2013-01-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Moberg Derma,"A double-blind, randomized, multi-centre, vehicle-controlled study of efficacy and safety of a new topical formulation with imiquimod (Limtop) applied 1,3 or 7 times weekly during 2 x 2 weeks treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004538-32,0,0,0 2011-004539-30,4,2016-09-01,2016-09-01,4,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"30 day, single-arm study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children with various manifestations of venous thrombosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004539-30,0,0,0 2011-004539-30,4,2016-09-01,2016-09-01,4,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,"30 day, single-arm study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children with various manifestations of venous thrombosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004539-30,0,0,0 2011-004539-30,4,2016-09-01,2016-09-01,4,1,1,0,0,0,2,0,0,1,0,0,1,0,1,BAYER HEALTHCARE AG,"30 day, single-arm study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children with various manifestations of venous thrombosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004539-30,0,0,0 2011-004540-22,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Ghent University Hospital,Desmopressin melt therapy in nocturnal polyuria patients: pharmacokinetic/dynamic study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004540-22,0,0,0 2011-004542-18,4,2013-02-15,2013-02-15,4,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX ™ 23) and Prevna...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004542-18,0,0,0 2011-004542-18,4,2013-02-15,2013-02-15,4,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX ™ 23) and Prevna...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004542-18,0,0,0 2011-004545-40,1,,,0,0,0,0,0,0,3,0,1,1,0,0,0,1,0,Medizinische Universität Graz,Pilotstudie zur Untersuchung der Effekte einer Vitamin D Supplementierung bei gesunden Frauen und Männern auf die Anzahl der FOXP3+ regulatorischen T-Zellen in der gastrointestinalen Mukosa: Stufe 3 d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004545-40,0,0,0 2011-004550-25,3,2013-03-28,2013-05-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,HAL Allergy B.V.,"A randomized, double-blind, placebo-controlled study to determine safety, tolerability and the optimal effective dose of SUBLIVAC FIX Birch in patients with allergic rhinitis/rhinoconjunctivitis cause...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004550-25,0,0,0 2011-004552-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Validation de l’effet antiviral du Midodrine identifié par l’analyse de la signature transcriptomique cellulaire de l’infection par les virus influenza A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004552-19,0,0,0 2011-004553-60,6,,,0,0,0,0,0,2,2,0,0,2,1,0,0,0,1,OPKO Biologics Ltd.,Safety and dose finding study of different MOD-4023 dose levels compared to daily r-hGH therapy in pre-pubertal growth hormone deficient children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004553-60,0,0,0 2011-004553-60,6,,,0,0,0,0,0,2,2,0,0,2,1,0,0,0,1,PROLOR Biotech Ltd.,Safety and dose finding study of different MOD-4023 dose levels compared to daily r-hGH therapy in pre-pubertal growth hormone deficient children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004553-60,0,0,0 2011-004554-26,3,2016-11-18,2016-11-18,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Leiden University Medical Center, division 3",Multi-modal effects of Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism; a randomised placebo-controlled Trial (TRUST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004554-26,0,0,0 2011-004554-26,3,2016-11-18,2016-11-18,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University College Cork,Multi-modal effects of Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism; a randomised placebo-controlled Trial (TRUST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004554-26,0,0,0 2011-004554-26,3,2016-11-18,2016-11-18,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Greater Glasgow and Clyde,Multi-modal effects of Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism; a randomised placebo-controlled Trial (TRUST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004554-26,0,0,0 2011-004554-26,3,2016-11-18,2016-11-18,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Glasgow,Multi-modal effects of Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism; a randomised placebo-controlled Trial (TRUST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004554-26,0,0,0 2011-004555-39,10,2014-03-18,2014-03-18,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokineti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004555-39,0,0,0 2011-004558-24,2,2021-03-12,2021-03-12,2,1,1,0,0,1,1,0,0,1,0,0,1,0,1,Celgene Corporation,"A PHASE 1A/1B, MULTICENTER, OPEN LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF THE DUAL DNA-PK AND TOR KINASE INHIBITOR, CC-115, ADMINISTER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004558-24,0,0,0 2011-004559-38,1,2017-05-01,2017-05-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Birmingham,A phase 2 study of the efficacy and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent Myelodysplastic Syndromes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004559-38,0,0,0 2011-004560-29,1,2013-02-01,2013-02-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Ghent University Hospital,Desmopressin melt therapy in nocturnal polyuria patients: pharmacodynamic study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004560-29,0,0,0 2011-004561-33,1,2016-09-06,2016-09-06,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Klinik für Innere Medizin III, Abteilung für Gastroenterologie und Hepatologie","A randomized, controlled, single-blinded, phase II study to investigate the safety and efficacy of intravenous infusions of FERINJECT® versus placebo on platelet activity in patients with iron deficie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004561-33,0,0,0 2011-004562-16,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Institute of Cancer Research,A Phase II Study of Axitinib in Patients with Metastatic Renal Cell Cancer Unsuitable for Nephrectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004562-16,0,0,0 2011-004562-16,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Royal Marsden Hospital NHS Foundation Trust,A Phase II Study of Axitinib in Patients with Metastatic Renal Cell Cancer Unsuitable for Nephrectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004562-16,0,0,0 2011-004564-30,5,2015-04-07,2015-04-07,4,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals,"A Two-Part, Open-Label, Single-Arm Phase 1/2 Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination With Peginterferon alfa-2b and Ribavirin in Pediatric Subjects Aged 3 to 17 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004564-30,0,0,0 2011-004564-30,5,2015-04-07,2015-04-07,4,1,1,0,0,0,2,0,0,1,0,0,1,0,1,VERTEX PHARMACEUTICALS INCOPORATED,"A Two-Part, Open-Label, Single-Arm Phase 1/2 Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination With Peginterferon alfa-2b and Ribavirin in Pediatric Subjects Aged 3 to 17 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004564-30,0,0,0 2011-004566-14,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,3,,Santeon-CAP study Dexamethasone in community-acquired pneumonia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004566-14,0,0,0 2011-004567-80,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Georg Hagmüller Institute for Vascular Research,The intraoperative arterial measurement of the blood flow after Iloproststimulation in diabetics and non-diabetics: Implication for Outcome - prediction and perioperative therapy. Intraoperative ar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004567-80,0,0,0 2011-004569-33,10,2017-02-06,2017-02-06,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,HUMAN GENOME SCIENCES INC,"A Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination with Azathioprine for the Maintenance of Remission in Wegener’...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004569-33,0,0,0 2011-004569-33,10,2017-02-06,2017-02-06,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)","A Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination with Azathioprine for the Maintenance of Remission in Wegener’...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004569-33,0,0,0 2011-004569-33,10,2017-02-06,2017-02-06,7,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC),"A Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination with Azathioprine for the Maintenance of Remission in Wegener’...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004569-33,0,0,0 2011-004570-28,8,2020-03-12,2020-03-12,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004570-28,0,0,0 2011-004570-28,8,2020-03-12,2020-03-12,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Human Genome Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004570-28,0,0,0 2011-004571-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,- Rescue of Progranulin HaploInsufficiency in Frontotemporal Dementia - Recupero del Deficit di Progranulina nella Demenza Frontotemporale,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004571-37,0,0,0 2011-004577-91,1,2015-06-05,2015-06-05,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Center for Cancer ImmunTerapi CCIT, Hæmatologisk Afd. 54P4",Kombination af IDO og Survivin peptidvaccine med Temozolamid kemoterapi til patienter med metastatisk malignt melanom. Et fase II studie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004577-91,0,0,0 2011-004578-27,15,2015-05-22,2015-06-22,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc,","A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS Studio multice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004578-27,0,0,0 2011-004578-27,15,2015-05-22,2015-06-22,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, New York 10017","A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS Studio multice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004578-27,0,0,0 2011-004578-27,15,2015-05-22,2015-06-22,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER INC.,"A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS Studio multice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004578-27,0,0,0 2011-004578-27,15,2015-05-22,2015-06-22,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA","A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS Studio multice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004578-27,0,0,0 2011-004579-35,14,2015-05-22,2015-06-09,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, New York 10017","A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004579-35,0,0,0 2011-004579-35,14,2015-05-22,2015-06-09,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA","A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004579-35,0,0,0 2011-004579-35,14,2015-05-22,2015-06-09,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc,","A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS AN INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004579-35,0,0,0 2011-004580-79,14,2016-04-27,2016-05-27,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, New York 10017","A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004580-79,0,0,0 2011-004580-79,14,2016-04-27,2016-05-27,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER LIMITED,"A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004580-79,0,0,0 2011-004580-79,14,2016-04-27,2016-05-27,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc,"A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004580-79,0,0,0 2011-004580-79,14,2016-04-27,2016-05-27,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA","A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF ORAL CP-690,550 AS A MAINTENANCE THERAPY IN SUBJECTS WITH ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004580-79,0,0,0 2011-004581-14,15,2020-08-06,2020-08-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER LIMITED,"A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS STUDIO MULTICENTRICO, IN APERTO DI CP-690,550 IN SOGGETTI CON COLITE ULCEROSA DA MODERATA A GR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004581-14,0,0,0 2011-004581-14,15,2020-08-06,2020-08-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, New York 10017","A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS STUDIO MULTICENTRICO, IN APERTO DI CP-690,550 IN SOGGETTI CON COLITE ULCEROSA DA MODERATA A GR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004581-14,0,0,0 2011-004581-14,15,2020-08-06,2020-08-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA","A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS STUDIO MULTICENTRICO, IN APERTO DI CP-690,550 IN SOGGETTI CON COLITE ULCEROSA DA MODERATA A GR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004581-14,0,0,0 2011-004581-14,15,2020-08-06,2020-08-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, New York 10017, United States","A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS STUDIO MULTICENTRICO, IN APERTO DI CP-690,550 IN SOGGETTI CON COLITE ULCEROSA DA MODERATA A GR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004581-14,0,0,0 2011-004581-14,15,2020-08-06,2020-08-06,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A MULTI-CENTER, OPEN-LABEL STUDY OF CP-690,550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS STUDIO MULTICENTRICO, IN APERTO DI CP-690,550 IN SOGGETTI CON COLITE ULCEROSA DA MODERATA A GR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004581-14,0,0,0 2011-004583-30,1,2012-11-30,2012-11-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BIAL Industrial Farmaceutica,"A MULTICENTER, PHASE II, RANDOMISED, DOUBLE?BLIND, PLACEBO CONTROLED CLINICAL TRIAL OF THE SUBCUTANEOUS IMMUNOTHERAPY IN DIFFERENT DOSES WITH PARALLEL GROUPS IN SUBJECTS WITH ALLERGIC RHINOCONJUNCTIVI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004583-30,0,0,0 2011-004584-67,3,2014-03-04,2014-03-04,2,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, double-blind, placebo controlled trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of lixisenatide in paediatric (10 - 17 years old) and adult patients with typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004584-67,1,1,0 2011-004585-15,1,2014-02-25,2014-02-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Charité - Universitätsmedizin Berlin,"Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004585-15,0,0,0 2011-004587-29,5,2012-08-28,2012-08-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Alcon Research Ltd.,"A Multicenter, Double-Masked Study of the Safety and Efficacy of Travoprost Ophthalmic Solution, 0.003% Compared to TRAVATAN in Patients with Open-Angle Glaucoma or Ocular Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004587-29,0,0,0 2011-004589-14,1,2013-08-06,2013-08-06,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Respicopea Limited,"A Multicentre, Double-Blind, Placebo-Controlled, Adaptive Pivotal Study of the Efficacy and Safety of Oral BC1036 in the Management of Cough",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004589-14,0,0,0 2011-004590-90,9,2014-12-09,2015-01-19,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004590-90,0,0,0 2011-004590-90,9,2014-12-09,2015-01-19,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Corporation, Inc.","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004590-90,0,0,0 2011-004590-90,9,2014-12-09,2015-01-19,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004590-90,0,0,0 2011-004590-90,9,2014-12-09,2015-01-19,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP & DOHME CORP.,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004590-90,0,0,0 2011-004590-90,9,2014-12-09,2015-01-19,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004590-90,0,0,0 2011-004592-36,2,2013-04-09,2013-04-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Galderma R&D,Subjects? satisfaction on pan facial aesthetic enhancement after treatment with Azzalure® and the Restylane® range Satisfacción del paciente con la mejoría estética facial global después del tratam...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004592-36,0,0,0 2011-004593-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Cologne,Phase II trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004593-29,0,0,0 2011-004594-82,1,2014-02-19,2014-02-19,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Schur Pharmazeutika GmbH & Co. KG,"Efficacy of an intravesical instillation with neomycin solution in acute cystitis: a double-blind, placebo-controlled trial in patients with permanent intravesical catheter",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004594-82,0,0,0 2011-004608-39,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,G.I.M.EM.A. Gruppo Italiano Malattie EMatologiche dell'Adulto,Eltrombopag in patients with delayed post transplant thrombocytopenia Eltrombopag in pazienti con trombocitopenia ritardata post-trapianto,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004608-39,0,0,0 2011-004609-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Laboratoires Bouchara-Recordati,Evaluation of the efficacy and safety of two methadone titration methods for the treatment of cancer-related pain with inadequate pain relief or intolerable side effects when treated with level 3 opio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004609-26,0,0,0 2011-004610-42,1,2013-04-04,2013-04-04,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,London School of Hygiene and Tropical Medicine,Evaluation of topical ibuprofen and steroid in the reduction of local reactions and symptoms from an Aedes aegypti mosquito bite,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004610-42,0,0,0 2011-004612-31,3,,,0,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Actelion pharmaceuticals Ltd,"A prospective, multicenter, non-comparative, open label extension of the FUTURE 5 study to assess safety and tolerability of the pediatric formulation of bosentan in children with pulmonary arterial h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004612-31,0,0,0 2011-004613-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Inst of Ophtalmology Lund University hospital,"The effect of intravitreal injections of Lucentis (ranibizumab) on retinal function in diabetic patients with diabetic macular edema and visual impairment Effekten av, i glaskroppen injicerat läk...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004613-17,0,0,0 2011-004616-36,12,2016-09-26,2016-09-27,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004616-36,0,0,0 2011-004616-36,12,2016-09-26,2016-09-27,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004616-36,0,0,0 2011-004617-16,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. PAOLO (A.O. DI RILIEVO NAZIONALE),(The advantage of choosing from preserved to preserved-free treatments for glaucoma. A clinical and confocal study) Il vantaggio del passaggio da terapia conservata a non conservata nel glaucoma. S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004617-16,0,0,0 2011-004618-40,9,2013-06-04,2016-06-04,6,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Amgen Inc.,"An Open-label, Single-arm Study to Assess the Safety and Tolerability of Cinacalcet HCl in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Years With Chronic Kidney Disease and S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004618-40,1,1,0 2011-004621-26,1,2016-01-12,2016-01-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Medical University Graz,The effect of vitamin D supplementation on immune response following hepatitis B vaccine in incident and prevalent hemodialysis patients with vitamin D deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004621-26,0,0,0 2011-004622-96,10,2013-06-07,2013-06-07,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004622-96,0,0,0 2011-004622-96,10,2013-06-07,2013-06-07,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (referred to as Merck)","A Phase III, Multicenter, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004622-96,0,0,0 2011-004622-96,10,2013-06-07,2013-06-07,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP & DOHME CORP.,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004622-96,0,0,0 2011-004622-96,10,2013-06-07,2013-06-07,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as","A Phase III, Multicenter, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004622-96,0,0,0 2011-004627-12,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,SOGUG - Spanish Oncology Genitourinary Group,"Phase II Study of Weekly Cabazitaxel for Advanced Prostate Cancer in ""Unfit"" Hormone-Refractory Patients Previously Treated with Docetaxel. Ensayo Fase II de Cabazitaxel Semanal en Cancer de Prosta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004627-12,0,0,0 2011-004631-31,1,2014-03-20,2014-03-20,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,United Therapeutics Corp.,"A 16 Week, Open Label, Multi-Centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of a Rapid Dose Titration Regimen of Subcutaneous Remodulin® Therapy in Subjects with Pulmon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004631-31,0,0,0 2011-004636-66,1,2012-12-10,2012-12-10,1,0,0,0,1,0,4,0,1,1,0,0,1,0,0,Uppsala University Hospital,Single-blinded randomized trial of Botulinumtoxin A (Vistabel®) and its objective paralytic effect in the facial muscles of healthy women: development of new neurophysiological measurements. Enkel...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004636-66,0,0,0 2011-004638-32,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase IIIA, observer-blind, randomized study to evaluate non-inferiority of a second dose of GSK Biologicals’ measles-mumps-rubella vaccine vs. a second dose of Merck & Co., Inc.’s MMR vaccine when ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004638-32,0,1,1 2011-004640-21,1,2012-09-17,2012-09-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Creabilis Limited,"A Randomized, Placebo-controlled Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w topical CT327 when Applied Twice Daily in Subjects with Psoriasis Vulgari...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004640-21,0,0,0 2011-004641-41,2,2012-10-23,2012-10-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomised, double-blind, placebo-controlled, multi-centre, 6-way cross-over, single-dose Phase IIa study to investigate the local and systemic effects of 3 different doses of inhaled AZD2115 compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004641-41,0,0,0 2011-004644-22,1,,,0,1,0,0,1,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, randomized, single-blind, controlled study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine as a 3-do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004644-22,0,1,1 2011-004650-25,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, randomized, open, controlled study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine as a 3-dose prima...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004650-25,0,1,1 2011-004651-40,3,2015-09-30,2015-09-30,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOXXON PHARMA AG,"A multi-center, open label, uncontrolled, Phase IIa clinical trial evaluating the safety and efficacy of NOX-A12 in combination with a background therapy of bortezomib and dexamethasone (VD) in previo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004651-40,0,0,0 2011-004651-40,3,2015-09-30,2015-09-30,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOXXON Pharma AG,"A multi-center, open label, uncontrolled, Phase IIa clinical trial evaluating the safety and efficacy of NOX-A12 in combination with a background therapy of bortezomib and dexamethasone (VD) in previo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004651-40,0,0,0 2011-004653-31,4,2012-04-18,2012-04-30,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A multicenter, single-arm trial evaluating the safety and efficacy of DEB025/Alisporivir in combination with pegylated interferon-α2a and ribavirin (peg-IFNα2a/RBV) in protease inhibitor treatment fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004653-31,0,0,0 2011-004653-31,4,2012-04-18,2012-04-30,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,NOVARTIS FARMA,"A multicenter, single-arm trial evaluating the safety and efficacy of DEB025/Alisporivir in combination with pegylated interferon-α2a and ribavirin (peg-IFNα2a/RBV) in protease inhibitor treatment fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004653-31,0,0,0 2011-004653-31,4,2012-04-18,2012-04-30,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Novartis Farmacéutica S.A,"A multicenter, single-arm trial evaluating the safety and efficacy of DEB025/Alisporivir in combination with pegylated interferon-α2a and ribavirin (peg-IFNα2a/RBV) in protease inhibitor treatment fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004653-31,0,0,0 2011-004657-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE PROGETTO EMATOLOGIA,Open label multicenter study of Eltrombopag for the treatment of Immune ThrombocytoPenia (ITP) secondary to Chronic Lymphoproliferative Disorders (LPDs) Open label multicenter study of Eltrombopag ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004657-11,0,0,0 2011-004659-37,4,2013-11-20,2013-11-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (FDC)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004659-37,0,0,0 2011-004659-37,4,2013-11-20,2013-11-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (FDC)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004659-37,0,0,0 2011-004659-37,4,2013-11-20,2013-11-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (FDC)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004659-37,0,0,0 2011-004659-37,4,2013-11-20,2013-11-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co.KG,"A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (FDC)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004659-37,0,0,0 2011-004660-30,4,2013-11-26,2013-11-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (FDC)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004660-30,0,0,0 2011-004660-30,4,2013-11-26,2013-11-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co.KG,"A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (FDC)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004660-30,0,0,0 2011-004660-30,4,2013-11-26,2013-11-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim b.v.,"A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (FDC)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004660-30,0,0,0 2011-004660-30,4,2013-11-26,2013-11-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (FDC)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004660-30,0,0,0 2011-004665-32,3,2013-12-31,2014-02-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK,The effect of insulin degludec in combination with liraglutide and metformin in subjects with type 2 diabetes qualifying for treatment intensification,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004665-32,0,0,0 2011-004665-32,3,2013-12-31,2014-02-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,The effect of insulin degludec in combination with liraglutide and metformin in subjects with type 2 diabetes qualifying for treatment intensification,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004665-32,0,0,0 2011-004666-15,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,The Medicines Company,"A Phase II, double-blind, parallel group, dose-selection study to compare antifibrinolytic MDCO-2010 vs. placebo and tranexamic acid in reducing blood loss in patients undergoing primary cardiac surge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004666-15,0,0,0 2011-004667-76,1,2012-09-28,2012-09-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cardoz AB,"An open-label, un-controlled, single-centre trial investigating the efficacy and safety of CRD007 tablets administered twice daily for 12 weeks in children with Duchenne Muscular Dystrophy (DMD) or Be...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004667-76,0,0,0 2011-004668-31,10,2015-09-15,2015-09-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SHIRE PHARMACEUTICALS LTD,"A Phase 3, Open-label, Multicentre Study to Provide Access to Guanfacine Hydrochloride Extended Release for European Subjects with Attention-deficit/Hyperactivity Disorder (ADHD) who Participated in S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004668-31,0,0,0 2011-004668-31,10,2015-09-15,2015-09-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shire Pharmaceutical Development Ltd,"A Phase 3, Open-label, Multicentre Study to Provide Access to Guanfacine Hydrochloride Extended Release for European Subjects with Attention-deficit/Hyperactivity Disorder (ADHD) who Participated in S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004668-31,0,0,0 2011-004670-28,1,2014-10-23,2014-10-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Aarhus University Hospital, Dept of Endocrinology and Internel Medicine (MEA)","Treatment of osteopenia with melatonin: Effects on BMD, muscle strength and quality of life Betydningen af melatoninbehandling til osteopenipatienter: Effekt på BMD, muskelfunktion og livskvalitet",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004670-28,0,0,0 2011-004671-37,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,GRUPO ESPAÑOL DE INVESTIGACION EN NEUROONCOLOGIA,"Phase II pilot, prospective, open label, multicenter Clinical Trial, to evaluate the safety and efficacy of PF299804, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004671-37,0,0,0 2011-004672-11,4,2017-04-24,2017-04-27,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOXXON Pharma AG,"A multi-centre, open label, uncontrolled, Phase IIa clinical trial evaluating the safety and efficacy of NOX-A12 in combination with a background therapy of bendamustine and rituximab (BR) in previous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004672-11,0,0,0 2011-004672-11,4,2017-04-24,2017-04-27,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOXXON PHARMA AG,"A multi-centre, open label, uncontrolled, Phase IIa clinical trial evaluating the safety and efficacy of NOX-A12 in combination with a background therapy of bendamustine and rituximab (BR) in previous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004672-11,0,0,0 2011-004676-11,1,2014-04-04,2014-04-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Multicenter, Double-Blind, Relapse Prevention Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Subjects with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004676-11,0,0,0 2011-004681-15,1,2013-10-14,2013-10-14,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Medizinische Universität Graz,Effects of the activation of peroxisome proliferator-activated receptors in patients with primary biliary cirrhosis Wirkung von Aktivierung von Peroxisom-Proliferator-aktivierten Rezeptoren bei Pat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004681-15,0,0,0 2011-004682-32,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,FONDAZIONE ISTITUTO SAN RAFFAELE-G.GIGLIO,"Intra-articular injection of botulinum toxin type A in hemiplegic shoulder pain: a multicentric, double blind randomised, versus steroid study. Valutazione dell'efficacia della tossina botulinica t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004682-32,0,0,0 2011-004683-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU University Medical,A phase II study of sorafenib and metformin in patients with locally advanced and/or metastatic non-smal cell lung cancer (NSCLC) with a K-Ras mutation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004683-30,0,0,0 2011-004686-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Leiden University Medical Center,A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients De rol van aspirine op de overleving van patienten met dikkedarmkanker; e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004686-32,0,0,0 2011-004687-30,4,2015-11-06,2015-11-06,4,0,0,0,0,2,3,0,0,1,0,0,1,0,1,MERRIMACK PHARMACEUTICALS,"NAPOLI 1: A Randomized, Open Label Phase 3 Study of MM-398 versus 5- Fluorouracil and Leucovorin in Patients with Metastatic Pancreatic Cancer. NAPOLI 1: Studio randomizzato, in aperto, di fase 3, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004687-30,0,0,0 2011-004687-30,4,2015-11-06,2015-11-06,4,0,0,0,0,2,3,0,0,1,0,0,1,0,1,Merrimack Pharmaceuticals Inc.,"NAPOLI 1: A Randomized, Open Label Phase 3 Study of MM-398 versus 5- Fluorouracil and Leucovorin in Patients with Metastatic Pancreatic Cancer. NAPOLI 1: Studio randomizzato, in aperto, di fase 3, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004687-30,0,0,0 2011-004690-87,1,2013-08-23,2013-08-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase IIb Efficacy and Safety Study of Adjunctive AZD6765 in Patients with Major Depressive Disorder (MDD) and a History of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004690-87,0,0,0 2011-004692-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HOSPITAL UNIVERSITARI DE BELLVITGE,COMBIVAR. Randomized double-blind trial of two parallel groups design to evaluate the efficacy of smoking cessation with combined (varenicline plus nicotine patches) versus monotherapy (varenicline) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004692-36,0,0,0 2011-004693-29,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI,Pegylated interferon alfa-2a USE FOR CONTROLLING virological rebound after suspension of antiretroviral treatment IN PATIENTS WITH CHRONIC HIV INFECTION USO DELL’INTERFERONE ALFA-2A PEGHILATO PER ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004693-29,0,0,0 2011-004695-11,7,2014-02-04,2015-05-15,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004695-11,0,0,0 2011-004697-28,1,2014-04-09,2014-04-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. W. Schwabe GmbH & Co. KG,"Randomised, double-blind trial to compare the treatment effects of Ginkgo biloba extract EGb 761® and pentoxifylline in patients with sub-chronic and chronic tinnitus focussing on psycho-social proble...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004697-28,0,0,0 2011-004698-98,5,2021-01-14,2021-01-14,4,1,0,0,2,0,3,0,0,1,1,0,1,0,0,Universität zu Köln,"A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lenalidomide (Revlimid®) as maintenance therapy for high-risk pateints with chr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004698-98,0,0,0 2011-004698-98,5,2021-01-14,2021-01-14,4,1,0,0,2,0,3,0,0,1,1,0,1,0,0,UNIVERSITY OF COLOGNE,"A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lenalidomide (Revlimid®) as maintenance therapy for high-risk pateints with chr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004698-98,0,0,0 2011-004698-98,5,2021-01-14,2021-01-14,4,1,0,0,2,0,3,0,0,1,1,0,1,0,0,"Deutsche CLL-Studiengruppe, Innere Medizin I, Uniklinik Köln","A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lenalidomide (Revlimid®) as maintenance therapy for high-risk pateints with chr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004698-98,0,0,0 2011-004698-98,5,2021-01-14,2021-01-14,4,1,0,0,2,0,3,0,0,1,1,0,1,0,0,"University of Cologne,","A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lenalidomide (Revlimid®) as maintenance therapy for high-risk pateints with chr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004698-98,0,0,0 2011-004701-24,5,2016-06-29,2016-06-29,1,0,0,0,2,1,0,0,0,2,0,0,0,0,1,Genzyme Corporation,"An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004701-24,1,0,0 2011-004701-24,5,2016-06-29,2016-06-29,1,0,0,0,2,1,0,0,0,2,0,0,0,0,1,AstraZeneca AB,"An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004701-24,1,0,0 2011-004701-24,5,2016-06-29,2016-06-29,1,0,0,0,2,1,0,0,0,2,0,0,0,0,1,ASTRAZENECA AB,"An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004701-24,1,0,0 2011-004702-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Department of Anaesthesia,Comparison of Ultrasound - Guided Continuous Rectus Sheath Blockade and Continuous Preperitoneal Wound Catheter Infiltration of Local Anaesthetic for Postoperative Analgesia following Laparotomy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004702-17,0,0,0 2011-004704-38,1,2014-02-19,2014-02-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GBG Forschungs GmbH,Dual blockage with Afatinib and Trastuzumab as neooadjuvant treatment for patients with lo-cally advanced or operable breast cancer receiving taxane-anthracycline containing chemo-therapy (DAFNE study...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004704-38,0,0,0 2011-004710-42,5,2013-07-31,2013-08-12,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer-Ingelheim RCV GmbH & Co KG,"Randomised, double-blind, placebo-controlled, 6 treatment, 4 period, incomplete cross-over trial to characterise the 24-hour lung function profiles of tiotropium + olodaterol fixed dose combination (2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004710-42,0,0,0 2011-004710-42,5,2013-07-31,2013-08-12,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co.KG,"Randomised, double-blind, placebo-controlled, 6 treatment, 4 period, incomplete cross-over trial to characterise the 24-hour lung function profiles of tiotropium + olodaterol fixed dose combination (2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004710-42,0,0,0 2011-004710-42,5,2013-07-31,2013-08-12,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"Randomised, double-blind, placebo-controlled, 6 treatment, 4 period, incomplete cross-over trial to characterise the 24-hour lung function profiles of tiotropium + olodaterol fixed dose combination (2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004710-42,0,0,0 2011-004710-42,5,2013-07-31,2013-08-12,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"Randomised, double-blind, placebo-controlled, 6 treatment, 4 period, incomplete cross-over trial to characterise the 24-hour lung function profiles of tiotropium + olodaterol fixed dose combination (2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004710-42,0,0,0 2011-004710-42,5,2013-07-31,2013-08-12,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Randomised, double-blind, placebo-controlled, 6 treatment, 4 period, incomplete cross-over trial to characterise the 24-hour lung function profiles of tiotropium + olodaterol fixed dose combination (2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004710-42,0,0,0 2011-004711-23,1,2015-03-20,2015-03-20,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Leeds Dental Institute,"Comparative studies of the anaesthetic efficacy of 4% Articaine used as mandibular infiltration versus 2% Lidocaine used as inferior dental nerve block, in extraction and pulpotomy of mandibular prima...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004711-23,0,0,0 2011-004712-32,1,2014-05-27,2014-05-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UNICANCER,"A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004712-32,0,0,0 2011-004714-41,1,,,0,1,0,0,0,0,3,0,0,0,0,0,0,0,0,GBG Forschungs GmbH,A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto) Eine rando...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004714-41,0,0,0 2011-004718-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AISAR ASSOCIAZIONE ITALIANA PER LO STUDIO DEGLI ANTIMICROBICI E DELLE RESISTENZE,Activities of Metronidazole + Clotrimazole in the treatment and prophylaxis of recurrent vaginal infections recurrent Candida albicans and Candida albicans spp do not. Attivita` dell`™associazione...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004718-40,0,0,0 2011-004720-35,6,,,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,Karolinska Institutet,"A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004720-35,0,0,0 2011-004720-35,6,,,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,"The Karolinska Instutute, ClinTRID","A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004720-35,0,0,0 2011-004720-35,6,,,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,"The Karolinska Institute, ClinTRID","A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004720-35,0,0,0 2011-004724-35,6,2014-07-15,2014-07-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects Studio d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004724-35,0,0,0 2011-004724-35,6,2014-07-15,2014-07-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects Studio d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004724-35,0,0,0 2011-004725-27,1,2012-05-24,2012-05-24,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Reckitt Benckiser Healthcare (UK) Ltd,"A single-centre, randomised, double-blind, two-way crossover, placebo-controlled pilot study, investigating the use of a novel intragastric and oesophageal pH catheter to characterise the antacid acti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004725-27,0,0,0 2011-004726-10,2,2018-05-31,2018-05-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amarin Pharma Inc.,"A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004726-10,0,0,0 2011-004728-36,9,2018-12-17,2018-12-27,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Intercept Pharmaceuticals, Inc.","A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004728-36,0,0,0 2011-004728-36,9,2018-12-17,2018-12-27,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"INTERCEPT PHARMACEUTICALS, INC.","A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004728-36,0,0,0 2011-004729-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION GELTAMO,OFATUMUMAB COMO PARTE DEL RÉGIMEN DE ACONDICIONAMIENTO DE INTENSIDAD REDUCIDA (RIC) EN PACIENTES CON LINFOMA B NO-HODGKIN DE ALTO RIESGO QUE RECIBEN UN TRANSPLANTE ALOGÉNICO DE PROGENITORES HEMATOPOYÉ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004729-29,0,0,0 2011-004730-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA,"A phase II multicentre, randomized, controlled open-label study on the use of anti-thymocyte globulin and rituximab for immunomodulation of graft-versus-host disease in allogeneic matched transplants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004730-34,0,0,0 2011-004733-14,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Medizinische Universität Wien,Intravenous S-Ketamine as an Analgesic Adjunct to General Anesthesia in chronic opioid-tolerant patient,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004733-14,0,0,0 2011-004734-33,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase II, non-randomised, open-label study to evaluate the safety and immunogenicity of the adjuvanted (pre-) pandemic H5N1 influenza candidate vaccine following a heterologous prime-boost schedule ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004734-33,0,1,1 2011-004735-32,1,2017-04-20,2017-04-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SOTIO a.s.,"Randomized, open-label, parallel-group, multi-centre phase II clinical trial with active cellular immunotherapy DCVAC/PCa in patients with castrate-resistant prostate cancer Randomizovaná, otevře...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004735-32,0,0,0 2011-004742-18,4,2015-04-21,2015-04-21,4,1,1,0,0,1,1,0,0,1,0,0,1,0,1,"Merckle GmbH, a member of the ratiopharm group, a subsidiary of Teva Pharmaceutical Industries Ltd. Germany","Multicenter, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100μg/kg XM22 in 21 Children with E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004742-18,0,0,0 2011-004742-18,4,2015-04-21,2015-04-21,4,1,1,0,0,1,1,0,0,1,0,0,1,0,1,Merckle GmbH,"Multicenter, Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, Tolerability, and Immunogenicity of a Single, Subcutaneous Dose of 100μg/kg XM22 in 21 Children with E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004742-18,0,0,0 2011-004744-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNICANCER,Adjuvant systemic treatment for oestrogen-receptor (ER)-positive HER2-negative breast carcinoma in women over 70 according to Genomic Grade (GG): chemotherapy + endocrine treatment versus endocrine tr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004744-22,0,0,0 2011-004745-40,1,2014-07-30,2014-07-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hull and East Yorkshire Hospitals NHS Trust.,Studies of the effects of a one week course of either azithromycin or metronidazole on plasma concentration of procalcitonin in patients with heart failure and elevated plasma procalcitonin concentrat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004745-40,0,0,0 2011-004748-23,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Neurologisk Afdeling,Risk of apoplexia cerebri in clopidogrel non-responders. Risiko for apoplexia cerebri hos clopidogrel non-respondere.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004748-23,0,0,0 2011-004749-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,TweeSteden hospital,The effects of neoadjuvant hormonal therapy on the course of PSA and testosterone in patients with low and intermediate-risk prostate carcinoma (NEO-ONE); A randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004749-41,0,0,0 2011-004751-39,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, randomized, open, active-controlled study to evaluate the safety and immunogenicity of a prime-boost schedule of the H5N1 candidate vaccine adjuvanted with AS03B administered to children ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004751-39,0,1,1 2011-004755-39,3,2015-05-05,2015-05-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.",A randomized phase II study of Bevacizumab/mFOLFOX6 vs. Bevacizumab/FOLFIRI with biomarker stratification in patients with previously untreated metastatic colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004755-39,0,0,0 2011-004759-37,5,2012-09-27,2012-09-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici SpA,"RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, 3-ARM PARALLEL GROUP, MULTI-NATIONAL, MULTI-CENTRE STUDY TO EVALUATE THE CARDIAC SAFETY OF TWO DOSES OF GLYCOPYRROLATE BROMIDE (25µG AND 50µG BID) DELIVERE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004759-37,0,0,0 2011-004760-29,1,,,0,0,0,0,0,0,3,0,1,1,0,0,0,1,0,Maria Victoria Ruiz Arzalluz,EFFECTIVENESS OF ADMINISTRATION TIMING OF ASPIRIN FROM DAYTIME TO NIGHTIME IN HYPERTENSIVE PATIENTS TREATED WITH LOW DOSE OF ASA IN SECONDARY PREVENTION. - TAHPS ?Efectividad de la Temporización de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004760-29,0,0,0 2011-004761-33,1,2014-05-30,2014-05-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Imperial College,A randomised double-blind placebo-controlled Phase 2B clinical trial of repeated application of gene therapy in patients with cystic fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004761-33,0,0,0 2011-004762-15,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,VU Univeristy Medical Centre,Early pharmacological intervention to prevent delirium: HAlopeRidol PrOphylaxis in Older emergency department patieNts. The HARPOON study Preventie van delirium door vroegtijdige pharmacologische i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004762-15,0,0,0 2011-004763-72,7,2012-03-13,2013-12-30,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-945429 in Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004763-72,0,0,0 2011-004763-72,7,2012-03-13,2013-12-30,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-945429 in Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004763-72,0,0,0 2011-004764-30,1,2017-10-24,2017-10-24,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU Nantes,Phase 2 study of a reduced-toxicity myeloablative conditionning regimen using fludarabine and full doses of IV busulfan in pediatric patients not eligible for standard myeloablative conditioning regi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004764-30,0,0,0 2011-004765-32,5,2013-07-05,2013-08-13,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SIGMA-TAU,"Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine (ST261) Modified Release Tablet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004765-32,0,0,0 2011-004765-32,5,2013-07-05,2013-08-13,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,"Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine (ST261) Modified Release Tablet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004765-32,0,0,0 2011-004770-28,7,2013-07-04,2013-08-13,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,"Phase III, Parallel-group, Placebo Controlled, Double-blind, Randomized, Multicenter International Study to Investigate the Safety and Efficacy of Propionyl-L-Carnitine (ST261) Modified Release Tablet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004770-28,0,0,0 2011-004771-36,6,2015-12-29,2015-12-29,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Valneva Austria GmbH,"A CONFIRMATORY PHASE II/III STUDY ASSESSING EFFICACY, IMMUNOGENICITY AND SAFETY OF IC43 RECOMBINANT PSEUDOMONAS VACCINE IN INTENSIVE CARE PATIENTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004771-36,0,0,0 2011-004771-36,6,2015-12-29,2015-12-29,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Intercell,"A CONFIRMATORY PHASE II/III STUDY ASSESSING EFFICACY, IMMUNOGENICITY AND SAFETY OF IC43 RECOMBINANT PSEUDOMONAS VACCINE IN INTENSIVE CARE PATIENTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004771-36,0,0,0 2011-004775-36,1,2015-01-21,2015-01-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GET SRL,"''A Phase III, multicenter, open-label study, to evaluate the efficacy and safety of different dosage regimens of 0.2 mg lofexidine hydrochloride (DIMATEX) in the treatment of withdrawal symptoms duri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004775-36,0,0,0 2011-004777-89,1,2015-09-04,2015-09-04,1,0,0,0,0,0,4,0,1,1,0,0,1,0,1,Cassella-med GmbH & Co. KG,Efficacy and safety of Euminz® (10% ethanolic solution of peppermint oil for topical use) compared to placebo in patients with episodic tension-type headache (ETTH) Wirksamkeit und Sicherheit von ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004777-89,0,0,0 2011-004779-35,2,2014-05-05,2014-05-13,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Institut de Recherches Internationales Servier,"Effects of oral chronic administration of ivabradine (7.5 mg bid) in comparison to placebo (bid) on top of beta-blockers, on central aortic blood pressure. Randomized, cross-over, double blind, multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004779-35,0,0,0 2011-004780-75,1,2014-01-24,2014-01-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AbbVie Deutschland GmbH & Co. KG,Long-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer’s Disease: An Open-Label Extension Study for Subjects Completing Study M10-985.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004780-75,0,0,0 2011-004783-30,4,2016-09-28,2016-09-28,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Sanofi aventis recherche et développement,"A pilot, exploratory, randomized, phase 2 safety study evaluating tumor cell (plasma cell) mobilization and apheresis product contamination in plerixafor plus non-pegylated G-CSF mobilized patients an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004783-30,0,0,0 2011-004787-30,1,2016-04-04,2016-04-04,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Charite Universitaetsmedizin Berlin,"Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya® Modifizierung des visuellen Outcome nach Optikusneuritis in CIS oder MS durch Gilenya®: Eine prospektive, stratifizi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004787-30,0,0,0 2011-004789-14,6,2015-07-01,2015-07-01,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sunovion Pharmaceuticals Inc.,"A Multicenter, Open-Label, Flexible-Dose Extension Study of Lurasidone Adjunctive to Lithium or Divalproex in Subjects with Bipolar I Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004789-14,0,0,0 2011-004790-90,2,2013-11-05,2013-11-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sunovion Pharmaceuticals Inc.,"A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004790-90,0,0,0 2011-004790-90,2,2013-11-05,2013-11-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SUNOVION PHARMACEUTICALS INC.,"A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004790-90,0,0,0 2011-004791-11,5,2013-12-19,2013-12-19,5,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Galderma R&D SNC,"Efficacy and safety of CD5024 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea over 16 weeks treatment, followed by a 36-week extension period",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004791-11,0,0,0 2011-004792-36,11,2021-08-16,2021-08-16,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,An Open-Label Randomized Phase III Trial of 936558 (Nivolumab) versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) Pharmacogenetics Blood Sa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004792-36,1,0,0 2011-004792-36,11,2021-08-16,2021-08-16,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,An Open-Label Randomized Phase III Trial of 936558 (Nivolumab) versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) Pharmacogenetics Blood Sa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004792-36,1,0,0 2011-004795-11,8,2016-01-08,2016-02-18,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Controlled Phase 3 Study to Evaluate Optimized Retreatment and Prolonged Therapy with Bortezomib (Velcade) in Patients with Multiple Myeloma in First or Second Relapse Studio random...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004795-11,0,0,0 2011-004795-11,8,2016-01-08,2016-02-18,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"A Randomized, Controlled Phase 3 Study to Evaluate Optimized Retreatment and Prolonged Therapy with Bortezomib (Velcade) in Patients with Multiple Myeloma in First or Second Relapse Studio random...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004795-11,0,0,0 2011-004798-99,1,,,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,Weill Medical College of Cornell University,Safety and Efficacy of SOD1 Inhibition By Pyrimethamine in Familial (ALS) Verträglichkeit und Wirksamkeit der SOD1 (Superoxiddismutase 1) Inhibition durch Pyrimethamin bei Patienten mit familiärer ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004798-99,0,0,0 2011-004800-40,6,2016-02-17,2016-02-17,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Amicus Therapeutics, Inc.",An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects with Fabry Disease. Uno studio di estensione in aperto per valutare...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004800-40,0,0,0 2011-004800-40,6,2016-02-17,2016-02-17,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects with Fabry Disease. Uno studio di estensione in aperto per valutare...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004800-40,0,0,0 2011-004800-40,6,2016-02-17,2016-02-17,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects with Fabry Disease. Uno studio di estensione in aperto per valutare...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004800-40,0,0,0 2011-004803-19,2,2013-01-09,2013-01-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase IIA, Multi centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Effect of 8 Weeks Treatment with Oral AZD3241 on Microglia Activation, as Measured by Positr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004803-19,0,0,0 2011-004804-38,1,2012-12-19,2012-12-19,1,0,0,0,0,1,2,0,1,1,0,0,1,0,1,ViroDefense Inc,"A Randomized, Blinded, Placebo-Controlled, Poliovirus Challenge Study To Evaluate The Therapeutic Efficacy, Safety, Tolerability And Pharmacokinetics Of Orally Administered V-073 In Healthy Adult Volu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004804-38,0,0,0 2011-004808-37,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Phase II clinical study on the activity of salvage therapy with high doses of oral clarithromycin in patients with extranodal marginal zone relapsed or refractory lymphoma Studio clinico di fase II...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004808-37,0,0,0 2011-004810-41,5,2014-06-20,2014-06-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004810-41,0,0,0 2011-004811-21,1,2013-01-25,2013-01-25,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,UZLeuven,"The effect of Sildenafil citrate (Viagra ®) on stomach motility, gastric emptying and food intake in healthy volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004811-21,0,0,0 2011-004812-40,5,2013-06-24,2013-06-24,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AstraZeneca AB,"A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody dire...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004812-40,0,0,0 2011-004812-40,5,2013-06-24,2013-06-24,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ASTRAZENECA,"A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody dire...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004812-40,0,0,0 2011-004815-22,1,2014-05-01,2014-05-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,3,Research Institute of Biological Psychiatry Sct. Hans,Individualised drug therapy based on pharmacogenomics: focus on carboxylesterase 1 (CES1) Individuelle forskelle i omsætningen af lægemidler,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004815-22,0,0,0 2011-004820-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación FISEVI,"Phase II, open-label clinical trial to evaluate the safety and efficacy of platelet-rich plasma and fibrin clot processed with PRGF-System tecnology in the treatment of anal fistulas in Crohn's patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004820-37,0,0,0 2011-004822-85,1,2017-05-12,2017-05-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ABCSG (Austrian Breast & Colorectal Cancer Study Group),"A prospective, open, randomized, phase-II study of a therapeutic cancer vaccine (L-BLP25, Stimuvax®) in the pre-operative treatment of women with primary breast cancer Eine prospektive, offene, ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004822-85,0,0,0 2011-004823-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI,Randomized prospective multicenter study on remifentanil analgesic efficacy in labor: intermittent intravenous infusion administration vs continuous intravenous infusion Studio prospettico multicen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004823-11,0,0,0 2011-004825-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Instituto de Investigaciones del Sueño,TREATMENT WITH ROTIGOTINE OF RLS PATIENTS WITH AN INSUFFICIENT RESPONSE TO DOPAMINE AGONIST WITH INTERMEDIATE HALF-LIFE. EVALUACIÓN DEL SÍNDROME DE PIERNAS INQUIETAS MEDIENTE EL TEST DE INMOVILIZAC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004825-29,0,0,0 2011-004826-87,1,2016-03-21,2016-03-21,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Fundacion Progreso y Salud,Randomized multicentric open-label phase III clinical trial to evaluate the efficacy of continual treatment versus discontinuation based in the presence of prodromes in a first episode of non-affecti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004826-87,0,0,0 2011-004829-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitetssjukhuset i Linköping,Påverkar valet av smärtlindring vid tjocktarm/ändtarmscancer recidiv och överlevnad? (EPICOL-studien).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004829-27,0,0,0 2011-004830-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"FAES FARMA, S.A.",Effects of bilastine on nasal volume after allergen-induced rhinitis in patients with allergic rhinitis Eficacia de bilastina sobre la obstrucción nasal en un modelo clínico de provocación nasal co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004830-32,0,0,0 2011-004831-30,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,UNICANCER,Safety and efficacy of radiotherapy combined with a 6-month LH-RH agonist and abiraterone hormone therapy treatment in biochemically-relapsing prostate cancer following surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004831-30,0,0,0 2011-004834-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,"Administration of concentrated Protein C in patients with severe sepsis and contraindications to activated protein C. A monocentric, randomised placebo-controlled study. Somministrazione di concent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004834-32,0,0,0 2011-004835-30,3,2017-05-22,2018-05-29,3,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Department of Medicine, Haugesund Hospital","Therapy for chronic cold agglutinin disease: A prospective, non-randomized international multicenter trial on the safety and efficacy of bendamustine and rituximab combination therapy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004835-30,0,0,0 2011-004836-76,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Urologkliniken USÖ,Suprefact1 Can Suprefact be administrated every forth month with good castration effect.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004836-76,0,0,0 2011-004844-23,2,2013-06-14,2013-06-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AMGEN INC.,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 299) Studio di fase 2, randomizzato, in doppio cie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004844-23,0,0,0 2011-004844-23,2,2013-06-14,2013-06-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 299) Studio di fase 2, randomizzato, in doppio cie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004844-23,0,0,0 2011-004845-42,3,2013-05-20,2013-05-20,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Amgen Inc.,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 165)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004845-42,0,0,0 2011-004847-35,1,2018-02-07,2018-02-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Medical Center Hamburg-Eppendorf,Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first) - A prospective multicenterphase IIA study -,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004847-35,0,0,0 2011-004849-40,3,2013-10-24,2013-11-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT 126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004849-40,0,0,0 2011-004849-40,3,2013-10-24,2013-11-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT 126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004849-40,0,0,0 2011-004852-20,1,2013-04-12,2013-04-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ALK-Abelló, S.A.",An open trial to assess the tolerability of AVANZ Olive immunotherapy Ensayo abierto para evaluar la tolerabilidad de la inmunoterapia con AVANZ Olivo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004852-20,0,0,0 2011-004853-18,7,2018-01-19,2018-01-19,7,1,1,0,0,1,3,0,0,1,0,0,1,0,1,"PTC Therapeutics, Inc",An Open-Label Study for Previously Treated Ataluren (PTC124) Patients with Nonsense Mutation Dystrophinopathy STUDIO IN APERTO SU PAZIENTI TRATTATI IN PRECEDENZA CON ATALUREN (PTC124) AFFETTI DA D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004853-18,0,0,0 2011-004853-18,7,2018-01-19,2018-01-19,7,1,1,0,0,1,3,0,0,1,0,0,1,0,1,"PTC Therapeutics, Inc.",An Open-Label Study for Previously Treated Ataluren (PTC124) Patients with Nonsense Mutation Dystrophinopathy STUDIO IN APERTO SU PAZIENTI TRATTATI IN PRECEDENZA CON ATALUREN (PTC124) AFFETTI DA D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004853-18,0,0,0 2011-004853-18,7,2018-01-19,2018-01-19,7,1,1,0,0,1,3,0,0,1,0,0,1,0,1,"PTC THERAPEUTICS, INC.",An Open-Label Study for Previously Treated Ataluren (PTC124) Patients with Nonsense Mutation Dystrophinopathy STUDIO IN APERTO SU PAZIENTI TRATTATI IN PRECEDENZA CON ATALUREN (PTC124) AFFETTI DA D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004853-18,0,0,0 2011-004854-25,1,2018-08-06,2018-08-06,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Cardiff University,"TRON: A randomised, double blind, placebo-controlled study of RAD001 (Everolimus) in the treatment of neurocognitive problems in tuberous sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004854-25,0,0,0 2011-004860-31,1,2016-09-01,2016-09-01,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,Medical University of Vienna,Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004860-31,0,0,0 2011-004867-65,2,2013-10-16,2013-10-16,1,1,1,0,0,1,1,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","Sequential, two-period study to assess the pharmacokinetics, safety & tolerability of single and multiple oral doses of AFQ056 in patients with FXS (Fragile X syndrome) aged 5-11 years (Cohort 1) and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004867-65,1,1,0 2011-004867-65,2,2013-10-16,2013-10-16,1,1,1,0,0,1,1,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"Sequential, two-period study to assess the pharmacokinetics, safety & tolerability of single and multiple oral doses of AFQ056 in patients with FXS (Fragile X syndrome) aged 5-11 years (Cohort 1) and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004867-65,1,1,0 2011-004868-30,13,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,0,University Medical Center Hamburg-Eppendorf,AN INTERNATIONAL PROSPECTIVE STUDY ON CLINICALLY STANDARD-RISK MEDULLOBLASTOMA IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH LOW-RISK BIOLOGICAL PROFILE (PNET 5 MB - LR) OR AVERAGE-RISK BIOLOGICAL PROFILE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004868-30,0,0,0 2011-004868-30,13,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,0,University Medical Centre Hamburg - Eppendorf,AN INTERNATIONAL PROSPECTIVE STUDY ON CLINICALLY STANDARD-RISK MEDULLOBLASTOMA IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH LOW-RISK BIOLOGICAL PROFILE (PNET 5 MB - LR) OR AVERAGE-RISK BIOLOGICAL PROFILE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004868-30,0,0,0 2011-004870-26,1,2013-04-02,2013-04-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 26-week treatment, multicenter, randomized, parallel group, blinded study to assess the efficacy and safety of QVA149 (110/50 µg q.d.) in patients with moderate to severe chronic obstructive pulmona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004870-26,0,0,0 2011-004878-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St. Antonius Hospital,Perioperative antibiotic use in the treatment of acute calculous cholecystitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004878-29,0,0,0 2011-004879-36,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,Comparative study of the immunogenicity and protective efficacy of GlaxoSmithKline Biologicals’ rec-DNA Hepatitis B vaccine (10µg) with or without Hepatitis B immunoglobulin (HBIG) in newborns of Hepa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004879-36,0,1,1 2011-004885-14,6,2014-09-24,2014-09-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combinatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004885-14,0,0,0 2011-004885-14,6,2014-09-24,2014-09-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, with and without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combinatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004885-14,0,0,0 2011-004886-34,2,2015-10-01,2015-10-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"OptiNose US, Inc","A 16-Week RaNdomized, Double-Blind, Placebo-Controlled, PArallel-Group, Multicenter Study EValuatInG the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of FluticAsone Propion...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004886-34,0,0,0 2011-004887-31,1,2015-07-03,2015-07-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"OptiNose US, Inc","A 16-Week RaNdomized, Double-Blind, Placebo-Controlled, PArallel-Group, Multicenter Study EValuatInG the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of FluticAsone Propion...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004887-31,0,0,0 2011-004889-15,12,2015-03-02,2018-09-19,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004889-15,0,0,0 2011-004890-10,1,2014-06-05,2014-06-05,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,Optimising Vitamin D Status in Older People: A Randomised Controlled Trial of Vitamin D Supplementation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004890-10,0,0,0 2011-004891-12,3,2015-04-16,2015-04-16,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A phase IIIA, randomized, observer-blind, controlled, multinational consistency study to evaluate the immunogenicity and safety of GSK Biologicals' MMR vaccine (209762) (Priorix®) compared to Merck & ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004891-12,0,0,0 2011-004891-12,3,2015-04-16,2015-04-16,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIA, randomized, observer-blind, controlled, multinational consistency study to evaluate the immunogenicity and safety of GSK Biologicals' MMR vaccine (209762) (Priorix®) compared to Merck & ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004891-12,0,0,0 2011-004893-28,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA O.I.R.M. - S. ANNA,PHASE II STUDY OF CLOFARABINE IN COMBINATION WITH CYTARABINE AND LIPOSOMAL DOXORUBICIN IN CHILDREN WITH EITHER LYMPHOBLASTIC OR MYELOID RELAPSE OR REFRACTORY ACUTE LEUKEMIA AND IN CHILDREN WITH SECOND...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004893-28,0,0,0 2011-004894-96,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Mikko Hippeläinen,ORAL ABSORPTION OF OXYCODONE AFTER CARDIAC BYPASS SURGERY OKSIKODONIN PER OS IMEYTYMINEN SYDÄMEN OHITUSLEIKKAUKSEN JÄLKEEN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004894-96,0,0,0 2011-004895-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie",Medical premedication in contrast to psychological preparation in children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004895-13,0,0,0 2011-004901-25,1,,,0,1,1,0,0,0,1,1,0,4,0,0,0,0,1,GlaxoSmithKline Research and Development Ltd,"An Open-Label, Two-Period, Randomized, Crossover Study to Assess the Relative Bioavailability of GSK1120212 Tablet Formulation and the GSK1120212 Pediatric Oral Solution Formulation Following Single-D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004901-25,0,1,1 2011-004903-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,,Hydroxychloroquine as an anti-autophagy and chromatin modulating drug in combination with erlotinib in non-small cell lung cancer (NSCLC) patients: a single-center single arm open-label phase II trial...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004903-20,0,0,0 2011-004905-26,3,2015-08-18,2015-08-18,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"Immunogenicity and safety study of GSK Biologicals? Priorix® vaccine (209762) at an end of shelf-life potency compared to Merck & Co., Inc.?s MMR vaccine when both are given on a 2-dose schedule to he...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004905-26,0,0,0 2011-004905-26,3,2015-08-18,2015-08-18,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline,"Immunogenicity and safety study of GSK Biologicals? Priorix® vaccine (209762) at an end of shelf-life potency compared to Merck & Co., Inc.?s MMR vaccine when both are given on a 2-dose schedule to he...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004905-26,0,0,0 2011-004906-12,1,2013-03-08,2013-03-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Erling Bjerregaard Pedersen, Medicinsk forskningsafsnit, Regionshospitalet Holstebro","Effect of hydroxyethyl starch on renal handling of sodium and water, vasoactive hormones,biomarkers and the circulatory system in patients undergoing hip replacement surgery Effekten af hydroxyethy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004906-12,0,0,0 2011-004908-37,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR,Phase II study on activity and tolerability of intralesional rituximab in relapsed or refractory patients affected by indolentCD-20 positive lymphoma of conjuntiva; evaluation of activity of adding au...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004908-37,0,0,0 2011-004910-41,1,2012-04-30,2012-04-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Southampton,A Randomised Controlled Trial to assess a food supplement (baker’s yeast extract) to support immune function and prevent cold and flu symptoms in a 50 to 70 year old population,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004910-41,0,0,0 2011-004912-43,1,2015-01-15,2015-01-15,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH,Fludarabine/Rituximab combined with escalating doses of Lenalidomide in untreated chronic lymphocytic leukemia (CLL) – a dose-finding study with escalating starting dose of Lenalidomide and concomitan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004912-43,0,0,0 2011-004914-40,4,2015-12-04,2015-12-04,3,1,1,0,0,0,1,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","AN OPEN-LABEL MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CP-690,550 IN PEDIATRIC PATIENTS FROM 2 TO LESS THAN 18 YEARS OF AGE WITH JUVENILE IDIOPATHIC ARTHRITIS (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004914-40,0,0,0 2011-004914-40,4,2015-12-04,2015-12-04,3,1,1,0,0,0,1,0,0,1,1,0,1,0,1,PFIZER INC.,"AN OPEN-LABEL MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CP-690,550 IN PEDIATRIC PATIENTS FROM 2 TO LESS THAN 18 YEARS OF AGE WITH JUVENILE IDIOPATHIC ARTHRITIS (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004914-40,0,0,0 2011-004915-22,10,,,0,0,1,0,0,0,2,0,0,2,1,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, New York 10017","A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) STUDIO DI FOLLOW-UP A LUNGO TERMINE, IN APERTO, SU CP-690,550 PER IL TRATTAMENTO DELL'ARTR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004915-22,0,0,0 2011-004915-22,10,,,0,0,1,0,0,0,2,0,0,2,1,0,0,0,1,"Pfizer Inc,","A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) STUDIO DI FOLLOW-UP A LUNGO TERMINE, IN APERTO, SU CP-690,550 PER IL TRATTAMENTO DELL'ARTR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004915-22,0,0,0 2011-004915-22,10,,,0,0,1,0,0,0,2,0,0,2,1,0,0,0,1,PFIZER INC.,"A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) STUDIO DI FOLLOW-UP A LUNGO TERMINE, IN APERTO, SU CP-690,550 PER IL TRATTAMENTO DELL'ARTR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004915-22,0,0,0 2011-004915-22,10,,,0,0,1,0,0,0,2,0,0,2,1,0,0,0,1,Pfizer Inc.,"A LONG-TERM, OPEN-LABEL FOLLOW-UP STUDY OF CP-690,550 FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (JIA) STUDIO DI FOLLOW-UP A LUNGO TERMINE, IN APERTO, SU CP-690,550 PER IL TRATTAMENTO DELL'ARTR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004915-22,0,0,0 2011-004916-51,10,2014-10-23,2014-10-30,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Spectrum Pharmaceuticals, Inc.","A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (ibritumomab tiuxetan) versus Observation in Patients at Least 60 Years of Age with Newly Diagnosed Diffuse Large B-cell Ly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004916-51,0,0,0 2011-004916-51,10,2014-10-23,2014-10-30,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SPECTRUM PHARMACEUTICALS INC,"A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (ibritumomab tiuxetan) versus Observation in Patients at Least 60 Years of Age with Newly Diagnosed Diffuse Large B-cell Ly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004916-51,0,0,0 2011-004923-11,16,2015-08-07,2015-09-10,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Ga...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004923-11,0,0,0 2011-004923-11,16,2015-08-07,2015-09-10,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AMGEN INC.,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Ga...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004923-11,0,0,0 2011-004927-11,1,2014-12-15,2014-12-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,CytRx Corporation,"A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects with Metastatic, Locally Adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004927-11,0,0,0 2011-004928-35,4,2014-06-03,2014-06-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment-Experienced Subjects with Genot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004928-35,0,0,0 2011-004930-33,2,2013-10-18,2013-10-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 24 week randomised, open label, 3 parallel-group comparison of once and twice daily biphasic insulin aspart (BIAsp) 30 plus sitagliptin and twice daily BIAsp 30, all in combination with metformin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004930-33,0,0,0 2011-004931-30,4,2012-11-30,2014-04-09,3,1,0,0,0,2,3,0,1,1,0,0,1,0,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase 3, Open Label, Multi-Center, Extension Study to Assess Antibody Persistence and Response to a Third or Fift Dose of Novartis Meningococcal B Recombinant Vaccine in 4-Year-Old Children Who Pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004931-30,0,0,0 2011-004931-30,4,2012-11-30,2014-04-09,3,1,0,0,0,2,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 3, Open Label, Multi-Center, Extension Study to Assess Antibody Persistence and Response to a Third or Fift Dose of Novartis Meningococcal B Recombinant Vaccine in 4-Year-Old Children Who Pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004931-30,0,0,0 2011-004934-32,1,,,0,0,1,0,0,1,2,0,0,4,0,0,0,0,0,National Cancer Institute,A phase I/II trial of vandetanib in children and adolescents with hereditary medullary thyroid cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004934-32,0,1,1 2011-004935-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,U.L.S.S. 9 DI TREVISO,Study “before-after”: Adherence Evaluation to antiretroviral therapy administered in two different ways: - EPIVIR (3TC) + VIREAD (TDF) versus TRUVADA (FTC + TDF) - EPIVIR (3TC) + ZIAGEN (ABC) ve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004935-30,0,0,0 2011-004936-75,1,2014-08-06,2014-08-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,An Evaluation of Losmapimod in patients with Chronic Obstructive Pulmonary Disease (COPD) with systemic inflammation stratified using fibrinogen (EVOLUTION),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004936-75,0,0,0 2011-004942-16,4,2019-11-20,2019-11-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA,"A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004942-16,0,0,0 2011-004942-16,4,2019-11-20,2019-11-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004942-16,0,0,0 2011-004943-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland",ICORG 11-24-NSABP PROTOCOL B-47 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclopho...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004943-32,0,0,0 2011-004944-23,1,2014-05-01,2014-05-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Charité Universitätsmedizin,"Prospektive open-label, multizentrische Phase IV Studie zur leberfunktionsangepassten Tacrolimus-Therapie nach Lebertransplantation (GRAFTT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004944-23,0,0,0 2011-004951-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA USL DI FORLI',Role of PET/CT with 18F-choline in biochemical relapse in prostate cancer patients treated with radical intent. Pet Col study. Ruolo dell`esame PET/TAC con 18F-Colina nelle recidive biochimiche da ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004951-38,0,0,0 2011-004953-17,1,2014-11-01,2014-11-01,1,1,0,0,1,0,2,0,1,1,0,0,1,0,0,Technical university Dresden,"Measurement of epidermal and dermal thickness under therapy with Pimecrolimus 1 % Creme (Elidel® 1 % Creme), Hydrocortisonacetat 1 % Creme (Hydrogalen® Creme), Betamethasonvalerat 0,1 % Creme (Betaga...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004953-17,0,0,0 2011-004955-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AMC, Amsterdam",Controlling Glucose during Elective hip Surgery to study the influence on Coagulation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004955-38,0,0,0 2011-004959-39,16,2014-12-31,2015-09-30,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 24-month, phase IIIb, randomized, double-masked, multicenter study assessing the efficacy and safety of two treatment regimens of 0.5 mg ranibizumab intravitreal injections guided by functional and/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004959-39,0,0,0 2011-004959-39,16,2014-12-31,2015-09-30,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A 24-month, phase IIIb, randomized, double-masked, multicenter study assessing the efficacy and safety of two treatment regimens of 0.5 mg ranibizumab intravitreal injections guided by functional and/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004959-39,0,0,0 2011-004959-39,16,2014-12-31,2015-09-30,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Farma,"A 24-month, phase IIIb, randomized, double-masked, multicenter study assessing the efficacy and safety of two treatment regimens of 0.5 mg ranibizumab intravitreal injections guided by functional and/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004959-39,0,0,0 2011-004963-56,6,2014-10-23,2014-12-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus Emtricitabine (FTC) and Tenofovir DF (TDF) to th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004963-56,0,0,0 2011-004963-56,6,2014-10-23,2014-12-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GILEAD SCIENCE INC.,"A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) plus Emtricitabine (FTC) and Tenofovir DF (TDF) to th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004963-56,0,0,0 2011-004964-32,6,2013-03-20,2013-06-21,2,1,1,0,0,0,3,0,0,1,0,0,1,0,1,KOWA RESEARCH EUROPE LTD,"A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, 12-Week Study of Pitavastatin in High-Risk Hyperlipidaemia in Childhood P/266/2011, P267/2011, P268/2011 Studio doppio cieco, rando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004964-32,0,0,0 2011-004964-32,6,2013-03-20,2013-06-21,2,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Kowa Research Europe, Ltd.","A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, 12-Week Study of Pitavastatin in High-Risk Hyperlipidaemia in Childhood P/266/2011, P267/2011, P268/2011 Studio doppio cieco, rando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004964-32,0,0,0 2011-004966-13,1,2013-06-25,2013-06-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A double-blind, placebo-controlled, study examining the effect of orally administered QAW039 on sputum eosinophil levels and other efficacy outcomes in patients with sputum eosinophilia and persistent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004966-13,0,0,0 2011-004967-65,1,2018-10-11,2018-10-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SOTIO a.s.,"Randomized, open-label, parallel-group, multi-centre phase II clinical trial with active cellular immunotherapy DCVAC/PCa in patients with localized high-risk prostate cancer after primary radiotherap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004967-65,0,0,0 2011-004974-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,89Zr-RO5323441 PET imaging in patients with recurrent glioblastoma treated with bevacizumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004974-27,0,0,0 2011-004977-10,2,2019-01-22,2019-01-22,1,1,0,0,0,0,0,0,0,2,0,0,0,0,0,"University Hospital Basel, Cardiology",Goal-directed Afterload Reduction in Acute Congestive Cardiac Decompensation Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004977-10,1,0,0 2011-004980-63,5,2015-07-01,2015-07-01,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd.,BOTOX® Treatment in Adult Patients with Post-Stroke Lower Limb Spasticity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004980-63,0,0,0 2011-004981-13,1,2013-01-11,2013-01-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Helsinn Healthcare SA,"Phase II, Double-blind, Randomized, Two-stage, Placebo-controlled Proof of Concept Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide (ZP1846) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004981-13,0,0,0 2011-004982-33,1,2013-05-07,2013-05-07,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,CytRx Corporation,"A Randomized, Placebo-Controlled Phase 2b Study of Tamibarotene Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin as First Line Treatment for Subjects with Advanced Non-Sm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004982-33,0,0,0 2011-004983-32,6,2014-04-17,2014-06-10,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,KOWA RESEARCH EUROPE LTD,"A 52-Week Open-Label Extension and Safety Study of Pitavastatin in High- Risk Hyperlipidaemia in Childhood, P/266/2011, P/267/2011, P/268/2011 Studio sull'estensione in aperto a 52 settimane e sul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004983-32,1,0,0 2011-004983-32,6,2014-04-17,2014-06-10,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Kowa Research Europe, Ltd.","A 52-Week Open-Label Extension and Safety Study of Pitavastatin in High- Risk Hyperlipidaemia in Childhood, P/266/2011, P/267/2011, P/268/2011 Studio sull'estensione in aperto a 52 settimane e sul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004983-32,1,0,0 2011-004984-55,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,SOCIETA' ITALIANA DI NEFROLOGIA,Controlled randomised interventional trial on the use of 25-OH D vitamin in haemodialysis patients. Trial di intervento randomizzato controllato sull`uso di 25(OH) vitamina D in pazienti in emodial...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004984-55,0,0,0 2011-004985-14,1,2017-05-22,2017-05-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sotio a.s.,"Randomized, open-label, parallel-group, multi-centre phase II clinical trial of active cellular immunotherapy DCVAC/PCa in patients with localized prostate cancer after primary radical prostatectomy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004985-14,0,0,0 2011-004986-34,1,2016-06-27,2016-06-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SOTIO a.s.,"Randomized, open-label, parallel-group, multi-centre phase II clinical trial with active cellular immunotherapy DCVAC/PCa in combination with hormone therapy in patients with metastatic prostate cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004986-34,0,0,0 2011-004988-68,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital General Universitario de Alicante,Saline solution versus Ringer lactate solution in the initial flluid therapy in the acute pancreatitis Suero fisiológico frente a Ringer Lactato en la fluidoterapia inicial de la pancreatitis aguda,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004988-68,0,0,0 2011-004989-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ghent University Hospital,The effect of morphine and different local anesthetics on human chondrocytes: an in vivo study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004989-16,0,0,0 2011-004990-10,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,Sahlgrenska Academy,"Double-blind placebo controlled study of the effects of OSU6162 on chronic fatigue in patients who suffered a mild traumatic brain injury Behandling av mental uttröttbarhet (""hjärntrötthet"") efter ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004990-10,0,0,0 2011-004994-94,7,2015-05-22,2015-05-22,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Corporation, Inc.","A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. difficile toxin B), and MK-341...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004994-94,0,0,0 2011-004994-94,7,2015-05-22,2015-05-22,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. difficile toxin B), and MK-341...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004994-94,0,0,0 2011-004994-94,7,2015-05-22,2015-05-22,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. difficile toxin B), and MK-341...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004994-94,0,0,0 2011-004995-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Erasmus MC,"Endovascular renal sympathetic denervation versus spironolactone for treatment-resistant hypertension: a randomized, multicentric study Endovasculaire renale sympathicusdenervatue versus spironolac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004995-13,0,0,0 2011-004996-35,1,2015-03-18,2015-03-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,Allopurinol as a possible new therapy for acute coronary syndromes: The Next Steps,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004996-35,0,0,0 2011-004997-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",Randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer Studio randomizzato di fase III sull'...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004997-27,0,0,0 2011-004998-83,1,2013-07-09,2013-07-09,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Merz Pharmaceuticals GmbH,"A Double-Blind, Randomized, Dose Selection Vehicle–Controlled Multicenter Clinical Study for Evaluation of the Safety, Tolerability, Efficacy, and Pharmacokinetics of topical Neramexane in Subjects wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004998-83,0,0,0 2011-005001-78,1,2015-03-28,2015-03-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Psychiatrie u. Psychotherapie, Abteil. für biologische Psychiatrie",Neural Correlates of SSRI Drug Response: Impact of Stress System Genes Neuronale Korrelate des Ansprechens auf eine Therapie mit SSRIs: Einflussnahme der im Stress-System involvierten genetischen V...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005001-78,0,0,0 2011-005002-30,1,2012-12-14,2012-12-14,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,ICORG-the All Ireland co-operative Oncology Research group,"Phase II Lap/Epi: Phase II evaluation of the combination of epirubicin and lapatinib in Her-2 positive, Topoisomerase II alpha positive, metastatic breast cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005002-30,0,0,0 2011-005003-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"VU University Medical Center, Department of Medical Oncology","A randomized multicenter clinical trial for patients with multi-organ, colorectal cancer metastases comparing the combination of chemotherapy and maximal tumor debulking versus chemotherapy alone.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005003-32,0,0,0 2011-005007-33,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,Laboratorios Biomendi S.A.U.,"A multicenter, randomized, double-blind, parallel groups, placebo-controlled trial to evaluate efficacy and safety of a new i.v. formulation of ibuprofen 800 mg every 6 hours in the management of post...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005007-33,0,0,0 2011-005008-14,1,2012-09-05,2012-09-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galapagos SASU,"Randomized, Double blind, Placebo-controlled, Multicenter, Phase II Study to Compare Four Dose Regimens of GLPG0634 Versus Placebo, in Combination With Methotrexate, Administered for 4 Weeks in the Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005008-14,0,0,0 2011-005011-93,1,2013-04-23,2013-04-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee and NHS Tayside,Use of diazoxide in hypoglycaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005011-93,0,0,0 2011-005011-93,1,2013-04-23,2013-04-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Tayside,Use of diazoxide in hypoglycaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005011-93,0,0,0 2011-005014-12,2,2014-07-15,2014-07-15,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Shionogi & Co., Ltd.","A Phase 1/2 Study to Evaluate the Safety, Tolerability, Immune Response, and Clinical Efficacy of Cancer Peptide Vaccine S-488210 in Patients with Unresectable Locoregionally Recurrent and/or Metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005014-12,0,0,0 2011-005015-82,1,,,0,1,1,0,0,1,3,0,0,4,0,0,0,0,1,Octapharma AG,Clinical study to evaluate the safety and tolerability of immunoglobulin intravenous (human) 10% (NewGam) administered at high infusion rates to patients with primary immunodeficiency diseases (extens...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005015-82,0,1,1 2011-005017-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,DIPAK Consortium,"A randomised, controlled clinical trial assessing the efficacy of Lanreotide to halt disease progression in ADPKD Een gerandomiseerde klinische studie die de effectiviteit van Lanreotide onderzoekt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005017-37,0,0,0 2011-005018-13,2,2014-02-04,2014-02-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharma A/S,"Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005018-13,0,0,0 2011-005019-96,8,2019-08-15,2019-08-15,7,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Amgen Inc,"A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005019-96,1,1,0 2011-005021-48,6,2012-08-01,2012-08-01,3,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Teva Pharmaceutical Industries,"A multicenter, double-blind, randomized, active controlled, parallel-group study to evaluate the efficacy, safety, tolerability and pharmacodynamic profiles of TL011 infusions compared with MabThera® ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005021-48,1,0,0 2011-005023-40,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,University of Birmingham,"ROMAZA: Phase I trial of combination therapy with romidepsin and azacitidine in patients with newly diagnosed, relapsed or refractory Acute Myeloid Leukaemia ineligible for conventional chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005023-40,0,0,0 2011-005026-21,1,2013-12-13,2013-12-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"KYTHERA Biopharmaceuticals, Inc.","Long-term, follow-up study of subjects who completed phase III trials ATX-101-10-16 or ATX-101-10-17 (sodium deoxycholate injection) for the reduction of localized subcutaneous fat in the submental ar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005026-21,0,0,0 2011-005029-31,1,2018-07-05,2018-07-05,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation systématique des troubles respiratoires au cours du sommeil chez l'enfant drépanocytaire : apport du traitement par Hydroxycarbamide lors de l'identification d'une hypoxémie isolée - essai ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005029-31,0,0,0 2011-005030-19,6,2013-10-31,2013-10-31,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Vectura Limited,"A randomised double-blind, parallel group, dose-ranging study to evaluate the efficacy and safety of three different total daily doses of fluticasone propionate inhaled from a new dry powder inhaler i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005030-19,0,0,0 2011-005031-96,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dr. Antonio Llombart Cussac,"?Estudio fase IIa, de farmacocinética y farmacodinámica, para confirmar el efecto inhibidor de temsirolimus sobre la vía mTOR en el cáncer de endometrio?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005031-96,0,0,0 2011-005032-26,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, open, randomized, controlled, multi-centre study to demonstrate the non-inferiority of the meningococcal serogroup C and the Haemophilus influenzae type b immune response of GlaxoSmithKli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005032-26,0,1,1 2011-005036-26,1,2012-06-14,2012-06-14,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Funxional Therapeutics Ltd,An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005036-26,0,0,0 2011-005037-39,1,2013-10-31,2013-10-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Lukács és Társa Gyógyszerkereskedelmi Betéti Társaság,"A Phase II Randomized, Controlled Parallel-Group Pilot Study to Assess the Safety and Efficacy of Kék Lukács Ointment Compared to Standard Silver Sulphadiazine (Dermazin®, SSD) Therapy in the Wound-he...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005037-39,0,0,0 2011-005040-10,4,2016-02-05,2016-09-09,2,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Prosensa Therapeutics BV,"A phase I/II, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple doses of PRO045 in subjects with Duchenne muscular dystrophy STUDIO IN APERTO DI FAS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005040-10,0,0,0 2011-005040-10,4,2016-02-05,2016-09-09,2,1,0,1,0,1,1,0,0,1,1,0,0,0,1,BioMarin Pharmaceutical Inc.,"A phase I/II, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple doses of PRO045 in subjects with Duchenne muscular dystrophy STUDIO IN APERTO DI FAS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005040-10,0,0,0 2011-005040-10,4,2016-02-05,2016-09-09,2,1,0,1,0,1,1,0,0,1,1,0,0,0,1,BioMarin Nederland B.V.,"A phase I/II, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple doses of PRO045 in subjects with Duchenne muscular dystrophy STUDIO IN APERTO DI FAS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005040-10,0,0,0 2011-005042-35,5,2016-09-09,2016-09-09,3,1,1,0,0,1,1,0,0,2,1,0,0,0,1,Prosensa Therapeutics BV,"A Phase I/II, open-label, dose escalating with 48 week treatment study to assess the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of BMN 053 (previously known as PRO053) in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005042-35,1,0,0 2011-005042-35,5,2016-09-09,2016-09-09,3,1,1,0,0,1,1,0,0,2,1,0,0,0,1,BioMarin Nederland B.V.,"A Phase I/II, open-label, dose escalating with 48 week treatment study to assess the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of BMN 053 (previously known as PRO053) in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005042-35,1,0,0 2011-005042-35,5,2016-09-09,2016-09-09,3,1,1,0,0,1,1,0,0,2,1,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Phase I/II, open-label, dose escalating with 48 week treatment study to assess the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of BMN 053 (previously known as PRO053) in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005042-35,1,0,0 2011-005045-13,1,2014-10-07,2014-10-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"An open-label, multi-center, 6-month extension study comparing the long-term efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implant i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005045-13,0,0,0 2011-005047-27,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,CIBERES (Centro de Investigación Biomédica en Red Enfermedades Respiratorias),"Estudio clínico aleatorizado, doble-ciego, controlado con placebo, para evaluar el efecto sobre la función endotelial de Roflumilast en pacientes con enfermedad pulmonar obstructiva crónica",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005047-27,0,0,0 2011-005049-11,7,2021-01-18,2021-01-18,5,1,0,0,0,2,3,0,0,2,0,0,0,0,1,Advanced Accelerator Applications,"A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005049-11,1,0,0 2011-005049-11,7,2021-01-18,2021-01-18,5,1,0,0,0,2,3,0,0,2,0,0,0,0,1,ADVANCED ACCELERATOR APPLICATIONS,"A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005049-11,1,0,0 2011-005054-59,1,2012-10-17,2012-10-17,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Biotie Therapies Inc.,"A double-blind, randomized, placebo-controlled study of the safety and efficacy of SYN115 as adjunctive therapy in levodopa-treated Parkinson’s subjects with end of dose wearing off",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005054-59,0,0,0 2011-005055-14,5,2013-04-08,2013-04-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Inc.,"A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005055-14,0,0,0 2011-005055-14,5,2013-04-08,2013-04-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GILEAD SCIENCE INC.,"A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005055-14,0,0,0 2011-005057-31,6,2017-09-18,2017-09-18,6,1,0,0,1,0,3,0,0,1,0,0,1,0,1,APOTEX Inc.,"A phase III, randomized, assessor-blinded, active-controlled, multicenter study of the efficacy and safety of APO-EPO as compared to Procrit® when given subcutaneously to patients with anemia of chron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005057-31,0,0,0 2011-005058-70,2,2013-03-14,2013-03-14,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,APOTEX Inc.,"A phase III, randomized, open-label, active-controlled, multicenter, correction phase study of the efficacy, safety, pharmacokinetics, and pharmacodynamics of APO-EPO (epoetin alfa) as compared to Epo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005058-70,0,0,0 2011-005059-15,1,2013-03-13,2013-03-13,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,uzleuven,"The effect of Buspirone on esophageal sensitivity in healthy volunteers: a randomized, double-blind, placebo-controlled, single-dosing study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005059-15,0,0,0 2011-005060-26,3,2014-10-02,2014-10-02,3,1,0,0,0,0,3,0,2,1,0,0,1,0,1,PURDUE PHARMA L.P.,"A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Effica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005060-26,0,0,0 2011-005060-26,3,2014-10-02,2014-10-02,3,1,0,0,0,0,3,0,2,1,0,0,1,0,1,Purdue Pharma L.P.,"A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Effica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005060-26,0,0,0 2011-005061-20,4,2014-10-09,2014-10-09,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Purdue Pharma L.P.,"A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Effica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005061-20,0,0,0 2011-005065-21,2,2013-10-02,2013-10-02,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Auxilium UK Limited,"Retreatment of recurrent contractures in joints effectively treated with AA4500 (collagenase clostridium histolyticum [XIAFLEX®/XIAPEX®]) in an Auxilium-sponsored Phase 3 Study in the United States, A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005065-21,0,0,0 2011-005066-38,1,2014-01-29,2014-01-29,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"A UK open-label, multicentre, exploratory Phase II study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005066-38,0,0,0 2011-005078-40,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,0,Statens Serum Institut,"A Phase III trial in subjects suspected to have tuberculosis, comparing the diagnostic performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in combination with a double blind randomised splitbody safe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005078-40,0,1,1 2011-005081-38,8,2018-11-23,2018-11-23,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,Phase III study of IV vinflunine in combination with methotrexate versus methotrexate alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck previously treated wit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005081-38,0,0,0 2011-005082-21,1,2016-10-15,2016-10-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Cologne,Targeted BEACOPP variants in patients with newly diagnosed advanced classical Hodgkin Lymphoma Targeted BEACOPP Varianten für Patienten mit Erstdiagnose eines fortgeschrittenen klassischen Hodgkin ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005082-21,0,0,0 2011-005085-37,5,2015-11-20,2015-11-20,3,1,0,1,0,1,1,0,1,1,1,0,0,0,1,Novartis Pharma Services AG,"A randomized, double blind placebo-controlled study to assess the safety, tolerability, pharmacokinetics and preliminary pharmacodynamics of single and multiple ascending doses of QBW251 in healthy su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005085-37,0,0,0 2011-005086-20,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Centre for Human Drug Research (CHDR),Effects of paracetamol on nociception in adolescents.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005086-20,0,0,0 2011-005090-22,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Southend Hospital,A study of efficacy and safety of delayed release prednisone in newly diagnosed cases of Giant Cell Arteritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005090-22,0,0,0 2011-005091-42,2,2016-07-27,2016-07-27,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Allergan Limited,"An Open Label (Stage 1) and Randomized (Stage 2), 24-Month Study of Safety and Efficacy of Bimatoprost Drug Delivery System in Patients With Open-Angle Glaucoma or Ocular Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005091-42,0,0,0 2011-005095-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,prospective randomized study Armyda Pro 240 studio prospettico randomizzato Armyda Pro 240,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005095-41,0,0,0 2011-005100-14,8,2013-07-02,2013-07-05,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, double-dummy, 4-week treatment, parallel-group study to evaluate the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in adul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005100-14,0,0,0 2011-005101-79,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur,Safety and Immunogenicity of a Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Child/Adolescent and Adult Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005101-79,0,1,1 2011-005102-30,1,2014-10-13,2014-10-13,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,University of Oxford,"A phase III randomised, open label clinical trial evaluating the immunogenicity of a 10-valent pneumococcal conjugate vaccine booster compared to the standard 13-valent pneumococcal conjugate vaccine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005102-30,0,0,0 2011-005103-32,7,2014-07-29,2014-10-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 2 Study of LY2127399 in Combination with Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005103-32,0,0,0 2011-005103-32,7,2014-07-29,2014-10-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ELI LILLY,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 2 Study of LY2127399 in Combination with Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005103-32,0,0,0 2011-005103-32,7,2014-07-29,2014-10-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 2 Study of LY2127399 in Combination with Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005103-32,0,0,0 2011-005107-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,dietary nutritional counseling or phosphate binders in the early stages of chronic kidney disease: effects on FGF 23 counselling dietetico-nutrizionale o chelante del fosforo nelle fasi precoci del...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005107-33,0,0,0 2011-005108-14,1,2012-08-24,2012-08-24,1,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A single- dose, open label, randomized, 3-way crossover, clinical pharmacology study of CHF 1535 100/6 pMDI (fixed combination of beclomethazone dipropionate 100 μg plus formoterol fumarate 6 μg) wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005108-14,0,0,0 2011-005109-56,8,2014-12-05,2014-12-05,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Recherche & Développement,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005109-56,0,0,0 2011-005111-91,1,2012-04-10,2012-04-10,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,CHU de Clermont-Ferrand,Effets de la prise d’une dose de charge de curcumine sur la vasoactivité artérielle du sujet fumeur sain âgé de 50 à 70 ans,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005111-91,0,0,0 2011-005114-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA USL DI FORLI',Switching from clopidogrel to prasugrel to protect early invasive treatment in acute coronary syndromes Switch da clopidogrel a prasugrel per migliorare il trattamento precocemente invasivo delle s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005114-11,0,0,0 2011-005115-82,7,2013-10-02,2013-12-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Santarus, Inc.","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX® 9 mg Extended-release Tablets as Add-on Therapy in Patients with Active, Mild or Modera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005115-82,0,0,0 2011-005116-28,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,3,,A phase I/II trial of Cabazitaxel +/- Rhenium-188 HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment. The ReCab trial ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005116-28,0,0,0 2011-005121-49,1,2016-03-17,2016-03-17,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Phase 2a Single-Arm Safety Study of Elotuzumab in Combination with Thalidomide and Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma Estudio de Fase 2a, de un solo grupo, d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005121-49,0,0,0 2011-005124-18,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,Leiden University Medical Center,Chronification and reversibility of migraine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005124-18,0,0,0 2011-005127-40,1,2012-11-13,2012-11-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Randomized, Double-Blind, Placebo- and Active Controlled Study of the Electrophysiological Effects of ABT-639 on Spontaneous Activity in C Nociceptors in Patients with Diabetic Peripheral Neuropathy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005127-40,0,0,0 2011-005132-26,14,2021-07-19,2021-07-19,11,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy Studio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005132-26,1,0,0 2011-005132-26,14,2021-07-19,2021-07-19,11,1,0,0,0,0,3,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy Studio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005132-26,1,0,0 2011-005134-19,1,2016-04-14,2016-04-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Birmingham,An open label pragmatic randomised controlled trial of nicotine patch preloading for smoking cessation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005134-19,0,0,0 2011-005136-25,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Matti Eskelinen,Rektustupen sisäinen katetripuudutus keskiviiva laparotomian jälkeisessä kivunhoidossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005136-25,0,0,0 2011-005138-21,1,2013-11-08,2013-11-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Targacept Inc.,"A double-blind, placebo-controlled, multicenter, parallel group study to assess efficacy, safety and tolerability of TC-5619 as augmentation therapy to improve negative symptoms and cognition in outpa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005138-21,0,0,0 2011-005145-12,1,2014-08-01,2014-08-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"University of Athens, Medical School","A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED CLINICAL TRIAL OF THE SAFETY AND EFFICACY OF ANAKINRA IN PATIENTS WITH HIDRADENITIS SUPPURATIVA (PROTOCOL: HIDRA03) ΜΙΑ ΔΙΠΛΗ ΤΥΦΛΗ, ΤΥΧΑΙΟΠΟΙΗΜΕΝΗ,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005145-12,0,0,0 2011-005150-62,2,2022-05-20,2022-05-20,1,0,0,1,0,0,1,0,0,2,0,0,0,0,0,LYSARC,A Phase Ib/II study of OBINUTUZUMAB combined with LENALIDOMIDE for the treatment of relapsed/refractory follicular and Aggressive (DLBCL and MCL) B-cell Lymphoma. Etude de phase Ib/II de l’Obinutuz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005150-62,1,0,0 2011-005150-62,2,2022-05-20,2022-05-20,1,0,0,1,0,0,1,0,0,2,0,0,0,0,0,GELARC,A Phase Ib/II study of OBINUTUZUMAB combined with LENALIDOMIDE for the treatment of relapsed/refractory follicular and Aggressive (DLBCL and MCL) B-cell Lymphoma. Etude de phase Ib/II de l’Obinutuz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005150-62,1,0,0 2011-005151-13,1,2013-08-14,2013-08-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Manchester,Open-label Pilot Study of Memantine in Chronic Cough Patients Attending a Specialist Clinic,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005151-13,0,0,0 2011-005151-13,1,2013-08-14,2013-08-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital of South Manchester,Open-label Pilot Study of Memantine in Chronic Cough Patients Attending a Specialist Clinic,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005151-13,0,0,0 2011-005152-34,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,José Miguel Cisneros Herreros,Randomized open label clinical trial directed to optimize the duration of empirical antimicrobial therapy in haematologic patients with febrile neutropenia Ensayo clínico abierto y aleatorizado par...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005152-34,0,0,0 2011-005154-57,5,2014-11-24,2015-10-13,4,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"An open-label extension study to assess efficacy, safety and tolerability of canakinumab and the efficacy and safety of childhood vaccinations in patients with Cryopyrin Associated Periodic Syndromes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005154-57,0,0,0 2011-005154-57,5,2014-11-24,2015-10-13,4,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label extension study to assess efficacy, safety and tolerability of canakinumab and the efficacy and safety of childhood vaccinations in patients with Cryopyrin Associated Periodic Syndromes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005154-57,0,0,0 2011-005155-14,4,2012-06-26,2012-06-26,1,1,1,0,0,0,2,0,0,2,1,0,0,0,1,sanofi-aventis Recherche et Développement,"An open-label, pharmacokinetic, pharmacodynamic, and tolerability study of AVE5026 administered at weight-adjusted doses to patients under 18 years of age with a Central Venous Line (CVL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005155-14,1,1,0 2011-005156-34,1,2020-08-02,2020-08-02,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,University College London,"Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for initial therapy of Waldenstrőm macroglobulinaemia: a randomised phase II stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005156-34,0,0,0 2011-005157-31,1,2015-07-31,2015-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA,"A phase II Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as treatment re-challenge in Patients, who have Epidermal Gro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005157-31,0,0,0 2011-005158-73,1,2016-05-18,2016-05-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GWT-TUD GmbH,Superficial vein thrombosis (SVT) treated for forty-five days with Rivaroxaban versus Fondaparinux,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005158-73,0,0,0 2011-005159-15,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","An Open-Label, Parallel-Group Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Doripenem in Pediatric Patients 3 Months to 17 Years of Age, Inclusive",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005159-15,0,1,1 2011-005160-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VU medical center,Hismys study. Misoprostol for cervical priming prior to hysteroscopy in postmenopausal and nulliparous premenopausal women; a multi-centre randomised placebo controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005160-23,0,0,0 2011-005161-20,1,2013-11-14,2013-11-14,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University College Dublin Clinical Research Centre,A Randomised Controlled Double-Blind Trial of Intranasal Fentanyl versus Intravenous Morphine in the Emergency Department Treatment of Severe Painful Sickle Cell Crises in Children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005161-20,0,0,0 2011-005165-21,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,University of Warwick,De-ESCALaTE HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus-positive oropha...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005165-21,0,0,0 2011-005165-21,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,VU University Medical Center,De-ESCALaTE HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus-positive oropha...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005165-21,0,0,0 2011-005167-24,2,2014-02-28,2014-02-28,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,PregLem S.A.,"A Phase II, Multicentre, Randomised, Two-Arm, Parallel Group, Double-Blind, Placebo controlled Study of the Steroid Sulfatase Inhibitor PGL2001 with concomitant administration of NETA (norethisterone ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005167-24,1,0,0 2011-005168-14,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Radboud University Nijmegen Medical Centre,Lean Body Mass as a determinant of docetaxel pharmacokinetics and toxicity (LEANDOC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005168-14,0,0,0 2011-005169-20,1,2014-04-15,2014-04-15,1,0,0,0,0,0,3,0,1,1,0,0,1,0,0,"Mech-Sense, Department og Gastroenterology, Aalborg Sygehus",Perifere opioid effekter,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005169-20,0,0,0 2011-005173-23,1,2013-10-28,2013-10-28,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics GmbH,"A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Different...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005173-23,0,0,0 2011-005174-27,1,2015-05-30,2015-05-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cliniques universitaires Saint Luc,Phase II study of High-Dose Rituximab in High Risk Chronic Lymphocytic Leukemia in Suboptimal Response after Induction Immunochemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005174-27,0,0,0 2011-005177-23,4,2013-11-15,2013-11-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB PHARMA SA/NV.,"An Open-Label, Multicenter, Single-Arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects with Epilepsy Switching from Levetiracetam to Brivaracetam due to Nonpsychoti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005177-23,0,0,0 2011-005177-23,4,2013-11-15,2013-11-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma SA,"An Open-Label, Multicenter, Single-Arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects with Epilepsy Switching from Levetiracetam to Brivaracetam due to Nonpsychoti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005177-23,0,0,0 2011-005178-43,7,2015-11-25,2015-11-30,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.","A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients with Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005178-43,0,0,0 2011-005178-43,7,2015-11-25,2015-11-30,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients with Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005178-43,0,0,0 2011-005178-43,7,2015-11-25,2015-11-30,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients with Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005178-43,0,0,0 2011-005179-18,4,2013-12-05,2013-12-11,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Forest Research Institute, Inc","A Double-blind, Placebo-controlled Study of Cariprazine (RGH-188) as Adjunctive Therapy In Major Depressive Disorder.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005179-18,0,0,0 2011-005180-24,2,2014-04-20,2014-05-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005180-24,0,0,0 2011-005186-20,14,2013-07-29,2014-12-22,13,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Corp.,A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects with Refractory Chronic Lymphocytic Leukemia (CLL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005186-20,0,0,0 2011-005186-20,14,2013-07-29,2014-12-22,13,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.",A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects with Refractory Chronic Lymphocytic Leukemia (CLL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005186-20,0,0,0 2011-005186-20,14,2013-07-29,2014-12-22,13,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects with Refractory Chronic Lymphocytic Leukemia (CLL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005186-20,0,0,0 2011-005186-20,14,2013-07-29,2014-12-22,13,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation.",A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects with Refractory Chronic Lymphocytic Leukemia (CLL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005186-20,0,0,0 2011-005187-25,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,SOCIETA' LABORATORIO FARMACEUTICO S.I.T. SRL,"Efficacy and tolerability clinical trial of an immunostimulant made from inactivated bacteria (BUCCALIN) in the prophylaxis of infection of the airways (rhinotracheobronchitis, colds). Double-blind mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005187-25,0,0,0 2011-005189-39,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,ICORG,"A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2 positive metastatic breast cancer. ICORG 11-10/TH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005189-39,0,0,0 2011-005189-39,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,All Ireland Cooperative Oncology Research Group (ICORG),"A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2 positive metastatic breast cancer. ICORG 11-10/TH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005189-39,0,0,0 2011-005189-39,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,ICORG -All Ireland Cooperative Oncology Research Group,"A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2 positive metastatic breast cancer. ICORG 11-10/TH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005189-39,0,0,0 2011-005189-39,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Cancer Trials Ireland,"A phase III randomized study of TH (Paclitaxel and Trastuzumab) versus THL (Paclitaxel, Trastuzumab and Lapatinib) in first line treatment of HER2 positive metastatic breast cancer. ICORG 11-10/TH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005189-39,0,0,0 2011-005194-23,3,2012-11-08,2012-11-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,ASTRAZENECA,"A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination with Paclitaxel versus Paclitaxel alone in Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005194-23,0,0,0 2011-005194-23,3,2012-11-08,2012-11-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AstraZeneca AB,"A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination with Paclitaxel versus Paclitaxel alone in Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005194-23,0,0,0 2011-005196-16,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,"Amylin Pharmaceuticals, Inc.",Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents with Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005196-16,0,1,1 2011-005197-40,2,2018-05-11,2018-05-11,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38MAPK Inhibitor, plus Gemcitabine and Carboplatin versus Gemcitabine and Carboplatin for Women with Platinum-Sensitive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005197-40,0,0,0 2011-005200-15,4,2013-09-03,2013-09-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients with Major Depressive Disorder.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005200-15,0,0,0 2011-005201-75,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Toulouse,Impact d’un traitement PREcoce par aMANtadine sur les DYSKinésies induites par la L-DOPA dans la maladie de Parkinson : étude comparative avec tirage au sort versus placebo.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005201-75,0,0,0 2011-005203-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,"A prospective, multicenter, open-label, patients with non-erosive gastroesophageal reflux disease (NERD) non-responders to therapy with PPIs Studio prospettico, multicentrico, in aperto, su pazient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005203-32,0,0,0 2011-005204-15,1,2020-11-19,2020-11-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Med Uni Graz, Univ. Klinik Innere Medizin,Abt. Rheumatologie und Immunologie",Ultrasound as biomarker for withdrawal of biological DMARDs in rheumatoid arthritis (RA-BioStop) Ultraschall als Biomarker für das Absetzen von biologischen DMARDs bei Patienten mit rheumatoider Ar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005204-15,0,0,0 2011-005205-71,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Leiden University,The effect of fludrocortisone on emotional information processing in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005205-71,0,0,0 2011-005205-71,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Leiden University Medical Center,The effect of fludrocortisone on emotional information processing in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005205-71,0,0,0 2011-005206-30,3,2013-01-28,2013-01-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-04937319 AND GLIMEPIRIDE IN ADULT PATIENTS WITH TYPE 2 DIABETES MELL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005206-30,0,0,0 2011-005207-32,1,,,0,1,0,0,0,1,2,0,0,3,0,0,0,0,0,The University of Birmingham,Phase II Randomised Trial of 5-Azacitidine versus 5-Azacitidine in combination with Vorinostat in patients with Relapsed Acute Myeloid Leukaemia ineligible for Intensive Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005207-32,0,0,0 2011-005208-14,1,2013-07-09,2013-07-09,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Norfolk and Norwich University Hospitals NHS Foundation Trust,Innovative Gel Aid for Administering Tablets to Stroke and Other Dysphagic Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005208-14,0,0,0 2011-005210-11,11,2019-11-21,2019-11-21,10,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Bayer HealthCare AG,"A Phase II/III, multicenter, partially randomized, open label trial investigating safety and efficacy of on-demand and prophylactic treatment with BAY 94-9027 in Severe Hemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005210-11,1,1,0 2011-005210-11,11,2019-11-21,2019-11-21,10,1,1,0,0,1,2,0,0,2,0,0,0,0,1,BAYER HEALTHCARE AG,"A Phase II/III, multicenter, partially randomized, open label trial investigating safety and efficacy of on-demand and prophylactic treatment with BAY 94-9027 in Severe Hemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005210-11,1,1,0 2011-005210-11,11,2019-11-21,2019-11-21,10,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Bayer AG,"A Phase II/III, multicenter, partially randomized, open label trial investigating safety and efficacy of on-demand and prophylactic treatment with BAY 94-9027 in Severe Hemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005210-11,1,1,0 2011-005214-11,1,2019-01-07,2019-01-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,GBG Forschungs GmbH,Neo- / adjuvant phase III trial to compare intense dose-dense chemotherapy to tailored dose-dense chemotherapy in patients with high-risk early breast cancer (GAIN-2 trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005214-11,0,0,0 2011-005215-86,1,2018-08-16,2018-08-16,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"Clovis Oncology, Inc.","A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-small Cell Lung Cancer (NSCLC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005215-86,0,0,0 2011-005216-28,3,2012-08-22,2012-08-22,2,1,0,0,1,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline,"A Multicenter, Randomized, Single-blind, Active-controlled, Parallel Group, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of a Single Intravenous (6 mg, 12 mg, 18 mg, 24 mg or 36 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005216-28,0,0,0 2011-005217-37,3,2013-06-13,2013-06-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,ELI LILLY AND COMPANY,"Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Valutazione della sicu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005217-37,0,0,0 2011-005217-37,3,2013-06-13,2013-06-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Eli Lilly and Company,"Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Valutazione della sicu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005217-37,0,0,0 2011-005218-13,1,2016-02-04,2016-02-04,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,Kings College London,"Rationalisation of antipsychotic drug use in older people, using [18F]-Fallypride PET",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005218-13,0,0,0 2011-005218-13,1,2016-02-04,2016-02-04,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,South London and Maudsley NHS Foundation Trust,"Rationalisation of antipsychotic drug use in older people, using [18F]-Fallypride PET",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005218-13,0,0,0 2011-005219-98,5,2016-06-29,2016-08-08,3,0,0,0,0,0,3,0,0,1,1,1,1,0,1,"Galena Biopharma, Inc","Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005219-98,0,0,0 2011-005224-18,1,,,0,1,0,0,1,0,3,0,0,1,0,0,0,1,1,GWT-TUD GmbH,Intravenous Ferric Carboxymaltose for improvement of metabolic parameters and vascular function in T2DM patients with iron deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005224-18,0,0,0 2011-005225-40,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,Bristol-Myers Squibb Company,"A Randomized, Multi-Center, Parallel Group, Single-Dose, Pharmacokinetics and Pharmacodynamics Study of Dapagliflozin in Children and Adolescents Aged 10 to 17 Years with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005225-40,0,1,1 2011-005226-21,7,2014-04-17,2014-04-29,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT,"A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated with Ruxolitinib and with a Current Diagnosis of Intermediate-2 or High-Risk Primary Myelofibrosis, P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005226-21,0,0,0 2011-005226-21,7,2014-04-17,2014-04-29,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Sanofi-aventis Recherche & Développement,"A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated with Ruxolitinib and with a Current Diagnosis of Intermediate-2 or High-Risk Primary Myelofibrosis, P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005226-21,0,0,0 2011-005228-17,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Kalmar County Council,Can treatment with vitamin D lower the incidence of osteoporosis in anorexia? Kan behandling med D-vitamin minska förekomsten av osteoporos vid anorexi?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005228-17,0,0,0 2011-005230-18,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,NCIC Clinical Trials Group,A Phase III randomized trial of metformin versus placebo on recurrence and survival in early stage breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005230-18,0,0,0 2011-005234-19,1,2014-01-25,2014-01-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Blodbanken, Rigshospitalet",The effect of prostacyclin on haemostasis as evaluated by thrombelastography and endothelial markers in patients undergoing major abdominal surgery. A pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005234-19,0,0,0 2011-005235-22,4,2015-05-01,2015-05-01,1,0,0,0,0,0,3,0,0,2,0,0,0,0,2,Monash University,"A randomised, placebo-controlled trial of erythropoietin in ICU patients with traumatic brain injury: Erythropoietin in Traumatic Brain Injury",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005235-22,1,0,0 2011-005235-22,4,2015-05-01,2015-05-01,1,0,0,0,0,0,3,0,0,2,0,0,0,0,2,MONASH UNIVERSITY,"A randomised, placebo-controlled trial of erythropoietin in ICU patients with traumatic brain injury: Erythropoietin in Traumatic Brain Injury",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005235-22,1,0,0 2011-005236-25,1,2015-06-16,2015-06-16,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Umeå University,A phase II multicenter pilot study of the safety and efficacy of Doxycycline/UrsoDeoxyCholicAcid on disease progression in ATTR amyloidosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005236-25,0,0,0 2011-005238-21,2,2016-03-23,2016-03-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"12 month, multi-center, open-label, prospective, randomized, parallel group study investigating a standard regimen in de novo kidney transplant patients versus a Certican® based regimen either in comb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005238-21,0,0,0 2011-005239-14,1,2016-09-14,2016-09-14,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Pertti Suominen,Stressikortisonihoidon merkitys lasten avosydänkirurgiassa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005239-14,0,0,0 2011-005240-10,1,2014-11-26,2014-11-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Imperial College London,"A phase II, open label, preoperative study to assess the efficacy of the novel steroid sulfatase inhibitor Irosustat in postmenopausal women with early oestrogen receptor positive breast cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005240-10,0,0,0 2011-005243-28,7,2012-09-05,2021-04-22,3,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Janssen-Cilag International NV,"A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005243-28,1,0,0 2011-005244-95,3,2013-02-05,2013-02-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A multi-national, randomized, double-blind, placebo-controlled, 3-period crossover study with GSK 573719 as monotherapy in adult subjects with asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005244-95,0,0,0 2011-005248-81,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Differentiated thyroid cancer: metabolic radiotherapy with high activity of radioiodine calculated by individual pre-therapy dosimetry Carcinoma tiroideo differenziato: radioterapia metabolica con ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005248-81,0,0,0 2011-005249-12,15,,,0,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Genzyme Corporation,"A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005249-12,0,1,0 2011-005249-12,15,,,0,1,1,0,0,0,3,0,0,2,0,0,0,0,1,GENZYME CORPORATION,"A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005249-12,0,1,0 2011-005251-13,13,2018-04-10,2018-04-10,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Amgen Inc,"A Randomized, Double blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Ulcerative Colitis Studio rand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005251-13,0,0,0 2011-005251-13,13,2018-04-10,2018-04-10,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AMGEN INC.,"A Randomized, Double blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Ulcerative Colitis Studio rand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005251-13,0,0,0 2011-005254-53,1,2013-02-01,2013-02-01,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Menarini Ricerche S.p.A,"A double-blind, randomised, placebo controlled, sequential ascending dose study, to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single intra-articular doses of fasitib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005254-53,0,0,0 2011-005256-34,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Erasmus MC,Sumatriptan non-responders: evaluation of a possible biomarker Sumatriptan non-responders: evaluatie van een mogelijke biomarker,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005256-34,0,0,0 2011-005257-31,2,,,0,1,1,0,0,0,2,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2 Multi-Center, Randomized Conversion Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belatacept Administered to Pediatric Subjects with a Stable Renal Transplant Revised prot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005257-31,0,1,0 2011-005258-70,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Fundación Universidad de Salamanca,"Ensayo clínico fase I/II prospectivo, abierto, no aleatorizado de tratamiento de la osteonecrosis de la cabeza femoral mediante la administración de células mesenquimales autólogas.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005258-70,0,0,0 2011-005260-20,1,2014-10-21,2014-10-21,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Roche Products Limited,"Randomised, Phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (MTX) dosage versus maintaining the dosage in patients with severe active rheum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005260-20,0,0,0 2011-005267-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO,A multi-center phase II randomized study of CustOmized Neoadjuvant ThErapy vs Standard chemoTherapy in non-small cell lung cancer (NSCLC) patients with resectable stage IIIA (N2) disease (CONTEST tria...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005267-24,0,0,0 2011-005270-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI,HIV-infected pregnant women treated with HAART: registry of pharmacokinetic parameters of new and commonly used antiretrovirals DONNE CON INFEZIONE DA HIV TRATTATE CON HAART: REGISTRO DEI PARAMETR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005270-35,0,0,0 2011-005271-16,1,2018-02-28,2018-02-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee & NHS Tayside,Does oral sodium bicarbonate therapy improve function and quality of life in older patients with chronic kidney disease and low-grade acidosis? A multicentre randomized placebo controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005271-16,0,0,0 2011-005273-23,1,2018-12-17,2018-12-17,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Liverpool Heart and Chest Hospital,HEAT-PPCI - How Effective are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention - A randomised controlled trial to compare unfractionated heparin versus bivalirudin in the treatme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005273-23,0,0,0 2011-005274-30,3,2020-02-28,2020-02-28,3,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Université catholique de Louvain,Efficacy and safety of a Double Icodextrin Dose in elderly incident CAPD patients on incremental Peritoneal Dialysis therapy: the DIDo study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005274-30,0,0,0 2011-005275-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Radio-guided minimally invasive resection of early colon cancer Resezione chirurgica mini invasiva radio-guidata dei tumori del colon in stadio iniziale,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005275-16,0,0,0 2011-005279-18,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Birmingham,A RandoMised study of best Available therapy versus JAK Inhibition in patients with high risk Polycythaemia Vera or Essential Thrombocythaemia who are resistant or intolerant to HydroxyCarbamide.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005279-18,0,0,0 2011-005280-24,9,2016-04-12,2016-09-01,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A double-blind, randomized, multicenter, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005280-24,0,0,0 2011-005280-24,9,2016-04-12,2016-09-01,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,NOVARTIS PHARMA AG,"A double-blind, randomized, multicenter, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 0.5 mg fingolimod administered orally once daily versus placebo in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005280-24,0,0,0 2011-005285-38,4,2019-01-31,2019-01-31,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Astellas Pharma Global Devlopment, Inc.","A randomized Phase II multicenter, Open Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination with the EOX (Epirubicin, Oxaliplatin, Capecitabine) regimen as First-Line Treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005285-38,0,0,0 2011-005285-38,4,2019-01-31,2019-01-31,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Astellas Pharma Global Development Inc.,"A randomized Phase II multicenter, Open Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination with the EOX (Epirubicin, Oxaliplatin, Capecitabine) regimen as First-Line Treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005285-38,0,0,0 2011-005287-21,7,2018-03-16,2018-03-16,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Long-Term Follow-up Study of Subjects Who Participated in A Clinical Trial in Which BMS-650032 and/or BMS-790052 Was Administered for the Treatment of Chronic Hepatitis C + Administrative Letter ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005287-21,0,0,0 2011-005287-21,7,2018-03-16,2018-03-16,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Long-Term Follow-up Study of Subjects Who Participated in A Clinical Trial in Which BMS-650032 and/or BMS-790052 Was Administered for the Treatment of Chronic Hepatitis C + Administrative Letter ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005287-21,0,0,0 2011-005289-39,1,2013-06-30,2013-06-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Radboud university medical center,Efficacy and safety of delta-9-tetrahydrocannabinol (delta-THC) in behavioural disturbances and pain in dementia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005289-39,0,0,0 2011-005292-17,2,2013-03-11,2013-03-11,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,TauRx Therapeutics Ltd,"A Double-Blind, Placebo-Controlled, Randomised, 4-Week Safety and Tolerability Study of LMTM in Subjects with Mild to Moderate Alzheimer’s Disease on Pre-Existing Stable Acetylcholinesterase Inhibitor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005292-17,0,0,0 2011-005293-31,9,2014-10-20,2014-11-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which Peginterferon Lambda-1a (BMS-914143) was Administered for the Treatment of Chronic Hepatitis C Revised Protocol 01...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005293-31,0,0,0 2011-005293-31,9,2014-10-20,2014-11-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which Peginterferon Lambda-1a (BMS-914143) was Administered for the Treatment of Chronic Hepatitis C Revised Protocol 01...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005293-31,0,0,0 2011-005296-16,1,2014-10-10,2014-10-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Medical Center Hamburg-Eppendorf,Capecitabine and bevacizumab with radiotherapy after 3-6 months chemotherapy for patients with oligometastatic colorectal cancer (OLGA trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005296-16,0,0,0 2011-005297-36,3,2012-11-16,2012-11-16,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An 8-week randomized, open label, multi-center study to evaluate the efficacy and safety of oral aliskiren 300 mg once daily under light meal versus fasted condition in patients with hypertension ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005297-36,0,0,0 2011-005297-36,3,2012-11-16,2012-11-16,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An 8-week randomized, open label, multi-center study to evaluate the efficacy and safety of oral aliskiren 300 mg once daily under light meal versus fasted condition in patients with hypertension ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005297-36,0,0,0 2011-005297-36,3,2012-11-16,2012-11-16,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Farmaceutica SA,"An 8-week randomized, open label, multi-center study to evaluate the efficacy and safety of oral aliskiren 300 mg once daily under light meal versus fasted condition in patients with hypertension ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005297-36,0,0,0 2011-005298-22,3,2014-02-05,2014-02-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd,"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects with Major Depressive Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005298-22,0,0,0 2011-005298-22,3,2014-02-05,2014-02-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Development Centre Europe Ltd.,"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects with Major Depressive Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005298-22,0,0,0 2011-005300-15,1,2014-02-28,2014-02-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Hvidovre,Treatment of Granuloma Umbilical in newborn babies - comparison of treatment with Silver Nitrate versus alcohol swaps versus steroid creme group IV. Behandling af navlegranulom hos spædbørn - samme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005300-15,0,0,0 2011-005303-32,1,2014-06-03,2014-06-03,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Nederland bv,Effects of bosentan in a HOMogenEous population of SSc subjects with an early or active SSc nailfold capillaroscopic pattern (HOME II) Effecten van bosentan in een homogene populatie van sclerode...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005303-32,0,0,0 2011-005305-73,1,2016-02-24,2016-02-24,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Medical Center of the Johannes Gutenberg-University Mainz,"Effects of clopidogrel vs prasugel vs ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting. A randomis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005305-73,0,0,0 2011-005307-33,4,2013-10-08,2013-10-08,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"Exploratory study of L.S.E.S.r. (PERMIXON 160 mg hard capsule) versus Tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH; a multinational, multicent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005307-33,0,0,0 2011-005316-28,2,2013-09-24,2013-09-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind, parallel group, placebo controlled, study in patients with non-chronic migraine to assess the efficacy, safety and tolerability of BID oral doses of BGG492 in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005316-28,0,0,0 2011-005317-37,2,2012-07-17,2012-07-17,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Thrombotech Ltd.,"Double blind, placebo controlled, escalating single-dose, pilot study to assess the safety of THR-18 when administered to patients suffering acute ischemic stroke and treated with tPA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005317-37,1,0,0 2011-005318-12,1,2015-01-12,2015-01-12,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,Phase 1 study of use of 5% Carbogen in treatment of paediatric non-convulsive status epilepticus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005318-12,0,0,0 2011-005320-17,1,2014-10-03,2014-10-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Effects of agomelatine versus escitalopram on emotional experiences in outpatients suffering from Major Depressive Disorder. An exploratory, randomised, double-blind, international, multicentre study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005320-17,0,0,0 2011-005321-51,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Parque Científico de la Universidad de Valladolid,Treatment of osteoarthritis with allogeneic mesenchymal cells (MSV *). Tratamiento de la gonartrosis con células mesenquimales alogénicas (MSV*). *MSV: Células mesenquimales estromales de la médul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005321-51,0,0,0 2011-005322-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,A Phase II Study exploring the feasibility of Azacitidine and Lenalidomide use (combination vs sequential treatment) for Higher-Risk Myelodysplastic Syndromes (MDS) (IPSS Risk: High or INT-2) Studi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005322-22,0,0,0 2011-005327-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Clinical trial randomized and controlled to compare the analgesic efficacy of the association zoledronic acid and 153Sm-lexidronam vs zoledronic acid in patients with skeletal metastases from hormono-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005327-41,0,0,0 2011-005328-17,19,2020-02-02,2020-02-19,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS ADJUVANT THERAPY I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005328-17,0,0,0 2011-005328-17,19,2020-02-02,2020-02-19,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS ADJUVANT THERAPY I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005328-17,0,0,0 2011-005329-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,G.I.M.EM.A.Gruppo Italiano Malattie Ematologiche dell'Adulto,"Phase 2 multicenter study to assess the efficacy and the safety of front-line Fludarabine, Cyclophosphamide and Ofatumumab (FCO2) chemoimmunotherapy in young (≤65 yrs) patients with Chronic Lymphocyti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005329-27,0,0,0 2011-005330-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,Prospective randomized study to evaluate the efficacy of different protocols IN DRUG PREVENTION OF BRAIN DAMAGE AFTER Carotid angioplasty with stent implantation (CAROTID ARMYDA trial). STUDIO PR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005330-18,0,0,0 2011-005333-39,1,2014-01-17,2014-01-17,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,National and Kapodistrial University of Athens,The effects of acute sildenafil administration on inflammatory markers in patients with vasculogenic erectile dysfunction. Η οξεία επίδραση της σιλδεναφίλης σε φλεγμονώδεις δείκτες σε ασθενείς με α...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005333-39,0,0,0 2011-005334-20,17,2019-09-11,2019-09-20,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2- positive advanced (metastatic or locally recurrent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005334-20,0,0,0 2011-005334-20,17,2019-09-11,2019-09-20,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2- positive advanced (metastatic or locally recurrent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005334-20,0,0,0 2011-005335-97,5,2017-11-21,2017-11-21,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of bevacizumab, and associated biomarkers, in combination with paclitaxel compared wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005335-97,0,0,0 2011-005335-97,5,2017-11-21,2017-11-21,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,F. Hoffmann-La Roche Ltd,"A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of bevacizumab, and associated biomarkers, in combination with paclitaxel compared wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005335-97,0,0,0 2011-005336-25,1,2014-06-14,2014-06-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Chemische Fabrik Kreussler & Co. GmbH,"A randomiszed, mono-center, placebo-controlled, double-blind, comparative study to evaluate the efficacy and safety of Dynexan® Mundgel in minors with acute painful sites of the mouth.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005336-25,0,0,0 2011-005339-15,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Omnivision GmbH,"Open, Observer-blind, two Parallel Group, Randomized, Multicentric Clinical Phase III Trial on the Comparison of Efficacy and Tolerability of a New Preservative-free Formulation of the Fixed Combinati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005339-15,0,0,0 2011-005343-27,1,2013-12-05,2013-12-05,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,Can metformin prevent endothelial ischemia and reperfusion injury? The Metformin-FMD trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005343-27,0,0,0 2011-005344-95,1,2014-06-01,2014-06-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Steno Diabetes Center,Time course of the blood pressure lowering effect of liraglutide therapy in type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005344-95,0,0,0 2011-005360-22,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,Vasa HVC,Does melatonin (CircadinR) worsen glucose tolerance in individuals with at (rs10830963) variant in the melatonin receptor 1B (MTNR1B) gene? Försämrar behandling med melatonin (CircadinR) glukostole...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005360-22,0,0,0 2011-005361-20,1,2018-08-29,2018-08-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Leeds,"A Phase II Trial of combination treatment with Vorinostat, Bortezomib and Dexamethasone in participants with Relapsed Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005361-20,0,0,0 2011-005363-24,1,2015-06-03,2015-06-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London,Vasopressin vs Noradrenaline as Initial therapy in Septic Shock,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005363-24,0,0,0 2011-005366-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Ambulance Service, Stockholm City Council",Treatment of pain in Ambulance Services with Sufenta® nasally compared to Morfin® intravenously.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005366-38,0,0,0 2011-005368-55,1,2013-01-06,2013-01-06,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Professor Joergen Berg Dahl,Effekten af Adductor-Kanal-Blokade på smerter hos patienter med VAS>60 ved aktiv knæfleksion 1. eller 2. postoperative døgn efter knæalloplastik,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005368-55,0,0,0 2011-005371-16,1,2015-02-03,2015-02-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Rigel Pharmaceuticals, Inc.",Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005371-16,0,0,0 2011-005372-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación FISEVI,"Open-label, phase III, randomized, clinical trial to evaluate the efficacy of two different HBV vaccination schemes in patients with hepatic cirrhosis candidates to liver transplantation (HEPATOTRAS) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005372-42,0,0,0 2011-005374-33,1,2014-06-26,2014-06-26,1,1,1,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur,Safety and Immunogenicity of the Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Children Aged 3 to 8 Years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005374-33,0,0,0 2011-005375-16,3,2013-10-31,2015-03-10,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Institut Produits Synthèse (IPSEN) AB,"A PHASE III PROSPECTIVE, MULTI-CENTER, RANDOMISED, EVALUATOR-BLINDED STUDY TO COMPARE NEUROMUSCULAR JUNCTION (NMJ) TARGETED TECHNIQUE FOR DYSPORT INJECTIONS IN UPPER LIMB SPASTICITY POST STROKE OR TRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005375-16,0,0,0 2011-005376-42,4,2013-08-26,2013-08-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy of NNC0114-0006 in subjects with active rheumatoid arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005376-42,0,0,0 2011-005377-23,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Guillem Cuatrecasas Cambra,"A phase II, single-center, prospective, randomized, double-blind, parallel and placebo-controlled pilot clinical study to assess the efficacy and safety of NUTROPIN® in combination with intensive reha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005377-23,0,0,0 2011-005378-44,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,LUMC,CONgenital Cmv: Efficacy of antiviral treatment in a Randomized controlled Trial CONgenitale Cmv: Effectiviteit van antivirale therapie in een geRandomiseerde gecontroleerd Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005378-44,0,0,0 2011-005384-24,2,2013-05-21,2013-05-21,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Auris Medical AG,TACTT1 Comparison of Single versus Repeat Doses of AM-101 in the Treatment of Acute Inner Ear Tinnitus Vergleich von Einzel- und Mehrfach-Dosierung von AM-101 bei der Behandlung von akutem Innen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005384-24,0,0,0 2011-005389-39,4,2013-04-25,2013-06-07,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A phase-II, double-blind, placebo-controlled, randomised, parallel-group,multi-centre study to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423 or twice daily ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005389-39,0,0,0 2011-005389-39,4,2013-04-25,2013-06-07,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA,"A phase-II, double-blind, placebo-controlled, randomised, parallel-group,multi-centre study to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423 or twice daily ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005389-39,0,0,0 2011-005392-16,1,2013-01-31,2013-01-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Dr Josep Ordi Ros,Study to evaluate the efficacy and safety of Anakinra in the treatment of articular manifestations refractory to conventional therapy in Systemic Lupus Erythematosus patients ESTUDIO PARA EVALUAR L...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005392-16,0,0,0 2011-005393-32,13,2015-05-25,2017-05-08,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV) i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005393-32,0,0,0 2011-005393-32,13,2015-05-25,2017-05-08,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Abbott GmbH & Co. KG,"An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination with Peginterferon α-2a and Ribavirin (pegIFN/RBV) i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005393-32,0,0,0 2011-005397-34,1,2015-03-01,2015-03-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Bristol NHS Foundation Trust,Xenon and cooling therapy in babies at high risk of brain injury following poor condition at birth: Randomised pilot study. (CoolXenon2 study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005397-34,0,0,0 2011-005398-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"ARAFARMA GROUP, S.A.","A randomized, multicenter, double-blind, double dummy and parallel study to evaluate the efficacy of the combination of Chondroitin sulfate and Glucosamine hydrochloride in a single dose chewable tabl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005398-22,0,0,0 2011-005399-40,6,2014-01-31,2014-01-31,3,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Amgen Inc,"A two part, Phase 2/3 Study to Assess the Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia Part A - Open-label, Single-arm, Multicenter Pilot Stu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005399-40,1,1,0 2011-005400-15,7,2018-05-07,2018-05-11,6,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 145 on LDL-C in Subjects With Severe Familial Hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005400-15,0,0,0 2011-005403-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA CARDARELLI,"Studio controllato, randomizzato, di fase II di trattamento neoadiuvante con Sorafenib prima dell'ablazione termica dell'epatocarcinoma di diamentro superiore ai 4 cm Studio controllato, randomizza...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005403-33,0,0,0 2011-005405-78,1,2014-11-07,2014-11-07,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Steen Bendix Haugaard,Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes Effekt af liraglutid og metformin på betacellen og hjertet hos k...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005405-78,0,0,0 2011-005408-13,2,2015-03-09,2015-03-12,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.","A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005408-13,0,0,0 2011-005408-13,2,2015-03-09,2015-03-12,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Ambit BioSciences Corporation,"A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005408-13,0,0,0 2011-005409-65,5,2014-10-09,2014-10-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatitis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005409-65,0,0,0 2011-005409-65,5,2014-10-09,2014-10-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Phase 3 Evaluation of Daclatasvir in Combination with Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination with Peginterferon Alfa-2a and RBV in Patients with Chronic Hepatitis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005409-65,0,0,0 2011-005414-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,The Nordic Myeloproliferative Neoplasm Group,Nordic Study of Multiferon® in Early-Stage Primary Myelofibrosis - a Multicentre Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005414-10,0,0,0 2011-005419-10,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,PH&T SPA,EVALUATION OF THE THERAPEUTIC EQUIVALENCE OF TRAVOPROST PR AND TRAVATAN. DOUBLE BLIND RANDOMIZED CLINICAL TRIAL IN SUBJECTS AFFECTED BY GLAUCOMA OR INTRAOCULAR HYPERTENSION. EVALUATION OF THE THER...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005419-10,0,0,0 2011-005422-21,6,2013-12-09,2013-12-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterfero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005422-21,0,0,0 2011-005422-21,6,2013-12-09,2013-12-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterfero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005422-21,0,0,0 2011-005433-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI,PHASE II OPEN STUDY ABOUT THE EFFECTIVENESS OF FENOFIBRATE AS ADD ON THERAPY FOR DRUG RESISTANT NOCTURNAL FRONTAL LOBE EPILEPSY (FNLE) . STUDIO DI EFFICACIA IN APERTO DI FASE II SULL' IMPIEGO DEL F...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005433-39,0,0,0 2011-005435-98,1,2016-09-05,2016-09-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Śląski Uniwersytet Medyczny w Katowicach,"A randomized, prospective, double-blind study with placebo to evaluate the efficacy of treatment of patients with angina resistant to pharmacological treatment and induced myocardial ischemia without...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005435-98,0,0,0 2011-005436-26,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Fédération Francophone de Cancérologie Digestive,Etude de phase I-II de radiochimiothérapie associée au panitumumab dans le traitement des carcinomes épidermoïdes localisés de l'anus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005436-26,0,0,0 2011-005437-39,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jules Bordet Institute,A phase II prospective imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT and an early FDG-PET/CT response to identify patients with advanced HER-2 positiv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005437-39,0,0,0 2011-005438-20,1,2016-04-30,2016-04-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Tampere,Effects of short-term atorvastatin treatment on prostate cancer - a pre-surgical pilot trial Lyhytaikaisen atorvastatiinin käytön vaikutus eturauhassyöpään - pilottitutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005438-20,0,0,0 2011-005439-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dept of Renal medicine,"A randomised, double-blind study to investigate the effects of intramuscular testosterone undecanoate (Nebido®) on anemia treatment in testosterone deficient men undergoing hemodialysis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005439-20,0,0,0 2011-005440-98,1,2013-12-19,2013-12-19,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,AKH Linz,Double blinded randomised trial for the evaluation of the effectiveness of prophylactic use of sildenafil for the prevention of pulmonary hypertensive crisis after congenital heart surgery Doppelbl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005440-98,0,0,0 2011-005441-13,3,2016-02-15,2019-02-15,2,0,0,0,0,0,2,0,0,2,0,0,0,0,0,INSERM,Evaluation of efficacy and safety of autologous MSCs combined to biomaterials to enhance bone healing in patients with delayed consolidation after long bone fracture requiring graft apposition or alt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005441-13,1,0,0 2011-005441-13,3,2016-02-15,2019-02-15,2,0,0,0,0,0,2,0,0,2,0,0,0,0,0,INSERM - Institut National de la Sant� et de la Recherche m�dicale,Evaluation of efficacy and safety of autologous MSCs combined to biomaterials to enhance bone healing in patients with delayed consolidation after long bone fracture requiring graft apposition or alt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005441-13,1,0,0 2011-005446-35,7,2014-09-29,2014-09-29,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3 Study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005446-35,0,0,0 2011-005446-35,7,2014-09-29,2014-09-29,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3 Study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005446-35,0,0,0 2011-005448-87,2,2015-03-27,2015-03-27,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF THE MAINTENANCE OF EFFICACY OF ETANERCEPT PLUS DMARD(S) COMPARED WITH DMARD(S) ALONE IN SUBJECTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING AN ADE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005448-87,0,0,0 2011-005449-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,prospective randomized ARMYDA RELOAD-ACS Studio prospettico randomizzato ARMYDA RELOAD-ACS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005449-11,0,0,0 2011-005450-60,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma Studio di Fase 3, randomizzato, in aperto su A+AVD rispetto ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005450-60,0,0,0 2011-005450-60,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Takeda Development Center (TDC) Americas, Inc.","A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma Studio di Fase 3, randomizzato, in aperto su A+AVD rispetto ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005450-60,0,0,0 2011-005450-60,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Millennium Pharmaceuticals, Inc","A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma Studio di Fase 3, randomizzato, in aperto su A+AVD rispetto ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005450-60,0,0,0 2011-005451-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"University Hospital, Grenoble",Micafungine versus placebo au cours du sepsis nosocomial chez des patients multi-colonisés à candida : Essai randomisé contrôlé EMPIRICUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005451-14,0,0,0 2011-005452-34,4,2014-05-14,2014-05-14,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Shire Development LLC,"A Phase 4, Randomised, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 Compared with OROS-MPH with a Placebo Referance Arm, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005452-34,0,0,0 2011-005456-33,1,2017-11-17,2017-11-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Med. Univ. Wien, Universitätsklinik für Kinder- und Jugendheilkunde",PREVENTING CHOLESTASIS IN PREMATURE INFANTS USING SMOFLIPID,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005456-33,0,0,0 2011-005457-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UZBrussel Department of Anesthesiology and Perioperative Medicine; Acute and Chronic Pain Therapy,The effect of the combination of midazolam with Ropivacaine in loco-regional anesthesia. Het effect van de combinatie van Ropivacaïne met Midazolam bij loco-regionale anesthesie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005457-31,0,0,0 2011-005461-21,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,FONDAZIONE ITALIANA LINFOMI ONLUS,"BENDAMUSTINE, LENALIDOMIDE AND RITUXIMAB (R2-B)COMBINATION AS A SECOND-LINE THERAPY FOR FIRST RELAPSED-REFRACTORY MANTLE CELL LYMPHOMAS: A PHASE II STUDY STUDIO DI FASE II SULL'USO COMBINATO DI BEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005461-21,0,0,0 2011-005465-20,1,2012-07-27,2012-07-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PeP-Tronic Medical AB,"A double-blind, placebo controlled single centre trial to evaluate the dose-relationship of the effects of vaginally administered oxytocin on the vaginal mucosal membrane in postmenopausal women En...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005465-20,0,0,0 2011-005467-25,1,2016-09-30,2016-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Leuven,Posttonsillectomy peritonsillar bupivacaine infiltration for pain relief in children. De infiltratie van bupivacaïne in de amandelloge na het wegnemen van de keelamandelen als pijnbehandeling bij ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005467-25,0,0,0 2011-005468-10,8,2020-09-11,2022-07-11,5,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refracto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005468-10,1,0,0 2011-005468-10,8,2020-09-11,2022-07-11,5,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refracto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005468-10,1,0,0 2011-005471-17,1,2017-02-01,2017-02-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Klinikum der Universität München-Großhadern,Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factors Phase II Studie zur Bestimmung der ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005471-17,0,0,0 2011-005473-22,2,2014-03-25,2014-03-25,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,EORTC,"Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005473-22,0,0,0 2011-005474-38,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Institut Jules Bordet,89Zr-Rituximab PET/CT-Imaging and Dosimetry and 90Y-Rituximab Radioimmunotherapy in CD20+ B-Cell lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005474-38,0,0,0 2011-005476-41,1,2015-09-30,2015-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Manchester Mental Health and Social Care Trust,Ketamine augmentation of ECT to improve outcomes in depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005476-41,0,0,0 2011-005477-24,1,2012-11-07,2012-11-07,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Oxford,A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-boost Malaria Vaccine Candidates: ChAd63 and MVA encoding ME-TRAP and the same Viral Vectors encoding CS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005477-24,0,0,0 2011-005479-17,2,2014-01-06,2014-01-06,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,"Ethicon Inc., a Johnson & Johnson Co.","A Single Blind, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL® as an Adjunct to Gastrointestinal Anastomosis Techniques",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005479-17,0,0,0 2011-005486-21,2,2013-11-14,2013-11-14,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare (UK) Ltd.,"A multicentre, randomised, double-blind, two arm, parallel group, placebo controlled, pilot study to assess the effect of Gaviscon Advance as add-on therapy in GORD patients with inadequate response t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005486-21,0,0,0 2011-005487-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITA' DEGLI STUDI DI PERUGIA,"A phase II, multi-center, open label study of the clinical activity and safety of the BRAF-V600 inhibitor vemurafenib (PLX-4032) in previously treated patients with hairy cell leukemia (HCL) carrying...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005487-13,0,0,0 2011-005488-25,1,2017-03-20,2017-03-20,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,UH Montpellier,Evaluation of the effectiveness of intradiscal injection of corticosteroids in the Modic I discopathies Evaluation de l'efficacité d'une injection intradiscale de corticoïdes dans les discopathies ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005488-25,0,0,0 2011-005491-41,11,2017-01-04,2017-01-04,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005491-41,0,0,0 2011-005491-41,11,2017-01-04,2017-01-04,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER INC.,"An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005491-41,0,0,0 2011-005491-41,11,2017-01-04,2017-01-04,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer S.L.U.,"An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005491-41,0,0,0 2011-005494-22,1,2014-05-09,2014-05-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Edinburgh,GaPP: A pilot randomised controlled trial of the efficacy and mechanism of action of gabapentin for the management of chronic pelvic pain in women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005494-22,0,0,0 2011-005494-22,1,2014-05-09,2014-05-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Lothian,GaPP: A pilot randomised controlled trial of the efficacy and mechanism of action of gabapentin for the management of chronic pelvic pain in women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005494-22,0,0,0 2011-005495-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Kell Osterlind,Individualised first line chemotherapy in metastatic colo-rectal cancer (mCRC). Is plasma TIMP-1 a predictive factor for best choise of first line chemotherapy in mCRC? Individualiseret valg af fø...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005495-42,0,0,0 2011-005496-17,14,2022-02-08,2022-02-08,11,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005496-17,1,0,0 2011-005496-17,14,2022-02-08,2022-02-08,11,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005496-17,1,0,0 2011-005497-28,1,2017-12-31,2017-12-31,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,Erasmus MC - Sophia,Pediatric Microdosing: elucidating age-related changes in oral absorption Pediatrische microdosering studie: ontrafelen van leeftijdgerelateerde veranderingen van orale absorptie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005497-28,0,0,0 2011-005498-21,1,2017-01-25,2017-01-25,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Med. Univ. Wien, Univ. Klinik für Radiodiagnostik",Breast lesion detection and characterization at contrast-Enhanced MRI of the breast: comparison of gadoterate meglumine versus gadobenate dimeglumine at 3 Tesla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005498-21,0,0,0 2011-005499-41,3,2013-09-05,2013-09-05,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A double blind, double dummy, randomised, multi-centre study to assess the tolerability and efficacy profile of vildagliptin compared to gliclazide as dual therapy with metformin in Muslim patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005499-41,0,0,0 2011-005499-41,3,2013-09-05,2013-09-05,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,"A double blind, double dummy, randomised, multi-centre study to assess the tolerability and efficacy profile of vildagliptin compared to gliclazide as dual therapy with metformin in Muslim patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005499-41,0,0,0 2011-005502-29,1,2012-11-27,2012-11-27,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Mona R Gätke,Optimization of surgical conditions during laparoscopic cholecystectomy with deep or moderate neuromuscular blockade Optimering af kirurgiske oversigtsforhold ved laparoskopisk kolecystektomi med d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005502-29,0,0,0 2011-005503-33,1,2013-01-09,2013-01-09,1,1,1,0,0,0,1,0,0,1,0,0,1,0,1,MedImmune Ltd,"A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of Tralokinumab in Adolescents with Asthma Otwarte badanie fazy pierwszej w celu oceny farmakokinetyki (PK) tralokinumabu u nastolatków ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005503-33,0,0,0 2011-005512-28,6,2014-11-12,2014-12-04,4,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"A phase II/III, randomised, double-blind, placebo-controlled, parallel group trial to evaluate safety and efficacy of tiotropium inhalation solution (2.5 µg and 5 µg) administered once daily in the af...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005512-28,0,0,0 2011-005512-28,6,2014-11-12,2014-12-04,4,1,1,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm. V,"A phase II/III, randomised, double-blind, placebo-controlled, parallel group trial to evaluate safety and efficacy of tiotropium inhalation solution (2.5 µg and 5 µg) administered once daily in the af...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005512-28,0,0,0 2011-005512-28,6,2014-11-12,2014-12-04,4,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer IngelheimRCV GmbH & co KG,"A phase II/III, randomised, double-blind, placebo-controlled, parallel group trial to evaluate safety and efficacy of tiotropium inhalation solution (2.5 µg and 5 µg) administered once daily in the af...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005512-28,0,0,0 2011-005512-28,6,2014-11-12,2014-12-04,4,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer IngelheimRCV GmbH & Co KG,"A phase II/III, randomised, double-blind, placebo-controlled, parallel group trial to evaluate safety and efficacy of tiotropium inhalation solution (2.5 µg and 5 µg) administered once daily in the af...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005512-28,0,0,0 2011-005513-37,6,2015-07-10,2015-07-10,5,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 4, NON-TREATMENT FOLLOW-UP FOR CARDIAC ASSESSMENTS FOLLOWING USE OF SMOKING CESSATION TREATMENTS IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005513-37,0,0,0 2011-005513-37,6,2015-07-10,2015-07-10,5,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"Pfizer, S.L.U.","A PHASE 4, NON-TREATMENT FOLLOW-UP FOR CARDIAC ASSESSMENTS FOLLOWING USE OF SMOKING CESSATION TREATMENTS IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005513-37,0,0,0 2011-005513-37,6,2015-07-10,2015-07-10,5,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017 US","A PHASE 4, NON-TREATMENT FOLLOW-UP FOR CARDIAC ASSESSMENTS FOLLOWING USE OF SMOKING CESSATION TREATMENTS IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005513-37,0,0,0 2011-005514-10,1,2017-02-01,2017-02-01,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A 2nd Open-Label Extension for 5 Years to: The Placebo-Controlled 1st Extension to a Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005514-10,0,0,0 2011-005518-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,NAMED SRL,effect of oral administration of red clover on menopausal symptoms of the syndrome induced by adjuvant hormonal treatment in women diagnosed with breast cancer effetto dell'assunzione orale di trif...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005518-12,0,0,0 2011-005519-10,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,"Med. Univ. Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie","Effekt von Kolloid-Lösungen auf plasmatische Blutgerinnung, Plättchenfunktion und Nierenfunktion – eine Probandenstudie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005519-10,0,0,0 2011-005522-22,1,2013-12-31,2013-12-31,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,"Oulu University Hospital, Department of Internal Medicine",The effects of PXR activation on blood pressure regulation PXR-aktivaation vaikutus verenpaineen säätelyyn,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005522-22,0,0,0 2011-005524-17,11,2017-05-03,2019-04-19,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A phase III randomized, double blind placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005524-17,0,0,0 2011-005524-17,11,2017-05-03,2019-04-19,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A phase III randomized, double blind placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005524-17,0,0,0 2011-005525-48,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Diakonhjemmet hospital,Potassium infusion for conversion of atrial fibrillation/atrial flutter.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005525-48,0,0,0 2011-005526-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medizinische Universität Wien,Tissue concentration of cefazolin and linezolid in sternal spongiosa in elective coronary artery bypass grafting: an in-vivo microdialysis study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005526-22,0,0,0 2011-005529-34,8,2016-02-10,2016-02-10,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,TauRx Therapeutics Ltd,"A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotempor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005529-34,0,0,0 2011-005533-39,3,2014-11-10,2014-11-10,2,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Debiopharm SA,A Phase I-II evaluation of the safety and efficacy of the oral HSP90 inhibitor Debio 0932 in combination with standard of care in first- and second-line therapy of patients with Stage IIIb or IV Non-s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005533-39,0,0,0 2011-005533-39,3,2014-11-10,2014-11-10,2,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Debiopharm International SA,A Phase I-II evaluation of the safety and efficacy of the oral HSP90 inhibitor Debio 0932 in combination with standard of care in first- and second-line therapy of patients with Stage IIIb or IV Non-s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005533-39,0,0,0 2011-005534-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Vrije Universiteit Brussel,The effect of peri-operative anti-inflammatory treatment on postoperative muscle weakness and muscle fatigue in elderly elective surgery patients: a double blinded randomized placebo-controlled trial....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005534-19,0,0,0 2011-005535-68,4,2014-05-28,2014-05-28,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo controlled study to assess efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005535-68,0,0,0 2011-005535-68,4,2014-05-28,2014-05-28,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled study to assess efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005535-68,0,0,0 2011-005537-39,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,GISCAD,"A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005537-39,0,0,0 2011-005538-20,1,2013-10-02,2013-10-02,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,BioAlliance Pharma,SAFETY AND EFFICACY OF INTRAMUSCULAR ELECTROTRANSFER OF PLASMID AMEP IN PATIENTS SUFFERING FROM ADVANCED OR METASTATIC MELANOMA: AN OPEN-LABEL PHASE I/II CLINICAL TRIAL THE AIMM STUDY (AMEP IN METASTA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005538-20,0,0,0 2011-005539-22,7,2015-06-22,2015-06-22,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"GENENTECH , INC","A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF MEHD7945A VERSUS CETUXIMAB IN PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE PROGRESSED DURING OR FOLLOWING PLA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005539-22,0,0,0 2011-005539-22,7,2015-06-22,2015-06-22,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF MEHD7945A VERSUS CETUXIMAB IN PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE PROGRESSED DURING OR FOLLOWING PLA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005539-22,0,0,0 2011-005540-99,1,2021-01-28,2021-01-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AGMT – Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH,"Randomised Phase II Pilot Studiy: Induction Chemotherapy with Docetaxel, Cisplatin und Cetuximab versus Docetaxel, Cisplatin und 5 FU followed by Radiotherapy with Cetuximab for locally advanced or n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005540-99,0,0,0 2011-005541-12,1,2012-06-11,2012-06-11,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Grethe Andersen,Efficacy of escitalopram treatment in acute stroke and the role of SERT genotype in stroke Effekten af escitalopram-behandling ved akut stroke og SERT genets betydning for stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005541-12,0,0,0 2011-005542-35,1,2017-12-05,2017-12-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,Multicenter randomized open-label three-arms controlled 12 months clinical proof of concept study to evaluate efficacy and safety of Ranibizumab alone or in combination with laser photocoagulation vs....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005542-35,0,0,0 2011-005544-10,1,2017-10-30,2017-10-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Imperial College London,Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005544-10,0,0,0 2011-005545-12,1,2018-09-30,2018-09-30,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,University of Leicester,Enhanced Control of Hypertension and Thrombolysis Stroke Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005545-12,0,0,0 2011-005547-27,5,2014-09-29,2015-09-22,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Genentech, Inc.","A PHASE II, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF FOLFIRI + MEHD7945A VERSUS FOLFIRI + CETUXIMAB IN SECOND LINE IN PATIENTS WITH KRAS WILD-TYPE METASTATIC ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005547-27,0,0,0 2011-005547-27,5,2014-09-29,2015-09-22,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GENENTECH , INC","A PHASE II, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF FOLFIRI + MEHD7945A VERSUS FOLFIRI + CETUXIMAB IN SECOND LINE IN PATIENTS WITH KRAS WILD-TYPE METASTATIC ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005547-27,0,0,0 2011-005550-57,5,2012-08-06,2012-08-06,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Teva Pharmaceutical Industries Ltd.,"A multinational, multicenter, randomized, parallel group, double blind, placebo controlled study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005550-57,0,0,0 2011-005553-31,1,2016-12-16,2016-12-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005553-31,0,0,0 2011-005554-62,1,2016-12-06,2016-12-06,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,Australian Sarcoma Group (ASSG),"Pharmacokinetics and Pharmacodynamics of Doxorubicin in Children, Adolescents and young adults with Newly Diagnosed Osteosarcoma, Ewing Family of Tumours and Hodgkin Lymphoma A Multi-Institutional Cro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005554-62,0,0,0 2011-005562-38,2,2018-12-21,2018-12-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Miltenyi Biotec GmbH,A multi-center phase I/II safety and feasibility study using CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in childr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005562-38,0,0,0 2011-005565-20,1,2013-02-21,2013-02-21,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"QUEEN MARY, UNIVERSITY OF LONDON",Comparison of the effects of the electronic cigarette and nicotine inhalator on tobacco withdrawal symptoms over 24 hours of abstinence,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005565-20,0,0,0 2011-005573-23,3,2012-08-31,2012-08-31,3,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Laboratoire HRA Pharma,"A prospective, randomized, double-blind parallel-arm, placebo-controlled study to assess the effects on ovarian activity of a combined oral contraceptive pill when preceded by the intake of ellaOne® (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005573-23,0,0,0 2011-005574-39,1,2015-01-30,2015-01-30,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Hull and East Yorkshire Hospitals NHS Trust,A Randomised Controlled Trial of Tumescent Anaesthesia in addition to Surgical Ligation and Stripping of the Great Saphenous Vein,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005574-39,0,0,0 2011-005575-16,1,2014-11-28,2014-11-28,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Hull & East Yorkshire Hospitals NHS Trust,Tumescent Anaesthesia in Endovenous Laser Ablation of Varicose Veins: A Randomised Controlled Trial of a Buffered Tumescent Solution,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005575-16,0,0,0 2011-005577-23,1,2013-01-27,2013-01-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Consumer Health,"A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of diclofenac potassium 25 mg in subjects with acute joint pain Randomisierte,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005577-23,0,0,0 2011-005581-37,1,2014-12-31,2014-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Newcastle upon Tyne Hospitals NHS Foundation Trust,Efficacy of Switch to Lopinavir/Ritonavir in Improving Cognitive function in Efavirenz treated patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005581-37,0,0,0 2011-005584-24,2,2017-09-20,2017-09-20,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bone Therapeutics S.A.,"A pivotal Phase IIb/III, multicentre, randomised, open, controlled study on the efficacy and safety of autologous osteoblastic cells (PREOB®) implantation in non-infected hypotrophic non-union fractur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005584-24,0,0,0 2011-005586-21,1,,,0,0,1,0,0,1,3,0,0,4,0,0,0,0,1,Bio Products Laboratory Limited,"A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX® in Chronic Idiopathic Thrombocytopenic Purpura",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005586-21,0,1,1 2011-005595-42,1,2014-12-01,2014-12-01,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,"Genzyme Corporation, a Sanofi company","A Phase 3/4, Prospective, Multinational, Open-label, Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients with Infantile-Onset Pompe Disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005595-42,0,0,0 2011-005597-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CASA DI CURA ABANO TERME POLISPECIALISTICA E TERMALE,Evaluation of the Discomfort Contrast Induced during Angiographic evaluation of peripheral arterial occlusive disease to define the treatment approach for percutaneous transluminal balloon angioplasty...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005597-28,0,0,0 2011-005603-32,1,2017-01-27,2017-01-27,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,German Cancer Research Center (DKFZ),Use of acetylsalicylic acid (ASA) for enhanced early detection of colorectal neoplasms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005603-32,0,0,0 2011-005604-15,1,,,0,1,0,0,1,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, randomised, controlled, single-blind study to evaluate the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered according to a 2-dose...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005604-15,0,1,1 2011-005606-30,1,2017-08-08,2017-08-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,Keratinocyte Growth Factor - promoting thymic reconstitution and preventing autoimmunity after alemtuzumab (Campath-1H) treatment of multiple sclerosis. CAM-THY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005606-30,0,0,0 2011-005612-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hannu Kokki,Pharmacokinetics of oxycodone in preterm and in infants Oksikodonin farmakokinetiikka keskosilla ja imeväisikäisillä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005612-28,0,0,0 2011-005615-87,1,2015-03-25,2015-03-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin","A multicenter, randomized, double-blind, placebo-controlled 12-week, parallel-group study with a 6 week follow up period to demonstrate efficacy and safety of subcutaneous Omalizumab in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005615-87,0,0,0 2011-005616-29,1,2018-05-16,2018-05-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Edinburgh,A multicentre randomised trial to establish the effect(s) of routine administration of Fluoxetine for six months in patients with a recent stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005616-29,0,0,0 2011-005616-29,1,2018-05-16,2018-05-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,NHS Lothian,A multicentre randomised trial to establish the effect(s) of routine administration of Fluoxetine for six months in patients with a recent stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005616-29,0,0,0 2011-005617-36,1,2014-10-02,2014-10-02,1,1,1,0,0,0,3,0,1,1,0,0,1,0,1,Statens Serum Institut,"A phase III contact tracing trial comparing the diagnostic performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in combination with a double blind randomized split body safety assessment of C-Tb versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005617-36,0,0,0 2011-005622-21,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Clinical Research Centre, Hvidovre University Hospital",Clinical Trials with bupivacain lozenge as local anaesthesia under upper gastrointestinal endoscopy Klinisk forsøg med bupivacainsugetabletter som lokalbedøvelse af svælget ved gastroskopiundersøge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005622-21,0,0,0 2011-005627-40,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,3,,Comparison of effectiveness of hepatitis B revaccination schemes in healthy non-responders Effectiviteit van verschillende hepatitis B vaccins bij hepatitis B vaccin non-responders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005627-40,0,0,0 2011-005628-16,1,2015-06-03,2015-06-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Cologne,FTO-genotype dependent weight reduction under treatment with bromocriptin in obese patients Gewichtsreduktion bei Adipositas unter der Therapie mit Bromocriptin in Abhängigkeit vom FTO-Genotyp,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005628-16,0,0,0 2011-005631-20,10,2014-02-13,2014-02-13,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd,"A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700 mcg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients With Diabetic Macu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005631-20,0,0,0 2011-005631-20,10,2014-02-13,2014-02-13,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALLERGAN LIMITED,"A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700 mcg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients With Diabetic Macu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005631-20,0,0,0 2011-005634-19,7,2014-01-23,2014-01-23,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MedImmune Ltd,A Phase 2b Study to Evaluate the Efficacy and Safety of Mavrilimumab in Subjects with Moderate-to-Severe Rheumatoid Arthritis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005634-19,0,0,0 2011-005636-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Foundation for Liver Research,Effect of Telaprevir in triple therapy for chronic hepatitis C patients on Intrahepatic immunological Mechanisms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005636-26,0,0,0 2011-005637-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE SANDRO PITIGLIANI PER LA LOTTA CONTRO I TUMORI-ONLUS,"PHASE 2, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF PD 0332991 (ORAL CDK 4/6 INHIBITOR) MONOTHERAPY AND PD 0332991 IN COMBINATION WITH THE ENDOCRINE THERAPY TO WHICH THE PATIENT HAS PROGRESSED IN TH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005637-38,0,0,0 2011-005638-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO,Phase III randomized trial of preoperative radiotherapy with an integrated simultaneous boost IMRT-IGRT) versus chemoradiotherapy for T3-4 rectal cancer STUDIO RANDOMIZZATO DI FASE III FRA SOLA RA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005638-20,0,0,0 2011-005643-26,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,ZAMBON ITALIA,"Cross-over pharmacokinetic study and pharmacodynamics of 2 different folate (5-MTHF and folic acid) in patients with liver cirrhosis with viral etiology. A randomized, open-label trial. Studio di f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005643-26,0,0,0 2011-005648-93,10,2015-09-30,2016-12-30,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MedImmune Ltd,An Open-label Extension Study to Evaluate the Long-term Safety of Mavrilimumab in Adult Subjects with Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005648-93,0,0,0 2011-005649-10,8,2014-06-26,2015-02-06,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MedImmune Limited,A Phase 2 Exploratory Study of Mavrilimumab versus Anti tumor Necrosis Factor in Subjects with Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005649-10,0,0,0 2011-005649-10,8,2014-06-26,2015-02-06,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MedImmune Ltd,A Phase 2 Exploratory Study of Mavrilimumab versus Anti tumor Necrosis Factor in Subjects with Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005649-10,0,0,0 2011-005650-54,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Prothrombin complex concentrate in the reduction of blood loss during otrhotopic liver transplantation. Prothrombine complex concentraat in de reductie van bloedverlies tijdens orthotope levertran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005650-54,0,0,0 2011-005653-31,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"LUMC, Department Infection Disease",Immune respons induced by vaccination with BCG Afweerreactie na BCG vaccinatie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005653-31,0,0,0 2011-005655-13,1,2016-06-09,2016-06-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Cologne,A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 - overexpression or - amplification or - mutation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005655-13,0,0,0 2011-005659-15,3,2022-05-24,2022-05-24,1,0,0,0,0,1,2,0,0,2,0,0,0,0,1,CELGENE CORPORATION,"A Phase 2a, open-label, dose finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta (β)- thalassemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005659-15,1,0,0 2011-005659-15,3,2022-05-24,2022-05-24,1,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Celgene Corporation,"A Phase 2a, open-label, dose finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta (β)- thalassemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005659-15,1,0,0 2011-005660-18,1,2012-08-04,2012-08-04,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Pharmanest AB,An open label pharmcokinetic study of a topical formulation of lidocaine (SHACT) for pain relief in women receiving an Intra Uterine Device.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005660-18,0,0,0 2011-005661-20,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,PROMO INTERNATIONAL SRL,"A double-blind, randomised, parallel group, active controlled, multicentre study to assess the therapeutic non-inferiority of SKP-021, a 0.3% ketoprofen patch, versus diclofenac sodium patch in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005661-20,0,0,0 2011-005666-37,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,ZAMBON ITALIA,Evaluation of the effect exerted by 5-methyltetrahydrofolate (5-MTHF) and folic acid in postmenopausal women Valutazione dell'effetto esercitato dal 5-Metiltetraidrofolato (5-MTHF) e dall'Acido Fol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005666-37,0,0,0 2011-005667-25,11,2018-07-30,2018-07-30,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Human Genome Sciences Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC),"A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005667-25,0,0,0 2011-005667-25,11,2018-07-30,2018-07-30,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"GlaxoSmithKline, LLC","A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005667-25,0,0,0 2011-005667-25,11,2018-07-30,2018-07-30,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,HUMAN GENOME SCIENCES INC,"A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005667-25,0,0,0 2011-005672-42,1,2019-01-28,2019-01-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)","A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Er...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005672-42,0,0,0 2011-005673-23,8,2012-01-08,2013-01-08,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Service AG,"A 12-week multi-center, randomized, double-blind, parallel-group study to assess the efficacy, safety and tolerability of the co-administration of NVA237 + indacaterol once daily vs. indacaterol once ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005673-23,0,0,0 2011-005673-23,8,2012-01-08,2013-01-08,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 12-week multi-center, randomized, double-blind, parallel-group study to assess the efficacy, safety and tolerability of the co-administration of NVA237 + indacaterol once daily vs. indacaterol once ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005673-23,0,0,0 2011-005673-23,8,2012-01-08,2013-01-08,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-week multi-center, randomized, double-blind, parallel-group study to assess the efficacy, safety and tolerability of the co-administration of NVA237 + indacaterol once daily vs. indacaterol once ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005673-23,0,0,0 2011-005673-23,8,2012-01-08,2013-01-08,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A 12-week multi-center, randomized, double-blind, parallel-group study to assess the efficacy, safety and tolerability of the co-administration of NVA237 + indacaterol once daily vs. indacaterol once ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005673-23,0,0,0 2011-005675-16,1,2014-02-28,2014-02-28,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,FERROKIN BIOSCIENCES INC.,"A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two FBS0701 Doses in the Treatment of Chronic Iron Overload ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005675-16,0,0,0 2011-005677-23,15,,,0,0,1,0,0,2,3,0,0,2,0,0,0,0,1,Novartis Pharma Service AG,"A two-year, double-blind, randomized, multicenter, active controlled study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005677-23,0,0,0 2011-005677-23,15,,,0,0,1,0,0,2,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A two-year, double-blind, randomized, multicenter, active controlled study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005677-23,0,0,0 2011-005677-23,15,,,0,0,1,0,0,2,3,0,0,2,0,0,0,0,1,Novartis Farmaceutica S.A.,"A two-year, double-blind, randomized, multicenter, active controlled study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005677-23,0,0,0 2011-005677-23,15,,,0,0,1,0,0,2,3,0,0,2,0,0,0,0,1,Novartis Farma,"A two-year, double-blind, randomized, multicenter, active controlled study to evaluate the safety and efficacy of fingolimod administered orally once daily versus interferon β-1a i.m. once weekly in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005677-23,0,0,0 2011-005678-47,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,GIULIANI,"A phase II multi-center, randomized, double-blind, controlled vs placebo, long-term extension study to evaluate the safety and tolerability of 40 mg GED-0301for the maintainance of Crohn’s disease in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005678-47,0,0,0 2011-005679-18,1,,,0,1,1,0,0,1,4,0,0,4,0,0,0,0,1,Bio Products Laboratory Limited,"A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005679-18,0,1,1 2011-005680-25,1,2014-12-17,2014-12-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London,A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patient...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005680-25,0,0,0 2011-005682-20,2,2014-11-20,2014-11-20,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc.,"A Randomized, Double-Blind, Pilot Study of the Safety and Physiological Effects of Two Doses of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005682-20,0,0,0 2011-005683-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Medizinische Universität Graz,"Effects of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial Studie zur Untersuchung der Effekte von Eple...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005683-21,0,0,0 2011-005686-20,9,2014-08-12,2014-08-12,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","?A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005686-20,0,0,0 2011-005688-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,Procedural pain treatment with transmucosal sublingual fentanyl tablet in colonoscopy patients Fentanyyliresoribletin teho ja turvallisuus kolonoskopiapotilaiden kipulääkityksenä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005688-26,0,0,0 2011-005689-39,5,2015-03-16,2015-03-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, 10017","A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005689-39,0,0,0 2011-005689-39,5,2015-03-16,2015-03-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York 10017","A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005689-39,0,0,0 2011-005692-16,3,2013-03-01,2013-03-01,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Janssen-Cilag International N.V.,"An Open-label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refrac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005692-16,0,0,0 2011-005692-16,3,2013-03-01,2013-03-01,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Genmab A/S,"An Open-label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refrac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005692-16,0,0,0 2011-005693-36,1,2012-07-04,2012-07-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,COSMO TECHNOLOGIES LTD,Intraepithelial neoplasia detection rate after single oral dose of methylene blue MMX modified release tablets administered to patients with long standing ulcerative colitis undergoing colonoscopy ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005693-36,0,0,0 2011-005694-23,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,COSMO TECHNOLOGIES LTD,Polyp detection rate after single oral dose of methylene blue MMX(R) modified release tablets administered to subjects undergoing outpatients colonoscopy Tasso di rilevamento dei polipi dopo sommin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005694-23,0,0,0 2011-005696-17,1,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,0,Instituto de Investigacion Sanitaria La Fe,"Multicenter, randomized, blinded clinical study comparing early use of total body moderate hypothermia plus topiramate or placebo in asphyxiated newborn infants evolving to moderate-to-severe hypoxic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005696-17,0,0,0 2011-005697-31,6,2018-01-05,2018-01-05,5,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A DURATION OF IMMUNITY STUDY, TO ASSESS PERSISTENCE OF hSBA RESPONSE FOR UP TO 48 MONTHS AFTER COMPLETION OF VACCINATION WITH BIVALENT rLP2086 VACCINE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005697-31,0,0,0 2011-005698-21,23,2017-12-11,2018-01-23,22,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Recherche & Développement,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005698-21,0,0,0 2011-005698-21,23,2017-12-11,2018-01-23,22,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005698-21,0,0,0 2011-005700-15,1,2015-06-26,2015-06-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Lennart Svensson Linköping University Medical Faculty,Can 5-HT3 receptor antagonists be used to limit vomiting in rota- and norovirus infections? Kan 5-HT3 receptorantagonister användas för att begränsa kräkningar vid rota- och norovirusinfektion?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005700-15,0,0,0 2011-005702-30,1,2012-10-31,2012-10-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Aarhus University Hospital, Department of Endocrinology and Internal Diseases","Interactions between exogenous Insulin Aspart, endogenous insulin and plasma glucose in type 2 diabetes mellitus patients Interaktioner mellem eksogent Insulin Aspart, endogent insulin og plasma gl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005702-30,0,0,0 2011-005703-33,2,2014-10-22,2014-10-22,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc.,"A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients with Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005703-33,0,0,0 2011-005704-15,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Hospital Universitario Infanta Cristina,Usefulness of lidocaine as topical pharyngeal anaesthesia in esophagogastroduodenoscopy under sedation with propofol UTILIDAD DE LA APLICACION DE LIDOCAINA COMO ANESTESIA TOPICA FARÍNGEA EN LAS ESO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005704-15,0,0,0 2011-005707-32,5,2015-07-28,2015-07-28,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients with C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005707-32,0,0,0 2011-005708-13,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Fundación para la Investigación Biomedica del Hospital 12 de Octubre,"An open-label, randomized, parallel-group, multicenter, non-inferiority trial comparing the effectiveness and safety of an immuno-guided strategy versus a viremia-guided strategy for the prevention of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005708-13,0,0,0 2011-005709-62,3,2012-12-06,2012-12-06,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Janssen-Cilag International N.V.,"An Open label, International, Multicenter, Dose Escalating Phase 1/2 Trial Investigating the Safety of Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005709-62,0,0,0 2011-005710-11,4,2013-12-03,2013-12-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOXXON Pharma AG,A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuria.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005710-11,0,0,0 2011-005713-37,22,2013-04-03,2013-04-25,20,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTELLAS PHARMA,"A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects with Overactive Bladder (OAB) Treated with Antimusc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005713-37,0,0,0 2011-005713-37,22,2013-04-03,2013-04-25,20,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd,"A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects with Overactive Bladder (OAB) Treated with Antimusc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005713-37,0,0,0 2011-005717-36,1,2018-11-12,2018-11-12,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Instituto de Investigación Sanitaria La Fe,Extremely low gestational age neonates randomly an assigned to be blindly resuscitated with 21% vs. 60% oxygen: influence upon mortality and chronic conditions in the neonatal period. Recién nacido...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005717-36,0,0,0 2011-005718-12,1,2020-02-18,2020-02-18,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"ARIAD Pharmaceuticals, Inc.","A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113 Estudio en fase 1/2 sobre la seguridad, tolerabilidad, far...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005718-12,0,0,0 2011-005721-43,8,2014-08-17,2014-08-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly CAZ1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005721-43,0,0,0 2011-005722-21,8,2014-08-18,2014-09-22,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly CA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005722-21,0,0,0 2011-005722-21,8,2014-08-18,2014-09-22,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA AB,"A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly CA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005722-21,0,0,0 2011-005724-17,12,2017-01-31,2017-01-31,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi aventis Groupe,"A Multicenter, Single arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients with Metastatic Colorectal Cancer (mCRC) Previously Treated wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005724-17,0,0,0 2011-005724-17,12,2017-01-31,2017-01-31,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SANOFI-AVENTIS GROUPE,"A Multicenter, Single arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients with Metastatic Colorectal Cancer (mCRC) Previously Treated wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005724-17,0,0,0 2011-005730-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,A.O. UNIVERSITARIA INTEGRATA DI VERONA,"Maintenance treatment with Lanreotide in Patients with small cell lung cancer (LD/ED) expressing SST receptors, responsive to a first line standard chemotherapy/radiotherapy Terapia di mantenimento...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005730-20,0,0,0 2011-005734-18,1,2013-09-13,2013-09-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Fresenius Kabi Deutschland GmbH,Prospective randomised controlled open-label explorative multi-centre pilot trial of Volulyte®-supplemented versus Albumin-supplemented fluid resuscitation for major burns,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005734-18,0,0,0 2011-005738-20,3,2017-02-10,2017-02-10,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Kyowa Hakko Kirin Pharma, Inc.","Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator’s Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005738-20,0,0,0 2011-005739-23,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,FONDAZIONE ITALIANA LINFOMI ONLUS,"Phase II study of age‐adjusted R‐BAC (Rituximab, Bendamustine, Cytarabine) as induction therapy in older patients with Mantle Cell Lymphoma (MCL) PROTOCOLLO FIL-RBAC500 RITUXIMAB-BENDAMUSTINA-CITA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005739-23,0,0,0 2011-005740-95,6,2014-10-13,2014-10-13,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450 with Ritonavir (ABT- 450/r), ABT-267, and ABT-333 With and Without Ribavirin i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005740-95,0,0,0 2011-005740-95,6,2014-10-13,2014-10-13,4,1,0,0,0,0,0,0,0,1,0,0,1,0,1,ABBOTT GMBH & Co. KG,"A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450 with Ritonavir (ABT- 450/r), ABT-267, and ABT-333 With and Without Ribavirin i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005740-95,0,0,0 2011-005741-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Asociación Colaboración Cochrane Iberoamericana,Clinical trial for the assessment of delayed antibiotic treatment in the non-complicated acute respiratory tract infections in pediatric. Ensayo clínico sobre la evaluación de la prescripción difer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005741-13,0,0,0 2011-005743-27,4,2014-01-22,2014-01-22,4,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, randomized, controlled, partially-blind study to demonstrate immunogenicity and assess safety of GlaxoSmithKline (GSK) Biologicals’ 11-valent and 12-valent pneumococcal polysaccharide and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005743-27,0,0,0 2011-005749-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses. A non-randomized single center study. Veiligheid en Haalbaarheid van TachoSil®: Toepassing op Oesofageale Anastomosen. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005749-10,0,0,0 2011-005762-38,3,2015-02-17,2015-02-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ABBOTT GMBH & Co. KG,"A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in Adults with Chronic Hepatitis C Virus Infection (PEARL-I)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005762-38,0,0,0 2011-005762-38,3,2015-02-17,2015-02-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in Adults with Chronic Hepatitis C Virus Infection (PEARL-I)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005762-38,0,0,0 2011-005762-38,3,2015-02-17,2015-02-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in Adults with Chronic Hepatitis C Virus Infection (PEARL-I)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005762-38,0,0,0 2011-005763-24,1,2014-03-10,2014-03-10,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,University of Oxford,BEST-D (Biochemical efficacy and safety trial of vitamin D): a dose-finding trial assessing biochemical and vascular effects of high dose vitamin D,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005763-24,0,0,0 2011-005766-38,1,2015-02-12,2015-02-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005766-38,0,0,0 2011-005775-16,1,2016-02-02,2016-02-02,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Research and Development Department,"A randomised, double blind, placebo-controlled trial of continuous subpectoral local anaesthetic infusion for pain and shoulder function following mastectomy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005775-16,0,0,0 2011-005781-38,1,2015-09-09,2015-09-09,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Amgen Research (Munich) GmbH,"An Open Label, Multicenter, Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of the Bispecific T-Cell Engager (BiTE) Blinatumomab in Patients with Relapsed/Refractory Diffuse Large B-Cell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005781-38,0,0,0 2011-005784-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Andres Iñiguez Romo,Dual antiplatelet therapy versus oral anticoagulation for a short time to prevent cerebral embolism after percutaneous aortic valve implantation. Multicenter randomized clinical trial. Doble Antiag...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005784-24,0,0,0 2011-005790-23,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Birmingham Children's Hospital NHS Foundation Trust,Comparison of adrenal recovery following short and long-term glucocorticoid therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005790-23,0,0,0 2011-005792-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska University Hospital,Effect of reduced cholinergic transmission by rocuronium on the hypoxic ventilatory response in patients with obstructive sleep apnea - before and after three months of continous positive airway press...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005792-16,0,0,0 2011-005795-42,1,2013-08-13,2013-08-13,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Janssen Cilag International N.V.,"An Open-label, Multicenter Phase 1/2 Study of JNJ-40346527, an FMS Inhibitor, in Subjects with Relapsed or Refractory Hodgkin Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005795-42,0,0,0 2011-005797-32,1,2014-10-29,2014-10-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Cologne,"Effentora® for Dyspnoea (EffenDys) - Fentanyl buccal tablet (FBT) for the relief of episodic dyspnoea (ED) in cancer patients: an open label, randomized, morphine-controlled, crossover, phase II trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005797-32,0,0,0 2011-005798-22,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,TETEC – Tissue Engineering Technologies – AG,A Clinical Study to Evaluate the Safety and Effectiveness of NOVOCART® 3D plus Compared to Microfracture in the Treatment of Articular Cartilage Defects of the Knee.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005798-22,0,0,0 2011-005799-41,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,CHU de Rennes (Rennes University Hospital Centre),Azole Therapy in Cystic Fibrosis (ATCF) : Efficacy of itraconazole and of voriconazole in patients with cystic fibrosis and presenting with persistent positive sputums for Aspergillus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005799-41,0,0,0 2011-005801-54,1,2013-07-04,2013-07-04,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Hvidovre Hospital,The effect of 1-84 parathyroidhormone in the treatment of proximal fracture of the humerus. Effekt af 1-84 PTH på opheling og restitution efter proximal humerus fraktur. En randomiseret og placebo-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005801-54,0,0,0 2011-005802-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar),Comparison of the analgesic efficacy of two different concentrations of epidural fentanyl (25mcg/ml and 8mcg/ml)to provide intraoperative analgesia. Ensayo clínico para comparación de la eficacia a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005802-31,0,0,0 2011-005805-66,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Unitat de Recerca en Pediatria Nutrició i Desenvolupament Humà,Dexametasona administration in first febrile urinary tract infection episode as renal damage prevention strategy. Administración de dexametasona en primer episodio de infección del tracto urinario ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005805-66,0,0,0 2011-005806-32,1,2012-05-16,2012-05-16,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,ikfe GmbH,Clinical Study to Collect Clinical Data Sets for Development of Insulin Glargine Titration Algorithms Klinische Studie zur Sammlung klinischer Daten in Hinblick auf die Entwicklung eines Insulin G...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005806-32,0,0,0 2011-005807-33,1,2016-01-27,2016-01-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Fakultät der Universität Bonn,Intravitreales Ranibizumab zur Therapie von Rissen des retinalen Pigmentepithels bei Pigmentepithelabhebung infolge altersbedingter Makuladegeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005807-33,0,0,0 2011-005808-14,1,2012-05-29,2012-05-29,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,Janssen R&D Ireland,"A Phase I, open-label, randomized, 3-panel, 3-way crossover trial in healthy adult subjects to assess the relative bioavailability of TMC435 following administration of 2 liquid formulations or 2 diff...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005808-14,0,0,0 2011-005809-77,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Maastricht University Medical Centre,Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolevulinic acid 20% versus two stage topical photodynamic therapy with methylaminolevulinate Be...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005809-77,0,0,0 2011-005814-12,1,2017-10-18,2017-10-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,"Phase II, randomised, placebo controlled, multicentre, feasibility study of low dose (metronomic) cyclophosphamide with or without nintedanib (BIBF 1120) in advanced ovarian cancer (METRO-BIBF)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005814-12,0,0,0 2011-005815-10,1,2015-02-12,2015-02-12,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Newcastle Upon Tyne Hospitals NHS Foundation Trust,Developmental Clinical Sciences: Does GM-CSF restore effective neutrophil function in critically ill patients?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005815-10,0,0,0 2011-005818-10,1,2015-02-28,2015-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH,PHASE II TRIAL OF RITUXIMAB (MABTHERA®) PLUS LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005818-10,0,0,0 2011-005820-17,2,2016-04-28,2016-04-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,Neoadjuvant BIBW 2992 followed by surgery in squamous cell carcinoma of the head and neck: an EORTC NOCI-HNCG window study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005820-17,0,0,0 2011-005820-17,2,2016-04-28,2016-04-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER,Neoadjuvant BIBW 2992 followed by surgery in squamous cell carcinoma of the head and neck: an EORTC NOCI-HNCG window study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005820-17,0,0,0 2011-005822-23,2,2017-02-20,2017-02-20,1,0,0,0,0,1,2,0,0,2,0,0,0,0,0,Haukeland University Hospital,CONTINUOUS SUBCUTANEOUS HYDROCORTISONE INFUSION IN CONGENITAL ADRENAL HYPERPLASIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005822-23,1,0,0 2011-005825-36,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Clinic per a la Recerca Biomèdica,"Midrodrine, octeotride and albumin for cirrhotic patients with functional renal impairment MIDODRINA, OCTEOTRIDA Y ALBÚMINA: EFECTO SOBRE LA FUNCIÓN RENAL DE PACIENTES CON CIRROSIS HEPÁTICA E INSUF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005825-36,0,0,0 2011-005833-38,1,2014-01-01,2014-01-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Medical University of Vienna,Removal of intestinal colonization with multi resistant bacteria by ingestion of Lactobacillus casei rhamnosus LCR 35 Entfernung einer intestinalen Kolonisation mit multiresistenten Bakterien durch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005833-38,0,0,0 2011-005836-25,17,2016-05-27,2019-04-30,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy Studio di fase IIIb in aperto sull'uso di regorafenib i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005836-25,0,0,0 2011-005836-25,17,2016-05-27,2019-04-30,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy Studio di fase IIIb in aperto sull'uso di regorafenib i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005836-25,0,0,0 2011-005836-25,17,2016-05-27,2019-04-30,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER HEALTHCARE AG,An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy Studio di fase IIIb in aperto sull'uso di regorafenib i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005836-25,0,0,0 2011-005838-19,1,2018-08-06,2018-08-06,1,0,0,0,1,0,3,0,0,1,0,0,1,0,0,Hospics Civils de Lyon,MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF THE RESECTION OF GLIOBLASTOMAS - THE RESECT STUDY EVALUATION MEDICO-ECONOMIQUE DE LA CHIRURGIE GUIDEE PAR FLUOR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005838-19,0,0,0 2011-005839-91,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ASOCIACIÓN INSTITUTO BIODONOSTIA,"Gabapentin int he disorder of the impulse control in the Parkinson´s Disease: multicentric study, double-blind, randomized, controlled with placebo. Gabapentina en el trastorno de control de impuls...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005839-91,0,0,0 2011-005840-87,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Swiss Group for Clinical Cancer Research SAKK,Carboplatin chemotherapy and involved node radiotherapy in stage IIA/B seminoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005840-87,0,0,0 2011-005843-28,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla,"RANDOMIZED OPEN-LABEL, MULTICENTRIC, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY OF A NEOADJUVANT CHEMOTHERAPY SCHEME CUSTOMIZED BY LEVELS OF BRCA1 AND ERCC1 IN WOMEN WITH PRIMARY HER2 NEGATIVE B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005843-28,0,0,0 2011-005846-36,1,2014-03-31,2014-03-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Gastroenterology MIDT,Safe evaluation of obstructive crohns disease using bloodflow Time-intensity curves and Elastography correlated to Neutrocytes and collagen counts and biomechanical properties Obtained in Stenotic Int...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005846-36,0,0,0 2011-005847-29,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,OSPEDALE POLICLINICO S. MATTEO,An Open Label Phase II Study on the Use of Panobinostat in Combination with Bortezomib and Dexamethasone as Induction in Multiple Myeloma Patients Candidate to High-Dose Therapy Studio di fase II s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005847-29,0,0,0 2011-005848-10,3,2012-11-02,2012-11-02,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"Analgesic profile of 3 new Ibuprofen lozenges (V0498TA01A 15mg, 25mg, 35mg) after single administration in acute sore throat pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005848-10,0,0,0 2011-005851-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,LYSARC,A RANDOMIZED PHASE III STUDY USING A PET-DRIVEN STRATEGY AND COMPARING GA101 OR RITUXIMAB IN COMBINATION WITH A CHEMOTHERAPY DELIVERED EVERY 14 DAYS (ACVBP OR CHOP) IN DLBCL CD20+ LYMPHOMA UNTREATED P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005851-15,0,0,0 2011-005852-33,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,Novartis Pharma AG,"An open-label, single-arm study to evaluate the efficacy, safety and PK of artemether-lumefantrine Dispersible Tablet in the treatment of acute uncomplicated Plasmodium falciparum malaria in infants <...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005852-33,0,1,1 2011-005856-32,1,2017-09-27,2017-09-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Fundación Progreso y Salud,Comparison of the efficacy of two rituximab treatment regimens in patients with lupus nephropathy resistant to conventional treatment Comparación de la eficacia de dos regímenes de tratamiento con ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005856-32,0,0,0 2011-005860-31,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"Immunogenicity of GlaxoSmithKline Biologicals’ MMR vaccine (209762) vs. M-M-R® II, when co-administered with hepatitis A, varicella and pneumococcal conjugate vaccines to children 12-15 months of age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005860-31,0,1,1 2011-005862-40,10,2015-01-29,2015-01-29,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo, in co-administration with donepezil (10 mg/day) in patients with moderate Alzheimer's Disease. A 24-week international, m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005862-40,0,0,0 2011-005862-40,10,2015-01-29,2015-01-29,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo, in co-administration with donepezil (10 mg/day) in patients with moderate Alzheimer's Disease. A 24-week international, m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005862-40,0,0,0 2011-005862-40,10,2015-01-29,2015-01-29,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratorios Servier S.L.,"Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo, in co-administration with donepezil (10 mg/day) in patients with moderate Alzheimer's Disease. A 24-week international, m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005862-40,0,0,0 2011-005863-25,1,2015-05-15,2015-05-15,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Katholieke Universiteit Leuven - Pharmacotechnology and Biopharmacy,Gastrointestinal behavior of tenofovir DF in healthy volunteers Gastrointestinaal gedrag van tenofovir DF in gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005863-25,0,0,0 2011-005864-11,8,2013-08-23,2013-09-18,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED PH-797804 FOR 12 WEEKS IN ADULTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005864-11,0,0,0 2011-005864-11,8,2013-08-23,2013-09-18,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, S.L.U.","A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED PH-797804 FOR 12 WEEKS IN ADULTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005864-11,0,0,0 2011-005864-11,8,2013-08-23,2013-09-18,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORALLY ADMINISTERED PH-797804 FOR 12 WEEKS IN ADULTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005864-11,0,0,0 2011-005866-39,4,2013-12-17,2013-12-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Comparison of LY2605541 versus Insulin Glargine Alone or in Combination with Pre study Oral Antihyperglycemic Medications in Patients with Type 2 Diabetes Mellitus Previously Treated with Basal Insu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005866-39,0,0,0 2011-005866-39,4,2013-12-17,2013-12-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,A Comparison of LY2605541 versus Insulin Glargine Alone or in Combination with Pre study Oral Antihyperglycemic Medications in Patients with Type 2 Diabetes Mellitus Previously Treated with Basal Insu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005866-39,0,0,0 2011-005868-25,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A randomised, open-label study to assess the immunogenicity and reactogenicity of GSK Biologicals’ DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course at 2-3-4 or 3-4-5 months...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005868-25,0,1,1 2011-005871-18,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,CLINICAL PHARMACOLOGY SPANISH SOCIETY,"Evaluation of clinical value of a standardized protocol for dose reduction in patients with axial Spondyloarthritis and persistent clinical remission with anti-TNF therapy: Open-label, controlled, ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005871-18,0,0,0 2011-005872-41,14,2013-09-26,2013-09-26,14,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd.,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005872-41,0,0,0 2011-005872-41,14,2013-09-26,2013-09-26,14,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ASTELLAS PHARMA,"QUTENZA versus pregabalin in subjects with peripheral neuropathic pain: an open-label, randomized, multicenter, noninferiority efficacy and tolerability study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005872-41,0,0,0 2011-005875-17,4,,,0,0,0,1,0,2,1,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A Phase Ib/II, multicenter, open-label, dose escalation study of LGX818 in combination with MEK162 in adult patients with BRAF V600 - dependent advanced solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005875-17,0,0,0 2011-005875-17,4,,,0,0,0,1,0,2,1,0,0,2,0,0,0,0,1,Array BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc),"A Phase Ib/II, multicenter, open-label, dose escalation study of LGX818 in combination with MEK162 in adult patients with BRAF V600 - dependent advanced solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005875-17,0,0,0 2011-005875-17,4,,,0,0,0,1,0,2,1,0,0,2,0,0,0,0,1,Novartis Farma S.p.A.,"A Phase Ib/II, multicenter, open-label, dose escalation study of LGX818 in combination with MEK162 in adult patients with BRAF V600 - dependent advanced solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005875-17,0,0,0 2011-005875-17,4,,,0,0,0,1,0,2,1,0,0,2,0,0,0,0,1,Array Biopharma Inc,"A Phase Ib/II, multicenter, open-label, dose escalation study of LGX818 in combination with MEK162 in adult patients with BRAF V600 - dependent advanced solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005875-17,0,0,0 2011-005878-37,6,2014-04-25,2014-04-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Aziende Chimiche Riunite Angelini Francesco - ACRAF S.p.A.,"A randomized, double-blind study comparing the efficacy and safety of Trazodone OAD and venlafaxine XR in the treatment of patients with Major Depressive Disorder.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005878-37,0,0,0 2011-005878-37,6,2014-04-25,2014-04-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ANGELINI,"A randomized, double-blind study comparing the efficacy and safety of Trazodone OAD and venlafaxine XR in the treatment of patients with Major Depressive Disorder.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005878-37,0,0,0 2011-005879-16,2,2012-06-12,2012-06-18,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Glenmark Pharmaceuticals SA,"A Phase II, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients with Painful Diabetic Neur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005879-16,0,0,0 2011-005881-38,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase II, randomized, double-blind study of Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine), one lot using new measles and rubella working seeds and one lot using old working seeds,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005881-38,0,1,1 2011-005882-19,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,Non-inferiority of GSK Biologicals’ measles-mumps-rubella-varicella (MMRV) vaccine 208136 vs Priorix™ and Priorix™ coadministered with Varilrix™ (comparator) and to evaluate non-inferiority of Priorix...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005882-19,0,1,1 2011-005884-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Endocrinologia y Nutricion. Hospital Universitari Bellvitge,Study of the effectiveness of bariatric surgery in the treatment of type II Diabetes Mellitus in patients with grade I obesity Ensayo clínico aleatorizado comparativo de la eficacia del tratamiento...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005884-25,0,0,0 2011-005886-19,1,2014-03-31,2014-03-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Gastroenterology MIDT,Correlation between intestinal blOod flow assessed by magNetic resonance imaging and ulTRASound Techniques (CONTRAST) Korrelering mellem blOdgennemstrømNing i Tarmen vurderet ved brug af avancerede...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005886-19,0,0,0 2011-005887-20,2,2013-10-05,2013-10-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"A prospective, randomized, double-blind, placebo-controlled, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the combined treatment of upper f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005887-20,0,0,0 2011-005889-38,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University College London,A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005889-38,0,0,0 2011-005902-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Farmacia. Hospital Universitari de Bellvitge,ENSAYO CLÍNICO PARA EVALUAR EL COMPORTAMIENTO FARMACOCINÉTICO DE MEROPENEM EN MEMBRANAS DE ADSORCIÓN INCREMENTADA (oXiris®) EN EL PACIENTE CRÍTICO SÉPTICO CON DISFUNCIÓN RENAL AGUDA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005902-30,0,0,0 2011-005903-34,1,2016-08-02,2016-08-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,G. L. Pharma GmbH,"Phase II, single centre, double blinded, cross-over dose confirmation study using two morphine-naloxone i.v. solutions Dosisfindungsstudie mit 2 Morphin-Naloxon Lösungen zur intravenösen Verabrei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005903-34,0,0,0 2011-005906-32,7,2017-09-21,2017-10-31,6,1,0,0,0,0,3,0,0,1,1,0,1,0,0,University Medical Center Hamburg-Eppendorf,"Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005906-32,0,0,0 2011-005909-79,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Clínic per a la Recerca Biomèdica,Magnetic resonance with gadoxetic acid for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. Evaluation of its impact for the non-invasive diagnosis. Resonancia magnética ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005909-79,0,0,0 2011-005912-27,4,2014-09-29,2016-01-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB IN COMBINATION WITH BEVACIZUMAB OR ONARTUZUMAB MONOTHERAPY IN PATIENTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005912-27,0,0,0 2011-005912-27,4,2014-09-29,2016-01-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB IN COMBINATION WITH BEVACIZUMAB OR ONARTUZUMAB MONOTHERAPY IN PATIENTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005912-27,0,0,0 2011-005913-35,1,2013-06-11,2013-06-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005913-35,0,0,0 2011-005914-12,2,2013-03-06,2013-03-06,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005914-12,0,0,0 2011-005917-35,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,CMC Contrast AB,"Accuracy in Diagnosis of Focal Liver Lesions following Oral Administration of CMC-001 Combined with Diffusion Weighted Magnetic Resonance Imaging (MRI) of the Liver. An Open-Label, Non-Randomised, Sin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005917-35,0,0,0 2011-005920-16,1,2015-10-13,2015-10-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Association Hospitalière CHU Brugmann,"Prospective, controled, randomized, double blind monocentric study evaluating the efficacy of the basic component of colloids (corn versus potato) on perioperative blood losses in elective cardiac sur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005920-16,0,0,0 2011-005923-42,5,2015-11-09,2018-10-10,2,0,0,1,0,1,1,0,0,2,1,0,0,0,0,TACL,"A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005923-42,1,0,0 2011-005923-42,5,2015-11-09,2018-10-10,2,0,0,1,0,1,1,0,0,2,1,0,0,0,0,Therapeutic Advances in Childhood Leukemia & Lymphoma,"A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005923-42,1,0,0 2011-005924-16,2,2013-10-28,2014-01-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott Laboratories Ireland Limited,"A 12-week, Double-blind, Randomized Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate /Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets vs. Matching Mono...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005924-16,0,0,0 2011-005928-17,1,2016-05-04,2016-05-04,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Katholieke Universiteit Leuven - Pharmacotechnology and Biopharmacy,Gastrointestinal behavior of itraconazole in healthy volunteers Gastrointestinaal gedrag van itraconazol in gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005928-17,0,0,0 2011-005929-49,1,2012-10-05,2012-10-05,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2a, Randomized, Double Blind, Placebo Controlled Study to Investigate the Effects of VX 787 Administered to Adult Volunteers Experimentally Inoculated with Live Influenza Virus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005929-49,0,0,0 2011-005932-24,9,2015-06-01,2015-06-01,6,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled, phase II study of BKM120 plus paclitaxel in patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or without PI3K pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005932-24,1,0,0 2011-005932-24,9,2015-06-01,2015-06-01,6,1,0,0,0,0,2,0,0,2,0,0,0,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo controlled, phase II study of BKM120 plus paclitaxel in patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or without PI3K pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005932-24,1,0,0 2011-005932-24,9,2015-06-01,2015-06-01,6,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A.,"A randomized, double-blind, placebo controlled, phase II study of BKM120 plus paclitaxel in patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or without PI3K pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005932-24,1,0,0 2011-005934-20,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Institut Paoli-Calmettes,Etude de phase I/II d'immunothérapie par protéine recwt1-A10+AS01B après greffe allogénique de cellules souches hématopoïétiques chez des patients porteurs d’une hémopathie myéloïde expri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005934-20,0,0,0 2011-005939-78,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,CESAR Central European Society for Anticancer Drug Research-EWIV,"A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study) Ei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005939-78,0,0,0 2011-005965-18,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Parc Taulí,Open randomized trial to compare the bleeding during endoscopic nasal surgery after hypotensive anesthesia with clonidine or remifentanil. Ensayo clínico aleatorizado abierto para comparar el sangr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005965-18,0,0,0 2011-005966-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU-ULg,Mesenchymal stem cell therapy for the treatment of severe or refractory inflammatory and/or autoimmune disorders.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005966-39,0,0,0 2011-005968-24,5,2017-03-05,2017-03-05,2,0,0,0,2,0,2,0,0,2,1,0,0,0,1,VAXON BIOTECH,"A multicenter, randomized, double-blind, placebo-controlled Phase IIb Efficacy Study of Vx-001, a peptide-based cancer vaccine aimed to maintain disease control after first line treatment in HLA-A*0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005968-24,1,0,0 2011-005968-24,5,2017-03-05,2017-03-05,2,0,0,0,2,0,2,0,0,2,1,0,0,0,1,Vaxon Biotech,"A multicenter, randomized, double-blind, placebo-controlled Phase IIb Efficacy Study of Vx-001, a peptide-based cancer vaccine aimed to maintain disease control after first line treatment in HLA-A*0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005968-24,1,0,0 2011-005970-41,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Radboud University Nijmegen Medical Centre,The effect of acetazolamide on lithium-induced nephrogenic diabetes insipidus in patients with an affective disorder: a pilot study Het effect van acetazolamide op lithium-geïnduceerde nefrogene di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005970-41,0,0,0 2011-005971-18,1,,,0,0,0,0,1,0,4,0,0,1,1,1,0,1,0,University Medical Center Utrecht,"TimeToStop (TTS) Trial, A randomised controlled trial of early versus late antiepileptic drug withdrawal after pediatric epilepsy surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005971-18,0,0,0 2011-005972-41,2,2013-06-12,2013-06-12,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","A PHASE 4 MULTICENTER, OPEN-LABEL, PILOT STUDY OF PREGABALIN AND PREDICTION OF TREATMENT RESPONSE IN PATIENTS WITH POSTHERPETIC NEURALGIA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005972-41,0,0,0 2011-005973-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,"A prospective, randomized, open-label trial of two abacavir/lamivudine based regimen (ABC/3TC + darunavir/ritonavir or ABC/3TC + raltegravir) in late presenter naïve patients (with CD4 count <200 cell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005973-21,0,0,0 2011-005975-17,8,2016-04-28,2016-04-28,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A two-part, randomized Phase II, double-blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in wo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005975-17,0,0,0 2011-005975-17,8,2016-04-28,2016-04-28,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A two-part, randomized Phase II, double-blind, multicenter trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in wo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005975-17,0,0,0 2011-005979-16,1,2018-04-20,2018-04-20,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Instituto de Investigación Sanitaria La Fe,PREECLAMPSIA OF PREVENTION IN PATIENTS THROUGH ovodonation aspirin in early gestation PREVENCIÓN DE PREECLAMPSIA EN PACIENTES DE OVODONACIÓN MEDIANTE LA ADMINISTRACIÓN DE ASPIRINA EN LA GESTACIÓN T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005979-16,0,0,0 2011-005980-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,,"Metformin and sitagliptin in patients with impaired glucose tolerance and a recent TIA or minor ischemic stroke - a multicenter, randomized, open-label phase II trial De veiligheid, verdraagbaarh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005980-26,0,0,0 2011-005981-39,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Unidad de VIH. Servicio de Enfermedades Infecciosas. Hospital de Bellvitge,Pilot simplification study to Lopinavir/ritonavir 800/200 mg monotherapy regimen once daily Estudio PILOTO de simplificación a una pauta de Lopinavir/ritonavir 800/200 mg en monoterapia una vez al ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005981-39,0,0,0 2011-005982-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Mónica Saldaña Valderas,"Randomized, placebo-controlled and double blind clinical trial to assess the efficacy of ubidecarenone in patients diagnosed with fibromyalgia Ensayo clínico aleatorizado, controlado con placebo y ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005982-18,0,0,0 2011-005983-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Phase II study of the fully human monoclonal antibody against transforming growth factor-beta (TGF-beta) receptor ALK1 (PF-03446962) in relapsed or refractory urothelial cancer (UC) failing first-line...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005983-12,0,0,0 2011-005984-25,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Bispebjerg Hospital,Inflammation after photodynamic therapy of actinic keratoses,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005984-25,0,0,0 2011-005989-38,4,2019-03-19,2019-03-19,1,0,0,0,0,1,2,0,0,2,0,0,0,0,0,Norwegian University of Science and Technology,A SAFETY AND EFFICACY STUDY OF ADDING LOW DOSE PEGYLATED IFN-ALPHA 2B TO STANDARD DOSE DASATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005989-38,1,0,0 2011-005991-40,8,2017-01-24,2017-01-24,7,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 6 Week, Randomized, Multicenter, Double-blind, Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension, With or Withou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005991-40,0,0,0 2011-005991-40,8,2017-01-24,2017-01-24,7,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 6 Week, Randomized, Multicenter, Double-blind, Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension, With or Withou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005991-40,0,0,0 2011-005991-40,8,2017-01-24,2017-01-24,7,1,1,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS PHARMA AG,"A 6 Week, Randomized, Multicenter, Double-blind, Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension, With or Withou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005991-40,0,0,0 2011-005992-17,3,2013-06-03,2013-06-03,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Double-Blind, Double-Randomization, Placebo-Controlled Study of the Efficacy of Intravenous Esketamine in Adult Subjects with Treatment-Resistant Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005992-17,0,0,0 2011-006001-10,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,A.O. UNIVERSITARIA INTEGRATA DI VERONA,"Efficacy of rituximab at the dose of 500 mg e.v., two infusions two weeks apart, versus rituximab at the usual dose of 1000 mg, two infusions two weeks apart, in patients affected by rheumatoid arthri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006001-10,0,0,0 2011-006002-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,Multicentre trial evaluating the immunogenicity of HPV vaccination in girls on immunosuppressive therapy. Essai clinique multicentrique évaluant la réponse immunologique de la vaccination contre l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006002-27,0,0,0 2011-006006-27,5,2016-09-26,2016-09-26,4,1,1,0,0,0,2,0,2,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Aprepitant in Pediatric Patients for the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006006-27,1,1,0 2011-006006-27,5,2016-09-26,2016-09-26,4,1,1,0,0,0,2,0,2,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Aprepitant in Pediatric Patients for the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006006-27,1,1,0 2011-006008-11,1,2016-07-21,2016-07-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Tayside Clinical Trials Unit, University of Dundee",Evaluation of effects of chronic dose exposure to cardioselective and non-cardioselective beta blockers on measures of cardiopulmonary function in moderate to severe COPD.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006008-11,0,0,0 2011-006009-85,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VU University medical center,Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006009-85,0,0,0 2011-006011-62,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Slotervaart Hospital,The ACER-study - the effects of galantamine on the variability and stability of walking among patients with Alzheimer's disease. De ACER-studie - effecten van galantamine op de variabiliteit en sta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006011-62,0,0,0 2011-006012-31,1,2012-08-07,2012-08-07,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Bispeberg Hospital,Reducing light sensitivity after photodynamic therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006012-31,0,0,0 2011-006013-34,2,2015-06-29,2015-06-29,1,1,1,0,0,0,3,0,1,2,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, open, controlled, multi-centric study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine when administered to children ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006013-34,1,1,0 2011-006014-14,1,2013-02-19,2013-02-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMW GmbH,"An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (AMW Leuprorelin 10.72 mg implant) applied...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006014-14,0,0,0 2011-006015-57,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,CHU de Clermont-Ferrand,"ETUDE CLINIQUE COMPARANT L’EFFICACITE DU PARACETAMOL PERMUQUEUX BUCCAL 125 MG VERSUS CELLE DU PARACETAMOL INJECTABLE 1 G, EN PERFUSION LENTE IV CHEZ DES PATIENTS SOUFFRANT DE DOULEUR AIGUË.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006015-57,0,0,0 2011-006017-34,2,2016-05-09,2016-05-09,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Novartis Pharma Services AG,"A phase Ib dose escalation/randomized phase II, multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006017-34,0,0,0 2011-006018-15,5,2014-02-11,2014-02-11,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Astellas Pharma Global Development, Inc. (APGD)","A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006018-15,0,0,0 2011-006019-73,1,2014-08-12,2014-08-12,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,"Randomized, double blind, placebo-controlled trial of Creon in patients with low faecal pancreatic elastase",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006019-73,0,0,0 2011-006020-20,4,2013-12-02,2013-12-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Astellas Pharma Global Development, Inc. (APGD)","A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006020-20,0,0,0 2011-006021-23,5,2016-03-25,2016-03-25,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Global Development Inc. (APGD),"A Phase 2, Open-Label, Non-Comparative, Multi-Center Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006021-23,0,0,0 2011-006021-23,5,2016-03-25,2016-03-25,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Global Development,"A Phase 2, Open-Label, Non-Comparative, Multi-Center Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006021-23,0,0,0 2011-006022-25,11,2018-06-04,2018-06-04,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB IN SUBJECTS WITH GIANT CELL ARTERITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006022-25,0,0,0 2011-006032-23,4,2014-10-05,2014-10-05,3,1,1,0,0,2,3,0,0,1,0,0,1,0,1,CSL Behring GmbH,"A Phase III Open-label, Multicenter, Pharmacokinetics, Safety, and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Children w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006032-23,0,0,0 2011-006032-23,4,2014-10-05,2014-10-05,3,1,1,0,0,2,3,0,0,1,0,0,1,0,1,CSL BEHRING GMBH,"A Phase III Open-label, Multicenter, Pharmacokinetics, Safety, and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Children w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006032-23,0,0,0 2011-006036-23,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Instituto Científico y Tecnológico de Navarra,Tratamiento de la Artrosis mediante la inyección intra-articular de Células Madre Mesenquimales de Medula Ósea y Plasma Rico en Factores de Crecimiento (PRGF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006036-23,0,0,0 2011-006037-42,1,2019-06-11,2019-06-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Institut Bergonié,Efficacité et tolérance du Pazopanib dans les tumeurs desmoides : essai de phase 2 randomisé,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006037-42,0,0,0 2011-006040-79,1,2017-10-02,2017-10-02,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Aarhus University Hospital, Department of Rheumatology U","The efficacy and safety of adding tocilizumab to methotrexate and intra-articular glucocorticosteroid treatment in early rheumatoid arthritis. A randomized, double-blinded, placebo-controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006040-79,0,0,0 2011-006041-14,1,2014-06-15,2014-06-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MerLion Pharmaceuticals GmbH,"A Multi-Dose, Double-Blind, Double-Dummy, Active Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Ho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006041-14,0,0,0 2011-006042-32,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,GE Healthcare Ltd and its affiliates,A Single-Arm Open-Label Multi-Center Study to Determine the Test-Retest Variability of PET Brain Imaging with Flutemetamol (18F) Injection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006042-32,0,0,0 2011-006049-14,1,2014-05-19,2014-05-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,The University of Birmingham,Vildalgliptin and Glucose Variability in Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006049-14,0,0,0 2011-006049-14,1,2014-05-19,2014-05-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Heart of England NHS Foundation Trust,Vildalgliptin and Glucose Variability in Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006049-14,0,0,0 2011-006050-91,4,2012-12-19,2012-12-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Service AG,A study to compare the efficacy and safety of once daily QVA149 vs. the once daily concurrent administration of QAB149 plus NVA237 in patients with moderate to severe chronic obstructive pulmonary dis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006050-91,0,0,0 2011-006050-91,4,2012-12-19,2012-12-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A study to compare the efficacy and safety of once daily QVA149 vs. the once daily concurrent administration of QAB149 plus NVA237 in patients with moderate to severe chronic obstructive pulmonary dis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006050-91,0,0,0 2011-006054-82,4,2013-03-27,2013-03-27,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Efficacy and safety assessment of two schemes of oral administration of once-daily extended release metformin (metformin XR) in type 2 diabetic patients previously treated with metformin in combinatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006054-82,0,0,0 2011-006056-37,8,2018-03-01,2018-05-14,6,1,0,0,0,0,3,0,0,1,1,0,1,0,0,Hamilton Health Sciences Corporation,"A large, international, randomized, placebo-controlled trial to assess the impact of dabigatran (a direct thrombin inhibitor) and omeprazole (a proton-pump inhibitor) in patients suffering myocardial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006056-37,0,0,0 2011-006057-28,2,2016-10-24,2016-10-24,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006057-28,0,0,0 2011-006058-94,5,2015-04-30,2015-05-11,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term effic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006058-94,0,0,0 2011-006058-94,5,2015-04-30,2015-05-11,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term effic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006058-94,0,0,0 2011-006058-94,5,2015-04-30,2015-05-11,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term effic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006058-94,0,0,0 2011-006059-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,A.O. UNIVERSITARIA INTEGRATA DI VERONA,The use of Tachosil as sealant in the prevention of lymphorrea after groin lymphadenectomy for vulvar cancer: a clinical controlled prospective trial Studio clinico controllato prospettico sull'uti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006059-13,0,0,0 2011-006062-40,2,2013-12-12,2013-12-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Who Have Fallen Recently and Have Muscle Weakness,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006062-40,0,0,0 2011-006063-22,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación Oftalmológica del Mediterráneo,Prevención del edema macular diabético en pacientes con retinopatía diabética tratados con Ozurdex® tras la cirugía de cataratas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006063-22,0,0,0 2011-006064-43,6,2016-11-30,2017-02-10,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"TiGenix, S.A. Unipersonal","A phase III, randomised, double blind, parallel group, placebo controlled, multicentre study to assess efficacy and safety of expanded allogeneic adipose-derived stem cells (eASCs) for the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006064-43,0,0,0 2011-006064-43,6,2016-11-30,2017-02-10,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"CELLERIX, S.A","A phase III, randomised, double blind, parallel group, placebo controlled, multicentre study to assess efficacy and safety of expanded allogeneic adipose-derived stem cells (eASCs) for the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006064-43,0,0,0 2011-006064-43,6,2016-11-30,2017-02-10,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"TiGenix, S.A.U.","A phase III, randomised, double blind, parallel group, placebo controlled, multicentre study to assess efficacy and safety of expanded allogeneic adipose-derived stem cells (eASCs) for the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006064-43,0,0,0 2011-006064-43,6,2016-11-30,2017-02-10,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,CELLERIX S.A.,"A phase III, randomised, double blind, parallel group, placebo controlled, multicentre study to assess efficacy and safety of expanded allogeneic adipose-derived stem cells (eASCs) for the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006064-43,0,0,0 2011-006064-43,6,2016-11-30,2017-02-10,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,TiGenix S.A.U.,"A phase III, randomised, double blind, parallel group, placebo controlled, multicentre study to assess efficacy and safety of expanded allogeneic adipose-derived stem cells (eASCs) for the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006064-43,0,0,0 2011-006066-40,1,2014-12-31,2014-12-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,The Rotterdam Eye Hospital,The post-cataract inflammatory reaction with combination therapy of topical steroid and NSAID.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006066-40,0,0,0 2011-006068-32,10,2016-03-07,2016-04-15,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Celldex Therapeutics, Inc","An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (Th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006068-32,0,0,0 2011-006070-73,3,2013-01-15,2013-01-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fostamatinib 100 mg Twice Daily on 24-hour Ambulatory Blood Pressure in Patients with Rheumatoid Art...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006070-73,0,0,0 2011-006083-45,1,2016-09-11,2016-09-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"SOLTI (Grupo Español de Estudio, Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos)",A phase II trial of BKM120 (a PI3K inhibitor) in patients with triple negative metastatic breast cancer Estudio fase II de BKM 120 (un inhibidor de PI3K) en pacientes con cáncer de mama triple nega...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006083-45,0,0,0 2011-006084-22,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Royal Liverpool University Hospital,Utilising drug levels and anti-drug antibodies to predict response to treatment in patients with Inflammatory Bowel Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006084-22,0,0,0 2011-006085-40,1,2020-10-15,2020-10-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cliniques Universitaires Saint Luc,A proof of concept study to evaluate the use of metabonomics and lipidomics in predicting toxicity and efficacy of anti-VEGF therapy in patients with metastatic clear cell renal cell carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006085-40,0,0,0 2011-006086-17,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Maria Fernanda Pedrero Escalas,"""Effectiveness of homeopathic treatment (Agraphis nutans 5CH, Thuya occidentalis 5CH, Kalium muriaticum and Arsenicum iodatum 9CH 9CH) as adjuvant secretory otitis in children"" ?Efectividad del tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006086-17,0,0,0 2011-006087-49,7,2019-02-22,2019-02-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006087-49,0,0,0 2011-006087-49,7,2019-02-22,2019-02-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006087-49,0,0,0 2011-006087-49,7,2019-02-22,2019-02-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006087-49,0,0,0 2011-006087-49,7,2019-02-22,2019-02-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006087-49,0,0,0 2011-006088-23,14,2018-04-25,2019-04-25,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectabl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006088-23,0,0,0 2011-006088-23,14,2018-04-25,2019-04-25,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectabl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006088-23,0,0,0 2011-006088-23,14,2018-04-25,2019-04-25,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectabl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006088-23,0,0,0 2011-006088-23,14,2018-04-25,2019-04-25,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A phase III, randomised, open-label study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to the BRAF inhibitor vemurafenib in subjects with unresectabl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006088-23,0,0,0 2011-006090-25,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Tartu Ülikooli kardioloogiakliinik,The Impact of Heart Rate on Central Hemodynamics of Antihypertensive Therapy Südame löögisageduse mõju tsentraalsele hemodünaamikale arteriaalse hüpertensiooni ravis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006090-25,0,0,0 2011-006094-26,1,,,0,0,1,0,0,1,2,0,0,4,0,0,0,0,1,Thallion Pharmaceuticals Inc,A Phase II Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 (caStx1) and 2 (caStx2) Administered Concomitantly to Children with Shiga Toxin-Producing Bacterial (STPB) Infection and Bloody Dia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006094-26,0,1,1 2011-006097-76,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""","RANDOMIZED PHASE 3 TRIAL EVALUATING THE EFFICACY OF LOCOREGIONAL TREATMENT WITH TRANSARTERIAL EMBOLIZATION (TAE) FOR LIVER METASTASIS, IN COMBINATION WITH OCTREOTIDE LAR, IN PATIENTS WITH NEUROENDOCRI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006097-76,0,0,0 2011-006099-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,"Effects of an antiandrogenic oral contraceptive on eating behaviour in women with bulimia – A randomized double blinded, placebo controlled study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006099-38,0,0,0 2011-006100-12,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO NIÑO JESUS,Clinical Trial Phase I / II to evaluate the safety and efficacy of the infusion of autologous CD34+ cells transduced with a lentiviral vector carrying the FANCA gene (orphan drug) for patients with Fa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006100-12,0,0,0 2011-006103-35,1,2012-08-18,2012-08-18,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Næstved hospital,The Oxygenation of the Brain DUring elective Caesarean section. A comparison of ephedrine versus phenylephrine Hjernens oxygenering under anæstesi til elektivt sectio ved brug af efedrin versus phe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006103-35,0,0,0 2011-006107-35,1,2014-01-21,2014-01-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Ghent University Hospital,Pharmacokinetics of small spectcrum beta-lactam antibiotics (Amoxicillin/Clavulanic Acid and Cefuroxime) on intensive care. Farmacokinetiek van Small Spectrum Beta-Lactam Antibiotica (Amoxicilline/...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006107-35,0,0,0 2011-006108-11,1,2018-10-27,2018-10-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pharma Mar, S.A.","A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer. Ensayo Clínico de fase II, multicéntrico de PM01183 en cáncer de mama metastásico no ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006108-11,0,0,0 2011-006109-85,1,2018-01-03,2018-01-03,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA,DIAGNOSTIC AND THERAPEUTIC STUDY FOR NEWLY DIAGNOSED RETINOBLASTOMA PATIENTS RTB AIEOP 012 PROTOCOLLO DIAGNOSTICO E TERAPEUTICO PER IL RETINOBLASTOMA ALLA DIAGNOSI RTB AIEOP 012,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006109-85,0,0,0 2011-006111-62,1,2013-11-26,2013-11-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006111-62,0,0,0 2011-006113-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AURORA PUJOL ONOFRE,"Effect of pioglitazone administred to patients with Adrenomyeloneuropathy: A phase II, Singlearm, Monocentric Trial. Efecto de la pioglitazona administrada a pacientes con Adrenomieloneuropatia: en...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006113-34,0,0,0 2011-006114-14,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Research and Development department,“Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on trial...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006114-14,0,0,0 2011-006115-59,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,"""A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN)"" ''Trial controllato randomizzato Rituximab Versus stero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006115-59,0,0,0 2011-006118-15,1,2014-09-08,2014-09-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"Multicentric cross-over trial to assess the glycemic profiles on 8 weeks of vildagliptin and sitagliptin treatment, each, in type-2 diabetic patients with a pre-existing cardiovascular disease pre-tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006118-15,0,0,0 2011-006119-70,7,2013-01-04,2013-01-04,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Biogen Idec Research Limited,"An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006119-70,0,0,0 2011-006120-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Centre Ljubljana,Efficacy and safety of selective vitamin D receptor activation with paricalcitol for reduction of proteinuria in kidney transplant recipients: a randomized controlled trial Učinkovitost in varnost ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006120-20,0,0,0 2011-006121-26,3,2013-11-25,2013-11-25,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Multicenter, Double-Blind, Placebo-Controlled Study of JNJ-40411813 as Adjunctive Treatment to an Antidepressant in Adults with Major Depressive Disorder with Anxiety Symptoms",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006121-26,0,0,0 2011-006123-37,1,2015-11-23,2015-11-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Solvotrin Innovations Ltd,Impact of Eplerenone on Asymptomatic Left Ventricular Diastolic Dysfunction in Diabetic Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006123-37,0,0,0 2011-006125-14,1,2014-12-18,2014-12-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche (Magyarország) Kft.,"A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS A WA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006125-14,0,0,0 2011-006127-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación FISEVI,"Phase II, open-label clinical trial to evaluate the safety and efficacy of platelet-rich plasma and fibrin clot in processed with PRGF-system technology, in the treatment of anal fistulas in Crohn's p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006127-38,0,0,0 2011-006129-17,1,2012-08-13,2012-08-13,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,PASCOE Pharmazeutische Präparate GmbH,"A randomized, double blind, placebo-controlled pilot study on the efficacy of Passiflora incarnata L. in an acute stressful situation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006129-17,0,0,0 2011-006130-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Karolinska Institutet,ESTABLISHING THE EFFECT(S) AND SAFETY OF FLUOXETINE INITIATED IN THE ACUTE PHASE OF STROKE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006130-16,0,0,0 2011-006131-38,6,2015-05-21,2015-05-21,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A multi-centre 3-year follow-up study to assess the durability of sustained virologic response in Alisporivirtreated chronic Hepatitis C patients Studio multicentrico di follow-up della durata di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006131-38,0,0,0 2011-006131-38,6,2015-05-21,2015-05-21,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,A multi-centre 3-year follow-up study to assess the durability of sustained virologic response in Alisporivirtreated chronic Hepatitis C patients Studio multicentrico di follow-up della durata di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006131-38,0,0,0 2011-006131-38,6,2015-05-21,2015-05-21,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmaceutica, S.A.",A multi-centre 3-year follow-up study to assess the durability of sustained virologic response in Alisporivirtreated chronic Hepatitis C patients Studio multicentrico di follow-up della durata di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006131-38,0,0,0 2011-006132-24,6,2013-09-30,2014-01-23,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,A multi-centre 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored alisporivir studies for chronic hepatitis C pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006132-24,0,0,0 2011-006132-24,6,2013-09-30,2014-01-23,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmaceutica, S.A.",A multi-centre 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored alisporivir studies for chronic hepatitis C pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006132-24,0,0,0 2011-006132-24,6,2013-09-30,2014-01-23,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,A multi-centre 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored alisporivir studies for chronic hepatitis C pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006132-24,0,0,0 2011-006134-17,6,2014-12-02,2014-12-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ZIOPHARM Oncology, Inc.","A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etoposid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006134-17,0,0,0 2011-006134-17,6,2014-12-02,2014-12-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ZIOPHARM ONCOLOGY, INC","A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etoposid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006134-17,0,0,0 2011-006135-29,2,2014-04-03,2014-04-03,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BRACCO IMAGING,"PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF PROHANCE WITH 0.1 mmol/kg OF GADOVIST/GADAVIST IN MAGNETIC RESONANCE IMAGING (MRI) OF THE BRAIN (TRUTH) S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006135-29,0,0,0 2011-006135-29,2,2014-04-03,2014-04-03,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bracco Imaging S.p.A.,"PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF PROHANCE WITH 0.1 mmol/kg OF GADOVIST/GADAVIST IN MAGNETIC RESONANCE IMAGING (MRI) OF THE BRAIN (TRUTH) S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006135-29,0,0,0 2011-006140-78,3,2018-05-23,2018-05-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & développement,"International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monoth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006140-78,0,0,0 2011-006151-10,1,2012-12-17,2012-12-17,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Sønderjylland Hospital, department of neurology",FAME - Fampyra outcome measures study: a study of responsiveness of different outcome measures to Fampyra treatment.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006151-10,0,0,0 2011-006152-36,1,2018-06-13,2018-06-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Middelfart Rygsektor,"Postoperative treatment with parathyroidea hormone Forteo® in patients undergoing posterolateral spinal fusion surgery. A prospektive and a randomized double-blinded, placebo-controlled study Parat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006152-36,0,0,0 2011-006156-37,1,2014-12-16,2014-12-16,1,0,0,0,1,1,2,0,0,1,0,0,1,0,0,UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II,"A double-blind, randomized, placebo-controlled, clinical trial to test the efficacy of Epoetin alfa on physical performance of Friedreich Ataxia patients. Studio in doppio-cieco, randomizzato, cont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006156-37,0,0,0 2011-006160-48,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Hellenic Cooperative Oncology Group,Phase II multicenter single-arm study evaluating the safety and efficacy of everolimus as a first-line treatment in newly-diagnosed patients with advanced GI neuroendocrine tumors. Πολυκεντρική μελ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006160-48,0,0,0 2011-006161-18,2,2015-12-22,2015-12-22,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIA, randomized, observer-blind, controlled, multinational study to evaluate the safety and immunogenicity of GSK Biologicals' MMR vaccine (209762) (Priorix®) compared to Merck & Co., Inc.’s ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006161-18,0,0,0 2011-006162-40,1,2021-12-19,2021-12-19,1,1,0,0,0,0,4,0,0,1,1,1,0,0,0,Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR),"NEW-ONSET DIABETES MELLITUS AFTER RENAL TRANSPLANTATION. A MULTICENTRE, PROSPECTIVE, RANDOMIZED, OPEN STUDY TO EVALUATE BELATACEPT-BASED VERSUS TACROLIMUS-BASED IMMUNOSUPPRESSION Diabetes mellitu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006162-40,0,0,0 2011-006163-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,Study to evaluate the pharmacokinetic of vitamin D (cholecalciferol) in patients with obesity after bariatric surgery in vitamin D deficiency and after normalization Estudio para evaluar la farmaco...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006163-22,0,0,0 2011-006165-18,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Academic Medical Center,A randomized double blind placebo controlled study on the effects of fenretinide Lym-X-Sorb on insulin sensitivity in obese insulin resistant subjects Een gerandomiseerde dubbelblinde placebogecont...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006165-18,0,0,0 2011-006168-30,1,2016-06-10,2016-06-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"R&D, Barts and The London NHS Trust",PEntoxifylline in Anaemia Resistant to erythropoietin (PEAR),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006168-30,0,0,0 2011-006171-19,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA MEYER,randomized multicentric clinical trial upon efficacy of two different drugs combination to eradication of early p.aeruginosa infection in cystic fibrosis patients over 5 years old. Studio randomi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006171-19,0,0,0 2011-006174-47,3,2013-04-25,2013-04-25,2,1,0,0,1,0,3,0,0,1,0,0,1,0,1,ProFibrix Inc.,"A Phase 3, Randomized, Single-Blind, Controlled Trial of Topical Fibrocaps™ in Intraoperative Surgical Haemostasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006174-47,0,0,0 2011-006174-47,3,2013-04-25,2013-04-25,2,1,0,0,1,0,3,0,0,1,0,0,1,0,1,ProFibrix BV,"A Phase 3, Randomized, Single-Blind, Controlled Trial of Topical Fibrocaps™ in Intraoperative Surgical Haemostasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006174-47,0,0,0 2011-006176-39,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,GOIM GRUPPO ONCOLOGICO MERIDIONALE,"Paclitaxel + Bevacizumab versus doxorubicina liposomiale non pegilata (Myocet), cyclophosfamide e Bevacizumab as the first line treatment in HER-2 negative metastatic breast cancer. Multicenter random...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006176-39,0,0,0 2011-006179-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Endocrinology and Nutrition Unit. Hospital Universitari Bellvitge.,Comparative randomized clinical trial between insulin analogues and human insulin in hospitalized patients treated with enteral nutrition and who present hyperglycemia. INSULINE study. Ensayo clíni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006179-20,0,0,0 2011-006180-21,2,2015-10-01,2015-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A PHASE IV, OPEN-LABEL, MULTICENTER STUDY OF DASATINIB IN CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS WITH CHRONIC LOW-GRADE NONHEMATOLOGIC TOXICITY TO IMATINIB",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006180-21,0,0,0 2011-006180-21,2,2015-10-01,2015-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A PHASE IV, OPEN-LABEL, MULTICENTER STUDY OF DASATINIB IN CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS WITH CHRONIC LOW-GRADE NONHEMATOLOGIC TOXICITY TO IMATINIB",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006180-21,0,0,0 2011-006181-41,7,2022-04-12,2022-04-12,5,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"An open label, randomized (2:1) Phase 2b study of Dasatinib vs. Imatinib in patients with Chronic Phase Chronic Myeloid Leukemia who have not achieved an optimal response to 3 months of therapy with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006181-41,1,0,0 2011-006182-18,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Danish Headache Center,"Ilt administreret via tre forskellige iltmasker ved behandling af akutte anfald af klyngehovedpine, et semirandomiseret, kontrolleret, cross-over studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006182-18,0,0,0 2011-006187-47,1,2012-12-05,2012-12-05,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Bristol-Myers Squibb International Corporation,"A 48-Week, Randomized, Open-Label Phase 3b Study Comparing the Antiviral Efficacy and Safety of ATV/RTV Plus 3TC with ATV/RTV plus TDF/FTC in HIV-1-Infected, Treatment-Naive Subjects, Followed by a 48...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006187-47,0,0,0 2011-006188-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Cerenis Therapeutics,CER-001 Infusions in Subjects with Familial HDL-c Deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006188-23,0,0,0 2011-006193-36,1,2018-01-23,2018-01-23,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Topiramate et obésité sévère de l'enfant et de l'adolescent,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006193-36,0,0,0 2011-006194-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,JOSE LUIS MONTERO ALVAREZ,"A phase IV, multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of Sorafenib in patients with hepatocellular carcinoma after radiological progression Estudio fase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006194-26,0,0,0 2011-006195-39,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Skånes universitetssjukhus,An open-label study to compare the prognostic value of (18F)Flutemetamol PET-imaging with longitudinal biomarker data in healthy volunteers and patients with mild cognitive impairment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006195-39,0,0,0 2011-006196-19,1,2014-01-31,2014-01-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Clinical Research Centre, Hvidovre University Hospital",Clinical Trials with lozenge as local anaesthesia as treatment of oral pain in burning mouth syndrome and Sjögrens syndrome Kliniske forsøg med lokalbedøvende sugetablet til behandling af mundsmert...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006196-19,0,0,0 2011-006197-88,1,,,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,Cristina Díaz de Heredia Rubio,Clinical Phase II Trial to evaluate efficacy and safety of CD34+ cells mobilization and collection after treatment with plerixafor and filgrastim in patients with Fanconi anemia for subsequent transd...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006197-88,0,0,0 2011-006198-25,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Hellenic Cooperative Oncology Group,"A Phase II, single-arm clinical trial of administration of cisplatin and 5-fluorouracil with afatinib as first-line therapy in patients with inoperable gastric or gastroesophageal junction cancer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006198-25,0,0,0 2011-006201-10,4,2015-10-14,2016-12-09,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,DOMPE' s.p.a.,"A phase 3, multicenter, randomized, double-blind, parallel assignment study to assess the efficacy and safety of reparixin in pancreatic islet transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006201-10,0,0,0 2011-006201-10,4,2015-10-14,2016-12-09,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Dompé s.p.a.,"A phase 3, multicenter, randomized, double-blind, parallel assignment study to assess the efficacy and safety of reparixin in pancreatic islet transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006201-10,0,0,0 2011-006204-13,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,University of Duisburg-Essen,"Efficacy and safety of oral prednisone as add-on therapy in the prophylactic treatment of episodic cluster headache: a randomized, placebo controlled parallel study. Wirksamkeit und Sicherheit vo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006204-13,0,0,0 2011-006205-95,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Toremifene in desmoid tumor: prospective clinical trial and identification of potential molecular targets Toremifene nel tumore desmoide: studio clinico prospettico e identificazione di potenziali ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006205-95,0,0,0 2011-006206-27,1,2013-05-23,2013-05-23,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Karolinska Institutet,Does 5-HT polymorphism contribute to pain regulation and efficacy of granisetron?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006206-27,0,0,0 2011-006207-36,1,2017-04-20,2017-04-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Proreo Pharma Innovation AG,"A multi centre, double blind, randomised, placebo controlled crossover study to evaluate the efficacy and tolerability of picotamide in the prophylaxis of migraine in patients presenting with migraine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006207-36,0,0,0 2011-006208-11,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,CAIBER,"A randomized, controlled multicenter clinical trial comparing endoscopic band ligation versus oral carvedilol in the primary prophylaxis of esophageal variceal bleeding in patients with cirrosis En...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006208-11,0,0,0 2011-006209-83,1,,,0,0,0,0,0,0,3,0,1,1,0,0,0,1,0,CHU - Hôpitaux de Rouen,"Evaluation of the Immune Response against Neisseria meningitidis B:14, P1-7,16 in subjects inoculated by MenBVac ® vaccine. Evaluation de la réponse Immunitaire contre la souche de Neisseria mening...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006209-83,0,0,0 2011-006210-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,Prospective randomized ARMYDA 600x2 STUDY STUDIO PROSPETTICO RANDOMIZZATO ARMYDA 600 x 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006210-13,0,0,0 2011-006215-56,1,2016-02-08,2016-02-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"BEL114424: A Phase 2 Pilot, Multicentered, Randomised, Double Blind, Placebo-Controlled Study to Evaluate the Potential for Efficacy and the Safety of Belimumab plus Standard of Care versus Placebo pl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006215-56,0,0,0 2011-006220-20,1,2013-07-09,2013-07-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Pharmanest AB,"A randomized, double-blind, placebo controlled, parallel group clinical study investigating the analgesic effect and safety of a topical formulation of lidocaine (SHACT) during and after insertion of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006220-20,0,0,0 2011-006224-21,1,2017-01-06,2017-01-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Jules Bordet Institute,"A pre-operative window study evaluating Denosumab, a RANK-Ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006224-21,0,0,0 2011-006227-38,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Ove B. Schaffalitzky de Muckadell,“Assessment of fibrotic liver disease in a medical admission ward and intervention with losartan as antifibrotic therapy in patients with alcoholic liverdisease” “Forekomsten af fibrotisk leversygd...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006227-38,0,0,0 2011-006228-19,1,2014-10-01,2014-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Psykiatrisk Center Ballerup,The treatment of traumatized refugees with Setraline versus Venlafaxine - a randomized trial. Behandling af traumatiserede flygtninge med Sertralin versus Venlafaxin – et randomiseret studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006228-19,0,0,0 2011-006234-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,"Evaluation of the efficacy of the tandem treatment [90Y-DOTA, TYR(3)]OCTREOTATE and [177Lu-DOTA, TYR(3)]OCTREOTATE in patients with neuroendocrine tumour expressing somatostatin receptors and refracto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006234-16,0,0,0 2011-006235-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,MDM S.P.A.,Sensory Motor Neuropathies of the sciatic nerve: a comparative evaluation of dextrorotatory enantiomer of thioctic acid and acetyl-L-carnitine. NEUROPATIE SENSITIVO MOTORIE DEL NERVO SCIATICO: VALU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006235-33,0,0,0 2011-006236-23,1,2014-05-28,2014-05-28,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Accord Healthcare Ltd.,"A Randomized, Double-Blind, Placebo-controlled, Three-arm, Parallel Assignment, Multi-centre, Therapeutic Equivalence Study of Two Tacrolimus 0.1% Topical Ointment Formulations in Adult Patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006236-23,0,0,0 2011-006237-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus University Rotterdam,Optimization of exercise therapy in type 2 diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006237-42,0,0,0 2011-006239-44,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Dutch Childhood Oncology Group,An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response (STOPIMAPED) Een internationaal samenwerkende studie om Im...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006239-44,0,0,0 2011-006241-15,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Linköping University Hospital,GLUTAmate for Metabolic Intervention in Coronary Surgery II Metabol intervention med glutamat vid operation för ischemisk hjärtsjukdom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006241-15,0,0,0 2011-006244-73,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Instituto Aragonés de Ciencias de la Salud,Evaluation of the efficacy of memantine in the treatment of fibromyalgia: a double-blind randomized control clinical trial. Evaluacion de la eficacia de memantina en el tratamiento de la fibromial...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006244-73,0,0,0 2011-006246-33,3,2016-09-23,2016-09-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis recherche et développement,"International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in Cancer Patients Who Have Derived Clinical Benefit From Inip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006246-33,0,0,0 2011-006246-33,3,2016-09-23,2016-09-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT,"International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in Cancer Patients Who Have Derived Clinical Benefit From Inip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006246-33,0,0,0 2011-006250-90,2,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,0,EANM Forschungs GmbH / EANM Research Ltd.,"Randomized double-blind placebo controlled Phase II study to evaluate the efficacy and safety of Sorafenib treatment in patients with advanced (recurrent, persistent and/or metastasizing) medullary th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006250-90,0,0,0 2011-006251-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),"Pilot clinical trial, controlled and randomized, Phase III, to evaluate security and efficacy of oral specific immunotherapy in HIV infected patients who suffer from grass pollen allergy. Studio cl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006251-11,0,0,0 2011-006253-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Cerus Corporation,A Randomized Controlled Double-Blind Phase 3 Study to Assess Characteristics of S-303 Treated RBC Components and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006253-29,0,0,0 2011-006254-85,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,FUNDACIÓN PROGRESO Y SALUD,"Placebo controlled, randomized and triple blind multicentric phase I/II clinical trial to evaluate the safety, feasibility and valoration of efficacy trends of intravenous administration of three dose...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006254-85,0,0,0 2011-006258-99,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Sección de Digestivo. Hospital Comarcal de Laredo,"FIRST-LINE ERADICATOR THERAPY OF HELICOBACTER PYLORI INFECTION: OPEN CLINICAL TRIAL, RANDOMIZED, MULTICENTRE, THREE-ARMED, COMPARING THE CLASSICAL TRIPLE THERAPY VERSUS A MODIFIED SEQUENTIAL THERAPY A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006258-99,0,0,0 2011-006259-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jules Bordet Institute,Phase II study on prospective evaluating the quantification of total choline by magnetic resonance spectroscopy (MRS) in breast tumours as an early predictive marker of neoadjuvant chemotherapy respon...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006259-12,0,0,0 2011-006260-52,2,2019-02-27,2019-02-27,2,0,0,1,0,0,1,0,0,1,0,0,0,0,1,THERAVECTYS,"A multi-center, randomized, double blind, placebo-controlled Phase I/II trial to compare the safety, tolerability and immunogenicity of the therapeutic THV01 vaccination at 5x10E6 TU, 5x10E7 TU or 5x1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006260-52,0,0,0 2011-006262-40,6,2016-03-29,2016-03-29,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec Research Limited,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of Mul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006262-40,0,0,0 2011-006266-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fédération Francophone de Cancérologie Digestive (FFCD),FFCD 1102 ETUDE DE PHASE II : TRAITEMENT DE PREMIERE LIGNE PAR FOLFIRINOX POUR LES PATIENTS AYANT UN CANCER DU RECTUM AVEC METASTASES SYNCHRONES NON RESECABLES FFCD 1102 ETUDE DE PHASE II : TRAITE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006266-41,0,0,0 2011-006268-27,1,,,0,0,0,0,0,0,3,0,1,1,0,0,0,1,0,CHU - Hôpitaux de Rouen,"Evaluation of the Immune Response against Neisseria meningitidis B:14,P1-7,16 in subjects inoculated by MenBVac (R) vaccine. Evaluation de la réponse immunitaire contre la souche de Neisseria Menin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006268-27,0,0,0 2011-006269-17,1,2013-10-31,2013-10-31,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"Cardiff University, Research & Development Commercial Department",A double blind placebo controlled randomised clinical trial to study the effect of Probiotics for the prevetion or amelioration of Antibiotic Associated Diarrhoea in residents of care homes in South W...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006269-17,0,0,0 2011-006270-13,1,2017-03-04,2017-03-04,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Banc de Sang i Teixits,A phase I-IIa safety and efficacy pilot clinical trial of intraarticular administration of autologous mesenchymal stem cells in meniscus injury Estudio clínico piloto de fase I-IIa de seguridad y e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006270-13,0,0,0 2011-006271-18,1,2012-08-16,2012-08-16,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 3 Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Influenza Vaccine (Fluvirin®), Flirmulation 2012/2013, when Administered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006271-18,0,0,0 2011-006272-39,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Lluita contra la SIDA,"CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY AND ECONOMIC IMPACT OF REDUCING DOSES OF DARUNAVIR IN PATIENTS INFECTED WITH HIV TREATED WITH DARUNAVIR / RITONAVIR ONCE A DAY ENSAYO CLINICO PARA EV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006272-39,0,0,0 2011-006275-20,1,2013-03-05,2013-03-05,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,LEO Pharma A/S,A phase II exploratory study evaluating the efficacy of topical cromoglicate solution(20mg/ml) compared to topical solution vehicle in the treatment of mastocytosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006275-20,0,0,0 2011-006276-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut de Recerca Hospital Sant Pau,"Prevention of postoperative bleeding in bone tumors surgery: A multicenter, randomized, parallel controlled clinical trial evaluating the efficacy of topic fibrin glue, topic tranexamic acid and norma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006276-40,0,0,0 2011-006277-25,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Novartis Vaccines and Diagnostics GmbH,"A Phase III Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture (Optaflu®), Form...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006277-25,0,0,0 2011-006278-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut de Recerca Hospital de la Sant Creu i Sant Pau,"Prevention of postoperative bleeding: A multicenter, randomized, parallel, controlled clinical trial, evaluating the efficacy of tranexamic acid and fibrin glue in patients undergoing interventions fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006278-15,0,0,0 2011-006280-21,1,2021-09-25,2021-09-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Jules Bordet Institute,Correlating the tumoral metabolic progression index measured by serial FDG PET-CT and apparent diffusion coefficient measured by MRI to patient's outcome in advance colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006280-21,0,0,0 2011-006283-42,1,2013-01-28,2013-01-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Kade Pharmazeutische Fabrik GmbH,Placebo-controlled double-blind trial investigating the efficacy and tolerability of Posterisan® akut with lidocaine (50 mg/g rectal ointment) in abatement of complaints associated with the anorectal ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006283-42,0,0,0 2011-006287-50,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Clínica Universidad de Navarra/Universidad de Navarra,"Phase III comparative clinical trial to evaluate the efficacy of amniotic membrane extract for the treatment of severe dry eye disease, in comparison with autologous serum eyedrops. Ensayo Clínico ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006287-50,0,0,0 2011-006288-23,1,2021-11-15,2021-11-15,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,ARCAGY,"Randomized double blind placebo-controlled phase II trial of Vargatef® in addition to first line chemotherapy with interval debulking surgery in patients with adenocarcinoma of the ovary, the fallopia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006288-23,0,0,0 2011-006290-25,1,2014-04-01,2014-04-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Copenhagen University Hospital Rigshospitalet, The Heart Center - Department of Thoracic Surgery",The Pulmonary Protection Trial (PP-Trial) Pulmonary dysfunction after open heart surgery: Randomized clinical trial with focus on lung-protective interventions The Pulmonary Protection Trial (PP-T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006290-25,0,0,0 2011-006291-39,9,2014-10-21,2014-10-21,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec Research Limited,"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neurit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006291-39,0,0,0 2011-006291-39,9,2014-10-21,2014-10-21,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BIOGEN IDEC RESEARCH LTD,"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neurit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006291-39,0,0,0 2011-006292-20,12,2019-06-10,2019-06-28,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006292-20,0,0,0 2011-006292-20,12,2019-06-10,2019-06-28,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GILEAD SCIENCES INC.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006292-20,0,0,0 2011-006293-72,3,2018-06-29,2018-06-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GILEAD SCIENCES INC.,"A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS 1101) for Previously Treated Chronic Lymphocytic Leukemia A Comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006293-72,0,0,0 2011-006293-72,3,2018-06-29,2018-06-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS 1101) for Previously Treated Chronic Lymphocytic Leukemia A Comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006293-72,0,0,0 2011-006294-26,3,2014-11-11,2014-11-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,"A Phase 3, Prospective, Open-label, Randomized Study to Evaluate Safety and Efficacy of Recombinant Activated FVII BI (rFVIIa BI) in the Treatment of Acute Bleeding Episodes per an On-Demand Regimen i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006294-26,0,0,0 2011-006300-12,1,2015-02-01,2015-02-01,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,"Medizinische Universität Graz, Kl. Abteilung für Endokrinologie und Stoffwechsel",Pilot study of the incretin effect on the immunological phenotype in healthy subjects and subjects with type 1 diabetes: Step 4 of the Austrian Diabetes Prevention Programme (ADPP-004). Pilotstudie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006300-12,0,0,0 2011-006301-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundació Clinic per a la Recerca Biomèdica,Perioperative Magnesium Sulphate as a cerebral protector in neurosurgical patients Sulfato de Magnesio perioperatorio como factor de protección cerebral en pacientes neuroquirúrgicos.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006301-10,0,0,0 2011-006302-28,1,,,0,0,0,0,1,0,2,0,1,0,0,0,0,0,0,UNIVERSITA' DEGLI STUDI DI PARMA,Dopamine modulation of oxytocin prosocial effects Modulazione dopaminergica dell'effetto prosociale dell'ossitocina,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006302-28,0,0,0 2011-006304-13,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA CARDARELLI,Effetto del precursore colinergico colina alfoscerato sui sintomi cognitivi e comportamentali in pazienti affetti da danno cognitivo lieve (mild cognitive impairment) Effetto del precursore coliner...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006304-13,0,0,0 2011-006308-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Fundación Investigación Hospital Ramón y Cajal,"phase II clinical trial, to study the efficacy and safety of topical rapamycin in reducing facial angiofibromas. Ensayo piloto, fase II, para el estudio de la eficacia y seguridad de la rapamicina ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006308-12,0,0,0 2011-006310-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University Hospital Frankfurt, Goethe University",CAO/ARO/AIO-12: Induction chemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer: A randomized phase II trial of the German Rectal Cancer Study Grou...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006310-13,0,0,0 2011-006312-31,2,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase I/II, Multicentre, Study Comprising a Safety Run-In of AZD5363 when Combined with Paclitaxel in Patients with Advanced or Metastatic Breast Cancer; Followed by a Randomised Expansion of AZD536...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006312-31,0,0,0 2011-006313-33,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Foro Andaluz para el Estudio de Tumores Torácicos (FAETT),"Phase II, multicenter, open study , first line treatment of intermittenty administered Erlotinib plus Carboplatin, paclitaxel and bebacizumab in patients with advanced none small and none squamous l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006313-33,0,0,0 2011-006314-14,5,2017-01-19,2017-01-19,2,1,0,1,0,0,1,0,0,1,1,1,0,0,1,CureVac GmbH,"A Randomised, Double-blind, Placebo-controlled, Phase I/II Trial of RNActive®-derived Cancer Vaccine (CV9104) in Asymptomatic or Minimally Symptomatic Patients with Metastatic Castrate-refractory Pros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006314-14,0,0,0 2011-006314-14,5,2017-01-19,2017-01-19,2,1,0,1,0,0,1,0,0,1,1,1,0,0,1,CureVac AG,"A Randomised, Double-blind, Placebo-controlled, Phase I/II Trial of RNActive®-derived Cancer Vaccine (CV9104) in Asymptomatic or Minimally Symptomatic Patients with Metastatic Castrate-refractory Pros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006314-14,0,0,0 2011-006319-69,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Pedro Villarejo Campos(Hospital Universitario Ciudad Real),Closed abdomen hyperthermic intraperitoneal chemotherapy with paclitaxel for advanced epithelial ovarian cancer QUIMIOHIPERTERMIA INTRAPERITONEAL CON PACLITAXEL MEDIANTE TÉCNICA CERRADA EN EL CÁNC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006319-69,0,0,0 2011-006320-20,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Synthon BV,"A multicenter, randomized, double-blind, multiple dose, crossover study to evaluate the safety and equivalence of serum phosphate control of a new sevelamer carbonate tablet formulation in comparison ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006320-20,0,0,0 2011-006321-20,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,FUNDACIÓN PROGRESO Y SALUD,"“Ensayo clínico, ciego y de grupos paralelos para analizar diferencias en la seguridad de roflumilast administrado una vez al día en días alternos durante dos semanas respecto a la pauta habitual una ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006321-20,0,0,0 2011-006322-25,2,2014-08-01,2014-08-01,1,1,0,0,0,1,0,0,0,1,1,1,1,0,1,Shire Development LLC,"A PHASE 3, OPEN-LABEL, MILTICENTRE, EXTENSION SAFETY AND TOLERABILITY STUDY FOR TRANSFUSIONALLY IRON OVERLOADED CHILDRE, ADOLISCENTS AND ADULTS USING FBS0701 (SSP-004184) STUDIO CLINICO MULTICENTRI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006322-25,0,0,0 2011-006322-25,2,2014-08-01,2014-08-01,1,1,0,0,0,1,0,0,0,1,1,1,1,0,1,FERROKIN BIOSCIENCES INC.,"A PHASE 3, OPEN-LABEL, MILTICENTRE, EXTENSION SAFETY AND TOLERABILITY STUDY FOR TRANSFUSIONALLY IRON OVERLOADED CHILDRE, ADOLISCENTS AND ADULTS USING FBS0701 (SSP-004184) STUDIO CLINICO MULTICENTRI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006322-25,0,0,0 2011-006323-37,3,2015-01-12,2015-01-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy with Saxagliptin added to Dapagliflozin in Combination ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006323-37,0,0,0 2011-006323-37,3,2015-01-12,2015-01-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy with Saxagliptin added to Dapagliflozin in Combination ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006323-37,0,0,0 2011-006324-20,3,2015-02-19,2015-02-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy with Dapagliflozin added to Saxagliptin in Combination with Me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006324-20,0,0,0 2011-006324-20,3,2015-02-19,2015-02-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy with Dapagliflozin added to Saxagliptin in Combination with Me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006324-20,0,0,0 2011-006326-24,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as Hormonal Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006326-24,0,0,0 2011-006326-24,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as Hormonal Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006326-24,0,0,0 2011-006329-42,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,Short course of Bortezomib in anemic patients with refractory cold agglutinin disease Ciclo breve di Bortezomib in pazienti anemici con crioagglutinemia refrattaria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006329-42,0,0,0 2011-006330-16,1,2019-12-09,2019-12-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Istituto di ricerche farmacologiche ""Mario Negri""",ATREUS TRIAL A PHASE II STUDY ON THE ACTIVITY OF TRABECTEDIN IN PRETREATED EPITHELIOID OR BIPHASIC/SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA (MPM) STUDIO DI FASE II SULL'ATTIVITA' DELLA TRABECTE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006330-16,0,0,0 2011-006331-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,OSPEDALE POLICLINICO S. MATTEO,"Efficacy and safety of long term local anaesthetic intralesional infusion in patients with mammary carcinoma undergoing mastectomy with breast reconstruction: a randomized, double-blind study. EFFI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006331-35,0,0,0 2011-006332-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ARCO,PHASE II RANDOMIZED STUDY OF MAINTENANCE TREATMENT WITH BEVACIZUMAB OR BEVACIZUMAB PLUS METRONOMIC CHEMOTHERAPY AFTER FIRST-LINE INDUCTION FOLFOXIRI PLUS BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006332-23,0,0,0 2011-006336-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Ghent,The effects of sodium oxybate in patients with chronic fatigue syndrome Het effect van natrium oxybaat bij patiënten met chronisch vermoeidheidssyndroom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006336-23,0,0,0 2011-006342-32,6,2022-08-11,2022-08-11,3,0,0,0,0,0,2,0,0,2,0,0,0,0,0,EORTC,Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006342-32,1,0,0 2011-006344-71,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Immanuel Krankenhaus Berlin,"Trichuris suis ova (TSO) as a additional therapy for rheumatoid arthritis patients with insufficient response to methotrexate. A prospective, double-blind, randomized, controlled monocenter study. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006344-71,0,0,0 2011-006350-87,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,HydrOxychloRoqUine and Sorafenib in locally advanced or Metastatic Hepatocellular Carcinoma as First line therapy: a multi-center phase II trial Idrossiclorochina e Sorafenib nel carcinoma epatoc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006350-87,0,0,0 2011-006352-36,1,2015-09-01,2015-09-01,1,0,1,0,0,0,3,0,0,1,0,0,1,0,0,"Lithuanian University of Health Sciences, Endocrinology Department","Obesity in children and adolescents: complications, associated risks and early intervention (lifestyle changes and insulin sensitivity improving medicine (metformin) effectiveness and safety evaluatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006352-36,0,0,0 2012-000026-22,1,2015-10-06,2015-10-06,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Omnivision GmbH,"Open, Observer-blind, two Parallel Group, Randomized, Multicentric Clinical Phase III Trial on the Comparison of Efficacy and Tolerability of a New Preservative-free Formulation of Travoprost 40 µg/ml...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000026-22,0,0,0 2012-000027-40,1,2013-07-25,2013-07-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & Développement,"An open-label, randomized, three-parallel-group study on pharmacodynamic effects of 8-week QD treatment with lixisenatide compared to liraglutide in patients with type 2 diabetes not adequately contro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000027-40,0,0,0 2012-000031-59,7,2013-06-30,2013-09-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALK-Abelló A/S,A dose-response evaluation of ALK tree AIT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000031-59,0,0,0 2012-000035-82,1,2016-09-20,2016-09-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biogen GmbH,"A 2:1 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of Fumaderm® in young patients aged 10 to 17 years with moderate to severe psoriasis vulgaris (KIFUderm s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000035-82,0,0,0 2012-000036-26,9,2014-12-19,2015-01-19,7,0,0,0,0,0,3,0,0,1,1,0,1,0,1,PregLem S.A.,": A Phase III, multicentre, randomized, double-blind clinical study, investigating the efficacy and safety of repeated 12-week courses of daily 5mg or 10mg doses of PGL4001 for the long-term managemen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000036-26,0,0,0 2012-000036-26,9,2014-12-19,2015-01-19,7,0,0,0,0,0,3,0,0,1,1,0,1,0,1,PREGLEM SA,": A Phase III, multicentre, randomized, double-blind clinical study, investigating the efficacy and safety of repeated 12-week courses of daily 5mg or 10mg doses of PGL4001 for the long-term managemen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000036-26,0,0,0 2012-000038-20,1,2014-05-26,2014-05-26,1,1,1,0,0,0,1,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A randomised, double-blind, placebo-controlled trial to assess safety, tolerability and pharmacokinetics of liraglutide in obese adolescent subjects aged 12 to 17 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000038-20,0,0,0 2012-000039-22,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,CHIESI,AN OPEN LABEL PLACEBO STUDY TO ASSESS THE INHALATION PROFILE OBTAINED BY ACOUSTIC MONITORING IN ASTHMATIC PATIENTS USING THE NEXTHALER DRY POWDER INHALER (DPI) DEVICE. Studio in Aperto con Placebo ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000039-22,0,0,0 2012-000041-12,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Zentiva k.s. Prague,Characterisation of ovulation inhibition and effects on metabolic parameters and haemostatic system of multiple administrations of a fixed-dose combination product containing 0.02 mg ethinylestradiol ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000041-12,0,0,0 2012-000042-35,4,2017-06-28,2018-06-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,BOTOX® Treatment in Pediatric Lower Limb Spasticity: Double-blind Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000042-35,0,0,0 2012-000043-27,4,2018-09-03,2018-09-03,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,BOTOX® Treatment in Pediatric Upper Limb Spasticity: Open-label Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000043-27,0,0,0 2012-000044-10,1,2017-03-13,2017-03-13,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,OMNIVISION,"Open, Observer-blind, two Parallel Group, Randomized, Multicentric Clinical Phase III Trial on the Comparison of Efficacy and Tolerability of a New Preservative-free Formulation of the Fixed Combinati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000044-10,0,0,0 2012-000045-12,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Centre François Baclesse,Relation entre la tolérance de l’évérolimus et la concentration sanguine résiduelle d’évérolimus pour le traitement du carcinome rénal avancé,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000045-12,0,0,0 2012-000046-35,8,2013-12-23,2018-09-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled phase III multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 16 weeks and to assess the long term effic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000046-35,0,0,0 2012-000046-35,8,2013-12-23,2018-09-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled phase III multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 16 weeks and to assess the long term effic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000046-35,0,0,0 2012-000046-35,8,2013-12-23,2018-09-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo-controlled phase III multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 16 weeks and to assess the long term effic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000046-35,0,0,0 2012-000048-89,1,2015-06-09,2015-06-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis France,"A Multicenter, Single arm, Open Label Clinical Trial Evaluating Safety and Health-Related Quality of Life of Aflibercept in Combination with Irinotecan/5FU chemotherapy (FOLFIRI) in Patients with Met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000048-89,0,0,0 2012-000054-63,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,FUNDACION INVESTIGACION BIOMEDICA HOSPITAL NINO JESUS,Salvage therapy with chemotherapy and Natural Killer cells in relapsed/refractory paediatric T cell lymphoblastic leukaemia and lymphoma. INFUSIÓN DE CÉLULAS NATURAL KILLER EN COMBINACIÓN CON QUIMI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000054-63,0,0,0 2012-000055-13,4,2015-09-18,2015-10-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Almirall S.A.,"A multi-center, randomized, double-blind, three-arm, 16 week, adaptive phase III clinical study to investigate the efficacy and safety of LAS41008 vs LASW1835 and vs Placebo in patients with moderate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000055-13,0,0,0 2012-000057-31,1,2014-01-06,2014-01-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,THERANOR sprl,"Multicentre, randomised, double-blind, parallel, placebo-controlled study evaluating the efficacy and safety of Early Self-Treatment of viral Upper respiratory tract infections with homeopathic oral A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000057-31,0,0,0 2012-000058-73,1,2016-03-19,2016-03-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Liverpool,"A multi-centre (UK) double-blind randomised parallel group placebo controlled trial to evaluate the efficacy, safety, and tolerability of Intravenous Immunoglobulin (IVIg) 0.5g/kg plus standard treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000058-73,0,0,0 2012-000058-73,1,2016-03-19,2016-03-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Walton Centre NHS Foundation Trust,"A multi-centre (UK) double-blind randomised parallel group placebo controlled trial to evaluate the efficacy, safety, and tolerability of Intravenous Immunoglobulin (IVIg) 0.5g/kg plus standard treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000058-73,0,0,0 2012-000061-21,16,2015-10-12,2016-07-19,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study Valuta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000061-21,0,0,0 2012-000061-21,16,2015-10-12,2016-07-19,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ELI LILLY AND COMPANY,Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study Valuta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000061-21,0,0,0 2012-000062-38,4,2017-07-01,2017-07-06,4,1,0,0,0,0,3,0,2,1,0,0,1,0,1,Allergan Limited,BOTOX® Treatment in Pediatric Upper Limb Spasticity: Double-blind Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000062-38,0,0,0 2012-000063-24,2,2012-07-30,2012-07-30,1,1,0,0,0,0,2,0,1,1,1,0,1,0,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Ph II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety & Immuno. of AGRIPPAL® S1 Vaccine, Formulation 2012-2013, in Non-elderly Adult and Elderly Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000063-24,0,0,0 2012-000063-24,2,2012-07-30,2012-07-30,1,1,0,0,0,0,2,0,1,1,1,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Ph II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety & Immuno. of AGRIPPAL® S1 Vaccine, Formulation 2012-2013, in Non-elderly Adult and Elderly Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000063-24,0,0,0 2012-000064-24,1,2013-11-30,2013-11-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,AB ANALITICA SRL,"Comparative assessment of diagnostic performance of C13-Urea Breath Test (BREATHQUALITY-UBT, oral solution C13-Urea 75 mg/10 mL) with 10 min protocol vs standard 30 min protocol to determinate the Hel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000064-24,0,0,0 2012-000066-37,2,2018-09-14,2018-09-18,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Nordmark Arzneimittel GmbH & Co. KG,"Double-blind, randomized, placebo-controlled study on efficacy, safety and tolerability of ancrod in patients with sudden sensorineural hearing loss Dvojitě zaslepená, randomizovaná, placebem kon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000066-37,0,0,0 2012-000067-25,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Princess Máxima Center for pediatric oncology,Protocol ALL-11: Treatment study protocol of the Dutch Childhood Oncology Group for children and adolescents (1-19 year) with newly diagnosed acute lymphoblastic leukemia Protocol ALL-11: Protocol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000067-25,0,0,0 2012-000068-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,The effects of dexmedetomidine on cerebral autoregulation and cerebral oxygenation in subarachnoid haemorrhage patients. Deksmedetomidiinin vaikutukset aivoverenkierron autoregulaatioon ja aivokud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000068-11,0,0,0 2012-000070-28,3,2013-11-21,2013-11-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000070-28,0,0,0 2012-000072-42,9,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,0,The University of Birmingham,A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma ? BEACON-Neuroblastoma Trial Estudio aleatorizado de fase IIb con ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000072-42,0,0,0 2012-000073-23,14,2014-09-01,2014-09-01,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000073-23,0,0,0 2012-000073-23,14,2014-09-01,2014-09-01,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMACEUTICA S.A,"An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000073-23,0,0,0 2012-000073-23,14,2014-09-01,2014-09-01,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000073-23,0,0,0 2012-000075-16,13,2016-02-28,2016-02-28,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer HealthCare AG,Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone- Refractory) Prostate Cancer Patients with Bone Metastasis Cloruro di radio-223 (Alpharadin) nei pazienti affetti da tumore alla p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000075-16,0,0,0 2012-000075-16,13,2016-02-28,2016-02-28,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer AG,Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone- Refractory) Prostate Cancer Patients with Bone Metastasis Cloruro di radio-223 (Alpharadin) nei pazienti affetti da tumore alla p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000075-16,0,0,0 2012-000075-16,13,2016-02-28,2016-02-28,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BAYER HEALTHCARE AG,Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone- Refractory) Prostate Cancer Patients with Bone Metastasis Cloruro di radio-223 (Alpharadin) nei pazienti affetti da tumore alla p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000075-16,0,0,0 2012-000080-25,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ROCHE,"A Phase IIb, Open Label, Single Arm, Multicenter Study to Evaluate the Effect of 48-weeks Peginterferon alfa-2a (PEG-IFN) Administration on Serum HBsAg in Chronic Hepatitis B, HBeAg-Negative, Genotype...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000080-25,0,0,0 2012-000083-24,4,2014-09-04,2014-09-04,2,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Shire ViroPharma Incorporated,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, DOSERANGING, CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) WITH RECOM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000083-24,1,0,0 2012-000083-24,4,2014-09-04,2014-09-04,2,1,0,0,0,0,2,0,0,2,1,0,0,0,1,ViroPharma Incorporated,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, DOSERANGING, CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) WITH RECOM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000083-24,1,0,0 2012-000084-24,4,2018-08-25,2018-08-25,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,BOTOX® Treatment in Pediatric Lower Limb Spasticity: Open-label Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000084-24,0,0,0 2012-000085-38,2,2012-08-14,2012-08-14,1,1,0,0,0,0,2,0,1,1,1,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, Adjuvanted with MF59C.1 Influenza Vaccine, Formulation 2012-2013, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000085-38,0,0,0 2012-000085-38,2,2012-08-14,2012-08-14,1,1,0,0,0,0,2,0,1,1,1,0,1,0,1,NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.,"A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, Adjuvanted with MF59C.1 Influenza Vaccine, Formulation 2012-2013, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000085-38,0,0,0 2012-000087-15,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,"A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF CYCLOPHOSPHAMIDE IN MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETHASONE TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000087-15,0,0,0 2012-000090-23,1,2017-12-19,2017-12-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Bristol,Mirtazapine added to SSRIs for treatment resistant depression in primary care: a placebo controlled randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000090-23,0,0,0 2012-000091-41,1,2019-07-25,2019-07-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University College London,A randomised phase 2 trial investigating the additional benefit of hydroxychloroquine(HCQ) to short course radiotherapy (SCRT) in patients aged 70 years and older with high grade gliomas (HGG),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000091-41,0,0,0 2012-000095-42,11,2016-09-15,2016-09-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000095-42,0,0,0 2012-000095-42,11,2016-09-15,2016-09-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim GmbH & Co.KG,"A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000095-42,0,0,0 2012-000095-42,11,2016-09-15,2016-09-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000095-42,0,0,0 2012-000095-42,11,2016-09-15,2016-09-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda","A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000095-42,0,0,0 2012-000095-42,11,2016-09-15,2016-09-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co.KG,"A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000095-42,0,0,0 2012-000095-42,11,2016-09-15,2016-09-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000095-42,0,0,0 2012-000095-42,11,2016-09-15,2016-09-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Italia S.p.A.,"A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000095-42,0,0,0 2012-000097-26,10,2018-06-24,2018-09-26,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,United Therapeutics Corporation,"A Phase III, International, Multi-Center, Randomized, Double- Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000097-26,0,0,0 2012-000098-21,11,2021-08-12,2021-08-12,8,1,0,0,0,1,3,0,0,2,0,0,0,0,1,United Therapeutics Corporation,An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension- A long term follow up to protocol TDE-PH-310 Studio di estensione in aperto su UT-15C in soggetti con ipert...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000098-21,1,0,0 2012-000098-21,11,2021-08-12,2021-08-12,8,1,0,0,0,1,3,0,0,2,0,0,0,0,1,UNITED THERAPEUTICS,An Open Label Extension Study of UT-15C in subjects with Pulmonary Arterial Hypertension- A long term follow up to protocol TDE-PH-310 Studio di estensione in aperto su UT-15C in soggetti con ipert...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000098-21,1,0,0 2012-000101-69,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,Astellas Pharma Europe Ltd. (APEL),"An exploratory, open label, single-arm study to evaluate the effect of Eligard® 6-month on biomarkers of disease in patients with metastatic prostate cancer. Een verkennend, open-label, enkel-arm o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000101-69,0,0,0 2012-000108-13,1,2014-09-11,2014-09-11,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Universitätsklinikum Münster,A phase II multicenter trial with Rivaroxaban in the treatment of livedoid vasculopathy assessing the pain on a visual analog scale (VAS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000108-13,0,0,0 2012-000109-66,9,2016-05-23,2016-05-23,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"TAIHO PHARMA USA, INC","RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAS-102 PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC COLORECTAL CANCER REFRACTORY TO STANDARD CHEMOTHERAPIES STUDI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000109-66,0,0,0 2012-000109-66,9,2016-05-23,2016-05-23,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Taiho Oncology, Inc.","RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAS-102 PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC COLORECTAL CANCER REFRACTORY TO STANDARD CHEMOTHERAPIES STUDI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000109-66,0,0,0 2012-000109-66,9,2016-05-23,2016-05-23,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Taiho Pharma USA, Inc.","RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAS-102 PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO PLUS BSC IN PATIENTS WITH METASTATIC COLORECTAL CANCER REFRACTORY TO STANDARD CHEMOTHERAPIES STUDI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000109-66,0,0,0 2012-000110-11,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Universitario Príncipe de Asturias,Evaluation of the analgesic efficacy of morphine chloride added to a solution of spinal low dose of local anesthetic as compared to standard doses of spinal local anesthetic alone in patients undergoi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000110-11,0,0,0 2012-000114-10,1,2014-09-30,2014-09-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CHEMI S.P.A.,"A Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of LF-PB 10 mg, 20 mg, and 30 mg to Treat Lymphorrhea Post Axillary Dissection in Breast Can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000114-10,0,0,0 2012-000122-21,1,2018-02-28,2018-02-28,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Department of Neurology, Roskilde Hospital",Acethylcholineesterase inhibition and orthostatic hypotension in patients with parkinsons disease Acethylcholinesterase inhibition og ortostatisk hypotension hos patienter med Parkinsons Sygdom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000122-21,0,0,0 2012-000123-41,9,2016-07-14,2016-07-14,8,1,0,0,2,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000123-41,0,0,0 2012-000123-41,9,2016-07-14,2016-07-14,8,1,0,0,2,0,4,0,0,1,0,0,1,0,1,Lilly S.A.,Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000123-41,0,0,0 2012-000123-41,9,2016-07-14,2016-07-14,8,1,0,0,2,0,4,0,0,1,0,0,1,0,1,ELI LILLY,Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000123-41,0,0,0 2012-000126-22,2,2014-01-03,2014-01-07,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects with T2DM.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000126-22,0,0,0 2012-000126-22,2,2014-01-03,2014-01-07,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects with T2DM.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000126-22,0,0,0 2012-000128-16,12,2018-01-30,2018-02-05,12,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Onyx Therapeutics, Inc.","A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone Versus Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000128-16,0,0,0 2012-000128-16,12,2018-01-30,2018-02-05,12,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"ONYX THERAPEUTICS, INC.","A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone Versus Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000128-16,0,0,0 2012-000130-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Medizinische Universität Graz, Univ. Klinik für Anästhesiologie und Intensivmedizin, Abt. Anästhesie und Intensivmedizin",PHANOS (PHysostigmine-enHAnced Opioid analgeSia) study Reduzierter Opioidverbrauch durch Physostigmin als Dauertropf zur postoperativen PCA – PHANOS (PHysostigmine-enhANced Opioid analgeSia) Folge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000130-19,0,0,0 2012-000134-19,1,2014-06-10,2014-06-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Aeterna Zentaris GmbH,"A randomised, phase 2 trial of AEZS-108 in chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000134-19,0,0,0 2012-000136-26,3,2015-01-21,2015-01-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 2, Open-Label, Single-Arm, Multidose Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000136-26,0,0,0 2012-000137-39,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma S.A.S,"Etude nationale multicentrique, randomisée, en ouvert, évaluant l’efficacité et la tolérance de l’évérolimus associé au mycophénolate sodique , en comparaison à un traitement standard associant tacrol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000137-39,0,0,0 2012-000138-20,11,2017-02-01,2017-02-01,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE BIOLOGICALS SA,"A phase III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals' herpes zoster gE/AS01B cand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000138-20,0,0,0 2012-000138-20,11,2017-02-01,2017-02-01,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline SA,"A phase III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals' herpes zoster gE/AS01B cand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000138-20,0,0,0 2012-000138-20,11,2017-02-01,2017-02-01,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals' herpes zoster gE/AS01B cand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000138-20,0,0,0 2012-000138-20,11,2017-02-01,2017-02-01,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Biologicals sa,"A phase III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals' herpes zoster gE/AS01B cand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000138-20,0,0,0 2012-000139-21,1,2018-08-01,2018-08-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Innere Medizin III","A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients with Rheumatoid Arthritis to a Specific Biologic Mode of Action",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000139-21,0,0,0 2012-000140-97,2,2013-10-23,2013-10-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,The efficacy of insulin degludec/liraglutide as add-on therapy in controlling glycaemia in adults with type 2 diabetes inadequately controlled on sulphonylurea with or without metformin therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000140-97,0,0,0 2012-000142-35,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,UNICANCER,A Prospective randomized phase III study of Androgen deprivation therapy with or without docetaxel with or without local radiotherapy with or without local radiotherapy with or without ABIRATERONE ACE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000142-35,0,0,0 2012-000145-12,1,2016-09-12,2016-09-12,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,The Newcastle upon Tyne Hospitals NHS Foundation Trust,Rituximab for the Treatment of Fatigue in Primary Biliary Cirrhosis (PBC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000145-12,0,0,0 2012-000146-35,10,2014-03-14,2014-03-26,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients with Type 2 Diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000146-35,0,0,0 2012-000147-27,1,2013-03-31,2013-03-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,University of Oxford,A Single-Blind Randomised Controlled Pilot trial of Corticosteroid Injection for Shoulder Pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000147-27,0,0,0 2012-000152-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,evaluation of the effect of treatment with DPP-4 inhibitor on endothelial function versus sulphonylurea on markers of oxidative stress and inflammation and platelet function in patients with diabetes ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000152-34,0,0,0 2012-000153-31,5,2014-02-06,2014-02-06,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Aires Pharmaceuticals, Inc","A Phase 2, Multi-Center, Open-Label study to evaluate the intermediate/long term safety and efficacy of AIR001 in subjects with WHO Group I Pulmonary Arterial Hypertension Eine multizentrische offe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000153-31,0,0,0 2012-000155-14,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Med. Universität Wien, Universitätsklinik für Innere Medizin II",In vivo assessment of the molecular mechanism of inhaled combination of beclomethasone and formoterol on cell differentiation factors and airway remodelling in COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000155-14,0,0,0 2012-000156-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,Etude du rizatriptan comme prémédication antalgique lors d’une pulpite irréversible.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000156-33,0,0,0 2012-000162-38,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,A phase III open-label study to assess the safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine when co-administered with GSK Biologicals’ Infanrix ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000162-38,0,1,1 2012-000164-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""","A factorial study comparing pemetrexed with gemcitabine and testing the efficacy of the addition of cisplatin in elderly patients with non squamous advanced, metastatic or recurrent NSCLC. Studio m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000164-25,0,0,0 2012-000165-20,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación para la Investigación biomédica del Hospital Universitario Ramón y Cajal. Madrid,SEQUENTIAL CLINICAL TRIAL TO EVALUATE THE EFFECTIVENESS OF INTRAVITREAL BEVACIZUMAB AS RESCUE TREATMENT OF RECURRENT MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH OZURDEX ENSAYO ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000165-20,0,0,0 2012-000166-37,4,2014-02-06,2014-02-06,4,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Aires Pharmaceuticals Inc,"A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects with WHO Group 1 Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000166-37,0,0,0 2012-000167-25,1,2018-03-30,2018-03-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UNICANCER,A multicentric randomized phase II study evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000167-25,0,0,0 2012-000171-17,6,2018-11-16,2018-11-16,4,1,1,0,0,0,0,0,0,2,0,0,0,0,1,Shire Pharmaceutical Development Ltd.,"A 3-part Open-label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Compare the Efficacy, Safety and Tolerability of 8 Weeks of Treatment With Lanthanum Carbonate and Calcium Carbonate us...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000171-17,1,1,0 2012-000173-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,HEALTHCARE ASSOCIATED BACTERIAL INFECTIONS IN HOSPITALIZED CIRRHOTIC PATIENTS. RANDOMIZED TRIAL:EMPIRICAL TRADIDIONAL ANTIBIOTIC THERAPY VS SECOND LINE THERAPY lE INFEZIONI BATTERICHE ASSOCIATE AL ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000173-22,0,0,0 2012-000174-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama),"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000174-37,0,0,0 2012-000179-17,1,2012-09-25,2012-09-25,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,ikfe GmbH,"Effect of Linagliptin in comparison with Glimepiride as add on to Metformin on postprandial beta cell function, postprandial metabolism and oxidative stress in patients with type 2 diabetes mellitus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000179-17,0,0,0 2012-000180-25,10,2016-12-28,2016-12-28,8,1,1,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A Phase III, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma who are on inhaled corti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000180-25,1,0,0 2012-000181-37,1,2012-11-29,2012-11-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Civitas Therapeutics, Inc.","A Randomized, Placebo-Controlled Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CVT-301 (Levodopa Inhalation Powder) in Patients with Parkinson’s Disease and Motor Response Flu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000181-37,0,0,0 2012-000184-24,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,ANTONIO JEREZ CALERO,"Whole body hypothermia + melatonin vs whole body hypothermia + placebo in asphyctic newborns. A multicentric, ramdomized, controlled and double blind clinical trial ESTUDIO MULTICENTRICO ALEATORIZA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000184-24,0,0,0 2012-000188-25,1,2020-03-12,2020-03-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,"Lormetazepam versus Midazolam used as sedatives for critically ill patients. Lormetazepam versus Midazolam als Basissedativum für intensivpflichtige Patienten Multizentrische, randomisierte, kont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000188-25,0,0,0 2012-000190-24,10,2016-12-20,2016-12-21,9,1,1,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TO ASSESS THE ORAL CORTICOSTEROID?SPARING EFFECT OF LEBRIKIZUMAB IN PATIENTS WITH SEVERE CORTICOSTEROID-DEPENDENT ASTHMA. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000190-24,0,0,0 2012-000190-24,10,2016-12-20,2016-12-21,9,1,1,0,0,0,2,0,0,1,0,0,1,0,1,"F. Hoffmann-La Roche Ltd, realizado en España por Roche Farma S.A.","A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TO ASSESS THE ORAL CORTICOSTEROID?SPARING EFFECT OF LEBRIKIZUMAB IN PATIENTS WITH SEVERE CORTICOSTEROID-DEPENDENT ASTHMA. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000190-24,0,0,0 2012-000191-41,4,2013-08-08,2013-08-08,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GENENTECH, Inc.","A PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF MPSK3169A IN PATIENTS WITH CORONARY HEART DISEASE OR HIGH RISK OF CORONARY HEART DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000191-41,0,0,0 2012-000196-17,1,2014-12-19,2014-12-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,,"The Effects of Inorganic Nitrite on cardiac and skeletal muscle: Physiology, pharmacology and therapeutic potential in patients suffering from Angina",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000196-17,0,0,0 2012-000196-17,1,2014-12-19,2014-12-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"NHS Grampian, Aberdeen Royal Infirmary","The Effects of Inorganic Nitrite on cardiac and skeletal muscle: Physiology, pharmacology and therapeutic potential in patients suffering from Angina",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000196-17,0,0,0 2012-000198-21,1,2014-10-15,2014-10-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Lluita contra la SIDA,A multicenter randomised opened study to assess the efficacy and safety of the withdrawal of nucleos/tide analogues in HIV-1-infected subjects with complete or intermediate resistance to these analogu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000198-21,0,0,0 2012-000200-15,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación de Investigación Biomédica. Instituto de Investigación Sanitaria del Hospital Universitario de la Princesa.,PHASE IV RANDOMIZED DOUBLE BLINDED AND MULTICENTER CLINICAL TRIAL FOR THE EVALUATION OF AN OXIGEN AND NITROUS OXIDE 50/50 MIXTURE USE IN RENAL COLIC TREATMENT BY AN EMERGENCY SERVICE. ENSAYO CLÍNIC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000200-15,0,0,0 2012-000201-72,1,2014-05-13,2014-05-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Aberdeen,"The Effects of Inorganic Nitrite on cardiac and skeletal muscle: Physiology, Pharmacology and Therapeutic Potential. Peripheral Arterial Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000201-72,0,0,0 2012-000204-15,1,2014-03-18,2014-03-18,1,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, 2 Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who are 2 Through 5 Years of Age and Have a CFTR Gating...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000204-15,0,0,0 2012-000209-63,2,2014-03-11,2014-03-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,The efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on GLP-1 receptor agonist and OAD therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000209-63,0,0,0 2012-000212-28,1,2018-07-02,2018-07-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Medizinische Universität Graz, Univ. Klinik für Dermatologie","A multi-center, randomized study on oral 8-methoxypsoralen plus UVA with or without maintenance therapy in mycosis fungoides EORTC/ISCL stage Ia to IIb. Eine multizentrische, randomisierte , klini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000212-28,0,0,0 2012-000214-11,1,2018-07-20,2018-07-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Birmingham,"BREVITY: A phase II study of brentuximab vedotin using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000214-11,0,0,0 2012-000215-89,3,2014-04-07,2014-04-18,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Institut de Recherches Internationales Servier,"Effects of ivabradine on vascular function in individuals at increased risk of developing cardiovascular disease and with impaired endothelial function An international, multicentre, randomised, doubl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000215-89,0,0,0 2012-000216-28,1,2018-05-22,2018-05-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Innere Medizin III","Treat-To-Target Trial of Continuous Subcutaneous , sensor-augmented insulin-pump therapy in new-onset diabetes after transplantation (SAPT-NODAT): Efficacy and Safety of an Intensive Insulin Protocol ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000216-28,0,0,0 2012-000218-12,3,2016-04-25,2016-04-25,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Pharma Services AG,"A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Va...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000218-12,0,0,0 2012-000218-12,3,2016-04-25,2016-04-25,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Seqirus UK Limited,"A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Va...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000218-12,0,0,0 2012-000220-18,1,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,University of Amsterdam,"Effects of melatonin treatment, light therapy, and sleep improvement on psychosocial, cognitive, and behavioural outcomes in children with Delayed Sleep Phase Syndrome and their parents Onderzoek n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000220-18,0,0,0 2012-000221-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Institut de Recerca Hospital Sant Pau,Estudio farmacogenético fase II randomizado para evaluar la eficacia y seguridad del esquema FOLFIRI con altas dosis de irinotecán (FOLFIRI-AD) en pacientes con cáncer colorrectal metastásico de acue...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000221-42,0,0,0 2012-000222-21,1,2013-05-02,2013-05-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,medac Gesellschaft für klinische Spezialpräparate mbH,"An open-label, randomized, two-period cross-over study of repeated subcutaneous injections of methotrexate 50mg/ml solution either by a pre-filled syringe (reference) or by a disposable pre-filled pen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000222-21,0,0,0 2012-000225-51,2,2018-05-22,2018-05-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Wien Universitätsklinik für Innere Medizin III,Insulin Therapy for the Prevention of New Onset Diabetes after Transplantation (ITP-NODAT) Prospective Study in Non-Diabetic De Novo Kidney Transplant Recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000225-51,0,0,0 2012-000225-51,2,2018-05-22,2018-05-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Fundació Institut Mar d'investigacions Mediques,Insulin Therapy for the Prevention of New Onset Diabetes after Transplantation (ITP-NODAT) Prospective Study in Non-Diabetic De Novo Kidney Transplant Recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000225-51,0,0,0 2012-000232-25,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Efficacité du prétraitement par levosimendan avant pontage aorto-coronaire sous circulation extra-corporelle chez des patients à haut risque (FE < 40%): essai randomisé, multicentrique, en double insu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000232-25,0,0,0 2012-000233-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Institut de Recerca de l?Hospital de la Santa Creu i Sant Pau,"Tratamiento de la leucemia mieloide aguda de novo con la combinación de idarrubicina en dosis creciente, citarabina y sensibilización (?priming?) con G-CSF. Estudio prospectivo en fase I/II de toxici...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000233-39,0,0,0 2012-000236-26,1,2014-12-19,2014-12-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,An exploratory study to investigate the haemodynamic effects of serelaxin in patients with compensated cirrhosis and portal hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000236-26,0,0,0 2012-000240-94,1,2014-01-16,2014-01-16,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Aarhus University Hospital,The Safety and Efficacy of The Histone Deacetylase Inhibitor Panobinostat for Purging HIV-1 from The Latent Reservoir (CLEAR) Study Sikkerhed og Effekt af Histone Deacetylase Inhibitoren Panobinos...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000240-94,0,0,0 2012-000241-13,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Dra. Martinez Payo-Hospital Universitario Puerta de Hierro,Prevention of preterm birth in women at risk identified by ultrasound: evaluation of two treatment strategies. Prevención de parto pretérmino en mujeres de riesgo identificadas por ecografía: evalu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000241-13,0,0,0 2012-000242-35,2,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,0,GENETHON,"A phase I/II, non randomized, multicenter, open-label study of autologous CD34+ cells transduced with the G1XCGD Lentiviral vector in patients with X-Linked Chronic Granulomatous Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000242-35,0,0,0 2012-000242-35,2,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,0,Genethon,"A phase I/II, non randomized, multicenter, open-label study of autologous CD34+ cells transduced with the G1XCGD Lentiviral vector in patients with X-Linked Chronic Granulomatous Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000242-35,0,0,0 2012-000247-27,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación Investigación Hospital Ramón y Cajal,Clinical benefit of diclofenac in patients with acute submassive pulmonary embolism: a randomized clinical trial EFICACIA DE DICLOFENACO EN PACIENTES CON TROMBOEMBOLIA DE PULMÓN SUBMASIVA: ENSAYO C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000247-27,0,0,0 2012-000248-91,1,2014-09-09,2014-09-09,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Institutt for nevromedisin, NTNU",Endoscopic block of the sphenopalatine ganglion with botulinum toxin in intractable cluster headache. Safety issues.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000248-91,0,0,0 2012-000250-55,1,2016-01-25,2016-01-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für innere Medizin III",Renin-Angiotensin System Quantification in patients treated with Aliskiren or Candesartan (RASQAL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000250-55,0,0,0 2012-000251-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,"A PHASE III MULTICENTER, RANDOMIZED STUDY COMPARING CONSOLIDATION WITH (90)YTTRIUM-LABELED IBRITUMOMAB TIUXETAN (ZEVALIN®) RADIOIMMUNOTHERAPY VS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000251-14,0,0,0 2012-000252-34,10,2015-03-20,2015-03-20,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cubist Pharmaceuticals, Inc.","A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients with Clostridium Difficile Associated Diarrhea",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000252-34,0,0,0 2012-000252-34,10,2015-03-20,2015-03-20,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cubist Pharmaceuticals, LLC (formerly known as Cubist","A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients with Clostridium Difficile Associated Diarrhea",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000252-34,0,0,0 2012-000253-30,1,2013-04-11,2013-04-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharma A/S,"An exploratory study evaluating the efficacy of cromoglicate cream compared to cream vehicle in the treatment of itch in psoriasis Eine explorative Studie, die die Wirksamkeit einer Cromoglicat-Cre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000253-30,0,0,0 2012-000254-64,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, open, controlled study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals’ 10- valent pneumococcal conjugate vaccine administered to children with sickle cell di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000254-64,0,1,1 2012-000255-13,14,2016-01-25,2016-01-31,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Portola Pharmaceuticals, Inc.","Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000255-13,0,0,0 2012-000255-13,14,2016-01-25,2016-01-31,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"PORTOLA PHARMACEUTICALS, INC.","Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000255-13,0,0,0 2012-000259-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University of Debrecen, Medical and Health Science Center, Department of Anaesthesiology and Intensive Therapy","Reversal of residual pipecuronium neuromuscular block using sugammadex: a randomized, double-blind, placebo controlled, dosefinding study A pipecuronium reziduális hatásának felfüggesztése sugammad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000259-14,0,0,0 2012-000260-17,1,2013-06-30,2013-06-30,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,IOULIA & IRENE TSETI PHARMACEUTICAL LABORATORIES S.A.-INTERMED S.A.,"A therapeutic equivalence study, comparing two chlorhexidine digluconate formulations, the test formulation Chlorel® Or. T. Sol. 0,2% w / v and the reference formulation Corsodyl® 0.2% w / v Mint Mout...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000260-17,0,0,0 2012-000263-24,1,2015-01-15,2015-01-15,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Medizinische Universität Wien, Univ. Klinik f. Dermatologie",Comparative study for efficacy and tolerability of topical imiquimod 5% cream therapy versus photodynamic therapy (ALA-PDT) of actinic keratoses on the hands and forearms in organ transplant recipient...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000263-24,0,0,0 2012-000265-20,1,2020-05-15,2020-05-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ABCSG (Austrian Breast & Colorectal Cancer Study Group),"A perioperative, single-arm multicenter Phase II academic trial to investigate the efficacy and safety of panitumumab in combination with irinotecan/5-fluorouracil/leucovorin (FOLFIRI) in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000265-20,0,0,0 2012-000269-19,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,"IBSA, Institute Biochimique S.A.","Prospective, open-label, uncontrolled clinical trial evaluating multiple controlled ovarian hyperstimulation cycles in oocyte donor, to assess the immunogenicity of FSH-IBSA Estudio prospectivo, ab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000269-19,0,0,0 2012-000275-16,1,2014-05-06,2014-05-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Hellenic Oncology Research Group (H.O.R.G.),A pilot phase II trial of cabazitaxel in patients with metastatic NSCLC progressing after docetaxel-based treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000275-16,0,0,0 2012-000281-38,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,1,Rottapharm,"A Randomized, Controlled Study To Investigate The Efficacy, Safety And Pharmacokinetics Of Legalon® Sil, Alone Or In Combination With Ribavirin, For The Prevention Of Recurrent Hepatitis C In Liver Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000281-38,0,0,0 2012-000282-20,1,,,0,1,1,0,0,1,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, randomized, open, controlled, multicenter primary vaccination study to demonstrate the non inferiority of the immunogenicity of meningococcal vaccine GSK134612 given intramuscularly versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000282-20,0,1,1 2012-000283-23,1,,,0,1,1,0,0,1,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, open, randomized, controlled primary vaccination study to demonstrate the non-inferiority of meningococcal vaccine GSK134612 given intramuscularly versus Mencevax™ ACWY given subcutaneous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000283-23,0,1,1 2012-000287-17,1,,,0,0,0,0,1,0,2,0,1,0,0,0,0,0,0,FONDAZIONE SANTA LUCIA,PROMOTION OF FUNCTIONAL RESTORATION THROUGH PHARMACOLOGICAL MODULATION OF BRAIN PLASTICITY WITH AMINOPYRIDINE IN PATIENTS WITH MULTIPLE SCLEROSIS STUDIED BY FUNCTIONAL MRI œPromozione del recupero ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000287-17,0,0,0 2012-000290-23,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación para la Investigación Biomédica del Hospital Universitario La Paz,Clinical trial phase IIa to safety treating critical ischemia non-revascularizable lower limb by mesenchymal stem cells. ENSAYO CLÍNICO FASE IIa PARA CONOCER LA SEGURIDAD DEL TRATAMIENTO DE LA ISQU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000290-23,0,0,0 2012-000291-42,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar),Effect of treatment with testosterone undecaonat in patients with Diabetes Mellitus Type 1 (DM-1) and hipogonadotrophic hypogonadism Efecto del tratamiento con undecaonato de testosterona en pacien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000291-42,0,0,0 2012-000292-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP),Phase IIa clinical trial to test the feasibility and safety of using autologous mesenchymal stem cells from fat in the local treatment of bronchopleural fistula Ensayo clínico Fase IIa para comprob...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000292-16,0,0,0 2012-000295-42,6,2014-09-16,2015-02-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GENFIT SA,"A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000295-42,0,0,0 2012-000295-42,6,2014-09-16,2015-02-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GENFIT,"A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000295-42,0,0,0 2012-000298-22,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Fundació Clínic per a la Recerca Biomèdica,"Study to assess the efficacy and safety of oral potassium citrate on the Prevention of nephrocalcinosis in extreme premature: a clinical trial, randomized, double-blind placebo controlled trial. Study...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000298-22,0,0,0 2012-000299-40,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,Novartis Pharma Services AG,"A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg evero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000299-40,0,1,1 2012-000300-15,1,2015-05-31,2015-05-31,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"Medizinische Universität Graz, Univ. Klinik Dermatologie, Forschungseinheit für Photodermatologie",Vitamin D supplementation in polymorphic light eruption: Randomized double-blinded placebo-controlled trial Vitamin D Therapie bei Polymorpher Lichtdermatose: Randomisierte doppelt-verblindede Plaz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000300-15,0,0,0 2012-000301-71,1,2022-09-12,2022-09-12,1,0,0,0,0,0,2,0,0,1,1,1,0,0,0,CHU-ULg,Donor Regulatory T cells (Treg) infusion (DTI) in patients with steroid-refractory chronic graft-versus-host disease (GVHD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000301-71,0,0,0 2012-000305-76,6,2015-04-01,2015-04-01,2,1,0,1,0,2,1,0,0,1,1,0,0,0,1,Novartis Pharma AG,"A phase Ib/II open-label, multi-center study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000305-76,0,0,0 2012-000305-76,6,2015-04-01,2015-04-01,2,1,0,1,0,2,1,0,0,1,1,0,0,0,1,Novartis Pharma Services AG,"A phase Ib/II open-label, multi-center study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000305-76,0,0,0 2012-000305-76,6,2015-04-01,2015-04-01,2,1,0,1,0,2,1,0,0,1,1,0,0,0,1,Novartis Farmacéutica S.A.,"A phase Ib/II open-label, multi-center study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000305-76,0,0,0 2012-000305-76,6,2015-04-01,2015-04-01,2,1,0,1,0,2,1,0,0,1,1,0,0,0,1,Novartis Farma,"A phase Ib/II open-label, multi-center study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000305-76,0,0,0 2012-000307-32,1,2021-03-09,2021-03-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Melan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000307-32,0,0,0 2012-000309-60,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Göteborgs universitet,Biochemical and neuropsychological effects on Premenstrual Dysphoric Disorder after acute administration of escitalopram Biokemiska och neuropsykologiska effekter av akut tillförsel av escitalopra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000309-60,0,0,0 2012-000311-87,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Fundación Fernández-Cruz,"A long-term, randomized, open-labeled, parallel-group trial to compare the effects of liraglutide and sulphonilurea both in combination with metformin on clinical, endothelial and image markers of car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000311-87,0,0,0 2012-000313-37,1,2018-12-31,2018-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,TYKS,"Neuroborrelioosin epidemiologia, taudinkuva, diagnostiikka ja hoito",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000313-37,0,0,0 2012-000317-36,5,2014-12-09,2014-12-09,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase IIA Open Label, Adaptive, Randomized Clinical Trial of Dalotuzumab (MK-0646) Treatment in Combination with Irinotecan Versus Cetuximab and Irinotecan for Patients with Metastatic Rectal Cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000317-36,0,0,0 2012-000320-18,1,2019-07-02,2019-07-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Parnassia Bavo Groep - PsyQ,Phase shift in adult ADHD of sleep and apetite. Faseverschuiving bij volwassenen met ADHD van Slaap en Eetlust (FASE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000320-18,0,0,0 2012-000321-41,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,FUNDACION HOSPITAL NACIONAL DE PARAPLEJICOS PARA LA INVESTIGACIÓN Y LA INTEGRACIÓN,PREVENTIVE TREATMENT OF BONE MASS LOSS WITH ALENDRONATE AND CALCIFEDIOL IN PATIENTS WITH ACUTE SPINAL CORD INJURY TRATAMIENTO PREVENTIVO CON ALENDRONATO Y CALCIFEDIOL DE LA PERDIDA DE MASA ÓSEA EN ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000321-41,0,0,0 2012-000322-21,1,2014-02-28,2014-02-28,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Sanaria Inc.,Controlled human malaria infection after immunization with cryopreserved Plasmodium falciparum sporozoites under chloroquine prophylaxis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000322-21,0,0,0 2012-000323-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Helse Bergen, Haukeland University Hospital",Randomised Trial of Contrast-enhanced Sonothrombolysis in acute ischaemic stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000323-41,0,0,0 2012-000324-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE DI MILANO,Administration of low doses of iodate MdC with fast speed injection in coronaric TCangiography . Somministrazione di basse dosi di MdC iodato a elevata velocita' d'iniezione in angioTC coronarica.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000324-17,0,0,0 2012-000326-22,1,2017-12-14,2017-12-14,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,"Queen Mary, University of London",A PHASE I/II DOSE ESCALATION TRIAL OF HDAC INHIBITOR TEFINOSTAT (CHR-2845) FOR CANCER ASSOCIATED INFLAMMATION IN HEPATOCELLULAR CARCINOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000326-22,0,0,0 2012-000327-40,9,2015-08-19,2015-08-19,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects with Heart Failure and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000327-40,0,0,0 2012-000332-25,1,2015-05-01,2015-05-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Birmingham,vitamin D replacement to prevent lung injury following oesophagectomy - a randomised controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000332-25,0,0,0 2012-000333-40,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,University Medical Center Utrecht,Towards plannable breast surgery: diagnostic accuracy of microbubble enhanced Iodine-125 seed localization of the sentinel lymph node (MIB study) Microbubble contrast echografie met Jodiumzaadjes ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000333-40,0,0,0 2012-000334-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE,Phase II multicenter study of low dose Cytarabine + Tosedostat for previously untreated older patients with acute myeloid leukemia (AML) Studio multicentrico di fase II con Citarabina a basse dosi ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000334-19,0,0,0 2012-000335-11,8,2018-03-15,2018-03-15,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000335-11,0,0,0 2012-000335-11,8,2018-03-15,2018-03-15,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MERCK SHARP & DOHME CORP.,"A Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000335-11,0,0,0 2012-000335-11,8,2018-03-15,2018-03-15,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.","A Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000335-11,0,0,0 2012-000341-13,1,2015-06-01,2015-06-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Weber & Weber GmbH & Co. KG,"Efficacy and Safety of an Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence: A Placebo Controlled, Randomized, Double-blinded Parallel-Group C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000341-13,0,0,0 2012-000343-26,1,2020-01-20,2020-01-20,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,"Academic Medical Center, Neurosurgery","Ultra-early tranexamic acid after subarachnoid hemorrhage. A prospective, randomized, multicenter study. Ultra-vroege toediening van tranexaminezuur na een subarachnoïdale bloeding. Een prospectiev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000343-26,0,0,0 2012-000344-10,1,2017-01-18,2017-01-18,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Medical Research Council,Adjunctive Rifampicin to Reduce Early mortality from Staphylococcus aureus bacteraemia: a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000344-10,0,0,0 2012-000344-10,1,2017-01-18,2017-01-18,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Kings College London,Adjunctive Rifampicin to Reduce Early mortality from Staphylococcus aureus bacteraemia: a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000344-10,0,0,0 2012-000345-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU Medical Center,"A phase II study of gefitinib and fulvestrant in patients with advanced, EGFR mutated non-small cell lung cancer pretreated with reversible EGFR tyrosine kinase inhibitors Een Fase II studie van ge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000345-12,0,0,0 2012-000347-28,7,2016-06-21,2016-06-21,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,Efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000347-28,0,0,0 2012-000347-28,7,2016-06-21,2016-06-21,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GRUNENTHAL GMBH,Efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000347-28,0,0,0 2012-000351-14,1,2016-12-22,2016-12-22,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Barts Health NHS Trust,A PHASE II STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT) OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000351-14,0,0,0 2012-000353-31,4,2017-09-21,2017-09-21,3,1,1,0,0,1,3,0,0,2,0,0,0,0,0,Consorzio per Valutazioni Biologiche e Farmacologiche,"Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate the efficacy and safety of deferiprone compared to deferasirox in paediatric patients aged from 1 month to less...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000353-31,1,1,0 2012-000353-31,4,2017-09-21,2017-09-21,3,1,1,0,0,1,3,0,0,2,0,0,0,0,0,CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE,"Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate the efficacy and safety of deferiprone compared to deferasirox in paediatric patients aged from 1 month to less...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000353-31,1,1,0 2012-000356-33,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Västra Götaland,"Delay in labour due to ineffective uterine contractions is still a major problem in modern obstetric care. It is one of the main reasons for the increased rate of operative deliveries, particularly am...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000356-33,0,0,0 2012-000362-38,3,2014-07-04,2014-07-04,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Birken AG,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000362-38,0,0,0 2012-000363-24,1,2015-01-01,2015-01-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Radboud University Medical Centre Nijmegen,The effect of dipyridamole on the pharmacokinetics of metformin.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000363-24,0,0,0 2012-000364-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomédica,FDDNP-PET FOR IN VIVO DIAGNOSIS OF TAUOPATHY IN UNCLASSIFIABLE PARKINSONISM PET-FDDNP Y DIAGNÓSTICO IN VIVO DE TAUPATÍA EN EL PARKINSONISMO INCLASIFICABLE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000364-21,0,0,0 2012-000368-90,4,2013-08-09,2013-09-08,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BIOGEN IDEC RESEARCH LTD,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000368-90,0,0,0 2012-000368-90,4,2013-08-09,2013-09-08,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec Research Limited,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000368-90,0,0,0 2012-000372-42,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació per la Recerca i la Docència Sant Joan de Déu,"A Phase IV, open-label, prospective, randomised clinical trial to evaluate the usefulness of measuring nitric oxide in exhaled air in the therapeutic management of adult patients with mild asthma E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000372-42,0,0,0 2012-000373-23,1,2013-08-22,2013-08-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,A trial comparing the efficacy and safety of two different titration algorithms for insulin degludec/insulin aspart in subjects with type 2 diabetes mellitus previously treated with insulin glargine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000373-23,0,0,0 2012-000375-16,1,2019-10-02,2019-10-02,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,CHU Dijon,"Effect of Liraglutide on fatty liver content evaluated by 1H-spectroscopy and lipoprotein kinetic, in patients with type 2 diabetes Effet du Liraglutide sur le contenu en graisse hépatique (évalué ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000375-16,0,0,0 2012-000379-18,1,2013-03-23,2013-03-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie",Plasma and synovial fluid pharmacokinetics of cefuroxime and linezolid in patients undergoing elective knee arthroscopy after a single intravenous dose of cefuroxime and linezolid: an exploratory micr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000379-18,0,0,0 2012-000382-20,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Peritoneal Mesothelioma: Optimize Outcomes by the Integration of new Prognostic Factors and Potential Therapeutic Targets in a Individualized Treatment based on Molecular Characterization and Chemosen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000382-20,0,0,0 2012-000384-24,1,2012-10-22,2012-10-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,A 4-Week Randomized Cross-Over Study to Evaluate Daily Lung Function Following the Administration of Albuterol/Salbutamol and Ipratropium in Subjects with Chronic Obstructive Pulmonary Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000384-24,0,0,0 2012-000385-38,1,2016-09-14,2016-09-14,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,BEL116472. A 2 year mechanistic study of belimumab in Idiopathic Membranous Glomerulonephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000385-38,0,0,0 2012-000386-20,1,2015-12-17,2015-12-17,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, 2-Arm, Roll-Over Study to Evaluate the Long-term Safety and Pharmacodynamics of Ivacaftor Treatment in Pediatric Subjects With Cystic Fibrosis and a CFTR Gating Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000386-20,0,0,0 2012-000387-19,1,2013-10-25,2013-10-25,1,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis who Have the R117H-CFTR Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000387-19,0,0,0 2012-000388-26,1,2013-11-13,2013-11-13,1,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Crossover Study With an Open-Label Period to Evaluate the Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Who Have ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000388-26,0,0,0 2012-000389-39,2,2016-04-18,2016-04-18,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects 6 Years of Age and Older with Cystic Fibrosis and a Non-G551D CFTR Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000389-39,0,0,0 2012-000391-42,1,2016-12-31,2016-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Martin-Luther-Universität Halle-Wittenberg,"Investigation on the peritoneal tissue concentrations of antibiotics in surgical patients with peritonitis using microdialysis. Example: linezolide, tigecycline Untersuchung der peritonealen Gewe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000391-42,0,0,0 2012-000393-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOIM GRUPPO ONCOLOGICO MERIDIONALE,a multicenter phase II trial of nab-paclitaxel and capecitabine as first line treatment in Her-2 negative metastatic breast cancer (MBC) studio di fase II sull'utilizzo di nanoparticle albumin-boun...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000393-35,0,0,0 2012-000394-23,3,2015-10-21,2015-10-21,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,SOLTI,"A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN®) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000394-23,0,0,0 2012-000397-30,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,FUNDACIÓN CANARIA DE INVESTIGACIÓN Y SALUD (FUNCIS),CLINICAL ASSESSMENT OF THE EFFECTS OF AUTOLOGOUS PLATELET-POOR PLASMA ON PREVENTION OF BRONCHOPLEURAL FISTULA AND LUNG DAMAGE IN PATIENTS UNDERGOING LUNG RESECTION SURGERY VALORACIÓN CLÍNICA DE LOS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000397-30,0,0,0 2012-000398-21,2,2014-12-23,2014-12-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Laboratorios del Dr. Esteve, S.A.","A proof-of-concept phase 2, randomized, placebo-controlled, double blind, multicentre clinical trial in 2 parallel groups to evaluate the efficacy and safety of E-52862 for reducing the incidence and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000398-21,0,0,0 2012-000399-41,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Laboratorios del Dr. Esteve. S.A.,"An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with postherpet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000399-41,0,0,0 2012-000400-14,2,2014-12-04,2014-12-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratorios del Dr. Esteve. S.A,"An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with painful di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000400-14,0,0,0 2012-000402-30,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Laboratorios del Dr. Esteve. S.A,"An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with post-surgi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000402-30,0,0,0 2012-000406-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,The influence of morning versus evening administration on tamoxifen pharmacokinetics De invloed van inname in de ochtend versus inname in de avond op de farmacokinetiek van tamoxifen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000406-29,0,0,0 2012-000411-91,1,2018-08-03,2018-08-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,"Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial Untersuchu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000411-91,0,0,0 2012-000413-36,1,2015-07-01,2015-07-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College,ACE-EPIC: ACE inhibitors to enhance the effects of pulmonary rehabilitation in COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000413-36,0,0,0 2012-000414-11,6,2018-07-30,2018-07-30,5,1,1,0,0,0,3,0,0,1,0,0,1,0,1,LETI Pharma GmbH,"Multicenter, placebo-controlled, long-term study of Depigoid Birch 5000 in adults and adolescents with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000414-11,0,0,0 2012-000416-28,4,2013-04-25,2013-07-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LETI Pharma GmbH,"A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients with Allergic Rhinitis and/or Rhinoconjunctivitis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000416-28,0,0,0 2012-000418-13,1,2014-07-31,2014-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000418-13,0,0,0 2012-000424-18,1,2015-10-26,2015-10-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London,A study to assess near infrared laparoscopy with indocyanine green (ICG) for intraoperative lymphatic imaging and sentinel lymph node identification during standard surgical resection for colonic canc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000424-18,0,0,0 2012-000425-45,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Effects of morning vs evening dosing on the pharmacokinetics and pharmacodynamics of sunitinib. Effect van ochtend- of avondinname van sunitinib op de medicijnspiegels in het bloed,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000425-45,0,0,0 2012-000427-41,5,2018-11-25,2018-11-25,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Cancer Prevention Pharmaceuticals, Inc.","A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of CPP-1X/Sulindac Compared With CPP-1X, Sulindac as Single Agents in Patients with Familial Adenomatous Polyposis (FAP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000427-41,0,0,0 2012-000432-26,1,,,0,0,1,0,0,0,4,0,0,0,0,0,0,0,0,Maastricht University Medical Centre,Prospective study on the metabolic and linear growth effects of growh hormone treatment in children with Kabuki Syndrome Prospectieve studie naar de metabole en lineaire groei-effecten van groeihor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000432-26,0,0,0 2012-000436-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Frederiksberg University Hospital,"Randomized, double-blinded and placebo-controlled clinical trial of the Rauvolfia-Citrus decoction in patients with type II diabetes Randomiseret, dobbelt-blind og placebo-kontrolleret klinisk fors...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000436-25,0,0,0 2012-000437-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Stichting Antoni van Leeuwenhoek Ziekenhuis,ARTFORCE - Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE. A randomised study with Cisplatinum or Cetuximab and standard or adaptive high dose radiotherapy for adva...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000437-39,0,0,0 2012-000438-21,1,2014-07-08,2014-07-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,"Multi-center, double-blind, placebo-controlled, randomized phase III study to prove the efficacy, safety and tolerability of Silexan (WS®1265) in patients with mixed anxiety and depressive disorder (I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000438-21,0,0,0 2012-000439-17,7,2013-09-12,2013-09-13,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.","A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000439-17,0,0,0 2012-000439-17,7,2013-09-12,2013-09-13,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharpe & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000439-17,0,0,0 2012-000439-17,7,2013-09-12,2013-09-13,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck, Sharpe & Dohme Corp., a subsidiary of Merck & Co. Inc (hereafter referred to as Merck)","A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000439-17,0,0,0 2012-000439-17,7,2013-09-12,2013-09-13,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MERCK SHARP & DOHME CORP.,"A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000439-17,0,0,0 2012-000439-17,7,2013-09-12,2013-09-13,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,","A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000439-17,0,0,0 2012-000439-17,7,2013-09-12,2013-09-13,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000439-17,0,0,0 2012-000441-12,1,2013-06-28,2013-06-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,VIROPHARMA Incorporated,"A randomized, double-blind, placebo-controlled pilot study to evaluate the safety and effect of Cinryze (C1 Esterase Inhibitor (Human)) for the treatment of acute antibody-mediated rejection in recipi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000441-12,0,0,0 2012-000442-35,6,2014-11-18,2014-11-18,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biomay AG,"PHASE II STUDY ON THE SAFETY AND EFFICACY OF BM32, A RECOMBINANT HYPOALLERGENIC VACCINE FOR IMMUNOTHERAPY OF GRASS POLLEN ALLERGY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000442-35,0,0,0 2012-000443-27,1,2012-08-12,2012-08-12,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"Dept. of Anesthesiology and Intensive Care, Charité - Campus Benjamin Franklin",Determination of the penetration of antibiotics into epithelial lining fluid during continuous infusion in mechanically ventilated ICU patients: example meropenem,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000443-27,0,0,0 2012-000444-10,6,2019-10-09,2019-10-09,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,A PHASE IV STUDY TO EVALUATE DECREASED DOSE FREQUENCY IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WHO EXPERIENCE LABORATORY ABNORMALITIES DURING TREATMENT WITH TOCILIZUMAB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000444-10,0,0,0 2012-000444-10,6,2019-10-09,2019-10-09,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,A PHASE IV STUDY TO EVALUATE DECREASED DOSE FREQUENCY IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WHO EXPERIENCE LABORATORY ABNORMALITIES DURING TREATMENT WITH TOCILIZUMAB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000444-10,0,0,0 2012-000445-12,1,2013-05-01,2013-05-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Department off Infectious Diseases, Aarhus University Hospital Skejby, Denmark",Immune Response to Bivalent or Quadrivalent Human Papilloma Virus vaccination in Patients with Chronic Renal Failure Immunrespons efter vaccination mod humant papilloma virus med bivalent eller tet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000445-12,0,0,0 2012-000447-27,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,"Universitätsklinikum Schleswig-Holstein, Campus Kiel",Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery Offene Studie zur funktionellen Charakterisierung von Arzneimittelm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000447-27,0,0,0 2012-000449-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Eero Pesonen,Heparin dose (300 IU/kg vs. 600 IU/kg) in coroanry artery bypass grafting Hepariiniannoksen merkitys sepelvaltimo-ohitusleikkauksen yhteydessä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000449-11,0,0,0 2012-000451-13,2,2019-05-01,2019-05-01,2,1,0,0,0,0,0,0,0,1,0,0,1,0,0,"Transplant Institute, Sahlgrenska University Hospital","A controlled randomized, open-label, multi-centre study evaluating if a steroid-free immunosuppressive protocol, based on ATG- induction, low tacrolimus-dose and therapeutic drug monitoring of mycophe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000451-13,0,0,0 2012-000451-13,2,2019-05-01,2019-05-01,2,1,0,0,0,0,0,0,0,1,0,0,1,0,0,Per Lindner,"A controlled randomized, open-label, multi-centre study evaluating if a steroid-free immunosuppressive protocol, based on ATG- induction, low tacrolimus-dose and therapeutic drug monitoring of mycophe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000451-13,0,0,0 2012-000452-34,8,2018-10-29,2018-11-27,6,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Steno Diabetes Center,Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000452-34,0,0,0 2012-000454-58,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospitals Leuven,"Prospective, monocentre phase I study of sequential infusion of Y90-labeled microspheres and Mitomycine C in patients with chemorefractory liver metastases from breast carcinoma Prospectieve, mono...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000454-58,0,0,0 2012-000458-72,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Juha Hartikainen,HYDROKORTISONIN VAIKUTUS BEETASALPAAJA METOPROLOLIN IMEYTYMISEEN SYDÄNLEIKKAUSPOTILAILLA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000458-72,0,0,0 2012-000459-15,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Clínic per la Recerca Biomèdica,"Phase IV/II open label study for the early evaluation of the response to treatment with Cisplatin, Gemcitabine and Bevacizumab in patientes with advanced or metastatic non small cell lung cancer. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000459-15,0,0,0 2012-000467-24,4,2014-03-24,2014-03-24,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Alnylam Pharmaceuticals, Inc.","A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients with TTR Amyloid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000467-24,0,0,0 2012-000473-23,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,GIOM - Gruppo Italiano Oncologia Nefrologica,PHASE II STUDY OF SUNITINIB AS RECHALLENGE THIRD-LINE THERAPY IN METASTATIC RENAL CANCER Studio di fase II con rechallenge di Sunitinib come trattamento di terza linea nel carcinma renale m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000473-23,0,0,0 2012-000477-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI,A randomized phase II study of FOLFORI plus or not CETUXIMAB in elderly advanced colorectal cancer patients. Studio randomizatto di fase II con FOLFIRI piu' CETUXIMAB o FOLFIRI da solo in pazienti ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000477-23,0,0,0 2012-000478-42,1,2015-06-02,2015-06-02,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Queen Mary, University of London",NEPTUNE: A Randomised Phase II Study of Neoadjuvant TAK-700 and Leuprorelin Acetate versus Surgery Alone in Intermediate and High Risk Clinically Localized Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000478-42,0,0,0 2012-000481-38,1,2013-06-10,2013-06-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Baxter Innovations GmbH,"Tolerability, Safety and Product Administration Evaluation of rHuPH20 Facilitated Subcutaneous Treatment with Immune Globulin (Human), 10% in Subjects with Primary Immunodeficiency Diseases – A Study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000481-38,0,0,0 2012-000482-21,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc,"A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FORMULATED IN MULTIDOSE VIALS GIVEN WITH ROUTINE PEDIATRIC ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000482-21,0,1,1 2012-000487-23,1,2016-04-01,2016-04-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin,A pilot trial to assess the efficacy of Argatroban (Argatra®) in critically ill patients with heparin resistance Eine Pilotstudie zur Untersuchung der Wirksamkeit von Argatroban (Argatra®) bei krit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000487-23,0,0,0 2012-000492-17,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Afdeling Klinische Neuropsychologie Vrije Universiteit Amsterdam,The Effects of Long-acting Methylphenidate on Academic Activity and Related Constructs in Children with ADHD: A Randomised Placebo Controlled Trial De effecten van langwerkend methylfenidaat op sch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000492-17,0,0,0 2012-000497-38,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Fundación FISEVI,"VERDI Study (VERifynow in Diabetes non-responsiveness: a study on switching from Clopidogrel to Prasugrel). A randomized, mono-center study comparing the treatment plan of a loading dose of prasugrel ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000497-38,0,0,0 2012-000509-54,2,2012-11-12,2012-11-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2B Trial to Evaluate the Safety and Efficacy of BMS-823778 in Overweight and Obese Subjects with Inadequately Control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000509-54,0,0,0 2012-000510-10,1,2018-02-16,2018-02-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Birmingham,A Phase IIa trial of 177 Lutetium Dotatate in Children with Primary Refractory or Relapsed High-Risk Neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000510-10,0,0,0 2012-000512-29,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Institut de Recerca Hospital Sant Pau,Sonothrombolysis potentiated by microbubbles as a novel treatment of acute ischemic stroke: a prospective randomized pilot study Sonotrombolisis potenciada por microburbujas como tratamiento nuevo ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000512-29,0,0,0 2012-000513-36,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,A.U.S.L. RIMINI,Validation of the use of lymphography with green indocyanine in identifying the sentinel node in breast cancer Validazione dell’utilizzo del verde indocianina nell’identificazione del linfonodo sen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000513-36,0,0,0 2012-000515-80,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Juan Córdoba,Effects of rifaximin administration in patients with severe acute alcoholic hepatitis. Comparative pilot study. Efectos de la administración de rifaximina en pacientes con hepatitis alcohólica agud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000515-80,0,0,0 2012-000516-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Centre Groningen,A prospective clinical study on the efficacy of collagenase clostridium histolyticum (CCH) injections in the thumb and first web space contractures in Dupuytren's Disease Een prospectief klinisch o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000516-28,0,0,0 2012-000517-37,1,2015-02-23,2015-02-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,A pilot study of Concerta XL in adult offenders with ADHD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000517-37,0,0,0 2012-000517-37,1,2015-02-23,2015-02-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,South London and Maudsley NHS Foundation Trust,A pilot study of Concerta XL in adult offenders with ADHD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000517-37,0,0,0 2012-000518-13,1,2016-05-04,2016-05-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Prof. Per Soelberg Sørensen,Immunomodulating and neuroprotective properties of autologous multipotent mesenchymal stem cells in patients with multiple sclerosis - A randomised placebo-controlled double-blinded phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000518-13,0,0,0 2012-000520-18,5,2013-05-07,2013-07-05,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, placebo controlled, 12-week treatment, parallel-group study to assess the efficacy, safety and pharmacokinetics of indacaterol acetate (75 and 150 μg o.d.) in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000520-18,0,0,0 2012-000522-22,1,2013-08-29,2013-08-29,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,Isofol Medical AB,"A Single-blind, Randomized Phase I/II study of Pharmacokinetic and Pharmacodynamic investigation of Modufolin® (60 or 200 mg/m2) compared to Levoleucovorin (60 or 200 mg/m2) in tumour, adjacent mucosa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000522-22,0,0,0 2012-000523-40,3,2014-07-16,2014-07-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Devlopment Ltd,"A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of GSK2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000523-40,0,0,0 2012-000524-18,6,2013-10-07,2013-10-07,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomized, multi-center, double-blind, doubledummy, parallel group study to evaluate the efficacy and safety of umeclidinium bromide/vilanterol compared with fluticasone propionate/salmeterol over ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000524-18,0,0,0 2012-000524-18,6,2013-10-07,2013-10-07,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A randomized, multi-center, double-blind, doubledummy, parallel group study to evaluate the efficacy and safety of umeclidinium bromide/vilanterol compared with fluticasone propionate/salmeterol over ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000524-18,0,0,0 2012-000525-45,1,2013-10-25,2013-10-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"DB2114930: A randomized, multi-center, double-blind, doubledummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol ov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000525-45,0,0,0 2012-000526-21,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,Västra Götalandregionen (VGR),Vaccination och immunologiskt minne hos nyligen stamcells-transplanterade patienter med multipelt myelom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000526-21,0,0,0 2012-000526-21,1,,,0,0,0,0,0,3,4,0,0,0,0,0,0,0,0,Västra Götalandregionen,Vaccination och immunologiskt minne hos nyligen stamcells-transplanterade patienter med multipelt myelom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000526-21,0,0,0 2012-000528-17,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Department of Experimental Clinical Oncology,A randomized multicenter study of accelerated fractionated radiotherapy with or without the hypoxic radiosensitizer nimorazole in the treatment of squamous cell carcinoma of the head and neck,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000528-17,0,0,0 2012-000528-17,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Aarhus University Hospital,A randomized multicenter study of accelerated fractionated radiotherapy with or without the hypoxic radiosensitizer nimorazole in the treatment of squamous cell carcinoma of the head and neck,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000528-17,0,0,0 2012-000528-17,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,North Estonia Medical Centre Foundation,A randomized multicenter study of accelerated fractionated radiotherapy with or without the hypoxic radiosensitizer nimorazole in the treatment of squamous cell carcinoma of the head and neck,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000528-17,0,0,0 2012-000529-31,8,2018-04-10,2018-04-10,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Amgen Inc,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000529-31,0,0,0 2012-000531-88,11,2013-03-13,2013-04-16,9,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Astellas Pharma Europe Ltd.,"A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000531-88,0,0,0 2012-000531-88,11,2013-03-13,2013-04-16,9,1,0,0,0,0,4,0,0,1,1,0,1,0,1,ASTELLAS PHARMA,"A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000531-88,0,0,0 2012-000533-39,13,2017-06-26,2017-06-26,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 2 years in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000533-39,0,0,0 2012-000533-39,13,2017-06-26,2017-06-26,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 2 years in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000533-39,0,0,0 2012-000533-39,13,2017-06-26,2017-06-26,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmaceutica, S.A.","A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 2 years in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000533-39,0,0,0 2012-000533-39,13,2017-06-26,2017-06-26,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 2 years in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000533-39,0,0,0 2012-000535-36,5,2013-06-17,2013-06-17,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Abbott GmbH & Co. KG,"A multicenter, randomized, double-blind, double dummy, parallel design study to assess pharmacokinetic, pharmacodynamic, safety and immunogenicity of a new adalimumab formulation compared to the curre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000535-36,0,0,0 2012-000535-36,5,2013-06-17,2013-06-17,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A multicenter, randomized, double-blind, double dummy, parallel design study to assess pharmacokinetic, pharmacodynamic, safety and immunogenicity of a new adalimumab formulation compared to the curre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000535-36,0,0,0 2012-000537-39,3,2014-01-15,2014-02-24,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Abbott GmbH & Co. KG,Long-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Comple...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000537-39,0,0,0 2012-000537-39,3,2014-01-15,2014-02-24,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AbbVie Deutschland GmbH & Co. KG,Long-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Comple...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000537-39,0,0,0 2012-000540-10,13,2019-05-16,2019-05-16,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"Multicenter, randomized, double-blind, parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple scleros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000540-10,0,0,0 2012-000541-12,14,2020-03-26,2020-03-26,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Actelion Pharmaceuticals Ltd.,"Multicenter, randomized, double-blind, parallel-group, add-on, superiority study to compare the efficacy and safety of ponesimod to placebo in subjects with active relapsing multiple sclerosis who are...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000541-12,0,0,0 2012-000542-35,1,2018-07-25,2018-07-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,The Clatterbridge Cancer Centre NHS Foundation Trust,Phase II multicentre study assessing the efficacy of Cabazitaxel in Patients with HER2-negative metastatic breast cancer and having unresectable brain metastases.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000542-35,0,0,0 2012-000543-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AMC,A Proof of Concept Study to Determine the Local Delivery and Efficacy of Intravenously Injected PEG-Liposomal Prednisolone Sodium Phosphate (Nanocort®) in Atherosclerotic Tissue in Subjects with Perip...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000543-27,0,0,0 2012-000547-27,1,2015-07-20,2015-07-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,East and North Hertfordshire NHS Trust,A Pilot Randomised Controlled Trial of Drug Treatment for Depression in Patients undergoing Haemodialysis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000547-27,0,0,0 2012-000547-27,1,2015-07-20,2015-07-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Hertfordshire,A Pilot Randomised Controlled Trial of Drug Treatment for Depression in Patients undergoing Haemodialysis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000547-27,0,0,0 2012-000550-60,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Medizinische Universität Wien, Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin 3",Pulsed oral sirolimus in autosomal dominant polycystic kidney disease Gepulstes orales Sirolimus bei autosomal-dominanter polyzystischer Nierenerkrankung,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000550-60,0,0,0 2012-000552-33,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Leiden University Medical Center,Adoptive T cell therapy plus vaccination in metastatic melanoma patients Adoptieve T cel therapie in combinatie met autologe tumor cel vaccinaties als behandeling voor patiënten met gemetastaseerd ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000552-33,0,0,0 2012-000558-71,3,2015-03-17,2015-03-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Synta Pharmaceuticals Corp.,An Open Label Multicenter Phase 2 Window Of Opportunity Study Evaluating Ganetespib (STA-9090) Monotherapy In Women With Previously Untreated Metastic HER2 Positive Or Triple Negative Breast Cancer ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000558-71,0,0,0 2012-000559-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FinnBladder,TREATMENT OF Ta BLADDER CANCER WITH HIGH RISK OF RECURRENCE – FLUORESCENCE CYSTOSCOPY WITH OPTIMIZED ADJUVANT MITOMYCIN-C,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000559-15,0,0,0 2012-000564-14,7,2015-02-24,2015-02-24,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,InterMune International AG.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000564-14,0,0,0 2012-000566-38,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNICANCER,"A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000566-38,0,0,0 2012-000571-16,9,2014-12-09,2014-12-22,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Inc.,An Open-Label Study of GS-7977 + Ribavirin with or without Peginterferon Alfa-2a in Subjects with Chronic HCV Infection who Participated in Prior Gilead HCV Studies.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000571-16,0,0,0 2012-000575-17,3,2015-03-16,2015-03-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratoires SMB S.A.,"A phase III, two-armed, randomised, double blind, parallel study to compare the efficacy and safety in high CHD-risk patients with mixed dyslipidaemia of a 12-week administration of a fixed dose combi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000575-17,0,0,0 2012-000575-17,3,2015-03-16,2015-03-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LABORATOIRES SMB S.A.,"A phase III, two-armed, randomised, double blind, parallel study to compare the efficacy and safety in high CHD-risk patients with mixed dyslipidaemia of a 12-week administration of a fixed dose combi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000575-17,0,0,0 2012-000576-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Cancer Trials Ireland,"S1007, A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000576-42,0,0,0 2012-000577-22,1,2016-03-30,2016-03-30,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,Palatability testing of a new paediatric formulation of valacyclovir for the prophylaxis and treatment of VZV and HSV infections in children – VALID 0 Smaaktest van een nieuwe kinderformulering van...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000577-22,0,0,0 2012-000578-41,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,"GENENTECH, Inc.","A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB (FCFD4514S) IN PATIENTS WITH GEOGRAPHIC ATROPHY WHO HAVE COMPLETED GENENTECH-SPONSORED LAMPA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000578-41,0,0,0 2012-000584-25,1,2018-03-31,2018-03-31,1,1,1,0,0,1,4,0,0,1,0,0,1,0,0,UZBrussel,Propofol and etomidate. Are they also safe for patients with Brugada-Syndrome?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000584-25,0,0,0 2012-000586-20,3,,,0,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Gilead Sciences Inc.,"A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000586-20,0,1,0 2012-000588-26,2,,,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,Leiden University Medical Center,Pharmacokinetics of Levosimendan in Children with acute heart failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000588-26,0,0,0 2012-000589-38,1,2021-11-08,2021-11-08,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000589-38,0,0,0 2012-000591-42,1,2013-06-21,2013-06-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Jennerex, Inc","A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients with Advanced H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000591-42,0,0,0 2012-000592-17,1,2013-08-23,2013-08-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Signe H. Østoft, Diabetes Research Division",The effects of GLP-1 in Maturity- onset diabetes of the young (MODY) Effekten af GLP-1 i maturity onset diabetes of the young (MODY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000592-17,0,0,0 2012-000594-24,1,2012-08-24,2012-08-24,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Royal Sussex County Hospital,An open study to investigate the effects of injection immunotherapy on allergen-specific T and B cell responses in adult patients with seasonal allergic rhinitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000594-24,0,0,0 2012-000596-16,1,2016-09-02,2016-09-02,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Lapland Hospital District/ Lapland Central Hospital,Smoking Cessation of Young Adults in Northern Finland Lapin nuorten tupakkatutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000596-16,0,0,0 2012-000597-38,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Instituto Catalán de Oncología,"Ensayo clínico FESGEN.DOC: Evaluación de la variabilidad interindividual en farmacocinética, eficacia y seguridad de Docetaxel en el tratamiento neoadyuvante de cáncer de mama. Estudio farmacocinético...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000597-38,0,0,0 2012-000598-22,1,2015-06-01,2015-06-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Berufsverband der niedergelassenen gynäkologischen Onkologen in Deutschland e.V.; BNGO e.V.,"Randomised, open-label phase II study to compare the safety and efficacy of lapatinib plus trastuzumab or lapatinib plus capecitabine in trastuzumab-resistant HER2-overexpressing metastatic breast can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000598-22,0,0,0 2012-000599-40,1,2016-12-09,2016-12-09,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,North Bristol NHS Trust,The efficacy of Indwelling Pleural Catheter placement versus IPC placement PLUS sclerosant (talc) in patients with malignant pleural effusions managed exclusively as out-patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000599-40,0,0,0 2012-000600-15,8,2019-01-23,2019-01-23,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000600-15,0,0,0 2012-000601-74,11,2016-12-15,2016-12-15,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell Ly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000601-74,0,0,0 2012-000601-74,11,2016-12-15,2016-12-15,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell Ly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000601-74,0,0,0 2012-000603-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Annadalstichting,Proton pump inhibitors in the prevention of iron reaccumulation in patients with hereditary hemochromatosis Maagzuurremmers ter voorkoming van ijzerstapeling bij patienten met erfelijke ijzerstapel...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000603-32,0,0,0 2012-000605-72,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,Universitair Medisch Centrum Utrecht,Unrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa Allogene stamcel transplantatie midd...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000605-72,0,0,0 2012-000606-29,1,2013-07-02,2013-07-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,An Extension Study of Navitoclax (ABT-263) in Subjects with Chronic Lymphocytic Leukemia (CLL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000606-29,0,0,0 2012-000609-58,7,2014-08-07,2014-11-30,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVO NORDISK,"A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000609-58,0,0,0 2012-000609-58,7,2014-08-07,2014-11-30,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novo Nordisk A/S,"A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000609-58,0,0,0 2012-000610-11,6,2014-08-04,2014-08-07,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVO NORDISK,"A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000610-11,0,0,0 2012-000610-11,6,2014-08-04,2014-08-07,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novo Nordisk A/S,"A randomised, double blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of NNC0109-0012, an anti-IL-20 biologic, in patients with active rheumatoid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000610-11,0,0,0 2012-000615-84,3,2016-11-04,2016-12-09,2,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Oxford,A Mechanistic Study Of Mifamurtide (MTP-PE) In Patients With Metastatic And/Or Recurrent Osteosarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000615-84,0,0,0 2012-000616-28,3,2016-07-15,2016-07-15,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Oxford,Phase II trial of Linsitinib (anti-IGFR/IR) in patients with relapsed and/or refractory Ewing Sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000616-28,0,0,0 2012-000619-10,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,Radboud University Nijmegen Medical Centre,Clinical proof-of-principle of the determination of the beta cell mass in vivo by SPECT imaging with the 111In-labeled GLP-1 analogue DTPA-[K40]-Exendin 4,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000619-10,0,0,0 2012-000620-17,3,2022-02-25,2022-02-25,2,0,0,0,0,0,3,0,0,2,0,0,0,0,0,"Landeshauptstadt Stuttgart, represented by the Executive Medical Director Klinikum Stuttgart","High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial IELSG43: Studio controllato, randomizzato ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000620-17,1,0,0 2012-000620-17,3,2022-02-25,2022-02-25,2,0,0,0,0,0,3,0,0,2,0,0,0,0,0,"Landeshauptstadt Stuttgart, represented by Prof. Dr. J. Graf, Leitender Aerztlicher Direktor Klinikum Stuttgart","High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial IELSG43: Studio controllato, randomizzato ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000620-17,1,0,0 2012-000620-17,3,2022-02-25,2022-02-25,2,0,0,0,0,0,3,0,0,2,0,0,0,0,0,"CITY OF STUTTGART, REPRESENTED BY KLINIKUM STUTTGART","High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial IELSG43: Studio controllato, randomizzato ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000620-17,1,0,0 2012-000622-22,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundació Clínic per a la Recerca Biomèdica,Aspirin for the enhancement of trophoblastic invasion in women with abnormal uterine artery Doppler at 11-14 weeks of gestation Acido acetilsalicílico para la mejora de la invasión trofoblástica en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000622-22,0,0,0 2012-000632-26,4,2015-06-24,2015-06-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,The Medicines Company,Effect of BivaliRudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3) Effetto di bivalirudina sugli esiti di intervento di sostituzione della valvola aortica 2/3 (BRAVO 2/3),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000632-26,0,0,0 2012-000632-26,4,2015-06-24,2015-06-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,THE MEDICINES COMPANY UK,Effect of BivaliRudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3) Effetto di bivalirudina sugli esiti di intervento di sostituzione della valvola aortica 2/3 (BRAVO 2/3),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000632-26,0,0,0 2012-000633-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Fundación para la Formación e Investigación Sanitaria,Extracorporeal photopheresis in liver transplantation. Clinical trial phase I/II safety and efficacy in patients with progressive withdrawal of immunosuppression. FOTOAFERESIS EXTRACORPÓREA EN EL ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000633-39,0,0,0 2012-000634-20,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,A.O. UNIVERSITARIA INTEGRATA DI VERONA,"Multicenter, pilot study to assess the safety and efficacy of Lenalidomide and Ofatumumab combination (Lenofa) in chronic lymphocytic leukenia (CLL) patients relapsed or refractory after fludarabine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000634-20,0,0,0 2012-000635-68,1,2015-06-09,2015-06-09,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University College Dublin,Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome or early multiple sclerosis and healthy control participants. An exploratory randomised double blind...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000635-68,0,0,0 2012-000637-39,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Gilead Sciences Inc.,An Open-Label Study to Explore the Clinical Efficacy of GS-7977 with Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant Ensayo abierto para explo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000637-39,0,0,0 2012-000638-21,2,2013-11-28,2013-11-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Randomized, Open-Label, Multicenter Study of the Safety, Efficacy, and Tolerability of Combination Treatment of Setrobuvir, Danoprevir, Ritonavir, and Copegus® with or without Mericitabine in Treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000638-21,0,0,0 2012-000639-16,2,2014-07-04,2014-07-04,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Synta Pharmaceuticals Corp,"A Single Arm, Phase 2 Study of Ganetespib in Subjects with Advanced Non- Small-Cell Lung Cancer with Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000639-16,1,0,0 2012-000640-10,1,2019-09-04,2019-09-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Velindre NHS Trust,A randomised Phase II study of two pre-operative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carboplatin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000640-10,0,0,0 2012-000642-35,1,2014-05-05,2014-05-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Crossover Study of MK-1029 in Adult Subjects with Persistent Asthma Who Remain Uncontrolled While Being Maintained on Montelukast",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000642-35,0,0,0 2012-000643-27,3,2014-07-30,2014-07-30,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Adaptive-Design, Dose-Ranging Study of MK-1029 in Adult Subjects with Persistent Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000643-27,0,0,0 2012-000643-27,3,2014-07-30,2014-07-30,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co Inc","A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Adaptive-Design, Dose-Ranging Study of MK-1029 in Adult Subjects with Persistent Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000643-27,0,0,0 2012-000644-94,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Val d’Aurelle - Paul Lamarque,A randomized phase II trial assessing Sorafenib (Nexavar®) in combination with irinotecan in metastatic colorectal cancer patients with KRAS mutated tumours after failure of all active drugs known to ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000644-94,0,0,0 2012-000645-13,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ErasmusMC,Infliximab Top-down Study in Kids with Crohn’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000645-13,0,0,0 2012-000646-35,14,2017-04-06,2017-04-14,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non Radiographic Axial Sp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000646-35,0,0,0 2012-000647-27,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Association hospitalière CHU BRUGMANN,"Analgésie post-césarienne : intérêt de l'injection sous-aponévrotique d'anesthésique local par cathéter multiperforé, par rapport à la morphine intrathécale.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000647-27,0,0,0 2012-000648-83,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE DI MILANO,POSITRON EMISSION TOMOGRAPHY/COMPUTERIZED TOMOGRAPHY/ECOCONTRAT OF THE PLAQUE ASSOCIATED WITH CEREBRAL MAGNETIC RESONANCE FOR THE CHARACTERISATION OF THE LESION IN VIVO INTIMA-MEDIA THICKENING ATHEROS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000648-83,0,0,0 2012-000649-11,2,2015-11-19,2015-11-19,1,1,0,0,2,0,4,0,0,1,0,0,1,0,0,St Stephen's Aids Trust,"A phase IV, open-label, single centre, single-arm, pilot study to assess Cerebrospinal fluid INflammatory markers after Addition of Maraviroc to MONotherapy darunavir/ritonavir – The CINAMMON Study SS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000649-11,0,0,0 2012-000649-11,2,2015-11-19,2015-11-19,1,1,0,0,2,0,4,0,0,1,0,0,1,0,0,St Stephen's AIDS Trust,"A phase IV, open-label, single centre, single-arm, pilot study to assess Cerebrospinal fluid INflammatory markers after Addition of Maraviroc to MONotherapy darunavir/ritonavir – The CINAMMON Study SS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000649-11,0,0,0 2012-000650-64,3,2019-04-09,2019-04-09,2,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open label, multi-center, efficacy and safety study of deferasirox in iron overloaded patients with non-transfusion dependent thalassemia (THETIS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000650-64,0,0,0 2012-000650-64,3,2019-04-09,2019-04-09,2,1,0,0,0,1,4,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An open label, multi-center, efficacy and safety study of deferasirox in iron overloaded patients with non-transfusion dependent thalassemia (THETIS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000650-64,0,0,0 2012-000651-13,2,2015-10-02,2015-10-02,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Amgen Inc.,"A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000651-13,0,0,0 2012-000653-32,1,2016-12-12,2016-12-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 1-week, open-label, multi-center study to explore conduction abnormalities during first dose administration of fingolimod in patients with relapsing-remitting multiple sclerosis (START)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000653-32,0,0,0 2012-000654-55,1,2014-05-19,2014-05-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Birmingham,Spironolactone to Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (CKD): A Pilot Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000654-55,0,0,0 2012-000656-34,7,2015-10-16,2016-10-16,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc.,A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAG...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000656-34,0,0,0 2012-000657-30,2,2016-08-11,2016-08-11,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics s.r.l.,"A Phase IIIB, Open Label, Multi-Center Extension Study of V72_28 to assess antibody persistence, and the safety and tolerability of a booster dose after the completion of the vaccination course in stu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000657-30,0,0,0 2012-000658-67,2,2014-02-17,2014-02-17,1,1,1,0,0,1,2,0,0,2,0,0,0,0,0,Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF),"Multi-centre, oral single dose experimental and modelling study to evaluate the pharmacokinetics of deferiprone in patients aged from 1 month to less than 6 years of age affected by transfusion-depend...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000658-67,1,1,0 2012-000658-67,2,2014-02-17,2014-02-17,1,1,1,0,0,1,2,0,0,2,0,0,0,0,0,Consorzio per Valutazioni Biologiche e Farmacologiche,"Multi-centre, oral single dose experimental and modelling study to evaluate the pharmacokinetics of deferiprone in patients aged from 1 month to less than 6 years of age affected by transfusion-depend...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000658-67,1,1,0 2012-000660-22,9,2016-04-12,2016-04-30,9,1,0,0,0,2,2,0,0,1,0,0,1,0,1,F. Hoffmann–La Roche Ltd,"A randomized, multicenter, adaptive phase II/III study to evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) versus taxane (docetaxel or paclitaxel) in patients with previously treate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000660-22,0,0,0 2012-000660-22,9,2016-04-12,2016-04-30,9,1,0,0,0,2,2,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A randomized, multicenter, adaptive phase II/III study to evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) versus taxane (docetaxel or paclitaxel) in patients with previously treate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000660-22,0,0,0 2012-000660-22,9,2016-04-12,2016-04-30,9,1,0,0,0,2,2,0,0,1,0,0,1,0,1,F. Hoffmann?La Roche Ltd,"A randomized, multicenter, adaptive phase II/III study to evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) versus taxane (docetaxel or paclitaxel) in patients with previously treate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000660-22,0,0,0 2012-000665-20,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Universitetssjukhuset Örebro,Evaluation of platelet function following cessation of ticagrelor - a study in patients with acute coronary syndrome and PCI with coronary stent Utvärdering av trombocytfunktionen efter utsättande ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000665-20,0,0,0 2012-000667-24,6,2015-06-11,2016-10-20,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AMGEN INC.,A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAG...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000667-24,0,0,0 2012-000667-24,6,2015-06-11,2016-10-20,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc.,A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAG...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000667-24,0,0,0 2012-000669-19,11,2016-09-16,2016-09-16,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A COMPARATIVE, RANDOMIZED, PARALLEL-GROUP, MULTI-CENTER, PHASE IIIB STUDY TO INVESTIGATE THE EFFICACY OF SUBCUTANEOUS (SC) RITUXIMAB VERSUS INTRAVENOUS (IV) RITUXIMAB BOTH IN COMBINATION WITH CHOP (R-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000669-19,0,0,0 2012-000669-19,11,2016-09-16,2016-09-16,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A COMPARATIVE, RANDOMIZED, PARALLEL-GROUP, MULTI-CENTER, PHASE IIIB STUDY TO INVESTIGATE THE EFFICACY OF SUBCUTANEOUS (SC) RITUXIMAB VERSUS INTRAVENOUS (IV) RITUXIMAB BOTH IN COMBINATION WITH CHOP (R-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000669-19,0,0,0 2012-000671-16,12,2013-07-10,2013-07-10,6,1,0,0,0,0,3,0,0,1,1,1,1,0,1,F. Hoffmann-La Roche Ltd,A Phase 3b Study To Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With Stable Cardiovascular Disease And Glucose Abnormalities,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000671-16,0,0,0 2012-000671-16,12,2013-07-10,2013-07-10,6,1,0,0,0,0,3,0,0,1,1,1,1,0,1,F. HOFFMANN - LA ROCHE LTD.,A Phase 3b Study To Evaluate The Potential Of Aleglitazar To Reduce Cardiovascular Risk In Patients With Stable Cardiovascular Disease And Glucose Abnormalities,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000671-16,0,0,0 2012-000672-42,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Bial Industrial Farmacéutica S.A.,Biological standardization of allergen extracts of pollen of Artemisa vulgaris and Platanus acerifolia and the acarus Dermatophagoides farinae in patients sensitized to them. ESTANDARIZACIÓN BIOLÓG...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000672-42,0,0,0 2012-000674-31,1,2019-02-18,2019-02-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 3-year, multi-center study to describe the long term changes of optical coherence tomography (OCT) parameters in patients under treatment with Gilenya®",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000674-31,0,0,0 2012-000675-16,7,2014-08-19,2015-07-30,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmaceutica S.A.,"A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) versus placebo plus BSC in the treatment of patients with advanced pancreatic neuroen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000675-16,0,0,0 2012-000675-16,7,2014-08-19,2015-07-30,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) versus placebo plus BSC in the treatment of patients with advanced pancreatic neuroen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000675-16,0,0,0 2012-000675-16,7,2014-08-19,2015-07-30,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) versus placebo plus BSC in the treatment of patients with advanced pancreatic neuroen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000675-16,0,0,0 2012-000677-23,7,2014-09-18,2014-09-18,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Phase II, multi-center, open-label, neoadjuvant, randomized study of weekly paclitaxel with or without LCL161 in patients with triple negative breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000677-23,0,0,0 2012-000677-23,7,2014-09-18,2014-09-18,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A Phase II, multi-center, open-label, neoadjuvant, randomized study of weekly paclitaxel with or without LCL161 in patients with triple negative breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000677-23,0,0,0 2012-000677-23,7,2014-09-18,2014-09-18,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis farmacéutica S.A.,"A Phase II, multi-center, open-label, neoadjuvant, randomized study of weekly paclitaxel with or without LCL161 in patients with triple negative breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000677-23,0,0,0 2012-000678-44,1,2013-06-04,2013-06-04,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Reckitt Benckiser Healthcare (UK) Ltd,"A single-centre, randomised, four-way crossover study to investigate the measurement of the acid pocket and subsequent gastro-oesophageal reflux episodes using a novel pH/impedance catheter in subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000678-44,0,0,0 2012-000679-18,2,2014-01-17,2014-01-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy with Saxagliptin and Dapagliflozin added to Metformin co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000679-18,0,0,0 2012-000679-18,2,2014-01-17,2014-01-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Add-On Therapy with Saxagliptin and Dapagliflozin added to Metformin co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000679-18,0,0,0 2012-000680-24,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Academisch Medisch Centrum,"Pain management after operative treatment of extremity fractures, a randomized clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000680-24,0,0,0 2012-000684-24,3,2019-03-04,2019-03-04,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","A Phase 1B/2 Study To Evaluate The Safety And Efficacy of PF-04449913, An Oral Hedgehog Inhibitor, In Combination With Intensive Chemotherapy, Low Dose ARA-C Or Decitabine In Patients With Acute Myelo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000684-24,0,0,0 2012-000690-23,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,0,National Institution of Health (NCI),"A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000690-23,0,1,1 2012-000694-23,7,2018-10-25,2018-10-25,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,PHARMACYCLICS INC.,"A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Sm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000694-23,0,0,0 2012-000694-23,7,2018-10-25,2018-10-25,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Pharmacyclics, Incorporated","A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Sm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000694-23,0,0,0 2012-000694-23,7,2018-10-25,2018-10-25,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Pharmacyclics LLC,"A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Sm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000694-23,0,0,0 2012-000694-23,7,2018-10-25,2018-10-25,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Pharmacyclics LLC an Abbvie Company,"A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Sm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000694-23,0,0,0 2012-000695-42,1,2019-02-26,2019-02-26,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"bluebird bio, Inc.",A Phase I/II Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the β-Hemoglobinopathies (Sickle Cell Anemia and β-Thalassemia Major) by Transplantation of Autologous CD34+ Stem Ce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000695-42,0,0,0 2012-000699-40,1,2014-04-02,2014-04-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRACCO IMAGING,A Study of BR55 in Contrast Enhanced Ultrasound Imaging in Patients with Ovarian and Breast Cancer. Ecografia con BR55 in pazienti con tumore della mammella e dell'ovaio,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000699-40,0,0,0 2012-000701-77,1,2013-12-31,2013-12-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Ghent University Hospital,Cytoreduction followed by Normothermic versus Hyperthermic Intraperitoneal Intraoperative Chemoperfusion: a Phase II Study in Peritoneal Carcinomatosis Cytoreductie gevolgd door normotherme versu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000701-77,0,0,0 2012-000706-30,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,Pfizer Inc,"An Open Label, Randomized, Single Dose, Two-Way Crossover bioequivalence Study Comparing a New 80 mg (2x40 mg) Pediatric Appropriate Formulation to an 80 mg Commercial Atorvastatin Calcium Tablet Form...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000706-30,0,1,1 2012-000708-14,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,"A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of Sorafenib in patients with advanced Renal Cell Carcinoma (RCC) after a radical resection of the metastases. Studio r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000708-14,0,0,0 2012-000709-59,2,2018-12-05,2018-12-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ICORG (the all-Ireland Cooperative Oncology Research Group),"A Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) Versus Placebo With FOLFIRI as Second-Line Therapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000709-59,0,0,0 2012-000709-59,2,2018-12-05,2018-12-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The Irish Clinical Oncology Research Group,"A Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) Versus Placebo With FOLFIRI as Second-Line Therapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000709-59,0,0,0 2012-000711-88,4,2015-05-31,2015-05-31,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"A Phase 2, Multicenter, Single-Arm, Study to Evaluate the Efficacy and Safety of Single-Agent Bruton' s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000711-88,0,0,0 2012-000712-29,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,OM Pharma SA,Clinical and immune modifying capacity of Broncho-Vaxom® tested by LPS challenge in healthy volunteers A randomized double-blind placebo-controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000712-29,0,0,0 2012-000714-11,5,2018-05-30,2018-05-30,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) and Corticosteroids...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000714-11,1,1,0 2012-000721-53,1,2018-06-07,2018-06-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Dept of Neurology, Umeå University Hospital, Umeå, Sweden",ITT-PMS Extension An extension study of intrathecal therapy with monoclonal antibodies in progressive multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000721-53,0,0,0 2012-000725-41,3,2013-06-17,2013-06-17,1,0,0,0,1,1,2,0,0,2,1,0,0,0,1,Cytheris S.A.,"A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy Studio multicentrico, controllato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000725-41,1,0,0 2012-000725-41,3,2013-06-17,2013-06-17,1,0,0,0,1,1,2,0,0,2,1,0,0,0,1,CYTHERIS,"A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy Studio multicentrico, controllato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000725-41,1,0,0 2012-000726-21,9,2014-09-29,2014-10-29,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathoge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000726-21,0,0,0 2012-000728-17,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,Pfizer Inc,"An Open Label, Randomized, Single Dose, Two-Way Crossover Bioequivalence Study Comparing a Pediatric Appropriate Formulation to a 10 mg Commercial Atorvastatin Calcium Tablet Formulation in Healthy Su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000728-17,0,1,1 2012-000729-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"Genentech, Inc.",MULTICENTER STUDY IN PATIENTS WITH CROHN?S DISEASE FOR CHARACTERIZATION OF MAGNETIC RESONANCE ENTEROGRAPHY ASSAYS FOR ASSESSMENT OF DISEASE ACTIVITY Estudio multicéntrico en pacientes con enfermeda...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000729-28,0,0,0 2012-000730-19,1,2014-09-03,2014-09-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Radboud University Nijmegen Medical Centre,"The analgesic efficacy of Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain: a Randomized, Double-blinded, Placebo-controlled, Parallel Design",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000730-19,0,0,0 2012-000734-19,1,2019-09-25,2019-09-25,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Banc de Sang i Teixits,Treatment of autologous mesenchymal stem cells derived from bone marrow as a potential therapeutic strategy for the treatment of multiple sclerosis Tratamiento con Células Troncales Mesenquimales A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000734-19,0,0,0 2012-000735-27,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,FONDAZIONE ITALIANA LINFOMI ONLUS,A phase II study of SGN-35 (brentuximab vedotin) of patients with relapsed or refractory Primary mediastinal large B-cell lymphoma (PMLBCL). Studio di fase II con SGN-35 (Brentuximab vedotin) nei p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000735-27,0,0,0 2012-000737-40,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,Bayer HealthCare Pharmaceuticals,"Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000737-40,0,1,1 2012-000738-21,2,2015-02-18,2015-02-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmaceutica SA,"""NeoPHOEBE: Pi3k inhibition in Her2 OverExpressing Breast cancEr A phase II, randomized, parallel cohort, two stage, double-blind, placebo-controlled study of neoadjuvant trastuzumab versus trastuzuma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000738-21,0,0,0 2012-000738-21,2,2015-02-18,2015-02-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"""NeoPHOEBE: Pi3k inhibition in Her2 OverExpressing Breast cancEr A phase II, randomized, parallel cohort, two stage, double-blind, placebo-controlled study of neoadjuvant trastuzumab versus trastuzuma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000738-21,0,0,0 2012-000741-12,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Double blind, Placebo controlled, Two-Way Crossover 7-day study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Dose Inhaled GW642444 25μg in Chi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000741-12,0,1,1 2012-000746-36,1,,,0,0,1,0,0,0,1,0,0,4,0,0,0,0,1,"Ferrer Internacional, S.A.",A phase I open-label multiple dose study to examine the systemic bioavailability and safety of twice daily topical applications of ozenoxacin 1% cream formulation in patients with impetigo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000746-36,0,1,1 2012-000747-26,1,2019-01-15,2019-01-15,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Helsinki Universiy Central Hospital,Administration of S-Ketamine during spinal surgery to reduce postoperative pain S- Ketamiinin annostelu selkäleikkauksen aikana leikkauksenjälkeisen kivun vähentämiseksi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000747-26,0,0,0 2012-000748-81,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Johanna Hästbacka,Matrix metalloproteinaasien inhibitio doksisykliinillä vaikeassa sepsiksessä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000748-81,0,0,0 2012-000750-66,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ICORG-the All Ireland Co-operative Oncology Research Group,Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000750-66,0,0,0 2012-000751-13,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo Gallego de Investigación en Tumores Digestivos - GITuD,Phase II study of first-line WHIT panitumumab and capecitabine in elderly patients with metastatic colorectal cancer and wild type KRAS Estudio de fase II de panitumumab y capecitabina como tratami...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000751-13,0,0,0 2012-000752-33,2,2012-10-05,2012-10-05,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Starpharma Pty Ltd,"A phase 3, double-blind, multicenter, randomized, placebo-controlled study to assess the efficacy and safety of SPL7013 Gel (VivaGel®) for the treatment of bacterial vaginosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000752-33,0,0,0 2012-000753-31,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A randomized, double-blind, placebo-controlled, two-way crossover 14-day study to invstigate the safety, tolerability,pharmacodynamics and pharmacokinetics of repeat dose inhaled fluticasone furoate 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000753-31,0,1,1 2012-000754-55,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A randomized, double-blind, repeat dose, two period crossover study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of inhaled fluticasone furoate/vilanterol 100/25 mcg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000754-55,0,1,1 2012-000756-34,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,NeuroVive Pharmaceutical AB,"Copenhagen Head Injury Ciclosporin (CHIC) Study: An open-label, uncontrolled Phase II -study to investigate pharmacokinetics, safety and biomarkers of effectiveness of NeuroSTAT® (ciclosporin) in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000756-34,0,0,0 2012-000765-20,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Kuopion yliopistollinen sairaala/silmätautien poliklinikka,"The Effect of Intravitreal Bevacizumab Injections in Patients with Macular Oedema Caused by AMD, CRVO or DME on the Plasticity of Nerves Studied by Visual Evoked Potentials Eri sairauksissa esiinty...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000765-20,0,0,0 2012-000769-19,6,2014-08-19,2014-08-19,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,Randomized phase II study of BEZ235 or everolimus in advanced pancreatic neuroendocrine tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000769-19,0,0,0 2012-000769-19,6,2014-08-19,2014-08-19,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,Randomized phase II study of BEZ235 or everolimus in advanced pancreatic neuroendocrine tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000769-19,0,0,0 2012-000769-19,6,2014-08-19,2014-08-19,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A",Randomized phase II study of BEZ235 or everolimus in advanced pancreatic neuroendocrine tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000769-19,0,0,0 2012-000770-36,2,2017-07-26,2017-07-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre Hospitalier Régional et Universitaire de Lille,"Efficacité et tolérance du nilotinib chez les patients atteints d'une maladie chronique du greffon contre l’hôte (Graft Versus Host, GVH) n'ayant pas répondu à l'imatinib mésilate.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000770-36,0,0,0 2012-000770-36,2,2017-07-26,2017-07-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU-ULg,"Efficacité et tolérance du nilotinib chez les patients atteints d'une maladie chronique du greffon contre l’hôte (Graft Versus Host, GVH) n'ayant pas répondu à l'imatinib mésilate.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000770-36,0,0,0 2012-000773-23,1,2013-03-20,2013-03-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Eli Lilly and Company,Study of the Safety and Efficacy of LY2623091 in Chronic Kidney Disease Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000773-23,0,0,0 2012-000775-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Jesús Villar Hernández,"A comparative, randomised controlled trial for evaluating the efficacy of dexamethasone administration in the treatment of patients with the Acute Respiratory Distress Syndrome Ensayo clínico compa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000775-17,0,0,0 2012-000776-42,6,2013-10-11,2013-10-11,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Menarini Ricerche S.p.A.,"Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study versus Allopurinol",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000776-42,0,0,0 2012-000776-42,6,2013-10-11,2013-10-11,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,MENARINI RICERCHE S.P.A.,"Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study versus Allopurinol",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000776-42,0,0,0 2012-000777-23,6,2014-09-30,2014-09-30,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Birken AG,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000777-23,0,0,0 2012-000778-46,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Forschungszentrum Jülich GmbH,Elucidation of Lithium Working Mechanism in Bipolar Disorder by means of Multi Modal Brain Imaging (LiBiDi) Erforschung des Lithiumwirkmechanismus bei bipolaren Störungen mit multi-modaler Bildgebu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000778-46,0,0,0 2012-000780-24,3,2014-12-15,2014-12-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Astellas Pharma Global Development, Inc.","A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000780-24,0,0,0 2012-000781-38,2,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"Direction de la recherche clinique du centre hospitalier universitaire de Tours, Bretonneau","Prospective, Randomized, open label, European, multicenter study of the efficacy of the linezolid-rifampin combination versus standard of care in the treatment of Gram-positive prosthetic hip joint in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000781-38,0,0,0 2012-000788-26,1,2015-10-29,2015-10-29,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,,"The Effects of Inorganic Nitrite on cardiac and skeletal muscle: Physiology, Pharmacology and Therapeutic Potential in patients with Chronic Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000788-26,0,0,0 2012-000788-26,1,2015-10-29,2015-10-29,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"NHS Grampian, Aberdeen Royal Infirmary","The Effects of Inorganic Nitrite on cardiac and skeletal muscle: Physiology, Pharmacology and Therapeutic Potential in patients with Chronic Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000788-26,0,0,0 2012-000789-39,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A Phase III, open, non-randomized, multi-centre, single dose study to assess immunogenicity and safety of Fluarix/Influsplit SSW 2012/2013 injected intramuscularly in adults (18 to 60 years) and in el...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000789-39,0,0,0 2012-000791-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,FUNDACION INVESTIGACION BIOMEDICA HOSPITAL UNIVERSITARIO LA PRINCESA,"OPEN, RANDOMIZED AND CONTROLLED STUDY OF SAFETY AND VIABILITY, TO EVALUATE THE NEUROPROTECTIVE EFFECT OF PLASMA GLUTAMATE DIALYSIS IN ACUTE ISCHEMIC STROKE. ESTUDIO DE VIABILIDAD Y SEGURIDAD, ABIER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000791-42,0,0,0 2012-000792-16,3,2013-03-12,2013-03-12,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,OCTAPHARMA AG,"“CLINICAL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND EFFICACY OF OCTAGAM 5% IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES”",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000792-16,0,0,0 2012-000793-30,15,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Charité - University Hospital of Berlin,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000793-30,0,0,0 2012-000793-30,15,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Manchester University NHS Foundation Trust,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000793-30,0,0,0 2012-000793-30,15,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Turku University Hospital,International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000793-30,0,0,0 2012-000796-16,4,2013-03-29,2013-03-29,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,OCTAPHARMA AG,"PROSPECTIVE, OPEN-LABEL, NON-CONTROLLED, MULTICENTER, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCTAGAM 10% IN PRIMARY IMMUNE THROMBOCYTOPENIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000796-16,0,0,0 2012-000797-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Hospital Virgen de la Salud, Toledo (Spain).",Clinical Trial with Cladribine (2-CDA) and Pegylated Interpheron Alfa-2a in patients with advanced systemic mastocytosis carrying D816V KIT mutation (or different mutations involving exon 17 of KIT). ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000797-35,0,0,0 2012-000800-13,1,2015-12-02,2015-12-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsklinik für Augenheilkunde und Optometrie,Influence of sustained-release dexamethasone on intraocular cytokines and growth factors and retinal blood vessels in retinal vein occlusion Einfluss von intravitrealem Dexamethason bei Venenversch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000800-13,0,0,0 2012-000801-64,1,2015-03-04,2015-03-04,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital of North Staffordshire,A Phase IV Acceptability and Feasibility Trial of the Effects of Medication on Memory in Idiopathic Nondementing Parkinson’s Disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000801-64,0,0,0 2012-000801-64,1,2015-03-04,2015-03-04,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Keele University,A Phase IV Acceptability and Feasibility Trial of the Effects of Medication on Memory in Idiopathic Nondementing Parkinson’s Disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000801-64,0,0,0 2012-000802-32,4,2015-05-20,2015-05-20,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open label long term, safety and tolerability extension to a randomized, double-blind, placebo controlled study of LCQ908 in subjects with Familial Chylomicronemia Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000802-32,0,0,0 2012-000802-32,4,2015-05-20,2015-05-20,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","An open label long term, safety and tolerability extension to a randomized, double-blind, placebo controlled study of LCQ908 in subjects with Familial Chylomicronemia Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000802-32,0,0,0 2012-000808-16,1,2016-06-30,2016-06-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Aarhus University Hospital,Effects of metformin on hepatic free fatty acid metabolism in type 2 diabetes asssessed by positron emission tomography Effekten af metforminbehandling på leverens lipidomsætning bestemt ved Positr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000808-16,0,0,0 2012-000809-67,1,2018-06-04,2018-06-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Hôpitaux Universitaires de Strasbourg,EFFICACITE CLINIQUE ET VASOCONSTRICTION CEREBRALE INDUITES PAR BLOOD PATCH VERSUS INJECTION PÉRIDURALE D’UNE SOLUTION D’HYDROXYETHYLAMIDON (VOLUVEN) CHEZ DES PATIENTS PRESENTANT DES CEPHALEES INVALID...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000809-67,0,0,0 2012-000810-12,13,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Charité - Universitätsmedizin Berlin,IntReALL HR 2010 International Study for Treatment of High Risk Childhood Relapsed ALL 2010,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000810-12,0,0,0 2012-000812-27,1,2014-09-08,2014-09-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Radboud University Nijmegen Medical Centre,"The analgesic efficacy of Δ9-THC (Namisol®) in patients with persistent postsurgical abdominal pain: a randomized, double-blinded, placebo-controlled, parallel design’",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000812-27,0,0,0 2012-000814-13,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Hospital Leuven,Glibenclamide treatment in hypotonia-cystinuria syndrome Glibenclamide ter behandeling van hypotonie-cystinurie syndroom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000814-13,0,0,0 2012-000819-82,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, multi-centre, open study to assess antibody persistence after completion of the 3-dose primary vaccination course with GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000819-82,0,1,1 2012-000823-42,3,2013-04-10,2013-04-10,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2 MULTI-CENTER, RANDOMIZED, DOUBLE-MASKED, PLACEBO CONTROLLED, MULTI-DOSE STUDY TO INVESTIGATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RN6G (PF 04382923) IN SUBJECTS WIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000823-42,0,0,0 2012-000825-33,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,MedImmune LLC,A Phase 3 Study of MEDI-524 (Motavizumab) for the Prevention of RSV Disease Among Native American Infants in the Southwestern United States,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000825-33,0,1,1 2012-000826-23,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, open, single centre study to assess the safety, reac-togenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate (10Pn-PD-DiT) vaccine (GSK 102485...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000826-23,0,1,1 2012-000827-42,4,2016-08-09,2016-08-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB PHARMA SA/NV.,"AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000827-42,0,0,0 2012-000827-42,4,2016-08-09,2016-08-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Pharma SA,"AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000827-42,0,0,0 2012-000829-44,2,2016-12-20,2016-12-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes and Moderate or Severe Chronic K...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000829-44,0,0,0 2012-000833-38,1,2014-03-31,2014-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Isis Pharmaceuticals, Inc.",A Phase 2 Study to Assess the Antiarrhythmic and Symptomatic Effect of the Second Generation Antisense Oligonucleotide ISIS 329993 Targeting CRP in Patients with Paroxysmal Atrial Fibrillation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000833-38,0,0,0 2012-000834-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTI FISIOTERAPICI OSPITALIERI,Molecular Biomarkers for Colorectal Liver Metastases Resectability after Chemotherapy with Cetuximab MARCATORI BIOMOLECOLARI DI RESECABILITA' PER METASTASI EPATICHE COLORETTALI TRATTATE CON CHEMIOT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000834-21,0,0,0 2012-000835-18,13,2014-12-15,2015-06-22,10,1,0,0,0,0,3,0,2,1,1,0,1,0,1,Novartis Pharma Services AG,"Open-label, single-arm extension study to the double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000835-18,0,0,0 2012-000835-18,13,2014-12-15,2015-06-22,10,1,0,0,0,0,3,0,2,1,1,0,1,0,1,Novartis Pharma AG,"Open-label, single-arm extension study to the double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000835-18,0,0,0 2012-000835-18,13,2014-12-15,2015-06-22,10,1,0,0,0,0,3,0,2,1,1,0,1,0,1,Novartis Farmaceutica S.A.,"Open-label, single-arm extension study to the double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000835-18,0,0,0 2012-000835-18,13,2014-12-15,2015-06-22,10,1,0,0,0,0,3,0,2,1,1,0,1,0,1,NOVARTIS FARMA,"Open-label, single-arm extension study to the double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000835-18,0,0,0 2012-000836-24,2,2014-05-06,2014-05-06,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"OraPharma, Inc.",Multi-Center Phase 3 Trial of Minocycline HCl 1mg Microspheres for the Use in Subjects with Peri-Implantitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000836-24,0,0,0 2012-000838-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,High-dose alkylating chemotherapy in oligo-metastatic breast cancer harboring homologous recombination deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000838-19,0,0,0 2012-000839-54,1,2012-08-16,2012-08-16,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Rigshospitalet,The effect of late naloxon-infusion on secondary hyperalgesia after a first degree burn injury Effekten af sen naloxon-infusion på sekundær hyperalgesi efter en førstegrads varmeskade,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000839-54,0,0,0 2012-000840-90,1,2018-11-04,2018-11-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),"Randomized phase II study to explore the influence of BRAF and PIK3K status on the efficacy of FOLFIRI plus Bevacizumab or Cetuximab, as first line therapy of patients with KRAS wild-type metastatic c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000840-90,0,0,0 2012-000842-36,1,2017-02-20,2017-02-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Leeds,A Phase I/IIa trial of VTD-panobinostat treatment and panobinostat maintenance in relapsed and relapsed/refractory multiple myeloma patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000842-36,0,0,0 2012-000845-11,3,2016-10-21,2016-10-21,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ApoPharma Inc,"A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000845-11,0,0,0 2012-000845-11,3,2016-10-21,2016-10-21,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ApoPharma Inc.,"A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000845-11,0,0,0 2012-000846-37,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),"Phase III, randomized clinical trial to evaluate FOLFOX + bebacizumab versus FOLFOXIRI + bebacizumab as first line treatment of patients with metastatic colorectal cancer not previously treated and wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000846-37,0,0,0 2012-000847-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Isala Klinieken Zwolle,"Efficacy of Arnica D1 ointment after upper blepharoplasty: a randomized, double-blind placebo-controlled study Het effect van Arnicazalf D1 na bovenooglidcorrectie: een gerandomiseerde, dubbelblind...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000847-28,0,0,0 2012-000850-75,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VU University Medical Center,Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000850-75,0,0,0 2012-000851-15,1,2016-11-24,2016-11-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Bristol,What is the clinical and cost effectiveness of oral steroids in the treatment of acute lower respiratory tract infection (LRTI)? A placebo controlled randomised trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000851-15,0,0,0 2012-000854-73,1,2013-03-01,2013-03-01,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,"THERACLONE SCIENCES, INC.","A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TCN-032 (HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST THE M2 PROTEIN OF INFLUENZA A VIRUS) IN SUBJECTS CHALLENGED WITH H3N2 INFLUENZA A VIRUS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000854-73,0,0,0 2012-000855-15,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,Novartis Pharma Services AG,"An open label, randomized, three period, single-dose, crossover study to determine the bioavailability of 300 mg aliskiren mini-tablets relative to the 300 mg aliskiren market tablet under fasted cond...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000855-15,0,1,1 2012-000856-33,1,2019-11-27,2019-11-27,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,Institut Pasteur,"A phase I/II, open-label, study of intracerebral administration of adeno-associated viral vector containing the human alpha-N-acetylglucosaminidase cDNA in children with Sanfilippo type B syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000856-33,0,0,0 2012-000859-14,8,2016-04-04,2016-04-04,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo, In Subjects with Moderate to Se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000859-14,0,0,0 2012-000866-40,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,ISTITUTO ORTOPEDICO RIZZOLI,Evaluation of the efficacy and suppression of the hypothalamic-pituitary-adrenal axis resulting in intrabursale single administration of cortisone in patients with calcific tendonitis of the rotator c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000866-40,0,0,0 2012-000867-25,2,2013-03-18,2013-03-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Omeros Corporation,"A Phase 3 Randomised, Double-Masked, Placebo-Controlled Study of the Pharmacokinetics of OMS302 and the Effect of OMS302 on Intraoperative Pupil Diameter and Early Postoperative Pain in Subjects Under...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000867-25,0,0,0 2012-000868-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,EFFECT OF TREATMENT WITH PENTOXIFYLLINE ABOUT THE RISK RATER OF POST-angioplasty restenosis IN PATIENTS WITH LOWER LIMB arterial disease EFFETTO DEL TRATTAMENTO CON PENTOSSIFILLINA SUL RISCHIO DI R...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000868-15,0,0,0 2012-000869-21,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"ISTITUTO NEUROLOGICO ""CARLO BESTA""",Pilot study: Imatinib for the treatment of plexiform neurofibromas in NF1 patients. Studio pilota sul trattamento con Imatinib di neurofibromi plessiformi in pazienti con neurofibromatosi di tipo ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000869-21,0,0,0 2012-000870-51,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Unidad de Gestión Clínica de Endocrinología y Nutrición,"RANDOMIZED CLINICAL TRIAL TO ASSESS THE EFFICACY OF TESTOSTERONE UNDECANOATE, METFORMIN, OR THE COMBINATION OF BOTH, FOR THE TREATMENT OF ISOLATED HYPOGONADOTROPIC HYPOGONADISM AND ERECTILE DYSFUNCTIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000870-51,0,0,0 2012-000871-17,5,2018-04-18,2018-04-18,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Argos Therapeutics, Inc.",An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000871-17,1,0,0 2012-000872-40,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Novartis Pharma Services AG,"A pilot study to assess the efficacy and safety of LCQ908 alone and in combination with fenofibrate or Lovaza® in patients with severe hypertriglyceridemia Multicentrická, randomizovaná, placebem k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000872-40,0,0,0 2012-000904-14,1,2015-06-01,2015-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Wien,PHARMACOKINETICS OF MICAFUNGIN DURING CONTINUOUS VENOVENOUS HEMOFILTRATION Pharmakokinetik von Micafungin während kontinuierlicher veno-venöser Hämodiafiltration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000904-14,0,0,0 2012-000905-53,7,2013-11-17,2013-12-03,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double blind, placebo controlled, parallel group efficacy and safety study of oral administration of empagliflozin twice daily versus once daily in two different daily doses over 16 we...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000905-53,0,0,0 2012-000905-53,7,2013-11-17,2013-12-03,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co.KG,"A randomised, double blind, placebo controlled, parallel group efficacy and safety study of oral administration of empagliflozin twice daily versus once daily in two different daily doses over 16 we...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000905-53,0,0,0 2012-000905-53,7,2013-11-17,2013-12-03,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A randomised, double blind, placebo controlled, parallel group efficacy and safety study of oral administration of empagliflozin twice daily versus once daily in two different daily doses over 16 we...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000905-53,0,0,0 2012-000905-53,7,2013-11-17,2013-12-03,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A","A randomised, double blind, placebo controlled, parallel group efficacy and safety study of oral administration of empagliflozin twice daily versus once daily in two different daily doses over 16 we...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000905-53,0,0,0 2012-000924-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,FONDAZIONE ITALIANA LINFOMI ONLUS,Phase II randomized study with R-DHAP +/- Bortezomib as induction therapy in relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) patients before High-Dose chemotherapy BEAM with autologous stem ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000924-16,0,0,0 2012-000927-42,1,2014-08-08,2014-08-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Randomised, Double-Blind, Placebo-Controlled, Cross-Over, Single-Centre Study to Investigate the Acute Lung Deflation Effects of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg Once Daily...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000927-42,0,0,0 2012-000928-18,1,2016-09-16,2016-09-16,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Hospital of the Ludwig-Maximilians-University of Munich,"Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atroph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000928-18,0,0,0 2012-000931-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,EFFECT OF ALBUMIN INFUSION TO PREVENT OVERT HEPATIC ENCEPHALOPATHY AFTER TRANSGIUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS). EFFETTO DELL'INFUSIONE DI ALBUMINA NELLA PREVENZIONE DELL'ENCEFALOPAT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000931-20,0,0,0 2012-000933-37,1,2016-01-11,2016-01-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,National and Kapodostrian University of Athens,"Phase II trial of ofatumumab combined with ESHAP as salvage therapy before autologous stem cell transplantation, for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) previous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000933-37,0,0,0 2012-000935-18,1,2017-06-08,2017-06-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Liverpool,TAILoR – (TelmisArtan and InsuLin Resistance in HIV): A Dose-Ranging Phase II Randomised Open-Labelled Trial of Telmisartan as a strategy for the Reduction of Insulin Resistance in HIV-Positive Indivi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000935-18,0,0,0 2012-000935-18,1,2017-06-08,2017-06-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal Liverpool and Broadgreen Hospitals NHS Trust,TAILoR – (TelmisArtan and InsuLin Resistance in HIV): A Dose-Ranging Phase II Randomised Open-Labelled Trial of Telmisartan as a strategy for the Reduction of Insulin Resistance in HIV-Positive Indivi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000935-18,0,0,0 2012-000938-19,1,2014-06-23,2014-06-23,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVINTETHICAL PHARMA SAGL,Safety and Efficacy of tablets containing extract of Hibiscus Sabdariffa (HS) and Propoli versus placebo in the treatment of the cystitis with Ciproxin Sicurezza ed efficacia di compresse contenent...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000938-19,0,0,0 2012-000939-42,1,2014-03-11,2014-03-11,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Elro Pharma,"A non-randomized, open-label, multi-centric dose-finding adaptive phase I/IIa study to assess safety, tolerability, pharmacokinetics and preliminary efficacy of repeated intravenous IPP-204106N admini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000939-42,0,0,0 2012-000941-11,1,,,0,1,0,0,0,1,4,0,0,1,0,0,0,1,1,Bracco Imaging S.p.A.,A PROSPECTIVE MULTICENTER COHORT STUDY EVALUATING THE LONG TERM RETENTION OF GADOLINIUM IN HUMAN BONE AND SKIN AFTER THE RETROSPECTIVE ADMINISTRATION OF MULTIHANCE® OR PROHANCE® IN COMPARISON WITH A C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000941-11,0,0,0 2012-000942-36,1,2016-07-12,2016-07-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guys and St Thomas NHS Foundation Trust,"Are phrophylactic antibiotics necessary before laparoscopic living kidney donation? A double blind, randomised, controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000942-36,0,0,0 2012-000943-29,6,2015-06-03,2015-06-03,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO4602522 ADDED TO BACKGROUND ALZHEIMER'S DISEASE THERAPY IN PATIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000943-29,0,0,0 2012-000943-29,6,2015-06-03,2015-06-03,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO4602522 ADDED TO BACKGROUND ALZHEIMER'S DISEASE THERAPY IN PATIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000943-29,0,0,0 2012-000946-37,2,2012-12-20,2012-12-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A randomized, double-blind, parallel-group, placebo-controlled study to assess the safety of REGN668 administered concomitantly with topical corticosteroids to patients with moderate-to-severe Atopic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000946-37,0,0,0 2012-000948-98,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Rigshospitalet,Effect of epinephrine on systemic absorption of mepivacaine administered for brachial plexus block in patients with end-stage renal disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000948-98,0,0,0 2012-000952-32,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Bayer HealthCare AG,"Open-label, multi-center study to evaluate the safety, efficacy, and plasma gadolinium concentrations after an intravenous injection of 0.1 mL/kg body weight Eovist/Primovist for enhanced magnetic res...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000952-32,0,1,1 2012-000955-15,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,"A phase IIa open-label, single arm, multi-center trial evaluating the safety of standard antiviral therapy (pegylated interferon and ribavirin) plus deferasirox in thalassemia patients with transfusio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000955-15,0,0,0 2012-000956-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St. Antonius Ziekenhuis,Pharmacokinetics of intravenous acetaminophen and its metabolites in morbidly obese patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000956-32,0,0,0 2012-000957-30,4,2015-03-27,2015-03-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd.,BOTOX® for the Treatment of Urinary Incontinence due to Neurogenic Detrusor Overactivity in Patients with Multiple Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000957-30,0,0,0 2012-000966-40,6,2015-06-01,2015-06-01,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Endocyte, Inc.","A Randomized, Open-Label Phase 2 Study of EC145 Single-agent and the Combination of EC145 plus Docetaxel Versus Docetaxel Alone in Participants with Folate-Receptor Positive [FR(++)] Second Line NSCLC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000966-40,0,0,0 2012-000967-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,,Concomitant Radiotherapy and Erlotinib in advanced lung cancer ThoRaT-studien Thoracal Radiotherapy and Tarceva® An open randomized multicenter phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000967-25,0,0,0 2012-000972-40,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Multicentered, Randomized, Open-Label, Pragmatic Use Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000972-40,0,0,0 2012-000973-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,,Transarterial Chemoembolization with Drug-Eluting Beads Loaded with Doxorubicin for the Treatment of Metastatic Breast Cancer to the Liver: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000973-22,0,0,0 2012-000975-18,1,2014-09-29,2014-09-29,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Abbott Laboratories GmbH,"Open-label, Randomized, Parallel-Group, Exploratory Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects with Nonalcoholic Steatohepatitis (NASH) and non-t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000975-18,0,0,0 2012-000979-17,5,2014-05-02,2014-05-02,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Zymenex A/S,"A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Repeated Lamazym Treatment of Subjects with alpha-Mannosidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000979-17,0,0,0 2012-000981-40,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,The Swedish AML Group,Azacitidine compared to conventional chemotherapy in consolidation of elderly patients (> 65 years) with AML in first complete remission,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000981-40,0,0,0 2012-000983-27,1,2013-01-12,2013-01-12,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Pharma Services AG,"A single-dose, open-label parallel-group study to assess the pharmacokinetics of LCZ696 in subjects with hepatic impairment compared to matched healthy subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000983-27,0,0,0 2012-000985-39,8,2017-05-04,2017-05-12,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, double-blind and open label, 2 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000985-39,0,0,0 2012-000985-39,8,2017-05-04,2017-05-12,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A multicenter, double-blind and open label, 2 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000985-39,0,0,0 2012-000985-39,8,2017-05-04,2017-05-12,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A multicenter, double-blind and open label, 2 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000985-39,0,0,0 2012-000987-11,1,2014-04-01,2014-04-01,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Anni Ravnbek Jensen,DEBIRI-TACE (DRUG ELUTING BEAD med IRINOTECAN-TRANS ARTERIEL CHEMO EMBOLIZATION) Intrahepatic chemoembolization with irinotecan-containing DC-BEADS combined with systemic chemotherapy and bevacizumab...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000987-11,0,0,0 2012-000988-25,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Gateshead Health NHS Trust Research & Development,To determine the feasibility of using Microbubble technology to detect sentinel nodes in vulvar cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000988-25,0,0,0 2012-000989-37,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Reinier de Graaf Groep,Local Infiltration Anaesthesia in Total Hip Arthroplasty by Anterior Supine Intermuscular Approach Locale infiltratie anesthesie in totale heup arthroplastie met de anterior supine intermusculaire ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000989-37,0,0,0 2012-000992-18,1,2016-11-04,2016-11-04,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,UMC Utrecht,"Proactive versus reactive inhibition in ADHD: Genetics, neurobiology and pharmacology Proactieve versus reactieve inhibitie bij ADHD: Genetica, neurobiologie en farmacologie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000992-18,0,0,0 2012-000994-22,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA,"Accuracy and clinical impact of 68-Ga-labeled octreotide analogues PET in diagnosis and staging of duodeno-pancreatic neuroendocrine tumours; proposal of a multicenter, prospective clinical trial A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000994-22,0,0,0 2012-000996-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,Phase II study of biweekly cabazitaxel in patients affected by castration resistant prostate cancer previously treated with docetaxel: evaluation of safety and quality of life. Phase II study of bi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000996-17,0,0,0 2012-000997-53,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,ANTIPLATELET TREATMENT FOR PREVENTION OF VASCULAR OUTCOMES IN PAD PATIENTS UNDERGOING PERIPHERAL REVASCULARIZATION. TRATTAMENTO ANTIPIASTRINICO NELLA PREVENZIONE DEGLI EVENTI VASCOLARI NEI PAZIENT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000997-53,0,0,0 2012-000999-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Effects of anatomical localization of the fentanyl patch on the pharmacokinetics and pharmacodynamics of fentanyl: a randomised cross-over trial Effecten van de anatomische lokatie van de fentanylp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000999-41,0,0,0 2012-001005-25,1,2013-10-21,2013-10-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A randomised, double-blind, double-dummy, placebo and active-controlled, three-way crossover study to evaluate the safety, tolerability and efficacy of 28-day inhaled CHF 6001 DPI (1200microgrammes da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001005-25,0,0,0 2012-001006-24,1,2017-06-28,2017-06-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Augenklinik Universitaetsallee,Ranibizumab and Vitrectomy in the Therapy of Diabetic Macular Edema (The RAVIT-DME-Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001006-24,0,0,0 2012-001010-42,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,ITALIAN SARCOMA GROUP,"A multicenter, prospective, randomized clinical trial for patients with relapsed osteosarcoma Studio clinico multicentrico, prospettico, randomizzato per il trattamento dei pazienti con osteosarco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001010-42,0,0,0 2012-001017-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IRCCS FONDAZIONE ISTITUTO NEUROLOGICO C. MONDINO,A randomized controlled trial of generic substitution of antiepileptic drugs Studio controllato randomizzato sulle implicazioni farmacocinetiche e cliniche della sostituzione di prodotti generici d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001017-16,0,0,0 2012-001019-22,1,,,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,"A.I.Virtanen Insitute, University of Kuopio",Treatment of chronic critical lower limb ischemia with combination of surgical bypass operation and adenoviral VEGF-DdNdC intramuscular gene transfer A Randomized Single-Blinded Placebo-controlled P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001019-22,0,0,0 2012-001020-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Helse Bergen HF, Haukeland University Hospital","A randomized phase II trial comparing bevacizumab monotherapy with dacarbazine (DTIC) in treatment of malignant melanoma, focusing on angiogenic markers and prevention of hypertension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001020-35,0,0,0 2012-001031-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para Formación e Investigación Sanitaria,Randomized controlled trial of the efficacy of fosfomycin vs ciprofloxacin as antibiotic prophylaxis before transrectal ultrasound guided prostate Ensayo clínico aleatorizado controlado de la efica...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001031-31,0,0,0 2012-001032-57,2,2012-07-25,2012-07-25,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Abbott Biologicals B.V.,"Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Northern Hemisphere Season 2012/2013. An Open-Label, Baseline- Controlled Study in Two Age Groups...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001032-57,0,0,0 2012-001038-32,10,2015-04-16,2015-05-27,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Ipsen Pharma,"A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF OF CONCEPT STUDY OF MAINTENANCE THERAPY WITH TASQUINIMOD IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WHO ARE NOT PROGRESSING AFT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001038-32,0,0,0 2012-001038-32,10,2015-04-16,2015-05-27,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,IPSEN PHARMA SAS,"A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PROOF OF CONCEPT STUDY OF MAINTENANCE THERAPY WITH TASQUINIMOD IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER WHO ARE NOT PROGRESSING AFT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001038-32,0,0,0 2012-001039-30,1,,,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,Hospital of Goethe-Universitiy,"BetHäm2012: A monocenter, single-blind, randomized, 2-armed, placebo-controlled, cross-over study to investigate coagulation markers in patients with haemophilia A after administration of Betain ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001039-30,0,0,0 2012-001042-18,3,2015-10-27,2015-10-27,1,1,1,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Booster Effect and Safety of a DTaP-IPV-Hib Combined Vaccine, with or without Hep B, in Healthy Subjects 11 to 18 Months of Age Who Received a Hexavalent or Hexavalent/Pentavalent Combined Vaccine dur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001042-18,0,0,0 2012-001044-22,1,2013-10-18,2013-10-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Galderma R&D SNC,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY TO DEMONSTRATE THE EFFICACY AND ASSESS THE SAFETY OF CD07805/47 GEL 0.5% APPLIED TOPICALLY ONCE DAILY IN SUBJECTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001044-22,0,0,0 2012-001049-42,1,2014-08-21,2014-08-21,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Department of Oncology, Rigshospitalet",MRI-perfusion and FLT- and FET-PET during bevacizumab monotherapy for patients with recurrent Glioblastoma Multiforme MR perfusion og FLT- og FET-PET i løbet af Bevacizumab monoterapi for recidiver...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001049-42,0,0,0 2012-001050-25,7,2015-11-04,2015-11-04,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001050-25,0,0,0 2012-001050-25,7,2015-11-04,2015-11-04,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmaceutica S.A,"A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001050-25,0,0,0 2012-001050-25,7,2015-11-04,2015-11-04,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A multicenter, open-label, randomized phase II study to evaluate the efficacy of AUY922 vs pemetrexed or docetaxel in NSCLC patients with EGFR mutations who have progressed on prior EGFR TKI treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001050-25,0,0,0 2012-001051-39,1,2018-09-30,2018-09-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Kuopio University Hospital, Clinic of Internal Medicine/Center of Medicine","A prospective phase II study to assess immunophenotypic remission after three-drug in-duction followed by randomized stem cell mobilization, autologous stem cell transplantation and lenalidomide maint...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001051-39,0,0,0 2012-001054-26,2,2014-01-10,2014-01-10,1,1,1,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety Study of a Hexavalent DTaP-IPV-Hep B-PRP-T Combined Vaccine or Infanrix hexa™ Concomitantly Administered With 13-Valent Pneumococcal Conjugate Vaccine (PCV13), at 3, 5, 11 to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001054-26,0,0,0 2012-001055-39,3,2014-11-27,2014-11-27,3,1,1,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Phase III, multi-center trial in 795 infants in the Czech Republic, Germany, and Spain. Subjects from the Czech Republic and Germany will be randomized in Groups 1 and 2 to receive in a blind-observer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001055-39,0,0,0 2012-001056-19,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,0,FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DEL HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS,ROLE OF BIOLOGICAL THERAPY IN ROTATOR CUFF TENDINOPATHY. EFFECTIVENESS OF PLASMA RICH IN GROWTH FACTOR (PRGF-ENDORET)REGARDING TO FUNCTIONAL CAPACITY AND PAIN COMPARED WITH THE CONVENTIONAL TREATMENT ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001056-19,0,0,0 2012-001062-15,3,2014-12-25,2014-12-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"An open-label, international, multicenter, interventional study exploring the efficacy of once-daily oral rivaroxaban (BAY 59-7939) for the treatment of left atrial/left atrial appendage thrombus in s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001062-15,0,0,0 2012-001066-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de salut de Barcelona ( Parc de Salut Mar),Sympathetic renal denervation versus increment of pharmacological treatment in resistant arterial hypertension Denervación simpática renal versus escalada terapéutica farmacológica en la hipertensi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001066-14,0,0,0 2012-001067-79,3,2016-04-29,2016-04-29,2,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Psioxus Therapeutics Ltd.,A Clinical Study Of ColoAd1 Administered by Sub-Acute Fractionated Intravenous Injection: Dose Escalation in Metastatic Epithelial Solid Tumours and Randomised Controlled Trial in Metastatic Colorecta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001067-79,0,0,0 2012-001091-11,5,2020-04-03,2020-04-03,2,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"BIAL - Portela & Ca, S.A.","OPEN-LABEL, 2-DOSE LEVEL TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY IN INFANTS WITH REFRACTORY EPILEPSY WITH PARTIAL-ONSET SEIZ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001091-11,1,0,0 2012-001096-37,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,sanofi-aventis Recherche & Développement,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to evaluate the Efficacy and Safety of SAR236553 (REGN727) in Patients With Heterozygous Familial Hypercholesterolemia and LDL-C hi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001096-37,0,0,0 2012-001098-94,2,2019-11-12,2019-11-12,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,GERCOR,A randomized phase II double-blind trial of sunitinib versus placebo in combination with lanreotide in patients with progressive advanced/metastatic midgut carcinoid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001098-94,0,0,0 2012-001099-13,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma GmbH,"Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001099-13,0,0,0 2012-001100-38,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,"DIPART. DI NEUROSCIENZE, SCIENZE RIPRODUTTIVE E ODONTOSTOMATOLOGICHE DELL’UNIVERSITà DEGLI STUDI DI NAPOLI “FEDERICO II""",Antagonists of Angiotensin II Receptors in sepsis Antagonisti dei recettori dell'angiotensina II nella sepsi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001100-38,0,0,0 2012-001101-24,1,2012-06-01,2012-06-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,CSL Limited,"A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2012/2013 Formulation of the Enzira® vaccine in Two Groups of Healthy Volunteers: ‘Adults’ (aged 18 to 59 y...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001101-24,0,0,0 2012-001102-14,6,2019-11-21,2019-11-29,4,1,0,0,0,2,3,0,0,1,0,0,1,0,0,Cambridge University Hospital NHS Foundation Trust,"An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001102-14,0,0,0 2012-001102-14,6,2019-11-21,2019-11-29,4,1,0,0,0,2,3,0,0,1,0,0,1,0,0,"University College Cork , Ireland","An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001102-14,0,0,0 2012-001102-14,6,2019-11-21,2019-11-29,4,1,0,0,0,2,3,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust,"An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001102-14,0,0,0 2012-001103-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,MANTAINANCE METRONOMIC PER OS NAVELBINE IN ADVANCED NSCLC PATIENTS AFTER PREVIOUS PLATINUM BASED CHEMOTHERAPY: A MULTICENTER RANDOMIZED BEST SUPPORTIVE CARE CONTROLLED PHASE II STUDY: MA.NI.LA. TRIAL....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001103-21,0,0,0 2012-001104-37,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospitals Bristol NHS Foundation Trust,Pulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001104-37,0,0,0 2012-001106-26,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,JAVIER MARTÍN BROTO,PHASE II MULTICENTRIC AND PROSPECTIVE TRIAL WITH GEMCITABINE AND RAPAMYCIN IN SECOND LINE OF METASTATIC OSTEOSARCOMA ENSAYO FASE II MULTICENTRICO Y PROSPECTIVO CON GEMCITABINA Y RAPAMICINA EN SEG...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001106-26,0,0,0 2012-001107-20,1,2014-04-09,2014-04-09,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"MicroDose Therapeutx, Inc., a wholly owned subsidiary of Teva Pharmaceuticals Industries, Ltd.","A Phase 2a Randomised, Double-Blind, Placebo-Controlled Repeat Dose Trial of the Activity of MDT-637 in Healthy Subjects Challenged with RSV-A (Memphis 37b)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001107-20,0,0,0 2012-001112-29,2,2020-09-02,2020-09-02,2,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Fa. Dr. Franz Köhler Chemie GmbH,"A Prospective, randomized, single blind, multicenter Phase III study of organ perfusion with Custodiol-N solution compared with Custodiol solution in Heart transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001112-29,0,0,0 2012-001112-29,2,2020-09-02,2020-09-02,2,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Dr. Franz Köhler Chemie GmbH,"A Prospective, randomized, single blind, multicenter Phase III study of organ perfusion with Custodiol-N solution compared with Custodiol solution in Heart transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001112-29,0,0,0 2012-001125-27,6,2015-09-29,2015-09-30,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet?s Disease uveitis Estudio controlado frente a placebo, aleatorizado, do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001125-27,0,0,0 2012-001125-27,6,2015-09-29,2015-09-30,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Laboratorios Servier S.L.,"A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet?s Disease uveitis Estudio controlado frente a placebo, aleatorizado, do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001125-27,0,0,0 2012-001125-27,6,2015-09-29,2015-09-30,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,"A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet?s Disease uveitis Estudio controlado frente a placebo, aleatorizado, do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001125-27,0,0,0 2012-001128-36,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Institut de Recerca HSCSP,Integral care program with or without palliative chemotherapy in patients with advanced cancer: multicentre randomized clinical trial. Programa de Atencion Integral (PAI) con o sin Quimioterapa pal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001128-36,0,0,0 2012-001131-31,1,2013-09-12,2013-09-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Department of Medical Research,Effekts of nebivolol on the nitric oxide system in patients with essentiel hypertension Effekten af nebivolol på NO-systemet hos patienter med essentiel hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001131-31,0,0,0 2012-001132-60,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,GlaxoSmithKline R&D Limited,"Open-label, multiple dose study to evaluate the pharmacokinetics, safety and tolerability of ezogabine/retigabine as adjunctive treatment in subjects aged from 12 years to less than 18 years with part...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001132-60,0,1,1 2012-001133-14,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","An Open Label, Intravenous to Oral Switch, Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Immunocompromised Children Aged 2 to <12 Years who are at Hi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001133-14,0,1,1 2012-001134-33,1,2014-12-31,2014-12-31,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Universitätsklinikum Ulm,"Randomized, Double-Blind, Placebo-Controlled Trial of Ferric Carboxymaltose Versus Placebo in Patients with Congestive Heart Failure Eine randomisierte, doppelblinde, Placebo-kontrollierte Studie ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001134-33,0,0,0 2012-001136-61,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,AstraZeneca AB,"A Phase III, Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety of Once Daily Esomeprazole for the Treatment of Clinically Diagnosed Gastroesophageal Reflux Disease (GE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001136-61,0,1,1 2012-001141-41,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,0,National Cancer Institute NCI,"A PHASE I STUDY OF IPILIMUMAB (ANTI-CTLA-4) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH TREATMENT REFRACTORY CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001141-41,0,1,1 2012-001142-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,"Efficacy and pharmacokinetics of a switch from a regimen consisting of emtricitabine, nevirapine and tenofovir to rilpivirine, emtricitabine and tenofovir in virologically suppressed HIV-1 infected pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001142-18,0,0,0 2012-001143-46,1,2013-10-10,2013-10-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,A randomized open-label study to compare safety and efficacy of vildagliptin versus NPH insulin add-on to glimepiride in patients with type 2 diabetes mellitus that do not reach adequate glycemic cont...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001143-46,0,0,0 2012-001144-22,1,2016-08-17,2016-08-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE SAS,"A RANDOMIZED, OPEN-LABEL, PHASE II STUDY ASSESSING THE EFFICACY AND THE SAFETY OF BEVACIZUMAB IN NEOADJUVANT THERAPY IN PATIENTS WITH FIGO STAGE IIIC/IV OVARIAN, TUBAL OR PERITONEAL ADENOCARCINOMA, IN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001144-22,0,0,0 2012-001145-40,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,"Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320",Open-label Extension Treatment with TNFR:Fc for Participating Patients in TNFR:Fc Clinical Trials,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001145-40,0,1,1 2012-001149-42,1,,,0,0,0,0,1,0,4,0,1,4,0,0,0,0,0,Medical Centre Haaglanden,Cyclopentolate induced EEG changes in children Cyclopentolaat geinduceerde EEG veranderingen bij kinderen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001149-42,0,0,0 2012-001150-26,1,2015-04-01,2015-04-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Steno Diabetes Center,"Liraglutide in type 1 diabetes. A randomised, double-blind, placebo controlled study of the effect of liraglutide as an additional treatment to insulin on HbA1c, body weight and hypoglycaemia in poorl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001150-26,0,0,0 2012-001151-39,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","An Open Label, Intravenous to Oral Switch, Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Immunocompromised Adolescents Aged 12 to <17 Years who are a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001151-39,0,1,1 2012-001152-19,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Antonio Moreno Galdó,Effect of supplementation with vitamin D on the acute bronchitis prevention during the first year of life. Efecto de la suplementación con vitamina D en la prevención de las bronquitis agudas duran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001152-19,0,0,0 2012-001154-26,1,,,0,0,1,0,0,0,1,0,0,4,0,0,0,0,0,Pediatric Brain Tumour Consortium,A phase I Clinical Trial of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumours,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001154-26,0,1,1 2012-001155-39,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,AstraZeneca AB,"Phase I trial of AZD2171, an orally bioavailable antiangiogenic agent, in children and adolescents with refactory or recurrent solid tumours or acute myelogenous leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001155-39,0,1,1 2012-001156-19,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,AstraZeneca LP,"A Randomized, Open-Label Study to Evaluate the Pharmacokinetics of Single Oral Doses of Esomeprazole Magnesium in Pediatric Patients 1 to 11 Years-Old Inclusive with Endoscopically-Proven Gastroesopha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001156-19,0,1,1 2012-001157-97,1,,,0,1,1,0,0,3,1,0,0,4,0,0,0,0,1,AstraZeneca AB,"A Randomized, Open-Label Study to Evaluate the Pharmacokinetics of Multiple Doses of Esomeprazole Magnesium in a Pediatric Population of 1 to 11 Year olds with Gastroesophageal Reflux Disease (GERD) o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001157-97,0,1,1 2012-001158-25,1,,,0,1,1,0,0,3,1,0,0,4,0,0,0,0,1,AstraZeneca AB,"A Randomized, Open-Label Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Esomeprazole Magnesium 20 mg and 40 mg in a Pediatric Population of 12 to 17 Year-Olds with Gastroesopha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001158-25,0,1,1 2012-001159-37,1,,,0,1,1,0,1,0,2,0,0,4,0,0,0,0,1,AstraZeneca AB,"A Single-Blind, Randomised, Parallel-Group, Single-Centre Pharmacokinetic and pH-Monitoring Study of Esomeprazole in Infants up to 24 Months of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001159-37,0,1,1 2012-001160-29,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,AstraZeneca AB,An Open Single-centre Study on the Pharmacokinetics and Pharmacodynamics of Esomeprazole After Once Daily Oral Administration for 7 Days in Preterm Infants and Neonates,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001160-29,0,1,1 2012-001169-33,1,2013-03-25,2013-03-25,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Department of Medical Research,Effects of tolvaptan on renal sodium and water handling and circulation during inhibition of the nitric oxide system in healthy subjects Effekten af tolvaptan på nyrernes behandling af vand og natr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001169-33,0,0,0 2012-001171-37,1,,,0,1,1,0,0,0,4,0,0,4,0,0,0,0,1,"Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320",A Phase IV Registry of Etanercept in Children With Juvenile Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001171-37,0,1,1 2012-001172-12,9,2013-09-25,2013-09-25,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, 12-week treatment, parallel-group study to evaluate the efficacy and safety of QMF149 (150 µg/160 µg o.d.) compared with salmeterol xinafoate/fluticasone propionate (50 µg/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001172-12,0,0,0 2012-001175-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Haukeland University hospital,LOW-DOSE KETAMINE AS ADJUVANT TREATMENT TO MORPHINE IN NEUROPATHIC CANCER PAIN.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001175-36,0,0,0 2012-001176-10,12,2018-05-01,2018-05-01,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International N.V.,"A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO13...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001176-10,0,0,0 2012-001177-93,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Sylentis,PILOT TRIAL FOR ASSESSMENT TOLERABILITY AND EFFECT OF SYL1001 IN PATIENS WITH OCULAR PAIN ENSAYO PILOTO PARA EVALUAR LA SEGURIDAD Y EL EFECTO DE SYL1001 EN PACIENTES CON DOLOR OCULAR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001177-93,0,0,0 2012-001178-28,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Fundación para la Investigación Biomédica del Hospital Universitario La Paz,"Multicentre, randomized, comparative and Add-on, in two parallel groups to assess the efficacy and safety of autologous mesenchymal stem cells derived from expanded adipose tissue (ASC) for the treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001178-28,0,0,0 2012-001180-77,1,,,0,0,1,0,0,1,2,0,0,4,0,0,0,0,1,AstraZeneca,"An open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocious ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001180-77,0,1,1 2012-001183-30,1,,,0,0,1,0,0,0,2,0,0,4,0,0,0,0,0,Nemours Children's Clinic,Double-blind trial investigating the safety and efficacy of the inhibitor anastrozole (arimidex) in delaying epiphyseal fusion and increasing height potential of adolescent males with growth hormone (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001183-30,0,1,1 2012-001186-33,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,"Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320",An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects With Plaque Psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001186-33,0,1,1 2012-001188-55,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,Double umbilical cord blood transplantation in high-risk hematological patients. A phase II study focussing on the mechanism of graft predominance,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001188-55,0,0,0 2012-001194-81,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. LUIGI GONZAGA,"Randomized Phase III Multicenter Trial of Customized Chemotherapy versus Standard of Care for 1st Line Treatment of Elderly Patients with Advanced Non-Small-Cell Lung Cancer Studio multicentrico, r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001194-81,0,0,0 2012-001200-38,4,2015-11-03,2015-11-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BCN Peptides S.A.,"Neurodegeneration as an early event in the pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, randomized controlled trial to assess the efficacy of neuroprotective drugs ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001200-38,0,0,0 2012-001201-24,1,2016-01-18,2016-01-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,SOLTI,"A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin (Myocet®) plus paclitaxel, trastuzumab, and pertuzumab in patients with operable HE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001201-24,0,0,0 2012-001208-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Medizinische Universität Wien, Univ.Klinik für Innere Medizin III, Abt.f.Endokrinologie und Stoffwechsel",A new therapeutic approach to prevent acute insulin-mediated complications in type 2 diabetes Subtitle: The effect of the combination of the GLP-1 Analog Liraglutide and Insulin LEvemir® vs. cOnventi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001208-39,0,0,0 2012-001209-26,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Charité Universitätsmedizin Berlin,Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and lithiumaugmentation (Li.-Aug.) of antidepressants inn the acute treatmet of therapy-resistant Depression. An open randomized study in a ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001209-26,0,0,0 2012-001217-16,1,2016-11-04,2016-11-04,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,UZLeuven,Dorsal penile nerve block(DPNB) for circumcision: a comparison of ultrasound-guided vs. landmark technique.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001217-16,0,0,0 2012-001218-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE SANTA LUCIA,EFFICACY OF ROTIGOTINE ON GAIT PERFORMANCE OF PARKINSONIAN PATIENTS Efficacia della rotigotina sul cammino nei pazienti con malattia di Parkinson,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001218-40,0,0,0 2012-001219-22,1,2014-05-06,2014-05-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,PregLem S.A.,A Phase IIa study investigating the efficacy and safety of the c-Jun-N-Terminal Kinase (JNK) inhibitor PGL5001 versus placebo administered for up to 5 months with concomitant administration of depot m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001219-22,0,0,0 2012-001221-27,4,2017-05-29,2017-05-29,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Primary Hypercholesterolemia Who are Intolerant to Statins...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001221-27,1,0,0 2012-001221-27,4,2017-05-29,2017-05-29,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"REGENERON PHARMACEUTICALS, INC.","A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Primary Hypercholesterolemia Who are Intolerant to Statins...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001221-27,1,0,0 2012-001222-95,3,2015-01-09,2015-01-09,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Regeneron Pharmaceuticals Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients with Heterozygous Familial Hypercholesterolemia Not Adequately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001222-95,0,0,0 2012-001223-13,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture or in Embryonated Chick...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001223-13,0,1,1 2012-001224-35,1,2014-07-01,2014-07-01,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Vejle Hospital,Cabazitaxel in platinum refractory ovarian cancer. A phase II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001224-35,0,0,0 2012-001226-10,1,2012-10-03,2012-10-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2B DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 FOLLOWING MONTHLY AND TWICE MONTHLY SUBCUTANE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001226-10,0,0,0 2012-001230-34,4,2013-06-05,2013-06-05,4,1,1,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, open-label, multicentre study to evaluate the immunogenicity, safety and reactogenicity of a revaccination dose of the GlaxoSmithKline Biologicals' quadrivalent seasonal influenza candida...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001230-34,0,0,0 2012-001230-34,4,2013-06-05,2013-06-05,4,1,1,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A phase III, open-label, multicentre study to evaluate the immunogenicity, safety and reactogenicity of a revaccination dose of the GlaxoSmithKline Biologicals' quadrivalent seasonal influenza candida...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001230-34,0,0,0 2012-001236-65,7,2018-08-15,2018-08-15,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001236-65,0,0,0 2012-001239-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Foundation for Liver Research,THE EFFECTS OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 ON THE NUTRITIONAL STATUS IN PATIENTS WITH LIVER CIRRHOSIS: A PILOT-STUDY. DE EFFECTEN VAN RECOMBINANTE HUMANE IGF-I OP DE VOEDINGSTOES...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001239-30,0,0,0 2012-001244-22,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,KU Leuven - Centre for Pharmacotherapy,Influence of obesity and gastric bypass on medication absorption: pharmacokinetic study Invloed van obesitas en gastric bypass op geneesmiddelenabsorptie: farmacokinetische studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001244-22,0,0,0 2012-001245-40,1,2015-12-18,2015-12-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,3,,CLINICAL AND PHARMACOKINETICS STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE AND BIOEQUIVALENCE OF LEVODOPA BENSERAZIDE GENERIC FORMULATION (TEVA ITALIA) VERSUS THE ORIGINATOR (MADOPAR®) STUDIO CLIN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001245-40,0,0,0 2012-001246-17,1,2014-12-02,2014-12-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Cebix Incorporated,"A Phase 2b, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of CBX129801 (Ersatta™), Long-Acting Synthetic C-Peptide, in Type 1 Diabetes Mellitus Subjects with M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001246-17,0,0,0 2012-001247-51,1,2014-01-28,2014-01-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Mika Harju,Hypertoninen suolaliuos silmänpaineen alentamisessa – vaikutus glaukooman eri alatyypeissä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001247-51,0,0,0 2012-001248-23,1,2017-07-27,2017-07-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,All Ireland Cooperative Oncology Research Group,Treatment of Inoperable Colorectal Cancer with Electrochemotherapy through an Endoscopic System,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001248-23,0,0,0 2012-001249-41,3,2017-11-17,2017-11-17,2,0,0,0,0,0,3,0,1,2,0,0,0,0,0,University Hospital of Zurich and City Hospital Waid,"Vitamin D3 – Omega3 – Home Exercise – HeALTHy Ageing and Longevity Trial Randomized, double-blind, placebo-controlled, multi-centre clinical trial Vitamine D3 – Omega3 – Programme d’entraînement à ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001249-41,1,0,0 2012-001251-40,6,2013-12-09,2014-01-18,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research and Development Limited,"A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001251-40,1,1,0 2012-001251-40,6,2013-12-09,2014-01-18,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001251-40,1,1,0 2012-001251-40,6,2013-12-09,2014-01-18,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"GlaxoSmithKline, S.A.","A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncontrolled refra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001251-40,1,1,0 2012-001254-26,2,2013-11-15,2013-11-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,An open label feasibility trial investigating FE 202158 as potential primary vasopressor treatment in patients with vasodilatory hypotension in early septic shock,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001254-26,0,0,0 2012-001258-25,6,2015-04-08,2015-04-08,5,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A phase III, multi-center, open label, uncontrolled trial to investigate the efficacy and safety of MK-8962 (corifollitropin alfa) in combination with human Chorionic Gonadotropin (hCG) in inducing i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001258-25,1,1,0 2012-001258-25,6,2015-04-08,2015-04-08,5,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.","A phase III, multi-center, open label, uncontrolled trial to investigate the efficacy and safety of MK-8962 (corifollitropin alfa) in combination with human Chorionic Gonadotropin (hCG) in inducing i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001258-25,1,1,0 2012-001259-37,3,2013-10-01,2013-10-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Metformin in Subjects with Type 2 Diabetes Mellitus.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001259-37,0,0,0 2012-001260-29,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,FONDAZIONE ISTITUTO SAN RAFFAELE-G.GIGLIO,Identification of predictive plasma Biomarkers and use of a high dosage statin during a procedure of Parrossistic Atrial Fibrillation pharmacological Cardioversion Identificazione di biomarcatori u...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001260-29,0,0,0 2012-001263-73,1,2013-06-05,2013-06-05,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,UZ Leuven,Involvement of corticotrophin-releasing hormone (CRH) and mucosal mast cells in stress-induced changes in intestinal permeability in healthy volunteers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001263-73,0,0,0 2012-001266-15,12,2016-04-26,2016-04-26,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001266-15,1,0,0 2012-001266-15,12,2016-04-26,2016-04-26,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001266-15,1,0,0 2012-001266-15,12,2016-04-26,2016-04-26,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"GlaxoSmithKline, S.A.",COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001266-15,1,0,0 2012-001266-15,12,2016-04-26,2016-04-26,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,COMBI-AD: A phase III randomized double blind study of dabrafenib (GSK2118436) in COMBInation with trametinib (GSK1120212) versus two placebos in the ADjuvant treatment of high-risk BRAF V600 mutatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001266-15,1,0,0 2012-001270-28,1,2014-03-28,2014-03-28,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Medical Centre of Postgraduate Education, Poland","The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial Często...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001270-28,0,0,0 2012-001279-35,3,2013-09-10,2013-10-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ipsen Pharma S.A.S,"A phase III single arm study to evaluate the efficacy, safety and local tolerability of a subcutaneous 3‑month formulation of triptorelin pamoate (11.25 mg) in patients with locally advanced or metast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001279-35,0,0,0 2012-001285-15,1,2016-03-04,2016-03-04,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Institut de Recerca Hospital Sant Pau,"Ensayo clínico aleatorizado, doble ciego, de grupos paralelos, controlado con placebo para la valoración de la eficacia del denosumab subcutáneo para la disminución de la resorción periprotésica en pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001285-15,0,0,0 2012-001288-58,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,0,Academic Medical Center,Boosting oxytocin after trauma: The effects of intranasal oxytocin administration on emotional and motivational brain processes in PTSD Versterken van oxytocine na trauma: De effecten van intrana...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001288-58,0,0,0 2012-001294-84,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,EDISON PHARMACEUTICALS INC.,Prospective open label trial to evaluate the maintenance of the efficacy and the long term safety of EPI-743 in children with Leigh Disease Studio prospettico in aperto per valutare il mantenimento...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001294-84,0,0,0 2012-001296-36,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,Photocure ASA,"A double blinded, prospective, randomized, vehicle controlled, multi-center study of photodynamic therapy with Visonac cream in patients with acne vulgaris",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001296-36,0,1,1 2012-001305-25,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase II, observer-blinded, multi-center, controlled study to assess the safety and immunogenicity of one dose of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroup ACWY tetanus toxoid conju...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001305-25,0,1,1 2012-001306-20,1,,,0,1,1,0,0,1,1,0,0,4,0,0,0,0,0,The National Cancer Institute (NCI),"A PHASE I STUDY OF PAZOPANIB AS A SINGLE AGENT FOR CHILDREN WITH RELAPSED OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001306-20,0,1,1 2012-001307-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Centro Nacional de Investigaciones Oncológicas Carlos III (CNIO),Selection of Individualize Therapy in Metastatic Colon Cancer Patients According to the Genome Expression Profile in Tumor Samples. Elección de terapias personalizadas en pacientes con carcinoma de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001307-20,0,0,0 2012-001309-26,4,2017-11-13,2018-04-05,3,1,1,0,0,1,2,0,0,1,1,0,1,0,1,CSL Behring GmbH,"A multicenter, open-label, multiple-dose, dose escalation study to investigate the pharmacokinetics, efficacy, and safety of rVIIa-FP (CSL689) in subjects with hemophilia (A or B) and inhibitors.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001309-26,0,0,0 2012-001309-26,4,2017-11-13,2018-04-05,3,1,1,0,0,1,2,0,0,1,1,0,1,0,1,CSL BEHRING GMBH,"A multicenter, open-label, multiple-dose, dose escalation study to investigate the pharmacokinetics, efficacy, and safety of rVIIa-FP (CSL689) in subjects with hemophilia (A or B) and inhibitors.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001309-26,0,0,0 2012-001314-42,4,2019-10-24,2019-10-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (belatacept)-based Immunosuppression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001314-42,0,0,0 2012-001316-35,13,2015-10-16,2015-10-16,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Grünenthal GmbH,"Efficacy, safety, and tolerability of oral Cebranopadol versus morphine sulphate PR in subjects with chronic moderate to severe pain related to cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001316-35,0,0,0 2012-001320-36,1,2020-01-13,2020-01-13,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Leeds,"A phase II randomised trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, velcade and dexamethasone (CVD) for first relapse or primary refractory multiple myeloma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001320-36,0,0,0 2012-001324-34,7,2014-03-25,2014-03-25,5,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Alcon Research Ltd,"A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001324-34,0,0,0 2012-001325-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOIM GRUPPO ONCOLOGICO MERIDIONALE,non-Pegylated liposomal doxrubicina (Myocet) + cyclophosphamide versus non pegylated liposomal doxorubicin (Myocet) + metronomic cyclophosphamide in metastatic breast cancer-a multicenter randomized p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001325-28,0,0,0 2012-001327-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundacion para la Investigación Biomédica del Hospital Gregorio Marañón,Assessing the efficacy and toxicity of intravenous immunoglobulin for the treatment of infections in patients with post solid organ transplantation IgG hypogammaglobulinemia EVALUACIÓN DE LA EFICAC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001327-12,0,0,0 2012-001333-14,1,,,0,1,1,0,1,0,3,0,0,4,0,0,0,0,1,Novartis Pharma AG,"A randomized, investigator-blinded, multicenter, parallel group study to compare efficacy, safety and tolerability of Coartem® dispersible tablet formulation vs. Coartem® 6-dose crushed tablet in the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001333-14,0,1,1 2012-001334-33,1,2016-01-08,2016-01-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Inovio Pharmaceuticals, Inc.","PHASE II PLACEBO-CONTROLLED STUDY OF VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA VACCINE) DELIVERED IM FOLLOWED BY ELECTROPORATION (EP) WITH CELLECTRA®-5P FOR THE TREATMENT OF BIOPSY-PROVEN CIN 2/3 OR CIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001334-33,0,0,0 2012-001335-31,1,,,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,"Univerzita Karlova v Praze, 2. lékařská fakulta",Adoptive transfer of CMV specific CD8+ T-cells to treat CMV infection after transplantation Adoptivní transfer CMV-specifických CD8+ T lymfocytů k léčbě CMV infekce po transplantaci,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001335-31,0,0,0 2012-001336-65,10,2015-08-24,2015-08-24,6,1,1,0,0,0,3,0,0,1,1,0,1,0,1,CSL Behring GmbH,"A Phase III Open-label Pharmacokinetic, Efficacy and Safety Study of rVIII-SingleChain in a Pediatric Population with Severe Hemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001336-65,0,0,0 2012-001337-13,2,2017-05-08,2017-05-08,2,1,0,0,0,0,2,0,0,1,1,0,1,0,0,APRO,A randomized phase II study to explore the efficacy and feasibility of upfront rotations between sunitinib and everolimus versus sequential treatment of first line sunitinib and second line everolimus...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001337-13,0,0,0 2012-001340-21,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,KEDRION,A Historically-Controlled Phase II/III study to Evaluate Efficacy and Safety of Kedrion Human Plasminogen Eye Drop Preparation in Patients Diagnosed with Ligneous Conjunctivitis Studio di Fase II/I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001340-21,0,0,0 2012-001341-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitätsklinik für Psychiatrie und Psychotherapie I,Propofol vs. Ketamin Propofol vs. Ketamin als Anästhetikum bei EKT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001341-41,0,0,0 2012-001344-22,1,2016-09-13,2016-09-13,1,1,0,0,1,0,2,0,1,1,1,1,1,0,1,GlaxoSmithKline Biologicals,"A phase II, randomised, single-blind study to develop read-outs aimed at detecting and characterising the early and adaptive immune responses and to evaluate the kinetics of the early response and rea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001344-22,0,0,0 2012-001348-24,1,2014-07-07,2014-07-07,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Joslin Diabetes Center,A pilot study of allopurinol to prevent GFR loss in type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001348-24,0,0,0 2012-001349-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZ Groeninge,Influence of dexamethasone on postoperative analgesia after combined spinal epidural for cesarean delivery. Invloed van dexamethasone op postoperatieve analgesie na gecombineerde spinale-epidurale ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001349-41,0,0,0 2012-001351-40,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,1,SOFAR SPA,ND Azione chemiopreventiva della mesalazina sul cancro del colon-retto: studio pilota per la valutazione degli effetti molecolari 'œin vivo' sulla via di segnalazione proliferativa della catenina.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001351-40,0,0,0 2012-001352-19,1,2017-06-06,2017-06-06,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Hochschule Hannover,BE-RELACs-Trial: Biomarkers Explaining RELevance of ACute Rejections,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001352-19,0,0,0 2012-001355-38,13,2008-01-29,2013-10-18,7,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"ARIAD Pharmaceuticals, Inc","A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Studio di Fase III, Randomizzato, in Aperto, c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001355-38,0,0,0 2012-001355-38,13,2008-01-29,2013-10-18,7,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"ARIAD PHARMACEUTICALS,INC.","A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Studio di Fase III, Randomizzato, in Aperto, c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001355-38,0,0,0 2012-001357-10,5,2014-07-30,2014-07-30,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd (TGRD),"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 mg and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001357-10,0,0,0 2012-001357-10,5,2014-07-30,2014-07-30,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Takeda Development Centre Europe Ltd.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1 mg and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001357-10,0,0,0 2012-001361-32,9,2014-04-01,2014-05-22,7,1,0,0,0,0,3,0,0,1,1,1,1,0,1,H. Lundbeck A/S,"Interventional, randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of brexpiprazole (1 and 3 mg/day) as adjunctive treatment in elderly ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001361-32,0,0,0 2012-001362-15,2,2013-10-29,2013-10-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001362-15,0,0,0 2012-001363-70,10,2013-12-04,2013-12-04,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN INC.,"A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001363-70,0,0,0 2012-001363-70,10,2013-12-04,2013-12-04,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001363-70,0,0,0 2012-001364-30,7,2013-11-19,2013-11-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Double-blind, Randomized, Multicenter Study to Evaluate Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001364-30,0,0,0 2012-001365-32,5,2013-12-11,2013-12-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001365-32,0,0,0 2012-001367-76,5,2016-02-23,2016-12-22,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PledPharma AB,"A double blinded, randomized, multi centre, three armed phase II trial of PledOx in two different doses in combination with FOLFOX6 compared to placebo + FOLFOX6 in patients with metastatic colorectal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001367-76,0,0,0 2012-001369-34,3,2014-04-02,2014-04-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & développement,"Double-blind, randomized, 8-week placebo-controlled and 16-week open label extension study investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients with Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001369-34,0,0,0 2012-001369-34,3,2014-04-02,2014-04-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT,"Double-blind, randomized, 8-week placebo-controlled and 16-week open label extension study investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients with Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001369-34,0,0,0 2012-001370-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Afdeling Urologie, Isala Klinieken","Pain treatment in renal colics; the role of Instanyl ® in prevention of hospitalization. A double-blinded, randomized, placebo-controlled trial. Pijnstilling bij niersteenkolieken; de rol van Insta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001370-28,0,0,0 2012-001371-37,1,2019-09-02,2019-09-02,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Dr. med. Tina Vilsbøll,The impact of liraglutide on glucose tolerance and the risk of type 2 diabetes in women with previous gestational diabetes mellitus Effekten af liraglutide på glukosetolerancen og risikoen for type...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001371-37,0,0,0 2012-001374-29,1,2014-05-12,2014-05-12,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,North Bristol NHS Trust,Delivering adequate nutrition to critically ill patients suffering delayed gastric emptying: RCT of nasointestinal feeding versus nasogastric feeding plus prokinetics.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001374-29,0,0,0 2012-001377-88,8,2021-10-26,2021-10-26,7,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Sun Pharma Global FZE,"A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222 / MK-3222), F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001377-88,0,0,0 2012-001377-88,8,2021-10-26,2021-10-26,7,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Sun Pharmaceutical Industries Limited,"A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222 / MK-3222), F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001377-88,0,0,0 2012-001377-88,8,2021-10-26,2021-10-26,7,0,0,0,0,0,3,0,0,1,0,0,0,0,1,"Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc.","A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222 / MK-3222), F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001377-88,0,0,0 2012-001380-76,9,2016-06-07,2016-06-08,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,H. Lundbeck A/S,"Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose long-term study to evaluate the maintenance of efficacy and safety of 1 to 3 mg/day of brexpiprazole as adju...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001380-76,0,0,0 2012-001381-15,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Sahlgrenska University Hospital Västra Götalandsregionen,Radiation Induced Cystits treated with Hyperbaric Oxygen. A Randomized controlled Trial Trykkammer behandling for lidelser i blæren forårsaget af strålebehandling – Et randomiseret kontrolleret fo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001381-15,0,0,0 2012-001382-32,2,2012-10-19,2012-10-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Randomized, Double-Blind, Placebo-Controlled Study to Explore Dose Effect and Frequency of Administration of AMG 151 in Subjects with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001382-32,0,0,0 2012-001389-14,1,2013-10-02,2013-10-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled three-period incomplete cross over study to compare the efficacy of QAW039 alone and in combination with Montelukast in patients with allergic rhinitis u...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001389-14,0,0,0 2012-001390-88,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institute for Clinical and Experimental Medicine,Cardioprotective and metabolic effects of metformin in patients with heart failure and diabetes Kardioprotektivní a metabolické účinky metforminu u nemocných s diabetem a srdečním selháním,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001390-88,0,0,0 2012-001394-87,1,2014-12-11,2014-12-11,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,King's College London,A prospective phase I/II study to evaluate allogeneic mesenchymal stromal cells for the treatment of skin disease in children with recessive dystrophic epidermolysis bullosa.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001394-87,0,0,0 2012-001396-37,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,"University Hospitals Leuven, Belgium",Determination of voriconazole in saliva - Validation in specifif subsets of patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001396-37,0,0,0 2012-001398-97,23,2016-11-11,2016-11-11,21,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001398-97,0,0,0 2012-001398-97,23,2016-11-11,2016-11-11,21,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN INC.,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001398-97,0,0,0 2012-001399-12,2,2016-02-29,2016-02-29,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Morphotek Inc.,A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001399-12,0,0,0 2012-001402-23,7,2015-12-01,2015-12-01,3,1,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd.,"A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB (MetMAb) IN COMBINATION WITH 5-FLUOROURACIL, FOLINIC ACID, AND OXALIPLATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001402-23,1,0,0 2012-001402-23,7,2015-12-01,2015-12-01,3,1,0,0,0,0,3,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB (MetMAb) IN COMBINATION WITH 5-FLUOROURACIL, FOLINIC ACID, AND OXALIPLATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001402-23,1,0,0 2012-001404-38,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,FONDAZIONE ITALIANA LINFOMI ONLUS,Phase IIa study on the role of Gemcitabine plus Romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. Studio di fase IIa sul ruolo di gemcitabina ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001404-38,0,0,0 2012-001410-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastatic m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001410-41,0,0,0 2012-001415-23,1,2016-06-30,2016-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Central European Society for Anticancer Drug Research - EWIV,A single arm Pharmacokinetic/Pharmacodynamic Study of Sunitinib and Pazopanib in Patients with Metastasized Renal Cell Carcinoma Eine einarmige pharmakokinetische/pharmakodynamische Studie mit Suni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001415-23,0,0,0 2012-001416-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC,Treatment of Cancer in the head and Neck: The Role of Hyperbaric Oxygen in Reducing Swallowing Problems Rol van hyperbare zuurstof therapie bij de vermindering van de slikklachten na bestraling,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001416-27,0,0,0 2012-001419-21,1,2015-09-16,2015-09-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsklinikum Bonn,"An open label, randomised, non-inferiority trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatitis C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001419-21,0,0,0 2012-001420-35,1,2015-02-02,2015-02-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Abteilung für Anästhesie, Intensiv- und Schmerzmedizin, Wilhelminenspital der Stadt Wien",The effect of a single skin treatment with Capsaicine 8% in low back pain Der Effekt einer topischen Capsaicin 8% Behandlung bei chronischem Rückenschmerz im Lumbalbereich,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001420-35,0,0,0 2012-001421-27,4,2021-10-08,2021-10-08,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001421-27,1,0,0 2012-001426-99,2,2015-01-13,2015-01-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Exelixis, Inc.","A Phase 3, randomized, double-blind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001426-99,0,0,0 2012-001427-12,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, placebo-controlled study of the safety, tolerability and effects on arterial structure and function of ACZ885 in patients with intermittent claudication",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001427-12,0,0,0 2012-001430-34,2,2015-08-14,2015-08-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Deutsche Homöopathie-Union, DHU-Arzneimittel GmbH & Co. KG","Therapeutic effectiveness, safety and tolerability of Tonsilotren tablets in patients (6 to 60 years old) with chronic tonsillitis. A randomized, international, multicenter, controlled clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001430-34,0,0,0 2012-001431-31,1,2013-09-10,2013-09-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II trial to investigate the efficacy and safety of 30 mcg and 100 mcg AS902330 given as one cycle of three intra-arti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001431-31,0,0,0 2012-001432-62,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Reinier de Graaf Groep,Local infiltration anesthesia in Total Knee Arthroplasty Locale infiltratie anesthesie in totale knie arthroplastie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001432-62,0,0,0 2012-001439-30,3,2019-07-12,2019-07-12,3,0,0,0,0,0,4,0,0,1,1,0,1,0,1,Navitas Life Sciences GmbH,Exploratory evaluation of the potential for long-term retention of Gadolinium in the bones of patients who have received Gadolinium based Contrast Agents according to their medical history.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001439-30,0,0,0 2012-001439-30,3,2019-07-12,2019-07-12,3,0,0,0,0,0,4,0,0,1,1,0,1,0,1,Ecron Acunova GmbH,Exploratory evaluation of the potential for long-term retention of Gadolinium in the bones of patients who have received Gadolinium based Contrast Agents according to their medical history.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001439-30,0,0,0 2012-001440-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,,A PHASE II TRIAL ON NON-SMALL-CELL LUNG CANCER STEM CELLS SENSITIVITY ASSAY (LUCAS) LUCAS: STUDIO DI FASE II SUL TEST DI SENSIBILITA' DELLE CELLULE TUMORALI STAMINALI DEL TUMORE POLMONARE NON-A-PIC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001440-22,0,0,0 2012-001443-49,2,2013-01-11,2013-01-11,1,1,1,0,0,0,1,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ER Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001443-49,1,1,0 2012-001445-40,3,2015-01-20,2015-04-30,3,0,0,0,0,2,3,0,0,1,1,1,1,0,1,Green Cross Corporation,"Determination of Safety, Efficacy, and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 years of age or older Diagnosed with Severe Hemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001445-40,0,0,0 2012-001446-18,4,2018-04-10,2018-05-25,4,1,1,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biosciences Inc.,"A MULTI-CENTER, OPEN-LABEL, EXPLORATORY STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS ≥1 MONTH TO <18 YEARS WITH EPILEPSY SYNDROMES ASSOCIATED WITH GENER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001446-18,0,0,0 2012-001447-43,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Academic Medical Center Amsterdam,Anticoagulants for Living Fetuses in women with recurrent miscarriage and inherited thrombophilia; ALIFE2 study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001447-43,0,0,0 2012-001449-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Medizinische Universität Graz, Kl. Abt. f. Endokrinoloie u. Stoffwechsel & Kl. Abt. f. Gastroenterologie u. Hepatologie","A randomized, double-blind, placebo controlled trial to evaluate vitamin D supplementation on serum 25 hydroxy- vitamin D level in cirrhotic patients Eine randomisierte, doppelblinde, Placebo-kon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001449-42,0,0,0 2012-001453-74,1,2015-12-31,2015-12-31,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Institute of Specific Prophylaxis and Tropical Medicine,Comparison of vaccination routes: subcutaneus versus intramuscular application of FSME-Immun® Routenvergleich: subkutane versus intramuskuläre Applikation von FSME-Immun®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001453-74,0,0,0 2012-001455-39,8,2016-06-30,2016-06-30,6,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Opsona Therapeutics Ltd,"A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001455-39,1,0,0 2012-001457-50,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,fUNDACIÓN iNVESTIGACIÓN HOSPITAL RAMÓN Y CAJAL,"Study on the effect of intravenous silimaryn in the perioperative period of liver transplantation (before, during and after) for the prevention and prognosis of hepatitis C virus reinfection of the gr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001457-50,0,0,0 2012-001458-24,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,RIVM,Cross-sectional surveillance study on pneumococcal serotypes and other pathogens in nasopharyngeal samples from infants and parents performed 6.5 years after introduction of pneumococcal vaccination i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001458-24,0,0,0 2012-001461-32,3,2016-07-15,2016-07-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,OncoGenex Technologies Inc.,A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Pro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001461-32,0,0,0 2012-001465-33,4,2015-04-13,2015-04-19,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,PregLem S.A.,"A Phase III, multicentre, extension study investigating the efficacy and safety of repeated intermittent 3-month courses of open-label administration of ulipristal acetate, in subjects with symptomati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001465-33,1,0,0 2012-001472-10,1,2014-08-23,2014-08-23,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Incyte Corporation,"A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF THE IDO INHIBITOR INCB024360 VERSUS TAMOXIFEN FOR SUBJECTS WITH BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FALLOP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001472-10,0,0,0 2012-001477-82,1,,,0,0,1,0,0,1,3,0,0,4,0,0,0,0,1,Children's Oncology Group (COG),A Children’s Oncology Group pilot study for the treatment of very high risk acute lymphoblastic leukemia in children and adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001477-82,0,1,1 2012-001481-16,1,,,0,1,0,1,0,0,1,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase I, double-blind, randomised, placebo-controlled study to assess the reactogenicity and safety of two doses of GlaxoSmithKline Biologicals’ (GSK) oral live attenuated liquid human rotavirus (HR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001481-16,0,1,1 2012-001483-29,1,2013-04-10,2013-04-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-WAY CROSSOVER STUDY TO EVALUATE THE EFFICACY AFTER ALLERGEN CHALLENGE, SAFETY, AND TOLERABILITY OF TWO DOSES OF INHALED CHF6001 DPI AFTER 9 DAYS O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001483-29,0,0,0 2012-001484-79,3,2014-10-29,2014-10-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Open-label, Active-controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001484-79,0,0,0 2012-001491-11,10,2016-07-28,2016-07-29,9,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Janssen-Cilag International NV,"An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001491-11,0,0,0 2012-001494-91,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Antwerp University Hospital,Wilms’ tumor (WT1) antigen-targeted dendritic cell vaccination to prevent relapse in adult patients with acute myeloid leukemia: a multicenter randomized phase II trial Wilms’ tumor (WT1) antigeng...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001494-91,0,0,0 2012-001495-11,8,2019-11-27,2019-11-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Queen Mary University London,The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BMMNC) on all causemortality in acute myocardial infarction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001495-11,0,0,0 2012-001495-11,8,2019-11-27,2019-11-27,7,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Queen Mary University of London,The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BMMNC) on all causemortality in acute myocardial infarction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001495-11,0,0,0 2012-001496-36,1,2015-06-01,2015-06-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Innere Medizin I, Klinische abteilung für Infektionen und Tropenme",Multiple-dose pharmacokinetics of ampicillin / sulbactam and amoxicillin / clavulanic acid during haemodialysis in longterm haemodialysis patients Bestimmung von Blutkonzentrationen von Ampicillin ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001496-36,0,0,0 2012-001497-29,4,2013-12-12,2013-12-12,2,1,1,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects with Severe Refractory Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001497-29,0,0,0 2012-001499-12,6,2016-04-26,2020-12-04,4,1,1,0,0,1,1,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001499-12,1,1,0 2012-001499-12,6,2016-04-26,2020-12-04,4,1,1,0,0,1,1,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001499-12,1,1,0 2012-001499-12,6,2016-04-26,2020-12-04,4,1,1,0,0,1,1,0,0,2,0,0,0,0,1,"GlaxoSmithKline, S.A.","Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001499-12,1,1,0 2012-001499-12,6,2016-04-26,2020-12-04,4,1,1,0,0,1,1,0,0,2,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001499-12,1,1,0 2012-001502-26,1,2015-10-28,2015-10-28,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E.",Intralesional steroid injection in radiation-induced esophageal strictures Injecção intralesional de corticosteróides em estenoses rádicas do esófago,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001502-26,0,0,0 2012-001505-24,5,2021-06-30,2021-10-31,3,0,0,0,0,0,4,0,0,2,1,0,0,0,0,The Rotunda Maternity Hospital,Highlow study Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two doses,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001505-24,1,0,0 2012-001505-24,5,2021-06-30,2021-10-31,3,0,0,0,0,0,4,0,0,2,1,0,0,0,0,Academic Medical Center,Highlow study Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two doses,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001505-24,1,0,0 2012-001505-24,5,2021-06-30,2021-10-31,3,0,0,0,0,0,4,0,0,2,1,0,0,0,0,Academic Medical Center (AMC),Highlow study Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two doses,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001505-24,1,0,0 2012-001509-25,1,2016-06-30,2016-06-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Southampton NHS Foundation Trust,"COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial A randomised, Phase II, double-blind, placebo-controlled, two arm Trial to establish whether Aspirin can reduce hearing loss/ototoxicity for p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001509-25,0,0,0 2012-001514-42,3,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 1/2, Dose-escalation, Open-label Study of Nivolumab or Nivolumab in Combination with Other Agents in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis Studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001514-42,0,0,0 2012-001514-42,3,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 1/2, Dose-escalation, Open-label Study of Nivolumab or Nivolumab in Combination with Other Agents in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis Studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001514-42,0,0,0 2012-001515-22,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Katholieke Universiteit Leuven,Cytomegalovirus infection and the influenza vaccination response in older persons,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001515-22,0,0,0 2012-001522-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,SWITCH STUDY STUDIO SWITCH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001522-10,0,0,0 2012-001524-35,8,2014-03-14,2014-03-14,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001524-35,0,0,0 2012-001525-27,2,2013-12-30,2013-12-30,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOXXON Pharma AG,Phase IIa study to characterize the effects of the Spiegelmer® NOX H94 on anemia of chronic disease in patients with cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001525-27,0,0,0 2012-001529-28,1,2016-12-23,2016-12-23,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Pharmacosmos A/S,"A Randomized, Prospective, Double-Blind, Comparative Placebo-Controlled Study of Intravenous Iron Isomaltoside 1000 (Monofer®) administered by Infusions to Iron-Deficient Blood Donors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001529-28,0,0,0 2012-001530-34,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,2,VU University Medical Center,"Varenicline, a partial nicotinic receptor agonist for the treatment of Excessive Daytime Sleepiness in Parkinson’s Disease: a placebo-controlled cross-over study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001530-34,0,0,0 2012-001530-34,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,2,Center Human Drug Research,"Varenicline, a partial nicotinic receptor agonist for the treatment of Excessive Daytime Sleepiness in Parkinson’s Disease: a placebo-controlled cross-over study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001530-34,0,0,0 2012-001534-34,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"A multi-center, intra-patient dose escalation phase II study to evaluate the preliminary efficacy, safety and pharmacokinetics of pasireotide (SOM230) subcutaneous (s.c.) followed by pasireotide LAR i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001534-34,0,0,0 2012-001539-30,4,2016-09-01,2016-09-01,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Millennium Pharmaceuticals, Inc.",A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients with Castration-Resistant Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001539-30,0,0,0 2012-001540-22,1,2013-09-30,2013-09-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Mads Werner,CAPSAICIN PATCH 8% FOR THE TREATMENT OF PERSISTENT PAIN AFTER INGUINAL HERNIOTOMY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001540-22,0,0,0 2012-001541-40,1,,,0,0,0,0,1,1,4,0,0,0,0,0,0,0,0,Vu University Medical Center,Effect of Carbon Dioxide Enriched Ambient Air on Pharmacokinetics and Deposition In Bronchiectasis Patients Using Tobramycin Inhalation: A proof of concept study. Het effect van koolstofdioxide ve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001541-40,0,0,0 2012-001542-18,1,2014-12-18,2014-12-18,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,DuPont Nutrition and Health Active Nutrition,Effect of a probiotic formula on reducing the risk for antibiotic-associated diarrhea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001542-18,0,0,0 2012-001544-21,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Vall d'Hebron Institut de Recerca (VHIR),Intravenous immunoglobulin for preparing myasthenia gravis patients for thymectomy and other surgical procedures preventing myasthenic crisis. Inmunoglobulina intravenosa para la prevención de cris...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001544-21,0,0,0 2012-001547-46,7,2017-05-31,2017-05-31,7,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F. Hoffmann-La Roche Ltd,Phase I followed by phase II study of the combination of trastuzumab emtansine (T-DM1) and capecitabine in HER2-positive metastatic breast cancer and HER2-positive locally advanced or metastatic gastr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001547-46,0,0,0 2012-001547-46,7,2017-05-31,2017-05-31,7,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,Phase I followed by phase II study of the combination of trastuzumab emtansine (T-DM1) and capecitabine in HER2-positive metastatic breast cancer and HER2-positive locally advanced or metastatic gastr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001547-46,0,0,0 2012-001548-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ParnassiaBavoGroup,"An open label study with objective sleepregistration on the effects of Doxazosin as treatment for PTSD, especially for sleep disturbance Een open label studie met objectieve slaapregistratie naar h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001548-23,0,0,0 2012-001551-39,1,2019-02-01,2019-02-01,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Per H. Rosenberg,Sitooko laskimoon annettu rasvaemulsio laskimoon annettua lidokaiinia? - farmakokineettinen ja neu-rofysiologinen tutkimus terveillä vapaaehtoisilla koehenkilöillä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001551-39,0,0,0 2012-001552-19,8,2020-03-30,2020-04-30,8,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared With Levetiracetam as Monotherapy in Pediatric Subjects Wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001552-19,0,0,0 2012-001556-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION IMABIS,"A Prospective, Randomized, Doubled-masked, Single Center, Clinical Comparison of Autologous Serum, Heterologous Serum and Umbilical Cord Serum Eye Drops in the Management of Dry Eye Syndrome ENSAYO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001556-19,0,0,0 2012-001557-46,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,"Sydvestjysk Sygehus, Esbjerg","Perioperativ installation of ropivacain in mastectomy – with or without axillary lymph node dissection after sentinel node diagnostics or known lymph node metastasis – A double-blind, randomized clini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001557-46,0,0,0 2012-001557-46,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Odense Universitetshospital,"Perioperativ installation of ropivacain in mastectomy – with or without axillary lymph node dissection after sentinel node diagnostics or known lymph node metastasis – A double-blind, randomized clini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001557-46,0,0,0 2012-001561-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,Etude de phase II randomisée multicentrique comparant l'efficacité d'une hormonothérapie courte concomitante à une radiothérapie versus une radiothérapie exclusive dans le traitement de rattrapage de ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001561-32,0,0,0 2012-001563-78,1,2012-10-17,2012-10-17,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Reata UK Limited,"A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Bardoxolone Methyl on Residual Renal Function (RRF) in Patients with End-Stage Renal Disease (ESRD) and Type 2 Dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001563-78,0,0,0 2012-001565-33,4,2015-10-20,2015-10-20,4,1,0,0,0,1,4,0,0,1,0,0,1,0,1,"Novartis Farmaceutica, S.A.","An open-label, crossover, interventional Phase IV study to compare the ease of use of tobramycin inhalation powder with tobramycin inhalation solution and nebulized colistimethate for the treatment of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001565-33,0,0,0 2012-001565-33,4,2015-10-20,2015-10-20,4,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label, crossover, interventional Phase IV study to compare the ease of use of tobramycin inhalation powder with tobramycin inhalation solution and nebulized colistimethate for the treatment of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001565-33,0,0,0 2012-001568-31,9,2013-01-16,2013-09-11,7,1,0,0,0,0,2,0,0,2,0,0,0,0,1,FOREST RESEARCH INSTITUTE,"A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients with Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001568-31,1,0,0 2012-001568-31,9,2013-01-16,2013-09-11,7,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Forest Research Institute, Inc","A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of the Safety and Efficacy of Memantine in Pediatric Patients with Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001568-31,1,0,0 2012-001570-29,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,University Medical Center Utrecht,Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT) for focal articular cartilage lesions of the knee; feasibility and safety Haalbaarheids en veiligheidsstudie van de In...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001570-29,0,0,0 2012-001571-36,7,2016-01-04,2016-02-23,5,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001571-36,0,0,0 2012-001573-93,5,2016-03-18,2016-03-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA™ Versus Efavirenz Plus TRUVADA™ in Antiretroviral Treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001573-93,0,0,0 2012-001574-28,2,2014-10-16,2014-10-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astex Pharmaceuticals Inc,A Phase 2 Study of Hsp90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001574-28,0,0,0 2012-001575-37,1,2017-02-21,2017-02-21,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Astex Pharmaceuticals, Inc.","A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC). Estudio del inhibidor de HSP90, AT13387, administrado como agente...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001575-37,0,0,0 2012-001576-12,1,2016-04-15,2016-04-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astex Pharmaceuticals Inc,"A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001576-12,0,0,0 2012-001578-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,St Olavs University Hospital,"An international, multicentre, open randomised parallel group trial comparing a two step approach to cancer pain relief with the standard three step approach of the WHO analgesic ladder in patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001578-26,0,0,0 2012-001578-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,The University of Edinburgh,"An international, multicentre, open randomised parallel group trial comparing a two step approach to cancer pain relief with the standard three step approach of the WHO analgesic ladder in patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001578-26,0,0,0 2012-001580-68,6,2016-05-10,2016-05-10,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,LYSARC,Phase 3 Multi-Center Randomized Study to Compare Efficacy and Safety of Romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with Previously Untreated Peripheral T-Cell Lymphoma. Ensayo clínico multic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001580-68,1,0,0 2012-001581-15,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,Bristol-Myers Squibb Company,"Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001581-15,0,1,1 2012-001582-33,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,University Hospital Erlangen,Intraindividual cross-over comparison of Gadobutrol and Gadoterate enhanced combined DSC-MR-Perfusion and MR-Angiography in patients with cerebrovascular disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001582-33,0,0,0 2012-001583-29,1,2016-01-12,2016-01-12,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University Hospital Erlangen,"Prospective, open-label, two-arm, parallel-group, single center phase IV clinical trial to evaluate the diagnostic value of a Gadobutrol enhanced dynamic susceptibility perfusion MRI (DSC-MRP) and a n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001583-29,0,0,0 2012-001584-77,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Menarini International Operations Luxembourg S.A.,Effect of Ranolazine in ischemic patients with indication of staged interventional therapy Effekt von Ranolazin bei Patienten mit Ischämie mit der Indikation einer interventionellen Therapie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001584-77,0,0,0 2012-001585-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FISEVI,Effect of the elimination of colonization by Pneumocystis jirovecii on inflammatory response in patients with chronic obstructive pulmonary disease Efecto de la eliminación de la colonización por P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001585-14,0,0,0 2012-001586-32,1,2014-07-01,2014-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Greater Glasgow and Clyde,The role of Qutenza (topical capsaicin 8%) in the treatment of chronic pain from critical ischaemia in patients with end stage renal failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001586-32,0,0,0 2012-001587-30,1,2017-04-18,2017-04-18,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,NHS Greater Glasgow and Clyde,The role of pre-emptive analgesia with Qutenza (topical capsaicin 8%) in preventing neuropathic pain following lower limb amputation: a pilot randomised controlled study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001587-30,0,0,0 2012-001589-13,1,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,Belfast Health and Social Care Trust,The effect of Aspirin on REducing iNflammation in human in vivo model of Acute lung injury (ARENA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001589-13,0,0,0 2012-001591-11,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Symptomatic treatment of pollen related allergic rhinoconjunctivitis and the relation with asthma with children in the General practice Symptomatische behandeling van pollen gerelateerd allergische...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001591-11,0,0,0 2012-001592-37,9,2015-02-11,2015-02-11,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Pierre Fabre Médicament; Represented by Institut de Recherche Pierre Fabre,"Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A Multicenter, Randomised, Double-blind, Parallel-group, Placebo-Controlled Study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001592-37,0,0,0 2012-001592-37,9,2015-02-11,2015-02-11,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A Multicenter, Randomised, Double-blind, Parallel-group, Placebo-Controlled Study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001592-37,0,0,0 2012-001594-93,1,2016-11-17,2016-11-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Innate Pharma,Double-Blind Placebo-Controlled Randomized Phase 2 Study of IPH2102 as Maintenance Treatment in Elderly patients with Acute Myeloid Leukemia (AML) in First Complete Remission,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001594-93,0,0,0 2012-001596-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,MIGUEL CASARES FERNÁNDEZ-ALVÉS,Application of Mesenchymal Stem Cells and full of plasma in the management of the burn wound in patients with large burn injury Aplicación de células madre mesenquimales y plasma rico en plaquetas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001596-36,0,0,0 2012-001597-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU University Medical Center,Tumor uptake of 89Zirconium-ofatumumab and 89Zirconium-rituximab in diffuse large B cell lymphoma patients Tumor opname van 89Zirconium-ofatumumab en 89Zirconium-rituximab bij patienten met een dif...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001597-29,0,0,0 2012-001598-10,1,2019-11-05,2019-11-05,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,University College London,"A phase I/II study of first line Ganetespib with pemetrexed/cisplatin, in patients with malignant pleural mesothelioma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001598-10,0,0,0 2012-001599-12,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,VU University Medical Center (VUmc),The clinical value of amyloid imaging with [18F]-AV45 in a population of memory clinic patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001599-12,0,0,0 2012-001600-38,1,2014-07-29,2014-07-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Furiex Pharmaceuticals,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001600-38,0,0,0 2012-001601-24,1,2014-01-09,2014-01-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Furiex Pharmaceuticals,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001601-24,0,0,0 2012-001609-25,7,2015-10-30,2015-11-11,6,0,0,0,0,1,3,0,0,1,1,0,1,0,1,XOMA (US) LLC,"A RandomizEd, Double-masked, Placebo-controlled Study of the SafetY and Efficacy of GevokizUmAb in the TReatment of Subjects with Non-infectious IntermeDiate, Posterior, or Pan- uveitis Currently Cont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001609-25,0,0,0 2012-001609-25,7,2015-10-30,2015-11-11,6,0,0,0,0,1,3,0,0,1,1,0,1,0,1,XOMA,"A RandomizEd, Double-masked, Placebo-controlled Study of the SafetY and Efficacy of GevokizUmAb in the TReatment of Subjects with Non-infectious IntermeDiate, Posterior, or Pan- uveitis Currently Cont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001609-25,0,0,0 2012-001610-42,7,2015-10-30,2015-11-11,6,0,0,0,0,1,3,0,0,1,1,0,1,0,1,XOMA (US) LLC,"A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001610-42,0,0,0 2012-001611-23,6,2014-03-25,2014-03-25,5,1,1,0,0,0,3,0,1,1,0,0,1,0,1,"Merck & Co., Inc.","A Double-Blind, Randomized, COntrolled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq(TM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001611-23,0,0,0 2012-001611-23,6,2014-03-25,2014-03-25,5,1,1,0,0,0,3,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Double-Blind, Randomized, COntrolled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq(TM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001611-23,0,0,0 2012-001611-23,6,2014-03-25,2014-03-25,5,1,1,0,0,0,3,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., una filial de Merck & Co., Inc.","A Double-Blind, Randomized, COntrolled, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of a New Formulation of RotaTeq(TM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001611-23,0,0,0 2012-001612-34,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación SEIMC-GESIDA,"A prostective, with one site, open-label not controled trial, for the observation of treatment with CIDOFOVIR 1%, 3 nights per week, during 4 weeks, of Anal Intraephitelial Neoplasia, high level, in H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001612-34,0,0,0 2012-001613-16,1,2012-11-02,2012-11-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sun Pharma Advanced Research Company Ltd. (SPARC),"Efficacy And Safety of Intranasal S0597 in Environmental Exposure Chamber Model of Seasonal Allergic Rhinitis: A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Parallel Group St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001613-16,0,0,0 2012-001616-33,8,2012-01-16,2013-07-09,7,1,0,0,0,0,2,0,0,2,0,0,0,0,1,FOREST RESEARCH INSTITUTE,"An Open-Label Study Of The Safety And Tolerability Of Memantine In Pediatric Patients With Autism, Asperger’s Disorder, Or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001616-33,1,0,0 2012-001616-33,8,2012-01-16,2013-07-09,7,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Forest Research Institute, Inc.","An Open-Label Study Of The Safety And Tolerability Of Memantine In Pediatric Patients With Autism, Asperger’s Disorder, Or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001616-33,1,0,0 2012-001618-40,2,2013-02-07,2013-02-07,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Eli Lilly and Company,Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled syringe or Auto-Injector in Patients with Rheumatoid Arthritis Who Have Had an Inadequate Response to Methot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001618-40,0,0,0 2012-001622-10,4,2015-04-28,2015-04-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A randomised, placebo-controlled, double-blind, parallel groups, multinational, multicentre trial assessing the effect of barusiban administered subcutaneously on the day of transfer on implantation a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001622-10,0,0,0 2012-001623-12,1,2018-03-09,2018-03-09,1,0,0,0,0,0,4,0,1,1,1,1,1,0,0,Leiden University Medical Center,Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001623-12,0,0,0 2012-001628-37,20,2016-10-20,2020-07-31,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A TWO-COHORT, OPEN-LABEL, MULTICENTER, STUDY OF TRASTUZUMAB EMTANSINE (T-DM1) IN HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PATIENTS WHO HAVE RECEIVED PRIOR ANTI-HER2 AND CHEMOTHERAPY-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001628-37,0,0,0 2012-001628-37,20,2016-10-20,2020-07-31,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"F. Hoffmann-La Roche Ltd (representado en España por Roche Farma, S.A)","A TWO-COHORT, OPEN-LABEL, MULTICENTER, STUDY OF TRASTUZUMAB EMTANSINE (T-DM1) IN HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PATIENTS WHO HAVE RECEIVED PRIOR ANTI-HER2 AND CHEMOTHERAPY-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001628-37,0,0,0 2012-001628-37,20,2016-10-20,2020-07-31,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A TWO-COHORT, OPEN-LABEL, MULTICENTER, STUDY OF TRASTUZUMAB EMTANSINE (T-DM1) IN HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PATIENTS WHO HAVE RECEIVED PRIOR ANTI-HER2 AND CHEMOTHERAPY-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001628-37,0,0,0 2012-001630-33,9,2013-01-16,2014-01-31,7,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Forest Research Institute, Inc","An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients with Autism, Asperger’s Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001630-33,1,0,0 2012-001630-33,9,2013-01-16,2014-01-31,7,1,0,0,0,0,2,0,0,2,1,0,0,0,1,FOREST RESEARCH INSTITUTE,"An Open-Label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients with Autism, Asperger’s Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001630-33,1,0,0 2012-001632-64,1,2013-01-30,2013-01-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open label, three-period, single sequence study to evaluate the pharmacokinetic drug-drug interaction between LCZ696 and sildenafil in subjects with mild to moderate hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001632-64,0,0,0 2012-001638-33,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Institute for Clinical and Experimental Medicine,Cholesterol 7alpha-hydroxylase polymorphism as a predictor cholesterolemia responsiveness Polymorfismus cholesterol-7alfa-hydroxylasy jako prediktor odpovídavosti cholesterolémie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001638-33,0,0,0 2012-001639-29,1,2013-07-10,2013-07-10,1,1,0,0,0,0,2,0,1,1,1,1,1,0,1,F. Hoffmann-La Roche Ltd,"A single center, double-blind, placebo-controlled, randomized, crossover, phase II study to assess the effect of Aleglitazar on cardiac energetics and function in patients with uncomplicated type 2 di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001639-29,0,0,0 2012-001640-22,4,2013-07-10,2013-07-10,2,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Alcon Research Ltd,"An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001640-22,1,0,0 2012-001642-17,7,2015-11-18,2015-11-18,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Developement Ltd,"An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001642-17,0,0,0 2012-001642-17,7,2015-11-18,2015-11-18,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.","An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001642-17,0,0,0 2012-001643-51,2,2017-05-31,2017-05-31,1,1,1,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"MEA115666: A multi-centre, open-label, long term safety study of mepolizumab in asthmatic subjects who participated in the MEA112997 trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001643-51,0,0,0 2012-001644-21,7,2015-03-13,2015-03-16,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"MEA115661: A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 trials.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001644-21,0,0,0 2012-001644-21,7,2015-03-13,2015-03-16,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","MEA115661: A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 trials.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001644-21,0,0,0 2012-001645-41,8,2014-02-19,2014-04-04,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Limited,"An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001645-41,0,0,0 2012-001645-41,8,2014-02-19,2014-04-04,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.","An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001645-41,0,0,0 2012-001646-18,7,2015-03-30,2015-03-30,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Developement Ltd,"A randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001646-18,0,0,0 2012-001646-18,7,2015-03-30,2015-03-30,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.","A randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001646-18,0,0,0 2012-001650-26,1,2017-02-18,2017-02-18,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Ruprecht-Karls-University Heidelberg, Med Faculty represented by Universitätsklinikum Heidelberg and its Commercial D","A randomised, placebo-controlled, double-blind, monocentre study on the application of physostigminsalicylate (Anticholium®) as adjunctive measure in perioperative sepsis/septic shock Eine randomi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001650-26,0,0,0 2012-001651-39,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,LOFARMA,"In-vivo biological standardization of Dermatophagoides, Betulaceae and Graminaceae extracts for the determination of the biological activity in HEP units Standardizzazione biologica in-vivo di estr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001651-39,0,0,0 2012-001653-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dipartimento di Pediatria Università Federico II di Napoli,New Therapeutic Options for the Maintenance of Remission of the Ulcerative Colitis in Pediatric Patients Mantenimento della remissione nella rettocolite ulcerosa in età pediatrica: nuove strategie ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001653-13,0,0,0 2012-001658-24,5,2015-07-28,2015-07-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Efficacy and safety of fixed-dose combination Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg versus Perindopril 5 mg / Indapamide 1.25 mg single pill in patients with uncontrolled essential h...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001658-24,0,0,0 2012-001661-32,1,2015-02-01,2015-02-01,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,"Vejle Hospital, Dept. of Oncology",Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients with Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer with Negative or Unknown BRCA Status,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001661-32,0,0,0 2012-001665-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Päijät-Häme Central Hospital,"Äkillistä välikorvatulehdusta sairastavan lapsen vuotavan putkikorvan hoito Prospektiivinen, randomoitu, plasebokontrolloitu kliininen kaksoisokko tutkimus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001665-33,0,0,0 2012-001666-15,3,2015-01-21,2015-01-21,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Efficacy and safety of 2 doses of agomelatine (10 mg/day or 25 mg/day) versus placebo given orally for 12 weeks in non depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001666-15,0,0,0 2012-001668-31,8,2014-04-14,2014-04-14,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation, in patients with stable coronary artery disease. A 6 to 12-month ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001668-31,0,0,0 2012-001668-31,8,2014-04-14,2014-04-14,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation, in patients with stable coronary artery disease. A 6 to 12-month ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001668-31,0,0,0 2012-001668-31,8,2014-04-14,2014-04-14,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratorios Servier S.L.,"Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation, in patients with stable coronary artery disease. A 6 to 12-month ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001668-31,0,0,0 2012-001669-34,2,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,0,"Med. Univ. Wien, Univ. Klinik f. Kinder- u. Jugendheilkunde, Klin. Abt.f. Pädiatrische Kardiologie",Genetic Influence on the Pharmacokinetic Behavor of Factor VIII,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001669-34,0,0,0 2012-001670-28,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Medizinische Fakultät der Technischen Universität München,"Angiotensin Converting Enzyme Inhibitor (ACE) Induced Angioedema BERINERT Randomized, double-blind, two arms, multicenter, Phase III study of Berinert for treatment of ACE induced Angioedema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001670-28,0,0,0 2012-001671-36,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación para la Investigación Biomédica,"A phase IV randomized, controlled clinical trial to compare the high flow oxygen therapy (group of intervention) opposite to the conventional oxygen therapy (group control) in patients with severe acu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001671-36,0,0,0 2012-001675-37,2,2014-08-19,2014-08-19,2,0,0,0,0,1,2,0,0,1,1,1,1,0,1,Sinoxa Pharma GmbH,"A Prospective, Open-label, Exploratory Study to Investigate the Safety, Efficacy, and Haemodynamics of Lisuride Subcutaneous Infusion as Add-on to Conventional Treatment in Patients with Pulmonary Art...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001675-37,0,0,0 2012-001676-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,"""MIRO"" study (Molecularly Oriented Immuno-radio-therapy): a multicenter phase II trail for the treatment on molecular basis of stage I / II Follicular Lymphoma with local radiotherapy with / without ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001676-11,0,0,0 2012-001680-72,4,2014-01-21,2014-01-21,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TAKEDA EUROPE RESEARCH & DEVELOPMENT CENTRE LTD,"A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed- Release Capsules for Relief of Heartburn, in Adolescent ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001680-72,0,0,0 2012-001680-72,4,2014-01-21,2014-01-21,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Development Centre Europe Ltd.,"A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed- Release Capsules for Relief of Heartburn, in Adolescent ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001680-72,0,0,0 2012-001680-72,4,2014-01-21,2014-01-21,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Development Centre Europe Ltd,"A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed- Release Capsules for Relief of Heartburn, in Adolescent ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001680-72,0,0,0 2012-001681-15,4,2014-11-10,2014-11-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TAKEDA EUROPE RESEARCH & DEVELOPMENT CENTRE LTD,"A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed- Release Capsules for Healing of Erosive Esophagitis and Maintenance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001681-15,0,0,0 2012-001681-15,4,2014-11-10,2014-11-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd,"A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed- Release Capsules for Healing of Erosive Esophagitis and Maintenance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001681-15,0,0,0 2012-001681-15,4,2014-11-10,2014-11-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Development Centre Europe Ltd.,"A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed- Release Capsules for Healing of Erosive Esophagitis and Maintenance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001681-15,0,0,0 2012-001681-15,4,2014-11-10,2014-11-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Development Centre Europe Ltd,"A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed- Release Capsules for Healing of Erosive Esophagitis and Maintenance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001681-15,0,0,0 2012-001682-33,1,2016-08-16,2016-08-16,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,Combined Immunotherapy and Trophic Adrenocortical Stimulation in New Onset Autoimmune Addison’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001682-33,0,0,0 2012-001683-29,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase 2/3, randomized, controlled, observer-blind, multi-center trial to evaluate the safety and immunogenicity of a two-dose primary vaccination series of monovalent A/Indonesia/5/2005 (H5N1) vacci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001683-29,0,1,1 2012-001685-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,ANTI-3-18F-FACBC IN COMPARISON TO 11C-CHOLINE PET/CT IN THE EVALUATION OF PATIENTS WITH SUSPECT PROSTATE CANCER RELAPSE ANTI-3-18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carbossilico) rispet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001685-15,0,0,0 2012-001689-13,9,2014-05-15,2014-05-19,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation in patients with chronic heart failure and left ventricular systol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001689-13,0,0,0 2012-001689-13,9,2014-05-15,2014-05-19,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation in patients with chronic heart failure and left ventricular systol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001689-13,0,0,0 2012-001689-13,9,2014-05-15,2014-05-19,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratorios Servier S. L.,Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation in patients with chronic heart failure and left ventricular systol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001689-13,0,0,0 2012-001690-84,6,2015-02-14,2015-02-27,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Safety and efficacy of fixed dose combination of Indapamide SR 1.5 mg / Amlodipine versus Valsartan / Amlodipine over 12-week of treatment with conditional titration based on the blood pressure contro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001690-84,0,0,0 2012-001699-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Laboratorios LETI, S.L.U","Prospective, open uncontrolled study to evaluate the safety of Depigoid with two pollen combinations ( Grasses/Olea and Grasses/ Parietaria) 2000 DPP/ml in patients with allergic rhinitis or rhinoconj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001699-12,0,0,0 2012-001700-37,8,2016-02-22,2016-03-02,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Celladon Corporation,"A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001700-37,0,0,0 2012-001704-38,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Sint Maartenskliniek,Effect of local anesthetic dose versus volume on block duration of single shot ultrasound-guided axillary brachial plexus block with mepivacaine Effect van dosis versus volume van mepivacaine op de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001704-38,0,0,0 2012-001705-24,1,2018-09-28,2018-09-28,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Hellenic Cooperative Oncology Group,Phase II single-arm study of first line treatment with gemcitabine and pazopanib in patients with inoperable locally advanced or metastatic biliary tree cancer (cholangiocarcinoma or gallbladder carci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001705-24,0,0,0 2012-001708-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Leuven,Prospective randomized trial concerning three different stimulation methods in IVF/ICSI treatment in poor responders Prospectief gerandomiseerd onderzoek van drie verschillende stimulatiemethodes ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001708-39,0,0,0 2012-001709-26,1,2012-09-13,2012-09-13,1,0,0,0,0,0,3,0,1,1,0,0,1,0,1,"Sevapharma,a.s.","Randomized, double-blind, placebo-controlled clinical trial of Immodin immunological efficacy in healthy adult volunteers. Randomizované, dvojitě zaslepené, placebem kontrolované klinické hodnocení...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001709-26,0,0,0 2012-001711-23,6,2018-09-28,2018-09-28,4,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients with Severe Haemophilia A Studio clinico...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001711-23,0,0,0 2012-001711-23,6,2018-09-28,2018-09-28,4,1,1,0,0,1,3,0,0,1,0,0,1,0,1,NOVO NORDISK,"A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients with Severe Haemophilia A Studio clinico...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001711-23,0,0,0 2012-001716-30,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Hospital Universitari de Bellvitge,"Randomized, prospective trial comparing antibiotic treatment to observation in renal transplant patients with asimptomatic bacteriuria Estudio prospectivo aleatorizado sobre tratamiento antibiótico...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001716-30,0,0,0 2012-001718-41,14,2014-11-03,2014-11-03,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001718-41,0,0,0 2012-001723-12,1,2018-04-12,2018-04-12,1,0,0,0,0,1,3,0,0,1,1,1,1,0,0,Fundació Clínic per a la Recerca Biomèdica,"A randomized, double-blinded, placebo-controlled study on the effects of adalimumab intralesional intestinal strictures of Crohn's disease patients Estudio aleatorizado, enmascarado, controlado co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001723-12,0,0,0 2012-001725-26,1,2019-09-11,2019-09-11,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,Johann Wolfgang Goethe-University,A Phase I/II Gene Therapy trial for X-CGD with a SIN gamma retroviral vector Phase I/II somatische Gentherapiestudie zur Behandlung der X-chromosomalen septischen Granulomatose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001725-26,0,0,0 2012-001729-28,2,2014-07-30,2014-07-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Infinity Pharmaceuticals, Inc.","A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose, Cross-Over, Efficacy and Safety Study of IPI-145 in Mild Asthmatic Subjects Undergoing Allergen Challenge",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001729-28,0,0,0 2012-001730-33,5,2013-07-19,2013-09-18,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"AVEO PHARMACEUTICALS, INC","A PHASE 2 RANDOMIZED, DOUBLE-BLIND, CROSSOVER, CONTROLLED, MULTI-CENTER, SUBJECT PREFERENCE STUDY OF TIVOZANIB HYDROCHLORIDE VERSUS SUNITINIB IN THE TREATMENT OF SUBJECTS WITH METASTATIC RENAL CELL CA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001730-33,0,0,0 2012-001730-33,5,2013-07-19,2013-09-18,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"AVEO PHARMACEUTICALS, INC.","A PHASE 2 RANDOMIZED, DOUBLE-BLIND, CROSSOVER, CONTROLLED, MULTI-CENTER, SUBJECT PREFERENCE STUDY OF TIVOZANIB HYDROCHLORIDE VERSUS SUNITINIB IN THE TREATMENT OF SUBJECTS WITH METASTATIC RENAL CELL CA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001730-33,0,0,0 2012-001733-13,9,2016-02-02,2016-02-02,6,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Circassia Limited,"A Double Blind, Randomised, Placebo Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001733-13,0,0,0 2012-001749-42,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Effects of treatment and withdrawal with inhaled beclomethasone/formoterol on lung inflammation in COPD. Effetti della terapia e della sospensione della terapia con beclometasone/formoterolo ina...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001749-42,0,0,0 2012-001751-38,1,2017-12-14,2017-12-14,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,CHRU de Lille,SECONDARY PROPHYLAXIS USE OF ROMIPLOSTIM FOR THE PREVENTION OF THROMBOCYTOPENIA IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001751-38,0,0,0 2012-001755-40,1,2014-03-04,2014-03-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE DI MILANO,"Propofol TCI (Target Controlled Infusion) vs. Fentanyl plus Midazolam for moderate sedation during endoscopy diagnostic procedures: a prospective, double-blind randomized trial. Sedazione moderata ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001755-40,0,0,0 2012-001757-21,3,2020-12-31,2020-12-31,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,Istituto Auxologico Italiano,European Society of Hypertension and Chinese Hypertension League Stroke in Hypertension Optimal Treatment Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001757-21,1,0,0 2012-001757-21,3,2020-12-31,2020-12-31,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,ISTITUTO AUXOLOGICO ITALIANO,European Society of Hypertension and Chinese Hypertension League Stroke in Hypertension Optimal Treatment Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001757-21,1,0,0 2012-001760-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,OSSERVATORIO EPIDEMIOLOGICO GISEA,Evaluation effects of treatment with IL-6R inhibitor on clinical response and biomarkers in patients with rheumatoid arthritis (RA) not responding to DMARDs and/or a first biological agent. Valutaz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001760-30,0,0,0 2012-001766-15,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación Pública Andaluza para la Gestion de la Investigación en Salud de Sevilla,Impact of azithromycin as an immunomodulator in patients with recurrent pneumonia and deficit of mannose-binding LECITHIN (MBL2012) Impacto de azitromicina como inmunomodulador en pacientes con neu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001766-15,0,0,0 2012-001767-71,5,2014-06-19,2014-06-21,3,1,1,0,0,0,3,0,0,1,0,0,1,0,2,"Melinta Therapeutics, Inc","A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DELAFLOXACIN COMPARED WITH VANCOMYCIN + AZTREONAM IN PATIENTS WITH ACUTE BACTERIAL SKIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001767-71,0,0,0 2012-001767-71,5,2014-06-19,2014-06-21,3,1,1,0,0,0,3,0,0,1,0,0,1,0,2,RIB-X THERAPEUTICS LIMITED,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DELAFLOXACIN COMPARED WITH VANCOMYCIN + AZTREONAM IN PATIENTS WITH ACUTE BACTERIAL SKIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001767-71,0,0,0 2012-001767-71,5,2014-06-19,2014-06-21,3,1,1,0,0,0,3,0,0,1,0,0,1,0,2,"Rib-X Pharmaceuticals, Inc","A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DELAFLOXACIN COMPARED WITH VANCOMYCIN + AZTREONAM IN PATIENTS WITH ACUTE BACTERIAL SKIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001767-71,0,0,0 2012-001768-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,ZENO-01 90Y ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) ZENO-01 90Y IBRITUMOMAB TIUXETANO IN PAZIENTI CON LI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001768-31,0,0,0 2012-001769-34,2,2014-07-31,2014-07-31,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AnaMar AB,"A double-blind, placebo controlled, parallel-group, randomised study of safety, tolerability and efficacy of AMAP102 in patients with osteoarthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001769-34,0,0,0 2012-001770-29,12,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"UCB BIOSCIENCES, Inc.","AN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001770-29,0,1,0 2012-001771-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FRANCISCO JAVIER BENITO FERNANDEZ,"PILOT CLINICAL TRIAL, RANDOMIZED AND CONTROLLED OF THE USE-OF OXYGEN AT HIGH FLOW IN CHILDREN IN THE PEDIATRIC EMERGENCY SERVICE. COD: OXAURP ENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO DEL USO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001771-36,0,0,0 2012-001772-11,1,2015-02-17,2015-02-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"An exploratory, double-blind, double-dummy, randomised, 2-period, crossover, Phase IIa study to assess the influence of oxycodone/naloxone prolonged-release tablets (OXN PR) and oxycodone prolonged-re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001772-11,0,0,0 2012-001777-86,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,3,,Pilot study for classification of attempted movement from the electroencephalogram in healthy participants with a temporary paralysis of one arm induced by local administration of rocuronium Pilot:...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001777-86,0,0,0 2012-001779-35,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Southampton,The effects of pregabalin augmentation of antidepressant drug on neuro-cognitive functioning in patients with generalized anxiety disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001779-35,0,0,0 2012-001781-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"IOBA, Universidad de Valladolid",Initial protocol setting for the treatment of choroidal neovascularization associated to myopia magna with intravitreal bevacizumab: 3 vs 1 (BENEMCOR.es study) Establecimiento del protocolo inicial...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001781-15,0,0,0 2012-001786-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic resp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001786-32,0,0,0 2012-001789-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Instituto de Investigacion Sanitaria La e,"Double-blind, randomized, controlled contraceptives, parallel group, to assess the effect on nerve fibers in patients diagnosed with endometriosis grade III / IV symptomatic ascending-dose oral quinag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001789-13,0,0,0 2012-001790-86,14,2018-08-15,2018-08-30,12,1,0,0,2,0,3,0,0,1,1,0,1,0,1,CTI Biopharma Corp.,A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001790-86,0,0,0 2012-001790-86,14,2018-08-15,2018-08-30,12,1,0,0,2,0,3,0,0,1,1,0,1,0,1,CELL THERAPEUTICS INC.,A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001790-86,0,0,0 2012-001790-86,14,2018-08-15,2018-08-30,12,1,0,0,2,0,3,0,0,1,1,0,1,0,1,"CTI Biopharma, Corp.",A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001790-86,0,0,0 2012-001790-86,14,2018-08-15,2018-08-30,12,1,0,0,2,0,3,0,0,1,1,0,1,0,1,CTI BioPharma Corp.,A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001790-86,0,0,0 2012-001790-86,14,2018-08-15,2018-08-30,12,1,0,0,2,0,3,0,0,1,1,0,1,0,1,"Cell Therapeutics, Inc.",A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or an E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001790-86,0,0,0 2012-001791-11,2,2014-01-22,2014-01-22,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"KaloBios Pharmaceuticals, Inc.","A Phase 2, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of KB003 in Subjects with Asthma Inadequately Controlled by Corticosteroids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001791-11,0,0,0 2012-001809-24,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Radboud University Nijmegen Medical Centre,Evaluation of urinary concentrating defects in lithium treated patients with a dDAVP test,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001809-24,0,0,0 2012-001812-50,1,2013-06-28,2013-06-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Oncozyme Pharma Inc,A Phase IIa Exploratory Study of OCZ103-OS in Combination with Platinum-Gemcitabine based Doublet First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001812-50,0,0,0 2012-001813-17,1,2017-11-07,2017-11-07,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Hull and East Yorkshire Hospitals NHS Trust,Study of apoptosis related changes and endothelial responses of multiple myeloma patients treated with chemotherapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001813-17,0,0,0 2012-001815-21,4,2013-10-02,2013-10-02,2,1,1,0,0,1,3,0,0,1,1,0,1,0,1,"Shire Regenerative Medicine, Inc.","A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with Generalize...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001815-21,0,0,0 2012-001816-42,1,2019-01-23,2019-01-23,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Kuopion yliopistollinen sairaala,Opioidien aiheuttama mahasuolikanavan toiminnanhäiriö selkärankaleikkauspotilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001816-42,0,0,0 2012-001818-42,5,2016-08-02,2016-08-02,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC","A Double-blind, Randomized, Sham?procedure?controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in Patients with Chronic Heart Failure Due ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001818-42,0,0,0 2012-001818-42,5,2016-08-02,2016-08-02,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Double-blind, Randomized, Sham?procedure?controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in Patients with Chronic Heart Failure Due ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001818-42,0,0,0 2012-001820-36,1,,,0,1,0,0,0,0,2,0,1,1,1,1,0,1,1,GlaxoSmithKline Biologicals,"A phase II observer blind, randomised, controlled study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ candidate tuberculosis vaccine GSK 692342 when administered to adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001820-36,0,0,0 2012-001821-28,5,2015-01-07,2015-01-07,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Amgen, Inc.",A Randomized Double-blind Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001821-28,0,0,0 2012-001822-89,1,2013-01-10,2013-01-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lofarma S.p.A.,A Dose Finding Study of the Efficacy of LAIS® Birch-Alder tablets in patients suffering from tree pollen-induced allergic rhinoconjunctivitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001822-89,0,0,0 2012-001824-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medizinsiche Universität Wien, Klinik für Innere Medizin III, Abteilung für Nephrologie und Dialyse",ORAL SODIUM BICARBONATE SUPPLEMENTATION IN PATIENTS WITH CHRONIC METABOLIC ACIDOSIS AND CHRONIC KIDNEY DISEASE Orale Natriumbicarbonat Substitution bei Patienten mit chronischer metabolischer Azido...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001824-36,0,0,0 2012-001825-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Fakultní nemocnice Ostrava,Czech Republic",Randomised clinical study of autologous bone marrow aspirate concentrate (BMAC) activity fo No_option_critical limb ischemia in Type-II diabetes mellitus (DILAEG) Randomizovaná klinická studie akti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001825-28,0,0,0 2012-001826-84,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Pécs,"The Effect of Vitamin D on the Frequency of Epileptic Seizures: A Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial A D-vitamin hatása az epilepsziás rohamok gyakoriságára: randomizá...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001826-84,0,0,0 2012-001827-11,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,Evaluation de l’efficacité et de la tolérance de deux vasopresseurs dans le traitement des hypotensions artérielles per-opératoires en chirurgie carotidienne : étude prospective randomisée contrôlée m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001827-11,0,0,0 2012-001828-35,8,2020-12-15,2020-12-29,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Randomized Open-Label Phase 3 Trial of BMS-936558 versus Investigator’s Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy Pharmacogenetics Blood...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001828-35,1,0,0 2012-001828-35,8,2020-12-15,2020-12-29,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Randomized Open-Label Phase 3 Trial of BMS-936558 versus Investigator’s Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy Pharmacogenetics Blood...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001828-35,1,0,0 2012-001829-27,4,2014-12-05,2014-12-05,2,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Actelion Pharmaceuticals Ltd.,Multi-center non-drug-interventional extension study to assess long-term safety and effects on growth in patients who received bosentan or placebo as adjunctive therapy to inhaled nitric oxide for per...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001829-27,1,0,0 2012-001830-32,5,2014-10-06,2014-10-06,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, double-dummy, randomised, multi-centre, comparative phase III clinical study on the efficacy and tolerability of an 8 week oral treatment with three times daily 1000 mg mesalazine versus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001830-32,0,0,0 2012-001831-30,6,2017-10-16,2018-03-15,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Isis Pharmaceuticals, Inc.","A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001831-30,0,0,0 2012-001831-30,6,2017-10-16,2018-03-15,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Ionis Pharmaceuticals, Inc.","A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001831-30,0,0,0 2012-001834-33,9,2015-02-25,2015-05-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Exelixis, Inc.","A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001834-33,0,0,0 2012-001834-33,9,2015-02-25,2015-05-25,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"EXELIXIS, INC.","A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001834-33,0,0,0 2012-001836-72,2,2014-08-13,2014-08-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Isis Pharmaceuticals, Inc.","An Open-label, Randomized, Active Comparator-Controlled, Adaptive Parallel-group Phase 2 Study to Assess the Safety and Efficacy of Multiple Doses of ISIS 416858 Administered Subcutaneously to Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001836-72,0,0,0 2012-001840-23,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,Bristol-Myers Squibb International Corporation,An exploratory study of the biologic effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination with Ipilimumab Treatment in Subjects with Advanced melanoma (Unresectable or metastat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001840-23,0,1,1 2012-001849-41,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Leids Universitair Medisch Centrum (LUMC),"Two-part, Randomized, Placebo-controlled, Repeated Stepped Infusion Dose Study of the Pharmacodynamics of Doxapram when Co-administered with Opioids (Protocol – doxapram-101).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001849-41,0,0,0 2012-001850-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ABCSG (Austrian Breast & Colorectal Cancer Study Group),"A prospective randomized phase II trial of FOLFIRINOX alone versus FOLFIRINOX followed by radiochemotherapy in patients with locally advanced, primarily inoperable pancreatic cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001850-24,0,0,0 2012-001852-20,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,Oslo University Hospital,A PHASE I/IIa STUDY OF UV1 VACCINATION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001852-20,0,0,0 2012-001855-38,1,2013-08-27,2013-08-27,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase IIb, Randomized, Placebo-Controlled, Dose-Finding Clinical Trial to Study the Safety and Efficacy of MK-8237 using an Environmental Exposure Chamber in Subjects with House Dust induced Allergi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001855-38,0,0,0 2012-001858-25,4,2015-07-02,2016-10-24,3,1,0,0,2,0,4,0,0,1,0,0,1,0,1,MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.,"A multicentre randomised, double-blind, parallel group study on the therapeutic efficacy and safety of Febuxostat (taken once daily) and the therapeutic efficacy and safety of Allopurinol on serum ur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001858-25,0,0,0 2012-001859-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,TElmisartan in the management of abDominal aortic aneurYsm (TEDY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001859-39,0,0,0 2012-001863-64,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Apeptico Forschung und Entwicklung GmbH,Proof of concept study in male and female intensive care patients to investigate the clinical effect of repetitive orally inhaled doses of AP301 on alveolar liquid clearance in acute lung injury,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001863-64,0,0,0 2012-001864-30,4,2013-11-12,2013-11-28,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Molecular Insight Pharmaceuticals, Inc",A Phase 2 Assessment of the Diagnostic Accuracy of 99mTc-MIP-1404 Imaging in Men with High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001864-30,0,0,0 2012-001868-29,6,2013-11-01,2013-11-01,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Double-Blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a fixed-dose combination [FDC] of sitagliptin and simvastatin) for the Treatment of Patients With Ty...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001868-29,0,0,0 2012-001869-33,7,2014-06-23,2014-06-23,7,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AstraZeneca AB,"A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study with an Optional Safety Extension Treatment Period up to 6 months, to Evaluate the Efficacy, Safet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001869-33,0,0,0 2012-001871-35,1,2013-08-16,2013-08-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"AC4116136: A multicenter, randomized, double-blind, parallelgroup study to evaluate the efficacy and safety of the addition of umeclidinium bromide Inhalation Powder (62.5mcg) once-daily to fluticason...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001871-35,0,0,0 2012-001873-10,4,2013-06-20,2013-09-26,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double- blind, 2 way cross-over study to determine 24-hour FEV1-time profile of inhaled tiotropium, delivered via the Respimat® inhaler, after 4 weeks of once daily [5 µg in the evening ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001873-10,0,0,0 2012-001873-10,4,2013-06-20,2013-09-26,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double- blind, 2 way cross-over study to determine 24-hour FEV1-time profile of inhaled tiotropium, delivered via the Respimat® inhaler, after 4 weeks of once daily [5 µg in the evening ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001873-10,0,0,0 2012-001875-35,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, randomized, open study to assess the immunogenicity, reactogenicity and safety of two different formulations of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001875-35,0,1,1 2012-001876-13,1,2014-04-29,2014-04-29,1,1,0,0,0,1,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase III, open, randomized, controlled, multicenter study to assess the immunogenicity and reactogenicity of GSK Biologicals’ meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001876-13,0,0,0 2012-001877-94,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,UNIVERSITY CLINIC GOLNIK,Significance of COX-2 inhibition in first line treatment of extensive disease small-cell lung cancer (ED-SCLC) POMEN COX-2 INHIBICIJE V PRVI LINIJI ZDRAVLJENJA RAZŠIRJENEGA DROBNOCELIČNEGA RAKA PL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001877-94,0,0,0 2012-001879-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Department of Oncology, Skåne University Hospital Lund",A randomized multicenter phase III study of cisplatin plus radiotherapy compared to cetuximab plus radiotherapy in locally advanced head and neck cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001879-37,0,0,0 2012-001881-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,A phase II clinical trial to evaluate the safety and efficacy of interferon gamma in elevating frataxin levels in Friedreich ataxia patients Studio clinico di fase 2 per valutare la sicurezza e l'e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001881-14,0,0,0 2012-001884-64,1,2020-08-10,2020-08-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Liverpool,A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Ant...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001884-64,0,0,0 2012-001884-64,1,2020-08-10,2020-08-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Walton Centre NHS Foundation Trust,A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Ant...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001884-64,0,0,0 2012-001886-33,5,2014-04-29,2014-04-29,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","Randomized, Controlled, Parallel Group, Double Blind Trial to Compare the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures Using a 2x2 Factor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001886-33,0,0,0 2012-001888-78,19,2019-12-11,2019-12-11,16,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Celgene Corporation,"A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA STUDIO MULTICENTRI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001888-78,0,0,0 2012-001888-78,19,2019-12-11,2019-12-11,16,1,0,0,0,1,3,0,0,1,1,0,1,0,1,CELGENE CORPORATION,"A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY WITH POMALIDOMIDE IN COMBINATION WITH LOW DOSE DEXAMETHASONE IN SUBJECTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA STUDIO MULTICENTRI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001888-78,0,0,0 2012-001889-14,1,2015-09-23,2015-09-23,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust,MicroBubble detection and Ultrasound guided Biopsy of axillary Lymph nodes in patients with Early breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001889-14,0,0,0 2012-001891-13,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,University Hospital Essen,"Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase I/I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001891-13,0,0,0 2012-001896-35,11,2015-12-31,2015-12-31,7,1,0,0,0,0,3,0,0,1,1,0,1,0,0,ETOP (European Thoracic Oncology Platform),A randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer who failed first line platinum based doublet chemotherapy stratified by Ve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001896-35,0,0,0 2012-001896-35,11,2015-12-31,2015-12-31,7,1,0,0,0,0,3,0,0,1,1,0,1,0,0,ETOP,A randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer who failed first line platinum based doublet chemotherapy stratified by Ve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001896-35,0,0,0 2012-001896-35,11,2015-12-31,2015-12-31,7,1,0,0,0,0,3,0,0,1,1,0,1,0,0,IBCSG,A randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer who failed first line platinum based doublet chemotherapy stratified by Ve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001896-35,0,0,0 2012-001898-90,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Maastricht University Medical Center,Effects of vernakalant and flecainide on atrial contractility in patients with atrial fibrillation De effecten van vernakalant en flecaïnide op de atriale contractiliteit bij patiënten met atriumfi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001898-90,0,0,0 2012-001900-39,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,A multicentre randomised phase II clinical trial of Inotuzumab Ozogamicin plus Rituximab and CVP (IO-R-CVP) versus Gemcitabine plus Rituximab and CVP (Gem-R-CVP) for the first line treatment of patien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001900-39,0,0,0 2012-001908-38,1,2018-03-31,2018-03-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie","The effect of intravenous ketamine on the MAC of sevoflurane – a randomized, placebo controlled, double blinded clinical trial Effekt von intravenösem S-Ketamin auf den MAC-Wert von Sevofluran",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001908-38,0,0,0 2012-001909-24,1,2015-09-14,2015-09-14,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,University Medical Center Utrecht,"A Multi Center, Prospective, Observational, Open-label, Pharmacokinetic Study of Tacrolimus in Heart and Lung Transplantation Patients during the First Days after Transplantation Een multi centrum,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001909-24,0,0,0 2012-001910-40,1,2018-07-17,2018-07-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie",The effect of intravenous glucocorticoids on the tearfilm in eyes with thyroid-associated ophthalmopathy Die Wirkung von intravenösen Glukokortikoiden auf den Tränenfilm bei endokriner Orbitopathie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001910-40,0,0,0 2012-001912-53,1,2019-02-25,2019-02-25,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Children's Hospital, Helsinki University Hospital",Inhaled salbutamol in elective caesarean section Salbutamoli-interventio elektiivisessä keisarileikkauksessa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001912-53,0,0,0 2012-001914-41,1,2013-09-25,2013-09-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergopharma Joachim Ganzer KG,Open label phase II multicentre clinical trial to evaluate safety during shortened uptitration of an allergoid grass pollen preparation in adult patients with IgE mediated allergic rhinitis / rhinocon...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001914-41,0,0,0 2012-001916-41,4,2015-11-17,2015-11-17,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,Inserm,Fluconazole versus Micafungin in neonates with suspected or culture-proven Candidiasis: a randomized pharmacokinetic and safety study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001916-41,1,0,0 2012-001918-42,1,2016-07-31,2016-07-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Ottawa Hospital Research Institute,"Effect of folic acid supplementation in pregnancy on preeclampsia - Folic Acid Clinical Trial (FACT) A randomized, double-blind, placebo-controlled, Phase III, international multi-centre study of 4.0 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001918-42,0,0,0 2012-001920-36,10,2014-07-10,2014-07-10,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Grünenthal GmbH,"Efficacy, safety, and tolerability of GRT6005 in subjects with moderate to severe chronic low back pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001920-36,0,0,0 2012-001920-36,10,2014-07-10,2014-07-10,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Grunenthal GmbH,"Efficacy, safety, and tolerability of GRT6005 in subjects with moderate to severe chronic low back pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001920-36,0,0,0 2012-001921-29,4,2013-08-02,2013-09-13,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Radius Health Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of BA058 Administered via a Coated Transdermal Microarray Delivery System (BA058 Transdermal) in Healthy Postmenopausal Women with Osteopo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001921-29,0,0,0 2012-001923-11,10,2015-06-25,2015-09-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pharmalink AB,"A Multicentre, Interventional Treatment, Randomised, Double-Blind, Single Group Assignment, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primary I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001923-11,0,0,0 2012-001923-11,10,2015-06-25,2015-09-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CROWN OY,"A Multicentre, Interventional Treatment, Randomised, Double-Blind, Single Group Assignment, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon® in Primary I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001923-11,0,0,0 2012-001924-37,1,2014-06-13,2014-06-13,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Fredericia Hospital,Relaxation of the ureter during ureterorenoscopy Relaksation af ureter under ureterorenoskopi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001924-37,0,0,0 2012-001930-32,1,2016-01-12,2016-01-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A randomised, double blind, cross-over trial comparing the safety and efficacy of insulin degludec and insulin glargine, both with insulin aspart as mealtime insulin in subjects with type 1 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001930-32,0,0,0 2012-001931-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Laboratorios LETI, S.L.U","Ensayo Clínico multicéntrico, abierto, para la comparación de la potencia biológica entre los extractos alergénicos nativo, despigmentado y despigmentado-polimerizado de epitelio de gato.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001931-30,0,0,0 2012-001935-30,4,2013-05-13,2014-06-09,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Elan Pharma International Ltd,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients with Bipolar I Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001935-30,0,0,0 2012-001937-15,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Laboratorios Leti, S.L.Unipersonal",Biological standardization of Chenopodium album allergen extract to determine the biological activity in HEP units. Estandarización biológica del extracto alergénico de Chenopodium album para deter...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001937-15,0,0,0 2012-001938-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Laboratorios Leti, S.L.Unipersonal",Biological standardization of Platanus acerifolia allergen extract to determine the biological activity in HEP units. Estandarización biológica del extracto alergénico de Platanus acerifolia para d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001938-34,0,0,0 2012-001939-31,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,LABORATORIOS LETI S.L.U,Biological standardization of Dermatophagoides pteronyssinus allergen extract to determine the biological activity in histamine equivalent units (HEP). Estandarización biológica del extracto alergé...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001939-31,0,0,0 2012-001941-42,1,2014-08-14,2014-08-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Västra Götalandsregionen (VGR),Addition of liraglutide to overweight patients with type 2 diabetes treated with multiple daily insulin injections (MDI) with inadequate glycaemic control Tillägg av liraglutid hos överviktiga pati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001941-42,0,0,0 2012-001942-16,8,2014-01-08,2014-01-08,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Inc.,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Efficacy and Safety of GS-7977 + Ribavirin for 12 Weeks in Treatment-Naïve and Treatment-Experienced Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001942-16,0,0,0 2012-001945-42,1,2016-08-17,2016-08-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Service AG,"A multicenter, double blind, randomized, parallel group, placebo-controlled study to evaluate the effects of intravenous serelaxin infusion on micro- and macrovascular function in patients with corona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001945-42,0,0,0 2012-001947-31,1,2015-08-05,2015-08-05,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Technische Universität Dresen,Ofatumumab Induction and Maintenance in Elderly Patients with Poor Risk CLL in the Context of Allogeneic Transplantation: CLLX4 Trial Ofatumumab Induktions- und Erhaltungstherapie bei älteren Patie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001947-31,0,0,0 2012-001948-21,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,Grupo Español de Tumores Huérfanos e Infrecuentes,Open Phase II Study of Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary. GreKo Study. Estudio fase II abierto de ketoconazol como inh...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001948-21,0,0,0 2012-001950-25,3,2014-10-11,2014-10-11,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Forest Research Institute, Inc., a wholly owned subsidiary of Forest Laboratories, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study with Vilazodone in Patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001950-25,0,0,0 2012-001952-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,BIVALIRUDIN PLUS STENTING IN lONG LESION TO AVOID PERIPROCEDURAL MYOCARDIAL NECROSIS TRIAL. BILLION TRIAL BIVALIRUDIN PLUS STENTING IN lONG LESION TO AVOID PERIPROCEDURAL MYOCARDIAL NECROSIS TRIAL....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001952-20,0,0,0 2012-001955-38,1,2016-07-30,2016-07-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),Open label Phase II study of Folfiri + Panitumumab using ultra-selection technology with next generation high sensitivity genotyping of patients with stage IV colorectal cancer refractory to irinoteca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001955-38,0,0,0 2012-001956-20,6,2013-08-06,2013-08-06,5,1,0,0,1,0,3,0,0,1,0,0,1,0,2,Relypsa Inc,"A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001956-20,0,0,0 2012-001960-31,1,2019-02-14,2019-02-14,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,UZ Leuven,Combined drug Approach to Prevent Ischemia-reperfusion injury during Transplantation of Livers (CAPITL): a first-in-men study Toediening geneesmiddelen ter vermindering van ischemie-reperfusie sc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001960-31,0,0,0 2012-001961-33,2,2016-02-03,2016-02-03,1,1,0,1,0,0,1,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A phase I/II, multicenter, open-label dose finding study of oral CFG920 in patients with metastatic castration-resistant prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001961-33,1,0,0 2012-001961-33,2,2016-02-03,2016-02-03,1,1,0,1,0,0,1,0,0,2,1,0,0,0,1,Novartis Farmacéutica S.A.,"A phase I/II, multicenter, open-label dose finding study of oral CFG920 in patients with metastatic castration-resistant prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001961-33,1,0,0 2012-001962-13,2,2017-06-01,2017-06-01,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma AG,"A phase Ib/II open-label, multi-center study of the combination of BYL719 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001962-13,0,0,0 2012-001962-13,2,2017-06-01,2017-06-01,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Farmaceutica S.A,"A phase Ib/II open-label, multi-center study of the combination of BYL719 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001962-13,0,0,0 2012-001965-34,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,"Servicio de Neurología, HU. Germans Trias i Pujol","Multicenter, randomized, double-blind clinical trial to compare the clinical and radiological efficacy of 625 mg vs 1250 mg of oral methylprednisolone in patients with multiple sclerosis in relapse. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001965-34,0,0,0 2012-001966-14,1,2016-08-17,2016-08-17,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"Genzyme, a Sanofi Company","A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients with Fabry Disease Estudio transversal sobre la función renal en varones jóvenes con enfermedad de Fabry sin tratam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001966-14,0,0,0 2012-001970-28,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Birmingham,Does CMV reactivation cause functional impairment of CMV specific CD4+ T-cells? The potential for valaciclovir to prevent CMV-mediated adverse modulation of the immune system in patients with ANCA-ass...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001970-28,0,0,0 2012-001975-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,Evaluation on the efficacy of docosahexaenoic acid for the treatment of nonalcoholic fatty liver disease in children Valutazione dell'efficacia terapeutica dell'acido docosaesaenoico nella steatoep...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001975-36,0,0,0 2012-001978-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,A Phase II study of intermittent letrozole plus transdermal estradiol gel 3 month-therapy as adjuvant endocrine treatment for postmenopausal women with hormone-receptor positive early stage breast c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001978-28,0,0,0 2012-001980-53,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO,Preliminary study on the effectiveness of low doses of Rituximab in patients with Graves’ orbitopathy (GO) poorly responding to immunosuppressive steroid treatment. Studio preliminare sull'efficaci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001980-53,0,0,0 2012-001983-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Juha Hartikainen,PERFUSION JA MINIPERFUSION VAIKUTUS BEETASALPAAJA METOPROLOLIN IMEYTYMISEEN SYDÄNLEIKKAUSPOTILAILLA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001983-31,0,0,0 2012-001984-66,11,2015-01-12,2015-01-12,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis Recherche & Développement,"A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment with Adalimu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001984-66,0,0,0 2012-001989-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universität des Saarlandes,"A randomised, placebo controlled, double blind, cross-over, single center clinical Study to investigate the effect of heart rate reduction with ivabradine on endothelial function and vascular stiffnes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001989-15,0,0,0 2012-001991-13,1,2015-05-26,2015-05-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PHILOGEN S.P.A.,A phase II study of intratumoral application of L19IL2/L19TNF in melanoma patients in clinical stage III or stage IV M1a with presence of injectable cutaneous and/or subcutaneous lesions. Studio ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001991-13,0,0,0 2012-001995-12,4,2016-07-01,2016-07-01,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,LFB BIOTECHNOLOGIES,"A European, randomised, double-blind, active comparator-controlled, cross-over, efficacy and safety study of a new 10% ready-to-use liquid human intravenous immunoglobulin (I10E) versus Kiovig® in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001995-12,0,0,0 2012-001996-34,1,2015-06-08,2015-06-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LFB BIOTECHNOLOGIES,"A comparative, double-blind, randomised, multicentre efficacy and safety study of ClairYg® versus Tégéline® in maintenance treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001996-34,0,0,0 2012-001998-93,3,2014-06-30,2014-06-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Service AG,"A multi-center, randomized, double-blind, 52-week study to assess the safety of QVA149 compared to QAB149 in patients with Chronic Obstructive Pulmonary Disease (COPD) who have moderate to severe airf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001998-93,0,0,0 2012-002002-46,1,2019-03-15,2019-03-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Universitätsklinik für Zahn-, Mund- und Kieferheilkunde, Med Uni Graz, Department für zahnärztliche Chirurgie","A phase III, randomized, controlled clinical pilot trial of lateral ridge augmentation using autogenous bone blocks or xenogenic bone block grafts loaded with recombinant human bone morphogenic protei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002002-46,0,0,0 2012-002009-23,11,2017-06-12,2017-06-12,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Hexal AG,"A randomized, double-blind, parallel-group Phase III study to demonstrate equivalent efficacy and to compare safety and immunogenicity of GP2015 and Enbrel® (EU-authorized) in patients with moderate t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002009-23,0,0,0 2012-002010-39,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universidad Autónoma de Madrid,Evaluation of safety and feasibility of bone marrow derived autologous MSCs to enhance bone healing in patients with avascular necrosis of femoral head,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002010-39,0,0,0 2012-002011-26,8,2015-03-30,2015-03-30,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Hexal AG,"A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel® in patients with moderate to s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002011-26,0,0,0 2012-002012-46,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA POLICLINICO DI MODENA,A pilot phase II study to assess the efficacy of Brentuximab Vedotin administered sequentally with ABVD chemotherapy in patients with untreated Hodgkin Lymphoma Studio pilota di fase II per valutar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002012-46,0,0,0 2012-002013-19,5,2014-05-20,2014-05-20,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Sanofi aventis Recherche&Développement,"A randomized, double-blind, placebo-controlled, multicenter study evaluating efficacy and safety of SAR339658 in patients with active moderate to severe Ulcerative Colitis (UC).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002013-19,0,0,0 2012-002018-37,11,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A RANDOMIZED, MULTICENTER, OPEN LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2-POSITIVE PRIMARY BREAST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002018-37,0,0,0 2012-002019-25,7,2014-10-09,2014-10-27,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ABBOTT GMBH & Co. KG,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)and ABT-333 Co-administered with Ribavirin (RBV) in Treatment-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002019-25,0,0,0 2012-002019-25,7,2014-10-09,2014-10-27,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)and ABT-333 Co-administered with Ribavirin (RBV) in Treatment-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002019-25,0,0,0 2012-002023-15,1,2018-05-11,2018-05-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Innere Medizin 3, Abteilung für Gastroenterologie und Hepatologie",Mesacol: The effect of mesalazine on molecular pathways of cell adhesion in ulcerative colitis Mesacol: Effekt von Mesalazin auf molekulare Zelladhäsionspathways bei Colitis ulcerosa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002023-15,0,0,0 2012-002024-32,1,2018-05-11,2018-05-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Innere Medizin 3, Abteilung für Gastroenterologie und Hepatologie",Mesapol: The effect of mesalazine on molecular pathways of cell adhesion in patients with colon polyps Mesapol: Effekt von Mesalazin auf Zelladhäsionspathways bei Patienten mit Dickdarmpolypen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002024-32,0,0,0 2012-002026-78,4,2016-12-23,2017-11-10,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ERYTECH Pharma,"A Multicentre, open, randomized, controlled phase IIb trial evaluating efficacy and tolerability of GRASPA (L-asparaginase encapsulated in red blood cells) plus low-dose cytarabine vs low-dose cytarab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002026-78,0,0,0 2012-002029-31,1,2020-10-15,2020-10-15,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Cancer Research UK,A Cancer Research UK Phase I/II study to compare [124I]mIBG PET/CT to [123I]mIBG imaging in patients with metastatic neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002029-31,0,0,0 2012-002030-37,13,2016-02-04,2016-02-04,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY10017, United States","A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (TU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002030-37,0,0,0 2012-002030-37,13,2016-02-04,2016-02-04,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (TU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002030-37,0,0,0 2012-002031-28,12,2017-12-13,2017-12-13,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Shire Human Genetic Therapie, Inc.",A MULTICENTER OPEN-LABEL EXTENSION STUDY TO ASSESS LONG-TERM SAFETY OF PF-00547659 IN SUBJECTS WITH ULCERATIVE COLITIS (TURANDOT II),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002031-28,0,0,0 2012-002031-28,12,2017-12-13,2017-12-13,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY10017, United States",A MULTICENTER OPEN-LABEL EXTENSION STUDY TO ASSESS LONG-TERM SAFETY OF PF-00547659 IN SUBJECTS WITH ULCERATIVE COLITIS (TURANDOT II),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002031-28,0,0,0 2012-002031-28,12,2017-12-13,2017-12-13,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Shire Human Genetic Therapies, Inc.",A MULTICENTER OPEN-LABEL EXTENSION STUDY TO ASSESS LONG-TERM SAFETY OF PF-00547659 IN SUBJECTS WITH ULCERATIVE COLITIS (TURANDOT II),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002031-28,0,0,0 2012-002035-29,9,2014-10-23,2014-10-23,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ABBOTT GMBH & Co. KG,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co administered with Ribavirin (RBV) in Treatment-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002035-29,0,0,0 2012-002035-29,9,2014-10-23,2014-10-23,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co administered with Ribavirin (RBV) in Treatment-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002035-29,0,0,0 2012-002035-29,9,2014-10-23,2014-10-23,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co administered with Ribavirin (RBV) in Treatment-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002035-29,0,0,0 2012-002039-28,1,2013-12-04,2013-12-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sandoz GmbH,Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta® Estudio pivotal en pacientes con cáncer de mama para investigar la eficacia y seguridad de LA-EP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002039-28,0,0,0 2012-002042-21,1,2021-06-25,2021-06-25,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Genentech, Inc.","AN OPEN-LABEL, PHASE I/II, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0032 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS AND IN COMBINATION WITH ENDOCRINE THERA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002042-21,0,0,0 2012-002046-20,1,,,0,0,0,0,1,0,2,0,0,1,0,0,0,1,0,ISTITUTO ONCOLOGICO VENETO,"Role of SAMITAL in prevention and treatment of oral mucositis in patients treated with chemo-radiation (CT/RT)for head-and-neck squamous cell carcinomas. A double-blind, Phase 2 placebo controlled, ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002046-20,0,0,0 2012-002047-26,5,2015-04-05,2016-04-05,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,FDC116115: A prospective study of sexual function in sexually active men treated for BPH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002047-26,0,0,0 2012-002047-26,5,2015-04-05,2016-04-05,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.",FDC116115: A prospective study of sexual function in sexually active men treated for BPH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002047-26,0,0,0 2012-002052-17,1,2021-02-11,2021-02-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Medizinische Universität Graz, Univ. Frauenklinik, Abteilung für Gynäkologie",Primary Imiquimod Treatment versus Surgery for Vulvar Intraepithelial Neoplasia: A Prospective Randomized Controlled Trial Primäre Therapie mit Imiquimod versus Chirurgie zur Behandlung der Vulvär...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002052-17,0,0,0 2012-002053-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Karolinska Institutet and University Hospital,"PET/CT-biopsi study A PET/CT biopsy sub study in patients who have given informed consent to participate in a randomized, dubbel blind, placebo controlled phase III trial with Capecitabine +/- Sorafe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002053-29,0,0,0 2012-002057-38,6,2015-02-05,2015-02-05,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Service AG,A placebo and active controlled study to assess the long-term safety of once daily QVA149 for 52 weeks in Chronic Obstructive Pulmonary Disease (COPD) patients with moderate to severe airflow limitati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002057-38,0,0,0 2012-002057-38,6,2015-02-05,2015-02-05,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A placebo and active controlled study to assess the long-term safety of once daily QVA149 for 52 weeks in Chronic Obstructive Pulmonary Disease (COPD) patients with moderate to severe airflow limitati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002057-38,0,0,0 2012-002059-40,1,2013-06-20,2013-06-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Potentiating clinical and immunological effects of chemotherapy by neutralizing acidic pH at tumor site: a phase II randomized study in melanoma patients Potenziamento degli effetti clinici e immun...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002059-40,0,0,0 2012-002062-13,3,2018-05-10,2018-05-10,2,1,1,0,0,0,2,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE IIA, INTERNATIONAL, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF 4 x 375 mg/m2 INTRAVENOUS RITUXIMAB IN PEDIATRIC PATIENTS WITH SEVERE GRANULOMATO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002062-13,0,0,0 2012-002062-13,3,2018-05-10,2018-05-10,2,1,1,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A PHASE IIA, INTERNATIONAL, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF 4 x 375 mg/m2 INTRAVENOUS RITUXIMAB IN PEDIATRIC PATIENTS WITH SEVERE GRANULOMATO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002062-13,0,0,0 2012-002064-27,2,2013-10-24,2013-10-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Pharma A/S,"A Phase 2, Randomized, Double-blind, 4-week Cross-over Trial to Investigate The Effect of a Once-daily Combination of 500 µg Roflumilast plus 10 mg Montelukast versus 10 mg Montelukast Alone on Pulmon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002064-27,0,0,0 2012-002066-12,5,2014-10-13,2014-10-13,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVAGALI Pharma S.A.S,"A Multicenter, Open Label, Interventional, Prospective, Non Randomized, One Cohort Extension Study To Assess the Sustainability of the Effect of NOVA22007 Following Treatment Discontinuation in Improv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002066-12,1,0,0 2012-002067-10,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Mesenchymal stromal cells for treatment of drug resistant pediatric Juvenile idiopathic arthritis Mesenchymale stromale cellen voor de behandeling van therapie-resistente juveniele idiopathische ar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002067-10,0,0,0 2012-002068-29,1,2015-04-23,2015-04-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Jan Stener Joergensen,Antibiotic Prophylaxis and Intervention for Postpartum Infections following Caesarean Section Forebyggelse af og intervention ved postoperative infektioner efter sectio,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002068-29,0,0,0 2012-002069-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hôpitaux Universitaires de Strasbourg,Randomized controlled clinical trial investigating Erlotinib for the treatment of chronic hepatitis C virus infection Evaluation de l'efficacité antivirale et de la tolerance à court terme de l'erl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002069-36,0,0,0 2012-002071-34,1,2013-07-03,2013-07-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Dance Pharmaceuticals, Inc.","Samba-01: A Phase 1/2 Trial Investigating the Pharmacokinetics, Pharmacodynamics and Safety of Inhaled Insulin in Subjects with Type 1 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002071-34,0,0,0 2012-002073-60,1,2016-10-15,2016-10-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Warwick,Liraglutide in PCOS (LIPOS) Study: Evaluation of the Efficacy of Liraglutide on Menstrual Cyclicity in Women with PCOS - a prospective randomised double-blind placebo-controlled study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002073-60,0,0,0 2012-002074-31,6,2019-04-26,2019-04-26,5,1,0,1,0,2,1,0,0,1,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002074-31,0,0,0 2012-002074-31,6,2019-04-26,2019-04-26,5,1,0,1,0,2,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002074-31,0,0,0 2012-002074-31,6,2019-04-26,2019-04-26,5,1,0,1,0,2,1,0,0,1,0,0,0,0,1,Novartis Pharma S.p.A.,"A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002074-31,0,0,0 2012-002076-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Pre-operative treatment with Erythropoietin and iron supplement for prevention of perioperative blood transfusion in cardiac surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002076-14,0,0,0 2012-002078-30,1,2014-06-18,2014-06-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.","Assessing the Efficacy and Tolerability of TRAVATAN® Solution without BAK, containing Polyquad® Preservative (travoprost 0.004%) versus LUMIGAN® 0.01% Solution with BAK (bimatoprost 0.01%) in Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002078-30,0,0,0 2012-002080-10,4,2021-01-26,2021-01-26,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Genentech, Inc.","A RANDOMIZED, PHASE II, PLACEBO-CONTROLLED STUDY OF GDC-0068, AN INHIBITOR TO AKT, IN COMBINATION WITH FLUOROPYRIMIDINE PLUS OXALIPLATIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC OR GAST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002080-10,1,0,0 2012-002083-27,1,2013-08-27,2013-08-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Kade Pharmazeutische Fabrik GmbH,Placebo-controlled double-blind trial investigating the efficacy and tolerability of Posterisan® akut with lidocaine 60 mg/suppository in abatement of complaints associated with hemorrhoids Placebo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002083-27,0,0,0 2012-002093-31,1,2012-01-11,2012-01-11,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Oulu University Hospital,Diagnosis community-acquired pneumonia in emergency unit Kotialkuisen keuhkokuumeen diagnoosi vastaanotolla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002093-31,0,0,0 2012-002094-58,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Unidad de Investigación en Tuberculosis de Barcelona (UITB),An evaluation of adherence to LTBI treatment with 12 doses of once weekly rifapentine and isoniazid given as self-administered versus directly-observed therapy: iAdhere Evaluación de la adherencia ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002094-58,0,0,0 2012-002096-34,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Crucell Holland B.V.,Research towards presence of Antibodies against European Bat Lyssavirus (EBLV) after immunization with Rabipur®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002096-34,0,0,0 2012-002099-15,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,1,Apodemus AB,"A randomised, double blind, placebo controlled trial to evaluate the safety and efficacy of Apovir for treatment of patients with Amyotrophic lateral sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002099-15,0,0,0 2012-002100-41,1,2013-04-18,2013-04-18,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Lipopeptide AB,"A double-blind, randomized, placebo-controlled, safety and pilot dose-response study of LL-37 in hard-to-heal venous leg ulcers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002100-41,0,0,0 2012-002104-40,11,2015-12-01,2015-12-01,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"An open-label phase IIIb study of riociguat in patients with in-operable CTEPH, or recurrent or persisting PH after surgical treatment who are not satisfactorily treated and cannot participate in any...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002104-40,0,0,0 2012-002104-40,11,2015-12-01,2015-12-01,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Bayer AG,"An open-label phase IIIb study of riociguat in patients with in-operable CTEPH, or recurrent or persisting PH after surgical treatment who are not satisfactorily treated and cannot participate in any...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002104-40,0,0,0 2012-002105-22,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Dra Itxarone Bilbao. Servicio de cirugía hepatobiliopancreatica y trasplantes. HUVH,Personal monitoring of liver transplant patients infected with Hepatitis C Virus. Pilot study to compare the evolution of Hepatitis C by receiving immunosuppression with tacrolimus in combination with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002105-22,0,0,0 2012-002106-48,1,2016-02-10,2016-02-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,3,University College Dublin,"An Investigative Study to characterize gene expression patterns in myeloid cells that are triggered during acute asthma exacerbations, and to identify associated genes/gene networks that are Omalizuma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002106-48,0,0,0 2012-002107-17,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,University of Birmingham,International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002107-17,0,0,0 2012-002117-19,3,2015-07-13,2015-07-13,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Intarcia Therapeutics, Inc.","A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients with T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002117-19,0,0,0 2012-002120-33,1,,,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,AZIENDA SANITARIA OSPEDALIERA O.I.R.M. - S. ANNA,Human Liver Stem Cells (HLSCs) in patients suffering from liver-based inborn metabolic diseases causing life-threatening neonatal onset of hyperammonemic encephalopathy Utilizzazione delle Cellule ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002120-33,0,0,0 2012-002122-67,3,2014-06-30,2014-06-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,European Organisation for Research and Treatment of Cancer (EORTC),Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH agonists or surgical castration. Ensayo ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002122-67,0,0,0 2012-002122-67,3,2014-06-30,2014-06-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,EORTC,Phase II randomized comparative trial of TAK-700 (Orteronel) versus bicalutamide in metastatic prostate cancer patients failing 1st line treatment with LHRH agonists or surgical castration. Ensayo ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002122-67,0,0,0 2012-002123-15,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,CHU de clermont-Ferrand,Intérêt d’un bloc nerveux bi-tronculaire (fémoral + sciatique) prolongé associé systématiquement à l’anesthésie générale au cours du pontage fémoro-poplité : étude de l'analgésie post-opératoire et de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002123-15,0,0,0 2012-002125-30,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZLeuven,Vitamin D supplementation in cutaneous malignant melanoma outcome D vitamin kiegészítő szedése a rosszindulatú bőrmelanóma klinikai kimenetelére,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002125-30,0,0,0 2012-002128-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO,"Open-Label, Phase II Study of Trastuzumab in Combination with Lapatinib or Pertuzumab in Combination with Trastuzumab in Patients with HER2-positive Metastatic Colorectal Cancer: the HERACLES Trial (H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002128-33,0,0,0 2012-002136-90,1,2014-12-19,2014-12-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,Treatment of hypertension at nigth in type 1 diabetes patients with no 24 hour variation of thier bloodpressure. Natlig hypertenson behandling hos type 1 diabetespatienter med nedsat døgnvariation ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002136-90,0,0,0 2012-002138-35,6,2019-02-12,2019-02-12,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Array BioPharma Inc.,"A phase Ib/II multi-center, open-label, dose escalation study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in patients with BRAF mutant metastatic colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002138-35,0,0,0 2012-002138-35,6,2019-02-12,2019-02-12,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A phase Ib/II multi-center, open-label, dose escalation study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in patients with BRAF mutant metastatic colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002138-35,0,0,0 2012-002138-35,6,2019-02-12,2019-02-12,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,ARRAY BIOPHARMA INC.,"A phase Ib/II multi-center, open-label, dose escalation study of LGX818 and cetuximab or LGX818, BYL719, and cetuximab in patients with BRAF mutant metastatic colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002138-35,0,0,0 2012-002154-23,1,2017-07-29,2017-07-29,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Martin-Luther-University Halle-Wittenberg,Phase I/II pilot trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in patients with relapsed or refractory acute myeloid leukemia (AML) when no intensive treatment is possible,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002154-23,0,0,0 2012-002156-16,1,2014-01-09,2014-01-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A randomized, multi-center, double-blind, doubledummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002156-16,0,0,0 2012-002175-34,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Med. Univ. Wien, Universitätsklinik f. Innere Medizin III, Abt. f. Nephrologie und Dialyse",Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients with Hypertension (EPOCH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002175-34,0,0,0 2012-002177-62,1,2013-09-04,2013-09-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALK-Abelló A/S,A Dose Response Evaluation of SLIToneULTRA HDM Mix Immunotherapy Estudio dosis-respuesta de la inmunoterapia con SLIToneULTRA Dermatophagoides mezcla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002177-62,0,0,0 2012-002179-32,1,2015-12-03,2015-12-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Hellenic Oncology Research Group (H.O.R.G.),"A Multicenter, Phase II, Single-Arm Clinical Trial of nab-Paclitaxel as salvage treatment for patients with Locally Advanced or Metastatic Adenocarcinomas of the Stomach and Gastro-esophageal junction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002179-32,0,0,0 2012-002181-12,8,2013-09-12,2013-10-08,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the SPONSOR or Merck)","A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Multicenter, Worldwide, Proof-of-Concept Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002181-12,0,0,0 2012-002181-12,8,2013-09-12,2013-10-08,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Multicenter, Worldwide, Proof-of-Concept Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002181-12,0,0,0 2012-002181-12,8,2013-09-12,2013-10-08,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as","A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Multicenter, Worldwide, Proof-of-Concept Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002181-12,0,0,0 2012-002182-35,3,2013-12-03,2013-12-03,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Cerexa, Inc. (subsidiary of Forest Laboratories)","A Multicenter, Multinational, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ceftaroline fosamil Versus Ceftriaxone Plus Vancomycin in Adult Subjects with Community-acquired Bac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002182-35,0,0,0 2012-002183-27,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,Hammersmith Medicines Research,Can netazepide eradicate the inflammatory response of the gastric mucosa to H. pylori infection?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002183-27,0,0,0 2012-002188-84,1,2012-10-30,2012-10-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare (UK) LTD,"A multi-centred, randomised, double-blind, two arm, parallel group, placebo-controlled, pilot study to assess the effect of Gaviscon Double Action Tablets in patients with reflux disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002188-84,0,0,0 2012-002193-31,1,2014-08-27,2014-08-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,"A Randomised, Double-blind, Single-centre, Controlled Trial of Low Dose Intradermal Allergen Immunotherapy in Adults with Seasonal Allergic Rhinitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002193-31,0,0,0 2012-002193-31,1,2014-08-27,2014-08-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's and St Thomas' NHS Foundation Trust,"A Randomised, Double-blind, Single-centre, Controlled Trial of Low Dose Intradermal Allergen Immunotherapy in Adults with Seasonal Allergic Rhinitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002193-31,0,0,0 2012-002198-72,1,2018-02-22,2018-02-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Imperial College London,"Targeted retreatment of incompletely recovered COPD exacerbations with ciprofloxacin: a double-blind, randomised, placebo-controlled, multicentre Phase III trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002198-72,0,0,0 2012-002199-15,1,2017-07-20,2017-07-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Imperial College London,"A Phase III double-blind, randomised, placebo controlled trial of long term therapy on Exacerbation Rate in patients with stable COPD using Doxycycline",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002199-15,0,0,0 2012-002203-18,6,2014-04-10,2014-04-14,5,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"Cerexa, Inc. (subsidary of Forest Laboratories)","A Multicenter, Randomized, Observer-Blinded, Active Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002203-18,1,1,0 2012-002203-18,6,2014-04-10,2014-04-14,5,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"Cerexa, Inc.","A Multicenter, Randomized, Observer-Blinded, Active Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002203-18,1,1,0 2012-002205-22,1,2013-11-11,2013-11-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,St Stephen's AIDS Trust,"A phase III, open-label, multi centre pilot study to assess the feasibility of switching, individuals receiving Atripla or Kivexa plus Efavarinz with continuing Central Nervous System (CNS) toxicity, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002205-22,0,0,0 2012-002206-52,3,2020-02-28,2020-02-28,2,1,0,1,0,0,1,0,0,1,1,0,0,0,1,MedImmune,"A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002206-52,0,0,0 2012-002208-41,4,2017-07-20,2017-07-20,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002208-41,0,0,0 2012-002208-41,4,2017-07-20,2017-07-20,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"An open-label phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002208-41,0,0,0 2012-002208-41,4,2017-07-20,2017-07-20,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"An open-label phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002208-41,0,0,0 2012-002211-25,1,2019-03-12,2019-03-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Oslo University Hospital, Dept of Urology","Prevention of bladder dysfunction in acute spinal cord injury A double-blind, randomized, placebo-controlled study to explore the effect of early treatment with Onabotulinumtoxin A in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002211-25,0,0,0 2012-002213-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Malmö Högskola, Odontologiska fakulteten",No Effekten av antibiotikaprofylax i samband med tandimplantatkirurgi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002213-19,0,0,0 2012-002214-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Oscar Lambret,"A PHASE II RANDOMIZED STUDY OF DOCETAXEL WITH OR WITHOUT NINTEDANIB (BIBF-1120) IN PATIENT RECEIVING A SECOND-LINE OF CHEMOTHERAPY FOR HER NEGATIVE, METASTATIC OR LOCALLY RECURRENT BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002214-38,0,0,0 2012-002215-26,4,2016-09-06,2016-09-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott Laboratories GmbH,"A Double-Blind, Double-Dummy, Randomized, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg daily versus Intravaginal Micronized Progesterone Caps...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002215-26,0,0,0 2012-002216-10,5,2016-10-03,2016-10-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Radius Health, Inc.",An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 or Placebo Treatment in Protocol BA058-05-003,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002216-10,0,0,0 2012-002217-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dept of Surgery,Postoperative treatment with Vitamin D for patients with a history of Bariatric Surgery in C and U County. Postoperativ Substitutionsbehandling med D-vitamin efter Obesitaskirurgi i CoU-län,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002217-19,0,0,0 2012-002217-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Landstinget i Uppsala,Postoperative treatment with Vitamin D for patients with a history of Bariatric Surgery in C and U County. Postoperativ Substitutionsbehandling med D-vitamin efter Obesitaskirurgi i CoU-län,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002217-19,0,0,0 2012-002219-25,11,2016-03-11,2016-03-11,8,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Intarcia Therapeutics, Inc.","A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002219-25,1,0,0 2012-002220-32,1,2019-12-31,2019-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,OYS,"The effects of contraceptive pill and hormonal vaginal ring on hormonal, inflammatory and metabolic parameters in women of reproductive age with polycystic ovary syndrome (PCOS). Ehkäisytabletin ja...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002220-32,0,0,0 2012-002222-70,1,2016-11-08,2016-11-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Medical Centre St Radboud,Pilot study: Targeting the inflammatory response after breast cancer surgery with lidocaïne and dexamethasone Pilot onderzoek: Perioperatieve infusie van lidocaïne en dexamethasone voor het vermind...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002222-70,0,0,0 2012-002224-32,1,2016-11-18,2016-11-18,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Fédération Francophone de Cancérologie Digestive,Evérolimus comme traitement après embolisation ou chimioembolisation de métastases hépatiques de tumeur endocrine digestive,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002224-32,0,0,0 2012-002226-76,1,2021-07-29,2021-07-29,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"Medical University of Vienna, Department of Clinical Pharmacology",High “on treatment” platelet reactivity in the Intensive Care Unit,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002226-76,0,0,0 2012-002228-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Diego Caicedo Valdés,Growth hormone (GH) angiogenic effect clinical trial on patients with lower limb critical ischemia. GHAS Study Ensayo clínico sobre el efecto angiogénico de la Hormona de Crecimiento (GH) en pacien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002228-34,0,0,0 2012-002230-37,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Erasmus Medical Center,“Novel Approach to Detect the Detailed Effects of Vildagliptin on Beta-cell Dynamics in Patients with Early-onset Type 2 Diabetes”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002230-37,0,0,0 2012-002232-85,17,2021-03-21,2021-03-31,15,1,0,0,0,0,0,0,0,2,1,0,0,0,1,Merck Sharp & Dohme Corp.,A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002232-85,1,0,0 2012-002232-85,17,2021-03-21,2021-03-31,15,1,0,0,0,0,0,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002232-85,1,0,0 2012-002232-85,17,2021-03-21,2021-03-31,15,1,0,0,0,0,0,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc",A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002232-85,1,0,0 2012-002233-11,1,2013-02-01,2013-02-01,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Bispebjerg Hospital,Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis in organ transplant recipients: Methods to improve treatment Fotodynamisk terapi med topikal methyl-aminolevulinat ti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002233-11,0,0,0 2012-002235-29,1,2014-04-08,2014-04-08,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Medizinische Universität Wien - Universitätsklinik für klinische Pharmakologie,Does acetylsalicylic acid reduce the mortality of patients admitted to an Intensive Care Unit,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002235-29,0,0,0 2012-002236-87,1,2013-03-01,2013-03-01,1,1,0,0,1,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare,Clinical Study to Evaluate the Efficacy of Chlorhexidine Mouthwashes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002236-87,0,0,0 2012-002237-11,1,2013-04-02,2013-04-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,Effectiveness of Adaptive Opioid Agonist Maintenance Pharmacotherapy and Behavioural Therapy for Opioid Use Disorder.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002237-11,0,0,0 2012-002237-11,1,2013-04-02,2013-04-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,South London and Maudsley NHS Foundation Trust,Effectiveness of Adaptive Opioid Agonist Maintenance Pharmacotherapy and Behavioural Therapy for Opioid Use Disorder.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002237-11,0,0,0 2012-002238-35,5,2014-05-23,2014-05-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd.,"A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of an Investigational Eye Drop Formulation with OPTIVE™ Unit-Dose for 3 Months in Subjects with Dry Eye Disease St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002238-35,0,0,0 2012-002238-35,5,2014-05-23,2014-05-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALLERGAN LIMITED,"A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of an Investigational Eye Drop Formulation with OPTIVE™ Unit-Dose for 3 Months in Subjects with Dry Eye Disease St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002238-35,0,0,0 2012-002240-24,3,2015-09-30,2015-09-30,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Allergan Ltd.,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of a Single Treatment of AGN-214868 in Patients With Postherpetic Neuralgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002240-24,0,0,0 2012-002242-20,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Royal Bournemouth & Christchurch Hospitals NHS Foundation Trust,"A single-centre, randomised controlled study of Entonox versus midazolam in upper GI endoscopy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002242-20,0,0,0 2012-002244-25,1,2013-02-11,2013-02-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Norfolk & Norwich University Hospital,"Prospective feasibility study for the evaluation of indocyanine green and near-infrared imaging in sentinel lymph node biopsy for cutaneous melanoma patients: The ""RED-GREEN-BLUE"" melanoma study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002244-25,0,0,0 2012-002245-37,6,2014-09-15,2014-11-22,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MCMV5322A/MCMV3068A FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN HIGH-RISK KIDNEY ALLOGRAFT RECIPIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002245-37,0,0,0 2012-002247-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Comarca Ezkerraldea-Enkarterri (OSAKIDETZA),"Feasibility, potential efficacy and safety of autologous platelet-rich plasma in the treatment of vascular venous ulcers in Primary Care (phase I and II pilot study) Factibilidad, eficacia potencia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002247-20,0,0,0 2012-002248-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Prevention of anthracycline-induced cardiotoxicity: a multicentre randomizedtrial comparing two therapeutic strategies. Prevenzione della cardiotossicita' da antracicline: uno studio multicentrico ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002248-26,0,0,0 2012-002249-39,8,2016-06-22,2016-07-07,7,1,1,0,0,0,2,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma Revised Protocol 00b - UK only - ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002249-39,1,1,0 2012-002250-23,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,Novartis Farmaceutica S.A.,Phase Ib dose finding study of abiraterone acetate plus BEZ235 or BKM120 in patients with castration-resistant prostate cancer Estudio de fase Ib de búsqueda de dosis de acetato de abiraterona más ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002250-23,0,0,0 2012-002251-42,10,2019-02-28,2019-03-03,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Asahi Kasei Pharma America Corporation,"A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE SAFETY AND EFFICACY OF ART-123 IN SUBJECTS WITH SEVERE SEPSIS AND COAGULOPATHY ESTUDIO FASE III, ALEATORIZADO, DOBLE CIEG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002251-42,0,0,0 2012-002252-17,6,2014-12-17,2015-12-17,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Interventional, randomised, double-blind, parallel-group, placebo-controlled, active-reference, flexible-dose study of brexpiprazole in patients with acute schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002252-17,0,0,0 2012-002253-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITA' DEGLI STUDI DI FIRENZE,A phase 2 study of Ruxolitinib in patients with splanchnic vein thrombosis associated with myeloproliferative neoplasm Studio di fase II del Ruxolitinib in pazienti con Trombosi delle Vene Splancni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002253-30,0,0,0 2012-002255-42,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Sun Pharma Global FZE,"A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002255-42,0,0,0 2012-002261-36,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,FluoroPharma Medical,A Phase II Open-Labeled Study to Evaluate CardioPET™ as a PET Imaging Agent for Evaluation of Myocardial Perfusion and Fatty Acid Uptake in Subjects with Coronary Artery Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002261-36,0,0,0 2012-002263-96,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,MUMC,dabigatran and rivaroxaban: prediction of anticoagulant effect Thrombin predict: Voorspellen van de mate van anticoagulante werking van twee orale anticoagulantia (dabigatran en rivaroxaban),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002263-96,0,0,0 2012-002270-31,4,2015-03-23,2015-03-23,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim,"A phase III, randomised, double-blind, parallel group, 24 week study to evaluate efficacy and safety of once daily empagliflozin 10 mg and 25 mg compared to placebo, all administered as oral fixed dos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002270-31,0,0,0 2012-002270-31,4,2015-03-23,2015-03-23,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Boehringer Ingelheim España, S.A","A phase III, randomised, double-blind, parallel group, 24 week study to evaluate efficacy and safety of once daily empagliflozin 10 mg and 25 mg compared to placebo, all administered as oral fixed dos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002270-31,0,0,0 2012-002271-34,4,2015-03-13,2015-03-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A","A phase III, randomized, double-blind, parallel group study to evaluate the efficacy and safety of linagliptin 5 mg compared to placebo, administered as oral fixed dose combination with empagliflozin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002271-34,0,0,0 2012-002271-34,4,2015-03-13,2015-03-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A phase III, randomized, double-blind, parallel group study to evaluate the efficacy and safety of linagliptin 5 mg compared to placebo, administered as oral fixed dose combination with empagliflozin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002271-34,0,0,0 2012-002271-34,4,2015-03-13,2015-03-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase III, randomized, double-blind, parallel group study to evaluate the efficacy and safety of linagliptin 5 mg compared to placebo, administered as oral fixed dose combination with empagliflozin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002271-34,0,0,0 2012-002271-34,4,2015-03-13,2015-03-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Unilfarma, Lda.","A phase III, randomized, double-blind, parallel group study to evaluate the efficacy and safety of linagliptin 5 mg compared to placebo, administered as oral fixed dose combination with empagliflozin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002271-34,0,0,0 2012-002272-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,CELLDEX THERAPEUTICS,"An International, Randomized, Double-Blind, Controlled Phase II Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Gliobla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002272-14,0,0,0 2012-002273-54,1,2013-03-12,2013-03-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ono Pharmaceutical Co. Ltd.,"A randomised, double-blind, placebo controlled, double dummy, four period crossover study to evaluate the efficacy, safety and tolerability of oral repeat doses of ONO-4053 and Cetirizine in subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002273-54,0,0,0 2012-002275-33,1,2018-05-24,2018-05-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Dept. of Gastroenterology, Universityhospital Odense",Renal and cardiac effects of terlipressin and dobutamin in cirrhosis and ascites. A randomised study. Renale og kardielle effekter af terlipressin og dobutamin ved cirrose og ascites. Et randomiser...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002275-33,0,0,0 2012-002278-30,1,2014-02-06,2014-02-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Erlangen,Effects of Linagliptin on Renal Endothelium Function in Patients with Type 2 Diabetes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002278-30,0,0,0 2012-002281-12,4,2014-01-08,2014-01-08,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BIONOR IMMUNO AS,"Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Reboosting Study with Vacc-4x in Subjects Infected with HIV-1 Who Have M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002281-12,1,0,0 2012-002281-12,4,2014-01-08,2014-01-08,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bionor Immuno AS,"Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Reboosting Study with Vacc-4x in Subjects Infected with HIV-1 Who Have M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002281-12,1,0,0 2012-002286-36,2,2013-03-01,2013-03-01,2,1,1,0,0,1,1,0,0,1,0,0,1,0,1,Swedish Orphan Biovitrum AB,"Taste and palatability of Orfadin suspension. An open, non-controlled 3-day study in pediatric patients with hereditary tyrosinemia type 1 treated with Orfadin.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002286-36,0,0,0 2012-002287-26,1,2017-08-31,2017-08-31,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,Greater Glasgow and Clyde NHS Board,Comparison of the caries-protective effect of fluoride varnish (Duraphat®) with treatment as usual in nursery school attenders receiving preventive oral health support through the Childsmile Programme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002287-26,0,0,0 2012-002287-26,1,2017-08-31,2017-08-31,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,University of Glasgow,Comparison of the caries-protective effect of fluoride varnish (Duraphat®) with treatment as usual in nursery school attenders receiving preventive oral health support through the Childsmile Programme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002287-26,0,0,0 2012-002291-13,2,2013-11-25,2013-11-25,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,InfectoPharm - Arzneimittel und Consilium GmbH,"Multicentre, prospective, double-blind, two-armed, placebo-controlled phase III study to evaluate the efficacy and safety of the treatment of diarrhoea with Lactobacillus rhamnosus GG (InfectoDiarrsto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002291-13,0,0,0 2012-002298-69,10,2016-01-06,2016-01-21,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Multi-Center, Randomized, Double Blind, Placebo and Active-Controlled study with exploratory dose-ranging, to investigate the efficacy and safety of 16 weeks treatment with subcutaneous QGE031 in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002298-69,0,0,0 2012-002298-69,10,2016-01-06,2016-01-21,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A Multi-Center, Randomized, Double Blind, Placebo and Active-Controlled study with exploratory dose-ranging, to investigate the efficacy and safety of 16 weeks treatment with subcutaneous QGE031 in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002298-69,0,0,0 2012-002299-15,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Universitair Medisch Centrum Utrecht,"The effect of glycopyrroniumbromide on nocturnal clozapine induced sialorrhea in psychiatric patients: a randomized, cross-over, double blind, placebo controlled trial with an extended open label phas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002299-15,0,0,0 2012-002302-43,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Dr. Reddy's Laboratories Ltd.,A study to investigate the analgesic effects of buprenorphine and milnacipram in healthy volunteers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002302-43,0,0,0 2012-002303-18,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,VU University Medical Center (VUmc),The Dutch Flutemetamol in Young Dementia Study De Nederlandse Flutemetamol in Vroege Dementie Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002303-18,0,0,0 2012-002308-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHRU de Brest,Etude de phase II évaluant l'association doxorubicine liposomale non-pégylée-dexaméthasone chez des patients immunocompétents présentant un lymphome cérébral réfractaire ou en rechute à une première l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002308-41,0,0,0 2012-002309-23,4,2015-01-26,2015-01-26,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes Melli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002309-23,0,0,0 2012-002314-39,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,The Medicines Company,Bivalirudin Infusion for Ventricular Infarction Limitation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002314-39,0,0,0 2012-002314-39,2,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,The Medicines Company Switzerland,Bivalirudin Infusion for Ventricular Infarction Limitation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002314-39,0,0,0 2012-002316-12,1,2014-01-14,2014-01-14,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,University Hospitals of the KU Leuven,The safety and feasibility of administering xenon to patients undergoing off-pump coronary artery bypass graft surgery: a pilot study XOPCAB – Xenon in Off-Pump Coronary Artery Bypass Grafting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002316-12,0,0,0 2012-002318-37,5,2016-06-24,2016-06-24,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Incyte Corporation,"Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002318-37,0,0,0 2012-002318-37,5,2016-06-24,2016-06-24,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,INCYTE,"Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002318-37,0,0,0 2012-002319-25,1,2015-07-01,2015-07-01,1,1,0,0,1,0,2,0,0,1,1,1,1,0,0,University of Texas Health Science Center,"A pilot, phase IIb, randomised, multicentre trial of Argatroban in combination with recombinant tissue plasminogen activator for acute stroke",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002319-25,0,0,0 2012-002320-33,3,2014-07-23,2014-07-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Glenmark Pharmaceuticals SA,"A Phase 2, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients with Painful Diabetic Perip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002320-33,0,0,0 2012-002321-30,1,2016-05-02,2016-05-02,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Odense University Hospital,"Randomized phase II trial with irinotecan as monotherapy compared to irinotecan and bevacizumab (BevIri) for patietns with platinum resistant non-resectable esophagus-, cardia or gastric cancer Ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002321-30,0,0,0 2012-002322-73,13,2015-09-29,2017-01-10,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo- and Active Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002322-73,0,0,0 2012-002322-73,13,2015-09-29,2017-01-10,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Lilly S.A.,"A Randomized, Double-Blind, Placebo- and Active Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002322-73,0,0,0 2012-002323-15,10,2014-09-02,2014-11-04,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002323-15,0,0,0 2012-002323-15,10,2014-09-02,2014-11-04,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY AND COMPANY,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002323-15,0,0,0 2012-002323-15,10,2014-09-02,2014-11-04,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002323-15,0,0,0 2012-002324-32,8,2015-08-26,2015-10-22,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY AND COMPANY,"A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002324-32,0,0,0 2012-002324-32,8,2015-08-26,2015-10-22,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002324-32,0,0,0 2012-002326-75,3,2016-04-18,2016-04-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ipsen Pharma,"A multicentre, open label, early stopping design, proof of concept study with tasquinimod in treating patients with advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002326-75,0,0,0 2012-002327-15,1,2016-09-21,2016-09-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Odense University Hospital,Phase II study with temozolomide and capecitabine for patients with refractory colorectal cancer Fase II forsøg med temozolomid og capecitabin til patienter med behandlingsresistent kolorektalcance...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002327-15,0,0,0 2012-002328-34,1,,,0,0,1,0,0,0,0,0,0,1,1,1,0,1,3,KEDRION S.P.A,"Efficacy and safety evaluation of Kedrion Fibrin Sealant as an adjuvant for the control of hemostasis in pediatric patients undergoing abdominal or orthopedic surgery. Multicenter, randomized, control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002328-34,0,0,0 2012-002332-85,5,2016-01-19,2016-01-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-3102 Versus Placebo in Subjects with Type 2 Diabetes Mellitus with Moderate or Severe Chronic Kidney ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002332-85,0,0,0 2012-002333-11,4,2014-05-06,2014-06-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Rosuvastatin versus Ezetimibe Added-on to Rosuvastatin versus Rosuvastatin Dose Increase in Patients Who are Not Cont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002333-11,0,0,0 2012-002333-11,4,2014-05-06,2014-06-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"REGENERON PHARMACEUTICALS, INC.","A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Rosuvastatin versus Ezetimibe Added-on to Rosuvastatin versus Rosuvastatin Dose Increase in Patients Who are Not Cont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002333-11,0,0,0 2012-002335-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University medical centre groningen,Evaluation of VEGF expression with 89Zr-bevacizumab PET scan in patients with relapsing multiple myeloma; a feasibility study Evaluatie van VEGF expressie met 89Zr-bevacizumab PET scan in patienten...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002335-28,0,0,0 2012-002337-11,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,0,Västra Götalandsregionen (VGR),A multicenter and randomised clinical study on pubertal replacement therapy in boys - Treatment of boys with absent or delayed puberty with rhFSH and two different formulations of testosterone in low ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002337-11,0,0,0 2012-002337-11,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,0,Sahlgrenska Academy-Gothenburg University Institute,A multicenter and randomised clinical study on pubertal replacement therapy in boys - Treatment of boys with absent or delayed puberty with rhFSH and two different formulations of testosterone in low ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002337-11,0,0,0 2012-002338-35,7,2018-02-28,2018-05-29,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Biosense Webster, Inc.",ATrial FibrillaTion ProgrESsion Trial (ATTEST Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002338-35,0,0,0 2012-002339-27,9,2014-12-19,2015-01-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying Anti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002339-27,0,0,0 2012-002339-27,9,2014-12-19,2015-01-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying Anti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002339-27,0,0,0 2012-002339-27,9,2014-12-19,2015-01-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY AND COMPANY,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying Anti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002339-27,0,0,0 2012-002340-24,12,2016-11-21,2016-11-21,10,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase IIb, Partially-Blinded Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002340-24,1,1,0 2012-002342-21,1,,,0,0,1,0,0,0,3,0,0,1,1,1,0,1,1,Kedrion S.P.A,Valutazione dell’Efficacia e della Sicurezza della Colla di Fibrina Kedrion come coadiuvante per il controllo dell’emostasi in pazienti pediatrici sottoposti ad interventi di cardiochirurgia a cuore a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002342-21,0,0,0 2012-002344-24,4,2014-04-29,2014-05-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Atorvastatin versus Ezetimibe Added-on to Atorvastatin versus Atorvastatin Dose Increase versus Switch to Rosuvastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002344-24,0,0,0 2012-002344-24,4,2014-04-29,2014-05-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"REGENERON PHARMACEUTICALS, INC.","A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Atorvastatin versus Ezetimibe Added-on to Atorvastatin versus Atorvastatin Dose Increase versus Switch to Rosuvastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002344-24,0,0,0 2012-002345-38,1,2015-06-08,2015-06-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,"A prospective randomised controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002345-38,0,0,0 2012-002346-20,2,2014-01-09,2014-01-09,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,A 26-week trial comparing efficacy and safety of insulin degludec/insulin aspart BID and insulin degludec OD plus insulin aspart in subjects with type 2 Diabetes Mellitus treated with basal insulin in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002346-20,0,0,0 2012-002347-23,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Danish Breast Cancer Group (DBCG),Phase II study of irinotecan weekly in combination with trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer and increased cancer cell copy number of TOP1”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002347-23,0,0,0 2012-002348-26,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Danish Breast Cancer Group (BDCG),Phase II study of irinotecan weekly in patients with locally advanced or metastatic HER2-negative breast cancer and increased cancer cell copy number of the topoisomerase 1 gene (TOP1)”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002348-26,0,0,0 2012-002354-23,10,2013-02-11,2021-03-10,7,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Eli Lilly and Company,A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002354-23,1,0,0 2012-002354-23,10,2013-02-11,2021-03-10,7,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Lilly S.A.,A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002354-23,1,0,0 2012-002356-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Stavanger University Hospital,Pre-emptive local anaesthesia in gynecological laparoscopy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002356-16,0,0,0 2012-002357-35,1,2016-05-23,2016-05-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London,Stem cells in Rapidly Evolving Active Multiple Sclerosis (STREAMS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002357-35,0,0,0 2012-002358-22,1,2013-04-02,2013-04-02,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Biologische Heilmittel Heel GmbH,"NEUPRO DB, efficacy profile of Neurexan in an experimental acute stress setting – an explorative double blind study in healthy probands",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002358-22,0,0,0 2012-002359-40,1,2013-04-04,2013-04-04,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Biologische Heilmittel Heel GmbH,"NEUPRO OL, Efficacy profile of Neurexan® in an experimental acute stress setting – an explorative open-label study in healthy probands",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002359-40,0,0,0 2012-002361-36,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,ONCOSUR,Neurotoxicity characterization phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer. Ensayo fase II randomizado...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002361-36,0,0,0 2012-002365-35,3,2014-11-11,2015-01-27,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Genzyme Corporation,"A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002365-35,0,0,0 2012-002370-30,1,2013-01-21,2013-01-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A PHASE II, MONOCENTRE, OPEN, RANDOMIZED, 6-WAY CROSS-OVER CLINICAL PHARMACOLOGY STUDY TO EVALUATE THE LUNG BIOAVAILABILITY OF BDP/B17MP AND FORMOTEROL AND THE TOTAL SYSTEMIC EXPOSURE ACROSS TWO DIFFE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002370-30,0,0,0 2012-002373-56,1,2016-10-28,2016-10-28,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Medical Research Council,PRe-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay men,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002373-56,0,0,0 2012-002378-30,1,2017-04-10,2017-04-10,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,CellAct Pharma GmbH,"Phase II Trial of CAP7.1 in adult patients with refractory malignancies Small cell lung carcinoma, Non-small cell lung carcinoma Biliary carcinoma CAP7.1 in einer Phase II Studie zur Behandlung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002378-30,0,0,0 2012-002379-32,1,2012-09-19,2012-09-19,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Omninvest Ltd.,"Tolerability and Immunogenicity Study of FLUVAL AB Influenza Vaccine (trivalent, seasonal, active ingredient content: 15 μgHA/strain/0.5 mL) in Adults and Elderly Persons",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002379-32,0,0,0 2012-002392-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,Phase I Hybrid study: combined stereotactic radiotherapy and conventional fractionation in stage II and III non small cell lung cancer with peripheral tumors smaller than 5 cm,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002392-33,0,0,0 2012-002393-32,1,2012-11-07,2012-11-07,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,L’OREAL RECHERCHE,"A monocenter, double-blind, randomized study to assess the antiperspirant efficacy of glycopyrrolate 2% versus placebo after topical applications on axilla of healthy volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002393-32,0,0,0 2012-002400-40,3,2019-05-10,2019-05-10,2,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Targovax ASA,A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002400-40,0,0,0 2012-002400-40,3,2019-05-10,2019-05-10,2,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Targovax AS,A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients with Resected Adenocarcinoma of the Pancreas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002400-40,0,0,0 2012-002401-22,1,,,0,1,0,0,1,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase III, open, randomized, controlled, multicenter study to assess the safety and immunogenicity of GlaxoSmithKline’s Biologicals’ (GSK Biologicals) Neisseria meningitidis serogroups A, C, W-135, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002401-22,0,1,1 2012-002403-18,1,2019-01-31,2019-01-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre Léon Berard,"PIK-ORL: A Phase II, multicenter trial aiming to evaluate BKM120 in monotherapy in patients with metastatic head and neck cancer recurrent or progressive under platin and cetuximab-based chemotherapy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002403-18,0,0,0 2012-002404-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,PRAsugrel versus TICagrelor for platelet inhibition in patients with non-ST segment elevation acute coronary syndrome (PRATIC) PRAsugrel contro TICagrelor per inibizione piastrinica in pazienti con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002404-41,0,0,0 2012-002406-46,1,2020-04-03,2020-04-03,1,1,0,1,1,0,1,1,1,1,0,0,0,0,0,"Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie",Epidermal Nerve Fibre Density Reduction as a Function of Application Time of topical high-dose and low-dose Capsaicin Dichte der epidermalen Nervenfasern (ENF) nach unterschiedlicher Expositionsdau...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002406-46,0,0,0 2012-002407-18,1,2014-04-23,2014-04-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee and NHS Tayside,DPP4 inhibitors in Type 1 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002407-18,0,0,0 2012-002407-18,1,2014-04-23,2014-04-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Tayside,DPP4 inhibitors in Type 1 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002407-18,0,0,0 2012-002408-42,1,2013-12-23,2013-12-23,1,1,0,1,0,0,1,1,1,1,0,0,0,0,1,Reckitt Benckiser Pharmaceuticals Inc.,"An Open-label, Randomised, Three -Way, Cross-Over Study to Assess the Pharmacokinetics, Safety and Tolerability of Two Formulations of RBP-6300 10mg in Healthy Volunteers under a Naltrexone Block in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002408-42,0,0,0 2012-002409-23,1,2015-04-16,2015-04-16,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Aarhus University Hospital,"Coagulation Profile in Patients Undergoing Video Assisted Thoracoscopic Surgery (VATS) for lung cancer - a randomized, controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002409-23,0,0,0 2012-002411-26,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Oslo University Hospital,A PHASE I/IIA STUDY OF UV1 VACCINATION IN PATIENTS WITH HORMONE-SENSITIVE METASTATIC PROSTATE CANCER.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002411-26,0,0,0 2012-002412-95,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Iho-ja allergiasairaala, HYKS",Voidaanko laspsuuden atooppisen ihottuman tehokkaalla hoidolla vaikuttaa estävästi muiden atooppisten oireiden puhkeamiseen?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002412-95,0,0,0 2012-002413-19,1,2013-06-27,2013-06-27,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-5806 in Healthy Volunteers Infected with Respiratory Syncytial Virus (RSV-A Memph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002413-19,0,0,0 2012-002414-39,17,2016-04-08,2017-03-22,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus Studio multicentrico...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002414-39,0,0,0 2012-002415-26,1,2013-05-31,2013-05-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Medizinische Universität Innsbruck,"Use of CM in contrast enhanced spectral digital mammography (spectral CEDM, CESM) in the diagnosis of breast pathologies. Evaluation of the technique in patients with histologically proven breast canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002415-26,0,0,0 2012-002417-19,2,2014-08-20,2014-08-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gilead Sciences Inc,"A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin for 24 weeks in Subjects with Recurrent Chronic HCV Post Liver Transplant",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002417-19,0,0,0 2012-002418-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,Prophylactic infusion of CD4 positive donor lymphocytes early after T-cell depleted allogeneic stem cell transplantation in patients with an unrelated donor Profylactische infusie van CD4 positieve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002418-38,0,0,0 2012-002422-78,1,2017-09-29,2017-09-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leicester,"Impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes: an open lable, randomised active-comparator trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002422-78,0,0,0 2012-002426-70,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"Phase III b, open, randomised, multicenter study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002426-70,0,1,1 2012-002427-15,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, partially double-blind clinical trial to evaluate the immu-nogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (new formulation) as compa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002427-15,0,1,1 2012-002428-34,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,GlaxoSmithKline Biolgicals,"A phase IV, partially double-blind, multicentre study to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (new formulation) as compa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002428-34,0,1,1 2012-002430-36,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,"Multicentre, randomised, double-blinded, placebo-controlled trial of efficacy of amoxicilline/clavulanic acid in patients affected by tic disorder colonized by GAS. No-proft stidy. Estudio multicen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002430-36,0,0,0 2012-002431-29,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,University Hospital of Ulm,A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002431-29,0,0,0 2012-002432-93,6,2014-09-02,2014-12-19,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novo Nordisk A/S,"A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy and safety of NNC0114-0006 in subjects with active Crohn?s disease Estudio aleatorizado, doble ciego...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002432-93,0,0,0 2012-002434-37,4,2014-02-04,2014-02-04,1,1,0,0,0,1,3,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002434-37,0,0,0 2012-002435-28,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University Medical Center Utrecht,A phase I/II “minor histocompatibility antigen” (mHag)-based Dendritic cell vaccination trial after allogeneic Stem Cell Transplantation to improve the safety and efficacy of donor Lymphocyte infusion...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002435-28,0,0,0 2012-002436-82,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Isabel Pinilla Lozano,Melatonin effects on visual and sleep patterns anomalies in subjects diagnosed with Retinitis Pigmentosa Efecto de la melatonina sobre las alteraciones visuales y del sueño en enfermos afectos de R...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002436-82,0,0,0 2012-002439-26,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"An open, multicentre, post-marketing surveillance (PMS) study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-IPV/Hib vaccine administered at 3 and 4 months of age and DTP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002439-26,0,1,1 2012-002443-26,1,2014-10-13,2014-10-13,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Oxford,"A phase II, multi-centre, open labelled randomised control trial to describe immune & transcriptomic responses to trivalent inactivated vaccine (TIV) & MF59 adjuvanted influenza vaccine (ATIV) in 14 -...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002443-26,0,0,0 2012-002447-14,5,2016-10-13,2016-11-17,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,OncoGenex Technologies Inc,"A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV- 1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002447-14,0,0,0 2012-002447-14,5,2016-10-13,2016-11-17,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,TEVA PHARMACEUTICALS INDUSTRIES LTD,"A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV- 1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002447-14,0,0,0 2012-002447-14,5,2016-10-13,2016-11-17,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,OncoGenex Technologies Inc.,"A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV- 1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002447-14,0,0,0 2012-002447-14,5,2016-10-13,2016-11-17,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Teva Pharmaceutical Industries, Ltd","A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV- 1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002447-14,0,0,0 2012-002448-25,1,,,0,1,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Edinburgh,Magnetic Resonance Imaging Using Ultrasmall Superparamagnetic Particles of Iron Oxide in Patients Under Surveillance for Abdominal Aortic Aneurysms to Predict Rupture or Surgical Repair: the MA3RS Tri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002448-25,0,0,0 2012-002448-25,1,,,0,1,0,0,0,0,4,0,0,3,0,0,0,0,0,NHS Lothian Health Board,Magnetic Resonance Imaging Using Ultrasmall Superparamagnetic Particles of Iron Oxide in Patients Under Surveillance for Abdominal Aortic Aneurysms to Predict Rupture or Surgical Repair: the MA3RS Tri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002448-25,0,0,0 2012-002449-40,8,2013-09-23,2013-09-23,8,1,0,0,0,0,2,0,2,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A multicenter, randomized, partially blinded, placebo-controlled clinical trial to evaluate the effect on primary dysmenorrheal of vaginal rings with an average daily release of 700 µg nomegestrol ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002449-40,0,0,0 2012-002450-24,1,2017-05-24,2017-05-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Inmunotek S.L.,"Randomized double-blind placebo-controlled prospective, parallel, single centre clinical trial of bacterial vaccine (BACTEK ®) sublingual (oral mucosa) in patients with repeat bronchospasm for the i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002450-24,0,0,0 2012-002451-41,7,2014-11-26,2015-01-29,5,1,0,0,1,0,3,0,0,1,1,0,1,0,1,Recordati S.p.A.,EFFICACY AND SAFETY OF A SINGLE TRUS-GUIDED INTRAPROSTATIC INJECTION OF NX-1207 IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA: A PHASE III EUROPEAN CLINIC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002451-41,0,0,0 2012-002452-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,GIDO (Grup d?investigació i divulgació en oncologia),Estudio Fase II de seguridad de bevacizumab en combinación con carboplatino y paclitaxel en pacientes ancianos (? 70 años) con cáncer de pulmón no microcítico,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002452-16,0,0,0 2012-002457-29,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Gilead Sciences Inc,"A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 24 weeks in Patients Infected with Chronic HCV with Cirrhosis and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002457-29,0,0,0 2012-002458-21,1,2015-04-30,2015-04-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MERCK SHARP & DOHME B.V.,"Open-label, Phase 4 Study, investigating the Incidence of Extra-Articular Manifestations in Subjects with Ankylosing Spondylitis treated with Golimumab Open-label fase 4 onderzoek, dat het optreden...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002458-21,0,0,0 2012-002459-41,8,2013-10-15,2013-10-15,8,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A multicenter, randomized, partially-blinded, Phase IIb dose-finding study on ovarian function, vaginal bleeding pattern, and pharmacokinetics associated with the use of combined vaginal rings releasi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002459-41,0,0,0 2012-002460-27,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,"Preoperative skin preparation to lower surgical site infection in breast cancer surgery: Povidone – iodine 10% aqueous solution versus 2%chlorhexidine in 70% isopropyl alcohol (ChloraPrep, Cardinal H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002460-27,0,0,0 2012-002465-35,8,2018-01-09,2018-02-07,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"FoldRx Pharmaceuticals, a Pfizer Company","A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826) 20...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002465-35,0,0,0 2012-002465-35,8,2018-01-09,2018-02-07,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Pfizer Inc,","A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826) 20...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002465-35,0,0,0 2012-002469-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO,Phase II clinical study on the efficacy and safety of procedural analgesia of oral transmucosal fentanyl citrate in oncologic patients eligible to permanent central venous catheter Studio clinico d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002469-37,0,0,0 2012-002470-31,10,2014-10-23,2014-10-23,9,1,0,0,2,0,2,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma Corporation (MTPC),"A phase II, multicentre, randomised, double-blind, parallel group, placebo-controlled, dose-finding study to evaluate the safety and efficacy of three different oral doses of MT-1303 administered for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002470-31,0,0,0 2012-002470-31,10,2014-10-23,2014-10-23,9,1,0,0,2,0,2,0,0,1,0,0,1,0,1,MITSUBISHI PHARMA CORPORATION,"A phase II, multicentre, randomised, double-blind, parallel group, placebo-controlled, dose-finding study to evaluate the safety and efficacy of three different oral doses of MT-1303 administered for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002470-31,0,0,0 2012-002471-34,14,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Celgene Corporation,"A Phase 3, Multicenter, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002471-34,0,0,0 2012-002471-34,14,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,CELGENE CORPORATION,"A Phase 3, Multicenter, Randomized, Double-Blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002471-34,0,0,0 2012-002472-14,8,2021-12-10,2021-12-20,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small cell Lung Cancer (NSCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002472-14,1,0,0 2012-002472-14,8,2021-12-10,2021-12-20,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small cell Lung Cancer (NSCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002472-14,1,0,0 2012-002473-61,8,2016-08-24,2016-08-24,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gilead Sciences Inc,"A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002473-61,0,0,0 2012-002476-14,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Jesper Ekelund,"The effect of various medications on emotioal processing, attention, experiences and sensory information processing",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002476-14,0,0,0 2012-002477-59,1,2018-02-05,2018-02-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Taneli Raivio, Helsingin yliopistollinen keskussairaala",Constitutional Delay of Growth and Puberty: towards evidence-based treatment Viivästyneen puberteetin hoito aromataasin estäjällä: randomisoitu kontrolloitu kliininen lääketutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002477-59,0,0,0 2012-002478-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Leiden University Medical Center,Arterial perfusion with t-PA in donation after cardiac death (DCD) to reduce the incidence of non-anastomotic biliary strictures after orthotopic liver transplantation Arteriële perfusie met t-PA b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002478-30,0,0,0 2012-002480-98,4,2014-08-11,2014-09-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma Corporation (MTPC),"A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral Do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002480-98,0,0,0 2012-002481-12,5,2014-09-15,2014-09-15,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma Corporation (MTPC),"A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral Do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002481-12,0,0,0 2012-002483-27,1,2015-11-24,2015-11-24,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Accenture,An Open-Label Phase I/II Study of GSK2110183 in Combination with Carboplatin and Paclitaxel in Subjects with Platinum-Resistant Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002483-27,0,0,0 2012-002487-27,13,2017-04-28,2021-05-28,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients >= 6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002487-27,0,0,0 2012-002487-27,13,2017-04-28,2021-05-28,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients >= 6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002487-27,0,0,0 2012-002487-27,13,2017-04-28,2021-05-28,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients >= 6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002487-27,0,0,0 2012-002487-27,13,2017-04-28,2021-05-28,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients >= 6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002487-27,0,0,0 2012-002487-27,13,2017-04-28,2021-05-28,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients >= 6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002487-27,0,0,0 2012-002487-27,13,2017-04-28,2021-05-28,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients >= 6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002487-27,0,0,0 2012-002487-27,13,2017-04-28,2021-05-28,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A","A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients >= 6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002487-27,0,0,0 2012-002487-27,13,2017-04-28,2021-05-28,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Unilfarma, Lda.","A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients >= 6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002487-27,0,0,0 2012-002487-27,13,2017-04-28,2021-05-28,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients >= 6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002487-27,0,0,0 2012-002487-27,13,2017-04-28,2021-05-28,9,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas S.A.,"A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients >= 6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002487-27,0,0,0 2012-002488-88,5,2016-12-29,2016-12-29,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Gilead Sciences Inc,"A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002488-88,0,0,0 2012-002489-11,4,2017-01-03,2017-01-03,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Gilead Sciences Inc,"A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002489-11,0,0,0 2012-002491-14,1,2015-01-01,2015-01-01,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Radboud University Nijmegen Medical Centre,"The effects of interferon-gamma on sepsis-induced immunoparalysis, a randomised double-blind placebo-controlled pilot (Phase IIIb) study De effecten van interferon-gamma op sepsis-geïnduceerde immu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002491-14,0,0,0 2012-002495-13,1,2013-11-27,2013-11-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Shire-Movetis NV,"An Open-label, Randomized, Crossover, Reader-blinded Study To Investigate the Effect of Prucalopride and Polyethylene Glycol 3350 on Colon Motility with Intraluminal Manometry in Subjects with Chronic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002495-13,0,0,0 2012-002499-15,2,2015-11-11,2015-11-11,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Acceleron Pharma, Inc.","A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients with β-Thalassemia Intermedia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002499-15,0,0,0 2012-002499-15,2,2015-11-11,2015-11-11,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ACCELERON PHARMA INC,"A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients with β-Thalassemia Intermedia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002499-15,0,0,0 2012-002503-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus University Medical Centre,Tobramycin nebulisation with I-neb (TONI) study in children with cystic fibrosis: pharmacokinetics and safety TONI studie: slimme vernevelaar voor tobramycine bij kinderen met cystic fibrosis: farm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002503-17,0,0,0 2012-002509-23,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),"Efficacia e Sicurezza di Eperisone Cloridrato come terapia in pazienti affetti da fibromialgia : Studio prospettico, monocentrico in doppio cieco, randomizzato, placebo controll Efficacia e Sicurez...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002509-23,0,0,0 2012-002513-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Karolinska University Hospital Solna,68Ga-DOTATOC-PET/CT for diagnosis of neuroendocrina tumours 68Ga-DOTATOC-PET/CT för diagnostik av neuroendokrina tumörer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002513-19,0,0,0 2012-002515-25,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Luis López Cortes - FISEVI,Pharmacokinetic interactions between Telaprevir and not powered Atazanavir with ritonavir in co-infected patients with HIV and HCV genotype 1 in treatment for chronic liver disease by HCV Interacc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002515-25,0,0,0 2012-002516-51,3,2014-09-24,2014-11-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biotest AG,"An open, prospective, single arm study investigating efficacy and safety of human hepatitis B immunoglobulin Zutectra in liver transplanted patients - the ZEUS Study Studio in aperto, prospettico, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002516-51,0,0,0 2012-002516-51,3,2014-09-24,2014-11-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BIOTEST AG,"An open, prospective, single arm study investigating efficacy and safety of human hepatitis B immunoglobulin Zutectra in liver transplanted patients - the ZEUS Study Studio in aperto, prospettico, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002516-51,0,0,0 2012-002518-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitari de Girona Dr. Josep Trueta,KETAMINE AND DEXAMETHASONE IN THE MANAGEMENT OF LOW BACK PAIN DURING ARTHRODESIS KETAMINA Y DEXAMETASONA EN EL MANEJO DEL DOLOR EN LA ARTRODESIS LUMBAR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002518-38,0,0,0 2012-002523-14,1,2018-10-22,2018-10-22,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Acceleron Pharma Inc.,"A Phase 2, Open-Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002523-14,0,0,0 2012-002525-29,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,UNICANCER,A phase II trial evaluating the Activity of Abiraterone Acetate plus Prednisone in Patients with a Molecular Apocrine HER2-negative locally advanced or metastatic Breast Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002525-29,0,0,0 2012-002526-67,1,2014-10-27,2014-10-27,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Sten Madsbad,Treatment with Liraglutide in type 1 diabetic patients. Effects on glycemic control and counterregulation and cognitive performance during hypoglycaemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002526-67,0,0,0 2012-002527-15,7,2016-05-19,2016-05-19,7,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Dompé s.p.a,"Study Brand Name : REPARO Study full title: An 8-week phase I/II, multicenter, randomized, double-masked, vehicle controlled parallel group study with a 48 or 56 week follow-up period to evaluate the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002527-15,0,0,0 2012-002527-15,7,2016-05-19,2016-05-19,7,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Dompé farmaceutici s.p.a,"Study Brand Name : REPARO Study full title: An 8-week phase I/II, multicenter, randomized, double-masked, vehicle controlled parallel group study with a 48 or 56 week follow-up period to evaluate the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002527-15,0,0,0 2012-002529-30,1,2014-01-03,2014-01-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dolorgiet GmbH & Co. KG,"Three-armed, randomized, double-blind dose-finding trial on efficiency and safety of Ibuprofen 5% gel, Ibuprofen 7,5% gel und Ibuprofen 10% gel in patients with actinic keratosis Olsen grade I/II D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002529-30,0,0,0 2012-002531-29,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Radboud University Medical Centre Nijmegen,A randomized phase IIa study: natural dendritic cells for immunotherapy of chemo-naive metastatic castration-resistant prostate cancer patients Een gerandomiseerd fase IIa studie: immunotherapie m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002531-29,0,0,0 2012-002533-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMCG,Comparison of the effects of atropine on haemodynamics and tissue oxygenation in anaesthesia with propofol and sufentanil versus propofol and remifentanil’,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002533-10,0,0,0 2012-002535-28,6,2019-07-10,2019-07-11,6,1,0,0,2,0,4,0,0,1,0,0,1,0,0,Joint Research & Development Office (Barts and The London School of Medicine & Dentistry),"A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA (R4-RA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002535-28,0,0,0 2012-002535-28,6,2019-07-10,2019-07-11,6,1,0,0,2,0,4,0,0,1,0,0,1,0,0,Joint Research & Development Office (Barts and The London School of Medicine & Dentistry) - Queen Mary University London,"A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA (R4-RA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002535-28,0,0,0 2012-002539-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU Amiens,Traitement néo-adjuvant des glioblastomes avec déficit neurologique inaugural marqué ou sévère par bévacizumab et témozolomide avant une radiothérapie éventuelle. Etude multicentrique de phase II.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002539-27,0,0,0 2012-002540-25,3,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"An open label, multi-center imatinib roll-over protocol for patients who have completed a previous Novartis sponsored imatinib study and are judged by the investigator to benefit from continued imatin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002540-25,0,0,0 2012-002541-37,1,2013-05-24,2013-05-24,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase II, open label, mono-centric study to evaluate the kinetics of mRNA expression after two doses of GSK Biologicals’ candidate tuberculosis (TB) vaccine GSK 692342 in healthy BCG-primed, HIV-neg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002541-37,0,0,0 2012-002542-20,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,LYSARC,"Efficacy of alternating immunochemotherapy consisting of R-CHOP + R-HAD versus R-CHOP alone, followed by maintenance therapy consisting of additional lenalidomide with rituximab versus rituximab alone...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002542-20,0,0,0 2012-002547-15,1,,,0,0,0,0,1,0,3,0,0,1,1,1,0,1,0,Instituto de Investigacion Sanitaria La Fe,UTILITY OF THE ocolytict MAINTENANCE TREATMENT IN THE MANAGEMENT OF THE THREAT OF PREMATURE UTILIDAD DEL TRATAMIENTO TOCOLÍTICO DE MANTENIMIENTO EN EL MANEJO DE LA AMENAZA DE PARTO PREMATURO (APP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002547-15,0,0,0 2012-002552-16,1,2017-12-31,2017-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospitals Birmingham NHS Foundation Trust,Cabazitaxel in platinum pre-treated patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression within 12 months of platinum based chemotherapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002552-16,0,0,0 2012-002553-38,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Itziar Astigarraga Aguirre,Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfecta Terapia celular basada en células madre mesenquimales aplicada a pacientes pediátricos con Osteogénesis Imperfecta.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002553-38,0,0,0 2012-002554-23,9,2020-03-24,2020-03-24,6,1,1,0,0,1,3,0,0,1,0,0,1,0,1,OCTAPHARMA AG,"Immunogenicity, Efficacy and Safety of Treatment with Human-cl rhFVIII in Previously Untreated Patients with Severe Haemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002554-23,0,0,0 2012-002555-42,2,2014-12-16,2016-01-25,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen R&D Ireland,"A Phase IIa, open-label trial to evaluate the safety, tolerability and efficacy of a 12 weeks combination therapy of TMC647055 and TMC435 with and without GSK2336805 with a pharmacokinetic enhancer wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002555-42,0,0,0 2012-002556-17,3,2020-05-31,2020-05-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UNICANCER,"A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002556-17,0,0,0 2012-002563-10,3,2017-08-10,2017-08-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,Multicenter open-label study to evaluate efficacy of gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) for detection of significant coronary artery disease (CAD) in subjects with known or ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002563-10,0,0,0 2012-002563-10,3,2017-08-10,2017-08-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,Multicenter open-label study to evaluate efficacy of gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) for detection of significant coronary artery disease (CAD) in subjects with known or ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002563-10,0,0,0 2012-002564-27,1,2017-01-30,2017-01-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,Pilot open study of testosterone replacement in non-alcoholic steatohepatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002564-27,0,0,0 2012-002566-12,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,ITALFARMACO,"A Two-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, and Effects on Histology and Different Clinical Parameters of Givinostat in Ambulant Children with Duchenne Muscular Dystrophy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002566-12,0,0,0 2012-002567-99,1,2013-10-15,2013-10-15,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Glenmark Pharmaceuticals SA,"An integrated Phase I/IIa study to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of inhaled GRC 17536 in healthy adult volunteers and multiple ascending doses in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002567-99,0,0,0 2012-002571-34,14,2017-09-08,2017-09-08,8,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,"A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metasta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002571-34,1,0,0 2012-002571-34,14,2017-09-08,2017-09-08,8,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Farmacéutica S.A,"A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metasta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002571-34,1,0,0 2012-002571-34,14,2017-09-08,2017-09-08,8,1,0,0,0,0,3,0,0,2,1,0,0,0,1,NOVARTIS FARMA,"A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metasta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002571-34,1,0,0 2012-002572-13,1,2013-10-26,2013-10-26,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Henrik Kehlet,"Efficacy of midodrine for the prevention of orthostatic hypotension during early mobilization after fast-track hip arthroplasty - a randomized, placebo controlled trial Effekten af midodrine-hydroc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002572-13,0,0,0 2012-002573-62,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,"The Karolinska Institute, ClinTRID",Doppler quantitative evaluation and follow-up over 12 months in RA patients with moderate and high disease activity who are candidates for biologic add-on therapy with Adalimumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002573-62,0,0,0 2012-002574-31,1,2019-08-16,2019-08-16,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,sanofi-aventis recherche & développement,"A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR421869, Administered to Patients with Retinitis Pigmentosa Associated with Usher Syndrome Type 1B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002574-31,0,0,0 2012-002575-34,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, open, multi-center study to evaluate the immunogenicity, reactogenicity and safety of a booster dose of GSK Biologicals’ MenACWY-TT vaccine administered at 6 years post-primary vaccinati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002575-34,0,1,1 2012-002576-14,1,2012-12-17,2012-12-17,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Tranzyme, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002576-14,0,0,0 2012-002581-12,2,2015-01-26,2015-01-26,2,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Mitsubishi Tanabe Pharma Corporation (MTPC),"A Multi-centre, Randomised, Controlled, Parallel Group, Open-label Study Evaluating the Efficacy, Safety and Tolerability of Three Doses of Colestilan (MCI-196) Compared to Standard Therapy with a Cal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002581-12,0,0,0 2012-002582-35,2,2014-12-17,2014-12-17,2,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Mitsubishi Tanabe Pharma Corporation (MTPC),"A Multi-centre, Open-label Study Evaluating the Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects with Chronic Kidney Disease Stages 3b to 5 and with Hyperphosphataemia not on Dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002582-35,0,0,0 2012-002583-27,1,,,0,1,1,0,0,0,3,0,0,1,1,1,0,1,1,Mitsubishi Tanabe Pharma Corporation (MTPC),"A Multi-centre, Flexible Dose, Parallel Group, Open-label, Active Control (Calcium-based Phosphate Binder), Long-term Extension Study Evaluating the Efficacy, Safety and Tolerability of Colestilan (MC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002583-27,0,0,0 2012-002587-27,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase II, double-blind, multicenter, randomized study to evaluate the immunogenicity and safety of GSK Biologicals’ quadrivalent influenza candidate vaccine GSK2321138A compared with GSK Biologicals...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002587-27,0,1,1 2012-002592-34,1,2018-11-06,2018-11-06,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,The Institute of Cancer Research,A Phase II Trial of Vinflunine chemotherapy in locally advanced and metastatic carcinoma of the penis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002592-34,0,0,0 2012-002595-13,1,2015-05-13,2015-05-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"AVID RADIOPHARMACEUTICALS, INC.","A randomized, multicenter, multicountry study to evaluate the effectiveness of Florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between Florbetapir (18F) P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002595-13,0,0,0 2012-002601-22,1,2018-04-30,2018-04-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Celgene Corporation,"AN OPEN-LABEL, RANDOMIZED, PHASE 2, PARALLEL, DOSE-RANGING, MULTICENTER STUDY OF SOTATERCEPT FOR THE TREATMENT OF PATIENTS WITH ANEMIA AND LOW- OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES OR NON-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002601-22,0,0,0 2012-002602-52,15,2016-06-30,2016-06-30,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bayer AG,"Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin's lymphomas Ensayo fase II, abierto, no controlado de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002602-52,1,0,0 2012-002602-52,15,2016-06-30,2016-06-30,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bayer HealthCare AG,"Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin's lymphomas Ensayo fase II, abierto, no controlado de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002602-52,1,0,0 2012-002602-52,15,2016-06-30,2016-06-30,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BAYER HEALTHCARE AG,"Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin's lymphomas Ensayo fase II, abierto, no controlado de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002602-52,1,0,0 2012-002603-17,4,2015-12-07,2015-12-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase IIIb, multicenter, multinational, randomized, double-blind, placebo controlled, parallel group study to evaluate the glycemic and renal efficacy of once daily administration of linagliptin 5 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002603-17,0,0,0 2012-002603-17,4,2015-12-07,2015-12-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A phase IIIb, multicenter, multinational, randomized, double-blind, placebo controlled, parallel group study to evaluate the glycemic and renal efficacy of once daily administration of linagliptin 5 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002603-17,0,0,0 2012-002603-17,4,2015-12-07,2015-12-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A phase IIIb, multicenter, multinational, randomized, double-blind, placebo controlled, parallel group study to evaluate the glycemic and renal efficacy of once daily administration of linagliptin 5 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002603-17,0,0,0 2012-002603-17,4,2015-12-07,2015-12-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A phase IIIb, multicenter, multinational, randomized, double-blind, placebo controlled, parallel group study to evaluate the glycemic and renal efficacy of once daily administration of linagliptin 5 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002603-17,0,0,0 2012-002604-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Centre Utrech,"RGNOSIS: Ecological Effects of Decolonisation Strategies in Intensive Care R-GNOSIS : Efectos en Cuidados Intensivos, sobre la Descontaminación ecológica, comparando diferentes estrategias",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002604-41,0,0,0 2012-002606-40,2,2013-07-29,2013-07-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Service AG,"A randomized, double-blind, parallel group study to evaluate metabolic effects of LCZ696 and amlodipine in obese hypertensive subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002606-40,0,0,0 2012-002607-18,1,2014-04-07,2014-04-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Marius Henriksen,COMBINED INTRA ARTICULAR CORTICOSTEROID AND EXERCISE IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE: A RANDOMISED TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002607-18,0,0,0 2012-002608-42,4,2014-01-30,2014-01-30,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,UCB Biosciences GmbH,"A Multicenter, Multinational, Double-blind, Placebo-controlled, 2-arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002608-42,0,0,0 2012-002609-22,2,2016-10-27,2016-10-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in autoinjectors to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tolera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002609-22,0,0,0 2012-002612-10,1,2014-12-23,2014-12-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Ina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002612-10,0,0,0 2012-002616-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA ""OSPEDALI RIUNITI DI BERGAMO"" (A.O. DI RILIEVO NAZIONALE)",Stage IIIC unresectable epithelial ovarian/tubal cancer with partial or complete response after 1st line neoadjuvant chemotherapy (3 cycles CBDCA+Paclitaxel): a phase 3 prospective randomized study ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002616-22,0,0,0 2012-002618-38,1,2015-10-01,2015-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,3,,Does preperitoneal local anesthesia in laparoscopic gastric bypass surgery reduce postoperative pain and opioid consumption? Vermindert preperitoneale lokale anesthesie postoperatieve pijn en opi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002618-38,0,0,0 2012-002619-24,11,2020-09-28,2020-09-28,9,1,1,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002619-24,0,0,0 2012-002619-24,11,2020-09-28,2020-09-28,9,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc,"A MULTI-CENTRE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, TWO-ARMED, PARALLEL GROUP STUDY TO EVALUATE EFFICACY AND SAFETY OF IV SILDENAFIL IN THE TREATMENT OF NEONATES WITH PERSISTENT PULMONARY HY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002619-24,0,0,0 2012-002620-32,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,"A randomised phase II study comparing LEnalidomide plus rituximab, GEmcitabine and methylprednisolone (LR-GEM) to rituximab, gemcitabine, methylprednisolone and cisplatiN (R-GEM-P) in second-line trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002620-32,0,0,0 2012-002622-75,1,2013-11-08,2013-11-08,1,0,0,0,0,0,3,0,1,1,0,0,1,0,0,Vibeke Hjortdal,Lymphatic dysfunction as a cause of calcium channel blocker oedema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002622-75,0,0,0 2012-002623-15,2,2015-08-07,2015-08-07,2,1,0,0,0,0,2,0,0,1,1,0,1,0,0,University of Leeds,GLiSten: Next generation intraoperative lymph node staging for stratified colon cancer surgery- Development Phase,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002623-15,0,0,0 2012-002627-15,16,2014-12-09,2014-12-09,14,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, double-blind, double-dummy, multi-center study to assess safety and efficacy of BAY 94-8862 in subjects with emergency presentation at the hospital because of worsening chronic heart fai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002627-15,0,0,0 2012-002628-34,1,2015-07-10,2015-07-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Thor Petersen,Optic neuritis and early treatment with methylprednisolone. Opticus neurit og tidlig behandling med Solu-medrol.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002628-34,0,0,0 2012-002630-36,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,0,The National Institute of Allergy and Infectious Diseases (NIAID),"A PHASE I/II, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF ETRAVIRINE (ETR) IN ANTIRETROVIRAL (ARV) TREATMENT-EXPERIENCED HIV-1 INFECTED INFANTS A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002630-36,0,1,1 2012-002630-36,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,0,The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"A PHASE I/II, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF ETRAVIRINE (ETR) IN ANTIRETROVIRAL (ARV) TREATMENT-EXPERIENCED HIV-1 INFECTED INFANTS A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002630-36,0,1,1 2012-002632-87,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,"Roche Farma, S.A.","Estudio de extensión a largo plazo de los estudios WA22762 y NA25220, multicéntrico, abierto para evaluar la seguridad y eficacia de tocilizumab subcutáneo en pacientes con artritis reumatoide moderad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002632-87,0,0,0 2012-002633-11,7,2018-08-07,2018-09-07,6,1,1,0,0,0,1,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"AN OPEN-LABEL, RANDOMIZED, ADAPTIVE, TWO-ARM, MULTICENTER TRIAL TO EVALUATE PHARMACOKINETICS AND PHARMACODYNAMICS OF TWO DOSES OF OSELTAMIVIR (TAMIFLU®) IN THE TREATMENT OF INFLUENZA IN IMMUNOCOMPROMI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002633-11,0,0,0 2012-002635-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,ASSESSMENT OF THE EFFICACY OF SUBTENON NATURAL LEUCOCYTIC INTERFERON-α (IFNα) FOR THE TREATMENT OF DIABETIC MACULAR EDEMA (DME): A PILOT STUDY. Studio pilota: stima dell'efficacia dell'interferone...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002635-28,0,0,0 2012-002637-11,1,2013-02-25,2013-02-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 6 months, randomized, multicenter, parallel-group, open-label study to evaluate the effect of an individualized patient support program on treatment satisfaction in Fingolimod (FTY720)-treated patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002637-11,0,0,0 2012-002638-35,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Stockholms Läns Landsting, Karolinska Universitetssjukhuset Huddinge, Anestesikliniken","ALBUMIN KINETICS BY 123I-HSA A validation study on healthy volunteers, patients with acute inflammation, and patiens scheduled for major abdominal surgery ALBUMINKINETIK MED 123I-HSA En valide...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002638-35,0,0,0 2012-002639-27,10,2016-03-15,2016-03-15,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma Corporation (MTPC),"A phase II, multicentre study to evaluate the long-term safety and efficacy of MT-1303 in subjects with relapsing-remitting multiple sclerosis who have completed the MT-1303-E04 study Studio multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002639-27,0,0,0 2012-002639-27,10,2016-03-15,2016-03-15,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MITSUBISHI TANABE PHARMA CORPORATION,"A phase II, multicentre study to evaluate the long-term safety and efficacy of MT-1303 in subjects with relapsing-remitting multiple sclerosis who have completed the MT-1303-E04 study Studio multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002639-27,0,0,0 2012-002640-25,1,2016-10-26,2016-10-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leeds/Leeds Teaching Hospitals NHS Trust,"A prospective, single-centre, feasibility study evaluating the prevalence of diagnostic clinical imaging features of subclinical enthesitis in patients with moderate to severe plaque psoriasis and the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002640-25,0,0,0 2012-002645-38,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,CRESIB-Barcelona Centre for International Health Research,Evolution of serologic biomarkers and diastolic function and segmentary contractility determined by echocardiography after treatment in Chagas diseases Evolución de los marcadores serológicos y de ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002645-38,0,0,0 2012-002648-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZ Leuven,Exploratory Propofol Dose Finding Study In Neonates.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002648-26,0,0,0 2012-002649-39,1,2013-09-03,2013-09-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,F. Hoffmann-La Roche Ltd,"A SINGLE-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY TO ASSESS THE EFFICACY OF ALEGLITAZAR ON INSULIN SENSITIVITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2D) WHO ARE INADE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002649-39,0,0,0 2012-002657-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HYKS-instituutti,Immunogenicity of repeated dose 13-valent pneumococcal conjugate vaccine compared to the existing recommended protocol of pneumococcal polysaccharide vaccine in adult kidney and liver transplant patie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002657-30,0,0,0 2012-002659-41,6,2022-04-06,2022-04-20,3,1,0,0,0,0,2,0,0,2,0,0,0,0,1,MorphoSys AG,"A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma Uno studio di fase IIa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002659-41,1,0,0 2012-002659-41,6,2022-04-06,2022-04-20,3,1,0,0,0,0,2,0,0,2,0,0,0,0,1,MORPHOSYS AG,"A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma Uno studio di fase IIa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002659-41,1,0,0 2012-002662-12,2,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Psyadon Pharmaceuticals Inc.,An Outpatient Phase 3 Efficacy Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects with Lesch-Nyhan Disease (LND).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002662-12,0,0,0 2012-002663-10,1,2015-03-16,2015-03-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,St Stephen's AIDS Trust,"A phase IV, open-label single-arm study investigating the pharmacokinetics and pharmacodynamics of the antiretroviral combination of rilpivirine and ritonavir-boosted darunavir in therapy-naive HIV-1 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002663-10,0,0,0 2012-002669-37,7,2016-10-24,2016-10-24,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MERCK SERONO SA,"A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutane...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002669-37,0,0,0 2012-002669-37,7,2016-10-24,2016-10-24,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Serono S.A. Geneva,"A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutane...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002669-37,0,0,0 2012-002672-13,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,"University of Oxford, Clinical Trials and Research Governance Office",Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) Trial: a prospective randomised open blinded endpoint trial to determine the effect of aldosterone receptor antagonism ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002672-13,0,0,0 2012-002675-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,"Surgical and aesthetic outcome, quality of life, and cost-effectiveness of keloid treatment Chirurgische en aesthetische resultaten, kwaliteit van leven en kosteneffectiviteit van keloïdbehandeling",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002675-34,0,0,0 2012-002677-53,2,2014-11-24,2014-11-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier (I.R.I.S.),Evaluation of the subcutaneous administration of 30 mg of S 78989 versus placebo and evaluation of the subcutaneous administration of 60 mg of S 78989 versus placebo on the reduction of arterial wall ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002677-53,0,0,0 2012-002678-29,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Lantheus Medical Imaging, Inc.","A Phase 3, Open-Label, Multicenter Study for the Assessment of Myocardial Perfusion using Positron Emission Tomography (PET) Imaging of Flurpiridaz F 18 Injection in Patients with Suspected or Known C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002678-29,0,0,0 2012-002682-36,1,2013-08-30,2013-08-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mylan Pharmaceuticals Inc.,"Comparison of the Efficacy of Diclofenac Sodium Topical Gel, 1% (Mylan) to Voltaren® Gel, 1% (Novartis US) and Placebo in Adult Subjects with Knee Osteoarthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002682-36,0,0,0 2012-002685-12,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University Hospital Regensburg,Treatment of steroid resistant severe acute gastrointestinal graft-versus-host disease with in vitro expanded donor-derived regulatory T cells A prospective open-label one-armed non-randomized multice...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002685-12,0,0,0 2012-002692-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Univ.-Klinik für Kinder- und Jugendheilkunde,Clinical study for the assessment of safety and efficacy of Bezafibrate as a drug therapy for patients with mitochondrial myopathies Klinische Studie zum Nachweis der Sicherheit und Wirksamkeit von...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002692-34,0,0,0 2012-002694-66,1,2019-02-01,2019-02-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Sakari Simula,Effect of fingolimod on cardiac autonomic regulation in MS-patients Fingolimodin vaikutus sydämen autonomiseen säätelyyn MS-tautia sairastavilla potilailla.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002694-66,0,0,0 2012-002699-14,5,2015-10-02,2015-10-02,3,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Pharmaxis Ltd.,"A randomised, multicentre, double-blind, placebo-controlled, crossover trial determining the efficacy of dry powder mannitol in improving lung function in subjects with Cystic Fibrosis aged six to sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002699-14,0,0,0 2012-002702-51,4,2020-04-30,2020-04-30,4,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of medical gastroenterology, Herlev Hospital","Discontinuation of infliximab therapy in patients with Crohn’s disease during sustained complete remission: A Nordic multi-center, double blinded, randomized, placebo controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002702-51,0,0,0 2012-002702-51,4,2020-04-30,2020-04-30,4,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of medical gastroenterology S, Odense University Hospital","Discontinuation of infliximab therapy in patients with Crohn’s disease during sustained complete remission: A Nordic multi-center, double blinded, randomized, placebo controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002702-51,0,0,0 2012-002704-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rigshospitalet,"Effect of Adductor-Canal-Blockade on postoperative pain, ability to walk and morphine consumption after total knee arthroplasty: A randomised study Effekten af Adductor-Kanal-Blokade vs placebo på ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002704-41,0,0,0 2012-002705-21,5,2015-12-30,2015-12-30,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Interventional, open-label, flexible-dose extension study of brexpiprazole in patients with schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002705-21,0,0,0 2012-002707-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE SANDRO PITIGLIANI PER LA LOTTA CONTRO I TUMORI-ONLUS,EFFECT: A randomized phase II study to evaluate the EFficacy and impact on Function of two different doses of nab-paclitaxEl in elderly patients with advanCed breasT cancer EFFECT: A randomized pha...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002707-18,0,0,0 2012-002709-23,1,2013-11-05,2013-11-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Evaluation of the feasibility of intra-arterial loco-regional chemotherapy in Patients with locally advanced breast cancer Valutazione della fattibilita' della chemioterapia intra-arteriosa locoreg...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002709-23,0,0,0 2012-002714-40,9,2017-04-13,2017-04-13,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Receptos, Inc.","A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002714-40,0,0,0 2012-002714-40,9,2017-04-13,2017-04-13,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Celgene International II Sàrl (CIS II),"A PHASE 2/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002714-40,0,0,0 2012-002716-10,3,2015-05-13,2015-05-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Prof. Dr. Kristian Reich,"An international prospective, double-blind, placebo-controlled phase III RCT in which patients with moderate to severe psoriasis vulgaris are treated with s.c. methotrexate using an optimized treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002716-10,0,0,0 2012-002718-38,1,,,0,1,0,0,0,1,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase II, open, controlled, multi-center study to evaluate the long-term antibody persistence at 1 year, 3 years and 5 years after the administration of one dose of GlaxoSmithKline (GSK) Biologicals...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002718-38,0,1,1 2012-002719-24,1,,,0,1,0,0,0,1,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase II, open, multi-center study to evaluate the long-term anti-body persistence at 1 year, 3 years and 5 years after the administration of one or two doses of GlaxoSmithKline (GSK) Biologicals’ m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002719-24,0,1,1 2012-002722-75,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IIb, open, randomised, controlled primary vaccination study to evaluate the non-inferiority and the persistence of the immune response of GSK Biologicals’ meningococcal serogroup ACWY conjugat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002722-75,0,1,1 2012-002727-15,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase II, randomized, controlled, observer-blind study to evaluate the impact of two formulations of GlaxoSmithKline (GSK) Biologicals’ combined 10-valent pneumococcal polysaccharide and non-typeabl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002727-15,0,1,1 2012-002731-28,2,2014-10-09,2014-10-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bioprojet,Randomized placebo controlled trial assessing the efficacy and safety of BP1.4979 in smoking cessation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002731-28,0,0,0 2012-002737-11,1,,,0,1,0,0,1,1,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A Phase III, randomised, partially-blind, controlled, multi-centric, multi-country study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals’ MenACWY-TT conjugate vaccine co-a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002737-11,0,0,0 2012-002741-38,1,2017-10-09,2017-10-09,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,SymbioPharm GmbH,"Randomized, double-blind, placebo-controlled, multi-centre study to evaluate the efficacy,safety and tolerability of oral treatment with non-pathogenic bacterial lysate of E. coli and E. faecalis cell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002741-38,0,0,0 2012-002742-20,11,2016-02-29,2016-02-29,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with Chronic Heart Failure with Preserved left ventricular Ejection Fraction An 8-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002742-20,0,0,0 2012-002742-20,11,2016-02-29,2016-02-29,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratorios Servier S.L.,"Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with Chronic Heart Failure with Preserved left ventricular Ejection Fraction An 8-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002742-20,0,0,0 2012-002744-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Effect of oral paricalcitol on endothelial function and FGF-23 in peritoneal dialysis patients: a pilot study Effetto della somministrazione orale di paracalcitolo sulla funzione endoteliale e su F...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002744-24,0,0,0 2012-002745-38,2,2017-12-13,2018-03-02,2,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Grupo Español de Investigacion en Sarcomas,Phase II Clinical Trial of Pazopanib to evaluate the activity and tolerability in patients with advanced and/or metastatic liposarcoma who have relapsed following standard therapies or for whom no sta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002745-38,0,0,0 2012-002745-38,2,2017-12-13,2018-03-02,2,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Grupo Español de Investigación en Sarcomas,Phase II Clinical Trial of Pazopanib to evaluate the activity and tolerability in patients with advanced and/or metastatic liposarcoma who have relapsed following standard therapies or for whom no sta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002745-38,0,0,0 2012-002748-25,2,2014-01-31,2014-01-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Ironwood Pharmaceuticals, Inc.","A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once Daily for 14 Days to Patients with Functional Dyspepsia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002748-25,0,0,0 2012-002751-42,7,2020-10-02,2020-10-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Seattle Genetics, Inc.","A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002751-42,0,0,0 2012-002755-42,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,"OBESITY AND ASPIRIN RESPONSIVENESS Cardioaspirina (acido acetilsalicilico, 100 mg gastroprotetto)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002755-42,0,0,0 2012-002758-22,5,2014-08-04,2014-08-04,4,1,0,0,0,0,3,0,1,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002758-22,1,0,0 2012-002758-22,5,2014-08-04,2014-08-04,4,1,0,0,0,0,3,0,1,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc","A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002758-22,1,0,0 2012-002758-22,5,2014-08-04,2014-08-04,4,1,0,0,0,0,3,0,1,2,0,0,0,0,1,Merck & Co. Inc.,"A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002758-22,1,0,0 2012-002760-27,7,2015-01-27,2015-05-14,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmaceutica, S.A.","A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis Studio di estensione della durata di 4 anni per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002760-27,0,0,0 2012-002760-27,7,2015-01-27,2015-05-14,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis Studio di estensione della durata di 4 anni per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002760-27,0,0,0 2012-002760-27,7,2015-01-27,2015-05-14,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis Studio di estensione della durata di 4 anni per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002760-27,0,0,0 2012-002760-27,7,2015-01-27,2015-05-14,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis Studio di estensione della durata di 4 anni per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002760-27,0,0,0 2012-002760-27,7,2015-01-27,2015-05-14,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A four year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active rheumatoid arthritis Studio di estensione della durata di 4 anni per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002760-27,0,0,0 2012-002761-35,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO,"Trattamento di prima linea della Leucemia Linfoblastica Acuta (LLA) Philadelphia positiva (Ph+)/BCR/ABL+ con un nuovo potente inibitore delle Tirosin-chinasi (TKI), AP24534 (Ponatinib). Studio multice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002761-35,0,0,0 2012-002762-12,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA SENESE,"A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMANIZED ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA Studio c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002762-12,0,0,0 2012-002763-10,2,2014-11-26,2014-11-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vascular Biogenics Ltd.,"A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002763-10,0,0,0 2012-002763-10,2,2014-11-26,2014-11-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vascular Biogenics Ltd,"A Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002763-10,0,0,0 2012-002764-27,8,2016-11-01,2016-12-16,7,1,0,0,0,0,0,0,0,1,0,0,1,0,0,"St. James Hospital, Ireland",A European Multicentre Double-Blind Placebo Controlled trial of Nilvadipine in Mild to Moderate Alzheimer's desease Studio Europeo multicentrico in doppio cieco per valutare l'efficacia di nilvadip...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002764-27,0,0,0 2012-002764-27,8,2016-11-01,2016-12-16,7,1,0,0,0,0,0,0,0,1,0,0,1,0,0,St James's Hospital,A European Multicentre Double-Blind Placebo Controlled trial of Nilvadipine in Mild to Moderate Alzheimer's desease Studio Europeo multicentrico in doppio cieco per valutare l'efficacia di nilvadip...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002764-27,0,0,0 2012-002764-27,8,2016-11-01,2016-12-16,7,1,0,0,0,0,0,0,0,1,0,0,1,0,0,ST. JAMES HOSPITAL,A European Multicentre Double-Blind Placebo Controlled trial of Nilvadipine in Mild to Moderate Alzheimer's desease Studio Europeo multicentrico in doppio cieco per valutare l'efficacia di nilvadip...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002764-27,0,0,0 2012-002765-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Istituto Europeo di Oncologia,SIB –IMRT using a modulated accelerated fractionation for head and neck cancer patients Frazionamento Accelerato MOdulato nel trattamento SIB-IMRT dei tumori della testa e del collO (FAMOSO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002765-36,0,0,0 2012-002766-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,A phase 2 study of temozolomide in patients affected by metastatic colonrectal cancer with hypermethylation of 06-methylguanine-dna-methyltransferase Studio di fase 2 con Temozolomide in pazienti a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002766-13,0,0,0 2012-002767-95,1,2016-06-13,2016-06-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,"Long term antibody response to CMV gB vaccine in patients requiring liver or renal transplant. A Phase II open, single-site study, in participants who received CMV gB vaccine or placebo in previous tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002767-95,0,0,0 2012-002768-28,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,CHU Clermont-Ferrand,Rôle de la dopamine dans le comportement d’aversion à la perte : étude chez le patient parkinsonien,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002768-28,0,0,0 2012-002769-37,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,"UK für Anästhesiologie und allgemeine Intensivmedizin, LKH Salzburg","Influence of the concentration of the local anesthetic ropivacaine in the quality of a ultrasound guided block of the regio collis lateralis for carotid endarterectomy: a prospective, randomized and c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002769-37,0,0,0 2012-002771-33,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,MSD ITALIA S.R.L.,An open label study assessing SVR and Viral Resistance profile with Boceprevir plus PEG-IFN plus Ribavirin triple therapy in HCV-1 infected patients with insulin resistance who have failed PEG-IFN plu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002771-33,0,0,0 2012-002772-13,1,2015-11-17,2015-11-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MSD ITALIA S.R.L.,"A multi-centre single-arm study to evaluate the efficacy and safety of BOCEPREVIR 44 weeks in addition to standard of care (SOC) in previously treatment failure (relapser, non-responders, both partial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002772-13,0,0,0 2012-002773-64,5,2017-07-10,2017-07-10,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Raptor Therapeutics Inc.,"A Long-Term Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Cystinosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002773-64,0,0,0 2012-002773-64,5,2017-07-10,2017-07-10,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Horizon Pharma USA, Inc.","A Long-Term Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Cystinosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002773-64,0,0,0 2012-002774-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,Pre-emptive targeted and optimized treatment of critical airway colonization to prevent Ventilator Associated Pneumonia: a randomized controlled study Trattamento precoce mirato e ottimizzato della...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002774-31,0,0,0 2012-002776-14,3,2016-04-30,2016-07-07,2,1,0,0,0,0,0,0,0,1,0,0,1,0,0,University of Oslo,"Ibuprofen versus mecillinam for uncomplicated cystitis in adult, non-pregnant women Ibuprofen versus mecillinam i behandlingen av ukomplisert cyctitt hos voksne, ikke-gravide kvinner",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002776-14,0,0,0 2012-002776-14,3,2016-04-30,2016-07-07,2,1,0,0,0,0,0,0,0,1,0,0,1,0,0,"University of Oslo, Faculty of medicine, Institute of Health and Society","Ibuprofen versus mecillinam for uncomplicated cystitis in adult, non-pregnant women Ibuprofen versus mecillinam i behandlingen av ukomplisert cyctitt hos voksne, ikke-gravide kvinner",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002776-14,0,0,0 2012-002777-56,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ROCHE,Cross-sectional multicenter study evaluating the IL28B polymorphism in patients with HBeAg-negative chronic hepatitis B treated with pegylated interferon alfa-2a in the course of Peg.Be.Liver study ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002777-56,0,0,0 2012-002784-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA,Clinical trial comparing contrast enhanced spectral digital mammography (CESM) and magnetic resonance imaging (MRI) to evaluate the effectiveness of neoadjuvant chemotherapy in patients with locally a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002784-10,0,0,0 2012-002785-12,7,2014-09-29,2015-01-16,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002785-12,0,0,0 2012-002786-35,1,2019-05-10,2019-05-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University College London,A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose with placebo in patients with anaemia undergoing major open abdominal surge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002786-35,0,0,0 2012-002787-27,7,2015-07-14,2015-07-17,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Ascendis Pharma A/S,"A multicenter, Phase 2, randomized, open label, active-controlled, parallel-group study investigating the safety, tolerability, and efficacy of different dose levels of ACP-001 administered once weekl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002787-27,0,0,0 2012-002790-55,3,2016-08-24,2016-08-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A double blind, randomized, placebo controlled phase II study to assess the efficacy of recPRAME +AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected PRAME-pos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002790-55,0,0,0 2012-002791-14,5,2015-07-30,2015-07-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects with Endometriosis Associated Pelvic Pain for 12 Wee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002791-14,0,0,0 2012-002792-34,1,2018-12-06,2018-12-06,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospitals Leicester NHS Trust,"Phenotyping bronchiectasis based on aetiology, exacerbation characteristics and response to erythromycin.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002792-34,0,0,0 2012-002793-30,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,A.O. SAN GERARDO,PHASE II RANDOMIZED STUDY FOR THE PREVENTION OF CUTANEOUS RASH INDUCED BY ERLOTINIB STUDIO RANDOMIZZATO DI FASE II SULLA PREVENZIONE DEL RASH CUTANEO INDOTTO DA ERLOTINIB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002793-30,0,0,0 2012-002795-13,1,2016-04-04,2016-04-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Birmingham,A phase II trial of Cyclosporin A in Early Adverse Risk CLL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002795-13,0,0,0 2012-002797-32,4,2013-10-15,2013-10-15,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticaso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002797-32,0,0,0 2012-002798-80,7,2020-06-30,2020-06-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Phase 3 Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults with Active Psoriatic Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002798-80,0,0,0 2012-002804-42,1,2013-07-22,2013-07-22,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,Bispebjerg Hospital,The effects of high dose beta2-agonists on physical performance in healthy male subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002804-42,0,0,0 2012-002805-23,8,2014-06-12,2014-06-12,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"KAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)","A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002805-23,0,0,0 2012-002805-23,8,2014-06-12,2014-06-12,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN INC.,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002805-23,0,0,0 2012-002806-31,9,2014-05-09,2014-05-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)","A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002806-31,0,0,0 2012-002806-31,9,2014-05-09,2014-05-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN INC.,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002806-31,0,0,0 2012-002807-17,1,2014-02-13,2014-02-13,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,L’OREAL RECHERCHE,"A monocenter, double-blind, randomized study to assess the antiperspirant efficacy of glycopyrrolate 2% versus Aluminium chlorohydrate 15% after topical applications on axilla of healthy volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002807-17,0,0,0 2012-002808-41,10,2015-07-15,2016-07-15,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)",A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002808-41,0,0,0 2012-002814-38,19,2020-01-28,2020-01-28,19,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SOTIO a.s.,"A Randomized, Double Blind, Multicenter, Parallel-group, Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligibl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002814-38,0,0,0 2012-002816-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rijnstate Hospital,"Prospective, pharmacokinetic study for determination of the relationship between lean body weight and anti-Xa activity 4 hours after subcutaneous injection of 5700 IU nadroparin in morbidly obese pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002816-19,0,0,0 2012-002817-20,1,2018-06-05,2018-06-05,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,CHU Dijon,Etude préliminaire visant à étudier l’effet de la rTMS et des antidépresseurs ISRS sur l’expression leucocytaire des gènes C-FOS et DUSP1 des patients traités pour un état dépressif,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002817-20,0,0,0 2012-002819-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CENTRO DI RIFERIMENTO ONCOLOGICO DI BASILICATA,FMISO F18 PET/CT as marker of hypoxia in patients undergoing radio- and chemotherapy [18F]FLUOROMISONIDAZOLE ([18F]-FMISO) IN METODICA PET-TC COME TRACCIANTE DELLA VALUTAZIONE IN-VIVO DELLA IPOSSIA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002819-26,0,0,0 2012-002820-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CENTRO DI RIFERIMENTO ONCOLOGICO DI BASILICATA,"FLT F-18 PET/CT in diagnosis, staging and terapy assessmentin tumours with accelereted replication 18F- FLUOROTIMIDINA (18F-FLT) IN METODICA PET-TC COME TRACCIANTE NELLA DIAGNOSI, STADIAZIONE E VAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002820-33,0,0,0 2012-002825-31,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SENESE,NEW CONSERVATIVE THERAPIES IN RETINOBLASTOMA: INTRAVITREAL AND SUBCONJUNCITIVAL INJECTION OF CHEMOTHERAPY in the intraoculars RTBs Nuove terapie conservative nel retinoblastoma (RTB): iniezione in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002825-31,0,0,0 2012-002826-55,2,2016-01-12,2016-01-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Associació Per a la Recerca Oncològica (APRO),A randomised Phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium Een gerandomiseerde Fase II/III studie met cabazitax...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002826-55,0,0,0 2012-002828-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fakultní nemocnice u sv. Anny v Brně,"RANDOMIZED, MULTICENTRIC STUDY COMPARING THE EFFECT OF TWO REGIMENS OF COMBINED IMMUNOSUPPRESIVE THERAPY IN THE TREATMENT OF INFLAMMATORY CARDIOMYOPATHY CZECH-ICIT (CZECH INFLAMMATORY CARDIOMYOPATHY I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002828-33,0,0,0 2012-002834-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMCG,"Evaluation of the effects of the addition of atropine during propofol/remifentanil induction of anesthesia on hemodynamics, microvascular blood flow and tissue oxygenenation in patients undergoing oph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002834-36,0,0,0 2012-002835-27,1,2013-01-07,2013-01-07,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Dr. Ritsert Pharma,"Double-blind, randomized clinical study to determine the efficacy of Anestherit® 10% on histamine-induced pruritus and UVB-light induced slight sunburn in healthy subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002835-27,0,0,0 2012-002836-97,1,2014-08-27,2014-08-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Tartu University Hospital,"Pharmacokinetics of penicillin, ampicillin and gentamicin in near- term and full-term neonates Ampitsilliini, penitsilliini ja gentamütsiini farmakokineetika vastsündinutel gestatsioonivanusega üle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002836-97,0,0,0 2012-002839-28,7,2016-01-21,2016-03-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A long-term, randomised, double-blind, placebo-controlled, multinational, multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002839-28,0,0,0 2012-002840-26,8,2014-03-03,2014-03-04,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,UCB Biosciences GmbH,"A MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PHASE 4 STUDY TO EVALUATE THE EFFICACY OF ROTIGOTINE ON PARKINSON’S DISEASE-ASSOCIATED APATHY, MOTOR SYMPTOMS, AND MOOD STUDIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002840-26,0,0,0 2012-002840-26,8,2014-03-03,2014-03-04,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,UCB BIOSCIENCES GMBH,"A MULTICENTER, MULTINATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM, PHASE 4 STUDY TO EVALUATE THE EFFICACY OF ROTIGOTINE ON PARKINSON’S DISEASE-ASSOCIATED APATHY, MOTOR SYMPTOMS, AND MOOD STUDIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002840-26,0,0,0 2012-002841-39,3,2021-04-28,2021-04-28,1,0,0,0,0,1,2,0,0,2,0,0,0,0,0,ARCAGY,"A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with relapse...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002841-39,1,0,0 2012-002841-39,3,2021-04-28,2021-04-28,1,0,0,0,0,1,2,0,0,2,0,0,0,0,0,ARCAGY GINECO,"A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with relapse...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002841-39,1,0,0 2012-002841-39,3,2021-04-28,2021-04-28,1,0,0,0,0,1,2,0,0,2,0,0,0,0,0,ARCAGY-GINECO,"A randomized, open label, phase II trial of bevacizumab plus weekly paclitaxel followed by bevacizumab monotherapy maintenance versus weekly paclitaxel followed by observation in patients with relapse...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002841-39,1,0,0 2012-002843-11,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Eisai Limited,"A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Earl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002843-11,0,0,0 2012-002844-25,1,2015-07-01,2015-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Palle Toft,The effect of Phrenic nerve blokade on acute and chronic shoulder pain in patients for lobectomy and pneumonectomy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002844-25,0,0,0 2012-002845-40,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Spirig Pharma AG,"Bi-center, open label, non-comparative trial exploring efficacy and safety of topical resiquimod gel (0.06%) in patients with nodular basal cell carcinoma (nBCC). Bizentrischer, offener, nicht-verg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002845-40,0,0,0 2012-002847-28,8,2016-05-18,2016-05-18,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TauRx Therapeutics Ltd,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild Alzheimer?s Disease Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002847-28,0,0,0 2012-002852-17,7,2016-03-23,2017-03-23,3,1,0,0,0,1,3,0,0,1,1,1,1,0,0,EORTC,"A PHASE III RANDOMIZED TRIAL OF GEMCITABINE (NSC# 613327) PLUS DOCETAXEL (NSC# 628503) FOLLOWED BY DOXORUBICIN (NSC# 123127) V. OBSERVATION FOR UTERUS-LIMITED, HIGH GRADE UTERINE LEIOMYOSARCOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002852-17,0,0,0 2012-002854-21,5,2013-03-11,2013-03-13,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Novartis Pharma Service AG,A 26-week multi-center randomized double-blind study to compare efficacy and safety of NVA237 versus placebo as an add-on to maintenance therapy with fixed-dose combination salmeterol/fluticasone prop...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002854-21,0,0,0 2012-002856-18,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU de Brest,ALdosterone antagonist Chronic HEModialysis Interventional Survival Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002856-18,0,0,0 2012-002857-41,1,2017-01-23,2017-01-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Universitätsklinik für Innere Medizin III, Medizinische Universität Wien",Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study) Bortezomib bei später Antikörper-mediierten Nierentransplantatabstoßung (BORTEJECT Studie),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002857-41,0,0,0 2012-002859-42,4,2016-08-04,2016-08-04,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multi-centre, double-blind, placebo controlled, proof of concept study to evaluate the efficacy and tolerability of BAF312 in patients with polymyositis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002859-42,0,0,0 2012-002862-11,13,2018-06-06,2018-06-06,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cubist Pharmaceuticals LLC, an indirect wholly-owned subsidiary of Merck Sharp & Dohme Corp.","A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated No...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002862-11,0,0,0 2012-002862-11,13,2018-06-06,2018-06-06,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cubist Pharmaceuticals, Inc","A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated No...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002862-11,0,0,0 2012-002862-11,13,2018-06-06,2018-06-06,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Cubist Pharmaceuticals LLC,"A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated No...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002862-11,0,0,0 2012-002862-11,13,2018-06-06,2018-06-06,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cubist Pharmaceuticals, Inc.","A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated No...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002862-11,0,0,0 2012-002862-11,13,2018-06-06,2018-06-06,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CUBIST PHARMACEUTICALS INC.,"A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated No...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002862-11,0,0,0 2012-002862-11,13,2018-06-06,2018-06-06,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cubist Pharmaceuticals LLC, an indirect wholly-owned subsidiary of Merck & Co.,Inc.","A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated No...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002862-11,0,0,0 2012-002862-11,13,2018-06-06,2018-06-06,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Cubist Pharmaceuticals GmbH,"A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated No...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002862-11,0,0,0 2012-002863-88,2,2014-01-22,2014-01-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO PHARMA A/S,A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen with Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas with Actinic Keratosis on Face/Scalp and Trunk/Extremities Un reg...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002863-88,0,0,0 2012-002866-11,5,2015-11-30,2015-11-30,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TauRx Therapeutics Ltd,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002866-11,0,0,0 2012-002867-86,1,2015-08-27,2015-08-27,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Statens Serum Institut,"Pneumococcal vaccination of Crohn patients - A randomized, non-blinded phase 4 clinical trial with the purpose of investigating the immune response against two different pneumococcal vaccines in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002867-86,0,0,0 2012-002870-30,1,2016-04-09,2016-04-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maint...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002870-30,0,0,0 2012-002871-32,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,Turku University hospital,Effects of rifampicin on the pharmacokinetics and pharmacodynamics of sublingual and intravenous buprenorphine: A four-phase cross-over study in healthy subjects.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002871-32,0,0,0 2012-002872-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Hyperthermic intra-peritoneal chemotherapy (HIPEC) in Ovarian cancer recurrence: Randomized trial on Survival Evaluation. Chirurgia e chemioipertermia intraperitoneale (HIPEC) versus sola Chirurgi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002872-15,0,0,0 2012-002873-77,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"University Medical Center Groningen, Department of Genetics",The effect of intranasal insulin on development and behaviour of children with Phelan-McDermid syndrome Het effect van intranasale insuline op ontwikkeling en gedrag van kinderen met het Phelan-McD...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002873-77,0,0,0 2012-002874-30,1,2014-12-31,2014-12-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Queen Mary University of London,AN OPEN LABEL RANDOMISED PHASE II STUDY COMPARING AZD2014 VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED METASTATIC RENAL CANCER AND PROGRESSION ON VEGF TARGETED THERAPY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002874-30,0,0,0 2012-002876-15,1,2015-03-01,2015-03-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Cassella-med GmbH & Co KG,"A randomised, multi-centre, parallel group, double-blind, placebo- and active-controlled clinical study to assess the efficacy and safety of Octenidine lozenges in the treatment of acute sore throat.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002876-15,0,0,0 2012-002877-71,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,European Commission FP7 Health 2010,"cGMP Enhancing Therapeutic Strategy for HFpEF: The cGETS Study An interventional, single blind, multicentre study. cGMP verhogende strategieën bij HFpEF: De cGETS Studie. Een interventionele, enke...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002877-71,0,0,0 2012-002879-34,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,Radboud University Nijmegen Medical Centre,Vaccination with minor histocompatibility antigen-loaded donor DC vaccines to boost graft-versus-tumor immunity after allogeneic stem cell transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002879-34,0,0,0 2012-002880-86,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Liverpool Heart and Chest Hospital NHS Trust,PRESERVING ΒETA-CELLS: ‘RESTING THE PANCREAS’ IN CYSTIC FIBROSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002880-86,0,0,0 2012-002882-37,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA,A comparison of reduced-dose prasugrel and clopidogrel in elderly patients with acute coronary syndrome undergoing early PCI Confronto tra prasugrel a dose ridotta e clopidogrel in pazienti anziani...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002882-37,0,0,0 2012-002887-29,1,2015-01-26,2015-01-26,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Cologne,Translational therapy in patients with Osteogenesis imperfecta - a pilot trial on treatment with the RANKL-antibody Denosumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002887-29,0,0,0 2012-002888-10,6,2019-02-21,2019-02-21,6,1,0,1,0,2,1,0,0,1,1,0,0,0,1,PCI BIOTECH AS,"A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex-induced Photochemical Internalisation (PCI) of Gemcitabine followed by Gemcitabine/Cisplatin Chemotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002888-10,0,0,0 2012-002888-10,6,2019-02-21,2019-02-21,6,1,0,1,0,2,1,0,0,1,1,0,0,0,1,PCI Biotech AS,"A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex-induced Photochemical Internalisation (PCI) of Gemcitabine followed by Gemcitabine/Cisplatin Chemotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002888-10,0,0,0 2012-002889-12,1,2013-10-10,2013-10-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Pär I Johansson,The effect of intraoperative low dose adrenaline on bleeding in total hip arthroplasty - a randomized placebo-controlled trial Evaluering af intraoperativ administration af lavdosis adrenalin på in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002889-12,0,0,0 2012-002890-71,1,2015-12-22,2015-12-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Flemming Bendtsen,Intestinal decontamination with rifaximin. Effects on the inflammatory and circulatory state in patients with cirrhosis and ascites - A randomised controlled clinical study Effekt af Rifaximin på...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002890-71,0,0,0 2012-002891-15,1,2017-04-20,2017-04-20,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,VU University Medical Center,Phase II study of sunitinib rechallenge in patients with metastatic renal cell carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002891-15,0,0,0 2012-002895-15,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Fundación Oftalmológica del Mediterráneo,Prophylactic effect of brimonidine on bleeding subconjunctival in 23G vitrectomy Efecto profiláctico de la brimonidina sobre la hemoarragia subconjuntival en la vitrectomía de 23G,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002895-15,0,0,0 2012-002896-32,2,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,AstraZeneca AB,"A multicenter, double-blind, placebo-controlled, pharmacokinetic, pharmacodynamic, safety and tolerability study in patients aged 12 to <18 years of age with a central venous catheter to support predi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002896-32,0,0,0 2012-002899-14,3,2014-04-08,2015-04-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, active-controlled, multicenter, 52-week study to evaluate the safety and efficacy of an LCZ696 regimen on arterial stiffness through assessment of central blood pressure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002899-14,0,0,0 2012-002899-14,3,2014-04-08,2015-04-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmaceutica S.A,"A randomized, double-blind, active-controlled, multicenter, 52-week study to evaluate the safety and efficacy of an LCZ696 regimen on arterial stiffness through assessment of central blood pressure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002899-14,0,0,0 2012-002899-14,3,2014-04-08,2015-04-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, active-controlled, multicenter, 52-week study to evaluate the safety and efficacy of an LCZ696 regimen on arterial stiffness through assessment of central blood pressure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002899-14,0,0,0 2012-002900-42,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,AstraZeneca AB,"A randomised, double-blind placebo- and active-controlled, multi-centre, 6-way cross-over, single-dose phase IIa study to investigate the bronchodilatory and systemic effects of 4 different doses of i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002900-42,0,0,0 2012-002903-16,1,2014-02-06,2014-02-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Convergence Pharmaceuticals Ltd,"A randomised, double-blind, crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in patients with post-herpetic neuralgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002903-16,0,0,0 2012-002911-24,2,2014-12-02,2014-12-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Protocol H9X-MC-GBDG A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Patients with Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AW...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002911-24,0,0,0 2012-002916-16,4,2018-03-26,2018-03-26,4,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, open-label, Phase IV study to investigate the management of pasireotide-induced hyperglycemia with incretin based therapy or insulin in adult patients with Cushing’s diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002916-16,0,0,0 2012-002917-20,2,2014-03-24,2014-03-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A multi-centre, randomised, double-blind, placebo-controlled, dose ranging study to evaluate the safety and efficacy of GSK2586184 in patients with chronic plaque psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002917-20,0,0,0 2012-002920-33,2,2016-05-11,2017-12-01,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Cerus Corporation,A Randomized Controlled Study to Evaluate Efficacy and Safety of S-303 Treated Red Blood Cells in Subjects with Thalassemia Major Requiring Chronic RBC Transfusion Studio controllato randomizzato...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002920-33,0,0,0 2012-002920-33,2,2016-05-11,2017-12-01,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,CERUS CORPORATION,A Randomized Controlled Study to Evaluate Efficacy and Safety of S-303 Treated Red Blood Cells in Subjects with Thalassemia Major Requiring Chronic RBC Transfusion Studio controllato randomizzato...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002920-33,0,0,0 2012-002925-30,1,2013-02-06,2013-02-06,1,1,0,0,1,0,3,0,1,1,0,0,1,0,0,University Ghent,The influence of oxytocin on automatic imitation De invloed van oxytocine op automatische imitatie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002925-30,0,0,0 2012-002927-14,1,2018-06-14,2018-06-14,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Ghent,Dosistitratie van lisinopril bij kinderen van 1 tot 18 jaar met primaire of secundaire hypertensie Dosistitratie van lisinopril bij kinderen van 1 tot 18 jaar met primaire of secundaire hypertensie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002927-14,0,0,0 2012-002933-12,1,2017-04-05,2017-04-05,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"University College London,","A Phase II pilot study to explore treatment with Sodium Valproate in Adults with McArdle Disease (Glycogen Storage Disorder Type V, GSDV)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002933-12,0,0,0 2012-002934-35,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Västra Götaland Regionen,NOPHO-DBH AML 2012 Protocol Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years NOPHO-DBH AML 2012 protokoll. Forskningsstudie för behandling av barn ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002934-35,0,0,0 2012-002935-27,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Maastricht University Medical Center,Diagnostic value of novel MR imaging techniques for the primary staging and restaging of rectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002935-27,0,0,0 2012-002938-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,DR. JAVIER ANIDO RUBIO,"NA COMPARACIÓN DE LA EFICACIA Y DURACIÓN DEL EFECTO CLÍNICO DE ONABOTULINUMTOXINA A, INCOBOTULINUMTOXINA A Y ABOBOTULINUMTOXINA A PARA EL TRATAMIENTO DE LAS LÍNEAS GLABELARES DE MODERADAS A PROFUND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002938-37,0,0,0 2012-002940-26,16,2022-02-13,2022-02-13,8,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002940-26,1,0,0 2012-002940-26,16,2022-02-13,2022-02-13,8,0,0,0,0,0,3,0,0,2,0,0,0,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002940-26,1,0,0 2012-002943-11,4,2014-01-28,2014-01-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,"Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus oxycodone/naloxone PR in non-opioid pre-treated subjects with uncontrolled severe chronic low back pain with a neuropa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002943-11,0,0,0 2012-002944-25,4,2018-03-02,2018-06-14,3,1,0,0,0,0,3,0,0,1,1,0,1,0,0,"St James's Hospital, Dublin","EuroHYP-1: European multicentre, randomised, phase III clinical trial of therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke Euro-HYP:...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002944-25,0,0,0 2012-002944-25,4,2018-03-02,2018-06-14,3,1,0,0,0,0,3,0,0,1,1,0,1,0,0,UNIVERSITY HOSPITAL ERLANGEN,"EuroHYP-1: European multicentre, randomised, phase III clinical trial of therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke Euro-HYP:...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002944-25,0,0,0 2012-002944-25,4,2018-03-02,2018-06-14,3,1,0,0,0,0,3,0,0,1,1,0,1,0,0,University Hospital Erlangen,"EuroHYP-1: European multicentre, randomised, phase III clinical trial of therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke Euro-HYP:...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002944-25,0,0,0 2012-002944-25,4,2018-03-02,2018-06-14,3,1,0,0,0,0,3,0,0,1,1,0,1,0,0,Universitätsklinikum Erlangen,"EuroHYP-1: European multicentre, randomised, phase III clinical trial of therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke Euro-HYP:...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002944-25,0,0,0 2012-002945-40,5,2016-10-18,2016-10-18,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim International GmbH,"Efficacy, safety and immunogenicity of BI 695501 versus adalimumab in patients with active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, active comparator trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002945-40,0,0,0 2012-002947-74,1,2014-01-01,2014-01-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Medizinische Universität Wien,"A prospective randomized, double blind, placebo-controlled, cross-over study to investigate the analgesic effect of Aspirin® to prevent the pain during the treatment with capsaicin patch 8% (Qutenza®)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002947-74,0,0,0 2012-002948-24,6,2015-05-14,2015-05-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Amgen, Inc.","An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment with AMG 785 in Postmenopausal Women with Osteoporosis Previously Treated with Bisphosphonate Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002948-24,0,0,0 2012-002952-17,1,2017-07-05,2017-07-05,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,University of Oxford,Effects of intravenous iron on hypoxic pulmonary responses in COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002952-17,0,0,0 2012-002954-21,3,2014-07-10,2014-07-10,1,1,0,0,2,0,2,0,0,1,1,1,1,0,1,Janssen-Cilag International N.V.,"An exploratory, blinded, randomized, placebo-controlled study in subjects with depressive disorder to investigate the effect of minocycline on relapse after successful intravenous ketamine/minocycline...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002954-21,0,0,0 2012-002956-18,2,2014-06-20,2014-06-20,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Ardea Biosciences, Inc.",A Long-Term Open-Label Extension Study for Subjects Completing a Phase 3 Efficacy and Safety Study of Lesinurad Monotherapy in Subjects with Gout,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002956-18,0,0,0 2012-002957-42,12,2016-05-04,2016-05-04,10,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Merck KGaA,"A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002957-42,0,0,0 2012-002957-42,12,2016-05-04,2016-05-04,10,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Threshold Pharmaceuticals,"A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002957-42,0,0,0 2012-002961-36,1,2014-05-23,2014-05-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis recherche et développement,"Phase II two stage dose finding run-in study of SAR3419, an anti-CD19 antibody-maytansine conjugate,administered as a single agent by intravenous infusion in patients with relapsed or Refractory Acute...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002961-36,0,0,0 2012-002962-11,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Interessenverband zur Qualitätsicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland (IQUO) e.V.,Optimizing Pazopanib Exposure in RCC Patients through Therapeutic Drug Monitoring Followed by Intrapatient Dose Escalation Optimierung der Pazopanib Exposition bei Patienten mit Nierenzellkarzinom ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002962-11,0,0,0 2012-002966-11,3,2016-05-20,2016-05-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Biologicals s.a.,"A phase II/III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the immunogenicity and safety of GSK Biologicals? herpes zoster HZ/su candidate vaccine when admin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002966-11,0,0,0 2012-002966-11,3,2016-05-20,2016-05-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II/III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the immunogenicity and safety of GSK Biologicals? herpes zoster HZ/su candidate vaccine when admin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002966-11,0,0,0 2012-002966-11,3,2016-05-20,2016-05-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A phase II/III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the immunogenicity and safety of GSK Biologicals? herpes zoster HZ/su candidate vaccine when admin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002966-11,0,0,0 2012-002968-27,4,2013-12-09,2014-05-07,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 48-week, double-blind, randomized, multi-center, parallelgroup study comparing structural changes in the retina and evolution of visual function after immediate versus delayed treatment with fingoli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002968-27,0,0,0 2012-002968-27,4,2013-12-09,2014-05-07,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farma,"A 48-week, double-blind, randomized, multi-center, parallelgroup study comparing structural changes in the retina and evolution of visual function after immediate versus delayed treatment with fingoli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002968-27,0,0,0 2012-002968-27,4,2013-12-09,2014-05-07,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmaceutica, S.A","A 48-week, double-blind, randomized, multi-center, parallelgroup study comparing structural changes in the retina and evolution of visual function after immediate versus delayed treatment with fingoli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002968-27,0,0,0 2012-002969-35,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Imperial College,Slow-wave sleep and daytime functioning in chronic fatigue syndrome: effects of sodium oxybate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002969-35,0,0,0 2012-002981-11,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,"Medizinische Universität Wien, Klinik für Innere Medizin III, Abteilung für Gastroenterologie und Hepatologie","Iron Deficiency, Platelet Phenotype and Thromboembolism in Cancer Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002981-11,0,0,0 2012-002988-10,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación para la investigacion Biomedica,"Randomized, double-blind, placebo-controlled trial to compare the effect, three months of follow-on pulse pressure and vascular function of isosorbide mononitrate extended release, associated with ant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002988-10,0,0,0 2012-002991-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,MR-imaging to diagnose endometriosis using Ablavar ® as contrast agent – a feasibility study’ MR-beeldvorming van endometriose met behulp van Ablavar ® als contrastmiddel diagnose - een haalbaarhei...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002991-15,0,0,0 2012-002992-33,6,2021-03-10,2021-03-10,3,1,0,0,0,2,3,0,0,2,0,0,0,0,1,Eisai Limited,"A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002992-33,1,0,0 2012-002993-29,1,2017-05-26,2017-05-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott Laboratories GmbH,"A Randomized, Open-label, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg daily versus Crinone 8% intravaginal progesterone gel 90 mg daily for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002993-29,0,0,0 2012-002996-32,1,2013-05-22,2013-05-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,IBSA Institut Biochimique S.A.,"Preliminary evaluation of the efficacy and local tolerability of Injectable Diclofenac at 5, 12.5, 25 and 50 mg/mL, administered locally prior to surgery for the prevention of post-operative pain afte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002996-32,0,0,0 2012-002998-62,1,2013-10-30,2013-10-30,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,Takeda Pharma A/S,"A Randomized, Single-Center, Observer-Blind, Vehicle- and Active Comparator-Controlled Phase 1b Study to Assess the Effect and Local Safety and Tolerability Of Roflumilast and BYK321084 – Phosphodiest...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002998-62,0,0,0 2012-003000-12,1,2014-03-18,2014-03-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Pharma A/S,"A Phase 2a, 15-Day, Randomized, Parallel Group, Double-Blind, Multi-Centre, Vehicle Controlled Trial to Assess the Efficacy and Local Safety of a Cream Containing 0.5% Roflumilast - a Phosphodiesteras...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003000-12,0,0,0 2012-003005-10,4,2021-04-25,2021-04-25,2,0,0,0,0,2,2,0,0,2,0,0,0,0,0,Gustave Roussy,"PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003005-10,1,0,0 2012-003005-10,4,2021-04-25,2021-04-25,2,0,0,0,0,2,2,0,0,2,0,0,0,0,0,Institut de cancérologie Gustave Roussy,"PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003005-10,1,0,0 2012-003006-27,2,2013-07-30,2013-07-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Glycotope GmbH,"A Phase II, Multicentre, Multinational, Randomised, Assessor-Blind Trial to Investigate the Efficacy and Safety of Various Dosages of FSH-GEX™ in Comparison With 150 IU Gonal-f® in Women Undergoing IC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003006-27,0,0,0 2012-003007-35,2,2014-03-17,2014-04-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,Bimatoprost in the Treatment of Eyelash Hypotrichosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003007-35,0,0,0 2012-003008-11,12,2019-07-21,2019-07-21,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffman-La Roche Ltd.,"A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR ME...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003008-11,0,0,0 2012-003008-11,12,2019-07-21,2019-07-21,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB VERSUS VEMURAFENIB PLUS GDC-0973 IN PREVIOUSLY UNTREATED BRAFV600-MUTATION POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR ME...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003008-11,0,0,0 2012-003009-88,4,2014-12-03,2014-12-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Daiichi Sankyo Development Ltd,"A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, MULTI-CENTER STUDY OF ADDING EDOXABAN OR CLOPIDOGREL TO ASPIRIN TO MAINTAIN PATENCY IN SUBJECTS WITH PERIPHERAL ARTERIAL DISEASE FOLLOWING FEMOROPOPLITEAL END...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003009-88,0,0,0 2012-003010-14,4,2013-07-17,2014-03-24,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003010-14,0,0,0 2012-003011-58,4,2012-07-02,2013-07-29,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003011-58,0,0,0 2012-003011-58,4,2012-07-02,2013-07-29,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003011-58,0,0,0 2012-003012-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,DIRECTION CENTRALE DU SERVICE DE SANTE DES ARMEES,Cardiovascular effects of esmolol alone and in combination with levosimendan during septic shock Effets cardiovasculaires associés à l'administration d'esmolol seul et en association au lévosimenda...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003012-31,0,0,0 2012-003023-38,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,Friedrich-Schiller-Universität Jena,"Phase II study of Bortezomib, Melphalan, Prednisone (VMP) followed by Lenalidomide maintenance vs. VMP without maintenance in Myeloma patients not eligible to high-dose chemotherapy and autologous ste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003023-38,0,0,0 2012-003025-25,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, double-blind, randomized, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered intramuscularly accor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003025-25,0,1,1 2012-003026-25,1,2016-08-17,2016-08-17,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Health Protection Agency,A phase IV study to evaluate the primary and booster immune responses of UK infants receiving a licensed 6-in-1 DTaP/IPV/Hib/HBV vaccine(Infanrix-Hexa™) with a 13-valent pneumococcal conjugate vaccine...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003026-25,0,0,0 2012-003029-11,1,2013-11-22,2013-11-22,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Steen Stender,"Ethyl ester Versus Triglyceride formulations of long chained omega-3 fatty acids in moderate hypertriglyceridemia - a randomized placebo-controlled clinical trial (EVT) Et dobbelt-blindt, placebo-k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003029-11,0,0,0 2012-003030-17,8,2019-01-31,2019-01-31,4,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003030-17,1,1,0 2012-003032-22,12,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,St. Anna Kinderkrebsforschung,ALL SCTped 2012 FORUM Allogeneic Stem Cell Transplantation in Children and Adolesecents with Acute Lymphoblastic Leukaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003032-22,0,0,0 2012-003032-22,12,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,ST.Anna Kinderkrebsforschung,ALL SCTped 2012 FORUM Allogeneic Stem Cell Transplantation in Children and Adolesecents with Acute Lymphoblastic Leukaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003032-22,0,0,0 2012-003033-42,1,2018-03-21,2018-03-21,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,Universitätsklinikum Erlangen,"Prospective, open-label, multicentre clinical trial, phase I/IIa, to investigate the safety and tolerability of allogeneic B-cell concentrates CD3+-depleted, CD19+-enriched, cryopreserved (single admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003033-42,0,0,0 2012-003034-16,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,University Hospital Olomouc,Antiarrhythmic and antiremodelation effects of ivabradin in ICD carriers Antiarytmické a antiremodelační účinky ivabradinu u nositelů ICD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003034-16,0,0,0 2012-003037-41,1,2012-09-21,2012-09-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klinische Abteilung für Lungenkrankheiten",Effects of Roflumilast on pulmonary vascular resistance in patients with COPD and sleep apnea (Overlap Syndrome) with and without non-invasive ventilation. A Pilot Study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003037-41,0,0,0 2012-003038-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Tratamiento de Tumores de Cabeza y Cuello,Ensayo de fase II de un régimen secuencial de quimioterapia de inducción con panitumumab y paclitaxel seguida de radioterapia más panitumumab en pacientes con cáncer de cabeza y cuello localmente avan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003038-17,0,0,0 2012-003043-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",A multicenter study in patients with stage III-IV epithelial ovarian cancer treated with carboplatin/paclitaxel with bevacizumab: clinical and biological prognostic factors Studio multicentrico in ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003043-29,0,0,0 2012-003052-37,1,2013-07-08,2013-07-08,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Norgine Ltd,Pharmacodynamic and clinical evaluation of dose and taste-optimised low volume PEG-based bowel cleansing solutions using the split-dosing intake regimen in healthy subjects and in subjects undergoing ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003052-37,0,0,0 2012-003054-92,4,,,0,1,0,0,0,1,3,0,0,1,1,1,0,1,1,"Novartis Farmaceutica, S.A.","An open-label, multi-arm, non-comparative safety and tolerability study of canakinumab (ACZ885) in patients with active Systemic Juvenile Idiopathic Arthritis (SJIA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003054-92,0,0,0 2012-003054-92,4,,,0,1,0,0,0,1,3,0,0,1,1,1,0,1,1,Novartis Pharma Services AG,"An open-label, multi-arm, non-comparative safety and tolerability study of canakinumab (ACZ885) in patients with active Systemic Juvenile Idiopathic Arthritis (SJIA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003054-92,0,0,0 2012-003056-36,20,2022-09-28,2022-09-28,1,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003056-36,1,0,0 2012-003056-36,20,2022-09-28,2022-09-28,1,0,1,0,0,0,3,0,0,2,1,0,0,0,1,NOVARTIS FARMA,"A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003056-36,1,0,0 2012-003056-36,20,2022-09-28,2022-09-28,1,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Farmacéutica S.A,"A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003056-36,1,0,0 2012-003057-29,3,2014-09-30,2014-09-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Xencor Inc.,"A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, ASCENDING MULTIPLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XMAB®5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003057-29,0,0,0 2012-003058-10,6,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,0,ETOP IBCSG Partners Foundation,A randomized phase II study evaluating different schedules of nab-Paclitaxel in metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003058-10,0,0,0 2012-003058-10,6,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,0,International Breast Cancer Study Group (IBCSG),A randomized phase II study evaluating different schedules of nab-Paclitaxel in metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003058-10,0,0,0 2012-003064-47,1,2012-11-30,2012-11-30,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Curis, Inc.","A Phase 1 open-label study to investigate the pharmacodynamics, metabolomics and pharmacokinetics of CUDC-101 in subjects with HER2 positive invasive breast cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003064-47,0,0,0 2012-003065-17,6,2021-01-13,2021-01-13,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive HER2 negative metastatic or locally advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003065-17,1,0,0 2012-003065-17,6,2021-01-13,2021-01-13,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A.,"An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive HER2 negative metastatic or locally advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003065-17,1,0,0 2012-003066-40,9,2016-10-05,2016-10-05,6,1,1,0,0,1,0,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A Phase II, multi-center, open-label, single-arm study of the efficacy and safety of oral LDE225 in patients with Hh-pathway activated relapsed medulloblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003066-40,0,0,0 2012-003066-40,9,2016-10-05,2016-10-05,6,1,1,0,0,1,0,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,"A Phase II, multi-center, open-label, single-arm study of the efficacy and safety of oral LDE225 in patients with Hh-pathway activated relapsed medulloblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003066-40,0,0,0 2012-003066-40,9,2016-10-05,2016-10-05,6,1,1,0,0,1,0,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"A Phase II, multi-center, open-label, single-arm study of the efficacy and safety of oral LDE225 in patients with Hh-pathway activated relapsed medulloblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003066-40,0,0,0 2012-003067-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,LUMC,Pneumonia treated with rifampicine attenuates inflammation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003067-22,0,0,0 2012-003070-39,4,2014-04-14,2014-04-14,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Cytos Biotechnology AG,"A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients with Moderate to Severe Allergic Asthma not Sufficiently Controlled on Current Standard Ther...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003070-39,0,0,0 2012-003072-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Academic Medical Center, University of Amsterdam",Oxytocin in PTSD: effectiveness as addition to Narrative Exposure Therapy Oxytocine bij PTSS: Effectiviteit als toevoeging bij Narratieve exposure therapie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003072-39,0,0,0 2012-003073-26,12,2016-10-20,2016-10-20,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003073-26,0,0,0 2012-003076-39,3,2015-01-28,2015-01-28,2,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Bioprojet,"A randomized, double blind study comparing BF2.649 (Pitolisant) to placebo in two parallel groups on the weekly frequency of cataplexy attacks and Excessive Daytime Sleepiness in narcoleptic patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003076-39,1,0,0 2012-003077-26,1,2014-03-14,2014-03-14,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Neurology, Odense University Hospital",Topical lidocaine for the treatment of focal peripheral neuropathic pain: response in relation to pain phenotype Topikalt lidokain til fokal perifer neuropatisk smerte: respons i forhold til fænoty...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003077-26,0,0,0 2012-003079-20,1,2014-12-24,2014-12-24,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"AVID RADIOPHARMACEUTICALS, INC.",Evaluation of florbetapir (18F) PET in subjects participating in the IRCCSFBF protocol Valutazione della scansione PET con florbetapir (18F) nei soggetti partecipanti al protocollo IRCCS-FBF,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003079-20,0,0,0 2012-003088-23,6,2014-09-24,2014-09-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Adults with Genotype 1 Chronic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003088-23,0,0,0 2012-003088-23,6,2014-09-24,2014-09-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Adults with Genotype 1 Chronic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003088-23,0,0,0 2012-003088-23,6,2014-09-24,2014-09-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ABBOTT GMBH & Co. KG,"A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Adults with Genotype 1 Chronic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003088-23,0,0,0 2012-003090-26,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,TECNIMEDE ? SOCIEDADE TÉCNICO MEDICINAL S.A.,STUDY TO EVALUATE THE PROPORTIONALITY OF 3 ORAL DOSES OF PIRLINDOLE IN HEALTHY VOLUNTEERS. Estudio para evaluar la proporcionalidad de 3 dosis de pirlindol administrado por vía oral en voluntarios ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003090-26,0,0,0 2012-003092-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA,Reinduction protocol for patients with high-risk neuroblastoma in first relapse Protocollo di reinduzione per pazienti affetti da Neuroblastoma ad alto rischio in prima recidiva,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003092-19,0,0,0 2012-003093-98,1,2016-08-19,2016-08-19,1,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Bio Products Laboratory Limited,"A Phase III Open, Multicentre Study to Confirm the Safety, Pharmacokinetics and Efficacy of BPL’s High Purity Factor X in the Prophylaxis of Bleeding in Factor X Deficient Children Under the Age of 12...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003093-98,0,0,0 2012-003097-45,3,2020-09-21,2020-10-23,3,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Acedemic Medical Center,Phase I/II feasibility study combining Brentuximab Vedotin (Adcetris) with second line salvage chemotherapy (DHAP) in Hodgkin lymphoma patients refractory to first line chemotherapy or in first relaps...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003097-45,0,0,0 2012-003101-10,6,2015-11-03,2015-11-03,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"MedImmune, LLC","A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003101-10,0,0,0 2012-003105-10,2,2013-05-10,2013-06-20,2,1,0,0,0,0,4,0,0,1,1,1,1,0,1,GlaxoSmithKline Research & Development Limited,"Study PTG116878, a Dose-Optimization Study of ezogabine/retigabine Immediate Release Tablets versus Placebo in the Adjunctive Treatment of Subjects with Partial-Onset Seizures.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003105-10,0,0,0 2012-003106-27,1,2013-07-17,2013-07-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared with Fluticasone Propionate/Salmeterol Inh...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003106-27,0,0,0 2012-003110-14,8,2014-10-29,2014-10-29,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or With...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003110-14,0,0,0 2012-003111-58,3,2018-08-07,2018-08-07,2,1,0,0,0,0,3,0,1,1,1,0,1,0,1,Takeda Development Centre Europe Ltd,"A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer’s Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003111-58,0,0,0 2012-003112-31,3,2019-07-11,2019-07-11,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,LEO Pharma A/S,"Risk of Squamous Cell Carcinoma on Skin Areas Treated with Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003112-31,0,0,0 2012-003114-13,1,2017-01-11,2017-01-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,West Hertfordshire Hospitals NHS Trust,Hydroxymethylglutaryl-CoA reductase inhibition with simvastatin in mechanically ventilated patients at high risk of delirium,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003114-13,0,0,0 2012-003120-21,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Groupe Francophone des Myélodysplasies (GFM),"A phaseI-II trial of acadesine in ipss high and int 2 myelodysplastic syndromes, acute myeloid leukemia with 20-30% marrow blasts and chronic myelomonocytic leukemia type 2 not responding to azacitidi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003120-21,0,0,0 2012-003123-38,7,2019-08-30,2019-08-30,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Receptos, Inc.","A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF INDUCTION THERAPY WITH RPC1063 IN PATIENTS WITH MODERATELY TO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003123-38,0,0,0 2012-003123-38,7,2019-08-30,2019-08-30,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Celgene International II Sàrl (CIS II).,"A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF INDUCTION THERAPY WITH RPC1063 IN PATIENTS WITH MODERATELY TO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003123-38,0,0,0 2012-003123-38,7,2019-08-30,2019-08-30,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Celgene International II Sàrl (CIS II),"A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL-GROUP STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF INDUCTION THERAPY WITH RPC1063 IN PATIENTS WITH MODERATELY TO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003123-38,0,0,0 2012-003125-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,A.O. UNIVERSITARIA INTEGRATA DI VERONA,Evaluation of platelet functional response in relation to the bioavailability of clopidogrel in patients with acute coronary syndromes without ST-segment elevation (NSTEACS). Valutazione della risp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003125-24,0,0,0 2012-003126-25,1,2020-03-11,2020-03-11,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Merck KGaA,"An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003126-25,0,0,0 2012-003131-28,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Instituto Palacios,Switching from Oral Bisphosphonates to Bazedoxifene once a day to evaluate effects on BMD in Postmenopausal Women. Evaluación de los efectos en la DMO en mujeres posmenopáusicas tras el cambio de b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003131-28,0,0,0 2012-003132-23,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,3,,Local tumescent anaesthesia with ambulatory phlebectomy according to Muller,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003132-23,0,0,0 2012-003136-23,1,2016-09-22,2016-09-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London,Lamotrigine And Borderline Personality Disorder: Investigating Long-Term Effectiveness,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003136-23,0,0,0 2012-003137-41,1,2012-12-31,2012-12-31,1,1,1,0,0,0,2,0,0,1,0,0,1,0,1,"BIAL - Portela & Ca, S.A.",DOUBLE-BLIND STUDY IN PAEDIATRIC EPILEPTIC SUBJECTS AGED FROM 5 TO LESS THAN 8 YEARS TO COMPARE THE SUBJECT PREFERENCE FOR ESL SUSPENSION FORMULATION WITH ALTERNATIVE FLAVOURS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003137-41,0,0,0 2012-003138-17,14,2017-01-06,2017-06-05,10,1,0,0,0,0,0,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A double-blind, placebo-controlled, randomised, Phase II study evaluating the efficacy and safety of addition of continuous multiple line bevacizumab treatment to lomustine in second (2nd)-line follow...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003138-17,0,0,0 2012-003138-17,14,2017-01-06,2017-06-05,10,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Roche Farma, S.A en nombre de F. Hoffmann-La Roche Ltd","A double-blind, placebo-controlled, randomised, Phase II study evaluating the efficacy and safety of addition of continuous multiple line bevacizumab treatment to lomustine in second (2nd)-line follow...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003138-17,0,0,0 2012-003139-50,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University of Bergen, Faculty of medicin and dentistry, Dep. of Clinical Dentistry","International, multicenter phase II uncontrolled prospective clinical trial: Jaw bone reconstruction using a combination of biomaterial and autologous mesenchymal stem cells prior to dental implant p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003139-50,0,0,0 2012-003140-68,1,2014-01-17,2014-01-17,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,MSD,A Pharmacokinetic Analysis of Posaconazole in the Plasma and Alveolar Compartment of Lung Transplant Recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003140-68,0,0,0 2012-003141-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,VU University Medical Center,Efficacy and feasibility of first-line treatment with risk-adapted dose-adjusted EPOCH-R (DA-EPOCH-R) in patients with Burkitt lymphoma. A phase II clinical trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003141-16,0,0,0 2012-003144-80,13,2020-02-17,2020-02-17,10,1,0,0,0,0,4,0,0,1,0,0,1,0,1,F. Hoffman-La Roche Ltd.,"A PHASE IV, POSTMARKETING, OPEN-LABEL, EXTENSION (ROLLOVER) STUDY OF VEMURAFENIB IN PATIENTS WITH BRAFV600 MUTATION?POSITIVE MALIGNANCIES PREVIOUSLY ENROLLED IN AN ANTECEDENT VEMURAFENIB PROTOCOL E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003144-80,0,0,0 2012-003146-32,1,2016-12-18,2016-12-18,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Hull and East Yorkshire Hospital Trust,A randomised control trial to determine whether a 5 day course of antibiotics is more clinically and cost effective than a 24 hour prophylactic course for the prevention of surgical site infection fol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003146-32,0,0,0 2012-003147-30,3,2014-09-12,2014-09-12,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Antisense Therapeutics Ltd,"A Phase II Randomised, Open-Label, Parallel Group Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Two Subcutaneous Dosing Regimens of ATL1103 in Adult Patients with Acromegaly.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003147-30,0,0,0 2012-003151-11,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE DI MILANO,"An open-label, single-arm, phase II, prospective, pilot study of tocilizumab in patients with Erdheim-Chester disease. Trial clinico pilota di fase II, in aperto, prospettico, a braccio singolo con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003151-11,0,0,0 2012-003152-37,1,2014-03-07,2014-03-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,A randomised trial comparing efficacy and safety after intensification with either insulin aspart once daily as add-on or changing to basal bolus treatment with insulin degludec and insulin aspart in ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003152-37,0,0,0 2012-003155-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZ. USL DI CESENA,Radiometabolic treatment with 90Y-DOTA0-Tyr3]-octreotide (90Y-DOTATOC) or [90Y-DOTA0-Tyr3-Thr8]-octreotate (90Y-DOTATATE)in tumours expressing somatostatin receptors Terapia radiometabolica recetto...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003155-11,0,0,0 2012-003158-10,3,2017-04-28,2018-01-18,2,1,0,0,0,0,3,0,0,2,0,0,0,0,0,The George Institute for Global Health,ADRENAL- ADjunctive coRticosteroid trEatment iN criticAlly ilL patients with septic shock.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003158-10,1,0,0 2012-003159-12,1,2013-12-16,2013-12-16,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,APOGEPHA Arzneimittel GmbH,Efficacy of propiverine hydrochloride extended release (ER) 45 mg in patients with neurogenic detrusor overactivity – an active-controlled single center crossover trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003159-12,0,0,0 2012-003160-44,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,"Orthopaedic Research Laboratory, Århus University Hospital",Treatment of moderate intervertebral disc degeneration with autologous bonemarrow derived mesenchymal stem cells (bMSC): Behandling af moderat intervertebral diskus degeneration med autologe knogle...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003160-44,0,0,0 2012-003162-41,1,2019-07-10,2019-07-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre Léon Bérard,"A randomized, multicenter, open-label, phase II study of the optimal scheme of administration of pazopanib in thyroid carcinoma Etude de phase II randomisée, multicentrique, en ouvert, du schema d'...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003162-41,0,0,0 2012-003164-50,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE DI MILANO,CONTRAST ENHANCED ULTRASOUND (CEUS) IN UVEAL MELANOMA: QUANTITATIVE ASSESSMENT OF TUMOR RESPONSE TO GAMMA KNIFE RADIOSURGERY (GKR) ECOGRAFIA CON MEZZO DI CONTRASTO (CEUS) NEL MELANOMA UVEALE: VALU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003164-50,0,0,0 2012-003169-16,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"Erasmus MC, University Medical Center Rotterdam",Immune monitoring to characterize T-cell responses of kidney transplant patients during co-stimulation blockade by belatacept,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003169-16,0,0,0 2012-003170-60,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,"A multicenter, phase III, randomized study to evaluate the efficacy of a response-adapted strategy to define maintenance after standard chemoimmunotherapy in patients with advanced-stage Follicular Ly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003170-60,0,0,0 2012-003172-39,1,2016-09-30,2016-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Innsbruck, Abteilung für Hygiene und Medizinische Mikrobiologie",Micafungin-Deescaltion study: Evalutating the rate of breakthrough infections of micafungin followed by fluconazole versus fluconazole (or other azoles) in febrile patients Micafungin-Deeskalations...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003172-39,0,0,0 2012-003173-25,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Dr. Andrés Poveda Velasco,"Clinica trial PHASE I-II of LEDC (Liposomal Encapsulated Doxorubicin Cytrate, Myocet®) + CARBOPLATIN IN EPITHELIAL ginecological CANCER Estudio Fase I-II multicéntrico, abierto, de la combinación d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003173-25,0,0,0 2012-003174-83,2,2014-09-09,2015-02-09,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly and Company,A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination with Carboplatin and Etoposide Followed by LY2940680 versus Carboplatin and Etoposide Plus Placebo Fo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003174-83,0,0,0 2012-003176-39,13,2018-01-16,2018-09-24,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biogen Idec Research Limited,"A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003176-39,0,0,0 2012-003176-39,13,2018-01-16,2018-09-24,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BIOGEN IDEC RESEARCH LTD,"A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003176-39,0,0,0 2012-003176-39,13,2018-01-16,2018-09-24,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biogen,"A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003176-39,0,0,0 2012-003178-22,4,2015-12-18,2015-12-18,3,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Astellas Pharma Europe B.V.,"A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose -Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Children...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003178-22,0,0,0 2012-003181-40,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Foundation for Liverdisease,Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: a multicentre randomized phase III clinical trial Voorbehandeling met bestraling...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003181-40,0,0,0 2012-003186-18,6,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A phase II, single arm, open label study of treatment-free remission in Chronic Myeloid Leukemia (CML) chronic phase (CP) patients after achieving sustained MR4.5 on nilotinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003186-18,0,0,0 2012-003186-18,6,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A.,"A phase II, single arm, open label study of treatment-free remission in Chronic Myeloid Leukemia (CML) chronic phase (CP) patients after achieving sustained MR4.5 on nilotinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003186-18,0,0,0 2012-003187-44,3,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,UNICANCER,"Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003187-44,0,0,0 2012-003188-23,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Merja Kokki,Opioidien aiheuttama mahasuolikanavan toiminnanhäiriö keisarileikkauspotilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003188-23,0,0,0 2012-003189-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Merja Kokki,Synnytyskivun lievitykseen käytetyn oksikodonin teho ja turvallisuus ja vaikutukset vastasyntyneeseen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003189-42,0,0,0 2012-003190-26,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,0,ACCORD (Academic and Clinical Central Office for Research & Development),REstart or STop Antithrombotics Randomised Trial (RESTART),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003190-26,0,0,0 2012-003191-39,1,2017-09-27,2017-09-27,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Oxford,The effect of a single-dose of d-cycloserine on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized placebo-controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003191-39,0,0,0 2012-003192-19,4,2019-07-19,2019-07-19,1,1,0,0,0,0,3,0,0,1,1,0,1,0,0,London School Of Hygiene and Tropical Medicine,"Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003192-19,0,0,0 2012-003194-25,2,2017-10-26,2017-10-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mabion S.A.,"Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20® (Mabion SA) Compared to MabThera® (rituximab, Roche) in Patients with Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003194-25,0,0,0 2012-003195-39,6,2019-12-19,2019-12-19,1,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents with Active Polyarticular Juvenile ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003195-39,1,1,0 2012-003197-57,1,2013-08-16,2013-08-16,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Pfizer Worldwide Research and Development,A MULTIPLE DOSE PHARMACOKINETIC OPEN-LABEL STUDY OF PREGABALIN (LYRICA) IN HEALTHY LACTATING WOMEN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003197-57,0,0,0 2012-003201-96,2,2015-12-03,2015-12-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,"A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003201-96,0,0,0 2012-003201-96,2,2015-12-03,2015-12-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003201-96,0,0,0 2012-003205-10,1,2016-07-14,2016-07-14,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Nottingham,A randomised placebo controlled trial of follow on Rifaximin for the prevention of relapse of Clostridium difficile associated diarrhoea.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003205-10,0,0,0 2012-003207-35,1,2014-12-02,2014-12-02,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,Karolinska University Hospital Solna,"Effects of ARA 290, a non-hematopoietic erythropoietin analog, on glucose tolerance, insulin secretion, insulin sensitivity and long-term glucose control in individuals with prediabetes and/or drug-n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003207-35,0,0,0 2012-003208-10,3,2016-01-08,2016-01-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"EnVivo Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003208-10,0,0,0 2012-003208-10,3,2016-01-08,2016-01-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Forum Pharmaceuticals Inc.,"A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003208-10,0,0,0 2012-003208-10,3,2016-01-08,2016-01-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FORUM Pharmaceuticals Inc.,"A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003208-10,0,0,0 2012-003209-92,3,2015-12-10,2015-12-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FORUM Pharmaceuticals Inc.,"A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003209-92,0,0,0 2012-003209-92,3,2015-12-10,2015-12-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Forum Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003209-92,0,0,0 2012-003209-92,3,2015-12-10,2015-12-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"EnVivo Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled, Parallel, 26 Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003209-92,0,0,0 2012-003213-34,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,ISTITUTO CLINICO HUMANITAS,MEthylprednisoloneNacinHepatIcResections “MENHIR” MEthylprednisoloneNacinHepatIcResections 'œMENHIR',https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003213-34,0,0,0 2012-003214-13,1,2017-07-14,2017-07-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003214-13,0,0,0 2012-003215-66,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,FIBio Hospital Universitario Ramón y Cajal,EFFECT OF MARAVIROC ON THE TRANSCRIPTION OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) IN RESTING CD4+ T LYMPHOCYTES IN PATIENTS ON ANTIRETROVIRAL TREATMENT WITH SUPPRESSED VIRAL LOAD EFECTO D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003215-66,0,0,0 2012-003217-33,1,2013-05-15,2013-05-15,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,"Immunological response of a single dose of 100,000 I.U. of cholecalciferol (vitamin D3) Immunologische Wirkungen einer Einmalgabe von 100.000 I.E. Cholecalciferol (Vitamin D3)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003217-33,0,0,0 2012-003218-14,6,2014-08-19,2014-08-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Develco Pharma Schweiz AG,"Randomised, double-blind, placebo-controlled, parallel-group design, multi-centre, dose-escalation phase III trial to investigate the efficacy, safety, and tolerability of Naloxone HCl PR tablets admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003218-14,0,0,0 2012-003219-77,1,2016-06-26,2016-06-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Copenhagen University Hospital, Rigshospitalet",Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Infusion af conivaptan hos patienter med kronisk stabilt hjertesvigt under arbejde,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003219-77,0,0,0 2012-003221-19,5,2016-02-22,2016-02-22,3,1,1,0,0,1,1,0,0,2,0,0,0,0,1,Baxalta Innovations GmbH,"BAX 930 (rADAMTS13) A PHASE 1 PROSPECTIVE, UNCONTROLLED, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS IN HEREDITARY TTP (THROMBOTIC THROMBOCYTOPENIC PURPUR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003221-19,1,1,0 2012-003222-24,1,2016-06-09,2016-06-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU de Clermont-Ferrand,/ Etude prospective de l’influence des faisceaux inhibiteurs descendants de la douleur sur l’efficacité du milnacipran utilisé pour la fibromyalgie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003222-24,0,0,0 2012-003223-38,3,2016-03-14,2016-03-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",EXTENSION STUDY EVALUATING TREATMENT WITH PF-05280586 VERSUS RITUXIMAB IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO HAVE PARTICIPATED IN OTHER PF-05280586 CLINICAL TRIALS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003223-38,0,0,0 2012-003226-25,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Fundacion Publica Andaluza para la Gestion de la Investigacion en Salud de Sevilla,"Phase I, randomized, open design trial to evaluate the effect of food (fasting, fat meal and standard meal) on the pharmacokinetics of abiraterone acetate at reduced doses, compared with conventional-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003226-25,0,0,0 2012-003227-38,2,2015-07-23,2015-07-23,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Merck Serono Ltd,"A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects with Chronic Anovulation Using the Gonal-f® Prefilled Pen in Women Undergoing Ovu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003227-38,0,0,0 2012-003227-38,2,2015-07-23,2015-07-23,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Merck Serono,"A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects with Chronic Anovulation Using the Gonal-f® Prefilled Pen in Women Undergoing Ovu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003227-38,0,0,0 2012-003228-19,5,2015-12-17,2015-12-17,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,FORUM Pharmaceuticals Inc.,"A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist, as an Adj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003228-19,0,0,0 2012-003228-19,5,2015-12-17,2015-12-17,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"FORUM Pharmaceuticals, Inc.","A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist, as an Adj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003228-19,0,0,0 2012-003228-19,5,2015-12-17,2015-12-17,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"EnVivo Pharmaceuticals, Inc.","A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist, as an Adj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003228-19,0,0,0 2012-003228-19,5,2015-12-17,2015-12-17,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Forum Pharmaceuticals Inc.,"A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist, as an Adj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003228-19,0,0,0 2012-003229-91,8,2015-08-06,2015-08-06,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Polyphor AG,"CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI) A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Multi-centre Study of POL6326, a CXCR4 Antago...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003229-91,0,0,0 2012-003230-17,9,2016-12-20,2016-12-20,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A RANDOMIZED, OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE PATIENT PREFERENCE WITH SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CD20+ DIFFU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003230-17,0,0,0 2012-003230-17,9,2016-12-20,2016-12-20,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A RANDOMIZED, OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE PATIENT PREFERENCE WITH SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CD20+ DIFFU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003230-17,0,0,0 2012-003234-16,1,2019-06-05,2019-06-05,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Hannover Medical School represented by Hannover Clinical Trial Center GmbH,Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD – The ABACOPD Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003234-16,0,0,0 2012-003239-47,7,2015-03-19,2015-07-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Interventional, open-label, flexible-dose extension study of aripiprazole once-monthly in patients with schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003239-47,0,0,0 2012-003241-15,1,,,0,0,0,1,0,0,1,1,1,3,0,0,0,0,0,Sheffield Children's NHS Foundation Trust,NeSST2: A multi-stage clinical study to develop a non-invasive Short Synacthen Test (SST) with nasally administered Synacthen and salivary cortisol. The validated non-invasive SST will be used to esta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003241-15,0,0,0 2012-003242-33,3,2017-02-08,2017-02-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY EXTENSION OF PHASE II STUDIES ABE4869g AND ABE4955g IN PATIENTS WITH MILD TO MODERATE ALZHEIMER?S DISEASE ESTUDIO MULTICÉNTRICO, ABIERTO, DE EXTENSIÓN A ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003242-33,0,0,0 2012-003244-76,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Medical University of Vienna,Feasibility of intraoperative hyperthermic intraperitoneal chemotherapy with carboplatin and paclitaxel in patients with advanced epithelial ovarian cancer – a combined phase I / II trial Untersuch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003244-76,0,0,0 2012-003251-11,1,2017-03-31,2017-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Linköping university,Pilot Trial to preserve residual insulin secretion in children and adolescents with recent onset Type 1 diabetes by using GAD-antigen (Diamyd) therapy in combination with Vitamin D and Ibuprofen .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003251-11,0,0,0 2012-003252-37,1,2013-06-18,2013-06-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Aarhus University Hospital, Department of Ophthalmology",The effect of topical anaesthesia on pharmacological mydriasis in patients screened for diabetic retinopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003252-37,0,0,0 2012-003253-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Inmunotek S.L.,"Randomized double-blind placebo-controlled prospective, parallel, multicentre clinical trial of bacterial polivalent vaccine (BACTEK ®)administered by sublingual mucosa in subjects with chronic obst...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003253-28,0,0,0 2012-003255-11,5,2015-03-18,2015-03-18,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,A Study Evaluating the Efficacy and Safety of BOTOX® and Solifenacin in Patients with Overactive Bladder and Urinary Incontinence,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003255-11,0,0,0 2012-003257-29,1,2014-03-02,2014-03-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare (UK),"A randomised, double-blind, multi-centre, placebo controlled parallel group study to evaluate the efficacy and tolerability of a new Ibuprofen patch in patients with acute sports related traumatic blu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003257-29,0,0,0 2012-003262-41,5,2015-12-07,2015-12-10,4,1,0,0,1,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A PHASE II, RANDOMIZED STUDY OF PACLITAXEL WITH GDC-0941 VERSUS PACLITAXEL WITH PLACEBO IN PATIENTS WITH LOCALLY RECURRENT OR METASTATIC BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003262-41,0,0,0 2012-003275-19,3,2013-06-20,2013-06-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pacira Pharmaceuticals, Inc.","A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Intercostal Nerve Block with Liposome Bupivacaine in Subjects Undergoing...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003275-19,0,0,0 2012-003276-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Hæmatologisk afdeling, Roskilde Sygehus, Region Sjælland",Investigation of the value of Iron and Bonemarrow stimulation in differential diagnostic of Polycythemia Vera and Essential Thrombocytosis Jern- og Knoglemarvsstimulationstest i Differentialdiagnos...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003276-39,0,0,0 2012-003280-22,6,2015-08-27,2015-08-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Phase 3 open label study evaluating the efficacy and safety of pegylated interferon lambda-1a, in combination with ribavirin and daclatasvir, for treatment of chronic HCV infection with treatment naïv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003280-22,0,0,0 2012-003281-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitätsklinikum Freiburg,"Efficacy of gencydo nasal spray on early nasal response after allergen exposition in patients with grass pollen allergy: a randomized, placebo controlled cross over study Wirksamkeit von Gencydo Na...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003281-40,0,0,0 2012-003286-18,5,2014-11-10,2014-11-27,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Smith & Nephew Inc.,A Phase 3 Randomized Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers (EU),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003286-18,0,0,0 2012-003289-42,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Academic Medical Center Amsterdam,Randomized Controlled Trial Investigating the Efficacy and Safety of Nebulized Heparin versus Placebo in Burn Patients with Inhalation Trauma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003289-42,0,0,0 2012-003291-38,5,2014-07-04,2014-07-04,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Open-Label, Multicenter Phase II Study of Ipilimumab Retreatment versus Chemotherapy for Subjects with Advanced Melanoma who Progressed after Initially Achieving Disease Control with Ipi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003291-38,0,0,0 2012-003291-38,5,2014-07-04,2014-07-04,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Open-Label, Multicenter Phase II Study of Ipilimumab Retreatment versus Chemotherapy for Subjects with Advanced Melanoma who Progressed after Initially Achieving Disease Control with Ipi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003291-38,0,0,0 2012-003292-19,7,2015-02-18,2015-02-19,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter, 24 week study assessing the safety and efficacy of lixisenatide in older patients with type 2 diabetes inadequately c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003292-19,0,0,0 2012-003298-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sociedad Andaluza de Trasplante de Órganos y Tejidos (SATOT),"Steroid withdrawal and novo donor-specific anti-HLA antibodies in renal transplant patients: a prospective, randomized and controlled study in parallel groups. Retirada de esteroides y anticuerpos ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003298-24,0,0,0 2012-003300-13,7,2017-04-18,2017-04-18,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Dr. Falk Pharma GmbH,"A randomised, double-blind, double-dummy, multi-centre, comparative parallel-group study to evaluate the efficacy of oral Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. placeb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003300-13,0,0,0 2012-003304-12,6,2015-08-04,2015-08-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",A Randomized Double Blind Placebo Controlled Parallel Group Study of the Efficacy and Safety of Pregabalin (BID) in Subjects with Post-Traumatic Peripheral Neuropathic Pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003304-12,0,0,0 2012-003305-10,6,2016-08-31,2016-08-31,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomized, double-blinded, regimen controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas (BC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003305-10,0,0,0 2012-003308-10,9,2017-03-02,2017-03-02,7,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Daiichi Sankyo Development Limited,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF TIVANTINIB (ARQ 197) IN SUBJECTS WITH MET DIAGNOSTIC-HIGH INOPERABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH ONE PRIOR SYSTEMIC THERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003308-10,0,0,0 2012-003308-10,9,2017-03-02,2017-03-02,7,1,0,0,0,2,3,0,0,1,1,0,1,0,1,"Daiichi Sankyo , Inc.","A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF TIVANTINIB (ARQ 197) IN SUBJECTS WITH MET DIAGNOSTIC-HIGH INOPERABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH ONE PRIOR SYSTEMIC THERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003308-10,0,0,0 2012-003308-10,9,2017-03-02,2017-03-02,7,1,0,0,0,2,3,0,0,1,1,0,1,0,1,DAIICHI SANKIO DEVELOPMENT LIMITED,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF TIVANTINIB (ARQ 197) IN SUBJECTS WITH MET DIAGNOSTIC-HIGH INOPERABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH ONE PRIOR SYSTEMIC THERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003308-10,0,0,0 2012-003309-91,3,2013-09-25,2013-09-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shire Development LLC,"The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003309-91,0,0,0 2012-003309-91,3,2013-09-25,2013-09-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Shire Development, LLC","The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003309-91,0,0,0 2012-003310-14,2,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Shire Development LLC,"The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003310-14,0,0,0 2012-003310-14,2,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,"Shire Development, LLC","The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003310-14,0,0,0 2012-003312-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE,Interest of preemptive treatment with ganciclovir or acyclovir in patients requiring prolonged mechanical ventilation and have either a cytomegalovirus replication in blood or an herpes simplex virus ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003312-30,0,0,0 2012-003313-34,4,2014-10-21,2014-10-28,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Shire Development LLC,"A Phase 3, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003313-34,0,0,0 2012-003314-13,7,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,"CLINIQUES UNIVERSITAIRES SAINT-LUC, UNIVERSITé CATHOLIQUE DE LOUVAIN, BRUXELLES, BELGIUM","RING ? RItuximab for lupus Nephritis with remission as a Goal, an investigator-initiated randomized international open multicentric study Rituximab para la remisión de la nefritis lúpica. Estudio i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003314-13,0,0,0 2012-003314-13,7,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,"Cliniques Universitaires Saint Luc, Université catholique de Louvain","RING ? RItuximab for lupus Nephritis with remission as a Goal, an investigator-initiated randomized international open multicentric study Rituximab para la remisión de la nefritis lúpica. Estudio i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003314-13,0,0,0 2012-003314-13,7,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,"Cliniques Universitaires Saint Luc, Université catholique de Louvain, Bruxelles","RING ? RItuximab for lupus Nephritis with remission as a Goal, an investigator-initiated randomized international open multicentric study Rituximab para la remisión de la nefritis lúpica. Estudio i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003314-13,0,0,0 2012-003315-63,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,FIBHULP,"RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, STUDY OF EFFECTIVENESS, TOLERABILITY AND SAFETY OF THERAPY WITH AMANTADINE IN DEGENERATIVE ATAXIAS ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003315-63,0,0,0 2012-003324-20,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"An open-label study to assess the immune persistence in healthy Chinese toddlers primed in infancy with three doses of GSK Biologicals’ DTPa-IPV/Hib vaccine, and to assess the safety and immunogenicit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003324-20,0,1,1 2012-003330-16,1,2015-08-27,2015-08-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GBG Forschungs GmbH (German Breast Group),"Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatment in patients with operable Triple Negative or lumina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003330-16,0,0,0 2012-003331-32,1,2018-04-07,2018-04-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,KULeuven and University Hospitals Leuven,"A PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF PRE-TRANSPLANT AND PROMPT POST-TRANSPLANT TREATMENT WITH AZITHROMYCIN TO IMPROVE EARLY ALLOGRAFT FUNCTION AND OUTCOME AFTER LUNG TRANSPLANTATION...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003331-32,0,0,0 2012-003332-23,5,2014-09-22,2014-09-22,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 42nd Street, New York, NY 10017, USA","A phase 2, randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of once-daily administration of a chemokine CCR2/5 receptor antagonist (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003332-23,0,0,0 2012-003333-42,2,2014-01-29,2014-01-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Riba...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003333-42,0,0,0 2012-003335-33,12,2016-12-01,2016-12-01,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"A multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to evaluate the effects of macitentan on exercise capacity in subjects with Eisenmenger Syndrome. Studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003335-33,0,0,0 2012-003335-33,12,2016-12-01,2016-12-01,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ACTELION PHARMACEUTICALS LTD.,"A multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to evaluate the effects of macitentan on exercise capacity in subjects with Eisenmenger Syndrome. Studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003335-33,0,0,0 2012-003338-17,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE),Phase II study of temozolomide in metastatic colorectal cancer patients resistant to standard therapies and with O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation Studio di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003338-17,0,0,0 2012-003340-72,3,2014-03-12,2014-03-12,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Merck Sharp & Dohme Corp.,A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of MK-5172 in Combination with Ribavirin (RBV) in Subjects with Chronic Hepatitis C Virus Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003340-72,1,0,0 2012-003342-33,1,2014-04-08,2014-04-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,Optimising the use of Entonox during screening colonoscopy: an open randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003342-33,0,0,0 2012-003343-29,1,2015-07-20,2015-07-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Birmingham,Simvastatin as adjuvant therapy to correct neutrophil dysfunction in older pneumonia patients - a randomised double blind placebo controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003343-29,0,0,0 2012-003344-74,2,2022-08-02,2022-08-02,1,0,0,1,0,0,1,0,0,2,0,0,0,0,0,HOVON Foundation,A phase I/II feasibility study of panoninostat alone and the combination of panobinostat and decitabine prior to donor lymphocyte infusion in recipients of allogeneic stem cell transplantation with po...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003344-74,1,0,0 2012-003346-32,2,2014-02-28,2014-02-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-week treatment, multi-center, randomized, double-blind, parallel group, placebo and active controlled study to assess the efficacy, safety, and tolerability of QVA149 (indacaterol maleate /glycop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003346-32,0,0,0 2012-003346-32,2,2014-02-28,2014-02-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A 12-week treatment, multi-center, randomized, double-blind, parallel group, placebo and active controlled study to assess the efficacy, safety, and tolerability of QVA149 (indacaterol maleate /glycop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003346-32,0,0,0 2012-003347-30,3,2014-02-28,2014-02-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-week treatment, multi-center, randomized, double-blind, parallel group, placebo and active controlled study to assess the efficacy, safety, and tolerability of QVA149 (indacaterol maleate /glycop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003347-30,0,0,0 2012-003348-63,1,2013-07-25,2013-07-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A randomized, placebo-controlled trial of BPS804 on safety and tolerability in patients with late-stage chronic kidney disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003348-63,0,0,0 2012-003349-13,6,2015-01-22,2015-01-28,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003349-13,0,0,0 2012-003349-13,6,2015-01-22,2015-01-28,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.,"Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003349-13,0,0,0 2012-003350-84,1,2013-10-28,2013-10-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo- and comparator-controlled study evaluating the effect of multiple doses of QGE031 compared to omalizumab in asthma induced by allergen bronchial provocation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003350-84,0,0,0 2012-003351-11,5,2015-05-01,2015-05-01,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Amgen Inc.,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003351-11,0,0,0 2012-003354-89,6,2015-05-06,2015-05-06,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. USA",A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 and MK-8742 +/-Ribavirin (RBV) in Subjects with Chronic Hepatitis C Virus Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003354-89,0,0,0 2012-003354-89,6,2015-05-06,2015-05-06,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Corp.,A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 and MK-8742 +/-Ribavirin (RBV) in Subjects with Chronic Hepatitis C Virus Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003354-89,0,0,0 2012-003359-12,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,VU University Medical Center,The effect of a high and low protamine-to-heparin dosing on perioperative hemostasis: a randomized clinical trial. Het effect van een hoge en lage protamine:heparine doseringsratio op perioperatie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003359-12,0,0,0 2012-003361-18,2,2015-04-17,2016-01-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after a failure to treat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003361-18,0,0,0 2012-003362-41,1,2015-07-29,2015-07-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Randomized, double-blind, multicentre study to compare the efficacy and safety of two different dosages of a novel budesonide suppository versus a mesalazine suppository versus a combination therapy o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003362-41,0,0,0 2012-003364-51,3,2017-01-06,2017-01-06,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Aurinia Pharmaceuticals Inc.,"A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) with Placebo in Achieving Remission in Patients with Active Lupus Nephritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003364-51,0,0,0 2012-003370-10,3,2015-03-30,2015-03-30,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with bullous pemphigo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003370-10,0,0,0 2012-003370-10,3,2015-03-30,2015-03-30,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo controlled, parallel group study evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of QGE031 in the treatment of patients with bullous pemphigo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003370-10,0,0,0 2012-003383-51,1,2019-02-22,2019-02-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Velindre NHS Trust,A randomised phase II trial of Olaparib maintenance versus placebo monotherapy in patients with non-small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003383-51,0,0,0 2012-003386-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMCG,PHARMACOKINETICS AND PHARMACODYNAMICS OF ERTAPENEM IN PATIENTS WITH TUBERCULOSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003386-18,0,0,0 2012-003387-43,4,2014-04-30,2014-04-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Naïve Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003387-43,0,0,0 2012-003389-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU DE POITIERS,A phase II study to assess the efficacy and safety of frontline combination of dasatinib (SPRYCEL®) and pegylated-interferon alpha 2b (Peg-IFNα2b) therapy in patients newly diagnosed with chronic phas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003389-42,0,0,0 2012-003390-26,3,2014-09-23,2014-09-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Birken AG,"Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 versus Standard of Care in Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003390-26,0,0,0 2012-003391-39,1,2016-10-25,2016-10-25,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital of Montpellier,Ballon aortic valvuloplasty performed without heparin to decrease vascular and bleeding complications of the procedure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003391-39,0,0,0 2012-003392-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003392-18,0,0,0 2012-003393-12,3,2014-06-25,2014-06-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biologische Heilmittel Heel GmbH,"Treatment of rotator cuff syndrome and bursitis: A double blind, controlled trial to assess the efficacy and safety of Traumeel® S injection versus corticosteroid injections and versus placebo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003393-12,0,0,0 2012-003395-40,1,2013-01-22,2013-01-22,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,"Watson Laboratories, Inc.","Double-blind, masked, randomized, three period crossover study to evaluate the changes in exhaled nitric oxide (eNO) following treatment with fluticasone propionate MDI Aerosol in patients with chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003395-40,0,0,0 2012-003396-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Cardiothoracic Surgery, Mater Misericordiae University Hospital",Is the optimal dose of preoperative statin associated with decreased end organ injury and better clinical outcome post cardiopulmonary bypass?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003396-20,0,0,0 2012-003398-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FUNDACIÓ PUIGVERT,"Randomized clinical trial to compare the effect of mannitol and hydroelectrolytic solutions as kidney function protector, in partial laparoscopic nephrectomies (MANCOL Study) Ensayo clínico aleator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003398-24,0,0,0 2012-003404-12,6,2015-03-14,2015-03-14,5,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Pharmacokinetics and safety of agomelatine in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with Depressive or Anxiety Disorder. An open-labelled, multicenter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003404-12,0,0,0 2012-003404-12,6,2015-03-14,2015-03-14,5,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherche Internationales Servier,"Pharmacokinetics and safety of agomelatine in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with Depressive or Anxiety Disorder. An open-labelled, multicenter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003404-12,0,0,0 2012-003405-98,1,2018-03-29,2018-03-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ACCORD University of Edinburgh,Developmental Clinical Studies - Reversing endometrial glucocorticoid deficiency in heavy menstrual bleeding,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003405-98,0,0,0 2012-003405-98,1,2018-03-29,2018-03-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"ACCORD, NHS Lothian",Developmental Clinical Studies - Reversing endometrial glucocorticoid deficiency in heavy menstrual bleeding,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003405-98,0,0,0 2012-003409-86,1,2014-12-18,2014-12-18,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KULeuven,"The effect of naloxone and methylnaltrexone on oesophageal sensitivity in healthy volunteers: a randomized, double-blind placebo controlled study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003409-86,0,0,0 2012-003412-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CUB - Hôpital Erasme,Efficiency and Safety of Ovarian Stimulation with Letrozole for fertility preservation in breast cancer patients. Etude de l'efficacité et de l'innocuité des stimulations ovariennes avec du letrozo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003412-31,0,0,0 2012-003413-33,1,2013-07-04,2013-07-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Randomized, Open-Label, Repeat Dosing (7 days), Four-Period Crossover Study to Compare the Pharmacokinetics, Efficacy and Safety of Tiotropium Bromide Delivered via Breath Actuated Inhaler (BAI), S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003413-33,0,0,0 2012-003414-14,4,2016-07-14,2016-09-02,2,1,1,0,0,0,1,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as","A Single-Dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Odanacatib in Adolescents Treated with Glucocorticoids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003414-14,1,1,0 2012-003414-14,4,2016-07-14,2016-09-02,2,1,1,0,0,0,1,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Single-Dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Odanacatib in Adolescents Treated with Glucocorticoids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003414-14,1,1,0 2012-003416-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación Academia Española de Dermatología y Venereología,"Multicenter, randomized, open clinical trial comparing three sessions of methyl-aminolevulinate 16% (Metvix®) photodynamic therapy versus a group without photodynamic therapy to treat onychomycosis. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003416-31,0,0,0 2012-003417-34,1,2014-02-17,2014-02-17,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,LABORATOIRES SMB S.A.,"A phase IV, two-armed, randomised, cross-over study to compare the compliance of a once-a-month administration of vitamin D3 (D-CURE®) to a daily administration of a fixed-dose combination of vitamin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003417-34,0,0,0 2012-003418-15,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Medizinische Universität Wien,Methylphenidate modified release as treatment option of MS-associated fatigue. A single-center randomized double-blind placebo-controlled trial. Retardiertes Methylphenidat als Behandlungsoption be...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003418-15,0,0,0 2012-003423-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,Prospective randomized study ARMYDA PRIME Studio prospettico randomizzato ARMYDA PRIME,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003423-37,0,0,0 2012-003426-24,1,2015-11-05,2015-11-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Riemser Pharma GmbH,A multicentre double blind placebo controlled clinical trial to assess efficacy and safety of Alvalin® (cathine hydrochloride) vs. placebo in 265 obese patients/group with a body mass index (BMI) betw...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003426-24,0,0,0 2012-003427-38,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,Shire Human Genetic Therapies,"A Multi-center, Open-label, Efficacy and Safety Study of Velaglucerase Alfa Enzyme Replacement Therapy in Children and Adolescents With Type 3 Gaucher Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003427-38,0,1,1 2012-003430-16,1,2013-06-19,2013-06-19,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Clinical Reasearch Centre, Hvidovre University Hospital",Effect of local anesthesia in patients with marginal periodontitis undergoing subgingival scaling Effekt af lokalanalgesi ved subgingival depuration af patienter med marginal parodontitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003430-16,0,0,0 2012-003431-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sociedad Española de retina y Vítreo,"A 12-month, phase IV, open-label, randomized, 2-arm, multicenter study assessing the efficacy and safety of a flexible individualized ?wait and extend? PRN regimen versus a PRN stabilization-criter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003431-37,0,0,0 2012-003432-24,7,2016-01-27,2016-01-27,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase II, multicenter, single-arm study of oral LDK378 in adult patients with ALK-activated non-small cell lung cancer previously treated with chemotherapy and crizotinib Studio di Fase II, multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003432-24,0,0,0 2012-003432-24,7,2016-01-27,2016-01-27,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A phase II, multicenter, single-arm study of oral LDK378 in adult patients with ALK-activated non-small cell lung cancer previously treated with chemotherapy and crizotinib Studio di Fase II, multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003432-24,0,0,0 2012-003432-24,7,2016-01-27,2016-01-27,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis Farmaceuica S.A.,"A phase II, multicenter, single-arm study of oral LDK378 in adult patients with ALK-activated non-small cell lung cancer previously treated with chemotherapy and crizotinib Studio di Fase II, multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003432-24,0,0,0 2012-003438-18,8,2017-01-06,2017-01-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Biologicals sa,"A Phase III, randomised, observer-blind, placebo controlled,multicentre study to assess the safety and immunogenicity of GSK Biologicals’ Herpes Zoster HZ/su candidate vaccine when administered intra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003438-18,0,0,0 2012-003438-18,8,2017-01-06,2017-01-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase III, randomised, observer-blind, placebo controlled,multicentre study to assess the safety and immunogenicity of GSK Biologicals’ Herpes Zoster HZ/su candidate vaccine when administered intra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003438-18,0,0,0 2012-003438-18,8,2017-01-06,2017-01-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE BIOLOGICALS SA,"A Phase III, randomised, observer-blind, placebo controlled,multicentre study to assess the safety and immunogenicity of GSK Biologicals’ Herpes Zoster HZ/su candidate vaccine when administered intra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003438-18,0,0,0 2012-003438-18,8,2017-01-06,2017-01-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline SA,"A Phase III, randomised, observer-blind, placebo controlled,multicentre study to assess the safety and immunogenicity of GSK Biologicals’ Herpes Zoster HZ/su candidate vaccine when administered intra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003438-18,0,0,0 2012-003439-41,4,2014-04-25,2014-04-25,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VX 509 using Magnetic Resonance Imaging and Arthroscopic Biopsies ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003439-41,0,0,0 2012-003442-32,1,2019-07-17,2019-07-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE SAS,"AN OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE III STUDY IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER RESPONDING TO FIRST LINE TREATMENT WITH INTRAVENOUS TRASTUZUMAB FOR AT LEAST 3 YEARS AND ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003442-32,0,0,0 2012-003445-15,1,2014-03-11,2014-03-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alkermes, Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects with Acute Exacerbation of Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003445-15,0,0,0 2012-003447-29,5,2016-01-20,2016-01-20,4,1,0,0,0,0,4,0,0,2,0,0,0,0,1,"Cubist Pharmaceuticals, Inc.",A COMPARATIVE EVALUATION OF THE SAFETY AND EFFICACY OF DAPTOMYCIN VERSUS STANDARD OF CARE IN PEDIATRIC SUBJECTS TWO-SEVENTEEN YEARS OF AGE WITH BACTEREMIA CAUSED BY STAPHYLOCOCCUS AUREUS. A daptomi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003447-29,1,1,0 2012-003450-92,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Instituto Grifols S.A.,"EVALUATION OF THE PHARMACOKINETIC PROFILE, CLINICAL EFFICACY AND SAFETY OF THE VON WILLEBRAND FACTOR CONTAINED IN FANHDI® (DOUBLE-INACTIVATED HUMAN ANTI-HEMOPHILIC FACTOR) IN PEDIATRIC PATIENTS WITH V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003450-92,0,0,0 2012-003457-28,12,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Celgene Corporation,"A phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003457-28,0,0,0 2012-003457-28,12,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,CELGENE CORPORATION,"A phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003457-28,0,0,0 2012-003460-47,7,2016-03-17,2016-03-17,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Refr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003460-47,0,0,0 2012-003460-47,7,2016-03-17,2016-03-17,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,LEXICON PHARMACEUTICALS INC,"A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Refr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003460-47,0,0,0 2012-003463-22,5,2015-01-22,2015-01-22,3,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who are Prior Rela...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003463-22,1,0,0 2012-003463-22,5,2015-01-22,2015-01-22,3,1,0,0,0,0,3,0,0,2,1,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3 Evaluation of the Safety and Efficacy of Lambda/RBV/DCV in Treatment Naïve Subjects with Chronic HCV Infection, who have Underlying Mild or Moderate Hemophilia or Patients who are Prior Rela...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003463-22,1,0,0 2012-003474-36,7,2018-01-22,2018-01-22,5,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naïve adult patients with ALK-activated non-small cell lung cancer Studio di Fase II multicentrico, a braccio singolo, con LDK...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003474-36,0,0,0 2012-003474-36,7,2018-01-22,2018-01-22,5,1,0,0,0,2,2,0,0,1,0,0,1,0,1,"Novartis Farmaceútica, S.A","A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naïve adult patients with ALK-activated non-small cell lung cancer Studio di Fase II multicentrico, a braccio singolo, con LDK...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003474-36,0,0,0 2012-003474-36,7,2018-01-22,2018-01-22,5,1,0,0,0,2,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naïve adult patients with ALK-activated non-small cell lung cancer Studio di Fase II multicentrico, a braccio singolo, con LDK...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003474-36,0,0,0 2012-003476-39,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,0,The University of Birmingham,Short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome; the PREDNOS 2 study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003476-39,0,0,0 2012-003476-39,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,0,Manchester University NHS Foundation Trust,Short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome; the PREDNOS 2 study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003476-39,0,0,0 2012-003479-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Handkirurgiska kliniken, Universitetssjukhuset Örebro","Lateral humerus epicondylitis- a clinical, muscle morpological, muscle metabolical and functional evaluation of a new model for treatment. Lateral Humerusepikondylit – en klinisk, muskelmorfologisk...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003479-20,0,0,0 2012-003480-21,1,2013-04-05,2013-04-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klin. Abt. für Endokrinologie und Stoffwechsel","An open, single-centre, non-controlled feasibility study on the performance of a tablet based workflow and decision support system with incorporated software algorithm used for glycaemic management in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003480-21,0,0,0 2012-003481-41,4,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI,Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer ETNA (Evaluating Treatment with Neoadjuvant Abraxane) Neoadjuvant chemotherapy with nab-paclitaxel...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003481-41,0,0,0 2012-003482-18,1,2017-08-16,2017-08-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ReNeuron Ltd,A Phase II Efficacy Study of Intracerebral CTX0E03 DP In Patients with Stable Paresis of the Arm Following an Ischaemic Stroke.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003482-18,0,0,0 2012-003483-46,2,2015-06-08,2015-06-08,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,University of Florida Board of Trustees,Impact of Aggressive Empiric Antibiotic Therapy and Duration of Therapy on the Emergence of Antimicrobial Resistance during the Treatment of Hospitalized Subjects with Pneumonia Requiring Mechanical V...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003483-46,0,0,0 2012-003484-22,2,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Helsinki University Central Hospital,Immune response to pneumococcal conjugate vaccine in adults receiving hepatitis A vaccine concomitantly,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003484-22,0,0,0 2012-003486-18,6,2016-05-19,2016-05-19,5,1,1,0,0,0,1,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,"A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH POLYARTICULAR-COURSE J...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003486-18,1,1,0 2012-003487-48,5,2017-04-03,2017-04-03,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Medicament,"Efficacy and safety international, multicentric, randomised,double- blind,placebo controlled study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003487-48,0,0,0 2012-003487-48,5,2017-04-03,2017-04-03,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"Efficacy and safety international, multicentric, randomised,double- blind,placebo controlled study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003487-48,0,0,0 2012-003488-23,10,2013-09-03,2013-09-03,6,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents with Tourette's Disorder ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003488-23,1,0,0 2012-003488-23,10,2013-09-03,2013-09-03,6,1,0,0,0,0,3,0,0,2,1,0,0,0,1,OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALISATION INC,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents with Tourette's Disorder ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003488-23,1,0,0 2012-003489-42,9,2014-08-23,2014-10-27,3,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents with Tourette?s Disorder Estudio clínico multicéntrico, abierto p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003489-42,1,0,0 2012-003490-26,5,2017-06-15,2017-06-15,3,1,1,0,0,0,1,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB FOLLOWING SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH SYSTEMIC JUVENILE IDIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003490-26,1,1,0 2012-003494-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI,EVALUATION OF THE EFFECT OF TESTOSTERONE REPLACEMENT THERAPY ON PROSTATIC INFLAMMATION AND LOWER URINARY TRACT SYMPTOMS IN HYPOGONADAL SUBJECTS Valutazione della efficacia della terapia sostitutiva...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003494-26,0,0,0 2012-003495-39,1,2012-12-03,2012-12-03,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Debiopharm SA,"A Two-Part, Sequential Design Study to Determine Debio 0932 Absolute Oral Bioavailability, Mass Balance Recovery, Metabolite Profiling and Structural Identification in 3 Cohorts of Healthy Male Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003495-39,0,0,0 2012-003499-37,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ITALFARMACO S.p.A,Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F positive Chronic Myeloproliferative Neoplasms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003499-37,0,0,0 2012-003499-37,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ITALFARMACO,Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F positive Chronic Myeloproliferative Neoplasms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003499-37,0,0,0 2012-003501-10,1,2016-05-05,2016-05-05,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Vall d'Hebron Institut de Recerca (VHIR),"Efficacy of dual antiretroviral treatment with maraviroc plus ritonavir-boosted darunavir in early rescue therapy in patients with HIV-1 infection: pilot, multicenter, randomized, controlled and open ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003501-10,0,0,0 2012-003504-12,1,2014-06-20,2014-06-20,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Medical Research Laboratory, Clinical institute of Medicine, Aarhus University Hospital",Glucocorticoid-induced inhibition of IGF-I activity: exploration of underlying mechanisms.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003504-12,0,0,0 2012-003505-10,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA,Phase II study of Eribulin in combination with Gemcitabine for the First-line Treatment of Patients with Locally Recurrent or Metastatic Triple Negative Breast Cancer. Protocol ERIGE. Studio di fas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003505-10,0,0,0 2012-003506-27,5,2014-07-11,2014-07-11,4,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"FAES FARMA, S.A.","A multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the safety and tolerability of 10 mg once daily bilastine in children from 2 to 11 years of age with eith...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003506-27,1,0,0 2012-003507-35,2,2014-02-03,2014-02-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"AVEO Pharmaceuticals, Inc.","A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-Center Study Comparing Tivozanib Hydrochloride In Combination With Paclitaxel Versus Placebo In Combination With Paclitaxel in the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003507-35,0,0,0 2012-003508-11,2,2014-09-18,2014-09-18,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon alfa-2a, Each in Combination with Ribavirin, in the Treatment of Naiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003508-11,0,0,0 2012-003510-13,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,IRCCS ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,A phase II non randomized study evaluating the role of Androgen Receptors as Targets for therapy of pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/AR-p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003510-13,0,0,0 2012-003511-63,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,IDIAP Jordi Gol,Efficacy of high doses of oral penicillin V versus high dose amoxicillin in the treatment of non-severe pneumonia treated at the adult community.PENIPNEUMO Study Eficacia de dosis altas de penicili...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003511-63,0,0,0 2012-003514-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II,HYPOVITAMINOSIS D AND ORGAN DAMAGE IN PATIENTS WITH HYPERTENSION: EFFECTS OF SUPPLEMENTATION WITH CHOLECALCIFEROL IPOVITAMINOSI D E DANNO D'ORGANO IN PAZIENTI CON IPERTENSIONE ARTERIOSA: EFFETTI DE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003514-14,0,0,0 2012-003515-58,11,2018-02-16,2018-02-16,9,1,0,0,0,0,0,0,0,1,0,0,1,0,2,ECRI,GLOBAL LEADERS: Comparative effectiveness of 1 month of ticagrelor plus aspirin followed by ticagrelor monotherapy versus a current-day intensive dual antiplatelet therapy in all-comers patients under...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003515-58,0,0,0 2012-003515-58,11,2018-02-16,2018-02-16,9,1,0,0,0,0,0,0,0,1,0,0,1,0,2,European Cardiovascular Research Institute,GLOBAL LEADERS: Comparative effectiveness of 1 month of ticagrelor plus aspirin followed by ticagrelor monotherapy versus a current-day intensive dual antiplatelet therapy in all-comers patients under...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003515-58,0,0,0 2012-003516-31,1,2016-05-03,2016-05-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CUB Erasme Hospital,Evaluation of tumoral perfusion modification by dynamic imaging after neoadjuvant chemotherapy combining gemcitabine and a Hedgehog inhibitor (Vismodegib) in patients with resectable pancreatic adenoc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003516-31,0,0,0 2012-003524-21,10,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"MedImmune, LLC","A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003524-21,0,0,0 2012-003528-19,1,2016-06-13,2016-06-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial",STEM CELL TRANSPLANTATION FOR ERADICATION OF MINIMAL PANCREATIC CANCER PERSISTING AFTER SURGICAL EXCISION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003528-19,0,0,0 2012-003530-16,4,2014-06-16,2018-09-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003530-16,0,0,0 2012-003531-40,5,2016-12-06,2017-05-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Medicament,Randomised phase II trial of oral vinorelbine and cisplatin followed by maintenance with single agent oral vinorelbine versus gemcitabine and cisplatin followed by maintenance with single agent gemcit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003531-40,0,0,0 2012-003531-40,5,2016-12-06,2017-05-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,Randomised phase II trial of oral vinorelbine and cisplatin followed by maintenance with single agent oral vinorelbine versus gemcitabine and cisplatin followed by maintenance with single agent gemcit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003531-40,0,0,0 2012-003532-23,4,2014-11-18,2014-11-18,4,1,0,0,0,2,4,0,0,1,0,0,1,0,1,NOVARTIS FARMA,"A 48 week extension to CTBM100C2401, a single arm open-label, multicenter, phase IV trial, to assess long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis Estens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003532-23,0,0,0 2012-003532-23,4,2014-11-18,2014-11-18,4,1,0,0,0,2,4,0,0,1,0,0,1,0,1,"Novartis Farmaceutica, S.A.","A 48 week extension to CTBM100C2401, a single arm open-label, multicenter, phase IV trial, to assess long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis Estens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003532-23,0,0,0 2012-003532-23,4,2014-11-18,2014-11-18,4,1,0,0,0,2,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 48 week extension to CTBM100C2401, a single arm open-label, multicenter, phase IV trial, to assess long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis Estens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003532-23,0,0,0 2012-003533-41,9,2015-01-22,2015-03-11,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infectio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003533-41,0,0,0 2012-003533-41,9,2015-01-22,2015-03-11,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infectio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003533-41,0,0,0 2012-003533-41,9,2015-01-22,2015-03-11,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infectio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003533-41,0,0,0 2012-003533-41,9,2015-01-22,2015-03-11,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Unilfarma, Lda.","A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infectio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003533-41,0,0,0 2012-003533-41,9,2015-01-22,2015-03-11,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infectio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003533-41,0,0,0 2012-003533-41,9,2015-01-22,2015-03-11,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infectio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003533-41,0,0,0 2012-003534-17,6,2014-01-14,2014-10-21,4,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Boehringer Ingelheim France,"A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype 1b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003534-17,0,0,0 2012-003534-17,6,2014-01-14,2014-10-21,4,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Boehringer Ingelheim Limited,"A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype 1b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003534-17,0,0,0 2012-003534-17,6,2014-01-14,2014-10-21,4,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Boehringer Ingelheim,"A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype 1b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003534-17,0,0,0 2012-003534-17,6,2014-01-14,2014-10-21,4,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Boehringer Ingelheim España S.A,"A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype 1b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003534-17,0,0,0 2012-003534-17,6,2014-01-14,2014-10-21,4,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase II randomised, double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin in patients with moderate hepatic impairment (Child-Pugh B) with genotype 1b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003534-17,0,0,0 2012-003535-27,7,2014-09-18,2015-03-11,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ελλάς Α.Ε.,"A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended popu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003535-27,0,0,0 2012-003535-27,7,2014-09-18,2015-03-11,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Unilfarma, Lda.","A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended popu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003535-27,0,0,0 2012-003535-27,7,2014-09-18,2015-03-11,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER ING.,"A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended popu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003535-27,0,0,0 2012-003535-27,7,2014-09-18,2015-03-11,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended popu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003535-27,0,0,0 2012-003535-27,7,2014-09-18,2015-03-11,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended popu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003535-27,0,0,0 2012-003535-27,7,2014-09-18,2015-03-11,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended popu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003535-27,0,0,0 2012-003535-27,7,2014-09-18,2015-03-11,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and ribavirin for chronic genotype 1 hepatitis C infection in an extended popu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003535-27,0,0,0 2012-003536-23,12,2014-10-10,2014-10-14,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003536-23,0,0,0 2012-003543-30,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Emotional Brain BV,"A double-blind, randomized, placebo-controlled, proof of concept study to investigate the differences between the combined administration of 0.5 mg sublingual testosterone and 10 mg buspirone and 10 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003543-30,0,0,0 2012-003544-68,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC. A phase IV study. Studio randomizzato cross-over per la valutazione della p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003544-68,0,0,0 2012-003547-29,1,2015-02-27,2015-02-27,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Onconova Therapeutics Inc.,"A Phase III, Multi-center, Randomized, Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined with Gemcitabine in Patients with Previously Untreated Metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003547-29,0,0,0 2012-003554-83,10,2019-12-13,2020-01-30,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A double-blind, placebo-controlled, randomized, multicenter phase III study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-pos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003554-83,0,0,0 2012-003554-83,10,2019-12-13,2020-01-30,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A double-blind, placebo-controlled, randomized, multicenter phase III study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-pos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003554-83,0,0,0 2012-003559-13,4,2014-12-15,2014-12-15,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Clinical non-inferiority study between Daflon 1000 mg, one oral suspension in a sachet per day and Daflon 500 mg, 2 tablets daily after eight weeks of treatment in patients suffering from symptomatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003559-13,0,0,0 2012-003560-49,1,2014-12-23,2014-12-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Macarthys Laboratories Limited (trading as Martindale Pharma),"A PHASE II, RANDOMISED, SINGLE CENTRE, OPEN-LABEL, TWO-ARM STUDY TO DETERMINE THE SAFETY AND EFFICACY OF BUPRENORPHINE ORAL LYOPHILISATE (XPRENOR ®) IN COMPARISON WITH BUPRENORPHINE SUBLINGUAL TABLETS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003560-49,0,0,0 2012-003561-17,4,2016-03-17,2016-03-17,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Edimer Pharmaceuticals, Inc.","A Phase 2 open-label, dose-escalation study to evaluate the safety, pharmacokinetics, immunogenicity and pharmacodynamics/efficacy of EDI200, an EDA-A1 replacement protein, administered to male infant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003561-17,0,0,0 2012-003566-41,5,2014-11-07,2014-11-07,3,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,A trial investigating the efficacy and safety of insulin degludec/insulin aspart once daily plus insulin aspart for the remaining meals versus insulin detemir once or twice daily plus meal time insuli...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003566-41,0,0,0 2012-003567-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,A.O. UNIVERSITARIA INTEGRATA DI VERONA,"Efficacy of topical application of zinc oxide ointment compared with zinc oxide paste and tocoferol, for treating diaper dermatitis in infant: a randomized, controlled, triple blind study Trial con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003567-22,0,0,0 2012-003570-77,1,2013-11-28,2013-11-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sterna biologicals GmbH & Co. KG,"Clinical study to investigate safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with mild allergic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003570-77,0,0,0 2012-003574-66,1,2017-11-01,2017-11-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Ortopædkirurgisk Forskning - Aarhus Universitetshospita,Osseointegrated transdermal femoral amputation prostheses - Denusomab Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003574-66,0,0,0 2012-003577-26,1,2014-02-27,2014-02-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Aarhus University Hospital,"Liraglutide Kidney: A randomised, double-blinded, cross-over study investigating the short-term impact of liraglutide on kidney function in diabetic patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003577-26,0,0,0 2012-003579-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO,Effect of the withdrawal of anti-thyroid treatment on the iodide 123 kynetics used for the dosmetry before radioiodine therapy with 131I for autoimmune hyperthyroidism. Effetto della sospensione de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003579-21,0,0,0 2012-003580-21,8,2015-06-04,2015-06-04,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes A 52-week randomised, treat-to-target, placebo-controlled, double-blinded, parallelgroup, mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003580-21,0,0,0 2012-003581-40,2,,,0,0,0,0,0,0,4,0,2,3,0,0,0,0,2,"Imperial College, Research Governance Manager","A prospective, observational study to examine the effects of ageing on the clinical outcomes of people living with HIV in England and Ireland.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003581-40,0,0,0 2012-003581-40,2,,,0,0,0,0,0,0,4,0,2,3,0,0,0,0,2,Imperial College London,"A prospective, observational study to examine the effects of ageing on the clinical outcomes of people living with HIV in England and Ireland.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003581-40,0,0,0 2012-003589-42,1,2013-09-04,2013-09-04,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Spirig Pharma AG,"Observational (non-interventional), follow-up trial assessing long-term local tolerability and efficacy (recurrence rate) of resiquimod gel in patients treated for actinic keratosis. Beobachtende F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003589-42,0,0,0 2012-003590-25,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Phase II study of the Pan-HER inhibitor Dacomitinib (PF-00299804) for patients with locally advanced or metastatic squamous cell carcinoma of the penis Phase II study of the Pan-HER inhibitor Dacom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003590-25,0,0,0 2012-003592-19,1,2017-04-30,2017-04-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CUB Erasme Hospital,"Evaluation of tumoral perfusion modification by dynamic imaging after chemotherapy combining gemcitabine and nab-paclitaxel (Abraxane) in patients with potentially operable, locally advanced or metast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003592-19,0,0,0 2012-003593-51,15,2019-06-04,2019-06-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Array BioPharma,"The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003593-51,0,0,0 2012-003593-51,15,2019-06-04,2019-06-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003593-51,0,0,0 2012-003593-51,15,2019-06-04,2019-06-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Array BioPharma Inc,"The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003593-51,0,0,0 2012-003593-51,15,2019-06-04,2019-06-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Array BioPharma Inc.,"The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003593-51,0,0,0 2012-003593-51,15,2019-06-04,2019-06-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Array Biopharma Inc,"The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003593-51,0,0,0 2012-003593-51,15,2019-06-04,2019-06-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farma S.p.A.,"The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003593-51,0,0,0 2012-003593-51,15,2019-06-04,2019-06-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003593-51,0,0,0 2012-003593-51,15,2019-06-04,2019-06-04,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Array BioPharma inc.,"The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003593-51,0,0,0 2012-003595-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Universitario La Paz,"A randomized, pilot clinical trial designed to compare, in human immunodeficiency virus infected patients who never have received antiretroviral therapy, the evolution of cerebral function and the neu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003595-39,0,0,0 2012-003599-38,13,2014-07-14,2014-07-17,11,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,"A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previousl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003599-38,0,0,0 2012-003600-12,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Sportmedisch expertisecentrum,"The effect of cold air on the airways of elite skaters and the protective role of the OMRON De beschermende rol van de OMRON op het effect van droge, koude lucht op de luchtwegen van eliteschaatser...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003600-12,0,0,0 2012-003607-36,3,2015-09-28,2015-09-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of CNTO 6785 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003607-36,0,0,0 2012-003608-11,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Birmingham,IciCLLe: Assessment of the Mechanism of Action of Ibrutinib (PCI-32765) in B-cell Receptor Pathway Inhibition in CLL.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003608-11,0,0,0 2012-003609-80,6,2017-11-07,2017-12-18,5,1,0,0,0,0,3,0,0,1,1,0,1,0,0,"Ruprecht-Karls-University Heidelberg, Medical Faculty",European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003609-80,0,0,0 2012-003616-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU medical center,Uptake and biodistribution of 89Zirconium-labeled ipilimumab in ipilimumab treated patients with metastatic melanoma Opname en biodistributie van 89Zirconium-gelabeld ipilimumab in patienten met ge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003616-31,0,0,0 2012-003617-34,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,University Medical Center Groningen,Pharmacokinetics and optimal dosage of caspofungin in critically ill patients with suspected invasive candidiasis. Farmacokinetiek en optimale dosering van caspofungin bij intensive care patiënten ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003617-34,0,0,0 2012-003618-15,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"IRCCS - Istituto di Ricerche Farmacologiche ""Mario Negri""","Multicenter, randomized, non-comparative, open-label phase II trial on the efficacy of Ortataxel and Fotemustine in recurrent glioblastoma Studio clinico multicentrico, italiano, randomizzato, non-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003618-15,0,0,0 2012-003620-20,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Tamsulosin to prevent the failures of early bladder catheter removal after acute urinary retention in elderly women hospitalized for an acute medical problem Tamsulosine pour prévenir les échecs de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003620-20,0,0,0 2012-003621-21,1,2019-07-30,2019-07-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité University Hospital Berlin,"Prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled, aerosolized Tobramycin (TOBI®) b.i.d. in patients with vent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003621-21,0,0,0 2012-003622-25,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, Compared with Placeb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003622-25,0,0,0 2012-003626-24,5,2015-06-19,2015-06-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Multicenter, Phase III, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of MK-3102 Monotherapy in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003626-24,0,0,0 2012-003627-38,6,2014-09-12,2014-09-12,5,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003627-38,0,0,0 2012-003627-38,6,2014-09-12,2014-09-12,5,1,0,0,1,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.",Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003627-38,0,0,0 2012-003629-40,1,2015-05-26,2015-05-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Placebo-controlled Double-blind, Multicenter, Phase 2 Dose Ranging Study To Assess The Efficacy And Safety of CNTO6785 In Subjects With Active Rheumatoid Arthritis Despite Methotrexate T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003629-40,0,0,0 2012-003630-16,2,2018-05-16,2019-05-07,2,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"German Heart Centre Munich, Department of","A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB– Ticagrelor i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003630-16,0,0,0 2012-003631-36,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Birmingham,CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL-101) in B-cell Receptor Pathway Inhibition in CLL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003631-36,0,0,0 2012-003632-23,7,2019-01-04,2019-01-04,5,1,1,0,0,1,2,0,0,1,1,0,1,0,1,Novimmune SA,"A Phase 2/3 , Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003632-23,0,0,0 2012-003632-23,7,2019-01-04,2019-01-04,5,1,1,0,0,1,2,0,0,1,1,0,1,0,1,NovImmune SA,"A Phase 2/3 , Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003632-23,0,0,0 2012-003633-42,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Royal Brompton and Harefield NHS Foundation Trust,"A randomized, double blind controlled trial comparing rituximab against intravenous cyclophosphamide in connective tissue disease associated interstitial lung disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003633-42,0,0,0 2012-003635-31,8,2015-05-14,2015-05-14,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galapagos NV,"Randomized, double-blind, placebo-controlled, multicenter, phase IIb dose finding study of GLPG0634 administered for 24 weeks in combination with methotrexate to subjects with moderately to severely a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003635-31,0,0,0 2012-003638-18,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,"Australasian Gastro-Intestinal Trials Group, Sydney University",Randomised Phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic CRC with either KRAS WT or G13D mutation. ICE CREAM: The Irinotecan Cetuximab Evaluation and ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003638-18,0,0,0 2012-003638-18,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,AGITG (Australasian Gastro - Intestinal Trial Group),Randomised Phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic CRC with either KRAS WT or G13D mutation. ICE CREAM: The Irinotecan Cetuximab Evaluation and ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003638-18,0,0,0 2012-003641-15,1,2019-05-31,2019-05-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,North Bristol NHS Trust,"Reducing pathology in Alzheimer’s Disease through Angiotensin taRgeting. The RADAR Trial. A phase II, two arm, double-blind, placebo-controlled, randomised trial to evaluate the effect of losartan on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003641-15,0,0,0 2012-003644-71,3,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,Pfizer Inc.,"A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Etanercept in Subjects with Rheumatoid Arthritis Who Have Had and Inadequate Response to Adalimumab or Infliximab Plu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003644-71,0,0,0 2012-003644-71,3,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,"Pfizer Inc., 235 EAst 42nd Street, New York, NY 10017, United States","A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Etanercept in Subjects with Rheumatoid Arthritis Who Have Had and Inadequate Response to Adalimumab or Infliximab Plu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003644-71,0,0,0 2012-003647-30,14,2017-05-09,2017-07-04,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Teva Pharmaceutical Industries Ltd,"A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two dose...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003647-30,0,0,0 2012-003647-30,14,2017-05-09,2017-07-04,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,TEVA PHARMACEUTICALS INDUSTRIES LTD,"A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two dose...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003647-30,0,0,0 2012-003648-59,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dept. of Neurology, Atrium Medical Centre","Oxygen treatment for cluster headache attacks at different flow rates. A double-blind, randomized, cross-over design study. Zuurstoftherapie met verschillende stroomsnelheden voor clusterhoofdpijn ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003648-59,0,0,0 2012-003649-14,10,2016-05-27,2019-07-31,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003649-14,0,0,0 2012-003649-14,10,2016-05-27,2019-07-31,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003649-14,0,0,0 2012-003650-88,9,2019-07-02,2019-09-06,7,1,0,0,0,2,2,0,0,1,0,0,1,0,1,BAYER AG,"A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma hyper...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003650-88,0,0,0 2012-003650-88,9,2019-07-02,2019-09-06,7,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Bayer AG,"A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma hyper...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003650-88,0,0,0 2012-003650-88,9,2019-07-02,2019-09-06,7,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma hyper...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003650-88,0,0,0 2012-003650-88,9,2019-07-02,2019-09-06,7,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Bayer AG,"A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma hyper...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003650-88,0,0,0 2012-003651-11,4,2014-09-10,2014-09-10,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study investigating the efficacy, safety, pharmacokinetic and biomarker profiles of Dupilumab (REGN668) administered to adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003651-11,0,0,0 2012-003652-36,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,The Rotterdam Eye Hospital,The Most Effective Treatment Strategy for Diabetic Macular Edema.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003652-36,0,0,0 2012-003654-86,6,2015-05-29,2015-05-29,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galapagos NV,"Randomized, double-blind, placebo-controlled, multicenter, phase IIb dose finding study of GLPG0634 administered for 24 weeks as monotherapy to subjects with moderately to severely active rheumatoid a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003654-86,0,0,0 2012-003655-11,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Gilead Sciences Inc.,"A multicenter, open-label, long-term follow-up safety and efficacy study of GLPG0634 treatment in subjects with moderately to severely active rheumatoid arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003655-11,0,0,0 2012-003655-11,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Galapagos NV,"A multicenter, open-label, long-term follow-up safety and efficacy study of GLPG0634 treatment in subjects with moderately to severely active rheumatoid arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003655-11,0,0,0 2012-003661-17,1,2014-11-10,2014-11-10,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,Moorfields Eye Hospital NHS Foundation Trust,A Multicentre Prospective Open-label Randomised Clinical Trial Comparing the Efficacy of Fixed versus PRN dosing of 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) in patients...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003661-17,0,0,0 2012-003664-41,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Balkanpharma-Razgrad AD,"Open-labeled, randomized, comparative clinical study of efficacy and safety of Levofloxan 0,5% eye drops in patients with Acute Bacterial Conjunctivitis. Открито, рандомизирано, сравнително клиничн...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003664-41,0,0,0 2012-003666-41,1,2022-09-16,2022-09-16,1,0,0,0,0,1,2,0,0,1,0,0,0,0,0,Jules Bordet Institute,The LuMEn study 177Lu-octreotate treatment outcome prediction using Multimodality imaging in refractory neuroEndocrine tumours,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003666-41,0,0,0 2012-003669-17,1,2017-03-02,2017-03-02,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University Medical Center Hamburg-Eppendorf,"Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma (NEOPA).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003669-17,0,0,0 2012-003670-11,6,2016-03-16,2016-03-16,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003670-11,0,0,0 2012-003672-39,5,2021-02-02,2021-02-02,3,1,0,0,0,1,2,0,0,2,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),Phase II trial of cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003672-39,1,0,0 2012-003677-25,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,IBSA INSTITUT BIOCHIMIQUE SA,Safety and bioavailability of Tirosint (Levothyroxine Sodium) Oral Solution administered as single dose with or without water in hypothyroid patients. Tollerabilità e biodisponibilità di Tirosint (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003677-25,0,0,0 2012-003678-13,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Institut Régional de Cancerologie de Montpellier - Val d’Aurelle,Phase I-II trial of gemcitabine plus nab-paclitaxel (GemBrax) followed by FOLFIRINOX as first-line treatment of patients with metastatic pancreatic adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003678-13,0,0,0 2012-003679-21,1,2016-11-16,2016-11-16,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Westdeutsche Studiengruppe GmbH,"A multicenter site, open label, phase II trial to validate predictive markers for the response evaluation of a combined chemo-immunotherapy in patients with HER2-positive early breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003679-21,0,0,0 2012-003680-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Putting Resistance under the Microscope II. ; A Randomized Controlled Trial on the effects of midazolam on the quality of postoperative recovery in patients Weerstand onder de Loep II; Een randomiz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003680-21,0,0,0 2012-003685-40,1,2014-03-20,2014-03-20,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Thoraxkirurgisk afd. Rigshospitalet,"""Doubble blinded RCT comparing 15 versus 30mg Toradol on postoperative VAS-score in ortopedic and ENT patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003685-40,0,0,0 2012-003686-17,20,2020-10-09,2020-11-12,18,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003686-17,0,0,0 2012-003686-17,20,2020-10-09,2020-11-12,18,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Lilly S.A.,"A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003686-17,0,0,0 2012-003687-52,7,2014-08-19,2014-08-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott GmbH & Co. KG,"A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003687-52,0,0,0 2012-003687-52,7,2014-08-19,2014-08-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003687-52,0,0,0 2012-003687-52,7,2014-08-19,2014-08-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ABBOTT GMBH & Co. KG,"A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003687-52,0,0,0 2012-003688-24,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,Treatment of Complex Regional Pain Syndrome type 1: A randomized placebo controlled double-blind study with ARA 290,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003688-24,0,0,0 2012-003689-41,1,2016-08-15,2016-08-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"A Phase IV multicentre, open label study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with everolimus (RAD001) in combination with exem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003689-41,0,0,0 2012-003690-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU Amiens,Administration de la téicoplanine par voie sous cutanée dans le traitement des infections ostéo-articulaires : Etude de tolérance,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003690-25,0,0,0 2012-003691-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,Administration of leukemia-reactive donor T cells after allogeneic stem cell transplantation or donor lymphocyte infusion to patients with persistent or relapsed mature B cell neoplasm with blood and/...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003691-40,0,0,0 2012-003696-18,1,2016-10-07,2016-10-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Cologne,Effect of a preinterventional calorie restriction on renal function after contrast agent exposition in patients at risk. Einfluss einer präinterventionellen kalorienreduzierten Diät auf die Nierenf...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003696-18,0,0,0 2012-003698-25,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University Hospital Southampton NHS Foundation Trust,Proof of concept clinical trial examining the effect of clopidogrel on allergen challenge in asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003698-25,0,0,0 2012-003699-37,6,2015-02-11,2015-02-11,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for 12 weeks in no...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003699-37,0,0,0 2012-003702-27,10,2016-10-13,2017-10-13,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Dr. Falk Pharma GmbH,"Randomized, double-blind, double-dummy, placebo-controlled, Phase III clinical trial on the efficacy and safety of a 12-weeks add-on treatment with LT-02 (gastro-resistant phosphatidylcholine granules...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003702-27,0,0,0 2012-003708-11,5,2018-09-06,2018-09-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Incorporated,"A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003708-11,0,0,0 2012-003708-11,5,2018-09-06,2018-09-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GILEAD SCIENCE INC.,"A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003708-11,0,0,0 2012-003710-13,1,2021-09-29,2021-09-29,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Academic Medical Center,C1-inhibitor improves efficacy of red blood cell transfusion in patients suffering from autoimmune hemolytic anemia – an open-labeled pilot trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003710-13,0,0,0 2012-003718-16,9,2021-04-08,2021-05-14,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Double-Blind Study of BMS-936558 (Nivolumab) vs Dacarbazine in Subjects with Previously Untreated, Unresectable or Metastatic Melanoma Pharmacogenetics Blood Sample Amendment 0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003718-16,0,0,0 2012-003721-22,4,2019-02-26,2019-02-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003721-22,0,0,0 2012-003721-22,4,2019-02-26,2019-02-27,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003721-22,0,0,0 2012-003722-24,1,2014-07-14,2014-07-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Moberg Derma AB,"An open, single-centre pilot study of efficacy and safety of topical MOB015B in the treatment of distal subungual onychomycosis (DSO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003722-24,0,0,0 2012-003724-20,4,2014-12-23,2014-12-23,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Infinity Pharmaceuticals, Inc","A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of IPI- 145 with Background Methotrexate in Subjects with Active Rheumatoid Arthritis and an In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003724-20,0,0,0 2012-003729-62,1,2017-09-04,2017-09-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"CENTER LABORATORIES, INC","A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of R-Verapamil in the Prophylaxis of Episodic Cluster Headache",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003729-62,0,0,0 2012-003735-32,2,2018-04-30,2018-04-30,1,1,0,0,0,0,3,0,0,2,1,0,0,0,1,AB Science,"A 96-weeks, prospective, multicentre, randomised, open label, active-controlled, parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to first line treatment, in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003735-32,1,0,0 2012-003736-23,1,2013-12-02,2013-12-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leeds,RETREAT(F) (REmoval of Treatment for patients in REmission in psoriatic ArThritis – Feasibility study). A randomised controlled trial to compare withdrawal of therapy versus continuing therapy in low ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003736-23,0,0,0 2012-003738-18,4,2015-07-20,2015-08-03,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with Ribavirin Compared to Telaprevir Co-administered with Pegylated Inter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003738-18,0,0,0 2012-003739-44,5,2014-01-09,2014-01-09,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Dignity Sciences Limited,"A Randomised, Double-blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Topically Applied DGLA Cream in Patients with Mild to Moderate Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003739-44,0,0,0 2012-003740-74,1,2013-12-16,2013-12-16,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Multi-Center, Phase IV, Randomized, Controlled, Observer Blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Trivalent Subunit Inactivated Influenza Vaccine in Healthy Subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003740-74,0,0,0 2012-003741-15,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,apceth GmbH & Co. KG,"Treatment of Advanced Gastrointestinal Cancer in a Phase I/II trial with modified autologous MSC_apceth_101. Open-label, multicentre, phase I/II. Behandlung von fortgeschrittenen Tumoren des Gastro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003741-15,0,0,0 2012-003743-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,A prospective randomized Phase II study to identify predictive biomarkers and mechanisms of therapy resistance in patients with HER2-negative metastatic breast cancer (MBC) treated with the combinatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003743-30,0,0,0 2012-003750-89,1,,,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,Philipps-University Marburg,"A placebo-controlled, double blind, randomised trial with crossover-design investigating the effect of oxytocin nasal spray on neuronal processes of empathy Placebo-kontrollierte, doppelblinde, ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003750-89,0,0,0 2012-003753-28,2,2013-12-20,2013-12-20,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Ventrus Biosciences,"A Phase 3B, Randomized, Double-Blind, Placebo-controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Topical Diltiazem Hydrochloride 2% Cream in subjects with Anal Fissure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003753-28,0,0,0 2012-003754-84,4,2015-07-16,2015-07-30,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered with and without Ribavirin Compared to Telaprevir Co-administered with Pegyl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003754-84,0,0,0 2012-003756-36,1,2015-07-01,2015-07-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Birmingham NHS Foundation,The Use of Glyceryl Trinitrate Patches in Arteriovenous Fistulas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003756-36,0,0,0 2012-003757-28,7,2018-07-30,2018-07-30,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A three-arm, randomized, open label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen rece...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003757-28,0,0,0 2012-003757-28,7,2018-07-30,2018-07-30,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A three-arm, randomized, open label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen rece...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003757-28,0,0,0 2012-003763-22,4,2015-07-16,2015-07-16,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Bayer HealthCare AG,"A combined Phase IIa / IIb study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naïve subjects with neovascular age related macular degenera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003763-22,0,0,0 2012-003763-22,4,2015-07-16,2015-07-16,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Bayer HealthCare Aktiengesellschaft,"A combined Phase IIa / IIb study of the efficacy, safety, and tolerability of repeated topical doses of regorafenib eye drops, in treatment-naïve subjects with neovascular age related macular degenera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003763-22,0,0,0 2012-003770-11,1,,,0,0,0,0,1,0,2,0,0,1,1,1,0,1,1,C4Pain ApS,"A multi-center, randomized parallel group pilot study to investigate the mechanism of action of tapentadol PR and oxycodone CR in subjects with osteoarthritis knee pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003770-11,0,0,0 2012-003771-18,2,2017-03-23,2017-03-23,2,1,1,0,0,0,3,0,0,1,0,0,1,0,1,GW Pharma Ltd.,"The efficacy, safety and tolerability of Sativex as an adjunctive treatment to existing anti-spasticity medications in children aged 8 to 18 years with spasticity due to cerebral palsy or traumatic ce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003771-18,0,0,0 2012-003774-76,1,2015-10-01,2015-10-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CUSL,Perioperative ketorolac in high risk breast cancer patients with and without inflammation. A prospective randomized placebo-controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003774-76,0,0,0 2012-003775-20,6,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Shire Human Genetics Therapies Inc,An Open-label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients with Metachromatic Leukodystrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003775-20,0,0,0 2012-003776-40,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Dr. Franz Köhler Chemie GmbH,"A Prospective Randomized Double Blind Multicenter Phase III Study Comparing two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N versus Custodiol Eine prospektive, randomisierte, doppelb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003776-40,0,0,0 2012-003778-16,1,2015-07-01,2015-07-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Guy's & St. Thomas' NHS Foundation Trust,A phase IV study to determine the oral and genital tract concentration of Maraviroc required for ex vivo protection from HIV-1 using Maraviroc 300mg stat,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003778-16,0,0,0 2012-003786-17,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,INSTITUT CURIE,Phase II study evaluating the efficacy of Lenalidomide in association with Rituximab in refractory or relapse of primary central nervous system lymphoma (PCNSL) - “Proof of concept”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003786-17,0,0,0 2012-003787-51,1,2014-06-30,2014-06-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Mona Ring Gätke,Recovery after laparoscopic hysterectomy with deep neuromuscular blockade and low intraabdominal pressure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003787-51,0,0,0 2012-003788-23,5,2016-08-23,2016-08-23,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Celgene Corporation,"A Phase 2 Multicenter, Randomized, Open Label, Multiple Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects with End-Stage Kidney Disease on Hemodialysis Swi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003788-23,0,0,0 2012-003789-41,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,University Medical Center Groningen,HER2-PET as a diagnostic tool in breast cancer patients with a clinical dilemma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003789-41,0,0,0 2012-003790-25,1,2013-07-03,2013-07-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Great Ormond Street Hospital for Children NHS Foundation Trust,Comparison of measured versus predicted blood propofol concentrations in children undergoing spinal surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003790-25,0,0,0 2012-003791-40,1,2013-08-09,2013-08-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Prosonix Limited,"An Investigation of the Efficacy, Tolerability and Safety of a Range of Doses of Orally Inhaled Glycopyrronium Bromide (PSX1002-GB pMDI) in Male and Female Patients with Moderate or Severe Chronic Obs...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003791-40,0,0,0 2012-003798-25,3,2015-05-29,2015-05-29,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Merrimack Pharmaceuticals Inc.,"Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with Trastuzumab in Patients with HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003798-25,0,0,0 2012-003805-86,1,2013-08-30,2013-08-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003805-86,0,0,0 2012-003806-28,1,2014-02-17,2014-02-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization,","A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003806-28,0,0,0 2012-003810-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NOGGO e.V.,"Pazopanib versus Pazopanib plus Gemcitabine in patients with relapsed or metastatic uterine leiomyosarcomas or other uterine tumour: a multi-center, randomized phase-II clinical trial of the NOGGO and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003810-15,0,0,0 2012-003814-15,1,2016-12-15,2016-12-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,HOSPICES CIVILS DE LYON,A multicenter phase II pilot open label study to evaluate the efficacy and safety of BKM120 in the treatment of patients with advanced or metastatic differentiated thyroid cancers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003814-15,0,0,0 2012-003815-71,1,2015-06-09,2015-06-09,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Department of Medical Research,The effect of furosemide on fluid volumes and biomarkers in urine for measurement of sodium and water channel activity in healthy subjects Effekten af furosemid på væskevoluminer og biomarkører i u...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003815-71,0,0,0 2012-003817-32,1,2015-06-19,2015-06-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London,Brain muscle axis during treatment of hepatic encephalopathy with L-ornithine L-aspartate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003817-32,0,0,0 2012-003835-40,1,2016-02-12,2016-02-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Birmingham,"A multicentre, phase II randomised controlled trial evaluating cabazitaxel versus docetaxel re-challenge for the treatment of metastatic Castrate Refractory Prostate Cancer, previously treated with do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003835-40,0,0,0 2012-003837-41,4,2015-09-16,2015-09-16,2,1,0,0,0,2,3,0,0,2,1,0,0,0,1,Eli Lilly and Company,"A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003837-41,1,0,0 2012-003857-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ULB ERASME HOSPITAL,"The Bacteriuria In Renal Transplantation study: A prospective, randomized, multicenter trial comparing antibiotics versus no treatment in the prevention of urinary tract infection in kidney transplant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003857-26,0,0,0 2012-003858-81,1,2014-12-03,2014-12-03,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"RWTH Aachen, Medizinische Fakultät",Effect of Linagliptin therapy on myocardial diastolic function in patients with type 2 diabetes mellitus Effekt von Linagliptin auf die myokardiale diastolische Dysfunktion in Patienten mit Diabete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003858-81,0,0,0 2012-003859-12,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,"RWTH Aachen University for the Medical Faculty, represented by Clinical Trial Center Aachen (CTC-A)",Linagliptin as a modulator of vascular inflammation in patients with type 2 diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003859-12,0,0,0 2012-003866-42,1,2018-03-15,2018-03-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,IST. DI RICERCHE FARMACOLOG. M. NEGRI,"Multicenter, randomized, non-comparative, open-label phase II trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in adult women with platin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003866-42,0,0,0 2012-003875-20,1,2016-12-01,2016-12-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitetssjukhuset Örebro,Postoperative pain relief following total hip arthroplasty. A comparison between 3-in-1 blockade (single shot) with ultrasound placement and local infiltration analgesia. Postoperativ smärtlindrin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003875-20,0,0,0 2012-003876-38,3,2016-10-12,2016-10-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Hexal AG (a Sandoz company),"A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003876-38,0,0,0 2012-003881-42,4,2013-11-19,2013-12-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2b, Multicenter, Open-Label Study in Rheumatoid Arthritis Subjects who Completed Preceding Study M13-390 with Adalimumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003881-42,0,0,0 2012-003882-17,1,2014-03-31,2014-03-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Charité Universitaetsmedizin Berlin,"Effects of modafinil, caffeine and methylphenidate on functional brain activity and cognitive performance in healthy subjects: a randomized, placebo-controlled, double-blind fMRI study. Effekte von...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003882-17,0,0,0 2012-003883-31,1,2019-05-17,2019-05-17,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,Grupo Español de Investigación en Cáncer de Ovario,A randomized phase II multi-centric open label clinical trial to determine the efficacy and toxicity of preoperative chemotherapy with or without bevacizumab in patients with advanced Ovarian Cancer. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003883-31,0,0,0 2012-003895-38,9,2016-03-02,2016-03-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomised, double-blind, multinational study to prevent major vascular events with Ticagrelor compared to Aspirin(ASA) in patients with acute ischaemic stroke or Transient Ischemic Attack (TIA). [S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003895-38,0,0,0 2012-003896-20,1,2017-11-15,2017-11-15,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,TAX-TORC: A Phase I multi-centre trial of the combination of AZD2014 (dual TORC1 and TORC2 inhibitor) and weekly paclitaxel in patients with solid tumours,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003896-20,0,0,0 2012-003896-20,1,2017-11-15,2017-11-15,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,The Institute of Cancer Research,TAX-TORC: A Phase I multi-centre trial of the combination of AZD2014 (dual TORC1 and TORC2 inhibitor) and weekly paclitaxel in patients with solid tumours,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003896-20,0,0,0 2012-003897-21,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Effects of TIcaGREloR on Circulating Microparticles and Micro-RNAs in patients with Non ST Elevation Acute Coronary Syndromes Effetto del TIcaGREloR sulle Microparticelle Circolanti e sui Micro-RNA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003897-21,0,0,0 2012-003902-28,9,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"An open label, multi-center nilotinib roll-over protocol for patients who have completed a previous Novartis-sponsored nilotinib study and are judged by the investigator to benefit from continued nil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003902-28,0,0,0 2012-003902-28,9,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A.,"An open label, multi-center nilotinib roll-over protocol for patients who have completed a previous Novartis-sponsored nilotinib study and are judged by the investigator to benefit from continued nil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003902-28,0,0,0 2012-003902-28,9,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,Novartis Farma S.p.A.,"An open label, multi-center nilotinib roll-over protocol for patients who have completed a previous Novartis-sponsored nilotinib study and are judged by the investigator to benefit from continued nil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003902-28,0,0,0 2012-003914-15,1,2019-05-14,2019-05-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Klinik für Innere Medizin III, Klin. Abteilung für Nephrologie und Dialyse",Continuos versus periodic intravenous iron supplementation in maintenance hemodialysis patients Kontinuierliche versus periodische intravenöse Eisentherapie bei chronischen Hämodialysepatienten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003914-15,0,0,0 2012-003915-73,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medizinische Universität Wien/Univ.klinik für Innere Medizin III/Abteilung für Nephrologie und Dialyse/Prof Josef Smolen,Effect of single dose i.v. iron supplementation on whole-genome transcription in patients with chronic kidney graft failure Auswirkung einer einmaligen i.v.-Eisensubstitution (Eisencarboxymaltose)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003915-73,0,0,0 2012-003921-13,1,2017-04-05,2017-04-05,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University College London,COMbination therapy for PulmonAry hypertension using RacEcadotril (COMPARE).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003921-13,0,0,0 2012-003923-39,1,2018-06-25,2018-06-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Tayside Medical Science Centre,Pilot study to evaluate whether treating persistent small airway dysfunction with extra-fine HFA-Beclometasone results in improved asthma control.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003923-39,0,0,0 2012-003936-21,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Hôpital de Jolimont,"A PROSPECTIVE MULTICENTRIC, PROOF OF CONCEPT STUDY TO EVALUATE THE VALUE OF 18-FDG-PET-SCAN ON TUMOUR RESPONSE IN PATIENTS WITH A PROGRESSIVE PANCREATIC ENDOCRINE TUMOUR RECEIVING A COMBINATION THERAP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003936-21,0,0,0 2012-003937-41,1,2015-12-27,2015-12-27,1,1,1,0,1,0,2,0,1,1,0,0,1,0,1,GSK Vaccines S.r.l,"Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003937-41,0,0,0 2012-003939-27,1,2015-08-19,2015-08-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Klaus Krogh,"Objective evaluation of the effects of pasireotide on gastrointestinal and colorectal transit times, rectal wall properties, and postprandial response in patients with carcinoid diarrhea Undersøgel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003939-27,0,0,0 2012-003941-13,5,2014-05-28,2014-05-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Comparison of LY2605541 versus Human Insulin NPH as Basal Insulin Treatment in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with 2 or more Oral Antihyperglycemic Me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003941-13,0,0,0 2012-003941-13,5,2014-05-28,2014-05-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,A Comparison of LY2605541 versus Human Insulin NPH as Basal Insulin Treatment in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with 2 or more Oral Antihyperglycemic Me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003941-13,0,0,0 2012-003942-33,1,2014-03-07,2014-03-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003942-33,0,0,0 2012-003943-32,1,2018-08-05,2018-08-05,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Charité University Medicine Berlin,Influence of diabetes control on treatment of diabetic macular edema with ranibizumab Einfluss eines Diabetes-Managements auf die Behandlung des diabetischen Makulaödems mit Ranibizumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003943-32,0,0,0 2012-003946-34,3,2015-08-03,2015-08-03,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"VIVUS, Inc.",A Qsymia™ CardiovascuLAr morbIdity and Mortality (AQCLAIM) Study in Subjects with Documented Cardiovascular Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003946-34,1,0,0 2012-003947-31,1,2020-04-20,2020-04-20,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Oxford University Hospitals NHS Trust,"Optimising Renal outcome in Myeloma renal failure A pilot study of Thalidomide, Bendamustine, and Dexamethasone (TBD) vs Bortezomib, Bendamustine, and Dexamethasone (BBD) in patients with renal failu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003947-31,0,0,0 2012-003948-67,4,2016-10-15,2016-11-10,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization,Inc","A Phase 3, Multicenter, Randomized, Double-blind, Placebo- and Active Comparator-controlled Trial of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003948-67,0,0,0 2012-003950-10,1,2014-02-21,2014-02-21,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"An open, phase IV, single-group, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immune response to a challenge dose of Engerix™-B Kinder in adolescents...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003950-10,0,0,0 2012-003954-95,1,2014-01-17,2014-01-17,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Spirig Pharma AG,"Prospective, randomized, double-blind, placebo-controlled, clinical trial to explore the anti-pruritic effect, the safety and local tolerability of a topical Sertaconazol cream 2% in patients with ato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003954-95,0,0,0 2012-003958-82,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,ISTITUTO ONCOLOGICO VENETO,Comparison of three different medicines for bowel cleasing for total colonoscopy. Confronto tra differenti sistemi di pulizia del colon per la preparazione alla colonscopia di screening,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003958-82,0,0,0 2012-003965-16,3,2021-04-15,2021-04-22,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Single-Arm Phase 2 Study of BMS-936558 in Subjects with Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003965-16,0,0,0 2012-003966-42,5,2014-12-06,2014-12-06,5,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Pulmagen Therapeutics LLP,"A Randomised, Double Blind, Placebo-Controlled, Multi-Centre, Parallel Group Study to Evaluate the Efficacy and Safety of ADC3680 Administered Once Daily as an Add-On Therapy to Inhaled Corticosteroid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003966-42,0,0,0 2012-003967-23,7,2015-05-04,2015-05-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pharmacyclics, Incorporated","A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic Leuk...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003967-23,0,0,0 2012-003968-44,6,2016-03-22,2016-03-22,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Pharmacyclics, Incorporated",An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 versus Chloram...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003968-44,1,0,0 2012-003968-44,6,2016-03-22,2016-03-22,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Pharmacyclics LLC,An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 versus Chloram...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003968-44,1,0,0 2012-003971-20,8,2014-10-23,2014-10-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cempra Pharmaceuticals, Inc.","A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in the Treatment of Adult Patients with Community-Acqui...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003971-20,0,0,0 2012-003973-24,3,2013-09-24,2014-01-24,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,A Multicenter Trial Comparing the Efficacy and Safety of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily with Tiotropium 18 mcg Once Daily over 24 Weeks in Subjects with Chronic Obstructive Pulmonary D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003973-24,0,0,0 2012-003973-24,3,2013-09-24,2014-01-24,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.",A Multicenter Trial Comparing the Efficacy and Safety of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily with Tiotropium 18 mcg Once Daily over 24 Weeks in Subjects with Chronic Obstructive Pulmonary D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003973-24,0,0,0 2012-003974-18,2,2014-11-28,2014-11-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vascular Biogenics Ltd.,"A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed by a 12-Week Extension Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in Subjects with Mild to Moderate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003974-18,0,0,0 2012-003977-24,1,2015-08-20,2015-08-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astex Pharmaceuticals Inc,A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment with Sorafenib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003977-24,0,0,0 2012-003981-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,University Medical Center Groningen,Estrogen receptor and androgen receptor imaging in metastatic breast cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003981-42,0,0,0 2012-003981-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,VUMC,Estrogen receptor and androgen receptor imaging in metastatic breast cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003981-42,0,0,0 2012-003983-32,5,2016-10-27,2016-10-27,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Cosmo Technologies Ltd,The safety and efficacy of Methylene Blue MMX® modified release tablets administered to subjects undergoing screening or surveillance colonoscopy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003983-32,1,0,0 2012-003984-23,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Fundació Clínic per a la Recerca Biomèdica,A phase III open label study to evaluate safety and efficacy of Boceprevir-response guided therapy in controlled HIV patients with chronic hepatitis C genotype 1 infection who failed previously to Peg...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003984-23,0,0,0 2012-003987-34,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,UZ Leuven,"“Therapeutic interventions on senescence markers after human kidney transplantation, does metformine meets his expectations?”",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003987-34,0,0,0 2012-003989-40,7,2014-04-29,2014-04-29,6,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003989-40,0,0,0 2012-003990-24,6,2014-04-17,2014-04-25,6,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003990-24,0,0,0 2012-003995-38,2,2016-02-04,2016-02-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A double-blind, placebo-controlled, study examining the effect of orally administered QAW039 (450 mg QD) on FEV1 and ACQ in non-atopic, asthmatic patients with a baseline, pre-bronchodilator FEV1 of 4...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003995-38,0,0,0 2012-003996-20,1,2015-04-28,2015-04-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alkermes, Inc.","A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects with Stable Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-003996-20,0,0,0 2012-004002-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Department of Dermatology and Allergology, University of Szeged",Comparison of the effectiveness of desloratadine monotherapy and the combined cinnarizine and iprazochrome therapy for the treatment of urticaria factitia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004002-10,0,0,0 2012-004004-36,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Med. Univ. Wien, UK für Kinder und Jugendheilkunde",Pilot Study to define the Feasibility of ex-vivo LPS stimulated Cytokine release for Testing Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solutions in Peritoneal Dialysis (PD) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004004-36,0,0,0 2012-004006-96,12,2016-01-07,2016-10-19,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Astrazeneca AB,"A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004006-96,0,0,0 2012-004006-96,12,2016-01-07,2016-10-19,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ASTRAZENECA,"A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004006-96,0,0,0 2012-004007-13,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Deutsches Krebsforschungszentrum (DKFZ,"A randomized, placebo-controlled, phase IIIb HPV vaccination trial with Gardasil® in patients with recurrent condylomata acuminata",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004007-13,0,0,0 2012-004008-37,1,2017-06-30,2017-06-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,GITMO,"A phase II multicentre open-label study on allogeneic stem cell transplantation from unrelated, cord-blood and family haploidentical donors in patients with active acute leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004008-37,0,0,0 2012-004013-13,8,2016-03-07,2016-06-18,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004013-13,0,0,0 2012-004018-33,5,2017-12-15,2017-12-15,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Philogen S.p.A.,A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004018-33,0,0,0 2012-004019-29,8,2014-01-22,2015-04-17,3,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple scl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004019-29,1,0,0 2012-004019-29,8,2014-01-22,2015-04-17,3,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple scl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004019-29,1,0,0 2012-004019-29,8,2014-01-22,2015-04-17,3,1,0,0,0,0,2,0,0,2,1,0,0,0,1,NOVARTIS FARMA,"A Phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled, adaptive dose-ranging study to evaluate the efficacy and safety of AIN457 in patients with relapsing multiple scl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004019-29,1,0,0 2012-004022-21,12,2014-04-01,2016-03-11,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A Phase II multi-center, open label, randomized study to assess safety and efficacy of two different schedules of oral LDE225 in adult patients with relapsed/refractory or untreated elderly patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004022-21,0,0,0 2012-004022-21,12,2014-04-01,2016-03-11,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,"A Phase II multi-center, open label, randomized study to assess safety and efficacy of two different schedules of oral LDE225 in adult patients with relapsed/refractory or untreated elderly patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004022-21,0,0,0 2012-004022-21,12,2014-04-01,2016-03-11,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA S.p.A.,"A Phase II multi-center, open label, randomized study to assess safety and efficacy of two different schedules of oral LDE225 in adult patients with relapsed/refractory or untreated elderly patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004022-21,0,0,0 2012-004023-20,9,2018-04-10,2018-04-10,7,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Novartis Pharma Services AG,"A Phase Ib/II, open-label, multi-center, dose-finding study to assess the safety and efficacy of the oral combination of LDE225 and INC424 (Ruxolitinib) in patients with myelofibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004023-20,0,0,0 2012-004023-20,9,2018-04-10,2018-04-10,7,1,0,1,0,1,1,0,0,1,1,0,0,0,1,NOVARTIS FARMA,"A Phase Ib/II, open-label, multi-center, dose-finding study to assess the safety and efficacy of the oral combination of LDE225 and INC424 (Ruxolitinib) in patients with myelofibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004023-20,0,0,0 2012-004023-20,9,2018-04-10,2018-04-10,7,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Novartis Farmacéutica S.A.,"A Phase Ib/II, open-label, multi-center, dose-finding study to assess the safety and efficacy of the oral combination of LDE225 and INC424 (Ruxolitinib) in patients with myelofibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004023-20,0,0,0 2012-004024-38,1,2014-05-05,2014-05-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Consumer Health S.A.,"A 4-week, randomized, double-blind, multi-center, vehicle-controlled, parallel group study to assess the efficacy and safety of diclofenac diethylamine 2.32% gel for the relief of signs and symptoms i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004024-38,0,0,0 2012-004025-24,1,2018-08-01,2018-08-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Liverpool,A trial of de-escalation and stopping treatment in chronic myeloid leukaemia patients with excellent responses to tyrosine kinase inhibitor therapy DESTINY(De- Escalation and Stopping Treatment of Im...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004025-24,0,0,0 2012-004025-24,1,2018-08-01,2018-08-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Royal Liverpool and Broagreen University Hospitals NHS Trust,A trial of de-escalation and stopping treatment in chronic myeloid leukaemia patients with excellent responses to tyrosine kinase inhibitor therapy DESTINY(De- Escalation and Stopping Treatment of Im...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004025-24,0,0,0 2012-004027-20,4,2020-10-28,2020-10-28,3,1,0,0,0,0,2,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects with Relapsed / Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004027-20,1,0,0 2012-004031-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hopital Erasme,Serum pharmacokinetics of Caspofungin in patients with liver failure.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004031-23,0,0,0 2012-004034-42,6,2016-03-07,2016-05-17,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004034-42,0,0,0 2012-004035-23,7,2019-09-15,2019-10-09,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Rel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004035-23,1,1,0 2012-004035-23,7,2019-09-15,2019-10-09,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as","A Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Rel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004035-23,1,1,0 2012-004035-23,7,2019-09-15,2019-10-09,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Merck)","A Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Rel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004035-23,1,1,0 2012-004035-23,7,2019-09-15,2019-10-09,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Merck Sharp & Dohme Corp.,"A Phase III Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Rel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004035-23,1,1,0 2012-004039-21,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,GlaxoSmithKline,"An open, multicentric, post-marketing surveillance study to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals’ live attenuated oral Human Rotavirus (HRV) vaccine, Rotarix when admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004039-21,0,1,1 2012-004040-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ospedale Regionale di Lugano,Natalizumab de-escalation to interferon-beta-1b in patients with relapsing-remitting multiple sclerosis: A multicenter study Natalizumab Deeskalation mit Interferon-beta-1b bei Patienten mit schubf...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004040-30,0,0,0 2012-004045-33,5,2014-07-10,2014-07-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Poxel S.A.,"A dose-ranging, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of 4 doses of imeglimin after 24 weeks of treatment in subjects with type 2 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004045-33,0,0,0 2012-004046-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"ORtopædkirurgisk Forskningsenhed, Aarhus Universitetshospital","A 4-way randomized double-blinded migration (RSA), bone density (DXA), and biomarker study assessing adaptive bone changes and implant fixation and longevity of the new Regenerex Porous Titanium Tibia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004046-15,0,0,0 2012-004048-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,"Multicenter single-arm pilot study evaluating efficacy of nilotinib in CML patients with molecular relapse after Glivec discontinuation within the context of the STIM trials (STIM and STIM2), Nilo Pos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004048-31,0,0,0 2012-004049-34,4,2013-05-30,2013-05-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from a stable dose of recombinant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004049-34,0,0,0 2012-004050-29,1,2013-05-07,2013-05-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A four-week Phase IIa, randomized, double-blind, placebocontrolled, parallel-group, multi-center study to evaluate the safety, efficacy and pharmacokinetics of GSK1278863 in subjects with anemia assoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004050-29,0,0,0 2012-004053-88,13,,,0,0,0,0,0,2,0,0,0,3,0,0,0,0,0,Justus-Liebig-University Giessen,EuroNet-Paediatric Hodgkin’s Lymphoma Group Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004053-88,0,0,0 2012-004053-88,13,,,0,0,0,0,0,2,0,0,0,3,0,0,0,0,0,Justus Liebig Universität Gießen,EuroNet-Paediatric Hodgkin’s Lymphoma Group Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004053-88,0,0,0 2012-004053-88,13,,,0,0,0,0,0,2,0,0,0,3,0,0,0,0,0,Jagiellonian University Medical College,EuroNet-Paediatric Hodgkin’s Lymphoma Group Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004053-88,0,0,0 2012-004053-88,13,,,0,0,0,0,0,2,0,0,0,3,0,0,0,0,0,Justus Liebig University of Giessen,EuroNet-Paediatric Hodgkin’s Lymphoma Group Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004053-88,0,0,0 2012-004053-88,13,,,0,0,0,0,0,2,0,0,0,3,0,0,0,0,0,"Justus Liebig University, Giesses",EuroNet-Paediatric Hodgkin’s Lymphoma Group Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004053-88,0,0,0 2012-004053-88,13,,,0,0,0,0,0,2,0,0,0,3,0,0,0,0,0,JUSTUS LIEBIG UNIVERSITY OF GIESSEN,EuroNet-Paediatric Hodgkin’s Lymphoma Group Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004053-88,0,0,0 2012-004053-88,13,,,0,0,0,0,0,2,0,0,0,3,0,0,0,0,0,Martin Luther University of Halle/Wittenberg,EuroNet-Paediatric Hodgkin’s Lymphoma Group Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004053-88,0,0,0 2012-004056-11,15,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects Wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004056-11,0,0,0 2012-004058-27,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO ONCOLOGICO VENETO,Cytoreductive surgery associated with Hyperthermic Intraperitoneal Chemotherapy versus standard Chemotherapy in the treatment of resectable colorectal carcinomatosis. A multicentric open randomized cl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004058-27,0,0,0 2012-004060-22,1,,,0,1,0,0,0,1,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase II, open, controlled, multicenter study to evaluate the long-term antibody persistence at 1, 3 and 5 years after the administration of a four dose vaccination series of Hib-MenCY-TT vaccine co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004060-22,0,1,1 2012-004062-17,1,2016-12-28,2016-12-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Aristotle University of Thessaloniki,"Efficacy of add-on pregabalin in the treatment of Generalized Anxiety Disorder comorbid with Major Depressive Disorder: a double-blind placebo-controlled study. Τυχαιοποιημένη, διπλά-τυφλή μελέτη, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004062-17,0,0,0 2012-004063-52,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA PATIENTS ACHIEVING AT LEAST VGPR AFTER INDUCTION THERAPY: MINIMAL RESIDUAL DISEASE MONITORING MANTENIMENTO CON LENALIDOMIDE IN PAZIENTI CON MIELOMA MU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004063-52,0,0,0 2012-004065-41,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Erasmus Medical Centre,Comparative study of pharmacokinetics of amlodipine besilate oral liquid and tablets in healthy Dutch volunteers Vergelijkend onderzoek naar de farmacokinetiek van amlodipine besilaat orale drank e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004065-41,0,0,0 2012-004071-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO,Study on the effectiveness and safety of the treatment of mild-moderate symptomatic hyponatremia due to syndrome of inappropriate secretion of antidiuretic hormone (SIADH) with Tolvaptan vs fluid res...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004071-39,0,0,0 2012-004072-19,8,2015-05-06,2015-05-06,7,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Vectura GmbH,"A randomized, double-blind, parallel group, placebo controlled Phase II study to evaluate the safety and efficacy of inhaled LASAG and Placebo, applied three times daily in adult hospitalized patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004072-19,0,0,0 2012-004072-19,8,2015-05-06,2015-05-06,7,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Activaero GmbH,"A randomized, double-blind, parallel group, placebo controlled Phase II study to evaluate the safety and efficacy of inhaled LASAG and Placebo, applied three times daily in adult hospitalized patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004072-19,0,0,0 2012-004074-25,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Ruhr-Universität Bochum,"Comparison of the efficacy and safety of two different starting dosages of prednisolone in early active rheumatoid arthritis: a randomized, placebo controlled trial Vergleich der Wirksamkeit und Si...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004074-25,0,0,0 2012-004076-19,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITY HOSPITALS LEUVEN/BELGIAN GYNAECOLOGICAL ONCOLOGY GROUP,"ENGOT-cx1/BGOG-cx1: ""Randomized double-blind Phase II study comparing 3-weekly carboplatin (AUC 5) + paclitaxel 175 mg/m2 with or without concomitant and maintenance nintedanib (NINTEDANIB) in advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004076-19,0,0,0 2012-004076-19,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZ Leuven / Belgian Gynaecological Oncology Group,"ENGOT-cx1/BGOG-cx1: ""Randomized double-blind Phase II study comparing 3-weekly carboplatin (AUC 5) + paclitaxel 175 mg/m2 with or without concomitant and maintenance nintedanib (NINTEDANIB) in advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004076-19,0,0,0 2012-004078-24,1,2019-11-15,2019-11-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,"Intravitreal Tissue Plasminogen Activator (tPA), Perfluoropropane (C3F8), and Ranibizumab for Neovascular Age-Related Macular Degeneration and Submacular Haemorrhage (TAPAS): A Randomized, Double-Mask...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004078-24,0,0,0 2012-004078-24,1,2019-11-15,2019-11-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,"Intravitreal Tissue Plasminogen Activator (tPA), Perfluoropropane (C3F8), and Ranibizumab for Neovascular Age-Related Macular Degeneration and Submacular Haemorrhage (TAPAS): A Randomized, Double-Mask...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004078-24,0,0,0 2012-004079-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Central Institute of Mental Health, Department of Psychiatry and Psychotherapy","Agomelatine treatment of major depressive episodes in the course of schizophrenic psychoses (AGOPSYCH). A single arm, prospective pilot study Agomelatin zur Behandlung majorer, depressiver Episode...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004079-38,0,0,0 2012-004081-18,1,2014-04-29,2014-04-29,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,Umecrine Mood AB,"A randomized, double-blind, placebo-controlled parallel-group study on safety, tolerability, pharmacokinetics and pharmacodynamics of UC1010 administered subcutaneously, single-dosing in healthy women...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004081-18,0,0,0 2012-004082-41,1,2021-02-28,2021-02-28,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Dekan of Faculty of Medicine of Goethe-University Frankfurt,"Monocenter, double blind, randomised, placebo controlled study t evaluate Physostigmin for the Treatment of delirium in perioperative intensive care medicine Monozentrische, doppelblinde, randomisi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004082-41,0,0,0 2012-004083-21,2,2015-04-30,2021-11-02,2,0,0,1,0,1,1,0,0,1,0,0,0,0,1,"Epizyme, Inc.","An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004083-21,0,0,0 2012-004087-22,1,2014-08-28,2014-08-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Innsbruck / Univ.-Klinik für Allg. und Chirurg. Intensivmedizin,Bicentric clinical trial with in vitro experiments to assess the effect of Fibrinogen (FGTW) on Coagulation in Thrombocytopenia Bizentrische Arzneimittelstudie mit in-vitro Experimenten zur Unters...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004087-22,0,0,0 2012-004089-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Universitätsklinik für Innere Medizin III, Klinische Abteilung für Rheumatologie, Medizinische Universität Wien",The effect of the interleukin-1 receptor antagonist Anakinra in patients with osteoarthritis of the hand: The AHOA (Anakinra in hand osteoarthritis) pilot study Interleukin-1 Receptor-Blockade mi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004089-16,0,0,0 2012-004090-16,4,2015-04-27,2015-04-27,2,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, placebo-controlled trial for establishing safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of multiple subcutaneous doses of BI 655064 in heal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004090-16,0,0,0 2012-004090-16,4,2015-04-27,2015-04-27,2,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Boehringer Ingelheim B.V,"A randomised, double-blind, placebo-controlled trial for establishing safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of multiple subcutaneous doses of BI 655064 in heal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004090-16,0,0,0 2012-004090-16,4,2015-04-27,2015-04-27,2,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, placebo-controlled trial for establishing safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of multiple subcutaneous doses of BI 655064 in heal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004090-16,0,0,0 2012-004090-16,4,2015-04-27,2015-04-27,2,1,0,1,0,0,1,0,1,1,0,0,0,0,1,"Boehringer Ingelheim España, S.A.","A randomised, double-blind, placebo-controlled trial for establishing safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of multiple subcutaneous doses of BI 655064 in heal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004090-16,0,0,0 2012-004091-19,3,2013-09-25,2013-09-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Auxilium UK Limited,"A Phase 3b open-label, historically-controlled study to assess the safety and efficacy of two concurrent injections of AA4500 in adult subjects with multiple Dupuytren’s contractures with palpable cor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004091-19,0,0,0 2012-004092-40,14,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A single-arm, multicenter, nilotinib treatment-free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004092-40,0,0,0 2012-004092-40,14,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A,"A single-arm, multicenter, nilotinib treatment-free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004092-40,0,0,0 2012-004092-40,14,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,NOVARTIS FARMA,"A single-arm, multicenter, nilotinib treatment-free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004092-40,0,0,0 2012-004096-38,10,2014-12-03,2015-12-23,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT,"A randomized, open-label, active-controlled, 3-arm parallel-group, 26- week study comparing the efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine thre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004096-38,0,0,0 2012-004096-38,10,2014-12-03,2015-12-23,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, open-label, active-controlled, 3-arm parallel-group, 26- week study comparing the efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine thre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004096-38,0,0,0 2012-004097-26,6,2016-05-18,2016-05-18,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (ibrutinib) in Subjects with Refractory Follicular Lymphoma Uno studio di fase II a braccio singolo, multicentrico, in aperto su ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004097-26,0,0,0 2012-004097-26,6,2016-05-18,2016-05-18,6,1,0,0,0,2,2,0,0,1,0,0,1,0,1,JANSSEN-CILAG INTERNATIONAL N.V.,"An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (ibrutinib) in Subjects with Refractory Follicular Lymphoma Uno studio di fase II a braccio singolo, multicentrico, in aperto su ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004097-26,0,0,0 2012-004098-26,6,2016-12-14,2016-12-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy St...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004098-26,0,0,0 2012-004098-26,6,2016-12-14,2016-12-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA,A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy St...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004098-26,0,0,0 2012-004099-20,7,2017-12-28,2017-12-28,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Auris Medical AG,Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 3 (TACTT3),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004099-20,0,0,0 2012-004100-35,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Fundació per la Recerca i la Docència Sant Joan de Déu,"A prospective, open-label, randomized, two-armed clinical trial to evaluate the efficacy and safety of a combination of ethinyl-estradiol and levonorgestrel versus a low-dose combination of pioglitazo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004100-35,0,0,0 2012-004103-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Jean Perrin,ISOTOVE study Isotopic study of the intraperitoneal distribution of locoregional post surgery chemotherapy for peritoneal carcinomatosis of ovarian origin Etude ISOTOVE Etude isotopique de la dist...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004103-12,0,0,0 2012-004104-35,4,2018-02-22,2018-02-22,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Array BioPharma Inc.,"A phase IB/II, multicenter, open label, study of LEE011 in combination with MEK162 in adult patients with NRAS mutant melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004104-35,0,0,0 2012-004104-35,4,2018-02-22,2018-02-22,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A phase IB/II, multicenter, open label, study of LEE011 in combination with MEK162 in adult patients with NRAS mutant melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004104-35,0,0,0 2012-004104-35,4,2018-02-22,2018-02-22,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,NOVARTIS FARMA S.p.A.,"A phase IB/II, multicenter, open label, study of LEE011 in combination with MEK162 in adult patients with NRAS mutant melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004104-35,0,0,0 2012-004108-37,7,2018-02-02,2018-10-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Nottingham,Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage TICH-2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004108-37,0,0,0 2012-004109-28,1,2014-07-02,2014-07-02,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Reckitt Benckiser Healthcare (UK) Ltd,"A randomised, 4 way crossover, double blind, placebo controlled pilot study in patients with reflux symptoms, to assess suppression of gastro-oesophageal reflux by ‘Gaviscon Double Action Mint ’ using...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004109-28,0,0,0 2012-004111-32,1,2014-05-30,2014-05-30,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Charité Universitätsmedizin Berlin,"Prospective, open-label, multicentre study on the incidence of Squamous Cell Carcinoma and Actinic Keratoses in solid organ transplant recipients treated with per protocol, cyclic field application of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004111-32,0,0,0 2012-004112-63,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Academic Medical Center,The Dutch STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset intrauterine growth Restriction) Trial The Dutch STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset intrauterine growt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004112-63,0,0,0 2012-004113-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"GZA vzw, GZA Ziekenhuizen, Sint-Augustinus","A Phase II, Open-Label, Safety, Efficacy and Pharmacodynamic Study of oral sonidegib in patients with Basal Cell Carcinoma (BCC) and prior exposure to Hedgehog Pathway inhibitors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004113-13,0,0,0 2012-004117-14,1,2014-11-22,2014-11-22,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cardiff University,A feasibility study to inform the design of a randomised controlled trial to identify the most clinically and cost effective length of Anticoagulation with Low molecular weight heparin In the treatmen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004117-14,0,0,0 2012-004118-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE),"High-dose cyclophosphamide role in the prophylaxis of GVHD in elderly patients (66-70 years) with acute leukemia or myelodysplasia high-risk, submitted to allogenic transplant of peripheral hematopoie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004118-33,0,0,0 2012-004123-20,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,"Centre du Cancer, Cliniques universitaires Saint-Luc","A single arm, multicenter, phase II study of BEZ235 as monotherapy in patients with locally advanced or metastatic Transitional Cell Carcinoma (TCC) after failure of platinum based chemotherapy. Et...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004123-20,0,0,0 2012-004124-38,2,2014-11-29,2014-11-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 with Atazanavir +/- Ritonavir (Open-Labe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004124-38,0,0,0 2012-004125-24,4,2021-01-19,2021-01-19,2,1,0,0,0,0,3,0,0,2,0,0,0,0,0,AGO Research GmbH,A prospective randomized Phase III trial of carboplatin/gemcitabing/bevacizumab vs caboplatin/pegylated lipsomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004125-24,1,0,0 2012-004125-24,4,2021-01-19,2021-01-19,2,1,0,0,0,0,3,0,0,2,0,0,0,0,0,Greater Glasgow Health Board,A prospective randomized Phase III trial of carboplatin/gemcitabing/bevacizumab vs caboplatin/pegylated lipsomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004125-24,1,0,0 2012-004126-17,1,2015-10-30,2015-10-30,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,GOIM GRUPPO ONCOLOGICO MERIDIONALE,Cisplatin and capecitabine (ECX) in stomach adenocarcinoma()tratment in advanced stage.Multicenter randomized phase II trial foolwed by GOIM. Docetaxel in associazione ad Oxaliplatino e Xeloda (DO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004126-17,0,0,0 2012-004128-39,8,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,"Millennium Pharmaceuticals, Inc","A Phase 4, Open?label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Estudio de fase 4, abierto, con un único grupo de trat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004128-39,0,0,0 2012-004128-39,8,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,"Takeda Development Center (TDC) Americas, Inc.","A Phase 4, Open?label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Estudio de fase 4, abierto, con un único grupo de trat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004128-39,0,0,0 2012-004131-23,1,2014-07-11,2014-07-11,1,1,0,0,0,0,2,0,1,1,1,1,1,0,1,Reckitt Benckiser Healthcare (UK) Ltd,"A single-centre, randomised, 2 way crossover, double blind, placebo controlled study in healthy volunteers, to characterise the antacid activity of Gaviscon Double Action Mint Liquid in the fasted sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004131-23,0,0,0 2012-004132-33,1,2014-04-03,2014-04-03,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Sunovion Pharmaceuticals Inc.,"A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder with Mixed Features (Protocol No D1050304)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004132-33,0,0,0 2012-004137-16,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, randomized, open-label, multicentre study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ combined DTPa-IPV/Hib vaccine administered as a three-dos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004137-16,0,1,1 2012-004138-41,1,2015-09-15,2015-09-15,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,AZIENDA OSPEDALIERA DI PARMA,Anti-viral T cell responses in patients with chronic HCV infection treated with telaprevir: can therapy induce functional T cell reconstitution? Risposte T-linfocitarie HCV-specifiche in pazienti c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004138-41,0,0,0 2012-004154-28,4,2014-06-17,2014-07-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Inc,"A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004154-28,0,0,0 2012-004160-22,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Leiden University Medical Center,IEMO 80-plus thyroid trial IEMO 80-plus schildklier studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004160-22,0,0,0 2012-004162-17,9,2016-05-04,2016-05-04,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research Limited,"A randomised, double-blind, double dummy, parallel group study comparing Fluticasone propionate / formoterol fumarate (flutiform®) 250/10 mcg (2 puffs BID) and flutiform® 125/5 mcg (2 puffs BID) versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004162-17,0,0,0 2012-004163-50,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación para la Investigación Biomédica del Hospital,"Comparative, randomized, double-blind clinical trial on end-tidal concentration of sevoflurane associated to remifentanil required for insertion of the Supreme Laryngeal Mask vs. Pro-Seal Laryngeal Ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004163-50,0,0,0 2012-004165-41,1,2019-10-18,2019-10-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Northwestern University,Hematopoietic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004165-41,0,0,0 2012-004166-18,1,2018-11-29,2018-11-29,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Fédération Francophone de Cancérologie Digestive (FFCD),Intra-arterial hepatic beads loaded with irinotecan (Debiri) with concomitant chemotherapy with FOLFOX in patients with colorectal cancer with unresectable liver metastases: a phase II multicenter stu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004166-18,0,0,0 2012-004169-42,11,2014-04-01,2014-04-01,6,1,0,0,0,0,3,0,0,1,1,1,1,0,1,H. Lundbeck A/S,"Interventional, open-label, long-term extension study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in patients with major depressive disorder.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004169-42,0,0,0 2012-004170-26,1,2013-09-09,2013-09-09,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Randomized double blinde placebo controlled trial to evaluate the efficacy of N-acetylcystein in patients with chronic pancreatitis and primary sclerosing cholangitis. Trial clinico randomizzato e ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004170-26,0,0,0 2012-004178-24,1,2015-04-30,2015-04-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Fresenius Medical Care Deutschland GmbH,Study to investigate the therapeutic equivalence of OsvaRen® tablets and OsvaRen® granules,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004178-24,0,0,0 2012-004179-38,14,2014-08-07,2014-08-07,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004179-38,0,0,0 2012-004180-43,11,2016-05-27,2021-06-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People usin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004180-43,0,0,0 2012-004180-43,11,2016-05-27,2021-06-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People usin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004180-43,0,0,0 2012-004180-43,11,2016-05-27,2021-06-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER AG,A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People usin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004180-43,0,0,0 2012-004180-43,11,2016-05-27,2021-06-15,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer B.V.,A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People usin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004180-43,0,0,0 2012-004181-18,1,2014-08-29,2014-08-29,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Rigshospitalet; Department of Anaesthesia,"The effect of dexamethasone in combination with paracetamol and ibuprofen as adjuvant, postoperative pain after herniated disk surgery Effekten af dexamethason i kombination med parace-tamol og ibu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004181-18,0,0,0 2012-004183-21,1,2016-05-27,2016-05-27,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,North Bristol NHS Trust,"A randomized, double blind, placebo controlled, cross over trial of Melatonin for the treatment of nocturia in adults with progressive multiple sclerosis, with an open label, single-arm extension stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004183-21,0,0,0 2012-004185-17,4,2015-03-24,2015-03-24,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multicenter, open-label, randomized, 3-arm, phase II profiling trial of pharmacokinetics, pharmacodynamics and safety of DEB025/Alisporivir in combination with ribavirin therapy in chronic hepatit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004185-17,0,0,0 2012-004188-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,Prospective randomized study FOR THE ASSESSMENT OF EFFECTS OF DIFFERENT Statins ON ENDOTHELIAL FUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE STUDIO PROSPETTICO RANDOMIZZATO PER LA VALUTAZIO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004188-38,0,0,0 2012-004190-12,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of MK-8808 versus MabThera™ in Patients with Advanced CD20-Positive Follicular Lymphoma. Studio multicentrico, random...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004190-12,0,0,0 2012-004194-12,1,2014-11-21,2014-11-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, HNO Klinik","The effect of BM32, a recombinant hypoallergenic vaccine for immunotherapy of grass pollen allergy, on immunoglobulin levels in nasal secretions of patients suffering from seasonal allergic rhinitis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004194-12,0,0,0 2012-004208-37,14,2016-07-29,2016-07-29,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc,"A Double-Blind, Randomized, Multi-Center, Placebo-Controlled, Parallel Group Study to Determine the Effects of Evolocumab (AMG-145) Treatment on Atherosclerotic Disease Burden As Measured By Intravasc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004208-37,0,0,0 2012-004211-31,1,2019-12-19,2019-12-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The Royal Marsden NHS Foundation Trust,Randomised double-blind controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline (PTX) in patients suffering long-term adverse effects of radiotherapy for pelvic cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004211-31,0,0,0 2012-004214-34,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),"Comparison of efficacy and acceptability of bisacodil and PEG-CS 2 L and PEG 4 L in patients with chronic inflammatory bowel disease: single center, randomized, single blind, parallel groups study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004214-34,0,0,0 2012-004221-25,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Sanofi Pasteur MSD,A phase 3 open-label study to evaluate the immunogenicity and safety of a mixed (HEXA/PENTA/HEXA) primary series schedule that includes V419 (PR5I) at 2 and 6 months of age and Pediacel® at 4 months o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004221-25,0,0,0 2012-004222-25,3,2017-02-10,2017-02-10,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AB Science,"A 12-week with possible extension, prospective, multicenter, randomised, double-blind, controlled, 2-parallel groups, phase 2b/3 study to compare efficacy and safety of masitinib to placebo, in the tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004222-25,1,0,0 2012-004223-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,WEEKLY PEMETREXED (ALIMTA®) AND RADIOTHERAPY IN LOCALLY ADVANCED OR LOCALLY RELAPSED NON-SQUAMOUS NON SMALL CELL LUNG CANCERS (NSCLC) Pemetrexed settimanale e Radioterapia nel Tumore del Polmone ad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004223-20,0,0,0 2012-004225-24,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004225-24,0,0,0 2012-004228-40,2,2017-06-29,2018-06-29,2,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Novartis Pharma Services AG,"A phase I, multi-center, open-label study of LEE011 in patients with malignant rhabdoid tumors and neuroblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004228-40,0,0,0 2012-004229-25,5,2015-10-05,2015-10-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg with Placebo on Glycemic Control in Patients with Type 2 Diabetes on Basal Insulin Glargine (AWARD-9: Assessment of Weekly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004229-25,0,0,0 2012-004229-25,5,2015-10-05,2015-10-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg with Placebo on Glycemic Control in Patients with Type 2 Diabetes on Basal Insulin Glargine (AWARD-9: Assessment of Weekly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004229-25,0,0,0 2012-004231-24,1,2015-05-05,2015-05-05,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Department für Virologie, Medizinische Universität Wien",Long-term immunity after primary vaccination against tick-borne encephalitis in the elderly,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004231-24,0,0,0 2012-004232-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Sahlgrenska Universtitetssjukhuset/SUS,Prophylactic treatment with methylprednisolone may reduce the cerebral inflammatory response and reduce the severity of cognitive dysfunction after cardiac surgery Kan profylaktisk behandling med m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004232-37,0,0,0 2012-004239-21,6,2016-11-30,2016-11-30,4,1,0,0,0,2,3,0,0,2,1,0,0,0,1,CELL THERAPEUTICS INC.,"A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004239-21,1,0,0 2012-004239-21,6,2016-11-30,2016-11-30,4,1,0,0,0,2,3,0,0,2,1,0,0,0,1,CTI BioPharma Corp.,"A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004239-21,1,0,0 2012-004240-30,1,2019-04-26,2019-04-26,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,Universitätsklinikum Erlangen,"Prospective, open-label, randomised, two-arm, controlled, multicentre clinical trial, phase I/IIa, for the evaluation of safety and efficacy of an adoptive immunotherapy with allogeneic CMV-/EBV-speci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004240-30,0,0,0 2012-004245-33,1,2015-01-29,2015-01-29,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Conatus Pharmaceuticals Inc.,"A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects with Acute-on-Chronic Liver Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004245-33,0,0,0 2012-004246-15,1,2018-06-12,2018-06-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,LYSARC,A Phase II study of oral JAK1/JAK2 inhibitor INC424 in adult patients with relapsed/refractory classical Hodgkin’s lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004246-15,0,0,0 2012-004257-81,1,2013-06-17,2013-06-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SmartPractice,Clinical Evaluation of Hydroxyisohexyl 3-cyclohexene carboxaldehyde (Lyral®) Dose Response Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004257-81,0,0,0 2012-004259-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación PETHEMA,"Multicenter, open-label, non-randomized Phase II trial of dasatinib in patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML) who meet criteria for late suboptimal response after prior imati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004259-36,0,0,0 2012-004260-22,1,2018-05-03,2018-05-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Oxford,A multi-centre randomised placebo-controlled trial of prophylactic enteral lactoferrin supplementation to prevent late-onset invasive infection in very preterm infants.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004260-22,0,0,0 2012-004263-47,4,2016-03-21,2016-03-21,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Merck KGaA,"Open-label, single-arm, phase IV, multicenter trial to explore the immunogenicity of the liquid formulation of Saizen® in subjects with adult growth hormone deficiency (AGHD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004263-47,0,0,0 2012-004285-18,1,2014-03-20,2014-03-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Helsingin yliopisto,The pain relieving effect of nitrous oxide during bone marrow aspiration and biopsy - a placebo-controlled and randomized trial Typpioksiduulin teho luuydinaspiraatioissa ja biopsioissa – lumekontr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004285-18,0,0,0 2012-004293-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,GeiserPHARMA SL,"Multisite, open, randomized, parallel and controlled clinical trial, to evaluate the efficacy and safety of a laxative fiber formula compared to Plantaben on objective and subjective parameters of the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004293-26,0,0,0 2012-004295-19,8,2019-08-28,2019-08-28,8,1,0,0,0,0,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer (EORTC),A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line ther...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004295-19,0,0,0 2012-004295-19,8,2019-08-28,2019-08-28,8,1,0,0,0,0,2,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer. EORTC,A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line ther...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004295-19,0,0,0 2012-004296-39,1,2015-01-08,2015-01-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Targid University Leuven,Functional Dyspepsia: validation of a questionnaire for symptom assessment in patients suffering from Postprandial Distress Syndrome (Functional Dyspepsia): assessment of sensitivity to change in PDS ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004296-39,0,0,0 2012-004297-26,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,Phase III clinical study of PET-TC with [18f]Fluoroethyilcholine ([18f]Fech) in prostate cancer: assessment of the additional role with respec to conventional imaging techniques PET-TC con il radi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004297-26,0,0,0 2012-004298-20,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Stockholm Centre for Dependency Disorders,The effect of methylphenidate on executive functioning in amphetamine dependent individuals with ADHD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004298-20,0,0,0 2012-004299-20,2,2015-05-12,2015-05-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Transition Therapeutics Ireland Ltd,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004299-20,0,0,0 2012-004299-20,2,2015-05-12,2015-05-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Elan Pharma International Ltd,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004299-20,0,0,0 2012-004300-35,1,2014-09-30,2014-09-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Profil Mainz GmbH & Co KG,"Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Comparison to Placebo in Patients with Hypertension and Albuminuria Wirkung von Linagliptin auf Endothel-, Renal- und Retina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004300-35,0,0,0 2012-004301-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE NIBIT,"A randomized, Phase III study of Fotemustine versus the Combination of Fotemustine and Ipilimumab in Patients with Metastatic Melanoma with brain metastasis Studio randomizzato di fase III di confr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004301-27,0,0,0 2012-004303-12,1,2015-09-14,2015-09-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in ≥18 and <45 Year-Old Subjects with Type 2 Diabetes Mellitus and Inadequat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004303-12,0,0,0 2012-004308-36,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Kings College London,A randomized controlled clinical trial to determine if a combined screening /treatment programme can prevent premature failure of renal transplants due to chronic rejection in patients with HLA antib...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004308-36,0,0,0 2012-004308-36,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Guy's and St Thomas' Foundation NHS Trust,A randomized controlled clinical trial to determine if a combined screening /treatment programme can prevent premature failure of renal transplants due to chronic rejection in patients with HLA antib...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004308-36,0,0,0 2012-004311-31,9,2014-12-01,2015-06-16,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Develco Pharma Schweiz AG,"Randomised, double-blind, placebo-controlled, parallel-group design, multi-centre, dose-escalation phase III trial to investigate the efficacy, safety, and tolerability of Naloxone HCl PR tablets admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004311-31,0,0,0 2012-004313-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Skåne University Hospital, Dept of Oncology",A prospective study of the use of 68Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors. En prospektiv studie av användandet av 68Ga-DOTA-TATE PET/CT hos patienter med neuroendokrina tumörer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004313-13,0,0,0 2012-004315-31,4,2019-07-09,2019-07-09,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Oncopeptides AB,An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients with Relapsed and/or Relapsed-Refractory Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004315-31,0,0,0 2012-004319-29,11,2017-01-27,2017-01-27,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,"A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared with Trastuzumab in Subjects with HER2 Positive Early Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004319-29,0,0,0 2012-004321-25,3,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,0,VU University Medical Center,"A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon α2b in patients with suboptimal molecular response or stable detectable molecular residual disease after...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004321-25,0,0,0 2012-004322-24,14,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Aragon Pharmaceuticals, Inc","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004322-24,0,0,0 2012-004322-24,14,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Aragon Pharmaceuticals,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004322-24,0,0,0 2012-004322-24,14,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Aragon Pharmaceuticals, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004322-24,0,0,0 2012-004326-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA,A Prospective Randomized study to Optimize Prednisone therapy for relapses of Idiopathic NEphrotic syndrome in children (PROPINE study) 1. Studio prospettico randomizzato per ottimizzare la terapia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004326-16,0,0,0 2012-004327-21,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Kennemer Gasthuis, afdeling maag-, darm-, leverziekten",PicoPrep versus KleanPrep: Efficacy and patient satisfaction of bowel preparation products before colonoscopy. A single-blinded randomised trial. Vergelijkend onderzoek naar effectiviteit en pati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004327-21,0,0,0 2012-004328-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE S. RAFFAELE DI MILANO,IMAGING OF NEUROINFLAMMATION IN NEURODEGENERATIVE DISEASES INMIND STUDIO DELLA NEUROINFIAMMAZIONE NELLE PATOLOGIE NEURODEGENERATIVE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004328-40,0,0,0 2012-004330-41,1,2015-04-16,2015-04-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford,"Do oral corticosteroids provide clinical and cost-effective symptom relief for sore throat? A multi-centre, double blind, randomized, placebo-controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004330-41,0,0,0 2012-004331-23,5,2018-06-05,2018-06-05,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-Naïve and Metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004331-23,0,0,0 2012-004334-42,1,2016-11-18,2016-11-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Bipolar I Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004334-42,0,0,0 2012-004335-23,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,Central Institute of Mental Health,"A four-week, multicentre, double-blinded, randomised, active- and placebo-controlled, parallel-group trial investigating efficacy and safety of cannabidiol in acute, early-stage schizophrenic patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004335-23,0,0,0 2012-004336-28,3,2014-06-27,2014-06-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergy Therapeutics (UK) Ltd.,"A multi-centre, double-blind dose-ranging study to evaluate the efficacy and safety/tolerability of Birch Modified Allergen Tyrosine-adsorbed + MPL (POLLINEX Quattro® Birch) in Subjects with seasonal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004336-28,0,0,0 2012-004339-21,1,2016-03-11,2016-03-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Recherche & Développement,"A Multicenter, Randomized, Open-Label, Parallel-Group Usability Study Of The Sarilumab Auto-Injector Device And A Prefilled Syringe In Patients With Moderate To Severe Active Rheumatoid Arthritis Who ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004339-21,0,0,0 2012-004342-14,3,2014-07-28,2014-07-29,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Vertex Pharmaceuticals Incorporated,A Phase 2/3 Open-label Extension Study to Evaluate Long-term Safety and Efficacy With VX 509 in a Treat to Target Setting in Subjects With Rheumatoid Arthritis on Disease-Modifying Antirheumatic Drugs,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004342-14,0,0,0 2012-004343-80,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA,"STUDY PHASE III, RANDOMIZED, DOUBLE-BLIND CONTROLLED TO EVALUATE THE EFFECTIVENESS OF FUROSEMIDE IN CONTINUOUS INFUSION VS ethacrynic acid IN CONTINUOUS INFUSION IN CHILDREN SUBJECT TO A heart surger...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004343-80,0,0,0 2012-004349-34,11,2015-10-21,2015-12-02,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Synta Pharmaceuticals Corporation,"A RANDOMIZED, PHASE 3 STUDY OF GANETESPIB IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG ADENOCARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004349-34,0,0,0 2012-004350-29,1,2015-01-01,2015-01-01,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,herlev hospital,Variations in plasma concentration in patients with non-small cell lung cancer on fixed-dose erlotinib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004350-29,0,0,0 2012-004354-28,1,2015-09-24,2015-09-24,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Børneafdelingen Kolding,Maintenance treatment in childhood constipation. A randomized placebo-controlled intervention study Vedligeholdelsesbehandling ved simpel obstipation. Et randomiseret placebo kontrolleret interven...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004354-28,0,0,0 2012-004355-37,4,2014-10-17,2014-10-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, WITHIN-SUBJECT, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06473871 IN REDUCING HYPERTROPHIC SKIN SCARRING",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004355-37,0,0,0 2012-004357-83,13,2018-05-18,2018-05-31,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc,"A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004357-83,0,0,0 2012-004359-35,11,2019-03-14,2019-03-14,8,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Grünenthal GmbH,An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 year...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004359-35,1,0,0 2012-004359-35,11,2019-03-14,2019-03-14,8,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Janssen Research & Development LLC,An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 year...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004359-35,1,0,0 2012-004360-22,12,2018-10-15,2018-10-15,12,1,1,0,0,0,2,0,0,1,1,0,1,0,1,Grünenthal GmbH,"An open label trial, enrolling subjects aged 6 years to less than 18 years suffering from pain requiring prolonged release opioid treatment, to evaluate the safety and efficacy of tapentadol PR versus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004360-22,0,0,0 2012-004362-17,4,2018-01-08,2018-01-08,2,0,0,0,0,0,3,0,0,2,0,0,0,0,0,ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE 'G. PASCALE',A multicenter phase III randomized study with second line chemotherapy plus or minus bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemothera...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004362-17,1,0,0 2012-004366-18,6,2022-09-01,2022-09-01,1,0,1,0,0,0,1,0,0,2,0,0,0,0,1,Janssen Biologics B.V.,"A Phase 1b Open-Label Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human anti-TNFα Antibody, in Pediatric Subjects with Moderately to Severely Active Ulc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004366-18,1,0,0 2012-004367-44,1,2013-06-27,2013-06-27,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KU LEUVEN,"A RANDOMISED, PLACEBO-CONTROLLED, CROSSOVER STUDY TO COMPARE THE EFFECT OF SODIUM PICOSULFATE AND PRUCALOPRIDE ON COLONIC SENSORY AND MOTOR RESPONSE TO DISTENSION IN HEALTHY SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004367-44,0,0,0 2012-004368-23,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Odense University Hospital,Feasible strategy for preventing blood clots in critically ill patients with acute kidney Injury Forebyggelse af Blodpropper hos patienter med akut nyresvigt på Intensiv-afdeling,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004368-23,0,0,0 2012-004369-42,6,2016-08-29,2016-09-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004369-42,0,0,0 2012-004369-42,6,2016-08-29,2016-09-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004369-42,0,0,0 2012-004372-19,1,2016-04-20,2016-04-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,HARRAS-PHARMA-CURARINA GmbH,"Comparative Study with a Propolis Cream vs. Aciclovir Cream in Patients with Herpes labialis A double-blind, randomised, two-arm study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004372-19,0,0,0 2012-004373-80,4,2015-03-21,2015-03-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Daiichi Sankyo, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects with Acute Spinal Cord ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004373-80,0,0,0 2012-004373-80,4,2015-03-21,2015-03-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Daiichi sankyo, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects with Acute Spinal Cord ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004373-80,0,0,0 2012-004373-80,4,2015-03-21,2015-03-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Asubio Pharmaceuticals, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects with Acute Spinal Cord ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004373-80,0,0,0 2012-004380-44,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase II, open-label, randomised controlled study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ candidate tuberculosis (TB) vaccine (M72/AS01E) when administered intr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004380-44,0,1,1 2012-004381-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St Olavs Hospital Trondheim University Hospital,Treatment of morbid obesity through intra-gastric injections of Botulinum toxin A: A pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004381-18,0,0,0 2012-004383-22,1,2017-03-21,2017-03-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Leipzig,"Perioperative complications in obese and non-obese patients: Prevention and treatment of wound infections and post-operative pain. Prospective, open, monocentric study to investigate perioperative tis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004383-22,0,0,0 2012-004384-48,4,2015-07-31,2015-07-31,4,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim,"A 48 weeks study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (randomised, dose-ranging, active-comparator-con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004384-48,0,0,0 2012-004384-48,4,2015-07-31,2015-07-31,4,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A 48 weeks study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (randomised, dose-ranging, active-comparator-con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004384-48,0,0,0 2012-004384-48,4,2015-07-31,2015-07-31,4,1,0,0,0,0,2,0,0,1,0,0,1,0,2,,"A 48 weeks study of three different dose regimens of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis (randomised, dose-ranging, active-comparator-con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004384-48,0,0,0 2012-004385-17,5,2016-09-05,2016-09-05,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Stand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004385-17,0,0,0 2012-004385-17,5,2016-09-05,2016-09-05,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Stand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004385-17,0,0,0 2012-004388-34,1,2014-06-20,2014-06-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Ferring Pharmaceuticals A/S,"A Double-blind, Randomised, Parallel-group Trial Investigating Sleep Behaviour and Daytime Performance in Nocturia Patients Treated with Desmopressin Orally Disintegrating Tablets as compared to Place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004388-34,0,0,0 2012-004389-16,3,2016-11-17,2016-11-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Ardea Biosciences, Inc.",A Long-Term Extension Study of Lesinurad in Combination with Allopurinol for Subjects Completing an Efficacy and Safety Study of Lesinurad and Allopurinol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004389-16,0,0,0 2012-004391-19,13,2020-09-30,2020-09-30,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., (Merck)",A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004391-19,0,0,0 2012-004391-19,13,2020-09-30,2020-09-30,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc.",A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004391-19,0,0,0 2012-004391-19,13,2020-09-30,2020-09-30,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004391-19,0,0,0 2012-004398-22,1,2020-10-01,2020-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Afd. A, OUH",intraperitoneal microdialysis after server peritonitis Peritoneal mikrodialyse efter svær diffus peritonit,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004398-22,0,0,0 2012-004403-13,1,2016-06-15,2016-06-15,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ. Klinik für Dermatologie",Placebo-controlled cross-over study on the efficacy of a non-steroidal antirheumatic drug for pain reduction during photodynamic therapy of actinic keratoses Placebo-kontrollierte Cross-over Studie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004403-13,0,0,0 2012-004406-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Hradec Kralove,The use of oxygen and hydrogen mixture for inhalation to prevent ischaemia-reperfusion injury Inhalační aplikace směsi kyslíku a vodíku k prevenci ischemicko-reperfuzního poškození,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004406-10,0,0,0 2012-004408-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,Etude de phase II évaluant l’efficacité du Pazopanib chez des patients ayant un carcinome des glandes salivaires en rechute et/ou métastatique.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004408-36,0,0,0 2012-004410-34,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,0,Cristina Peris Martínez,Influence of timolol maleate (ophthalmic gel 1 mg/g) on the keratometry and the parameters of corneal biomechanics in patients with keratoconus. Influencia del maleato de timolol (gel oftálmico 1mg...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004410-34,0,0,0 2012-004411-31,12,2018-01-12,2018-01-12,11,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"Long term, single-arm, open-label extension study of protocol AC-055-305 to assess the safety, tolerability and efficacy of macitentan in subjects with Eisenmenger Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004411-31,0,0,0 2012-004411-31,12,2018-01-12,2018-01-12,11,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"Long term, single-arm, open-label extension study of protocol AC-055-305 to assess the safety, tolerability and efficacy of macitentan in subjects with Eisenmenger Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004411-31,0,0,0 2012-004411-31,12,2018-01-12,2018-01-12,11,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ACTELION PHARMACEUTICALS LTD.,"Long term, single-arm, open-label extension study of protocol AC-055-305 to assess the safety, tolerability and efficacy of macitentan in subjects with Eisenmenger Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004411-31,0,0,0 2012-004412-55,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO,Cabazitaxel in relapsed high-risk HOrmone-SEnsitive prostate cancer patients. A multicentric Randomized phase II study. C.HO.SE. Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004412-55,0,0,0 2012-004413-14,4,2014-11-04,2014-11-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,A trial comparing the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004413-14,0,0,0 2012-004416-66,1,2013-10-14,2013-10-14,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Oxford,"A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches using the ChAd63 and MVA vectors encoding the antigens ME-TRAP, CS and AMA1.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004416-66,0,0,0 2012-004418-32,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Akershus University Hospital,Cabazitaxel as salvage treatment for cisplatin-resistant germ cell cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004418-32,0,0,0 2012-004418-32,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Oslo University Hospital,Cabazitaxel as salvage treatment for cisplatin-resistant germ cell cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004418-32,0,0,0 2012-004418-32,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,"Oslo University Hospital, Cancer Research Un it",Cabazitaxel as salvage treatment for cisplatin-resistant germ cell cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004418-32,0,0,0 2012-004418-32,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Oslo University Hospital - Cancer Department,Cabazitaxel as salvage treatment for cisplatin-resistant germ cell cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004418-32,0,0,0 2012-004421-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden Universtity Medical Center,Sequential FLAMSA chemotherapy and T cell depleted reduced intensity conditioning allogeneic stem cell transplantation (TCD FLAMSA-RIC alloSCT) in elderly acute myeloid leukemia and high risk myelodys...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004421-24,0,0,0 2012-004423-20,4,2013-06-20,2013-06-25,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,STUDY OF EFFICACY AND SAFETY OF V0498 VERSUS PLACEBO IN ACUTE SORE THROAT PAIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004423-20,0,0,0 2012-004423-20,4,2013-06-20,2013-06-25,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Centre de Recherche et Développement Pierre Fabre,STUDY OF EFFICACY AND SAFETY OF V0498 VERSUS PLACEBO IN ACUTE SORE THROAT PAIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004423-20,0,0,0 2012-004424-38,1,2017-09-01,2017-09-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Department of Haematology, Aalborg University Hospital","A randomized, open-label phase III study of Clarithromycin, Sulfamethoxa-zole/Trimethoprim or observation in combination with standard therapy in patients with newly diagnosed multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004424-38,0,0,0 2012-004429-26,1,2016-01-05,2016-01-05,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Silence Therapeutics GmbH,A Phase Ib/IIa study of combination therapy with Gemcitabine and Atu027 in subjects with locally advanced or metastatic pancreatic adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004429-26,0,0,0 2012-004434-42,12,2020-02-19,2020-02-19,8,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Bayer HealthCare AG,"A multi-center, phase III, non-controlled, open-label trial to evaluate the pharmacokinetics, safety, and efficacy of BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated childr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004434-42,1,1,0 2012-004434-42,12,2020-02-19,2020-02-19,8,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Bayer AG,"A multi-center, phase III, non-controlled, open-label trial to evaluate the pharmacokinetics, safety, and efficacy of BAY 94-9027 for prophylaxis and treatment of bleeding in previously treated childr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004434-42,1,1,0 2012-004436-36,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Odense University Hospital,A prospective pilotstudy of immunological and radiological effects of intrathecal rituximab in patients with secondary progressive multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004436-36,0,0,0 2012-004437-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,Pharmacokinetic evaluation and tolerability of dry powder tobramycin by a novel device in patients with non cystic fibrosis bronchiectasis Farmacokinetische evaluatie en verdraagzaamheid van droog ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004437-16,0,0,0 2012-004439-22,5,2019-01-09,2019-01-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term efficac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004439-22,0,0,0 2012-004441-32,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación Teknon,Pilot clinical trial to determine the feasibility and safety of MSV * cryopreserved in the treatment of gonartrosis. * MSV = mesenchymal progenitor cells of expanded autologous bone marrow with GMP pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004441-32,0,0,0 2012-004442-15,1,2014-03-03,2014-03-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Leipzig,"High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients bei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004442-15,0,0,0 2012-004444-30,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Citospin,Treatment of degenerative disc disease with allogenic mesenchymal cells—MSV-- Tratamiento de la discopatía degenerativa lumbar con células mesenquimales alogénicas (MSV*).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004444-30,0,0,0 2012-004445-32,1,2014-03-03,2014-03-03,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Univar BV,A Phase I Pharmacokinetic Profiling Study in Patients Receiving Trientine Dihydrochloride for the Treatment of Wilson’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004445-32,0,0,0 2012-004450-28,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University of Turku,Effect of chemotherapy on endothelial function in patients with testicular cancer Solunsalpaajahoitojen aiheuttamat muutokset verisuonen sisäkerroksen toiminnassa kivessyöpöpotilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004450-28,0,0,0 2012-004450-28,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Turku University Hospital,Effect of chemotherapy on endothelial function in patients with testicular cancer Solunsalpaajahoitojen aiheuttamat muutokset verisuonen sisäkerroksen toiminnassa kivessyöpöpotilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004450-28,0,0,0 2012-004451-37,1,2015-12-17,2015-12-17,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Per F. Jensen,"Multimodal analgesia in video-assisted thoracic surgery with interostal catheter and glucocorticoid - a randomized, double-blind, placebo-controlled study. Multimodal analgesi ved video-assisteret ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004451-37,0,0,0 2012-004455-36,10,2017-09-18,2017-10-27,8,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F.Hoffmann-La Roche Ltd,"AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER PHASE I/II TRIAL OF RO5424802 GIVEN ORALLY TO NON - SMALL CELL LUNG CANCER PATIENTS WHO HAVE ALK MUTATION AND FAILED CRIZOTINIB TREATMENT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004455-36,0,0,0 2012-004455-36,10,2017-09-18,2017-10-27,8,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER PHASE I/II TRIAL OF RO5424802 GIVEN ORALLY TO NON - SMALL CELL LUNG CANCER PATIENTS WHO HAVE ALK MUTATION AND FAILED CRIZOTINIB TREATMENT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004455-36,0,0,0 2012-004456-11,1,2015-04-08,2015-04-08,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, randomised, open-label, multicentre, clinical trial to assess the safety and immunogenicity of GSK Biologicals’ HZ/su vaccine when administered intramuscularly according to a 0,2-month sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004456-11,0,0,0 2012-004457-88,3,2015-04-08,2015-04-08,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shire Development LLC,"A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years with Moderate to Severe Binge Eating ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004457-88,0,0,0 2012-004458-27,9,2017-09-06,2017-09-29,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Gilead Sciences Inc.,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Diso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004458-27,0,0,0 2012-004461-41,3,2017-09-19,2017-09-19,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Kiadis Pharma Netherlands B.V.,"An exploratory, open-label, multicenter study to evaluate the safety and efficacy of ATIR, donor T-lymphocytes depleted ex vivo of host alloreactive T-cells, in patients with a hematologic malignancy,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004461-41,0,0,0 2012-004462-18,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Service of Neurology CHU Liege,An exploratory research on the influence of amyloid deposit (measured with (18F)flutemetamol) on disconnection in the “core episodic network” and between regions involved in anosognosia for memory imp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004462-18,0,0,0 2012-004463-41,2,2015-12-02,2015-12-02,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Medica Scientia Innovation Research (MedSIR ARO),"- Ensaio clínico prospectivo, de fase IIa, multicêntrico, sem ocultação e não controlado para avaliar a eficacia e tolerabilidade do tratamento com eribulina como agente único de primeira linha em ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004463-41,0,0,0 2012-004470-25,1,2013-08-23,2013-08-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare (UK) Ltd,"A multicentre, randomised, double-blind, two arm, parallel group, pilot study to assess the effect of Gaviscon® Double Action Mint as add-on therapy in GORD patients with inadequate response to once d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004470-25,0,0,0 2012-004473-25,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Phase 1, Open-label, Multiple-dose, and Age De-escalation Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004473-25,0,1,1 2012-004476-19,4,2016-04-12,2016-04-15,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Pharmacyclics LLC,"An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004476-19,0,0,0 2012-004482-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FRANCISCO J. BLANCO GARCÍA,Evaluation of the clinical utility of a standardized protocol of strategies for the reduction of doses in patients with rheumatoid arthritis (RA) in persistent clinical remission in treatment with bio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004482-40,0,0,0 2012-004483-22,1,2016-10-20,2016-10-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Mental Health Service, Esbjerg",NACOS - The effect of N-acetylcystein for depressive symptoms in patients with bipolar depression - A double blind randomized placebo-controlled trial with follow up NACOS - Effekten af N-acetylcys...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004483-22,0,0,0 2012-004486-41,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Karolinska University Hospital, Huddinge, Sweden",Vaccination of antibody deficient patients with Prevenar13 - a comparative study between antibody response and cellular immunity. Konjugerat pneumokockvaccin till patienter med antikroppsbrist – en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004486-41,0,0,0 2012-004489-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,WAVE: Weekly nab-paclitaxel (Abraxane®) Versus Epirubicin in women with early breast cancer who are elderly or unfit for a 3-weekly polychemotherapy regimen: a Phase II Randomized Trial evaluating Act...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004489-17,0,0,0 2012-004490-10,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Ghent University Hospital,A Multicenter Open label Phase 2 study of Carfilzomib Weekly plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004490-10,0,0,0 2012-004491-18,3,2014-06-13,2014-06-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of 28 Day Oral Administration of BAY 85-8501 in Patients with non-Cystic Fibrosis Bron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004491-18,0,0,0 2012-004492-38,13,2019-09-09,2019-12-16,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Puma Biotechnology, Inc.",A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004492-38,0,0,0 2012-004493-26,8,2016-09-28,2016-09-28,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004493-26,0,0,0 2012-004493-26,8,2016-09-28,2016-09-28,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer AG,"A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004493-26,0,0,0 2012-004494-23,2,2014-07-18,2014-07-28,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline Research & Development Ltd,"Study MAG104615, a Proof of Concept Study for GSK249320 versus placebo in Stroke Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004494-23,0,0,0 2012-004495-19,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,1,Philogen S.p.A.,A Phase I/II Dose Escalation study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine for patients with metastatic melanoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004495-19,0,0,0 2012-004496-40,2,2015-08-15,2015-08-15,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Eli Lilly and Company,Study of the Safety and Efficacy of LY3016859 after Multiple Intravenous Dosing in Diabetic Nephropathy Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004496-40,0,0,0 2012-004502-93,15,2022-05-27,2022-05-27,8,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004502-93,1,0,0 2012-004503-13,1,2014-03-21,2014-03-21,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Bispebjerg Hospital,Effect of Glococorticosteroids on physical performance in patients with chronic obstructive pulmonary disease and acute inflammatory response after exercise Effect of Glococorticosteroids on physic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004503-13,0,0,0 2012-004504-35,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,IRCCS CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI,"The use of Oxytocin as adjunctive therapy for the treatment of schizophrenia: a randomized, double blind trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004504-35,0,0,0 2012-004508-36,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Fondazione Michelangelo - Avanzamento dello studio e cura dei tumori,"Brentuximab vedotin (SGN-35) as salvage therapy for males with advanced and platinum-resistant germ-cell tumors. An open label, single group, Phase 2 trial Terapia di salvataggio con brentuximab ve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004508-36,0,0,0 2012-004509-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Antidepressant treatments during pregnancy and lactation: prediction of drug exposure through breastfeeding and evaluation of drug effect on the neonatal adaptation and the development of the young ch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004509-29,0,0,0 2012-004511-30,1,2016-09-23,2016-09-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,"A randomised controlled trial to compare the effect of micronized progesterone and Medroxyprogesterone Acetate on the vascular elasticity, lipid profile and coagulation cascade of women with premature...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004511-30,0,0,0 2012-004513-14,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,An open-label study to assess the immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ IPV vaccine (Poliorix) administered as a booster dose at 18 months of age in healthy Chinese t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004513-14,0,1,1 2012-004515-32,3,2014-05-01,2014-05-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Multicenter, Open-Label, Long-Term Safety and Efficacy Study of the Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Adult Subjects with Moderate t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004515-32,0,0,0 2012-004518-32,1,2018-12-12,2018-12-12,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Medizinische Universität Wien,"ITIC2 Trial - Topical Imiquimod versus Conization to Treat Cervical Intraepithelial Neoplasia: Randomised Controlled, Non-inferiority Trial ITIC2 Studie - Topische Imiquimod Therapie versus Konisat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004518-32,0,0,0 2012-004524-38,1,2017-04-12,2017-04-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,IFCT,Phase III study comparing the efficacy of paclitaxel-bevacizumab with docetaxel in 2nd or 3rd line of treatment of non squamous Non Small Cells Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004524-38,0,0,0 2012-004527-20,9,2015-08-20,2015-10-03,8,1,1,0,0,1,3,0,0,1,0,0,1,0,1,"PTC Therapeutics, Inc",A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients with Nonsense Mutation Dystrophinopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004527-20,0,0,0 2012-004531-23,5,2016-06-01,2016-06-01,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adult Su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004531-23,0,0,0 2012-004537-16,1,2016-08-01,2016-08-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Leeds,An Open Label Multi-Centre Preoperative Window of Opportunity Study of Afatinib in Stage Ia to IIb Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004537-16,0,0,0 2012-004538-40,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Hospital General de Ciudad Real,Magnesium associated to intratecal lidocaine decreases the incidence of the Transitory Neurologic Syndrome following same-day-surgery ?El magnesio asociado a la lidocaína intratecal disminuye la i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004538-40,0,0,0 2012-004539-22,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY,"An open label, single arm, phase II study to evaluate the activity and toxicity of Panitumumab in pre-treated patients with advanced well differentiated neuroendocrine tumor (G1 and G2) Studio di f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004539-22,0,0,0 2012-004540-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,"Injection treatment of ranula with OK 432 - A prospective, randomized, placebo controlled, double-blind study Injektionsbehandling av ranula med OK 432 - en prospektiv, randomeriserad, dubbelbl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004540-29,0,0,0 2012-004544-30,9,2013-04-08,2019-01-14,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Limited,"A phase III, randomised, open label, active-controlled study of an interferon-free regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pegylat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004544-30,0,0,0 2012-004544-30,9,2013-04-08,2019-01-14,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim,"A phase III, randomised, open label, active-controlled study of an interferon-free regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pegylat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004544-30,0,0,0 2012-004544-30,9,2013-04-08,2019-01-14,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Norway KS,"A phase III, randomised, open label, active-controlled study of an interferon-free regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pegylat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004544-30,0,0,0 2012-004544-30,9,2013-04-08,2019-01-14,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim AB,"A phase III, randomised, open label, active-controlled study of an interferon-free regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pegylat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004544-30,0,0,0 2012-004544-30,9,2013-04-08,2019-01-14,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A phase III, randomised, open label, active-controlled study of an interferon-free regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pegylat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004544-30,0,0,0 2012-004544-30,9,2013-04-08,2019-01-14,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim France,"A phase III, randomised, open label, active-controlled study of an interferon-free regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pegylat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004544-30,0,0,0 2012-004544-30,9,2013-04-08,2019-01-14,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase III, randomised, open label, active-controlled study of an interferon-free regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pegylat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004544-30,0,0,0 2012-004544-30,9,2013-04-08,2019-01-14,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Boehringer Ingelheim españa, S.A.","A phase III, randomised, open label, active-controlled study of an interferon-free regimen of BI 207127 in combination with Faldaprevir and Ribavirin compared to Telaprevir in combination with pegylat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004544-30,0,0,0 2012-004545-32,7,2014-05-19,2014-05-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Menarini Ricerche S.p.A.,"A randomized, double-blind, placebo and active-controlled, parallel-group study to evaluate the analgesic efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride oral fixed combinat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004545-32,0,0,0 2012-004545-32,7,2014-05-19,2014-05-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Menarini Ricerche S.p.A,"A randomized, double-blind, placebo and active-controlled, parallel-group study to evaluate the analgesic efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride oral fixed combinat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004545-32,0,0,0 2012-004546-15,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,CHU de Nice,Assessment of incidence of adverse events in a naive pediatric population treated with an antipsychotic drug over 12 months follow-up EVALUATION DE L’INCIDENCE DES EVENEMENTS INDESIRABLES EN POPULA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004546-15,0,0,0 2012-004548-31,6,2014-02-05,2014-02-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Menarini Ricerche S.p.A.,"A randomized, double-blind, placebo and active-controlled, parallel-group study to evaluate the analgesic efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride oral fixed combinat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004548-31,0,0,0 2012-004550-28,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AIO-Studien-gGmbH,EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004550-28,0,0,0 2012-004551-36,5,2015-04-13,2015-04-13,4,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Novartis Pharma Services AG,"A phase Ib/II, multicenter, study of LEE011 in combination with LGX818 in adult patients with BRAF mutant melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004551-36,0,0,0 2012-004551-36,5,2015-04-13,2015-04-13,4,1,0,1,0,0,1,0,0,1,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase Ib/II, multicenter, study of LEE011 in combination with LGX818 in adult patients with BRAF mutant melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004551-36,0,0,0 2012-004551-36,5,2015-04-13,2015-04-13,4,1,0,1,0,0,1,0,0,1,1,0,0,0,1,NOVARTIS FARMA S.p.A.,"A phase Ib/II, multicenter, study of LEE011 in combination with LGX818 in adult patients with BRAF mutant melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004551-36,0,0,0 2012-004554-28,1,2013-11-22,2013-11-22,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Rigshospitalet,"Effect of Adductor-Kanal-Blokade vs femoralis-Blokade on muskelstyrke, mobility and smerter with high smerte responders 1. and 2. postoperative day after total knæalloplastik Effekten af Adductor-K...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004554-28,0,0,0 2012-004555-36,1,2017-05-30,2017-05-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Centre Hospitalier Intercommunal de Créteil,A prospective randomized controlled multicentre trial comparing half-dose photodynamic therapy (PDT) with high-density subthreshold micropulse laser treatment in patients with chronic central serous c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004555-36,0,0,0 2012-004556-11,1,2015-08-03,2015-08-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,OSPEDALE S. RAFFAELE DI MILANO,"Randomized,multicenter,open-label, study of monoterapy with darunavir/ritonavir or lopinavir/ritonavir vs standard of care in virologically suppressed HIV-infected patients. Studio randomizzato, in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004556-11,0,0,0 2012-004560-21,1,2014-01-01,2014-01-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,The effect of ticagrelor on the adenosine system Het effect van ticagrelor op het adenosinesysteem,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004560-21,0,0,0 2012-004577-12,1,2017-01-19,2017-01-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.",Phase II biomarker study evaluating the upfront combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib versus the combination after eight weeks of monotherapy with dabrafenib or tramet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004577-12,0,0,0 2012-004579-37,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,National Institute of Mental Health,Animal and human serotonergic model of schizophrenia: validity evaluated by qEEG and fMRI Animální a humánní serotonergní model schizofrenie: validita hodnocená pomocí qEEG a fMRI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004579-37,0,0,0 2012-004583-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA,Verification of the effectiveness of intravenous sildenafil compared to other pulmonary vasodilators used in the test vessel reactivity of pulmonary Verifica dell'efficacia del sildenafil per via e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004583-22,0,0,0 2012-004585-18,1,2016-09-30,2016-09-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Philipps-Universität Marburg,"Perioperative administration of Tapentadol – tolerance, safety and effects on postoperative rehabilitation and quality of life. Randomized, controlled study to compare the analgesic therapy with tape...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004585-18,0,0,0 2012-004586-41,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,CHU de Bordeaux,Cognitive remediation in Attention Deficit Disorder with or without Hyperactivity (ADHD) children : Comparison between three therapeutic strategies : cognitive remediation with a virtual classroom sof...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004586-41,0,0,0 2012-004599-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,TAYS/teho-osasto,PHARMACOKINETICS OF ENOXAPARIN IN INTENSIVE CARE PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004599-21,0,0,0 2012-004600-35,1,2021-01-05,2021-01-05,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,KULeuven,"Effect of diet-induced weight loss on motilin, ghrelin, bitter taste perception, hunger and the migrating motor complex: a prospective study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004600-35,0,0,0 2012-004601-27,9,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017","A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 3 STUDY OF PD-0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004601-27,0,0,0 2012-004601-27,9,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Pfizer Inc,"A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 3 STUDY OF PD-0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004601-27,0,0,0 2012-004601-27,9,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Pfizer Inc.,"A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 3 STUDY OF PD-0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004601-27,0,0,0 2012-004602-97,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Javier Olascoaga Urtaza,"?Vitamin D as add-on treatment for relapsing-remitting multiple sclerosis: an unicentric, randomized, double-blinded, placebo-controlled clinical trial? ?Vitamina D como tratamiento adyuvante para ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004602-97,0,0,0 2012-004605-27,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA,Study Prospective Randomized Controlled Double-Blind: Comparison of tear substitute (Siccafluid) and Autologous Serum in Dry Eye Disease Studio Prospettico Randomizzato Controllato in Doppio Cieco:...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004605-27,0,0,0 2012-004606-10,3,2017-06-29,2017-06-29,2,1,0,0,0,2,4,0,0,1,1,0,1,0,1,Bio Products Laboratory Limited,"Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic Optivate® Treatment in Subjects with Severe Haemophilia A.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004606-10,0,0,0 2012-004606-10,3,2017-06-29,2017-06-29,2,1,0,0,0,2,4,0,0,1,1,0,1,0,1,BIO PRODUCTS LABORATORY LIMITED (BPL),"Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic Optivate® Treatment in Subjects with Severe Haemophilia A.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004606-10,0,0,0 2012-004619-30,3,2018-07-18,2018-07-19,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MedImmune, LLC, a wholly owned subsidiary of AstraZeneca","A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults with Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004619-30,0,0,0 2012-004620-38,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Phase 2, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004620-38,0,1,1 2012-004621-24,4,2014-02-12,2014-02-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,Emollients in the management of atopic dermatitis in children: prevention of flares.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004621-24,0,0,0 2012-004622-14,1,2011-03-31,2011-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,Concentration/meditation as a novel means to limit inflammation: a randomized controlled pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004622-14,0,0,0 2012-004625-25,5,2015-12-23,2015-12-23,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,A clinical trial comparing efficacy and safety of insulin degludec/liraglutide (IDegLira) in subjects with type 2 diabetes mellitus using two different titration algorithms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004625-25,0,0,0 2012-004627-20,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Pascoe pharmazeutische Präparate GmbH,"Randomized double-blind, placebo controlled study with NEURAPAS® balance in addition to psychoeducation or psychotherapy in adolescents from 12 to 17 years suffering from mild depressive episodes with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004627-20,0,0,0 2012-004628-39,3,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase I/II, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of AZD9291 in Patients with Advanced Non Small Cell Lung Ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004628-39,0,0,0 2012-004628-39,3,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,AstraZeneca,"A Phase I/II, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of AZD9291 in Patients with Advanced Non Small Cell Lung Ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004628-39,0,0,0 2012-004631-22,1,2015-12-31,2015-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Leuven,TapERA: Maintaining remission in RA while tapering Etanercept.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004631-22,0,0,0 2012-004704-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Thiazide diuretics versus calcium channel blockers for the treatment of tacrolimus-induced hypertension in dermatology patients: a single-center randomized cross-over trial. Thiazide diuretica vers...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004704-35,0,0,0 2012-004707-12,4,2020-08-28,2020-08-28,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An open-label, multi-center everolimus roll-over protocol for patients who have completed a previous Novartis-sponsored everolimus study and are judged by the investigator to benefit from continued ev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004707-12,0,0,0 2012-004707-12,4,2020-08-28,2020-08-28,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,NOVARTIS FARMA,"An open-label, multi-center everolimus roll-over protocol for patients who have completed a previous Novartis-sponsored everolimus study and are judged by the investigator to benefit from continued ev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004707-12,0,0,0 2012-004707-12,4,2020-08-28,2020-08-28,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","An open-label, multi-center everolimus roll-over protocol for patients who have completed a previous Novartis-sponsored everolimus study and are judged by the investigator to benefit from continued ev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004707-12,0,0,0 2012-004742-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI,Evaluation of the risk of nephrotoxicity caused by the intravenous administration of nonionic iodinated contrast media Valutazione del rischio della nefrotossicita' conseguente alla somministrazio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004742-16,0,0,0 2012-004743-68,1,2017-10-06,2017-10-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Puma Biotechnology, Inc.",A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients with Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004743-68,0,0,0 2012-004758-27,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Medizinische Universität Wien, Universitätsklinik für Augenheilkunde",fMRI analysis of the visual cortex in neovascular age-related macular degeneration fMRT Analyse des visuellen Kortex bei neovaskulärer altersbedingter Makuladegeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004758-27,0,0,0 2012-004762-18,1,2016-07-07,2016-07-07,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Madaus GmbH,"Controlled, prospective, multicentre, open, randomized study to investigate the contraceptive efficacy, bleeding patterns, metabolic effects, cycle-associated complaints, acceptance, and safety of an ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004762-18,0,0,0 2012-004763-45,7,2016-07-19,2016-07-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with donepezil; study 1 Randomizované dvojit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004763-45,0,0,0 2012-004764-22,10,2016-12-20,2017-07-08,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with donepezil; Study 2",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004764-22,0,0,0 2012-004765-40,5,2017-01-12,2017-01-12,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Randomised, double-blind, parallel-group, placebo-controlled study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with an acetylcholinesterase inhibitor; Study 3",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004765-40,0,0,0 2012-004766-17,6,2021-02-17,2021-02-17,3,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Kyowa Kirin Pharmaceutical Development, Inc.","Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma (CTCL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004766-17,1,0,0 2012-004766-17,6,2021-02-17,2021-02-17,3,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Kyowa Hakko Kirin Pharma, Inc.","Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma (CTCL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004766-17,1,0,0 2012-004768-23,1,2016-07-13,2016-07-13,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,STELIC INSTITUTE & CO.,A Phase 2a Trial of STNM01 by a Single Submucosal Injection to Investigate the Mucosal Healing Efficacy in Patients with Ulcerative Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004768-23,0,0,0 2012-004770-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,CLOpidogrel versus TIcagreLor for antiplatelet maintenance in DIAbetic patients (CLOTILDIA) CLOpidogrel versus TIcagreLor per la terapia antiaggregante di mantenimento nei pazienti DIAbetici sottop...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004770-25,0,0,0 2012-004779-38,15,2014-08-31,2014-10-30,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,"Effects of ivabradine on plaque burden, morphology and composition in patients with clinically indicated coronary angiography. A randomised double-blind placebo-controlled international multicentre st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004779-38,0,0,0 2012-004779-38,15,2014-08-31,2014-10-30,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Laboratorios Servier S.L.,"Effects of ivabradine on plaque burden, morphology and composition in patients with clinically indicated coronary angiography. A randomised double-blind placebo-controlled international multicentre st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004779-38,0,0,0 2012-004785-18,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University Medical Center Groningen,PET imaging of neuroinflammatory consequences of chronic repetitive head injury in Muay Thai boxing,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004785-18,0,0,0 2012-004786-40,2,2015-05-18,2015-05-18,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Protalix Ltd.,"A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004786-40,0,0,0 2012-004792-39,3,2017-07-13,2017-07-13,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 with RBV in H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004792-39,0,0,0 2012-004793-26,2,2014-06-25,2014-06-25,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,"TAIHO PHARMA USA, INC","AN OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY COMPARING TAS-102 VERSUS TOPOTECAN OR AMRUBICIN IN PATIENTS REQUIRING SECOND-LINE CHEMOTHERAPY FOR SMALL CELL LUNG CANCER THAT IS REFRACTORY OR SENSITIVE TO FI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004793-26,0,0,0 2012-004793-26,2,2014-06-25,2014-06-25,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,"Taiho Pharma USA, Inc.","AN OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY COMPARING TAS-102 VERSUS TOPOTECAN OR AMRUBICIN IN PATIENTS REQUIRING SECOND-LINE CHEMOTHERAPY FOR SMALL CELL LUNG CANCER THAT IS REFRACTORY OR SENSITIVE TO FI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004793-26,0,0,0 2012-004795-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Folktandvården Västra Götaland,"Utilisation of botulinum toxin type A on masticatory muscel hyperactivity in CP - a randomized, controlled study. Utvärdering av injektioner med botulinum toxin vid tuggmuskulär hyperaktivitet hos ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004795-19,0,0,0 2012-004796-39,1,2015-11-03,2015-11-03,1,0,0,0,1,0,4,0,0,1,1,1,1,0,0,Fondazione IRCCS Policlinico San Matteo,A Comparative Study of Oxycodone/Naloxone versus Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Knee and/or hip Pain Due to Osteoarthritis Studio comparativo tra le due associaz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004796-39,0,0,0 2012-004798-17,2,2015-03-23,2015-03-23,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"Phase II, Multi-center, Open-label Study of Single-agent LGX818 Followed by a Rational Combination With Agents After Progression on LGX818, in Adult Patients With Locally Advanced or Metastatic BRAF V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004798-17,0,0,0 2012-004798-17,2,2015-03-23,2015-03-23,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","Phase II, Multi-center, Open-label Study of Single-agent LGX818 Followed by a Rational Combination With Agents After Progression on LGX818, in Adult Patients With Locally Advanced or Metastatic BRAF V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004798-17,0,0,0 2012-004799-21,3,2015-07-31,2015-07-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Krka, d.d., Novo mesto",The Efficacy and Safety of ROSUvastatin Dose Titration in the Treatment of PATients with Hyperlipidemia (ROSU-PATH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004799-21,0,0,0 2012-004799-21,3,2015-07-31,2015-07-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"KRKA ČR, s. r. o.",The Efficacy and Safety of ROSUvastatin Dose Titration in the Treatment of PATients with Hyperlipidemia (ROSU-PATH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004799-21,0,0,0 2012-004799-21,3,2015-07-31,2015-07-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"KRKA Magyarország Kft., Budapest",The Efficacy and Safety of ROSUvastatin Dose Titration in the Treatment of PATients with Hyperlipidemia (ROSU-PATH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004799-21,0,0,0 2012-004801-28,3,2018-03-26,2018-03-26,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"Multi-centre, randomized, double-blind, parallel-group study evaluating the effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder once daily compared with Vilanterol (VI) Inhalation Powd...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004801-28,0,0,0 2012-004801-28,3,2018-03-26,2018-03-26,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","Multi-centre, randomized, double-blind, parallel-group study evaluating the effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder once daily compared with Vilanterol (VI) Inhalation Powd...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004801-28,0,0,0 2012-004805-29,1,2015-09-25,2015-09-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"The Heart Center, Rigshospitalet",Beta 3 agonist treatment in heart failure (BEAT-HF) Beta 3 agonist treatment in heart failure (BEAT-HF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004805-29,0,0,0 2012-004807-10,1,2016-06-01,2016-06-01,1,1,0,0,1,0,2,0,0,1,1,1,1,0,0,University Medical Center Hamburg Eppendorf,Relapse Escalation treatment trial in Optic Neuritis (RESCON): Multi-centre RCT to study the efficacy of plasma exchange (PE) as an escalation treatment strategy in steroid-unresponsive Optic Neuritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004807-10,0,0,0 2012-004808-34,2,2018-11-16,2018-11-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004808-34,0,0,0 2012-004819-31,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,National Kapodistrian University of Athens,Multicenter open-label RCT to compare colistin alone vs. colistin plus meropenem Trial randomizzato controllato multicentrico per la valutazione dell'efficacia di colistina rispetto a colistina ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004819-31,0,0,0 2012-004819-31,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,RADBOUD UNIVERSITY NIJMEGEN MEDICAL CENTER,Multicenter open-label RCT to compare colistin alone vs. colistin plus meropenem Trial randomizzato controllato multicentrico per la valutazione dell'efficacia di colistina rispetto a colistina ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004819-31,0,0,0 2012-004821-26,1,2016-11-10,2016-11-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"Prospective, double-blind, placebo-controlled, randomized, parallel-group, multi-center study with an open-label extension period to investigate the efficacy and safety of two different doses of NT 20...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004821-26,0,0,0 2012-004824-39,1,2016-04-27,2016-04-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST,The use of GnRH antagonist versus co-flare protocol for women with low ovarian reserve undergoing first cycle of in vitro fertilization,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004824-39,0,0,0 2012-004825-26,1,2016-11-09,2016-11-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"GTx, Inc.","Phase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with castration resistant prostate cancer maintained on androg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004825-26,0,0,0 2012-004826-92,7,2015-07-09,2015-07-13,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and safety of semaglutide once-weekly versus exenatide ER 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004826-92,0,0,0 2012-004827-19,7,2015-10-12,2015-11-26,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin and/or TZD in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004827-19,0,0,0 2012-004842-14,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Institut de cancérologie Gustave Roussy,PHASE I / II STUDY OF SEQUENTIAL HIGH-DOSE CHEMOTHERAPY WITH STEM CELL SUPPORT IN CHILDREN YOUNGER THAN 5 YEARS OF AGE WITH HIGH-RISK MEDULLOBLASTOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004842-14,0,0,0 2012-004845-34,4,2016-04-19,2016-04-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis recherche et développement,"A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously Every 2 Weeks in Patients with Non-Infectious, Intermediate, Poste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004845-34,0,0,0 2012-004847-61,1,2015-06-10,2015-06-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Queen Mary University of London,A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004847-61,0,0,0 2012-004851-35,1,2016-10-24,2016-10-24,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,"Children´s Hospital, University of Helsinki",Once versus twice daily mesalazine to introduce remission in pediatric ulcerative colitis: a randomized controlled trial Eurooppalainen haavaisen paksusuolitulehduksen lääkehoidon yksinkertaistamis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004851-35,0,0,0 2012-004852-13,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Anestesikliniken,Low fresh gas flow during elective general anaesthesia - A pilot study comparing Desflurane and Sevoflurane for anaesthetic controllability during wash-in and for haemodynamic control during elective...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004852-13,0,0,0 2012-004854-27,11,2015-10-15,2016-05-10,6,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Novartis Pharma services AG,"A 26 week, randomized, active-controlled safety study of double-blind formoterol fumarate in free combination with an inhaled corticosteroid versus an inhaled corticosteroid in adolescent and adult pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004854-27,0,0,0 2012-004856-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klinische Abteilung für Nephrologie","Changes of cytokines and regulatory T cells in renal transplant recipients after switch to the mTOR inhibitor Everolimus. A Single center trial, non-blinded, non-randomized. Veränderungen des Immu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004856-12,0,0,0 2012-004857-10,2,,,0,1,0,0,0,0,3,0,0,1,1,0,0,1,1,Bayer HealthCare AG,"A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004857-10,0,0,0 2012-004857-10,2,,,0,1,0,0,0,0,3,0,0,1,1,0,0,1,1,Bayer AG,"A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004857-10,0,0,0 2012-004860-22,1,2021-07-05,2021-07-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Institute Jules Bordet,The [PEARL] Study : Pet imaging as a biomarker of Everolimus Added value in hormone Refractory postmenopausaL women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004860-22,0,0,0 2012-004863-29,1,2016-08-08,2016-08-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospitals Leuven (Gasthuisberg),Direct thrombin inhibitors versus low molecular weight heparins as thromboprophylaxis in Staphylococcus aureus bacteraemia. A prospective randomized controlled academic single-centre feasibility study...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004863-29,0,0,0 2012-004863-29,1,2016-08-08,2016-08-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,agentschap innoveren en ondernemen,Direct thrombin inhibitors versus low molecular weight heparins as thromboprophylaxis in Staphylococcus aureus bacteraemia. A prospective randomized controlled academic single-centre feasibility study...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004863-29,0,0,0 2012-004864-24,1,2013-12-27,2013-12-27,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Bionorica SE,"Randomized, placebo-controlled, double-blind, cross-over trial with Bronchipret and Sinupret to evaluate acceleration of mucociliary clearance (MCC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004864-24,0,0,0 2012-004866-16,4,2015-04-30,2015-06-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled Parallel Study with an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004866-16,0,0,0 2012-004866-16,4,2015-04-30,2015-06-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized, Double-Blind, Placebo-Controlled Parallel Study with an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004866-16,0,0,0 2012-004867-38,5,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,NOVO NORDISK. S.P.A.,Safety and Efficacy of nonacog beta pegol (N9-GP) in Previously Untreated Patients with Haemophilia B An open-label single-arm multicentre non-controlled phase 3a trial investigating safety and effic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004867-38,0,0,0 2012-004867-38,5,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,Novo Nordisk A/S,Safety and Efficacy of nonacog beta pegol (N9-GP) in Previously Untreated Patients with Haemophilia B An open-label single-arm multicentre non-controlled phase 3a trial investigating safety and effic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004867-38,0,0,0 2012-004868-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,Phase II single arm open pilot study to demonstrate the efficacy of midostaurin in symptom improvement and decrease of mast cell burden in patients with indolent or smoldering systemic mastocytosis ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004868-22,0,0,0 2012-004873-14,6,2016-11-04,2017-10-25,3,0,0,0,0,0,3,0,0,2,0,0,0,0,0,University Eye Clinic Maastricht UMC,PREvention of Macular EDema after cataract surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004873-14,1,0,0 2012-004873-14,6,2016-11-04,2017-10-25,3,0,0,0,0,0,3,0,0,2,0,0,0,0,0,University Eye Clinic Maastricht,PREvention of Macular EDema after cataract surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004873-14,1,0,0 2012-004876-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO,Study on the effectiveness of two different formulations of L-thyroxine compress and liquid oral solution) in pregnant patients affected with hypothyroidism. Studio sull'™efficacia della terapia co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004876-20,0,0,0 2012-004877-26,7,2018-10-10,2018-10-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd.,BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004877-26,0,0,0 2012-004877-26,7,2018-10-10,2018-10-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004877-26,0,0,0 2012-004878-26,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Karolinska University Hospital Solna,"Antibiotic prophylaxis in patients undergoing primary or secondary breast reconstruction with implants, a randomized parallel two armed prospective clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004878-26,0,0,0 2012-004879-38,5,2018-05-29,2018-05-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASE III NEOADJUVANT STUDY EVALUATING TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB COMPARED WITH CHEMOTHERAPY PLUS TRASTUZUMAB AND PERTUZUMAB FOR PATIENTS WIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004879-38,0,0,0 2012-004880-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medizinische Universität Graz, Klinische Abteilung für Geburtshilfe, Univ. Klinik für Frauenheilkunde und Geburtshilfe",Efficacy of induction of labor on term using a double balloon catheter compared to Dinoprostone vaginal-insert – a multicenter randomized controlled trial. Erfolgsrate bei Geburtseinleitung am Term...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004880-36,0,0,0 2012-004883-23,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Henning Beck-Nielsen,Individually tailored treatment in type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004883-23,0,0,0 2012-004884-29,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,1,BioInvent International AB,"A single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With BI-505, a Human Anti–Intercellular Adhesion Molecule 1 Monoclonal Antibody, In Patients With Smold...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004884-29,0,0,0 2012-004886-42,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,University of Crete,Study of the effect of the thrombopoietin receptor agonist eltrombopag on thrombocytopenia and megakaryopoiesis of patients with lower and intermediate-1 risk myelodysplastic syndromes. Μελέτη αξιο...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004886-42,0,0,0 2012-004888-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI,"Intensive Phosphate Control in Development of Renal End Points and Mortality in CKD (the IPeR Study) Controllo intensivo della fosforemia, mediante dieta ipofosforica e chelanti del fosforo nei con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004888-41,0,0,0 2012-004890-25,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERO-UNIVERSITARIA S. MARIA DELLA MISERICORDIA DI UDINE,"Botulinum Toxin Serotype A randomized double-blind, placebo controlled multicentre study for degenerative coxarthrosis. Studio randomizzato, multicentrico, in doppio cieco controllato con placebo s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004890-25,0,0,0 2012-004891-20,1,2014-10-02,2014-10-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A randomised, double-blind (sponsor-unblind), placebo controlled, cross-over study to investigate the efficacy, effect on cough reflex sensitivity, safety, tolerability and pharmacokinetics of inhaled...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004891-20,0,0,0 2012-004892-37,3,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,"Academic Medical Center, Department of Haematology, University of Amsterdam",N-Acetylcysteine in patients with Sickle Cell Disease. Reducing the incidence of daily life pain in patients with sickle cell disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004892-37,0,0,0 2012-004892-37,3,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Academic Medical Center,N-Acetylcysteine in patients with Sickle Cell Disease. Reducing the incidence of daily life pain in patients with sickle cell disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004892-37,0,0,0 2012-004893-25,1,2017-12-13,2017-12-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Imperial College London,RITUXILUP - An open label randomised multicentre controlled trial of RITUXImab and mycophenolate mofetil (MMF) without oral steroids for the treatment of LUPus nephritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004893-25,0,0,0 2012-004895-21,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Clatterbridge Cancer Centre NHS Foundation Trust,Phase II randomised placebo controlled NEOadjuvant chemotherapy study of Nintedanib with Gemcitabine and Cisplatin in locally advanced muscle invasive BLADder cancEr,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004895-21,0,0,0 2012-004896-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IELSG (International Extranodal Lymphoma Study Group),A PHASE II STUDY OF CHLORAMBUCIL IN COMBINATION WITH SUBCUTANEOUS RITUXIMAB FOLLOWED BY MAINTENANCE THERAPY WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004896-38,0,0,0 2012-004898-30,7,2019-10-03,2019-10-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,Long-term Extension Study of BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004898-30,0,0,0 2012-004898-30,7,2019-10-03,2019-10-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd.,Long-term Extension Study of BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004898-30,0,0,0 2012-004898-30,7,2019-10-03,2019-10-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd,Long-term Extension Study of BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004898-30,0,0,0 2012-004900-37,1,2013-03-20,2013-03-20,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,"J. Uriach y Compañía, S.A.","A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel group study to assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of oral Rupatadine in Healthy Japanese Subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004900-37,0,0,0 2012-004902-82,11,2021-05-28,2021-06-04,8,1,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCLINE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004902-82,1,0,0 2012-004905-29,6,2015-08-30,2015-08-31,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 plus Pegylated Interferon alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects with Chronic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004905-29,0,0,0 2012-004907-10,9,2019-06-03,2019-06-03,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as the SPONSOR or Merck)","A Multi-Center, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients with Advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004907-10,0,0,0 2012-004907-10,9,2019-06-03,2019-06-03,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (de aquí en adelante se referenciará como Promotor o Merck)","A Multi-Center, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients with Advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004907-10,0,0,0 2012-004907-10,9,2019-06-03,2019-06-03,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Multi-Center, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients with Advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004907-10,0,0,0 2012-004910-33,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,Phase II study of single-agent Pazopanib (Votrient) for patients with relapsed or refractory germ-cell tumors (GCT). Studio di fase II con ™inibitore tirosin-kinasico Pazopanib in pazienti affetti ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004910-33,0,0,0 2012-004915-30,4,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,0,HOVON Foundation,"Treatment of severe steroid-refractory acute GvHD with mesenchymal stromal cells. A phase III, randomized double-blind multi-center HOVON study. Behandeling van ernstige steroïde-ongevoelige acute...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004915-30,0,0,0 2012-004916-79,1,2014-09-26,2014-09-26,1,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Lofarma S.p.A.,"Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS® Grass tablets for patients with grass pollen-induced allergic rhinoconjunctivitis, a phase III study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004916-79,0,0,0 2012-004917-14,1,2013-05-03,2013-05-03,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,LABORATOIRES SMB S.A,"A phase IV, randomised, double-blinded, parallel study to estimate the dose-response of vitamin D (D-CURE®) supplementation on the 25-hydroxyvitamin D serum concentration in patients with vitamin D de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004917-14,0,0,0 2012-004920-39,3,2015-07-22,2015-07-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-38518168 in Symptomatic Adult Subjects with Uncontrolled, Persistent Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004920-39,0,0,0 2012-004928-38,1,2018-04-30,2018-04-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama),A phase III clinical trial to evaluate patient´s preference of subcutaneous trastuzumab (SC) versus intravenous (IV) administration in patients with HER2 positive Advanced Breast Cancer (ABC) who hav...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004928-38,0,0,0 2012-004931-22,2,2015-06-15,2015-06-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate glycaemic control on sitagliptin and metformin A szitagliptinről liraglutidr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004931-22,0,0,0 2012-004938-42,1,2013-06-28,2013-06-28,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,"Experimental Human Rhinovirus Infection, a randomized placebo-controlled pilot study Experimentele menselijke Rhinovirus Infectie, een gerandomiseerde placebo-gecontroleerde pilot studie.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004938-42,0,0,0 2012-004939-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHRU de TOURS,Effet de la COmbinaison de Méthotrexate et d’Adalimumab sur la Réduction de l’Immunisation au cours de la Spondylarthrite ankylosante Effet de la COmbinaison de Méthotrexate et d’Adalimumab sur la ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004939-23,0,0,0 2012-004940-31,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Dept of medical sciences, Rheumatology","Dermal inflammation in psoriatic arthritis, the association to molecular mass of hyaluronan and effect of adalimumab. A prospective, open-label, multi-center study of hyaluronan molecular mass distrib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004940-31,0,0,0 2012-004942-14,3,2017-01-06,2019-01-09,3,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, 104-weeks treatment study to evaluate the efficacy, safety, tolerability and pharmacokinetics of telbivudine oral solution and tablets in children and adolescents with comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004942-14,0,0,0 2012-004944-31,3,2015-08-30,2015-08-30,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,EVER Neuro Pharma GmbH,"Comparison of Cerebrolysin and donepezil: A randomized, double-blind, controlled trial on efficacy and safety in patients with mild to moderate Alzheimer?s disease Comparación entre la cerebrolisin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004944-31,0,0,0 2012-004946-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospitals Leuven,Impact of timolol/dorzolamide therapy on autoregulation in glaucoma patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004946-13,0,0,0 2012-004949-32,2,2013-08-20,2014-08-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Theravance, Inc.","A Phase 2, Randomised, Double-Blind, Multiple−Dose, Five−Period, Incomplete-Block, Crossover Study to Examine the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Multiple Doses of T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004949-32,0,0,0 2012-004950-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Sahlgrenska universitetssjukhuset,Effect of valproic acid on fibrinolysis in humans with atherosclerosis Effekt av valproinsyra på fibrinolysen i människa med åderförkalkningssjukdom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004950-27,0,0,0 2012-004951-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI,"Disulfiram, obesity and binge eating disorder Disulfiram, obesita' e binge eating disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004951-35,0,0,0 2012-004952-12,1,2016-04-15,2016-04-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Acucela Inc.,"A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) with Placebo for the Treatment of Geographic Atrophy Ass...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004952-12,0,0,0 2012-004954-27,1,2013-11-07,2013-11-07,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,"Clinical Trials and Research Governance, University of Oxford",A single centre open-label randomised controlled trial of long term pituitary down-regulation before in vitro fertilisation for women with endometriosis: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004954-27,0,0,0 2012-004955-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI,A single-center randomized double-blind placebo-controlled trial “Treatment of Systemic Sclerosis with Rituximab: evaluation of the effectiveness of B-cell depletion therapy”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004955-35,0,0,0 2012-004956-12,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO NAZIONALE PER LA CURA TUMORI,"A phase II, open label, single arm trial of neoadjuvant therapy in patients with triple negative breast cancer evaluating the efficacy of eribulin mesylate following anthracycline and taxane and corre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004956-12,0,0,0 2012-004961-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Medical Oncology, VUmc",Measurement of tumor kinase inhibitor concentrations using PET imaging in patients with advanced solid malignancies Het meten van concentraties kinaseremmer in tumorlesies bij patienten met vergevo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004961-42,0,0,0 2012-004965-41,3,2014-01-16,2014-02-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dignity Sciences Limited,"A Randomised, Double-blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Topically Applied DGLA Cream in Patients with Mild to Moderate Acne Vulgaris",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004965-41,0,0,0 2012-004966-16,23,2015-09-15,2015-09-15,21,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 52-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) with s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004966-16,0,0,0 2012-004966-16,23,2015-09-15,2015-09-15,21,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 52-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) with s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004966-16,0,0,0 2012-004966-16,23,2015-09-15,2015-09-15,21,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farma,"A 52-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) with s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004966-16,0,0,0 2012-004966-16,23,2015-09-15,2015-09-15,21,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmaceutica, S.A.","A 52-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) with s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004966-16,0,0,0 2012-004969-40,1,2017-01-10,2017-01-10,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Fertility Clinic, Copenhagen University Hospital, Rigshospitalet",An AMH based indivdualised controlled ovarian stimulation regiment using Corifollitrophin or graded doses of rFSH versus a standard protocol. A randomised controlled trial Anti Mullersk Hormon (AMH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004969-40,0,0,0 2012-004970-24,1,2015-07-21,2015-07-21,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Clinic per a la Recerca Biomèdica,Virological and immunological safety of a dose reduction strategy antiretroviral regimen with efavirenz / tenofovir / emtricitabine Seguridad virológica e inmunológica de una estrategia de reducció...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004970-24,0,0,0 2012-004975-37,7,2015-06-22,2015-06-22,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Teva Pharmaceutical Industries Ltd.,"A 64-Week (12-week core phase and 52-week safety extension), Phase II, Multicenter, Randomized, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults with Grow...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004975-37,0,0,0 2012-004977-23,3,2022-01-27,2022-01-27,1,1,0,0,0,0,3,0,0,1,0,0,0,0,1,"SFJ LungCancer, Ltd.","ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF 00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL CELL LU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004977-23,0,0,0 2012-004979-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VieCuri Medical Center,"Levosimendan in Acute Kidney Injury Study, a prospective, randomized, monocenter, double blind, placebo-controlled study to investigate the efficacy and safety of Levosimendan in Intensive Care Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004979-39,0,0,0 2012-004980-39,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Oxford,A double blind randomised controlled trial on neuroprotection of amiloride in optic neuritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004980-39,0,0,0 2012-004982-41,5,2015-10-30,2015-10-30,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,H. Lundbeck A/S,"Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose study of brexpiprazole as adjunctive treatment to paroxetine or sertraline in adult patients suffering from ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004982-41,0,0,0 2012-004984-27,8,2014-11-19,2014-11-19,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004984-27,0,0,0 2012-004987-23,5,2014-03-21,2014-03-21,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Cytokinetics Inc,"A Phase IIb, multi-national, double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004987-23,0,0,0 2012-004988-42,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Sandwell and West Birmingham Hospitals NHS Trust,REVISE-Diabesity: Randomisation to Endoluminal intestinal liner alone Versus with Incretin analogue in SustainEd Diabesity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004988-42,0,0,0 2012-004992-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,South-Eastern Norway Regional Health Authority,"The effects of n-3 polyunsaturated fatty acids on glomerular filtration rate, proteinuria, fibrosis and inflammation in the kidney transplant and cardiovascular risk markers in kidney transplant recip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004992-37,0,0,0 2012-004992-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oslo University Hospital Rikshospitalet,"The effects of n-3 polyunsaturated fatty acids on glomerular filtration rate, proteinuria, fibrosis and inflammation in the kidney transplant and cardiovascular risk markers in kidney transplant recip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004992-37,0,0,0 2012-004993-25,1,2013-07-04,2013-07-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Verisfield (UK) Ltd,"A multicenter, randomized, patient-blind, investigator-blind, placebo-controlled, crossover study of Lidocaine + Prilocaine/Verisfield (2.5+2.5)% w/w cream and EMLA/AstraZeneca cream, in patients unde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004993-25,0,0,0 2012-004994-16,8,2014-12-11,2015-01-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Multiple dose trial examining dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004994-16,0,0,0 2012-004996-38,17,2017-01-24,2017-01-24,15,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"UCB BIOSCIENCES, Inc.","A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WITH EPILEPSY >=4 YEARS TO <17 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004996-38,1,1,0 2012-004996-38,17,2017-01-24,2017-01-24,15,1,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB BIOSCIENCES Inc.,"A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WITH EPILEPSY >=4 YEARS TO <17 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004996-38,1,1,0 2012-004998-53,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,National and Kapodistrian University of Athens,A phase II study of the efficacy of the combination of ofatumumab with fludarabine and cyclophosphamide in patients with relapsed or refractory Waldenström’s Macroglobulinemia. Μελέτη φάσης ΙΙ της ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004998-53,0,0,0 2012-005000-17,4,2015-03-20,2015-03-20,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, parallel-group proof of concept study to evaluate the effect of AFQ056 in obsessive compulsive disorder (OCD) patients resistant to Selective Serotonin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005000-17,0,0,0 2012-005002-22,1,2016-06-15,2016-06-15,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Hannover Medical School,ACEMg mediated hearing preservation in cochlear implant patients receiving different electrode lengths,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005002-22,0,0,0 2012-005003-40,1,2013-08-13,2013-08-13,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,MUCOS Pharma GmbH & Co. KG,"Effects of Wobenzym® plus in healthy, sportive people after eccentric exercise - a randomized, two-stage, double-blind, placebo-controlled cross-over trial Wirkung von Wobenzym® plus bei gesunden S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005003-40,0,0,0 2012-005007-41,6,2015-07-22,2015-07-22,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Randomised, Double Blind, Double Dummy, Parallel Group Study Comparing UMEC/VI (A Fixed Combination Of Umeclidinium and Vilanterol) With Tiotropium In COPD Subjects Who Continue To Have Symptoms on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005007-41,0,0,0 2012-005007-41,6,2015-07-22,2015-07-22,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.","A Randomised, Double Blind, Double Dummy, Parallel Group Study Comparing UMEC/VI (A Fixed Combination Of Umeclidinium and Vilanterol) With Tiotropium In COPD Subjects Who Continue To Have Symptoms on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005007-41,0,0,0 2012-005010-19,1,2018-06-14,2018-06-14,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Consorzio Mario Negri Sud,Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005010-19,0,0,0 2012-005012-26,22,2022-04-13,2022-04-13,14,1,1,0,0,0,3,0,0,2,1,0,0,0,1,UCB Biosciences Inc.,"A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS WITH EPILEPSY WITH PARTIAL ONSET SEIZURES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005012-26,1,0,0 2012-005013-38,1,2014-04-07,2014-04-07,1,0,0,0,0,0,4,0,0,1,0,0,1,0,3,,Effect of GLP-1 on microvascular function in patients with type 2 diabetes Effekt af GLP-1 behandling på mikrovaskulær funktion hos patienter med type 2 diabetes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005013-38,0,0,0 2012-005019-14,1,2017-02-21,2017-02-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Nottingham,The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study (STAKT Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005019-14,0,0,0 2012-005021-76,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,1,EDISON PHARMACEUTICALS INC.,"A Phase 2A Randomized, Placebo Controlled Trial of EPI-743 in Children with Rett Syndrome Studio di Fase 2A, Randomizzato, Controllato con Placebo, di EPI-743 in Bambini con Sindrome di Rett",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005021-76,0,0,0 2012-005025-70,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsingin Yliopistollinen keskussairaala,Reducing high intraocular pressure with hypertonic saline infusion before eyesurgery Hypertoninen keittosuolaliuos silmänpaineen alentamisessa ennen silmäleikkausta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005025-70,0,0,0 2012-005026-30,5,2014-11-06,2015-11-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Samsung Bioepis Co., Ltd.","A Randomised, Double-Blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB4 Compared to Enbrel® in Subjects with Moderate to Sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005026-30,0,0,0 2012-005030-11,1,2014-04-24,2014-04-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,IBSA INSTITUT BIOCHIMIQUE SA,"Multicentre, randomized, double-blind, placebo-controlled clinical trial to evaluate the short-term efficacy and safety of two different treatment regimens of Betamethasone valerate 2.25 mg medicated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005030-11,0,0,0 2012-005032-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Association Bigorre Douleurs,Transmucosal Effentora® efficacy and safety for pre-emptive procedural pain treatment in opioid tolerant cancer patients. Évaluation de l’efficacité antalgique et de la tolérance d’Effentora® par v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005032-29,0,0,0 2012-005035-85,1,2015-06-02,2015-06-02,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside,"A proof of concept study in allergic rhinitis, to evaluate the differential effects of doxazosin between single and chronic dosing on nasal airway calibre",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005035-85,0,0,0 2012-005036-28,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,CENTRE ANTOINE LACASSAGNE,Pharmacogenetic study in castration-resistant prostate cancer patients treated with abiraterone acetate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005036-28,0,0,0 2012-005037-37,3,2016-07-04,2016-07-04,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Puma Biotechnology, Inc.",A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients with Metastatic HER2-Amplified or Triple-Negative Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005037-37,0,0,0 2012-005040-20,1,2014-04-15,2014-04-15,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,Effect of Macrodex versus lactated Ringer on coagulation in major surgery. A randomised clincal trial. Effekt af kolloidet Macrodex versus Ringer-laktat på koagulation ved elektiv urologisk kirurgi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005040-20,0,0,0 2012-005042-37,2,2014-07-28,2014-10-20,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Bionorica SE,"Prospective, double-blind, placebo-controlled, parallel-group, multi-centre randomized clinical trial to proof efficacy and safety of 20 mg (2 tablets of 10 mg) VAC BNO 1095 FCT in patients suffering ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005042-37,0,0,0 2012-005048-46,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione GISCAD,First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH FOLFIRI e bevacizumab nel trattamento di prima linea in pazienti con c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005048-46,0,0,0 2012-005050-35,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University Medical Center Groningen,Phase Ib/II study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005050-35,0,0,0 2012-005054-30,8,2016-05-11,2017-05-24,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Merz Pharmaceuticals GmbH,"Prospective, multicenter, randomized, double-blind, parallel-group, dose-response study of three doses Xeomin® (incobotulinumtoxinA, NT 201) for the treatment of lower limb spasticity in children and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005054-30,1,1,0 2012-005055-17,6,2017-01-16,2017-01-16,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Merz Pharmaceuticals GmbH,"Open-label, non-controlled, multicenter long-term study to investigate the safety and efficacy of Xeomin® (incobotulinumtoxin A, NT 201) for the treatment of spasticity of the lower limb(s) or of comb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005055-17,1,1,0 2012-005059-18,5,2017-04-13,2017-04-13,3,1,0,0,2,0,3,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A Phase III, randomised, observer-blind, placebo-controlled, multicentre clinical study to assess the immunogenicity and safety of GSK Biologicals' HZ/su candidate vaccine when administered intramuscu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005059-18,0,0,0 2012-005059-18,5,2017-04-13,2017-04-13,3,1,0,0,2,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase III, randomised, observer-blind, placebo-controlled, multicentre clinical study to assess the immunogenicity and safety of GSK Biologicals' HZ/su candidate vaccine when administered intramuscu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005059-18,0,0,0 2012-005059-18,5,2017-04-13,2017-04-13,3,1,0,0,2,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Biologicals s.a.,"A Phase III, randomised, observer-blind, placebo-controlled, multicentre clinical study to assess the immunogenicity and safety of GSK Biologicals' HZ/su candidate vaccine when administered intramuscu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005059-18,0,0,0 2012-005059-18,5,2017-04-13,2017-04-13,3,1,0,0,2,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A Phase III, randomised, observer-blind, placebo-controlled, multicentre clinical study to assess the immunogenicity and safety of GSK Biologicals' HZ/su candidate vaccine when administered intramuscu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005059-18,0,0,0 2012-005060-10,8,2016-02-01,2016-02-01,6,0,1,0,0,1,3,0,0,1,0,0,1,0,1,Novagali Pharma S.A.S.,"A MULTICENTER, RANDOMIZED, DOUBLE-MASKED, 3 PARALLEL ARMS, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NOVA22007 1MG/ML (CICLOSPORIN/CYCLOSPORINE) EYE DROPS, EMULSION ADMINISTERED IN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005060-10,0,0,0 2012-005060-10,8,2016-02-01,2016-02-01,6,0,1,0,0,1,3,0,0,1,0,0,1,0,1,NOVAGALI PHARMA SAS,"A MULTICENTER, RANDOMIZED, DOUBLE-MASKED, 3 PARALLEL ARMS, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF NOVA22007 1MG/ML (CICLOSPORIN/CYCLOSPORINE) EYE DROPS, EMULSION ADMINISTERED IN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005060-10,0,0,0 2012-005062-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE),"An open label, single arm, phase II study of nilotinib 300 mg BID in newly diagnosed CP-CML patients, in order to verify disappearance of CD34+/lin-Ph+ cells from bone marrow during treatment. Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005062-34,0,0,0 2012-005063-28,1,2017-11-14,2017-11-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Gothenburg,Release of substance P during peritoneal dialysis: effects of intervention. Controlled cross-over study of the neurokinin-1 receptor antagonist Aprepitant Frisättning av substans P under peritoneal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005063-28,0,0,0 2012-005066-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VU University Medical Center,Effect of Growth Hormone replacement therapy on cardiovascular risk factors in adult patients with severe growth hormone deficiency: association with IGF-I concentration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005066-36,0,0,0 2012-005068-82,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,The Rotterdam Eye Hospital,An alternative approach for treatment of infantile esotropia with botulinum toxin A.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005068-82,0,0,0 2012-005075-14,1,2014-09-09,2014-09-09,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Wien,Minimal local anaesthetic volumes for sciatic nerve blockade: A clinical evaluation of ED99 volumes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005075-14,0,0,0 2012-005076-34,1,2015-09-29,2015-09-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Cliniques Universitaires Saint-Luc, Neurologie","Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters. A cross-over, double-blinded, placebo-controlled study. Fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005076-34,0,0,0 2012-005078-70,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University Medical Center Hamburg-Eppendorf,Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) A random...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005078-70,0,0,0 2012-005078-70,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,UNIVERSITäTKLINIKUM HAMBURG-EPPENDORF,Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) A random...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005078-70,0,0,0 2012-005082-13,1,,,0,1,1,0,0,0,1,0,0,1,0,0,0,1,1,Biogen Idec Research Limited,"A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects with Relapsing Remitting Multiple Scleros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005082-13,0,0,0 2012-005086-12,5,2016-02-15,2016-02-25,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Octapharma AG,Active-controlled phase IIIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005086-12,0,0,0 2012-005087-10,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma Services AG,"A 12-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in COPD pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005087-10,0,0,0 2012-005092-14,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,ALK-Abelló S.A.,Molecular and Cellular Mechanism in the course of Immunotherapy with a Phleum pratense oral lyophilisate Mecanismos moleculares y celulares implicados en la inmunoterapia con un liofilizado oral de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005092-14,0,0,0 2012-005093-54,2,2015-06-12,2015-06-12,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Double-Blind, Placebo-Controlled, Randomized, Twostage, Parallel-Group, Adaptive Design Phase 2a Study to Evaluate the Effects of BMS-813160 in Subjects with Type 2 Diabetes Mellitus and Diabetic Ki...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005093-54,0,0,0 2012-005096-13,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AvL),Clinical and pharmacological feasibility study with 2B3-101 in patients with breast cancer and leptomeningeal metastases Klinisch en farmacologisch feasibility studie met 2B3-101 in patienten met...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005096-13,0,0,0 2012-005097-66,1,2016-11-07,2016-11-07,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,HOMVIORA Arzneimittel - Dr. Hagedorn GmbH & Co.,"Effect of two homeopathic preparations on blood pressure in comparison to metoprolol (trade name Beloc-Zok® mite 47,5 mg) in 90 patients suffering from mild hypertonia. A prospective, confirmatory, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005097-66,0,0,0 2012-005101-51,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,National Institute of Health and the Environment (Dutch acronym: RIVM),Tick Test & Prophylaxis Proof,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005101-51,0,0,0 2012-005102-22,2,2013-10-23,2013-10-23,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A 12-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in COPD pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005102-22,0,0,0 2012-005111-12,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,FOCUS4 – Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trial programme,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005111-12,0,0,0 2012-005113-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Universitätsklinik für Neurologie, Medizinische Universität Wien","A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis Amilorid Hydrochlorothiazid bei akuter, autoimmun-vermittelter Optik...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005113-39,0,0,0 2012-005114-20,10,2016-12-06,2020-04-01,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005114-20,0,0,0 2012-005114-20,10,2016-12-06,2020-04-01,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc","A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005114-20,0,0,0 2012-005115-13,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,LABORATOIRES MAYOLY SPINDLER,"A randomized, assessor-blinded, multicenter, international study investigating efficacy, patient's acceptance, safety and tolerability of Sodium Phosphate tablets compared to split dose Polyethylene G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005115-13,0,0,0 2012-005123-32,1,2017-04-27,2017-04-27,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Cardiff University,Oral steroids for the resolution of otitis media with effusion in children study (OSTRICH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005123-32,0,0,0 2012-005124-15,18,2020-07-08,2020-07-08,16,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia chromosome-positive CML after two different durations of con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005124-15,0,0,0 2012-005124-15,18,2020-07-08,2020-07-08,16,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Farma,"A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia chromosome-positive CML after two different durations of con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005124-15,0,0,0 2012-005124-15,18,2020-07-08,2020-07-08,16,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia chromosome-positive CML after two different durations of con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005124-15,0,0,0 2012-005127-33,1,2016-09-30,2016-09-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,University Ghent,"Pharmacokinetic and pharmacodynamic evaluation of linezolid administered intravenously in MRSA-positive, morbidly obese patients with pneumonia. Evaluatie van de farmacokinetiek en pharmacodynami...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005127-33,0,0,0 2012-005129-57,2,2015-06-23,2015-06-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"KRKA ČR, s.r.o.",The Efficacy and Safety of Valsartan and Combination of Valsartan and Hydrochlorothiazide in the Treatment of Patients with mild to moderate Arterial Hypertension.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005129-57,0,0,0 2012-005129-57,2,2015-06-23,2015-06-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Krka, d.d., Novo mesto",The Efficacy and Safety of Valsartan and Combination of Valsartan and Hydrochlorothiazide in the Treatment of Patients with mild to moderate Arterial Hypertension.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005129-57,0,0,0 2012-005137-37,1,,,0,0,1,0,0,0,2,0,1,0,0,0,0,0,1,Bavarian Nordic A/S,"Open-label, non-controlled, multicenter immunogenicity and safety study of MVA-BN® smallpox vaccine in children from birth to less than 12 years of age Offene, nicht kontrollierte, multizentrische...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005137-37,0,0,0 2012-005138-12,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,GELTAMO (Grupo Cooperativo Español de Linfoma/Trasplante Autólogo de Médula Ósea),Randomized phase II study of treatment with R-CHOP vs Bortezomib-R-CAP for young patients with poor IPI diffuse large B-cell lymphoma. Estudio fase II aleatorizado de tratamiento de los pacientes ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005138-12,0,0,0 2012-005139-99,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,Étude de phase II randomisée comparant un traitement d’entretien par cetuximab seul à une pause thérapeutique en cas de cancer colorectal métastatique avec gène KRAS sauvage répondeur ou contrôlés apr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005139-99,0,0,0 2012-005141-20,1,2014-11-07,2014-11-07,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Royal Liverpool University Hospital,"FULL TITLE: Pneumococcal Conjugate Vaccine (PCV-13) and Experimental Human Pneumococcal Carriage Study (EHPC) Study. KEY WORDS: mucosa, innate, cellular, humoral, Streptococcus pneumoniae, pneumococcu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005141-20,0,0,0 2012-005141-20,1,2014-11-07,2014-11-07,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Liverpool School of Tropical Medicine,"FULL TITLE: Pneumococcal Conjugate Vaccine (PCV-13) and Experimental Human Pneumococcal Carriage Study (EHPC) Study. KEY WORDS: mucosa, innate, cellular, humoral, Streptococcus pneumoniae, pneumococcu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005141-20,0,0,0 2012-005143-24,2,2016-10-25,2016-10-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1 or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005143-24,0,0,0 2012-005146-38,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ANTONIO PEREZ MARTINEZ,"""LANK-2"": activated and expanded NK cell immunotherapy together with salvage chemotherapy in children, adolescents and young adults with relapsed or refractary acute leukemia ""LANK-2"": INMUNOTERAPI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005146-38,0,0,0 2012-005150-34,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Erasmus MC,Dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005150-34,0,0,0 2012-005157-23,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,Fondazione IRCCS Istituto Nazionale Tumori,A Phase I/II Study of Danusertib in Combination with Romidepsin in Adult Patients with Mature Peripheral T Cell Lymphoma (PTCL) Studio di Fase I/II di Danusertib in Combinazione con Romidepsina in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005157-23,0,0,0 2012-005159-18,1,2016-06-21,2016-06-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Imperial College, London",An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005159-18,0,0,0 2012-005161-12,1,2017-05-15,2017-05-15,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Oasmia Pharmaceutical AB,"A multi-country, multicenter, randomized, open-label, parallel group study to assess the efficacy and safety of Docecal compared with Taxotere® Starptautisks, daudzcentru, randomizēts, atklāts, par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005161-12,0,0,0 2012-005170-65,3,2014-06-18,2014-06-18,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase IIa Open Label, Randomized Clinical Trial to Study the Safety and Efficacy of Vintafolide and the Combination of Vintafolide and Paclitaxel Compared to Paclitaxel in Subjects with Advanced Tri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005170-65,0,0,0 2012-005173-32,1,2014-09-30,2014-09-30,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,FAST-consortium,FAST-Fish - Food Allergy Specific Treatment for fish allergy FAST-fisk - fødevare allergi specific behandling af fiske allergi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005173-32,0,0,0 2012-005174-56,1,2015-07-10,2015-07-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Comparison of Pharmacodynamics When Receiving a Double Dose of Insulin Peglispro or Insulin Glargine in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Crossover Design Study: The IMAGINE 8...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005174-56,0,0,0 2012-005180-27,9,2017-11-01,2017-11-01,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis Studio di fase 3, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005180-27,0,0,0 2012-005183-94,1,2015-02-23,2015-02-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma S.A.S.,"Etude multicentrique, randomisée, contrôlée, en ouvert d'une durée de 24 semaines, comparant la stratégie metformine/vildagliptine + insuline basale versus metformine/sulfamide + insuline basale chez ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005183-94,0,0,0 2012-005184-27,8,2014-09-01,2014-10-29,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase 2 Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Inhaled JNJ-49095397 (RV568) in Subjects with Moderate to Severe Chronic Obstructive Pulmonary Disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005184-27,0,0,0 2012-005192-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE),Strategic study of dual-therapy with darunavir/ritonavir and rilpivirine QD versus triple-therapy in patients with suppressed viral load: virological efficacy and evaluation of non-HIV related morbidi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005192-14,0,0,0 2012-005194-32,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Institut Jules Bordet,A phase II trial evaluating Cabazitaxel in patients with brain metastasis secondary to breast and non-small-cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005194-32,0,0,0 2012-005197-63,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Ana M. Wägner,"Effect of liraglutide on physical performance: a randomised, double-blind, controlled study in patiens with type 2 diabetes. Efecto del tratamiento con liraglutida sobre el rendimiento físico: un e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005197-63,0,0,0 2012-005198-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,LAURA TARRATS VELASCO,EFFICACY OF ADMINISTRATION OF HYOSCINE BUTILBROMIDE (BUSCOPAN®) ON PREGNANT WOMEN IN FIRST STAGE OF LABOUR IN CASE OF CERVIX RIGIDITY. (BBH V.04-2013 EUDRACT: 2012-005198-30) EFICACIA DE LA ADMI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005198-30,0,0,0 2012-005200-18,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy, immunogenicity and safety of two doses of GSK Biologicals’ oral live attenuated liquid human rotav...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005200-18,0,1,1 2012-005201-48,14,2018-07-17,2018-08-28,13,1,0,0,0,1,2,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm. V,"Double blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005201-48,0,0,0 2012-005201-48,14,2018-07-17,2018-08-28,13,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Double blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005201-48,0,0,0 2012-005201-48,14,2018-07-17,2018-08-28,13,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim,"Double blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005201-48,0,0,0 2012-005201-48,14,2018-07-17,2018-08-28,13,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"Double blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005201-48,0,0,0 2012-005201-48,14,2018-07-17,2018-08-28,13,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim AB,"Double blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005201-48,0,0,0 2012-005201-48,14,2018-07-17,2018-08-28,13,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda","Double blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005201-48,0,0,0 2012-005201-48,14,2018-07-17,2018-08-28,13,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim bv,"Double blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005201-48,0,0,0 2012-005201-48,14,2018-07-17,2018-08-28,13,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Limited,"Double blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005201-48,0,0,0 2012-005201-48,14,2018-07-17,2018-08-28,13,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim France,"Double blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005201-48,0,0,0 2012-005201-48,14,2018-07-17,2018-08-28,13,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Boehringer Ingelheim España, S.A.","Double blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005201-48,0,0,0 2012-005213-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CENTRE JEAN PERRIN,Phase II pilot study assessing efficacy of a Cisplatine – Métronomic Cyclophosphamide treatment in Patients with Stade IV Triple Negative breast Cancer Secondary Resistant to Anthracyclines and Taxane...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005213-39,0,0,0 2012-005214-19,1,2018-10-18,2018-10-18,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Academic Medical Center, Department of Rheumatology","A randomized, double-blind, placebo-controlled trial of golimumab+methotrexate versus methotrexate alone in methotrexate-naïve patients with psoriatic arthritis Een gerandomiseerd, dubbel blind, pl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005214-19,0,0,0 2012-005215-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Department of Anesthesiology and Intensive Care Medicine,"Children's mood/anxiety, pain, nausea and behavioral changes after premedication with Clonidine versus Midazolam in ENT day surgery. Barns sinnesstämning/oro, smärta, illamående och beteendeförändr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005215-42,0,0,0 2012-005216-26,1,2014-06-30,2014-06-30,1,1,0,0,1,0,2,0,1,1,0,0,1,0,0,"Faculty of Odontology, University of Iceland",A study of the effect of monocaprin in dental adhesive/dental gel on Candida infection in the oral cavity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005216-26,0,0,0 2012-005219-18,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,St. Elisabeth Ziekenhuis,"The influence of dropsize of tropicamide 0.5% eyedrops on pupildilation De invloed van de druppelgrootte van tropicamide 0,5% oogdruppels op de mate van pupilverwijding",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005219-18,0,0,0 2012-005220-15,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,University Medical Center Groningen,Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early diabetes Pleiotrope effecten van Linagliptin monotherapie op arteriële stijfheid bij vroege diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005220-15,0,0,0 2012-005222-30,1,2015-11-05,2015-11-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,UNIVERSITA' DI GENOVA,Feasibility study to assess safety of high dose of lanreotide in net patients poorly controlled by standard doses of SSA Sicurezza del trattamento con lanreotide ad alte dosi in pazienti affetti da...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005222-30,0,0,0 2012-005223-32,1,2016-09-19,2016-09-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Klinik für Innere Medizin I, Abt. Onkologie",A Phase II trial of Ofatumumab in patients with lymphoma of the of the mucosa associated lymphoid tissue (MALT-Lymphoma) Ofatumumab (Arzerra®) bei Patienten mit Lymphom des Mukosa-assoziierten ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005223-32,0,0,0 2012-005226-29,4,2015-07-30,2015-08-31,2,0,0,0,1,1,3,0,0,2,0,0,0,0,2,Centro Hospitalar de São João E.P.E.,Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005226-29,1,0,0 2012-005226-29,4,2015-07-30,2015-08-31,2,0,0,0,1,1,3,0,0,2,0,0,0,0,2,Erasmus MC,Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005226-29,1,0,0 2012-005226-29,4,2015-07-30,2015-08-31,2,0,0,0,1,1,3,0,0,2,0,0,0,0,2,Hospital S. Joao,Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005226-29,1,0,0 2012-005226-29,4,2015-07-30,2015-08-31,2,0,0,0,1,1,3,0,0,2,0,0,0,0,2,University hospital Brussel,Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005226-29,1,0,0 2012-005226-29,4,2015-07-30,2015-08-31,2,0,0,0,1,1,3,0,0,2,0,0,0,0,2,Jagiellonian University Medical College,Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005226-29,1,0,0 2012-005226-29,4,2015-07-30,2015-08-31,2,0,0,0,1,1,3,0,0,2,0,0,0,0,2,Wolfson Medical Center,Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005226-29,1,0,0 2012-005227-33,1,2017-02-01,2017-02-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Respiratory Diseases, Aarhus University Hospital",Effect of Intralymphatic Immunotherapy on Basophil Response and Plasma Cell Kinetics in Allergic Patients Effekt af intralymfatisk immunterapi på basophil response og plasma celle kinetik hos aller...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005227-33,0,0,0 2012-005232-29,1,2013-10-30,2013-10-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharma Patent Kft,"Controlled, randomized, four-arm comparative, open label, multi-centric trial to compare the efficacy and safety parameters of the once-a-week or once-a-month administered 7000 IU, or 30000 IU vitamin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005232-29,0,0,0 2012-005241-20,3,2017-03-03,2017-03-03,1,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Pierre Fabre Medicament,Phase I-II study of F14512 in combination with cytarabine in patients 60 years old and older with acute myeloid leukemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005241-20,0,0,0 2012-005243-25,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Sanofi Pasteur,"Immunogenicity and Safety of the Trivalent Influenza Vaccine (Split-Virion, Inactivated), Northern Hemisphere 2013-2014 Formulation (Intradermal Route)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005243-25,0,0,0 2012-005246-38,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University of Oslo,The effects of methylphenidate on brain processes for decision making in adult attention deficit hyperactivity disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005246-38,0,0,0 2012-005249-19,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Cliniques universitaires Saint-Luc,Randomized Phase 2 study comparing pathological responses observed on colorectal cancer metastases resected after preoperative treatment combining cetuximab with FOLFOX or FOLFIRI in RAS and B-RAF WT ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005249-19,0,0,0 2012-005252-41,2,2018-11-21,2018-11-21,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Novartis Farmaceutica, S.A.",An open-label multi-center single agent panobinostat rollover protocol for patients who have completed a previous Novartis-sponsored panobinostat study and are judged by the investigator to benefit fr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005252-41,0,0,0 2012-005252-41,2,2018-11-21,2018-11-21,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,An open-label multi-center single agent panobinostat rollover protocol for patients who have completed a previous Novartis-sponsored panobinostat study and are judged by the investigator to benefit fr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005252-41,0,0,0 2012-005253-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Lipid Pharmaceuticals,Lýsisstílar við hægðatregðu í fullorðnum,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005253-24,0,0,0 2012-005254-30,1,2017-03-07,2017-03-07,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,University Medical Center Hamburg-Eppendorf,"Multicenter, randomized, double-blind, placebo controlled trial of 2 mg melatonin for circadian phase adjustment and improvement of metabolic control in night shift workers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005254-30,0,0,0 2012-005255-17,1,2017-11-01,2017-11-01,1,1,0,0,1,0,2,0,1,1,0,0,1,0,0,University of Leeds,Chronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European population,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005255-17,0,0,0 2012-005257-22,1,2016-09-03,2016-09-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Birmingham,Remifentanil intravenous patient controlled analgesia (PCA) versus intramuscular pethidine for pain relief in labour: a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005257-22,0,0,0 2012-005259-18,10,2016-04-08,2016-04-08,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,AOP Orphan Pharmaceuticals AG,"A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005259-18,0,0,0 2012-005260-10,1,2017-03-10,2017-03-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Uppsala Clinical Research Center,Bivalirudin versus Heparin in NST and ST-Evaluation myocardial infarction on modern antiplatelet therapy in SWEDEHEART (the VALIDATE - SWEDEHEART-trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005260-10,0,0,0 2012-005262-35,14,2014-04-28,2014-06-18,13,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with first...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005262-35,0,0,0 2012-005263-27,1,2017-10-05,2017-10-05,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU POITIERS,EVALUATION OF EARLY PRE-OPERATIVE INTRAVESICAL INSTILLATION OF MYTOMYCIN-C AFTER TRANSURETHRAL RESECTION OF BLADDER TUMOR COMPARED TO EARLY POST-OPERATIVE INSTILLATION. A RANDOMIZED MULTICENTER STUDY...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005263-27,0,0,0 2012-005264-98,1,2015-08-12,2015-08-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University hospitals Leuven,A comparison between continuous systemic Lidocain and patient controlled intravenous morphine administration for pain control after posterior spinal fusion (PSF) in adolescent idiopatic scoliosis (AIS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005264-98,0,0,0 2012-005265-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fondazione IRCCS Policlinico San Matteo,Efficacy of intralesional infusion of local anesthetics in patients undergoing major abdominal surgery: a randomized double-blind trial. Efficacia dell’infusione intralesionale di anestetico loca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005265-13,0,0,0 2012-005271-14,2,2014-06-18,2014-06-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sunovion Pharmaceuticals Inc,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LOW-DOSE LURASIDONE IN ACUTELY PSYCHOTIC SUBJECTS WITH SCHIZOPHRENIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005271-14,0,0,0 2012-005272-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose NVALT,Iressa RE-challenge in advanced NSCLC EGFR mutated patients who responded to an EGFR-TKI used as first-line or previous treatment. Het opnieuw geven van Iressa in EGFR-gemuteerde patienten die ree...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005272-34,0,0,0 2012-005273-31,1,2016-10-05,2016-10-05,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,Public Health England,A phase III/IV randomised open-label study and comparison of the immunogenicity and safety of a single adolescent booster dose of a meningococcal group C conjugate-containing booster vaccine (Meningit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005273-31,0,0,0 2012-005275-14,1,2022-01-31,2022-01-31,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Diakonhjemmet Hospital AS,Remission in rheumatoid arthritis – assessing withdrawal of disease-modifying antirheumatic drugs in a non-inferiority design,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005275-14,0,0,0 2012-005278-71,1,2010-12-31,2010-12-31,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,Helsinki University Central Hospital,The brain opioid system and emotional experiences arising while viewing social interactions. Aivojen opioidijärjestelmä ja tunnekokemusten synty sosiaalisten vuorovaikutusten katselun aikana.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005278-71,0,0,0 2012-005280-27,4,2014-06-05,2014-06-05,2,0,0,0,0,0,2,0,0,1,1,0,1,0,1,AFFiRiS AG,"A randomized, controlled, parallel group, double-blind, multi-centre, phase IIb study to assess safety and clinical activity of continued AFFITOPE® AD02 vaccinations of patients who participated in th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005280-27,0,0,0 2012-005282-12,1,2020-10-08,2020-10-08,1,0,0,0,1,0,2,0,0,1,0,0,1,0,2,University of Edinburgh,TOFFEE Trial Toxicity OF Fluoropyrimidines: A comparative study of the cardiotoxicity of capEcitabine and tEysuno,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005282-12,0,0,0 2012-005282-12,1,2020-10-08,2020-10-08,1,0,0,0,1,0,2,0,0,1,0,0,1,0,2,Research and Development NHS Lothian,TOFFEE Trial Toxicity OF Fluoropyrimidines: A comparative study of the cardiotoxicity of capEcitabine and tEysuno,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005282-12,0,0,0 2012-005283-97,13,2016-04-11,2016-11-04,10,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Onyx Therapeutics,"A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005283-97,0,0,0 2012-005283-97,13,2016-04-11,2016-11-04,10,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Onyx Therapeutics, Inc","A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005283-97,0,0,0 2012-005283-97,13,2016-04-11,2016-11-04,10,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Onyx Therapeutics, Inc.","A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005283-97,0,0,0 2012-005287-10,10,2017-06-09,2017-07-07,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,XBiotech Germany GmbH,"A Phase III Double-blinded, Placebo Controlled Study of Xilonix? for Improving Survival in Metastatic Colorectal Cancer Estudio de fase III, doble ciego, controlado con placebo de Xilonix? para la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005287-10,0,0,0 2012-005287-10,10,2017-06-09,2017-07-07,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,XBIOTECH GERMANY GMBH,"A Phase III Double-blinded, Placebo Controlled Study of Xilonix? for Improving Survival in Metastatic Colorectal Cancer Estudio de fase III, doble ciego, controlado con placebo de Xilonix? para la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005287-10,0,0,0 2012-005288-29,1,2014-01-30,2014-01-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,G. Pohl-Boskamp GmbH & Co. KG,"A single-center randomized, active-controlled, observer-blinded, parallel group trial to evaluate the efficacy and safety of a topical dimeticone formulation (Loion®) compared to 10% saliclylic acid i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005288-29,0,0,0 2012-005291-34,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"AMC, Amsterdam","Perioperative intravenous insulin, GIK or GLP-1 treatment in DM Perioperatief intraveneus insuline, GIK of GLP-1 behandeling in DM",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005291-34,0,0,0 2012-005292-14,1,2014-06-30,2014-06-30,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Heikki Swan,Dantrolene in catecholaminiergic polymorphic ventricular tachycardia DANTROLEENI KATEKOLIAMIINIHERKÄSSÄ KAMMIOTAKYKARDIASSA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005292-14,0,0,0 2012-005295-33,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,UZ Leuven-Department of Urology,"Monocentric, open-label, phase III study that compares the efficiency and tolerance between intravesical oxybutynin and oral fesoterodine in children (5-16y) with neurogenic detrusor overactivity.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005295-33,0,0,0 2012-005299-32,1,2016-08-03,2016-08-03,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie",Effect of breathing 100% oxygen on brain metabolites measured by 7-Tesla MRI Die Auswirkung von 100% Sauerstoff Atmung auf Stoffwechselprodukte des Gehirns die mit dem 7-Tesla MRT gemessen werden.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005299-32,0,0,0 2012-005303-40,1,2016-07-04,2016-07-04,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Medizinsche Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie",The effect of audio-visual brainwave entrainment on sedation level in children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005303-40,0,0,0 2012-005310-19,1,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,0,FUNDACION PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL_ FPA,Double-blind randomized clinical trial to evaluate the efficacy and safety of levosimendan as preischemic myocardial conditioner in pediatric cardiac surgery Ensayo clínico aleatorizado doble ciego...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005310-19,0,0,0 2012-005312-26,1,2016-11-02,2016-11-02,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Hospital of the University of Munich, Grosshadern",Sustained release 4-aminopyridine (Fampyra®) in cerebellar gait disorder Retardiertes 4-Aminopyridin (Fampyra®) bei cerebellärer Gangstörung,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005312-26,0,0,0 2012-005313-39,1,2016-03-09,2016-03-09,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA Spedali Civili di Brescia,"Scheme of treatment with high-dose lanreotide in acromegalic patients poorly responsive to treatment with standard doses."" “Schema di trattamento con lanreotide ad alte dosi in pazienti acromegalic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005313-39,0,0,0 2012-005314-19,1,2016-06-17,2016-06-17,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with Pneumovax 23 in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005314-19,0,0,0 2012-005321-78,4,2014-11-12,2014-11-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, parallel group study evaluating efficacy and safety of QAW039 in the treatment of patients with moderate to severe atopic dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005321-78,0,0,0 2012-005324-16,3,2015-01-22,2015-01-22,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Genzyme Corporation,Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005324-16,0,0,0 2012-005325-67,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Centre Hospitalier de Toulouse,"Evaluation of tolerance, suckling and food intake after repeated nasals administrations of Oxytocin in PWS infants Etude de tolérance d’administrations intranasales répétées d’ocytocine selon 3 sch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005325-67,0,0,0 2012-005326-29,1,2017-08-25,2017-08-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,International Breast Cancer Study Group (IBCSG),A randomized phase II trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for locally advanced endocrine resp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005326-29,0,0,0 2012-005327-33,1,2017-11-30,2017-11-30,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,The Christie NHS Foundation Trust,A Phase II Trial to Assess the Activity of NY-ESO-1 Targeted T Cells in Advanced Oesophagogastric Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005327-33,0,0,0 2012-005328-14,1,2014-07-02,2014-07-02,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Spinal Cord Injury Centre of Western Denmark,Effect of Sativex on neuropathic pain and spasticity following spinal cord injury Effekten af Sativex på neuropatiske smerter og spasticitet hos rygmarvsskadede,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005328-14,0,0,0 2012-005329-56,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Dept of oncology,A phase ll trial of combination chemotherapy with intravenous oxaliplatin combined with tablet capecitabin in patients with recidivant breastcancer En fase II undersøgelse af kombinationsbehandling...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005329-56,0,0,0 2012-005330-10,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Erasmus University Medical Centre,Maternal pharmacokinetics and pharmacodynamics of nicardipine (iv) during treatment of severe hypertension in pregnancy. Maternale pharmacokinetiek en pharmacodynamiek van intraveneus nicardipine b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005330-10,0,0,0 2012-005331-90,5,2019-11-12,2019-11-12,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005331-90,0,0,0 2012-005332-29,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,VU University Medical Centre,Prevention of depression and poor physical function in older persons with vitamin D supplementation Preventie van depressie en matig lichamelijk functioneren bij ouderen met vitamine D-suppletie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005332-29,0,0,0 2012-005333-36,3,2017-09-20,2020-02-04,3,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Bone Therapeutics S.A.,"A pilot Phase I/IIa, multicentre, open proof-of-concept study on the efficacy and safety of allogeneic osteoblastic cells (ALLOB®) implantation in non-infected delayed-union fractures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005333-36,0,0,0 2012-005335-83,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oslo University Hospital Rikshospitalet,"A Randomized Open-label Study: Efficacy and safety of basiliximab combined with tacrolimus, mycophenolate and low-dose corticosteroids vs thymoglobulin, tacrolimus, mycophenolate and high-dose cortic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005335-83,0,0,0 2012-005337-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Istituto Clinico Humanitas,ANTI-MULLERIAN HORMONE (AMH) AS A MARKER OF OVARIAN RESERVE IN YOUNG BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY + GnRH ANALOGUE Ruolo dell’Ormone Antimülleriano (AMH) quale marcatore della riser...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005337-37,0,0,0 2012-005338-13,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,Istituto Clinico Humanitas - Humanitas Cancer Center,OFATUMUMAB-BENDAMUSTINE FOR RELAPSED/REFRACTORY INDOLENT LYMPHOMA: A MULTICENTER PHASE 2 TRIAL OFATUMUMAB–BENDAMUSTINA PER I LINFOMI INDOLENTI RECIDIVANTI/REFRATTARI: UNO STUDIO MULTICENTRICO DI FA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005338-13,0,0,0 2012-005340-24,1,2013-12-13,2013-12-13,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Liverpool (UniLiv),"An international, multicentre, randomised, open-label, no-treatment controlled, parallel group, dose-response study to investigate the effect of once daily nitisinone on 24-hour urinary homogentisic a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005340-24,0,0,0 2012-005344-15,1,2014-08-13,2014-08-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Adyton, s.r.o.","A Double Blind Study Aiming To Evaluate The Efficacy Of Bladder Instillation With Botulinum Toxin (200U) + TC-3 Gel In Comparison To Instillation With Botulinum Toxin (200U) + TC-3 Gel + DMSO, To DMSO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005344-15,0,0,0 2012-005346-38,1,2015-02-23,2015-02-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Lumena Pharmaceuticals, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTi), IN THE TREATMENT OF CHOLESTATIC ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005346-38,0,0,0 2012-005348-92,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO,PROGASS PRucalopride On the GAstreonteric transit in Systemic Sclerosis PROGASS Studio per valutare l’effetto della Prucalopride sul transito gastroenterico in pazienti affetti da sclerosi sis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005348-92,0,0,0 2012-005349-20,1,2014-12-31,2014-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Kuopio University Hospital,Diagnostic accuracy of contrast-enhanced ultrasound-guided axillary core biopsy in preoperative staging of the newly diagnosed invasive breast cancer - a prospective study. Ultraäänivarjoainetehost...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005349-20,0,0,0 2012-005350-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Centre Groningen,Effects Of extra-fine particle HFA-becLomethasone (HFA-QVAR) Versus course particle treatment In smokers and ex-smokers with Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005350-39,0,0,0 2012-005352-41,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI CREMONA,"A phase II randomized, open-label study evaluating the addition of trastuzumab to (nabTM)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with HER2 positi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005352-41,0,0,0 2012-005357-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AUSL VITERBO,Preventing injection pain by Clostridium Histolyticum Collagenase Administration for teatment of Dupuytrens contracture Prevenzione del dolore con uso diInjection anestetico locale EMLA nella infi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005357-23,0,0,0 2012-005359-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITA' CAMPUS BIOMEDICO,Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study RIDUZIONE DELLA FREQUENZA CARDIACA DOPO ASSUNZIONE DI IVABRAD...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005359-18,0,0,0 2012-005361-12,1,2013-01-11,2013-01-11,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,HOPITAL SAINT JOSEPH,MEOPA (equimolar mixture of oxygen and protoxide of nitrogen) versus local anesthetic for analgesia during the biopsy of trophoblast. MEOPA (mélange équimolaire d'oxygène et de protoxyde d'azote) v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005361-12,0,0,0 2012-005362-35,1,2014-06-15,2014-06-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Instituto de Inmunología y Alergia INMUNAL SAU,"Biological standardization of pollen of Phleum pratense, Olea europaea, mite extract Dermatophagoides pteronyssinus and animal allergen Felis domesticus. Open label, single center, phase II study. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005362-35,0,0,0 2012-005366-35,1,,,0,0,0,0,0,0,3,0,1,1,0,0,0,1,0,BIOVOMED,Evaluation of the immunogenicity and safety of a booster dose of Pfizer’s 13-valent pneumococcal conjugate vaccine in children primed with 3 doses of either GSK’s 10-valent pneumococcal conjugate vacc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005366-35,0,0,0 2012-005367-27,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,BIOVOMED,Evaluation of the immunogenicity and safety of a booster dose of Pfizer’s 13-valent pneumococcal conjugate vaccine (PCV) in children primed with 2 doses of either GSK’s 10-valent PCV or Pfizer’s 13-va...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005367-27,0,0,0 2012-005370-62,1,2017-11-08,2017-11-08,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"OSPEDALE CIVILE SAN SALVATORE, ASL 04, L'AQUILA","“No-profit” clinical study for the improvement of clinical practice, to evaluate the efficacy of anakinra in reducing the glycated haemoglobin in patients affected by rheumatoid arthritis and diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005370-62,0,0,0 2012-005371-13,14,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Double- Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab Versus Ipilimumab Monotherapy in Subjects with Previously Untreated, Unresectable or Metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005371-13,0,0,0 2012-005372-34,1,2014-09-15,2014-09-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,The role of paroxetine in patients taking telaprevir-based HCV therapy: lack of a drug-drug interaction? (ROLEX),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005372-34,0,0,0 2012-005374-57,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Department of Breast and Endocrine Surgery, Karolinska University Hospital",Primary hyperparathyroidism: Short-term calcimimetics treatment – Relevance for parathyroid surgery decisions?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005374-57,0,0,0 2012-005375-14,3,2017-05-23,2017-05-23,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Nordion (Canada) Inc.,A prospective randomized clinical trial on 90Yttrium trans-arterial radio-Embolization (Therasphere) vs. standard of care (sorafenib) for the treatment of advanced Hepatocellular carcinoma (HCC) with ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005375-14,0,0,0 2012-005375-14,3,2017-05-23,2017-05-23,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Biocompatibles UK Ltd,A prospective randomized clinical trial on 90Yttrium trans-arterial radio-Embolization (Therasphere) vs. standard of care (sorafenib) for the treatment of advanced Hepatocellular carcinoma (HCC) with ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005375-14,0,0,0 2012-005376-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Cliniques universitaires Saint-Luc,Randomized Phase 2 study comparing pathological responses observed on colorectal cancer metastases resected after preoperative treatment combining bevacizumab with FOLFOX or FOLFIRI. Etude randomis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005376-34,0,0,0 2012-005377-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HYKS Naistensairaala,Randomized trial of treatment and follow-up of vaginal intraepithelial neoplasia (VAIN) Emättimen solumuutosten seuranta- ja hoitotutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005377-31,0,0,0 2012-005378-73,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE NEOPLASIE SANGUE ONLUS,"Allogeneic Transplantation after a Conditioning with Thiotepa, Busulfan and Fludarabin for the treatment of refractory/early relapsed aggressive B-cell non Hodgkin lymphomas: a Phase II Multi-Center T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005378-73,0,0,0 2012-005381-35,2,2014-04-23,2014-04-23,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,EPIFARMA SRL,"Randomized, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to evaluate safety and efficacy of Diclofenac 1% gel vs. placebo gel in patients with acute traumatic blunt so...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005381-35,0,0,0 2012-005387-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of hospital Pharmacy, Medical Centre Haaglanden",Effect of Roux-en-Y gstric bypass surgery in morbidly obese patients on Pharmacokinetics of (Acetyl)salicylic acid and Omeprazole.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005387-10,0,0,0 2012-005389-36,1,2014-04-30,2014-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Creabilis Limited,"A phase II randomised, double blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of CT327 topical ointment (0.05% and 0.5% w/w) compared to vehicle, in subjects with mil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005389-36,0,0,0 2012-005394-31,1,2018-07-04,2018-07-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UCL,"MS-SMART: A Multi-Arm Phase IIb Randomised, Double Blind Placebo-Controlled Clinical Trial Comparing The Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005394-31,0,0,0 2012-005395-34,1,2019-02-28,2019-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Erasmus MC,Prospective evaluation of the predictive value of a circulating tumor cell (CTC) sensitivity profile to Cisplatin chemotherapy in metastatic breast cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005395-34,0,0,0 2012-005397-63,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,"Novartis Farmacéutica, S.A,","An open-label, multi-center, expanded access study of RAD001 in patients with angiomyolipoma associated with tuberous sclerosis complex (TSC) Estudio abierto, multicéntrico, de acceso expandido con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005397-63,0,0,0 2012-005398-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA OSPEDALI GALLIERA,Diagnostic efficacy and prognostic method [18F] DOPA-PET/CT in study of neuroblastoma: comparison with 123I-MIBG scintigraphy Efficacia diagnostica e prognostica della metodica [18F]DOPA-PET/CT nel...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005398-30,0,0,0 2012-005399-32,1,2016-06-10,2016-06-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERA DI PARMA,"Randomized, open label, two parallel arms, intervention trial comparing the effect of DPP-IV inhibitor Vildagliptin vs. Glibenclamide on circulating EPCs. Trial di intervento monocentrico, randomiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005399-32,0,0,0 2012-005401-41,17,2014-11-11,2014-11-25,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd,"A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects who have Received Solifenacin for 4 Weeks and Warrant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005401-41,0,0,0 2012-005404-17,1,2015-06-23,2015-06-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Center for Neuropsychiatric Schizophrenia Research,Treatment of antipsychotic associated obesity with a GLP-1 Analogue: the TAO study Behandling af antipsykotika-associeret fedme med en GLP-1 analog: TAO studiet,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005404-17,0,0,0 2012-005407-40,1,2014-11-01,2014-11-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Thomas Bergholt,"Peroperative Tranexamic acid as prophylaxis of bleeding related to benign hysterectomy - a randomized, placebo-controlled trial Peroperativ Tranexamsyre som blødningsprofylakse ved benign Hysterek...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005407-40,0,0,0 2012-005409-38,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI),Pilot study phase III to evaluate the efficacy and safety of Trimethoprim-sulfamethoxazole in the treatment of idiopathic pulmonary fibrosis Estudio piloto fase III para evaluar la eficacia y segur...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005409-38,0,0,0 2012-005410-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Jessaziekenhuis Hasselt,"Developing a Patient Model of Controlled, Radial Artery Access Site Bleeding for Deciding on Anticoagulation Reversal in Patients Treated by Systemic Anticoagulants.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005410-19,0,0,0 2012-005412-25,9,2016-11-02,2016-11-02,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy u...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005412-25,0,0,0 2012-005412-25,9,2016-11-02,2016-11-02,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy u...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005412-25,0,0,0 2012-005413-40,7,2017-01-03,2017-01-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, multicenter, study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and longterm efficacy u...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005413-40,0,0,0 2012-005413-40,7,2017-01-03,2017-01-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo-controlled, multicenter, study to demonstrate the efficacy at 16 weeks of secukinumab 150 and 300 mg s.c. and to assess safety, tolerability and longterm efficacy u...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005413-40,0,0,0 2012-005414-18,1,2020-04-17,2020-04-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Medical Center Freiburg,Thiotepa- Fludarabine- Treosulfan (TFT) conditioning for 2nd allogeneic PBSCT from a different unrelated donor in patients with AML relapsing from prior allogeneic HCT Konditionierung mit Thiotepa-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005414-18,0,0,0 2012-005416-26,1,2015-09-21,2015-09-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Mario Negri Institute,"A Prospective, Randomized, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess The Renal and Humoral Effects of Sevelamer Carbonate in Patients with Chronic Kidney Disease and Residual Proteinuri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005416-26,0,0,0 2012-005417-38,14,2015-11-11,2015-11-11,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to vas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005417-38,0,0,0 2012-005417-38,14,2015-11-11,2015-11-11,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to vas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005417-38,0,0,0 2012-005417-38,14,2015-11-11,2015-11-11,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farma S.p.A.,"A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to vas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005417-38,0,0,0 2012-005418-20,12,2015-09-02,2015-09-09,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to va...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005418-20,0,0,0 2012-005418-20,12,2015-09-02,2015-09-09,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farma S.p.A.,"A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to va...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005418-20,0,0,0 2012-005418-20,12,2015-09-02,2015-09-09,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to va...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005418-20,0,0,0 2012-005422-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AIO Studien gGmbH,Randomized Phase II study for evaluation of efficacy and safety of maintenance treatment with 5-FU/FA plus panitumumab vs. 5-FU/FA alone after prior induction treatment with mFOLFOX6 plus panitumumab ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005422-30,0,0,0 2012-005427-32,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Fondazione IRCCS Istituto Nazionale dei Tumori,Randomized controlled trial of metformin and dietary restriction to prevent age-related morbid events in people with metabolic syndrome Sperimentazione controllata randomizzata di restrizione calo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005427-32,0,0,0 2012-005428-14,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Italian Sarcoma Group,A Phase II study on Trabectedin in advanced retroperitoneal leiomyosarcoma and well differentiated/dedifferentiated liposarcoma Studio di fase II su trabectedina nei leiomiosarcomi e nei liposarco...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005428-14,0,0,0 2012-005430-11,3,2014-11-30,2015-11-30,2,1,1,0,0,1,1,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc.,"A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients with Late-Infantile Neuronal Ceroid Lipofus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005430-11,0,0,0 2012-005431-86,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen,Evaluation of 18F-FDHT PET/CT as an early treatment response marker in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide. Evaluatie van 18F-FDHT PET/C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005431-86,0,0,0 2012-005432-28,4,2014-11-07,2014-11-13,4,1,1,0,0,0,2,0,0,1,1,0,1,0,1,Teva Pharmaceuticals Industries Ltd.,"An open label, randomized, active controlled, dose finding study to evaluate the pharmacodynamics, pharmacokinetics, efficacy and safety of balugrastim at doses of 300 μg/kg and 670 μg/kg in pediatric...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005432-28,0,0,0 2012-005435-87,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica Hospital Gregorio Marañón,"EFFECT OF ADJUVANT TREATMENT WITH N - ACETYLCYSTEINE DURING 48 WEEKS ON THE LOSS OF GREY SUBSTANCE AND OXIDATIVE METABOLISM IN PATIENTS WITH EARLY ONSET PSYCHOTIC EPISODES: BLIND, PLACEBO-CONTROLLED, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005435-87,0,0,0 2012-005439-10,1,2016-05-17,2016-05-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"University of Leipzig Ritterstr. 26, 04109 Leipzig",Re-treatment with intravitreal application of ranibizumab guided by morphological macular changes documented by optical coherence tomography (OCT) in patients with macular edema due to branch retinal ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005439-10,0,0,0 2012-005443-24,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,UMCG,"Development of a pharmacokinetic/pharmacodynamic model of dexmedetomidine, and the effect of repeated auditory stimulation on pharmacodynamics of dexmedetomidine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005443-24,0,0,0 2012-005447-25,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Academic Medical Center Amsterdam, department of Internal Medicine","The use of Rienso, an ultrasmall superparamagnetic particle of iron-oxide, as a MRI contrast agent to image inflammation in the atherosclerotic plaque",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005447-25,0,0,0 2012-005449-19,1,2015-10-01,2015-10-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Hull and East Yorkshire Hospitals NHS Trust,"A double-blind, randomised controlled trial of percutaneous transluminal angioplasty (PTA) & Ramipril versus PTA & placebo in the management of intermittent claudication (IC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005449-19,0,0,0 2012-005450-30,2,2017-11-30,2017-11-30,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,Medizinische Universität Innsbruck,Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment Anti-läkemedelsan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005450-30,1,0,0 2012-005454-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hanna Pitkänen,Can magnesium enhance blood coagulation amongst patients with alcohol induced liver cirrhosis? Voidaanko magnesiumin annolla parantaa alkoholimaksakirroosia sairastavien potilaiden veren hyytymisom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005454-35,0,0,0 2012-005459-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SMARTPRACTICE,"Clinical Evaluation of Metal Panel Allergens Mercury, Aluminum and Palladium Dose Response Study Clinical Evaluation of Metal Panel Allergens Mercury, Aluminum and Palladium Dose Response Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005459-18,0,0,0 2012-005461-13,5,2016-12-02,2020-04-16,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,NOVARTIS FARMA S.p.A,A phase Ib/II trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with estrogen receptor positive Her2 negative locally advanced or metastat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005461-13,0,0,0 2012-005461-13,5,2016-12-02,2020-04-16,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,A phase Ib/II trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with estrogen receptor positive Her2 negative locally advanced or metastat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005461-13,0,0,0 2012-005461-13,5,2016-12-02,2020-04-16,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Novartis Farmacéutica, S.A.",A phase Ib/II trial of LEE011 in combination with everolimus (RAD001) and exemestane in the treatment of postmenopausal women with estrogen receptor positive Her2 negative locally advanced or metastat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005461-13,0,0,0 2012-005466-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Academic Medical Center,Therapeutic Vaccination against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005466-34,0,0,0 2012-005476-33,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic Non?Small Cell Lung Cancer Patients with Activating EGFR Mutations Who...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005476-33,0,0,0 2012-005476-33,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Lilly S.A,"A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic Non?Small Cell Lung Cancer Patients with Activating EGFR Mutations Who...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005476-33,0,0,0 2012-005476-33,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Eli Lilly and Company Limited,"A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic Non?Small Cell Lung Cancer Patients with Activating EGFR Mutations Who...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005476-33,0,0,0 2012-005477-31,7,2016-03-24,2016-05-31,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005477-31,0,0,0 2012-005477-31,7,2016-03-24,2016-05-31,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005477-31,0,0,0 2012-005480-28,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Institut d?Investigació en Atenció Primaria IDIAP Jordi Gol,Effectiveness of adaptation of the dose of iron supplementation in pregnancy on maternal-child health. Randomized clinical trial (ECLIPSES) Efectividad de la adaptación de la dosis de suplementació...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005480-28,0,0,0 2012-005481-35,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Uppsala University Hospital,"A controlled, randomized, assessor blinded, open-label study to investigate whether initiation of everolimus will reduce the incidence of developing a new Squamous Cell Carcinoma (SCC) and other malig...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005481-35,0,0,0 2012-005482-12,1,2015-10-08,2015-10-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University College Dublin,The effect of glucagon-like-peptide 1 (GLP-1) analogues on inflammation in humans with diabetic kidney disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005482-12,0,0,0 2012-005483-10,1,2016-12-01,2016-12-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College Dublin,Dipeptidyl peptidase-4 Inhibition and Narrow-band Ultraviolet-B light in Psoriasis (DINUP): A Randomised Clinical Trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005483-10,0,0,0 2012-005485-36,5,2014-11-17,2014-11-17,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gedeon Richter Plc,"A Randomized, Double-blind, Parallel-group Study to Investigate the Efficacy, Safety and Tolerability of Cariprazine in Patients with Predominant Negative Symptoms of Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005485-36,0,0,0 2012-005486-13,1,2015-02-04,2015-02-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The National Eye Institute,A Phase II Randomized Study to Compare Anti-VEGF Agents in the Treatment of Diabetic Macular Edema (CADME),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005486-13,0,0,0 2012-005489-37,6,2021-06-02,2021-06-02,5,1,1,0,0,2,3,0,0,1,0,0,1,0,1,CSL Behring GmbH,"A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005489-37,0,0,0 2012-005490-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klin. Abt. für Endokrinologie und Stoffwechsel","An open, single-centre, non-controlled feasibility study using a softwarealgorithm based insulin therapy to control blood glucose in type 1 diabetic patients Eine offene, monozentrische, nicht kon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005490-31,0,0,0 2012-005492-13,1,2013-08-26,2013-08-26,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,Janssen infectious diseases BVBA,"A Phase I, open-label, randomized, 3-way crossover study in 3 Panels of healthy, adult subjects to assess the relative bioavailability of TMC207 following single-dose administration of two pediatric f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005492-13,0,0,0 2012-005495-34,4,2018-12-20,2018-12-20,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO AND ACTIVE-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005495-34,0,0,0 2012-005496-14,2,2018-08-28,2018-08-28,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Merz Pharmaceuticals GmbH,"Prospective, multicenter, randomized, double-blind, parallel-group, dose-response study of three doses Xeomin® (incobotulinumtoxinA, NT 201) for the treatment of upper limb spasticity alone or combine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005496-14,1,1,0 2012-005498-29,1,2016-11-08,2016-11-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Celica, Biomedical Center, d.o.o.",Preparation and application of autologous immunohybridoma cells for the treatment of prostate cancer Priprava in uporaba avtolognih imunohibridomov za zdravljenje karcinoma prostate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005498-29,0,0,0 2012-005499-33,1,2015-06-15,2015-06-15,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,Grünenthal GmbH,Relative bioavailability trial to investigate the pharmacokinetics of tapentadol following the administration of 3 prototype tapentadol 25 mg prolonged release (PR) granule formulations compared to a ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005499-33,0,0,0 2012-005500-18,1,2019-07-15,2019-07-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,"A pharmacokinetic study: ranibizumab, aflibercept and the effect of vitrectomy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005500-18,0,0,0 2012-005500-18,1,2019-07-15,2019-07-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,"A pharmacokinetic study: ranibizumab, aflibercept and the effect of vitrectomy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005500-18,0,0,0 2012-005504-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institute of oncology,"VINCRISTINE OR CIS-PLATIN, BOTH IN COMBINATION WITH GEMCITABINE OR PEMETREXED FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER – VIP TRIAL VINKRISTIN ALI CIS-PLATIN, OBA V KOMBINACIJI Z GEM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005504-17,0,0,0 2012-005505-51,1,2016-01-15,2016-01-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University College Dublin,Dipeptidyl peptidase-4 Inhibition in Psoriasis patients with diabetes (DIP): A Randomized Clinical Trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005505-51,0,0,0 2012-005507-40,1,2014-02-13,2014-02-13,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,NOVARTIS FARMA S.p.A,"An open-label, single arm study to provide access to fingolimod to MS patients who completed fingolimod phase IIIb studies and who benefited from treatment with fingolimod or do not have suitable alte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005507-40,0,0,0 2012-005510-20,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,1,"Cephalon, Inc.","A Randomized, Open-Label Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Single and Multiple Doses of Armodafinil (50, 100, and 150 mg/day) in Children and Adolescents with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005510-20,0,0,0 2012-005511-11,1,2015-11-26,2015-11-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,RACD Cardiff University,Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: a prospective double blind randomised control trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005511-11,0,0,0 2012-005513-40,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,Jesper Ekelund,Histamine H2 antagonism as adjuvant therapy in treatment resistant schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005513-40,0,0,0 2012-005513-40,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,HYKS Psykiatrikeskus,Histamine H2 antagonism as adjuvant therapy in treatment resistant schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005513-40,0,0,0 2012-005514-18,1,2014-01-10,2014-01-10,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,Study of the Effect of Ticagrelor and Clopidogrel on the Immune Response of Healthy Volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005514-18,0,0,0 2012-005520-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IFCT,Phase III study comparing maintenance by pemetrexed or gemcitabine to surveillance in elderly patient (≥ 70 year old) with advanced Non Small Cell Lung Cancer controlled by induction chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005520-15,0,0,0 2012-005521-73,3,2014-04-17,2014-04-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galapagos NV,"Exploratory, Phase II, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GLPG0974 in subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005521-73,0,0,0 2012-005522-29,1,2014-09-07,2014-09-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005522-29,0,0,0 2012-005524-15,2,2015-08-18,2015-08-18,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Elan Pharma International Ltd,A 12-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease. Estudio de extensión de 12 semanas para evaluar l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005524-15,0,0,0 2012-005525-75,1,2016-02-18,2016-02-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,St Stephen's AIDS Trust,"An open label, randomised, pilot trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatitis C genotype ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005525-75,0,0,0 2012-005528-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Hospital,Comparison of Novel Articaine Lozenge Versus Placebo for Upper Gastrointestinal Endoscopy in Adults. A Randomized Double-blinded Controlled Study Artikaiini nielun puudutuksessa gastroskopian yhtey...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005528-13,0,0,0 2012-005535-90,1,2019-11-22,2019-11-22,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU Mont-Godinne,Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) in relapse after allogeneic s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005535-90,0,0,0 2012-005538-12,1,2020-08-18,2020-08-18,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Birmingham,A Randomised Trial of the FLAMSA-BU Conditioning Regimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005538-12,0,0,0 2012-005539-10,1,2016-11-09,2016-11-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005539-10,0,0,0 2012-005541-21,8,2014-06-13,2014-06-18,6,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A dose-finding phase Ib study followed by a randomized, double-blind phase II study of carboplatin and paclitaxel with or without buparlisib in patients with previously untreated metastatic non-small ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005541-21,0,0,0 2012-005541-21,8,2014-06-13,2014-06-18,6,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Farmacéutica S.A.,"A dose-finding phase Ib study followed by a randomized, double-blind phase II study of carboplatin and paclitaxel with or without buparlisib in patients with previously untreated metastatic non-small ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005541-21,0,0,0 2012-005541-21,8,2014-06-13,2014-06-18,6,1,0,1,0,0,1,0,0,1,0,0,0,0,1,NOVARTIS FARMA,"A dose-finding phase Ib study followed by a randomized, double-blind phase II study of carboplatin and paclitaxel with or without buparlisib in patients with previously untreated metastatic non-small ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005541-21,0,0,0 2012-005542-38,11,2018-02-13,2018-04-17,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,","A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Du...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005542-38,0,0,0 2012-005542-38,11,2018-02-13,2018-04-17,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Du...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005542-38,0,0,0 2012-005545-20,1,,,0,1,0,0,0,1,3,0,0,1,1,1,0,1,0,Institut Jules Bordet,The CaStOR study Carcinoid Tumors after failure of Somatostatin analogs: a randomized phase III of Octreotide Lutate Peptid Receptor radionuclide Therapy (PRRT) versus inteRferon α-2b,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005545-20,0,0,0 2012-005546-38,13,2017-02-02,2017-03-02,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Aeterna Zentaris GmbH,"Randomised controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005546-38,0,0,0 2012-005547-24,1,2015-02-11,2015-02-11,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD,A phase III open-label randomised study to evaluate the immunogenicity and safety of the concomitant administration of a new Hexavalent DTaP-IPV-HepB-PRP-T combined vaccine (Hexavalent vaccine) given ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005547-24,0,0,0 2012-005559-17,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,Rosa Herrera Castro,"Hemodynamic consequences of isobaric levobupivacaine versus hyperbaric bupivacaine for spinal anesthesia in patients over 65 years, underwent hip surgery Repercusión hemodinámica de la levobupivaca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005559-17,0,0,0 2012-005563-27,3,2015-05-06,2015-05-07,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,VITAL THERAPIES INCORPORATED,"A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005563-27,0,0,0 2012-005563-27,3,2015-05-06,2015-05-07,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Vital Therapies Inc.,"A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005563-27,0,0,0 2012-005563-27,3,2015-05-06,2015-05-07,2,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Vital Therapies, Inc.","A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005563-27,0,0,0 2012-005565-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZ Groeninge,"The effect of low dose intravenous dexamethasone on the analgesic duration of single shot interscalene block with ropivacaine for shoulder surgery. A prospective, double blind, randomized, placebo con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005565-12,0,0,0 2012-005569-10,1,2018-08-15,2018-08-15,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,University Hospital Essen,"Biopsy- and biology-driven optimization of targeted therapy of metastatic melanoma in BRAF inhibitor non-pretreated and pretreated subjects with advanced, non-resectable (Stage IIIC) or metastatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005569-10,0,0,0 2012-005570-56,1,2016-11-05,2016-11-05,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge,Glucose Lowering In Non-diabetic hyperglycaemia Trial (GLINT) - a randomised controlled trial to establish the effectiveness and cost-effectiveness of metformin in preventing cardiovascular events ove...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005570-56,0,0,0 2012-005571-14,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,0,INSTITUTO DE INVESTIGACION SANITARIA LA FE,"CLINICAL TRIAL, SINGLE BLIND, RANDOMIZED, CONTROLLED PROSPECTIVE EVALUATION FOR OPTIMUM TIME INTERVAL BETWEEN ACETATE ADMINISTRATION AND PUNCTURE TRIPTORELIN FOLLICULAR IN IVF TREATMENT ENSAYO CLÍN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005571-14,0,0,0 2012-005573-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,zna middelheim,Effects of the combination of dexamethasone or clonidine with ropivacaine during a popliteal block : a prospective double blind randomized trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005573-31,0,0,0 2012-005575-13,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Antwerp University Hospital,Prophylactic vaccination with autologous dendritic cells against human cytomegalovirus: a pilot study in patients awaiting kidney transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005575-13,0,0,0 2012-005576-33,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Laboratoires Théa,"Efficacy and safety assessment of intracameral T2380 (Fixed combination of lidocaïne, phenylephrine and tropicamide) to obtain mydriasis in patients with small pupils for cataract surgery by phacoemul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005576-33,0,0,0 2012-005578-79,1,2016-11-04,2016-11-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ISTITUTO CLINICO HUMANITAS,A single-Arm Phase II Study of Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-resistant MET high subjects with locally advanced or metastatic colorectal cancer with wild-type KRAS Studio di ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005578-79,0,0,0 2012-005580-27,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,ISTITUTO CLINICO HUMANITAS,"MULTI-CENTER, PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF HAPLOIDENTICAL BONE MARROW TRANSPLANTATION USING REDUCED INTENSITY CONDITIONING (RIC) REGIMEN AND POST-TRANSPLANT CYCLOPHOSPHAMIDE, IN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005580-27,0,0,0 2012-005583-10,1,2014-11-17,2014-11-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Efficacy and safety of FIAsp in a basal-bolus regimen versus basal insulin therapy, both in combination with metformin in adult Subjects with type 2 diabetes Učinkovitost in varnost FIAsp v bazalno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005583-10,0,0,0 2012-005586-13,3,2018-05-08,2018-05-08,1,1,0,0,0,0,2,0,0,2,1,0,0,0,1,AB SCIENCE,"A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with seve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005586-13,1,0,0 2012-005586-13,3,2018-05-08,2018-05-08,1,1,0,0,0,0,2,0,0,2,1,0,0,0,1,AB Science,"A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with seve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005586-13,1,0,0 2012-005587-94,5,2014-04-07,2015-06-01,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Ferring International Pharmascience Center US, Inc.","A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 26 Weeks",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005587-94,0,0,0 2012-005588-28,7,2014-04-07,2014-05-03,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Ferring International Pharmascience Center US, Inc.","A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005588-28,0,0,0 2012-005589-37,1,2019-07-31,2019-07-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Warwick,select-d: Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005589-37,0,0,0 2012-005590-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,"A double blind, placebo controlled Phase 2 study comparing the effects of ARA 290 on neuropathic symptoms of patients with type 2 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005590-32,0,0,0 2012-005591-33,1,2015-06-17,2015-06-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Universitätsklinik f. Innere Medizin III, Medizinische Universität Wien",Response-guided triple therapy using boceprevir in combination with PEGIFN/RBV in HIV/HCV coinfected patients Individualisierte Tripeltherapie mit Boceprevir in Kombination mit PEGIFN/RBV bei HIV/H...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005591-33,0,0,0 2012-005592-13,1,2016-12-20,2016-12-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,Mechanisms of Exercise Benefit with Intravenous Iron in Chronic Heart Failure: The Ferric Iron in Heart Failure (FERRIC HF) II Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005592-13,0,0,0 2012-005592-13,1,2016-12-20,2016-12-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,Mechanisms of Exercise Benefit with Intravenous Iron in Chronic Heart Failure: The Ferric Iron in Heart Failure (FERRIC HF) II Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005592-13,0,0,0 2012-005593-64,1,2018-03-15,2018-03-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH,"Capecitabine in combination with Bendamustine in women with pretreated locally advanced or metastatic Her2-negative breast cancer, a Phase II Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005593-64,0,0,0 2012-005599-33,1,2016-11-17,2016-11-17,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Lékařská fakulta Univerzity Karlovy v Hradci Králové,"Utilization of Autologous Multipotent Mesenchymal Stem Cells in the Management of the Large Skeletal Defects during Revision Total Hip Arthroplasty: a Prospective, Non-randomized, Open-Label Study to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005599-33,0,0,0 2012-005601-46,7,2015-05-13,2015-05-13,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Ferring International Pharmascience Center US, Inc.","A Multicenter, Open-label, Safety and Tolerability Extension Trial of 5 mg and 10 mg Elobixibat Daily in the Treatment of Chronic Idiopathic Constipation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005601-46,0,0,0 2012-005606-22,2,2015-01-23,2015-01-23,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,OxThera AB,"A Phase 1/2, randomised, placebo-controlled, double-blind, multi-centre study to evaluate the efficacy and safety of OC5 to reduce urinary oxalate in subjects with primary hyperoxaluria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005606-22,0,0,0 2012-005612-26,4,2016-01-13,2016-01-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Efficacy and safety of tianeptine oral administration (25 to 50 mg/day) in elderly patients suffering from Major Depressive Disorder. A 8-week, randomized, double-blind, flexible-dose, parallel groups...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005612-26,0,0,0 2012-005615-92,5,2015-06-12,2015-06-12,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A two part, double blind, placebo controlled, study to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of multiple doses of QBM076 in patients with COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005615-92,0,0,0 2012-005617-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Tuebingen,Pharmacokinetics of Tigecycline in Patients Receiving Continuous Renal Replacement Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005617-39,0,0,0 2012-005624-15,4,2016-06-03,2016-06-03,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A phase Ib/II, open-label study of LJM716 in combination with BYL719 compared to taxane or irinotecan in patients with previously treated esophageal squamous cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005624-15,0,0,0 2012-005624-15,4,2016-06-03,2016-06-03,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,"A phase Ib/II, open-label study of LJM716 in combination with BYL719 compared to taxane or irinotecan in patients with previously treated esophageal squamous cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005624-15,0,0,0 2012-005625-78,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Karolinska Institutet,Food Allergy Surpression Therapy during protection with Xolair,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005625-78,0,0,0 2012-005626-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CUB Erasme Hospital,Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (non resectable) and metastatic cholangiocarcinoma: a randomized double-blinded phase II trial. Evalua...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005626-30,0,0,0 2012-005627-32,1,2016-03-28,2016-03-28,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge,"A randomised, double blind, placebo controlled crossover study of the influence of the HCN channel blocker ivabradine in a healthy volunteer pain model - an enriched population study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005627-32,0,0,0 2012-005628-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE,Transplantation of Human Fetal Liver Cells for the Treatment of Patients with Decompensated Liver Cirrhosis Trapianto di cellule epatiche fetali umane per il trattamento della cirrosi epatica scom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005628-13,0,0,0 2012-005629-65,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,University of Birmingham,Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005629-65,0,0,0 2012-005636-29,1,2015-03-20,2015-03-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Idenix Pharmaceuticals, Inc.","3-Year, Observational Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005636-29,0,0,0 2012-005637-36,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have bee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005637-36,0,0,0 2012-005637-36,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have bee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005637-36,0,0,0 2012-005637-36,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS FARMA S.p.A.,"A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have bee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005637-36,0,0,0 2012-005639-10,1,,,0,1,0,0,0,1,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, open, multi-center study to evaluate the long-term anti-body persistence at 6, 7, 8, 9 and 10 years after the administration of one dose of GlaxoSmithKline (GSK) Biologicals’ meningococc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005639-10,0,1,1 2012-005640-14,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Erasmus MC,The effects of hormonal contraception on the HPA-axis functioning De effecten van hormonal anticonceptie op het functioneren van de HPA-as,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005640-14,0,0,0 2012-005641-21,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, open, controlled study to assess the persistence of antibodies after one dose of GlaxoSmithKline Biologicals’ meningococcal serogroup ACWY conjugate vaccine (MenACWY-TT) given intramuscul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005641-21,0,1,1 2012-005643-24,2,2014-08-14,2014-08-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Xention Limited,"A Multi-Centre, Randomised, Double Blind, Placebo Controlled, Parallel Group Study of TA 8995 in Patients with Mild Dyslipidaemia, Alone and In Combination with Statin Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005643-24,0,0,0 2012-005644-26,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,2,Atrium Medical Centre,Administration of intranvenous ferric carboxymaltose to children with IBD Toediening van IV ijzer carboxymaltose aan kinderen met IBD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005644-26,0,0,0 2012-005645-20,1,2014-09-16,2014-09-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, 10017","A PHASE 2B, MULTI-SITE, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY, SAFETY, LOCAL TOLERABILITY AND PHARMACOKINETICS OF 2 DOSE STRENGTHS AND 2 REGIMENS OF TOFACI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005645-20,0,0,0 2012-005651-17,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Oslo Universitetssykehus,Plexus brachialis block and circulation. Comparing effects on skin microcirculation and macro circulation of lidocain brachial plexus block with versus without epinephrine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005651-17,0,0,0 2012-005652-42,1,2016-03-10,2016-03-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Charité, Universitätsmedizin Berlin",Biomarkers Of The Humoral Immune Response After Conversion To Belatacept In Comparison To Conventional Immunosuppressive Therapy In Renal Transplant Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005652-42,0,0,0 2012-005653-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,2,Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital,TachoSil patch application as replacement of closed suction wound drainage by parotid gland surgery; a prospective study. TachoSil applicatie als vervanging van wonddrainage bij parotischirurgie; e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005653-22,0,0,0 2012-005653-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,2,Takeda Nederland B.V.,TachoSil patch application as replacement of closed suction wound drainage by parotid gland surgery; a prospective study. TachoSil applicatie als vervanging van wonddrainage bij parotischirurgie; e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005653-22,0,0,0 2012-005655-16,1,2018-01-26,2018-01-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Institut Jules Bordet,Regorafenib Assessment in Refractory advanced Colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005655-16,0,0,0 2012-005657-24,2,2021-08-17,2021-08-17,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Ulm,"Personalized marker-driven early switch to aflibercept in patients with metastatic colorectal cancer. A run in marker determination phase followed by a marker-driven randomized part - a multicenter, m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005657-24,0,0,0 2012-005658-52,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,/ Impact d’une supplémentation en vitamine D sur les fonctions immunitaires : Etude chez des sujets âgés de plus de 65 ans vaccinés contre la grippe.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005658-52,0,0,0 2012-005660-98,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Lund University,Effect of a single oral dose DPP-4 inhibitor sitagliptin on islet function after intake of a standardized mixed meal in patients with type 2 diabetes Effekt av Sitagliptin 100mg på regleringen av ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005660-98,0,0,0 2012-005661-13,1,2014-09-30,2014-09-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AbbVie Deutschland GmbH & Co. KG,Long-Term Safety and Efficacy of ABT-126 in Subjects with Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005661-13,0,0,0 2012-005663-27,1,2013-11-13,2013-11-13,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,"HOC, Rigshospitalet",Effect of a late naloxone-infusion on secondary hyperalgesia after a first degree heat injury.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005663-27,0,0,0 2012-005664-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UZ Leuven Orthopedic research,InductOs® (rhBMP-2; dibotermin alfa) vs. autologous bone grafting for the treatment of nonunion of the docking site in tibial bone transport,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005664-10,0,0,0 2012-005665-12,13,2017-06-28,2017-06-28,12,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.","A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005665-12,1,0,0 2012-005665-12,13,2017-06-28,2017-06-28,12,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Medivation, Inc","A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005665-12,1,0,0 2012-005665-12,13,2017-06-28,2017-06-28,12,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Medivation, Inc., a wholly ownwd subsidiary of Pfizer Inc.","A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005665-12,1,0,0 2012-005666-35,1,2016-05-18,2016-05-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Wolverhampton NHS trust,Can Intravenous Iron Reduce Transfusion rates in Anaemic patients undergoing Cardiac Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005666-35,0,0,0 2012-005671-14,1,2014-11-11,2014-11-11,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, randomised, open-label, multicentre clinical trial to assess the safety and immunogenicity of GSK Biologicals’ HZ/su candidate vaccine when administered subcutaneously as compared to intr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005671-14,0,0,0 2012-005672-34,1,2018-03-26,2018-03-26,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Institut für Spezifische Prophylaxe,Application of FSME-Immun® in allergic patients Applikation von FSME-Immun® in Allergikern,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005672-34,0,0,0 2012-005674-61,3,2014-01-06,2014-01-06,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Mesoblast, Inc","A double-blind, randomized, placebo-controlled, multi-center, dose escalation study of a single intravenous infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in the treatment of biologic-naïve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005674-61,0,0,0 2012-005678-76,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ALLEGRIA onlus,"Twenty-four month, multicenter, prospective, randomized, double-blind, placebo controlled, parallel-group study to evaluate the efficacy, safety, tolerability, and cost-effectiveness of allergen speci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005678-76,0,0,0 2012-005682-12,1,2014-08-30,2014-08-30,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Dept. of Clinical Immunology,THE EFFECT OF PLASMA ON THE ENDOTHELIUM IN CRITICAL ILLNESS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005682-12,0,0,0 2012-005683-10,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,FUNDACIÓN PETHEMA,"Estudio fase III nacional, multicéntrico, abierto, aleatorizado, de tratamiento de inducción con bortezomib/lenalidomida/dexametasona (VRD-GEM), seguido de altas dosis de quimioterapia con melfalán-20...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005683-10,0,0,0 2012-005685-35,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Forward Pharma GmbH,"A randomised, double blind, double dummy, active comparator and placebo controlled confirmative non-inferiority trial of FP187 compared to Fumaderm in moderate to severe plaque psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005685-35,0,0,0 2012-005686-12,3,2013-11-12,2013-11-19,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Galderma R&D,"Patient-Reported outcomes of Brimonidine Tartrate 0.5% gel for treatment of severe facial erythema of rosacea Patientrapporterade utfall av brimonidintartrat 0,5 % gel för behandling av svårt ansik...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005686-12,0,0,0 2012-005687-97,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Medtronic Inc.,Effects of Transvenous Vagus Nerve Stimulation on Immune Response: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005687-97,0,0,0 2012-005694-31,3,2016-04-12,2016-04-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Adenovir Pharma AB,"Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Multi-C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005694-31,0,0,0 2012-005695-34,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase II randomized, open, controlled study of the safety and immunogenicity of GlaxoSmithKline Biologicals’ candidate Plasmodium falciparum malaria vaccine RTS,S/AS01E, when incorporated into an Ex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005695-34,0,1,1 2012-005696-14,1,2016-09-16,2016-09-16,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,"A phase 3 randomised non-inferiority trial to evaluate the use of imatinib, nilotinib and ponatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005696-14,0,0,0 2012-005698-30,1,2016-02-15,2016-02-15,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Clinical Trial Center Aachen,Impact of Xenon-anaesthesia on the renal function after partial nephrectomy - PaNeX: Partial Nephrectomy under Xenon,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005698-30,0,0,0 2012-005699-33,1,2017-09-04,2017-09-04,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,CHU Caen,Etude de la pharmacocinétique de la daptomycine en administration intrapéritonéale chez les patients en dialyse péritonéale présentant une infection péritonéale. Etude de la pharmacocinétique de la...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005699-33,0,0,0 2012-005701-43,1,2014-02-13,2014-02-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Fresenius Kabi Deutschland GmbH,Therapeutic Equivalence Study of Propofol Using Target-Controlled Infusion of Propofol 2% (20 mg/mL) MCT Fresenius Compared with Diprivan® 20 mg/mL (AstraZeneca) in Patients Undergoing Elective Surger...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005701-43,0,0,0 2012-005702-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP,International prospective Phase 2 trial addressing the efficacy of first-line Chlamydophila psittaci-eradicating therapy with protracted administration of doxycycline followed by eradication monitorin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005702-22,0,0,0 2012-005704-17,1,2017-01-23,2017-01-23,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Julie Gehl,Calcium electroporation for the treatment of cutaneous metastases. Calcium elektroporation til behandling af kutane metastaser.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005704-17,0,0,0 2012-005705-49,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,zna middelheim,“Comparison of the onset and duration of postoperative analgesia using a popliteal block with different concentrations of local anesthetics »,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005705-49,0,0,0 2012-005710-19,1,2014-04-08,2014-04-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005710-19,0,0,0 2012-005713-39,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,St. Antonius Hospital,Response to influenza vaccination in lymphoma patients treated with CHOP and rituximab (RITUXIVAC) Respons op influenza- en pneumokokkenvaccinatie bij patiënten met multipel myeloom die worden beha...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005713-39,0,0,0 2012-005716-26,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, double blind (observer-blind), randomized, controlled multi-center study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005716-26,0,1,1 2012-005718-20,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase 2, open, randomized, controlled, multi-center study to evaluate the safety and immunogenicity of 7 infant immunization schedules of the RTS,S/AS01E candidate vaccine against P. falciparum.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005718-20,0,1,1 2012-005720-15,2,2015-06-05,2015-06-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, active-controlled, parallel group, 52-week study to evaluate the effect of LCZ696 compared to olmesartan on regional aortic stiffness in subjects with essential hypertensio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005720-15,0,0,0 2012-005723-33,1,2018-03-15,2018-03-15,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,GGZ Oost Brabant,Efficacy of amantadine on behavioural and emotional problems and impairment of executive functioning due to acquired brain injury to the frontal lobes: a series of single case experimental design stud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005723-33,0,0,0 2012-005726-30,1,2018-03-14,2018-03-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin,"A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005726-30,0,0,0 2012-005727-32,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,Sanquin Blood Supply Foundation,Pharmacokinetics and safety of the intravenous human immunoglobulin product Nanogam 100 mg/ml,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005727-32,0,0,0 2012-005730-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,KRANKENHAUS SALEM DER EVANG. STADTMISSION HEIDELBERG GGMBH,"Effect of Clomethiazole (Distraneurin®) on CYP2E1 Activity, transaminases, Liver fat content, and liver stiffness during Alcohol Detoxification – a pilot Study Effekt von Clomethiazol (Distraneurin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005730-11,0,0,0 2012-005732-28,1,2014-06-23,2014-06-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Belgium,"A multicentre, open-label switch study to investigate the necessity of dose adjustment after switching from L-Thyroxine Christiaens® to the new levothyroxine sodium test formulation in (near) total th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005732-28,0,0,0 2012-005733-37,5,2015-08-25,2015-08-25,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Samsung Bioepis Co., Ltd.","A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB2 Compared to Remicade® in Subjects with Moderate to S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005733-37,0,0,0 2012-005735-91,19,2015-10-22,2015-10-22,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005735-91,0,0,0 2012-005736-29,18,2016-09-08,2016-09-08,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Soli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005736-29,0,0,0 2012-005738-12,1,2015-02-20,2015-02-20,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Alder Hey Children's NHS Foundation Trust,Liverpool Pharmacokinetic/pharmacodynamics study of teicoplanin in children (LIPSTIC).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005738-12,0,0,0 2012-005742-38,1,2015-11-30,2015-11-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Central Manchester University Hospitals NHS Foundation Trust,Early phase triple blind placebo controlled RCT of simvastatin treatment for autism in young children with Neurofibromatosis Type 1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005742-38,0,0,0 2012-005743-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Oscar Lambret,"ACTIVITY AND SAFETY OF REGORAFENIB IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA PREVIOUSLY TREATED WITH ANTHRACYCLIN-BASED CHEMOTHERAPY: A MULTINATIONAL, RANDOMIZED, PHASE II, PLACEBO-CONTROLLED TR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005743-24,0,0,0 2012-005745-20,1,2016-01-26,2016-01-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MolMed S.p.A.,NGR018: Randomized phase II study of NGR-hTNF plus an anthracycline versus an anthracycline alone in platinum-resistant ovarian cancer NGR018: studio randomizzato di fase II sulla somministrazione...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005745-20,0,0,0 2012-005748-12,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in locally advanced Gastric Carcinoma: international randomized and multicentric Phase III Study Resección D2 y HIPEC (quimioper...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005748-12,0,0,0 2012-005749-18,1,2015-12-07,2015-12-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Athersys, Inc","Double-Blind, Randomized, Placebo-Controlled, Phase 2 Safety and Efficacy Trial of MultiStem® in Adults With Ischemic Stroke",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005749-18,0,0,0 2012-005750-27,5,2014-11-21,2014-11-21,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma Corporation (MTPC),"A Phase IIa, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT-1303 in Subjects with Moderate to Severe Chron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005750-27,0,0,0 2012-005753-23,9,2021-05-18,2021-05-19,4,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Swedish Orphan Biovitrum AG,"A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005753-23,1,0,0 2012-005753-23,9,2021-05-18,2021-05-19,4,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Novimmune SA,"A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005753-23,1,0,0 2012-005753-23,9,2021-05-18,2021-05-19,4,1,1,0,0,1,2,0,0,2,0,0,0,0,1,NovImmune SA,"A multicentre study for the long-term follow-up of HLH patients who received treatment with NI-0501, an anti-interferon gamma monoclonal antibody",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005753-23,1,0,0 2012-005754-38,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,HOSPITAL DE GALDAKAO-USANSOLO,Title : COMPARISON OF THE EFFECTIVENESS OF TWO PROTOCOLS FOR BOWEL CLEANING FOR CAPSULE ENDOSCOPY STUDIO Título: COMPARACIÓN DE LA EFECTIVIDAD DE DOS PROTOCOLOS DE LIMPIEZA INTESTINAL PARA EL ESTUD...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005754-38,0,0,0 2012-005760-99,3,2013-11-11,2013-11-11,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Shire Development LLC,"A Phase 4, Randomized-withdrawal, Double-blind, Placebo controlled, Parallel-group Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects with Symptomatic Ort...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005760-99,0,0,0 2012-005761-12,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Shire Development LLC,"A Phase 4, Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects with Symptomatic Orthostatic Hypoten...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005761-12,0,0,0 2012-005767-27,7,2016-06-06,2016-06-06,5,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Opsona Therapeutics Ltd,"Follow-up Protocol to the Double-Blind Parts A and B of the Phase II Opsona Study OPN305-102 (A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adapt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005767-27,1,0,0 2012-005768-90,2,2014-02-14,2014-02-14,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Opsona Therapeutics Ltd,"Follow-up Protocol to the Open-Label Phase 0 Part of the Phase II Opsona Study OPN-305-102 (A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005768-90,0,0,0 2012-005770-57,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"department of OBstetrics, Sahlgrenska university hospital",Clinical effect of Atenativ treatment on uterine blood flow and the amount of Atenativ needed to maintain a normal antithrombin level during two weeks in early and severe preeclampsia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005770-57,0,0,0 2012-005772-34,9,2015-10-30,2015-11-25,8,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier (IRIS),"A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy of gevokizumab 60mg subcutaneously every 4 weeks over 24 weeks in the treatment of patients with polymyositis or d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005772-34,0,0,0 2012-005772-34,9,2015-10-30,2015-11-25,8,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Laboratorios Servier S.L,"A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy of gevokizumab 60mg subcutaneously every 4 weeks over 24 weeks in the treatment of patients with polymyositis or d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005772-34,0,0,0 2012-005772-34,9,2015-10-30,2015-11-25,8,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Servier Research and Development Ltd.,"A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy of gevokizumab 60mg subcutaneously every 4 weeks over 24 weeks in the treatment of patients with polymyositis or d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005772-34,0,0,0 2012-005776-34,5,2016-08-17,2016-08-17,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY AND ACTIVITY OF DNIB0600A COMPARED TO PEGYLATED LIPOSOMAL DOXORUBICIN ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH PLATINUM-R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005776-34,0,0,0 2012-005776-34,5,2016-08-17,2016-08-17,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farma, S.A en nombre de Genentech, Inc.","A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY AND ACTIVITY OF DNIB0600A COMPARED TO PEGYLATED LIPOSOMAL DOXORUBICIN ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH PLATINUM-R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005776-34,0,0,0 2012-005778-74,10,2015-04-27,2016-01-04,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"The efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes. A 26 week randomised, insulin capped, placebo-controlled, double-blind, parallel group, multinational, multi-cen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005778-74,0,0,0 2012-005782-12,1,2014-12-16,2014-12-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharmacosmos A/S,"A, Randomized Comparative, Open-Label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by High Single Dose Infusions or Standard Medical Care in Women after Postpartum Haemorrhage",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005782-12,0,0,0 2012-005783-10,1,2015-07-04,2015-07-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharmacosmos A/S,"A Randomized Comparative, Open-Label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by High Single Dose In-fusions or Red Blood Cell transfusion in Women with Severe Postpar-tum I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005783-10,0,0,0 2012-005788-28,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Landeskrankenhaus Fedkirch,Influence of Body Mass Index on the identification rate of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005788-28,0,0,0 2012-005789-36,1,2013-08-08,2013-08-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FluidDA nv,"Double blind, double dummy, randomized, two way cross-over study to compare the effects of Seretide® Evohaler (supplied by Allen & Hanburys, UK) and a generic test HFA pMDI (manufactured by Cipla Ltd,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005789-36,0,0,0 2012-005793-63,4,2014-02-26,2014-03-24,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind, double-dummy, parallel-group dose-finding study to evaluate the change in HbA1c after 12 weeks monotherapy with LIK066 doses ranging from 2.5mg to 150mg daily...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005793-63,0,0,0 2012-005793-63,4,2014-02-26,2014-03-24,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Farma SpA,"A multi-center, randomized, double-blind, double-dummy, parallel-group dose-finding study to evaluate the change in HbA1c after 12 weeks monotherapy with LIK066 doses ranging from 2.5mg to 150mg daily...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005793-63,0,0,0 2012-005794-31,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Verona Pharma plc,"A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005794-31,0,0,0 2012-005796-14,1,2015-09-29,2015-09-29,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,Medizinische Universität Wien,"A randomized, pilot study to assess the impact of single nucleotide polymorphisms in the ABCB1 and ABCG2 genes on brain and organ distribution of dual Pgp/BCRP substrates in humans. Pilotstudie ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005796-14,0,0,0 2012-005797-58,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Kvinnokliniken, Universitetessjukhuset i Linköping, landstinget i Östergötland",Contraception after gastric bypass - part three How does gastric bypass affect the pharmacocinetics of oral desogestrel? Antikonception efter fetmakirurgi- delstudie 3 Hur påverkar fetmakirurgi m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005797-58,0,0,0 2012-005803-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitetssjukhuset Örebro,Evaluation of platelet function following cessation of ticagrelor - a study in patients with acute coronary syndrome and PCI with coronary stent Utvärdering av trombocytfunktionen efter utsättande ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005803-42,0,0,0 2012-005804-16,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,CHU de Toulouse,"Front-line therapy with Carfilzomib, Lenalidomide, and Dexamethasone (CRd) induction followed by autologous stem cell transplantation, CRd consolidation and Lenalidomide maintenance in Newly Diagnose...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005804-16,0,0,0 2012-005805-36,1,2017-05-18,2017-05-18,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Celgene Corporation,"A Phase 1/2, Dose and Schedule Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Azacitidine (CC-486) in Subjects with Acute Myeloid Leukemia or Mye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005805-36,0,0,0 2012-005807-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"""Sapienza"" University of Rome","RANDOMIZED CLINICAL TRIAL, PLACEBO-CONTROLLED, SPLIT-MOUTH, A DOUBLE-BLIND, FOR THE EVALUATION OF THE EFFECTIVENESS OF PRE-emptive ANALGESIA BY ADMINISTRATION OF PARACETAMOL 500MG + codeine 30mg, FOR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005807-41,0,0,0 2012-005808-17,1,2014-11-17,2014-11-17,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Radboud University Medical Centre,"The analgesic efficacy of perioperative Δ9-THC (Namisol®) in patients undergoing major abdominal surgery: a randomized, double blinded, placebo-controlled, parallel design",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005808-17,0,0,0 2012-005809-53,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,A prospective study to determine the minimal biologic drug serum trough concentration required to maintain stable disease activity in psoriasis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005809-53,0,0,0 2012-005810-21,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Robugen GmbH,Effects of Korodin Herz-Kreislauf-Tropfen on low blood pressure and cognitive functions in adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005810-21,0,0,0 2012-005812-24,1,2014-09-16,2014-09-16,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Karolinska University Hospital,Acute ventilatory response to hypoxia during sedation with dexmedetomidine compared to propofol in healthy volunteers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005812-24,0,0,0 2012-005815-25,1,2014-04-14,2014-04-14,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy at-Risk Adults...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005815-25,0,0,0 2012-005816-25,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,"Pfizer Inc (235 East 42nd Street, New York, New York 10017)","A phase III, open, multi-centre, controlled study to evaluate the long-term antibody persistence at 2, 3, 4, 5 and 6 years after a booster dose of meningococcal serogroup A, C, W-135, Y- tetanus toxoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005816-25,0,0,0 2012-005822-31,2,2014-01-21,2014-02-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Civitas Therapeutics, Inc.","A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT 301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005822-31,0,0,0 2012-005823-34,5,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ViiV Healthcare UK Limited,"A Phase IIIb, randomized, open-label study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005823-34,0,0,0 2012-005823-34,5,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"ViiV Healthcare, S.L.","A Phase IIIb, randomized, open-label study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005823-34,0,0,0 2012-005824-13,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,Menarini International Operation Luxembourg SA,"Pilot study on efficacy of bilastine in preventing angioedema symptoms in patients with angioedema of unknown etiology (idiopathic angioedema, IAE) Studio pilota sull'efficacia di Bilastina nella p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005824-13,0,0,0 2012-005830-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ISTITUTO AUXOLOGICO ITALIANO,"Parenteral iron supplementation, chemoreflex response, quality of life and exercise capacity in patients with chronic heart failure Terapia marziale endovenosa, risposte chemoriflesse, qualita' di ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005830-12,0,0,0 2012-005834-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Stichting NVALT studies,Switch maintenance treatment with gemcitabine for patients with malignant mesothelioma who do not progress after 1st line therapy with a pemetrexed-platinum combination. A randomised open label phase ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005834-12,0,0,0 2012-005841-19,5,2015-06-30,2015-06-30,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,DermaTools Biotech GmbH,"A Multicentric, Double Blind, randomised, Comparative Phase III Study of the Efficacy of the new Wound Healing Solution Diperoxochloric acid (DPOCL, DermaPro®) compared to isotonic Sodium Chloride Sol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005841-19,0,0,0 2012-005842-39,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"NU-sjukvården, Norra Älvsborgs Länssjukhus","Treatment of eosinophilic esophagitis with mometason furoat aerosol: a randomised, placebo-controled phase II study for evaluation of treatment effect on group level including symtom questionnaires ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005842-39,0,0,0 2012-005845-19,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Fundación para la Investigación biomédica del Hopsital Gregorio Marañón,Transmyocardial Autologous injection of mononuclear Bone-marrow derived stem cells in infants with HYpoplastic left ventricle syndrome: the TABHY study Ensayo clínico de factibilidad y seguridad de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005845-19,0,0,0 2012-005846-39,2,2019-12-31,2019-12-31,1,0,0,0,0,1,2,0,0,2,1,0,0,0,0,University of Heidelberg,"Phase II, multicenter, open-label, single-arm trial in advanced and relapsed Angiosarcomas, to evaluate the efficacy of pazopanib (Votrient) in combination with standard of care treatment paclitaxel (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005846-39,1,0,0 2012-005848-21,16,2018-01-15,2018-03-29,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SONAR: Study O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-005848-21,0,0,0 2013-000001-23,14,2017-07-06,2017-07-06,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000001-23,0,0,0 2013-000001-23,14,2017-07-06,2017-07-06,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lundbeck España S.A.,An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000001-23,0,0,0 2013-000007-17,4,2013-12-27,2013-12-27,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Takeda Global Development Centre Europe Ltd.,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50mg Compared With Placebo as an Add-On to Glimepiride in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000007-17,0,0,0 2013-000007-17,4,2013-12-27,2013-12-27,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Takeda Development Centre Europe Ltd.,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50mg Compared With Placebo as an Add-On to Glimepiride in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000007-17,0,0,0 2013-000007-17,4,2013-12-27,2013-12-27,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Takeda Global Research & Development Centre (Europe) Ltd.,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50mg Compared With Placebo as an Add-On to Glimepiride in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000007-17,0,0,0 2013-000013-20,6,2014-11-04,2014-11-04,4,1,1,0,0,1,1,0,0,2,0,0,0,0,1,Novo Nordisk A/S,"A randomised, open-labelled, active-controlled, multinational, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of long-acting growth ho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000013-20,1,0,0 2013-000014-38,1,2015-05-18,2015-05-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Grenoble,"Evaluation de l'efficacité et de la tolérance du sildénafil ""à la demande"" dans le phénomène de Raynaud",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000014-38,0,0,0 2013-000015-24,1,2020-05-14,2020-05-14,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Great Ormond Street Hospital,"90-Yttrium-labelled anti-CD66 monoclonal antibody as part of a reduced intensity conditioning regimen prior to allogeneic haematopoietic stem cell transplantation: an open label, dose escalating phase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000015-24,0,0,0 2013-000017-21,1,2019-03-01,2019-03-01,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,"Aarhus University Hospital, Dept. of anaesthesiology and intensive care","SATA 1 – Stress, Anxiety and Type A personality and analgetics (qualityinsurance project). Level of analgetics in anaesthesia for cardiac surgery evaluated by BIS and EEG monitoring, haemodynamic effe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000017-21,0,0,0 2013-000018-39,2,2019-03-01,2019-03-01,2,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH gGmbH),Clinical trial for the treatment of acute myeloid leukemia in children and adolescents Klinische Prüfung zur Behandlung der akuten myeloischen Leukämien bei Kindern und Jugendlichen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000018-39,0,0,0 2013-000022-63,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Aarhus University,Acyl and desacyl ghrelin: The Yin and Yang of glucose homeostasis and insulin sensitivity? -Acute metabolic effects of desacyl ghrelin in insulin resistant patients HORMONERNE ACYL- OG DESACYL-GHR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000022-63,0,0,0 2013-000024-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AOU di Bologna, Policlinico S.Orsola-Malpighi",Use of PRP from umbilical cord in post-extractive sites Uso del PRP da cordone ombelicale in siti post estrattivi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000024-34,0,0,0 2013-000026-57,1,2018-11-01,2018-11-01,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Karolinska Institutet,Effect of granisetron on facial skin sensitivity in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000026-57,0,0,0 2013-000029-29,1,2017-07-10,2017-07-10,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Centre Hospitalier Régional Universitaire de Besancon,Study of the effect of oxytocin on emotion regulation in adolescents with insecure attachment Etude de l'effet de l'ocytocine sur la régulation émotionnelle chez des adolescents à l’attachement ins...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000029-29,0,0,0 2013-000030-35,1,2015-06-05,2015-06-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Medical Center Hamburg-Eppendorf,Reduction of Ischemic Myocardium with Ranolazine-Treatment in patients with acute myocardial Ischemia – RIMINI-Pilot-Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000030-35,0,0,0 2013-000031-27,1,2014-02-04,2014-02-04,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Moorfields Eye Hospital,Intravitreal Ranibizumab (Lucentis) Therapy in Patients with Diabetic Ischaemic Macular Oedema (DIME),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000031-27,0,0,0 2013-000043-78,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University of Essen,"Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo®; Ipilimumab, Yervoy®) versus obser...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000043-78,0,0,0 2013-000044-25,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Debiopharm S.A.,"A Phase I/II randomized study to determine the maximum tolerated dose, safety, pharmacokinetics and antitumor activity of Debio1143 combined with concurrent Chemo-Radiation Therapy in patients with lo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000044-25,0,0,0 2013-000046-19,17,2018-04-19,2018-05-02,16,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Oral Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000046-19,0,0,0 2013-000048-24,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Hear Center of Semmelweis University,"Randomised clinical trial evaluating the safety and effectiveness of esmolol and metoprolol for heart rate control of patients referred to coronary CT angiography Randomizált klinikai vizsgálat, me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000048-24,0,0,0 2013-000051-40,4,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Genzyme Corporation,A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000051-40,0,0,0 2013-000052-17,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,The Newcastle Upon Tyne Hospitals NHS Foundation Trust,Pilot study to investigate the early prediction of toxicity following induction chemotherapy in Ewing’s sarcoma by blood-borne biomarkers and correlation with age-dependent pharmacokinetic variation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000052-17,0,0,0 2013-000054-22,1,2016-08-04,2016-08-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche Products Limited,"OPEN-LABEL, PHASE IIIB STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS TOCILIZUMAB (MONOTHERAPY OR COMBINATION THERAPY WITH METHOTREXATE OR OTHER DMARDS) IN PATIENTS WITH ACTIVE RHEUMATOID A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000054-22,0,0,0 2013-000055-41,5,2015-12-23,2016-02-01,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000055-41,0,0,0 2013-000056-18,1,2013-12-09,2013-12-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,BioTech Tools S.A.,"Safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM administered subcutaneously to hay fever patients. A Phase IIa dose-escalation study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000056-18,0,0,0 2013-000057-44,1,2015-12-02,2015-12-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Mediwound Ltd,Feasibility Study: Enzymatic Debridement in Patients (Adults) with Partial Thickness and Full Thickness Burns - Protocol MW 2008-09-03,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000057-44,0,0,0 2013-000059-42,4,2014-11-17,2014-11-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared with the Addition of Sitagliptin in Subjects with Type 2 Diabetes Melli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000059-42,0,0,0 2013-000063-91,7,2016-03-11,2016-03-18,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A 52-week, Double Blind, Double dummy, Randomized, Multinational, Multicentre, 3-arm Parallel Group, active Controlled Clinical Trial of fixed combination of beclometasone dipropionate plus formoterol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000063-91,0,0,0 2013-000068-27,2,2016-11-03,2016-11-03,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Xenikos BV,A Phase Ib/IIa multicentric study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins (T-Guard) for the treatment of steroid-resistant acute Graft-versus-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000068-27,0,0,0 2013-000075-33,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Fondazione IRCCS Istituto Nazionale Tumori,"Multidisciplinary approach for poor prognosis sinonasal tumors: Phase II study of chemotherapy, surgery, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in op...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000075-33,0,0,0 2013-000076-16,1,2018-10-08,2018-10-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,CENTRE LEON BERARD,"BENEFIT - A multicenter phase II study evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) prior to autologous stem cell transplant for first and second chemosensitive relapses in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000076-16,0,0,0 2013-000077-68,1,2018-09-18,2018-09-18,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Medical Center - University of Freiburg,Imatinib continuation versus Nilotinib 300 mg twice daily in patients with chronic myeloid leukemia (CML) in chronic phase and major molecular response (MMR) without molecular response ≥ 4.5 log (MR4....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000077-68,0,0,0 2013-000078-30,1,2015-02-11,2015-02-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Valeas SpA,Evaluation in patients affected by middle of the night (MONT) awakenings using different dosages of triazolam Valutazione in pazienti con risveglio intra-sonno di differenti dosaggi di triazolam,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000078-30,0,0,0 2013-000081-11,12,2014-03-20,2014-03-20,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.",A 12-Week Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® 160/4.5 mcg Inhalation Powder Versus SYMBICORT® TURBOHALER® 200/6 mcg in Adult and Adolescent Patients with Persistent Asthm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000081-11,0,0,0 2013-000082-37,1,2015-12-08,2015-12-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abbvie Deutschland GmbH & Co. KG,A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000082-37,0,0,0 2013-000086-36,1,2014-03-28,2014-03-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,HAL Allergy B.V.,"A prospective, randomized, open, multi-centre study to assess safety of PURETHAL Birch given with a rush up-dosing regimen to patients with allergic rhinitis/rhinoconjunctivitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000086-36,0,0,0 2013-000087-29,16,2018-10-05,2018-10-08,15,1,0,0,0,1,3,0,0,1,0,0,1,0,1,F. Hoffmann- La Roche Ltd.,"A multicenter, open-label, single-arm, phase IIIb, international study evaluating the safety of Obinutuzumab alone or in combination with chemotherapy in patients with previously untreated or relapsed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000087-29,0,0,0 2013-000087-29,16,2018-10-05,2018-10-08,15,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Roche Farma, S.A. , en nombre de F. Hoffmann- La Roche Ltd.","A multicenter, open-label, single-arm, phase IIIb, international study evaluating the safety of Obinutuzumab alone or in combination with chemotherapy in patients with previously untreated or relapsed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000087-29,0,0,0 2013-000092-33,1,2022-05-26,2022-05-26,1,0,0,0,1,0,4,0,0,1,1,1,0,0,0,"Medizinische Universität Wien, Univ.Klinik.f.Dermatologie","Enhanced efficacy of photodynamic therapy in combination with 5% imiquimod -a randomised, prospective, observer-blinded study in patients with non melanoma skin cancer Erhöhte Wirksamkeit der photo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000092-33,0,0,0 2013-000093-29,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Astellas Pharma Global Development, Inc.","A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000093-29,0,0,0 2013-000098-65,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Tromsø,Treatment of Axial Spondyloarthritis with reduced doses of NSAIDs: Application of pharmacotherapeutic conditioning in clinical practice.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000098-65,0,0,0 2013-000100-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jules Bordet Institute,Histological study of the (intravenously injected) Indocyanine Green (ICG) distribution in tumour bearing breasts and in axillary pieces of dissection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000100-41,0,0,0 2013-000101-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Helsinki,The effect of antiherpes medication with valaciclovir on cognition and function in patients with Alzheimer disease The HEVALITZ Study - Pilot study Hiljaisen herpesvirusinfektion merkitys Alzheim...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000101-24,0,0,0 2013-000102-37,9,2018-10-03,2018-10-03,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Inc.,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Diso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000102-37,0,0,0 2013-000103-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Nantes,Antifungal prophylaxis with Micafungin after cord blood allogeneic stem cell transplantation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000103-16,0,0,0 2013-000104-42,1,2014-04-09,2014-04-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,DAIICHI SANKYO DEVELOPMENT LTD.,"Open-label, Non-randomized Study of U3-1287 in Combination with Erlotinib in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) - Extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000104-42,0,0,0 2013-000106-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,GnRH analog as a luteal phase support in frozen-thawed embryo transfer cycles. A Pilot study Luteaalivaiheen GnRH-analogituen vaikutus pakastealkionsiirtojen ennusteeseen. Pilottitutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000106-29,0,0,0 2013-000107-17,1,2016-10-06,2016-10-06,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,"Hospital of the University of Munich, Grosshadern",Pharmacological therapy of episodic ataxia type 2: a placebo-controlled comparison of the efficacy of 4-aminopyridine sustained-release (Fampyra TM) and acetazolamide (Acemit TM) Pharmakologische ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000107-17,0,0,0 2013-000110-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundacion para la investigación biomédica del hospital Ramón y Cajal de Madrid,Clinical effectiveness and effect on COX-2 expression of the sequential treatment of actinic keratoses (AK) with photodynamic therapy (PDT) and diclofenac 3% gel: a phase IV clinical trial. Efectiv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000110-37,0,0,0 2013-000113-20,8,2016-10-28,2016-10-28,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Abraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation","A PHASE 2/3, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF WEEKLY nab®-PACLITAXEL IN COMBINATION WITH GEMCITABINE OR CARBOPLATIN, COMPARED TO GEMCITABINE/CARBOPLATIN, AS FIRST LINE TREATMENT IN SUBJEC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000113-20,0,0,0 2013-000114-38,7,2015-06-25,2015-06-25,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Biotest AG,"A 24-week phase IIb, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of tregalizumab (BT061) in combination with methotrexate in the treatment of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000114-38,0,0,0 2013-000116-14,9,2014-08-04,2014-08-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ALMIRALL, S. A., Research and Development (R&D) Centre","A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY AND TOLERABILITY OF TWICE-DAILY ACLIDINIUM BROMIDE /FORMOTEROL FUMARATE COMPARED WITH TWICE-DAILY SALM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000116-14,0,0,0 2013-000119-25,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,1,masimo,"Study of the cerebral effects of sevoflurane, propofol and remifentanil as measured by the spontaneous electro-encephalogram",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000119-25,0,0,0 2013-000120-33,10,2020-06-04,2020-06-04,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bayer AG,"An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000120-33,1,0,0 2013-000120-33,10,2020-06-04,2020-06-04,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bayer HealthCare AG,"An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000120-33,1,0,0 2013-000120-33,10,2020-06-04,2020-06-04,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,BAYER AG,"An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000120-33,1,0,0 2013-000121-31,1,2017-04-14,2017-04-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Prof., dr. med. Anders Fink-Jensen",Does a GLP-1 receptor agonist change glucose tolerance in antipsychotic-treated patients? Effekt af GLP-1 receptor agonisten liraglutid på glukosetolerance hos patienter i antipsykotisk behandling.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000121-31,0,0,0 2013-000122-60,1,,,0,0,1,0,0,0,4,0,0,0,0,0,0,0,0,"Karolinska University Hospital, Division of Pediatrics/Astrid Lindgren Children´s Hospital",The effect of dexmedetomidine as an adjuvant to local anaesthetics for ilioinguinal blocks in paediatric patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000122-60,0,0,0 2013-000123-13,1,2017-07-19,2017-07-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NV ROCHE SA,A single arm multi-center study investigating the at home administration of trastuzumab subcutaneous vial for the treatment of patients with HER2-positive early breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000123-13,0,0,0 2013-000124-34,1,2015-03-05,2015-03-05,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,PD Dr. Maria De Santis,"Circulating Tumor cells in urothelial cancer patients relapsing after or refractory to platinum based first line chemotherapy Nachweis zirkulierender Tumorzellen bei Patienten mit Urothelkarzinom, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000124-34,0,0,0 2013-000133-12,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Azienda Ospedaliera Universitaria Integrata Verona,A randomized controlled multicentre open-label parallel arm study to assess the non-inferiority of the safety of bevacizumab compared to ranibizumab (allocation 4:1) administered by intravitreal injec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000133-12,0,0,0 2013-000138-37,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,NKI-AvL,Treatment of PERItoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy Behandeling van peritoneale uitzaaiingen in maagkanker pati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000138-37,0,0,0 2013-000139-28,1,2014-11-17,2014-11-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Christie NHS Foundation Trust,A single arm double-blind placebo controlled cross-over trial of Aprepitant for the treatment of cough in lung cancer: “CALC” Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000139-28,0,0,0 2013-000142-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,VISIOTACT PHARMA,"- ENSAYO CLÍNICO ABIERTO, ALEATORIZADO CON EVALUACIÓN CIEGA POR EL INVESTIGADOR PARA EVALUAR NO INFERIORIDAD DE LATANOPROST 50µg/ml COLIRIO COMPARADO CON XALATAN COLIRIO EN EL TRATAMIENTO DEL GLAUC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000142-19,0,0,0 2013-000144-26,5,2018-11-06,2018-11-06,3,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Celgene Corporation,"A Phase 1/2, multicenter, open-label, dose-finding study to assess the safety, tolerability, and preliminary efficacy of weekly nab-paclitaxel in pediatric patients with recurrent or refractory solid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000144-26,1,1,0 2013-000144-26,5,2018-11-06,2018-11-06,3,1,1,0,0,0,1,0,0,2,0,0,0,0,1,"Abraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation","A Phase 1/2, multicenter, open-label, dose-finding study to assess the safety, tolerability, and preliminary efficacy of weekly nab-paclitaxel in pediatric patients with recurrent or refractory solid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000144-26,1,1,0 2013-000144-26,5,2018-11-06,2018-11-06,3,1,1,0,0,0,1,0,0,2,0,0,0,0,1,"Abraxis BioScience, LLC, a wholly-owned subsidiary Celgene Corporation","A Phase 1/2, multicenter, open-label, dose-finding study to assess the safety, tolerability, and preliminary efficacy of weekly nab-paclitaxel in pediatric patients with recurrent or refractory solid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000144-26,1,1,0 2013-000145-39,2,,,0,0,0,0,2,0,3,0,1,3,0,0,0,0,1,Novartis Vaccines and Diagnostics s.r.l,"A Phase 3, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of Single Dose of Novartis Meningococcal ACWY Conjugate Vaccine, administered to Healthy T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000145-39,0,0,0 2013-000161-36,1,2015-01-12,2015-01-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.,","Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267) Estudio de fase 2 demostrativo preliminar de la actividad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000161-36,0,0,0 2013-000164-28,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"Idera Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, 12-week Dose-Ranging Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000164-28,0,0,0 2013-000170-30,1,2014-12-12,2014-12-12,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Mech-Sense, Aalborg University Hospital","Effects of oxycodon and venlafaxine on human pain processing. A randomized, double-blinded, placebo-controlled, cross-over study Oxycodon og venlafaxins effekter på det humane smertenetværk Et ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000170-30,0,0,0 2013-000173-77,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Institut Jules Bordet,TRIUMPH Trial A phase II TRial evalUating the Menstrual and ovarian function of young breast cancer patients treated with a cycloPHosphamide-free regimen composed of doxorubicin and paclitaxel,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000173-77,0,0,0 2013-000175-33,9,2016-12-27,2016-12-28,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Phase III, randomized, double-blind, placebo controlled study to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma who are on inhaled corticosteroids and a second c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000175-33,0,0,0 2013-000176-15,10,2017-01-03,2017-01-03,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Phase III, randomized, double-blind, placebo controlled study to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma who are on inhaled corticosteroids and a second c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000176-15,0,0,0 2013-000177-69,4,2017-12-18,2017-12-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF ATEZOLIZUMAB (MPDL3280A) IN PATIENTS WITH PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000177-69,0,0,0 2013-000179-34,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Maastricht University,More creative on cocaine?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000179-34,0,0,0 2013-000180-81,2,2014-08-27,2014-08-27,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"A single-arm, open-label, multicentre, non-randomised, study to assess the effect and tolerability of standardised laxative therapy (SLT) for the reversal of opioid-induced constipation (OIC) in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000180-81,0,0,0 2013-000182-37,6,2022-06-02,2022-06-02,4,1,0,0,0,0,2,0,0,2,0,0,0,0,0,LYSARC,BRENTUXIMAB VEDOTIN ASSOCIATED WITH CHEMOTHERAPY IN UNTREATED PATIENTS WITH STAGE I/II UNFAVOURABLE HODGKIN LYMPHOMA - A RANDOMIZED PHASE II LYSA-FIL-EORTC INTERGROUP STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000182-37,1,0,0 2013-000189-12,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University Medical Centre Nijmegen,Effects of the selective mineralocorticoid receptor antagonist eplerenone on extracellular formation of adenosine De effecten van de selectieve mineralocorticoid receptorantagonist eplerenone op de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000189-12,0,0,0 2013-000192-33,15,2014-12-24,2014-12-24,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"KAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)","A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000192-33,0,0,0 2013-000200-41,9,2020-08-28,2020-10-17,6,1,1,0,0,2,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A multi-center, open label, non-controlled phase II study to evaluate efficacy and safety of oral nilotinib in pediatric patients with newly diagnosed Ph+ chronic myelogenous leukemia (CML) in chronic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000200-41,1,0,0 2013-000200-41,9,2020-08-28,2020-10-17,6,1,1,0,0,2,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A multi-center, open label, non-controlled phase II study to evaluate efficacy and safety of oral nilotinib in pediatric patients with newly diagnosed Ph+ chronic myelogenous leukemia (CML) in chronic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000200-41,1,0,0 2013-000200-41,9,2020-08-28,2020-10-17,6,1,1,0,0,2,2,0,0,2,0,0,0,0,1,NOVARTIS FARMA S.p.A.,"A multi-center, open label, non-controlled phase II study to evaluate efficacy and safety of oral nilotinib in pediatric patients with newly diagnosed Ph+ chronic myelogenous leukemia (CML) in chronic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000200-41,1,0,0 2013-000201-23,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,St. Antonius Ziekenhuis,A randomised clinical trial evaluating the effect of remifentanil vs fentanyl during cardiac surgery on the incidence of chronic thoracic pain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000201-23,0,0,0 2013-000205-23,1,2014-10-08,2014-10-08,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,"Department of surgery, Herlev Hospital","The analgesic effects of melatonin: A randomized, placebo-controlled, double-blinded study on healthy volunteers Melatonins analgetiske effekter: et randomiseret, dobbeltblindet placebokontrollere...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000205-23,0,0,0 2013-000208-41,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Teva Pharmaceutical Industries Ltd.,"A 12-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Once-Weekly Intra-Muscular Injections of TV-1380 (150 mg/week or 300 m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000208-41,0,0,0 2013-000209-22,1,2017-08-28,2017-08-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Research and Development Nottingham University Hospital,A pilot study to assess the efficacy of intravenous iron isomaltoside 1000 (Monofer®) in the management of anaemia associated with the palliative management of upper gastrointestinal adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000209-22,0,0,0 2013-000211-24,1,2014-12-10,2014-12-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Ruprecht-Karls-University Heidelberg,"A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuvant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000211-24,0,0,0 2013-000212-22,3,2015-01-08,2015-01-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GW Research Ltd,"A double-blind, randomised, placebo-controlled, parallel group study of GWP42003 as adjunctive therapy in the first line treatment of schizophrenia or related psychotic disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000212-22,0,0,0 2013-000219-25,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,AOU Meyer,Early eradication of S. Aureus (MRSA) in patients with cystic fibrosis: a randomized multicenter study. Eradicazione precoce di S. Aureus meticillino-resistente (MRSA) in pazienti affetti da fibros...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000219-25,0,0,0 2013-000225-30,1,2014-10-03,2014-10-03,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,DiaMedica USA Inc.,"A DOUBLE-BLINDED, PLACEBO-CONTROLLED, SINGLE DOSE AND MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PROOF OF CONCEPT OF DM-199 IN HEALTHY SUBJECTS AN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000225-30,0,0,0 2013-000226-55,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Fundacion Renal Iñigo Alvarez Toledo,European Multicenter and Open-Label Controlled Randomized Trial to evaluate the Efficacy of Sequential Treatment with Tacrolimus-Rituximab versus Steroids plus Cyclophosphamide in patientes with Prima...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000226-55,0,0,0 2013-000228-33,1,2016-08-10,2016-08-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,NHS Greater Glasgow & Clyde,Inhibition of complement activation (eculizumab®) in Guillain-Barré Syndrome study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000228-33,0,0,0 2013-000228-33,1,2016-08-10,2016-08-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,The University of Glasgow,Inhibition of complement activation (eculizumab®) in Guillain-Barré Syndrome study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000228-33,0,0,0 2013-000232-10,4,2020-03-12,2020-03-12,4,1,0,0,0,1,4,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc",A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000232-10,0,0,0 2013-000235-27,1,2015-03-22,2015-03-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Odense universitets Hospital,"Interscalener blockade for surgery on the shoulder, a comparison of two dosing regimens: Fixed intermittent bolus with the possibility of PCA (Patient controlled administration) Vs. continuous infusio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000235-27,0,0,0 2013-000236-94,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),Phase II study of Regorafenib as a single agent for first-line treatment of patients with metastatic colorectal cancer (MCRC) who are fragile and/or not candidates for polychemotherapy Estudio fase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000236-94,0,0,0 2013-000238-37,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,VU University medical center,Treatment guided by detection of Minimal Residual Disease after allogeneic stem cell transplantation in Acute Myeloid Leukaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000238-37,0,0,0 2013-000239-28,12,2018-09-11,2018-09-16,12,1,0,0,0,0,0,0,0,1,0,0,1,0,1,AstraZeneca AB,"DECLARE Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000239-28,0,0,0 2013-000240-26,1,2015-08-07,2015-08-07,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,King's College London,Cannabidiol as an add-on therapy in treatment-refractory psychotic disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000240-26,0,0,0 2013-000240-26,1,2015-08-07,2015-08-07,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,South London and Maudsley NHS Foundation Trust,Cannabidiol as an add-on therapy in treatment-refractory psychotic disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000240-26,0,0,0 2013-000241-39,8,2017-02-08,2017-03-13,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line treatment in patients with RAS mutant Hepatocel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000241-39,0,0,0 2013-000241-39,8,2017-02-08,2017-03-13,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bayer AG,"A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in combination with sorafenib as first line treatment in patients with RAS mutant Hepatocel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000241-39,0,0,0 2013-000242-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Low dose dexamethasone in newly diagnosed sarcoidosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000242-18,0,0,0 2013-000245-39,2,2014-02-11,2014-03-14,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Rottapharm S.p.A,Rescue effect of daily infusions with Legalon® SIL in Hepatitis C Virus-infected patients who are incomplete responders to standard pegylated interferon/ribavirin (dual therapy) or pegylated interfero...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000245-39,0,0,0 2013-000250-22,1,2018-02-07,2018-02-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A single dose, double-blind, placebo-controlled, parallel study to assess the pharmacodynamics, pharmacokinetics and safety and tolerability of VAY736 in patients with primary Sjögren’s syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000250-22,0,0,0 2013-000256-18,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,Novartis Farmacéutica S.A.,"A single-arm, open label, multi-center phase II study investigating oral everolimus tablets with dose titration in pediatric patients with relapsed or refractory Hodgkin lymphoma Estudio de un solo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000256-18,0,0,0 2013-000260-28,1,2013-09-09,2013-09-09,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,Diurnal Ltd,"A single centre, open label, randomised, crossover study in dexamethasone-suppressed healthy adult male volunteers to compare the pharmacokinetics of Infacort® versus immediate-release hydrocortisone ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000260-28,0,0,0 2013-000261-36,2,2015-12-11,2015-12-11,1,1,1,0,0,1,2,0,0,2,0,0,0,0,1,LFB Biotechnologies,"Clinical pharmacology, efficacy and safety study of FGTW in paediatric patients with severe congenital fibrinogen deficiency Etude de pharmacologie clinique, d’efficacité et de tolérance du FGTW ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000261-36,1,1,0 2013-000262-11,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Chiesi Farmaceutici S.p.A.,An Open Label Placebo Study To Assess The Inhalation Profile Obtained By Acoustic Monitoring In COPD Patients Using The NEXThaler® Dry Powder Inhaler (DPI) Device. Studio in aperto con placebo per ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000262-11,0,0,0 2013-000263-88,7,2015-12-05,2015-12-05,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects with Moderately to Severely Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000263-88,0,0,0 2013-000266-11,4,,,0,0,0,0,0,2,2,0,0,2,1,0,0,0,0,Hospices Civils de Lyon,"EWOC-1 (Elderly Women Ovarian Cancer) Trial: Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000266-11,0,0,0 2013-000266-11,4,,,0,0,0,0,0,2,2,0,0,2,1,0,0,0,0,HOSPICES CIVILS DE LYON,"EWOC-1 (Elderly Women Ovarian Cancer) Trial: Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage III-IV advanced ovarian cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000266-11,0,0,0 2013-000267-84,8,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000267-84,0,0,0 2013-000267-84,8,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,Recordati AG,"An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000267-84,0,0,0 2013-000267-84,8,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000267-84,0,0,0 2013-000267-84,8,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,NOVARTIS FARMA,"An open label, multicenter pasireotide roll over protocol for patients who have completed a previous Novartis sponsored pasireotide study and are judged by the investigator to benefit from continued p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000267-84,0,0,0 2013-000276-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jules Bordet Institute,Feasibility study of the (intravenously injected) Indocyanine green (ICG) imaging of tumoral implants in patients with peritoneal carcinomatosis from ovarian carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000276-15,0,0,0 2013-000277-72,15,2016-04-01,2022-08-23,13,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Array BioPharma Inc.,"The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000277-72,1,0,0 2013-000277-72,15,2016-04-01,2022-08-23,13,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Array BioPharma Limited,"The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000277-72,1,0,0 2013-000280-84,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Finnish melanoma group,COBRA: TOL+ INTERFERON-alpha COMBINED WITH VEMURAFENIB (BRAF-mutation positive patients) OR TOL + INTERFERON- alpha (BRAF-mutation negative patients) FOR PATIENTS WITH ADVANCED MELANOMA AS 1st CHEMOTH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000280-84,0,0,0 2013-000281-11,5,2015-05-15,2015-05-15,4,1,0,1,0,0,1,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase Ib/II, open-label, multicenter study of AEB071 and MEK162 in adult patients with metastatic uveal melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000281-11,1,0,0 2013-000281-11,5,2015-05-15,2015-05-15,4,1,0,1,0,0,1,0,0,2,1,0,0,0,1,Novartis Farma S.p.A.,"A phase Ib/II, open-label, multicenter study of AEB071 and MEK162 in adult patients with metastatic uveal melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000281-11,1,0,0 2013-000281-11,5,2015-05-15,2015-05-15,4,1,0,1,0,0,1,0,0,2,1,0,0,0,1,Novartis Pharma Services,"A phase Ib/II, open-label, multicenter study of AEB071 and MEK162 in adult patients with metastatic uveal melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000281-11,1,0,0 2013-000283-28,1,2018-02-07,2018-02-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Institut Bergonié,Efficacy and Safety of PD-0332991 in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 study Efficacité et tolérance du PD-0332991 chez les pati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000283-28,0,0,0 2013-000286-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Gustave Roussy,A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic non-seminomatous germ-cell tumors Etude de phase II prospective évaluant le cabazitaxel chez de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000286-36,0,0,0 2013-000287-29,3,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,Università del Piemonte Orientale,EARLY PREDICTION OF EFFICACY OF ENDOCRINE THERAPY IN BREAST CANCER: PILOT STUDY AND VALIDATION WITH 18F FLUOROESTRADIOL (FES) PET/CT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000287-29,0,0,0 2013-000287-29,3,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,e.o. ospedali galliera,EARLY PREDICTION OF EFFICACY OF ENDOCRINE THERAPY IN BREAST CANCER: PILOT STUDY AND VALIDATION WITH 18F FLUOROESTRADIOL (FES) PET/CT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000287-29,0,0,0 2013-000288-10,7,2017-04-04,2017-04-05,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Servier Research and Development Ltd,"An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000288-10,0,0,0 2013-000288-10,7,2017-04-04,2017-04-05,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,"An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000288-10,0,0,0 2013-000288-10,7,2017-04-04,2017-04-05,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Laboratorios Servier S.L.,"An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000288-10,0,0,0 2013-000288-10,7,2017-04-04,2017-04-05,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Institut de Recherches Internationales de Servier,"An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000288-10,0,0,0 2013-000290-73,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,FUNDACION C.V. HOSPITAL PROVINCIAL DE CASTELLON,"Randomized, double-blind, phase IV trial comparing the efficacy of two methods of sedation in patients scheduled for outpatient diagnostic-therapeutic colonoscopy. Ensayo clínico fase IV aleatoriza...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000290-73,0,0,0 2013-000292-33,1,,,0,0,0,0,1,0,4,0,0,1,1,1,0,1,0,Laura Sararols Ramsay,Comparative study of the mydriatic effect of Mydriasert vs the use of topical instillation of phenylephrine (10%) and tropicamide (1%) before catarcat surgery. Estudio comparativo del efecto midriá...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000292-33,0,0,0 2013-000293-29,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,"A prospective, multi-centre, open label, non-randomised two stage phase II clinical trial evaluating the efficacy of abiraterone in patients with epithelial ovarian (including fallopian tube and prima...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000293-29,0,0,0 2013-000293-29,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,The Institute of Cancer Research,"A prospective, multi-centre, open label, non-randomised two stage phase II clinical trial evaluating the efficacy of abiraterone in patients with epithelial ovarian (including fallopian tube and prima...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000293-29,0,0,0 2013-000297-30,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,KU Leuven - Drug Delivery & Disposition,The use of the non-absorbable marker paromomycin sulfate for the evaluation of the gastrointestinal transit Evaluatie van de gastrointestinale transit aan de hand van de niet-absorbeerbare merker p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000297-30,0,0,0 2013-000300-42,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,0,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),A long-term outcome study with the IL-1 receptor antagonist Anakinra/Kineret® in patients with Neonatal onset multisystem inflammatory disease (Nomid/Cinca syndrome),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000300-42,0,1,1 2013-000301-23,10,2014-02-19,2014-04-03,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Double-Blind, Randomized Trial to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus For Whom Metformin is Inappr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000301-23,0,0,0 2013-000307-17,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Washington University in St. Louis,"A Phase II/III randomized, double-blind, placebo-controlled multi-center study of 2 potential disease modifying therapies in individuals at risk for and with dominantly inherited Alzheimer's disease (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000307-17,0,0,0 2013-000309-21,5,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"AOU di Bologna, Policlinico S.Orsola-Malpighi",Antibiotic Prophylaxis and Renal Damage In Congenital abnormalities of the kidney and urinary Tract Antibakterielle Prophylaxe und Nierenparenchymschäden bei angeborenen Fehlbildungen der Nieren un...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000309-21,0,0,0 2013-000309-21,5,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Fondazione IRCCS “Ca’ Granda” Ospedale Maggiore Policlinico,Antibiotic Prophylaxis and Renal Damage In Congenital abnormalities of the kidney and urinary Tract Antibakterielle Prophylaxe und Nierenparenchymschäden bei angeborenen Fehlbildungen der Nieren un...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000309-21,0,0,0 2013-000311-25,9,2014-09-23,2014-10-08,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bayer Healthcare AG,"A prospective, single-arm, multicenter, uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with RAS mutant Hepatocellular Carcinoma (HCC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000311-25,0,0,0 2013-000313-20,1,2015-11-12,2015-11-12,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU de Saint-Etienne,Evaluation of the biological response to clopidogrel in patients with ischemic stroke: role of platelet alpha2-adrenergic receptors Evaluation de la réponse biologique au clopidogrel chez des pati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000313-20,0,0,0 2013-000314-38,8,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),"A randomised phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000314-38,0,0,0 2013-000314-38,8,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,0,EORTC AISBL/IVZW,"A randomised phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000314-38,0,0,0 2013-000315-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU SAINT-ETIENNE,"Pharmaco-epidemiology of the treatment of the symptomatic pulmonary embolism among in-patients and 75 years old or more: prospective, multicentric ""PEAGE"" cohort Pharmaco-épidémiologie du traitemen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000315-24,0,0,0 2013-000319-26,14,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,"A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-smal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000319-26,0,0,0 2013-000319-26,14,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-smal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000319-26,0,0,0 2013-000319-26,14,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,NOVARTIS FARMA S.p.A.,"A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-smal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000319-26,0,0,0 2013-000320-33,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,HOVON Foundation,Feasibility and Efficacy of dose adjusted Melphalan – Prednisone – Bortezomib (MPV) in elderly patients ≥ 75 years of age with newly diagnosed Multiple Myeloma; a nonrandomised phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000320-33,0,0,0 2013-000321-31,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Chiesi Farmaceutici S.p.A.,"A multi-center, un-controlled, open-labeled trial of the long-term safety of Velmanase Alfa aftercare treatment of subjects with alpha-Mannosidosis whom previously participated in Velmanase Alfa - tri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000321-31,0,0,0 2013-000322-66,17,2018-01-17,2018-01-17,13,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000322-66,0,0,0 2013-000322-66,17,2018-01-17,2018-01-17,13,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Farma SpA,"A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000322-66,0,0,0 2013-000322-66,17,2018-01-17,2018-01-17,13,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000322-66,0,0,0 2013-000324-34,1,2018-04-23,2018-04-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Limited,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Long-Term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000324-34,0,0,0 2013-000326-54,2,2022-06-24,2022-06-24,1,0,0,0,0,0,3,0,0,1,0,0,0,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000326-54,0,0,0 2013-000327-14,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Abteilung für Endokrinologie und Stoffwechsel","High dose intravenous iron in blood donors with iron deficiency: a randomized, controlled trial Intravenöse Hochdosis-Eisentherapie bei BlutspenderInnen mit Eisenmangel: eine randomisierte, kontrol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000327-14,0,0,0 2013-000330-35,1,2018-04-28,2018-04-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Graz,Effects of Linagliptin on endothelial function and global arginine bioavailability ratio in coronary artery disease patients with early diabetes Effekte von Linagliptin auf die Endothelfunktion und...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000330-35,0,0,0 2013-000334-36,1,2014-04-04,2014-04-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Sager Pharma Ltd.,"A randomised, multicentre, open-label, cross-over study to investigate the efficacy and safety of Keplat® and Flector® patch in patients with pain caused by Osteoarthritis of the knee Randomizált, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000334-36,0,0,0 2013-000336-97,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Zymenex A/S,"A multi-center, un-controlled, open-labeled trial of the long-term safety of Lamazym aftercare treatment of subjects with alpha-Mannosidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000336-97,0,0,0 2013-000336-97,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Chiesi Farmaceutici S.p.A.,"A multi-center, un-controlled, open-labeled trial of the long-term safety of Lamazym aftercare treatment of subjects with alpha-Mannosidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000336-97,0,0,0 2013-000337-13,2,2020-01-10,2020-01-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Universitätsklinikum Erlangen,"Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study Prediction of response to Certolizumab-Pegol in RA (PreC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000337-13,0,0,0 2013-000338-37,1,2016-06-22,2016-06-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Technische Universität München, vertreten durch das Klinikum rechts der Isar","Evaluation of the necessity of a pharmacological treatment with antipsychotics for the prevention of relapse in long-term stabilized schizophrenic patients: a randomized, single-blind, longitudinal tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000338-37,0,0,0 2013-000341-39,1,,,0,1,0,1,0,1,1,0,0,3,0,0,0,0,0,University of Birmingham,A Phase Ib Study of Eltrombopag and Azacitidine in Patients with High Risk Myelodysplastic Syndromes and Related Disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000341-39,0,0,0 2013-000342-19,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Roche Nederland B.V.,"MULTI-CENTER, OPEN LABEL, SINGLE ARM PHASE IIIB STUDY ON SAFETY AND EFFICACY OF SUBCUTANEOUS (SC) TOCILIZUMAB (TCZ) IN MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE (MTX) OR OTHER NON-BIOLOGIC DISEA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000342-19,0,0,0 2013-000343-11,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"Clinical Research Centre, Hvidovre University Hospital",Clinical trial with lozenges as local anesthesia for allogeneic bone marrow transplant patients with oral mucositis Klinisk forsøg med sugetabletter som lokal smertebehandling til allogen knoglema...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000343-11,0,0,0 2013-000344-25,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,Nerviano Medical Sciences S.r.l.,Phase II study of oral PHA-848125AC in patients with malignant thymoma previously treated with multiple lines of chemotherapy Studio di fase II di PHA-848125AC somministrato per via orale in pazien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000344-25,0,0,0 2013-000357-41,1,2015-03-18,2015-03-18,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"The Alimentary Pharmabiotic Centre, University College Cork",Identification of the Microbiota Dependent Response to Rifaximin in Irritable Bowel Syndrome Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000357-41,0,0,0 2013-000359-42,1,2016-07-11,2016-07-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE HELLAS S.A.,"Multicenter, open label, phase IIIb study to evaluate the safety and tolerability of subcutaneous tocilizumab as monotherapy and/or in combination with methotrexate or other non-biologic disease modif...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000359-42,0,0,0 2013-000361-36,1,2018-06-01,2018-06-01,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,Joint Research Office,"A phase IIa/b, randomised, double-blind, placebo-controlled, single-site, parallel group clinical trial to examine cannabidiol (CBD) as a pharmacological treatment for cannabis dependence in a young c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000361-36,0,0,0 2013-000364-28,1,2016-04-22,2016-04-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Profil Institut für Stoffwechselforschung GmbH,Effects of Linagliptin on active GLP-1 concentrations in subjects with renal impairment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000364-28,0,0,0 2013-000366-11,15,2016-05-17,2016-05-17,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Tillotts Pharma AG,"A Randomised Active-Controlled Double-Blind and Open Label Extension Study to Evaluate the Efficacy, Long-term Safety and Tolerability of TP05 3.2 g/day for the Treatment of Active Ulcerative Colitis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000366-11,0,0,0 2013-000370-30,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Norrlands University Hospital,Diagnosis and follow up of neuroendocrine tumours with 68Ga-DotaToc PET/CT Diagnostik och uppföljning av neuroendokrina tumörer med 68Ga-DotaToc PET/CT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000370-30,0,0,0 2013-000371-32,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Dermapharm AG,"Randomised, double-blind, vehicle controlled trial comparing Amphotericin B 100.000 I.E./g oral gel vs. Ampho-Moronal® suspension vs. modified vehicle to suspension in adult patients with oropharyngea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000371-32,0,0,0 2013-000372-15,1,2015-03-20,2015-03-20,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase III, randomized, open-label, multicentre clinical trial to assess the immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with GSK Biologicals’...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000372-15,0,0,0 2013-000373-76,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase III, randomized, double blind multicenter study, to evaluate consistency, immunogenicity, safety and reactogenicity of 3 lots of GSK Biologicals’ herpes zoster HZ/su candidate vaccine when adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000373-76,0,0,0 2013-000381-11,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Academisch Medisch Centrum,Paracetamol or NSAID's in acute musculoskeletal syndromes Paracetamol of NSAID's bij acute musculoskeletale syndromen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000381-11,0,0,0 2013-000383-28,2,2018-06-26,2018-06-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dexcel Pharma Technologies Ltd.,The Efficacy and Safety of Chlorhexidine Gluconate Chip (PerioChip®) in Therapy of Peri-implantitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000383-28,0,0,0 2013-000384-87,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Ghent University Hospital,"Intraperitoneal atomization of levobupivacaine during gynecological laparoscopic procedures : Impact on pain, opioid use and length of recovery room stay (IPLA).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000384-87,0,0,0 2013-000388-10,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,0,"AZIENDA ULSS N.9 - TREVISO, UOC PEDIATRIA",Oral steroids for reducing renal scarring in infants with febrile urinary tract infections at high risk for renal scar development: a randomized controlled trial Terapia steroidea orale per la pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000388-10,0,0,0 2013-000389-12,1,2016-06-30,2016-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cardiff University,ANti-psychotic Drug REduction in primary care for Adults with Learning Disabilities (ANDREA-LD): A Randomised Double-blind Placebo Controlled Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000389-12,0,0,0 2013-000390-70,7,2017-08-28,2017-08-28,5,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000390-70,1,0,0 2013-000393-30,1,2014-08-21,2014-08-21,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Oxford,"A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01B + ChAd63 and MVA encoding ME-TRAP and also RTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000393-30,0,0,0 2013-000395-15,1,2019-09-05,2019-09-05,1,1,0,0,1,0,3,0,0,1,1,1,1,0,0,Moorfields Eye Hospital NHS Foundation Trust,The use of bevacizumab as a modulator of wound healing following trabeculectomy surgery: A Single Centre Randomised Controlled Phase III Pilot Study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000395-15,0,0,0 2013-000397-30,1,2018-04-16,2018-04-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,King's College London,Minocycline in Alzheimer's disease efficacy trial:The MADE trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000397-30,0,0,0 2013-000397-30,1,2018-04-16,2018-04-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,South London and Maudsley NHS Foundation Trust,Minocycline in Alzheimer's disease efficacy trial:The MADE trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000397-30,0,0,0 2013-000400-42,1,2016-11-10,2016-11-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Zytoprotec GmbH,"Prospective, randomized, multi-center, double-blind, controlled, two-period, two-treatment, crossover, phase II trial to evaluate the safety and efficacy of PD-protec® in peritoneal dialysis in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000400-42,0,0,0 2013-000405-23,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Karolinska University Hospital,Susceptibility changes among oral microorganisms following single dose antibiotic prophylaxis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000405-23,0,0,0 2013-000407-16,4,2014-06-30,2014-06-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Convergence Pharmaceuticals Ltd,A randomised three week double-blind crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in the treatment of neuropathic pain in patients with diabetic peripheral...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000407-16,0,0,0 2013-000408-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU AMIENS,Evaluation de la cholangiographie par fluorescence au vert d'indocyanine versus bleu de méthylène dans la prévention des fuites biliaires post-opératoires après hépatectomie : étude prospective random...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000408-40,0,0,0 2013-000410-38,1,2014-07-28,2014-07-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharma A/S,Topical Aprepitant in Prurigo Patients (iTAPP) An exploratory phase IIa trial with topically applied aprepitant in patients with prurigo Topisches Aprepitant bei Patienten mit Prurigo (iTAPP) Ein...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000410-38,0,0,0 2013-000415-25,1,2014-09-30,2014-09-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Clinirx Tangent Research,"A randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Naproxen, Simvastatin and their combination, compared to placebo as add-on to anti-psychotics in the treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000415-25,0,0,0 2013-000416-24,1,2014-09-04,2014-09-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Charité-Universitätsmedizin Berlin, Department of Dermatology, Clinical Research Center for Hair and Skin Science",THE EFFECT OF AZELAIC ACID ON SYMPTOMS OF ACNE IN FEMALE PATIENTS AGE 20-45 WITH MILD TO MODERATE PAPULOPUSTULAR ACNE (ACNE TARDA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000416-24,0,0,0 2013-000418-39,6,2019-09-16,2019-09-16,1,0,0,0,1,0,3,0,0,2,1,0,0,0,0,FUNDACION DE INVESTIGACION EN RED EN ENFERMEDADES,Early Prevention of Diabetes Complications in people with Hyperglycaemia in Europe,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000418-39,1,0,0 2013-000418-39,6,2019-09-16,2019-09-16,1,0,0,0,1,0,3,0,0,2,1,0,0,0,0,FUNDACION DE INVESTIGACION EN RED EN ENFERMEDADES CARDIOVASCULARES (FIRCAVA),Early Prevention of Diabetes Complications in people with Hyperglycaemia in Europe,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000418-39,1,0,0 2013-000418-39,6,2019-09-16,2019-09-16,1,0,0,0,1,0,3,0,0,2,1,0,0,0,0,EVIDEM CONSULTORES SL (EVIDEM),Early Prevention of Diabetes Complications in people with Hyperglycaemia in Europe,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000418-39,1,0,0 2013-000420-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,sanofi-aventis France,"Etude de phase IV, de non infériorité, multicentrique, randomisée, en double aveugle, comparant la pristinamycine (2g x 2 par jour pendant 2 jours puis 1g x 3 par jour pendant 5 à 7 jours) à l’amoxici...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000420-34,0,0,0 2013-000421-31,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CHU d'Angers,Réversion préventive systématique versus réversion en cas d'hémorragie intracranienne chez les patients prenant un traitement antivitamine K et venant de subir un traumatisme cranien léger Réversio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000421-31,0,0,0 2013-000422-58,6,2022-01-10,2022-01-10,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA?) 300 mg in Patients with Papillary or Poorly Differentiated Thyr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000422-58,1,0,0 2013-000422-58,6,2022-01-10,2022-01-10,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Genzyme Corporation,"A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA?) 300 mg in Patients with Papillary or Poorly Differentiated Thyr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000422-58,1,0,0 2013-000423-14,5,2019-03-06,2019-03-06,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000423-14,0,0,0 2013-000426-62,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,0,Centre for Human Drug Research,"A randomized, double blind, placebo-controlled crossover study to investigate the effects of a selective serotonergic reuptake inhibitor on resting state fMRI in healthy volunteers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000426-62,0,0,0 2013-000432-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,DUTCH BELGIAN COOPERATIVE GROUP FOR HEMATOLOGY ONCOLOGY - HOVON,"A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF PROLONGED THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000432-10,0,0,0 2013-000434-35,2,2014-12-08,2015-01-08,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Amgen, Inc","A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate the Noninferiority of Romosozumab at a 90 mg/mL Concentration Compared With a 70 mg/mL Concentration in Postmenopausal Women With Ost...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000434-35,0,0,0 2013-000444-26,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Tedec-Meiji Farma, S.A.",Phase III clinical trial to evaluate the efficacy and safety of chondroitin sulphate and glucosamine sulphate in combination versus placebo in patients with osteoarthritis of the knee. Ensayo clíni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000444-26,0,0,0 2013-000445-39,2,2020-04-30,2020-04-30,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"GlaxoSmithKline, S.A.","A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malign...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000445-39,0,0,0 2013-000445-39,2,2020-04-30,2020-04-30,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,GlaxoSmithKline Research and Development Limited,"A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed, refractory hematologic malign...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000445-39,0,0,0 2013-000450-22,2,2021-02-22,2021-02-22,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,LYSARC,Sub-cutaneous Rituximab-miniCHOP versus Sub-cutaneous Rituximab-miniCHOP + lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for patients of 80 years old or more. A multicentric phase III st...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000450-22,0,0,0 2013-000452-18,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Cosmo Technologies Ltd.,Staining efficacy and safety of Methylene Blue enemas in patients undergoing flexible rectosigmoidoscopy Efficacia della colorazione e sicurezza di clisteri di blu di metilene in pazienti sottopost...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000452-18,0,0,0 2013-000453-44,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,3,,The full scope of oxytocinergic influences on the parental brain: Maternal defensiveness and grandparent-child interactions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000453-44,0,0,0 2013-000454-22,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,3,,"(Grand)parenting, oxytocin, and the oxytocin receptor gene: an fMRI and observational study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000454-22,0,0,0 2013-000456-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Hospital Maastricht,Plaque at risk (ParisK): Molecular imaging of plaque vulnerability using 18F-choline PET-CT and MRI in carotid artery atherosclerosis patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000456-17,0,0,0 2013-000458-23,1,2014-04-14,2014-04-14,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Niuvannniemi Hospital,Sodium benzoate for treatment of attenuated/transient psychosis. A randomized placebo-controlled trial Natriumbentsoaatti lievien psykoosioireiden hoidossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000458-23,0,0,0 2013-000464-29,2,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,"Astellas Pharma Global Development, Inc. (APGD)","A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000464-29,0,0,0 2013-000469-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hillerød Hospital,Peroral antibiotic treatment of endocarditis Peroral antibiotisk behandling av endocarditis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000469-35,0,0,0 2013-000472-16,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Fundación Interhospitalaria para la Investigación Cardiovascular,COMPARISON OF SWITCHING PRASUGREL OR TICAGRELOR IN ELDERLY PATIENTS WITH CORONARY ARTERY DISEASE ON CLOPIDOGREL THERAPY WITH HIGH PLATELET REACTIVITY: A RANDOMIZED PHARMACODYNAMIC STUDY EFECTOS DEL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000472-16,0,0,0 2013-000473-68,7,2015-01-28,2015-01-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Grünenthal GmbH,"Efficacy, safety and tolerability of multiple doses of oral cebranopadol in subjects with moderate to severe chronic pain due to diabetic peripheral neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000473-68,0,0,0 2013-000476-14,1,2014-12-10,2014-12-10,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,LANDSTINGET I ÖSTERGÖTLAND,TARGET-CONTROLLED INFUSION (TCI) WITH PROPOFOL AND REMIFENTANIL AS ANALGO-SEDATION IN WOUND CARE IN PATIENTS WITH BURNS MÅL-KONTROLLERAD INFUSION (TCI) MED PROPOFOL OCH REMIFENTANIL SOM ANALGO-SED...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000476-14,0,0,0 2013-000478-32,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Jose Ignacio Martin Gomez,Pilot randomised trial to assess the safety and potential efficacy of platelet rich plasma tenotomy for the treatment of chronic epicondylitis Estudio clínico piloto aleatorizado para valorar la se...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000478-32,0,0,0 2013-000482-36,1,2015-04-09,2015-04-09,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Lumena Pharmaceuticals, Inc.","A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTi), IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000482-36,0,0,0 2013-000483-29,1,2014-08-12,2014-08-12,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,Bispebjerg Hospital,The influence of exercise and hydration to the pharmacological response to inhaled terbutalin and salbutamol in men Betydningen af arbejde og hydreringsstatus for det farmakologiske respons af inha...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000483-29,0,0,0 2013-000485-11,1,2014-09-01,2014-09-01,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,University Hospitals of the KU Leuven,Xenon as an adjuvant to propofol anaesthesia in patients undergoing off-pump coronary artery bypass graft surgery: a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000485-11,0,0,0 2013-000486-37,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Clínic per a la Recerca Biomèdica,Rosuvastatin versus Protease Inhibitor Switching for Hypercholesterolaemia in HIV-infected Adults. Rosuvastatina versus sustitución del Inhibidor de la Proteasa en pacientes adultos con infección ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000486-37,0,0,0 2013-000487-28,10,2015-06-26,2015-06-26,7,0,0,0,0,0,2,0,0,2,0,0,0,0,1,STALLERGENES SA,A dose ranging study investigating the efficacy and safety of sublingual immunotherapy tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000487-28,1,0,0 2013-000488-95,4,2017-03-14,2017-03-14,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MEDICE Arzneimittel Pütter GmbH & Co. KG,Efficacy and tolerability of nicotinamide as add-on therapy compared to placebo in dialysis-dependent patients with hyperphosphatemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000488-95,0,0,0 2013-000490-79,8,2015-07-28,2017-12-04,5,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AB Science,"A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000490-79,1,0,0 2013-000491-14,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,AB Science,"A prospective, multicenter, open-label, centrally allocated, active-controlled, phase 2 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000491-14,0,0,0 2013-000491-14,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,AB SCIENCE,"A prospective, multicenter, open-label, centrally allocated, active-controlled, phase 2 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000491-14,0,0,0 2013-000492-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,T cell and interferon expression in tonsils after sublingual immunotherapy and/or nasal live attenuated influenza vaccine T-solu- ja interferoniekspressio nielurisoissa kielenalusimmunoterapian s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000492-32,0,0,0 2013-000493-30,4,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,AB Science,"A prospective, multicentre, open-label, randomized, active-controlled, 3 parallel groups, phase 2 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000493-30,0,0,0 2013-000494-67,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Klinik for håndkirurgi, Gentofte hospital","Needle fasciotomi vs collagenase for treatment of Dupuytrens contracture in 2nd, 3rd, 4th and 5th metacarpophalangeal joint. Nålefasciotomi vs collagenasebehandling af Dupuytrens kontraktur i 2., 3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000494-67,0,0,0 2013-000498-56,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMCG,1. Does supported faecal production accelerates the final diagnosis in children with acute abdominal pain? 2. Primary CMV and HHV-6 infection associated with the pathogenesis of acute appendicitis in ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000498-56,0,0,0 2013-000499-14,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation de l’efficacité de l’azithromycine dans la prévention du syndrome de bronchiolite oblitérante au décours de l’allogreffe de cellules souches hématopoïétiques (ALLOZITHRO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000499-14,0,0,0 2013-000501-22,1,2015-06-03,2015-06-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cardiff Univeristy,A national cancer research institute acute myeloid leukaemia working group pilot trial under the auspices of the cardiff experimental cancer medicine centre to establish the feasibility of combining t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000501-22,0,0,0 2013-000503-17,4,2017-03-30,2017-03-30,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Flexible Dosing of Brexpiprazole (OPC-34712) in the Treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000503-17,0,0,0 2013-000504-41,3,2017-03-15,2017-03-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole (OPC-34712) in the Treatment of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000504-41,0,0,0 2013-000506-37,6,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,0,University Hospital Ulm,"Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for patients with Waldenström's Macroglobulinemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000506-37,0,0,0 2013-000508-40,8,2018-03-07,2018-03-07,6,1,1,0,1,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000508-40,0,0,0 2013-000511-24,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD,Efficacy of short duration sequential therapy versus standard intravenous therapy for patients with uncomplicated catheter related bacteremia due to S. aureus methicillin-susceptible. EFICACIA DE ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000511-24,0,0,0 2013-000516-25,7,2018-07-18,2018-07-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Inc.,A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal Impairment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000516-25,0,0,0 2013-000517-20,3,,,0,1,0,0,0,1,2,0,0,2,0,0,0,0,1,"Clovis Oncology, Inc.","A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000517-20,0,0,0 2013-000518-39,6,2022-07-07,2022-07-07,3,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Clovis Oncology, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000518-39,1,0,0 2013-000521-31,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Gerencia de Atención Primaria de Mallorca,"Efficacy and safety of gabapentin versus placebo to prevent the incidence of PostHerpetic Neuralgia Ensayo clínico, aleatorizado, doble-ciego para evaluar la eficacia y seguridad de la gabapentina ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000521-31,0,0,0 2013-000522-58,1,2016-07-29,2016-07-29,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Klinikum der Universität München,"A randomized, double blind, phase II trial of pazopanib versus placebo as maintenance therapy in patients with retroperitoneal and visceral high-risk soft tissue sarcomas following prior- and/or adjuv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000522-58,0,0,0 2013-000525-31,8,2014-11-19,2014-11-19,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000525-31,0,0,0 2013-000529-30,1,2015-03-04,2015-03-04,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,Walton Centre Foundation Trust,A pilot study to assess efficacy of prolonged-Release oral fampridine on ambulation and visual function in Neuromyelitis Optica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000529-30,0,0,0 2013-000531-27,9,2022-05-21,2022-08-15,2,0,0,0,0,1,0,0,0,2,1,0,0,0,0,UNIVERSITY MEDICAL CENTER UTRECHT,"Corticosteroids or clobazam for ESES syndrome: a European, multicenter, randomized, controlled clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000531-27,1,0,0 2013-000531-27,9,2022-05-21,2022-08-15,2,0,0,0,0,1,0,0,0,2,1,0,0,0,0,University Medical Center Utrecht,"Corticosteroids or clobazam for ESES syndrome: a European, multicenter, randomized, controlled clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000531-27,1,0,0 2013-000531-27,9,2022-05-21,2022-08-15,2,0,0,0,0,1,0,0,0,2,1,0,0,0,0,University Medical Centre Utrecht,"Corticosteroids or clobazam for ESES syndrome: a European, multicenter, randomized, controlled clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000531-27,1,0,0 2013-000533-12,2,2016-02-16,2016-02-16,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Camurus AB,"A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Two Patient Groups with Acromegaly and Neuroendocrine Tumours (NET) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000533-12,0,0,0 2013-000534-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Castellano Leonesa de Hematología y Hemoterapia (FUCALHH),Phase II clinical trial in the treatment of cytopenias allogeneic post-transplant with a sequential infusion of allogeneic mesenchymal cells expanded in vitro. ENSAYO CLÍNICO EN FASE II DE TRATAMIE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000534-35,0,0,0 2013-000536-10,12,2017-03-14,2017-03-14,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Amgen Inc.,"A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000536-10,0,0,0 2013-000537-12,4,2015-03-18,2015-03-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Phase 3, Multicenter, randomized, double-blind study evaluating the efficacy and safety of ABP 501 compared with Adalimumab in subjects with moderate to severe plaque psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000537-12,0,0,0 2013-000540-26,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,CVie Therapeutics Company Limited,"The clinical study of the safety and efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure - A multicenter, randomized, double-blind, placebo controlled, parallel group clinical stu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000540-26,0,0,0 2013-000542-19,2,2013-12-27,2013-12-27,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Takeda Development Centre Europe Ltd.,"A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Sitagliptin 100 mg When Used in Combina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000542-19,0,0,0 2013-000542-19,2,2013-12-27,2013-12-27,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Takeda Development Centre (Europe) Ltd.,"A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Sitagliptin 100 mg When Used in Combina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000542-19,0,0,0 2013-000544-26,1,2016-01-21,2016-01-21,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,Galderma R&D,Determination of antifungal activity of Loceryl® Nail Lacquer 5% when used concomitantly with a cosmetic nail varnish compared to a Loceryl® Nail Lacquer 5% alone in treatment of toenail Distal Subung...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000544-26,0,0,0 2013-000545-39,1,2013-08-20,2013-08-20,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine (Agrippal®) in Healthy Adult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000545-39,0,0,0 2013-000547-85,1,2015-10-28,2015-10-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Fundació Lluita contra la SIDA,MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM PROTEASE INHIBITORS TO DOLUTEGRAVIR IN HIV-1-INFECTED SUBJECTS WITH LOW BONE MINERAL DENSITY ENSAYO CLÍNICO MULTICÉNTR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000547-85,0,0,0 2013-000548-25,4,2016-11-24,2016-11-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pharma Mar S.A. Sociedad Unipersonal,A Randomized-Controlled Three-arm Phase II Study of Lurbinectedin (PM01183) Alone or In Combination with Gemcitabine and a control arm with Docetaxel as Second-Line Treatment in Unresectable Non-Small...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000548-25,0,0,0 2013-000551-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,Towards patient tailored cancer treatment supported by molecular imaging IMPACT: IMaging PAtients for Cancer drug selecTion – Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000551-41,0,0,0 2013-000552-18,2,2015-06-02,2015-06-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bausch & Lomb Incorporated,"A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X 0.024% (Latanoprostene Bunod) Ophthalmic Solution With Timolol Maleate Ophthalmic Solut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000552-18,0,0,0 2013-000553-45,3,2014-11-26,2014-11-26,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bausch & Lomb Incorporated,"A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X 0.024% (Latanoprostene Bunod) Ophthalmic Solution With Timolol Maleate Ophthalmic Solut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000553-45,0,0,0 2013-000556-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Parc Taulí,Randomized clinical trial to compare the control of postoperative pain in laparoscopic sigmoidectomy by administering local anesthetic epidural catheter analgesia with intravenous morphine patient-con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000556-17,0,0,0 2013-000559-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospitals Leuven,Plasma protein binding characteristics of voriconazole in specific subsets of patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000559-42,0,0,0 2013-000560-28,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Oslo University Hospital,PHASE I/II TRIAL OF MOC31PE IMMUNOTOXIN IN PERITONEAL CARCINOMATOSIS FROM COLORECTAL CARCINOMA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000560-28,0,0,0 2013-000563-81,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA,Metformin treatment of minimal hepatic encephalopathy in patients with liver cirrhosis Tratamiento con metformina de la encefalopatía hepática mínima en pacientes con cirrosis hepática,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000563-81,0,0,0 2013-000564-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Sahlgrenska University Hospital,The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000564-29,0,0,0 2013-000568-28,10,2017-03-13,2017-03-13,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A PHASE II RANDOMIZED, DOUBLE-BLIND STUDY OF NEOADJUVANT LETROZOLE PLUS GDC-0032 VERSUS LETROZOLE PLUS PLACEBO IN POSTMENOPAUSAL WOMEN WITH ER-POSITIVE/HER2-NEGATIVE, EARLY STAGE BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000568-28,0,0,0 2013-000568-28,10,2017-03-13,2017-03-13,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farma S.A en nombre de Genentech, Inc.","A PHASE II RANDOMIZED, DOUBLE-BLIND STUDY OF NEOADJUVANT LETROZOLE PLUS GDC-0032 VERSUS LETROZOLE PLUS PLACEBO IN POSTMENOPAUSAL WOMEN WITH ER-POSITIVE/HER2-NEGATIVE, EARLY STAGE BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000568-28,0,0,0 2013-000572-15,2,2014-04-30,2014-04-30,1,0,0,0,0,0,4,0,0,2,0,0,0,0,1,"GlaxoSmithKline, S.A.",Investigation of immune mechanisms relating to lapatinib associated hepatotoxicity: ex vivo T cell biology investigation relating to lapatinib induced liver adverse events using PBMCs from patients se...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000572-15,1,0,0 2013-000572-15,2,2014-04-30,2014-04-30,1,0,0,0,0,0,4,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,Investigation of immune mechanisms relating to lapatinib associated hepatotoxicity: ex vivo T cell biology investigation relating to lapatinib induced liver adverse events using PBMCs from patients se...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000572-15,1,0,0 2013-000574-30,2,2015-09-01,2015-09-01,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Vifor (International) Inc.,"A Randomised, Assessor- and Patient-blind, Multicentre, Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration of Ferric Carboxymaltose in Improving Outcomes in Iron Def...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000574-30,0,0,0 2013-000577-77,3,2020-03-31,2020-03-31,1,1,0,0,0,0,3,0,0,2,0,0,0,0,0,University of Cologne,EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION ACRONYM: SABATO (Staphylococcus aureus Bacteremia Antibiotic Treatment Options),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000577-77,1,0,0 2013-000577-77,3,2020-03-31,2020-03-31,1,1,0,0,0,0,3,0,0,2,0,0,0,0,0,University of Düsseldorf,EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION ACRONYM: SABATO (Staphylococcus aureus Bacteremia Antibiotic Treatment Options),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000577-77,1,0,0 2013-000580-93,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Fondazione IRCCS Istituto Nazionale Tumori,"Multidisciplinary approach for poor prognosis sinonasal tumors: Phase II study of chemotherapy, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in inoperable ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000580-93,0,0,0 2013-000581-10,1,2018-06-14,2018-06-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Nottingham University NHS Trust,Evaluation of inflammatory markers in patients on topical anti-glaucoma drop therapy; a comparative trial of preserved and non-preserved primary medical treatment (eye drops) in patients with glaucoma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000581-10,0,0,0 2013-000582-36,8,2014-05-13,2014-05-13,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Biota Scientific Management Pty Ltd.,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Investigate the Efficacy and Safety of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults with Symptomat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000582-36,0,0,0 2013-000583-29,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Universitair Ziekenhuis Brussel,Corifollitropin alfa followed by hp-HMG versus recombinant FSH in young poor ovarian responders. A multicentre randomized controlled clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000583-29,0,0,0 2013-000586-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Miquel Pujol Rojo (Infectious Diseases Service-Hospital Universitari de Bellvitge-IDIBELL),Randomized multicenter study to assess efficacy of Daptomycin plus Fosfomycin versus Daptomycin monotherapy for treatment of methicillin resistant Staphylococcus aureus bacteremia in hospitalized pati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000586-37,0,0,0 2013-000594-69,6,2015-10-08,2016-01-15,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Biogen Idec Research Limited,"A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects with Lupus Nephritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000594-69,0,0,0 2013-000601-23,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine (Fluvirin®) in Healthy Adul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000601-23,0,0,0 2013-000603-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Utrecht,HYPerbaric OXygen therapy for benign anastomotIC esophageal strictures: a pilot study Hyperbare zuurstof therapie voor benigne esophageal anastomosen: een pilot studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000603-16,0,0,0 2013-000604-41,11,2016-04-07,2016-04-21,9,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000604-41,0,0,0 2013-000607-16,1,2013-08-20,2013-08-20,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine Including MF59C.1 Adjuvant (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000607-16,0,0,0 2013-000614-38,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Dr. Willmar Schwabe GmbH & Co. KG,"Monocenter, prospective, randomized placebo-controlled, double blind phase II trial to evaluate protective effects of Gingko biloba extract EGb 761® on temporary hearing damage caused by noise. Mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000614-38,0,0,0 2013-000615-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Cliniques universitaires Saint-Luc,"Tacrolimus disposition in pediatric transplantation: influence of age, genetic polymorphisms, intestinal and hepatic relative contribution on pharmacokinetics, in relationship with clinical outcomes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000615-24,0,0,0 2013-000617-20,1,2014-05-09,2014-05-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lofarma S.p.A.,"A Dose Finding Study of the Efficacy of LAIS® Mites Sublingual tablets in patients suffering from house dust mite-induced allergic rhinoconjunctivitis A prospective, double-blind, placebo-controlled r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000617-20,0,0,0 2013-000619-26,13,2016-11-04,2016-11-04,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000619-26,0,0,0 2013-000619-26,13,2016-11-04,2016-11-04,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000619-26,0,0,0 2013-000619-26,13,2016-11-04,2016-11-04,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000619-26,0,0,0 2013-000620-34,4,2014-03-14,2014-03-14,3,1,1,0,0,0,1,0,0,2,1,0,0,0,1,LFB Biotechnologies,"A Multicentre Phase III Study on the Efficacy, Safety and Pharmacokinetics of LFB-IgSC in Patients with Primary Immunodeficiency (PID) Syndromes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000620-34,1,0,0 2013-000621-30,1,2013-09-08,2013-09-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Vaccines and Diagnostics GmbH,"A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine Produced in Mammalian Cell ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000621-30,0,0,0 2013-000622-55,4,2014-06-04,2014-06-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients with Primary Hypercholesterolemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000622-55,0,0,0 2013-000626-63,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000626-63,0,0,0 2013-000626-63,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Gilead Sciences Inc,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000626-63,0,0,0 2013-000629-30,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Department of surgery, Herlev Hospital","The sun protective effect of melatonin: a randomized, placebo-controlled, double-blinded study on healthy volunteers. Melatonins solbeskyttende effekt: et randomiseret, dobbeltblindet, placebokontr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000629-30,0,0,0 2013-000630-35,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Alder Hey Children's NHS Foundation Trust,Pilot study on use of Sulphur hexafluoride Microbubbles (SonoVue®) as a Magnetic Resonance Imaging contrast agent in the imaging of brain tumours.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000630-35,0,0,0 2013-000631-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,PhaRmacodynamic Effect of antiplatelet agents in elderly patients: Standard clopidogrel versus prasugrEl low dose Therapy. Effetto farmacodinamico degli antiaggreganti nei pazienti anziani: terapi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000631-27,0,0,0 2013-000632-94,2,2015-05-08,2015-05-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000632-94,0,0,0 2013-000634-35,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Cosmo Technologies Ltd.,Effect of oral administration of Methylene Blue MMX® tablets on double-stranded DNA damage assessed by γH2AX analysis of colon biopsy samples Effetto della somministrazione orale di Methylene Blu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000634-35,0,0,0 2013-000636-10,6,2022-10-13,2022-10-13,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Gilead Sciences Inc,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000636-10,1,0,0 2013-000636-10,6,2022-10-13,2022-10-13,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000636-10,1,0,0 2013-000639-29,1,2017-02-20,2017-02-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ABCSG (Austrian Breast & Colorectal Cancer Study Group),"A prospective, open, randomized, academic phase II, two-arm trial evaluating the effect of fibrin-coated collagen (TachoSil®) on postoperative pancreatic leakage and fistula formation from the pancrea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000639-29,0,0,0 2013-000642-20,4,2017-01-25,2017-01-25,4,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects with Acute Myelogenou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000642-20,0,0,0 2013-000642-20,4,2017-01-25,2017-01-25,4,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects with Acute Myelogenou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000642-20,0,0,0 2013-000643-40,1,2017-06-05,2017-06-05,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Instituto de Medicina Molecular,"A multicentre, randomized, double-blind, parallel–group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy, in improving dactylitis and enthesitis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000643-40,0,0,0 2013-000647-12,1,2019-05-28,2019-05-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE S.p.A.,"A single arm, multicentre, phase IIIb study to evaluate safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab administered during induction phase or maintenance in previously untr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000647-12,0,0,0 2013-000652-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hopital Erasme,Pharmacokinetics study of piperacillin-tazobactam and meropenem in obese patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000652-18,0,0,0 2013-000653-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jules Bordet Institute,Feasibility study of the (intravenously injected) ICG imaging of tumoral implants in patients with peritoneal carcinomatosis from colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000653-42,0,0,0 2013-000654-22,1,2015-02-26,2015-02-26,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Dermapharm AG,"Randomised, double-blind, double-dummy, vehicle controlled parallel trial comparing a novel mometasone furoate nasal spray vs. Nasonex® nasal spray vs. vehicle nasal spray in patients with allergic rh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000654-22,0,0,0 2013-000657-50,17,2015-12-08,2015-12-14,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197) S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000657-50,0,0,0 2013-000657-50,17,2015-12-08,2015-12-14,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.",A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197) S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000657-50,0,0,0 2013-000663-83,1,2013-11-29,2013-11-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,The effect of Adductor-Channel Blockade with high pain responders after reconstruction of the anterior cruciate ligament Effekten af Adductor-Kanal-Blokade (AKB) hos high pain responders efter reko...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000663-83,0,0,0 2013-000665-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZ Brussel,"A phase II, open label study of everolimus with fulvestrant in postmenopausal women with hormone receptor-positive HER-2 negative AI and fulvestrant treated, locally advanced or metastatic breast canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000665-36,0,0,0 2013-000672-15,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,1,"Onconova Therapeutics, Inc.","A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000672-15,0,0,0 2013-000674-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AOU SAN LUIGI GONZAGA - SCDU ONCOLOGIA MEDICA,"Multicenter clinical trial, randomized phase II ""window of opportunity"" which aims to test the biological activity of abiraterone acetate administered as neoadjuvant therapy in patients with prostate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000674-30,0,0,0 2013-000684-85,11,2021-10-26,2021-11-26,7,0,0,0,0,0,3,0,0,2,0,0,0,0,2,TESARO Inc.,"A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000684-85,1,0,0 2013-000684-85,11,2021-10-26,2021-11-26,7,0,0,0,0,0,3,0,0,2,0,0,0,0,2,"TESARO UK Limited, (c/o Sisec Limited)","A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000684-85,1,0,0 2013-000684-85,11,2021-10-26,2021-11-26,7,0,0,0,0,0,3,0,0,2,0,0,0,0,2,TESARO Inc,"A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician's choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000684-85,1,0,0 2013-000685-11,10,2021-12-26,2021-12-26,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,TESARO Inc.,A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000685-11,1,0,0 2013-000686-37,3,2018-06-06,2018-06-06,3,0,0,1,0,0,1,0,0,1,0,0,0,0,1,"Tesaro, Inc.","A Phase 1/2a, Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients with Advanced Solid Tumors and Lymphomas",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000686-37,0,0,0 2013-000691-15,11,2020-04-30,2020-06-05,9,1,0,0,0,1,0,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000691-15,0,0,0 2013-000698-57,5,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Medivation, Inc.","A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple-Negative Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000698-57,0,0,0 2013-000699-14,2,2016-12-23,2016-12-23,1,1,0,1,0,1,1,0,0,1,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase Ib/II, open-label, multicenter study of INC280 in combination with buparlisib in adult patients with recurrent glioblastoma Fase Ib/II open label multicenter onderzoek met INC280 in combina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000699-14,0,0,0 2013-000699-14,2,2016-12-23,2016-12-23,1,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Novartis Pharma Services AG,"A Phase Ib/II, open-label, multicenter study of INC280 in combination with buparlisib in adult patients with recurrent glioblastoma Fase Ib/II open label multicenter onderzoek met INC280 in combina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000699-14,0,0,0 2013-000702-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,TAYS Sydänkeskus Oy,Postoperatiivisen deksmedetomidiinisedaation vaikutukset hemodynamiikkaan ekstubaation yhteydessä Postoperatiivisen deksmedetomidiinisedaation vaikutukset hemodynamiikkaan ekstubaation yhteydessä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000702-31,0,0,0 2013-000705-23,6,2016-01-06,2016-01-06,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, multicenter, parallel group, dose-finding, pivotal, phase IIb/III study to evaluate the efficacy, safety and tolerability of intravenous BYM338 at 52 we...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000705-23,0,0,0 2013-000705-23,6,2016-01-06,2016-01-06,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Farma SpA,"A randomized, double-blind, placebo-controlled, multicenter, parallel group, dose-finding, pivotal, phase IIb/III study to evaluate the efficacy, safety and tolerability of intravenous BYM338 at 52 we...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000705-23,0,0,0 2013-000706-36,3,2017-01-06,2017-01-06,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE® Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000706-36,0,0,0 2013-000711-24,1,2016-05-24,2016-05-24,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Søren Rittig,The effect of combining anticholinergic treatment and transcutaneous electrical nerve stimulation in children suffering from daytime urinary incontinence and an overactive bladder.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000711-24,0,0,0 2013-000715-25,1,2013-11-26,2013-11-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MEDICE Arzneimittel Pütter GmbH & Co.KG,"A multi-center, randomized, double-blind, phase II trial with intraindividual comparison to assess superiority of Soventol HydroCort 1% cream versus vehicle on lesional skin in patients with mild atop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000715-25,0,0,0 2013-000716-21,1,2015-03-18,2015-03-18,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Apeptico Forschung und Entwicklung GmbH,Pilot study to investigate the clinical effect of orally inhaled AP301 on treatment of primary graft dysfunction (PGD) in mechanically ventilated patients after primary lung transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000716-21,0,0,0 2013-000717-20,19,2020-05-28,2020-05-28,14,1,1,0,0,0,3,0,0,2,1,0,0,0,1,UCB Biosciences Inc.,"A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WITH EPILEPSY >=1 MONTH TO <4 Y...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000717-20,1,1,0 2013-000719-26,1,2015-10-29,2015-10-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,e-Therapeutics plc,"A single centre, double blind, non-inferiority study to evaluate the antidepressant activity of Viotra™ compared with amitriptyline in the treatment of major depressive disorder (MDD) in patients who ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000719-26,0,0,0 2013-000721-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU DE POITIERS,Comparison of neuromuscular blockade’s monitoring and clinical assessment during cisatracurium paralysis in critically ill patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000721-31,0,0,0 2013-000722-54,9,2022-08-31,2022-08-31,5,1,0,0,0,0,4,0,0,2,0,0,0,0,1,"Medivation, Inc.","A Phase 4, Randomized, Double Blind, Placebo Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000722-54,1,0,0 2013-000722-54,9,2022-08-31,2022-08-31,5,1,0,0,0,0,4,0,0,2,0,0,0,0,1,"Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.","A Phase 4, Randomized, Double Blind, Placebo Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000722-54,1,0,0 2013-000723-14,1,2017-12-06,2017-12-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,"A Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000723-14,0,0,0 2013-000726-66,8,2021-07-12,2021-07-12,5,0,0,0,0,2,3,0,0,2,0,0,0,0,0,Grupo Español de Tumores Neuroendocrinos (GETNE),"Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by evero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000726-66,1,0,0 2013-000727-13,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Amgen Inc,"Single arm, Companion Study to Myelodysplastic Syndrome (MDS) 20090160 Using Darbepoetin alfa for the Treatment of Anaemic Subjects With Myelodysplastic Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000727-13,0,0,0 2013-000734-35,2,2020-07-09,2020-07-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,LYSARC,Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and FDG-PET positivity after 2 cycles of ABVD Brentuximab vedotin en traitement de consolidation chez d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000734-35,0,0,0 2013-000737-12,1,2015-06-08,2015-06-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lallemand Pharma International AG,"The Influence of Polyvalent Mechanical Bacterial Lysate (ISMIGEN®) on Clinical Course of Asthma and Related Immunological parameters in Asthmatic Children (EOLIA Study): Randomized, Double Blind, Plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000737-12,0,0,0 2013-000738-36,9,2015-06-23,2015-07-23,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,"A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety OF ABP 215 Compared with Bevacizumab in Subjects with Advanced Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000738-36,0,0,0 2013-000743-33,4,2014-07-15,2014-07-15,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Shire Development LLC and International Affiliates,"A 48-week, Open-label, 2-arm, Parallel-group, Randomized Exploratory Study to Assess Liver Iron Concentration Measured by FerriScan® (R2) Magnetic Resonance Imaging in β-thalassemia Subjects Administe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000743-33,0,0,0 2013-000744-26,8,2017-03-30,2017-03-30,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"Phase II multicenter randomized, double blind, placebo controlled study assessing the efficacy of buparlisib (BKM120) plus paclitaxel vs. placebo plus paclitaxel in patients with platinum pre-treated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000744-26,0,0,0 2013-000744-26,8,2017-03-30,2017-03-30,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farma S.p.A.,"Phase II multicenter randomized, double blind, placebo controlled study assessing the efficacy of buparlisib (BKM120) plus paclitaxel vs. placebo plus paclitaxel in patients with platinum pre-treated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000744-26,0,0,0 2013-000744-26,8,2017-03-30,2017-03-30,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","Phase II multicenter randomized, double blind, placebo controlled study assessing the efficacy of buparlisib (BKM120) plus paclitaxel vs. placebo plus paclitaxel in patients with platinum pre-treated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000744-26,0,0,0 2013-000747-11,3,2016-02-25,2016-02-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Hexal AG,"A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar adalimumab (GP2017) and Humira® in patients with moderate to s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000747-11,0,0,0 2013-000750-21,1,2017-05-17,2017-05-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University College London,"The HALT-LTBI study: Phase IV, multi-site, unblinded, randomised trial of prophylactic daily rifampicin/isoniazid vs. weekly rifapentine/isoniazid for latent tuberculosis infection (LTBI)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000750-21,0,0,0 2013-000752-18,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Janssen-Cilag International N.V.,"An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Protea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000752-18,0,0,0 2013-000759-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fondazione Toscana Gabriele Monasterio,"A prospective, open-label, single center, cross-over, controlled, randomized, phase III study to test superiority of the oral solution of synthetic thyroxine compared to tablet preparation for treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000759-41,0,0,0 2013-000762-11,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxorubic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000762-11,0,0,0 2013-000766-11,1,2017-01-17,2017-01-17,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU Toulouse,"Etude pilote, prospective, multicentrique, randomisée, en ouvert, comparant deux protocoles d’immunosuppression utilisant en traitement d’induction : soit un anticorps monoclonal antirécepteur de l’In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000766-11,0,0,0 2013-000768-27,13,2017-10-03,2019-02-15,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000768-27,0,0,0 2013-000768-27,13,2017-10-03,2019-02-15,13,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Bayer AG,"Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000768-27,0,0,0 2013-000770-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS ISTITUTO SCIENTIFICO ROMAGNOLO PER LO,Phase II study of up-front chemotherapy and neo-adjuvant short-course radiotherapy for resectable rectal carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000770-30,0,0,0 2013-000771-33,1,2018-12-22,2018-12-22,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,LYSARC,BIBLOS (BTK Inhibition in B-cell LymphOmaS) BIBLOS (inhibition BTK dans les lymphomes à cellules B),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000771-33,0,0,0 2013-000773-71,1,2015-02-20,2015-02-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Department of Oncology, Aarhus University Hospital",A multicenter phase II study evaluating the efficacy and tolerability of vemurafenib in combination with Pegylated Interferon and Interleukin-2 in patients with BRAF-mutated metastatic melanoma Et ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000773-71,0,0,0 2013-000774-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amphia Hospital,The effect on blood loss with combined topical and intravenous tranexamic acid in cardiac surgery patients: a randomized double-blind placebo-controlled trial Het effect van de combinatie lokale en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000774-30,0,0,0 2013-000775-32,9,2015-07-01,2018-06-12,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi Pasteur Inc,"Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000775-32,0,0,0 2013-000778-31,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,"CLINICA DERMATOLOGICA POLICLINICO UMBERTO I ""SAPIENZA""",Role of Vitamin D in maintaining the integrity of epidermal barrier in psoriatic skin Ruolo della Vitamina D nel mantenimento dell'integrità della barriera epidermica nella cute psoriasica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000778-31,0,0,0 2013-000782-36,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Ghent University Hospital,Effect of TachoSil® on incidence of symptomatic and radiographic lymphoceles after extended pelvic lymph node dissection in prostate and bladder cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000782-36,0,0,0 2013-000783-29,2,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"ViiV Healthcare, S.L.",A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral regim...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000783-29,0,0,0 2013-000783-29,2,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,ViiV Healthcare UK Limited,A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral regim...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000783-29,0,0,0 2013-000788-98,1,2014-07-25,2014-07-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Double-blind, Placebo-controlled Phase IIa Study to Assess the Pharmacodynamics, Safety, and Pharmacokinetics of AZD4901 When Given in Multiple Doses to Females with Polycystic Ovary Syn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000788-98,0,0,0 2013-000789-13,2,2016-01-31,2016-01-31,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,VU University Medical Center,"DALI: Vitamin D And Lifestyle Intervention for Gestational Diabetes Mellitus (GDM) Prevention - A European multicentre, randomised trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000789-13,0,0,0 2013-000791-15,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,CHU de Saint-Etienne,Evaluation of postoperative administration of tranexamic acid on reducing blood loss after hip prothesis surgery. Evaluation de l’administration post-opératoire d’acide tranexamique sur la réducti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000791-15,0,0,0 2013-000793-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oslo University Hospital - Rikshospitalet,The PedTac study Development of a pediatric pharmacokinetic population model for Tacrolimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000793-30,0,0,0 2013-000795-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZ Brussel,An open-label pilot clinical trial of MAGE-A3 and MAGE-C1 mRNA electroporated autologous dendritic cell vaccination in combination with lenalidomide maintenance therapy for multiple myeloma after firs...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000795-15,0,0,0 2013-000796-32,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Policlinico A. Gemelli,"A multiple centre, randomised, open label, prospective clinical study to compare the efficacy and safety of a combination of tacrolimus with everolimus versus the combination of tacrolimus with MMF, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000796-32,0,0,0 2013-000797-30,1,2017-03-26,2017-03-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Department of Medical Research, Odense University Hospital, Svendborg Hospital",Inhibition of aldosterone to diminish diffuse myocardial fibrosis in atrial fibrillation Hæmning af aldosteron for reduktion af diffus fibrose i myokardiet hos patienter med aftrieflimren,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000797-30,0,0,0 2013-000798-59,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novalon S.A,"Phase III, open-label, multi-centre study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 3.6 mg goserelin subcutaneous implant (Novalon) in women with confirmed endome...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000798-59,0,0,0 2013-000799-14,2,2016-05-03,2016-05-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novalon S. A.,"Phase III, open-label, multi-center study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 10.8 mg goserelin subcutaneous implant (Novalon) in male patients with prostat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000799-14,0,0,0 2013-000801-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Academic Medical Center,Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: alternative versus standard stimulation protocols; the STIM-trial De effectiviteit van hormoonstimulatie vo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000801-21,0,0,0 2013-000808-41,8,2015-02-04,2015-03-20,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Randomized, double-blind, double-dummy, active-controlled, 4 period complete cross-over study to compare the effect on lung function of 6 weeks once daily treatment with orally inhaled tiotropium+olod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000808-41,0,0,0 2013-000808-41,8,2015-02-04,2015-03-20,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH&Co KG,"Randomized, double-blind, double-dummy, active-controlled, 4 period complete cross-over study to compare the effect on lung function of 6 weeks once daily treatment with orally inhaled tiotropium+olod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000808-41,0,0,0 2013-000808-41,8,2015-02-04,2015-03-20,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm. V,"Randomized, double-blind, double-dummy, active-controlled, 4 period complete cross-over study to compare the effect on lung function of 6 weeks once daily treatment with orally inhaled tiotropium+olod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000808-41,0,0,0 2013-000808-41,8,2015-02-04,2015-03-20,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"Randomized, double-blind, double-dummy, active-controlled, 4 period complete cross-over study to compare the effect on lung function of 6 weeks once daily treatment with orally inhaled tiotropium+olod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000808-41,0,0,0 2013-000808-41,8,2015-02-04,2015-03-20,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","Randomized, double-blind, double-dummy, active-controlled, 4 period complete cross-over study to compare the effect on lung function of 6 weeks once daily treatment with orally inhaled tiotropium+olod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000808-41,0,0,0 2013-000808-41,8,2015-02-04,2015-03-20,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"Randomized, double-blind, double-dummy, active-controlled, 4 period complete cross-over study to compare the effect on lung function of 6 weeks once daily treatment with orally inhaled tiotropium+olod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000808-41,0,0,0 2013-000808-41,8,2015-02-04,2015-03-20,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Danmark A/S,"Randomized, double-blind, double-dummy, active-controlled, 4 period complete cross-over study to compare the effect on lung function of 6 weeks once daily treatment with orally inhaled tiotropium+olod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000808-41,0,0,0 2013-000809-23,6,2020-12-14,2020-12-14,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AB Science,"A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo in c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000809-23,1,0,0 2013-000809-23,6,2020-12-14,2020-12-14,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AB SCIENCE,"A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo in c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000809-23,1,0,0 2013-000815-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital,THE OSLO STUDY OF CLONIDINE IN ELDERLY PATIENTS WITH DELIRIUM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000815-26,0,0,0 2013-000819-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,Autologous BM derived MSCs in combination with everolimus to preserve renal structure and function in renal recipients Autologe therapie met mesenchymale stromale cellen verkregen uit het beemnerg ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000819-25,0,0,0 2013-000821-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Enrique Rey Díaz-Rubio,CLINICAL RESPONSE TO 5HT4 RECEPTORS AGONIST (PRUCALOPRIDE): GASTROCOLIC REFLEX ESTUDIO DEL REFLEJO GASTROCOLICO: INFLUENCIA DE PRUCALOPRIDA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000821-30,0,0,0 2013-000823-15,1,2018-07-31,2018-07-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Charité – Universitätsmedizin Berlin,Neuroprotection with Dexmedetomidine in patients undergoing elective cardiac or abdominal surgery Neuroprotektion durch Dexmedetomidin bei Patienten mit kardio- oder abdominalchirurgischen Eingriff...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000823-15,0,0,0 2013-000827-15,1,2015-02-17,2015-02-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, Tricase",LATE ONSET PARKINSON’S DISEASE IN SUBJECTS 70 YEARS AND OLDER: POSSIBLE USE OF ROTIGOTINE Insorgenza tardiva della malattia di Parkinson in pazienti con più di 70 anni di età: possibile utilizzo di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000827-15,0,0,0 2013-000829-31,1,2018-09-14,2018-09-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche Nederland B.V.,"A LOCAL, OPEN LABEL, MULTICENTRE, PHASE IIIB STUDY, INVESTIGATING SUBCUTANEOUS TRASTUZUMAB ADMINISTERED AT HOME WITH SINGLE INJECTION DEVICE IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000829-31,0,0,0 2013-000830-37,8,2018-06-11,2018-11-19,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,OPKO Biologics Ltd.,"A Phase 3, Multicenter Study Designed to Evaluate the Efficacy and Safety of a Long Acting hGH Product (MOD-4023) in Adult Subjects with Growth Hormone Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000830-37,0,0,0 2013-000830-37,8,2018-06-11,2018-11-19,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,PROLOR Biotech Ltd.,"A Phase 3, Multicenter Study Designed to Evaluate the Efficacy and Safety of a Long Acting hGH Product (MOD-4023) in Adult Subjects with Growth Hormone Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000830-37,0,0,0 2013-000832-85,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Fondazione Salvatore Maugeri, IRCCS",INTRAMUSCULAR CLODRONATE 200 MG IN THE THERAPY OF HANDS IN PHASE ALGIC OSTEOARTHROSIS - A 6 MONTHS PILOT OPEN STUDY. CLODRONATO INTRAMUSCOLARE 200 MG NELLA TERAPIA DELLA OSTEOARTROSI DELLE MANI IN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000832-85,0,0,0 2013-000833-11,9,2014-12-18,2015-08-04,6,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Novartis Pharma Services AG,A Phase Ib/II study of docetaxel with or without buparlisib as second line therapy for patients with advanced or metastatic squamous non-small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000833-11,0,0,0 2013-000833-11,9,2014-12-18,2015-08-04,6,1,0,1,0,0,1,0,0,1,1,0,0,0,1,"Novartis Farmacéutica, S.A.",A Phase Ib/II study of docetaxel with or without buparlisib as second line therapy for patients with advanced or metastatic squamous non-small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000833-11,0,0,0 2013-000833-11,9,2014-12-18,2015-08-04,6,1,0,1,0,0,1,0,0,1,1,0,0,0,1,NOVARTIS FARMA S.p.A.,A Phase Ib/II study of docetaxel with or without buparlisib as second line therapy for patients with advanced or metastatic squamous non-small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000833-11,0,0,0 2013-000834-36,1,2019-12-19,2019-12-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Medical Center Utrecht,"Simvastatin addition to improve symptoms, cognition and metabolic syndrome in patients with recent-onset schizophrenia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000834-36,0,0,0 2013-000846-20,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Parc Taulí,Comparison of the effects of bupivacain or levobupivacain on cerebral oxigenation during intradural anesthesia in elderly patients who undergo major orthopaedic surgery for hip replacement Efecto s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000846-20,0,0,0 2013-000848-26,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Barcelona Macula Foundation,"Phase IV study to evaluate the efficacy of aflibercept in subjects with neovascular age-related macular degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of ant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000848-26,0,0,0 2013-000850-23,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,INSERM,Not available in English Analyse chez des sujets adultes sains de la réponse à un vaccin polysaccharidique 23-valent (Pneumo23) induisant une réponse T-indépendante dans le but d'établir quelles so...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000850-23,0,0,0 2013-000851-42,1,2017-03-28,2017-03-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ICM- VAL D’AURELLE,Etude multicentrique de phase II évaluant une supplémentation en vitamine D à haute dose dans la correction de la carence vitaminique D des patientes prises en charge par chimiothérapie adjuvante pour...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000851-42,0,0,0 2013-000855-42,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A Phase III, open-label, non-randomised, multi-centre, single dose study to assess immunogenicity and safety of Fluarix / Influsplit SSW 2013/2014 injected intramuscularly in adults (18 to 60 years of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000855-42,0,0,0 2013-000856-16,3,2015-04-08,2015-04-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis recherche et développement,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients with Moderate to Severe Uncontrolled Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000856-16,0,0,0 2013-000858-22,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Sanofi-Aventis Groupe,"A Single-Arm, Open Label Study of Aflibercept as Maintenance Therapy Following Induction with Aflibercept in Combination with XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000858-22,0,0,0 2013-000860-27,6,2017-09-15,2017-09-25,5,1,0,1,0,1,1,0,0,1,0,0,0,0,1,ITALFARMACO S.p.A,A two-part study to assess the safety and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000860-27,0,0,0 2013-000861-36,1,2014-09-03,2014-09-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ensinger Mineral-Heilquellen GmbH,"Double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of „Ensinger Schiller Quelle Heilwasser“ on improvement of bowel function Doppelblinde, randomisierte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000861-36,0,0,0 2013-000862-13,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 2, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000862-13,0,0,0 2013-000863-94,1,2017-01-31,2017-01-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,A single blind study comparing the efficacy of Glycopyrronium and Hyoscine on drooling in children with neurodisability - DRI Trial (Drooling Reduction Intervention),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000863-94,0,0,0 2013-000864-28,12,2016-12-20,2016-12-20,11,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Cubist Pharmaceuticals LLC, an indirect wholly-owned subsidiary of Merck Sharp & Dohme Corp.","A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000864-28,1,1,0 2013-000864-28,12,2016-12-20,2016-12-20,11,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Cubist Pharmaceuticals, Inc.","A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000864-28,1,1,0 2013-000864-28,12,2016-12-20,2016-12-20,11,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Cubist Pharmaceuticals, LLC","A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000864-28,1,1,0 2013-000864-28,12,2016-12-20,2016-12-20,11,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Cubist Pharmaceuticals, a wholly owned subsidiary of Merck & Co., LLC","A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000864-28,1,1,0 2013-000867-10,1,2017-07-27,2017-07-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leeds,"Effects of Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction (HF-PEF): Cardiac MRI, Echocardiography, Exercise Physiology & Quality of Life Assessment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000867-10,0,0,0 2013-000868-29,4,2015-02-05,2015-04-15,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB IN COMBINATION WITH ERLOTINIB AS FIRST LINE TREATMENT FOR PATIENTS WITH M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000868-29,0,0,0 2013-000869-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Parc Taulí,Multidisciplinary approach versus conventional approach in colonic preparation of hospitalized patients. A randomized controlled trial abordaje multidisciplinar vs. abordaje convencional en la prep...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000869-36,0,0,0 2013-000872-14,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,University College London,Adoptive Immunotherapy with CD25/71 allodepleted donor T cells to improve immunity after unrelated donor stem cell transplant (ICAT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000872-14,0,0,0 2013-000873-56,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Federico Diaz González,"Randomized, two paralel groups, open clinical trial stratified by severity to stimate the cost-effectivity of surgical vs corticosteroid injection treatment on carpal tunnel syndrome Ensayo clínico...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000873-56,0,0,0 2013-000875-33,3,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"Academic Medical Center, University of Amsterdam","Prevention of Phantom Limb Pain After Transtibial Amputation (PLATA) - Randomized, double-blind, controlled, multi-center trial comparing Optimized intravenous pain control vs Optimized intravenous pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000875-33,0,0,0 2013-000881-12,2,2013-08-03,2013-08-03,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Abbott Biologicals B.V,"Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Northern Hemisphere Season 2013/2014. An Open-Label, Baseline- Controlled Study in Two Age Groups...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000881-12,0,0,0 2013-000883-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University hospital,"EFFECTS OF RIFAXIMIN, BY MODULATION OF THE GUT MICROBIOTA, ON MARKERS OF SYSTEMIC INFLAMMATION IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY - AN EXPLORATORY OPEN-LABEL RANDOMIZED CONTROLLED TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000883-27,0,0,0 2013-000885-13,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,UNICANCER,Secured access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000885-13,0,0,0 2013-000886-35,1,2013-12-27,2013-12-27,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Takeda Development Centre Europe Ltd.,"A Phase 2 Randomized, Placebo-Controlled, Double-Blind Parallel-Group, Multicenter Study to Evaluate the Glycemic Effects and Safety of Fasiglifam 25 mg Twice Daily and 50 mg Once Daily on Glycemic Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000886-35,0,0,0 2013-000887-27,1,2018-08-29,2018-08-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Wien,Pilot Trial: The effects of intravenous heme arginate on HO-1 expression and oxidative stress in the human heart,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000887-27,0,0,0 2013-000891-13,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,Steigerwald Arzneimittelwerk GmbH,"A randomised, double-blind, placebo-controlled multi-centre study to investigate the effectiveness and safety of STW5-II as add-on treatment for induction of remission in patients with mild to moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000891-13,0,0,0 2013-000893-32,1,2018-07-03,2018-07-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Queen Mary University of London,Squamous cell carcinoma prevention in organ transplant recipients using topical treatments: a feasibility study (SPOT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000893-32,0,0,0 2013-000894-56,7,2015-06-22,2015-06-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Menarini Ricerche S.p.A.,"A 12-week double-blind, randomised, placebo-controlled, parallel group phase III study, followed by a 4-week randomised withdrawal period to evaluate the efficacy and safety of oral ibodutant 10 mg on...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000894-56,0,0,0 2013-000895-14,7,2015-10-30,2015-11-03,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Menarini Ricerche S.p.A.,"A 52-week, double-blind, randomised, placebo-controlled, parallel-group phase III study with re-randomisation at week 25 to evaluate the efficacy and safety of oral ibodutant 10 mg once daily in femal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000895-14,0,0,0 2013-000898-68,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,Velindre NHS Trust,A phase 1b/2 randomised placebo controlled trial of fulvestrant +/- AZD5363 in postmenopausal women with advanced breast cancer previously treated with a third generation aromatase inhibitor.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000898-68,0,0,0 2013-000899-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Department of Pharmacy Unversitätsmedizin Mainz,Investigation of pharmacokinetics of Linezolid and Meropenem in patients receiving continuous renal replacement therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000899-16,0,0,0 2013-000900-41,1,2014-04-28,2014-04-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"F. Hoffmann-La Roche, Ltd.","A STUDY TO MEASURE SERUM PERIOSTIN, ASTHMA-RELATED BIOMARKERS AND RESPONSE TO PREDNISOLONE IN ADULT AND ADOLESCENT PATIENTS WITH SEVERE ORAL CORTICOSTEROID-DEPENDENT ASTHMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000900-41,0,0,0 2013-000901-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rode Kruis Ziekenhuis,"A randomized clinical trial on the effectiveness, cost-effectiveness and quality of life of Flaminal® versus Flammazine® in the treatment of superficial and deep partial thickness burns Gerandomise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000901-21,0,0,0 2013-000902-40,4,2017-12-08,2017-12-08,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,Phase II Randomized Double Blind Placebo controlled Trial of Combination of Pimasertib with SAR245409 or of Pimasertib with SAR245409 Placebo in Subjects with Previously Treated Unresectable Low Grade...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000902-40,0,0,0 2013-000903-18,4,2022-03-01,2022-03-01,3,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Astellas Pharma Global Development, Inc. (APGD)","A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000903-18,1,0,0 2013-000905-22,1,2015-09-23,2015-09-23,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Hôpitaux Universitaires de Strasbourg,à compléter ETUDE DE L’EFFET DU DROPERIDOL ET DE L’ONDANSETRON SUR L’INCIDENCE DE L’AKATHISIE POST OPERATOIRE EN CHIRURGIE GYNECOLOGIQUE AMBULATOIRE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000905-22,0,0,0 2013-000906-52,4,2020-09-25,2020-09-25,4,1,0,1,0,1,1,0,0,1,1,0,0,0,1,BioArctic AB,"An Open, Randomized, Rehabilitation-controlled Study to Assess Safety, Tolerability, and Efficacy of Heparin Activated Recombinant Human Fibroblast Growth Factor 1 on a Biodegradable Device in Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000906-52,0,0,0 2013-000909-24,1,2020-04-16,2020-04-16,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Erasmus MC,"""OPTI-CLOT"": Peri-Operative PharmacokineTIc-guided dosing of CLOTting factor in Hemophilia. ""OPTIi-CLOT"": Peri-OPeratieve farmacokineTIsch-gestuurde toediening van stollingsfactoren in hemofilie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000909-24,0,0,0 2013-000914-38,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR),A study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies Estudio para seleccionar la mejor opción terapéutica basado...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000914-38,0,0,0 2013-000915-26,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,FUNDACIÓN PROGRESO Y SALUD,"Clinical Trial Phase III single-center, open-label efficacy of intracoronary infusion of bone marrow mononuclear cells in patients with occlusion Autologous chronic coronary revascularization and vent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000915-26,0,0,0 2013-000916-10,5,2015-10-12,2015-10-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CSL Behring GmbH,"A double-blind, randomized, placebo-controlled, cross-over study to evaluate the clinical efficacy and safety of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the prophy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000916-10,0,0,0 2013-000918-37,12,2015-12-17,2016-04-28,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high-ri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000918-37,0,0,0 2013-000918-37,12,2015-12-17,2016-04-28,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.","A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high-ri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000918-37,0,0,0 2013-000923-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,FARMEX SA,"A multicenter, double-blind, randomized, parallel arm comparative study for the assessment of the safety and efficacy of azidamfenicol eye drops (Thilocof®/FARMEX) versus tobramycine eye drops (Τobrex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000923-15,0,0,0 2013-000925-30,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Uppsala University,How common are mood and sexual side-effects from combined oral contraceptives? Hur vanligt är det med humör- och sexuella biverkningar av p-piller?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000925-30,0,0,0 2013-000930-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Laboratorios Salvat, S.A.",A phase II clinical trial to assess the effect of HC-SVT-1001 (autologous fat stem adult mesenchymal cells expanded and combined with a tricalcium phosphate biomaterial) and HC-SVT-1002 (allogeneic fa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000930-37,0,0,0 2013-000931-28,6,2017-07-28,2017-08-15,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Glycotope GmbH,"A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX TM After Chemotherapy in Patients With Recurrent Epithelial O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000931-28,0,0,0 2013-000934-36,5,2017-01-30,2017-01-30,4,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Limited,"A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Assoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000934-36,0,0,0 2013-000935-29,7,2017-09-26,2017-11-21,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Amgen Inc.,"A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000935-29,0,0,0 2013-000938-35,1,2014-03-03,2014-03-03,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Luitpold Pharmaceuticals, Inc.","A Single Arm, Open Label Study to compare the Pharmacokinetics, Safety, and Efficacy of SPRIX® (intranasal ketorolac tromethamine) in 12 to 17 Year-Old Patients vs. Adult Patients (18 - 64 Years) Unde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000938-35,0,0,0 2013-000944-25,2,2015-05-11,2015-05-11,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Farma S.p.A.,"A three year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in subjects with active rheumatoid arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000944-25,0,0,0 2013-000944-25,2,2015-05-11,2015-05-11,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A three year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in subjects with active rheumatoid arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000944-25,0,0,0 2013-000945-37,1,2013-06-13,2013-06-13,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,bioCSL Pty Ltd,"A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of the Enzira® vaccine in Two Groups of Healthy Volunteers: ‘Adults’ (aged 18 to 59 y...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000945-37,0,0,0 2013-000949-39,5,2015-11-20,2015-11-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Smith & Nephew Inc.,An Observational Study Providing 12 Months of Safety Follow-Up from First Exposure to HP802-247 in Subjects Who Participated in Study 802-247-09-032(EU),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000949-39,0,0,0 2013-000950-23,1,2015-02-20,2015-02-20,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU Dijon,Intérêt de la cryothérapie ou de l'aérosolisation par corticoïdes sur les troubles de la déglutition en post-opératoire précose après thyroïdectomie totale.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000950-23,0,0,0 2013-000951-42,18,2018-11-15,2019-11-15,18,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000951-42,0,0,0 2013-000952-17,1,2015-12-31,2015-12-31,1,0,0,0,1,0,3,0,0,1,0,0,1,0,0,Prague Psychiatric Centre,The Role of mTOR (Mammalian Target of Rapamycin) Signaling Pathway in the Antidepressive Effect of Ketamine in Patients with Depressive Disorder. Uloha mTOR (mammalian target or rapamycin) signalni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000952-17,0,0,0 2013-000954-23,2,,,0,0,0,1,0,1,1,0,0,2,1,0,0,0,1,"Edge Therapeutics, Inc.","PHASE 1/2a MULTICENTER, CONTROLLED, RANDOMIZED, OPEN LABEL, DOSE ESCALATION, SAFETY, TOLERABILITY, AND PHARMACOKINETIC STUDY COMPARING EG-1962 AND NIMODIPINE IN PATIENTS WITH ANEURYSMAL SUBARACHNOID H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000954-23,0,0,0 2013-000956-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Erasmus Medical Center,Effect of low-dose ketamine on postoperative delirium in patients undergoing noncardiac surgery: a pilot study. Effect van ketamine op post-operatieve delier bij patienten die niet hartchirurgische...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000956-16,0,0,0 2013-000959-40,12,2019-04-05,2019-04-05,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000959-40,0,0,0 2013-000961-36,2,2014-12-04,2015-03-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Kedrion SpA,Tolerability and safety evaluation of the administration of Ig VENA at high infusion rates. Open label phase III study. Bewertung der Verträglichkeit und Sicherheit der Verabreichung von Ig VENA be...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000961-36,0,0,0 2013-000962-13,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Imperial College London,"Evaluating the effects of the novel GLP-1 analogue, liraglutide, in patients with Alzheimer’s disease (ELAD study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000962-13,0,0,0 2013-000965-34,9,2017-01-26,2017-01-26,8,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Limited,"A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Assoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000965-34,0,0,0 2013-000966-12,1,2018-09-12,2018-09-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,"Autologous Stem Cells in Achilles Tendinopathy (ASCAT)- A phase II, single centre, proof of concept study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000966-12,0,0,0 2013-000970-31,1,2020-04-01,2020-04-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Technische Universität Dresden,"Randomized, placebo-controlled multicenter trial of lithium plus treatment as usual (TAU) for acute suicidal ideation and behaviour in patients with suicidal major depressive episode",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000970-31,0,0,0 2013-000971-34,1,2018-11-22,2018-11-22,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,Jørgen Agnholt,Mucosal immune regulation by high dose vitamin D treatment in Crohn’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000971-34,0,0,0 2013-000973-54,4,2014-01-06,2014-01-06,3,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Galderma R&D SNC,"Multi-centre, randomized, investigator-blind, intra-individual active and vehicle-controlled study, comparing Metvix® Natural Daylight Photodynamic Therapy versus Metvix® conventional Photodynamic The...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000973-54,0,0,0 2013-000975-33,1,2015-05-31,2015-05-31,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Landspitali - The National University Hospital of Iceland,"Novel Assays for the Determination of Urinary 2,8-Dihydroxyadenine and Other Key Urinary Purine Metabolites - Rare Diseases Clinical Research Network Protocol Version 1",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000975-33,0,0,0 2013-000980-10,6,2017-06-08,2017-06-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Britannia Pharmaceuticals Limited,"TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson?s disease patients with motor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000980-10,0,0,0 2013-000980-10,6,2017-06-08,2017-06-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,STADA Arzneimittel AG,"TOLEDO Multicenter, parallel-group, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of apomorphine subcutaneous infusion in Parkinson?s disease patients with motor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000980-10,0,0,0 2013-000981-12,4,2017-03-22,2017-03-22,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","An open-label, phase II, randomized, pilot study to assess the effect in term of erythroid improvement of deferasirox combined with erythropoietin compared to erythropoietin alone in patients with low...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000981-12,0,0,0 2013-000981-12,4,2017-03-22,2017-03-22,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA S.p.A,"An open-label, phase II, randomized, pilot study to assess the effect in term of erythroid improvement of deferasirox combined with erythropoietin compared to erythropoietin alone in patients with low...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000981-12,0,0,0 2013-000981-12,4,2017-03-22,2017-03-22,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An open-label, phase II, randomized, pilot study to assess the effect in term of erythroid improvement of deferasirox combined with erythropoietin compared to erythropoietin alone in patients with low...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000981-12,0,0,0 2013-000985-13,1,2013-10-31,2013-10-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Astellas Pharma Europe Ltd.,"A MULTICENTRE, SINGLE-ARM, OPEN-LABEL STUDY TO CHARACTERISE THE RELATIONSHIP BETWEEN PRE-TRANSPLANT PHARMACOKINETICS OF ADVAGRAF® AND THE DOSE REQUIRED POST-TRANSPLANT TO ACHIEVE TARGET TROUGH LEVELS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000985-13,0,0,0 2013-000992-33,1,2015-03-22,2015-03-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare,A Clinical Study to Assess the Efficacy and Onset of Pain Relief of Topical MFC51123 Diclofenac-Menthol Gel versus Controls in Ankle Sprain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000992-33,0,0,0 2013-000993-32,1,2017-12-13,2017-12-13,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital Leuven,Does prolonged GnRH downregulation prior to ART improve the clinical pregnancy rate in postoperative endometriosis patients? A RCT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000993-32,0,0,0 2013-000998-68,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Medizinische Universität Wien, Abteilung für Anästhesie und Intensivmedizin",Advanced antibiotic prophylaxis for optimal perioperative protection during coronary artery bypass grafting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000998-68,0,0,0 2013-000999-15,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,0,University Hospital Regensburg,The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation - M reg Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000999-15,0,0,0 2013-001001-91,7,2020-11-17,2020-11-17,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Exelixis, Inc.","A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001001-91,1,0,0 2013-001003-36,2,2016-04-19,2016-04-19,1,1,0,0,2,0,0,0,0,1,0,0,1,0,1,Metacure Ltd.,The DIAMOND for the Treatment of Type 2 Diabetes: Can Blood Triglycerides level be the predictor for therapy efficiency? Therapie von Typ 2 Diabetes mittels DIAMOND® System:Auswirkung der Triglycer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001003-36,0,0,0 2013-001003-36,2,2016-04-19,2016-04-19,1,1,0,0,2,0,0,0,0,1,0,0,1,0,1,METACURE LIMITED,The DIAMOND for the Treatment of Type 2 Diabetes: Can Blood Triglycerides level be the predictor for therapy efficiency? Therapie von Typ 2 Diabetes mittels DIAMOND® System:Auswirkung der Triglycer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001003-36,0,0,0 2013-001005-82,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Galileo Research Srl,Phase II trial of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with ovarian carcinoma with minimal or microscopic residual disease at second look laparotomy/l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001005-82,0,0,0 2013-001008-13,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Sint Maartenskliniek,Fast-track rehabilitation protocol for Total Knee Arthroplasty: A Randomized Controlled Trial comparing Local Infiltration Analgesia with Femoral Nerve Block Fast track revalidatie protocol voor to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001008-13,0,0,0 2013-001010-14,17,2020-08-19,2020-08-19,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Exelixis, Inc.","A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001010-14,0,0,0 2013-001010-14,17,2020-08-19,2020-08-19,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Clinical Technology Centre (International) Limited,"A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001010-14,0,0,0 2013-001012-30,5,2014-05-08,2014-05-08,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Sanofi-aventis recherche & développement,A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001012-30,0,0,0 2013-001018-14,3,2016-08-23,2016-08-23,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A phase Ib, open-label study of oral BGJ398 in combination with oral BYL719 in adult patients with select advanced solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001018-14,0,0,0 2013-001023-39,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,Roche Austria GmbH,"LISAH: AN OPEN-LABEL, RANDOMISED PHASE II STUDY ASSESSING QUALITY OF LIFE ASSOCIATED WITH SUBCUTANEOUS TRASTUZUMAB INJECTED INTO THE THIGH OR UPPER ARM IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001023-39,0,0,0 2013-001024-19,1,2018-12-31,2018-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford,An open label single-arm study of the immunogenicity and reactogenicity of a 13-valent pneumococcal conjugate vaccine (Prevenar13®) given to children with type 1 diabetes mellitus who have not previou...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001024-19,0,0,0 2013-001025-53,2,2015-07-18,2015-07-18,1,0,0,0,0,0,4,0,0,1,1,1,1,0,1,Biogen Idec Research Limited,"A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsule",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001025-53,0,0,0 2013-001028-21,1,2015-03-12,2015-03-12,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,ABCSG (Austrian Breast & Colorectal Cancer Study Group),"P01 - A prospective, randomized, multicenter trial of additional radiochemotherapy to neoadjuvant chemotherapy in patients with locally advanced pancreatic adenocarcinoma P01 - Prospektive, randomi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001028-21,0,0,0 2013-001029-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Center,Efficacy and safety of trough level-based dose reduction during infliximab maintenance treatment in Crohn’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001029-17,0,0,0 2013-001033-40,8,2015-12-04,2015-12-31,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Verastem Inc,"A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS 6063 in Subjects with Malignant Pleural Mesothelioma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001033-40,0,0,0 2013-001034-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AMC Amsterdam,Super ovulation in intrauterine insemination: FSH or Clomifene citrate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001034-18,0,0,0 2013-001036-22,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,SOLTI,PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab in Stage I to IIIA HER2-positive breast cancer Fenotipo HER2-enriquecido determinado por la ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001036-22,0,0,0 2013-001037-40,1,2016-01-29,2016-01-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,InflaRx GmbH,"A phase II randomized, placebo-controlled, double-blind, dose controlled trial in patients suffering from early, newly developing abdominal or pulmonary derived septic organ dysfunction to evaluate sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001037-40,0,0,0 2013-001040-62,6,2020-09-25,2020-09-25,5,1,0,0,0,0,3,0,0,2,0,0,0,0,0,German Breast GBG Forschungsgesellschaft mbH,"Phase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor positive, HER2 normal primary breast cancer with high relapse risk ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001040-62,1,0,0 2013-001040-62,6,2020-09-25,2020-09-25,5,1,0,0,0,0,3,0,0,2,0,0,0,0,0,GBG Forschungs GmbH,"Phase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor positive, HER2 normal primary breast cancer with high relapse risk ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001040-62,1,0,0 2013-001045-14,4,2017-06-20,2017-07-20,3,1,1,0,0,1,1,0,0,1,0,0,1,0,1,Promethera Biosciences,SAF 001: A long-term safety follow-up study of patients having received infusions of HepaStem.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001045-14,0,0,0 2013-001047-31,6,2017-05-23,2017-05-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001047-31,0,0,0 2013-001048-73,1,2017-11-10,2017-11-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001048-73,0,0,0 2013-001051-12,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,Nottingham University Hospitals NHS Trust,Early low dose steroids for adults admitted to hospital with influenza-like illness during a pandemic: a randomised placebo controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001051-12,0,0,0 2013-001055-12,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Biogen Idec Italia S.r.l.,"Flu-like syndrome Inhibition Giving anti-histaminic Therapy. Randomized cross-over, single-center, randomized, placebo-controlled, double-blind study to evaluate the efficacy of cetirizine on Flu-like...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001055-12,0,0,0 2013-001056-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IRCCS Istituto Giannina Gaslini,The Effectiveness and Population Pharmacokinetics and Pharmacogenomics of a Reduced Dose of Tranexamic Acid for Craniosynostosis Surgery: A multicenter study. The TXA Study. Studio multicentrico su...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001056-35,0,0,0 2013-001057-27,9,2016-01-13,2016-01-13,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A 52-week, double-blind, randomized, multinational, multicentre, 2-arm parallel-group, active-controlled clinical trial of fixed combination of beclometasone dipropionate plus formoterol fumarate plus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001057-27,0,0,0 2013-001058-85,1,2015-09-07,2015-09-07,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Wörwag Pharma GmbH & Co. KG,"EFFECTS OF BENFOTIAMINE ON INTRAEPIDERMAL NERVE FIBER DENSITY (IENFD) AND DIABETIC NEUROPATHY IN SUBJECTS WITH SENSORIMOTOR DIABETIC POLYNEUROPATHY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001058-85,0,0,0 2013-001060-38,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Academic Medical center,Pre-operative Decitabine in colon cancer: a proof of principal study Pre-operatief Decitabine bij patiënten met dikkedarmkanker,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001060-38,0,0,0 2013-001062-41,1,2015-12-08,2015-12-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,2,"RWTH Aachen University, represented by the Rector, himself represented by Clinical Trial Center (CTC-A)",Neoadjuvant chemotherapy with Cabazitaxel in high risk prostate cancer patients prior to radical prostatectomy Neoadjuvante Chemotherapie mit Cabazitaxel vor der radikalen Prostatektomie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001062-41,0,0,0 2013-001064-27,1,2015-08-19,2015-08-19,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Hospitals Leuven,Placebo-controlled trial with vitamin D to prevent worsening/relieve aromatase inhibitor-induced musculoskeletal symptoms in breast cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001064-27,0,0,0 2013-001065-17,1,2016-02-17,2016-02-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO),"Phase II, randomised, multicentre study with two treatment arms (R-COMP versus R-CHOP) in newly diagnosed elderly patients (?60 years) with non-localised diffuse large B-cell lymphoma (DLBCL)/follicul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001065-17,0,0,0 2013-001067-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Centre Groningen,PHOspholamban RElated CArdiomyopathy STudy - intervention (i-PHORECAST) Fosfolamban gerelateerde cardiomyopathie studie - interventie (i-PHORECAST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001067-23,0,0,0 2013-001069-18,1,2016-04-04,2016-04-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University College London (UCL),MINeralocorticoid receptor antagonist pretreatment to MINIMISE reperfusion injury after ST-Elevation Myocardial Infarction(STEMI).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001069-18,0,0,0 2013-001071-20,1,2015-09-15,2015-09-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,The Christie NHS Foundation Trust,A Randomised Phase II Study in Metastatic Melanoma to Evaluate the Efficacy of Adoptive Cellular Therapy with Tumour Infiltrating Lymphocytes (TIL) and Assessment of High versus Low Dose Interleukin-2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001071-20,0,0,0 2013-001074-15,1,2019-04-24,2019-04-24,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Genmab A/S,"First-in-human, dose-escalating safety study of tissue factor specific antibody drug conjugate tisotumab vedotin (HuMax®-TF-ADC) in patients with locally advanced and/or metastatic solid tumors known ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001074-15,0,0,0 2013-001080-23,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Javier P. Gisbert,"Rifaximin associated with the classic triple therapy (inhibitor proton pump, amoxicillin and clarithromycin) for eradication of Helicobacter pylori infection Rifaximina asociado a la triple terapia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001080-23,0,0,0 2013-001081-42,1,2016-06-13,2016-06-13,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Hannover Medical School,Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection with Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001081-42,0,0,0 2013-001083-28,1,2019-12-05,2019-12-05,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Pfizer Inc,"A Phase III, randomised, open, controlled, multicentre, primary vaccination study to evaluate the immunogenicity and persistence of 1 and 2 doses of meningococcal conjugate vaccine MenACWY-TT in toddl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001083-28,0,0,0 2013-001088-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Städtisches Klinikum München GmbH,"A PROSPECTIVE, MULTICENTER, PHASE-II TRIAL EVALUATING EFFICACY AND SAFETY OF BENDAMUSTINE + GA101 (BG) IN PATIENTS WITH RELAPSED CLL FOLLOWED BY MAINTENANCE THERAPY WITH GA101 FOR RESPONDING PATIENTS....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001088-22,0,0,0 2013-001089-40,6,2017-11-07,2018-03-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An extension study to evaluate the sustainability of clinical benefits, safety and tolerability of secukinumab in patients with active Ankylosing Spondylitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001089-40,0,0,0 2013-001089-40,6,2017-11-07,2018-03-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farma SpA,"An extension study to evaluate the sustainability of clinical benefits, safety and tolerability of secukinumab in patients with active Ankylosing Spondylitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001089-40,0,0,0 2013-001090-24,8,2017-12-11,2017-12-11,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled phase III multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long-term safety, tolerability and efficacy up to 3 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001090-24,0,0,0 2013-001090-24,8,2017-12-11,2017-12-11,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo-controlled phase III multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long-term safety, tolerability and efficacy up to 3 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001090-24,0,0,0 2013-001091-38,1,2016-11-01,2016-11-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sterna biologicals GmbH & Co. KG,"A phase IIa, single-centre, randomised, vehicle-controlled, double-blind trial for assessment of efficacy, safety and tolerability of the topical formulation SB011 containing a human GATA-3 specific D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001091-38,0,0,0 2013-001093-16,1,2015-01-31,2015-01-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Oculis ehf.,Comparison of non-MMC trabeculectomy and dexamethasone nanoparticles eye drops with MMC trabeculectomy and Maxidex®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001093-16,0,0,0 2013-001094-25,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A Phase III, open-label, non-randomised, multi-centre, single dose study to assess the immunogenicity and safety of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) Influspli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001094-25,0,0,0 2013-001096-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Molecular and Clinical Medicine; ""Sapienza"" University of Rome",ASSOCIATION BETWEEN PROTON-PUMP INHIBITORS (PPI) and METRONOMIC CAPECITABINE (mCAP) AS SALVAGE TREATMENT FOR PATIENTS WITH ADVANCED GASTRO-INTESTINAL TUMOURS: A RANDOMIZED PHASE II STUDY Inibitori ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001096-20,0,0,0 2013-001097-24,1,2014-04-24,2014-04-24,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Portsmouth Hospitals NHS trust,Use of N-Acetylcysteine (NAC) and Simeticone as a pre-endoscopic drink to improve mucosal visualisation during gastroscopy: A randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001097-24,0,0,0 2013-001100-10,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,"Novartis Farmacéutica, S.A.","An open-label, multi-center protocol to provide QTI571 to PAH patients who participated in one of the extension studies and are judged by the investigator to benefit from continued QTI571 treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001100-10,0,0,0 2013-001103-36,1,2014-12-17,2014-12-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside,Randomised controlled single and chronic dosing crossover comparison of extra fine particle formoterol and coarse particle salmeterol in asthmatic patients with persistent small airways dysfunction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001103-36,0,0,0 2013-001105-81,4,2014-08-08,2014-08-08,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Actavis Group PTC ehf.,Randomized Clinical Trial to Compare the Pregnancy Rates of Vaginally Applied Cyclogest® Pessary and Crinone® 8% Gel After In-vitro Fertilization,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001105-81,0,0,0 2013-001110-15,7,2021-12-14,2021-12-15,5,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Boehringer Ingelheim AB,A Phase Ib/II Randomized Study of BI 836845 in Combination with Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women with Locally Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001110-15,0,0,0 2013-001110-15,7,2021-12-14,2021-12-15,5,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Boehringer Ingelheim Limited,A Phase Ib/II Randomized Study of BI 836845 in Combination with Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women with Locally Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001110-15,0,0,0 2013-001110-15,7,2021-12-14,2021-12-15,5,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,A Phase Ib/II Randomized Study of BI 836845 in Combination with Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women with Locally Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001110-15,0,0,0 2013-001110-15,7,2021-12-14,2021-12-15,5,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Boehringer Ingelheim bv,A Phase Ib/II Randomized Study of BI 836845 in Combination with Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women with Locally Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001110-15,0,0,0 2013-001110-15,7,2021-12-14,2021-12-15,5,0,0,0,0,0,2,0,0,1,0,0,0,0,1,BOEHRINGER INGELHEIM FRANCE,A Phase Ib/II Randomized Study of BI 836845 in Combination with Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women with Locally Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001110-15,0,0,0 2013-001110-15,7,2021-12-14,2021-12-15,5,0,0,0,0,0,2,0,0,1,0,0,0,0,1,SCS Boehringer Ingelheim Comm. V,A Phase Ib/II Randomized Study of BI 836845 in Combination with Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women with Locally Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001110-15,0,0,0 2013-001110-15,7,2021-12-14,2021-12-15,5,0,0,0,0,0,2,0,0,1,0,0,0,0,1,"Boehringer Ingelheim España, S.A.",A Phase Ib/II Randomized Study of BI 836845 in Combination with Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women with Locally Advanced or Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001110-15,0,0,0 2013-001113-32,1,2014-02-19,2014-02-19,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,PAION UK Limited,"A Randomized, Single-blind Phase II Study Evaluating the Efficacy, Safety and Pharmacokinetics of Remimazolam in General Anesthesia in Adult Patients Undergoing Cardiac Surgery, Including Follow-up Se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001113-32,0,0,0 2013-001118-14,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Roche Farma, S.A.",Ensayo Clínico Fase IIIb abierto no-controlado para evaluar la seguridad del cambio de rituximab intravenoso a rituximab subcutáneo durante el tratamiento de primera línea de Linfoma No-Hodgkin Folicu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001118-14,0,0,0 2013-001119-54,5,2017-02-17,2017-02-17,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,Effect of Passive Immunization on the Progression of Mild Alzheimer?s Disease: Solanezumab (LY2062430) versus Placebo Efecto de la inmunización pasiva en la progresión de la enfermedad de Alzheime...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001119-54,0,0,0 2013-001123-39,1,2013-09-29,2013-09-29,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,SerumWerk Bernburg AG,An open label study on safety and pharmacokinetics of an intravenous administered single dose of Feramyl 200 mg in healthy blood donors compared to a single dose of Feramyl 1000 mg in IBD patients to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001123-39,0,0,0 2013-001124-19,5,2017-06-29,2017-06-29,4,0,0,0,0,1,3,0,0,1,0,0,1,0,1,"Onconova Therapeutics, Inc.","Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients with Myelodysplastic Syndrome with Excess Blast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001124-19,0,0,0 2013-001132-22,1,2018-07-31,2018-07-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo Español Multidisciplinar de Melanoma,"A MULTICENTER, SINGLE ARM, PHASE 2 CLINICAL STUDY ON THE COMBINATION OF RADIATION THERAPY AND IPILIMUMAB, FOR THE TREATMENT OF PATIENTS WITH MELANOMA AND BRAIN METASTASES. ESTUDIO CLÍNICO DE FASE I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001132-22,0,0,0 2013-001138-17,1,2014-07-03,2014-07-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Orthopedic Research in Aarhus,In vivo measurement of cefuroxime in subcutaneous and bone tissue using microdialysis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001138-17,0,0,0 2013-001140-61,1,2015-12-29,2015-12-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GW Research Ltd.,"A randomised, double blind, placebo controlled, parallel group, dose ranging study of GWP42004 as add on to metformin in the treatment of participants with Type 2 diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001140-61,0,0,0 2013-001141-14,6,2014-11-28,2022-04-17,6,1,0,0,0,0,4,0,0,1,0,0,0,0,1,F.Hoffmann-La Roche Ltd.,"A PHASE 4, BLOOD SAMPLE COLLECTION STUDY FOR EXPLORATORY EVALUATION OF THE ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS WITH TREATMENT RESPONSES FROM SUBJECTS WITH HBEANTIGEN POSITIVE OR NEGATIVE CH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001141-14,0,0,0 2013-001142-34,8,2017-12-05,2018-08-31,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche. Ltd.,"A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001142-34,0,0,0 2013-001143-31,1,2015-03-01,2015-03-01,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Bispebjerg University Hospital,TARGET “Targeting the small airways in asthma” Does fine particle ICS improve peripheral airway inflammation and function in patients with insufficient response to large particle ICS?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001143-31,0,0,0 2013-001145-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,"Traitement endoscopique de l’œsophage hypercontractile par injection de toxine botulinique : étude prospective, randomisée, contrôlée en double aveugle Traitement endoscopique de l’œsophage hyperco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001145-14,0,0,0 2013-001146-34,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Oscar Lambret,"Impact of a treatment with zoledronic acid on bone mineral density in patients with metastatic castration-resistant prostate cancer, chemo-naïve and receiving abiraterone acetate Impact d’un traite...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001146-34,0,0,0 2013-001147-31,1,2015-11-19,2015-11-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Aarhus University Hospital, Department of Cardiology",Aortic Valve Stenosis and Myocardial Efficiency – a Prognostic Marker and a Target for Intervention?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001147-31,0,0,0 2013-001150-10,9,2018-05-17,2018-07-17,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Alexion Pharmaceuticals, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001150-10,0,0,0 2013-001151-12,9,2021-07-12,2021-07-12,5,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-NMO-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001151-12,1,0,0 2013-001152-35,2,2016-07-13,2016-07-13,2,1,1,0,0,1,1,0,0,1,0,0,1,0,1,Ultragenyx Pharmaceutical Inc.,"An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of UX003 rhGUS Enzyme Replacement Therapy in Patients with MPS 7",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001152-35,0,0,0 2013-001154-98,1,2014-10-30,2014-10-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,2,H Lundbeck A/S,"Interventional, randomized, double-blind, cross-over, placebo-controlled study to investigate the effects of nalmefene after single dose on the blood oxygen level dependent (BOLD) fMRI signal in the v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001154-98,0,0,0 2013-001154-98,1,2014-10-30,2014-10-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,2,,"Interventional, randomized, double-blind, cross-over, placebo-controlled study to investigate the effects of nalmefene after single dose on the blood oxygen level dependent (BOLD) fMRI signal in the v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001154-98,0,0,0 2013-001161-16,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ROCHE SPA,"NATIONAL PHASE IIIB PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, OPEN LABEL STUDY TO ASSESS THE SAFETY OF SUBCUTANEOUS TRASTUZUMAB AND MOLECULAR BIOMARKERS IN PATIENTS WITH EARLY AND LOCALLY ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001161-16,0,0,0 2013-001163-24,7,2017-09-13,2017-11-06,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001163-24,0,0,0 2013-001164-29,1,2014-04-01,2014-04-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Department of anesthesiology,Optimizing surgical conditions: Intraabdominal distance during gynecologic laparoscopic surgery with and without muscle relaxation (The measurement study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001164-29,0,0,0 2013-001167-22,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,3,,Spinal Morphine in laparoscopic gastro-intestinal surgery Spinaal Morfine in laparoscopische gastro-intestinale chirurgie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001167-22,0,0,0 2013-001169-18,1,2019-06-25,2019-06-25,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Onyx Therapeutics, Inc.","Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001169-18,0,0,0 2013-001176-38,12,2015-09-17,2015-09-17,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A 2-Part Phase III randomized, open label, multicenter study of LGX818 plus MEK162 versus vemurafenib and LGX818 monotherapy in patients with unresectable or metastatic BRAF V600 mutant melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001176-38,1,0,0 2013-001176-38,12,2015-09-17,2015-09-17,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Array BioPharma Inc.,"A 2-Part Phase III randomized, open label, multicenter study of LGX818 plus MEK162 versus vemurafenib and LGX818 monotherapy in patients with unresectable or metastatic BRAF V600 mutant melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001176-38,1,0,0 2013-001176-38,12,2015-09-17,2015-09-17,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Array BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.),"A 2-Part Phase III randomized, open label, multicenter study of LGX818 plus MEK162 versus vemurafenib and LGX818 monotherapy in patients with unresectable or metastatic BRAF V600 mutant melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001176-38,1,0,0 2013-001176-38,12,2015-09-17,2015-09-17,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS FARMA S.p.A,"A 2-Part Phase III randomized, open label, multicenter study of LGX818 plus MEK162 versus vemurafenib and LGX818 monotherapy in patients with unresectable or metastatic BRAF V600 mutant melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001176-38,1,0,0 2013-001178-20,3,2018-09-13,2018-09-13,3,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Uppsala University Hospital, MHT, Department of Nephrology",Cardiovascular (CV) risk prediction and CV biomarkers in renal transplant recipients treated with belatacept compared to calcineurin inhibitors (CNI). Open randomized 12 month study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001178-20,0,0,0 2013-001178-20,3,2018-09-13,2018-09-13,3,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Uppsale University Hospital, MHT, Department of Nephrology",Cardiovascular (CV) risk prediction and CV biomarkers in renal transplant recipients treated with belatacept compared to calcineurin inhibitors (CNI). Open randomized 12 month study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001178-20,0,0,0 2013-001179-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,Prospective phase II study of Gemcitabine plus platinium salt in combination with bevacizumab (Avastin®) for metastatic collecting duct carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001179-19,0,0,0 2013-001184-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMCG,Pharmacokinetic Parameters of 960 mg Co-trimoxazole Once Daily in Patients with Tuberculosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001184-24,0,0,0 2013-001185-41,4,2018-03-22,2018-03-28,4,1,0,0,0,0,0,0,0,1,1,0,1,0,0,University of California San Francisco,"Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, a randomized, double blind, multicentre clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001185-41,0,0,0 2013-001185-41,4,2018-03-22,2018-03-28,4,1,0,0,0,0,0,0,0,1,1,0,1,0,0,University of California San Francisco Stroke Sciences Group,"Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, a randomized, double blind, multicentre clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001185-41,0,0,0 2013-001188-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,Interleukin 2 and zolendronic acid as maintaining treatment in multiple myeloma patients after autologous bone marrow transplant Mantenimento Immunologico con interleuchina-2 e acido zoledronico in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001188-22,0,0,0 2013-001189-40,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,University of Tartu,PHARMACOKINETICS OF ORAL SPIRONOLACTONE IN CHILDREN UP TO 2 YEARS OF AGE SUUKAUDSE SPIRONOLAKTOONI FARMAKOKINEETIKA KUNI 2- AASTASTEL LASTEL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001189-40,0,0,0 2013-001190-24,7,2016-12-12,2016-12-16,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"A controlled, parallel group, open-label, multicenter extension study to investigate efficacy and safety of oral BAY 85-3934 and darbepoetin alfa comparator in the long term treatment of anemia in pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001190-24,0,0,0 2013-001190-24,7,2016-12-12,2016-12-16,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer Healthcare AG,"A controlled, parallel group, open-label, multicenter extension study to investigate efficacy and safety of oral BAY 85-3934 and darbepoetin alfa comparator in the long term treatment of anemia in pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001190-24,0,0,0 2013-001190-24,7,2016-12-12,2016-12-16,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer AG,"A controlled, parallel group, open-label, multicenter extension study to investigate efficacy and safety of oral BAY 85-3934 and darbepoetin alfa comparator in the long term treatment of anemia in pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001190-24,0,0,0 2013-001190-24,7,2016-12-12,2016-12-16,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer AG,"A controlled, parallel group, open-label, multicenter extension study to investigate efficacy and safety of oral BAY 85-3934 and darbepoetin alfa comparator in the long term treatment of anemia in pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001190-24,0,0,0 2013-001191-38,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Novartis Farmacéutica, S.A.","Multicentric, randomized, open-label, controlled study, of 12 months of follow-up to assess the effect in renal function of a immunosuppressive treatment based on tacrolimus minimization in combinati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001191-38,0,0,0 2013-001192-21,6,2015-11-23,2015-11-23,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, parallel group, open-label, multicenter study to investigate the efficacy and safety of oral BAY 85-3934 and active comparator (darbepoetin alfa) in the maintenance treatment of anemia i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001192-21,0,0,0 2013-001193-14,6,2015-09-15,2015-10-23,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, placebo-controlled, double-blind, parallel group, multicenter study to investigate the efficacy and safety of 5 fixed doses of BAY 85- 3934 administered orally in the correction of anemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001193-14,0,0,0 2013-001194-25,6,2016-01-29,2016-03-31,3,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001194-25,0,0,0 2013-001194-25,6,2016-01-29,2016-03-31,3,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Lilly S.A.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001194-25,0,0,0 2013-001196-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO MILANO,PROSPECTIVE STUDY ON THE EFFECTIVENESS OF TWO DIFFERENT DOSES OF INTRAVENOUS METHYLPREDNISOLONE IN THE TREATMENT OF ACUTE DYSTHYROID OPTIC NEUROPATHY STUDIO PROSPETTICO SULL'EFFICACIA DI DUE DIFFE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001196-20,0,0,0 2013-001199-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,KULeuven,Histamine 1 receptor antagonist ebastine as novel treatment in IBS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001199-39,0,0,0 2013-001203-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Instituto Português de Oncologia do Porto Francisco Gentil, EPE",Phase II trial of the addition of Lapatinib to Capecitabine versus Capecitabine alone as radio-sensitizers in KRAS wild type resectable rectal cancer Ensaio de Fase II que estuda a adição de Lapat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001203-36,0,0,0 2013-001205-84,8,2018-10-05,2018-10-05,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Randomized, double-blind, double-dummy, placebo-controlled, Phase III clinical trial on the efficacy and safety of a 48-weeks treatment with gastro-resistant phosphatidylcholine (LT-02) versus placebo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001205-84,0,0,0 2013-001208-12,1,2015-05-01,2015-05-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,Switching to aflibercept in patients with neovascular AMD not responding to anti-VEGF treatment. Overstappen op aflibercept in patiënten die niet reageren op anti-VEGF therapie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001208-12,0,0,0 2013-001211-75,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001211-75,0,0,0 2013-001212-30,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,3,,"Modulation of immune function by parenteral fish oil in patients with Crohn’s disease and high inherent Tumor Necrosis Factor-alfa production, a randomized, single blinded, cross-over study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001212-30,0,0,0 2013-001217-33,1,2019-09-25,2019-09-25,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, partial-blind, placebo-controlled trial evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of VAY736 in the treatment of patients with pemphigus vulgaris",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001217-33,0,0,0 2013-001218-14,1,2016-01-05,2016-01-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Bristol NHS Foundation Trust,A double blind randomised control trial to measure the effect of the addition of clindamycin to flucloxacillin for the treatment of limb cellulitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001218-14,0,0,0 2013-001219-57,3,,,0,0,0,1,0,0,1,2,0,2,0,0,0,0,1,NOVARTIS FARMA S.p.A.,"A phase Ib/II, multicenter, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001219-57,0,0,0 2013-001219-57,3,,,0,0,0,1,0,0,1,2,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase Ib/II, multicenter, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001219-57,0,0,0 2013-001219-57,3,,,0,0,0,1,0,0,1,2,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A phase Ib/II, multicenter, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001219-57,0,0,0 2013-001221-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Akershus university hospital,Dupytren’s disease study A randomized controlled trial comparing clostridium histolyticum with needle aponeurotomy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001221-13,0,0,0 2013-001222-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aalborg University Hospital,Markers of bonestatus in Diabetes Mellitus patients (type 1 and type 2) and the effect of antiresorptive treatment on glycemic markers. Markører for knoglestatus hos Diabetes Mellitus patienter (ty...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001222-26,0,0,0 2013-001225-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,Quantitative myocardial perfusion response to adenosine and regadenoson in patients with suspected coronary artery disease Adenosiinin ja regadenosonin vertailu sydänlihaksen verenvirtauksen PET tu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001225-11,0,0,0 2013-001226-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTI OSPITALIERI DI CREMONA,"A phase II randomized, open-label neo-adjuvant study of standard chemotherapy regimen compared to high dose chemotherapy regimen with autologous stem cell transplantation in patients with triple negat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001226-25,0,0,0 2013-001227-40,3,2014-07-04,2014-07-04,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Serodus ASA,"A randomized, double-blind, placebo-controlled, cross-over, multi-center study assessing the safety, tolerability and efficacy of SER100 10 mg s.c. twice daily for 2 days in patients with Isolated Sys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001227-40,1,0,0 2013-001229-15,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal,The efficacy of oral and intravenous administration of sodium chloride in the prophylaxis of nephropathy induced by iodinated contrasts in outpatients Eficacia de la administración de cloruro sódic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001229-15,0,0,0 2013-001230-17,1,2018-06-12,2018-06-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Hospices Civils de Lyon,La mélatonine restaure-t-elle l’architecture du sommeil chez les enfants avec autisme ? Etude de phase II. La mélatonine restaure-t-elle l’architecture du sommeil chez les enfants avec autisme ? Et...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001230-17,0,0,0 2013-001231-51,4,2016-07-27,2016-07-27,3,1,1,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur,Efficacy and Immunogenicity Study of Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Healthy Children Aged 6 to 35 Months,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001231-51,0,0,0 2013-001236-21,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Kjeld Schmiegelow,Plasma kinetics for tablet and liquid formulations of 6-mercaptopurine in childhood acute lympholastic leukemia Plasmakinetik for tablet of flydende form af 6-mercapturine hos børn med akut lymphob...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001236-21,0,0,0 2013-001237-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Norwegian University of Science and Technology,A Randomized Phase III Study Comparing Maintenance Pemetrexed Therapy After Induction Chemotherapy Versus Pemetrexed at Progression in Advanced Non-Small-Cell Lung Cancer Randomisert fase III studi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001237-41,0,0,0 2013-001240-64,1,2018-06-19,2018-06-19,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Bispebjerg Hospital,Effect of intact GLP-1 (7-36) and GLP-1 metabolite (9-36) on coronary and peripheral vascular function in adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001240-64,0,0,0 2013-001241-13,8,2014-10-21,2018-01-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A three-year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active psoriatic arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001241-13,0,0,0 2013-001241-13,8,2014-10-21,2018-01-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farma SpA,"A three-year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with active psoriatic arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001241-13,0,0,0 2013-001244-56,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Pharmacy, Uppsala University","An open, multicenter, single dose, parallel study, evaluating the pharmacokinetics of doxorubicin and its active metabolite (doxorubicinol) after a hepatic intra-arterial injection of either a lipiodo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001244-56,0,0,0 2013-001245-14,7,2022-01-26,2022-01-26,5,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Celgene Corporation,"A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lympho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001245-14,1,0,0 2013-001248-67,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,almirall,CLINICAL TRIAL PHASE IIIb to evaluate predictors of response to linaclotide in patients with irritable bowel syndrome and explore the impact on intestinal symptoms ENSAYO CLÍNICO FASE IIIb para eva...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001248-67,0,0,0 2013-001249-15,1,2015-09-08,2015-09-08,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Otsuka Novel Products GmbH,"A Two-Part Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients with Advanced Cancers that are Poorly Responsive to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001249-15,0,0,0 2013-001250-10,5,2016-07-28,2016-07-28,3,0,0,0,1,0,4,0,0,2,0,0,0,0,1,Laboratoires Thea,"Safety and Efficacy assessment of Monoprost® (unpreserved latanoprost) in comparison with Lumigan® 0.01 % and Lumigan® 0.03% UD, in patients with open angle glaucoma or ocular hypertension, stabilized...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001250-10,1,0,0 2013-001256-36,1,2014-07-14,2014-07-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Fachingen Heil- und Mineralbrunnen GmbH,Pilot study with Staatl. Fachingen STILL for functional dyspepsia (particularly heartburn) Pilotstudie mit Staatl. Fachingen STILL bei funktionellen dyspeptischen Beschwerden (insbesondere Sodbrenn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001256-36,0,0,0 2013-001258-82,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,European Institute for Cystic Fibrosis Research (IERFC),"A phase II pilot clinical study of experimental research to evaluate the functional rescue of CFTR protein through proteostasis regulators Studio clinico pilota di ricerca sperimentale di fase II, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001258-82,0,0,0 2013-001259-11,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Zon MW,Tacrolimus suppositories versus beclomethason suppositories for the treatment of proctitis refractory to local 5-ASA. De effecten van tacrolimus zetpillen vergeleken met beclomethason zetpillen bij...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001259-11,0,0,0 2013-001260-34,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Maastricht University Medical Center,TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001260-34,0,0,0 2013-001262-42,1,2019-11-13,2019-11-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,National Stroke Research Institute,STOP-AUST: The Spot sign and Tranexamic acid On Preventing ICH growth – AUStralasia Trial STOP-AUST -tutkimus traneksaamihapon käytöstä aivoverenvuodon kasvun estämisessä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001262-42,0,0,0 2013-001263-23,3,2016-05-05,2016-05-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RO5186582 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001263-23,0,0,0 2013-001263-23,3,2016-05-05,2016-05-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farma, S.A. en nombre de F. Hoffmann-La Roche Ltd","A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RO5186582 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001263-23,0,0,0 2013-001265-16,4,2016-06-01,2016-06-01,3,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Novartis Pharma Services AG,"An Open-Label, Single-arm, Phase Ib/II study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR inhibitor) in Patients with CD79-mutant or ABC subtype Diffuse Large B-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001265-16,0,0,0 2013-001265-16,4,2016-06-01,2016-06-01,3,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Novartis Farma S.p.A,"An Open-Label, Single-arm, Phase Ib/II study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR inhibitor) in Patients with CD79-mutant or ABC subtype Diffuse Large B-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001265-16,0,0,0 2013-001267-23,1,2014-10-29,2014-10-29,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharma Patent Kft,"Open label multicentric study to evalute the safety and efficacy of CitrokalciumD 300 mg/300 NE tablets in patients assessed deficiency for supplementation of calcium and vitamin D. Nyílt, mul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001267-23,0,0,0 2013-001268-44,1,,,0,0,1,0,0,0,4,0,0,4,0,0,0,0,1,"Chiesi USA, Inc.","Open label study to assess the efficacy, safety and dosing of clevidipine in pediatric patients undergoing surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001268-44,0,1,1 2013-001269-18,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Universitätsklinikum Ulm (AöR),"A multicenter phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs). DETECT IV – Multizentrische, prospektive, offene Ph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001269-18,0,0,0 2013-001271-20,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,L. Molteni & C dei F.lli Alitti Società di Esercizio S.p.A.,"A multicenter randomized open trial to evaluate the efficacy of fentanyl pectin nasal spray (FPNS) versus Physician Choice (PC) - Usual Care (UC), in reducing incidental predictable breakthrough pain ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001271-20,0,0,0 2013-001275-21,1,2019-12-09,2019-12-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre Jean Perrin,Phase II study: individualization of dosage of irinotecan in the FOLFIRI according to the genetic polymorphism of UGT1A1 in the first line treatment of metastatic colorectal cancer Etude de phase I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001275-21,0,0,0 2013-001276-38,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,PsiOxus Therapeutics Ltd,A Clinical Study Of ColoAd1 Administered Intraperitoneally: Dose Finding and Proof of Concept in Platinum-Resistant Epithelial Ovarian Cancer Estudio clínico de ColoAd1 (INN: EnAd) administrado por...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001276-38,0,0,0 2013-001277-24,10,2016-10-10,2016-10-10,9,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Amgen Inc,"A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG 337 in Subjects with MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001277-24,1,0,0 2013-001279-19,3,2015-07-09,2015-07-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Amgen, Inc","A Multicenter, Double-blind, Randomized Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001279-19,0,0,0 2013-001280-23,3,2017-01-03,2017-01-03,3,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Isofol Medical AB,"An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the Modufolin® Dose with Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity duri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001280-23,0,0,0 2013-001284-23,3,2018-04-24,2018-04-24,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merckle GmbH,"A randomized, phase IIIB, open-label, two-arm, multicenter, comparatiVe study on efficacy and safety of lipegfilgrastim (Lonquex, TEVA) in comparison to pegfilgrastim (Neulasta®, Amgen) in elderly pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001284-23,0,0,0 2013-001287-34,1,2015-03-17,2015-03-17,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A single blind, placebo controlled pilot study to explore the safety and tolerability of a single oral dose of 30 mg BAY 1067197 in patients with chronic heart failure on the background of preexisting...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001287-34,0,0,0 2013-001291-38,9,2015-12-30,2017-01-31,7,1,1,0,0,1,1,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"Open, non-controlled, dose escalating Phase I trial to evaluate the pharmacokinetics, pharmacodynamics, tolerability and toxicity of volasertib in paediatric patients from 2 years to less than 18 year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001291-38,0,0,0 2013-001291-38,9,2015-12-30,2017-01-31,7,1,1,0,0,1,1,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd,"Open, non-controlled, dose escalating Phase I trial to evaluate the pharmacokinetics, pharmacodynamics, tolerability and toxicity of volasertib in paediatric patients from 2 years to less than 18 year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001291-38,0,0,0 2013-001291-38,9,2015-12-30,2017-01-31,7,1,1,0,0,1,1,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"Open, non-controlled, dose escalating Phase I trial to evaluate the pharmacokinetics, pharmacodynamics, tolerability and toxicity of volasertib in paediatric patients from 2 years to less than 18 year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001291-38,0,0,0 2013-001291-38,9,2015-12-30,2017-01-31,7,1,1,0,0,1,1,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"Open, non-controlled, dose escalating Phase I trial to evaluate the pharmacokinetics, pharmacodynamics, tolerability and toxicity of volasertib in paediatric patients from 2 years to less than 18 year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001291-38,0,0,0 2013-001291-38,9,2015-12-30,2017-01-31,7,1,1,0,0,1,1,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"Open, non-controlled, dose escalating Phase I trial to evaluate the pharmacokinetics, pharmacodynamics, tolerability and toxicity of volasertib in paediatric patients from 2 years to less than 18 year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001291-38,0,0,0 2013-001291-38,9,2015-12-30,2017-01-31,7,1,1,0,0,1,1,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co.KG,"Open, non-controlled, dose escalating Phase I trial to evaluate the pharmacokinetics, pharmacodynamics, tolerability and toxicity of volasertib in paediatric patients from 2 years to less than 18 year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001291-38,0,0,0 2013-001294-24,1,2017-11-11,2017-11-11,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Medizinischen Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin/Charité - Universitätsmedizin Berlin,The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Natural regulatory T-cells (nTregs) Trial. Die ONE-Studie: Ein einheitlicher Ansatz zur Bewer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001294-24,0,0,0 2013-001295-38,1,2013-12-23,2013-12-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klin. Abt. für Endokrinologie und Stoffwechsel","An open, single-centre, non-controlled study of efficacy, safety and usability of the GlucoTab system for glycaemic management in non-critically ill patients with type 2 diabetes at general wards",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001295-38,0,0,0 2013-001296-20,1,2016-04-19,2016-04-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Medizinische Universität Innsbruck,Randomized Phase IV Trial to Compare Cetuximab with Concomitant Radiation Therapy with Concomitant Mitomycin-C and 5-FU with Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of The Head...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001296-20,0,0,0 2013-001303-36,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud,Intrarticular injections of platelet-rich plasma in pain?s treatment of the Osteoarthritic Knee INFILTRACIÓN INTRARTICULAR DE PLASMA RICO EN PLAQUETAS EN EL TRATAMIENTO DEL DOLOR DE RODILLA CON AR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001303-36,0,0,0 2013-001304-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud,"Evaluation of myocardial and clinical beneficial effect of sevoflurane in intraoperative and postoperative myocardial revascularization surgery, compared with propofol Evaluación del efecto bene...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001304-11,0,0,0 2013-001308-13,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,LABORATORIOS LETI S.L.U,Biological standardization of Alternaria alternata allergen extract to determine the biological activity in histamine equivalent units (HEP). Estandarización biológica del extracto alergénico de Al...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001308-13,0,0,0 2013-001309-98,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"LABORATORIOS LETI, S.L.Unipersonal",Biological standarization of Cupressus arizonica allergen extract to determine the biological activity in histamine equivalent units (HEP) Estandarización biológica del extracto alergénico de Cupre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001309-98,0,0,0 2013-001310-15,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"LABORATORIOS LETI, S.L.U",Biological standardization of Artemisia vulgaris allergen extract to determine the biological activity in histamine equivalent units (HEP). Estandarización biológica del extracto alergénico de Arte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001310-15,0,0,0 2013-001312-30,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Università di Napoli Federico II,Long term effects of selective beta1-adrenoceptor blockade with bisoprolol on hospital readmissions of elderly patients with coexisting heart failure and chronic obstructive pulmonary disease: a multi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001312-30,0,0,0 2013-001314-15,5,2017-07-24,2017-07-24,4,1,0,0,0,0,3,0,1,2,0,0,0,0,1,Merck & Co. Inc,"A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, administered in Prea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001314-15,1,1,0 2013-001314-15,5,2017-07-24,2017-07-24,4,1,0,0,0,0,3,0,1,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, administered in Prea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001314-15,1,1,0 2013-001315-71,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Mercedes Zumarraga Ortiz,Dopaminergic genotype of schizophrenic patients and the benefit of adjunctive aripiprazole to risperidone treatment. The effect on hormonal and metabolic measures Perfil dopaminérgico de los pacien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001315-71,0,0,0 2013-001318-14,1,2013-10-21,2013-10-21,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,PH&T SpA,"MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED, CLINICAL STUDY TO DEMONSTRATE THE THERAPEUTIC CLINICAL EQUIVALENCE OF TWO MOMETASONE NASAL SPRAYS IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001318-14,0,0,0 2013-001322-26,3,2017-06-30,2021-11-18,3,1,0,0,0,1,2,0,0,1,0,0,0,0,1,SOTIO a.s.,"A randomized, open-label, three-arm, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to first line standard chemotherapy (carboplatin and paclitaxel) in women with new...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001322-26,0,0,0 2013-001323-38,3,2018-05-17,2018-05-17,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,SOTIO a.s.,"A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to standard chemotherapy (carboplatin and gemcitabine) in women with relapsed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001323-38,0,0,0 2013-001325-24,3,2016-08-02,2016-08-02,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,SOTIO a.s.,"A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to standard chemotherapy in women with relapsed platinum resistant epithelial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001325-24,0,0,0 2013-001326-25,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación SENEFRO,Efficacy and safety of paricalcitol in the reduction of secondary hyperparathyroidism after renal transplantation. Eficacia y seguridad del paricalcitol para la reducción del hiperparatiroidismo se...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001326-25,0,0,0 2013-001330-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro,Comparison between diagnostic accuracy of [11C]-choline PET/CT and conventional imaging in prostate cancer patients Confronto tra l’accuratezza diagnostica della [11C]-colina e dell’imaging conven...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001330-17,0,0,0 2013-001332-22,1,2015-06-30,2015-06-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Birmingham,PEPtalk 2: Pilot of a randomised controlled trial to compare VZIG and aciclovir as post-exposure prophylaxis against chickenpox in children with cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001332-22,0,0,0 2013-001347-31,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,Abbott Laboratories GmbH,"A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects with Diabetes Mellitus type 2 Est...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001347-31,0,0,0 2013-001352-34,8,2020-06-26,2020-06-27,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc,","A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001352-34,0,0,0 2013-001352-34,8,2020-06-26,2020-06-27,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001352-34,0,0,0 2013-001353-28,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,InterMune Inc.,"An Open-Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone when Administered to Patients with Systemic Sclerosis-Related Interstitial Lung Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001353-28,0,0,0 2013-001354-95,1,2016-03-31,2016-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Keele University,"A randomised, multi-centre, open-label, active-comparator, pragmatic clinical trial of low-dose colchicine versus naproxen in patients with acute gout.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001354-95,0,0,0 2013-001356-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"""G. d'Annunzio"" University","Effects of liraglutide or lifestyle counselling on subcutaneous adipose tissue and visceral adipose tissue distribution, circulating adipokine concentration, insulin sensitivity and beta-cell performa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001356-36,0,0,0 2013-001357-26,1,2017-11-28,2017-11-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Clinical Trial Center Aachen,HIGH DOSE SUPPLEMENTATION OF SELENIUM IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) IMPLANT SURGERY – A DOUBLE BLIND RANDOMISED CONTROLLED TRIAL DOPPELBLIND RANDOMISIERT KONTROLLIERTE STUDIE ZUR ANWENDU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001357-26,0,0,0 2013-001358-81,2,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,Coretherapix S.L.U.,"""First-in-human clinical trial, double blind, randomized with placebo, open for the six first patients (dose ranging), to evaluate the safety and efficacy of intracoronary infusion of allogeneic human...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001358-81,0,0,0 2013-001359-11,7,2016-09-23,2016-09-25,6,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,"A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX 855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001359-11,0,0,0 2013-001359-11,7,2016-09-23,2016-09-25,6,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Baxalta Innovations GmbH,"A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX 855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001359-11,0,0,0 2013-001360-36,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,ULB - Unité de Recherche en Lymphologie - Faculté des Sciences de la motricité,Evaluation of the benefit of lymphofluoroscopy in the validation of the manual drainage techniques on lymphedema Evaluation de l'intérêt de la lymphofluoroscopie dans la validation des techniques d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001360-36,0,0,0 2013-001361-16,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,CHU AMIENS,"Randomized prospective clinical study evaluating the usefulness of fibrin glue (TISSEEL) to prevent gastric fistula, intra abdominal haemorrhage and intra abdominal loco regional collections after Lap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001361-16,0,0,0 2013-001362-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione IRCCS Istituto Nazionale dei Tumori,"Perioperative treatment with COI-B (Capecitabine, Oxaliplatin, Irinotecan and Bevacizumab) of high risk or borderline resectable colorectal liver metastases Trattamento perioperatorio con COI-B (Ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001362-42,0,0,0 2013-001363-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Oslo University Hospital,N-of-1 trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001363-23,0,0,0 2013-001364-30,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Bispebjerg Hospital,"Ultrasoundguided transmuscular quadrates lumborum block after elective laparoscopic cholecystectomy. A prospective, randomised clinical trial. Ultralydsvejledt Transmuskulær Quadratus Lumborum blok...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001364-30,0,0,0 2013-001368-46,6,2016-04-04,2016-04-04,6,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001368-46,0,0,0 2013-001368-46,6,2016-04-04,2016-04-04,6,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001368-46,0,0,0 2013-001370-20,4,2016-12-01,2016-12-01,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Glaxo Group Ltd,"OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects with Pemphigus Vulgaris",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001370-20,0,0,0 2013-001370-20,4,2016-12-01,2016-12-01,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma AG,"OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects with Pemphigus Vulgaris",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001370-20,0,0,0 2013-001371-20,6,2022-02-23,2022-02-23,4,0,0,0,0,1,4,0,0,2,0,0,0,0,1,GlaxoSmithKline Research and Development Ltd,Study 200170: A Rollover Study to Provide Continued Treatment with Eltrombopag,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001371-20,1,0,0 2013-001371-20,6,2022-02-23,2022-02-23,4,0,0,0,0,1,4,0,0,2,0,0,0,0,1,"GlaxoSmithKline, S.A.",Study 200170: A Rollover Study to Provide Continued Treatment with Eltrombopag,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001371-20,1,0,0 2013-001383-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Witten-Herdecke University,Hypericum perforatum to improve post-operative Pain Outcome after monosegmental Spinal microdistectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001383-31,0,0,0 2013-001384-23,15,2014-08-22,2014-09-01,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Regado Biosciences, Inc.","A RANDOMIZED, OPEN-LABEL, MULTI-CENTER, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF THE REG1 ANTICOAGULATION SYSTEM COMPARED TO BIVALIRUDIN IN PATIENTS UNDERGOING P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001384-23,0,0,0 2013-001389-40,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Mari Grönroos,Daylight-PDT in the treatment of actinic keratosis: a pilot study comparing two different light sensitizers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001389-40,0,0,0 2013-001393-19,1,2017-05-31,2017-05-31,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Uppsala university,CD19-targeting 3rd generation CAR T cells for refractory B cell malignancy - a phase I/IIa trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001393-19,0,0,0 2013-001394-25,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Universidad de Salamanca,"Prospective, randomized, open-label, blinded-endpoint, paralell groups, multicentric clinical trial to compare the efficacy of administration of enalapril 20 mg + lercanidipine 10 mg versus enalapril ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001394-25,0,0,0 2013-001400-11,1,2013-12-14,2013-12-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of anesthesiology, Bispebjerg Hospital",Optimal postoperative pain management by ultrasoundguided abdominal wall nerve blockade for laparoscopic surgery for acute appendicitis - a randomised controlled trial. Optimal smertebehandling med...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001400-11,0,0,0 2013-001402-28,1,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 2/3, Multicenter, Open-label, Multicohort, Two-Part Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001402-28,0,0,0 2013-001405-90,1,2020-06-25,2020-06-25,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,GENSIGHT-BIOLOGICS,"A phase I/IIa, non randomized, escalating dose, open-label study to evaluate safety and efficacy of GS010 (rAAV2/2-ND4) in patients suffering from Leber Hereditary Optic Neuropathy due to mutations in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001405-90,0,0,0 2013-001407-36,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Medizinische Universität Graz,Assessment of Hepatic Glucose Production Following Repeated Glucagon Administration in Type 1 Diabetes Patients Untersuchung der hepatischen Glukoseproduktion nach wiederholter Glukagon-Bolusgabe b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001407-36,0,0,0 2013-001409-10,1,2013-11-01,2013-11-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Odense University Hospital,FATIMS - Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Fampyra induced immunomodulatory T cell responses in MS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001409-10,0,0,0 2013-001410-16,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Netherlands Heart Foundation,Effects of low-dose aspirin taken at bedtime vs. on awakening on circadian rhythm of platelet function in healthy subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001410-16,0,0,0 2013-001416-30,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación Oncosur,?Multicenter study of a single arm to evaluate the safety of eribulin in 3rd line chemotherapy for patients with HER2-negative metastatic or locally advanced previously treated with anthracyclines and...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001416-30,0,0,0 2013-001417-32,5,2016-08-17,2016-08-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheumatoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001417-32,0,0,0 2013-001418-13,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Sanofi-aventis recherche & développement,"A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001418-13,0,0,0 2013-001419-64,1,2015-06-15,2015-06-15,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Takeda Vaccines (Montana), Inc.","A Phase II, Randomized, Controlled, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Adjuvant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001419-64,0,0,0 2013-001420-19,1,2013-06-21,2013-06-21,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,bioCSL Pty Ltd,"A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of a bioCSL split virion, inactivated influenza vaccine in Healthy Volunteers aged 18...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001420-19,0,0,0 2013-001421-55,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,Novartis Pharma S.A.S,An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001421-55,0,0,0 2013-001422-25,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Biogen Idec Italia S.r.l.,Single country study assessing cognition in Relapsing Remitting Multiple Sclerosis patients treated with BG00012 Studio “single-country” per la valutazione delle funzioni cognitive in pazienti aff...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001422-25,0,0,0 2013-001426-26,2,2014-06-26,2014-06-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A phase 2, randomized, open label study to evaluate the efficacy, safety, pharmacodynamics, pharmacokinetics of the anti-ALK-1 MAB PF-03446962 in combination with best supportive care vs. best support...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001426-26,0,0,0 2013-001428-20,1,2016-04-25,2016-04-25,1,0,0,0,1,1,2,0,0,1,0,0,1,0,0,Aarhus University Hospital,"Randomized, single-blind crossover study of subcutaneous immunoglobulin in newly diagnosed patients with chronic inflammatory demyelinating polyradiculoneuropathy Randomiseret, enkelt blindet cross...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001428-20,0,0,0 2013-001432-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,INSTITUT CURIE,A Multicenter Open label Phase II study of Pomalidomide and Cyclophosphamide and Dexamethasone in relapse/refractory Multiple Myeloma patients who were first treated within the IFM/DFCI 2009 trial ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001432-22,0,0,0 2013-001435-48,1,2019-02-26,2019-02-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Keele University,The clinical and cost effectiveness of a steroid injection versus a night splint for Carpal Tunnel Syndrome: a pragmatic randomised trial in primary care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001435-48,0,0,0 2013-001436-22,1,2016-06-30,2016-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee/NHS Tayside,Does ALlopurinol regress lefT ventricular hypertrophy in End stage REnal Disease: The ALTERED study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001436-22,0,0,0 2013-001439-34,9,2015-11-19,2015-11-19,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Genzyme Corporation,"A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001439-34,0,0,0 2013-001442-34,1,2013-09-24,2013-09-24,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,McNeil AB,"A SINGLE-DOSE, RANDOMIZED, TWO-PERIOD, CROSSOVER STUDY TO ASSESS BIOEQUIVALENCE BETWEEN TWO IBUPROFEN 200 MG TABLET FORMULATIONS, IN HEALTHY ADULTS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001442-34,0,0,0 2013-001443-31,1,2020-06-04,2020-06-04,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,CHU de Nantes,"Phase II trial studying the efficacy of a triplet combination of MLN9708, lenalidomide and dexamethasone as induction prior to, and as consolidation after high-dose therapy with peripheral stem cell t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001443-31,0,0,0 2013-001445-13,1,2014-01-09,2014-01-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, double-blind, multicenter, 2-period single-dose cross-over study to assess the early bronchodilation of Glycopyrronium bromide (44 µg o.d.) compared to Tiotropium (18 µg. o.d.) in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001445-13,0,0,0 2013-001447-31,1,2018-03-07,2018-03-07,1,0,0,0,0,1,3,0,0,1,1,1,1,0,0,Liverpool Heart and Chest Hospital NHS Foundation Trust,"A randomised controlled trial to study the effect of acetazolamide on the incidence of blood-stained CSF, effect on cerebrospinal fluid (CSF) pressure, CSF drainage and neurological dysfunction in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001447-31,0,0,0 2013-001448-75,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Optimer Pharmaceutical, Inc. (a Cubist company)","A Phase 2A, Multi-Center, Open-Label, Uncontrolled Study to Determine the Safety, Tolerability, and Pharmacokinetics of fidaxomicin Oral Suspension or Tablets in Pediatric Subjects With Clostridium di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001448-75,0,1,1 2013-001449-15,15,2022-06-27,2022-06-27,11,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.",AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001449-15,1,0,0 2013-001463-23,1,2018-09-13,2018-09-13,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,GERCOR,Randomized Phase II Study of Weekly ABI-007 plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients with Metastatic Pancreatic Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001463-23,0,0,0 2013-001467-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Italian Sarcoma Group,SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001467-23,0,0,0 2013-001472-38,6,2019-04-26,2019-04-26,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Aprea Therapeutics AB,"PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001472-38,0,0,0 2013-001472-38,6,2019-04-26,2019-04-26,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Aprea AB,"PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001472-38,0,0,0 2013-001473-24,3,2015-08-31,2015-10-14,2,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Eli Lilly and Company,"An Individualized treatMent aPproach for oldER patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001473-24,0,0,0 2013-001476-37,6,2020-10-01,2021-11-17,3,1,1,0,0,0,2,0,0,2,1,0,0,0,0,PENTA Foundation,"SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17) - A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001476-37,1,0,0 2013-001476-37,6,2020-10-01,2021-11-17,3,1,1,0,0,0,2,0,0,2,1,0,0,0,0,Fondazione PENTA ONLUS,"SMILE: Strategy for Maintenance of HIV suppression with elvitegravir+darunavir/ritonavir in children (PENTA 17) - A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001476-37,1,0,0 2013-001477-25,1,2015-02-11,2015-02-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, double-blind, placebo-controlled, multicenter cross-over study to assess the effects of a 3 week therapy each with QVA149 versus placebo on pulmonary function and average physical activi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001477-25,0,0,0 2013-001479-18,1,2018-06-30,2018-06-30,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Manchester University NHS Foundation Trust,"A Phase III, Double Blinded, Randomised, Placebo Controlled Clinical Trial of High Dose Oral Genistein Aglycone in Patients with Sanfilippo Syndrome (Mucopolysaccharidosis III)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001479-18,0,0,0 2013-001483-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Istituto Oncologico Veneto,XELODA metronomic IN PATIENTS WITH advanced hepatocellular carcinoma AND FUNCTIONALITY 'LIVER CHILD-PUGH B XELODA METRONOMICO NEI PAZIENTI CON EPATOCARCINOMA AVANZATO e FUNZIONALITA' EPATICA CHILD-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001483-39,0,0,0 2013-001484-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,BOOG Study Center,Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-line treatment in advanced triple negative Breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001484-23,0,0,0 2013-001486-17,1,2016-03-11,2016-03-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Biogen Idec Research Limited,"A Multicenter, Open-Label, Single-Arm Study to Evaluate Gastrointestinal Tolerability in Subjects with Relapsing-Remitting Multiple Sclerosis Receiving Dimethyl Fumarate (TOLERATE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001486-17,0,0,0 2013-001490-25,1,2017-11-20,2017-11-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Aberdeen,"A randomised, double-blind placebo controlled trial of the effectiveness of low dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001490-25,0,0,0 2013-001490-25,1,2017-11-20,2017-11-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,NHS Grampian,"A randomised, double-blind placebo controlled trial of the effectiveness of low dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001490-25,0,0,0 2013-001492-20,4,2014-08-07,2014-08-11,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novo Nordisk A/S,"A randomised, active comparator, double-blind, multi centre, parallel, phase 2a trial, investigating the mechanism of action of NNC0109-0012 (anti-IL-20 mAb) through synovial biopsies in subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001492-20,0,0,0 2013-001494-24,2,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,"Razor Genomics, Inc.",A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I Non-Squamous Non-Small Cell Lung Cancer Identified as High Risk by the Pervenio? Lung RS Assay E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001494-24,0,0,0 2013-001494-24,2,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,"Encore Clinical, Inc",A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I Non-Squamous Non-Small Cell Lung Cancer Identified as High Risk by the Pervenio? Lung RS Assay E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001494-24,0,0,0 2013-001496-21,1,2016-01-08,2016-01-08,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Harry Scheinin,The Neural Mechanisms of Anesthesia and Human Consciousness,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001496-21,0,0,0 2013-001497-16,11,2018-07-06,2018-07-06,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001497-16,0,0,0 2013-001498-25,20,2017-01-01,2017-01-27,17,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001498-25,0,0,0 2013-001498-25,20,2017-01-01,2017-01-27,17,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001498-25,0,0,0 2013-001498-25,20,2017-01-01,2017-01-27,17,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Farma SpA,"A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001498-25,0,0,0 2013-001503-37,1,2015-04-26,2015-04-26,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Marianne Kiszka-Kanowitz,Effect of low-dose Azathioprine and Allopurinol compared to Azathioprine on clinical outcomes in Inflammatory Bowel Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001503-37,0,0,0 2013-001505-93,2,2014-11-13,2014-11-13,1,1,1,0,0,1,1,0,0,2,0,0,0,0,1,Bioprojet Pharma,"A MULTI-CENTRE, SINGLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS OF PITOLISANT (BF2.649) IN CHILDREN FROM 6 TO LESS THAN 18 YEARS WITH NARCOLEPSY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001505-93,1,0,0 2013-001506-29,5,,,0,0,1,0,0,1,0,0,0,2,0,0,0,0,1,BIOPROJET PHARMA,"DOUBLE BLIND, MULTICENTRE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE SAFETY AND EFFICACY OF PITOLISANT IN CHILDREN FROM 6 TO LESS THAN 18 YEARS WITH NARCOLEPSY WITH/WITHOUT CATAPLEXY, FOLLOWED ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001506-29,0,0,0 2013-001506-29,5,,,0,0,1,0,0,1,0,0,0,2,0,0,0,0,1,Bioprojet,"DOUBLE BLIND, MULTICENTRE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE SAFETY AND EFFICACY OF PITOLISANT IN CHILDREN FROM 6 TO LESS THAN 18 YEARS WITH NARCOLEPSY WITH/WITHOUT CATAPLEXY, FOLLOWED ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001506-29,0,0,0 2013-001511-70,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Maastricht University Medical Center,"Efficacy, safety and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutations related small fiber neuropathy: a randomized, double-blind, placebo controlled, crossover trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001511-70,0,0,0 2013-001513-33,1,2014-03-17,2014-03-17,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Laboratorios León Farma S.A.,Phase II trial to evaluate the maintenance of ovulation inhibition with LF111 (drospirenone 4.0 mg 24/4 regimen) after scheduled 24-hour delays in pill intake.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001513-33,0,0,0 2013-001514-15,2,2015-04-09,2015-04-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec Research Limited,"A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischemic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001514-15,0,0,0 2013-001517-32,8,2014-09-23,2014-09-23,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Kowa Research Europe,A dose finding study to assess the safety and efficacy of K-877 in patients with statin-controlled LDL-C but abnormal lipid levels,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001517-32,0,0,0 2013-001521-43,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,"Queen Mary, University of London","A Phase II, double blind, randomised, placebo-controlled study of the AKT inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001521-43,0,0,0 2013-001521-43,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Queen Mary University of London,"A Phase II, double blind, randomised, placebo-controlled study of the AKT inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001521-43,0,0,0 2013-001523-39,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,Sunovion Pharmaceuticals Inc.,"A PHASE 1 OPEN-LABEL, MULTICENTER, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF LURASIDONE IN SUBJECTS 6 TO 17 YEARS OLD WITH SCHIZOPHRENIA SPECTR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001523-39,0,1,1 2013-001525-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Studying the metabolism of sorafenib (Nexavar®) by OATP1B blockage in adult cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001525-10,0,0,0 2013-001526-26,11,2015-04-17,2016-07-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","An Observational Follow-Up Study for: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001526-26,0,0,0 2013-001526-26,11,2015-04-17,2016-07-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp.,","An Observational Follow-Up Study for: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001526-26,0,0,0 2013-001527-39,7,2016-12-19,2016-12-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Auris Medical AG,AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) ? an open-label extension to the TACTT3 study Extensión en abierto del estudio TACTT3: AM-101 en el tratamiento postagudo de ti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001527-39,0,0,0 2013-001534-18,1,2015-03-16,2015-03-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AesRx,"A Phase 2, Exploratory, Placebo-Controlled, Multicenter, Double-Blind Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Five Dose Regimens of Aes-103 Given for 28 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001534-18,0,0,0 2013-001538-16,4,2018-02-13,2018-02-13,3,1,0,0,0,0,2,0,0,2,0,0,0,0,1,LEO Pharma A/S,"Effect of Calcipotriol plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 months) with Scalp and Body Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001538-16,1,0,0 2013-001539-35,2,2014-10-23,2014-10-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,POXEL S.A.,"A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of one dose of imeglimin versus placebo after 18 weeks of treatment in subjects with type 2 diabetes mel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001539-35,0,0,0 2013-001540-60,1,2017-09-26,2017-09-26,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Mech-Sense, Aalborg University Hospital",A novel approach to assess gastrointestinal adverse effects of opioids En ny tilgang til at evaluere opioiders bivirkninger på mavetarmsystemet.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001540-60,0,0,0 2013-001543-31,5,2016-03-21,2016-04-20,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001543-31,0,0,0 2013-001546-34,2,2020-05-14,2020-05-14,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,University Hospital Tübingen,Neoadjuvant treatment with the combination of vemurafenib and cobimetinib (GDC-0973) in limited metastasis of malignant melanoma (AJCC stage IIIC/IV) and integrated biomarker study: a single armed ph...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001546-34,0,0,0 2013-001549-15,1,2018-06-11,2018-06-11,1,1,0,0,0,1,3,0,1,1,0,0,1,0,1,"Pfizer Inc (235 East 42nd Street, New York, New York 10017)",The long-term antibody persistence of MenACWY-TT vaccine (PF-06866681) versus Meningitec® or Mencevax® ACWY in healthy adolescents and adults and a booster dose of MenACWY-TT administered 10 years pos...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001549-15,0,0,0 2013-001550-98,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,University Hospital of Ulm,Prospective controlled phase 2 trial of cabazitaxel in patients with temozolomide refractory glioblastoma multiforme (GBM) - The C-GBM Study -,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001550-98,0,0,0 2013-001551-13,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following Fir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001551-13,0,0,0 2013-001554-10,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Radboudumc,Mifepristone and misoprostol versus misoprostol alone for uterine evacuation after early pregnancy failure: a pilot study Mifepristone en misoprostol versus misoprostol alleen bij de behandeling va...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001554-10,0,0,0 2013-001555-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jules Bordet Institute,Evaluation of Near-Infra-Red Imaging after peri-areolar and subcutaneous injections of ICG in comparison with the lymphoscintigraphic technique using intra-mammary and peri-tumoral injection of 99mTc-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001555-12,0,0,0 2013-001556-35,9,2015-01-16,2015-01-23,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Octapharma AG,"Prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of individually tailored prophylaxis with Human-cl rhFVIII in previously treated adult patients with severe haemop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001556-35,0,0,0 2013-001557-27,2,2015-09-23,2015-09-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLLED TRIALTO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF PF-04360365 (PONEZUMAB) IN ADULT SUBJECTS WITH PROBABLE CEREBRAL AMYL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001557-27,0,0,0 2013-001558-87,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Karolinska University Hospital,Safety of normalising slightly elevated plasma glucose by Exenatide in acute ischemic stroke patients treated with intravenous thrombolysis: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001558-87,0,0,0 2013-001559-11,1,2017-03-01,2017-03-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Herlev University Hospital,"Chemotherapy with gemcitabine, capecitabine, irinotecan and bevacizumab to patients with cholangiocarcinoma after progression on first line treatment.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001559-11,0,0,0 2013-001562-42,4,2015-03-31,2015-03-31,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, parallel group, active-controlled study to compare the systolic blood pressure lowering efficacy of aliskiren, ramipril and a combination of aliskiren and amlodipine, with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001562-42,0,0,0 2013-001562-42,4,2015-03-31,2015-03-31,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, parallel group, active-controlled study to compare the systolic blood pressure lowering efficacy of aliskiren, ramipril and a combination of aliskiren and amlodipine, with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001562-42,0,0,0 2013-001564-37,1,2015-12-18,2015-12-18,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH,"One arm, Open label, Interventional, non-comparative Study to assess Changes in Lipids and Lipoproteins in HIV infected Women with Hyperlipidemia after Switch from boosted Protease Inhibitors to Ralte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001564-37,0,0,0 2013-001569-17,1,2016-07-05,2016-07-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche S.p.A.,"A national, open-label, single-arm, phase IIIB study to evaluate the efficacy of weekly tocilizumab subcutaneous, administered as monotherapy or in combination with methotrexate and/or other DMARDS in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001569-17,0,0,0 2013-001570-14,1,2014-11-03,2014-11-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,F. Hoffmann-La Roche Ltd.,A phase IB/II study to evaluate the safety and efficacy of vismodegib in relapsed/refractory acute myelogenous leukemia (AML) and relapsed/refractory high-risk myelodysplastic syndrome (MDS).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001570-14,0,0,0 2013-001584-22,1,2014-08-28,2014-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gerolsteiner Brunnen GmbH & Co. KG,Pilot study with St. Gero for heartburn Pilotstudie mit St. Gero Heilwasser bei Sodbrennen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001584-22,0,0,0 2013-001590-25,4,2016-11-17,2016-11-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) MONOTHERAPY IN SUBJECTS WITH ACTIVE PSORIATIC A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001590-25,0,0,0 2013-001592-20,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,3,,Pilot study for studying the influence of low-dose propofol on the classification of movements from the electroencephalogram in healthy participants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001592-20,0,0,0 2013-001596-21,2,2015-12-02,2016-02-23,2,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Polyphor Ltd,"A phase II, open-label, multi-center study to assess pharmacokinetics (PK), safety and efficacy of POL7080 co-administered with standard of care (SoC) treatment in patients with ventilator- associated...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001596-21,0,0,0 2013-001599-40,1,2018-10-19,2018-10-19,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Charité - Universitätsmedizin Berlin,"Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001599-40,0,0,0 2013-001600-11,2,2013-10-21,2013-10-21,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,"Sangart, Inc.","A Phase 2 Multi-center, Randomized, Double-blind, Comparator-Controlled Dose Finding Study to Evaluate MP4CO for the Acute Treatment of Vaso-occlusive Crises in Subjects with Sickle Cell Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001600-11,0,0,0 2013-001601-85,1,2016-01-04,2016-01-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Münster,"Aprepitant in histamine-refractory chronic pruritus: a multicenter, randomized, double-blind, placebo-controlled, cross-over, phase II trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001601-85,0,0,0 2013-001602-28,1,2015-02-04,2015-02-04,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD S.N.C.,"An open-label, controlled, multi-centre study of the immunogenicity and safety of a challenge dose of HBVAXPRO® to explore the anamnestic immune response in healthy children vaccinated 10 years ago wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001602-28,0,0,0 2013-001607-36,1,2020-08-07,2020-08-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,SLL,Diagnosis of infection in prothesis by 18F-FDG-WBC-PET/CT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001607-36,0,0,0 2013-001613-33,1,2015-03-17,2015-03-17,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Thoraxclinic at the University of Heidelberg,Iloprost for Bridging to Heart Transplantation in Patients with Pulmonary Hypertension and Left Heart Failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001613-33,0,0,0 2013-001616-30,7,2017-01-03,2017-01-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A controlled, assessor-blind, parallel groups, multicentre, multinational trial evaluating the immunogenicity of FE 999049 in repeated cycles of controlled ovarian stimulation in women undergoing an a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001616-30,0,0,0 2013-001617-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AUSL di Piacenza,Thrombolysis in Minor Stroke Trombolisi negli ictus minori,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001617-32,0,0,0 2013-001619-62,4,2015-10-26,2015-10-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"IBSA, Institut Biochimique S.A.","A multicentre, comparative, randomised, double-blind, double-dummy clinical trial on the efficacy and safety of Condrosulf® versus Celebrex® and versus a placebo in the treatment of knee osteoarthriti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001619-62,0,0,0 2013-001620-20,1,2014-01-31,2014-01-31,1,0,0,0,1,0,3,0,1,1,0,0,1,0,1,Laboratorios Casen-Fleet S.L.U.,"Randomized, multicentre, single blind study to evaluate the effectiveness of two administration schedules of CitraFleet (sodium picosulfate plus magnesium citrate) to cleanse the colon Randomisiert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001620-20,0,0,0 2013-001626-26,1,2021-10-02,2021-10-02,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Saarland University,Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver cirrhosis and ascites (INCA trial) Einfluss einer NOD2-Genotyp-gesteuerten Antibiotikaprophylaxe auf das Über...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001626-26,0,0,0 2013-001627-39,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Greater Glasgow and Clyde,A randomized phase II/III study to assess the efficacy of trametinib (GSK 1120212) in patients with recurrent or progressive low-grade serous ovarian cancer or peritoneal cancer (GOG-0281),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001627-39,0,0,0 2013-001627-39,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Glasgow,A randomized phase II/III study to assess the efficacy of trametinib (GSK 1120212) in patients with recurrent or progressive low-grade serous ovarian cancer or peritoneal cancer (GOG-0281),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001627-39,0,0,0 2013-001629-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IRCCS AOU SAN MARTINO- IST,"A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatment of post-menopausal patients with endocrine-responsive ea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001629-23,0,0,0 2013-001630-18,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli – Fondazione “G.Pascale”,Multicentre phase 2 study of neoadjuvant oxaliplatin and capecitabine followed by chemo-radiotherapy in patients with locally advanced carcinoma of esphago-gastric junction. Studio multicentrico ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001630-18,0,0,0 2013-001632-21,5,2015-01-07,2015-01-07,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Maruho Europe Limited,"A randomized, double-blind, parallel group phase III multi-center trial to compare twice daily topical application of M518101, Daivonex® and vehicle in patients with plaque psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001632-21,0,0,0 2013-001633-41,2,2019-02-15,2019-02-15,2,0,0,0,0,1,3,0,0,1,0,0,1,0,0,University of Liverpool (UniLiv),"An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria aft...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001633-41,0,0,0 2013-001634-17,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA S. PAOLO,LONG-TERM 24-HOUR INTRAOCULAR PRESSURE CONTROL AND PROGRESSION RATE OBTAINED WITH THE ASSOCIATION OF COMBIGAN IN THE MORNING AND GANFORT IN THE EVENING COMPARED WITH LATANOPROST IN HIGH RISK OPEN-ANGL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001634-17,0,0,0 2013-001635-51,3,2015-02-16,2015-02-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Acacia Pharma Ltd,"Randomised, double-blind, dose-finding Phase II study to assess the efficacy of APD403 in the prevention of nausea and vomiting caused by cisplatin- or anthracycline/ cyclophosphamide (AC)-based chemo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001635-51,0,0,0 2013-001636-22,4,2017-05-15,2017-05-15,4,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Hospital of the University of Munich, Grosshadern","A prospective, randomized, parallel-group, open label, non-inferiority, multicenter trial of a 12 month vs. a short-term platelet function testing guided prasugrel therapy in acute coronary syndrome p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001636-22,0,0,0 2013-001636-22,4,2017-05-15,2017-05-15,4,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Klinikum der Universität München,"A prospective, randomized, parallel-group, open label, non-inferiority, multicenter trial of a 12 month vs. a short-term platelet function testing guided prasugrel therapy in acute coronary syndrome p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001636-22,0,0,0 2013-001637-40,1,2017-07-10,2017-07-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,MSD Italia s.r.l,Switching from regimens consisting of a RTV -boosted protease inhibitor plus TDF/ FTC to a combination of RAltegravir pluis NevIrapine and IAmivudine in HIV patients with suppressed viremia and and i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001637-40,0,0,0 2013-001639-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"1st Dep. of Medicine, General University Hospital (VFN) in Prague",Contribution to verify the effectiveness of adding granulocyte stimulating factor (G-CSF) to therapy 5 - Azacitidine patients with the high risk Myelodysplastic syndrome. Příspěvek k ověření účinn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001639-38,0,0,0 2013-001640-56,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Para la Investigación Biomédica de Córdoba,"Crossover clinical trial, randomized, double blind, placebo controlled trial. Modulation of cellular mediators and repair endothelial damage in patients with chronic renal disease through inhibition o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001640-56,0,0,0 2013-001643-30,2,2014-06-24,2014-06-24,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Farmacéutica S. A,"An 8-week randomized, double-blind, placebo-controlled factorial study to evaluate the efficacy and safety of LCZ696 alone and in combination with amlodipine in patients with essential hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001643-30,0,0,0 2013-001643-30,2,2014-06-24,2014-06-24,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An 8-week randomized, double-blind, placebo-controlled factorial study to evaluate the efficacy and safety of LCZ696 alone and in combination with amlodipine in patients with essential hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001643-30,0,0,0 2013-001644-65,3,2016-08-31,2016-08-31,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Alnylam Pharmaceuticals, Inc.","A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Hav...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001644-65,0,0,0 2013-001647-32,1,2019-07-18,2019-07-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Essai randomisé contre placebo, multicentrique, de non-infériorité comparant l’efficacité d’un traitement antibiotique court de 14 jours versus 21 jours dans les prostatites aiguës non nosocomiales, à...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001647-32,0,0,0 2013-001648-79,1,2017-12-31,2017-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Odense University Hospital,Epirubicin as 2nd line treatment to patients with TOP2A gene amplified and oxaliplatin refractory metastatic colerectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001648-79,0,0,0 2013-001650-94,1,2017-08-15,2017-08-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergan Limited,An Exploratory Study of the Safety and Efficacy of BOTOX® for the Treatment of Premature Ejaculation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001650-94,0,0,0 2013-001652-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001652-36,0,0,0 2013-001653-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic non small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001653-27,0,0,0 2013-001656-35,10,2020-01-09,2020-04-03,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Biogen Idec Research Limited,"A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera? (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects with Relapsing-Remitting Multiple S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001656-35,0,0,0 2013-001657-28,7,2019-11-26,2019-11-26,4,1,0,0,0,0,4,0,0,1,0,0,1,0,0,UNIVERSITY MEDICAL SCHOOL OF THE JOHANNES GUTENBERG UNIVERSITY MAINZ,Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial (HoT-PE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001657-28,0,0,0 2013-001657-28,7,2019-11-26,2019-11-26,4,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Medical Center of the Johannes Gutenberg University Mainz,Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial (HoT-PE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001657-28,0,0,0 2013-001659-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZLeuven,"Acute effects of Sildenafil on the hemodynamics, Right Ventricle performance and cyclic GMP concentration in Heart failure patients with preserved left ventricular ejection fraction and patients after...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001659-10,0,0,0 2013-001662-42,6,2017-11-21,2017-11-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001662-42,0,0,0 2013-001663-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO MILANO,Clinical and immunomodulatory effects of antibiotic therapy + pidotimod versus antibiotic therapy alone in patients with community-acquired pneumonia (CAP) Effetti immunomodulatori e clinici della ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001663-23,0,0,0 2013-001664-34,1,2018-04-24,2018-04-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Belfast HSC Trust,Vit-D in CRC - A Randomised Double Blind Placebo-Controlled Clinical Trial Of a Single Oral Cholecalciferol Treatment Against Surrogate End Point Biomarkers (SEBs) In Colon Cancer (CRC) Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001664-34,0,0,0 2013-001664-34,1,2018-04-24,2018-04-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Queens University Belfast,Vit-D in CRC - A Randomised Double Blind Placebo-Controlled Clinical Trial Of a Single Oral Cholecalciferol Treatment Against Surrogate End Point Biomarkers (SEBs) In Colon Cancer (CRC) Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001664-34,0,0,0 2013-001665-16,1,2016-06-15,2016-06-15,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,University Hospital Grenoble,Intranasal Sufentanyl analgesia Versus Morphine IV in Emergency room. Analgésie au Sufentanyl par voie Intra Nasale Versus Morphine IV aux Urgences,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001665-16,0,0,0 2013-001669-17,7,2017-01-03,2017-01-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the efficacy and safety of FE 999049 with follitropin alfa (GONAL-F) in controlled ovarian stimula...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001669-17,0,0,0 2013-001676-38,13,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, in Patients receivi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001676-38,0,0,0 2013-001677-24,1,2015-09-30,2015-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee,Do ACE inhibitors reduce postural instability in older people?: Towards a novel approach to falls prevention.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001677-24,0,0,0 2013-001677-24,1,2015-09-30,2015-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Tayside,Do ACE inhibitors reduce postural instability in older people?: Towards a novel approach to falls prevention.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001677-24,0,0,0 2013-001682-16,11,2019-11-11,2019-11-11,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001682-16,0,0,0 2013-001685-42,1,2015-01-29,2015-01-29,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Rigshospitalet,Changes in coagulation and platelet reactivity in HIV-1 infected patients switching between abacavir and tenofovir containing antiretroviral regimens,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001685-42,0,0,0 2013-001686-16,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Hôpitaux Universitaires de Strasbourg,EVALUATION D'UN GEL DE MORPHINE ORAL DANS LES MUCITES CHIMIOINDUITES DE L'ENFANT ET DU JEUNE ADULTE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001686-16,0,0,0 2013-001688-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Cirugía General y Digestiva Hospital Universitario de Bellvitge,Randomized multicenter trial in colorectal cancer patients with non-resectable metastasis. Impact of tumor resection versus chemotherapy alone in survival. ENSAYO CLÍNICO MULTICÉNTRICO ALEATORIZADO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001688-22,0,0,0 2013-001689-41,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Leeds,"Pain Reduction with Oral Methotrexate in knee Osteoarthritis, a pragmatic phase III trial of Treatment Effectiveness",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001689-41,0,0,0 2013-001694-24,10,2018-10-17,2018-10-17,6,1,1,0,0,0,3,0,0,2,1,0,0,0,1,SUNOVION PHARMACEUTICALS INC.,"A 104-WEEK, FLEXIBLE-DOSE, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN PEDIATRIC SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001694-24,1,1,0 2013-001694-24,10,2018-10-17,2018-10-17,6,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Sunovion Pharmaceuticals Inc.,"A 104-WEEK, FLEXIBLE-DOSE, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN PEDIATRIC SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001694-24,1,1,0 2013-001695-38,9,2015-12-29,2015-12-29,5,1,1,0,0,0,3,0,0,2,0,0,0,0,1,SUNOVION PHARMACEUTICALS INC.,"A 6-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001695-38,1,1,0 2013-001695-38,9,2015-12-29,2015-12-29,5,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Sunovion Pharmaceuticals Inc.,"A 6-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001695-38,1,1,0 2013-001696-21,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA,Prospective blinded study of the absorption of levothyroxine oral solution (Tirosint ® single-dose oral solution) in patients with hypothyroidism.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001696-21,0,0,0 2013-001697-17,2,2017-06-01,2017-06-01,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Ipsen Pharma GmbH,"PHASE II, MULTICENTRE, OPEN LABEL STUDY TO EVALUATE THE EFFICACY OF THE COMBINATION OF LANREOTIDE AUTOGEL 120 MG AND TEMOZOLOMIDE IN PATIENTS WITH PROGRESSIVE GASTRO-ENTERO-PANCREATIC NEUROENDOCRINE T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001697-17,0,0,0 2013-001699-39,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GlaxoSmithKline Research Development Ltd,"A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with advance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001699-39,0,0,0 2013-001701-85,3,2014-06-10,2014-06-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Akron Molecules GmbH,"A placebo controlled, double blind, randomised, 8-week phase IIa proof of concept study to assess the efficacy and safety of AKR 202 in patients with osteoarthritis pain.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001701-85,0,0,0 2013-001705-87,8,2021-12-10,2021-12-10,5,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001705-87,1,0,0 2013-001705-87,8,2021-12-10,2021-12-10,5,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"GlaxoSmithKline, S.A.","A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001705-87,1,0,0 2013-001705-87,8,2021-12-10,2021-12-10,5,0,0,0,0,1,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001705-87,1,0,0 2013-001707-36,8,2016-04-28,2016-07-06,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001707-36,0,0,0 2013-001710-15,1,2019-02-26,2019-02-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ARCAGY-GINECO,Phase II study in patient in first line for HER - metastasis breast cancer treated with eribulin and bevacizumab ESSAI DE PHASE II EVALUANT L’ASSOCIATION ÉRIBULINE (HALAVEN®) + BEVACIZUMAB (AVASTI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001710-15,0,0,0 2013-001714-15,1,2017-07-22,2017-07-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie",Phase II trial of capecitabine (Xeloda®) + nab-paclitaxel (Abraxane®) in patients with metastatic pancreatic cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001714-15,0,0,0 2013-001715-76,1,2014-10-16,2014-10-16,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KU Leuven-Drug Delivery and Disposition,Gastrointestinal behavior of simvastatin in healthy volunteers Gastrointestinaal gedrag van simvastatine in gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001715-76,0,0,0 2013-001716-30,1,2014-03-13,2014-03-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Clinical Research Center for Hair and Skin Science,"Exploratory, controlled, randomized, observer-blind intrainidividual clinical trial to evaluate the efficacy and the tolerability of topically applied 0.1% tyrothricin (Tyrosur® Gel) in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001716-30,0,0,0 2013-001722-25,1,2018-09-27,2018-09-27,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,VU University Medical Center,Cholinesterase inhibitors to slow progression of visual hallucinations in Parkinson’s disease: a multi-center placebo-controlled trial (CHEVAL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001722-25,0,0,0 2013-001724-19,1,2016-05-13,2016-05-13,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie",Pilot study to assess P-glycoprotein function at the blood-brain barrier of patients with mild to moderate Alzheimer's disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001724-19,0,0,0 2013-001725-10,1,2016-08-01,2016-08-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Wien,Bronchoscopic indocyanine green fluorescence imaging for the evaluation of tracheal perfusion after surgery Bronchoskopische ICG-Fluoreszenzanalyse in der Trachealchirurgie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001725-10,0,0,0 2013-001728-20,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ALK-Abelló S. A.,An open trial to assess the tolerability of AVANZ® Salsola immunotherapy Ensayo abierto para evaluar la tolerabilidad de la inmunoterapia con AVANZ® Salsola,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001728-20,0,0,0 2013-001729-26,5,2020-10-12,2020-10-12,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Celgene Corporation,"Phase 3b, Randomized Trial of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® (Bortezomib) Induction Therapy in Newly Diagnosed Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001729-26,0,0,0 2013-001731-40,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Radboud University Nijmegen Medical Centre,Influence of exceptional patient characteristics on everolimus exposure De invloed van bijzondere patientkarakteristieken op everolimus blootstelling,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001731-40,0,0,0 2013-001732-21,1,2017-11-17,2017-11-17,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Centre d'Etude des Cellules Souches (CECS),"A randomized, double blind, placebo-controlled phase II study of metformin in myotonic dystrophy type 1 patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001732-21,0,0,0 2013-001733-41,1,2014-06-06,2014-06-06,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Harju Mika,Hypertonic saline - the effect of repeating doses Hypertoninen keittosuolaliuos – toistetun annoksen vaikutus silmänpaineeseen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001733-41,0,0,0 2013-001734-17,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University of Rome Foro Italico,Short-term effects of testosterone enhantate and gel on neuro-physiological function Effetti a breve termine della somministrazione di testosterone enantato e gel sulla funzione neuro-fisiologica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001734-17,0,0,0 2013-001737-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZ Leuven,Effect of curcumin addition to standard treatment on tumour-induced inflammation in endometrial carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001737-40,0,0,0 2013-001740-54,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,"Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc.","A 28-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222 / MK-3222, Followed by an Op...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001740-54,0,0,0 2013-001743-31,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,VU University Medical Center,The cardiovascular effects of hyperoxia during and shortly after CABG surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001743-31,0,0,0 2013-001744-65,7,2018-11-23,2018-11-28,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Shire Development LLC,"A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Paediatric Subjects with Mild to Moderate Ulcerative Colitis, in both Acute ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001744-65,0,0,0 2013-001744-65,7,2018-11-23,2018-11-28,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Shire Devlopment LLC,"A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Paediatric Subjects with Mild to Moderate Ulcerative Colitis, in both Acute ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001744-65,0,0,0 2013-001746-33,9,2020-01-30,2020-01-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind Study to Evaluate Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001746-33,0,0,0 2013-001747-31,19,2019-05-27,2019-06-07,17,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma services AG,"A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001747-31,0,0,0 2013-001747-31,19,2019-05-27,2019-06-07,17,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA S.p.A.,"A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001747-31,0,0,0 2013-001747-31,19,2019-05-27,2019-06-07,17,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001747-31,0,0,0 2013-001747-31,19,2019-05-27,2019-06-07,17,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001747-31,0,0,0 2013-001753-26,1,2014-02-20,2014-02-20,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Pierre Fabre Dermo-cosmétique,"Clinical and biophysics evaluation of the cutaneous modifications following the local use of a lotion containing 0,1 % of trétinoïne. Evaluation clinique et biophysique des modifications cutanées s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001753-26,0,0,0 2013-001754-10,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,DBV Technologies S.A,Open-label follow-up study of the VIPES study to evaluate long-term efficacy and safety of the Viaskin Peanut,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001754-10,0,0,0 2013-001757-28,1,2017-02-28,2017-02-28,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Salford Royal NHS Foundation Trust,Does subcutaneous interleukin-1 receptor antagonist reduce inflammation following ischaemic stroke compared to placebo?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001757-28,0,0,0 2013-001759-10,6,2016-12-29,2016-12-29,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Bayer AG,"An open-label, international, multicenter, single-arm, uncontrolled, phase IIIb study of riociguat in patients with pulmonary arterial hypertension (PAH) who demonstrate an insufficient response to tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001759-10,0,0,0 2013-001759-10,6,2016-12-29,2016-12-29,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"An open-label, international, multicenter, single-arm, uncontrolled, phase IIIb study of riociguat in patients with pulmonary arterial hypertension (PAH) who demonstrate an insufficient response to tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001759-10,0,0,0 2013-001760-31,4,2016-10-17,2016-10-17,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,Clinical efficacy and safety of J022X ST in the prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) in children with a high risk of recurrence,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001760-31,0,0,0 2013-001764-35,1,2014-12-31,2014-12-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Diabeteszentrum Bad Lauterberg,ANTIDIABETIC EFFECTS OF ADDING A DPP-4 INHIBITOR (SITAGLIPTIN) TO PRE-EXISTING TREATMENT WITH AN INCRETIN MIMETIC (LIRAGLUTIDE) IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH METFORMIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001764-35,0,0,0 2013-001766-42,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Seahorse Scientific Services Ltd.,"A Multiple-Dose, Single Period, Phase II Dose Ranging Study to Examine Testagen™ TDS®-Testosterone 5% in Adult Male Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001766-42,0,0,0 2013-001767-23,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Seahorse Scientific Services Ltd.,"A Single-Dose, Single Period, Phase II Pharmacokinetic Study To Examine TDS®-Testosterone For Its Potential To Be Inadvertently Transferred By Skin Contact After Dosing In Healthy Adult Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001767-23,0,0,0 2013-001768-48,6,2016-06-22,2016-09-12,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,BioMarin Pharmaceutical Inc,A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects with Late-onset Pompe Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001768-48,0,0,0 2013-001770-19,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Technische Universität Dresden,"6 month, multi-center, open-label, prospective, randomized trial, investigating a standard regimen of an advagraf based immunosuppressive regimen in de-novo renal transplant patients versus a slowe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001770-19,0,0,0 2013-001772-38,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,A.N.M.C.O.-Fondazione Italiana lotta Malattie Cardiovasc,STEM-AMI OUTCOME TRIAL STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial STEM-AMI OUTCOME TRIAL Mobilizzazione di cellule staminali in uno studio di outcome in pazienti con infa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001772-38,0,0,0 2013-001775-20,1,2014-01-31,2014-01-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pharmanest AB,A phase 2 study investigating the feasibility of using a topical formulation of lidocaine (SHACT) for hysteroscopy in women.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001775-20,0,0,0 2013-001783-36,1,2014-08-14,2014-08-14,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Novartis Farmacéutica, S.A.","A randomized 8-week double-blind, parallel-group, active-controlled, multicenter study to evaluate efficacy and safety of LCZ696 200 mg in comparison with olmesartan 20 mg in essential hypertensive pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001783-36,0,0,0 2013-001788-21,7,2015-10-21,2015-11-30,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TAKEDA DEVELOPMENT CENTRE EUROPE LTD,"A multicenter, randomized, double-blind phase 3 study to evaluate tolerability and pharmacokinetics of 500μg roflumilast once daily with an up-titration regimen in COPD, including an open-label down-t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001788-21,0,0,0 2013-001790-25,6,2016-09-02,2016-09-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Foresee Pharmaceuticals Co., Ltd.","An Open-Label, Single-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects with Advanced Prostate Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001790-25,0,0,0 2013-001791-38,1,2015-06-27,2015-06-27,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Graz; Universitätsklinik für Innere Medizin; Abteilung für Endokrinologie und Stoffwechsel,Evaluation of the Hydraulic Tissue Resistance at the Site of Subcutaneous Insulin Infusion and Determination of Its Relationship to Insulin Absorption and Duration of Use of the Infusion Site Besti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001791-38,0,0,0 2013-001793-21,2,2014-04-16,2014-04-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PHARMATHEN S.A.,"Efficacy and tolerability of brinzolamide in patients with elevated intraocular pressure: a double-blind, randomized, parallel, verum-controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001793-21,0,0,0 2013-001794-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA,PhaRmacodynamic Effect of Therapy with PraSugrel or TicagrElor in acute coronary syndrome paTients with Diabetes Mellitus. RESET 2D Trial Effetti farmacodinamici della terapia con Prasugrel e Ticag...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001794-24,0,0,0 2013-001795-38,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO,"CRANIAL-FACIAL PAIN TREATMENT: PROSPECTIC, RANDOMIZED, OPEN-LABEL STUDY ON TRANSNASAL NONSURGICAL BLOCKADE VERSUS PHARMACOLOGICAL THERAPY IL TRATTAMENTO DEL DOLORE CRANIO FACCIALE: STUDIO PROSPETTI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001795-38,0,0,0 2013-001796-20,2,,,0,1,0,0,1,1,2,0,0,1,1,0,0,1,1,Galderma R&D SNC,"Efficacy, safety and pharmacokinetics of 2 concentrations and 2 dosage regimens of CD5789 in subjects with Lamellar Ichthyosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001796-20,0,0,0 2013-001798-26,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CHU DE POITIERS,"A multicenter, open-label, Prospective, randomized parallel group Phase III study investigating the benefit on Renal function of a CNI-free regimen with MyfOrtic® (mycophenolate sodium) and Certican® ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001798-26,0,0,0 2013-001799-39,4,2016-02-17,2016-02-17,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A double blind, randomized, placebo-controlled study to evaluate, safety, tolerability, efficacy and preliminary dose-response of BAF312 in patients with active dermatomyositis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001799-39,0,0,0 2013-001800-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,"Neoadjuvant phase II trial combining [3 FEC 100 followed by 3 docetaxel associated with trastuzumab plus pertuzumab] or [6 docetaxel, carboplatin associated with trastuzumab plus pertuzumab] according...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001800-13,0,0,0 2013-001803-35,3,2014-11-05,2014-12-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis recherche et développement,"A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001803-35,0,0,0 2013-001804-12,3,2018-09-01,2018-09-01,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,ISA Therapeutics B.V.,"A multicenter, open label Phase I/II study to determine the safety and immune modulating effects of the therapeutic Human Papilloma Virus Type 16 (HPV16) E6/E7 Synthetic Long Peptides Vaccine (ISA101)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001804-12,0,0,0 2013-001807-35,1,,,0,1,0,0,0,1,4,0,0,1,1,1,0,1,0,"Department of Nuclear Medicine, Odense University Hospital","Imaging with 111In-Octreotide SPECT-CT compared to 68Ga-DOTATATE PET-CT in patients admitted for evaluation of GastroEnteroPancreatic NeuroEndocrine Tumours, GEP-NETs",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001807-35,0,0,0 2013-001810-14,4,2018-03-26,2018-03-26,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"EyePoint Pharmaceuticals, Inc.","A PHASE III, MULTI-NATIONAL, MULTI-CENTER, RANDOMIZED, MASKED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A FLUOCINOLONE ACETONIDE INTRAVITREAL (FAI) INSERT IN SUBJECTS WITH CHRONIC NON-INFECTIOUS UV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001810-14,0,0,0 2013-001810-14,4,2018-03-26,2018-03-26,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,pSivida Corporation,"A PHASE III, MULTI-NATIONAL, MULTI-CENTER, RANDOMIZED, MASKED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A FLUOCINOLONE ACETONIDE INTRAVITREAL (FAI) INSERT IN SUBJECTS WITH CHRONIC NON-INFECTIOUS UV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001810-14,0,0,0 2013-001811-56,1,2018-04-30,2018-04-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Graz, Universitätsklinik für Zahn-, Mund- und Kieferheilkunde",The effect of systemic antibiotics on clinical and patient-centered outcomes of implant therapy and simultaneous guided bone regeneration. A randomised controlled clinical trial. Wirkung einer syst...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001811-56,0,0,0 2013-001812-30,1,2019-01-04,2019-01-04,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,The Christie NHS Foundation Trust,"A Phase III, randomised, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy for patients with locally advanced/metastatic biliary tract canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001812-30,0,0,0 2013-001818-14,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University Medical Center Groningen,RELATE and PREDICT TRD A pharmacological and neuroimaging study investigating neurobiological effects of Selective Serotonin Reuptake Inhibitors and Norepinephrine Reuptake inhibitors on dopaminergic ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001818-14,0,0,0 2013-001822-24,1,2013-08-01,2013-08-01,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Professor Jørgen B. Dahl,The effect of different doses (mass) of local anesthetic on duration of adductor canal block in healthy volunteers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001822-24,0,0,0 2013-001823-38,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,"National Institute of Public Health and Environment (RIVM, the Netherlands)",Second meningococcal vaccination in Dutch children: Study to compare the tetravalent MenACWY-TT conjugate vaccine with the monovalent MenC-TT conjugate vaccine. Tweede meningokokken vaccinatie bij ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001823-38,0,0,0 2013-001827-38,7,2015-05-04,2015-05-04,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"Study DB2116961, a multicentre, randomised, blinded, parallel group study to compare UMEC/VI (Umeclidinium/Vilanterol) in a fixed dose combination with Indacaterol plus Tiotropium in symptomatic subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001827-38,0,0,0 2013-001829-76,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Paula Diéguez García,"INTERCOSTAL BRANCHES BLOCK IN THE MIDAXILLARY LINE VERSUS PARAVERTEBRAL BLOCK, ULTRASOUND-GUIDED FOR NOT RECONSTRUCTIVE BREAST SURGERY. RANDOMIZED CLINICAL TRIAL BLOQUEO DE LAS RAMAS DE LOS NERVIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001829-76,0,0,0 2013-001830-16,4,2016-09-16,2016-09-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Adjunctive Therapy in Subjects with Signs and Symptoms of O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001830-16,0,0,0 2013-001832-23,5,2018-02-28,2018-02-28,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Neurim Pharmaceuticals (1991) Ltd.,"A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CIRCADIN® TO ALLEVIATE SLEEP DISTURBANCES IN CHILDREN WITH NEURODEVELOPMENTAL DISABILITIES",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001832-23,1,1,0 2013-001834-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ISTITUTI FISIOTERAPICI OSPITALIERI,EVALUATION OF SEIZURE CONTROL AND QUALITY OF LIFE IN PATIENTS WITH BRAIN TUMOR RELATED EPILEPSY TREATED WITH LACOSAMIDE AS ADD-ON THERAPY: A PROSPECTIVE EXPLORATIVE STUDY VALUTAZIONE DEL CONTROLLO ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001834-16,0,0,0 2013-001835-33,8,2014-08-05,2014-08-05,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A multicenter, randomized, double-blind, parallel group study to assess the safety and tolerability of initiating LCZ696 in heart failure patients comparing two titration regimens.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001835-33,0,0,0 2013-001835-33,8,2014-08-05,2014-08-05,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farma SpA,"A multicenter, randomized, double-blind, parallel group study to assess the safety and tolerability of initiating LCZ696 in heart failure patients comparing two titration regimens.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001835-33,0,0,0 2013-001835-33,8,2014-08-05,2014-08-05,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma services AG,"A multicenter, randomized, double-blind, parallel group study to assess the safety and tolerability of initiating LCZ696 in heart failure patients comparing two titration regimens.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001835-33,0,0,0 2013-001835-33,8,2014-08-05,2014-08-05,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, parallel group study to assess the safety and tolerability of initiating LCZ696 in heart failure patients comparing two titration regimens.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001835-33,0,0,0 2013-001838-17,2,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,Syner-Med (PP) Ltd,"A MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP PLACEBO-CONTROLLED CLINICAL STUDY FOR THE ASSESSMENT OF THE IMMUNOMODULATORY EFFICACY, SAFETY AND CLINICAL IMPACT AFTER THREE AND S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001838-17,0,0,0 2013-001838-17,2,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,InmunoteK S.L.,"A MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP PLACEBO-CONTROLLED CLINICAL STUDY FOR THE ASSESSMENT OF THE IMMUNOMODULATORY EFFICACY, SAFETY AND CLINICAL IMPACT AFTER THREE AND S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001838-17,0,0,0 2013-001838-17,2,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,"Inmunotek, S.L.","A MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP PLACEBO-CONTROLLED CLINICAL STUDY FOR THE ASSESSMENT OF THE IMMUNOMODULATORY EFFICACY, SAFETY AND CLINICAL IMPACT AFTER THREE AND S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001838-17,0,0,0 2013-001838-17,2,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,"INMUNOTEK, S.L.","A MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP PLACEBO-CONTROLLED CLINICAL STUDY FOR THE ASSESSMENT OF THE IMMUNOMODULATORY EFFICACY, SAFETY AND CLINICAL IMPACT AFTER THREE AND S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001838-17,0,0,0 2013-001842-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OYS,The Preterm infants’ Paracetamol Study -- PreParaS PARASETAMOLI PIENEN KESKOSEN HOIDOSSA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001842-33,0,0,0 2013-001849-13,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,ASLTO2-Maria Vittoria Hospital Cardiology,AnakInRa Treatment of Recurrent Idiopathic Pericarditis Trattamento della pericardite ricorrente idiopatica con anakinra,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001849-13,0,0,0 2013-001850-83,1,2018-06-22,2018-06-22,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU- Hôpitaux de Rouen,Adaptation to neonatal life after an anesthetic protocol using remifentanil for general anesthesia for caesarean section in a context of prematurity - REAGI Protocol (Remifentanil for General Anesthe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001850-83,0,0,0 2013-001851-11,7,2015-01-13,2016-08-29,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Lupin Limited,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Comparative, Multicenter, Phase 2 Clinical Study to Evaluate Efficacy and Safety of Two Doses of LND101001 Monotherapy in Patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001851-11,0,0,0 2013-001851-11,7,2015-01-13,2016-08-29,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Lupin Atlantis Holdings S.A.,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Comparative, Multicenter, Phase 2 Clinical Study to Evaluate Efficacy and Safety of Two Doses of LND101001 Monotherapy in Patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001851-11,0,0,0 2013-001852-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sociedad Española de Medicina Interna,"Randomized, double blinded, multicenter study, to asses Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics vs Loop diuretics with placebo in Patients With Decompensated Heart ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001852-36,0,0,0 2013-001855-11,2,2016-07-12,2016-07-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Limited,"Secukinumab In patients with moderate to severe active, chronic plaque psoriasis who have failed on TNFα antaGoNists: A clinical Trial EvalUating Treatment REsults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001855-11,0,0,0 2013-001856-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU DE POITIERS,Efficacy and safety of Aflibercept (Eylea®) in proliferative diabetic retinopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001856-36,0,0,0 2013-001858-10,7,2021-04-05,2021-04-05,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"SK Life Science, Inc.","A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose- Response Trial of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures, with Optional Open-Label Extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001858-10,1,0,0 2013-001862-41,8,2017-07-08,2017-07-08,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica , S.A.","A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001862-41,0,0,0 2013-001862-41,8,2017-07-08,2017-07-08,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001862-41,0,0,0 2013-001862-41,8,2017-07-08,2017-07-08,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farma S.p.A,"A phase II randomized, double-blind placebo controlled, study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001862-41,0,0,0 2013-001863-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,BOOG Study Center,Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer - the TRAIN-2 study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001863-21,0,0,0 2013-001864-50,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"National Institute for Public Health and the Environment (RIVM, the Netherlands)",Long-term memory immunity against Bordetella pertussis in children 9 years of age who have been vaccinated with acellular pertussis vaccines: effect of an extra preadolescent acellular booster vaccina...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001864-50,0,0,0 2013-001866-40,1,2016-06-21,2016-06-21,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"University Hospital Schleswig-Holstein, UKSH Campus Kiel","The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study Die Wirkung von...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001866-40,0,0,0 2013-001868-40,1,2017-03-27,2017-03-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust,Scheduling nab-paclItaxEl with GEmcitabine (SIEGE): Randomised phase II trial to investigate two different schedules of nab-paclitaxel (Abraxane) combined with gemcitabine as first line treatment for ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001868-40,0,0,0 2013-001869-16,1,2014-05-14,2014-05-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boiron Laboratoires,"A randomised, multi-centre, parallel group, double-blind, placebo-controlled study to assess the efficacy and safety of Oscillococcinum® in the treatment of symptoms of Influenza-like illness (ILI)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001869-16,0,0,0 2013-001870-38,8,2017-04-04,2017-04-04,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Grifols Therapeutics Inc.,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alphal-Proteinase Inhibitor (Human) in Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001870-38,1,0,0 2013-001870-38,8,2017-04-04,2017-04-04,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Grifols Therapeutics LLC,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alphal-Proteinase Inhibitor (Human) in Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001870-38,1,0,0 2013-001873-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,County Council of Östergötland,Will intrathecal analgesia contribute to a faster recovery compared with epidural analgesia after open surgery for gynecological cancer. An open controlled randomized study. Ger spinal smärtlindri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001873-25,0,0,0 2013-001874-12,5,2015-05-28,2015-05-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alcon Research, Ltd","Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001874-12,0,0,0 2013-001876-39,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Apocare Pharma GmbH,"An open-label phase IIb study to evaluate the safety, tolerability and efficacy of Fotolon® as a photosensitising agent for the local treatment of airway-obstructing non small cell lung cancer (NSCLC)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001876-39,0,0,0 2013-001877-26,13,2016-05-03,2016-05-03,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,"An open-label, multi-site trial to describe the safety and tolerability of oral cebranopadol administered for 26 weeks in subjects with cancer-related pain who have completed treatment in the KF6005/0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001877-26,0,0,0 2013-001879-20,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Birmingham,Phase I/II study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001879-20,0,0,0 2013-001881-40,1,2017-02-15,2017-02-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,North Bristol NHS Trust (NBT),An Extension Study to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via onvection Enhanced Delivery ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001881-40,0,0,0 2013-001884-21,4,2015-08-21,2015-08-21,3,1,0,0,0,2,3,0,0,1,1,1,1,0,1,VITAL THERAPIES INCORPORATED,"A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH ACUTE ALCOHOLIC HEPATITIS (AAH) WHO HAVE FAILED STEROID THERAPY Estudio multicéntrico,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001884-21,0,0,0 2013-001884-21,4,2015-08-21,2015-08-21,3,1,0,0,0,2,3,0,0,1,1,1,1,0,1,"VITAL THERAPIES, INC.","A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH ACUTE ALCOHOLIC HEPATITIS (AAH) WHO HAVE FAILED STEROID THERAPY Estudio multicéntrico,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001884-21,0,0,0 2013-001885-41,2,2014-04-22,2014-04-22,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Delenex Therapeutics AG,"A multi-center, double-blinded, randomized, placebo-controlled, phase II study to evaluate the safety, tolerability and efficacy of a topical application of DLX105 onto lesional skin in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001885-41,0,0,0 2013-001888-23,6,2016-07-05,2016-07-08,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc","A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Pl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001888-23,0,0,0 2013-001890-26,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Dipartimento di Medicina e Chirurgia Traslazionale dell’Università degli Studi di Firenze,Recombinant human parathyroid hormone [rh PTH(1-34): Teriparatide] as therapy for refractory hypoparathyroidism Ormone paratiroideo ricombinante umano [rh PTH(1-34): Teriparatide] per il trattament...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001890-26,0,0,0 2013-001895-40,1,2015-11-09,2015-11-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Biogen Idec Research Limited,"A Phase 4, Randomized, Double-Blind Study with a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects with Relapsing-Remitting Multiple Sclerosis Treated with Tecfi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001895-40,0,0,0 2013-001899-38,1,2014-11-07,2014-11-07,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Single dose, double-blind, placebo-controlled, single center, randomized cross-over study to investigate safety, tolerability, pharmacodynamics and pharmacokinetic properties of BAY 63-2521 after oral...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001899-38,0,0,0 2013-001900-13,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,AstraZeneca AB,"A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Ant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001900-13,0,1,1 2013-001903-36,7,2021-07-28,2021-07-28,4,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Celgene Corporation,"A PHASE 2 MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE EFFICACY AND SAFETY OF POMALIDOMIDE (CC-4047) IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001903-36,1,0,0 2013-001912-31,10,2020-01-13,2020-01-13,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Dr. Falk Pharma GmbH,"Randomised, double-blind, placebo-controlled, multi-centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001912-31,0,0,0 2013-001912-31,10,2020-01-13,2020-01-13,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,DR. FALK PHARMA GMBH,"Randomised, double-blind, placebo-controlled, multi-centre trial on the efficacy and safety of budesonide for induction of remission in incomplete microscopic colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001912-31,0,0,0 2013-001913-34,6,2014-08-26,2014-08-26,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Tetraphase Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Ertapenem in Complicated Intra-abdominal Infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001913-34,0,0,0 2013-001918-15,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,GlaxoSmithKline Biologicals,"A phase IV, open-label, single-centre study to assess the long-term persistence of hepatitis A antibodies in healthy adults, primed 21 to 25 years earlier with GSK Biologicals’ hepatitis A vaccine Hav...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001918-15,0,0,0 2013-001921-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,"Randomised, masked, placebo-controlled study to evaluate the effects of a single intravenous dose of hyoscine bromide on the duration and pain in the latent and active labor Ensayo clínico aleator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001921-19,0,0,0 2013-001922-24,1,2018-11-12,2018-11-12,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University College London (UCL),The effect of remote ischaemic preconditioning and glyceryl trinitrate on peri-operative myocardial injury in cardiac bypass surgery patients (ERIC-GTN study)- a four arm randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001922-24,0,0,0 2013-001924-20,7,2015-09-24,2015-09-24,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Atopix Therapeutics Ltd.,A study of the effect of OC000459 on signs & symptoms in subjects with moderate to severe atopic dermatitis: A randomised double blind placebo controlled parallel group study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001924-20,0,0,0 2013-001924-20,7,2015-09-24,2015-09-24,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Atopix Therapeutics Limited,A study of the effect of OC000459 on signs & symptoms in subjects with moderate to severe atopic dermatitis: A randomised double blind placebo controlled parallel group study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001924-20,0,0,0 2013-001926-25,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Universitair Ziekenhuis Antwerpen,Sugammadex and the diaphragm: recovery of diaphragmatic function and neuromuscular blockade,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001926-25,0,0,0 2013-001928-19,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,GERCOR,Multi-Line Therapy Trial in Unresectable Wild-Type KRAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001928-19,0,0,0 2013-001939-47,5,2016-12-19,2016-12-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily Versus Raltegravir 4...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001939-47,0,0,0 2013-001940-71,1,2015-07-31,2015-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,OM Pharma SA,"A Randomized, Placebo Controlled, Double Blinded, Mechanistic trial to investigate the effects of Broncho-Vaxom (OM-85 BV) on the innate immune system in patients with COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001940-71,0,0,0 2013-001944-76,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Leeds,FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001944-76,0,0,0 2013-001948-60,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Sint Franciscus Gasthuis Rotterdam,"Effects of high and low dose vitamin D on postprandial leukocyte activation, oxidative stress and vascular function in healthy overweight and obese females Effect van hoge en lage dosering vitamin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001948-60,0,0,0 2013-001949-13,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Royal Marsden NHS Foundation Trust,An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Loc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001949-13,0,0,0 2013-001951-11,5,2015-11-13,2015-11-13,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Aquinox Pharmaceuticals Inc.,The FLAGSHIP Study: A 12-week Phase II Study to Evaluate the Efficacy and Safety of AQX-1125 Following Exacerbations in Patients with Chronic Obstructive Pulmonary Disease (COPD) by Targeting the SHIP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001951-11,0,0,0 2013-001953-28,1,2016-07-15,2016-07-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside,Proof of concept study to evaluate single and chronic dosing effects of ultra-long acting bronchodilator therapy on mannitol challenge in asthmatic patients taking inhaled corticosteroids,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001953-28,0,0,0 2013-001954-88,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Helsinki University Centrel Hospital,Immune response to intradermally administrated Ixiaro in healthy adults: a randomized study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001954-88,0,0,0 2013-001955-11,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Psicofundación. Fundación Española para Promoción, Desarrollo Científico y Profesional de la Psicología",A pilot study to treat emotional disorders in Primary Care with evidence-based psychological techniques: A randomized controlled trial Proyecto piloto para tratar los desórdenes emocionales en Aten...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001955-11,0,0,0 2013-001958-10,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,"ImunomedicA, a.s.","A Prospective, Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Confirmatory Study Assessing Efficacy and Safety of the IMUNOR Therapy Versus Placebo in Children with Recurrent Res...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001958-10,0,0,0 2013-001965-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Debreceni Egyetem Orvos- és Egészségtudományi Centrum Aneszteziológiai és Intenzív Terápiás Tanszék,Incidence of postoperative residual neuromuscular blockade following the administration of rocuronium: A randomized placebo controlled study. Posztoperatív reziduális neuromuszkuláris blokád előfor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001965-17,0,0,0 2013-001966-40,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Companion Diagnostics BV,"A double blind, randomized, placebo controlled, cross-over, Lybridos dose finding study to validate the predictive power of the diagnostic model for Lybrido and Lybridos efficacy and to identify and e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001966-40,0,0,0 2013-001967-22,1,2018-03-31,2018-03-31,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Papworth Hospital NHS Foundation Trust,A phase II study to investigate the protective effects of Glucagon­-like Peptide-­1 (GLP­-1) in patients undergoing elective angioplasty and stenting.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001967-22,0,0,0 2013-001969-16,4,2017-10-27,2017-10-27,1,1,1,0,0,0,2,0,0,2,1,0,0,0,1,"Gilead Sciences, Inc.","A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (BR) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001969-16,1,1,0 2013-001970-33,1,2014-08-26,2014-08-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Proximagen Limited,"A Double-Blind, Randomised, Exploratory Study to Investigate the Safety, Efficacy and Pharmacokinetics of PRX167700 in Subjects with Knee Osteoarthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001970-33,0,0,0 2013-001974-11,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,INSTITUTO DE INVESTIGACION SANITARIA LA FE,PILOT TRIAL FOR THE EVALUATION OF HEPATOTEST IN PREOPERATIVE ASSESSMENT IN LIVER FUNCTION. ESTUDIO PILOTO PARA LA EVALUACIÓN DEL HEPATOTEST EN LA VALORACIÓN PREOPERATORIA DE LA FUNCIÓN HEPÁTICA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001974-11,0,0,0 2013-001976-39,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Centre for Human Drug Research,"Randomized, open-label, crossover study into the contribution of the intestines and kidney in the diurnal variation of Levofloxacin pharmacokinetics Een onderzoek naar de dag/nacht ritmes in de opn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001976-39,0,0,0 2013-001981-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INSTITUT DE CANCEROLOGIE DE L'OUEST,Pilot feasibility study of fertility preservation by ovarian stimulation associated with tamoxifen and oocyte or embryo freezing prior chemotherapy for breast cancer. Etude pilote de faisabilité de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001981-40,0,0,0 2013-001983-52,1,2014-06-20,2014-06-20,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Genentech Inc.,"A randomized, double-blind, placebo-controlled, phase 2a study in healthy volunteers, to evaluate the efficacy and safety of MHAA4549A in an Influenza challenge model",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001983-52,0,0,0 2013-001984-21,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Aberdeen & NHS Grampian,PRE-EMPT: Preventing Recurrence of Endometriosis by Means of long acting Protestogen Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001984-21,0,0,0 2013-001985-41,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Onconova Therapeutics Inc.,"A Phase II Study of Oral Rigosertib in Patients with Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma A szájon át szedett Rigosertib Fáz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001985-41,0,0,0 2013-001986-18,6,2016-01-25,2016-01-25,5,1,0,1,0,2,1,0,0,1,1,0,0,0,1,Array BioPharma Inc.,"A phase Ib/II, open-label, multi-center, dose escalation study of MEK162 in combination with panitumumab in adult patients with mutant RAS or wild-type RAS metastatic colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001986-18,0,0,0 2013-001986-18,6,2016-01-25,2016-01-25,5,1,0,1,0,2,1,0,0,1,1,0,0,0,1,NOVARTIS FARMA S.p.A.,"A phase Ib/II, open-label, multi-center, dose escalation study of MEK162 in combination with panitumumab in adult patients with mutant RAS or wild-type RAS metastatic colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001986-18,0,0,0 2013-001986-18,6,2016-01-25,2016-01-25,5,1,0,1,0,2,1,0,0,1,1,0,0,0,1,Novartis Pharma AG,"A phase Ib/II, open-label, multi-center, dose escalation study of MEK162 in combination with panitumumab in adult patients with mutant RAS or wild-type RAS metastatic colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001986-18,0,0,0 2013-001989-42,1,2018-03-12,2018-03-12,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Boris Modrau,Theophylline Effect in Acute Ischemic Stroke Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001989-42,0,0,0 2013-001997-18,5,2016-08-01,2016-09-15,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Achaogen, Inc.","A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared with Colistin in Patients with Infection due to Carbapenem-Resistant Enterobacteriaceae ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001997-18,0,0,0 2013-001998-24,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Saarland University,"A prospective, multicenter, double blind, placebo-controlled, two-arm parallel group phase 3 trial to evaluate the effect of early postnatal additional high dose oral vitamin A supplementation of 5000...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001998-24,0,0,0 2013-001999-38,4,2014-09-29,2014-09-29,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Neovacs SA,"A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy of Neovacs’ TNF-Kinoid in Adult Subjects with Active Rheumatoid Arthritis despite Methotrexate Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001999-38,1,0,0 2013-002000-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospitals Leuven,The effects of right paravertebral blockade on biventricular performance in patients with chronic pulmonary hypertension scheduled for minimally invasive mirtral valve surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002000-14,0,0,0 2013-002005-59,6,2017-07-24,2018-07-24,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3b, Multicenter, Open-label, Randomized Withdrawal Trial of the Effects of Titrated Oral SAMSCA® (Tolvaptan) on Serum Sodium, Pharmacokinetics, and Safety in Children and Adolescent Subjects H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002005-59,0,0,0 2013-002007-34,3,2016-09-13,2016-09-13,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche a/s,"Tocilizumab SC in patients with active rheumatoid arthritis and inadequate response to DMARDs. A single-arm, open-label study to evaluate safety, tolerability and efficacy. In a sub-group of patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002007-34,0,0,0 2013-002009-70,1,2019-02-20,2019-02-20,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Academic Medical Center,Quadrivalent HPV vaccination after effective treatment of Anal Intraepithelial Neoplasia in HIV+ men,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002009-70,0,0,0 2013-002012-27,1,2017-10-03,2017-10-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,LANDSTINGET I ÖSTERGÖTLAND,Ketamine dose finding study in pediatric burn wound care Ketamindossökande studie för pediatrisk brännskadevård,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002012-27,0,0,0 2013-002014-13,1,2019-12-09,2019-12-09,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,NHS greater Glasgow and Clyde,A phase I/randomised phase II trial of abiraterone acetate with or without RO5503781 / idasanutlin in patients with metastatic castration resistant prostate cancer who have not previously received ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002014-13,0,0,0 2013-002014-13,1,2019-12-09,2019-12-09,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Glasgow University,A phase I/randomised phase II trial of abiraterone acetate with or without RO5503781 / idasanutlin in patients with metastatic castration resistant prostate cancer who have not previously received ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002014-13,0,0,0 2013-002015-98,1,2020-09-23,2020-09-23,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Fundación Progreso y Salud,"Clinical trial phase III multicenter, double-blind, randomized, placebo-controlled trial evaluating the efficacy of intracoronary infusion of autologous adult stem mononuclear bone marrow unexpanded o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002015-98,0,0,0 2013-002016-27,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,Grünenthal GmbH,"Open-label evaluation of the pharmacokinetic profile, safety, and efficacy of tapentadol oral solution for the treatment of post-surgical pain in children and adolescents aged from 2 years to less tha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002016-27,0,1,1 2013-002018-11,1,2021-02-26,2021-02-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination with Ipilimumab vs Ipilimumab alone in Subjects with Previously Untreated, Unresectable or Metastatic Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002018-11,0,0,0 2013-002023-41,1,2021-01-07,2021-01-07,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,VU University Medical Center,Image guided treatment optimalization with cetuximab for patients with metastatic colorectal cancer: IMPACT - CRC Optimalisatie van de behandeling van uitgezaaide dikke darmkanker met cetuximab mid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002023-41,0,0,0 2013-002026-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ErasmusMC,Rectal and oral omeprazole treatment of gastroesophageal reflux in infants with esophageal atresia or congenital diaphragmatic hernia. A pharmacodynamic and pharmacokinetic study Rectale en orale...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002026-22,0,0,0 2013-002027-42,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,INSTITUTO DE INVESTIGACION SANITARIA LA FE,PROSPECTIVE AND RANDOMIZED STUDY FOR ASSESSMENT OF CONTROLLED OVARIAN STIMULATION WITH ALFA Corifollitropin IN PATIENTS WITH OVARIAN RESPONSE EXPECTED OR POOR IN VITRO FERTILIZATION CYCLE. ESTUDIO ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002027-42,0,0,0 2013-002029-40,1,2015-03-31,2015-03-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Karolinska Institutet,Aprepitant – effect and safety in treatment of atopic dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002029-40,0,0,0 2013-002031-26,1,2014-01-31,2014-01-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospitals Southampton NHS Foundation Trust,Safety of Nasal Influenza Immunisation in Egg Allergic Children - The SNIFFLE study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002031-26,0,0,0 2013-002034-21,1,2016-09-20,2016-09-20,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,EB House Austria,Diacerein for the treatment of Epidermolysis bullosa simplex Diacerein für die Behandlung von Epidermolysis bullosa simplex,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002034-21,0,0,0 2013-002036-24,1,2016-09-15,2016-09-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Cologne,"A non-randomised, non-comparative monocenter investigator initiated trial to assess the efficacy and safety of Carmustine in patients with BRCA1/2-associated advanced breast and ovarian cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002036-24,0,0,0 2013-002037-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,The effect of correction of metabolic acidosis in chronics kidney disease on intrarenal RAS activity. Het effect van het corrigeren van metabole acidose bij chronische nierinsufficientie op de acti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002037-38,0,0,0 2013-002042-36,8,2016-01-29,2016-01-29,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen Biologics B.V.,A Phase 2a Open-label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects with Moderately to Severely Active Ulcerative Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002042-36,0,0,0 2013-002049-13,1,2016-12-31,2016-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Oulu University Hospital,Erlotinib treatment beyond progression in EGFR mutant or patients who have responded to EGFR TKI in stage IIIB/IV NSCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002049-13,0,0,0 2013-002050-78,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,NVALT,"A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced nonsmall cell lung cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002050-78,0,0,0 2013-002051-15,1,2015-07-22,2015-07-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Innsbruck Medical University, Department of Radiology, Section of Microinvasive Therapy",Systemic hypotension following intravenous administration of contrast medium during computed tomography.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002051-15,0,0,0 2013-002053-30,4,2018-02-14,2018-02-14,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Merck KGaA,"A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liver Fu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002053-30,0,0,0 2013-002055-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITY OF SASSARI,"RANDOMIZED, CONTROLLED, MULTI-CENTER, INTERNATIONAL CLINICAL STUDY ON THE MOOD-STABILIZING EFFECTS OF MEMANTINE AS AN AUGMENTING AGENT vs. LAMOTRIGINE FOR ONGOING TREATMENT IN BIPOLAR-I DISORDER PATIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002055-15,0,0,0 2013-002057-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,DOuleurs chroniques et VItamine D : une étude pilote en médecine de ville.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002057-29,0,0,0 2013-002062-39,1,2014-12-01,2014-12-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Azienda Ospedaliero-Universitaria Meyer,Safety and efficacy of propranolol eye drops in neonates with retinopathy of prematurity: a pilot study (DROP-ROP).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002062-39,0,0,0 2013-002063-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,S.C.D.U. MEDICINA INTERNA 1 Ospedale San Luigi Orbassano,A prospective open-label Phase 2 study of METYRAPONE as a preoperative treatment in patients with ACTH-independent Cushing’s syndrome due to adrenal adenoma. Studio prospettico in aperto di fase ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002063-26,0,0,0 2013-002066-39,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,"Azienda Ospedaliera di Reggio Emilia Arcispedale ""S.Maria Nuova""/IRCCS",The Reggio Emilia study on bromfenac for patients with PseudoEXfoliation syndrome undergoing cataract surgery: the REPEX study Effetto del bromfenac collirio in pazienti con pseudoesfoliatio lentis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002066-39,0,0,0 2013-002067-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Landspitali University Hospital,Difference between dosages needed of proton pump inhibitors for females and males,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002067-26,0,0,0 2013-002073-22,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,"The Christie NHS Foundation Trust, R&D",A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma( PIANO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002073-22,0,0,0 2013-002074-46,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli – Fondazione “G.Pascale”,"Multicentre, two-stage, phase 2 study of neoadjuvant FOLFIRINOX followed by chemo-IMRT in patients with locally advanced unresectable pancreatic cancer Studio multicentrico di fase II, di chemioter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002074-46,0,0,0 2013-002076-41,14,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002076-41,0,0,0 2013-002077-21,5,2017-09-29,2017-09-29,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Auris Medical AG,Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002077-21,0,0,0 2013-002078-30,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Onze-Lieve-Vrouw Ziekenhuis,Acceleromyography and diaphragm electromyographic activity during neostigmine or sugammadex enhanced recovery from moderate residual neuromuscular blockade after rocuronium 0.6 mg kg-1: a double blind...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002078-30,0,0,0 2013-002079-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Erasme,Pharmacokinetics of Caspofungin after one dose in patients with liver failure.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002079-16,0,0,0 2013-002080-26,2,2014-09-15,2014-09-15,1,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Vaccines & Diagnostics AG,"A Phase III, Observer-Blind, Randomized Multicenter Study to Evaluate the Safety of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture (tivc) or in Embryonated Eggs (TIV),...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002080-26,0,0,0 2013-002081-39,1,2014-12-08,2014-12-08,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Novartis Vaccines & Diagnostics AG,"A Phase I/II, Randomized, Observer-Blind, Multicenter Study to Evaluate Immunogenicity and Safety of Four Influenza Vaccines in Healthy Pediatric Subjects 6 to < 48 Months of Age.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002081-39,0,0,0 2013-002082-19,7,2014-02-19,2014-02-19,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Teva Pharmaceutical Industries, Ltd.","A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002082-19,0,0,0 2013-002084-26,2,,,0,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Multicenter, Double-Blind, Randomized, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002084-26,0,1,0 2013-002084-26,2,,,0,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Merck Sharp & Dohme Corp.,"A Multicenter, Double-Blind, Randomized, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002084-26,0,1,0 2013-002085-39,1,2016-08-29,2016-08-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Kuopio University Hospital,Effect of dexketoprofen on analgesic concentration of oxycodone after laparoscopic cholecystectomy DEKSKETOPROFEENIN VAIKUTUS OKSIKODONIN ANALGEETTISEEN PITOISUUTEEN PLASMASSA LAPAROSKOOPPISEN SAPP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002085-39,0,0,0 2013-002088-25,5,2015-10-21,2015-10-21,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled multiple dose study of subcutaneous ACZ885 for the treatment of abdominal aortic aneurysm",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002088-25,0,0,0 2013-002090-21,2,2019-02-05,2019-02-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,2013-002090-21,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002090-21,0,0,0 2013-002091-41,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Academisch medisch centrum,Right vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system Rechterhartkamer dysfunctie bij tetralogie van Fallot: inhibitie van het Renine-angioten...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002091-41,0,0,0 2013-002094-22,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Royal Brompton and Harefield NHS Foundation Trust (RB&HFT),Comparison of ultra-low-dose Oral versus Transdermal Hormone Therapy on coagulation activation and metabolic risk factors for Cardiovascular Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002094-22,0,0,0 2013-002095-40,3,2016-04-06,2016-04-06,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc.,235 East 42nd Street, New York, NY 10017",A RANDOMIZED PHASE 2 STUDY OF PF-05212384 PLUS IRINOTECAN VERSUS CETUXIMAB PLUS IRINOTECAN IN PATIENTS WITH KRAS AND NRAS WILD TYPE METASTATIC COLORECTAL CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002095-40,0,0,0 2013-002096-18,3,2015-04-01,2015-08-05,2,1,0,1,0,0,1,0,0,1,1,0,0,0,1,"Pfizer Inc.,235 East 42nd Street, New York, NY 10017","AN OPEN-LABEL, MULTI-CENTER, RANDOMIZED PHASE 1B/2 STUDY OF PF05212384 PLUS 5-FLUOROURACIL-LEUCOVORIN-IRINOTECAN (FOLFIRI) VERSUS BEVACIZUMAB PLUS FOLFIRI IN METASTATIC COLORECTAL CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002096-18,0,0,0 2013-002101-62,1,2015-10-13,2015-10-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Leeds,Pomalidomide in relapsed and refractory multiple myeloma (RRMM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002101-62,0,0,0 2013-002106-31,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Academic Medical Center,The DANCE study: Duration of ANtibiotic therapy for CEllulitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002106-31,0,0,0 2013-002108-15,1,2016-02-12,2016-02-12,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Mari Grönroos,Treating actinic keratoses with natural daylight PDT: comparing two light sensitizers (ALA vs. MAL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002108-15,0,0,0 2013-002109-73,6,2020-07-23,2020-07-23,3,1,0,0,0,1,2,0,0,1,1,0,1,0,0,Greater Glasgow Health Board,A Randomised Phase II Study of Nintedanib (BIBF1120) Compared to Chemotherapy in Patients with Recurrent Clear Cell Carcinoma of the Ovary or Endometrium,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002109-73,0,0,0 2013-002110-12,13,2022-08-03,2022-08-03,8,1,0,0,0,1,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH BEND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002110-12,1,0,0 2013-002111-10,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Dr. Juan Macías Sánchez,"Cambios esteatosis hepática debido a cambiar efavirens por RALTEGRAVIR conjunta de dos análogos de nucleósidos en pacientes coinfectados por VIH / VHC,: Estudio Steral CAMBIOS EN LA ESTEATOSIS HEPÁ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002111-10,0,0,0 2013-002112-27,2,2019-08-01,2019-08-01,1,1,0,0,0,1,3,0,0,2,0,0,0,0,1,MEDDAY Pharmaceuticals SA,Effect of MD1003 in chronic visual loss related to optic neuritis in multiple sclerosis: a pivotal randomized double masked placebo controlled study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002112-27,1,0,0 2013-002112-27,2,2019-08-01,2019-08-01,1,1,0,0,0,1,3,0,0,2,0,0,0,0,1,MEDDAY SAS,Effect of MD1003 in chronic visual loss related to optic neuritis in multiple sclerosis: a pivotal randomized double masked placebo controlled study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002112-27,1,0,0 2013-002113-35,1,2020-06-04,2020-06-04,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,MEDDAY SAS,Effect of MD1003 in spinal progressive multiple sclerosis: a pivotal randomized double blind placebo controlled study MD1003 dans le traitement des formes progressives spinales de sclerose en plaqu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002113-35,0,0,0 2013-002114-12,17,2019-11-14,2019-11-20,14,1,1,0,0,1,3,0,0,2,0,0,0,0,2,,"Open-label, randomized, parallel-group, active-controlled, multi-centre non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002114-12,1,1,0 2013-002114-12,17,2019-11-14,2019-11-20,14,1,1,0,0,1,3,0,0,2,0,0,0,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"Open-label, randomized, parallel-group, active-controlled, multi-centre non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002114-12,1,1,0 2013-002114-12,17,2019-11-14,2019-11-20,14,1,1,0,0,1,3,0,0,2,0,0,0,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"Open-label, randomized, parallel-group, active-controlled, multi-centre non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002114-12,1,1,0 2013-002114-12,17,2019-11-14,2019-11-20,14,1,1,0,0,1,3,0,0,2,0,0,0,0,2,Boehringer Ingelheim France,"Open-label, randomized, parallel-group, active-controlled, multi-centre non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002114-12,1,1,0 2013-002114-12,17,2019-11-14,2019-11-20,14,1,1,0,0,1,3,0,0,2,0,0,0,0,2,Boehringer Ingelheim,"Open-label, randomized, parallel-group, active-controlled, multi-centre non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002114-12,1,1,0 2013-002114-12,17,2019-11-14,2019-11-20,14,1,1,0,0,1,3,0,0,2,0,0,0,0,2,Boehringer Ingelheim Norway KS,"Open-label, randomized, parallel-group, active-controlled, multi-centre non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002114-12,1,1,0 2013-002114-12,17,2019-11-14,2019-11-20,14,1,1,0,0,1,3,0,0,2,0,0,0,0,2,Boehringer Ingelheim Ellas,"Open-label, randomized, parallel-group, active-controlled, multi-centre non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002114-12,1,1,0 2013-002114-12,17,2019-11-14,2019-11-20,14,1,1,0,0,1,3,0,0,2,0,0,0,0,2,Boehringer Ingelheim Finland Ky,"Open-label, randomized, parallel-group, active-controlled, multi-centre non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002114-12,1,1,0 2013-002114-12,17,2019-11-14,2019-11-20,14,1,1,0,0,1,3,0,0,2,0,0,0,0,2,"Boehringer Ingelheim España, S.A.","Open-label, randomized, parallel-group, active-controlled, multi-centre non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002114-12,1,1,0 2013-002114-12,17,2019-11-14,2019-11-20,14,1,1,0,0,1,3,0,0,2,0,0,0,0,2,Boehringer Ingelheim AB,"Open-label, randomized, parallel-group, active-controlled, multi-centre non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002114-12,1,1,0 2013-002114-12,17,2019-11-14,2019-11-20,14,1,1,0,0,1,3,0,0,2,0,0,0,0,2,SCS Boehringer Ingelheim Comm. V,"Open-label, randomized, parallel-group, active-controlled, multi-centre non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002114-12,1,1,0 2013-002115-99,1,2014-04-23,2014-04-23,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Summit Corporation plc,"SMT C1100 - A Phase 1, Open-label, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Paediatric Patients with Duchenne Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002115-99,0,0,0 2013-002116-27,5,2014-08-13,2014-08-13,3,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Nutrition Science Partners Limited,"A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis (NATRUL-3)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002116-27,0,0,0 2013-002122-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus University Medical Center,The influence of electroencephalographic Narcotrend Index™- guidance of of propofol administration on recovery from procedural sedation for gastrointestinal endoscopy in paediatric patients De invl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002122-23,0,0,0 2013-002123-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Lovisenberg Diaconal Hospital,"Effects of intraarticular IL1-Ra on pain and inflammatory mediators after knee arthroscopy –a double blind, placebo controlled study using microdialysis technique",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002123-41,0,0,0 2013-002124-17,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació de Recerca de L?Institut de Microcirurgia Ocular,Phase IV study to evaluate genetic variants of VEGF pathway as biomarkers of VEGF Trap-Eye treatment efficacy in subjects with neovascular age-related macular degeneration (wAMD). Ensayo clínico en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002124-17,0,0,0 2013-002125-27,3,2015-08-31,2015-08-31,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Onyx Therapeutics, Inc.","Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002125-27,0,0,0 2013-002126-23,1,2016-06-23,2016-06-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Apodemus AB,"A randomized, double blind, placebo controlled trial to evaluate the safety and efficacy of Apovir for treatment of patients with Alzheimer’s disease En randomiserad, dubbelblind, placebokontrolle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002126-23,0,0,0 2013-002129-43,1,2014-07-29,2014-07-29,1,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Lofarma S.p.A.,Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS®Birch-Alder tablets for patients with tree pollen-induced allergic rhinoconjunctivitis A Phase III study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002129-43,0,0,0 2013-002132-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"RWTH Aachen University, represented by the Rector, himself represented by the Dean of the Medical Faculty",RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT Trial Ruxolitinib im Vergleich zur besten verfügbaren T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002132-25,0,0,0 2013-002133-37,11,2017-07-12,2018-11-20,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Cortendo AB,"An Open Label Study to Assess the Safety and Efficacy of COR—003 (2S, 4R-Ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002133-37,0,0,0 2013-002134-21,9,2020-01-28,2020-02-27,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ARIAD Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited)","A Randomized Phase 2 Study of AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002134-21,0,0,0 2013-002134-21,9,2020-01-28,2020-02-27,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ARIAD Pharmaceuticals, Inc.","A Randomized Phase 2 Study of AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002134-21,0,0,0 2013-002134-21,9,2020-01-28,2020-02-27,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ARIAD Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceutical Ltd)","A Randomized Phase 2 Study of AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002134-21,0,0,0 2013-002135-15,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Iniciativa Andaluza en Terapias Avanzadas a través de la Fundación Progreso y Salud,Opened phase II controlled and randomized clinical trial to evaluate the efficacy in the intra-arterial infusion with mononuclear autologous bone marrow stem cells in patients with ischemic stroke ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002135-15,0,0,0 2013-002137-38,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Pfizer Inc,"A Phase 2, Randomized, ACTIVE-CONTROLLED, observer-blinded Trial, to Assess the Safety, Tolerability, and Immunogenicity of Gardasil® (HPV) Vaccine and BIVALENT RLP2086 Vaccine When Administered Conco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002137-38,0,1,1 2013-002138-20,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Centre Jean Perrin,"Multicenter randomized phase II study, double-blind, comparing Taxotere plus curcumin versus Taxotere plus placebo combination in first-line treatment of prostate cancer metastatic castration resistan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002138-20,0,0,0 2013-002139-15,1,2015-12-14,2015-12-14,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,POLICLINICO GEMELLI,STUDY COMPARING LIQUID FORMULATION OF LEVOTHYROXINE AND SOLID FORMULATION OF LEVOTHYROXINE ON THE STATE OF WELL- BEING QUALITY OF LIFE AND THE HORMONAL AND METABOLIC PARAMETERS IN THYROIDECTOMIZED PAT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002139-15,0,0,0 2013-002143-29,1,,,0,0,0,0,0,0,3,0,1,1,1,1,0,1,0,POLICLINICO GEMELLI,Pharmacological modulation of inflammation and platelet activation in inflammatory bowel diseases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002143-29,0,0,0 2013-002144-82,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Effects of aprepitant (Emend ®) on the pharmacokinetics of fentanyl Effect van aprepitant (Emend ®) op de farmacokinetiek van fentanyl,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002144-82,0,0,0 2013-002145-11,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Pfizer Inc,"A Phase 2, Randomized, Active-controlled, observer-blindED Trial, to Assess the Safety, Tolerability, and Immunogenicity of MCV4, TDAP Vaccine and bivalent RLP2086 Vaccine When Administered Concomitan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002145-11,0,1,1 2013-002147-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dutch Colorectal Cancer Group,"S-1 versus capecitabine in the first line treatment of metastatic colorectal cancer patients, the SALTO randomised phase III study of the Dutch Colorectal Cancer Group. A safety evaluation of oral flu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002147-28,0,0,0 2013-002148-95,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI),"Optimal duration of the antimicribial treatment for bloodstream infections produced by Enterobacteriaceae. Clinical trial ""SHORTEN"". Optimización de la duración del tratamiento antimicrobiano de la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002148-95,0,0,0 2013-002149-13,6,2015-03-06,2015-03-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"MDVI, LLC","A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects with Uncomplicated Influenza",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002149-13,0,0,0 2013-002150-79,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,N.V. Roche S.A.,"TOSCARA: An open-label, single-arm study to evaluate the efficacy, safety and tolerability of tocilizumab (TCZ) subcutaneous in TCZ-naïve patients with active rheumatoid arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002150-79,0,0,0 2013-002153-30,1,2013-09-17,2013-09-17,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Omninvest Ltd.,"Tolerability and Immunogenicity Study of FLUVAL AB Influenza Vaccine (trivalent, seasonal, active ingredient content: 15 μgHA/strain/0.5 mL) for the Use in the Season 2013/2014 in Adults and Elderly S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002153-30,0,0,0 2013-002154-67,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Dra. Cristina Avendaño Solá,"RANDOMIZED CLINICAL TRIAL, PLACEBO COMPARED TO EVALUATE THE EFFICACY AND SAFETY OF MINOCYCLINE IN ANGELMAN SYNDROME (A-MANECE STUDY) ENSAYO CLINICO DOBLE CIEGO, RANDOMIZADO, COMPARADO CON PLACEBO P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002154-67,0,0,0 2013-002157-29,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Ernesto Pérez Persona,"Clinical, multicenter, single-arm, with a scheme of treatment with low doses of Bortezomib / Melphalan / Prednisone (Velcade) (MPV) in patients with multiple myeloma (MM) newly diagnosed symptomatic> ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002157-29,0,0,0 2013-002163-26,3,2016-03-11,2016-03-11,3,1,1,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A multicentre, randomised, double-blind, parallel group, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of benralizumab in asthmatic adults and adolescents inadequatley controll...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002163-26,0,0,0 2013-002164-53,1,2014-09-24,2014-09-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Abteilung für Allgemeine Anästhesie und Intensivmedizin",The reversed isolated forearm technique to regionally reverse rocuronium induced muscle relaxation – a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002164-53,0,0,0 2013-002165-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Medical Center Leeuwarden,Hypernatraemia and diuretics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002165-19,0,0,0 2013-002166-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sint Antonius Hospital,"Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002166-39,0,0,0 2013-002169-21,3,2014-12-04,2014-12-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,",A Phase II Clinical Trial to Evaluate the Efficacy and Safety of a Combination Regimen of MK-5172 with/without MK-8742 and/or Ribavirin (RBV) in Treatment-naive Subjects with Chronic Hepatitis C Genot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002169-21,0,0,0 2013-002169-21,3,2014-12-04,2014-12-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,A Phase II Clinical Trial to Evaluate the Efficacy and Safety of a Combination Regimen of MK-5172 with/without MK-8742 and/or Ribavirin (RBV) in Treatment-naive Subjects with Chronic Hepatitis C Genot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002169-21,0,0,0 2013-002170-49,8,2019-03-22,2019-08-02,6,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002170-49,0,0,0 2013-002170-49,8,2019-03-22,2019-08-02,6,1,0,0,0,2,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica , S.A.",A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002170-49,0,0,0 2013-002170-49,8,2019-03-22,2019-08-02,6,1,0,0,0,2,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA S.p.A.,A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002170-49,0,0,0 2013-002172-40,1,2015-04-09,2015-04-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Isis Pharmaceuticals, Inc.","A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 426115 (an Antisense Glucocorticoid Receptor Antagonist) Administered Subcutaneous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002172-40,0,0,0 2013-002174-43,1,2017-11-09,2017-11-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,IPSEN NV,"AN INTERNATIONAL, MULTICENTRIC, PROSPECTIVE, OPEN LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 MG ASSOCIATED TO STANDARD OF CARE IN THE TREATMENT OF CLINICAL SYMPTOMS ASSOC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002174-43,0,0,0 2013-002181-39,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,ApoPharma Inc.,The efficacy and safety of Ferriprox® for the treatment of transfusional iron overload in patients with sickle cell disease or other anemias,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002181-39,0,0,0 2013-002183-63,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IOBA,"Unicenter, double masked, crossover clinical trial to assess the efficacy of FML (0.1% Fluorometolone) in dry eye patients Ensayo clínico, unicéntrico, doble enmascarado, cruzado, para evaluar la e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002183-63,0,0,0 2013-002184-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Rouen,Efficacy of parietal continous infiltration of local anesthesic on diaphragmatic function after upper abdominal surgery through a subcostal incision Efficacité de l’analgésie par infiltration pré ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002184-26,0,0,0 2013-002185-39,1,2014-01-22,2014-01-22,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Crucell Holland B.V,"Randomised, Double-Blind, Placebo-Controlled, Phase IIa Study in Healthy Volunteers to Evaluate the Protective Efficacy and Safety of CR8020 in an Influenza Challenge Model",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002185-39,0,0,0 2013-002188-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,"REDUCTION OF POST-THYROIDECTOMY TRANSIENT HYPOCALCEMIA WITH CHOLECALCIFEROL 200,000 IU OS ADMINISTERED FOR ONE MONTH BEFORE SURGERY RIDUZIONE DELLA IPOCALCEMIA TRANSITORIA POST-TIROIDECTOMIA CON CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002188-24,0,0,0 2013-002189-38,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Erasmus Medical Center,OPTIMIZING PERIPHERAL CIRCULATION WITH VASODILATOR THERAPY IN CRITICALLY ILL PATIENTS WITH CIRCULATORY SHOCK: A PILOT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002189-38,0,0,0 2013-002190-22,1,2014-10-21,2014-10-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PannonPharma Ltd.,"Therapeutic clinical trial of three types of “Phlogosol concentrate for gargle” products, comparing their efficacy in reducing different inflammations of the oral cavity. (Changing the active ingredi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002190-22,0,0,0 2013-002191-41,11,2015-07-14,2019-01-15,11,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Alexion Pharmaceuticals, Inc.","A PHASE III, OPEN-LABEL, EXTENSION TRIAL OF ECU-MG-301 TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN SUBJECTS WITH REFRACTORY GENERALIZED MYASTHENIA GRAVIS (gMG)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002191-41,0,0,0 2013-002192-18,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Translational Research In Oncology,"A randomized open-label Phase II study of letrozole plus afatinib (BIBW2992) versus letrozole alone in first-line treatment of advanced ER+, HER2- postmenopausal breast cancer with low ER expression ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002192-18,0,0,0 2013-002193-45,2,2015-03-02,2015-03-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Alkermes Inc.,"A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALK 3831, in Adults with Schizophrenia Treated with Olanzapine Randomizovaná, multice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002193-45,0,0,0 2013-002194-22,1,2017-06-22,2017-06-22,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Ipsen Limited,"A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progress...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002194-22,0,0,0 2013-002195-40,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University College London,A randomised controlled trial of the ketogenic diet in the treatment of epilepsy in children under the age of two years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002195-40,0,0,0 2013-002200-13,5,2018-10-03,2018-10-03,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A Phase 2, multicenter, open-label study of BGJ398 in patients with recurrent resectable or unresectable Glioblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002200-13,0,0,0 2013-002200-13,5,2018-10-03,2018-10-03,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A Phase 2, multicenter, open-label study of BGJ398 in patients with recurrent resectable or unresectable Glioblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002200-13,0,0,0 2013-002200-13,5,2018-10-03,2018-10-03,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA S.p.A,"A Phase 2, multicenter, open-label study of BGJ398 in patients with recurrent resectable or unresectable Glioblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002200-13,0,0,0 2013-002201-66,1,2014-04-04,2014-04-04,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"An exploratory, randomized, double-blind, placebo-controlled study to investigate the effect of BYM338 on muscle in patients requiring prolonged mechanical ventilation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002201-66,0,0,0 2013-002202-31,3,2014-11-21,2015-10-08,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Polyphor Ltd.,"A phase II, open-label, multi-center study to assess the tolerance, safety, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of POL7080 in the treatment of patients with acute exacerbation of no...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002202-31,0,0,0 2013-002205-54,1,,,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude de phase II d'un traitement par Humira® au cours du syndrome de Netherton,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002205-54,0,0,0 2013-002210-12,1,2019-05-23,2019-05-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Population Health Research Institute,"A randomized, comparative effectiveness study of complete versus culprit-only revascularization strategies to treat multi-vessel disease after primary percutaneous coronary intervention for ST-segment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002210-12,0,0,0 2013-002214-13,1,2016-03-14,2016-03-14,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Institut de Recerca de l?Hospital de la Santa Creu i Sant Pau ? IIB Sant Pau,Evaluation of oxidative stress associated with the administration of two different concentrations of oxygen for the maintenance of general anesthesia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002214-13,0,0,0 2013-002217-36,1,2015-06-30,2015-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Dept. of Anaesthesiology, Odense University Hospital",Crystalloid versus colloid for goal directed haemodynamic optimisation in major abdominal cancer surgery. Krystalloid versus kolloid til målrettet hæmodynamisk optimering ved større abdominal cance...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002217-36,0,0,0 2013-002223-42,10,2021-06-25,2021-06-25,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002223-42,1,0,0 2013-002223-42,10,2021-06-25,2021-06-25,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer Inc,","A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER PAI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002223-42,1,0,0 2013-002226-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University of Bergen, Department of Global Public Health and Primary Care",Efficacy of Pain Treatment on Depression in Patients with Dementia. A Randomized Clinical Trial of Efficacy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002226-23,0,0,0 2013-002228-18,1,,,0,1,0,0,1,0,3,0,0,1,0,0,0,1,1,AB-BIOTICS S.A.,A randomized controlled clinical trial for assessing the effectiveness of pharmacogenetic information obtained with NEUROFARMAGEN in the treatment of patients with mental disorders Ensayo clínico a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002228-18,0,0,0 2013-002233-37,1,2014-05-12,2014-05-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 6-week randomised, double-blind, parallel-group trial evaluating compatibility and safety of FIAsp and insulin aspart with an external continuous subcutaneous insulin infusion system in adult subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002233-37,0,0,0 2013-002236-24,11,2018-02-05,2018-03-02,10,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Baxalta Innovations GmbH,A Phase 3b Continuation study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients with Severe Hemophilia A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002236-24,0,0,0 2013-002236-24,11,2018-02-05,2018-03-02,10,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,A Phase 3b Continuation study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients with Severe Hemophilia A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002236-24,0,0,0 2013-002238-19,1,2014-04-01,2014-04-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VI in subjects with Chronic Obstructive Pulmonary Disease (COPD) -Study...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002238-19,0,0,0 2013-002239-44,2,2014-04-21,2014-04-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A study to compare the addition of umeclidinium bromide (UMEC) to fluticasone furoate (FF)/vilanterol (VI), with placebo plus FF/VI in subjects with Chronic Obstructive Pulmonary Disease (COPD) -Study...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002239-44,0,0,0 2013-002241-11,6,2015-01-22,2015-01-22,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shionogi Inc.,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002241-11,0,0,0 2013-002243-29,6,2014-11-24,2014-11-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm. V,"A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium + olodaterol fixed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002243-29,0,0,0 2013-002243-29,6,2014-11-24,2014-11-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd,"A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium + olodaterol fixed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002243-29,0,0,0 2013-002243-29,6,2014-11-24,2014-11-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium + olodaterol fixed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002243-29,0,0,0 2013-002243-29,6,2014-11-24,2014-11-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium + olodaterol fixed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002243-29,0,0,0 2013-002243-29,6,2014-11-24,2014-11-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium + olodaterol fixed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002243-29,0,0,0 2013-002243-29,6,2014-11-24,2014-11-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ky,"A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium + olodaterol fixed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002243-29,0,0,0 2013-002244-86,1,2015-06-23,2015-06-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Dompé s.p.a.,"Effect of reparixin on long-term outcomes after pancreatic islet transplantation in type 1 diabetes mellitus patients. A non-interventional, monocentre study to extend up to 3 years the follow-up of p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002244-86,0,0,0 2013-002245-11,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"BLUEBIRD BIO, INC.",Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002245-11,0,0,0 2013-002245-11,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"bluebird bio, Inc.",Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002245-11,0,0,0 2013-002247-28,1,2015-08-28,2015-08-28,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Rigshospitalet,The effect of chlorzoxazone of moderate to severe postoperative pain after back surgery Effekten af Chlorzoxazon på moderate til svære postoperative smerter efter rygkirurgi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002247-28,0,0,0 2013-002248-98,3,2019-12-16,2019-12-16,1,0,0,0,0,0,2,0,2,2,0,0,0,0,0,TRAILNET COORDINATING CENTER AT THE UNIVERSITY OF SOUTH FLORIDA,Anti-CD3 MAB (Teplizumab) for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus ANTI-CD3 MAB (TEPLIZUMAB) per la prevenzione del diabete in PARENTI a rischio di sviluppare di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002248-98,1,0,0 2013-002248-98,3,2019-12-16,2019-12-16,1,0,0,0,0,0,2,0,2,2,0,0,0,0,0,TrialNet Coordinating Center University of South Florida,Anti-CD3 MAB (Teplizumab) for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus ANTI-CD3 MAB (TEPLIZUMAB) per la prevenzione del diabete in PARENTI a rischio di sviluppare di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002248-98,1,0,0 2013-002248-98,3,2019-12-16,2019-12-16,1,0,0,0,0,0,2,0,2,2,0,0,0,0,0,TrialNet Coordinating Center,Anti-CD3 MAB (Teplizumab) for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus ANTI-CD3 MAB (TEPLIZUMAB) per la prevenzione del diabete in PARENTI a rischio di sviluppare di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002248-98,1,0,0 2013-002249-13,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,TrialNet Coordinating Center,CTLA-4Ig (Abatacept) for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002249-13,0,0,0 2013-002253-30,1,2016-12-19,2016-12-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Neurological Department, Aarhus University Hospital",Efficacy of citalopram treatment in acute stroke Effekten af citalopram-behandling ved akut stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002253-30,0,0,0 2013-002254-70,4,2016-10-12,2016-10-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Kyowa Hakko Kirin Pharma, Inc.","A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaulate the Efficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Severe P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002254-70,0,0,0 2013-002254-70,4,2016-10-12,2016-10-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Kyowa Kirin Pharmaceutical Development, Inc.","A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaulate the Efficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Severe P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002254-70,0,0,0 2013-002255-15,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,"A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamics and safety study of a new paediatric eurartesim dispersible formulation and crushed film coated eurartesim tablet, in infant pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002255-15,0,1,1 2013-002257-30,1,2013-12-06,2013-12-06,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,"Amicus Therapeutics, Inc.",AN OPEN-LABEL SAFETY AND DOSE-FINDING STUDY OF INTRAVENOUS DUVOGLUSTAT CO-ADMINISTERED WITH RECOMBINANT HUMAN ACID α-GLUCOSIDASE IN SUBJECTS WITH POMPE DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002257-30,0,0,0 2013-002258-60,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Radboud University Nijmegen Medical Centre,prediction of everolimus-induced interstitial lung disease in breast cancer patients; maximizing efficacy by reducing toxicity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002258-60,0,0,0 2013-002259-14,1,2017-02-09,2017-02-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Oxford,The effect of lixisenatide in type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002259-14,0,0,0 2013-002260-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medisch Centrum Leeuwarden,The effect of Roux-en-Y gastric bypass on the rate and extent of absorption of metoprolol from an immediate release tablet in female bariatric patient volunteers: a single oral dose study before and a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002260-10,0,0,0 2013-002261-18,1,2016-05-23,2016-05-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Synphora AB,"A randomized, double-blind, placebo-controlled, parallel group study to determine the efficacy, the duration of action, and safety of latanoprost in patients with Menière’s disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002261-18,0,0,0 2013-002264-24,4,2014-11-24,2015-01-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas SA,"A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium+ oldaterol fixed do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002264-24,0,0,0 2013-002264-24,4,2014-11-24,2015-01-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium+ oldaterol fixed do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002264-24,0,0,0 2013-002264-24,4,2014-11-24,2015-01-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A randomised, double-blind, placebo- and active-controlled parallel group study to assess the efficacy of 12 weeks of once daily treatment of two doses of orally inhaled tiotropium+ oldaterol fixed do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002264-24,0,0,0 2013-002266-40,1,2016-04-21,2016-04-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, double-blind, placebo-controlled, multicenter, exploratory evaluation of surrogate markers of cardiovascular risk in patients with active chronic plaque-type psoriasis treated for 52 wee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002266-40,0,0,0 2013-002267-25,1,2018-06-06,2018-06-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,UK Multicentre Open-label Randomised Controlled Trial Of IV Iron Therapy In Incident Haemodialysis Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002267-25,0,0,0 2013-002269-21,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,"Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto",Metformin in diastolic dysfunction of metabolic syndrome A metformina na disfunção diastólica da síndrome metabólica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002269-21,0,0,0 2013-002270-52,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitari de Girona Dr.Josep Trueta,Effects of cinacalcet versus conventional treatment on metabolism bone and vascular involvement in advanced chronic renal failure Efectos del cinacalcet versus tratamiento convencional sobre el met...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002270-52,0,0,0 2013-002271-17,4,2017-09-29,2017-09-29,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Multi-center, Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002271-17,0,0,0 2013-002272-40,2,2021-09-20,2021-09-20,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,"Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen","PROSPECTIVE, RANDOMIZED TRIAL OF TICAGRELOR VERSUS PRASUGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME Ticagrelor versus Prasugrel bei Patienten mit akutem Koronarsyndrom ̶ eine prospektive, ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002272-40,1,0,0 2013-002272-40,2,2021-09-20,2021-09-20,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,"Deutsches Herzzentrum München, Klinik an der Technischen Universität München","PROSPECTIVE, RANDOMIZED TRIAL OF TICAGRELOR VERSUS PRASUGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME Ticagrelor versus Prasugrel bei Patienten mit akutem Koronarsyndrom ̶ eine prospektive, ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002272-40,1,0,0 2013-002273-22,1,2014-11-25,2014-11-25,1,1,1,0,0,0,4,0,1,1,0,0,1,0,0,Azienda Ospedaliera L. Sacco - Clinica Pediatrica,"Efficacy of Pidotimod in the prevention of respiratory infections in healthy children: a randomized, double blind, placebo controlled study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002273-22,0,0,0 2013-002274-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medisch Centrum Leeuwaarden,The effect of Roux-en-Y gastric bypass on the rate and extent of absorption of metoprolol from a controlled release tablet in female bariatric patient volunteers: a single oral dose study before and a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002274-41,0,0,0 2013-002282-19,3,2022-06-01,2022-06-01,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,"European Palliative Care Research Centre (PRC), NTNU","A randomised, open-label trial of a Multimodal Intervention (Exercise, Nutrition and Anti-inflammatory Medication) plus standard care versus standard care alone to prevent / attenuate cachexia in adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002282-19,1,0,0 2013-002282-19,3,2022-06-01,2022-06-01,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Norwegian University of Science and technology,"A randomised, open-label trial of a Multimodal Intervention (Exercise, Nutrition and Anti-inflammatory Medication) plus standard care versus standard care alone to prevent / attenuate cachexia in adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002282-19,1,0,0 2013-002283-25,10,2015-03-03,2015-03-03,10,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study To Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002283-25,0,0,0 2013-002287-11,12,2015-06-04,2015-06-22,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four dos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002287-11,0,0,0 2013-002288-25,12,2015-09-16,2015-09-16,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four dos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002288-25,0,0,0 2013-002288-25,12,2015-09-16,2015-09-16,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,"A randomized parallel-group, placebo-controlled, double-blind, multi-center dose finding phase II trial exploring the pharmacodynamic effects, safety and tolerability, and pharmacokinetics of four dos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002288-25,0,0,0 2013-002290-21,2,2016-04-13,2016-04-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bio Products Laboratory Limited,"A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Im...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002290-21,0,0,0 2013-002291-41,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Celgene Corporation,"A Randomized, Open Label, Multi-Center Phase 2 Study of nab-Paclitaxel versus Epigenetic Modifying Therapy of CC-486 with nab-Paclitaxel in Subjects with Chemotherapy Naïve Metastatic Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002291-41,0,0,0 2013-002293-41,6,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,AB Science,"A prospective, multicenter, double-randomised, double-blind, 2-parallel groups, phase 3 study to compare as first line therapy efficacy and safety of masitinib in combination with gemcitabine, to gemc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002293-41,0,0,0 2013-002296-17,1,2014-11-12,2014-11-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks with Ribavirin or for 24 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002296-17,0,0,0 2013-002300-13,1,2015-05-01,2015-05-01,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,CHEMO France,"A study to evaluate the effect on the endometrium of a new formulation containing 4 mg drospirenone (Drospirenone 4 mg film-coated tablet) administered over a period of 13 cycles. A monocentric, open,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002300-13,0,0,0 2013-002302-32,4,2017-03-23,2017-03-23,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc.","An Open-label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002302-32,0,0,0 2013-002304-14,4,2016-02-29,2016-02-29,2,1,1,0,0,0,1,0,0,2,0,0,0,0,1,BOEHRINGER INGELHEIM FRANCE,"An open-label, randomised, multicentre, single-dose, parallel group trial to evaluate pharmacokinetics and pharmacodynamics of empagliflozin in children and adolescents from 10 to less than 18 years ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002304-14,1,1,0 2013-002304-14,4,2016-02-29,2016-02-29,2,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Boehringer Ingelheim Pharmaceuticals (Pty) Ltd.,"An open-label, randomised, multicentre, single-dose, parallel group trial to evaluate pharmacokinetics and pharmacodynamics of empagliflozin in children and adolescents from 10 to less than 18 years ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002304-14,1,1,0 2013-002304-14,4,2016-02-29,2016-02-29,2,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GesmbH + CoKG,"An open-label, randomised, multicentre, single-dose, parallel group trial to evaluate pharmacokinetics and pharmacodynamics of empagliflozin in children and adolescents from 10 to less than 18 years ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002304-14,1,1,0 2013-002304-14,4,2016-02-29,2016-02-29,2,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An open-label, randomised, multicentre, single-dose, parallel group trial to evaluate pharmacokinetics and pharmacodynamics of empagliflozin in children and adolescents from 10 to less than 18 years ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002304-14,1,1,0 2013-002306-31,2,2014-06-24,2014-06-24,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","An open-label, long term (52 week) extension study to evaluate the safety, tolerability, and efficacy of treatment with LCZ696 monotherapy and LCZ696 in combination with amlodipine in patients with es...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002306-31,0,0,0 2013-002306-31,2,2014-06-24,2014-06-24,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An open-label, long term (52 week) extension study to evaluate the safety, tolerability, and efficacy of treatment with LCZ696 monotherapy and LCZ696 in combination with amlodipine in patients with es...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002306-31,0,0,0 2013-002308-15,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Guys & St. Thomas' NHS Foundation Trust,A phase I/II dose finding study evaluating the safety and tolerability of CAPecitabine and AflIbercept in patients with unresectable metasTAtic colorectaL cancer deemed unsuitable for doublet/ triplet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002308-15,0,0,0 2013-002312-27,1,2015-12-04,2015-12-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Zealand Pharma,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess Clinical Efficacy and Safety of Danegaptide in Patients with ST-Elevation Myocardial Infarction undergoing Primary Percut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002312-27,0,0,0 2013-002316-27,1,2016-06-06,2016-06-06,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Medizinische Universität Wien,Hemodynamic effects of stored blood transfusion in intensive care patients Hämodynamische Auswirkungen der Transfusion gelagerter Erythrozytenkonzentrate bei Intensivpatienten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002316-27,0,0,0 2013-002318-11,11,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Biogen Idec Research Limited,"Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002318-11,0,0,0 2013-002319-82,2,2014-05-13,2014-05-13,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,BioCryst Pharmaceuticals Inc.,A Phase 2a double-blind placebo-controlled 2-period crossover study to evaluate the safety and efficacy of BCX4161 as a prophylactic treatment to reduce the frequency of attacks in subjects with hered...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002319-82,0,0,0 2013-002321-34,1,2015-08-31,2015-08-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ipsen Innovation,"A phase III, double blind, randomised, placebo controlled study to assess the efficacy and safety of a single treatment of Clostridium botulinum toxin type A to improve the appearance of moderate to s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002321-34,0,0,0 2013-002324-16,2,2018-09-13,2018-09-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, partially blind, placebo-controlled, proof-of-concept study to assess the effect of a single infusion of VAY736 on disease activity as measured by brain MRI scans in patients with relaps...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002324-16,0,0,0 2013-002327-42,2,2014-07-02,2014-07-02,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Allergan Limited,Long-term Study of BOTOX® Treatment in Adult Patients with Upper Limb Spasticity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002327-42,0,0,0 2013-002340-90,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Ghent University Hospital,Study of the molecular mechanisms underlying the cross-neutralizing capacity of AS04-adjuvanted HPV vaccine (Cervarix®) in comparison with the aluminiumhydroxyphosphate sulphate adjuvanted HPV vaccine...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002340-90,0,0,0 2013-002341-11,1,2014-12-10,2014-12-10,1,1,0,0,1,0,4,0,1,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,A SINGLE BLIND PHASE IV PHARMACODYNAMIC STUDY TO EVALUATE NEUTROPHIL DISTRIBUTION KINETICS AND FUNCTION FOLLOWING SINGLE-DOSE TOCILIZUMAB TREATMENT IN HEALTHY SUBJECTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002341-11,0,0,0 2013-002343-29,5,2015-04-28,2015-04-28,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients with Primary Hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002343-29,0,0,0 2013-002345-11,6,2014-04-05,2016-05-08,6,1,1,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A multicentre, randomised, double-blind, parallel group, placebo-controlled, Phase III efficacy and safety study of benralizumab (MEDI-563) added to high-dose inhaled corticosteroid plus long-acting b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002345-11,0,0,0 2013-002346-37,2,2015-08-11,2015-08-11,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Allergan Limited,BOTOX® Treatment in Adult Patients with Upper Limb Spasticity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002346-37,0,0,0 2013-002347-28,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ACROSS: Associació Catalana per a la Recerca Oncològica i les seves implicacions sanitàries i Socials,Phase II interventional trial for the assessment of histological responses in all resected colorectal cancer liver metastases after preoperative cetuximab-based chemotherapy. Ensayo clínico fase II...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002347-28,0,0,0 2013-002348-99,1,2017-07-19,2017-07-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Aristotle University Thessaloniki,"A randomised, double blind, placebo-controlled study of the effect of liraglutide on arterial blood pressure in hypertensive patients with type 2 diabetes mellitus Μία τυχαιοποιημένη, διπλά τυφλή, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002348-99,0,0,0 2013-002349-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Unit of Infectious Diseases, Department of Medical Scieces, University of Torino c/o ASLTO2, Amedeo di Savoia Hospital",“Switching HIV-positive Women With Undetectable Viremia on Tenofovir/Emtricitabine plus Boosted Atazanavir to RALtegravir (400 mg twice-daily) plus Boosted ATazanavir (300/100 mg once-daily): A Pilot ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002349-12,0,0,0 2013-002351-15,7,2014-09-02,2014-09-02,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Merck KGaA,"A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-?-1a 30 µg IM Weekly i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002351-15,0,0,0 2013-002352-32,4,2014-07-25,2014-07-25,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,AstraZeneca AB,"A multicentre, randomised, double-blind, paralllel group, placebo-controlled, Phase 3 efficacy and safety study of benralizumab (MEDI-563) added to medium dose inhaled corticosteroid plus long acting ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002352-32,0,0,0 2013-002354-72,1,2016-07-04,2016-07-04,1,1,1,0,1,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie",A QUALITATIVE ANALYSIS OF SEDATION IN INFANTS WITH CAUDAL BLOCKADE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002354-72,0,0,0 2013-002358-57,5,2015-07-27,2015-07-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to investigate the Safety and Efficacy of ABT-494 Given with Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002358-57,0,0,0 2013-002358-57,5,2015-07-27,2015-07-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to investigate the Safety and Efficacy of ABT-494 Given with Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002358-57,0,0,0 2013-002359-14,1,2015-09-28,2015-09-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intesnivmedizin und Schmerztherapie",Ultrasound Guided Caudal Blockade in Children between 30 and 50kg: A Feasibility Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002359-14,0,0,0 2013-002362-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de Parc de Salut de Barcelona (Parc de Salut MAR),Reducing the dose of sugammadex 50% reverse the neuromuscular blockade of rocuronium effectively after general anesthesia. Reducir la dosis de sugammadex un 50% revierte el bloqueo neuromuscular de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002362-39,0,0,0 2013-002363-26,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Vejle Hospital,Neoadjuvant chemotherapy versus standard treatment in patients with locally advanced colon cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002363-26,0,0,0 2013-002366-40,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,"St George’s, University of London",Neonatal and Paediatric Pharmacokinetics of Antimicrobials study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002366-40,0,0,0 2013-002370-51,1,,,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,Academic Medical Center,Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with locally advanced or metastasized pancreatic cancer Fase I/II studie met LDE225 in combinatie met gemci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002370-51,0,0,0 2013-002371-17,6,2016-10-31,2016-10-31,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002371-17,0,0,0 2013-002373-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Vrije Universiteit Medical Center,ThE SoF-Trial (SoFT) - The Effect of Sevelamer on FGF23 Trial - A clinical trial assessing the quantitative effect of phosphate binding therapy on FGF23.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002373-22,0,0,0 2013-002377-21,9,2020-11-12,2020-12-11,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002377-21,1,0,0 2013-002378-26,1,2018-04-12,2018-04-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Västerbottens Läns Landsting,Switch To RItuXimab in MS extension An extension study of STRIX-MS - a phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy approa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002378-26,0,0,0 2013-002379-17,1,2015-04-28,2015-04-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Oslo University Hospital healt Trust,MECILLINAM FOR TREATMENT OF GENITAL CHLAMYDIA INFECTION IN ASYMPTOMATIC MEN.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002379-17,0,0,0 2013-002379-17,1,2015-04-28,2015-04-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Oslo universitetssykehus health trust,MECILLINAM FOR TREATMENT OF GENITAL CHLAMYDIA INFECTION IN ASYMPTOMATIC MEN.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002379-17,0,0,0 2013-002379-17,1,2015-04-28,2015-04-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Oslo University Hospital Health Trust,MECILLINAM FOR TREATMENT OF GENITAL CHLAMYDIA INFECTION IN ASYMPTOMATIC MEN.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002379-17,0,0,0 2013-002380-25,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CKF at Västmanlands hospital Västerås,"A Randomized, Open-label Study to compare Propofol Anaesthesia with Sevoflurane Anaesthesia in terms of Overall Survival in Patients with Surgical Intervention for either Breast-, Colon- or Rectalcanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002380-25,0,0,0 2013-002386-18,1,2018-06-27,2018-06-27,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,RWTH Aachen Clinical Trials Center Aachen (CTC-A),"Network connectivity and inhibitory control under atomoxetin challenge - A pharamacological ""resting state"" and ""inhibitory task"" fMRI study in patients with ADHD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002386-18,0,0,0 2013-002388-25,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Azienda Ospedaliera Ospedali Riuniti Marche Nord,"Phase II study to evaluate the safety and the efficacy of rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone (R-COMP 14) as front-line therapy for patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002388-25,0,0,0 2013-002390-21,1,2013-11-26,2013-11-26,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,Effects of oxygen status on endotoxemia induced inflammation and Hypoxia Inducible Factor 1-a. A pilot proof of principle study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002390-21,0,0,0 2013-002394-22,2,2014-06-18,2014-06-18,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Salix Pharmaceuticals, Inc.",A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects with Irritable Bowel Syndrome with Diarrhoea (IBS-D),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002394-22,0,0,0 2013-002395-40,1,2018-02-16,2018-02-16,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,Ghent University Hospital,Prospective intervention trial with adjuvant metformin in girls and boys with classic CAH (METFOR CAH).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002395-40,0,0,0 2013-002396-17,1,2013-12-04,2013-12-04,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Birmingham Community Healthcare NHS Trust,The effect of Pramipexole on recovery from chronic post-stroke aphasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002396-17,0,0,0 2013-002403-34,5,2021-12-31,2021-12-31,2,0,0,0,0,0,2,0,0,2,1,0,0,0,0,"Queen Mary, University of London",A Randomized Phase II Study of Fulvestrant in Combination with the dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant alone in Estrogen Receptor Positive Advanced or Metastatic Breast Cancer. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002403-34,1,0,0 2013-002405-61,9,2017-03-20,2020-12-23,5,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Infinity Pharmaceuticals, Inc",A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002405-61,1,0,0 2013-002405-61,9,2017-03-20,2020-12-23,5,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Verastem, INC",A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002405-61,1,0,0 2013-002405-61,9,2017-03-20,2020-12-23,5,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Verastem, Inc",A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002405-61,1,0,0 2013-002406-31,9,2016-10-05,2017-03-03,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Infinity Pharmaceuticals, Inc","A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of IPI-145 in Combination with Rituximab vs Rituximab in Subjects with Previously-Treated Follicular Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002406-31,0,0,0 2013-002408-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oslo University Hospital,"Phase IV ipilimumab in melanoma A National, Multicenter, Interventional Study in Patients with Unresectable or Metastatic Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002408-15,0,0,0 2013-002409-75,1,2018-04-13,2018-04-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Charite,"Intra-individual, comparison of the MRI contrast agents gadoxetic acid (Primovist®) versus gadoterate meglumine (Dotarem®) in liver MRI of patients with HCC and underlying cirrhosis Intraindividuel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002409-75,0,0,0 2013-002414-12,1,2020-02-03,2020-02-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PARI Pharma GmbH,"A randomised, open, controlled pilot study to investigate the efficacy and safety of Buparid/PARI SINUS versus Budes® Nasal Spray in the therapy of Chronic Rhinosinusitis (CRS) with polyposis nasi in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002414-12,0,0,0 2013-002415-10,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University Medical Center Groningen,[18F]-labelled FDHT in PET/CT for detection and staging of bone metastases in hormone naïve prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002415-10,0,0,0 2013-002416-27,10,2017-02-12,2017-02-12,5,0,0,0,0,0,4,0,0,2,1,0,0,0,0,Fundacio Clinic per a la recerca biomedica,"Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital morta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002416-27,1,0,0 2013-002416-27,10,2017-02-12,2017-02-12,5,0,0,0,0,0,4,0,0,2,1,0,0,0,0,"Medical University of Graz, Department of Internal Medicine, Division of Gastroenterology and Hepatology","Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital morta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002416-27,1,0,0 2013-002416-27,10,2017-02-12,2017-02-12,5,0,0,0,0,0,4,0,0,2,1,0,0,0,0,Fundacio Clinic per a la Recerca Biomedica,"Albumin administration in the prevention of hepatorenal syndrome and death in patients with cirrhosis, bacterial infections other than spontaneous bacterial peritonitis and high risk of hospital morta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002416-27,1,0,0 2013-002417-35,3,2021-10-07,2021-10-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Oncology, Karolinska University Hospital","A multicenter, randomized phase II trial of vinflunine/gemcitabine versus carboplatin /gemcitabine as first line treatment in patients with metastatic urothelial carcinoma unfit for cisplatin based ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002417-35,0,0,0 2013-002418-11,1,2013-11-20,2013-11-20,1,1,0,0,1,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Consumer Healthcare,A study to evaluate the effect of a 67% Sodium Bicarbonate containing toothpaste on Chlorhexidine Digluconate tooth staining,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002418-11,0,0,0 2013-002419-87,1,2018-04-26,2018-04-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Queen Mary University London,Oxcarbazepine as a neuroprotective agent in MS: phase 2a trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002419-87,0,0,0 2013-002421-30,1,2020-03-03,2020-03-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PARI Pharma GmbH,"A randomised, open, controlled pilot study to investigate the potential of Buparid/PARI SINUS versus Budes® Nasal Spray to avoid or postpone sinus surgery in adult patients with Chronic Rhinosinusitis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002421-30,0,0,0 2013-002428-17,1,2015-09-25,2015-09-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Gastroenheden D, Herlev Hospital",Nurse Administered Propofol Sedation vs combined sedation with midazolam/fentanil for colonoscopy in patients with IBD. A randomised controlled trial of satisfaction and adhearence to treatment progra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002428-17,0,0,0 2013-002429-52,3,2016-03-09,2016-03-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche Farma S.A,"A PHASE IIIb STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF SUBCUTANEOUS (SC) TOCILIZUMAB (TCZ) GIVEN AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE (MTX) OR OTHER NON-BIOLOGICS DMARDs...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002429-52,0,0,0 2013-002429-52,3,2016-03-09,2016-03-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche Farma S.A.,"A PHASE IIIb STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF SUBCUTANEOUS (SC) TOCILIZUMAB (TCZ) GIVEN AS MONOTHERAPY OR IN COMBINATION WITH METHOTREXATE (MTX) OR OTHER NON-BIOLOGICS DMARDs...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002429-52,0,0,0 2013-002431-15,8,2017-05-29,2017-05-29,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 12-month, phase IV, randomized, open label, multicenter study to compare efficacy of 0.5 mg ranibizumab PRN compared to 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stabil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002431-15,0,0,0 2013-002433-38,1,2019-01-23,2019-01-23,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU de Toulouse,"Essai de phase IV, multicentrique, ouvert, visant à tester la différence d’efficacité du Natalizumab, versus le fingolimod, 2 médicaments ayant une AMM pour le traitement de la sclérose en plaques B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002433-38,0,0,0 2013-002437-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Maastricht University Medical Centre,"Effects on Intra-Coronary Attenuation using low iodine concentrations (240 mg, 300 mg and 370 mg iodine per ml) while maintaining identical IDR",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002437-37,0,0,0 2013-002439-10,1,2016-11-30,2016-11-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Warwick,Perioperative Analgesia for Knee Arthroplasty: A prospective randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002439-10,0,0,0 2013-002439-10,1,2016-11-30,2016-11-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Coventry & Warwickshire NHS Trust,Perioperative Analgesia for Knee Arthroplasty: A prospective randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002439-10,0,0,0 2013-002441-12,3,2019-09-06,2019-09-06,3,1,0,0,0,1,3,0,0,1,0,0,1,0,0,European Organisation for Research and Treatment of Cancer,"A blind randomized multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic radiosensitizer nimorazole (Nimoral), using a 15 gene signature for hypoxia in the treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002441-12,0,0,0 2013-002447-29,2,2016-09-01,2016-09-01,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Oryzon Genomics S.A.,"A phase I study of Human Pharmacokinetics and Safety of ORY-1001, and LSD1 inhibitor, in relapsed or refractory acute leukaemia (AL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002447-29,0,0,0 2013-002449-12,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Westfriesgasthuis,"Does buprenorphine (Temgesic) 0,3 mg prolongs the analgesic effect of a blockade of the femoral nerve with 20 ml ropivacaïne HCL Fresenius Kabi 0,2% for patiënts with a total knee replacement. A prosp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002449-12,0,0,0 2013-002450-69,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,1,Laboratorio Reig Jofré S.A,"Estudio de fase III, aleatorizado, abierto con evaluación ciega, multicéntrico, de no-inferioridad, con control activo y con placebo, para evaluar la seguridad y la eficacia de la aplicación tópica de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002450-69,0,0,0 2013-002451-15,2,2016-11-03,2016-11-03,1,1,0,0,1,0,2,0,1,1,0,0,1,0,0,GlaxoSmithKline Biologicals SA,"A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of GSK Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to GSK Me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002451-15,0,0,0 2013-002453-29,4,2017-05-04,2017-05-04,2,1,1,0,1,1,3,0,0,2,0,0,0,0,1,Shire ViroPharma Incorporated,"A PHASE 3, MULTICENTER, RANDOMIZED, SINGLE-BLIND, DOSE-RANGING, CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS ADMINISTRATION OF CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) FOR THE PR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002453-29,1,0,0 2013-002453-29,4,2017-05-04,2017-05-04,2,1,1,0,1,1,3,0,0,2,0,0,0,0,1,ViroPharma Incorporated,"A PHASE 3, MULTICENTER, RANDOMIZED, SINGLE-BLIND, DOSE-RANGING, CROSSOVER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS ADMINISTRATION OF CINRYZE® (C1 ESTERASE INHIBITOR [HUMAN]) FOR THE PR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002453-29,1,0,0 2013-002454-78,3,2015-10-22,2015-10-22,2,1,1,0,0,0,4,0,1,1,0,0,1,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase IIIb, Open Label, Controlled, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Novartis Meningococcal Group B Vaccine when administered to Immunocompr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002454-78,0,0,0 2013-002457-30,1,2016-11-10,2016-11-10,1,1,0,0,1,0,2,0,0,1,1,1,1,0,0,St George's University of London,An open label randomised controlled trial investigating the effect of donepezil on regional cerebral blood flow in adults with aneurysmal subarachnoid haemorrhage.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002457-30,0,0,0 2013-002458-66,1,2014-11-26,2014-11-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Subjects with Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002458-66,0,0,0 2013-002466-39,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,The Christie NHS Foundation Trust,A randomised placebo-controlled trial of synchronous NIMorazole versus RADiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma not suitable for synchronous chemother...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002466-39,0,0,0 2013-002467-26,1,2016-08-22,2016-08-22,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,"480 Biomedical, Inc.",The SPRINT trial: An Evaluation of the 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System v1.2 in the Treatment of de novo SFA Lesions Eine Bewertung des Medikamenten beschichtet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002467-26,0,0,0 2013-002468-20,1,2014-11-18,2014-11-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects with Genotype 1 Chronic Hepatitis C,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002468-20,0,0,0 2013-002470-46,2,2016-06-06,2016-06-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chugai Pharmaceutical Co. Ltd,"A Phase II, randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of CIM331 in atopic dermatitis patients who are inadequately controlled...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002470-46,0,0,0 2013-002480-26,1,2017-02-22,2017-02-22,1,0,1,0,0,0,3,0,0,1,0,0,1,0,1,BIOSE,"Study of the efficacy and safety of treatment with total freeze-dried culture of Lcr Regenerans® administered intravaginally in the prevention of recurrent vulvovaginal candidiasis. International, ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002480-26,0,0,0 2013-002482-19,4,2017-08-12,2017-08-12,2,1,0,0,1,0,4,0,0,1,0,0,1,0,1,"IBSA, Institut Biochimique S.A.",Randomised clinical trial comparing highly purified FSH formulation (Fostimon®) and recombinant FSH (Gonal-F®) in GnRH-antagonist controlled ovarian hyperstimulation cycles,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002482-19,0,0,0 2013-002482-19,4,2017-08-12,2017-08-12,2,1,0,0,1,0,4,0,0,1,0,0,1,0,1,IBSA Institut Biochimique S.A.,Randomised clinical trial comparing highly purified FSH formulation (Fostimon®) and recombinant FSH (Gonal-F®) in GnRH-antagonist controlled ovarian hyperstimulation cycles,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002482-19,0,0,0 2013-002482-19,4,2017-08-12,2017-08-12,2,1,0,0,1,0,4,0,0,1,0,0,1,0,1,IBSA Institut Biochimique SA,Randomised clinical trial comparing highly purified FSH formulation (Fostimon®) and recombinant FSH (Gonal-F®) in GnRH-antagonist controlled ovarian hyperstimulation cycles,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002482-19,0,0,0 2013-002483-84,4,2014-10-28,2014-10-28,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.p.A.,"Multicenter, randomized, blinded, two-period cross-over study to assess the effect of glycopyrronium (44 micrograms QD) versus tiotropium (18 micrograms QD) on morning symptoms and pulmonary function ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002483-84,0,0,0 2013-002483-84,4,2014-10-28,2014-10-28,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S. A.","Multicenter, randomized, blinded, two-period cross-over study to assess the effect of glycopyrronium (44 micrograms QD) versus tiotropium (18 micrograms QD) on morning symptoms and pulmonary function ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002483-84,0,0,0 2013-002483-84,4,2014-10-28,2014-10-28,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"Multicenter, randomized, blinded, two-period cross-over study to assess the effect of glycopyrronium (44 micrograms QD) versus tiotropium (18 micrograms QD) on morning symptoms and pulmonary function ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002483-84,0,0,0 2013-002484-26,1,2018-08-06,2018-08-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,LFB Biomédicaments,"A RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ON THE EFFICACY AND SAFETY OF A THERAPEUTIC STRATEGY OF POST PARTUM HAEMORRHAGE COMPARING EARLY ADMINISTRATION OF HUMAN FIBRINOGEN VER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002484-26,0,0,0 2013-002492-17,1,2019-04-01,2019-04-01,1,0,0,1,0,1,1,0,0,1,1,1,0,0,0,St. Anna Kinderkrebsforschung,Treatment of adenovirus and cytomegalovirus infection post human allogeneic stem cell transplantation with short-term expanded virus-specific T cells Behandlung von Adeno- und Cytomegalie-Virusinfe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002492-17,0,0,0 2013-002505-62,1,2018-01-24,2018-01-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,SarCaBon: A randomised phase II trial of Saracatinib versus placebo for cancer-induced bone pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002505-62,0,0,0 2013-002506-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr Antonio Gimeno,"Clinical trial phase IV, randomized, to evaluate the efficacy of Polyethylene glycol plus ascorbic acid vs Polyethylene glycol alone in patients with a history of poorly prepared colonoscopy . Ens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002506-31,0,0,0 2013-002507-34,3,2015-03-30,2015-03-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Genkyotex Innovation SAS,"A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients with Type 2 Diabetes and Albuminuria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002507-34,0,0,0 2013-002508-15,6,2017-05-02,2017-06-02,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002508-15,0,0,0 2013-002510-12,1,2015-04-24,2015-04-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biofrontera Bioscience GmbH,"A randomized, double-blind, phase III multi-center study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) versus placebo in the field-directed treatment of mild to moderate actinic keratosi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002510-12,0,0,0 2013-002511-99,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO ONCOLOGICO VENETO,"Role of PET/ CT with 18F-fluorocholine in the staging of patients with intermediate/high risk prostate cancer. Phase III, randomized, open-label clinical trial Ruolo della PET/TC con 18F-fluorocoli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002511-99,0,0,0 2013-002512-27,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Maastricht University,The role of bile acids in human brown adipose tissue metabolism De rol van galzuren in bruin vet metabolisme in de mens,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002512-27,0,0,0 2013-002513-35,21,2017-04-25,2017-04-28,17,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002513-35,0,0,0 2013-002513-35,21,2017-04-25,2017-04-28,17,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA S.p.A.,"A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002513-35,0,0,0 2013-002513-35,21,2017-04-25,2017-04-28,17,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S. A.","A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002513-35,0,0,0 2013-002515-10,1,2019-11-26,2019-11-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Medical Center Freiburg,"Treatment of Optic Neuritis with Erythropoietin: a randomised, double-blind, placebo-controlled trial Behandlung der Optikusneuritis mit Erythropoietin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002515-10,0,0,0 2013-002516-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Altération de la Réponse dopaminergique à l'Administration de Psychostimulants par Inhibition de la Dopamine beta-hydroxylase. Exploration par TEP du mécanisme d'action d'une nouvelle stratégie thérap...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002516-27,0,0,0 2013-002517-35,1,2014-04-22,2014-04-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Médicament/Institut de Recherche Pierre Fabre,Bronchodilator properties and safety of a repeated dose of V0162 inhalation powder in asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002517-35,0,0,0 2013-002518-11,14,2019-12-27,2019-12-27,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES MELLI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002518-11,0,0,0 2013-002519-90,2,2016-07-28,2016-07-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study with a 26-Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002519-90,0,0,0 2013-002520-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AOU di Bologna, Policlinico S.Orsola-Malpighi","Randomized phase II study of 3 vs 6 courses of neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002520-17,0,0,0 2013-002521-27,3,2015-02-13,2015-02-13,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V. (APEB),A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects with Peripheral Neuropathic Pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002521-27,0,0,0 2013-002522-23,3,2015-04-02,2016-04-02,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer Healthcare AG,"A double blinded, placebo controlled, study to investigate the safety, tolerability, pharmacokinetics and acute cardiovascular responses of a 7 day oral treatment with the partial adenosine A1 recepto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002522-23,0,0,0 2013-002523-42,4,2016-07-06,2016-07-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A multicenter, randomized, double-blind, parallel group, placebo-controlled, Phase 3 efficacy and safety study of benralizumab (MEDI-563) to reduce oral corticosteroid use in patients with uncontrolle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002523-42,0,0,0 2013-002524-16,2,2019-05-28,2019-12-01,2,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Dept of Oncology. Haukeland University Hospital,Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55%,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002524-16,0,0,0 2013-002526-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medizinische Universität Innsbruck,Impact of 68Ga-DOTAOTC PET for diagnosis of newly diagnosed or recurrent meningiomas Einfluss der 68Ga-DOTATOC PET zur Diagnostik von neudiagnostizierten bzw. rezidivierenden Meningeomen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002526-23,0,0,0 2013-002528-17,5,2017-03-24,2017-03-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002528-17,0,0,0 2013-002535-24,1,2014-09-22,2014-09-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Ethicon Inc., a Johnson & Johnson Co.","A Phase III Randomized, Controlled, Superiority Study Evaluating EVARREST™ Fibrin Sealant Patch Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Hepatic Surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002535-24,0,0,0 2013-002537-37,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biologicals' meningococcal conjugate vaccine, MenACWY-TT (GSK 134612) in healthy inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002537-37,0,1,1 2013-002538-18,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, single-group, open-label, multicentre study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002538-18,0,1,1 2013-002539-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Freiburg,Multicenter randomized double masked parallel design exploratory study to assess safety and efficacy of two different doses of intravitreal anti-VEGF treatment with ranibizumab (0.12 mg vs. 0.20 mg) i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002539-13,0,0,0 2013-002545-10,1,2018-12-19,2018-12-19,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,A. Carlsson Research AB,"An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Park...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002545-10,0,0,0 2013-002546-36,1,2014-04-18,2014-04-18,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie","Heat-, Cold-, and Mechanical Painthresholds under exposition of high dose topical Capsaicin Hitze-, Kälte- und Mechanoschmerzschwellen unter Exposition mit hochdosiertem topischem Capsaicin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002546-36,0,0,0 2013-002549-12,11,2019-07-15,2019-07-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 3, MULTICENTER, LONG-TERM OBSERVATIONAL STUDY OF SUBJECTS FROM TANEZUMAB STUDIES WHO UNDERGO A TOTAL KNEE, HIP OR SHOULDER REPLACEMENT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002549-12,0,0,0 2013-002549-12,11,2019-07-15,2019-07-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc.,","A PHASE 3, MULTICENTER, LONG-TERM OBSERVATIONAL STUDY OF SUBJECTS FROM TANEZUMAB STUDIES WHO UNDERGO A TOTAL KNEE, HIP OR SHOULDER REPLACEMENT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002549-12,0,0,0 2013-002553-29,1,2016-03-12,2016-03-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Jens Sønksen,Metabolic changes due to iatrogenic hypogonadism in patients with prostate cancer: orchiectomy vs. triptorelin Metaboliske ændringer hos patienter med prostatakræft som følge af iatrogen hypogonadi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002553-29,0,0,0 2013-002554-78,2,2016-02-17,2016-02-17,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Protalix Ltd.,"An Extension of Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Eve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002554-78,0,0,0 2013-002556-32,1,2017-02-23,2017-02-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Newcastle upon Tyne Hospitals NHS Foundation Trust,Antibiotic treatment for intermittent bladder catheterisation: A randomised controlled trial of once daily prophylaxis (The AnTIC study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002556-32,0,0,0 2013-002557-30,1,,,0,0,1,0,0,0,4,0,1,4,0,0,0,0,1,Proveca Ltd,"A two-staged, open label, single dose, two period, two-sequence, crossover study to compare the bioavailability of 2 mg Glycopyrronium Bromide from a new oral solution (2 mg/5 ml) (Test Product) with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002557-30,0,1,1 2013-002558-64,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,dipartimento di neurologia e psichiatria,"A randomised, placebo-controlled trial investigating the role of fampiridina in improving cognitive function of patients with multiple sclerosis. Studio randomizzato contro placebo sull’efficacia ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002558-64,0,0,0 2013-002561-19,1,2015-11-30,2015-11-30,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"Medizinische Universität Wien, Univ.Klinik f.Frauenheilkunde,Abt. f.Geburtshilfe und Feto-maternale Medizin","A prospective, double blind, randomised, placebo controlled trial to evaluate the effect of a long term tokolysis with atosiban on the pregnancy outcome. A pilot study. Eine prospektive, doppelblin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002561-19,0,0,0 2013-002562-39,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Institut de Recherches Internationales Servier (IRIS),"An exploratory, open-label, single centre, phase II, proof of concept study of gevokizumab treatment in patients with Schnitzler syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002562-39,0,0,0 2013-002563-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU University Medical Centre,Pilot study to determine the effect of fractionated radiotherapy on expression of pro-angiogenic factors in oeshophagus carcinoma Een pilot studie om het effect te onderzoeken van gefractioneerde r...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002563-25,0,0,0 2013-002564-69,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH,"Double-blind, placebo-controlled multicenter phase II trial to evaluate the efficacy and safety of romiplostim for the treatment of chemotherapy-induced thrombocytopenia in subjects with relapsed o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002564-69,0,0,0 2013-002567-26,1,2017-09-25,2017-09-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Hellenic Cooperative Oncology Group,Single-arm phase II study of maintenance therapy with aflibercept after first-line treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients Μελέτη φάσης ΙΙ μιας ομάδας θεραπ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002567-26,0,0,0 2013-002572-40,15,2017-06-30,2017-06-30,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche et développement,"Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002572-40,0,0,0 2013-002573-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,A.O PAPA GIOVANNI XXIII- BERGAMO,"PROBE TRIAL (Pilot Rilpivirine Observational Evaluation) Monocenter, national, prospective, open label, pilot, proof-of-concept study on the use of rilpivirine as substitutive agent for the HAART nucl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002573-22,0,0,0 2013-002579-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,C. HOSPITALARIO VIRGEN DEL ROCIO,"PHASE III CLINICAL TRIAL, single-center, randomized, double blind IN TWO GROUPS PARALLELS TO COMPARE THE EFFICACY AND SAFETY OF RICH PLASMA GROWTH FACTORS (PRGF) IN FRONT OF fibrin glue (TISSUCOL ®) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002579-16,0,0,0 2013-002580-26,8,2022-09-28,2022-09-28,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Pfizer Inc,"Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Fulvestrant (FASLODEX) with or without PD-0332991 (PALBOCICLIB) ± Goserelin in Women with Hormone Receptor-Positive, Her2-Ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002580-26,1,0,0 2013-002580-26,8,2022-09-28,2022-09-28,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Pfizer Inc.,"Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Fulvestrant (FASLODEX) with or without PD-0332991 (PALBOCICLIB) ± Goserelin in Women with Hormone Receptor-Positive, Her2-Ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002580-26,1,0,0 2013-002580-26,8,2022-09-28,2022-09-28,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017","Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Fulvestrant (FASLODEX) with or without PD-0332991 (PALBOCICLIB) ± Goserelin in Women with Hormone Receptor-Positive, Her2-Ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002580-26,1,0,0 2013-002581-39,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AZ Sint Jan Brugge-Oostende AV,Impact of deep neuromuscular block versus inhalation and TIVA on laparoscopic surgical workspace,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002581-39,0,0,0 2013-002583-80,1,2014-01-28,2014-01-28,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Department of Dermatology, Bispebjerg University Hospital",Treatment of Actinic Keratoses with Ingenol Mebutate and topical glucocorticosteroid - a safety study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002583-80,0,0,0 2013-002584-25,1,2017-04-21,2017-04-21,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,King's College London,Naltrexone Enhanced Addiction Treatment (NEAT): A randomised controlled trial of the clinical and cost-effectiveness of extended-release naltrexone and oral naltrexone.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002584-25,0,0,0 2013-002584-25,1,2017-04-21,2017-04-21,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,South London and Maudsley NHS Foundation Trust,Naltrexone Enhanced Addiction Treatment (NEAT): A randomised controlled trial of the clinical and cost-effectiveness of extended-release naltrexone and oral naltrexone.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002584-25,0,0,0 2013-002588-24,3,2014-09-10,2014-09-10,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica , S.A.",A randomized pre-surgical pharmacodynamics study to assess the biological activity of LEE011 plus letrozole versus single agent letrozole in primary breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002588-24,0,0,0 2013-002588-24,3,2014-09-10,2014-09-10,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma AG,A randomized pre-surgical pharmacodynamics study to assess the biological activity of LEE011 plus letrozole versus single agent letrozole in primary breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002588-24,0,0,0 2013-002589-38,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Universität Innsbruck, Institut für Biomedizinische Alternsforschung",Primary and booster vaccination in old age: Hepatitis A and Hepatitis B Primär- und Auffrischungsimpfungen im Alter: Hepatitis A und Hepatitis B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002589-38,0,0,0 2013-002596-18,6,2018-09-12,2018-09-12,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002596-18,0,0,0 2013-002597-44,4,2017-05-04,2017-05-04,4,1,0,1,0,0,1,0,0,1,1,0,0,0,1,"Onyx Therapeutics, Inc.","Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002597-44,0,0,0 2013-002605-65,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Azienda Ospedaliera di Reggio Emilia Arcispedale S.Maria Nuova/IRCCS,Radioreceptor therapy with labeled somatostatin analogues in tumors with high expression of somatostatin receptors. Terapia radiorecettoriale con analoghi marcati della somatostatina in tumori con ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002605-65,0,0,0 2013-002607-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INSERM-ANRS,Pilot study to assess efficacy and safety of Sofosbuvir/Ledipasvir (GS-5885) fixed-dose combination with Ribavirin in NS3/4A protease inhibitor-experienced subjects with HCV genotype 1 infection and H...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002607-33,0,0,0 2013-002608-15,3,2016-04-13,2016-04-13,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis Farma SpA,"A two-part placebo-controlled study to evaluate the safety, tolerability and preliminary efficacy of BVS857 in patients with spinal and bulbar muscular atrophy (SBMA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002608-15,0,0,0 2013-002608-15,3,2016-04-13,2016-04-13,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A two-part placebo-controlled study to evaluate the safety, tolerability and preliminary efficacy of BVS857 in patients with spinal and bulbar muscular atrophy (SBMA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002608-15,0,0,0 2013-002609-78,6,2021-06-03,2022-02-01,5,1,0,0,0,0,2,0,0,2,0,0,0,0,0,ETOP (European Thoracic Oncology Platform),A randomised open-label phase II trial of consolidation ipilimumab in limited-stage SCLC after chemo-radiotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002609-78,1,0,0 2013-002610-13,3,2015-04-24,2015-04-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 with Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002610-13,0,0,0 2013-002611-96,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR),Pilot study to determine the efficacy of anakinra (antagonist of interleukin-1 receptor) administered for 3 months in improving inflammatory signs observed by MRI in patients with erosive/inflammatory...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002611-96,0,0,0 2013-002616-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,"Cytoreductive treatment of dabrafenib combined with trametinib to allow complete surgical resection in patients with BRAF mutated, prior unresectable stage III or IV melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002616-28,0,0,0 2013-002618-10,4,2015-11-20,2015-11-20,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"EnVivo Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer?s Disease Currently or Previously...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002618-10,0,0,0 2013-002618-10,4,2015-11-20,2015-11-20,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Forum Pharmaceuticals Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer?s Disease Currently or Previously...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002618-10,0,0,0 2013-002620-17,5,,,0,1,0,1,0,0,1,0,0,2,0,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",Phase 1/2 study of PF-06463922 (an ALK/ROS1 tyrosine kinase inhibitor) in patients with advanced non-small cell lung cancer harboring specific molecular alterations.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002620-17,0,0,0 2013-002620-17,5,,,0,1,0,1,0,0,1,0,0,2,0,0,0,0,1,"Pfizer Inc,",Phase 1/2 study of PF-06463922 (an ALK/ROS1 tyrosine kinase inhibitor) in patients with advanced non-small cell lung cancer harboring specific molecular alterations.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002620-17,0,0,0 2013-002622-23,8,2015-09-03,2016-11-06,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim International GmbH,Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002622-23,0,0,0 2013-002625-35,1,2015-05-21,2015-05-21,1,0,0,0,0,1,3,0,0,1,1,1,1,0,0,All Ireland Co-operative Oncology Research Group (ICORG),Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002625-35,0,0,0 2013-002626-23,11,2015-11-19,2016-05-31,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen, in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002626-23,0,0,0 2013-002626-23,11,2015-11-19,2016-05-31,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farma SpA,"A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen, in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002626-23,0,0,0 2013-002626-23,11,2015-11-19,2016-05-31,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen, in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002626-23,0,0,0 2013-002628-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,COMBAT MEDICAL LTD,"HIVEC (Hyperthermic IntraVEsical Chemotherapy) FOR PATIENTS WITH INTERMEDIATE RISK NMIBC COMPARED WITH STANDARD INTRAVESICAL INSTILLATION OF CHEMOTHERAPY AS ADYUVANT TREATMENT. A COMPARATIVE, PROSPEC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002628-18,0,0,0 2013-002631-19,1,2019-05-28,2019-05-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Essai pilote multicentrique évaluant l’immunogénicité d’une stratégie vaccinale anti-pneumococcique innovante chez des adultes splénectomisés - SPLENEVAC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002631-19,0,0,0 2013-002636-25,1,2019-03-18,2019-03-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Birmingham,A Randomised Multicentre Open Label Blinded End Point Trial to Compare the Effects of Spironolactone to Chlortalidone on Left Ventricular Mass and Arterial Stiffness in Stage 3 Chronic Kidney Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002636-25,0,0,0 2013-002638-19,1,2015-01-28,2015-01-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee & NHS Tayside,The Effect of Spironolactone on Pain in Older People with Osteoarthris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002638-19,0,0,0 2013-002641-11,1,2016-07-07,2016-07-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gilead Sciences Inc.,"A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002641-11,0,0,0 2013-002642-37,4,2016-04-05,2016-04-05,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002642-37,0,0,0 2013-002643-28,4,2016-06-29,2016-07-05,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, LONG-TERM SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002643-28,0,0,0 2013-002644-87,7,2016-04-15,2016-05-06,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED,PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002644-87,0,0,0 2013-002645-11,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"SBI Pharmaceuticals Co., Ltd.","An Open-label, Randomized Study to Evaluate Safety, Tolerability and Pharmacokinetics of 5-ALA/SFC in Cancer Patients with Solid Tumors with Chemotherapy Induced Anemia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002645-11,0,0,0 2013-002646-36,14,2016-11-01,2017-03-22,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, ny 10017","PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB(PF-04950615), IN REDUCING THE OCCURRENCE OF MAJO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002646-36,0,0,0 2013-002646-36,14,2016-11-01,2017-03-22,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB(PF-04950615), IN REDUCING THE OCCURRENCE OF MAJO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002646-36,0,0,0 2013-002647-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,Clinical trial to evaluate the efficacy and tolerability of electrochemotherapy for palliative treatment in patients with head and neck squamous cell carcinoma Ensayo clínico para evaluar la eficac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002647-29,0,0,0 2013-002648-10,1,2015-06-03,2015-06-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bruno Farmaceutici S.p.a.,THE EFFECT OF A DAILY AND WEEKLY ADMINISTRATION OF DIFFERENT DOSES OF CALCIDIOL ON 25(OH)D3 SERUM LEVELS AND ON MINERAL AND BONE METABOLIC MARKERS IN POSTMENOPAUSAL FEMALE SUBJECTS OVER 55 YEARS OF AG...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002648-10,0,0,0 2013-002651-15,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Zon MW,"Adjusting infliximab dose in IBD patients in remission, based on infliximab trough levels: the study on Infliximab Levels in IBD patients Steering Treatment, the ILIST pilot Het aanpassen van de d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002651-15,0,0,0 2013-002652-32,1,2014-06-06,2014-06-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, placebo-controlled, double-blind, single dose, cross-over study to evaluate the efficacy and safety of orally inhaled tiotropium + olodaterol as both a fixed dose combination and a free ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002652-32,0,0,0 2013-002653-30,6,2015-11-05,2015-11-11,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Forum Pharmaceuticals Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer?s Disease Currently or Previously...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002653-30,0,0,0 2013-002653-30,6,2015-11-05,2015-11-11,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"EnVivo Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer?s Disease Currently or Previously...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002653-30,0,0,0 2013-002654-75,7,2015-11-15,2015-12-23,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Forum Pharmaceuticals Inc.,A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects with Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication Ensayo d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002654-75,0,0,0 2013-002656-32,1,2016-05-04,2016-05-04,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Univ.Klinik für Innere Medizin III, Abt.f.Endokrinologie und Stoffwechsel",The impact of free fatty acid (FFA-) suppression on myocardial lipids and function in patients with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002656-32,0,0,0 2013-002659-14,4,2017-06-30,2017-06-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Recherche & Développement,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Alirocumab in Patients with Primary Hypercholesterolemia Not Treated With a Statin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002659-14,0,0,0 2013-002660-17,3,2015-12-02,2015-12-02,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Farma SpA,Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002660-17,0,0,0 2013-002660-17,3,2015-12-02,2015-12-02,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002660-17,0,0,0 2013-002662-40,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AS.T.R.O.,PERtuzumab-trastuzumab plus lEetrozoLe In endocrine Sensitive breast cancer: a phase II neoAdjuvant study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002662-40,0,0,0 2013-002663-25,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,0,VU University Medical Center,"A phase I- IIa open-label clinical trial, evaluating the therapeutic vaccine hVEGF26-104/RFASE in patients with advanced solid tumors Een fase I-IIa klinische studie naar het therapeutisch vaccin h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002663-25,0,0,0 2013-002664-10,7,2014-10-28,2014-12-18,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, parallel group, 52-week study evaluating the efficacy, safety and tolerability of NVA237 in patients with poorly controlled asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002664-10,0,0,0 2013-002664-10,7,2014-10-28,2014-12-18,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Farma SpA,"A randomized, double-blind, parallel group, 52-week study evaluating the efficacy, safety and tolerability of NVA237 in patients with poorly controlled asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002664-10,0,0,0 2013-002666-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,TAYS Sydänkeskus Oy,Aorttastenoosin vaikutukset hemodynamiikkaan (DYNAMIC-AS) ETL R10056 Aorttastenoosin vaikutukset hemodynamiikkaan (DYNAMIC-AS) ETL R10056,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002666-38,0,0,0 2013-002670-40,1,2018-11-15,2018-11-15,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,VU University Medical Center (VUmc),Noninvasive Imaging of Vulnerable Inflammatory Coronary Plaque using Cardiac PET/CT in Humans: a feasibility study Onderzoek naar het gebruik van verschillende PET-tracers voor het vaststellen van ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002670-40,0,0,0 2013-002671-18,7,2015-10-29,2015-10-31,7,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An explorarory, 12 week, randomised, partially double-blinded, placebo-controlled parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002671-18,0,0,0 2013-002671-18,7,2015-10-29,2015-10-31,7,1,0,0,1,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm. V,"An explorarory, 12 week, randomised, partially double-blinded, placebo-controlled parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002671-18,0,0,0 2013-002671-18,7,2015-10-29,2015-10-31,7,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Danmark A/S,"An explorarory, 12 week, randomised, partially double-blinded, placebo-controlled parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002671-18,0,0,0 2013-002671-18,7,2015-10-29,2015-10-31,7,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"An explorarory, 12 week, randomised, partially double-blinded, placebo-controlled parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002671-18,0,0,0 2013-002671-18,7,2015-10-29,2015-10-31,7,1,0,0,1,0,3,0,0,1,0,0,1,0,1,"Unilfarma, Lda.","An explorarory, 12 week, randomised, partially double-blinded, placebo-controlled parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002671-18,0,0,0 2013-002671-18,7,2015-10-29,2015-10-31,7,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"An explorarory, 12 week, randomised, partially double-blinded, placebo-controlled parallel group trial to explore the effects of once daily treatments of orally inhaled tiotropium + olodaterol fixed d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002671-18,0,0,0 2013-002675-17,1,2019-06-12,2019-06-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Clínic per a la Recerca Biomèdica,Ticagrelor and absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization Ticagrelor e implante de stent biorreabs...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002675-17,0,0,0 2013-002681-39,6,2015-05-14,2015-06-03,6,1,0,0,2,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and development,"A 24-week, Phase 2B, randomized, active-controlled, parallel group, multi-center study to evaluate the safety and efficacy of GSK1278863 in subjects with anemia associated with chronic kidney disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002681-39,0,0,0 2013-002681-39,6,2015-05-14,2015-06-03,6,1,0,0,2,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A 24-week, Phase 2B, randomized, active-controlled, parallel group, multi-center study to evaluate the safety and efficacy of GSK1278863 in subjects with anemia associated with chronic kidney disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002681-39,0,0,0 2013-002682-19,7,2015-02-06,2015-02-06,6,1,0,0,2,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase 2B, randomized, blinded, dose-ranging, active-controlled, parallel-group, multi-center study to evaluate the dose response relationship of GSK1278863 over the first 4 weeks of treatment and ev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002682-19,0,0,0 2013-002682-19,7,2015-02-06,2015-02-06,6,1,0,0,2,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A Phase 2B, randomized, blinded, dose-ranging, active-controlled, parallel-group, multi-center study to evaluate the dose response relationship of GSK1278863 over the first 4 weeks of treatment and ev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002682-19,0,0,0 2013-002684-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,S.I.C.O.G. ONLUS,Phase II study of liposomal doxorubicin in combination with trastuzumab plus cyclophosphamide followed by docetaxel plus trastuzumab as primary systemic therapy for patients with locally advanced brea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002684-25,0,0,0 2013-002686-19,2,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"Lund University, Clinical Coagulation Research Unit, Skane University Hospital",Hemophilia Inhibitor PUP Study Anti-faktor VIII hämmande antikroppar hos tidigare obehandlade patienter med ärftlig blödarsjuka,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002686-19,0,0,0 2013-002686-19,2,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano,Hemophilia Inhibitor PUP Study Anti-faktor VIII hämmande antikroppar hos tidigare obehandlade patienter med ärftlig blödarsjuka,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002686-19,0,0,0 2013-002690-22,1,2013-12-16,2013-12-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PeP-Tonic Medical AB,A pharmacokinetic study of vaginally and intravenously administered oxytocin in postmenopausal women with vaginal atrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002690-22,0,0,0 2013-002696-18,2,2016-02-02,2016-02-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sunovion Respiratory Development Inc.,"A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter, Long-Term Safety Trial of Treatment with Nebulized SUN-101 in Patients with COPD: GOLDEN-5 (Glycopyrrolate for Obstructive Lun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002696-18,0,0,0 2013-002701-56,2,2022-08-15,2022-08-15,1,0,1,0,0,1,2,0,0,2,0,0,0,0,1,"Origin Biosciences, Inc.","A Phase 2, multicenter, multinational, open-label, dose-escalation study to evaluate the safety and efficacy of ORGN001 (formerly ALXN1101) in pediatric patients with Molybdenum Cofactor Deficiency (M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002701-56,1,0,0 2013-002702-30,6,2022-09-13,2022-09-13,3,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Alexion Pharma GmbH,"A PHASE 2/3, MULTICENTER, MULTICENTER, MULTINATIONAL, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALX1101 IN NEONATES WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A Estudio abierto, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002702-30,1,0,0 2013-002702-30,6,2022-09-13,2022-09-13,3,0,1,0,0,1,2,0,0,2,0,0,0,0,1,"Origin Biosciences, Inc.","A PHASE 2/3, MULTICENTER, MULTICENTER, MULTINATIONAL, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALX1101 IN NEONATES WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A Estudio abierto, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002702-30,1,0,0 2013-002705-65,1,2015-07-27,2015-07-27,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,TARGID,The effect of Prucalopride (Resolor) on gastric motor function and gastric sensitivity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002705-65,0,0,0 2013-002707-33,14,2019-05-02,2019-05-02,14,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Sierra Oncology, Inc.","A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocyth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002707-33,0,0,0 2013-002707-33,14,2019-05-02,2019-05-02,14,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Sierra Oncology Inc.,"A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocyth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002707-33,0,0,0 2013-002707-33,14,2019-05-02,2019-05-02,14,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Gilead Sciences Inc,"A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocyth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002707-33,0,0,0 2013-002707-33,14,2019-05-02,2019-05-02,14,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocyth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002707-33,0,0,0 2013-002707-33,14,2019-05-02,2019-05-02,14,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Sierra Oncology, Inc","A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocyth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002707-33,0,0,0 2013-002708-14,1,2014-02-28,2014-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Schülke & Mayr GmbH,Phase II study to assess bacterial count reduction of three Octenidine mouthwash concentrations in comparison to a placebo in patients with mild gingivitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002708-14,0,0,0 2013-002709-79,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Academic Medical Center, Department of Rheumatology",Mechanism of action study of anti-IL17 treatment in spondyloarthritis: Impact on cellular and molecular pathways of synovial inflammation and tissue remodeling.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002709-79,0,0,0 2013-002710-13,1,2017-10-17,2017-10-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hospices Civils de Lyon,Supplémentation en vitamine D chez des enfants et adolescents suivis en néphrologie pédiatrique: étude de l’efficacité du protocole habituel de service (cholécalciférol) et de son impact sur la calciu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002710-13,0,0,0 2013-002711-94,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,HOVON Foundation,"HOVON 124 WM study: A prospective phase I/II trial of the combination of ixazomib citrate, rituximab and dexamethasone in patients with relapsed or progressive Waldenström's macroglobulinemia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002711-94,0,0,0 2013-002713-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,MediPsych SA,"Randomized, controlled trial of the effectiveness of add-on tolcapone to usual antipsychotic therapy on cognitive and negative symptoms of patients with schizophrenia genotyped for COMT polymorphisms",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002713-35,0,0,0 2013-002714-12,1,2015-07-24,2015-07-24,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU DE CLERMONT FERRAND,Effets très précoces d’une dose de charge de rosuvastatine sur la fonction endothéliale,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002714-12,0,0,0 2013-002716-28,8,2015-12-10,2021-03-05,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc.,"A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician?s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002716-28,0,0,0 2013-002716-28,8,2015-12-10,2021-03-05,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Medivation, Inc.","A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician?s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002716-28,0,0,0 2013-002716-28,8,2015-12-10,2021-03-05,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Medivation, Inc., a wholly-owned subsidiary of Pfizer, Inc.","A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician?s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002716-28,0,0,0 2013-002716-28,8,2015-12-10,2021-03-05,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Medivation, Inc., a wholly-owned subsidiary of Pfizer","A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician?s Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002716-28,0,0,0 2013-002717-35,5,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Medivation, Inc.","A Phase 2, Randomized, Double Blind, Placebo Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estroge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002717-35,0,0,0 2013-002720-16,1,2020-01-21,2020-01-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Stockholms Läns Sjukvårdsområde (SLSO),"EMPHAS I Evaluation of Methylphenidate (MPH) in adults with ADHD and SUD - clinical pharmacology study A Cross-sectional, Open-label, Non-randomized Single-Center Study on Adults with ADHD and Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002720-16,0,0,0 2013-002722-23,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Medisch Spectrum Twente,The protective effect of a single dose inhaled steroid with different body postures against exercise induced bronchoconstriction Het beschermende effect van een enkele dosis inhalatiecorticosteroi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002722-23,0,0,0 2013-002723-42,1,2018-04-16,2018-04-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Rigshospitalet,Electrochemotherapy of Head and Neck Cancer Elektrokemoterapi af hoved-hals cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002723-42,0,0,0 2013-002726-23,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Janssen R&D, Ireland","Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002726-23,0,0,0 2013-002727-42,1,2018-07-13,2018-07-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU de Nantes,"Etude prospective, monocentrique, évaluant l’efficacité de l’antalgie par cathéter périnerveux continu à la Ropivacaïne, chez des patients hospitalisés pour angiodermite nécrosante",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002727-42,0,0,0 2013-002728-17,1,2014-07-30,2014-07-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Glenmark Pharmaceuticals SA,"A Phase 2a, Multi-Centre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Efficacy, Safety and Tolerability of Inhaled GRC 17536, Administered for 4 Weeks, in Patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002728-17,0,0,0 2013-002730-21,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Cardiff University,A Trial for Older Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002730-21,0,0,0 2013-002734-20,1,2020-10-21,2020-10-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Research and Innovation Department,A Randomised Controlled Trial Investigating the Pharmacodynamic Effect of Ticagrelor Monotherapy on Platelet Reactivity in Patients with Coronary Artery Disease: The TEMPLATE Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002734-20,0,0,0 2013-002735-23,3,2016-09-01,2016-09-01,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,InnaVirVax,"Assessment of the therapeutic properties of the VAC-3S immunoprotective vaccine when combined with standard antiretroviral therapy (ART) in the course of HIV-1 infection. A European multicenter, rand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002735-23,1,0,0 2013-002735-23,3,2016-09-01,2016-09-01,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,InnaVirVax SA,"Assessment of the therapeutic properties of the VAC-3S immunoprotective vaccine when combined with standard antiretroviral therapy (ART) in the course of HIV-1 infection. A European multicenter, rand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002735-23,1,0,0 2013-002736-24,1,2017-08-18,2017-08-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Uppsala University,Does Ticagrelor inhibit growth of small abdominal aortic aneurysms? A randomised controlled trial (TicAAA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002736-24,0,0,0 2013-002737-38,2,2020-02-29,2020-02-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Cologne,A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002737-38,0,0,0 2013-002740-85,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,BTI BIOTECHNOLOGY INSTITUTE IMASD,"A Pilot Randomized, Double-blind, Placebo-controlled Clinical Trial to Obtain Preliminary Data on Efficacy and Safety in the Application of PRGF-Endoret by Mesotherapy, in the Treatment of Male and Fe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002740-85,0,0,0 2013-002742-37,6,2020-10-08,2020-10-16,5,0,0,0,0,0,2,0,0,2,0,0,0,0,0,AIO-Studien-gGmbH,Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002742-37,1,0,0 2013-002744-89,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Erasmus MC,Bioavailability of oral ciprofloxacin tablets and suspension in pediatric cancer patients De biologische beschikbaarheid van ciprofloxacine tabletten en suspensie in pediatrische kanker patienten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002744-89,0,0,0 2013-002748-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación en Enfermedades del Aparato Digestivo,"A double-blind, randomized, multicenter, placebo-controlled, parallel-group phase IV clinical trial to assess the efficacy of pancreatic enzyme replacement therapy (PERT) in patients with pancreatic e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002748-10,0,0,0 2013-002753-30,4,2018-09-21,2018-09-21,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"FibroGen, Inc.","A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Incident-dialysis Patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002753-30,0,0,0 2013-002755-15,1,2017-04-04,2017-04-04,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Ganymed Pharmaceuticals AG,A first-in-human dose escalation and dose finding phase I/II trial of IMAB027 in patients with recurrent advanced ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002755-15,0,0,0 2013-002758-62,6,2018-02-09,2018-07-16,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck KGaA,"A Phase IIb, Multi-Center, Long-Term Extension Trial to Evaluate the Safety and Tolerability of Atacicept in Subjects with Systemic Lupus Erythematosus (SLE) who Completed Protocol EMR-700461-023 (ADD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002758-62,0,0,0 2013-002763-25,2,2015-06-16,2015-06-16,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,NeRRe Therapeutics Ltd,"A randomised, double-blind, placebo-controlled study to evaluate the efficacy of two different dose levels of orvepitant (10 and 30 mg) compared with placebo on EGFRi-induced intense pruritus in oncol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002763-25,0,0,0 2013-002764-12,1,2015-04-07,2015-04-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"University Hospital, Limoges",The Pectoral Nerve Block (PECBLOCK) for the Treatment of Pain After Breast Cancer Surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002764-12,0,0,0 2013-002766-39,13,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Centre Léon Bérard,"An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma. Ένα διεθνές κλινικό πρόγραμμα για τη διάγνωση και τη θεραπεία παιδιών, ε...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002766-39,0,0,0 2013-002766-39,13,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,CENTRE LEON BERARD,"An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma. Ένα διεθνές κλινικό πρόγραμμα για τη διάγνωση και τη θεραπεία παιδιών, ε...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002766-39,0,0,0 2013-002766-39,13,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Centre Leon Berard,"An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma. Ένα διεθνές κλινικό πρόγραμμα για τη διάγνωση και τη θεραπεία παιδιών, ε...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002766-39,0,0,0 2013-002766-39,13,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Centre de lutte contre le cancer Léon Bérard,"An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma. Ένα διεθνές κλινικό πρόγραμμα για τη διάγνωση και τη θεραπεία παιδιών, ε...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002766-39,0,0,0 2013-002766-39,13,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Children's Health Ireland at Crumlin,"An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma. Ένα διεθνές κλινικό πρόγραμμα για τη διάγνωση και τη θεραπεία παιδιών, ε...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002766-39,0,0,0 2013-002769-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medisch Spectrum Twente,The protective effect of a single dose salbutamol against exercise induced inspiratory airflow obstruction in asthmatic children. Het beschermende effect van een enkele dosis salbutamol tegen insp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002769-20,0,0,0 2013-002770-43,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Clínica Universidad de Navarra/Universidad de Navarra,"Multicenter randomized, double-blind, placebo-controlled parallel clinical trial to assess efficacy and safety of Omalizumab (Xolair®) in a new indication: cholinergic urticaria. Estudio multicéntr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002770-43,0,0,0 2013-002773-21,6,2016-12-08,2016-12-08,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002773-21,0,0,0 2013-002774-51,1,2010-12-31,2010-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Helsinki University Central Hospital,Genetic influences on pain and oxycodone consumption following mastectomy Rintasyövän vuoksi hoidettavien naisten kivun hoito,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002774-51,0,0,0 2013-002775-17,7,2014-09-08,2014-12-02,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Andromeda Biotech Ltd,OPEN-LABEL STUDY TO EVALUATE LONG TERM SAFETY AND TREATMENT EFFECT OF DIAPEP277® IN SUBJECTS WHO HAVE COMPLETED STUDY 1001,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002775-17,0,0,0 2013-002775-17,7,2014-09-08,2014-12-02,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Andromeda Biotech Ltd,: 42 Hayarkon str,Yavne,81227, Israel",OPEN-LABEL STUDY TO EVALUATE LONG TERM SAFETY AND TREATMENT EFFECT OF DIAPEP277® IN SUBJECTS WHO HAVE COMPLETED STUDY 1001,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002775-17,0,0,0 2013-002777-22,6,2018-07-30,2018-07-30,5,1,0,0,0,0,4,0,0,1,1,0,1,0,0,"University of Leeds, Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine",Targeted Ultrasound in Rheumatoid Arthritis (TURA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002777-22,0,0,0 2013-002778-38,10,2015-10-28,2015-10-30,8,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier (IRIS),"A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy and safety of gevokizumab in the treatment of patients with giant cell arteritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002778-38,0,0,0 2013-002778-38,10,2015-10-28,2015-10-30,8,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Laboratorios Servier SL,"A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy and safety of gevokizumab in the treatment of patients with giant cell arteritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002778-38,0,0,0 2013-002778-38,10,2015-10-28,2015-10-30,8,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier ( IRIS ),"A randomised, double-blind, placebo-controlled proof-of concept study of the efficacy and safety of gevokizumab in the treatment of patients with giant cell arteritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002778-38,0,0,0 2013-002780-26,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002780-26,0,1,1 2013-002781-39,9,2015-09-17,2015-09-23,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"Prospective, Double-Blind, Multicenter Study Evaluating the Safety of Repeat Doses of IV Serelaxin in Subjects with Chronic Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002781-39,0,0,0 2013-002781-39,9,2015-09-17,2015-09-23,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"Prospective, Double-Blind, Multicenter Study Evaluating the Safety of Repeat Doses of IV Serelaxin in Subjects with Chronic Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002781-39,0,0,0 2013-002781-39,9,2015-09-17,2015-09-23,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis farma SpA,"Prospective, Double-Blind, Multicenter Study Evaluating the Safety of Repeat Doses of IV Serelaxin in Subjects with Chronic Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002781-39,0,0,0 2013-002783-12,2,2017-09-29,2017-09-29,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bayer AG,"A multi-center, open-label, randomized cross-over study to compare the acute tolerability and pharmacokinetics of BAY Q 6256 (iloprost; Ventavis) inhalation using the I-Neb nebulizer and the FOX nebul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002783-12,0,0,0 2013-002783-12,2,2017-09-29,2017-09-29,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bayer HealthCare AG,"A multi-center, open-label, randomized cross-over study to compare the acute tolerability and pharmacokinetics of BAY Q 6256 (iloprost; Ventavis) inhalation using the I-Neb nebulizer and the FOX nebul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002783-12,0,0,0 2013-002784-25,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Thrombotargets Europe,"A Phase II, randomized, controlled, double blind study to evaluate the haemostatic efficacy and safety of TT-173 applied in the donor site of patients undergoing skin graft. Estudio fase II, aleato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002784-25,0,0,0 2013-002785-39,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,Laboratoires BOIRON,"Evaluation de l’efficacité et de la tolérance de Coryzalia dans le traitement des symptômes du rhume chez les enfants : étude de phase IIIb, nationale, multicentrique, randomisée, en double aveugle, c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002785-39,0,0,0 2013-002790-22,3,2015-05-26,2015-05-26,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"An open-label, randomized, parallel group study assessing the immunogenicity and safety of sarilumab administered as monotherapy in patients with active rheumatoid arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002790-22,0,0,0 2013-002795-41,13,2016-11-01,2017-04-03,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, ny 10017","PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF MAJO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002795-41,0,0,0 2013-002797-42,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,1,Leiden University Medical Centre,Alcohol and Oxycodone - The influence of the combination of alcohol and an opioid on ventilation in healthy young and elderly volunteers - the 'A&O' study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002797-42,0,0,0 2013-002799-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dipartimento di Medicina Interna e Specialità Mediche - Policlinico Umberto I - Sapienza Università di Roma,Statins in the prevention of myocardial damage in pneumonia Le statine nella prevenzione del danno miocardico associato a polmonite,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002799-42,0,0,0 2013-002802-30,7,2015-08-27,2015-08-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002802-30,0,0,0 2013-002804-15,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IV, open-label, multicentre, non-comparative study to assess reactogenicity and safety of co-administration of GlaxoSmithKline (GSK) Biologicals’ inactivated poliomyelitis vaccine PoliorixTM a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002804-15,0,1,1 2013-002805-76,5,2016-11-16,2016-11-16,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Development Centre Europe Ltd.,"A 24-week randomized, double-blind, placebo-controlled, phase 2 dose finding study to evaluate the efficacy and safety of 3 doses of namilumab (20 mg, 80 mg and 150 mg) in combination with methotrexat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002805-76,0,0,0 2013-002806-30,4,2015-09-22,2016-02-23,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Takeda Development Centre Europe Ltd.,"A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding and Proof of Concept Study, to Assess the Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Namilum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002806-30,0,0,0 2013-002807-32,1,2014-11-11,2014-11-11,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Aarhus University Hospital, Department of Cardiology","Antibiotic treatment for patients with infectious endocarditis: continuous infusion, guided by therapeutic drug monitoring, versus intermittent infusions (the CONTENT study). Antibiotikabehandling ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002807-32,0,0,0 2013-002810-11,7,2017-10-23,2017-10-23,4,1,1,0,0,0,3,0,0,1,1,1,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002810-11,0,0,0 2013-002812-28,2,2016-04-12,2016-04-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A single arm, multicenter, phase IIa study to explore the efficacy and safety of ruxolitinib (INC424) in regularly transfused patients with thalassemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002812-28,0,0,0 2013-002812-28,2,2016-04-12,2016-04-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.p.A,"A single arm, multicenter, phase IIa study to explore the efficacy and safety of ruxolitinib (INC424) in regularly transfused patients with thalassemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002812-28,0,0,0 2013-002815-88,1,2013-12-31,2013-12-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,UZ Brussel,Randomised comparative trial of Bupivacaine and 2-Chloroprocaine by caesarean section. Vergelijkende gerandomiseerde studie van BupivacaÏne en 2- ChloroprocaÏne bij keizersnede.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002815-88,0,0,0 2013-002818-12,4,2018-09-17,2019-01-28,3,1,0,0,1,0,3,0,0,1,0,0,1,0,0,The John Hopkins University,"A phase III, randomized, open-label, 500-subject clinical trial of minimally invasive surgery plus rt-PA in the treatment of intracerebral haemorrhage.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002818-12,0,0,0 2013-002819-10,2,2014-08-25,2014-08-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbott Laboratories GmbH,"A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ? 12 years of Age with Pancreatic Exocrine Insufficiency Due to Cysti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002819-10,0,0,0 2013-002820-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St. Antonius Hospital,Comparison of a single dose fibrinogen with placebo and the number of blood transfusions after ascending aorta surgery (FIBTEG study) Vergelijking van een eenmalige gift fibrinogeen met placebo en ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002820-18,0,0,0 2013-002821-41,1,2014-09-23,2014-09-23,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"Persistence of hepatitis B antibodies, immunogenicity and safety of GSK Biologicals’ hepatitis B vaccine EngerixTM-B Kinder (SKF103860) challenge dose in adolescents vaccinated with four doses of Infa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002821-41,0,0,0 2013-002822-21,1,2019-08-15,2019-08-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford,The early use of Antibiotics for at Risk CHildren with InfluEnza in primary care (ARCHIE): a double-blind randomised placebo-controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002822-21,0,0,0 2013-002825-52,1,2015-06-19,2015-06-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Hochschule Hannover,"Single-center, open-label, single-arm Phase IIa study in kidney transplant patients with acute T-cell-mediated rejection in renal transplant according to Banff criteria (class IA and IB) without (stag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002825-52,0,0,0 2013-002826-22,1,2016-01-18,2016-01-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Surrey,The effect of Lixisenatide on triacylglycerol and glucose metabolism in patients with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002826-22,0,0,0 2013-002830-19,2,2017-07-31,2017-07-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Two-Part Study to Evaluate the Efficacy of Tenofovir Alafenamide versus Placebo Added to a Failing Regimen Followed by Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafena...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002830-19,0,0,0 2013-002836-26,1,2015-09-10,2015-09-10,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KU Leuven - Drug Delivery & Disposition,Gastrointestinal behavior of posaconazol in healthy human volunteers Gastrointestinaal gedrag van posaconazol in gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002836-26,0,0,0 2013-002838-20,2,2017-11-10,2017-11-15,2,0,0,0,0,1,3,0,0,1,0,0,1,0,0,Academic Medical Center,The effect of Vitamin D3 to prevent post-operative relapse of Crohn’s Disease: a placebo-controlled randomized trial (DETECT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002838-20,0,0,0 2013-002843-26,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients age...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002843-26,0,0,0 2013-002844-10,6,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002844-10,0,0,0 2013-002845-12,3,2017-11-10,2017-11-10,1,0,1,0,0,0,2,0,0,2,0,0,0,0,0,SERMAS (Hospital la Paz),An international multicentre open-label comparative therapeutic exploratory trial to investigate the role of a new neonatal formulation of dobutamine in the treatment of haemodynamic insufficiency in ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002845-12,1,0,0 2013-002845-12,3,2017-11-10,2017-11-10,1,0,1,0,0,0,2,0,0,2,0,0,0,0,0,Servicio Madrileño de Salud (SERMAS),An international multicentre open-label comparative therapeutic exploratory trial to investigate the role of a new neonatal formulation of dobutamine in the treatment of haemodynamic insufficiency in ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002845-12,1,0,0 2013-002845-12,3,2017-11-10,2017-11-10,1,0,1,0,0,0,2,0,0,2,0,0,0,0,0,Brighton & Sussex University Hospitals NHS Trust,An international multicentre open-label comparative therapeutic exploratory trial to investigate the role of a new neonatal formulation of dobutamine in the treatment of haemodynamic insufficiency in ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002845-12,1,0,0 2013-002847-28,1,2017-04-03,2017-04-03,1,1,1,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"Multicenter, open-label, dose escalation study to evaluate safety, tolerability and pharmacokinetics of RLX030 in addition to standard of care in pediatric patients from birth to <18 years of age, hos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002847-28,0,0,0 2013-002848-93,2,2016-05-30,2016-05-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Radboud University Medical Centre,Pharmacokinetics of micafungin (Mycamin ®) as antifungal prophylaxis given twice weekly intravenously compared to micafungin given daily to patients at risk for developing an invasive fungal disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002848-93,0,0,0 2013-002850-54,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma S.A.S,"A 24 month open-label, multicenter, phase IIIb study of the efficacy and safety of Lucentis® (ranibizumab 0,5mg) in diabetic patients with visual impairment due to macular edema evaluating a treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002850-54,0,0,0 2013-002854-66,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University Hospital Southampton NHS Foundation Trust,Southampton Pregnancy Intervention for the Next Generation - a randomised controlled trial of vitamin D and nurse support in improving the diet and body composition of young women and their children.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002854-66,0,0,0 2013-002855-13,4,2016-03-29,2016-03-29,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Cardeas Pharma,"A Randomized Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered via the Investigational eFlow® Inline System in Mechanically Ventilated Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002855-13,1,0,0 2013-002856-33,1,2015-01-05,2015-01-05,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Alnylam Pharmaceuticals, Inc.","A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients with Transthyretin (TTR) Cardiac Amyloidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002856-33,0,0,0 2013-002857-32,6,2015-12-30,2015-12-30,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galapagos NV,"Double-Blind, Randomized, Placebo-Controlled, Multi Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn’s Disease With Evidence of Mucosal Ulceration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002857-32,0,0,0 2013-002860-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AMC,The risk of cardiovascular disease in Ankylosing Spondylitis; A Single Center Cross-Sectional Study Evaluating The Association Between Inflammation In Ankylosing Spondylitis And Vascular Inflammation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002860-19,0,0,0 2013-002861-20,2,2014-08-11,2014-09-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lek Pharmaceuticals d.d.,"A multi-centre, randomised, double-blind, parallel-group phase III study to investigate the efficacy, safety, and tolerability of a generic calcipotriol-betamethasone ointment formulation compared to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002861-20,0,0,0 2013-002872-42,8,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,"Puma Biotechnology, Inc","An Open-Label, Phase 2 Basket Study of Neratinib in Patients With Solid Tumors With Somatic Activation HER Mutations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002872-42,0,0,0 2013-002878-47,4,2015-04-27,2015-04-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A trial comparing sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously treated with insulin deglud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002878-47,0,0,0 2013-002882-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Västra Götalands Center för utveckling av prehospital akutsjukvård,DETermination of the role of OXygen in Acute Myocardial Infarction (DETO₂X-AMI) trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002882-20,0,0,0 2013-002883-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,"Walking the Isobole of drug Interaction: Comparison of hemodynamic effects, cerebral and tissue oxygenation for 4 equipotent combinations of propofol and remifentanil",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002883-20,0,0,0 2013-002884-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AMC,Pessary or Progesterone to Prevent Preterm delivery in women with short cervical length Pessarium of progesteron ter preventie van vroeggeboorte in vrouwen met een korte cervixlengte,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002884-24,0,0,0 2013-002885-38,3,2017-09-28,2017-09-28,2,1,1,0,1,1,2,0,0,1,0,0,1,0,1,Shire HGT Inc,"A Controlled,Randomized,Two-arm,Open-label,Assessor-blinded,Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction with Elaprase® in Pediatric Patients with Hunter Syndrome and Ea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002885-38,0,0,0 2013-002886-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UMC St Radboud,A phase Ib-II study of the combination of cetuximab and methotrexate in recurrent or metastatic squamous cell carcinoma of the head and neck. A study of the Dutch Head and Neck Society.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002886-20,0,0,0 2013-002892-16,5,2018-05-07,2018-05-07,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A multicentre, multinational, randomised, parallel-group, placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-0092 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002892-16,0,0,0 2013-002893-35,5,2016-08-26,2016-08-26,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Trevena Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002893-35,0,0,0 2013-002895-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Region Skåne,"Glaucoma Intensity Treatment Study – Intensive non-invasive glaucoma treatment vs conventional stepwise treatment – a prospective, randomized phase IV study of disease progression in glaucoma (GITS Ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002895-42,0,0,0 2013-002896-17,1,2015-10-29,2015-10-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Orthopädisches Spital Speising,Functional evaluation of two therapy concepts: dynamic orthoses and BoNT Funktionelle Evaluierung von zwei Theraphiekonzepten: dynamischen Orthesen und BoNT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002896-17,0,0,0 2013-002897-30,3,2017-10-19,2017-10-19,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Gilead Sciences Inc.,A Phase 2b Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 HCV-Infected Subjects with Renal Insufficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002897-30,0,0,0 2013-002899-41,1,2016-03-31,2016-03-31,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Ipsen Pharma,"A dose escalation, proof of concept, phase IIa study to investigate the safety and tolerability, the pharmacokinetic and the pharmacodynamic of BN82451B, administered twice daily over 4 weeks, in male...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002899-41,0,0,0 2013-002900-15,1,2016-03-31,2016-03-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Salsarulo Pharma,Clinical trial to evaluate the efficacy and safety of oral Transidose in patients suffering from constipation. Klinische Prlifung zur Evaluierung der Wirksamkeit und Unbedenklichkeit von oraler Tra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002900-15,0,0,0 2013-002902-29,6,2016-11-18,2016-11-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A.","A phase II, multicenter, randomized, double-blind, multiple dose, placebo-controlled, parallel-group study to evaluate the efficacy, pharmacokinetics, and safety of BI 655066, an IL-23 p19 antagonist ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002902-29,0,0,0 2013-002902-29,6,2016-11-18,2016-11-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,2,,"A phase II, multicenter, randomized, double-blind, multiple dose, placebo-controlled, parallel-group study to evaluate the efficacy, pharmacokinetics, and safety of BI 655066, an IL-23 p19 antagonist ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002902-29,0,0,0 2013-002902-29,6,2016-11-18,2016-11-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Limited,"A phase II, multicenter, randomized, double-blind, multiple dose, placebo-controlled, parallel-group study to evaluate the efficacy, pharmacokinetics, and safety of BI 655066, an IL-23 p19 antagonist ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002902-29,0,0,0 2013-002902-29,6,2016-11-18,2016-11-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim bv,"A phase II, multicenter, randomized, double-blind, multiple dose, placebo-controlled, parallel-group study to evaluate the efficacy, pharmacokinetics, and safety of BI 655066, an IL-23 p19 antagonist ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002902-29,0,0,0 2013-002902-29,6,2016-11-18,2016-11-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,2,SCS Boehringer Ingelheim Comm.V,"A phase II, multicenter, randomized, double-blind, multiple dose, placebo-controlled, parallel-group study to evaluate the efficacy, pharmacokinetics, and safety of BI 655066, an IL-23 p19 antagonist ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002902-29,0,0,0 2013-002902-29,6,2016-11-18,2016-11-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase II, multicenter, randomized, double-blind, multiple dose, placebo-controlled, parallel-group study to evaluate the efficacy, pharmacokinetics, and safety of BI 655066, an IL-23 p19 antagonist ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002902-29,0,0,0 2013-002916-28,1,2016-04-11,2016-04-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and its Effect on Immune Tolerance in Subjects with Relapsing Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002916-28,0,0,0 2013-002918-12,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,Amvac Kft,"Randomized, prospective, double blind clinical study to evaluate the effectiveness, dosage and safety of lactobacillus vaccine for management of bacterial vaginosis in a non-selected patient populatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002918-12,0,0,0 2013-002922-21,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,FISEVI,"Randomized, phase III, multicentre, open-labelled clinical trial, to evaluate the efficacy of fosfomycin vs meropenem in the treatment of bacteremic urinary tract infection caused by Escherichia coli ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002922-21,0,0,0 2013-002924-17,2,2014-01-27,2014-01-27,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Albireo AB,"A double-blind, randomized, placebo-controlled, study to demonstrate the efficacy and safety of 250 mg or 1 g A3384 administered orally twice daily for two weeks to patients with Bile Acid Malabsorpti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002924-17,0,0,0 2013-002928-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,F.Schreuder,vitamin D and nonspecific musculoskeletal pain in non-Wesren immigrants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002928-16,0,0,0 2013-002931-25,1,2015-02-19,2015-02-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Vanda Pharmaceuticals Inc.,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT, ANTIPRURITIC STUDY OF THE NEUROKININ-1 RECEPTOR ANTAGONIST VLY-686 IN SUBJECTS WITH TREATMENT-RESISTANT PRURITUS ASSOCIATED WITH ATOPI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002931-25,0,0,0 2013-002932-25,2,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,0,ACADEMIC MEDICAL CENTER,Multimodal treatment of perianal fistulas in Crohn's disease: seton vs anti-TNF vs advancement plasty,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002932-25,0,0,0 2013-002932-25,2,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,0,Academic Medical Center,Multimodal treatment of perianal fistulas in Crohn's disease: seton vs anti-TNF vs advancement plasty,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002932-25,0,0,0 2013-002936-26,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Christoffer Hedetoft,Optimizing of glycemic control for surgical patients with diabetes type 2. Optimeret blodsukkerkontrol hos indlagte kirurgiske patienter med type 2 diabetes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002936-26,0,0,0 2013-002938-20,1,2016-07-11,2016-07-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Nottingham,An open label trial of azithromycin in chronic productive cough,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002938-20,0,0,0 2013-002940-94,1,2014-02-20,2014-02-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline,"A randomised, double-blind, placebo-controlled, 3 way, incomplete block cross over study in subjects with allergic rhinitis to assess the effect of once daily single and repeat doses of intranasal Flu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002940-94,0,0,0 2013-002945-12,4,2016-07-01,2016-07-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis recherche et développement,"Six-month, Randomized, Open-label, Parallel-group Comparison of SAR342434 to Humalog® in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Safety Extension Perio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002945-12,0,0,0 2013-002947-27,3,2015-08-05,2015-08-05,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Sylentis S.A.U.,"A phase II, observer masked, active controlled study of SYL040012 for the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension (SYLTAG)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002947-27,0,0,0 2013-002948-91,5,2015-06-09,2015-06-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shionogi Inc.,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002948-91,0,0,0 2013-002949-11,11,2016-01-12,2016-01-12,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shionogi Inc.,"A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluate the Long-term Safety of Naldemedine for the Treatment of Opioid-induced Constipation in Subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002949-11,0,0,0 2013-002949-11,11,2016-01-12,2016-01-12,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shionogi Inc,"A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluate the Long-term Safety of Naldemedine for the Treatment of Opioid-induced Constipation in Subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002949-11,0,0,0 2013-002950-56,8,2016-09-28,2016-09-28,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"Prospective, randomized, placebo-controlled, double-blind, multicenter, parallel-group, 24-week study to assess the efficacy, safety and tolerability of macitentan in subjects with inoperable chronic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002950-56,0,0,0 2013-002951-14,1,2018-01-17,2018-01-17,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,University College London,"Human papillomavirus infection: a randomised controlled trial of Imiquimod cream (5%) versus Podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002951-14,0,0,0 2013-002952-34,5,2019-01-18,2019-03-25,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ATLANTIC PHARMACEUTICALS LTD,"A Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Topical Alicaforsen Enema in Subjects with Active, Chronic, Antibiotic Refractory Primary Idiopathic Pouchitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002952-34,0,0,0 2013-002952-34,5,2019-01-18,2019-03-25,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Atlantic Healthcare Europe B.V,"A Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Topical Alicaforsen Enema in Subjects with Active, Chronic, Antibiotic Refractory Primary Idiopathic Pouchitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002952-34,0,0,0 2013-002952-34,5,2019-01-18,2019-03-25,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Atlantic Pharmaceuticals Limited,"A Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Topical Alicaforsen Enema in Subjects with Active, Chronic, Antibiotic Refractory Primary Idiopathic Pouchitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002952-34,0,0,0 2013-002955-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AFAR,Effects of Vildaglipin and Glimepiride on Glycemic Variability and on Cardiovascular parameters in patients with type 2 diabetes in failure with basal insulin EFFETTI DEL VILDAGLIPTIN E DELLA GLIME...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002955-13,0,0,0 2013-002964-22,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Ghent University Hospital,"Influence of aromatase inhibitors on insulin sensitivity, liver and hart function in obese men INVLOED VAN AROMATASE INHIBITOREN OP INSULINEGEVOELIGHEID EN LEVERFUNCTIE BIJ OBESE MANNEN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002964-22,0,0,0 2013-002966-38,1,2014-04-11,2014-04-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A PHASE II, PARTIAL-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 5-WAY CROSS-OVER CLINICAL PHARMACOLOGY STUDY TO EVALUATE THE PHARMACODYNAMICS OF BDP/B17MP AND FORMOTEROL ACROSS TWO DIFFERENT DOSE LEVELS OF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002966-38,0,0,0 2013-002970-32,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,"KRKA, tovarna zdravil, d. d., Novo mesto",A COMPARISON OF THERAPEUTIC EQUIVALENCE BETWEEN THE TEST AND THE REFERENCE FORMULATION OF FIXED COMBINATION OF CETYLPYRIDINIUM CHLORIDE 1.0 mg/BENZYDAMINE HYDROCHLORIDE 3 mg IN SUBJECTS WITH SORE THRO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002970-32,0,0,0 2013-002973-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione GISCAD,A Phase II randomized trial comparing a combination of Abraxane and Gemcitabine versus Gemcitabine alone as first line treatment in locally advanced unresectable pancreatic cancer. Studio clinico d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002973-23,0,0,0 2013-002977-23,2,2016-10-11,2016-12-24,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Montavit Ges.m.b.H.,"Double-blind, randomised, placebo-controlled study evaluating the efficacy and Safety of Tavipec® capsules in acute Rhinosinusitis A prospective, multi-centre, parallel group, interventional clinical ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002977-23,0,0,0 2013-002979-17,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,IVI Sevilla,Comparative study between the usage of corifollitropin alfa and daily recombinant FSH in the ovarian stimulation of low responders Estudio comparativo entre el uso de corifolitropina alfa y FSH rec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002979-17,0,0,0 2013-002980-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS San Raffaele di Roma,Comparative study to evaluate the effect on platelet aggregation of two different doses (20 and 40 mg) of acetylsalicylic acid administered sublingually compared to the dose of 100 mg of acetylsalicyl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002980-24,0,0,0 2013-002982-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Merja Kokki,Dexketoprofeenin käyttö selkäleikkauspotilailla: teho ja turvallisuus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002982-20,0,0,0 2013-002984-24,1,2015-01-19,2015-01-19,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Phenex Pharmaceuticals AG,A Safety Pilot Study of Px-104 in non alcoholic fatty liver disease (NAFLD) patients Pilotstudie zur Untersuchung der Sicherheit von Px-104 in Patienten mit nichtalkoholischer Fettlebererkrankung,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002984-24,0,0,0 2013-002986-21,2,2016-04-05,2016-04-05,1,0,0,0,0,1,3,0,0,1,0,0,1,0,1,"Mast Therapeutics, Inc.","Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial of MST-188 (purified pol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002986-21,0,0,0 2013-002987-17,7,2017-08-17,2017-08-17,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Alnylam Pharmaceuticals, Inc","APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ALN-TTR02 in Transthyretin (TTR)-Mediated Polyneuropathy (Famili...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002987-17,0,0,0 2013-002988-25,1,2016-05-20,2016-05-20,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Advicenne Pharma,"A multicentre, open-label, non-inferiority sequential study, evaluating the efficacy, safety, tolerability and acceptability of ADV7103 compared to standard of care in distal renal tubular acidosis pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002988-25,0,0,0 2013-002991-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Foundation for Liver Research,Effect of ASV and DCV therapy on the quality of immune status in chronic HCV patients Investigator initiated research proposal nr. AI447-108,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002991-42,0,0,0 2013-002996-16,1,2018-06-30,2018-06-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Inserm-ANRS,ANRS SHS155 STIMAGO: Pilote study to evaluate the benefits and the risks of methylphenidate for the treatment of cocain dependence. ANRS SHS155 STIMAGO : Etude pilote pour l’évaluation des bénéfic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002996-16,0,0,0 2013-002997-33,7,2016-12-15,2016-12-15,6,1,0,0,0,0,3,0,0,1,1,1,1,0,1,OPHTHOTECH CORPORATION,"A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (anti PDGF-b pegylated aptamer) administered in combination with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002997-33,0,0,0 2013-003000-39,6,2015-03-14,2015-06-08,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Evaluation of the pharmacodynamics, pharmacokinetics and safety of repeated escalating oral doses of S 38844 versus placebo in patients with chronic heart failure and left ventricular systolic dysfunc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003000-39,0,0,0 2013-003001-26,1,2016-02-24,2016-02-24,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,University of Bristol,"Choice Of Moisturiser in Eczema Treatment (COMET): A feasibility study of pragmatic, single blind, randomised clinical trial to compare the clinical and cost effectiveness of leave-on emollients in tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003001-26,0,0,0 2013-003002-91,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,Menarini International Operation Luxembourg SA,"Pilot study on efficacy and safety of bilastine in preventing angioedema attacks in patients with recurrent angioedema of unkown etiology (idiopatic angioedema, rIAE) Studio pilota sull'efficacia ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003002-91,0,0,0 2013-003009-24,1,2013-10-13,2013-10-13,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,PIERRE FABRE MEDICAMENT,PHASE I-II STUDY OF F17752 IN PATIENTS WITH ADVANCED SOLID TUMOURS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003009-24,0,0,0 2013-003013-18,1,2015-05-20,2015-05-20,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Biogen Idec Research Ltd,"A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of 2 Vial Strengths of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in Previously Treated Subjects With Seve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003013-18,0,0,0 2013-003016-45,1,2015-02-02,2015-02-02,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Araim Pharmaceuticals,"A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of patients with sarcoidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003016-45,0,0,0 2013-003017-18,4,2016-12-15,2017-01-19,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,OPHTHOTECH CORPORATION,"A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of FovistaTM (anti PDGF-b pegylated aptamer) administered in combination wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003017-18,0,0,0 2013-003018-42,13,2017-08-14,2017-10-11,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,OPHTHOTECH CORPORATION,"A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista? (Anti PDGFB pegylated aptamer) administered in combination with e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003018-42,0,0,0 2013-003022-92,10,2019-01-11,2019-01-11,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Astellas Pharma Global Development, Inc.","A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003022-92,0,0,0 2013-003023-10,1,2014-06-01,2014-06-01,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,"Department of Surgery, Herlev Hospital","MELATOX: Pharmacodynamic evaluation of topical use of melatonin as sun protection: a randomized, double blinded, placebo controlled crossover study on healthy volunteers. MELATOX: Evaluering af mel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003023-10,0,0,0 2013-003032-77,10,2020-02-07,2020-02-07,9,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Abbvie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Ulcerative Colitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003032-77,0,0,0 2013-003032-77,10,2020-02-07,2020-02-07,9,1,1,0,0,0,3,0,0,1,1,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Ulcerative Colitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003032-77,0,0,0 2013-003038-34,2,2017-02-16,2017-02-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Sumitomo Dainippon Pharma Co., Ltd.","A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of SM-13496 for the Treatment of Bipolar I Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003038-34,0,0,0 2013-003039-31,2,2018-02-17,2018-02-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Sumitomo Dainippon Pharma Co., Ltd.",A Long-Term Study of SM-13496 in Patients with Bipolar I Disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003039-31,0,0,0 2013-003042-16,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"Dance Biopharm, Inc.",Samba-02: An Investigation of the Dose-Response and Subject Variability of Inhaled Insulin in Subjects with Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003042-16,0,0,0 2013-003043-36,6,2015-03-08,2015-03-30,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CHIESI FARMACEUTICI S.p.A,"A multicentre, randomised, double-blind, active-controlled, 3-way cross-over study to evaluate the efficacy and safety of a free combination of 3 doses of CHF 5259 (glycopyrrolate) plus Foster® 100/6µ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003043-36,0,0,0 2013-003045-42,1,2015-06-12,2015-06-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CytoVac A/S,"An Open-labelled, Randomized Phase II Multicentre Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients with Glioblastoma Multiforme M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003045-42,0,0,0 2013-003046-17,7,2017-04-12,2017-04-12,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,A re-treatment safety study of radium-223 dichloride in subjects with castration-resistant prostate cancer with bone metastases who received an initial course of six doses of radium-223 dichloride 50 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003046-17,0,0,0 2013-003046-17,7,2017-04-12,2017-04-12,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,A re-treatment safety study of radium-223 dichloride in subjects with castration-resistant prostate cancer with bone metastases who received an initial course of six doses of radium-223 dichloride 50 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003046-17,0,0,0 2013-003047-29,2,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,0,Greater Glasgow and Clyde Health Board,BALLAD - A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma. BALLAD- undersøgelse af adjuverende kemoterapi efter operation for adenocarcinom i tolvf...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003047-29,0,0,0 2013-003047-29,2,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,0,University of Glasgow,BALLAD - A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma. BALLAD- undersøgelse af adjuverende kemoterapi efter operation for adenocarcinom i tolvf...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003047-29,0,0,0 2013-003048-21,1,2017-05-31,2017-05-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Cologne,CONTROLING INTESTINAL COLONIZATION OF HIGH-RISK PATIENTS WITH EXTENDED- SPECTRUM BETALACTAMASE PRODUCING ENTEROBACTERIACEAE (ESBL-E) – A RANDOMIZED TRIAL (CLEAR) Kontrolle der intestinalen Kolonisi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003048-21,0,0,0 2013-003049-41,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,National Institute of Child Health,"A Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003049-41,0,0,0 2013-003050-25,9,2017-02-23,2017-02-27,6,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003050-25,0,0,0 2013-003051-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Kuopion yliopistollinen sairaala,Dexketoprofeenin käyttö polven tekonivelleikkauspotilailla: teho ja turvallisuus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003051-37,0,0,0 2013-003056-21,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GWT-TUD GmbH,Evaluation of an additional therapeutic approach to diabetic macular edema by combining standard therapy (intravitreal injection of a VEGF‐inhibitor) with micropulse diode laser treatment in a randomi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003056-21,0,0,0 2013-003058-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Grenoble,PREMATURE EVALUATION OF THE ANSWER BY TEP HAS THE CHOLINE IN THE METASTATIC PROSTATE CANCER EVALUATION PRECOCE DE LA REPONSE PAR TEP A LA CHOLINE DANS LE CANCER DE LA PROSTATE METASTATIQUE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003058-25,0,0,0 2013-003060-31,6,2014-08-13,2014-08-13,4,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Nutrition Science Partners Limited,"A Phase III Double Blind, Multi-Center Placebo Controlled Maintenance Trial of HMPL-004 in Subjects with Mild to Moderate Ulcerative Colitis with Clinical Remission or Response from Induction Therapy....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003060-31,0,0,0 2013-003062-13,2,2017-04-19,2017-04-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase II, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ investigational vaccine GSK2838504A, when a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003062-13,0,0,0 2013-003067-59,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA G. BROTZU,"A single-center, randomized, double-blind, placebo-controlled, cross-over study of intranasal oxytocin in young adults with Autism Spectrum Disorder Studio monocentrico, cross-over, randomizzato, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003067-59,0,0,0 2013-003068-30,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,LUMC,CONgenital Cytomegalovirus: Efficacy of antiviral treatment in a non-Randomized Trial with historical control group CONgenitaal Cytomegalovirus: Effectiviteit van antivirale behandeling in een niet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003068-30,0,0,0 2013-003073-10,9,2016-04-07,2016-04-07,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development,"A Phase III, 24 week, randomized, double blind, double dummy, parallel group study (with an extension to 52 weeks in a subset of subjects) comparing the efficacy, safety and tolerability of the fixed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003073-10,0,0,0 2013-003075-35,13,2017-07-06,2017-07-17,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003075-35,0,0,0 2013-003075-35,13,2017-07-06,2017-07-17,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination FF/UMEC/VI with the fixed dose dual com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003075-35,0,0,0 2013-003076-12,2,2018-10-31,2018-10-31,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,BioMarin Pharmaceutical Inc.,"A Phase 2, 2-Stage. 2-Cohort Study of BMN 673 Administered to Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer Estudio de fase 2, de 2 etapas y 2 cohortes, en e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003076-12,0,0,0 2013-003076-12,2,2018-10-31,2018-10-31,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Medivation, Inc.","A Phase 2, 2-Stage. 2-Cohort Study of BMN 673 Administered to Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer Estudio de fase 2, de 2 etapas y 2 cohortes, en e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003076-12,0,0,0 2013-003078-28,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,RIVM,Immunological effect of early extra MMR immunization in infants between 6 and 12 months of age in an outbreak setting Immunologisch effect van een vroege extra BMR vaccinatie in zuigelingen tussen ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003078-28,0,0,0 2013-003080-59,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Azienda Ospedaliero-Universitaria Pisana,"PHASE III ITALIAN MULTICENTER STUDY COMPARING THE COMBINATION OF 5-FLUOROURACIL/FOLINIC ACID, OXALIPLATIN AND IRINOTECAN (FOLFOXIRI) VERSUS GEMCITABINE AS ADJUVANT TREATMENT FOR RESECTED PANCREATIC CA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003080-59,0,0,0 2013-003083-31,1,2014-12-12,2014-12-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,OmniVision GmbH,"Open, Observer-blind, two Parallel Group, Randomized, Multicentric Clinical Phase III Trial on the Comparison of Efficacy and Tolerability of a New Preservative-free Formulation of Brimonidine 2 mg/ml...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003083-31,0,0,0 2013-003084-61,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003084-61,0,0,0 2013-003084-61,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma,"A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003084-61,0,0,0 2013-003084-61,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003084-61,0,0,0 2013-003084-61,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Service AG,"A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003084-61,0,0,0 2013-003084-61,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003084-61,0,0,0 2013-003086-34,8,2017-05-31,2017-05-31,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003086-34,0,0,0 2013-003086-34,8,2017-05-31,2017-05-31,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.p.A.,"A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003086-34,0,0,0 2013-003086-34,8,2017-05-31,2017-05-31,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A 52-week, multicenter, randomized, double-blind, placebo-controlled study of subcutaneous secukinumab to demonstrate efficacy as assessed by palmoplantar pustulosis Psoriasis Area and Severity Index ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003086-34,0,0,0 2013-003088-76,1,2021-06-26,2021-06-26,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Clinical Evaluation Research Unit (CERU),SodiUm SeleniTe Adminstration IN Cardiac Surgery surgery (SUSTAIN CSX®-trial) - A randomized controlled trial of high dose sodium-selenite administration in high risk cardiac surgical patients Natr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003088-76,0,0,0 2013-003090-98,1,2020-07-22,2020-07-22,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,RIVM,Maternal pertussis (Tdap) vaccination and its effects on the immune response of the newborn up to 12 months of age. Maternale Kinkhoest vaccinatie en de effecten hiervan op de immuunrespons van bab...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003090-98,0,0,0 2013-003093-27,8,2018-01-29,2018-01-29,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination with Either Bendamustine and Rituximab (BR) or Rituximab,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003093-27,1,0,0 2013-003094-10,3,2014-08-16,2015-02-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Spectrum Pharmaceuticals, Inc.","Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim use for the Management of Neutropenia in Patients with Breast Cancer who are Candidates for Adjuvant and Neoadjuvant Chemotherapy w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003094-10,0,0,0 2013-003094-10,3,2014-08-16,2015-02-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Spectrum Pharmaceuticals,"Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim use for the Management of Neutropenia in Patients with Breast Cancer who are Candidates for Adjuvant and Neoadjuvant Chemotherapy w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003094-10,0,0,0 2013-003095-12,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Allergopharma GmbH & Co. KG,Double-blind phase IV multicentre clinical trial to evaluate and compare specific and non specific effects of SCIT by use of an Environmental Challenge Chamber after treatment with Allergovit® grasses...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003095-12,0,0,0 2013-003096-35,1,2016-02-15,2016-02-15,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Nuvo Research GmbH,"A multi-centre, randomised, placebo-controlled, double-blind, parallel-group study on the efficacy and safety of WF10 and its main constituents in patients with refractory allergic rhinitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003096-35,0,0,0 2013-003098-88,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar),"An open, controlled, double-blind, with placebo clinical trial and randomized in subgroups of pediatric patients with allergic and non-allergic asthma, with deficiency, insufficiency or normal levels ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003098-88,0,0,0 2013-003098-88,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,"Kern Pharma, S.L.","An open, controlled, double-blind, with placebo clinical trial and randomized in subgroups of pediatric patients with allergic and non-allergic asthma, with deficiency, insufficiency or normal levels ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003098-88,0,0,0 2013-003100-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dutch Growth Research Foundation,"Standardized versus individualized growth hormone treatment of short children born small for gestational age: Effects on short-term and longterm efficacy, long-term psychosocial development, glucose m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003100-39,0,0,0 2013-003104-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Fakultní nemocnice Ostrava,Czech republic",Randomised Clinical Study of Safety of Efficacy of Extracelular Matrix and Autologous Platelet Rich Plasma Concentrate for Wound Healing (Leg Ulcers Biodesign Wound Healing – LEGEND(A) Study) Inves...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003104-39,0,0,0 2013-003105-25,2,2017-04-24,2017-04-24,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Sahlgrenska University Hospital / The Queen Silvia Children´s Hospital,The prophylactic effect of levosimendan in reducing acute kidney injury postoperatively in pediatric patients undergoing corrective heart surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003105-25,1,0,0 2013-003107-19,1,2019-01-07,2019-01-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Birmingham,Phase II clinical trial investigating the use of epigallocatechin-3-gallate (Veregen) in the treatment of vulval intraepithelial neoplasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003107-19,0,0,0 2013-003107-19,1,2019-01-07,2019-01-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Sandwell and West Birmingham Hospitals NHS Trust,Phase II clinical trial investigating the use of epigallocatechin-3-gallate (Veregen) in the treatment of vulval intraepithelial neoplasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003107-19,0,0,0 2013-003111-22,2,2015-12-22,2015-12-22,2,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals S.A.,"A Phase II, Randomized, Comparative, Observer-Blind, Multi-Center Study Evaluating the Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003111-22,0,0,0 2013-003113-17,3,2018-06-29,2018-06-29,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc.","An Open-Label, Phase 2 Study to Evaluate the Oral Combination of MLN9708 With Cyclophosphamide and Dexamethasone In Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003113-17,0,0,0 2013-003117-18,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,University Hospital Ulm,Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) AMLSG 21-13,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003117-18,0,0,0 2013-003117-18,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Universitätsklinikum Ulm,Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) AMLSG 21-13,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003117-18,0,0,0 2013-003118-42,7,2018-08-09,2018-08-09,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,"A three arm randomized, open-label Phase II study of radium-223 dichloride 50 kBq/kg (55 kBq/kg after implementation of NIST update) versus 80 kBq/kg (88 kBq/kg after implementation of NIST update), a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003118-42,0,0,0 2013-003118-42,7,2018-08-09,2018-08-09,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A three arm randomized, open-label Phase II study of radium-223 dichloride 50 kBq/kg (55 kBq/kg after implementation of NIST update) versus 80 kBq/kg (88 kBq/kg after implementation of NIST update), a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003118-42,0,0,0 2013-003125-28,3,2020-04-29,2020-04-29,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,St. Antonius Hospital,Antiplatelet therapy for patients undergoing transcatheter aortic valve implantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003125-28,1,0,0 2013-003126-83,5,2014-08-26,2014-08-28,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Merck KGaA,"A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-?-1a 30 µg IM Weekly i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003126-83,1,0,0 2013-003127-11,19,2016-04-04,2016-04-29,19,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A prospective, multicenter, 12-week, randomized open-label study to evaluate the efficacy and safety of glycopyrronium (50 micrograms o.d.) or indacaterol maleate and glycopyrronium bromide fixed-dose...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003127-11,0,0,0 2013-003127-11,19,2016-04-04,2016-04-29,19,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A prospective, multicenter, 12-week, randomized open-label study to evaluate the efficacy and safety of glycopyrronium (50 micrograms o.d.) or indacaterol maleate and glycopyrronium bromide fixed-dose...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003127-11,0,0,0 2013-003127-11,19,2016-04-04,2016-04-29,19,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Farma S.p.A.,"A prospective, multicenter, 12-week, randomized open-label study to evaluate the efficacy and safety of glycopyrronium (50 micrograms o.d.) or indacaterol maleate and glycopyrronium bromide fixed-dose...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003127-11,0,0,0 2013-003128-35,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Grupo Español de Tumores Huérfanos e Infrecuentes (GETHI),Open label phase II clinical trial of Orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors. The Greko II study. Ensayo clínico fase II abierto de Orteronel (TA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003128-35,0,0,0 2013-003129-27,3,2016-07-07,2016-07-07,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Novartis Farmacéutica, S.A.",Phase Ib/II multicenter study of buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma multiforme (GBM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003129-27,0,0,0 2013-003129-27,3,2016-07-07,2016-07-07,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,Phase Ib/II multicenter study of buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma multiforme (GBM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003129-27,0,0,0 2013-003131-30,13,2015-05-29,2015-06-17,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/ lixisenatide fixed ratio combination to i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003131-30,0,0,0 2013-003132-79,9,2015-07-07,2015-07-09,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A randomized, 30-week, active-controlled, open label, 2-treatment arm, parallel-group, multicenter study comparing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003132-79,0,0,0 2013-003133-14,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Luzitin, S.A.","An open-label study to investigate the tolerability, pharmacokinetics and anti-tumor effect following photodynamic therapy (PDT) with single-ascending doses of LUZ11 in patients with advanced head and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003133-14,0,0,0 2013-003134-33,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Regeneron Pharmaceuticals, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF 3-MONTH SUBCUTANEOUS REGN1033 TREATMENT IN PATIENTS WITH SARCOPENIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003134-33,0,0,0 2013-003144-23,1,2016-05-18,2016-05-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,Pregnancy And chronic hypertension: NifeDipine or labetalol as Antihypertensive treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003144-23,0,0,0 2013-003144-23,1,2016-05-18,2016-05-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's and St Thomas' NHS Foundation Trust,Pregnancy And chronic hypertension: NifeDipine or labetalol as Antihypertensive treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003144-23,0,0,0 2013-003145-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FRANCISCO JAVIER BENITO FERNANDEZ,"PILOT RANDOMISED CONTROLLED TRIAL USIDNG DEXAMETHASONE VESUS PREDNISOLONA/PREDNISONA IN CHILDREN WITH ACUTE ASTHMA IN PEDIATRIC EMERGENCY WARD ENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO DEL US...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003145-42,0,0,0 2013-003147-27,4,2015-08-11,2015-08-11,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY 10017 US","A PHASE 2, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF A CHEMOKINE CCR2/5 RECEPTOR ANTAGONIST (PF-04634817) WITH THAT OF RAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003147-27,0,0,0 2013-003148-21,14,2016-02-04,2016-02-04,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Daiichi Sankyo Development Ltd,"A prospective, randomised, open-label, blinded endpoint evaluation (PROBE) parallel group study comparing edoxaban (DU-176b) with enoxaparin/warfarin followed by warfarin alone in subjects undergoing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003148-21,0,0,0 2013-003150-25,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,IRCCS ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI,Phase II Trial of Temozolomide in Patients affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer with MGMT methylation. GOPAV03,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003150-25,0,0,0 2013-003155-38,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase III, double-blind, randomised, controlled, multi-country, multi-centre study to evaluate the immunogenicity and safety of GSK Biologicals’ quadrivalent influenza vaccine candidate, GSK2282512A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003155-38,0,1,1 2013-003156-21,9,2020-02-29,2020-02-29,8,1,0,0,0,0,3,0,0,1,0,0,1,0,0,ETOP (European Thoracic Oncology Platform),"A randomised, open-label phase III trial evaluating the addition of denosumab to standard first-line anticancer treatment in advanced NSCLC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003156-21,0,0,0 2013-003156-21,9,2020-02-29,2020-02-29,8,1,0,0,0,0,3,0,0,1,0,0,1,0,0,ETOP (European Thoracic Oncology Platform) c/o IBCSG Coordinating Center,"A randomised, open-label phase III trial evaluating the addition of denosumab to standard first-line anticancer treatment in advanced NSCLC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003156-21,0,0,0 2013-003157-16,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Ordination Dr. Hommer,"An open, non-randomized study on the effect of preservative free tafluprost (Saflutan® Augentropfen) in patients with ocular hypertension or with primary open angle glaucoma with an uncontrolled intra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003157-16,0,0,0 2013-003165-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS-IRST of Meldola,"Peptide Receptor Radionuclide Therapy (PRRT) with Radiolabelled Somatostatin Analogue 177Lu-DOTATATE in advanced gastro-entero-pancreatic Neuroendocrine Tumors, FDG-PET negative patients: a prospecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003165-34,0,0,0 2013-003166-14,4,2015-04-08,2015-04-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Gedeon Richter Plc.,"Multiple, fixed-dose, comparative efficacy and safety evaluation of RGB-02 and Neulasta® in patients undergoing chemotherapy treatment known to induce neutropenia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003166-14,0,0,0 2013-003167-58,8,2019-01-08,2019-01-08,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003167-58,0,0,0 2013-003168-29,1,2016-04-01,2016-04-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Radboud University Nijmegen Medical Center,"A randomized, double-blind, placebo-controlled clinical trial assessing the efficacy of combining pasireotide with aspiration sclerotherapy to improve volume reduction of dominant hepatic cysts",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003168-29,0,0,0 2013-003169-33,1,2015-05-31,2015-05-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Anders Troelsen,Evaluation of intra articular Tranexamic acid for reduction of total blood loss in total knee unilateral arthroplasty Evaluering af intraartikulær Tranexamsyre til reduktion af total blødning ved ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003169-33,0,0,0 2013-003170-27,5,2020-12-29,2021-01-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,0,GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama),Phase III study of Palbociclib (PD-0332991) in combination with Endocrine therapy (exemestano or fulvestrant) versus chemotherapy (capecitabine) in Hormonal Receptor (HR) positive/HER2 negative Metast...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003170-27,0,0,0 2013-003171-35,1,2014-10-28,2014-10-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Profil Institut für Stoffwechselforschung GmbH,"A bicentric open-label, randomized, two-parallel-group study investigating the impact of combined Lantus®(insulin glargine) and Lyxumia ®(lixisenatide) on insulin secretion and gastric emptying in sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003171-35,0,0,0 2013-003174-27,1,,,0,1,0,0,0,1,3,0,0,0,0,0,0,0,0,CHU de Nantes,A PHASE III STUDY OF VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) VERSUS VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003174-27,0,0,0 2013-003176-12,1,2018-01-16,2018-01-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,IPSEN S.p.A,"A PHASE II, MULTICENTRE, RANDOMIZED CONTROLLED STUDY EVALUATING THE QUALITY OF LIFE IN PATIENTS WITH INOPERABLE MALIGNANT BOWEL OBSTRUCTION TREATED WITH LANREOTIDE AUTOGEL 120 MG IN COMBINATION WITH S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003176-12,0,0,0 2013-003177-99,8,2020-07-06,2020-12-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003177-99,0,0,0 2013-003177-99,8,2020-07-06,2020-12-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, 10017",PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003177-99,0,0,0 2013-003177-99,8,2020-07-06,2020-12-31,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, 10017",PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003177-99,0,0,0 2013-003183-31,8,2016-02-08,2016-02-08,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ITALFARMACO S.p.A.,"A Randomized, Multicenter, Phase II study to Investigate Efficacy and Safety of ITF2984 in Acromegalic patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003183-31,0,0,0 2013-003184-62,1,2018-10-24,2018-10-24,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,A phase I study of SGI-110 combined with irinotecan followed by a randomized phase II study of SGI-110 combined with irinotecan versus regorafenib in previously treated metastatic colorectal cancer pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003184-62,0,0,0 2013-003187-31,1,2017-11-28,2017-11-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,NHS Greater Glasgow & Clyde,Misoprostol for the Healing of Small Bowel Ulceration in Patients with Obscure Blood Loss while Taking Low-Dose Aspirin or Non-Steroidal Anti-inflammatory Drugs [MASTERS Trial],https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003187-31,0,0,0 2013-003190-99,1,2016-08-08,2016-08-08,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,CHU de Grenoble,"Evaluation of the use of an oral direct anti-Xa anticoagulant, Apixaban in prevention of venous thromboembolic disease in patients treated with IMiDs during myeloma: a pilot study Evaluation de l’...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003190-99,0,0,0 2013-003191-12,2,2022-04-25,2022-04-25,1,0,0,0,0,1,3,0,0,1,0,0,0,0,0,Technische Universität Dresden,Randomized comparison between two dose levels of daunorubicin and between one versus two cycles of in-duction therapy for adult patients with acute myeloid leukemia ≤65 years Randomisierter Vergle...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003191-12,0,0,0 2013-003194-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Consorzio Oncotech,A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Eribulin in Combination With Bevacizumab for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Bre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003194-10,0,0,0 2013-003195-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Bordeaux,"A multicenter, two arms, randomized, open label clinical Phase IV study investigating the proportion of CMV seropositive kidney transplant recipients who will develop a CMV infection within the first ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003195-12,0,0,0 2013-003196-35,1,2016-09-27,2016-09-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London,Assessing the subjective intensity of oral psilocybin in patients with treatment-resistant depression: A Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003196-35,0,0,0 2013-003197-27,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Nantes,Phase 2 multicentric open-label study of switch from abacavir/lamivudine fixed dose combination plus nevirapine to abacavir/lamivudine/dolutegravir in virologically suppressed HIV-1 infected adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003197-27,0,0,0 2013-003199-11,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GETAID,Changing the coUrse of cRohn's disease with an Early use of adalimumab: The CURE study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003199-11,0,0,0 2013-003199-11,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GETAID - Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives,Changing the coUrse of cRohn's disease with an Early use of adalimumab: The CURE study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003199-11,0,0,0 2013-003200-39,1,2017-10-19,2017-10-19,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,University College London,"A phase II, single centre, randomised, placebo-controlled, 3-part trial to assess the safety, tolerability and efficacy of Zibotentan in patients with renal disease secondary to scleroderma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003200-39,0,0,0 2013-003201-26,21,2017-05-31,2017-06-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003201-26,0,0,0 2013-003201-26,21,2017-05-31,2017-06-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003201-26,0,0,0 2013-003201-26,21,2017-05-31,2017-06-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Denmark A/S,"A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003201-26,0,0,0 2013-003201-26,21,2017-05-31,2017-06-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003201-26,0,0,0 2013-003201-26,21,2017-05-31,2017-06-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda","A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003201-26,0,0,0 2013-003201-26,21,2017-05-31,2017-06-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003201-26,0,0,0 2013-003201-26,21,2017-05-31,2017-06-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003201-26,0,0,0 2013-003201-26,21,2017-05-31,2017-06-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas,"A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003201-26,0,0,0 2013-003201-26,21,2017-05-31,2017-06-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003201-26,0,0,0 2013-003201-26,21,2017-05-31,2017-06-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003201-26,0,0,0 2013-003201-26,21,2017-05-31,2017-06-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003201-26,0,0,0 2013-003201-26,21,2017-05-31,2017-06-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Italia S.p.A.,"A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003201-26,0,0,0 2013-003201-26,21,2017-05-31,2017-06-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co. KG,"A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003201-26,0,0,0 2013-003201-26,21,2017-05-31,2017-06-05,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tripl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003201-26,0,0,0 2013-003204-40,1,2019-06-04,2019-06-04,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Edinburgh,Paracetamol treatment in hypertension: effect on blood pressure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003204-40,0,0,0 2013-003204-40,1,2019-06-04,2019-06-04,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Lothian,Paracetamol treatment in hypertension: effect on blood pressure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003204-40,0,0,0 2013-003205-25,7,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003205-25,0,1,0 2013-003205-25,7,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,NOVARTIS FARMA S.P.A.,"A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003205-25,0,1,0 2013-003205-25,7,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003205-25,0,1,0 2013-003205-25,7,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003205-25,0,1,0 2013-003205-25,7,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003205-25,0,1,0 2013-003205-25,7,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003205-25,0,1,0 2013-003205-25,7,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Services Pharma AG,"A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003205-25,0,1,0 2013-003207-19,2,,,0,1,0,0,0,2,0,0,0,1,0,0,0,1,0,Radboud University Nijmegen Medical Center,"An international, multicenter, randomized controlled clinical trial assessing the efficacy of Ursodeoxycholic acid as a volume reducing treatment for symptomatic polycystic livers ?Estudio multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003207-19,0,0,0 2013-003211-22,1,2022-07-11,2022-07-11,1,0,0,0,0,1,3,0,0,1,0,0,0,0,0,University of Cologne,"A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A CLL Patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003211-22,0,0,0 2013-003214-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Parc Taulí,"Single center randomized clinical study to compare the efficacy of diuretics in patients in hemodialysis with residual renal function Estudio unicéntrico, aleatorizado para comparar la eficacia de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003214-41,0,0,0 2013-003215-21,3,2015-10-19,2015-10-19,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,GUERBET,"DOTAREM® Pharmacokinetics, Safety and Efficacy Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive) DOTAREM® Studie zur Pharmakokinetik, Sicherhei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003215-21,0,0,0 2013-003219-22,1,2017-07-07,2017-07-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hertfordshire Partnership University NHS Foundation Trust,A randomised controlled feasibility trial comparing clinical and cost effectiveness of cognitive behavioural therapy (CBT) and selective serotonin reuptake inhibitors (SSRI) and their combination in t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003219-22,0,0,0 2013-003219-22,1,2017-07-07,2017-07-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Hertfordshire,A randomised controlled feasibility trial comparing clinical and cost effectiveness of cognitive behavioural therapy (CBT) and selective serotonin reuptake inhibitors (SSRI) and their combination in t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003219-22,0,0,0 2013-003220-36,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Albert Schweitzer hospital,Remifentanil use for procedural sedation and analgesia in the emergency department Remifentanil voor procedurele sedatie en analgesie op de spoedeisende hulp,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003220-36,0,0,0 2013-003227-11,1,2015-04-16,2015-04-16,1,1,1,0,0,0,1,0,0,1,0,0,1,0,1,Durata Therapeutics International B.V.,"PHASE 1, OPEN LABEL, SINGLE DOSE STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF DALBAVANCIN IN HOSPITALIZED CHILDREN AGED 3 MONTHS TO 11 YEARS RECEIVING STANDARD INTRAVENOUS ANT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003227-11,0,0,0 2013-003228-35,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,0,Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR),Study of the preliminary efficacy and safety of topical cysteamine formulated in viscous solution in cystinosis patients Estudio de la eficacia preliminar y seguridad de la cisteamina tópica formul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003228-35,0,0,0 2013-003230-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medizinische Universität Graz,The use of 5-aminolevulinic acid (gliolan) mediated protoporphyrin IX fluorescence to label neighbouring infiltration zones in meningiomas 5-Aminolävulinsäure (gliolan) vermittelte Protoporphyrin ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003230-32,0,0,0 2013-003233-15,1,2014-10-22,2014-10-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A multicenter, randomized, double-blind, placebo-controlled pilot study of quilizumab in patients with refractory chronic spontaneous urticaria (CSU).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003233-15,0,0,0 2013-003234-32,1,2018-12-31,2018-12-31,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,Universitätsklinikum Münster,Pathological changes in the myocardial microvasculature - a MR-based quantification Pathologische Veränderungen der myokardialen Mikrovaskulatur – eine MR-basierte Quantifizierung,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003234-32,0,0,0 2013-003235-30,3,2017-05-24,2017-09-24,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Lilly S.A.,"Phase 2/3 Study of Monotherapy LY2157299 Monohydrate in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003235-30,0,0,0 2013-003235-30,3,2017-05-24,2017-09-24,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Phase 2/3 Study of Monotherapy LY2157299 Monohydrate in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003235-30,0,0,0 2013-003239-31,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,HOV GmbH,"A randomised, placebo-controlled, single-centre, double-blind study to evaluate the efficacy, safety and tolerability of topically applied piroxicam gel in patients with recurrent herpes labialis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003239-31,0,0,0 2013-003240-23,1,2015-09-01,2015-09-01,1,0,0,0,0,1,4,0,0,1,1,1,1,0,0,St. James' Hospital,PERSONALising Factor VIII prophylaxis regimens: Efficacy of standard versus pharmacokinetically based regimens in adult patients with severe Haemophilia A (PERSONAL trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003240-23,0,0,0 2013-003241-42,2,2015-11-17,2020-09-09,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biofrontera Bioscience GmbH,"A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) in comparison to Metvix® in the treatment of non-aggressive basal cell carcinoma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003241-42,0,0,0 2013-003243-36,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Unidad de VIH - Servicio de Enfermedades Infecciosas. Hospital de Bellvitge,Dolutegravir HIV-1 viral decay and pharmacokinetics in semen in ARV-naïve patients initiating Abacavir/Lamivudine plus Dolutegravir. Cinética del descenso de la carga viral del VIH-1 y concentrac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003243-36,0,0,0 2013-003244-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,S.I.C.O.G. ONLUS,B-FOLFIRI followed by B-FOLFOX/B-XELOX or the reverse sequence versus standard B-FOLFIRI for the first-line treatment of metastatic colorectal cancer: a randomized SICOG study. SEveSTA study (Sequen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003244-23,0,0,0 2013-003250-25,9,2020-06-25,2020-10-13,7,1,0,0,0,1,4,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",A Phase 4 Safety and Efficacy Study of Bosutinib (Bosulif®) in Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with One or More Tyrosine Kinase Inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003250-25,0,0,0 2013-003252-20,2,2017-08-04,2017-08-04,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Biotest AG,"An open-label, two-stage Phase I/IIa dose escalation study of BT062 in metastatic triple receptor-negative breast cancer and in metastatic transitional cell carcinoma of the urinary bladder Eine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003252-20,0,0,0 2013-003253-21,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Universitätsklinikum Münster,B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents B-NHL 2013 - Behandlungsprotokoll der NHL-BF...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003253-21,0,0,0 2013-003254-24,11,2016-10-19,2016-10-19,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003254-24,0,0,0 2013-003255-38,1,2017-02-23,2017-02-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University hospitals Leuven,Systemic administration of Lidocain for oncological gynaecological surgery: the effect on postoperative pain and consumption of Morphine Systemische toediening van lidocaïne bij oncologische gynae...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003255-38,0,0,0 2013-003256-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione Italiana Linfomi,"A PHASE II PROSPECTIVE STUDY OF HIGH-DOSE myeloablative therapy, WITH STEM CELL DEVICES SUPPORT IN ELDERLY PATIENTS (from 65 to 76 years) with relapsed aggressive non-Hodgkin lymphoma OR RESISTANT TO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003256-20,0,0,0 2013-003257-20,1,2017-12-15,2017-12-15,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST,Evaluation of Treosulfan pharmacokinetics (PK) in children undergoing allogeneic haematopoietic stem cell transplantation (HSCT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003257-20,0,0,0 2013-003259-39,2,,,0,1,1,0,0,0,2,0,0,1,0,0,0,1,1,Neurochlore,A Phase II dose ranging study of Bumetanide solution in children and adolescents with autism spectrum disorders.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003259-39,0,0,0 2013-003260-32,1,2016-01-16,2016-01-16,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,,The Effects of Isovolumetric and Isoeffective Infusions of Colloid Versus Crystalloid on Renal Blood Flow and Cardiac Output,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003260-32,0,0,0 2013-003262-13,11,2021-01-19,2021-01-19,9,1,0,0,0,2,3,0,0,2,0,0,0,0,1,CSL Behring GmbH,"A Phase 3 Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII-SingleChain, CSL627) in Subjects with Severe Hemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003262-13,1,0,0 2013-003265-34,6,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,HOVON,Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multipl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003265-34,0,0,0 2013-003265-34,6,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,HOVON Foundation,Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multipl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003265-34,0,0,0 2013-003265-34,6,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon),Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multipl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003265-34,0,0,0 2013-003266-14,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003266-14,0,0,0 2013-003267-55,1,2016-08-29,2016-08-29,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"An international, multicenter, open-label, one-arm study in 150 infants vaccinated with a 3-dose primary series of the DTaP-IPV-Hep B-PRP-T combined vaccine in the Russian Federation and Poland.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003267-55,0,0,0 2013-003268-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AUSL Piacenza,Hyperbaric oxygen therapy in the treatment of sudden hydiopatic sensorineural hearing loss L'ossigenoterapia iperbarica nella sordità improvvisa idiopatica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003268-29,0,0,0 2013-003269-33,6,2017-03-01,2017-03-01,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MedImmune LLC,"A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003269-33,0,0,0 2013-003269-33,6,2017-03-01,2017-03-01,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MedImmune LLC( a wholly owned subsidiary of AstraZeneca PLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA)","A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003269-33,0,0,0 2013-003269-33,6,2017-03-01,2017-03-01,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MedImmune LLC (a wholly owned subsidiary of AstraZeneca PLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA)","A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003269-33,0,0,0 2013-003269-33,6,2017-03-01,2017-03-01,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MedImmune LLC(a wholly owned subsidiary of AstraZeneca PLC, One MedImmune Way, Gaithersburg, Maryland, 20878, USA )","A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Inadequately Controlled, Severe Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003269-33,0,0,0 2013-003270-28,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Instituto de Inmunología y Alergia INMUNAL S.A..U.,Biological standardization of allergenic extracts of Dermatophagoides farinae and Lolium perenne. Open label. Single Center. Phase II Study. Estandarización biológica de extractos alergénicos de De...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003270-28,0,0,0 2013-003272-12,1,2016-12-21,2016-12-21,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Moorfields Eye Hospital,Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003272-12,0,0,0 2013-003275-36,4,2016-04-27,2016-06-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Subjects with Chronic Plaq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003275-36,0,0,0 2013-003290-95,5,2017-08-03,2017-08-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26-WEEK MULTICENTER STUDY WITH A 78-WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003290-95,0,0,0 2013-003295-12,1,2018-05-15,2018-05-15,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Roskilde University Hospital,Combination Therapy Interferon Alpha + JAK1-2 Inhibitor in The Ph-Negative Chronic Myeloid Neoplasms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003295-12,0,0,0 2013-003296-34,1,2018-09-27,2018-09-27,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Single Blind, Randomised, Placebo Controlled, Repeat Dose, Dose Escalating Study Investigating Safety, Tolerability Pharmacokinetics, Pharmacodynamics and the Beta-Cell Preserving Effect of Otelixiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003296-34,0,0,0 2013-003299-10,1,2018-08-07,2018-08-07,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,The Netherlands Cancer Institute,Phase I/II study with the combination of dacomitinib and PD-0325901 in metastatic KRAS mutation positive non-small cell lung cancer Fase I/II studie met de combinatie van dacomitinib en PD-0325901 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003299-10,0,0,0 2013-003301-26,1,2016-09-27,2016-09-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Newcastle Upon Tyne Hospitals NHS Foundation Trust,A randomised placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis (IPF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003301-26,0,0,0 2013-003303-18,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,Gedeon Richter Polska Sp. z o. o.,Clinical phase IV study assessing the efficacy and safety of the medicinal product Groprinosin in treatment of recurrent airway inflammation in children with impaired cellular immunity and diagnosed o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003303-18,0,0,0 2013-003304-39,1,2020-08-28,2020-08-28,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Fertilitycenter Odense,Assisted reproduction and the early luteal phase The effect of ovulation induction on the endocrine profile Assisteret reproduktion og den tidlige luteal fase Ovulationsinduktionens påvirkning a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003304-39,0,0,0 2013-003305-25,6,2018-02-15,2018-02-15,6,1,0,0,0,1,4,0,0,1,0,0,1,0,1,CSL Behring GmbH,"An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento® in Subjects with Von Willebrand Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003305-25,0,0,0 2013-003306-45,1,2018-07-31,2018-07-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Tübingen,"An open-label, uncontrolled, single arm phase II trial of BKM120 (Buparlisib) in patients with metastatic melanoma with brain metastases not eligible for surgery or radiosurgery Offene unverblin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003306-45,0,0,0 2013-003307-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ANZIC RESEARCH CENTRE,"""Sedation Practices in Intensive Care Evaluation: SPICE III – A Prospective Multicentre Randomised Controlled Trial of Early Goal Direct Sedation vs. Standard Care Sedation” Valutazione delle moda...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003307-20,0,0,0 2013-003309-24,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,0,Grete Andersen,Lamotrigine as treatment of Myotonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003309-24,0,0,0 2013-003310-40,1,2015-06-08,2015-06-08,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Luitpold Pharmaceuticals, Inc.","A Single Arm, Open Label Study of the Safety, Efficacy, and Pharmacokinetics of SPRIX® (intranasal ketorolac tromethamine) in 0 to 11 year-Old Patients Undergoing Open Surgical Procedures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003310-40,0,0,0 2013-003313-17,7,2016-03-08,2016-06-16,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Bendamustine and Rituximab for Previously Untreated Chronic Lymphocyt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003313-17,0,0,0 2013-003314-41,10,2016-03-07,2016-05-17,10,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003314-41,0,0,0 2013-003319-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fondazione IRCCS Istituto Nazionale dei Tumori,SUBLINGUAL FENTANYL VERSUS SUBCUTANEOUS MORPHINE FOR THE MANAGEMENT OF SEVERE CANCER PAIN EPISODES IN PATIENTS ON OPIOID TREATMENT: A DOUBLE-BLIND RANDOMIZED NON–INFERIORITY TRIAL. fentanyl subl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003319-23,0,0,0 2013-003320-36,2,2018-03-30,2018-03-30,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Allergan Limited,Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003320-36,0,0,0 2013-003321-28,5,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Genzyme Corporation,"An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of Avalglucosidase Alfa (NeoGAA, GZ402666) In Patients With Pompe ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003321-28,0,0,0 2013-003323-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"""Sapienza"" University of Rome","RANDOMIZED CLINICAL TRIAL, PLACEBO-CONTROLLED, SPLIT-MOUTH, A DOUBLE-BLIND, FOR THE EVALUATION OF THE EFFECTIVENESS OF PREemptive ANALGESIA BY ADMINISTRATION OF IBUPROFEN 400MG, FOR THE CONTROL OF POS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003323-11,0,0,0 2013-003324-36,1,2016-01-30,2016-01-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Charles University in Prague, Faculty of Medicine in Hradec Králové",Kinetically guided removal of plazma pegylated liposomal doxorubicin to enhance the benefit of cytostatic therapy of patients with ovarian cancer. Kineticky řízené odstranění plazmatického pegylova...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003324-36,0,0,0 2013-003327-11,1,2017-10-21,2017-10-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Southampton,"Alternative Treatments of Adult female Urinary Tract Infection: a double blind, placebo controlled,factorial randomised trial of Uva ursi and open pragmatic trial of ibuprofen.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003327-11,0,0,0 2013-003328-35,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Centre Hospitalier Départemental Vendée,Efficacité de la Silodosine dans la Thérapie Médicale Expulsive des Calculs urétéraux pelviens de 4 à 10 mm. Etude randomisée.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003328-35,0,0,0 2013-003330-32,9,2019-01-11,2019-01-11,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"F.HOFFMANN-LA ROCHE representado en España por Roche Farma,S.A","A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH PD L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003330-32,0,0,0 2013-003330-32,9,2019-01-11,2019-01-11,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH PD L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003330-32,0,0,0 2013-003331-30,12,2019-01-09,2019-01-09,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003331-30,0,0,0 2013-003331-30,12,2019-01-09,2019-01-09,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Roche Farma, S.A. en nombre de F. Hoffmann-La Roche Ltd","A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003331-30,0,0,0 2013-003333-15,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"A 12 months, prospective, multicenter, open-label, single arm interventional study assessing the safety and tolerability of 0.5 mg ranibizumab in mono/bilateral wet AMD patients in eyes with BCVA belo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003333-15,0,0,0 2013-003334-33,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,NOVARTIS FARMA,"A 12-month, open-label, interventional, multicentre study to investigate the current criteria driving re-treatment with ranibizumab upon relapse in patients with visual impairment due to choroidal neo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003334-33,0,0,0 2013-003336-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLGIA,"A Phase IIb study of topic DAC-0060, a synthetic histone deacetylase inhibitor, plus Tazarotene in patients with cutaneous basal cell carcinoma (BCC) Studio di Fase IIb con DAC-0060 topico, un ini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003336-72,0,0,0 2013-003341-41,4,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Crucell Holland B.V.,"Multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of CR8020 and CR6261 in hospitalized patients with influenza A infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003341-41,0,0,0 2013-003342-16,6,2016-09-30,2016-09-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Zeria Pharmaceutical Co., Ltd.","A Phase III, Multicentre, Single-arm, Open-label Study to Evaluate the Long-term Safety of Z-338 in Subjects with Functional Dyspepsia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003342-16,0,0,0 2013-003346-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitari Sagrat cor,Comparative study between continuous perfusion and split doses in the treatment of postoperative pain Estudio comparativo entre dosis fraccionadas y perfusión continua en el tratamiento del dolor p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003346-16,0,0,0 2013-003349-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasme hospital,what are the optimal doses of cefuroxime for cirrhotic patients? Quelles sont les doses optimales de cefuroxime à administrer chez les patients obèses?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003349-41,0,0,0 2013-003352-20,1,2017-11-09,2017-11-09,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University Medical Center of Johannes -Gutenberg University Mainz,Correlation of functional and structural outcomes with serum antibody profiles in patients with neovascular age-related macular degeneration treated with ranibizumab and healthy subjects: a prospectiv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003352-20,0,0,0 2013-003354-24,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Vrij Universiteit Medical Center,Influence of exogenous growth hormone administration on circulating levels of Klotho in healthy and CKD subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003354-24,0,0,0 2013-003356-21,1,2014-04-01,2014-04-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Profil Institut für Stoffwechselforschung GmbH,"A phase IIa, dose-finding, double-blind, placebo-controlled, double-dummy, randomized, eightfold cross-over study to investigate the glucose lowering effects of dextromethorphan alone or in combinatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003356-21,0,0,0 2013-003357-17,1,2018-02-28,2018-02-28,1,1,0,0,0,1,4,0,1,1,1,1,1,0,0,Prof. Asbjørn Mohr Drewes,"RESET Trial A randomized, double-blinded, single-centre, parallel-group, placebo-controlled, prospective trial of S-ketamine for pain treatment in chronic pancreatitis (RESET trial) ”RESET trial” ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003357-17,0,0,0 2013-003358-25,6,2016-10-03,2016-11-23,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Genticel,"A double-blind, randomised, placebo-controlled, Phase II study to evaluate ProCervix efficacy to clear HPV 16 and HPV 18 infection in women with normal cytology or ASCUS/LSIL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003358-25,1,0,0 2013-003359-39,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Clínic per a la Recerca Biomèdica,Bisphosphonate Therapy with Zoledronic acid or Tenofovir Switching to Improve Low Bone Mineral Density in HIV-Infected Adults Tratamiento con ácido zoledrónico vs sustitución de tenofovir para mejo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003359-39,0,0,0 2013-003363-64,1,2016-05-12,2016-05-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,"A randomised, double blind, placebo controlled, single centre, 60 week trial of Exenatide once weekly for the treatment of moderate severity Parkinson’s disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003363-64,0,0,0 2013-003365-34,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Specialisttandvårdskliniken Västmanlands sjukhus Västerås,Pain relief following an intra-articular single dose metylprednisolon vs. placebo on temporomandibular joint artralgia patientens. A randomized controlled blinded multicenter study. Smärtlindring e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003365-34,0,0,0 2013-003368-29,3,2020-06-17,2020-06-17,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,vasopharm GmbH,"EFFICACY OF VAS203 IN PATIENTS WITH MODERATE AND SEVERE TRAUMATIC BRAIN INJURY. A confirmatory, placebo-controlled, randomised, double blind, multi-centre study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003368-29,0,0,0 2013-003369-33,1,2019-06-30,2019-06-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of cologne,"JeRiCHO (JAK-inhibition in recurrent classical Hodgkin Lymphoma): A phase II, open-label, prospective, non-randomized, multicenter clinical trial with the JAK-inhibitor ruxolitinib in patients with re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003369-33,0,0,0 2013-003370-27,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,"Rainer Rupprecht, Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität Regensburg am Bezirksklinikum","Functional MRI (fMRI) after challenge and treatment with antidepressants and their relation to the clinical course, to the Hypothalamus-Hypophysis-Adrenocortical Axis and the colon microbiome Funkt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003370-27,0,0,0 2013-003373-10,1,2015-06-03,2015-06-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ALMIRALL S.A.,"A DOUBLE-BLIND, PLACEBO-CONTROLLED, 2 PERIOD CROSSOVER CLINICAL STUDY TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE 400 ΜCG BID ON COPD SYMPTOMS AND SLEEP QUALITY AFTER 3 WEEKS OF TREATMENT IN PATIENTS W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003373-10,0,0,0 2013-003378-28,1,2014-12-30,2014-12-30,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,"Department of Medicine, Køge University Hospital","THE ROLE OF PHAGES IN MICROBIAL GUT ECOLOGY A STUDY OF INTERACTIONS BETWEEN ANTIBIOTICS AND THE GUT MICROBIOTA IN HEALTHY VOLUNTEERS A PARALLEL, SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003378-28,0,0,0 2013-003388-79,1,2018-11-19,2018-11-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Roche Farma, S.A.",PHASE II TRIAL TO EVALUATE THE EFFICACY OF OBINUTUZUMAB (RO5072759) + BENDAMUSTINE TREATMENT IN PATIENTS WITH REFRACTORY OR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA ENSAYO CLÍNICO FASE II PARA EVALUA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003388-79,0,0,0 2013-003390-95,13,2021-04-16,2021-04-16,10,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICACY AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMER’S DISEASE; PART II: OPEN-LABEL EXTENS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003390-95,1,0,0 2013-003390-95,13,2021-04-16,2021-04-16,10,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A en nombre de F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICACY AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMER’S DISEASE; PART II: OPEN-LABEL EXTENS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003390-95,1,0,0 2013-003397-27,2,2014-11-12,2014-11-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety Of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered vi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003397-27,0,0,0 2013-003398-91,12,2022-06-30,2022-06-30,6,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Celgene Corporation,"A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003398-91,1,0,0 2013-003399-10,3,2015-04-22,2015-04-22,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD S.N.C.,"A Randomized, Double-Blinded, Controlled with GARDASIL® (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerabilit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003399-10,0,0,0 2013-003400-39,2,2017-10-16,2017-10-16,1,1,1,0,0,1,1,0,0,2,1,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003400-39,1,0,0 2013-003401-26,2,2019-05-17,2019-05-17,2,1,1,0,0,0,4,0,0,1,0,0,1,0,1,Ethicon Inc.,"A Prospective, Randomized, Controlled, Study Evaluating EVICEL® Fibrin Sealant as an Adjunct to Hemostasis During Abdominal, Retroperitoneal, Pelvic or Thoracic (Non-Cardiac) Surgery in Pediatric Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003401-26,0,0,0 2013-003402-40,9,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,"Exelixis, Inc.","A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003402-40,0,0,0 2013-003402-40,9,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,"EXELIXIS, INC.","A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003402-40,0,0,0 2013-003403-19,1,2014-07-01,2014-07-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Karolinska University Hospital,Study of T- and B-cell immunity after vaccination with a virosomebased influenza vaccine (Inflexal V) in patients who have undergone hematopoietic allogeneic stem cell transplantation. Studie av ce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003403-19,0,0,0 2013-003404-39,1,2015-11-20,2015-11-20,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,"Department of Medical Research, Regional Hospital Holstebro","The effect of sodium nitrite infusion on renal variables, brachial and central blood pressure during enzyme inhibition by allopurinol, enalapril or acetazolamid in healthy subjects. A randomized, doub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003404-39,0,0,0 2013-003405-26,4,2020-05-12,2020-05-12,1,0,0,0,0,1,2,0,0,2,1,0,0,0,0,Erasmus MC,The effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003405-26,1,0,0 2013-003410-41,4,2015-04-14,2015-04-15,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,AOP Orphan Pharmaceuticals AG,"A phase III randomized, multicenter, double-blind, active controlled study to compare the efficacy and safety of two different anagrelide formulations in patients with Essential Thrombocythemia (TEAM-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003410-41,0,0,0 2013-003413-18,2,2021-01-13,2021-01-13,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Leiden University Medical Center,Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003413-18,1,0,0 2013-003413-18,2,2021-01-13,2021-01-13,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,King’s College London,Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003413-18,1,0,0 2013-003413-18,2,2021-01-13,2021-01-13,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Guy's and St. Thomas' NHS Foundation Trust,Arthritis Prevention In the Pre-clinical Phase of RA with Abatacept.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003413-18,1,0,0 2013-003418-42,1,2018-02-14,2018-02-14,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Wörwag Pharma GmbH & Co. KG,"Effect of Mg-Orotate administration on cardiocirculatory Performance, the muscular concentration of phosphocreatine and the adaptation of muscle cellular level: A double blind, randomized, placebo-con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003418-42,0,0,0 2013-003420-37,10,2018-03-13,2018-03-13,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN AS ADJUNCTIVE THERAPY IN CHILDREN 1 MONTH THROUGH <4 YEARS OF AGE WITH PARTIAL ONSET SEIZ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003420-37,0,0,0 2013-003421-28,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,0,Technische Universität Dreden,Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia Randomisiert-kontrollierte Phase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003421-28,0,0,0 2013-003427-10,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) administered to Indi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003427-10,0,1,1 2013-003428-34,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IV, non-randomised, open-label, multicentre study with two parallel groups to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine admin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003428-34,0,1,1 2013-003429-28,1,2017-04-19,2017-04-19,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase IV, observer-blind, randomized, controlled, multicentric study to assess the safety and immunogenicity of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix™) administered intramuscularl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003429-28,0,0,0 2013-003431-29,1,2015-09-21,2015-09-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farma S.p.A.,A multicenter medical safety follow-up study for patients with partial onset seizures who received more than 28 days of total exposure to BGG492 in studies CBGG492A2207 and/or CBGG492A2212.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003431-29,0,0,0 2013-003433-15,1,2019-10-28,2019-10-28,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,CHU de Toulouse,Effets du L-ThreoDOPS à long terme (3 mois) sur l’hypotension orthostatique et certains symptômes non moteurs dans l’atrophie multisystématisée (AMS) : étude comparative avec tirage au sort versus pla...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003433-15,0,0,0 2013-003434-32,14,2016-06-28,2016-06-28,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003434-32,0,0,0 2013-003434-32,14,2016-06-28,2016-06-28,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farma SpA,"A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003434-32,0,0,0 2013-003434-32,14,2016-06-28,2016-06-28,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmaceutica, S.A.","A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003434-32,0,0,0 2013-003438-33,11,2016-05-27,2016-05-27,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bayer HealthCare AG,"A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003438-33,1,0,0 2013-003438-33,11,2016-05-27,2016-05-27,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bayer AG,"A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003438-33,1,0,0 2013-003438-33,11,2016-05-27,2016-05-27,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bayer AG,"A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003438-33,1,0,0 2013-003439-31,6,2018-10-25,2018-10-25,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003439-31,0,0,0 2013-003440-22,1,2017-12-31,2017-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University College London,"a phase IV, double-blind randomised placebo-controlled, parallel group multi-site trial of sertraline compared to placebo in patients presenting with depressive symptoms in primary care where treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003440-22,0,0,0 2013-003444-24,15,2018-08-10,2018-10-10,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas SA,"Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetyls...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003444-24,0,0,0 2013-003444-24,15,2018-08-10,2018-10-10,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetyls...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003444-24,0,0,0 2013-003444-24,15,2018-08-10,2018-10-10,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Italia S.p.A.,"Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetyls...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003444-24,0,0,0 2013-003444-24,15,2018-08-10,2018-10-10,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetyls...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003444-24,0,0,0 2013-003444-24,15,2018-08-10,2018-10-10,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetyls...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003444-24,0,0,0 2013-003444-24,15,2018-08-10,2018-10-10,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm. V,"Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetyls...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003444-24,0,0,0 2013-003444-24,15,2018-08-10,2018-10-10,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.","Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetyls...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003444-24,0,0,0 2013-003444-24,15,2018-08-10,2018-10-10,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetyls...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003444-24,0,0,0 2013-003446-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Abnoba GmbH,Intravesical Mistletoe Extract in Superficial Bladder Cancer: A phase III efficacy study (TIM) Eine Phase III Wirksamkeitsstudie zur intravesikalen Instillation von Mistel-Extrakt bei oberflächli...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003446-16,0,0,0 2013-003449-40,1,2014-12-09,2014-12-09,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Omninvest Ltd.,"Immunogenicity and Tolerability Study of FLUVAL AB Novo Suspension for Injection (trivalent, seasonal influenza vaccine, active ingredient content: 6 μg HA/strain/0.5 ml) for Children and Adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003449-40,0,0,0 2013-003450-24,6,2016-05-13,2016-06-01,4,1,0,0,0,1,2,0,0,2,0,0,0,0,1,"Shire Human Genetic Therapies, Inc","A Randomized, Controlled, Open-label, Multicenter, Phase IIb Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration via an Intrathecal Drug Delivery Device in Ped...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003450-24,1,0,0 2013-003452-21,3,2018-02-14,2018-02-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003452-21,0,0,0 2013-003452-21,3,2018-02-14,2018-02-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003452-21,0,0,0 2013-003452-21,3,2018-02-14,2018-02-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003452-21,0,0,0 2013-003453-13,9,2015-09-07,2015-11-05,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cempra Pharmaceuticals, Inc.","A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003453-13,0,0,0 2013-003457-25,9,2022-03-21,2022-03-21,8,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Actelion Pharmaceuticals Ltd.,"Long term, multicenter, single-arm, open-label extension study of the MERIT-1 study, to assess the safety, tolerability and efficacy of macitentan in subjects with inoperable chronic thromboembolic pu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003457-25,1,0,0 2013-003458-26,10,2016-03-14,2017-03-21,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CSL Behring LLC,"A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003458-26,0,0,0 2013-003459-39,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, open, randomized, controlled, multicenter study to assess the co-administration of Rotarix (GlaxoSmithKline Biologicals’) with Hib-MenCY-TT (GlaxoSmithKline Biologicals’ Meningococcal Gr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003459-39,0,1,1 2013-003460-31,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,GGZ-Drenthe,The effect of low doses of mirtazapine and quetiapine on sleep and daytime functioning.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003460-31,0,0,0 2013-003462-14,2,2015-09-09,2015-09-09,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ACTELION Pharmaceuticals Ltd.,"A multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with pulmonary arterial hypertension to psychometrically validate the French, Italian and Spanish versions of the PAH-S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003462-14,0,0,0 2013-003464-31,2,2015-09-23,2015-09-23,2,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Ethicon Inc,"A Single-blinded, Randomized, Controlled, Comparative Phase III Study Evaluating the Safety and Effectiveness of EVARREST™ Fibrin Sealant Patch as an Adjunct to Hemostasis During Cardiovascular Surger...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003464-31,0,0,0 2013-003466-13,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Goethe University Frankfurt,"Treatment optimization in adult patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma by individualised, targeted and intensified treatment - a phase IV-trial with a pha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003466-13,0,0,0 2013-003467-60,5,2016-12-13,2016-12-13,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients with Knee Osteoarthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003467-60,0,0,0 2013-003468-30,7,2016-07-29,2016-07-29,3,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Sucampo Pharma Europe Ltd.,"A Multicentre, Randomised, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years with Functional Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003468-30,1,0,0 2013-003468-30,7,2016-07-29,2016-07-29,3,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Sucampo Pharma Americas, LLC","A Multicentre, Randomised, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years with Functional Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003468-30,1,0,0 2013-003469-32,1,2015-12-09,2015-12-09,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University College London,"A Single Arm Phase II trial of BMN 673 for inoperable, advanced endometrial cancer with retrospective PTEN, MSI and MRE11 analysis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003469-32,0,0,0 2013-003478-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Maria Nabal Vicuña (Paliative Care Supportive Team-Hospital Universitari Arnau de Vilanova de Lleida),The effect on quality of life of Vitamin D administration for advanced cancer treatment. A randomized controlled trial El efecto sobre la calidad de vida de la administración de Vitamina D para el ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003478-29,0,0,0 2013-003479-36,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, controlled, partially-blind study to assess the reactogenicity, safety and immunogenicity of GSK Biologicals' 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003479-36,0,1,1 2013-003481-14,1,2019-06-19,2019-06-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,National Institute of Diabetes and Digestive and Kidney Diseases,Study of allopurinol to prevent GFR loss in type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003481-14,0,0,0 2013-003486-34,1,2015-11-21,2015-11-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Knowledge Centre for Rheumatology and Back Diseases,"Systemic versus ultrasound-guided local glucocorticoid treatment, among rheumatoid arthritis patients with tenosynovitis - a randomized double blind study Systemisk versus ultralyds-guided loka...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003486-34,0,0,0 2013-003488-71,1,2018-06-27,2018-06-27,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Oxford,A pilot study of the impact of BCG administration on the immunogenicity of serogroup C meningococcal conjugate vaccine in healthy infants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003488-71,0,0,0 2013-003489-15,2,2018-09-17,2018-09-17,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ACTELION Pharmaceuticals Ltd.,"An extension of AC-055-310, a multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with pulmonary arterial hypertension to psychometrically validate the French, Italian and S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003489-15,0,0,0 2013-003490-10,5,2015-02-17,2015-02-17,4,1,0,0,1,0,4,0,0,1,0,0,1,0,0,AIBILI (EVICR.net),Intraocular Pressure And Tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or preservative free Latanoprost 0.005% Unit Dose (LUDPF) (Monopost)in patients with Ocular hyperte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003490-10,0,0,0 2013-003492-35,1,2020-09-15,2020-09-15,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University of Bonn,Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation with Dabigatran after Pulmonary Vein Isolation for Atrial Fibrillation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003492-35,0,0,0 2013-003493-27,2,2014-06-30,2014-06-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability and efficacy of orally administered QAL964 in patients with active rheumatoid arthritis on stable doses of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003493-27,0,0,0 2013-003501-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Mesoestetic Pharma group S.L.,"Efficacy and safety of a 4% hydroquinone cream (Melanoderm 4%) for the treatment of melasma: a randomized controlled split-face study. Ensayo clínico, aleatorizado, según el procedimiento ?split fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003501-25,0,0,0 2013-003503-19,4,2017-10-04,2017-10-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mologen AG,Randomized Clinical Trial of Maintenance Therapy with Immunomodulator MGN1703 in Patients with Extensive Disease Small Cell Lung Cancer after Platinum-Based First-Line Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003503-19,0,0,0 2013-003505-26,1,2021-11-03,2021-11-03,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,AGMT gemeinnützige GmbH,A “window of opportunity” trial with Brentuximab Vedotin and Imatinib in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma or patients ineligible for chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003505-26,0,0,0 2013-003510-41,1,2016-08-29,2016-08-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A two part, Phase IIa, randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin (GSK1325756) in symptom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003510-41,0,0,0 2013-003514-40,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University Hospital of North Norway,The effect of vitamin D supplementation on cardiovascular risk factors in subjects with low serum 25-hydroxyvitamin D levels,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003514-40,0,0,0 2013-003519-23,16,2019-01-25,2019-01-25,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003519-23,0,0,0 2013-003520-37,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatment i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003520-37,0,0,0 2013-003522-83,1,2013-12-11,2013-12-11,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Professor Jørgen B. Dahl,Adductor canal block and effect of 10 versus 30 ml ropivacaine on muscle strength: a randomized study in helathy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003522-83,0,0,0 2013-003526-92,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,INSERM,see below Comparaison d'une nouvelle technique de mesure de l'insulinorésistance avec la technique de référence: utilisation du 6-DIG comme marqueur du transport du glucose.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003526-92,0,0,0 2013-003527-11,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"ViiV Healthcare, S.L.","ING200336: A Prospective, Interventional Pharmacokinetic and Safety Study of DTG/ABC/3TC in Pregnant Women. ING200336: Estudio prospectivo intervencional para evaluar la farmacocinética y segurida...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003527-11,0,0,0 2013-003530-33,8,2014-07-25,2021-07-29,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) with ABT-494",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003530-33,0,0,0 2013-003532-68,1,2016-07-29,2016-07-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Guy's and St Thomas NHS Foundation Trust,"Fibrinogen concentrate supplementation in the management of bleeding during paediatric cardiopulmonary bypass: a phase 1B/2A, open label dose escalation study (Version 1.0, Jan 28, 2014)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003532-68,0,0,0 2013-003533-16,1,,,0,1,0,0,0,1,4,0,0,1,0,0,0,1,0,Radboud University Nijmegen Medical Centre,Individualizing Pazopanib therapy by exploRing the role of Early metabolic responsE and drug exposure as a preDICTor for treatment outcome in patients with STS Is het vroeg meten van de tumorstofwi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003533-16,0,0,0 2013-003535-30,3,2015-10-25,2016-10-25,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase III, double blind, randomized, comparative study of the safety and immunogenicity of GSK Biologicals’ Varilrix HSA-free varicella vaccine and Varilrix™ given as a 2 dose course in the second y...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003535-30,0,0,0 2013-003542-17,2,2020-11-20,2020-11-20,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Charité Universitätsmedizin Berlin,"A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with rupa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003542-17,1,0,0 2013-003545-41,7,2015-01-20,2016-10-26,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic Th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003545-41,0,0,0 2013-003546-16,1,2016-06-03,2016-06-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Klin. Abt. für Endokrinologie & Stoffwechsel, Universitätsklinik für Innere Medizin III","The Link between Obesity And Vitamin D in bariatric patients with omega-loop bypass surgery: a randomized controlled, double-blinded clinical supplementation trial - LOAD LOAD - Der Zusammenhang zw...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003546-16,0,0,0 2013-003547-39,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Isala Klinieken,"Dexmedetomidine vs. clonidine in delirious intensive care patients: a randomised open-label trial Dexmedetomidine vs clonidine: effect op delirante intensive care patiënten; een gerandomiseerd, ope...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003547-39,0,0,0 2013-003548-22,1,2014-07-31,2014-07-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"Johnson & Johnson Consumer & Personal Products Worldwide, Division of Johnson & Johnson Consumer Companies, Inc",Four Week Clinical Efficacy of An Ethyl Lauroyl Arginate HCL (LAE) Mouth Rinse: Effect on Gingivitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003548-22,0,0,0 2013-003552-21,3,2015-08-25,2015-10-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Comparison of the Oxyntomodulin Analog, LY2944876, to Once-Weekly Exenatide and to Placebo in Patients with Type 2 Diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003552-21,0,0,0 2013-003553-16,4,2015-06-16,2015-10-01,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc.,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Brodalumab in Subjects with Psoriatic Arthritis: AMVISION-2",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003553-16,0,0,0 2013-003554-25,11,2015-06-11,2015-10-22,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc.,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects with Psoriatic Arthritis: AMVISION-1",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003554-25,0,0,0 2013-003556-20,1,2016-09-07,2016-09-07,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Dept. of Intensive Care 4131, Copenhagen University Hospital, Rigshospitalet","Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial Behandling af patienter med nekrotiserende bløddelsinfektioner med intravenøs, polyspecifik immunoglobulin G",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003556-20,0,0,0 2013-003557-24,2,2021-11-12,2021-11-12,1,1,1,0,1,0,0,0,0,2,0,0,0,0,1,Ethicon Inc,"A Prospective, Randomised, Controlled, Study Evaluating the Safety and Effectiveness of EVARREST® Sealant Matrix in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003557-24,1,0,0 2013-003558-26,1,,,0,1,1,0,0,0,3,0,0,3,0,0,0,0,1,Ethicon Inc,"A Prospective, Randomized, Controlled, Study Evaluating the Safety and Efficacy of EVICEL® used for Suture-line sealing in Dura-Mater Closure during Paediatric Neurosurgical Cranial Procedures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003558-26,0,0,0 2013-003559-39,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,The University of Dundee,Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease (ALL-HEART),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003559-39,0,0,0 2013-003559-39,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,NHS TAYSIDE,Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease (ALL-HEART),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003559-39,0,0,0 2013-003561-34,3,2017-10-02,2017-10-02,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Pharmacyclics Incorporated,"A Multicenter, Open-Label, Phase 2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Relapsed/Refractory Marginal Zone Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003561-34,0,0,0 2013-003561-34,3,2017-10-02,2017-10-02,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Pharmacyclics LLC,"A Multicenter, Open-Label, Phase 2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Relapsed/Refractory Marginal Zone Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003561-34,0,0,0 2013-003563-58,1,2017-07-25,2017-07-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Nottingham University Hospitals NHS Trust,"A Phase II, single-centre exploratory study to assess the value of hypoxia imaging with [18F]HX4 PET/CT in predicting outcome for patients with squamous cell carcinoma of head and neck and non-small c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003563-58,0,0,0 2013-003564-31,2,,,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,Univar B.V.,"Multicentre, Retrospective Study to Assess Long-Term Outcomes of Chelator-Based Treatment With Trientine in Wilson Disease Patients Withdrawn from Therapy With Studio retrospettivo multicentrico pe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003564-31,0,0,0 2013-003564-31,2,,,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,UNIVAR LTD,"Multicentre, Retrospective Study to Assess Long-Term Outcomes of Chelator-Based Treatment With Trientine in Wilson Disease Patients Withdrawn from Therapy With Studio retrospettivo multicentrico pe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003564-31,0,0,0 2013-003566-13,1,2014-03-15,2014-03-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Afferent Pharmaceuticals, Inc.","A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Way Cross-over Study to evaluate the effect of AF-219 on methacholine hyper-reactivity in subjects with asthma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003566-13,0,0,0 2013-003573-10,1,2015-12-22,2015-12-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee & NHS Tayside,Can Vitamin D supplementation improve Hepatitis C cure rates: A pilot multicentre randomised controlled clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003573-10,0,0,0 2013-003578-28,1,2017-01-20,2017-01-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Andreas Kjær,The intraoperative use of fluorescent tracers and multimodal imaging techniques in treatment of head and neck cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003578-28,0,0,0 2013-003579-36,4,2016-05-27,2016-05-27,1,0,1,0,0,1,1,0,0,2,0,0,0,0,1,Bayer AG,"A multi-center, open-label, non-randomized, phase I dose escalation study of regorafenib (BAY 73-4506) in pediatric subjects with solid malignant tumors that are recurrent or refractory to standard th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003579-36,1,0,0 2013-003579-36,4,2016-05-27,2016-05-27,1,0,1,0,0,1,1,0,0,2,0,0,0,0,1,Bayer HealthCare AG,"A multi-center, open-label, non-randomized, phase I dose escalation study of regorafenib (BAY 73-4506) in pediatric subjects with solid malignant tumors that are recurrent or refractory to standard th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003579-36,1,0,0 2013-003582-34,5,2017-04-10,2017-04-18,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003582-34,0,0,0 2013-003583-31,6,2020-04-07,2020-04-07,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","Randomized, open label, multicenter phase IIIb study evaluating the efficacy and safety of ruxolitinib versus best available therapy in patients with polycythemia vera who are hydroxyurea resistant or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003583-31,0,0,0 2013-003583-31,6,2020-04-07,2020-04-07,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"Randomized, open label, multicenter phase IIIb study evaluating the efficacy and safety of ruxolitinib versus best available therapy in patients with polycythemia vera who are hydroxyurea resistant or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003583-31,0,0,0 2013-003583-31,6,2020-04-07,2020-04-07,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.p.A,"Randomized, open label, multicenter phase IIIb study evaluating the efficacy and safety of ruxolitinib versus best available therapy in patients with polycythemia vera who are hydroxyurea resistant or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003583-31,0,0,0 2013-003585-14,4,2015-11-16,2015-11-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOXXON PHARMA AG,"Safety, PK/PD and efficacy of NOX-H94 in dialysis patients with ESA-hyporesponsive anaemia: A randomized, double blind, placebo controlled parallel group study with a single blind cross-over group",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003585-14,0,0,0 2013-003585-14,4,2015-11-16,2015-11-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOXXON Pharma AG,"Safety, PK/PD and efficacy of NOX-H94 in dialysis patients with ESA-hyporesponsive anaemia: A randomized, double blind, placebo controlled parallel group study with a single blind cross-over group",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003585-14,0,0,0 2013-003586-34,11,2017-03-22,2017-03-22,10,0,0,0,0,1,3,0,0,1,0,0,1,0,1,Cyclacel Limited,A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003586-34,0,0,0 2013-003587-31,4,2016-09-28,2016-09-28,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) in Subjects with Type 2 Diabetes Mellit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003587-31,0,0,0 2013-003588-73,3,2015-08-31,2016-06-20,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Alexion Pharmaceuticals Inc.,AN OPEN-LABEL PROOF OF CONCEPT PHASE IIA TRIAL OF ALXN1007 FOR THE TREATMENT OF NON-CRITERIA MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003588-73,0,0,0 2013-003588-73,3,2015-08-31,2016-06-20,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ALEXION PHARMACEUTICALS INCORPORATED,AN OPEN-LABEL PROOF OF CONCEPT PHASE IIA TRIAL OF ALXN1007 FOR THE TREATMENT OF NON-CRITERIA MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003588-73,0,0,0 2013-003589-15,13,2016-02-18,2016-02-19,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Alexion Pharmaceuticals, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN SUBJECTS WITH REFRACTORY GENERALIZED MYASTHENIA GRAVIS (GMG)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003589-15,0,0,0 2013-003592-35,1,2017-03-31,2017-03-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Public Health England,"A phase III/IV open-label study of the immunogenicity and safety of a single dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for each of three successive years in children naïve to, or i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003592-35,0,0,0 2013-003594-99,1,2015-07-09,2015-07-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside,Proof of Concept Evaluation of Drug-Device Interaction with aclidinium bromide via Genuair® and tiotropium bromide via HandiHaler® in COPD using Impulse Oscillometry,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003594-99,0,0,0 2013-003595-12,6,2019-11-05,2019-11-05,5,1,1,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors Etude de phase II du pazopanib (GW786034, N° NSC 737754) chez des enfant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003595-12,1,1,0 2013-003595-12,6,2019-11-05,2019-11-05,5,1,1,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline,"A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors Etude de phase II du pazopanib (GW786034, N° NSC 737754) chez des enfant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003595-12,1,1,0 2013-003595-12,6,2019-11-05,2019-11-05,5,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors Etude de phase II du pazopanib (GW786034, N° NSC 737754) chez des enfant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003595-12,1,1,0 2013-003596-35,2,2020-12-29,2020-12-29,1,1,1,0,0,2,1,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003596-35,1,0,0 2013-003596-35,2,2020-12-29,2020-12-29,1,1,1,0,0,2,1,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003596-35,1,0,0 2013-003600-40,7,2016-02-11,2016-02-11,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biogen Idec Research Limited,"A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003600-40,0,0,0 2013-003601-25,1,2016-11-01,2016-11-01,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Charité Universitätsmedizin Berlin,"A multicenter, Double-blind, RandOmised, two arm Parallel group trial to determine the effects of torasemide versus furosemide on one marker (PIP) of cardiac fibrosis in patient with Diastolic Heart F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003601-25,0,0,0 2013-003603-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus University Medical Center,Influence of an acidic beverage on the absorption of erlotinib Invloed van zure dranken op de absorptie van erlotinib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003603-19,0,0,0 2013-003604-39,6,2019-09-30,2019-09-30,6,1,1,0,0,1,2,0,0,1,0,0,1,0,1,medac GmbH,Clinical phase II trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematolog...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003604-39,0,0,0 2013-003604-39,6,2019-09-30,2019-09-30,6,1,1,0,0,1,2,0,0,1,0,0,1,0,1,medac Gesellschaft für klinische Spezialpräparate mbH,Clinical phase II trial to describe the safety and efficacy of Treosulfan-based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematolog...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003604-39,0,0,0 2013-003605-26,4,2016-08-05,2016-08-05,1,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Prosensa Therapeutics B.V.,"A phase II, open label, extension study to assess the effect of PRO044 in patients with Duchenne muscular dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003605-26,0,0,0 2013-003605-26,4,2016-08-05,2016-08-05,1,1,0,0,0,1,2,0,0,1,1,0,1,0,1,BioMarin Nederland B.V.,"A phase II, open label, extension study to assess the effect of PRO044 in patients with Duchenne muscular dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003605-26,0,0,0 2013-003610-41,9,2015-10-28,2015-10-28,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Laboratorios Servier S.L.,"Dose-response study of gevokizumab (S 78989) 3mg, 10mg, 30mg or 60mg in patients with type 2 diabetes and diabetic kidney disease (DKD) Estudio dosis-respuesta de 3 mg, 10 mg, 30 mg ó 60 mg de gevo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003610-41,0,0,0 2013-003610-41,9,2015-10-28,2015-10-28,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,"Dose-response study of gevokizumab (S 78989) 3mg, 10mg, 30mg or 60mg in patients with type 2 diabetes and diabetic kidney disease (DKD) Estudio dosis-respuesta de 3 mg, 10 mg, 30 mg ó 60 mg de gevo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003610-41,0,0,0 2013-003611-21,1,2015-07-20,2015-07-20,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Karolinska Institutet,Safety of fluconazol treatment of premature and full-term newborns - a study on interactions by NSAIDs with fluconazole in respect of pharmacodynamic endpoints with urinary excretion of vasoact...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003611-21,0,0,0 2013-003619-24,1,2019-02-01,2019-02-01,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Lourdes Lozano-Bailen,"Benefits of liquid oxygen in COPD patients without evidence of domiciliary oxygen therapy, presenting desaturation on exertion. Beneficios del oxígeno líquido en pacientes con EPOC, sin criterios d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003619-24,0,0,0 2013-003621-28,8,2017-11-14,2020-10-08,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003621-28,0,0,0 2013-003622-86,6,2007-11-26,2021-09-10,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003622-86,0,0,0 2013-003625-29,6,2014-12-09,2015-01-27,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Hanmi Pharmaceutical Co., Ltd.","A Phase II, 12-week, double-blind, randomised, parallel group, multi-centre, international trial to assess the effect on glycaemic control of five doses of HM11260C versus placebo or open-label liragl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003625-29,0,0,0 2013-003626-88,1,2019-11-10,2019-11-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Fakultní nemocnice Plzeň,The utilization of mesenchymal stem cells (MSC) for the treatment of graft versus host disease (GVHD) after allogeneic stem cell transplantation. Využití mesenchymálních kmenových buněk (MSC) k léč...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003626-88,0,0,0 2013-003629-27,11,2019-08-20,2019-08-20,8,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Bioverativ Therapeutics Inc.,"An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003629-27,0,0,0 2013-003629-27,11,2019-08-20,2019-08-20,8,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Bioverativ Therapeutic Inc.,"An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003629-27,0,0,0 2013-003629-27,11,2019-08-20,2019-08-20,8,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Biogen Idec Research Ltd,"An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003629-27,0,0,0 2013-003632-71,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,Clínica Universidad de Navarra/Universidad de Navarra,Dendritic cell-based immunotherapy for advanced solid tumours of children and young adults INMUNOTERAPIA BASADA EN EL USO DE CÉLULAS DENDRÍTICAS EN TUMORES SÓLIDOS AVANZADOS DE NIÑOS Y ADULTOS JÓVE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003632-71,0,0,0 2013-003639-31,10,2020-06-12,2020-06-12,6,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Infinity Pharmaceuticals, Inc",A Study of IPI-145 and Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003639-31,1,0,0 2013-003639-31,10,2020-06-12,2020-06-12,6,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Verastem, INC",A Study of IPI-145 and Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003639-31,1,0,0 2013-003639-31,10,2020-06-12,2020-06-12,6,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Verastem, Inc",A Study of IPI-145 and Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003639-31,1,0,0 2013-003640-23,2,2016-05-27,2016-05-27,2,1,0,0,0,0,0,0,0,1,0,0,1,0,0,AIBILI - Association for Innovation and Biomedical Research on Light and Image,"Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003640-23,0,0,0 2013-003643-31,1,2016-12-19,2016-12-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Birmingham,Assessing the therapeutic efficacy and safety of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017) in idiopathic intracranial hypertension (IIH).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003643-31,0,0,0 2013-003644-23,6,2016-05-03,2016-05-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Paratek Pharma LLC,"A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adult Subjects with Acute Bacterial Skin and Skin Struct...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003644-23,0,0,0 2013-003644-23,6,2016-05-03,2016-05-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Paratek Pharma, LLC","A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adult Subjects with Acute Bacterial Skin and Skin Struct...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003644-23,0,0,0 2013-003645-42,7,2017-12-04,2020-12-28,4,1,0,0,0,1,2,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A single arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003645-42,1,0,0 2013-003646-16,1,2015-08-02,2015-08-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomized, double-blind, placebo-controlled, parallel groups study to investigate the safety and tolerability, efficacy, pharmacokinetics and pharmacodynamics of three BI 187004 doses given once d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003646-16,0,0,0 2013-003650-24,2,2017-03-22,2017-03-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Karyopharm Therapeutics, Inc.","A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 (Selinexor) in Patients with Advanced Gynaecologic Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003650-24,0,0,0 2013-003650-24,2,2017-03-22,2017-03-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Karyopharm,"A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 (Selinexor) in Patients with Advanced Gynaecologic Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003650-24,0,0,0 2013-003652-20,2,2015-05-31,2015-05-31,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,D-Pharm Ltd.,Pilot trial of intravenous DP-b99 in the treatment of first-ever episode of non-obstructive acute high-risk pancreatitis Pilotná štúdia intravenózneho podania DP-b99 pri liečbe vôbec prvej epizódy ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003652-20,0,0,0 2013-003658-26,1,2018-12-18,2018-12-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,VU University Medical Center,Treat-to-target strategy for early RA patients in usual clinical practice: The COBRA Cohort Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003658-26,0,0,0 2013-003660-31,4,2015-05-28,2015-05-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Alvine Pharmaceuticals, Inc.","A Phase 2b, Randomized, Double-Blind, PLacebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003660-31,0,0,0 2013-003664-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical Center Alkmaar,‘Effect of omega-3 fatty acids on the perioperative immune response and erythrocyte function’ 'Het effect van omega-3 vetzuren op de peri-operatieve immuunreactie en erythrocyt functie',https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003664-32,0,0,0 2013-003666-13,6,2016-07-25,2016-07-26,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer-Ingelheim bv,"A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003666-13,0,0,0 2013-003666-13,6,2016-07-25,2016-07-26,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003666-13,0,0,0 2013-003666-13,6,2016-07-25,2016-07-26,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003666-13,0,0,0 2013-003666-13,6,2016-07-25,2016-07-26,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003666-13,0,0,0 2013-003666-13,6,2016-07-25,2016-07-26,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003666-13,0,0,0 2013-003666-13,6,2016-07-25,2016-07-26,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A 48 weeks, phase II, randomized, double-blind, placebo-controlled, proof of concept and dose finding study of three different dose regimens of BI 655066 administered subcutaneously in patients with a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003666-13,0,0,0 2013-003668-30,2,2020-01-23,2020-01-23,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Karyopharm Therapeutic, Inc.",A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients with Recurrent Gliomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003668-30,0,0,0 2013-003678-29,1,2017-08-01,2017-08-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Tübingen,"Phase II multicenter, open‐label, single arm clinical Study of Pomalidomide and dexamethasonE in RelapSed myeloma Plus rEsponse adapted Cyclophosphamide as a Tailored InnoVativE strategy Eine multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003678-29,0,0,0 2013-003679-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus Medical Centre Rotterdam,Postoperative Ileus reduction by NicOtine gum CHewIng after Operation: a pilot cohort study Reductie van postoperatieve ileus met behulp van het kauwen van nicotine kauwgum; pilot studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003679-36,0,0,0 2013-003683-31,8,2016-03-14,2016-03-22,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An open-label, multi-center, extension study to evaluate the long-term safety of subcutaneous 240mg QGE031 given every 4 weeks for 52 weeks in allergic asthma patients who completed study CQGE031B2201",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003683-31,0,0,0 2013-003683-31,8,2016-03-14,2016-03-22,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farma SpA,"An open-label, multi-center, extension study to evaluate the long-term safety of subcutaneous 240mg QGE031 given every 4 weeks for 52 weeks in allergic asthma patients who completed study CQGE031B2201",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003683-31,0,0,0 2013-003684-54,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Center Amsterdam,Analgesic efficacy of saphenous nerve blockade for outpatient knee anterior cruciate ligament surgery De effectiviteit van locale verdoving van de nervus saphenus voor pijnbestrijding bij kruisban...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003684-54,0,0,0 2013-003689-15,1,2020-06-04,2020-06-04,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Klinikum der Universität München,"Stop exogenous allergic alveolitis (EAA) in childhood: healthy into adulthood – a randomized, double-blind, placebo-controlled, parallel-group study to evaluate prednisolone treatment and course of di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003689-15,0,0,0 2013-003695-13,5,2017-09-30,2017-09-30,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Glycotope GmbH,"Randomized, controlled, open label, multicenter, phase II study to evaluate the efficacy and safety of CetuGEX? plus chemotherapy in comparison to cetuximab plus chemotherapy for the treatment of pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003695-13,0,0,0 2013-003697-26,5,2016-06-01,2016-06-06,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003697-26,0,0,0 2013-003698-82,8,2016-05-26,2016-06-06,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) with Sitagliptin Compared with Ertugliflozin Alon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003698-82,0,0,0 2013-003701-25,3,2015-09-10,2015-09-10,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Tacurion Pharma Inc,"A Phase II, Multicenter,Randomization, Double-Blind, Parallel Group, Placebo-Controlled, Forced Titration Proof of Concept Study to Assess Efficacy, Safety, Tolerability and the Therapeutic Ratio of A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003701-25,1,0,0 2013-003704-39,4,2017-12-04,2017-12-04,2,0,0,0,0,0,4,0,0,2,0,0,0,0,0,St Stephen's AIDS Trust,An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppres...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003704-39,1,0,0 2013-003704-39,4,2017-12-04,2017-12-04,2,0,0,0,0,0,4,0,0,2,0,0,0,0,0,NEAT-ID,An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppres...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003704-39,1,0,0 2013-003707-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Absorption of sublingual delivered fentanyl (Abstral®) in head and neck cancer patients treated with curatively aimed chemo-radiotherapy Absorptie van sublinguaal fentanyl (abstral) bij pt met hoof...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003707-18,0,0,0 2013-003713-18,7,2017-07-10,2017-07-10,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc","A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Sm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003713-18,0,0,0 2013-003714-40,4,2020-09-09,2020-09-09,2,0,0,0,0,1,2,0,0,2,1,0,0,0,0,Klinikum der Ludwig-Maximilian-Universität München,"Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group to evaluate the efficacy and saf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003714-40,1,0,0 2013-003714-40,4,2020-09-09,2020-09-09,2,0,0,0,0,1,2,0,0,2,1,0,0,0,0,Klinikum der Universität München,"Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group to evaluate the efficacy and saf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003714-40,1,0,0 2013-003727-11,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,"Helsinki University Hospital, Department of Gastroenterology",Randomised open-labelmulticenter study evaluating ciprofloxacin in severe alcoholic hepatitis in addition to prednisolon therapy Satunnaistettu avoin vertailututkimus siprofloksasiinista predniso...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003727-11,0,0,0 2013-003729-27,1,2016-11-01,2016-11-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Queen Mary University of London,Telaprevir in patients with genotype 3 HCV : pilot clinical study to evaluate efficacy and predictability of therapy in patients who have failed to respond to pegylated interferon and ribavirin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003729-27,0,0,0 2013-003730-33,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,Fondazione Melanoma ONLUS,Phase I-II study of the combination vemurafenib plus PEG-interferon in advanced melanoma patients harboring the V600BRAF mutation Studio di fase I-II della combinazione dei farmaci vemurafenib più ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003730-33,0,0,0 2013-003731-29,1,,,0,0,0,0,1,0,4,0,0,4,0,0,0,0,0,"SSE, Nevroklinikken, Oslo Universitetssykehus",Could working memory training with computer games be an alternative to stimulant medication for children and adolescents with attention deficits and epilepsy? Arbeidsminnetrening m dataspill hos ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003731-29,0,0,0 2013-003732-72,1,2017-03-01,2017-03-01,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Imperial College London,"Randomised placebo-controlled study of grass pollen allergen immunotherapy tablet (AIT) for seasonal rhinitis: time course of nasal, cutaneous and immunological outcomes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003732-72,0,0,0 2013-003733-15,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,VU University medical center,The Dutch CSF and PET Biomarker Concordance of Alzheimer’s Disease pathology study De Nederlandse CSF en PET Biomarker Concordantie van Alzheimer pathologie studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003733-15,0,0,0 2013-003738-34,7,,,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized Phase 2b, Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM) Revised Protocol 01, incorporati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003738-34,0,0,0 2013-003740-23,1,2017-04-27,2017-04-27,1,0,0,0,0,1,3,0,0,1,1,1,1,0,1,AB Science,"A prospective, multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 2b/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003740-23,0,0,0 2013-003741-42,1,2015-07-01,2015-07-01,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,"Medizinische Universität Innsbruck, Abteilung für Nuklearmedizin",PROSPECTIVE STUDY OF [68GA]NODAGA-RGD-PET FOR THE DIAGNOSIS OF HEPATOCELLULAR CARCINOMA AND THE ASSESSMENT OF TREATMENT RESPONSE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003741-42,0,0,0 2013-003742-16,1,2015-05-12,2015-05-12,1,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Cangene Europe Limited,"Pharmacokinetics, Safety and Efficacy of Recombinant Factor IX Product, IB1001, in Patients with Severe Hemophilia B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003742-16,0,0,0 2013-003749-40,6,2019-06-28,2019-06-28,6,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Roche Farma, S.A. en nombre de F. Hoffmann- La Roche Ltd.","A Phase Ib/II, open label study evaluating the safery and pharmacokinetics of GDC-0199 (ABT-199) in combination with Rituximab (R) or Obinutuzumab (G) plus cyclophosphamide, doxorubicin, vincristine, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003749-40,0,0,0 2013-003749-40,6,2019-06-28,2019-06-28,6,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F. Hoffmann- La Roche Ltd.,"A Phase Ib/II, open label study evaluating the safery and pharmacokinetics of GDC-0199 (ABT-199) in combination with Rituximab (R) or Obinutuzumab (G) plus cyclophosphamide, doxorubicin, vincristine, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003749-40,0,0,0 2013-003751-38,1,2015-04-21,2015-04-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, open-label, randomized, 2-arm, phase II trial of pharmacodynamics, pharmacokinetics and safety of two dose regimens of DEB025/alisporivir in combination with ribavirin therapy in chro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003751-38,0,0,0 2013-003752-21,6,2021-12-17,2021-12-23,3,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Chugai Pharmaceutical Co. Ltd,"A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of Satralizumab (SA237) in patients with Neuromyelitis Op...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003752-21,1,0,0 2013-003752-21,6,2021-12-17,2021-12-23,3,1,1,0,0,1,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,"A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of Satralizumab (SA237) in patients with Neuromyelitis Op...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003752-21,1,0,0 2013-003757-22,1,2014-10-13,2014-10-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,"A phase IIa, 28-day treatment, multi-center, randomized, comparator-controlled, observer-blind trial with intra-individual left/right comparison to investigate the anti-psoriatic efficacy and the safe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003757-22,0,0,0 2013-003760-30,11,2015-07-02,2015-07-02,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck KGaA,"A multicenter, randomized, double-blind, placebo-controlled phase III trial of tecemotide versus placebo in subjects with completed concurrent chemo-radiotherapy for unresectable stage III non-small c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003760-30,0,0,0 2013-003763-56,4,2016-11-23,2016-12-31,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.,Proof of Concept Study of Eurartesim® in Patients with Imported Uncomplicated Plasmodium Vivax Malaria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003763-56,0,0,0 2013-003768-30,1,,,0,1,0,0,1,0,4,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IV, single-blind, randomized, multicenter study to assess the immunogenicity and safety of GSK Biologicals’ dTpa vaccine (Boostrix™) using a new syringe presentation in healthy adolescents age...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003768-30,0,1,1 2013-003771-35,6,2017-09-07,2017-09-20,4,1,0,0,0,1,2,0,0,2,1,0,0,0,1,Ultragenyx Pharmaceutical Inc,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003771-35,1,0,0 2013-003774-27,1,2014-09-10,2014-09-10,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,AlgiPharma AS,"An open label, randomised, two-way crossover scintigraphic study to investigate lung deposition of radiolabelled OligoG delivered as a dry powder and as a nebulised solution in cystic fibrosis patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003774-27,0,0,0 2013-003778-29,4,2016-11-03,2016-11-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University College London,Combined Multi-Marker Screening and Randomised Patient Treatment with Aspirin for Evidence-based Pre-eclampsia Prevention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003778-29,0,0,0 2013-003780-65,2,2015-06-17,2015-06-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects with Moderate to Severe Active Rheumatoid Arthritis who have Exp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003780-65,0,0,0 2013-003784-56,1,2014-12-17,2014-12-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,VUAB Pharma a.s.,"An open, randomized, clinical trial parallel-controlled with Mycostatin oral suspension, evaluating the efficacy of Nystatin oral gel and Nystatin oral suspension in adult patients with oropharyngeal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003784-56,0,0,0 2013-003785-14,1,2019-02-27,2019-02-27,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK-3475 in Subjects with Advanced Renal Cell Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003785-14,0,0,0 2013-003788-67,4,2014-11-08,2014-11-08,2,1,0,0,1,0,3,0,0,1,1,0,1,0,1,"Watson Laboratories, Inc. - A subsidiary of Actavis, Inc.","A Randomised, Parallel Group, Assessor-Blind, Multicentre Study to Compare the Safety and Efficacy of Actavis rhFSH with Follitropin Alfa (GONAL-f?) in Stimulating Multiple Follicular Development in W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003788-67,0,0,0 2013-003789-15,5,2019-09-01,2019-09-01,5,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Nordic Myeloma Study Group,Phase II study of carfilzomib- cyclophosphamide-dexamethasone and high-dose melphalan followed by randomization between observa-tion or maintenance with carfil-zomib and dexamethasone in pa-tients wit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003789-15,0,0,0 2013-003790-10,1,2013-12-24,2013-12-24,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie",DEXMEDETOMIDINE FOR PERIPHERAL NERVE BLOCKADE: A DOSE-FINDING STUDY IN VOLUNTEERS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003790-10,0,0,0 2013-003791-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Helsinki University,SIGNAL TRANSDUCTION IN NAFLD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003791-12,0,0,0 2013-003795-13,2,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,Long-term follow-up study to monitor the growth and development of pediatric patients previously treated with everolimus in study CRAD001M2301,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003795-13,0,0,0 2013-003798-82,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Hull & East Yorkshire Hospitals NHS Trust,Multi-centre Randomised Controlled Trial of Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) withdrawal in advanced renal disease; The STOP-ACEi Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003798-82,0,0,0 2013-003800-38,1,2014-10-17,2014-10-17,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Department of Medical Research,"The effects of tolvaptan on renal handling of water and sodium, vasoactive hormones and circulatory system, during basal conditions and during inhibition of the nitric oxide system in healthy subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003800-38,0,0,0 2013-003807-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"HUS, Leikkaus- ja anestesiaosasto",Periferal local anesthetic infusion for postoperative pain after above knee amputation Perifeerinen puuduteinfuusio reisiamputaation jälkeisen kivun hoidossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003807-20,0,0,0 2013-003809-26,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,SOTIO a.s.,"Open-label, one-arm, multi-centre phase II clinical trial with second cycle of active cellular immunotherapy DCVAC/PCa in patients with localized prostate cancer after primary radical prostatectomy an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003809-26,0,0,0 2013-003810-42,1,2017-10-05,2017-10-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Edinburgh (ACCORD),A pragmatic group sequential placebo controlled randomised trial to determine the effectiveness of Glyceryl trinitrate for retained placenta (GOT-IT Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003810-42,0,0,0 2013-003810-42,1,2017-10-05,2017-10-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Lothian (ACCORD),A pragmatic group sequential placebo controlled randomised trial to determine the effectiveness of Glyceryl trinitrate for retained placenta (GOT-IT Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003810-42,0,0,0 2013-003811-23,1,2020-06-08,2020-06-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,SOGUG - Spanish Oncology Genitourinary Group,Abirateriona acetate maintenance in combination with docetaxel after disease progression to abiraterona acetate in metastatic castration resistant prostate cancer. Randomized phase II study. Manten...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003811-23,0,0,0 2013-003812-30,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,UCB Biosciences Inc.,A MULTICENTER POSTMARKETING STUDY TO EVALUATE THE PLACENTAL TRANSFER OF CERTOLIZUMAB PEGOL IN PREGNANT WOMEN RECEIVING TREATMENT WITH CIMZIA® (CERTOLIZUMAB PEGOL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003812-30,0,0,0 2013-003815-23,1,2015-09-10,2015-09-10,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KU Leuven,Evaluation of the intraluminal behaviour of fenofibrate in healthy volunteers Evaluatie van het intraluminale gedrag van fenofibraat in gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003815-23,0,0,0 2013-003817-16,11,2015-08-05,2015-08-05,9,1,0,0,1,0,3,0,0,1,0,0,1,0,2,Merck KGaA,"A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris® (follitropin alfa and lutropin alfa) and GONAL-f® (follitropin alfa)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003817-16,0,0,0 2013-003817-16,11,2015-08-05,2015-08-05,9,1,0,0,1,0,3,0,0,1,0,0,1,0,2,Merk KGaA,"A phase III, randomized, controlled, single-blind, multicentre, parallel arm trial to assess the efficacy and safety of Pergoveris® (follitropin alfa and lutropin alfa) and GONAL-f® (follitropin alfa)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003817-16,0,0,0 2013-003820-36,18,2015-05-27,2021-06-16,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (DCM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003820-36,0,0,0 2013-003820-36,18,2015-05-27,2021-06-16,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Orion Corporation Orion Pharma,"A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (DCM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003820-36,0,0,0 2013-003820-36,18,2015-05-27,2021-06-16,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (DCM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003820-36,0,0,0 2013-003820-36,18,2015-05-27,2021-06-16,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (DCM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003820-36,0,0,0 2013-003822-96,5,2015-11-15,2015-11-15,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd.,"A prospective, multicenter, double-blind, randomized, placebo-controlled, parallel group, 12-week study to evaluate the safety and tolerability of macitentan in subjects with combined pre- and post-ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003822-96,0,0,0 2013-003826-10,1,2017-12-19,2017-12-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,IRCCS- Mario Negri Institute,"EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA TE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003826-10,0,0,0 2013-003828-36,1,2018-05-17,2018-05-17,1,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Advicenne Pharma,"A multicentre, open-label, extension study, evaluating the safety and tolerability and the efficacy of ADV7103 at long term in distal renal tubular acidosis patients. Multicentrické, otvorené, pred...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003828-36,0,0,0 2013-003829-29,7,2017-04-26,2017-04-26,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects with Metastatic Colorect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003829-29,0,0,0 2013-003829-29,7,2017-04-26,2017-04-26,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Symphogen A/S,"Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects with Metastatic Colorect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003829-29,0,0,0 2013-003830-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Asklepios Fachkliniken München Gauting,Pleurectomy/decortication and hypterthermic intrathoracic chemotherapy compared to pleurectomy/decortication in patients with malignant pleural mesothelioma Pleurektomie/Dekortikation und hyperthe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003830-34,0,0,0 2013-003831-31,9,2016-11-21,2016-11-21,8,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003831-31,0,0,0 2013-003831-31,9,2016-11-21,2016-11-21,8,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003831-31,0,0,0 2013-003832-54,1,2020-06-17,2020-06-17,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Mirum Pharmaceuticals, Inc.","A MULTICENTRE EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND DURABILITY OF THE THERAPEUTIC EFFECT OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003832-54,0,0,0 2013-003833-14,3,2020-05-08,2020-05-08,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Lumena Pharmaceuticals, Inc.","AN OPEN LABEL STUDY OF THE EFFICACY AND LONG TERM SAFETY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTi), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC PATIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003833-14,0,0,0 2013-003833-14,3,2020-05-08,2020-05-08,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Mirum Pharmaceuticals, LLC.","AN OPEN LABEL STUDY OF THE EFFICACY AND LONG TERM SAFETY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTi), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC PATIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003833-14,0,0,0 2013-003833-14,3,2020-05-08,2020-05-08,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Mirum Pharmaceuticals, Inc.","AN OPEN LABEL STUDY OF THE EFFICACY AND LONG TERM SAFETY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTi), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC PATIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003833-14,0,0,0 2013-003834-33,2,2015-01-20,2015-01-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Protocol I1R-MC-GLDI The Effect of LY2409021 on Blood Pressure and Pulse Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Subjects with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003834-33,0,0,0 2013-003839-30,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003839-30,0,0,0 2013-003842-18,1,,,0,0,0,0,0,1,4,0,0,1,1,1,0,1,0,Erasmus MC,Prevention of renal and bladder damage in children with spina bifida by means of early injections with Botulinum-Toxin-A (Botox): a pilot study. Preventie van nier- en blaasschade bij kinderen met ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003842-18,0,0,0 2013-003855-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Miguel Giovanni Uriol Rivera,Benefits of paricalcitol (Selective vitamin D receptor activator indicated for the prevention and treatment of secondary hyperparathyroidism) on anaemia of inflammation in dialysis patients receiving...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003855-38,0,0,0 2013-003856-19,11,2019-10-11,2019-10-11,8,1,1,0,0,0,2,0,0,2,0,0,0,0,1,Sanofi-aventis recherche et développement,Open label extension study to evaluate the long-term safety and tolerability of dupilumab in patients with asthma who participated in previous dupilumab asthma clinical study Estudio de extensión a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003856-19,1,1,0 2013-003858-25,5,2015-09-02,2015-09-02,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc.",A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney Dise...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003858-25,0,0,0 2013-003858-25,5,2015-09-02,2015-09-02,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney Dise...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003858-25,0,0,0 2013-003859-37,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, single-group, open-label study to assess the safety and reactogenicity of GSK Biologicals’ combined reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) vaccine Boostrix ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003859-37,0,1,1 2013-003862-15,1,2015-12-21,2015-12-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Jens Faber,"Liraglutide in Polycystic Ovary Syndrome A randomised, double-blind, placebo-controlled study of the effect of Liraglutide in Polycystic ovary syndrome on risk markers of vascular Thrombosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003862-15,0,0,0 2013-003865-32,2,2014-07-01,2014-07-01,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Tokai Pharmaceuticals, Inc.",A Pharmacokinetic and Pharmacodynamic Translational Investigation of Galeterone in Patients with Metastatic Castration Resistant Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003865-32,0,0,0 2013-003866-15,3,2013-04-14,2015-06-16,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Celgene Corporation,"MPACT EXTENSION STUDY: MULTICENTER, SURVIVAL DATA COLLECTION IN SUBJECTS PREVIOUSLY ENROLLED IN PROTOCOL CA046",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003866-15,0,0,0 2013-003867-76,1,2017-03-01,2017-03-01,1,1,0,0,1,0,3,0,0,1,1,1,1,0,0,University Hospitals Birmingham NHS Foundation Trust,"A prospective, randomised controlled trial to determine the safety and efficacy of steroid impregnated tape compared to standard therapy with silver nitrate in the treatment of over-granulating perito...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003867-76,0,0,0 2013-003868-31,3,2017-12-04,2017-12-04,3,1,0,1,0,0,1,0,0,1,0,0,0,0,0,"Medizinische Universität Innsbruck, AGO Studienzentrale","A two-part, multicentre, international phase I and II trial assessing the safety and efficacy of the Hsp90 inhibitor ganetespib in combination with paclitaxel weekly in women with high-grade serous, h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003868-31,0,0,0 2013-003868-31,3,2017-12-04,2017-12-04,3,1,0,1,0,0,1,0,0,1,0,0,0,0,0,"Medical University of Innsbruck, Austrian AGO Trial Centre","A two-part, multicentre, international phase I and II trial assessing the safety and efficacy of the Hsp90 inhibitor ganetespib in combination with paclitaxel weekly in women with high-grade serous, h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003868-31,0,0,0 2013-003873-85,1,2021-01-11,2021-01-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Helsinki University Central Hospital,"Doxapram as an Additive to Propofol Sedation in Sedation for ERCP - a Placebo controlled, randomized, double-blinded, prospective study DOKSAPRAAMI PROPOFOLI-SEDAATION LISÄLÄÄKKEENA ERCP:n HOIDOSSA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003873-85,0,0,0 2013-003874-29,3,2016-07-26,2016-07-28,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Clovis Oncology Italy s.r.l.,"A single arm, open-label, phase 2 study to assess the efficacy and safety of lucitanib given orally as a single agent to patients with advanced/metastatic lung cancer and FGF, VEGF, or PDGF related ge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003874-29,0,0,0 2013-003874-29,3,2016-07-26,2016-07-28,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,EOS S.p.A.,"A single arm, open-label, phase 2 study to assess the efficacy and safety of lucitanib given orally as a single agent to patients with advanced/metastatic lung cancer and FGF, VEGF, or PDGF related ge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003874-29,0,0,0 2013-003877-87,4,2020-06-09,2020-06-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Octapharma Pharmazeutika Prod.Ges.m.b.H,"CLINICAL PHASE III STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY, TOLERABILITY AND SAFETY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM 16.5%) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003877-87,0,0,0 2013-003881-15,4,2014-06-13,2014-10-24,3,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Anergis SA,"Long-term, up to 3-year follow-up of a multicentre, randomized, double-blind, placebo-controlled trial (AN004T) assessing the efficacy and tolerability of 2 dosing regimens of AllerT, a combination of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003881-15,0,0,0 2013-003883-30,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Aziende Chimiche Riunite Angelini Francesco ACRAF S.p.A,"Efficacy and safety of paracetamol in comparison to ibuprofen for patent ductus arteriosus treatment in preterm infants. A randomized, open label, comparator-controlled, prospective study. Efficaci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003883-30,0,0,0 2013-003884-71,8,2020-07-15,2020-07-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme Corporation,A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003884-71,0,0,0 2013-003885-15,2,2014-07-29,2014-07-29,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Omeros Corporation,"A Phase 3 Randomised, Double-Masked, Placebo-Controlled Study of the Effect of OMS302 on Intraoperative Pupil Diameter in Subjects at High Risk of Intraoperative Floppy Iris Syndrome Undergoing Intrao...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003885-15,0,0,0 2013-003886-33,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Bracco Imaging S.p.A.,"PHASE IV, DOUBLE-BLIND, MULTI-CENTER, RANDOMIZED, TWO-ARM CROSSOVER STUDY TO COMPARE 0.1 mmol/kg OF MULTIHANCE® WITH 0.1 mmol/kg OF DOTAREM® AND 0.05 mmol/kg OF MULTIHANCE® WITH 0.1 mmol/kg OF DOTAREM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003886-33,0,0,0 2013-003888-59,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Amsterdam,ADHD: Medication or Meditation? ADHD: Medicatie of Meditatie?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003888-59,0,0,0 2013-003889-14,4,,,0,1,1,0,0,0,3,0,0,2,1,0,0,0,0,Institut National de la Santé et de la Research Médicale,"A randomised, placebo controlled trial of azithromycin for the prevention of chronic disease of prematurity in preterm infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003889-14,0,0,0 2013-003892-36,1,2016-09-05,2016-09-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,INMUNAL SAU,"Biological standardization of allergenic extracts of Platanus acerifolia, Salsola kali, Chenopodium album y Artemisia vulgaris . Open label. Multicenter. Phase II Study. Estandarización biológica d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003892-36,0,0,0 2013-003893-29,15,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bayer HealthCare AG,"A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003893-29,0,0,0 2013-003893-29,15,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bayer AG,"A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003893-29,0,0,0 2013-003893-29,15,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,BAYER AG,"A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003893-29,0,0,0 2013-003896-37,1,2015-01-08,2015-01-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,URSAPHARM Arzneimittel GmbH,"Efficacy and tolerability of Bromelain tablets hysan® in patients with chronic rhinosinusitis. A prospective, double-blind, randomized, placebo-controlled multi-centre trial. A proof of concept study....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003896-37,0,0,0 2013-003898-98,1,2016-12-15,2016-12-15,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Ospedale San Raffaele,COMPARISON OF WHITE LIGHT TUR VS PHOTODYNAMIC DIAGNOSIS (PDD)- GUIDED TUR AS ASSESSED BY SECOND LOOK TUR FOR THE TREATMENT OF HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER (NMIBC) IMPATTO DELLA RESE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003898-98,0,0,0 2013-003899-12,1,2015-01-28,2015-01-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Protocol 271-12-205: A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003899-12,0,0,0 2013-003905-24,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,SFJ Pharma Ltd. II,ADJUVANT AXITINIB TREATMENT OF RENAL CANCER: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF ADJUVANT AXITINIB VS. PLACEBO IN SUBJECTS AT HIGH RISK OF RECURRENT RCC TRATAMIENTO ADYUVANTE DEL CÁNCER RENA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003905-24,0,0,0 2013-003909-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMCG,Bayesian optimized Propofol Target-Controlled Infusion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003909-26,0,0,0 2013-003910-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,"A Randomized Phase II, placebo-controlled , multicenter study evaluating efficacy and safety of regorafenib in patients with metastatic bone sarcomas.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003910-42,0,0,0 2013-003911-23,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,CHU Toulouse,Evaluation of cardiac uptake during a PET examination 18F Flutematamol (Vizamyl®) in cardiac damage amyloid. Evaluation de la fixation cardiaque lors d’un examen TEP au 18F Flutematamol (Vizamyl®) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003911-23,0,0,0 2013-003914-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medizinische Universität Wien, Univ.-Klinik für Innere Medizin I, Klinische Abteilung für Infetionen und Tropenmedizin",Multiple-dose Pharmacokinetics of Ceftaroline during continuous and intermittent renal replacement therapy in patients requiring renal replacement therapy Bestimmung von Blutkonzentrationen von Cef...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003914-42,0,0,0 2013-003927-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,Development of an innovative Gallium 68 radiolabeling of DOTATOC (68Ga-DOTATOC) for PET-CT imaging of neuro-endocrine tumors and preliminary clinical evaluation MISE AU POINT D'UN NOUVEAU MARQUA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003927-12,0,0,0 2013-003931-30,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,Hôpital Universitaire Des Enfants Reine Fabiola,"A prospective open-label study on efficacy and tolerability of colloidal bismuth sub-citrate as adjunctive therapy to a combination of esomeprazole, amoxicillin and metronidazole for 10 days for Helic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003931-30,0,0,0 2013-003932-56,4,2021-02-03,2021-02-03,2,1,0,0,0,0,2,0,0,2,0,0,0,0,0,University of Liverpool,"ESPAC-5F: European Study Group for Pancreatic Cancer - Trial 5F Four arm, prospective, multicentre, randomised feasibility trial of immediate surgery compared with neoadjuvant chemotherapies and neo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003932-56,1,0,0 2013-003932-56,4,2021-02-03,2021-02-03,2,1,0,0,0,0,2,0,0,2,0,0,0,0,0,Royal Liverpool and Broardgreen University Hospitals Trust,"ESPAC-5F: European Study Group for Pancreatic Cancer - Trial 5F Four arm, prospective, multicentre, randomised feasibility trial of immediate surgery compared with neoadjuvant chemotherapies and neo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003932-56,1,0,0 2013-003933-14,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Romark Laboratories L.C.,A Phase III Randomized Double-Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003933-14,0,0,0 2013-003934-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Fondazione Italiana Linfomi Onlus,A pilot phase II study with BRENTUXIMAB VEDOTIN as pre-ASCT induction therapy in relapsed/refractory Hodgkin’s lymphoma patients non responding to IGEV salvage treatment. Studio pilota di fase II ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003934-33,0,0,0 2013-003935-32,4,2016-10-14,2021-12-13,4,1,1,0,0,0,1,0,0,1,1,0,0,0,1,AstraZeneca AB,"A Phase I, Open-Label, Multicentre Study to Assess the Pharmacokinetics and Safety of Naloxegol in Paediatric Patients Ages ? 6 Months to < 18 Years Receiving Treatment with Opioids Ensayo fase I, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003935-32,0,0,0 2013-003935-32,4,2016-10-14,2021-12-13,4,1,1,0,0,0,1,0,0,1,1,0,0,0,1,Kyowa Kirin Pharmaceutical Development Ltd.,"A Phase I, Open-Label, Multicentre Study to Assess the Pharmacokinetics and Safety of Naloxegol in Paediatric Patients Ages ? 6 Months to < 18 Years Receiving Treatment with Opioids Ensayo fase I, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003935-32,0,0,0 2013-003938-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medizinische Universität Graz,Genetic alterations in genes coding for transporters and metformin resistance,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003938-32,0,0,0 2013-003939-30,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer Revised Protocol 01 incorporating Protocol amendment 01,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003939-30,0,0,0 2013-003940-21,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Systemic antibiotic therapy (amoxicillin plus metronidazole) as an adjunct to surgical treatment of peri-implantitis; a single blind randomized controlled study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003940-21,0,0,0 2013-003941-41,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Medisch Spectrum Twente,Reversibility of pulmonary function after inhaling salbutamol in different doses in standard and forward leaning body posture in asthmatic children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003941-41,0,0,0 2013-003945-40,8,2016-05-04,2016-05-05,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, parallel-group, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of different doses of BAY 1002670 in subjects with uterine fibroids over 3 months",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003945-40,0,0,0 2013-003946-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione Italiana Linfomi ONLUS,Phase II study on the role of brentuximab vedotin as single agent in the treatment of relapsed/refractory CD30 positive peripheral T cell lymphoma (PTCL) patients Studio di fase 2 sul ruolo di bren...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003946-17,0,0,0 2013-003947-51,2,2021-01-19,2021-01-19,1,0,0,1,0,0,1,0,0,2,1,0,0,0,0,NKI-AVL,Phase I/prospective randomized phase II trial Of the Safety and Efficacy of tamoxifen in combination with the Isoform selective Pi3K inhibitor GDC-0032 compared with tamoxifen alONe in hormone recepto...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003947-51,1,0,0 2013-003949-41,1,2018-10-01,2018-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,VU medical Center,"Role of different phosphate binders on absorption of vitamin K, metabolism of matrix γ-carboxy-glutamaat (Gla) proteïne (MGP). Rol van verschillende fosfaatbinders t.a.v. absorptie van vitamine K, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003949-41,0,0,0 2013-003953-13,7,2017-03-01,2017-03-01,4,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Peregrine Pharmaceuticals, Inc.","A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone in Patients with Previously Treated Stage IIIb/IV Non-Squamous Non-Smal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003953-13,1,0,0 2013-003956-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis (JIA) Preventie van recidieven door risico-aangepast staken van de behandeling bij...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003956-18,0,0,0 2013-003968-31,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Edinburgh (ACCORD),A phase II RCT of topical menthol gel versus placebo in the treatment of chemotherapy induced peripheral neuropathic pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003968-31,0,0,0 2013-003968-31,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Lothian (ACCORD),A phase II RCT of topical menthol gel versus placebo in the treatment of chemotherapy induced peripheral neuropathic pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003968-31,0,0,0 2013-003972-11,1,2020-05-13,2020-05-13,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Institut für Klinisch-Onkologische Forschung Krankenhaus Nordwest GmbH,Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer Randomisierte multizentrische Phase II/III Studie mit adju...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003972-11,0,0,0 2013-003976-11,2,2017-04-25,2018-08-21,2,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Helsinki University Central Hospital,Effects of S-1 and capecitabine in combination with oxaliplatin on the coronary artery blood flow in patients metastatic gastrointestinal tract adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003976-11,0,0,0 2013-003978-27,1,2015-02-17,2015-02-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects with Chronic Genot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003978-27,0,0,0 2013-003980-74,3,2016-05-26,2016-05-26,2,1,0,0,1,0,2,0,1,1,1,0,1,0,1,Bayer HealthCare AG,"Multi-center, randomized, comparator-controlled, single-blind, parallel-group study to investigate the pharmacodynamics, pharmacokinetics and safety of an intrauterine system releasing BAY 1007626, as...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003980-74,0,0,0 2013-003980-74,3,2016-05-26,2016-05-26,2,1,0,0,1,0,2,0,1,1,1,0,1,0,1,Bayer AG,"Multi-center, randomized, comparator-controlled, single-blind, parallel-group study to investigate the pharmacodynamics, pharmacokinetics and safety of an intrauterine system releasing BAY 1007626, as...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003980-74,0,0,0 2013-003982-32,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Arthroscopic Surgery Unit,Pilot study to evaluate combination of intraosseous with intra-articular infiltrations of plasma rich in growth factors (PRGF®-Endoret®) in the treatment of knee osteoarthritis. Estudio piloto para...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003982-32,0,0,0 2013-003984-72,5,2015-07-02,2015-07-02,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) Who...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003984-72,0,0,0 2013-003984-72,5,2015-07-02,2015-07-02,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) Who...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003984-72,0,0,0 2013-003984-72,5,2015-07-02,2015-07-02,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co.KG,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 with Background Methotrexate (MTX) in Subjects with Active Rheumatoid Arthritis (RA) Who...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003984-72,0,0,0 2013-003990-89,5,2022-03-16,2022-03-16,4,0,0,0,0,1,2,0,0,2,0,0,0,0,0,University of Cologne,Brentuximab vedotin or B-CAP in the treatment of older patients with newly diagnosed classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II trial- Brentuksimabivedotiini vai B-CAP hoito iäkkä...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003990-89,1,0,0 2013-003991-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Katholieke Universiteit Leuven,Optimization of procedural sedation protocol used for dental care delivery in people with mental disability Optimalisatie van medicamenteuze ondersteuning bij tandheelkundige zorgverlening aan pe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003991-11,0,0,0 2013-003997-28,3,2018-12-27,2018-12-27,2,1,1,0,0,1,3,0,0,1,1,0,1,0,1,Octapharma Pharmazeutika Produktionsges.m.b.H.,"Extension Study for Patients who completed GENA-05 (NuProtect) – to Investigate Immunogenicity, Efficacy and Safety of Treatment with Human-cl rhFVIII",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003997-28,0,0,0 2013-003997-28,3,2018-12-27,2018-12-27,2,1,1,0,0,1,3,0,0,1,1,0,1,0,1,"Octapharma Pharmazeutika Produktions GmbH,","Extension Study for Patients who completed GENA-05 (NuProtect) – to Investigate Immunogenicity, Efficacy and Safety of Treatment with Human-cl rhFVIII",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003997-28,0,0,0 2013-003998-10,1,2022-05-29,2022-05-29,1,0,0,0,0,1,3,0,0,1,0,0,0,0,0,Academic medical center,A randomized clinical trial investigating Lanreotide For output reduction in patients with high-output Enterocutaneous fistula,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-003998-10,0,0,0 2013-004000-19,7,2016-04-26,2016-11-30,3,1,0,0,0,1,3,0,0,2,1,0,0,0,1,"Cell Therapeutics, Inc.","A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004000-19,1,0,0 2013-004000-19,7,2016-04-26,2016-11-30,3,1,0,0,0,1,3,0,0,2,1,0,0,0,1,CTI BioPharma Corp.,"A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004000-19,1,0,0 2013-004002-25,6,2018-01-22,2018-03-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in autoinjectors, to demonstrate efficacy at 24 weeks and to assess the long term safety, tolera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004002-25,0,0,0 2013-004002-25,6,2018-01-22,2018-03-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in autoinjectors, to demonstrate efficacy at 24 weeks and to assess the long term safety, tolera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004002-25,0,0,0 2013-004002-25,6,2018-01-22,2018-03-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farma SpA,"A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in autoinjectors, to demonstrate efficacy at 24 weeks and to assess the long term safety, tolera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004002-25,0,0,0 2013-004005-11,1,2015-09-25,2015-09-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004005-11,0,0,0 2013-004006-26,1,2016-08-31,2016-08-31,1,0,0,0,0,0,4,0,1,1,1,1,1,0,0,Knowledge Centre for Rheumatology and Back Diseases,Optical images for monitoring treatment changes in rheumatoid arthritis – a longitudinal study with Rheumascan Optiske billeder ved behandlingskrævende reumatoid artrit - Et longitudinelt monitore...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004006-26,0,0,0 2013-004008-20,7,2016-11-22,2020-11-05,5,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Infinity Pharmaceuticals, Inc",A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004008-20,1,0,0 2013-004008-20,7,2016-11-22,2020-11-05,5,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Verastem, Inc.",A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004008-20,1,0,0 2013-004008-20,7,2016-11-22,2020-11-05,5,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Verastem, Inc",A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004008-20,1,0,0 2013-004009-25,1,2020-01-27,2020-01-27,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,ValiRx plc,"A Phase I/II, Dose Escalation Study to Assess the Safety and Tolerability of VAL201 in Patients with Locally Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004009-25,0,0,0 2013-004011-41,2,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,2,"Boehringer Ingelheim España, S.A.","A Phase Ib/II, Multicentre, Open Label, Randomized Study of BI 836845 in Combination With Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004011-41,0,0,0 2013-004011-41,2,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,2,Boehringer Ingelheim bv,"A Phase Ib/II, Multicentre, Open Label, Randomized Study of BI 836845 in Combination With Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004011-41,0,0,0 2013-004013-41,1,2015-11-08,2015-11-08,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Thomas Fichnter Bendtsen,Supra Sacral Parallel Shift - ultrasound/MR image fusion guided lumbosacral plexus block Supra Sacral Parallel Shift - ultralyd/MR billedfusionsvejledt plexus lumbosacralis blokade,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004013-41,0,0,0 2013-004014-17,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Fondazione Italiana Linfomi ONLUS,Phase II study with Ga101-DHAP as induction therapy in relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) patients before High-Dose chemotherapy BEAM with autologous stem cell transplantation (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004014-17,0,0,0 2013-004019-37,6,2015-11-30,2015-11-30,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given with Methotrexate in Subjects with Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004019-37,0,0,0 2013-004024-11,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Academic Psychiatric Center - AMC-UvA,"New pharmacotherapeutic treatment options for crack-cocaine dependent people in the Netherlands: A double-blind, placebo-controlled randomized feasibility study of sustained release dexamphetamine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004024-11,0,0,0 2013-004025-88,9,2021-08-31,2021-10-21,2,0,1,0,0,1,3,0,0,2,0,0,0,0,1,Novo Nordisk A/S,Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Previously Untreated Patients with Haemophilia A An open-label single-arm multicentre non-controlled phase 3a trial investigating safety and ef...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004025-88,1,0,0 2013-004028-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,Replacement therapy with modified-release hydrocortisone (Plenadren) in patients with central adrenal insufficiency TERAPIA SOSTITUTIVA CON IDROCORTISONE A RILASCIO CONTROLLATO (PLENADREN) NEI PAZI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004028-12,0,0,0 2013-004031-71,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Spaarne Hospital,Local infiltration with anesthetics vs placebo in patients with elective total hip replacement (thr) in fast-track protocol Lokale infiltratie met anaesthetica vs placebo bij patiënten met een elec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004031-71,0,0,0 2013-004033-32,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA,"AN OPEN, MONOCENTRIC, NOT CONTROLLED CLINICAL TRIAL TO DEVELOP AND EVALUATE THE CLINICAL APPLICATION OF A NEW BETA PROBE FOR RADIOGUIDED SURGERY IN MENINGIOMA TUMOR STUDIO ESPLORATIVO, MONOCENTRICO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004033-32,0,0,0 2013-004034-15,11,2017-11-03,2017-11-03,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects with Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004034-15,0,0,0 2013-004036-30,1,2014-06-25,2014-06-25,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Alios BioPharma,"A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respiratory S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004036-30,0,0,0 2013-004037-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,Characterisation of maximum lesion count during treatment (Lmax) by non-invasive study with high definition optical coherence tomography (HD-OCT) and reflectance confocal microscopy (RCM) Caracteri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004037-32,0,0,0 2013-004039-60,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,CENTRE LEON BERARD,"A multicenter study to evaluate a risk-adapted strategy for treatment of extra cranial non seminomateous malignant germ cell tumour in children, adolescent and young adult Etude multicentrique éval...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004039-60,0,0,0 2013-004041-17,1,2015-02-25,2015-02-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Xention Limited,"A double-blind, randomised, placebo-controlled, crossover study to assess the efficacy of XEN-D0501, a TRPV1 antagonist, in reducing the frequency of cough in patients with chronic obstructive pulmona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004041-17,0,0,0 2013-004042-42,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King’s College London,A study to investigate the potential renoprotective role of sodium-glucose transporter-2 (SGLT-2) antagonist Dapagliflozin in Type 2 diabetic patients with diabetic nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004042-42,0,0,0 2013-004042-42,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Guy's and St Thomas NHS Foundation Trust,A study to investigate the potential renoprotective role of sodium-glucose transporter-2 (SGLT-2) antagonist Dapagliflozin in Type 2 diabetic patients with diabetic nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004042-42,0,0,0 2013-004043-23,1,,,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,Idenix Pharmaceuticals Inc.,A Phase I/IIa Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004043-23,0,0,0 2013-004051-20,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,FUNDACIÓN ESPAÑOLA DE REUMATOLOGIA,NOT CONTROLLED STUDY TO ASSESS THE EFFICACY OF TOCILIZUMAB IN PATIENTS WITH MODERATE OR SEVERE RHEUMATOID ARTHRITIS WHO ARE CANDIDATES TO BE TREATED WITH A BIOLOGICAL THERAPY AS MONOTHERAPY ESTUDIO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004051-20,0,0,0 2013-004054-21,7,2022-07-25,2022-07-25,4,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Celgene Corporation,"Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004054-21,1,0,0 2013-004055-20,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,A phase II randomised trial of biomarkers to assess (dose-) response in patients with metastatic castration resistant prostate cancer treated with radium-223.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004055-20,0,0,0 2013-004055-20,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Institute of Cancer Research,A phase II randomised trial of biomarkers to assess (dose-) response in patients with metastatic castration resistant prostate cancer treated with radium-223.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004055-20,0,0,0 2013-004065-13,1,2015-06-01,2015-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Central Manchester University Hospitals NHS Foundation Trust,Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004065-13,0,0,0 2013-004069-14,4,2019-09-25,2019-09-25,4,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Fédération Francophone de Cancérologie Digestive (FFCD),"A european, multicentre, phase II/III randomised double-blind, placebo controlled study evaluating lanreotide as maintenance therapy in patients with non-resectable duodeno-pancreatic neuroendocrine t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004069-14,0,0,0 2013-004071-13,10,2017-02-17,2017-02-17,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Paratek Pharma LLC,"A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects with Community-Acquired Bacterial Pneu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004071-13,0,0,0 2013-004071-13,10,2017-02-17,2017-02-17,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Paratek Pharma, LLC","A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Moxifloxacin IV/PO for Treating Adult Subjects with Community-Acquired Bacterial Pneu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004071-13,0,0,0 2013-004076-34,3,2016-12-22,2016-12-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Astellas Pharma Global Development, Inc.","A phase II open-label rollover study for subjects that have participated in a linsitinib trial Badanie otwarte fazy II typu “rollover”, stanowiące kontynuację badania dla uczestników biorących udzi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004076-34,0,0,0 2013-004081-33,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fédération Francophone de Cancérologie Digestive (FFCD),EFFICACY AND SAFETY of aflibercept ASSOCIATED WITH A FOLFIRI CHEMOTHERAPY IN 1ST LINE TREATMENT OF PATIENTS SUFFERING FROM METASTATIC COLORECTAL CANCER Phase II - single arm - multicenter EFFICACI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004081-33,0,0,0 2013-004089-33,1,2015-04-01,2015-04-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre for Human Drug Research,"A Phase 1, Open Label, Exploratory Study for the Intra-operative Imaging of Folate Receptor Alpha Positive Ovarian and Lung Cancer using the Tumor Specific Imaging Agent EC17 Een fase 1, open label...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004089-33,0,0,0 2013-004090-28,1,,,0,1,0,0,0,1,4,0,0,1,0,0,0,1,1,"Fold RX Pharmaceuticals, a Pfizer Company",TRANSTHYRETIN-ASSOCIATED AMYLOIDOSES OUTCOMES SURVEY (THAOS) – OPTIONAL BLOOD SAMPLE COLLECTION SUBSTUDY Sondaggio Sugli Esiti dell’Amiloidosi da Transtiretina (Transthyretin-Associated Amyloidosis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004090-28,0,0,0 2013-004091-34,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,A randomised Phase II study of Enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration - Resistant Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004091-34,0,0,0 2013-004091-34,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,The Institute of Cancer Reseacrh,A randomised Phase II study of Enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration - Resistant Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004091-34,0,0,0 2013-004101-75,1,2018-05-15,2018-05-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UZ Leuven,Randomized crossover trial to assess the effects and quality of life in patients with locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel: QOLI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004101-75,0,0,0 2013-004103-40,9,2017-04-12,2017-05-15,6,0,0,0,0,0,3,0,0,1,1,0,1,0,1,CytRx Corporation,"A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects with Metastatic, Locally Advanced, or Unresect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004103-40,0,0,0 2013-004105-11,1,2015-05-01,2015-05-01,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Gilead Sciences Inc.,"A Phase 2, Open-label, Randomized Study to Evaluate Safety and Efficacy of Momelotinib in Subjects with Polycythemia Vera or Essential Thrombocythemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004105-11,0,0,0 2013-004108-20,1,2018-08-09,2018-08-09,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,Radboud University Nijmegen Medical Centre,Improving the tolerability of the oral targeted anti-cancer drug pazopanib by food intake (DIET),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004108-20,0,0,0 2013-004109-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione Italiana Linfomi Onlus,A phase II study of Brentuximab Vedotin (BV) in the treatment of elderly Hodgkin lymphoma (HL) patients at first relapse or with primary refractory disease Studio di fase II con l’utilizzo di Bren...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004109-24,0,0,0 2013-004111-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Academic Medical Center,"Feasibility study of chemoradiation, TRAstuzumab and Pertuzumab in resectable HER2+ esophageal carcinoma Haalbaarheidsstudie van chemoradiatie, trastuzumab en Pertuzumab in resectable HER2 + slokd...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004111-42,0,0,0 2013-004117-40,1,2016-02-16,2016-02-16,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Fidia Farmaceutici SpA,"Randomized, controlled, double-blinded clinical trial, with open-label extension on the efficacy of ultrasound guided injection of hyaluronic acid (500-730 KDa) (HYALGAN®) versus saline solution in th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004117-40,0,0,0 2013-004120-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VU University Medical Center,PI3K pathway analysis in tumor tissue and circulating DNA to obtain further insight in the efficacy of everolimus when combined with exemestane. A side-study protocol attached to standard treatment wi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004120-11,0,0,0 2013-004122-28,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,The Leeds Teaching Hospitals NHS Trust,"An investigator‐initiated double‐blind, parallel‐group randomised controlled trial of GOLimumab and Methotrexate versus Methotrexate in very early PsA using clinical and whole body MRI outcomes: the G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004122-28,0,0,0 2013-004124-11,1,2018-12-13,2018-12-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,Double blind randomised multicentre study to assess the effect of local anaesthesia during vaginal hysterectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004124-11,0,0,0 2013-004127-36,1,2014-11-30,2014-11-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Podřipská nemocnice s poliklinikou, Roudnice n.L., s.r.o","Offline monitoring of parallel concentrations of intravenously administered anesthetics, opiates and relaxants in breath and in blood during anesthesia - a pilot study Sledování paralelních koncent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004127-36,0,0,0 2013-004130-15,1,2014-09-29,2014-09-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Charité-Universitätsmedizin Berlin, Department of Dermatology, Clinical Research Center for Hair and Skin Science","Investigator-initiated clinical research trial on the effects of 5% Minoxidil topical foam on gene expression, hair growth and scalp microenvironment in men with androgenetic alopecia Investigator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004130-15,0,0,0 2013-004132-29,3,2015-09-21,2015-12-04,2,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Swedish Orphan Biovitrum AB (Publ),"An open-label, non-randomized, sequential, multicenter study to evaluate the pharmacokinetics, efficacy and safety of once daily dosing compared to twice daily dosing of Orfadin in patients diagnosed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004132-29,0,0,0 2013-004133-33,8,,,0,1,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"RANDOMIZED, MULTICENTER, PHASE III, OPEN LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT NAÏVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004133-33,0,0,0 2013-004133-33,8,,,0,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Roche Farma, S.A. en nombre de F. Hoffmann-La Roche Ltd","RANDOMIZED, MULTICENTER, PHASE III, OPEN LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT NAÏVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004133-33,0,0,0 2013-004134-15,1,,,0,0,0,0,0,1,3,0,0,1,0,0,0,1,0,Dutch Growth Research Foundation,"Intranasal administration of oxytocin in children and young adults with Prader-Willi Syndrome. A randomized, double-blind, placebo-controlled trial. Effects on satiety and food intake, and social beha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004134-15,0,0,0 2013-004136-30,15,2017-06-26,2017-09-28,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)",A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004136-30,0,0,0 2013-004137-32,2,2017-10-02,2017-10-02,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc.,"A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children with Achondroplasia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004137-32,0,0,0 2013-004139-62,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Novartis Farmacéutica S. A.,"A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of everolimus plus letrozole in the firs...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004139-62,0,0,0 2013-004140-32,1,2018-12-31,2018-12-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Unidad de Cirugia Artroscópica,"CLINICAL STUDY TO ASSES THERAPEUTIC USE OF PLATELET RICH PLASMA IN ACUTE MUSCLE INJURIES IN ELITE ATHLETES"" ?ESTUDIO CLÍNICO SOBRE EL USO TERAPÉUTICO DEL PLASMA RICO EN PLAQUETAS EN LESIONES MUSCU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004140-32,0,0,0 2013-004148-49,8,2017-06-01,2017-06-01,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06438179 AND INFLIXIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004148-49,0,0,0 2013-004150-16,3,2016-06-20,2016-09-12,3,1,0,0,0,1,3,0,0,1,1,1,1,0,1,A.T. Development Switzerland SARL,International Open-Label Extension of the Phase 3 Study CL-503012 with KIACTA™ in Patients with AA Amyloidosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004150-16,0,0,0 2013-004153-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche",MAINtenance Afinitor (MAIN-A): A randomized trial comparing maintenance aromatase inhibitors (AIs) + everolimus (Afinitor) vs. AIs in patients withHR+ metastatic breast cancer with disease control aft...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004153-24,0,0,0 2013-004154-22,14,2018-06-22,2018-06-22,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Cubist Pharmaceuticals LLC,A Phase 3 Randomised Double-Blind Study Comparing TR-701FA and Linezolid in Ventilated Gram-Positive Nosocomial Pneumonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004154-22,0,0,0 2013-004154-22,14,2018-06-22,2018-06-22,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Cubist Pharmaceuticals LLC, an indirect wholly-owned subsidiary of Merck Sharp & Dohme Corp.",A Phase 3 Randomised Double-Blind Study Comparing TR-701FA and Linezolid in Ventilated Gram-Positive Nosocomial Pneumonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004154-22,0,0,0 2013-004154-22,14,2018-06-22,2018-06-22,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,CUBIST PHARMACEUTICALS INC.,A Phase 3 Randomised Double-Blind Study Comparing TR-701FA and Linezolid in Ventilated Gram-Positive Nosocomial Pneumonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004154-22,0,0,0 2013-004154-22,14,2018-06-22,2018-06-22,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Cubist Pharmaceuticals, LLC.",A Phase 3 Randomised Double-Blind Study Comparing TR-701FA and Linezolid in Ventilated Gram-Positive Nosocomial Pneumonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004154-22,0,0,0 2013-004154-22,14,2018-06-22,2018-06-22,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Cubist Pharmaceuticals LLC, an indirect wholly -owned subsidiary of Merck Sharp &Dohme Corp.",A Phase 3 Randomised Double-Blind Study Comparing TR-701FA and Linezolid in Ventilated Gram-Positive Nosocomial Pneumonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004154-22,0,0,0 2013-004154-22,14,2018-06-22,2018-06-22,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Trius Therapeutics, a Wholly Owned Subsidiary of Cubist Pharmaceuticals, Inc.",A Phase 3 Randomised Double-Blind Study Comparing TR-701FA and Linezolid in Ventilated Gram-Positive Nosocomial Pneumonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004154-22,0,0,0 2013-004154-22,14,2018-06-22,2018-06-22,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Trius Therapeutics, a Wholly Owned Subsidiary of Cubist",A Phase 3 Randomised Double-Blind Study Comparing TR-701FA and Linezolid in Ventilated Gram-Positive Nosocomial Pneumonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004154-22,0,0,0 2013-004154-22,14,2018-06-22,2018-06-22,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Cubist Pharmaceuticals, LLC., an indirect wholly-owned subsidiary of Merck Sharp & Dohme Corp.",A Phase 3 Randomised Double-Blind Study Comparing TR-701FA and Linezolid in Ventilated Gram-Positive Nosocomial Pneumonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004154-22,0,0,0 2013-004157-24,7,2017-07-10,2017-07-10,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,CSL Behring GmbH,"Multicenter, open-label extension study to investigate the long-term safety and efficacy of IgPro20 in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in subjects com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004157-24,0,0,0 2013-004158-81,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline GmbH & Co. KG,"A multi-centre, single-blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1% / benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004158-81,0,1,1 2013-004162-34,3,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AB SCIENCE,"A prospective, multicenter, randomized, double-blind, placebo-controlled, two-parallel groups, phase III clinical trial to compare the efficacy and safety of masitinib to placebo in patients with loca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004162-34,0,0,0 2013-004162-34,3,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AB Science,"A prospective, multicenter, randomized, double-blind, placebo-controlled, two-parallel groups, phase III clinical trial to compare the efficacy and safety of masitinib to placebo in patients with loca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004162-34,0,0,0 2013-004166-33,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,FO.NE.SA.Onlus,"A PHASE III, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004166-33,0,0,0 2013-004167-32,6,2016-02-24,2016-02-24,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, open-label, multicenter, two arm, phase II study to investigate the benefits of an improved deferasirox formulation (film-coated tablet)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004167-32,0,0,0 2013-004167-32,6,2016-02-24,2016-02-24,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.p.A,"A randomized, open-label, multicenter, two arm, phase II study to investigate the benefits of an improved deferasirox formulation (film-coated tablet)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004167-32,0,0,0 2013-004167-32,6,2016-02-24,2016-02-24,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, open-label, multicenter, two arm, phase II study to investigate the benefits of an improved deferasirox formulation (film-coated tablet)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004167-32,0,0,0 2013-004169-14,1,2015-10-02,2015-10-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Erlangen,"Randomized, placebo controlled, crossover clinical study to analyse the effect of dapagliflozin on microvascular and macrovascular circulation and total body sodium content Randomisierte, placeboko...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004169-14,0,0,0 2013-004172-35,4,2017-01-17,2017-02-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Samsung Bioepis Co., Ltd.","A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004172-35,0,0,0 2013-004174-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMC St Radboud,Pharmacokinetics of nitrofurantoin in the elderly,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004174-10,0,0,0 2013-004176-35,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"Department of Rheumatology, Skåne University Hospital","A randomized, double blind, placebo-controlled, proof-of-concept study of FP187 in patients with mild to moderate Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004176-35,0,0,0 2013-004187-56,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"Georg-August-Universität Göttingen, Stiftung Öffentlichen Rechts, Universitätsmedizin Göttingen","International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < 18 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004187-56,0,0,0 2013-004189-33,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Haukeland University Hospital,ULTRADIAN SUBCUTANEOUS HYDROCORTISONE (USHI) INFUSION IN ADDISON’S DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004189-33,0,0,0 2013-004191-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ghent University Hospital,"Evaluation of the effects and plasma concentration of the potent platelet inhibitor ticagrelor, after crushed and non-crushed intake, after semi-urgent coronary bypass and in patients after cardiac ar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004191-35,0,0,0 2013-004194-27,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase III, randomized, multicenter study, double-blind for the immunogenicity and consistency evaluation of 3 lots of GSK Biologicals’ Haemophilus influenzae type b (Hib) conjugate vaccine and singl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004194-27,0,1,1 2013-004195-36,1,2017-05-09,2017-05-09,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,University College of London,"A randomised, double-blind, placebo-controlled, phase II clinical trial with a cross-over design assessing efficacy of a single dose of bumetamide in reducing focal attack severity in hypokalaemic per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004195-36,0,0,0 2013-004198-28,5,2016-03-14,2016-05-25,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer AG,"A randomized, double blind, placebo-controlled, multicenter phase II study to evaluate efficacy and safety of roniciclib in subjects with extensive-stage disease small cell lung cancer (SCLC) who are ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004198-28,0,0,0 2013-004198-28,5,2016-03-14,2016-05-25,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer Healthcare AG,"A randomized, double blind, placebo-controlled, multicenter phase II study to evaluate efficacy and safety of roniciclib in subjects with extensive-stage disease small cell lung cancer (SCLC) who are ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004198-28,0,0,0 2013-004200-19,1,2017-10-26,2017-10-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge,Pancreatic Resectability in Cancers with Known Limited Extension (PRICKLE) - A single-centre phase 2a study of Gemcitabine plus Nab-paclitaxel for borderline unresectable locally advanced pancreatic c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004200-19,0,0,0 2013-004203-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fakultní nemocnice Královské Vinohrady,"A randomized, 12 months, active controlled study of the efficacy of repeated doses of intravitreal aflibercept in subjects with prolipherative diabetic retinopathy Randomizovaná, 12 měsíční, aktivn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004203-39,0,0,0 2013-004204-19,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,0,Hospices Civils de Lyon,Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004204-19,0,0,0 2013-004205-89,1,2017-03-02,2017-03-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Oxford Radcliffe Hospitals NHS Trust,Randomized multicentre pilot study of LCZ696 versus irbesartan in patients with chronic kidney disease: UK Heart and Renal Protection (HARP)-III,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004205-89,0,0,0 2013-004206-26,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Vakgroep Huisartsgeneeskunde VUB,The effect of methylphenidate (Ritalin ®) on the severity of stuttering.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004206-26,0,0,0 2013-004213-41,2,2015-05-04,2015-05-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,A Phase II Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects with Chronic Hepatitis C Virus Infection who failed prior Direct ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004213-41,0,0,0 2013-004213-41,2,2015-05-04,2015-05-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase II Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects with Chronic Hepatitis C Virus Infection who failed prior Direct ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004213-41,0,0,0 2013-004219-36,1,2014-06-16,2014-06-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Paracelsus Mediznische Privatuniversität, Universitätsklinik für Anästhesiologie, perioperative Medizin und Intensiv",Magnetic Resonance Imaging of Local Anesthetic Distribution: A Comparison of 5 and 15 milliliters of ropivacaine 0.75% for ultrasound guided interscalene plexus blockade,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004219-36,0,0,0 2013-004223-37,1,2015-01-12,2015-01-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, multicenter, open-label, cross-over study to assess lung function and patient preference after a 4 week treatment each with QVA149 vs. tiotropium in patients with stable chronic obstruct...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004223-37,0,0,0 2013-004224-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Region Skåne,Prospective randomized trial comparing the effects of oxytocin and carbetocin on circulation and vascular tone at cesarean section Prospektiv randomiserad studie jämförande effekter av oxytocin oc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004224-10,0,0,0 2013-004228-12,1,2022-06-04,2022-06-04,1,0,0,0,0,0,4,0,0,1,1,1,0,0,0,"Medizinische Universität Wien, univ. Klinik f. Dermatologie","Enhanced efficacy of photodynamic therapy in combination with 3,75% imiquimod - a randomised, prospective , observer-blinded study in patients with actinic keratosis Erhöhte Wirksamkeit der photody...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004228-12,0,0,0 2013-004229-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Raul de la Fuente-Fernandez,Placebo responses in different stages of frontostriatal dysfunction in Parkinson's disease Respuestas placebo en diferentes estadios de disfuncion frontoestriatal en la enfermedad de Parkinson,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004229-10,0,0,0 2013-004232-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZ Brussel,A phase II proof of concept study to evalute the efficacy and safety of deep subcutaneous lanreotide Autogel 120 mg / 28 days on symptoms and healing of the esophageal and gastric mucosa in patients w...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004232-29,0,0,0 2013-004235-77,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,0,NHS Greater Glasgow & Clyde,Xanthine oxidase inhibition for improvement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004235-77,0,0,0 2013-004235-77,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Glasgow,Xanthine oxidase inhibition for improvement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004235-77,0,0,0 2013-004241-17,1,2016-04-11,2016-04-11,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University College Dublin CRC,An Open-Label Randomized-Controlled Trial of Early Screening Test For Pre-Eclampsia and Growth restriction : A Pilot Study (TEST Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004241-17,0,0,0 2013-004244-37,1,2016-12-20,2016-12-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London | Imperial College NHS Healthcare Trust,The control of brain networks after traumatic brain injury: a neuroimaging and neuropsychological study of dopamine and cognition,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004244-37,0,0,0 2013-004246-41,1,2020-03-19,2020-03-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Sandwell and West Birmingham Hospitals NHS Trust,A phase III randomised study of folic acid supplementation in the management of menopausal symptoms in cancer survivors and healthy postmenopausal women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004246-41,0,0,0 2013-004246-41,1,2020-03-19,2020-03-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Birmingham,A phase III randomised study of folic acid supplementation in the management of menopausal symptoms in cancer survivors and healthy postmenopausal women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004246-41,0,0,0 2013-004247-24,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Antwerp University Hospital (UZA),Translational stem cell research in ophthalmology - regenerating the anterior cornea through standardized transplantation of limbal epithelial stem cells: a phase II multicenter trial Translationee...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004247-24,0,0,0 2013-004249-17,1,2018-03-23,2018-03-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,The Newcastle upon Tyne Hospitals NHS Foundation Trust,"A randomised, placebo controlled trial of extra-oesophageal reflux treatment in the management of upper respiratory symptoms. [TOPPITS: Trial of Proton Pump Inhibitors in Throat Symptoms]",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004249-17,0,0,0 2013-004250-13,4,2015-04-30,2015-04-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Hanmi Pharmaceutical Co., Ltd.","A Phase II, 16-week, double-blind, placebo-controlled, parallel-group, randomised, multicentre trial to assess effect on glycaemic control of three doses of HM11260C in subjects with inadequately cont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004250-13,0,0,0 2013-004251-21,3,2015-02-17,2015-02-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Hanmi Pharmaceutical Co., Ltd.","A 20-week, double blind, randomized, placebo controlled, parallel group trial to assess the safety and efficacy of HM11260C on body weight in obese subjects without diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004251-21,0,0,0 2013-004262-34,1,2017-11-07,2017-11-07,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ERYTECH Pharma,"Phase II, randomized, controlled, clinical trial exploring efficacy and safety of ERY001 (L-asparaginase encapsulated in Red Blood Cells) in association with gemcitabine or FOLFOX4 in second-line ther...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004262-34,0,0,0 2013-004269-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Insituto Aragonés de Ciencias de la Salud,Aspirin and colorectal cancer prevention. Exploring the platelet hypothesis of its mechanism of action Ácido acetil salicílico en la prevención del cáncer colorrectal. Papel de las plaquetas en su ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004269-15,0,0,0 2013-004271-12,1,2015-01-30,2015-01-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dompé s.p.a,An open-label study evaluating safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops at different doses in patients with Dry Eye Eine offene Studie zur Evaluierung der Sich...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004271-12,0,0,0 2013-004275-12,1,2015-09-28,2015-09-28,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Eli Lilly and Company,"A Phase 2, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of LY2409021 Compared to Sitagliptin in Subjects with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004275-12,0,0,0 2013-004276-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospital Regional Universitario. IBIMA,"Phase II, Double-blind, randomized, 1-way cross-over, to investigate the effectiveness of the combination of ascorbic acid (vitamin C) and tocopherol (vitamin E) versus placebo for the treatment of de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004276-35,0,0,0 2013-004277-27,7,2020-05-25,2020-05-25,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"PHASE III, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBOCONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (INDUCTION OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH ADALIMUMAB AND PLACEBO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004277-27,0,0,0 2013-004278-88,13,2020-04-16,2020-04-16,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche Farma S.A en nombre de F. Hoffmann-La Roche Ltd,"PHASE III, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004278-88,0,0,0 2013-004278-88,13,2020-04-16,2020-04-16,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"PHASE III, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004278-88,0,0,0 2013-004279-11,4,2020-03-19,2020-03-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"PHASE III, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (INDUCTION OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH ADALIMUMAB AND PLACEB...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004279-11,0,0,0 2013-004280-31,6,2020-04-06,2020-06-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY (MAINTENANCE OF REMISSION) AND SAFETY OF ETROLIZUMAB COMPARED WITH PLACEBO IN PATIENTS WITH MODERATE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004280-31,0,0,0 2013-004282-14,12,2020-06-04,2020-06-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004282-14,0,0,0 2013-004282-14,12,2020-06-04,2020-06-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche Farma S.A. en nombre de F. Hoffmann-La Roche Ltd,"PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004282-14,0,0,0 2013-004288-30,1,2014-11-11,2014-11-11,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,CeQur Corp.,"A Prospective, Single Center, Post-Market Observational Study to Assess the Efficacy, Safety, and Patient Reported Outcomes of Insulin Delivery with PaQ® in Patients with Type 2 Diabetes Mellitus.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004288-30,0,0,0 2013-004291-35,8,2017-07-04,2017-07-04,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled study of canakinumab in patients with Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), with subsequent randomized withdrawal/ dosing frequency reducti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004291-35,0,0,0 2013-004291-35,8,2017-07-04,2017-07-04,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Novartis Farma SpA,"A randomized, double-blind, placebo controlled study of canakinumab in patients with Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), with subsequent randomized withdrawal/ dosing frequency reducti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004291-35,0,0,0 2013-004291-35,8,2017-07-04,2017-07-04,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo controlled study of canakinumab in patients with Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), with subsequent randomized withdrawal/ dosing frequency reducti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004291-35,0,0,0 2013-004293-10,1,,,0,1,0,0,1,0,4,0,0,1,1,1,0,1,0,Hospital Universitari de Tarragona Joan XXIII,Efficacy of treatment by iontophoresis of botulinum toxin type A free from complexing proteins for stump hyperhidrosis Eficacia del tratamiento mediante iontoforesis de toxina botulínica tipo A sin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004293-10,0,0,0 2013-004294-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Concept Foundation,Mifepristone and misoprostol for the termination of pregnancy at 64-140 days since LMP Medicinsk abort med två olika doseringsintervall i graviditetsvecka 9-20,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004294-27,0,0,0 2013-004295-35,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Medical University Innsbruck - Department für Kinder- und Jugendheilkunde (Pädiatrie III),Lung Clearance Index as an OUTcome parameter to detect the efficacy f Aztreonam Lysine Inhalation in cystic fibrosis patients with near normal spirometry - an observational proof-of concept study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004295-35,0,0,0 2013-004297-98,6,2017-01-16,2017-01-16,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,Study 117113: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004297-98,0,0,0 2013-004298-28,8,2017-01-17,2017-01-17,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,Study 117106: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients. Estudio 117106: Mepolizumab frente a placebo como tratamiento complementario en pacientes con EP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004298-28,0,0,0 2013-004298-28,8,2017-01-17,2017-01-17,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.",Study 117106: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients. Estudio 117106: Mepolizumab frente a placebo como tratamiento complementario en pacientes con EP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004298-28,0,0,0 2013-004302-26,4,2017-06-05,2017-06-05,4,1,1,0,0,0,1,0,0,1,0,0,1,0,1,Santen Oy,"A phase I study to evaluate the pharmacokinetics, safety and tolerability of preservative free tafluprost ophthalmic solution (0.0015%) in pediatric patients diagnosed with glaucoma or ocular hyperten...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004302-26,0,0,0 2013-004303-39,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Stichting NVALT Studies,A randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatinum pemetrexed as first-line therapy for advanced EGFR mutated non-small-cell lung cancer. The NVALT17 study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004303-39,0,0,0 2013-004304-19,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa™ vaccine when administered to healthy infants as primary vacc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004304-19,0,1,1 2013-004307-39,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Birmingham,"Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neo-adjuvant 5-Fluorouracil, Epirubicin and Cyclophosphamide...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004307-39,0,0,0 2013-004311-45,1,2016-06-01,2016-06-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Copenhagen University Hospital Rigshospitalet, Department of Cardiology B 2143","GLP-1 ANALOGS FOR NEUROPROTECTION AFTER OUT-OF-HOSPITAL CARDIAC ARREST, A RANDOMIZED CLINICAL TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004311-45,0,0,0 2013-004313-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UMCG,"Effect of pre-operative pain treatment by means of duloxetine on postoperative outcome after total hip or knee arthroplasty Effecten van pre-operatieve pijnbehandeling, middels duloxetine, op posto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004313-41,0,0,0 2013-004316-22,1,2014-12-12,2014-12-12,1,0,0,0,1,0,4,0,0,1,1,1,1,0,3,,INFLUENCE OF NITRATES ON BONE REMODELLING AND ENDOTHELIAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS Influence des nitrates sur la Rénovation de bone et la fonction endothéliale chez les p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004316-22,0,0,0 2013-004317-40,1,2018-01-31,2018-01-31,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,"The Heart Centre, Rigshospitalet","Adrenaline versus amiodarone for out of hospital cardiac arrest due to shockable rhythms (ventricular fibrillation and pulseless ventricular tachycardia) - ADRAMIO. A randomized, double blind, multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004317-40,0,0,0 2013-004319-33,1,2014-11-20,2014-11-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase 2b, Randomized, Double blind, Placebo-controlled, Parallel group, Multicentre Dose finding Study to evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphatemia in End-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004319-33,0,0,0 2013-004320-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CARLOS SANTOS VILLAR,A ONE YEAR STUDY ON THE USE OF TRANEXAMIC ACID IN BENIGN PROSTATIC HYPERPLASIA SURGERY ESTUDIO PILOTO A UN AÑO DEL USO DEL ACIDO TRANEXAMICO EN CIRUGIA DE HIPERPLASIA BENINGNA DE PROSTATA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004320-11,0,0,0 2013-004321-83,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut Català d'Oncologia (ICO),A randomised phase III trial comparing a strategy based on molecular analysis to the empiric strategy in patients with carcinoma of an unknoun primary (CUP) Ensayo Clínico Aleatorizaco de Fase III ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004321-83,0,0,0 2013-004322-28,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),ReVAch : Test pharmacologique de réactivité vasculaire pulmonaire endothéliale dépendante à l'acétylcholine dans l'hypertension artérielle pulmonaire avec shunt cardiaque congénital de l'enfant et de ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004322-28,0,0,0 2013-004323-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación PETHEMA para el tratamiento de la leucemia y el linfoma,Single nucleotide polymorphism association with response and toxic effects in patients with Ph+ CP-CML treated with bosutinib after relapse or intolerance to previous treatment. Estudio de correlac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004323-37,0,0,0 2013-004324-11,2,2019-01-15,2019-01-15,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,Stichting NVALT studies,Phase II study with oral fibroblast growth factor-1 inhibitor BIBF1120 as second line treatment in lung carcinoma patients harboring fibroblast growth factor receptor-1 gene amplification (NVALT-15 st...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004324-11,1,0,0 2013-004325-91,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,NOVARTIS FARMA S.p.A,"Multicenter, prospective, open-label, controlled, randomized, parallel groups study to evaluate the renal function of adult liver transplant recipients treated with two everolimus-based immunosuppress...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004325-91,0,0,0 2013-004328-12,3,2021-07-01,2021-07-01,1,1,0,0,0,1,2,0,0,2,0,0,0,0,1,GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH,Prospective validation of a predictive model of response to romiplostim in patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia - the EUROPE-trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004328-12,1,0,0 2013-004332-29,1,2015-11-10,2015-11-10,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,UZLeuven,The influence of erythromycin and bitter administration on ad libitum food intake in healthy volunteers and patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004332-29,0,0,0 2013-004333-33,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Imperial College London,"Phase 1 of dose escalation of extracorporeal shockwave treatment only and in combination DPP-4 inhibitor and parathyroid hormone (non-randomised, open-labelled) & Phase II of combination treatments of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004333-33,0,0,0 2013-004338-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHRU De Lille,Phase II study evaluating the interest of Vismodegib as neo-adjuvant treatment of basal cell carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004338-13,0,0,0 2013-004341-17,2,2020-12-17,2020-12-17,1,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Pharmacyclics LLC,"A Multicenter Open-Label Phase 1b/2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse La...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004341-17,1,0,0 2013-004342-42,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Medisch Centrum Alkmaar,The effect of fish oil supplements on hemorheological parameters and walking distance in patients with intermittent claudication Het effect van visolie supplementen op hemorheoligische factoren en ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004342-42,0,0,0 2013-004343-23,1,,,0,1,0,1,0,1,1,0,0,1,1,1,0,1,1,"INSTITUTO GRIFOLS, S.A.","Studio per indagare le proprietà farmacocinetiche (per vedere quanto è attivo il farmaco di studio nel sangue e quanto tempo ci vuole per il farmaco di studio per uscire dal sangue), l'efficacia e la ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004343-23,0,0,0 2013-004353-24,1,2017-03-03,2017-03-03,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Universität Leipzig,Wound Management in Post-Bariatric Surgery Investigation for the reduction of the mean drainage volume in patients after abdominoplasty / lower body lift using Artiss Fibrin Sealant in comparison to t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004353-24,0,0,0 2013-004355-20,1,2017-01-13,2017-01-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal Brompton and Harefield NHS Foundation Trust,"Randomised, controlled crossover trial to evaluate the Effects of Ambulatory Oxygen on health status in patients with Fibrotic Lung Disease (FLD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004355-20,0,0,0 2013-004358-12,1,,,0,0,0,0,1,0,4,0,0,1,1,1,0,1,0,"Gentofte Hospital, Dep. of Medicine","Nurse Administered Propofol Sedation vs. Midazolam- with Fentanyl-sedation for Flexible Bronchoscopy: A randomized, Single Blind, Controlled Study of Safety and Satisfaction. Nurse Administered P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004358-12,0,0,0 2013-004359-18,1,2018-05-25,2018-05-25,1,0,0,1,0,1,1,0,0,1,1,1,0,0,0,University College London (UCL) hereby represented by UCL Comprehensive Clinical Trials Unit(CCTU),RegenVOX: Phase I/IIa clinical trial of stem cell based tissue engineered partial laryngeal implants in adult patients with end-stage laryngotracheal stenosis with 24 months follow-up,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004359-18,0,0,0 2013-004362-34,13,2021-02-26,2021-02-26,11,1,0,0,0,1,0,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A MULTINATIONAL, MULTICENTER STUDY TO ASSESS THE EFFECTS OF ORAL SILDENAFIL ON MORTALITY IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004362-34,0,0,0 2013-004366-34,2,2014-06-20,2016-01-13,2,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Medizinische Universität Wien,Neutralizing Antibody Titers 6 Years after the Third Dose of Inactivated Japanese Encephalitis Vaccine and Projected Duration of Protection Neutralisierende Antikörpertiter 6 Jahre nach der dritte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004366-34,0,0,0 2013-004368-74,1,2020-01-29,2020-01-29,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,OxThera Intellectual Property AB,A phase 2 open-label multi-centre study to evaluate the efficacy and safety of Oxabact® to reduce plasma oxalate in patients with primary hyperoxaluria who are on dialysis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004368-74,0,0,0 2013-004370-10,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Grupo Español de Sindromes Mielodisplásicos (GESMD),A phase II study of ruxolitinib (INCB018424) to evaluate efficacy and safety in Patients with Proliferative Chronic Myelomonocytic Leukemia (CMML) Estudio en fase II para evaluar la eficacia y la s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004370-10,0,0,0 2013-004371-12,8,2016-05-18,2016-11-11,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Daiichi Sankyo Development Limited,"Phase 3, Randomized, Placebo-Controlled, Double-blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) in Combination with Erlotinib in EGFR Wild-type Subjects with Locally Advanced or Metastatic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004371-12,0,0,0 2013-004375-12,1,2017-01-10,2017-01-10,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Center of Mech-Sense,"TODINELI Trial A randomized, double-blinded, single-centre, parallel-group, placebo-controlled, prospective trial of the neuroprotective effect of Liraglutide for treatment of diabetic neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004375-12,0,0,0 2013-004376-35,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,0,Hellenic Cardiovascular Research Society,"A Single Center, Phase II, Assessor-Blinded, RaNdomized, Active Controlled, Parallel-Group Trial to COmpare Ticagrelor Versus Clopidogrel on the REduction of ArteriaL STiffness and Wave Reflections in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004376-35,0,0,0 2013-004380-31,2,2018-09-05,2018-09-05,1,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Cell Medica Inc.,A Phase 2 open label study to investigate the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive extranodal NK/T-cell lymphoma (ENKTCL).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004380-31,0,0,0 2013-004383-62,1,2015-01-20,2015-01-20,1,0,0,0,0,1,3,0,0,1,1,1,1,0,1,Green Cross Corporation,An open label Safety and Efficacy extension study of GreenGene™ F in Previously Treated Patients Diagnosed with Severe Hemophilia A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004383-62,0,0,0 2013-004384-31,7,2017-05-01,2017-05-01,3,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Sucampo Pharma Americas LLC,"A Multicentre, Long-term Safety, Efficacy and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged ?6 to <18 years with Functional Constipation Estudio multicéntrico a largo plazo so...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004384-31,1,0,0 2013-004384-31,7,2017-05-01,2017-05-01,3,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Sucampo AG,"A Multicentre, Long-term Safety, Efficacy and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged ?6 to <18 years with Functional Constipation Estudio multicéntrico a largo plazo so...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004384-31,1,0,0 2013-004384-31,7,2017-05-01,2017-05-01,3,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Sucampo Pharma Americas, LLC","A Multicentre, Long-term Safety, Efficacy and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged ?6 to <18 years with Functional Constipation Estudio multicéntrico a largo plazo so...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004384-31,1,0,0 2013-004385-34,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Institut régional du Cancer - Montpellier - Val d'Aurelle,Activity of Regorafenib in combination with modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in patients with advanced Biliary Tract Cancer (BTC): A Phase Ib-II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004385-34,0,0,0 2013-004391-35,3,2016-11-25,2016-11-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Puma Biotechnology Inc.,A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophospham...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004391-35,0,0,0 2013-004392-12,7,2015-09-03,2015-09-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and safety of semaglutide once weekly versus insulin glargine once daily as add on to metformin with or without sulphonylurea in insulin-naïve subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004392-12,0,0,0 2013-004394-27,3,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,HOVON Foundation,Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004394-27,0,0,0 2013-004396-12,1,,,0,1,0,0,0,1,3,0,0,1,1,1,0,1,0,Azienda Ospedaliero-Universitaria Meyer,"Efficacy of ketamine in refractory convulsive status epilepticus in children: a multicenter, randomized, controlled, open-label, no-profit, with sequential design study. Efficacia della ketamina n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004396-12,0,0,0 2013-004397-99,1,2016-06-30,2016-06-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Instituto Tecnológico PET, S.A.U. (ITP)","A Phase III Clinical Trial to evidence the safety and efficacy of the radio-drug 18f-Fluorocholine (18F-FCH), using Positron Emission Tomography (PET) for the diagnosis of the prostate carcinoma in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004397-99,0,0,0 2013-004398-28,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Medical Research Council Clinical Trials Unit at UCL,A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004398-28,0,0,0 2013-004398-28,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Tata Memorial Centre for India,A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004398-28,0,0,0 2013-004398-28,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University College London (UCL),A phase III double-blind placebo-controlled randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004398-28,0,0,0 2013-004404-19,1,2015-04-25,2015-04-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hull and East Yorkshire Hospitals NHS Trust,"A Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of 28 Day Treatment with Fostair® pMDI 200/12 on biomarkers of platelet adhesion in Patients with Idiopathic pulmon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004404-19,0,0,0 2013-004405-30,1,2018-06-21,2018-06-21,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,Arno Therapeutics Inc,A Phase 1 Study of Onapristone in Patients with Advanced Castration-resistant Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004405-30,0,0,0 2013-004406-25,1,2018-05-28,2018-05-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Faculdade de Ciências Médicas da Universidade Nova de Lisboa,Biomarkers identification of anti-TNF α agent’s efficacy in Ankylosing Spondylitis patients using a transcriptome analysis and mass spectrometry,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004406-25,0,0,0 2013-004411-53,1,2016-03-16,2016-03-16,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,University of Leuven,Brain mechanisms underlying the effect of the motilin receptor agonist erythromycin on hunger in normal weight subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004411-53,0,0,0 2013-004412-22,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,UCR Uppsala Clinical Research Center,"TRIAL OF CAFFEINE TO ALLEVIATE DYSPNEA RELATED TO TICAGRELOR (TROCADERO) A double-blinded, placebo-controlled, randomized, multicenter, development phase II study Studie för att undersöka om k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004412-22,0,0,0 2013-004418-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital,Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological rationale for the optimal selection of treatment regimens.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004418-17,0,0,0 2013-004420-11,1,2018-01-19,2018-01-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,KU Leuven - UZ Leuven,Azithromycin for acute COPD exacerbations with hospitalisation: the BACE trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004420-11,0,0,0 2013-004422-29,6,2016-11-21,2016-11-21,5,1,1,0,0,1,3,0,0,1,0,0,1,0,1,"Ionis Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Infantile-onset Spinal Muscul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004422-29,0,0,0 2013-004422-29,6,2016-11-21,2016-11-21,5,1,1,0,0,1,3,0,0,1,0,0,1,0,1,"Isis Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Infantile-onset Spinal Muscul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004422-29,0,0,0 2013-004423-36,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,MSD Italia s.r.l.,"Randomized, parallel group, controlled trial to compare two different “NMB + reversal” strategies in adult obese patients underwent laparoscopic abdominal surgery (Phase 4; Protocol No. MK-8616-104-00...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004423-36,0,0,0 2013-004427-37,1,,,0,0,1,0,0,1,2,0,0,0,0,0,0,0,0,PARENT PROJECT ONLUS,"Multicentre, randomised, double-blind, dose titration design in patients with Duchenne muscular dystrophy to evaluate the efficacy and the tolerability of the combinations of Ibuprofen (200 mg bid) an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004427-37,0,0,0 2013-004429-97,3,2016-12-08,2017-02-17,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004429-97,0,0,0 2013-004430-15,5,2016-10-14,2016-10-14,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Double-Blind, Randomized, Placebo Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects with Implantable Cardioverter-Defibr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004430-15,0,0,0 2013-004435-72,21,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004435-72,0,0,0 2013-004435-72,21,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A. en nombre de F. Hoffmann-La Roche Ltd,AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004435-72,0,0,0 2013-004437-33,1,2019-06-18,2019-06-18,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,Centre Hospitalier de Toulouse,Effets de l'administration intranasale répétée d'ocytocine chez des patients adultes présentant un syndrome de Prader-Willi. Effets de l'administration intranasale répétée d'ocytocine chez des pat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004437-33,0,0,0 2013-004444-31,1,2019-11-04,2019-11-04,1,0,0,0,1,0,4,0,0,1,1,1,1,0,3,,"Effects and consequences for mother and child from treatment for depression A prospective randomized, placebo- controlled, trial with internet-based cognitive behavior therapy and sertraline or plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004444-31,0,0,0 2013-004445-17,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL UNIVERSITARI DE BELLVITGE,"A PROSPECTIVE RANDOMIZED STUDY FOR PREDICTING HUMAN CYTOMEGALOVIRUS (hCMV) INFECTION ACCORDING TO BASELINE hCMV-SPECIFIC T-CELL RESPONSE IN KIDNEY TRANSPLANT PATIENTS ESTUDIO PROSPECTIVO, ALEATORIZ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004445-17,0,0,0 2013-004446-42,1,2016-12-01,2016-12-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Skåne University Hospital,THE IMPORTANCE OF ALBUMIN INFUSION RATE FOR PLASMA VOLUME EXPANSION FOLLOWING MAJOR ABDOMINAL SURGERY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004446-42,0,0,0 2013-004447-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Tays,Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center Randomized Controlled Study Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections with Endoprosth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004447-23,0,0,0 2013-004450-21,1,2017-05-11,2017-05-11,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Merck Serono S.p.A.,"Multicenter, open-label, 12 weeks, phaseIV pRospectivE randomized study aimed at evaLuating whether sc IFN beta 1a (Rebif®) administered In the morning may affEct the severity of Flu-like syndrome and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004450-21,0,0,0 2013-004456-38,1,2015-05-14,2015-05-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Xention Limited,"A double blind, randomised, placebo-controlled, crossover study assessing the use of XEN D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004456-38,0,0,0 2013-004458-34,1,2019-10-17,2019-10-17,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,University of Essen,"A Phase I/II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004458-34,0,0,0 2013-004460-66,1,2016-12-21,2016-12-21,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Jørgen Jeppesen,Oral potassium supplementation in healthy men - interactions with the renin-angiotensin-aldosterone system and the sympathetic nervous system Peroralt kaliumtilskud i raske mænd – interaktioner me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004460-66,0,0,0 2013-004461-13,1,2016-09-26,2016-09-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, two-period crossover study to assess the effect of inhaled QVA149 on global and regional lung function and gas exchange in patients with moderate to sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004461-13,0,0,0 2013-004462-33,1,2014-02-25,2014-02-25,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Professor Jørgen B. Dahl,An estimate of the ED95 of lidocain 1.0% for filling the adductor canal when placing an adductor canal block in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004462-33,0,0,0 2013-004464-54,2,2017-07-07,2017-07-07,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, double-masked, sham-controlled phase 3b/4 study of the efficacy, safety, and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004464-54,0,0,0 2013-004464-54,2,2017-07-07,2017-07-07,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bayer AG,"A randomized, double-masked, sham-controlled phase 3b/4 study of the efficacy, safety, and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004464-54,0,0,0 2013-004466-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hyks Silmätautien klinikka,"The effect of hypertonic saline on blood electrolytes, acid-base balance and hormones that regulate blood pressure Hypertonisen keittosuolaliuoksen vaikutus veren elektrolyytteihin, happoemästasees...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004466-34,0,0,0 2013-004468-69,7,2015-12-18,2016-04-29,5,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Teva Pharmaceutical Industries, Ltd.","A Phase 2, Randomized, Open-Label, Safety and Dose-Finding Study Comparing 3 Different Doses of Weekly TV-1106 and Daily Recombinant Human Growth Hormone (Genotropin®) Therapy in Treatment-Naive, Pre-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004468-69,1,0,0 2013-004469-15,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Rottapharm S.p.A.,"Effect of CCK antagonists in Obstructive Sleep Apnea (OSA) syndrome. A randomized, double-blind, cross-over study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004469-15,0,0,0 2013-004473-28,8,2017-08-16,2018-02-12,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004473-28,0,0,0 2013-004474-96,5,2017-07-20,2017-08-02,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 52-week, double-blind, randomised, multi-centre, parallel-group,Phase III study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort® (budesonide/formoterol) T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004474-96,0,0,0 2013-004475-13,1,2018-09-28,2018-09-28,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Fredericia Hospital,Pharmacological relaxation of the ureter when using access sheaths during ureterorenoscopy Farmakologisk relaksation af ureter under anvendelse af ureteral access sheath i forbindelse med ureterore...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004475-13,0,0,0 2013-004476-36,1,2018-12-06,2018-12-06,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects with Primary Myelofibrosis, Post polycythemia Vera Myelofibrosis, Post essential Thrombocythemia Myelofibrosis,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004476-36,0,0,0 2013-004478-80,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospital Bristol NHS Foundation Trust,XENON AND COOLING THERAPY IN BABIES AT HIGH RISK OF BRAIN INJURY FOLLOWING POOR CONDITION AT BIRTH: A RANDOMISED OUTCOME STUDY (COOLXENON3 STUDY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004478-80,0,0,0 2013-004479-11,1,2021-07-23,2021-07-23,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,DIAKO Ev. Diakonie-Krankenhaus Bremen gGmbH,"Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With 4 Courses of Rituximab SC Followed by 4 Courses of Rituximab SC, 4 Courses of Rituximab SC Combined With...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004479-11,0,0,0 2013-004480-31,1,2021-01-25,2021-01-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Bone Therapeutics S.A.,"A Pilot Phase IIa, Multicentre, Open, Proof-of-concept Study on the Safety and the Efficacy of Allogeneic Osteoblastic Cells (ALLOB®) implantation in Lumbar Spinal Fusion",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004480-31,0,0,0 2013-004481-34,2,2016-10-28,2016-10-28,2,1,0,0,0,1,2,0,0,1,1,1,1,0,0,University of Cologne,"RANDOMIZED PHASE 2 TRIAL COMPARING EXPERIMENTAL IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 S.C.,GM-CSF) IN RECURRENT HIGH RISK NEUROBLASTOMA PATIENTS WITH STANDARD IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004481-34,0,0,0 2013-004482-14,6,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A phase I/II, multicenter, open-label study of EGFRmut?TKI EGF816,administered orally in adult patients with EGFRmut solid malignancies Estudio fase I/II, multicéntrico, abierto del TKI EGF816-EGFR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004482-14,0,0,0 2013-004482-14,6,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A phase I/II, multicenter, open-label study of EGFRmut?TKI EGF816,administered orally in adult patients with EGFRmut solid malignancies Estudio fase I/II, multicéntrico, abierto del TKI EGF816-EGFR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004482-14,0,0,0 2013-004482-14,6,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase I/II, multicenter, open-label study of EGFRmut?TKI EGF816,administered orally in adult patients with EGFRmut solid malignancies Estudio fase I/II, multicéntrico, abierto del TKI EGF816-EGFR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004482-14,0,0,0 2013-004484-31,1,2016-10-21,2016-10-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Innsbruck / Allg. u. chirug. Intensivmedizin,Rivaroxaban and PCC: Prothrombin Complex Concentrate in patients with bleeding complications related to Rivaroxaban Eine prospektive klinische Pilotstudie zur Untersuchung der Wirksamkeit von Proth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004484-31,0,0,0 2013-004488-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Haga Hospital,Targeting Antibiotics to Pseudomonas Aeruginosa in Small airways (TAPAS) study in patients with cystic fibrosis: pharmacokinetics (PK) Targeting van Antibiotica naar Pseudomonas Aeruginosa in de S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004488-30,0,0,0 2013-004489-32,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,CureVac AG,"An open label Randomised Phase II Trial of RNActive® Cancer Vaccine (CV9104) in high risk and intermediate risk patients with prostate cancer Eine unverblindete, randomisierte Phase-II-Studie mit R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004489-32,0,0,0 2013-004493-96,6,2018-12-29,2019-01-29,5,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"CELLTRION, Inc.","A Phase 1/3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, Each...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004493-96,0,0,0 2013-004494-28,11,2018-10-30,2018-10-30,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004494-28,0,0,0 2013-004494-28,11,2018-10-30,2018-10-30,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004494-28,0,0,0 2013-004495-34,1,2017-06-30,2017-06-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Public Health England,"A randomised controlled trial comparing two pertussis-containing vaccines in pregnancy and vaccine responses in UK mothers and their infants (immunising Mums Against Pertussis, iMAP2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004495-34,0,0,0 2013-004496-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Jules Bordet,Study of the (intravenously injected) ICG distribution in tumour bearing breasts and in axillary pieces of dissection of patients who have received neo-adjuvant therapy for histologically proven mamma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004496-12,0,0,0 2013-004497-10,8,2017-02-15,2017-02-15,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Celltrion, Inc.","A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess the Safety of CT-P13 Compared to Remicade in Patients With Active Crohn´s Disease E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004497-10,0,0,0 2013-004498-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Jules Bordet,Near-Infrared fluorescence imaging during neck dissection in head and neck cancer patients after intravenous injection of Indocyanine Green (a feasibility study) Imagerie en fluorescences infraro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004498-29,0,0,0 2013-004501-12,1,2014-10-01,2014-10-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Departement of Anesthesiology, Næstved Hospital",Effect of a lateral nerve of the thigh block on postoperative pain after total hip replacement surgery: a clinical radomised trial. Effekt af nervus cutaneus femoris lateralis-blokade på postopera...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004501-12,0,0,0 2013-004502-26,2,2015-11-21,2015-11-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and safety of semaglutide once-weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004502-26,0,0,0 2013-004503-39,9,2022-07-18,2022-07-18,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"Instituto Grifols, S.A.","A multicenter, prospective, randomized, placebo-controlled, double-blind, parallel-group clinical trial to assess the efficacy and safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004503-39,1,0,0 2013-004505-14,1,2018-09-21,2018-09-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Oslo University Hospital HF, Ullevål Hospital, FORMI-Formidlingsenheten for muskel- og skjelettlidelser",Antibiotic treatment in patients with chronic low back pain and Modic Changes: a double-blind randomized placebo-controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004505-14,0,0,0 2013-004508-21,11,2018-11-14,2018-11-14,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER INC,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004508-21,0,0,0 2013-004508-21,11,2018-11-14,2018-11-14,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004508-21,0,0,0 2013-004508-21,11,2018-11-14,2018-11-14,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004508-21,0,0,0 2013-004512-22,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,Tays,"Treatment of keloidscars with intralesional triamcinolone and 5-fluorouracil injections - prospective, randomized, controlled trial- pilot stydy Keloidiarpien hoito triamsinolonilla ja 5-fluorouras...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004512-22,0,0,0 2013-004516-21,5,2016-03-14,2016-03-14,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Immunomedics, Inc.","An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with Metastatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004516-21,0,0,0 2013-004519-28,1,2015-05-07,2015-05-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,A phase II trial to evaluate the anti-psoriatic efficacy and tolerability of tazarotene in a gel formulation in patients with mild to moderate nail psoriasis - parallel group comparison,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004519-28,0,0,0 2013-004524-11,1,2015-05-14,2015-05-14,1,1,0,0,1,0,4,0,1,1,0,0,1,0,1,Proctor and Gamble Technical Centres Ltd,"A 2-arm, randomised, single - (investigator) blind, controlled, parallel design study in common cold sufferers experiencing cough and nasal congestion to assess the effects of Vicks® VapoRub® (VVR) on...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004524-11,0,0,0 2013-004525-84,9,2018-10-23,2018-10-23,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"CELLTRION, Inc.","A Phase 3, Double-Blind, Randomized, Parallel-Group, Active-Controlled Study to Compare the Efficacy and Safety of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients with HER2-Posit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004525-84,0,0,0 2013-004526-28,1,,,0,1,0,0,0,1,3,0,0,1,1,1,0,1,0,"National Institutes of Health/National Heart, Lung and Bood Institute","A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Ha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004526-28,0,0,0 2013-004527-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medizinische Universität Graz / Endokrinologie und Stoffwechsel,"An open, non-randomized, single-center pilotstudy investigating the feasibility of determining the endogenous glucose production during a hypoglycaemic clamp in type 1 diabetes mellitus subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004527-36,0,0,0 2013-004529-99,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Bionorica SE,"A double-blind, controlled, parallel-group, randomized, multicenter clinical trial to assess the efficacy and safety of a herbal drug containing centaury, lovage root, and rosemary leaf (CLR) in compa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004529-99,0,0,0 2013-004532-30,3,2019-05-07,2019-05-07,1,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Merz Pharmaceuticals GmbH,"Prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004532-30,1,1,0 2013-004533-32,2,2018-09-04,2018-09-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biogen Idec Research Limited,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of BG00012 in Subjects From the Asia Pacific Region and Other Countries With Relapsing-Remitting Multiple Scleros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004533-32,0,0,0 2013-004535-72,1,2015-09-19,2015-09-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Tallaght Hospital, Dublin 24, Ireland","A prospective, single-centre, cohort study to determine the pharmacokinetic and pharmacodynamic parameters of teicoplanin in adult patients with haematological malignancy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004535-72,0,0,0 2013-004538-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Azienda Ospedaliera Universitaria Integrata Verona,Identification of a specific systemic transcriptome able to differentiate patients with renal transplantation in chronic treatment with tacrolimus from those with mTOR inhibitors. Identificazione ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004538-14,0,0,0 2013-004539-57,1,2015-02-05,2015-02-05,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,ALIO MEDICA Sp. z o.o.,"A phase III, double-blind, placebo-controlled, randomized, three-arm parallel, study assessing efficacy and safety of 4 months of diosmin administration for the treatment of lower extremity teleangiec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004539-57,0,0,0 2013-004544-32,1,2014-06-19,2014-06-19,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Celltrion, Inc","Randomized, double-blind, placebo-controlled, single-centre, phase IIa study in healthy volunteers to evaluate the efficacy and safety of CT-P27 in an influenza challenge model",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004544-32,0,0,0 2013-004548-44,3,2015-07-08,2015-07-08,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared with Vilanterol Inhalation Powder (VI) 25 mcg Once Daily ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004548-44,0,0,0 2013-004551-20,8,2016-03-07,2016-05-13,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004551-20,0,0,0 2013-004551-20,8,2016-03-07,2016-05-13,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004551-20,0,0,0 2013-004552-38,4,2015-09-17,2015-09-17,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Array Biopharma Inc.,"A Phase II, Multi-center, Open-label Study of sequential LGX818/MEK162 combination followed by a Rational Combination With targeted agents After Progression, to overcome resistance in Adult Patients W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004552-38,1,0,0 2013-004552-38,4,2015-09-17,2015-09-17,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Array BioPharma Inc.,"A Phase II, Multi-center, Open-label Study of sequential LGX818/MEK162 combination followed by a Rational Combination With targeted agents After Progression, to overcome resistance in Adult Patients W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004552-38,1,0,0 2013-004552-38,4,2015-09-17,2015-09-17,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,NOVARTIS FARMA S.p.A.,"A Phase II, Multi-center, Open-label Study of sequential LGX818/MEK162 combination followed by a Rational Combination With targeted agents After Progression, to overcome resistance in Adult Patients W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004552-38,1,0,0 2013-004555-21,7,2017-01-25,2017-02-15,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"CELLTRION, Inc.","A Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10, Rituxan and MabThera in Patients with Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004555-21,0,0,0 2013-004556-38,9,2015-04-20,2016-03-01,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Tetraphase Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Levofloxacin in Complicated Urinary Tract Infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004556-38,0,0,0 2013-004561-13,5,2020-10-26,2020-10-26,2,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Isis Pharmaceuticals, Inc",An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004561-13,1,0,0 2013-004561-13,5,2020-10-26,2020-10-26,2,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Ionis Pharmaceuticals, Inc",An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004561-13,1,0,0 2013-004562-33,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTI FISIOTERAPICI OSPITALIERI,"PHASE II STUDY TO EVALUATE SAFETY AND EFFICACY OF A BIO-RIASSORBABLE SUBCUTANEOUS IMPLANT OF AFAMELANOTIDE IN HAILEY-HAILEY DISEASE (HHD) PATIENTS Studio, di fase II, per valutare la sicurezza e l’...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004562-33,0,0,0 2013-004564-55,2,2014-12-16,2014-12-16,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,MEDITOP Gyógyszeripari Kft,"A randomized, multicenter, double-blind, placebo controlled, parallel study to assess the efficacy and safety of the combined administration of sertraline and lamotrigine in subjects with chronic low ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004564-55,1,0,0 2013-004565-14,2,2016-10-07,2016-10-07,1,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Edimer Pharmaceuticals, Inc.",Extension Study of XLHED-Affected Male Subjects treated with EDI200 in Protocol ECP-002,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004565-14,1,0,0 2013-004567-30,3,2015-04-15,2015-04-15,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,A single arm open label study to evaluate the pharmacodynamics and safety of a 4 wk treatment with BI 144807 in patients with newly diagnosed wet age related macular degeneration (wAMD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004567-30,0,0,0 2013-004567-30,3,2015-04-15,2015-04-15,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,A single arm open label study to evaluate the pharmacodynamics and safety of a 4 wk treatment with BI 144807 in patients with newly diagnosed wet age related macular degeneration (wAMD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004567-30,0,0,0 2013-004569-16,6,2016-06-18,2016-06-18,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety, and Efficacy of Etanercept Manufactured Using the High Capacity Process Administered to Subjects with Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004569-16,0,0,0 2013-004569-16,6,2016-06-18,2016-06-18,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety, and Efficacy of Etanercept Manufactured Using the High Capacity Process Administered to Subjects with Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004569-16,0,0,0 2013-004571-12,1,2017-04-30,2017-04-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Inserm-ANRS,Evaluation of the pharmacokinetic properties and the tolerance of raltegravir during the third trimester of pregnancy Evaluation des propriétés pharmacocinétiques et de la tolérance du raltégravir...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004571-12,0,0,0 2013-004575-13,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"Dipartimento di Scienze Cardiologiche, Toraciche e Vascolari-Università di Padova","A prospective, randomized clinical trial comparing Rivaroxaban vs warfarin in high risk patients with antiphospholipid syndrome (TRAPS). Studio clinico prospettico, randomizzato di confronto tra Ri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004575-13,0,0,0 2013-004579-11,8,2018-04-09,2018-04-09,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca,"A Randomised, Double-blind, Double Dummy, Chronic Dosing (56 week) Placebo-controlled, Parallel group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of 3 Doses of Benralizumab (MED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004579-11,0,0,0 2013-004581-34,8,2016-11-02,2016-11-02,6,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"PTC Therapeutics, Inc.",A Phase 3 Efficacy and Safety Study of Ataluren (PTC124®) in Patients with Nonsense Mutation Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004581-34,1,0,0 2013-004582-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Department of Anesthesiology and Perioperative Medicine,Haemodynamic effects of xenon or sevoflurane anesthesia on microcirculation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004582-14,0,0,0 2013-004583-56,1,2016-05-25,2016-05-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MSD,"Golimumab: A Phase 4, UK Open Label, Single arm Study on its Utilization and Impact in Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004583-56,0,0,0 2013-004586-13,2,,,0,1,0,0,0,0,4,0,1,1,1,0,0,1,1,GlaxoSmithKline Biologicals,"A phase IV, open-label, multi-centre study to assess the long-term persistence of hepatitis A and B antibodies in healthy adult subjects, primed 16 to 20 years earlier with GSK Biologicals’ combined h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004586-13,0,0,0 2013-004586-13,2,,,0,1,0,0,0,0,4,0,1,1,1,0,0,1,1,GlaxoSmithKline Biologicals s.a.,"A phase IV, open-label, multi-centre study to assess the long-term persistence of hepatitis A and B antibodies in healthy adult subjects, primed 16 to 20 years earlier with GSK Biologicals’ combined h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004586-13,0,0,0 2013-004587-65,2,2018-04-17,2018-04-17,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Novartis Farma,"A phase Ib/II study of LEE011 in combination with fulvestrant and BYL719 or BKM120 in the treatment of postmenopausal women with hormone receptor positive, HER2 negative locally recurrent or advanced ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004587-65,0,0,0 2013-004587-65,2,2018-04-17,2018-04-17,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Novartis Pharma Services AG,"A phase Ib/II study of LEE011 in combination with fulvestrant and BYL719 or BKM120 in the treatment of postmenopausal women with hormone receptor positive, HER2 negative locally recurrent or advanced ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004587-65,0,0,0 2013-004588-30,2,2015-03-13,2015-03-13,1,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"NPS Pharmaceuticals, Inc.","A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year through 17 Years, with Short Bowel Syndrome who are Dependent on Parenteral Support",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004588-30,1,0,0 2013-004589-32,1,2018-03-01,2018-03-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Southampton,Bath Additives for the Treatment of cHildhood Eczema (BATHE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004589-32,0,0,0 2013-004590-27,9,2018-04-10,2018-04-10,7,1,1,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca,"Randomised, double-blind, 56 week placebo-controlled, parallel group, multicentre, phase 3 study to evaluate the efficacy and safety of 2 doses of benralizumab in patients with moderate to very severe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004590-27,0,0,0 2013-004593-95,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación ACE,Evaluating the effectiveness of the use of intravenous infusions of adenosine triphosphate (ATP) in patients with moderate Alzheimer's Disease and severe: Double-blind dose finding clinical trial. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004593-95,0,0,0 2013-004595-35,4,2017-08-31,2017-08-31,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Bayer AG,"Multi-center phase 2 study to assess the safety, tolerability and early signs of efficacy of tid orally administered BAY63-2521 in adult deltaF508 homozygous Cystic Fibrosis patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004595-35,0,0,0 2013-004595-35,4,2017-08-31,2017-08-31,3,1,0,0,0,2,2,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"Multi-center phase 2 study to assess the safety, tolerability and early signs of efficacy of tid orally administered BAY63-2521 in adult deltaF508 homozygous Cystic Fibrosis patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004595-35,0,0,0 2013-004596-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Azienda ospedaliera universitaria Ospedali Riuniti,HOME INFUSION THERAPY WITH ILOPROST USING A PORTABLE SYRINGE PUMP FOR THE TREATMENT OF PERIPHERAL ULCERS AND RAYNAUD'S PHENOMENON IN SYSTEMIC SCLEROSIS. SOMMINISTRAZIONE DOMICILIARE DI ILOPROST ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004596-12,0,0,0 2013-004599-36,1,2017-06-22,2017-06-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sterna biologicals GmbH & Co. KG,"SB012 for the treatment of active ulcerative colitis (SECURE): a prospective, multi-centre, randomised, double-blind, placebo-controlled phase IIa clinical trial to evaluate the efficacy, pharmacokine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004599-36,0,0,0 2013-004600-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Azienda Ospedaliera Fatebenefratelli e Oftalmico - Milano, Italy","Multicenter, interventional, single-arm, phase IV study evaluating tolerability of Eribulin and its relationship with a set of polymorphisms in an unselected population of female patients with metasta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004600-19,0,0,0 2013-004604-19,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Heinrich-Heine-Universität Düsseldorf,Delayed Gadolinium-enhanced Magnetic resonance Imaging (MRI) of Cartilage - A pilot study to measure the effect of Adalimumab plus Methotrexat (MTX) versus Placebo plus MTX on cartilage in early rheum...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004604-19,0,0,0 2013-004605-38,2,2016-09-20,2016-09-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of non-alcoholic fatty liver disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004605-38,0,0,0 2013-004606-26,1,2022-02-01,2022-02-01,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,"Med. Uni. Wien, Klinik f. Innere Med. I",Exploratory study investigating ocular blood flow in colorectal cancer patients before and after treatment with anti-angiogenic therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004606-26,0,0,0 2013-004607-39,1,2017-07-25,2017-07-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,CUB Hopital Erasme,Safety of preoperative administration of hemin to reduce the risk of acute kidney injury after on-pump cardiac surgery: a pilot randomised study in double blind.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004607-39,0,0,0 2013-004612-22,1,2014-12-06,2014-12-06,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Immune Targeting Systems Ltd,"A randomised, double-blind, placebo-controlled study to assess the safety, tolerability, efficacy and immunogenicity of an influenza A vaccine (Vaccine FP-01.1) in healthy volunteers following virus c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004612-22,0,0,0 2013-004614-18,6,2020-07-07,2020-07-07,4,1,1,0,0,0,1,0,0,2,1,0,0,0,1,Basilea Pharmaceutica International Ltd,An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Ceftobiprole in Neonate and Infant Subjects Aged up to 3 Months Undergoing Treatment with Systemic Antibiotics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004614-18,1,1,0 2013-004614-18,6,2020-07-07,2020-07-07,4,1,1,0,0,0,1,0,0,2,1,0,0,0,1,Basilea Pharmaceutica International Ltd.,An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Ceftobiprole in Neonate and Infant Subjects Aged up to 3 Months Undergoing Treatment with Systemic Antibiotics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004614-18,1,1,0 2013-004615-45,3,2020-03-16,2020-03-16,2,1,1,0,2,0,3,0,0,2,0,0,0,0,1,Basilea Pharmaceutica International Ltd,"A multicentre, randomized, investigator-blind, active-controlled study to evaluate the safety, tolerability, pharmacokinetics and efficacy of ceftobiprole versus intravenous standard-of-care cephalosp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004615-45,1,1,0 2013-004615-45,3,2020-03-16,2020-03-16,2,1,1,0,2,0,3,0,0,2,0,0,0,0,1,Basilea Pharmaceutica International Ltd.,"A multicentre, randomized, investigator-blind, active-controlled study to evaluate the safety, tolerability, pharmacokinetics and efficacy of ceftobiprole versus intravenous standard-of-care cephalosp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004615-45,1,1,0 2013-004616-21,1,2016-02-12,2016-02-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsklinikum Münster,"A 32-week, monocentric, exploratory, single arm study to assess immune function and MRI disease activity in patients with relapsing remitting multiple sclerosis (RRMS) transferred from previous treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004616-21,0,0,0 2013-004619-31,15,2016-05-05,2016-07-18,15,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Astellas Pharma Europe Ltd.,"A phase IIIb/IV randomized, controlled, open label, parallel group study to compare the efficacy of vancomycin therapy to extended duration fidaxomicin therapy in the sustained clinical cure of Clostr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004619-31,0,0,0 2013-004620-10,1,2016-10-18,2016-10-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Johan Hellgren,"A double blind, placebo controlled randomized study of nasal steroid spray treatment on the quality of life and objective sleep parameters in children with sleep disorder breathing. En dubbelblind,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004620-10,0,0,0 2013-004622-29,7,2015-11-19,2016-06-17,5,1,0,0,0,0,4,0,1,1,1,0,1,0,1,Biogen Idec Research Limited,"A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004622-29,0,0,0 2013-004623-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Ziekenhuis Oost-Limburg,"Topical application of tranexamic acid compared to the intravenous administration in total hip arthroplasty with the direct anterior approach. A prospective, randomized, clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004623-36,0,0,0 2013-004625-81,4,2016-01-22,2016-01-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT PATIENTS WITH MILD TO MODERATE ASTHMA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004625-81,0,0,0 2013-004626-28,1,2019-06-13,2019-06-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Turku University Hospital,Does targeting of S1P receptors reduce microglial activation in multiple sclerosis? Mikroglian aktivaatio MS-taudissa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004626-28,0,0,0 2013-004629-96,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Department of Nuclear Medicine, Odense University Hospital",Diagnostic Modalities in Nuclear Medicine in Well-Differentiated Thyroid Cancer Diagnostiske modaliteter indenfor nuklearmedicin ved differentieret thyroideacancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004629-96,0,0,0 2013-004630-14,1,2015-03-13,2015-03-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A 12 Week, Randomized, Open-Label, Parallel Group Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) Spiromax(160/4.5 and 320/9 mcg) as Compared to SYMBICORT® TURBOHALER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004630-14,0,0,0 2013-004631-77,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medizinische Universität Graz/Endokrinologie und Stoffwechsel,Exercise and Blood Glucose Levels in Patients with Type I Diabetes - a Pilot Study Blutzuckereinstellung bei Diabetes mellitus Typ I in Abhängigkeit von unterschiedlichen Belastungen - eine Pilots...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004631-77,0,0,0 2013-004632-30,2,2016-02-11,2016-02-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered via...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004632-30,0,0,0 2013-004635-69,1,2019-10-25,2019-10-25,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,VU University Medical Center,A phase II study of obinutuzumab monotherapy in rituximab-refractory follicular lymphoma Obinutuzumab monotherapie voor rituximab-refractair folliculair lymfoom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004635-69,0,0,0 2013-004636-29,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,KU Leuven - Drug Delivery & Disposition,Supersaturation and precipitation of diclofenac in the stomach of healthy human volunteers Supersaturatie en precipitatie van diclofenac in de maag van gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004636-29,0,0,0 2013-004637-33,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Laboratorios Farmalider S.A.,"Clinical trial phase III, multicenter, randomised, double-blind, double-dummy, parallel treatment design, active-controlled and placebo, to evaluate the analgesic efficacy and safety of ibuprofen argi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004637-33,0,0,0 2013-004642-41,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,University Hospital Southampton NHS Foundation Trust,Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004642-41,0,0,0 2013-004644-28,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,"RWTH Aachen University, represented by the Rector, himself, represented by the Dean of the Medical Faculty",Administration of Rifaximin to improve Liver Regeneration and Outcome following Major Liver Resection Verabreichung von Rifaximin zur Verbesserung der Leberfunktion und des Ausgangs einer großen Le...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004644-28,0,0,0 2013-004646-42,1,2015-12-01,2015-12-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Q-MED AB,"A randomized, evaluator-blinded, comparative study to evaluate the efficacy and safety of different injection volumes of botulinum toxin type A, Azzalure®, in the glabellar lines.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004646-42,0,0,0 2013-004649-18,1,2017-09-01,2017-09-01,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Jens Hilligsø,The effect of phrenic nerve block on postoperative shoulder pain in patients for liver resection – a double blinded randomised controlled trial. Effekten af nervus phrenicus blok som postoperativ s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004649-18,0,0,0 2013-004650-25,5,2016-11-22,2016-11-22,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Alexion Pharmaceuticals Incorporated,"A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multi-Center Study of Eculizumab for the Prevention of Delayed Graft Function after Kidney Transplantation in Adult Subjects at Increase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004650-25,0,0,0 2013-004653-25,1,2019-11-30,2019-11-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Repha GmbH,Clinical trial for examination of efficacy and safety of ANGOCIN® Anti-Infekt N versus placebo in the continous prophylaxis of chronically recurring uncomplicated cystitis Klinische Prüfung zur Unt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004653-25,0,0,0 2013-004654-13,8,2016-04-10,2016-04-11,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,"An Open-Label, Single-arm Extension Study to Evaluate the Long-term Safety and Efficacy of ABP 501 in Subjects with Moderate to Severe Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004654-13,0,0,0 2013-004655-21,1,2017-06-28,2017-06-28,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Kern Pharma S.L.,New Dosing Systems in Paediatrics. Application to the individualization of the dose of fentanyl in neonatal patients. Nuevos Sistemas de Dosificación en Pediatría. Aplicación a la individualizació...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004655-21,0,0,0 2013-004656-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Prof. Dr. Karl-Heinz Emmerich,Assessment of the suitability of serum VEGF level as diagnostic factor in macula edema caused by retinal or central retinal vein occlusion under therapy with Lucentis® (ranibizumab) Bewertung der E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004656-38,0,0,0 2013-004657-24,1,2018-03-05,2018-03-05,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Southampton University,"A randomised, double-blind, placebo controlled, feasibility study exploring the role of Chinese herbal medicine in the treatment of women with recurrent urinary tract infections.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004657-24,0,0,0 2013-004659-19,9,2016-10-19,2016-10-19,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Bayer Healthcare AG, D-51368 Leverkusen, Germany","Randomized, double-blind, placebo-controlled, multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004659-19,0,0,0 2013-004659-19,9,2016-10-19,2016-10-19,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Bayer AG,"Randomized, double-blind, placebo-controlled, multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004659-19,0,0,0 2013-004659-19,9,2016-10-19,2016-10-19,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Bayer AG,"Randomized, double-blind, placebo-controlled, multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004659-19,0,0,0 2013-004662-33,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,A Randomized Phase 3 Study of LY2835219 plus Best Supportive Care versus Erlotinib plus Best Supportive Care in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed After P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004662-33,0,0,0 2013-004664-58,4,2017-05-02,2017-05-02,3,0,0,0,0,1,3,0,0,1,1,1,1,0,0,"Paediatric Pulmonary Service, Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark","RANDOMIZED CONTROLLED TRIAL (RCT) TO DETERMINE THE EFFICACY AND SAFETY OF AZITHROMYCIN (AZN) MAINTENANCE THERAPY FOR 6 MONTHS IN SUBJECTS WITH PCD - A DOUBLE-BLIND, PARALLEL GROUP STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004664-58,0,0,0 2013-004666-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University of Debrecen, Medical and Health Science Center, Department of Anaesthesiology and Intensive Therapy","Reversal of vecuronium induced residual neuromuscular block using sugammadex: a prospective, dobule-blind, randomized, controlled, dosefinding study A vecuronium reziduális hatásának felfüggesztése...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004666-34,0,0,0 2013-004668-71,5,2020-06-26,2020-06-26,5,1,0,0,0,1,3,0,0,1,0,0,1,0,0,University College London,An Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004668-71,0,0,0 2013-004669-15,3,2017-05-31,2017-05-31,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Circassia Limited,An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years after the Administration of Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004669-15,0,0,0 2013-004671-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Leuven,Predictive value of biomarkers in patients with amnestic mild cognitive impairment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004671-12,0,0,0 2013-004672-35,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,"Cook Myosite, Incorporated",A Prospective Nonrandomized Study of Autologous Muscle Derived cell (AMDC) Transplantation for Treatment of Fecal Incontinence,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004672-35,0,0,0 2013-004674-97,10,2017-08-25,2017-08-25,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004674-97,0,0,0 2013-004679-11,5,2016-03-09,2016-03-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc,"A Randomized, Double-blind Pharmacokinetic Study of PF-05280014 Plus Taxotere and Carboplatin Versus Herceptin Plus Taxotere And Carboplatin For The Neoadjuvant Treatment Of Patients With Operable HER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004679-11,0,0,0 2013-004682-14,4,2014-12-23,2014-12-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Omthera Pharmaceuticals, Inc.","A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004682-14,0,0,0 2013-004686-14,1,2015-03-04,2015-03-04,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,LEO Pharma A/S,LEO 90100 aerosol foam compared to calcipotriol plus betamethasone dipropionate gel in subjects with psoriasis vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004686-14,0,0,0 2013-004688-30,4,2016-02-11,2016-02-23,2,1,0,0,0,0,4,0,0,1,1,0,1,0,1,H. Lundbeck A/S,"Interventional, open-label study of 18 mg Selincro® as needed use, in the treatment of patients with alcohol dependence in primary care",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004688-30,0,0,0 2013-004698-29,7,2016-04-15,2016-04-15,6,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Threshold Pharmaceuticals, Inc.","A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination with TH-302 vs. Pemetrexed in Combination with Placebo as Second-line Chemotherapy for Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004698-29,1,0,0 2013-004704-19,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King's College London,"Globifer Forte® Oral Haem and Non-haem Iron Supplementation in Heart Failure: A Randomised, DoubleBlind, Placebo Controlled, Double Dummy, Part Mechanistic.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004704-19,0,0,0 2013-004704-19,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King's College Hospital NHS Foundation Trust,"Globifer Forte® Oral Haem and Non-haem Iron Supplementation in Heart Failure: A Randomised, DoubleBlind, Placebo Controlled, Double Dummy, Part Mechanistic.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004704-19,0,0,0 2013-004705-59,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Hôpital Erasme, ULB",Monocentric phase III clinical trial using citalopram (antidepressive compound fequently used in clinic) added to the standard of care (radio- combined with temozolomide chemotherapy and followed by t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004705-59,0,0,0 2013-004706-25,1,2015-11-01,2015-11-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Edinburgh (ACCORD),A Feasibility study looking at the use of Glibenclamide and metfoRmin versus stAndard Care in gEstational diabeteS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004706-25,0,0,0 2013-004706-25,1,2015-11-01,2015-11-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Lothian (ACCORD),A Feasibility study looking at the use of Glibenclamide and metfoRmin versus stAndard Care in gEstational diabeteS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004706-25,0,0,0 2013-004708-20,1,2016-07-29,2016-07-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College London,A placebo controlled single centre double blind randomised trial to investigate the efficacy of rifaximin versus placebo in improving systemic inflammation and neutrophil malfunction in patients with ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004708-20,0,0,0 2013-004708-20,1,2016-07-29,2016-07-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,A placebo controlled single centre double blind randomised trial to investigate the efficacy of rifaximin versus placebo in improving systemic inflammation and neutrophil malfunction in patients with ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004708-20,0,0,0 2013-004709-17,1,,,0,0,0,0,0,0,2,0,1,1,1,1,0,1,0,Rigshospitalet,"Effect of High-dose Naloxone Infusion on Pain and Hyperalgesia in Inguinal Post-herniotomy Patients – A Randomized, Placebo-controlled, Double-blind Study Effekt af Høj-dosis Naloxon Infusion på sm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004709-17,0,0,0 2013-004711-50,12,2020-04-30,2021-02-07,4,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Astellas Pharma Europe Ltd,"A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004711-50,1,0,0 2013-004714-18,4,2016-12-17,2016-12-17,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Incyte Corporation,"A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004714-18,0,0,0 2013-004719-32,1,2014-06-11,2014-06-11,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Mundipharma Research Ltd,"A single (assessor) - blind, randomised, three-period, cross-over study to compare the safety of flutiform® pMDI, fluticasone pMDI and beclometasone Autohaler® in paediatric subjects aged 5 to less ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004719-32,0,0,0 2013-004720-11,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"ALK-Abelló, S.A.",An open trial to assess the tolerability of AVANZ® Cupressus immunotherapy Ensayo abierto para evaluar la tolerabilidad de la inmunoterapia con AVANZ® Cupressus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004720-11,0,0,0 2013-004724-11,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Karolinska Institute,"Surgical treatment of peri-implantitis with and without systemically adjunctive antibiotics A prospective, open, randomized, three armed, parallel, placebo controlled clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004724-11,0,0,0 2013-004726-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Allergy Centre,Double-blind randomised controlled study to down regulate allergic responses in adults with allergic rhinoconjunctivitis by using three intralymphatic injections of grass and/or birch allergen one mon...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004726-28,0,0,0 2013-004728-13,10,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without Abemaciclib, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004728-13,0,0,0 2013-004728-13,10,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Lilly S.A.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without Abemaciclib, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004728-13,0,0,0 2013-004735-68,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Azienda Ospedaliero Universitaria Careggi, Firenze",Short-Term Effect of Levodropropizine on Respiratory Centre Output in Normal Subjects and Patients with Intractable Chronic Cough,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004735-68,0,0,0 2013-004737-33,1,2017-10-30,2017-10-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Hôpitaux Universitaires de Strasbourg,"A prospective, multicenter, randomized, open-label study of 12 week duration to evaluate the effect of VILDagliptin added to insulin on glycaemic control in haemoDIALyzed patients with type 2 diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004737-33,0,0,0 2013-004739-55,6,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,NOVARTIS PHARMA SERVICES AG,"A randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients with iron o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004739-55,0,0,0 2013-004739-55,6,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,"A randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance, efficacy and safety of an improved deferasirox formulation (granules) in pediatric patients with iron o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004739-55,0,0,0 2013-004741-16,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Ana de Pedro Muñoz,Effect of preoperatory administration of submucous tramadol on the success rate of inferior alveolar nerve block on mandibular molars with irreversible pulpitis Efecto de la administración preopera...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004741-16,0,0,0 2013-004742-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Kern Pharma S.L.,New Dosing Systems in Paediatrics. Application to the individualization of the dose of fentanyl in patients between 1 month and 16 years of age. Nuevos Sistemas de Dosificación en Pediatría. Aplic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004742-41,0,0,0 2013-004743-23,1,2016-08-26,2016-08-26,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Hull and East Yorkshire Hospital Trust,A randomised controlled trial to assess the clinical and cost effectiveness of pre-operative skin cleansing with chlorhexidine and povidone-iodine in preventing surgical site infection and establish t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004743-23,0,0,0 2013-004747-23,1,2015-05-29,2015-05-29,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Bionor Pharma ASA,"An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization using Vacc-4x + rhuGM-CSF, and HIV-1 Reactivation using Romidepsin, on the Viral Reservoir in Virologicall...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004747-23,0,0,0 2013-004749-18,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Karolinska University Hospital,Home abortion up to 10 weeks of gestation Abort i hemmet upp till graviditetsvecka 10,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004749-18,0,0,0 2013-004750-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rode Kruis Ziekenhuis,"Omega-3 fatty acids in bariatric gastric bypass surgery: effects on liver volume, immune response and erythrocyte function Visolie bij een maagverkleining: het effect op de grootte van de lever, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004750-24,0,0,0 2013-004755-21,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CHU de Bordeaux,Multicenter double-blind randomized clinical trial assessing efficacy and safety of exenatide in the treatment of hypothalamic obesity after craniopharyngioma therapy. Essai multicentrique randomis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004755-21,0,0,0 2013-004766-34,7,2019-12-04,2020-12-04,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004766-34,0,0,0 2013-004766-34,7,2019-12-04,2020-12-04,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.p.A.,"A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004766-34,0,0,0 2013-004766-34,7,2019-12-04,2020-12-04,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004766-34,0,0,0 2013-004768-72,10,2020-11-26,2020-11-26,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer AG,"A randomized, double-blind, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of two different doses of vilaprisan (BAY 1002670) versus placebo in women with symptomatic end...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004768-72,0,0,0 2013-004768-72,10,2020-11-26,2020-11-26,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,BAYER HEALTHCARE AG,"A randomized, double-blind, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of two different doses of vilaprisan (BAY 1002670) versus placebo in women with symptomatic end...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004768-72,0,0,0 2013-004769-15,1,2018-12-17,2018-12-17,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Augenheilkunde",fMRI analysis of the visual cortex in neovascular Age-related Macular Degeneration fMRT Analyse des visuellen Kortex bei neovaskulärer altersbedingter Makuladegeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004769-15,0,0,0 2013-004770-10,3,2018-01-31,2018-01-31,2,1,0,1,0,0,1,0,0,1,0,0,0,0,0,International Breast Cancer Study Group (IBCSG),"A phase Ib/II trial evaluating the efficacy of MK-3475 and trastuzumab in patients with trastuzumab-resistant, HER2-positive metastatic breast cancers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004770-10,0,0,0 2013-004773-27,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Children's Oncology Group,Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004773-27,0,0,0 2013-004776-35,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Radboud University Medical Centre Nijmegen,Cross-sectional study of 24-hour ambulatory blood pressure measurements and left ventricular mass using echocardiograms in late adolescents and adults with ADHD (ADDUCE protocol WP8 (cardiovascular)),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004776-35,0,0,0 2013-004778-84,2,,,0,1,0,0,0,0,3,0,1,1,1,1,0,1,1,GlaxoSmithKline,"A Phase IIIb, open-label, multi-centric study to evaluate the immunogenicity of one dose of GSK Biologicals? MenACWY-TT conjugate vaccine administered intramuscularly in healthy adolescents aged 10 to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004778-84,0,0,0 2013-004778-84,2,,,0,1,0,0,0,0,3,0,1,1,1,1,0,1,1,GlaxoSmithKline Biologicals,"A Phase IIIb, open-label, multi-centric study to evaluate the immunogenicity of one dose of GSK Biologicals? MenACWY-TT conjugate vaccine administered intramuscularly in healthy adolescents aged 10 to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004778-84,0,0,0 2013-004779-11,4,2015-07-31,2015-07-31,4,1,1,0,0,1,3,0,0,1,0,0,1,0,1,"rEVO Biologics, Inc.","A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients with Inhibitors to Factor VIII or IX",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004779-11,0,0,0 2013-004781-34,1,2017-01-23,2017-01-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AbbVie Farmacéutica S.L.U.,Rapidity of onset of response to Adalimumab in luminal Crohn's disease. RAPIDA study. Rapidez en el inicio de la respuesta a Adalimumab en pacientes con enfermedad de Crohn luminal. Estudio Rápida,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004781-34,0,0,0 2013-004782-14,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,"Medizinische Universität Wien, KIMIII, Abteilung für Endokrinologie und Stoffwechsel",Assessment of changes in metabolic activity in liver & skeletal muscle in patients suffering from acromegaly - a 31P/1H magnetic resonance spectroscopy pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004782-14,0,0,0 2013-004787-62,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"SOD Anestesia e Terapia Intensiva, DAI Oncologia, AOU Careggi, Firenze",Evaluation of muscle function recovery after deep neuromuscular blockade by acceleromyography of the adductor pollicis or diaphragmatic echography: comparison between sugammadex and neostigmine V...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004787-62,0,0,0 2013-004791-35,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Novo Nordisk A/S’,Efficacy and safety of turoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated Chinese patients with haemophilia A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004791-35,0,1,1 2013-004795-35,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Chimerix, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004795-35,0,0,0 2013-004796-12,1,2020-02-19,2020-02-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AIO-Studien-gGmbH,"Prospective Randomized Multicenter Phase II Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Prospektive, randomisierte Phase-II Studie zur intensivie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004796-12,0,0,0 2013-004798-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,"The effects of propranolol on fear of tooth or molar removal: A randomized, placebo-controlled, double-blind, parallel design trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004798-29,0,0,0 2013-004805-14,1,2017-10-17,2017-10-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Medical Center Groningen,Vitamin K antagonist (VKA)versus New Oral Anticoagulants (NOACs) in patients with currently well controlled VKA therapy for non-valvular atrial fibrillation: a pilot study Vitamine K antagonisten (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004805-14,0,0,0 2013-004808-19,3,2018-04-04,2018-09-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CFZ533 in patients with primary Sjög...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004808-19,0,0,0 2013-004809-24,1,,,0,0,0,0,0,0,4,0,1,3,0,0,0,0,0,Guy's & St. Thomas' NHS Foundation Trust,The role of Home packs of HIV Post-Exposure Prophylaxis for sexual exposure (PEPSE) to improve the speed and appropriate uptake of PEPSE in high risk individuals,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004809-24,0,0,0 2013-004810-16,5,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Taiho Oncology Inc,A dose-finding Phase 1 study of TAS-120 in patients with advanced solid tumors with or without Fibroblast Growth Factor/Receptor (FGF/FGFR)-related abnormalities followed by a Phase 2 study in patien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004810-16,0,0,0 2013-004810-16,5,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"Taiho Pharma USA, Inc.",A dose-finding Phase 1 study of TAS-120 in patients with advanced solid tumors with or without Fibroblast Growth Factor/Receptor (FGF/FGFR)-related abnormalities followed by a Phase 2 study in patien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004810-16,0,0,0 2013-004812-24,5,2016-04-05,2016-04-08,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Incyte Corporation,"A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer Estudio de Fase 2, ale...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004812-24,0,0,0 2013-004813-41,17,2016-10-20,2016-10-20,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Italia S.p.A.,A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004813-41,0,0,0 2013-004813-41,17,2016-10-20,2016-10-20,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004813-41,0,0,0 2013-004813-41,17,2016-10-20,2016-10-20,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm. V,A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004813-41,0,0,0 2013-004813-41,17,2016-10-20,2016-10-20,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim bv,A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004813-41,0,0,0 2013-004813-41,17,2016-10-20,2016-10-20,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim France,A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004813-41,0,0,0 2013-004813-41,17,2016-10-20,2016-10-20,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Finland Ky,A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004813-41,0,0,0 2013-004813-41,17,2016-10-20,2016-10-20,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Boehringer Ingelheim España, S.A.",A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004813-41,0,0,0 2013-004813-41,17,2016-10-20,2016-10-20,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim AB,A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004813-41,0,0,0 2013-004813-41,17,2016-10-20,2016-10-20,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004813-41,0,0,0 2013-004813-41,17,2016-10-20,2016-10-20,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Danmark A/S,A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004813-41,0,0,0 2013-004813-41,17,2016-10-20,2016-10-20,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim KS,A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004813-41,0,0,0 2013-004813-41,17,2016-10-20,2016-10-20,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.",A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004813-41,0,0,0 2013-004813-41,17,2016-10-20,2016-10-20,15,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim Limited,A Phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0g idarucizumab (BI 655075) in patients treated wtih dabigatran ete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004813-41,0,0,0 2013-004816-22,4,2015-02-02,2015-02-02,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA S.p.A,"The ReTreatment Trial: A phase II, open-label, single-arm study of re-treating myelofibrosis patients with ruxolitinib/Jakavi after treatment interruption due to loss of response and/or adverse event",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004816-22,0,0,0 2013-004816-22,4,2015-02-02,2015-02-02,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"The ReTreatment Trial: A phase II, open-label, single-arm study of re-treating myelofibrosis patients with ruxolitinib/Jakavi after treatment interruption due to loss of response and/or adverse event",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004816-22,0,0,0 2013-004816-22,4,2015-02-02,2015-02-02,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","The ReTreatment Trial: A phase II, open-label, single-arm study of re-treating myelofibrosis patients with ruxolitinib/Jakavi after treatment interruption due to loss of response and/or adverse event",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004816-22,0,0,0 2013-004819-40,1,2015-09-11,2015-09-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Double-blind, Placebo Controlled, 2-arm, Parallel-group, 26-week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004819-40,0,0,0 2013-004826-27,1,2014-10-14,2014-10-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A phase II, multicentre, double blind, randomised, 5-way cross-over study to test the non-inferiority of the acute bronchodilator effect of CHF 1535 200/6 µg NEXThaler® versus CHF 1535 100/6 µg NEXTh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004826-27,0,0,0 2013-004830-14,1,2016-08-25,2016-08-25,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Ultragenyx Pharmaceutical Inc.,An Open-Label Phase 2 Study to Assess Safety and Clinical Effects of UX007 in Subjects with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004830-14,0,0,0 2013-004834-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,"Treatment of port wine stains using Pulsed Dye Laser, Erbium Yag Laser and topical sirolimus in an open label pilot study (POLAR). Behandeling van wijnvlekken met behulp van de Pulsed Dye Laser, de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004834-14,0,0,0 2013-004835-60,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rijnstate Hospital,Vitamin Deficiencies and Supplementation in Morbidly obese Vitamine Deficiënties en Suppletie bij Morbide Obesen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004835-60,0,0,0 2013-004836-31,1,2016-02-29,2016-02-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Montavit Ges.m.b.H.,"Double-blind, randomised, placebo-controlled study evaluating the efficacy and safety of Tavipec capsules in acute Bronchitis A prsopective, multi-centre, parallel group, interventional clinical phase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004836-31,0,0,0 2013-004837-34,1,2019-08-08,2019-08-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,"Lung HeXeRT: Advanced proton, hyperpolarised 3helium and 129xenon magnetic resonance imaging for lung cancer radiotherapy planning and evaluation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004837-34,0,0,0 2013-004838-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Mª Carmen Fariñas Álvarez. Hospital Universitario Marques de Valdecilla,"Intestinal colonization by multiresistant enterobacteria in patients with kidney and liver transplantation: multicentre cohort study and randomized, controlled, open clinical trial. Colonización in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004838-15,0,0,0 2013-004842-40,1,,,0,1,0,0,0,1,4,0,0,1,0,0,0,1,1,Instituto Grifols S.A.,Pilot study to evaluate the effect of plasma exchange in motor and cognitive function in patients with amyotrophic lateral sclerosis Estudio piloto sobre los efectos del recambio plasmático en la d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004842-40,0,0,0 2013-004850-97,1,2021-11-23,2021-11-23,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Cancer Trials Ireland,A Phase II Study of Radium-223 in Combination with Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004850-97,0,0,0 2013-004851-19,1,2017-06-16,2017-06-16,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"ACORN Research, LLC",A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004851-19,0,0,0 2013-004854-46,1,2019-05-01,2019-05-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Herlev University Hospital,"Randomized 1. Line treatment with gemcitabine, capecitabine, oxaliplatin vs gemcitabin and cisplatin to patients with cholangiocarcinoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004854-46,0,0,0 2013-004858-18,1,2019-07-02,2019-07-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Vejle Hospital,Tocotrienol as a nutritional supplement in patients with advanced ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004858-18,0,0,0 2013-004860-78,1,2015-02-23,2015-02-23,1,0,0,0,1,0,3,0,0,1,1,1,1,0,1,G. Pohl-Boskamp GmbH & Co. KG,"A randomised, active-controlled, observer-blind, non-inferiority study to investigate the efficacy, safety and tolerability of a local treatment with dimeticone-based pediculicides in head lice infest...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004860-78,0,0,0 2013-004862-32,1,,,0,0,0,0,0,1,2,0,1,0,0,0,0,0,0,Istituto Europeo Oncologia,A Randomized Phase II Trial of Low Dose Aspirin versus Placebo in High-Risk Individuals with CT Screen Detected Subsolid Lung Nodules.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004862-32,0,0,0 2013-004863-30,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Università Campus Bio-Medico di Roma,EVALUATION OF EFFECT OF MAGNESIUM SULFATE ADDED TO THE ropivacaine for the sciatic nerve block at popliteus Valuatazione dell'effetto dell'aggiunta del Magnesio Solfato alla ropivacaina nel blocco ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004863-30,0,0,0 2013-004864-69,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Fundació Sant Joan de Deu de Barcelona,Phase II single arm institutional study to assess Dinutuximab combined with the cytokines granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-2 in patients with high-risk neuroblastoma no...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004864-69,0,0,0 2013-004866-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Göteborgs Universitet,"A short term open, randomized cross over trial trial exploring the effect of carbonic anhydrase inhibition by acetazolamide on sleep apnea associated hypertension Blodtryckssänkande effekten av ka...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004866-33,0,0,0 2013-004867-29,8,2017-09-25,2017-09-25,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,An open-label canakinumab (ACZ885) dose reduction or dose interval prolongation efficacy and safety study in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Een open-label studie met ca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004867-29,0,0,0 2013-004867-29,8,2017-09-25,2017-09-25,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.p.A.,An open-label canakinumab (ACZ885) dose reduction or dose interval prolongation efficacy and safety study in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Een open-label studie met ca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004867-29,0,0,0 2013-004867-29,8,2017-09-25,2017-09-25,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.",An open-label canakinumab (ACZ885) dose reduction or dose interval prolongation efficacy and safety study in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Een open-label studie met ca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004867-29,0,0,0 2013-004875-12,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Fakultní nemocnice Ostrava,Application of PRP (plattelet rich plasma) to the lateral epicondyle of the humerus Aplikace PRP (plattelet rich plasma) k laterálnímu epikondylu humeru,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004875-12,0,0,0 2013-004876-37,2,2016-03-09,2016-03-09,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Pharmaleads SA,"A 4 week phase 2a, multicentre, randomised, double-blind, placebo-controlled add-on study into safety, tolerability and efficacy of 200 mg t.i.d. of PL37 in patients with peripheral neuropathic pain ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004876-37,0,0,0 2013-004879-13,1,2017-05-30,2017-05-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Freiburg,α-RT; Phase II open-label study to evaluate the efficacy and safety of Radium-223 dichloride in combination with external beam radiotherapy (EBRT) vs. EBRT alone in the treatment of advanced castrati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004879-13,0,0,0 2013-004881-33,2,2018-12-31,2018-12-31,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Universitätsklinikum Würzburg,"Pharmacovigilance in children and adolescents: clinical trial protocol, subproject 1: Large Simple Trial, IIIb on the (off-label-) use of antidepressants and antipsychotics Pharmakovigilanz in der...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004881-33,0,0,0 2013-004881-33,2,2018-12-31,2018-12-31,2,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Kompetenznetz TDM-KJP e.V.,"Pharmacovigilance in children and adolescents: clinical trial protocol, subproject 1: Large Simple Trial, IIIb on the (off-label-) use of antidepressants and antipsychotics Pharmakovigilanz in der...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004881-33,0,0,0 2013-004882-15,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Universität Leipzig,A multicentre randomized controlled trial evaluating the rate of sustained remission and the safety when stopping nucleos(t)ide analogue treatment in non-cirrhotic HBeAg-negative chronic Hepatitis B p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004882-15,0,0,0 2013-004884-30,1,2020-04-29,2020-04-29,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,BIOPROJET PHARMA,"Randomized double blind parallel groups sequential, placebo controlled, trial assessing the efficacy and safety of BP1.4979 in Resteless Legs Syndrome (RLS).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004884-30,0,0,0 2013-004885-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ospedale Valduce,"The impact of split dosing preparation on adenoma detection rate: a randomized, investigator-blind, controlled trial L'impatto della preparazione a dosi frazionate (split-dose) sull'adenoma detecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004885-32,0,0,0 2013-004886-14,1,2020-07-13,2020-07-13,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,"Dep. Nuclear medicine, Odense university hospital",MET-PET-study - Comparative study of Tc-99m- sestamibi SPECT/ldCT with C-11-L-Methionin PET/diagnostic CT and theri ability to locate paratyroid adenomas preoperatively. MET-PET-studiet - Sammen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004886-14,0,0,0 2013-004888-31,4,2016-07-26,2016-08-03,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"A randomised, double-blind, double-dummy, cross-over multicenter study to demonstrate equivalence in analgesic efficacy and bowel function taking oxycodone equivalents of 120 and 160 mg per day as ach...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004888-31,0,0,0 2013-004890-28,10,2015-12-23,2020-09-08,6,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Daiichi Sankyo Inc.,A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After Fir...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004890-28,1,0,0 2013-004890-28,10,2015-12-23,2020-09-08,6,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Ambit Biosciences Corporation,A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After Fir...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004890-28,1,0,0 2013-004890-28,10,2015-12-23,2020-09-08,6,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Daiichi Sankyo Inc,A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After Fir...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004890-28,1,0,0 2013-004903-37,7,2015-08-19,2016-10-12,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Sunovion Pharmaceuticals Inc.,"A RANDOMIZED, 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, FLEXIBLE DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN CHILDREN AND ADOLESCENT SUBJECTS WITH BIPOLAR I DEPRESS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004903-37,1,1,0 2013-004903-37,7,2015-08-19,2016-10-12,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,SUNOVION PHARMACEUTICALS INC.,"A RANDOMIZED, 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, FLEXIBLE DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN CHILDREN AND ADOLESCENT SUBJECTS WITH BIPOLAR I DEPRESS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004903-37,1,1,0 2013-004905-15,1,2016-04-26,2016-04-26,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"Respiratory Research Unit, Bispebjerg Hospital",Does asthma phenotype have impact on disease control Har astmafænotyperne betydning for sygdomskontrol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004905-15,0,0,0 2013-004908-20,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,UZ Brussel,Cerebral effect of paracetamol measured by f-MRI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004908-20,0,0,0 2013-004910-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Centre Hospitalier régional Universitaire de Besançon,Therapeutic multicentric phase II trial evaluating the efficacy of omalizumab (Xolair ®) in idiopathic refractory severe solar urticaria Essai thérapeutique de phase II multicentrique évaluant l’e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004910-16,0,0,0 2013-004916-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Ospedale San Raffaele,Monotherapy with Ofatumumab for RElapsed/refractory Splenic B-cell marginal zone lymphoma (MORE) Monoterapia con Ofatumumab per pazienti affetti da linfoma marginale splenico in ricaduta/REfrattari...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004916-23,0,0,0 2013-004918-18,2,2020-06-04,2020-06-04,1,0,0,0,0,0,4,0,0,2,1,0,0,0,0,Ghent University Hospital,Optimising adalimumab treatment in psoriasis with concomitant methotrexate.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004918-18,1,0,0 2013-004918-18,2,2020-06-04,2020-06-04,1,0,0,0,0,0,4,0,0,2,1,0,0,0,0,Academic Medical Center,Optimising adalimumab treatment in psoriasis with concomitant methotrexate.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004918-18,1,0,0 2013-004919-43,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"SOD Medicina e Cardiologia Geriatrica, Centro per lo Studio della Sincope - Università degli Studi di Firenze-AOUCareggi",Suspension of vasoactive drugs in reflex vasodepressive syncope: a randomized controlled trial Studio randomizzato controllato sulla sospensione dei farmaci vasoattivi nella sincope riflessa vasode...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004919-43,0,0,0 2013-004920-12,1,2014-03-02,2014-03-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LETI Pharma GmbH,Non-interventional Study in Allergic Patients Suffering from Grass Pollen Induced Rhinitis/Rhinoconjunctivitis with or without Asthma. Retrospective Assessment of the Efficacy of a Perennial Specific ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004920-12,0,0,0 2013-004934-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut klinické a experimentální medicíny,EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY EVEROLIMUS VE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004934-14,0,0,0 2013-004936-31,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,Ministry of Infrastructure and the Environment,Establish limits for fitness to drive with prolonged use of ICADTS class III medication,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004936-31,0,0,0 2013-004939-73,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,KULEUVEN,"A RANDOMISED, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFECT OF LINACLOTIDE ON COLONIC MOTILITY ASSESSED WITH INTRALUMINAL COLONIC MANOMETRY IN HEALTHY SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004939-73,0,0,0 2013-004940-48,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"Danderyds Hospital, Department of Clinical Sciences, Division of Orthopaedics","Denosumab For Treating Periprosthetic Osteolysis After Uncemented Total Hip Arthroplasty. A randomized, double-blind, placebo-controlled trial using volumetric computed tomography.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004940-48,0,0,0 2013-004946-41,1,2021-03-03,2021-03-03,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,KULeuven,"The influence of GLP-1 analog, liraglutide, on gastric accommodation, gastric emptying, hunger and the migrating motor complex in healthy volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004946-41,0,0,0 2013-004952-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Erasmus MC Cancer Institute,Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases The CHARISMA randomized multicenter clinical trial Neo-adjuvant...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004952-39,0,0,0 2013-004953-26,1,2021-01-31,2021-01-31,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Ghent University Hospital,CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004953-26,0,0,0 2013-004954-58,1,,,0,1,0,0,0,0,2,0,1,1,1,1,0,1,0,Bispebjerg University Hospital,Near infrared imaging and measurement of extremity lymphatic collector function using indocyanine green Nær-infrarød billeddannelse og måling af lymfekarrenes funktion i ekstremiteterne med indocya...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004954-58,0,0,0 2013-004955-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Azienda Ospedaliera di Padova,PARACETAMOL VERSUS IBUPROFEN FOR PATENT DUCTUS ARTERIOSUS TREATMENT IN PRETERM INFANTS. PARACETAMOLO VERSUS IBUPROFENE PER IL TRATTAMENTO DEL DOTTO DI BOTALLO PERVIO NEL NEONATO PRETERMINE: Stud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004955-19,0,0,0 2013-004956-39,1,2016-05-18,2016-05-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Klinikum der Universität München,Study to evaluate the impact of donor-specific HLA-antibodies on graft function and survival after renal transplantation - Long term follow up of the SMART study population Studie zur Einschätzung ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004956-39,0,0,0 2013-004958-18,12,2016-06-23,2016-06-23,10,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Amgen, Inc.","A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004958-18,1,1,0 2013-004959-21,2,2015-10-28,2015-10-28,2,1,0,1,0,2,1,0,0,1,0,0,0,0,1,NOVARTIS FARMA S.p.A,"A phase Ib/II, multi-center, study of oral LGH447 in combination with oral BYL719 in patients with relapsed and refractory multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004959-21,0,0,0 2013-004959-21,2,2015-10-28,2015-10-28,2,1,0,1,0,2,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A phase Ib/II, multi-center, study of oral LGH447 in combination with oral BYL719 in patients with relapsed and refractory multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004959-21,0,0,0 2013-004961-14,1,2017-07-27,2017-07-27,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Kliniken Kärnan Urology Centre,Pilot study to investigate the mode of action (MoA) of Uro-Vaxom® on a molecular level in pre-menopausal women suffering from recurrent urinary tract infections (rUTI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004961-14,0,0,0 2013-004966-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZ Brussel,A phase II clinical trial on the combination of dabrafenib and trametinib for BRAF-inhibitor pretreated patients with advanced BRAF V600 mutant melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004966-33,0,0,0 2013-004968-56,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Oxford Clinical Trials & Research Governance,A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/-nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004968-56,0,0,0 2013-004969-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Heidi Mäkinen,Measurement of levels of infliximab and anti-infliximab antibodies in rheumatic patients Infliksimabin jäännöspitoisuuksien ja vasta-aineiden mittaaminen reumatologisilla potilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004969-14,0,0,0 2013-004973-29,7,2015-10-30,2015-11-02,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,"A safety open-label study of Gevokizumab in the treatment of patients with chronic non-infectious Uveitis disease, an eXtension study. The EYEGUARD-X study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004973-29,0,0,0 2013-004973-29,7,2015-10-30,2015-11-02,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Laboratorio Servier S.L.,"A safety open-label study of Gevokizumab in the treatment of patients with chronic non-infectious Uveitis disease, an eXtension study. The EYEGUARD-X study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004973-29,0,0,0 2013-004974-82,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,"PETALS study : PEgylated interferon-alpha2a and TAsigna® for first Line therapy of Philadelphia chromosome-positive chronic phase CML patientS Etude randomisée de phase III, comparant le taux de ré...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004974-82,0,0,0 2013-004977-28,1,2016-08-31,2016-08-31,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,Safety and intake effect of EPs®7630 (an extract from the roots of Pelargonium sidoides),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004977-28,0,0,0 2013-004978-95,1,2021-03-03,2021-03-03,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KULeuven,"the influence of a DPP-4 inhibitor, vildaglitpin, on hunger and the migrating motor complex in healthy volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004978-95,0,0,0 2013-004979-13,1,2016-12-12,2016-12-12,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Rigshospitalet, 2032","Treatment of Preoperative Anaemia in Patients with Urogenital Cancer: A Randomised Double-Blind Placebo-Controlled Study of Intravenous Iron Isomaltide 1000 Monofer© versus Saline Et randomiseret, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004979-13,0,0,0 2013-004984-30,1,2018-05-08,2018-05-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Development Centre Europe Ltd,A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Compl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004984-30,0,0,0 2013-004987-80,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CUB - Hôpital Erasme,"Colistin use in Cystic Fibrosis patients: pharmacokinetic studies (intravenous administration) in relation with pharmacodynamics, tolerance profile and risk of selection of resistance.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004987-80,0,0,0 2013-004988-32,1,,,0,1,0,0,0,1,4,0,0,1,0,0,0,1,0,Erasmus MC,Rotterdam Observational Study in CIDP of Pharmacokinetics of Intravenous γ-globulin Rotterdamse observationele studie bij CIDP naar de farmacokinetiek van intraveneuze γ-globuline,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004988-32,0,0,0 2013-004999-35,3,2015-01-06,2015-02-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Menarini Ricerche S.p.A.,"A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, FOUR PARALLEL ARM, DOSE-FINDING STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE INTRA-ARTICULAR INJECTIONS OF FASIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004999-35,0,0,0 2013-005001-31,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Dra. Carmen Gómez Vaquero (Servicio de Reumatología del Hospital Universiari de Bellvitge - Idibell),Randomized clinical trial on the prevention of radiographic progression with zoledronic acid in patients with early rheumatoid arthritis and low disease activity Ensayo clínico aleatorizado sobre l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005001-31,0,0,0 2013-005003-14,1,2015-05-08,2015-05-08,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Drug Delivery Solutions ApS,"A randomized, multi-centre, observer-blind, controlled exploratory study to assess efficacy and safety of new topical formulations (MC2-01) in patients with plaque psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005003-14,0,0,0 2013-005006-66,1,2014-03-11,2014-03-11,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,Procter and Gamble,"A 2-arm, randomised, single - (Investigator) blind, controlled, parallel design study in common cold sufferers experiencing nasal congestion to assess the speed of action of Vicks® VapoRub® (VVR)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005006-66,0,0,0 2013-005007-13,4,2019-04-25,2019-04-25,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Gilead Sciences Inc.,"A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005007-13,0,0,0 2013-005007-13,4,2019-04-25,2019-04-25,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Sierra Oncology, Inc.","A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005007-13,0,0,0 2013-005008-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Cancer Trials Ireland,"A phase II Study of the Efficacy and Safety of lenalidomide, subcutaneous bortezomib, and dexamethasone combination therapy for patients with newly diagnosed multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005008-32,0,0,0 2013-005009-30,1,2018-02-26,2018-02-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Gloucestershire Hospitals NHS Foundation Trust and,"An open label, randomised controlled feasibility pilot study to evaluate whether nasal fentanyl alone and in combination with buccal midazolam give better symptom control to dying patients when compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005009-30,0,0,0 2013-005010-36,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Thomas Fichtner Bendtsen,"The effect of protracted saphenous nerve and obturator nerve blockade versus saphenous nerve blockade versus local infiltration analgesia in opioid consumption, pain, blockade duration of action and m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005010-36,0,0,0 2013-005013-13,4,2015-10-16,2015-10-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Samsung Bioepis Co., Ltd.","A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity of SB5 Compared to Humira® in Subjects with M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005013-13,0,0,0 2013-005014-34,1,2014-05-12,2014-05-12,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,NOVARTIS FARMA S.p.A.,"A phase II, single arm, open-label, multicenter, study of oral LGX818 in patients with BRAF V600 mutant advanced non-small cell lung cancer that have progressed during or after at least one prior chem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005014-34,0,0,0 2013-005015-28,1,2016-06-13,2016-06-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of four orally administrated doses of BI 409306 during a 12-week treatment period in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005015-28,0,0,0 2013-005017-12,1,2021-05-10,2021-05-10,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Parnassia Bavo Groep - PsyQ,"Looking into the eye of ADHD. Investigating the relationship between ADHD, the delayed circadian rhythm and the functioning of the eye. In het oog van ADHD. Onderzoek naar de relatie tussen ADHD, h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005017-12,0,0,0 2013-005020-42,21,2019-11-19,2019-11-20,20,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Abbvie Deutschland GmbH & Co. KG,"Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005020-42,0,0,0 2013-005024-42,3,2016-06-08,2016-06-08,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Tigercat Pharma, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Study of the Neurokinin-1 Receptor Antagonist VPD-737 in Subjects with Prurigo Nodularis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005024-42,0,0,0 2013-005024-42,3,2016-06-08,2016-06-08,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Menlo Therapeutics, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Study of the Neurokinin-1 Receptor Antagonist VPD-737 in Subjects with Prurigo Nodularis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005024-42,0,0,0 2013-005025-23,1,2019-03-05,2019-03-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Banc de Sang i Teixits (BST),"A phase IIa, unicenter, prospective, randomized, parallel, two-arms, single-dose, open-label with blinded assessor pilot clinical trial to assess ex vivo expanded adult autologous mesenchymal stromal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005025-23,0,0,0 2013-005027-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CASA SOLLIEVO DELLA SOFFERENZA IRCCS,IMPACT OF VITAMIN D SUPPLEMENTATION ON SKELETAL AND NON SKELETAL MANIFESTATIONS IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM SUBMITTED TO PARATHYROIDECTOMY OR FOLLOWED WITHOUT SURGERY Impatto della...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005027-16,0,0,0 2013-005031-24,8,2017-10-09,2017-10-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005031-24,0,0,0 2013-005031-24,8,2017-10-09,2017-10-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005031-24,0,0,0 2013-005031-24,8,2017-10-09,2017-10-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005031-24,0,0,0 2013-005031-24,8,2017-10-09,2017-10-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.","A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005031-24,0,0,0 2013-005031-24,8,2017-10-09,2017-10-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Italia S.p.A.,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005031-24,0,0,0 2013-005031-24,8,2017-10-09,2017-10-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005031-24,0,0,0 2013-005031-24,8,2017-10-09,2017-10-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005031-24,0,0,0 2013-005031-24,8,2017-10-09,2017-10-09,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005031-24,0,0,0 2013-005036-20,1,2016-04-15,2016-04-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Stellaris Pharmaceuticals ApS,Recombinant Factor VIIa: Local treatment of severe postpartum hemorrhage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005036-20,0,0,0 2013-005039-26,1,2019-02-01,2019-02-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Efficacité et tolérance d'un traitement de première intention par tocilizumab dans la maladie de Takayasu: étude française multicentrique prospective. "" TOCITAKA """,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005039-26,0,0,0 2013-005040-28,7,2017-10-09,2017-10-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005040-28,0,0,0 2013-005040-28,7,2017-10-09,2017-10-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005040-28,0,0,0 2013-005040-28,7,2017-10-09,2017-10-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005040-28,0,0,0 2013-005040-28,7,2017-10-09,2017-10-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005040-28,0,0,0 2013-005040-28,7,2017-10-09,2017-10-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Italia S.p.A.,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005040-28,0,0,0 2013-005040-28,7,2017-10-09,2017-10-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.","A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005040-28,0,0,0 2013-005042-11,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,Fundación Investigación Sanitaria en León,EndoTic ? Endothelium and Ticagrelor: Pharmacological effects beyond antiplatelet effect EndoTic ? Endotelio y Ticagrelor: Efectos farmacológicos más allá de la antiagregación,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005042-11,0,0,0 2013-005043-86,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Saint-Etienne,Reactivity of the autonomic nervous system after a nociceptive stress in the newborn: Interest of sucrose and non-nutritive sucking. Réactivité du système nerveux autonome après un stress nocicepti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005043-86,0,0,0 2013-005044-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Consorzio Oncotech,"A randomised, multicentre, open-label Phase II trial investigating activity of chemotherapy and lapatinib and Trastuzumab in patients with HER2-positive metastatic breast cancer (MBC) refractory to an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005044-29,0,0,0 2013-005054-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Ospedale San Raffaele s.r.l.,A mechanistic study to evaluate the effect of Serelaxin on left ventricular function and its correlation with outcome in acute heart failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005054-30,0,0,0 2013-005056-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ghent University Hospital,Longterm efficiency and safety of intravitreal injections with bevacizumab in patients with neovascularisation or macular edema.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005056-15,0,0,0 2013-005062-19,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Medical University of Graz - Division of Endocrinology and Metabolism,An exploratory study to evaluate dermal open flow microperfusion’s (dOFM) ability to assess bioequivalence and non-bioequivalence of topical acyclovir formulations in healthy volunteers Eine explo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005062-19,0,0,0 2013-005065-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medizinische Universität Innsbruck, Universitätsklinik für Innere Medizin I","Concentrations of echinocandins in ascites, pleural effusion, bile, wound secretion and cerebrospinal fluid – a pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005065-38,0,0,0 2013-005075-40,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Research Programs' Unit, Diabetes & Obesity, University of Helsinki","The effect of Liraglutide treatment on postprandial chylomicron and VLDL kinetics, liver fat and de novo lipogenesis. A single-center randomized controlled study. Liraglutidin vaikutus aterian jälk...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005075-40,0,0,0 2013-005077-52,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dra. Antònia Dalmau i Llitjós. Servicio de Anestesia, Reanimación y Terapéutica del Dolor del HUB-Idibell",Double-Blind Randomized Clinical trial to assess the pain reduction in wound healing with previous application of cutaneous lidocaine solution versus placebo ENSAYO CLÍNICO RANDOMIZADO DOBLE CIEGO ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005077-52,0,0,0 2013-005081-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOSPICES CIVILS DELYON,Phase II study evaluating the efficacy of aflibercept for the treatment of idiopathic choroidal neovascularization in young subjects: the INTUITION study Etude INTUITION Etude de phase II évaluant ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005081-19,0,0,0 2013-005083-26,1,2014-06-30,2014-06-30,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Galderma R&D SNC,Effect of CD07805/47 gel in subjects presenting with flushing related to erythematotelangiectatic or papulopustular rosacea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005083-26,0,0,0 2013-005085-19,5,2022-02-07,2022-02-10,3,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are int...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005085-19,1,0,0 2013-005085-19,5,2022-02-07,2022-02-10,3,0,0,0,0,1,2,0,0,2,0,0,0,0,1,NOVARTIS FARMA S.p.A.,"A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are int...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005085-19,1,0,0 2013-005085-19,5,2022-02-07,2022-02-10,3,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"QED Therapeutics, Inc.","A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are int...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005085-19,1,0,0 2013-005086-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Sidney kimmel Comprehensive Cancer Center at Johns Hopkins,"A multi-institutional open label, trial evaluating the efficacy of Gemcitabine and Docetaxel in patients with relapsed or refractory metastatic colorectal adenocarcinoma with methylated CHFR and/or mi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005086-40,0,0,0 2013-005087-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION HOSPITAL DE MADRID,Gemcitabine plus nab-paclitaxel versus folfirinox as neoadjuvant treatment in patients with potentially resectable pancreatic carcinoma. NeoPAN Study Tratamiento Neoadyuvante con gemcitabina mas na...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005087-25,0,0,0 2013-005088-13,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Blocs partiels du droit antérieur et du soléaire avec la toxine botulique de type A (Xeomin®) pour l'amélioration de la marche chez l'hémiparétique. Essai randomisé multicentrique contrôlé contre pla...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005088-13,0,0,0 2013-005090-53,8,2016-10-24,2016-10-24,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, double-blind, double-dummy, parallel- group, multi-center phase IIb study to assess the efficacy and safety of different dose combinations of an aromatase inhibitor and a progestin in an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005090-53,0,0,0 2013-005090-53,8,2016-10-24,2016-10-24,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,"A randomized, double-blind, double-dummy, parallel- group, multi-center phase IIb study to assess the efficacy and safety of different dose combinations of an aromatase inhibitor and a progestin in an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005090-53,0,0,0 2013-005091-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,POLICLINICO GEMELLI,Variation of choroidal Thickness 15 days after the first ranibizumab intravitreal injection in naïve patients WIth Neovascular age-related macular degeneration: pilot Study. –,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005091-17,0,0,0 2013-005095-18,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Institute of Cancer Research,A phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005095-18,0,0,0 2013-005098-28,7,2017-06-12,2018-04-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grifols Therapeutics Inc.,"A multicenter, prospective, open-label, non-controlled clinical trial to assess the efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in patients with Myas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005098-28,0,0,0 2013-005098-28,7,2017-06-12,2018-04-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grifols Therapeutics LLC,"A multicenter, prospective, open-label, non-controlled clinical trial to assess the efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in patients with Myas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005098-28,0,0,0 2013-005098-28,7,2017-06-12,2018-04-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Grifols Therapeutics LLC.,"A multicenter, prospective, open-label, non-controlled clinical trial to assess the efficacy and safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in patients with Myas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005098-28,0,0,0 2013-005099-17,6,2019-02-14,2020-01-13,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Grifols Therapeutics Inc.,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/ Chromatography Purified (lGIV -C) as a Corticosteroid S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005099-17,0,0,0 2013-005099-17,6,2019-02-14,2020-01-13,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Grifols Therapeutics LLC,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/ Chromatography Purified (lGIV -C) as a Corticosteroid S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005099-17,0,0,0 2013-005100-34,1,2018-01-10,2018-01-10,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of VX-970 as a Single Agent in Combination With Carboplatin in Subjects With Advanced Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005100-34,0,0,0 2013-005101-31,14,2020-04-17,2020-04-17,13,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Avillion Development 1 Limited,"A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005101-31,0,0,0 2013-005101-31,14,2020-04-17,2020-04-17,13,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Pfizer Inc,"A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005101-31,0,0,0 2013-005101-31,14,2020-04-17,2020-04-17,13,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005101-31,0,0,0 2013-005104-33,3,2018-02-15,2018-02-15,2,1,0,1,0,0,1,0,0,2,0,0,0,0,1,Alios BioPharma,"A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dosing an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005104-33,1,0,0 2013-005104-33,3,2018-02-15,2018-02-15,2,1,0,1,0,0,1,0,0,2,0,0,0,0,1,"Janssen Research & Development, LLC","A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dosing an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005104-33,1,0,0 2013-005106-64,1,2017-04-30,2017-04-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Innsbruck,Continous wound infiltration after hallux valgus surgery Kontinuierliche Wundinfiltration nach Hallux valgus Operation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005106-64,0,0,0 2013-005107-13,1,,,0,1,0,0,0,0,4,0,0,3,0,0,0,0,0,Epsom and St Helier University Hospitals NHS Trust R&D Dpt,A pilot study of the use of oral modafinil added to standard care in hypercapnic respiratory failure in COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005107-13,0,0,0 2013-005108-32,5,2016-08-09,2017-02-01,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO5520985 (VANUCIZUMAB) PLUS FOLFOX VERSUS BEVACIZUMAB PLUS FOLFOX IN PATIENTS WITH PREVIOUSLY UNTREATED ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005108-32,0,0,0 2013-005109-30,1,2015-05-05,2015-05-05,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Centre Hospitalier Départemental Vendée,L’utilisation de la ropivacaïne facilite-t-elle la cholécystectomie par voie coelioscopique en chirurgie ambulatoire ?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005109-30,0,0,0 2013-005114-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki UNiversity Central Hospital,"Administration of S-ketamine for negative pressure wound therapy dressing change associated pain: a randomized, prospective, placebo-controlled cross-over study S-ketamiini alipaineimulaitteen sid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005114-35,0,0,0 2013-005114-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Central Hospital,"Administration of S-ketamine for negative pressure wound therapy dressing change associated pain: a randomized, prospective, placebo-controlled cross-over study S-ketamiini alipaineimulaitteen sid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005114-35,0,0,0 2013-005116-10,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Dr. Daniel Podzamczer Palter (Unidad de VIH. Servicio de Enfermedades Infecciosas. Hospital de Bellvitge).,Elvitegravir concentrations in seminal plasma in HIV-1 infected patients (?ELVIs Study?) Concentraciones de Elvitegravir en plasma seminal en pacientes infectados por el virus VIH-1 (?Estudio ELVIs...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005116-10,0,0,0 2013-005118-36,2,2014-10-20,2014-10-20,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Chelsea Therapeutics, Incorporated",A clinical study of Patients with symptomatic neurogenic orthostatic HypOtENsion to assess sustaIned effects of droXidopa therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005118-36,0,0,0 2013-005122-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,MDM S.p.A.,"A phase II, randomized, double-blind, parallel groups study to assess the efficacy and safety of Nimodipine 20 mg + Betahistine 16 mg versus Placebo + Betahistine 16 mg in the treatment of vertigo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005122-33,0,0,0 2013-005124-42,1,2015-06-11,2015-06-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lukács és Társa Gyógyszerkereskedelmi Betéti Társaság,"A Phase II/III Adaptive, Seamless, Prospective, Randomized, Controlled, Parallel, Open Multicenter Study to Assess the Safety and Efficacy of Kék Lukács Ointment Compared to Standard Silver Sulfadiazi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005124-42,0,0,0 2013-005127-16,1,2015-12-02,2015-12-02,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,"Instituto Grifols, S.A.","A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis during Peripheral Vascular Surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005127-16,0,0,0 2013-005128-40,1,2015-12-28,2015-12-28,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,"Instituto Grifols, S.A.","A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Parenchymous Tissue Open Surgerie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005128-40,0,0,0 2013-005129-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione Italiana Linfomi,"FASE II STUDY WITH BORTEZOMIB, RITUXIMAB AND BENDAMUSTIN –BRB- FOR NON-HODGKIN LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIA’S PATIENTS AT FIRST RELAPSE STUDIO DI FASE II CON BORTEZOMIB,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005129-22,0,0,0 2013-005130-38,1,2015-10-15,2015-10-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALK-Abello A/S,Evaluation of the efficacy and safety of AVANZ® Phleum pratense in grass pollen-induced allergic rhinitis during controlled exposure in an environmental challenge chamber,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005130-38,0,0,0 2013-005134-38,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,ISTITUTI FISIOTERAPICI OSPITALIERI - IRE,Phase I-II study of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) in combination with liposomal encapsulated doxorubicin (LDox) in patients with HER2 negative metastatic breast c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005134-38,0,0,0 2013-005135-24,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Cristina Fernandez Pérez,Clinical Trial crossed athletic population according UGT2B17 polymorphism. Impact on the steroid profile Ensayo Clinico cruzado en población deportiva segun polimorfismo UGT2B17. Impacto en el perf...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005135-24,0,0,0 2013-005137-20,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician?s Choice Chemotherapy in the Treatment of Metastatic Brea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005137-20,0,0,0 2013-005138-39,2,2019-03-01,2019-03-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005138-39,0,0,0 2013-005155-32,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Sarcomas (GEIS),"A phase 2, single arm, multi center trial evaluating the efficacy of the combination of sirolimus and cyclophosphamide in metastatic or unresectable myxoid liposarcoma and chondrosarcoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005155-32,0,0,0 2013-005155-32,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,"A phase 2, single arm, multi center trial evaluating the efficacy of the combination of sirolimus and cyclophosphamide in metastatic or unresectable myxoid liposarcoma and chondrosarcoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005155-32,0,0,0 2013-005157-75,6,,,0,0,0,0,0,2,2,0,0,2,1,0,0,0,0,HOVON,Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005157-75,0,0,0 2013-005157-75,6,,,0,0,0,0,0,2,2,0,0,2,1,0,0,0,0,HOVON Foundation,Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005157-75,0,0,0 2013-005159-34,1,2015-06-04,2015-06-04,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,"Instituto Grifols, S.A.","A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Soft Tissue Open Surgeries",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005159-34,0,0,0 2013-005161-40,6,2016-07-14,2016-08-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Daiichi Sankyo Development Ltd,"A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005161-40,0,0,0 2013-005162-20,6,2017-01-12,2017-01-12,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Daiichi Sankyo, Inc","A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005162-20,0,0,0 2013-005162-20,6,2017-01-12,2017-01-12,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Daiichi Sankyo, Inc.","A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005162-20,0,0,0 2013-005162-20,6,2017-01-12,2017-01-12,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Daiichi Sankyo Development Ltd,"A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005162-20,0,0,0 2013-005163-10,7,2016-07-07,2016-07-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Daiichi Sankyo Development Ltd,"A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005163-10,0,0,0 2013-005163-10,7,2016-07-07,2016-07-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Daiichi Sankyo, Inc.","A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 in Subjects with Pain Associated with Fibromyalgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005163-10,0,0,0 2013-005164-26,16,2017-04-19,2017-04-19,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Daiichi Sankyo, Inc.",An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated with Fibromyalgia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005164-26,0,0,0 2013-005164-26,16,2017-04-19,2017-04-19,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Daiichi Sankyo Development Ltd,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated with Fibromyalgia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005164-26,0,0,0 2013-005164-26,16,2017-04-19,2017-04-19,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Daiichi Sankyo Inc.,An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated with Fibromyalgia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005164-26,0,0,0 2013-005178-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jules Bordet Institute,Study of the (intravenously injected) Indocyanine Green distribution in the margins of breast cancer after tumorectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005178-23,0,0,0 2013-005179-41,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Fondazione Italiana Linfomi ONLUS (FIL-ONLUS),ROMIDEPSIN IN COMBINATION WITH CHOEP AS FIRST LINE TREATMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN YOUNG PATIENTS WITH NODAL PERIPHERAL T-CELL LYMPHOMAS: A PHASE I-II STUDY. ROMIDEPSINA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005179-41,0,0,0 2013-005199-17,1,2017-01-09,2017-01-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Institut de Recerca HSCSP,Efficacy and safety of topical administration of timolol maleate 0.5% solution in the treatment of Child Proliferative Hemangioma Early Stage Surface. Randomized Controlled Study Eficacia y segurid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005199-17,0,0,0 2013-005201-31,1,2017-01-09,2017-01-09,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Karolinska University Hospital,Pharmacokinetic profile and pharmacodynamic effects after intranasal naloxone administration in volunteers and pediatric patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005201-31,0,0,0 2013-005209-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ghent University Hospital,The effect of Hydroxyethylstarch 6% 130/0.4 in a balanced electrolyte solution (Volulyte®) compared to gelatine (Geloplasma®) on microvascular reactivity and tissue oxygen saturation during haemodilut...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005209-30,0,0,0 2013-005212-98,5,2021-11-24,2021-11-24,2,1,0,1,0,0,1,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH POLYARTICULAR-COURSE AND SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005212-98,1,0,0 2013-005212-98,5,2021-11-24,2021-11-24,2,1,0,1,0,0,1,0,0,2,1,0,0,0,1,Roche Farma S.A. en nombre de F. Hoffmann-La Roche Ltd,LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH POLYARTICULAR-COURSE AND SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005212-98,1,0,0 2013-005222-29,7,2015-11-20,2015-11-20,6,0,0,0,1,0,3,0,0,2,0,0,0,0,1,Laboratoires THÉA,"Efficacy and Safety assessment of fixed combination unpreserved Latanoprost eye drops and Timolol 0.5% (T2347) versus Xalacom® in ocular hypertensive or glaucomatous patients. Phase III, internationa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005222-29,1,0,0 2013-005234-37,4,2016-09-19,2016-09-19,2,1,1,0,0,0,3,0,1,2,0,0,0,0,1,Laboratorios León Farma S.A.,"Multicentre, Open-Label Trial to Assess the Safety and Tolerability of LF111 (Drospirenone 4.0 mg) Over 6 Cycles in Female Adolescents, With a 7-Cycle Extension Phase",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005234-37,1,0,0 2013-005240-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AOU di Bologna, Policlinico S.Orsola-Malpighi","OPEN LABEL, PHASE IIA MULTICENTER STUDY OF DASATINIB IN THE TREATMENT OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL) RELAPSED/REFRACTORY OR NOT AMENABLE TO CONVENTIONAL THERAPY-PTCL-DASA01 Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005240-28,0,0,0 2013-005268-25,3,2015-02-06,2015-02-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CHIESI FARMACEUTICI SPA,"A MULTINATIONAL, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED , 2-WAY CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GLYCOPYRROLATE BROMIDE ADMINISTERED VIA PMDI (CHF 5259), FOR T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005268-25,0,0,0 2013-005269-37,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,St. Antonius Hospital,RITUXIMAB IN LIFE THREATENING THERAPY RESISTANT PROGRESSIVE INTERSTITIAL PNEUMONITIS Rituximab in levensbedreigende en therapie resistente progressieve interstitiële pneumonitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005269-37,0,0,0 2013-005274-22,2,2018-10-02,2018-10-02,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Shionogi & Co., Ltd","A multicenter, open-label, phase 2 study of S-588410 as maintenance monotherapy after first-line platinum-containing chemotherapy in patients with advanced and/or metastatic bladder cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005274-22,0,0,0 2013-005282-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione IRCCS Istituto Nazionale dei Tumori di Milano,Effects of high Intra-abdominal pressure on tissue diffusion and pharmacokinectics of cisplatin during HIPEC Gli effetti dell’alta pressione intra-addominale sulla diffusione tissutale e sulla farm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005282-39,0,0,0 2013-005293-22,1,2016-04-15,2016-04-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 ug, 2 Actuations Twice Daily, and Symbicort pMDI 80/4.5 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005293-22,0,0,0 2013-005305-31,1,2017-08-23,2017-08-23,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Folktandvården Östergötland,Ice as topical anaesthesia before injection in the oral mucosa –a randomized unblinded cross-over study in adolescents. Comparison between ice and lidokain gel 5%. Kyla som ytanestesi före injekti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005305-31,0,0,0 2013-005309-30,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Fondazione IRCCS Istituto Nazionale dei Tumori,"open label, randomized, pilot study on the activity of olanzapine with or without delayed dexamenthasone versus dexamenthasone alone for the prevention of delayed nausea and vomiting in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005309-30,0,0,0 2013-005310-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación en Enfermedades del Aparato Digestivo,"A phase IV double-blind, randomized, placebo-controlled, multi-center study with pancreatic enzyme replacement therapy (PERT) in subjects suffering from pancreatic exocrine insufficiency (PEI) after a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005310-35,0,0,0 2013-005311-27,8,2017-05-18,2017-06-26,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005311-27,0,0,0 2013-005319-28,1,2017-04-28,2017-04-28,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Central and North West London NHS Foundation Trust,Improving GHB withdrawal with baclofen (The GHB Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005319-28,0,0,0 2013-005323-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Pharmacokinetic and pharmacodynamic properties of amlodipine oral solution in the pediatric population Farmacokinetische en farmacodynamische eigenschappen van amlodipine orale oplossing bij de ped...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005323-17,0,0,0 2013-005324-41,2,2016-09-06,2016-09-06,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Genzyme Corporation,"A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Enzyme Replacement Therapy (ERT) Treatment-naïve Adult Male Patients Diagnosed w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005324-41,0,0,0 2013-005325-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Rijnstate Hospital,Short-term Efficacy of Stellate Ganglion Block in Men to reduce Hot Flushes related to Androgen Deprivation Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005325-23,0,0,0 2013-005326-38,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hannover Medical School,"A multicenter, randomized, double-blind, placebo-controlled study to demonstrate that digitoxin reduces a composite of overall mortality and hospitalization for worsening heart failure in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005326-38,0,0,0 2013-005327-16,1,2015-09-16,2015-09-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The University of Edinburgh,A Randomized Open Label Pilot Study to Compare Targinact vs. Oxycodone in Early Return of Gastrointestinal Function after Colorectal Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005327-16,0,0,0 2013-005327-16,1,2015-09-16,2015-09-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,NHS Lothian,A Randomized Open Label Pilot Study to Compare Targinact vs. Oxycodone in Early Return of Gastrointestinal Function after Colorectal Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005327-16,0,0,0 2013-005329-22,1,2017-09-30,2017-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,iOMEDICO AG,"An open label, randomized controlled prospective multicenter two arm phase IV trial to determine Patient preference for everolimus in combination with exemestane or capecitabine in combination with b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005329-22,0,0,0 2013-005333-21,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Novartis Pharma Services AG,"A multiple-dose, double-blind, placebo-controlled, parallel study to assess the efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005333-21,0,0,0 2013-005334-37,1,2016-01-26,2016-01-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Medical University of Vienna / Medizinische Universität Wien,Effects of once-daily administered GLP-1 Receptoragonist Lixisenatide in combination with basal Insulin on glycemic control in patients with type-2 diabetes mellitus not achieving therapeutic targets ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005334-37,0,0,0 2013-005335-25,7,2019-03-06,2019-04-25,5,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Bioven (Europe) Ltd.,"A Phase III, open-label, multicentre, randomised trial to establish safety and efficacy of an EGF cancer vaccine in inoperable, late stage IV biomarker positive, wild type EGF-R, NSCLC patients eligib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005335-25,0,0,0 2013-005336-23,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Oxford,Outcome After Selective Early Treatment for Closure of Patent Ductus Arteriosus in Pre-term Babies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005336-23,0,0,0 2013-005338-39,1,2015-10-02,2015-10-02,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Edinburgh,An assessment of intra-lesional 3% polidocanol solution in the treatment of digital myxoid cysts,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005338-39,0,0,0 2013-005338-39,1,2015-10-02,2015-10-02,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,NHS Lothian,An assessment of intra-lesional 3% polidocanol solution in the treatment of digital myxoid cysts,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005338-39,0,0,0 2013-005343-82,3,2017-08-15,2017-08-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","An Expanded Access Protocol for Idelalisib in Combination with Rituximab for Relapsed, Previously Treated Subjects with Chronic Lymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005343-82,0,0,0 2013-005345-36,1,2015-03-23,2015-03-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Ardelyx, Inc.","An exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel design study to evaluate the safety, tolerability, and pharmacodynamics of AZD1722 in CKD patients with type 2 diabetes m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005345-36,0,0,0 2013-005346-10,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,0,Thomas Fichtner Bendtsen,Shamrock versus Lumbar Ultrasound Trident – Ultrasound guided block of the lumbar plexus Shamrock versus Lumbar Ultrasound Trident – Ultralydvejledt blokade af plexus lumbalis – Metodestudie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005346-10,0,0,0 2013-005348-28,8,2016-10-14,2016-10-14,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Aradigm Corporation,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005348-28,0,0,0 2013-005350-29,1,2015-07-21,2015-07-21,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,Effect of Human Albumin versus crystalloid on coagulation competence during elective urologic surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005350-29,0,0,0 2013-005355-32,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,"National Institute for Public Health and the Environment (RIVM, the Netherlands)",Memory response against Bordetella pertussis in adults: immunological effects of an acellular pertussis booster vaccination Geheugen reactie tegen Bordetella pertussis in volwassenen: immunologisch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005355-32,0,0,0 2013-005357-79,8,2017-02-21,2017-02-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharmaxis Limited,Long Term Administration of Inhaled Mannitol in Cystic Fibrosis – A Safety and Efficacy Trial in Adult Cystic Fibrosis Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005357-79,0,0,0 2013-005357-79,8,2017-02-21,2017-02-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PHARMAXIS LTD,Long Term Administration of Inhaled Mannitol in Cystic Fibrosis – A Safety and Efficacy Trial in Adult Cystic Fibrosis Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005357-79,0,0,0 2013-005362-19,1,2021-08-30,2021-08-30,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Charité - Universitätsmedizin Berlin,Therapy of antibody-mediated autoimmune diseases by Bortezomib (TAVAB) Therapie antikörper-vermittelter Autoimmunerkrankungen durch Bortezomib (TAVAB),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005362-19,0,0,0 2013-005363-52,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"Department of Neurology, Academic Medical Center",Intravenous immunoglobulin overtreatment in chronic inflammatory demyelinating polyneuropathy (CIDP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005363-52,0,0,0 2013-005364-26,1,2018-05-22,2018-05-22,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,University Medical Center of the Johannes Gutenberg University Mainz,"Resolution of Left Atrial-Appendage Thrombus – Effects of Dabigatran in patients with AF (RE-LATED AF) – A Prospective, multicenter, randomized, open-label, controlled, explorative, blinded-endpoint (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005364-26,0,0,0 2013-005365-39,1,2016-02-26,2016-02-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Research in Real-Life Ltd,A guideline approach to therapy step-down utilising Flutiform®: change and step-down (FFLU-X study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005365-39,0,0,0 2013-005366-19,7,2016-10-12,2016-10-12,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Aradigm Corporation,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005366-19,0,0,0 2013-005368-24,1,2016-09-05,2016-09-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"INMUNOTEK, S.L.",Extract allergen from Betula verrucosa. Test sensitivity and specificity of diagnostic in prick test preparation. Extracto alergénico de Betula verrucosa. Ensayo de la sensibilidad y de la especifi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005368-24,0,0,0 2013-005371-40,1,,,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,Szpital im. Jana Pawla II,Medical laser and stem cells in treatment ischemic heart disease Użycie lasera medycznego i komórek macierzystych w leczeniu krańcowej postaci choroby niedokrwiennej serca,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005371-40,0,0,0 2013-005373-43,5,2020-05-28,2020-05-28,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Lumena Pharmaceuticals Inc,"Long-Term, Open-Label Study with a Double-Blind, Placebo Controlled, Randomized Drug Withdrawal Period of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients with A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005373-43,0,0,0 2013-005373-43,5,2020-05-28,2020-05-28,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Mirum Pharmaceuticals, Inc.","Long-Term, Open-Label Study with a Double-Blind, Placebo Controlled, Randomized Drug Withdrawal Period of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients with A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005373-43,0,0,0 2013-005373-43,5,2020-05-28,2020-05-28,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Mirum Pharmaceuticals,Inc.","Long-Term, Open-Label Study with a Double-Blind, Placebo Controlled, Randomized Drug Withdrawal Period of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients with A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005373-43,0,0,0 2013-005373-43,5,2020-05-28,2020-05-28,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Lumena Pharmaceuticals LLC,"Long-Term, Open-Label Study with a Double-Blind, Placebo Controlled, Randomized Drug Withdrawal Period of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients with A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005373-43,0,0,0 2013-005376-17,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,Erasmus Medical Center,Sandostatin therapy in sarcoidosis Sandostatine therapie bij sarcoïdose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005376-17,0,0,0 2013-005381-19,1,2015-11-19,2015-11-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Kitov Pharmaceuticals Ltd,A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects with Hypertension Requiring Antihypertensive Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005381-19,0,0,0 2013-005384-66,1,2016-03-09,2016-03-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Endo Ventures Limited,"A phase 3b, open-label pilot study to evaluate the safety and effectiveness of up to four treatment cycles of AA4500 in combination with the ErecAid® Esteem® Manual Vacuum Therapy System in men with P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005384-66,0,0,0 2013-005387-25,1,,,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,"Sapienza, University of Rome","Phase 2a Study of an Immunotherapeutic Vaccine, DPX-Survivac, Alone or with Low dose Cyclophosphamide in Primary Glioblastoma Patients Receiving Standard of Care Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005387-25,0,0,0 2013-005391-17,1,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,Eisai Limited,An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 4 years of ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005391-17,0,0,0 2013-005393-22,2,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,QLT Inc.,A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransferase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005393-22,0,0,0 2013-005394-45,1,2018-08-07,2018-08-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Inmunotek, S.L.",Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen extract. Determination of the allergenic potency in vivo histamine equivalent units (HEP) Extracto alergénico de Dermatophagoid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005394-45,0,0,0 2013-005395-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Effects of GLP1 agonist liraglutide in patients with antipsychotic-drugs-associated diabetes mellitus Effecten van GLP1-agonist Liraglutide bij patienten met diabetes mellitus ten gevolge van ant...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005395-18,0,0,0 2013-005398-32,1,2017-02-13,2017-02-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Liverpool Women's NHSFT,A randomised controlled trial of sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005398-32,0,0,0 2013-005398-32,1,2017-02-13,2017-02-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Liverpool,A randomised controlled trial of sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005398-32,0,0,0 2013-005399-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Benedicto Crespo. Servicio Psiquiatría. Hospital Universitario Marqués de Valdecilla/IDIVAL,"Randomized, flexible-dose, open-label comparison to investigate the effectivenes of second generation antipsychotics in first episode psychosis patients. Estudio abierto randomizado a dosis flexibl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005399-16,0,0,0 2013-005402-65,1,2016-04-14,2016-04-14,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Institut de Recerca HSCSP,Efficacy and safety of anakinra (antagonist of the interleukin-1 receptor) in the treatment of periarticular inflammation in patients refractory to NSAID and / or steroids Eficacia y seguridad de a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005402-65,0,0,0 2013-005406-54,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Antoni van Leeuwenhoek ziekenhuis,Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2 to standard ipilimumab tr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005406-54,0,0,0 2013-005412-10,10,2016-12-29,2016-12-29,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ocera Therapeutics Inc,"Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (ornithine phenylacetate) in Hospitalized Patients with Cirrhosis and Associated Hyperammonemia with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005412-10,0,0,0 2013-005417-13,1,2015-05-08,2015-05-08,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Hansa Medical AB,"A PHASE II STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF INTRAVENOUS IDES AFTER ADMINISTRATION OF ASCENDING DOSES IN CHRONIC KIDNEY DISEASE PATIENTS Fas II för att ut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005417-13,0,0,0 2013-005418-37,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Philogen S.p.A.,"A multicenter, randomized, double-blind, placebo-controlled phase II study to evaluate safety and clinical efficacy of two different doses of F8IL10 (Dekavil) administered subcutaneously to patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005418-37,0,0,0 2013-005420-42,1,2017-05-19,2017-05-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital Leuven,Is postoperative IUI better than expectant management in infertile endometriosis patients with good prognosis based on EFI score?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005420-42,0,0,0 2013-005426-30,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO PRINCIPE DE ASTURIAS,USE OF NITROUS OXIDE FOR PAIN RELIEF IN DIFFERENT HISTEROSCOPY PROCEDURES UTILIZACIÓN DE ÓXIDO NITROSO PARA ALIVIO DEL DOLOR EN LOS DISTINTOS PROCEDIMIENTOS HISTEROSCÓPICOS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005426-30,0,0,0 2013-005427-16,9,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005427-16,0,0,0 2013-005428-41,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,"Department of experimental and clinical medicine ""F. Magrassi""",Phase III study of RegorAfenib VErsus placebo as maintenance therapy in RAS wiLd type metastatic coLOrectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005428-41,0,0,0 2013-005428-41,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,"Department of experimental and clincial medicine ""F. Magrassi""",Phase III study of RegorAfenib VErsus placebo as maintenance therapy in RAS wiLd type metastatic coLOrectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005428-41,0,0,0 2013-005429-21,4,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Menzies Institute of Medical Research University of Tasmania,Multicentre randomised controlled trial of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation on continuous positive airway pressure (CPAP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005429-21,0,1,0 2013-005429-21,4,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,"Menzies Institute of Medical Research, University of Tasmania",Multicentre randomised controlled trial of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation on continuous positive airway pressure (CPAP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005429-21,0,1,0 2013-005429-21,4,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Menzies Research Institute Tasmania,Multicentre randomised controlled trial of minimally-invasive surfactant therapy in preterm infants 25-28 weeks gestation on continuous positive airway pressure (CPAP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005429-21,0,1,0 2013-005430-37,1,2015-11-13,2015-11-13,1,0,0,0,1,0,4,0,0,1,1,1,1,0,0,North Bristol NHS Trust,Use of co-trimoxazole to prevent pneumonia in patients with severe head injury,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005430-37,0,0,0 2013-005435-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dutch Colorectal Cancer Group,Treatment strategies in colorectal cancer patients with initially irresectable liver-only metastases. CAIRO5 a randomized phase 3 study of the Dutch Colorectal Cancer Group (DCCG),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005435-24,0,0,0 2013-005438-39,1,2014-04-01,2014-04-01,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Department of Dermatology D92, Bispebjerg Hospital",Pulse photodynamic therapy with methyl aminolevulinate activated by a halogen lamp Puls-fotodynamisk terapi med methylaminolevulinat aktiveret ved halogenlampe,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005438-39,0,0,0 2013-005439-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Maastricht University Medical Centre,"Topical sinecatechins ointment in treatment of primary superficial Basal Cell Carcinoma: a double blind, randomized, placebo-controlled trial. Lokale behandeling met sinecatechins zalf als behandel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005439-26,0,0,0 2013-005446-11,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Goethe-University Frankfurt,"A prospective phase I/II study to investigate the feasibility, safety and efficacy of IL-15 activated cytokine induced killer (CIK) cells in relapsing patients with acute leukemia or myelodysplastic s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005446-11,0,0,0 2013-005449-35,6,2017-03-02,2018-06-05,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"PTC Therapeutics, Inc.",An Open-Label Safety and Efficacy Study for Patients with Nonsense Mutation Cystic Fibrosis Previously Treated with Ataluren (PTC124®),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005449-35,0,0,0 2013-005451-32,3,2015-12-22,2015-12-22,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF),Effects of F17464 in acute exacerbation of schizophrenia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005451-32,0,0,0 2013-005452-15,5,2016-04-15,2016-04-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Rigel Pharmaceuticals, Inc.","A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005452-15,0,0,0 2013-005453-76,5,2016-08-31,2016-08-31,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Rigel Pharmaceuticals, Inc.","A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005453-76,0,0,0 2013-005454-30,10,2021-02-03,2021-02-03,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Rigel Pharmaceuticals, Inc.",A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005454-30,1,0,0 2013-005455-32,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,Janssen-Cilag International NV,"Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 years of age with Type 2 D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005455-32,0,1,1 2013-005456-15,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Sarcomas,A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients with Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC) Ensayo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005456-15,0,0,0 2013-005464-25,10,2015-09-02,2015-09-02,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.",Assessment of Anatomical and Functional Outcomes in Patients Treated with Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005464-25,0,0,0 2013-005464-25,10,2015-09-02,2015-09-02,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Alcon Research Ltd,Assessment of Anatomical and Functional Outcomes in Patients Treated with Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005464-25,0,0,0 2013-005466-19,1,,,0,0,0,0,0,0,3,0,1,1,0,0,0,1,0,RadboudUMC,Cytokine inhibition in Chronic Fatigue Syndrome patients - a pilot study. Cytokine inhibitie in patiënten met het chronisch vermoeidheidssyndroom.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005466-19,0,0,0 2013-005471-40,1,2017-11-21,2017-11-21,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,The Christie NHS Foundation Trust,PAZOFOS: A Phase Ib and Randomised Phase II Trial of Pazopanib with or without Fosbretabulin in Advanced Recurrent Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005471-40,0,0,0 2013-005473-52,1,2016-10-24,2016-10-24,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Hospital of South West Jutland,Prevention of bleeding and edema in bi-maxillary orthognathic surgery; the effectiveness of tranexamic acid on intraoperative bleeding in orthognathic surgery Den præventive effektivitet af tranexa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005473-52,0,0,0 2013-005475-41,1,,,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,UZ Brussel,Sulfamethoxazole treatment of primary PREPL deficiency Sulfamethoxazole ter behandeling van primaire PREPL deficiëntie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005475-41,0,0,0 2013-005478-22,5,2019-11-07,2019-11-07,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Pharmacyclics LLC,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Previously Treated Waldenstrom´s Macroglobulinemia Estudio en fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005478-22,0,0,0 2013-005478-22,5,2019-11-07,2019-11-07,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Pharmacyclics, Incorporated","A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Previously Treated Waldenstrom´s Macroglobulinemia Estudio en fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005478-22,0,0,0 2013-005478-22,5,2019-11-07,2019-11-07,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Pharmacyclics,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Previously Treated Waldenstrom´s Macroglobulinemia Estudio en fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005478-22,0,0,0 2013-005479-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Erasmus MC, Dept. Urology",Pilot study: Toxicity of oestradiol for adjuvant endocrine therapy in locally confined prostate cancer Pilot studie: Toxiciteit van oestradiol als adjuvante endorcriene therapie bij lokaal beperkte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005479-42,0,0,0 2013-005481-19,1,2015-05-01,2015-05-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Aarhus University Hospital,High Dose Antioxidant Treatment for Patients with Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005481-19,0,0,0 2013-005483-25,2,2016-08-08,2016-08-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Summit (Oxford) Limited,"A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200 mg BID) for 10 days Compared with Fidaxomicin (200 mg BID) for 10 days for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005483-25,0,0,0 2013-005485-19,1,2019-08-01,2019-08-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Ruprecht-Karls-University Heidelberg, Med Faculty represented by University Clinic HD and its Comm. Director","Bendamustine, Prednisone and Velcade® for first-line treatment of patients with symptomatic multiple myeloma not eligible for high-dose chemotherapy followed by autologous stem cell transplantation (B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005485-19,0,0,0 2013-005486-39,5,2018-05-23,2018-05-23,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005486-39,1,0,0 2013-005486-39,5,2018-05-23,2018-05-23,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Roche Farma, S.A. en nombre de F. Hoffmann-La Roche Ltd","A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005486-39,1,0,0 2013-005487-26,4,2016-09-28,2017-08-21,4,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Bristol-Myers Squibb International Corporation,"A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005487-26,0,0,0 2013-005487-26,4,2016-09-28,2017-08-21,4,1,0,0,0,0,2,0,0,1,1,0,1,0,2,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005487-26,0,0,0 2013-005487-26,4,2016-09-28,2017-08-21,4,1,0,0,0,0,2,0,0,1,1,0,1,0,2,ViiV Healthcare UK Limited,"A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005487-26,0,0,0 2013-005489-20,9,2018-06-21,2018-06-21,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"PTC Therapeutics, Inc.",A Phase 3 Extension Study of Ataluren (PTC124) in Patients with Nonsense Mutation Dystrophinopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005489-20,0,0,0 2013-005494-53,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Norfolk and Norwich University Hospitals NHS Foundation Trust,"A Study of the Histopathological Changes within Ectopic Endometrial Tissue, in Subjects with Known Pelvic Endometriosis Following Treatment with Ulipristal Acetate, a Selective Progesterone Receptor M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005494-53,0,0,0 2013-005499-16,1,2014-06-20,2014-06-20,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Rigshospitalet, 2121","Pilot Study with Treatment of Short Bowel Syndrome Patients with end-jejunostomi with the Glucagon-Like Peptide-1 analogue, Liraglutide (Victoza®) Pilotstudie med behandling af korttarmspatienter m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005499-16,0,0,0 2013-005500-33,7,2016-06-14,2016-06-14,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novo Nordisk A/S,"A 26-week open label, randomised, 2-armed, parallel group, multi-centre trial investigating efficacy and safety of insulin detemir versus insulin Neutral Protamine Hagedorn in combination with metform...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005500-33,0,0,0 2013-005503-13,1,2019-08-13,2019-08-13,1,1,0,0,1,0,2,0,0,1,1,1,1,0,0,"Essen University Hospital, University of Essen, Klinik für Allgemein-, Viszeral- und Transplantationschirugie",A prospective randomized single blind monocenter phase II study of organ perfusion with Custodiol-N compared with Custodiol solution in living donor kidney transplantation Eine prospektive randomi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005503-13,0,0,0 2013-005504-34,2,2020-04-27,2020-04-27,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CESAR Central European Society for Anticancer Drug Research - EWIV,Randomized phase II CAbazitaxel dose Individualization and Neutropenia prevention TriAl (CAINTA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005504-34,0,0,0 2013-005506-56,2,2018-01-04,2018-01-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mabion SA,"Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (rituximab by Hoffman-La Roche) in Patients with Diffuse Large B-cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005506-56,0,0,0 2013-005506-56,2,2018-01-04,2018-01-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MABION S.A.,"Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (rituximab by Hoffman-La Roche) in Patients with Diffuse Large B-cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005506-56,0,0,0 2013-005508-33,5,,,0,1,1,0,0,1,2,0,0,2,0,0,0,0,1,medac Gesellschaft für klinische Spezialpräparate mbH,Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patients wit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005508-33,0,0,0 2013-005508-33,5,,,0,1,1,0,0,1,2,0,0,2,0,0,0,0,1,medac Gesellschaft fuer klinische Spezialpräparate mbH,Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patients wit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005508-33,0,0,0 2013-005508-33,5,,,0,1,1,0,0,1,2,0,0,2,0,0,0,0,1,medac GmbH,Clinical phase II trial to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation (HSCT) in paediatric patients wit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005508-33,0,0,0 2013-005509-29,1,2019-04-19,2019-04-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Hospices Civils de Lyon,Efficacité des immunoglobulines humaines normales (IGHN) dans les chocs toxiques (staphylococciques et streptococciques) : étude de faisabilité pédiatrique. Efficacité des immunoglobulines humai...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005509-29,0,0,0 2013-005512-10,10,2019-09-23,2019-09-23,8,1,1,0,0,1,3,0,0,1,1,0,1,0,1,Biogen Idec Research Ltd,"An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005512-10,0,0,0 2013-005512-10,10,2019-09-23,2019-09-23,8,1,1,0,0,1,3,0,0,1,1,0,1,0,1,Bioverativ Therapeutics Inc.,"An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005512-10,0,0,0 2013-005520-42,1,2014-10-31,2014-10-31,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,The effects of BCG-vaccination on the innate immune response and immunoparalysis in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005520-42,0,0,0 2013-005521-23,1,2015-05-30,2015-05-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,QUALIPHAR NV,Efficacy and safety assessment of Chlorhexidine hydrochloride - Lidocaine hydrochloride (MEDICA ®) versus placebo in adult patients with sore throat and/or acute pharyngitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005521-23,0,0,0 2013-005524-42,1,2020-01-20,2020-01-20,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Reade,Prevention of rheumatoid arthritis by atorvastatin in seropositive arthralgia patients: a multi-center doubleblind randomized placebo-controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005524-42,0,0,0 2013-005525-23,9,2021-09-28,2021-09-28,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Janssen-Cilag International N.V.,"Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005525-23,1,0,0 2013-005528-40,2,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,The Children's Memorial Health Institute,"Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – Tuberous Sclerosis Complex. Een lange-termijn, prospectieve studie om k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005528-40,0,0,0 2013-005528-40,2,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Vrije Universiteit Brussel,"Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – Tuberous Sclerosis Complex. Een lange-termijn, prospectieve studie om k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005528-40,0,0,0 2013-005529-22,1,2015-09-28,2015-09-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,Platelet inhibition in comatose patients receiving oral anti platelet therapy through a naso-gastric tube after undergoing acute percutaneous coronary intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005529-22,0,0,0 2013-005532-23,3,2019-08-27,2019-08-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Clovis Oncology, Inc.","TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO 1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005532-23,0,0,0 2013-005533-20,2,,,0,0,0,0,2,0,4,0,0,2,1,0,0,0,0,OSPEDALE SAN RAFFAELE IRCCS,VOLATILE ANESTHETICS TO REDUCE MORTALITY IN CARDIAC SURGERY. A MULTICENTRE RANDOMIZED CONTROLLER STUDY L'EFFETTO DEGLI ANESTETICI ALOGENATI SULLA SOPRAVVIVENZA AD UN ANNO DALL'INTERVENTO CARDIOCHIR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005533-20,0,0,0 2013-005533-20,2,,,0,0,0,0,2,0,4,0,0,2,1,0,0,0,0,Ghent University Hospital,VOLATILE ANESTHETICS TO REDUCE MORTALITY IN CARDIAC SURGERY. A MULTICENTRE RANDOMIZED CONTROLLER STUDY L'EFFETTO DEGLI ANESTETICI ALOGENATI SULLA SOPRAVVIVENZA AD UN ANNO DALL'INTERVENTO CARDIOCHIR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005533-20,0,0,0 2013-005533-20,2,,,0,0,0,0,2,0,4,0,0,2,1,0,0,0,0,San Raffaele Hospital,VOLATILE ANESTHETICS TO REDUCE MORTALITY IN CARDIAC SURGERY. A MULTICENTRE RANDOMIZED CONTROLLER STUDY L'EFFETTO DEGLI ANESTETICI ALOGENATI SULLA SOPRAVVIVENZA AD UN ANNO DALL'INTERVENTO CARDIOCHIR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005533-20,0,0,0 2013-005534-38,6,2022-07-20,2022-07-20,1,0,1,0,0,1,0,0,0,2,0,0,0,0,1,Eisai Ltd.,Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005534-38,1,1,0 2013-005535-24,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,University of South Florida,"Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non Severe, Granulomatosis with Polyangiitis (Wegener’s) (ABROGATE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005535-24,0,0,0 2013-005535-24,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Univeristy of South Florida,"Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non Severe, Granulomatosis with Polyangiitis (Wegener’s) (ABROGATE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005535-24,0,0,0 2013-005536-17,1,2018-07-31,2018-07-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau ? IIB Sant Pau,"Multicenter, randomized and double-blinded clinical trial on the use of antibiotic prophylaxis for EUS guided FNA of pancreatic cystic lesions Ensayo clínico multicéntrico, aleatorizado y doble cie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005536-17,0,0,0 2013-005540-28,1,2014-07-03,2014-07-03,1,1,0,1,0,1,1,0,0,1,1,1,0,0,1,NOVARTIS FARMA,"A phase Ib/II, multicenter study of LJM716 in combination with cetuximab in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005540-28,0,0,0 2013-005541-36,3,2019-12-31,2019-12-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Nordic Lymphoma Group,"A phase II trial of ibrutinib, lenalidomide and rituximab for patients with relapsed/refractory mantle cell lymphoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005541-36,0,0,0 2013-005542-11,9,2019-06-28,2019-06-28,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,"A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared with Rituximab in Subjects with CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005542-11,0,0,0 2013-005543-90,5,2018-10-08,2018-10-08,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Amgen Inc,"A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005543-90,0,0,0 2013-005545-37,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,AIO-Studien-gGmbH,A Phase II Study of Cabazitaxel for Patients with Breast or Lung Cancer and Recurrent or Progressive Brain Metastases (CaBaMet) Phase II Studie zur Behandlung mit Cabazitaxel von Patienten mit rezi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005545-37,0,0,0 2013-005546-11,1,2015-12-14,2015-12-14,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"DEPARTMENT OF DERMATOLOGY, UNIVERSITY OF MODENA AND REGGIO EMILIA",Characterisation of maximum actinic keratosis (AK) lesions count during treatment (Lmax) by non-invasive study with high definition optical coherence tomography (HD-OCT) and reflectance confocal micro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005546-11,0,0,0 2013-005548-27,2,2018-10-22,2018-10-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A,"A Phase 2 Study of LY2835219 for Patients with Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005548-27,0,0,0 2013-005548-27,2,2018-10-22,2018-10-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Phase 2 Study of LY2835219 for Patients with Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005548-27,0,0,0 2013-005549-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Barcelona Macula Foundation Research for Vision,"An open-label investigator sponsored trial to investigate the safety, tolerability and development of subfoveal fibrosis by intravitreal administration of altering regimens of FovistaTM (Anti-PDGF-B ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005549-35,0,0,0 2013-005550-30,5,2016-02-03,2016-02-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,HAL Allergy B.V.,"A randomized, double-blind, placebo-controlled (DBPC), parallel group study to assess the clinical efficacy and safety of SUBLIVAC FIX Birch immunotherapy in patients suffering from allergic rhinitis/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005550-30,0,0,0 2013-005551-32,4,2016-04-20,2016-04-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Amgen, Inc.","A Multicenter, Randomized, Double blind, Placebo controlled Study to Compare the Efficacy and Safety of Romosozumab With Placebo in Men With Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005551-32,0,0,0 2013-005552-15,9,2020-12-25,2020-12-25,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,"A Phase 2, Multicenter, Open-label, Single-arm Trial to Evaluate the Correlation Between Objective Response Rate and Baseline Immunoprofile Intratumoral CD8+ Cell Density in Subjects With Unresected S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005552-15,0,0,0 2013-005557-73,5,2017-09-29,2017-09-29,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LFB BIOTECHNOLOGIES,"An international, multicentre, efficacy and safety study of I10E in initial and maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005557-73,0,0,0 2013-005558-31,5,2017-07-04,2017-07-28,4,1,0,0,0,2,3,0,0,1,1,0,1,0,1,LFB BIOTECHNOLOGIES,"International, multicentre, efficacy and safety study of I10E in the maintenance treatment of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM study I10E-130...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005558-31,0,0,0 2013-005559-34,2,2022-10-21,2022-10-21,1,0,0,0,0,0,2,0,0,1,1,0,0,0,0,AIO-Studien-gGmbH,"Neoadjuvant plus adjuvant or only adjuvant nab-Paclitaxel plus Gemcitabine for resectable pancreatic cancer - The AIO-NEONAX trial (AIO-PAK-0313) A prospective, randomized, controlled, phase II study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005559-34,0,0,0 2013-005565-40,1,2018-10-28,2018-10-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Biomedical Engineering, Linköping University",Optical measurement with 5-ALA during surgical resection of brain tumors in children Optisk mätning med 5-ALA vid kirurgisk resektion av hjärntumör hos barn,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005565-40,0,0,0 2013-005568-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medisch Spectrum Twente,The reduction of Apneas in Preterm Infants: Low-Flow versus Caffeine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005568-24,0,0,0 2013-005569-38,1,,,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,Cutanea Life Sciences,A phase I/IIa open-label First-in-Human study to assess safety and pharmacokinetics and explore biomarker effects of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide in su...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005569-38,0,0,0 2013-005570-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Lund University,"Comparison of three DPP-4 inhibitors on 24 hour blood glucose, incretin hormones and islet function in patients with type 2 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005570-22,0,0,0 2013-005571-40,4,2018-10-11,2018-10-11,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,Diagram B.V.,Randomized Evaluation of short-term DUal anti platelet therapy in patients with acute coronary syndrome treated with the COMBO dual-therapy stEnt,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005571-40,1,0,0 2013-005572-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medical Center,Optimizing propofol dosing for (preterm) newborn infants that need endotracheal intubation Optimaliseren van de dosis propofol voor sedatie bij endotracheale intubatie van (premature) neonaten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005572-17,0,0,0 2013-005573-51,2,2016-06-22,2016-06-22,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Sverige AB,"A 12-week, multicenter, cross-over, placebo-controlled, double-blind study to determine the impact of QVA149 (indacaterol/glycopyrronium) 85/43 µg on nocturnal oxygen levels in Chronic Obstructive Pul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005573-51,0,0,0 2013-005575-41,14,2018-01-02,2018-01-02,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.P.A.,"A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading regimen to assess efficacy, safety, and tolerab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005575-41,0,0,0 2013-005575-41,14,2018-01-02,2018-01-02,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading regimen to assess efficacy, safety, and tolerab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005575-41,0,0,0 2013-005575-41,14,2018-01-02,2018-01-02,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading regimen to assess efficacy, safety, and tolerab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005575-41,0,0,0 2013-005576-18,4,2016-03-11,2016-03-11,3,1,0,0,0,0,2,0,1,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of CNP520 in healthy elderly subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005576-18,0,0,0 2013-005577-43,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, open-label study to assess the immunogenicity and reactogenicity of GSK Biologicals’ DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course at 3, 4.5 and 6 months of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005577-43,0,1,1 2013-005579-42,3,2021-04-15,2021-04-15,3,1,0,1,0,1,1,0,0,1,0,0,0,0,1,uniQure biopharma B.V.,"A phase I/II, open-label, uncontrolled, single-dose, dose-ascending, multi-centre trial investigating an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005579-42,0,0,0 2013-005581-19,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Bambino Gesù Children’s Hospital,Immune memory to HPV induced by Gardasil in girls and boys Memoria immunologica indotta da Gardasil verso il Papilloma Virus nei maschi e nelle femmine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005581-19,0,0,0 2013-005583-25,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Consorci Parc de Salut Mar de Barcelona,"Multicenter, randomized, open label, controlled clinical trial that compares the efficacy of the combination of colistin and meropenem versus monotherapy for the treatment of bacteremia and pneumonia ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005583-25,0,0,0 2013-005586-39,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,Biogen Idec Research Limited,"A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya® to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005586-39,0,0,0 2013-005587-26,1,2016-06-22,2016-06-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Auris Medical Inc.,Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 2 (TACTT2) Účinnost a bezpečnost látky AM-101 při léčbě akutního periferního tinnitu 2 (TACTT2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005587-26,0,0,0 2013-005588-24,1,2017-01-19,2017-01-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Auris Medical Inc.,AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) – an open-label extension to the TACTT2 study Použití látky AM-101 v postakutní léčbě periferního tinnitu 1 (AMPACT1)-otevřené ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005588-24,0,0,0 2013-005590-41,1,2021-05-27,2021-05-27,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,Netherlands Cancer Institute,A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA-1 or -2 mutated Her2 negative advanced breast cancer a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005590-41,0,0,0 2013-005594-51,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,KU Leuven,Gastrointestinal behavior of abirateronacetaat in healthy volunteers Gastrointestinale gedrag van abirateronacetaat in gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005594-51,0,0,0 2013-005595-17,5,2017-08-02,2017-08-02,4,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Polichem S.A.,"Multicentre, open label study to assess the tolerability of P-3058 nail solution in paediatric patients affected by mild-to-moderate onychomycosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005595-17,0,0,0 2013-005596-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Fondazione IRCCS Istituto Nazionale dei Tumori,Phase II Study of Axitinib in Advanced Solitary Fibrous Tumor Studio di fase 2 su Axitinib nel tumore solitario fibroso avanzato,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005596-40,0,0,0 2013-005614-35,6,2017-07-18,2017-07-28,5,1,1,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005614-35,0,0,0 2013-005615-27,4,2017-09-21,2017-09-21,3,1,1,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005615-27,0,0,0 2013-005617-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospitals Leuven,Determination of the equivalent dose of phenylephrine and Akrinor in the prevention of post-spinal hypotension during Cesarean section. Bepaling van de equivalente dosis van fenylefrine en Akrinor ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005617-13,0,0,0 2013-005619-28,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Hospices Civils de Lyon,Influence of lipid emulsions for parenteral nutrition on the fonctional state of cutaneous barrier Influence des émulsions lipidiques pour nutrition parentéral sur l'état fonctionnel de la barriè...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005619-28,0,0,0 2013-005621-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis,PeRsOnalized treatment fOr patients with pleural eFfusions due to malignant pleural mesothelioma or lung cancer in second or third line. An open label phase II study (Acronym: the PROOF study) Gep...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005621-24,0,0,0 2013-005623-16,1,2020-02-07,2020-02-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Minna Honkila,ANTIBIOTICS VERSUS PLACEBO FOR ACUTE BACTERIAL CONJUNCTIVITIS IN CHILDREN: A RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL ANTIMIKROBIHOIDON TEHO LASTEN AKUUTISSA KONJUNKTIVIITISSA – SATUNNAISTE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005623-16,0,0,0 2013-005625-22,2,2015-06-08,2015-06-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Trevi Therapeutics, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCL ER Tablets in Hemodialysis Patients with Uremic Pruritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005625-22,0,0,0 2013-005626-29,2,2015-11-24,2015-11-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Trevi Therapeutics, Inc.",An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCL ER Tablets in Hemodialysis Patients with Uremic Pruritus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005626-29,0,0,0 2013-005627-17,3,2016-08-11,2016-08-11,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Trevi Therapeutics, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCL ER Tablets in Prurigo Nodularis Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005627-17,0,0,0 2013-005628-41,3,2017-07-26,2017-07-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Trevi Therapeutics, Inc.",An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCL ER Tablets in Prurigo Nodularis Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005628-41,0,0,0 2013-005629-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"First Department of Medicine, University of Szeged",Diagnostic use of 99mTecnetium labeled infliximab in Crohn’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-005629-21,0,0,0 2014-000037-23,1,2015-03-06,2015-03-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharma A/S,"Clinical Study Protocol Safety and efficacy of escalating doses of LEO 43204 applied once daily for two consecutive days on full balding scalp in subjects with actinic keratosis Part 1: A phase 1, m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000037-23,0,0,0 2014-000042-30,6,2016-12-08,2017-02-15,3,1,0,0,1,1,3,0,0,1,1,1,1,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects with Long QT-3 Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000042-30,0,0,0 2014-000042-30,6,2016-12-08,2017-02-15,3,1,0,0,1,1,3,0,0,1,1,1,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects with Long QT-3 Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000042-30,0,0,0 2014-000043-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione IRCCS Istituto Nazionale dei Tumori,A Phase 2 study of Paclitaxel and Ifosfamide plus either Cisplatin or Carboplatin for patients with metastatic non-transitional cell carcinoma of the bladder and the urinary tract,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000043-32,0,0,0 2014-000047-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,VU University Medical Centre,The effect of high-resistance muscle strength training and vitamin D supplementation in persons with knee osteoarthritis Het effect van hoog-intensieve spierkrachttraining en vitamine D suppletie b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000047-33,0,0,0 2014-000048-14,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GORTEC,"Randomized, controlled trial of Platinum-Cetuximab combined either with Docetaxel (TPEx) or with 5FU (Extreme) in patients with recurrent/metastatic squamous cell cancer of the head and neck Estudi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000048-14,0,0,0 2014-000049-56,6,2016-04-18,2016-04-18,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-la roche Ltd,"A phase II, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of lebrikizumab in patients with persistent moderate to severe atopic dermatitis that is inadequately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000049-56,0,0,0 2014-000049-56,6,2016-04-18,2016-04-18,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farma, S.A. , en nombre de F. Hoffmann- La Roche","A phase II, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of lebrikizumab in patients with persistent moderate to severe atopic dermatitis that is inadequately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000049-56,0,0,0 2014-000050-10,1,2021-03-31,2021-03-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Fédération Francophone de Cancérologie Digestive,"Chemoembolisation of patient with hepatocellular carcinoma, not selective for a curative treatment, by microsphere charged with idarubicin Chimioembolisation des carcinomes hépatocellulaires ne re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000050-10,0,0,0 2014-000052-29,1,,,0,1,0,1,0,0,1,0,1,1,0,0,0,1,1,Statens Serum Institut,"Safety and immunogenicity of 3 adjuvated reduced dose inactivated poliovirus vaccines (IPV-Al SSI) and non-adjuvated full dose IPV SSI, given as a booster vaccination to adolescents with a history ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000052-29,0,0,0 2014-000057-37,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,University Medical Centre Utrecht,A B2-agonist as a CFTR activator in CF,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000057-37,0,0,0 2014-000060-17,1,2014-07-29,2014-07-29,1,1,0,0,0,0,3,0,1,1,1,1,1,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, open-label, non-randomised, multicentre study to assess the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine when administered intramuscularly according to a 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000060-17,0,0,0 2014-000062-22,4,2016-05-23,2016-05-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization,","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults with Majo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000062-22,0,0,0 2014-000070-19,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,Cancer Research UK,"A Cancer Research UK Phase I Study of MOv18 IgE, a first in class chimeric IgE antibody against folate receptor-α, in patients with advanced solid tumours",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000070-19,0,0,0 2014-000074-19,3,2018-06-29,2018-06-29,3,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Gamida Cell Ltd,"Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescents and Adult Patients with Hematological Malignancies Allogene s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000074-19,0,0,0 2014-000077-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Sapienza University of Rome,"Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000077-39,0,0,0 2014-000078-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU Toulouse,Effet de l’administration intramyocardique de cellules mésenchymateuses dans le traitement de l’ischémie myocardique avec dysfonction ventriculaire gauche guidée par le système NOGA : Etude multicentr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000078-21,0,0,0 2014-000084-40,1,2016-06-06,2016-06-06,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,"Nora Therapeutics, Inc.","A randomized, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000084-40,0,0,0 2014-000091-25,1,2018-04-30,2018-04-30,1,1,0,0,0,1,4,0,0,1,1,1,1,0,0,Royal Brompton and Harefield NHS Foundation Trust,"A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost (Ventavis®) in patients with Eisenmenger syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000091-25,0,0,0 2014-000092-62,4,2016-04-01,2016-04-01,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Genzyme Corporation,Single arm study to assess comprehensive infusion guidance for the management of the infusion associated reaction (IARs) in Relapsing-Remitting Multiple Sclerosis (RRMS) patients treated with Lemtrada...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000092-62,0,0,0 2014-000095-26,2,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Laboratoires Leurquin Mediolanum S.A.S.,"A randomised, parallel-group, open-label Phase II trial of the immunological effects of three regimens of GX301 vaccination in castration-resistant prostate cancer patients who have achieved response ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000095-26,0,0,0 2014-000096-80,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University or Tromsø,Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000096-80,0,0,0 2014-000097-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Charité Universitätsmedizin Berlin,"Open, comparative, randomized study on the efficacy, safety and bioavailability of highly concentrated inhaled epinephrine (4 mg L-epinephrine / ml, Infectokrupp® Inhal) versus epinephrine autoinjecto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000097-19,0,0,0 2014-000098-38,1,2018-04-23,2018-04-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Groupe Francophone des Myélodysplasies (GFM),"A phase II trial of SGI-110 in patients with ipss high and int 2 myelodysplastic syndrome, acute myeloid leukemia with 20-30% marrow blasts and chronic myelomonocytic leukemia type 2 not responding to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000098-38,0,0,0 2014-000101-12,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, multi-centre, double-blind, randomised study to assess the non-inferiority of a commercial lot of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate (10Pn-PD-DiT) vaccine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000101-12,0,1,1 2014-000102-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Clinica Medica 5,"Effect of administration ""add on"" of Rifaximin on portal hypertension of patients with liver cirrhosis and esophageal varices in standard therapy with propranolol Effetto della somministrazione “ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000102-35,0,0,0 2014-000103-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,,Plasma levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept in patients with exudative age-related macular degeneration.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000103-27,0,0,0 2014-000106-35,13,2017-09-08,2018-01-23,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Roche Farma S.A. en nombre de F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000106-35,0,0,0 2014-000106-35,13,2017-09-08,2018-01-23,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000106-35,0,0,0 2014-000107-27,12,2017-11-20,2018-01-29,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000107-27,0,0,0 2014-000107-27,12,2017-11-20,2018-01-29,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Roche Farma S.A en nombre de F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000107-27,0,0,0 2014-000109-11,4,2016-06-28,2016-07-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Fujifilm Kyowa Kirin Biologics Co., Ltd.","A Randomised, Blinded, Active-Controlled Study to Compare FKB327 Efficacy and Safety with the Comparator Humira® in Rheumatoid Arthritis Patients Inadequately Controlled on Methotrexate.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000109-11,0,0,0 2014-000110-61,3,2018-01-18,2018-01-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Fujifilm Kyowa Kirin Biologics Co., Ltd.","An Open-label Extension Study to Compare the Long-term Efficacy, Safety, Immunogenicity and Pharmacokinetics of FKB327 and Humira® in Patients with Rheumatoid Arthritis on Concomitant Methotrexate",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000110-61,0,0,0 2014-000112-33,1,2021-01-15,2021-01-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,University Medical Center Utrecht,Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation. A randomised phase II clinical trial. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000112-33,0,0,0 2014-000113-31,4,2017-02-22,2017-02-22,4,1,0,0,0,2,2,0,0,1,0,0,1,0,1,River Vision Development Corporation,"A randomized, double-masked, placebo-controlled, efficacy and safety study of RV 001, an insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody (fully human), administered every 3 weeks (q...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000113-31,0,0,0 2014-000117-31,1,2018-12-14,2018-12-14,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge,"To assess the safety of continuous IV administration of the CXCR4 antagonist, plerixafor (Mozobil), at potentially active plasma concentrations and assess its impact on the immune microenvironment in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000117-31,0,0,0 2014-000124-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Center,"Antibiotic prophylaxis to prevent wound infections following implant removal after foot, ankle and lower leg fractures. Antibioticaprofylaxe ter preventie van wondinfecties na verwijderen osteosynt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000124-14,0,0,0 2014-000126-38,1,2018-04-27,2018-04-27,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Oxford,"Towards improved meningococcal vaccines: a randomised, descriptive, open label study exploring the relationship between gene expression signatures with reactogenicity and immunogenicity following vacc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000126-38,0,0,0 2014-000127-24,1,2020-06-03,2020-06-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Rigshospitalet, Department of Oncology",Study assessing the effects of chemotherapy in advanced esophagogastric adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000127-24,0,0,0 2014-000128-22,1,2021-06-29,2021-06-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,LYSARC,A randomized phase III trial evaluating two strategies of rituximab administration for the treatment of first line/low tumor burden follicular lymphoma (Follicular Lymphoma IV/SC Rituximab Therapy) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000128-22,0,0,0 2014-000129-19,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,"Karolinska University Hospital, Huddinge","A randomized , double-blind, placebo-controlled study of antidepressant effects of the endogen compound neuropeptide y (NPY) in patients suffering from major depressive disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000129-19,0,0,0 2014-000130-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE NEOPLASIE SANGUE ONLUS (FO.NE.SA. Onlus),"Prospective, phase II study to evaluate the efficacy and the safety of a combination of bendamustine-melphalan as preparative regimen to autologous transplantation of hematopoietic cells for multiple...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000130-37,0,0,0 2014-000132-41,9,2018-04-19,2018-05-18,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000132-41,0,0,0 2014-000137-22,3,2015-09-06,2015-09-06,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4 and GT6 Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000137-22,0,0,0 2014-000140-15,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Fondazione Neureca Onlus,Comparative Polysomnographic Study of Oxycodone/Naloxone or Pramipexole for the Treatment of Restless Legs Syndrome Studio polisonnografico comparativo ossicodone/naloxone vs pramipexolo nel trat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000140-15,0,0,0 2014-000148-14,8,2016-10-31,2021-04-30,7,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Daiichi Sankyo , Inc","A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000148-14,1,0,0 2014-000148-14,8,2016-10-31,2021-04-30,7,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Daiichi Sankyo, Inc.","A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000148-14,1,0,0 2014-000148-14,8,2016-10-31,2021-04-30,7,1,0,0,0,1,3,0,0,2,0,0,0,0,1,DAIICHI SANKYO INC.,"A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000148-14,1,0,0 2014-000148-14,8,2016-10-31,2021-04-30,7,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Daiichi Sankyo Development Limited,"A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000148-14,1,0,0 2014-000149-53,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Karolinska University Hospital, Huddinge","’D-STAPH’ Vitamin D supplementation to persistent carriers of MRSA – A double blind, randomised controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000149-53,0,0,0 2014-000155-81,1,2017-08-24,2017-08-24,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Hull and East Yorkshire Hospitals NHS Trust,"A parallel group, double-blind, randomised placebo-controlled trial comparing the efficacy and cost-effectiveness of 20mg daily oral modified release morphine (MRM) versus placebo on the intensity of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000155-81,0,0,0 2014-000156-28,8,2020-08-25,2020-08-25,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A MULTICENTER, MULTINATIONAL, PHASE II STUDY TO EVALUATE PERJETA® IN COMBINATION WITH HERCEPTIN® AND STANDARD NEOADJUVANT ANTHRACYCLINE-BASED CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE, LOCALLY ADVAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000156-28,0,0,0 2014-000156-28,8,2020-08-25,2020-08-25,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farma, S.A. en nombre de F. Hoffmann-La Roche Ltd","A MULTICENTER, MULTINATIONAL, PHASE II STUDY TO EVALUATE PERJETA® IN COMBINATION WITH HERCEPTIN® AND STANDARD NEOADJUVANT ANTHRACYCLINE-BASED CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE, LOCALLY ADVAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000156-28,0,0,0 2014-000157-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,A study to assess the anti-albuminuric effects and variability in response to dapagliflozin in subjects with type 2 diabetes Het effect van dapagliflozine op de eiwituitscheiding en variabiliteit i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000157-37,0,0,0 2014-000162-22,7,2020-04-29,2020-04-29,5,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Laboratoire HRA Pharma,"Prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing?s syndrome during a 12-week treatment period followed by a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000162-22,0,0,0 2014-000172-26,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Laboratorios LETI S.L.U,"A multicentre, open label, phase IIb clinical trial to evaluate safety, tolerability and efficacy of the depigmented modified allergen extract of two mites mixes at 200 DPP/ml (DP/MG/14-1 Dermatophago...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000172-26,0,0,0 2014-000173-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Jan van Breemen Research Institute Reade and VU University Medical Centre,The effect of IL-1 inhibition by anakinra in acute gout - A proof of concept study-,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000173-39,0,0,0 2014-000174-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Universitätsklinikum Ulm,Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A Prospective Randomized Multicenter Study comparing Thrombopoetin-Recep...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000174-19,0,0,0 2014-000175-43,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA PROVINCIALE PER I SERVIZI SANITARI DELLA PROVINCIA AUTONOMA DI TRENTO,CHemotherapy plus Enzalutamide In first line therapy for castration Resistant prOstate caNcer A multicentric Randomized phase II study. Ch.E.I.R.O.N. Trial Chemioterapia ed enzalutamide come terap...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000175-43,0,0,0 2014-000177-39,1,,,0,1,0,0,1,0,4,0,0,1,0,0,0,1,0,IRCCS Policlinico San Donato,Albumin vs. Plasma for PEdiAtric pRiming (APPEAR) trial Studio randomizzato controllato Plasma vs. Albumina per il priming perdiatrico,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000177-39,0,0,0 2014-000178-20,5,2017-07-28,2017-07-28,1,0,0,0,0,1,2,0,0,2,0,0,0,0,0,Erasmus Medical Centre,Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. Behandeling met een schildklierhormoon a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000178-20,1,0,0 2014-000178-20,5,2017-07-28,2017-07-28,1,0,0,0,0,1,2,0,0,2,0,0,0,0,0,Centre Hospitalier de Toulouse,Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial. Behandeling met een schildklierhormoon a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000178-20,1,0,0 2014-000179-18,1,2017-09-01,2017-09-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Birmingham,Local Oestrogen Treatment in Postmenopausal Women Undergoing Pelvic Organ Prolapse Surgery (LOTUS) - Feasibility Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000179-18,0,0,0 2014-000179-18,1,2017-09-01,2017-09-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Birmingham Women's Hospital,Local Oestrogen Treatment in Postmenopausal Women Undergoing Pelvic Organ Prolapse Surgery (LOTUS) - Feasibility Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000179-18,0,0,0 2014-000180-41,1,2016-12-02,2016-12-02,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Medical Center - University of Freiburg,Carriage of 3GCREB in patients at risk for relapsing infection: randomized controlled trial of intestinal decolonization with colistin plus rifaximin. Infektionsprävention durch intestinale Dekolon...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000180-41,0,0,0 2014-000181-21,1,2016-03-01,2016-03-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Charite - Universitätsmedizin Berlin,"Disease activity controlled dose escalating study to assess the efficacy, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in chronic spontaneous urticaria. Krankheitsaktivitätsgesteu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000181-21,0,0,0 2014-000182-45,1,2015-02-26,2015-02-26,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Royal Brompton and Harefield NHS Foundation Trust,A pilot study into health pre and post treatment with intravenous Aminophylline and Hydrocortisone in severe asthmatics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000182-45,0,0,0 2014-000184-40,11,2022-03-23,2022-03-28,8,1,1,0,0,1,3,0,0,2,1,0,0,0,1,AMGEN INC.,"Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta Prospektivní, multicentrické, jednoramenné klinic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000184-40,1,1,0 2014-000184-40,11,2022-03-23,2022-03-28,8,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Amgen Inc.,"Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta Prospektivní, multicentrické, jednoramenné klinic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000184-40,1,1,0 2014-000184-40,11,2022-03-23,2022-03-28,8,1,1,0,0,1,3,0,0,2,1,0,0,0,1,"Amgen, Inc.","Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta Prospektivní, multicentrické, jednoramenné klinic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000184-40,1,1,0 2014-000184-40,11,2022-03-23,2022-03-28,8,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Amgen Limited,"Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta Prospektivní, multicentrické, jednoramenné klinic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000184-40,1,1,0 2014-000185-22,11,2021-01-17,2021-03-11,10,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Amgen Inc.,"A Phase 1b/2, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With MK-3475 for Treatment of Previously Untreated, Unresected, Stage IIIB to IVM1c Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000185-22,0,0,0 2014-000196-85,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Institut Bergonié,A phase Ib study of metronomic Cyclophosphamide and Methotrexate combined with Zoledronic acid and Sirolimus in patients with solid tumor with bone metastasis and advanced pretreated Osteosarcoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000196-85,0,0,0 2014-000197-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMBERTO I - POLICLINICO DI ROMA,Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing PercuTaneous Coronary Intervention: DiffErences Between the LoAding Dose of Ticagrelor and ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000197-19,0,0,0 2014-000199-25,1,2018-05-24,2018-05-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Queen Mary, University of London","A Phase II, randomised, open-label study of Gemcitabine/Carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide Apatorsen (OGX-427) in advanced squamous cell l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000199-25,0,0,0 2014-000200-10,2,2021-08-16,2021-08-16,1,0,0,0,0,1,3,0,0,2,0,0,0,0,0,Fondazione Italiana Sindromi Mielodisplastiche (FISM Onlus),A Randomized Phase III study of Decitabine (DAC) with or without Hydroxyurea (HY) versus HY in patients with advanced proliferative Chronic Myelomonocytic Leukemia (CMML),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000200-10,1,0,0 2014-000200-10,2,2021-08-16,2021-08-16,1,0,0,0,0,1,3,0,0,2,0,0,0,0,0,Groupe Francophone des Myélodysplasies (GFM),A Randomized Phase III study of Decitabine (DAC) with or without Hydroxyurea (HY) versus HY in patients with advanced proliferative Chronic Myelomonocytic Leukemia (CMML),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000200-10,1,0,0 2014-000202-35,1,2017-09-14,2017-09-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de LIMOGES,"Prevention of early ventilator-associated pneumonia with antibiotic therapy in patients treated with mild therapeutic hypothermia after cardiac arrest. Randomized, multicenter double-blind placebo-co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000202-35,0,0,0 2014-000206-36,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,3,,"DRD4 genotype as a moderator of L-Dopa intervention effects on parent-related neurocognitive processes, behaviors, and attitudes: A micro-trial of differential susceptibility to pharmacological interv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000206-36,0,0,0 2014-000217-30,7,2017-10-09,2017-10-09,6,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Orion Corporation,"EFFICACY OF ORM-12741 ON AGITATION/AGGRESSION SYMPTOMS IN PATIENTS WITH ALZHEIMER’S DISEASE: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTRE STUDY OF 12 WEEKS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000217-30,1,0,0 2014-000217-30,7,2017-10-09,2017-10-09,6,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Orion Corporation Orion Pharma,"EFFICACY OF ORM-12741 ON AGITATION/AGGRESSION SYMPTOMS IN PATIENTS WITH ALZHEIMER’S DISEASE: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTRE STUDY OF 12 WEEKS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000217-30,1,0,0 2014-000219-15,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,VU Medical Center,Amyloid pathology in cognitively normal elderly subjects Amyloid pathologie in cognitief normale ouderen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000219-15,0,0,0 2014-000221-20,1,2018-05-29,2018-05-29,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Zürich,Treatment of Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis with RNS60 Administered Intravenously – a Phase IIa Clinical Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000221-20,0,0,0 2014-000222-38,5,2016-06-27,2016-06-27,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,PERMIXON® 160 mg hard capsule versus placebo in the treatment of symptomatic lower urinary tract symptoms due to benign prostatic hyperplasia. PERMIXON® 160 mg cápsulas duras frente a placebo en ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000222-38,0,0,0 2014-000222-38,5,2016-06-27,2016-06-27,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT (Represented by: Institut de Recherche Pierre Fabre),PERMIXON® 160 mg hard capsule versus placebo in the treatment of symptomatic lower urinary tract symptoms due to benign prostatic hyperplasia. PERMIXON® 160 mg cápsulas duras frente a placebo en ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000222-38,0,0,0 2014-000224-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,MAASTRO Clinic,Non invasive imaging of [18F]HX4 with Positron-Emission-Tomography (PET) in Cervix Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000224-17,0,0,0 2014-000226-38,11,2017-04-14,2017-04-14,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/day, Split-dose) in Subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000226-38,0,0,0 2014-000227-24,1,,,0,0,0,1,0,1,1,0,0,4,0,0,0,0,0,University of Birmingham,"A Study of Thiotepa, Ifosphamide, Etoposide and Rituximab for the treatment of relapsed or refractory primary central nervous system lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000227-24,0,0,0 2014-000228-52,2,2015-05-30,2015-05-30,1,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Ferrer Internacional, SA","A phase III 2 arms, multicenter, randomised, double-blind study to assess the efficacy and safety of ozenoxacin 1% cream applied twice daily for 5 days versus placebo in the treatment of patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000228-52,1,0,0 2014-000229-19,4,2016-04-25,2016-04-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"An interventional, randomised, double-blind, parallel-group, placebo-controlled study on the efficacy of vortioxetine on cognitive dysfunction in patients with partial or full remission of major depre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000229-19,0,0,0 2014-000230-34,5,2016-02-05,2016-02-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"An interventional, randomised, double-blind, parallel-group, placebo-controlled, active-referenced (paroxetine), fixed-dose study on the efficacy of vortioxetine on cognitive dysfunction in working pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000230-34,0,0,0 2014-000231-16,3,2016-03-01,2016-03-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"An interventional, randomised, double-blind, parallel-group, active-comparator, flexible-dose study on the efficacy of vortioxetine versus escitalopram on cognitive dysfunction in patients with inadeq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000231-16,0,0,0 2014-000234-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"rijnstate hospital, the netherlands","PHARMACOKINETICS OF CARBOPLATIN AFTER ADJUSTED DOSING FOR HIGH BMI, LOW SERUM CREATININE, AND MAXIMAL RENAL FUNCTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000234-33,0,0,0 2014-000238-43,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University of Tartu,Effect of repeated administration of liraglutide on insulinogenic indices. Liraglutiidi korduva manustamise toime insuliini sekretsioonile.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000238-43,0,0,0 2014-000241-74,1,2016-10-11,2016-10-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen Biologics, BV","A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Ankylosing Spondylitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000241-74,0,0,0 2014-000242-30,4,2017-03-22,2017-03-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen Biologics, BV","A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNF alpha Monoclonal Antibody, Administered Intravenously, in Subjects with Active Psoriatic Arthritis Estudi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000242-30,0,0,0 2014-000246-30,1,2020-05-08,2020-05-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest gGmbH,Intravenous ferric carboxymaltose vs. oral iron substitution in patients with metastatic colorectal cancer (CRC) and iron deficiency anemia: a randomized multicenter treatment optimization study. I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000246-30,0,0,0 2014-000251-89,1,2015-11-15,2015-11-15,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Antwerp University Hospital,A controlled double-blind crossover trial of ganaxolone in children with fragile X syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000251-89,0,0,0 2014-000253-36,9,2020-11-06,2020-11-06,9,1,0,0,0,2,2,0,0,1,1,0,1,0,1,MedImmune LLC,"A Double-masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000253-36,0,0,0 2014-000254-11,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Department of Neurology,ROLE OF ENDOTHELIAL INFLAMMATION IN DEMYELINATING DISEASES OF THE CENTRAL NERVOUS SYSTEM ROLE OF ENDOTHELIAL INFLAMMATION IN DEMYELINATING DISEASES OF THE CENTRAL NERVOUS SYSTEM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000254-11,0,0,0 2014-000255-85,8,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Janssen-Cilag International N.V.,"Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000255-85,0,0,0 2014-000256-28,6,2017-10-19,2017-10-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline research & Development,"A Randomised, Multicentre, Open Label, Phase II study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib with Capecitabine for the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000256-28,0,0,0 2014-000256-28,6,2017-10-19,2017-10-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development,"A Randomised, Multicentre, Open Label, Phase II study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib with Capecitabine for the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000256-28,0,0,0 2014-000256-28,6,2017-10-19,2017-10-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Randomised, Multicentre, Open Label, Phase II study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib with Capecitabine for the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000256-28,0,0,0 2014-000258-12,1,2016-04-29,2016-04-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Orthopedic Research in Aarhus,Pharmacokinetics of vancomycin in cancellous and cortical bone obtained by microdialysis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000258-12,0,0,0 2014-000259-99,12,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Birmingham,"International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcomavx Studio internazionale controllato, randomizzato per il trattamento ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000259-99,0,0,0 2014-000259-99,12,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,UNIVERSITY OF BIRMINGHAM,"International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcomavx Studio internazionale controllato, randomizzato per il trattamento ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000259-99,0,0,0 2014-000260-17,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Universität Innsbruck, Institut für Biomedizinische Alternsforschung",Pneumococcal conjugate vaccines in the elderly: The role of carrier-specific T cells Konjugierte Pneumokokken-Impfstoffe im Alter: Einfluss von Trägerprotein-spezifischen T-Zellen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000260-17,0,0,0 2014-000261-51,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,CHU de Clermont-Ferrand,"POPCUR : a randomized, controlled, double bind study, comparing curcuma to placebo, associated with thiopurines, in the prevention of post-operative Crohn's disease recurrence Etude controllée, ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000261-51,0,0,0 2014-000265-43,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Max-Planck-Institut für Psychiatrie,"A randomized, placebo-controlled trial comparing the treatment effect of Pegvisomant and the SSRI Escitalopram on depressive acromegalic patients Doppelblinde, Randomisierte, Plazebo-kontrollier...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000265-43,0,0,0 2014-000268-17,12,2022-05-13,2022-05-13,9,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Celgene Corporation,"A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000268-17,1,0,0 2014-000268-17,12,2022-05-13,2022-05-13,9,0,0,0,0,1,3,0,0,2,0,0,0,0,1,CELGENE CORPORATION,"A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000268-17,1,0,0 2014-000269-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,German Foundation for Chronically Ill,Efficacy and tolerance of Beta Blocker and Procoralan uptitration in chronic heart failure patients under telemedical control: „70 bpm on day 28“ Wirksamkeit und Verträglichkeit einer kombinierten ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000269-27,0,0,0 2014-000272-26,1,2018-11-21,2018-11-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Moorfields Eye Hospital NHS Foundation Trust,A Multicentre Phase III Double-masked Randomised Controlled Non-Inferiority Trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eyle...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000272-26,0,0,0 2014-000273-39,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Belfast Health and Social Care Trust,"Neo-adjuvant Androgen Deprivation Therapy, Pelvic Radiotherapy and RADium-223 for new presentation T1-4 N0/1 M1B adenocarcinoma of prostate (ADRRAD Trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000273-39,0,0,0 2014-000274-20,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Genethon,LONG TERM SAFETY FOLLOW UP OF PATIENTS ENROLLED IN THE PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME(GTG 002-07 AND GTG 003-08),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000274-20,0,0,0 2014-000275-14,3,2016-10-13,2016-10-13,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Phase II, randomized, double-blind, placebo-controlled bronchoscopy study to evaluate the effects of Lebrikizumab on airway eosinophilic inflammation in patients with uncontrolled asthma on inhaled ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000275-14,0,0,0 2014-000279-15,1,2015-12-23,2015-12-23,1,1,1,0,1,0,2,0,0,1,0,0,1,0,1,Circassia Limited,"A Multi-Centre, Single-Blind Study to Assess the Safety of Cat-PAD in Cat Allergic Paediatric Subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000279-15,0,0,0 2014-000284-40,1,2015-03-06,2015-03-06,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,University of Aberdeen,An open label investigation of the tolerability and pharmacokinetics of oral cysteamine in adults with Cystic Fibrosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000284-40,0,0,0 2014-000284-40,1,2015-03-06,2015-03-06,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,NHS Grampian,An open label investigation of the tolerability and pharmacokinetics of oral cysteamine in adults with Cystic Fibrosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000284-40,0,0,0 2014-000290-39,3,2016-01-04,2016-01-04,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A multicentre, multinational, randomised, open-labelled, parallel-group, active-controlled trial to compare the safety of once weekly dosing of NNC0195-0092 with daily Norditropin® FlexPro® for 26 wee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000290-39,0,0,0 2014-000291-25,1,2017-04-28,2017-04-28,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,IBSA Institut Biochimique S.A.,"A single-center, prospective, randomized, double-blind, intra-patient (left-to-right) placebo-controlled, pilot study to assess the efficacy and safety of a betamethasone valerate 0.1% medicated plast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000291-25,0,0,0 2014-000293-20,5,2016-02-11,2016-12-22,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Incyte Corporation,"INCB 18424-362 A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000293-20,0,0,0 2014-000294-39,7,2016-02-11,2016-10-14,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Incyte Corporation,"A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Hav...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000294-39,0,0,0 2014-000296-12,1,2016-06-14,2016-06-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Turku University Hospital,Voidaanko S1P-reseptoreihin vaikuttamalla vähentää mikroglia-solukon aktiivisuutta ms-potilaan aivoissa? PET-tutkimus käyttäen [11C]PK11195 radioligandia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000296-12,0,0,0 2014-000298-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jules Borde Institute,Near-Infrared fluorescence imaging during neck dissection in head and neck cancer patients after peritumoral injection of Indocyanine Green (a feasibility study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000298-37,0,0,0 2014-000299-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Unfallkrankenhaus Salzburg,"Dexmedetomidine for saphenous nerve blockade in patients undergoing anterior cruciate ligament replacement: a randomized, placebo-controlled, triple blinded study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000299-25,0,0,0 2014-000300-10,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Instituto de Investigación Biomédica de Bellvitge (Fundació IDIBELL),Phase IV study to evaluate the efficacy of aflibercept in naive patients with retinal angiomatous proliferation (RAP) lesions on an individualized ?Treat and Extend? (TAE) regimen. AFLIRAP Study. E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000300-10,0,0,0 2014-000302-34,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,"Haukeland Universitetssykehus, Helse Bergen, Barneklinikken",Ipratropium bromide ved anstrengelsesutløst laryngeal obstruksjon (EILO - Exercise Induced Laryngeal Obstruction).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000302-34,0,0,0 2014-000303-28,1,2018-06-19,2018-06-19,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,"Multi-center, prospective, controlled, randomized, single-blinded study to evaluate the efficacy of vibrotactile neuro-feedback additionally to intake of Ginkgo biloba special extract EGb 761® for the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000303-28,0,0,0 2014-000304-96,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU University Medical Center (VUmc),Sentinel lymph node identification in colon cancer using a radioactive and fluorescent tracer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000304-96,0,0,0 2014-000305-13,16,2018-04-02,2018-05-05,16,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000305-13,0,0,0 2014-000306-36,1,2015-06-15,2015-06-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Xention Limited,"A double-blind, randomised, placebo-controlled, crossover study to assess the efficacy of XEN D0501, a TRPV1 antagonist, in reducing the frequency of cough in patients with chronic idiopathic cough",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000306-36,0,0,0 2014-000307-26,1,2019-07-30,2019-07-30,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Iniciativa Andaluza en Terapias Avanzadas-Fundación Pública Andaluza Progreso y Salud,"Clinical trial Phase I/II, test of concept, double blind, randomized, controlled with placebo, to evalue the safety and efficiency of the treatment with expanded adult mesenchymal stem cells from allo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000307-26,0,0,0 2014-000308-82,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitair Ziekenhuis Brussel,"Lanthanum Carbonate (Fosrenol®) to reduce oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis: a short-term, prospective, open-label, efficacy and safety clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000308-82,0,0,0 2014-000311-13,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,CHRU de Brest,Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients aged 70 years and older : a Randomized Placebo-Controlled Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000311-13,0,0,0 2014-000313-31,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,GlaxoSmithKline Research & Development Ltd,"A double-blind (sponsor unblind), placebo controlled, randomised, parallel group study to evaluate the safety, tolerability and pharmacokinetics of multiple doses of GSK2269557 administered as a dry p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000313-31,0,0,0 2014-000314-54,8,2017-10-05,2017-10-05,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"Study 201312: A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects with a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000314-54,1,1,0 2014-000314-54,8,2017-10-05,2017-10-05,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"GlaxoSmithKline, S. A.","Study 201312: A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects with a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000314-54,1,1,0 2014-000316-34,2,2015-11-12,2015-11-12,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,NOVARTIS FARMA S.P.A.,"A phase I/II multicenter, open-label study of CLR457 administered orally in adult patients with advanced solid malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000316-34,0,0,0 2014-000316-34,2,2015-11-12,2015-11-12,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A phase I/II multicenter, open-label study of CLR457 administered orally in adult patients with advanced solid malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000316-34,0,0,0 2014-000319-15,1,2019-10-28,2019-10-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Fundación PETHEMA,"A phase III, multicentre, randomized, open label clinical trial comparing azacytidine (Vidaza®) versus fludarabine plus cytarabine in elderly patients with newly diagnosed acute myeloid leukemia. E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000319-15,0,0,0 2014-000323-25,9,2021-01-11,2021-05-27,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Randomized Open-Label Phase III Trial of MK-3475 versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000323-25,0,0,0 2014-000324-19,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,KU Leuven - Drug Delivery & Disposition,Collection and characterization of gastrointestinal fluids in different populations and conditions Collectie en karakterisering van gastrointestinale vochten in verschillende populaties en conditie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000324-19,0,0,0 2014-000328-47,3,2021-07-07,2021-07-07,3,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000328-47,0,0,0 2014-000331-16,2,2018-09-25,2018-09-25,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Rigel Pharmaceuticals Inc,"A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000331-16,1,0,0 2014-000333-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Beaumont Hospital,Alcohol-based povidone iodine versus chlorhexidine-alcohol in the prevention of surgical site infection: A prospective comparative study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000333-23,0,0,0 2014-000334-30,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Fondazione IRCCS ''IStituto Nazionale dei Tumori'',Immunomodulatory effect of esomeprazole antitumoral and high-dose under neoadjuvant and adjuvant in patients with melanoma in stage III. Randomized pilot study treatment vs control EFFETTO IMMUNOMO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000334-30,0,0,0 2014-000335-17,1,2015-06-12,2015-06-12,1,1,0,0,1,0,4,0,1,1,1,1,1,0,0,Research and Development University Hospital of North Staffordshire,The Effect of Rotigotine on Memory in Idiopathic Parkinson's Disease without Cognitive Impairment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000335-17,0,0,0 2014-000335-17,1,2015-06-12,2015-06-12,1,1,0,0,1,0,4,0,1,1,1,1,1,0,0,Keele University,The Effect of Rotigotine on Memory in Idiopathic Parkinson's Disease without Cognitive Impairment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000335-17,0,0,0 2014-000336-42,10,2021-01-18,2021-01-18,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000336-42,1,0,0 2014-000338-46,10,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ASTRAZENECA AB,"A Phase III, Open label, Randomised, Multi-centre, International Study of MEDI4736, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000338-46,0,0,0 2014-000338-46,10,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase III, Open label, Randomised, Multi-centre, International Study of MEDI4736, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000338-46,0,0,0 2014-000340-15,4,2015-09-21,2015-09-21,2,1,1,0,0,0,1,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A multicentre, open-label, single ascending dose Phase 1 study to evaluate the pharmacokinetics, safety and tolerability of mirabegron OCAS tablets in pediatric subjects from 5 to less than 18 years o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000340-15,0,0,0 2014-000342-30,2,2015-05-22,2015-05-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000342-30,0,0,0 2014-000342-30,2,2015-05-22,2015-05-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000342-30,0,0,0 2014-000343-32,6,2018-12-04,2018-12-04,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,","A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000343-32,0,0,0 2014-000343-32,6,2018-12-04,2018-12-04,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Limited,"A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, GT5, and GT6 Infection who a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000343-32,0,0,0 2014-000345-70,18,2020-05-28,2020-05-28,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel with or without the PARP Inhibitor Veliparib (ABT-888) in Her-2 Negative Metastatic or Locally Advanced Unresectable BRCA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000345-70,1,0,0 2014-000346-30,1,2018-11-28,2018-11-28,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Universität Leipzig,"An open-label, multicenter study of INC424 monotherapy or in combination with azacitidine for patients with post-myeloproliferative disorders (MPD) – AML or with CMML Eine offene, multizentrische S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000346-30,0,0,0 2014-000348-14,1,2014-03-25,2014-03-25,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Odense University Hospital, Department of Neurology",Statin-treatment and peripheral neuropathy - a randomized clinical trial Statin-behandling og perifer neuropati - et randomiseret klinisk forsøg,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000348-14,0,0,0 2014-000349-59,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"department of experimental and clinical medicine ""F. Magrassi""",METAL (METformin in Advanced Lung cancer) study: PHASE II STUDY OF METFORMIN PLUS ERLOTINIB IN SECOND LINE THERAPY OF STAGE IV NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS Studio METAL (metformina n...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000349-59,0,0,0 2014-000350-11,1,2015-04-27,2015-04-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Multiplex Pharma Holdings LLC,"An open label, randomized study to investigate the safety of weekly pentosan polysulfate injections in adult patients with Mucopolysaccharidosis Type I receiving enzyme replacement therapy. Eine of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000350-11,0,0,0 2014-000352-29,10,2017-12-06,2017-12-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY ASSESSING THE EFFICACY AND SAFETY OF PF-06410293 AND ADALIMUMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000352-29,0,0,0 2014-000354-11,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Radboud UMC,"The Efficacy of Ibogaine in the Treatment of Addiction; an open label, single fixed dose pilot-study of the efficacy of ibogaine in opioid-dependent subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000354-11,0,0,0 2014-000358-13,11,2016-12-16,2016-12-16,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",A PHASE 3b/4 RANDOMIZED DOUBLE BLIND STUDY OF 5 MG OF TOFACITINIB WITH AND WITHOUT METHOTREXATE IN COMPARISON TO ADALIMUMAB WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000358-13,0,0,0 2014-000358-13,11,2016-12-16,2016-12-16,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",A PHASE 3b/4 RANDOMIZED DOUBLE BLIND STUDY OF 5 MG OF TOFACITINIB WITH AND WITHOUT METHOTREXATE IN COMPARISON TO ADALIMUMAB WITH METHOTREXATE IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000358-13,0,0,0 2014-000360-17,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,1,TARGEON,"Acceptability study of a new paediatric form of vigabatrin in infants and children with infantile spasms or pharmaco-resistant partial epilepsy. Observational, descriptive, open-label, multi-centric, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000360-17,0,0,0 2014-000361-52,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,KULeuven,Pilot study: Anti-inflammatory effect of preoperative stimulation of the enteric nervous system: a potential new therapeutic intervention to shorten gastroparesis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000361-52,0,0,0 2014-000363-40,2,2021-04-12,2021-04-12,1,0,0,0,0,1,3,0,0,2,0,0,0,0,0,European Society for Blood and Marrow Transplantation,A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for severe aplastic anemia patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000363-40,1,0,0 2014-000368-17,6,2016-11-25,2016-11-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals Corporation,"An open label, multi-center, extension study to evaluate long-term safety and tolerability of dovitinib in patients with solid tumors, who continue to receive treatment with dovitinib (TKI258) in Nova...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000368-17,0,0,0 2014-000368-17,6,2016-11-25,2016-11-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","An open label, multi-center, extension study to evaluate long-term safety and tolerability of dovitinib in patients with solid tumors, who continue to receive treatment with dovitinib (TKI258) in Nova...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000368-17,0,0,0 2014-000368-17,6,2016-11-25,2016-11-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open label, multi-center, extension study to evaluate long-term safety and tolerability of dovitinib in patients with solid tumors, who continue to receive treatment with dovitinib (TKI258) in Nova...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000368-17,0,0,0 2014-000368-17,6,2016-11-25,2016-11-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.p.A.,"An open label, multi-center, extension study to evaluate long-term safety and tolerability of dovitinib in patients with solid tumors, who continue to receive treatment with dovitinib (TKI258) in Nova...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000368-17,0,0,0 2014-000370-19,4,2017-07-03,2017-07-03,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Clovis Oncology, Inc.","TIGER-1: A Randomized, Open-Label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000370-19,0,0,0 2014-000370-19,4,2017-07-03,2017-07-03,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"CLOVIS ONCOLOGY, INC","TIGER-1: A Randomized, Open-Label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000370-19,0,0,0 2014-000377-40,2,2015-08-13,2015-08-13,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Mast Therapeutics, Inc.","Evaluation of MST-188 in Acute Lower Limb Ischemia: A Phase 2 Randomized Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial Evaluating the Safety and Efficacy Of MST-188 in Subjects with Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000377-40,0,0,0 2014-000379-14,2,2016-09-27,2016-09-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alkermes, Inc.",A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-5 Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000379-14,0,0,0 2014-000380-41,5,2017-11-20,2017-11-20,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Alkermes, Inc.",A Phase 3 Multicenter Study of the Long-term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000380-41,0,0,0 2014-000382-41,4,2019-10-29,2019-10-29,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A randomized, double-blind, double-dummy active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000382-41,0,0,0 2014-000383-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.I.M.EM.A. Gruppo Italiano Malattie EMatologiche dell'Adulto,National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented St...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000383-18,0,0,0 2014-000385-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Ospedale San Raffaele di Milano,Nerve Growth Factor eye drops as a novel treatment for vision loss in patients with Retinitis Pigmentosa: from preclinical to clinical Phase II trial. Nerve Growth Factor in collirio come trattamen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000385-22,0,0,0 2014-000388-41,1,2015-04-22,2015-04-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The Rotterdam Eye Hospital,"Does oral administration of dabigatran etexilate, a direct thrombin inhibitor, achieve clinical significant concentrations of dabigatran and thrombin inhibiting activity in vitreous and subretinal flu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000388-41,0,0,0 2014-000392-33,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,University Medical Center Groningen,Fixed versus variable dosing strategy of prothrombin complex concentrate for bleeding complications of vitamin K antagonists Vergelijking van een vaste versus variabele dosering prothrombine comple...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000392-33,0,0,0 2014-000394-39,3,2018-09-01,2019-12-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Odense University Hospital,Full dose S-1 monotherapy compared to reduced dose S-1/oxaliplatin combination therapy as first-line treatment for older patients with metastatic colorectal cancer S1 eller S1/oxaliplatin som 1. li...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000394-39,0,0,0 2014-000395-26,1,2016-10-31,2016-10-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Biogen GmbH,"A 3-year open-label, exploratory, single arm study to describe long term changes in the visual system of patients with relapsing remitting multiple sclerosis (RRMS) on oral dimethyl fumarate Eine 3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000395-26,0,0,0 2014-000397-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Effects of Combined Treatment of Surgery and Liraglutide on Glycemic Variability and Control in type 2 Diabetes Mellitus: The Ctrl-DM2 Study Effecten van gecombineerde behandeling van chirurgie en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000397-19,0,0,0 2014-000399-25,3,2015-12-23,2015-12-23,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Alkermes, Inc.",A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000399-25,0,0,0 2014-000400-99,2,2019-05-07,2019-05-07,2,1,0,0,0,1,2,0,0,1,0,0,1,0,0,CHU-ULg,"10-day decitabine, fludarabine and 2 Gray TBI as conditioning strategy for poor and very poor risk AML in CR1",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000400-99,0,0,0 2014-000400-99,2,2019-05-07,2019-05-07,2,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Radboud university medical center,"10-day decitabine, fludarabine and 2 Gray TBI as conditioning strategy for poor and very poor risk AML in CR1",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000400-99,0,0,0 2014-000404-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Clinico San Carlos,"Effectiveness, tolerability and impact in the ocular surface of Bimatoprost and Tafluprost pods in patients with glaucoma and ocular hypertension Eficacia hipotensora, tolerabilitad e impacto sobre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000404-10,0,0,0 2014-000406-35,3,2018-10-30,2018-10-30,3,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Ultragenyx Pharmaceuticals Inc.,"A Randomized, open Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the anti-FGF23 antibody, KRN23, in Pediatric Patients with X-linked Hypophosphatemia (XLH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000406-35,0,0,0 2014-000411-14,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,NAVARRBIOMED-FUNDACION MIGUEL SERVET,A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological mismatch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000411-14,0,0,0 2014-000411-14,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Mecklin Jukka-Pekka,A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological mismatch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000411-14,0,0,0 2014-000411-14,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,The Newcastle upon Tyne Hospitals NHS Foundation Trust,A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological mismatch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000411-14,0,0,0 2014-000413-31,1,2015-12-04,2015-12-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Exploratory, interventional, open-label, fixed-dose study with Selincro® as-needed use, in alcohol dependent patients with liver impairment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000413-31,0,0,0 2014-000417-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen,"Randomized, double-blind, placebo-controlled phase III study (ASAP III study) to assess the efficacy and safety of Abatacept treatment in patients with primary Sjögren’s syndrome (ASAP III study = Aba...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000417-31,0,0,0 2014-000418-75,7,2018-06-19,2018-06-19,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000418-75,0,0,0 2014-000419-15,5,2015-03-11,2015-03-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Durata Therapeutics International B.V.,"A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000419-15,0,0,0 2014-000420-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Radboud University Medical Centre, department of Psychiatry",Slow continuous subcutaneous flumazenil infusion for benzodiazepine dependence: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000420-15,0,0,0 2014-000422-38,1,,,0,0,0,0,0,1,2,0,1,0,0,0,0,0,0,"Skåne University Hospital, Region Skåne",An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000422-38,0,0,0 2014-000424-23,7,2017-05-30,2017-06-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A 2-month, Observational, Rollover Trial to Evaluate the Safety of Subjects with Agitation Associated with Dementia of the Alzheimer's Type who were Previously Treated with Brexpiprazole (OPC-34712) o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000424-23,0,0,0 2014-000428-12,5,2015-11-20,2018-02-21,2,1,0,0,0,1,2,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,"A randomized, blinded, placebo-controlled, phase II trial of LEE011 in patients with relapsed, refractory, incurable teratoma with recent progression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000428-12,1,0,0 2014-000428-12,5,2015-11-20,2018-02-21,2,1,0,0,0,1,2,0,0,2,1,0,0,0,1,NOVARTIS FARMA S.P.A.,"A randomized, blinded, placebo-controlled, phase II trial of LEE011 in patients with relapsed, refractory, incurable teratoma with recent progression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000428-12,1,0,0 2014-000428-12,5,2015-11-20,2018-02-21,2,1,0,0,0,1,2,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, blinded, placebo-controlled, phase II trial of LEE011 in patients with relapsed, refractory, incurable teratoma with recent progression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000428-12,1,0,0 2014-000429-18,1,2017-09-28,2017-09-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"DIATER, Laboratorio de Diagnóstico y Aplicaciones Terapéuticas, S.A.","Multicenter, randomized, parallel-group, double-blind, placebo-controlled clinical trial for evaluating the clinical efficacy and safety of intradermal immunotherapy with polimerised Phleum pratense, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000429-18,0,0,0 2014-000436-41,1,2021-04-09,2021-04-09,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Hospices Civils de Lyon,Prévention des crises Epileptiques à la phase Aiguë des accidents vasculaires Cérébraux Hémorragiques Prévention des crises Epileptiques à la phase Aiguë des accidents vasculaires Cérébraux Hémorr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000436-41,0,0,0 2014-000440-15,3,2014-07-21,2014-07-21,1,0,0,1,0,1,1,0,0,2,0,0,0,0,1,"Acerta Pharma, BV","A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000440-15,1,0,0 2014-000440-15,3,2014-07-21,2014-07-21,1,0,0,1,0,1,1,0,0,2,0,0,0,0,1,ACERTA PHARMA BV,"A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000440-15,1,0,0 2014-000440-15,3,2014-07-21,2014-07-21,1,0,0,1,0,1,1,0,0,2,0,0,0,0,1,Acerta Pharma BV,"A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000440-15,1,0,0 2014-000443-33,6,2016-04-27,2016-06-29,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Coherus BioSciences, Inc","A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Rheumatoid Arthritis and Inadequate Response to Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000443-33,0,0,0 2014-000443-33,6,2016-04-27,2016-06-29,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Coherus Biosciences, Inc","A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Rheumatoid Arthritis and Inadequate Response to Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000443-33,0,0,0 2014-000444-14,3,2016-04-27,2016-04-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Coherus Biosciences, Inc","A Double-Blind, Randomized, Parallel-Group, Active Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel ® in Subjects With Chronic Plaque Psoriasis (CHS-0214-04) (RaPsOdy)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000444-14,0,0,0 2014-000445-79,4,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,Merck KGaA,"A Phase II, open-label, multicenter trial to investigate the clinical activity and safety of MSB0010718C in subjects with Merkel cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000445-79,0,0,0 2014-000446-30,1,,,0,0,0,0,0,0,3,0,1,1,1,1,0,1,0,Maasstad Ziekenhuis,"Metformin vs Control to prevent gestational diabetes mellitus (GDM) in women with a high risk for GDM, an open label randomized controlled trial. The Medico-GDM trial. Metformin versus controle gro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000446-30,0,0,0 2014-000447-32,1,2019-10-15,2019-10-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"The Fertility Clinic, Skive regional Hospital",The exogenous progesterone free luteal phase after GnRHa trigger – a randomized controlled pilot study in normo-responder IVF patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000447-32,0,0,0 2014-000448-13,1,2019-10-15,2019-10-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"The Fertility Clinic, Skive Regional Hospital",The exogenous progesterone free luteal phase after GnRHa trigger – a randomized controlled pilot study in high-responder IVF patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000448-13,0,0,0 2014-000449-65,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundacion para La Investigación Biomédica Hospital Universitario La Paz (FIBHULP),PILOT STUDY OF the EFFECTIVENESS of PROBIOTICS and LACTITOL for the INTESTINAL Decolonization of PEOPLE CARRIERS of Klebsiella pneumoniae producers of carbapenemase OXA-48 TYPE: STUDIO DESPROBIOXA ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000449-65,0,0,0 2014-000452-28,1,2016-06-24,2016-06-24,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Section for Transfusion Medicine, Capitol Region Blood Bank",Vasculopathic Injury and Plasma as Endothelial Rescue – OCTAplas trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000452-28,0,0,0 2014-000453-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Azienda Ospedaliera di Padova,Sequential treatment with nucleotide analogue and peg-interferon in patients with HBV-related chronic hepatitis. TRATTAMENTO SEQUENZIALE CON ANALOGO NUCLEOTIDICO E PEG-INTERFERONE IN PAZIENTI CON E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000453-37,0,0,0 2014-000456-29,3,2016-10-31,2016-10-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Ferrer Internacional, S.A.",EFFICACY AND SAFETY OF INHALED LOXAPINE COMPARED WITH IM ANTIPSYCHOTIC IN ACUTELY AGITATED PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000456-29,0,0,0 2014-000457-36,1,2016-11-18,2016-11-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU CAEN,A comparative dynamic study of myocardial perfusion reserve explored by cardiac WATER labelled O-15 -PET vs Tc99mibi D-SPECT in coronAry arterY disease. Protocol WATER -DAY Evaluation de la réserve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000457-36,0,0,0 2014-000459-10,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Population Health Research Institute (PHRI),A cluster Crossover Trial Comparing Conventionl vs Incremental Antibiotic Therapy for the Prevention or Arrhytmia Device Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000459-10,0,0,0 2014-000461-43,11,2017-05-23,2017-08-07,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Genentech Inc.,"A PHASE 2 RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000461-43,0,0,0 2014-000461-43,11,2017-05-23,2017-08-07,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Genentech, Inc.","A PHASE 2 RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000461-43,0,0,0 2014-000463-40,2,2018-12-03,2018-12-03,2,1,0,1,0,0,1,0,0,1,0,0,0,0,0,University of Oxford,A Sequential Phase I study of MEK1/2 inhibitors PD-0325901 or Binimetinib combined with cMET inhibitor Crizotinib in RAS Mutant and RAS Wild Type(with aberrant c-MET) Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000463-40,0,0,0 2014-000464-17,8,2021-12-17,2022-02-10,4,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Allergan Limited,BOTOX® in the Treatment of Urinary Incontinence Due to Overactive Bladder in Patients 12 to 17 Years of Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000464-17,1,0,0 2014-000469-35,4,2019-08-31,2019-08-31,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A RANDOMIZED, PHASE II, MULTICENTER, PLACEBO-CONTROLLED STUDY OF IPATASERTIB (GDC-0068), AN INHIBITOR OF AKT, IN COMBINATION WITH PACLITAXEL AS FRONT-LINE TREATMENT FOR PATIENTS WITH METASTATIC TRIPLE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000469-35,0,0,0 2014-000470-19,1,2017-12-22,2017-12-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,3,Centre Hospitalier Universitaire Brugmann,comparative study between conventional epidural versus ambulatory epidural: effect during labor in pregnant women étude comparative entre péridurale classique versus péridurale déambulatoire: effet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000470-19,0,0,0 2014-000473-39,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Fundacio Parc Taulí,Randomized and prospective clinical trial about the therapeutic use of diatrizoic acid (Gastrografin®) in postoperative ileus. Estudio prospectivo y aleatorizado sobre el uso terapéutico del ácido ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000473-39,0,0,0 2014-000476-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Netherlands Cancer Institute,Dynamics of Androgen Receptor genomics and transcriptomics after neoadjuvant androgen ablation (DARANA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000476-26,0,0,0 2014-000477-39,1,2016-11-28,2016-11-28,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,University Hospital Ulm,Dose Finding safety run in Phase followed by a randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000477-39,0,0,0 2014-000478-20,6,2016-07-14,2016-07-14,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York,NY 10017","A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBOCONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000478-20,0,0,0 2014-000478-20,6,2016-07-14,2016-07-14,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, ny 10017","A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBOCONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000478-20,0,0,0 2014-000484-41,1,2017-05-05,2017-05-05,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge,"A Non-Randomised, Open Label, Pilot Trial of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA Related Overgrowth",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000484-41,0,0,0 2014-000488-42,1,2018-10-31,2018-10-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Leiden University Medical Center,The SYNBioSe Study A proof-of-concept study involving synergetic B-cell imunnomodulation in patients with refractory systemic lupus erythematosus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000488-42,0,0,0 2014-000489-23,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Can-Fite BioPharma Ltd.,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of CF102 in the Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects with Child-Pugh Class B ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000489-23,0,0,0 2014-000493-19,1,2015-12-14,2015-12-14,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Diabeteszentrum Bad Lauterberg,"A randomized, controlled, prospective trial examining the effectiveness of two insulin titration algorithms of long acting insulin (insulin glargine, Lantus® or insulin detemir, Levemir®) in subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000493-19,0,0,0 2014-000496-64,1,2016-04-01,2016-04-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Dr. Daniel Podzamczer Palter. Hospital Univesitari de Bellvitge. Unidad de VIH.,Viral suppression in Cerebrospinal Fluid in HIV-1 infected patients receiving Ritonavir-boosted Atazanavir plus lamivudine dual theraphy. SCALA study Supresión viral en el líquido cefalorraquídeo e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000496-64,0,0,0 2014-000499-24,7,2019-09-02,2019-09-02,5,1,1,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,Follow-Up Study to Assess Long-Term Safety and Outcomes in Infants Born to Mothers Participating in Retosiban Treatment Studies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000499-24,1,0,0 2014-000499-24,7,2019-09-02,2019-09-02,5,1,1,0,0,0,3,0,0,2,0,0,0,0,1,GLAXOSMITHKLINE S.P.A.,Follow-Up Study to Assess Long-Term Safety and Outcomes in Infants Born to Mothers Participating in Retosiban Treatment Studies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000499-24,1,0,0 2014-000501-13,4,2021-02-23,2021-02-23,3,1,0,0,0,0,2,0,0,2,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),"Phase II study of cabozantinib in patients with metastatic gastrointestinal stromal tumor (GIST) who progressed during neoadjuvant, adjuvant or palliative therapy with imatinib and sunitinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000501-13,1,0,0 2014-000506-35,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,Carfilzomib/Cyclophosphamide/Dexamethasone with maintenance carfilzomib in untreated transplant-eligible patients with symptomatic MM to evaluate the benefit of upfront ASCT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000506-35,0,0,0 2014-000507-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Oslo University Hospital, Division of Emergencies and Critical Care",The Clinical Carbetocin Myocardium Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000507-27,0,0,0 2014-000510-59,1,2018-08-28,2018-08-28,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,"Dept of Plastic Surgery, Breast Surgery & Burns",Fat transplantation enriched with ex vivo expanded adipose-derived autologous mesenchymal stem cells in reconstruction of the breast. Fedttransplantation beriget med opformerede adipøst-deriverede ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000510-59,0,0,0 2014-000515-14,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación SEIMC-GESIDA,"Comparative, randomized, open study to evaluate maintenance with Darunavir/ritonavir once daily plus Lamivudine once daily versus continuing Darunavir/ritonavir once-daily plus Tenofovir/Emtricitabine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000515-14,0,0,0 2014-000517-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,Effect of perioperative ketamine on postoperative outcome – a randomized placebo-controlled trial Het effect van preoperative ketamine op de postoperatieve uitkomst - een gerandomiseerde placebo-ge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000517-31,0,0,0 2014-000520-14,2,2019-05-16,2019-05-16,1,1,0,0,0,0,2,0,0,2,0,0,0,0,0,University Medical Center Utrecht,Prednisolone addition for atients with recent onset psychotic disorder: the role of immune-modulating strategies in the treatment of psychosis. Prednisolon additie voor patiënten met recent ontstan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000520-14,1,0,0 2014-000524-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Utrecht,"A randomized, placebo-controlled, double blind, cross-over trial to study the effects of adding bezafibrate to standard lipid lowering therapy on postprandial lipids in patients with familial dysbetal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000524-26,0,0,0 2014-000526-37,1,2018-07-31,2018-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GSO Global Clinical Research B.V.,An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination with the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Relapsed Or Refractory AML,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000526-37,0,0,0 2014-000529-19,4,2015-03-05,2015-03-05,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D,"A 12 week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects with COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000529-19,0,0,0 2014-000530-29,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,University Hospital Basel,Canakinumab for the Prevention of Recurrences After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation (CONVERT-AF) Trial - A Randomized Double Blind Placebo Controlled Study ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000530-29,0,0,0 2014-000531-17,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Patients with EGFRm+/T790M+, Locally Advanced or Metastatic NSCLC who have Progressed Following Prior Therapy w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000531-17,0,0,0 2014-000533-22,3,2018-10-30,2018-10-30,2,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Alexion Pharmaceuticals Inc,"A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants with Rapidly Progressive Lysosomal Acid Lipase Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000533-22,0,0,0 2014-000533-22,3,2018-10-30,2018-10-30,2,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Synageva BioPharma Corp.,"A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants with Rapidly Progressive Lysosomal Acid Lipase Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000533-22,0,0,0 2014-000537-24,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,INSTITUTO DE INVESTIGACION SANITARIA LA FE,"Pilot clinical trial phase I / IIa to determine condition, low dose and effectiveness of liver function tests (Hepatotest) Ensayo clínico piloto fase I/IIa para determinar condiciones, dosis mínima...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000537-24,0,0,0 2014-000540-15,1,2016-04-15,2016-04-15,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Cardiff University,Prostaglandin F2-alpha eye drops (Bimatoprost) in thyroid eye disease: a randomised controlled double blind crossover trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000540-15,0,0,0 2014-000543-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Antwerp University Hospital,"An open-label, randomized, controlled, multi-center, Phase II trial comparing Panitumumab versus Bevacizumab in combination with oxaliplatin - 5 FU (FOLFOX) first-line treatment according Ras Wil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000543-33,0,0,0 2014-000545-78,9,2016-04-28,2016-04-28,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Rempex Pharmaceuticals, Inc.","A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CARBAVANCE? (MEROPENEM/RPX7009) COMPARED TO PIPERACILLIN/TAZOBACTAM IN THE T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000545-78,0,0,0 2014-000546-30,4,2017-07-05,2017-07-05,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Rempex Pharmaceuticals, Inc.","A PHASE 3, MULTI-CENTER, RANDOMIZED, OPEN-LABEL STUDY OF CARBAVANCE (MEROPENEM/RPX7009) VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH SELECTED SERIOUS INFECTIONS DUE TO CARBAPENEM RESISTANT ENTEROBAC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000546-30,0,0,0 2014-000547-32,1,2016-03-10,2016-03-10,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,University of Nottingham,A Randomised Controlled Trial of Adjunctive Systemic Therapy for Vulval Erosive Lichen Planus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000547-32,0,0,0 2014-000550-12,6,2017-07-07,2017-10-12,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,XBiotech Germany GmbH,"A Double Blind, Placebo Controlled, Pivotal Phase III Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory To Standard Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000550-12,0,0,0 2014-000551-81,1,2017-07-20,2017-07-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A 6-month, open label, randomised, efficacy study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via the Dry Powder Inhaler Ellipta™ co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000551-81,0,0,0 2014-000554-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación PETHEMA,"A randomized, open-label, national multicenter, phase III trial studying maintenance treatment with lenalidomide and dexamethasone versus lenalidomide, dexamethasone and MLN9708 after autologous hemat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000554-10,0,0,0 2014-000555-93,3,2021-06-15,2021-06-15,1,0,0,0,0,0,3,0,0,2,1,0,0,0,0,University Hospital Erlangen,Abatacept reversing subclinical Inflammation as measured by MRI in ACPA positive Arthralgia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000555-93,1,0,0 2014-000555-93,3,2021-06-15,2021-06-15,1,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Universitätsklinikum Erlangen,Abatacept reversing subclinical Inflammation as measured by MRI in ACPA positive Arthralgia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000555-93,1,0,0 2014-000557-36,1,,,0,0,0,0,1,0,2,0,0,1,0,0,0,1,0,Fondazione IRCCS Istituto Nazionale dei tumori,A Phase 2 study of the Aurora kinase A inhibitor Alisertib (MLN8237) in patients with relapsed or refractory transitional-cell carcinoma of the bladder and urothelial tract Studio di fase 2 con l’i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000557-36,0,0,0 2014-000562-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,VU University Medical Center,Amyloid-PET as a diagnostic marker in daily practice. Amyloid-PET als een diagnostische marker in de dagelijkse praktijk.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000562-21,0,0,0 2014-000563-41,1,,,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar),Recombinant hGH Biomarkers Discovery Estudio de biomarcadores indicativos de la exposición a hormona de crecimiento recombinante,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000563-41,0,0,0 2014-000565-47,15,2019-01-30,2019-01-30,12,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000565-47,0,0,0 2014-000565-47,15,2019-01-30,2019-01-30,12,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000565-47,0,0,0 2014-000566-22,10,2017-04-05,2017-05-04,7,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"30-day, open-label, active-controlled, randomized study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000566-22,0,0,0 2014-000566-22,10,2017-04-05,2017-05-04,7,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,"30-day, open-label, active-controlled, randomized study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000566-22,0,0,0 2014-000569-35,1,2019-03-29,2019-03-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Cologne,"A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib (BIG) followed by ibrutinib and GA101 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000569-35,0,0,0 2014-000570-19,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Institute of Specific Prophylaxis and Tropical Medicine,Applikation of FSME-IMMUN® in obese persons Applikation von FSME-IMMUN® bei adipösen Personen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000570-19,0,0,0 2014-000574-19,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA,Experimental study for the evaluation of the effect of radioactive iodine therapy on free thyroxine circulating levels after oral administration of sodium levo-thyroxine in patients thyroidectomized ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000574-19,0,0,0 2014-000576-26,5,2018-03-16,2018-03-16,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A PHASE II, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF GDC-0199 (ABT- 199) PLUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN COMPARISON WITH BR ALONE OR GDC-0199 PLUS RITUXIMAB (R) IN PATIENTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000576-26,0,0,0 2014-000578-20,7,2019-02-06,2019-02-06,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.P.A.,"A phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) metastatic to the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000578-20,0,0,0 2014-000578-20,7,2019-02-06,2019-02-06,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) metastatic to the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000578-20,0,0,0 2014-000578-20,7,2019-02-06,2019-02-06,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) metastatic to the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000578-20,0,0,0 2014-000579-20,4,2017-01-20,2017-01-20,1,1,0,1,0,1,1,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A phase Ib, open-label, multicenter, dose escalation and expansion study, to evaluate the safety, pharmacokinetics and activity of INC280 in combination with cetuximab in c-MET positive CRC and HNSCC ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000579-20,1,0,0 2014-000579-20,4,2017-01-20,2017-01-20,1,1,0,1,0,1,1,0,0,2,0,0,0,0,1,NOVARTIS FARMA,"A phase Ib, open-label, multicenter, dose escalation and expansion study, to evaluate the safety, pharmacokinetics and activity of INC280 in combination with cetuximab in c-MET positive CRC and HNSCC ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000579-20,1,0,0 2014-000579-20,4,2017-01-20,2017-01-20,1,1,0,1,0,1,1,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase Ib, open-label, multicenter, dose escalation and expansion study, to evaluate the safety, pharmacokinetics and activity of INC280 in combination with cetuximab in c-MET positive CRC and HNSCC ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000579-20,1,0,0 2014-000580-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University of Cologne,"A prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 (Obinutuzumab) and ABT-199 (Venetoclax) followed by ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000580-40,0,0,0 2014-000582-47,1,2022-03-09,2022-03-09,1,0,0,0,0,1,2,0,0,1,0,0,0,0,0,University of Cologne,"A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000582-47,0,0,0 2014-000583-18,15,2019-10-19,2019-11-19,13,1,1,0,0,2,3,0,0,2,1,0,0,0,2,Boehringer Ingelheim Ellas,"Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000583-18,1,0,0 2014-000583-18,15,2019-10-19,2019-11-19,13,1,1,0,0,2,3,0,0,2,1,0,0,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000583-18,1,0,0 2014-000583-18,15,2019-10-19,2019-11-19,13,1,1,0,0,2,3,0,0,2,1,0,0,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000583-18,1,0,0 2014-000583-18,15,2019-10-19,2019-11-19,13,1,1,0,0,2,3,0,0,2,1,0,0,0,2,Boehringer Ingeheim RCV GmbH & Co KG,"Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000583-18,1,0,0 2014-000583-18,15,2019-10-19,2019-11-19,13,1,1,0,0,2,3,0,0,2,1,0,0,0,2,Boehringer Ingelheim Italia S.p.A.,"Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000583-18,1,0,0 2014-000583-18,15,2019-10-19,2019-11-19,13,1,1,0,0,2,3,0,0,2,1,0,0,0,2,Boehringer Ingelheim AB,"Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000583-18,1,0,0 2014-000583-18,15,2019-10-19,2019-11-19,13,1,1,0,0,2,3,0,0,2,1,0,0,0,2,SCS Boehringer Ingelheim Comm.V,"Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000583-18,1,0,0 2014-000583-18,15,2019-10-19,2019-11-19,13,1,1,0,0,2,3,0,0,2,1,0,0,0,2,"Boehringer Ingelheim España, S.A.","Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000583-18,1,0,0 2014-000583-18,15,2019-10-19,2019-11-19,13,1,1,0,0,2,3,0,0,2,1,0,0,0,2,Boehringer Ingelheim Finland Ky,"Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000583-18,1,0,0 2014-000583-18,15,2019-10-19,2019-11-19,13,1,1,0,0,2,3,0,0,2,1,0,0,0,2,Boehringer Ingelheim France,"Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000583-18,1,0,0 2014-000584-41,3,,,0,0,1,0,0,1,2,0,0,2,1,0,0,0,1,"Bellicum Pharmaceuticals, Inc.",Phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000584-41,0,0,0 2014-000586-45,1,2019-12-20,2019-12-20,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KU Leuven,Oxytocin-based pharmacotherapy for Autism Spectrum Disorders: Investigating the neural and behavioral effects of a promising intervention approach Oxytocine voor gebruik bij Autisme Spectrum stoorn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000586-45,0,0,0 2014-000588-42,2,2021-08-10,2021-08-10,2,0,1,0,0,0,2,0,0,1,0,0,1,0,0,Medical University Greifswald,PHASE II STUDY OF MONOCLONAL ANTIBODY CH14.18/CHO CONTINUOUS INFUSION IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMA Phase-II-Studie zur kontinuierlichen Infusion des monoklonalen An...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000588-42,0,0,0 2014-000590-39,1,2020-02-06,2020-02-06,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Cologne,"A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofatumu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000590-39,0,0,0 2014-000593-19,4,2016-02-08,2016-02-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® pMDI 160/4.5 µg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000593-19,0,0,0 2014-000594-39,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000594-39,0,0,0 2014-000599-24,1,2017-10-18,2017-10-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Universitätsklinikum Essen, Westdeutsches Tumorzentrum","Molecularly stratified parallel group phase II trial of the phosphoinositide 3-kinase (PI3K) inhibitor BKM120 in combination with tamoxifen in patients with hormone receptor-positive, HER2-negative in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000599-24,0,0,0 2014-000602-36,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,KUleuven,"The effect of corticotrophin-releasing hormone (CRH) on esophageal sensitivity in healthy volunteers: a randomized, single-blind, placebo-controlled study Het effect van corticotropine-releasing ho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000602-36,0,0,0 2014-000605-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Thiazide diuretics versus calcium channel blockers for the treatment of calcineurin inhibitor-induced hypertension in patients with psoriasis or eczema: a single-center randomized cross-over trial. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000605-12,0,0,0 2014-000608-90,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,Fondazione IRCCS Policlinico San Matteo,Eltrombopag for inherited thrombocytopenias.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000608-90,0,0,0 2014-000611-14,4,2015-03-08,2015-03-24,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive Pulm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000611-14,0,0,0 2014-000612-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UniversitätsSpital Zürich,"Erythropoietin for the repair of cerebral injury in very preterm infants, a randomized, double-blind, placebo-controlled, prospective, and multicenter clinical study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000612-34,0,0,0 2014-000614-64,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Department of Immunology, Genetics and Pathology (IGP), Rudbeck Laboratory, Uppsala University",Study of recombinant adenovirus in patients with neuroendocrine tumors; safety and efficay,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000614-64,0,0,0 2014-000619-14,1,2017-01-30,2017-01-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,German Breast Group,"A randomized phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto) Eine randomi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000619-14,0,0,0 2014-000623-24,2,2016-11-03,2016-12-14,2,1,1,0,0,0,2,0,0,1,1,1,1,0,1,Grünenthal GmbH,"Open-label evaluation of the population pharmacokinetic profile, safety, tolerability, and efficacy of tapentadol oral solution for the treatment of post-surgical pain in children aged from birth to l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000623-24,0,0,0 2014-000627-24,2,2015-08-17,2015-08-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A follow-up study to examine the presence of anti-human growth hormone antibodies following a randomised, open-label, parallel-group, multi-centre trial (FE 999905 CS07) in which the efficacy and safe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000627-24,0,0,0 2014-000634-34,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,CHU Toulouse,IFM 2014-02 study: A randomized phase III study of Bortezomib-Melphalan 200 conditioning regimen versus Melphalan 200 for frontline transplant eligible patients with multiple myeloma Etude IFM 2014...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000634-34,0,0,0 2014-000643-33,1,2017-08-09,2017-08-09,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Placebo Controlled, Double-blind, Multi-centre, Single Dose, Parallel Group, Randomised Clinical Trial of GSK2862277 in Patients undergoing Oesophagectomy Surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000643-33,0,0,0 2014-000647-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,"Investigation of the efficacy of degarelix as an acute treatment for patients with pedophilic disorder to reduce the risk for sexual child molestation: a prospective, randomized, double blind, and pla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000647-32,0,0,0 2014-000650-11,4,2017-09-28,2019-08-01,4,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Promethera Biosciences,"A prospective, open label, multi-country, multicenter, efficacy and safety study of several infusions of Promethera HepaStem in Urea Cycle Disorders pediatric patients HEP002: Estudio prospectivo, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000650-11,0,0,0 2014-000652-28,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,A.I.E.O.P.,Study Protocol LAM 2013/01 protocollo LAM 2013/01,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000652-28,0,0,0 2014-000656-29,1,2015-10-05,2015-10-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MSD Belgium BVBA/SPRL,Preference for a prefilled syringe or Smartject™ device for delivering SIMPONI (golimumab) in patients suffering from moderate to severe ulcerative colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000656-29,0,0,0 2014-000657-36,1,2018-12-31,2018-12-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Medical Center Groningen,Open-label crossover trial to investigate the efficacy of treatments in apomorphine-induced skin reactions Open-label crossover onderzoek naar de effectiviteit van behandelingen bij apomorfine-geïn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000657-36,0,0,0 2014-000659-10,1,,,0,1,0,1,0,1,1,0,1,1,1,1,0,1,1,TikoMed AB,"A randomised, open-label, placebo-controlled, single centre study in healthy male volunteers to explore efficacy, safety and tolerability of single doses of low molecular weight dextran sulfate (LMW-D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000659-10,0,0,0 2014-000667-40,6,2017-06-22,2017-06-22,5,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Arena Pharmaceuticals, Inc.","A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients with Pulmonary Arterial Hypertension Az APD811 – egy orálisan alkalm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000667-40,1,0,0 2014-000668-16,1,2017-05-30,2017-05-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,ATVB Verein,The LOW-BP-VIENNA (Lowering Blood Pressure in Primary Care in Vienna) Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000668-16,0,0,0 2014-000669-39,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Gregers Gautier Hermann,Endoscopic treatment of neoplasia in the upper urinary tract and the value of fluorescence guided endoscopic follow up.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000669-39,0,0,0 2014-000672-25,7,2015-06-15,2015-06-16,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Copr., a subsidary of Merck & Co.",A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection with Advanced Cirrhosis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000672-25,0,0,0 2014-000672-25,7,2015-06-15,2015-06-16,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection with Advanced Cirrhosis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000672-25,0,0,0 2014-000672-25,7,2015-06-15,2015-06-16,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidary of Merck & Co.",A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection with Advanced Cirrhosis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000672-25,0,0,0 2014-000673-40,1,2021-08-26,2021-08-26,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,ous,Prospective randomized trial between Percutaneous Needle Fasciotomy and Xiapex injection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000673-40,0,0,0 2014-000674-18,3,2019-02-25,2019-11-11,3,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Arbor Pharmaceuticals, LLC.","A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hyp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000674-18,0,0,0 2014-000675-13,1,2020-11-25,2020-11-25,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Erasmus University Medical Center,Natalizumab (Tysabri®) for the treatment of anti-Hu associated paraneoplastic neurological syndromes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000675-13,0,0,0 2014-000676-26,3,2015-02-28,2015-02-28,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Prima BioMed Ltd,A Phase 2 Trial of Cvac (Autologous Dendritic Cells Pulsed with Recombinant Human Fusion Protein [Mucin 1-Glutathione S-Transferase] Coupled to Oxidized Polymannose) in Patients with Resected Stage I ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000676-26,0,0,0 2014-000678-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UZ Brussel,Does isocapnic hyperventilation hasten early recovery with sevoflurane and desflurane in O2/air?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000678-20,0,0,0 2014-000681-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ErasmusMC,EFFECT OF ISO-OSMOLAR CONTRAST MEDIUM ON CORONARY OPACIFICATION AND HEART RHYTHM IN CORONARY CT ANGIOGRAPHY (ISO-COR),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000681-22,0,0,0 2014-000682-50,1,2016-04-30,2016-04-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Hospitals Coventry and Warwickshire NHS Trust,Facet-joint injections for people with persistent non-specific low back pain (FIS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000682-50,0,0,0 2014-000682-50,1,2016-04-30,2016-04-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"University of Warwick, Research Support Services",Facet-joint injections for people with persistent non-specific low back pain (FIS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000682-50,0,0,0 2014-000693-18,1,2016-07-19,2016-07-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Dipartimento di Medicina, Università di Perugia",A PHASE II STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF ACTINOMYCIN D IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH NUCLEOPHOSMIN (NPM1) GENE MUTATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000693-18,0,0,0 2014-000694-39,4,2016-09-09,2016-09-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Starpharma Pty Ltd,"A phase 3, double-blind, multicentre, randomised, placebo-controlled study to determine the efficacy and safety of SPL7013 Gel (VivaGel®) to prevent the recurrence of bacterial vaginosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000694-39,0,0,0 2014-000698-38,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,MEDDAY SAS,MD1003 IN ADRENOMYELONEUROPATHY: A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY MD1003 en la adrenomieloneuropatía: un estudio aleatorizado con doble enmascaramiento controlado por placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000698-38,0,0,0 2014-000699-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU Angers-DAMR,"Essai de phase 3 visant à améliorer la survie globale des LAM de l’adulte de 18 à 60 ans en comparant l’idarubicine à forte dose à la daunorubicine à l’induction, la cytarabine à haute-dose et à dose ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000699-24,0,0,0 2014-000701-13,4,2015-11-18,2015-11-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Isis Pharmaceuticals, Inc.","A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000701-13,0,0,0 2014-000701-13,4,2015-11-18,2015-11-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Ionis Pharmaceuticals, Inc.","A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000701-13,0,0,0 2014-000703-26,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer (mCRC) with any RAS or BRAF mutation previously treated with FOLFOXIRI plus bevacizumab. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000703-26,0,0,0 2014-000706-34,1,2015-07-06,2015-07-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS THE IMMUNE RESPONSE FOLLOWING ADMINISTRATION OF ZOSTER VACCINE TO SUBJECTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB (CP-6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000706-34,0,0,0 2014-000707-28,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Aarhus University Hospital,"Displacement of popliteal sciatic nerve catheters after major foot and ankle surgery. Long axis (LAX) compared with short axis (SAX), a MR/US image fusion study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000707-28,0,0,0 2014-000709-10,1,2020-11-02,2020-11-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsklinikum Münster,"Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential Alemtuzumab in der autoimmunen, entzündlichen Neurodegeneration: Wirkmechanismen und Neu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000709-10,0,0,0 2014-000710-53,4,2017-11-10,2018-05-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GALDERMA R&D, LLC",A multicenter open label uncontrolled study of the long term safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 26 weeks in pediatric subjects (2 to 16 years and 11 months of a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000710-53,0,0,0 2014-000712-34,1,2016-10-13,2016-10-13,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Hansa Medical AB,"A PHASE II STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY AND PHARMACOKINETICS OF INTRAVENOUS ASCENDING DOSES OF IDES IN KIDNEY TRANSPLANTATION En Fas II-studie för att utvärdera säkerhet, to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000712-34,0,0,0 2014-000714-65,1,,,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,Pherecydes Pharma SA,Evaluation of phage therapy for the treatment of Pseudomonas aeruginosa wound infections in burned patients (Phase I-II clinical trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000714-65,0,0,0 2014-000717-31,1,2019-05-27,2019-05-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,UZ Leuven,"A randomised, double-blind, placebo-controlled study of celecoxib after collagenase injection for adults with Dupuytren’s disease at high risk of recurrence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000717-31,0,0,0 2014-000719-15,4,2020-06-17,2020-06-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000719-15,0,0,0 2014-000720-18,4,2020-07-01,2020-07-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000720-18,0,0,0 2014-000721-20,2,2016-05-24,2016-05-24,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000721-20,0,0,0 2014-000722-38,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,EORTC AISBL/IVZW,"INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000722-38,0,0,0 2014-000722-38,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,European Organization for the Research and Treatment of Cancer,"INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000722-38,0,0,0 2014-000722-38,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,European Organisation for Research and Treatment of Cancer,"INtegratioN of trastuzumab, with or without pertuzumab, into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000722-38,0,0,0 2014-000726-37,4,2020-09-29,2022-05-11,3,0,0,1,0,0,1,0,0,1,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000726-37,0,0,0 2014-000726-37,4,2020-09-29,2022-05-11,3,0,0,1,0,0,1,0,0,1,1,0,0,0,1,Novartis Pharma Services AG,"A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000726-37,0,0,0 2014-000726-37,4,2020-09-29,2022-05-11,3,0,0,1,0,0,1,0,0,1,1,0,0,0,1,NOVARTIS FARMA S.P.A.,"A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000726-37,0,0,0 2014-000727-25,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Isala Klinieken,The effect of ARTISS on latissimus dorsi donor site seroma formation after breast reconstruction: a randomised controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000727-25,0,0,0 2014-000728-97,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Academic MS Center Limburg,"Regulation of the stress-axis by vitamin D3 in subjects with multiple sclerosis; a double-blinded, randomized, placebo-controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000728-97,0,0,0 2014-000742-30,6,2015-10-23,2015-10-23,5,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Baxter Innovations GmbH,"A phase 3 prospective, uncontrolled, multicenter study evaluating pharmacokinetics, efficacy, safety, and immunogenicity of BAX 855 (PEGylated full-length Recombinant FVIII) in previously treated pedi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000742-30,0,0,0 2014-000742-30,6,2015-10-23,2015-10-23,5,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Baxalta Innovations GmbH,"A phase 3 prospective, uncontrolled, multicenter study evaluating pharmacokinetics, efficacy, safety, and immunogenicity of BAX 855 (PEGylated full-length Recombinant FVIII) in previously treated pedi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000742-30,0,0,0 2014-000747-32,7,2016-07-07,2016-07-07,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MYLAN GmbH,"AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL-GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN’S INSULIN GLARGINE WITH LANTUS® IN TYPE 1 DIABETES MELLITUS PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000747-32,0,0,0 2014-000750-11,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,Study to compare immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose presentation to the licensed Synflorix™ (10Pn-PD-DiT) vaccine when co-administered with DTPw-combination vaccine in healthy infan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000750-11,0,1,1 2014-000757-36,1,2016-03-30,2016-03-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Clinirx Tangent Research,A randomized trial administering aspirin vs. placebo as add-on to antipsychotics in patients with schizophrenia or schizoaffective disorder with high CRP levels,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000757-36,0,0,0 2014-000758-12,1,2020-05-05,2020-05-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,INSTITUT PAOLI CALMETTES,Study of pharmacokinetics of intravenous busulfan (Busilvex ®) in the conditioning allogeneic transplantation in patients with high-risk hematological disease. Etude de pharmacocinétique du Busulfa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000758-12,0,0,0 2014-000760-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Prof. Peter Licht,Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000760-18,0,0,0 2014-000761-40,8,2017-08-14,2017-08-14,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AM-Pharma B.V.,"A Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Parallel-Group, Proof of Concept, and Dose-Finding Adaptive Phase 2a/2b Study to Investigate the Safety, Tolerability and Efficacy and Effect ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000761-40,0,0,0 2014-000763-41,1,2019-01-15,2019-01-15,1,0,0,0,0,0,2,0,1,1,1,1,1,0,0,FUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA,Study of genetic Alzheimer?s disease mutation carriers in preclinical stages of the disease: 18F-Florbetaben Positron Emission Tomography study. Estudio de sujetos con riesgo de enfermedad de Alzhe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000763-41,0,0,0 2014-000770-19,8,2018-10-04,2018-10-04,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000770-19,0,0,0 2014-000771-24,1,2015-03-21,2015-03-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Cardioxyl Pharmaceuticals, Inc.","A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6-Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients with Systolic Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000771-24,0,0,0 2014-000774-18,11,2017-09-15,2017-09-20,7,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Boston Biomedical, Inc.","A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of BBI608 plus Weekly Paclitaxel vs. Placebo plus Weekly Paclitaxel in Adult Patients with Advanced, Previously Treated Gastric ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000774-18,0,0,0 2014-000777-38,1,2017-11-08,2017-11-08,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,Fondazione IRCCS Istituto Nazionale dei Tumori,Activity and safety of second line SOrafenib After Pazopanib in patients with metastatic renal cell carcinoma (SOAP Study) Attività e sicurezza della seconda linea con sorafenib dopo pazopanib nei ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000777-38,0,0,0 2014-000778-20,2,2018-06-20,2018-06-20,1,1,1,0,0,0,2,0,1,2,0,0,0,0,1,"Takeda Vaccines, Inc.","A Phase II, Randomized, Double-Blind, Dosage, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine combined with Aluminum Hydroxide adjuvant in Ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000778-20,1,1,0 2014-000779-26,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Asociación Instituto Biodonostia,Efficacy of subcutaneous butylscopolamine vs placebo for control to death rattle in agony. Randomized clinical trial. Eficacia de la buscapina subcutánea vs placebo en el control de los estertores ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000779-26,0,0,0 2014-000780-40,7,2018-09-26,2018-09-26,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000780-40,0,0,0 2014-000782-53,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Università degli Studi di Torino-Dipartimento di Biotecnologie Molecolari e Scienze della Salute,"A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCyd) as pre transplant INDUCTION and post transplant consolidation or CARFILZOMIB, LENALIDOMID...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000782-53,0,0,0 2014-000784-41,1,2017-12-01,2017-12-01,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Department of Medicine and Endocrinology,"Amino acids in ileal pouch-anal anastomosis for ulcerative colitis: a randomized, double-blind placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000784-41,0,0,0 2014-000785-21,2,2015-10-23,2015-10-23,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur,Immunogenicity and Lot-to-Lot Consistency Study of a Quadrivalent Influenza Vaccine in Adult and Elderly Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000785-21,0,0,0 2014-000791-26,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,CHRU TOURS,Lévétiracétam pour le traitement en première intention des convulsions du nouveau-né : étude de phase II Lévétiracétam pour le traitement en première intention des convulsions du nouveau-né : étude...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000791-26,0,0,0 2014-000792-11,1,2019-07-04,2019-07-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Warwick,Prehospital Assessment of the Role of Adrenaline: Measuring the Effectiveness of Drug administration In Cardiac arrest,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000792-11,0,0,0 2014-000793-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SOLTI,"A Phase II, Randomized Study of T DM1 versus T DM1 plus short induction with docetaxel in first line treatment for locally advanced or metastatic HER2+ breast cancer. Estudio fase II, aleatorizado,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000793-19,0,0,0 2014-000804-88,4,2016-01-15,2016-01-15,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Millennium Pharmaceuticals, Inc.",A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000804-88,0,0,0 2014-000805-11,4,2016-01-15,2016-01-15,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Millennium Pharmaceuticals, Inc.",A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000805-11,0,0,0 2014-000808-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,PREDIX HER2 - Neoadjuvant response-guided treatment of HER2 positive breast cancer. Part of a platform of translational phase II trials based on molecular subtypes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000808-10,0,0,0 2014-000809-12,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Karolinska University Hospital,PREDIX Luminal A - Neoadjuvant response-guided treatment of slowly proliferating hormone receptor positive tumors. Part of a set of translational phase II trials based on molecular subtypes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000809-12,0,0,0 2014-000810-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,PREDIX Luminal B - Neoadjuvant response-guided treatment of estrogen receptor positive tumors with high proliferation or slow proliferation with metastatic nodes or young patients. Part of a set of tr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000810-72,0,0,0 2014-000814-73,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Birmingham,"National Lung Matrix Trial: Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000814-73,0,0,0 2014-000815-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Azienda Ospedaliera, Polo Universitario Luigi Sacco, Milano",Effects of a late add-on therapy of pegylated interferon (peg-IFNA) to ongoing nucleos(t)ide analogs (NUCs) in patients with chronic hepatitis B (CHB). Studio randomizzato e controllato sugli effet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000815-15,0,0,0 2014-000816-32,2,2015-08-12,2015-08-12,2,0,0,0,1,0,3,0,0,1,0,0,1,0,1,"ProFibrix, A wholly owned subsidary of the Medicines Company","A Phase 3b, Randomized, Single-Blind, Controlled, Comparative Efficacy and Safety Study of Topical Fibrocaps™ (Raplixa™) and Tachosil® in Surgical Hemostasis during Hepatic Resection Eine randomis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000816-32,0,0,0 2014-000817-30,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,0,University Medical Centre Utrecht,Comparing the effect of curcumin and genistein to treatment with Ivacaftor in CF patients with a class III mutation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000817-30,0,0,0 2014-000824-12,5,2015-06-19,2015-06-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc",A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with Pegylated Interferon and Ribavirin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000824-12,0,0,0 2014-000824-12,5,2015-06-19,2015-06-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with Pegylated Interferon and Ribavirin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000824-12,0,0,0 2014-000826-39,1,2015-01-30,2015-01-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Ortopædkirurgisk afdeling Odense Universitetshospital,Determining the tissue concentration of dicloxacillin using Microdialysis (on healthy male subjects) Bestemmelse af vævskoncentrationen af dicloxacillin med Mikrodialyse (på mandlige frivillige for...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000826-39,0,0,0 2014-000828-24,1,2017-10-27,2017-10-27,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Inserm-ANRS,A non-comparative phase II trial evaluating the capacity of the dual combination raltegravir/etravirine to maintain virological success in HIV-1 infected patients of at least 45 years of age with an H...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000828-24,0,0,0 2014-000830-42,2,2015-10-23,2015-10-23,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, 10017","A Randomized, 18-Week, Placebo Controlled, Double Blind, Parallel Group Study of the Safety and Efficacy of PF-05212377 (SAM-760) in Subjects with Mild to Moderate Alzheimer's Disease with Existing Ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000830-42,0,0,0 2014-000834-50,7,2019-11-28,2019-11-29,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,MOLOGEN AG,IMPALA-Trial: Evaluation of an immunomodulatory maintenance treatment in patients with metastatic colorectal cancer with tumor reduction during induction treatment - A phase III trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000834-50,1,0,0 2014-000835-17,1,2019-01-14,2019-01-14,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,GELTAMO (Grupo Cooperativo Español de Linfoma/Trasplante Autólogo de Médula Ósea),"PHASE I-II CLINICAL TRIAL FOR THE EVALUATION OF THE ROLE OF BRENTUXIMAB VEDOTIN PLUS ETOPOSIDE, SOLUMODERIN, HIGH DOSE ARA-C AND CIS-PLATIN IN THE TRANSPLANT AND POST-TRANSPLANT MANAGEMENT FOR PATIENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000835-17,0,0,0 2014-000838-39,1,2019-06-14,2019-06-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GEINO,"Clinical Trial Phase IIB randomized, multicenter, of continuation or non-continuation with 6 cycles of temozolomide after the first 6 cycles of standard first-line treatment in patients with glioblast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000838-39,0,0,0 2014-000839-16,1,2015-10-02,2015-10-02,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"HovedOrtoCentret, Rigshospitalet",The effect of intraoperative ketamine on opioid consumption and pain after spine surgery in opioid-dependent patients Effekten af intraoperativ ketamin på opioid forbrug og smerter efter rygkirurgi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000839-16,0,0,0 2014-000844-13,3,2016-07-19,2016-12-16,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Algipharma AS,"A double-blind, randomized, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000844-13,0,0,0 2014-000845-64,1,2015-03-10,2015-03-10,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,The Royal Marsden NHS Foundation Trust,A multicentre randomised phase II study of aflibercept plus chemotherapy in patients with colorectal liver-only metastases deemed to be inoperable or unsuitable for upfront liver resection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000845-64,0,0,0 2014-000846-32,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Fundació Privada Hospital Asil de Granollers,EFFECT OF SEROTONIN AND LEVODOPA FUNCTIONAL RECOVERY IN PATIENTS WITH CEREBRAL INFARCTION EFECTO DE LA SEROTONINA Y LA LEVODOPA EN LA RECUPERACION FUNCIONAL DE PACIENTES CON INFARTO CEREBRAL.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000846-32,0,0,0 2014-000848-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Grenoble,Endothelin and Ischemic optic Neuropathy study group Evaluation des effets du bosentan dans la prise en charge des patients à la phase aiguë de la neuropathie optique ischémique antérieure aiguë,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000848-14,0,0,0 2014-000857-35,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","An open label, randomized, phase 2 study of Paclitaxel and Panitumumab compared to Paclitaxel alone in patients with relapsed or refractory urothelial cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000857-35,0,0,0 2014-000859-91,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,CHRU de TOURS,Relation entre la déplétion des LYmphocytes T et la réponse clinique au RITUximab dans la polyarthrite rhumatoïde. Relation entre la déplétion des LYmphocytes T et la réponse clinique au RITUximab ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000859-91,0,0,0 2014-000860-16,1,2020-08-07,2020-08-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Technische Universität München Fakultaet fuer Medizin,Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction Metabolische und Molekulare Responseevaluation zur Therapie-Indi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000860-16,0,0,0 2014-000861-32,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Justus Liebig Universität Giessen,"Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF) A randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial Erfo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000861-32,0,0,0 2014-000865-34,2,2015-06-07,2015-06-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"A multi-center, double-blind, randomized, placebo-controlled, parallel group, exploratory Phase 2 study to assess efficacy and safety of selexipag in adult subjects with Raynaud's Phenomenon secondary...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000865-34,0,0,0 2014-000868-17,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Clínica Universidad de Navarra/Universidad de Navarra,Effect of dexmedetomidine vs propofol on basal ganglia activity (local field potentials) recorded through implanted stimulators Efecto de dexmedetomidina vs propofol en el registro de la actividad ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000868-17,0,0,0 2014-000870-20,1,2021-10-05,2021-10-05,1,0,0,0,0,0,2,0,1,1,1,1,1,0,1,Immungenetics AG,"An open-label, multicenter, controlled pharmaco-dynamic clinical trial to explore the Amyloid beta draining effect of Thiethylperazine (TEP) in subjects with early-to-mild dementia due to Alzheimer’s ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000870-20,0,0,0 2014-000871-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Eva Marie Erfurth,Effects of Exenatid on Weigth during diet and Caloric Restriction in patients with Craniopharyngioma and Hypothalamic obesity Postoperativ behandlingsstrategier för pt med craniopahryngiom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000871-17,0,0,0 2014-000871-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Lund University,Effects of Exenatid on Weigth during diet and Caloric Restriction in patients with Craniopharyngioma and Hypothalamic obesity Postoperativ behandlingsstrategier för pt med craniopahryngiom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000871-17,0,0,0 2014-000880-42,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Leeds,GALACTIC: GA-101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000880-42,0,0,0 2014-000881-23,1,2015-12-24,2015-12-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MYLAN GmbH,"AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN’S INSULIN GLARGINE WITH LANTUS® IN TYPE 2 DIABETES MELLITUS PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000881-23,0,0,0 2014-000882-34,1,2015-11-13,2015-11-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Ghent,Catheter based adjuvant intraperitoneal chemotherapy for carcinomatosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000882-34,0,0,0 2014-000883-16,3,2015-03-05,2015-08-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Devlopment Ltd,A Clinical Study to Evaluate Four Doses of Umeclidinium Bromide in Combination with Fluticasone Furoate in COPD Subjects with an Asthmatic Component,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000883-16,0,0,0 2014-000884-42,3,2015-06-15,2015-06-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Tiotropium 18 mcg in Subjects with Chronic Obstructive Pulmo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000884-42,0,0,0 2014-000885-23,5,2015-06-02,2015-06-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development,"A Randomized, Parallel-group, Open-label Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Glycopyrronium 44 mcg in Subjects with Chronic Obstructive Pulmonary Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000885-23,0,0,0 2014-000885-23,5,2015-06-02,2015-06-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A Randomized, Parallel-group, Open-label Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg compared with Glycopyrronium 44 mcg in Subjects with Chronic Obstructive Pulmonary Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000885-23,0,0,0 2014-000887-16,1,2020-03-03,2020-03-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The Royal Marsden NHS Foundation Trust,A phase II randomised study evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in post-menopausal women with ER+ primary breast canc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000887-16,0,0,0 2014-000887-16,1,2020-03-03,2020-03-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The Institute of Cancer Research,A phase II randomised study evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in post-menopausal women with ER+ primary breast canc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000887-16,0,0,0 2014-000898-39,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Scandinavian Sarcoma Group,Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000898-39,0,0,0 2014-000899-25,4,2019-09-23,2019-09-23,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Faron Pharmaceuticals Ltd,"A Phase II Double-blind, Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Prevention of Multi-Organ Failure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000899-25,0,0,0 2014-000902-37,1,2015-11-04,2015-11-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet",Conservative vs. Liberal Approach to fluid therapy of Septic Shock in Intensive Care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000902-37,0,0,0 2014-000904-88,8,2016-09-27,2017-04-25,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd,"A 24 week randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of once daily linagliptin, 5 milligrams orally, as add on to basal insulin in elderly Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000904-88,0,0,0 2014-000904-88,8,2016-09-27,2017-04-25,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A 24 week randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of once daily linagliptin, 5 milligrams orally, as add on to basal insulin in elderly Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000904-88,0,0,0 2014-000904-88,8,2016-09-27,2017-04-25,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A 24 week randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of once daily linagliptin, 5 milligrams orally, as add on to basal insulin in elderly Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000904-88,0,0,0 2014-000904-88,8,2016-09-27,2017-04-25,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A 24 week randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of once daily linagliptin, 5 milligrams orally, as add on to basal insulin in elderly Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000904-88,0,0,0 2014-000904-88,8,2016-09-27,2017-04-25,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A 24 week randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of once daily linagliptin, 5 milligrams orally, as add on to basal insulin in elderly Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000904-88,0,0,0 2014-000904-88,8,2016-09-27,2017-04-25,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Danmark A/S,"A 24 week randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of once daily linagliptin, 5 milligrams orally, as add on to basal insulin in elderly Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000904-88,0,0,0 2014-000904-88,8,2016-09-27,2017-04-25,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas SA,"A 24 week randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of once daily linagliptin, 5 milligrams orally, as add on to basal insulin in elderly Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000904-88,0,0,0 2014-000906-36,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,Laboratorios Gebro Pharma S.A.,"Randomized, parallel, multicenter, phase IV clinical trial to assess the efficacy of hyaluronic acid/chondroitin sulfate versus fosfomycin trometamol in recurrent urinary tract infection prevention. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000906-36,0,0,0 2014-000907-29,2,2015-04-24,2015-04-24,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Hevert-Arzneimittel GmbH & Co. KG,"Efficacy and safety of Sinusitis Hevert SL tablets compared to placebo in adult patients with acute, uncomplicated rhinosinusitis. A multicenter, randomized, double-blind, placebo-controlled, parallel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000907-29,0,0,0 2014-000914-76,10,2016-08-16,2017-08-16,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Shionogi Inc.,"A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000914-76,0,0,0 2014-000917-30,4,2015-05-08,2015-05-08,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Biogen Idec Research Limited,"A Multicenter, Open-Label Immunogenicity and Safety Study of subcutaneous Natalizumab 300 mg administered to Subjects with Relapsing Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000917-30,0,0,0 2014-000918-61,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospitals Bristol NHS Foundation trust,A randomised phase II pilot study of 3 weekly Cabazitaxel versus weekly Paclitaxel chemotherapy in the first line treatment of HER2 negative metsastatic breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000918-61,0,0,0 2014-000920-26,8,2017-12-15,2018-01-08,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"KARYOPHARM THERAPEUTICS, INC.","A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) versus Specified Physician s Choice in Patients older or equal to 60 Years Old with Rela...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000920-26,0,0,0 2014-000920-26,8,2017-12-15,2018-01-08,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Karyopharm Therapeutics, Inc.","A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) versus Specified Physician s Choice in Patients older or equal to 60 Years Old with Rela...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000920-26,0,0,0 2014-000923-25,4,2015-09-26,2015-09-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A 12-Week, Double-Blinded, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/ Salmeterol Multidose Dry Powder Inhaler in A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000923-25,0,0,0 2014-000924-11,1,2021-10-20,2021-10-20,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,"Ruprecht-Karls-University Heidelberg, Medical Faculty Mannheim represented by the chancellor",Phase IIA Study on therapy with the NF-kB inhibiting and apoptosis inducing drug dimethylfumarate (DMF) in Patients with Cutaneous T cell lymphoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000924-11,0,0,0 2014-000925-19,5,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Bayer AG,"A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL) - CHRONOS-2 Studio randomizzato, in doppio cieco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000925-19,0,0,0 2014-000925-19,5,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,BAYER HEALTHCARE AG,"A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL) - CHRONOS-2 Studio randomizzato, in doppio cieco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000925-19,0,0,0 2014-000925-19,5,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Bayer Healthcare AG,"A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL) - CHRONOS-2 Studio randomizzato, in doppio cieco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000925-19,0,0,0 2014-000931-18,1,2016-12-12,2016-12-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Ersi Voskaridou-Dimoula,"EVALUATION OF EFFICACY OF DENOSUMAB IN PATIENTS WITH THALASSEMIA MAJOR AND OSTEOPOROSIS: A RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-SITE, DOUBLE BLIND PHASE 2B CLINICAL TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000931-18,0,0,0 2014-000933-21,1,2017-03-01,2017-03-01,1,1,1,0,0,0,2,0,1,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, CONTROLLED, OBSERVER-BLINDED STUDY TO DESCRIBE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF NEISSERIA MENINGITIDIS SEROGROUP B BIVALENT RECOMBINANT LIPOPROTEIN 2086 VACCINE (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000933-21,0,0,0 2014-000934-53,2,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,1,Celsion Corporation,"A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) using standardized Radiofrequency Ablati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000934-53,0,0,0 2014-000936-40,1,2015-12-15,2015-12-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GWT-TUD GmbH,pilot study to investigate the effect of e.-coli-nissle as probiotic adjuvant to antidiabetic standard care in patients with diabetic mellitus type 2 Pilotstudie zur Untersuchung der Wirkung von E....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000936-40,0,0,0 2014-000944-13,1,2016-04-25,2016-04-25,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Genocea Biosciences, Inc.","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GEN-004, a Pneumococcal Protein Subunit Vaccine, on Colonization Following Intranasa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000944-13,0,0,0 2014-000949-77,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Adocia,"A double-blinded, randomised, four -period crossover euglycemic clamp trial investigating the dose-response and dose-exposure relationship of BC222 insulin lispro in three different doses in subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000949-77,0,0,0 2014-000952-26,1,2018-04-03,2018-04-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Edinburgh,Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients with Necrotic High-risk Coronary Plaque Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000952-26,0,0,0 2014-000952-26,1,2018-04-03,2018-04-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Academic and Clinical Central Office for Research and Development,Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients with Necrotic High-risk Coronary Plaque Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000952-26,0,0,0 2014-000955-10,3,2015-04-18,2015-04-18,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase III, double-blind, randomized, multicenter study to assess safety and immunogenicity of GlaxoSmithKline Biologicals? Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) manufactured with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000955-10,0,0,0 2014-000955-10,3,2015-04-18,2015-04-18,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline,"A Phase III, double-blind, randomized, multicenter study to assess safety and immunogenicity of GlaxoSmithKline Biologicals? Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) manufactured with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000955-10,0,0,0 2014-000959-92,1,2015-02-23,2015-02-23,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Department of Clinical Pharmacology Q,"A randomized, double-blinded, Placebo controlled study of simvastatins possible effect on oxidative stress on healthy volunteers Et randomiseret, dobbelt-blindet, placebo-kontrolleret studie af sim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000959-92,0,0,0 2014-000962-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Parc de Salut Mar,Effect of dexmedetomidine on monitoring of motor evoked potentials in patients undergoing supratentorial craniotomy or brainstem surgery Efecto de dexmetomidina sobre la monitorización de potencia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000962-23,0,0,0 2014-000963-42,1,2015-07-17,2015-07-17,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,F. Hoffmann-La Roche Ltd.,"A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of oral vismodegib for the treatment of idiopathic pulmonary fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000963-42,0,0,0 2014-000964-16,1,2016-05-31,2016-05-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,IVI Valencia,Uterine fibroids: Impact of ulipristal acetate 10 mg on ART results. Miomas uterinos: Impacto del acetato de ulipristal 10 mg en los resultados de reproducción asistida,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000964-16,0,0,0 2014-000966-23,1,2014-09-01,2014-09-01,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,The effects of BCG-vaccination on the immune response induced by influenza-vaccination in healthy volunteers A pilot proof-of-principle study De effecten van BCG vaccinatie op de door influenza v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000966-23,0,0,0 2014-000967-42,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,National Institute for Public Health and the Environment (RIVM),Strengthening memory immunity in the aged population by vaccinating re-elderly Stimuleren van geheugen immuniteit in de ouder wordende populatie door mensen op middelbare leeftijd te vaccineren,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000967-42,0,0,0 2014-000969-47,1,2016-04-29,2016-04-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital of Toulouse,"Clinical efficacy of coordinated boluses in type 1 diabetic patients treated with insulin pumps: a multicentric, randomised, cross over study (COBOL study). Evaluation de l’efficacité clinique des ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000969-47,0,0,0 2014-000972-24,5,2015-07-02,2015-07-02,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomized, Double blind, Placebo controlled, Multi center, Cross over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous Familial Hypercholesterolemia (HoFH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000972-24,0,0,0 2014-000973-38,1,2014-12-01,2014-12-01,1,1,0,0,1,0,3,0,1,1,1,1,1,0,0,RWTH Aachen vertreten durch das CTC-A,Xenon-inhalation: elimination of xenon and its effect on erythropoetin-levels in blood of healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000973-38,0,0,0 2014-000975-21,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación Retinaplus +,A phase IV study to evaluate the effectiveness of aflibercept in naive patients with macular edema secondary to Central Retinal Vein Occlusion (CRVO) on an individualized Treat and Extend regimen. NEU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000975-21,0,0,0 2014-000980-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University Vienna,Feasibility and safety of intensified preoperative glucose control in patients with type 2 diabetes undergoing cardiovascular surgery – a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000980-42,0,0,0 2014-000986-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS Ospedale San Raffaele U.O. Oculistica,Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Angioid Streaks (EYLEA-STRIE) Aflibercept intravitreale per la neovascolarizzazione coroideale secondaria a Strie Angioidi (EY...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000986-30,0,0,0 2014-000988-41,1,2019-10-10,2019-10-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Liverpool,"A randomized, controlled multi-centre trial of 26 weeks of subcutaneous Liraglutide (a GLP1 receptor agonist), with or without continuous positive airway pressure (CPAP), in patients with Type 2 Diabe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000988-41,0,0,0 2014-000991-25,1,2017-12-22,2017-12-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Central Manchester University Hospitals NHS Foundation Trust,Pre-surgical metformin for women with endometrial cancer: a randomised placebo controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000991-25,0,0,0 2014-000993-20,1,2017-11-13,2017-11-13,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Center for Research and Development Uppsala University/County Council of Gävleborg,Dosing of intraarticular triamcinolone hexacetonid for knee synovitis in chronic polyarthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000993-20,0,0,0 2014-000995-24,2,2015-11-26,2015-11-26,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GW Research Ltd,"A double-blind, placebo-controlled two-part study to investigate the dose-ranging safety and pharmacokinetics, followed by the efficacy and safety of cannabidiol (GWP42003-P) in children and young adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000995-24,0,0,0 2014-000996-18,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Complejo Hospitalario Torrecárdenas,CLINICAL TRIAL TO EVALUATE THE EFFICACY AND THE SECURITY OF DEXAMETASONE+BUPIBACAINE+ARTICAINE+EPINEFRINE “VERSUS” ARTICAINE+EPINEFRINE IN THE POSTQUIRURGICAL PAIN OF THIRD MOLAR SURGERY ENSAYO CLÍ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000996-18,0,0,0 2014-000998-39,4,2016-02-09,2016-02-09,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Helsinn Healthcare SA,"Randomized, double-blind, parallel group, placebo-controlled, dose finding study in colorectal cancer patients receiving 5-FU-based chemotherapy to assess the efficacy of different doses of s.c. elsig...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000998-39,0,0,0 2014-000999-26,2,2015-05-08,2015-05-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Jazz Pharmaceuticals, Inc.","An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (asparaginase Erwinia chrysanthemi)/Erwinase® (crisantaspase) Administered Following Hypersensitivity to E. coli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000999-26,0,0,0 2014-001001-40,2,2016-05-15,2016-05-15,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,DermaTools Biotech GmbH,"A multicentre, double-blind, randomised, controlled phase II/III study to evaluate the efficacy and safety of the new wound healing solution Diperoxochloric acid (DPOCl, DermaPro®) in patients with ve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001001-40,0,0,0 2014-001002-17,1,2020-11-10,2020-11-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,LYSARC,"A prospective phase II study of bendamustine in patients aged over 60 years with classical Hodgkin lymphoma treated by prednisone, vinblastine, and doxorubicin Etude prospective de phase II évaluan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001002-17,0,0,0 2014-001005-41,1,2016-01-29,2016-01-29,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Ghent University Hospital,"Evaluation of FLuid REsuscitation with Sterofundin ® ISO (Ringerfundin), Plasma-Lyte® or NaCl 0.9%. (FluReS study) Evaluatie van vochtresuscitatie met sterofundin, Plasma-Lyte en fysiologisch",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001005-41,0,0,0 2014-001006-18,2,2017-02-27,2017-02-27,2,1,1,0,0,1,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"Multicenter, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controlled ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001006-18,0,0,0 2014-001008-23,1,2016-08-23,2016-08-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"The Newcastle Upon Tyne Hospital NHS Foundation Trust, Freeman Hospital",Riociguat in patients with respiratory disease and hypoxia – a proof-of-concept study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001008-23,0,0,0 2014-001011-39,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Gilead Sciences, Inc.","A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001011-39,0,0,0 2014-001012-19,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,VU University Medical Center,Effects of fingolimod on functional brain adaptation and clinical measures in multiple sclerosis Het effect van fingolimod op functionele breinadaptatie en klinische maten in multiple sclerose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001012-19,0,0,0 2014-001013-81,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Centro Hospitalar de São João, EPE",Treatment of Bladder Pain Syndrome with Onabotulinum toxin A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001013-81,0,0,0 2014-001014-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per la Recerca Biomèdica,Brain Amyloid-Beta burden as per florbetaben (Neuraceq) pet and cognitive outcomes after deep brain stimulation in Parkinsin's disease Carga de amiloidosis cerebral medida por PET con Florbetaben (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001014-25,0,0,0 2014-001017-61,14,2021-03-24,2021-03-24,10,1,0,0,0,0,2,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST-LINE METASTATIC COLORECTAL CANCER (MODUL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001017-61,1,0,0 2014-001017-61,14,2021-03-24,2021-03-24,10,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Roche Farma S.A. en nombre de F. Hoffmann-La Roche Ltd,A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST-LINE METASTATIC COLORECTAL CANCER (MODUL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001017-61,1,0,0 2014-001022-14,16,2021-05-13,2021-05-13,14,1,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001022-14,1,0,0 2014-001023-80,1,2020-07-20,2020-07-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Danish Head and Neck Cancer Group (DAHANCA),"DAHANCA 26. A phase II unblinded, randomized study of paclitaxel and capecitabine with or without cetuximab as first line treatment of recurrent or metastatic squamous cell head and neck cancer (HNSCC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001023-80,0,0,0 2014-001026-16,1,2015-06-12,2015-06-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Dermal Laboratories Limited,"Randomised, double-blind, bilateral comparison of two emollients in patients with dry skin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001026-16,0,0,0 2014-001029-34,1,2017-06-30,2017-06-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,ELPEN Pharmaceutical Co. Inc,Evaluation of the effect of the inhaled combination budesonide -formoterol (Pulmoton® Elpenhaler®) in exhaled nitric oxide (FeNO) of patients with bronchial asthma. Αξιολόγηση της επίδρασης του εισ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001029-34,0,0,0 2014-001030-29,1,,,0,1,0,0,0,0,3,0,1,1,1,1,0,1,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Double-blind, Lot-to-Lot Consistency Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001030-29,0,0,0 2014-001032-11,3,2020-10-16,2020-10-16,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Omeros Corporation,"A Phase 2, uncontrolled, three-stage, dose-escalation cohort study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and clinical activity of OMS721 in adults with thrombotic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001032-11,0,0,0 2014-001042-24,5,2016-01-06,2016-01-06,4,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Abbott Biologicals B.V.,"Randomized, Double-Blind, Active-Controlled Study in Adults to Assess the Safety and Immunogenicity of Abbott’s Candidate Quadrivalent Influenza Vaccine and its Non-Inferiority to Trivalent Influenza ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001042-24,0,0,0 2014-001044-38,1,2016-11-03,2016-11-03,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,Radboud University Nijmegen Medical Center,Influence of an Acidic Beverage (Coca-Cola) on the exposure to Imatinib (GLIvec) after major gastrecTomY in patients with Gastrointestinal Stromal Tumors (ABILITY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001044-38,0,0,0 2014-001047-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sankt Eriks Eye Hospital,Randomized trial comparing injection frequency between Aflibercept and Ranibizumab in patients with Central Retinal Vein Occlusion with a treat and extent algorithm,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001047-21,0,0,0 2014-001048-40,4,2018-01-31,2018-01-31,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, 10017","A phase 2, double-blind, randomized safety and efficacy study of Glasdegib (PF-04449913) versus placebo in patients with Myelofibrosis previously treated with ruxolitinib.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001048-40,0,0,0 2014-001049-25,6,2016-02-05,2016-02-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Initial Combination of Ertugliflozin (MK-8835/PF-049717...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001049-25,0,0,0 2014-001050-41,1,2020-04-16,2020-04-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Robarts Clinical Trials,A Cluster Randomized Controlled Trial of an Enhanced Treatment Algorithm for the Management of Crohn's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001050-41,0,0,0 2014-001051-23,6,2017-09-12,2017-09-12,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Array BioPharma Inc.,A Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001051-23,0,0,0 2014-001052-39,9,2015-08-14,2015-08-14,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Array BioPharma Inc.,"The FACTOR Study (Filanesib and Carfilzomib Treatment of Relapsed/Refractory Multiple Myeloma): A Multinational, Randomized, Open-label Phase 3 Study of Filanesib (ARRY-520) + Carfilzomib Versus Singl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001052-39,0,0,0 2014-001053-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,AstraZeneca AB,"A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients with a History of Frequent Acute Exacerbations while on Maint...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001053-16,0,0,0 2014-001054-42,6,2017-09-21,2017-09-21,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,CSL Behring GmbH,"An open-label, randomized study to evaluate the long-term clinical safety and efficacy of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the prophylactic treatment of her...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001054-42,0,0,0 2014-001054-42,6,2017-09-21,2017-09-21,6,1,0,0,0,2,3,0,0,1,0,0,1,0,1,CSL BEHRING GMBH,"An open-label, randomized study to evaluate the long-term clinical safety and efficacy of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the prophylactic treatment of her...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001054-42,0,0,0 2014-001062-10,2,2015-06-08,2015-06-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A randomised, assessor-blinded, multi-centre trial comparing the efficacy, safety and tolerability of the PICOPREP tailored dosing schedule to the PICOPREP day-before dosing schedule for colon cleansi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001062-10,0,0,0 2014-001063-12,3,2016-04-27,2016-04-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Evolus Inc.,"A phase III, multi-center, randomized, double blind, active and placebo control, single dose trial to demonstrate the efficacy and safety of DWP-450 in adult subjects for treatment of moderate-to-seve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001063-12,0,0,0 2014-001068-36,1,2018-03-06,2018-03-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Central Manchester University Hospitals NHS Foundation Trust,Onabotulinum toxin-A versus extended release tolterodine in the management of idiopathic overactive bladder in children: A pilot randomised controlled trial (OVERT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001068-36,0,0,0 2014-001069-28,10,2020-01-13,2020-05-27,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca AB,A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001069-28,0,0,0 2014-001074-34,2,2015-11-10,2015-11-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Camurus AB,"A Phase II, Open Label, Active Control, Multi-National, Multi-Centre, Randomized, Parallel Group Study Assessing Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of CAM2032 q1m (Leuprolide Acet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001074-34,0,0,0 2014-001076-58,2,2016-03-07,2016-03-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergan Limited,BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001076-58,0,0,0 2014-001077-14,2,2017-06-13,2017-06-13,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"An open label, single-arm phase IV study to assess the efficacy and safety of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001077-14,0,0,0 2014-001081-99,1,2016-03-02,2016-03-02,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,ImCyse S.A,"A clinical trial to document safety and radiological disease activity in patients with relapsing-remitting multiple sclerosis treated with autologous CD4+ cells, stimulated and expanded ex vivo by a m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001081-99,0,0,0 2014-001085-10,1,2017-05-31,2017-05-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Ltd,"A phase IV, prospective, open label, uncontrolled, European study in patients with neovascular age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching from intravitrea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001085-10,0,0,0 2014-001086-27,8,2018-07-02,2018-07-02,7,1,1,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI- 563) in Asthmatic Adults and Adolescents on Inhal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001086-27,0,0,0 2014-001088-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,MEDA,Academic study on the effects of MP 29-02 nasal spray on inflammatory mediators in allergic rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001088-11,0,0,0 2014-001089-90,1,,,0,0,0,1,0,0,1,0,0,4,0,0,0,0,1,"Oriel Therapeutics, a Sandoz Company",Study to Test the Product Robustness of a Dry Powder Inhalation Device When Used in Normal Clinical Practice with Young Asthma Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001089-90,0,0,0 2014-001090-14,1,2020-01-02,2020-01-02,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Diurétique versus placebo dans l’embolie pulmonaire avec dilatation du ventricule droit,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001090-14,0,0,0 2014-001093-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Istituto Clinico Humanitas,An Open-Label Phase II Study of regorafenib In Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND Studio di fase II in aperto sull’uso di regorafenib in pazi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001093-34,0,0,0 2014-001096-31,3,2016-07-13,2016-07-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study comparing the safety and efficacy of ABT-981 to placebo in subjects with erosive hand osteoarthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001096-31,0,0,0 2014-001097-34,9,2018-10-02,2018-10-02,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MedImmune, LLC","A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001097-34,0,0,0 2014-001098-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Antwerp University Hospital,Adjuvant dendritic-cell immunotherapy plus temozolomide following surgery and chemoradiation in patients with newly diagnosed glioblastoma Adjuvante dendritische cel immuuntherapie plus temozolomid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001098-15,0,0,0 2014-001101-40,1,2018-09-06,2018-09-06,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University College London (UCL),"Sclero XIII: A phase II ,double-blind, randomized, placebo-controlled study to investigate pharmacokinetics (PK), safety and efficacy of intravenous factor XIII treatment in patients with systemic scl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001101-40,0,0,0 2014-001102-17,2,2016-10-26,2016-10-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 26-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial with a Blinded 26-week Long -term Extension Period to Evaluate the Efficacy and Safety ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001102-17,0,0,0 2014-001105-41,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Celgene Corporation,"A Phase 2, open-label, multicenter study to assess safety and efficacy of second/third-line treatment with nab-paclitaxel (ABI-007) in combination with epigenetic modifying therapy of CC-486, or immun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001105-41,0,0,0 2014-001111-39,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Radboud University Nijmegen Medical Center,Once daily DArunavir/ritonavir in HIV-infected children 6-12 years old: a PHarmacokiNEtic validation of model-based dosing recommendations (DAPHNE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001111-39,0,0,0 2014-001114-26,11,2018-07-20,2018-08-08,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remissi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001114-26,0,0,0 2014-001115-39,1,2020-01-23,2020-01-23,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Barts Health NHS Trust,A phase IV single-blind placebo-controlled cross-over study to investigate the efficacy of greater occipital nerve block with local anaesthetic and steroid in patients with chronic migraine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001115-39,0,0,0 2014-001117-41,5,2018-03-07,2018-09-24,3,1,0,0,0,0,4,0,1,2,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IV, open-label, non-randomised, multi-centre study to assess the immunogenicity and safety of Infanrix hexa? administered as primary vaccination in healthy infants born to mothers given Boostr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001117-41,1,1,0 2014-001117-41,5,2018-03-07,2018-09-24,3,1,0,0,0,0,4,0,1,2,0,0,0,0,1,GlaxoSmithKline S.A.,"A phase IV, open-label, non-randomised, multi-centre study to assess the immunogenicity and safety of Infanrix hexa? administered as primary vaccination in healthy infants born to mothers given Boostr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001117-41,1,1,0 2014-001117-41,5,2018-03-07,2018-09-24,3,1,0,0,0,0,4,0,1,2,0,0,0,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A phase IV, open-label, non-randomised, multi-centre study to assess the immunogenicity and safety of Infanrix hexa? administered as primary vaccination in healthy infants born to mothers given Boostr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001117-41,1,1,0 2014-001118-24,2,2015-05-04,2015-05-04,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase III, placebo-controlled, observer-blind, randomised, multi-centre study to describe the immunogenicity and safety of GSK Biologicals’ Quadrivalent Split Virion Influenza Vaccine 2014/2015 Infl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001118-24,0,0,0 2014-001119-38,4,2017-10-24,2017-10-24,3,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase IV, observer-blind, randomised, cross-over, placebo-controlled, multicentre study to assess the immunogenicity and safety of a single dose of Boostrix? in pregnant women. Estudio multicéntr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001119-38,0,0,0 2014-001119-38,4,2017-10-24,2017-10-24,3,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GlaxoSmithKline,"A Phase IV, observer-blind, randomised, cross-over, placebo-controlled, multicentre study to assess the immunogenicity and safety of a single dose of Boostrix? in pregnant women. Estudio multicéntr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001119-38,0,0,0 2014-001119-38,4,2017-10-24,2017-10-24,3,1,0,0,0,0,4,0,1,1,0,0,1,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A Phase IV, observer-blind, randomised, cross-over, placebo-controlled, multicentre study to assess the immunogenicity and safety of a single dose of Boostrix? in pregnant women. Estudio multicéntr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001119-38,0,0,0 2014-001120-30,5,2019-07-11,2019-07-11,3,1,0,0,0,0,4,0,1,2,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IV, open-label, non-randomised, multi-centre study to assess the immunogenicity and safety of a booster dose of Infanrix hexa? in healthy infants born to mothers vaccinated with Boostrix? duri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001120-30,1,1,0 2014-001120-30,5,2019-07-11,2019-07-11,3,1,0,0,0,0,4,0,1,2,0,0,0,0,1,"GlaxoSmithKline Biologicals SA,","A phase IV, open-label, non-randomised, multi-centre study to assess the immunogenicity and safety of a booster dose of Infanrix hexa? in healthy infants born to mothers vaccinated with Boostrix? duri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001120-30,1,1,0 2014-001120-30,5,2019-07-11,2019-07-11,3,1,0,0,0,0,4,0,1,2,0,0,0,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A phase IV, open-label, non-randomised, multi-centre study to assess the immunogenicity and safety of a booster dose of Infanrix hexa? in healthy infants born to mothers vaccinated with Boostrix? duri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001120-30,1,1,0 2014-001120-30,5,2019-07-11,2019-07-11,3,1,0,0,0,0,4,0,1,2,0,0,0,0,1,GlaxoSmithKline S.A.,"A phase IV, open-label, non-randomised, multi-centre study to assess the immunogenicity and safety of a booster dose of Infanrix hexa? in healthy infants born to mothers vaccinated with Boostrix? duri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001120-30,1,1,0 2014-001126-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.O.N.O. (Gruppo Oncologico Nord Ovest),"A phase II single-arm study of cetuximab plus irinotecan as rechallenge 3rd-line treatment of kras, nras and braf wild-type irinotecan-pretreated metastatic colorectal cancer patients progressing aft...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001126-15,0,0,0 2014-001127-69,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001127-69,0,0,0 2014-001127-69,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001127-69,0,0,0 2014-001128-31,1,2021-01-19,2021-01-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cancer Trials Ireland,Phase II Single-arm Study evaluating Neo-adjuvant (pre-radical radiotherapy) Abiraterone acetate (plus prednisolone) and Gonadotropin-Releasing Hormone (GnRH) agonist in high risk localised prostate c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001128-31,0,0,0 2014-001129-34,9,2017-03-06,2017-03-06,5,0,0,0,0,0,3,0,0,1,1,0,1,0,1,AnGes Inc.,"A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AMG0001 IN SUBJECTS WITH CRITICAL LIMB ISCHEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001129-34,0,0,0 2014-001131-36,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Osmotica Pharmaceutical Corp.,"A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodopa-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001131-36,0,0,0 2014-001132-10,2,2016-05-19,2016-05-19,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Osmotica Pharmaceutical Corp.,"A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodopa-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001132-10,1,0,0 2014-001146-13,2,2022-04-28,2022-04-28,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Amgen Inc.,"A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001146-13,1,0,0 2014-001148-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Heart Center Freiburg - Bad Krozingen,Pharmacodynamic comparison of thienopyridine loading strategies in patients undergoing elective coronary stenting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001148-40,0,0,0 2014-001149-25,3,2015-09-21,2015-09-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A 12-Week, Double-Blinded, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/ Salmeterol Multidose Dry Powder Inhaler in A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001149-25,0,0,0 2014-001155-22,1,2016-08-04,2016-08-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Mona Ring Gätke,Muscle relaxation during open upper abdominal surgery -can the surgical conditions be optimized? (The laparotomy study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001155-22,0,0,0 2014-001156-28,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,Abiogen Pharma SpA,"A randomized, double-blind, placebo controlled study to assess the safety and the efficacy of Neridronate ampoules 25 mg, after repeated intramuscular administrations, in patients with Complex Regiona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001156-28,0,0,0 2014-001157-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundació Parc Taulí,"Efficacy and safety of intranasal administration of haloperidol in agitated schizophrenic patients: a controlled, blinded, randomized and single-center clinical trial Eficacia y seguridad de la adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001157-17,0,0,0 2014-001158-41,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,SPARKLE SRL,"“Technical and diagnostic performances of PET/CT with 64Cu(II)Cl2 in localization of metastases from prostate carcinoma, in patients undergoing restaging for disease progression during ADT” “Perfor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001158-41,0,0,0 2014-001161-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,European Uro- Oncology Group (EUOG),"An Exploratory Phase 2, open-label, single-arm, efficacy and imaging Study of Oral Enzalutamide (MDV3100) Androgen Receptor (AR)-Directed Therapy in Chemo-Naïve patients with Progressive Prostate Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001161-27,0,0,0 2014-001162-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,European Uro- Oncology Group (EUOG),"An Exploratory Phase 2, open-label, single-arm, efficacy and imaging Study of Oral Enzalutamide (MDV3100) Androgen Receptor (AR)-Directed Therapy in Hormono-Naïve patients with Metastatic Prostate Can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001162-10,0,0,0 2014-001163-12,1,2018-07-03,2018-07-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Herlev University Hospital, Oncology Dept.","A Single Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Gemcitabine (GEM) and Capecitabine (CAP) with or without T-ChOSTM as adjuvant therapy in patients with surgically resecte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001163-12,0,0,0 2014-001165-27,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Mylan Pharma UK Ltd,"A Randomized, Double-Blind, Parallel Group 24 Week Placebo-Controlled Efficacy and Safety Study with a 28 Week Long Term Extension, of Nebulized Fluticasone Propionate (FP) /Formoterol Fumarate (FF) C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001165-27,0,0,0 2014-001167-12,2,2021-06-27,2021-06-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Essen,"A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001167-12,0,0,0 2014-001169-28,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,0,Centre Hospitalier de Toulouse,Traitement précoce de patients pédiatriques présentant un syndrome hémolytique et urémique typique par l’anticorps monoclonal anti-C5 eculizumab : essai...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001169-28,0,0,0 2014-001170-33,1,,,0,0,0,0,1,1,4,0,0,0,0,0,0,0,0,St. Antonius Hospital,Local Gentamicin in Redon treated Post-sternotomy Mediastinitis Lokale gentamicine in de behandeling van mediastinitis na openhartchirurgie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001170-33,0,0,0 2014-001171-31,2,2015-08-10,2015-08-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Almirall Hermal GmbH,"Multicentre, randomized, parallel, double-blind, vehicle controlled study to evaluate the efficacy and safety of Actikerall® solution in the field-directed treatment of actinic keratoses grade I to II...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001171-31,0,0,0 2014-001174-34,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Pfizer Inc.,"A PHASE 4/3, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 50 TO 65 YEARS OF AGE AND IN CHILDREN 6 TO 17 YEA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001174-34,0,1,1 2014-001175-31,1,2017-05-23,2017-05-23,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Almac Discovery,A phase I open-label multicentre dose-escalation study of subcutaneous ALM201 in patients with advanced ovarian cancer and other solid tumours.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001175-31,0,0,0 2014-001182-27,1,,,0,1,0,0,1,0,4,0,0,1,1,1,0,1,1,Novartis Pharma GmbH,"A randomized, single-blinded, multicenter, phase IV study to compare systemic VEGF protein dynamics following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001182-27,0,0,0 2014-001185-10,1,2016-01-31,2016-01-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,IBSA Institut Biochimique SA,"Effect of a progesterone 25 mg solution (Pleyris, IBSA Farmaceutici Italia, srl) administered by oral route compared to an oral progesterone 200 mg capsule (Prometrium, Rottapharm SpA) on the endometr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001185-10,0,0,0 2014-001189-87,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Swiss Group for Clinical Cancer Research,Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks - A Non-Inferiority Phase III trial Verhinderung von symptomatischen Komplikationen am Skel...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001189-87,0,0,0 2014-001193-34,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Clínic per a la recerca biomèdica,COMPARISON OF TWO ANTIRETROVIRAL ALTERNATIVE COMBINATIONS IN HIV-1 POST-EXPOSURE PROPHYLAXIS: TENOFOVIR+EMTRICITABINE (TRUVADA®) + LOPINAVIR/RITONAVIR (KALETRA®) VS TENOFOVIR+EMTRICITABINA+ COBICISTAT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001193-34,0,0,0 2014-001197-34,1,2017-05-10,2017-05-10,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A repeat-dose, open-label, parallel-group study to assess the pharmacokinetics of GSK1278863 and metabolites in subjects with End Stage Renal Disease undergoing peritoneal dialysis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001197-34,0,0,0 2014-001198-15,6,2016-02-12,2016-02-12,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.",A PHASE 3 CONFIRMATORY STUDY INVESTIGATING THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001198-15,0,0,0 2014-001202-17,1,2017-03-09,2017-03-09,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Q-med AB,"An evaluator-blinded multi-center study of combined treatment with Azzalure/Dysport, Restylane/Emervel filler and Restylane skinbooster as compared to single treatment with either Azzalure/Dysport alo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001202-17,0,0,0 2014-001203-50,1,2016-12-17,2016-12-17,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Q-med AB,"An evaluator-blinded multi-center study of combined treatment with Azzalure, Restylane/Emervel filler and Restylane skinbooster as compared to single treatment with either Azzalure alone or Restylane/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001203-50,0,0,0 2014-001204-21,1,2017-04-10,2017-04-10,1,1,0,0,0,1,4,0,0,1,1,1,1,0,1,Novartis Pharma GmbH,"An 8 week open-label interventional multicenter study to evaluate the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥ 6 years of age, chronically infected with Pseud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001204-21,0,0,0 2014-001205-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Sociedade Portuguesa de Cardiologia,"VIldagliptin as an ischemic PERconditioning mimetic agent in Acute Myocardial Infarction – A single centre, randomized, parallel-group, double-blind clinical trial, for assessing the effectiveness of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001205-41,0,0,0 2014-001207-42,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERO UNIVERSITARIA DI PARMA,Multicenter randomized trial comparing erlotinib vs mono-chemotherapy in the third-line treatment of non-small cell lung cancer (NSCLC) patients with EGFR-mutated or unknown Studio randomizzato mul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001207-42,0,0,0 2014-001208-23,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Velindre NHS Trust,"A randomised, double blind, placebo controlled, phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001208-23,0,0,0 2014-001210-26,1,2019-05-02,2019-05-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PROBELTE PHARMA S.A.,"Biological standardization of allergen extracts of pollen of Dactylis glomerata, Festuca pratensis, Lolium perenne, Phleum pratense and Poa pratensis in patients sensitized to them. Estandarizació...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001210-26,0,0,0 2014-001211-39,2,2017-02-01,2017-02-01,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Alkermes, Inc.","A Phase 2, Efficacy, Safety, and Tolerability Study of ALKS 3831 in Schizophrenia with Alcohol Use Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001211-39,0,0,0 2014-001213-12,1,2015-08-22,2015-08-22,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Shire Orphan Therapies, Inc.","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety and Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001213-12,0,0,0 2014-001215-39,8,2019-02-27,2019-02-27,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A randomised, double-blind, double-dummy, placebo-controlled, parallel-group multi-centre clinical proof-of-principle trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigatin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001215-39,0,0,0 2014-001216-19,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,NHS Greater Glasgow & Clyde,Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose esca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001216-19,0,0,0 2014-001216-19,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,University of Glasgow,Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose esca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001216-19,0,0,0 2014-001218-24,1,2017-03-28,2017-03-28,1,0,0,0,0,0,4,0,1,1,1,1,1,0,1,Trichocare Diagnostics Ltd,"An open label, intra-subject, controlled multi-centre study to assess the concordance (specificity and sensitivity) between Colourstart® Test 73 mcg Cutaneous Patch and Finn Chamber in the detection o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001218-24,0,0,0 2014-001220-30,3,2020-02-12,2020-05-06,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.","An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab in C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001220-30,0,0,0 2014-001220-30,3,2020-02-12,2020-05-06,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab in C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001220-30,0,0,0 2014-001220-30,3,2020-02-12,2020-05-06,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab in C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001220-30,0,0,0 2014-001222-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Bioavailability of voriconazole in critically ill patients Biologische beschikbaarheid van voriconazol bij intensive care patiënten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001222-15,0,0,0 2014-001225-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,Secured access to vemurafenib for patients with tumors harboring BRAF genomic alterations.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001225-33,0,0,0 2014-001229-34,1,2017-02-22,2017-02-22,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Alnylam Pharmaceuticals, Inc.","A Phase 2, Open-label Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTRSC in Patients with Transthyretin (TTR) Cardiac Amyloidosis Who Have Previousl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001229-34,0,0,0 2014-001231-36,5,2017-02-08,2017-02-08,5,1,0,0,0,0,4,0,2,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,A phase IV trial to assess the effectiveness of Apixaban compared with usual care anticoagulation in subjects with non-valvular Atrial Fibrillation undergoing cardioversion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001231-36,0,0,0 2014-001232-11,7,2019-08-08,2019-08-08,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"Study 200622: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of mepolizumab in the treatment of adolescent and adult subjects with severe hypereosinophilic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001232-11,0,0,0 2014-001232-11,7,2019-08-08,2019-08-08,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"Study 200622: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of mepolizumab in the treatment of adolescent and adult subjects with severe hypereosinophilic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001232-11,0,0,0 2014-001232-11,7,2019-08-08,2019-08-08,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","Study 200622: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of mepolizumab in the treatment of adolescent and adult subjects with severe hypereosinophilic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001232-11,0,0,0 2014-001233-89,14,2019-06-17,2019-06-17,11,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Astex Pharmaceuticals, Inc.","A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Inte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001233-89,0,0,0 2014-001237-83,4,2018-07-26,2018-07-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF TRASTUZUMAB EMTANSINE IN PATIENTS WITH HER2 IHC-POSITIVE, LOCALLY ADVANCED OR METASTATIC NON?SMALL CELL LUNG CANCER WHO HAVE RECEIVED AT LEAST ONE PRIOR CH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001237-83,0,0,0 2014-001237-83,4,2018-07-26,2018-07-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farma, S.A en nombre de F. Hoffmann-La Roche Ltd","A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF TRASTUZUMAB EMTANSINE IN PATIENTS WITH HER2 IHC-POSITIVE, LOCALLY ADVANCED OR METASTATIC NON?SMALL CELL LUNG CANCER WHO HAVE RECEIVED AT LEAST ONE PRIOR CH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001237-83,0,0,0 2014-001240-38,3,2016-09-12,2016-09-12,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Karyopharm Therapeutics Inc.,A Phase 2 Study of the Safety and Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Initial or Refractory/Relapsed Richters Transformati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001240-38,0,0,0 2014-001240-38,3,2016-09-12,2016-09-12,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Karyopharm Therapeutics, Inc.",A Phase 2 Study of the Safety and Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Initial or Refractory/Relapsed Richters Transformati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001240-38,0,0,0 2014-001241-24,2,2020-01-24,2020-01-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Service AG,"Long-term, open-label, multicenter study assessing long-term cardiovascular risks in patients treated with fingolimod",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001241-24,0,0,0 2014-001241-24,2,2020-01-24,2020-01-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Farma SpA,"Long-term, open-label, multicenter study assessing long-term cardiovascular risks in patients treated with fingolimod",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001241-24,0,0,0 2014-001243-20,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Helsinki University Central Hospital,"Syntethic vs. natural estrogen in combined oral contraception- effect on insulinsensitivity, inflammation, coagulation and endometrium. A comparison with a progestin-only preparation. Synteettinen ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001243-20,0,0,0 2014-001244-38,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Imperial College London,Preventing Recurrent Gestational Diabetes Mellitus with Early Metformin Intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001244-38,0,0,0 2014-001245-24,1,2015-11-12,2015-11-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","An open-Label, multicenter study to evaluate the efficacy and safety of sofosbuvir/ledipasvir fixed-dose combination ± ribavirin for 12 or 24 weeks in chronic genotype 1 HCV infected subjects who part...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001245-24,0,0,0 2014-001249-26,4,2021-12-31,2021-12-31,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,GILEAD SCIENCES INCORPORATED,A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-Spo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001249-26,1,0,0 2014-001249-26,4,2021-12-31,2021-12-31,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Gilead Sciences, Inc.",A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment with a Sofosbuvir-Based Regimen without Interferon for Chronic Hepatitis C Infection in Gilead-Spo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001249-26,1,0,0 2014-001250-41,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Region Östergötland,THE IMPACT OF VITAMIN D ON PHYSICAL TRAINING OF VITAMIN D DEFICIENT PATIENTS WITH COPD: A PROSPECTIVE RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTI-CENTRE STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001250-41,0,0,0 2014-001253-16,1,2014-11-20,2014-11-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & développement,"A multi-center, open-label, single-arm, multiple dose study with HOE901-U300 to assess the Ease of Use and Safety of a new U300 pen injector in insulin-naïve patients with T2DM Eine multizentrische...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001253-16,0,0,0 2014-001259-22,4,2016-02-03,2016-02-09,3,1,1,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"open-label, single dose, tolerability, Pharmacokinetic/Pharmacodynamics and safety study of dabigatran etexilate given at the end of standard anticoagulant therapy in children aged less than 1 year o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001259-22,1,1,0 2014-001259-22,4,2016-02-03,2016-02-09,3,1,1,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim (Canada) Ltd/Ltée,"open-label, single dose, tolerability, Pharmacokinetic/Pharmacodynamics and safety study of dabigatran etexilate given at the end of standard anticoagulant therapy in children aged less than 1 year o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001259-22,1,1,0 2014-001259-22,4,2016-02-03,2016-02-09,3,1,1,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim Italia S.p.A.,"open-label, single dose, tolerability, Pharmacokinetic/Pharmacodynamics and safety study of dabigatran etexilate given at the end of standard anticoagulant therapy in children aged less than 1 year o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001259-22,1,1,0 2014-001259-22,4,2016-02-03,2016-02-09,3,1,1,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim France,"open-label, single dose, tolerability, Pharmacokinetic/Pharmacodynamics and safety study of dabigatran etexilate given at the end of standard anticoagulant therapy in children aged less than 1 year o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001259-22,1,1,0 2014-001263-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione Ricerca Traslazionale (FoRT),Crizotinib in pretreated metastatic non-small-cell lung cancer with MET amplification or ROS1 translocation (METROS) Crizotinib nel tumore pretrattato al polmone non a piccole cellule con amplifica...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001263-12,0,0,0 2014-001270-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Národný onkologický ústav,"A treatment strategy of the Use of 1st line Chemotherapy in Patients with Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors based on tumor marker decline: A Phase II Trial of paclitaxel, i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001270-33,0,0,0 2014-001273-13,1,2017-05-15,2017-05-15,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Hospital of Grenoble,Traitement des carcinomes à cellules de Merkel inopérables et/ou métastatiques par analogue de la somatostatine - Etude Nationale multicentrique mono-bras de phase II - PHRC Merkel,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001273-13,0,0,0 2014-001274-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Fondazione IRCCS Istituto Nazionale dei Tumori,"Phase II trial of abiraterone acetate in patients with relapsed and/or metastatic, castration resistant, salivary gland cancers. Studio di fase II con abiraterone acetato nel paziente con tumore ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001274-34,0,0,0 2014-001276-56,2,2016-12-31,2016-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,North Bristol NHS - Southmead Hospital,"A prospective, open label, randomised controlled clinical trial, with pharmacokinetic-pharmacodynamic validation, to compare antimicrobial treatment with oral minocycline plus rifampicin to treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001276-56,0,0,0 2014-001276-56,2,2016-12-31,2016-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Hellenic Institute for the Study of Sepsis,"A prospective, open label, randomised controlled clinical trial, with pharmacokinetic-pharmacodynamic validation, to compare antimicrobial treatment with oral minocycline plus rifampicin to treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001276-56,0,0,0 2014-001277-14,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,Royal Papworth Hospital NHS Foundation Trust,A Randomised Mechanistic Study Comparing the Effects of Different Anti-platelet Combinations (Ticagrelor vs. Placebo/ Clopidogrel) with Aspirin in Patients presenting with STEMI Treated with Primary P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001277-14,0,0,0 2014-001280-13,1,2020-03-19,2020-03-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Acceleron Pharma Inc.,An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 for the Treatment of Anemia in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Previously Enrolled i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001280-13,0,0,0 2014-001281-94,2,2020-04-28,2020-04-28,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Acceleron Pharma, Inc.",An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 in Patients with β-Thalassemia Previously Enrolled in Study A536-04,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001281-94,0,0,0 2014-001284-12,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University Medical Center Groningen,The Role of the Dopamine D2 Receptor System in Pornographic Addiction – A [11C]-Raclopride PET Study De rol van het dopamine D2 receptorsysteem in pornografieverslaving - een studie met [11C]-Racl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001284-12,0,0,0 2014-001285-10,12,2021-08-27,2021-08-27,8,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at Le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001285-10,1,0,0 2014-001286-28,16,2019-01-18,2019-01-18,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS- 936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001286-28,0,0,0 2014-001287-35,1,2019-01-02,2019-01-02,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Clínica Universidad de Navarra/Universidad de Navarra,A randomized phase II pilot study to evaluate safety and efficacy of the addition of vismodegib to standard neoadjuvant chemotherapy in triple negative breast cancer patients. Estudio piloto aleat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001287-35,0,0,0 2014-001290-14,1,2016-08-06,2016-08-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MERCK ROMANIA SRL,Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania using Electronic Device RebiSmart™ Studiu clinic prospectiv faza IV privind eficacitatea t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001290-14,0,0,0 2014-001291-56,2,2016-10-04,2016-10-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001291-56,0,0,0 2014-001291-56,2,2016-10-04,2016-10-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001291-56,0,0,0 2014-001295-65,4,2016-10-11,2016-10-11,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,TxCell,"A phase IIb, multicentre, randomised, double-blinded (DB), placebo-controlled, multi-dose and multi-injection, parallel groups study to evaluate the efficacy and the safety of Ovasave (ovalbumin-speci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001295-65,0,0,0 2014-001296-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Universitario de La Paz,Pharmacokinetic and pharmacodynamic optimization of amikacin treatment in patients with terminal renal failure under conventional hemodialysis: randomized clinical trial of two model of administration...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001296-32,0,0,0 2014-001299-79,1,2017-06-19,2017-06-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Department of Infectious Diseases, Odense University Hospital",Pneumococcal vaccination of rheumatoid arthritis patients in immunomodulatory therapy Pneumokokvaccination af reumatologiske patienter i immunmodulerende behandling,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001299-79,0,0,0 2014-001300-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Nîmes,"Evaluation de trois types d’infiltrations dans le cadre du traitement des épicondylalgies latérales : Leukocyte – Platelet Rich Plasma (L-PRP) versus Toxine botulique de type A (Xeomin®, MERZ) versus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001300-22,0,0,0 2014-001301-40,1,2015-10-16,2015-10-16,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,University of Oxford,"A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Concomitant Administration of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01¬B + ChAd63 and MV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001301-40,0,0,0 2014-001303-52,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Azienda Ospedaliero-Universitaria di Parma,Treatment of relapsed/refractory leukemia with intravenous administration of Dacarbazine Trattamento della leucemia acuta mieloide recidivata/refrattaria con somministrazione endovenosa di Dacarbaz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001303-52,0,0,0 2014-001305-41,1,2018-12-12,2018-12-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,GWT-TUD GmbH,MICROVASCULAR AND ANTIINFLAMMATORY EFFECTS OF RIVAROXABAN COMPARED TO LOW DOSE ASPIRIN IN TYPE 2 DIABETIC PATIENTS WITH VERY HIGH CARDIOVASCULAR RISK AND SUBCLINICAL INFLAMMATION Mikrovaskuläre und...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001305-41,0,0,0 2014-001309-42,7,2017-12-29,2017-12-29,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label, multi-center, Expanded Treatment Protocol (ETP) of ruxolitinib in patients with Polycythemia Vera who are Hydroxyurea resistant or intolerant and for whom no treatment alternatives are ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001309-42,0,0,0 2014-001314-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Institutet,"The effect of on demand versus continuous use of proton pump inhibitors on reflux symptoms, quality of life and self-rated health in patients with gastro-oesophageal reflux disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001314-25,0,0,0 2014-001315-40,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli,Amyloid Imaging in the “Italian Network for autosomal dominant Alzheimer’s disease and frontotemporal lobar degeneration (ItalianDIAfN)” Amyloid-PET all’interno dello studio “Network italiano per l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001315-40,0,0,0 2014-001319-38,1,2020-09-09,2020-09-09,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,"Monocenter prospective open single-arm phase IV study of the effects of hawthorn extract WS® 1442 on arterial micro-vascular structure and macro-vascular function, persistance and erectile function o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001319-38,0,0,0 2014-001321-32,1,2017-12-22,2017-12-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Clinical Microbiology, Hvidovre Hospital",The efficacy of pivmecillinam 3 days respectively 5 days t.i.d against community acquired uncomplicated urinary tract infections,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001321-32,0,0,0 2014-001323-76,1,2019-02-25,2019-02-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Linköping University,"Open Label trial to evaluate the tolerability of a combination therapy consisting of GAD-alum (Diamyd®), etanercept and vitamin D in children and adolescents newly diagnosed with type 1 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001323-76,0,0,0 2014-001325-33,4,2020-10-31,2020-10-31,2,1,0,0,0,0,2,0,0,2,0,0,0,0,0,Charité - Universitätsmedizin Berlin,Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001325-33,1,0,0 2014-001326-15,2,2020-06-02,2020-06-02,1,1,0,1,0,1,1,0,0,2,0,0,0,0,1,"Ignyta, Inc.","A Phase 1/2a, Multicenter, Open-Label Study of Oral RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for TrkA, TrkB, TrkC, ROS1, or ALK Molecular Alterati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001326-15,1,0,0 2014-001326-15,2,2020-06-02,2020-06-02,1,1,0,1,0,1,1,0,0,2,0,0,0,0,1,Ignyta Inc.,"A Phase 1/2a, Multicenter, Open-Label Study of Oral RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for TrkA, TrkB, TrkC, ROS1, or ALK Molecular Alterati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001326-15,1,0,0 2014-001330-29,1,2016-01-27,2016-01-27,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Ernesto Pérez Persona,No Ensayo piloto aleatorizado de dosis habitual de lenalidomida vs reducción de dosis en pacientes con mieloma múltiple en recaída que han alcanzado máxima respuesta.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001330-29,0,0,0 2014-001332-11,1,2016-12-06,2016-12-06,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Royal College of Surgeons,Aspirin for Optimising Pregnancy Outcome in Pregestational Diabetes: Pilot for The IRELAND Study (Investigating the Role of Early Low-dose Aspirin iN preexisting Diabetes),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001332-11,0,0,0 2014-001333-88,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,Academic Medical Center,A phase Ib/II study on the addition of Nab-paclitaxel (Abraxane) to capecitabine and oxaliplatin in the first-line treatment of metastastasized oesophagogastric carcinoma Een fase I/II onderzoek na...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001333-88,0,0,0 2014-001337-86,1,2016-05-19,2016-05-19,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Otonomy Inc.,"A 6-month, prospective, randomized, multicenter, placebo-controlled safety study of OTO-104 given at 3-month intervals by intratympanic injection in subjects with unilateral Meniere's disease, followe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001337-86,0,0,0 2014-001338-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Central hospital,Influence of propofol and desfluran on the cerebral circulation and recovery after anesthesia Propofolin ja desfluraanin yhteisvaikutus aivojen verenvirtauksen autoregulaatioon ja anestesiasta toip...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001338-27,0,0,0 2014-001342-21,1,2016-07-31,2016-07-31,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,Topical tropomysin kinase (TRK) inhibitor as a treatment for inherited CYLD defective skin tumours (TRAC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001342-21,0,0,0 2014-001348-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación pública andaluza para la gestión de la investigación en salud de Sevilla (FISEVI),"A Phase II, randomized clinical trial to assess the impact of antiretroviral therapy over viral load in seminal fluid in antiretroviral-naive HIV-positive patients Ensayo clínico fase II, aleatoriz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001348-39,0,0,0 2014-001351-23,1,2019-04-26,2019-04-26,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"EyeGene, Inc","A phase IIa, randomized, placebo-controlled, double-blind, parallel study to investigate the efficacy of EG-Mirotin subcutaneously administered in multiple doses on diabetic macular edema in diabetic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001351-23,0,0,0 2014-001352-36,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,3,,The effect of dopamine on reading motivation and achievement. Het effect van dopamine op leesmotivatie en -prestatie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001352-36,0,0,0 2014-001353-16,8,2019-03-28,2019-03-28,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bayer AG,"A Randomised, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001353-16,0,0,0 2014-001353-16,8,2019-03-28,2019-03-28,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A Randomised, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001353-16,0,0,0 2014-001354-42,6,2021-03-02,2021-03-02,4,1,0,0,0,0,4,0,0,2,0,0,0,0,0,Örebro University Hospital,"Influenza vaccination After Myocardial Infarction (IAMI trial). A multicenter, prospective, randomized controlled clinical trial based on national angiography and angioplasty registries",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001354-42,1,0,0 2014-001355-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,Ephedrine as add-on therapy for patients with myasthenia gravis Efedrine als toegevoegde behandeling voor patiënten met myasthenia gravis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001355-23,0,0,0 2014-001356-31,6,2014-12-21,2015-12-21,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,AOP Orphan Pharmaceuticals AG,"An open-label, single arm, Phase III study to assess the self-administration of AOP2014 using a pre-filled pen, developed for the treatment of Polycythemia Vera patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001356-31,0,0,0 2014-001357-17,8,2021-04-29,2021-04-29,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,AOP Orphan Pharmaceuticals AG,"An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously participat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001357-17,0,0,0 2014-001361-28,7,2021-10-20,2021-10-20,4,1,0,1,0,0,1,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,"A Phase Ib/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin (DCDS4501A) in combination with rituximab (R) or obinutuzumab (G) plus bendamustine (B) in relaps...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001361-28,1,0,0 2014-001361-28,7,2021-10-20,2021-10-20,4,1,0,1,0,0,1,0,0,2,0,0,0,0,1,"Roche Farma S.A., que representa en España a F.Hoffmann-La Roche","A Phase Ib/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin (DCDS4501A) in combination with rituximab (R) or obinutuzumab (G) plus bendamustine (B) in relaps...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001361-28,1,0,0 2014-001362-10,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,Bayer HealthCare AG,Routine prophylaxis treatment versus On-demand treatment for Children with severe Hemophilia A: comparison of all bleeding events in Chinese Hemophilia patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001362-10,0,1,1 2014-001363-12,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Klinikum der Universität München, Medizinische Klinik und Poliklinik III",Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001363-12,0,0,0 2014-001363-12,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,KroHem,Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001363-12,0,0,0 2014-001363-12,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,KLINIKUM DER UNIVERSITAET MUENCHEN,Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001363-12,0,0,0 2014-001363-12,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HOVON Foundation,Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001363-12,0,0,0 2014-001365-26,6,2015-08-24,2017-05-26,4,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Anthera pharmaceuticals, Inc","A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects with IgA Nephropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001365-26,1,0,0 2014-001365-26,6,2015-08-24,2017-05-26,4,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Anthera Pharmaceuticals, Inc","A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects with IgA Nephropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001365-26,1,0,0 2014-001367-13,1,2019-04-24,2019-04-24,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,"Medizinische Universtät Wien, Universitätsklinik für Innere Medizin I","An open-label, prospective, single-centre, phase II study to assess dose and dose interval requirements with respect to efficacy and safety of AOP2014, PEG-Proline-Interferon alpha-2b, in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001367-13,0,0,0 2014-001369-28,1,2017-12-10,2017-12-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Gateshead Health NHS Foundation Trust,THYRoxine in Acute Myocardial Infarction (ThyrAMI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001369-28,0,0,0 2014-001372-66,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus Medical Center,Tacrolimus monotherapy in immunologically low-risk kidney transplant recipients: a pilot randomized-controlled study. Tacrolimus monotherapie bij niertransplantatie patiënten met een immunologisch ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001372-66,0,0,0 2014-001374-34,1,2014-07-17,2014-07-17,1,1,0,0,1,0,2,0,1,1,0,0,1,0,1,MEDICE Arzneimittel Pütter GmbH & Co. KG,"A monocentric, observer-blind, randomized clinical study using an abrasive wound model with an intra-individual comparison to investigate the wound healing properties of a topical wound healing produc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001374-34,0,0,0 2014-001377-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre,"A multicenter, single arm, phase II clinical trial of pimecrolimus administered topically to patients with Stages Ia-IIa mycosis fungoides. Ensayo clínico de fase II, multicéntrico y con un único g...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001377-14,0,0,0 2014-001379-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dipartimento di Medicina,A PHASE II OPEN LABEL SINGLE CENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF THE BRAF-V600 INHIBITOR DABRAFENIB (TAFINLAR) IN PREVIOUSLY TREATED PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) CARRYING TH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001379-29,0,0,0 2014-001380-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Abelardo Garcia De Lorenzo / Teresa Nuñez-Villaveiran,Effects of the treatment with propranolol in the burnt adult intubated patient with sinusal tachycardia induced by burns. EFECTOS DEL TRATAMIENTO DE LA TAQUICARDIA SINUSAL INDUCIDA POR LA QUEMADUR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001380-13,0,0,0 2014-001381-96,1,2016-05-04,2016-05-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Graz / Endokrinologie und Stoffwechsel,"A randomized, double blind, two-period cross-over trial investigating the effect of liraglutide as add on to intensive insulin treatment on the endogenous glucose production in subjects with C-peptide...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001381-96,0,0,0 2014-001382-26,1,2020-05-31,2020-05-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,TAYS Sydänsairaala,Adenosine in initial cardioplegia Adenosiinilla aloitettu kardioplegia sydämen suojana,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001382-26,0,0,0 2014-001384-12,1,2021-03-03,2021-03-03,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KULEUVEN,IS THE ABSENCE OF PAN-COLONIC PRESSURIZATIONS A RELEVANT PATHOPHYSIOLOGICAL MECHANISM IN A SUBGROUP OF PATIENTS WITH CHRONIC IDIOPHATIC CONSTIPATION?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001384-12,0,0,0 2014-001389-93,4,2019-01-31,2019-01-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Jazz Pharmaceuticals,"A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of Xyrem with an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001389-93,0,0,0 2014-001391-54,5,2017-09-07,2017-09-07,3,1,1,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid Use in Adults and Adolesc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001391-54,0,0,0 2014-001393-34,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,UZ Leuven,Ilaris® (canakinumab) efficacy and safety in CAPS patients without confirmed mutation on exon 3 of gene CIAS1 and young (<2yrs) CAPS patients with severe neurological (CINCA) phenotype.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001393-34,0,0,0 2014-001394-13,14,2022-08-26,2022-08-26,7,0,0,0,0,2,3,0,0,2,0,0,0,0,1,"Takeda Development Center Americas, Inc.","A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001394-13,1,0,0 2014-001394-13,14,2022-08-26,2022-08-26,7,0,0,0,0,2,3,0,0,2,0,0,0,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001394-13,1,0,0 2014-001394-13,14,2022-08-26,2022-08-26,7,0,0,0,0,2,3,0,0,2,0,0,0,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001394-13,1,0,0 2014-001397-33,10,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Hamilton Health Sciences Corporation through its Population Health Research Institute,APIXABAN FOR THE REDUCTION OF THROMBO-EMBOLISM IN PATIENTS WITH DEVICE-DETECTED SUB-CLINICAL ATRIAL FIBRILLATION Apixaban voor de reductie van thrombo-embolische complicaties bij patiënten met devi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001397-33,0,0,0 2014-001397-33,10,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Hamilton Health Sciences through the Population Health Research Institute,APIXABAN FOR THE REDUCTION OF THROMBO-EMBOLISM IN PATIENTS WITH DEVICE-DETECTED SUB-CLINICAL ATRIAL FIBRILLATION Apixaban voor de reductie van thrombo-embolische complicaties bij patiënten met devi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001397-33,0,0,0 2014-001400-22,2,2016-10-20,2016-10-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 for the Treatment of Virally-Suppressed Subjects with Chronic Hepatitis B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001400-22,0,0,0 2014-001401-41,2,,,0,0,0,0,0,2,4,0,0,3,0,0,0,0,2,ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM,Targeting Antibiotics to Pseudomonas Aeruginosa in Small airways (TAPAS) study in patients with cystic fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001401-41,0,0,0 2014-001401-41,2,,,0,0,0,0,0,2,4,0,0,3,0,0,0,0,2,,Targeting Antibiotics to Pseudomonas Aeruginosa in Small airways (TAPAS) study in patients with cystic fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001401-41,0,0,0 2014-001402-18,1,2020-12-31,2020-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ALEJANDRA GARCIA BOTELLA,"CD133 + CELL INFUSION IN PATIENTS WITH COLORECTAL LIVER ORIGIN METASTASES GOING TO BE SUBMITTED TO A MAJOR LIVER RESECTION INFUSIÓN DE CELULAS CD133+, EN PACIENTES CON METÁSTASIS HEPÁTICAS DE ORIGE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001402-18,0,0,0 2014-001406-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Ventilator Associated Pneumonia: addition of Tobramycin Inhalation antibiotic treatment to standard IV antibiotic treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001406-17,0,0,0 2014-001408-23,2,2018-04-26,2018-04-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Celgene Corporation,"NAB-PACLITAXEL (ABRAXANE®) PLUS GEMCITABINE IN SUBJECTS WITH LOCALLY ADVANCED PANCREATIC CANCER (LAPC): AN INTERNATIONAL, OPEN-LABEL, MULTI-CENTER, PHASE 2 STUDY (LAPACT) NAB-PACLITAXEL (ABRAXANE®)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001408-23,0,0,0 2014-001411-39,4,2022-04-07,2022-04-07,2,0,0,1,0,1,1,0,0,2,1,0,0,0,1,Abeona Therapeutics Europe SL.,Phase I/II gene transfer clinical trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001411-39,1,0,0 2014-001411-39,4,2022-04-07,2022-04-07,2,0,0,1,0,1,1,0,0,2,1,0,0,0,1,Abeona Therapeutics Inc,Phase I/II gene transfer clinical trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001411-39,1,0,0 2014-001417-79,1,2019-10-08,2019-10-08,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Linköping University,"Open Label Pilot Trial in patients with recent-onset T1D to evaluate the safety, diabetes status and immune response of GAD-antigen (Diamyd®) therapy administered into lymph nodes in combination with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001417-79,0,0,0 2014-001419-38,1,2018-12-31,2018-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Center for Cancer Immune Therapy,T-cell therapy in combination with vemurafenib for BRAF mutated metastatic melanoma T-celle terapi i kombination med vemurafenib til patienter med BRAF muteret metastatisk malignt melanom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001419-38,0,0,0 2014-001420-29,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Center for Cancer Immune Therapy,T cell therapy in combination with peginterferon for metastatic malignant melanoma T-celle terapi i kombination med peginterferon til patienter med metastatisk malignt melanom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001420-29,0,0,0 2014-001422-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hellenic Oncology Research Group,"An open label, non-randomized, phase two trial in metastatic colorectal cancer (mCRC) with the combination of mFOLFIRI plus Aflibercept as first treatment: MINOAS trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001422-16,0,0,0 2014-001425-32,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Imperial College London,"RIVER - Research In Viral Eradication of HIV Reservoirs, A two-arm (proof of concept) randomised phase II trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001425-32,0,0,0 2014-001427-79,3,2018-03-16,2018-03-16,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ApoPharma Inc,Long-term Safety and Efficacy Study of Deferiprone in Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001427-79,0,0,0 2014-001427-79,3,2018-03-16,2018-03-16,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,APOTEX EUROPE B.V.,Long-term Safety and Efficacy Study of Deferiprone in Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001427-79,0,0,0 2014-001427-79,3,2018-03-16,2018-03-16,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ApoPharma Inc.,Long-term Safety and Efficacy Study of Deferiprone in Patients with Pantothenate Kinase-Associated Neurodegeneration (PKAN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001427-79,0,0,0 2014-001429-33,2,2018-01-22,2018-01-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects with Primary Immune Thrombocytopenia (ITP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001429-33,0,0,0 2014-001432-11,1,2014-11-10,2014-11-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Adocia,"A double-blinded, randomised, three-period crossover euglycaemic clamp trial investigating the pharmacokinetics, glucodynamics and safety of BC222 human insulin, human insulin (Huminsulin® Normal) and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001432-11,0,0,0 2014-001433-83,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundación INCLIVA,Loop Diuretics Dosage in Patients with Acute Heart Failure and Renal Failure: Conventional versus Carbohydrate Antigen 125 guided Strategy Dosificación de los Diuréticos de Asa en Pacientes con Ins...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001433-83,0,0,0 2014-001434-29,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AS Kevelt,A Phase II Study of Sodium Cridanimod in Conjunction with Progestin Therapy in Patients with Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001434-29,0,0,0 2014-001436-10,5,2016-06-21,2016-06-21,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Incyte Corporation,"A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non?Small Cell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001436-10,0,0,0 2014-001438-27,2,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,0,Academic Medical Center,The effect of bezafibrate on cholestatic itch,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001438-27,0,0,0 2014-001440-38,1,2014-09-18,2014-09-18,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,"Department of Dermatology D92, Bispebjerg Hospital",Methods to increase PpIX formation in the skin of healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001440-38,0,0,0 2014-001441-24,1,2018-02-01,2018-02-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical University Innsbruck,Short-term effect of SGLT 2-inhibitor dapagliflozin on postprandial glucose excursion and insulin sensitivity in type 1 diabetic patients. Kurzzeiteffekt des SGLT 2- Inhibitors Dapagliflozin auf di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001441-24,0,0,0 2014-001442-16,5,2015-07-30,2015-08-13,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-WAY CROSS-OVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CHF 5259 (GLYCOPYRROLATE BROMIDE) pMDI ON TOP OF QVAR® pMDI FOR THE TREATMENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001442-16,0,0,0 2014-001444-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rijnstate Hospital,Optimizing iron suppletion after Roux-en-Y Gastric Bypass,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001444-37,0,0,0 2014-001446-24,1,2015-01-22,2015-01-22,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Phase 1, Single Dose, 4-Period Crossover Study to Assess the Bioavailability of an Mirabegron Oral Suspension Relative to the Mirabegron Prolonged Release Tablet and to Assess the Effect of Food on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001446-24,0,0,0 2014-001449-26,2,2017-03-17,2017-03-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Seikagaku Corporation,"A Multicenter, Open-label Study of SI-6603 in Patients with Lumbar Disc Herniation (Phase III)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001449-26,0,0,0 2014-001452-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,". IMPACT DE L’INHALATION D’UN MELANGE EQUIMOLAIRE OXYGENE – PROTOXYDE D’AZOTE (MEOPA) SUR LA DOULEUR ET L’ANXIETE DURANT UNE PONCTION LOMBAIRE : ETUDE CONTROLEE, RANDOMISEE, EN DOUBLE AVEUGLE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001452-28,0,0,0 2014-001453-17,1,2016-05-23,2016-05-23,1,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Clementia Pharmaceuticals Inc.,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects with Fibrodysplasia Ossi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001453-17,0,0,0 2014-001456-39,1,2017-12-31,2017-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,IRCCS Ospedale San Raffaele,Tranexamic acid in major vascular surgery (Tranex-AAA) Acido tranexamico nella chirurgia vascolare maggiore (Tranex-AAA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001456-39,0,0,0 2014-001457-16,2,2015-11-05,2015-11-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomised, double-blind, double-dummy, multi-site, phase III, single dose, 4-way cross-over pharmacodynamic study evaluating the efficacy of Bricanyl Turbuhaler M3 compared to Bricanyl Turbuhaler M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001457-16,0,0,0 2014-001458-40,10,2019-02-22,2019-02-22,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Roche Farma, S.A. en nombre de F. Hoffmann-La Roche Ltd","A MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF HERCEPTIN® SC IN COMBINATION WITH PERJETA® AND DOCETAXEL IN TREATMENT OF PATIENTS WITH HER2?POSITIVE ADVANCED BREAST CANCER (METASTATIC OR LOCALLY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001458-40,0,0,0 2014-001458-40,10,2019-02-22,2019-02-22,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A MULTICENTER, OPEN-LABEL, SINGLE-ARM SAFETY STUDY OF HERCEPTIN® SC IN COMBINATION WITH PERJETA® AND DOCETAXEL IN TREATMENT OF PATIENTS WITH HER2?POSITIVE ADVANCED BREAST CANCER (METASTATIC OR LOCALLY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001458-40,0,0,0 2014-001459-22,1,2016-03-11,2016-03-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bial Industrial Farmacéutica S.A.,"OPEN CLINICAL TRIAL, MULTICENTER, WITH SUBCUTANEOUS IMMUNOTHERAPY IN DEPOT PRESENTATION, IN PATIENTS WITH ALLERGY RHINOCONJUNCTIVITIS SENSITIZED TO PARIETARIA JUDAICA ENSAYO CLÍNICO ABIERTO, MULTIC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001459-22,0,0,0 2014-001461-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FIMABIS,Evaluation of the effect of organic preservation with the use of levosimendan after cardiac surgery in patients with low output syndrom compared with dobutamine. Evaluación del efecto de preservaci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001461-27,0,0,0 2014-001462-99,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Essai thérapeutique de phase II évaluant l’efficacité de l’injection de Cellules Stromales Mésenchymateuses (CSMs) sur la symptomatologie de complications chroniques sévères des radiothérapies abdom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001462-99,0,0,0 2014-001463-12,1,2018-04-23,2018-04-23,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),A phase III multi-centre double-blind placebo controlled study analysing the efficacity and safety of daily administration of a P2Y12 inhibitor (Clopidogrel) for the treatment of locally advanced or m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001463-12,0,0,0 2014-001466-10,1,2015-12-08,2015-12-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Copenhagen University Hospital, Rigshospitalet, Juliane Marie Centre, Department of Anaesthesiology",does intraoperative clonidine reduce postoperative agitation in children anaesthetized with sevofluran? A RCT including pharmacokinetic investigation REDUCERER PEROPERATIV CLONIDIN POSTOPERATIV AGI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001466-10,0,0,0 2014-001470-34,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Royal Marsden NHS Foundation Trust,Pilot institutional study evaluating 5-fluorouracil following radiation therapy in children and young adults with relapsed/refractory ependymoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001470-34,0,0,0 2014-001471-31,5,2016-05-23,2016-05-23,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Phase 2 Randomized Controlled Trial (RCT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001471-31,0,0,0 2014-001473-14,9,2022-09-12,2022-09-12,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001473-14,1,0,0 2014-001477-13,1,2017-03-03,2017-03-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin in Adults with Genotype 1 and Ombitasvir/Paritabprevir/Ritonavir with Ribaviri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001477-13,0,0,0 2014-001478-32,1,2016-12-06,2016-12-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"An Exploratory Study to Evaluate the Kinetics of Viral Load Decline with Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy with Low Dose Ribavirin (RBV), Full Dose RBV or RBV A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001478-32,0,0,0 2014-001484-12,4,2016-10-04,2016-10-04,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomized, placebo-controlled, phase III trial on the efficacy and tolerability of a 6-week treatment with budesonide effervescent tablets vs. placebo for induction of clinico-pathologi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001484-12,0,0,0 2014-001485-99,7,2020-12-11,2020-12-11,4,1,0,0,0,1,3,0,0,2,1,0,0,0,1,DR. FALK PHARMA GMBH,"Double-blind, randomized, placebo-controlled, phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets vs. placebo for mainte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001485-99,1,0,0 2014-001485-99,7,2020-12-11,2020-12-11,4,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomized, placebo-controlled, phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets vs. placebo for mainte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001485-99,1,0,0 2014-001486-27,7,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,0,European Orgainzation for the Research and Treatment of Cancer (EORTC),"10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001486-27,0,0,0 2014-001486-27,7,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,0,European Organisation for the Research and Treatment of Cancer (EORTC),"10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001486-27,0,0,0 2014-001487-35,8,2016-12-21,2017-01-05,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A Multinational, Multicentre, Randomised, Open-Label, Active-Controlled, 26-Week, 2-Arm, Parallel Group Study to Evaluate the Non-Inferiority of Fixed Combination of Beclometasone Dipropionate Plus Fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001487-35,0,0,0 2014-001488-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Landstinget Västmanland,"Effects of expectations, medication and placebo on objective and self-rated performance during the Quantified Behavior Test in terms of the ADHD core signs hyperactivity, inattention and impulsivity i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001488-11,0,0,0 2014-001489-85,4,2016-06-24,2016-07-24,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,FORUM Pharmaceuticals Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects with P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001489-85,0,0,0 2014-001491-62,1,2015-12-11,2015-12-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,NAICONS Srl.,"Clinical efficacy and safety of NAI-Acne gel 3% applied twice-a-day to patients with facial acne vulgaris Dvojito zaslepené, randomizované, pilotné klinické skúšanie s paralelnými skupinami na sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001491-62,0,0,0 2014-001493-34,1,2018-03-02,2018-03-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,photonamic GmbH & Co. KG,Evaluation of the suitability of PD P 506 A in the photodynamic therapy of Distal Subungual Onychomycosis (DSO) of the great toenail.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001493-34,0,0,0 2014-001496-31,7,2017-04-07,2017-04-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Coadministered with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus Infection and Cirr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001496-31,0,0,0 2014-001498-15,4,2015-07-10,2016-03-14,3,1,0,1,0,0,1,0,0,1,1,0,0,0,1,F. Hoffmann- La Roche Ltd.,"OPEN-LABEL PHASE Ib/II, MULTICENTER STUDY OF THE COMBINATION OF RO5479599 WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) OF SQUAMOUS HISTOLO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001498-15,0,0,0 2014-001499-73,1,2017-01-16,2017-01-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Leuven,"Transversus abdominis plane blok, continous systemic administration of lidocain and patient controlled intravenous morphine - 3 methods for postoperative pain control after laparoscopic colorectal sur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001499-73,0,0,0 2014-001501-41,2,2016-08-07,2021-09-08,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.",A Multinational Trial to Collect Blood Samples to Explore Potential Genetic/Biomarkers Related to Increased Risk of Liver Injury in Adult Subjects from Prior Tolvaptan Clinical Trials for Autosomal Do...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001501-41,0,0,0 2014-001502-18,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women Wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001502-18,0,0,0 2014-001502-18,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Lilly S.A.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women Wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001502-18,0,0,0 2014-001509-42,8,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001509-42,0,0,0 2014-001513-35,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,2,NHS Blood and Transplant.,"TREATT: TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia A double blind, randomised controlled trial evaluating the safety and efficacy of Tranexamic acid in patients with haematological ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001513-35,0,0,0 2014-001513-35,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,2,NHS Blood and Transplant,"TREATT: TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia A double blind, randomised controlled trial evaluating the safety and efficacy of Tranexamic acid in patients with haematological ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001513-35,0,0,0 2014-001514-26,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,0,Comarca Ezkerraldea-Enkarterri (OSAKIDETZA),Efficacy of Autologous Platelet-Rich Plasma in the treatment of vascular ulcers in Primary Care: Clinical trial phase III. Eficacia del Plasma Rico en Plaquetas autólogo en el tratamiento de úlcera...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001514-26,0,0,0 2014-001516-19,10,2018-11-09,2018-11-19,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization,","A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Immediate-release Tolvaptan (OPC-41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic K...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001516-19,0,0,0 2014-001518-25,1,2015-03-30,2015-03-30,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Pharmacosmos A/S,"A Phase III, Randomised, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) against Placebo in Subjects with Iron Deficiency Anaemia and who are Intolerant or Unresponsiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001518-25,0,0,0 2014-001519-38,5,2017-06-20,2018-03-01,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,"Efficacy and safety of 3 doses of S 47445 versus placebo in patients with Alzheimer's disease at mild to moderate stages with depressive symptoms. A 24-week international, multi-centre, randomized, do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001519-38,0,0,0 2014-001523-69,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Istituto Nazionale Tumori di Napoli - Fondazione ""G. Pascale""",Preclinical and clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of head and neck,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001523-69,0,0,0 2014-001524-30,12,2018-02-28,2018-03-09,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc.,"A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001524-30,0,0,0 2014-001530-28,1,2017-01-23,2017-01-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics and efficacy of multiple doses of QBW251 in patients with COPD.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001530-28,0,0,0 2014-001532-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Ospedale San Raffaele,MONO-INSTITUTIONAL PHASE II TRIAL ADDRESSING TOLERABILITY AND ACTIVITY OF R-CHOP CHEMOIMMUNOTHERAPY PRECEDED BY BLOOD-BRAIN BARRIER PERMEABILIZATION BY NGR-TUMOR NECROSIS FACTOR IN PATIENTS WITH RELAP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001532-11,0,0,0 2014-001534-29,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Subjects Aged 2 to 45 Years in the Philippines,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001534-29,0,1,1 2014-001537-92,1,2015-02-28,2015-02-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Southampton NHS Foundation Trust,Safety of Nasal Influenza Immunisation in Egg Allergic Children - The SNIFFLE 2 study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001537-92,0,0,0 2014-001538-28,2,2016-05-03,2016-05-03,1,0,0,0,0,0,4,0,1,2,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Recherche de l’excrétion du virus vaccinal de la rougeole dans le lait de femmes vaccinées en postpartum par un vaccin trivalent Rougeole-Rubéole-Oreillons(RRO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001538-28,1,0,0 2014-001540-38,3,2017-04-12,2017-04-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus. A 52-week, randomised, double-blind, placebo-controlled, nine-armed, parallel group, multi-c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001540-38,0,0,0 2014-001541-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Freiburg,Neuroenhancement of Interpersonal Psychotherapy in Major Depression Augmentation von Interpersoneller Psychotherapie durch D-Cycloserin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001541-24,0,0,0 2014-001545-25,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Centre for Human Drug Research,"Randomized, double-blind, placebo-controlled, three way crossover, double dummy, single centre study evaluating the effect of haloperidol 2 mg and lorazepam 1 mg on posturography and underlying system...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001545-25,0,0,0 2014-001546-25,1,2019-08-05,2019-08-05,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,VU University Medical Center,Short versus extended antibiotic treatment with a carbapenem for high-risk febrile neutropenia in hematology patients with Fever of Unknown Origin: a randomized multicenter open-label non-inferiority ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001546-25,0,0,0 2014-001549-26,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,GRUPO ESPAñOL DE INVESTIGACIóN EN SARCOMAS,"Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus RAdiotherapy in Soft Tissue Sarcoma patients Studio prospettico di fase I-II, multicentrico, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001549-26,0,0,0 2014-001549-26,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,GEIS,"Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus RAdiotherapy in Soft Tissue Sarcoma patients Studio prospettico di fase I-II, multicentrico, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001549-26,0,0,0 2014-001550-42,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Medizinische Universität Wien,Patient stratification and treatment response prediction in neuropharmacotherapy using PET/MR – Predicting drug efficacy using hybrid PET/MR imaging with pharmacological challenge and multireceptor m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001550-42,0,0,0 2014-001551-22,1,2018-10-20,2018-10-20,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Charité Universitätsmedizin,Reduction of postoperative wound infections by antiseptica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001551-22,0,0,0 2014-001552-29,1,2017-04-22,2017-04-22,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Abteilung für Anästhesie und allgemeine Intensivmedizin",Determination of the minimal alveolar concentration of Sevoflurane in patient with end stage liver disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001552-29,0,0,0 2014-001558-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Uzsoki Hospital,Expanded Access Study of MEK162 in Metastatic or Unresectable NRAS Mutation-positive Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001558-40,0,0,0 2014-001560-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Brain Center Rudolf Magnus, University Medical Center Utrecht, Department of Psychiatry, Utrecht , the Netherlands",Bumetanide in Autism Medication and BIomarker study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001560-35,0,0,0 2014-001561-27,2,2022-02-01,2022-02-01,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,VU university medical center,Vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia: comparing one-hour infusions with bolus injections (the VINCA-study) Vincristine-geïnduceerde perifere neuro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001561-27,1,0,0 2014-001563-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen,Efficacy of Single inhaler Maintenance And Reliever Therapy (SMART) with Spiromax® budesonide/formoterol versus fixed dose treatment with Diskus® fluticasone/salmeterol in COPD Effectiviteit van '...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001563-12,0,0,0 2014-001571-31,1,2015-06-22,2015-06-22,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Laboratorios LETI, S.L. Unipersonal","A randomized (open-label design), parallel group, multicentre study to evaluate the safety and tolerability of two different doses of Depigoid 34% GrassesMix, 33% Olea europaea and 33% Salsola kali a ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001571-31,0,0,0 2014-001577-13,1,2017-12-22,2017-12-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Manchester University NHS Foundation Trust,Copper Chelation in Hypertrophic Cardiomyopathy: Open-label pilot study of Trientine in patients with hypertrophic cardiomyopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001577-13,0,0,0 2014-001578-32,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,CENTRE ANTOINE LACASSAGNE,A phase I/II study of pazopanib in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and RT-CT (PAZOGLIO study) Étude de phase I/II visant à évalu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001578-32,0,0,0 2014-001579-30,5,2017-10-01,2017-10-01,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Teva Pharmaceutical Industries Ltd.,"A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001579-30,0,0,0 2014-001580-12,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,CHU de DIJON,INTERET DE L’ONDANSETRON INTRAVEINEUX EN PREVENTION DES HYPOTENSIONS INDUITES PAR LA RACHIANESTHESIE POUR CESARIENNE : ETUDE MONOCENTRIQUE RANDOMISEE CONTROLEE EN DOUBLE AVEUGLE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001580-12,0,0,0 2014-001581-10,1,2014-12-02,2014-12-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Tigercat Pharma, Inc.","A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects with Chronic Pruritus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001581-10,0,0,0 2014-001582-27,3,2017-06-22,2017-06-22,2,1,1,0,0,0,3,0,0,1,1,1,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Pilot Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety, Efficacy, and Pharmacokinetics of Titrated Oral SAMSCA® (Tolvaptan) in Children and Adolescent Subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001582-27,0,0,0 2014-001585-98,3,2017-07-31,2017-07-31,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"DELCATH SYSTEMS, INCORPORATIONS",An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan/HDS Treatment in Patients with Unresectable Hepatocellular Carcinoma or Intra hepatic Cholangiocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001585-98,0,0,0 2014-001585-98,3,2017-07-31,2017-07-31,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Delcath Systems, Inc",An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan/HDS Treatment in Patients with Unresectable Hepatocellular Carcinoma or Intra hepatic Cholangiocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001585-98,0,0,0 2014-001586-27,1,,,0,1,0,0,0,1,2,0,1,1,1,1,0,1,1,SOM Innovation Biotech SL (SOM Biotech),Study of SOM0226 in familial amyloid polyneuropathy (FAP) patients and asymptomatic carriers to evaluate protein stabilization activity Estudio de SOM0226 en pacientes con polineuropatía amiloide f...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001586-27,0,0,0 2014-001587-35,1,2014-02-16,2014-02-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Erasmus Medical Centre, Department of Anesthesiology",Dexmedetomidine in awake implantation of neuromodulative systems. Dexmedetomidine bij wakkere implantatie van een neuromodulatief systeem.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001587-35,0,0,0 2014-001589-85,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Astrazeneca AB,"A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001589-85,0,0,0 2014-001594-14,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Universitätsklinikum Erlangen,"Prospective, single-centre, open-label, one-arm clinical trial, phase I/IIa, to assess the safety and tolerability and to investigate the predictive power of FITC-Adalimumab, when topically applied tw...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001594-14,0,0,0 2014-001603-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AIL CATANIA ASSOCIAZIONE ITALIANA CONTRO LEUCEMIE-LINFOMI E MIELOMA ONLUS,"“Arrest Imatinib or Dasatinib in CML patients with Deep Molecular Responses” (AID MORE) ""Interruzione di Imatinib o Dasatinib in pazienti con LMC con risposta molecolare profonda"" (AID MORE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001603-42,0,0,0 2014-001617-12,13,2018-01-16,2018-01-16,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"ARIAD PHARMACEUTICALS, INC.","A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001617-12,1,0,0 2014-001617-12,13,2018-01-16,2018-01-16,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"ARIAD Pharmaceuticals, Inc. (a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited)","A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001617-12,1,0,0 2014-001617-12,13,2018-01-16,2018-01-16,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"ARIAD Pharmaceuticals, Inc.","A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001617-12,1,0,0 2014-001617-12,13,2018-01-16,2018-01-16,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"ARIAD Pharmaceuticals, Inc. ( a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited)","A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001617-12,1,0,0 2014-001617-12,13,2018-01-16,2018-01-16,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"Takeda Development Center Americas, Inc.","A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001617-12,1,0,0 2014-001619-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Maastricht University Medical Centre,Contrast enhanced Diffusion-weighted Magnetic Resonance Imaging for detection of pathologic lymph nodes in ovarian cancer – a feasibility study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001619-37,0,0,0 2014-001620-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL),"Phase II clinical trial to evaluate the combination of lenalidomide with R-GDP (rituximab, gemcitabine, dexamethasone and cisplatin) in patients diagnosed with refractory diffuse large B-cell lymphoma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001620-29,0,0,0 2014-001621-33,1,2015-06-26,2015-06-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dermapharm AG,"Multicenter, randomised, double-blind clinical trial on the efficacy and safety of medicinal products containing Diclofenac in patients with actinic keratosis Multizentrische, randomisierte, doppel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001621-33,0,0,0 2014-001631-36,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Colonis Pharma Limited,"A Double-blind, Randomised, Placebo Controlled Study of the Efficacy of Glycopyrronium bromide 1mg /5ml in the Treatment of Non-drug Induced Hypersalivation with an Open Single-arm Extension to Invest...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001631-36,0,0,0 2014-001633-84,15,,,0,0,1,0,0,1,0,0,0,3,0,0,0,0,1,"Onyx Therapeutics, Inc., an Amgen Inc. subsidiary",Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001633-84,0,0,0 2014-001633-84,15,,,0,0,1,0,0,1,0,0,0,3,0,0,0,0,1,Amgen Inc.,Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001633-84,0,0,0 2014-001633-84,15,,,0,0,1,0,0,1,0,0,0,3,0,0,0,0,1,"Onyx Therapeutics, Inc.",Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001633-84,0,0,0 2014-001634-28,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.","A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001634-28,0,0,0 2014-001634-28,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Medivation, Inc.","A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001634-28,0,0,0 2014-001634-28,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,MEDIVATION INC.,"A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001634-28,0,0,0 2014-001634-28,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Medivation, Inc., a wholly owned subsidairy of Pfizer Inc.","A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001634-28,0,0,0 2014-001637-88,1,2017-08-10,2017-08-10,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,John Vissing,"A phase 2a study to explore treatment with Sodium Valproate in adults with McArdle Disease (Glycogen Storage Disorder Type V, GSDV) Et åbent, fase 2a pilotstudie, der undersøger effekten af behandl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001637-88,0,0,0 2014-001638-27,2,2017-06-23,2017-06-23,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,"Fast Forward Pharmaceuticals, B.V.","A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed with Primary Biliary Cirrhosis (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001638-27,0,0,0 2014-001639-35,2,,,0,1,0,0,1,0,4,0,0,1,1,0,0,1,1,NOVARTIS PHARMA SERVICES AG,"A 24-week, randomized, single-masked, multicenter, phase IV study to compare systemic VEGF levels following monthly Intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until week 24 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001639-35,0,0,0 2014-001639-35,2,,,0,1,0,0,1,0,4,0,0,1,1,0,0,1,1,Novartis Pharma GmbH,"A 24-week, randomized, single-masked, multicenter, phase IV study to compare systemic VEGF levels following monthly Intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept until week 24 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001639-35,0,0,0 2014-001640-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU DE POITIERS,Efficacy of Aflibercept (Eylea®) on Type 3 choroidal neovascularization.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001640-38,0,0,0 2014-001641-24,4,2016-04-04,2016-04-04,3,0,0,0,0,0,3,0,0,1,1,1,1,0,1,NephroGenex,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin (pyridoxamine dihydrochloride) in Subjects With Nephropathy Due to Type 2 Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001641-24,0,0,0 2014-001642-16,2,2020-02-10,2020-02-10,1,1,0,1,0,0,1,0,0,2,0,0,0,0,1,Takeda Development Centre Europe Ltd.,"A Phase 1, Randomized, Open-Label, Parallel-Design, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Capsules in Infants Aged 1 to 11...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001642-16,1,0,0 2014-001643-20,3,2016-07-07,2016-07-07,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Genzyme Corporation,"A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001643-20,0,0,0 2014-001644-38,5,2017-08-16,2018-11-26,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Salix Pharmaceuticals, Inc.","A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001644-38,0,0,0 2014-001644-38,5,2017-08-16,2018-11-26,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Salix Pharmaceuticals, Inc. subsidiary of Valeant Pharmaceuticals International In","A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001644-38,0,0,0 2014-001645-24,5,2017-12-31,2018-12-31,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Salix Pharmaceuticals, Inc.","A Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001645-24,0,0,0 2014-001645-24,5,2017-12-31,2018-12-31,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Salix Pharmaceuticals, Inc subsidiary of Valeant Pharmaceuticals International Inc","A Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001645-24,0,0,0 2014-001647-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GIOGer (Gruppo Italiano di Oncologia Geriatrica),Weekly cabazitaxel in elderly MCRPC (Metastatic Castration Resistant Prostate Cancer) patients progressing after docetaxel treatment: a phase II study Cabazitaxel settimanale nei pazienti anziani c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001647-20,0,0,0 2014-001655-23,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,0,Rodrigo Aguilera,Establishment of an Athlete's Internal Metabolic Reference Using an Isotopic Signature or Isotopic Fingerprint of ?13C Values DETERMINACIÓN DE LA HUELLA ISOTÓPICA DE LOS METABOLITOS DE TESTOSTERONA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001655-23,0,0,0 2014-001656-34,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Innovacell Biotechnologie AG,Skeletal muscle-derived cell implantation in female patients with stress urinary incontinence: a multinational and multicenter open follow-up study Клетъчна трансплантация на извлечени от скелетна...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001656-34,0,0,0 2014-001661-27,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Sociedad Española de Cardiología,Comparison of TIcagrelor and clopidogrel in patients with Coronary artery diseaSe and type 2 Diabetes Mellitus (TICS-DM): a randomized pharmacodynamic study Comparación entre Ticagrelor y Clopidogr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001661-27,0,0,0 2014-001662-94,5,2017-02-13,2017-02-13,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Circassia Ltd.,"A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects with a History of House Dust Mite-Induced Rhinoconjunctivitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001662-94,0,0,0 2014-001666-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Center Amsterdam,Local delivery of CER-001 in advanced plaques Proof-of-concept for apoA-1 as initiator of reverse cholesterol transport (LOCATION) Lokale afgifte van CER-001 in gevorderde plaques Conceptueel bewij...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001666-10,0,0,0 2014-001670-34,3,2016-01-07,2016-01-14,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Alize Pharma,"A Phase IIa, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and effects of AZP-531, an Unacylated Ghrelin analog, on food-related behavior in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001670-34,0,0,0 2014-001671-30,1,2019-11-06,2019-11-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre Eugène Marquis,Evaluation of cobimetinib + vemurafenib combination treatment in patients with brain metastasis BRAFV600 mutated cutaneous melanoma Evaluation de l'association du Cobimetinib et du Vemurafenib chez...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001671-30,0,0,0 2014-001672-55,5,2020-08-20,2020-08-20,2,1,0,0,1,1,3,0,0,1,0,0,1,0,1,MediWound Ltd.,"A multicenter, multinational, randomized, controlled, assessor blinded study, performed in subjects with thermal burns, to evaluate the efficacy and safety of NexoBrid compared to Gel Vehicle and comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001672-55,0,0,0 2014-001672-55,5,2020-08-20,2020-08-20,2,1,0,0,1,1,3,0,0,1,0,0,1,0,1,MEDIWOUND LTD,"A multicenter, multinational, randomized, controlled, assessor blinded study, performed in subjects with thermal burns, to evaluate the efficacy and safety of NexoBrid compared to Gel Vehicle and comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001672-55,0,0,0 2014-001673-14,11,,,0,0,0,0,0,1,0,0,0,3,0,0,0,0,1,NOVARTIS PHARMA SERVICES AG,Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001673-14,0,0,0 2014-001673-14,11,,,0,0,0,0,0,1,0,0,0,3,0,0,0,0,1,Novartis Pharma Services AG,Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001673-14,0,0,0 2014-001673-14,11,,,0,0,0,0,0,1,0,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.",Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001673-14,0,0,0 2014-001675-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IUCPQ,Aspirin versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation with the Edwards Valve. A Randomized Study (the ARTE trial). Estudio randomizado ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001675-32,0,0,0 2014-001682-27,3,2015-11-23,2015-12-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001682-27,0,0,0 2014-001683-35,5,2015-09-23,2015-09-23,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001683-35,0,0,0 2014-001687-36,2,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An open label extension trial assessing the safety and and efficay of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis. Avoin jatkotutkimus, jossa ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001687-36,0,0,0 2014-001687-36,2,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,1,Boehringer Ingelheim,"An open label extension trial assessing the safety and and efficay of BI 655066 administered subcutaneously in patients with moderate to severe chronic plaque psoriasis. Avoin jatkotutkimus, jossa ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001687-36,0,0,0 2014-001694-14,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001694-14,0,1,1 2014-001700-21,5,2020-01-10,2020-01-10,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Amgen Inc.,"An Open-Label, Multi-center, Expanded Access Protocol of Blinatumomab for the Treatment of Pediatric and Adolescent Subjects with Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001700-21,0,0,0 2014-001702-18,1,2015-08-27,2015-08-27,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Thomas Fichtner Bendtsen,Analgesic duration of a preoperative single-shot femoral nerve block with Bupivacaine and adjuvant Dexamethasone in patients with hip fracture Analgetisk virkningsvarighed af protraheret nervus fem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001702-18,0,0,0 2014-001703-41,4,2018-11-07,2018-11-07,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Wilson Therapeutics AB,"A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older with an Extension Phase ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001703-41,0,0,0 2014-001703-41,4,2018-11-07,2018-11-07,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Alexion Pharmaceuticals, INC.","A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older with an Extension Phase ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001703-41,0,0,0 2014-001703-41,4,2018-11-07,2018-11-07,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older with an Extension Phase ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001703-41,0,0,0 2014-001704-22,14,2017-07-04,2017-07-10,13,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Chiesi Farmaceutici S.p.A.,"A 52-week, Double Blind, Double dummy, Randomized, Multinational, Multicentre, 2-arm Parallel Group, active Controlled Clinical Trial of fixed combination of beclometasone dipropionate plus formoterol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001704-22,0,0,0 2014-001704-22,14,2017-07-04,2017-07-10,13,1,0,0,0,0,3,0,0,1,0,0,1,0,2,CHIESI FARMACEUTICI S.P.A.,"A 52-week, Double Blind, Double dummy, Randomized, Multinational, Multicentre, 2-arm Parallel Group, active Controlled Clinical Trial of fixed combination of beclometasone dipropionate plus formoterol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001704-22,0,0,0 2014-001705-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Tampereen yliopistollinen sairaala,Laskimonsisäinen PCA (patient-controlled analgesia) -oksikodoni verrattuna suun kautta otettavaan oksikodoniin keisarileikkauksen jälkeisen kivun lievityksessä – satunnaistettu vertaileva tutkimus ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001705-40,0,0,0 2014-001706-17,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Safety of ChimeriVax™ Dengue Tetravalent Vaccine in Subjects Aged 2 to 45 Years in Mexico,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001706-17,0,1,1 2014-001707-53,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001707-53,0,1,1 2014-001708-24,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001708-24,0,1,1 2014-001709-41,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Viet Nam,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001709-41,0,1,1 2014-001710-25,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Efficacy and Safety of Dengue Vaccine in Healthy Children Aged 4 to 11 Years in Thailand,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001710-25,0,1,1 2014-001711-40,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001711-40,0,1,1 2014-001713-26,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Large-Scale Safety of Tetravalent Dengue Vaccine in Healthy Subjects Aged 2 to 45 Years in Singapore,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001713-26,0,1,1 2014-001714-26,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly with Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001714-26,0,1,1 2014-001715-39,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001715-39,0,1,1 2014-001716-19,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001716-19,0,1,1 2014-001717-11,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001717-11,0,1,1 2014-001718-25,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001718-25,0,0,0 2014-001719-37,1,2016-02-17,2016-02-17,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,TetraLogic Pharmaceuticals,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine with or without Birinapant with a Single Arm Open-Label Run-In Phase in Subjects with Higher Risk Myelodysplastic Syndrome ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001719-37,0,0,0 2014-001720-30,1,2015-04-23,2015-04-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Drossapharm AG,"A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of an etofenamate 5% (EFM) cutaneous patch applied twice daily in patients with a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001720-30,0,0,0 2014-001733-86,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Maastricht University,The effect of L-arginine on brown adipose tissue metabolism in South Asian and white Caucasian subjects Het effect van L-arginine op bruin vet metabolisme in Hindoestaanse en Caucasische mannen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001733-86,0,0,0 2014-001736-11,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly with Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001736-11,0,1,1 2014-001737-88,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Long-Term Safety Follow-Up of Thai Children Who Were Included in an Efficacy Study of a Tetravalent Dengue Vaccine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001737-88,0,1,1 2014-001739-35,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Università di Modena e ReggioEmilia,An Open-Label Study to Explore the Clinical Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant in HIV-HCV infected patie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001739-35,0,0,0 2014-001740-38,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Intérêt de l’azythromycine dans le traitement des syndromes hémolytiques et urémiques post diarrhée,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001740-38,0,0,0 2014-001743-20,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,IVI Madrid,"A Multicentre, prospective, randomised clinical trial comparing the cost and efficacy of corifolitropina alfa vs Recombinant FSH and / or HP-hMG Ensayo clínico multicéntrico, prospectivo y aleatori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001743-20,0,0,0 2014-001744-38,5,2016-01-18,2016-01-18,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"GALDERMA RESEARCH & DEVELOPMENT, LLC","A multicenter, randomized, double blind, parallel group, vehicle controlled, study of the safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 8 weeks in pediatric subjects (2 to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001744-38,0,0,0 2014-001744-38,5,2016-01-18,2016-01-18,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"GALDERMA R&D, LLC","A multicenter, randomized, double blind, parallel group, vehicle controlled, study of the safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 8 weeks in pediatric subjects (2 to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001744-38,0,0,0 2014-001745-25,3,2017-04-20,2017-04-20,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Celgene Corporation,"A Phase 2, Multicenter, International, Single Arm Study to Assess the Safety and Efficacy of Single Agent CC-486 (Oral Azacitidine) in Previously Treated Subjects With Locally Advanced or Metastatic N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001745-25,0,0,0 2014-001748-39,1,2017-03-30,2017-03-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU d'Angers,"TRAnexamic Acid for Preventing postpartum hemorrhage following a vaginal delivery : a multicenter randomised, double blind placebo controlled trial L'acide tranexamique en prévention de l'hémorra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001748-39,0,0,0 2014-001749-26,11,2022-08-15,2022-08-15,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001749-26,1,0,0 2014-001750-42,14,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001750-42,0,0,0 2014-001751-23,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,IRCCS Burlo Garofolo,Comparative evaluation of the effectiveness of EMLA vs. Ralydan in the procedures for venipuncture and venous cannulation. Randomized controlled trial.. Valutazione comparativa dell'efficacia di Ra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001751-23,0,0,0 2014-001752-31,1,2014-07-04,2014-07-04,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Professor Jørgen B. Dahl,The effect of different doses (mass) of local anesthetic on duration of adductor canal block in healthy volunteers - part 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001752-31,0,0,0 2014-001753-17,2,2017-01-04,2017-01-04,1,1,0,1,0,1,1,0,0,1,1,0,0,0,1,"aTyr Pharma, Inc.","A Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients with Molecularly Defined G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001753-17,0,0,0 2014-001755-23,2,2017-02-23,2017-02-23,2,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Galderma R&D SNC,A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 50μg/g CREAM IN SUBJECTS WITH ACNE VULGARIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001755-23,0,0,0 2014-001757-16,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,GWT-TUD GmbH,"Pomalidomide, ixazomib, and dexamethasone (PId) with or without intensification by cyclophosphamide (PICd): A phase II study in relapsed or refractory multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001757-16,0,0,0 2014-001759-22,3,2016-08-25,2016-08-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratoire Innotech International,"Assessment of the efficacy of POLYGYNAX® in the empirical treatment of infectious vaginitis International, multicentre, randomised, double-blind, parallel group study, comparative versus miconazole",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001759-22,0,0,0 2014-001764-35,6,2019-04-27,2019-04-27,6,1,0,1,0,0,1,0,0,1,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001764-35,0,0,0 2014-001772-55,5,2017-04-03,2017-04-03,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TEVA Pharmaceutical Industries Ltd,"A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 μg/kg tbo-filgrastim in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001772-55,0,0,0 2014-001777-13,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Radboud umc,The effect of insulin-induced hypoglycemia on brain lactate accumulation and regional cerebral blood flow in patients with type 1 diabetes mellitus with and without hypoglycemia unawareness and non-di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001777-13,0,0,0 2014-001778-32,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,0,Bo Feldt-Rasmussen,Glycaemic and cardiovascular efficacy of liraglutide in prediabetic patients with end-stage renal disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001778-32,0,0,0 2014-001783-34,12,2017-02-24,2017-02-24,11,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomised, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0517/Fosaprepitant and Ondansetron Versus Ondansetron for the Prevention of Chemotherapy-Induced Nause...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001783-34,1,1,0 2014-001783-34,12,2017-02-24,2017-02-24,11,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase III, Randomised, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0517/Fosaprepitant and Ondansetron Versus Ondansetron for the Prevention of Chemotherapy-Induced Nause...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001783-34,1,1,0 2014-001784-13,1,2019-12-31,2019-12-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Queen Mary University of London,"PROVENT: A randomised, double blind, placebo controlled feasibility study to examine the clinical effectiveness of aspirin and/or Vitamin D3 to prevent disease progression in men on active surveillanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001784-13,0,0,0 2014-001785-95,3,2017-02-02,2017-02-02,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Biota Pharmaceuticals, Inc.","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults with Symptomatic Human Rhinovirus Infection.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001785-95,0,0,0 2014-001786-26,1,2016-08-12,2016-08-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Steno Diabetes Center,"A randomised, doublet blinded, placebo controlled cross-over study of Allopurinols effect to prevent loss of kidney function in type 1 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001786-26,0,0,0 2014-001787-36,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,EORTC AISBL/IVZW,A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001787-36,0,0,0 2014-001787-36,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001787-36,0,0,0 2014-001795-53,5,2020-03-09,2020-03-09,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone rece...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001795-53,0,0,0 2014-001796-31,1,2015-02-16,2015-02-16,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,L’OREAL SA,"A monocenter, double-blind, randomized study to assess the kinetic of antiperspirant efficacy of Glycopyrrolate 0.2% and 0.02% versus placebo during 4 days of topical applications on axilla of healthy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001796-31,0,0,0 2014-001801-42,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,Maastricht University,Sensitivity of driving-related psychometric tests to the effects of two widely prescribed benzodiazepines: diazepam and oxazepam,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001801-42,0,0,0 2014-001809-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IDIPAZ,Scheduling of GnRH antagonist FIV-ICSI cycles with estrogen or contraceptive oral pills in previous luteal phase. Comparison of results against no treatment. PROGRAMACIÓN DE CICLOS FIV-ICSI CON ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001809-40,0,0,0 2014-001810-24,11,,,0,1,0,0,0,1,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX (GDC-0199/ABT 199) VERSUS OBINUTUZUMAB AND CHL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001810-24,0,0,0 2014-001810-24,11,,,0,1,0,0,0,1,3,0,0,3,0,0,0,0,1,"Roche Farma, S.A, en nombre de F. Hoffmann-La Roche Ltd","A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX (GDC-0199/ABT 199) VERSUS OBINUTUZUMAB AND CHL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001810-24,0,0,0 2014-001815-38,3,2016-04-20,2016-04-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,"Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001815-38,0,0,0 2014-001816-20,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,"Academic Medical Center, Amsterdam","Fractional CO2 laser assisted delivery of topical anesthetics: a randomized controlled pilot study Toediening van topicale anaesthetica met behulp van fractionele CO2-laser: een gerandomiseerde, ge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001816-20,0,0,0 2014-001821-34,6,2017-07-04,2017-07-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001821-34,0,0,0 2014-001823-56,1,2017-01-20,2017-01-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospitals Birmingham NHS Foundation Trust,A randomised controlled trial to compare the clinical effectiveness and safety of gentamicin and ceftriaxone in the treatment of gonorrhoea.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001823-56,0,0,0 2014-001824-32,12,2018-03-12,2018-03-12,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001824-32,0,0,0 2014-001824-32,12,2018-03-12,2018-03-12,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001824-32,0,0,0 2014-001825-33,3,2017-10-18,2017-10-18,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline Research & Development Ltd,Study 110933: Albiglutide versus Placebo in insulin-treated Subjects with new-onset type 1 diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001825-33,0,0,0 2014-001826-13,7,2017-08-25,2017-08-25,6,1,1,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban Therapy for Women in Spontaneous Preterm Labor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001826-13,0,0,0 2014-001826-13,7,2017-08-25,2017-08-25,6,1,1,0,0,0,3,0,0,1,1,0,1,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban Therapy for Women in Spontaneous Preterm Labor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001826-13,0,0,0 2014-001834-27,5,2020-09-24,2020-09-24,4,1,1,0,0,1,3,0,0,1,0,0,1,0,1,GW Research Ltd,An open label extension study to investigate the safety of cannabidiol (GWP42003-P; CBD) in children and adults with inadequately controlled Dravet or Lennox-Gastaut Syndromes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001834-27,0,0,0 2014-001835-35,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación Santiago Dexeus Font (Dexeus),Transdermal testosterone gel for poor ovarian responders. A multicenter double-blind placebo controlled randomized trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001835-35,0,0,0 2014-001835-35,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Universitair Ziekenhuis Brussel,Transdermal testosterone gel for poor ovarian responders. A multicenter double-blind placebo controlled randomized trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001835-35,0,0,0 2014-001836-12,1,2017-03-27,2017-03-27,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,Institute of Tropical Medicine,Boostability for rabies in last-minute travelers: One Day Rabies Pre-exposure Intradermal Vaccination followed by one day Postexposure Intradermal Vaccination,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001836-12,0,0,0 2014-001837-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fédération Francophone de Cancérologie Digestive,PHASE II RANDOMIZED TRIAL EVALUATING AFLIBERCEPT ASSOCIATED WITH SCHEME LV5FU2 AS FIRST LINE TREATMENT OF NON-RESECTABLE METASTATIC COLORECTAL CANCERS ETUDE DE PHASE II RANDOMISEE EVALUANT L’AFLIBE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001837-10,0,0,0 2014-001838-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"""G. d'Annunzio"" University",PrevenTion of contrast‐inducEd nephroAThy with urinE alkalinization: the TEATE study Prevenzione della nefropatia indotta da mezzo di contrasto con alcalinizzazione delle urine: studio TEATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001838-29,0,0,0 2014-001852-43,1,2016-02-01,2016-02-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Neuroscience, NTNU",Botulinum toxin type A block of the sphenopalatine ganglion in chronic migraine. Safety issues,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001852-43,0,0,0 2014-001855-22,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital,Phase I/II study with the combination of afatinib and selumetinib in advanced KRAS mutant positive and PIK3CA wildtype non-small cell lung cancer and colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001855-22,0,0,0 2014-001856-51,1,2021-11-15,2021-11-15,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Aleksander Krag,Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease: A randomized placebo controlled clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001856-51,0,0,0 2014-001857-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Carlos Fernandez Galvan,Evaluating the effectiveness of TAP and management epidural morphine chloride in Caesarean sections. EVALUAR LA EFICACIA DEL TAP Y LA ADMINISTRACIÓN DE CLORURO MÓRFICO POR VÍA EPIDURAL EN CESÁREAS ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001857-17,0,0,0 2014-001858-41,2,2020-04-20,2020-04-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astra Zeneca AB,A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001858-41,0,0,0 2014-001860-36,1,2016-04-26,2016-04-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Forehead and Glabellar Facial Rhytides,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001860-36,0,0,0 2014-001862-84,4,2020-01-30,2020-01-30,4,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Isofol Medical AB,"An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of [6R] 5,10-Methylene Tetrahydrofolate (Modufolin®) in Combination with a Fixed Dose of 5-Fluorouracil (5-FU) alone or together with a Fixed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001862-84,0,0,0 2014-001863-11,2,2015-05-14,2015-05-14,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Ewopharma AG.,"A Phase 4, Randomised, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy of Isoprinosine® in Comparison With Placebo in Subjects With Confirmed Acute Respiratory Viral Infection...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001863-11,0,0,0 2014-001864-36,1,2018-10-31,2018-10-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,uzleuven,"A PLACEBO-CONTROLLED STUDY ON THE EFFECT OF RIKKUNSHITO ON GASTRIC ACCOMMODATION AND NUTRIENT TOLERANCE, QUANTIFIED BY INTRAGASTRIC PRESSURE MONITORING DURING INTRAGASTRIC NUTRIENT INFUSION, IN FUNCTI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001864-36,0,0,0 2014-001866-90,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Children's Oncology Group,Treatment of Patients for newly diagnoised High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine in the Very High Risk Stratum,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001866-90,0,0,0 2014-001874-32,1,,,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,Universitätsklinikum Tübingen,"Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia investigated in a randomized, wait list controlled, observer-m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001874-32,0,0,0 2014-001876-75,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral selinexor (KPT-330) to standard induction chemotherapy in AML and high risk...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001876-75,0,0,0 2014-001882-28,1,2017-11-27,2017-11-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Thoraxklinik-Heidelberg gGmbH,Early Treatment of Borderline Pulmonary Arterial Hypertension Associated with Systemic Sclerosis (SSc-APAH) Frühe Behandlung von grenzwertig erhöhten Lungendrucken bei Patienten mit Sklerodermie/sy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001882-28,0,0,0 2014-001890-15,3,2015-05-11,2015-05-19,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Auspex Pharmaceuticals, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA Randomizované, dvojito zaslepené, placebom kontrolované ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001890-15,0,0,0 2014-001891-73,4,2020-12-14,2020-12-14,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Auspex Pharmaceuticals, Inc.","AN OPEN-LABEL, LONG-TERM SAFETY STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA Nyílt elrendezésű klinikai vizsgálat a közepesen súlyos és súlyos tardí...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001891-73,0,0,0 2014-001892-30,2,2014-12-05,2014-12-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galapagos NV,"Phase II, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients With Moderate Crohn’s Diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001892-30,0,0,0 2014-001893-32,5,2015-10-22,2015-11-09,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galapagos NV,"Phase II, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients with Moderate to Severe Ulce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001893-32,0,0,0 2014-001894-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Administration de GRanulocyte–Macrophage Colony-stimulating Factor (GM-CSF) pour diminuer les Infections acquises en réanimation au cours de l’immunoDépression induite par le sepsis.Etude multicentri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001894-15,0,0,0 2014-001895-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Västerbottens läns landsting,VIP-VIZA intensive multimodal cardiovascular intervention sub-study - a phase 2 randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001895-72,0,0,0 2014-001900-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Jari Halonen,"METOPROLOLIN VAIKUTUS ANESTESIAAN, KIPULÄÄKKEEN TARPEESEEN JA KIVUN ILMENEMISEEN RINTASYÖPÄLEIKKAUSPOTILAILLA METOPROLOLIN VAIKUTUS ANESTESIAAN, KIPULÄÄKKEEN TARPEESEEN JA KIVUN ILMENEMISEEN RINTAS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001900-23,0,0,0 2014-001905-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,AOP Oprhan Pharmaceuticals AG,Open-label Two-arm PD and PK Study of Landiolol in Patients with Tachycardic Atrial Fibrillation or Atrial Flutter,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001905-42,0,0,0 2014-001911-38,1,2019-08-14,2019-08-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo Español de Linfoma y Trasplante Autólogo de Médula ósea,AN OPEN MULTICENTER PHASE II STUDY OF EFFICACY AND TOXICITY OF MAINTENANCE SUBCUTANEOUS RITUXIMAB AFTER RESCUE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA NON-ELIGIBLE FOR A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001911-38,0,0,0 2014-001912-20,1,2021-07-21,2021-07-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"University Medical Center Utrecht, The Netherlands",Adult mesenchymal stem cells to regenerate the neonatal brain: the PASSIoN trial (Perinatal Arterial Stroke treated with Stem cells IntraNasally) Volwassen mesenchymale stamceltherapie voor regene...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001912-20,0,0,0 2014-001915-37,2,2016-11-02,2016-11-02,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Grünenthal GmbH,"A randomized, double-blind trial investigating the efficacy and safety of intravenous neridronic acid in subjects with complex regional pain syndrome type I (CRPS-I)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001915-37,0,0,0 2014-001916-20,4,2015-02-02,2015-02-02,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Mylan Pharma UK Ltd,"A Randomized, Double-Blind, Parallel Group 24 Week Placebo-Controlled Efficacy and Safety Study with a 28 Week Long Term Extension, of Nebulized Fluticasone Propionate (FP) /Formoterol Fumarate (FF) C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001916-20,0,0,0 2014-001917-20,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia Undergoing Lipid Aphe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001917-20,0,0,0 2014-001919-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,"Lengthening Adalimumab Dosing Interval in IBD patients in long term remission, the LADI study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001919-39,0,0,0 2014-001920-31,1,2020-01-03,2020-01-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,A PHASE II RANDOMIZED AND CONTROLLED INVESTIGATION OF SIX WEEKS OF ORAL VALGANCICLOVIR THERAPY IN INFANTS AND CHILDREN WITH CONGENITAL CYTOMEGALOVIRUS INFECTION AND HEARING LOSS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001920-31,0,0,0 2014-001921-34,2,2018-07-03,2018-07-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc.",A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001921-34,0,0,0 2014-001922-14,11,2017-09-28,2017-10-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim International GmbH,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001922-14,0,0,0 2014-001922-14,11,2017-09-28,2017-10-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001922-14,0,0,0 2014-001922-14,11,2017-09-28,2017-10-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001922-14,0,0,0 2014-001922-14,11,2017-09-28,2017-10-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001922-14,0,0,0 2014-001922-14,11,2017-09-28,2017-10-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Danmark A/S,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001922-14,0,0,0 2014-001922-14,11,2017-09-28,2017-10-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001922-14,0,0,0 2014-001922-14,11,2017-09-28,2017-10-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001922-14,0,0,0 2014-001922-14,11,2017-09-28,2017-10-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001922-14,0,0,0 2014-001922-14,11,2017-09-28,2017-10-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ltd,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001922-14,0,0,0 2014-001922-14,11,2017-09-28,2017-10-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 52 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001922-14,0,0,0 2014-001923-53,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rafael Bielza Galindo,"Intravenous iron, early functional recovery and delirium in patients atients with hip fracture Hierro intravenoso, recuperación funcional precoz y delirium en pacientes con fractura de cadera",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001923-53,0,0,0 2014-001924-31,1,2015-06-15,2015-06-15,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,Exploring novel mechanisms of vaccine failure and induction of pulmonary immunity following live attenuated influenza vaccination in HIV infected and uninfected individuals: a pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001924-31,0,0,0 2014-001929-32,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Gustave Roussy,Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001929-32,0,0,0 2014-001930-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ,"A randomized, evaluator blinded clinical trial to compare clinical efficacy of four different analgesic strategies in patients undergoing Extracorporeal Shock Wave Lithotripsy (ESWL). Ensayo clínic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001930-26,0,0,0 2014-001931-36,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001931-36,0,0,0 2014-001931-36,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001931-36,0,0,0 2014-001931-36,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001931-36,0,0,0 2014-001931-36,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS FARMA S.p.A.,"A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001931-36,0,0,0 2014-001936-12,1,2022-03-31,2022-03-31,1,0,0,0,0,1,2,0,0,1,1,1,0,0,1,Sanquin Plasma Products BV,Efficacy and Safety of human apotransferrin in patients with β-thalassemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001936-12,0,0,0 2014-001941-25,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,0,Rigshospitalet 2121,"Pilot Study with Treatment of Short Bowel Syndrome Patients with dipeptidyl-peptidase 4 inhibitor, Sitagliptin (Januvia®) Pilotstudie med behandling af korttarmspatienter med di-peptidylpeptidase 4...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001941-25,0,0,0 2014-001942-24,1,2019-03-01,2019-03-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology",The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in subjects with type 1 diabetes and high risk of nocturnal severe hypoglycaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001942-24,0,0,0 2014-001946-10,1,,,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,Cipla Ltd.,"A randomised, single dose, open label, two-period crossover study evaluating bioequivalence of salmeterol xinafoate HFA pMDI 25μg per actuation manufactured by Cipla Ltd, India (test product) with sal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001946-10,0,0,0 2014-001947-18,6,2015-10-26,2017-02-22,5,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"Isis Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Later-onset Spinal Muscular A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001947-18,1,0,0 2014-001947-18,6,2015-10-26,2017-02-22,5,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Later-onset Spinal Muscular A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001947-18,1,0,0 2014-001948-37,1,2018-09-21,2018-09-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,North Bristol NHS Trust,"Intramuscular oxytocics: A multi-centre randomised comparison study of intramuscular Carbetocin, Syntocinon and Syntometrine for the third stage of labour following vaginal birth",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001948-37,0,0,0 2014-001949-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Philogen S.p.A.,A Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Rituximab in relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001949-25,0,0,0 2014-001950-41,1,2018-06-06,2018-06-06,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Papworth Hospital NHS Foundation Trust - Research and Development Department,The effect of acute intravenous (iv) morphine administration on Sleep Disordered Breathing (SDB) in patients with moderate Obstructive Sleep Apnoea (OSA): A paired design trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001950-41,0,0,0 2014-001953-18,1,2015-09-01,2015-09-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ ABT-450/ Ritonavir and Dasabuvir in Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001953-18,0,0,0 2014-001954-40,1,2015-08-31,2015-08-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,SciencePharma spółka z ograniczoną odpowiedzialnością sp. k.,"A randomized, multicenter, parallel, open-label study comparing the safety of the test investigational medicinal product (IMP) Enoxaparin Sodium 40 with the reference IMP Clexane for the prevention of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001954-40,0,0,0 2014-001956-52,1,2017-11-08,2017-11-08,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Fondazione IRCCS Istituto Nazionale dei Tumori,Activity and safety of third line tyrosin kinase inhibitor (TKI) after 2 tyrosin kinase inhibitors(TKIs) in patients with metastatic renal cell carcinoma (mRCC) (Tokio Study) Attività e sicurezza d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001956-52,0,0,0 2014-001957-17,1,2021-06-04,2021-06-04,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Umeå University Hospital,"THE EFFECT OF DIFLUNISAL ON FAMILIAL TRANSTHYRETIN AMYLOIDOSIS: An open label phase III extension study of the diflunisal trials (IND 68092 and DFNS01), and an open label observational study on previ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001957-17,0,0,0 2014-001959-24,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Hospital Essen,"BoTN: Onabotulinumtoxin A for the treatment of trigeminal neuralgia: Efficacy, safety and neurophysiological alterations under therapy – a prospective, controlled trial BoTN: Onabotulinumtoxin A zu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001959-24,0,0,0 2014-001966-87,2,2016-08-23,2016-08-23,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"FERRER INTERNACIONAL, S.A.","Double-blind, randomized, placebo-controlled cross-over dose finding study of two doses of lorediplon in adult patients with insomnia disorder Dvostruko slijepo, randomizirano, placebom kontroliran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001966-87,0,0,0 2014-001967-11,6,2017-04-05,2017-04-05,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Probiodrug AG,"A Phase 2A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Trial of PQ912 in Subjects with early Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001967-11,0,0,0 2014-001968-35,1,2020-08-11,2020-08-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Klinikum der Universität München - AöR vertreten durch den Vorstand des Bereiches umanmedizinH,Add-on spironolactone for the treatment of schizophrenia Evaluation der Effektivität der add-on Behandlung von Spironolacton bei Patienten mit einer Schizophrenie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001968-35,0,0,0 2014-001969-27,3,2015-06-10,2015-06-10,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,Albiglutide Versus Placebo as Add-on to Intensified Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001969-27,0,0,0 2014-001971-30,18,2017-12-27,2017-12-27,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma services AG,A multicenter study to evaluate safety and tolerability in patients with chronic heart failure and reduced ejection fraction from PARADIGM-HF receiving open label LCZ696,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001971-30,0,0,0 2014-001971-30,18,2017-12-27,2017-12-27,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,A multicenter study to evaluate safety and tolerability in patients with chronic heart failure and reduced ejection fraction from PARADIGM-HF receiving open label LCZ696,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001971-30,0,0,0 2014-001971-30,18,2017-12-27,2017-12-27,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farma SPA,A multicenter study to evaluate safety and tolerability in patients with chronic heart failure and reduced ejection fraction from PARADIGM-HF receiving open label LCZ696,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001971-30,0,0,0 2014-001971-30,18,2017-12-27,2017-12-27,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.",A multicenter study to evaluate safety and tolerability in patients with chronic heart failure and reduced ejection fraction from PARADIGM-HF receiving open label LCZ696,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001971-30,0,0,0 2014-001972-70,4,2016-04-25,2016-05-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Reasearch & Development,"A randomised, double-blind (sponsor unblinded), placebocontrolled, parallel-group, multicentre study to evaluate the efficacy and safety of GSK2269557 administered in addition to standard of care in a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001972-70,0,0,0 2014-001973-15,1,2015-12-14,2015-12-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"University Clinic in Nephrology and Hypertension, Department of Medical Research","Renal Handling of Water and Sodium in Autosomal Dominant Polycystic Kidney Disease. The effects of tolvaptan on renal handling of water and sodium , vasoactive hormones and central hemodynamics during...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001973-15,0,0,0 2014-001974-32,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma GmbH,"A randomized, double-blind, multicenter study to assess the efficacy and safety of 16 weeks secukinumab dosage interval shortening (2-weekly 300 mg s.c.) in comparison to continued standard treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001974-32,0,0,0 2014-001976-75,16,2016-11-11,2016-11-11,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients with Clinically Evident Cardiovascular Disease and Receiving Statin Backgroun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001976-75,0,0,0 2014-001977-15,10,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Karyopharm Therapeutics, Inc.",A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001977-15,0,0,0 2014-001978-33,1,2019-06-30,2019-06-30,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Brighton and Sussex University Hospitals NHS Trust,How can we optimise inhaled beta2 agonist dose as 'reliever' medicine for wheezy pre-school children?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001978-33,0,0,0 2014-001983-36,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,AIO-Studien-gGmbH,"Maintaining ERBB blockade in EGFR-mutated lung cancer (MARBLE) - A randomized, open-label, phase II study of maintaining pan-ERBB blockade following platinum-based induction chemotherapy in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001983-36,0,0,0 2014-001984-11,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E DELLA CURA DEI TUMORI,"“Neo-Adjuvant Treatment with the CDK4,6 inhibitor Palbociclib in HER2-positive and ER-positive breast cancer: effect on Ki67 and apoptosis before, during and after treatment “",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001984-11,0,0,0 2014-001985-86,5,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,SILLAJEN,"A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcino...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001985-86,0,0,0 2014-001985-86,5,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,SillaJen Inc.,"A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcino...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001985-86,0,0,0 2014-001988-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Academic Medical Center, Amsterdam",Fractional CO2 laser assisted delivery of topical articaine and epinephrine solution vs. topical EMLA administration: a randomized controlled pilot study Toediening van topicale articaïne en epinef...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001988-12,0,0,0 2014-001989-97,1,2018-04-30,2018-04-30,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,OA Doz. Dr. Thomas Müller c/o B&S Zentrallabor Konventhospital Barmherzige Brüder Linz,Clinical study to investigate the efficiency of vascular occlusion prevention by ticagrelor after stent implantation in patients with peripheral artery disease (PAD) and high platelet reactivity durin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001989-97,0,0,0 2014-001991-76,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial","Initial treatment of idiopathic nephrotic syndrome in children with mycophenolate mofetil vs. prednisone: A randomized, controlled, multicenter study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001991-76,0,0,0 2014-001992-30,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Leicester,A randomised controlled phase II trial of oral vinorelbine as second line therapy for patients with malignant pleural mesothelioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001992-30,0,0,0 2014-001995-71,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,1,Plazmaferezis Állomás Közhasznú Nonprofit Kft,Open label multicenter prospective trial to assess the tetanus titer in subject of regular plasmapharesis Nyílt multicentrikus követéses klinikai vizsgálat a tetanus emlékeztető oltásban részesült...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001995-71,0,0,0 2014-002001-37,3,2020-03-31,2020-03-31,1,1,0,0,0,0,2,0,0,1,1,0,1,0,0,Queen Mary University London,Phase II window of opportunity study of short term preoperative treatment with enzalutamide (alone or in combination with exemestane) in patients with primary breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002001-37,0,0,0 2014-002002-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMCG,A multicentre randomized double-blind placebo controlled discontinuation trial of methylphenidate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002002-20,0,0,0 2014-002003-25,1,2017-02-06,2017-02-06,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Barts Health NHS Trust,A Phase II Trial of Aflibercept Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Metastatic Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002003-25,0,0,0 2014-002004-24,14,2018-10-11,2018-12-03,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002004-24,0,0,0 2014-002007-13,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,"Instituto Grifols, S.A.","A multicenter, randomized, placebo-controlled, double-blind and crossover pilot trial with human alpha-1 antitrypsin in patients with chronic fatigue syndrome Ensayo clínico piloto, multicéntrico,a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002007-13,0,0,0 2014-002008-25,3,2019-03-25,2019-03-25,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"Sarepta Therapeutics, Inc.","A 2-Part, Randomized, Double-Blind, Placebo-Controlled, Dose Titration, Safety, Tolerability, and Pharmacokinetics Study (Part 1) Followed by an Open-Label Efficacy and Safety Evaluation (Part 2) of S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002008-25,0,0,0 2014-002009-40,14,2020-10-01,2020-10-01,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002009-40,0,0,0 2014-002010-24,1,2018-01-27,2018-01-27,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),SNPeCPR pour la prise en charge des arrêts cardiaques extra-hospitaliers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002010-24,0,0,0 2014-002013-37,6,2017-05-08,2017-05-08,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,TauRx Therapeutics Ltd,"An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer?s Disease or Behavioral Variant Frontotemporal Dementia Estudio de exte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002013-37,0,0,0 2014-002014-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Országos Onkológiai Intézet,"An open label, single center, non-randomised, phase II study of efficacy Olaparib in patients with BRCA mutation posistive previously treated advanced ocarium cancer Olaparib hatékonyságának vizsgá...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002014-22,0,0,0 2014-002017-28,1,2021-03-03,2021-03-03,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KULEUVEN,ROLE OF THE TYPE AND SITE OF DISTENSION IN THE EVALUATION OF DRUGS EFFICACY IN MODULATING THE SENSORY AND MOTOR RESPONSE OF THE DESCENDING COLON AND THE RECTUM IN MAN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002017-28,0,0,0 2014-002018-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AOU di Bologna Policlinico S.Orsola-Malpighi,5-Metyl-tetrahydrofolate in the treatment of portal hypertension in cirrhotics in pharmacologic prophylaxis of variceal bleeding with beta-blockers: a double-blind randomized controlled trial 5-m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002018-21,0,0,0 2014-002021-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fondazione IRCCS Istituto Nazionale dei Tumori,Decurarization After Thoracic Anesthesia - A prospective multicenter double-blind randomized trial comparing sugammadex vs neostigmine reversal after thoracic anesthesia Decurarization After Thora...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002021-35,0,0,0 2014-002022-12,6,2021-01-31,2021-01-31,5,0,0,0,0,1,2,0,0,2,0,0,0,0,0,"Clinical Trials Unit, Rigshospitalet","A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002022-12,1,0,0 2014-002036-14,1,2016-06-30,2016-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Lars Bo Svendsen,"The effect of epidural anaesthesia on systemic and splanchnic hemodynamic during gastroesophageal resections, a randomized controlled trial Effekt af epidural anæstesi på systemisk og splanknisk hæ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002036-14,0,0,0 2014-002037-59,1,2019-01-11,2019-01-11,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Exalenz BioScience Ltd.,Clinical Study of the BreathID® LF System to train the algorithm for the ¹³C-Methacetin Breath Test (MBT) in assessment of Portal Hypertension in Patients with Compensated Liver Cirrhosis Estudio c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002037-59,0,0,0 2014-002039-32,1,2019-06-03,2019-06-03,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,"Rigshospitalet, Copenhagen University Hospital","PlenadrEMA study - Effect of modified-release compared to conventional hydrocortisone on fatigue, measured by Ecological Momentary Assessments; a pilot study to assess feasibility, responsiveness of o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002039-32,0,0,0 2014-002041-22,1,2018-06-18,2018-06-18,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,An Open Label Continuation Study of the Oral AKT Inhibitor GSK2110183 in Subjects with Solid Tumors and Hematologic Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002041-22,0,0,0 2014-002044-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Hospital of Grenoble,ROpivacaïne par cathéter cicatriciel versus Morphine épidurale dans l’ANalgésie après Césarienne En cours de travail.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002044-41,0,0,0 2014-002047-18,1,2015-11-19,2015-11-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,HAL Allergy B.V.,"A randomized, double-blind, placebo-controlled study to determine tolerability and safety of different dosages of SUBLIVAC FIX Mite mixture in patients with allergic rhinitis / rhinoconjunctivitis cau...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002047-18,0,0,0 2014-002048-42,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,An single arm open-label multi-centre extension study of pertuzumab administered as a single agent or in combination with other anti-cancer therapies in patients previously enrolled in a Hoffmann-La R...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002048-42,0,0,0 2014-002048-42,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Roche Farma, S.A. en nombre de F. Hoffmann-La Roche Ltd",An single arm open-label multi-centre extension study of pertuzumab administered as a single agent or in combination with other anti-cancer therapies in patients previously enrolled in a Hoffmann-La R...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002048-42,0,0,0 2014-002052-84,1,2015-01-12,2015-01-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,STX Pharma,An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Mild to Moderate Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002052-84,0,0,0 2014-002053-19,9,,,0,0,0,1,0,1,1,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,An open-label multi-part first-in-human study of oral LMI070 in infants with Type 1 spinal muscular atrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002053-19,0,0,0 2014-002053-19,9,,,0,0,0,1,0,1,1,0,0,2,1,0,0,0,1,NOVARTIS FARMA S.p.A.,An open-label multi-part first-in-human study of oral LMI070 in infants with Type 1 spinal muscular atrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002053-19,0,0,0 2014-002054-39,2,2015-12-01,2015-12-01,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,DexTech Medical AB,"A randomized, double-blind, placebo-controlled multi-centre phase II study to evaluate efficacy and tolerability of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002054-39,0,0,0 2014-002056-40,1,2016-06-16,2016-06-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Diakonhjemmet Hospital AS,"A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002056-40,0,0,0 2014-002061-30,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,University Hospital Southampton NHS Foundation Trust,Therapeutic HPV vaccine trial +/- anti-CD40 in HPV-driven squamous cell carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002061-30,0,0,0 2014-002063-14,1,2020-02-04,2020-02-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GEMCAD (Grupo Español Multidisciplinar en Cáncer Digestivo),"Induction FOLFOX with or without Aflibercept followed by chemoradiation in High Risk Locally Advanced Rectal Cancer. Phase II randomized, multicenter, open label trial Tratamiento de inducción con ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002063-14,0,0,0 2014-002068-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,DIRECTION CENTRALE DU SERVICE DE SANTE DES ARMEES,Prospective Multicentric Open Randomised Controlled Trial comparing Topical Aluminium Chloride to Onabotulinumtoxin A Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs) Etude prosp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002068-34,0,0,0 2014-002069-31,7,2019-09-03,2019-09-03,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Pharmacyclics, LLC","A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton?s Tyrosine Kinase Inhibitor Ibrutinib in Combination with Obinutuzumab versus Chlorambucil in Combination with Obinutuzumab in Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002069-31,0,0,0 2014-002069-31,7,2019-09-03,2019-09-03,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Pharmacyclics LLC,"A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton?s Tyrosine Kinase Inhibitor Ibrutinib in Combination with Obinutuzumab versus Chlorambucil in Combination with Obinutuzumab in Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002069-31,0,0,0 2014-002069-31,7,2019-09-03,2019-09-03,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Pharmacyclics, Incorporated","A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton?s Tyrosine Kinase Inhibitor Ibrutinib in Combination with Obinutuzumab versus Chlorambucil in Combination with Obinutuzumab in Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002069-31,0,0,0 2014-002071-29,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,DIPARTIMENTO DI ONCOLOGIA MEDICA USL8,A RANDOMIZED PROSPECTIVE MULTICENTRE PHASE II STUDY OF ANDROGEN DEPRIVATION THERAPY (ADT) PLUS RADIOTHERAPY WITH OR WITHOUT ABIRATERONE ACETATE AND PREDNISONE IN LOCALLY ADVANCED VERY HIGH-RISK PROSTA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002071-29,0,0,0 2014-002072-92,4,2018-11-30,2018-11-30,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate The Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 In Ambulatory Boys With Duc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002072-92,0,0,0 2014-002083-33,1,2017-05-26,2017-05-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee/NHS Tayside,Does Allopurinol regress Left Ventricular Hypertrophy in Patients with Treated Essential Hypertension?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002083-33,0,0,0 2014-002092-28,1,2017-07-27,2017-07-27,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,KULeuven - TARGID,The effect of acotiamide on gastric motility and satiation in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002092-28,0,0,0 2014-002095-93,4,2016-02-17,2016-02-17,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir plus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002095-93,0,0,0 2014-002096-29,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Speising Orthopaedic Hospital Vienna,Application of Intrawound Vancomycin Powder in Spinal Fusion Surgery to Reduce Postoperative Surgical Site Infections - A Prospective Randomized Controlled Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002096-29,0,0,0 2014-002098-12,3,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Biogen Idec Research Limited,"An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002098-12,0,0,0 2014-002107-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,General Hospital Linz,Double blind randomized study to evaluate the efficiency of intravenous ferric carboxymaltose in preventing anemia after cardiopulmonary bypass in children with congenital heart disease Doppelblin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002107-16,0,0,0 2014-002108-25,3,2020-07-17,2020-07-17,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Celgene Corporation,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, FOLLOWED BY AN ACTIVE-TREATMENT PHASE TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002108-25,0,0,0 2014-002108-25,3,2020-07-17,2020-07-17,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Amgen Inc.,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, FOLLOWED BY AN ACTIVE-TREATMENT PHASE TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002108-25,0,0,0 2014-002111-41,12,2017-02-21,2017-02-21,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,VIIV HEALTHCARE UK LIMITED,A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Re...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002111-41,1,0,0 2014-002111-41,12,2017-02-21,2017-02-21,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Re...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002111-41,1,0,0 2014-002111-41,12,2017-02-21,2017-02-21,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ViiV Healthcare UK Limited,A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Re...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002111-41,1,0,0 2014-002111-41,12,2017-02-21,2017-02-21,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Re...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002111-41,1,0,0 2014-002112-16,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,Analysis of the immune response to Fendrix as compared to double-dose Engerix B in HIV-infected non-responders to standard Hepatitis B vaccination courses,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002112-16,0,0,0 2014-002113-39,13,2016-05-27,2019-08-13,13,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer HealthCare AG,"A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002113-39,0,0,0 2014-002113-39,13,2016-05-27,2019-08-13,13,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer AG,"A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002113-39,0,0,0 2014-002113-39,13,2016-05-27,2019-08-13,13,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bayer AG,"A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002113-39,0,0,0 2014-002114-23,9,2016-05-27,2016-05-27,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bayer AG,"A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002114-23,1,0,0 2014-002114-23,9,2016-05-27,2016-05-27,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bayer HealthCare AG,"A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002114-23,1,0,0 2014-002117-28,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,ACERTA PHARMA BV,"An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma Estudio de fase II abierto sobre ACP-196 en sujetos con linfoma de células del manto",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002117-28,0,0,0 2014-002117-28,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Acerta Pharma BV,"An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma Estudio de fase II abierto sobre ACP-196 en sujetos con linfoma de células del manto",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002117-28,0,0,0 2014-002117-28,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Acerta Pharma B.V.,"An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma Estudio de fase II abierto sobre ACP-196 en sujetos con linfoma de células del manto",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002117-28,0,0,0 2014-002118-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Randers Regional Hospital,Zoledronate against fractures in children with cerebral palsy Zoledronat mod frakturer hos børn med cerebral parese,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002118-21,0,0,0 2014-002119-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Jules Bordet,Influence of a new model of relative hypoxia on the evolution of erythropoietin and haemoglobin in patients undergoing breast reconstruction by a Deep Inferior Epigastric Perforator Flap.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002119-41,0,0,0 2014-002121-35,3,2016-06-16,2016-06-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Open Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 or 24 Weeks in Kidney Transplant Recipients with Chronic H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002121-35,0,0,0 2014-002122-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,az turnhout,Longitudinal Fascia Iliaca Compartment Block for Total Hip Arthroplasty,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002122-12,0,0,0 2014-002123-10,9,2020-08-05,2020-08-05,5,1,0,1,0,1,1,0,0,2,0,0,0,0,1,Boehringer Ingelheim Limited,"Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002123-10,1,0,0 2014-002123-10,9,2020-08-05,2020-08-05,5,1,0,1,0,1,1,0,0,2,0,0,0,0,1,Boehringer Ingelheim bv,"Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002123-10,1,0,0 2014-002123-10,9,2020-08-05,2020-08-05,5,1,0,1,0,1,1,0,0,2,0,0,0,0,1,Boehringer Ingelheim Italia S.p.A.,"Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002123-10,1,0,0 2014-002123-10,9,2020-08-05,2020-08-05,5,1,0,1,0,1,1,0,0,2,0,0,0,0,1,SCS Boehringer Ingelheim Comm. V,"Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002123-10,1,0,0 2014-002123-10,9,2020-08-05,2020-08-05,5,1,0,1,0,1,1,0,0,2,0,0,0,0,1,Boehringer Ingelheim France,"Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002123-10,1,0,0 2014-002123-10,9,2020-08-05,2020-08-05,5,1,0,1,0,1,1,0,0,2,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002123-10,1,0,0 2014-002123-10,9,2020-08-05,2020-08-05,5,1,0,1,0,1,1,0,0,2,0,0,0,0,1,"Boehringer Ingelheim España, S.A.","Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002123-10,1,0,0 2014-002123-10,9,2020-08-05,2020-08-05,5,1,0,1,0,1,1,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002123-10,1,0,0 2014-002124-27,1,2017-09-11,2017-09-11,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,"Endocrine Research Unit, Odense University Hospital",GLP-1 Agonist and Bone: Effects of Exenatide on Bone Metabolism GLP-1 Agonist og Knogle: Effekter af Exenatid på knoglemetabolismen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002124-27,0,0,0 2014-002125-35,1,2016-05-10,2016-05-10,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Algipharma AS,"A randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OligoG) for 28 days in subjects with Cystic Fibrosis using aztreonam due to chronic colonization wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002125-35,0,0,0 2014-002128-28,2,2018-05-30,2018-05-30,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Dr. F. Köhler Chemie GmbH,"A Prospective Multicenter Phase 2/3 Clinical Trial with Sodium Thiosulfate for the Treatment of Calciphylaxis Prospektive, multizentrische Phase 2/3-Studie mit Natriumthiosulfat zur Behandlung von ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002128-28,0,0,0 2014-002131-34,5,2016-11-11,2016-12-13,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002131-34,0,0,0 2014-002134-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ospedale L. Sacco - Azienda Ospedaliera-Polo Universitario,"Evalutation of maraviroc therapy in PI-treated HIV+ patients at intermediate-low risk for cardiovascular diseases: a phase IV, randomized, open study VALUTAZIONE DELLA TERAPIA CON MARAVIROC IN PAZ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002134-31,0,0,0 2014-002135-34,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Innate Pharma,Open label single arm Phase Ib-II study of pre-operative IPH2201 in patients with locally advanced resectable squamous cell carcinoma of the oral cavity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002135-34,0,0,0 2014-002137-58,4,2017-04-12,2017-04-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gilead Sciences Inc,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respiratory ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002137-58,0,0,0 2014-002139-33,1,2016-05-29,2016-05-29,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Bispebjerg University Hospital,Pharmacokinetics of inhaled salmeterol administrated in healthy trained males Farmakokinetik for inhaleret salmeterol hos raske trænede mænd,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002139-33,0,0,0 2014-002140-40,1,2017-02-13,2017-02-13,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Bispebjerg University Hospital,Pharmacological properties of in haled and oral terbutalin administrated in healthy trained males Farmakologiske egenskaber for inhaleret og oral terbutalin hos raske trænede mænd,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002140-40,0,0,0 2014-002142-50,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,St. Antonius Hospital,"A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery. Een gera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002142-50,0,0,0 2014-002146-44,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years) PROTOCOLE GRAALL-2014 Protocole multicentrique de traitement des Leucémies Aiguës Lymphobla...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002146-44,0,0,0 2014-002147-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Center,A randomized controlled double-blinded trial comparing the effect of on Demand ROcuronium boluses vs continuous infusion on rating of surgical and anesthesia conditions and need for reversal in Patien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002147-18,0,0,0 2014-002150-39,2,2016-12-07,2016-12-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind, placebo controlled, study to evaluate the efficacy and safety of CSJ148 compared to placebo to prevent human cytomegalovirus (HCMV) replication in stem cell t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002150-39,0,0,0 2014-002151-26,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Zambon Spa,"A Double Blind, Double Dummy, Randomized, Two Way Cross-Over Study To Compare The Effects Of Z7200 And Symbicort® Turbohaler On Functional Respiratory Imaging Parameters In Asthmatic Patients Dubbe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002151-26,0,0,0 2014-002154-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Vinforce - Institut für Osteoporoseforschung,"Teriparatide for fracture repair in humans: A prospective, randomized, double-blind placebo-controlled pilot study in female and male patients with proximal humerus fracture The TERAFRAP Study Te...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002154-39,0,0,0 2014-002155-25,1,2015-12-04,2015-12-04,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Takeda Development Centre Europe Ltd,"An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Subjects With Hypogonadotropic Hypogonadism",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002155-25,0,0,0 2014-002158-38,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,BioMarin Pharmaceutical Inc,"A Study of Respiratory Muscle Strength, including Effort-Independent Measures, in Subjects with Late-Onset Pompe Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002158-38,0,0,0 2014-002159-24,5,2016-06-07,2016-06-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects in the Early (Predementia) Alzheimer's...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002159-24,0,0,0 2014-002161-30,7,2018-11-16,2018-11-16,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim International GmbH,"A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Small...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002161-30,0,0,0 2014-002167-16,7,2021-12-06,2021-12-06,3,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Eisai Limited,"An Open-Label, Multicenter Study with an Extension Phase to Evaluate the Safety, Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral Suspension when Administered as an Adjunctive Ther...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002167-16,1,1,0 2014-002168-34,1,2019-11-22,2019-11-22,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Doc. MUDr. Petr Kolář, PhD, Oční klinika FN Brno",Study To Determine Efficacy of Aflibercept For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration Stanovení účinnosti Afliberceptu v léčbě zmnožení cév uvn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002168-34,0,0,0 2014-002169-30,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,Planning treatment for oesophago-gastric cancer: a randomised maintenance therapy trial (PLATFORM Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002169-30,0,0,0 2014-002170-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,Treatment of Cervical Spinal Cord Injury with Imatinib – a safety and feasibility study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002170-36,0,0,0 2014-002171-29,2,2018-08-09,2018-08-09,1,0,0,0,0,0,4,0,0,2,1,0,0,0,0,"Hospital of the University of Munich, Grosshadern",Intensified Loading with Prasugrel versus Moderate Loading with Clopidogrel in PCI-treated Patients with Biomarker-Negative Angina pectoris.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002171-29,1,0,0 2014-002172-92,4,2019-10-08,2019-10-08,4,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Celgene Corporation,"A randomized, multicenter, open-label, Phase 2 study with a safety run-in part to evaluate safety, pharmacodynamics and efficacy of azacitidine compared to no anticancer treatment in children and youn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002172-92,0,0,0 2014-002175-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione IRCCS Istituto Nazionale dei Tumori,Efficacy and safety of single agent pan-HER inhibitor Dacomitinib in the treatment of locally advanced unresectable or metastatic squamous cell cancer of the skin or with clinical contraindication to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002175-28,0,0,0 2014-002176-83,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Clinirx Tangent Research,A randomized trial administering Sodium Nitroprusside vs. placebo as add-on to antipsychotics in patients with schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002176-83,0,0,0 2014-002177-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ZonMW GGG,Step-down versus step-up analgesics in patients with (sub)acute sciatica in primary care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002177-11,0,0,0 2014-002178-35,1,2019-08-14,2019-08-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,VU University Medical Center,"A phase 4, monocenter, randomized, open label, comparator-controlled, parallel-group, mechanistic intervention trial to assess the effect of 8-week treatment with the glucagon-like peptide-1 receptor ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002178-35,0,0,0 2014-002179-27,1,2015-10-08,2015-10-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Autifony Therapeutics Limited,A Balanced Randomised Placebo Controlled Double-blind Phase IIa Study to Investigate the Efficacy and Safety of AUT00063 Versus Placebo in Subjective Tinnitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002179-27,0,0,0 2014-002182-29,4,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,1,Pfizer Inc.,"An Open-Label, Multicenter Study To Evaluate The Pharmacokinetics Of Single And Multiple Intravenous Doses Of Pantoprazole In Two Age Cohorts Of Hospitalized Pediatric Subjects 1 To 16 Years Of Age Wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002182-29,0,0,0 2014-002182-29,4,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 1007","An Open-Label, Multicenter Study To Evaluate The Pharmacokinetics Of Single And Multiple Intravenous Doses Of Pantoprazole In Two Age Cohorts Of Hospitalized Pediatric Subjects 1 To 16 Years Of Age Wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002182-29,0,0,0 2014-002184-14,5,2017-10-26,2017-10-26,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BMS-931699 vs. Placebo on a Background of Limited Standard of care in the Treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002184-14,0,0,0 2014-002185-78,5,2015-08-19,2015-08-19,4,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Norgine Ltd,"A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) versus MOVIPREP® using a 2-Da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002185-78,0,0,0 2014-002186-30,5,2015-08-19,2015-08-19,4,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Norgine Ltd,"A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) versus a Sodium Picosulfate a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002186-30,0,0,0 2014-002187-32,1,2016-09-16,2016-09-16,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Danish Myeloma Study Group,A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002187-32,0,0,0 2014-002188-13,1,2018-05-21,2018-05-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Liverpool,Emergency Treatment with Levetiracetam or Phenytoin in Status Epilepticus in Children (EcLiPSE) – an open label randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002188-13,0,0,0 2014-002188-13,1,2018-05-21,2018-05-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Alder Hey Children's NHS Foundation Trust,Emergency Treatment with Levetiracetam or Phenytoin in Status Epilepticus in Children (EcLiPSE) – an open label randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002188-13,0,0,0 2014-002189-64,3,2016-01-19,2017-04-14,2,0,0,0,0,0,2,0,0,2,0,0,0,0,2,CytRx Corporation,"A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects with Metastatic Small Cell Lung Cancer Who Either Relapse...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002189-64,1,0,0 2014-002193-37,1,,,0,1,0,0,0,3,3,0,0,3,0,0,0,0,0,Moorfields Eye Hospital NHS Foundation Trust,A phase 3 multi-centre double-masked randomised controlled trial of adjunctive intraocular and periocular steroid (triamcinolone acetonide) versus standard treatment in eyes undergoing vitreoretinal s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002193-37,0,0,0 2014-002194-10,1,2015-07-09,2015-07-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Dermo-Cosmétique,An intra-individual randomized controlled study to evaluate the efficacy and tolerance of the product RV4421A BS0042 in association with a moderately potent topical corticosteroid in adults with Atopi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002194-10,0,0,0 2014-002195-90,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Cardiff University,Adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome (AML19),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002195-90,0,0,0 2014-002204-24,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,University Medical Center Groningen,REVERSAL OF ANTICOAGULANT EFFECT OF DABIGATRAN® BY PROTHROMBIN COMPLEX CONCENTRATE (BERIPLEX®) ASSESSED WITH A NOVEL METHOD OF BLOOD LOSS MEASUREMENT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002204-24,0,0,0 2014-002205-38,1,2018-03-22,2018-03-22,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,INTERCEPT PHARMACEUTICALS INC.,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled,Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects with Primary Sclerosing Cholangitis Uno studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002205-38,0,0,0 2014-002206-20,7,2022-02-18,2022-02-18,5,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002206-20,1,0,0 2014-002208-26,12,2006-10-06,2016-10-06,10,1,0,0,0,0,3,0,1,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.","A Phase 3, randomized, active-comparator controlled clinical trial to study the contraceptive efficacy and safety of the MK-8342B (etonogestrel + 17?-estradiol) vaginal ring and the levonorgestrel-eth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002208-26,0,0,0 2014-002208-26,12,2006-10-06,2016-10-06,10,1,0,0,0,0,3,0,1,1,1,0,1,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, randomized, active-comparator controlled clinical trial to study the contraceptive efficacy and safety of the MK-8342B (etonogestrel + 17?-estradiol) vaginal ring and the levonorgestrel-eth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002208-26,0,0,0 2014-002208-26,12,2006-10-06,2016-10-06,10,1,0,0,0,0,3,0,1,1,1,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase 3, randomized, active-comparator controlled clinical trial to study the contraceptive efficacy and safety of the MK-8342B (etonogestrel + 17?-estradiol) vaginal ring and the levonorgestrel-eth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002208-26,0,0,0 2014-002209-39,1,2019-07-29,2019-07-29,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,The Netherlands Cancer Institute,Phase I/II study with lapatinib plus trametinib in patients with metastatic KRAS mutant non-small cell lungcancer Fase I/II studie met de combinatie van lapatinib met trametinib bij patiënten met ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002209-39,0,0,0 2014-002210-23,1,2018-11-28,2018-11-28,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Rigshospitalet,Can local intramuscular botulinum toxin improve dysphagia in patients with myopathic dysphagia and constriction of the cricoid muscle?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002210-23,0,0,0 2014-002212-16,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma GmbH,"Exploratory study on the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers in patients with moderate to severe plaque-type psoriasis treated with subcutaneous secukinumab (300...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002212-16,0,0,0 2014-002215-42,1,,,0,0,0,0,1,0,3,0,0,4,0,0,0,0,0,IRCCS Burlo Garofolo,Single-blind randomized controlled trial for acute abdomen analgesia in Pediatric Emergency department Trial controllato randomizzato in singolo cieco per l’analgesia nell’addome acuto in Pronto So...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002215-42,0,0,0 2014-002217-31,3,2018-03-07,2018-03-07,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,"Astellas Pharma Global Development, Inc.","A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002217-31,0,0,0 2014-002219-41,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Erasmus Medical Centre,A prospective single-centre double blind randomized study on the efficacy and safety of 4 weekly pasireotide LAR administration in combination with or without weekly pegvisomant in previously controll...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002219-41,0,0,0 2014-002221-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hôpital Universitaire Des Enfants Reine Fabiola,Prospective Randomized Study Comparing the Efficacy and Safety of Pleural Drainage by Video-Assisted Thoracoscopic With Pleural Drain Associated With Urokinase in the Treatment of Parapneumonic Pleura...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002221-35,0,0,0 2014-002223-10,1,2017-12-11,2017-12-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Hull and East Yorkshire Hospitals NHS Trust,A randomised controlled trial of a new daily skincare regimen for lowering the incidence of pinsite infections following circular frame surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002223-10,0,0,0 2014-002224-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St. Antonius Hospital,A new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment Infliximab doseren op basis van serumconcentraties bij ernstig sarcoidose: ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002224-26,0,0,0 2014-002226-13,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Rigshospitalet,A multimodality imaging approach for early detection and prediction of cardiotoxicity in Doxorubicin-treated patients with malignant lymphom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002226-13,0,0,0 2014-002227-96,1,2015-09-18,2015-09-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,County Council of Östergötland,Inhibition of platelet aggregation after administration of three different ticagrelor loading dose formulations in patients with stable angina referred for coronary angiography Blodplättshämmande b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002227-96,0,0,0 2014-002228-28,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino,"A double blind, placebo controlled, parallel groups, multicenter study on filgrastim in amyotrophic lateral sclerosis STUDIO MULTICENTRICO, A DOPPIO CIECO, CONTROLLATO CON PLACEBO, A GRUPPI PARALLE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002228-28,0,0,0 2014-002230-32,8,2021-09-16,2021-09-16,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A MULTISTAGE, PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB PLUS PACLITAXEL, COBIMETINIB PLUS ATEZOLIZUMAB PLUS PACLITAXEL, OR COBIMETINIB PLUS ATEZOLIZUMAB PLUS NAB-PACLITAXEL AS F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002230-32,1,0,0 2014-002230-32,8,2021-09-16,2021-09-16,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,F. Hoffman-La Roche Ltd.,"A MULTISTAGE, PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB PLUS PACLITAXEL, COBIMETINIB PLUS ATEZOLIZUMAB PLUS PACLITAXEL, OR COBIMETINIB PLUS ATEZOLIZUMAB PLUS NAB-PACLITAXEL AS F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002230-32,1,0,0 2014-002230-32,8,2021-09-16,2021-09-16,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"F. Hoffman-La Roche Ltd., realizado en España por Roche Farma S.A.","A MULTISTAGE, PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB PLUS PACLITAXEL, COBIMETINIB PLUS ATEZOLIZUMAB PLUS PACLITAXEL, OR COBIMETINIB PLUS ATEZOLIZUMAB PLUS NAB-PACLITAXEL AS F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002230-32,1,0,0 2014-002236-14,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,University Hospital Ulm,"Phenprocoumon versus Dabigatran in subjects with atrial fibrillation and left atrial thrombus - a prospective, randomized, controlled, open-label one year follow-up pilot study Phenprocoumon (Marcu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002236-14,0,0,0 2014-002238-29,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,3,,Paclitaxel-trastuzumab in EGFR-mutated NSCLC patients after progression on TKI-treatment; a pilot study behandeling met paclitaxel-trastuzumab bij EGFR-gemuteerde NSCLC patienten nadat zij progress...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002238-29,0,0,0 2014-002239-33,1,2014-12-01,2014-12-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"TARGID, KU Leuven",The effect of corticotrophin-releasing hormone (CRH) on esophageal motility in healthy volunteers Het effect van corticotropine-releasing hormoon (CRH) op de motiliteit van de slokdarm in gezonde v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002239-33,0,0,0 2014-002240-40,11,2017-11-06,2020-08-14,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Jun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002240-40,0,0,0 2014-002240-40,11,2017-11-06,2020-08-14,10,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Lilly, S.A.","A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Jun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002240-40,0,0,0 2014-002241-22,2,2019-05-24,2019-05-24,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002241-22,0,0,0 2014-002243-17,1,2020-03-02,2020-03-02,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Clínica Universidad de Navarra/Universidad de Navarra,Conscious sedation for procedures in Dental and Minor Maxillofacial Surgery Unit: optimization of the dexmedetomidine dose (Dexdor®). Sedación consciente para procedimientos de Unidad Dental y Ciru...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002243-17,0,0,0 2014-002245-21,1,2014-11-12,2014-11-12,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Ulrik Grevstad,"Effect of adductor canal block vs. placebo on muscle strength, mobilisation and pain on the first post-operative day after total knee athroplasty",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002245-21,0,0,0 2014-002246-41,2,2016-12-15,2016-12-15,1,1,0,1,0,1,1,0,0,1,1,0,0,0,1,"Roche Farma S.A., en nombre de F. Hoffmann-La Roche Ltd.","A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6885247 FOLLOWING 12 WEEKS OF TREA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002246-41,0,0,0 2014-002246-41,2,2016-12-15,2016-12-15,1,1,0,1,0,1,1,0,0,1,1,0,0,0,1,F. Hoffmann-La Roche Ltd.,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6885247 FOLLOWING 12 WEEKS OF TREA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002246-41,0,0,0 2014-002248-42,2,2020-03-12,2020-03-12,2,1,0,1,0,0,1,0,0,1,0,0,0,0,0,"Bonkolab, Rigshospitalet","The TEAM Study (Thiopurine EnhAnced Maintenance therapy) A Phase 1-2 Study of 6-Thioguanine in Combination with Methotrexate and 6-Mercaptopurine During Maintenance Therapy of Childhood, Adolescent,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002248-42,0,0,0 2014-002249-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Universitätsklinikum Ulm (AöR),"DETECT V/CHEVENDO: A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002249-22,0,0,0 2014-002251-26,2,2015-02-24,2015-02-24,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Institut de Recherches Internationales Servier,Long-term safety study of abexinostat (S 078454) per os given as single-agent in haematological malignancies – Extension study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002251-26,0,0,0 2014-002253-19,4,2016-11-25,2016-11-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A randomized, double-blind, double-dummy, parallel group, multicenter study of once daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, twice daily Fluticasone Propionate/Salmeterol 250...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002253-19,0,0,0 2014-002253-19,4,2016-11-25,2016-11-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A randomized, double-blind, double-dummy, parallel group, multicenter study of once daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, twice daily Fluticasone Propionate/Salmeterol 250...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002253-19,0,0,0 2014-002253-19,4,2016-11-25,2016-11-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development,"A randomized, double-blind, double-dummy, parallel group, multicenter study of once daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, twice daily Fluticasone Propionate/Salmeterol 250...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002253-19,0,0,0 2014-002254-40,6,2016-11-29,2016-11-29,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ObsEva SA,"A phase 2, double-blind, dose-finding, placebo-controlled study to assess the safety and efficacy of a single oral administration of OBE001 to improve embryo implantation following IVF or ICSI.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002254-40,0,0,0 2014-002257-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Ramón y Cajal,"Single-center, randomized, open, controlled by echocardiography to evaluate the effect of serelaxina in the functioning of the right ventricle and its potential in the prognosis of acute heart failure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002257-19,0,0,0 2014-002259-24,7,2018-09-27,2018-09-27,4,1,1,0,0,0,2,0,0,2,1,0,0,0,1,Grünenthal GmbH,"Open-label evaluation of the population pharmacokinetic profile, safety, tolerability, and efficacy of intravenous tapentadol solution for injection for the treatment of post-surgical pain in children...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002259-24,1,0,0 2014-002263-15,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,sanofi aventis S.p.A,"Effects of GLP-1 Receptor Agonist Lixisenatide on Post-prandial Lipid Profile in Obese Type 2 Diabetic Patients Effetti della Lixisenatide, agonista del recettore GLP-1, sul profilo lipidico post-p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002263-15,0,0,0 2014-002264-33,1,2018-05-11,2018-05-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Ole Hamberg,Rifaximin in alcoholic hepatitis: effects on inflammatory and metabolic markers. Rifaximin ved alkoholisk hepatitis: Virkning på inflammatoriske og metaboliske markører,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002264-33,0,0,0 2014-002265-30,1,2016-05-20,2016-05-20,1,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Diurnal Limited,"A Phase 3 open-label study of Infacort® in neonates, infants and children less than 6 years of age with adrenal insufficiency.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002265-30,0,0,0 2014-002266-71,1,2018-12-04,2018-12-04,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,NHS Greater Glasgow and Clyde,The role of Qutenza (topical capsaicin 8%) in treating neuropathic pain from arteriovenous fistulae in patients with end stage renal failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002266-71,0,0,0 2014-002267-15,1,2014-12-30,2014-12-30,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Hvidovre Hospital,Treatment of hypoglycemia with glucagon among patients with type 1 diabetes mellitus Glukagon til behandling af hypoglykæmi i type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002267-15,0,0,0 2014-002272-88,12,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002272-88,0,0,0 2014-002273-11,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002273-11,0,0,0 2014-002273-11,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002273-11,0,0,0 2014-002275-28,22,2017-03-03,2017-03-29,20,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002275-28,0,0,0 2014-002275-28,22,2017-03-03,2017-03-29,20,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Ellas SA,"A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002275-28,0,0,0 2014-002275-28,22,2017-03-03,2017-03-29,20,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Limited,"A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002275-28,0,0,0 2014-002275-28,22,2017-03-03,2017-03-29,20,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002275-28,0,0,0 2014-002275-28,22,2017-03-03,2017-03-29,20,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim bv,"A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002275-28,0,0,0 2014-002275-28,22,2017-03-03,2017-03-29,20,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Boehringer Ingelheim España, S.A.","A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002275-28,0,0,0 2014-002275-28,22,2017-03-03,2017-03-29,20,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Unilfarma, Lda.","A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002275-28,0,0,0 2014-002275-28,22,2017-03-03,2017-03-29,20,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Finland Ky,"A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002275-28,0,0,0 2014-002275-28,22,2017-03-03,2017-03-29,20,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Danmark A/S,"A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002275-28,0,0,0 2014-002275-28,22,2017-03-03,2017-03-29,20,1,0,0,0,0,3,0,0,1,0,0,1,0,2,,"A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002275-28,0,0,0 2014-002275-28,22,2017-03-03,2017-03-29,20,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim AB,"A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002275-28,0,0,0 2014-002275-28,22,2017-03-03,2017-03-29,20,1,0,0,0,0,3,0,0,1,0,0,1,0,2,SCS Boehringer Ingelheim Comm.V,"A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002275-28,0,0,0 2014-002275-28,22,2017-03-03,2017-03-29,20,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Italia S.p.A.,"A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002275-28,0,0,0 2014-002277-11,15,2019-11-25,2019-12-25,14,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Amgen Inc,"Double-blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for Low Density Lipoprotein-Cholesterol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002277-11,1,1,0 2014-002279-27,4,2016-04-01,2016-04-01,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Hi-Tech Pharmacal Co., Inc.","A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Three-Arm, Multi-Site Study to Evaluate the Clinical Equivalence of Diclofenac Sodium Topical Gel 1% (Hi-Tech Pharmacal Co., Inc.) with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002279-27,0,0,0 2014-002281-70,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV-1?infected patients (<100 CD4+ T cells/?L) taking antiretroviral regimens based on dolutegravir or ritonavir-boosted darunav...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002281-70,0,0,0 2014-002282-30,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,County council of Ostergotland,Effects of oxygen treatment on mechanisms involved in ischemia-reperfusion injury: A pilot study in healthy volunteers. Effekter av syrgasbehandling på mekanismer involverade i ischemi-reperfusions...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002282-30,0,0,0 2014-002283-32,5,2018-09-13,2018-09-13,4,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children with Genotype 2 or 3 Chronic HCV Infecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002283-32,1,1,0 2014-002284-15,1,2017-02-10,2017-02-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,St Stephen's AIDS Trust,"SSAT058: A phase IV, open-label, multi centre pilot study to assess changes in cerebral function parameters in patients without perceived Central Nervous System (CNS) symptoms when switched from tenof...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002284-15,0,0,0 2014-002285-76,1,2016-10-17,2016-10-17,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Hvidovre University Hospital,"The Effects of Liraglutide in Patients With Insulin Pump Treated Type 1 Diabetes: A Randomized, Placebo-Controlled Trial. The Lira Pump Trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002285-76,0,0,0 2014-002286-30,6,2015-06-19,2016-01-26,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",PHASE 2 STUDY OF SINGLE-AGENT PF 03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002286-30,0,0,0 2014-002288-14,9,2017-07-05,2017-07-05,7,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"Scioderm, An Amicus Therapeutics Company","A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients with Epidermolysis Bullosa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002288-14,1,0,0 2014-002288-14,9,2017-07-05,2017-07-05,7,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"Scioderm INC, An Amicus Therapeutics Company","A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients with Epidermolysis Bullosa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002288-14,1,0,0 2014-002288-14,9,2017-07-05,2017-07-05,7,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"Scioderm, INC.","A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients with Epidermolysis Bullosa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002288-14,1,0,0 2014-002289-62,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,"SIGMA-TAU, Industrie Farmaceutiche Riunite S.p.A.","Electroneurographic and clinical evaluation in patients with mild / moderate Carpal Tunnel Syndrome , following conservative pharmacological treatment with Nicetile®.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002289-62,0,0,0 2014-002295-87,1,2015-10-07,2015-10-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SynAgile Corporation,"A Phase IIa study to assess the safety, tolerability, plasma pharmacokinetics and efficacy of intermittent oral administration of standard levodopa/carbidopa vs. semi-continuous intra-oral administrat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002295-87,0,0,0 2014-002300-24,1,2019-12-11,2019-12-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,Albumin To prevenT Infection in chronic liveR failurE (ATTIRE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002300-24,0,0,0 2014-002305-38,1,2017-06-01,2017-06-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee/ NHS Tayside,Does allopurinol reduce right ventricular mass in lung disease associated pulmonary hypertension?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002305-38,0,0,0 2014-002306-21,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,Hôpital Universitaire Des Enfants Reine Fabiola,"Monocentric, prospective randomized controlled clinical trial assessing the effect on the lower limb spinal motoneuron excitability, the efficacy in term of morphinic sparing and safety of of early c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002306-21,0,0,0 2014-002309-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Osakidetza,"EFFECTIVENESS OF ROPIVACAINE 0.1% INTRAPERITONEAL IN POSTOPERATIVE PAIN CONTROL IN GYNECOLOGIC LAPAROSCOPIC SURGERY "" EFICACIA DE LA ROPIVACAINA 0,1% INTRAPERITONEAL EN EL CONTROL DEL DOLOR POSTOPE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002309-39,0,0,0 2014-002311-41,5,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,GETAID,A proSpective randomized controlled trial comParing infliximAb-antimetabolites combination therapy to anti-metabolites monotheRapy and infliximab monothErapy in Crohn’s disease patients in sustained s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002311-41,0,0,0 2014-002311-41,5,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Edinburgh,A proSpective randomized controlled trial comParing infliximAb-antimetabolites combination therapy to anti-metabolites monotheRapy and infliximab monothErapy in Crohn’s disease patients in sustained s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002311-41,0,0,0 2014-002317-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Azienda Ospedaliera Papa Giovanni XXIII,An Open-Label Study to Explore the Clinical Efficacy of GS 7977 (Sofosbuvir -Sovaldi®) with Ribavirin as Pre-Emptive Administration in Transplant-Recipients with Hepatitis C Virus (HCV) active infecti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002317-32,0,0,0 2014-002317-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AISF (Associazione Italiana per lo Studio del Fegato),An Open-Label Study to Explore the Clinical Efficacy of GS 7977 (Sofosbuvir -Sovaldi®) with Ribavirin as Pre-Emptive Administration in Transplant-Recipients with Hepatitis C Virus (HCV) active infecti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002317-32,0,0,0 2014-002319-41,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Ana Boto de los Bueis,Clinical and virologic assesment of two therapeutic options: antiviral Ganciclovir 0.15% ophthalmic gel and physiologic saline solution 0.9% used in patients with acute adenoviral conjuntivitis. VA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002319-41,0,0,0 2014-002320-27,12,2016-12-22,2016-12-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Celgene International II Sàrl (CIS II),"A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple sclero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002320-27,0,0,0 2014-002320-27,12,2016-12-22,2016-12-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Receptos, Inc.","A Phase 3, multi-center, randomized, Double-Blind, double-dummy, active controlled, parallel group study to evaluate the efficacy and safety of RPC1063 administered orally to relapsing multiple sclero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002320-27,0,0,0 2014-002321-35,7,2021-07-19,2021-07-19,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eisai Limited,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 years of Age With Inadequately Control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002321-35,0,0,0 2014-002321-35,7,2021-07-19,2021-07-19,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,EISAI LIMITED,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 years of Age With Inadequately Control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002321-35,0,0,0 2014-002322-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rijnstate Hospital,Optimizing Iron suppletion trial after Roux- en -Y Gastric Bypass Optimaliseren van ijzersuppletie na Roux- en -Y gastric bypass,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002322-12,0,0,0 2014-002323-10,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Rijnstate,Iron absorptiontrail after Roux- en -Y Gastric Bypass,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002323-10,0,0,0 2014-002324-27,4,2016-02-09,2016-02-09,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Mylan GmbH,"Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL 1401H and European Sourced Neulasta® in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002324-27,0,0,0 2014-002333-63,6,2015-09-24,2016-09-06,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,"A randomized, double blind, placebo-controlled, parallel, international multicenter study assessing the efficacy of S066913 in patients with paroxysmal atrial fibrillation Double-blind, International...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002333-63,0,0,0 2014-002335-34,1,2016-05-11,2016-05-11,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Guy's and St Thomas NHS Foundation Trust,A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin (IVIg) versus standard therapy for the treatment of transverse myelitis in adults and children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002335-34,0,0,0 2014-002336-14,1,2017-08-14,2017-08-14,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Hosptial Bristol NHS Foundation trust,A phase II study of Cabazitaxel chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002336-14,0,0,0 2014-002338-29,2,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,1,"Acetylon Pharmaceuticals, Inc.","A PHASE 1B/2 MULTI-CENTER, OPEN LABEL, DOSE- ESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, SAFETY, AND EFFICACY OF ACY-1215 (RICOLINOSTAT) IN COMBINATION WITH POMALIDOMIDE AND LOW-DOSE DEX...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002338-29,0,0,0 2014-002340-40,1,2015-03-27,2015-03-27,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Pfizer Limited,"A Randomized, Double-Blind, Placebo-Controlled 2-Way Crossover Study to Evaluate the Efficacy, Safety and Tolerability of PF-03715455 Administered Twice Daily By Inhalation for 4 Weeks in Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002340-40,0,0,0 2014-002341-22,1,2015-11-13,2015-11-13,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Graz; Universitätsklinik für InnereMedizin; Abteilung für Endokrinologie und Stoffwechsel,Evaluation of the Effect of Glucagon Solutions on the Glucose Concentration at the Subcutaneous Administration Site in Type 1 Diabetic Patients. Beurteilung der Wirkung von Glukagon-Lösungen auf di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002341-22,0,0,0 2014-002345-21,1,2017-04-28,2017-04-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Dr Eloy Espin,"Antibiotic prophylaxis oral vs parenteral + parenteral in colonic surgery: a prospective, randomized, multicenter clinical trial. Profilaxis antibiótica parenteral vs oral + parenteral en cirugía ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002345-21,0,0,0 2014-002346-42,1,2015-12-04,2015-12-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Copenhagen University Hospital, Hvidovre",Clinical trial with lozenges as local pain treatment for head and neck cancer patients with oral mucostis Klinisk forsøg med sugetabletter som lokal smertebehandling til hoved/hals cancer patiente...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002346-42,0,0,0 2014-002348-42,1,2018-04-15,2018-04-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Birmingham,Effectiveness of progesterone to prevent miscarriage in women with early pregnancy bleeding: A randomised placebo-controlled trial (PRISM Trial: PRogesterone In Spontaneous Miscarriage Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002348-42,0,0,0 2014-002349-23,10,2017-03-15,2017-03-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe BV (APEB),"A Phase 2, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002349-23,0,0,0 2014-002351-26,16,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002351-26,0,0,0 2014-002351-26,16,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002351-26,0,0,0 2014-002352-12,1,2015-09-09,2015-09-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"On Target Laboratories , LLC","A Single Ascending Dose, Open Label, Exploratory Study of OTL-038 for the Intra-operative Imaging of Folate Receptor Alpha Positive Ovarian, Renal Cell and Endometrial Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002352-12,0,0,0 2014-002356-27,4,2016-06-14,2016-06-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,","A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic HCV GT1, GT4 and GT6 Infection with Inherited Blood ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002356-27,0,0,0 2014-002356-27,4,2016-06-14,2016-06-14,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Limited,"A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic HCV GT1, GT4 and GT6 Infection with Inherited Blood ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002356-27,0,0,0 2014-002358-38,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Retrophin, Inc","PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002358-38,0,0,0 2014-002358-38,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Travere Therapeutics, Inc.","PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002358-38,0,0,0 2014-002362-74,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Skåne University Hospital, Department of Oncology",Palliative short-course hypofractionated radiotherapy followed by chemotherapy in adenocarcinoma of the esophagus or esophogastric junction trial - a phase II clinical trial protocol.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002362-74,0,0,0 2014-002363-15,1,2017-04-03,2017-04-03,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,University Medical Center of the Johannes Gutenberg University Mainz,"EVITA Trial: Effect of VItamin D as add-on Therapy for vitamin D insufficient patients with severe Asthma: a randomized, double-blind, placebo-controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002363-15,0,0,0 2014-002370-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Slotervaart Hospital,"Randomized, double-blind, placebo-controlled trial of the effectiveness and safety of dapagliflozin on blood glucose control during glucocorticoid treatment for acute exacerbation COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002370-36,0,0,0 2014-002372-89,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 1/2 Multicenter Study of BMS-986012 in Subjects with Relapsed/Refractory Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002372-89,0,0,0 2014-002374-36,1,2020-08-26,2020-08-26,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"The Karolinska Institutet, ClinTRID","A multicenter, randomized, open-label, blinded-assessor, follow-up, phase 4 study in patients with rheumatoid arthritis who have completed the initial treatment part (active conventional therapy versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002374-36,0,0,0 2014-002381-73,1,2018-01-26,2018-01-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Moorfields Eye Hospital,Individualizing therapy for neovascular age-related macular degeneration with aflibercept,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002381-73,0,0,0 2014-002382-30,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Clatterbridge Cancer Centre NHS Foundation Trust,Phase II study of neoadjuvant cisplatin and gemcitabine chemotherapy versus upfront surgery in patients with resectable proximal biliary tract cancer:,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002382-30,0,0,0 2014-002384-15,1,2018-04-30,2018-04-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsklinik für Augenheilkunde und Optometrie,"Intravitreal Aflibercept treatment in RAP-Lesions, PED, hemorrhagic CNV and PCV Untersuchung der Wirksamkeit von Aflibercept bei Sonderformen der neovaskulären altersbedingten Makuladegeneration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002384-15,0,0,0 2014-002385-74,8,2017-11-25,2017-12-18,7,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bayer AG,"7-day study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children from birth to less than 6 months with arterial or venous thrombosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002385-74,0,0,0 2014-002385-74,8,2017-11-25,2017-12-18,7,1,0,1,0,0,1,0,0,1,0,0,0,0,1,BAYER HEALTHCARE AG,"7-day study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children from birth to less than 6 months with arterial or venous thrombosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002385-74,0,0,0 2014-002385-74,8,2017-11-25,2017-12-18,7,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bayer HealthCare AG,"7-day study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in children from birth to less than 6 months with arterial or venous thrombosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002385-74,0,0,0 2014-002386-30,1,2020-03-25,2020-03-25,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Verein für Krebsforschung,Efficacy and Safety of Mistletoe Extract in the Palliative Therapy of Patients Suffering from Pancreatic Cancer (PALM-Pan),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002386-30,0,0,0 2014-002387-32,1,2017-12-13,2017-12-13,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Liverpool,"Phase IIa, Randomised, Controlled, Open-Label Trial of Rosuvastatin for the Prevention of Aminoglycoside-Induced Kidney Toxicity in Children with Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002387-32,0,0,0 2014-002388-13,12,2018-04-25,2019-05-24,11,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Celgene Corporation,"A Phase 2, multicenter, open-label study to evaluate the pharmacokinetics, pharmacodynamics, safety and activity of azacitidine and to compare azacitidine to historical controls in pediatric subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002388-13,0,0,0 2014-002389-62,9,2017-11-28,2017-11-28,8,1,0,1,0,1,1,0,0,1,0,0,0,0,1,IPSEN PHARMA SAS,"Phase IIA, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and parmacodynamics of a single dose of lanreotide PRF in subjects with a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002389-62,0,0,0 2014-002389-62,9,2017-11-28,2017-11-28,8,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Ipsen Group,"Phase IIA, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and parmacodynamics of a single dose of lanreotide PRF in subjects with a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002389-62,0,0,0 2014-002389-62,9,2017-11-28,2017-11-28,8,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Ipsen Pharma SAS,"Phase IIA, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and parmacodynamics of a single dose of lanreotide PRF in subjects with a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002389-62,0,0,0 2014-002389-62,9,2017-11-28,2017-11-28,8,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Ipsen Pharma,"Phase IIA, open label, dose ascending study to determine the maximum tolerated dose, safety and tolerability, pharmacokinetics and parmacodynamics of a single dose of lanreotide PRF in subjects with a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002389-62,0,0,0 2014-002392-28,1,2020-12-17,2020-12-17,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Charité Univeritaetsmedizin Berlin,Setmelanotide (RM-493) Treatment Trial in Patients with rare genetic disorders of obesity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002392-28,0,0,0 2014-002393-37,1,2018-10-23,2018-10-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Birmingham,"A single arm, two-stage, multi-centre, phase II clinical trial investigating the safety and activity of the use of BTT1023, a human monoclonal antibody targeting vascular adhesion protein (VAP-1), in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002393-37,0,0,0 2014-002399-10,7,2016-05-20,2016-05-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & développement,"A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients with Type 2 Diabetes Inadequately Controlled...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002399-10,0,0,0 2014-002405-37,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,"Incline Therapeutics Inc, a wholly owned subsidiary of The Medicines Company","An open label evaluation of the safety and clinical utility of the active, separated system with enhanced controller (SSEC) fentanyl 40 mcg for the management of acute postoperative pain in pediatric ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002405-37,0,1,1 2014-002407-25,9,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,1,Bayer AG,A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002407-25,0,0,0 2014-002408-26,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002408-26,0,0,0 2014-002416-16,1,2020-05-25,2020-05-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bone Therapeutics S.A.,"A Pilot Phase IIa, Multicentre, Open, Proof-of-concept Study on the Safety and the Efficacy of Allogeneic Osteoblastic Cells (ALLOB®) Implantation in Rescue Interbody Fusion",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002416-16,0,0,0 2014-002417-36,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Fondazione IRCCS Istituto Nazionale dei Tumori,"An open-label, randomized, multicenter, phase II trial designed to estimate the activity of CAPTEM combination versus FOLFIRI as second line treatment in patients who have progressed on or after first...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002417-36,0,0,0 2014-002418-22,1,2019-10-10,2019-10-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Trio Medicines Ltd,"Randomized, placebo-controlled trial of YF476, a gastrin receptor antagonist, in Barrett’s esophagus (10-505; T-016)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002418-22,0,0,0 2014-002421-35,5,2017-03-27,2017-03-27,2,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Isis Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002421-35,1,0,0 2014-002421-35,5,2017-03-27,2017-03-27,2,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002421-35,1,0,0 2014-002425-35,1,2017-12-15,2017-12-15,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,"National Poisons Information Center, University Medical Center Utrecht","A Single Centered, Prospective, Open-labeled, Pharmacokinetic Pilot Study of Tacrolimus Administration via Rectiole Een enkel centrum, prospectief, open-label, farmacokinetische pilot studie naar t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002425-35,0,0,0 2014-002439-32,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Charité – Universitätsmedizin Berlin,A Randomized Phase II Trial of Transarterial Radioembolization with Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolization with Cisplatin (TACE) in Patients with Liver Metastases from Uvea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002439-32,0,0,0 2014-002440-41,1,2016-08-11,2016-08-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Rigshospitalet, Capital Region Bloodbank 2034, Section for Transfusion Medicine","Safety and efficacy of iloprost and eptifibatide co-administration compared to standard therapy in patients with septic shock – a randomized, controlled, double-blind investigator-initiated trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002440-41,0,0,0 2014-002442-45,7,2017-09-12,2017-09-12,6,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Kompetenznetz Vorhofflimmern e.V. [German Atrial Fibrillation Competence Network association (AFNET e.V.)],AXAFA - AFNET 5 Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002442-45,0,0,0 2014-002442-45,7,2017-09-12,2017-09-12,6,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Kompetenznetz Vorhofflimmern e.V. [Atrial Fibrillation NETwork (AFNET)],AXAFA - AFNET 5 Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002442-45,0,0,0 2014-002442-45,7,2017-09-12,2017-09-12,6,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Kompetenznetz Vorhofflimmern e.V. (AFNET) [Atrial Fibrillation NETwork],AXAFA - AFNET 5 Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002442-45,0,0,0 2014-002444-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC,A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma. Inductie en co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002444-40,0,0,0 2014-002446-47,5,2019-01-16,2019-01-16,4,1,0,0,0,0,2,0,0,1,0,0,1,0,0,European Organization for Research and Treatment of Cancer (EORTC),Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002446-47,0,0,0 2014-002447-18,2,2021-06-18,2021-06-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc",A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002447-18,0,0,0 2014-002448-42,1,2018-05-15,2018-05-15,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"GlycoMimetics, Inc.","A Phase I/II, open-label multicenter study to determine safety, pharmacokinetics and efficacy of GMI-1271 in combination with chemotherapy in patients with acute myeloid leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002448-42,0,0,0 2014-002451-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Psychiatry, Helsinki University Central Hospital","The effect of intranasal ketamine on suicidality in severely depressed and suicidal patients. Randomized, placebo-controlled study KETAMIININ VAIKUTUS ITSETUHOISUUTEEN KETAMIINI-INHALAATIO ECT-HOIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002451-26,0,0,0 2014-002455-26,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Karolinska Institute,The use of intravenous Iron oxide as a contrast agent for cardiac magnetic resonance imaging.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002455-26,0,0,0 2014-002456-90,1,2016-03-15,2016-03-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Stockholm Centre for Dependency Disorders, Department of Clinical Neuroscience, Karolinska Institutet",Integrated Exposure-Based Therapy for Co-occurring Posttraumatic Stress Disorder and Alcohol Dependence: Effects of the FAAH inhibitor PF-04457845 on Extinction. A Randomized Controlled Trial. Int...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002456-90,0,0,0 2014-002460-33,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA - IRCCS,ANTI MEK THERAPY WITH REFAMETINIB TO PREVENT RESISTANCE TO EGFR-TARGETED TREATMENT IN METASTATIC COLORECTAL CANCERS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002460-33,0,0,0 2014-002465-30,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,Dip. Pediatria UOC Gastroenterologia ed Epatologia Pediatrica,Spontaneous study on the efficacy and safety of an oral viscous suspension of budesonide administered to children affected by eosinophilic esophagitis. Studio spontaneo di fase II sull’efficacia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002465-30,0,0,0 2014-002471-28,3,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,Janssen Sciences Ireland UC,"An open-label, roll-over study with rilpivirine in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs) in human immunodeficiency virus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002471-28,0,1,0 2014-002471-28,3,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,Janssen Sciences Ireland Unlimited Company,"An open-label, roll-over study with rilpivirine in combination with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs) in human immunodeficiency virus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002471-28,0,1,0 2014-002474-36,5,2017-07-14,2017-07-14,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002474-36,0,0,0 2014-002475-29,2,2017-04-17,2017-04-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002475-29,0,0,0 2014-002476-92,18,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,Amgen Inc.,"A Randomized, Open-label, Controlled Phase 3 Adaptive Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002476-92,0,1,0 2014-002476-92,18,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,Amgen Inc,"A Randomized, Open-label, Controlled Phase 3 Adaptive Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002476-92,0,1,0 2014-002479-28,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Justus-Liebig University,GM-CSF Inhalation to improve HOst defense and Pulmonary barrier rEstoration GM-CSF Inhalation zur Verbesserung der Wirtsabwehr und der Wiederherstellung der alveolären Barrierefunktion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002479-28,0,0,0 2014-002480-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,The Dutch Working Group on Immunotherapy of Oncology (WIN-O),"A Phase II, Open-Label, Multicenter Study of Vemurafenib plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Metastatic Melanoma; Response Monitoring and Resistance Prediction with Positron Emis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002480-15,0,0,0 2014-002481-78,1,2015-06-26,2015-06-26,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Exponential Biotherapies Inc,"Randomized double blind placebo-controlled clinical safety, tolerability and pharmacokinetic/-dynamic study on the effects of escalating single intravenous doses of EA-230 on the innate immune respons...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002481-78,0,0,0 2014-002484-15,1,2016-05-25,2016-05-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMW GmbH,"An open label, multiple dose, Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy of AMW goserelin 3.6 mg implant in its application system Eine offene, P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002484-15,0,0,0 2014-002485-70,3,2020-05-07,2020-05-07,2,1,0,1,0,0,1,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase I/IIa Study of BMS 986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects with Select Advanced Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002485-70,1,0,0 2014-002492-29,1,2016-06-08,2016-06-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of anaesthesia and intensive care, Hvidovre Hospital",The effect of Single-Dose Glucocorticoid on Postoperative delirium among Elderly Hip Fracture Patientes: A Randomized Placebo Controlled Study Effekten af præoperativ høj dosis methylprednisolon på...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002492-29,0,0,0 2014-002494-12,2,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Odense University Hostital,Magnolia Study Prolonged Protection from Bone Disease in Multiple Myeloma. An open label phase 4 multicenter international randomised trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002494-12,0,0,0 2014-002494-12,2,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Odense University Hospital,Magnolia Study Prolonged Protection from Bone Disease in Multiple Myeloma. An open label phase 4 multicenter international randomised trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002494-12,0,0,0 2014-002496-28,2,,,0,0,1,0,0,2,2,0,0,3,0,0,0,0,1,Clementia Pharmaceuticals Inc.,"A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects with Fibrodysplasia Ossificans Progressiva (FO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002496-28,0,1,0 2014-002497-37,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Istituto Oncologico del Veneto IRCCS – UOC Oncologia Medica 2,"TIvantinib as Maintenance treatment in Extended Small-cell lung cancer (TIMES) Phase II clinical trial, single arm, two stage Tivantinib come terapia di mantenimento nei pazienti con carcinoma po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002497-37,0,0,0 2014-002500-24,1,2016-07-28,2016-07-28,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,AB2 Bio Ltd.,"Open-label, multicenter, dose-escalating phase II study to investigate the safety, tolerability, and early signs of efficacy of subcutaneous administrations of Tadekinig alfa (IL-18BP) in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002500-24,0,0,0 2014-002501-38,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,ULB - Unité de Recherche en Lymphologie,The occlusion pressure of superficial lymphatics in the upper extremity of healthy volunteers: A Near infrared lymphofluoroscopy approach,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002501-38,0,0,0 2014-002508-26,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"IRCCS - Istituto di Ricerche Farmacologiche ""Mario Negri""",Outcome-related factors in patients with metastatic renal cell carcinoma treated with everolimus after failure of a first-line treatment with VEGF inhibitor Fattori associati all’esito in pazienti ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002508-26,0,0,0 2014-002509-39,1,2015-08-18,2015-08-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GALDERMA R&D,Effect of Patient Education on Treatment Adherence and Satisfaction among Acne Patients Receiving Once-Daily EpiduoTM Gel Treatment in Primary Care Clinics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002509-39,0,0,0 2014-002510-23,1,2017-12-21,2017-12-21,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,University hospitals of Leuven,as an adjuvant to sevoflurane anaesthesia in children undergoing interventional or diagnostic cardiac catheterization: a randomized controlled clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002510-23,0,0,0 2014-002513-27,9,2016-06-10,2016-06-10,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic as...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002513-27,0,0,0 2014-002513-27,9,2016-06-10,2016-06-10,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A randomised, double-blind, placebo-controlled, parallel-group, multi-centre 24-week study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic as...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002513-27,0,0,0 2014-002514-23,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,VU Medical Center,Reduction Of Microvascular Injury Utilizing Sonolysis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002514-23,0,0,0 2014-002517-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fédération Francophone de Cancérologie Digestive (FFCD),Randomised phase III trial evaluating adjuvant chemotherapy after the stage III colon adenocarcinoma resection for patient of 70 year old or more ETUDE DE PHASE III RANDOMISEE EVALUANT LA CHIMI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002517-39,0,0,0 2014-002519-40,1,2017-05-24,2017-05-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sintetica S.A.,"A prospective, randomised, non-inferiority study of Chloroprocaine 2% and the active control Ropivacaine 0.75% (AstraZeneca) in ultrasound-guided axillary nerve block for short-duration distal upper l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002519-40,0,0,0 2014-002522-12,4,,,0,0,1,0,0,0,2,0,0,2,0,0,0,0,2,Assistance Publique - Hôpitaux de Paris (AP-HP),European phase-II clinical trial evaluating efficacy of low dose rhIL-2 in patients with recently diagnosed type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002522-12,0,0,0 2014-002524-27,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,University Medical Center Utrecht,"A randomized, placebo-controlled, double blind, 4-period, cross-over trial, to study blood pressure lowering effects of losartan, Moxonidine and Low sodium diet in former pre-eclamptic women",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002524-27,0,0,0 2014-002536-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Régional et Universitaire de Lille,Evaluation of the efficacy of antibiotic therapy combined with corticosteroids in severe alcoholic hepatitis Evaluation de l’efficacité d’une thérapie antibiotique combinée aux corticostéroïdes d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002536-13,0,0,0 2014-002539-32,3,2021-12-31,2021-12-31,1,0,0,0,0,0,0,0,0,2,0,0,0,0,0,St. Olavs University Hospital,Does botulinum toxin A make walking easier i in children with cerebral palsy?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002539-32,1,0,0 2014-002541-22,5,2020-12-29,2020-12-29,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,sanofi-aventis recherche & développement,"A randomized, double-blind, parallel-group study assessing the efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002541-22,1,0,0 2014-002544-40,1,,,0,0,0,0,1,0,3,0,0,1,1,1,0,1,0,Hôpitaux Universitaires de Strasbourg,THE TREATMENT OF HYPERTENSION ASSOCIATED WITH SEVERE PREECLAMPSIA. A RANDOMIZED CONTROLLED TRIAL OF URAPIDIL VERSUS NICARDIPINE. The URANIC trial. Traitement de l'hypertension au cours de la pré-é...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002544-40,0,0,0 2014-002546-49,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,scPharmaceuticals Inc,"A single center, randomized, open-label, cross-over exploratory study to evaluate the pharmacodynamic and pharmacokinetic response to a subcutaneous administration or oral administration of furosemide...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002546-49,0,0,0 2014-002547-17,1,2016-01-21,2016-01-21,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,VU University Medical Center,Grey matter microglial imaging with [18F]DPA-714 in progressive MS patients Beeldvorming van microglia in de grijze stof met [18F]DPA-714 bij progressieve MS patiënten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002547-17,0,0,0 2014-002550-39,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Genzyme Corporation,"A 208-week three-part, open-label, multicenter, multinational study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of GZ/SAR402671 in combination with Cerezy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002550-39,0,0,0 2014-002553-19,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,"Medizinische Universität Graz, Universitätsklinik für Dermatologie","Bimatoprost 0,3mg/ml- Eyedrops for lash-lenghtening - Pilot Study Bimatoprost 0,3mg/ml- Augentropfen zur Wimpernverlänngerung - Pilotstudie, Halbseitenversuch",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002553-19,0,0,0 2014-002555-26,1,2015-12-31,2015-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Dept. of Intensive Care Medicine, Copenhagen University Hospital, Rigshospitalet",MEROPENEM and CIPROFLOXACIN DOSING IN THE CRITICALLY ILL PATIENT WITH SEPTIC SHOCK – A SINGLE CENTER PHARMACOKINETIC STUDY Doseringen af meropenem og ciprofloxacin til patienter med septisk shock...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002555-26,0,0,0 2014-002556-77,6,2016-10-10,2016-10-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma Corporation (MTPC),"A Phase II, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT 1303 in Subjects with Moderate to Severe Active...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002556-77,0,0,0 2014-002557-19,6,2017-08-24,2017-08-24,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma Corporation (MTPC),"A Phase II, Open-label, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects with Moderate to Severe Active Crohn’s Disease who have Completed the MT-1303-E13 Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002557-19,0,0,0 2014-002560-33,2,2020-04-02,2020-04-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UNICANCER,"Open-label, randomized, multicenter, international, parallel exploratory phase II study, comparing 3 FEC-3 Docetaxel chemotherapy to letrozole + palbociclib combination as neoadjuvant treatment of sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002560-33,0,0,0 2014-002564-32,1,2018-11-25,2018-11-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Belfast Health and Social Care Trust,"ASpirin as a Treatment for ARDS (STAR) trial: a randomised, double-blind, allocation concealed, placebo-controlled phase 2 trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002564-32,0,0,0 2014-002565-30,8,2020-02-21,2020-02-21,7,1,0,0,0,0,0,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Open-Label, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Che...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002565-30,0,0,0 2014-002568-33,9,2018-03-03,2018-03-05,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in Combination with Insulin Degludec in Children and Adolescents with Type 1 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002568-33,0,0,0 2014-002568-33,9,2018-03-03,2018-03-05,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK. S.P.A.,Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in Combination with Insulin Degludec in Children and Adolescents with Type 1 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002568-33,0,0,0 2014-002569-32,1,2020-12-01,2020-12-01,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Academic Medical Center,Biomedical interventions for HIV prevention in MSM in Amsterdam: a demonstration project Biomedische interventies voor hiv preventie in MSM in Amsterdam: een demonstratieproject,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002569-32,0,0,0 2014-002574-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fédération Francophone de Cancérologie Digestive,Phase II randomized study evaluation of FOLFIRINOX +/- LV5FU2 in maintenance and FIRGEM in 1rst line of metastatic pancreas cancer Phase II randomisée dans le cancer pancréatique métastatique évalu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002574-36,0,0,0 2014-002576-91,1,2015-12-18,2015-12-18,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,OmniVision GmbH,"Therapeutic Equivalence (non-inferiority), Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic Formulation of Travoprost 40μg/ml...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002576-91,0,0,0 2014-002579-27,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Istituto Clinico Humanitas,Pilot study on the efficacy of golimumab in the induction and maintenance of clinical and endoscopic remission in patients with steroid-dependent ulcerative colitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002579-27,0,0,0 2014-002587-33,1,2017-02-01,2017-02-01,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","An Open-Label 5-Year 2nd Extension to: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporoti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002587-33,0,0,0 2014-002588-14,1,2016-03-19,2016-03-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,UNI-PHARMA SA,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE IV CLINICAL STUDY OF THE EFFICACY AND SAFETY OF A NEW FORMULATION OF PARACETAMOL FOR THE MANAGEMENT OF FEVER OF INFECTIOUS ORIGIN ΜΙΑ ΔΙΠΛΗ-ΤΥΦΛ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002588-14,0,0,0 2014-002590-10,1,2019-12-24,2019-12-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Effect of bronchodilators on effort induced dyspnoea in patients suffering lung hypertension Effets des bronchodilatateurs sur la dyspnée induite par l’effort physique chez les patients atteints d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002590-10,0,0,0 2014-002592-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fakultní nemocnice Ostrava,"A randomized, double blind, placebo controlled study to evaluate the efficacy and safety of mirabegron 50 mg versus placebo in patients with neurogenic detrusor overactivity Randomizovaná, dvoj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002592-29,0,0,0 2014-002594-11,4,2017-09-01,2017-09-01,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GW Research Ltd.,"A double blind, randomized, placebo-controlled, two-part study to investigate the pharmacokinetics, followed by efficacy and safety of GWP42006 as add-on therapy in patients with inadequately controll...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002594-11,0,0,0 2014-002595-82,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Westfriesgasthuis,"A randomised, double blind clinical trial comparison the effect of a ultrasound-guided transversus abdominis plane (TAP) block and wound infiltration on postoperative pain (48h) for open inguinal hern...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002595-82,0,0,0 2014-002596-28,2,2017-07-20,2017-07-20,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,PTC Therapeutics Inc.,A Phase 2 Study of Ataluren (PTC124) as Treatment for Nonsense Mutation Mucopolysaccharidosis Type I,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002596-28,0,0,0 2014-002598-13,8,2016-09-14,2016-10-10,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International N.V.,"Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects with Signs and Symptoms of Osteoart...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002598-13,0,0,0 2014-002599-95,1,2016-01-13,2016-01-13,1,1,0,0,0,0,3,0,1,1,1,1,1,0,1,Novartis Pharma Services AG,"A Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Administ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002599-95,0,0,0 2014-002600-24,5,2016-01-18,2016-01-18,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Zambon S.P.A.,"A TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF SAFINAMIDE 100 MG, ONCE DAILY, AS ADD ON THERAPY, IN IDIOPATHIC PARKINSON?S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002600-24,0,0,0 2014-002600-24,5,2016-01-18,2016-01-18,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ZAMBON SPA,"A TWO YEAR, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF SAFINAMIDE 100 MG, ONCE DAILY, AS ADD ON THERAPY, IN IDIOPATHIC PARKINSON?S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002600-24,0,0,0 2014-002601-38,7,2015-08-27,2018-10-04,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A 24-Month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker and Pharmacokinetics Study of AZD3293 in Early Alzheimer's Disease (The...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002601-38,0,0,0 2014-002601-38,7,2015-08-27,2018-10-04,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A 24-Month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker and Pharmacokinetics Study of AZD3293 in Early Alzheimer's Disease (The...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002601-38,0,0,0 2014-002601-38,7,2015-08-27,2018-10-04,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AstraZeneca AB,"A 24-Month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker and Pharmacokinetics Study of AZD3293 in Early Alzheimer's Disease (The...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002601-38,0,0,0 2014-002602-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI IRST - IRCCS,CLINICAL AND TRASLATIONAL PHASE II STUDY OF LIPOSOMAL DOXORUBICIN PLUS DOCETAXEL AND TRASTUZUMAB WITH METFORMIN AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY ADVANCED HER2 POSITIVE BREAST CAN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002602-20,0,0,0 2014-002604-25,3,2018-05-03,2018-05-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Randomized, Multicenter, Double- Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin versus Placebo in Addition to Paclitaxel and Carboplatin in Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002604-25,0,0,0 2014-002605-38,10,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002605-38,0,1,0 2014-002605-38,10,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002605-38,0,1,0 2014-002606-20,7,,,0,0,1,0,0,1,0,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002606-20,0,1,0 2014-002610-23,2,2021-08-10,2021-08-10,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 1/2 Study of ABT-199 in Combination with Low-Dose Cytarabine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia Who Are ≥ 65 Years of Age and Who Are Not Eligible for Standard Anthrac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002610-23,0,0,0 2014-002613-31,1,,,0,1,0,1,0,0,1,0,0,3,0,0,0,0,0,Queen Mary University of London,A Phase Ib/IIa study of AZD2014 in combination with Selumetinib in patients with advanced cancers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002613-31,0,0,0 2014-002616-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,NKI-AVL,Pilot for high-resolution SPECT imaging of breast cancer lumpectomy specimens for 3D identification and quantification of resection margins Pilot voor het identificeren en kwantificeren van resect...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002616-16,0,0,0 2014-002619-40,7,2016-01-21,2016-01-21,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.",A PHASE 3 CONFIRMATORY STUDY INVESTIGATING THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002619-40,0,0,0 2014-002620-26,4,2017-01-24,2017-01-24,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Incyte Corporation,"A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002620-26,0,0,0 2014-002624-28,9,2018-04-25,2018-04-25,5,1,1,0,0,2,3,0,0,1,1,0,1,0,2,Nutrinia Ltd.,"A Multi-center, Double-blind, Randomized Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Gastrointestinal Maturation in Preterm Infants. Estudio multicéntrico, aleatoriza...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002624-28,0,0,0 2014-002624-28,9,2018-04-25,2018-04-25,5,1,1,0,0,2,3,0,0,1,1,0,1,0,2,NUTRINIA LTD.,"A Multi-center, Double-blind, Randomized Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Gastrointestinal Maturation in Preterm Infants. Estudio multicéntrico, aleatoriza...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002624-28,0,0,0 2014-002624-28,9,2018-04-25,2018-04-25,5,1,1,0,0,2,3,0,0,1,1,0,1,0,2,Nutrinia,"A Multi-center, Double-blind, Randomized Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Gastrointestinal Maturation in Preterm Infants. Estudio multicéntrico, aleatoriza...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002624-28,0,0,0 2014-002625-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,PerioC Ltd,The effect of locally delivered ciclosporin as an adjunct to healing after treatment of periodontal pockets,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002625-35,0,0,0 2014-002627-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA,"A randomized, double-blind, controlled, monocenter, pivotal phase IIb study to evaluate the efficacy and safety of riluzole versus mexiletine in patients with non dystrophic myotonia mutated in SCN4A ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002627-10,0,0,0 2014-002628-29,1,2017-11-11,2017-11-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,"Evaluating the effectiveness of intravenous ciclosporin on reducing reperfusion injury in patients undergoing primary percutaneous coronary intervention: a double-blind, phase II, randomised controlle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002628-29,0,0,0 2014-002629-36,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"UCB Biosciences, Inc","A multicenter, open-label study to investigate the pharmacokinetics of commercial lacosamide oral formulation as therapy in children (aged 1 month to 17 years) with epilepsy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002629-36,0,1,1 2014-002630-31,6,2018-09-27,2018-09-27,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase IIIb multicenter, open-label, single arm study to evaluate the efficacy and safety of pasireotide in patients with acromegaly inadequately controlled with first generation somatostatin analogu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002630-31,0,0,0 2014-002630-31,6,2018-09-27,2018-09-27,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.P.A.,"A phase IIIb multicenter, open-label, single arm study to evaluate the efficacy and safety of pasireotide in patients with acromegaly inadequately controlled with first generation somatostatin analogu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002630-31,0,0,0 2014-002632-14,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Fondazione PENTA ONLUS,A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002632-14,0,0,0 2014-002632-14,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,PENTA Foundation,A randomised trial of dolutegravir (DTG)-based antiretroviral therapy vs. standard of care (SOC) in children with HIV infection starting first-line or switching to second-line ART,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002632-14,0,0,0 2014-002636-13,3,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Oslo University Hospital,Study of Antithrombotic Treatment after Intracerebral Haemorrhage (STATICH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002636-13,0,0,0 2014-002639-32,1,2019-12-20,2019-12-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,King's College London,"A randomised, double-blind, placebo-controlled, parallel-group trial of Vitamin D supplementation compared to placebo in people presenting with their First Episode of psychosis (DFEND) Neuroprotection...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002639-32,0,0,0 2014-002639-32,1,2019-12-20,2019-12-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,South London and Maudsley NHS Foundation Trust,"A randomised, double-blind, placebo-controlled, parallel-group trial of Vitamin D supplementation compared to placebo in people presenting with their First Episode of psychosis (DFEND) Neuroprotection...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002639-32,0,0,0 2014-002643-18,5,2020-05-25,2020-08-03,2,0,0,0,0,0,4,0,0,2,1,0,0,0,0,Charité Universitätsmedizin Berlin,"REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosuppr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002643-18,1,0,0 2014-002643-18,5,2020-05-25,2020-08-03,2,0,0,0,0,0,4,0,0,2,1,0,0,0,0,"Charité Universitätsmedizin Berlin, Medizinische Klinik m.S. Nephrologie","REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosuppr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002643-18,1,0,0 2014-002644-40,7,2019-06-26,2019-07-26,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 2b, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4- ANTIGEN VACCINE (SA4Ag) IN ADULTS UNDERGOING ELECTIVE OPEN POSTERIOR SPIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002644-40,0,0,0 2014-002644-40,7,2019-06-26,2019-07-26,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Pfizer Inc.,"A PHASE 2b, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4- ANTIGEN VACCINE (SA4Ag) IN ADULTS UNDERGOING ELECTIVE OPEN POSTERIOR SPIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002644-40,0,0,0 2014-002654-39,2,2022-01-31,2022-01-31,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,HOVON Foundation,A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002654-39,1,0,0 2014-002655-26,6,2016-01-08,2016-01-08,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,BioCryst Pharmaceuticals Inc,"OPuS-2 A multicentre, randomised, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX4161 for 12 weeks as an oral prophylaxis treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002655-26,0,0,0 2014-002655-26,6,2016-01-08,2016-01-08,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,BIOCRYST PHARMACEUTICALS INC.,"OPuS-2 A multicentre, randomised, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX4161 for 12 weeks as an oral prophylaxis treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002655-26,0,0,0 2014-002659-25,1,2017-03-06,2017-03-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.",An Open-Label Safety Study of Patients with Severe Eosinophilic Asthma Who Were Previously Enrolled in the Reslizumab Open Label Extension Study C38072/3085,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002659-25,0,0,0 2014-002665-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Krankenhaus Nordwest gGmbH,Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric juncti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002665-30,0,0,0 2014-002666-76,2,2018-01-31,2018-01-31,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd.,An open-label study to characterize the pharmacokinetics and pharmacodynamics of mepolizumab administered subcutaneously in children from 6 to 11 years of age with severe eosinophilic asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002666-76,1,1,0 2014-002666-76,2,2018-01-31,2018-01-31,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,An open-label study to characterize the pharmacokinetics and pharmacodynamics of mepolizumab administered subcutaneously in children from 6 to 11 years of age with severe eosinophilic asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002666-76,1,1,0 2014-002667-15,1,2014-12-17,2014-12-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Innsbruck, Innere Medizin VI",Effect of Dual Bronchodilatation on Broncholysis Testing in COPD Patients Untersuchung des Effektes einer dualen Bronchodilatation auf den Broncholysetest bei COPD Patienten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002667-15,0,0,0 2014-002672-86,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AO OSPEDALE NIGUARDA CA' GRANDA,PHASE II CLINICAL TRIAL FOR A STEPWISE PROGRESSION IN THE TREATMENT OF CARDIOGENIC SHOCK STUDIO DI FASE II PER LA VALUTAZIONE DI UN APPROCCIO TERAPEUTICO MULTISTEP IN PAZIENTI CON SHOCK CARDIOGENO ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002672-86,0,0,0 2014-002673-11,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 2/3, Open-Label Study to Evaluate the Safety and Efficacy of E/C/F/TAF in HIV-1 Infected Virologically Suppressed Adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002673-11,0,1,1 2014-002674-36,1,2018-08-20,2018-08-20,1,0,0,0,0,1,2,0,0,1,1,1,1,0,3,,DOES ARGININE ENHANCE GALACTOSE OXIDATIVE CAPACITY IN CLASSIC GALACTOSEMIA? A PILOT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002674-36,0,0,0 2014-002675-29,7,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Celgene Corporation,"A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy and Safety of CC-486 (oral azacitidine) Alone and in Combination with Durvalumab (MEDI4736)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002675-29,0,0,0 2014-002675-29,7,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,CELGENE CORPORATION,"A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy and Safety of CC-486 (oral azacitidine) Alone and in Combination with Durvalumab (MEDI4736)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002675-29,0,0,0 2014-002683-32,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Durata Therapeutics International B.V.,"A Phase 3, double-blinded, randomized, comparator trial of the safety and efficacy of a single dose of dalbavancin to twice daily linezolid for the treatment of community acquired bacterial pneumonia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002683-32,0,0,0 2014-002685-70,1,2017-03-14,2017-03-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Lund University,The Effect of Sitagliptin on Glucagon Dynamics and Incretin Hormones During Mild Hypoglycemia in Elderly Patients with Metformin-Treated Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002685-70,0,0,0 2014-002688-14,2,2016-06-21,2016-06-21,2,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase II, randomised, observer-blind, controlled, multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of different formulations of GlaxoSmithKl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002688-14,0,0,0 2014-002694-11,12,2019-08-06,2019-08-06,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A phase III, double-blind, randomised study to assess the efficacy and safety of AZD9291 versus a standard of care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as first-line treatment in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002694-11,1,0,0 2014-002695-86,1,2020-07-17,2020-07-17,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,IKF-Klinische Krebsforschung GmbH am Krankenhaus Nordwest,PETRARCA / FLOT6 FLOT vs. FLOT/Herceptin/Perjeta for perioperative therapy of adenocarcinoma of the stomach and gastroesophageal junction expressing HER-2 A phase II/III trial of the AIO PETRARCA ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002695-86,0,0,0 2014-002697-37,1,2018-12-07,2018-12-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,Single-centre open label exploratory phase IIb pilot study of exogenous oral Melatonin for the treatment of Nocturia in adults with Parkinson’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002697-37,0,0,0 2014-002698-13,6,2016-09-27,2016-12-30,6,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genexine, Inc","A randomized, active-controlled, multiple-dose, open-label study to evaluate the safety, tolerability, and efficacy of the long-acting antibody-fused recombinant human growth hormone (GX-H9) in adult ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002698-13,0,0,0 2014-002699-98,1,2018-03-13,2018-03-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford,OxLith: Exploration of the short-term physical and psychological effects of lithium in mood instability,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002699-98,0,0,0 2014-002701-38,5,2019-10-23,2019-10-23,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Amicus Therapeutics, Inc.","An Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in subjects with Fabry Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002701-38,0,0,0 2014-002702-21,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Martin-Luther-Universität Halle- Wittenberg,"A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 addition to consolidation therapy in AML patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002702-21,0,0,0 2014-002705-38,2,2015-06-12,2015-06-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Orion Corporation Orion Pharma,"STUDY COMPARING BRONCHODILATOR EFFICACY OF TWO DRY POWDER INHALERS, BUDESONIDE/FORMOTEROL EASYHALER AND SYMBICORT TURBUHALER; A RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, MULTICENTRE, SINGLE DOSE, CROSSO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002705-38,0,0,0 2014-002708-26,1,2017-09-13,2017-09-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Surrey,A randomised double blind placebo controlled pilot trial of oxytocin efficacy in treating detoxified opioid dependent individuals,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002708-26,0,0,0 2014-002710-23,1,2018-01-11,2018-01-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),A pilot clinical trial of reverse transcriptase inhibitors in children with Aicardi-Goutières syndrome (AGS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002710-23,0,0,0 2014-002713-32,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Korea UCB Co. Ltd.,"A Multi-Center, Open-label, Randomized Study to Evaluate the Long Term Effectiveness of Levetiracetam as Monotherapy in Comparison With Oxcarbazepine in Subjects With Newly or Recently Diagnosed Parti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002713-32,0,1,1 2014-002714-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Fondazione G.I.M.EM.A. Onlus Gruppo Italiano Malattie Ematologiche dell'Adulto,A phase 2 multicenter study to assess the activity and the safety of front-line Ibrutinib plus Rituximab (IR) in unfit patients with Chronic Lymphocytic Leukemia (CLL). Studio multicentrico di ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002714-23,0,0,0 2014-002715-41,3,,,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS,"A phase IIa multicenter trial to assess the efficacy, and safety of Anakinra in patients with intravenous immunoglobulin-resistant Kawasaki disease Kawakinra Studio multicentrico di fase II per val...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002715-41,0,0,0 2014-002715-41,3,,,0,0,0,0,0,1,0,0,0,2,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"A phase IIa multicenter trial to assess the efficacy, and safety of Anakinra in patients with intravenous immunoglobulin-resistant Kawasaki disease Kawakinra Studio multicentrico di fase II per val...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002715-41,0,0,0 2014-002716-16,1,2015-12-31,2015-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"An 8-week randomised, double-blind, parallel, multiple dose trial comparing NNC0123-0000-0338 in a tablet formulation and insulin glargine in subjects with type 2 diabetes currently treated with oral ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002716-16,0,0,0 2014-002720-27,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Clínic per a la Recerca Biomèdica,Simplification from Tenofovir plus Lamivudine or Emtricitabine plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir plus Lamivudine in Virologically-Suppressed-HIV-Infected Adults...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002720-27,0,0,0 2014-002722-13,2,2021-07-12,2021-07-12,2,0,0,1,0,0,1,0,0,1,0,0,0,0,0,LYSARC,Phase I/II feasibility study of Brentuximab Vedotin in refractory / relapsed Hodgkin lymphoma patients who are treated by chemotherapy (ICE) in second line and eligible for autologous transplantation ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002722-13,0,0,0 2014-002736-13,13,2015-12-18,2015-12-18,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Teva Pharmaceutical Industries Ltd.,"A phase 3, multicenter, randomized, open-label, comparator-controlled study to assess safety and tolerability of weekly TV-1106 compared to daily rhGH (Genotropin®) in adults with growth hormone-defic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002736-13,0,0,0 2014-002739-32,1,2016-05-17,2016-05-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU de Montpellier,COLIN Intérêt de la COLchicine dans la prise en charge de l’INfarctus aigu du myocarde avec activité inflammatoire importante. -Etude pilote,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002739-32,0,0,0 2014-002740-41,1,2020-03-23,2020-03-23,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,Fundación Pethema,"Phase I/II, Multicenter, Open Label, Clinical Trial of Filanesib (ARRY-520) in combination with Pomalidomide and Dexamethasone for relapsed/refractory MM patients Ensayo clínico de Fase I/II abiert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002740-41,0,0,0 2014-002741-21,1,2016-08-01,2016-08-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Advanced Accelerator Applications SA,Safety and tolerability of 68Ga-DOTATOC for injection in patients with proven gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002741-21,0,0,0 2014-002742-42,1,2017-08-11,2017-08-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee/ NHS Tayside,Research into the Effect Of SGLT2 inhibition on left ventricular Remodelling in patients with heart failure and diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002742-42,0,0,0 2014-002744-40,1,2016-06-30,2016-06-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Section For Surgical Pathophysiology, Rigshospitalet","Preoperative intraarticular injection of methylprednisolone, in patients scheduled for total knee-arthroplasty",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002744-40,0,0,0 2014-002746-50,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Mari Salmivuori,Superficial basal cell cancer's photodynamic therapy: comparing three photosensitises: hexylaminolevulinate versus methylaminolevulinate and aminolevulinic acid nano emulsion versus methylaminolevuli...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002746-50,0,0,0 2014-002749-23,3,2019-03-28,2019-03-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AGMT gGmbH,Ixazomib in combination to thalidomide - dexamethasone for patients with relapsed and/or refractory multiple myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002749-23,0,0,0 2014-002751-25,1,2019-07-09,2019-07-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,The Walton Centre NHS Foundation Trust,Multi-centre randomised control trial comparing the clinical and cost effectiveness of trans-foraminal epidural steroid injection to surgical microdiscectomy for the treatment of chronic radicular pai...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002751-25,0,0,0 2014-002752-50,1,2017-04-26,2017-04-26,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,INSTITUT CURIE,Phase II clinical trial evaluating the efficacy of the dual inhibition of PIK/Akt/mTor signaling pathway by PF-05212384 (PKI-587) for patients with myeloid neoplasm secondary to chemo-radiotherapy (t-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002752-50,0,0,0 2014-002756-11,1,2015-11-24,2015-11-24,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Dermatology D92, Bispebjerg Hospital",Photodynamic therapy with varying application times for treatment of actinic keratosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002756-11,0,0,0 2014-002765-30,11,2020-07-30,2020-08-26,4,0,0,0,0,0,4,0,0,2,1,0,0,0,0,EGRIS,European Long-acting Antipsychotics in Schizofrenia Trial EULAST,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002765-30,1,0,0 2014-002765-30,11,2020-07-30,2020-08-26,4,0,0,0,0,0,4,0,0,2,1,0,0,0,0,University Medical Center Utrecht,European Long-acting Antipsychotics in Schizofrenia Trial EULAST,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002765-30,1,0,0 2014-002766-73,1,2017-01-23,2017-01-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Portsmouth Hospitals NHS Trust,"The effect of oral Vitamin D supplementation on endothelial function, vascular inflammation, oxidative stress and insulin sensitivity in patients with impaired fasting glucose: A randomised, double bl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002766-73,0,0,0 2014-002790-11,1,2020-03-09,2020-03-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Ludwig-Maximilians Universität München,Evaluation of additional peripheral panretinal LASER-treatment on recurrences of macular edema due to CRVO undergoing anti-VEGF treatment with ranibizumab Evaluierung eines „Treat-and-Extend“ Sche...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002790-11,0,0,0 2014-002794-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Academic Medical Center,Adjuvant hyperthermic intraperitoneal chemotherapy in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicenter trial Adjuvante hypertherme intraperit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002794-11,0,0,0 2014-002796-28,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,University Medical Center Groningen (UMCG),The Clinical Efficacy And Subclinical Effects on arterial STIFFNESS of bosentan therapy added to usual care in patients with systemic sclerosis with digital ulcers. De klinische effectiviteit en su...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002796-28,0,0,0 2014-002798-12,1,2022-04-02,2022-04-02,1,1,0,0,0,0,2,0,0,1,1,1,0,0,0,Odense University Hospital,Neoadjuvant chemotherapy in patients with biliary tract carcinomas - A Nordic phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002798-12,0,0,0 2014-002800-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Antoni van Leeuwenhoek Hospital-Nuclear Medicine department,Zirconium-89 Trastuzumab tracer uptake in metastatic breast cancer: A pilot study. Zirkonium-89 Trastuzumab tracer opname in gemetastaseerd mammacarcinoom: Een pilot studie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002800-25,0,0,0 2014-002802-19,1,2017-02-25,2017-02-25,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Department of Anaesthesiology,"Optimizing surgical conditions during laparoscopic umbilical, incisional –and linea alba herniotomy with deep neuromuscular blockade (The hernia study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002802-19,0,0,0 2014-002807-10,9,2018-09-03,2018-09-30,7,1,1,0,0,0,1,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole (POS) in Immunocompromised Pediatric Subjects with Neutropenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002807-10,1,1,0 2014-002807-10,9,2018-09-03,2018-09-30,7,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Merck Sharp & Dohme Corp.,"A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole (POS) in Immunocompromised Pediatric Subjects with Neutropenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002807-10,1,1,0 2014-002807-10,9,2018-09-03,2018-09-30,7,1,1,0,0,0,1,0,0,2,0,0,0,0,1,MSD Regional Business Support Center GmbH,"A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole (POS) in Immunocompromised Pediatric Subjects with Neutropenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002807-10,1,1,0 2014-002808-25,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Academic Medical Center Amsterdam,Immune phenotyping in chronic hepatitis C patients treated with Sofosbuvir and Daclatasvir combination with or without Ribavirin for 12 or 24 weeks -SODA study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002808-25,0,0,0 2014-002823-86,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,The George Institute for Global Health Australia,Enhanced Control of Hypertension and Thrombolysis Stroke Study Estudio de control más estricto de la hipertensión y trombolisis en el ataque cerebrovascular,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002823-86,0,0,0 2014-002826-11,4,2017-07-10,2017-07-10,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Array BioPharma Inc.,"A phase Ib/II multi-center, open label, dose escalation study of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant KRAS wild-type metastatic colorectal cancer harboring Wnt pathway mutatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002826-11,0,0,0 2014-002827-87,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Center,Multicenter randomized controlled trial comparing Ferric(III)carboxymaltose infusion with oral iron suppletion in the treatment of preoperative anemia in colorectal cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002827-87,0,0,0 2014-002830-30,1,2015-12-22,2015-12-22,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KU Leuven - Drug Delivery & Disposition,Supersaturation and precipitation of indinavir in the stomach of healthy human volunteers Supersaturatie en precipitatie van indinavir in de maag van gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002830-30,0,0,0 2014-002832-15,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,VU university medical center,Ulipristal versus Gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy: a double blind randomized controlled trial Ulipristal versus Gonadotropine-releasing hormoon agonists voo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002832-15,0,0,0 2014-002833-70,1,2020-01-06,2020-01-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,UZLeuven,Radium-223 in patients with PSA progression and without clinical metastases following maximal local therapy: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002833-70,0,0,0 2014-002834-30,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Amgen Inc.,"A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects in Europe With Unresected Stage IIIB to IVM1c Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002834-30,0,0,0 2014-002835-32,2,2019-11-07,2019-11-07,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Roche Farma, S.A. en nombre de F. Hoffmann-La Roche Ltd","AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION PHASE IB STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND THERAPEUTIC ACTIVITY OF RO7009789 (CD40 AGONIST) IN COMBINATION WITH MPDL3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002835-32,0,0,0 2014-002835-32,2,2019-11-07,2019-11-07,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"AN OPEN-LABEL, MULTICENTER, DOSE-ESCALATION PHASE IB STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND THERAPEUTIC ACTIVITY OF RO7009789 (CD40 AGONIST) IN COMBINATION WITH MPDL3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002835-32,0,0,0 2014-002839-33,2,2016-05-03,2016-05-03,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Pharming Group NV,"A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Efficacy and Safety of Recombinant Human C1 Inhibitor in the Prophylaxis of Angioedema Att...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002839-33,0,0,0 2014-002839-33,2,2016-05-03,2016-05-03,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,PHARMING GROUP NV,"A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Efficacy and Safety of Recombinant Human C1 Inhibitor in the Prophylaxis of Angioedema Att...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002839-33,0,0,0 2014-002840-42,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Aberdeen,Dose assessment of melatonin in sepsis trial (DAMSEL 2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002840-42,0,0,0 2014-002840-42,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Grampian,Dose assessment of melatonin in sepsis trial (DAMSEL 2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002840-42,0,0,0 2014-002841-23,9,2016-02-03,2016-03-02,7,1,1,0,0,0,1,0,0,1,1,0,1,0,1,Ablynx NV,"A Phase I/IIa Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With Respiratory Syncytial Virus Lower Respiratory Tract Infection, Consisting of an Open-label...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002841-23,0,0,0 2014-002844-42,4,2016-02-16,2016-02-16,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis recherche et développement,"Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog® in Adult Patients With Type 2 Diabetes Mellitus also Using Insulin Glargine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002844-42,0,0,0 2014-002845-23,8,2022-03-11,2022-03-11,2,0,1,0,0,1,4,0,0,2,0,0,0,0,1,Chiesi Farmaceutici S.p.A.,"Multinational, multicentre, prospective, open-label, uncontrolled clinical trial to assess the efficacy and safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002845-23,1,0,0 2014-002845-23,8,2022-03-11,2022-03-11,2,0,1,0,0,1,4,0,0,2,0,0,0,0,1,Holostem Terapie Avanzate s.r.l.,"Multinational, multicentre, prospective, open-label, uncontrolled clinical trial to assess the efficacy and safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002845-23,1,0,0 2014-002845-23,8,2022-03-11,2022-03-11,2,0,1,0,0,1,4,0,0,2,0,0,0,0,1,Holostem Terapie Avanzate S.r.l.,"Multinational, multicentre, prospective, open-label, uncontrolled clinical trial to assess the efficacy and safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002845-23,1,0,0 2014-002845-23,8,2022-03-11,2022-03-11,2,0,1,0,0,1,4,0,0,2,0,0,0,0,1,Holostem Terapie Avanzate S.r.l.,"Multinational, multicentre, prospective, open-label, uncontrolled clinical trial to assess the efficacy and safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002845-23,1,0,0 2014-002845-23,8,2022-03-11,2022-03-11,2,0,1,0,0,1,4,0,0,2,0,0,0,0,1,CHIESI FARMACEUTICI S.P.A.,"Multinational, multicentre, prospective, open-label, uncontrolled clinical trial to assess the efficacy and safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002845-23,1,0,0 2014-002850-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA,EFFICACY AND SAFETY OF EARLY POSTOPERATIVE CHEMOTHERAPY INTRAPERITONEAL (EPIC) WITH PACLITAXEL IN THE RADICAL SURGERY TREATMENT OF OVARIAN PERITONEAL CARCINOMATOSIS EFICACIA Y SEGURIDAD DE LA QUIMI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002850-38,0,0,0 2014-002854-37,1,,,0,1,0,0,0,0,4,0,0,3,0,0,0,0,1,Novartis Pharma GmbH,"A 12-months, randomized, VA-assessor blinded, multicenter, controlled phase IV trial to investigate non-inferiority of two treatment algorithms (discretion of the investigator vs. pro re nata) of 0.5 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002854-37,0,0,0 2014-002855-25,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"EIP Pharma, LLC","A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic 11C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002855-25,0,0,0 2014-002864-33,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,The Florey Institute of Neuroscience and Mental Health,EXTEND (International): Extending the time for Thrombolysis in Emergency Neurological Deficits (International),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002864-33,0,0,0 2014-002865-31,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,NOVARTIS FARMA S.p.A.,"A 24-week, multicenter, proSpective, open-label stUdy to evaluate the efficacy in terms of non-inferiority with respect to PASI 90 response rate and the safety PRofile of sEcukinuMab 300 mg in Cw6-neg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002865-31,0,0,0 2014-002866-65,6,2017-09-22,2017-09-22,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI ± Bevacizumab Versus Placebo Plus FOLFIRI ± Bevacizumab in Previously Untreated Metastatic Colorectal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002866-65,0,0,0 2014-002867-13,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Sanofi-aventis,"Multinational, randomized, double blind, double dummy, pharmacokinetic study of telithromycin oral suspension (25 mg/kg once daily for 7-10 days), with secondary assessments of safety relative to azit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002867-13,0,1,1 2014-002872-95,1,2018-08-31,2018-08-31,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Novartis Pharma S.A.S,A French open-label extension study of canakinumab in patients with Systemic Juvenile Idiopathic Arthritis (SJIA) who participated in the international phase III study CACZ885G2301E1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002872-95,0,0,0 2014-002876-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Istituto Clinico Humanitas,A PHASE II STUDY OF THE COMBINATION OF GEMCITABINE AND IMATINIB MESYLATE IN PEMETREXED-PRETREATED PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA STUDIO DI FASE II DELLA COMBINAZIONE DI GEMCITABINA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002876-10,0,0,0 2014-002919-41,2,2020-11-10,2020-11-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Cook MyoSite Incorporated,"A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Female Subjects with Stress Urinary Incontinence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002919-41,0,0,0 2014-002925-36,1,2016-02-19,2016-02-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects with Chronic Hepatitis C Viru...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002925-36,0,0,0 2014-002927-90,1,2017-02-23,2017-02-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 with and without RBV in Subjects with Chronic Hepatitis C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002927-90,0,0,0 2014-002928-27,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,VU university medical center,Observing Platelet Activability in a Once daily vs. a More frequent Aspirin intake regimen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002928-27,0,0,0 2014-002929-35,3,2019-03-28,2019-05-30,3,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Novartis Pharma Services AG,"A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and KLB expression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002929-35,0,0,0 2014-002929-35,3,2019-03-28,2019-05-30,3,1,0,1,0,0,1,0,0,1,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and KLB expression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002929-35,0,0,0 2014-002932-15,1,2015-01-19,2015-01-19,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Bispebjerg University Hospital,The effect of inhaled glucocorticoids on the content of Na+/K+ pumps in human skeletal muscle,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002932-15,0,0,0 2014-002939-34,4,2018-04-09,2018-04-09,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GW Research Ltd,"A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002939-34,0,0,0 2014-002940-42,2,2016-05-02,2016-05-02,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GW Research Ltd,"A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox-Gastaut syndrom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002940-42,0,0,0 2014-002941-23,2,2016-02-26,2016-02-26,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GW Research Ltd.,"A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P; CBD) as adjunctive treatment for seizures associated with Lennox- Gastaut syndro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002941-23,0,0,0 2014-002942-33,2,2017-06-07,2017-06-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GW Research Ltd,"A phase 2, double-blind, randomized, placebo-controlled study to investigate possible drug-drug interactions between clobazam and cannabidiol (GWP42003-P)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002942-33,0,0,0 2014-002945-23,4,2016-11-01,2016-11-01,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Takeda Development Centre Europe Ltd.,"A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002945-23,0,0,0 2014-002948-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación PETHEMA,"A phase II multicenter study of carfilzomib, lenalidomide and dexamethasone (KRd) plus high-dose therapy with melphalan-200 and autologous stem cell transplantation, followed by consolidation with KRd...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002948-40,0,0,0 2014-002950-38,6,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002950-38,0,1,0 2014-002962-57,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Egyesített Szent István és Szent László Kórház - Rendelőintézet,"Hepatitis C meggyógyítása, cryoglobunaemia és szövödményeinek (vaculitis, neuritis) megszüntetése",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002962-57,0,0,0 2014-002970-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Maastricht University Medical Center,Human intestinal ischemia and reperfusion Humane darm ischemie en reperfusie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002970-36,0,0,0 2014-002972-95,1,2015-04-24,2015-04-24,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novartis Pharma Services AG,"Phase 3b, Open label, Uncontrolled, Single-arm, Single-centre Study to Evaluate the Safety of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Healthy Adults from 18 to 50 Year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002972-95,0,0,0 2014-002973-13,1,2016-05-17,2016-05-17,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,CHU de NIMES,Sampling Antibiotics in Renal Replacement Therapy: the AZUREA contribution Taux plasmatiques d’antibiotiques pendant un traitement de suppléance rénale chez les patients de réanimation: la contribu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002973-13,0,0,0 2014-002974-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Umeå University,Is home abortion mora acceptable for teenagers than abortion at the clinic? A randomized trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002974-35,0,0,0 2014-002977-12,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,Maastriccht University,BRAIN KINETICS OF NEUROTRANSMISSION DURING THC INTOXICATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002977-12,0,0,0 2014-002978-36,1,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,The University of Oxford,"Vaccines Against Salmonella Typhi: a phase IIb, single centre, observer-blind, randomised controlled trial to assess the immunogenicity and protective efficacy of Vi conjugated (Vi-TCV) and unconjugat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002978-36,0,0,0 2014-002981-64,3,2019-06-03,2019-06-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Celgene Corporation,"A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002981-64,0,0,0 2014-002981-64,3,2019-06-03,2019-06-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CELGENE CORPORATION,"A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002981-64,0,0,0 2014-002984-14,1,2017-02-28,2017-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ACTELION Pharmaceuticals Ltd,"A multicenter, randomized, double-blind, placebo-controlled, dose-response study to investigate the biological activity, safety, tolerability, and pharmacokinetics of ACT-334441 in subjects with syste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002984-14,0,0,0 2014-002986-30,5,2018-09-05,2018-09-05,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,OCTAPHARMA AG,"Prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of personalized prophylaxis with Human-cl rhFVIII in previously treated adult patients with severe haemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002986-30,0,0,0 2014-002987-34,5,2015-04-29,2016-12-15,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2, Randomized, Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who are Asymptomat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002987-34,0,0,0 2014-002988-16,2,2021-02-26,2021-02-26,1,1,0,0,0,0,0,0,0,1,1,1,1,0,0,Royal College of Surgeons in Ireland,The Use of Milrinone in Neonates with Persistent Pulmonary Hypertension of the Newborn: A Randomised Controlled Trial Pilot Study (MINT 1),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002988-16,0,0,0 2014-002992-27,4,2016-03-04,2016-06-30,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.",201496: A Study to Evaluate the Efficacy and Safety of 15mg BID Losmapimod (GW856553) Compared to Placebo in Frequently Exacerbating Subjects with Chronic Obstructive Pulmonary Disease (COPD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002992-27,0,0,0 2014-002992-27,4,2016-03-04,2016-06-30,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,201496: A Study to Evaluate the Efficacy and Safety of 15mg BID Losmapimod (GW856553) Compared to Placebo in Frequently Exacerbating Subjects with Chronic Obstructive Pulmonary Disease (COPD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002992-27,0,0,0 2014-002996-27,1,2017-06-30,2017-06-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Great Ormond Street Hospital For Children NHS Foundation Trust,Optimising effectiveness and minimising toxicity of intravenous salbutamol in children with acute asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002996-27,0,0,0 2014-002997-35,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,University of Oxford,"A phase III multi-centre randomised, double blind, placebo controlled trial to assess the role of intravenous immunoglobulin in the management of children with encephalitis (The IgNiTE study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002997-35,0,0,0 2014-002998-11,1,2017-01-27,2017-01-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Rigshospitalet, Capital Region Bloodbank 2034, Section for Transfusion Medicine","Safety and efficacy of low-dose Iloprost administration and blood pressure target in addition to standard therapy, as compared to standard therapy alone, in post-cardiac- arrest-syndrome patients – a ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002998-11,0,0,0 2014-002999-83,1,2021-12-31,2021-12-31,1,0,0,0,0,0,4,0,0,1,1,1,0,0,0,Johan Styrke,Ciprofloxacin vs Trimetoprim/Sulfametoxazol for transrectal prostate biopsy - a randomized double blind phaze IV multicentre clinical trial Ciprofloxacin vs Trimetoprim/Sulfametoxazol vid transrekt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002999-83,0,0,0 2014-003002-32,6,2016-10-24,2016-10-24,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,ASTELLAS PHARMA EUROPE LIMITED,Open label study to evaluate the pharmacokinetics of fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects with Clostridium difficile Infection (CDI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003002-32,0,0,0 2014-003002-32,6,2016-10-24,2016-10-24,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Astellas Pharma Europe Ltd.,Open label study to evaluate the pharmacokinetics of fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects with Clostridium difficile Infection (CDI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003002-32,0,0,0 2014-003003-30,1,2020-07-30,2020-07-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,HOSPICES CIVILS DE LYON,ENALEPSIE EFFICACY OF NALOXONE IN REDUCING POSTICTAL CENTRAL RESPIRATORY DYSFUNCTION IN PATIENTS WITH EPILEPSY.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003003-30,0,0,0 2014-003004-69,1,2019-04-10,2019-04-10,1,0,0,0,1,0,3,0,0,1,0,0,1,0,0,CHU de Nantes,Intérêt du contrôle Raisonné de l’Inflation Hydro-Sodée en Réanimation– protocole IRIHS-RÉA. Etude multicentrique randomisée.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003004-69,0,0,0 2014-003006-33,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Radboud University Medical Center,Effect of Gelofusine on 111In-DTPA-AHX-Lys40-Exendin 4 uptake in the kidney Het effect van Gelofusine op de nieropname van 111In-DTPA-AHX-Lys40-Exendin 4,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003006-33,0,0,0 2014-003007-29,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"University Hospitals Leuven, department of pediatrics",The Polysaccharide Antibody Response Study: Typhim Vi response and allohemagglutinins versus Pneumo 23 vaccine response in the diagnosis of Specific Polysaccharide Antibody Deficiency.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003007-29,0,0,0 2014-003008-53,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,University Medical Center Utrecht,Clonidine Augmentation Therapy in Schizophrenia Clonidine Augmentatie therapie in Schizofrenie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003008-53,0,0,0 2014-003010-93,1,2015-04-09,2015-04-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Sint Maartenskliniek,Pharmacokinetic Profile of Ropivacaïne after Periarticular Local Infiltration Analgesia for Primary Total Knee Arthroplasty Farmacokinetiek van ropivacaïne bij LIA voor TKP-operatie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003010-93,0,0,0 2014-003012-36,6,2016-07-19,2016-08-08,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ablynx NV,"A Phase IIb Multicenter, Randomized, Double-blind Study of ALX-0061 Administered Subcutaneously as Monotherapy, in Subjects with Moderate to Severe Rheumatoid Arthritis who are Intolerant to Methotrex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003012-36,0,0,0 2014-003021-18,11,2015-10-21,2016-01-08,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biogen Idec Research Limited,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003021-18,0,0,0 2014-003022-40,1,2017-09-11,2017-09-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsklinikum Münster,Comparison of the bacterial microbiota in the skin and gut of psoriasis patients before and after sytemic treatment with adalimumab and ustekinumab or cyclosporin Vergleichende Untersuchung der bak...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003022-40,0,0,0 2014-003023-22,1,2018-07-16,2018-07-16,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE,"Open trial with randomized withdrawal of treatment, to evaluate the efficacy of azithromycin in the treatment of bronchiectasis excluding cystic fibrosis in children (AZI-STOP study) ESSAI EN OUVE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003023-22,0,0,0 2014-003024-46,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Repha GmbH,"Efficacy, safety and tolerability of Angocin Anti-Infekt N versus Placebo for MRSA eradication Klinische Prüfung zur Untersuchung der Wirksamkeit, Sicherheit und Verträglichkeit der Anwendung von A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003024-46,0,0,0 2014-003025-18,1,2019-07-30,2019-07-30,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,King's College London,"In Vivo Generation of Optimal Tumour Antigen-specific Anticancer Immune Responses, by Vaccination with Human Telomerase Reverse Transcriptase (hTERT) Peptides, in Combination with Specific Adjuvants a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003025-18,0,0,0 2014-003025-18,1,2019-07-30,2019-07-30,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Guy's and St Thomas NHS Foundation Trust,"In Vivo Generation of Optimal Tumour Antigen-specific Anticancer Immune Responses, by Vaccination with Human Telomerase Reverse Transcriptase (hTERT) Peptides, in Combination with Specific Adjuvants a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003025-18,0,0,0 2014-003027-21,2,2017-01-16,2017-01-16,2,0,0,1,0,0,1,0,0,1,1,1,0,0,1,Piramal Imaging SA,"Open-label, multi center PET/CT (positron emission tomography/computed tomography) study for investigation of safety and diagnostic performance of the 68Ga labeled PET tracer [68Ga]RM2 following a sin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003027-21,0,0,0 2014-003029-16,2,2017-08-02,2017-08-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A phase II randomized, double-blind study of ipatasertib (GDC-0068), an inhibitor to Akt in combination with paclitaxel as neoadjuvant treatment for patients with early stage triple negative breast ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003029-16,0,0,0 2014-003031-19,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,IELSG (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP),"An international phase II trial assessing tolerability and efficacy of sequential Methotrexate-Aracytin-based combination and R-ICE combination, followed by high-dose chemotherapy supported by autolog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003031-19,0,0,0 2014-003031-19,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,International Extranodal Lymphoma Study Group,"An international phase II trial assessing tolerability and efficacy of sequential Methotrexate-Aracytin-based combination and R-ICE combination, followed by high-dose chemotherapy supported by autolog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003031-19,0,0,0 2014-003032-39,3,2018-09-26,2018-09-26,3,1,0,1,0,0,1,0,0,1,1,0,0,0,1,NOVARTIS FARMA S.P.A.,A phase Ib/II study of the ALK inhibitor ceritinib in combination with the CDK4/6 inhibitor LEE011 in patients with ALK-positive Non-small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003032-39,0,0,0 2014-003032-39,3,2018-09-26,2018-09-26,3,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Novartis Pharma Services AG,A phase Ib/II study of the ALK inhibitor ceritinib in combination with the CDK4/6 inhibitor LEE011 in patients with ALK-positive Non-small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003032-39,0,0,0 2014-003032-39,3,2018-09-26,2018-09-26,3,1,0,1,0,0,1,0,0,1,1,0,0,0,1,"Novartis Farmacéutica, S.A.",A phase Ib/II study of the ALK inhibitor ceritinib in combination with the CDK4/6 inhibitor LEE011 in patients with ALK-positive Non-small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003032-39,0,0,0 2014-003033-26,6,2016-07-19,2016-08-08,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ablynx NV,"A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination with Methotrexate, in Subjects with Moderate to Se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003033-26,0,0,0 2014-003034-42,5,2018-08-14,2018-08-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ablynx NV,"A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Moderate to Severe Rheumatoid Arthritis who Have Completed One ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003034-42,0,0,0 2014-003037-26,6,2019-07-19,2019-07-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Limited,The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003037-26,0,0,0 2014-003039-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,A. O. Istituti Ospitalieri di Cremona,RANDOMIZED PHASE II STUDY WITH SEQUENTIAL NON-CROSS RESISTANT CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED INOPERABLE OR METASTATIC GASTRO-ESOPHAGEAL ADENOCARCINOMA STUDIO RANDOMIZZATO DI FASE II...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003039-20,0,0,0 2014-003040-12,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,MDM S.p.A.,"A phase III, multicenter, randomized, parallel groups study to assess the efficacy and safety of 0,5 mg Tizaspray® administered intranasally versus Sirdalud® 2 mg tablets, in patients with acute low b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003040-12,0,0,0 2014-003041-10,16,2017-05-08,2017-12-14,14,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of RAnibizumab compared with laser therapy for the treatment of INfants BOrn prematurely With retinopathy of prematurit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003041-10,0,0,0 2014-003041-10,16,2017-05-08,2017-12-14,14,1,1,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.p.A.,"RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of RAnibizumab compared with laser therapy for the treatment of INfants BOrn prematurely With retinopathy of prematurit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003041-10,0,0,0 2014-003042-27,6,2021-03-29,2021-03-29,3,0,0,0,0,1,2,0,0,2,0,0,0,0,1,United Therapeutics Corporation,An Open-Label Extension Study of APD811-003 in Patients with Pulmonary Arterial Hypertension Az APD811-003 vizsgálat nyílt kiterjesztett vizsgálata pulmonális artériás hipertóniában szenvedő betege...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003042-27,1,0,0 2014-003042-27,6,2021-03-29,2021-03-29,3,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Arena Pharmaceuticals, Inc.",An Open-Label Extension Study of APD811-003 in Patients with Pulmonary Arterial Hypertension Az APD811-003 vizsgálat nyílt kiterjesztett vizsgálata pulmonális artériás hipertóniában szenvedő betege...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003042-27,1,0,0 2014-003043-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital General de Vic,Infiltration of bupivacaine and triamcinolone at Milligan-Morgan hemorrhoidectomy surgical site to manage postoperative pain Infiltración de bupivacaina y triamcinolona en la hemorroidectomía de Mi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003043-35,0,0,0 2014-003046-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dipartimento di Medicina,A PHASE II OPEN-LABEL SINGLE-CENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF THE BRAF-V600 INHIBITOR VEMURAFENIB (ZELBORAF) IN COMBINATION WITH THE B-CELL TARGETING ANTIBODY RITUXIMAB (MABTHERA) I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003046-27,0,0,0 2014-003047-35,1,2017-04-28,2017-04-28,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Avid Radiopharmaceuticals, Inc.",Evaluation of 18F-AV-1451 kinetic modeling in patients in Alzheimer's disease and healthy controls,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003047-35,0,0,0 2014-003048-11,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,GIPIT,"FEcal transplant, a Dazzling debut to Eradicate colonization with eXtreme drug resistant bacteria? La transplantation fécale, un brillant début pour éradiquer la colonisation à Bactéries Hautement...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003048-11,0,0,0 2014-003052-31,6,2020-10-13,2020-10-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Sciences Ireland UC,"A Phase 3, randomized, active-controlled, open-label study to evaluate switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once-daily single tablet regimen versus conti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003052-31,0,0,0 2014-003052-31,6,2020-10-13,2020-10-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Janssen R&D, Ireland","A Phase 3, randomized, active-controlled, open-label study to evaluate switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once-daily single tablet regimen versus conti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003052-31,0,0,0 2014-003052-31,6,2020-10-13,2020-10-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Science Ireland Unlimited Company,"A Phase 3, randomized, active-controlled, open-label study to evaluate switching to a darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once-daily single tablet regimen versus conti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003052-31,0,0,0 2014-003053-34,1,2016-03-01,2016-03-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,IPPMed – Institut für Pharmakologie und Präventive Medizin GmbH,"Randomized, double-blind, placebo controlled, crossover clinical study to analyse the effect of empagliflozin on microvascular circulation Randomisierte, doppelblinde, placebokontrollierte, klinis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003053-34,0,0,0 2014-003055-60,2,2020-09-30,2020-09-30,2,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Medical University of Vienna,"Evaluation of the pharmacodynamic effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction in a randomized, double blind, placebo controlled, par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003055-60,0,0,0 2014-003056-31,2,2020-07-07,2020-07-07,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Celgene Corporation,"Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC-122 and the Combinations of CC-122 and Ibrutinib and CC-122 and Obinutuzumab in Subjects with Chronic Lymphoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003056-31,0,0,0 2014-003060-20,5,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003060-20,0,0,0 2014-003060-20,5,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,NOVARTIS FARMA S.P.A.,"A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003060-20,0,0,0 2014-003064-21,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Hospital Universitari de Girona Dr. Josep Trueta,THE USE OF ASPIRIN AS PRIMARY PREVENTION IN PATIENTS WITH DIABETES USO DE LA ASPIRINA COMO PREVENCIÓN PRIMARIA EN PACIENTES CON DIABETES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003064-21,0,0,0 2014-003065-15,9,2020-04-24,2020-04-24,7,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.","A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE III STUDY OF IDASANUTLIN, AN MDM2 ANTAGONIST, WITH CYTARABINE VERSUS CYTARABINE PLUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTORY ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003065-15,0,0,0 2014-003065-15,9,2020-04-24,2020-04-24,7,1,0,0,0,1,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE III STUDY OF IDASANUTLIN, AN MDM2 ANTAGONIST, WITH CYTARABINE VERSUS CYTARABINE PLUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTORY ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003065-15,0,0,0 2014-003065-15,9,2020-04-24,2020-04-24,7,1,0,0,0,1,3,0,0,1,1,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE III STUDY OF IDASANUTLIN, AN MDM2 ANTAGONIST, WITH CYTARABINE VERSUS CYTARABINE PLUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTORY ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003065-15,0,0,0 2014-003066-24,14,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,MediWound Ltd.,"A multicenter, multinational, randomized, controlled, open label study, performed in children with thermal burns, to evaluate the efficacy and safety of NexoBrid as compared to standard of care (SOC) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003066-24,0,0,0 2014-003066-24,14,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,MEDIWOUND LTD,"A multicenter, multinational, randomized, controlled, open label study, performed in children with thermal burns, to evaluate the efficacy and safety of NexoBrid as compared to standard of care (SOC) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003066-24,0,0,0 2014-003067-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS,"177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) plus Capecitabine versus Lu-PRRT in FDG positive, gastro-entero-pancreatic neuroendocrine tumors: a randomized phase II study. (Lu-Ca-S) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003067-38,0,0,0 2014-003071-37,1,2016-04-13,2016-04-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Quantum Genomics,"Multicenter, randomized, double-blind, two-period, placebo controlled, forced-titration proof of concept crossover study to compare QGC001 with placebo in patients with grade I or II essential hyperte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003071-37,0,0,0 2014-003072-24,1,2015-11-30,2015-11-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharma A/S,Patient insights following use of LEO 90100 aerosol foam and Daivobet® gel in subjects with psoriasis vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003072-24,0,0,0 2014-003076-22,1,2021-01-26,2021-01-26,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Central Institute of Mental Health Mannheim (ZI),Multimodal Prevention of First Psychotic Episode – a 2x2-Factorial Randomized Trial investigating the efficacy of Acetylcysteine (ACC) and Integrated Preventive Psychological Intervention (IPPI) in Su...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003076-22,0,0,0 2014-003077-42,1,2017-01-05,2017-01-05,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Imperial College, London","A single-centre, double-blind, randomised, placebo-controlled crossover study to evaluate the effect of solithromycin on airway inflammation in male and female patients with chronic obstructive pulmon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003077-42,0,0,0 2014-003079-40,1,2021-06-24,2021-06-24,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,"Ruprecht-Karls-University Heidelberg, Medical Faculty represented by University Hospital Heidelberg",A randomized phase III trial on the effect of elotuzumab in VRD induction /consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma Randomisierte Phase III-Studie für Pat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003079-40,0,0,0 2014-003080-38,2,2018-09-27,2018-09-27,1,1,0,0,0,0,2,0,0,2,0,0,0,0,0,"Radboud University, Nijmegen Medical Centre, Donders Institute for Brain, Cognition and Behaviour",Glutamatergic Medication in the Treatment of Obsessive-Compulsive Disorder (OCD) and Autism Spectrum Disorder (ASD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003080-38,1,0,0 2014-003080-38,2,2018-09-27,2018-09-27,1,1,0,0,0,0,2,0,0,2,0,0,0,0,0,"Radboud University Nijmegen Medical Centre, Donders Institute for Brain, Cognition and Behaviour",Glutamatergic Medication in the Treatment of Obsessive-Compulsive Disorder (OCD) and Autism Spectrum Disorder (ASD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003080-38,1,0,0 2014-003083-21,8,2022-03-08,2022-03-08,4,1,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH A PLATINUM AGENT (CISPLATIN OR CARBOPLATIN) IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR PD-L1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003083-21,1,0,0 2014-003083-21,8,2022-03-08,2022-03-08,4,1,0,0,0,0,3,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH A PLATINUM AGENT (CISPLATIN OR CARBOPLATIN) IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR PD-L1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003083-21,1,0,0 2014-003084-37,2,2021-11-22,2021-12-21,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,SOTIO a.s.,A phase I/II study to evaluate safety and efficacy of DCVAC/LuCa added to standard first line chemotherapy with carboplatin and paclitaxel +/- immune enhancers (interferon-α and hydroxychloroquine) vs...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003084-37,0,0,0 2014-003087-20,1,2018-04-10,2018-04-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,IRCCS Ospedale Pediatrico Bambino Gesù,"Determination of Plasmatic and CSF Levels Of High Doses Of Micafungin in Neonates Suffering from Systemic Candidiasis and/or Candida meningitis. Determinazione dei livelli, nel sangue e nel liquido...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003087-20,0,0,0 2014-003090-42,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003090-42,0,0,0 2014-003090-42,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,EORTC AISBL/IVZW,REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003090-42,0,0,0 2014-003100-78,1,2015-07-06,2015-07-06,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Summit (Oxford) Limited,"SMT C11003 - A Phase 1b placebo-controlled, multi-centre, randomized, double-blind 3-period dose escalation study to evaluate the pharmacokinetics (PK) and safety of SMT C1100 in paediatric patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003100-78,0,0,0 2014-003106-33,9,2017-12-07,2017-12-07,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (ANTI− PDL1 ANTIBODY) COMPARED WITH GEMCITABINE+CISPLATIN OR CARBOPLATIN FOR PD-L1−SELECTED, CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV SQUAMOU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003106-33,0,0,0 2014-003106-33,9,2017-12-07,2017-12-07,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (ANTI− PDL1 ANTIBODY) COMPARED WITH GEMCITABINE+CISPLATIN OR CARBOPLATIN FOR PD-L1−SELECTED, CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV SQUAMOU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003106-33,0,0,0 2014-003107-29,4,2018-04-23,2018-05-22,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,GALMED Pharmaceuticals LTD.,"A Phase IIb, double blind, randomized controlled clinical trial to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic- Steatohepatitis (NASH).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003107-29,1,0,0 2014-003107-29,4,2018-04-23,2018-05-22,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,GALMED PHARMACEUTICALS LTD.,"A Phase IIb, double blind, randomized controlled clinical trial to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic- Steatohepatitis (NASH).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003107-29,1,0,0 2014-003108-56,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Fundación para la investigación biomédica del Hospital Ramón y Cajal,Clinical Trial: Feaseability and security of the treatment of Bronchopulmonary Dysplasia in preterm babies with expanded umbilical cord allogenic fetal mesenchymal stem cells. Ensayo Clínico Fase I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003108-56,0,0,0 2014-003111-10,2,2018-05-15,2018-05-15,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Cell Medica Ltd,A single arm Phase I/II study of the safety and efficacy of gene-modified WT1 TCR therapy in patients with myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML) who have failed to achieve or...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003111-10,0,0,0 2014-003116-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Akershus University Hospital,Postoperative analgesia with oxycodone after caesarean section,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003116-37,0,0,0 2014-003117-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Can Methylphenidate (Ritalin) improve memory and attention in mild cognitive impairment? An EEG study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003117-28,0,0,0 2014-003119-13,1,2018-07-20,2018-07-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Joint Research Office- UCL,"Can simvastatin significantly reduce the amount of immunosuppressive medication required by patients with sight threatening uveitis? A phase IIb, single site, randomized, placebo controlled, double bl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003119-13,0,0,0 2014-003120-48,1,2017-12-28,2017-12-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Hospices Civils de Lyon,Etude des modulations du système immunitaire des patients atteints de mélanome et traités par anticorps monoclonaux anti-PD1. Etude concernant les patients atteints de mélanome métastatique Etude...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003120-48,0,0,0 2014-003121-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,D.A.S.T. BIOTECH PHARM Ε.Π.Ε.,"Randomized, double-blind intervention study of efficacy and safety of the product Vioplex-T compared with placebo in patients with open sores (pressure ulcers). Τυχαιοποιημένη, διπλά τυφλή παρεμβατ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003121-17,0,0,0 2014-003123-22,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,José Castillo Sanchez,"""Randomized clinical trial with two parallel groups, double-blind, placebo-controlled trial to investigate whether administration of CBG000592 (riboflavin/vitamin B2) in patients with acute ischemic s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003123-22,0,0,0 2014-003124-44,1,2022-04-05,2022-04-05,1,0,0,0,0,1,3,0,0,1,0,0,0,0,0,DKMS gemeinnützige GmbH,Evaluation of the impact of remission induction chemotherapy prior to allogeneic stem cell transplantation in relapsed and poor-response patients with AML,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003124-44,0,0,0 2014-003126-40,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,UNIVERSITà DEGLI STUDI MILANO BICOCCA,Allogeneic haematopoietic stem cell transplantation from a matched donor in patients with chronic myeloid leukemia failing to gain normal hemopoiesis under TKIs therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003126-40,0,0,0 2014-003127-22,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,SOGUG (Spanish Oncology Genitourinary Group),Phase II study with pazopanib and weekly paclitaxel in metastatic or locally advanced squamous penile carcinoma patients previously treated with cisplatin based chemotherapy Estudio fase II de trat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003127-22,0,0,0 2014-003132-39,4,2019-04-26,2019-04-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER AG,"Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept - a randomized, open-label, active-controlled, pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003132-39,0,0,0 2014-003132-39,4,2019-04-26,2019-04-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept - a randomized, open-label, active-controlled, pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003132-39,0,0,0 2014-003132-39,4,2019-04-26,2019-04-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept - a randomized, open-label, active-controlled, pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003132-39,0,0,0 2014-003135-19,5,2016-08-19,2016-08-19,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Auspex Pharmaceuticals, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003135-19,0,0,0 2014-003137-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,José Manuel Porcel Pérez Hospital Arnau de Vilanova de Lleida Servicio Medicina Interna,Optimal duration of antibiotic treatment in patients with complicated parapneumonic pleural effusions or empyema: a randomized clinical trial Duración óptima del tratamiento antibiótico en pacient...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003137-25,0,0,0 2014-003138-18,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,University College Cork,STRIDER Ireland: A Randomised Controlled Trial of Sildenafil Therapy In Dismal Prognosis Early‐Onset Intrauterine Growth Restriction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003138-18,0,0,0 2014-003140-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UMC Utrecht,Optimizing DMARD-therapy for primary Sjogren's Syndrome - Leflunomide and Hydroxychloroquine combination therapy for patients with primary Sjogren's Syndrome Optimaliseren van DMARD-therapie voor h...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003140-12,0,0,0 2014-003141-10,1,2019-01-10,2019-01-10,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Ghent University Hospital,Invloed van UDCA op fecale galzoutensamenstelling van IBD patiënten: piloot studie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003141-10,0,0,0 2014-003142-27,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Fundació Clinic per a la Recerca Biomédica,"A pilot 24-week open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of dual therapy with Raltegravir/Lamivudine combination when replacing standard combin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003142-27,0,0,0 2014-003144-12,1,2014-11-25,2014-11-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Profil Institut für Stoffwechselforschung GmbH,A trial to compare the pharmacokinetics and pharmacodynamics of insulin lispro administered s.c. into lipohypertrophic or normal abdominal adipose tissue in subjects with diabetes mellitus type 1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003144-12,0,0,0 2014-003145-99,1,2019-05-14,2019-05-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge,A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis already o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003145-99,0,0,0 2014-003147-35,1,2017-07-14,2017-07-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003147-35,0,0,0 2014-003148-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Center,Mechanism of action study of Ustekinumab treatment in psoriatic arthritis: Impact on cellular and molecular pathways of synovial inflammation and tissue remodeling,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003148-11,0,0,0 2014-003150-13,1,2020-12-26,2020-12-26,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Technische Universität Dresden,A randomized placebo-controlled phase 2 study of decitabine with or without eltrombopag in AML patients ≥65 years of age not eligible for intensive chemotherapy Randomisierte Placebo-kontrollierte ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003150-13,0,0,0 2014-003151-62,1,2015-01-30,2015-01-30,1,0,0,1,0,0,1,1,1,1,1,1,0,0,1,Infectopharm Arzneimittel und Consilium GmbH,"A randomised, two-period two-stage cross-over study on the relative bioavailability of two different formulations of single doses of noscapine (phase I/IV, open-label) in healthy volunteers (fasted st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003151-62,0,0,0 2014-003155-57,9,2016-03-07,2016-03-07,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS FARMA S.p.A.,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled study to investigate the efficacy and safety of 52 weeks treatment with QGE031 s.c. in Asthma Patients not adequately controlled by medium-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003155-57,0,0,0 2014-003155-57,9,2016-03-07,2016-03-07,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled study to investigate the efficacy and safety of 52 weeks treatment with QGE031 s.c. in Asthma Patients not adequately controlled by medium-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003155-57,0,0,0 2014-003155-57,9,2016-03-07,2016-03-07,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmaceutica, S.A.","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled study to investigate the efficacy and safety of 52 weeks treatment with QGE031 s.c. in Asthma Patients not adequately controlled by medium-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003155-57,0,0,0 2014-003156-31,1,2017-10-24,2017-10-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU GRENOBLE,"Etude de la tolérance du fentanyl intranasal (Pecfent®) dans le traitement des douleurs procédurales chez la personne âgée, avec ou sans traitement de fond.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003156-31,0,0,0 2014-003158-15,1,,,0,1,0,0,1,0,2,0,1,1,0,0,0,1,1,Reckitt Benckiser Healthcare (UK) Limited,"A randomised, assessor blind, placebo controlled exploratory study in healthy volunteers, to characterise the acid neutralisation activity of sodium alginate oral suspension in the fasted state, using...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003158-15,0,0,0 2014-003159-73,5,2016-12-31,2016-12-31,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Merrimack Pharmaceuticals, Inc.","A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician's Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Pos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003159-73,1,0,0 2014-003162-25,3,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research Ltd,Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Su...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003162-25,0,0,0 2014-003164-21,6,2017-06-22,2017-07-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Tobira Therapeutics, Inc.",Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003164-21,0,0,0 2014-003164-21,6,2017-06-22,2017-07-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Tobira Therapeutics, Inc., a subsidiary of Allergan plc",Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003164-21,0,0,0 2014-003164-21,6,2017-06-22,2017-07-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Tobira Therapeutics, a subsidiary of Allergan plc",Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003164-21,0,0,0 2014-003165-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AOU di Bologna Policlinico S.Orsola-Malpighi,18F-FACBC PET/CT FOR STAGING HIGH RISK PROSTATE CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003165-15,0,0,0 2014-003167-38,2,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,0,Radboudumc,68Ga-NODAGA-exendin-4 PET/CT in patients with AHH - a prospective comparative evaluation of preoperative imaging Under the FP7 project Betacure (602812); Personalized diagnosis and treatment of hyperi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003167-38,0,0,0 2014-003167-38,2,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,0,"Hospital District of Southwest Finland, Turku University Hospital",68Ga-NODAGA-exendin-4 PET/CT in patients with AHH - a prospective comparative evaluation of preoperative imaging Under the FP7 project Betacure (602812); Personalized diagnosis and treatment of hyperi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003167-38,0,0,0 2014-003171-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University Hospital Wuerzburg,Transfer of Streptamer-selected multi-antigen specific T cells to prevent infections and relapse and to reduce the risk of Graft-versus-Host Disease after allogeneic stem cell transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003171-39,0,0,0 2014-003174-17,1,2015-12-24,2015-12-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare (UK) Limited,"A multicentre, randomised, double-blind, two arm, parallel group, placebo controlled pivotal study to assess the effect of a sodium alginate liquid suspension as add-on therapy in GORD patients with i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003174-17,0,0,0 2014-003177-42,7,2019-03-20,2021-01-15,6,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Catalan Institute of Oncology,Multinational study assessing the acceptability and determinants of compliance to HPV vaccination to women in screening ages 25 to 45 years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003177-42,0,0,0 2014-003177-42,7,2019-03-20,2021-01-15,6,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Ghent University Hospital,Multinational study assessing the acceptability and determinants of compliance to HPV vaccination to women in screening ages 25 to 45 years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003177-42,0,0,0 2014-003185-25,14,2021-06-09,2021-06-29,10,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE AND HER2 NEGATIVE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003185-25,1,0,0 2014-003185-25,14,2021-06-09,2021-06-29,10,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Roche Farma, S.A., en nombre de F. Hoffmann- La Roche Ltd.","A PHASE III, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE AND HER2 NEGATIVE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003185-25,1,0,0 2014-003186-24,6,2020-07-22,2020-07-22,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Allergan Limited,The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003186-24,1,0,0 2014-003186-24,6,2020-07-22,2020-07-22,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Abbvie Deutschland GmbH & Co. KG,The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003186-24,1,0,0 2014-003187-20,1,2016-09-30,2016-09-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Barts Health NHS Trust,A multicentre double-blind randomised controlled trial to assess the clinical- and cost-effectiveness of facet-joint injections in selected patients with non-specific low back pain: a feasibility stud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003187-20,0,0,0 2014-003189-26,1,2017-08-30,2017-08-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee/NHS Tayside,Metformin and its Effects on Myocardial Dimension and Left ventricular hypertrophy in normotensive patients with Coronary Artery Disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003189-26,0,0,0 2014-003190-42,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Cancer Trials Ireland,Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003190-42,0,0,0 2014-003191-23,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Cancer Trials Ireland,"Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003191-23,0,0,0 2014-003191-23,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,"Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland","Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003191-23,0,0,0 2014-003192-28,1,2019-07-18,2019-07-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,SOGUG,Phase II multicenter study to analyze the predictive value of fusion gene TMPRSS2-ETS in response to enzalutamide in patients with metastatic CRPC no previously treated with chemotherapy Estudio fa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003192-28,0,0,0 2014-003193-17,5,2019-07-31,2019-07-31,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BAYER AG,"A multi center, single arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003193-17,0,0,0 2014-003193-17,5,2019-07-31,2019-07-31,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bayer AG,"A multi center, single arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003193-17,0,0,0 2014-003196-39,4,2016-10-13,2016-10-13,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes. A 26-week, multicentre, double-blind, randomised, controlled dose-fi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003196-39,0,0,0 2014-003197-16,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Bambino Gesù Children's Hospital,"A Phase III randomized, controlled, open-label on the effects of parenteral nutrition early start to the late start in the ICU cardiac surgery Studio di fase III randomizzato controllato in aperto ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003197-16,0,0,0 2014-003198-40,5,2019-12-09,2019-12-09,3,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Genzyme Corporation,"A Phase 1/2, Multi-Center, Open-Label, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of Recombinant Human Acid Sphingomyelinase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003198-40,1,1,0 2014-003204-70,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Javier Domínguez Ortega,Pilot study on asthma control in patients with grass- pollen allergic rhinitis treated with 5 grass-pollen sublingual immunotherapy (Staloral®) vs placebo Estudio piloto sobre el control del asma e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003204-70,0,0,0 2014-003205-15,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003205-15,0,0,0 2014-003205-15,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003205-15,0,0,0 2014-003206-32,5,2020-07-02,2021-01-18,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (MPDL3280A, ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN+NAB-PACLITAXEL FOR CHEMOTHERA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003206-32,0,0,0 2014-003207-30,12,2020-09-04,2020-09-04,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL WITH OR WITHOUT BEVACIZUMAB COMPARED WITH CARBOPLATIN+PACLITAXEL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003207-30,0,0,0 2014-003208-59,12,2021-02-17,2021-02-17,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (MPDL3280A, ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN+PACLITAXEL OR ATEZOLIZUMAB IN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003208-59,0,0,0 2014-003209-14,1,2019-10-18,2019-10-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Hôpitaux Universitaires de Strasbourg,ASSESSMENT OF EARLY CHANGES OBSERVABLE IN DIFFUSION MRI IN RESPONSE TO TYSABRI TREATMENT TO TWO YEARS IN PATIENTS WITH MULTIPLE SCLEROSIS EVALUATION DES CHANGEMENTS PRÉCOCES VISIBLES À L’IRM DE DI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003209-14,0,0,0 2014-003212-36,5,,,0,0,0,1,0,2,1,0,0,3,0,0,0,0,1,Acerta Pharma BV,"An Open-label, Phase 1b/2 Study of ACP-196 in Subjects with Waldenström Macroglobulinemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003212-36,0,0,0 2014-003213-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SciencePharma spółka z ograniczoną odpowiedzialnością sp. j.,"A randomized, multicenter, open-label, two-arm, parallel, phase III study to evaluate the efficacy and safety of nicotinic acid administered in combination with simvastatin for 6 months in comparison ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003213-29,0,0,0 2014-003216-37,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,3,,Efficacy of Verapamil/ Verapamil-Kenacort injection versus Kenacort injection in Scar Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003216-37,0,0,0 2014-003217-28,6,2016-10-28,2016-10-28,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ObsEva SA,"A phase 2, double-blind, parallel group, randomised, placebo controlled, proof of concept study to assess the safety and efficacy of OBE001 after oral administration in pregnant women with threatened ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003217-28,0,0,0 2014-003218-98,3,2016-06-10,2016-07-13,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,LEO Pharma A/S,Efficacy and safety of ingenol mebutate gel 0.015% compared to diclofenac sodium gel 3% in subjects with actinic keratoses on the face or scalp.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003218-98,0,0,0 2014-003220-52,5,2017-11-21,2017-11-21,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,CELGENE CORPORATION,"A Phase 2, Randomized, Open-Label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Wo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003220-52,0,0,0 2014-003220-52,5,2017-11-21,2017-11-21,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Celgene Corporation,"A Phase 2, Randomized, Open-Label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Wo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003220-52,0,0,0 2014-003224-40,8,2016-03-30,2016-09-19,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International N.V.,"Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Fulranumab as Adjunctive Therapy in Subjects with Signs and Symptoms of O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003224-40,0,0,0 2014-003224-40,8,2016-03-30,2016-09-19,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,"Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Fulranumab as Adjunctive Therapy in Subjects with Signs and Symptoms of O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003224-40,0,0,0 2014-003227-21,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Fondazione IRCCS Istituto Nazionale dei Tumori Milano,Phase II study on Inlyta® (axitinib) in recurrent and/or metastatic salivary gland cancers (SGCs) of the upper aerodigestive tract Studio di fase 2 con Inlyta® (Axitinib) nel tumore delle ghiandole...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003227-21,0,0,0 2014-003229-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Inst of OPhthalmology, Lund University",To compare the effect of Eylea given every other month after three injections to treatment with a gradual extension intervals. and examine retinal function with electroretinography (ERG) in patients w...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003229-17,0,0,0 2014-003231-19,19,2018-11-07,2018-11-08,18,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR META...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003231-19,0,0,0 2014-003231-19,19,2018-11-07,2018-11-08,18,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Roche Farma, S.A. en nombre de F. Hoffmann-La Roche Ltd","A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR META...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003231-19,0,0,0 2014-003233-26,9,2019-04-20,2019-04-29,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"MedImmune, LLC",A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003233-26,0,0,0 2014-003233-26,9,2019-04-20,2019-04-29,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"MEDIMMUNE, LLC",A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003233-26,0,0,0 2014-003233-26,9,2019-04-20,2019-04-29,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"MedImmune, LLC, a wholly owned subsidiary of AstraZeneca",A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003233-26,0,0,0 2014-003237-25,1,2018-03-15,2018-03-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Oxford,A blinded randomised placebo-controlled trial investigating the efficacy of morphine analgesia for procedural pain in infants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003237-25,0,0,0 2014-003239-21,4,2017-05-15,2017-05-15,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"An open-label, multi-center, expanded treatment protocol of oral panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and relapsed and refractory multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003239-21,0,0,0 2014-003239-21,4,2017-05-15,2017-05-15,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"An open-label, multi-center, expanded treatment protocol of oral panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and relapsed and refractory multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003239-21,0,0,0 2014-003240-12,11,2017-07-31,2017-08-03,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT- 494 for the Induction of Symptomatic and Endoscopic Remission in Subjects with Moderately to Severely Active Crohn's Disease w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003240-12,0,0,0 2014-003240-12,11,2017-07-31,2017-08-03,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT- 494 for the Induction of Symptomatic and Endoscopic Remission in Subjects with Moderately to Severely Active Crohn's Disease w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003240-12,0,0,0 2014-003242-28,5,2017-06-01,2017-06-01,5,1,1,0,1,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam when given in combination with metronida...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003242-28,0,0,0 2014-003242-28,5,2017-06-01,2017-06-01,5,1,1,0,1,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam when given in combination with metronida...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003242-28,0,0,0 2014-003243-34,4,2017-12-30,2017-12-30,3,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline in Neonates and Young Infants with Late-Onset Sepsis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003243-34,0,0,0 2014-003243-34,4,2017-12-30,2017-12-30,3,1,1,0,0,0,2,0,0,1,0,0,1,0,1,ASTRAZENECA AB,"Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline in Neonates and Young Infants with Late-Onset Sepsis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003243-34,0,0,0 2014-003243-34,4,2017-12-30,2017-12-30,3,1,1,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline in Neonates and Young Infants with Late-Onset Sepsis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003243-34,0,0,0 2014-003244-13,5,2017-09-15,2017-09-15,5,1,1,0,1,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam compared with cefepime in children from ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003244-13,0,0,0 2014-003244-13,5,2017-09-15,2017-09-15,5,1,1,0,1,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam compared with cefepime in children from ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003244-13,0,0,0 2014-003246-26,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,"Hyperion Therapeutics, Inc.","A Phase 2, Fixed-Sequence, Open-Label, Switch-Over Study of the Safety and Tolerability of HPN 100 Compared to Sodium Phenylbutyrate in Children 6–17 Years of Age with Urea Cycle Disorders, with a Lon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003246-26,0,1,1 2014-003247-36,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,"Hyperion Therapeutics, Inc.","A Phase 2, Fixed-Sequence, Open-Label, Switch-Over Study of the Safety and Tolerability of HPN 100 Compared to Sodium Phenylbutyrate in Children 6–17 Years of Age with Urea Cycle Disorders, with a Lon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003247-36,0,1,1 2014-003248-12,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,"Hyperion Therapeutics, Inc.","A Switch-Over, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of HPN-100, Followed by Long-Term Treatment with HPN-100, in Pediatric Subjects under 6 Years of Age with Urea Cycle Disor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003248-12,0,1,1 2014-003249-82,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,"Hyperion Therapeutics, Inc.","A Switch-Over, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of HPN-100, Followed by Long-Term Treatment with HPN-100, in Pediatric Subjects under 6 Years of Age with Urea Cycle Disor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003249-82,0,1,1 2014-003250-13,2,2017-06-05,2017-06-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Theravance Biopharma R&D, Inc.","A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003250-13,0,0,0 2014-003252-31,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University of Turku,Dose response study of Patient Controlled Analgesia (PCA) of Dexmedetomidine in orthopaedic spine surgery patients Itseannosteltavan (PCA) deksmetomidiinin annos-vastetutkimus ortopedisilla selän l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003252-31,0,0,0 2014-003255-54,1,2018-04-24,2018-04-24,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,Gedeon Richter Plc,"A Double-blind, Randomised, Comparative Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Evaluation of RGB-03 and MabThera® Combined with Methotrexate in Rheumatoid Arthritis Patients Dvojitě ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003255-54,0,0,0 2014-003260-20,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Centre,"CHAMP: Children with Arthritis: Monotherapy or Polytherapy. A multicentre, single-blinded, randomized treat to target, one-year follow-up clinical trial in patients with recent onset Juvenile Idiopath...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003260-20,0,0,0 2014-003261-20,1,2017-07-22,2017-07-22,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Hvidovre University Hospital,Dual-Hormone Closed-Loop Glucose Control in Type 1 Diabetes Automatisk regulering af blodsukkeret med insulin og glukagon hos patienter med type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003261-20,0,0,0 2014-003262-25,1,2017-09-05,2017-09-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","An open label, single group assignment design study to correlate soluble ST2 with clinical, endoscopic and histological activity in moderate to severe Ulcerative Colitis patients under golimumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003262-25,0,0,0 2014-003263-37,6,2016-03-14,2016-03-14,5,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Phase 2A Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged ≥6 to <18 Years With Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003263-37,1,1,0 2014-003265-19,1,2016-07-07,2016-07-07,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Genzyme Corporation,A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003265-19,0,0,0 2014-003268-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jules Bordet Institute,Study evaluating breast cancer tumorectomy guided by Near-Infrared imaging after the intravenous injection of free Indocyanine Green,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003268-19,0,0,0 2014-003269-46,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,0,Erasmus MC - Sophia,Pediatric microdosing midazolam: elucidating age-related changes in oral drug absorption,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003269-46,0,0,0 2014-003272-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Jordi Montero Homs- Unidad de Neuromuscular- Servicio de Neurología- Hospital Universitario de Bellvitge,Prospective Pilot Study of the treatment of compression of median nerve neuropathy with Nucleo CMP Forte®. Estudio piloto prospectivo del tratamiento con Núcleo CMP forte en la neuropatia compresiv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003272-23,0,0,0 2014-003273-42,1,2020-04-09,2020-04-09,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU de Nice,Comparing a diuretic vascular filling in the initial management of acute pulmonary embolism with right ventricular dysfunction normotensive Comparaison d’un traitement diurétique au remplissage vas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003273-42,0,0,0 2014-003277-42,9,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,MERUS N.V.,"A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003277-42,0,0,0 2014-003277-42,9,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Merus N.V.,"A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003277-42,0,0,0 2014-003277-42,9,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Merus B.V.,"A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003277-42,0,0,0 2014-003280-38,1,2020-09-02,2020-09-02,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Medical University of Vienna,Positron Emission Tomography assessment of Ketamine Binding of the Serotonin Transporter and its Relevance for Rapid Antidepressant Response Die Rolle des Serotonintransporters bei der akuten anti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003280-38,0,0,0 2014-003282-19,7,2021-10-21,2021-10-21,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in relapsed and refractory Multiple Myeloma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003282-19,1,0,0 2014-003282-19,7,2021-10-21,2021-10-21,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in relapsed and refractory Multiple Myeloma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003282-19,1,0,0 2014-003284-38,1,2019-10-07,2019-10-07,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Evgen Pharma plc,SFX-01 AFTER SUBARACHNOID HAEMORRHAGE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003284-38,0,0,0 2014-003286-21,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,University College Dublin,"A multicentre, interventional, parallel group, randomised, open-label, exploratory study to assess the earlier introduction of Ivabradine in the Management of Systolic Dysfunction Heart Failure. The Q...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003286-21,0,0,0 2014-003294-42,4,2019-06-28,2019-06-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB BIOSCIENCES Inc.,"A MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF INTRAVENOUS LACOSAMIDE IN CHILDREN (≥1 MONTH TO <17 YEARS OF AGE) WITH EPILEPSY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003294-42,0,0,0 2014-003295-23,6,2020-07-13,2020-07-13,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) .",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003295-23,0,0,0 2014-003298-40,1,2017-09-18,2017-09-18,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Instituto de Investigación La Fe,STUDY OF THE EFFICACY AND SAFETY MANAGEMENT OF LIRAGLUTIDE IN TYPE 2 DIABETIC PATIENTS HOSPITALIZED WITH ACUTE CORONARY SYNDROME. IMPACT ON CARDIOVASCULAR RISK FACTOR. ESTUDIO DE LA EFICACIA Y SEGU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003298-40,0,0,0 2014-003299-22,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,TNO.Netherlands Organization for Applied Scientific Research,Effects of Single Dose of Bilastine 20mg on Flying Ability in Healthy Volunteers Under Conditions of Simulated Cabin Pressure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003299-22,0,0,0 2014-003303-30,1,2018-12-20,2018-12-20,1,1,0,0,0,1,3,0,0,1,1,1,1,0,0,Dutch Childhood Oncology Group,TropicALL study; Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a randomized controlled trial TropicALL studie; Tromboprofylaxe in kinde...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003303-30,0,0,0 2014-003304-73,9,2016-12-06,2016-12-06,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1 and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003304-73,0,0,0 2014-003304-73,9,2016-12-06,2016-12-06,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,","A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1 and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003304-73,0,0,0 2014-003304-73,9,2016-12-06,2016-12-06,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1 and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003304-73,0,0,0 2014-003304-73,9,2016-12-06,2016-12-06,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.","A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT1 and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003304-73,0,0,0 2014-003305-15,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,HK Clinical Trials,Prospectuve study on the treatment of normal tension glacuoma with selective laser trabeculoplasty,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003305-15,0,1,1 2014-003306-33,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Radboud university medical center,Liposomal amphotericin B (Ambisome) pharmacokinetics given as a single intravenous dose to obese patients (ASPEN).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003306-33,0,0,0 2014-003307-30,4,2017-04-19,2017-04-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"UCB Celltech, UK Registered Branch of UCB Pharma SA","A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Multiple Doses of UCB4940 Administered as Add-On to Certolizumab Pegol Th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003307-30,0,0,0 2014-003313-28,1,2018-06-29,2018-06-29,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Hannover Medical School,"SGLT2 inhibition with empagliflozin in patients with type 2 diabetes mellitus: Influences on left ventricular mass, function, and cardiac lipid content (EMPATROPHY)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003313-28,0,0,0 2014-003319-12,1,2019-04-23,2019-04-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The Royal Marsden NHS Foundation Trust,Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003319-12,0,0,0 2014-003319-12,1,2019-04-23,2019-04-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The Insitute of Cancer Research,Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003319-12,0,0,0 2014-003320-51,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,CENTRE ANTOINE LACASSAGNE,A phase 1/2 clinical trial to assess safety and efficacy of a new treatment for Hodgkin lymphoma's disease combining Adcetris¿ and Levact¿ in Old patients Studio di fase I/II di valutazione della s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003320-51,0,0,0 2014-003326-41,2,2017-07-24,2017-07-24,1,1,1,0,0,0,3,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Limited,"Randomized, Double-Blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003326-41,0,0,0 2014-003326-41,2,2017-07-24,2017-07-24,1,1,1,0,0,0,3,0,0,1,1,0,1,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"Randomized, Double-Blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003326-41,0,0,0 2014-003330-12,6,2017-07-18,2017-07-18,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SRL,"A double-blind, randomized, placebo-controlled study of the efficacy, safety/tolerability, and pharmacokinetic profile of UCB0942 in adult patients with highly drug-resistant focal epilepsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003330-12,0,0,0 2014-003330-12,6,2017-07-18,2017-07-18,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SPRL,"A double-blind, randomized, placebo-controlled study of the efficacy, safety/tolerability, and pharmacokinetic profile of UCB0942 in adult patients with highly drug-resistant focal epilepsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003330-12,0,0,0 2014-003331-18,1,2016-10-18,2016-10-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, univ. Klinik f. Dermatologie",The influence of occlusive application of 5-aminolaevulinic acid (ALA) on the efficacy of photodynamic therapy for actinic keratosis Einfluß der okklusiven Applikation von 5 Aminolävulinsäure (ALA)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003331-18,0,0,0 2014-003338-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,Role of Nitric Oxide (NO) in pre-oxygenation before anesthetic induction in patients with Pulmonary Hypertension (PH) in cardiac surgery. Feasibility study. Rôle du Monoxyde d'Azote (NO) en pré-ox...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003338-15,0,0,0 2014-003339-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut d'Investigació Sanitària Pere Virgili (IISPV),"Open, randomized, with two parallel treatment groups combined therapy with bleomycin and with bleomycin electrochemotherapy (EQ) in patients with plantar warts large clinical trial virus. Diagnosis an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003339-21,0,0,0 2014-003341-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rijnstate,"Registry of the treatment of primay insufficiency of the great saphenous vein with a diameter >/= 12 mm, anterolateral branches, or great saphenous vein insufficiency below the knee with mechano-chemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003341-10,0,0,0 2014-003343-35,1,2015-12-15,2015-12-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Thomas Fichtner Bendtsen,The effect of saphenous nerve and obturator nerve block combined with systemic high dose glucocorticoid versus local infiltration analgesia combined with a systemic high dose glucocorticoid on opioid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003343-35,0,0,0 2014-003346-27,1,,,0,1,0,1,0,1,1,0,0,1,1,1,0,1,1,"ATYR PHARMA, INC.","An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003346-27,0,0,0 2014-003347-35,4,2017-05-03,2017-05-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003347-35,0,0,0 2014-003347-35,4,2017-05-03,2017-05-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.","A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003347-35,0,0,0 2014-003347-35,4,2017-05-03,2017-05-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003347-35,0,0,0 2014-003351-65,2,2018-06-15,2018-06-15,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,RDD Pharma Ltd.,"The Effect of Intra-anal Nifedipine, Used As Add-on to Conservative Therapy, on Pain in Patients with Anal Fissure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003351-65,0,0,0 2014-003355-56,3,2017-05-08,2017-05-08,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"OncoMed Pharmaceuticals, Inc.","A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane® plus Placebo versus Gemcitabine, Abraxane® plus 1 or 2 Truncated Courses of Demcizumab in Subjects with 1st-Line Metastatic Panc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003355-56,0,0,0 2014-003356-30,4,2017-07-04,2017-07-04,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"OncoMed Pharmaceuticals, Inc.","A 3-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo versus Carboplatin, Pemetrexed plus 1 or 2 Truncated Courses of Demcizumab in Subjects with Non-Squamous Non-Small...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003356-30,0,0,0 2014-003358-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"James Martin Shannon, MB Bch NUI",Intraoperative use of dexamethasone in day-case gynaecological surgery and its impact on sleep quality in the postoperative period.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003358-15,0,0,0 2014-003369-50,1,2015-08-20,2015-08-20,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,PASCOE pharmazeutische Präparate GmbH,"Proof of effectiveness of Pascoflair using qantitative measurement of electric brain activity during examination stress in 40 subjects suffering from test anxiety. A double-blind, randomized, placebo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003369-50,0,0,0 2014-003371-34,2,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Basilea Pharmaceutica International Ltd.,An open-label Phase 1/2a study of oral BAL101553 in adult patients with advanced solid tumors and in adult patients with recurrent or progressive glioblastoma or high-grade glioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003371-34,0,0,0 2014-003372-23,1,,,0,0,1,0,0,1,2,0,0,4,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2, Open-label, Multicenter, Single-arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antimycobacterial Activity of TMC207 in Combination With a Background Regimen (BR) of Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003372-23,0,1,1 2014-003380-38,1,2014-11-05,2014-11-05,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"R&D department, Hull and East Yorkshire Hospitals NHS Trust",The effect of oxygen on exercise performance in chronic heart failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003380-38,0,0,0 2014-003382-17,7,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA? Once-Daily in Treatment-Naïve ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003382-17,0,0,0 2014-003384-38,11,2016-10-18,2016-11-18,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MULTIPLE DUPILUMAB DOSE REGIMENS ADMINISTERED AS MONOTHERAPY FOR MAINTAINING TREATMENT RESPONSE I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003384-38,0,0,0 2014-003384-38,11,2016-10-18,2016-11-18,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"REGENERON PHARMACEUTICALS, INC.","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MULTIPLE DUPILUMAB DOSE REGIMENS ADMINISTERED AS MONOTHERAPY FOR MAINTAINING TREATMENT RESPONSE I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003384-38,0,0,0 2014-003385-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"GGZ inGeest, parner VUmc","The Recall-study: Rivastigmine for ECT-induced Cognitive Adverse effects in Late Life Depression: a multicenter, randomized, double-blind, placebo-controlled, crossover trial De Recall studie: Riv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003385-24,0,0,0 2014-003386-22,1,2016-05-11,2016-05-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Sophiris Bio Corp,"A Single Centre, Open Label, Phase IIa Study, Evaluating the Safety and Tolerability of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Significant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003386-22,0,0,0 2014-003388-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Masarykova univerzita,"COMBINED ANTITUMOR THERAPY WITH EX VIVO MANIPULATED DENDRITIC CELLS PRODUCING INTERLEUKIN-12 IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH PROGRESSIVE, RECURRENT OR PRIMARILY METASTATIC HIGH-RISK TUM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003388-39,0,0,0 2014-003389-26,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Birmingham,Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003389-26,0,0,0 2014-003392-32,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Cardiff University,"A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003392-32,0,0,0 2014-003392-32,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Velindre NHS Trust,"A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003392-32,0,0,0 2014-003395-23,1,2016-04-01,2016-04-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Section for Surgical Pathophysiology, Rigshospitalet","Effect of preoperative intravenous highdose methylprednisolone on quadriceps muscle function, endothelial function, complement activation and glucose homeostasis in patients scheduled for total knee-a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003395-23,0,0,0 2014-003400-70,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,AstraZeneca K.K.,"A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MEDI3250 Compared to Placebo in Healthy Japanese Children age 7 years through 18 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003400-70,0,1,1 2014-003401-15,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,AstraZeneca K.K.,A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children age 2 years through 6 years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003401-15,0,1,1 2014-003402-33,2,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,"ChemoCentryx, Inc.",An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003402-33,0,0,0 2014-003403-29,1,2019-06-11,2019-06-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Innsbruck Medical University,Pharmacokinetics of trimethoprim-sulfametrole in critically ill patients on continuous veno-venous haemofiltration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003403-29,0,0,0 2014-003408-65,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Edinburgh,Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003408-65,0,0,0 2014-003408-65,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,NHS Lothian,Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003408-65,0,0,0 2014-003409-13,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,CSL Behring,A Multicenter Study of Long-Term Clinical Outcomes of Immune Globulin Subcutaneous (Human) (SCIG) IgPro20 in Subjects with Primary Immunodeficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003409-13,0,1,1 2014-003412-37,1,2018-12-19,2018-12-19,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Keele University,Improving outcomes for patients with hip osteoarthritis: a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003412-37,0,0,0 2014-003413-28,5,2016-04-11,2016-04-11,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase 2, Open-label Study to Investigate the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003413-28,0,0,0 2014-003418-10,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI IRST - IRCCS,PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 90Y-DOTATOC IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL AND MANTLE CELL LYMPHOMAS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003418-10,0,0,0 2014-003419-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA SAN GERARDO, MONZA, ITALIA","A Pilot Randomized Controlled Trial of Switch to tenofovir disoproxil fumarate/emtricitabine/rilpivirine (TDF/FTC/RPV) versus continue TDF/FTC/efavirenz (EFV) treatment among virologically suppressed,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003419-12,0,0,0 2014-003420-46,4,2015-11-30,2017-03-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mylan GmbH (Mylan),"Multicenter, Double-Blind, Randomized, 2-Arm, Parallel-Group, Equivalence Study Evaluating Efficacy and Safety Similarity of Mylan Adalimumab (MYL-1401A) Compared With Humira® in Subjects With Moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003420-46,0,0,0 2014-003422-41,1,2018-02-01,2018-02-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Oulu University Hospital, Department of Internal Medicine",The effects of PXR activation on hepatic fat content PXR-aktivaation vaikutus maksan rasvoittumiseen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003422-41,0,0,0 2014-003423-21,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Bellerophon Pulse Technologies LLC,"An Exploratory, Two-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects with World Health Organization (WHO) Group 3 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003423-21,0,0,0 2014-003425-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Debreceni Egyetem Klinikai Központ,"Az optimális premedikációs stratégia kidolgozása fogyatékkal élő betegek altatásos fogászati beavatkozásaihoz;orális midazolam, valamint két különböző dózisú intranasalis dexmedetomidine hatásainak ö...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003425-18,0,0,0 2014-003432-39,1,2016-03-14,2016-03-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University","A 24-week, single centre, randomized, parallel-group, double-blind, placebo controlled Phase II study to evaluate the efficacy on body weight of dapagliflozin 10 mg once daily in combination with exen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003432-39,0,0,0 2014-003434-93,3,2017-01-24,2017-01-24,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003434-93,1,0,0 2014-003434-93,3,2017-01-24,2017-01-24,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Isis Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003434-93,1,0,0 2014-003436-39,1,2019-07-22,2019-07-22,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Tolérance et acceptabilité d'une suspension de glibenclamide (GLIBENTEK) chez des enfants ayant un diabète sucré rare secondaire à une mutation des canaux potassiques ATP-dépendants (Kir6.2 ou SUR1),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003436-39,0,0,0 2014-003437-26,5,2018-03-29,2018-03-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Clovis Oncology, Inc","TIGER-3: A Phase 3, Open-Label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003437-26,0,0,0 2014-003437-26,5,2018-03-29,2018-03-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"CLOVIS ONCOLOGY, INC","TIGER-3: A Phase 3, Open-Label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003437-26,0,0,0 2014-003438-20,5,2022-04-14,2022-07-19,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Astra Zeneca AB,"A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician's Choice Single Agent Chemotherapy in the Treatment of Pl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003438-20,1,0,0 2014-003438-20,5,2022-04-14,2022-07-19,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ASTRAZENECA AB,"A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician's Choice Single Agent Chemotherapy in the Treatment of Pl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003438-20,1,0,0 2014-003443-35,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,AVEO Pharmaceuticals,"A Phase 2, multicenter, randomized, double-blind study of ficlatuzumab plus erlotinib versus placebo plus erlotinib in subjects who have previously untreated metastatic, EGFR-mutated non-small cell lu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003443-35,0,0,0 2014-003446-27,1,2015-12-23,2015-12-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen R&D Ireland,"A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination with Sofosbuvir in Treatment-Naïve or -Experienced Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003446-27,0,0,0 2014-003453-34,8,2017-12-29,2017-12-29,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheumatoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003453-34,0,0,0 2014-003453-34,8,2017-12-29,2017-12-29,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheumatoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003453-34,0,0,0 2014-003455-61,1,2020-01-15,2020-01-15,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Tayside Academic Sciences Centre,Perindopril and Leucine to improve muscle function in older people,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003455-61,0,0,0 2014-003457-34,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Charité - Universitätsmedizin Berlin,"Safety of autologous CardAP-cells in patients with dilatative cardiomyopathy: an open, monocentric, double-arm, 3+3 dose escalation, phase I/II study Sicherheit autologer CardAP-Zellen in Patienten...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003457-34,0,0,0 2014-003459-76,2,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,0,"Istituto Auxologico Italiano, IRCCS",REducing blood pressure Variability in Essential hypertension with RAmipril vErsus Nifedipine GITS Trial Riduzione della variabilità della pressione arteriosa nell’ipertensione essenziale con ramip...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003459-76,0,0,0 2014-003466-25,1,2017-05-01,2017-05-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Anders Gadegaard Jensen,Anesthesia and Intensive Care Unit, Odense University Hospital","Randomized, double-blind, prospective, placebo-controlled trial of the effect of intravenous lidocaine infusion for postoperative pain management and bowel function in robot assisted laparoscopic colo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003466-25,0,0,0 2014-003467-37,1,2020-09-24,2020-09-24,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,CHU de Toulouse,"Evaluation of Ixazomib, Lenalidomide, Dexamethasone Induction and extended Consolidation followed by Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 years eligible for High D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003467-37,0,0,0 2014-003468-19,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,VU University Medical Center,The effects of hyperoxia on organ dysfunction and outcome in critically ill patients with SIRS Het effect van hyperoxie op orgaan dysfunctie en overleving in Intensive Care patienten met SIRS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003468-19,0,0,0 2014-003469-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU University Medical Center,The application of contrast-enhanced ultrasound to facilitate thrombolysis in patients with acute peripheral arterial occlusions.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003469-10,0,0,0 2014-003470-17,3,2015-10-10,2015-10-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Krka, d.d. Novo mesto","The efficacy and safety of olmesartan medoxomil/amlodipine fixed combination in patients with grade 1 to grade 2 arterial hypertension. An international randomized, double-blind, 10-week multi-factori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003470-17,0,0,0 2014-003473-42,1,2018-12-31,2018-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Nottingham,Home Interventions and Light therapy for the treatment of vitiligo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003473-42,0,0,0 2014-003474-16,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Helsinki University Hospital,Immune response elicited by concomitant administration of oral typhoid fever (Vivotif®) and cholera (Dukoral®) vaccines Samanaikaisesti annosteltujen suun kautta otettavien lavantauti (Vivotif®) ja...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003474-16,0,0,0 2014-003479-52,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Maastricht University Medical Centre,"Surgical excision versus combined therapy with Curettage and Imiquimod for the treatment of Nodular Basal Cell Carcinoma: an open, non-inferiority, randomized controlled trial Chirurgische excisie ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003479-52,0,0,0 2014-003480-37,3,2020-12-10,2020-12-10,1,1,1,0,0,1,2,0,0,2,0,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients with CLN2 Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003480-37,1,0,0 2014-003481-25,1,2018-05-07,2018-05-07,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Universitätsklinikum Münster,"A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis Eine 24-w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003481-25,0,0,0 2014-003482-25,4,2018-09-27,2018-09-27,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Service AG,"A 28 week, randomized, double-blind, placebo-controlled, two-part, multi-center, parallel group dose range finding study to assess the effect of monthly doses of bimagrumab 70, 210, and 700 mg on skel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003482-25,0,0,0 2014-003482-25,4,2018-09-27,2018-09-27,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 28 week, randomized, double-blind, placebo-controlled, two-part, multi-center, parallel group dose range finding study to assess the effect of monthly doses of bimagrumab 70, 210, and 700 mg on skel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003482-25,0,0,0 2014-003482-25,4,2018-09-27,2018-09-27,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A 28 week, randomized, double-blind, placebo-controlled, two-part, multi-center, parallel group dose range finding study to assess the effect of monthly doses of bimagrumab 70, 210, and 700 mg on skel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003482-25,0,0,0 2014-003484-38,1,2019-02-25,2019-02-25,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Essai randomisé versus placebo, en double aveugle, de l'efficacité d'un anticorps humanisé dirigé contre le récepteur soluble de l'IL6 (tocilizumab) chez des patients souffrant d'une arthrose digitale...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003484-38,0,0,0 2014-003485-24,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc.","A Phase 1, Non-comparative, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Ceftolozane/tazobactam in Pediatric Patients Receiving Standard of Care Antibiotic The...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003485-24,0,1,1 2014-003486-14,2,2018-09-12,2018-09-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"UCB Biopharma, SPRL","A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-group Study Followed by a Dose-blind Period and Open-label Follow-up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003486-14,0,0,0 2014-003490-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"PROF.BRUNANGELO FALINI,DR.SSA MARIA PAOLA MARTELLI,UNIVERSITA' DI PERUGIA","A PHASE 2A STUDY ON THE CLINICAL ACTIVITY AND SAFETY OF ACTINOMYCIN-D IN PATIENTS WITH NPM1-MUTATED AML AGED =70 YEARS AND/OR UNFIT FOR INTENSIVE CHEMOTHERAPY, EITHER NEWLY DIAGNOSED OR PREVIOUSLY TRE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003490-41,0,0,0 2014-003491-23,1,2016-03-09,2016-03-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,AIBILI – Association for Innovation and Biomedical Research on Light and Image,"A non-randomised, open-label, multicenter phase 4 pilot study on the effect and safety of Iluvien® in chronic diabetic macular edema patients considered insufficiently responsive to available therapie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003491-23,0,0,0 2014-003492-36,8,2018-12-17,2018-12-17,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"UCB Biopharma, SPRL","A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- And Active-Controlled Study Followed By A Placebo-Controlled Maintenance Period And Open-Label Follow-Up To Evaluate The Effi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003492-36,0,0,0 2014-003496-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"University Hospital, Limoges","Designing a Bayesian model of the plasma clearance of Calcium edetate de sodium, with a limited sampling strategy for the calculation of Glomerular Filtration Rate (GFR) and validity assessment compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003496-29,0,0,0 2014-003498-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Vienna,Effects of dalfampridine on mobility in the context of daily life,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003498-41,0,0,0 2014-003501-15,1,2017-11-30,2017-11-30,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Reata Pharmaceuticals, Inc.","A PHASE 2 STUDY OF THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF RTA 408 IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003501-15,0,0,0 2014-003502-33,2,2016-08-29,2016-08-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel group, Phase 3 Trial to Evaluate the Safety and Efficacy of Once Weekly Exenatide Therapy Added to Titrated Basal Insulin Glargine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003502-33,0,0,0 2014-003503-29,2,2017-12-28,2017-12-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 28-week, Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study with a 24-week Extension Phase Followed by a 52-week Extension Phase to Evaluate the Efficacy and Safety of Simultane...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003503-29,0,0,0 2014-003504-79,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,"Novartis Vaccines & Diagnostics, Inc.","A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Evaluate the Lot to Lot Consistency of Investigational Meningococcal ACWY Conjugate Vaccine when One Dose is Administered to He...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003504-79,0,1,1 2014-003509-13,5,2018-02-21,2018-02-21,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TAKEDA DEVELOPMENT CENTRE EUROPE LTD,An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003509-13,0,0,0 2014-003509-13,5,2018-02-21,2018-02-21,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Takeda Development Centre Europe Ltd,An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003509-13,0,0,0 2014-003510-82,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNICANCER,"_ Essai de phase III, randomisé, comparant une chimiothérapie par Folfirinox à la gemcitabine dans le traitement du cancer pancréatique localement avancé",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003510-82,0,0,0 2014-003511-11,6,2015-11-19,2015-11-19,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Two-part, Open-label, Randomised, Crossover, Multicentre, Phase II Study to Investigate the Presence of Pancreatic Exocrine Insufficiency (PEI) in Patients with Type 2 Diabetes Mellitus, and to Inve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003511-11,0,0,0 2014-003512-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jules Bordet Institute,Study of the (intravenously injected) ICG (Indocyanine Green) imaging of tumoral implants in patients with peritoneal carcinomatosis from colorectal origin.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003512-37,0,0,0 2014-003513-28,3,2018-10-24,2018-10-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"UCB Biopharma, SPRL","A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group Study Followed by a Dose-blind Period and Open Label Follow-up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003513-28,0,0,0 2014-003514-91,1,,,0,1,1,0,1,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Compare the Safety of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine with that of a Licensed Meningococcal ACWY Poly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003514-91,0,1,1 2014-003527-22,14,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or ruxolitinib and panobinostat (LBH589)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003527-22,0,0,0 2014-003527-22,14,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,NOVARTIS FARMA S.P.A.,"An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or ruxolitinib and panobinostat (LBH589)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003527-22,0,0,0 2014-003527-22,14,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study or ruxolitinib and panobinostat (LBH589)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003527-22,0,0,0 2014-003529-16,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,0,Joint Research & Development Office (QMUL),"Stratification of Biologic Therapies for RA by Pathobiology (STRAP): A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, Toc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003529-16,0,0,0 2014-003532-39,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Leiden University Medical Center,The effect of sitagliptin on brown adipose tissue and whole-body metabolism in overweight pre-diabetic men,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003532-39,0,0,0 2014-003540-12,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,NewLink Genetics Corporation,"A Phase 2 Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination with a Taxane Chemotherapy in Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003540-12,0,0,0 2014-003543-35,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Ghent University Hospital,"A clinical study to generate a set of data characterising clinical events, physiological responses, and innate and adaptive immune responses following a single intramuscular immunisation with FluadTM ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003543-35,0,0,0 2014-003544-12,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,. EFFET DE L'ADMINISTRATION PREVENTIVE DE CICLOSPORINE A CHEZ LE DONNEUR D'ORGANES SUR LA FONCTION DES REINS TRANSPLANTES : ETUDE RANDOMISEE CONTROLEE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003544-12,0,0,0 2014-003546-27,1,2017-12-19,2017-12-19,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,Universitätsklinikum Bonn,Chromoendoscopy versus conventional endoscopy in Patients with polyposis syndrome Chromoendoskopie versus konventionelle Endoskopie bei Patienten mit Polyposis-Erkrankungen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003546-27,0,0,0 2014-003547-35,4,2016-06-01,2016-06-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Interventional, open-label, flexible-dose, long-term study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in elderly patients with major depressive disorder with an i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003547-35,0,0,0 2014-003549-90,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Landstinget Sörmland Landstingskansliet, Hälso-och Sjukvårdsledningen",Is it possible to improve humoral response to TBE vaccine in elderly (50+ year olds) by means of changed dosage intervals/number of doses?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003549-90,0,0,0 2014-003552-31,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Kinderkrankenhaus AUF DER BULT,"A Randomized, Double-Blind, Placebo-controlled, Single-center Phase 1 Pilot Study to Explore the Safety and Pharmacokinetics of a Single-Dose of DAPAglifozin as Add-on to Intravenous Insulin-Infusion ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003552-31,0,0,0 2014-003556-31,5,2021-09-28,2021-09-28,4,1,0,0,0,1,0,0,0,2,0,0,0,0,1,"Premacure AB, A Member of the Shire Group of Companies",Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003556-31,1,0,0 2014-003556-31,5,2021-09-28,2021-09-28,4,1,0,0,0,1,0,0,0,2,0,0,0,0,1,"PREMACURE AB, A MEMBER OF SHIRE GROUP OF COMPANIES",Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003556-31,1,0,0 2014-003558-15,6,2016-07-01,2016-07-01,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003558-15,0,0,0 2014-003561-15,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,University Hospital of Tuebingen,Safety and Tolerance of Immunomodulating Therapy with Donor-specific Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation Sicherheit und Verträglichkeit der Anwendung von Mesench...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003561-15,0,0,0 2014-003563-38,9,2016-07-18,2017-03-15,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Amgen, Inc.",A Multicenter Single-arm Extension Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects With Chronic Kidney Di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003563-38,1,1,0 2014-003563-38,9,2016-07-18,2017-03-15,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Amgen, Ltd",A Multicenter Single-arm Extension Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects With Chronic Kidney Di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003563-38,1,1,0 2014-003569-12,7,2018-10-08,2018-10-18,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Interventional, randomised, double-blind, active-controlled, fixed-dose study of Lu AF35700 in patients with Treatment-resistant Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003569-12,0,0,0 2014-003572-23,1,2018-11-20,2018-11-20,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Gamida Cell Ltd,"Allogeneic Stem Cell Transplantation of CordIn™, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies Greffe allogénique de cellules souches...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003572-23,0,0,0 2014-003573-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Västra Götalandsregionen,Antibody-mediated immune response after immunization with FSME-Immun(R) against Tick Borne Encephalitis(TBE) after hematopoietic autologous and allogeneic stem cell transplantation. Studie av antik...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003573-42,0,0,0 2014-003574-16,5,2021-07-23,2021-07-23,4,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.",A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003574-16,1,0,0 2014-003575-38,7,2016-07-06,2016-07-06,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Baxalta Innovations GmbH,"A PHASE 3 PROSPECTIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF rVWF WITH OR WITHOUT ADVATE IN ELECTIVE SURGICAL PROCEDURES IN SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003575-38,0,0,0 2014-003575-38,7,2016-07-06,2016-07-06,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Baxter Innovations GmbH,"A PHASE 3 PROSPECTIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF rVWF WITH OR WITHOUT ADVATE IN ELECTIVE SURGICAL PROCEDURES IN SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003575-38,0,0,0 2014-003576-23,4,2018-01-23,2018-01-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GUERBET,"P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) Studio di ricerca della dose di P03277 in risonanze magnetiche per immagini (Magnetic Resonance Imaging, M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003576-23,0,0,0 2014-003578-17,2,2018-08-24,2018-08-24,1,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- RBV in Adolescents and Children with Chronic HCV-Infec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003578-17,1,1,0 2014-003581-25,1,2019-09-30,2019-09-30,1,1,0,0,0,1,3,0,0,1,1,1,1,0,0,University Hospital Tuebingen,"Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - Randomised, double-blind, placebo-controlled cohort trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003581-25,0,0,0 2014-003582-24,7,2018-11-12,2018-11-12,2,1,1,0,0,0,3,0,0,1,1,0,1,0,0,Universitätsklinikum Erlangen,"A double blind, randomised, multicentre, active controlled, parallel-group, phase III trial to evaluate the efficacy, safety and pharmacokinetics of intravenous clonidine (hydrochloride) compared to m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003582-24,0,0,0 2014-003583-20,2,2019-09-17,2019-09-17,2,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc","A 34-week Follow-up to: A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy MK-0431A (A Fixed-Dose Combination Tablet of Sitaglipt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003583-20,0,0,0 2014-003583-20,2,2019-09-17,2019-09-17,2,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co. Inc.","A 34-week Follow-up to: A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy MK-0431A (A Fixed-Dose Combination Tablet of Sitaglipt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003583-20,0,0,0 2014-003588-39,1,2019-02-05,2019-02-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Birmingham,Torch: A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed refractory DLBCL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003588-39,0,0,0 2014-003589-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sahlgrenska Universitetssjukhuset/Sahlgrenska,"The effect of levosimendan, on renal blood flow, function and oxygen uptake during acute renal failure after cardiac surgery Effekten av levosimendan, en hjärtstimulerande medicin, på njurens blodf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003589-25,0,0,0 2014-003590-41,1,2015-08-25,2015-08-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Engelhard Arzneimittel GmbH & Co.KG,"Randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety of a liquid containing ivy leaves dry extract vs. placebo in the treatment of acute cough Randomisierte,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003590-41,0,0,0 2014-003595-23,1,,,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,Watson Laboratories Inc.,"A double-blinded, parallel-group, randomized, single dose study to assess the pharmacokinetic bioequivalence of ciprofloxacin (0.3%) and dexamethasone (0.1%) otic suspension (Indoco for Actavis) versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003595-23,0,0,0 2014-003596-27,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Asociación de Oncología Médica del Hospital de Cruces (ASONMEC),"A Phase II Study of Nab-paclitaxel and Gemcitabine, in Elderly Patients with Previously Untreated, Metastatic Pancreatic Adenocarcinoma Estudio fase II de nab-paclitaxel y gemcitabina en pacientes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003596-27,0,0,0 2014-003597-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Josep Llop Talaveron,"Pilot, randomized, double-blind clinical trial to determine the phytosterolaemia in hospitalized patients treated with total parenteral nutrition and gamma-glutamyltransferase alteration ENSAYO CLÍ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003597-17,0,0,0 2014-003598-41,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,CUB - Hôpital Erasme,Pilot study of incretin analogs as new therapeutics for Friedreich's Ataxia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003598-41,0,0,0 2014-003599-21,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,Sociedad Española de Cardiología,Platelet reactivity after TAVI: A multicenter randomized clinical trial Evalaución de la REACtividad plaquetaria Tras la implAntacion de Valvula aortIca percutanea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003599-21,0,0,0 2014-003601-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital,"ACETYLSALICYLIC ACID AS SECONDARY PREVENTION IN COLORECTAL CANCER (ASAC TRIAL) A multi-centre, double-blinded, randomized, placebo-controlled clinical intervention trial with ASA in patients undergoin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003601-15,0,0,0 2014-003602-32,1,2016-12-22,2016-12-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Limoges,Comparison of Efficacy and Safety of Metvixia® Natural Daylight Photodynamic Therapy Versus Conventional Metvixia® Photodynamic Therapy in patients With grade I and II actinic keratosis of the scalp: ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003602-32,0,0,0 2014-003604-75,3,2019-10-16,2019-10-16,3,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Novartis Pharma AG,"A Phase Ib/II, open-label, multicenter study of oral HDM201 in combination with oral LEE011 in adult patients with liposarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003604-75,0,0,0 2014-003604-75,3,2019-10-16,2019-10-16,3,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Novartis Pharma Services AG,"A Phase Ib/II, open-label, multicenter study of oral HDM201 in combination with oral LEE011 in adult patients with liposarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003604-75,0,0,0 2014-003604-75,3,2019-10-16,2019-10-16,3,1,0,1,0,0,1,0,0,1,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase Ib/II, open-label, multicenter study of oral HDM201 in combination with oral LEE011 in adult patients with liposarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003604-75,0,0,0 2014-003605-15,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,CSL Behring AG,"A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (PID)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003605-15,0,1,1 2014-003607-30,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,CSL Behring AG,"A Phase III Open-Label, Prospective, Multicenter Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human), IgPro20 in Subjects With Primary Immunodefic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003607-30,0,1,1 2014-003608-61,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,CSL Behring,"A Multicenter Study of Efficacy, Safety, Tolerability, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003608-61,0,1,1 2014-003609-14,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,CSL Behring,"A Multicenter Follow-up Study of Long-term Safety, Tolerability, and Efficacy of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003609-14,0,1,1 2014-003610-86,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,"A double blind randomized controlled trial comparing the efficacy of 7% lidocaine / 7% tetracaine cream versus 2,5% lidocaine / 2,5% prilocaine cream for local anaesthesia during laser treatment of ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003610-86,0,0,0 2014-003613-28,5,2016-01-27,2016-01-27,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, vehicle controlled, active comparator, parallel group study to evaluate safety, tolerability and preliminary efficacy of topical LFX453 formulations in patients with actinic keratosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003613-28,0,0,0 2014-003614-87,1,2017-12-31,2017-12-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Oslo University Hospital,"Novel Imaging of the Eustachian Tube, a CT study using dilute iodixanol in an adult population",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003614-87,0,0,0 2014-003621-18,6,2016-10-05,2016-10-05,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,DUAL?VII - Insulin degludec/liraglutide (IDegLira) vs. basal-bolus therapy: A clinical trial comparing efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in subj...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003621-18,0,0,0 2014-003622-41,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,UCB Pharma SA,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Uncontroll...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003622-41,0,1,1 2014-003625-17,8,2021-11-04,2021-11-12,6,1,0,0,0,2,2,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003625-17,1,0,0 2014-003625-17,8,2021-11-04,2021-11-12,6,1,0,0,0,2,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003625-17,1,0,0 2014-003626-40,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003626-40,0,0,0 2014-003626-40,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003626-40,0,0,0 2014-003629-16,1,2020-01-27,2020-01-27,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"University Hospital/Inselspital Berne, Department for Medical Oncology",A randomized phase II trial comparing BeEAM with BEAM as conditioning regimen for autologous stem cell transplantation (ASCT) in lymphoma patients (BEB-trial).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003629-16,0,0,0 2014-003630-23,13,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003630-23,0,0,0 2014-003630-23,13,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003630-23,0,0,0 2014-003637-26,1,2016-05-26,2016-05-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZenenca AB,"A double-blind randomized placebo-controlled, parallel-group 12 week study to investigate the effects of Epanova® compared to placebo and compared to Fenofibrate on liver Fat content in hypertriglyce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003637-26,0,0,0 2014-003638-26,1,2015-12-11,2015-12-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A double-blind randomized placebo-controlled, parallel-group 12 week study to investigate the effects of Epanova® and dapagliFlozin on liver Fat contEnt in type 2 diabetiC patienTs;",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003638-26,0,0,0 2014-003641-95,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Nicasio Pérez Castellano,Randomized clinical trial to study effective pharmacological cardioversion of paroxysmal atrial fibrillation by blocking ionic currents atrioselectivas by treatment with vernakalant vs Flecainide E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003641-95,0,0,0 2014-003642-26,3,2019-01-21,2019-01-21,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Orion Corporation Orion Pharma,"SAFETY AND PHARMACOKINETICS OF ODM-204 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): OPEN, NONRANDOMISED, UNCONTROLLED, MULTICENTRE, DOSE ESCALATION, FIRST-IN-MAN STUDY WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003642-26,0,0,0 2014-003644-12,1,2018-04-04,2018-04-04,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Neuromuscular Research Unit, Rigshospitalet",The effect of Triheptanoin in adults with McArdle Disease (Glycogen Storage Disease Type V) Effekten af Triheptanoin hos voksne med McArdle sygdom (Glycogen Storage Disease Type V),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003644-12,0,0,0 2014-003645-10,1,2017-05-01,2017-05-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Department of Endocrinology and Internal Medicine,Physiological interactions between the adrenal- and the parathyroid glands described by controlled clinical trials Fysiologiske interaktioner mellem binyre- og parathyroideaaksen belyst ved kontrol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003645-10,0,0,0 2014-003647-34,1,2020-06-03,2020-06-03,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,University Hospital Ulm,Phase Ib/IIa study of palbociclib in MLL-rearranged acute leukemias Eine Phase Ib/IIa Studie zur Therapie mit Palbociclib bei Patienten mit akuter Leukämie und einer Veränderung im MLL-Gen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003647-34,0,0,0 2014-003651-54,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMCG,‘Off-label use of Risperidone in Children and Adolescents (ORCA): a double-blind placebo-controlled discontinuation trial’,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003651-54,0,0,0 2014-003655-66,10,2022-07-26,2022-07-26,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Phase 3, Randomized, Double-Bind, Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003655-66,1,0,0 2014-003655-66,10,2022-07-26,2022-07-26,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Phase 3, Randomized, Double-Bind, Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003655-66,1,0,0 2014-003655-66,10,2022-07-26,2022-07-26,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Lilly S.A,"A Phase 3, Randomized, Double-Bind, Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003655-66,1,0,0 2014-003656-31,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003656-31,0,0,0 2014-003657-33,2,2018-09-24,2018-09-24,2,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Biogen Idec Research Limited,"A phase 2, randomized, double-blind, sham-procedure controlled study to assess the safety and tolerability and explore the efficacy of ISIS 396443 (BIIB058) administered intrathecally in subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003657-33,0,0,0 2014-003661-18,1,2017-01-01,2017-01-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Hospices Civils de Lyon,Phase II study evaluating the efficacy of aflibercept for the treatment of choroidal neovascularization complicating angioid streaks in young subjects: the ASTRID study Etude ASTRID Etude de phase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003661-18,0,0,0 2014-003666-25,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,NOVARTIS PHARMA S.A.S,"A 52-week, single-arm study to evaluate psoriasis severity and its psychosocial impact using the Simplified Psoriasis Index at 16 weeks, as well as long-term safety, tolerability and efficacy of secuk...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003666-25,0,0,0 2014-003667-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Riitta Veijola,Incretin-based therapy in preclinical type 1 diabetes in adults. Inkretiini-perusteinen tyypin 1 diabeteksen esiasteen hoito aikuisilla.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003667-37,0,0,0 2014-003669-97,1,2017-04-10,2017-04-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Biogen Idec,"A Multicenter, Open-Label Safety Study of Natalizumab administered to Subjects with Relapsing Forms of Multiple Sclerosis who participated in STRATA. Een multicenter, open label veiligheidsstudie v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003669-97,0,0,0 2014-003671-30,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,0,ALIANZA ESPAÑOLA DE FAMILIAS DE VON HIPPEL-LINDAU,"Therapeutic effect of propranolol in a series of patients with von Hippel-Lindau disease and retinal hemangioblastomas in short, medium and long term treatment. Efecto terapéutico de propranolol en...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003671-30,0,0,0 2014-003673-42,3,2018-11-02,2018-11-22,2,1,0,0,0,0,2,0,0,1,1,0,1,0,2,"Merrimack Pharmaceuticals, Inc.","A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003673-42,0,0,0 2014-003679-48,2,2017-05-17,2017-05-17,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF alpha Naive Subjects With Active Radiographic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003679-48,0,0,0 2014-003680-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,VU university medical center,Pharmacokinetics of two different high dose regimes of intravenous vitamin C in critically ill patients Farmacokinetiek van twee verschillende hoge doseerregimes van intraveneus vitamine C bij IC p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003680-38,0,0,0 2014-003688-39,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Cutanea Life Sciences,"A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Efficacy and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of Digoxin and Furosemide in Cuta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003688-39,0,0,0 2014-003689-26,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Cutanea Life Sciences,"A randomized, double-blind, placebo controlled study to assess the pharmacodynamics, safety/tolerability and efficacy of omiganan in patients with mild to moderate atopic dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003689-26,0,0,0 2014-003691-23,1,2021-12-01,2021-12-01,1,1,0,0,1,0,4,0,0,1,0,0,0,0,0,Maastricht Universitair Medisch Centrum,Topical Ingenol mebutate versus 5% 5-fluorouracil versus 5% Imiquimod versus photodynamic therapy in the treatment of actinic keratosis: a multi-center randomized efficacy and cost-effectiveness study...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003691-23,0,0,0 2014-003695-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Phase II study evaluating the efficacy of aflibercept for the treatment of inflammatory choroidal neovascularization in young subjects: the ALINEA study Etude ALINEA : Etude de phase II évaluant l’...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003695-23,0,0,0 2014-003697-17,3,2017-01-17,2017-01-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003697-17,0,0,0 2014-003698-41,16,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co. Inc.",A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003698-41,0,0,0 2014-003698-41,16,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003698-41,0,0,0 2014-003701-15,2,2015-05-28,2015-05-28,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Amgen Inc.,"A Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Axial Spondyloarthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003701-15,0,0,0 2014-003702-33,1,2019-01-22,2019-01-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Birmingham,IMPRESS-AF: IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003702-33,0,0,0 2014-003707-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),ETUDE PILOTE DE L'EFFET DU PRIVIGEN SUR DES PATIENTS TRANSPLANTES RENAUX A RISQUE DE PERTE DU GREFFON PAR REJET HUMORAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003707-30,0,0,0 2014-003708-62,2,2016-09-21,2016-09-21,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A 32-week randomised, multinational, treat-to-target, open label, parallel group comparison of stepwise insulin intensification of biphasic insulin aspart (BIAsp) 30 and basal-bolus therapy with insul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003708-62,0,0,0 2014-003710-84,1,2016-08-02,2016-08-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London,The Central Nervous System Effects of Two Different HIV-Integrase Inhibitor Containing Antiretroviral Regimens.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003710-84,0,0,0 2014-003713-28,1,2015-09-22,2015-09-22,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Univeritetssjukhuset Örebro,What is the post operative opioid-reducing effect of the beta-receptor-agonist esmolol when administered during laparoscopic gastric by-pass surgery? Comparison between standard anesthesia and anesthe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003713-28,0,0,0 2014-003713-28,1,2015-09-22,2015-09-22,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Universitetssjukhuset Örebro,What is the post operative opioid-reducing effect of the beta-receptor-agonist esmolol when administered during laparoscopic gastric by-pass surgery? Comparison between standard anesthesia and anesthe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003713-28,0,0,0 2014-003716-36,1,2017-02-24,2017-02-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MedImmune Limited, a wholly owned subsidiary of AstraZeneca","A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Overweight and Obese Subjects with a Hist...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003716-36,0,0,0 2014-003717-29,7,2020-07-06,2020-07-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003717-29,0,0,0 2014-003718-10,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,UMCG,A placebo-controlled discontinuation trial of off-label used risperidone in people with intellectual disability Een placebo-gecontroleerde afbouwstudie naar off-label risperidon gebruik door mensen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003718-10,0,0,0 2014-003720-43,1,2020-12-31,2020-12-31,1,0,0,0,1,0,3,0,0,1,0,0,1,0,0,Fakultní nemocnice Ostrava,"""Prevention of nicotine abstinence in critically ill patients after major surgery"" „Prevence nikotinové abstinence u kriticky nemocných pacientů po velkých chirurgických výkonech“",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003720-43,0,0,0 2014-003721-18,6,2019-09-18,2019-09-18,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial with a Blinded 104-week Long -term Extension Period to Evaluate the Efficacy and Safety...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003721-18,0,0,0 2014-003722-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Istituto Oncologico Veneto – IOV‐IRCCS,"Regorafenib in relapsed glioblastoma. REGOMA study Randomized, controlled open‐label phase II clinical trial Regorafenib nella recidiva di glioblastoma. Studio REGOMA Studio clinico di fase II, con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003722-41,0,0,0 2014-003723-21,1,2020-09-30,2020-09-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Belgian Society of Medical Oncology,"A prospective, Belgian multi-center, single-arm, phase II study of neoadjuvant weekly paclitaxel and carboplatin followed by dose dense epirubicin and cyclophosphamide in stage II and III triple negat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003723-21,0,0,0 2014-003725-17,2,2016-02-05,2016-02-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MedImmune Limited,"A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis EINE P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003725-17,0,0,0 2014-003725-17,2,2016-02-05,2016-02-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MedImmune,"A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis EINE P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003725-17,0,0,0 2014-003727-22,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Geneva University Hospitals,A randomized controlled multicenter trial of a five day course of oral colistin and neomycin followed by restoration of the gut microbiota using fecal transplantation to eradicate intestinal carriag...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003727-22,0,0,0 2014-003728-39,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Tampere University Hospital,Effects of maternal oxytocin on social information processing in mothers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003728-39,0,0,0 2014-003730-10,1,2015-09-21,2015-09-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Anesthesiology, Næstved Hospital",Effect of a lateral nerve of the thigh block on post-operative pain among patients with pain (VAS>40mm) during flexion of the hip the first or second postoperative day Effekten af Nervus cutaneus f...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003730-10,0,0,0 2014-003731-20,4,2021-02-05,2021-02-05,3,1,0,0,0,0,2,0,0,1,1,0,1,0,2,Novartis Pharma Services AG,"A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003731-20,0,0,0 2014-003731-20,4,2021-02-05,2021-02-05,3,1,0,0,0,0,2,0,0,1,1,0,1,0,2,NOVARTIS FARMA S.P.A.,"A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003731-20,0,0,0 2014-003731-20,4,2021-02-05,2021-02-05,3,1,0,0,0,0,2,0,0,1,1,0,1,0,2,"Novartis Farmacéutica, S.A.","A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003731-20,0,0,0 2014-003733-25,1,2017-09-11,2017-09-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU de BORDEAUX,Pilot Study related to the effect of clopidogrel on plasmatic soluble CD40 ligand during systemic lupus erythematous Essai pilote de phase I/II testant l’effet du clopidogrel sur les taux plasmati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003733-25,0,0,0 2014-003737-26,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc,"A Phase 4, 6-week, randomized double-blind, multicenter, active-controlled trial to evaluate the effects of Celecoxib (Celebrex®) or Naproxen on blood pressure in paediatric subjects with juvenile idi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003737-26,0,1,1 2014-003738-24,3,2016-03-10,2016-03-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Adamas Pharmaceuticals, Inc.",ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients with Levodopa-Induced Dyskinesia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003738-24,0,0,0 2014-003739-20,4,2018-02-28,2018-02-28,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Adamas Pharmaceuticals, Inc.",Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa-Induced Dyskinesia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003739-20,0,0,0 2014-003740-13,2,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,CHU de Nantes,"A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma patients -OAsIs",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003740-13,0,0,0 2014-003740-13,2,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,Centre Hospitalier Universiaire de Nantes,"A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma patients -OAsIs",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003740-13,0,0,0 2014-003746-27,2,2017-12-11,2017-12-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Octapharma Pharmazeutika Produktionsges.m.b.H, Oberlaaer Strasse 235, A-1100 Vienna, Austria","A randomised, cross-over study to compare quality of life and satisfaction in primary immunodeficient patients treated with subcutaneous injections of Gammanorm® 165 mg/mL administered with two differ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003746-27,0,0,0 2014-003753-34,1,2016-10-07,2016-10-07,1,0,1,0,0,0,1,0,0,1,1,1,1,0,1,"Cempra Pharmaceuticals, Inc.","A Phase 1, Open-label, Multi-center Study to Determine the Pharmacokinetics (PK) and Safety of Solithromycin as Add-on Therapy in Adolescents and Children with Suspected or Confirmed Bacterial Infecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003753-34,0,0,0 2014-003755-64,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Helena Elding Larsson,"A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd® in combination with Vitamin D on the progression to type 1 diabetes in children with multiple ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003755-64,0,0,0 2014-003756-32,1,2017-04-10,2017-04-10,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,Central Manchester University Hospitals NHS Foundation Trust,A pilot study evaluating the influence of chronobiology on Hepatitis B responses in health-care students attending the University of Salford,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003756-32,0,0,0 2014-003757-33,2,2020-05-19,2020-05-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.,Evaluation of the efficacy and safety of prulifloxacin vs levofloxacin in the treatment of Chronic Bacterial Prostatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003757-33,0,0,0 2014-003764-20,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,CSL Behring LLC,"A Prospective, Multicenter, Open Enrollment Study of Human Plasma-Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003764-20,0,1,1 2014-003768-19,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,CSL Limited,"A Phase III, Randomized, Observer-blind, Multi-center, Noninferiority Comparison of the Immune Response of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Trivalent Inactivated Split-V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003768-19,0,1,1 2014-003770-16,1,2016-12-08,2016-12-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merz Pharmaceuticals GmbH,"A prospective, open-label, multicenter, repeat-dose trial to investigate the safety and efficacy of NT 201 (incobotulinumtoxinA) in the combined treatment of upper facial lines (horizontal forehead li...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003770-16,0,0,0 2014-003772-23,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,CSL Behring AG,A Multicenter Extension Study on the Safety and Efficacy of IgPro10 in Patients With Primary Immunodeficiency (PID),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003772-23,0,1,1 2014-003773-42,5,2020-09-18,2020-09-18,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pharma Mar S.A.,A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003773-42,0,0,0 2014-003773-42,5,2020-09-18,2020-09-18,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pharma Mar S.A. Sociedad Unipersonal,A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003773-42,0,0,0 2014-003774-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,A.R.T.I.C. (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie ),"Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride (XOFIGO®) in renal cell carcinoma patients with bone metastases Etude de phaseI/II de recherche de dose, d’évaluation de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003774-16,0,0,0 2014-003778-17,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Sintetica S.A.,"Spinal anaesthesia with Chloroprocaine HCl 1% for elective lower limb procedures of short duration: a prospective, randomised, observer-blind study in adult patients Anestesia spinale con Cloropro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003778-17,0,0,0 2014-003779-48,1,2015-03-23,2015-03-23,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,LABORATOIRES SMB S.A.,"A phase IV, randomised, cross-over study to estimate the influence of food on the 25-hydroxyvitamin D3 serum level after vitamin D3 (D-CURE®) supplementation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003779-48,0,0,0 2014-003785-24,1,2015-12-18,2015-12-18,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Uzsoki Utcai Kórház,Treatment of pancreatic adenocarcinoma with the combinationof carboplatin and velparib Hasnyálmirigy adenocarcinoma kezelése karboplatin és veliparib kombinációjával,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003785-24,0,0,0 2014-003787-21,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Klinikum der Ludwig-Maximilians-Univ. Münch , Klinikum Großhadern (vertreten durch die kaufmännische Direktion)",Randomised study of the efficacy of cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus cetuximab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003787-21,0,0,0 2014-003788-39,1,2016-08-15,2016-08-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Profil Mainz GmbH & Co KG,"Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects with Type 2 Diabetes Mellitus on Previous Metformin Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003788-39,0,0,0 2014-003789-25,1,2021-03-13,2021-03-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Department of surgery, Herlev Hospital","The anxiolytic effects of melatonin: A randomized, placebo-controlled, double-blinded clinical study. Anxiolytisk effekt af melatonin: et randomiseret, dobbelt-blindet, placebo-kontrolleret klinis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003789-25,0,0,0 2014-003790-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Spherium Biomed,"Randomised, double-blinded, placebo and active comparator controlled exploratory clinical trial to assess the efficacy and safety of a triple combination of Ibuprofen, magnesium and ascorbic acid in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003790-41,0,0,0 2014-003791-23,5,2019-06-05,2020-06-05,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,Protocol I4T-MC-JVDB Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second Line Gastric or Gastroesophageal Junction Adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003791-23,0,0,0 2014-003792-34,1,2017-01-16,2017-01-16,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,GWT-TUD GmbH,RANDOMIZED DOUBLE BLIND PARALLEL DESIGN STUDY COMPARING RISK OF NOCTURNAL HYPOGLYCEMIA AND CRITICAL ARRHYTHMIAS WITH SITAGLIPTIN VERSUS GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES INSUFFICIENTLY CONT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003792-34,0,0,0 2014-003796-32,14,2015-12-18,2015-12-28,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Teva Pharmaceutical Industries Ltd.,"A phase 3, multicenter, randomized, double-blind, placebo-controlled efficacy, safety and tolerability study of TV-1106 in growth hormone-deficient adults who are not current users of rhGH treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003796-32,0,0,0 2014-003798-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CONSORZIO ONCOTECH,Randomized phase III study of fulvestrant as maintenance therapy after first-line chemotherapy in HER2 negative postmenopausal metastatic breast cancer patients Studio randomizzato di fase III di F...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003798-41,0,0,0 2014-003799-22,7,2017-05-16,2017-05-16,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Civitas Therapeutics, Inc.","A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson’s Disease Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003799-22,0,0,0 2014-003803-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospital Universitario Araba (Sede Santiago),Adjunct pioglitazone IN THE TREATMENT OF BIPOLAR DISORDER. PIOGLITAZONA COMO COADYUVANTE EN EL TRATAMIENTO DEL TRASTORNO BIPOLAR.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003803-31,0,0,0 2014-003804-66,4,2019-08-01,2019-08-01,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Celgene Corporation,"A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER, SAFETY AND EFFICACY STUDY TO EVALUATE NAB-PACLITAXEL (ABRAXANE®) AS MAINTENANCE TREATMENT AFTER INDUCTION WITH NAB-PACLITAXEL PLUS CARBOPLATIN IN SUBJ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003804-66,0,0,0 2014-003804-66,4,2019-08-01,2019-08-01,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,CELGENE CORPORATION,"A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER, SAFETY AND EFFICACY STUDY TO EVALUATE NAB-PACLITAXEL (ABRAXANE®) AS MAINTENANCE TREATMENT AFTER INDUCTION WITH NAB-PACLITAXEL PLUS CARBOPLATIN IN SUBJ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003804-66,0,0,0 2014-003806-33,1,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Aegerion Pharmaceuticals Inc.,"A Phase 3, Single-arm, Open-label, International, Multi-center Study to Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients with Homozygous Familial Hypercholesterolemia on Stable Lip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003806-33,0,0,0 2014-003808-77,1,2016-09-28,2016-09-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A multi-centre, randomised, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, and tolerability of repeat doses of inhaled GSK2269557 in adults with persistent, unc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003808-77,0,0,0 2014-003810-96,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,"RWTH Aachen University for the Medical Falculty, represented by Clinical Trial Center Aachen (CTC-A)",Emergence times and airway reactions in general laryngeal mask airway anesthesia: a randomized multicenter controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003810-96,0,0,0 2014-003811-13,1,2019-03-19,2019-03-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Antoni van Leeuwenhoek - Netherlands Cancer Institute,"Selecting cancer patients for treatment using Tumor Organoids, the SENSOR study Het selecteren van kanker patiënten voor een behandeling met behulp van Tumor Organoids, de SENSOR studie.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003811-13,0,0,0 2014-003812-36,5,2020-08-13,2020-08-13,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Morphotek Inc,"A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003812-36,0,0,0 2014-003812-36,5,2020-08-13,2020-08-13,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Eisai Ltd.,"A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003812-36,0,0,0 2014-003812-36,5,2020-08-13,2020-08-13,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Eisai Limited,"A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003812-36,0,0,0 2014-003817-28,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Region Östergötland,Does bisfosfonat preserve the bone volume in transplanted bone in the jaw? Bevarar bisfosfonat benvolymen hos transplanterat ben i käken?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003817-28,0,0,0 2014-003818-92,1,2018-01-17,2018-01-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Ospedale San Raffaele, UO Chirurgia Vascolare",CUstodiol vs RInger: whaT Is the Best Agent?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003818-92,0,0,0 2014-003822-42,1,2016-01-20,2016-01-20,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A Phase 4, Single-Arm, Open-Label Study describing the safety and immunogenicity of Bexsero in healthy subjects aged 12 years to <19 years.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003822-42,0,0,0 2014-003824-36,16,2021-09-07,2021-09-08,12,1,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003824-36,1,0,0 2014-003824-36,16,2021-09-07,2021-09-08,12,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Roche Farma S.A en nombre de F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003824-36,1,0,0 2014-003824-36,16,2021-09-07,2021-09-08,12,1,0,0,0,0,3,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003824-36,1,0,0 2014-003833-24,1,2019-07-10,2019-07-10,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,AGMT – Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH,"Randomized phase III study: Supplemental parenteral nutrition for patients with locally advanced inoperable tumors of the head and neck, receiving definitive radiotherapy with Cetuximab or Cisplatin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003833-24,0,0,0 2014-003834-21,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Erasmus Medical Center Rotterdam,Effectiveness of penfluridol (oral long acting neuroleptic) as compared to second generation oral neuroleptics in psychotic disorder patients: an open label randomized controlled trial. Effectivite...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003834-21,0,0,0 2014-003835-20,6,2017-03-30,2017-03-31,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"ALNYLAM PHARMACEUTICALS, INC.","A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003835-20,0,0,0 2014-003835-20,6,2017-03-30,2017-03-31,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Alnylam Pharmaceuticals, Inc.","A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003835-20,0,0,0 2014-003836-38,7,2016-02-16,2016-02-16,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003836-38,0,0,0 2014-003836-38,7,2016-02-16,2016-02-16,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Corporation, Inc.","A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003836-38,0,0,0 2014-003841-86,2,2016-12-02,2016-12-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ipsen Innovation,"A phase III, randomised, double blind, placebo controlled and open label phase, multicentre study to investigate the efficacy and safety of BTX-A-HAC NG in the treatment of moderate to severe glabella...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003841-86,0,0,0 2014-003844-11,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,"Department of Oncology, Linköping University Hospital, Linköping, Sweden","Continous treatment with bevacizumab in elderly patients with mCRC: an open label, single arm, prospective phase IV trial to evaluate outcome and safety of continuous bevacizumab treatment in combinat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003844-11,0,0,0 2014-003846-29,1,2015-11-10,2015-11-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Revalesio Corporation,"A Phase IIA randomized, double-blind, placebo controlled, cross-over study to evaluate the effects of multiple doses of inhaled RNS60 and Budesonide on the late phase asthmatic response to allergen ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003846-29,0,0,0 2014-003849-10,9,2017-12-19,2017-12-19,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.P.A.,"A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab (150 mg) in pre-filled syringe, with or without loading regimen, to demonstrate efficacy, safety...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003849-10,0,0,0 2014-003849-10,9,2017-12-19,2017-12-19,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase III, randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab (150 mg) in pre-filled syringe, with or without loading regimen, to demonstrate efficacy, safety...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003849-10,0,0,0 2014-003850-15,9,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A phase II, multicenter study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) Studio di Fase II, multicentrico, con l’inibitore...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003850-15,0,0,0 2014-003850-15,9,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,NOVARTIS FARMA S.P.A.,"A phase II, multicenter study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) Studio di Fase II, multicentrico, con l’inibitore...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003850-15,0,0,0 2014-003850-15,9,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase II, multicenter study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) Studio di Fase II, multicentrico, con l’inibitore...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003850-15,0,0,0 2014-003855-76,15,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144 STUDIO IN APERTO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003855-76,0,0,0 2014-003855-76,15,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144 STUDIO IN APERTO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003855-76,0,0,0 2014-003855-76,15,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Roche Farma S.A. en nombre de F. Hoffmann-La Roche Ltd,AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144 STUDIO IN APERTO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003855-76,0,0,0 2014-003856-30,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Cliniques Universitaires Saint Luc,Sandostatin (Octreotide LAR) may lead to clinical improvement through receptor occupation optimisation. A prospective interventional trial of patients with neuro-endocrine tumors with carcinoid syndro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003856-30,0,0,0 2014-003858-14,1,2015-05-13,2015-05-13,1,0,0,0,1,0,2,0,1,1,0,0,1,0,0,"Multidisciplinary Pain Center 7612, Rigshospitalet",Does Hyperbaric Oxygen Therapy Attenuate Secondary Hyperalgesia Areas Induced by a Thermal Injury in Human Volunteers? A Randomized Controlled Cross-over Study with a Blinded Observer. Hyperbar Ox...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003858-14,0,0,0 2014-003859-61,9,2019-11-04,2019-11-04,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,Randomized Phase II study comparing single agent oral vinorelbine administered with two different schedules in patients with Advanced Non Small Cell Lung Cancer unfit for a platinum-based chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003859-61,0,0,0 2014-003859-61,9,2019-11-04,2019-11-04,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MéDICAMENT,Randomized Phase II study comparing single agent oral vinorelbine administered with two different schedules in patients with Advanced Non Small Cell Lung Cancer unfit for a platinum-based chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003859-61,0,0,0 2014-003860-19,7,2020-09-21,2020-09-28,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PIERRE FABRE MEDICAMENT,"Randomised Phase II Study comparing, as first-line chemotherapy, single-agent Oral Vinorelbine administered with two different schedules in patients with Advanced Breast Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003860-19,0,0,0 2014-003863-40,10,2018-09-10,2020-11-13,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003863-40,0,0,0 2014-003863-40,10,2018-09-10,2020-11-13,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA AB,"A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003863-40,0,0,0 2014-003865-11,11,2018-05-31,2018-06-08,10,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Prothena Therapeutics Limited,"A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2- Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003865-11,0,0,0 2014-003865-11,11,2018-05-31,2018-06-08,10,1,0,0,0,1,3,0,0,1,1,0,1,0,1,PROTHENA THERAPEUTICS LIMITED,"A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2- Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003865-11,0,0,0 2014-003873-41,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,MAASTRO Clinic,Non invasive imaging of tumor hypoxia with [18F]HX4 Positron-Emission-Tomography (PET): A phase II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003873-41,0,0,0 2014-003874-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"National Institute for Infectious Diseases ""Lazzaro Spallanzani"" IRCCS",Antiretroviral Pre-exposure prophylaxis for natural conception (PrEP-C) in serodiscordant female partners of HIV-infected men in sustained virologic suppression Profilassi antiretrovirale pre-espo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003874-17,0,0,0 2014-003876-22,6,2021-06-02,2021-08-16,4,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"An open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CDZ17...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003876-22,1,0,0 2014-003876-22,6,2021-06-02,2021-08-16,4,1,0,0,0,1,2,0,0,2,0,0,0,0,1,NOVARTIS PHARMA SERVICES AG,"An open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CDZ17...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003876-22,1,0,0 2014-003877-40,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003877-40,0,0,0 2014-003877-40,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"ALNYLAM PHARMACEUTICALS, INC.","A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003877-40,0,0,0 2014-003878-16,10,2017-12-12,2017-12-22,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A Phase 3 randomized, double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003878-16,0,0,0 2014-003878-16,10,2017-12-12,2017-12-22,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER INC,"A Phase 3 randomized, double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003878-16,0,0,0 2014-003878-16,10,2017-12-12,2017-12-22,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc,"A Phase 3 randomized, double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous non-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003878-16,0,0,0 2014-003879-37,2,2016-09-14,2016-09-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects with Signs and Symptoms of Osteoart...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003879-37,0,0,0 2014-003880-38,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Phase 1/2, Dose-Escalation Safety, Tolerability and Efficacy Study of BMN 270, an Adenovirus-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII in Patients with Severe Haemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003880-38,0,0,0 2014-003882-10,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,CHRU de Lille,Evaluation of the effectiveness of a treatment involving one (or several ) antibiotic (s) with 14-day tobramycin ( Nebcine® ) by intravenous injection versus the same antibiotic treatment (s ) associa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003882-10,0,0,0 2014-003890-40,7,2016-11-14,2016-11-14,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,Randomized Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003890-40,0,0,0 2014-003890-40,7,2016-11-14,2016-11-14,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,Randomized Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003890-40,0,0,0 2014-003890-40,7,2016-11-14,2016-11-14,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,Randomized Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003890-40,0,0,0 2014-003890-40,7,2016-11-14,2016-11-14,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,Randomized Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003890-40,0,0,0 2014-003890-40,7,2016-11-14,2016-11-14,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,Randomized Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003890-40,0,0,0 2014-003890-40,7,2016-11-14,2016-11-14,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.",Randomized Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003890-40,0,0,0 2014-003890-40,7,2016-11-14,2016-11-14,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Italia S.p.A.,Randomized Evaluation of dabigatran etexilate Compared to warfarIn in pulmonaRy vein ablation: assessment of an uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003890-40,0,0,0 2014-003891-22,1,2018-05-18,2018-05-18,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Medical University Innsbruck,"Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line CTX: angiogenic biomarker identification, phase II trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003891-22,0,0,0 2014-003893-17,2,2021-03-30,2021-03-30,1,1,0,0,0,2,2,0,0,1,0,0,1,0,0,"SAKK, Swiss Group for Clinical Cancer Research",Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial Kombinationstherapie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003893-17,0,0,0 2014-003893-17,2,2021-03-30,2021-03-30,1,1,0,0,0,2,2,0,0,1,0,0,1,0,0,SAKK,Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial Kombinationstherapie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003893-17,0,0,0 2014-003894-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Azienda Ospedaliero-Universitaria di Parma,Effect of a Peg-interferon alfa 2A pulse on HBV-specific T cell responses in chronic hepatitis HBeAg negative patients under long-term nucleos(t)ide treatment Effetto di Peginterferone alfa-2a sull...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003894-41,0,0,0 2014-003895-21,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Biogen MA Inc,"A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003895-21,0,1,1 2014-003896-41,2,2018-08-13,2018-08-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MedImmune, LLC","A Phase 2a, Randomized, Placebo-controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects with Primary Sjogren’s Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003896-41,0,0,0 2014-003898-42,4,2016-06-15,2016-06-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.",An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003898-42,0,0,0 2014-003914-10,1,2018-12-31,2018-12-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,uzleuven,ELABORATION OF A PATIENT-FRIENDLY TREATMENT STRATEGY WITH CAPSAICIN NASAL SPRAY IN PATIENTS WITH IDIOPATHIC RHINITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003914-10,0,0,0 2014-003920-32,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,0,INSERM,Study phase II open label study using triheptanoin in patients with a deficiency of glmucose transporter type 1 (GLUT-1) Etude de phase II en ouvert utilisant la triheptanoïne chez des patients sou...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003920-32,0,0,0 2014-003923-23,1,2018-11-20,2018-11-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London,GLP-1 Receptor Agonist interVentIon for poor responders afTer bariAtric Surgery: The GRAVITAS trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003923-23,0,0,0 2014-003924-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Tumores Neuroendocrinos (GETNE),A phase II trial to assess the activity and safety of Palbociclib in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET). Estudio fase II para evalu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003924-34,0,0,0 2014-003929-17,7,2020-07-21,2020-07-21,6,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,Open label multicenter Phase I/II study of the safety and efficacy of PDR001 administered to patients with advanced malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003929-17,0,0,0 2014-003929-17,7,2020-07-21,2020-07-21,6,1,0,1,0,0,1,0,0,1,0,0,0,0,1,NOVARTIS PHARMA SERVICES AG,Open label multicenter Phase I/II study of the safety and efficacy of PDR001 administered to patients with advanced malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003929-17,0,0,0 2014-003929-17,7,2020-07-21,2020-07-21,6,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Novartis Farmacéutica, S.A.",Open label multicenter Phase I/II study of the safety and efficacy of PDR001 administered to patients with advanced malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003929-17,0,0,0 2014-003930-17,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,EORTC AISBL/IVZW,"A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLOWED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003930-17,0,0,0 2014-003930-17,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,European Organisation for Research and Treatment of Cancer,"A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLOWED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003930-17,0,0,0 2014-003930-17,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),"A RANDOMIZED PHASE III TRIAL COMPARING CONVENTIONAL-DOSE CHEMOTHERAPY USING PACLITAXEL, IFOSFAMIDE, AND CISPLATIN (TIP) WITH HIGH-DOSE CHEMOTHERAPY USING MOBILIZING PACLITAXEL PLUS IFOSFAMIDE FOLLOWED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003930-17,0,0,0 2014-003932-38,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,VU University medical center (VUmc),Advanced imaging in laparoscopic HIPEC for peritoneal carcinomatosis of colorectal orgin to improve cytoreduction; a feasibility study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003932-38,0,0,0 2014-003933-24,9,2017-08-12,2017-08-14,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003933-24,0,0,0 2014-003933-24,9,2017-08-12,2017-08-14,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003933-24,0,0,0 2014-003934-22,1,2015-10-15,2015-10-15,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Valneva Austria GmbH,"DOSE-CONFIRMATION, IMMUNOGENICITY AND SAFETY STUDY OF THE CLOSTRIDIUM DIFFICILE VACCINE CANDIDATE VLA84 IN HEALTHY ADULTS AGED 50 YEARS AND OLDER. RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE II STUD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003934-22,0,0,0 2014-003935-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis,A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Study Eenarmige fase II study ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003935-20,0,0,0 2014-003942-28,11,2017-02-23,2017-02-23,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Takeda Development Centre Europe, Ltd.","Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003942-28,0,0,0 2014-003942-28,11,2017-02-23,2017-02-23,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,TAKEDA DEVELOPMENT CENTRE EUROPE LTD,"Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003942-28,0,0,0 2014-003947-36,1,2015-10-26,2015-10-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NeRRe Therapeutics Ltd,Evaluation of orvepitant in an exploratory open-label clinical study in chronic treatment-refractory cough,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003947-36,0,0,0 2014-003950-15,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,Zymenex A/S,"A single center, open label clinical trial investigating the long-term efficacy of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) treatment in subjects with alpha-Mannosidosis who previously...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003950-15,0,0,0 2014-003951-72,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Gruppo Oncologico Italiano Ricerca Cancro (GOIRC),Phase II randomized multicenter study of Everolimus as maintenance therapy for metastatic neuroendocrine carcinoma with pulmonary or gastroenteropancreatic origin. Studio multicentrico randomizzat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003951-72,0,0,0 2014-003952-29,10,2016-05-27,2016-05-27,1,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Bayer Healthcare AG,"Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (PAH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003952-29,1,1,0 2014-003952-29,10,2016-05-27,2016-05-27,1,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Bayer AG,"Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (PAH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003952-29,1,1,0 2014-003954-15,2,2017-10-12,2017-10-12,2,1,0,0,1,0,3,0,0,1,0,0,1,0,1,"Ethicon, Inc.","A single blinded, randomized, controlled study to evaluate the safety and effectiveness of EVICEL® Fibrin sealant (Human) compared to a Hydrogel sealant as an adjunct to sutured dural repair",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003954-15,0,0,0 2014-003956-30,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Centre for Human Drug Research,"A single-centre randomized double-blind, double-dummy, placebo-controlled, four-way crossover study in healthy subjects to investigate the effect of ethanol 0.5 and 1.0 g/L and alprazolam 1 mg on a dr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003956-30,0,0,0 2014-003960-20,6,2016-08-11,2019-03-07,4,1,1,0,0,1,2,0,0,1,1,0,1,0,1,"SHIRE HUMAN GENETIC THERAPIES, INC",A Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration via an Intrathecal Drug Delivery Device in Pedia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003960-20,0,0,0 2014-003960-20,6,2016-08-11,2019-03-07,4,1,1,0,0,1,2,0,0,1,1,0,1,0,1,"Shire human Genetic Therapies, Inc.",A Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration via an Intrathecal Drug Delivery Device in Pedia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003960-20,0,0,0 2014-003960-20,6,2016-08-11,2019-03-07,4,1,1,0,0,1,2,0,0,1,1,0,1,0,1,"Shire Human Genetic Therapies, Inc.",A Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration via an Intrathecal Drug Delivery Device in Pedia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003960-20,0,0,0 2014-003961-49,7,2015-08-26,2016-08-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Upsher-Smith Laboratories, Inc.","A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003961-49,0,0,0 2014-003963-39,1,,,0,0,0,1,0,0,1,0,1,4,0,0,0,0,1,Bristol-Myers Squibb Company,An In Vitro Comparison of Apixaban Activity in Adult and Pediatric Plasma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003963-39,0,1,1 2014-003964-18,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,Bristol-Myers Squibb Company,"Evaluation of the Pharmacokinetics of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin in Children and Adolescents Aged 10 to 17 Years with Type 2 Diabetes Mellitus Following Oral Administration of S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003964-18,0,1,1 2014-003965-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Targeted therapy with Imatinib for treatment of poor prognosis mesenchymal-type resectable colon cancer: a proof-of-concept study in the preoperative window period. Gerichte therapie met imatinib v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003965-11,0,0,0 2014-003968-20,3,2019-05-15,2019-05-15,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Dompé farmaceutici s.p.a.,"A phase 2, multicentre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003968-20,0,0,0 2014-003969-24,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Vicente Estrada Pérez,"Randomized clinical trial to analysis of pain after administration intramuscular benzathine penicillin needle gauge and length greater local anesthetic or not, in the administration with a traditional...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003969-24,0,0,0 2014-003970-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SANITARIA DI FIRENZE,"A multicentre randomized, double-blinded and placebo-controlled clinical trial on the efficacy and safety of once daily propranolol 80 mg retard for the prevention of cutaneous malignant melanoma recu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003970-18,0,0,0 2014-003972-21,4,2017-07-06,2017-07-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Daiichi Sankyo Development Ltd,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED SAFETY STUDY OF DS-5565 FOR TREATMENT OF PAIN DUE TO FIBROMYALGIA IN SUBJECTS WITH CHRONIC KIDNEY DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003972-21,0,0,0 2014-003972-21,4,2017-07-06,2017-07-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Daiichi Sankyo, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED SAFETY STUDY OF DS-5565 FOR TREATMENT OF PAIN DUE TO FIBROMYALGIA IN SUBJECTS WITH CHRONIC KIDNEY DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003972-21,0,0,0 2014-003973-41,4,2018-02-26,2018-02-26,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Ferring Pharmaceuticals A/S,"A Double-blind, Randomised, Placebo-controlled, Phase 2b/3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients with Vasopressor-dependent Septic Shoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003973-41,0,0,0 2014-003978-16,1,2016-11-15,2016-11-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Section for Transfusion Medicine, Capitol Region Blood Bank",Pilot Randomized trial of Fibrinogen in Trauma Haemorrhage (PRooF-iTH).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003978-16,0,0,0 2014-003985-25,1,2016-12-21,2016-12-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Serodus ASA,"Multi-centre, randomized, double-blind, placebo-controlled, phase II study assessing in two sequential cohorts the safety, efficacy and tolerability of a 15 mg BID and a 30 mg BID doses of SER150TBS i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003985-25,0,0,0 2014-003986-11,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,IVI Madrid,"Prospective, double-blinded, randomized clinical trial to evaluate the potential benefitial effect of resveratrol for preventing the ovarian hyperstimulation syndrome. Ensayo clínico randomizado co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003986-11,0,0,0 2014-003989-24,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Sanofi,Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003989-24,0,1,1 2014-003997-18,6,2018-01-26,2018-01-26,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Grifols Therapeutics Inc.,"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/ Chromatography Purified (IGIV -C) in Symptomatic Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003997-18,0,0,0 2014-004002-15,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Sanofi,"Local, Phase IV, Multicenter, Double-blind, Randomized, Parallel, With Two Treatment Arms, Placebo-controlled Study to Evaluate the Reduction of Inflammatory Symptoms in the Treatment of Bacterial Pha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004002-15,0,1,1 2014-004010-28,5,2019-11-27,2019-11-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER",A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004010-28,0,0,0 2014-004010-28,5,2019-11-27,2019-11-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004010-28,0,0,0 2014-004010-28,5,2019-11-27,2019-11-27,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004010-28,0,0,0 2014-004011-37,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,BioMarin Pharmaceutical Inc.,"A Phase 2, Multicenter, Open-Label, Exploratory Biomarker Study of Talazoparib (BMN 673) Monotherapy in Patients with Recurrent or Metastatic Solid Tumors Estudio de Fase 2, multicéntrico, abierto ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004011-37,0,0,0 2014-004013-85,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Friedrich Schiller University Jena,Sequential versus simultaneous vaccination with pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPV23) in unvaccinated older adults: Immunological memory and antibody l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004013-85,0,0,0 2014-004015-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SAN PAOLO,"Role of a switch strategy to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate (QUAD) on HIV reservoir and immune activation. Effetti di una strategia di switch terapeutico ver...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004015-36,0,0,0 2014-004016-11,1,2019-03-19,2019-03-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Bristol,What is the clinical and cost effectiveness of benzocaine/phenazone ear drops for reducing antibiotic consumption and ear pain in children aged between 6 months and 10 years presenting to primary care...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004016-11,0,0,0 2014-004020-21,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación para la investigación biomédica del Hospital Clínico San Carlos,Reintroduction of platinum-based therapy after treatment with trabectedin in patients with relapsed ovarian cancer resistant to platinum Reintroducción de tratamiento basado en platino después del ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004020-21,0,0,0 2014-004021-41,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Edinburgh,Prediction of Recurrent Events with 18F-Fluoride to Identify Ruptured and High-risk Coronary Artery Plaques in Patients with Myocardial Infarction - the PREFFIR study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004021-41,0,0,0 2014-004021-41,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Lothian,Prediction of Recurrent Events with 18F-Fluoride to Identify Ruptured and High-risk Coronary Artery Plaques in Patients with Myocardial Infarction - the PREFFIR study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004021-41,0,0,0 2014-004023-40,9,2018-09-17,2018-09-17,8,1,1,0,1,0,3,0,0,2,1,0,0,0,1,"Cubist Pharmaceuticals LLC, an indirect wholly-owned subsidiary of Merck Sharp & Dohme Corp.",PHASE 3 STUDY OF IV TO ORAL 6-DAY TEDIZOLID PHOSPHATE COMPARED WITH 10-DAY COMPARATOR IN SUBJECTS 12 TO <18 YEARS WITH cSSTI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004023-40,1,1,0 2014-004023-40,9,2018-09-17,2018-09-17,8,1,1,0,1,0,3,0,0,2,1,0,0,0,1,"Cubist Pharmaceuticals, LLC, an idirect wholly owned subsidiary of Merck Sharp&Dohme Corp.",PHASE 3 STUDY OF IV TO ORAL 6-DAY TEDIZOLID PHOSPHATE COMPARED WITH 10-DAY COMPARATOR IN SUBJECTS 12 TO <18 YEARS WITH cSSTI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004023-40,1,1,0 2014-004023-40,9,2018-09-17,2018-09-17,8,1,1,0,1,0,3,0,0,2,1,0,0,0,1,"Cubist Pharmaceuticals, Inc.",PHASE 3 STUDY OF IV TO ORAL 6-DAY TEDIZOLID PHOSPHATE COMPARED WITH 10-DAY COMPARATOR IN SUBJECTS 12 TO <18 YEARS WITH cSSTI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004023-40,1,1,0 2014-004023-40,9,2018-09-17,2018-09-17,8,1,1,0,1,0,3,0,0,2,1,0,0,0,1,"Cubist Pharmaceuticals LLC, an indirect wholly-owned subsidary of Merck Sharp & Dohme Corp.",PHASE 3 STUDY OF IV TO ORAL 6-DAY TEDIZOLID PHOSPHATE COMPARED WITH 10-DAY COMPARATOR IN SUBJECTS 12 TO <18 YEARS WITH cSSTI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004023-40,1,1,0 2014-004025-40,2,2016-01-29,2016-01-29,1,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Patara Pharma,Treatment of Chronic Idiopathic Cough (CIC) and Chronic Cough in patients with Idiopathic Pulmonary Fibrosis (IPF) with PA101.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004025-40,1,0,0 2014-004026-17,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004026-17,0,0,0 2014-004026-17,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc",A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004026-17,0,0,0 2014-004027-52,8,2022-03-22,2022-03-22,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,ARCAGY-GINECO,"Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB ? IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004027-52,1,0,0 2014-004027-52,8,2022-03-22,2022-03-22,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,ARCAGY Research,"Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB ? IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004027-52,1,0,0 2014-004029-41,1,2020-06-25,2020-06-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Oncology, Haukeland University Hospital",Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An open label phase-II study with 6 infusions of cyclophosphamide 4 weeks apart. Cyclofosfamid ved myalgisk encefalopati/kron...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004029-41,0,0,0 2014-004031-40,1,2020-11-29,2020-11-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Respiratory Diseases, Aarhus University Hospital",Training in intralymphatically injection technique. A realistic learning study Oplæring i intralymfatisk injektionsteknik. Et realistisk læringsstudie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004031-40,0,0,0 2014-004032-19,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Radboud University Medical Center,"A randomised, open-label clinical trial assessing the efficacy of octreotide to decrease iron infusion and blood transfusion requirements in patients with refractory anaemia due to gastrointestinal bl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004032-19,0,0,0 2014-004035-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,CONSORZIO ONCOTECH,Fulvestrant ed EVerolimus più EXemestane nel carcinoma mammario metastatico” “Fulvestrant followed by everolimus plus exemestane vs examestane and everolimus followed by fulvestrant in postmenopausal ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004035-38,0,0,0 2014-004036-19,1,2020-01-31,2020-01-31,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Cologne,"GHSG-AFM13 An open-label, randomized, multicenter phase II trial with AFM13 in patients with relapsed or refractory Hodgkin Lymphoma GHSG-AFM13 Eine offene, randomisierte, multizentrische Phase II ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004036-19,0,0,0 2014-004037-10,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Cempra Pharmaceuticals, Inc.","A phase 1, open-label, multi-centre study to determine the PK and safety of a 5-day oral dosing of solithromycin as add-on therapy to antimicrobial agent administered to adolescent with suspected or c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004037-10,0,1,1 2014-004039-37,4,2018-04-10,2018-04-10,1,1,1,0,2,0,2,0,0,2,0,0,0,0,1,"Cempra Pharmaceuticals, Inc.","A Phase 2/3, Randomised, Partly blinded (blinded investigator), Multi-center, Comparative Study to Determine the Safety and activity of Solithromycin (Intravenous and oral) in paediatric patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004039-37,1,1,0 2014-004039-37,4,2018-04-10,2018-04-10,1,1,1,0,2,0,2,0,0,2,0,0,0,0,1,"Cempra Pharmaceuticals, Inc","A Phase 2/3, Randomised, Partly blinded (blinded investigator), Multi-center, Comparative Study to Determine the Safety and activity of Solithromycin (Intravenous and oral) in paediatric patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004039-37,1,1,0 2014-004040-36,1,,,0,0,1,0,0,0,3,0,0,4,0,0,0,0,1,"Cempra Pharmaceuticals, Inc.",A Study to Evaluate the Efficacy and Safety of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea (SOLITAIRE-U).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004040-36,0,1,1 2014-004041-26,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Cempra Pharmaceuticals , Inc","A Phase I, open-label, multi-centre study to evaluate the PK and safety of solithromycin as add-on therapy to antimicrobial agent administered to paediatric subjects with a suspected or confirmed bact...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004041-26,0,1,1 2014-004042-96,3,2017-11-01,2017-11-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANTEN INCORPORATED,"A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects with Non-Infectious Uveitis of the Posterior Se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004042-96,0,0,0 2014-004042-96,3,2017-11-01,2017-11-01,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Santen Incorporated,"A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects with Non-Infectious Uveitis of the Posterior Se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004042-96,0,0,0 2014-004048-36,16,2022-04-21,2022-04-21,11,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,RAINBOW extension study: an extension study to evaluate the long term efficacy and safety of RAnibizumab compared with laser therapy for the treatment of INfants BOrn prematurely With retinopathy of p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004048-36,1,0,0 2014-004049-29,1,2020-01-29,2020-01-29,1,1,0,0,1,0,2,0,1,1,0,0,1,0,0,University of Leicester,Investigating Aspirin and Ticagrelor for the prevention of tumour cell-induced platelet aggregation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004049-29,0,0,0 2014-004058-32,1,2019-04-30,2019-04-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Norfolk and Norwich University Hospital NHS Foundation Trust,The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-trimoxazole (EME-TIPAC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004058-32,0,0,0 2014-004065-25,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Royal Marsden,Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004065-25,0,0,0 2014-004066-20,4,2019-08-25,2019-08-25,3,1,0,0,0,2,4,0,0,1,0,0,1,0,2,Actelion Pharmaceuticals Ltd.,"A prospective, multicenter, single-arm, open-label, phase 4 study to evaluate the effects of macitentan on Right vEntricular remodeling in Pulmonary ArterIal hypeRtension assessed by cardiac magnetic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004066-20,0,0,0 2014-004066-20,4,2019-08-25,2019-08-25,3,1,0,0,0,2,4,0,0,1,0,0,1,0,2,ACTELION PHARMACEUTICALS LTD,"A prospective, multicenter, single-arm, open-label, phase 4 study to evaluate the effects of macitentan on Right vEntricular remodeling in Pulmonary ArterIal hypeRtension assessed by cardiac magnetic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004066-20,0,0,0 2014-004068-39,4,2016-04-19,2016-07-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,janssen-Cilag International NV,"A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combinat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004068-39,0,0,0 2014-004068-39,4,2016-04-19,2016-07-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combinat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004068-39,0,0,0 2014-004070-42,1,2017-02-21,2017-02-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Sahlgrenska Academy,"An Exploratory, Phase IIa Cross-Over Study to Demonstrate the Efficacy and Safety of A4250 in Patients with Primary Biliary Cirrhosis and Cholestatic Pruritus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004070-42,0,0,0 2014-004072-30,1,2020-01-10,2020-01-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo Español de Tumores Neuroendocrinos,A phase II trial to assess the activity and safety of TH-302 in combination with sunitinib in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET) previ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004072-30,0,0,0 2014-004075-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,St Olavs University Hospital,"A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004075-23,0,0,0 2014-004077-16,1,2016-02-08,2016-02-08,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University College London Joint Research Office,A Phase IV randomised controlled trial of the selective serotonin reuptake inhibitor Sertraline versus Cognitive Behavioural Therapy for anxiety symptoms in people with Generalised Anxiety Disorder (G...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004077-16,0,0,0 2014-004078-40,1,2015-10-13,2015-10-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,CeQur Corp.,"A Prospective, Single Center, Observational Study to Assess the Performance, Safety, and Patient Reported Outcomes of Insulin Delivery with PaQ® in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004078-40,0,0,0 2014-004081-21,1,2016-04-21,2016-04-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratorios Farmalíder S.A.,"A PHASE III, MULTICENTRE, INTERNATIONAL, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, PLACEBO AND ACTIVE COMPARATORCONTROLLED CLINICAL TRIAL TO EVALUATE THE ANALGESIC EFFICACY AND SAFETY OF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004081-21,0,0,0 2014-004082-25,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,0,Hellenic Cardiovascular Research Society,"A multicenter, prospective, randomized, open label, blinded endpoint, active-comparator trial to assess the MIcrovascular integrity and left ventricular function Recovery after clopidogrel or Ticagrel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004082-25,0,0,0 2014-004086-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AIO-Studien-gGmbH,Induction Treatment with nab-Paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and nab-Paclitaxel/Ge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004086-24,0,0,0 2014-004088-19,1,2016-12-01,2016-12-01,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Universitätsklinikum Erlangen,Postoperative pain treatment after elective cardiac surgery using patient-controlled target-controlled infusion (TCI-PCA) with hydromorphone vs. patient-controlled analgesia (PCA) with morphine Pos...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004088-19,0,0,0 2014-004092-23,5,2020-12-31,2020-12-31,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing?s dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004092-23,0,0,0 2014-004092-23,5,2020-12-31,2020-12-31,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing?s dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004092-23,0,0,0 2014-004094-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Universiteit Utrecht,Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias. Het effect van het toevoegen van cannabidiol bij exposure behandeling van patiënten met therapieresistente...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004094-17,0,0,0 2014-004095-31,1,2019-03-21,2019-03-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Freistaat Bayer respresented by University of Regensburg represented by Kaufmännischer Direktor,"A prospective phase II, randomized multi-center trial of a combined modularized treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus nivolumab in patients with squamo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004095-31,0,0,0 2014-004101-33,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Wyeth Korea, Inc.",A Clinical Study to Evaluate the Efficacy and Safety of Cyclosporine (CsA) and Sirolimus (SRL) Induction Followed by Cyclosporine Withdrawal in Korean Renal Allograft Recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004101-33,0,1,1 2014-004102-15,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Wyeth,An open label comparative study of de novo renal allograft recipients receiving CsA + MMF + corticosteroids versus CsA + Rapamune + corticosteroids with further CsA elimination in the Rapamune arm wi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004102-15,0,1,1 2014-004103-73,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Wyeth Kabushiki Kaisha (Wyeth K.K.),"A long-term, open-label study of TNR-001 in Japanese Juvenile Idiopathic Arthritis Subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004103-73,0,1,1 2014-004104-30,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pharmacia & Upjohn S.A.,Treatment With Recombinant Human Growth Hormone (Genotonorm) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and Safety,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004104-30,0,1,1 2014-004105-32,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc,Prevention of Retarded Growth by Early Treatment With Recombinant Human Growth Factor (Genotonorm) in Children With Systemic Forms of Chronic Juvenile Arthritis Receiving Long-Term Corticosteroid Ther...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004105-32,0,1,1 2014-004106-15,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,"Wyeth Pharmaceutical Co., Ltd","An Evaluation of the Safety and Efficacy of On-Demand Treatment with Xyntha (B-Domain Deleted Recombinant Factor VIII, Albumin Free) in Chinese Subjects with Hemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004106-15,0,1,1 2014-004108-31,2,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,RedHill Biopharma Ltd.,"A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately Active Crohn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004108-31,0,0,0 2014-004110-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS Ospedale San Raffaele,"A monocentric, open-label pilot study to assess the safety and efficacy of minimal islet transplantation in patients with new-onset type 1 diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004110-28,0,0,0 2014-004111-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,BUDAI HEPATOLÓGIAI CENTRUM,Individual Patient Access to AbbVie ABT-450/rítonavir/ABT-267 and ABT 333 Coadministered witb Ribavirín (RBV) in Patient with Genotype 1 Hepatitis C Vírus Infection witb Cirrhosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004111-37,0,0,0 2014-004112-11,1,2018-07-24,2018-07-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Imperial College London,ALERT: A phase II study of alternating eribulin and hormonal therapy in pre-treated ER+ve breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004112-11,0,0,0 2014-004113-85,4,2016-06-22,2016-06-22,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Patara Pharma, LLC","Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study with PA101 in Patients with Indolent Systemic Mastocytosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004113-85,0,0,0 2014-004113-85,4,2016-06-22,2016-06-22,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"PATARA PHARMA, LLC","Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study with PA101 in Patients with Indolent Systemic Mastocytosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004113-85,0,0,0 2014-004119-35,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,IBSA Institut Biochimique SA,"Multicentre, prospective, double-blind, in parallel groups, randomized, placebo-controlled clinical trial to evaluate the short-term efficacy and safety of Betamethasone valerate 2.25 mg medicated pla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004119-35,0,0,0 2014-004120-21,1,2018-05-24,2018-05-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD,"CLINICAL TRIAL RANDOMIZED, DOUBLE-BLIND CONTROLLED, PHASE III, TO EVALUATE THE USE OF PLATELET RICH PLASMA IN FRONT HYALURONIC ACID IN COXARTHROSIS. ENSAYO CLÍNICO ALEATORIZADO, DOBLE CIEGO, CONTRO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004120-21,0,0,0 2014-004122-18,1,2017-07-06,2017-07-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"University of Dundee, Tayside Clinical Trials Unit",A Prospective Study to Evaluate the Effect of Allopurinol on Muscle Energetics in Older People with Impaired Physical Function.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004122-18,0,0,0 2014-004130-25,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Durata Therapeutic International B.V.,"A phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Hematogenous Osteomyel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004130-25,0,0,0 2014-004131-40,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,CSL Limited,"A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability of CSL Limited's Influenza Virus Vaccine in a paediatric population aged greater than or equal to 6 months to less th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004131-40,0,1,1 2014-004132-20,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,AstraZeneca K.K.,"A multicentre, double-blind, randomised, parallel-group, Phase III study to assess efficacy and safety of D9421-C 9 mg versus Mesalazine 3 g in patients with active Crohn’s Disease in Japan",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004132-20,0,1,1 2014-004133-16,1,2019-05-21,2019-05-21,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Hull and east Yorkshire Hospitals Trust,Exploratory multicentre prospective double blinded randomised controlled pilot study of the effect of intravenous iron supplementation(Monofer)in iron deficient but not anaemic patients with Chronic K...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004133-16,0,0,0 2014-004134-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centro Masve -Università degli Studi di Firenze-AOUC,"A MULTICENTER, PROSPECTIVE, SINGLE ARM, OPEN-LABEL, PILOT STUDY ON THE BENEFIT/COST/SAFETY PROFILE OF SOFOSBUVIR FOR SYMPTOMATIC MIXED CRYOGLOBULINEMIA Studio pilota multicentrico, prospettico, a s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004134-26,0,0,0 2014-004143-13,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Shire Human Genetic Therapies, Inc.",An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction with Elaprase® in Patients with Hunter Syndrome an...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004143-13,0,0,0 2014-004145-27,1,2017-01-03,2017-01-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Arrowhead Pharmaceuticals Inc.,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004145-27,0,0,0 2014-004155-32,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Wyeth Research,"An Open-Label, Single-Arm, Safety and Efficacy Study of Recombinant Human Factor IX (rFIX; BeneFIX ) in Children Less Than 6 Years of Age With Severe Hemophilia B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004155-32,0,1,1 2014-004156-65,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,"Wyeth Pharmaceutical Co, Ltd.","An Evaluation of the Safety and Efficacy of On-Demand Treatment with BeneFIX (Nonacog Alfa, Recombinant Factor IX) in Chinese Subjects with Hemophilia B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004156-65,0,1,1 2014-004158-32,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,"Wyeth Pharmaceuticals, Inc. Acting through its division Wyeth Research, a Pfizer Company",PILOT: Characterization of the Prevnar Infant Long-Term Immune Response Versus a Prevnar-Naïve Cohort,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004158-32,0,1,1 2014-004160-38,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,KABI PHARMACIA S.A.,A 2 Year Multicenter Study of Genotropin Treatment of Short Prepubertal Children with Intra-Uterine Growth Retardation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004160-38,0,1,1 2014-004161-24,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","An Open-Label, Dose-Escalating Study of the Pharmacokinetics, Safety and Tolerability of Fesoterodine in Pediatric Overactive Bladder Patients Aged 8-17 Years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004161-24,0,1,1 2014-004162-17,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc,"A Multicenter, 10-Week, Randomized, Double-Blind Study Of Sertraline And Placebo In Children And Adolescents With Posttraumatic Stress Disorder (PTSD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004162-17,0,1,1 2014-004163-21,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc,"Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004163-21,0,1,1 2014-004164-38,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Pfizer Inc,"An Open Label, Randomized, Single Dose, Parallel Arm Study To Determine Pharmacokinetics Of Azithromycin Following Oral Administration Of Immediate-Release (IR) Or Extended-Release (ER) Formulation In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004164-38,0,1,1 2014-004166-23,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,"Pfizer, Inc.","A 7-Day, Open-Label, Multicenter, Pharmacokinetic (PK) Study (Part 1) Followed by A 7-Day, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study (Part 2) of Int...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004166-23,0,1,1 2014-004167-20,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Japan Inc,"A Phase 3, Multi-Center, Open-Label Study To Confirm Safety, Efficacy And Tolerability Of Sildenafil Citrate 20 Mg Three Times a Day (TID) In Subjects With Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004167-20,0,1,1 2014-004172-32,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Pfixer Inc,"A Four-Year Open-Label Multi-Center Randomized Two-Arm Study of Genotropin in Idiopathic Short Stature Subjects: Comparing an Individualized, Target-Driven Treatment Regimen to Standard Dosing of Geno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004172-32,0,1,1 2014-004173-16,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,"Pfizer, Inc.","A Multicenter, Open-Label, Single Arm Study Assessing Dyad (Subject And Caregiver) Perception Of Convenience And Preference Of The Newly Developed Mark VII Pen",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004173-16,0,1,1 2014-004174-42,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Japan Inc.,"An Open-Label, Multicenter Study Evaluating, The Efficacy, Safety And Pharmacokinetics Of Gabapentin As Adjunctive Therapy In Pediatric Subjects With Partial Seizures When Other Antiepileptics Do Not ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004174-42,0,1,1 2014-004175-23,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Japan Inc,"A 52 weeks, open-label, multicenter study evaluating the efficacy and safety of gabapentin as adjunctive therapy in pediatric subjects who have completed the 12 weeks treatment in study A9451162.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004175-23,0,1,1 2014-004176-35,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer,Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Post Surgical Dental Pain: Study I,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004176-35,0,1,1 2014-004177-16,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,"Pfizer Japan, Inc.","A Phase 4, Randomized, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of DTaP Vaccine in Healthy Infants Given With a 7-valent Pneumococcal Conjugate Vaccine in Japan.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004177-16,0,1,1 2014-004178-40,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,"Pfizer, Inc.","A Phase 4, Open-label Trial to Assess the Safety, Tolerability, and Immunogenicity of Prevenar in Older Infants and Young Children in China Who Are Naive to Previous Pneumococcal Vaccination",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004178-40,0,1,1 2014-004179-22,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,"Wyeth, A Pfizer Company",A Study To Evaluate Pneumococcal Antipolysaccharide Antibody Concentrations in Subjects That Participated in the Wyeth Prevenar Safety and Immunogenicity Study 0887X-101518,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004179-22,0,1,1 2014-004180-20,1,,,0,1,0,1,0,0,1,0,1,4,0,0,0,0,1,Pfizer Inc,"A Phase 1 Open-label Study to Assess the Safety and Tolerability of a Single Dose of 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Adults, Children and Infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004180-20,0,1,1 2014-004181-21,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Pfizer Japan, Inc.","A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Given With DTaP Compared to Open-Labe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004181-21,0,1,1 2014-004183-38,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Pfizer, Inc.","An open, intravenous multiple dose, multi-centre study to investigate the pharmacokinetics, safety and toleration of Voriconazole in children aged 2-12 years who require treatment for the prevention o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004183-38,0,1,1 2014-004184-21,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,"Pfizer, Inc.","An open-label, intravenous to oral switch, multiple dose, multi-centre study to investigate the pharmacokinetics, safety and tolerability of Voriconazole in hospitalized children aged 2 to <12 years w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004184-21,0,1,1 2014-004189-64,3,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,0,Erasmus MC,Hunting for the OFF-target properties of Ticagrelor on endothelial function and other circulating biomarkers in humans Alla ricerca delle propriet¿ fuori prescrizione del Ticagrelor: funzione endot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004189-64,0,0,0 2014-004189-64,3,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,0,ERASMUS MC,Hunting for the OFF-target properties of Ticagrelor on endothelial function and other circulating biomarkers in humans Alla ricerca delle propriet¿ fuori prescrizione del Ticagrelor: funzione endot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004189-64,0,0,0 2014-004190-16,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Hospices Civils de Lyon,Determination of the optimal dose of ephedrine to treat hypotension during surgery of newborn to six months infant Détermination de la dose optimale d’éphédrine dans le traitement de l’hypotension ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004190-16,0,0,0 2014-004193-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Rennes,Development of a tool for adapting dosage of fluoroquinolones by using a population pharmacokinetic model Elaboration d’un outil d’aide à l’adaptation de posologie de fluoroquinolones par l’utilisa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004193-41,0,0,0 2014-004194-16,1,2018-06-08,2018-06-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,"A multicenter, single-arm, phase II study to evaluate the activity of pre-operative zoledronate in triple negative breast cancer patients, according to p53 level",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004194-16,0,0,0 2014-004197-42,1,2020-12-15,2020-12-15,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,University Hospital of Ulm,A proof of concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 Treatment Protocol) for rec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004197-42,0,0,0 2014-004201-33,1,2016-12-29,2016-12-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Arrowhead Research Corporation,"A Multicenter, Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with Chronic Hepatitis B Virus (HBV) Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004201-33,0,0,0 2014-004207-78,1,2015-12-16,2015-12-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Aarhus University Hospital,Comparison of the effect of saphenous block with plain bupivacaine vs. protracted bupivacaine mixture as a supplement to continuos sciatic catheter after major ankle and foot surgery: a randomized stu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004207-78,0,0,0 2014-004210-28,1,2016-12-31,2016-12-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Nuclear Medicine, Aalborg University Hospital",68Ga-PSMA PET/CT vs. MRI/CT vs. lymphadenectomy for the identification of lymph node metastases in locally advanced prostate cancer patients: a diagnostic test accuracy study 68Ga-PSMA PET/CT versu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004210-28,0,0,0 2014-004221-41,14,2016-10-26,2016-10-28,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BAYER AG,"A randomized, parallel-group, double-blind placebo-controlled and open label active-controlled, multi-center study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004221-41,0,0,0 2014-004221-41,14,2016-10-26,2016-10-28,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, parallel-group, double-blind placebo-controlled and open label active-controlled, multi-center study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004221-41,0,0,0 2014-004221-41,14,2016-10-26,2016-10-28,13,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,"A randomized, parallel-group, double-blind placebo-controlled and open label active-controlled, multi-center study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004221-41,0,0,0 2014-004223-46,8,2018-06-21,2018-06-21,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Stallergenes,"A randomized, double-blind, placebo-controlled, multi-center study of the efficacy and safety of STG320 sublingual tablets of house dust mite (HDM) allergen extracts in adults and adolescents with HDM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004223-46,0,0,0 2014-004223-46,8,2018-06-21,2018-06-21,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,STALLERGENES,"A randomized, double-blind, placebo-controlled, multi-center study of the efficacy and safety of STG320 sublingual tablets of house dust mite (HDM) allergen extracts in adults and adolescents with HDM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004223-46,0,0,0 2014-004223-46,8,2018-06-21,2018-06-21,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Stallergenes S.A.,"A randomized, double-blind, placebo-controlled, multi-center study of the efficacy and safety of STG320 sublingual tablets of house dust mite (HDM) allergen extracts in adults and adolescents with HDM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004223-46,0,0,0 2014-004224-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Université catholique de Louvain,Temocillin pharmacokinetics in paediatrics Pharmacocinétique de la témocilline en pédiatrie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004224-22,0,0,0 2014-004226-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ Onkotrápiás Klinika,"Metasztatikus ER+ HER2- férfi emlőrák fulvestant és CKD 4/6 inhibitor palbociclib kezelésae többszörös megelőző kemoterápia, endokrin terápia és molekuláris célzott terápia után",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004226-18,0,0,0 2014-004228-23,1,2017-04-05,2017-04-05,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Inserm,"N/A Etude pilote, comparative, monocentrique, randomisée, en cross over, en double aveugle, contre placebo, testant l'efficacité de l'huile de triheptanoïne dans les Hémiplégies Alternantes de l'En...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004228-23,0,0,0 2014-004232-19,1,2017-01-22,2017-01-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Luitpold Pharmaceuticals, Inc.","A Multi-center, Open-label, Single Arm Study to Characterize the Pharmacokinetics and Pharmacodynamics Profile of Intravenous Ferric Carboxymaltose in Pediatric Subjects 1 –17 years old with Iron Defi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004232-19,0,0,0 2014-004235-39,1,2022-03-03,2022-03-03,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,"Folktandvården, Landstinget Dalarna",Pain control in surgical intervention. Biomarkers in acute and chronical post operative pain Smärtlindring vid kirurgisk intervention och biomarköranalys vid utveckling av akut och långvarig smärta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004235-39,0,0,0 2014-004236-19,1,2018-02-21,2018-02-21,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Landstinget i Östergötland,Pudendal block after posterior vaginal surgery. A randomized controlled trial on postoperative pain. Pudendusblockad efter bakre vaginal kirurgi. En randomiserad kontrollerad studie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004236-19,0,0,0 2014-004238-25,1,2016-11-30,2016-11-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Royal Wolverhampton NHS Trust,Pharmacokinetics and Pharmacodynamics of Platelet P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention (PCI) for Acute Myocardial Infarction: A Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004238-25,0,0,0 2014-004239-37,5,2018-03-29,2018-03-29,4,0,0,0,0,0,4,0,0,2,0,0,0,0,1,AUXILIUM UK LTD,"Long-term safety, curvature deformity characterization, and immunogenicity over time in subjects previously treated with AA4500 for Peyronie?s disease in studies AUX-CC-802, AUX-CC-803, AUX CC 804, an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004239-37,1,0,0 2014-004239-37,5,2018-03-29,2018-03-29,4,0,0,0,0,0,4,0,0,2,0,0,0,0,1,Auxilium UK Limited,"Long-term safety, curvature deformity characterization, and immunogenicity over time in subjects previously treated with AA4500 for Peyronie?s disease in studies AUX-CC-802, AUX-CC-803, AUX CC 804, an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004239-37,1,0,0 2014-004239-37,5,2018-03-29,2018-03-29,4,0,0,0,0,0,4,0,0,2,0,0,0,0,1,Endo Ventures Limited,"Long-term safety, curvature deformity characterization, and immunogenicity over time in subjects previously treated with AA4500 for Peyronie?s disease in studies AUX-CC-802, AUX-CC-803, AUX CC 804, an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004239-37,1,0,0 2014-004244-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IRCCS Ospedale San Raffaele,AMYLOID LOAD IN PRODROMAL AD WITH LIMBIC-PREDOMINANT PHENOTYPE PRINCIPAL INVESTIGATOR - STUDIO DEL CARICO DI AMILOIDE IN AD PRODROMICO CON FENOTIPO LIMBICO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004244-35,0,0,0 2014-004248-36,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Novartis Pharma Services AG,"A phase 3, Observed-Blind, Randomized, Multi-center Study to Evaluate Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004248-36,0,1,1 2014-004249-29,1,2016-12-31,2016-12-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,The Newcastle Upon Tyne Hospitals NHS Foundation Trust,"An Open Label, Non-Randomised, Phase II study to Determine if Dabigatran and its Metabolites are Detectable in Breast Milk Following Oral Administration to Non-Breastfeeding Mothers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004249-29,0,0,0 2014-004250-34,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Janssen R&D Ireland,"A Phase 2, Open-label, Single-arm Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of 12 Weeks Treatment With Simeprevir and Daclatasvir in Subjects With Chronic Hepatitis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004250-34,0,0,0 2014-004252-60,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,"Vaccine Research Center, University of Tampere",Shedding and immune response of rotavirus vaccine (RotaTeq) Rotavirusrokotteen (RotaTeq) erittyminen ja immuunivaste,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004252-60,0,0,0 2014-004254-33,2,2016-08-10,2016-10-08,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Infirst+ HEALTHCARE Ltd,"A Three Arm Double blind, Randomised Multicentre Study to Investigate the Non-Inferiority of a Soft Gel Capsule of Ibuprofen Lipid Formulation (total daily dose 1200 mg) versus a Standard Soft Gel Ibu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004254-33,0,0,0 2014-004255-31,1,2015-05-09,2015-05-09,1,0,0,0,1,0,3,0,0,1,0,0,1,0,1,infirst HEALTHCARE,"A real world, single-blind, randomised study to compare an OTC cough medicine (cs1002) containing diphenhydramine, levomenthol and ammonium chloride with a simple linctus containing citric acid monohy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004255-31,0,0,0 2014-004261-24,1,2017-02-24,2017-02-24,1,1,0,0,0,1,2,0,1,1,1,1,1,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,AN OPEN-LABEL PHASE 2 STUDY TO ASSESS THE EFFECT OF C5AR ANTAGONIST THERAPY BY CCX168 ORAL ADMINISTRATION ON EX VIVO THROMBUS FORMATION AND DISEASE ACTIVITY IN ESRD PATIENTS WITH ATYPICAL HEMOLYTIC U...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004261-24,0,0,0 2014-004265-25,1,,,0,0,1,0,0,1,2,0,0,1,0,0,0,1,0,University Medical Centre Utrecht,"2-STEP: A single-centre, phase II study to evaluate the safety, tolerability and pharmacokinetics of 2-Iminobiotin (2-IB) in neonates with gestational age of ≥36 weeks with moderate to severe perinata...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004265-25,0,0,0 2014-004266-26,9,2016-10-14,2016-10-14,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Tic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004266-26,0,0,0 2014-004267-20,1,2019-11-15,2019-11-15,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Medical Center - University of Freiburg,"Multicenter, randomized Phase 2 Trial to determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) versus BAT in Steroid-refractory acute Graft-versus-Host Disease (aGvHD) Mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004267-20,0,0,0 2014-004268-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Semmelweis Egyetem Transzplantációs és Sebészeti Klinika,Individual Patient Access to AbbVie ABT-450/ritopnavir/ABT-267 and ABT-333 Coadministeres with ribavirin (RBV) in Adult Liver Transplant Recipient with Genotype 1 Hepatitis C Virus Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004268-38,0,0,0 2014-004269-26,4,2022-01-31,2022-02-01,2,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Nordic Society of Gynaecological Oncology (NSGO),"Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004269-26,1,0,0 2014-004269-26,4,2022-01-31,2022-02-01,2,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Nordic Society of Gynaecological Oncology - Clinical Trial Unit,"Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004269-26,1,0,0 2014-004269-26,4,2022-01-31,2022-02-01,2,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU),"Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004269-26,1,0,0 2014-004271-22,4,2018-06-07,2018-07-02,3,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Regents of the University of Minnesota,Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004271-22,0,0,0 2014-004272-29,1,2018-01-23,2018-01-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Great Ormond Street Hospital NHS foundation Trust,Phase II clinical trial to evaluate safety and efficacy of mobilisation and collection of CD34+ cells after treatment with plerixafor and filgrastim in patients with Fanconi anaemia for subsequent tra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004272-29,0,0,0 2014-004274-41,6,2018-06-28,2018-06-28,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Janssen-Cilag International N.V.,"A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alzhei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004274-41,0,0,0 2014-004278-40,1,2022-05-13,2022-05-13,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Bristol-Myers Squibb International Corporation,Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004278-40,0,0,0 2014-004281-25,4,2016-09-15,2016-09-15,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Millennium Pharmaceuticals, Inc.",A Phase 1b/Adaptive Phase 2 Study of Docetaxel With or Without MLN1117 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004281-25,1,0,0 2014-004281-25,4,2016-09-15,2016-09-15,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"MILLENNIUM PHARMACEUTICALS, INC.",A Phase 1b/Adaptive Phase 2 Study of Docetaxel With or Without MLN1117 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004281-25,1,0,0 2014-004282-25,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CHU de Bordeaux,Subcutaneous route and pharmacology of metoclopramide - SOPHA-Méto SOus-cutanée et PHArmacologie du Métoclopramide - SOPHA-Méto,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004282-25,0,0,0 2014-004283-37,3,2021-02-09,2021-02-09,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Astellas Pharma Global Development, Inc.","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004283-37,1,0,0 2014-004283-37,3,2021-02-09,2021-02-09,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004283-37,1,0,0 2014-004295-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Oulu University Hospital, Department of Anaesthesia",Postoperative pain management after heart valve surgery using parasternal block and PCA Oxycodone Sydänläppäleikkauksen jälkeinen kivunhoito käyttäen parasternaalipuudutusta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004295-28,0,0,0 2014-004296-22,1,2017-05-02,2017-05-02,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Centre Eugène Marquis,Anticholinergics impact in the treatment of acute irritative urinary toxicity during radiotherapy for prostate cancer Impact des anticholinergiques dans le traitement de la toxicité urinaire irrita...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004296-22,0,0,0 2014-004297-42,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,UMC Utrecht,Effect of Switching Atripla to Eviplera on neurocognitive and emotional functioning Effect van switchen van Atripla naar Eviplera op neurocognitief en emotioneel functioneren,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004297-42,0,0,0 2014-004298-18,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,AUSL 8,"Ticagrelor vs. clopidogrel in patients undergoing implantation of paclitaxel-eluting stents in the femoropopliteal district: a randomized, nested pilot study using Frequency-Domain Optical Coherence T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004298-18,0,0,0 2014-004299-41,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dipartimento di Scienze mediche Oncologia Medica Policlinico Gemelli,ERbitux MEtastatic colorectal cancer Strategy Study: A phase III randomized two arm study with FOLFIRI + Cetuximab until disease progression compared to FOLFIRI + Cetuximab for 8 cycles followed by Ce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004299-41,0,0,0 2014-004299-41,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dipartimento di Scienze Mediche Oncologia Medica Policlinico Gemelli,ERbitux MEtastatic colorectal cancer Strategy Study: A phase III randomized two arm study with FOLFIRI + Cetuximab until disease progression compared to FOLFIRI + Cetuximab for 8 cycles followed by Ce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004299-41,0,0,0 2014-004313-82,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Anaesthesia and Operative Services, Kuopio University Hospital",Efficacy and safety of epidural oxycodone Oksikodonin teho ja turvallisuus epiduraalisen annon jälkeen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004313-82,0,0,0 2014-004314-29,6,2017-01-24,2017-01-24,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"MULTICENTRE, OPEN LABEL, RANDOMIZED, TWO-ARM, PARALLEL-GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF ENVARSUS® COMPARED WITH TACROLIMUS USED AS PER CURRENT CLINICAL PRACTICE IN THE INITIAL MAINTENANCE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004314-29,0,0,0 2014-004314-29,6,2017-01-24,2017-01-24,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,CHIESI FARMACEUTICI S.P.A.,"MULTICENTRE, OPEN LABEL, RANDOMIZED, TWO-ARM, PARALLEL-GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF ENVARSUS® COMPARED WITH TACROLIMUS USED AS PER CURRENT CLINICAL PRACTICE IN THE INITIAL MAINTENANCE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004314-29,0,0,0 2014-004317-90,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud University Medical Center Nijmegen,Visualizing beta cells in patients with remission of T2DM after bariatric surgery Beeldvorming van beta cellen in patienten met remissie van type 2 diabetes na bariatrische chirurgie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004317-90,0,0,0 2014-004318-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oslo University Hospital,Intravenous bisphosphonate in stress fracture treatment -A randomised controlled double blinded multicenter trial Intravenøs bisfosfonat ved stressfrakturer -En randomisert kontrollert dobbelt blin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004318-27,0,0,0 2014-004331-39,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Vall Hebron Institut de Recerca,HIV Reservoir Dynamics After Switching To Dolutegravir in Patients on a PI/r Based Regimen. A Phase IV Open Randomized Trial Dinámica de los reservorios de HIV después de cambiar a Dolutegravir en ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004331-39,0,0,0 2014-004333-57,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"UCB Japan Co., Ltd.","A Double-blind, Randomized, Placebo-controlled 5 Parallel Groups, Confirmatory Trial on the Efficacy and Safety of Levetiracetam used as add-on Therapy at doses of 0.5 to 3 g/day in Patients From 16 t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004333-57,0,1,1 2014-004334-26,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,UCB Japan Co. Ltd,"A Multicenter, Open, Long-term Follow-up Study to Evaluate the Safety and Efficacy of L059 (Levetiracetam) at Individual Optimal Dose Ranging From 500 to 3000 mg/Day in Twice Daily Administration in S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004334-26,0,1,1 2014-004335-39,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,UCB Japan Co. Ltd.,"An Open Label, Single-Arm, Multi-Center Study on the Efficacy, Safety and Pharmacokinetics of Levetiracetam in Pediatric Patients (4 to 16 Years) With Partial Seizures Despite Treatment With 1 or 2 An...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004335-39,0,1,1 2014-004340-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico,Randomized controlled trial of two different combinations of Calcium-containing Phosphate binders (Ca-PiB) plus non-Calcium-non-Aluminum containing Phosphate binders (no-Ca-Al-PiB): a pharma-economic ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004340-35,0,0,0 2014-004341-27,3,2018-11-19,2018-11-19,2,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a History ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004341-27,1,1,0 2014-004343-12,1,2018-06-01,2018-06-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Mater Research Institute University of Queensland,Impact on Caesarean Section Rates Following Injections of Sterile Water,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004343-12,0,0,0 2014-004344-35,1,2015-02-16,2015-02-16,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Leiden University Medical Center,The effect of tetanus revaccination in patients with myasthenia gravis Het effect of tetanus revaccinatie in patienten met myasthenia gravis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004344-35,0,0,0 2014-004346-10,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Alder Hey Children's NHS Foundation Trust,Study to evaluate the optimal dose of remifentanil infusion(effective dose in 80% of patients) required to ensure apnoea (of 30 seconds duration) during magnetic resonance imaging of the heart under g...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004346-10,0,0,0 2014-004347-12,1,2018-04-30,2018-04-30,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,Hybrigenics SA,Exploratory Study of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study Etude exploratoire de l'inécalcitol dans la maladie résiduelle de la leucémie myéloïde chronique ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004347-12,0,0,0 2014-004349-29,1,2017-04-07,2017-04-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Rigshospitalet,Mesenchymal stem cells for radiation-induced xerostomia (MESRIX) in previous HPV-positive oropharyngeal head and neck cancer patients Mesenkymale stamceller til behandling af stråleinduceret xerost...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004349-29,0,0,0 2014-004350-34,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc",A Comparative Bioavailability Study of a Tablet versus an Investigational Oral Suspension of Vorapaxar,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004350-34,0,1,1 2014-004353-14,2,2019-08-08,2019-08-08,2,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Effect of liraglutide for weight management in pubertal adolescent subjects with obesity. 56-week, double-blind, randomised, parallel-group, placebo-controlled multi-national trial followed by a 26-we...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004353-14,0,0,0 2014-004354-34,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"UCB Japan Co., Ltd.","A 26-week, multi-center, open-label study to investigate the efficacy and safety of CDP870 in active Crohn’s disease patients, who showed clinical efficacy in a remission induction study (Study C87037...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004354-34,0,1,1 2014-004357-13,1,2016-06-14,2016-06-14,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Odense University Hospital,Coagaulation in patients with atrial fibrillation: The effect of dabigatran Koagulationssystemet hos patienter med atrieflimren: Dabigatrans virkning på koagulationsmålinger,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004357-13,0,0,0 2014-004358-32,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Institut Jules Bordet,Biomarker Research Study for PF-03084014 in cHEmoresistant triple negative breast cAncer - “RHEA” study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004358-32,0,0,0 2014-004363-21,3,2016-10-31,2016-11-30,3,0,0,0,0,0,3,0,0,1,1,1,1,0,1,"Marinus Pharmaceuticals, Inc","A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Partial-Onset Seizures Followe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004363-21,0,0,0 2014-004367-20,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Sanofi Pasteur,A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccines in Healthy Toddlers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004367-20,0,0,0 2014-004371-22,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,ADIENNE SA,"Phase IV study to assess, the effect of hepatic impairment on the pharmacokinetics of Thiotepa and the potential of Thiotepa to alter the QT interval in pedatric patients undergoing allogeneic haemato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004371-22,0,0,0 2014-004372-27,5,2018-04-12,2018-04-12,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Theravance Biopharma Antibiotics, Inc.","A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects with Staphylococcus aureus Bacteremia Including Infective E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004372-27,1,0,0 2014-004372-27,5,2018-04-12,2018-04-12,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"THERAVANCE BIOPHARMA ANTIBIOTICS, INC.","A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects with Staphylococcus aureus Bacteremia Including Infective E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004372-27,1,0,0 2014-004372-27,5,2018-04-12,2018-04-12,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Theravance Biopharma Ireland Limited,"A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects with Staphylococcus aureus Bacteremia Including Infective E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004372-27,1,0,0 2014-004375-23,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"UCB BIOSCIENCES, Inc.",An open-label extension study to assess the safety and seizure frequency associated with long-term oral lacosamide for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004375-23,0,1,1 2014-004376-39,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"UCB Biosciences, Inc.","An Open-Label, Multicenter, Parallel-Group, Two-Arm Study Comparing the Pharmacokinetics of Keppra XR in Children (Aged 12 - 16 Years Old) With Epilepsy and in Adults (Aged 18 - 55 Years Old) With Epi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004376-39,0,1,1 2014-004377-16,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,UCB Japan Co. Ltd.,"An Open-label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Levetiracetam Used as Monotherapy in Newly or Recently Diagnosed Epilepsy Patients Aged Older Than or Equal to 16 Ye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004377-16,0,1,1 2014-004378-40,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,UCB BIOSCIENCES Inc.,"A Multicenter, Open-label Trial to Assess the Safety and Tolerability of a Single Intravenous Loading Dose of Lacosamide Followed by Oral Lacosamide Maintenance as Adjunctive Therapy in Subjects With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004378-40,0,1,1 2014-004379-22,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"UCB BIOSCIENCES, Inc.",An Open-Label Pilot Study to Assess the Safety of Oral Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004379-22,0,1,1 2014-004380-20,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Sanol GmbH,"A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized and Multi-center Trial to Investigate Efficacy and Safety in Subjects With Iron Deficiency Anemia for Ferrous (II) Glycine Sulphat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004380-20,0,1,1 2014-004381-24,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,UCB Celltech,"A Phase 2, Open-label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Active Crohn's Disease (NURTURE Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004381-24,0,1,1 2014-004382-25,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,UCB Japan Co. Ltd.,"An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Levetiracetam in Japanese Patients (≥4 to <16 Years) With Uncontrolled Generalized Tonic-c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004382-25,0,1,1 2014-004383-37,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"UCB BIOSCIENCES, Inc.","A Multicenter, Open-Label, 2-Group, Dose Escalation Study of Monotherapy Administration of Rotigotine in Pediatric Subjects With Idiopathic Restless Legs Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004383-37,0,1,1 2014-004384-21,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"UCB BIOSCIENCES, Inc.","A Multicenter, Open-label Extension Trial to Assess the Long-term Safety and Tolerability of Lacosamide as Adjunctive Therapy in Subjects With Partial-onset Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004384-21,0,1,1 2014-004386-24,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II,Effect of GH receptor antagonist on insulin resistance associated with acromegaly Effetto dell¿antagonista del recettore del GH (pegvisomant) sul metabolismo glucidico in pazienti affetti da acrome...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004386-24,0,0,0 2014-004388-20,1,2018-05-03,2018-05-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cancer Research UK,"A Cancer Research UK randomised, double-blind, placebo-controlled Phase IIa trial of AMG 319 given orally as a neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative hea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004388-20,0,0,0 2014-004392-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Turku University Hospital,68Ga-NODAGA-RGD cardiac PET in patients with acute myocardial infarction or chronic total coronary occlusion 68-Ga-NODAGA-RGD-peptidin käyttö sydänlihaksen angiogeneesin kuvantamisessa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004392-23,0,0,0 2014-004393-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CUB Hospital Erasme,"A double-blind, placebo-controlled study of the impact of prophylactic treatment with Galantamine 8mg of cognitive impairment during an electroconvulsive therapy (ECT) in patients with major depressi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004393-41,0,0,0 2014-004395-28,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Azienda Ospedaliero-Universitaria di Parma,Phase II randomized study of maintenance regorafenib vs placebo in no progression patients after first-line platinum and fluoropyrimidines based chemotherapy in HER2 negative locally advanced/metastat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004395-28,0,0,0 2014-004396-23,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"UCB, Inc.","A 19-week, Randomized, Double-blind, Multicenter, Placebo-controlled Safety Study to Evaluate the Cognitive and Neuropsychological Effects of Levetiracetam 20-60 mg/kg/day, Divided in Twice Daily Dosi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004396-23,0,1,1 2014-004397-42,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,UCB Pharma Inc.,"An open-label, multi-center, follow-up trial to evaluate the long-term safety and efficacy of brivaracetam used as adjunctive treatment at a flexible dose up to a maximum of 200 mg/day in subjects age...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004397-42,0,1,1 2014-004398-18,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"UCB BIOSCIENCES, Inc.",An Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral SPM 927 in Patients With Partial Seizures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004398-18,0,1,1 2014-004399-42,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"UCB Japan Co., Ltd.","A Phase II, Multi-center, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Assess the Safety and Efficacy of CDP870/Certolizumab Pegol, Dosed Subcutaneously in Patients With Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004399-42,0,1,1 2014-004400-30,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"UCB Japan Co., Ltd.","A multi-center, open-label study to investigate the efficacy and safety of CDP870 in active Crohn’s Disease patients, who showed no clinical efficacy in a remission induction study (Study C87037) but ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004400-30,0,1,1 2014-004401-32,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,UCB Japan Co. Ltd.,"A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment With Oral Levetiracetam, in Epilepsy Patients Aged ≥16 Years, With General...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004401-32,0,1,1 2014-004402-15,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,"UCB Korea Co.,Ltd.","A Randomized, Open-label, Parallel Group, Multi-center, Comparative, Phase IV Trial of Levetiracetam (LEV) Versus Topiramate (TPM) as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004402-15,0,1,1 2014-004409-34,3,2017-05-01,2017-05-01,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Euroscreen S.A,"Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Polyc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004409-34,0,0,0 2014-004409-34,3,2017-05-01,2017-05-01,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ogeda S.A,"Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Polyc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004409-34,0,0,0 2014-004410-29,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics S.r.l,"A Phase 2b/3, Multi-Center, Observer-Blind, Controlled Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents Aged 11-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004410-29,0,1,1 2014-004412-11,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Canbex Therapeutics Ltd,"A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004412-11,0,0,0 2014-004414-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitari Mutua Terrassa,"Controlled, randomized trial, comparing the efficacy of paromomicin and cotrimoxazol versus metronidazol in the eradication of Blastocystis hominis in patients with gastrointestinal symptoms. Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004414-28,0,0,0 2014-004415-37,3,2020-11-19,2020-11-19,2,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week double...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004415-37,0,0,0 2014-004416-11,2,2019-02-10,2019-02-10,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Modus Therapeutics AB,"A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004416-11,0,0,0 2014-004418-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klin. Abt. f. Endokrinologie und Stoffwechsel",Standardized tight blood glucose management versus usual glycaemic control in patients undergoing allogeneic stem cell transplantation – a pilot trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004418-27,0,0,0 2014-004419-35,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,NHS Greater Glasgow and Clyde,Inhibition of Co-Stimulation in Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004419-35,0,0,0 2014-004419-35,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Glasgow,Inhibition of Co-Stimulation in Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004419-35,0,0,0 2014-004420-22,1,2020-03-20,2020-03-20,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University College Cork,Enhancing malignant melanoma immunological engagement using sequential therapy with ipilimumab and electrochemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004420-22,0,0,0 2014-004422-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITY OF FLORENCE,Double-blinded placebo-controlled study on men with lower urinary tract symptoms secondary to prostatic hyperplasia (LUTS-BPH) to assess changes in pressure flow study (PFS) and in molecular profile o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004422-17,0,0,0 2014-004425-41,3,2016-12-05,2016-12-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Euroscreen S.A,"A Phase IIa, Double-Blind, Placebo-Controlled, Study of ESN364 Administered for 12 Weeks to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Women Presenting With Ute...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004425-41,0,0,0 2014-004427-40,3,2015-10-07,2015-10-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients with Mild to Moderate Persistent Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004427-40,0,0,0 2014-004429-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Diater Laboratorio de Diagnósticos y Aplicaciones Terapéuticas, S.A.","Open multicenter clinical trial to confirm the maximum no reactive dose of allergoid of polymerized Dermatophagoides pteronyssinus, in patients with allergic rhinoconjunctivitis or mild or moderate as...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004429-42,0,0,0 2014-004430-26,1,2018-03-26,2018-03-26,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Queen Mary University of London,FEASIBILITY of IBIS 3. An International Breast Intervention Study investigating Prevention Of Late Recurrence in ER+ breast cancer survivors following 5 years of adjuvant treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004430-26,0,0,0 2014-004431-38,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Lofarma S.p.A.,"Double-blind, placebo-controlled, parallel-group, randomized multicentre study to assess the efficacy and safety of LAIS® Ragweed Sublingual tablet in patients with allergic rhinoconjunctivitis to rag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004431-38,0,0,0 2014-004432-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC Cancer Institute,Activity of trastuzumab based chemotherapy in metastatic breast patients with HER2-negative primary tumor but HER2 positive circulating tumor cells (CareMore-Trastuzumab),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004432-18,0,0,0 2014-004435-40,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Menarini Ricerche Spa,"A double-blind, randomised, placebo-controlled, two parallel arm study to evaluate the efficacy of a single intra-articular dose of fasitibant given in extemporaneous combination with sodium hyalurona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004435-40,0,0,0 2014-004436-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,G.O.N.O.,First-line FOLFOXIRI plus bevacizumab followed by reintroduction of FOLFOXIRI plus bevacizumab at progression versus FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab at progression in firs...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004436-19,0,0,0 2014-004437-22,2,2020-08-04,2020-08-04,2,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Liverpool,"A Randomised three-arm, open label, Phase II study of continuous Selumetinib versus continuous or interrupted Selumetinib in combination with weekly Paclitaxel in metastatic Uveal Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004437-22,0,0,0 2014-004438-24,13,2019-06-24,2019-06-26,12,1,1,0,0,2,2,0,0,1,1,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004438-24,0,0,0 2014-004438-24,13,2019-06-24,2019-06-26,12,1,1,0,0,2,2,0,0,1,1,0,1,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004438-24,0,0,0 2014-004442-10,1,2017-11-01,2017-11-01,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,UZ Leuven,"Intraocular pressure and tolerability Study of Preserved Bimatoprost 0.1% (BMD) or Tafluprost Unit Dose Preservative Free 15microgram/ml (TUDPF) (Saflutan), in patients with Ocular hypertension or gl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004442-10,0,0,0 2014-004445-26,1,2018-03-07,2018-03-07,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,World Health Organization,"A phase III, randomized, double-blind, active, controlled, multinational, multicentre, non-inferiority trial using Carbetocin room temperature stable (RTS) for the prevention of postpartum haemorrhag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004445-26,0,0,0 2014-004446-95,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A Phase IV, open-label, controlled, multi-center study to evaluate the 5-year antibody persistence among children who previously received Novartis MenACWY conjugate vaccine at 2 to 10 years of age and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004446-95,0,1,1 2014-004448-37,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University Medical Center Groningen,Visualising neuroinflammation in chronic fatigue syndrome patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004448-37,0,0,0 2014-004449-28,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fédération Francophone de Cancérologie Digestive,A randomized multicenter phase II trial of a sequential chemotherapy of nab-paclitaxel + gemcitabine followed by FOLFIRI.3 versus nab-paclitaxel + gemcitabine in first line of pancreatic adenocarcinom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004449-28,0,0,0 2014-004454-34,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,Novo Nordisk A/S,"A randomised, double-blind, placebo-controlled trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of liraglutide in obese children aged 7 to 11 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004454-34,0,1,1 2014-004458-33,2,2015-02-03,2015-02-03,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Chimerix UK Limited,"An Open-Label, Multicenter Study of the Safety, Tolerability and Antiviral Activity of Brincidofovir (CMX001) for Treatment of Ebola Virus Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004458-33,0,0,0 2014-004463-20,4,2017-03-20,2017-03-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004463-20,0,0,0 2014-004464-38,10,2017-06-19,2017-06-19,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Amgen Inc,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004464-38,0,0,0 2014-004465-24,1,2015-11-26,2015-11-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharma A/S,Safety and efficacy of repeat use of Picato® 0.05% in the treatment of anogenital warts,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004465-24,0,0,0 2014-004467-20,1,2015-06-04,2015-06-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Avexxin AS,"A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Dose-escalation, Single Centre Study to Assess the Safety and Efficacy of AVX001 when Administered Topically Once Daily in Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004467-20,0,0,0 2014-004471-23,10,2018-05-09,2018-05-09,9,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford,Antivirals for influenza -Like Illness? An rCt of Clinical and Cost effectiveness in primary CarE. Antiviral behandling mot influensaliknande sjukdom? En RCT för att bedöma klinisk effekt och kostn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004471-23,0,0,0 2014-004472-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University medical Centre,TREAT EARLY ARTHRALGIA TO REVERSE OR LIMIT IMPENDING EXACERBATION TO RHEUMATOID ARTHRITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004472-35,0,0,0 2014-004473-16,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Masarykův onkologický ústav,Prospective study investigating efficacy of lanreotide on decrease of chemotherapy induced diarrhoea (CID) in patiens with colorectal carcinoma. Prospektivní studie zkoumající účinnost lanreotidu ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004473-16,0,0,0 2014-004474-42,1,2017-10-24,2017-10-24,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Copenhagen University Hospital at Hvidovre,"Treatment of equinus gait caused by dynamic tightening of the calf muscles in children with cerebral palsy. A randomized, placebo controlled Botulinum toxin type A volume/response study. Behandling...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004474-42,0,0,0 2014-004475-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Radboud University Nijmegen,Enhancement of exposure therapy for social anxiety disorder with testosterone: A randomized clinical trial De toegevoegde waarde van testosteron bij exposuretherapie voor sociale angststoornis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004475-23,0,0,0 2014-004476-30,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics SRL,"A Phase 3, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of Novartis rMenB+OMV NZ Vaccine Formulated with Outer Membrane Vesicle (OMV) Manufactured...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004476-30,0,1,1 2014-004477-16,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Novartis Healthcare Pvt. Ltd., Vaccines Division","A phase 3, multi-center, open-label study to evaluate immunogenicity and safety of Novartis Meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy subjects from 2 to 75 years of age in India.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004477-16,0,1,1 2014-004478-41,1,2018-11-28,2018-11-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,King's College London,Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004478-41,0,0,0 2014-004478-41,1,2018-11-28,2018-11-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Guy's and St Thomas' NHS Foundation Trust,Phase III trial in IntrahepaTic CHolestasis of pregnancy (ICP) to Evaluate urSodeoxycholic acid (UDCA) in improving perinatal outcomes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004478-41,0,0,0 2014-004480-20,6,2017-04-10,2017-04-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Randomized, Double-blind Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004480-20,0,0,0 2014-004480-20,6,2017-04-10,2017-04-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 2, Randomized, Double-blind Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004480-20,0,0,0 2014-004482-24,9,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase II clinical trial of MK-3475 (pembrolizumab) in subjects with relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004482-24,0,0,0 2014-004482-24,9,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidary of Merck & Co., Inc.",A Phase II clinical trial of MK-3475 (pembrolizumab) in subjects with relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004482-24,0,0,0 2014-004482-24,9,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co Inc",A Phase II clinical trial of MK-3475 (pembrolizumab) in subjects with relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004482-24,0,0,0 2014-004482-24,9,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,",A Phase II clinical trial of MK-3475 (pembrolizumab) in subjects with relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004482-24,0,0,0 2014-004482-24,9,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., filial de Merck & Co., Inc.",A Phase II clinical trial of MK-3475 (pembrolizumab) in subjects with relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004482-24,0,0,0 2014-004482-24,9,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc",A Phase II clinical trial of MK-3475 (pembrolizumab) in subjects with relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004482-24,0,0,0 2014-004483-38,1,2018-04-20,2018-04-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME),"TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial TMP001 bei schubförmig-remittierender Multipler Sklerose - eine multizentrische, o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004483-38,0,0,0 2014-004485-21,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Hellenic Cooperative Oncology Group,A study of cabazitaxel treatment in castration resistant bone metastatic prostate cancer patients evaluating the tumor microenvironment Μια μελέτη αξιολόγησης του μικροπεριβάλλοντος του όγκου σε ασ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004485-21,0,0,0 2014-004486-25,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,University Hospital Policlinico Umberto I,Prevention of the reperfusion myocardical damage in patients with acute myocardial infarct submitted to primary PCI through infusion of 'glutatione sale sodico' ev. Prevenzione del danno miocardico...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004486-25,0,0,0 2014-004488-19,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Radboud University Medical Center,"Pharmacokinetics, safety and efficacy of atazanavir /dolutegravir/lamivudine regimen as maintenance regimen in pa-tients with intolerance and/or resistance to NRTIs, NNRTIs and RTV: a pilot study (PRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004488-19,0,0,0 2014-004489-85,2,2018-11-30,2018-11-30,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Morphotek Inc,"A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004489-85,0,0,0 2014-004490-17,1,2016-04-28,2016-04-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Bipebjerg University Hospital,Effect of ACE-Inhibition on Microvascular Function in Women with Assessed Microvascular Dysfunction and No Obstructive Coronary Artery Disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004490-17,0,0,0 2014-004491-31,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Abbott Japan Co., Ltd","Multi-center, Open-label, Uncontrolled Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less with Immunocompromised Medical Conditions",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004491-31,0,1,1 2014-004492-23,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics Srl,"A Phase 3, Single Center, Open-label, Controlled, Randomized Study to Evaluate the Safety and Immunogenicity of Novartis Men ACWY vaccine administered either alone or concomitantly with a Combined Tet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004492-23,0,1,1 2014-004493-42,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Abbvie previously known as Abbott,"A Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children with Central Precocious Puberty",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004493-42,0,1,1 2014-004494-16,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Abbvie previously known as Abbott,"A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children with Central Precocious Puberty",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004494-16,0,1,1 2014-004495-36,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Abbvie previously known as Abbott,Study of Lupron Depot in the Treatment of Central Precocious Puberty,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004495-36,0,1,1 2014-004498-17,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A Multi-center, Phase III, Randomized, Observer Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Trivalent Subunit Inactivated Influenza Vaccine (Agriflu™) in Healthy Children...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004498-17,0,1,1 2014-004499-47,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,"A case control, phase II, monocentric, randomized study, utilizing Zinc as enhancer of immune recovery and immune reconstitution in auto-transplant for multiple myeloma Studio clinico randomizzato ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004499-47,0,0,0 2014-004500-30,1,2017-07-12,2017-07-12,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,King's College London,A phase I/II study evaluating allogeneic mesenchymal stromal cells in adults with recessive dystrophic epidermolysis bullosa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004500-30,0,0,0 2014-004500-30,1,2017-07-12,2017-07-12,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,Guy's and St Thomas NHS Foundation Trust,A phase I/II study evaluating allogeneic mesenchymal stromal cells in adults with recessive dystrophic epidermolysis bullosa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004500-30,0,0,0 2014-004501-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Center,"Infusion VErsus STimulation, a cost-effectiveness analysis of the treatment in advanced Parkinson's disease comparing Continuous Intrajejunal Levodopa Infusion to the traditional standard treetment De...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004501-32,0,0,0 2014-004502-15,1,2016-04-28,2016-04-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Steno Diabetes Center,"Antiproteinuric Effects of Liraglutide Treatment in Patients with Type 2 Diabetes and Albuminuria: A Randomized, Placebo-Controlled Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004502-15,0,0,0 2014-004504-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Helse Fonna, Haugesund Sykehus","""Haemodynamic stability of bupivacaine with and without adrenaline for paracervical block during general anesthesia. A randomized controlled double blinded study.""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004504-29,0,0,0 2014-004506-15,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Takeda Development Centre Europe Ltd.,"A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 1 to 11 Y...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004506-15,0,0,0 2014-004506-15,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Takeda Development Center Americas, Inc","A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 1 to 11 Y...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004506-15,0,0,0 2014-004507-73,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Takeda Development Centre Europe Ltd.,"A Phase 2, Double Blind, Up to 40 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004507-73,0,0,0 2014-004507-73,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Takeda Development Center Americas, Inc","A Phase 2, Double Blind, Up to 40 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004507-73,0,0,0 2014-004509-34,5,2019-05-28,2019-05-28,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Curis, Inc.","Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC Alterations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004509-34,0,0,0 2014-004510-28,6,2019-06-17,2019-06-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Immunicum AB,"An open-label, randomized, controlled, multicenter, phase II study evaluating safety and efficacy of intratumorally administered Intuvax pre-nephrectomy followed by Sunitinib post-nephrectomy, compare...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004510-28,0,0,0 2014-004510-28,6,2019-06-17,2019-06-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Immunicum Aktiebolag,"An open-label, randomized, controlled, multicenter, phase II study evaluating safety and efficacy of intratumorally administered Intuvax pre-nephrectomy followed by Sunitinib post-nephrectomy, compare...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004510-28,0,0,0 2014-004511-36,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Of Leeds,"A randomised phase II trial of Cyclophosphamide and Dexamethasone in combination with Ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004511-36,0,0,0 2014-004512-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,INSTITUTO DE INVESTIGACION SANITARIA FJD,"Multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of vitamin D on ventricular remodeling in patients with acute myocardial infarction: Test VITDAMI (Vitamin D in A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004512-11,0,0,0 2014-004513-90,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud UMC,Optimizing abiraterone (Zytiga®) therapy by exploring the relation between an early biomarker - drug exposure - as a predictor for drug response in patients with mCRPC (OPTIMUM - STUDY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004513-90,0,0,0 2014-004515-37,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A Phase II, Randomized, Controlled, Open Label, Single-Center Study to Evaluate the Immunogenicity, Safety and Tolerability of Fluad-H5N1 and Seasonal Influenza Vaccine in Adult Subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004515-37,0,1,1 2014-004517-84,2,2017-02-10,2017-02-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ITF Research Pharma S.L.U,"A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND MULTI-CENTRE CLINICAL TRIAL TO ASSESS THE SAFETY OF 0.005 % ESTRIOL VAGINAL GEL IN HORMONE RECEPTOR-POSITIVE POSTMENOPAUSAL WOM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004517-84,0,0,0 2014-004519-35,4,2015-05-19,2015-07-07,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Abbott Laboratories GmbH,"A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects with Pancreatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004519-35,0,0,0 2014-004522-17,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Imperial College London & Imperial College Healthcare NHS Trust,The mechanism of action of N-ACetylcysteine for reducing the risk of Infection in Alcoholic Hepatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004522-17,0,0,0 2014-004523-51,6,2017-09-27,2017-09-27,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,UCB CELLTECH (UK BRANCH OF UCB PHARMA SA),"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJOGREN?S SYNDROME ESTUDIO PRUEBA DE CON...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004523-51,0,0,0 2014-004523-51,6,2017-09-27,2017-09-27,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"UCB Celltech, UK","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UCB5857 OVER 12 WEEKS IN SUBJECTS WITH PRIMARY SJOGREN?S SYNDROME ESTUDIO PRUEBA DE CON...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004523-51,0,0,0 2014-004525-41,4,2017-08-23,2017-08-23,3,0,1,0,0,1,3,0,0,2,0,0,0,0,1,"Versartis, Inc.","Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004525-41,1,0,0 2014-004527-42,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Abbott Laboratories LLC,"A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis® in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004527-42,0,1,1 2014-004531-39,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Abbott Deutschland GmbH & Co. KG,"A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004531-39,0,1,1 2014-004532-18,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Abbott,"A Multi-Center, Open-Label Efficacy, Safety, and Pharmacokinetic Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004532-18,0,1,1 2014-004533-13,3,2016-11-29,2016-11-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & développement,"A 21-Week, Open-label, Randomized, Controlled, Parallel-group, Multi-center Study Evaluating the Efficacy and Safety of HOE901-U300 Administered According to a Device-Supported Treat-to-target Regimen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004533-13,0,0,0 2014-004535-40,2,2016-06-22,2016-06-22,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Develco Pharma Schweiz AG,"Prospective, single-blind, placebo-controlled, three-treatment, three-period, adaptive multi-centre Phase IIa (proof-of-concept) trial to investigate the efficacy, safety, and tolerability of Ketamine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004535-40,0,0,0 2014-004537-95,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics Inc.,"A Phase 3b, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine when Administered with Routine Infant Vaccinations to Healthy Infant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004537-95,0,1,1 2014-004543-12,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics Srl.,"A Phase II, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Fluad® and Fluzone® Influenza Vaccines in Healthy Children Aged 6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004543-12,0,1,1 2014-004544-36,2,2015-12-07,2015-12-07,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Boehringer Ingelheim International GmbH,"A Phase III, randomized, double-blind, multi-center, multi-national trial to evaluate efficacy and safety of BI 695500 versus rituximab as a first-line immunotherapy treatment in patients with low tum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004544-36,0,0,0 2014-004545-27,7,2019-01-09,2019-01-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004545-27,0,0,0 2014-004545-27,7,2019-01-09,2019-01-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004545-27,0,0,0 2014-004551-32,1,2017-03-22,2017-03-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Charité Universitätsmedizin Berlin,Daclatasvir plus Sofosbuvir for chronic HCV-infected renal transplant patients – a pilot study of efficacy and safety,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004551-32,0,0,0 2014-004552-64,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"Center for Digestive Diseases, Karolinska University Hospital","MISTRAL - Mistletoe therapy in primary and recurrent inoperable pancreatic cancer - A phase III prospective, randomized, double blinded, multicenter, parallel group, placebo controlled clinical trial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004552-64,0,0,0 2014-004554-34,1,2017-05-31,2017-05-31,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,Bispebjerg Hospital,"An open label, explorative pharmacokinetic trial, to investigate the Cytochrome (CYP) CYP3A4, - 2E1 and – 1A2 clearance in Obese – versus Non Obese Children by use of well-tested probes (midazolam, ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004554-34,0,0,0 2014-004555-31,4,2016-11-04,2016-11-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ZS Pharma Inc,"A Phase 3 Multicenter, Multi-dose, Open-label Maintenance Study to Investigate the Long-term Safety and Efficacy of ZS (Sodium Zirconium Cyclosilicate), an Oral Sorbent, in Subjects with Hyperkalemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004555-31,0,0,0 2014-004557-14,4,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,0,King's College London,Prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004557-14,0,0,0 2014-004557-14,4,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,0,King?s College Hospital NHS Foundation Trust,Prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004557-14,0,0,0 2014-004557-14,4,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,0,King’s College Hospital NHS Foundation Trust,Prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004557-14,0,0,0 2014-004558-33,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Abbott Japan Co., Ltd.","A Multicenter, Open-label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004558-33,0,1,1 2014-004559-29,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,AbbVie Inc.,"A Multi-Center, Randomized, Double-Blind, Placebo-controlled Study of Adalimumab in Japanese Subjects with Moderately to Severely Active Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004559-29,0,1,1 2014-004560-38,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Abbott Deutschland GmbH & Co. KG,"A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004560-38,0,1,1 2014-004562-22,5,2015-11-04,2016-01-08,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biogen Idec Research Limited,"A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients with Mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004562-22,0,0,0 2014-004564-38,2,2017-07-04,2017-07-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research Limited,"A randomised, open label, two-period, cross-over, multi-centre study to compare correct inhaler handling of fluticasone/ formoterol breath-actuated inhaler (K-haler®) with that of Symbicort® Turbohale...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004564-38,0,0,0 2014-004565-24,3,2016-02-09,2016-03-07,2,1,0,0,1,0,3,0,0,1,1,0,1,0,1,PAION UK Limited,"A Randomized, Single-blind, Propofol-controlled Phase III Study Evaluating the Efficacy and Safety of Remimazolam in General Anesthesia in Adult Patients Undergoing Cardiac Surgery, Including Follow-u...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004565-24,0,0,0 2014-004567-21,4,2017-05-11,2017-05-11,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Orion Corporation Orion Pharma,"Effects of ODM-109 on respiratory function in patients with ALS. A randomised, double blind, placebo-controlled, cross-over, 3-period, multicentre study with open-label follow-up extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004567-21,0,0,0 2014-004572-34,5,2018-06-12,2018-06-12,4,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merrimack Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 plus Nab-paclitaxel and Gemcitabine versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004572-34,0,0,0 2014-004577-16,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A Phase 3b, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of Me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004577-16,0,1,1 2014-004578-40,1,2017-04-06,2017-04-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,St Stephen's AIDS Trust,"A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal tub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004578-40,0,0,0 2014-004579-22,5,2019-03-27,2019-04-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd.,Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004579-22,0,0,0 2014-004580-20,5,2019-04-03,2019-04-03,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd.,Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004580-20,0,0,0 2014-004581-16,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Merck Sharp & Dohme (China) Ltd.,An Immunogenicity and Safety Study of GARDASIL™ in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004581-16,0,1,1 2014-004582-24,1,,,0,1,1,0,1,0,2,0,0,4,0,0,0,0,1,"Schering-Plough Research Institute, a division of Schering Corporation","A Randomized, Evaluator-Blind, Crossover, Single Dose Study of the Bronchodilator Effect of Formoterol Fumarate in Combination With Mometasone Furoate Metered Dose Inhaler Delivered With and Without a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004582-24,0,1,1 2014-004583-38,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Schering-Plough Research Institute, a division of Schering Corporation",An Open-Label Study to Assess the Safety and Tolerability of Zenhale® (a Fixed-Dose Combination of Mometasone Furoate/Formoterol Fumarate Delivered by Metered Dose Inhaler) in 40 Subjects with Persist...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004583-38,0,1,1 2014-004584-20,4,2017-10-20,2018-02-20,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004584-20,0,0,0 2014-004585-22,4,2017-11-06,2017-11-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004585-22,0,0,0 2014-004586-24,8,2018-02-15,2018-02-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004586-24,0,0,0 2014-004586-24,8,2018-02-15,2018-02-16,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004586-24,0,0,0 2014-004587-38,11,2017-09-28,2017-10-30,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004587-38,0,0,0 2014-004587-38,11,2017-09-28,2017-10-30,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,"An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004587-38,0,0,0 2014-004588-19,8,2017-08-08,2020-06-22,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects with Treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004588-19,0,0,0 2014-004588-19,8,2017-08-08,2020-06-22,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects with Treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004588-19,0,0,0 2014-004590-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UMC Utrecht,18F-Choline PET/CT for patients with primary hyperparathyroidism and negative SPECT/CT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004590-16,0,0,0 2014-004592-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,"Phase IV randomized, double blind, placebo-controlled study: role of hypovitaminosis D in heart failure and possible advantages of cholecalciferol (Vit D) administration Studio di fase IV randomizz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004592-23,0,0,0 2014-004597-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universität Heidelberg vertreten durch die kaufmännische Direktorin,LGX818 in combination with MEK162 in refractory or relapsed multiple myeloma patients with BRAFV600E or BRAFV600K mutation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004597-42,0,0,0 2014-004599-49,6,2018-04-18,2018-04-18,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004599-49,0,0,0 2014-004601-32,1,2015-01-21,2015-01-21,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Gentofte Hospital,"The Effect of Local Anesthetic Volume within the Adductor Canal on Quadriceps Function Evaluated by Electromyography: A Randomized, Observer-Masked, Placebo-Controlled Study in Volunteers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004601-32,0,0,0 2014-004603-78,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004603-78,0,1,1 2014-004604-29,1,2018-01-01,2018-01-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Jens Rolighed Larsen,Sevoflurane versus standard general anesthesia in elective open abdominal aortic aneurism surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004604-29,0,0,0 2014-004605-33,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,"Novartis Vaccines & Diagnostics, Inc.","A Phase 3, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine When Administered with Routine Infant V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004605-33,0,1,1 2014-004610-29,1,2016-09-23,2016-09-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Skanes University Hospital,Ciclosporin to Protect Renal function In Cardiac Surgery. CiPRICS. A Phase II Double Blind Randomized Placebo Controlled Study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004610-29,0,0,0 2014-004612-10,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Bayer HealthCare AG,"A multicenter, double-blind, randomized, placebo controlled study to evaluate the efficacy and safety of an oral contraceptive preparation YAZ (drospirenone 3 mg / ethinylestradiol 20 µg) for 6 treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004612-10,0,1,1 2014-004613-93,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Bayer HealthCare AG,"Open label study to evaluate the effect, safety and tolerability of 250µg (8 MIU) interferon beta 1b (Betaferon) given subcutaneously every other day (for 24 weeks) in patients of Chinese origin with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004613-93,0,1,1 2014-004616-12,3,2017-05-17,2017-05-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of CDZ173 in patients with primary Sjögren’s syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004616-12,0,0,0 2014-004617-82,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics SRL,"A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Children, Adolescents and Adults in Russia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004617-82,0,1,1 2014-004619-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Biocompatibles UK Ltd.,A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004619-36,0,0,0 2014-004621-40,1,,,0,0,1,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,The effect of oral ondansetron on referral rate in children aged 6 months to 6 years attending in primary care out of hours service with acute gastro-enteritis and vomiting.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004621-40,0,0,0 2014-004622-18,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Bayer HealthCare AG,"A prospective, open-label, non-randomized, naturalistic, long-term safety surveillance, observational study of either ciprofloxacin (either as oral suspension, oral tablets or sequential IV followed b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004622-18,0,1,1 2014-004624-21,5,2018-10-31,2018-10-31,4,1,0,0,0,1,4,0,0,1,0,0,1,0,1,ACTELION Pharmaceuticals Ltd.,"A randomized, double-blind, placebo-controlled, prospective, multicenter, parallel group study to assess the safety and efficacy of macitentan in patients with portopulmonary hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004624-21,0,0,0 2014-004628-23,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Sanofi,Comparison of Teicoplanin and Vancomycin in Terms of Efficacy and Side Effect Profile During Initial Antibiotic Treatment of Febrile Neutropenic Patients at High Risk For Gram-Positive Infection: Mult...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004628-23,0,1,1 2014-004629-42,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Sanofi,"Bacillus Clausii in Preventing Antibiotic-Associated Diarrhea Among Filipino Infant and Children: A Multi-Center, Randomized, Open-Label Controlled (Treatment vs No Treatment) Clinical Trial of Effica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004629-42,0,1,1 2014-004630-26,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Sanofi-aventis,"Multinational, Randomized, Double-Blind, Double Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 10 Days Penicillin V 13.3 mg/kg Tid in Children 6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004630-26,0,1,1 2014-004631-39,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Sanofi-aventis,"Multinational, randomized, double blind, comparative study to evaluate the efficacy and safety of telithromycin, 800 mg once daily for 5 days, versus penicillin V, 500 mg three times daily for 10 days...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004631-39,0,1,1 2014-004632-19,6,2018-09-18,2018-12-06,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004632-19,0,0,0 2014-004633-96,6,2018-07-17,2018-09-18,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA AB,"A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004633-96,0,0,0 2014-004633-96,6,2018-07-17,2018-09-18,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004633-96,0,0,0 2014-004634-26,1,2017-04-30,2017-04-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Royal Liverpool University Hospital,The Effect of Live Attenuated Influenza Vaccine (LAIV) on Experimental Human Pneumococcal Colonisation (EHPC) Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004634-26,0,0,0 2014-004634-26,1,2017-04-30,2017-04-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Liverpool School of Tropical Medicine,The Effect of Live Attenuated Influenza Vaccine (LAIV) on Experimental Human Pneumococcal Colonisation (EHPC) Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004634-26,0,0,0 2014-004636-19,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Sanofi Aventis,"Phase III Comparative Study to Assess the Efficacy and Safety of Oral Rehydration Therapy (ORT) in Combination With Spores of Bacillus Clausii (Enterogermina)Versus ORT Alone, Administered for 5 Days ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004636-19,0,1,1 2014-004637-47,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Sanofi-aventis,"Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 5 Days Azithromycin 10 mg/kg od Followed by 5 mg/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004637-47,0,1,1 2014-004638-24,1,2017-03-17,2017-03-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Ghent University Hospital,"Pharmacokinetics of ciprofloxacine in pediatric patients, a pilot study – SAFE PEDRUG.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004638-24,0,0,0 2014-004639-38,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Sanofi,A study of effectiveness and safety of Apidra in combination with Lantus therapy in basal-bolus insulin regimen in inadequately controlled children and adolescents with Type 1 diabetes in the Russian ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004639-38,0,1,1 2014-004640-35,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Sanofi,"A 24-week, Randomized, Open-label, Parallel Group, Multicenter Comparison of Lantus® (Insulin Glargine) Given Once Daily Versus Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabete...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004640-35,0,1,1 2014-004641-27,1,2018-06-08,2018-06-08,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,UZLeuven,BOTOX in the treatment of urinary incontinence due to neurogenic detrusor overactivity in patients 3 months - 17 years BOTOX in de behandeling van neurogene blaasdysfunctie bij kinderen tussen 3 ma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004641-27,0,0,0 2014-004643-12,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Sanofi-aventis,"Post-marketing study of Amaryl® (Glimepiride) in patients with type 2 diabetes to investigate pediatric and adult population pharmacokinetics [multicenter, non-comparative, 12-28 weeks, non-blind titr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004643-12,0,1,1 2014-004644-35,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,Sanofi-aventis,"Single dose, open label safety, tolerability, pharmacokinetic and pharmacodynamic evaluation of three different eplivanserin doses in children aged 6-17 years with insomnia of various origins",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004644-35,0,1,1 2014-004645-27,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Sanofi,"A randomized, multicenter, double-blind, placebo-controlled, parallel group study of the 12 month effect of treatment with once daily triamcinolone acetonide (NASACORT® AQ Nasal Spray 110 μg) on the g...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004645-27,0,1,1 2014-004646-98,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Sanofi,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Pharmacodynamic Effect of a 6-week Treatment With Triamcinolone Acetonide Aqueous Nasal Spray 110 μg an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004646-98,0,1,1 2014-004649-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Matrizyme Pharma Corporation,"A 2-stage study to evaluate single doses of MZ-004 at different dose levels in patients with chronic total occlusions. STAGE 1: Open label Training Stage. STAGE 2: Double-blind, randomized, Placeb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004649-28,0,0,0 2014-004650-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IRCCS FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE C. MONDINO,Neuromodulation strategies to enhance the effects of gait rehabilitation in multiple sclerosis patients with cerebellar ataxia Neuromodulation strategies to enhance the effects of gait rehabilitati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004650-34,0,0,0 2014-004653-14,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,The Clatterbridge Cancer Centre NHS Foundation Trust,"A Phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with Gemcitabine in patient with metastatic pancreatic carcinoma. (ACELARATE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004653-14,0,0,0 2014-004655-31,1,2018-07-18,2018-07-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Debiopharm International S.A.,Preoperative window-of-opportunity (WoO) study of Debio 1143 with or without cisplatin (CDDP) in patients with resectable squamous cell carcinoma of the head and neck. Etude pré-opératoire explorat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004655-31,0,0,0 2014-004659-30,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,sanofi-aventis,"Four-week, open-label, multicenter, randomized, parallel-group study to investigate the pharmacokinetics, safety, tolerability and the effects on leak point pressure of 2 oral doses of alfuzosin (0.1 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004659-30,0,1,1 2014-004660-37,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi,"Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004660-37,0,1,1 2014-004661-25,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi,"Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Tangerina Mix",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004661-25,0,1,1 2014-004662-26,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi,Safety Dermatological Evaluation: genital Mucosa Irritation - Product tested: Dermacyd PH_DETINLYN Sweet Flower.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004662-26,0,1,1 2014-004663-20,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi,Safety Dermatological Evaluation: genital mucosa irritation - Product tested: Dermacyd PH_DETINBACK Sweet Flower,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004663-20,0,1,1 2014-004664-38,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi,Safety Dermatological Evaluation: genital mucosa irritation - Product tested: Dermacyd PH_DETINLYN Tangerine Mix.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004664-38,0,1,1 2014-004665-24,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi,Safety Dermatological Evaluation: genital mucosa irritation - Product tested: Dermacyd PH_DETINBACK Tangerine Mix.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004665-24,0,1,1 2014-004666-14,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi,Safety Dermatological Evaluation: acceptability with pediatric follow up – Dermacyd Infantile LACAC_L_04678,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004666-14,0,1,1 2014-004673-16,3,2018-02-09,2018-02-20,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"PROSPECTIVE, MULTICENTRE, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY TO COMPARE THE EFFICACY OF MAINTENANCE TREATMENT WITH TOCILIZUMAB WITH OR WITHOUT GLUCOCORTICOID DISCONTINUATION IN RHEUMATOID ARTHRITI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004673-16,0,0,0 2014-004673-16,3,2018-02-09,2018-02-20,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"PROSPECTIVE, MULTICENTRE, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY TO COMPARE THE EFFICACY OF MAINTENANCE TREATMENT WITH TOCILIZUMAB WITH OR WITHOUT GLUCOCORTICOID DISCONTINUATION IN RHEUMATOID ARTHRITI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004673-16,0,0,0 2014-004674-42,5,,,0,0,1,0,0,0,4,0,0,3,0,0,0,0,1,"Gilead Sciences, Inc",A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead Sponsored Chronic Hepatitis C Infection Trials,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004674-42,0,0,0 2014-004674-42,5,,,0,0,1,0,0,0,4,0,0,3,0,0,0,0,1,"Gilead Sciences, Inc.",A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead Sponsored Chronic Hepatitis C Infection Trials,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004674-42,0,0,0 2014-004674-42,5,,,0,0,1,0,0,0,4,0,0,3,0,0,0,0,1,GILEAD SCIENCES INCORPORATED,A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead Sponsored Chronic Hepatitis C Infection Trials,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004674-42,0,0,0 2014-004676-29,10,2021-03-15,2021-03-15,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Sanofi-aventis Groupe,"A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)- targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated with Docetaxel and Who Ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004676-29,0,0,0 2014-004676-29,10,2021-03-15,2021-03-15,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SANOFI-AVENTIS GROUPE,"A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)- targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated with Docetaxel and Who Ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004676-29,0,0,0 2014-004677-17,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Kvinnokliniken, Universitetssjukhuset i Linköping, Landstinget i Östergötland",Contraception after gastric bypass - part 4 How does gastric bypass affect the pharmacocinetics of oral levonorgestrel? Antikonception efter fetmakirurgi - delstudie 4 Hur påverkar fetmakirurgi med...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004677-17,0,0,0 2014-004678-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,Etude prospective de phase II d’évaluation d’une prise en charge multimodale des métastases ganglionnaires inguinales des carcinomes épidermoïdes du pénis par lymphadénectomie bilatérale et chimiothér...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004678-41,0,0,0 2014-004680-21,1,2017-05-15,2017-05-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, double-blinded, single-center, placebo controlled, cross-over study to assess the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) on cardiac function in patients with chr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004680-21,0,0,0 2014-004682-24,5,2016-02-17,2016-02-17,3,1,0,0,0,0,0,0,0,1,1,0,1,0,1,PIERRE FABRE MEDICAMENT,"Efficacy of DC071 mouthwash (0,2 % chlorhexidine digluconate) in peri-surgical care for preventing alveolar osteitis after third molar extraction. Prospective, multicenter, randomised, double-blind, p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004682-24,0,0,0 2014-004682-24,5,2016-02-17,2016-02-17,3,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Institut de Recherche Pierre Fabre - Centre de R&D Pierre Fabre,"Efficacy of DC071 mouthwash (0,2 % chlorhexidine digluconate) in peri-surgical care for preventing alveolar osteitis after third molar extraction. Prospective, multicenter, randomised, double-blind, p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004682-24,0,0,0 2014-004683-38,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Fondazione per il Tuo cuore onlus-ANMCO,Effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin on left ventricular myocardial DYsfunction in patients with type 2 DiAbetes mellitus and concentric left ventricular geometry. Ef...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004683-38,0,0,0 2014-004684-20,8,2021-12-13,2021-12-13,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA NEZASLEPENÉ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004684-20,1,0,0 2014-004684-20,8,2021-12-13,2021-12-13,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA NEZASLEPENÉ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004684-20,1,0,0 2014-004684-20,8,2021-12-13,2021-12-13,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Roche Farma S.A en nombre de F. Hoffmann-La Roche LTD,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA NEZASLEPENÉ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004684-20,1,0,0 2014-004685-25,8,2021-07-21,2021-07-21,6,1,1,0,0,0,1,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE I/II, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF COBIMETINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004685-25,1,0,0 2014-004687-37,1,2018-02-28,2018-02-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College Healthcare NHS Trust,Use of Methylnaltrexone for the Treatment of Opioid Induced Constipation & Gastro-Intestinal Stasis in Intensive Care Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004687-37,0,0,0 2014-004688-19,7,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,MorphoSys AG,"A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004688-19,0,0,0 2014-004689-11,12,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,MorphoSys AG,"A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004689-11,0,0,0 2014-004689-11,12,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,MORPHOSYS AG,"A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004689-11,0,0,0 2014-004692-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University of Torino,MARAT Study “Pharmacokinetics of MARaviroc and boosted ATazanavir dual regimen in stable HIV-infected patients” Studio MARAT “Farmacocinetica della terapia duale con atazanavir/ritonavir e maraviro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004692-22,0,0,0 2014-004693-42,8,,,0,0,1,0,0,1,2,0,0,2,1,0,0,0,1,"Intercept Pharmaceuticals, Inc.","A Multicenter, Open Label, Single- and Multiple-Dose, Dose Finding Study to Assess the Effects of Obeticholic Acid in Pediatric Subjects with Biliary Atresia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004693-42,0,0,0 2014-004694-16,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics Inc.,"A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of ProQuad™ Vaccine When Administered Concomitantly with Novartis Meningococcal ACWY Conjugate Vaccine t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004694-16,0,1,1 2014-004696-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"HOSPITAL UNIVERSITARIO LA PAZ, SERVICIO DE ANESTESIA",Breakthrough pain incidence in pregnant women comparing two Epidural analgesia shemes added to a continuous infusion (bowling planned indicators and analgesia epidural patient controlled): double-blin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004696-24,0,0,0 2014-004697-41,8,2019-06-06,2019-06-06,7,1,1,0,0,0,1,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"AN EARLY-PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI?PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS ESTUDI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004697-41,0,0,0 2014-004698-17,5,2020-01-31,2020-01-31,2,1,0,0,0,0,2,0,0,2,0,0,0,0,0,Medica Scientia Innovation Research (MedSIR),"A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with HER2 negative, ER+ metastatic bre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004698-17,1,0,0 2014-004701-32,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,3,Karolinska University Hospital,Postoperative pain management after major surgery in neonates. Establishing success rate using epidural analgesia and subcutaneous wound catheter infusion.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004701-32,0,0,0 2014-004702-14,1,2018-06-15,2018-06-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,Efficacy and Tolerability of Menthacarin in Patients (≥ 18 years old) suffering from symptoms of Irritable Bowel Syndrome (IBS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004702-14,0,0,0 2014-004704-29,6,2018-08-13,2018-08-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,"A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects with Moderate to Severe Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004704-29,0,0,0 2014-004707-67,1,2021-01-08,2021-01-08,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Hospices Civils de Lyon,REDUCTION BY PASIREOTIDE OF THE EFFLUENT VOLUME IN HIGH-OUTPUT ENTEROSTOMY IN PATIENTS REFRACTORY TO USUAL MEDICAL TREATMENT: PHASE II MULTICENTRIC RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004707-67,0,0,0 2014-004708-30,8,2017-09-15,2017-09-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Daiichi Sankyo Development Ltd,"A PHASE 3B, PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF (LMW) HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004708-30,0,0,0 2014-004708-30,8,2017-09-15,2017-09-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Daiichi Sankyo , Inc.","A PHASE 3B, PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF (LMW) HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004708-30,0,0,0 2014-004708-30,8,2017-09-15,2017-09-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Daiichi Sankyo, Inc.","A PHASE 3B, PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF (LMW) HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004708-30,0,0,0 2014-004712-10,4,2017-08-31,2017-08-31,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pearl Therapeutics, Inc.","A Randomized, Double Blind, Chronic Dosing (24 Weeks), Placebo Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects with Moderate to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004712-10,0,0,0 2014-004713-91,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitair Ziekenhuis Brussel,Epidural ropivacaine as part of a multimodal postoperative pain treatment following thoracolumbar spinal fusion surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004713-91,0,0,0 2014-004714-28,1,,,0,1,0,0,0,1,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase 2, randomised, observer-blind, controlled, multi country study to assess the safety and immunogenicity of a single intramuscular dose of GSK Biologicals’ investigational recombinant chimpanzee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004714-28,0,1,1 2014-004715-37,5,2015-11-17,2015-11-17,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"AstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden","A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD symptoms including cough when administered to patients with COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004715-37,0,0,0 2014-004718-27,1,2017-11-15,2017-11-15,1,0,0,0,1,0,3,0,0,1,0,0,1,0,1,Medical Unviersity of Warsaw,"A randomised, multicenter, single-blinded, parallel-group study to assess efficacy, safety and tolerability of the combination of Immediate Release (IR) tramadol with micronized magnesium lactate as f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004718-27,0,0,0 2014-004719-36,1,2019-04-29,2019-04-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,R-Pharm,"A Randomized, Double-Blind, Parallel-Group, Placebo Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004719-36,0,0,0 2014-004721-40,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"Genexine, Inc","A Randomized, Double-Blind, Placebo-controlled, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004721-40,0,0,0 2014-004725-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR),Interfascial effectiveness of ultrasound-guided blocking in transurethral resection of bladder tumor Eficacia del bloqueo obturador interfascial ecoguiado en la resección transuretral de tumor vesi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004725-40,0,0,0 2014-004729-42,1,2019-07-04,2019-07-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,2,"Odense University Hospital, department M","The effect of testosterone replacement in patients with hypogonadotroph hypogonadism due to opioid treatment for non-malignant disease A double-blinded, randomized and placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004729-42,0,0,0 2014-004729-42,1,2019-07-04,2019-07-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,2,Odense University Hospital,"The effect of testosterone replacement in patients with hypogonadotroph hypogonadism due to opioid treatment for non-malignant disease A double-blinded, randomized and placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004729-42,0,0,0 2014-004731-39,3,2016-11-23,2016-11-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, dose relation, pharmacokinetics and pharmacodynamics of CJM112 in moderate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004731-39,0,0,0 2014-004732-19,3,2016-05-13,2016-05-13,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LETI Pharma GmbH,"A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum versus Placebo in Patients with Allergic Rhinitis and/or Rhin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004732-19,0,0,0 2014-004734-25,1,,,0,1,0,0,1,0,2,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 2, Single-Blind, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine OMV When Administered at an 0-2-6-Month Schedule i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004734-25,0,1,1 2014-004735-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,Phase II Study of cisplatin and everolimus in patients with metastatic or unresectable neuroendocrine carcinomas (NEC) of extrapulmonary origin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004735-39,0,0,0 2014-004739-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VU Univeristy Medical Centre,Follow-up of the FRUIT-RCT; aspirin resistance and cardiovascular risk factors in women after recurrent hypertensive disorders in pregnancy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004739-38,0,0,0 2014-004740-35,1,2015-07-10,2015-07-10,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,"Department of surgery, Odense University Hospital",Loperamide vs. Placebo's effect on ileostomy output: A clincal randomized patientblinded crossover study Loperamid vs. Placebos effekt på ileostomioutput: Et klinisk deltagerblindet randomiseret cr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004740-35,0,0,0 2014-004741-27,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Leeds,Comparison of Alitretinoin with PUVA as the first line treatment in patients with severe chronic hand eczema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004741-27,0,0,0 2014-004742-10,1,2016-06-21,2016-06-21,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of medical Research, Regional Hospital Holstebro","The effect of 0,9% NaCl on the kidney function, vasoactive hormones, biomarkers and glycosaminglycanes in plasma in patients operated on for primary hiparthrosis. Effekten af 0,9% NaCl på på nyrern...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004742-10,0,0,0 2014-004746-99,3,2016-11-17,2016-11-17,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,AstraZeneca AB,"An Open-Label Long-Term Extension to the Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (aged 6 to <18 years) with Homozygous ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004746-99,0,0,0 2014-004748-37,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,MSD Korea LTD.,Korean Study of “Real-world” Montelukast Use in Mild Asthmatic Children with Concomitant Allergic Rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004748-37,0,1,1 2014-004749-28,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Banyu Pharmaceutical Co., Ltd.",MK-476 Phase III Open Label Exploratory Comparative Study -Acute Exacerbations of Asthma- Protocol number: 334,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004749-28,0,1,1 2014-004751-31,1,2016-12-15,2016-12-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Arrowhead Research Corporation,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004751-31,0,0,0 2014-004757-14,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase III Observer-Blind, Randomized, Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Immunogenicity of Two Trivalent Subunit Inactivated Influenza Vaccines (Agrippal® and Fluvir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004757-14,0,1,1 2014-004758-33,1,2022-05-01,2022-05-01,1,0,0,0,0,0,3,0,0,1,0,0,0,0,0,Medical University of Vienna,"Randomized Assessment of patients with clinically suspected Prostate cancer after multiparametric metabolic hybrid Imaging to evaluate its potential clinical Domain: A prospective, randomized, multi-a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004758-33,0,0,0 2014-004759-30,1,2016-05-30,2016-05-30,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,LEO Pharma A/S,A psoriasis plaque test trial with LP0113 spray in patients with psoriasis vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004759-30,0,0,0 2014-004760-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Riitta Veijola,"Incretin-based therapy in non-symptomatic, early diagnosed type 1 diabetics Inretiini-perusteinen varhaisen tyypin 1 diabeteksen hoito",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004760-37,0,0,0 2014-004761-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Riitta Veijola,Incretin-based therapy in late preclinical type 1 diabetes Inkretiini-perusteinen hoito tyypin 1 diabeteksen myöhäisessä esiasteessa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004761-25,0,0,0 2014-004762-23,1,2018-04-27,2018-04-27,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,CHRU Besançon,NO ETUDE CONTROLEE RANDOMISEE EN CROSS OVER DE L’EFFET DE L’OCYTOCINE EN SPRAY NASAL SUR LES ACTIVATIONS CEREBRALES LIEES A L’ATTACHEMENT EN POPULATION GENERALE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004762-23,0,0,0 2014-004766-15,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",MK-518B Food Effect Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004766-15,0,1,1 2014-004767-21,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",MK-0518B (EU Sourced Lamivudine) Bioequivalence Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004767-21,0,1,1 2014-004774-42,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Double-Blind, Randomized, Placebo-Controlled Cross-over Clinical Trial to Study the Efficacy and Safety of MK-0476 in Japanese Pediatric Subjects with Seasonal Allergic Rhinitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004774-42,0,1,1 2014-004775-23,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Merck Frosst Canada Ltd.,"RADAR: SingulaiR® in Asthma anD Allergic Rhinitis An 8 week multicenter, open-label, observational study to evaluate the effectiveness of adding Montelukast Sodium (SINGULAIR®) 10 mg per day to inhale...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004775-23,0,1,1 2014-004776-27,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,"Merck & Co., Inc.","A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Bronchodilatory Effect of MK-0476 in Patients with Chronic Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004776-27,0,1,1 2014-004778-41,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,"Alcon Research, Ltd.",Assessment of Anatomical and Functional Outcomes in Subjects Treated with Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004778-41,0,0,0 2014-004779-21,5,2019-01-02,2019-01-02,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtric...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004779-21,0,0,0 2014-004780-21,1,2022-01-02,2022-01-02,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,University Medical Center of the Johannes Gutenberg,GOAL trial: Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with PixantrOne for the treatment of patients with relapsed Aggressive B-cell Lymphoma GOAL-S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004780-21,0,0,0 2014-004781-15,3,2018-06-06,2018-06-06,1,0,0,0,0,1,3,0,0,2,0,0,0,0,2,Intergroupe Francophone du Myelome (IFM),"Study of Daratumumab in Combination with Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) in the First Line Treatment of Transplant Eligible Subjects with Newly Diagnosed Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004781-15,1,0,0 2014-004782-24,6,2019-04-03,2019-07-25,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Promedior, Inc.",A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004782-24,0,0,0 2014-004782-24,6,2019-04-03,2019-07-25,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"PROMEDIOR, INC.",A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004782-24,0,0,0 2014-004783-38,1,2018-05-31,2018-05-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,Study of two regimens of TicagrElor compared to clopidogrel in patients undergoing ELective Percutaneous Coronary Intervention (STEEL PCI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004783-38,0,0,0 2014-004784-20,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Instituto Bernabeu,"Subcutaneous progesterone ( Prolutex ) versus vaginal progesterone capsules (Progeffik) for endometrial preparation in fresh donated oocyte recipients: A prospective, randomized, single-blind, pilot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004784-20,0,0,0 2014-004786-25,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Actelion Pharmaceuticals Ltd.,"Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel-group, group-sequential, adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004786-25,0,0,0 2014-004786-25,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,ACTELION PHARMACEUTICALS LTD,"Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel-group, group-sequential, adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004786-25,0,0,0 2014-004787-37,3,2016-05-27,2016-08-12,3,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cysti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004787-37,0,0,0 2014-004788-18,5,2017-02-16,2017-02-16,3,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004788-18,0,0,0 2014-004794-16,2,2018-03-16,2018-05-11,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm. V,An open label multicenter Phase Ib/II trial to determine the dose of BI 836826 in combination with gemcitabine and oxaliplatin (GemOx) and the efficacy of BI 836826 – GemOx versus rituximab ( R ) with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004794-16,0,0,0 2014-004794-16,2,2018-03-16,2018-05-11,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,An open label multicenter Phase Ib/II trial to determine the dose of BI 836826 in combination with gemcitabine and oxaliplatin (GemOx) and the efficacy of BI 836826 – GemOx versus rituximab ( R ) with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004794-16,0,0,0 2014-004796-23,6,2020-03-23,2020-03-23,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dompé Farmaceutici s.p.a.,"A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004796-23,0,0,0 2014-004798-17,1,2017-09-18,2017-09-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Erlangen,"Evaluation of inflammatory and structural joint damage in patients with psoriasis and psoriatic arthritis treated with secukinumab: A phase 2, single arm, single centre mode of action study (Psoriasis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004798-17,0,0,0 2014-004799-50,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Federico Martinon Torres,Evaluation of the immunoregulatory role of pneumococcal conjugate vaccination in pediatric patients with allergic asthma or type 1 diabetes mellitus versus pediatric population control. Evaluación ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004799-50,0,0,0 2014-004804-31,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,1,"Shire Human Genetic Therapies, Inc","A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients with MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Ye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004804-31,0,0,0 2014-004805-34,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Sanofi-aventis Research & Development,"A Two Part Protocol Using Double Blind Placebo Control to Assess the Safety, Tolerability, and Pharmacokinetics of Single Escalating Intra-articular Doses Followed by Assessment of Efficacy, Safety, T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004805-34,0,0,0 2014-004806-14,6,2019-07-16,2019-07-16,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Therakos, Inc.",Single-Arm Study to Assess the Efficacy of UVADEX® (methoxsalen) Sterile Solution in Conjunction with the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute Gra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004806-14,0,0,0 2014-004809-33,1,2019-04-19,2019-04-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR),Albumin infusion effects in patients with cirrhosis hepatic encephalopathy EFECTOS DE LA ADMINISTRACIÓN DE ALBÚMINA EN PACIENTES CON CIRROSIS Y ENCEFALOPATIA HEPÁTICA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004809-33,0,0,0 2014-004812-12,2,2016-01-08,2016-01-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.",Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Subjects with Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004812-12,0,0,0 2014-004817-98,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,Ελληνική Αιματολογική Εταιρεία,"Administration of Rapidly Generated Multivirus-Specific Cytotoxic TLymphocytes for the Treatment of CMV, EBV, and BK virus Infections post Allogeneic Stem Cell Transplant Χορήγηση ταχέως παραγόμενω...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004817-98,0,0,0 2014-004818-28,10,2016-11-16,2016-11-16,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,NOVARTIS PHARMA SERVICES AG,"A randomized, double-blind, parallel group, 26-week study evaluating the efficacy, safety and tolerability of NVA237 given once or twice daily, in patients with moderate and severe chronic obstructive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004818-28,0,0,0 2014-004818-28,10,2016-11-16,2016-11-16,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, parallel group, 26-week study evaluating the efficacy, safety and tolerability of NVA237 given once or twice daily, in patients with moderate and severe chronic obstructive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004818-28,0,0,0 2014-004819-37,3,2020-09-07,2020-09-07,3,1,0,0,0,0,4,0,0,1,1,0,1,0,0,University College Dublin,"A multi-centre, prospective, randomised trial of short course alendronate therapy or placebo combined with vitamin D and calcium to prevent loss of bone mineral density in antiretroviral-naïve, HIV-1 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004819-37,0,0,0 2014-004820-24,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Fundació Clínic per a la Recerca Biomèdica,"Cost-effectiveness of different antiretroviral treatment in patients HIV naive. Randomized clinical, not masked, trial comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 we...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004820-24,0,0,0 2014-004824-22,5,,,0,1,0,0,0,2,3,0,0,2,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004824-22,0,0,0 2014-004824-22,5,,,0,1,0,0,0,2,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004824-22,0,0,0 2014-004824-22,5,,,0,1,0,0,0,2,3,0,0,2,0,0,0,0,1,Lilly S.A.,"A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004824-22,0,0,0 2014-004825-42,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,ACTA,Effect of Delmopinol on treatment of Peri - implant mucositis : a randomised controlled clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004825-42,0,0,0 2014-004827-29,10,2018-11-16,2018-11-16,1,0,1,0,0,1,3,0,0,2,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long term Treatment With VX 661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Hom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004827-29,1,0,0 2014-004830-25,1,2017-01-23,2017-01-23,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Oslo University Hospital,Kidney Cancer Integrated Therapy (KIT) - Personalized integrated therapy for patients with advanced kidney cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004830-25,0,0,0 2014-004832-20,7,2020-07-29,2020-07-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Randomized Phase 2 Study of Abemaciclib (LY2835219) versus Docetaxel in Patients with Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated with Platinum-based Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004832-20,0,0,0 2014-004832-20,7,2020-07-29,2020-07-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,A Randomized Phase 2 Study of Abemaciclib (LY2835219) versus Docetaxel in Patients with Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated with Platinum-based Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004832-20,0,0,0 2014-004837-13,8,2017-01-20,2017-01-20,6,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cysti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004837-13,0,0,0 2014-004838-25,5,2017-09-19,2017-09-19,4,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004838-25,0,0,0 2014-004840-36,1,2015-12-01,2015-12-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Hevert-Arzneimittel GmbH & Co. KG,"Proof of effectiveness of Calmvalera Hevert using qantitative measurement of electrical brain activity on 24 subjects during image and video-mediated cognitive and emotional stress. A double-blind, ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004840-36,0,0,0 2014-004842-92,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Fondazione Melanoma ONLUS,A three arms prospective randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients with me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004842-92,0,0,0 2014-004842-92,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Fondazione Melanoma (ONLUS),A three arms prospective randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients with me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004842-92,0,0,0 2014-004842-92,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,FONDAZIONE MELANOMA ONLUS,A three arms prospective randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients with me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004842-92,0,0,0 2014-004844-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Enrique de Madaria Pascual,A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis Ensayo piloto controlado y aleatorizado con indometacina en pancreatitis aguda.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004844-37,0,0,0 2014-004848-36,6,2018-01-19,2018-01-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,"An open-label, single-arm Phase II study in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) to evaluate efficacy and safety of treatment with single agent copanlisib and the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004848-36,0,0,0 2014-004848-36,6,2018-01-19,2018-01-19,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"An open-label, single-arm Phase II study in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) to evaluate efficacy and safety of treatment with single agent copanlisib and the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004848-36,0,0,0 2014-004849-26,1,2019-09-01,2019-09-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UMC Utrecht,PARACHUTE-trial Prospective Analysis of an individualized dosing Regimen of ATG (Thymoglobulin) in Children Undergoing HCT: redUcing Toxicity and improving Efficacy – a single arm phase II study ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004849-26,0,0,0 2014-004850-32,5,2018-11-17,2018-11-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults with Type 2 Diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004850-32,0,0,0 2014-004850-32,5,2018-11-17,2018-11-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults with Type 2 Diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004850-32,0,0,0 2014-004851-30,7,2019-06-18,2019-06-18,4,1,1,0,0,0,3,0,0,2,1,0,0,0,1,PHARM – Pharmaceutical Research Management srl,"Randomized, double-blind, double-dummy, active controlled, multicentre, non-inferiority phase III study to compare the pharmacokinetic, efficacy and safety of gabapentin liquid formulation to tramadol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004851-30,1,0,0 2014-004851-30,7,2019-06-18,2019-06-18,4,1,1,0,0,0,3,0,0,2,1,0,0,0,1,PHARM - PHARMACEUTICAL RESEARCH MANAGEMENT SRL,"Randomized, double-blind, double-dummy, active controlled, multicentre, non-inferiority phase III study to compare the pharmacokinetic, efficacy and safety of gabapentin liquid formulation to tramadol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004851-30,1,0,0 2014-004852-77,2,2020-03-13,2020-03-13,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Genentech, Inc","AN OPEN-LABEL, PHASE I/IIA STUDY OF GDC-0810 IN POSTMENOPAUSAL WOMEN WITH LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTOR POSITIVE BREAST CANCER ESTUDIO ABIERTO EN FASE I/IIA CON GDC 0810 EN MUJER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004852-77,0,0,0 2014-004854-33,1,2020-01-03,2020-01-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Muenster,Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH-Trial). Regionale Citrat- versus systemis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004854-33,0,0,0 2014-004856-68,3,2016-02-15,2016-02-15,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"CymaBay Therapeutics, Inc.","A 12-week, open-label, dose-escalating, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004856-68,0,0,0 2014-004857-15,2,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Sylentis,DOSE-FINDING STUDY TO ASSESS THE SAFETY AND EFFECT OF SYL1001 IN PATIENTS WITH OCULAR PAIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004857-15,0,0,0 2014-004859-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dipartimento di Biotecnologie Molecolari e Scienze per la Salute Università degli Studi di Torino,"A MULTIARM, OPEN LABEL, RANDOMIZED PHASE II STUDY OF MLN9708 PLUS ORAL DEXAMETHASONE or PLUS ORAL CYCLOPHOSPHAMIDE AND DEXAMETHASONE or PLUS BENDAMUSTINE AND DEXAMETHASONE or PLUS ORAL THALIDOMIDE AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004859-31,0,0,0 2014-004860-39,1,2019-11-25,2019-11-25,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,OSPEDALE SAN RAFFAELE,A phase I/II study evaluating safety and efficacy of autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene for the treatment of ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004860-39,0,0,0 2014-004862-89,1,2016-02-13,2016-02-13,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,KULeuven,The effect of mirtazapine (REMERGON®) on gastric motility and satiation in healthy subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004862-89,0,0,0 2014-004865-26,5,2020-05-14,2020-05-14,2,0,0,0,0,1,3,0,0,2,1,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) Therapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects with Advanced Parkinson'...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004865-26,1,0,0 2014-004867-19,1,2016-04-24,2016-04-24,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Clinic for General Anesthesiology, Intensive Care and Pain Management",Perioperative fluid management in patients receiving major abdominal surgery – Effects of normal saline versus an acetate buffered balanced infusion solution on the necessity of catecholamines for car...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004867-19,0,0,0 2014-004868-38,9,2019-12-06,2019-12-06,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004868-38,0,0,0 2014-004868-38,9,2019-12-06,2019-12-06,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN INC.,A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004868-38,0,0,0 2014-004869-24,10,2018-07-06,2018-07-06,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,"A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004869-24,0,0,0 2014-004871-22,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Open-Label Clinical Trial to Study the Safety and Pharmacokinetics of MK-0476 in Japanese Pediatric Subjects Aged 1 to 15 Years Old with Perennial Allergic Rhinitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004871-22,0,1,1 2014-004872-47,1,2016-06-10,2016-06-10,1,1,0,0,1,0,2,0,1,1,0,0,1,0,0,"Karolinska Institutet, Department of Laboratory Medicine, Clinical Physiology C1:82,Karolinska Univ. Hosp., Huddinge",The effects of COX-inhibiting drugs on skeletal muscle adaptations to resistance exercise in healthy adults. Effekter av COX-inhiberande läkemedel på skelettmuskelns anpassning till styrketräning h...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004872-47,0,0,0 2014-004874-41,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Nordic MDS study group,"Safety, Efficacy and Immune Response of Histamine Dihydrochloride and Low-dose Interleukin-2 in Chronic Myelomonocytic Leukemia (CMML) En studie för att utvärdera effekt och biverkningar av Interle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004874-41,0,0,0 2014-004875-21,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation",Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Protocol No. P05067),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004875-21,0,1,1 2014-004878-42,4,2016-09-02,2016-09-02,3,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Minerva Neurosciences, Inc.","A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of MIN-101 in Patients With Negative Symptoms of Schizoph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004878-42,1,0,0 2014-004879-23,1,2015-03-02,2015-03-02,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Bispebjerg Hospital,"Does perineural dexamethason prolong duration of an adductor canal block when controlling for a systemic effect? A randomized, blinded, crossover study in healthy volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004879-23,0,0,0 2014-004882-26,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,Nitto Denko Corporation,"A Phase 1b/2, Open Label, Randomized, Repeat Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Biological Activity and Pharmacokinetics of ND L02 s0201 Injection, a Vitamin A-coupled L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004882-26,0,0,0 2014-004884-19,1,2018-03-13,2018-03-13,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,King's College London,Phase I study of lentiviral-mediated COL7A1 gene-modified autologous fibroblasts in adults with recessive dystrophic epidermolysis bullosa (RDEB),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004884-19,0,0,0 2014-004884-19,1,2018-03-13,2018-03-13,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,Guy's and St Thomas' NHS Foundation Trust,Phase I study of lentiviral-mediated COL7A1 gene-modified autologous fibroblasts in adults with recessive dystrophic epidermolysis bullosa (RDEB),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004884-19,0,0,0 2014-004886-26,22,2018-03-08,2018-03-08,21,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Alcon Research Ltd,"A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6mg Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004886-26,0,0,0 2014-004886-26,22,2018-03-08,2018-03-08,21,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ALCON RESEARCH. LTD.,"A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6mg Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004886-26,0,0,0 2014-004887-39,1,2016-03-08,2016-03-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Samsung Bioepis Co., Ltd","An Open-labelled, Single-arm, Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects with Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004887-39,0,0,0 2014-004895-48,1,2015-12-10,2015-12-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Profil Institut für Stoffwechselforschung GmbH,Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology and Metabolic Control in Patients with Type 2 Diabetes Mellitus on Stable Metformin Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004895-48,0,0,0 2014-004897-40,4,2019-10-21,2019-10-21,2,0,1,0,0,0,2,0,0,2,1,0,0,0,1,PHARM – Pharmaceutical Research Management srl,"Randomized, double-blind, placebo controlled, multi-centre, superiority Phase II study to evaluate the safety, pharmacokinetic, efficacy of gabapentin liquid formulation as add-on to morphine in child...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004897-40,1,0,0 2014-004897-40,4,2019-10-21,2019-10-21,2,0,1,0,0,0,2,0,0,2,1,0,0,0,1,PHARM - PHARMACEUTICAL RESEARCH MANAGEMENT SRL,"Randomized, double-blind, placebo controlled, multi-centre, superiority Phase II study to evaluate the safety, pharmacokinetic, efficacy of gabapentin liquid formulation as add-on to morphine in child...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004897-40,1,0,0 2014-004898-16,1,2018-11-29,2018-11-29,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Medizinische Universität Wien,A study to investigate (R)-11C-verapamil PET as a predictive biomarker for epilepsy surgery outcome Studie zur Untersuchung von (R)-11C-verapamil PET als Biomarker für das Ergebnis von epilepsiechi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004898-16,0,0,0 2014-004899-35,1,2019-07-01,2019-07-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Maastricht University,Morphine for palliative treatment of refractory dyspnea in patients with advanced COPD: benefits and respiratory adverse effects Palliatieve behandeling van refractaire dyspnoe bij patiënten met ge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004899-35,0,0,0 2014-004900-31,1,2017-02-06,2017-02-06,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","AN OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY, TOLERABILITY AND EFFICACY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE WHO PREVIOUSLY COMPLETED STUDY A8241021",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004900-31,0,0,0 2014-004902-13,3,2016-09-29,2016-09-29,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004902-13,0,0,0 2014-004903-63,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics Inc.,"An Open-Label, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Adolescents Who Previously Received MenACWY-CRM Conjugate Vaccine or Menactra",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004903-63,0,1,1 2014-004904-31,2,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,1,Mundipharma Pharmaceuticals B.V.,"An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004904-31,0,0,0 2014-004906-14,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc,"An Open Label, Non-Comparative Study To Evaluate Parasitological Clearance Rates and Pharmacokinetics of Azithromycin and Chloroquine Following Administration of a Fixed Dose Combination of Azithromyc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004906-14,0,1,1 2014-004909-33,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Manchester University NHS Foundation Trust,Thrombin Inhibition Preoperatively in Early Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004909-33,0,0,0 2014-004910-27,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Multicenter, Noncomparative, Open-label Study to Estimate the Safety, Efficacy, and Pharmacokinetics of MK-0991 (Caspofungin) in Japanese Children and Adolescents with Documented Candida or Aspergil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004910-27,0,1,1 2014-004911-35,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,"Merck & Co., Inc.","A Multicenter, Open-Label, Noncomparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in Children with Documented Candida or Aspergillus Infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004911-35,0,1,1 2014-004915-35,2,2016-05-01,2018-10-04,2,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Novartis Pharma AG,"A randomized, double blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of inhaled QBW276 in patients with cystic fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004915-35,0,0,0 2014-004916-12,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation",Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Protocol No. P05106).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004916-12,0,1,1 2014-004917-10,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Schering-Plough S.A. de C.V.,"A Double-Blind Placebo-Controlled, Randomized, Parallel-Group, Multicenter Clinical Trial To Evaluate Efficacy And Safety Of Mometasone Furoate Nasal Spray In Children With Adenoid Hypertrophy. SNORE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004917-10,0,1,1 2014-004918-28,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation",PLACEBO-CONTROLLED STUDY OF MOMETASONE FUROATE NASAL SPRAY (MFNS) 200 MCG QD IN THE RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS (SAR) (Protocol No. P05528),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004918-28,0,1,1 2014-004919-36,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation",PLACEBO-CONTROLLED STUDY OF MOMETASONE FUROATE NASAL SPRAY (MFNS) 200 MCG QD IN THE RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS (SAR),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004919-36,0,1,1 2014-004920-23,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation",PLACEBO-CONTROLLED STUDY OF MOMETASONE FUROATE NASAL SPRAY (MFNS) 200 MCG QD IN THE RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS (SAR) (Protocol No. P05583),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004920-23,0,1,1 2014-004921-41,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Corporation Schering-Plough K.K.,"Multicenter, double-blind, randomized, placebo-controlled study of mometasone furoate nasal spray in pediatric subjects with perennial allergic rhinitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004921-41,0,1,1 2014-004922-16,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Corporation Schering-Plough K.K.,A study of long-term (12-24 weeks) administration of mometasone furoate nasal spray in pediatric subjects with perennial allergic rhinitis (Protocol No. P06333),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004922-16,0,1,1 2014-004923-40,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Schering-Plough Levant,"Double blind, placebo controlled trial, evaluating the role of Nasonex® in the management of nasal obstruction secondary to adenoids hypertrophy in children.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004923-40,0,1,1 2014-004924-23,1,,,0,1,0,0,1,0,2,0,0,4,0,0,0,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation","Efficacy and Safety of Concurrent Administration of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spray Administered Once Daily (QD) vs. Oxymetazoline Twice Daily (BID), Mometasone Fu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004924-23,0,1,1 2014-004925-42,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Schering-Plough Research Institute, a Division of Schering Corporation",Efficacy and Safety of 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) vs Placebo as Adjunctive Treatment to Antibiotics in Relief of Symptoms of Acute Bacterial Sinusitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004925-42,0,1,1 2014-004926-17,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Schering-Plough S.A.de C.V.,"OPEN LABEL, 12-WEEK CLINICAL TRIAL TO ASSESS EFFICACY, SAFETY, TREATMENT ADHERENCE AND QUALITY OF LIFE IMPACT ON MOMETASONE FUROATE DRY POWDER 400 MCG ONCE DAILY IN PERSISTENT MILD-MODERATE ASTHMATIC ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004926-17,0,1,1 2014-004927-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Med. Univ. Wien, Innere Med. I",REgorafenib’s Liquid BiopsY (RELY): A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer. a non-profit investigator-initiat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004927-27,0,0,0 2014-004928-21,13,2017-10-23,2017-10-23,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, double blind, placebo-controlled, multi-center, Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004928-21,0,0,0 2014-004928-21,13,2017-10-23,2017-10-23,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double blind, placebo-controlled, multi-center, Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004928-21,0,0,0 2014-004928-21,13,2017-10-23,2017-10-23,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,NOVARTIS FARMA S.P.A.,"A randomized, double blind, placebo-controlled, multi-center, Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004928-21,0,0,0 2014-004932-20,7,2018-02-02,2018-03-19,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Limited,"A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 (risankizumab) as add-on therapy over 24 week...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004932-20,0,0,0 2014-004932-20,7,2018-02-02,2018-03-19,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 (risankizumab) as add-on therapy over 24 week...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004932-20,0,0,0 2014-004932-20,7,2018-02-02,2018-03-19,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 (risankizumab) as add-on therapy over 24 week...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004932-20,0,0,0 2014-004932-20,7,2018-02-02,2018-03-19,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim RCV GmbH & CoKG,"A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 (risankizumab) as add-on therapy over 24 week...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004932-20,0,0,0 2014-004932-20,7,2018-02-02,2018-03-19,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim bv,"A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 (risankizumab) as add-on therapy over 24 week...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004932-20,0,0,0 2014-004932-20,7,2018-02-02,2018-03-19,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 (risankizumab) as add-on therapy over 24 week...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004932-20,0,0,0 2014-004937-15,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,BIONOMICS LIMITED,"A randomized, double-blinded, placebo and lorazepam-controlled, four-way crossover, Phase II study to evaluate the effects of single oral administration of BNC210 on brain activity changes captured by...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004937-15,0,0,0 2014-004938-25,12,2019-09-24,2019-09-24,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER AG,"An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004938-25,0,0,0 2014-004938-25,12,2019-09-24,2019-09-24,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004938-25,0,0,0 2014-004938-25,12,2019-09-24,2019-09-24,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004938-25,0,0,0 2014-004939-39,7,2017-09-26,2018-04-18,6,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Gilead Sciences International Ltd.,"Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxicit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004939-39,0,0,0 2014-004939-39,7,2017-09-26,2018-04-18,6,1,0,0,0,0,4,0,0,1,1,0,1,0,1,GILEAD SCIENCES INCORPORATED,"Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxicit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004939-39,0,0,0 2014-004940-36,7,2017-11-23,2017-11-23,5,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Sanofi-aventis Recherche & Développement,"A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Persistent Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004940-36,1,1,0 2014-004942-91,8,2017-04-19,2017-04-19,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shionogi Ltd,"A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004942-91,0,0,0 2014-004944-37,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co. Inc","Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma.: A randomized, double-blind Phase 3 trial of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004944-37,0,0,0 2014-004944-37,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma.: A randomized, double-blind Phase 3 trial of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004944-37,0,0,0 2014-004946-83,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,2,Clinipace GLobal Ltd.,"A Phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer Ensayo Clínico Fase III, prospectivo, aleatorizado, d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004946-83,0,0,0 2014-004946-83,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,2,Clinipace Global Ltd.,"A Phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer Ensayo Clínico Fase III, prospectivo, aleatorizado, d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004946-83,0,0,0 2014-004946-83,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,2,Spanish Lung Cancer Group,"A Phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer Ensayo Clínico Fase III, prospectivo, aleatorizado, d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004946-83,0,0,0 2014-004948-35,1,2019-08-29,2019-08-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge,"A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic chronic subdural haematoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004948-35,0,0,0 2014-004951-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,"Traitement de l’hypertension intracrânienne chez les patients traumatisés crâniens graves : rôle des curares. Etude physiopathologique, randomisée versus placebo.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004951-30,0,0,0 2014-004952-80,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc,"Phase 3, Open-Label, Randomized, Comparative Study to Evaluate Azithromycin plus Chloroquine and Sulfadoxine plus Pyrimethamine Combinations for Intermittent Preventive Treatment of Falciparum Malaria...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004952-80,0,1,1 2014-004953-14,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Pfizer, Inc.","A Phase 3, Randomized, Active-Controlled Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 7-Valent Pneumococcal Conjugate Vac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004953-14,0,1,1 2014-004954-33,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Central Finland Hospital District,"Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in ischemic Ventricular Tachyarrhythmias. A prospective, randomized multicentre study MANTRA-VT Katetriablaatio tai rytmihäiriölääkitys ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004954-33,0,0,0 2014-004958-34,1,2016-10-09,2016-10-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leicester,Midazolam Measurement and Modelling using Matrix Samplers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004958-34,0,0,0 2014-004959-30,4,2016-10-10,2016-10-10,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A randomised, double-blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in patients with in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004959-30,0,0,0 2014-004959-30,4,2016-10-10,2016-10-10,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Boehringer Ingelheim España, S.A.","A randomised, double-blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in patients with in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004959-30,0,0,0 2014-004959-30,4,2016-10-10,2016-10-10,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Norway KS,"A randomised, double-blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in patients with in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004959-30,0,0,0 2014-004959-30,4,2016-10-10,2016-10-10,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in patients with in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004959-30,0,0,0 2014-004961-26,2,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,0,McMaster University,Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center Randomized Controlled Study Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections with Endoprosth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004961-26,0,0,0 2014-004962-76,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Solenne BV,The treatment of Rosacea with Oxofulleram. A pilot study to assess the clinical applicability of Oxofulleram De behandeling van Rosacea met Oxofulleram. Een pilotonderzoek naar de klinische toepasb...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004962-76,0,0,0 2014-004964-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sint Antonius Ziekenhuis,Clonidine as Additive for Locoregional Postoperative Analgesia in Foot and Anckle Surgery Verlenging van poplitea blok door toevoeging van clonidine als additivum bij enkel- en voetchirurgie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004964-39,0,0,0 2014-004972-49,3,2017-06-30,2017-06-30,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A randomized, open label, controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of LFG316 in patients with transplant associate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004972-49,0,0,0 2014-004973-17,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A phase 3, multicenter, open-label study to evaluate immunogenicity and safety of Novartis Meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy subjects from 2 to 18 years in Taiwan.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004973-17,0,1,1 2014-004975-22,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Oral and Maxillofacial Surgery Department of Vall d'Hebron Hospital,Advances in the management of mandibular osteoradionecrosis: Pentoxyfilline and Tocopherol as medical treatment. Avances en el manejo de la osteoradionecrosis mandibular: pentoxifilina y tocoferol ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004975-22,0,0,0 2014-004978-42,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,CHU DE POITIERS,"Pilot randomized double blind, placebo controlled trial of the efficacy of simvastatin for smoking cessation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004978-42,0,0,0 2014-004981-52,1,2019-10-10,2019-10-10,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Hospital Essen,Nab-Paclitaxel (Abraxane®) and Gemcitabine as first line therapy in patients with cholangiocarcinoma ineligible for cisplatin-based chemotherapy – a pilot study The NACHO trial (GEMNABCCC-001),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004981-52,0,0,0 2014-004982-25,4,2019-07-29,2019-07-29,4,1,0,1,0,1,1,0,0,1,0,0,0,0,1,GlaxoSmithKline Research and Development Ltd,"A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with NUT midline carcinoma (NMC) and other c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004982-25,0,0,0 2014-004982-25,4,2019-07-29,2019-07-29,4,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"GlaxoSmithKline, S.A.","A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with NUT midline carcinoma (NMC) and other c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004982-25,0,0,0 2014-004983-39,5,2016-01-19,2016-01-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Melinta Therapeutics, Inc","A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IV AND ORAL DELAFLOXACIN COMPARED WITH VANCOMYCIN + AZTREONAM IN PATIENTS WITH ACUTE BA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004983-39,0,0,0 2014-004989-23,2,2018-05-18,2018-05-18,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"GTx, Inc.","A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004989-23,0,0,0 2014-004992-21,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics S.r.l,"A Phase 2b/3, Multi-Center, Extension Study of V72P10 to Assess Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004992-21,0,1,1 2014-004993-40,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Merck & Co., Inc.","A Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Sitagliptin in Adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004993-40,0,1,1 2014-004995-49,3,2018-11-20,2018-11-20,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Genzyme Corporation,"An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed with Fabry Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004995-49,0,0,0 2014-004996-22,5,2017-09-29,2017-09-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Phase 2a, Randomized, Double-blind, Placebo- and Naproxen-controlled, Parallel-group Study to Assess the Analgesic Efficacy of ASP7692 in Patients with Pain Due to Osteoarthritis of the Knee",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-004996-22,0,0,0 2014-005000-19,4,2019-03-04,2019-03-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005000-19,0,0,0 2014-005001-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,DR. ALEJANDRO SOUSA ESCANDÓN,"CHEMO-RESECTION WITH HYPERTHERMIC INTRAVESICAL INSTILLATION (HIVEC-R) VS STANDARD TREATMENT IN PATIENTS WITH NMIBT: COMPARATIVE, PROSPECTIVE AND RANDOMIZED STUDY OF EFFICACY AND TOLERABILITY QUIMIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005001-20,0,0,0 2014-005003-24,6,2016-09-23,2016-09-23,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec Research Limited,"Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005003-24,0,0,0 2014-005004-21,1,2018-02-26,2018-02-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Universitätsklinikum Tübingen, STZ eyetrial am Department für Augenheilkunde","THOR - Tübingen Choroideremia gene therapy trial open label Phase 2 clinical trial using an adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1) THOR – Tübingen Choroideremie, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005004-21,0,0,0 2014-005005-20,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Karolinska Institute,"Karisma Pilot: A randomized, open pilot study to investigate the mammographic density reduction in healthy women ,within the Karma cohort, for two different doses of tamoxifen.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005005-20,0,0,0 2014-005006-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SOLTI,PATRICIA: A Phase II clinical trial of palbociclib and trastuzumab with or without letrozole in postmenopausal pretreated HER2-positive locally advanced or metastatic breast cancer patients PATRICI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005006-38,0,0,0 2014-005010-31,7,2019-04-09,2019-04-12,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Insmed Inc.,"A Randomized, Open Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium complex (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005010-31,0,0,0 2014-005011-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Radboudumc,Nano MRI on 7 Tesla: A technical validation study in rectal and breast cancer Nano MRI op 7 Tesla: Een eerste validatie study op 7 Tesla in rectum en borst kanker,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005011-17,0,0,0 2014-005012-42,14,2021-12-23,2021-12-23,8,0,0,0,0,1,0,0,0,2,1,0,0,0,1,Intercept Pharmaceuticals Inc.,"A Phase 3b, Double Blind, Randomized, Placebo Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005012-42,1,0,0 2014-005013-23,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A Phase III Open Label, Multi-Center Pediatric Study in China Comparing a Booster Dose of Vaxem™ Hib to HIBERIX®",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005013-23,0,1,1 2014-005014-36,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics S.r.l.,"Phase 2, Observer-Blind, Controlled, Randomized, Multi-Center Extension Study to Evaluate Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenAC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005014-36,0,1,1 2014-005015-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Oulu University Hospital,Chemoimmunotherapy in conjunction with blood-brain-barrier opening in patients with newly diagnosed or relapsed primary central nervous system lymphoma Kemoimmunoterapia yhdistettynä veriaivoesteen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005015-16,0,0,0 2014-005016-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dipartimento di Oncologia-Università degli studi di Torino,"""Multicenter, prospective, open label study , in patients with non small cell lung cancer (NSCLC), stage IIIB / IV or recurrent, after the failure of first line chemotherapy in which it's possible a t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005016-42,0,0,0 2014-005017-23,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE MICHELANGELO ONLUS PER L'AVANZAMENTO DELLO STUDIO E LA CURA DEI TUMORI,Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative Locally Advanced Breast Cancer undergoing treatment with nab-paclitaxel and carboplatin Estudio sobre un tratamiento neoadyuva...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005017-23,0,0,0 2014-005017-23,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fondazione Michelangelo Onlus - Avanzamento dello studio e cura dei tumori,Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative Locally Advanced Breast Cancer undergoing treatment with nab-paclitaxel and carboplatin Estudio sobre un tratamiento neoadyuva...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005017-23,0,0,0 2014-005017-23,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fondazione Michelangelo - Avanzamento dello studio e cura dei tumori,Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative Locally Advanced Breast Cancer undergoing treatment with nab-paclitaxel and carboplatin Estudio sobre un tratamiento neoadyuva...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005017-23,0,0,0 2014-005018-47,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS,"A PHASE II, RANDOMIZED, MULTICENTER STUDY TO ASSESS THE EFFICACY OF NAB-PACLITAXEL-BASED DOUBLET AS FIRST LINE THERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY (CUP): the AGNOSTOS trial A phase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005018-47,0,0,0 2014-005021-13,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,"Merck & Co., Inc.","A Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus (Amphotericin B) Liposome for Injection as Empirical Therapy in Pedi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005021-13,0,1,1 2014-005024-10,3,2018-01-15,2018-01-15,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER",A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005024-10,0,0,0 2014-005024-10,3,2018-01-15,2018-01-15,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Eli Lilly and Company,A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005024-10,0,0,0 2014-005026-35,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,Centre Hospitalier Universitaire de Rennes,Study DEXA-OP. Can the dexaméthasone replace the kétoprofène in the strategy of per-operating multimodal analgesia in pediatric ambulatory surgery? A double-blind randomized comparative study. Etu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005026-35,0,0,0 2014-005028-92,1,2015-03-13,2015-03-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Adocia,Blood glucose control with BC222 insulin lispro compared to insulin lispro (Humalog®) after ingestion of a standardised meal.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005028-92,0,0,0 2014-005030-54,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,"Merck & Co., Inc.","A Multicenter, Open, Sequential Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 2 Separate Doses of Caspofungin Acetate in Children Between the Ages of 3 to 24 M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005030-54,0,1,1 2014-005032-34,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,"Merck & Co., Inc.","A Multicenter, Sequential-Panel, Open-Label, Noncomparative Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Caspofungin Acetate in Neonates and Infants Less Than 3 Months of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005032-34,0,1,1 2014-005033-31,1,2016-11-29,2016-11-29,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Addmedica S.A.S,"Evaluation of the impact of renal function on the pharmacokinetics of hydroxyurea (Siklos®) in patients with sickle cell disease with normal renal function, with hyperfiltration, or with renal failure...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005033-31,0,0,0 2014-005034-66,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,"Amgen, Inc.","An Open-label, Randomized, Single-dose, 3-period, 3-treatment Crossover Study to Assess the Comparative Bioavailability of 5mg Cinacalcet Capsules to the 30mg Commercial Formulation Cinacalcet Tablets...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005034-66,0,1,1 2014-005035-13,1,2019-10-31,2019-10-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Edinburgh,GaPP 2: A multi-centre randomised controlled trial of the efficacy and mechanism of action of gabapentin for the management of chronic pelvic pain in women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005035-13,0,0,0 2014-005035-13,1,2019-10-31,2019-10-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,NHS Lothian,GaPP 2: A multi-centre randomised controlled trial of the efficacy and mechanism of action of gabapentin for the management of chronic pelvic pain in women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005035-13,0,0,0 2014-005036-33,1,,,0,1,0,1,0,0,1,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,A phase I study to investigate safety and reactogenicity of Vaxem Hib in healthy children aged 16 – 20 months and infants aged 2 - 4 months.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005036-33,0,1,1 2014-005040-18,1,2015-10-23,2015-10-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Kirurgisk afdeling, Nordsjællands Hospital",Preoperativ dexamethasone for patients undergoing laparoscopy for suspected appendicitis. Dexamethason præoperativt forud for diagnostisk laparoskopi hos patienter mistænkt for appendicitis acuta.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005040-18,0,0,0 2014-005041-41,1,2015-10-02,2015-10-02,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Janssen Sciences Ireland UC,"A Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the antiviral activity, safety, and pharmacokinetics of repeated doses of orally administered JNJ-53718678 against Respirat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005041-41,0,0,0 2014-005042-21,2,2019-05-28,2019-05-28,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Lilly S.A.,"A Single-Arm, Multicenter, Phase 1b Study with an Expansion Cohort to Evaluate Safety and Efficacy of Necitumumab in Combination with Abemaciclib in Treatment of Patients with Stage IV Non-Small Cell ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005042-21,0,0,0 2014-005042-21,2,2019-05-28,2019-05-28,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Eli Lilly and Company,"A Single-Arm, Multicenter, Phase 1b Study with an Expansion Cohort to Evaluate Safety and Efficacy of Necitumumab in Combination with Abemaciclib in Treatment of Patients with Stage IV Non-Small Cell ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005042-21,0,0,0 2014-005045-53,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Landstinget Västmanland,"Effects of expectations, medication and placebo on objective and self-rated performance during the Quantified Behavior Test in terms of the ADHD core signs hyperactivity, inattention and impulsivity i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005045-53,0,0,0 2014-005047-40,3,2015-08-25,2015-08-25,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Sanofi-Aventis AG,"A Randomized, Double Blind, Single Dose, Crossover Study, in Subjects with Mild to Moderate Asthma, to Compare the Pharmacodynamic (Bronchodilator) Responses of 12.5/250 µg and 50/250 µg Salmeterol / ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005047-40,0,0,0 2014-005052-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,Total versus corrected body weight for dosage of sugammadex in morbidly obese patients. Peso corporeo corretto versus peso corporeo totale per il dosaggio del sugammadex in pazienti con obesità pat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005052-25,0,0,0 2014-005053-40,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics S.r.l,"A Phase III, Observer-Blind, Randomized, Multi-center Study to Evaluate the Safety, Tolerability, and Immunogenicity of Fluad and Agriflu Compared to the Non Adjuvanted Trivalent Influenza Vaccine Flu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005053-40,0,1,1 2014-005055-11,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A phase 3, multi-center, observer-blind, placebocontrolled, randomized study to evaluate the immunogenicity and safety of Novartis Meningococcal ACWY conjugate vaccine in healthy subjects from 11 to 5...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005055-11,0,1,1 2014-005057-39,4,2016-02-03,2016-02-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ziarco Pharma Ltd,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFECTS OF 8 WEEKS TREATMENT WITH ORAL ZPL-3893787 (30 MG OD X 56 DAYS) ON PRURITUS IN ADULT SUBJECTS WITH MODERAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005057-39,0,0,0 2014-005059-25,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,"Novartis Vaccines &Diagnostics, Inc.","A Phase 2b, Open-Label, Multi-Center Study to Evaluate the Persistence of Antibody Response and to Assess the Immune Response to a Booster Dose of MenACWY Conjugate Vaccine in Subjects Previously Vacc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005059-25,0,1,1 2014-005060-15,14,2019-12-03,2019-12-16,12,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck KGaA,"A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005060-15,0,0,0 2014-005061-72,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"Phase 3, randomized, open label, controlled multi center study to evaluate the safety and immunogenicity of 4 doses of MenACWY conjugate vaccine, administered concomitantly with routine vaccines, amon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005061-72,0,1,1 2014-005062-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Germans Trias i Pujol,"Randomized, double-blind, placebo controlled clinical trial to assess the phrenic nerve functional status after periphrenic lidocaine infiltration in lung resection surgery. ENSAYO CLINICO PILOTO P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005062-30,0,0,0 2014-005064-15,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-ALV),"Safety, feasibility and cost-effectiveness of genotype-directed individualized dosing of fluoropyrimidines Veiligheid, haalbaarheid en kosten-effectiviteit van geïndividualiseerd doseren op basis v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005064-15,0,0,0 2014-005066-30,3,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,0,UNIVERSITY OF BIRMINGHAM,International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005066-30,0,0,0 2014-005066-30,3,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,0,University of Birmingham,International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005066-30,0,0,0 2014-005066-30,3,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,0,The University of Birmingham,International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005066-30,0,0,0 2014-005067-32,6,2018-12-28,2018-12-28,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Protocol I4T-MC-JVCZ Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination with Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesoph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005067-32,0,0,0 2014-005067-32,6,2018-12-28,2018-12-28,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Lilly S.A.,"Protocol I4T-MC-JVCZ Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination with Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesoph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005067-32,0,0,0 2014-005068-13,8,2021-11-19,2021-11-19,6,0,0,0,0,2,3,0,0,2,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005068-13,1,0,0 2014-005068-13,8,2021-11-19,2021-11-19,6,0,0,0,0,2,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005068-13,1,0,0 2014-005068-13,8,2021-11-19,2021-11-19,6,0,0,0,0,2,3,0,0,2,0,0,0,0,1,Lilly S.A.,"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005068-13,1,0,0 2014-005069-60,2,,,0,1,0,0,0,0,2,0,0,1,1,0,0,1,0,Medical Center - University of Freiburg,R-CPOP as first line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005069-60,0,0,0 2014-005070-11,3,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV H...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005070-11,0,0,0 2014-005073-37,1,2016-08-09,2016-08-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Nuclear Medicine, Aalborg University Hospital","68Ga-PSMA PET/CT for detection of recurrent prostate cancer: Comparison with 18F-fluoride PET/CT, MRI and DW-MRI 68Ga-PSMA PET/CT til at identificere prostatacancer recidiv: sammenligning med 18F-f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005073-37,0,0,0 2014-005074-11,1,2017-08-30,2017-08-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital South Manchester NHS Foundation Trust,The Role of GABAb receptor mechanisms in cough: Double-blind randomised controlled trial of Lesogaberan in Chronic cough patients with positive and negative symptom association probabilities,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005074-11,0,0,0 2014-005075-88,1,,,0,1,0,0,1,0,3,0,1,4,0,0,0,0,1,Novartis Pharma K.K,"A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1Mon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005075-88,0,1,1 2014-005077-36,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Örebro Läns Landsting,Simplified basic immunisation after transplantation of stem cells Förenklad grundvaccination efter stamcellstransplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005077-36,0,0,0 2014-005079-10,3,2016-10-31,2016-10-31,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Tokai Pharmaceuticals Inc,"ARMOR3-SV: A Phase 3, Randomized, Open-Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) with Metastatic (M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005079-10,0,0,0 2014-005083-15,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics S.r.l.,"A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Novartis rMenB+OMV NZ Vaccine in Healthy Subjects Aged 11 to 17 years in Korea.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005083-15,0,1,1 2014-005084-32,3,2016-11-18,2016-11-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomized, double-blind, placebo-controlled, parallel group, multi-centre Phase IIa study in asthma patients comparing the efficacy and safety of once daily inhaled Interferon beta-1a to placebo, a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005084-32,0,0,0 2014-005086-70,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,SHIRE DEVELOPMENT LLC AND INTERNATIONAL AFFILIATES,A Multicenter Study to Monitor for the Potential Development of Renal Tumors in Subjects With Transfusional Iron Overload Who Were Previously Exposed to Deferitazole Studio multicentrico per monit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005086-70,0,0,0 2014-005088-34,1,2019-07-29,2019-07-29,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Cardiff University,"A randomised controlled, double blind trial investigating the efficacy of fluoxetine treatment in improving memory and learning impairments in patients with mesial temporal lobe epilepsy: Fluoxetine, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005088-34,0,0,0 2014-005093-11,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,InnaVirVax,"Multicentre, open-label, phase I/IIa clinical study of an immunoprotective therapeutic vaccine candidate (VAC-3S) in Human Immunodeficiency Virus type 1 (HIV-1) chronically infected patients virologi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005093-11,0,0,0 2014-005095-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS,Olaparib as salvage treatment for cisplatin-resistant germ cell tumor. Olaparib as salvage treatment for cisplatin-resistant germ cell tumor.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005095-28,0,0,0 2014-005096-85,8,2018-02-09,2018-02-09,6,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Merckle GmbH,"Safety and Efficacy of LONQUEX® (Lipegfilgrastim) in Comparison to Pegfilgrastim (Neulasta®, Amgen Inc.) and Placebo in Patients with Non-Small-Cell Lung Cancer Receiving First-Line Chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005096-85,0,0,0 2014-005097-11,4,2019-08-14,2020-03-31,4,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ETOP (European Thoracic Oncology Platform),A feasibility trial evaluating anti-PD1 nivolumab consolidation after standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B NSCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005097-11,0,0,0 2014-005098-35,3,2017-09-15,2017-09-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,ETOP (European Thoracic Oncology Platform),Afatinib in pretreated patients with advanced NSCLC harbouring HER2 exon 20 mutations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005098-35,0,0,0 2014-005099-27,1,2016-02-15,2016-02-15,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Institut de Recerca de l?Hospital de la Santa Creu i Sant Pau ? IIB Sant Pau,"randomized, single blind, prospective clinical study to compare hFSH-HP (Fostipur) and hMG-HP (Menopur) in patients with polycystic ovary ander a FIV/ICSI cicle. Estudio clínico prospectivo, random...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005099-27,0,0,0 2014-005101-21,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Genera Research Ltd,"Safety, tolerability, systemic pharmacokinetics and efficacy of a single dose of Osteogrow (rhBMP6 in autologous Whole Blood Coagulum Derived [WBCD] carrier) delivered locally to the fracture site in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005101-21,0,0,0 2014-005102-38,3,2018-07-26,2018-10-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co. KG,BI 655066 / ABBV-066 (risankizumab) versus placebo In a Multicenter randomized double-blind study in patients with Moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with r...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005102-38,0,0,0 2014-005102-38,3,2018-07-26,2018-10-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,BI 655066 / ABBV-066 (risankizumab) versus placebo In a Multicenter randomized double-blind study in patients with Moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with r...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005102-38,0,0,0 2014-005102-38,3,2018-07-26,2018-10-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,BI 655066 / ABBV-066 (risankizumab) versus placebo In a Multicenter randomized double-blind study in patients with Moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with r...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005102-38,0,0,0 2014-005105-20,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A phase IV, uncontrolled, open-label, multi-center study in children and adolescents: Evaluation of long-term immunogenicity in subjects boosted with a new pediatric TBE vaccine (free of protein-deriv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005105-20,0,1,1 2014-005106-38,1,,,0,1,0,0,1,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A Pivotal Randomized, Single-Blind, Dose-Finding Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated Novel ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005106-38,0,1,1 2014-005107-24,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1) 2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005107-24,0,1,1 2014-005109-19,1,2021-11-09,2021-11-09,1,0,0,0,0,0,3,0,0,1,1,1,0,0,0,University Hospital Tuebingen,Apixaban for treatment of embolic stroke of undetermined source Apixaban zur Behandlung von embolischen Schlaganfall unbestimmter Quelle,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005109-19,0,0,0 2014-005111-16,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Instituto de Investigaciones del Sueño,Response to gabapentin enacarbil in two groups of RLS patients: Previously exposed to long-term treatment with dopaminergic agents versus dopaminergic treatment-naive patients. ?Respuesta al trata...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005111-16,0,0,0 2014-005112-42,2,2019-12-03,2019-12-03,2,1,0,0,0,1,2,0,0,1,0,0,1,0,0,INSERM,"A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005112-42,0,0,0 2014-005114-33,1,2017-04-01,2017-04-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,UZ Leuven,Effectiveness of Botulinum Toxin Infiltration for treatment of upper limb dysfunctions after treatment for breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005114-33,0,0,0 2014-005115-16,1,,,0,1,1,0,0,1,3,0,0,4,0,0,0,0,1,Octapharma AG,"Prospective, open-label, uncontrolled, Phase III study to assess the efficacy, safety, and pharmacokinetics of Octafibrin for on-demand treatment of acute bleeding and to prevent bleeding during and a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005115-16,0,1,1 2014-005116-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Padova,"Postoperative pulmonary function in patients undergoing laparoscopic sleeve gastrectomy after administration of sugammadex and neostigmine. A double-blind, randomized controlled trial. La funzione ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005116-41,0,0,0 2014-005117-23,2,2017-09-18,2017-09-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,BI 655066/ABBV-066 (risankizumab) versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis (UltIMMa-1) BI 65506...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005117-23,0,0,0 2014-005117-23,2,2017-09-18,2017-09-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co. KG,BI 655066/ABBV-066 (risankizumab) versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis (UltIMMa-1) BI 65506...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005117-23,0,0,0 2014-005118-49,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis,"Randomized Phase II, 2-arm study of Pembrolizumab after high dose radiation (SBRT) versus Pembrolizumab alone in patients with advanced non-small cell lung cancer. Acronym: PEMBRO-RT study Gerando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005118-49,0,0,0 2014-005119-17,11,2017-07-26,2017-08-09,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bayer AG,Open-label Phase-4 study to examine the change of vision-related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2 mg aflibercept accordi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005119-17,0,0,0 2014-005119-17,11,2017-07-26,2017-08-09,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bayer HealthCare AG,Open-label Phase-4 study to examine the change of vision-related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2 mg aflibercept accordi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005119-17,0,0,0 2014-005121-13,1,2018-05-07,2018-05-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Regensburg,"Prospective, randomized, controlled, multicenter, two-armed, study comparing daylight photodynamic therapy using MAL with cryosurgery for the treatment and prophylaxis of actinic keratoses in photodam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005121-13,0,0,0 2014-005123-27,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS,Complementary vaccination with dendritic cells pulsed with autologous tumor lysate in resected stage III and IV melanoma patients: a phase II randomized trial (ACDC adjuvant Trial) Complementary v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005123-27,0,0,0 2014-005125-12,1,2019-12-16,2019-12-16,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Dr. Albert Lecube, Ph.D., M.D.","MULTICENTRE RANDOMIZED DOUBLE BLIND, CROSSOVER, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFECT OF LIRAGLUTIDE ON LUNG FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (LIRALUNG STUDY) E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005125-12,0,0,0 2014-005126-35,1,2021-01-19,2021-01-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GBG Forschungs GmbH,"A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer DESIREE - Eine multizent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005126-35,0,0,0 2014-005127-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMC Utrecht,Markers of Efficacy of Xolair (Omalizumab) in Chronic Spontaneous Urticaria Markers voor de effectiviteit van omalizumab bij chronische spontane urticaria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005127-27,0,0,0 2014-005128-91,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics S.r.l.,Evaluating the safeness of Agrippal® S1 in preventing flu on Vietnamese volunteers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005128-91,0,1,1 2014-005129-10,1,2020-12-31,2020-12-31,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Irina Elovaara,Multiple Sclerosis and Menopause: the effect of hormone replacement therapy on clinical picture and immunology of multiple sclerosis MS-tauti ja vaihdevuodet: hormonikorvaushoidon vaikutus MS-taudi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005129-10,0,0,0 2014-005130-55,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University of Cologne,HD21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparision of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005130-55,0,0,0 2014-005133-30,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Novartis Vaccines & Diagnostics, Inc.","A Phase 3b, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005133-30,0,1,1 2014-005134-64,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,2,Bristol-Myers Squibb Company,"Phase I/II Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, ATAZANAVIR, ATV, REYATAZ™) in Combination Regimens in Antiretroviral Therapy (ART)-Naïve and Experien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005134-64,0,1,1 2014-005134-64,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,2,National Institute of Allergy and Infectious Diseases (NIAID),"Phase I/II Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, ATAZANAVIR, ATV, REYATAZ™) in Combination Regimens in Antiretroviral Therapy (ART)-Naïve and Experien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005134-64,0,1,1 2014-005135-13,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,A Phase III Observer blind Single-Coordinating Center Pediatric Study in China Comparing a Booster Dose of Vaxem™ Hib to HIBERIX® When Given as Part of a Local Dosing Regimen in Infants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005135-13,0,1,1 2014-005136-33,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A Phase III Observer-Blind, Randomized, Controlled, Single-Coordinating Center Pediatric Study in China Comparing Vaxem Hib to HIBERIX® Using a Local Dosing Regimen in Infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005136-33,0,1,1 2014-005137-32,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,ENCELADUS Pharmaceuticals BV,"A Phase I-IIa, Open label, Multi-Center, Dose Escalating Study to Evaluate the Safety of Intravenous Pegylated Liposomal Dexamethasone Sodium Phosphate (Oncocort) as Monotherapy in Patients with Previ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005137-32,0,0,0 2014-005139-14,5,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Janssen-Cilag International N.V.,A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma Uno studio randomizzato di fase 2 per valutare tre programmi di dosaggio di daratumumab nel mi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005139-14,0,0,0 2014-005139-14,5,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma Uno studio randomizzato di fase 2 per valutare tre programmi di dosaggio di daratumumab nel mi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005139-14,0,0,0 2014-005140-18,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,ENTE OSPEDALIERO OSPEDALI GALLIERA,Diagnostic and clinical value of fused 64CuCl2-PET/MRI in prostate cancer relapse. Comparison with multiparametric MRI (mMRI) and 18F-Choline-PET/MRI Efficacia diagnostica e impatto clinico della ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005140-18,0,0,0 2014-005142-21,3,2015-11-17,2015-11-17,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Takeda Development Centre Europe Limited,"A Multicenter, Randomized, Double Blind, Placebo Controlled, Proof of Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Weekly Subcutaneous MLN1202, in Improving Diabetic Nephropathy Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005142-21,0,0,0 2014-005145-51,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Maastricht University Medical Centre,"A randomised controlled multicenter trial comparing ultrasound-accelerated catheter-directed thrombolysis, combined with standard anticoagulant therapy, with standard anticoagulant therapy alone, for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005145-51,0,0,0 2014-005147-40,6,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,VIIV HEALTHCARE UK LIMITED,"A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005147-40,0,0,0 2014-005147-40,6,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ViiV Healthcare UK Limited,"A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005147-40,0,0,0 2014-005147-40,6,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"ViiV Healthcare, S.L.","A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005147-40,0,0,0 2014-005148-16,5,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,VIIV HEALTHCARE UK LIMITED,"A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005148-16,0,0,0 2014-005148-16,5,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ViiV Healthcare UK Limited,"A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005148-16,0,0,0 2014-005148-16,5,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"ViiV Healthcare, S.L.","A Phase III, randomized, multicenter, parallel-group, noninferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005148-16,0,0,0 2014-005149-40,1,2017-03-01,2017-03-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratoire GlaxoSmithKline,An open label non randomized access study of Trametinib for patients with advanced unresectable (stage IIIc) or distant metastatic (stage IV) BRAF V600E/K mutation positive cutaneous melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005149-40,0,0,0 2014-005153-39,14,2017-06-23,2017-06-23,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-blind, Placebo controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients with Type 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005153-39,0,0,0 2014-005153-39,14,2017-06-23,2017-06-23,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEXICON PHARMACEUTICALS INC.,"A Phase 3, Randomized, Double-blind, Placebo controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients with Type 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005153-39,0,0,0 2014-005156-26,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Dr. Enrique Alday,Effects of neuromuscular block reversal with sugammadex vs neostigmine on postoperative respiratory outcomes after major abdominal surgery. A randomized controlled trial. EFECTO DE LA REVERSION DE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005156-26,0,0,0 2014-005159-24,1,,,0,1,0,0,1,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A Phase III, observer-blind, randomized, controlled, multi-center study to inventigate the immunogenicity and safety of the Vaxem Hib™ in 2-4 months old healthy infants in China, according to the reco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005159-24,0,1,1 2014-005160-15,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics S.r.l.,"Phase 2, Observer Blinded, Controlled, Randomized Multi-Center Study in Adolescents, to Evaluate Safety, Tolerability and Immunogenicity of Four Different rMenB plus MenACWY Formulations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005160-15,0,1,1 2014-005161-72,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines & Diagnostics,"A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine with One Dose of Licensed Meningococcal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005161-72,0,1,1 2014-005162-29,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,University of Insubria,"Treatment of portal, mesenteric, and splenic vein thrombosis with rivaroxaban. A pilot, prospective cohort study Officiële titel: Behandeling van portale, mesenterische en splenische veneuze tro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005162-29,0,0,0 2014-005164-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Klinikum der Universität München, Medizinische Klinik und Poliklinik III","A prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib) in Combination with Obinutuzumab (GA 101) in Patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005164-15,0,0,0 2014-005169-63,5,2017-05-12,2017-05-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nabriva Therapeutics AG,"A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005169-63,0,0,0 2014-005170-11,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Cliniques universitaires Saint Luc,"Can we get conscious sedation in optimal safety conditions in an emergency department, by combining dexmedetomidine with alfentanil? Peut-on obtenir une sédation consciente, dans des conditions opt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005170-11,0,0,0 2014-005172-28,4,2019-07-17,2019-07-17,2,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Montreal Heart Institute,COLCHICINE CARDIOVASCULAR OUTCOMES TRIAL (COLCOT) COLCHICINE CARDIOVASCULAR OUTCOMES TRIAL (COLCOT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005172-28,1,0,0 2014-005172-28,4,2019-07-17,2019-07-17,2,0,0,0,0,0,3,0,0,2,0,0,0,0,0,MONTREAL HEART INSTITUTE,COLCHICINE CARDIOVASCULAR OUTCOMES TRIAL (COLCOT) COLCHICINE CARDIOVASCULAR OUTCOMES TRIAL (COLCOT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005172-28,1,0,0 2014-005174-11,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Uppsala University Hospital,"A randomized, double-blinded placebo-controlled, paralleled designed, investigator sponsored study of the effect of the GLP-1 receptor agonist liraglutide on beta-cell function in C-peptide positive t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005174-11,0,0,0 2014-005179-10,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Charalampos Vlachopoulos,Effect of long-term testosterone replacement therapy on arterial stiffness and endothelial function in male patients with hypogonadism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005179-10,0,0,0 2014-005181-30,12,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,2,ABCSG GmbH,PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor po...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005181-30,0,0,0 2014-005181-30,12,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,2,ABCSG GMBH,PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor po...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005181-30,0,0,0 2014-005183-15,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,CSL Limited,"A Phase II, Multicentre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children Aged >= 6 Months to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005183-15,0,1,1 2014-005185-30,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A Randomized, Open Label, Single Center, Dose- and Regimen-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted and Non-Adjuvanted Egg-Derived, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005185-30,0,1,1 2014-005186-73,1,2017-09-30,2017-09-30,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Bispebjerg University Hospital,Impact of intense exercise on pharmacokinetics of glucocorticoides in relation to doping analysis Intens trænings indvirkning på glukokortikoids farmakokinetik i relation til doping analyse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005186-73,0,0,0 2014-005188-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,GORTEC,"Phase III trial of laryngeal preservation comparating Induction chemotherapy with cisplatin, 5-fluorouracil and docetaxel (TPF) followed by radiotherapy and concomitant administration of radiotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005188-34,0,0,0 2014-005189-31,1,2015-10-01,2015-10-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Dept Hematology SLB Vejle,“Monoclonal antibodies for treatment of multiple myeloma. Present status and aspects of effector mechanisms with emphasis on the CD38 antibody daratumumab ”.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005189-31,0,0,0 2014-005190-36,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,Amgen Inc,A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Panitumumab in Children with Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005190-36,0,1,1 2014-005192-89,1,2018-10-31,2018-10-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Hospira UK Ltd.,Post-Marketing Observational Cohort Study of Patients with Inflammatory Bowel Disease (IBD) Treated with CT-P13 in Usual Clinical Practice (CONNECT-IBD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005192-89,0,0,0 2014-005193-11,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King's College London,METformin And Longevity (METAL): A window of opportunity study investigating biological effects of metformin in localised prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005193-11,0,0,0 2014-005193-11,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Guy's and St Thomas' NHS Foundation Trust,METformin And Longevity (METAL): A window of opportunity study investigating biological effects of metformin in localised prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005193-11,0,0,0 2014-005194-37,2,2017-05-10,2017-05-10,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Orphazyme ApS,A prospective non-therapeutic study in patients diagnosed with Niemann-Pick disease type C in order to characterise the individual patient disease profile and historic signo-symptomatology progression...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005194-37,0,0,0 2014-005197-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII,Sugammadex and neurogical effects central SUGAMMADEX ED EFFETTI NEUROLOGICI CENTRALI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005197-11,0,0,0 2014-005199-27,5,2020-09-08,2020-09-08,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Eisai Limited,"A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005199-27,0,0,0 2014-005199-27,5,2020-09-08,2020-09-08,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,EISAI LIMITED,"A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005199-27,0,0,0 2014-005199-27,5,2020-09-08,2020-09-08,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Eisai Ltd.,"A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005199-27,0,0,0 2014-005200-13,1,2018-12-31,2018-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Ghent University,study of the pharmacokinetics and pharmacodynamics of desmopressin oral lyophilisate - route of administration in the pediatric patient population - SAFEPEDRUG Studie naar farmacokinetiek en farmac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005200-13,0,0,0 2014-005203-24,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,A Post Marketing Surveillance Study to monitor the reactogenicity and safety of Vaxem™Hib when administered according to the prescribing information in Korea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005203-24,0,1,1 2014-005206-37,2,2018-05-22,2018-05-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a MonoAminergic antidepressant in Adults with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005206-37,0,0,0 2014-005207-25,1,2018-07-10,2018-07-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Manchester University NHS Foundation Trust,Observational study of lidocaine levels in children after airway topicalisation during direct laryngotracheobronchosopy (DLTB).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005207-25,0,0,0 2014-005210-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Hamburg-Eppendorf,Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial (MMM 02 study) Ruxolitinib Behandlung versus al...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005210-28,0,0,0 2014-005215-16,1,2020-02-21,2020-02-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU Brugmann,A psychomotor recuperation study after deep sedation for colonoscopy between target controlled and manual titration of propofol.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005215-16,0,0,0 2014-005217-24,15,2016-09-21,2016-11-16,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc","A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulcerat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005217-24,0,0,0 2014-005221-12,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Greater Glasgow and Clyde,"OCTOPUS: Ovarian Cancer Trials of Weekly Paclitaxel - Umbrella Study A Randomised, Phase II Umbrella Trial of a Weekly Paclitxel +/- Novel Agents in Platinum-Resistant Ovarian Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005221-12,0,0,0 2014-005221-12,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The University of Glasgow,"OCTOPUS: Ovarian Cancer Trials of Weekly Paclitaxel - Umbrella Study A Randomised, Phase II Umbrella Trial of a Weekly Paclitxel +/- Novel Agents in Platinum-Resistant Ovarian Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005221-12,0,0,0 2014-005235-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sahlgrenska University hospital of gothenburg Department of dermatology,"Therapy-treatment (PDT) on Acne, a study to optimize the number of treatments, the right light-dose and the right pre-treatment in order to obtain a longterm remission-time",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005235-13,0,0,0 2014-005238-76,1,2017-07-01,2017-07-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Centro Hospitalar do Porto,Can adequacy of anesthesia depth and quality of recovery be influenced by the level of neuromuscular blockade: a randomized controlled study assessing propofol and remifentanil requirements and qualit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005238-76,0,0,0 2014-005239-15,1,2019-02-11,2019-02-11,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,Effects of mineralocorticoid receptor stimulation on cognitive bias and social cognition in patients with major depression and healthy controls: what’s the role of NMDA receptors? Effekte der Min...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005239-15,0,0,0 2014-005241-45,10,2021-06-10,2021-06-10,9,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005241-45,1,0,0 2014-005241-45,10,2021-06-10,2021-06-10,9,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck, Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005241-45,1,0,0 2014-005244-17,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,PPM SERVICES S.A.,AN OPEN LABEL CLINICAL STUDY TO EVALUATE THE LONG-TERM DERMAL SAFETY PROFILE OF 12-WEEKS TOPICAL ADMINISTRATION OF TWO DIFFERENT DOSES OF N-ACETYL-GED-0507-34-LEVO GEL IN PATIENTS WITH MILD TO MODERAT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005244-17,0,0,0 2014-005246-22,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Novartis Vaccines and Diagnostics, S.r.l.","A phase III, observer-blind, randomized, controlled, single center study to investigate immunogenicity and safety of VaxemTM Hib in 13 - 59 months old healthy children in China, according to the recom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005246-22,0,1,1 2014-005251-39,9,2018-10-12,2018-10-12,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pharma Mar S.A., Sociedad Unipersonal",Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005251-39,0,0,0 2014-005251-39,9,2018-10-12,2018-10-12,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharma Mar S.A.,Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005251-39,0,0,0 2014-005251-39,9,2018-10-12,2018-10-12,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pharma Mar, S.A.",Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005251-39,0,0,0 2014-005251-39,9,2018-10-12,2018-10-12,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"PHARMA MAR, S.A. SOCIEDAD UNIPERSONAL",Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005251-39,0,0,0 2014-005253-39,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,Bayer HealthCare AG,A Prospective Study to Evaluate the Effect of rFVIII-FS in Different Prophylactic Regimens on Bleeding Events Frequency and Development of Arthropathy in Previously Treated and Minimally Treated Hemop...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005253-39,0,1,1 2014-005255-87,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Assistance Publique Hôpitaux de MARSEILLE,"Efficacy of adjuvant Imatinib in patients with intermediate-risk gastrointestinal stromal tumor with a high-risk Genomic Grade Index. Multicenter, prospective, randomized study. Evaluation de l’eff...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005255-87,0,0,0 2014-005256-26,13,2017-09-20,2017-12-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Finland Ky,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 26 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005256-26,0,0,0 2014-005256-26,13,2017-09-20,2017-12-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim AB,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 26 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005256-26,0,0,0 2014-005256-26,13,2017-09-20,2017-12-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 26 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005256-26,0,0,0 2014-005256-26,13,2017-09-20,2017-12-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 26 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005256-26,0,0,0 2014-005256-26,13,2017-09-20,2017-12-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 26 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005256-26,0,0,0 2014-005256-26,13,2017-09-20,2017-12-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim France,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 26 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005256-26,0,0,0 2014-005256-26,13,2017-09-20,2017-12-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Ellas SA,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 26 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005256-26,0,0,0 2014-005256-26,13,2017-09-20,2017-12-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda","A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 26 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005256-26,0,0,0 2014-005256-26,13,2017-09-20,2017-12-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim bv,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 26 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005256-26,0,0,0 2014-005256-26,13,2017-09-20,2017-12-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,2,Boehringer Ingelheim Ltd,"A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of empagliflozin as adjunctive to insulin therapy over 26 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005256-26,0,0,0 2014-005258-20,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novartis Pharma GmbH,"A 24-week, randomized, controlled, multicenter, open-label study with blinded assessment of the efficacy of subcutaneous secukinumab compared to Fumaderm® in adults with moderate to severe plaque psor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005258-20,0,0,0 2014-005259-20,1,2017-09-15,2017-09-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Investigacion Independiente,"FASE IV-II CLINICAL TRIAL, PROOF OF CONCEPT, RANDOMIZED, SIMULATED CONTROLLED TREATMENT, DOUBLE BLINDED AND UNICENTRIC WITH TWO PARALLEL GROUPS, TO EVALUATE SAFETY AND EFFICACY OF INTRAVITREAL ADMINIS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005259-20,0,0,0 2014-005260-15,5,2018-05-17,2018-05-23,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Faron Pharmaceuticals Ltd,"A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Moderate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005260-15,0,0,0 2014-005261-69,3,2016-08-15,2016-08-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,RECKITT BENCKISER HEALTHCARE (UK) LIMITED,"A multi-centre, randomised, double-blind, two arm, parallel group, placebo-controlled study to assess the effect of Sodium Alginate Chewable Tablets on symptoms of gastro-oesophageal reflux disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005261-69,0,0,0 2014-005261-69,3,2016-08-15,2016-08-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Reckitt Benckiser Healthcare (UK) Limited,"A multi-centre, randomised, double-blind, two arm, parallel group, placebo-controlled study to assess the effect of Sodium Alginate Chewable Tablets on symptoms of gastro-oesophageal reflux disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005261-69,0,0,0 2014-005263-33,1,2018-07-02,2018-07-02,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Medizinische Fakultät der Universität Bonn,Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum Intravitreales Aflibercept (Eylea®) zur The...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005263-33,0,0,0 2014-005264-14,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),NA FancoMob: Etude pilote évaluant la faisabilité de la mobilisation sanguine et de la collection des cellules CD34+ après traitement par G-CSF et plérixafor chez des patients atteints d'Anémie de ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005264-14,0,0,0 2014-005268-13,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Bayer HealthCare AG,"An Open Label, Actual Use Study in Consumers Taking an Extended-Release Over the Counter NSAID in a Naturalistic Setting",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005268-13,0,1,1 2014-005269-66,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Bayer HealthCare AG,"A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of an Extended Release Naproxen Sodium Tablet in Postsurgical Dental...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005269-66,0,1,1 2014-005270-11,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Bayer HealthCare AG,Comparative Onset of Action of a Fast Release Aspirin Tablet in a Dental Impaction Pain Model,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005270-11,0,1,1 2014-005271-81,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Bayer HealthCare AG,"A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of a Fast Release Aspirin 1000 mg in Postsurgical Dental Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005271-81,0,1,1 2014-005272-28,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Bayer HealthCare AG,"A Randomized, Double-Blind, Placebo Controlled Trial to Assess the Analgesic Efficacy and Safety of Extended Release Naproxen Sodium Tablets in Postsurgical Dental Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005272-28,0,1,1 2014-005273-37,3,2016-05-25,2016-05-25,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Santen Oy,A phase IV study on changes in ocular signs and symptoms in patients with with ocular hypertension or open-angle glaucoma switched from Ganfort¿ eye drops (bimatoprost 0.03%/timolol 0.5%) to Taptiqom¿...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005273-37,0,0,0 2014-005273-37,3,2016-05-25,2016-05-25,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SANTEN OY,A phase IV study on changes in ocular signs and symptoms in patients with with ocular hypertension or open-angle glaucoma switched from Ganfort¿ eye drops (bimatoprost 0.03%/timolol 0.5%) to Taptiqom¿...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005273-37,0,0,0 2014-005277-36,1,2019-09-30,2019-09-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo Español Multidisciplicinar de Melanoma (GEM),"A randomized Phase II study of vemurafenib plus cobimetinib continuous versus intermittent, in previously untreated BRAFV600- mutation positive patients with unresectable locally advanced or metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005277-36,0,0,0 2014-005278-12,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Bayer HealthCare AG,"A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of a Fast Release Aspirin 650 mg in Postsurgical Dental Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005278-12,0,1,1 2014-005279-10,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Allergan Ltd.,"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005279-10,0,0,0 2014-005281-30,6,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Allergan Ltd.,"A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Skin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005281-30,0,0,0 2014-005281-30,6,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Allergan Ltd,"A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Skin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005281-30,0,0,0 2014-005281-30,6,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Durata Therapeutic International B.V. (an Allergan Affiliate),"A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Skin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005281-30,0,0,0 2014-005282-78,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IV, randomised, open-label, controlled study to assess the immunogenicity and safety of the diphtheria, tetanus, pertussis and inactivated poliovirus (DPT-IPV) vaccine Squarekids™ when co-admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005282-78,0,1,1 2014-005286-69,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Kuopion yliopistollinen sairaala/Ensihoitokeskus,Intranasal fentanyl in pre-hospital analgesia Intranasaalinen fentanyyli ensihoidon kivunhoidossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005286-69,0,0,0 2014-005287-15,1,2017-12-21,2017-12-21,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Technische Universität München, Fakultät für Medizin",- PRE-POINT-EARLY STUDY - Pilot study using oral insulin at early age for immune efficacy in primary prevention of type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005287-15,0,0,0 2014-005289-31,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,CHEMI S.P.A.,"A multicentre, double blind, randomized placebo controlled trial to assess the effect of LF-PB on seroma formation in women with breast cancer undergoing Axillary Lymph Node Dissection Studio mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005289-31,0,0,0 2014-005296-81,1,2016-09-09,2016-09-09,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,BioMarin Pharmaceutical Inc.,"A 24 week Randomized Double-Blind, Placebo-Controlled Study followed by 72 week open-label extension to assess the efficacy, safety and tolerability of drisapersen sodium in subjects with Duchenne Mus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005296-81,0,0,0 2014-005297-12,2,2016-03-04,2016-03-04,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A single blind, multicenter pilot study to investigate the safety and tolerability of a 14 day oral treatment with different doses of the chymase inhibitor BAY 1142524 in comparison to placebo in clin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005297-12,0,0,0 2014-005297-12,2,2016-03-04,2016-03-04,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Bayer AG,"A single blind, multicenter pilot study to investigate the safety and tolerability of a 14 day oral treatment with different doses of the chymase inhibitor BAY 1142524 in comparison to placebo in clin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005297-12,0,0,0 2014-005299-26,2,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Janssen-Cilag International N.V.,"An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005299-26,0,0,0 2014-005301-21,2,2021-01-22,2021-01-22,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Allergan Ltd.,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005301-21,1,0,0 2014-005302-38,1,2021-01-25,2021-01-25,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd.,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005302-38,0,0,0 2014-005303-24,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Medytox Inc,"A Multicenter, Long-term, Open-label Study to Evaluate the Safety of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines and Lateral Canthal Lines",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005303-24,0,0,0 2014-005303-24,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Allergan Ltd.,"A Multicenter, Long-term, Open-label Study to Evaluate the Safety of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines and Lateral Canthal Lines",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005303-24,0,0,0 2014-005305-20,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Bayer HealthCare AG,A Pilot Self Selection Trial of an Extended-Release Over-the-Counter Analgesic,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005305-20,0,1,1 2014-005306-37,2,2016-02-08,2016-02-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomized, double-blind, multiple dosing (14 days), placebo-controlled, incomplete block crossover, multi-center study to assess efficacy and safety of three dose levels of AZD7594, given once dail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005306-37,0,0,0 2014-005308-12,1,2020-08-31,2020-08-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Region Sjælland, Slagelse Hospital",Treatment of MRSA throat carriage with mupirocin irrigation Behandling af MRSA svælgbærerskab med skylning med mupirocin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005308-12,0,0,0 2014-005309-18,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A Ph III, Single Arm, Multi-Center, Open-Label Study to Assess the Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent Vaccine Quinvaxem® (DTwP-Hib-HepB Vaccine) when Administered to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005309-18,0,1,1 2014-005310-28,1,2015-12-18,2015-12-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Open-Label, Randomized Study of Daclatasvir, Sofosbuvir, and Ribavirin for 12 vs. 16 weeks in Treatment-Naïve and Treatment-Experienced Patients with Genotype 3 Chronic Hepatitis C Infection with Comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005310-28,0,0,0 2014-005316-41,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Bayer HealthCare AG,An Actual Use Trial In A Simulated OTC Environment of an Extended-Release Over-the-Counter NSAID,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005316-41,0,1,1 2014-005317-23,1,2019-05-22,2019-05-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside,Effects of ultra-long acting bronchodilator therapy assessed by impulse oscillometry in smoking asthmatics taking inhaled corticosteroids,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005317-23,0,0,0 2014-005318-50,3,2016-07-25,2016-07-25,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"AstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden","A MULTIPLE DOSE, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL CLINICAL TRIAL TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE FIXED-DOSE COMBINATION ON LUNG HYPERINFLATION, EXE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005318-50,0,0,0 2014-005320-10,1,2016-11-08,2016-11-08,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,CHU de DIJON,Non-randomised Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA- Related Overgrowth,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005320-10,0,0,0 2014-005323-27,1,2018-09-12,2018-09-12,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Michigan,"A phase II study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis—a double-blind, placebo-controlled, randomized controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005323-27,0,0,0 2014-005324-10,5,2019-09-04,2019-09-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"CELLTRION, Inc.","A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Compare Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005324-10,0,0,0 2014-005324-10,5,2019-09-04,2019-09-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CELLTRION INC.,"A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Compare Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005324-10,0,0,0 2014-005325-12,12,2019-01-07,2019-01-07,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Onyx Therapeutics, Inc.","A Randomized, Open-label, Phase 3 Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination with Dexamethasone, Comparing Once-weekly versus Twice-weekly Car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005325-12,0,0,0 2014-005325-12,12,2019-01-07,2019-01-07,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Onyx Therapeutics, Inc.; an Amgen Inc. subsidiary","A Randomized, Open-label, Phase 3 Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination with Dexamethasone, Comparing Once-weekly versus Twice-weekly Car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005325-12,0,0,0 2014-005327-27,1,,,0,0,0,0,0,0,3,0,1,4,0,0,0,0,1,Robugen GmbH,Effects of Korodin Herz-Kreislauf-Tropfen on low blood pressure and cognitive functions in adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005327-27,0,0,0 2014-005329-11,3,2016-01-21,2016-01-21,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Flexion Therapeutics,"A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients with Osteoarthritis of the Knee",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005329-11,0,0,0 2014-005330-58,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,SAKK (Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung),A phase I/II open label clinical trial assessing safety and efficacy of intravesical instillation of VPM1002BC in patients with recurrent non-muscle invasive bladder cancer after standard BCG therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005330-58,0,0,0 2014-005331-14,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,IVI Madrid,A prospective randomized trial to analyze the effect of the gonadotropin administered during controlled ovarian stimulation on embryo kinetics of development Efecto del tipo de gonadotropina emplea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005331-14,0,0,0 2014-005337-31,1,2017-12-21,2017-12-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU Brugmann,"Crystalloids or colloids for goal-directed fluid therapy with closed-loop assistance in major surgery? Etude de phase IV, multicentrique, prospective, contrôlée, randomisée, en double aveugle compa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005337-31,0,0,0 2014-005338-74,2,2022-05-24,2022-05-24,2,0,0,0,0,1,2,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"An open-label proof of concept study to assess the efficacy, safety and pharmacokinetics of LFG316, an anti-C5 monoclonal antibody in patients with paroxysmal nocturnal hemoglobinuria (PNH) Atviras...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005338-74,0,0,0 2014-005339-15,22,2017-05-08,2017-05-22,20,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 wee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005339-15,0,0,0 2014-005339-15,22,2017-05-08,2017-05-22,20,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.P.A.,"Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 wee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005339-15,0,0,0 2014-005339-15,22,2017-05-08,2017-05-22,20,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 wee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005339-15,0,0,0 2014-005341-44,1,2018-06-08,2018-06-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical University of Graz,Molecular-biological tumor profiling for drug treatment selection in patients with advanced and refractory carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005341-44,0,0,0 2014-005344-17,1,2020-01-15,2020-01-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Anesthesiology and Operative Intensive Care Medicine, Charité (CBF)","Oral cannabidivarin (CBDV) solution for treatment of HIV-associated neuropathic pain – a randomized, double-blind, placebo-controlled phase II study. Orale Cannabidivarin (CBDV) Lösung zur Behandlu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005344-17,0,0,0 2014-005345-50,1,2016-11-04,2016-11-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Masarykův onkologický ústav,Diagnostic feasibility and morfological and functional correlation of PET examination in use of [18F]-Fluorocholin inj. in patients with prostate cancer Diagnostická proveditelnost a morfologicko-f...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005345-50,0,0,0 2014-005350-19,1,2021-04-10,2021-04-10,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),"A phase I/II study of nab-paclitaxel (Abraxane®) and gemcitabine followed by modified FOLFOX (AG-mFOLFOX) in patients with previously untreated, metastatic pancreatic adenocarcinoma Estudio fase I ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005350-19,0,0,0 2014-005352-25,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,KU Leuven,The effect of oxytocin on the training of attachment-related interpretation bias Het effect van oxytocine op het trainen van gehechtheid gerelateerde interpretatie bias,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005352-25,0,0,0 2014-005355-83,8,2017-03-02,2017-06-02,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"PTC Therapeutics, Inc.",A Phase 3 extension Study of Ataluren (PTC124®) in Patients with Nonsense Mutation Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005355-83,0,0,0 2014-005363-33,2,2019-04-09,2019-04-09,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,VU university medical center,Reducing Micro Vascular dysfunction In revascularized STEMI patients by off-target properties of ticagrelor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005363-33,1,0,0 2014-005364-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Phase II trial of Afatinib as induction treatment in patients with stage IIIA or stage IIIB N2 requiring neoadjuvant treatment for pN2 non squamous non small cell lung cancer (NSCLC) with EGFR-activa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005364-14,0,0,0 2014-005366-30,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University of Helsinki,RESOLVING THE NEUROBIOLOGICAL MECHANISMS OF ANXIETY DISORDERS – BRAIN IMAGING SUB-STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005366-30,0,0,0 2014-005367-32,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA,"PROTEIN MISFOLDING, AMYOTROPHIC LATERAL SCLEROSIS AND GUANABENZ: A PHASE II RCT WITH FUTILITY DESIGN MISFOLDING PROTEICO, SCLEROSI LATERALE AMIOTROFICA E GUANABENZ: STUDIO CLINICO RANDOMIZZATO DI F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005367-32,0,0,0 2014-005368-13,5,2018-11-07,2018-11-07,4,1,0,1,0,0,1,2,0,1,1,0,0,0,1,ARCHIGEN BIOTECH LIMITED,"A Randomized, Double-blind, Parallel Group, Multicenter Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of SAIT101 versus MabThera® versus Rituxan® in Patients with Rheum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005368-13,0,0,0 2014-005368-13,5,2018-11-07,2018-11-07,4,1,0,1,0,0,1,2,0,1,1,0,0,0,1,Archigen Biotech Limited,"A Randomized, Double-blind, Parallel Group, Multicenter Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of SAIT101 versus MabThera® versus Rituxan® in Patients with Rheum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005368-13,0,0,0 2014-005369-64,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Consorci MAr Parc de Salut de Barcelona,Improve the myocardial reperfusion in ST elevation myocardial infarction: a randomized study between standard percutaneous coronary intervention with thrombectomy and pharmacological approach guided b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005369-64,0,0,0 2014-005370-11,1,2018-12-12,2018-12-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospitals Leuven,Xenon for the prevention of postoperative delirium in cardiac surgery: Aprosptective randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005370-11,0,0,0 2014-005375-91,11,2017-05-19,2017-05-19,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005375-91,0,0,0 2014-005376-29,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Academic Medical Center, Gastroenterology","An open label interventional phase 4 study to evaluate efficacy, safety and mucosal healing of early versus late use of vedolizumab in Crohn's disease: the LOVE-CD study (LOw countries VEdolizumab in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005376-29,0,0,0 2014-005377-36,1,2016-11-29,2016-11-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"AstraZeneca AB, R&D Mölndal","An 8-week, single centre, randomized, parallel-group, double-blind, placebo controlled phase IV study to evaluate Dapagliflozin 10 mg once daily effects on insulin resistance in subjects with type 2 d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005377-36,0,0,0 2014-005378-12,2,2016-09-08,2016-09-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Efficacy and Safety of Fixed-Dose Combination atorvastatin / amlodipine / perindopril versus Fixed-Dose Combination of atorvastatin / amlodipine in Patients with Hypertension and Dyslipidemia. Effi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005378-12,0,0,0 2014-005378-12,2,2016-09-08,2016-09-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherche Internationales Servier,Efficacy and Safety of Fixed-Dose Combination atorvastatin / amlodipine / perindopril versus Fixed-Dose Combination of atorvastatin / amlodipine in Patients with Hypertension and Dyslipidemia. Effi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005378-12,0,0,0 2014-005379-10,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,Emiliano Hernández Galilea,Study of tear osmolarity and Quality of Life on patients treated with unpreserved latanoprost 0.005% ESTUDIO DE LA OSMOLARIDAD DE LA LÁGRIMA Y DE LA CALIDAD DE VIDA EN PACIENTES TRATADOS CON LATANO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005379-10,0,0,0 2014-005382-79,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,A phase II study with bendamustine plus brentuximab vedotin in Hodgkin’s lymphoma and CD30 + peripheral T-cell lymphoma in first salvage setting: the BBV regimen. Studio di fase II con Bendamustina...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005382-79,0,0,0 2014-005383-14,1,2016-06-03,2016-06-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Aarhus University Hospital,"Protracted mixture of local anaesthetics for major foot and ankle surgery. A randomized double-blind, controlled study comparing Bupivacaine-epinephrine 0.5% and Bupivacaine-epinepherine 0.5% plus dex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005383-14,0,0,0 2014-005384-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,PIQUR Therapeutics AG,"Open-Label, Non-randomized Phase 2 study with Safety Run-in Evaluating Efficacy and Safety of PQR309 in Patients with Relapsed or Refractory Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005384-33,0,0,0 2014-005386-67,4,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,Amgen Inc.,"A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005386-67,0,0,0 2014-005387-15,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,INTERNATIONAL BREAST CANCER STUDY GROUP,A Phase II Study of Palbociclib plus Fulvestrant for pretreated patients with ER+/HER2- Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005387-15,0,0,0 2014-005387-15,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,ETOP IBCSG Partners Foundation,A Phase II Study of Palbociclib plus Fulvestrant for pretreated patients with ER+/HER2- Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005387-15,0,0,0 2014-005387-15,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,International Breast Cancer Study Group (IBCSG),A Phase II Study of Palbociclib plus Fulvestrant for pretreated patients with ER+/HER2- Metastatic Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005387-15,0,0,0 2014-005388-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,Single arm prospective clinical study to evaluate the efficacy of combination therapy sofosbuvir+ribavirin+peg-interferon in experienced patients with HCV-GT1 Studio clinico prospettico a braccio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005388-34,0,0,0 2014-005389-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HôPITAUX UNIVERSITAIRES DE GENèVE,Incremental diagnostic value of Florbetaben Imaging vs other core biomarkers for Alzheimer Disease in patients with Mild Cognitive Impairment. An Investigator-Initiated Sponsored Study. Valore dia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005389-31,0,0,0 2014-005390-36,1,,,0,1,0,0,0,1,3,0,0,3,0,0,0,0,0,The University of Liverpool,"Optimal utilisation of biologic drugs in Behçet’s Disease: a randomised controlled trial of infliximab (IFX) verses alpha interferon (aIFN), with genotyping and metabolomic profiling, towards a strati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005390-36,0,0,0 2014-005391-29,1,2018-08-31,2018-08-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical University of Vienna,Effects of mannitol on delayed graft function after cadaveric renal transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005391-29,0,0,0 2014-005392-90,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Novartis Pharma Services AG,"A Phase IV, Open-Label, Multi-Center Study to Evaluate the Safety and the 1-year Persistence of Antibody Response Among Children Who Received 4 Doses of the Novartis MenACWY Conjugate Vaccine at 2, 4,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005392-90,0,1,1 2014-005394-37,5,2020-10-30,2020-10-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3K? Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005394-37,0,0,0 2014-005394-37,5,2020-10-30,2020-10-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3K? Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005394-37,0,0,0 2014-005396-82,8,2016-06-27,2017-01-08,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PIERRE FABRE MEDICAMENT,Randomized phase III study comparing vinflunine-gemcitabine and gemcitabine-carboplatin combinations in patients ineligible to cisplatin with advanced or metastatic urothelial carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005396-82,0,0,0 2014-005396-82,8,2016-06-27,2017-01-08,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PIERRE FABRE MéDICAMENT,Randomized phase III study comparing vinflunine-gemcitabine and gemcitabine-carboplatin combinations in patients ineligible to cisplatin with advanced or metastatic urothelial carcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005396-82,0,0,0 2014-005401-20,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,CSL Limited,"An Open-label, Multi-centre Study to Assess the Efficacy and Safety of Biostate® in Patients With von Willebrand's Disease (VWD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005401-20,0,1,1 2014-005407-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IKEM,Effect of early administration of eplerenone in patients after acute myocardial infarction Efekt časného podání eplerenonu u pacientů po akutním infarktu myokardu,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005407-24,0,0,0 2014-005411-16,3,2017-09-26,2017-09-26,1,0,0,0,1,0,2,0,0,2,0,0,0,0,1,Exalenz Bioscience Ltd.,Clinical Study of the BreathID® System to train the algorithm for the 13C-Octanoate Breath Test with or without the 13C-Methacetin Breath Test (OBT and MBT respectively) for correlation with histologi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005411-16,1,0,0 2014-005413-23,8,2017-09-27,2017-09-27,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Cytokinetics, Inc.","A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005413-23,0,0,0 2014-005413-23,8,2017-09-27,2017-09-27,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"CYTOKINETICS, INC.","A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients with Amyotrophic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005413-23,0,0,0 2014-005416-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Uppsala University. Department of Women's and children's health,Clondine in repeated doses for children in pain - a farmacokinetic study Klonidin i upprepade doser för barn med smärta - en farmakokinetisk studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005416-42,0,0,0 2014-005418-45,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Christine Bengtsson,Improved cardiovascular risk factors and inflammatory markers in Rheumatoid Arthritis and Systemic Lupus Erythematosus? New aspects of Hydroxychloroquine – an interventional study (HCQCVDRASLE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005418-45,0,0,0 2014-005418-45,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Solveig Wållberg-Jonsson,Improved cardiovascular risk factors and inflammatory markers in Rheumatoid Arthritis and Systemic Lupus Erythematosus? New aspects of Hydroxychloroquine – an interventional study (HCQCVDRASLE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005418-45,0,0,0 2014-005419-18,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,silvia sanchez ramon,"CLINICAL TRIAL, PHASE III, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED WITH INTRAVENOUS IMMUNOGLOBULIN HUMAN FOR THE TREATMENT OF REPEAT ABORTION WITH IMMUNE ETIOLOGY PROTOCOLO ENSAYO CLÍNICO FASE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005419-18,0,0,0 2014-005420-10,1,2016-11-16,2016-11-16,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomised, double-blind, double-dummy, parallel-group, multicenter, phase IIb study to evaluate the effect of ticagrelor 10 mg and 45 mg bid versus placebo in reducing the number of days with pain ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005420-10,0,0,0 2014-005422-35,1,2017-01-24,2017-01-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London-Imperial College Healthcare NHS Trust,THE ROLE OF BUSPIRONE IN ATTENUATING LEVODOPA-INDUCED DYSKINESIAS IN PATIENTS WITH PARKINSON'S DISEASE: A CLINICAL AND POSITRON EMISSION TOMOGRAPHY STUDY WITH 11C-PHNO.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005422-35,0,0,0 2014-005424-97,1,2016-01-11,2016-01-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,NOVARTIS PHARMA SAS,"A phase IV, multicenter, single-arm and open-label study to explore the impact on quality of life of omalizumab (Xolair®) in patients with chronic spontaneous urticaria (CSU) who remain symptomatic de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005424-97,0,0,0 2014-005425-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Evaluation of a stategy based on the 3-month screening biopsy to optimize the immunosuppression in renal transplantation Evaluation de la biopsie de dépistage des 3 mois pour optimiser l’immunosupp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005425-13,0,0,0 2014-005428-81,1,2018-10-15,2018-10-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"A Phase I/II, Open-Label, Multicentre Study to Assess The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of AZD4547 in Patients with glioma positive for an FGFR fusion Relapsed/Refractor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005428-81,0,0,0 2014-005429-11,10,2019-08-14,2019-08-14,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 with a Long-Term Open-Label Extension in Patients with Chronic Cluster Headache",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005429-11,0,0,0 2014-005429-11,10,2019-08-14,2019-08-14,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 with a Long-Term Open-Label Extension in Patients with Chronic Cluster Headache",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005429-11,0,0,0 2014-005429-11,10,2019-08-14,2019-08-14,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 with a Long-Term Open-Label Extension in Patients with Chronic Cluster Headache",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005429-11,0,0,0 2014-005431-13,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Tampere University Hospital,Effects of maternal oxytocin on social information processing in mothers and infants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005431-13,0,0,0 2014-005432-33,2,2017-06-09,2017-06-09,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Ultragenyx Pharmaceutical Inc.,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sialic Acid Extended-Release Tablets in Patients with GNE Myopathy (GNEM) or Hereditary Inclusion Bo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005432-33,0,0,0 2014-005432-33,2,2017-06-09,2017-06-09,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ULTRAGENYX PHARMACEUTICAL INC.,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sialic Acid Extended-Release Tablets in Patients with GNE Myopathy (GNEM) or Hereditary Inclusion Bo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005432-33,0,0,0 2014-005438-69,3,2018-06-29,2018-06-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF ONARTUZUMAB IN PATIENTS WITH SOLID TUMORS ON STUDY TREATMENT PREVIOUSLY ENROLLED IN AN F. HOFFMANN-LA ROCHE- AND/OR GENENTECH-SPONSORED STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005438-69,0,0,0 2014-005438-69,3,2018-06-29,2018-06-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd.,"AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF ONARTUZUMAB IN PATIENTS WITH SOLID TUMORS ON STUDY TREATMENT PREVIOUSLY ENROLLED IN AN F. HOFFMANN-LA ROCHE- AND/OR GENENTECH-SPONSORED STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005438-69,0,0,0 2014-005438-69,3,2018-06-29,2018-06-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffman-La Roche Ltd.,"AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF ONARTUZUMAB IN PATIENTS WITH SOLID TUMORS ON STUDY TREATMENT PREVIOUSLY ENROLLED IN AN F. HOFFMANN-LA ROCHE- AND/OR GENENTECH-SPONSORED STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005438-69,0,0,0 2014-005439-15,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Akershus University Hospital,Apixaban for treatment of venous thrombosis in patients with cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005439-15,0,0,0 2014-005440-17,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Private Universität Witten/Herdecke gGmbH,"Tolerability and analgesic efficacy of Loxapine in patients with refractory, chemotherapy-induced neuropathic pain Verträglichkeit und analgetische Wirksamkeit von Loxapin bei Patienten mit therapi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005440-17,0,0,0 2014-005443-40,3,2020-08-10,2020-08-10,2,0,0,0,0,0,4,0,0,2,0,0,0,0,0,"Academic Medical Center, Gastroenterology","An open label interventional phase 4 study to Evaluate Efficacy, Safety and Mucosal Healing of early versus late use of vedolizumab in ulcerative colitis: the LOVE-UC study (LOw countries VEdolizumab ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005443-40,1,0,0 2014-005443-40,3,2020-08-10,2020-08-10,2,0,0,0,0,0,4,0,0,2,0,0,0,0,0,Academic Medical Center/ Gastroenterology,"An open label interventional phase 4 study to Evaluate Efficacy, Safety and Mucosal Healing of early versus late use of vedolizumab in ulcerative colitis: the LOVE-UC study (LOw countries VEdolizumab ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005443-40,1,0,0 2014-005448-17,1,2015-09-09,2015-09-09,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,Janssen Sciences Ireland UC,"A Phase 1, open-label, randomized, 2-panel, 3-way crossover study in healthy adult subjects to assess the relative bioavailability of simeprevir following single dose administration of age-appropriate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005448-17,0,0,0 2014-005450-19,1,2016-05-17,2016-05-17,1,1,1,0,0,0,1,0,0,1,0,0,1,0,1,MedImmune LLC (a wholly owned subsidiary of AstraZeneca PLC),"A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of MEDI9929 in Adolescents with Mild to Moderate Asthma Otwarte badanie fazy pierwszej w celu oceny farmakokinetyki MEDI9929 u nastolatk...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005450-19,0,0,0 2014-005452-26,1,2016-02-17,2016-02-17,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,OptiNose AS,"A randomized, placebo controlled, double-blind, double-dummy, 3-period cross-over study in adult patients with autism spectrum disorders evaluating cognitive response, eye-gaze, and heart rate variabi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005452-26,0,0,0 2014-005454-19,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Erasmus MC,The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial De Dolutegravir mono-therapie voor HIV studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005454-19,0,0,0 2014-005459-13,4,2017-02-13,2017-02-13,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Infinity Pharmaceuticals, Inc.","A Two-arm, Phase 1b/2 Study of IPI-145 Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005459-13,0,0,0 2014-005462-30,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,The Medicines Company,"A multiple dose, dose-finding, placebo controlled, double blind, randomized trial to compare the effect of treatment on plaque burden as determined by intravascular ultrasound and evaluate the efficac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005462-30,0,0,0 2014-005467-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Haga Teaching Hospital,A randomised controlled trial on the effect of laxative therapy in children with functional abdominal pain Een gerandomiseerde dubbelblinde placebo-gecontroleerde studie naar het effect van laxeren...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005467-32,0,0,0 2014-005468-14,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Medical University of Vienna, Department of Clinical Pharmacology",Latanoprost preserved versus unpreserved: effect on tear film thickness as measured with OCT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005468-14,0,0,0 2014-005469-58,1,2018-01-24,2018-01-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Ghent University Hospital,Determination of the minimum local anesthetic dose (MLAD) of spinal chloroprocaine for inguinal herniorrhaphy in ambulatory surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005469-58,0,0,0 2014-005471-88,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"INMUNOTEK, S.L.","Double blind, placebo-controlled, dose finding, prospective, multicenter clinical trial for the treatment of rhinitis/rinoconjuntivitis against grass pollen allergy Ensayo clínico prospectivo multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005471-88,0,0,0 2014-005472-29,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER,Safety and efficay of 0.2% propranolol eye drops in newborns with retinopathy of prematurity: a pilot study Sicurezza e efficacia del trattamento con propranololo 0.2% per uso topico nei neonati a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005472-29,0,0,0 2014-005473-36,1,2020-02-05,2020-02-05,1,1,0,0,0,1,4,0,1,1,0,0,1,0,0,Universitätsklinikum Freiburg,Modeling of lipoprotein in patients with familial hypercholesterolemia compared to healthy subjects Modelling der Lipoproteine bei Patienten mit familiärer Hypercholesterinämie im Vergleich zu gesu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005473-36,0,0,0 2014-005474-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"USS Centro di Fisiopatologia della Riproduzione, A.O. Papa Giovanni XXIII","Pilot clinical study multicenter, prospective, randomized, open, non-profit to evaluate the efficacy of progesterone administered with different dose subcutaneously compared to progesterone administer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005474-11,0,0,0 2014-005475-86,1,2017-11-10,2017-11-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The Newcastle upon Tyne Hospitals NHS Foundation Trust,Anti-platelet Therapy in the Primary Prevention of Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005475-86,0,0,0 2014-005477-37,10,2018-08-05,2018-08-05,7,1,1,0,0,1,3,0,0,1,1,0,1,0,1,BAXALTA INNOVATIONS GMBH,"Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005477-37,0,0,0 2014-005477-37,10,2018-08-05,2018-08-05,7,1,1,0,0,1,3,0,0,1,1,0,1,0,1,Baxalta Innovations GmbH,"Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005477-37,0,0,0 2014-005484-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Lund University,"Double-blind, randomized placebo controlled study on the effect from cortisone treatment of vestibular neuritis - function, subjective well-being and stress Dubbelblind randomiserad placebokontroll...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005484-32,0,0,0 2014-005486-75,6,2018-02-12,2018-02-12,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER",neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005486-75,0,0,0 2014-005486-75,6,2018-02-12,2018-02-12,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005486-75,0,0,0 2014-005486-75,6,2018-02-12,2018-02-12,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005486-75,0,0,0 2014-005487-15,5,2017-02-07,2017-02-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Jazz Pharmaceuticals Inc.,"A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005487-15,0,0,0 2014-005487-15,5,2017-02-07,2017-02-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JAZZ PHARMACEUTICALS INC,"A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005487-15,0,0,0 2014-005489-31,4,2017-12-08,2017-12-08,3,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Jazz Pharmaceuticals Inc.,"A Long-Term, Open-Label Safety and Maintenance of Efficacy Study of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of Excessive Sleepiness in Subjects with Narcolepsy or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005489-31,0,0,0 2014-005490-37,18,2021-08-31,2021-08-31,12,1,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005490-37,1,0,0 2014-005490-37,18,2021-08-31,2021-08-31,12,1,0,0,0,0,3,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005490-37,1,0,0 2014-005490-37,18,2021-08-31,2021-08-31,12,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Roche Farma S.A. que representa en España a F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005490-37,1,0,0 2014-005491-28,7,2018-12-31,2018-12-31,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A MULTICENTRE OPEN-LABEL SINGLE-ARM PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH METASTATIC, RECURRENT OR PERSISTENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005491-28,0,0,0 2014-005491-28,7,2018-12-31,2018-12-31,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A MULTICENTRE OPEN-LABEL SINGLE-ARM PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH METASTATIC, RECURRENT OR PERSISTENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005491-28,0,0,0 2014-005491-28,7,2018-12-31,2018-12-31,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farma, S.A en nombre de F. Hoffmann-La Roche Ltd","A MULTICENTRE OPEN-LABEL SINGLE-ARM PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH METASTATIC, RECURRENT OR PERSISTENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005491-28,0,0,0 2014-005493-11,1,2019-09-02,2019-09-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre Hospitalier de Pau,Intrathecal Rituximab in Progressive Multiple Sclerosis Effet du Rituximab intrathécal dans la SEP progressive,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005493-11,0,0,0 2014-005496-87,13,2022-02-23,2022-02-23,8,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Baxalta Innovations GmbH,"A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005496-87,1,0,0 2014-005496-87,13,2022-02-23,2022-02-23,8,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Baxalta Innovation GmbH,"A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005496-87,1,0,0 2014-005496-87,13,2022-02-23,2022-02-23,8,0,0,0,0,1,3,0,0,2,0,0,0,0,1,BAXTER S.P.A.,"A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005496-87,1,0,0 2014-005498-35,6,2019-07-10,2019-07-10,3,0,0,0,0,0,4,0,0,2,0,0,0,0,0,The Office of Interventional Cardiovascular Research and Clinical Trials at Icahn School of Medicine at Mount Sinai,TWILIGHT Study - Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005498-35,1,0,0 2014-005498-35,6,2019-07-10,2019-07-10,3,0,0,0,0,0,4,0,0,2,0,0,0,0,0,INTERVENTIONAL CARDIOVASC. RESEARCH & CLINICAL TRIALS AT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,TWILIGHT Study - Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005498-35,1,0,0 2014-005498-35,6,2019-07-10,2019-07-10,3,0,0,0,0,0,4,0,0,2,0,0,0,0,0,Mount Sinai,TWILIGHT Study - Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005498-35,1,0,0 2014-005508-62,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTI FISIOTERAPICI OSPITALIERI,"A phase II, randomized, non-comparative, pre-surgical study of atorvastatin or observation in Ki-67 positive, TAZ-expressing early breast cancer patients Atorvastatina vs osservazione in pazienti ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005508-62,0,0,0 2014-005510-34,1,2016-04-11,2016-04-11,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,Medicines for Malaria Venture,Evaluation of the prophylactic antimalarial activity of a single dose of DSM265 in non-immune healthy adult volunteers by controlled human malaria infection with PfSPZ Challenge,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005510-34,0,0,0 2014-005514-31,2,2016-12-19,2016-12-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Jazz Pharmaceuticals Inc.,"A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Safety and Efficacy of JZP 110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005514-31,0,0,0 2014-005515-16,2,2016-11-11,2016-11-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Jazz Pharmaceuticals Inc.,"A Six-Week, Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of Exc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005515-16,0,0,0 2014-005518-44,1,2017-01-11,2017-01-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dermapharm AG,"Double-blind, randomised clinical study comparing efficacy and safety of Gentamicin 0.1%_Betamethasone 0.05% Cream (Test) vs. Diprogenta(R) Cream (Reference) vs. Vehicle in patients with bacterial inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005518-44,0,0,0 2014-005519-18,1,2017-06-09,2017-06-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dermapharm AG,"Double-blind, randomised clinical study comparing efficacy and safety of Gentamicin 0.1%_Betamethasone 0.05% Ointment (Test) vs. Diprogenta(R) Ointment (Reference) vs. Vehicle in patients with bacteri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005519-18,0,0,0 2014-005521-12,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO,"MANAGMENT OF PATIENT WITH MODERATE TO SEVERE POSTOPERATIVE PAIN AFTER SURGERY FOR HYSTERECTOMY: BLIND, RANDOMZATED, CONTROLLATED EXPERIMENTAL STUDY ON THE CONTROL OF PAIN SYNTOMS AND SIDE EFFECTS THOU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005521-12,0,0,0 2014-005523-27,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS),Multicenter prospective randomized trial of the effect of rivaroxaban on survival and development of complications of portal hypertension in patients with cirrhosis Estudio prospectivo multicéntric...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005523-27,0,0,0 2014-005525-13,8,2017-10-10,2017-10-10,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared with the Addition of Dapagliflo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005525-13,0,0,0 2014-005526-35,1,2017-10-25,2017-10-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biotest AG,"A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated dose, Multicentre Phase IIa Proof-of-Concept Study with BT063 in Subjects with Systemic Lupus Erythematosus (BT063 in SLE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005526-35,0,0,0 2014-005527-27,6,2016-05-19,2016-08-02,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005527-27,0,0,0 2014-005527-27,6,2016-05-19,2016-08-02,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2, Multicenter, Open-Label Extension (OLE) Study with ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005527-27,0,0,0 2014-005529-11,5,2018-12-06,2018-12-06,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,Ultragenyx Pharmaceutical Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of KRN23 in Adults with X-linked Hypophosphatemia (XLH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005529-11,0,0,0 2014-005529-11,5,2018-12-06,2018-12-06,5,1,0,0,0,2,3,0,0,1,0,0,1,0,1,ULTRAGENYX PHARMACEUTICAL INC,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of KRN23 in Adults with X-linked Hypophosphatemia (XLH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005529-11,0,0,0 2014-005530-64,9,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,ACERTA PHARMA BV,"A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005530-64,0,0,0 2014-005530-64,9,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,Acerta Pharma BV,"A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005530-64,0,0,0 2014-005531-13,1,2019-06-19,2019-06-19,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Univerity of Bonn,"Multicenter, open-label single arm phase II study testing the tolerability and the efficacy of Bosutinib step-in dosing in Chronic Phase CML patients intolerant or refractory to previous Imatinib, Nil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005531-13,0,0,0 2014-005534-55,1,2020-12-01,2020-12-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU de Nîmes,Etude de la variabilité pharmacocinétique du sunitinib chez les patients atteints de cancer du rein métastatique: recherche de déterminants pharmacogénétiques Etude de la variabilité pharmacocinéti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005534-55,0,0,0 2014-005537-30,1,2016-01-01,2016-01-01,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Radboud university medical center,Does ticagrelor modulate the inflammatory respons to human endotoxemia? Heeft ticagrelor een effect op de inflammatoire respons geinduceerd door humane endotoxemie?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005537-30,0,0,0 2014-005541-50,2,2020-11-30,2020-11-30,1,1,0,1,0,1,1,0,0,2,0,0,0,0,0,Sarcoma Alliance for Research Through Collaboration (SARC),"ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide and/or Irinotecan in Patients with Previously Treated, incurable Ewing Sarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005541-50,1,0,0 2014-005541-50,2,2020-11-30,2020-11-30,1,1,0,1,0,1,1,0,0,2,0,0,0,0,0,Sarcoma Alliance for Research through Collaboration (SARC),"ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide and/or Irinotecan in Patients with Previously Treated, incurable Ewing Sarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005541-50,1,0,0 2014-005544-18,2,2020-08-26,2020-08-26,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Protalix Ltd.,A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for 24 Months to Adult Fabry Patients Estudio de extensión multicéntrico de PRX-102 administrado media...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005544-18,0,0,0 2014-005548-17,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,HOSPICES CIVILS DE LYON,TREATMENT OF PENDULAR NYSTAGMUS WITH GABAPENTIN AND MEMANTINE IN PATIENTS WITH MULTIPLE SCLEROSIS or OCULOPALATAL TREMOR: A CONTROLED OPEN-LABEL STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005548-17,0,0,0 2014-005550-18,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Tw...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005550-18,0,0,0 2014-005553-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,Effects of Sativex on blood leukocytes in patients with lymphoma/chronic lymphocytic leukaemia Effekt av Sativex på blodleukocyter hos patienter med lymfom/kronisk lymfatisk leukemi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005553-39,0,0,0 2014-005554-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud University Medical Center Nijmegen,Visualizing beta cells in patients with postprandial hyperinsulinemic hypoglycemia after bariatric surgery Beeldvorming van beta cellen in patiënten met postprandiale hyperinsulinemische hypoglycae...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005554-20,0,0,0 2014-005555-80,1,2017-02-21,2017-02-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pierre Fabre Dermatologie represented by IRPF,Efficacy and safety of Hemangiol solution in the treatment of high risk infantile hemangioma. A Multinational Single Arm Study Eficacia y seguridad de la solución Hemangiol en el tratamiento del he...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005555-80,0,0,0 2014-005556-25,1,2017-09-15,2017-09-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Investigacion Independiente,"Open extension study for patients with age related macula degeneration who participated in the Fase IV-II clinical trial randomized, simulatedcontrolled treatment to evaluate safety and efficacy of i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005556-25,0,0,0 2014-005558-21,1,2016-02-12,2016-02-12,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Lumena Pharmaceuticals LLC,"A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients with Primary Sclerosing Cholangit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005558-21,0,0,0 2014-005559-16,4,2017-06-12,2017-06-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A multicenter, randomized, double-blind, placebo and active-controlled phase 2b dose-finding study of QGE031 as add-on therapy to investigate the efficacy and safety in patients with Chronic Spontaneo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005559-16,0,0,0 2014-005559-16,4,2017-06-12,2017-06-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A multicenter, randomized, double-blind, placebo and active-controlled phase 2b dose-finding study of QGE031 as add-on therapy to investigate the efficacy and safety in patients with Chronic Spontaneo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005559-16,0,0,0 2014-005559-16,4,2017-06-12,2017-06-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, placebo and active-controlled phase 2b dose-finding study of QGE031 as add-on therapy to investigate the efficacy and safety in patients with Chronic Spontaneo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005559-16,0,0,0 2014-005562-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,PIAM FARMACEUTICI S.P.A.,Role of citicoline as supportive therapy in Parkinson’s disease. Ruolo della citicolina nella terapia di supporto nella malattia di Parkinson.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005562-30,0,0,0 2014-005567-33,5,2017-05-10,2017-05-10,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Menarini International Operations Luxembourg S.A.,"The Effect of Intensive Urate Lowering Therapy (ULT) with Febuxostat in Comparison with Allopurinol on Cardiovascular Risk in Patients with Gout Using Surrogate Markers: a Randomized, Controlled Trial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005567-33,0,0,0 2014-005567-33,5,2017-05-10,2017-05-10,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L.,"The Effect of Intensive Urate Lowering Therapy (ULT) with Febuxostat in Comparison with Allopurinol on Cardiovascular Risk in Patients with Gout Using Surrogate Markers: a Randomized, Controlled Trial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005567-33,0,0,0 2014-005568-14,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Pharma Services A.G.,"A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005568-14,0,1,1 2014-005569-58,21,2019-11-27,2020-01-09,21,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of Rivaroxaban to reduce the risk of major thrombotic vascular events i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005569-58,0,0,0 2014-005569-58,21,2019-11-27,2020-01-09,21,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of Rivaroxaban to reduce the risk of major thrombotic vascular events i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005569-58,0,0,0 2014-005569-58,21,2019-11-27,2020-01-09,21,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER AG,"An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of Rivaroxaban to reduce the risk of major thrombotic vascular events i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005569-58,0,0,0 2014-005569-58,21,2019-11-27,2020-01-09,21,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of Rivaroxaban to reduce the risk of major thrombotic vascular events i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005569-58,0,0,0 2014-005571-89,2,2016-07-30,2016-07-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Futura Medical Developments Ltd.,"A randomized, double-blind, placebo-controlled, home use, cross-over clinical trial of topically-applied glyceryl trinitrate (GTN) for the treatment of Erectile Dysfunction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005571-89,0,0,0 2014-005572-28,1,2016-06-24,2016-06-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"Open-label, Multicentre, Randomized Clinical Trial To Compare The Pharmacokinetics Of Envarsus® Tablets And Advagraf® Capsules Administered Once Daily In Adult De-novo Kidney Transplant Patients Et...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005572-28,0,0,0 2014-005573-36,1,2016-04-28,2016-04-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pierre Fabre Dermatologie represented by the Institut de Recherche Pierre Fabre (IRPF),"Assessment of the efficacy of a new formulation of minoxidil (DC120) on hair growth, in a minizone model in androgenetic alopecia in men",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005573-36,0,0,0 2014-005574-11,1,2015-12-21,2015-12-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nuvo Research GmbH,"A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of an Diclofenac 2% (w/w) cutaneous solution applied twice daily in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005574-11,0,0,0 2014-005575-84,1,2018-10-21,2018-10-21,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Clermont-Ferrand,". Hydroxyéthylamidon (HEA 130/0.4/6%) versus NaCl 0,9% pour l’optimisation individualisée du remplissage vasculaire en chirurgie abdominale à risques élevés de complications postopératoires. Étude...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005575-84,0,0,0 2014-005576-28,1,2019-01-17,2019-01-17,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,VACCIBODY A.S.,An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women with High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3) Exploratorische Sic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005576-28,0,0,0 2014-005577-36,1,2016-05-01,2016-05-01,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Teijo Saari,"Individualising propofol and oxycodone therapy in neonates using pharmacogenomic profiling, population based modeling and simulations. Propofolin ja oksikodonin annostelun yksilöllinen optimointi v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005577-36,0,0,0 2014-005579-10,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,IPSEN S.P.A.,EFFICACY AND SAFETY OF LANREOTIDE ATG 120 MG IN COMBINATION WITH TEMOZOLOMIDE IN SUBJECTS WITH PROGRESSIVE WELL DIFFERENTIATED THORACIC NEUROENDOCRINE TUMORS EFFICACIA E SICUREZZA DI LANREOTIDE ATG...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005579-10,0,0,0 2014-005582-73,9,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,Acerta Pharma BV,"A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005582-73,0,0,0 2014-005582-73,9,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,ACERTA PHARMA BV,"A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005582-73,0,0,0 2014-005585-30,1,,,0,0,0,1,0,1,1,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Traitement de la lymphohistiocytose familiale par l’Alemtuzumab (Campath®) en première intention - C-HLH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005585-30,0,0,0 2014-005586-75,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Gustave Roussy,A Randomized double-blind Phase II trial evaluating maintenance olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer Ensayo clínico fase II aleatorizado d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005586-75,0,0,0 2014-005589-31,1,2016-12-31,2016-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of infectious Diseases, Odense University Hospital","4 Week treatment for Injecting Drug Users with chronic hepatitis C A phase 4, post marketing randomized clinical open label trial comparing 4 weeks of Ledipasvir/Sofosbuvir (co-formulated) and Ribav...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005589-31,0,0,0 2014-005593-11,1,2015-07-20,2015-07-20,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,"University Hospital of Dermatology, Paracelsus Medical University",Diacerein for the treatment of atopic dermatitis Diacerein zur Behandlung von atopischer Dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005593-11,0,0,0 2014-005594-36,1,2017-12-26,2017-12-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Portsmouth Hospitals NHS Trust,"A Phase IV, Randomised, Double-Blind, Controlled, Parallel Group Trial to Evaluate the Effectiveness and Safety of Balneum Plus vs Emollient in the Treatment of Uraemic Pruritus in Haemodialysis Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005594-36,0,0,0 2014-005595-28,1,2017-03-16,2017-03-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,AIO-Studien-gGmbH,Induction therapy with gefitinib followed by taxane platinum chemotherapy and intercalated gefitinib in NSCLC stages II-IIIB with activating EGFR mutation – A single arm Phase II trial. Einleitung...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005595-28,0,0,0 2014-005596-90,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St. Lucas Andreas Hospital,Comparison of femoral nerve block with posterior capsule infiltration versus anterior and posterior capsule infiltration after total knee replacement. Vergelijking van nervus femoralis blokkade met...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005596-90,0,0,0 2014-005599-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud University Medical Center Nijmegen,Visualizing beta cells in morbid obese patients with T2D before and after bariatric surgery (NL51980.091.15) Beeldvorming van beta cellen in morbide obese patienten met T2D voor en na bariatrische ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005599-27,0,0,0 2014-005603-25,10,2022-06-14,2022-06-14,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-POSITIVE, HIGH RISK MUSCLE INVASIVE UROTHELI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005603-25,1,0,0 2014-005603-25,10,2022-06-14,2022-06-14,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.","A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-POSITIVE, HIGH RISK MUSCLE INVASIVE UROTHELI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005603-25,1,0,0 2014-005606-38,11,2021-11-30,2021-11-30,10,0,0,0,0,0,3,0,0,2,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Mode...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005606-38,1,0,0 2014-005606-38,11,2021-11-30,2021-11-30,10,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Mode...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005606-38,1,0,0 2014-005607-24,7,2019-10-24,2019-10-24,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ipsen Innovation,"Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005607-24,0,0,0 2014-005607-24,7,2019-10-24,2019-10-24,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,IPSEN INNOVATION,"Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005607-24,0,0,0 2014-005610-37,1,2017-10-01,2017-10-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Central Manchester University Hospitals NHS Foundation Trust,PROgesterone Therapy for Endometrial Cancer prevention in obese women (PROTEC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005610-37,0,0,0 2014-005611-16,1,2019-10-23,2019-10-23,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Academic Medical Center, University of Amsterdam",Effect of Intravenous Administration of C1-inhibitor on Inflammation and Coagulation after Bronchial Instillation of House Dust Mite Allergen and Lipopolysaccharide in Allergic Asthma Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005611-16,0,0,0 2014-005612-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Meander Medical Centre,Vitamin c to Improve Tissue healing by Administration of Multiple INtravenous dosages Het effect van intraveneuze suppletie van ascorbinezuur op wondgenezing bij vaatchirurgische patiënten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005612-41,0,0,0 2014-005613-24,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundación Investigación Biomédica Hospital Universitario Puerta de Hierro,Intrathecal administration (pattern 100/3) of expanded autologous adult bone marrow mesenchymal troncal cells in established chronic spinal cord injuries Administración intratecal (pauta 100/3) de ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005613-24,0,0,0 2014-005614-29,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,CELGENE CORPORATION,"A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus pembrolizuma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005614-29,0,0,0 2014-005614-29,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Celgene Corporation,"A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus pembrolizuma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005614-29,0,0,0 2014-005615-17,2,2015-11-17,2015-11-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Verona Pharma plc,"A Phase II, randomised, double blind, placebo controlled, seven way crossover study to assess the effect of single doses of RPL554 compared to salbutamol and placebo administered by nebuliser on lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005615-17,0,0,0 2014-005619-18,2,2015-08-21,2015-08-21,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Takeda Development Centre Europe Ltd.,"A Randomized, Open-Label, 2-Way Cross-over, Phase 4 Study to Evaluate Subject Preference and Acceptability of a New Formulation of Calcichew D3 in Adult Patients Eligible for Calcium and Vitamin D Sup...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005619-18,0,0,0 2014-005623-27,3,2016-06-09,2016-06-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Rhythm Pharmaceuticals, Inc.","A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients with Vomiting Symptoms and Moderate to Severe Diabetic Gastropares...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005623-27,0,0,0 2014-005623-27,3,2016-06-09,2016-06-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Motus Therapeutics, Inc.","A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients with Vomiting Symptoms and Moderate to Severe Diabetic Gastropares...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005623-27,0,0,0 2014-005624-98,4,2016-01-25,2016-01-25,2,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Biogen Idec Research Limited,"A Randomized, Placebo-Controlled, Parallel-Group Study in Pediatric Subjects Ages 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 for the Treatment of Relapsing-Remitting Forms of M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005624-98,0,0,0 2014-005624-98,4,2016-01-25,2016-01-25,2,0,0,0,0,0,3,0,0,1,1,1,1,0,1,BIOGEN IDEC RESEARCH LIMITED,"A Randomized, Placebo-Controlled, Parallel-Group Study in Pediatric Subjects Ages 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 for the Treatment of Relapsing-Remitting Forms of M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005624-98,0,0,0 2014-005630-60,5,2018-01-12,2018-01-12,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biotie Therapies Inc.(a wholly owned subsidiary of Acorda Therapeutics Inc.),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study with an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005630-60,0,0,0 2014-005630-60,5,2018-01-12,2018-01-12,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biotie Therapies Inc.,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study with an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005630-60,0,0,0 2014-005630-60,5,2018-01-12,2018-01-12,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BIOTIE THERAPIES INC.,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study with an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005630-60,0,0,0 2014-005630-60,5,2018-01-12,2018-01-12,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biotie Therapies Inc. (a wholly owned subsidiary of Acorda Therapeutics Inc.),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study with an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005630-60,0,0,0 2014-005634-59,1,2017-12-06,2017-12-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Aarhus University Hospital,Toll-like receptor 9 enhancement of antiviral immunity in chronic HIV-1 infection: a phase 1b/2a trial (TEACH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005634-59,0,0,0 2014-005635-14,4,2017-02-20,2017-02-20,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Open-label, multi-centre, proof of concept phase IIa clinical trial on the efficacy and tolerability of an 8 week oral treatment with once daily 9 mg budesonide in patients with active ulcerative coli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005635-14,0,0,0 2014-005638-71,1,,,0,1,1,0,0,1,3,0,0,4,0,0,0,0,1,Ultragenyx Pharmaceutical Inc.,"A Randomized, Placebo-Controlled, Blind-Start, Single-Crossover Phase 3 Study to Assess the Efficacy and Safety of UX003 rhGUS Enzyme Replacement Therapy in Patients with MPS 7",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005638-71,0,1,1 2014-005639-15,7,2018-10-03,2018-10-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,A 104 week clinical trial comparing long term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005639-15,0,0,0 2014-005639-15,7,2018-10-03,2018-10-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK. S.P.A.,A 104 week clinical trial comparing long term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005639-15,0,0,0 2014-005640-18,1,2015-06-23,2015-06-23,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Køge Sygehus,"Does perineural clonidin prolong the duration of an adductor canal block when controlling for a systemic effect? - a randomized, blinded, paired study in healthy volunteers. Forlænger perineural ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005640-18,0,0,0 2014-005642-22,1,2016-09-05,2016-09-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Pia Jæger,"Adductor canal block with continuous infusion versus intermittent boluses and morphine consumption: A randomized, triple-masked, controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005642-22,0,0,0 2014-005651-89,1,2015-09-09,2015-09-09,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Køge Sygehus,"Does perineural dexmedetomidine prolong the duration of an adductor canal block when controlling for a systemic effect? - a randomized, blinded, paired study in healthy volunteers Forlænger perineu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005651-89,0,0,0 2014-005656-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Westfriesgasthuis,"Amitriptyline 10% and ketamine 10% cream in neuropathic pain: A randomised, double-blind, placebo-controlled cross-over pilot study with a three months open follow-up Amitriptyline 10% en ketami...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005656-26,0,0,0 2014-005657-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Tampere University Hospital,Synnytyksen aikaisen sokeritasapainon vaikutus neonataalihypoglykemiaan insuliinihoitoisilla raskausdiabeetikoilla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005657-39,0,0,0 2014-005658-20,1,2017-11-16,2017-11-16,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"FibroGen, Inc.","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005658-20,0,0,0 2014-005659-19,1,,,0,1,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Birmingham,A phase II study of the use of azacitidine for the treatment of patients with chronic graft-versus-host-disease who have failed therapy with corticosteroids,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005659-19,0,0,0 2014-005663-32,10,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous secukinumab compared to placebo and etanercept (in a single blinded arm) after twel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005663-32,0,0,0 2014-005663-32,10,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous secukinumab compared to placebo and etanercept (in a single blinded arm) after twel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005663-32,0,0,0 2014-005663-32,10,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A,"A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous secukinumab compared to placebo and etanercept (in a single blinded arm) after twel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005663-32,0,0,0 2014-005666-29,1,2018-04-10,2018-04-10,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,4D Pharma,"A Phase 1 randomised, double-blind, placebo-controlled study to assess the safety and tolerability of Bacteroides thetaiotaomicron in young people aged 16 to 18 years with stable Crohn's disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005666-29,0,0,0 2014-005669-54,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel",Clinical safety study on 5-Aminolevulinic acid (5-ALA) in children and adolescents with supratentorial brain tumours Klinisch veiligheidsonderzoek naar 5-Aminolevulinic acid (5-ALA) bij kinderen en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005669-54,0,0,0 2014-005671-92,10,2019-07-05,2019-07-26,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"PEARL THERAPEUTICS, INC.","A Randomized, Double Blind, Multi Center, Parallel Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations over a 52 Week Treatment Period in Subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005671-92,0,0,0 2014-005671-92,10,2019-07-05,2019-07-26,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pearl Therapeutics, Inc.","A Randomized, Double Blind, Multi Center, Parallel Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations over a 52 Week Treatment Period in Subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005671-92,0,0,0 2014-005674-11,1,,,0,0,1,0,0,1,1,0,0,4,0,0,0,0,0,National Cancer Institute,"A PHASE 1/2 STUDY OF NIVOLUMAB (IND# 124729) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AS A SINGLE AGENT AND IN COMBINATION WITH IPILIMUMAB",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005674-11,0,1,1 2014-005679-96,8,2018-06-04,2018-09-03,7,1,1,0,0,1,3,0,0,1,1,0,1,0,1,"Scioderm, INC",An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of ZorblisaTM (SD-101-6.0) in Patients with Epidermolysis Bullosa An Open Label Multi-Center Extension Study to Evaluate ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005679-96,0,0,0 2014-005679-96,8,2018-06-04,2018-09-03,7,1,1,0,0,1,3,0,0,1,1,0,1,0,1,"SCIODERM, INC",An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of ZorblisaTM (SD-101-6.0) in Patients with Epidermolysis Bullosa An Open Label Multi-Center Extension Study to Evaluate ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005679-96,0,0,0 2014-005679-96,8,2018-06-04,2018-09-03,7,1,1,0,0,1,3,0,0,1,1,0,1,0,1,"Scioderm, INC, An Amicus Therapeutics Company",An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of ZorblisaTM (SD-101-6.0) in Patients with Epidermolysis Bullosa An Open Label Multi-Center Extension Study to Evaluate ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005679-96,0,0,0 2014-005684-32,1,2018-09-15,2018-09-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,The Royal Marsden NHS Foundation Trust,[18F] DIHYDRO-TESTOSTERONE PET IMAGING IN PATIENTS WITH PROGRESSIVE PROSTATE CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005684-32,0,0,0 2014-005685-30,1,,,0,1,0,0,0,1,3,0,0,1,1,1,0,1,1,ApoPharma Inc.,Long-term safety and efficacy study of Ferriprox® for the treatment of transfusional iron overload in patients with sickle cell disease or other anemias.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005685-30,0,0,0 2014-005696-93,11,2016-01-05,2016-01-05,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Sanofi-aventis recherche & développement,"Phase II, Open Label, Single Arm Study Assessing the Clinical Benefit of SAR125844, Administered as Single Agent by Weekly Intravenous (IV) Infusion, for the Treatment of Patients with Advanced Pretre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005696-93,0,0,0 2014-005696-93,11,2016-01-05,2016-01-05,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"Phase II, Open Label, Single Arm Study Assessing the Clinical Benefit of SAR125844, Administered as Single Agent by Weekly Intravenous (IV) Infusion, for the Treatment of Patients with Advanced Pretre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005696-93,0,0,0 2014-005697-10,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Fondazione Italiana Linfomi ONLUS,GA101-miniCHOP regimen for the treatment of elderly unfit patients with diffuse large B-cell non-Hodgkin’s lymphoma. A phase II study of the Fondazione Italiana Linfomi (FIL). Trattamento di prima...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005697-10,0,0,0 2014-005700-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Abteilung für Augenheilkunde, AKH Linz",Aqueous Humor cytokine Levels following intravitreal ranibizumab or dexamethasone therapy in patients with diabetic macular edema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005700-24,0,0,0 2014-005701-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,Shifting pain modulation towards anti-nociceptivity: Mechanism-specific pharmacological prevention of post sternotomy pain: the MASTER study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005701-20,0,0,0 2014-005702-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medical Center,Top-Down Infliximab Study in Kids with Crohn's disease (TISKids) Top-down Infliximab Studie bij Kinderen met de ziekte van Crohn (TISKids),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005702-37,0,0,0 2014-005717-23,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL™ (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL™ at 9-18 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005717-23,0,1,1 2014-005722-35,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Glostrup University Hospital,Measures of inflammation in low back pain (LBP) and anti-TNFα for the treatment of deemed discogenic LBP - an explorative study Measures of inflammation in low back pain (LBP) and anti-TNFα for the...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005722-35,0,0,0 2014-005724-10,3,2017-10-12,2017-10-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,STEALTH BIOTHERAPEUTICS,"A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects with Stable Heart Fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005724-10,0,0,0 2014-005724-10,3,2017-10-12,2017-10-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Stealth BioTherapeutics Inc.,"A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects with Stable Heart Fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005724-10,0,0,0 2015-000050-38,14,2019-01-24,2019-02-05,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A Phase III, randomized, double-blind, placebo controlled multi-center study of subcutaneous secukinumab (150 mg and 300 mg) in prefilled syringe to demonstrate efficacy (including inhibition of struc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000050-38,0,0,0 2015-000050-38,14,2019-01-24,2019-02-05,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.p.A.,"A Phase III, randomized, double-blind, placebo controlled multi-center study of subcutaneous secukinumab (150 mg and 300 mg) in prefilled syringe to demonstrate efficacy (including inhibition of struc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000050-38,0,0,0 2015-000050-38,14,2019-01-24,2019-02-05,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A Phase III, randomized, double-blind, placebo controlled multi-center study of subcutaneous secukinumab (150 mg and 300 mg) in prefilled syringe to demonstrate efficacy (including inhibition of struc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000050-38,0,0,0 2015-000051-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Klaus Olkkola/University of Helsinki,"The pharmacokinetics and –genomics of remifentanil, and its effects on the depth-of-anaesthesia monitors and the protein synthesis in children. Remifentaniilin farmakokinetiikka ja –genomiikka sekä...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000051-24,0,0,0 2015-000053-21,1,2017-12-15,2017-12-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,FLUIDDA nv,Placebo controlled study to assess the effect of Roflumilast in hyperinflated COPD patients in addition to LABA/LAMA therapy using Functional Respiratory Imaging. Placebo-gecontroleerde studie om h...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000053-21,0,0,0 2015-000054-37,1,2018-05-16,2018-05-16,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,Institute of Tropical Medicine,Be-PrEP-ared: HIV prevention with Pre-exposure prophylaxis – a demonstration project in high risk men having sex with men in Belgium,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000054-37,0,0,0 2015-000056-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UMC Utrecht,89Zr-rituximab PET/CT for detection of central nervous system lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000056-23,0,0,0 2015-000057-20,5,2021-12-08,2021-12-13,3,0,0,0,0,0,4,0,0,2,1,0,0,0,1,B. Braun Melsungen AG,"PROSPECTIVE, RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTI-CENTRIC, INTERNATIONAL, STUDY ON THE EFFICACY AND SAFETY OF AN EARLY TARGET CONTROLLED PLASMA VOLUME REPLACEMENT THERAPY WITH A BALANCED GELATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000057-20,1,0,0 2015-000060-34,1,2016-11-07,2016-11-07,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,CHU de Nîmes,"Effets vasculaires et métaboliques d'une supplémentation en Vitamine D associée à une prise en charge hygiéno-diététique chez l'Adolescent Obèse: étude prospective, randomisée, contrôlée Effets vas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000060-34,0,0,0 2015-000066-62,8,2017-09-18,2017-09-18,7,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Estimate the Efficacy and Safety of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000066-62,1,1,0 2015-000066-62,8,2017-09-18,2017-09-18,7,1,1,0,0,0,3,0,0,2,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Estimate the Efficacy and Safety of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000066-62,1,1,0 2015-000072-99,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ilkka Helenius,EFFECT OF PREGABALIN ON IMMEDIATE POSTOPERATIVE AND LONGTERM PAIN AND SPINAL MONITORING IN CHILDREN UNDERGOING INSTRUMENTED SPINAL SURGERY. A placebo-controlled randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000072-99,0,0,0 2015-000075-27,5,2017-09-15,2017-09-15,1,0,1,0,0,1,3,0,0,2,0,0,0,0,1,"Horizon Therapeutics, Inc","A Randomised, Controlled, Open-Label Crossover Study of the Safety, Pharmacokinetics and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate [GPB]) Oral Liquid and Sodium Phenylbutyrate (NaPBA) in Ph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000075-27,1,0,0 2015-000075-27,5,2017-09-15,2017-09-15,1,0,1,0,0,1,3,0,0,2,0,0,0,0,1,"Horizon Therapeutics, LLC","A Randomised, Controlled, Open-Label Crossover Study of the Safety, Pharmacokinetics and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate [GPB]) Oral Liquid and Sodium Phenylbutyrate (NaPBA) in Ph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000075-27,1,0,0 2015-000078-36,1,2015-08-27,2015-08-27,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Thomas Fichtner Bendtsen,Analgetisk effekt af proksimal supplerende nervus obturatorius blokade efter insufficient analgetisk effekt af nervus femoralis blokade hos patienter med hoftenær femurfraktur Analgetisk effekt af ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000078-36,0,0,0 2015-000087-34,11,2018-04-18,2019-01-08,9,1,1,0,0,0,2,0,0,2,0,0,0,0,1,Merckle GmbH,"An Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Lipegfilgrastim 100 μg/kg Body...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000087-34,1,0,0 2015-000089-72,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Policlinico Gemelli-CIC- UCSC,FAT GENE EXPRESSION IN OVERWEIGHT AND OBESE PATIENTS WITH PERSISTENTLY ACTIVE RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT AND CLINICAL RESPONSE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000089-72,0,0,0 2015-000091-10,1,2015-10-20,2015-10-20,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Rigshospitalet, department of surgical Gastroenterology, C-Tx",RCT-comparison of two hemostatic devices (Hemopath vs. Tachosil) in liver resection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000091-10,0,0,0 2015-000095-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska Institutet,Botulinum toxin-A as a treatment for chronic muscle-related pain in adults with spastic cerebral palsy: a randomized controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000095-10,0,0,0 2015-000097-35,2,2017-04-19,2017-12-19,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily evaluate the safety, tolerability, pharmacokinetics and efficacy of CFZ533 in patients with moderate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000097-35,0,0,0 2015-000102-19,1,2017-01-02,2017-01-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Section for Surgical Pathophysiology, Rigshospitalet","Effect of preoperative intravenous highdose methylprednisolone on orthostatic intolerance, sleeping pattern, glucose homeostasis and immune signaling in patients scheduled for total hip-arthroplasty",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000102-19,0,0,0 2015-000104-26,3,2019-03-26,2019-03-26,2,1,1,0,0,1,2,0,0,2,1,0,0,0,1,Ultragenyx Pharmaceutical Inc.,An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less than 5 Years Old,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000104-26,1,1,0 2015-000105-39,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Perle Bioscience Inc.,"A PHASE 2B/3, MULTICENTER, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE COMBINATION OF CYCLOSPORINE AND OMEPRAZOLE AND OMEPRAZOLE ALONE IN PARTICIPANTS WITH NEW ONSET TYPE 1 DIABETES Estudio de Fas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000105-39,0,0,0 2015-000106-19,2,2020-02-28,2020-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc","A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF GDC-0810 VERSUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER RESISTANT TO AROMATASE INHIBITOR THERAPY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000106-19,0,0,0 2015-000107-94,1,2017-08-29,2017-08-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,CHRU de Brest,Etude ESPER : Epargne Sanguine au cours de la pose d’une Prothèse de hanche totale grâce à l’Exacyl® chez le patient traité par Rivaroxaban,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000107-94,0,0,0 2015-000111-41,4,2020-11-19,2020-11-19,2,1,1,0,0,0,3,0,0,1,1,0,1,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Rib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000111-41,0,0,0 2015-000111-41,4,2020-11-19,2020-11-19,2,1,1,0,0,0,3,0,0,1,1,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Rib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000111-41,0,0,0 2015-000114-22,16,2017-07-18,2017-07-18,14,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 26-week, randomized, double blind, parallel-group multicenter study to assess the efficacy and safety of QVA149 (110/50 ?g o.d.) vs tiotropium (18 ?g o.d.) + salmeterol/fluticasone propionate FDC (5...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000114-22,0,0,0 2015-000120-28,1,2015-07-02,2015-07-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,RSPR Pharma AB,"A Double-Blind, Randomised, Placebo-controlled, Cross-over, Phase 2 Mannitol Challenge Study, Investigating the Efficacy of CRD007 in Adult Subjects with Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000120-28,0,0,0 2015-000125-36,1,2019-03-31,2019-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Tübingen,Daptomycin concentration in drainage fluid and blood samples of ICU patients Konzentration von Daptomycin im Blut und in der Wundflüssigkeit bei kritisch kranken Patienten der anästhesiologischen I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000125-36,0,0,0 2015-000133-70,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Novartis Vaccines and Diagnostics, Inc","A Phase III, Stratified, Randomized, Double-Blind, Multicenter, Non-Inferiority Study to Evaluate Safety and Immunogenicity of Cell-Based Quadrivalent Subunit Influenza Virus Vaccine and Cell-Based Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000133-70,0,1,1 2015-000134-30,13,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000134-30,0,0,0 2015-000134-30,13,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Lilly S.A.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000134-30,0,0,0 2015-000134-30,13,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000134-30,0,0,0 2015-000140-42,8,2017-04-05,2017-04-05,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.","A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000140-42,1,0,0 2015-000140-42,8,2017-04-05,2017-04-05,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Astellas Pharma Global Development, Inc. (APGD)","A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000140-42,1,0,0 2015-000142-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU CLERMONT-FERRAND,/ Kétamine et douleur neuropathique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000142-29,0,0,0 2015-000148-40,1,2020-06-05,2020-06-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Plymouth Hospitals NHS Trust,"Simvastatin as a neuroprotective treatment for Parkinson's disease: a double-blind, randomised, placebo controlled futility study in patients of moderate severity.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000148-40,0,0,0 2015-000149-22,8,2018-06-04,2018-06-04,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Cluster Headache",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000149-22,0,0,0 2015-000149-22,8,2018-06-04,2018-06-04,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Cluster Headache",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000149-22,0,0,0 2015-000159-26,1,2016-12-29,2016-12-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase 2a, Multi-centre, Single-arm Trial of the Combination of AZD2014 and Weekly Paclitaxel in Patients with Relapsed or Refractory Squamous Non-Small Cell Lung Cancer After at Least One Line of Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000159-26,0,0,0 2015-000160-34,1,2016-06-17,2016-06-17,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,OmniVision GmbH,"Therapeutic Equivalence (non-inferiority), Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic Formulation of 0.2% Brimonidine/0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000160-34,0,0,0 2015-000162-59,1,2021-09-17,2021-09-17,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU Clermont-Ferrand,"Evaluation of botulinum toxin injection efficacy in the treatment of head essential tremor by a multi-center, randomized, double–blind, parallel-group, placebo-controlled study Evaluation de l’effi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000162-59,0,0,0 2015-000167-14,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,CELSION CORPORATION,HEAT-ACTIVATED TARGET THERAPY RADIOTHERAPY + HYPERTHERMIA + LYSO THERMOSENSITIVE LIPOSOMAL DOXORUBICIN) OF LOCALREGIONAL RELAPSE IN BREAST CANCER PATIENTS Terapia target attivata dal calore (radiot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000167-14,0,0,0 2015-000168-32,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Mesenchymal stem cells for Angiogenesis and Neovascularization in digital Ulcers of Systemic sclerosis Mesenchymale stamcellen voor angiogenese en neovascularisatie bij digitale ulcera van patiënt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000168-32,0,0,0 2015-000172-98,1,2018-01-31,2018-01-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,The University of Leicester,An Open Label Oxygen Enhanced Imaging Biomarker Study to Assess the Role of Fluticasone/Formoterol upon Airway Function in Moderate to Severe Persistent Asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000172-98,0,0,0 2015-000175-27,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,bioCSL Pty Ltd,"A Phase IV, Multicenter, Randomized, Observer-blind, Parallel-arm Study to Evaluate the Safety and Tolerability of CSL’s Trivalent Influenza Virus Vaccine (CSL TIV) in Children 5 to Less Than 9 Years ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000175-27,0,1,1 2015-000176-10,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,CSL Limited,"A Phase II, Multicenter, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL’s 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000176-10,0,1,1 2015-000177-12,1,,,0,1,0,1,0,0,1,0,1,4,0,0,0,0,1,CSL Limited,"An Observer-Blind, Randomized, Comparator-Controlled, Single-Centre Study to Evaluate the Tolerability, Safety, and Immunogenicity of Inactivated Influenza Vaccine, CSL Limited in a Healthy Pediatrics...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000177-12,0,1,1 2015-000178-36,1,2018-11-28,2018-11-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of New South Wales,"A phase II, open-label, single arm, multicentre, international trial of sofosbuvir and GS-5816 for people with chronic hepatitis C virus infection and recent injection drug use",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000178-36,0,0,0 2015-000179-29,7,2020-03-23,2020-03-23,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS PHARMA SERVICES AG,A randomized phase II study of MCS110 combined with carboplatin and gemcitabine in advanced Triple Negative Breast Cancer (TNBC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000179-29,0,0,0 2015-000179-29,7,2020-03-23,2020-03-23,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,A randomized phase II study of MCS110 combined with carboplatin and gemcitabine in advanced Triple Negative Breast Cancer (TNBC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000179-29,0,0,0 2015-000179-29,7,2020-03-23,2020-03-23,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.",A randomized phase II study of MCS110 combined with carboplatin and gemcitabine in advanced Triple Negative Breast Cancer (TNBC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000179-29,0,0,0 2015-000180-13,1,2019-07-09,2019-07-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medisch Centrum Haaglanden,"The value of a High-Volume Image-Guided Injections (HVIGI) in chronic midportion Achilles tendinopathy: a double-blind, placebo-controlled, randomised clinical trial De waarde van Hoog-Volume Inje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000180-13,0,0,0 2015-000181-60,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Nutrinia Ltd.,"A Multi-Center, Randomized, Double-Blind, Three-Arm, Parallel-Group trial to assess the efficacy and safety of NTRA-9620 in infants with Short Bowel Syndrome (SBS) following surgical resection.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000181-60,0,0,0 2015-000182-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHDR,"A randomized, double-blind, placebo-controlled, cross-over study to assess the effects of fampridine on eye movements and nerve conduction in patients with multiple sclerosis (MS) and a unilateral or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000182-31,0,0,0 2015-000185-59,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Merja Kokki,"The effect of oxycodone to placental and fetal circulation during the phase I of labor and the efficacy, safety and neonatal effects of oxycodone. Oksikodonin vaikutus sikiön, istukan ja kohdun ve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000185-59,0,0,0 2015-000188-15,7,2019-06-25,2019-06-25,7,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Allergopharma GmbH & Co. KG,A multicenter randomized double-blind placebo-controlled clinical trial for evaluation of efficacy and safety of specific immunotherapy with an aluminium hydroxide-adsorbed allergoid preparation of h...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000188-15,0,0,0 2015-000189-71,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,. Comparaison des concentrations plasmatiques pour une anesthésie optimale chez les obèses et les non obèses,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000189-71,0,0,0 2015-000190-12,5,2017-04-20,2017-08-03,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000190-12,0,0,0 2015-000192-27,1,2019-11-19,2019-11-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Oslo University Hospital,GutHeart: Targeting Gut microbiota to treat Heart failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000192-27,0,0,0 2015-000193-35,1,2019-03-08,2019-03-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre François Baclesse,A phase II study of ABT-263 as single agent in women with platinum resistant/refractory recurrent ovarian cancer Etude de phase II évaluant l’intérêt de l'ABT-263 en monothérapie dans le cancer de ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000193-35,0,0,0 2015-000194-12,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,CONSORZIO ONCOTECH,Isoquercetin as an adjunct therapy in patients with kidney cancer receiving first-line sunitinib: a phase I/II trial Isoquercetina come terapia di supporto nei pazienti affetti da tumore del rene i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000194-12,0,0,0 2015-000195-98,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,HOVON Foundation,"A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transpl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000195-98,0,0,0 2015-000196-27,1,,,0,1,0,0,0,0,4,0,0,3,0,0,0,0,0,QMUL and Bart's Health NHS trust,"Tendinopathy treatment effects and mechanisms 1 (TEAM 1): A randomised clinical trial of eccentric loading, high volume injection and shock wave therapy for Achilles tendinopathy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000196-27,0,0,0 2015-000197-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI,"insulin resistance, obesity and gastrointestinal bacteria Insulino-Resistenza, Obesità e Batteri Gastrointestinali",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000197-35,0,0,0 2015-000199-86,1,2016-02-10,2016-02-10,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,"University of Copenhagen, The Novo Nordisk Foundation Center For Basic Metabolic Research, section of Metabolic Genetic",Effects of metformin on human gut microbiota Effekten af metformin på tarmens bakteriesammensætning,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000199-86,0,0,0 2015-000202-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Groupement des Hôpitaux de l’Institut Catholique de Lille (GHICL),"Effect and tolerance of ketamine's subcutaneous bolus during painful care, refractory of bedsore, ulcer, vascular wound care in palliative care units. Effet et tolérance de bolus sous-cutanés de ké...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000202-20,0,0,0 2015-000203-89,5,2019-10-18,2019-10-18,2,0,1,0,0,0,2,0,0,2,1,0,0,0,0,Fondazione PENTA Onlus,"Multi-centre, randomised, open label, phase IIb study to compare the efficacy, safety and pharmacokinetics (PK) of an optimised dosing to a standard dosing regimen of vancomycin in neonates and infant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000203-89,1,0,0 2015-000205-39,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"UCB, Inc.","A Multi-Center, Randomized, Double Blind, Placebo Controlled Parallel Group Study of the Safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d Dosing in Children Aged 1 to < 6 Years S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000205-39,0,1,1 2015-000206-18,1,2016-08-19,2016-08-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"PharmaMar S.A., Sociedad Unipersonal",Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients with Selected Solid Tumors Evaluación del efecto de lurbinectedina (PM01183) en la repolariz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000206-18,0,0,0 2015-000207-13,1,2019-04-30,2019-04-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Tayside Clinical Trials Unit, University of Dundee",Proof of concept study to assess the differential effects of chronic beta-blockade (celiprolol versus bisoprolol) on cardiopulmonary outcomes at rest and during exercise in chronic obstructive pulmona...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000207-13,0,0,0 2015-000208-25,3,2022-02-14,2022-02-14,1,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Takeda Development Centre Europe Ltd.,"A Multicenter, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000208-25,1,1,0 2015-000218-23,1,2016-10-12,2016-10-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Aarhus University Hospital, Skejby",Concentration of Meropenem in Plasma and Subcutis in Patients on ECMO Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000218-23,0,0,0 2015-000221-37,9,2021-07-12,2021-07-23,8,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc. (Takeda)","A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients with Higher-Risk Myelodysplastic S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000221-37,0,0,0 2015-000221-37,9,2021-07-12,2021-07-23,8,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients with Higher-Risk Myelodysplastic S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000221-37,0,0,0 2015-000222-11,1,2020-02-07,2020-02-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University College London,"A phase II, randomised, double-blind, placebo- controlled, multi-site, parallel group clinical trial to examine ketamine as a pharmacological treatment for alcohol dependence in an alcohol dependent p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000222-11,0,0,0 2015-000223-85,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Örebro University Hospital,"The effects of Vitamin D supplementation on cardiorespiratory fitness and adiposity in overweight men. A randomised, double-blind, placebo controlled study. Förbättrar D-vitamin fysisk arbetsförmåg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000223-85,0,0,0 2015-000225-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Helsinki University Hospital,PBA (4-phenylbutyrate) in the prevention of intraocular pressure increase caused by glucocorticoids PBA (4-fenyylibentsoehappo) glukokortikoidien aiheuttaman silmänpaineen nou-sun estolääkityksenä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000225-36,0,0,0 2015-000229-35,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Beaumont Hospital,A prospective randomised control trial comparing local anaesthetic subcutaneous wound injection versus local anaesthetic wound percolation in distal forearm fractures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000229-35,0,0,0 2015-000230-29,5,,,0,0,0,1,0,1,1,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000230-29,0,0,0 2015-000232-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Consorcio Hospital General Universitario de Valencia . Servicio de Anestesia , Reanimacion y tto del Dolor",Analgesic efficacy of levobupivacaine administered by wet wound dressing for the management split-thickness skin graft donor sites Eficacia analgésica de la levobupivacaína administrada mediante ap...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000232-15,0,0,0 2015-000233-73,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Helsinki University Central Hospital,HYDROXYCHLOROQUINE IN ACUTE CORONARY SYNDROME: PREVENTION OF RECURRENT CARDIOVASCULAR EVENTS Hydroksiklorokiini akuutissa koronaari syndroomassa: Tulevien kardiovaskulaaritapahtumien ehkäisy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000233-73,0,0,0 2015-000239-34,4,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Medizinische Universität Wien,NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; a prospective randomized trial NT-proBNP selektierte Prävention kardialer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000239-34,0,0,0 2015-000239-34,4,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Medical University of Vienna,NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; a prospective randomized trial NT-proBNP selektierte Prävention kardialer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000239-34,0,0,0 2015-000246-34,11,2019-04-03,2019-04-03,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000246-34,0,0,0 2015-000246-34,11,2019-04-03,2019-04-03,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000246-34,0,0,0 2015-000246-34,11,2019-04-03,2019-04-03,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000246-34,0,0,0 2015-000251-24,1,2019-09-06,2019-09-06,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Fundacio Privada Clinic per a la Recerca Biomedica,Impact of extremely early antiretroviral therapy to reduce VIral REservoir and induce functional CURE of HIV-1 infection. A pilot comparative study. Impacto de la terapia antirretroviral muy precoz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000251-24,0,0,0 2015-000253-21,2,2018-05-29,2018-05-29,1,0,0,0,2,1,2,0,0,2,0,0,0,0,1,Therabron Therapeutics Inc.,Efficacy of recombinant human club (clara) cell 10kDa protein (CC10) administered to premature neonates with respiratory distress syndrome.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000253-21,1,0,0 2015-000263-14,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Walton Centre NHS Foundation Trust,Mycophenolate Treatment for Longstanding Complex Regional Pain Syndrome (MYPS I),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000263-14,0,0,0 2015-000265-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Janne Räsänen,Daylight photodynamic therapy for actinic keratoses: a multicentre study comparing two photosensitizers (BF-200 ALA versus MAL) Aktiinikeratoosien fotodynaaminen hoito auringonvalolla: kahden valoh...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000265-32,0,0,0 2015-000266-64,2,2017-02-21,2017-02-21,2,1,0,0,1,0,3,0,0,1,0,0,1,0,1,USV Limited,"A Randomised, Multi-Centre, Assessor-Blinded, Active-Controlled, Parallel Group, Equivalence Phase III Study Comparing the Safety and Efficacy of USV Pegfilgrastim and Neulasta® in Breast Cancer Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000266-64,0,0,0 2015-000266-64,2,2017-02-21,2017-02-21,2,1,0,0,1,0,3,0,0,1,0,0,1,0,1,USV Private Limited,"A Randomised, Multi-Centre, Assessor-Blinded, Active-Controlled, Parallel Group, Equivalence Phase III Study Comparing the Safety and Efficacy of USV Pegfilgrastim and Neulasta® in Breast Cancer Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000266-64,0,0,0 2015-000268-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitätsklinikum Erlangen,"Prospective, open-label, randomised, single-centre, two-arm, parallel-group, cross-over controlled clinical study, phase 4, to investigate the efficacy of tropicamid 0.5% eyedrops compared to cyclopen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000268-32,0,0,0 2015-000269-30,11,2020-07-15,2020-07-28,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF ATEZOLIZUMAB IN ADVANCED SOLID TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000269-30,0,0,0 2015-000269-30,11,2020-07-15,2020-07-28,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.","AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF ATEZOLIZUMAB IN ADVANCED SOLID TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000269-30,0,0,0 2015-000269-30,11,2020-07-15,2020-07-28,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF ATEZOLIZUMAB IN ADVANCED SOLID TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000269-30,0,0,0 2015-000270-36,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Umeå University Hospital,"A randomized Phase II, open label multicenter cross-over study, to evaluate biomarkers, in 2nd line treatment of metastatic Castration Resistant Prostate Cancer (mCRPC) with abiraterone and cabazitaxe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000270-36,0,0,0 2015-000273-13,1,2016-05-17,2016-05-17,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals of North Midlands NHS Trust,Mobilisation of endothelial progenitor cells by statin therapy in patients with coronary disease: a proof of concept pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000273-13,0,0,0 2015-000274-35,1,2019-11-21,2019-11-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,FUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA,"An open-label, randomized, controlled clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virolog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000274-35,0,0,0 2015-000276-10,5,2017-03-24,2017-03-31,3,0,0,0,0,1,2,0,0,2,0,0,0,0,0,Academisch Medisch Centrum bij de Universiteit van Amsterdam (AMC),FAST – Food Allergy Specific ImmunoTherapy A multinational phase IIb study to investigate the efficacy and safety of subcutaneous immunotherapy with a modified fish- parvalbumin given in single rising...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000276-10,1,0,0 2015-000276-10,5,2017-03-24,2017-03-31,3,0,0,0,0,1,2,0,0,2,0,0,0,0,0,FAST Consortium under EU 7. FWP,FAST – Food Allergy Specific ImmunoTherapy A multinational phase IIb study to investigate the efficacy and safety of subcutaneous immunotherapy with a modified fish- parvalbumin given in single rising...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000276-10,1,0,0 2015-000276-10,5,2017-03-24,2017-03-31,3,0,0,0,0,1,2,0,0,2,0,0,0,0,0,"Academisch Medisch Centrum bij de Universiteit van Amsterdam (AMC) Prof. dr. M. M. Levi, Dean & Chair",FAST – Food Allergy Specific ImmunoTherapy A multinational phase IIb study to investigate the efficacy and safety of subcutaneous immunotherapy with a modified fish- parvalbumin given in single rising...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000276-10,1,0,0 2015-000277-12,1,2016-03-11,2016-03-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 2 Multicenter, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Toreforant (JNJ-38518168) for the Treatment of Subjects with Moderate to Severe Plaquetype Psoriasis „Wieloośro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000277-12,0,0,0 2015-000284-14,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Calgary,Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000284-14,0,0,0 2015-000287-34,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"AROG PHARMACEUTICALS, INC.","A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000287-34,0,0,0 2015-000287-34,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Arog Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000287-34,0,0,0 2015-000288-16,9,2017-05-17,2017-08-31,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Refractory Subjects With Active Radiographic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000288-16,0,0,0 2015-000289-67,4,2017-05-22,2017-09-26,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloarth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000289-67,0,0,0 2015-000290-12,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Clínica IVI Barcelona,Randomized Clinical Trial comparing the endometrial transformation with 25 mg/day of subcutaneous progesterone (Prolutex) versus 50 mg/day intramuscular progesterone (Prontogest) Ensayo clínico ra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000290-12,0,0,0 2015-000294-13,4,2020-01-31,2020-01-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) - (KEYNOTE-086) Ensayo clínico de fase II de pembrolizumab (MK-3475) en mono...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000294-13,0,0,0 2015-000295-94,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,St Olavs University Hospital,Use of long acting opioids for pre- and postoperative analgesia in primary total knee arthroplasty. A double-blinded randomized control trial. Tapentadol vs Oxycodon vs Placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000295-94,0,0,0 2015-000298-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA ""ISTITUTI OSPITALIERI"" DI CREMONA","A phase II, open label, controlled study of olaparib in locally advanced ER, PgR and HER2 negative (Triple Negative) and in locally advanced germline BRCA mutation-positive breast cancer patients: bio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000298-11,0,0,0 2015-000301-40,1,2019-07-21,2019-07-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Queen Mary University of London,"A randomised, blinded, placebo-controlled Phase 2a study to evaluate the safety and efficacy of Artesunate treatment in severely injured trauma patients with traumatic haemorrhage.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000301-40,0,0,0 2015-000303-21,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,Biogen Idec Italia S.r.l.,"A Phase IV, interventional, multicenteR, double-blind, randomized, placebo-controlled study tO explore the onset of efficacy on Magnetic resonance disease activity of BG00012 (dimethyl fumarate) in Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000303-21,0,0,0 2015-000304-26,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"Gilead Sciences, Inc.",A Rollover Protocol to Provide Subjects Completing the FTC-203 Study in South Africa with Continued Access to Emtricitabine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000304-26,0,1,1 2015-000306-18,3,2016-04-12,2016-04-12,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Minerva Neurosciences, Inc.","A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of 2 doses of MIN-117 in Adult Subjects with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000306-18,0,0,0 2015-000307-10,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital,"AZD9291, an irreversible EGFR-TKI, in relapsed EGFR-mutated non-small cell lung cancer patients previously treated with an EGFR-TKI, coupled to extensive translational studies.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000307-10,0,0,0 2015-000307-10,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo university hospital,"AZD9291, an irreversible EGFR-TKI, in relapsed EGFR-mutated non-small cell lung cancer patients previously treated with an EGFR-TKI, coupled to extensive translational studies.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000307-10,0,0,0 2015-000313-40,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000313-40,0,1,1 2015-000318-24,4,2018-01-22,2018-10-22,4,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Dept. of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet",Stress Ulcer Prophylaxis in the Intensive Care Unit,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000318-24,0,0,0 2015-000319-41,15,2020-06-07,2020-06-17,13,1,1,0,0,0,3,0,0,1,1,0,1,0,1,CELGENE INTERNATIONAL II SàRL,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000319-41,0,0,0 2015-000319-41,15,2020-06-07,2020-06-17,13,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Celgene International II Sàrl (CIS II),"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000319-41,0,0,0 2015-000319-41,15,2020-06-07,2020-06-17,13,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Celgene International II Sàrl,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000319-41,0,0,0 2015-000319-41,15,2020-06-07,2020-06-17,13,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Celgene International II Sárl (CIS II),"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000319-41,0,0,0 2015-000322-11,1,2015-09-10,2015-09-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Graz; Universitätsklinik für Innere Medizin; Abteilung für Endokrinologie und Stoffwechsel,Assessment of the Duration of Glucagon’s Waning Effect on the Hepatic Glucose Production in Type 1 Diabetes Patients Untersuchung der Dauer der Glukagonwirkung auf die hepatische Glukoseproduktion ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000322-11,0,0,0 2015-000323-86,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Oxford,"A randomised, parallel group, double blind, placebo controlled, add on clinical trial to investigate whether the lithium mimetic, ebselen, can reduce symptoms of hypomania and mania in bipolar patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000323-86,0,0,0 2015-000324-29,5,2020-12-14,2021-03-17,2,1,0,1,0,2,1,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination with Nivolumab in Subjects with Selected Advanced...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000324-29,1,0,0 2015-000333-71,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","First-line FOLFOX-4 plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type, metastatic colorectal cancer: the VALENTIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000333-71,0,0,0 2015-000334-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Professor Thomas John Kiernan,"Peripheral endothelial function assessment of patients on ticagrelor versus clopidogrel who have undergone percutaneous coronary intervention - a randomized, crossover study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000334-30,0,0,0 2015-000335-32,1,2017-08-29,2017-08-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Steno Diabetes Center,Effects of dapagliflozin treatment on urinary proteomic patterns in patients with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000335-32,0,0,0 2015-000339-34,11,2019-01-22,2019-04-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB BIOSCIENCES GmbH,"MULTICENTER, OPEN-LABEL (PART A) FOLLOWED BY A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY (PART B) TO EVALUATE MAINTENANCE OF REMISSION IN SUBJECTS WITH ACTIVE AXIAL SPONDYLOAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000339-34,0,0,0 2015-000340-42,15,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000340-42,0,0,0 2015-000340-42,15,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000340-42,0,0,0 2015-000340-42,15,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Farma S.p.A.,"SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000340-42,0,0,0 2015-000344-42,8,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Celgene Corporation,"A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000344-42,0,0,0 2015-000353-20,5,2018-09-27,2018-09-27,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Vectura Limited,"A randomised, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two doses of nebulised budesonide delivered by the VR475 Inhalation System, with an open-lab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000353-20,1,1,0 2015-000357-20,3,2017-06-22,2017-06-22,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A Multi-Centre, Open-Label, Randomised Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients with Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000357-20,0,0,0 2015-000359-26,1,,,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,"Laboratorios del Dr. Esteve, S.A.","Phase I/II safety, tolerability and initial efficacy study of adeno-associated viral vector serotype 9 containing human sulfamidase gene after intracerebroventricular administration to patients with M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000359-26,0,0,0 2015-000360-34,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Technische Universitaet Muenchen Fakultaet fuer Medizin,"DUALIS A prospective, multicenter, randomized, open-label trial to assess the safety, tolerability and efficacy of dual therapy with boosted Darunavir + Dolutegravir when switching from standard of ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000360-34,0,0,0 2015-000361-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS),Efficacy of metformin in gestational diabetes not controlled by diet compared to the use of insulin Eficacia del tratamiento con metformina en diabetes gestacional no controlada con dieta frente al...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000361-31,0,0,0 2015-000362-53,3,2018-09-19,2018-09-19,1,0,0,0,0,1,2,0,0,2,1,0,0,0,0,ASSOCIAZIONE QOL-ONE,"Efficacy of eltrombopag plus lenalidomide combination therapy in patients with IPSS low and intermediate-risk myelodysplastic syndrome with isolated del5q: a multicenter, randomized, double-blind, pla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000362-53,1,0,0 2015-000366-66,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Gilead Sciences, Inc.",Dose Optimization Study of Idelalisib in Follicular Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000366-66,0,0,0 2015-000366-66,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,GILEAD SCIENCES INCORPORATED,Dose Optimization Study of Idelalisib in Follicular Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000366-66,0,0,0 2015-000371-26,7,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,GENZYME CORPORATION,"A Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Repeat Dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of olipudase alfa in Patients With Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000371-26,0,0,0 2015-000371-26,7,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Genzyme Corporation,"A Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Repeat Dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of olipudase alfa in Patients With Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000371-26,0,0,0 2015-000372-95,5,2018-01-16,2018-02-15,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ablynx N.V.,"A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000372-95,0,0,0 2015-000373-13,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Amarantus BioScience Holdings, Inc.","Phase 2, multicenter, randomized, double-blind, placebo-controlled, four-period cross-over, dose-range finding study to evaluate the safety, tolerability and efficacy of Eltoprazine in the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000373-13,0,0,0 2015-000377-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,MISOBOLD - Prostate cancer hypoxia using BOLD MRI and 18F-FMISO PET imaging Imagerie de l'hypoxie par IRM fonctionnelle BOLD et TEP-TDM au 18F-Misonidazole (18F-FMISO) des tumeurs de prostate à ha...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000377-12,0,0,0 2015-000380-13,11,2022-06-14,2022-06-14,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"MacroGenics, Inc.","A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000380-13,1,0,0 2015-000380-13,11,2022-06-14,2022-06-14,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"MACROGENICS, INC.","A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000380-13,1,0,0 2015-000382-31,2,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,GlaxoSmithKline Biologicals S.A.,"A Phase 3, Open-label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults who Received Different Primary Vaccination Regimens of Pre-exposure Prophyl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000382-31,0,0,0 2015-000385-55,1,2018-01-29,2018-01-29,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Hospices Civils de Lyon,TEMPO : Efficacité du TIMOLOL en administration nasale pour le traitement des épistaxis dans la maladie de Rendu-Osler. Essai randomisé en double insu contre placebo TEMPO : Efficacité du TIMOLOL ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000385-55,0,0,0 2015-000386-31,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,Role of SAMITAL in pediatric age ¿ a feasibility study in children with/or at risk of oral mucositis due to chemotherapy and/or radiotherapy Ruolo di SAMITAL¿ in et¿ pediatrica ¿ studio di fattibil...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000386-31,0,0,0 2015-000388-15,1,2019-02-27,2019-02-27,1,1,0,0,0,1,3,0,0,1,1,1,1,0,0,University of the University of Munich,"Prophylactic treatment of vestibular paroxysmia with carbamazepine: a prospective, randomized, placebo-controlled, cross-over, multi-center trial Therapie der Vestibularisparoxysmie mit Carbamazepi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000388-15,0,0,0 2015-000389-69,3,2019-04-15,2019-10-11,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Ultragenyx Pharmaceutical Inc,An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000389-69,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim AB,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim Norway KS,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim Finland Ky,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim RCV GmbH & Co. KG,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim Limited,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,Boehringer-Ingelheim RCV GmbH&Co KG,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim Ellas SA,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim France,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,"Boehringer Ingelheim España, S.A.","A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,SCS Boehringer Ingelheim Comm. V,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,Boehringer-Ingelheim Pharma GmbH & Co. KG,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda","A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim bv,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000392-28,18,2018-11-28,2018-11-28,17,1,0,0,0,1,3,0,0,1,1,0,1,0,2,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000392-28,0,0,0 2015-000393-34,1,2017-06-06,2017-06-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Central Manchester University Hospitals NHS Foundation Trust,"Clinical trial of the investigational medicinal product, local anaesthetic levo-bupivacaine in infants 3 - 6 months post natal age.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000393-34,0,0,0 2015-000395-97,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,"Gilead Sciences, Inc.","A Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis, Mild Lung Disease, and P. aeruginosa (AIR-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000395-97,0,1,1 2015-000395-97,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Gilead Sciences Pty Ltd,"A Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis, Mild Lung Disease, and P. aeruginosa (AIR-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000395-97,0,1,1 2015-000395-97,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,"Gilead Sciences Canada, Inc.","A Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis, Mild Lung Disease, and P. aeruginosa (AIR-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000395-97,0,1,1 2015-000396-26,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,"Gilead Sciences, Inc.",Expanded Access Program for Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection Who Have Limited Treatment Options and are at Risk for Disease ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000396-26,0,1,1 2015-000397-36,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,"Gilead Sciences, Inc.",Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients with Cystic Fibrosis and Pseudomonas aeruginosa Airway Infection Who Have Limited Treatment Options and are at Risk for...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000397-36,0,1,1 2015-000398-11,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000398-11,0,1,1 2015-000399-81,1,2020-03-27,2020-03-27,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,RHEACELL GmbH & Co. KG,"AN INTERVENTIONAL, SINGLE ARM, PHASE I/IIA CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF APZ2 ON WOUND HEALING OF CHRONIC VENOUS ULCER (CVU)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000399-81,0,0,0 2015-000400-26,8,2020-06-23,2020-06-23,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline R&D Ltd,"A randomized, double blind (sponsor open), comparative, multicenter study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab coadministration in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000400-26,0,0,0 2015-000400-26,8,2020-06-23,2020-06-23,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A randomized, double blind (sponsor open), comparative, multicenter study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab coadministration in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000400-26,0,0,0 2015-000400-26,8,2020-06-23,2020-06-23,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A randomized, double blind (sponsor open), comparative, multicenter study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab coadministration in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000400-26,0,0,0 2015-000402-19,1,2018-11-27,2018-11-27,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,TC BioPharm Ltd,"An Adaptive Study of the Safety, Tolerability and Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients with Advanced Cancers which are Refractory to Current Treatment or who have I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000402-19,0,0,0 2015-000404-25,1,2017-07-21,2017-07-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomized, controlled multi-centre parallel group study to assess the efficacy and safety of multiple doses of a topically applied combination containing diclofenac 2% + capsaicin 0.075% (2 g formu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000404-25,0,0,0 2015-000408-24,2,2021-05-05,2021-05-05,2,1,1,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000408-24,0,0,0 2015-000410-22,1,2020-01-01,2020-01-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"The Cardiovascular MR Group, Dept. 2011, Rigshospitalet",Influence of liraglutide on diastolic cardiac function and myocardial perfusion as determined by magnetic resonance imaging in patients with type 2 diabetes: a double-blind randomized parallel-group t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000410-22,0,0,0 2015-000411-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Department of Nuclear Medicine and Endocrinology, Paracelsus Medical University Salzburg",Comparison of the detection of parathyroid adenoms using Tc-99m MIBI scintigraphy and F-18 Choline PET/CT in patients with primary hyperparathyroidism Vergleich der Detektion von Nebenschilddrüsen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000411-40,0,0,0 2015-000413-48,5,2018-09-28,2018-09-30,3,0,0,0,0,0,2,0,0,1,1,0,1,0,1,ACS BIOMARKER,"Bioprofiling response to mineralocorticoid receptor antagonists for the prevention of heart failure. A proof of concept clinical trial within the EU FP 7 ""HOMAGE"" programme ¿ Heart OMics in AGing R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000413-48,0,0,0 2015-000413-48,5,2018-09-28,2018-09-30,3,0,0,0,0,0,2,0,0,1,1,0,1,0,1,ACS Biomarker,"Bioprofiling response to mineralocorticoid receptor antagonists for the prevention of heart failure. A proof of concept clinical trial within the EU FP 7 ""HOMAGE"" programme ¿ Heart OMics in AGing R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000413-48,0,0,0 2015-000417-44,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"DELCATH SYSTEMS, INCORPORATIONS","A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma Estudio aleatorizado, con ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000417-44,0,0,0 2015-000417-44,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Delcath Systems, Ltd","A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma Estudio aleatorizado, con ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000417-44,0,0,0 2015-000417-44,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Delcath Systems, Inc","A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma Estudio aleatorizado, con ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000417-44,0,0,0 2015-000418-23,1,2021-08-25,2021-08-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Ghent University Hospital,Intraoperative intraperitoneal chemoperfusion to treat peritoneal minimal residual disease in stage III ovarian cancer: a randomized phase II trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000418-23,0,0,0 2015-000419-42,1,2016-05-17,2016-05-17,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Aalborg University Hospital,Naloxegol and assessments of opioid induced bowel dysfunction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000419-42,0,0,0 2015-000424-28,12,2019-01-23,2019-02-04,12,1,0,0,0,1,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000424-28,0,0,0 2015-000424-28,12,2019-01-23,2019-02-04,12,1,0,0,0,1,3,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB VERSUS PLACEBO IN PATIENTS WITH SYSTEMIC SCLEROSIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000424-28,0,0,0 2015-000431-32,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Universidad Autónoma de Madrid (U.A.M.),"A MULTI-CENTRE, OPEN-LABEL, RANDOMIZED, COMPARATIVE CLINICAL TRIAL OF TWO DIFFERENT DOSES OF BONE MARROW AUTOLOGOUS HUMAN MESENCHYMAL STEM CELLS PLUS BIOMATERIAL VERSUS ILIAC CREST AUTOLOGOUS GRAFT, F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000431-32,0,0,0 2015-000435-33,7,2017-07-13,2017-07-13,5,1,0,1,0,0,1,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,A phase I pharmacokinetic and safety study of tocilizumab (TCZ) in patients less than 2 years old with active systemic juvenile idiopathic arthritis (sJIA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000435-33,1,0,0 2015-000435-33,7,2017-07-13,2017-07-13,5,1,0,1,0,0,1,0,0,2,0,0,0,0,1,Roche Farma S.A en nombre de F. Hoffmann-La Roche Ltd,A phase I pharmacokinetic and safety study of tocilizumab (TCZ) in patients less than 2 years old with active systemic juvenile idiopathic arthritis (sJIA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000435-33,1,0,0 2015-000436-15,1,2020-06-28,2020-06-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Aarhus Universitet,Photodynamic diagnosis (PDD) in flexible cystoscopy – a randomized study with focus on significant recurrence Photodynamisk Diagnostisk (PDD) ved fleksible cystoskopier- et randomiseret studie med...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000436-15,0,0,0 2015-000442-39,1,2017-03-01,2017-03-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Clinica Universidad de Navarra/Universidad de Navarra,PHASE II STUDY OF NEOADJUVANT NIVOLUMAB IN PATIENTS WITH GLIOBLASTOMA MULTIFORME Estudio fase II con nivolumab neoadyuvante en pacientes con glioblastoma multiforme,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000442-39,0,0,0 2015-000449-21,5,2020-12-31,2020-12-31,4,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Novartis Pharma Services AG,"A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000449-21,0,0,0 2015-000449-21,5,2020-12-31,2020-12-31,4,1,0,1,0,0,1,0,0,1,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000449-21,0,0,0 2015-000449-21,5,2020-12-31,2020-12-31,4,1,0,1,0,0,1,0,0,1,1,0,0,0,1,NOVARTIS FARMA S.P.A.,"A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000449-21,0,0,0 2015-000452-24,2,2019-10-15,2019-12-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000452-24,0,0,0 2015-000454-38,1,2021-02-19,2021-02-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progress...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000454-38,0,0,0 2015-000456-15,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Kings College London,"The prevention of pre-term birth in women who develop a short cervix. A multi-centre randomised controlled trial to compare three treatments; cervical cerclage, cervical pessary and vaginal progester...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000456-15,0,0,0 2015-000456-15,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Guys and St Thomas' NHS Foundation Trust,"The prevention of pre-term birth in women who develop a short cervix. A multi-centre randomised controlled trial to compare three treatments; cervical cerclage, cervical pessary and vaginal progester...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000456-15,0,0,0 2015-000458-40,1,2018-08-10,2018-08-10,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Diurnal Limited,"Open-label, long-term follow-up of safety and biochemical disease control of Infacort® in neonates, infants and children with congenital adrenal hyperplasia and adrenal insufficiency previously enroll...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000458-40,0,0,0 2015-000459-25,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Janssen Sciences Ireland UC,"A Phase 2, 2-panel, Open-label, Randomized Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000459-25,0,0,0 2015-000460-34,2,2017-07-07,2017-07-07,2,0,0,0,0,1,3,0,0,1,0,0,1,0,0,Hospital of the University of Munich,"Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT) Wirksamkeit von Acetyl-DL-Le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000460-34,0,0,0 2015-000462-62,1,2018-01-01,2018-01-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Radboud university medical centre,The effects of statins on skeletal muscle mitochondria: is exercise the medicine? De effecten van statines op skeletspier mitochondria: is inspanning het medicijn?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000462-62,0,0,0 2015-000463-13,1,2015-06-12,2015-06-12,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Mylan Pharma UK Ltd,AN OPEN STUDY TO ASSESS THE ROBUSTNESS OF THE CRC749 DEVICE BY PHARMACEUTICAL PERFORMANCE FOLLOWING TWICE DAILY DOSING OF MGR001 ADMINISTERED VIA ORAL INHALATION IN SUBJECTS WITH ASTHMA OR CHRONIC OBS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000463-13,0,0,0 2015-000464-34,1,2016-05-19,2016-05-19,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Afferent Pharmaceuticals, Inc.",A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000464-34,0,0,0 2015-000465-31,1,2019-11-25,2019-11-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Charité - Universitätsmedizin Berlin,"Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression Cannabidiol in bipol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000465-31,0,0,0 2015-000466-57,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 1, Single-dose Study to Evaluate the Relative Bioavailability of Cobicistat (COBI) Age-Appropriate Pediatric Tablet Formulations Compared with Adult COBI 150-mg Tablets in Healthy Adult Volunt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000466-57,0,1,1 2015-000468-33,1,2021-02-15,2021-02-15,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Nantes,Comparaison de l’efficacité et de la tolérance d’une injection sous-conjonctivale de triamcinolone et d’un implant intravitréen de dexaméthasone sur l’œdème maculaire inflammatoire,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000468-33,0,0,0 2015-000471-27,3,2018-12-03,2018-12-03,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 24 week off drug extension, parallel group, study assessing durability of effect on skeletal muscle strength and function following a 6-month double-blind, placebo controlled study evaluating bimagr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000471-27,0,0,0 2015-000471-27,3,2018-12-03,2018-12-03,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A 24 week off drug extension, parallel group, study assessing durability of effect on skeletal muscle strength and function following a 6-month double-blind, placebo controlled study evaluating bimagr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000471-27,0,0,0 2015-000473-12,1,2017-09-29,2017-09-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,UMCG,The effectiveness of single dose Ultibro Breezhaler (indacaterol/glycopyrronium) by sd-DPI versus ipratropium/salbutamol by nebulizer in improving FEV1 and dyspnea during stable state of COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000473-12,0,0,0 2015-000474-35,1,2016-02-09,2016-02-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Afferent Pharmaceuticals, Inc.",A Dose Escalation Study to Assess the Efficacy and Tolerance of AF-219 in Subjects with Refractory Chronic Cough,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000474-35,0,0,0 2015-000475-27,1,2020-04-27,2020-04-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU de Limoges,Multicenter phase II trial of Nintedanib plus docetaxel in second line of treatment in patients with no squamous non small cell lung cancer refractory to first line chemotherapy (REFRACT study) Et...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000475-27,0,0,0 2015-000479-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Genzyme Corporation,A Phase II Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia Otevřená studie fáze II hodnotící sargramostim u pacientů...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000479-28,0,0,0 2015-000480-14,15,2018-08-08,2018-10-08,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Takeda Development Centre Europe, Ltd.","A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, with a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000480-14,0,0,0 2015-000480-14,15,2018-08-08,2018-10-08,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TAKEDA DEVELOPMENT CENTRE EUROPE LTD,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, with a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000480-14,0,0,0 2015-000481-58,13,2019-10-14,2019-10-14,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Takeda Development Centre Europe, Ltd.","A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000481-58,0,0,0 2015-000481-58,13,2019-10-14,2019-10-14,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TAKEDA DEVELOPMENT CENTRE EUROPE LTD,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000481-58,0,0,0 2015-000482-31,15,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Takeda Development Centre Europe, Ltd.","A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects with Ulcerative Colitis and Crohn?s Disease Estudio abierto, de fase IIIb para est...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000482-31,0,0,0 2015-000482-31,15,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,TAKEDA DEVELOPMENT CENTRE EUROPE LTD,"A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects with Ulcerative Colitis and Crohn?s Disease Estudio abierto, de fase IIIb para est...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000482-31,0,0,0 2015-000484-13,4,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Agios Pharmaceuticals Inc,"A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients with Pyruvate Kinase Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000484-13,0,0,0 2015-000484-13,4,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"AGIOS PHARMACEUTICALS, INC.","A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients with Pyruvate Kinase Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000484-13,0,0,0 2015-000486-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Anaesthesiology and Intensive Care, University of Tartu",The effect of milrinone on central and regional blood flow in preterm neonates undergoing patent ductus arteriosus ligation. Milrinooni toime tsentraalsele ja regionaalsele verevoolule enneaegsetel...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000486-31,0,0,0 2015-000488-15,1,2018-08-16,2018-08-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Leipzig,Vigilance regulation as predictor of response to Psychostimulants in adult patients with ADHD Vigilanzregulation als Prädiktor der Response auf Psychostimulanzien bei adulten Patienten mit ADHS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000488-15,0,0,0 2015-000492-27,1,2019-06-27,2019-06-27,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Intérêt du cyclophosphamide associé aux corticostéroïdes dans le traitement des EXcerbations Aiguës de FIbrose Pulmonaire idiopathique - un essai randomisé,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000492-27,0,0,0 2015-000493-35,7,2019-11-13,2019-11-13,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"IONIS PHARMACEUTICALS, INC.","A Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients with Partial Lipodystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000493-35,0,0,0 2015-000493-35,7,2019-11-13,2019-11-13,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Ionis Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients with Partial Lipodystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000493-35,0,0,0 2015-000493-35,7,2019-11-13,2019-11-13,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Isis Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients with Partial Lipodystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000493-35,0,0,0 2015-000493-35,7,2019-11-13,2019-11-13,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Akcea Therapeutics,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients with Partial Lipodystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000493-35,0,0,0 2015-000493-35,7,2019-11-13,2019-11-13,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Akcea Therapeutics, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients with Partial Lipodystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000493-35,0,0,0 2015-000499-89,1,2017-06-20,2017-06-20,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Royal College Of Surgeons Ireland,To measure the effects of Aspirin loading dose of 300mgs in healthy controls using AA LTA and the Dynamic Platelet Function Assay (DPFA).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000499-89,0,0,0 2015-000500-26,1,,,0,0,1,0,0,0,2,0,0,4,0,0,0,0,1,Rapidscan Pharma Solutions EU Ltd (RPS EU Ltd),"An Open-label, Single Ascending-dose, Pharmacokinetic and Safety Study of Regadenoson (Rapidscan®) in Paediatric Patients with Cardiovascular Conditions and Diseases",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000500-26,0,0,0 2015-000502-19,1,2022-05-31,2022-05-31,1,0,0,0,0,0,4,0,1,1,0,0,0,0,0,"Medical University of Vienna, Department of Psychiatry and Psychotherapy","Effects of sex steroid hormones on serotonin synthesis and degradation measured with PET Effekte von Sexualhormonen auf Serotoninsynthese und -Abbau, gemessen mit PET",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000502-19,0,0,0 2015-000505-39,1,2017-07-18,2017-07-18,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,CHU de Bordeaux,The role of dexchlorpheniramine (Polaramine®) to prevent hemodynamic instability after separation from cardiopulmonary bypass during cardiac surgery. Intérêt de la dexchlorphéniramine (Polaramine®)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000505-39,0,0,0 2015-000507-44,5,2019-02-21,2019-07-04,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ipsen Innovation,"A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT® F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000507-44,0,0,0 2015-000508-24,1,2017-03-23,2017-03-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Newcastle Upon Tyne Hospitals NHS Trust,A Feasibility Study of Bezafibrate in Mitochondrial Myopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000508-24,0,0,0 2015-000510-22,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,Banc de Sang i Teixits,CLINICAL EFFICACY OF PLATELET GEL FROM CORD BLOOD FOR THE TREATMENT OF DIABETIC FOOT ULCERS EFICACIA CLÍNICA DEL GEL DE PLAQUETAS DE SANGRE DE CORDÓN UMBILICAL PARA EL TRATAMIENTO DE ÚLCERAS DEL PI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000510-22,0,0,0 2015-000511-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Inserm-ANRS,"Phase II, randomized, multicentric, clinical trial of a therapeutic vaccination, with ex vivo generated autologous Dentritic Cells pulsed with HIV lipopetides, combined or not with a TLR-3 agonist (po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000511-40,0,0,0 2015-000512-18,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,Genzyme Corporation Inc,"A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000512-18,0,1,1 2015-000515-41,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000515-41,0,0,0 2015-000515-41,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Pfizer Inc,"A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000515-41,0,0,0 2015-000515-41,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,PFIZER INC,"A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000515-41,0,0,0 2015-000518-23,4,2017-01-25,2017-01-25,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,OPHTHOTECH CORPORATION,"A phase 2b randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista® (Anti-PDGFBB pegylated aptamer) administered in combination with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000518-23,0,0,0 2015-000519-42,2,2017-01-20,2017-01-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,OPHTHOTECH CORPORATION,Role of multimodal imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month Phase 2a open label study of Fovista® (anti-PDGF therapy) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000519-42,0,0,0 2015-000519-42,2,2017-01-20,2017-01-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"IVERIC bio, Inc.",Role of multimodal imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month Phase 2a open label study of Fovista® (anti-PDGF therapy) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000519-42,0,0,0 2015-000520-29,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,1,apceth GmbH & Co. KG,Treatment of Advanced Gastrointestinal Adenocarcinoma in a Phase I/II trial with modified allogeneic MSC_apceth_111 Behandlung von fortgeschrittenen Adenokarzinomen des Gastrointestinaltraktes in e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000520-29,0,0,0 2015-000530-30,1,2017-04-03,2017-04-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Center for Cancer Immune Therapy,T cell therapy for patients with advanced Ovarian Cancer T celle terapi til patienter med metastatisk ovariecancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000530-30,0,0,0 2015-000531-32,5,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Novo Nordisk A/S,"A randomised, multinational, active-controlled,(open-labelled), dose finding, (double-blinded), parallel group trial investigating efficacy and safety of once-weekly NNC0195-0092 treatment compared to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000531-32,0,0,0 2015-000535-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,"Phase II, Open-Label Study to Evaluate Safety and Explore Efficacy of Escalating Doses of Bevacizumab-IRDye800CW as an Optical Imaging Agent to Detect Cancer Tissue Delineation During Tumor Resection ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000535-33,0,0,0 2015-000537-69,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Universitair Ziekenhuis Brussel,Real time monitoring of blood propofol concentration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000537-69,0,0,0 2015-000538-31,1,2021-08-27,2021-08-27,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité University medicine Berlin,NEUORIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the knee joint NEUORIMPA - Intraartikuläre Applikation von Opioiden bei chronischer Arthritis des Kniegelenks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000538-31,0,0,0 2015-000541-24,9,2019-09-06,2019-09-06,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017",A Multicenter Open-Label Study of Etanercept Withdrawal and Retreatment in Subjects with Non-Radiographic Axial Spondyloarthritis who Achieved Adequate 24 Week Response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000541-24,0,0,0 2015-000541-24,9,2019-09-06,2019-09-06,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pfizer Inc.,A Multicenter Open-Label Study of Etanercept Withdrawal and Retreatment in Subjects with Non-Radiographic Axial Spondyloarthritis who Achieved Adequate 24 Week Response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000541-24,0,0,0 2015-000541-24,9,2019-09-06,2019-09-06,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",A Multicenter Open-Label Study of Etanercept Withdrawal and Retreatment in Subjects with Non-Radiographic Axial Spondyloarthritis who Achieved Adequate 24 Week Response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000541-24,0,0,0 2015-000541-24,9,2019-09-06,2019-09-06,8,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017",A Multicenter Open-Label Study of Etanercept Withdrawal and Retreatment in Subjects with Non-Radiographic Axial Spondyloarthritis who Achieved Adequate 24 Week Response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000541-24,0,0,0 2015-000543-16,6,2016-09-20,2016-09-20,6,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000543-16,0,0,0 2015-000545-22,1,2018-01-25,2018-01-25,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Aarhus University hospital,"Effects of Tranexamic Acid on on Intra- and Postoperative bleeding, Blood transfusion and Coagulation in Children Undergoing Craniosynostosis Surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000545-22,0,0,0 2015-000547-17,3,2019-12-30,2019-12-30,3,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"Five Prime Therapeutics, Inc.","A Phase 1/2 Study of FPA008, an anti-CSF1 Receptor Antibody, in Patients with Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (dt-TGCT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000547-17,0,0,0 2015-000549-21,1,2017-02-20,2017-02-20,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,King's College London,MAGnetic versus STAndard technique for sentinel node biopsy in breast cancer compared in a Randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000549-21,0,0,0 2015-000549-21,1,2017-02-20,2017-02-20,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Guy's and St. Thomas' NHS Foundation Trust,MAGnetic versus STAndard technique for sentinel node biopsy in breast cancer compared in a Randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000549-21,0,0,0 2015-000550-37,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,LUMC,"Effect of Sodium NItroprusside (SNP) on R,S- and S-Ketamine-induced psychotropic side effects, hemodynamic changes and pain relief in healthy volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000550-37,0,0,0 2015-000554-38,4,2017-06-11,2017-06-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ipsen Innovation,"A Phase III, Multicenter, Double Blind, Randomised, Placebo Controlled Study to Assess the Efficacy and the Safety of a Single Cycle of Dysport Solution in the Treatment of Upper Limb Spasticity in Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000554-38,0,0,0 2015-000554-38,4,2017-06-11,2017-06-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,IPSEN INNOVATION,"A Phase III, Multicenter, Double Blind, Randomised, Placebo Controlled Study to Assess the Efficacy and the Safety of a Single Cycle of Dysport Solution in the Treatment of Upper Limb Spasticity in Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000554-38,0,0,0 2015-000555-24,4,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,AMC MEDICAL RESEARCH B.V.,"Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Determine the Efficacy and Safety of Vedolizumab in Prevention of Endoscopic Recurrence of Crohn's Disease in Patients with Ileo-colo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000555-24,0,0,0 2015-000555-24,4,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Academic Medical Center Amsterdam,"Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Determine the Efficacy and Safety of Vedolizumab in Prevention of Endoscopic Recurrence of Crohn's Disease in Patients with Ileo-colo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000555-24,0,0,0 2015-000556-14,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS,Vaccination with dendritic cells pulsed with autologous tumor homogenate in combination with HD-IL2 and immunomodulating radiotherapy in metastatic RCC: a phase II trial (RENALVax-2) Vaccination wi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000556-14,0,0,0 2015-000557-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Vall de Hebron Hospital,Immunogenicity and efficacy of the vaccine against Hepatitis B virus in immunosuppressed patients antiHBc positive with low titers of anti-HBs. Assessment of clinical usefulness in preventing reactiva...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000557-21,0,0,0 2015-000558-40,4,2017-02-06,2017-02-06,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A multicenter, randomised, double blind, placebo-controlled, incomplete block, 3-way cross-over study to evaluate the efficacy and safety of 4 doses of glycopyrronium bromide DPI in moderate to severe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000558-40,0,0,0 2015-000561-31,12,2018-09-15,2018-10-23,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Polichem S.A.,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, VEHICLE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF P-3058 10% NAIL SOLUTION IN THE TREATMENT OF ONYCHOMYCOSIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000561-31,0,0,0 2015-000563-14,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"Holbæk Sygehus, Region Sjælland i Danmark",GDT in Urgent Abdominal Surgery - A Clinical Randomized Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000563-14,0,0,0 2015-000568-32,1,2019-09-30,2019-09-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Universität Köln,Obinutuzumab containing conditioning regimen for CLL patients and patients with Richter`s transformation requiring an allogeneic stem cell transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000568-32,0,0,0 2015-000569-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS ISTITUTO GIANNINA GASLINI,"Ofatumumab in children with steroid- and calcineurin-inhibitor-resistant nephrotic syndrome: a double-blind randomized, controlled, superiority trial Uso di Ofatumumab nei bambini affetti da sindro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000569-30,0,0,0 2015-000570-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II,Prophylaxis of Hepatitis B reactivation in patients with HBV occult infection and rheumatological diseases candidates to immune suppressive treatments of finite duration. PROFILASSI DELLA RIATTIVAZ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000570-35,0,0,0 2015-000574-35,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,1,"Visterra, Inc.","A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Antiviral Activity of a Single Intravenous Dose of VIS410 in Healthy Subjects after a Viral Inocul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000574-35,0,0,0 2015-000575-27,14,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000575-27,0,0,0 2015-000577-13,1,,,0,0,0,1,1,0,1,0,0,1,1,1,0,1,0,Oslo University Hospital,Therapeutic effects of BNP in uncontrolled hypertensive patients 1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000577-13,0,0,0 2015-000578-37,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,Maastricht University Medical Centre+,The effect of Nandrolone Decanoate Injection and Leucine Supplementation on Muscle Loss During Immobilisation Het effect van nandrolone decanoate injectie en leucine supplementen op spierverlies t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000578-37,0,0,0 2015-000580-14,1,2020-01-09,2020-01-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UNICANCER,"A single arm, open-label, phase II study to assess the efficacy of rucaparib in metastatic breast cancer patients with a BRCAness genomic signature.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000580-14,0,0,0 2015-000581-58,1,2018-08-01,2018-08-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Revmatologicky ustav Praha,"A Randomized, Biomarker Trial to Predict Therapeutic Responses of Patients with Rheumatoid Arthritis to a Specific Biologic Mode of Action Randomizovaná studie biomarkerů predikce terapeutické odp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000581-58,0,0,0 2015-000582-31,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,Genzyme Corporation Inc,"An Exploratory, Open-Label Study of the Safety and Efficacy of High Dose or High Dosing Frequency Myozyme® (alglucosidase alfa) Treatment in Patients with Pompe Disease Who Do Not Have an Optimal Resp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000582-31,0,1,1 2015-000583-34,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,Genzyme Corporation Inc,An Exploratory Study of the Safety and Efficacy of Immune Tolerance Induction (ITI) in Patients with Pompe Disease Who Have Previously Received Myozyme,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000583-34,0,1,1 2015-000584-14,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,Genzyme Corporation Inc,An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naïve CRIM(-) Patients with Infantile-Onset Pompe Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000584-14,0,1,1 2015-000585-61,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,"Genzyme, a Sanofi Company","A Multicenter, Multinational, Open-Label Study of Anti-Laronidase Antibody Formation and Urinary GAG Levels in Patients with Mucopolysaccaridosis I (MPS I) Being Treated with Aldurazyme® (laronidase)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000585-61,0,1,1 2015-000590-12,1,2015-10-05,2015-10-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A 24-month multi-center, open-label, randomized, controlled study to evaluate the evolution of renal function in maintenance liver transplant recipients receiving either RAD001 (everolimus) plus reduc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000590-12,0,0,0 2015-000592-27,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Helsinki University Central Hospital,Immunodeficiency in cartilage-hair hypoplasia: sub-project on safety of vaccination against chickenpox,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000592-27,0,0,0 2015-000595-10,2,2016-07-14,2016-07-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MedImmune Ltd,"A Phase 2a, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects with Moderate-to-Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000595-10,0,0,0 2015-000596-27,1,2018-01-19,2018-01-19,1,1,0,0,1,1,2,0,1,1,0,0,1,0,1,Janssen Vaccines & Prevention BV,"A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-Boost Regimens of the Candidate Prophylactic Vaccines for Ebola A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000596-27,0,0,0 2015-000602-18,1,2020-07-24,2020-07-24,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,"National Heart, Lung, and Blood Institute (NHLBI)","A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus Host-Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000602-18,0,0,0 2015-000604-25,1,2020-05-28,2020-05-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Danish Cancer Society Research Center,HBOT LYCA: Hyperbaric Oxygen Therapy to reduce Lymphoedema after Breast Cancer - an explorative clinical trial HBOT LYCA: Hyperbar Oxygen Terapi for at reducere lymfødem efter bryst kræft - en eksp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000604-25,0,0,0 2015-000606-20,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Pfizer, Inc.","Four Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disord...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000606-20,0,1,1 2015-000607-15,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc,26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000607-15,0,1,1 2015-000608-24,1,2015-04-09,2015-04-09,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,Aarhus University Hospital,TMS Electrochemotherapy for Glioblastoma Multiforme TMS elektrokemoterapi - ny behandling af glioblastom hjernekræft,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000608-24,0,0,0 2015-000609-38,9,2017-09-26,2018-01-29,6,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Allergan Limited,"A Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000609-38,1,0,0 2015-000609-38,9,2017-09-26,2018-01-29,6,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"MedImmune, Ltd, a wholly owned subsidiary of AstraZeneca UK","A Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000609-38,1,0,0 2015-000609-38,9,2017-09-26,2018-01-29,6,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"MEDIMMUNE, LLC","A Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000609-38,1,0,0 2015-000609-38,9,2017-09-26,2018-01-29,6,1,0,0,0,0,2,0,0,2,1,0,0,0,1,MedImmune Limited,"A Phase 2B Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000609-38,1,0,0 2015-000612-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Hospital of North Norway,Significance of intrauterine progestogen therapy in endometrial proliferative conditions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000612-17,0,0,0 2015-000617-43,13,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS FARMA S.P.A.,"MONALEESA-3: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2-ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000617-43,0,0,0 2015-000617-43,13,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"MONALEESA-3: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2-ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000617-43,0,0,0 2015-000617-43,13,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"MONALEESA-3: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2-ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000617-43,0,0,0 2015-000617-43,13,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","MONALEESA-3: A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of men and postmenopausal women with hormone receptor positive, HER2-ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000617-43,0,0,0 2015-000618-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Västra Götalandsregionen/NÄL,Treatment of osteoradionecrosis (ORN) with pentoxifylline and α-tocopherol (PENTO) Behandling av osteoradionekros (ORN) med pentoxifyllin och α-tokoferol (PENTO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000618-23,0,0,0 2015-000619-42,1,2019-12-31,2019-12-31,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,FIBICO,"An open, Phase II, clinical trial to evaluate the effectiveness of decreased intestinal absorption of phosphorus in the progression of renal disease in patients with metabolic syndrome Ensayo clíni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000619-42,0,0,0 2015-000620-28,15,2019-04-12,2019-04-12,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis groupe,"A Multi-Country, Multicenter, Single-Arm, Open-Label Study to Document the Safety, Tolerability and Effect of Alirocumab on atherogenic lipoproteins in High Cardio-Vascular Risk Patients With Severe H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000620-28,0,0,0 2015-000624-28,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,IRCCS ISTITUTO GIANNINA GASLINI,"Ofatumumab versus Rituximab in children with steroid and calcineurin inhibitor-dependent idiopatic nephrotic syndrome: an open-label, randomized, controlled, superiority trial. Ofatumumab versus Ri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000624-28,0,0,0 2015-000625-37,1,2018-10-25,2018-10-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Blue Earth Diagnostics Limited,"A phase 3, open-label study to assess the clinical utility of fluciclovine (18F) PET/CT in patients with prostate cancer with biochemical recurrence after radical treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000625-37,0,0,0 2015-000629-35,1,2016-11-10,2016-11-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Plymouth Hospitals NHS Trust,(Feasibility) Open label Randomised Controlled Trial of Hyperoxic O2 Therapy vs. Normoxic O2 Therapy in Sepsis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000629-35,0,0,0 2015-000630-30,6,2019-06-18,2019-06-25,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AXON NEUROSCIENCE SE,"“ADAMANT” A 24-months randomised, placebo-controlled, parallel group, double blinded, multi centre, phase 2 study to assess safety and efficacy of AADvac1 applied to patients with mild Alzheimer’s dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000630-30,0,0,0 2015-000630-30,6,2019-06-18,2019-06-25,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AXON Neuroscience SE,"“ADAMANT” A 24-months randomised, placebo-controlled, parallel group, double blinded, multi centre, phase 2 study to assess safety and efficacy of AADvac1 applied to patients with mild Alzheimer’s dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000630-30,0,0,0 2015-000632-15,6,2017-03-13,2017-03-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Coherus BioSciences, Inc.","A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-1420 Versus Humira® in Subjects With Chronic Plaque Psoriasis (PsOsim)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000632-15,0,0,0 2015-000634-29,10,2018-08-13,2018-08-13,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS PEMETREXED OR DOCETAXEL IN ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON SMALL CELL LUNG CANCER PATIENTS PREVIOUSLY TREATED ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000634-29,0,0,0 2015-000634-29,10,2018-08-13,2018-08-13,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.","RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS PEMETREXED OR DOCETAXEL IN ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON SMALL CELL LUNG CANCER PATIENTS PREVIOUSLY TREATED ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000634-29,0,0,0 2015-000634-29,10,2018-08-13,2018-08-13,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"RANDOMIZED, MULTICENTER, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VERSUS PEMETREXED OR DOCETAXEL IN ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON SMALL CELL LUNG CANCER PATIENTS PREVIOUSLY TREATED ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000634-29,0,0,0 2015-000636-15,1,2016-12-31,2016-12-31,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Bangor University,A randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000636-15,0,0,0 2015-000640-42,4,2017-01-31,2017-01-31,2,1,0,0,0,1,4,0,0,1,0,0,1,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000640-42,0,0,0 2015-000640-42,4,2017-01-31,2017-01-31,2,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co.KG,"A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000640-42,0,0,0 2015-000640-42,4,2017-01-31,2017-01-31,2,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000640-42,0,0,0 2015-000640-42,4,2017-01-31,2017-01-31,2,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000640-42,0,0,0 2015-000641-23,1,2018-06-08,2018-06-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Central and North West London NHS Foundation Trust,Aggression Following TBI: Effectiveness of Risperidone (AFTER)-a feasibility RCT.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000641-23,0,0,0 2015-000644-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU University medical center (VUmc),Laparoscopic advanced Imaging Techniques in Endometriosis therapy: LITE-study. A pilot trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000644-42,0,0,0 2015-000645-23,1,2016-06-02,2016-06-02,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,CIBER (Centro de Investigacion Biomedica en Red),"Safety, tolerability and efficacy of nocturnal hypertension treatment with domperidone in the sleep apnea-hypopnea syndrome. Pilot study. Seguridad, tolerabilidad y eficacia del tratamiento de la h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000645-23,0,0,0 2015-000650-38,2,2017-09-20,2017-09-20,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bone Therapeutics S.A.,"A Phase IIA, multicentre, open study on the safety and efficacy of allogeneic osteoblastic cells (ALLOB®) implantation in multiple non-infected delayed-union (DU) fractures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000650-38,0,0,0 2015-000654-38,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,"Akershus University Hospital, Norway",Secondary prophylaxis after hip fracture. An evaluation og two organisational models based on choise of treatment: a comparison of efficacy and applicability of hospital based treatment with zoledron...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000654-38,0,0,0 2015-000655-24,1,2016-05-10,2016-05-10,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,rigshospitalet,Denosumab and male infertility: a prospective intervention study Denosumab og mandlig infertilitet: et prospektivt interventionsstudie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000655-24,0,0,0 2015-000658-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region Jönköpings län,Randomized multicenter study of Acupressure combined with personalized antiemetics based on genetic variations (SNPs) in women undergoing neoadjuvant or adjuvant chemotherapy EC / FEC against breast c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000658-39,0,0,0 2015-000660-33,4,2016-03-21,2016-03-21,2,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Zafgen Inc.,"Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of Beloranib in Obese Subjects with Prader-Willi Syndrome to Evaluate Food-related Behavior, Total Body Weight, and Safety Over 52 Weeks",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000660-33,0,0,0 2015-000662-65,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, double-blind, randomized, placebo-controlled multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000662-65,0,0,0 2015-000665-30,4,2017-10-18,2017-10-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Coherus BioSciences, Inc.",An Open-Label Safety Extension Study (OLSES) Evaluating the Long term Safety and Durability of Response of CHS 0214 (CHS 0214-05),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000665-30,0,0,0 2015-000665-30,4,2017-10-18,2017-10-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"COHERUS BIOSCIENCES, INC.",An Open-Label Safety Extension Study (OLSES) Evaluating the Long term Safety and Durability of Response of CHS 0214 (CHS 0214-05),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000665-30,0,0,0 2015-000679-28,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,OSPEDALE SAN RAFFAELE,Prognostic value of 18F-FAZA PET/CT in high grade glioma: comparison with MRI and correlation with hypoxia biomarkers. Ruolo prognostico della PET/TC con 18F-FAZA nei gliomi ad alto grado: confront...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000679-28,0,0,0 2015-000681-55,2,2021-07-14,2021-07-14,1,1,0,1,0,0,1,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000681-55,1,0,0 2015-000681-55,2,2021-07-14,2021-07-14,1,1,0,1,0,0,1,0,0,2,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000681-55,1,0,0 2015-000682-30,1,2018-11-12,2018-11-12,1,1,1,0,0,1,3,0,1,1,0,0,1,0,0,Tartu University Hospital,Botulinum neurotoxin type A treatment for sialorrhea in central nervous system diseases LIIGSE SÜLJEERITUSE RAVI BOTULISMITOKSIINIGA NEURODEGENERATIIVSETE HAIGUSTEGA PATSIENTIDEL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000682-30,0,0,0 2015-000684-13,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,A Phase II study of the combination of Ofatumumab and Ibrutinib followed by allogeneic bone marrow transplant or consolidation for pretreated high risk patients with Chronic Lymphocytic Leukemia ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000684-13,0,0,0 2015-000686-32,1,2020-03-26,2020-03-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,German Heart Centre Munich,"Revacept, a novel inhibitor of platelet adhesion in patients with stable coronary artery disease undergoing elective percutaneous coronary interventions: A phase II, multicentre, randomised, dose-fin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000686-32,0,0,0 2015-000687-33,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Leiden University Medical Center,"Randomized placebo-controlled trial to investigate clinical efficacy, anti-inflammatory properties and safety of prednisolone in hand osteoarthritis: a proof-of-concept study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000687-33,0,0,0 2015-000690-13,1,2016-06-30,2016-06-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3b, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults with Chronic HCV Infection.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000690-13,0,0,0 2015-000691-94,1,2019-11-25,2019-11-25,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU de Bordeaux,Self-help program for hypnotics withdrawal in insomniac patients: A randomized controlled clinical trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000691-94,0,0,0 2015-000693-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",Phase II study on Lenvatinib in recurrent and/or metastatic adenoid cystic carcinomas (ACC) of the salivary glands of the upper aerodigestive tract Studio di fase II con Lenvatinib in pazienti affe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000693-35,0,0,0 2015-000696-27,1,2019-03-08,2019-03-08,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,prof. dr. M.A.F.J. van de Laar,Anakinra versus treatment as usual in the treatment of acute gout Anakinra versus standaardbehandeling bij acute jicht,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000696-27,0,0,0 2015-000697-35,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,"Genzyme, a Sanofi Company",Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The INFORM Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000697-35,0,1,1 2015-000699-91,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Fundació Hospital Vall Hebron Institut de Recerca,Two treatment strategies with Ribavirin for Chronic Hepatitis E and severe acute forms randomized study Estudio aleatorizado de dos estrategias de tratamiento con Ribavirina para la Hepatitis Cróni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000699-91,0,0,0 2015-000700-26,1,2016-09-30,2016-09-30,1,1,1,0,0,0,1,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A multicentre, open-label, single dose, phase 1 study to evaluate the pharmacokinetics, safety and tolerability of mirabegron oral suspension in pediatric subjects from 3 to less than 12 years of age ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000700-26,0,0,0 2015-000702-19,1,2017-02-27,2017-02-27,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,Haemostatic and Fibrinolytic Analysis of Low Molecular Weight Heparin Injections versus Unfractionated Heparin Infusion as Post-CABG Thromboprophylaxis Hæmostatisk og Fibrinolytisk Analyse af Lavm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000702-19,0,0,0 2015-000704-25,1,2018-12-11,2018-12-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Queen Mary University of London,Prevention of Aortic Stenosis Pilot Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000704-25,0,0,0 2015-000709-38,1,2016-06-23,2016-06-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Medical University of Graz,Acute Effects of Benzbromaron on the pulmonary circulation Akute Effekte von Benzbromaron auf die pulmonale Zirkulation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000709-38,0,0,0 2015-000711-40,5,2018-07-29,2018-07-29,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Diurnal Ltd,"A Phase III study of efficacy, safety and tolerability of Chronocort® compared with standard glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000711-40,0,0,0 2015-000716-18,8,2018-05-17,2018-05-17,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A 52 week, randomized, double blind, multinational, multicentre, active controlled, 2-arm parallel group trial comparing CHF 5993 100/6/12.5 µg pMDI (fixed combination of extrafine beclometasone dipro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000716-18,0,0,0 2015-000717-40,10,2018-05-28,2018-05-28,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A 52 week, randomized, double blind, multinational, multicentre, active controlled, 3-arm parallel group trial comparing CHF 5993 200/6/12.5 µg pMDI (fixed combination of extrafine beclometasone dipro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000717-40,0,0,0 2015-000717-40,10,2018-05-28,2018-05-28,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,CHIESI FARMACEUTICI S.P.A.,"A 52 week, randomized, double blind, multinational, multicentre, active controlled, 3-arm parallel group trial comparing CHF 5993 200/6/12.5 µg pMDI (fixed combination of extrafine beclometasone dipro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000717-40,0,0,0 2015-000725-37,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,"Gilead Sciences, Inc.",A Phase 1 Study to Evaluate the Bioavailability of Boosted Age-Appropriate Pediatric Elvitegravir (EVG) Tablet or Suspension Formulation Compared with Adult EVG 150 mg Tablets in Healthy Adult Volunte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000725-37,0,1,1 2015-000726-11,3,2019-05-31,2019-05-31,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Shire Viropharma, Inc.",A randomized double-blind placebo-controlled study to evaluate the efficacy and safety of Cinryze® (C1 esterase inhibitor [human]) for the treatment of acute antibody-mediated rejection in kidney tran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000726-11,0,0,0 2015-000727-85,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Tenofovir DF as Part of an Optimized Antiretroviral Regimen in HIV-1-Infected Adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000727-85,0,1,1 2015-000728-27,7,2018-09-05,2018-09-05,7,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Seqirus UK Limited,"A Phase III, Randomized, Observer-Blind, Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000728-27,0,0,0 2015-000730-30,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Hull and East Yorkshire Hospitals NHS Trust,A randomised clinical trial comparing endovenous laser ablation and mechanochemical ablation (ClariVein®) in the management of superficial venous insufficiency.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000730-30,0,0,0 2015-000733-76,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Goethe-Universität Frankfurt, Universitätsklinikum, Med. Klinik II","A multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lympho-bl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000733-76,0,0,0 2015-000734-30,6,2021-12-17,2021-12-17,5,1,0,0,0,0,4,0,0,2,1,0,0,0,1,AstraZeneca AB,"An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000734-30,1,0,0 2015-000735-32,9,2020-09-07,2020-09-07,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000735-32,1,0,0 2015-000735-32,9,2020-09-07,2020-09-07,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000735-32,1,0,0 2015-000736-15,5,2018-02-27,2018-02-27,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Alcon Research, Ltd.",Additive Effect of Twice Daily Brinzolamide 1% /Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000736-15,0,0,0 2015-000748-41,1,2017-12-01,2017-12-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Exeter,Autoimmune Diabetes Accelerator Prevention Trial (adAPT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000748-41,0,0,0 2015-000749-21,1,2019-05-10,2019-05-10,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Hochschule Hannover,Botulinumtoxin A for emotional stabilization in borderline personality disorder Botulinumtoxin A zur emotionalen Stabilisierung bei der Borderline-Persönlichkeitsstörung,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000749-21,0,0,0 2015-000751-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jaro Karppinen,"ZOLEDRONIC ACID, A LONG-ACTING BISPHOSPHONATE, FOR CHRONIC LOW BACK PAIN DUE TO MODIC CHANGES: A RANDOMIZED CONTROLLED TRIAL Zoledronihappo, pitkävaikutteinen bisfosfonaatti, Modic muutoksiin liitt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000751-25,0,0,0 2015-000752-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Helsinki,The efficacy of adalimumab and conventional antirheumatic drugs in alleviating axial and aortic inflammation detected in PET/CT in patients with axial spondyloarthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000752-20,0,0,0 2015-000753-20,1,,,0,1,1,0,0,1,2,0,0,1,0,0,0,1,1,"Alexion Pharmaceuticals, Inc.","A PHASE I/II OPEN LABEL STUDY IN MPS IIIB SUBJECTS TO INVESTIGATE THE SAFETY, BIODISTRIBUTION, PHARMACOKINETICS, AND PHARMACODYNAMICS/EFFICACY OF SBC-103 ADMINISTERED INTRAVENOUSLY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000753-20,0,0,0 2015-000754-38,5,2020-09-30,2020-09-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Science Ireland Unlimited Company,"A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed dose combination r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000754-38,0,0,0 2015-000754-38,5,2020-09-30,2020-09-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen Sciences Ireland UC,"A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed dose combination r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000754-38,0,0,0 2015-000754-38,5,2020-09-30,2020-09-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed dose combination r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000754-38,0,0,0 2015-000758-39,5,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,"Department of Hematology, Aarhus University Hospital","A Phase 1/2 study of the combination of pixantrone, etoposide, bandamustine and, in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T-cell phenotyp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000758-39,0,0,0 2015-000762-65,1,2019-09-19,2019-09-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Technische Universität München, School of Medicine, represented by Dean",Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000762-65,0,0,0 2015-000790-13,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,"FAES FARMA, S.A.","A single-centre, randomized, double-blind, crossover, single-dose clinical trial to compare bilastine, desloratadine, rupatadine and placebo in the suppression of wheal and flare induced by intraderma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000790-13,0,0,0 2015-000793-36,1,2017-08-08,2017-08-08,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Rigshospitalet, Copenhagen University Hospitals",Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia in Patients following Groin-Hernia-Repair. A companion study to: Pharmacokinetics of High-dose Target-controlled Naloxo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000793-36,0,0,0 2015-000796-28,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Fundacio Clinic per a la Recerca Biomèdica,"A pilot, single-blind, placebo-controlled study to assess efficacy and safety of interfascial blockade of the painful trapezius muscle in patients with fribromyalgia EFICACIA Y SEGURIDAD DEL BLOQUE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000796-28,0,0,0 2015-000799-92,8,2017-04-03,2017-04-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Groupe,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Alirocumab in insulin treated patients with type 1 or type 2 diabetes and with hypercholeste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000799-92,0,0,0 2015-000799-92,8,2017-04-03,2017-04-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-AVENTIS GROUPE,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Alirocumab in insulin treated patients with type 1 or type 2 diabetes and with hypercholeste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000799-92,0,0,0 2015-000799-92,8,2017-04-03,2017-04-03,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis Group,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Alirocumab in insulin treated patients with type 1 or type 2 diabetes and with hypercholeste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000799-92,0,0,0 2015-000801-38,2,2017-08-14,2017-08-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research Limited,"A two-arm, randomised, assessor-blind, parallel group study to evaluate the effect of fluticasone/formoterol breath actuated inhaler (BAI) and Relvar Ellipta DPI on ventilation heterogeneity in subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000801-38,0,0,0 2015-000804-24,5,2017-11-07,2017-11-07,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase III study to Evaluate the Glycemic Efficacy and Renal Safety of dapagliflozin in patients with Type 2 Diabetes Mellit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000804-24,0,0,0 2015-000809-39,1,2018-03-08,2018-03-08,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Alexion Pharma International Sàrl,"An Open-label, Multicenter, Expanded Access Program for Asfotase Alfa (human recombinant tissue-nonspecific alkaline phosphatase fusion protein) Treatment for Patients with Infantile- or Juvenile-onse...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000809-39,0,0,0 2015-000814-23,6,2018-08-20,2018-08-20,2,1,0,0,0,1,2,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,"A Phase II, open label, multi-center, multi-arm study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of anaplastic lymphoma k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000814-23,1,0,0 2015-000814-23,6,2018-08-20,2018-08-20,2,1,0,0,0,1,2,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase II, open label, multi-center, multi-arm study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of anaplastic lymphoma k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000814-23,1,0,0 2015-000814-23,6,2018-08-20,2018-08-20,2,1,0,0,0,1,2,0,0,2,1,0,0,0,1,NOVARTIS PHARMA SERVICES AG,"A Phase II, open label, multi-center, multi-arm study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of anaplastic lymphoma k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000814-23,1,0,0 2015-000815-42,1,2022-08-30,2022-08-30,1,0,0,0,0,0,2,0,1,1,0,0,0,0,0,"Rigshospitalet, Copenhagen University Hospitals",Pharmacokinetics of High-dose Target-controlled Naloxone Infusion. Companion study to: Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia in Patients following Groin-Hern...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000815-42,0,0,0 2015-000817-32,1,,,0,1,0,0,0,0,4,0,1,3,0,0,0,0,0,University of Oxford,Assessment of post booster antibody responses in UK infants given a reduced priming schedule of meningococcal serogroup B and 13 valent pneumococcal conjugate vaccines,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000817-32,0,0,0 2015-000820-27,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,1,"Inmunotek, S.L.","Double blind, placebo-controlled, dose finding, prospective, multicenter clinical trial for the treatment of rhinitis/rinoconjuntivitis against a mixture of Dermatophagoides pteronyssinus and Dermatop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000820-27,0,0,0 2015-000821-35,1,2021-05-27,2021-05-27,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,Radboud University Medical Center,Visualizing beta cells after Intrahepatic Islet of Langerhans Transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000821-35,0,0,0 2015-000825-35,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,Rigshospitalet Blegdamsvej,"The effect of the glucagon-like peptide-1 analogue, liraglutide (Victoza®), on jejunostomy output and intestinal absorption in short bowel syndrome patients, a double-blind cross-over study Effekte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000825-35,0,0,0 2015-000826-13,4,2016-10-26,2016-10-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,The Medicines Company,"A placebo-controlled, double-blind, randomized trial to compare the effect of treatment on plaque burden as determined by intravascular ultrasound and to evaluate the efficacy, pharmacokinetics, safet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000826-13,0,0,0 2015-000827-94,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,UMC Utrecht,A phase I/II post cord blood HCT dendritic cells vaccination trial directed against WT1 for pediatric acute myeloid leukemia: the U-DANCE-anti-AML trial Een fase I/II onderzoek naar dendritische ce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000827-94,0,0,0 2015-000828-28,1,,,0,0,0,0,1,1,3,0,0,0,0,0,0,0,0,UMC Utrecht,Titlle: Subcutaneous immunoglobulins with rHuPH20 in multifocal motor neuropathy (MMN) It is an interventional cross-over study where the use of the combination of subcutaneous immunoglobulins toget...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000828-28,0,0,0 2015-000829-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dutch Pancreatitis Study Group,Fluid hydration to prevent post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis: the FLUYT-prevent trial. a multicenter randomized controlled superiority trial. Intraveneuze voch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000829-37,0,0,0 2015-000832-13,4,,,0,0,0,0,0,2,2,0,0,3,0,0,0,0,0,Plymouth Hospitals NHS Trust,"Randomised, open label study of rituximab/ibrutinib vs rituximab/chemotherapy in older patients with untreated mantle cell lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000832-13,0,0,0 2015-000832-13,4,,,0,0,0,0,0,2,2,0,0,3,0,0,0,0,0,University Hospitals Plymouth NHS Trust,"Randomised, open label study of rituximab/ibrutinib vs rituximab/chemotherapy in older patients with untreated mantle cell lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000832-13,0,0,0 2015-000833-64,1,2017-02-10,2017-02-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU Amiens-Picardie,Comparaison de trois biomédicaments en termes d’évolution des sous-populations lymphocytaires régulatrices et pro-inflammatoires chez des patients atteints de polyarthrite rhumatoïde.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000833-64,0,0,0 2015-000839-33,2,2018-03-28,2018-03-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharma A/S,Safety and Effect of LEO 90100 aerosol foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) with Plaque Psoriasis A phase 2 trial evaluating the safety and effic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000839-33,0,0,0 2015-000841-22,1,2015-12-21,2015-12-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A randomised, double-blind, two-way crossover study to investigate the effect of inhaled fluticasone furoate on short-term growth in paediatric subjects with asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000841-22,0,0,0 2015-000846-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Stockholm South General Hospital,"Effects on re-endothelialisation with Bydureon treatment add on to Insulin versus Insulin alone, both in combination with Metformin in type 2 diabetic subjects (Rebuild Study).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000846-42,0,0,0 2015-000849-23,2,2022-07-19,2022-07-19,1,0,0,0,0,1,4,0,0,2,0,0,0,0,1,B. Braun Melsungen AG,"A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL TRIAL ON HOME PARENTERAL NUTRITION USING AN OMEGA-3 FATTY ACID ENRICHED MCT/LCT LIPID EMULSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000849-23,1,0,0 2015-000850-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Assessment of Loading with the P2Y12 inhibitor Ticagrelor or clopidogrel to Halt ischemic Events in patients Undergoing elective coronary Stenting: the ALPHEUS study. Hodnocení účinku úvodní dávky...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000850-39,0,0,0 2015-000852-12,5,2018-03-31,2018-11-14,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Takeda Development Centre Europe, Ltd.",A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Proportion of Subjects With Fistula Healing in 2 Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment of Fistulizing Crohn's Di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000852-12,0,0,0 2015-000856-16,1,2015-07-03,2015-07-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Lluita contra la SIDA,Removal of dolutegravir by hemodialysis in HIV-infected patients with end-stage renal disease. ESTUDIO EXPLORATORIO PARA EVALUAR LA EXTRACCIÓN DE DOLUTEGRAVIR POR LA HEMODIÁLISIS EN PACIENTES INFEC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000856-16,0,0,0 2015-000857-19,2,2017-06-21,2017-06-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Phase 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults with Asthma Inadequately Con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000857-19,0,0,0 2015-000860-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud University Medical Center,"Personalizing enzalutamide (Xtandi®) therapy by understanding the relation between the decrease in the expression profile of a panel of preselected microRNAs, tumor related mRNAs and treatment respons...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000860-32,0,0,0 2015-000865-29,6,2018-01-24,2018-01-31,4,1,1,0,0,0,3,0,0,1,1,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients with Uncontrolled Asthma and Elevated Blood Eosinophils",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000865-29,0,0,0 2015-000866-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS,"Feasibility, efficacy and safety of Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin and Doxorubicin in patients with peritoneal carcinomatosis from colorectal, ov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000866-72,0,0,0 2015-000868-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ZKES GmbH,"Randomized, placebo controlled phase III trial of a microbiological concomitant therapy/prevention of chemotherapeutical induced diarrhea (caused by inflammation and an impaired intestinal barrier) wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000868-34,0,0,0 2015-000870-36,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Maxima Medical center,Epiphysiodesis for adolescents; what is the most effective postoperative pain treatment? An RCT Epifysiodese bij adolescenten; wat is de meest effectieve postoperatieve pijnstilling? Een RCT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000870-36,0,0,0 2015-000871-28,7,2019-03-12,2019-03-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed on Regimens containing ABC/3TC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000871-28,0,0,0 2015-000871-28,7,2019-03-12,2019-03-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed on Regimens containing ABC/3TC",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000871-28,0,0,0 2015-000872-89,1,2018-11-12,2018-11-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford,ANODE: a randomised controlled trial of prophylactic ANtibiotics to investigate the prevention of infection following Operative vaginal DElivery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000872-89,0,0,0 2015-000874-36,1,2019-10-15,2019-10-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Norfolk and Norwich University Hospitals NHS Trust,The efficacy and safety of two topical antiseptic solutions for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: a feasibility study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000874-36,0,0,0 2015-000875-28,1,2016-12-15,2016-12-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,NHS Blood & Transplant,"A multi-centre, randomised, double blind, placebo-controlled trial evaluating the effects of early administration of fibrinogen concentrate in adults with major traumatic haemorrhage. E-FIT 1 Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000875-28,0,0,0 2015-000881-73,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Rennes,"Multicentre, cross-over, PRAgmatic trial in Atopic Dermatitis testing long-term control effectiveness of new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supple...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000881-73,0,0,0 2015-000882-29,1,2019-12-31,2019-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Reinier de Graaf Groep,Spinal hyperbaric Prilocaine 2% 60 or 80 mg: a dosing study in day care patients. Prilocaine 2% hyperbaar voor spinaal anesthesie 60 of 80 mg: een doseringsstudie bij dagbehandelingspatienten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000882-29,0,0,0 2015-000886-30,2,2017-04-20,2018-12-13,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicentre Phase II Study of AZD1775 plus Chemotherapy in Patients with Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000886-30,0,0,0 2015-000887-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Västra Götalandsregionen/NÄL,Prophylactic treatment of osteoradionecrosis (ORN) with pentoxifylline and α-tocopherol (PENTO) Profylaktisk behandling av osteoradionekros (ORN) med pentoxifyllin och α-tokoferol (PENTO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000887-32,0,0,0 2015-000891-85,2,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Phase 2 Open-Label Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients < 18 years of age with CLN2 Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000891-85,0,0,0 2015-000891-85,2,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,BioMarin Pharmaceutical Inc,"A Phase 2 Open-Label Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients < 18 years of age with CLN2 Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000891-85,0,0,0 2015-000892-28,10,2017-10-05,2017-10-05,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A 52-Week Multicenter, Randomized, Blinded, Parallel Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis Studio di 52sett...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000892-28,0,0,0 2015-000892-28,10,2017-10-05,2017-10-05,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A 52-Week Multicenter, Randomized, Blinded, Parallel Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis Studio di 52sett...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000892-28,0,0,0 2015-000892-28,10,2017-10-05,2017-10-05,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A 52-Week Multicenter, Randomized, Blinded, Parallel Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis Studio di 52sett...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000892-28,0,0,0 2015-000894-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS,Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer: a phase II study Vaccinazione complementare con cellule...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000894-11,0,0,0 2015-000896-28,3,2017-02-15,2017-02-18,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Baxalta Innovations GmbH,"A Phase 2a Randomized, Open-Label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination with 5-FU/Leucovorin or Panitumumab versus Standard of Care in Subjects with Metastatic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000896-28,0,0,0 2015-000897-36,1,,,0,1,0,0,0,0,3,0,0,0,0,0,0,0,1,AB science,"A prospective, multicentre, double-blind, randomized, placebo-controlled, phase 3 study to evaluate efficacy and safety of masitinib with irinotecan in patients with advanced-stage esophagogastric ade...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000897-36,0,0,0 2015-000904-24,5,2017-09-27,2018-01-12,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc","A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington's Disease Studio multicentrico in aperto finalizzato alla valutazione d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000904-24,0,0,0 2015-000904-24,5,2017-09-27,2018-01-12,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC","A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington's Disease Studio multicentrico in aperto finalizzato alla valutazione d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000904-24,0,0,0 2015-000905-38,5,2019-04-25,2019-05-23,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pharmacyclics LLC,"A randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of the Bruton?s Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000905-38,0,0,0 2015-000905-38,5,2019-04-25,2019-05-23,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PHARMACYCLICS SWITZERLAND GMBH,"A randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of the Bruton?s Tyrosine Kinase inhibitor ibrutinib in combination with nab-paclitaxel and gemcitabine versus placebo in co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000905-38,0,0,0 2015-000906-20,1,2015-07-24,2015-07-24,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Shire Human Genetic Therapies Inc,"An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients with Alagille Syndrome (ALGS) or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000906-20,0,0,0 2015-000907-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,MPDL3280A treatment in patients with locally advanced or metastatic solid tumors after or during investigational imaging,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000907-19,0,0,0 2015-000914-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"DIPARTIMENTO DI SCIENZE BIOMEDICHE SPERIMENTALI E CLINICHE, UNIVERSITà DI FIRENZE","Cardiac toxicity prevention in non-metastatic breast cancer patients treated with anthracycline-based chemotherapy: a randomized, placebo controlled, phase 3 trial - SAFE trial. MONITORAGGIO E PREV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000914-23,0,0,0 2015-000915-42,1,2016-03-16,2016-03-16,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHRU de Brest,Comparaison de l’injection d’un bolus d’analogue d’insuline rapide avant ou après le repas chez des patients diabétiques de type 1 traités par pompe à insuline.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000915-42,0,0,0 2015-000922-12,10,2017-06-02,2017-06-02,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Teva Pharmaceutical Industries, Ltd","A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000922-12,0,0,0 2015-000922-12,10,2017-06-02,2017-06-02,9,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC","A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Treated with Subcutaneous In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000922-12,0,0,0 2015-000923-10,1,2017-05-03,2017-05-03,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,BASQUE HEALTH SYSTEM,Evaluation of the efficacy and safety of administering lidocaine spray in oesophagogastroduodenoscopies: A randomized clinical trial. Evaluación de la eficacia y seguridad de la administración de l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000923-10,0,0,0 2015-000925-36,3,2017-11-29,2017-11-29,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A 12-month randomized, multiple dose, open-label study evaluating safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of an anti-CD40 monoclonal antibody, CFZ533, in combinat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000925-36,0,0,0 2015-000925-36,3,2017-11-29,2017-11-29,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,"A 12-month randomized, multiple dose, open-label study evaluating safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of an anti-CD40 monoclonal antibody, CFZ533, in combinat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000925-36,0,0,0 2015-000927-96,1,2019-03-20,2019-03-20,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU of Rennes,Treatment of chronic subdural hematoma by corticosteroids : a prospective randomized study Traitement par corticoïdes des hématomes sous-duraux chroniques : une étude prospective randomisée,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000927-96,0,0,0 2015-000929-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GOELAMS,EPAG 2015 : A phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag administered to elderly patients with acute myeloid leukemia receiving induction chemotherapy ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000929-37,0,0,0 2015-000934-31,15,2016-10-03,2016-10-13,9,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Innocoll Pharmaceuticals Limited,"A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination with Systemic Antibiotic Therapy in Diabetic Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000934-31,1,0,0 2015-000934-31,15,2016-10-03,2016-10-13,9,0,0,0,0,0,3,0,0,2,0,0,0,0,1,INNOCOLL PHARMACEUTICALS LIMITED,"A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination with Systemic Antibiotic Therapy in Diabetic Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000934-31,1,0,0 2015-000937-54,9,2018-08-30,2018-08-30,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,DRUG DELIVERY SOLUTIONS ApS (PART OF MC2 BIOTEK GROUP),"A phase II, multicenter, randomized, double-masked, 4 parallel arms, controlled 6-month trial designed to evaluate the safety and efficacy of PAD ciclosporin (CsA 0.06% and 0.03%) ophthalmic dispersio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000937-54,0,0,0 2015-000937-54,9,2018-08-30,2018-08-30,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MC2 Therapeutics Ltd.,"A phase II, multicenter, randomized, double-masked, 4 parallel arms, controlled 6-month trial designed to evaluate the safety and efficacy of PAD ciclosporin (CsA 0.06% and 0.03%) ophthalmic dispersio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000937-54,0,0,0 2015-000937-54,9,2018-08-30,2018-08-30,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,DRUG DELIVERY SOLUTIONS ApS,"A phase II, multicenter, randomized, double-masked, 4 parallel arms, controlled 6-month trial designed to evaluate the safety and efficacy of PAD ciclosporin (CsA 0.06% and 0.03%) ophthalmic dispersio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000937-54,0,0,0 2015-000939-33,17,2019-01-18,2019-03-11,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,TAKEDA DEVELOPMENT CENTRE EUROPE LTD,"A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000939-33,0,0,0 2015-000939-33,17,2019-01-18,2019-03-11,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Takeda Development Centre Europe, Ltd.","A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000939-33,0,0,0 2015-000943-17,1,2018-07-12,2018-07-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Radboudumc,Tight control dose reductions of biologics in psoriasis patients with low disease activity: a randomized pragmatic trial. Dosis reductie van biologics op geleide van ziekteactiviteit in psoriasis p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000943-17,0,0,0 2015-000944-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","A PILOT STUDY TO TEST THE FEASIBILITY OF A TWO-ARM, DOUBLE BLIND, PARALLEL-GROUP, RANDOMIZED CONTROLLED TRIAL FOR THE COMPARISON OF THE DURATION OF THE ANALGESIC EFFICACY OF A SINGLE MATRIX TRANSDERMA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000944-41,0,0,0 2015-000946-41,6,2020-02-07,2020-02-07,5,1,0,0,1,0,2,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Jan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000946-41,1,0,0 2015-000946-41,6,2020-02-07,2020-02-07,5,1,0,0,1,0,2,0,0,2,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Jan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000946-41,1,0,0 2015-000946-41,6,2020-02-07,2020-02-07,5,1,0,0,1,0,2,0,0,2,0,0,0,0,1,Geron Corporation,"A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Jan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000946-41,1,0,0 2015-000948-42,8,2018-12-20,2018-12-20,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ- 54861911 in Subjects who are Asymptomatic At Risk for Develop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000948-42,1,0,0 2015-000948-42,8,2018-12-20,2018-12-20,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ- 54861911 in Subjects who are Asymptomatic At Risk for Develop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000948-42,1,0,0 2015-000950-39,21,2016-05-27,2021-02-02,20,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000950-39,0,0,0 2015-000950-39,21,2016-05-27,2021-02-02,20,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000950-39,0,0,0 2015-000950-39,21,2016-05-27,2021-02-02,20,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000950-39,0,0,0 2015-000950-39,21,2016-05-27,2021-02-02,20,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER AG,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000950-39,0,0,0 2015-000952-11,12,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,"TESARO, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000952-11,0,0,0 2015-000952-11,12,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,"TESARO, INCORPORATED","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000952-11,0,0,0 2015-000952-11,12,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,TESARO Inc.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000952-11,0,0,0 2015-000952-11,12,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,"TESARO, Inc. a GSK company","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000952-11,0,0,0 2015-000955-25,1,,,0,0,0,0,1,0,2,0,0,4,0,0,0,0,0,Centre Hospitalier Régional Universitaire de Nancy,"Evaluation of the efficiency of folinic acid in children with autism spectrum disorders: a pilot study ""EFFET"" Évaluation de l’efficacité de l’acide folinique chez les enfants présentant des troubl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000955-25,0,0,0 2015-000958-38,3,2017-06-30,2017-06-30,2,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"LFB USA, INC.","A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Pediatric Patients from birth to <12 years old with Inhibitors...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000958-38,1,0,0 2015-000958-38,3,2017-06-30,2017-06-30,2,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"LFB USA, Inc.","A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Pediatric Patients from birth to <12 years old with Inhibitors...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000958-38,1,0,0 2015-000959-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Abteilung für Augenheilkunde, AKH Linz",Clinical characterization of the treatment of diabetic macular edema with aflibercept in an outpatient setting by evaluation of a regional network of ophthalmologic care givers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000959-24,0,0,0 2015-000962-76,9,2018-05-22,2018-05-22,7,1,0,1,0,0,1,0,0,1,0,0,0,0,1,BAYER AG,Single-dose study testing a rivaroxaban dry powder formulation for oral suspension in children from 6 months to 12 years with previous thrombosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000962-76,0,0,0 2015-000962-76,9,2018-05-22,2018-05-22,7,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bayer Health Care AG,Single-dose study testing a rivaroxaban dry powder formulation for oral suspension in children from 6 months to 12 years with previous thrombosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000962-76,0,0,0 2015-000962-76,9,2018-05-22,2018-05-22,7,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bayer AG,Single-dose study testing a rivaroxaban dry powder formulation for oral suspension in children from 6 months to 12 years with previous thrombosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000962-76,0,0,0 2015-000963-15,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,University of Edinburgh,MAcrophage Therapy for Liver Cirrhosis (MATCH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000963-15,0,0,0 2015-000963-15,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,NHS Lothian,MAcrophage Therapy for Liver Cirrhosis (MATCH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000963-15,0,0,0 2015-000964-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Erasmus Medical Center, Department of Anesthesiology",Dexmedetomidine versus propofol in awake implantation of a neuromodulative system. Dexmedetomidine versus propofol tijdens de implantatie van een neuromodulatief systeem,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000964-33,0,0,0 2015-000965-30,8,2019-03-15,2019-03-15,7,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A Phase IIIB, non-randomized, open-label, multi-country, multi-centric cross-vaccination study to evaluate the safety of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine when administered intram...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000965-30,0,0,0 2015-000965-30,8,2019-03-15,2019-03-15,7,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase IIIB, non-randomized, open-label, multi-country, multi-centric cross-vaccination study to evaluate the safety of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine when administered intram...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000965-30,0,0,0 2015-000965-30,8,2019-03-15,2019-03-15,7,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A Phase IIIB, non-randomized, open-label, multi-country, multi-centric cross-vaccination study to evaluate the safety of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine when administered intram...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000965-30,0,0,0 2015-000966-72,8,2019-08-01,2019-08-08,6,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Biogen Idec Research Limited,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000966-72,1,0,0 2015-000967-15,9,2019-08-01,2019-08-05,7,1,0,0,0,0,3,0,0,2,1,0,0,0,1,BIOGEN IDEC RESEARCH LIMITED,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000967-15,1,0,0 2015-000967-15,9,2019-08-01,2019-08-05,7,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Biogen Idec Research Limited,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000967-15,1,0,0 2015-000968-34,1,2021-03-25,2021-03-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A Phase IV single arm, multicenter, open-label study assessing deep molecular response in adult patients with newly diagnosed Philadelphia chromosome positive CML in chronic phase after two years of t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000968-34,0,0,0 2015-000972-88,12,2021-06-06,2022-06-06,8,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,","A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000972-88,1,0,0 2015-000972-88,12,2021-06-06,2022-06-06,8,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.","A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000972-88,1,0,0 2015-000972-88,12,2021-06-06,2022-06-06,8,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Merck Sharp & Dohme Corp.,"A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000972-88,1,0,0 2015-000972-88,12,2021-06-06,2022-06-06,8,0,0,0,0,0,3,0,0,2,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000972-88,1,0,0 2015-000978-35,1,2016-03-01,2016-03-01,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University Hospital Tübingen,Statin Treatment of Oxysterol Pathology in SPG5: a Randomized Controlled Trial -Proof of Principle Therapie der Oxysterol-Pathologie bei Patienten mit SPG5: Eine randomisierte kontrollierte Stdie ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000978-35,0,0,0 2015-000979-27,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics,"A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000979-27,0,1,1 2015-000981-70,7,2018-06-27,2018-06-29,6,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Centre Hospitalier Universitaire de Saint-Etienne,"A multicentre, randomised, double-blind, controlled, phase IIIb study to assess the efficacy and safety of Rivaroxaban 10mg od versus Enoxaparin 4000 IU for VTE PROphylaxis in NOn Major Orthopaedic Su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000981-70,1,0,0 2015-000982-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,Personalized pharmacological treatment of chronic obstructive pulmonary disease based on phenotyping: interventional study Terapia farmacologica personalizzata in pazienti con broncopneumopatia cro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000982-30,0,0,0 2015-000984-15,2,2016-02-08,2016-02-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergy Therapeutics (UK) Ltd,"A multi-centre, double-blind, placebo-controlled study to explore the safety and efficacy of Birch Modified Allergen Tyrosine adsorbed + MPL (POLLINEX® Quattro Plus 1.0 mL Birch [PQ Birch]) in subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000984-15,0,0,0 2015-000988-14,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,PROMETHERA Biosciences S.A./N.V.,"Title: Open, Prospective, Historic-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Infusion of Liver Cell Suspension (HHLivC) in Children with Urea Cycle Disorders",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000988-14,0,1,1 2015-000990-11,19,2020-04-13,2020-04-14,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer HealthCare AG,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000990-11,0,0,0 2015-000990-11,19,2020-04-13,2020-04-14,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000990-11,0,0,0 2015-000990-11,19,2020-04-13,2020-04-14,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000990-11,0,0,0 2015-000990-11,19,2020-04-13,2020-04-14,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BAYER AG,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000990-11,0,0,0 2015-000992-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"Krka, d.d., Novo mesto",A comparison of the severity of acute pain and the frequency of chronic pain after post-operative analgesia of lower and higher intensity following surgical emptying of the axillary gland in breast ca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000992-28,0,0,0 2015-000995-88,1,2018-07-30,2018-07-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pierre Fabre Médicament,"Study of efficacy and safety of V0305 solution in children suffering from Iron Deficiency Anaemia (IDA). Phase 3, multicentre, single arm open-label study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-000995-88,0,0,0 2015-001000-58,1,2020-06-29,2020-06-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR),COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI trial Terapia combinada en el infarto de miocardio: The COMBAT-MI trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001000-58,0,0,0 2015-001001-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,¿A randomized placebo controlled phase II study with metformin in metabolic-unbalanced breast cancer survivors at higher risk for recurrence (MetBreCS)¿ ¿Studio randomizzato in doppio cieco di fase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001001-14,0,0,0 2015-001005-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Parc Taulí,Randomized open label clinical trial to compare two regimens of intravenous iron therapy after colorectal neoplastic surgery. Ensayo clínico aleatorizado abierto que compara dos pautas de ferrotera...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001005-13,0,0,0 2015-001006-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Centre Groningen (UMCG),Groningen Intervention study for the Preservation of cardiac function with sodium thiosulfate after ST-segment elevation myocardial infarction Groningen Interventiestudie voor de preservatie van de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001006-34,0,0,0 2015-001012-35,3,2018-12-03,2018-12-03,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"GTx, Inc.","A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001012-35,1,0,0 2015-001020-27,9,2020-11-10,2020-11-10,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) Studio clinico di ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001020-27,1,0,0 2015-001020-27,9,2020-11-10,2020-11-10,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc",A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) Studio clinico di ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001020-27,1,0,0 2015-001022-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Holy Stone Healthcare Co., Ltd.","A Phase 2a, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of IBD98-M Delayed-release Capsules to Induce Remission in Patients with Active, Mild to Moderate Ulcerative...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001022-42,0,0,0 2015-001023-23,1,2017-12-22,2017-12-22,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,Imperial College London,A Phase I clinical trial to assess the safety and immunogenicity of HIV DNA-C CN54ENV immunisations administered via the Intramuscular and Intradermal methods with and without electroporation followed...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001023-23,0,0,0 2015-001030-16,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics Inc.,"A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adoles...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001030-16,0,1,1 2015-001033-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO,The management of post-operative pain nia patients undergoing cardiac surgery mini - invasive minithoracotomy : Randomized trial La gestione del dolore post-operatorio nei pazienti sottoposti a chi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001033-24,0,0,0 2015-001035-20,1,2019-03-11,2019-03-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,DRK-Blutspendedienst NSTOB,"Phase III, randomized, double-blind, multicentre clinical trial on clinical efficacy and safety of platelet concentrates treated with the THERAFLEX UV-Platelets procedure in comparison to conventional...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001035-20,0,0,0 2015-001039-18,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,"Astellas Pharma Korea, Inc.","Open-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf [Cap.]®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticost...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001039-18,0,1,1 2015-001040-11,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Astellas Pharma China, Inc.","A Multicentre, Open-Label, Randomized, Controlled Study of Long-Term Intermittent Maintain Treatment with 0.03% Tacrolimus Ointment in Pediatric Patient with Moderate to Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001040-11,0,1,1 2015-001041-83,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Astellas Pharma Canada Inc.,"Clinical and Laboratory Evaluation of Acute Rejection, Myocyte Growth, Repair, and Oxidative Stress Following de novo Cardiac Transplant: A Comparison between Tacrolimus- and Cyclosporine- based Immun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001041-83,0,1,1 2015-001042-28,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Ortho-McNeil Janssen Scientific Affairs LLC,"Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral and Cognitive Effects of CONCERTA on Older Children with ADHD (The ABC Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001042-28,0,1,1 2015-001043-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Pharmacokinetics of Lorazepam Oral Liquid in Paediatric ICU Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001043-37,0,0,0 2015-001047-36,4,2017-08-16,2017-08-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK. S.P.A.,Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in combination with Insulin Degludec in Adults with Type 1 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001047-36,0,0,0 2015-001047-36,4,2017-08-16,2017-08-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapid® both in combination with Insulin Degludec in Adults with Type 1 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001047-36,0,0,0 2015-001048-12,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,GEIS (Grupo Español de Investigación en Sarcomas),"Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line setting for patients with metastatic and/or unresectable KIT/PDGFR Wild Type GIST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001048-12,0,0,0 2015-001048-12,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,GRUPO ESPAñOL DE INVESTIGACIóN EN SARCOMAS,"Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line setting for patients with metastatic and/or unresectable KIT/PDGFR Wild Type GIST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001048-12,0,0,0 2015-001049-10,1,2016-02-03,2016-02-03,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,AbbVie Deutschland GmbH & Co. KG,"Open-label Study to Evaluate the Safety and Efficacy of the Combination of Ombitasvir, Paritaprevir/r ± Dasabuvir with Ribavirin (RBV) in Adult Patients with GT1 or GT4 Chronic HCV Infection and Respo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001049-10,0,0,0 2015-001050-16,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,GILEAD SCIENCES INCORPORATED,A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects with Chronic Hepatitis B Infection. Studio di registro di follow-up a lungo termine di soggetti trattati i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001050-16,0,0,0 2015-001059-63,1,2019-03-05,2019-03-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Aalborg University,BONATHIAD - Bone Association with Thiazide Diuretics.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001059-63,0,0,0 2015-001065-76,1,2020-02-19,2020-02-19,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Blocage du Récepteur de l’Angiotensine II chez des sujets atteints de syndrome d’Ehlers Danlos vasculaire : essai muliticentrique randomisé contrôlé en double insu contre placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001065-76,0,0,0 2015-001070-18,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Janssen-Cilag Taiwan,The Effective and Tolerable Titration Scheme and Dosage in Children with Attention-deficit hyperactivity disorder Treated with OROS-Methylphenidate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001070-18,0,1,1 2015-001072-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Turku University Hospital,Clinical and virological efficacy of pegylated interferon alpha in the treatment of rhinovirus infection in patients with primary hypogammaglobulinemia: randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001072-22,0,0,0 2015-001076-22,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"Fujisawa Healthcare, Inc.","A PHASE II, OPEN-LABEL, MULTI-CENTER STUDY TO ASSESS THE PHARMACOKINETICS, LONG-TERM SAFETY AND TOLERABILITY OF TACROLIMUS IN STABLE PEDIATRIC LIVER TRANSPLANT PATIENTS CONVERTED FROM A PROGRAF® BASED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001076-22,0,1,1 2015-001077-40,3,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Turku University Hospital,INNOVATIVE STEROID TREATMENT TO REDUCE ASTHMA DEVELOPMENT IN CHILDREN AFTER FIRST-TIME RHINOVIRUS INDUCED WHEEZING – THE INSTAR STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001077-40,0,0,0 2015-001077-40,3,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,St. Olavs Hospital,INNOVATIVE STEROID TREATMENT TO REDUCE ASTHMA DEVELOPMENT IN CHILDREN AFTER FIRST-TIME RHINOVIRUS INDUCED WHEEZING – THE INSTAR STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001077-40,0,0,0 2015-001077-40,3,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,St Olavs Hospital HF,INNOVATIVE STEROID TREATMENT TO REDUCE ASTHMA DEVELOPMENT IN CHILDREN AFTER FIRST-TIME RHINOVIRUS INDUCED WHEEZING – THE INSTAR STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001077-40,0,0,0 2015-001081-26,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Ortho-McNeil Janssen Scientific Affairs LLC,"The ABC Study: A Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral, and Cognitive Effects of CONCERTA on Older Children with ADHD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001081-26,0,1,1 2015-001084-39,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Janssen Korea Ltd,"Efficacy and learning skill after OROS Methylphenidate treatment in adolescents with Attention-Deficit/Hyperactivity Disorder: A 12-week, multi-center, open-label study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001084-39,0,1,1 2015-001086-50,1,2017-04-08,2017-04-08,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Køge Sygehus,Treatment of hypoglycemia following gastric bypass surgery Behandling af hypoglykæmi efter gastric bypass,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001086-50,0,0,0 2015-001088-38,18,2016-06-30,2016-06-30,1,0,0,0,2,1,3,0,0,2,1,0,0,0,1,Bayer AG,"A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001088-38,1,0,0 2015-001088-38,18,2016-06-30,2016-06-30,1,0,0,0,2,1,3,0,0,2,1,0,0,0,1,BAYER HEALTHCARE AG,"A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001088-38,1,0,0 2015-001088-38,18,2016-06-30,2016-06-30,1,0,0,0,2,1,3,0,0,2,1,0,0,0,1,Bayer HealthCare AG,"A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001088-38,1,0,0 2015-001090-40,1,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,0,The London Clinic,An open label pilot study to investigate the effects of two preparations of hydrocortisone (Hydrocortisone 100mg/ml and Solu-Cortef) injected intramuscularly into the deltoid and upper thigh muscle du...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001090-40,0,0,0 2015-001092-49,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Sahlgrenska Akademien Wallenberglaboratoriet,Valproic acid regulation of plasma PAI-1 Valproinsyras reglering av plasma PAI-1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001092-49,0,0,0 2015-001093-17,1,2018-09-10,2018-09-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside,Proof of concept study to assess downstream effects of using combined intranasal fluticasone propionate plus azelastine nasal spray on asthmatic inflammation in patients with persistent asthma and all...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001093-17,0,0,0 2015-001096-43,1,2019-03-23,2019-03-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHRU de Tours,Treatment of superficial voluminous complicated slow-flow vascular malformations with sirolimus: a phase 2 trial in children observational-phase designed,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001096-43,0,0,0 2015-001097-18,13,2022-08-22,2022-08-22,7,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001097-18,1,0,0 2015-001097-18,13,2022-08-22,2022-08-22,7,0,0,0,0,1,3,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinum-based First Line Chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001097-18,1,0,0 2015-001098-42,9,2017-08-16,2017-08-16,6,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Ablynx NV,"A Phase III double-blind, randomized, parallel group, multicenter placebo-controlled trial to study the efficacy and safety of caplacizumab in patients with acquired thrombotic thrombocytopenic purpur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001098-42,1,1,0 2015-001098-42,9,2017-08-16,2017-08-16,6,1,1,0,0,1,3,0,0,2,0,0,0,0,1,ABLYNX NV,"A Phase III double-blind, randomized, parallel group, multicenter placebo-controlled trial to study the efficacy and safety of caplacizumab in patients with acquired thrombotic thrombocytopenic purpur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001098-42,1,1,0 2015-001101-14,1,2017-08-11,2017-08-11,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,"Driving fitness under acute and subchronic application of Silexan® (WS® 1265) in comparison to placebo and Lorazepam with healthy volunteers in two successive, randomized, double-blind, crossover desi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001101-14,0,0,0 2015-001102-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,"Optimizing Ponatinib USe (OPUS). Studio GIMEMA di fase 2 sull¿efficacia e sul profilo di rischio di ponatinib, 30 mg al giorno, in pazienti con Leucemia Mieloide Cronica (LMC) in Fase Cronica, resiste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001102-34,0,0,0 2015-001103-31,1,2016-06-16,2016-06-16,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Autoimmune Technologies, LLC","A Phase 2a, Randomized, Double-blind, Placebo-controlled Assessment of the Safety and Protective Efficacy of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Healthy Adult Subjects who a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001103-31,0,0,0 2015-001105-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,"Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, single-arm, two-stage, phase 2 study. Regorafenib monotherapy as second-line ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001105-13,0,0,0 2015-001106-33,14,2021-03-11,2021-03-11,11,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled multicenter study of secukinumab 150 mg in patients with active non-radiographic axial spondyloarthritis to evaluate the safety, tolerability and efficac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001106-33,1,0,0 2015-001106-33,14,2021-03-11,2021-03-11,11,1,0,0,0,0,3,0,0,2,1,0,0,0,1,NOVARTIS PHARMA SERVICES AG,"A randomized, double-blind, placebo-controlled multicenter study of secukinumab 150 mg in patients with active non-radiographic axial spondyloarthritis to evaluate the safety, tolerability and efficac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001106-33,1,0,0 2015-001106-33,14,2021-03-11,2021-03-11,11,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Farmacéutica S.A.,"A randomized, double-blind, placebo-controlled multicenter study of secukinumab 150 mg in patients with active non-radiographic axial spondyloarthritis to evaluate the safety, tolerability and efficac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001106-33,1,0,0 2015-001108-76,1,2017-05-31,2017-05-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Herlev Hospital, Department of Anaesthesiology I65N9","""AnAnkle Trial"": Peripheral nerve block vs. spinal anaesthesia for ankle fracture surgery – implications on pain profile and quality of recovery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001108-76,0,0,0 2015-001109-15,1,2020-02-18,2020-02-18,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,INSTITUTO DE INVESTIGACION SANITARIA LA FE,A Phase III clinical trial randomized and blinded on the use of inhaled tobramycin compared with placebo in patients undergoing mechanical ventilation and colonized by Gram negative bacteria for effec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001109-15,0,0,0 2015-001110-97,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Consorci Mar Parc de Salut de Barcelona,DEXMEDETOMIDINA VERSUS PROPOFOL FOR SEDATION DURING ECOBRONCHOSCOPY DEXMEDETOMIDINA VERSUS PROPOFOL PARA SEDACIÓN EN ECOBRONCOSCOPIAS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001110-97,0,0,0 2015-001111-12,3,2021-11-23,2021-11-23,3,0,0,1,0,1,1,0,0,1,1,0,0,0,1,Boehringer Ingelheim B.V.,"An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001111-12,0,0,0 2015-001111-12,3,2021-11-23,2021-11-23,3,0,0,1,0,1,1,0,0,1,1,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001111-12,0,0,0 2015-001111-12,3,2021-11-23,2021-11-23,3,0,0,1,0,1,1,0,0,1,1,0,0,0,1,SCS Boehringer Ingelheim Comm.V,"An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001111-12,0,0,0 2015-001112-35,5,2020-05-14,2020-06-11,4,1,0,0,0,0,2,0,0,1,1,0,1,0,0,Queen Mary University of London,A phase II study investigating preoperative MPDL3280A in operable transitional cell carcinoma of the bladder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001112-35,0,0,0 2015-001119-11,1,2018-05-16,2018-05-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Oryx GmbH & Co KG,"A non-controlled, single arm, open label, Phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer Eine nicht-kontrolliert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001119-11,0,0,0 2015-001120-29,4,2017-12-13,2017-12-13,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Genmab A/S,Dose-escalating and cohort expansion safety trial of tissue factor specific antibody drug conjugate tisotumab vedotin (HuMax®-TF-ADC) in patients with locally advanced and/or metastatic solid tumors k...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001120-29,0,0,0 2015-001122-42,3,2017-02-17,2017-02-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Phase II, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lebrikizumab in patients with chronic obstructive pulmonary disease and a history of exacerbations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001122-42,0,0,0 2015-001123-22,1,2020-11-24,2020-11-24,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,AIO-Studien-gGmbH,"A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients with Metastatic Squamous - Non-Small Cell Lung C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001123-22,0,0,0 2015-001126-41,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,1,University Hospitals Leuven,The effect of transversus abdominis plane block on postoperative analgesia after combined spinal epidural anesthesia for Cesarean delivery. Het effect van een TAP-blok op de postoperatieve pijnbest...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001126-41,0,0,0 2015-001127-24,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Tampere Heart Hospital,Pharmacokinetics of enoxaparin after coronary artery bypass graft surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001127-24,0,0,0 2015-001128-52,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,Alexion Pharma International Sàrl,"A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Historical Control Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ENB-0040 (Human Recombinant Tissue-Nonsp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001128-52,0,1,1 2015-001129-17,4,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,AOP Orphan Pharmaceuticals AG,"A multicenter, open-label study to investigate the effectiveness and safety of AOP Landiolol in controlling supraventricular tachycardia in pediatric patients (LANDI-PED).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001129-17,0,0,0 2015-001135-20,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Södertälje sjukhus AB,Volume kinetics for 20% albumin in conscious and anaesthetized humans with and without inflammation. Volymkinetik för 20% albumin hos vakna och sövda människor med och utan inflammation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001135-20,0,0,0 2015-001136-37,2,2016-07-05,2016-07-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Rottapharm Biotech S.r.l.,"A randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy, safety and tolerability of CR4056 administered for 2 weeks in patients with osteoarthritis of the knee wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001136-37,0,0,0 2015-001138-10,3,2019-04-08,2019-04-08,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Ipsen Pharma SAS,"Efficacy of diosmectite (Smecta®) in the symptomatic treatment of acute diarrhoea in adults. A multicentre, randomised, double-blind, placebo-controlled, parallel groups study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001138-10,0,0,0 2015-001141-80,1,2019-05-06,2019-05-06,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Andrés Poveda,Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 in combination with olaparib in patients with advanced solid tumors Estudio de Fase Ib/II para evaluar la eficacia y la tolera...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001141-80,0,0,0 2015-001142-28,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Fondazione EMN Italy Onlus,"A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE III STUDY OF POMALIDOMIDE-DEXAMETHASONE (Pom-dex) versus POMALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE (Pom-cyclo-dex) IN MULTIPLE MYELOMA (MM) PATIENTS WHO E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001142-28,0,0,0 2015-001145-93,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Étude pharmacocinétique de la lidocaïne par voie intraveineuse en chirurgie bariatrique - Etude SPIRAL (Safety Profile of IntRAvenous Lidocaïne use in coelioscopic bariatric surgery) Étude pharmac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001145-93,0,0,0 2015-001146-29,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Hospital Central de la Defensa,Selective local anesthesia versus a combined medication injection with corticosteroids in degenerartive spine TRATAMIENTO CON ANESTESIA LOCAL SELECTIVA FRENTE A LA INFILTRACIÓN LOCAL COMBINADA CON ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001146-29,0,0,0 2015-001150-15,1,2019-03-18,2019-03-18,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,MEDDAY PHARMACEUTICALS,"SERENDEM study: MD1003 in patients suffering from demyelinating neuropathies, an open label pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001150-15,0,0,0 2015-001151-68,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Technische Universität Dresden,A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLines-based chemotherapy (AIDA regimen) for patient with newLy diagnose...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001151-68,0,0,0 2015-001151-68,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,FUNDACION PETHEMA,A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLines-based chemotherapy (AIDA regimen) for patient with newLy diagnose...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001151-68,0,0,0 2015-001151-68,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Technische Universitt Dresden,A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLines-based chemotherapy (AIDA regimen) for patient with newLy diagnose...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001151-68,0,0,0 2015-001151-68,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,TECHNISCHE UNIVERSITäT DRESDEN,A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLines-based chemotherapy (AIDA regimen) for patient with newLy diagnose...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001151-68,0,0,0 2015-001152-29,12,2022-07-31,2022-08-31,4,0,1,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,201956: A Long-term Access Programme for Subjects with Severe Asthma who Participated in a GSK-sponsored Mepolizumab Clinical Study 201956: Programma di accesso a lungo termine per soggetti con asm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001152-29,1,0,0 2015-001152-29,12,2022-07-31,2022-08-31,4,0,1,0,0,0,3,0,0,2,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,201956: A Long-term Access Programme for Subjects with Severe Asthma who Participated in a GSK-sponsored Mepolizumab Clinical Study 201956: Programma di accesso a lungo termine per soggetti con asm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001152-29,1,0,0 2015-001154-14,4,2018-10-12,2018-10-12,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Takeda Development Centre Europe Ltd,"A Randomized, Double-Blind, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once Daily Oral Vonoprazan 20 mg or Vonoprazan 40 mg Compared to Esomeprazole 40 mg for the Treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001154-14,0,0,0 2015-001157-32,4,2017-03-17,2017-04-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Albireo AB,An Exploratory Phase II Study to demonstrate the Safety and Efficacy of A4250 in Children with Cholestatic Pruritus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001157-32,0,0,0 2015-001166-26,10,2022-04-04,2022-04-04,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001166-26,1,0,0 2015-001167-39,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Sanofi S.p.A.,"Studio nazionale, randomizzato, controllato, in aperto, a gruppi paralleli per confrontare l’efficacia e la sicurezza di due diversi approcci con algoritmo di titolazione (gestito dal medico vs gestit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001167-39,0,0,0 2015-001172-21,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,Genzyme Japan K.K.,"A Phase 1, Open-label, Multi-center Study of Clofarabine in Japanese Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001172-21,0,1,1 2015-001173-41,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,Genzyme Corporation,"An Open-Label, Multi-Center Safety and Tolerability Pilot Combination Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Patients with Acute Lymphoblasti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001173-41,0,1,1 2015-001174-18,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,Genzyme Corporation,A Phase I/II Dose-Escalation Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemias,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001174-18,0,1,1 2015-001179-36,4,2018-11-26,2018-11-26,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,RedHill Biopharma Ltd.,"A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately to Severely ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001179-36,0,0,0 2015-001181-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Venter Pharma S.L.,"Evaluation of the impact of LacTEST on diagnostic thinking and on patient management, and of the reproducibility (Test-Retest), for the diagnosis of hypolactasia in adults and elderly patients present...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001181-26,0,0,0 2015-001183-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación PETHEMA,Lenalidomide and dexamethasone (Ld) versus Clarithromycin / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as initial therapy in Multiple Myeloma. Lenalidomida y dexametasona (Ld) versus Claritrom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001183-19,0,0,0 2015-001184-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASL 5 SPEZZINO,Assessing Florbetaben PET Patterns in MCI Patients for an Improved Prediction of Conversion to AD Valutazione della distribuzione regionale delle placche di β-amiloide tramite PET cerebrale con Neu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001184-39,0,0,0 2015-001186-46,1,2018-05-10,2018-05-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,sanofi Belgium,"A 28-week, prospective, single-arm, open label phase 4 study to evaluate treatment optimization with once-daily insulin glargine HOE901-300 IU/ml in combination with prandial rapid-acting insulin anal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001186-46,0,0,0 2015-001189-24,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO,Oral vs Intravenous Aspirin administration in patients with ST-elevation Myocardial Infarction undergoing primary PCI. SOmministrazione oraLE vs enDOvenosa di aspirina in pazienti con infarto mioc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001189-24,0,0,0 2015-001190-40,1,2020-02-10,2020-02-10,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude prospective, randomisée, multicentrique des effets de l'administration du XARELTO ® (Rivaroxaban) au cours de la thrombose portale chronique.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001190-40,0,0,0 2015-001192-48,1,2020-09-10,2020-09-10,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,CHU CAEN,Traitement du ptosis des dystrophies musculaires oculo-pharyngées par autogreffes de myoblastes. Traitement du ptosis des dystrophies musculaires oculo-pharyngées par autogreffes de myoblastes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001192-48,0,0,0 2015-001195-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Sørlandet Hospital,"NoTOPain Novel Treatment Option for neuropathic Pain A randomized, cross-over, placebo-controlled, double-blind, single-center, phase II study of cetuximab in patients with treatment-refractory, non...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001195-21,0,0,0 2015-001196-46,1,2018-08-30,2018-08-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Medical University of Vienna,Effect of simvastatin withdrawal on ocular endothelial function,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001196-46,0,0,0 2015-001197-18,1,2017-06-12,2017-06-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Biogen Idec Norway,The effect of Tecfidera® (Dimethyl Fumarate) on the gut microbiota as a causal factor for GI associated adverse events.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001197-18,0,0,0 2015-001199-23,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,The Institute of Cancer Research,InPACT - International Penile Advanced Cancer Trial (International Rare Cancer Initiative),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001199-23,0,0,0 2015-001200-55,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region Östergötland,A single postoperative bisphosphonate infusion to improve patient reported function after hip or knee replacement.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001200-55,0,0,0 2015-001202-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA,"A preliminary, multicenter study on the relationship between cortical damage and blood brain barrier damage in Multiple Sclerosis patients with high cortical disease activity. Correlation between [11C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001202-34,0,0,0 2015-001206-33,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE SAN RAFFAELE,A pilot phase II study of a nucleoside sparing regimen of Dolutegravir + Atazanavir/r in HIV-1 infected patients with detectable viremia (Dolatav Study) A pilot phase II study of a nucleoside spari...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001206-33,0,0,0 2015-001208-80,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Grenoble University Hospital,β2-mimétiques et système nerveux central : effets du salbutamol sur l’excitabilité corticale et l’activation cérébrale (Betactiv),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001208-80,0,0,0 2015-001211-13,1,2019-03-21,2019-03-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,OSPEDALE SAN RAFFAELE,IMAGING OF NEUROINFLAMMATION AND NEURODEGENERATION IN ALZHEIMER’S DISEASE STUDIO DELLA NEUROINFIAMMAZIONE E NEURODEGENERAZIONE NELLA MALATTIA DI ALZHEIMER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001211-13,0,0,0 2015-001214-10,1,2017-12-31,2017-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Aalborg universitets hospital,Analgetic effect of perioperative klorzoxazon at total hip or knee arthroplasty Analgetisk effekt af perioperative klorzoxazon ved total hofte- og knæalloplastik,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001214-10,0,0,0 2015-001214-10,1,2017-12-31,2017-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Ortopædkirurgisk forskningsenhed, Aalborg universitetshospital",Analgetic effect of perioperative klorzoxazon at total hip or knee arthroplasty Analgetisk effekt af perioperative klorzoxazon ved total hofte- og knæalloplastik,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001214-10,0,0,0 2015-001216-35,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Johnson & Johnson Taiwan Ltd,From Immediate-release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001216-35,0,1,1 2015-001217-27,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Janssen Korea Ltd,An Open-label Prospective Trial to Evaluate Functional Outcomes of OROS Methylphenidate in Children with ADHD (FOSCO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001217-27,0,1,1 2015-001218-92,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Janssen Korea Ltd,"A prospective, open-labeled, multicenter study of optimal dosages of OROS-methylphenidate in treating children and adolescents with Attention-Deficit Hyperactivity Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001218-92,0,1,1 2015-001219-11,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Johnson & Johnson Pharmaceutical Research and Development, L.L.C.",A randomized double-blind (withdrawal) phase 3 study to evaluate the efficacy and tolerability of pancrelipase MT capsules compared with placebo in the treatment of subjects with cystic fibrosis-depen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001219-11,0,1,1 2015-001220-31,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Johnson & Johnson Pharmaceutical Research and Development, L.L.C.","Risperidone in the Treatment of Children and Adolescents With Autistic Disorder: A Double-Blind, Placebo-Controlled Study of Efficacy and Safety, Followed by an Open-Label Extension Study of Safety",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001220-31,0,1,1 2015-001221-16,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Janssen Cilag N.V./S.A,A Prospective Study of the Clinical Outcome Following Treatment Discontinuation After Remission in First-Episode Schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001221-16,0,1,1 2015-001222-42,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Johnson & Johnson Pharmaceutical Research and Development, L.L.C.","A double-blind trial comparing the efficacy, tolerability and safety of monotherapy topiramate versus phenytoin in subjects with seizures indicative of new onset epilepsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001222-42,0,1,1 2015-001223-23,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,"Johnson & Johnson Pharmaceutical Research and Development, L.L.C.","TOPAMAX (Topiramate) Initiated as Monotherapy in Epilepsy (TIME): A Multicenter, Outpatient, Open-Label, Study to Evaluate the Dosing, Effectiveness and Safety of TOPAMAX as Monotherapy in the Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001223-23,0,1,1 2015-001225-16,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,Johnson & Johnson Pharmaceutical Research & Development L.L.C,"An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Doripenem in Pediatric Subjects 6 to 17 Years of age, Inclusive, With Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001225-16,0,1,1 2015-001226-42,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","An Open-Label, Single-Dose Study to Assess the Safety of 500-mg Mebendazole Chewable Formulation in Children 2 to 10 Years of Age, Inclusive",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001226-42,0,1,1 2015-001234-22,1,2021-05-26,2021-05-26,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,Academic Medical Center,"A randomized placebo-controlled study in patients with a Gallium-68 DOTATATE PET/CT positive, clinically non-functioning pituitary macroadenoma (NFMA) of the effect of Lanreotide autosolution on Tumor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001234-22,0,0,0 2015-001235-20,1,2018-08-24,2018-08-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,St George's University of London,Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001235-20,0,0,0 2015-001237-24,1,2016-08-25,2016-08-25,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,Galderma R&D,Subject adherence and satisfaction for treatment of Onychomycosis with Loceryl® Nail Lacquer 5% versus Ciclopoli® Nail Lacquer. Therapietreue und Zufriedenheit der Patienten bei der Behandlung von ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001237-24,0,0,0 2015-001239-19,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,CHRU de TOURS,Effects of low-dose corticosteroids on survival of severe Community-Acquired Pneumonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001239-19,0,0,0 2015-001241-84,8,2018-12-05,2018-12-05,7,1,0,1,0,0,1,0,0,1,1,0,0,0,1,NOVARTIS FARMA S.P.A.,"A phase Ib/II, open-label, multicenter trial with oral cMET inhibitor INC280 alone and in combination with erlotinib versus platinum/pemetrexed in adult patients with EGFR mutated, cMET-amplified, loc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001241-84,0,0,0 2015-001241-84,8,2018-12-05,2018-12-05,7,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Novartis Pharma Services AG,"A phase Ib/II, open-label, multicenter trial with oral cMET inhibitor INC280 alone and in combination with erlotinib versus platinum/pemetrexed in adult patients with EGFR mutated, cMET-amplified, loc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001241-84,0,0,0 2015-001241-84,8,2018-12-05,2018-12-05,7,1,0,1,0,0,1,0,0,1,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase Ib/II, open-label, multicenter trial with oral cMET inhibitor INC280 alone and in combination with erlotinib versus platinum/pemetrexed in adult patients with EGFR mutated, cMET-amplified, loc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001241-84,0,0,0 2015-001243-36,18,2018-09-11,2019-03-19,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"BIAL-PORTELA & Cª, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS MONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSET SEIZURES: A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001243-36,0,0,0 2015-001243-36,18,2018-09-11,2019-03-19,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"BIAL - Portela & Ca, S.A.","EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS MONOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED PARTIAL-ONSET SEIZURES: A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001243-36,0,0,0 2015-001245-89,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,Sanofi-aventis,"Relative bioavailability study between 75 mg tablet and 75 mg solution of Clopidogrel (SR25990C) after single oral administration to young healthy men. Open, crossover, randomized and monocenter study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001245-89,0,1,1 2015-001246-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Cliniques Universitaires Saint-Luc, Université catholique de Louvain",Ultrasound scores as imaging biomarkers of early response to subcutaneous tocilizumab in association with methotrexate in early rheumatoid arthritis (TOVERA study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001246-28,0,0,0 2015-001248-12,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER,Randomized crossover trial for the evaluation of the possible effects in the intestine of two different pharmaceutical forms of L - Thyroxine in patients with primary acquired hypothyroidism Studi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001248-12,0,0,0 2015-001249-10,7,2016-01-22,2016-12-22,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc","A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Crohn's Disease Studio multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001249-10,0,0,0 2015-001249-10,7,2016-01-22,2016-12-22,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Crohn's Disease Studio multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001249-10,0,0,0 2015-001258-13,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, observer-blind, multi-centre, multi-country, randomized study to evaluate the immunogenicity and safety of thimerosal-free (TF) Fluarix™ (GSK Biologicals) compared with Fluzone® (Sanofi P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001258-13,0,1,1 2015-001259-63,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Clinical Science, Intervention and Technology, Karolinska Institute",Intralymphatic immunotherapy in increasing doses up to 10 000 SQ-U -a human randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001259-63,0,0,0 2015-001265-11,3,2019-07-04,2019-07-04,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GENSIGHT-BIOLOGICS,"A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for 6 Months or Less by Leb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001265-11,0,0,0 2015-001265-11,3,2019-07-04,2019-07-04,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GENSIGHT BIOLOGICS,"A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for 6 Months or Less by Leb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001265-11,0,0,0 2015-001266-26,3,2018-12-19,2018-12-19,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GENSIGHT BIOLOGICS,"A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for more than 6 Months and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001266-26,0,0,0 2015-001266-26,3,2018-12-19,2018-12-19,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GENSIGHT-BIOLOGICS,"A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for more than 6 Months and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001266-26,0,0,0 2015-001267-39,2,2017-08-08,2017-08-08,1,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3b, 2-part, Randomized, Double-blind, Placebo-controlled Crossover Study With a Long term Open-label Period to Investigate Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001267-39,1,0,0 2015-001268-20,7,2020-11-24,2020-11-24,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SPR,"AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF UCB0942 WHEN USED AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET SEIZURES IN ADULT SUBJECTS WITH HI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001268-20,0,0,0 2015-001268-20,7,2020-11-24,2020-11-24,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SRL,"AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF UCB0942 WHEN USED AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET SEIZURES IN ADULT SUBJECTS WITH HI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001268-20,0,0,0 2015-001268-20,7,2020-11-24,2020-11-24,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SPRL,"AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF UCB0942 WHEN USED AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET SEIZURES IN ADULT SUBJECTS WITH HI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001268-20,0,0,0 2015-001274-17,9,2020-02-10,2020-02-20,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001274-17,1,0,0 2015-001274-17,9,2020-02-10,2020-02-20,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001274-17,1,0,0 2015-001275-50,12,2020-03-10,2020-03-19,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001275-50,0,0,0 2015-001275-50,12,2020-03-10,2020-03-19,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination with Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001275-50,0,0,0 2015-001279-39,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ASTRAZENECA AB,"A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001279-39,0,0,0 2015-001279-39,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001279-39,0,0,0 2015-001282-13,1,2017-03-24,2017-03-24,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Ghent University Hospital,Evaluation of acute normovolemic hemodilution on coagulation during liver surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001282-13,0,0,0 2015-001284-40,1,2017-10-02,2017-10-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Aarhus University Hospital,"The effect of liraglutide on bone turnover, bone mass and bone cell function",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001284-40,0,0,0 2015-001289-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ghent University Hospital,99m Tc- sestaMIBI/pertechnetaat SPECT subtractie beeldvorming versus 18F-Fluorocholine PET/CT voor de preoperatieve lokalisatie van hyperfunctionerende parathyroïden bij primaire hyperparathyroidie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001289-24,0,0,0 2015-001292-51,5,2016-01-08,2016-01-08,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,CHIASMA INC.,Follow-Up Study in Patients with Acromegaly Previously Participating in Chiasma Study CH-ACM-01,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001292-51,0,0,0 2015-001292-51,5,2016-01-08,2016-01-08,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Chiasma, Inc.",Follow-Up Study in Patients with Acromegaly Previously Participating in Chiasma Study CH-ACM-01,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001292-51,0,0,0 2015-001297-18,1,2018-01-03,2018-01-03,1,1,0,1,1,1,1,0,1,1,0,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","A Phase 1/2, Randomized, Single-Blind, Placebo-Controlled, Single-Ascending, and Multiple-Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-AA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001297-18,0,0,0 2015-001298-42,7,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,EORTC AISBL/IVZW,A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001298-42,0,0,0 2015-001298-42,7,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,European Organisation for Research and Treatment of Cancer,A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001298-42,0,0,0 2015-001298-42,7,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001298-42,0,0,0 2015-001306-33,3,2018-01-12,2018-03-29,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,PIQUR Therapeutics AG,"Open-label, non-randomized, phase 2 study evaluating efficacy and safety of PQR309 in patients with relapsed or refractory primary CNS lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001306-33,0,0,0 2015-001309-14,1,2019-05-02,2019-05-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Heidelberg,"Comparison of the efficacy of using a human acellular dermis (Epiflex®) against the surgical standard procedure for closing an open abdomen with respect to avoiding ventral hernia. A monocenter, part...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001309-14,0,0,0 2015-001313-26,1,2015-12-21,2015-12-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA,Effects of Bilastine on F1 Simulator driving performance in patients affected by allergic rhinitis and/or urticaria Effetti della Bilastina sulla capacità di guida al simulatore di Formula 1 in paz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001313-26,0,0,0 2015-001314-10,4,2018-11-16,2018-11-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT,"A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001314-10,0,0,0 2015-001316-34,6,2021-04-27,2021-04-27,3,1,0,0,0,1,2,0,0,2,1,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001316-34,1,0,0 2015-001316-34,6,2021-04-27,2021-04-27,3,1,0,0,0,1,2,0,0,2,1,0,0,0,1,Eli Lilly and Company,"A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001316-34,1,0,0 2015-001316-34,6,2021-04-27,2021-04-27,3,1,0,0,0,1,2,0,0,2,1,0,0,0,1,Lilly S.A.,"A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001316-34,1,0,0 2015-001317-28,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,UMC Utrecht,A B2-agonist as a CFTR activator in CF - Part 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001317-28,0,0,0 2015-001318-92,12,2020-01-20,2021-01-20,10,1,0,0,0,1,3,0,0,2,1,0,0,0,1,"ARIAD Pharmaceuticals, Inc.","A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001318-92,1,0,0 2015-001318-92,12,2020-01-20,2021-01-20,10,1,0,0,0,1,3,0,0,2,1,0,0,0,1,"ARIAD Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (ARIAD)","A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001318-92,1,0,0 2015-001320-31,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Janssen Pharmaceutical K.K,"A Double-blind, Placebo-controlled Study, Followed by an Open-label Extension Study Evaluating the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents with Irritability Associated...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001320-31,0,1,1 2015-001321-17,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Oxford,A randomised control trial of 5-Aminolevulinic Acid in combination with Sodium Ferrous Citrate to Enhance Cardioprotection in Adults undergoing Cardiac Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001321-17,0,0,0 2015-001323-23,1,2018-09-28,2018-09-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospitals Bristol NHS Foundation Trust,A phase II trial of Tocilizumab in anti-TNF refractory patients with JIA associated uveitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001323-23,0,0,0 2015-001324-36,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Marinus Pharmaceuticals, Inc.","A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children with PCDH19 Female Pediatric Epilepsy Studio pilota, multicentrico, in aperto con ganaxolone in bambine affette da epiless...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001324-36,0,0,0 2015-001327-23,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto,Eltrombopag as Second line Therapy in adult patients with primary Immune Thrombocytopenia (ESTIT study) in an attempt to achieve long-term remission: a single arm multicenter phase II clinical and bio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001327-23,0,0,0 2015-001334-21,1,2017-06-26,2017-06-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Lund University,Study of the Effect of Vildagliptin versus Dapagliflozin on Glucagon Response to Mixed Meal in Metformin-treated Subjects with Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001334-21,0,0,0 2015-001339-19,2,,,0,1,1,0,0,0,2,0,0,3,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 2/3, Open-Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001339-19,0,1,0 2015-001341-86,6,2020-01-28,2020-01-28,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NEOVACS,"A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNa-Kinoid in Adult Subjects with Systemic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001341-86,0,0,0 2015-001341-86,6,2020-01-28,2020-01-28,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Neovacs S.A.,"A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNa-Kinoid in Adult Subjects with Systemic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001341-86,0,0,0 2015-001341-86,6,2020-01-28,2020-01-28,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Neovas S.A.,"A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNa-Kinoid in Adult Subjects with Systemic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001341-86,0,0,0 2015-001342-28,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,CHU Angers,TOMOSCINTIGRAPHIE HYBRIDE AUX LEUCOCYTES MARQUES DANS LE DIAGNOSTIC DES INFECTIONS DE PROTHESES VASCULAIRES. Etude LEUCOPRO® TOMOSCINTIGRAPHIE HYBRIDE AUX LEUCOCYTES MARQUES DANS LE DIAGNOSTIC DES...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001342-28,0,0,0 2015-001343-37,4,2017-01-20,2017-01-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN INC.,"A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evoloc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001343-37,0,0,0 2015-001343-37,4,2017-01-20,2017-01-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evoloc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001343-37,0,0,0 2015-001344-11,7,,,0,0,1,0,0,1,4,0,2,3,0,0,0,0,1,Chiesi Farmaceutici S.p.A.,"Multinational, multicenter, prospective, long-term safety and efficacy follow-up study after Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration of corneal epithelium in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001344-11,0,0,0 2015-001344-11,7,,,0,0,1,0,0,1,4,0,2,3,0,0,0,0,1,Holostem Terapie Avanzate S.r.l.,"Multinational, multicenter, prospective, long-term safety and efficacy follow-up study after Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration of corneal epithelium in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001344-11,0,0,0 2015-001344-11,7,,,0,0,1,0,0,1,4,0,2,3,0,0,0,0,1,Holostem Terapie Avanzate s.r.l.,"Multinational, multicenter, prospective, long-term safety and efficacy follow-up study after Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration of corneal epithelium in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001344-11,0,0,0 2015-001344-11,7,,,0,0,1,0,0,1,4,0,2,3,0,0,0,0,1,CHIESI FARMACEUTICI S.P.A.,"Multinational, multicenter, prospective, long-term safety and efficacy follow-up study after Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for restoration of corneal epithelium in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001344-11,0,0,0 2015-001346-29,8,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001346-29,0,0,0 2015-001351-71,2,2018-03-28,2018-03-28,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001351-71,0,0,0 2015-001355-76,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University College London,Phase III randomised trial of immunomodulatory therapy in high risk solitary bone plasmacytoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001355-76,0,0,0 2015-001359-60,1,2017-11-29,2017-11-29,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Aarhus University Hospital,Influence of vasopressors on brain oxygenation and microcirculation in anesthetized patients with cerebral tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001359-60,0,0,0 2015-001360-19,5,2017-07-31,2018-07-31,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ADIENNE SA,"Prospective, phase II/III, randomized clinical study to compare BEGEDINA® versus ""conventional treatment"" for treating steroid resistant acute graft-versus host disease Studio clinico randomizzato ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001360-19,0,0,0 2015-001361-27,1,2020-04-09,2020-04-09,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,The Institute of Cancer Research,CTC-STOP: Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001361-27,0,0,0 2015-001364-19,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,F. HOFFMANN - LA ROCHE LTD.,A phase Ib/II study evaluating the safety and efficacy of MPDL3280A in combination with either obinutuzumab plus bendamustine or obinutuzumab plus CHOP in patients with follicular lymphoma or diffuse ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001364-19,0,0,0 2015-001368-20,2,2018-09-05,2018-09-05,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,AIBILI - Association for Innovation and Biomedical Research on Light and Image,"A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001368-20,0,0,0 2015-001368-20,2,2018-09-05,2018-09-05,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,AIBILI - Association for Innovation and Biomedical Research ob Light and Image,"A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001368-20,0,0,0 2015-001377-40,4,2018-04-09,2018-04-10,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"PHASE II, EXPLORATORY, MULTICENTER, NON RANDOMIZED, SINGLE AGENT COHORT STUDY TO DETERMINE BEST TUMOR RESPONSE WITH TRASTUZUMAB EMTANSINE IN HER2 OVEREXPRESSING SOLID TUMORS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001377-40,0,0,0 2015-001377-40,4,2018-04-09,2018-04-10,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farma, S.A. que representa en España a F. Hoffmann-La Roche Ltd","PHASE II, EXPLORATORY, MULTICENTER, NON RANDOMIZED, SINGLE AGENT COHORT STUDY TO DETERMINE BEST TUMOR RESPONSE WITH TRASTUZUMAB EMTANSINE IN HER2 OVEREXPRESSING SOLID TUMORS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001377-40,0,0,0 2015-001377-40,4,2018-04-09,2018-04-10,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"PHASE II, EXPLORATORY, MULTICENTER, NON RANDOMIZED, SINGLE AGENT COHORT STUDY TO DETERMINE BEST TUMOR RESPONSE WITH TRASTUZUMAB EMTANSINE IN HER2 OVEREXPRESSING SOLID TUMORS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001377-40,0,0,0 2015-001381-26,2,2016-11-30,2016-11-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,CERENIS THERAPEUTICS SA,"A PHASE II MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FOCUSING TRIAL OF CER-001 IN SUBJECTS WITH ACUTE CORONARY SYNDROME",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001381-26,0,0,0 2015-001382-10,1,,,0,1,0,0,0,1,2,0,0,3,0,0,0,0,0,University Hospitals Bristol NHS Foundation Trust,Treatment of Barth Syndrome by CARDIOlipin MANipulation (CARDIOMAN): A randomised placebo controlled pilot trial conducted by the nationally commissioned Barth Syndrome Service,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001382-10,0,0,0 2015-001383-18,1,,,0,1,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Oxford,An open label Phase 2 clinical trial of retinal gene therapy for choroideremia using an adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001383-18,0,0,0 2015-001394-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Raimo Tuuminen,Predictability of response of aflibercept treatment for wet age-related macular degeneration under the treat-and-moderate extend regimen (TMER) treatment model Silmänpohjan kostean ikärappeuman afl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001394-41,0,0,0 2015-001395-21,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Genzyme Corporation,An Open-Label Extension Study of Subcutaneously Administered Fitusiran in Patients with Moderate or Severe Hemophilia A or B who Have Participated In A Previous Clinical Study with Fitusiran,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001395-21,0,0,0 2015-001396-40,4,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.",An open-label extension study to assess the long-term safety and efficacy of dupilumab in patients ≥6 months to <18 years of age with atopic dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001396-40,0,0,0 2015-001401-13,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University Hospitals Birmingham NHS Foundation Trust,A Multi-Centre Randomised Controlled Trial of Pre-Hospital Blood Product Administration versus Standard Care for Traumatic Haemorrhage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001401-13,0,0,0 2015-001402-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHRU de Brest,Efficacité et sécurité des injections intramusculaires de toxine botulinique précoces dans la prévention de la déformation de l’épaule des nourrissons atteints de paralysie obstétricale du plexus brac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001402-34,0,0,0 2015-001407-31,7,2019-03-22,2019-04-18,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Sma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001407-31,0,0,0 2015-001409-15,1,2016-07-06,2016-07-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKlineResearch & Developemnt Ltd,Study 201012: A Dose-Finding Study of batefenterol (GSK961081) via Dry Powder Inhaler in Patients with COPD.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001409-15,0,0,0 2015-001410-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación de Investigación Biomédica Hospital Universitario de la Princesa,"Anti-TNF discontinuation in patients with inflammatory bowel disease: Multicentre, prospective, randomized clinical trial and economic evaluation SUSPENSIÓN DEL TRATAMIENTO ANTI-TNF EN PACIENTES CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001410-10,0,0,0 2015-001411-12,6,2017-02-13,2017-02-13,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS FARMA S.P.A.,"Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tolerability of intravenous BYM338 in patients with sporadic inclusion body myositis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001411-12,0,0,0 2015-001411-12,6,2017-02-13,2017-02-13,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tolerability of intravenous BYM338 in patients with sporadic inclusion body myositis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001411-12,0,0,0 2015-001431-20,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Centre for Human Drug Research,"A randomized, double blind, double-dummy placebo controlled, 3-way cross-over study to determine the test-retest reliability of, and the effect of oral retigabine and riluzole on, peripheral motor ner...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001431-20,0,0,0 2015-001434-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Universitätsmedizin Greifswald, KöR",A method for measuring volume changes of the alveolar ridge during dental implantation using 3D scanning 3D-oberflächenscanbasierte Verlaufsmessung der Extraktionsalveole nach Alveolenmanagement be...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001434-16,0,0,0 2015-001435-21,3,2020-03-18,2020-03-18,2,0,0,0,0,0,2,0,0,1,1,0,1,0,1,"Hanmi Pharmaceutical Co., Ltd.","A single-arm, open-label, Phase 2 study evaluating the efficacy, safety and pharmacokinetics of HM61713 (BI 1482694) in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001435-21,0,0,0 2015-001435-21,3,2020-03-18,2020-03-18,2,0,0,0,0,0,2,0,0,1,1,0,1,0,1,"HANMI PHARM. CO., LTD.","A single-arm, open-label, Phase 2 study evaluating the efficacy, safety and pharmacokinetics of HM61713 (BI 1482694) in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001435-21,0,0,0 2015-001438-46,5,2019-05-16,2019-05-16,5,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001438-46,0,0,0 2015-001438-46,5,2019-05-16,2019-05-16,5,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, New York 10017","EFFICACY, SAFETY AND TOLERABILITY OF TOFACITINIB FOR TREATMENT OF POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (JIA) IN CHILDREN AND ADOLESCENT SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001438-46,0,0,0 2015-001439-20,1,2016-05-03,2016-05-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College Healthcare NHS Trust and Imperial College London,A Feasibility Randomised Controlled Trial: Effects of Oral Sodium Bicarbonate Supplementation in Patients on Haemodialysis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001439-20,0,0,0 2015-001442-29,7,2021-01-18,2021-01-18,4,1,0,0,0,0,2,0,0,2,0,0,0,0,1,ASTRAZENECA AB,"A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001442-29,1,0,0 2015-001442-29,7,2021-01-18,2021-01-18,4,1,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001442-29,1,0,0 2015-001443-36,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,ARQULE INC,"A Phase 1/2 Study of ARQ 087 in Adult Subjects with Advanced Solid Tumors with FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma with FGFR2 Gene Fusion A Phase 1/2 Study of ARQ 08...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001443-36,0,0,0 2015-001447-37,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,University Medical Center Groningen,Efficacy of oral alitretinoin versus oral azathioprine in patients with severe chronic non-hyperkeratotic hand eczema. A randomized prospective open-label trial with blinded outcome assessment. Eff...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001447-37,0,0,0 2015-001448-13,1,2016-01-15,2016-01-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Galderma R&D,Benzaknen® 5% Gel in combination with Dermotivin® Soft Liquid cleanser and non-comedogenic Cetaphil® Dermacontrol Moisturizer SPF30 in the treatment of mild-to-moderate acne vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001448-13,0,0,0 2015-001449-93,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase II, observer-blind follow-up study with two groups to assess the reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine (GSK1024850A),...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001449-93,0,1,1 2015-001452-30,1,2019-06-05,2019-06-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Copenhagen University Hospital Rigshospitalet,"A Randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig Cell Insufficiency (Einstein-intervention) Randomiseret, dobbeltblinde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001452-30,0,0,0 2015-001453-32,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Novartis Vaccines and Diagnostics Srl,"A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension study in Chinese children after a 2 + 1 dose series of either CRM197- conjugate Haemophilus influenzae type b vaccine or tet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001453-32,0,1,1 2015-001456-29,1,2020-08-07,2020-08-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,"A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Treatment Resistant Unipolar Major Depressive Disorder (MDD) Eine d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001456-29,0,0,0 2015-001458-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Etude de l'efficacité analgésique de la morphine seule ou combinée à du paracétamol et/ou de l'ibuprofène chez les enfants ayant une fracture d'un os long: Morphapain study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001458-14,0,0,0 2015-001463-39,4,2018-12-14,2019-01-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eisai Ltd.,"A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel-Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-001463-39,0,0,0 2015-001464-19,6,2018-02-21,2018-02-21,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,GE Healthcare Ltd. and its affiliates,AdreView Myocardial Imaging for Risk Evaluation. A multicentre trial to guide ICD implantation in NYHA class II & III heart failure patients with 30%6 OR CREATININE CLEARANC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004606-41,0,0,0 2015-004607-24,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,AZ Groeninge,Comparison of the spread of local anesthetics in the fascia iliaca compartment between the classical “transverse” technique and the longitudinal supra-inguinal technique.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004607-24,0,0,0 2015-004613-24,2,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Radboudumc,Hit hard and early. The effect of high dose methylprednisolon on nailfold capillary changes and biomarkers in early SSc: a 12-week randomized double-blind placebo-controlled trial. Het effect van h...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004613-24,0,0,0 2015-004614-26,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Oncobiologics Limited,"A Randomized, Double-Blind, Multicenter, Equivalence Study of ONS-3010 and Humira® for the Treatment of Patients with Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004614-26,0,0,0 2015-004616-37,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GENENTECH Inc.,"An open-label, multicenter, biomarker study to explore the mechanism of action of ocrelizumab and B-cell biology in patients with relapsing multiple sclerosis or primary progressive multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004616-37,0,0,0 2015-004617-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Canaria de Investigación Sanitarias,Enzalutamide and hypofractionated radiation therapy in intermediate-risk localized prostate cancer Enzalutamida y radioterapia hipofraccionada en cáncer de próstata localizado de riesgo intermedio.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004617-25,0,0,0 2015-004618-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CUB- Hopital Erasme,Study of the inter-individual variation of PhArmaCo-kinetics of InFliximab during treatment Induction in patients with Crohn’s disease and Ulcerative Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004618-10,0,0,0 2015-004620-60,3,2020-07-15,2020-07-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 kg o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004620-60,0,0,0 2015-004620-60,3,2020-07-15,2020-07-15,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS PHARMA AG,"A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 kg o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004620-60,0,0,0 2015-004625-14,7,2016-03-28,2016-03-28,2,1,1,0,0,1,1,0,0,2,1,0,0,0,1,Boehringer Ingelheim bv,"Open-label, dose-escalating trial to evaluate the tolerability, toxicity, safety, pharmacokinetics, pharmacodynamics and activity of volasertib added to the standard intensive salvage chemotherapy reg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004625-14,1,0,0 2015-004625-14,7,2016-03-28,2016-03-28,2,1,1,0,0,1,1,0,0,2,1,0,0,0,1,Boehringer Ingelheim Italia S.p.A.,"Open-label, dose-escalating trial to evaluate the tolerability, toxicity, safety, pharmacokinetics, pharmacodynamics and activity of volasertib added to the standard intensive salvage chemotherapy reg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004625-14,1,0,0 2015-004625-14,7,2016-03-28,2016-03-28,2,1,1,0,0,1,1,0,0,2,1,0,0,0,1,BOEHRINGER INGELHEIM,"Open-label, dose-escalating trial to evaluate the tolerability, toxicity, safety, pharmacokinetics, pharmacodynamics and activity of volasertib added to the standard intensive salvage chemotherapy reg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004625-14,1,0,0 2015-004625-14,7,2016-03-28,2016-03-28,2,1,1,0,0,1,1,0,0,2,1,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"Open-label, dose-escalating trial to evaluate the tolerability, toxicity, safety, pharmacokinetics, pharmacodynamics and activity of volasertib added to the standard intensive salvage chemotherapy reg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004625-14,1,0,0 2015-004625-14,7,2016-03-28,2016-03-28,2,1,1,0,0,1,1,0,0,2,1,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Open-label, dose-escalating trial to evaluate the tolerability, toxicity, safety, pharmacokinetics, pharmacodynamics and activity of volasertib added to the standard intensive salvage chemotherapy reg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004625-14,1,0,0 2015-004625-14,7,2016-03-28,2016-03-28,2,1,1,0,0,1,1,0,0,2,1,0,0,0,1,SCS Boehringer Ingelheim Comm.V,"Open-label, dose-escalating trial to evaluate the tolerability, toxicity, safety, pharmacokinetics, pharmacodynamics and activity of volasertib added to the standard intensive salvage chemotherapy reg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004625-14,1,0,0 2015-004626-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","Safety of Lanreotide 120 mg ATG in combination with Metformin in patients with progressive advanced Well-differentiated gastro-intestinal (GI) or lung carcinoids. A pilot, one-arm, open-label, prosp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004626-34,0,0,0 2015-004627-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,The Netherlands Cancer Institute,A multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery vs. neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery vs. neo-adjuvant chemoradiot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004627-31,0,0,0 2015-004631-13,8,2017-11-07,2017-11-07,6,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Mereo BioPharma 1 Ltd,"A Phase IIa, two-part, randomised, multi-centre, multinational, double-blind, placebo-controlled, parallel group study to compare the efficacy and safety of BCT197 when added on to standard of care fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004631-13,1,0,0 2015-004631-13,8,2017-11-07,2017-11-07,6,1,0,0,0,0,2,0,0,2,0,0,0,0,1,MEREO BIOPHARMA GROUP LTD,"A Phase IIa, two-part, randomised, multi-centre, multinational, double-blind, placebo-controlled, parallel group study to compare the efficacy and safety of BCT197 when added on to standard of care fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004631-13,1,0,0 2015-004632-35,1,2019-11-25,2019-11-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, double-blind, active-controlled study to assess the effect of LCZ696 compared with enalapril to improve exercise capacity in patients with heart failure with reduced ejection fraction (H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004632-35,0,0,0 2015-004633-27,6,2022-01-18,2022-01-18,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received 4...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004633-27,1,0,0 2015-004637-27,1,2016-10-06,2016-10-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medizinische Universität Graz,"A randomized, double-blind, three arm, three treatment period, cross-over trial to investi-gate the effect of a SGLT-2 inhibitor, a DPP-4 inhibitor and a SGLT-2 inhibitor + DPP-4 inhibitor on glucagon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004637-27,0,0,0 2015-004656-22,1,2018-05-28,2018-05-28,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,Institut de Recerca HSCSP,Pilot study of the [18F]THK-5351 positron emission tomography (PET) tracer in different tauopathies. ESTUDIO PILOTO DEL TRAZADOR DE TOMOGRAFÍA POR EMISIÓN DE POSITRONES (PET) PARA TAU [18F]THK-5351...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004656-22,0,0,0 2015-004657-40,1,2020-05-01,2020-05-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Region Örebro län,Minimizing contrast agent in computed tomography pulmonary angiography Datortomografisk lungembolidiagnostik med minimal mängd kontrastmedel,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004657-40,0,0,0 2015-004698-34,1,2017-11-30,2017-11-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University Of Turku,Pharmacokinetics of subcutaneously given dexmedetomidine in healthy volunteers Ihonalaisesti annostellun deksmedetomidiinin farmakokinetiikka terveillä koehenkilöillä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004698-34,0,0,0 2015-004699-31,10,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Eli Lilly and Company,"Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004699-31,0,0,0 2015-004699-31,10,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Lilly, S.A.","Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004699-31,0,0,0 2015-004699-31,10,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004699-31,0,0,0 2015-004702-42,3,2017-07-21,2017-09-21,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Regulus Therapeutics Inc.,"A Multi-Center, Parallel Group, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of a Single Subcutaneous Injection of RG-101 Combined with Oral GSK2878175 Taken Once Daily for 6, 9, or 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004702-42,0,0,0 2015-004703-23,6,2019-04-22,2019-04-24,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shionogi Ltd.,"A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004703-23,0,0,0 2015-004703-23,6,2019-04-22,2019-04-24,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shionogi B.V.,"A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004703-23,0,0,0 2015-004708-51,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"LUMC, VRSP",Facilitating Sexual Memory consolidation by a partial NMDA receptors agonist,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004708-51,0,0,0 2015-004709-17,1,2019-07-15,2019-07-15,1,0,0,0,0,0,4,0,0,1,0,0,1,0,3,,None,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004709-17,0,0,0 2015-004711-21,4,2017-09-05,2017-09-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004711-21,0,0,0 2015-004713-24,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,IRCCS ISTITUTO CLINICO HUMANITAS,"A Multicenter, Open Label, Pilot Study to Investigate Tolerability and Efficacy of MK5172 (Grazoprevir) / MK8742 (Elbasvir) Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004713-24,0,0,0 2015-004715-20,1,2018-07-17,2018-07-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"SANOFI-AVENTIS, S.A.",Phase IV study to evaluate the safety and efficacy of the treatment of hyperglycemia with Gla-300 in basal-bolus regimen in hospitalised T2D patients poorly controlled with basal insulin and/or non-in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004715-20,0,0,0 2015-004717-25,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE PER LA RICERCA OSPEDALE MAGGIORE DI BERGAMO - FROM,The benefit/risk profile of pegylated proline-Interferon alpha-2b (AOP2014) added to the best available strategy based on phlebotomies in low-risk patients with Polycythemia Vera (PV). The Low-PV rand...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004717-25,0,0,0 2015-004722-34,10,,,0,0,0,0,1,1,0,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA met...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004722-34,0,0,0 2015-004722-34,10,,,0,0,0,0,1,1,0,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA met...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004722-34,0,0,0 2015-004723-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA,"Proof of concept study, a randomized, controlled, open and prospective period of one year to evaluate the effectiveness of treatment with saxagliptin / dapagliflozin + metformin vs insulin glargine + ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004723-31,0,0,0 2015-004724-62,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UCD,Golimumab (GLM) dose Optimisation to Adequate Levels to Achieve Response in Colitis. (GOAL-ARC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004724-62,0,0,0 2015-004725-13,9,2020-08-17,2020-08-17,8,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Shire ViroPharma Incorporated,"A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004725-13,0,0,0 2015-004725-13,9,2020-08-17,2020-08-17,8,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"SHIRE HUMAN GENETIC THERAPIES, INC","A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004725-13,0,0,0 2015-004726-34,13,2022-06-19,2022-06-19,9,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Shire ViroPharma Incorporated,"A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegalovirus (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004726-34,1,1,0 2015-004726-34,13,2022-06-19,2022-06-19,9,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Takeda Development Center Americas, Inc.","A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegalovirus (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004726-34,1,1,0 2015-004726-34,13,2022-06-19,2022-06-19,9,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Takeda Development Center Americas, Inc","A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegalovirus (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004726-34,1,1,0 2015-004726-34,13,2022-06-19,2022-06-19,9,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"SHIRE HUMAN GENETIC THERAPIES, INC","A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegalovirus (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004726-34,1,1,0 2015-004727-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS,RANDOMIZED PHASE II TRIAL IN SSTr2 POSITIVE TUMORS TO OPTIMIZE THE INTERVAL BETWEEN CYCLES OF PRRT WITH 177LU DOTATATE (LUTHREE) Studio di fase II randomizzato finalizzato ad ottimizzare l’interva...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004727-31,0,0,0 2015-004729-15,3,2016-10-14,2016-10-14,1,0,0,0,0,2,2,0,0,1,1,0,1,0,1,"INFINITY PHARMACEUTICALS, INC.","A Phase 2, Randomized Study of Duvelisib Administered in Combination with Rituximab vs R-CHOP in Subjects with Relapsed/Refractory Follicular Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004729-15,0,0,0 2015-004729-15,3,2016-10-14,2016-10-14,1,0,0,0,0,2,2,0,0,1,1,0,1,0,1,"Infinity Pharmaceuticals, Inc.","A Phase 2, Randomized Study of Duvelisib Administered in Combination with Rituximab vs R-CHOP in Subjects with Relapsed/Refractory Follicular Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004729-15,0,0,0 2015-004731-12,1,2020-06-15,2020-06-15,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University of Cologne,Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients with Retinal Detachment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004731-12,0,0,0 2015-004735-12,8,2020-01-27,2020-01-27,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN INC.,"A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects with HIV and with Hyperlipidemia and/or Mi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004735-12,0,0,0 2015-004735-12,8,2020-01-27,2020-01-27,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects with HIV and with Hyperlipidemia and/or Mi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004735-12,0,0,0 2015-004738-90,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Arthroscopic Surgery Unit,"Efficacy, safety and systemic effect of intra-articular and intraosseous infiltrations of Platelet Rich Plasma in patients with knee osteoarthritis: Randomized Clinical Trial Eficacia, seguridad y...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004738-90,0,0,0 2015-004741-54,3,2017-04-26,2017-05-01,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"SEATTLE GENETICS, INC.","A phase 2 study of brentuximab vedotin in combination with standard of care treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [RCHOP]) or RCHP (rituximab, cyclophosphami...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004741-54,0,0,0 2015-004741-54,3,2017-04-26,2017-05-01,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Seattle Genetics, Inc.","A phase 2 study of brentuximab vedotin in combination with standard of care treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [RCHOP]) or RCHP (rituximab, cyclophosphami...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004741-54,0,0,0 2015-004745-70,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Center (AMC),"Efficacy of intranasal ketamine on acute suicidality, a double blind randomized placebo-controlled trial (Ketamine Trial Amsterdam, KETA) Effectiviteit van intranasale ketamine op acute suïcidalit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004745-70,0,0,0 2015-004747-39,1,2020-12-15,2020-12-15,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,Oslo University Hospital,"A phase II study of pembrolizumab in patients with malignant peripheral nerve sheath tumor (MPNST), not eligible for curative surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004747-39,0,0,0 2015-004760-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VU Medical Centre,89Zirconium-labeled nivolumab and 18F-labeled anti-PD-L1 as predictive imaging biomarkers of response and toxicity in nivolumab treated patients with non-small-cell lung cancer – a feasibility study ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004760-11,0,0,0 2015-004762-28,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,ITALIAN SARCOMA GROUP,"Multicentric prospective, randomized, clinical trial for the treatment of patient with relapsed Osteosarcoma (OS) Studio clinico multicentrico, prospettico, randomizzato per il trattamento dei pazi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004762-28,0,0,0 2015-004764-10,1,2017-11-09,2017-11-09,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Essa Pharmaceuticals Corp.,"A Phase 1/2 Open-label Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of Oral EPI-506 in Patients with Metastatic Castration-resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004764-10,0,0,0 2015-004765-90,1,2016-11-21,2016-11-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Dr. Reddy’s Laboratories, Ltd","A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004765-90,0,0,0 2015-004768-12,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Novo Nordisk A/S,A 38 week trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004768-12,0,0,0 2015-004770-16,1,2017-11-30,2017-11-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Jens Børglum,Ultrasoundguided Transmuscular Quadratus Lumborum(TQL) block for percutaneous nephrolithotomy (PNL) - a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004770-16,0,0,0 2015-004774-14,9,2020-06-05,2020-06-18,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Akebia Therapeutics, Inc.","Phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the maintenance treatment of anemia in subjects with non-dialysis-dependent chronic k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004774-14,0,0,0 2015-004774-14,9,2020-06-05,2020-06-18,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"AKEBIA THERAPEUTICS, INC.","Phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the maintenance treatment of anemia in subjects with non-dialysis-dependent chronic k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004774-14,0,0,0 2015-004775-78,13,2018-08-06,2018-08-06,12,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Biogen Idec Research Limited,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004775-78,0,0,0 2015-004775-78,13,2018-08-06,2018-08-06,12,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Convergence Pharmaceuticals Ltd,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004775-78,0,0,0 2015-004775-78,13,2018-08-06,2018-08-06,12,1,0,0,0,0,2,0,0,1,1,0,1,0,1,CONVERGENCE PHARMACEUTICALS LTD,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004775-78,0,0,0 2015-004779-64,2,2018-08-30,2018-08-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Air Liquide Santé International,"Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) for the Treatment of Peripheral Neuropathic Pain: a Randomised, International, Multicentre, Placebo-Controlled, Phenotype-stratified Phase IIa Stu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004779-64,0,0,0 2015-004780-36,4,2022-03-24,2022-03-24,4,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Amgen Inc,"A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004780-36,0,0,0 2015-004780-36,4,2022-03-24,2022-03-24,4,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Amgen Inc.,"A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004780-36,0,0,0 2015-004782-92,4,2018-01-02,2018-01-03,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nabriva Therapeutics AG,"A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC-3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004782-92,0,0,0 2015-004783-11,3,2017-11-20,2017-11-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec Research Limited,"A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004783-11,0,0,0 2015-004789-27,1,2017-01-13,2017-01-13,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Bispebjerg Hospital,Topical brimonidine to reduce post-inflammatory response after IPL- treatment and effect on IPL-efficacy in patients with facial telangiectasias Topikal brimonidin til reduktion af inflammatorisk r...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004789-27,0,0,0 2015-004790-32,2,2017-01-21,2017-01-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"A 29-day, randomized, double-blinded, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy, safety and pharmacokinetics of three-times weekly dosing of GSK1278863 in hemodia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004790-32,0,0,0 2015-004794-33,1,2016-06-22,2016-06-22,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Patara Pharma, LLC",Treatment of Uremic Pruritus with Inhaled PA101B in Patients with End-Stage Renal Disease Requiring Hemodialysis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004794-33,0,0,0 2015-004796-68,10,2019-02-07,2019-02-08,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Biogen Idec Research Limited,"An Uncontrolled, Open-Label Extension Study to Evaluate the Long Term Safety, Tolerability, and Maintenance of Effect of BIIB074 (Vixotrigine) in Subjects With Neuropathic Pain From Lumbosacral Radicu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004796-68,0,0,0 2015-004796-68,10,2019-02-07,2019-02-08,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CONVERGENCE PHARMACEUTICALS LTD,"An Uncontrolled, Open-Label Extension Study to Evaluate the Long Term Safety, Tolerability, and Maintenance of Effect of BIIB074 (Vixotrigine) in Subjects With Neuropathic Pain From Lumbosacral Radicu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004796-68,0,0,0 2015-004796-68,10,2019-02-07,2019-02-08,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Convergence Pharmaceuticals Ltd,"An Uncontrolled, Open-Label Extension Study to Evaluate the Long Term Safety, Tolerability, and Maintenance of Effect of BIIB074 (Vixotrigine) in Subjects With Neuropathic Pain From Lumbosacral Radicu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004796-68,0,0,0 2015-004798-34,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Amicus Therapeutics, Inc.","AN OPEN-LABEL, FIXED-SEQUENCE, ASCENDING-DOSE, FIRST-IN-HUMAN STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF INTRAVENOUS INFUSIONS OF ATB200 CO-ADMINISTE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004798-34,0,0,0 2015-004800-46,1,2016-09-23,2016-09-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Kirurgisk Afdeling, Nordsjællands Hospital",Preoperative methylprednisolone to patients suspected of appendicitis undergoing laparoscopy. Høj dosis methylprednisolon præoperativt forud for diagnostisk laparoskopi hos patienter mistænkt for a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004800-46,0,0,0 2015-004805-17,4,2018-04-17,2018-04-17,3,1,1,0,0,0,2,0,0,2,0,0,0,0,1,Actelion Pharmaceuticals Ltd.,"A prospective, multicenter study to investigate the pharmacokinetics, safety, and efficacy of cadazolid versus vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004805-17,1,0,0 2015-004806-40,6,2016-11-23,2016-11-23,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA,Bilastine and Montelukast in patients with seasonal allergic rhinoconjunctivitis and asthma: Efficacy of concomitant administration Bilastin i montelukast u bolesnika sa sezonskim alergijskim rino...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004806-40,0,0,0 2015-004806-40,6,2016-11-23,2016-11-23,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Menarini International Operations Luxembourg S.A.,Bilastine and Montelukast in patients with seasonal allergic rhinoconjunctivitis and asthma: Efficacy of concomitant administration Bilastin i montelukast u bolesnika sa sezonskim alergijskim rino...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004806-40,0,0,0 2015-004813-26,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,1,Gamida Cell Ltd,"Long Term Follow Up for Patients who have received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells Seguimiento a lar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004813-26,0,0,0 2015-004814-84,1,2019-10-18,2019-10-18,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Sint Antonius Hospital,"Individualized dosing of aminoglycosides, quinolones and glycopeptide antibiotics in (morbidly) obese patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004814-84,0,0,0 2015-004816-39,3,2020-11-02,2020-11-02,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab or Ipilimumab in Advanced Solid Tumors Estudio fase 1/2a de BMS-986178 administrado en monoterapia y en combina...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004816-39,0,0,0 2015-004816-39,3,2020-11-02,2020-11-02,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab or Ipilimumab in Advanced Solid Tumors Estudio fase 1/2a de BMS-986178 administrado en monoterapia y en combina...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004816-39,0,0,0 2015-004820-69,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,CSL Limited,"An Open-Label, Multi-Centre Study to Evaluate the Safety, Tolerability and Immunogenicity of CSL's Influenza Vaccine in a Paediatric Population (= or >6 Months to < 9 Years of Age).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004820-69,0,1,1 2015-004821-15,7,2017-06-20,2017-06-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK Abello A/S,Efficacy and safety of the SQ tree SLIT-tablet in subjects with moderate to severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch group,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004821-15,0,0,0 2015-004824-77,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Ente Ospedaliero Ospedali Galliera Genova,"A randomized, phase II, double-blind, placebo-controlled, multicenter, 2x2 factorial design biomarker tertiary prevention trial of low-dose aspirin and metformin in resected stage I-III colorectal can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004824-77,0,0,0 2015-004824-77,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ENTE OSPEDALIERO OSPEDALI GALLIERA,"A randomized, phase II, double-blind, placebo-controlled, multicenter, 2x2 factorial design biomarker tertiary prevention trial of low-dose aspirin and metformin in resected stage I-III colorectal can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004824-77,0,0,0 2015-004825-14,4,2019-08-23,2019-09-23,3,1,0,0,0,0,4,0,0,1,1,0,1,0,1,AstraZeneca AB,"A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients with Type 2 Diabetes Mellitus and Hea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004825-14,0,0,0 2015-004826-32,4,2019-05-10,2019-05-10,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Orion Corporation Orion Pharma,"Safety and pharmacokinetics of ODM-207 in patients with selected advanced solid tumours: an open-label, non-randomised, uncontrolled, multicentre, first-in-human study with cohort expansion",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004826-32,0,0,0 2015-004827-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA ""BIANCHI-MELACRINO-MORELLI""","RAPID VERSUS SLOW WITHDRAWAL OF ANTIEPILEPTIC MONOTHERAPY IN TWO-YEAR SEIZURE-FREE ADULTS PATIENTS WITH EPILEPSY (RASLOW) STUDY: A PRAGMATIC MULTICENTRE, PROSPECTIVE, RANDOMIZED, CONTROLLED STUDY. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004827-30,0,0,0 2015-004828-66,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Medica Scientia Innovation Research (MedSIR ARO),A phase IIa clinical trial to evaluate the safety and efficacy of osirmertinib (AZD9291) in first-line patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer an...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004828-66,0,0,0 2015-004830-81,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,A multicenter study to evaluate the anti-viral activity of an interferon-free treatment with ledipasvir/sofosbuvir (G1 and G4) and sofosbuvir/velpatasvir (G2 and G3) for patients with hepatitis C viru...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004830-81,0,0,0 2015-004831-11,5,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Celgene International II Sàrl,"A Phase 1/2, multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004831-11,0,0,0 2015-004835-10,8,2018-03-26,2018-03-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Palip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004835-10,0,0,0 2015-004835-10,8,2018-03-26,2018-03-26,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,"A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Palip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004835-10,0,0,0 2015-004836-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Anaesthesiology and Intensive Care, University of Tartu",Dose dependent effects of dobutamine on central and regional blood flow in preterm and term neonates Dobutamiini annusest sõltuv toime tsentraalsele ja regionaalsele verevoolule enneaegsetel ja aja...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004836-36,0,0,0 2015-004841-13,4,2017-10-12,2017-10-12,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Inc.,"A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homoz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004841-13,0,0,0 2015-004841-13,4,2017-10-12,2017-10-12,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homoz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004841-13,0,0,0 2015-004841-13,4,2017-10-12,2017-10-12,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Vertex Pharmaceuticals, Inc.","A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homoz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004841-13,0,0,0 2015-004843-38,1,2016-07-09,2016-07-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Sanofi-Aventis Groupe,"A Randomized, Double-blind, 2x2 Cross-over Euglycemic Clamp Study in Two Parallel Cohorts to Compare the Pharmacodynamic and Pharmacokinetic Properties of 0.4 and 0.6 U/kg/day Insulin Glargine (Toujeo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004843-38,0,0,0 2015-004844-20,2,2019-07-10,2021-06-07,2,0,0,0,0,1,3,0,0,1,1,0,1,0,1,"Advaxis, Inc",Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004844-20,0,0,0 2015-004845-25,2,2019-10-07,2019-10-07,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F. Hoffmann-La Roche Ltd,A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with atezolizumab plus polatuzumab vedotin in patients with relapsed or refractory follicular lymphoma and rituxim...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004845-25,0,0,0 2015-004845-25,2,2019-10-07,2019-10-07,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,A phase Ib/II study evaluating the safety and efficacy of obinutuzumab in combination with atezolizumab plus polatuzumab vedotin in patients with relapsed or refractory follicular lymphoma and rituxim...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004845-25,0,0,0 2015-004846-25,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Maastricht University,Immunization against oxLDL in patients with lysosomal lipid diseases and associated metabolic disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004846-25,0,0,0 2015-004847-37,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"FONDAZIONE G. D'ANNUNZIO, CHIETI",A pilot study on Edoxaban for the resolution of left atrial thrombosis in patients with non-valvular atrial fibrillation Studio pilota su edoxaban per la risoluzione della trombosi atriale sinistra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004847-37,0,0,0 2015-004849-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Clinic od Munich-Großhadern (represented by the medical management),Randomised study to investigate FOLFOXIRI plus cetuximab or FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer (FIRE-4.5) Randomisierte Studie zur Unter...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004849-11,0,0,0 2015-004850-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Vejle Hospital,A randomized investigation of side effects to FOLFOXIRI in combination with tocotrienol or placebo as first line treatment of metastatic colorectal cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004850-17,0,0,0 2015-004851-28,3,2019-01-10,2019-01-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Evgen Pharma PLC,A Multicentre Phase 2 Study of SFX-01 Treatment and Evaluation in Patients with Estrogen Receptor (ER) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer Pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004851-28,0,0,0 2015-004856-24,12,,,0,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Daiichi Sankyo, Inc.","A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004856-24,0,0,0 2015-004856-24,12,,,0,1,0,0,0,1,3,0,0,2,0,0,0,0,1,DAIICHI SANKYO INC.,"A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004856-24,0,0,0 2015-004858-17,1,2019-02-05,2019-02-05,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,University Medical Center Utrecht (UMCU),REMission INDuction in very early Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004858-17,0,0,0 2015-004860-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centro Nacional Investigaciones Oncológicas (CNIO),Integrated Genomics and Avatar Mouse Models for Personalized Treatment of Pancreatic Cancer Elección de terapias personalizadas en pacientes con carcinoma de páncreas metastásico de acuerdo al anál...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004860-12,0,0,0 2015-004861-97,10,2022-07-07,2022-07-07,4,1,0,1,0,0,1,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE I/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (ANTI PD-L1 ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004861-97,1,0,0 2015-004861-97,10,2022-07-07,2022-07-07,4,1,0,1,0,0,1,0,0,2,0,0,0,0,1,F. Hoffman-La Roche Ltd.,"A PHASE I/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (ANTI PD-L1 ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004861-97,1,0,0 2015-004861-97,10,2022-07-07,2022-07-07,4,1,0,1,0,0,1,0,0,2,0,0,0,0,1,"Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.","A PHASE I/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (ANTI PD-L1 ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004861-97,1,0,0 2015-004863-35,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Helsinki University Hospital Comprehensive Cancer Center Hematology,A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004863-35,0,0,0 2015-004863-35,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Hospital District of Helsinki and Uusimaa/Helsinki University Hospital HUS,A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004863-35,0,0,0 2015-004864-12,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline,"A Multicenter, Randomized, Double-Blind, Parallel Group, 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone Propionate/Salmet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004864-12,0,1,1 2015-004865-10,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKiline Research and Development LTD.,"A Randomized, Parallel Group, Double-Blind, Comparative Trial Assessing Lung Function and Other Measures of Asthma Control in Adults and Adolescents, at least 12 Years of Age, with Asthma, Who Have Ei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004865-10,0,1,1 2015-004866-27,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development,"A repeat-dose, open-label, randomized, incomplete block design in pediatric subjects with asthma, ages 4 - 11 years, to compare systemic exposure and pharmacodynamics of fluticasone propionate and sal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004866-27,0,1,1 2015-004867-35,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline Research and Development Ltd.,"A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004867-35,0,1,1 2015-004868-11,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development,"A randomised, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered once daily compared...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004868-11,0,1,1 2015-004869-88,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline K.K. (GSK),"A multicenter, open-label study to evaluate preventive efficacy for herpes simplex virus infection and safety of 256U87 (valaciclovir hydrochloride) in adult and pediatric hematopoietic stem cell tran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004869-88,0,1,1 2015-004870-14,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study to determine the efficacy and safety of nebulized fluticasone propionate 1mg twice daily compared with or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004870-14,0,1,1 2015-004871-59,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development,"A randomised, double-blind, placebo-controlled, parallel group, multicentre study to evaluate the efficacy and safety of fluticasone furoate/vilanterol trifenatate (FF/VI) inhalation powder delivered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004871-59,0,1,1 2015-004872-31,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline,"The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004872-31,0,1,1 2015-004873-34,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,A Comparison of Fluticasone Furoate Nasal Spray (FFNS) versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004873-34,0,1,1 2015-004874-13,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline,An open label study to determine the pharmacokinetic profiles of amoxicillin and clavulanate in adolescent patients weighing at least 40kg and no more than 16 years of age receiving AUGMENTIN™XR (amox...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004874-13,0,1,1 2015-004875-61,1,2017-04-20,2017-04-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU TOULOUSE,Influence of apelin on insulin sensitivity in type 2 diabetic volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004875-61,0,0,0 2015-004876-31,1,2020-06-04,2020-06-04,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"An open-label, single arm study to investigate the safety, pharmacokinetics and pharmacodynamics of repeat doses of inhaled nemiralisib in patients with APDS/PASLI",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004876-31,0,0,0 2015-004878-15,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline K.K. (GSK),"A multi-center, uncontrolled, open-label, evaluation of lamotrigine monotherapy in adult subjects with newly diagnosed epilepsy or recurrent epilepsy (currently untreated).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004878-15,0,1,1 2015-004880-35,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Multicenter, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004880-35,0,1,1 2015-004881-27,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,Clinical assessment of GW815SF Salmeterol/fluticasone propionate (HFA MDI) in pediatric patients with bronchial asthma -A long term (24-week) study-,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004881-27,0,1,1 2015-004882-10,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,A study to compare GW815SF HFA MDI with concomitant treatment with salmeterol xinafoate DPI plus fluticasone propionate DPI and to assess long-term safety of GW815SF HFA MDI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004882-10,0,1,1 2015-004883-12,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004883-12,0,1,1 2015-004884-35,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development,"A repeat-dose, open-label, 2-session study to assess the systemic exposure to, and pharmacodynamics of, fluticasone propionate HFA inhalation aerosol 88 mcg administered twice-daily for 28 days delive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004884-35,0,1,1 2015-004885-27,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004885-27,0,1,1 2015-004886-98,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline,"A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily-In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004886-98,0,1,1 2015-004887-13,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Double-Blind, Parallel Group study of ADVAIR™ DISKUS™ 100/50 and FLOVENT™DISKUS™ 100, both twice daily, in a Pediatric Population during the Fall Viral Season.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004887-13,0,1,1 2015-004888-37,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,GlaxoSmithKline Research and Development Ltd,"A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spray ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004888-37,0,1,1 2015-004889-28,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004889-28,0,1,1 2015-004890-34,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline K.K.,Phase III study of adefovir dipivoxil tablets in patients with compensated chronic hepatitis B (comparative study against lamivudine).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004890-34,0,1,1 2015-004891-31,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults and Adolescent...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004891-31,0,1,1 2015-004892-61,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004892-61,0,1,1 2015-004893-14,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development,"A Randomised, Multi-centre, Double-blind, Double-dummy, two way cross-over, twelve weeks noninferiority study to evaluate the efficacy, safety and tolerability of combination dry powder Fluticasone Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004893-14,0,1,1 2015-004896-60,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality risk Decitabine-cytarabine chemotherapie bij oudere AML en hoog risico MDS patiën...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004896-60,0,0,0 2015-004898-32,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd.,"Pediatric Asthma Clinical Effectiveness study (PEACE). A Randomized, Double-Blind, Double Dummy, Parallel Group comparative clinical study of Salmeterol/Fluticasone propionate Inhalation Powder (50/10...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004898-32,0,1,1 2015-004899-30,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd.,"Multi-center, Randomised, Double-blind, Parallel, Placebo Controlled Study Of 0.05% Clobetasone Butyrate Cream in Subjects with Eczema to evaluate the Efficacy and Safety.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004899-30,0,1,1 2015-004900-44,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development,"A Multi-center, Randomized, Double-blind, Vehicle-Controlled, Phase 2 Study of the Safety and Efficacy of Benzoyl peroxide/Clindamycin gel and Tazarotene cream when used in combination in the Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004900-44,0,1,1 2015-004901-18,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development,Clinical Evaluation of lamotrigine in Epilepsy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004901-18,0,1,1 2015-004902-41,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd.,Clinical Evaluation of 506U78 in Japanese Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004902-41,0,1,1 2015-004903-22,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A randomized, double-blind, multicenter, superiority Phase III study to assess the safety and efficacy of Topical Retapamulin Ointment 1%, applied twice daily versus Placebo Ointment in Adults and Chi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004903-22,0,1,1 2015-004904-50,1,2019-06-13,2019-06-13,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GW Research Ltd,"A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of Cannabidiol (GWP42003-P) in infants with Infantile Spasms following an initial open label pilot study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004904-50,0,0,0 2015-004905-17,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development,"A randomised, double-blind, placebo controlled, parallel group , flexible dose study to evaluate the efficacy and safety of Paxil® Tablets in children and adolescents with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004905-17,0,1,1 2015-004907-22,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Medicines Development (Infectious Diseases),"A multicenter, open-label study to assess the efficacy and safety of potassium clavulanate/amoxicillin (CVA/AMPC 1:14 combination) in the treatment of [Japanese] children with acute bacterial rhinosin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004907-22,0,1,1 2015-004909-16,1,,,0,1,0,0,1,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline R&D Ltd,"A Multicentre, Randomized, Assessor-blind, Comparator-Controlled, Parallel-Group Clinical Trial to Establish the Efficacy and Safety of Duac™(1% clindamycin as clindamycin phosphate and 5% benzoyl per...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004909-16,0,1,1 2015-004912-39,2,2017-11-10,2017-11-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Pfizer, Inc.","A 15-WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARK...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004912-39,0,0,0 2015-004914-79,5,2021-10-15,2021-10-15,4,0,0,1,0,0,1,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors Estudio fase 1/2a de BMS-986205 administrado en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004914-79,1,0,0 2015-004914-79,5,2021-10-15,2021-10-15,4,0,0,1,0,0,1,0,0,2,1,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors Estudio fase 1/2a de BMS-986205 administrado en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004914-79,1,0,0 2015-004916-39,1,2018-05-30,2018-05-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Digestive Disease Center, Bispebjerg Hospital",PreOperative Steroid in Abdominal Wall Reconstruction: A Double-blinded Randomized Clinical Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004916-39,0,0,0 2015-004917-26,6,2018-11-08,2018-11-20,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"PARION SCIENCES, INC.","A Phase 2a, 2-part, Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivacaftor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004917-26,0,0,0 2015-004917-26,6,2018-11-08,2018-11-20,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Parion Sciences, Incorporated","A Phase 2a, 2-part, Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivacaftor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004917-26,0,0,0 2015-004918-22,1,2017-04-04,2017-04-04,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Ghent University Hospital,A comparison of chloroprocaine 3% versus levobupivacaine 0.5% for epidural anesthesia during caesarean section.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004918-22,0,0,0 2015-004919-20,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,MULTIMEDICA S.P.A.,A pilot study of nintedanib for lymphangioleiomyomatosis (LAM) A pilot study of nintedanib for lymphangioleiomyomatosis (LAM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004919-20,0,0,0 2015-004920-67,7,2021-05-28,2021-05-28,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination with Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination with Ipilimumab 3 mg/kg in Subjects with Previously Unt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004920-67,1,0,0 2015-004920-67,7,2021-05-28,2021-05-28,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination with Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination with Ipilimumab 3 mg/kg in Subjects with Previously Unt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004920-67,1,0,0 2015-004936-36,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,University of Cologne,"A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004936-36,0,0,0 2015-004937-29,1,2019-05-01,2019-05-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,VU University Medical Center,Towards early identification of response to CABAZItaxel in patients with metastatic castration-resistant prostate cancer: potential of 18F-Choline PET-CT (CABAZIPET). Vroegtijdig identificeren va...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004937-29,0,0,0 2015-004956-23,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,Institut de Recerca HSCSP,"COLIBRI STUDY, Cooper and Levonorgestrel Intrauterine Device (IUD) Barcelona Research Initiative. A randomized controlled trial to compare the menstrual bleeding profile among cooper and 13,5mg levono...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004956-23,0,0,0 2015-004959-50,1,2021-11-18,2021-11-18,1,1,0,0,0,0,3,0,0,1,0,0,0,0,1,S.E. Carburos Metálicos S.A. grupo Air Products,HELIOX-DRIVEN BETA2-AGONISTS NEBULIZATION FOR CHILDREN WITH MODERATE TO SEVERE ACUTE ASTHMA: A RANDOMIZED CONTROLLED TRIAL HELIOX COMO VEHÍCULO EN LA NEBULIZACIÓN DE BETA 2-AGONISTAS EN NIÑOS CON A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004959-50,0,0,0 2015-004960-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INTERGRUPPO MELANOMA ITALIANO,SEQUENTIAL THERAPY WITH VEMURAFENIB AND ELECTROCHEMOTHERAPY FOR IN-TRANSIT MELANOMA METASTASES: A MULTICENTER SINGLE ARM PHASE II CLINICAL PROSPECTIVE STUDY OF THE ITALIAN MELANOMA INTERGROUP (IMI) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004960-12,0,0,0 2015-004977-34,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,"CSL Behring, LLC","Study of immune deficiency patients treated with subcutaneous immunoglobulin (IgPro20, Hizentra®) on weekly and biweekly schedules",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004977-34,0,1,1 2015-004982-10,1,2017-02-27,2017-02-27,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Harry Scheinin,The Neural Mechanisms of Anesthesia and Human Consciousness (Part 6),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004982-10,0,0,0 2015-004984-35,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Epizyme, Inc.","Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004984-35,0,0,0 2015-004986-99,2,2019-01-11,2019-01-11,1,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"NovaBiotics, Ltd","A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Investigating the Optimal Dose Regimen, Efficacy, and Safety of Adding Oral Cysteamine in Adult Patients with Cystic Fibrosis (CF) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004986-99,1,0,0 2015-004990-34,8,2018-01-30,2018-01-30,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared with the Withdrawal of Sitagliptin Du...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004990-34,0,0,0 2015-004990-34,8,2018-01-30,2018-01-30,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared with the Withdrawal of Sitagliptin Du...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004990-34,0,0,0 2015-004991-31,10,2019-08-16,2019-08-16,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Incyte Corporation,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 / E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004991-31,0,0,0 2015-004991-31,10,2019-08-16,2019-08-16,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INCYTE CORPORATION,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 / E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004991-31,0,0,0 2015-004992-62,7,2020-02-28,2020-02-28,6,1,1,0,0,0,3,0,0,1,0,0,1,0,1,IPSEN PHARMA SAS,"A PHASE 3, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, STUDY OF THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL/ DEPOT 120 MG PLUS BSC VS. PLACEBO PLUS BSC FOR TUMOR CONTROL IN SUBJECTS WITH WE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004992-62,0,0,0 2015-004992-62,7,2020-02-28,2020-02-28,6,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Ipsen Biopharmaceuticals, Inc","A PHASE 3, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, STUDY OF THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL/ DEPOT 120 MG PLUS BSC VS. PLACEBO PLUS BSC FOR TUMOR CONTROL IN SUBJECTS WITH WE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004992-62,0,0,0 2015-004998-33,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University of Heidelberg,Multicenter prospective trial after first unsuccesful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistance of molecular remission afte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004998-33,0,0,0 2015-004998-33,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,VU University Medical Center,Multicenter prospective trial after first unsuccesful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistance of molecular remission afte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-004998-33,0,0,0 2015-005003-88,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,Survival Improvement with Cholecalciferol in Patients on Dialysis – The SIMPLIFIED Registry Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005003-88,0,0,0 2015-005004-28,1,2019-04-04,2019-04-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London,Stratified Treatment OPtimisation for HCV-1 (STOPHCV-1),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005004-28,0,0,0 2015-005007-86,3,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Kite Pharma Inc.,A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) (ZUMA-1),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005007-86,0,0,0 2015-005007-86,3,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Kite Pharma, Inc.",A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) (ZUMA-1),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005007-86,0,0,0 2015-005008-27,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Kite Pharma, Inc.",A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005008-27,0,0,0 2015-005008-27,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Kite Pharma Inc.,A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005008-27,0,0,0 2015-005009-35,3,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Kite Pharma Inc.,A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005009-35,0,0,0 2015-005009-35,3,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Kite Pharma, Inc.",A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005009-35,0,0,0 2015-005010-30,9,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,"Kite Pharma, Inc.",A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005010-30,0,0,0 2015-005010-30,9,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,KITE PHARMA INC.,A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005010-30,0,0,0 2015-005010-30,9,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,Kite Pharma Inc.,A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005010-30,0,0,0 2015-005013-76,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,ACCORD office,GEM3: A double blind placebo controlled trial of a combination of methotrexate and gefitinib versus methotrexate alone as a treatment for ectopic pregnancy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005013-76,0,0,0 2015-005013-76,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,NHS Lothian R&D Office,GEM3: A double blind placebo controlled trial of a combination of methotrexate and gefitinib versus methotrexate alone as a treatment for ectopic pregnancy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005013-76,0,0,0 2015-005014-30,1,2021-11-01,2021-11-01,1,0,0,0,0,0,3,0,0,1,0,0,0,0,0,"Medical University of Vienna, Department of Internal medicine I","A prospective randomized, double blind study on safety and efficacy of Alprostadil as additional Anticoagulant in Patients with veno- venous ECMO",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005014-30,0,0,0 2015-005016-15,1,2017-10-30,2017-10-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Radboudumc,"Accuracy of lymph node imaging in prostate cancer: A prospective cohort study to determine the concordance between two imaging modalities, “Combidex” magnetic resonance imaging (Nano MRI) and 68Ga-PSM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005016-15,0,0,0 2015-005017-71,1,2019-05-15,2019-05-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre François Baclesse,Diagnostic value of 18F-choline PET in patients with indeterminate cytology thyroid nodule : A pilot study Intérêt diagnostique de la TEP à la 18-F Choline chez les patients porteurs d’un nodule th...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005017-71,0,0,0 2015-005019-34,3,2019-05-03,2019-05-03,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,"Novartis Farmacéutica, S.A.",A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005019-34,0,0,0 2015-005019-34,3,2019-05-03,2019-05-03,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Novartis Pharma Services AG,A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005019-34,0,0,0 2015-005021-39,2,2019-03-19,2019-03-19,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab in prefilled syringes, to compare efficacy at 16 weeks with placebo and to assess safety and tol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005021-39,0,0,0 2015-005023-11,4,2018-01-17,2018-05-31,4,1,0,0,0,2,2,0,0,1,1,1,1,0,1,MERCK KGAA,"A Phase II, randomized, double-blind, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-associated interstitia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005023-11,0,0,0 2015-005023-11,4,2018-01-17,2018-05-31,4,1,0,0,0,2,2,0,0,1,1,1,1,0,1,Merck KGaA,"A Phase II, randomized, double-blind, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-associated interstitia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005023-11,0,0,0 2015-005033-53,5,2018-06-21,2018-06-21,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Edge Therapeutics, Inc","Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005033-53,0,0,0 2015-005033-53,5,2018-06-21,2018-06-21,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Edge Therapeutics, Inc.","Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005033-53,0,0,0 2015-005034-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de DIJON,Effets de la Dapagliflozine sur la cinétique des lipoprotéines chez des patients diabétiques de type 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005034-21,0,0,0 2015-005035-41,1,2018-12-17,2018-12-17,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Theranexus SA,SAFETY AND EFFICACY OF THN102 ON SLEEPINESS IN NARCOLEPTIC PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005035-41,0,0,0 2015-005040-33,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,"Pfizer, Inc.","An Open-label, Single-arm, Post- Authorization Pragmatic Clinical Trial On The Safety And Efficacy Of Xyntha (moroctocog-alfa (af-cc), Recombinant FVIII) In Subjects With Hemophilia A In Usual Care Se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005040-33,0,1,1 2015-005041-31,3,2020-04-06,2020-04-06,3,1,1,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial with a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005041-31,0,0,0 2015-005042-66,5,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005042-66,0,0,0 2015-005043-13,1,2020-03-07,2020-03-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Birmingham,"Evaluating different rate control therapies in permanent atrial fibrillation: A prospective, randomised, open-label, blinded endpoint study comparing digoxin and beta-blockers as initial rate control ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005043-13,0,0,0 2015-005045-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Erasmus MC,Switching to Tenofovir Alafenamide Fumarate or ABACavir in patients with Tenofovir Disoproxil Fumarate associated eGFR decline. A randomized clinical trial. Switchen naar tenofovir alafenamide fu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005045-31,0,0,0 2015-005046-55,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Umeå University Hospital,"Evaluation of [68Ga]PSMA PET/MRI in intermediate and high risk prostate cancer – a comparison with mpMRI, [11C]ACE PET/CT and histopathological validation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005046-55,0,0,0 2015-005051-28,6,2018-10-29,2018-10-29,5,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Amgen Inc,"An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to less than 18 Years with Second...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005051-28,1,1,0 2015-005053-12,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Merck Sharp & Dohme Corp.,"A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005053-12,0,0,0 2015-005053-12,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005053-12,0,0,0 2015-005054-36,1,2017-09-06,2017-09-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase-II, Randomized, Placebo-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Safety of MK-1029 in Adult Subjects with Persistent Asthma That is Uncontrolled While Receiving Mont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005054-36,0,0,0 2015-005056-96,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,0,Daniel Sanabria Lucena,Use of tramadol in healthy volunteers. Effects on physical performance and sustained attention in cycling. Uso de tramadol en voluntarios sanos. Efectos en el rendimiento físico y la atención soste...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005056-96,0,0,0 2015-005063-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,A randomized presurgical study with different schedules of exemestane in postmenopausal women with stage 0-II ER-positive breast cancer Studio prechirurgico randomizzato con exemestane a posologie ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005063-16,0,0,0 2015-005064-42,1,2016-11-04,2016-11-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Afferent Pharmaceuticals, Inc.",A 12-Week Study to Assess the Efficacy and Safety of AF-219 in Subjects with Treatment Refractory Chronic Cough,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005064-42,0,0,0 2015-005067-17,2,2016-12-06,2016-12-06,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Civitas Therapeutics, a wholly owned subsidiary of Acorda Therapeutics, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson?s Disease Patients With Motor Response Fluctuat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005067-17,0,0,0 2015-005067-17,2,2016-12-06,2016-12-06,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Civitas Therapeutics, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson?s Disease Patients With Motor Response Fluctuat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005067-17,0,0,0 2015-005069-21,5,2019-02-20,2019-02-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lilly S.A.,A Phase 2 Study of LY2606368 in Patients with Extensive Stage Disease Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005069-21,0,0,0 2015-005069-21,5,2019-02-20,2019-02-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company Limited,A Phase 2 Study of LY2606368 in Patients with Extensive Stage Disease Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005069-21,0,0,0 2015-005069-21,5,2019-02-20,2019-02-20,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Phase 2 Study of LY2606368 in Patients with Extensive Stage Disease Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005069-21,0,0,0 2015-005071-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Heart Center Freiburg - Bad Krozingen,Pharmacodynamic comparison of different oral P2Y12-receptor inhibitor loading strategies for transitioning from cangrelor in patients undergoing coronary stenting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005071-25,0,0,0 2015-005078-39,3,2017-01-31,2017-01-31,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,NeuroDerm Ltd.,"A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety, tolerability and pharmacokinetics of 2 dosing regimens of ND0612H, a solution of levodopa/ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005078-39,0,0,0 2015-005078-39,3,2017-01-31,2017-01-31,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,NEURODERM LTD.,"A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety, tolerability and pharmacokinetics of 2 dosing regimens of ND0612H, a solution of levodopa/ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005078-39,0,0,0 2015-005079-26,3,2016-08-11,2016-08-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim International GmbH,"ELUXA 2: An international, randomised, multi-centre, active controlled, open-label Phase III study evaluating the efficacy of BI 1482694 versus standard platinum doublet chemotherapy in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005079-26,0,0,0 2015-005081-30,4,2017-04-27,2017-04-27,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,H. Lundbeck A/S,"Interventional, randomised, double-blind, parallel-group study of the efficacy and safety of initial administration of 17 mg vortioxetine intravenously with 10 mg/day vortioxetine orally in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005081-30,0,0,0 2015-005086-23,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Linnéuniversitetet,Mekobalamin's (Vitamin B12) effect on long-term pain in women with fibromyalgi. Mekobalamin´s (vitamin B12) effekt på långvarig smärta hos kvinnor med diagnostiserad fibromyalgi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005086-23,0,0,0 2015-005090-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE FADOI,"Rivaroxaban or placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer: a randomized, double blind, placebo-controlled study. THE PRO-LAPS STUDY II Rivaroxa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005090-20,0,0,0 2015-005092-24,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,FUNDACIÓ SANT JOAN DE DÉU,"A prospective, open-label, randomized, two-armed clinical trial to evaluate the efficacy and safety of a combination of ethinyl-estradiol and levonorgestrel versus a low-dose combination of pioglitazo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005092-24,0,0,0 2015-005093-38,6,2018-11-19,2019-01-21,6,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur MSD S.N.C,An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005093-38,0,0,0 2015-005093-38,6,2018-11-19,2019-01-21,6,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck Co., Inc",An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005093-38,0,0,0 2015-005097-37,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Essen,"A phase II, multicenter, open-label, randomized-controlled trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti- PD-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005097-37,0,0,0 2015-005098-19,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,EORTC AISBL/IVZW,Phase IIIb randomized trial comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005098-19,0,0,0 2015-005098-19,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),Phase IIIb randomized trial comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localized ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005098-19,0,0,0 2015-005100-28,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,MASTELLI SRL,"A phase IV, single-arm, open-label clinical trial to evaluate the efficacy and safety of PLACENTEX ¿ Polydeoxyribonucleotide i.m. in patients with fibrotic and atrophic cutaneous lesions in scleroder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005100-28,0,0,0 2015-005101-36,12,2017-08-15,2017-08-15,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,sanofi-aventis Groupe,"A 24-Week, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo® and Tresiba® in Insulin-Naive Patients with Type 2 Diabetes Mellitus Not Adequately Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005101-36,0,0,0 2015-005101-36,12,2017-08-15,2017-08-15,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,SANOFI-AVENTIS GROUPE,"A 24-Week, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo® and Tresiba® in Insulin-Naive Patients with Type 2 Diabetes Mellitus Not Adequately Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005101-36,0,0,0 2015-005103-89,2,2019-10-15,2019-10-15,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,"Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie",Open-label single arm phase II study on pembrolizumab for recurrent primary central nervous system lymphoma (PCNSL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005103-89,0,0,0 2015-005105-36,6,2018-10-25,2018-10-26,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pharmacyclics Switzerland GmbH,An Open-label study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005105-36,0,0,0 2015-005105-36,6,2018-10-25,2018-10-26,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"PHARMACYCLICS, INC.",An Open-label study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005105-36,0,0,0 2015-005110-30,1,,,0,0,0,0,0,1,4,0,0,1,1,1,0,1,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","A multicenter randomized trial to evaluate the efficacy of fentanyl pectin nasal spray (FPNS) versus Physician Choice (PC) - Usual Care (UC), in reducing incidental predictable breakthrough pain (IP-B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005110-30,0,0,0 2015-005111-32,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,ABOCA S.P.A. SOCIETà AGRICOLA,"Multicenter, Prospective, Comparative, Randomized Controlled Clinical investigation on the performance of Promelaxin® micro-enemas versus oral administration of Macrogol 4000, in the treatment of chro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005111-32,0,0,0 2015-005112-15,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"Inselspital, Universitätspital Bern",TARGETED TISSUE PERFUSION VERSUS MACROCIRCULATORY-GUIDED STANDARD CARE IN PATIENTS WITH SEPTIC SHOCK (TARTARE-2S),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005112-15,0,0,0 2015-005113-73,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005113-73,0,0,0 2015-005117-72,5,2021-05-17,2021-05-17,1,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Agios Pharmaceuticals, Inc.","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005117-72,1,0,0 2015-005117-72,5,2021-05-17,2021-05-17,1,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"AGIOS PHARMACEUTICALS, INC.","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005117-72,1,0,0 2015-005120-26,1,2016-07-27,2016-07-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research and Development Limited,"A Phase II, Randomized, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Efficacy, Safety, and Tolerability of Single Doses of GSK2140944 in the Treatment of Uncomplicated Urogenital G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005120-26,0,0,0 2015-005124-25,1,2017-10-26,2017-10-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novalon S.A.,"Open-label, multi-center, randomized parallel group study to assess the pharmacokinetic (PK) profile of Zoreline 3.6 mg goserelin subcutaneous implant (test product, Novalon S.A.) and of Zoladex® 3.6 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005124-25,0,0,0 2015-005130-22,3,2016-12-20,2016-12-20,1,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Fundación para la Formación e Investigación Sanitaria (FFIS),Randomised Controlled Trial with Pravastatin versus Placebo for Prevention of Pre-eclampsia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005130-22,1,0,0 2015-005131-40,8,2020-08-22,2020-08-22,6,1,0,0,0,1,2,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005131-40,1,0,0 2015-005131-40,8,2020-08-22,2020-08-22,6,1,0,0,0,1,2,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005131-40,1,0,0 2015-005134-21,1,2017-11-21,2017-11-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Noven Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 in Subjects Diagnosed with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005134-21,0,0,0 2015-005136-18,1,2018-03-21,2018-03-21,1,0,0,0,1,0,2,0,0,1,0,0,1,0,1,Arbutus Biopharma Corporation,"A Phase 2a, Single-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti-Viral Activity, and Pharmacokinetics of ARB-001467 in Non-Cirrhotic, HBeAg-Negative and Positive Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005136-18,0,0,0 2015-005137-42,4,2017-11-03,2017-11-03,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,DEBIOPHARM INTERNATIONAL S.A.,"A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Neoadjuvant Carboplatin and Paclitaxel, With or Without Debio 1143 in Patients With Newly Diagnosed Advanced Epithelial Ovarian Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005137-42,0,0,0 2015-005137-42,4,2017-11-03,2017-11-03,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Debiopharm International SA,"A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Neoadjuvant Carboplatin and Paclitaxel, With or Without Debio 1143 in Patients With Newly Diagnosed Advanced Epithelial Ovarian Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005137-42,0,0,0 2015-005140-33,1,2021-02-20,2021-02-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Odense Universitets Hospital,"Can Fat Derived Stem Cells (SVF) be Used in the Treatment of Erectile Dysfunction After Prostatectomy- randomized, placebo-controlled, double-blind clinical trial. Kan fedtderiverede stamceller (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005140-33,0,0,0 2015-005141-32,5,2019-11-22,2019-11-22,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Mylan GmbH,"Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous No...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005141-32,0,0,0 2015-005141-32,5,2019-11-22,2019-11-22,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MYLAN GMBH,"Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin®, in the First-line Treatment of Patients with Stage IV Non-Squamous No...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005141-32,0,0,0 2015-005143-13,2,2019-10-08,2019-10-08,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Targovax Oy,"A randomised Phase II open-label study with a Phase Ib safety lead-in cohort of ONCOS-102, an immune-priming GM-CSF coding oncolytic adenovirus, and pemetrexed/cisplatin in patients with unresectable ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005143-13,0,0,0 2015-005143-13,2,2019-10-08,2019-10-08,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Targovax ASA,"A randomised Phase II open-label study with a Phase Ib safety lead-in cohort of ONCOS-102, an immune-priming GM-CSF coding oncolytic adenovirus, and pemetrexed/cisplatin in patients with unresectable ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005143-13,0,0,0 2015-005146-55,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Vakgroep Huisartsgeneeskunde Vrije Universiteit Brussel,The effect of methylphenidate (Ritalin®) on the severity of stuttering.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005146-55,0,0,0 2015-005147-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,"The effect of low dietary glycemic index, excercise and vitamin D on breast cancer recurrence in women L¿effetto della combinazione di dieta a basso indice glicemico, esercizio fisico e vitamina D ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005147-14,0,0,0 2015-005151-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitario de Canarias,Randomized prospective clinical trial to evaluate the rate of early recurrence in bladder cancer in non-muscle invasive between the chemohyperthermia (QH) with mitomycin-C prior to transurethral resec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005151-27,0,0,0 2015-005152-10,1,2017-06-08,2017-06-08,1,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A,"A SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSS-OVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 35/4 NEXTHALER® (DPI FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE (BDP) 35 µg PLUS FORMOTEROL FUMARA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005152-10,0,0,0 2015-005153-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,Phase II trial on trabectedin in the treatment of advanced uterine and ovarian carcinosarcoma (Cs) – MITO 26 Studio di Fase II con Trabectedina nel trattamento del carcinosarcoma ovarico o uterino ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005153-12,0,0,0 2015-005154-35,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,University Hospital Brussels (UZ Brussel),N-acetylcysteine for the treatment of cannabis dependence: working mechanisms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005154-35,0,0,0 2015-005155-27,2,2018-03-06,2018-03-06,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Krka, d.d., Novo mesto",Comparison of the efficacy and safety of the fixed-dose combination of xylometazoline and dexpanthenol in SeptaNazal® and xylometazoline in nasal congestion in patients after surgery in the nose and p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005155-27,0,0,0 2015-005155-27,2,2018-03-06,2018-03-06,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,KRKA-FARMA d.o.o.,Comparison of the efficacy and safety of the fixed-dose combination of xylometazoline and dexpanthenol in SeptaNazal® and xylometazoline in nasal congestion in patients after surgery in the nose and p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005155-27,0,0,0 2015-005156-94,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Eli Lilly and Company,"Protocol I3Y-MC-JPCE A Phase 1b Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005156-94,0,0,0 2015-005156-94,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Lilly S.A.,"Protocol I3Y-MC-JPCE A Phase 1b Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005156-94,0,0,0 2015-005159-28,1,2016-12-29,2016-12-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MetrioPharm AG,"A randomized (1:1), double-blind, parallel, placebo-controlled exploratory pilot study to evaluate the safety, pharmacokinetics and efficacy of systemic (po) application of MP1032 in patients with mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005159-28,0,0,0 2015-005160-41,5,2021-11-11,2021-11-11,5,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Biogen Idec Research Limited,A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005160-41,0,0,0 2015-005160-41,5,2021-11-11,2021-11-11,5,0,0,0,0,0,3,0,0,1,0,0,0,0,1,"Alkermes, Inc.",A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005160-41,0,0,0 2015-005161-23,12,2019-10-17,2019-10-17,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 4, Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction with Surgery in Subjects with Moderate to Severe Hidradeni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005161-23,0,0,0 2015-005161-23,12,2019-10-17,2019-10-17,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 4, Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction with Surgery in Subjects with Moderate to Severe Hidradeni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005161-23,0,0,0 2015-005162-34,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Basel,"Randomized, multi-center phase II clinical trial for the regeneration of cartilage lesions in the knee using nasal chondrocyte-based tissue (NTEC) or nasal chondrocyte-based cell (N-CAM)-therapies ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005162-34,0,0,0 2015-005163-16,1,2019-02-11,2019-02-11,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark","Effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis. A randomised, double blind, placebo-controlled, parallel group, single-centre trial Effekten...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005163-16,0,0,0 2015-005170-38,5,2018-06-08,2018-06-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, placebo-controlled, 52-weeks study to demonstrate the efficacy, safety and tolerability of subcutaneous secukinumAb injections with 2 mL pre-fiLLed syringes (3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005170-38,0,0,0 2015-005170-38,5,2018-06-08,2018-06-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A multicenter, randomized, double-blind, placebo-controlled, 52-weeks study to demonstrate the efficacy, safety and tolerability of subcutaneous secukinumAb injections with 2 mL pre-fiLLed syringes (3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005170-38,0,0,0 2015-005171-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,"Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005171-24,0,0,0 2015-005173-20,5,2022-04-24,2022-04-24,2,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Celgene International II Sàrl,"A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005173-20,1,0,0 2015-005176-17,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Bellicum Pharmaceuticals, Inc.","A Phase I Study of Safety, Pharmacokinetics and Efficacy of Donor BPX-501 Cells and AP1903 Infusion for Children with Recurrent or Minimal Residual Disease Hematologic Malignancies After Allogeneic Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005176-17,0,0,0 2015-005177-21,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Assistance Publique Hôpitaux de MARSEILLE,Dose-Finding of Propranolol in combination with metronomic fixed oral cyclophosphamide based on Bivariate efficacy-tolerability outcome in patients with locally advanced or metastatic angiosarcoma : A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005177-21,0,0,0 2015-005179-25,2,2017-06-27,2017-06-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pacira Pharmaceuticals, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block with EXPAREL for Postsurgical Analgesia in Subjects Under...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005179-25,0,0,0 2015-005180-16,5,2019-12-01,2019-12-01,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Fundación para la Formación e Investigación Sanitaria,"Early vaginal progesterone for the prevention of spontaneous preterm birth in twins: A randomised, placebo controlled, double-blinded trial .EVENTS Uso precoz de progesterona para la prevención del...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005180-16,1,0,0 2015-005181-33,1,,,0,1,0,0,1,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,"Safety and Immunogenicity Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) versus Tetanus Toxoid, Reduced Diphtheria Toxoid and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005181-33,0,1,1 2015-005182-23,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety of the Inactivated Poliomyelitis Vaccine (IMOVAX Polio™) Administered at 2, 3, and 4 Months of Age and Followed by a Booster Dose at 18 Months of age in Healthy Infants in Ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005182-23,0,1,1 2015-005183-42,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of Fractional Doses of Sanofi Pasteur’s Inactivated Poliomyelitis Vaccine (IMOVAX Polio™) Administered Intradermally versus Full Doses of Inactivated Poliomyelitis Vaccine (I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005183-42,0,1,1 2015-005184-16,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of Fractional Booster Dose of sanofi pasteur’s Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intradermally versus Full Booster Dose of Inactivated Poliomyelit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005184-16,0,1,1 2015-005185-34,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Sanofi Pasteur China,"Safety study of IMOVAX Polio in selected cities in China, an observational post marketing study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005185-34,0,1,1 2015-005186-23,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Sanofi Pasteur China,"Large scale safety study of IMOVAX Polio in selected cities in China, an observational post marketing study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005186-23,0,1,1 2015-005187-42,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Aventis K.K.,Immunogenicity and Safety of the SP059 Given Subcutaneously as a Three-Dose Primary and Booster Vaccination in Infants in Japan,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005187-42,0,1,1 2015-005188-17,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of different sequential schedules of Inactivated Poliomyelitis Vaccine (IMOVAX Polio®) followed by Oral Poliomyelitis Vaccine in Healthy Infants in China versus Oral Poliomye...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005188-17,0,1,1 2015-005189-48,1,,,0,1,0,0,1,0,4,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine versus Lanzhou Institute of Biological Products Meningococcal (Groups A and C) Polysaccharide Vaccine ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005189-48,0,1,1 2015-005190-21,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of ADACEL Polio (TdcP-IPV Vaccine) Administered at 6 to 8 Years of Age as a Fifth Dose (Pre-School Booster) in Healthy Children in Taiwan,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005190-21,0,1,1 2015-005191-18,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety of Sanofi Pasteur’s AVAXIM 80U Pediatric Vaccine Administered in Healthy Adolescents, Children and Toddlers in People’s Republic of China Followed by a Booster Dose 6 Months ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005191-18,0,1,1 2015-005192-24,1,,,0,1,0,0,1,0,4,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly with TRIMOVAX™ in 12-13 Months old Healthy Hepatitis A Seronegative Turkish Children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005192-24,0,1,1 2015-005193-38,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,A Controlled Study of the Safety and Immunogenicity of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005193-38,0,1,1 2015-005194-20,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free in Comparison with the Reference Purified Vero Rabies Vaccine in Post-exposure Use in Healthy Subjects in China,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005194-20,0,1,1 2015-005195-22,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur KK,Immunogenicity and Safety of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine Given in Japanese Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005195-22,0,1,1 2015-005196-24,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Sanofi Pasteur Limited,"Three-, Five-, and Ten-Year Data on the Long-Term Immunogenicity of Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005196-24,0,1,1 2015-005197-38,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur Limited,"Six-Month, One-Year, Three-Year, Five-Year and Ten-Year Data on the Long-Term Immunogenicity of Td-mIPV, Tdap-vIPV, Td, aP and Tdap in Adolescents and Adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005197-38,0,1,1 2015-005202-10,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ISTITUTO EUROPEO DI ONCOLOGIA,"An open label, single-center, not controlled, exploratory study to develop and evaluate the application of a new technique of radioguided surgery in gastro-entero-pancreatic neuroendocrine tumors (RAD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005202-10,0,0,0 2015-005209-36,6,2018-03-08,2018-03-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus. A 52-week Randomised, Open-label, Active-controlled Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005209-36,0,0,0 2015-005209-36,6,2018-03-08,2018-03-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK. S.P.A.,"Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus. A 52-week Randomised, Open-label, Active-controlled Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005209-36,0,0,0 2015-005210-30,6,2018-03-30,2018-05-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus. A 52-week randomised, double-blind, active- and placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005210-30,0,0,0 2015-005211-32,1,2019-08-05,2019-08-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Daiichi Sankyo, Inc.","A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of DS-1040b when Added to Sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005211-32,0,0,0 2015-005212-14,4,2017-05-23,2017-05-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A phase IIIB, 24-week randomised, double-blind study to compare 'closed' triple therapy (FF/UMEC/VI) with 'open' triple therapy (FF/VI + UMEC), in subjects with chronic obstructive pulmonary disease (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005212-14,0,0,0 2015-005212-14,4,2017-05-23,2017-05-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A phase IIIB, 24-week randomised, double-blind study to compare 'closed' triple therapy (FF/UMEC/VI) with 'open' triple therapy (FF/VI + UMEC), in subjects with chronic obstructive pulmonary disease (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005212-14,0,0,0 2015-005212-14,4,2017-05-23,2017-05-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A phase IIIB, 24-week randomised, double-blind study to compare 'closed' triple therapy (FF/UMEC/VI) with 'open' triple therapy (FF/VI + UMEC), in subjects with chronic obstructive pulmonary disease (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005212-14,0,0,0 2015-005215-33,7,2020-04-06,2020-04-06,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo controlled, 2- part, adaptive design, multicenter 12-week study to assess safety, tolerability and efficacy of LJN452 in patients with non-alcoholic steatohepatitis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005215-33,0,0,0 2015-005215-33,7,2020-04-06,2020-04-06,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled, 2- part, adaptive design, multicenter 12-week study to assess safety, tolerability and efficacy of LJN452 in patients with non-alcoholic steatohepatitis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005215-33,0,0,0 2015-005215-33,7,2020-04-06,2020-04-06,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo controlled, 2- part, adaptive design, multicenter 12-week study to assess safety, tolerability and efficacy of LJN452 in patients with non-alcoholic steatohepatitis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005215-33,0,0,0 2015-005216-15,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,ABOCA S.P.A. SOCIETà AGRICOLA,"Relief of heartburn and epigastric pain comparing Neobianacid® with omeprazole: a randomized, double blind, double dummy, reference product controlled, parallel group, non-inferiority clinical study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005216-15,0,0,0 2015-005219-34,1,2021-10-28,2021-10-28,1,0,0,0,0,0,3,0,0,1,1,1,0,0,0,Technische Universitaet Muenchen Fakultaet fuer Medizin,Parenteral Nutrition during neoadjuvant chemotherapy for patients with advanced cancer of the GE-junction/esophagus/stomach/pancreas or rectum for reduction of postoperative morbiditiy Parenterale ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005219-34,0,0,0 2015-005220-26,9,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Acerta Pharma BV,"A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005220-26,0,0,0 2015-005220-26,9,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,ACERTA PHARMA BV,"A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005220-26,0,0,0 2015-005222-19,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Leiden University Medical Center,Effect of neuromuscular blockade and reversal by sugammadex versus neostigmine on breathing when hypoxic or hypercapnic in volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005222-19,0,0,0 2015-005223-90,9,2018-08-07,2018-08-07,6,0,0,0,0,1,3,0,0,1,1,1,1,0,1,Bellerophon Pulse Technologies LLC,"A PHASE 3, PLACEBO CONTROLLED, DOUBLE-BLIND, RANDOMIZED, CLINICAL STUDY TO DETERMINE EFFICACY, SAFETY AND TOLERABILITY OF PULSED, INHALED NITRIC OXIDE (iNO) VERSUS PLACEBO IN SYMPTOMATIC SUBJECTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005223-90,0,0,0 2015-005223-90,9,2018-08-07,2018-08-07,6,0,0,0,0,1,3,0,0,1,1,1,1,0,1,BELLEROPHON PULSE TECHNOLOGIES LLC,"A PHASE 3, PLACEBO CONTROLLED, DOUBLE-BLIND, RANDOMIZED, CLINICAL STUDY TO DETERMINE EFFICACY, SAFETY AND TOLERABILITY OF PULSED, INHALED NITRIC OXIDE (iNO) VERSUS PLACEBO IN SYMPTOMATIC SUBJECTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005223-90,0,0,0 2015-005226-19,1,2016-09-19,2016-09-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Medical University of Innsbruck,Accelerated wound healing in diabetic ulcers by Sitagliptin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005226-19,0,0,0 2015-005228-24,2,2017-07-07,2017-07-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pacira Pharmaceuticals, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block with EXPAREL for Postsurgical Analgesia in Subjects Und...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005228-24,0,0,0 2015-005231-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UMBERTO I - POLICLINICO DI ROMA,"Effect of Aspirin on renal disease progression in patients with type 2 diabetes: a multicentre double-blind, placebo-controlled, randomised trial. The LEDA (renaL disEase progression by aspirin in Dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005231-40,0,0,0 2015-005234-21,8,2021-01-21,2021-01-21,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (galcanezumab) in Patients with Episodic or Chronic Cluster Headache",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005234-21,0,0,0 2015-005234-21,8,2021-01-21,2021-01-21,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (galcanezumab) in Patients with Episodic or Chronic Cluster Headache",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005234-21,0,0,0 2015-005234-21,8,2021-01-21,2021-01-21,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (galcanezumab) in Patients with Episodic or Chronic Cluster Headache",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005234-21,0,0,0 2015-005238-23,2,2019-07-22,2019-07-22,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,The Rockefeller University,"A phase 2a, randomized study of the combination of romidepsin and 3BNC117 to evaluate the effects on the HIV-1 reservoir (ROADMAP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005238-23,0,0,0 2015-005238-23,2,2019-07-22,2019-07-22,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Rockefeller University,"A phase 2a, randomized study of the combination of romidepsin and 3BNC117 to evaluate the effects on the HIV-1 reservoir (ROADMAP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005238-23,0,0,0 2015-005240-33,1,2016-06-15,2016-06-15,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,The Mentholatum Company Ltd,"A single centre, randomised, single-blind, parallel group single dose study to compare the speed of onset of ibuprofen gel, ibuprofen gel with levomenthol, and diclofenac gel in the relief of pain fro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005240-33,0,0,0 2015-005241-31,6,2021-05-13,2021-05-13,4,0,0,0,0,1,3,0,0,2,0,0,0,0,1,ERYDEL S.P.A.,"A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005241-31,1,0,0 2015-005241-31,6,2021-05-13,2021-05-13,4,0,0,0,0,1,3,0,0,2,0,0,0,0,1,EryDel S.p.A.,"A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005241-31,1,0,0 2015-005242-60,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Liverpool,"RESILIENT: RandomisEd, controlled, double blind Study to assess mechanistic effects of combination therapy of dapagliflozin with Exenatide QW versus dapagliflozin alone in obese (BMI>30 kg/m2) patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005242-60,0,0,0 2015-005246-59,1,2017-06-01,2017-06-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Michael Patrick Achiam,Endoscopic electroporation in esophageal cancer Endoskopisk elektroporation til behandling af øsofagus tumorer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005246-59,0,0,0 2015-005247-14,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Centre Hospitalier Universitaire Brugmann,"Effect of levobupivacaine infiltration versus placebo on perineal postpartum pain in episiotomy of primiparous, after instrumental delivery: randomized double blind clinical trial. Effet sur la do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005247-14,0,0,0 2015-005248-33,2,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,SUSTRENIM Study – GIMEMA CML1415 Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing Nilotinib versus Imatinib with switch to Nilotinib in absence of...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005248-33,0,0,0 2015-005248-33,2,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Fondazione GIMEMA Franco Mandelli ONLUS,SUSTRENIM Study – GIMEMA CML1415 Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing Nilotinib versus Imatinib with switch to Nilotinib in absence of...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005248-33,0,0,0 2015-005255-27,3,2019-10-31,2019-10-31,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,DYAX CORP.,HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005255-27,0,0,0 2015-005255-27,3,2019-10-31,2019-10-31,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Dyax Corp. (an indirect, wholly-owned subsidiary of Shire plc.)",HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005255-27,0,0,0 2015-005255-27,3,2019-10-31,2019-10-31,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Dyax Corp., (an indirect, wholly-owned subsidiary of Shire plc.)",HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005255-27,0,0,0 2015-005256-97,10,2020-06-01,2020-06-01,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Astex Pharmaceuticals, Inc.","A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005256-97,0,0,0 2015-005256-97,10,2020-06-01,2020-06-01,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ASTEX PHARMACEUTICALS,"A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005256-97,0,0,0 2015-005257-12,7,2020-11-30,2020-11-30,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Astex Pharmaceuticals, Inc.","A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005257-12,0,0,0 2015-005258-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,LUMC,"A randomized, double blind, placebo-controlled study on the effect of 3 months treatment with the analgesic tapentadol on conditioned pain modulation (CPM) and pain relief in patients with chronic pai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005258-37,0,0,0 2015-005259-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,LUMC,"A randomized, double blind, placebo-controlled study on the effect of 3 months treatment with the analgesic tapentadol on conditioned pain modulation (CPM) and pain relief in patients with chronic low...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005259-28,0,0,0 2015-005260-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Academic Medical Centre,Efficacy of optimized thiopurine therapy in ulcerative colitis. Effectiviteit van geoptimaliseerde thiopurine therapie in colitis ulcerosa.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005260-41,0,0,0 2015-005263-16,5,2020-06-08,2020-06-08,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Pharmatrophix Inc,"A 6-months prospective, multi-center, double-blind, placebo-controlled, randomized, adaptive-trial-design study to evaluate safety, tolerability and exploratory endpoints of either placebo or two diff...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005263-16,1,0,0 2015-005268-41,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Hellenic Cooperative Oncology Group,Phase ΙΙ (window) preoperative study of olaparib with or without cisplatin or no treatment in patients with histologically proven squamous cell carcinoma of the head and neck who are candidates for su...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005268-41,0,0,0 2015-005273-20,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,FONDAZIONE ITALIANA LINFOMI ONLUS,"Multicenter phase II single arm open-label study on the feasibility, safety and efficacy of combination of CHOP-21 supplemented with Obinutuzumab and Ibrutinib in untreated young high risk Diffuse L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005273-20,0,0,0 2015-005274-38,1,2017-05-09,2017-05-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Region Östergötland,Patient-controlled sedation with propofol versus combined sedation during bronchoscopy – a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005274-38,0,0,0 2015-005275-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL UNIVERSITARI DE BELLVITGE,Conversion pharmacodynamic study in stable renal transplant patients receiving tacrolimus two times a day to a new formulation of tacrolimus - LCP Tacro - 1 time a day. Estudio Farmacodinámico de c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005275-24,0,0,0 2015-005276-14,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Sykehuset Østfold HF,Prolonging the response by low-dose Rituximab maintenance therapy in immune thrombocytopenia: a randomized placebo-controlled trial- the PROLONG trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005276-14,0,0,0 2015-005278-40,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Radboudumc,"Molecular imaging before and during (chemo-) radiotherapy in patients with locally advanced Head and Neck, thoracic and pelvic tumors: prognostic and predictive value of 18F-fluoroazomycin arabinoside...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005278-40,0,0,0 2015-005279-25,1,2017-07-06,2017-07-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharma A/S,LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris A phase 2a proof of concept study comparing an oral tablet formulation of LEO 32731 with a corresponding placebo tablet in patients...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005279-25,0,0,0 2015-005281-29,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Hospital Tuebingen,Prospective phase I/II study: Patient-individualized peptide vaccination based on whole exome sequencing with adjuvant GM-CSF in children with relapsed acute lymphoblastic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005281-29,0,0,0 2015-005282-22,4,2019-01-19,2019-01-19,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Adaptive Dose-Finding Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005282-22,0,0,0 2015-005284-16,1,2016-07-14,2016-07-14,1,1,1,0,0,0,1,0,1,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase I, Open-Label Study to Investigate the Pharmacokinetics and Pharmacodynamics of Etonogestrel (ENG) and 17ß-Estradiol (E2) in Healthy female Postmenarcheal Adolescents and Healthy Female Adults...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005284-16,0,0,0 2015-005285-38,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The University of Leeds,Phase II proof of concept study of Abatacept (Orencia) in individuals who aRe Considered At risk of Developing Inflammatory Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005285-38,0,0,0 2015-005286-24,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,3,,Baclofen in managing acute alcohol withdrawal,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005286-24,0,0,0 2015-005287-41,1,2016-06-03,2016-06-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Zealand Pharma A/S,"A randomized, double-blind trial of single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients to describe the pharmacokinetics and pharmacodynamics of ZP4207 as compared to mar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005287-41,0,0,0 2015-005288-17,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,ΕΛΛΗΝΙΚΗ ΕΤΑΙΡΕΙΑ ΙΑΤΡΙΚΗΣ ΕΚΠΑΙΔΕΥΣΗΣ (Hellenic Society of Medical Education),"A study of the effects of dapagliflozin on ambulatory aortic pressure, arterial stiffness and urine albumin excretion in patients with type 2 diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005288-17,0,0,0 2015-005293-38,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,SANOFI PASTEUR SA,Immunogenicity and Safety of the sanofi pasteur’s DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) versus sanofi pasteur’s DTacP-IPV Combined Vaccine (TETRAXIM™) given simultaneously at separate sites wi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005293-38,0,1,1 2015-005297-37,1,2020-02-14,2020-02-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,Bone Evaluation in HIV-positive women over 40 who Switch from TDF + 3TC/FTC + NNRTI to Triumeq,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005297-37,0,0,0 2015-005298-19,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,Ludwig Institute for Cancer Research Ltd.,Phase 1/2 Study of anti-PD-L1 in Combination with Chemo(radio)therapy for Oesophageal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005298-19,0,0,0 2015-005300-29,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,"Malmö University, Faculty of Odontology",Prevention and treatment of initial rotcaries among elderly in Skåne. Prevention och behandling av initial rotkaries hos äldre i Skåne. En randomiserad studie av effekten av enstaka applicering a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005300-29,0,0,0 2015-005303-91,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERA UNIVERSITARIA SENESE,Clinical Trial of pharmacokinetics of calcifediol (25OHD3) in women with postmenopausal osteoporosis Studio sui lievelli circolanti di 25OHD3 in donne affette da osteoporosi postmenopausale trattat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005303-91,0,0,0 2015-005306-11,1,2021-05-31,2021-05-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"St. Olavs Hospital, trondheim University Hospital","Pharmacological treatment of insomnia in palliative care A randomized, double-blind, placebo controlled, parallel-group, multicenter trial investigating the short time effectiveness of zopiclone on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005306-11,0,0,0 2015-005307-83,8,2019-11-05,2019-11-05,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,R-Pharm International LLC,"A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005307-83,0,0,0 2015-005307-83,8,2019-11-05,2019-11-05,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,R-Pharm,"A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005307-83,0,0,0 2015-005308-27,3,2019-04-24,2019-10-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,R-Pharm,"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005308-27,0,0,0 2015-005308-27,3,2019-04-24,2019-10-01,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,R-Pharm International LLC,"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005308-27,0,0,0 2015-005309-35,8,2021-09-01,2021-09-01,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,R-Pharm International LLC,"A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005309-35,1,0,0 2015-005309-35,8,2021-09-01,2021-09-01,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,R-Pharm,"A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005309-35,1,0,0 2015-005309-35,8,2021-09-01,2021-09-01,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"R-Pharm International, LLC.","A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005309-35,1,0,0 2015-005311-32,1,2016-04-06,2016-04-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Graz; Universitätsklinik fürInnere Medizin; Abteilung für Endokrinologie und Stoffwechsel,Assessment of the Hydraulic Tissue Resistance at the Site of Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes Untersuchung des hydraulischen Gewebswiderstandes am Ort der subkutanen ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005311-32,0,0,0 2015-005313-79,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Raimo Tuuminen,Non-steroidal anti-inflammatory medication in cataract surgery Kaihileikkauksen non-steroidaalinen anti-inflammatorinen lääkitys,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005313-79,0,0,0 2015-005314-29,1,2016-10-27,2016-10-27,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,OMNIVISION GmbH,"Randomized, open-label, two parallel group clinical trial, conducted under blinding evaluator conditions to compare the efficacy and tolerability of preservative-free formulation of Latanoprost 50µg/m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005314-29,0,0,0 2015-005317-68,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Acerta Pharma, BV",A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005317-68,0,0,0 2015-005317-68,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Acerta Pharma B.V.,A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005317-68,0,0,0 2015-005322-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Radboud University Nijmegen Medical Centre,"A randomized, double-blind, placebo-controlled phase III study to evaluate active immunization in adjuvant therapy of patients with stage IIIB and IIIC melanoma with natural dendritic cells pulsed wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005322-19,0,0,0 2015-005325-39,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Dr. Antonio Arroyo Sebastián,"A RANDOMIZED, CONTROLLED, CLINICAL TRIAL TO COMPARE PERIPHERAL PARENTERAL NUTRITION (PeriOlimel N4-E) VS CONVENTIONAL FLUID THERAPY IN ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOL IN COLORECTAL CAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005325-39,0,0,0 2015-005326-19,5,2018-05-15,2018-05-15,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment. A 26-week randomised, double-blind, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005326-19,0,0,0 2015-005327-63,5,2017-04-07,2017-04-07,5,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Novo Nordisk A/S,"A multi-centre, comparative, double blind, randomised cross-over trial investigating single dose pharmacokinetics and safety of turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005327-63,0,0,0 2015-005333-49,1,2016-10-05,2016-10-05,1,1,0,0,0,1,3,0,0,1,1,1,1,0,1,"Alnylam Pharmaceuticals, Inc.","A Multicenter, Multinational, Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Revusiran in Patients with Transthyretin-mediated Familial Amyloidotic Cardiomyopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005333-49,0,0,0 2015-005334-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL DE PALAMÓS,"CLINICAL TRIAL FOR THE TREATMENT OF PAIN IN HEMODIALYSIS PUNCTURE WITH LIDOCAINE / PRILOCAINE, VERSUS CHLOROETHYL, CROSSOVER RANDOMIZED STUDY ENSAYO CLÍNICO PARA EL TRATAMIENTO DEL DOLOR EN LA PUNC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005334-22,0,0,0 2015-005337-45,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,SANOFI PASTEUR SA,Immunogenicity and Safety of a Booster Dose of Polysaccharide Pneumococcal vaccine (Pneumo 23®) in 12 to 18 Months-Old Children Primed with Three Doses of Pneumococcal Conjugate Vaccine (Prevnar®) in ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005337-45,0,1,1 2015-005338-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Amsterdam,Targeting fear memory by disrupting the process of memory reconsolidation: A new intervention for panic disorder. Het verstoren van geheugenrecondolidatie als behandeling voor paniekstoornis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005338-23,0,0,0 2015-005339-42,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,NKI-AVL,"Safety, immunogenicity and clinical response of sig-HELP-E6SH/E7SH-kdel, injected in the epidermis by DNA tattoo, in HPV16-positive vulvar intraepithelial neoplasia: a phase I/II study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005339-42,0,0,0 2015-005342-63,1,2018-09-04,2018-09-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Liverpool,Mindex: The efficacy and safety of very low dose dexamethasone used to facilitate the extubation of ventilator dependent preterm babies who are at high risk of bronchopulmonary dysplasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005342-63,0,0,0 2015-005346-58,3,2020-12-31,2020-12-31,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin,Tacrolimus after rATG and infliximab induction immunosuppression Tacrolimus después de inmunodepresión por inducción con rATG e infliximab-,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005346-58,0,0,0 2015-005347-14,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,CHU DE NIMES,"Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients: A randomized, double-blind, placeb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005347-14,0,0,0 2015-005348-33,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,SANOFI PASTEUR LTD,"Immunogenicity and safety of Sanofi Pasteur’s DTaP-IPV combined vaccine (TETRAXIM™) given as a three-dose primary vaccination in South Korean healthy infants, as compared to commercially available DTa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005348-33,0,1,1 2015-005349-29,1,2017-06-30,2017-06-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Xellia d.o.o.,Plasma levels of crystalline degradation product 1 (CDP-1) in vancomycin- treated patients with normal or impaired renal function Razina kristaliničnog razgradnog proizvoda 1 (KRP-1) u krvnoj plazm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005349-29,0,0,0 2015-005351-27,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Royal Brompton & Harefield NHS Foundation Trust,A randomised controlled pilot trial of the feasibility and safety of therapy withdrawal in asymptomatic patients with a prior diagnosis of dilated cardiomyopathy & recovered cardiac function.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005351-27,0,0,0 2015-005352-10,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,SANOFI PASTEUR INTERNATIONAL,"Immunogenicity and Safety of the Aventis Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Given as a Three-Dose Primary Vaccination at 2, 4 and 6 Months of Age and Followed by a Booster Dose at 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005352-10,0,1,1 2015-005353-12,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,SANOFI PASTEUR SA,"Immunogenicity and Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Given as a Three-Dose Primary Vaccination at 2, 3 and 4 Months of Age or 3, 4 and 5 Months of Age and followed by a Boost...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005353-12,0,1,1 2015-005354-35,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,SANOFI PASTEUR INTERNATIONAL,"Immunogenicity and Safety of the Aventis Pasteur DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™), Given as a Three-Dose Primary Vaccination at 6, 10, and 14 Weeks of Age and Followed by a Booster Dose a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005354-35,0,1,1 2015-005356-99,9,2019-06-07,2019-08-22,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005356-99,0,0,0 2015-005356-99,9,2019-06-07,2019-08-22,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005356-99,0,0,0 2015-005356-99,9,2019-06-07,2019-08-22,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005356-99,0,0,0 2015-005357-12,5,2019-03-13,2019-03-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Protocol I8B-MC-ITRN A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination with Insulin Glargine or Insulin Degludec in Adults with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005357-12,0,0,0 2015-005357-12,5,2019-03-13,2019-03-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ELI LILLY ITALIA,"Protocol I8B-MC-ITRN A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination with Insulin Glargine or Insulin Degludec in Adults with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005357-12,0,0,0 2015-005357-12,5,2019-03-13,2019-03-13,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"Protocol I8B-MC-ITRN A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination with Insulin Glargine or Insulin Degludec in Adults with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005357-12,0,0,0 2015-005358-36,6,2020-01-06,2020-01-06,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Prospective, Randomized, Double Blind Comparison of LY900014 to Humalog in Adults with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion Studio prospettico, randomizzato, in doppio c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005358-36,0,0,0 2015-005358-36,6,2020-01-06,2020-01-06,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Prospective, Randomized, Double Blind Comparison of LY900014 to Humalog in Adults with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion Studio prospettico, randomizzato, in doppio c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005358-36,0,0,0 2015-005358-36,6,2020-01-06,2020-01-06,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Prospective, Randomized, Double Blind Comparison of LY900014 to Humalog in Adults with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion Studio prospettico, randomizzato, in doppio c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005358-36,0,0,0 2015-005382-23,3,2019-06-11,2019-08-01,3,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Immune Design Ltd,Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin?s Lymphoma Ensayo de fase I/II de G100 intratumoral con o sin pembrolizumab en pacientes c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005382-23,0,0,0 2015-005383-42,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,FONDAZIONE TOSCANA GABRIELE MONASTERIO,Use of buspiron in chemioreflex modulation and central apnea treatment in heart failure patients (BREATH: BuspiRon for chEmoreflex modulation and central Apnea treatment in Heart failure patients). Ph...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005383-42,0,0,0 2015-005384-16,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,FONDAZIONE TOSCANA GABRIELE MONASTERIO,"A prospective single-arm, monocentric, phase-II explorative study on evaluation of diagnostic use of the PET tracer (18F)-florbetaben (Neuraceq®) in patient with patient with suspected cardiac amyloid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005384-16,0,0,0 2015-005385-38,10,2020-10-28,2020-10-28,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Genfit SA,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Non-Alcoholic Steatohepatitis (NASH) and fibrosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005385-38,0,0,0 2015-005389-51,1,2020-11-12,2020-11-12,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHRU DE BREST,Safety and Efficacy of tocilizuMAb versus placebo in Polymyalgia rHeumatica with glucocORticoid dEpendence SEMAPHORE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005389-51,0,0,0 2015-005390-21,1,2021-01-19,2021-01-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GELTAMO,"Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab, gemcitabine, oxaliplatin and dexamethasone followed by Ibrutinib maitenance in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005390-21,0,0,0 2015-005396-25,7,2020-06-18,2020-06-18,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Open-label, Safety Extension Study with Benralizumab (MEDI-563) for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting ?2 Agonist (MELTEMI) Ensayo de extensión de seguridad,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005396-25,0,0,0 2015-005398-18,1,2018-01-31,2018-01-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,AbbVie Deutschland GmbH & Co. KG,Treating patients with early axial spondyloarthritis to target – a 1 year randomized controlled study taking an intense treatment approach versus routine treatment (STRIKE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005398-18,0,0,0 2015-005399-12,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,DKMS gemeinnützige GmbH,A randomized controlled trial comparing outcome after hematopoietic cell transplantation from a partially matched unrelated versus haploidentical donor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005399-12,0,0,0 2015-005400-28,1,2017-03-30,2017-03-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergopharma GmbH & Co. KG,Open label phase II multicenter clinical trial to evaluate safety during accelerated dose escalation of an allergoid birch pollen preparation in patients with IgE mediated allergic rhinitis or rhinoco...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005400-28,0,0,0 2015-005402-11,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Guys and St Thomas NHS Foundation Trust,The Impact of the Combination of the GLP-1 Analogue Liraglutide (Victoza®) and Laparoscopic Adjustable Gastric Banding (LAGB) on Diabetes Control,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005402-11,0,0,0 2015-005403-87,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,SANOFI PASTEUR SA,Immunogenicity and Safety of the sanofi pasteur’s DTacP-IPV Combined Vaccine (TETRAXIM™) given as a booster dose at 4 to 6 years of life in children previously vaccinated with PENTAXIM™ in the study E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005403-87,0,1,1 2015-005404-29,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,SANOFI PASTEUR SA,"Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005404-29,0,1,1 2015-005405-36,13,2019-01-08,2019-02-28,7,0,0,0,0,0,3,0,0,2,1,0,0,0,1,LABORATOIRES THEA,EFFICACY AND SAFETY ASSESSMENT OF T1580 VERSUS VEHICLE IN DRY EYE DISEASE TREATMENT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005405-36,1,0,0 2015-005405-36,13,2019-01-08,2019-02-28,7,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Laboratoires Théa,EFFICACY AND SAFETY ASSESSMENT OF T1580 VERSUS VEHICLE IN DRY EYE DISEASE TREATMENT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005405-36,1,0,0 2015-005406-11,2,2017-06-21,2017-07-15,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Astrazeneca AB,"A Multi-Center, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin 5mg Co-administered with Dapagliflozin 5mg compared to S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005406-11,0,0,0 2015-005416-15,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Medical Center - University of Freiburg,An open label phase II study of Sirolimus in patients with segmental overgrowth syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005416-15,0,0,0 2015-005417-76,2,2021-06-24,2021-06-24,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,NOVARTIS PHARMA SERVICES AG,"A phase Ib/II, open-label, multi-center study of INC280 in combination with PDR001 or PDR001 single agent in advanced hepatocellular carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005417-76,0,0,0 2015-005417-76,2,2021-06-24,2021-06-24,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A phase Ib/II, open-label, multi-center study of INC280 in combination with PDR001 or PDR001 single agent in advanced hepatocellular carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005417-76,0,0,0 2015-005418-31,17,2020-07-20,2020-07-20,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS PHARMA SERVICES AG,"A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005418-31,0,0,0 2015-005418-31,17,2020-07-20,2020-07-20,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005418-31,0,0,0 2015-005418-31,17,2020-07-20,2020-07-20,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005418-31,0,0,0 2015-005418-31,17,2020-07-20,2020-07-20,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005418-31,0,0,0 2015-005419-33,16,2019-12-17,2020-10-22,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005419-33,0,0,0 2015-005419-33,16,2019-12-17,2020-10-22,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005419-33,0,0,0 2015-005419-33,16,2019-12-17,2020-10-22,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005419-33,0,0,0 2015-005419-33,16,2019-12-17,2020-10-22,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005419-33,0,0,0 2015-005419-33,16,2019-12-17,2020-10-22,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS PHARMA SERVICES AG,"A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005419-33,0,0,0 2015-005421-40,1,2018-12-01,2018-12-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal College of Surgeons in Ireland,The use of topical Glyceryl Trinitrate (GTN) and eccentric exercises in the treatment of mid portion Achilles Tendinopathy: a randomised placebo controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005421-40,0,0,0 2015-005426-19,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Rigshospitalet, Copenhagen University Hospitals","""Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia in Patients following Recovery from Impacted Mandibular Third Molar Extraction. A Randomized, Placebo-controlled, Doub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005426-19,0,0,0 2015-005427-10,2,2019-09-02,2019-09-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,LUX-Bladder 1: Phase II open label single arm exploratory trial of oral afatinib monotherapy following platinum failure for patients with advanced/metastatic urothelial tract carcinoma with genetic al...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005427-10,0,0,0 2015-005427-10,2,2019-09-02,2019-09-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.",LUX-Bladder 1: Phase II open label single arm exploratory trial of oral afatinib monotherapy following platinum failure for patients with advanced/metastatic urothelial tract carcinoma with genetic al...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005427-10,0,0,0 2015-005431-41,3,2022-01-31,2022-01-31,3,1,0,0,0,1,3,0,0,1,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Opt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005431-41,0,0,0 2015-005431-41,3,2022-01-31,2022-01-31,3,1,0,0,0,1,3,0,0,1,0,0,0,0,1,Chugai Pharmaceutical Co. Ltd,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Opt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005431-41,0,0,0 2015-005437-53,6,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,0,Erasmus Medical Center,"A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies Study ITCC 053 Studio di fase 1B su crizotinib in associazione ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005437-53,0,0,0 2015-005437-53,6,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,0,ERASMUS MEDICAL CENTER,"A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies Study ITCC 053 Studio di fase 1B su crizotinib in associazione ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005437-53,0,0,0 2015-005438-24,9,2019-10-11,2019-11-19,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to placebo in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005438-24,0,0,0 2015-005438-24,9,2019-10-11,2019-11-19,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to placebo in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005438-24,0,0,0 2015-005438-24,9,2019-10-11,2019-11-19,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas AE,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to placebo in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005438-24,0,0,0 2015-005438-24,9,2019-10-11,2019-11-19,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Finland Ky,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to placebo in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005438-24,0,0,0 2015-005438-24,9,2019-10-11,2019-11-19,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Norway KS,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to placebo in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005438-24,0,0,0 2015-005438-24,9,2019-10-11,2019-11-19,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to placebo in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005438-24,0,0,0 2015-005438-24,9,2019-10-11,2019-11-19,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim GmbH & Co KG,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to placebo in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005438-24,0,0,0 2015-005438-24,9,2019-10-11,2019-11-19,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to placebo in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005438-24,0,0,0 2015-005438-24,9,2019-10-11,2019-11-19,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy and safety of orally administered BI 425809 during a 12-week treatment period compared to placebo in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005438-24,0,0,0 2015-005439-41,1,2020-01-31,2020-01-31,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Polish Lymphoma Research Group (PLRG),EVALUATION OF EFFICACY AND SAFETY OF OBINUTUZUMAB PREEMPTIVE TREATMENT AT THE TIME OF THE MOLECULAR RELAPSE AFTER FIRST LINE IMMUNOCHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN MANTLE CELL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005439-41,0,0,0 2015-005443-14,7,2019-09-05,2019-11-05,7,1,0,0,0,1,3,0,1,1,1,0,1,0,1,Octapharma Pharmazeutika Produktionsges.m.b.H.,"Prospective, double-blind, randomized, multicenter phase III study evaluating efficacy and safety of three different dosages of NewGam in patients with chronic inflammatory demyelinating poly(radiculo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005443-14,0,0,0 2015-005444-33,6,2017-05-29,2017-06-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 24 week treatment, multicenter, randomized, double blinded, double dummy, parallel-group, clinical trial evaluating the efficacy and safety of aclidinium bromide 400 mcg/formoterol fumarate 12 mcg f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005444-33,0,0,0 2015-005445-32,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"BIOrest, Ltd.",The BLADE-PCI Trial (PHASE IIB LIPOSOMAL ALENDRONATE STUDY): Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005445-32,0,0,0 2015-005448-32,4,2022-07-13,2022-07-13,3,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Diurnal Ltd,"A Phase III extension study of efficacy, safety and tolerability of Chronocort® in the treatment of congenital adrenal hyperplasia Eine Phase III Verlängerungsstudie zur Untersuchung der Wirksamke...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005448-32,1,0,0 2015-005450-36,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Bristol-Myers Squibb Company,"A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms With Switchover, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005450-36,0,1,1 2015-005453-13,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Fundació clínic per a la Recerca Biomèdica,PILOT STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF GRAZOPREVIR + ELBASVIR FOR 12 OR 16 WEEKS IN LIVER TRANSPLANT RECIPIENTS “ESTUDIO PILOTO PARA EVALUAR LA EFICACIA Y TOLERABILIDAD DE GRAZOPR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005453-13,0,0,0 2015-005454-35,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Birmingham,Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005454-35,0,0,0 2015-005455-28,1,,,0,1,1,0,0,1,1,1,0,4,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7239361 (BMS-986089) in Ambulator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005455-28,0,1,1 2015-005460-42,1,,,0,0,0,0,0,1,3,0,0,1,0,0,0,1,0,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud,"Phase III clinical trial, double-blind, cross-way, to evaluate the safety and efficacy ascorbic acid (vitamin C) and tocopherol (vitamin E) combination versus placebo for the treatment of cognitive an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005460-42,0,0,0 2015-005464-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Gustave Roussy,A phase II study to assess the efficacy of the anti-PD-L1 antibody atezolizumab (MPDL3280A) administered with stereotactic ablative radiotherapy (SABR) in patients with metastatic tumours Ensayo c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005464-42,0,0,0 2015-005467-16,1,2018-11-01,2018-11-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Maastricht University,Peppermint oil for the treatment of Irritable Bowel Syndrome: optimizing therapeutic strategies using targeted delivery Pepermuntolie voor behandeling van het Prikkelbare Darm Syndroom: het optimal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005467-16,0,0,0 2015-005469-22,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University of Calgary,"Multi-Centre, prosepective randomised open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care in the prevention of disability...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005469-22,0,0,0 2015-005471-24,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ARCAGY-GINECO,"A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemoth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005471-24,0,0,0 2015-005473-20,1,2017-04-13,2017-04-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UZ Leuven,Pilot study on robot assisted retinal vein cannulation with ocriplasmin infusion for central retinal vein occlusion. Behandeling van central retinaal veneuze occlusie met intraveneuze toediening va...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005473-20,0,0,0 2015-005482-23,5,2017-04-14,2017-07-14,5,1,1,0,0,0,3,0,1,1,0,0,1,0,1,Abbott Biologicals B.V.,"Randomized, Double-Blind and Active-Controlled Study in Children and Adolescents Aged 3–17 Years to Assess the Safety and Immunogenicity of Abbott’s Candidate Quadrivalent Influenza Vaccine and its No...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005482-23,0,0,0 2015-005486-23,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"Dr. Reddy's Laboratories, Ltd","A Multi-center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of DFD-04 (itraconazole) Ointment, 5% in Patients with Inflammatory L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005486-23,0,0,0 2015-005488-18,3,2017-04-26,2017-04-26,3,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"Oncoethix GmbH, a wholly owned subsidiary of Merck Sharp & Dohme Corp.","A Phase IB Dose Exploration Trial with MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects with Selected Advanced Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005488-18,0,0,0 2015-005489-46,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,Umeå University,Recovery of gastric function after treatment with shortacting opioids. Återhämtning av magsäcksfunktion efter behandling med kortverkande opioioder.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005489-46,0,0,0 2015-005490-20,1,2018-10-08,2018-10-08,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ProMetic BioTherapeutics Inc.,"A Phase 2/3, Open-Label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of ProMetic Plasminogen Intravenous Infusion in Subjects with Hypoplasminogenemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005490-20,0,0,0 2015-005491-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Actavis Hungary Gyógyszermarketing és Kereskedelmi Korlátolt Felelősségű Társaság,"The effect of pancreatic enzyme replacement therapy on glucose metabolism, nutritional parameters, incretin response and beta-cell function in patients with diabetes mellitus and exocrine pancreatic i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005491-20,0,0,0 2015-005492-25,1,2016-10-07,2016-10-07,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,PrEP Biopharm Ltd.,"A phase IIa, randomised, double-blind, placebo-controlled study using outpatient setting to investigate the duration of effect and evaluate further safety of PrEP-001 given prophylactically in healthy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005492-25,0,0,0 2015-005495-19,3,2017-11-27,2017-11-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Axovant Sciences, Inc.","A Phase 2b, double-blind, randomized, placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies (DLB) Studio di Fase 2b, randomizzato, in doppio cieco, controllato con placebo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005495-19,0,0,0 2015-005495-19,3,2017-11-27,2017-11-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AXOVANT SCIENCES LTD.,"A Phase 2b, double-blind, randomized, placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies (DLB) Studio di Fase 2b, randomizzato, in doppio cieco, controllato con placebo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005495-19,0,0,0 2015-005495-19,3,2017-11-27,2017-11-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Axovant Sciences Inc.,"A Phase 2b, double-blind, randomized, placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies (DLB) Studio di Fase 2b, randomizzato, in doppio cieco, controllato con placebo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005495-19,0,0,0 2015-005497-38,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Birmingham,Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloprolifeRatIve Neoplasms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005497-38,0,0,0 2015-005499-46,1,2016-11-30,2016-11-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Arrowhead Pharmaceuticals, Inc.","A Multicenter, Open-Label Study to Evaluate ARC-520 Administered Alone and in Combination with Other Therapeutics in Patients with Chronic Hepatitis B Virus (HBV) Infection (MONARCH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005499-46,0,0,0 2015-005503-84,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Kompetenznetz Vorhofflimmern e.V.,A Safety Study Assessing Oral Anticoagulation with Apixaban versus Vitamin-K Antagonists in Patients with Atrial Fibrillation and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005503-84,0,0,0 2015-005504-28,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,European Organisation for Research and Treatment of Cancer,"Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005504-28,0,0,0 2015-005507-89,1,2017-06-15,2017-06-15,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Department of Cardio-Thoracic and Vascular Surgery, Aarhus University Hospital",The pulmonary effect of bronchodilation on adult VSD patients with persistent or surgically corrected VSD Luftvejsudvidelses effekt på hjertelungefunktionen hos voksne født med ventrikel septum de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005507-89,0,0,0 2015-005513-72,2,2017-04-04,2017-04-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, MULTICENTER, DOSE-RANGING, STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-04965842 IN SUBJECTS WITH MODERATE TO SEVERE ATOPI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005513-72,0,0,0 2015-005519-34,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR),"Phase II, open, one-site, pilot Clinical trial for assessing the pharmacokinetic characteristics, safety and tolerability after conversion of the immuno-suppressive regimen with Advagraf® to Envarsus®...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005519-34,0,0,0 2015-005521-39,8,2021-01-11,2021-01-11,6,1,1,0,0,2,3,0,0,2,1,0,0,0,1,BAXALTA INNOVATIONS GMBH,"A Phase 3, Multicenter, Single-arm, Open-label Study of the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX 802) in Subjects with Congenital Hemophilia A with Factor VIII ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005521-39,1,0,0 2015-005521-39,8,2021-01-11,2021-01-11,6,1,1,0,0,2,3,0,0,2,1,0,0,0,1,Baxalta Innovations GmbH,"A Phase 3, Multicenter, Single-arm, Open-label Study of the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX 802) in Subjects with Congenital Hemophilia A with Factor VIII ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005521-39,1,0,0 2015-005522-19,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,"Saniona, A/S","A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE, TWO-CENTRE, SAFETY AND EFFICACY STUDY OF CO-ADMINISTRATION OF TESOFENSINE/METOPROLOL TREATMENT IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005522-19,0,0,0 2015-005524-26,2,2020-09-18,2020-09-18,1,1,0,0,0,1,2,0,0,1,1,0,1,0,1,GRIFOLS BIOLOGICALS INC.,"A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of Plasma-Derived Factor VIIII/VWF Alphanate® in Immune Tolerance Induction Therapy in Subjects with Congenital Hemophil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005524-26,0,0,0 2015-005524-26,2,2020-09-18,2020-09-18,1,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Grifols Biologicals Inc.,"A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of Plasma-Derived Factor VIIII/VWF Alphanate® in Immune Tolerance Induction Therapy in Subjects with Congenital Hemophil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005524-26,0,0,0 2015-005525-39,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,Proof-of-concept study of ibrutinib in c-MYC and HER2 amplified gastrooesophageal carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005525-39,0,0,0 2015-005527-12,1,2018-12-10,2018-12-10,1,0,0,0,0,1,2,0,0,1,1,1,1,0,3,,Sirolimus for the treatment of severe intestinal polyposis in patients with familial adenomatous polyposis (FAP); a pilot study Sirolimus voor de behandeling van ernstige intestinale polyposis bij ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005527-12,0,0,0 2015-005529-37,1,2020-07-30,2020-07-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Bente Lomholt Langdahl,Treatment with zoledronic acid subsequent to denosumab in osteoporosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005529-37,0,0,0 2015-005532-18,5,2020-12-14,2021-02-04,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pluristem Ltd.,"A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005532-18,0,0,0 2015-005535-40,4,2018-08-26,2018-08-26,1,1,0,0,1,0,3,0,0,1,1,0,1,0,1,Baxter Healthcare Corporation,"A Randomised Controlled Study to Evaluate the Efficacy and Safety of Fibrin Sealant, Vapour Heated, Solvent/Detergent Treated (FS VH S/D 500 s-apr) Compared to DuraSeal Dural Sealant as an Adjunct to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005535-40,0,0,0 2015-005536-17,5,2019-08-16,2019-10-09,3,1,0,0,0,1,3,0,0,1,1,0,1,0,1,ULTRAGENYX PHARMACEUTICAL INC.,"A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1 De...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005536-17,0,0,0 2015-005536-17,5,2019-08-16,2019-10-09,3,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Ultragenyx Pharmaceutical Inc,"A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1 De...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005536-17,0,0,0 2015-005537-50,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,Birmingham Women's Hospital,High Or Low Dose Syntocinon® for delay in labour: the HOLDS trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005537-50,0,0,0 2015-005538-23,1,2018-09-19,2018-09-19,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHRU de Brest,Analgesia and physiotherapy in children with cerebral palsy (ANTALKINECP): Double blind cross-over placebo controlled study of Ibuprofen in children with cerebral palsy undergoing physiotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005538-23,0,0,0 2015-005540-34,1,2017-06-08,2017-06-08,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,"Sun Pharma Advanced Research Company, Ltd. (SPARC)","A Multi-Center, Investigator-Masked, Randomized, Crossover, Equivalence Study of the Safety and Efficacy of Once Daily Brimonidine Tartrate 0.35% Ophthalmic Suspension Compared with Brimonidine Tartra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005540-34,0,0,0 2015-005541-30,4,2018-12-13,2018-12-13,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,UCB BioPharma SPRL,"AN OPEN-LABEL, EXPLORATORY, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF UCB5857 IN SUBJECTS WITH ACTIVATED PHOSPHOINOSITIDE 3 KINASE (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005541-30,0,0,0 2015-005542-56,1,2019-11-14,2019-11-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Copenhagen University Hospital Bispebjerg,"Effects of anti-TSLP on airway hyperresponsiveness and mast cell phenotype in asthma - A randomized double-blind, placebo-controlled trial of MEDI9929 The UPSTREAM study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005542-56,0,0,0 2015-005543-14,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,Safety and efficacy of Belimumab After B cell depletion therapy in systemic LUPUS erythematosus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005543-14,0,0,0 2015-005544-33,1,2016-04-10,2016-04-10,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Thomas Fichtner Bendtsen,Shamrock – Ultrasound/MR image fusion guided lumbar plexus blocks Shamrock – Ultralyd/MR billedfusionsvejledt plexus lumbalis blokade,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005544-33,0,0,0 2015-005546-63,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA,Peptide receptor radionuclide therapy in tumors with high expression of somatostatine receptors. Terapia radiorecettoriale con analoghi marcati della somatostatina in tumori con elevata espressione...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005546-63,0,0,0 2015-005548-32,5,2018-01-09,2018-01-09,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A 24-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 4 DOSES OF CHF 6001 DPI IN PATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005548-32,0,0,0 2015-005549-30,1,2016-12-01,2016-12-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University",A single-dose cross-over study to assess direct and indirect effects of dapagliflozin on pancreatic alpha and beta cells in patients with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005549-30,0,0,0 2015-005550-35,2,2017-12-28,2018-12-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, REPEATED DOSE, THREE-WAY CROSSOVER STUDY TO EVALUATE THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF TWO DOSES OF CHF 6001 DPI IN SUBJECTS WITH MOD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005550-35,0,0,0 2015-005551-27,1,2019-04-18,2019-04-18,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Chiesi Farmaceutici,"A First in Human Randomised, Double-Blind, Placebo-Controlled Study of Single Ascending Doses in Healthy Male Volunteers and Repeated Ascending Dose in Asthmatic Patients Followed by a 3-Way Cross-Ove...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005551-27,0,0,0 2015-005553-13,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Cutanea Life Sciences,"A PHASE 2, RANDOMIZED, VEHICLE-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EXPLORE THE PHARMACODYNAMICS, SAFETY AND EFFICACY OF TOPICAL OMIGANAN IN PATIENTS WITH EXTERNAL GENITAL WARTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005553-13,0,0,0 2015-005555-27,4,2022-04-28,2022-04-28,3,0,0,0,0,0,2,0,0,2,0,0,0,0,0,University Hospital Basel,Prevention of Cerebral Ischaemia in Stent Treatment for Carotid Artery Stenosis - A randomised multi-centre phase II trial comparing Ticagrelor versus Clopidogrel with outcome assessment on MRI (PRECI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005555-27,1,0,0 2015-005556-10,11,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005556-10,0,0,0 2015-005556-10,11,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005556-10,0,0,0 2015-005559-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Within-patient variability in tacrolimus pharmacokinetics in renal transplant patients treated with different tacrolimus formulations.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005559-29,0,0,0 2015-005561-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Klaus Olkkola,Effect of CYP2D6 polymorphism on the analgesic efficacy and side-effects of codeine CYP2D6-isoentsyymin geneettisen polymorfian vaikutus kodeiinin analgeettiseen tehoon ja haittavaikutuksiin päiväk...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005561-23,0,0,0 2015-005564-41,1,2017-04-24,2017-04-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,An open label study to evaluate the safety and efficacy of 12 week treatment with CFZ533 in patients with Graves' disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005564-41,0,0,0 2015-005565-23,4,2017-12-29,2017-12-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A multicenter, randomized, double-blind, placebo-controlled 3-period complete cross-over study to assess the bronchodilator effects and safety of glycopyrronium bromide (NVA237) (25 µg and 50 µg o.d.)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005565-23,0,0,0 2015-005566-33,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Klinikum der Universitaet Muenchen AoeR,APixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF) Apixaban versus Phenprocoumon: Oral...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005566-33,0,0,0 2015-005568-40,1,2020-02-17,2020-02-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Werkgroep Cardiologische centra Nederland,Low-dose colchicine for secondary prevention of cardiovascular disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005568-40,0,0,0 2015-005572-17,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,CHU TOULOUSE,"Assessment in real life of the association and its determinants between adverse events, and plasma concentrations of two protein kinases inhibitors: Ibrutinib (IMBRUVICA®) and idelalisib (ZYDELIG®) in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005572-17,0,0,0 2015-005573-21,3,2017-11-17,2017-11-17,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,pro-ACTINA S.A.,Exploratory phase II study in patients after treatment of high grade brain tumors to assess the technical performance of Tc-99m tetrofosmin for differentiation of recurrence versus radiation necrosis ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005573-21,0,0,0 2015-005574-38,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,Institut Jules Bordet,"The DESIGN trial A randomised, Double-blind, placEbo-controlled Study to assess the effectIveness of pectoral nerves block (Pecs) after breast surGery on Piritramide coNsumption.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005574-38,0,0,0 2015-005576-22,1,,,0,0,0,1,0,1,1,0,0,1,1,1,0,1,1,BAXALTA INNOVATIONS GMBH,"A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005576-22,0,0,0 2015-005577-20,3,2017-06-07,2017-06-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Human Immunodeficiency Virus-1 (HIV-1)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005577-20,0,0,0 2015-005580-16,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Steno Diabetes Center A/S,"A Phase 1b, open label, uncontrolled non-randomised single dose study to examine the safety of topically applied bone marrow derived allogeneic mesenchymal stromal cells (REDDSTAR ORBCEL-M) seeded in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005580-16,0,0,0 2015-005585-32,1,2020-12-17,2020-12-17,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen",Synergy effect of the appetite hormone GLP-1 (LiragluTide) and Exercise on maintenance of weight loss and health after a low calorie diet - the S-LiTE randomized trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005585-32,0,0,0 2015-005589-43,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur Limited,Safety and immunogenicity of Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis (ADACEL™) Vaccine compared to Component Pertussis Vaccine and Diphtheria and Tetanus Toxoids Adso...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005589-43,0,1,1 2015-005590-20,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,SANOFI PASTEUR,"Safety Among Adolescents and Adults of Revaccination with Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 4 to 5 Years After a Previous Dose",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005590-20,0,1,1 2015-005593-38,2,2019-03-27,2019-03-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus. A 52 week Randomised, Open-label, Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005593-38,0,0,0 2015-005594-21,1,2019-06-18,2019-06-18,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Adaptimmune LLC,A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients with Synovial Sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005594-21,0,0,0 2015-005597-38,13,2020-12-15,2020-12-15,10,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005597-38,1,0,0 2015-005597-38,13,2020-12-15,2020-12-15,10,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005597-38,1,0,0 2015-005597-38,13,2020-12-15,2020-12-15,10,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A. que representa en España a F. Hoffmann-La Roche Ltd,An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005597-38,1,0,0 2015-005599-51,7,2019-05-13,2019-05-13,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cidara Therapeutics Inc.,"A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of CD101 Injection vs Intravenous Caspofungin Followed By Oral Fluconazole Step-down in the Treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005599-51,0,0,0 2015-005599-51,7,2019-05-13,2019-05-13,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"CIDARA THERAPEUTICS, INC","A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of CD101 Injection vs Intravenous Caspofungin Followed By Oral Fluconazole Step-down in the Treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005599-51,0,0,0 2015-005600-28,1,2018-02-22,2018-02-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Exponential Biotherapies Inc.,Randomized double blind placebo-controlled phase II study on the effects of EA-230 on the innate immune response following on-pump cardiac surgery Gerandomiseerde dubbel blinde placebo gecontroleer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005600-28,0,0,0 2015-005601-37,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,CHU Clermont-Ferrand,"IMPACT OF 5% LIDOCAINE MEDICATED PLASTER ON ALLODYNIC SYMPTOMS OF LOCALIZED NEUROPATHIC PAIN AFTER KNEE SURGERY. A prospective, randomized, placebo controlled study in parallel groups. Impact de l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005601-37,0,0,0 2015-005605-36,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,SCICLONE PHARMACEUTICALS ITALY S.R.L.,"Thymosin alpha 1 plus maintenance therapy with the Standard of Care (SoC) chemotherapy plus cisplatin (or carboplatin) in patients with metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR wild type ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005605-36,0,0,0 2015-005607-92,6,2018-09-12,2018-10-12,4,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Quantum Genomics,"A Phase II randomized, placebo controlled, double-blind, multi-centre study to assess safety and efficacy of incremental doses of QGC001 in patients upon discharge from hospital admission for worsenin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005607-92,1,0,0 2015-005607-92,6,2018-09-12,2018-10-12,4,0,0,0,0,0,2,0,0,2,1,0,0,0,1,QUANTUM GENOMICS,"A Phase II randomized, placebo controlled, double-blind, multi-centre study to assess safety and efficacy of incremental doses of QGC001 in patients upon discharge from hospital admission for worsenin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005607-92,1,0,0 2015-005609-34,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,Fundación CRIS de investigación para vencer el cáncer,Abrogation of chronic monoclonal antibody treatment-induced T-cell exhaustion with DURVALUMAB (MEDI4736) in advanced HER-2 negative breast cancer: a pilot proof-of-concept trial Supresión con durva...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005609-34,0,0,0 2015-005614-30,1,2018-07-25,2018-07-25,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Uzsoki Utcai Kórház,SOAP Antibiotic prophylaxis trial Systemic versus combined systemic and Oral Antibiotic Prophylaxis in elective colorectal surgery SOAP Antibiotikum profilaxis klinikai vizsgálat A Szisztémás és ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005614-30,0,0,0 2015-005615-32,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Stealth BioTherapeutics Inc.,"A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of 4 Weeks Treatment with Subcutaneous Elamipretide on Left Ventricular Function in Subjects with Stable Heart Fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005615-32,0,0,0 2015-005616-14,2,2017-06-29,2017-06-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients with Chronic Hepatitis C Virus Genotype 1 ? 6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005616-14,0,0,0 2015-005619-33,2,2018-09-25,2018-09-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005619-33,0,0,0 2015-005619-33,2,2018-09-25,2018-09-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK. S.P.A.,Effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005619-33,0,0,0 2015-005622-19,2,2017-12-08,2017-12-08,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only. A 26-week, randomised, double-blind, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005622-19,0,0,0 2015-005624-26,1,2017-07-07,2017-07-07,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,"Windtree Therapeutics, Inc. (formerly Discovery Laboratories, Inc.)","A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 26 to 28 Weeks PMA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005624-26,0,0,0 2015-005625-39,9,2018-06-12,2018-12-31,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study) Studio randomizzato, in doppio cieco, controllato con p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005625-39,0,0,0 2015-005625-39,9,2018-06-12,2018-12-31,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ELI LILLY AND COMPANY,"A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study) Studio randomizzato, in doppio cieco, controllato con p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005625-39,0,0,0 2015-005626-19,2,2018-05-23,2018-05-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Civitas Therapeutics, Inc.","A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005626-19,0,0,0 2015-005626-19,2,2018-05-23,2018-05-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Civitas Therapeutics, a wholly owned subsidiary of Acorda","A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005626-19,0,0,0 2015-005627-84,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc.,"A pivotal open label, two-arm, multi-center trial to evaluate the safety and immunogenicity of a single dose of Adacel® vaccine in persons 10 to <11 years of age with the intent to extend the licensur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005627-84,0,1,1 2015-005628-25,1,,,0,1,0,1,0,0,1,0,1,4,0,0,0,0,1,Sanofi-Aventis K.K.,"Immunogenicity and Safety of The tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (SP306) as a Booster in Japanese Adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005628-25,0,1,1 2015-005629-38,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc.,Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005629-38,0,1,1 2015-005630-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,National and Kapodistrian University of Athens,"A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr with Acetylsalicylic Acid versus CLopidogrel with Acety...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005630-21,0,0,0 2015-005637-47,1,2018-10-09,2018-10-09,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Oncology, Aarhus University Hospital",Randomized study of AZD9291 treatment of EGFR M+ NSCLC patients progressing on first line erlotinib. A study based upon detection of EGFR M+ ctDNA in plasma and urine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005637-47,0,0,0 2015-005640-34,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,CHIESI FARMACEUTICI S.P.A.,"Envarsus® tablets administered once daily in combination with everolimus in elderly de-novo kidney transplant recipients: open-label, multicentre, single-arm, pharmacokinetic and clinical study EN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005640-34,0,0,0 2015-005642-59,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET","Phase II trial: uPAR-PET for prognostication in patients with non-small cell lung cancer, malignant pleural mesothelioma and large cell neuroendocrine carcinoma of the lung",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005642-59,0,0,0 2015-005645-31,2,2018-05-04,2018-05-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double-blind (sponsor open) placebo-controlled, parallel group, 8-week treatment study to investigate the safety, pharmacodynamics, and effect of the TLR7 agonist, GSK2245035, on the all...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005645-31,0,0,0 2015-005650-35,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,0,Centre for Human Drug Research,Proof-of-pharmacology clinical trial on a vaccine that elicits a protective humoral immune response against oxidized low density lipoprotein,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005650-35,0,0,0 2015-005657-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HUS - Naistentautien ja synnytysten tulosyksikkö,Pain an medical abortion -Predicting factors of pain and optimal pain management among teenaged women compared to adult women Kipu ja lääkkeellinen raskaudenkeskeytys -kipukokemusta ennakoivat teki...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005657-12,0,0,0 2015-005660-42,1,2018-06-20,2018-06-20,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Institut de Recerca HSCSP,"Randomized, single blind, prospective clinical study to compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in patients with polycystic ovary under a FIV/ICSI cicle. Estudio clínico prospectivo, rando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005660-42,0,0,0 2015-005663-17,5,2020-12-11,2020-12-11,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Samsung Bioepis Co., Ltd.",A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005663-17,0,0,0 2015-005666-37,4,2020-04-29,2020-04-29,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,DexTech Medical AB,"A randomized, double-blind, dose finding, repeat dose Phase II multicentre study of ODX for the treatment of patients with castration resistant prostate cancer (CRPC) and skeletal metastases",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005666-37,0,0,0 2015-005674-37,2,2019-08-20,2019-08-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005674-37,0,0,0 2015-005676-25,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Edinburgh,Sensing using Neutrophil Activation Probe on the Intensive Therapy Unit,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005676-25,0,0,0 2015-005676-25,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Lothian,Sensing using Neutrophil Activation Probe on the Intensive Therapy Unit,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005676-25,0,0,0 2015-005681-37,1,2019-03-19,2019-03-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BIOIBERICA S.A.,Evaluation of the evolution of imaging markers of cartilage degradation in patients with knee osteoarthritis receiving DROGLICAN®: a Pilot Study Evaluation de l'évolution des marqueurs d'imagerie d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005681-37,0,0,0 2015-005682-24,1,2018-11-30,2018-11-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Sven Olaf Skouby, Professor, MD, DMSc. Unit of Reproductive Medicine, Herlev/Gentofte Hospital",REDUCING THE IMPACT OF OVARIAN STIMULATION - THE RIOT PROJECT STUDY RIOT A: THE ROLE OF AROMATASE INHIBITOR IN REDUCING THE DETRIMENTAL EFFECTS OF OVARIAN STIMULATION TO OPTIMIZE OUTCOMES IN FRESH EMB...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005682-24,0,0,0 2015-005683-41,1,2018-01-09,2018-01-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Sven O. Skouby, Professor, MD, DMSc. Unit of reproductive Medicine, Herlev/Gentofte Hospital",REDUCING THE IMPACT OF OVARIAN STIMULATION - THE RIOT PROJECT RIOT STUDY B: MAPPING THE ENDOCRINE DETERMINANTS OF OVARIAN STIMULATION TO OPTIMIZE OUTCOMES IN FRESH EMBRYO TRANSFER CYCLES ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005683-41,0,0,0 2015-005685-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hôpital Erasme,"Evaluation of microcirculation alterations in cardiac surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and biological analysis Evaluation des altérations de la m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005685-30,0,0,0 2015-005688-18,1,2021-02-28,2021-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Hematology, Aalborg University Hospital",A randomized controlled trial of alendronate as preventive treatment against the development of gluco-corticoid-induced osteoporosis in patients being treated for malignant lymphoma En randomiseret...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005688-18,0,0,0 2015-005689-40,2,2017-06-29,2017-06-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"CoLucid Pharmaceuticals, Inc.","A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A randomized, double-blind, placebo-controlled parallel group study (SPARTAN)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005689-40,0,0,0 2015-005691-26,2,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,0,University Medical Center Groningen,Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005691-26,0,0,0 2015-005695-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,NKI-AVL,Treatment of PERitoneal dissemination in Stomach Cancer patients with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: the PERISCOPE II study Behandeling van het peritoneaal gem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005695-15,0,0,0 2015-005696-24,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Merck KGaA,A Phase II single-arm trial to investigate tepotinib in advanced (locally advanced or metastatic) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISIO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005696-24,0,0,0 2015-005696-24,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,MERCK KGAA,A Phase II single-arm trial to investigate tepotinib in advanced (locally advanced or metastatic) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISIO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005696-24,0,0,0 2015-005699-21,11,2022-03-09,2022-03-09,8,0,0,0,0,0,3,0,2,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005699-21,1,0,0 2015-005699-21,11,2022-03-09,2022-03-09,8,0,0,0,0,0,3,0,2,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005699-21,1,0,0 2015-005700-28,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Erasmus MC,An evaluation of the effectivity of the current treatment of uncomplicated urinary tract infections with fosfomycin. Een evaluatie van de doeltreffendheid van de behandeling van ongecompliceerde ur...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005700-28,0,0,0 2015-005704-29,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,CONSORZIO ONCOTECH,A standard regimen of dexamethasone in comparison to two dex-sparing regimens in addition to NEPA in preventing CINV in na¿ve NSCLC patients to be treated with cisplatin based chemotherapy: a three-ar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005704-29,0,0,0 2015-005706-11,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,Vita Green Europa S.A.,"Single-site, open, randomized clinical trial to assess the non-inferiority of Cysticlean® versus Fosfomicina in the treatment of cystitis in women in Spain. Ensayo clínico unicéntrico, abierto y co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005706-11,0,0,0 2015-005707-92,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Dermapharm AG,"Double-blind, randomised clinical study comparing efficacy and safety of Miconazole 2% Fluprednidene 0.1% Cream (Test) vs. Vobaderm® Cream (Reference) vs. Vehicle in patients with moderate to severely...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005707-92,0,0,0 2015-005715-32,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,"Karolinska Institutet Stockholm, Sweden",SOdium-glucose CO-transporter inhibition in patients with Type 2 Diabetes and Ischemic Heart Failure (SOCODIHF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005715-32,0,0,0 2015-005717-80,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Ferrer Internacional S.A,"Clinical trial of phase 1/2 to evaluate the feasibility, safety, tolerability and preliminary efficacy of the administration of FAB117-HC, a drug whose active ingredient is HC016, allogeneic adipose d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005717-80,0,0,0 2015-005721-39,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,Eli Lilly and Company,"A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-dose Ifosfamide in Pediatric Patients with Relapsed or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005721-39,0,1,1 2015-005731-41,7,2022-09-15,2022-09-15,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005731-41,1,0,0 2015-005732-18,3,2021-09-16,2021-09-16,2,1,1,0,0,0,1,0,0,2,0,0,0,0,1,"Daiichi Sankyo , Inc.","A Phase 1, Open-Label, Single-dose, Non-randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients Estudio en fase I, en abierto, de dosis única y no rando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005732-18,1,0,0 2015-005735-40,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,0,Radboud university medical center,Safety and protective efficacy of BCG vaccination against controlled human malaria infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005735-40,0,0,0 2015-005736-17,1,2018-08-22,2018-08-22,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,University Medical Center Utrecht,Prevention of severe infectious complications after colorectal surgery using antimicrobial decontamination of the digestive tract (PreCaution trial) Het voorkomen van ernstige infectieuze complicat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005736-17,0,0,0 2015-005738-23,1,2020-05-13,2020-05-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A phase II, patient and investigator-blinded, randomized, placebo-controlled study to evaluate efficacy, safety and tolerability of BAF312 in patients with stroke due to intracerebral hemorrhage (ICH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005738-23,0,0,0 2015-005740-34,1,2020-02-03,2020-02-03,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Universitätsklinikum Tübingen,Effectiveness of Dapagliflozin + Saxagliptin to revert from a standard basalbolus insulin treatment (BBIT) regimen to a basal supported oral therapy (BOT) in patients with Type 2 Diabetes – a randomis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005740-34,0,0,0 2015-005741-31,1,2021-05-14,2021-05-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AIO-Studien-gGmbH,Fostering efficacy of anti – PD-1 – treatment: Nivolumab plus radiotherapy in advanced NSCLC Förderung der Wirksamkeit einer anti-PD-1-Behandlung (Immuntherapie Nivolumab) in Kombination mit Stra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005741-31,0,0,0 2015-005742-58,1,2016-06-28,2016-06-28,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase II, randomised, observer-blind, controlled, study to assess the reactogenicity and safety of a single intramuscular dose of GlaxoSmithKline (GSK) Biologicals’ investigational respiratory syncy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005742-58,0,0,0 2015-005743-14,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,St Georges University Hospital NHS Foundation Trust,Fetal Atrial Flutter & Supraventricular Tachycardia (FAST) Therapy Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005743-14,0,0,0 2015-005744-34,1,2021-12-15,2021-12-15,1,0,0,0,0,0,4,0,0,1,1,1,0,0,0,University Medical Centre Hamburg-Eppendorf,"Randomized, Double-Blinded, Controlled Trial of Intravenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency Eine multizentrische, prospektive, randomisierte, kontrollie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005744-34,0,0,0 2015-005749-30,1,2021-02-05,2021-02-05,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Karolinska Institutet,"A randomized, doubleblind, placebo-controlled multicenter trial to evaluate the safety and efficacy of rituximab (Mabthera) in subjects with new onset myasthenia gravis; the RINOMAX study EN RANDOM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005749-30,0,0,0 2015-005751-27,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,XOMA (US) LLC,"A Multi-Center, Open-Label, Randomized, Single-Dose, Controlled Trial of Intravenously Administered XOMA 213 in Suppression of Lactation after Delivery in Postpartum Women Ensayo multicéntrico, abi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005751-27,0,0,0 2015-005752-10,1,2019-07-26,2019-07-26,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospitals of North Midlands NHS Trust,The relationship between computerised tomographic coronary angiography (CTCA) calcium scoring and endothelial progenitor cell (EPC) count. Study A and B.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005752-10,0,0,0 2015-005753-12,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Birmingham,"Prospective, open-label, randomised pilot study to assess two possible routes of Faecal Microbiota Transplant (FMT) delivery in patients with ulcerative colitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005753-12,0,0,0 2015-005756-10,1,2016-07-21,2016-07-21,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Gemphire Therapeutics Inc.,"A Phase 2 Randomized, Double-Blind, Dose-Finding Study to Assess the Efficacy, Safety, and Tolerability of Gemcabene in Patients with Hypercholesterolemia on a High-Intensity Stable Statin Therapy (RO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005756-10,0,0,0 2015-005757-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Charité – Universitätsmedizin Berlin,"Effect of IV iron (ferric carboxymaltose, Ferinject) on exercise tolerance, symptoms and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005757-12,0,0,0 2015-005758-36,5,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"TG THERAPEUTICS, INC.","A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005758-36,0,0,0 2015-005758-36,5,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,TG Therapeutics,"A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005758-36,0,0,0 2015-005760-42,3,2018-02-15,2018-05-03,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mereo BioPharma 2 Limited,"A Phase IIb multicentre, double-blind, dose-ranging, randomised, placebo-controlled study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005760-42,0,0,0 2015-005760-42,3,2018-02-15,2018-05-03,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MEREO BIOPHARMA GROUP LTD,"A Phase IIb multicentre, double-blind, dose-ranging, randomised, placebo-controlled study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005760-42,0,0,0 2015-005761-23,3,2021-03-03,2021-03-03,1,1,0,1,2,1,1,0,0,2,0,0,0,0,1,"CTD HOLDINGS, INC.",A Phase I/II study to evaluate the safety and pharmacokinetics of intravenous Trappsol Cyclo (HP-ß-CD) in patients with Niemann-Pick disease type C (NPC-1) and the pharmacodynamic effects of treatment...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005761-23,1,0,0 2015-005761-23,3,2021-03-03,2021-03-03,1,1,0,1,2,1,1,0,0,2,0,0,0,0,1,"Cyclo Therapeutics, Inc.",A Phase I/II study to evaluate the safety and pharmacokinetics of intravenous Trappsol Cyclo (HP-ß-CD) in patients with Niemann-Pick disease type C (NPC-1) and the pharmacodynamic effects of treatment...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005761-23,1,0,0 2015-005762-28,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,IVI Valencia,Analysis of follicular steroid synthesis during controlled ovarian stimulation with recombinant FSH vs HMG in GnRH antagonist cycles Análisis de la esteroidogénesis folicular en estimulación ováric...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005762-28,0,0,0 2015-005765-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VU Medical Centre,Companion biomarker development for MEDI4736 treated non-small-cell lung cancer patients using 89Zirconium-labeled MEDI4736 – a feasibility study Biomarker ontwikkeling voor MEDI4736 in de behandel...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005765-23,0,0,0 2015-005766-39,1,2017-12-28,2017-12-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated with the Investigational PI3Kδ Inhibitor, GS-9820",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005766-39,0,0,0 2015-005772-16,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Department of Surgery, Herlev Hospital","The safety and pharmacokinetics of intraperitoneal administration of granulocyte-macrophage colony-stimulating factor, fosfomycin, and metronidazole in patients undergoing appendectomy for uncomplicat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005772-16,0,0,0 2015-005773-21,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,INSTITUTO DE INVESTIGACIÓN SANITARIA LA FE,Impact of the serratus plane block in pain and the use of opioids in breast surgery Impacto del bloqueo del plano del músculo serrato (serratus plane block) en el dolor y el consumo de opioides en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005773-21,0,0,0 2015-005774-37,1,2019-10-23,2019-10-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo Español de Tumores Neuroendocrinos. SECRETARÍA TÉCNICA GETNE (GETNE),Phase II study to evaluate efficacy of rechallenge with Sunitinib in Patients with Metastatic Pancreatic Neuroendocrine Tumor (pNETs) well differentiated G1/2 advanced or metastatic who previously fai...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005774-37,0,0,0 2015-005776-24,1,2019-09-20,2019-09-20,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Dr. Manuel Rodríguez Yáñez,Intensive treatment of blood pressure in acute ischemic stroke. TICA 2 study. Tratamiento intensivo de la presión arterial en el ictus isquémico agudo. Estudio TICA 2.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005776-24,0,0,0 2015-005777-20,1,2021-10-21,2021-10-21,1,0,0,0,0,0,3,0,0,1,0,0,0,0,0,Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Translational Medicine and Pharmacology ITMP,"Impact of concomitant Methotrexate on efficacy, safety and adherence of Ustekinumab-treatment in patients with active Psoriatic Arthritis (MUST-Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005777-20,0,0,0 2015-005780-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,IRCCS Bambino Gesù Children's Hospital,A phase 2 controlled study with blinded outcome assessment on the efficacy of Bumetanide vs no drug treatment for cognitive improvement to rescue cognitive functions in children and adolescents with D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005780-16,0,0,0 2015-005781-39,2,2021-12-27,2021-12-27,2,0,0,0,0,1,3,0,0,1,0,0,0,0,1,Baxalta Innovations GmbH,"A Phase 3b/4, Prospective, Multicenter, Open-label, Randomized, Crossover Study of Tolerability and Safety of FEIBA Reconstituted in Regular or 50% Reduced Volume and of Faster Infusion Rates in Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005781-39,0,0,0 2015-005784-17,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Erasmus MC cancer institute,The effects of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib in patients with a metastatic colorectal cancer (mCRC) or gastrointestinal stromal tumour (GIST). De eff...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005784-17,0,0,0 2015-005786-23,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Banc de Sang i Teixits,"A phase I/IIa, randomized, double-blind, single-dose, placebo controlled, two-way crossover clinical trial to assess the safety and to obtain efficacy data in intrathecal administration of expanded Wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005786-23,0,0,0 2015-005787-42,5,2018-05-10,2018-05-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ITF RESEARCH PHARMA SLU,"A Phase 2, Dose-ranging, 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005787-42,0,0,0 2015-005787-42,5,2018-05-10,2018-05-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ITF Research Pharma SLU,"A Phase 2, Dose-ranging, 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.0...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005787-42,0,0,0 2015-005789-42,2,2020-01-27,2020-01-27,1,1,1,0,0,0,1,0,0,2,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT,"Randomized, Double-blind, Placebo-controlled, Dose escalation, Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients with Type 2 Diabetes Mellitus Not Adequately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005789-42,1,1,0 2015-005792-25,1,2017-12-18,2017-12-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Manchester University NHS Foundation Trust,Feasibility study on the effects of L-citrulline on uteroplacental and cardiovascular function in hypertensive pregnant women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005792-25,0,0,0 2015-005799-90,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,"E L I C O : Evaluation de la Lidocaïne par voie Intraveineuse en chirurgie Carcinologique ORL Essai thérapeutique randomisé, contrôlé, en double aveugle, versus placebo évaluant l'épargne morphinique ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005799-90,0,0,0 2015-005800-27,1,2017-11-18,2017-11-18,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, multi-center, double blind (sponsor open), placebo-controlled study to assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of GSK3117391 in subjects with mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005800-27,0,0,0 2015-005804-27,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CHU CAEN,"Essai randomisé, contrôlé, en double aveugle, de l'anakinra contre placebo, en adjonction à la corticothérapie dans l'artérite à cellules géantes. Essai randomisé, contrôlé, en double aveugle, de l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005804-27,0,0,0 2015-005805-35,11,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Array BioPharma Inc. (a whole owned subsidiary of Pfizer Inc),"A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005805-35,0,0,0 2015-005805-35,11,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Array BioPharma Inc.,"A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005805-35,0,0,0 2015-005805-35,11,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ARRAY BIOPHARMA INC.,"A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005805-35,0,0,0 2015-005806-12,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Novartis Farmaceútica S.A.,"A phase I/II, open-label, multi-center study of the safety and efficacy of BLZ945 as single agent and in combination with PDR001 in adults patients with advanced solid tumors Estudio fase I/II, abi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005806-12,0,0,0 2015-005810-31,1,2018-05-24,2018-05-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MEDDAY PHARMACEUTICALS,"Effect of MD1003 in amyotrophic lateral sclerosis: a randomized, double blind placebo controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005810-31,0,0,0 2015-005811-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"VU Medical Center, Amsterdam",Pregnancy reLated Acute hyperTension INtervention Action: a randomized trial comparing labetalol and nicardipine in women with acute hypertension in pregnancy (Platina-trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005811-34,0,0,0 2015-005814-31,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,NEURODERM LTD.,"A multicenter, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005814-31,0,0,0 2015-005814-31,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,NeuroDerm Ltd.,"A multicenter, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005814-31,0,0,0 2015-005817-61,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Tuebingen,iVAC-CLL01: Patient-individualized peptide vaccination after first line therapy of CLL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005817-61,0,0,0 2015-005820-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"A.O.U. Università degli Studi della Campania ""Luigi Vanvitelli""",A randomized study to evaluate the efficacy of ingenol mebutate on actinic keratoses and field cancerization compared to cryotherapy Studio randomizzato per valutare l'efficacia di ingenolo mebutat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005820-24,0,0,0 2015-005837-37,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,CHU CAEN,ASSOCIATION RITUXIMAB - BENDAMUSTINE - ARACYTINE DANS LE TRAITEMENT DES LYMPHOMES B DIFFUS À GRANDES CELLULES REFRACTAIRES OU EN RECHUTE : ETUDE DE PHASE II ASSOCIATION RITUXIMAB - BENDAMUSTINE - ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005837-37,0,0,0 2015-005838-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZLeuven,Circulating tumor DNA guiding (Olaparib) Lynparza® treatment in Ovarian Cancer (CLIO). Establishing the value of a ctDNA-based HRD assay for predicting olaparib response in women with relapsed ovarian...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005838-22,0,0,0 2015-005842-69,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Sanofi Pasteur Limited,"Immune Responses in Adults to Revaccination with Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005842-69,0,1,1 2015-005843-15,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Sanofi Pasteur Limited,"One-, Three-, Five-, Eight- and Ten-Year Data on the Long- Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adults and Adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005843-15,0,1,1 2015-005844-32,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Sanofi Pasteur Limited,"One-, Three-, Five- and Ten-Year Data on the Long-Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adolescents 11–14 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005844-32,0,1,1 2015-005845-30,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur Limited,"One-, Three-, Five-, and Ten-Year Data on the Long-Term Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) in Adults and Adolescents (11-64 yea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2015-005845-30,0,1,1 2016-000037-51,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000037-51,0,0,0 2016-000037-51,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000037-51,0,0,0 2016-000048-32,1,2018-11-26,2018-11-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,RWTH Aachen University/CTC-A,Evaluation of the Therapeutic Effects of Testosterone on Pain Perception in case of Chronic Pain Disorder Evaluation des Therapieeffekts von Testosteron auf die Schmerzwahrnehmung bei Anhaltender ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000048-32,0,0,0 2016-000049-30,2,2018-10-24,2018-10-24,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Medical Enterprises Europe B.V,"A multicenter, single-arm study evaluating the efficacy of Synergo radiofrequency-induced thermochemotherapy effect (RITE) with Mitomycin C( Synergo + MMC) in non-muscle invasive bladder cancer (NMIBC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000049-30,0,0,0 2016-000050-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de DIJON,"Evaluation de l’efficacité analgésique d’un bloc du muscle grand dentelé dans la chirurgie valvulaire par thoracotomie, en comparaison avec un cathéter intra-cicatriciel, au CHU de Dijon. Essai cliniq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000050-36,0,0,0 2016-000051-27,6,2018-04-23,2018-04-23,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,HAL Allergy B.V.,"A randomized, double-blind, placebo-controlled (DBPC) parallel-group multi-centre study to assess the efficacy and safety of PURETHAL Mites subcutaneous immunotherapy (SCIT) in patients with allergic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000051-27,0,0,0 2016-000054-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Interhospitalaria Investigación Cardiovascular,Effects of Intravenous Lysine Acetylsalicylate versus Oral Aspirin on Platelet Responsiveness in Patients with ST-segment Elevation Myocardial Infarction: a Pharmacodynamic study (ECCLIPSE-STEMI trial...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000054-35,0,0,0 2016-000060-42,2,2018-11-06,2018-11-06,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sunovion Pharmaceuticals Inc.,"A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lurasidone (SM-13496) in Acutely Psychotic Subjects with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000060-42,0,0,0 2016-000061-23,2,2019-01-31,2019-01-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sunovion Pharmaceuticals Inc.,"A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000061-23,0,0,0 2016-000063-16,1,2016-11-02,2016-11-02,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Galderma R&D SNC,Efficacy and safety of CD5024 1% in acne vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000063-16,0,0,0 2016-000064-42,4,2017-11-14,2017-11-24,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of M2951 in Subjects with Rheumatoid Arthritis on Stable Methotrexate Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000064-42,0,0,0 2016-000065-23,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Imperial College London,An international multi-centre randomised phase II study to assess the efficacy of TAK228 in combination with intravenous weekly paclitaxel compared with weekly paclitaxel alone in women with advanced/...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000065-23,0,0,0 2016-000066-34,1,2017-10-23,2017-10-23,1,1,1,0,0,0,4,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000066-34,0,0,0 2016-000067-16,1,2018-01-04,2018-01-04,1,1,0,0,1,1,2,0,0,1,0,0,1,0,1,AMO Pharma Ltd.,"A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400 mg Or 1000 mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000067-16,0,0,0 2016-000068-40,6,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Centre Hamburg-Eppendorf,Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000068-40,0,0,0 2016-000068-40,6,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITäTKLINIKUM HAMBURG-EPPENDORF,Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000068-40,0,0,0 2016-000069-22,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Celgene Corporation,"A PHASE 2, OPEN-LABEL, SINGLE-ARM ROLLOVER STUDY TO EVALUATE LONG-TERM SAFETY IN SUBJECTS WHO PARTICIPATED IN OTHER CELGENE SPONSORED CC-486 (ORAL AZACITIDINE) CLINICAL TRIALS IN SOLID TUMORS AND HEMA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000069-22,0,0,0 2016-000071-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR),TIME OF ADMINISTRATION OF TRANEXAMIC ACID TO PREVENT BLEEDING IN TOTAL KNEE ARTHROPLASTY DETERMINAR EL MOMENTO DE ADMINISTRACIÓN DE ÁCIDO TRANEXÁMICO PARA PREVENIR EL SANGRADO EN CIRUGÍA DE PRÓTE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000071-24,0,0,0 2016-000072-17,7,2022-05-12,2022-05-12,2,1,0,0,0,1,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITHOUT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000072-17,1,0,0 2016-000072-17,7,2022-05-12,2022-05-12,2,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.","A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITHOUT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000072-17,1,0,0 2016-000072-17,7,2022-05-12,2022-05-12,2,1,0,0,0,1,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITHOUT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000072-17,1,0,0 2016-000073-21,5,2020-11-11,2020-11-11,3,1,1,0,0,1,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000073-21,1,0,0 2016-000073-21,5,2020-11-11,2020-11-11,3,1,1,0,0,1,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000073-21,1,0,0 2016-000073-21,5,2020-11-11,2020-11-11,3,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd","A MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000073-21,1,0,0 2016-000076-23,5,2017-06-22,2017-07-03,5,0,0,0,0,0,2,0,0,1,0,0,1,0,1,ANERGIS SA,"A MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO ASSESS THE EFFICACY AND TOLERABILITY OF TWO DOSING REGIMENS OF ALLERT, A COMBINATION OF CONTIGUOUS OVERLAPPING PEPTIDES DERIVED FRO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000076-23,0,0,0 2016-000078-39,1,2016-12-13,2016-12-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,PLIVA Hrvatska d.o.o.,"A prospective, multicentre, uncontrolled study of Geonistin vaginal tablets effectiveness with pharmacokinetic evaluation for unspecific and mixed vulvovaginal infections characterized by vaginal disc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000078-39,0,0,0 2016-000080-16,1,2019-01-21,2019-01-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Vejle Hospital,Tocotrienol in combination with neoadjuvant chemotherapy for women with breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000080-16,0,0,0 2016-000081-33,1,2017-07-13,2017-07-13,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Ligartis GmbH,Phase Ib/II study assessing the neo-adjuvant combination therapy of vinflunine with cisplatin followed by radical cystectomy in patients with muscle-invasive bladder cancer Phase Ib/II Studie zur B...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000081-33,0,0,0 2016-000082-23,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Reinier de Graaf Groep,Median Local Anaesthetic Dose (MLAD) of intrathecal Bupivacaine in total knee arthroplasty,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000082-23,0,0,0 2016-000084-16,3,2018-12-21,2018-12-21,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"NanoCarrier Co, Ltd","A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine in Patients with Advanced Solid Tumors or Squamous Non-Small Cell Lung, Biliary Tract, and Bladder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000084-16,0,0,0 2016-000084-16,3,2018-12-21,2018-12-21,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"NANOCARRIER CO, LIMITED","A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine in Patients with Advanced Solid Tumors or Squamous Non-Small Cell Lung, Biliary Tract, and Bladder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000084-16,0,0,0 2016-000085-32,1,,,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,TRANSGENE SA,A phase I/IIa trial to evaluate the safety and efficacy of the combination of the oncolytic immunotherapy Pexa-Vec with the PD-1 receptor blocking antibody nivolumab in the first-line treatment of adv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000085-32,0,0,0 2016-000087-42,2,2021-09-06,2021-09-06,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,University College Dublin,"A multicentre, prospective, single arm, open-label 96 week observational trial of the tolerability, adherence and efficacy of a dolutegravir/abacavir/lamivudine single tablet regimen in HIV-1 antibody...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000087-42,0,0,0 2016-000089-45,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,ORBUS THERAPEUTICS INC.,"A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000089-45,0,0,0 2016-000089-45,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Orbus Therapeutics, Inc.","A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000089-45,0,0,0 2016-000092-24,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University Medical Center Utrecht,The PLCRC substudy Ultra high field 7.0 Tesla MR Spectroscopy to monitor capecitabine metabolism in liver metastases – a proof of concept study De PLCRC substudie Ultra hoog veld 7.0 Tesla MR Sprec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000092-24,0,0,0 2016-000095-17,1,2022-06-01,2022-06-01,1,0,0,1,0,1,1,0,0,1,1,1,0,0,1,Holostem Terapie Avanzate s.r.l.,"PROSPECTIVE, OPEN-LABEL, UNCONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF AUTOLOGOUS CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED WITH A GAMMA-RETROVI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000095-17,0,0,0 2016-000097-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Labo'Life,"Randomized, double-blind, placebo-controlled study to measure 2L®ALERG (homeopathic drug) efficacy on symptoms of allergic rhinitis and allergic rhinoconjunctivitis in patients with a seasonal allergy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000097-38,0,0,0 2016-000101-37,2,2017-07-24,2017-07-24,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Subjects with Moderate to Severe Primary Sjö...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000101-37,0,0,0 2016-000101-37,2,2017-07-24,2017-07-24,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (lulizumab) or BMS-986142 in Subjects with Moderate to Severe Primary Sjö...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000101-37,0,0,0 2016-000102-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,"Randomized, double-blind, placebo-controlled trial to evaluate the efficacy of continuous subcutaneous apomorphine infusion in Parkinson’s disease patients with refractory visual hallucinations.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000102-11,0,0,0 2016-000105-36,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc","A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH – 1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000105-36,0,0,0 2016-000105-36,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"REGENERON PHARMACEUTICALS, INC.","A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH – 1 (PD-1), IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000105-36,0,0,0 2016-000106-11,1,2018-02-20,2018-02-20,1,0,1,0,0,0,2,0,0,1,0,0,1,0,0,Limoges Hospital,"EVALUATION OF THE EFFICIENCY OF TREATMENT BY BUMETANIDE ON AUTISTIC CHILDREN WITH A KNOWN ETIOLOGY: MULTICENTER AND DOUBLE-BLIND STUDY WITH RANDOMIZED PARALLEL GROUP, AGAINST PLACEBO. Evaluation de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000106-11,0,0,0 2016-000108-27,6,2017-05-08,2017-05-08,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Eli Lilly and Company,"A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab versus Placebo in Prodromal Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000108-27,0,0,0 2016-000108-27,6,2017-05-08,2017-05-08,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Lilly S.A.,"A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab versus Placebo in Prodromal Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000108-27,0,0,0 2016-000109-35,1,2020-10-22,2020-10-22,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Royal Marsden NHS Foundation Trust,A PHASE I/II TRIAL OF COMBINATION NAB-PACLITAXEL AND NINTEDANIB OR NAB-PACLITAXEL AND PLACEBO IN RELAPSED NSCLC ADENOCARCINOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000109-35,0,0,0 2016-000113-70,1,2019-06-03,2019-06-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Southampton NHS Foundation Trust,Clinical efficacy and mechanistic evaluation of Eplerenone for Central serous chorio-retinopathy – the VICI randomised trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000113-70,0,0,0 2016-000115-32,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Evestra GmbH,"Characterization of ovulation inhibition of a new vaginal delivery system (EVE 112, Evestra/Germany) containing etonogestrel and ethinylestradiol – an open label, single centre, comparative, parallel-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000115-32,0,0,0 2016-000117-76,3,2021-03-31,2021-03-31,2,1,0,1,0,0,1,0,1,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase 1/2, randomized, observer-blind, controlled, multi-center, dose-escalation study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ respiratory syncytial virus (RSV) inv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000117-76,0,0,0 2016-000117-76,3,2021-03-31,2021-03-31,2,1,0,1,0,0,1,0,1,1,0,0,0,0,1,GlaxoSmithKline S.A.,"A Phase 1/2, randomized, observer-blind, controlled, multi-center, dose-escalation study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ respiratory syncytial virus (RSV) inv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000117-76,0,0,0 2016-000117-76,3,2021-03-31,2021-03-31,2,1,0,1,0,0,1,0,1,1,0,0,0,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A Phase 1/2, randomized, observer-blind, controlled, multi-center, dose-escalation study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals’ respiratory syncytial virus (RSV) inv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000117-76,0,0,0 2016-000118-31,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge,A randomised phase II double-blinded placebo-controlled trial of intravenous immunoglobulins and rituximab in patients with antibody-associated psychosis (SINAPPS2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000118-31,0,0,0 2016-000121-40,7,2020-10-06,2020-10-06,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 3 Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000121-40,1,1,0 2016-000125-38,1,2020-12-01,2020-12-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,PIQUR Therapeutics AG,"Open-label, Non-randomized Phase 2 Study With Safety Run-in Evaluating Efficacy and Safety of PQR309 in Patients with Relapsed or Refractory Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000125-38,0,0,0 2016-000126-19,7,2017-12-27,2017-12-27,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Stealth BioTherapeutics Inc.,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment with Elamipretide in Patients Hospitalized with Congestion due to Heart F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000126-19,0,0,0 2016-000133-40,4,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,GUSTAVE ROUSSY,European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000133-40,0,0,0 2016-000133-40,4,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,Gustave Roussy,European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000133-40,0,0,0 2016-000134-22,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,Chiesi Farmaceutici S.p.A.,"A Prospective, Open-Label, Single-Arm, Multi-Center Study to Assess The Pharmacokinetics/Pharmacodynamics (PK/PD) AND Safety Of Different Cangrelor Doses In Neonatal Subjects At Risk Of Thrombosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000134-22,0,1,1 2016-000135-40,1,2021-04-01,2021-04-01,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Zealand University Hospital, Department of Surgery",Endoscopic assisted electrochemotherapy in addition to neoadjuvant treatment of locally advanced rectal cancer: a randomized clinical phase II trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000135-40,0,0,0 2016-000136-17,1,2020-01-06,2020-01-06,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,Friedrich Schiller University Jena,"Prospective, randomized, multicenter clinical trial on the impact of Therapeutic Drug Monitoring (TDM) of piperacillin on organ functions and survival in the treatment of severe sepsis or septic shock...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000136-17,0,0,0 2016-000137-52,1,,,0,0,0,0,1,1,2,0,0,1,1,1,0,1,1,Neovacs SA,"A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects with Dermatomyositis. Ein...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000137-52,0,0,0 2016-000141-31,1,2019-08-08,2019-08-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,London School of Hygiene and Tropical Medicine,A SERIES OF RANDOMISED CONTROLLED N-of 1 TRIALS IN PATIENTS WHO HAVE DISCONTINUED OR WISH TO DISCONTINUE STATIN USE DUE TO MUSCLE-RELATED SYMPTOMS TO ASSESS IF ATORVASTATIN TREATMENT CAUSES MORE MUSCL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000141-31,0,0,0 2016-000147-13,1,2022-04-23,2022-04-23,1,0,0,0,0,0,3,0,0,1,1,1,0,0,0,CHU de LIMOGES,"Is there an interest in repeating the vaginal administration of dinoprostone ( Propess® ) , to promote cervical ripening of pregnant women at term? Y a-t-il un interet à répéter l’administration de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000147-13,0,0,0 2016-000152-96,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GETAID,Intensive Treatment to Reach the target with Golimumab in ulcErative coliTis – In-TARGET Traitement intensif par golimumab pour atteindre la cible thérapeutique dans la rectocolite hémorragique (RC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000152-96,0,0,0 2016-000154-34,4,2017-12-01,2017-12-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®,as an Active Control, on Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000154-34,0,0,0 2016-000154-34,4,2017-12-01,2017-12-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pearl Therapeutics, Inc.","A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®,as an Active Control, on Lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000154-34,0,0,0 2016-000155-28,7,2018-04-04,2018-04-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"PEARL THERAPEUTICS, INC.","A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 compared to PT005 in Subjects With Moderate to Very Severe COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000155-28,0,0,0 2016-000155-28,7,2018-04-04,2018-04-04,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pearl Therapeutics, Inc. (Pearl)","A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 compared to PT005 in Subjects With Moderate to Very Severe COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000155-28,0,0,0 2016-000158-36,1,2017-05-03,2017-05-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PEPTONIC medical AB,"A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000158-36,0,0,0 2016-000160-42,1,2016-07-31,2016-07-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,UK für Anästhesiologie und allgemeine Intensivmedizin,Effect of inhaled budenoside on the incidence and severity of Acute Mountain Sickness at 4559 m Effekt von inhalativem Budesonid auf die Inzidenz und den Schweregrad der Akuten Bergkrankheit in 455...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000160-42,0,0,0 2016-000164-42,1,2017-10-03,2017-10-03,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Tayside Medical Sciences Centre on behalf of University of Dundee,JAB02 Repurposing allopurinol as a novel anti-inflammatory treatment for persistent allergic asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000164-42,0,0,0 2016-000165-23,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,ComparIsoN oF Optimal Hypertension RegiMens (Part of the Ancestry Informative Markers in Hypertension (AIM HY) Programme – AIM HY-INFORM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000165-23,0,0,0 2016-000166-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Noordwest Ziekenhuisgroep,"Effects of long term ToBrAmycin InhalaTion SoluTion (TIS) once daiLy on Exacerbation rate in patients with non-cystic fibrosis bronchiectasis. A double blind, randomized, placebo and TIS twice daily ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000166-35,0,0,0 2016-000167-16,2,2021-01-15,2021-01-15,2,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Sahlgrenska University Hospital,DIsulfiram REsponse as add-on to ChemoTherapy in recurrent Glioblastoma: A randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000167-16,0,0,0 2016-000171-24,1,2021-02-15,2021-02-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Národný onkologický ústav,"Phase II study of gemcitabine, carboplatin and VELIPARIB (ABT-888) in refractory testicular germ cell cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000171-24,0,0,0 2016-000172-19,1,2019-01-23,2019-01-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"RWTH Aachen University for the Medical Faculty, represented by Center for Transitional & Clinical Research Aachen (CTC-A",Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients with Type 2 Diabetes Empagliflozin als Modulator des systemischen Gefäßwiderstands und Herzzeitvolumens b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000172-19,0,0,0 2016-000176-20,7,2018-07-13,2018-07-31,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Alcon Research Ltd,Safety and Efficacy with Twice Daily Brinzolamide 1% / Brimonidine 0.2% (SIMBRINZA) as an Adjunctive Therapy to Travoprost 0.004% / Timolol 0.5% (DUOTRAV),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000176-20,0,0,0 2016-000186-23,3,2019-07-23,2019-07-23,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"Open-label, multicenter, single arm, phase III study to collect additional safety and efficacy data with deferasirox film-coated tablets in patients completing study CICL670F2201",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000186-23,0,0,0 2016-000186-23,3,2019-07-23,2019-07-23,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,NOVARTIS PHARMA SERVICES AG,"Open-label, multicenter, single arm, phase III study to collect additional safety and efficacy data with deferasirox film-coated tablets in patients completing study CICL670F2201",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000186-23,0,0,0 2016-000187-42,4,2021-11-17,2021-11-17,2,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3b, Two-part, Multicenter, One Year Randomized, Double-blind, Placebo-controlled Trial of the Safety, Pharmacokinetics, Tolerability, and Efficacy of Tolvaptan followed by a Two Year Open-labe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000187-42,1,0,0 2016-000189-45,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,"DIPARTIMENTO SCIENZE CHIRURGICHE, ONCOLOGICHE E GASTROENTEROLOGICHE (DISCOG) - UNIVERSITA' DI PADOVA",ADJUVANT TREATMENT FOR HIGH-RISK TRIPLE NEGATIVE BREAST CANCER PATIENTS WITH THE ANTI-PD-L1 ANTIBODY AVELUMAB: A PHASE III RANDOMIZED TRIAL. Studio randomizzato di fase III sull’utilizzo dell’antic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000189-45,0,0,0 2016-000189-45,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Padova,ADJUVANT TREATMENT FOR HIGH-RISK TRIPLE NEGATIVE BREAST CANCER PATIENTS WITH THE ANTI-PD-L1 ANTIBODY AVELUMAB: A PHASE III RANDOMIZED TRIAL. Studio randomizzato di fase III sull’utilizzo dell’antic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000189-45,0,0,0 2016-000191-21,7,2020-03-19,2020-03-19,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 4 open-label randomized controlled study COmparing the effectiveness of adalimumab iNTROduction and methotrexate dose escaLation in subjects with Psoriatic Arthritis (CONTROL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000191-21,0,0,0 2016-000191-21,7,2020-03-19,2020-03-19,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,A Phase 4 open-label randomized controlled study COmparing the effectiveness of adalimumab iNTROduction and methotrexate dose escaLation in subjects with Psoriatic Arthritis (CONTROL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000191-21,0,0,0 2016-000193-38,6,2021-12-14,2022-03-01,5,0,0,0,0,0,2,0,0,1,1,0,0,0,0,Nordic Society of Gynaecological Oncology (NSGO),ENGOT-EN1/FANDANGO: A randomized phase II trial of first-line combination chemotherapy with nintedanib / placebo for patients with advanced or recurrent endometrial cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000193-38,0,0,0 2016-000193-38,6,2021-12-14,2022-03-01,5,0,0,0,0,0,2,0,0,1,1,0,0,0,0,Nordic Society of Gynaecological Oncology (NSGO) - CTU,ENGOT-EN1/FANDANGO: A randomized phase II trial of first-line combination chemotherapy with nintedanib / placebo for patients with advanced or recurrent endometrial cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000193-38,0,0,0 2016-000195-19,1,2018-03-01,2018-03-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Royal Wolverhampton NHS Trust,"The Effect of Intravenous Cangrelor and Oral Ticagrelor on Platelets, the Microcirculation and Myocardial Damage in Patients admitted with STEMI Treated by Primary Percutaneous Coronary Intervention ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000195-19,0,0,0 2016-000196-24,6,2020-03-30,2020-05-07,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Reata Pharmaceuticals, Inc.",A STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000196-24,0,0,0 2016-000197-38,1,2018-08-31,2018-08-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Edinburgh,A double blind randomised parallel group trial of paracetamol versus placebo in conjunction with strong opioids for cancer related pain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000197-38,0,0,0 2016-000197-38,1,2018-08-31,2018-08-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,NHS Lothian,A double blind randomised parallel group trial of paracetamol versus placebo in conjunction with strong opioids for cancer related pain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000197-38,0,0,0 2016-000202-11,4,2019-01-14,2019-01-14,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffman-La Roche Ltd.,"A Phase III, open-label, multicenter, three-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy vs. regorafenib in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000202-11,0,0,0 2016-000202-11,4,2019-01-14,2019-01-14,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A Phase III, open-label, multicenter, three-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy vs. regorafenib in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000202-11,0,0,0 2016-000203-82,1,2018-07-27,2018-07-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Shire Human Genetic Therapies, Inc.","A Phase 2 Double-Blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000203-82,0,0,0 2016-000206-10,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,Shanghai Henlius Biotech Inc.,"Double-blind, Randomized, Multicenter, Phase III Clinical Study to Compare the Efficacy and to Evaluate the Safety and Immunogenicity of Trastuzumab Biosimilar HLX02 and EU-sourced Herceptin® in Previ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000206-10,0,0,0 2016-000207-90,1,2017-01-06,2017-01-06,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,BIPROJET PHARMA,"A Multisite Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Pitolisant (BF2.649) For Alcohol Use Disorder Treatment. Многоцентрово, рандомизирано, двойно-сляпо, контролирано с плацебо...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000207-90,0,0,0 2016-000209-35,1,2020-08-27,2020-08-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,Adjuvant rituximab – a potential treatment for the young patient with Graves’ hyperthyroidism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000209-35,0,0,0 2016-000210-29,6,2020-06-04,2020-06-04,5,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma Services AG,"A Phase Ib/II, open label, multicenter study of MCS110 in combination with PDR001 in patients with advanced malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000210-29,0,0,0 2016-000210-29,6,2020-06-04,2020-06-04,5,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase Ib/II, open label, multicenter study of MCS110 in combination with PDR001 in patients with advanced malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000210-29,0,0,0 2016-000211-33,1,2019-08-28,2019-08-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Papworth Hospital NHS Foundation Trust,Dose Effect Relationship of a Single Dose of Rituximab on the Kinetics of B Lymphocytes in Patients with Acute ST-Segment Myocardial Infarction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000211-33,0,0,0 2016-000212-16,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Helsinki University Central Hospital,"Hydrocortisone vs. pasireotide in preventing pancreatic fistula and other complications after pancreatic resection - a prospective, randomized, controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000212-16,0,0,0 2016-000214-30,1,2020-11-19,2020-11-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitätsklinikum Freiburg,Empagliflozin and its effect on heart failure in type 2 diabetes Wirkung von Empagliflozin auf Herzinsuffizienz in Patienten mit Diabetes mellitus Typ 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000214-30,0,0,0 2016-000215-32,1,2020-11-20,2020-11-20,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University of Antwerp,"Effect of Pycnogenol® on Attention-Deficit Hyperactivity Disorder (ADHD): A randomized, double blind, placebo and active product controlled multicenter trial. Effect van Pycnogenol® op Aandachtstek...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000215-32,0,0,0 2016-000221-39,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,AbbVie Inc,"A Prospective, International, Multicenter, Open-Label, Non-Controlled Study of Safety and Effectiveness of Palivizumab, in Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000221-39,0,1,1 2016-000222-19,10,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,University Hospital Tuebingen,Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome ¿ a blinded randomized placebo-controlled parallel group multicenter trial for superiority ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000222-19,0,0,0 2016-000222-19,10,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,Oslo University Hospital,Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome ¿ a blinded randomized placebo-controlled parallel group multicenter trial for superiority ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000222-19,0,0,0 2016-000222-19,10,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,UMC Utrecht,Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome ¿ a blinded randomized placebo-controlled parallel group multicenter trial for superiority ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000222-19,0,0,0 2016-000222-19,10,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,UNIVERSITATSKLINIKUM TUBINGEN,Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome ¿ a blinded randomized placebo-controlled parallel group multicenter trial for superiority ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000222-19,0,0,0 2016-000226-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Association AERCOT,FAISABILITE DE LA PROTHESE TOTALE DU GENOU EN AMBULATOIRE : APPORT DU BLOC SCIATIQUE FAISABILITE DE LA PROTHESE TOTALE DU GENOU EN AMBULATOIRE : APPORT DU BLOC SCIATIQUE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000226-19,0,0,0 2016-000227-71,15,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,0,Erasmus Medical Center,A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000227-71,0,0,0 2016-000227-71,15,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,0,Erasmus MC,A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000227-71,0,0,0 2016-000228-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UZ Brussel,Eradication of H. pylori infection in Belgium: bismuth versus first line therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000228-24,0,0,0 2016-000229-38,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000229-38,0,0,0 2016-000235-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Region Skåne,Stopping anti-TNF treatment in Crohn’s and Colitis patients in remission Utsättning av anti-TNF terapi hos patienter med ulcerös kolit eller Crohns sjukdom i lugn fas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000235-40,0,0,0 2016-000237-48,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Leiden University Medical Center,The effect of Mirabegron on brown adipose tissue in healthy young white Caucasian and South Asian men,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000237-48,0,0,0 2016-000238-23,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Leiden University Medical Center,The effect of Exenatide on brown adipose tissue activity and energy expenditure in healthy young men,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000238-23,0,0,0 2016-000240-34,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Rexgenero Limited,"The Efficacy and Safety of Intra-Arterial Administration of REX-001 to Treat Ischaemic Rest Pain in Subjects with Critical Limb Ischaemia Rutherford Category 4 and Diabetes Mellitus: A Pivotal, Placeb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000240-34,0,0,0 2016-000246-62,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Novartis,"A Study of Magnetic Resonance Imaging Assessment of Cardiac and Liver Iron Load in Patients With Haemoglobinopathies, Myelodysplastic Syndromes (MDS) or Other Anaemias Treated With Exjade® (Deferasiro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000246-62,0,1,1 2016-000248-32,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,Novartis Pharmaceuticals Corporation,"A randomized, open-label, single center, phase I, cross-over study to evaluate the pharmacokinetic comparability of deferasirox new tablet formulation with the reference dispersible formulation in hea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000248-32,0,1,1 2016-000249-30,1,2017-01-25,2017-01-25,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Hansa Medical AB,"A PHASE II PILOT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACODYNAMICS AND PHARMACOKINETICS OF IDES IN ASYMPTOMATIC ANTIBODY-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) PATIENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000249-30,0,0,0 2016-000250-35,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE IN P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000250-35,0,0,0 2016-000250-35,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.","A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE IN P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000250-35,0,0,0 2016-000250-35,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI?PD-L1 ANTIBODY) IN COMBINATION WITH GEMCITABINE/CARBOPLATIN VERSUS GEMCITABINE/CARBOPLATIN ALONE IN P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000250-35,0,0,0 2016-000252-99,1,2017-07-13,2017-07-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Drossapharm AG,"A randomized, double-blind, multi-center, placebo-controlled, parallel group study to evaluate the efficacy and safety of an etofenamate 5% cutaneous patch applied twice daily in subjects with acute u...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000252-99,0,0,0 2016-000259-28,12,2021-06-11,2021-06-11,8,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000259-28,1,1,0 2016-000263-17,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,F. Hoffmann-La Roche AG,Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000263-17,0,1,1 2016-000274-37,1,2017-04-05,2017-04-05,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,MCM Vaccine B.V.,Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4- to 5 year old Children Previously Vaccinated with a 2-dose or 3-dose Infants series and Toddler dose with VAXELIS® o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000274-37,0,0,0 2016-000275-25,1,2020-10-21,2020-10-21,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000275-25,0,0,0 2016-000276-23,1,2019-01-03,2019-01-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A multiple treatment session, open label phase 2 clinical study of GSK2398852 administered following and together with GSK2315698 in cohorts of patients with cardiac amyloidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000276-23,0,0,0 2016-000279-26,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Erasmus MC,Trigeminovascular effects of propranolol in migraine treatment Trigeminovasculaire effecten van propranolol bij de behandeling van migraine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000279-26,0,0,0 2016-000280-16,13,2019-02-22,2019-03-22,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000280-16,0,0,0 2016-000280-16,13,2019-02-22,2019-03-22,11,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000280-16,0,0,0 2016-000281-39,12,2019-02-22,2019-03-25,12,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 100 mg b.i.d. in reducing 24-hour average pain intensity score in patients with painful diabetic neu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000281-39,0,0,0 2016-000281-39,12,2019-02-22,2019-03-25,12,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A","A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 100 mg b.i.d. in reducing 24-hour average pain intensity score in patients with painful diabetic neu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000281-39,0,0,0 2016-000283-41,1,2020-12-09,2020-12-09,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Finn Sellebjerg,Dimethyl fumarate treatment of primary progressive multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000283-41,0,0,0 2016-000284-17,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Universitätsmedizin Mainz,Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy (VinoMetro). ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000284-17,0,0,0 2016-000285-28,4,2020-01-29,2020-01-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A phase II randomised, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000285-28,0,0,0 2016-000285-28,4,2020-01-29,2020-01-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase II randomised, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000285-28,0,0,0 2016-000285-28,4,2020-01-29,2020-01-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A phase II randomised, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000285-28,0,0,0 2016-000285-28,4,2020-01-29,2020-01-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A phase II randomised, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000285-28,0,0,0 2016-000286-23,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,"Telios Pharma, Inc.","Phase I/II, First in Human, Dose Escalation Trial of TL-895 in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansion in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000286-23,0,0,0 2016-000287-42,2,2019-09-27,2019-09-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,CHU DE LIMOGES,A Multicentre Open label Phase II study of Daratumumab in AL Amyloidosis Patients not in VGPR or Better,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000287-42,0,0,0 2016-000287-42,2,2019-09-27,2019-09-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,CHU de Limoges,A Multicentre Open label Phase II study of Daratumumab in AL Amyloidosis Patients not in VGPR or Better,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000287-42,0,0,0 2016-000288-18,6,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Eli Lilly and Company,"A Randomized, Open-Label, Phase 2 Study of Abemaciclib plus Tamoxifen or Abemaciclib Alone, in Women with Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000288-18,0,0,0 2016-000288-18,6,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Lilly S.A.,"A Randomized, Open-Label, Phase 2 Study of Abemaciclib plus Tamoxifen or Abemaciclib Alone, in Women with Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000288-18,0,0,0 2016-000290-20,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"Phase IIb randomized, open-label, controlled, multi-center study of the efficacy, safety and immunogenicity of GSK Biologicals’ candidate malaria vaccine RTS,S/AS01E evaluating schedules with or witho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000290-20,0,1,1 2016-000293-37,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"An open-label, multi-center rollover protocol for patients who have participated in a Novartis-sponsored ribociclib (LEE011) study and are continuing to benefit from ribociclib as single agent or in c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000293-37,0,0,0 2016-000293-37,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","An open-label, multi-center rollover protocol for patients who have participated in a Novartis-sponsored ribociclib (LEE011) study and are continuing to benefit from ribociclib as single agent or in c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000293-37,0,0,0 2016-000296-24,1,2020-07-28,2020-07-28,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Institut de Recherches Internationales Servier (I.R.I.S),"Phase I, open label, dose-escalation study to evaluate the safety, expansion and persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor),...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000296-24,0,0,0 2016-000297-38,4,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,1,Institut de Recherches Internationales Servier (I.R.I.S),Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000297-38,0,0,0 2016-000297-38,4,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,1,Laboratorios Servier S.L.,Long-term follow-up study of patients who have previously been exposed to UCART19 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000297-38,0,0,0 2016-000298-20,3,2021-06-04,2021-06-04,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Sintetica S.A.,Comparison of epidural Chloroprocaine 3% and Ropivacaine 0.75% for unplanned Caesarean section in labouring women who have an epidural catheter in situ Vergleich von Chloroprocain 3 % und Ropivacai...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000298-20,0,0,0 2016-000300-28,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca,"A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza¿) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000300-28,0,0,0 2016-000300-28,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ASTRAZENECA SPA,"A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza¿) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000300-28,0,0,0 2016-000301-37,6,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Genzyme Corporation,"Open label, Two Cohort (with and without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients with Gaucher Disease Type 1 and Type 3",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000301-37,0,1,0 2016-000302-12,4,2017-12-28,2017-12-28,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"ARCA biopharma, Inc.",GENETIC-AF – A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000302-12,0,0,0 2016-000304-29,1,2018-03-28,2018-03-28,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health",Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000304-29,0,0,0 2016-000307-93,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,Novartis Pharmaceuticals Corporation,"A randomized, open label, single center, phase I, two way, cross-over study to evaluate the pharmacokinetic comparability of deferasirox new granule formulation with the reference dispersible formulat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000307-93,0,1,1 2016-000308-28,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,Novartis,"A randomized, open label, six sequences, cross-over study in healthy Japanese subjects to evaluate the pharmacokinetic comparability of deferasirox granule formulation with the reference dispersible t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000308-28,0,1,1 2016-000309-34,1,2016-11-30,2016-11-30,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Medical University of Vienna,Vorapaxar in the human endotoxemia model,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000309-34,0,0,0 2016-000312-15,1,2020-10-01,2020-10-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Treatment tapering in oligoarticular or rheumatoid factor negative polyarticular Juvenile Idiopathic Arthritis with inactive disease on biologic therapy Décroissance thérapeutique dans l'arthrite ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000312-15,0,0,0 2016-000315-32,1,2017-12-19,2017-12-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,"Clinical Trial to Explore Treatment Effects of Ginkgo biloba Extract EGb 761® in Patients with Chronic Tinnitus and Effect Modification by Etiology, Biological Factors and Concomitant Pathologies. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000315-32,0,0,0 2016-000316-15,1,2018-06-12,2018-06-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dr. Willmar Schwabe GmbH & Co. KG,"Clinical Trial to Explore Treatment Effects of Ginkgo biloba Extract EGb 761® in Patients with Different Types of Vertigo and Effect Modification by Type of Vertigo, Chronicity and Concomitant Patholo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000316-15,0,0,0 2016-000317-78,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,"PROVECTUS BIOPHARMACEUTICALS, INC.",PV-10 Intralesional Injection vs Systemic Chemotherapy or Intralesional Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma PV-10 Intralesional Injection vs Systemic Chemot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000317-78,0,0,0 2016-000318-31,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Erasmus MC,Ledipasvir and sofosbuvir for 8 weeks for the treatment of chronic hepatitis C genotype 4 in patients without cirrhosis. HepNed-001 study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000318-31,0,0,0 2016-000322-19,1,,,0,1,0,0,0,1,2,0,0,3,0,0,0,0,1,Ultragenyx Pharmaceutial Inc.,An Open-label Long-Term Safety and Efficacy Extension Study in Subjects with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Previously Enrolled in UX007 or Triheptanoin Studies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000322-19,0,0,0 2016-000323-43,2,2020-03-17,2020-03-17,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"MedImmune, LLC, a wholly-owned subsidiary of AstraZeneca PLC","A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malignanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000323-43,0,0,0 2016-000326-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,St Olavs Hospital Trondheim University Hospital,"Treatment of obesity in adolescents by endoscopic injection of Botulinum toxin A - A randomised, double blind, placebo-controlled phase II-trial followed by an open-label cohort-controlled extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000326-19,0,0,0 2016-000327-10,2,2018-10-31,2019-07-15,2,1,0,0,0,2,2,0,0,1,0,0,1,0,1,GWT-TUD GmbH,SINGLE AGENT JNJ-56022473 IN MDS AND AML PATIENTS FAILING HYPOMETHYLATING AGENT BASED THERAPY Etude de phase II avec JNJ-56022473 en monothérapie chez les patients présentant un syndrome myélodyspl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000327-10,0,0,0 2016-000331-41,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,Centre for Human Drug Research,"A randomized, open-label, vehicle-controlled, parallel, dose-ranging study to assess the pharmacodynamics of topically applied Imiquimod in healthy volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000331-41,0,0,0 2016-000335-40,1,2018-07-02,2018-07-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A TWO-COHORT RANDOMIZED PHASE II, DOUBLEBLIND, PARALLEL GROUP STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS EVALUATING THE EFFICACY AND SAFETY OF GDC-0853 COMPARED WITH PLACEBO AND ADALIMUMAB IN ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000335-40,0,0,0 2016-000338-23,1,2018-06-22,2018-06-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Nottingham,"Does a low exhaled Nitric Oxide level exclude a clinical benefit from inhaled corticosteroids in suspected asthma; a double-blind, randomised, placebo controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000338-23,0,0,0 2016-000339-42,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,CENTRO PER LA PREVENZIONE E CURA DEL TABAGISMO,Efficacy of smoking cessation with varenicline for e-cigarettes users: a randomized controlled trial (VAREVAPE) EFFICACIA DELLA VARENICLINA NELLA DISASSUEFAZIONE DAL FUMO NEI FUMATORI DI SIGARETTA ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000339-42,0,0,0 2016-000340-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL UNIVERSITARI DE BELLVITGE,Dose optimization of tacrolimus using Bayesian prediction including pharmacogenetic variables in renal transplant patients. OPTImización de la dosis de tacroliMUS mediante predicción bayesiana en ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000340-34,0,0,0 2016-000342-60,1,2018-07-09,2018-07-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Norfolk and Norwich University Hospital,Fatigue in Sarcoidosis - A feasibility study investigating the treatment of fatigue in stable sarcoidosis patients using methylphenidate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000342-60,0,0,0 2016-000343-14,4,2020-01-23,2020-01-23,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,UCB Biopharma SPRL,"Multicenter, Open-Label Study To Assess The Effects Of Certolizumab Pegol On The Reduction Of Anterior Uveitis Flares In Axial Spondyloarthritis Subjects With A History Of Anterior Uveitis (C-VIEW)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000343-14,0,0,0 2016-000343-14,4,2020-01-23,2020-01-23,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,UCB Biopharma SPRL.,"Multicenter, Open-Label Study To Assess The Effects Of Certolizumab Pegol On The Reduction Of Anterior Uveitis Flares In Axial Spondyloarthritis Subjects With A History Of Anterior Uveitis (C-VIEW)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000343-14,0,0,0 2016-000345-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VU medical center,Towards personalized dosing of natalizumab in multiple sclerosis Op weg naar een gepersonaliseerde behandeling met natalizumab in multiple sclerose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000345-31,0,0,0 2016-000346-61,1,2019-07-02,2019-07-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Blueclinical, Ltd.","A Phase II, Multicenter, Single-Arm, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of Triple Therapy with Dolutegravir plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000346-61,0,0,0 2016-000347-14,1,,,0,0,0,0,0,1,2,0,1,0,0,0,0,0,0,IDIBAPS,Cell proliferation in pulmonary hypertension: mollecular imaging detection by FDG PET. Comparative study between patients and healthy subjects Proliferación celular en la hipertensión pulmonar: Det...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000347-14,0,0,0 2016-000354-35,1,2017-02-06,2017-02-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Aarhus University Hospital,High dose antioxidant treatment of patients with cystic fibrosis evaluated by measuring desmosine/isodesmosine in urine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000354-35,0,0,0 2016-000355-27,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University Hospitals of North Midlands NHS Trust,The effect on Endothelial progenitor cells (EPCs) by statin loading in “all comers” with an Acute Coronary Syndrome (ACS).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000355-27,0,0,0 2016-000357-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Stichting Longgeneeskunde Fryslan,The role of dynamic hyperinflation in asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000357-12,0,0,0 2016-000359-29,7,2020-03-17,2020-03-25,7,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Flamel Ireland Limited,"A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000359-29,0,0,0 2016-000359-29,7,2020-03-17,2020-03-25,7,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Flamel Ireland Limited (trading under the business name Avadel Ireland),"A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000359-29,0,0,0 2016-000360-42,3,2018-01-10,2018-01-10,3,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Ultragenyx Pharmaceutical Inc.,A Phase 3b Open-label Extension Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients with GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000360-42,0,0,0 2016-000360-42,3,2018-01-10,2018-01-10,3,1,0,0,0,1,3,0,0,1,1,1,1,0,1,ULTRAGENYX PHARMACEUTICAL INC.,A Phase 3b Open-label Extension Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients with GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000360-42,0,0,0 2016-000361-22,4,2022-01-12,2022-01-12,3,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Double-Blind Study with an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Pediatric Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000361-22,1,0,0 2016-000367-16,1,2019-05-20,2019-05-20,1,0,0,0,0,0,4,0,1,1,1,1,1,0,0,Radboud University Nijmegen,The effect of oxytocin administration on empathy and emotion recognition in healthy and antisocial adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000367-16,0,0,0 2016-000370-38,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,"Rigshospitalet, Klinisk Farmakologisk Afd. Q7642","A randomized, double-blinded, placebo-controlled trial that evaluates the effect of empagliflozin on oxidative stress in patients with type 2 diabetes Et randomiseret, dobbelt-blindet, placebo-kont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000370-38,0,0,0 2016-000371-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Laboratorios Ordesa,"Multicenter pilot study for comparison of the efficacy of vaginal capsules with boric acid and L. gasseri and L. rhamnosus versus other vaginal drugs, in patients with bacterial or candida Vulvovagini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000371-24,0,0,0 2016-000373-21,3,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,"IRX THERAPEUTICS, INC.","A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX-2 Regimen in Patients with Newly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity Studio di f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000373-21,0,0,0 2016-000373-21,3,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,"IRX Therapeutics, Inc.","A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX-2 Regimen in Patients with Newly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity Studio di f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000373-21,0,0,0 2016-000374-37,12,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,BAXALTA INNOVATIONS GMBH,Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000374-37,0,0,0 2016-000374-37,12,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Baxalta Innovations GmbH,Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000374-37,0,0,0 2016-000375-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Danderyds sjukhus AB,Double blind placebo-controlled RCT of the efficacy and safety of intramuscular injections of Botulinum Toxin A as a treatment for provoked vestibulodynia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000375-25,0,0,0 2016-000376-26,1,2017-03-01,2017-03-01,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Ziarco Pharma Ltd,"A Randomised, Adaptive Design, Double-Blind (3rd Party Open), Placebo Controlled, Sequential Group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Applicatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000376-26,0,0,0 2016-000377-20,1,2017-12-21,2017-12-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Viking Therapeutics, Inc.","A Phase II, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Multi-Center Study to Explore the Efficacy, Safety and Tolerability of VK5211 in Subjects with Acute Hip Fracture",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000377-20,0,0,0 2016-000378-38,11,2021-10-12,2021-10-12,6,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Protalix Ltd.,"A Randomized, Double blind, Active Control Study of the Safety and Efficacy of PRX-102 compared to Agalsidase Beta on Renal Function in Patients with Fabry Disease Previously Treated With Agalsidase ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000378-38,1,0,0 2016-000388-18,1,2016-11-18,2016-11-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Diasolve Ltd,"A randomised crossover investigation to evaluate and compare the effectiveness, safety and feasibility of a novel dedicated Over-The-Wire FFR Infusion MicroCatheter (HYPEREM IC) for measuring fraction...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000388-18,0,0,0 2016-000390-20,7,2017-06-28,2017-06-28,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,TOPIVERT Pharma Limited,"A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Symptomatic Ulcerative Colit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000390-20,0,0,0 2016-000393-37,1,2016-09-02,2016-09-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma Sprl,"A MULTICENTER, SUBJECT-BLIND, INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY/TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE INTRAVENOUS DOSES OF BIMEKIZUMAB (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000393-37,0,0,0 2016-000394-21,6,2018-03-20,2018-03-20,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc,A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN® (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000394-21,0,0,0 2016-000395-13,1,2018-01-31,2018-01-31,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Hepatera LLC,"A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination with Tenofovir Compared to Tenofovir Alone to Suppress HBV Repl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000395-13,0,0,0 2016-000398-19,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Ghent University,"Pilot study: pharmacokinetics of beta-lactam antibiotics, piperacillin-tazobactam, ceftazidim and meropenem in blood and sputum of cystic fibrosis patients. Pilot study: farmacokinetiek van de bèta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000398-19,0,0,0 2016-000399-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AIO-Studien-gGmbH,A phase III study testing the role of PRoactivE coaching on PAtient REported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of pembrolizumab + axitinib ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000399-28,0,0,0 2016-000401-36,7,2022-02-22,2022-02-22,3,0,0,0,0,1,3,0,0,2,0,0,0,0,1,ITALFARMACO S.p.A.,"Randomised, double blind, placebo controlled, multicentre study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000401-36,1,0,0 2016-000404-28,2,2017-09-25,2017-09-25,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Norge AS,"5, 6 or 7 year follow-up control after the SCHEDULE study (SCANDINAVIAN HEART TRANSPLANT EVEROLIMUS DE NOVO STUDY WITH EARLY CNI AVOIDANCE) Title of the original SCHEDULE study: A controlled randomiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000404-28,0,0,0 2016-000406-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus University Medical Center,The influence of electroencephalographic Narcotrend Index™ - guidance of propofol administration on recovery from procedural sedation for gastrointestinal endoscopy in children between 1 and 12 years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000406-11,0,0,0 2016-000407-84,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Enrique Bárez Hernandez,Efficacy and safety of epidural administration of betamethasone and dexamethasone by caudal route for the treatment of radicular pain: randomized clinical trial. Eficacia y seguridad de la administ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000407-84,0,0,0 2016-000408-27,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC),Phase II study of NAB-paclitaxel in SensiTivE and Refractory relapsed SCLC (NABSTER trial) Studio di Fase II di Nab-paclitaxel nel carcinoma polmonare a piccole cellule (SCLC) recidivato sensibile ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000408-27,0,0,0 2016-000409-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Bambino Gesù Children's Hospital,"Explorative study on the clinical efficacy and tolerability of methylprednisolone aceponate cream and a new topical medical device in paediatric patients with mild to moderate Atopic Dermatitis, test...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000409-35,0,0,0 2016-000410-30,1,2020-08-27,2020-08-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical University of Vienna, Department of Obstetrics and Gynecology","PREOPERATIVE LOCALLY APPLIED OESTROGEN IN POSTMENOPAUSAL WOMEN WITH PELVIC ORGAN PROLAPSE: CHANGES IN SUBJECTIVE AND OBJECTIVE OUTCOME: A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000410-30,0,0,0 2016-000411-32,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,"Regeneron Pharmaceuticals, Inc.","AN OPEN-LABEL, SINGLE-ARM, PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE AND MULTIPLE DOSES OF REGN1500 IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000411-32,0,0,0 2016-000416-15,1,2017-07-28,2017-07-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects with Chronic HCV Infection who have Received a Liver Transplan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000416-15,0,0,0 2016-000417-73,1,2017-10-27,2017-10-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000417-73,0,0,0 2016-000418-31,1,2021-05-03,2021-05-03,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,Robert Bosch Gesellschaft für medizinische Forschung mbH,GENOTYPE AND PHENOTYPE GUIDED SUPPLEMENTATION OF TAMOXIFEN STANDARD THERAPY WITH ENDOXIFEN IN BREAST CANCER PATIENTS. GENOTYP- UND PHÄNOTYPBASIERTE SUPPLEMENTIERUNG EINER STANDARD-TAMOXIFENTHERAPIE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000418-31,0,0,0 2016-000419-34,1,2020-12-01,2020-12-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Nantes,Evaluation de l’efficacité d’une supplémentation en Citrulline sur le délai d’accouchement de femmes hospitalisées dans le cadre de pré-éclampsies modérées ou sévères,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000419-34,0,0,0 2016-000420-26,4,2018-05-30,2018-05-30,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,UCB Biopharma SPRL,"A MULTICENTER, SUBJECT-BLIND, INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF AN IV LOADING DOSE FOLLOWED BY SC ADMINIST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000420-26,0,0,0 2016-000421-39,1,2020-03-16,2020-03-16,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,University Hospital Regensburg represented by Kaufmännischer Direktor,"Randomized Phase II trial with safety run-in phase evaluating low-dose azacitidine, all-trans retinoic acid and pioglitazone versus standard dose azacitidine in patients >=60 years with acute myeloid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000421-39,0,0,0 2016-000423-13,14,2017-11-20,2018-05-16,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000423-13,0,0,0 2016-000423-13,14,2017-11-20,2018-05-16,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000423-13,0,0,0 2016-000423-13,14,2017-11-20,2018-05-16,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Roche Farma que representa en España a F. Hoffmann-La Roche Ltd,"A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000423-13,0,0,0 2016-000424-25,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CHU Saint-Etienne,Low-molecular-weight heparin in constituted vascular intrauterine growth restriction. Randomized multicenter trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000424-25,0,0,0 2016-000425-40,1,2017-11-13,2017-11-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Genentech Inc.,"A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY, ADMINISTERED AS MONOTHERAPY FOR THE TREATMENT OF ACUTE UNCOMPLICATED SEASONAL INFLUENZA A INFECTION IN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000425-40,0,0,0 2016-000426-20,9,2019-07-09,2019-07-10,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Jazz Pharmaceuticals Inc.,"A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000426-20,0,0,0 2016-000426-20,9,2019-07-09,2019-07-10,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Jazz Pharmaceuticals,"A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000426-20,0,0,0 2016-000429-38,1,2018-07-17,2018-07-17,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Plexxikon Inc.,"A Phase 2a Study of the Safety, Tolerability, and Pharmacodynamic Effects of Pexidartinib in Subjects with Mild to Moderate Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000429-38,0,0,0 2016-000431-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Health Ministry,Randomized controlled study evaluating the effect of a biotherapy treatment (anti-RANKL ligand antibody: Denosumab) on bone and vascular metabolism in osteoporotic chronic kidney disease Etude cont...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000431-40,0,0,0 2016-000432-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center of Hamburg Eppendorf,"A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Pri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000432-17,0,0,0 2016-000433-51,2,2021-06-22,2021-06-22,2,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Medical Center Hamburg-Eppendorf,DAratumumab iN combination with BorTEzomib and Dexamethasone in subjects with relapsed or relapsed and refractory Multiple Myeloma and severe renal impairment including subjects undergoing hemodialysi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000433-51,0,0,0 2016-000434-21,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,1,Biogen Portugal,"PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current Su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000434-21,0,0,0 2016-000435-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC),"Phase II, Open Label, Randomized, Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Subcutaneous (SC) Trastuzumab in Patients with Operable or Locally Advanced/Inflammatory HER2-po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000435-41,0,0,0 2016-000437-43,1,2018-08-23,2018-08-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Guy's and St Thomas NHS Foundation Trust,The time to protection and adherence requirements of Raltegravir with or without lamivudine in protection from HIV infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000437-43,0,0,0 2016-000439-42,1,,,0,0,0,0,0,0,4,0,1,3,0,0,0,0,0,Guy's & St. Thomas' NHS Foundation Trust,The time to protection and adherence requirements of TRUVADA® and DESCOVY® required for protection from HIV-1 infection: bridging the data gaps,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000439-42,0,0,0 2016-000441-32,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Blekinge county council,"REgistry-based randomized controlled trial of treatment Duration and mortality in long-term OXygen therapy (REDOX) A Multicenter, Phase III, Registry-Based, Randomized Controlled Trial (R-RCT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000441-32,0,0,0 2016-000446-56,1,,,0,0,0,0,1,0,3,0,0,4,0,0,0,0,1,Cristália Produtos Químicos Farmacêuticos Ltda.,Clinical study to compare recombinant human growth hormone Cristalia (r-hGH Cristalia) versus Genotropin® in prepubertal children with growth deficiency due to deficiency of growth hormone. Estudo ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000446-56,0,1,1 2016-000454-36,8,2017-08-09,2017-09-29,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Combination Therapy in Subjects Aged 12 Years and Older With Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000454-36,0,0,0 2016-000454-36,8,2017-08-09,2017-09-29,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,VERTEX PHARMACEUTICALS INCORPORATED,"A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Combination Therapy in Subjects Aged 12 Years and Older With Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000454-36,0,0,0 2016-000459-28,6,2022-06-29,2022-06-29,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ViiV Healthcare UK Limited,"A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000459-28,1,0,0 2016-000459-28,6,2022-06-29,2022-06-29,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,VIIV HEALTHCARE UK LIMITED,"A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000459-28,1,0,0 2016-000460-42,5,2018-01-05,2018-01-05,3,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Allakos, Inc.","A Phase 2, Randomized, Double-Blind, Placebo Controlled, Study to Evaluate Multiple Doses of AK001 in Patients With Moderate to Severe Nasal Polyposis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000460-42,1,0,0 2016-000461-23,1,2021-06-24,2021-06-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000461-23,0,0,0 2016-000464-42,1,2019-05-28,2019-05-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Genzyme GmbH,"A Prospective, Open-label, Interventional Phase IIIb Clinical Trial to Investigate the Effectiveness of an Additional Course of Alemtuzumab in Relapsing Remitting Multiple Sclerosis Patients After 2 C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000464-42,0,0,0 2016-000466-33,1,2018-02-01,2018-02-01,1,1,0,0,0,1,4,0,0,1,1,1,1,0,0,"Department of Pediatric oncology, Aarhus University hospital",Pharmacokinetics and pharmacodynamics of Piperacillin-Tazobactam (PT) in pediatric oncology patients with fever and neutropenia. Farmakokinetiske og farmakodynamiske studier af Piperacillin-Tazoba...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000466-33,0,0,0 2016-000467-16,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Spherium Biomed,EVALUATION OF SP14019-F-01 TOPICAL SOLUTION FOR THE TREATMENT OF ATOPIC DERMATITIS. PILOT STUDY (CYCLATOP STUDY) EVALUACIÓN DE LA SOLUCIÓN DE USO CUTÁNEO SP14019-F-01 PARA EL TRATAMIENTO DE LA DERM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000467-16,0,0,0 2016-000468-41,7,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,NOVARTIS PHARMA SERVICES AG,"An open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 (leniolisib) in patients with APDS/PASLI (Activated phosphoinositi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000468-41,0,0,0 2016-000468-41,7,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"An open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 (leniolisib) in patients with APDS/PASLI (Activated phosphoinositi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000468-41,0,0,0 2016-000472-22,10,2018-11-30,2018-11-30,8,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, randomized, 12-week treatment, double blind study to assess the efficacy and safety of QMF149 (150/80 microgram) compared with MF Twisthaler® (200 microgram) in adult and adolescent pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000472-22,0,0,0 2016-000473-20,1,2018-03-16,2018-03-16,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Novartis Pharma services AG,A prospective evaluation of natriuretic peptide based referral of CHF patients in primary care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000473-20,0,0,0 2016-000474-38,4,2018-06-05,2018-06-05,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Zogenix International Limited,"A Multicenter, 2-Cohort Trial to First Assess the Pharmacokinetic and Safety Profile of a Single Dose of ZX008 (Fenfluramine Hydrochloride) Oral Solution When Added to Standard of Care (Cohort 1), Fol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000474-38,0,0,0 2016-000475-24,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AGMT gGmbH,"A randomized Phase II, 2-armed study in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM) comparing Carfilzomib + Thalidomide + dexamethasone (KTd) versus Carfilzomib + ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000475-24,0,0,0 2016-000477-21,1,2019-06-20,2019-06-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Georg-August-Universität Göttingen, Stiftung Öffentlichen Rechts, Universitätsmedizin Göttingen",Reducing antibiotic use for uncomplicated urinary tract infection in gen-eral practice by treatment with Uva ursi - a comparative effectiveness trial Verringerung des Einsatzes von Antibiotika bei ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000477-21,0,0,0 2016-000481-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA,TERIPARATIDE FOR THE PRIMARY PREVENTION OF POST-SURGICAL HYPOCALCEMIA TERIPARATIDE FOR THE PRIMARY PREVENTION OF POST-SURGICAL HYPOCALCEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000481-32,0,0,0 2016-000483-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ISPPCC - CHU Chrarleroi - Hôpital Civil Marie Curie - Clinique du Sein,"Clinical, operating, prospective, academy, study of not inferiority of the Green Indocyanine (ICG) marking method, versus the radio-isotopic method, of sentinel nodes in breast. Etude Clinique acad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000483-42,0,0,0 2016-000485-34,6,2019-10-29,2019-10-29,5,1,1,0,0,1,3,0,0,1,1,0,1,0,1,"TRACON Pharmaceuticals, Inc.",A randomized Phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000485-34,0,0,0 2016-000486-23,1,2020-12-31,2020-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Helsinki University Central Hospital,Spinal or epidural fentanyl or sufentanil for labour pain in early phase of the labour Spinaalinen tai epiduraalinen fentanyyli tai sufentaniili alkuvaiheen synnytyskivun lievityksessä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000486-23,0,0,0 2016-000488-17,6,2019-02-11,2019-02-11,4,0,0,0,0,0,2,0,0,1,0,0,1,0,1,ILTOO PHARMA,"A Phase II, multi-centre, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety and pharmacokinetics of ILT-101 in patients with active moderate to severe systemic lupus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000488-17,0,0,0 2016-000489-50,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO,"A Phase II, Single Arm, Open Label, Efficacy and Safety Study of NEOD001 in Subjects with Light Chain (AL) Amyloidosis with Hepatic Involvement Studio di fase II, open label, a singolo braccio, tes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000489-50,0,0,0 2016-000490-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"A.O.U. Università degli Studi della Campania ""Luigi Vanvitelli""","Evaluation of efficacy, safety and patient¿s satisfaction of daylight photodynamic therapy (DL-PDT) in the treatment of actinic keratosis on the face and scalp and related field cancerization carried ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000490-20,0,0,0 2016-000494-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Skåne University Hospital, Department of Oncology",A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Based Treatment with Focus on Mechanisms of Resistance to Endocrine Based Treatment (fulvestrant/aromatas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000494-20,0,0,0 2016-000497-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ana Vallejo De la Cueva,Dexmedetomidine versus current clinical practice for non-invasive mechanical ventilation: a randomized clinical trial Dexmedetomidina versus practica clínica habitual durante la ventilación mecáni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000497-38,0,0,0 2016-000498-19,1,2019-07-17,2019-07-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.",A PHASE II OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA29350 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000498-19,0,0,0 2016-000499-83,6,2019-06-14,2019-06-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orally a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000499-83,0,0,0 2016-000499-83,6,2019-06-14,2019-06-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orally a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000499-83,0,0,0 2016-000499-83,6,2019-06-14,2019-06-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orally a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000499-83,0,0,0 2016-000499-83,6,2019-06-14,2019-06-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim bv,"A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orally a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000499-83,0,0,0 2016-000499-83,6,2019-06-14,2019-06-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm. V,"A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orally a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000499-83,0,0,0 2016-000500-29,1,2020-05-28,2020-05-28,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),A randomized Crossover TrIal to Compare recombinant human rhPTH(1-34) to the ASsociation alfacalcidol/hydrochlorothiazide in the treatment of Autosomal Dominant Hypocalcemia Essai randomisé en cro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000500-29,0,0,0 2016-000501-36,1,,,0,0,0,0,0,1,4,0,0,1,1,1,0,1,1,BAYER AG,"An open-label, multi-national, multi-center, single-arm, uncontrolled, longterm extension study of orally administered riociguat in patients with symptomatic pulmonary arterial hypertension (PAH) who ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000501-36,0,0,0 2016-000502-11,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,EKOS Corporation,Study of the Optimum Duration of Acoustic Pulse Thrombolysis (APT) Procedure in the Treatment of Acute Submassive Pulmonary Embolism (OPTALYSE PE).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000502-11,0,0,0 2016-000503-87,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Pharma Patent Kft,"A multicentre, Phase III, randomised, double blind, placebo-controlled study to assess the safety and the efficacy of a weekly administered dose of 30,000 IU vitamin D (colecalciferol) in deficient p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000503-87,0,0,0 2016-000506-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Limoxifen BV,Proof-of-concept study on treating cognitive side-effects of Tamoxifen with guanfacine in postmenopausal women with E2/Pg receptor-positive breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000506-11,0,0,0 2016-000507-86,5,2020-09-24,2020-09-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A 52-week open-label (sponsor-blind), randomized, active controlled, parallel-group, multi-center study to evaluate the efficacy and safety of daprodustat compared to recombinant human erythropoietin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000507-86,0,0,0 2016-000507-86,5,2020-09-24,2020-09-24,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A 52-week open-label (sponsor-blind), randomized, active controlled, parallel-group, multi-center study to evaluate the efficacy and safety of daprodustat compared to recombinant human erythropoietin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000507-86,0,0,0 2016-000509-35,1,2018-04-04,2018-04-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Protalix Biotherapeutics Ltd.,"An Open Label, Proof of Concept Study to Assess the Safety, PK and Explore Efficacy of OPRX-106 in Patients with Active Mild to Moderate Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000509-35,0,0,0 2016-000510-30,8,2020-01-31,2020-01-31,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Novo Nordisk A/S,"A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000510-30,0,0,0 2016-000510-30,8,2020-01-31,2020-01-31,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,NOVO NORDISK. S.P.A.,"A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000510-30,0,0,0 2016-000515-32,1,2016-12-02,2016-12-02,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Per Løgstrup Poulsen,Antiplatelet and vascular effects of aspirin in healthy persons and patients with type 2 diabetes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000515-32,0,0,0 2016-000516-15,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,CONSORZIO UNIVERSITARIO UNIFARM,Intestinal mucosal concentrations from three mesalazine pharmaceutical formulations and correlation with efficacy in patients with mild/moderate ulcerative colitis Valutazione delle concentrazioni ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000516-15,0,0,0 2016-000518-31,4,2018-03-26,2018-03-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lycera Corp.,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF INDUCTION THERAPY WITH LYC-30937-EC IN SUBJECTS WITH ACTIVE ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000518-31,0,0,0 2016-000521-38,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,EORTC AISBL/IVZW,Nintedanib as maintenance treatment of malignant pleural mesothelioma (NEMO): a double-blind randomized phase II study of the EORTC Lung Cancer Group,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000521-38,0,0,0 2016-000521-38,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,European Organisation for Research and Treatment of Cancer,Nintedanib as maintenance treatment of malignant pleural mesothelioma (NEMO): a double-blind randomized phase II study of the EORTC Lung Cancer Group,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000521-38,0,0,0 2016-000522-18,8,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,2,UMBERTO I - POLICLINICO DI ROMA,Risk Stratified randomised controlled trial in paediatric Crohn's Disease: Methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or at high risk for aggressive di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000522-18,0,0,0 2016-000522-18,8,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,2,PIBDNet,Risk Stratified randomised controlled trial in paediatric Crohn's Disease: Methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or at high risk for aggressive di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000522-18,0,0,0 2016-000522-18,8,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,2,PIBD-Net,Risk Stratified randomised controlled trial in paediatric Crohn's Disease: Methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or at high risk for aggressive di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000522-18,0,0,0 2016-000522-18,8,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,2,PIBD net,Risk Stratified randomised controlled trial in paediatric Crohn's Disease: Methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or at high risk for aggressive di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000522-18,0,0,0 2016-000522-18,8,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,2,PIBDnet (Pediatric Inflammatory Bowel Disease Network),Risk Stratified randomised controlled trial in paediatric Crohn's Disease: Methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or at high risk for aggressive di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000522-18,0,0,0 2016-000524-25,1,2018-11-20,2018-11-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab, to demonstrate efficacy after twelve weeks of treatment and to assess safety, tolerability and long-term ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000524-25,0,0,0 2016-000532-17,1,2015-10-12,2015-10-12,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,K.U. Leuven,"Effect of methylnaltrexone on intragastric pressure, the occurrence of transient lower esophageal sphincter relaxations and reflux events in healthy subjects: a double-blind, placebo-controlled, rando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000532-17,0,0,0 2016-000539-42,1,,,0,1,0,0,0,0,3,0,1,1,0,0,0,1,1,Reckitt Benckiser Healthcare (UK) Limited,"A randomised, single dose, crossover, open label, placebo controlled confirmatory study in healthy volunteers to characterise the acid neutralisation activity of Gaviscon Double Action Liquid in the f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000539-42,0,0,0 2016-000540-33,3,2017-01-26,2017-01-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PPM Services S.A.,"A double-blind, randomised, placebo-controlled clinical study to evaluate the efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel, 1 and 2%, applied once daily for 12 weeks in patients with mild to m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000540-33,0,0,0 2016-000541-31,14,2020-11-09,2020-11-09,12,1,0,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A phase 3 randomized, open-label (sponsor-blind), activecontrolled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000541-31,1,0,0 2016-000541-31,14,2020-11-09,2020-11-09,12,1,0,0,0,0,3,0,0,2,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A phase 3 randomized, open-label (sponsor-blind), activecontrolled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000541-31,1,0,0 2016-000542-65,16,2021-04-19,2021-04-19,14,1,0,0,0,0,3,0,0,2,1,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to eva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000542-65,1,0,0 2016-000542-65,16,2021-04-19,2021-04-19,14,1,0,0,0,0,3,0,0,2,1,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to eva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000542-65,1,0,0 2016-000543-13,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Liverpool,"A window of opportunity study to assess the biological effects of enobosarm in oestrogen receptor positive, androgen receptor positive early breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000543-13,0,0,0 2016-000547-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,BGOG-UZLeuven,BGOG-cx3: Prospective randomized Phase II trial comparing doxorubicin alone versus doxorubicin and atezolizumab in recurrent cervical cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000547-14,0,0,0 2016-000548-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,LYSARC,Phase II study to evaluate the efficacy of upfront obinutuzumab in mantle cell lymphoma patients treated by DHAP followed by autologous transplantation plus obinutuzumab maintenance then MRD driven ma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000548-33,0,0,0 2016-000556-95,3,2019-06-27,2019-07-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharma A/S,LEO 90100 twice weekly maintenance regimen for psoriasis vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000556-95,0,0,0 2016-000557-13,1,2017-01-23,2017-01-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,ASIT biotech S.A.,Assessment of safety and clinical tolerability of hdmASIT+TM administered subcutaneously in house dust mite-induced allergic rhinoconjunctivitis patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000557-13,0,0,0 2016-000558-37,5,,,0,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Merck Sharp & Dohme Corp,A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects with PIK3CA-related Overgrowth Spectrum and Proteus Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000558-37,0,0,0 2016-000558-37,5,,,0,1,0,0,0,1,2,0,0,2,0,0,0,0,1,"ArQule, Inc.",A Phase 1/2 Study of ARQ 092 (Miransertib) in Subjects with PIK3CA-related Overgrowth Spectrum and Proteus Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000558-37,0,0,0 2016-000559-28,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Oxford,"Randomised phase II Trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum–resistant ovarian cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000559-28,0,0,0 2016-000563-16,1,2018-06-05,2018-06-05,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,K.U. Leuven,"Effect of citalopram on fasting and postprandial lower esophageal sphincter function in healthy subjects: a double-blind, placebo-controlled, randomized, cross-over study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000563-16,0,0,0 2016-000564-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hannover Medical School,A randomized multi-centre double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders (CANNA-TICS) Randomisiert...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000564-42,0,0,0 2016-000565-23,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,,TAILOR - a randomized clinical trial: Tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or schizophreniform psychosis in rem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000565-23,0,0,0 2016-000568-41,11,2019-06-20,2019-06-20,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GILEAD SCIENCES INCORPORATED,"A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000568-41,0,0,0 2016-000568-41,11,2019-06-20,2019-06-20,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000568-41,0,0,0 2016-000569-21,8,2018-06-26,2018-06-26,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000569-21,0,0,0 2016-000570-37,9,2019-05-08,2019-05-08,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Randomized, Double-blind, Placebo-and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000570-37,0,0,0 2016-000571-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clinic per a la Recerca Biomèdica,"Seeking the ideal anti-hypertensive therapy in obesity-related hypertension. An open-label, single center, randomized clinical trial. Estudio unicéntrico, aleatorizado, abierto, sobre la búsqueda d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000571-25,0,0,0 2016-000573-20,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,"Department of Sports Medicine, Institute for Sport Sciences, Justu-Liebig-University of Gießen",Effects of MUTAFLOR® on exercise-induced gastro-intestinal dysfunction Effekte von MUTAFLOR® auf die belastungsinduzierte Störung der gastrointestinalen Integrität,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000573-20,0,0,0 2016-000574-38,1,2019-11-27,2019-11-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical University Vienna, Gender Medicine Unit, Div. of Endocrinology, Dep of Medicine III","A 24 week monocentric prospective randomized, placebo-controlled trial to evaluate Efficacy of combination of Exenatide and Dapagliflozin compared to Dapagliflozin and Placebo and its effects on hep...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000574-38,0,0,0 2016-000578-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO,RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN METASTATIC COLON-RECTAL CARCINOMA RESISTANT TO STANDARD TREATMENTS TRANSLATE – Colon-rectal STUDY ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIEN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000578-39,0,0,0 2016-000579-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO,RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN PROSTATE CARCINOMA RESISTANT TO STANDARD TREATMENTS TRANSLATE – prostate STUDY ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000579-26,0,0,0 2016-000580-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO,RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN RENAL CELL CARCINOMA RESISTANT TO STANDARD TREATMENTS TRANSLATE – kidney STUDY ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000580-17,0,0,0 2016-000581-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO,RESTORE IMMUNE COMPETENCE AGAINST CANCER CELLS IN BREAST CARCINOMA RESISTANT TO STANDARD TREATMENTS ATTIVAZIONE DELLA RISPOSTA IMMUNITARIA IN PAZIENTI RESISTENTI AL TRATTAMENTO STANDARD - studio “...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000581-31,0,0,0 2016-000585-36,2,2017-04-27,2017-04-27,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A Randomized, Open-Label, 8-Week Cross-Over Study to Compare Umeclidinium/Vilanterol with Tiotropium/Olodaterol Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000585-36,0,0,0 2016-000585-36,2,2017-04-27,2017-04-27,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Open-Label, 8-Week Cross-Over Study to Compare Umeclidinium/Vilanterol with Tiotropium/Olodaterol Once-Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000585-36,0,0,0 2016-000587-42,8,2018-01-08,2018-01-08,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Axovant Sciences Limited,"A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000587-42,0,0,0 2016-000587-42,8,2018-01-08,2018-01-08,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,AXOVANT SCIENCES LTD.,"A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000587-42,0,0,0 2016-000588-17,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000588-17,0,0,0 2016-000588-17,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Merck Sharp & Dohme Corp.,"A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000588-17,0,0,0 2016-000589-47,6,2022-04-01,2022-04-01,4,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000589-47,1,0,0 2016-000589-47,6,2022-04-01,2022-04-01,4,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000589-47,1,0,0 2016-000589-47,6,2022-04-01,2022-04-01,4,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Merck Sharp & Dohme Corp.,"A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000589-47,1,0,0 2016-000592-24,3,2018-01-04,2018-01-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MUNDIPHARMA RESEARCH GMBH & CO. KG,"A Randomized, Double-Blind, Multicenter, Placebo- and active Comparator-Controlled Study to evaluate Efficacy and Safety of MR308 in the Treatment of Acute Pain After Third Molar Tooth Extraction (STA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000592-24,0,0,0 2016-000592-24,3,2018-01-04,2018-01-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"A Randomized, Double-Blind, Multicenter, Placebo- and active Comparator-Controlled Study to evaluate Efficacy and Safety of MR308 in the Treatment of Acute Pain After Third Molar Tooth Extraction (STA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000592-24,0,0,0 2016-000593-38,5,2018-06-29,2018-06-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research GmbH & Co. KG,"A Randomized, Double-Blind, Multicenter, Placebo- and active Comparator-Controlled Study to evaluate Efficacy and Safety of MR308 in the Treatment of Acute Pain After Abdominal Hysterectomy Surgery un...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000593-38,0,0,0 2016-000598-19,4,2018-11-26,2018-11-26,2,1,0,0,0,0,3,0,1,2,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IIIA, randomised, observer-blind, multi-centre study to evaluate the clinical consistency of three production lots of the Porcine circovirus (PCV)-free liquid formulation of GlaxoSmithKline (G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000598-19,1,1,0 2016-000598-19,4,2018-11-26,2018-11-26,2,1,0,0,0,0,3,0,1,2,0,0,0,0,1,GlaxoSmithKline S.A.,"A phase IIIA, randomised, observer-blind, multi-centre study to evaluate the clinical consistency of three production lots of the Porcine circovirus (PCV)-free liquid formulation of GlaxoSmithKline (G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000598-19,1,1,0 2016-000599-87,1,2019-04-04,2019-04-04,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Queen Mary University of London,"Response guided therapy with daclatasvir, sofosbuvir and ribavirin for 12 or 24 weeks in patients with genotype 3 chronic hepatitis C virus: is longer therapy worthwhile?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000599-87,0,0,0 2016-000600-29,7,2017-04-07,2019-07-15,4,1,1,0,0,1,3,0,0,1,1,0,1,0,1,ULTRAGENYX PHARMACEUTICAL INC.,"A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients with X-linked Hypophosphatemia (XLH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000600-29,0,0,0 2016-000600-29,7,2017-04-07,2019-07-15,4,1,1,0,0,1,3,0,0,1,1,0,1,0,1,Ultragenyx Pharmaceuticals Inc,"A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients with X-linked Hypophosphatemia (XLH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000600-29,0,0,0 2016-000601-36,1,,,0,0,0,0,0,1,3,0,0,1,0,0,0,1,0,FONDAZIONE SERENA ONLUS,"CLINICAL EFFICACY OF NIV AND MODAFINIL ON EXCESSIVE DAYTIME SLEEPINESS: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL IN DM1 EFFICACIA DELLA VENTILAZIONE NON INVASIVA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000601-36,0,0,0 2016-000602-10,12,2020-10-05,2020-10-05,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Santhera Pharmaceuticals (Switzerland) Limited,"A Phase III Double-blind, Randomized, Placebo-Controlled Study assessing the Efficacy, Safety and Tolerability of Idebenone in Patients with Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000602-10,0,0,0 2016-000602-10,12,2020-10-05,2020-10-05,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,SANTHERA PHARMACEUTICALS,"A Phase III Double-blind, Randomized, Placebo-Controlled Study assessing the Efficacy, Safety and Tolerability of Idebenone in Patients with Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000602-10,0,0,0 2016-000603-91,3,2021-10-12,2021-10-12,2,1,0,1,0,0,1,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with N ivolumab (BMS-936558) in Subjects with Advanced Solid Tumors Studio di fase 1/2a di BMS-986179 somministrato in monoter...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000603-91,1,0,0 2016-000603-91,3,2021-10-12,2021-10-12,2,1,0,1,0,0,1,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with N ivolumab (BMS-936558) in Subjects with Advanced Solid Tumors Studio di fase 1/2a di BMS-986179 somministrato in monoter...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000603-91,1,0,0 2016-000606-11,1,,,0,0,0,0,1,0,4,0,0,4,0,0,0,0,0,Region Ostergotland,"Melatonin compared to sleep deprivation for sleep EEG recordings in children: impact on epileptiform discharges and sleep, contributing factors on the results and the influence on children's and paren...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000606-11,0,0,0 2016-000608-27,1,2017-02-28,2017-02-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Aarhus University Hospital,The effect of subsartorial saphenous block on postoperative pain following major ankle and hind foot surgery Effekten af subsartorial saphenusblokade på postoperative smerter efter stor ankel- og b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000608-27,0,0,0 2016-000609-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Vall d´Hebrón,Study of the use of Liposomal Iron in the treatment of iron deficiency anemia in pregnancy and puerperium Estudio de empleo de Hierro Liposomado en el tratamiento de la anemia ferropénica en el emb...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000609-36,0,0,0 2016-000612-14,5,2019-05-13,2019-05-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim International GmbH,"BI 695501 versus Humira® in patients with active Crohn’s disease: a randomized, double-blind, multicenter, parallel group, exploratory trial comparing efficacy, endoscopic improvement, safety, and imm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000612-14,0,0,0 2016-000613-79,4,2018-01-17,2018-01-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim International GmbH,"Efficacy, Safety, and Immunogenicity of BI 695501 versus Humira® in Patients with Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000613-79,0,0,0 2016-000614-29,6,2020-06-03,2020-06-03,3,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Novo Nordisk A/S,A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients with Severe Haemophilia A without Inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000614-29,1,0,0 2016-000614-29,6,2020-06-03,2020-06-03,3,1,0,0,0,1,2,0,0,2,0,0,0,0,1,NOVO NORDISK. S.P.A.,A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients with Severe Haemophilia A without Inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000614-29,1,0,0 2016-000615-33,1,2021-02-25,2021-02-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Charite Universitaetsmedizin,Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing sp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000615-33,0,0,0 2016-000616-15,1,2018-03-21,2018-03-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cassiopea S.P.A.,An Open Label Evaluation of the Adrenal Suppression Potential and Trough Plasma Concentrations of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects 9 to <12 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000616-15,0,0,0 2016-000617-67,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,A phase II study to investigate the activity and safety of anti-PD-L1 antibody (Durvalumab) In ADvancEd pretreated malignant pleural Mesothelioma - DIADEM Study A phase II study to investigate the ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000617-67,0,0,0 2016-000618-30,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,GWT-TUD GmbH,Phase 2 Clinical Trial with Ponatinib as a Second Line Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to prior First Line Tyrosine Kinase Inhibitor Treatme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000618-30,0,0,0 2016-000620-26,1,2021-08-24,2021-08-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase II/III, Open-label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-3682 + Grazoprevir + MK-8408 Fixed Dose Combination) in Subjects with Chronic Hepa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000620-26,0,0,0 2016-000621-39,2,,,0,0,0,0,0,0,2,0,0,1,1,0,0,1,1,SYMPHOGEN A/S,"An Open-label, Multicenter, Phase 2 Trial Investigating Sym004 in Patients with Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies and Documented Mutation of Extra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000621-39,0,0,0 2016-000621-39,2,,,0,0,0,0,0,0,2,0,0,1,1,0,0,1,1,Symphogen A/S,"An Open-label, Multicenter, Phase 2 Trial Investigating Sym004 in Patients with Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies and Documented Mutation of Extra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000621-39,0,0,0 2016-000622-19,2,2019-11-12,2019-11-12,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000622-19,0,0,0 2016-000623-73,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACIÓN INVESTIGACIÓN BIOMÉDICA HOSPITAL PUERTA DE HIERRO,"LIDOCAINE IN ISCHEMIA-REPERFUSION INJURY FROM MICROSURGICAL BREAST RECONSTRUCTION. RANDOMISED UNICENTRIC, DOUBLE-BLIND, CLINICAL, CONTROLLED TRIAL. LIDOCAÍNA EN LA LESIÓN POR ISQUEMIA-REPERFUSIÓN E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000623-73,0,0,0 2016-000624-25,2,2017-04-18,2017-04-18,1,1,0,1,0,1,1,0,0,1,1,1,0,0,1,"ATYR PHARMA, INC.","An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Fascioscapulohumeral Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000624-25,0,0,0 2016-000624-25,2,2017-04-18,2017-04-18,1,1,0,1,0,1,1,0,0,1,1,1,0,0,1,"aTyr Pharma, Inc.","An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients with Limb Girdle and Fascioscapulohumeral Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000624-25,0,0,0 2016-000625-39,5,2021-12-21,2021-12-21,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects with Active Systemic Lupus Er...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000625-39,1,0,0 2016-000628-24,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Leeds,A randomised placebo-controlled phase III trial of the effect of the omega-3 fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver meta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000628-24,0,0,0 2016-000629-38,3,2018-07-23,2018-07-23,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT,"A Randomized, Double-blind, Placebo-controlled Parallel Arm Dose Titration Study to Assess the Effects of SAR407899 in Patients with Microvascular Angina (MVA) and/or Persistent Stable Angina despite ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000629-38,0,0,0 2016-000630-22,9,2019-08-30,2020-05-15,5,1,0,0,0,1,3,0,0,2,1,0,0,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000630-22,1,0,0 2016-000631-40,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,Triiodothyronine for repair of left ventricular dysfunction and Remodeling in STEMI Patients Η Τριϊωδοθυρονίνη για την επιδιόρθωση της δυσλειτουργίας και της αναδιαμόρφωσης της αριστερής κοιλίας σε...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000631-40,0,0,0 2016-000634-21,6,2022-01-24,2022-01-24,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn¿...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000634-21,1,0,0 2016-000634-21,6,2022-01-24,2022-01-24,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn¿...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000634-21,1,0,0 2016-000635-40,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"UCB BIOSCIENCES, Inc.","AN OPEN-LABEL, LONG-TERM FOLLOW-UP STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND EFFICACY OF ROTIGOTINE TRANSDERMAL SYSTEM AS MONOTHERAPY IN ADOLESCENTS WITH RESTLESS LEGS SYNDROME",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000635-40,0,1,1 2016-000636-18,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Sunuvion Pharmaceuticals Inc,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000636-18,0,0,0 2016-000637-43,4,2016-10-21,2016-10-21,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Sunovion Pharmaceuticals Inc.,"An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson's Disease Complicated by Motor Fluctuations (""OFF"" E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000637-43,1,0,0 2016-000637-43,4,2016-10-21,2016-10-21,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,SUNOVION PHARMACEUTICALS INC,"An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson's Disease Complicated by Motor Fluctuations (""OFF"" E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000637-43,1,0,0 2016-000640-34,3,2018-09-24,2018-09-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),A randomized phase 2 study comparing different dose-approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients Estudio aleatorizado fase 2 de com...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000640-34,0,0,0 2016-000640-34,3,2018-09-24,2018-09-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GRUPO DE TRATAMIENTO DE LOS TUMORES DIGESTIVOS (TTD GROUP),A randomized phase 2 study comparing different dose-approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients Estudio aleatorizado fase 2 de com...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000640-34,0,0,0 2016-000641-31,22,2021-12-13,2021-12-13,20,1,0,0,0,0,2,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000641-31,1,0,0 2016-000642-62,21,2021-01-14,2021-01-14,20,1,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Coli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000642-62,1,0,0 2016-000642-62,21,2021-01-14,2021-01-14,20,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Coli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000642-62,1,0,0 2016-000643-13,1,2022-07-18,2022-07-18,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Herlev & Gentofte Hospital,"A MULTINATIONAL, RANDOMIZED, PHASE II STUDY OF THE COMBINATION OF NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT IL-6R INHIBITOR, TOCILIZUMAB, AS FIRST-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000643-13,0,0,0 2016-000644-34,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, open, randomised, multicentre study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ combined reduced antigen content diphtheria-tetanus toxoids and acellular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000644-34,0,1,1 2016-000645-31,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase II, partially double-blind, randomised, controlled, single-centre study to assess the immunogenicity and reactogenicity of three different formulations of GSK Biologicals’ DTPw-HBV-IPV/Hib can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000645-31,0,1,1 2016-000647-14,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,University Hospital Toulouse,"Treatment with HMG-COA reductase inhibitor (simvastatin) of growth and bone abnormalities in children with Noonan syndrome : a phase III randomised, double-blind, placebo-controlled therapeutic trial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000647-14,0,0,0 2016-000649-30,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Impact of the administration of Fludrocortisone the fluid and electrolyte balance in great premature. Pilot study. Impact de l’administration de Fludrocortisone sur la balance hydro-électrolytique ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000649-30,0,0,0 2016-000657-12,7,2021-05-25,2021-05-27,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Genzyme Corporation,"Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients with Early-stage Parkinson's Disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000657-12,0,0,0 2016-000658-37,1,2018-05-11,2018-05-11,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Medizinische Universität Wien,"Neoadjuvant chemotherapy with gemcitabine and cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) in muscle-invasive urothelial carcinoma of the bladder Ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000658-37,0,0,0 2016-000661-23,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,IRCCS - Istituto di Ricerche Farmacologiche Mario Negri,NOVEL STROMAL CELL THERAPY FOR DIABETIC KIDNEY DISEASE (NEPHSTROM Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000661-23,0,0,0 2016-000662-38,6,2021-10-29,2021-10-29,2,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"MEDIMMUNE, LLC",A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000662-38,1,0,0 2016-000662-38,6,2021-10-29,2021-10-29,2,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"MedImmune, LLC, a wholly owned subsidiary of AstraZeneca PLC",A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000662-38,1,0,0 2016-000669-21,5,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety ext...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000669-21,0,1,0 2016-000669-21,5,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim Limited,"A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety ext...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000669-21,0,1,0 2016-000669-21,5,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim bv,"A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety ext...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000669-21,0,1,0 2016-000669-21,5,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.","A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety ext...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000669-21,0,1,0 2016-000671-25,15,2019-09-02,2019-09-02,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000671-25,0,0,0 2016-000671-25,15,2019-09-02,2019-09-02,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000671-25,0,0,0 2016-000674-38,22,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis Eine Phase 3 multizentrische, Langzeit Folge-Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000674-38,0,0,0 2016-000674-38,22,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis Eine Phase 3 multizentrische, Langzeit Folge-Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000674-38,0,0,0 2016-000676-15,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Danish Headache Center,"GON-block in Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study (DHC-GON-1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000676-15,0,0,0 2016-000678-40,5,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,1,Takeda Development Centre Europe Limited,Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000678-40,0,0,0 2016-000679-25,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,INSTITUT DE RECERCA HSCSP,"A prospective, randomized, double-blind and placebo-controlled, parallel group, phase II study to compare the efficacy and safety of candesartan versus placebo on cognitive impairment associated with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000679-25,0,0,0 2016-000684-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oslo University Hospital,Brachial plexus block and rebound pain after radius fixation with a polar plate.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000684-16,0,0,0 2016-000685-39,11,2020-03-19,2020-03-19,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis A 72-week randomised, double-blind, place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000685-39,0,0,0 2016-000686-23,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Erasmus MC,The Rotterdam Antiplatelet Therapy in Vascular Patients Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000686-23,0,0,0 2016-000687-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA UNITÀ SANITARIA LOCALE DI MODENA,COMBINED SUBSTITUTIVE THERAPY WITH LEVOTHYROXINE AND LIOTHYRONINE IN THYROIDECTOMIZED PATIENTS: EFFECTS ON PERIPHERICAL TISSUES. A PROSPECTIVE RANDOMIZED CONTROLLED DOUBLE BLIND STUDY. TERAPIA SOS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000687-41,0,0,0 2016-000692-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA USL TOSCANA SUD EST Sezione di Arezzo,"""Evaluation of efficacy and accuracy of a CTA low dose protocol for Pazients with EVAR"" ""Protocollo per la valutazione efficacia diagnostica di un protocollo TC a bassa dose radiante e volume di md...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000692-24,0,0,0 2016-000696-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA,INDUCTION FOLFIRINOX AND RADIOCHEMOTHERAPY IN LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA FOLFIRINOX DI INDUZIONE E RADIO-CHEMIOTERAPIA CONCOMITANTE NELL¿ADENOCARCINOMA DEL PANCREAS LOCALMENTE AVA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000696-25,0,0,0 2016-000700-29,8,2020-03-10,2020-05-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MEDDAY PHARMACEUTICALS,Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000700-29,0,0,0 2016-000700-29,8,2020-03-10,2020-05-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MEDDAY PHARMACEUTICALS SA,Effect of MD1003 in progressive multiple sclerosis: a randomized double blind placebo controlled study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000700-29,0,0,0 2016-000704-28,6,,,0,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Gamida Cell Ltd,"A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord Bl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000704-28,0,0,0 2016-000706-12,9,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,Goethe University Frankfurt,"A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Ren...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000706-12,0,0,0 2016-000706-12,9,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,GOETHE UNIVERSITY FRANKFURT,"A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Ren...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000706-12,0,0,0 2016-000707-81,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,"Section for Transfusion Medicine, Capitol Region Blood Bank",Vasculopathic Injury and Plasma as Endothelial Rescue in septic shock (SEPSIS) trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000707-81,0,0,0 2016-000708-26,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,"Evaluation of clinical response in relation to the immunological status change in RRMS patients treated with Gilenya (fingolimod) for 12 months. Studio clinico della durata di 12 mesi, per caratter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000708-26,0,0,0 2016-000709-36,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,UCL,Research into Antipsychotic Discontinuation and Reduction (RADAR): A Randomised Controlled Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000709-36,0,0,0 2016-000712-15,1,2019-01-18,2019-01-18,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dermapharm AG,"Double-blind, randomised clinical study comparing efficacy and safety of Imiquimod 5% Cream (Test) vs. Aldara® 5% Cream (Reference) vs. Vehicle in patients with actinic keratosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000712-15,0,0,0 2016-000715-33,1,2019-03-15,2019-03-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee & NHS Tayside,Does Dapaglifozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000715-33,0,0,0 2016-000722-19,2,2018-07-12,2018-07-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000722-19,0,0,0 2016-000723-94,2,2018-03-09,2018-03-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Lyric Pharmaceuticals, Inc.","A Phase 2, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Intravenous Ulimorelin (LP101) in Patients with Enteral Feeding Intoleran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000723-94,0,0,0 2016-000725-39,8,2022-09-22,2022-09-22,2,0,0,0,0,1,3,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000725-39,1,0,0 2016-000725-39,8,2022-09-22,2022-09-22,2,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000725-39,1,0,0 2016-000728-24,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Janssen Research & Development, LLC","A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000728-24,0,1,1 2016-000734-21,1,2019-07-22,2019-07-22,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Dundee & NHS Tayside,Investigating the mechanism of inhaled corticosteroids associated pneumonia by longitudinal characterisation of the airway microbiome in patients with severe COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000734-21,0,0,0 2016-000735-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU LILLE,Antimicrobial treatment in patients with ventilator-associated tracheobronchitis: a prospective randomized placebo-controlled double-blind multicenter trial Antibiothérapie chez les patients prése...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000735-41,0,0,0 2016-000740-34,1,2019-02-05,2019-02-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Dr. Borja Maroto Rodríguez,Treatment of functional EPIFORA with Botulinum Toxin versus lateral tarsal strip Tratamiento de la epífora funcional con Toxina Botulínica tipo A (IncobotulinumtoxinA) frente a la tira tarsal later...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000740-34,0,0,0 2016-000742-61,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,"CLINICAL STUDY OF NIVOLUMAB COMBINED WITH IPILIMUMAB IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA. (NIVOLUMABIPILIMUMAB AT 1MG/KG – NIVOIPI01) Studio di fase II, di combinazione Nivolumab e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000742-61,0,0,0 2016-000744-34,3,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, randomized, observer-blind, placebo controlled, multicenter clinical trial to assess Herpes Zoster recurrence and the reactogenicity, safety and immunogenicity of GSK Biologicals’ Herpes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000744-34,0,0,0 2016-000744-34,3,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,1,GlaxoSmithKline S.A.,"A phase III, randomized, observer-blind, placebo controlled, multicenter clinical trial to assess Herpes Zoster recurrence and the reactogenicity, safety and immunogenicity of GSK Biologicals’ Herpes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000744-34,0,0,0 2016-000746-59,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HYKS Naistensairaala,Randomized trial of treatment of vaginal intraepithelial neoplasia (VAIN).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000746-59,0,0,0 2016-000749-30,4,2017-10-26,2017-10-26,4,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers 12 to 23 Months of Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000749-30,0,0,0 2016-000750-35,9,,,0,1,1,0,0,1,2,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A TWO-PART SEAMLESS, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE BLIND STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RISDIPLAM (RO7034067) I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000750-35,0,0,0 2016-000754-35,1,2020-10-30,2020-10-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,The University of Manchester,The effect of Denosumab on Pain and bone Marrow Lesions in symptomatic Knee Osteo-arthritis: A Randomised Double Blind Placebo controlled Clinical Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000754-35,0,0,0 2016-000755-27,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Klinikum der Universität München,FIRST LINE THERAPY OF ADVANCED STAGE FOLLICULAR LYMPHOMA IN PATIENTS < 60 YEARS NOT ELIGIBLE FOR STANDARD IMMUNOCHEMOTHERAPY AND ALL PATIENTS ≥ 60 YEARS Prospective randomized evaluation of single age...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000755-27,0,0,0 2016-000756-98,3,2018-01-18,2018-01-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Forest Laboratories LLC, an Allergan Affiliate","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in Patients with Bipolar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000756-98,0,0,0 2016-000757-13,4,2017-07-19,2017-07-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Forest Laboratories LLC, an Allergan Affiliate","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in Patients with Bipolar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000757-13,0,0,0 2016-000758-37,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,F. Hoffmann-La Roche AG,A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000758-37,0,1,1 2016-000764-42,2,2020-07-28,2020-07-28,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UNICANCER,A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000764-42,0,0,0 2016-000765-22,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,"Pfizer, Inc.","An Open-label, Single-arm, Post-authorization Pragmatic Clinical Trial On The Safety And Efficacy Of Benefix (nonacog Alfa, Recombinant Factor IX) In Subjects With Hemophilia B In Usual Care Settings ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000765-22,0,1,1 2016-000766-29,4,2017-09-05,2017-09-05,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"OTONOMY, INC.","A 6-MONTH, MULTICENTER, PHASE 3, OPEN-LABEL EXTENSION SAFETY STUDY OF OTO-104 GIVEN AT 3-MONTH INTERVALS BY INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000766-29,0,0,0 2016-000766-29,4,2017-09-05,2017-09-05,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Otonomy Inc.,"A 6-MONTH, MULTICENTER, PHASE 3, OPEN-LABEL EXTENSION SAFETY STUDY OF OTO-104 GIVEN AT 3-MONTH INTERVALS BY INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000766-29,0,0,0 2016-000767-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS,A randomized phase II trial of captem or folfiri as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000767-17,0,0,0 2016-000775-24,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,King's College London,CXCR2 inhibition: a novel approach to treating coronary heart disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000775-24,0,0,0 2016-000775-24,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Guys & St Thomas' NHS Foundation trust,CXCR2 inhibition: a novel approach to treating coronary heart disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000775-24,0,0,0 2016-000778-40,7,,,0,1,1,0,0,1,2,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A TWO PART SEAMLESS, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN INFANTS WITH TYPE1 SPINAL MUSCULAR ATROPHY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000778-40,0,0,0 2016-000782-22,1,2019-02-04,2019-02-04,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Medical University of Graz,A pilot study of peroral Vorinostat (Zolinza) in patients with refractory histone deacetylase-positive uterine sarcoma. Vorinostat (Zolinza) zur Behandlung von Patientinnen mit einem fortgeschritt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000782-22,0,0,0 2016-000783-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Alfa Wassermann Polska Sp. z o.o.,"A phase 3, prospective, open, pilot, monocentric study to evaluate the effect of sulodexide administered at registered dose on morphology and functional properties of the venous endothelium in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000783-42,0,0,0 2016-000784-16,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Akershus University Hospital,Focal cartilage defects in the knee – A randomized controlled trial comparing Autologous Chondrocyte Implantation with arthroscopic debridement,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000784-16,0,0,0 2016-000785-37,3,,,0,0,1,0,0,0,2,0,0,2,1,0,0,0,1,"Gilead Sciences, Inc.","A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000785-37,0,1,0 2016-000785-37,3,,,0,0,1,0,0,0,2,0,0,2,1,0,0,0,1,GILEAD SCIENCES INCORPORATED,"A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000785-37,0,1,0 2016-000786-24,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,IRCCS Burlo Garofolo,"Thalidomide, a novel immunological treatment to modify the natural history of paediatric Crohn's disease: a new proposal from a well-established paediatric research network Talidomide: un nuovo tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000786-24,0,0,0 2016-000789-53,1,2017-07-17,2017-07-17,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische Intensivmedizin,"A pilot trial to investigate the administration of von Willebrand factor concentrate (Willfact®, LFB France) in adult patients during extracorporeal membrane oxygenation Eine Pilotstudie zum Einflu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000789-53,0,0,0 2016-000790-21,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Radboudumc,Effect of the GLP-1 receptor agonist exenatide on impaired hypoglycaemic awareness in type 1 diabetes Effect van de GLP-1 receptor agonist exenatide op verminderde hypoglykemie symptoomgewaarwordin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000790-21,0,0,0 2016-000794-20,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Radboud University Medical Center,Visualizing beta cells in patients with a history of gestational diabetes Beeldvorming van beta cellen in patienten met een geschiedenis van zwangerschapsdiabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000794-20,0,0,0 2016-000807-99,9,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,4SC AG,"A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000807-99,0,0,0 2016-000809-36,2,2019-03-21,2019-05-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University College London,"Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia (CAP): a randomised controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000809-36,0,0,0 2016-000809-36,2,2019-03-21,2019-05-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Medical Research Council Clinical Trials Unit at UCL,"Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia (CAP): a randomised controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000809-36,0,0,0 2016-000810-31,1,,,0,0,0,0,1,0,4,0,1,1,1,1,0,1,0,Maastricht University,Impact of L-Carnitine infusion on Lipid induced Insulin resistance Effect van L-Carnitine infusie op lipiden geïnduceerde insuline resistentie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000810-31,0,0,0 2016-000813-63,1,2016-12-31,2016-12-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Universitair Ziekenhuis Brussel,Comparative doubleblind study with prilocaine 2 % and 2-chloroprocaine for elective caesarean section.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000813-63,0,0,0 2016-000814-31,15,2019-06-26,2019-06-26,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"MAXIMISE (Managing AXIal Manifestations in Psoriatic Arthritis with SEcukinumab), a randomized, double-blind, placebo-controlled, multicenter, 52 week study to assess the efficacy and safety of secuki...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000814-31,0,0,0 2016-000814-31,15,2019-06-26,2019-06-26,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NOVARTIS PHARMA SERVICES AG,"MAXIMISE (Managing AXIal Manifestations in Psoriatic Arthritis with SEcukinumab), a randomized, double-blind, placebo-controlled, multicenter, 52 week study to assess the efficacy and safety of secuki...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000814-31,0,0,0 2016-000814-31,15,2019-06-26,2019-06-26,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","MAXIMISE (Managing AXIal Manifestations in Psoriatic Arthritis with SEcukinumab), a randomized, double-blind, placebo-controlled, multicenter, 52 week study to assess the efficacy and safety of secuki...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000814-31,0,0,0 2016-000816-14,6,2022-09-16,2022-09-16,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Clovis Oncology, Inc.","ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000816-14,1,0,0 2016-000816-14,6,2022-09-16,2022-09-16,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"CLOVIS ONCOLOGY, INC","ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000816-14,1,0,0 2016-000818-29,1,2018-11-30,2018-11-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,"Ironwood Pharmaceuticals, Inc.","A Phase 4, Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study of the Effect of Linaclotide on Abdominal Girth in Participants with Irritable Bowel Syndrome w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000818-29,0,0,0 2016-000821-37,3,2018-05-25,2018-05-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic Hepa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000821-37,0,0,0 2016-000823-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA,P-HIPEC CYTOREDUCTION PLUS HIPEC IN PATIENTS AFFECTED BY PERITONEAL CARCINOMATOSIS: A FEASIBILITY TRIAL P-HIPEC Fattibilit¿ della cito-riduzione associata ad HIPEC nei pazienti con carcinosi per...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000823-24,0,0,0 2016-000825-38,1,2018-09-18,2018-09-18,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Hannover Medical School,SGLT2-inhibition with Empagliflozin reduces progression of diabetic retinopathy in patients with high risk of diabetic macular edema (The SUPER-Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000825-38,0,0,0 2016-000826-21,4,2017-06-20,2017-06-20,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"Multi-center, double-blind, randomized, placebo-controlled, active reference, parallel-group, polysomnography dose response study to assess the efficacy and safety of ACT-541468 in adult subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000826-21,0,0,0 2016-000827-16,1,2017-06-29,2017-06-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"Multi-center, double-blind, randomized, placebo-controlled, 5-period, 5-treatment crossover, polysomnography dose-response study to assess the efficacy and safety of ACT-541468 in elderly subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000827-16,0,0,0 2016-000829-39,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,"Royal Brompton and Harefiled NHS Foundation Trust, Royal Brompton Hospital",Iron and Chronic Obstructive Pulmonary Disease (COPD) Exercise Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000829-39,0,0,0 2016-000831-41,4,2017-01-16,2017-07-17,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"AMAG Pharmaceuticals, Inc.","A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000831-41,0,0,0 2016-000833-40,1,2020-11-12,2020-11-12,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,The Institute of Cancer Research,Phase I ’run in’ study followed by randomised phase II trial testing intra-tumoural hydrogen peroxide as a radiation sensitizer in patients with locally advanced/recurrent breast cancer in terms of to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000833-40,0,0,0 2016-000838-21,3,2020-01-31,2020-01-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"AKEBIA THERAPEUTICS, INC.","Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects with Incident Dialysis-Dependent Chronic Kidney ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000838-21,0,0,0 2016-000838-21,3,2020-01-31,2020-01-31,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Akebia Therapeutics, Inc.","Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects with Incident Dialysis-Dependent Chronic Kidney ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000838-21,0,0,0 2016-000840-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA,Clinical and Urodynamic Evaluation of Bladder dysfunction in multiple sclerosis patients treated with Sativex Valutazione clinica e urodinamica della funzione vescicale in pazienti affetti da Scle...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000840-32,0,0,0 2016-000842-79,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Institut Jules Bordet,Prospective evaluation of 68Ga-PSMA PET-CT for Recurrence detection of Prostate Cancer and its impact on patient management The ProsPERo Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000842-79,0,0,0 2016-000847-16,1,,,0,0,1,0,0,1,1,0,0,4,0,0,0,0,0,"National Cancer Institute, Cancer Therapy Evaluation Program","A Phase 1/2 Study of the Mitogen Activated Protein Kinase Kinase(MEK) 1 Inhibitor Selumetinib (AZD6244, ARRY-142886, Hydrogen Sulfate) in Children With Neurofibromatosis Type 1 (NF1) and Inoperable Pl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000847-16,0,1,1 2016-000849-30,5,2020-11-05,2020-11-05,3,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"Shire Human Genetic Therapies, Inc.","A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome Who Completed TED-C14-006 Original PIP P/238/2010",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000849-30,1,0,0 2016-000850-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Archivel Farma S.L.,"Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients with Multi-Drug Resistant Tuberculosis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000850-36,0,0,0 2016-000852-91,1,2020-02-01,2020-02-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Leiden University Medical Center,Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation: AfterDmab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000852-91,0,0,0 2016-000857-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Bank of Cyprus Oncology Centre,A Phase II study of Switch Maintenance Pembrolizumab in patients with Non Small Cell Lung Cancer (NSCLC) who do not progress after First Line Platinum Doublet Chemotherapy Μελέτη Φάσης ΙΙ με θεραπε...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000857-11,0,0,0 2016-000859-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus University Medical Center,Efficacy and mode of action of apremilast (Otezla) in moderate hidradenitis suppurativa. An exploratory pilot study. Effectiviteit en mode of action van apremilast in matig-ernstige hidradenitis s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000859-27,0,0,0 2016-000860-40,5,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,CELGENE CORPORATION,"A PHASE 1B/2A MULTICENTER, OPEN-LABEL, DOSE- ESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF CC-220 AS MONOTHERAPY AND IN CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000860-40,0,0,0 2016-000860-40,5,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Celgene Corporation,"A PHASE 1B/2A MULTICENTER, OPEN-LABEL, DOSE- ESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF CC-220 AS MONOTHERAPY AND IN CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000860-40,0,0,0 2016-000862-49,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The University of Birmingham,Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000862-49,0,0,0 2016-000863-17,1,2020-07-14,2020-07-14,1,1,1,0,0,1,3,0,0,1,0,0,1,0,1,"Shire Human Genetic Therapies, Inc.","A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Subjects with Short Bowel Syndrome Who Completed TED-C13-003 Original PIP P/238/2010",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000863-17,0,0,0 2016-000864-41,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Centre Hospitalier Universitaire Brugmann,A randomized controlled trial of lidocaine patch for lower limb amputation pain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000864-41,0,0,0 2016-000866-44,2,2018-08-15,2018-08-15,2,0,0,1,0,0,1,0,0,1,1,0,0,0,1,"NanoCarrier Co, Ltd",Phase I/II Clinical Trial of NC-6004 in Combination with 5-FU and Cetuximab as First-line Treatment in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of The Head and Neck,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000866-44,0,0,0 2016-000867-18,1,2017-01-02,2017-01-02,1,1,0,0,1,0,4,0,1,1,1,1,1,0,0,KU Leuven,THE EFFECT OF CODEINE ON GASTRIC MOTILITY AS MEASURED WITH AN INTRAGASTRIC BALLOON,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000867-18,0,0,0 2016-000868-42,8,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Pfizer Inc.,"A PHASE 3 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61MG] IN SUBJECTS DIAGNOSED W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000868-42,0,0,0 2016-000868-42,8,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,PFIZER INC,"A PHASE 3 MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826-83) 20 MG OR 80 MG [OR TAFAMIDIS (PF-06291826-00) 61MG] IN SUBJECTS DIAGNOSED W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000868-42,0,0,0 2016-000869-23,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Institute of Cancer Research,Targeting cancer care with the use of genetic profiling,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000869-23,0,0,0 2016-000870-39,1,2018-10-30,2018-10-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Cutanea Life Sciences,"A phase 2, randomized, vehicle-controlled, double-blind study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide in H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000870-39,0,0,0 2016-000871-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,"Studio di Fase II, randomizzato, in aperto, controllato di fattibilit¿ dell¿impiego di doxiciclina nel tumore mammario in stadio precoce A Phase II Open-Label Randomized Controlled Pre-Surgical Fea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000871-26,0,0,0 2016-000877-19,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Starpharma Pty Ltd.,"A phase 1/2 dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics and preliminary efficacy of DTX-SPL8783 (a docetaxel (DTX)-dendrimer conjugate) as monotherapy in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000877-19,0,0,0 2016-000878-38,7,2019-01-29,2019-01-29,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK. S.P.A.,Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® both in Combination with Insulin Degludec with or without Metformin in Adults with Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000878-38,0,0,0 2016-000878-38,7,2019-01-29,2019-01-29,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® both in Combination with Insulin Degludec with or without Metformin in Adults with Type 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000878-38,0,0,0 2016-000879-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Jules Bordet,Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined with Endocrine Therapy in Estrogen Receptor Positive/ HER2 Negative Breast CAncer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000879-24,0,0,0 2016-000880-18,1,2017-07-25,2017-07-25,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,Special Account for Research Funds-University of Patras,"A randomized, pharmacodynamic comparison of low dose ticagrelor to clopidogrel in patients with prior myocardial infarction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000880-18,0,0,0 2016-000882-22,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,0,Karolinska Institute,"Karisma II: A randomized, double blinded, six-armed placebo controlled study to imnvestigate optimal dose of tamoxifen with the most favourable side effect spectra and with density reduction non-infer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000882-22,0,0,0 2016-000884-17,1,2021-03-03,2021-03-03,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Dr Alberto Domínguez-Rodríguez,"A multicenter, open-label, randomized of MOrphine and MEperidine in patients admitted for acute heart failure in emergency departments: the MOME study Ensayo clínico, multicéntrico, randomizado, a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000884-17,0,0,0 2016-000888-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University of Vienna,Bronchoscopic indocyanine green fluorescence imaging for the evaluation of anastomotic healing after lung transplantation Bronchoskopische ICG-Fluoreszenzanalyse nach einer Lungentransplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000888-16,0,0,0 2016-000889-35,1,2018-02-06,2018-02-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre Hospitalier Universitaire Brugmann,"Comparison of two methods of administration of the epidural, by programmed intermittent bolus or continuous perfusion, on the incidence of instrumented deliveries and cesareans in primiparous women. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000889-35,0,0,0 2016-000891-54,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Aging Research Center, Karolinska Institutet and Stockholm University","Effects of enhanced dopaminergic neurotransmission on working memory training efficiency in the healthy elderly - A prospective, single center, randomized, double blind, placebo controlled, parallel g...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000891-54,0,0,0 2016-000894-19,4,2020-11-05,2020-11-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000894-19,0,0,0 2016-000894-19,4,2020-11-05,2020-11-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000894-19,0,0,0 2016-000896-26,1,2017-08-04,2017-08-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Herlev Gentofte Hospital,Effect of Tadalafil on cerebral large arteries in stroke patients. Effekten af Tadalafil på hjernens store arterier i patienter med apopleksi.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000896-26,0,0,0 2016-000897-39,3,2017-08-07,2017-08-07,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.",Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Subjects with Moderate to Severe Rheumatoid Arthritis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000897-39,0,0,0 2016-000898-20,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,MeiraGTx UK Ltd,"Long term follow-up study of participants following an open label, multi-centre, Phase I/II dose escalation trial of an adeno-associated virus vector (AAV2/5-OPTIRPE65) for gene therapy of adults and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000898-20,0,0,0 2016-000899-23,4,2018-09-24,2018-09-24,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Corcept Therapeutics Incorporated,Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing¿s Syndrome Studio di fase 2 sulla sicurezza ed efficacia di CORT125134 nel trattamento della sindrome d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000899-23,0,0,0 2016-000899-23,4,2018-09-24,2018-09-24,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,CORCEPT THERAPEUTICS,Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing¿s Syndrome Studio di fase 2 sulla sicurezza ed efficacia di CORT125134 nel trattamento della sindrome d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000899-23,0,0,0 2016-000903-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oulu University Hospital,Efficacy and blood concentrations of epidural hydromorphone in labour Epiduraalisen hydromorfonin teho ja veripitoisuudet synnyttäjällä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000903-10,0,0,0 2016-000904-27,2,2018-08-06,2018-08-06,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Efficacy and safety of semaglutide once-weekly versus placebo as add on to SGLT-2i in subjects with type 2 diabetes mellitus. A 30-week randomised, double-blind, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000904-27,0,0,0 2016-000906-12,8,2018-06-27,2018-09-06,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Aquinox Pharmaceuticals (Canada) Inc.,"The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000906-12,0,0,0 2016-000912-13,4,2018-10-22,2018-10-22,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000912-13,0,0,0 2016-000912-13,4,2018-10-22,2018-10-22,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000912-13,0,0,0 2016-000916-14,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Eisai Ltd.,"A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000916-14,0,0,0 2016-000916-14,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,EISAI LIMITED,"A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000916-14,0,0,0 2016-000917-59,2,2016-11-29,2016-11-29,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,Arrowhead Pharmaceuticals Inc,"An Open-Label, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Effect on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels of ARC-AAT as evidenced by changes in liver biopsy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000917-59,0,0,0 2016-000917-59,2,2016-11-29,2016-11-29,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,"Arrowhead Pharmaceuticals, Inc","An Open-Label, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Effect on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels of ARC-AAT as evidenced by changes in liver biopsy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000917-59,0,0,0 2016-000919-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,F2G Limited,An open label phase IIa clinical study to evaluate the safety and pharmacokinetics of intravenous and oral F901318 (combined with caspofungin) for antifungal prophylaxis in patients undergoing chemoth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000919-33,0,0,0 2016-000920-25,1,2017-01-20,2017-01-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,A study of very low dose twice-daily compared to standard low dose once-daily aspirin following acute coronary syndromes - WILL lOWer dose aspirin be more effective following ACS?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000920-25,0,0,0 2016-000925-38,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,University College London (UCL),GO-8: Gene therapy for haemophilia A using a novel serotype 8 capsid pseudotyped adeno-associated viral vector encoding Factor VIII-V3,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000925-38,0,0,0 2016-000926-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fakultní nemocnice Hradec Králové,Innovation of method cryopreservation for clinical use autologous multipotent mesenchymal stem cells (MSCs) for treatment of extensive skeletal defects in revision surgery of total hip arthroplasty+ ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000926-21,0,0,0 2016-000929-40,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Janssen Research & Development, LLC",A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000929-40,0,1,1 2016-000933-37,12,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000933-37,0,0,0 2016-000933-37,12,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000933-37,0,0,0 2016-000935-42,1,2017-12-11,2017-12-11,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Institut Jules Bordet,Assessment of Metabolic and pathological Response to Treatment with Radio-chemotherapy (RCT) and Immunotherapy (ImT) before Surgery in locally advanced Esophageal and gastro-esophageal junction cancer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000935-42,0,0,0 2016-000936-17,3,2022-06-01,2022-06-01,1,0,0,1,0,1,1,0,0,2,0,0,0,0,1,GW Research Ltd,"A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of GWP42003-P in Conjunction with Hypothermia in Neonates with Mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000936-17,1,0,0 2016-000939-41,1,,,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,Anna Karlberg,Diagnostic assessment of 18F-fluciclovine (FACBC) - PET/MRI in the evaluation of suspected cerebral gliomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000939-41,0,0,0 2016-000940-32,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents with Active Juve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000940-32,0,1,1 2016-000942-77,15,,,0,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Genzyme Corporation,"A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase Alf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000942-77,0,1,0 2016-000942-77,15,,,0,1,1,0,0,1,3,0,0,2,1,0,0,0,1,GENZYME CORPORATION,"A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of Avalglucosidase Alfa (neoGAA, GZ402666) and Alglucosidase Alf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000942-77,0,1,0 2016-000943-14,1,2019-02-22,2019-02-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Olatec Therapeutics LLC,"A Phase 2 Single-Center, Proof-of-Concept Safety and Efficacy Study of Orally Administered OLT1177 Capsules with Successive, Result-Dependent Dose Adaptation in Subjects with an Acute Gout Flare Ee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000943-14,0,0,0 2016-000945-29,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA,Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS) Attività di Abiraterone nel trattamento della sindrome di Cushing in pazie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000945-29,0,0,0 2016-000946-69,3,2017-05-18,2017-05-18,3,1,0,0,1,0,3,0,0,1,0,0,1,0,1,AZAD Pharma AG,"A PHASE III, MULTICENTRE, RANDOMISED, INVESTIGATOR-MASKED, CROSS- OVER, COMPARATIVE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF THE GENERIC BRINZOLAMIDE 10 MG/ML + TIMOLOL 5 MG/ML EYE DROPS S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000946-69,0,0,0 2016-000951-29,5,2021-03-10,2021-03-10,3,1,1,0,0,1,0,0,0,2,0,0,0,0,1,"SAREPTA THERAPEUTICS, INC.","An Open-Label Safety, Tolerability, and Pharmacokinetics Study of Eteplirsen in Young Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000951-29,1,0,0 2016-000951-29,5,2021-03-10,2021-03-10,3,1,1,0,0,1,0,0,0,2,0,0,0,0,1,"Sarepta Therapeutics, Inc","An Open-Label Safety, Tolerability, and Pharmacokinetics Study of Eteplirsen in Young Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000951-29,1,0,0 2016-000951-29,5,2021-03-10,2021-03-10,3,1,1,0,0,1,0,0,0,2,0,0,0,0,1,"Sarepta Therapeutics, Inc.","An Open-Label Safety, Tolerability, and Pharmacokinetics Study of Eteplirsen in Young Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000951-29,1,0,0 2016-000955-28,3,2021-07-08,2021-07-08,2,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A phase 2/3 study investigating the pharmacokinetics, safety, and efficacy of Dupilumab in patients aged ≥6 months to <6 years with moderate-to- severe atopic dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000955-28,1,0,0 2016-000958-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE,RIDTS Study - Rivaroxaban for the treatment of symptomatic Isolated Distal deep vein Thrombosis “RIVAROXABAN PER 6 O PER 12 SETTIMANE NEL TRATTAMENTO DELLE TROMBOSI VENOSE PROFONDE DISTALI ISOLATE ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000958-36,0,0,0 2016-000961-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Ziekenhuis Oost-Limburg,Quality of analgesia after ultrasound-guided specific blocks of the distal tibial and deep peroneal nerves with 15 mL of a 50:50 mixture bupivacaine 0.5% and liposome bupivacaine (Exparel®) )1.3% vs....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000961-22,0,0,0 2016-000965-21,3,2021-11-11,2021-11-11,1,1,0,0,0,1,2,0,0,1,1,1,0,0,1,ONCOPEPTIDES AB,"A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab. E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000965-21,0,0,0 2016-000965-21,3,2021-11-11,2021-11-11,1,1,0,0,0,1,2,0,0,1,1,1,0,0,1,Oncopeptides AB,"A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab. E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000965-21,0,0,0 2016-000968-42,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,INSTITUTO DE INVESTIGACION SANITARIA LA FE,Study on the healing of the partial skin graft donor site in burn patients after application of platelet-rich plasma (PRP) or plasma rich in growth factors versus usual therapeutical practice. Estu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000968-42,0,0,0 2016-000971-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Charles University in Prague, Medical Faculty",Liposoms (drug delivery systems) in kinetically guided therapy of ovarian platinum-resistant carcinoma with doxorubicin using plasmafiltration Lipozomy (drug delivery systems) v kineticky řízené lé...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000971-26,0,0,0 2016-000972-91,8,2019-12-11,2019-12-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab to demonstrate efficacy in the treatment of enthesitis at the Achilles tendon up to 1 year in adult patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000972-91,0,0,0 2016-000972-91,8,2019-12-11,2019-12-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS PHARMA SERVICES AG,"A randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab to demonstrate efficacy in the treatment of enthesitis at the Achilles tendon up to 1 year in adult patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000972-91,0,0,0 2016-000972-91,8,2019-12-11,2019-12-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab to demonstrate efficacy in the treatment of enthesitis at the Achilles tendon up to 1 year in adult patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000972-91,0,0,0 2016-000977-19,4,2018-09-25,2018-09-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase 2 Placebo-Controlled, Randomized, Double Blind, Adaptive Dose Trial of the Safety and Efficacy of Inhaled AZD1419 in Adults With Eosinophilic, Moderate to Severe Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000977-19,0,0,0 2016-000978-38,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,DAIICHI SANKYO ITALIA S.P.A.,"Randomized, prospective double-blind placebo controlled study for the evaluation of the number, duration and severity of Respiratory Tract Infections in adults with risk of recurrence after standard t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000978-38,0,0,0 2016-000979-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Daiichi Sankyo Italia SpA,"Randomized, prospective double-blind placebo controlled study for the evaluation of the number, duration and severity of Upper Respiratory Tract Infections in children with risk of recurrence after st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000979-24,0,0,0 2016-000981-46,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,INSTITUT CURIE,First-line treatment of Ewing tumours with primary extrapulmonary dissemination in patients from 2 to 50 years - Traitement de 1ère intention de patients âgés de 2 à 50 ans atteints de tumeur d’Ewi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000981-46,0,0,0 2016-000988-16,3,2018-08-22,2018-08-22,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Efficacy and Safety of Oral Semaglutide versus Placebo in Subjects with Type 2 Diabetes Mellitus treated with insulin - 52-week, randomised, double-blind, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000988-16,0,0,0 2016-000989-35,3,2018-11-16,2018-11-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and safety of semaglutide versus canagliflozin as add-on to metformin in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000989-35,0,0,0 2016-000991-49,13,2022-05-24,2022-05-24,5,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Daiichi Sankyo, Inc.","A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTI-CENTER, CONTROLLED TRIAL TO EVALUATE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN AND TO COMPARE THE EFFICACY AND SAFETY OF EDOXABAN WITH STANDARD OF ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000991-49,1,0,0 2016-000992-26,4,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen,Volatile Anesthetic Protection Of Renal transplants 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000992-26,0,0,0 2016-000994-19,1,2018-12-05,2018-12-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gerolsteiner Brunnen GmbH & Co. KG,"Doubleblind, randomised, placebo-controlled clinical trial to evaluate the safety and efficacy of Gerolsteiner Heilwasser in NERD patients with heartburn Doppelblinde, randomisierte, placebokontrol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000994-19,0,0,0 2016-000996-26,1,2019-01-31,2019-01-31,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Region Ostergotland,"Volumekinetics for hyperoncotic albumin in burn patients as well as for healthy subjects. Volymskinetik för 20% albumin hos friska försökspersoner, samt brännskadade patienter",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000996-26,0,0,0 2016-000997-39,1,,,0,1,0,0,0,1,2,0,0,3,0,0,0,0,0,Newcastle Upon Tyne Hospitals NHS Foundation Trust,"Eculizumab in Shiga-Toxin producing E. Coli Haemolytic Uraemic Syndrome (ECUSTEC): A Randomised, Double-Blind, Placebo-Controlled Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000997-39,0,0,0 2016-000998-20,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,BIOIBÉRICA S.A,"Double-Blind, Randomised, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of the Combination of Chondroitin Sulphate and Glucosamine Hydrochloride in Patients with Hand Osteoarth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-000998-20,0,0,0 2016-001001-16,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,F. Hoffmann-La Roche AG,"A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Persistency of Response with or without Xolair after Long-Term Therapy (XPORT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001001-16,0,1,1 2016-001004-33,1,,,0,1,1,0,0,1,3,0,0,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, 2-Part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001004-33,0,1,1 2016-001005-16,11,2019-03-10,2019-03-10,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event. International, multi-centre, randomized, double-blind placebo-controlled phase II study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001005-16,0,0,0 2016-001005-16,11,2019-03-10,2019-03-10,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event. International, multi-centre, randomized, double-blind placebo-controlled phase II study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001005-16,0,0,0 2016-001005-16,11,2019-03-10,2019-03-10,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratorios Servier S.L.,"Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event. International, multi-centre, randomized, double-blind placebo-controlled phase II study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001005-16,0,0,0 2016-001005-16,11,2019-03-10,2019-03-10,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Servier Research and Development Ltd UK,"Randomized Efficacy and Safety Trial with Oral S 44819 after Recent ischemic cerebral Event. International, multi-centre, randomized, double-blind placebo-controlled phase II study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001005-16,0,0,0 2016-001006-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academisch Medisch Centrum,The Efficacy of TRH in Intensive Care patients; a dose finding study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001006-41,0,0,0 2016-001008-49,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,F. Hoffmann-La Roche AG,"A randomized, multicenter trial of oseltamivir doses of 75 mg for 5 or 10 days versus 150 mg for 5 or 10 days in influenza patients with pandemic (H1N1) 2009",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001008-49,0,1,1 2016-001010-17,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,"Imperial College, London",Nucleos(t)ide withdrawal in HBeAg negative hepatitis B virus infection to promote HBsAg clearance. (NUC-B),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001010-17,0,0,0 2016-001011-21,1,2019-02-26,2019-02-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Litaphar S.L.,"A prospesctive, open-label 12-weeks treatment study to determine the effect of tadalafil 5 mg on clitoral blood flow in menopausal and hipertensive women with sexual interest and arousal disorder ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001011-21,0,0,0 2016-001018-76,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001018-76,0,0,0 2016-001018-76,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001018-76,0,0,0 2016-001019-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,LIEGE University Hospital,A pilot trial of triheptanoin for the preventive treatment of migraine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001019-19,0,0,0 2016-001022-34,1,2018-12-21,2018-12-21,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,"AVIZOREX PHARMA, S.L.","A phase I/II, double-blind, placebo-controlled study assessing the safety and efficacy of AVX-012 ophthalmic solution in subjects with mild-to-moderate dry eye syndrome Ensayo clínico fase I/II, do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001022-34,0,0,0 2016-001026-33,1,2017-12-04,2017-12-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET",Phase II trial: uPAR PET/CT and FDG PET/MRI for preoperative staging of bladder cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001026-33,0,0,0 2016-001028-80,5,2019-04-01,2019-04-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"Efficacy and safety of SAR156597 in the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc): A randomized, double-blind, placebo-controlled, 24-week, proof of concept study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001028-80,0,0,0 2016-001028-80,5,2019-04-01,2019-04-01,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"Efficacy and safety of SAR156597 in the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc): A randomized, double-blind, placebo-controlled, 24-week, proof of concept study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001028-80,0,0,0 2016-001030-94,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Philipps University Marburg,Efficacy and safety of pegylated-proline-interferon alpha 2B (AOP2014) in maintaining deep molecular remissions in patients with chronic myeloid leukemia (CML) who discontinue ABL-kinase inhibitory th...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001030-94,0,0,0 2016-001033-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FILO,REMODEL - WM3 An Open Label non-randomized Phase II Study exploring «chemo-free » treatment association with Idelalisib + Obinutuzumab in Patient with relapsed/refractory Waldenstrom’s Macroglobulinem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001033-27,0,0,0 2016-001034-10,1,2020-02-20,2020-02-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,IRCCS-A.O.U. SAN MARTINO-IST,Neurophysiological assessment of the effect of Sativex (THC/CBD oromucosal spray) as add-on to treat spasticity following stroke Valutazione neurofisiologica dell'effetto del Sativex (THC/CBD Spray...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001034-10,0,0,0 2016-001038-91,2,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Leiden university medical centre,"A randomised, open-label clinical trial assessing the efficacy and safety of mycophenolate mofetil versus azathioprine for induction of remission in treatment naive autoimmune hepatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001038-91,0,0,0 2016-001039-11,5,2019-07-15,2019-07-16,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001039-11,0,0,0 2016-001042-25,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,1,F. Hoffmann-La Roche AG,"A Study to Investigate the Impact of Pharmacogenetics on CellCept Use, in Patients Participating in a Study in Renal Transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001042-25,0,1,1 2016-001043-39,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,F. Hoffmann-La Roche AG,"An Open-Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose Vs Concentration Controlled Cellcept Regimens For Patients Following A Single Organ Renal Transplantation In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001043-39,0,1,1 2016-001044-18,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,F. Hoffmann-La Roche AG,"A phase IIIb, openlabel, comparative, randomized study on resistance of Influenza A/H1N1 2009 virus to treatment with Oseltamivir at standard dose versus double dose",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001044-18,0,1,1 2016-001045-12,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,F. Hoffmann-La Roche AG,A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001045-12,0,1,1 2016-001046-26,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,F. Hoffmann-La Roche AG,Multiple Ascending Dose (MAD) Phase I Study of the IGF-1R Antagonist R1507 Administered as an Intravenous Infusion in Children and Adolescents with Advanced Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001046-26,0,1,1 2016-001049-24,1,2019-03-15,2019-03-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Actinogen Medical,"XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects with Mild Dementia due to Alzheimer’s Disease (A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001049-24,0,0,0 2016-001054-17,1,2021-06-17,2021-06-17,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHRU de Tours,Double-blinded multicenter randomized controlled trial comparing inhaled amikacin versus placebo to prevent ventilator associated pneumonia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001054-17,0,0,0 2016-001055-50,1,2016-12-19,2016-12-19,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Empros Pharma AB,"A, single center, controlled, multiple dose, randomized study during two weeks, investigating the effect of the test formulation on efficacy, safety and markers for appetite regulation, glucose and li...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001055-50,0,0,0 2016-001056-22,1,2019-05-20,2019-05-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical Univerity Vienna,Neodolpasse® Infusion Solution versus diclofenac 75 mg infusion in the treatment of postoperative pain after elective knee surgery - an exploratory placebo-controlled clinical study to investigate the...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001056-22,0,0,0 2016-001057-40,2,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Dimension Therapeutics, Inc.","A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Late-Onset OTC D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001057-40,0,0,0 2016-001057-40,2,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Ultragenyx Pharmaceutical, Inc.","A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Late-Onset OTC D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001057-40,0,0,0 2016-001058-16,2,2021-09-30,2021-09-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Nordic Lymphoma Group,A Phase II Trial of Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001058-16,0,0,0 2016-001060-11,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Fundació Sant Joan de Déu,"A Phase I, unicentric, open and dose escalation clinical trial to evaluate the safety and the activity of the oncolytic adenovirus VCN-01 in patients with refractory retinoblastoma Ensayo clínico f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001060-11,0,0,0 2016-001061-83,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Astellas Pharma Global Development, Inc.","A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001061-83,0,0,0 2016-001061-83,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.","A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001061-83,0,0,0 2016-001062-28,8,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,ACTELION Pharmaceuticals Ltd,"A multicenter, open-label, randomized, event-driven study to assess efficacy, safety and pharmacokinetics of macitentan versus standard of care in children with pulmonary arterial hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001062-28,0,1,0 2016-001063-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Rennes,Randomised phase III study testing nivolumab versus chemotherapy in first line treatment of PS 2 or elderly (more than 70 years old) patients with advanced non-small cell lung cancer Etude randomis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001063-36,0,0,0 2016-001064-11,4,2019-05-10,2019-05-10,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Nichi-Iko Pharmaceutical Co., Ltd.","A Randomized, Double-Blind, Multicenter, 3-Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients with Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001064-11,0,0,0 2016-001067-36,12,2020-03-03,2020-03-30,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BAYER AG,"A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phospho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001067-36,0,0,0 2016-001067-36,12,2020-03-03,2020-03-30,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bayer AG,"A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phospho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001067-36,0,0,0 2016-001072-29,5,2021-05-11,2021-05-11,3,1,1,0,0,0,2,0,0,1,0,0,1,0,1,"BIAL - Portela & Ca, S.A.","OPEN-LABEL, 2-DOSE LEVEL TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ESLICARBAZEPINE ACETATE (ESL) AS ADJUNCTIVE THERAPY IN INFANTS WITH REFRACTORY EPILEPSY WITH PARTIAL-ONSET SEIZ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001072-29,0,0,0 2016-001080-36,3,2019-05-17,2019-05-17,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Amgen Incorporated,A Phase 1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001080-36,0,0,0 2016-001083-11,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,D-ALBA Front-Line Sequential Treatment of Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients with Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001083-11,0,0,0 2016-001087-11,1,2020-07-08,2020-07-08,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,Belfast Health and Social Care Trust,Chemoprevention in BRCA1 mutation carriers - a proof of concept study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001087-11,0,0,0 2016-001091-30,1,2017-07-25,2017-07-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ORASIS Pharmaceuticals Ltd,"A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Repeated Administration, Crossover Study to Establish Safety, Tolerability, and Efficacy of PresbiDrops in Presbyopic Subjects Dvojno slepa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001091-30,0,0,0 2016-001094-33,3,2022-06-29,2022-06-29,2,1,0,0,0,1,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A MULTICENTER, OPEN-LABEL, PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB GIVEN EVERY 4 WEEKS (Q4W) IN PATIENTS WITH HEMOPHILIA A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001094-33,1,0,0 2016-001094-33,3,2022-06-29,2022-06-29,2,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.","A MULTICENTER, OPEN-LABEL, PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB GIVEN EVERY 4 WEEKS (Q4W) IN PATIENTS WITH HEMOPHILIA A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001094-33,1,0,0 2016-001096-73,1,2017-12-28,2017-12-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Medivir AB,"An Open-Label, One-Arm Phase II Extension Study to Evaluate Safety and Tolerability of MIV-711 in Patients with Knee Joint Osteoarthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001096-73,0,0,0 2016-001097-15,3,2021-12-29,2021-12-29,3,0,0,0,0,1,3,0,0,1,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) (VENICE II)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001097-15,0,0,0 2016-001098-34,2,2019-05-08,2019-05-08,2,1,0,0,0,0,2,0,2,1,0,0,1,0,1,Eli Lilly and Company,"Protocol I6T-MC-AMAF A Phase 2, Multicenter, Randomized, Parallel-arm, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001098-34,0,0,0 2016-001099-31,3,,,0,1,0,0,0,2,2,0,0,1,0,0,0,1,1,Eli Lilly and Company,"A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001099-31,0,0,0 2016-001099-31,3,,,0,1,0,0,0,2,2,0,0,1,0,0,0,1,1,Lilly S.A.,"A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001099-31,0,0,0 2016-001099-31,3,,,0,1,0,0,0,2,2,0,0,1,0,0,0,1,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001099-31,0,0,0 2016-001102-42,6,2018-08-30,2018-08-30,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SPRL,"A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001102-42,0,0,0 2016-001103-23,4,2018-07-16,2018-07-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SPRL,"A MULTICENTER, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ACTIVE PSORIATIC ARTHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001103-23,0,0,0 2016-001104-36,1,2020-03-25,2020-03-25,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,RIVM,Immunogenicity and safety study of a third measles mumps rubella (MMR-3) vaccine dose in healthy young adults in The Netherlands Onderzoek naar de immunogeniciteit en veiligheid van een derde vacc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001104-36,0,0,0 2016-001106-42,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Dermapharm AG,"Double-blind, randomised clinical study comparing efficacy and safety of Calcipotriol 50 µg/g_Betamethasone 0.5 mg/g Gel (Test) vs. Daivobet(R) Gel (Reference) vs. Vehicle in patients with scalp psori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001106-42,0,0,0 2016-001108-47,1,2019-01-01,2019-01-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Hospital Universitari Vall Hebron-Institut de Recerca (VHIR),Impact of eradication of asymptomatic bacteriuria on reducing the incidence of early infection in patients with periprosthetic femoral fractures requiring hip hemiarthroplasty Impacto de la erradic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001108-47,0,0,0 2016-001117-25,3,2018-11-30,2018-11-30,3,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001117-25,0,0,0 2016-001119-19,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Pfizer Inc.,Ocular Effects Of Azithromycin Oral Solution In Pediatric Patients With Pharyngitis/tonsillitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001119-19,0,1,1 2016-001120-54,1,2018-02-12,2018-02-12,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University Hospitals Coventry and Warwickshire NHS Trust,Does the DPP4 Inhibitor (Sitagliptin) Increase Endometrial Mesenchymal Stem Cells in Women with Recurrent Miscarriage?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001120-54,0,0,0 2016-001121-14,14,2019-08-08,2019-11-01,13,1,1,0,0,2,3,0,0,1,0,0,1,0,1,"ChemoCentryx, Inc.","A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001121-14,0,0,0 2016-001121-14,14,2019-08-08,2019-11-01,13,1,1,0,0,2,3,0,0,1,0,0,1,0,1,"CHEMOCENTRYX, INC.","A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001121-14,0,0,0 2016-001124-66,1,2019-01-11,2019-01-11,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,University Hospital Toulouse,Evaluation of the effect of double inhibition of angiotensin II AT1 receptor and neprilysin activity on sympatic nervous system activity in patient with heart failure (B2AN-SNS) Etude de l’effet du...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001124-66,0,0,0 2016-001125-13,1,2019-10-14,2019-10-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,IMEA (Institut de Médecine et d’Epidémiologie Appliquée)–Fondation Léon M’Ba,Pilot study - Short duration therapy of acute hepatitis C genotypes 1 or 4 in HIV-infected patients: efficacy and tolerability of grazoprevir 100mg/elbasvir 50mg during 8 weeks Etude pilote SAHIV -...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001125-13,0,0,0 2016-001126-33,1,2019-07-07,2019-07-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,NHS Blood and Transplant,"A placebo-controlled double blind, randomised feasibility trial of Desmopressin (DDAVP) in critical illness prior to procedures.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001126-33,0,0,0 2016-001127-32,2,2018-02-16,2018-02-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ACADIA Pharmaceuticals Inc.,"A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001127-32,0,0,0 2016-001128-78,2,2019-02-25,2019-02-25,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ACADIA Pharmaceuticals Inc.,A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001128-78,0,0,0 2016-001132-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC),"A double-blind, placebo controlled, randomized multicenter Phase II Study evaluating Gemcitabine with or without Ramucirumab as II line treatment for advanced malignant pleural mesothelioma Studio ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001132-36,0,0,0 2016-001135-12,4,2018-02-05,2018-02-05,4,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase II, randomised, observer-blind, controlled, multi-country study to rank different formulations of GSK Biologicals’ investigational RSV vaccine (GSK3003891A), based on immunogenicity, reactogen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001135-12,0,0,0 2016-001139-10,2,2019-04-15,2019-04-15,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Epizyme, Inc.","A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with Relapsed or Refractory BAP1 deficientMalignant Mesothelioma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001139-10,0,0,0 2016-001143-40,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Therapeutic Research Unit,"Long-term effects of Roux-en-Y Gastric Bypass on morphine exposure after oral administration of immediate release morphine, in comparison with subjects without surgery Impact à long terme du bypass...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001143-40,0,0,0 2016-001145-11,5,2019-01-17,2019-01-17,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Ascendis Pharma Endocrinology Division A/S,"A multicenter, Phase 3, randomized, open-label, active-controlled, parallel-group trial investigating the safety, tolerability, and efficacy of TransCon hGH administered once a week versus standard da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001145-11,0,0,0 2016-001156-22,1,2016-10-16,2016-10-16,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KU Leuven - Drug Delivery and Disposition,The gastrointestinal behavior of aprepitant in healthy volunteers Het gastrointestinaal gedrag van aprepitant in gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001156-22,0,0,0 2016-001158-16,4,2018-08-22,2018-08-22,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","A PHASE 2A, MULTICENTER, SINGLE ARM, OPEN-LABEL, TWO-STAGE, STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06480605 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001158-16,0,0,0 2016-001158-16,4,2018-08-22,2018-08-22,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER INC,"A PHASE 2A, MULTICENTER, SINGLE ARM, OPEN-LABEL, TWO-STAGE, STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06480605 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001158-16,0,0,0 2016-001159-37,1,2018-10-15,2018-10-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Multi-Site, Open-Label, Partially-Randomized Trial of the Efficacy and Safety of Fixed Dose Elbasvir/Grazoprevir (EBR/GZR) Based Regimens in French Subjects with Chronic Hepatitis C Virus (HCV) Geno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001159-37,0,0,0 2016-001160-11,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,F. Hoffmann-La Roche AG,"An Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Tacrolimus Ointment in the Treatment of Atopic Dermatitis in Pediatric Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001160-11,0,1,1 2016-001163-37,5,2019-11-14,2019-11-18,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis incl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001163-37,0,0,0 2016-001164-11,2,2019-01-09,2019-01-09,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,Open-label safety trial of intravenous neridronic acid in subjects with complex regional pain syndrome (CRPS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001164-11,0,0,0 2016-001165-88,3,2017-10-16,2017-10-16,1,0,0,0,0,0,3,0,0,1,1,0,1,0,1,"Intarcia Therapeutics, Inc.","A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001165-88,0,0,0 2016-001166-29,1,2022-02-04,2022-02-04,1,1,0,0,0,0,2,0,0,1,1,1,0,0,0,University Medical Centre Hamburg-Eppendorf,A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic stem cell transplantation (aHSCT) in high inflammatory multiple sclerosis (COAST) Eine randomisiert...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001166-29,0,0,0 2016-001170-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis ulcerosa),Efficacy of high-dose corticosteroid pulses added to conventional oral corticosteroid course in comparison with monotherapy oral corticosteroid course for moderate flares of ulcerative colitis: a ran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001170-15,0,0,0 2016-001176-30,1,2021-01-12,2021-01-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Clinical Research Institute, HUCH Ltd.",Effects of PCSK9 inhibition by Evolocumab on postprandial lipid metabolism in type 2 diabetes Evolokumabin vaikutus aterian jälkeiseen rasva-aineenvaihduntaan tyypin 2 diabetesta sairastavilla hen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001176-30,0,0,0 2016-001177-32,4,2020-08-21,2020-08-21,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Promethera Biosciences,Multicenter Phase II Safety and Preliminary Efficacy Study of 2 dose regimens of HepaStem in Patients with Acute on Chronic Liver Failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001177-32,0,0,0 2016-001178-13,2,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,2,Helsinki University Central Hospital,Phase 2 study of carfilzomib + elotuzumab + dexamethasone for relapsed or progressed multiple myeloma after 1-3 prior treatment lines Faasi 2 kliininen lääketutkimus karfiltsomibi + elotutsumabi + ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001178-13,0,0,0 2016-001179-60,2,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,A.R.T.I.C (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie),"Randomized multicenter, phase III trial evaluating the safety of 2 schedules of cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men (≥ 65 years) with metastatic castration-resista...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001179-60,0,0,0 2016-001180-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Rijnstate Hospital,Short-term Efficacy of Stellate Ganglion Block to reduce Hot Flushes Korte termijn effecten van stellatum ganglion blokkade op het verminderen van opvliegers bij vrouwen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001180-36,0,0,0 2016-001182-87,2,2019-02-09,2019-02-09,2,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Radboud University Medical Centre,Pharmacokinetics of posaconazole (Noxafil(R)) as prophylaxis for invasive fungal disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001182-87,0,0,0 2016-001186-85,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Felipe Villacampa,HIVEC HR: USE OF CHEMOHYPERTHERMIA WITH INTRAVESICAL MITOMYCIN (HIVEC) FOR THE TREATMENT OF PATIENTS WITH NMIBC AND HIGH RISK (HR) HIVEC HR: USO DE LA QUIMIOHIPERTERMIA CON MITOMICINA INTRAVESICAL ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001186-85,0,0,0 2016-001191-30,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,"Department of Obstetrics & Gynecology, Copenhagen University Hospital, Rigshospitalet",Use of TachoSil® for the prevention of postoperative complications after groin dissection in vulva cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001191-30,0,0,0 2016-001193-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Oncology, Aarhus University Hospital","Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy (FASTERCC). A randomized, double-blind, phase II tri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001193-15,0,0,0 2016-001199-31,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,3,,Improving treatment of right ventricular failure in pulmonary hypertension patients. Het verbeteren van de behandeling van rechter hartfalen in patiënten met pulmonale hypertensie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001199-31,0,0,0 2016-001202-42,4,2020-09-10,2020-09-10,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase II, Open-Label, Multi-Arm Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients with Platinum Refractory Extensive-Stage Small-Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001202-42,1,0,0 2016-001203-23,9,2022-05-19,2022-05-19,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001203-23,1,0,0 2016-001204-39,3,2020-03-20,2020-03-20,3,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Moberg Pharma AB (publ),"A multi-centre, randomized, two-armed, parallel group and evaluator-blinded study of efficacy and safety of topical MOB015B in the treatment of mild to moderate distal subungual onychomycosis (DSO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001204-39,0,0,0 2016-001205-16,12,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001205-16,0,0,0 2016-001205-16,12,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001205-16,0,0,0 2016-001209-17,7,2022-01-03,2022-01-03,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Celgene International II Sàrl,"A PHASE 2, MULTICENTER, OPEN-LABEL, STUDY TO DETERMINE THE SAFETY AND EFFICACY FOR THE COMBINATION OF DURVALUMAB (DURVA) AND DARATUMUMAB (DARA) (D2) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001209-17,1,0,0 2016-001209-17,7,2022-01-03,2022-01-03,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,CELGENE INTERNATIONAL II SàRL,"A PHASE 2, MULTICENTER, OPEN-LABEL, STUDY TO DETERMINE THE SAFETY AND EFFICACY FOR THE COMBINATION OF DURVALUMAB (DURVA) AND DARATUMUMAB (DARA) (D2) IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001209-17,1,0,0 2016-001211-21,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,HOVON Foundation,Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in first ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001211-21,0,0,0 2016-001213-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Franciscus Gasthuis,Infection prevention and immune modulation by bacterial lysates: gaining insight into the mechanism of an old therapy in patients with asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001213-24,0,0,0 2016-001214-24,2,2017-11-27,2017-11-28,2,0,0,1,0,1,1,0,0,1,0,0,0,0,1,Proteostasis Therapeutics,"A Phase I/II Multi-center, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects with Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001214-24,0,0,0 2016-001216-37,1,2019-08-10,2019-08-10,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Hôpitaux Universitaires de Strasbourg,Comparaison de deux stratégies d’administration de l’albumine humaine chez des malades agressés de réanimation présentant une hypoalbuminémie ≤ 20g/L.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001216-37,0,0,0 2016-001219-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Herlev Gentofte Hospital,Effect of glucagon-like peptide 1 (GLP-1) based diabetes medication on blood flow velocity in ischemic stroke patients Effekt af glukagon-lignende peptid 1 (GLP-1) baseret sukkersygemedicin på blod...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001219-18,0,0,0 2016-001221-14,1,2017-02-02,2017-02-02,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Herlev Gentofte Hospital,Effect of glucagon-like peptide 1 (GLP-1) based diabetes medication on blood flow velocity in persons without cerebrovascular disease. Effekt af glukagon-lignende peptid 1 (GLP-1) baseret sukkersyg...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001221-14,0,0,0 2016-001223-31,1,2019-10-27,2019-10-27,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,King's College Hospital NHS Foundation Trust,"Incidence of Invasive Fungal Disease in Patients receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001223-31,0,0,0 2016-001224-63,9,2020-11-10,2020-12-04,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001224-63,0,0,0 2016-001225-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fédération Francophone de Cancérologie Digestive,PHASE II RANDOMISEE EVALUANT L’EFFICACITE ET LA TOLERANCE DE 2 STRATEGIES THERAPEUTIQUES COMBINANT LE BEVACIZUMAB A LA CHIMIOTHERAPIE: DESESCALADE VERSUS ESCALADE CHEZ DES PATIENTS AYANT UN CANCER COL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001225-13,0,0,0 2016-001227-31,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University Zurich, University Hospital Balgrist, Spinal Cord Injury Center","Antibodies against Nogo-A to enhance plasticity, regeneration and functional recovery after acute spinal cord injury",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001227-31,0,0,0 2016-001227-31,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Zurich,"Antibodies against Nogo-A to enhance plasticity, regeneration and functional recovery after acute spinal cord injury",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001227-31,0,0,0 2016-001233-27,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,CHU Amiens Picardie,Efficacity and safety of metformin extended release (XR) in diabetic patients with CKD in stages 1 to 3 (METXR/CKD) Efficacité et tolérance de la metformine à diffusion prolongée (XR) chez le sujet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001233-27,0,0,0 2016-001237-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Instituto Gallego de Medicina Vascular (IGAMEVAS S.L.),"A randomized, unicenter, parallel study of the effect of dapagliflozin on central blood pressure reduction compared to glimepiride in adult subjects with type 2 Diabetes Mellitus and inadequate glycem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001237-27,0,0,0 2016-001238-89,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR),IRON DEFICIENCY IN PATIENTS WITH COPD: IMPACT OF TOPPING WITH IRON CARBOXYMALTOSE. FACE STUDY (ASSESSMENT IN PATIENTS WITH FERINJECT AND IRON DEFICIENCY COPD TO IMPROVE EXERCISE TOLERANCE) DEFICIEN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001238-89,0,0,0 2016-001239-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Orthopädisches Spital Speising,"PONV – Histamin - Vitamin C A prospecitve, Placebo-controlled dobbleblind study PONV – Histamin - Vitamin C eine prospektive, placebo-kontrollierte Doppelblindstudie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001239-11,0,0,0 2016-001240-19,1,2017-04-19,2017-04-19,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Synlogic,Clearance of the probiotic strain Escherichia coli Nissle 1917 in the gastrointestinal tract of healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001240-19,0,0,0 2016-001242-25,1,2018-08-13,2018-08-13,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Blueberry Therapeutics Ltd.,"An Early Phase Development, Partly Blinded, Positive and Vehicle Controlled, Randomized, Non-inferiority Investigation of the Pharmacokinetics, Safety and Efficacy of BB2603 Cutaneous Hand-Pump Spray ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001242-25,0,0,0 2016-001244-19,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,"GlaxoSmithKline, S.A.","A Phase II, multicenter, randomized, double-blind (sponsor-unblind), placebo- controlled, parallel group trial to evaluate the efficacy and safety of sirukumab in subjects with severe, poorly controll...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001244-19,0,0,0 2016-001246-26,2,2017-07-08,2017-07-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Wockhardt Bio AG,"A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001246-26,0,0,0 2016-001247-39,6,2021-10-18,2021-10-18,3,1,1,0,0,0,2,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Prospective, Randomized, Open Label, Multi-center Study of the Safety and Pharmacokinetics of Apixaban versus Vitamin K Antagonist or LMWH in Pediatric Subjects with Congenital or Acquired Heart Dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001247-39,1,0,0 2016-001248-20,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Centre François Baclesse,Impact of new generation hormono-therapy on cognitive functions in elderly patients treated for a metastatic prostate cancer Impact des hormonothérapies de nouvelles générations sur les fonctions c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001248-20,0,0,0 2016-001252-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,DIPARTIMENTO DI ONCOLOGIA-UNIVERSITA' DEGLI STUDI DI TORINO,Pembrolizumab (MK-3475) as maintainance unresectable stage III NSCLC after chemo-radiotherapy (MP-LALC- Maintainance Pembrolizumab in Locally Advanced Lung Cancer). Pembrolizumab (MK3475) come tera...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001252-22,0,0,0 2016-001253-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE,Impact of cabazitaxel on metastatic bone disease in patients with castration resistant prostate cancer previously treated with docetaxel Impatto di cabazitaxel sulle metastasi ossee in pazienti aff...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001253-41,0,0,0 2016-001254-17,10,2022-05-16,2022-05-16,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001254-17,1,0,0 2016-001254-17,10,2022-05-16,2022-05-16,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA SERVICES AG,"A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001254-17,1,0,0 2016-001254-17,10,2022-05-16,2022-05-16,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A multicenter, randomized, double-blind, active-controlled study to evaluate the effects of LCZ696 compared to valsartan on cognitive function in patients with chronic heart failure and preserved ejec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001254-17,1,0,0 2016-001255-49,2,2019-01-28,2019-03-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety, and tolerability of ACZ885 (canakinumab) in patients with pulmonary sarcoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001255-49,0,0,0 2016-001256-22,4,2021-08-03,2021-08-03,1,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Gliknik Inc,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (with Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001256-22,1,0,0 2016-001256-22,4,2021-08-03,2021-08-03,1,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Gliknik Inc.,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (with Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001256-22,1,0,0 2016-001259-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE RICERCA TRASLAZIONALE (FORT),PF-06463922 for crizotinib pretreated ROS1 positive non-small-cell lung cancer: a phase II Trial (PFROST) PF-06463922 nel tumore al polmone non a piccole cellule con traslocazione ROS1 pretrattat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001259-34,0,0,0 2016-001262-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut de Terapia Regenerativa Tissular S.L. (ITRT),"Treatment of Refractory Patellar Tendinopathy with MSV *. Comparative study with P-PRP *MSV are bone marrow autologous mesenchymal stem cells, selected and cultured under Good manufacturing Practices ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001262-28,0,0,0 2016-001263-37,1,2018-12-18,2018-12-18,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,UZ Gent,Phase I trial of stereotactic body radiotherapy with concurrent pembrolizumab in metastatic urothelial cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001263-37,0,0,0 2016-001264-11,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,University Medical Center of the Johannes Gutenberg-University Mainz,"A phase IV, single-center, randomized, double-blind, placebo-controlled, parallel group study on the effects of empagliflozin on left ventricular diastolic function compared to usual care in individua...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001264-11,0,0,0 2016-001265-92,1,2017-12-21,2017-12-21,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"University of Oxford, CTRG",A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of adjuvanted R21 at different doses and the Combination Malaria Vaccine Candidate Regimen of adjuvanted R21 + ChA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001265-92,0,0,0 2016-001266-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Paoli Calmettes,Active surveillance with or without a 6 months Apalutamide treatment in low risk prostate cancer: a phase II randomized multicenter trial Surveillance active avec ou sans traitement de 6 mois par ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001266-29,0,0,0 2016-001267-36,1,2016-10-07,2016-10-07,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,McNeil AB,PHARMACODYNAMIC EFFECTS OF NICOTINE MOUTH SPRAY AND CYTISINE TABLET. A STUDY IN HEALTHY SMOKERS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001267-36,0,0,0 2016-001269-10,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Erasmus MC Cancer Institute,A pharmacokinetic study of Docetaxel and Prednisone in men with metastatic castration-resistant or hormone-sensitive prostate cancer. Een farmacokinetische studie van docetaxel en prednison bij man...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001269-10,0,0,0 2016-001271-68,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001271-68,0,0,0 2016-001271-68,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited","A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001271-68,0,0,0 2016-001272-29,7,2017-07-24,2017-08-08,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,BioCryst Pharmaceuticals Inc,"A randomized, double-blind, placebo-controlled, dose-ranging, parallel-group study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of BCX7353 as a preventative tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001272-29,0,0,0 2016-001275-80,1,2017-01-20,2017-01-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,XOMA (US) LLC,"An Open-Label Study of XOMA 358, with Optional Dose Escalation, in Patients with Congenital Hyperinsulinism",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001275-80,0,0,0 2016-001278-13,1,2019-12-31,2019-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Taina Sipponen,"Immunologic, genetic and microbiomic predictors of the treatment response for TNFalpha-blocking drugs – prospective follow-up cohort of patients with Crohn’s disease or ulcerative colitis Immunolo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001278-13,0,0,0 2016-001296-67,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,"DUAL ENERGY CONTRAST ENHANCED DIGITAL MAMMOGRAPHY PERFORMANCE EVALUATION IN COMPARISON OF CONVENTIONAL DIGITAL MAMMOGRAPHY, TOMOSINTESIS AND MR IMAGING IN WOMEN FOLLOW-UP FOR BREAST CARCINOMA VAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001296-67,0,0,0 2016-001304-37,6,2019-02-22,2019-02-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase III, randomized, double-blind, active controlled, parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual combin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001304-37,0,0,0 2016-001304-37,6,2019-02-22,2019-02-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A Phase III, randomized, double-blind, active controlled, parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual combin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001304-37,0,0,0 2016-001304-37,6,2019-02-22,2019-02-22,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A Phase III, randomized, double-blind, active controlled, parallel group study, comparing the efficacy, safety and tolerability of the fixed dose combination FF/UMEC/VI with the fixed dose dual combin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001304-37,0,0,0 2016-001305-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon - Direction de la Recherche Clinique et de l'Innovation,Assessment of the efficacy of bevacizumab in combination with Folfiri as second-line treatment after the failure of the cisplatin (or carboplatin)-etoposide combination in patients suffering from an a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001305-16,0,0,0 2016-001306-41,9,2018-09-18,2018-09-21,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alder BioPharmaceuticals, Inc.","A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Chronic Migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001306-41,0,0,0 2016-001313-24,1,2020-06-03,2020-06-03,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,"Technische Universität München, Fakultät für Medizin",SUbstition of PERioperative Albumin Deficiency Disorders Einfluss der Therapie einer perioperativen Hypoalbuminämie auf postoperative Komplikationen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001313-24,0,0,0 2016-001314-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA,A phase II study of Pembrolizumab plus Carboplatin in BRCA-related metastatic breast cancer Studio di Fase II della combinazione di Pembrolizumab e Carboplatino nelle pazienti con tumore della mamm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001314-25,0,0,0 2016-001317-25,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Single-Arm, Phase 2 Study of Ramucirumab in Combination with Weekly Docetaxel in Patients with Stage IV Non-Small Cell Lung Cancer Following Disease Progression after Prior Platinum-based Chemothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001317-25,0,0,0 2016-001317-25,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Lilly S.A.,"A Single-Arm, Phase 2 Study of Ramucirumab in Combination with Weekly Docetaxel in Patients with Stage IV Non-Small Cell Lung Cancer Following Disease Progression after Prior Platinum-based Chemothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001317-25,0,0,0 2016-001318-11,6,2019-12-17,2020-01-09,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Protalix Ltd.,An Open Label Study of the Safety and Efficacy of PRX 102 in Patients with Fabry Disease Currently Treated With REPLAGAL® (Agalsidase alfa),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001318-11,0,0,0 2016-001321-14,5,2022-02-01,2022-02-01,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Incyte Corporation,"A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001321-14,1,0,0 2016-001328-77,4,2017-12-27,2017-12-27,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A 26-Week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001328-77,0,0,0 2016-001330-97,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,CHRU de Brest,"Prévention des Fausses Couches Spontanées Répétées par Hydroxychloroquine. Essai thérapeutique multicentrique, randomisé, en double insu, contre placebo. Prévention des Fausses Couches Spontanées...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001330-97,0,0,0 2016-001331-12,1,2021-12-03,2021-12-03,1,0,0,0,0,0,2,0,0,1,1,1,0,0,0,AIO-Studien-gGmbH,"A randomized phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with head and neck cancers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001331-12,0,0,0 2016-001332-35,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Academic Medical Center Amsterdam,A nationwide open-label multi-center prospective cohort study of nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer Een open-label multicenter prospectief cohortstu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001332-35,0,0,0 2016-001335-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hellenic Oncology Research Group,"A longitudinal study evaluating molecular changes associated with resistance to first and third (AZD9291) generation EGFR TKIs in patients with EGFR mutant NSCLC using ""liquid biopsy""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001335-12,0,0,0 2016-001340-19,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Radboud University Medical Center,"An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requirements and endoscopy frequency in patients with Rendu-Osler-Weber and gastrointestinal bleeding",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001340-19,0,0,0 2016-001341-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,. Comparaison de l'efficacité analgésique de dexaméthasone péri-nerveuse versus intraveineuse en adjuvant de l'anesthésie loco-régionale pour la chirurgie de l'avant-pied,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001341-41,0,0,0 2016-001352-21,1,2021-07-28,2021-07-28,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,"Ability Pharmaceuticals, SL","A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC Estudio a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001352-21,0,0,0 2016-001353-41,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,VU University medical center Amsterdam,Oxygenation of Affected Limbs in CRPS-I Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001353-41,0,0,0 2016-001356-22,1,2017-08-25,2017-08-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sun Pharma Advanced Research Company Ltd.,A PLACEBO-CONTROLLED RANDOMIZED WITHDRAWAL EVALUATION OF THE EFFICACY AND SAFETY OF BACLOFEN ER CAPSULES (GRS) IN SUBJECTS WITH SPASTICITY DUE TO MULTIPLE SCLEROSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001356-22,0,0,0 2016-001357-40,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,"Klinik für Kardiologie, Herz- und Diabeteszentrum NRW","High-Flow-Therapy for the treatment of Cheyne-Stokes-Respiration in chronic heart failure: A randomized, controlled, cross-over trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001357-40,0,0,0 2016-001359-36,3,,,0,0,0,1,2,0,1,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors Ensayo fase 1/2 de la combinac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001359-36,0,0,0 2016-001360-11,6,2020-01-24,2020-01-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"AKEBIA THERAPEUTICS, INC.","Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat For The Maintenance Treatment of Anemia in Subject With Dialysis-Dependent Chronic Kidney...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001360-11,0,0,0 2016-001360-11,6,2020-01-24,2020-01-24,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Akebia Therapeutics, Inc.","Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat For The Maintenance Treatment of Anemia in Subject With Dialysis-Dependent Chronic Kidney...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001360-11,0,0,0 2016-001361-81,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INSTITUT DE CANCEROLOGIE DE L'OUEST,Etude diagnostique comparative multicentrique et prospective de la TEP/TDM au 68Ga-HBED-CC-PSMA et des procédures d’imagerie conventionnelle dans le bilan des cancers de prostate en rechute biologiqu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001361-81,0,0,0 2016-001363-37,1,2018-11-10,2018-11-10,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Clermont-Ferrand,"A Phase 3, Global, Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non-severe ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001363-37,0,0,0 2016-001365-92,1,2019-06-19,2019-06-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Center for Diabetes Research, Gentofte Hospital","Meal-time Administration of exenatide for Glycaemic control in type 1 diabetic Cases: A randomised, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001365-92,0,0,0 2016-001367-36,17,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GILEAD SCIENCES INCORPORATED,"Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001367-36,0,0,0 2016-001367-36,17,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Gilead Sciences, Inc.","Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001367-36,0,0,0 2016-001367-36,17,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Galapagos NV,"Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001367-36,0,0,0 2016-001371-69,1,2017-10-19,2017-10-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Lluita contra la SIDA,Tenofovir DP concentrations in seminal cells and semen quality in HIV-1 infected patients receiving a TAF containing regimen Concentraciones de Tenofovir DP en células seminales y calidad del semen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001371-69,0,0,0 2016-001373-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Region Ostergotland,"Clinical Study Protocol An open phase IV,RCT, evaluating patient controlled sedation, in three different dosages of propofol in healthy subjects undergoing elective gynaecological out-patient surger...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001373-33,0,0,0 2016-001378-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Wuerzburg,"A randomized, sham-controlled trial of pallidal neurostimulation versus botulinum toxine treatment for cervical dystonia. Eine randomisierte, sham-kontrollierte Vergleichsstudie von tiefer Hirnstim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001378-13,0,0,0 2016-001379-66,1,,,0,1,0,0,0,0,2,0,1,1,1,1,0,1,0,Radboud university medical center,Controlled Human Malaria Infection study to assess gametocytaemia and mosquito transmissibility in participants challenged with Plasmodium falciparum by sporozoite challenge to establish a model for t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001379-66,0,0,0 2016-001383-10,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Rijnstate ziekenhuis,Evaluating the effect of short term withdrawal of PPI's in patients for reducing stomach wall uptake with 99mTc Sestamibi for myocardial perfusion imaging Het afbouwen van PPI (Proton Pump Inhibito...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001383-10,0,0,0 2016-001384-37,2,,,0,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"Alexion Pharmaceuticals, Inc.","An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients with Refractory Generalized Myasthenia Gravis (gMG)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001384-37,0,0,0 2016-001387-12,3,2019-01-14,2019-01-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A randomized, subject and investigator-blind, placebo-controlled study of CLR325 in chronic stable heart failure patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001387-12,0,0,0 2016-001392-78,16,2020-03-31,2020-03-31,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001392-78,0,0,0 2016-001392-78,16,2020-03-31,2020-03-31,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GILEAD SCIENCES INCORPORATED,"Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001392-78,0,0,0 2016-001396-69,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,1,"Kura Oncology Inc.,",An Open Label Phase II Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell LymphomaLymphoma Estudio fase II abierto de Tipifarnib en pacientes con recaída o refractarios a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001396-69,0,0,0 2016-001397-15,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Institut klinické a experimentální medicíny,"A prospective, randomized study to compare the effect on tissue oxygenation and clinical outcome of autologous bone marrow-derived mononuclear cell therapy with standard treatment in patients with cri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001397-15,0,0,0 2016-001398-34,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Institut klinické a experimentální medicíny,"A prospective, randomized study to assess the effect of autologous bone marrow-derived mononuclear cell therapy and its combination with percutaneous transluminal angioplasty (PTA) in comparison with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001398-34,0,0,0 2016-001399-31,9,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001399-31,0,0,0 2016-001399-31,9,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001399-31,0,0,0 2016-001401-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Utrecht,The SUGAR-DIP trial: Oral medication strategy versus insulin for diabetes in pregnancy De SUGAR-DIP trial: Orale medicatie strategie versus insuline voor diabetes gravidarum,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001401-16,0,0,0 2016-001402-41,6,2019-08-23,2019-08-23,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesopha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001402-41,0,0,0 2016-001402-41,6,2019-08-23,2019-08-23,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc","A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined with Nivolumab versus Nivolumab Alone in Subjects with Unresectable or Recurrent Gastric or Gastroesopha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001402-41,0,0,0 2016-001403-23,6,2019-09-17,2019-09-19,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects with Adv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001403-23,0,0,0 2016-001403-23,6,2019-09-17,2019-09-19,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects with Adv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001403-23,0,0,0 2016-001406-42,1,2021-05-27,2021-05-27,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,"Hæmatologisk Afdeling, Sjælland Sygehus, Roskilde","Statin- and bisphosphonate treatment in patients with the Philadelphia-negative chronic myeloproliferative neoplasms - essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001406-42,0,0,0 2016-001407-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama),A Phase II Clinical Trial to analyse Olaparib Response in patients with BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETA-Breast study). Ensayo Clínico Fase II para an...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001407-23,0,0,0 2016-001409-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helse More og Romsdal Hospital Trust,"A prospective, open randomized, parallel-group study to evaluate the outcome of discontinuing or continuing anti-tumor necrosis factor treatment in patients with ulcerative colitis in sustained clinic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001409-18,0,0,0 2016-001411-20,2,2018-11-06,2018-11-06,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma AG,"Long-term, open label, multicenter, extension study to evaluate the safety and tolerability of QCC374 in patients with PAH",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001411-20,0,0,0 2016-001412-38,1,2018-07-11,2018-07-11,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma AG,"A randomized, parallel-group, placebo-controlled subject and investigator blinded study to assess the safety, tolerability, pharmacokinetics and efficacy of QCC374 in the treatment of pulmonary arteri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001412-38,0,0,0 2016-001413-24,1,2019-05-25,2019-05-25,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU de Rennes,Intérêt du TAP (Transverse Abdominis Plane) bloc bilatéral échoguidé pour l’analgésie post opératoire des chirurgies rachidiennes par voie antérieure. Intérêt du TAP (Transverse Abdominis Plane) bl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001413-24,0,0,0 2016-001417-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Franciscus Gasthuis,"POSTPRANDIAL LIPEMIA, INFLAMMATION, AND VASCULAR FUNCTION IN DIABETES MODULATED BY SGLT2 INHIBITION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001417-24,0,0,0 2016-001421-13,1,2020-08-15,2020-08-15,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,AGMT gGmbH,Ixazomib (MLN9708) in combination with carboplatin in pretreated women with advanced triple negative breast cancer (CARIXA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001421-13,0,0,0 2016-001424-55,6,2019-01-03,2019-01-03,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,BioCryst Pharmaceuticals Inc.,"A randomized, double-blind, placebo-controlled, dose-ranging, study to evaluate the efficacy, safety and tolerability of single doses of BCX7353 as an acute attack treatment in subjects with hereditar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001424-55,0,0,0 2016-001427-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Helsinki / CLUE Working Group,Antibiotic prophylaxis before extracorporeal shock wave lithotripsy (APPEAL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001427-30,0,0,0 2016-001429-16,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,HORAMA SA,Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients Harboring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression. Etude de sécurité et d’efficac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001429-16,0,0,0 2016-001432-35,10,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negativ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001432-35,0,0,0 2016-001435-13,1,2019-03-08,2019-03-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU de Bordeaux,Description of the ability to learn how to handle inhaler devices in COPD Etude descriptive de la capacité d’apprendre à utiliser des systèmes d’inhalation dans la bronchopneumopathie chronique ob...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001435-13,0,0,0 2016-001436-35,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,"Service of Neurology, CHU Liege",How sleep and circadian rhythmicity promote cognitive fitness and protect against cognitive decline in the elderly population Comment le sommeil et les rythmes circadiens favorisent une bonne cogni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001436-35,0,0,0 2016-001437-27,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Efficacy of furosemide versus vascular filling in Patients with Acute Myocardial Infarction with Right Ventricular Extension: a multicentric randomized controlled trial. Efficacité du furosémide ve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001437-27,0,0,0 2016-001439-11,1,2016-12-22,2016-12-22,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KU Leuven - Drug Delivery and Disposition,Influence of bicarbonate on drug gastrointestinal behaviour and disposition Invloed van bicarbonaat op het gastrointestinaal gedrag en de dispositie van een geneesmiddel,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001439-11,0,0,0 2016-001440-18,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,university medical center utrecht,Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in cystic fibrosis patients and healthy controls Pharmacokinetische interacties tussen ivacaftor en cytochroom P450...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001440-18,0,0,0 2016-001443-39,5,2018-10-18,2018-10-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Proximagen Ltd.,"A Randomised, Parallel Arm, Placebo-Controlled, Double-Blind, Study of the Safety and Efficacy of PRX167700 Added to Existing Non-steroidal Anti-inflammatory Therapy in Adults with Moderate-to-Severe ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001443-39,0,0,0 2016-001443-39,5,2018-10-18,2018-10-18,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BenevolentAI Cambridge Ltd.,"A Randomised, Parallel Arm, Placebo-Controlled, Double-Blind, Study of the Safety and Efficacy of PRX167700 Added to Existing Non-steroidal Anti-inflammatory Therapy in Adults with Moderate-to-Severe ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001443-39,0,0,0 2016-001444-20,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,"Beijing Novartis Pharma Co., Ltd.","An Open-label, Single-arm, Multicenter, Phase IV, 52-week Study to Evaluate the Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients with Chronic Hepatitis B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001444-20,0,1,1 2016-001445-61,4,2018-07-25,2018-07-25,2,1,1,0,0,0,1,0,0,1,1,1,1,0,1,Menarini Ricerche S.p.A.,"Open label, multi-centre, parallel group study to compare the pharmacokinetics (PK), pharmacodynamics (PD) and safety of febuxostat between pediatric patients (>=6<18 years of age) and adults. Estu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001445-61,0,0,0 2016-001446-25,2,2020-11-27,2020-11-27,1,1,0,1,0,1,1,0,0,1,1,0,0,0,2,REGENXBIO Inc.,AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects with Homozygous Familial Hypercholesterolemia (HoFH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001446-25,0,0,0 2016-001446-25,2,2020-11-27,2020-11-27,1,1,0,1,0,1,1,0,0,1,1,0,0,0,2,University of Pennsylvania,AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects with Homozygous Familial Hypercholesterolemia (HoFH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001446-25,0,0,0 2016-001447-39,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,AB SCIENCE,"A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase 3 study to compare efficacy and safety of ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001447-39,0,0,0 2016-001447-39,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,AB Science,"A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase 3 study to compare efficacy and safety of ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001447-39,0,0,0 2016-001448-21,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Merck KGaA,"A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 with a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients with Relapsing Multiple Sclerosis to Evaluate Efficacy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001448-21,0,0,0 2016-001449-16,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Biogen Idec Research Limited,"A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Subjects With Trigeminal Neuralgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001449-16,0,0,0 2016-001452-22,1,2022-02-14,2022-02-14,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Zealand University Hospital,Treatment effect of colesevelam for bile acid diarrhoea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001452-22,0,0,0 2016-001454-18,1,2021-10-31,2021-10-31,1,1,0,0,0,0,2,0,0,1,0,0,0,0,0,Center for Cancer Immune Therapy,T cell therapy for patients with advanced Renal Cell Carcinoma T celle terapi til patienter med metastisk renalcelle karcinom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001454-18,0,0,0 2016-001455-42,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,0,Radboud Universitair Medisch Centrum,The influence of metformin and a hypocaloric diet on thyroid radioactive iodide uptake in healthy volunteers: a pilot study De effecten van metformine en een hypocalorische dieet of schildklier jod...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001455-42,0,0,0 2016-001456-21,12,2020-03-13,2020-06-19,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN TH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001456-21,0,0,0 2016-001456-21,12,2020-03-13,2020-06-19,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc.,",A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN TH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001456-21,0,0,0 2016-001456-21,12,2020-03-13,2020-06-19,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER INC,A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN TH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001456-21,0,0,0 2016-001456-21,12,2020-03-13,2020-06-19,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc.,A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN TH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001456-21,0,0,0 2016-001459-28,1,2017-08-30,2017-08-30,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Immodulon Therapeutics Ltd,A Novel Phase I/IIa Open label Study of IMM 101 in Combination with Selected Standard of Care (SOC) Regimens in Patients with Metastatic Cancer or Unresectable Cancer at Study Entry.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001459-28,0,0,0 2016-001460-11,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,UCL CCTU,"Corneal cross-linking versus standard care in children with keratoconus, a randomised, multicentre, observer-masked trial of efficacy and safety",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001460-11,0,0,0 2016-001463-36,11,2021-06-22,2021-11-01,6,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Genzyme Corporation,"ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001463-36,1,1,0 2016-001463-36,11,2021-06-22,2021-11-01,6,1,1,0,0,1,3,0,0,2,1,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001463-36,1,1,0 2016-001463-36,11,2021-06-22,2021-11-01,6,1,1,0,0,1,3,0,0,2,1,0,0,0,1,"ALNYLAM PHARMACEUTICALS, INC.","ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001463-36,1,1,0 2016-001464-11,12,2020-11-10,2021-07-14,7,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Genzyme Corporation,"ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001464-11,1,1,0 2016-001464-11,12,2020-11-10,2021-07-14,7,1,1,0,0,1,3,0,0,2,1,0,0,0,1,"ALNYLAM PHARMACEUTICALS, INC.","ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001464-11,1,1,0 2016-001464-11,12,2020-11-10,2021-07-14,7,1,1,0,0,1,3,0,0,2,1,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001464-11,1,1,0 2016-001466-28,14,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia who are Ineligibl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001466-28,0,0,0 2016-001466-28,14,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia who are Ineligibl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001466-28,0,0,0 2016-001467-36,7,2020-07-21,2020-07-21,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,VIFOR (INTERNATIONAL) INC.,"A Randomised, Double-blind Placebo Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart Fail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001467-36,0,0,0 2016-001467-36,7,2020-07-21,2020-07-21,6,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Vifor (International) Inc.,"A Randomised, Double-blind Placebo Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart Fail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001467-36,0,0,0 2016-001468-12,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Tarveda Therapeutics, Inc.","A Phase 1/2a, open-label multicenter study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEN-221 in patients with somatostatin receptor 2 expressing advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001468-12,0,0,0 2016-001477-33,9,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,Baxalta Innovations GmbH,"A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF with or without ADVATE in the Treatment and Control of Bleeding...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001477-33,0,0,0 2016-001478-14,8,2020-07-06,2020-07-06,6,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Baxalta Innovations GmbH,"A PROSPECTIVE, PHASE 3, OPEN LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001478-14,0,0,0 2016-001480-36,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Centre Hospitalier Régional et Universitaire de Lille,Assessment of the IgG trough level in subjects with primary immunodeficiency switching from standard subcutaneous immunoglobulin (SCIG) to every other week HyQvia Évaluation du taux résiduel d’IgG...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001480-36,0,0,0 2016-001485-29,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"G1 Therapeutics, Inc","Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination with Fulvestrant in Patients with Hormone Receptor-Positive, HER2 Negative Locally Advanced or Metastatic Breast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001485-29,0,0,0 2016-001486-90,1,2020-01-13,2020-01-13,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Dose reduction of antenatal betamethasone given to prevent the neonatal complications associated with very preterm birth: a randomized, multicentre, double blind placebo-controlled non inferiority tri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001486-90,0,0,0 2016-001490-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,Phase II randomized study comparing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001490-33,0,0,0 2016-001491-29,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNICANCER,"A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high-risk stage III colon cancer in adjuvant setting",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001491-29,0,0,0 2016-001493-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colore...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001493-15,0,0,0 2016-001496-75,2,2017-09-20,2017-09-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects with Active Rheumatoid Arthritis on Ba...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001496-75,0,0,0 2016-001499-31,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,LYSARC,A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL) patients treated by R-CHOP Etude de phase Ib-II du taze...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001499-31,0,0,0 2016-001502-42,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Eli Lilly and Company Limited,Effect of Early Growth Hormone Treatment on Long-term Growth and Skeletal Maturation in Girls With Turner Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001502-42,0,1,1 2016-001503-23,10,2017-05-17,2020-10-23,8,1,1,0,0,1,3,0,0,1,1,0,1,0,1,Ablynx NV,Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001503-23,0,0,0 2016-001503-23,10,2017-05-17,2020-10-23,8,1,1,0,0,1,3,0,0,1,1,0,1,0,1,ABLYNX NV,Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001503-23,0,0,0 2016-001505-17,2,2017-03-30,2017-03-30,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"FAES FARMA, S.A.",An exploratory study to evaluate the efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases. Estudio exploratorio para evaluar ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001505-17,0,0,0 2016-001508-45,1,2018-12-11,2018-12-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),Phase II clinical trial to evaluate the efficacy of FOLFIRI + aflibercept in patients with metastatic colorectal cancer previously treated with oxaliplatin with or without ACE polymorphisms Estudio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001508-45,0,0,0 2016-001510-20,1,2019-04-01,2019-04-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Aalborg University Hospital,Treatment of Primary Hyperparathyroidism with Denosumab and Cinacalcet,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001510-20,0,0,0 2016-001511-20,1,2019-11-19,2019-11-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Institute for Pharmacology and Toxicology,Pharmacokinetica of Cefuroxime Pharmakokinetik von Cefuroxim in der perioperativen Antibiotikaprophylaxe am Bewegungsapparat,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001511-20,0,0,0 2016-001512-38,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Maastricht University,Investigation of psychomotor performance to evaluate clinical impairment and pharmacokinetic aspects of methadone and buprenorphine: a double-blind placebo-controlled randomized trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001512-38,0,0,0 2016-001513-25,1,2018-04-30,2018-04-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Aarhus University Hospital,Metformin in patients with chronic and acute heart failure: Pharmacokinetics and polymorphisms in genes encoding membrane metformin transporter proteins,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001513-25,0,0,0 2016-001514-20,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001514-20,0,0,0 2016-001514-20,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001514-20,0,0,0 2016-001515-20,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI,EFFECT OF TERIFLUNOMIDE ON T CELL SUBPOPULATIONS IN PERIPHERAL BLOOD FROM RRMS PATIENTS Effetto della teriflunomide su sottopopolazioni cellulari T del sangue periferico in pazienti affetti da Sc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001515-20,0,0,0 2016-001516-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"PROF.EFISIO PUXEDDU, SEZIONE MEDICINA INTERNA SCIENZE ENDOCRINE E METABOLICHE, UNIVERSITà DI PERUGIA",Levothyroxine soft-gel efficacy with variation of intaking time in hypothyroidism replacement therapy Valutazione dell¿efficacia della levotiroxina in capsule molli nella terapia sostitutiva dell¿...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001516-38,0,0,0 2016-001518-39,4,2019-07-05,2019-07-05,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Kowa Research Institute, Inc.","A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Open-Label Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001518-39,0,0,0 2016-001519-19,1,,,0,1,0,0,1,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier Départemental Vendée de la Roche sur Yon,"Cathéter au canal des adducteurs sous sartorial (KTSS) versus cathéter fémoral (KTF) dans une démarche de réhabilitation rapide après prothèse totale de genou : Etude contrôlée, randomisée.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001519-19,0,0,0 2016-001520-66,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,UNICANCER,Efficacy and safety of fentanyl citrate in painful access induced during diagnostic or therapeutic examinations in cancer patients Efficacité et tolérance du citrate de fentanyl dans les accès doul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001520-66,0,0,0 2016-001521-13,1,2021-10-27,2021-10-27,1,1,0,0,0,1,2,0,0,1,0,0,0,0,0,Med. Univ. Wien,A PHASE II TRIAL OF LONG-TERM TREATMENT WITH AZITHROMYCIN IN PATIENTS WITH LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001521-13,0,0,0 2016-001523-31,1,2019-08-16,2019-08-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Steno Diabetes Center Copenhagen,"Effect of liraglutide on vascular inflammation in type-2 diabetes: A randomized, placebo-controlled, double-blind, parallel clinical PET/CT trial Effekten af Liraglutid på vaskulær inflammation ho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001523-31,0,0,0 2016-001528-69,1,2020-04-07,2020-04-07,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Royal College of Surgeons in Ireland,PENICILLIN FOR THE EMERGENCY DEPARTMENT-DIRECTED OUTPATIENT TREATMENT OF CELLULITIS (PEDOCELL) STUDY: A NON-INFERIORITY ADAPTIVE RANDOMISED CONTROLLED TRIAL.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001528-69,0,0,0 2016-001529-15,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AZIENDA SOCIO-SANITARIA TERRITORIALE DI LECCO (ASST LECCO),Randomized Anticoagulation Trial In Opcab HIGH DOSE VERSUS LOW DOSE HEPARINIZATION IN PATIENTS Randomized Anticoagulation Trial In Opcab HIGH DOSE VERSUS LOW DOSE HEPARINIZATION IN PATIENTS UNDERGO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001529-15,0,0,0 2016-001530-10,1,2019-07-22,2019-07-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Royal Devon & Exeter NHS Foundation Trust,A randomised controlled trial of topical intranasal tranexamic acid versus placebo to reduce the need for nasal packing in patients presenting to the Emergency Department with spontaneous epistaxis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001530-10,0,0,0 2016-001531-12,1,2017-10-11,2017-10-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lupin Limited,"A Phase II, Dose Ranging, Exploratory Clinical Study to Assess the Efficacy, Pharmacodynamics, and Safety of LNP1955 in Patients with Moderate-to-Severe Plaque Psoriasis II. fázisú, dózistartomány-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001531-12,0,0,0 2016-001532-35,2,2017-10-11,2017-10-11,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Lupin Limited,"A Phase II, Dose Ranging, Exploratory Clinical Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of LNP1955 in Patients with Moderate to Severe Rheumatoid Arthritis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001532-35,0,0,0 2016-001533-28,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,0,Children's Oncology Group,"A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001533-28,0,1,1 2016-001536-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV co-infected patients Estudio abierto de fase III para evaluar la eficacia y la seguridad del tratamiento con Grazoprevir+Elbasvir para l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001536-36,0,0,0 2016-001549-13,4,2019-07-26,2019-07-26,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc.","A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF MSTT1041A IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001549-13,0,0,0 2016-001554-18,1,,,0,1,0,0,1,0,4,0,0,1,1,1,0,1,0,"RWTH Aachen University represented by the Rector, represented by the Dean of the Medical Faculty",English: Are Antipsychotics Neurotoxic or Neuroprotective? A Randomised Multicentre Longitudinal Study for Comparison of Two Therapy Strategies for the Treatment of Schizophrenia. Sind Antipsycho...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001554-18,0,0,0 2016-001555-41,1,2018-07-31,2018-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SUNOVION PHARMACEUTICALS INC.,"A 4-Week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexibly-dosed, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adult Subjects With Sch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001555-41,0,0,0 2016-001556-21,1,2019-01-29,2019-01-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SUNOVION PHARMACEUTICALS INC.,A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects with Schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001556-21,0,0,0 2016-001557-41,1,2017-09-05,2017-09-05,1,0,0,0,0,0,3,0,1,1,0,0,1,0,1,Adimmune Corporation,"A Phase III, Multi-center, Single-dose, Randomized, Double-blind, Non-inferiority and Lot-to-lot Consistency Study of Immunogenicity and Safety Evaluation of AdimFlu-S Quadrivalent Inactivated Influen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001557-41,0,0,0 2016-001560-11,18,2019-12-16,2020-03-16,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001560-11,0,0,0 2016-001560-11,18,2019-12-16,2020-03-16,14,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A,"A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001560-11,0,0,0 2016-001561-88,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Novartis Pharmaceuticals,"A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001561-88,0,1,1 2016-001563-36,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,Novartis Pharmaceuticals,A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001563-36,0,1,1 2016-001566-28,1,2020-05-13,2020-05-13,1,0,0,0,0,1,4,0,0,1,1,1,1,0,0,University College Dublin,Usage of Omics Technology for Identification of Critical Mediators and Pathways in Patients with Hidradenitis Suppurativa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001566-28,0,0,0 2016-001567-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,Efficacy of single dose intranasal dexmedetomidine for conscious sedation in dental practice in dentophobic uncooperative patients with intellectual disability.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001567-37,0,0,0 2016-001568-12,1,2017-05-31,2017-05-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dermapharm AG,"A multi-centre, randomised, double-blind, parallel-group phase III study to investigate the efficacy, safety, and tolerability of a generic calcipotriol-betamethasone ointment formulation compared to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001568-12,0,0,0 2016-001569-97,1,2021-12-08,2021-12-08,1,0,0,0,0,1,2,0,0,1,0,0,0,0,0,University Hospital Ghent,A phase II Investigation of Pembrolizumab (Keytruda) in combination with radiation and an immune modulatory cocktail in patients with cervical and uterine cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001569-97,0,0,0 2016-001575-71,2,2018-01-29,2018-01-29,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer, Inc.","A 15 WEEK, PHASE 2, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, FLEXIBLE DOSE STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH EARLY STAGE PARKINSON’S DISEA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001575-71,0,0,0 2016-001576-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU TOULOUSE,"Interest of Intra-nodal injection of gentamicin for the treatment of suppurated cat scratch disease’s lymphadenitis: a randomized controlled study. ""BIGG"" : Bartonellosis and intra-nodal injection of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001576-30,0,0,0 2016-001577-33,1,2022-01-24,2022-01-24,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Clínica Universidad de Navarra,Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients. Ensayo en fase I del virus DNX2401 para los gliomas difusos de protuberancia de nuevo diagnósti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001577-33,0,0,0 2016-001580-37,1,2019-06-07,2019-06-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical University of Vienna,Empagliflozin in Post-Transplantation Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001580-37,0,0,0 2016-001583-11,4,2019-02-22,2019-02-22,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,G1 Therapeutics,Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001583-11,0,0,0 2016-001584-36,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Universitetssjukhuset Örebro,"Is high oxygen concentration a riskfactor for postoperative complications? A prospective, randomized, singel blinded study in elderly patients undergoing vascular surgery Är hög syrgaskoncentratio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001584-36,0,0,0 2016-001585-29,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of Lumacaftor/Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis Who Have an A455E-CFTR Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001585-29,0,0,0 2016-001586-87,1,2018-08-28,2018-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Resolve Therapeutics, LLC","A Phase 2, Double Blind, Placebo Controlled Study of RSLV-132 in Subjects with Primary Sjogren’s Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001586-87,0,0,0 2016-001590-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Manuel Macía Cortiñas,Comparison of two protocols of controlled ovarian stimulation with highly purified menotropin in low-responder patients according to Bologna criteria treated in Spanish public hospitals. Comparació...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001590-32,0,0,0 2016-001591-30,1,2019-06-06,2019-06-06,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Odense University Hospital,"Treatment of congenital nephrogenic diabetes insipidus with a guanylate cyclase stimulator, riociguat or a phosphodiesterase type 5 inhibitor, sildenafil Behandling af medfødt nefrogen diabetes ins...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001591-30,0,0,0 2016-001593-15,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau,"A Multi-center, Randomized, Double blind, Prospective Study to Evaluate the Efficacy and Safety of high induction doses of adalimumab in moderate to severe psoriasis patients. The DEEP study. Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001593-15,0,0,0 2016-001596-75,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Parc Taulí,"Multicentre controlled, randomized clinical trial to compare the efficacy and safety of ambulatory treatment of mild acute diverticulitis without antibiotics with the standard treatment with antibiot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001596-75,0,0,0 2016-001597-15,1,2019-12-27,2019-12-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Erasmus MC cancer institute,"Influence of a fatty beverage (Milk) on the absorption of erlotinib: a randomized, cross-over pharmacokinetic study (MERLOT-study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001597-15,0,0,0 2016-001598-33,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,SOFAR S.P.A.,"Comparison of two methods for in vivo diagnosis of Helicobacter pylori infection, by means of a tablet of 13C-Urea. Confronto di due metodiche per la diagnosi in vivo dell’infezione da Helicobacter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001598-33,0,0,0 2016-001599-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis,Ipilimumab and Nivolumab in the Treatment of malignant Pleural Mesothelioma: a Phase II study Ipilimumab en Nivolumab bij de behandeling van maligne pleuraal mesothelioom: een fase II studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001599-31,0,0,0 2016-001600-40,1,2020-03-04,2020-03-04,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Clínica Universidad de Navarra,Phase II randomized trial of DNX-2401 oncolytic adenovirus added to standard of care for newly diagnosed glioblastoma Estudio randomizado Fase II del adenovirus oncolítico DNX-2401 añadido al trata...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001600-40,0,0,0 2016-001603-23,1,2019-01-20,2019-01-20,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Clermont-Ferrand,. Administration individualisée de sufentanil guidée sur la mesure de Analgesia Nociception Index (ANI) par rapport au standard de soin en chirurgie abdominale majeure : étude randomisée contrôlée ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001603-23,0,0,0 2016-001604-28,5,2021-08-11,2021-08-12,2,1,0,1,0,0,1,0,0,2,1,0,0,0,1,Merck KGaA,"A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare Tepotinib(MSC2156119J) Combined with Gefitinib Versus Chemotherapy as Second-line Treatment in Subjects with MET Positive, Locally Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001604-28,1,0,0 2016-001604-28,5,2021-08-11,2021-08-12,2,1,0,1,0,0,1,0,0,2,1,0,0,0,1,MERCK KGAA,"A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare Tepotinib(MSC2156119J) Combined with Gefitinib Versus Chemotherapy as Second-line Treatment in Subjects with MET Positive, Locally Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001604-28,1,0,0 2016-001606-42,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,VALEAS SPA - INDUSTRIA CHIMICA E FARMACEUTICA,"EXPLORATIVE, RANDOMIZED, PLACEBO CONTROLLED STUDY FOR THE CLINICAL EVALUATION OF PIDOTIMOD IN FEMALE PATIENTS WITH RECURRENT, UNCOMPLICATED URINARY TRACT INFECTIONS. STUDIO ESPLORATIVO, RANDOMIZZAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001606-42,0,0,0 2016-001607-23,7,2020-08-26,2020-08-26,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age with Uncontrolled Persistent Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001607-23,1,1,0 2016-001611-20,1,2021-01-30,2021-01-30,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,University of Tübingen,Pathophysiology-based therapy of epileptic encephalopathies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001611-20,0,0,0 2016-001614-16,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,INSTITUT CLAUDIUS REGAUD,A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab (Medi4736) for patients with recurrent glioblastoma. Essai...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001614-16,0,0,0 2016-001615-21,3,2018-08-16,2018-11-22,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety of PF-06252616 in Boys with Duchenne Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001615-21,0,0,0 2016-001615-21,3,2018-08-16,2018-11-22,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Pfizer Inc.,"A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety of PF-06252616 in Boys with Duchenne Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001615-21,0,0,0 2016-001618-18,1,2022-01-27,2022-01-27,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,CHU Toulouse,STAR Comparison of two STrategies of glucocorticoid withdrawal in rheumatoid Arthritis patients in low disease activity or Remission STAR: Comparaison de deux stratégies de sevrage en corticoïdes ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001618-18,0,0,0 2016-001619-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,UMC Utrecht,Genistein as an add-on treatment for CF?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001619-19,0,0,0 2016-001627-31,6,2021-05-06,2021-05-06,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Sumitomo Dainippon Pharma Oncology, Inc.","A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001627-31,1,0,0 2016-001627-31,6,2021-05-06,2021-05-06,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"BOSTON BIOMEDICAL, INC.","A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001627-31,1,0,0 2016-001627-31,6,2021-05-06,2021-05-06,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Boston Biomedical, Inc.","A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001627-31,1,0,0 2016-001628-72,1,2021-12-27,2021-12-27,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Medical Center - University of Freiburg,Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients Altersadaptierte Hochdosistherapie gefolgt von autologer Stammzelltransplant...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001628-72,0,0,0 2016-001631-12,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,CSL Behring KK,Prospective open-label single-arm study of the pharmacokinetics and safety of intravenous IgPro10 in Japanese subjects with primary immunodeficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001631-12,0,1,1 2016-001634-10,7,2021-03-18,2021-07-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001634-10,0,0,0 2016-001634-10,7,2021-03-18,2021-07-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001634-10,0,0,0 2016-001635-12,4,2019-07-01,2019-11-20,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001635-12,0,0,0 2016-001635-12,4,2019-07-01,2019-11-20,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001635-12,0,0,0 2016-001637-27,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,South London and Maudsley NHS Foundation Trust,A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001637-27,0,0,0 2016-001637-27,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King's College London,A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001637-27,0,0,0 2016-001638-84,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Meander Medical Center,Thiopurines with Low Dose Allopurinol: a prospective one way cross-over study Thiopurines gecombineerd met een lage dosering allopurinol: een prospectieve one way cross-over studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001638-84,0,0,0 2016-001641-79,1,2017-03-30,2017-03-30,1,0,1,0,0,0,2,0,0,1,1,1,1,0,1,Janssen-Cilag International NV,"A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, Viral Kinetics, and Pharmacokinetics of Orally Administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001641-79,0,0,0 2016-001642-26,2,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,0,"Leuven Research & Development (LRD) at University of Leuven, Belgium",STREAM-2 (STrategic Reperfusion in elderly patients Early After Myocardial Infarction),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001642-26,0,0,0 2016-001643-39,11,,,0,1,0,0,0,0,0,0,0,2,0,0,0,0,1,"Astellas Pharma Global Development, Inc. (APGD)","A Phase 2 Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001643-39,0,0,0 2016-001643-39,11,,,0,1,0,0,0,0,0,0,0,2,0,0,0,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.","A Phase 2 Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001643-39,0,0,0 2016-001643-39,11,,,0,1,0,0,0,0,0,0,0,2,0,0,0,0,1,"Astellas Pharma Global Development, Inc.","A Phase 2 Multicenter, Randomized, Double-Blind, Placebo- Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001643-39,0,0,0 2016-001644-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,National University of ireland Galway,A Randomised Placebo Controlled Trial of the effectiveness of Early MEtformin in Addition to Usual Care in the Reduction of Gestational Diabetes Mellitus Effects (EMERGE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001644-19,0,0,0 2016-001645-64,10,2021-10-07,2022-03-11,7,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001645-64,1,0,0 2016-001645-64,10,2021-10-07,2022-03-11,7,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001645-64,1,0,0 2016-001646-25,5,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ViiV Healthcare UK Limited,"A Phase III, Randomized, Multicenter, Parallel-group, Open- Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001646-25,0,0,0 2016-001646-25,5,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,VIIV HEALTHCARE UK LIMITED,"A Phase III, Randomized, Multicenter, Parallel-group, Open- Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001646-25,0,0,0 2016-001646-25,5,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"ViiV Healthcare, S.L.","A Phase III, Randomized, Multicenter, Parallel-group, Open- Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001646-25,0,0,0 2016-001647-39,4,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,VIIV HEALTHCARE UK LIMITED,"A Phase III, randomized, multicenter, parallel-group, noninferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting rilpiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001647-39,0,0,0 2016-001647-39,4,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ViiV Healthcare UK Limited,"A Phase III, randomized, multicenter, parallel-group, noninferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting rilpiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001647-39,0,0,0 2016-001647-39,4,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"ViiV Healthcare, S.L.","A Phase III, randomized, multicenter, parallel-group, noninferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting rilpiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001647-39,0,0,0 2016-001651-49,14,2018-05-25,2018-05-25,11,1,1,0,0,0,2,0,0,2,0,0,0,0,1,Ablynx NV,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose Ranging Study of ALX-0171 in Infants and Young Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001651-49,1,1,0 2016-001653-40,7,2018-10-16,2018-10-16,5,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Janssen-Cilag International NV,"A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered ALS-008176 Regim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001653-40,0,0,0 2016-001654-18,8,2019-11-04,2020-04-28,7,1,1,0,0,1,3,0,0,1,1,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys with Duchenne Muscular Dystrophy Étude randomisée, en doubl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001654-18,0,0,0 2016-001654-18,8,2019-11-04,2020-04-28,7,1,1,0,0,1,3,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys with Duchenne Muscular Dystrophy Étude randomisée, en doubl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001654-18,0,0,0 2016-001654-18,8,2019-11-04,2020-04-28,7,1,1,0,0,1,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys with Duchenne Muscular Dystrophy Étude randomisée, en doubl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001654-18,0,0,0 2016-001655-44,1,2020-12-31,2020-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,TAYS Sydänsairaala,Statiinien käyttö ja eteisvärinän esiintyvyys sydänleikkauksen jälkeen Statiinien käyttö ja eteisvärinän esiintyvyys sydänleikkauksen jälkeen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001655-44,0,0,0 2016-001656-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Ziekenhuis Oost Limburg,The utility of liposomal bupivacaine for anesthesia and analgesia in patients treated with collagenase for the release of Dupuytren’s contracture: A randomized controlled trial. Gebruik van liposo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001656-22,0,0,0 2016-001657-41,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination with Azacitidine in Subjects with Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001657-41,0,0,0 2016-001658-16,3,2017-08-24,2019-10-02,2,1,0,1,0,0,1,0,0,1,1,1,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 1 Dose Escalation and Phase 2 Randomized, Open-Label Study of Nivolumab and Veliparib in Combination with Platinum Doublet Chemotherapy in Subjects with Metastatic or Advanced Non-Small Cell L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001658-16,0,0,0 2016-001659-32,4,2019-06-27,2019-07-26,2,0,0,1,0,0,1,0,0,2,1,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001659-32,1,0,0 2016-001661-91,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,F. Hoffmann-La Roche AG,Open-label Comparative Randomized Study of the Efficacy and Safety of Orlistat (Xenical) in Complex Therapy of Obesity and Metabolic Disorders in Adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001661-91,0,1,1 2016-001663-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Erasmus MC, Department of Dermatology",Cost-effectiveness of adalimumab with adjuvant surgery versus adalimumab monotherapy in the treatment of hidradenitis suppurativa. Kosteneffectiviteit van adalimumab met adjuvante chirurgie versus ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001663-36,0,0,0 2016-001668-13,6,2018-09-13,2018-11-15,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,GE Healthcare Ltd.,"Parallel-Group, Placebo-Controlled Randomized Study Investigating the Effect of Intravenous Iso-osmolar Iodinated Contrast Material Iodixanol (Visipaque™ Injection 320 mgI/mL) on Renal Function in Adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001668-13,0,0,0 2016-001668-13,6,2018-09-13,2018-11-15,5,1,0,0,0,0,4,0,0,1,1,0,1,0,1,GE Healthcare Ltd. and its Affiliates,"Parallel-Group, Placebo-Controlled Randomized Study Investigating the Effect of Intravenous Iso-osmolar Iodinated Contrast Material Iodixanol (Visipaque™ Injection 320 mgI/mL) on Renal Function in Adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001668-13,0,0,0 2016-001671-79,1,2022-06-02,2022-06-02,1,0,0,0,0,0,4,0,0,1,0,0,0,0,1,Novartis Pharma GmbH,"A randomized, multicenter 28 week study to compare the efficacy and safety of combining Cosentyx (Secukinumab) (4-weekly, 300 mg s.c.) with a lifestyle intervention to Cosentyx therapy alone in adult ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001671-79,0,0,0 2016-001673-32,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),PREVENTION OF POSTOPERATIVE PANCREATIC FISTULA BY SOMATOSTATIN (PREFIPS) PREVENTION DES FISTULES PANCREATIQUES PAR LA SOMATOSTATINE (PREFIPS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001673-32,0,0,0 2016-001676-29,2,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,0,Oslo University Hospital (OUS),PROMO: A phase II study of Pembrolizumab in patients with Relapsed Or Metastatic Osteosarcoma not eligible for curative surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001676-29,0,0,0 2016-001676-29,2,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,0,OSLO UNIVERSITETSSYKEHUS HF,PROMO: A phase II study of Pembrolizumab in patients with Relapsed Or Metastatic Osteosarcoma not eligible for curative surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001676-29,0,0,0 2016-001677-33,14,2018-12-06,2018-12-06,12,1,1,0,0,0,2,0,1,1,0,0,1,0,1,"MedImmune, LLC","A Phase 2b Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001677-33,0,0,0 2016-001677-33,14,2018-12-06,2018-12-06,12,1,1,0,0,0,2,0,1,1,0,0,1,0,1,"MEDIMMUNE, LLC","A Phase 2b Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001677-33,0,0,0 2016-001680-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. José Maria Ruiz Moreno,"A prospective, non-randomised, multicenter study on the efficacy and safety of ILUVIEN® in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT) Estudi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001680-37,0,0,0 2016-001681-28,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Takeda Development Center Americas, Inc.","An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001681-28,0,0,0 2016-001681-28,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited","An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001681-28,0,0,0 2016-001684-36,6,2017-07-31,2017-07-31,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,PPM SERVICES S.A.,"A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF GED-0507-34-LEVO (GED0507) FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITIS Studio d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001684-36,0,0,0 2016-001684-36,6,2017-07-31,2017-07-31,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,PPM SERVICES SA,"A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF GED-0507-34-LEVO (GED0507) FOR TREATMENT OF SUBJECTS WITH ACTIVE ULCERATIVE COLITIS Studio d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001684-36,0,0,0 2016-001685-29,7,2019-11-12,2019-11-12,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging, Phase 2b Study of the Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of BMS-986231 in Hospit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001685-29,0,0,0 2016-001685-29,7,2019-11-12,2019-11-12,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging, Phase 2b Study of the Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of BMS-986231 in Hospit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001685-29,0,0,0 2016-001688-35,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, alone or in combination with Tremelimumab, in patients with advanced and relapsed germ cell tumors ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001688-35,0,0,0 2016-001690-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Eero Pekkonen,Apomorfiini-infuusiohoito edenneen Parkinsonin taudin hoidossa Apomorfiini-infuusiohoito edenneen Parkinsonin taudin hoidossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001690-33,0,0,0 2016-001692-67,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer Ensayo fase 1/2 aleatorizado de BMS-986012 en c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001692-67,0,0,0 2016-001693-15,1,,,0,1,0,0,1,0,4,0,0,1,0,0,0,1,0,INSTITUTO DE INVESTIGACIÓN SANITARIA LA FE,Individualized Pneumoperitoneum Pressure in Colorectal laparoscopic surgery versus standard therapy (IPPCollapse II) Presión individualizada de insuflación del pneumoperitoneo en cirugía laparoscóp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001693-15,0,0,0 2016-001694-32,13,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.",A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001694-32,0,0,0 2016-001694-32,13,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Astellas Pharma Global Development, Inc.",A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001694-32,0,0,0 2016-001696-79,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Khondrion BV,"A double-blind, randomized, placebo-controlled, single-center, two-way cross-over study with KH176 in patients with the mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation and clinical signs of mitochon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001696-79,0,0,0 2016-001706-42,1,2017-03-01,2017-03-01,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Celgene Corporation,"A Phase 2, Open-Label, Multiple Cohort, Single-Arm, Multi-Center Trial To Determine The Safety, Feasibility, And Efficacy Of JCAR015 In Adult Subjects With B-Cell Acute Lymphoblastic Leukemia Ensay...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001706-42,0,0,0 2016-001714-14,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.,"Clinical evaluation of switching to Lithiofor® (Lithium Sulphate Slow –Release, Li-SR tablets) from Carbolithium® (Lithium Carbonate Immediate-Release, Li-IR, capsules) in Bipolar patients, poorly tol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001714-14,0,0,0 2016-001715-21,1,2019-01-29,2019-01-29,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,UZ Leuven,"Intravenous ketamine for Treatment Resistant Depression: Exploring biomarkers of response and relapse A double-blind, randomized controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001715-21,0,0,0 2016-001716-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IVI BILBAO,Influence instillation plasma rich in growth factors in endometrial cavity Influencia de la instilación de Plasma Rico en Factores de Crecimiento en cavidad endometrial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001716-38,0,0,0 2016-001717-24,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,AstraZeneca AB,"Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vacc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001717-24,0,1,1 2016-001718-31,1,2019-06-27,2019-06-27,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"University of Oxford, CTRG","A Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium falciparum malaria vaccine candidate RH5.1/AS01",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001718-31,0,0,0 2016-001719-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Uppsala University,"Selecitve progesterone receptor modulators for treatment of premenstrual dysphoric disorder. A randomized, double-blind, placebo controlled study. Selektiv progesteronreceptor-modulerare för behand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001719-19,0,0,0 2016-001736-35,1,2019-09-04,2019-09-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ObsEva SA,"A randomized, double-blind, placebo-controlled, phase 2b dose-ranging study to assess the efficacy and safety of OBE2109 in subjects with endometriosis associated pain.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001736-35,0,0,0 2016-001737-27,12,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Janssen-Cilag International N.V.,"A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001737-27,0,0,0 2016-001737-27,12,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001737-27,0,0,0 2016-001754-18,7,,,0,0,0,1,0,1,1,0,0,2,1,0,0,0,1,Sun Pharma Advanced Research Company (SPARC) Limited,"A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001754-18,0,0,0 2016-001754-18,7,,,0,0,0,1,0,1,1,0,0,2,1,0,0,0,1,Sun Pharma Advanced Research Company Ltd.,"A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001754-18,0,0,0 2016-001755-45,2,2017-09-26,2017-09-26,1,0,0,0,0,0,2,0,0,1,1,0,1,0,1,"Mateon Therapeutics, Inc.","FOCUS: A Multicenter, Multinational, Double-blind, 2-Arm, Randomized, Phase 2/3, Study of Physician’s Choice Chemotherapy (PCC) (Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevaci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001755-45,0,0,0 2016-001758-17,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King's College London,Effect of Lixisenatide on arterial stiffness in patients with diabetic nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001758-17,0,0,0 2016-001758-17,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Guy's and St Thomas' NHS Foundation Trust,Effect of Lixisenatide on arterial stiffness in patients with diabetic nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001758-17,0,0,0 2016-001760-10,1,2021-10-19,2021-10-19,1,1,0,0,0,1,2,0,0,1,0,0,0,0,0,AGMT gGmbH,Phase II single-arm “window-of-opportunity” study of a combination of obinutuzumab (GA-101) and venetoclax (ABT-199) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001760-10,0,0,0 2016-001762-29,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,SUNOVION PHARMACEUTICALS,"A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects with Parkinson’s Disease Complicated by Motor Fluctuations ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001762-29,0,0,0 2016-001764-11,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,"PTC Therapeutics, Inc.","A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001764-11,0,1,1 2016-001767-37,9,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Astellas Pharma Global Development Inc.,"A Phase 3, Double blind, Randomized, Multicenter, Parallel Group, Placebo controlled Sequential Dose Titration Study to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Pediatric Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001767-37,0,0,0 2016-001767-37,9,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.","A Phase 3, Double blind, Randomized, Multicenter, Parallel Group, Placebo controlled Sequential Dose Titration Study to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Pediatric Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001767-37,0,0,0 2016-001772-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO,"Clinical burden of anemia in inflammatory bowel disease: Role of Iron Deficiency And iron Replacement Therapy, therapeutic trial Impatto clinico dell’anemia nelle malattie infiammatorie intestinali...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001772-30,0,0,0 2016-001774-15,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,OSPEDALE SAN RAFFAELE,THE ROLE OF 18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS IL RUOLO DELLA TECNICA DI IMAGING TC/PET CON 18F-FAZA NELLA IDENTIFICAZIONE DELLE META...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001774-15,0,0,0 2016-001777-33,1,2018-08-02,2018-08-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Charité Universitätsmedizin Berlin,EVALUATION OF CEREBRAL THROMBOEMBOLISM AFTER TAVR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001777-33,0,0,0 2016-001779-54,1,2021-07-22,2021-07-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama),A multicenter phase II trial to evaluate the efficacy and safety of pembrolizumab and gemcitabine in patients with HER2-negative Advanced Breast Cancer (ABC). “PANGEA-Breast” Ensayo multicéntrico f...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001779-54,0,0,0 2016-001783-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",Assessment of Ramucirumab plus paclitaxel as switch MANteInance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: th...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001783-12,0,0,0 2016-001784-36,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Rheinische Friedrich-Wilhelms-Universität Bonn,Multicentre prospective trial for extracranial malignant germ cell tumours including a randomized comparison of Carboplatin and Cisplatin Multizentrische prospektive Studie zu einem randomisierten ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001784-36,0,0,0 2016-001785-29,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,St. Vincent's University Hospital,Combined Effect of CFTR Modifiers and Intensive Antibiotic Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001785-29,0,0,0 2016-001787-10,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Instituto Grifols S.A.,"Effects of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with ""Acute-On-Chronic Liver Failure"" (ACLF) at High Risk of Hospital Efectos del recambio plasmá...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001787-10,0,0,0 2016-001787-10,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"INSTITUTO GRIFOLS, S.A.","Effects of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with ""Acute-On-Chronic Liver Failure"" (ACLF) at High Risk of Hospital Efectos del recambio plasmá...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001787-10,0,0,0 2016-001788-34,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Center for Translational and Clinical Research (CTC-A),"Prospective, randomized study concerning personalized medicine with Pentaglobin® after interventional infectious source control in peritonitis patients Prospektive, randomisierte Studie zur Persona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001788-34,0,0,0 2016-001788-34,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,"RWTH Aachen University, represented by the Rector, represented by the dean of the medical faculty","Prospective, randomized study concerning personalized medicine with Pentaglobin® after interventional infectious source control in peritonitis patients Prospektive, randomisierte Studie zur Persona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001788-34,0,0,0 2016-001789-28,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Instituto Grifols S.A.,Prevention of Mortality with Long-Term Administration of Human Albumin in Subjects with Decompensated Cirrhosis and Ascites,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001789-28,0,0,0 2016-001789-28,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"INSTITUTO GRIFOLS, S.A.",Prevention of Mortality with Long-Term Administration of Human Albumin in Subjects with Decompensated Cirrhosis and Ascites,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001789-28,0,0,0 2016-001790-33,1,2018-07-27,2018-07-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Ghent,"A PHASE II, SINGLE-CENTRE, PROSPECTIVE EXPLORATORY TRIAL TO ASSESS THE EFFICACY OF LANREOTIDE AUTOGEL 120 MG IN THE SYMPTOMATIC TREATMENT OF ACUTE RADIATION INDUCED DIARRHEA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001790-33,0,0,0 2016-001793-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,LactoResearch sprl,PROSPECTIVE STUDY OF THE EFFICIENCY OF PROBIOTIC MIXTURE TO IMPROVE LACTOSE DIGESTION AND SYMPTOMS OF LACTOSE INTOLERANCE ETUDE PROSPECTIVE DE L’EFFICACITE D’UN MELANGE PROBIOTIQUE POUR L’AMELIORAT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001793-15,0,0,0 2016-001794-32,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,"A Phase II, Multicenter, Non Randomized, Open Label Study of Nivolumab In Recurrent and/or Metastatic Salivary Gland Carcinoma of the Head and Neck.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001794-32,0,0,0 2016-001795-30,11,2018-09-10,2018-10-26,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Daiichi Sankyo, Inc.",Evaluation of Edoxaban in Anticoagulant Naïve Patients with Non-Valvular Atrial Fibrillation (NVAF) and high Creatinine Clearance,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001795-30,0,0,0 2016-001797-15,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"VU University Medical Center, Department of Medical Oncology","A phase II/III study of high-dose, intermittent sunitinib in patients with recurrent glioblastoma multiforme Een fase II/III studie met intermitterend, hoge dosis sunitinib bij patiënten met een re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001797-15,0,0,0 2016-001800-49,2,2019-03-22,2019-03-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients with Type 2 Diabetes Mellitus Who ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001800-49,0,0,0 2016-001800-49,2,2019-03-22,2019-03-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis Recherche & Développement,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients with Type 2 Diabetes Mellitus Who ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001800-49,0,0,0 2016-001801-17,3,2019-09-06,2019-09-06,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin compared to Glimepiride or Place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001801-17,0,0,0 2016-001801-17,3,2019-09-06,2019-09-06,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & développement,"A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin compared to Glimepiride or Place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001801-17,0,0,0 2016-001803-22,8,2019-05-07,2019-05-16,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin compared to Empagliflozin, and Placebo in Patients with Type 2 Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001803-22,0,0,0 2016-001803-22,8,2019-05-07,2019-05-16,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT,"A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin compared to Empagliflozin, and Placebo in Patients with Type 2 Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001803-22,0,0,0 2016-001803-22,8,2019-05-07,2019-05-16,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin compared to Empagliflozin, and Placebo in Patients with Type 2 Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001803-22,0,0,0 2016-001804-43,5,2019-09-27,2019-09-27,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-aventis Recherche & Développement,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glyc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001804-43,0,0,0 2016-001804-43,5,2019-09-27,2019-09-27,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glyc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001804-43,0,0,0 2016-001805-18,1,2018-05-16,2018-05-16,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,NBMI Science AB,"A randomised, placebo-controlled, blinded, cross-over, pilot study to explore safety and efficacy of NBMI treatment of patients with mild, moderate and severe Chronic Obstructive Pulmonary Disease (CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001805-18,0,0,0 2016-001806-40,2,2018-10-25,2018-10-25,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Taiho Oncology, Inc.","A Randomized, Open-Label, Multi-Center, International Phase 2 Study of TAS-114 in Combination with S-1 in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001806-40,0,0,0 2016-001807-22,1,,,0,0,0,0,0,0,2,0,1,4,0,0,0,0,0,uh Montpellier,Modalities of vitamin D supplementation and the risk of hypercalcemia in children aged 2 to 6 years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001807-22,0,0,0 2016-001809-16,1,2018-03-20,2018-03-20,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,Efficacy and safety of chlorthalidone 25 mg in hypertensive patients. Αποτελεσματικότητα και ασφάλεια της δόσης 25 mg χλωρθαλιδόνης σε υπερτασικούς ασθενείς.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001809-16,0,0,0 2016-001812-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitario Vall d'Hebron,"Acute uncomplicated diverticulitis: prospective, controlled, randomized, multicenter clinical trial of non-antibiotic outpatient treatment (TASDA trial). Diverticulitis aguda no complicada: ensayo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001812-39,0,0,0 2016-001815-19,2,2020-07-03,2020-07-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Deutsches Krebsforschungszentrum (DKFZ), Stiftung des öffentlichen Rechts","An open-label, single-arm, rater-blinded, multicenter phase 1/2 study to assess safety and diagnostic accuracy and radiotherapeutic implications of pre-operative Ga-68-PSMA-11 PET/CT imaging in compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001815-19,0,0,0 2016-001816-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,GORTEC,Phase III randomized trial comparating concomittant administration of radiotherapy with cisplatin versus radiotherapy only for treatment of sinuses tumors and salivary glands Essai de Phase III ran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001816-39,0,0,0 2016-001823-30,3,2021-06-18,2021-06-18,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,SIFI SpA,"Randomized, Assessor-Masked, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Comparison with 0.02% PHM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001823-30,1,0,0 2016-001823-30,3,2021-06-18,2021-06-18,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,SOCIETÀ INDUSTRIA FARMACEUTICA ITALIANA (SIFI) SPA,"Randomized, Assessor-Masked, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Comparison with 0.02% PHM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001823-30,1,0,0 2016-001825-15,10,2018-12-17,2018-12-17,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, New York",A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULATIO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001825-15,0,0,0 2016-001825-15,10,2018-12-17,2018-12-17,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,PFIZER INC,A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULATIO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001825-15,0,0,0 2016-001825-15,10,2018-12-17,2018-12-17,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc.,A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULATIO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001825-15,0,0,0 2016-001826-33,3,2019-11-20,2019-11-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NoNO Inc.,"A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects with Acute Ischemic Stroke Underg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001826-33,0,0,0 2016-001828-56,1,2017-05-30,2017-05-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,National Institute for Health and Welfare,"Rahapeliriippuvuuden hoitaminen nopeasti vaikuttavalla opioidinsalpaajalla (naloksonia sisältävä nenäsumute), tutkijalähtöinen tutkimus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001828-56,0,0,0 2016-001830-91,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,3,Health Clinics Limited,"A NON RANDOMISED, NON BLINDED REAL WORLD STUDY OF THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF METABOLIC MEDICINES FOR THE TREATMENT OF CANCER COMPARED AGAINST HISTORICAL CONTROLS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001830-91,0,0,0 2016-001831-10,3,2017-08-08,2017-08-08,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"An open-label, single arm, repeat dose, multi-centre study to evaluate the use of a safety syringe for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma (Study...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001831-10,1,1,0 2016-001832-36,4,2017-11-27,2017-11-30,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"An open-label, single arm, repeat dose, multi-centre study to evaluate the use of an autoinjector for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma (Study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001832-36,1,1,0 2016-001833-29,4,2019-06-17,2019-06-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and effi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001833-29,0,0,0 2016-001834-82,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001834-82,0,0,0 2016-001835-11,4,2020-01-29,2020-01-29,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (Master Protocol Revised version 02 dated 27-Jul-2016 + Sub-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001835-11,0,0,0 2016-001835-11,4,2020-01-29,2020-01-29,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (Master Protocol Revised version 02 dated 27-Jul-2016 + Sub-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001835-11,0,0,0 2016-001839-13,1,2017-09-09,2017-09-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Ghent University Hospital,"Influence of a bolus administration of ephedrine and phenylephrine on spinal oxygen saturation, measured with NIRS. Invloed van een bolustoediening van ephedrine en phenylephrine op het zuurstofgeh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001839-13,0,0,0 2016-001840-20,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,Novartis Pharmaceuticals Corporation,"A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001840-20,0,1,1 2016-001841-23,1,2020-03-12,2020-03-12,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,Banc de Sang i Teixits,"A multicenter, randomized, open-label, two-arms phase I/II clinical trial to asses efficacy and safety of cord blood eye drops in neurotrophic keratopathy Estudio clínico de fase I/II, multicéntric...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001841-23,0,0,0 2016-001846-24,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,Antwerp University Hospital,"Metabolism of Isotonic versus Hypotonic Maintenance Solutions in fasting healthy Adults (MIHMoSA), a Single-Blind Randomized Crossover Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001846-24,0,0,0 2016-001848-20,4,2021-12-31,2022-04-29,3,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Nordic Society of Gynaecological Oncology (NSGO)-CTU,"A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001848-20,1,0,0 2016-001848-20,4,2021-12-31,2022-04-29,3,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Nordic Society of Gynaecological Oncology (NSGO)-Clinical Trial Unit,"A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001848-20,1,0,0 2016-001848-20,4,2021-12-31,2022-04-29,3,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU),"A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001848-20,1,0,0 2016-001848-20,4,2021-12-31,2022-04-29,3,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Nordic Society of Gynaecological Oncology (NSGO),"A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001848-20,1,0,0 2016-001849-15,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,IFCT,"A PHASE II PROSPECTIVE IMMUNE NEOADJUVANT THERAPY STUDY OF DURVALUMAB (MEDI4736) IN EARLY STAGE NON-SMALL CELL LUNG CANCER Etude de phase II évaluant une immunothérapie néoadjuvante, le durvalumab,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001849-15,0,0,0 2016-001850-16,1,2017-02-08,2017-02-08,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,"University of Copenhagen, The Novo Nordisk Foundation Center For Basic Metabolic Research, Section of Metabolic Genetic","Studies of interplays between insulin resistance associated with immunosuppression and the gut and saliva microbiota composition of young, healthy men Undersøgelse af sammenspillet mellem insulinre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001850-16,0,0,0 2016-001852-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,"A feasibility study of niraparib for advanced, BRCA1-like, HER2-negative breast cancer patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001852-23,0,0,0 2016-001853-41,1,2019-04-05,2019-04-05,1,0,0,0,0,1,3,0,0,1,1,1,1,0,0,Academic Medical Center,Intensive endoscopic therapy versus conventional treatment for untreated benign anastomotic strictures after esophagectomy: a pilot and randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001853-41,0,0,0 2016-001857-42,3,2020-09-07,2020-09-07,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,sanofi-aventis recherche & développement,"A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001857-42,1,0,0 2016-001857-42,3,2020-09-07,2020-09-07,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Hanmi Pharmaceutical Co., Ltd.","A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001857-42,1,0,0 2016-001859-43,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001859-43,0,0,0 2016-001859-43,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001859-43,0,0,0 2016-001860-12,4,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,NOVARTIS PHARMA SERVICES AG,"A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001860-12,0,0,0 2016-001860-12,4,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001860-12,0,0,0 2016-001860-12,4,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001860-12,0,0,0 2016-001860-12,4,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001860-12,0,0,0 2016-001863-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Universitätsklinik für Klinische Pharmakologie, Medizinische Universität Wien",Effects of Tromethamine on Cerebral Oxygenation and Metabolism in Patients Suffering Intractable Intracranial Hypertension – an exploratory study. Der Effekt von Tromethamine auf die zerebrale Oxy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001863-35,0,0,0 2016-001864-12,2,2018-07-23,2018-07-23,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,IRCCS - Istituto di Ricerche Farmacologiche Mario Negri,"An international, multicenter, phase II, randomized, parallel-arm trial investigating the role of two different metronomic chemotherapy regimens in locally advanced or metastatic triple negative breas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001864-12,0,0,0 2016-001864-12,2,2018-07-23,2018-07-23,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,"An international, multicenter, phase II, randomized, parallel-arm trial investigating the role of two different metronomic chemotherapy regimens in locally advanced or metastatic triple negative breas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001864-12,0,0,0 2016-001865-99,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Catharina Ziekenhuis,"Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone: a multicentre, open-label, parallel-group, phase II-III, randomised superiori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001865-99,0,0,0 2016-001867-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,TikoMed AB,"Open, Randomized, Active Comparator-controlled, Multi-Center Study to Evaluate Safety and Efficacy of IBsolvMIR® in Islet Transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001867-35,0,0,0 2016-001868-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Paoli Calmettes,"A prospective, multicentre, open-label, randomized, phase II study of Pembrolizumab in combination with neoadjuvante (F)EC-Paclitaxel regimen in HER2-negative inflammatory breast cancer. Etude de p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001868-11,0,0,0 2016-001875-57,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Erasmus University Medical Center Rotterdam,Desmopressin and FVIII concentrate combination treatment in non-severe hemophilia A patients undergoing minor interventions Desmopressine en FVIII-concentraat combinatiebehandeling in niet-ernstige...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001875-57,0,0,0 2016-001876-31,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King's College London,Feasibility of the safe withdrawal of inhaled corticosteroids in patients with mild to moderate COPD prescribed outside guidelines (SWAP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001876-31,0,0,0 2016-001876-31,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Guy's and St Thomas NHS Foundation Trust,Feasibility of the safe withdrawal of inhaled corticosteroids in patients with mild to moderate COPD prescribed outside guidelines (SWAP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001876-31,0,0,0 2016-001877-34,1,,,0,0,0,0,1,0,4,0,0,3,0,0,0,0,0,South London and Maudsley NHS Foundation Trust,Improving understanding of Heroin Overdose Testing: diamorphine dose-escalation testing in a treated population,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001877-34,0,0,0 2016-001877-34,1,,,0,0,0,0,1,0,4,0,0,3,0,0,0,0,0,King's College London,Improving understanding of Heroin Overdose Testing: diamorphine dose-escalation testing in a treated population,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001877-34,0,0,0 2016-001878-15,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,Eisai Medical Research Inc.,Single and Multiple Dose Pharmacokinetics and Safety Study of Rabeprazole Sodium in 12 to 16 Year Old Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001878-15,0,1,1 2016-001879-73,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,Eisai Medical Research Inc.,Safety and Efficacy of Rabeprazole in the Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001879-73,0,1,1 2016-001881-27,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001881-27,0,0,0 2016-001881-27,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001881-27,0,0,0 2016-001881-27,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Roche Farma S.A. que representa en España a F. Hoffmann-La Roche Ltd,"A phase III, multicenter, randomized, placebo-controlled, double-blind study of atezolizumab (anti-PD-L1 antibody) as adjuvant therapy in patients with renal cell carcinoma at high risk of developing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001881-27,0,0,0 2016-001883-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Herlev & Gentofte Hospital, Oncology Dept.","A PROSPECTIVE RANDOMIZED, OPEN-LABEL PHASE 2 STUDY OF IMMUNE CHECKPOINT INHIBITION, NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN COMBINATION WITH RADIATION THERAPY IN PRETREATED PATIENTS WITH METASTATIC PA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001883-12,0,0,0 2016-001885-27,5,2018-12-03,2018-12-03,5,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A MULTICENTER, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SUBCUTANEOUS AND/OR INTRAVENOUS PF-06741086 IN SUBJEC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001885-27,0,0,0 2016-001888-36,1,2021-02-28,2021-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Medica Scientia Innovation Research (MedSIR ARO),A phase II clinical trial of radium-223 activity in patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide bes...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001888-36,0,0,0 2016-001891-31,3,2017-07-10,2017-07-10,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SPRL,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinectics, and Pharmacodynamics of Bimekizumab in Adult subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001891-31,0,0,0 2016-001892-57,3,2018-09-25,2018-09-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SPRL,"A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects with Moderate to Se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001892-57,0,0,0 2016-001894-34,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,Eisai Inc.,"A Phase 1 Study of Eribulin Mesylate (E7389, IND #116,292), a Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (Excluding CNS), Including Lympho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001894-34,0,1,1 2016-001896-63,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,Eisai Medical Research Inc.,An Ascending Bioavailability of a New Oral Suspension of E3810,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001896-63,0,1,1 2016-001897-13,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,ITM SOLUCIN GMBH,"A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to target...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001897-13,0,0,0 2016-001897-13,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,ITM Solucin GmbH,"A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to target...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001897-13,0,0,0 2016-001898-32,2,2022-04-15,2022-04-15,1,1,1,0,0,0,2,0,1,2,0,0,0,0,1,Seqirus UK Limited,"A Phase 2, Randomized, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Several Doses of Antigen and MF59 Adjuvant Content in a Monovalent H5N1 Pandemic Influenza Vaccine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001898-32,1,1,0 2016-001900-47,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Maastricht University Medical Centre +,The effect of lidocaine infusion on ad libitum food intake and satiety in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001900-47,0,0,0 2016-001901-18,1,2022-01-07,2022-01-07,1,0,0,0,0,0,4,0,1,1,0,0,0,0,0,"The Danish National University Hospital ""Rigshospitalet""","Measles-mumps-rubella vaccine at 6 months of age, immunology, and childhood morbidity in a high-income setting Mæslinge-fåresyge-røde hunde-vaccine ved 6 måneders alderen, immunologi, og morbiditet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001901-18,0,0,0 2016-001906-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Royal College of Surgeons in Ireland,A randomised control trial of intra articular injectates in knee osteoarthritis: A comparison of corticosteroid (Methylprednisolone Acetate) and NSAID (Ketorolac tromethamine) injections,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001906-41,0,0,0 2016-001916-39,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,"A phase IV, single-blind, randomized, controlled, single-center study evaluating the efficacy of amoxicillin+clavulanic acid Vs no treatment in preventing complications after tooth extraction and the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001916-39,0,0,0 2016-001921-15,5,2020-03-30,2020-03-30,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"Randomised, double-blind, double-dummy, multicentre study to compare the efficacy and safety of once daily novel 4 mg budesonide suppository versus once daily 2 mg budesonide foam in patients with acu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001921-15,0,0,0 2016-001923-30,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,TRIALNET COORDINATING CENTER AT THE UNIVERSITY OF SOUTH FLORIDA,Exploring Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus Studio sugli effetti dell'insulina orale sul sistema immunitario nei famigliari a rischio di diabete melli...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001923-30,0,0,0 2016-001925-15,1,2021-08-30,2021-08-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Alcedis GmbH,"Evaluation of immunological effects of the RANKL-inhibitor Denosumab when administered concurrently with PD1-blocking antibodies (Nivolumab, Pembrolizumab) in patients with metastatic malignant melan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001925-15,0,0,0 2016-001928-54,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001928-54,0,0,0 2016-001928-54,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001928-54,0,0,0 2016-001930-93,1,2017-11-28,2017-11-28,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Generon (Shanghai) Corporation Ltd.,"A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001930-93,0,0,0 2016-001935-12,5,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,0,"Universitätsklinikum Schleswig-Holstein, Campus Kiel",AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001935-12,0,0,0 2016-001935-12,5,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,0,AIEOP- Associazione Italiana Ematologia Oncologia Pediatrica,AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001935-12,0,0,0 2016-001938-96,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Central Hospital,Treatment of Giardia lamblia infections in children: randomized open-labeled trial comparing rectal metronidazole with oral tinidazole Lasten Giardia lamblia infektion hoito,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001938-96,0,0,0 2016-001940-20,1,2017-03-26,2017-03-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Central Manchester University Hospitals NHS Foundation Trust,"A Pilot, Randomised, Unblinded, Feasibility, Safety, Biochemical and Physiological Efficacy Study of 20% vs 5% Human Albumin Solution for Fluid Bolus Therapy in Critically Ill Adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001940-20,0,0,0 2016-001941-26,2,2019-10-25,2019-10-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"Phase IIIb, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects with Previously Untreated Unresectable or Metastatic Melanoma Estudio fase IIIb, aleatori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001941-26,0,0,0 2016-001941-26,2,2019-10-25,2019-10-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"Phase IIIb, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects with Previously Untreated Unresectable or Metastatic Melanoma Estudio fase IIIb, aleatori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001941-26,0,0,0 2016-001948-19,4,2018-12-03,2018-12-03,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Primary Sj¿grens Syndrome Studio di Fase 3 Randomizz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001948-19,0,0,0 2016-001948-19,4,2018-12-03,2018-12-03,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Primary Sj¿grens Syndrome Studio di Fase 3 Randomizz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001948-19,0,0,0 2016-001950-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Isifer AB,"A randomized, double blind, controlled, parallel group, multi-centre phase II clinical study of lidocaine pertubation as a treatment for couples with unexplained infertility",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001950-16,0,0,0 2016-001955-29,8,2019-08-28,2019-12-04,7,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Retrophin, Inc.","Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), a Phosphopantothenate replacement therapy, in patients with Pantothenate Kinase-associated Neurodegeneration (PKAN): A Randomized, Dou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001955-29,0,0,0 2016-001955-29,8,2019-08-28,2019-12-04,7,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"RETROPHIN, INC","Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), a Phosphopantothenate replacement therapy, in patients with Pantothenate Kinase-associated Neurodegeneration (PKAN): A Randomized, Dou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001955-29,0,0,0 2016-001956-22,5,2022-03-18,2022-03-18,4,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Janssen-Cilag International N.V.,A Randomized Double-blind Pharmacokinetic study of Ustekinumab in Pediatric Subjects with Moderately to Severely Active Crohn's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001956-22,1,1,0 2016-001962-27,6,2018-08-13,2018-09-07,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001962-27,0,0,0 2016-001962-27,6,2018-08-13,2018-09-07,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Sanofi-aventis recherche & développement,Open-label Phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic Triple Negative Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001962-27,0,0,0 2016-001963-35,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc.,A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001963-35,0,1,1 2016-001964-13,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Sanofi Pasteur Korea Ltd,Regulatory Post-Marketing Surveillance (PMS) Study for AVAXIM 160U (Hepatitis A Vaccine),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001964-13,0,1,1 2016-001965-98,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,"Prolong Pharmaceuticals, LLC","A randomized and open-label dose-finding, phase 2, efficacy, safety, and pharmacokinetic study of once-per-cycle prophylactic injections of ANF-RHO™ versus pegfilgrastim (Neulasta®) in non-metastatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001965-98,0,0,0 2016-001966-27,8,2020-01-10,2020-01-10,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Archigen Biotech Limited,"A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001966-27,0,0,0 2016-001967-35,1,2018-09-26,2018-09-26,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,"Universitätsklinik für Dermatologie, Paracelsus medizinische Privatuniversität Salzburg","A double-blind, placebo-controlled cross-over study to assess the efficacy of topical calcipotriol (Psorcutan®-ointment containing 0.05 µg/g calcipotriol) to improve wound healing in dystrophic epider...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001967-35,0,0,0 2016-001971-61,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Radboudumc,The effects of acetylsalicylic acid on immunoparalysis following human endotoxemia. Het effect van acetylsalicylzuur op immuunparalyse na humane endotoxemie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001971-61,0,0,0 2016-001972-31,4,2018-12-07,2021-07-22,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer, Inc.","A Single Arm, Open Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001972-31,0,0,0 2016-001972-31,4,2018-12-07,2021-07-22,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A Single Arm, Open Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001972-31,0,0,0 2016-001972-31,4,2018-12-07,2021-07-22,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Medivation, Inc.","A Single Arm, Open Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001972-31,0,0,0 2016-001977-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Nîmes,"L-carnitine as an adjunct treatment for septic shock patients with acute kidney injury: a multicentre, randomized, 2-parallel group, superiority trial L-carnitine comme traitement complémentaire po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001977-34,0,0,0 2016-001979-70,12,2020-03-16,2020-03-16,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Inventiva S.A.,"A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001979-70,0,0,0 2016-001979-70,12,2020-03-16,2020-03-16,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Inventiva S.A.S,"A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001979-70,0,0,0 2016-001979-70,12,2020-03-16,2020-03-16,12,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PRM|PRM_DEFAULT,"A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001979-70,0,0,0 2016-001984-35,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Antoni van Leeuwenhoek ziekenhuis,Multicenter Phase 2 Study to Identify of the Optimal neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001984-35,0,0,0 2016-001984-35,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Antoni van leeuwenhoek ziekenhuis,Multicenter Phase 2 Study to Identify of the Optimal neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001984-35,0,0,0 2016-001984-35,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Antoni van Leeuwenhoek Hospital,Multicenter Phase 2 Study to Identify of the Optimal neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001984-35,0,0,0 2016-001987-12,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,SOCIETA' ITALIANA DI REUMATOLOGIA - SIR,"Open-label, randomized controlled trial comparing tocilizumab to anti-TNF treatment and discovery of biomarkers for treatment selection in rheumatoid arthritis patients with inadequate response to a f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001987-12,0,0,0 2016-001988-36,5,2020-07-03,2020-07-03,4,1,1,0,0,1,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A 24-month Multicenter, Open-label Phase II Trial Investigating the Safety and Efficacy of Repeated velmanase alfa (recombinant human alpha-mannosidase) Treatment in Pediatric Patients below 6 years o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001988-36,0,0,0 2016-001988-36,5,2020-07-03,2020-07-03,4,1,1,0,0,1,2,0,0,1,0,0,1,0,1,CHIESI FARMACEUTICI S.P.A.,"A 24-month Multicenter, Open-label Phase II Trial Investigating the Safety and Efficacy of Repeated velmanase alfa (recombinant human alpha-mannosidase) Treatment in Pediatric Patients below 6 years o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001988-36,0,0,0 2016-001989-29,2,2018-07-18,2018-07-18,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Ipsen Pharma SAS,"An International, Multicentre, Prospective, Single Arm Study to Assess the Effect on Voluntary Movements of AbobotulinumtoxinA 1500 U Administered in Both Upper and Lower Limbs in Conjunction with a G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001989-29,0,0,0 2016-001989-29,2,2018-07-18,2018-07-18,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Ipsen Pharma,"An International, Multicentre, Prospective, Single Arm Study to Assess the Effect on Voluntary Movements of AbobotulinumtoxinA 1500 U Administered in Both Upper and Lower Limbs in Conjunction with a G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001989-29,0,0,0 2016-001991-31,7,2020-10-13,2020-10-13,4,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Novartis Pharma AG,Expanded treatment protocol for relapsed/refractory pediatric/young adult acute lymphoblastic leukemia patients to be treated with CTL019.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001991-31,0,0,0 2016-001991-31,7,2020-10-13,2020-10-13,4,1,0,0,0,1,0,0,0,1,0,0,1,0,1,NOVARTIS PHARMA AG,Expanded treatment protocol for relapsed/refractory pediatric/young adult acute lymphoblastic leukemia patients to be treated with CTL019.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001991-31,0,0,0 2016-001991-31,7,2020-10-13,2020-10-13,4,1,0,0,0,1,0,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.",Expanded treatment protocol for relapsed/refractory pediatric/young adult acute lymphoblastic leukemia patients to be treated with CTL019.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001991-31,0,0,0 2016-002000-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACIÓ SANT JOAN DE DÉU,Open clinical trial phase IIa to study the isoniazid suspension absoption of 10mg/ml for the tuberculosis infection treatment in patients under the age of 6 Ensayo clínico abierto fase IIa de estud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002000-31,0,0,0 2016-002001-19,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VALL D'HEBRON INSTITUTE OF ONCOLOGY (VHIO),A phase II open-label study with the anti-PD-L1 Atezolizumab monoclonal antibody in combination with Bevacizumab in patients with advanced chemotherapy resistant colorectal cancer and MSI-like molecul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002001-19,0,0,0 2016-002001-19,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VHIO,A phase II open-label study with the anti-PD-L1 Atezolizumab monoclonal antibody in combination with Bevacizumab in patients with advanced chemotherapy resistant colorectal cancer and MSI-like molecul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002001-19,0,0,0 2016-002004-10,6,2020-10-13,2020-11-13,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Jazz Pharmaceuticals, Inc.","A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Under...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002004-10,0,0,0 2016-002005-19,2,2018-06-01,2018-06-01,1,1,0,0,0,0,3,0,0,2,1,0,0,0,1,vTv THERAPEUTICS LLC,"RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER REGISTRATION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TTP488 IN PATIENTS WITH MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002005-19,1,0,0 2016-002006-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI""",Study on Efficacy and safety of an early proactive Switch To ElvitegraviR/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in patients with a primary HIV-1 infection Study on Efficacy and...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002006-39,0,0,0 2016-002013-21,2,2019-06-18,2019-06-18,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Theracos Sub, LLC","A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin versus Glimepiride in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002013-21,0,0,0 2016-002014-52,1,2019-10-28,2019-10-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Medical Center Utrecht,DUAL HOMING MECHANISMS OF EOSINOPHILS TO THE SPUTUM; ONLY ONE OF WHICH IS SENSITIVE FOR MEPOLIZUMAB Duaal mechanisme verantwoordelijk voor het aantrekken van eosinofiele granulocyten naar de long; ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002014-52,0,0,0 2016-002015-17,1,2019-01-01,2019-01-01,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Odense University Hospital,Low-flow Low-gradient Aortic Stenosis – Diagnostic Usefullness of Ivabradine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002015-17,0,0,0 2016-002016-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboudumc,Neuroinflammation in cognitive decline post-cardiac surgery: the FOCUS study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002016-40,0,0,0 2016-002017-22,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002017-22,0,0,0 2016-002017-22,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002017-22,0,0,0 2016-002019-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Uppsala Clinical Research center,Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002019-16,0,0,0 2016-002021-11,3,2017-12-13,2017-12-21,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Luitpold Pharmaceuticals, Inc.","IRON CLAD: Can Iron Lessen Anemia Due to cancer and chemotherapy: A multicenter, randomized, double-blinded, controlled study to investigate the efficacy and safety of Injectafer® (ferric carboxymalto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002021-11,0,0,0 2016-002022-37,1,2018-02-06,2018-02-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) Delivered via a SelfDose™ Device in the Treatment of Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002022-37,0,0,0 2016-002025-11,14,,,0,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Alexion Pharmaceuticals Incorporated,"A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Na¿ve Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) STUDIO DI FASE 3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002025-11,0,0,0 2016-002025-11,14,,,0,1,0,0,0,1,3,0,0,2,1,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Na¿ve Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) STUDIO DI FASE 3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002025-11,0,0,0 2016-002025-11,14,,,0,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Alexion Pharmaceuticals Inc.,"A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Na¿ve Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) STUDIO DI FASE 3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002025-11,0,0,0 2016-002026-36,5,2022-04-08,2022-04-08,2,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Alexion Pharmaceuticals Incorporated,"A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002026-36,1,0,0 2016-002026-36,5,2022-04-08,2022-04-08,2,1,0,0,0,1,3,0,0,2,0,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002026-36,1,0,0 2016-002026-36,5,2022-04-08,2022-04-08,2,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Alexion Pharmaceuticals Inc.,"A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002026-36,1,0,0 2016-002027-29,8,,,0,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Alexion Pharmaceuticals Incorporated,Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Na¿ve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Studio a braccio singolo su ALXN1210 somministrato ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002027-29,0,0,0 2016-002027-29,8,,,0,1,1,0,0,1,3,0,0,2,0,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Na¿ve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Studio a braccio singolo su ALXN1210 somministrato ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002027-29,0,0,0 2016-002027-29,8,,,0,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Alexion Pharmaceuticals Inc.,Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Na¿ve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Studio a braccio singolo su ALXN1210 somministrato ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002027-29,0,0,0 2016-002029-12,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,ETOP (European Thoracic Oncology Platform),A randomised phase II trial of osimertinib and bevacizumab versus osimertinib alone as second-line treatment in stage IIIb-IVb NSCLC with confirmed EGFRm and T790M,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002029-12,0,0,0 2016-002032-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundacio Privada Clinic per a la Recerca Biomedica,Comparative study of the efficacy of oral versus intravenous hydration as a preventive measure of contrast-induced nephropathy (CIN) in patients with renal insufficiency (RI) grade III under study con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002032-33,0,0,0 2016-002033-30,7,2018-10-15,2018-10-25,4,0,0,0,0,0,3,0,0,2,1,0,0,0,1,NEURODERM LTD.,"A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of continuous subcutaneous ND0612 infusion Given as adju...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002033-30,1,0,0 2016-002033-30,7,2018-10-15,2018-10-25,4,0,0,0,0,0,3,0,0,2,1,0,0,0,1,NeuroDerm Ltd.,"A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of continuous subcutaneous ND0612 infusion Given as adju...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002033-30,1,0,0 2016-002035-15,1,2020-12-31,2020-12-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Helsinki University Central Hospital,"Outcome after total knee arthroplasty under general or spinal anesthesia, a randomized study Polven tekonivelleikkauspotilaan toipuminen yleisanestesian tai spinaalipuudutuksen jälkeen, satunnaiste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002035-15,0,0,0 2016-002036-32,10,2018-12-20,2018-12-20,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Medivation, Inc.","A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002036-32,1,0,0 2016-002036-32,10,2018-12-20,2018-12-20,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Pfizer Inc.,"A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002036-32,1,0,0 2016-002036-32,10,2018-12-20,2018-12-20,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Medivation, Inc. a wholly owned subsidiary of Pfizer Inc.","A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002036-32,1,0,0 2016-002036-32,10,2018-12-20,2018-12-20,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,MEDIVATION INC.,"A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002036-32,1,0,0 2016-002041-31,2,2016-11-11,2016-11-11,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Single-Arm, Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Patients with Locally Advanced or Metastatic Squamous Non-Small Cell Lu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002041-31,1,0,0 2016-002041-31,2,2016-11-11,2016-11-11,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Single-Arm, Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Patients with Locally Advanced or Metastatic Squamous Non-Small Cell Lu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002041-31,1,0,0 2016-002044-16,4,2020-03-12,2020-03-12,3,1,0,0,0,2,2,0,0,1,0,0,1,0,1,Amgen Inc.,A Phase 2/3 Multi-center Study of Evaluate the Safety and Efficacy of Blinatumomab in Subjects with Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002044-16,0,0,0 2016-002045-36,1,2019-04-20,2019-04-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"University of Oxford, Clinical Trials and Research Governance",Lifestyle induced weight loss and Liraglutide in the treatment of non-alcoholic steatohepatitis (NASH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002045-36,0,0,0 2016-002046-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Minna Honkila / OYS,Isotonic versus hypotonic intravenous fluids in hospitalised children - a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002046-23,0,0,0 2016-002048-18,1,2019-09-23,2019-09-23,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,UNIVERSIDAD REY JUAN CARLOS,"Clinical Trial to determine efficacy and safety of healing with platelet-rich plasma, fibrin and leukocytes compared to standard healing with nitrofurazone ointment in subjects with onychocryptosis. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002048-18,0,0,0 2016-002052-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,Continuous infusion versus intermittent administration of meropenem in critically ill patients. A multicenter randomized double blind trial. Continuous infusion versus intermittent administration o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002052-24,0,0,0 2016-002053-38,1,2019-04-09,2019-04-09,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,Medical University Innsbruck,"A Phase I/IIa study to evaluate safety, biodistribution, dosimetry and preliminary diagnostic performance of 68Ga-NeoBOMB1 in patients with advanced TKI-treated GIST using positron-emission tomography...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002053-38,0,0,0 2016-002056-25,1,2017-04-18,2017-04-18,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects with Type 2 Diabetes M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002056-25,0,0,0 2016-002057-38,7,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Janssen-Cilag International N.V.,A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002057-38,0,0,0 2016-002059-89,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Ruprecht-Karls-University Heidelberg, Medical Faculty represented by University Hospital Heidelberg",Therapy of Nodal Follicular Non-Hodgkin Lymphoma (WHO grade 1/2) in Clinical Stage I/II using Response Adapted Involved Site Radiotherapy in Combination with Gazyvaro,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002059-89,0,0,0 2016-002061-54,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI,"""Switch between originator infliximab (Remicade®) and biosimilar infliximab (Remsima®) in the treatment of rheumatoid arthritis, spondyloarthritis and chronic inflammatory bowel diseases. Evaluation o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002061-54,0,0,0 2016-002062-31,2,2019-08-21,2019-08-21,1,1,0,0,0,1,3,0,0,2,0,0,0,0,0,ETOP (European Thoracic Oncology Platform),A multicentre randomised phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002062-31,1,0,0 2016-002064-13,2,2018-07-03,2018-07-03,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Hansa Medical AB,A Phase II Study to Evaluate the Efficacy of IdeS (IgG endopeptidase) to Desensitize Transplant Patients with a Positive Crossmatch Test,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002064-13,0,0,0 2016-002065-66,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Miikka Tervonen,Intranasal dexmedetomidine sedation during intra-articular joint injections in pediatric population Nenään annosteltava deksmedetomidiini lastenreumapotilaiden toimenpiteen aikaisena rauhoittavana ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002065-66,0,0,0 2016-002066-32,14,2022-05-27,2022-05-27,10,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Amryt Research Limited,"Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow up of Oleogel S10 in Patients with Inherited Epidermolysis Bullosa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002066-32,1,0,0 2016-002067-33,1,2017-12-21,2017-12-21,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Akari Therapeutics Plc,"COBALT: Coversin Global Study: An Open-Label, Safety and Efficacy Trial in PNH Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002067-33,0,0,0 2016-002068-14,1,2021-10-13,2021-10-13,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Medical University of Vienna,Investigation of antidepressant efficacy of oral ketamine treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002068-14,0,0,0 2016-002069-77,2,2017-08-21,2017-09-14,2,0,0,1,0,0,1,0,1,1,0,0,0,0,1,Regulus Therapeutics Inc.,"An Observational Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Have Previously Received RG-101 Hosszú távú biztonságosságot és hatásosságot megfigyelő utánkövető vizsgálat, olyan vi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002069-77,0,0,0 2016-002071-96,3,2019-11-06,2019-11-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Single-Arm, Multicenter, Open-Label, Phase 2 Study of nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy plus Necitumumab (LY3012211) in the First-Line Treatment of Patients with Stage IV Squa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002071-96,0,0,0 2016-002071-96,3,2019-11-06,2019-11-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Lilly, S.A.","A Single-Arm, Multicenter, Open-Label, Phase 2 Study of nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy plus Necitumumab (LY3012211) in the First-Line Treatment of Patients with Stage IV Squa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002071-96,0,0,0 2016-002072-26,1,2019-10-25,2019-10-25,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Multicenter randomized placebo controlled trial assessing the efficacy of oral adjuvant magnesium supplementation in the treatment of alcohol withdrawal syndrome. Essai randomisé contrôlé contre pl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002072-26,0,0,0 2016-002075-10,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,NHS Greater Glasgow & Clyde,Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002075-10,0,0,0 2016-002075-10,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Glasgow,Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002075-10,0,0,0 2016-002076-28,1,2020-12-15,2020-12-15,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Phase II Study of Pembrolizumab (MK-3475) as First Line Single Drug Therapy in Patients with unresectable Squamous Cell Carcinoma of the Skin Etude de phase II de l'administration de Pembrolizumab...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002076-28,0,0,0 2016-002077-35,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,José Luís Díez Martín,"CLINICAL TRIAL PHASE I / II, SINGLE-CENTER, HISTORICAL CONTROL, TO EVALUATE THE EFFECTIVENESS OF DONOR IL-15-STIMULATED NK CELLS POST TRANSPLANT INFUSION, IN ACUTE LEUKEMIA PATIENTS WITH POOR PROGNOSI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002077-35,0,0,0 2016-002079-93,1,2019-03-26,2019-03-26,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Incyte Biosciences International Sàrl,"A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002079-93,0,0,0 2016-002081-31,1,2018-09-10,2018-09-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Anæstesiologisk-intensiv afd V, Odense Universitets Hospital",Investigation of dose response relationships when using low dose naltrexone (LDN) for the treatment of fibromyalgia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002081-31,0,0,0 2016-002082-65,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Andreas Kjaer,Phase II trial: uPAR-PET/CT for prognostication in head- and neck cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002082-65,0,0,0 2016-002083-13,1,2017-08-31,2017-08-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Public Health England,An observational follow up study of a randomised parallel group phase IV study to evaluate the duration of the immune response to vaccine and non-vaccine HPV types in UK adolescent females who receive...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002083-13,0,0,0 2016-002085-31,1,2021-11-10,2021-11-10,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Kurort Forschungsverein Bad Steben e.V.,Determining the immunological and pain reducing effects of serial radon balneology in patients with musculoskeletal disorders. Bestimmung der immunologischen und Schmerz lindernden Wirkung von seri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002085-31,0,0,0 2016-002086-54,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Utrecht,"A randomized trial of the effect of antiplatelet therapy (Aspirin, Aspirin and Clopidogrel or Ticagrelor) on the occurrence of atherothrombotic and cardiovascular adverse events following lower extrem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002086-54,0,0,0 2016-002088-33,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,"Impact and Costs of Health Care Education, Phone Reminders and enhanced follow-up intervention on Prescription adherence, Treatment Satisfaction and Effectiveness in patients with Multiple Actinic Ker...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002088-33,0,0,0 2016-002089-29,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine Given at 6, 10, and 14 Weeks of Age in Infants in India Who Previously Received a Dose of Hepatitis B Vaccine at Bir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002089-29,0,1,1 2016-002092-10,2,2018-07-11,2018-09-03,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Evestra GmbH,Comparative reference-controlled investigation of bleeding pattern under treatment with a vaginal delivery system (EVE112) containing a fixed dose combination of etonogestrel and ethinylestradiol – A ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002092-10,0,0,0 2016-002093-12,6,2021-05-13,2021-05-13,5,1,0,0,0,0,2,0,0,2,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),A Phase II multicenter study comparing the efficacy of the oral angionenesis inhibitor nintedanib with the intravenous cytotoxis compound ifosfamide for treatment of patients with advanced metastatic ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002093-12,1,0,0 2016-002093-12,6,2021-05-13,2021-05-13,5,1,0,0,0,0,2,0,0,2,0,0,0,0,0,European Organisation for Research and Treatment of,A Phase II multicenter study comparing the efficacy of the oral angionenesis inhibitor nintedanib with the intravenous cytotoxis compound ifosfamide for treatment of patients with advanced metastatic ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002093-12,1,0,0 2016-002093-12,6,2021-05-13,2021-05-13,5,1,0,0,0,0,2,0,0,2,0,0,0,0,0,European Organisation for Research and Treatment of Cancer,A Phase II multicenter study comparing the efficacy of the oral angionenesis inhibitor nintedanib with the intravenous cytotoxis compound ifosfamide for treatment of patients with advanced metastatic ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002093-12,1,0,0 2016-002094-36,2,2018-08-01,2018-08-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function with Benralizumab in Severe, Unco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002094-36,0,0,0 2016-002095-26,10,2020-04-13,2020-04-23,7,1,1,0,0,0,2,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children with a History of Respiratory Sy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002095-26,0,0,0 2016-002095-26,10,2020-04-13,2020-04-23,7,1,1,0,0,0,2,0,0,1,1,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children with a History of Respiratory Sy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002095-26,0,0,0 2016-002096-96,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Maastricht University Medical Center,"TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia, a multicenter, open-label, non-randomized, controlled study (TOPIC-3 study) Imiquimod behandeling van hooggradige CIN-l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002096-96,0,0,0 2016-002097-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Cardiology, University Medical Centre Ljubljana",Comparison of modified-release and standard tacrolimus immunosuppression regimens in heart transplant recipients Primerjava učinkov tacrolimusa s podaljšanim sproščanjem in standardnega tacrolimusa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002097-13,0,0,0 2016-002100-25,3,2018-04-11,2018-04-11,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,ThromboGenics NV,"A Phase 2, single-masked, multicentre study to evaluate the safety and efficacy of 2 dose levels of THR-317 for the treatment of diabetic macular oedema (DME)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002100-25,0,0,0 2016-002101-19,2,2020-04-27,2020-04-27,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma Services AG,"A multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety and tolerability of ACZ885 (canakinumab) in pediatric and young adult patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002101-19,0,0,0 2016-002105-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki City Hospital Haartman,Laboratory measurement of direct oral anticoagulants on patients with atrial fibrillation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002105-18,0,0,0 2016-002107-26,5,2018-10-02,2018-10-02,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,UCB Biopharma SPRL,"AN OPEN-LABEL ADAPTIVE STUDY FOR THE ASSESSMENT OF SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF RADIPRODIL IN SUBJECTS WITH DRUG-RESISTANT INFANTILE SPASMS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002107-26,0,0,0 2016-002109-20,1,,,0,1,1,0,0,1,3,0,0,4,0,0,0,0,1,"Spark Therapeutics, Inc.",A Safety and Efficacy Study in Subjects with Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002109-20,0,1,1 2016-002110-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU CLERMONT-FERRAND,Evaluation of the effectiveness and safety of ethosuximide in the treatment of abdominal pain associated with irritable bowel syndrome Evaluation de l’efficacité et de la tolérance de l’éthosuximid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002110-42,0,0,0 2016-002112-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region Östergötland,Can Insuline improve the healing of dental implants? Kan insulin förbättra läkningen av tandimplantat?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002112-41,0,0,0 2016-002113-21,5,2019-07-17,2021-07-17,5,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter, randomized, double-blind, active-controlled, 2 week treatment, parallel-group study to assess the efficacy and safety of indacaterol acetate delivered via the Concept1 inhalation device...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002113-21,0,0,0 2016-002114-50,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Sahlgrenska University Hospital,A multicenter phase II open label study to evaluate efficacy of concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002114-50,0,0,0 2016-002118-40,3,2019-03-05,2019-03-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dilafor AB,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Effect of continuous infusion of Tafoxiparin as an Adjunct Treatment to Oxytocin for up to 36 hours in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002118-40,0,0,0 2016-002119-16,1,2020-10-31,2020-10-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Aflofarm Farmacja Polska Sp. z o.o.,Multi-center phase 3 clinical study of fever reduction effectiveness in children age 24-72 months using combined therapy (ibuprofen plus paracetamol) compared to monotherapy with paracetamol and/or ib...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002119-16,0,0,0 2016-002120-83,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INSTITUT DE CANCEROLOGIE DE L'OUEST RENE GAUDUCHEAU,Study evaluation of 2nd hormone line response by -[18F]fluoro-17β-œstradiol (FES) PET/CT in metastatic breast cancer patients Etude d’évaluation de la réponse à l’hormonothérapie de 2ème ligne par ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002120-83,0,0,0 2016-002122-36,6,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002122-36,0,0,0 2016-002122-36,6,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002122-36,0,0,0 2016-002125-11,6,2019-03-11,2019-04-15,6,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Celltrion, Inc","A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002125-11,0,0,0 2016-002126-36,4,2018-11-06,2018-11-06,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F. Hoffmann - Roche Ltd,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RO7123520 AS ADJUNCT TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002126-36,0,0,0 2016-002126-36,4,2018-11-06,2018-11-06,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RO7123520 AS ADJUNCT TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002126-36,0,0,0 2016-002127-28,1,2017-07-07,2017-07-07,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Hvidovre University Hospital,"The impact of subcutaneous glucagon before, during and after exercise. A study in patients with type 1 diabetes mellitus Virkningen af glukagon før, under og efter træning Hos personer med type 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002127-28,0,0,0 2016-002128-10,5,,,0,0,0,1,0,1,1,0,1,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"An adaptive Phase I/II study to assess safety, efficacy, pharmacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002128-10,0,0,0 2016-002128-10,5,,,0,0,0,1,0,1,1,0,1,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"An adaptive Phase I/II study to assess safety, efficacy, pharmacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria (PNH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002128-10,0,0,0 2016-002129-12,1,2020-10-12,2020-10-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),A randomized phase IIb study of cyclophosphamide (Cy) versus anti-thymocyte globulin (ATG) for the prophylaxis of graft-versus-host disease (GVHD) after reduced-intensity conditioning allogeneic perip...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002129-12,0,0,0 2016-002130-72,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Division of Thoracic and Hyperbaric Surgery, Medical University Graz",Hyperbaric Oxygenation (HBO) in traumatic spinal cord injury. Hyperbare Sauerstofftherapie (HBO) bei traumatischen Rückenmarksverletzungen.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002130-72,0,0,0 2016-002134-74,1,2017-05-25,2017-05-25,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,PepTcell Limited (trade name SEEK),"Phase IIb Study of the Efficacy of FLU-v, a Broad Spectrum Influenza Vaccine in an H1N1 Influenza Healthy Human Challenge Model",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002134-74,0,0,0 2016-002135-15,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Janssen-Cilag GmbH,"Multicenter, randomized, open-label, efficacy assessor-blinded, active comparator-controlled phase 3b study to compare the efficacy of guselkumab to fumaric acid esters (Fumaderm® initial/ Fumaderm®) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002135-15,0,0,0 2016-002138-63,1,2020-03-31,2020-03-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SOCIETÀ INDUSTRIA FARMACEUTICA ITALIANA (SIFI) SPA,"A prospective, multi-center, controlled, double-blind study to evaluate the efficacy and tolerability of a steroid/antibiotic associated treatment following cataract extraction by means of phaco-emuls...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002138-63,0,0,0 2016-002143-42,1,2017-08-29,2017-08-29,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Odense University Hospital,A designed Patient-centered Intervention to Improve medical Adherence in Topical Treatment of psoriasis - A Study protocol En designet patient-centreret intervention til at forbedre medicinsk adhær...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002143-42,0,0,0 2016-002146-23,9,2018-09-19,2018-09-28,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Arsanis, Inc.","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus aureus Pneumonia in Heavily Colonized...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002146-23,0,0,0 2016-002146-23,9,2018-09-19,2018-09-28,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ARSANIS INC.,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus aureus Pneumonia in Heavily Colonized...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002146-23,0,0,0 2016-002148-17,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,LUMC,Reversal of opioid-induced respiratory depression (OIRD) by ketamine in healthy volunteers – the ORKA trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002148-17,0,0,0 2016-002154-20,17,2021-02-26,2021-02-26,15,1,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA SERVICES AG,"A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002154-20,1,0,0 2016-002154-20,17,2021-02-26,2021-02-26,15,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002154-20,1,0,0 2016-002154-20,17,2021-02-26,2021-02-26,15,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002154-20,1,0,0 2016-002154-20,17,2021-02-26,2021-02-26,15,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002154-20,1,0,0 2016-002157-38,1,2021-09-23,2021-09-23,1,1,0,0,0,1,3,0,0,1,0,0,1,0,0,Radboud University Medical Center,Treatment of congenital vascular malformations using Sirolimus: improving quality of Life Behandeling van congenitale vasculaire malformaties met Sirolimus: een studie om de kwaliteit van leven te ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002157-38,0,0,0 2016-002160-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,St. Antonius Hospital,68Ga-DOTA-NOC PET/CT for the imaging of disease activity in neurologic and cardiac sarcoidosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002160-14,0,0,0 2016-002161-56,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Mateusz Gola,Towards the understanding of neuronal mechanisms of compulsive sexual behaviors - pharmacotherapy Badania neuronalnych mechanizmów kompulsywnych zachowań seksualnych - farmakoterapia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002161-56,0,0,0 2016-002162-30,8,2022-07-06,2022-07-06,5,0,0,0,0,0,0,0,0,2,0,0,0,0,1,Fresenius Kabi Deutschland GmbH,"Prospective, randomized, controlled, double-blind, multicentre, multinational study on the safety and efficacy of 6% Hydroxyethyl starch (HES) solution versus an electrolyte solution in patients unde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002162-30,1,0,0 2016-002162-30,8,2022-07-06,2022-07-06,5,0,0,0,0,0,0,0,0,2,0,0,0,0,1,B. Braun Melsungen AG,"Prospective, randomized, controlled, double-blind, multicentre, multinational study on the safety and efficacy of 6% Hydroxyethyl starch (HES) solution versus an electrolyte solution in patients unde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002162-30,1,0,0 2016-002163-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Hamburg-Eppendorf,Comparative Effectiveness Trial of Transoral Head and Neck Surgery followed by adjuvant Radio(chemo)therapy versus primary Radiochemotherapy for Oropharyngeal Cancer (TopROC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002163-34,0,0,0 2016-002164-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZ Brussel,Quantification of 68GaNOTA-Anti-HER2 VHH1 Uptake in metastasis of Breast carcinoma patients and Assessment of Repeatability – Pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002164-13,0,0,0 2016-002165-63,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Aarhus University Hospital,A direct comparison of Oral Navelbine given either classic or metronomic in metastatic breast cancer En direkte sammenligning af Navelbine Oral (Vinorelbine) kemoterapi givet enten klassisk eller...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002165-63,0,0,0 2016-002167-33,3,2018-09-04,2018-09-04,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,"A randomized, double-blind multicenter study to assess the safety and efficacy of a six month oral treatment with the chymase inhibitor BAY 1142524 at a dose of 25 mg BID in comparison to placebo on t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002167-33,0,0,0 2016-002170-13,2,2020-10-23,2020-10-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AIO-Studien-gGmbH,A randomized phase II study with NIVOlumab or continuation of therapy as an early SWITCH approach in patients with advanced or metastatic renal cell carcinoma (RCC) and disease control after 3 months ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002170-13,0,0,0 2016-002171-94,2,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Mensia Technologies SA,Effectiveness of a personalized Neurofeedback Training device (ADHD@Home) as compared with Methylphenidate in the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder: A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002171-94,0,0,0 2016-002172-27,1,2017-09-04,2017-09-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,DOMPé FARMACEUTICI S.P.A.,"A 8 weeks, Phase II, single-centre, randomized, double-masked, vehicle-controlled, parallel group study with 4 weeks of follow-up to evaluate preliminary efficacy and safety of recombinant human Nerve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002172-27,0,0,0 2016-002176-27,6,2022-06-25,2022-06-25,4,0,0,0,0,0,0,0,0,2,0,0,0,0,1,B. Braun Melsungen AG,"Pragmatic, prospective, randomized, controlled, double-blind, multicentre, multinational study on the safety and efficacy of a 6% Hydroxyethyl starch (HES) solution versus an electrolyte solution in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002176-27,1,0,0 2016-002176-27,6,2022-06-25,2022-06-25,4,0,0,0,0,0,0,0,0,2,0,0,0,0,1,Fresenius Kabi Deutschland GmbH,"Pragmatic, prospective, randomized, controlled, double-blind, multicentre, multinational study on the safety and efficacy of a 6% Hydroxyethyl starch (HES) solution versus an electrolyte solution in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002176-27,1,0,0 2016-002177-35,1,2019-02-22,2019-02-22,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Masarykova univerzita,The effect of gabapentin used as a preemptive to the emergence and development chronic neuropathic pain in patients after spinal cord trauma Vliv preemptivního podávání gabapentinu na vznik a rozvo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002177-35,0,0,0 2016-002179-91,1,2017-03-10,2017-03-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Millendo Therapeutics, Inc.","A Double-blind, Randomized, Parallel-group, Placebo-controlled Study of MLE4901 for the Treatment of Polycystic Ovary Syndrome (PCOS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002179-91,0,0,0 2016-002180-33,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Centrum Neurologii Krzysztof Selmaj,Multiple sclerosis therapy with transdermal myelin peptide stimulation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002180-33,0,0,0 2016-002181-32,1,2017-08-30,2017-08-30,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,Regulus Therapeutics Inc.,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Dose Selection, and Preliminary Efficacy of Weekly RG 012 Injections in Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002181-32,0,0,0 2016-002183-13,1,2017-08-09,2017-08-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Betagenon AB,"Effect on fasting plasma glucose (FPG) of once daily oral administration during 28 days of O304 suspension in subjects with Type 2 Diabetes (T2D). A single-centre, randomised, parallel-group, double-b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002183-13,0,0,0 2016-002184-34,1,2019-10-15,2019-10-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET",Phase II trial: uPAR-PET/CT in Radium-223-dichloride treatment of patients with metastatic castration-resistant prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002184-34,0,0,0 2016-002186-56,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,GUSTAVE ROUSSY,Randomised phase III multicentric study comparing efficacy of doxorubicin with trabectedin followed by trabectedin in non-progressive patients versus doxorubicine alone as first-line therapy in patien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002186-56,0,0,0 2016-002190-35,4,2019-10-28,2019-10-28,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Amgen Inc,A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002190-35,0,0,0 2016-002192-10,1,2018-03-23,2018-03-23,1,1,1,0,0,0,1,0,0,1,0,0,1,0,1,Shield TX (UK) Limited,"A phase 1, open label, randomised, repeat dose, parallel group study to evaluate the pharmacokinetics, safety and tolerability of ferric maltol at the three dosage levels in paediatric subjects aged 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002192-10,0,0,0 2016-002195-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Tartu,Pharmacokinetics and tissue penetration of amoxicillin/clavulanic acid in patients with sepsis and septic shock,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002195-27,0,0,0 2016-002197-13,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Servicio de Anestesiología y Reanimación,IMPLICATION OF TWO ANESTHETIC TECHNIQUES: SEVOFLURANE VERSUS PROPOFOL TO REDUCE BLOOD LOSS IN ORTHOGNATHIC SURGERY IMPLICACIÓN DE DOS TÉCNICAS ANESTÉSICAS: SEVOFLURANE VERSUS PROPOFOL PARA REDUCIR ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002197-13,0,0,0 2016-002198-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL UNIVERSITARI DE BELLVITGE - IDIBELL,"A single-center, randomized, open-label, 12 months study, with two parallel group to compare the efficacy of everolimus combination + tacrolimus in regression of left ventricular hypertrophy vs tacrol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002198-37,0,0,0 2016-002199-28,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Dr. August Wolff GmbH & Co. KG Arzneimittel,"Prospective, open-label, multicenter, multinational, randomized trial to investigate the non-inferiority of treatment with Vagisan® Moisturising Cream in comparison to an Estriol containing cream in a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002199-28,0,0,0 2016-002200-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,International Breast Cancer Study Group (IBCSG),A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) versus weekly paclitaxel as first or second-line treatment in patients with ER-positive/HER2-neg...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002200-39,0,0,0 2016-002204-84,7,2021-02-05,2021-02-05,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects with Active Crohn’s Disease (SERENITY)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002204-84,1,0,0 2016-002205-19,7,2021-02-05,2021-02-26,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Incyte Corporation,"A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002205-19,1,0,0 2016-002205-19,7,2021-02-05,2021-02-26,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,INCYTE CORPORATION,"A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002205-19,1,0,0 2016-002207-26,5,2017-09-25,2017-09-25,5,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Tetraphase Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared with Ertapenem in Complicated Urinary Tract Infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002207-26,0,0,0 2016-002208-21,6,2017-05-19,2017-05-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Tetraphase Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Meropenem in Complicated Intra-abdominal Infections",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002208-21,0,0,0 2016-002209-20,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,CHU-Hôpitaux de Rouen,PRODIGE 50 - ASPIK : French prospective randomised double blind study on aspirin versus placebo in resected colon cancer with PI3K mutation stage III or II high risk PRODIGE 50 - ASPIK: Etude pros...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002209-20,0,0,0 2016-002210-46,1,2018-11-17,2018-11-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Medical Centre RadboudUMC,Study: Reduces intravenous lidocaine the need for alfentanyl during colonoscopy under Procedural Sedation and Analgesia?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002210-46,0,0,0 2016-002211-18,13,2016-10-14,2021-01-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A 12-week double-blind, randomized, multicenter study comparing the efficacy and safety of once monthly subcutaneous 140 mg AMG 334 against placebo in adult episodic migraine patients who have failed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002211-18,0,0,0 2016-002211-18,13,2016-10-14,2021-01-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS PHARMA SERVICES AG,"A 12-week double-blind, randomized, multicenter study comparing the efficacy and safety of once monthly subcutaneous 140 mg AMG 334 against placebo in adult episodic migraine patients who have failed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002211-18,0,0,0 2016-002211-18,13,2016-10-14,2021-01-28,12,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"A 12-week double-blind, randomized, multicenter study comparing the efficacy and safety of once monthly subcutaneous 140 mg AMG 334 against placebo in adult episodic migraine patients who have failed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002211-18,0,0,0 2016-002212-41,1,2017-12-19,2017-12-19,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,"Stiftung Hannoversche Kinderheilanstalt, Kinder - und Jugendkrankenhaus AUF DER BULT, Diabeteszentrum für Kinder - und J","A Randomized, Double-Blind, Placebo-controlled, Single-center Phase 1 Inpatient Pilot Study to Explore the Safety and Efficacy of DAPAglifozin as Add-on to day and night closed-loop control using the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002212-41,0,0,0 2016-002213-21,1,2017-11-06,2017-11-06,1,0,0,0,0,0,2,0,1,1,1,1,1,0,1,Vanda Pharmaceuticals Inc,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL PROOF OF CONCEPT STUDY TO EVALUATE THE EFFECTS OF MULTIPLE ORAL DOSES OF TASIMELTEON AND MATCHING PLACEBO IN TRAVELERS WITH JET LA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002213-21,0,0,0 2016-002214-47,1,2017-07-21,2017-07-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Kitov Pharmaceuticals Ltd,A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine on Renal and Vascular Function in Subjects with Existing Hypertension Req...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002214-47,0,0,0 2016-002216-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,"BOSUTINIB EFFICACY SAFETY TOLERABILITY (BEST) STUDY IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS FAILING FRONT-LINE TREATMENT WITH OTHER TYROSINE KINASE INHIBITORS STUDIO DI EFFICACIA, SICUREZZA E ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002216-40,0,0,0 2016-002217-22,1,2017-11-27,2017-11-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Sjællands University Hospital, Køge",Validation of stimulated ∆FGF19 for diagnosing bile acid diarrhoea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002217-22,0,0,0 2016-002218-36,5,2018-11-09,2018-11-09,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Eli Lilly and Company,"An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination with Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002218-36,0,0,0 2016-002218-36,5,2018-11-09,2018-11-09,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Lilly S.A.,"An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination with Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002218-36,0,0,0 2016-002221-11,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,University Hospital Southampton NHS Foundation Trust,A Phase I study of 131-1 mIBG followed by Nivolumab and Dinutuximab beta in children with relapsed/refractory neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002221-11,0,0,0 2016-002222-37,1,2018-02-08,2018-02-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Herlev og Gentofte Hospital,A randomized phase II study between regorafenib and continuing biologic treatment to multi treated patients with colorectal cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002222-37,0,0,0 2016-002223-28,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,0,CHRU DE TOURS,Tau brain imaging in typical and atypical Alzheimer’s Disease (AD) Imagerie de la protéine Tau dans les formes typiques et atypiques de la maladie d’Alzheimer (MA).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002223-28,0,0,0 2016-002225-10,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,"Impact of empagliflozin on left ventricular functions: a single center, phase III, randomized, open-label, active treatment-controlled, parallel study in patients with type 2 diabetes and normal left ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002225-10,0,0,0 2016-002226-36,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Noorik Biopharmaceuticals AG,"A double-blind, placebo-controlled, escalating-dose study of the effect of N-003 on renal function, pharmacodynamics, pharmacokinetics, safety and tolerability in patients with advanced liver disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002226-36,0,0,0 2016-002230-69,2,2018-10-11,2018-10-11,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals S.A.,"A Phase 2b, Open-Label, Multi-Center Study Assessing the Immunological Persistence of Antibodies at Approximately 2 years After the last Meningococcal Vaccination in Study V102_15 and the Response to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002230-69,0,0,0 2016-002236-32,1,2019-04-22,2019-04-22,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Immunocore Limited,"An Open-label, Multi-Center, Rollover Study in Patients with Advanced Melanoma After Completing an IMCgp100 Clinical Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002236-32,0,0,0 2016-002237-30,1,2017-09-30,2017-09-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Odense University Hospital,Optimizing Colon Capsule Endoscopy in follow up program on patients with colorectal polyps assessing three booster procedures for motility enhancement,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002237-30,0,0,0 2016-002240-17,1,2019-08-12,2019-08-12,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,"Millendo Therapeutics, Inc.","A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002240-17,0,0,0 2016-002244-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland","A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002244-16,0,0,0 2016-002251-13,1,2018-04-10,2018-04-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Oulu university hospital,The effect of intravenous single-dose dexamethasone on pain after total knee replacement surgery. Laskimonsisäisen deksametasonin kerta-annoksen vaikutus polven tekonivelleikkauksen jälkeiseen kipu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002251-13,0,0,0 2016-002253-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Angers,Mesure de la clairance plasmatique du iohexol chez les patients sortant de réanimation après insuffisance rénale aiguë Mesure de la clairance plasmatique du iohexol chez les patients sortant de ré...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002253-38,0,0,0 2016-002254-20,4,2018-04-16,2019-04-16,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim International GmbH,"VOLTAIRE-X: Pharmacokinetics, safety, immunogenicity and efficacy of BI 695501 versus Humira® in patients with moderate to severe chronic plaque psoriasis: a randomized, double-blind, parallel-arm, mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002254-20,0,0,0 2016-002255-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Oncology, Herlev Hospital",Electrochemotherapy versus standard radiatiotherapy for the treatment of basal cell carcinoma Elektrokemoterapi versus strålebehandling til behandling af basalcellecarcinom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002255-25,0,0,0 2016-002256-25,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Guy's and St Thomas' NHS Foundation Trust,HYPATIA: A prospective randomised controlled trial of HYdroxychloroquine to improve Pregnancy outcome in women with AnTIphospholipid Antibodies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002256-25,0,0,0 2016-002257-37,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,UNICANCER,Secured access to nivolumab for adult patients with selected rare cancer types,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002257-37,0,0,0 2016-002259-11,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,GRUNENTHAL PHARMA S.A.,"A multicenter, open-label, single-arm, Phase IIIb trial to evaluate the effectiveness, safety, tolerability, usability and health economics resource utilization of Zalviso® for management of acute mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002259-11,0,0,0 2016-002260-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,UNICANCER,Secured access to pembrolizumab for adult patients with selected rare cancer types.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002260-14,0,0,0 2016-002262-31,1,2020-02-07,2020-02-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002262-31,0,0,0 2016-002265-60,6,2020-06-29,2020-06-29,4,1,1,0,1,0,3,0,0,1,0,0,1,0,1,IPSEN PHARMA SAS,"EFFICACY, SAFETY AND TOLERABILITY OF A BOWEL CLEANSING PREPARATION (EZICLEN®/IZINOVA®) IN PAEDIATRIC SUBJECTS UNDERGOING COLONOSCOPY: A PHASE III, MULTICENTRE, RANDOMISED, COMPARATIVE STUDY VERSUS KLE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002265-60,0,0,0 2016-002265-60,6,2020-06-29,2020-06-29,4,1,1,0,1,0,3,0,0,1,0,0,1,0,1,Ipsen Pharma,"EFFICACY, SAFETY AND TOLERABILITY OF A BOWEL CLEANSING PREPARATION (EZICLEN®/IZINOVA®) IN PAEDIATRIC SUBJECTS UNDERGOING COLONOSCOPY: A PHASE III, MULTICENTRE, RANDOMISED, COMPARATIVE STUDY VERSUS KLE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002265-60,0,0,0 2016-002267-33,1,2019-06-26,2019-06-26,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,University of Oxford,"A parallel group phase I/II marker lesion study to assess the safety, tolerability and efficacy of intravenous or intravesical pembrolizumab in intermediate risk recurrent non-muscle invasive bladder ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002267-33,0,0,0 2016-002268-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,"A PHASE II, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE CENTER STUDY OF THE EFFECT OF EMPAGLIFLOZIN, A SGLT-2 INHIBITOR, ON ENDOGENOUS GLUCOSE PRODUCTION AND PLASMA GLUCAGON LEVEL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002268-15,0,0,0 2016-002269-77,5,2021-11-18,2022-03-30,2,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002269-77,1,0,0 2016-002269-77,5,2021-11-18,2022-03-30,2,0,0,0,0,1,3,0,0,2,1,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002269-77,1,0,0 2016-002270-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,"Clinical trial phase II, prospective, open, randomized, controlled study to evaluate the preventive effect of trimetazidine on the cardiotoxicity of trastuzumab and chemotherapy in patients with breas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002270-12,0,0,0 2016-002271-97,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,F2G Limited,An open label phase IIa clinical study to evaluate the safety and pharmacokinetics of oral F901318 (combined with fluconazole and posaconazole) for antifungal prophylaxis in patients undergoing chemot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002271-97,0,0,0 2016-002272-27,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Saarland University,"Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002272-27,0,0,0 2016-002273-35,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Novartis Pharma Services AG,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002273-35,0,1,1 2016-002276-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medisch Spectrum Twente,The predictive value of the acute effect of beclomethasone-dipropionate on a mannitol challenge test for the outcome of longterm treatment with beclomethasone-dipropionate in childhood asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002276-27,0,0,0 2016-002277-35,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Edinburgh,LACunar Intervention (LACI-2) Trial-2: Assessment of safety and efficacy of cilostazol and isosorbide mononitrate to prevent recurrent lacunar stroke and progression of cerebral small vessel disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002277-35,0,0,0 2016-002277-35,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,NHS Lothian,LACunar Intervention (LACI-2) Trial-2: Assessment of safety and efficacy of cilostazol and isosorbide mononitrate to prevent recurrent lacunar stroke and progression of cerebral small vessel disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002277-35,0,0,0 2016-002278-11,10,2021-04-15,2021-04-26,8,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Boehringer Ingelheim International GmbH,"A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fractio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002278-11,1,0,0 2016-002278-11,10,2021-04-15,2021-04-26,8,1,0,0,0,0,3,0,0,2,1,0,0,0,1,BOEHRINGER INGELHEIM INTERNATIONAL GMBH,"A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fractio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002278-11,1,0,0 2016-002280-34,9,2020-05-25,2020-05-28,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER INGELHEIM INTERNATIONAL GMBH,"A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002280-34,0,0,0 2016-002280-34,9,2020-05-25,2020-05-28,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim International GmbH,"A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002280-34,0,0,0 2016-002281-31,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Neurim Pharmaceuticals (1991) Ltd.,"A randomized, double-blind, placebo-controlled, study of oral treatment of piromelatine in patients with ocular hypertension (OHT) or primary open angle glaucoma (POAG). Estudio aleatorizado, doble...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002281-31,0,0,0 2016-002282-61,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Novartis Pharma AG,"Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet (Jupiter)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002282-61,0,1,1 2016-002286-60,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,A PHASE II/III RANDOMIZED STUDY OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MALIGNANT PLEURAL MESOTHELIOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002286-60,0,0,0 2016-002286-60,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Canadian Cancer Trials Group,A PHASE II/III RANDOMIZED STUDY OF PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MALIGNANT PLEURAL MESOTHELIOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002286-60,0,0,0 2016-002287-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Erasmus MC Cancer Institute,Death rattle in the dying phase: is prophylactic treatment useful? Reutelen in de stervensfase: is profylactische behandeling zinvol?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002287-14,0,0,0 2016-002288-32,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Greek Corporation of Invasive Cardiology,Ticagrelor Potentiation of Remote Ischemic Preconditioning: The Ticagrelor in Remote Ischemic Preconditioning (TRIP) study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002288-32,0,0,0 2016-002290-35,1,2019-10-25,2019-10-25,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,MeiraGTx UK II Limited,"An open label, multi-centre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/8-hCARp.hCNGB3) for gene therapy of adults and children with achromatopsia owing to d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002290-35,0,0,0 2016-002293-12,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,PHARMACYCLICS LLC,Phase 2 study of the combination of ibrutinib plus venetoclax in subjects with treatment-naïve chronic lymphocytic leukemia / small lymphocytic lymphoma Estudio de fase II sobre la politerapia de i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002293-12,0,0,0 2016-002293-12,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,Pharmacyclics LLC,Phase 2 study of the combination of ibrutinib plus venetoclax in subjects with treatment-naïve chronic lymphocytic leukemia / small lymphocytic lymphoma Estudio de fase II sobre la politerapia de i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002293-12,0,0,0 2016-002294-35,1,2017-12-14,2017-12-14,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,GlaxoSmithKline Research & Development Ltd,"A phase I/II, open-label, 2 arm study to investigate the safety, clinical activity, pharmacokinetics and pharmacodynamics of GSK2879552 administered alone or in combination with azacitidine, in adult ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002294-35,0,0,0 2016-002299-28,17,2020-09-14,2020-09-14,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002299-28,0,0,0 2016-002299-28,17,2020-09-14,2020-09-14,16,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN INC.,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002299-28,0,0,0 2016-002302-39,2,2019-07-12,2019-07-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novavax, Inc.","A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine with Aluminum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002302-39,0,0,0 2016-002307-26,6,2021-08-17,2021-10-01,4,0,0,0,0,1,2,0,0,2,0,0,0,0,0,AIO-Studien-gGmbH,A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Renal Cell Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002307-26,1,0,0 2016-002307-26,6,2021-08-17,2021-10-01,4,0,0,0,0,1,2,0,0,2,0,0,0,0,0,AIO-STUDIEN-GGMBH,A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Renal Cell Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002307-26,1,0,0 2016-002311-18,11,2020-01-09,2020-11-30,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Institut de Recherches Internationales Servier,An open-label early access phase IIIb study of trifluridine / tipiracil (S 95005/TAS-102) in patients with a pretreated metastatic colorectal cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002311-18,0,0,0 2016-002311-18,11,2020-01-09,2020-11-30,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Laboratorios Servier S. L.,An open-label early access phase IIIb study of trifluridine / tipiracil (S 95005/TAS-102) in patients with a pretreated metastatic colorectal cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002311-18,0,0,0 2016-002311-18,11,2020-01-09,2020-11-30,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,An open-label early access phase IIIb study of trifluridine / tipiracil (S 95005/TAS-102) in patients with a pretreated metastatic colorectal cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002311-18,0,0,0 2016-002311-18,11,2020-01-09,2020-11-30,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Servier Portugal - Especialidades Farmacêuticas Lda.,An open-label early access phase IIIb study of trifluridine / tipiracil (S 95005/TAS-102) in patients with a pretreated metastatic colorectal cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002311-18,0,0,0 2016-002312-41,11,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc",Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002312-41,0,0,0 2016-002312-41,11,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002312-41,0,0,0 2016-002312-41,11,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Merck Sharp & Dohme LLC,Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002312-41,0,0,0 2016-002313-22,1,,,0,0,1,0,0,0,2,0,0,4,0,0,0,0,1,ADVICENNE PHARMA SA,"A randomised, active controlled, open-label, 2-way cross-over, multicentre study to investigate the palatability, acceptability, pharmacokinetics, safety and tolerability, and treatment compliance of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002313-22,0,0,0 2016-002315-17,3,2018-01-15,2018-01-15,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Madrigal Pharmaceuticals, Inc.","A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002315-17,1,0,0 2016-002317-22,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Geriatric Centre, Umeå University hospital",Feasibility and effects on markers in spinal fluid in persons with early Alzheimer's disease when treated with Valaciklovir - open Fas II pilot study (VALZ-Pilot) Genomförbarhet och effekt på markö...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002317-22,0,0,0 2016-002320-83,5,2020-07-16,2020-10-01,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Rhythm Pharmaceuticals, Inc.","An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset POMC Deficiency Obesity ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002320-83,0,0,0 2016-002321-11,1,2019-11-29,2019-11-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Helena Tinkanen, Tampereen yliopistollinen sairaala","Scientific title: A Protocol for a Randomized, Controlled Study to Compare the Use of Gonodotropin-releasing Hormone Agonist Triptoreline (Gonapeptyl®) for Luteal Phase Support Versus Natural Luteal P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002321-11,0,0,0 2016-002322-37,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,"TROPHIMMUN, a phase II trial of avelumab in chemo-resistant gestational trophoblastic neoplasias (GTN) TROPHIMMUN, Essai de phase II pour évaluer l’efficacité de l’avelumab chez des patientes atte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002322-37,0,0,0 2016-002323-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitair Ziekenhuis Brussel,Blood concentration and pharmacokinetic analysis of propofol following administration of single induction dose in small children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002323-28,0,0,0 2016-002324-92,1,2021-01-06,2021-01-06,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children (NEPHROVIR3) Efficacité du Lévamisole dans le maintien de la rémission a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002324-92,0,0,0 2016-002325-11,1,2017-11-21,2017-11-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Univerity Hospital Leuven,"Intravenous regional anesthesia versus axillar block for hand surgery in day-care hospitall: A prospective, randomised, comparative trial Intraveneuze regionale anesthesie vs axillair blok voor han...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002325-11,0,0,0 2016-002326-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Region Hovedstadens psykiatriske hospital,Effects of erythropoietin (EPO) on cognitive side-effects of electroconvulsive therapy (ECT) (EPO-T) Effekt af erythropoietin (EPO) på kognitive bivirkninger ved elektrokonvulsiv terapi (ECT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002326-36,0,0,0 2016-002327-29,1,2018-06-19,2018-06-19,1,1,1,0,0,0,1,0,0,1,0,0,1,0,1,Gedeon Richter Plc.,"Open-Label, Multicentre, Multiple Dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Cariprazine in Adolescent Subjects with Schizophrenia, Schizoaffective- and Schizophreniform Disor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002327-29,0,0,0 2016-002328-10,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,FONDAZIONE TELETHON,"A Phase I/II Open Label, Dose Escalation, Safety Study in Subjects with Mucopolysaccharidosis type VI (MPS VI) Using Adeno-Associated Viral Vector 8 to Deliver the human ARSB gene to Liver.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002328-10,0,0,0 2016-002331-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fédération Francophone de Cancérologie Digestive,Essai de phase III randomisé évaluant le FOLFOX avec ou sans DOCETAXEL (TFOX) en 1ère ligne de chimiohtérapie des adénocarcinomes oeso-gastriques localement avancés ou métastatiques,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002331-16,0,0,0 2016-002333-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GEMCAD (Grupo Español Multidisciplinar en Cáncer Digestivo),Preoperative induction therapy with 12 weeks of Panitumumab in combination with mFOLFOX-6 in an enriched population (Quadruple Wild-Type) of patients with mrT3 rectal cancer of the middle third with c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002333-29,0,0,0 2016-002335-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI,A ß-d-glucan guided antifungal stewardship strategy for the management of patients with severe abdominal sepsis. A multicenter interventional explorative study with a pharmadynamic/pharmachokinetic su...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002335-14,0,0,0 2016-002337-30,7,2018-08-15,2018-08-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A 12 WEEK RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL GROUP, ACTIVE AND PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILE OF PF-06650833 IN SUBJECTS WITH ACTIVE RHEU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002337-30,0,0,0 2016-002337-30,7,2018-08-15,2018-08-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc.,","A 12 WEEK RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL GROUP, ACTIVE AND PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILE OF PF-06650833 IN SUBJECTS WITH ACTIVE RHEU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002337-30,0,0,0 2016-002337-30,7,2018-08-15,2018-08-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A 12 WEEK RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL GROUP, ACTIVE AND PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILE OF PF-06650833 IN SUBJECTS WITH ACTIVE RHEU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002337-30,0,0,0 2016-002342-23,1,,,0,0,0,0,1,0,4,0,1,1,0,0,0,1,0,VU University Medical Center,The cardiovascular dose-response to supplemental oxygen in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002342-23,0,0,0 2016-002344-16,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Leeds,"Targeted treatment early with etanercept (biosimilar) plus methotrexate or methotrexate with T2T care for DMARD-naïve early RA patients. A prospective, longitudinal cohort study with an embedded pilot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002344-16,0,0,0 2016-002347-41,9,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin ly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002347-41,0,1,0 2016-002347-41,9,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin ly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002347-41,0,1,0 2016-002349-50,4,2019-08-05,2019-08-05,2,0,0,1,0,0,1,0,0,2,1,0,0,0,0,THE NETHERLANDS CANCER INSTITUTE,Phase I/II study with galunisertib (LY2157299) combined with capecitabine in patients with advanced chemotherapy resistant colorectal cancer and an activated TGF-β signature,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002349-50,1,0,0 2016-002349-50,4,2019-08-05,2019-08-05,2,0,0,1,0,0,1,0,0,2,1,0,0,0,0,Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital (NKI-AVL),Phase I/II study with galunisertib (LY2157299) combined with capecitabine in patients with advanced chemotherapy resistant colorectal cancer and an activated TGF-β signature,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002349-50,1,0,0 2016-002351-16,1,2021-09-15,2021-09-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Technische Universität München, Fakultät für Medizin, represented by Dean","An investigator-initiated, randomized, double-blind, placebo controlled study of Apremilast to demonstrate efficacy in subjects with nummular eczema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002351-16,0,0,0 2016-002352-24,1,2017-03-31,2017-03-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College Healthcare NHS Trust,Safety of Nasal Influenza Immunisation in Children with Asthma: The SNIFFLE 4 study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002352-24,0,0,0 2016-002353-38,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ottawa Heart Institute Research Corporation (OHIRC),The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002353-38,0,0,0 2016-002353-38,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ottawa Heart Institute,The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002353-38,0,0,0 2016-002354-20,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"DOTT.SSA CARMELINDA RUGGIERO,ISTITUTO DI GERIATRIA E GERONTOLOGIA, UNIVERSITà DEGLI STUDI DI PERUGIA",EFFECTIVNESS OF WARFARIN REVERSAL USING INTRAVENOUS VITAMIN K AMONG HIP FRACTURE OLDER PERSONS: A RANDOMIZED CLINICAL TRIAL EFFECTIVNESS OF WARFARIN REVERSAL USING INTRAVENOUS VITAMIN K AMONG HI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002354-20,0,0,0 2016-002358-18,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Medsenic,Phase II study of first line treatment of Chronic Graft versus Host Disease with Arsenic Trioxide Étude de phase II du traitement en première ligne de la réaction chronique du greffon contre l’hôte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002358-18,0,0,0 2016-002360-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Rigshospitalet, Dapartment of of Clinical Physiology, Nuclear Medicine and PET",Phase II trial: PET/CT for staging advanced and localized oral and oropharyngeal cancer Fase II studie: Kan uPAR PET/CT benyttes til specifik diagnostik af tumorvæv i avanceret og lokaliseret oral ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002360-14,0,0,0 2016-002364-13,3,2020-03-17,2020-03-17,2,1,0,0,0,0,2,0,0,1,1,0,1,0,0,THE NETHERLANDS CANCER INSTITUTE,MoTriColor: A phase II study of vinorelbine in advanced BRAF-like colon cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002364-13,0,0,0 2016-002364-13,3,2020-03-17,2020-03-17,2,1,0,0,0,0,2,0,0,1,1,0,1,0,0,Netherlands Cancer Institute- Antoni van Leeuwenhoek hospital (NKI-AVL),MoTriColor: A phase II study of vinorelbine in advanced BRAF-like colon cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002364-13,0,0,0 2016-002365-63,4,2018-07-19,2018-07-19,4,1,0,1,0,0,1,0,0,1,1,0,0,0,1,"Gilead Sciences, Inc.","A Phase 1b Study Followed by an Open label, Parallel, Randomized Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of GS-5829 in Combination with Exemestane or Fulvestrant Comparing with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002365-63,0,0,0 2016-002367-34,1,2021-01-21,2021-01-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Hjertemedicinsk klinik, Rigshospitalet",Beta 3 agonist treatment in heart failure (BEAT-HF II) Behandling med beta 3 agonist ved hjertesvigt (BEAT-HF II),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002367-34,0,0,0 2016-002368-15,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,UCB Biopharma SPRL,"A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderate t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002368-15,0,0,0 2016-002370-12,1,2018-08-27,2018-08-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité Universitätsmedizin Berlin,PROOF OF CONCEPT STUDY OF HYQVIA IN PATIENTS WITH IMMUNOGLOBULIN DEFICIENCY AND RECURRENT INFECTIONS WITH CHRONIC FATIGUE SYNDROME Proof of Concept Studie mit HyQvia bei Patienten mit Immunglobinma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002370-12,0,0,0 2016-002372-27,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,BAZ Megyei és Egyetemi Oktató Kórház,Administration of blinatumomab to one pediatric patient Blinatumomab használata egy gyermek betegnél,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002372-27,0,0,0 2016-002373-35,1,2020-09-01,2020-09-01,1,0,0,0,1,0,2,0,1,1,0,0,1,0,3,,The Effects of Dietary Peptides on Human Brown Adipose Tissue Ruoansulatuspeptidien vaikutus ihmisen ruskeaan rasvaan,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002373-35,0,0,0 2016-002374-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Central Hospital/ Women's hospital,Oxycodone compared to meperidine in the treatment of labour pain Oksikodoni verrattuna petidiiniin synnytyskivun hoidossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002374-12,0,0,0 2016-002379-89,1,2020-09-06,2020-09-06,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Ghent University Hospital,Treatment of acute locomotoric pain in the geriatric patient: comparison of effectiveness and safety between step 2 (weak opioids) and step 3 (strong opioids) pain relief of the WHO-ladder.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002379-89,0,0,0 2016-002381-31,1,2017-08-31,2017-08-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Public Health England,"An observational follow up study of a phase II/III, open label, randomised study of the safety, reactogenicity and immunogenicity of a single dose of meningococcal ACWY conjugate vaccine (Menveo, Glax...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002381-31,0,0,0 2016-002382-62,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,The effects of RNS60 on ALS biomarkers L'effetto del farmaco RNS60 sui biomarcatori della SLA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002382-62,0,0,0 2016-002383-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC,Umbilical cord blood transplantation in high-risk hematological patients using stemregenin-1 expanded hematopoietic stem cells. A feasibility study focussing on engraftment and hematopoietic recovery....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002383-13,0,0,0 2016-002385-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Professor Peter Humaidan, The Fertility Clinic Skive","A double-blind, placebo-controlled multicenter trial on the effect of clindamycin and a live biotherapeutic on the reproductive outcomes of IVF patients with abnormal vaginal microbiota",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002385-31,0,0,0 2016-002388-33,1,2018-06-10,2018-06-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Friedrich-Schiller-University Jena,Therapeutic drug monitoring (TDM) for personalized antibiotic treatment with piperacillin-tazobactam (PipTaz) in patients with febrile neutropenia after myelo-suppressive cytostatic chemotherapy T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002388-33,0,0,0 2016-002389-29,1,2017-08-31,2017-08-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Bellerophon Pulse Technologies, LLC","An Exploratory Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Respiratory Imaging (FRI) Parameters in Subjects with World Health Organization (WHO) Group 3 Pul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002389-29,0,0,0 2016-002391-27,2,2015-07-01,2018-07-04,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"BIAL - Portela & Ca, S.A.",Efficacy and safety of opicapone in clinical practice in Parkinson’s Disease patients with wearing-off motor fluctuations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002391-27,0,0,0 2016-002392-10,1,2018-06-23,2018-06-23,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,UZ Leuven,Reconsolidation interference versus retrieval interference as the basis for experimental amnesia in humans – The effect of drug state at memory retrieval,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002392-10,0,0,0 2016-002393-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fédération Francophone de Cancérologie Digestive,Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 +/- Irinotecan and targeted therapy in first-line treatment of metastatic colorectal cancer restricted to the liver Oxal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002393-12,0,0,0 2016-002396-99,5,2018-10-15,2018-10-15,4,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Novo Nordisk A/S,"Safety, tolerability, and pharmacokinetics study of single and multiple subcutaneous doses of turoctocog alfa pegol in patients with haemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002396-99,0,0,0 2016-002397-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Reinier de Graaf Groep,Median Local Anaesthetic dose (MLAD) of Intrathecal Prilocaïne in total hip arthroplasty with the anterior approach.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002397-12,0,0,0 2016-002399-28,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA,Rapamycin (Sirolimus) treatment for amyotrophic lateral sclerosis Rapamycin (Sirolimus) treatment for amyotrophic lateral sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002399-28,0,0,0 2016-002405-19,2,2017-08-11,2017-08-11,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"An open label, randomised, three arm, single dose, multicentre, parallel group study in healthy subjects to compare the pharmacokinetics of subcutaneous mepolizumab when delivered as a liquid drug pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002405-19,0,0,0 2016-002408-13,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,UMC Utrecht,Bumetanide to Ameliorate Tuberous Sclerosis Complex Hyperexcitable Behaviors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002408-13,0,0,0 2016-002411-17,7,2021-03-31,2021-03-31,6,1,0,0,0,1,2,0,0,2,0,0,0,0,1,UCB Biopharma SPRL,"A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects with Chronic Inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002411-17,1,0,0 2016-002411-17,7,2021-03-31,2021-03-31,6,1,0,0,0,1,2,0,0,2,0,0,0,0,1,UCB Biopharma SRL,"A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects with Chronic Inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002411-17,1,0,0 2016-002412-40,4,2018-01-08,2018-02-09,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Axovant Sciences Ltd.,A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Dementia with Lewy Bodies (DLB),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002412-40,0,0,0 2016-002412-40,4,2018-01-08,2018-02-09,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AXOVANT SCIENCES LTD.,A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Dementia with Lewy Bodies (DLB),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002412-40,0,0,0 2016-002413-22,1,,,0,1,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,"Open label, Randomized (1:1), clinical trial to evaluate switching from dual regimens based on Dolutegravir plus a reverse transcriptase inhibitor to elvitegravir/cobicistat/emtricitabine/tenofovir a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002413-22,0,0,0 2016-002416-41,4,2020-04-15,2020-04-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A randomized, double-blind, multi-dose, placebo-controlled study to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primary b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002416-41,0,0,0 2016-002416-41,4,2020-04-15,2020-04-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomized, double-blind, multi-dose, placebo-controlled study to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primary b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002416-41,0,0,0 2016-002416-41,4,2020-04-15,2020-04-16,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A randomized, double-blind, multi-dose, placebo-controlled study to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primary b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002416-41,0,0,0 2016-002417-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Rigshospitalet,uPAR-PET/MR in glioma uPAR-PET/MR af gliom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002417-21,0,0,0 2016-002422-36,5,2021-09-29,2021-09-29,4,0,0,0,0,2,2,0,0,2,0,0,0,0,1,INCYTE CORPORATION,"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002422-36,1,0,0 2016-002422-36,5,2021-09-29,2021-09-29,4,0,0,0,0,2,2,0,0,2,0,0,0,0,1,Incyte Corporation,"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002422-36,1,0,0 2016-002423-29,1,2020-06-16,2020-06-16,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,incyte Corporation,"A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002423-29,0,0,0 2016-002426-37,1,2017-09-23,2017-09-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Engelhard Arzneimittel GmbH & Co.KG,"Randomized, placebo-controlled, double-blind, multi-center trial to evaluate the efficacy and safety of 2 Prospan® posologies (2x 7.5 mL/day and 3x 5 mL/day) in the treatment of acute bronchitis Ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002426-37,0,0,0 2016-002427-28,2,2019-07-23,2019-07-23,2,0,0,0,0,1,3,0,0,1,0,0,1,0,1,"Asklepion Pharmaceuticals, LLC","A Phase III Double-Blind, Randomized, Placebo Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-citrulline for the Prevention of Clinical Sequelae of Acute L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002427-28,0,0,0 2016-002429-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,PERSONALIZED TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER PATIENTS ACCORDING TO CIRCULATING TUMOR CELLS KINETIC DURING CHEMOTHERAPY Traitement personnalisé des patients atteints de ca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002429-12,0,0,0 2016-002430-76,3,,,0,0,0,0,0,1,0,0,0,3,0,0,0,0,0,"Radboudumc, Amalia Children’s Hospital, Department of Pediatrics","Double-blind, randomized, placebo controlled noninferiority intervention study to REduce STEroids in Relapsing Nephrotic syndrome Dubbelblinde, gerandomiseerde, placebo-gecontroleerde non-inferiori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002430-76,0,0,0 2016-002433-30,1,2021-10-02,2021-10-02,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Hvidovre Hospital,"Low-dose azathioprine and allopurinol versus azathioprine monotherapy for patients with ulcerative colitis: protocol for an investigator initiated, open, multicentre, parallel arm, randomised controll...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002433-30,0,0,0 2016-002435-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación de Investigación HM Hospitales,"Pilot study to assess physical exercise intervention in neoadjuvant treatment with nab-paclitaxel in patients with triple negative breast cancer Estudio piloto para evaluar la intervención, mediant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002435-15,0,0,0 2016-002438-58,1,2019-03-20,2019-03-20,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bayer AG,A phase 1b/2 trial to evaluate the safety and efficacy of radium-223 dichloride (BAY 88-8223) in combination with bortezomib and dexamethasone in early relapsed multiple myeloma Ensayo de fase Ib/I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002438-58,0,0,0 2016-002439-14,9,2019-05-13,2019-05-16,6,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Shire Human Genetic Therapies, Inc.","A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002439-14,1,0,0 2016-002439-14,9,2019-05-13,2019-05-16,6,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"SHIRE HUMAN GENETIC THERAPIES, INC","A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002439-14,1,0,0 2016-002442-23,2,2020-05-18,2020-05-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Sclerosing Cholangitis Without Cirrhosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002442-23,0,0,0 2016-002443-42,2,2019-09-04,2019-09-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002443-42,0,0,0 2016-002445-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Enrique de Madaria,"SIMBA trial: Simvastatin in the Prevention of Recurrent Acute Pancreatitis, a Triple Blind Randomized Controlled Trial Ensayo SIMBA: Simvastatina en la prevención de pancreatitis aguda recurrente: ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002445-31,0,0,0 2016-002446-23,4,2020-02-26,2020-02-26,2,1,1,0,0,0,2,0,0,2,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002446-23,1,1,0 2016-002446-23,4,2020-02-26,2020-02-26,2,1,1,0,0,0,2,0,0,2,0,0,0,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002446-23,1,1,0 2016-002451-21,5,2019-01-31,2019-01-31,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects with Moderate to Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002451-21,0,0,0 2016-002452-25,5,2020-11-04,2020-11-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB BIOPHARMA SPRL,"A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF INTRAVENOUS BRIVARACETAM IN SUBJECTS =1 MONTH TO <16 YEARS OF AGE WITH EPILEPSY STUDIO MULTICENTRICO IN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002452-25,0,0,0 2016-002452-25,5,2020-11-04,2020-11-04,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SRL,"A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF INTRAVENOUS BRIVARACETAM IN SUBJECTS =1 MONTH TO <16 YEARS OF AGE WITH EPILEPSY STUDIO MULTICENTRICO IN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002452-25,0,0,0 2016-002453-38,8,2019-11-06,2020-07-21,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Nektar Therapeutics,"A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002453-38,0,0,0 2016-002453-38,8,2019-11-06,2020-07-21,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,NEKTAR THERAPEUTICS,"A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002453-38,0,0,0 2016-002454-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Rennes,Apomorphine Pump in Early Stage of Parkinson’s Disease Pompe à apomorphine au stade précoce de la maladie de Parkinson,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002454-20,0,0,0 2016-002455-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Efficacy study of the quadrivalent Human Papilloma Virus (HPV) vaccine to prevent recurrence of External Genital Warts (EGW) in patients who were cured in the first place Étude de l’efficacité de l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002455-20,0,0,0 2016-002459-38,1,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,Children's Hospital of Eastern Ontario,Rapid normalization of Vitamin D in critically ill children: A phase II dose evaluation randomized controlled trial (VITdAL-PICU pilot),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002459-38,0,0,0 2016-002460-13,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Medical University of Graz,"Effect of High-Dose Vitamin D3 on 28-Day Mortality in Adult Critically Ill Patients with Severe Vitamin D Deficiency The UK arm of an International Multi-Centre, Placebo-Controlled, Phase III Double-B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002460-13,0,0,0 2016-002460-13,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Medical Unviersity of Graz,"Effect of High-Dose Vitamin D3 on 28-Day Mortality in Adult Critically Ill Patients with Severe Vitamin D Deficiency The UK arm of an International Multi-Centre, Placebo-Controlled, Phase III Double-B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002460-13,0,0,0 2016-002461-66,11,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A phase 3, multi-center, open-label, randomized study of oral ABL001 (asciminib) versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002461-66,0,0,0 2016-002461-66,11,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase 3, multi-center, open-label, randomized study of oral ABL001 (asciminib) versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002461-66,0,0,0 2016-002461-66,11,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A phase 3, multi-center, open-label, randomized study of oral ABL001 (asciminib) versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002461-66,0,0,0 2016-002464-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Sarcomas (GEIS),Phase II trial of nab-paclitaxel for the treatment of desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcoma Ensayo fase II de nab-paclitaxel para e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002464-14,0,0,0 2016-002467-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AIO-Studien-gGmbH,"Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancer - An open label, non-comparative, randomized, multicenter phase II trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002467-34,0,0,0 2016-002473-35,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Biogen Idec Research Limited,"A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002473-35,0,0,0 2016-002474-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Innovatiefonds Zorgverzekeraars,Medication Optimization for ADHD: MOVA study Implementation and evaluation of double-blind placebo-controlled titration in clinical practice,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002474-13,0,0,0 2016-002478-11,1,2021-08-12,2021-08-12,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Medical University of Vienna, Department of Internal medicine I",Very low doses of Rituximab for off-label treatment – a Pilot Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002478-11,0,0,0 2016-002480-34,1,2020-04-30,2020-04-30,1,1,0,1,0,1,1,0,0,1,1,1,0,0,1,F. Hoffmann-La Roche Ltd,A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH IDASANUTLIN AND VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND OBINUTUZUMAB OR RI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002480-34,0,0,0 2016-002481-31,1,2017-11-16,2017-11-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002481-31,0,0,0 2016-002482-54,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,"A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002482-54,0,0,0 2016-002482-54,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffman-La Roche Ltd.,"A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002482-54,0,0,0 2016-002482-54,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002482-54,0,0,0 2016-002485-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen,Optimisation of [68Ga] PSMA-11 PET/CT Imaging Protocol for localizing primary prostate cancer prior to radical prostatectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002485-31,0,0,0 2016-002490-36,5,2021-10-22,2021-10-22,3,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"CytomX Therapeutics, Inc","AN OPEN-LABEL, DOSE-FINDING AND PROOF OF CONCEPT STUDY OF THE PD-L1 PROBODY™ THERAPEUTIC, CX-072, AS MONOTHERAPY AND IN COMBINATION WITH YERVOY® (IPILIMUMAB) OR WITH ZELBORAF® (VEMURAFENIB) IN SUBJECT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002490-36,1,0,0 2016-002491-26,4,2021-07-30,2021-07-30,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002491-26,1,0,0 2016-002492-95,2,2018-04-27,2018-04-27,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma AG,"A randomized, subject and investigator blinded, placebo controlled, multi-center study in parallel groups to assess the efficacy and safety of CJM112 in patients with moderate to severe inflammatory a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002492-95,0,0,0 2016-002493-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,NKI-AVL,Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002493-13,0,0,0 2016-002494-34,2,2017-08-14,2017-08-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses versus Placebo in Patients with Type 2 Diabetes on Metformin Monotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002494-34,0,0,0 2016-002496-10,2,2018-01-09,2018-01-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Nonalcoholic Steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002496-10,0,0,0 2016-002498-36,3,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Clinical Evaluation of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002498-36,0,0,0 2016-002498-36,3,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,National Institutes of Health - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Clinical Evaluation of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002498-36,0,0,0 2016-002499-29,8,,,0,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Alexion Pharmaceuticals Inc.,"A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002499-29,0,0,0 2016-002499-29,8,,,0,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Alexion Pharmaceuticals Incorporated,"A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome (aHUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002499-29,0,0,0 2016-002503-26,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI),Phase Ib/II trial to evaluate safety and efficacy of oral ixazomib in combination with sirolimus and tacrolimus in the prophylaxis of chronic graft-versus-host disease Ensayo de fase Ib/II para eva...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002503-26,0,0,0 2016-002504-43,2,2020-06-22,2020-06-22,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,LIDDS AB,"A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection into the Prostate in Patients with Localized Prostate Cancer, Assign...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002504-43,0,0,0 2016-002508-16,1,2021-03-01,2021-03-01,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Department of Dermatology D92, Bispebjerg Hospital",Optimized photodynamic therapy for basal cell carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002508-16,0,0,0 2016-002509-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,"A randomized, open-label, multicenter, phase III, 2-arm study comparing efficacy and tolerability of the intensified variant ‘dose-dense/dose-intense ABVD’ (ABVD DD-DI) with an interim PET response-ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002509-21,0,0,0 2016-002510-50,1,2020-03-31,2020-03-31,1,1,0,0,0,1,4,0,0,1,1,1,1,0,1,CSL Behring GmbH,"A low-interventional Multicentre Post-Authorisation Safety Study for Voncento/Biostate/Aleviate for Routine Prophylaxis, Treatment of Bleeding Events and/or Surgery in Male Subjects with Haemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002510-50,0,0,0 2016-002512-40,4,2017-05-24,2017-05-24,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin (GSK1325756) co-administered with a standard-of-care antiviral (oseltamivir), in the treatment of adults hospitali...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002512-40,0,0,0 2016-002512-40,4,2017-05-24,2017-05-24,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.","A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin (GSK1325756) co-administered with a standard-of-care antiviral (oseltamivir), in the treatment of adults hospitali...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002512-40,0,0,0 2016-002513-22,6,2018-06-18,2018-06-18,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidimium, and Salmeterol in subjects with chronic obstructive pu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002513-22,0,0,0 2016-002513-22,6,2018-06-18,2018-06-18,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidimium, and Salmeterol in subjects with chronic obstructive pu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002513-22,0,0,0 2016-002513-22,6,2018-06-18,2018-06-18,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A 24-week treatment, multi-center, randomized, double-blind, double-dummy, parallel group study to compare Umeclidinium/Vilanterol, Umeclidimium, and Salmeterol in subjects with chronic obstructive pu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002513-22,0,0,0 2016-002519-17,1,,,0,1,0,0,0,0,4,0,1,1,1,1,0,1,0,KU Leuven - Drug Delivery and Disposition,Supersaturation and precipitation of tacrolimus in the stomach of healthy volunteers Supersaturatie en precipitatie van tacrolimus in de maag van gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002519-17,0,0,0 2016-002522-36,9,2020-05-13,2020-05-13,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma AG,"An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002522-36,0,0,0 2016-002522-36,9,2020-05-13,2020-05-13,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS PHARMA AG,"An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002522-36,0,0,0 2016-002522-36,9,2020-05-13,2020-05-13,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastrointes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002522-36,0,0,0 2016-002523-28,1,2016-10-20,2016-10-20,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Moorfields Eye Hospital,A Pilot Study Evaluating the Effect of Intravitreal Fluocinolone Acetonide (0.19mg) in Patients with Retinitis Pigmentosa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002523-28,0,0,0 2016-002526-36,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,1,Clementia Pharmaceuticals Inc.,"A Phase 2, Open-Label, Efficacy and Safety Study of an RARγ-Specific Agonist (Palovarotene) to Prevent Heterotopic Ossification in Subjects with Fibrodysplasia Ossificans Progressiva (FOP) Étude e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002526-36,0,0,0 2016-002528-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Vestfold Hospital Trust,TOF trial: A randomized double blinded controlled Trial comparing low dose Of sugammadex and neostigmine aFter use of rocuronium during general anesthesia in patients undergoing non-cardiac surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002528-10,0,0,0 2016-002529-12,5,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002529-12,0,0,0 2016-002529-12,5,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002529-12,0,0,0 2016-002531-15,1,2018-06-07,2018-06-07,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,UCL Comprehensive Clinical Trials Unit,"A phase II, open label, non-randomised, single centre, clinical trial of ANX776 in Healthy Volunteers and patients with Glaucoma, Age-Related Macular Degeneration, and Optic Neuritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002531-15,0,0,0 2016-002538-58,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,"Avdeling for Anestesi, Intensiv og Operasjon Bærum Sykehus",QUADRATUS LUMBORUM BLOCK FOR PERIOPERATIVE ANALGESIA IN PATIENTS TREATED WITH ABDOMINOPLASTY. A RANDOMISED CONTROLLED TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002538-58,0,0,0 2016-002539-14,1,2017-12-04,2017-12-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AnaptysBio Inc,Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity upon House Dust Mite Skin Challenge in Patients Suffering from Moderate to Severe Atopic Dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002539-14,0,0,0 2016-002543-41,2,2018-10-09,2018-10-09,2,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Janssen-Cilag International NV,"An Open-label Randomized Phase 1b/2 Study of the Efficacy and Safety of JNJ-64041757, a Live Attenuated Listeria monocytogenes Immunotherapy, in Combination with Nivolumab Versus Nivolumab Monotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002543-41,0,0,0 2016-002545-32,7,,,0,0,0,0,1,0,3,0,0,3,0,0,0,0,1,"Ablative Solutions, Inc","A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects with Hypertension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002545-32,0,0,0 2016-002547-42,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,"Imperial College London, Joint Research Compliance Office","Open-Label Proof of Concept Feasibility Study to Explore the Safety, Tolerability and Potential Role of MDMA-Assisted Psychotherapy for the Treatment of Detoxified Patients with Alcohol Use Disorder.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002547-42,0,0,0 2016-002548-18,1,2017-05-26,2017-05-26,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Karolinska Institutet Södersjukhuset,Hemodynamic effects from administration of body temperature warmed versus room temperature fluid boluses in healthy volunteers Hemodynamiska effekter av kroppsvarma eller rumstempererade vätskeinfu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002548-18,0,0,0 2016-002550-20,1,2022-04-04,2022-04-04,1,0,0,0,0,0,2,0,0,1,1,1,0,0,0,University of Ulm,"Allogeneic microbiota-reconstitution (AMR) for the Treatment of patients with diarrhea-predominant irritable bowel Syndrome (IBS-D) - the AMIRA trial Placebo-kontrollierte, oligozentrische Studie z...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002550-20,0,0,0 2016-002551-22,1,2021-06-04,2021-06-04,1,1,1,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"Study HZA114971, A Multicentre Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg once daily ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002551-22,0,0,0 2016-002552-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Georges François Leclerc,Pemetrexed (Alimta®) in maintenance in patients with impaired renal function: multicenter randomized Phase 4 study comparing two strategies for dose calculation Pemetrexed (Alimta®) en maintenance ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002552-24,0,0,0 2016-002554-21,7,2020-02-07,2020-02-07,5,1,1,0,0,1,2,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB0092 in Participants with Progressive Supranuclear Palsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002554-21,1,0,0 2016-002554-21,7,2020-02-07,2020-02-07,5,1,1,0,0,1,2,0,0,2,1,0,0,0,1,Biogen Idec Research Limited,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB0092 in Participants with Progressive Supranuclear Palsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002554-21,1,0,0 2016-002554-21,7,2020-02-07,2020-02-07,5,1,1,0,0,1,2,0,0,2,1,0,0,0,1,BIOGEN IDEC RESEARCH LIMITED,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB0092 in Participants with Progressive Supranuclear Palsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002554-21,1,0,0 2016-002555-17,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"AZIENDA OSPEDALIERO - UNIVERSITARIA ""POLICLINICO - VITTORIO EMANUELE""","OSIRIS (OSImertinib Rechallenge TKI In Subsequent line of therapy) A Phase II, Noncomparative, Open label, Multicentre, Study of AZD9291, in Patients with Locally Advanced or Metastatic EGFR mutated, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002555-17,0,0,0 2016-002556-24,1,2020-02-06,2020-02-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A national phase IIIb, multi-center, open label study for women and men with hormone-receptor positive, HER2-negative locally advanced or metastatic breast cancer treated with ribociclib (LEE011) in c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002556-24,0,0,0 2016-002557-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Hamburg-Eppendorf,Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem cell transplantation for multiple myeloma. A phase II study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002557-38,0,0,0 2016-002571-10,3,2018-08-08,2018-08-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma Corporation (MTPC),"A Phase IIa, Multi-Centre, Randomised, Double-Blind, Cross-Over, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of MT-8554 in Subjects with Painful Diabetic Peripheral Neurop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002571-10,0,0,0 2016-002573-35,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,"University Health Network, Toronto","A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002573-35,0,0,0 2016-002576-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut régional du Cancer de Montpellier,Lean body mass normalization of oxaliplatin based chemotherapy for stage III colon cancer patients treated in adjuvant satting: Impact on Oxaliplatin induced sensitive neurotoxicity. A multicenter pha...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002576-27,0,0,0 2016-002578-11,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Alder Hey Children's NHS Foundation Trust,The cystic fibrosis (CF) anti-staphylococcal antibiotic prophylaxis trial (CF START); a randomised registry trial to assess the safety and efficacy of flucloxacillin as a longterm prophylaxis agent fo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002578-11,0,0,0 2016-002579-83,4,2019-06-26,2019-09-26,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002579-83,0,0,0 2016-002580-34,1,2018-01-11,2018-01-11,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Theracos Sub, LLC",A double blind placebo controlled study to evaluate the effect of bexagliflozin tablets on hemoglobin A1c in patients with type 2 diabetes mellitus and moderate renal impairment Estudio doble ciego...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002580-34,0,0,0 2016-002583-14,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Novartis Pharmaceuticals Corp,"A Randomized, Open-label, Multi-center, Phase II Study to Evaluate the Safety and Efficacy of Deferasirox (ICL670) 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002583-14,0,1,1 2016-002584-33,16,2021-04-23,2021-04-23,14,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell tran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002584-33,1,0,0 2016-002584-33,16,2021-04-23,2021-04-23,14,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A.,A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell tran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002584-33,1,0,0 2016-002585-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Infektionskliniken Danderyds sjukhus AB,"A randomised, multicentre, controlled trial to study the duration of supplemental oxygen treatment in adults with Mycoplasma pneumoniae pneumonia treated with betamethasone in addition to antibiotics",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002585-32,0,0,0 2016-002586-64,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,ELKE University of Athens,"A randomized, pharmacodynamic study of cangrelor administration in STEMI patients loaded with ticagrelor Χορήγηση κανγκρελόρης μετά από φόρτιση με τικαγκρελόρη έναντι φόρτισης με τικαγκρελόρη μόν...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002586-64,0,0,0 2016-002588-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Radboudumc,USPIO- enhanced High Field MRI for restaging lymph node status in rectal cancer: an explorative study ultra-hoog veld nano-MRI voor de herstadiering van het lokaal uitgebreid rectumcarcinoom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002588-32,0,0,0 2016-002589-30,1,2019-01-08,2019-01-08,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU DE BORDEAUX,Dynamic Contrast enhanced ultrasound for predict and assess rectal cancer response after neo-adjuvant chemoradiation – RECT Radio-chimiothérapie du cancer rectal : Apport de l’échographie de contra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002589-30,0,0,0 2016-002595-27,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,University Medical Center Utrecht,Cytoreductive surgery and Intraperitoneal chemotherapy and for Stomach CAncer: a feasibility study Cytoreductie en Intraperitoneale chemotherapie voor Maagkanker: een faesibility studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002595-27,0,0,0 2016-002596-10,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Incyte Corporation,"A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002596-10,0,0,0 2016-002597-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS,A PHASE II TRIAL OF RECHALLENGE WITH PANITUMUMAB DRIVEN BY RAS CLONAL-MEDIATED DYNAMIC OF RESISTANCE. THE CHRONOS TRIAL. STUDIO DI FASE II CON PANITUMUMAB “RE-CHALLENGE” GUIDATA DALLA DINAMICA DEL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002597-12,0,0,0 2016-002598-36,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Imperial College London,Randomised Clinical Trial of Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002598-36,0,0,0 2016-002599-29,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,HOVON Foundation,"A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002599-29,0,0,0 2016-002600-90,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,"Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and fra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002600-90,0,0,0 2016-002601-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Basque Health Service,Effectiviness and safety of the administration of ondansetron versus placebo for the treatment of vomit in children with mild and moderate dehydration: randomized clinical trial Eficacia y segurida...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002601-19,0,0,0 2016-002602-39,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Radboud University Medical Center,FGF23 response in hypophosphatemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002602-39,0,0,0 2016-002606-39,1,2021-12-31,2021-12-31,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Nemocnice Na Homolce,Resurgence in sternotomy fortified by vitamin D supplementation in cardiac surgery Sledování vlivu suplementace vitaminem D na pooperační hojení ran v kardiochirurgii,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002606-39,0,0,0 2016-002608-19,4,2018-01-31,2018-01-31,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,A Prospective 3-Year Follow-up Study in Subjects Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Vi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002608-19,0,0,0 2016-002611-18,3,2018-01-15,2018-01-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Grünenthal GmbH,"An exploratory, randomized, double-blind, double-dummy, placebo- and active-controlled Phase II trial to evaluate the efficacy and safety of a topical application of GRT7019 in subjects with chronic p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002611-18,0,0,0 2016-002612-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Department of Oncology Rigshospitalet,A phase II study of selinexor (KPT-330) in patients with advanced thymic epithelial tumour (TET) progressing after primary chemotherapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002612-40,0,0,0 2016-002617-21,1,2017-04-05,2017-04-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Zealand Pharma A/S,"A randomised, sequential, cross-over trial assessing pharmacokinetic and pharmacodynamic responses after micro-doses of ZP4207 administered subcutaneously to patients with type 1 diabetes mellitus und...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002617-21,0,0,0 2016-002620-92,1,2017-03-30,2017-03-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Nuvo Pharmaceuticals Inc.,"A multi-centre, randomised, controlled, double-blind, parallel-group study on the efficacy and safety of Pennsaid-2% topical skin solution in patients with Grade I-II ankle sprain Multizentrische, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002620-92,0,0,0 2016-002621-10,12,2022-05-13,2022-05-13,8,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer Studio di sicurezza di fase IIIb/IV sulla somministrazione di niv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002621-10,1,0,0 2016-002621-10,12,2022-05-13,2022-05-13,8,0,0,0,0,0,3,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer Studio di sicurezza di fase IIIb/IV sulla somministrazione di niv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002621-10,1,0,0 2016-002623-29,1,2017-08-22,2017-08-22,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Aalborg Universitets Hospital,The Effect of Morphine on the Human Central Nervous System,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002623-29,0,0,0 2016-002625-11,18,2022-03-16,2022-03-16,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffman-La Roche Ltd.,"AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002625-11,1,0,0 2016-002625-11,18,2022-03-16,2022-03-16,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Roche Farma S.A., que representa en España a F. Hoffman-La Roche Ltd.","AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002625-11,1,0,0 2016-002625-11,18,2022-03-16,2022-03-16,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"AN OPEN LABEL, SINGLE ARM, MULTICENTER, SAFETY STUDY OF ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL OR NON-UROTHELIAL CARCINOMA OF THE URINARY TRACT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002625-11,1,0,0 2016-002626-37,1,2022-07-20,2022-07-20,1,0,0,0,0,1,2,0,0,1,0,0,0,0,0,University of Cologne,"Nivolumab and AVD in earlystage unfavorable classical Hodgkin lymphoma - A GHSG randomized, multicenter phase II trial Nivolumab und AVD für Patienten mit klassischem Hodgkin Lymphom im intermediär...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002626-37,0,0,0 2016-002628-96,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Imperial College London,"A multi-centre, double-blind, randomised, controlled clinical trial of Rifaximin to reduce infection in patients admitted to hospital with decompensated cirrhosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002628-96,0,0,0 2016-002629-13,8,2018-10-26,2018-10-26,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Cytokinetics, Inc.","A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) who Completed VITALITY-ALS (CY 4031)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002629-13,0,0,0 2016-002629-13,8,2018-10-26,2018-10-26,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"CYTOKINETICS, INC.","A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients with Amyotrophic Lateral Sclerosis (ALS) who Completed VITALITY-ALS (CY 4031)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002629-13,0,0,0 2016-002634-69,8,2021-05-27,2021-05-27,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","Protocol I1F-MC-RHBY A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002634-69,0,0,0 2016-002634-69,8,2021-05-27,2021-05-27,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Protocol I1F-MC-RHBY A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002634-69,0,0,0 2016-002634-69,8,2021-05-27,2021-05-27,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"Protocol I1F-MC-RHBY A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002634-69,0,0,0 2016-002635-15,1,2018-10-02,2018-10-02,1,0,0,0,0,0,3,0,1,1,1,1,1,0,0,VU Medical Center,Study to Identify Factors associated with Resilience to Clinical Dementia at Old Age Studie naar de beschermende factoren voor dementie bij mensen boven de 90 jaar,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002635-15,0,0,0 2016-002638-54,2,2021-11-04,2021-11-04,1,0,0,1,0,1,1,0,0,2,0,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients with Acute Intermittent Porphyria who have Completed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002638-54,1,0,0 2016-002639-14,3,2019-07-16,2019-07-16,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002639-14,0,0,0 2016-002642-23,3,2020-12-09,2020-12-09,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novadip Biosciences,"A prospective multi-centre, randomised, controlled study to evaluate the safety and preliminary effectiveness of NVD-001 for the treatment of low grade degenerative lumbar spondylolisthesis by interbo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002642-23,0,0,0 2016-002642-23,3,2020-12-09,2020-12-09,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novadip Biosciences S.A.,"A prospective multi-centre, randomised, controlled study to evaluate the safety and preliminary effectiveness of NVD-001 for the treatment of low grade degenerative lumbar spondylolisthesis by interbo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002642-23,0,0,0 2016-002643-41,1,2016-12-19,2016-12-19,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Department of Anesthesiology, Næstved Hospital","Sensory distribution of lateral femoral cutaneous nerve block - a randomised, blinded, paired trial in heathy volunteers Sensorisk udbredelse af nervus cutaneous femoris lateralis blokade - Et ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002643-41,0,0,0 2016-002648-18,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE HOPITAUX MARSEILLE,“EVALUATION OF AN INNOVATIVE TREATMENT FOR RADIOCARPAL OSTEOARTHRITIS USING INTRA-ARTICULAR INJECTION OF A MIXTURE OF AUTOLOGOUS MICROFAT AND AUTOLOGOUS PLATELET-RICH PLASMA” « EVALUATION D’UN TRAI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002648-18,0,0,0 2016-002649-41,5,2021-11-08,2022-04-13,3,0,0,0,0,0,3,0,0,1,1,0,0,0,1,Octapharma Pharmazeutika Produktionsges.m.b.H,"A Phase III, randomized, double-blind, multicenter study to assess the efficacy and safety of OCTAPLEX, a four-factor prothrombin complex concentrate (4F-PCC), compared to the 4F-PCC Beriplex® P/N (Kc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002649-41,0,0,0 2016-002651-25,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,"Research Governance and Integrity, University of Manchester",A Phase II Randomised Controlled Study of Oral Prednisolone in Early Diffuse Cutaneous Systemic Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002651-25,0,0,0 2016-002652-25,2,2019-02-27,2019-02-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"ACHILLION PHARMACEUTICALS, INC.","A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of ACH-0144471 in Untreated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002652-25,0,0,0 2016-002652-25,2,2019-02-27,2019-02-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Achillion Pharmaceuticals, Inc.","A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of ACH-0144471 in Untreated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002652-25,0,0,0 2016-002654-21,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospital Southampton NHS Foundation Trust,"A PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH-DOSE THERAPY.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002654-21,0,0,0 2016-002656-24,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Oxford (Clinical Trials and Research Governance)),A randomised placebo-controlled clinical trial of fenofibrate to prevent progression of non-proliferative retinopathy in diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002656-24,0,0,0 2016-002657-38,4,2018-11-27,2018-11-27,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Relypsa, Inc","A Randomized, Double-Blind, Placebo controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients with Resistant Hypertension and Chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002657-38,0,0,0 2016-002658-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department für Kinder- und Jugendheilkunde, Pädiatrie I",Influence of pulsatile dexamethasone therapy in childhood epilepsia on the immune Systeme. Einflüsse der pulsatilen Dexamethason-Therapie auf das Immunsystem bei der Behandlung kindlicher Epilepsie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002658-19,0,0,0 2016-002660-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorcio Hospital General Universitario de Valencia,Treatment of Ferropenic Anaemia due to acute gastrointestinal bleeding: oral vs intravenous iron therapy TRATAMIENTO DE LA ANEMIA FERROPÉNICA POSTHEMORRAGIA DIGESTIVA AGUDA: FERROTERAPIA ORAL VS IV,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002660-13,0,0,0 2016-002663-33,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Alloksys Life Sciences BV,Preventing Oxidative stress induced Ischemic Injury and Systemic Inflammation complications during and after invasive Cardiac surgery with Alkaline Phosphatase (APPIRED III),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002663-33,0,0,0 2016-002667-34,2,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"AN OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF OCRELIZUMAB IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002667-34,0,0,0 2016-002667-34,2,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"AN OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF OCRELIZUMAB IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002667-34,0,0,0 2016-002670-12,1,,,0,0,0,0,0,3,2,0,0,3,0,0,0,0,0,Univeristy of Leeds,MUK nine b: OPTIMUM. A phase II study evaluating multiple novel agentsoptimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002670-12,0,0,0 2016-002671-10,1,2017-05-05,2017-05-05,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A two-part trial to evaluate the safety, tolerability, clinical effect and systemic exposure potential of topically applied GSK2981278 ointment in subjects with plaque psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002671-10,0,0,0 2016-002673-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,PRO-IMPLANT Foundation,"Efficacy and safety of intravenous fosfomycin in prosthetic joint infection (PJI) caused by staphylococci, streptococci, enterococci and gram-negative bacilli, including mixed infections and culture n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002673-35,0,0,0 2016-002674-12,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Asociación Terapéutica Investigación Oncológica (ATRIO),"A phase II, randomised, opened and multicenter study, to evaluate the effect of metronomic oral Vinorelbine vs the best treatment of support as maintenance therapy after first-line chemotherapy based ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002674-12,0,0,0 2016-002674-12,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO),"A phase II, randomised, opened and multicenter study, to evaluate the effect of metronomic oral Vinorelbine vs the best treatment of support as maintenance therapy after first-line chemotherapy based ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002674-12,0,0,0 2016-002675-97,5,2017-10-27,2018-01-09,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Ono Pharmaceutical Co., Ltd.","A randomised, double-blind, placebo controlled, parallel group, multi-centre, study to evaluate the efficacy, safety, tolerability and pharmacokinetics of ONO-4474 in patients with pain due to osteoar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002675-97,0,0,0 2016-002676-27,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,2,Medica Scientia Innovation Research (MedSIR),Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002676-27,0,0,0 2016-002676-27,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,2,MEDICA SCIENTIA INNOVATION RESEARCH S.L.,Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002676-27,0,0,0 2016-002678-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut Català d’Oncologia,"An open label biomarker pilot study of the antitumoral acrivity of denosumab in the pre-operative setting of early breast cancer Estudio piloto, abierto, de biomarcadores de la actividad antitumora...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002678-11,0,0,0 2016-002680-34,1,2018-11-28,2018-11-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Clínica Universidad de Navarra/Universidad de Navarra,Effects of different concentrations of dexmedetomidine on basal ganglia neuronal activity (local field potentials) in Parkinson's disease. Efecto de diferentes concentraciones de dexmedetomidina en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002680-34,0,0,0 2016-002681-31,9,2019-01-02,2019-01-02,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,"A randomized, active-comparator-controlled, multicenter study to assess the safety and efficacy of different doses of BAY 1213790 for the prevention of venous thromboembolism in patients undergoing el...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002681-31,0,0,0 2016-002683-14,12,2019-06-06,2019-06-06,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Daiichi Sankyo Europe GmbH,Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent plac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002683-14,0,0,0 2016-002683-14,12,2019-06-06,2019-06-06,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,DAIICHI SANKYO EUROPE GMBH,Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent plac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002683-14,0,0,0 2016-002688-32,9,2018-04-20,2018-04-20,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shionogi Ltd.,"A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared with Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients with Influenza at High Risk of Influen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002688-32,0,0,0 2016-002689-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Medica Scientia Innovation Research (MedSIR ARO),"Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER2-negative breast cancer Ensayo fase II, abierto y multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002689-30,0,0,0 2016-002690-35,1,2019-04-15,2019-04-15,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Scandinavian Biopharma AB,"A randomized, placebo-controlled phase IIb (OEV 123) study to evaluate safety, immunogenicity, diagnostic methodology, and estimate vaccine efficacy of an oral enterotoxigenic Escherichia coli (ETEC)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002690-35,0,0,0 2016-002691-27,1,2020-08-31,2020-08-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Academic Medical Center,"An open label exploratory analysis of the histological, immunological and microbiome changes of the colonic mucosa during treatment with tofacitinib for moderate-severe ulcerative colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002691-27,0,0,0 2016-002692-98,1,2019-06-06,2019-06-06,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GAMA Healthcare,"An evaluation of the efficacy of HEXI-PREP by Clinell Wipes versus placebo and ChloraPrep, for use in pre-operative skin preparation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002692-98,0,0,0 2016-002696-10,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Novartis Pharma AG,"An open-label first-in-human single ascending dose study to explore the safety, tolerability and efficacy of subretinal administration of CPK850 gene therapy in patients with retinitis pigmentosa caus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002696-10,0,0,0 2016-002698-36,5,2018-08-06,2018-08-06,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,UCB Biopharma SPRL,"A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects with Moderate to Sever...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002698-36,0,0,0 2016-002700-78,1,2018-08-27,2018-08-27,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KU Leuven - Drug Delivery and Disposition,Supersaturation and precipitation of ritonavir in the gastrointestinal tract of healthy volunteers Supersaturatie en precipitatie van ritonavir in het gastrointestinaal stelsel van gezonde vrijwill...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002700-78,0,0,0 2016-002705-19,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO,"A phase IV, randomized, controlled, double-blind study on efficacy and safety of OM-85 in children with recurrent respiratory tract infections Studio farmacologico di fase IV, randomizzato, contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002705-19,0,0,0 2016-002707-25,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,IRCCS ISTITUTO CLINICO HUMANITAS,Comparison between two therapeutic strategies for the maintenance of clinical and endoscopic remission in patients with ulcerative colitis treated by infliximab (SCILLA). Confronto tra due strategi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002707-25,0,0,0 2016-002708-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de NIMES,Pharmacokinetic study on echinocandins for patients with septic shock following secondary peritonitis Etude pharmacocinétique des échinocandines chez les patients en choc septique sur péritonite se...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002708-17,0,0,0 2016-002714-45,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Instituto de Investigación Sanitaria Fundación Jiménez Díaz,"""Pilot study to assess the efficacy of treatment with metformin in patients with Hidradenitis suppurativa refractory to standard treatment "" “Estudio piloto para evaluar la eficacia del tratamiento...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002714-45,0,0,0 2016-002716-41,1,2019-08-21,2019-08-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ROCHE SAS,"AN EXTENSION STUDY TO EVALUATE LONG TERM SAFETY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH GIANT CELL ARTERITIS WHO HAVE COMPLETED WA28119 CORE STUDY IN FRANCE, AND SUBSEQUENTLY HAVING FLARE OR PERS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002716-41,0,0,0 2016-002718-32,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"BOSTON BIOMEDICAL, INC.","A Phase III Randomized, Open-Label Clinical Trial of BBI-608 plus Weekly Paclitaxel versus Weekly Paclitaxel Alone in Patients with Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002718-32,0,0,0 2016-002718-32,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Boston Biomedical, Inc.","A Phase III Randomized, Open-Label Clinical Trial of BBI-608 plus Weekly Paclitaxel versus Weekly Paclitaxel Alone in Patients with Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002718-32,0,0,0 2016-002720-91,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,CyTuVax BV,Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002720-91,0,0,0 2016-002722-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FUNDACIÓ LLUITA CONTRA LA SIDA,"Randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of Raltegravir intensification (1.200 mg QD) on the gut microbiota of chronically HIV-1 infected subject over time: T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002722-36,0,0,0 2016-002724-83,3,2017-11-02,2018-11-27,2,1,0,0,0,0,2,0,0,1,1,0,1,0,0,Erasmus MC,"A phase IIa randomized, placebo controlled, double blinded study to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral ther...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002724-83,0,0,0 2016-002725-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITà DEGLI STUDI DI PERUGIA,"HEAD TO HEAD COMPARISON IN PHARMACOKINETICS AND PHARMACODYNAMICS, AND CLINICAL EFFICACY BETWEEN INSULIN GLARGINE U300 AND INSULIN DEGLUDEC IN TYPE 1 DIABETES HEAD TO HEAD COMPARISON IN PHARMACOKINE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002725-11,0,0,0 2016-002728-94,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Sahlgrenska University Hospital,"A phase I/II, open-label study of safety, immune activation and efficacy of histamine dihydrochloride and low-dose interleukin-2 in adult tyrosine kinase inhibitor-treated patients with chronic myeloi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002728-94,0,0,0 2016-002731-14,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,IBSA INSTITUT BIOCHIMIQUE SA,"Prospective, randomised, double-blind, placebo controlled, phase III clinical study assessing the efficacy of 25 mg natural progesterone administered subcutaneously in restoring the normal luteal phas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002731-14,0,0,0 2016-002732-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS,Radiometabolic Therapy (RMT) with 177Lu PSMA 617 in advanced castration resistant prostate cancer (CRPC): efficacy and toxicity evaluation Terapia radiometabolica (RMT) con 177Lu PSMA 617 nei tumor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002732-32,0,0,0 2016-002733-30,3,2017-07-14,2017-07-14,3,1,0,1,0,0,1,0,1,1,1,1,0,0,1,GlaxoSmithKline Biologicals,"A Phase I/II, randomised, observer-blind, controlled multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of GSK Biologicals’ investigational RSV ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002733-30,0,0,0 2016-002733-30,3,2017-07-14,2017-07-14,3,1,0,1,0,0,1,0,1,1,1,1,0,0,1,GlaxoSmithKline S.A,"A Phase I/II, randomised, observer-blind, controlled multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of GSK Biologicals’ investigational RSV ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002733-30,0,0,0 2016-002735-16,1,2018-08-30,2018-08-30,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Otto-von-Guericke-Universität Magdeburg,"Correlation between common clinical outcome parameters, CTC-changes and ARV7-status (androgen receptor splice variant 7) in patients with mCRPC treated with first line abiraterone acetat (Zytiga®) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002735-16,0,0,0 2016-002736-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,CENTRE LEON BERARD,CHEMOIMMUNE - A Phase II study evaluating an anti-PD1 monoclonal antibody (pembrolizumab) in lymphopenic metastatic breast cancer patients treated with metronomic cyclophosphamide CHEMOIMMUNE - Et...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002736-33,0,0,0 2016-002738-55,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,"Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis ( IPOXA ) IPOXA, Essai de Phase I/II en escala...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002738-55,0,0,0 2016-002739-14,4,2017-11-08,2017-11-14,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Sanofi-aventis recherche & développement,"Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients with Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002739-14,0,0,0 2016-002739-14,4,2017-11-08,2017-11-14,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients with Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002739-14,0,0,0 2016-002743-41,1,2017-06-26,2017-06-26,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Engelhard Arzneimittel GmbH & Co. KG,"Prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center trial to evaluate the efficacy and safety of cineole vs. placebo in the treatment of acute non-purulent rhinosin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002743-41,0,0,0 2016-002744-17,10,2020-01-10,2020-01-10,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"MULTICENTER, INTERNATIONAL, DOUBLEBLIND, TWO-ARM, RANDOMIZED, PLACEBO CONTROLLED PHASE II TRIAL OF PIRFENIDONE IN PATIENTS WITH UNCLASSIFIABLE PROGRESSIVE FIBROSING ILD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002744-17,0,0,0 2016-002744-17,10,2020-01-10,2020-01-10,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"MULTICENTER, INTERNATIONAL, DOUBLEBLIND, TWO-ARM, RANDOMIZED, PLACEBO CONTROLLED PHASE II TRIAL OF PIRFENIDONE IN PATIENTS WITH UNCLASSIFIABLE PROGRESSIVE FIBROSING ILD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002744-17,0,0,0 2016-002744-17,10,2020-01-10,2020-01-10,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Roche Farma S.A, que representa en España a F. Hoffmann-La Roche Ltd","MULTICENTER, INTERNATIONAL, DOUBLEBLIND, TWO-ARM, RANDOMIZED, PLACEBO CONTROLLED PHASE II TRIAL OF PIRFENIDONE IN PATIENTS WITH UNCLASSIFIABLE PROGRESSIVE FIBROSING ILD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002744-17,0,0,0 2016-002749-42,12,2021-09-23,2021-09-23,10,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"Gilead Sciences, Inc.","Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002749-42,1,1,0 2016-002761-63,13,2021-04-06,2021-04-06,9,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Inovio Pharmaceuticals, Inc.","A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA¿ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR HPV-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002761-63,1,0,0 2016-002761-63,13,2021-04-06,2021-04-06,9,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"INOVIO PHARMACEUTICALS, INC.","A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VGX-3100 DELIVERED INTRAMUSCULARLY FOLLOWED BY ELECTROPORATION WITH CELLECTRA¿ 5PSP FOR THE TREATMENT OF HPV-16 AND/OR HPV-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002761-63,1,0,0 2016-002763-34,16,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Gilead Sciences, Inc.",A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease Studio di estensione a lungo termine per la valutazione della sicurezza di Filgotinib in soggetti c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002763-34,0,0,0 2016-002763-34,16,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Galapagos NV,A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease Studio di estensione a lungo termine per la valutazione della sicurezza di Filgotinib in soggetti c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002763-34,0,0,0 2016-002763-34,16,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GILEAD SCIENCES INCORPORATED,A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease Studio di estensione a lungo termine per la valutazione della sicurezza di Filgotinib in soggetti c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002763-34,0,0,0 2016-002765-58,17,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Gilead Sciences, Inc.",A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002765-58,0,0,0 2016-002765-58,17,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,GILEAD SCIENCES INCORPORATED,A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002765-58,0,0,0 2016-002765-58,17,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Galapagos NV,A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002765-58,0,0,0 2016-002765-58,17,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Gilead Sciences, Inc",A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002765-58,0,0,0 2016-002766-31,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Leids Universitair Medisch Centrum,"A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in advanced chordoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002766-31,0,0,0 2016-002766-31,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,UCL,"A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in advanced chordoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002766-31,0,0,0 2016-002768-15,1,2020-10-01,2020-10-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Entospletinib with and without Obinutuzumab in Subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002768-15,0,0,0 2016-002769-72,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Næstved Hospital,"DEXRAR: DEXamethasone in Revision ARthroplasty: A randomised, blinded, 2-group clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002769-72,0,0,0 2016-002771-10,5,2021-01-13,2021-01-13,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Molecular Partners AG,"A Phase II open-label, single-arm, multicenter trial of MP0250 plus bortezomib+dexamethasone in patients with refractory and relapsed multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002771-10,0,0,0 2016-002772-27,3,2018-08-09,2018-08-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Angelini S.p.A.,"Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy: randomized, controlled, pilot study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002772-27,0,0,0 2016-002772-27,3,2018-08-09,2018-08-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,A.C.R.A.F. SpA (Angelini SpA),"Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy: randomized, controlled, pilot study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002772-27,0,0,0 2016-002777-35,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,IBSA INSTITUT BIOCHIMIQUE SA,"Prospective, double-blind, randomised, placebo controlled, phase III clinical study assessing the efficacy of natural progesterone 25 mg/bid administered subcutaneously in the maintenance of early pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002777-35,0,0,0 2016-002778-11,10,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,EISAI LIMITED,"A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002778-11,0,0,0 2016-002778-11,10,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Eisai Ltd,"A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002778-11,0,0,0 2016-002780-34,3,2017-09-26,2017-11-07,2,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Versartis, Inc.","An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children with Growth Hormone Deficiency The VISTA Study: Versartis Long-Term Safety Study of Somava...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002780-34,0,0,0 2016-002781-31,4,2018-06-20,2018-06-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergy Therapeutics (UK) Ltd,"A multi-centre, double-blind, randomised, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Birch Modified Allergen Tyrosine adsorbed + MPL in the prevention of seasonal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002781-31,0,0,0 2016-002782-57,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Institut des maladies génétiques - Imagine,Phase 2 study of Brentuximab Vedotin associated with CHP followed by consolidation with high-dose therapy / autologous stem-cell transplantation as frontline treatment of patients with enteropathy-ass...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002782-57,0,0,0 2016-002784-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Radboudumc,Deferoxamine in Aneurysmal Subarachnoid Hemorrhage pilot trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002784-34,0,0,0 2016-002784-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,Deferoxamine in Aneurysmal Subarachnoid Hemorrhage pilot trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002784-34,0,0,0 2016-002785-31,3,2022-05-13,2022-05-13,2,0,1,0,0,0,2,0,0,2,1,0,0,0,1,"Vifor Pharma, Inc.","A Phase 2, Open-Label, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer for Oral Suspension in Children and Adolescents 2 to < 18 Years of Age with Ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002785-31,1,0,0 2016-002785-31,3,2022-05-13,2022-05-13,2,0,1,0,0,0,2,0,0,2,1,0,0,0,1,"Relypsa, Inc.","A Phase 2, Open-Label, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer for Oral Suspension in Children and Adolescents 2 to < 18 Years of Age with Ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002785-31,1,0,0 2016-002786-62,1,,,0,1,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Départemental Vendée,ROPISIO - Etude de l’effet antalgique de l’infiltration périnéale de ropivacaïne 0.75% versus placebo dans la douleur périnéale post épisiotomie : étude randomisée en double aveugle.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002786-62,0,0,0 2016-002790-35,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,INSERM,Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002790-35,0,0,0 2016-002794-35,15,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002794-35,0,0,0 2016-002794-35,15,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002794-35,0,0,0 2016-002794-35,15,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002794-35,0,0,0 2016-002796-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR),Assessment of intrapulmonary concentrations of meropenem administered by continuous infusion in postoperative pneumonia. Evaluación de las concentraciones intrapulmonares de meropenem tras perfusi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002796-10,0,0,0 2016-002799-28,2,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Transgene,A phase Ib/II trial evaluating the combination of TG4001 and avelumab in patients with HPV-16 positive recurrent or metastatic malignancies and expansion cohort to oropharyngeal squamous cell carcinom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002799-28,0,0,0 2016-002801-20,6,2019-03-04,2019-03-05,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,A trial comparing the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without oral a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002801-20,0,0,0 2016-002804-14,7,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Zogenix International Limited,An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults with Dravet Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002804-14,0,0,0 2016-002804-14,7,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc",An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults with Dravet Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002804-14,0,0,0 2016-002805-21,1,2020-02-17,2020-02-17,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU Clermont-Ferrand,Evaluation du nalméfène dans les troubles du contrôle des impulsions chez des patients ayant une maladie de Parkinson : une étude thérapeutique prospective ouverte,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002805-21,0,0,0 2016-002807-24,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Gastric Cancer - Master Protocol Amendment 06 dated 13-Aug-2021 - Sub-protocol A ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002807-24,0,0,0 2016-002807-24,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Gastric Cancer - Master Protocol Amendment 06 dated 13-Aug-2021 - Sub-protocol A ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002807-24,0,0,0 2016-002808-19,3,2018-04-02,2018-04-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,A.C.R.A.F. S.p.A. (Aziende Chimiche Riunite Angelini Francesco),Phase III study to evaluate the efficacy of a novel antimycotic vaginal pessary combination (containing Benzydamine HCl 6 mg and Econazole nitrate 150 mg) in the Treatment of uncomplicated vulvovagina...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002808-19,0,0,0 2016-002808-19,3,2018-04-02,2018-04-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.,Phase III study to evaluate the efficacy of a novel antimycotic vaginal pessary combination (containing Benzydamine HCl 6 mg and Econazole nitrate 150 mg) in the Treatment of uncomplicated vulvovagina...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002808-19,0,0,0 2016-002808-19,3,2018-04-02,2018-04-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.p.A.,Phase III study to evaluate the efficacy of a novel antimycotic vaginal pessary combination (containing Benzydamine HCl 6 mg and Econazole nitrate 150 mg) in the Treatment of uncomplicated vulvovagina...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002808-19,0,0,0 2016-002811-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitätsklinik für Dermatologie und Allergologie der Paracelsus medizinischen Privatuniversität Salzburg,Phase II Study of Nivolumab in Patients with Locally Advanced/ Metastatic Squamous Cell Carcinoma of the Skin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002811-16,0,0,0 2016-002813-24,1,2017-03-01,2017-03-01,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,Bayer AG,"Relative bioavailability study to investigate the pharmacokinetics, safety and tolerability of a single oral dose of finerenone 20 mg as suspension (pediatric formulation), intact tablet and crushed t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002813-24,0,0,0 2016-002814-29,4,2022-05-30,2022-05-30,2,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"SOAR Trial, A two-part study: Interventional phase II single-arm trial to assess efficacy and safety of Eltrombopag combined with cyclosporine as first line therapy in patients with severe acquired ap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002814-29,1,0,0 2016-002814-29,4,2022-05-30,2022-05-30,2,0,0,0,0,1,2,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"SOAR Trial, A two-part study: Interventional phase II single-arm trial to assess efficacy and safety of Eltrombopag combined with cyclosporine as first line therapy in patients with severe acquired ap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002814-29,1,0,0 2016-002814-29,4,2022-05-30,2022-05-30,2,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A","SOAR Trial, A two-part study: Interventional phase II single-arm trial to assess efficacy and safety of Eltrombopag combined with cyclosporine as first line therapy in patients with severe acquired ap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002814-29,1,0,0 2016-002817-22,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,TETEC Tissue Engineering Technologies - AG,"Prospective, Multicenter, Single-arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of NOVOCART® Inject plus in the Treatment of Cartilage Defects of the Knee",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002817-22,0,0,0 2016-002819-18,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,0,Bispebjerg University Hospital,Pharmacological effects of acute and accumulated salbutamol in relation to doping analysis Farmakologiske effekter af akut og akkumuleret salbutamol i relation til doping analyse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002819-18,0,0,0 2016-002820-10,3,2018-09-12,2018-09-12,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biogen Idec Research Limited,"A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) Switching from Natalizuma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002820-10,0,0,0 2016-002820-10,3,2018-09-12,2018-09-12,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BIOGEN IDEC RESEARCH LIMITED,"A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) Switching from Natalizuma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002820-10,0,0,0 2016-002822-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Treatment with azacitidine of recurrent gliomas with IDH1/2 mutation: AGIR Traitement par azacitidine des Gliomes avec mutation IDH1/2 en rechute : AGIR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002822-35,0,0,0 2016-002823-27,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,INFECTOPHARM Arzneimittel GmbH,"Placebo-kontrollierte, multizentrische, randomisierte, doppelblinde Phase III-Studie zur Verbesserung der gastrointestinalen Verträglichkeit einer per-oralen Antibiotikatherapie durch add-on-Gabe von ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002823-27,0,0,0 2016-002824-98,1,2018-12-04,2018-12-04,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Fundació Hospital Vall Hebron Institut de Recerca,"Comparison of three techniques in the management of the postoperatory acute pain, after a general anesthesia based on the control of the nociception. Comparación de tres técnicas en el manejo del ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002824-98,0,0,0 2016-002826-35,6,2019-04-30,2019-04-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to a Sulfonylurea alone or in combination with Metformin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002826-35,0,0,0 2016-002826-35,6,2019-04-30,2019-04-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis Recherche & Développement,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to a Sulfonylurea alone or in combination with Metformin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002826-35,0,0,0 2016-002827-27,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Edinburgh Molecular Imaging Ltd.,"A Phase IIb, Open Label Study for the Detection of Dysplastic Colorectal Polyps during Colonoscopy after EMI-137 Injection in Patients with High Suspicion of Colorectal Cancer. Fase IIb, open studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002827-27,0,0,0 2016-002828-85,13,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,University of Birmingham,Paediatric Hepatic International Tumour Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002828-85,0,0,0 2016-002828-85,13,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Medical University of Gdansk,Paediatric Hepatic International Tumour Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002828-85,0,0,0 2016-002831-14,1,2021-12-17,2021-12-17,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Incyte Corporation,"A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002831-14,0,0,0 2016-002832-34,1,2019-09-27,2019-09-27,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Liverpool Heart & Chest Hospital,"Aztreonam for inhalation for the treatment of acute exacerbations in cystic fibrosis. An open-label, randomised, cross-over pilot study of AZLI plus intravenous Colistin versus standard dual intraveno...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002832-34,0,0,0 2016-002833-31,1,2019-03-04,2019-03-04,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma Services AG,"A randomized, patient and investigator blinded, placebo-controlled, multicenter study to assess the safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with non-alcoholic steatoh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002833-31,0,0,0 2016-002834-59,2,2019-08-14,2019-08-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanifit Therapeutics S.A.,"A double-blind, randomised, placebo-controlled study to assess the effect of SNF472 on progression of cardiovascular calcification on top of standard of care in end-stage-renal-disease (ESRD) patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002834-59,0,0,0 2016-002834-59,2,2019-08-14,2019-08-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratoris Sanifit,"A double-blind, randomised, placebo-controlled study to assess the effect of SNF472 on progression of cardiovascular calcification on top of standard of care in end-stage-renal-disease (ESRD) patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002834-59,0,0,0 2016-002835-14,1,2017-08-24,2017-08-24,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Nordsjællands Hospital Hillerød,Supraclavicular catheter for regional anesthesia of the shoulder - an explorative study in healthy volunteers. Supraklavikulært kateter til blokade af skuldernerver - et eksplorativt studie på rask...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002835-14,0,0,0 2016-002837-31,5,2017-08-11,2017-08-24,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galapagos NV,"A phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2222 in ivacaftor-treated subjects with Cystic Fibrosis harbouring one F508del CFTR mutation and a second gating (class ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002837-31,0,0,0 2016-002843-40,1,2018-05-30,2018-05-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase IIb, 24 week, randomized, double-blind, 3 arm parallel group study, comparing the efficacy, safety and tolerability of two doses of umeclidinium bromide administered once-daily via a dry powde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002843-40,0,0,0 2016-002844-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Medical University of Vienna, Dpt. of Pediatrics",Preventive sublingual immunotherapy for house dust mite sensitized preschool children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002844-18,0,0,0 2016-002845-46,1,2018-05-11,2018-05-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Alios BioPharma, Inc.","A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir, with or without Simeprevir, in Treatment-Naïve Subjects with Genotype 1, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002845-46,0,0,0 2016-002846-21,1,2018-11-19,2018-11-19,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,BCN Peptides S.A.,"CLINICAL TRIAL PHASE IIa PROOF OF CONCEPT, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED IN PATIENTS WITH NEUROPATHIC PAIN DUE TO PERIPHERAL NERVE INJURY ENSAYO CLÍNICO FASE IIa DE PRUEBA DE CONCEPT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002846-21,0,0,0 2016-002851-92,4,2018-03-27,2018-03-27,3,0,0,0,0,1,0,0,0,2,1,0,0,0,1,"ANTHERA Pharmaceuticals, Inc.",An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002851-92,1,0,0 2016-002852-26,6,2018-08-29,2018-08-29,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck KGaA,"A multicenter, randomized, double-blind, Phase III trial to evaluate the safety, immunogenicity, and efficacy of MSB11022 compared with Humira® in patients with moderately to severely active rheumatoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002852-26,0,0,0 2016-002854-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZ Leuven,"Neoadjuvant degarelix +/- apalutamide (ARN-509) followed by radical prostatectomy for intermediate and high-risk prostate cancer: a randomized, placebo-controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002854-19,0,0,0 2016-002855-48,18,2021-10-25,2021-10-28,14,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Bayer AG,"A randomized, parallel-group, double-blind, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002855-48,1,0,0 2016-002855-48,18,2021-10-25,2021-10-28,14,1,0,0,0,0,3,0,0,2,1,0,0,0,1,BAYER HEALTHCARE AG,"A randomized, parallel-group, double-blind, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002855-48,1,0,0 2016-002856-26,1,2021-01-05,2021-01-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,SRH Wald-Klinikum Gera GmbH,"A PHASE II, SINGLE-ARMED, MULTICENTER TRIAL OF NEOADJUVANT VISMODEGIB IN PATIENTS WITH LARGE AND/OR RECURRENT RESECTABLE BASAL CELL CARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002856-26,0,0,0 2016-002858-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GETNE (Grupo Español de Tumores Neuroendocrinos),A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with advanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin (the DUNE trial). Estudio c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002858-20,0,0,0 2016-002859-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Erasmus MC,Withdrawing off-label antipsychotics in people with intellectual disabilities: why does it fail? Antipsychotica afbouwen bij mensen met een verstandelijke beperking: waarom lukt het niet?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002859-19,0,0,0 2016-002860-15,2,2017-11-14,2017-11-16,2,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Galderma R&D SNC,"A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50μg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002860-15,0,0,0 2016-002862-30,6,2017-12-12,2017-12-12,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILE OF PF-06651600 IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE RHEUMAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002862-30,0,0,0 2016-002862-30,6,2017-12-12,2017-12-12,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017 US","A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILE OF PF-06651600 IN SUBJECTS WITH MODERATE TO SEVERE ACTIVE RHEUMAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002862-30,0,0,0 2016-002863-32,2,2017-08-18,2017-08-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A phase IIa, randomised, multi-centre, double blind, placebo-controlled 3 periods, crossover study to investigate the efficacy, pharmacokinetics, safety and tolerability of inhaled AZD8871 administer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002863-32,0,0,0 2016-002868-14,5,2018-08-02,2018-08-02,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, dose-finding study to evaluate the change in weight after 24 weeks treatment with 8 doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002868-14,0,0,0 2016-002873-36,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine at 2, 4, and 6 Months of Age versus Sanofi Pasteur's DTaP-IPV//PRP~T Combined Vaccine at 2, 4, and 6 Months of Age +...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002873-36,0,1,1 2016-002875-81,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UMC Utrecht,Bumetanide for the Autism Spectrum Clinical Effectiveness Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002875-81,0,0,0 2016-002878-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ghent University Hospital,Comparison of continuous infusion versus automated bolus of local anesthetic for postoperative analgesia with popliteal sciatic nerve blockade (nerve catheters) in ambulatory foot surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002878-13,0,0,0 2016-002879-96,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,UCB Japan Co. Ltd.,"An open-label, multicenter, long-term, follow-up study in Japan to evaluate the safety, tolerability, and efficacy of adjunctive treatment with oral L059 (levetiracetam) in epilepsy subjects with gene...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002879-96,0,1,1 2016-002880-33,1,2018-09-10,2018-09-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Turku,Bioavailability and pharmacokinetics of intranasal dexmedetomidine in children Nenän limakalvolle annostellun deksmedetomidiinin farmakokinetiikka lapsipotilailla ja imeväisillä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002880-33,0,0,0 2016-002883-15,5,2019-09-30,2019-09-30,5,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Seqirus UK Limited,"A Phase III/IV, Stratified, Randomized, Observer Blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine Comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002883-15,0,0,0 2016-002885-30,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,Novel strategies of antithrombotic prophylaxis in patients with Essential Thrombocythemia (ET) at high risk of cardiovascular events: comparison of different dosing regimens of administration of low-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002885-30,0,0,0 2016-002886-77,1,2019-05-03,2019-05-03,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU de Nantes,Etude pilote monocentrique observationnelle de l’activité ostéoblastique dans la dégénérescence des bioprothèses aortiques par tomographie par émission de positons au 18F Sodium Fluoride,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002886-77,0,0,0 2016-002887-14,1,2020-05-01,2020-05-01,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,University of Turku,Dose response study of Patient Controlled Analgesia (PCA) of S-ketamine in orthopaedic spine surgery patients Itseannosteltavan S-ketamiinin annos-vastetutkimus ortopedisilla selän luudutusleikkaus...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002887-14,0,0,0 2016-002888-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Essai multicentrique, randomisé, contrôlé, comparant l'immunogénicité et la tolérance de deux stratégies innovantes de vaccination anti-pneumococcique au schéma de vaccination standard chez des patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002888-33,0,0,0 2016-002889-32,1,2017-03-15,2017-03-15,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,KU Leuven,THE RELATIONSHIP BETWEEN GASTRIC MOTILITY AND EMPTYING AS MEASURED WITH AN INTRAGASTRIC BALLOON AND BREATH TESTING,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002889-32,0,0,0 2016-002890-37,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Esther Aleo Lujan,Double-blind randomized clinical trial to compare presurgery anxiolysis in children treated with hydroxyzine versus non-pharmacological intervention (distractoria technique clown). Ansiolisis preop...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002890-37,0,0,0 2016-002892-80,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medica Scientia Innovation Research (MedSIR),A two-stage Simon Design phase II study for NOn-BRCA metastatic BReast cancer (MBC) patients with homologous recombination deficiency treated with OLAparib single agent (NOBROLA study) Estudio de f...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002892-80,0,0,0 2016-002893-11,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Karolinska University Hospital,"A Phase 2, international, multicenter, open-labeled, randomised trial of palbociclib and fulvestrant versus standard oral capecitabine in patients with hormone receptor positive / HER2 negative advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002893-11,0,0,0 2016-002894-36,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Medical University of Vienna (MUW),"""An open, monocentric, uncontrolled phase 4 trial to characterise cellular and humoral immune responses following the first booster immunisation with the inactivated, purified Japanese Encephalitis va...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002894-36,0,0,0 2016-002895-29,1,2017-03-17,2017-03-17,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,Bayer AG,"Relative bioavailability study to investigate the pharmacokinetics, safety and tolerability of single oral doses of finerenone 1.25 mg and 5 x 0.25 mg oro-dispersible tablet (pediatric formulation) in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002895-29,0,0,0 2016-002897-10,1,2017-08-14,2017-08-14,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,KU Leuven - Drug Delivery and Disposition,"Determination of free concentrations of paracetamol, amxocilline and valsartan in the duodenum by using a capillary diffusion catheter Vrije concentratie bepaling van paracetamol, amoxicilline en v...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002897-10,0,0,0 2016-002898-35,10,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002898-35,0,0,0 2016-002898-35,10,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002898-35,0,0,0 2016-002902-37,5,2019-11-05,2020-01-21,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Octapharma Pharmazeutika Produktionsges.m.b.H.,"PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF OCTAGAM 10% IN PATIENTS WITH DERMATOMYOSITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002902-37,0,0,0 2016-002903-25,4,2017-05-04,2017-05-04,1,0,0,0,0,2,2,0,0,2,0,0,0,0,1,Celgene Corporation,A Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002903-25,1,0,0 2016-002904-15,8,2019-12-02,2019-12-02,5,1,0,1,0,0,1,0,0,1,1,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY 10017","PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIENTS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002904-15,0,0,0 2016-002906-38,1,2018-11-28,2018-11-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,MC Slotervaart,Reducing pain and discomfort during and after bone marrow aspiration Vermindering van pijn en ongemak tijdens en na een beenmergpunctie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002906-38,0,0,0 2016-002908-15,1,2019-03-25,2019-03-25,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Sint Maartenskliniek,REDO study: RhEumatoid arthritis REtreatment with ultra-low dose Rituximab: Disease Outcome after Dose Optimization REDO studie: Reumatoïde artritis herbehandeling met ultra lage dosis rituximab: z...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002908-15,0,0,0 2016-002910-38,1,2022-01-01,2022-01-01,1,1,0,0,0,0,4,0,0,1,1,1,0,0,0,Hvidovre University Hospital,Basal-bolus insulin therapy with Insulin Degludec and insulin Aspart versus standard therapy for the inpatient management of type 2 diabetes: The IDA2 study Basal-bolus insulin med insulin Degludec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002910-38,0,0,0 2016-002911-16,1,2019-11-04,2019-11-04,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Maastricht University Medical Center,PET/MRI and plaque vulnerability A feasibility study of 18F-Flutemetamol in atherosclerosis PET/MRI onderzoek naar ‘kwetsbare aderverkalking’: een studie naar 18F-Flutemetamol uptake in aderverkalk...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002911-16,0,0,0 2016-002913-23,1,2019-01-18,2019-01-18,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Fundación Hospital Alcorcón,Phase II clinical trial to evaluate the effect of 25 OH vitamin D on renal progression in patients with Chronic Kidney Disease stage 3 and 25OH vitamin D deficiency Ensayo clínico fase II para eval...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002913-23,0,0,0 2016-002915-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS),Impact on oxidative stress of novel analogues of insulin in people with type 1 diabetes. Low- intervention clinical trial. Ineox Study Impacto sobre el estrés oxidativo de los distintos análogos d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002915-17,0,0,0 2016-002916-42,2,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,DBV TECHNOLOGIES S.A.,Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin® Peanut (PEOPLE Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002916-42,0,0,0 2016-002918-43,11,2021-07-20,2021-07-20,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn¿s Disease Patients Treated with Ustekinumab Studio comparativo relativo alle strategie di mantenimento ""treat to target""...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002918-43,1,0,0 2016-002918-43,11,2021-07-20,2021-07-20,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International N.V.,"Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn¿s Disease Patients Treated with Ustekinumab Studio comparativo relativo alle strategie di mantenimento ""treat to target""...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002918-43,1,0,0 2016-002919-18,9,,,0,0,1,0,0,1,1,0,0,2,1,0,0,0,1,DAIICHI SANKYO INC.,"A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002919-18,0,0,0 2016-002919-18,9,,,0,0,1,0,0,1,1,0,0,2,1,0,0,0,1,"Daiichi Sankyo, Inc.","A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002919-18,0,0,0 2016-002920-10,3,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Klinikum der Universitaet Muenchen AoeR,TREAT-SVDs: EffecTs of Amlodipine and other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases Effecten van amlodipine en andere bloeddrukverlagende middelen op de m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002920-10,0,0,0 2016-002924-99,1,,,0,1,0,0,1,0,4,0,0,1,0,0,0,1,0,Radboudumc,The effectiveness of deep versus moderate neuromuscular blockade during laparoscopic donor nephrectomy in enhancing postoperative recovery. Het effect van diepe spierverslapping tijdens laparoscopi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002924-99,0,0,0 2016-002926-35,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,Alder Hey Children's Foundation NHS Trust,Pharmacokinetics of post-operative Cefuroxime in infants undergoing cardiac surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002926-35,0,0,0 2016-002927-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University of Oulu, Department of Pediatrics, PEDEGO-Research unit",Effect of antimicrobial treament of acute otitis media on the intestinal micobiome in children: A randomized controlled trial Korvatulehduksen antibioottihoidon vaikutus lapsen suoliston mikrobiomi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002927-27,0,0,0 2016-002930-62,1,2019-04-04,2019-04-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GUERBET,Proof of Concept study concerning efficacy of P03277 MR Imaging in HCC diagnosis Phase IIa Clinical Study Étude de preuve de concept relative à l’efficacité du P03277 dans l’imagerie par résonance...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002930-62,0,0,0 2016-002934-57,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,UCB Biopharma SPRL,"A multicenter, 48-week, open-label extension study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002934-57,0,0,0 2016-002935-14,1,2019-06-18,2019-06-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medical University of Vienna, Internal Medicine III, Clinical Div. of Nephrology and Dialysis",Effect of empagliflozin on the renin-angiotensin system in patients with chronic kidney disease with and without type 2 diabetes Effekt von Empagliflozin auf das Renin-Angiotensin-System bei Patie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002935-14,0,0,0 2016-002936-34,1,2019-07-19,2019-07-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Francisco Javier Belda Nacher,"Effects on surgical site infection of an individualized perioperative openlung ventilatory strategy with high versus conventional inspiratory oxygen fraction (iPROVEO2). A comparative, prospective, mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002936-34,0,0,0 2016-002937-31,18,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"An Open-Label, single-arm study to Evaluate the Effectiveness and Safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis STUDIO IN APERTO, A SINGOLO BRACCIO, PER ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002937-31,0,0,0 2016-002937-31,18,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A. (Soc.unipersonal)que realiza el ensayo en España y que actúa como representante de F.Hoffmann-La Roche,"An Open-Label, single-arm study to Evaluate the Effectiveness and Safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis STUDIO IN APERTO, A SINGOLO BRACCIO, PER ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002937-31,0,0,0 2016-002937-31,18,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"An Open-Label, single-arm study to Evaluate the Effectiveness and Safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis STUDIO IN APERTO, A SINGOLO BRACCIO, PER ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002937-31,0,0,0 2016-002938-73,5,2017-10-20,2017-10-20,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Argenx BVBA,"A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002938-73,0,0,0 2016-002938-73,5,2017-10-20,2017-10-20,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ARGEN-X BVBA,"A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002938-73,0,0,0 2016-002939-15,8,2019-03-08,2019-03-08,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,VHsquared Ltd,"A Phase 2 study to investigate the efficacy, safety, and tolerability of six weeks treatment with V565 in subjects with active Crohn’s disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002939-15,0,0,0 2016-002940-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Antoni van Leeuwenhoek,"Nivolumab, Ipilimumab and COX2-inhibition in early stage colon cancer: an unbiased approach for signals of sensitivity",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002940-17,0,0,0 2016-002941-49,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Essen (Anstalt des öffentlichen Rechts),Enhancing Radioiodine Incorporation into Radio Iodine Refractory Thyroid Cancers with MAPK Inhibition: A single center pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002941-49,0,0,0 2016-002943-40,1,2016-11-23,2016-11-23,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Alnylam Pharmaceuticals Inc,"A Phase 2, Open-label, Single Dose, Study of Subcutaneously Administered ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria who are Inadequate Responders to Eculizumab Estudio en fase II,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002943-40,0,0,0 2016-002944-18,1,2017-04-10,2017-04-10,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Bial Industrial Farmacéutica S.A.,"MULTICENTRE, RANDOMIZED, DOUBLE BLIND CLINICAL TRIAL PHASE II, WITH SUBCUTANEOUS POLYMERIZED DEPOT IMMUNOTHERAPY AT DIFFERENT DOSES IN PARALLEL PLACEBO-CONTROLLED GROUPS IN PATIENTS WITH ALLERGIC RHIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002944-18,0,0,0 2016-002949-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Clínic per la recerca Biomédica,β3 adrenergic agoniSt treatment in chronic Pulmonary HypERtEnsion secondary to heart failure: a randomized placebo-controlled phase 2 clinical trial Tratamiento con agonistas B3 en hipertensión pul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002949-32,0,0,0 2016-002949-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CNIC,β3 adrenergic agoniSt treatment in chronic Pulmonary HypERtEnsion secondary to heart failure: a randomized placebo-controlled phase 2 clinical trial Tratamiento con agonistas B3 en hipertensión pul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002949-32,0,0,0 2016-002950-19,4,2020-07-08,2020-07-22,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Merck KGaA,"A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002950-19,0,0,0 2016-002956-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,Olevia for the prevention of atrial fibrillation post heart valve-surgery. OLEVIA per la prevenzione della fibrillazione atriale post-operatoria nei pazienti sottoposti a chirurgia valvolare cardia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002956-25,0,0,0 2016-002958-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI,"Study HCV-art: An Open-Label, pilot Study, to Explore the Clinical Safety and Efficacy of Sofosbuvir/Ledipasvir in Hepatitis C Virus (HCV) Chronic Patients with Arthritis Studio pilota, monocentric...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002958-21,0,0,0 2016-002959-17,1,2018-05-31,2018-05-31,1,1,0,1,0,1,1,0,0,1,1,1,0,0,1,Kiadis Pharma Netherlands B.V.,"An exploratory, open-label study to evaluate the safety and feasibility of ATIR201, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002959-17,0,0,0 2016-002961-79,2,2020-03-20,2020-03-24,2,1,0,0,0,0,4,0,0,1,1,0,1,0,1,AstraZeneca AB,"DAPASALT: An Open Label, Phase IV, Mechanistic, Three-Arm Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin treatment in Type 2 Diabetes Mellitus Patients with Either Preserved or Impai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002961-79,0,0,0 2016-002964-15,1,2020-01-31,2020-01-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals,"The Effect of Selenium Supplementation on Musculoskeletal Health in Older Women Double-blind, randomised, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002964-15,0,0,0 2016-002965-67,1,,,0,0,0,0,0,1,2,0,1,0,0,0,0,0,0,AMC,"An open, non-randomized, parallel-group pharmokinetic and -dynamic, investigator-initiated study on effects of obeticholic acid (OCA) in bile of patients with primary biliary cholangitis (PBC) and non...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002965-67,0,0,0 2016-002966-29,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novartis Pharma AG,"Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002966-29,0,0,0 2016-002966-29,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002966-29,0,0,0 2016-002966-29,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002966-29,0,0,0 2016-002971-91,6,2020-05-14,2020-05-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.","A Randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of Orally administered BI 1467335 for 12 weeks with a 12 week ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002971-91,0,0,0 2016-002971-91,6,2020-05-14,2020-05-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A Randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of Orally administered BI 1467335 for 12 weeks with a 12 week ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002971-91,0,0,0 2016-002971-91,6,2020-05-14,2020-05-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A Randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of Orally administered BI 1467335 for 12 weeks with a 12 week ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002971-91,0,0,0 2016-002971-91,6,2020-05-14,2020-05-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A Randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of Orally administered BI 1467335 for 12 weeks with a 12 week ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002971-91,0,0,0 2016-002971-91,6,2020-05-14,2020-05-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas SA,"A Randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of Orally administered BI 1467335 for 12 weeks with a 12 week ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002971-91,0,0,0 2016-002971-91,6,2020-05-14,2020-05-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Norway KS,"A Randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of Orally administered BI 1467335 for 12 weeks with a 12 week ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002971-91,0,0,0 2016-002972-29,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,IDIBAPS,"Pilot study on the infusion of differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002972-29,0,0,0 2016-002974-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,María Carmen Bravo Laguna,"Phase III, randomized, multicenter, double-blind clinical trial to evaluate two echo-guided administration regimens of ibuprofen in the treatment of patent ductus arteriosus: impact on intestinal prog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002974-11,0,0,0 2016-002976-28,10,2020-03-13,2020-03-26,7,1,0,0,0,0,2,0,0,2,1,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002976-28,1,0,0 2016-002976-28,10,2020-03-13,2020-03-26,7,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002976-28,1,0,0 2016-002976-28,10,2020-03-13,2020-03-26,7,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Novartis Farmacéutica S.A.,"A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002976-28,1,0,0 2016-002977-37,7,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the Investigator to benefit from continued trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002977-37,0,0,0 2016-002977-37,7,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the Investigator to benefit from continued trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002977-37,0,0,0 2016-002977-37,7,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A,"An open-label, multi-center long-term safety roll-over study in patients with tuberous sclerosis complex (TSC) and refractory seizures who are judged by the Investigator to benefit from continued trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002977-37,0,0,0 2016-002978-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,Assessment of the feasibility and clinical efficacy of the ICG - 99mTc - nanocolloid for sentinel lymph node biopsy Valutazione della fattibilit¿ ed efficacia clinica del ICG-99mTc-Nanocolloide pe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002978-13,0,0,0 2016-002980-33,11,2022-06-21,2022-06-21,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"BEIGENE USA, INC.","A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton’s Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström’s Macroglobu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002980-33,1,0,0 2016-002980-33,11,2022-06-21,2022-06-21,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"BeiGene USA, Inc.","A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton’s Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström’s Macroglobu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002980-33,1,0,0 2016-002980-33,11,2022-06-21,2022-06-21,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,BeiGene Ltd. c/o BeiGene USA Inc.,"A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton’s Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström’s Macroglobu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002980-33,1,0,0 2016-002980-33,11,2022-06-21,2022-06-21,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"BeiGene Ltd. c/o BeiGene USA, Inc.","A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton’s Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström’s Macroglobu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002980-33,1,0,0 2016-002980-33,11,2022-06-21,2022-06-21,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,BeiGene Ltd. c/o BeiGene USA Inc.,"A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton’s Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects with Waldenström’s Macroglobu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002980-33,1,0,0 2016-002981-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Groupement des Hôpitaux de l’Institut Catholique de Lille,"ETUDE MULTICENTRIQUE D’EQUIVALENCE, CONTROLEE RANDOMISEE, OUVERTE, COMPARANT L’EFFICACITE DE LA COLCHICINE ET DE LA PREDNISONE DANS LA POUSSEE DE RHUMATISME A DEPOTS DE PYROPHOSPHATE DE CALCIUM DIHYDR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002981-29,0,0,0 2016-002983-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,SERVICIO DE NEFROLOGIA,PILOT STUDY TO COMPARE THE EFFICACY OF EVOLOCUMAB VS LDL-APHERESIS IN PATIENTS WITH HYPERCHOLESTEROLEMIA ESTUDIO PILOTO COMPARATIVO DE LA EFICACIA DE EVOLOCUMAB VERSUS LDL-AFERESIS EN PACIENTES CON...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002983-16,0,0,0 2016-002984-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI,Treatment of the Reynaud's Disease associated with ischemic ulcers in patients affected by sistemic sclerosis Trattamento del Fenomeno di Raynaud a rischio di ulcere ischemiche in pazienti con scle...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002984-32,0,0,0 2016-002985-30,3,2018-06-04,2018-06-04,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, Inc.","An Open-Label, Dose-Finding Study of Vedolizumab IV for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Patients who Have Undergone Allogeneic Hematopoietic Stem C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002985-30,0,0,0 2016-002988-33,1,2017-07-04,2017-07-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,InflaRx GmbH,An open label Phase II trial to evaluate the safety of IFX-1 in patients with moderate to severe Hidradenitis suppurativa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002988-33,0,0,0 2016-002991-28,1,2020-06-12,2020-06-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford,"GRASP: Getting it Right: Addressing Shoulder Pain. Clinical and cost effectiveness of progressive exercise compared to best practice advice, with or without corticosteroid injection, for the treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002991-28,0,0,0 2016-002993-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC Cancer Institute,A single arm phase 2 multicenter study determining the response to Cabazitaxel in metastatic prostate cancer (mCRPC) patients with AR-V7 positive circulating tumor cells (CTCs) Fase 2 multicentrisc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002993-11,0,0,0 2016-002995-29,5,2018-09-20,2018-09-20,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International N.V.,"A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002995-29,0,0,0 2016-002996-91,2,2019-07-08,2019-07-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"CymaBay Therapeutics, Inc.","An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inade...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-002996-91,0,0,0 2016-003002-14,2,2018-12-20,2018-12-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"An escalating dose, randomized, placebo-controlled incomplete block, 2-period cross-over study to assess the dose response for topical efficacy via airway responsiveness to adenosine-5'-monophosphate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003002-14,0,0,0 2016-003003-54,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,F. Hoffmann-La Roche AG,"An Open-label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir in the Treatment of Infants Less Than One Year of Age With Influenza Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003003-54,0,1,1 2016-003004-31,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,F. Hoffmann-La Roche AG,"An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir (Tamiflu) in the Treatment of Children 1 to 12 Years of Age With Influenza Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003004-31,0,1,1 2016-003010-26,1,,,0,0,0,0,0,0,3,0,1,1,1,1,0,1,0,"Centre Hospitalier Universitaire Saint Pierre , ULB",Hyperbaric Bupivacaine Versus Hyperbaric Prilocaine 2% for Cesarean Section Under Spinal Anesthesia: a Randomised and Controlled Clinical Trial Bupivacaine hyperbare 0.5% versus prilocaine hyperb...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003010-26,0,0,0 2016-003013-96,1,2016-12-29,2016-12-29,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Avexxin AS,"A Randomised, Blinded, Placebo-controlled, Single Centre Pilot Study to evaluate the Safety and Efficacy of AVX001 3% Ointment (NG) administered Topically Once Daily to Patients with mild, moderate or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003013-96,0,0,0 2016-003014-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UMBERTO I - POLICLINICO DI ROMA,MULTICENTER RANDOMIZED STUDY ON THE EFFICACY OF IMMUNOSUPPRESSION IN PATIENTS WITH VIRUS-NEGATIVE INFLAMMATORY CARDIOMYOPATHY Studio randomizzato sull’efficacia della terapia immunosoppressiva nei ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003014-28,0,0,0 2016-003015-34,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Helix BioPharma Corp,"A Phase II Open-Label, Randomized Study of Immunoconjugate L-DOS47 in Combination with Vinorelbine/Cisplatin Versus Vinorelbine/Cisplatin Alone in Patients with Lung Adenocarcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003015-34,0,0,0 2016-003016-12,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,Janssen Sciences Ireland UC,"A study to assess the acceptability/swallowability of DRV-containing FDC tablets in HIV-1 infected adolescents, using matching placebo tablets. Rezolsta: EMEA-001280-PIP01-12-M01 Decision: P/0256/201...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003016-12,0,1,1 2016-003018-29,1,2019-02-27,2019-02-27,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Herlev and Gentofte Hospital,Apremilast as anti-pruritic treatment in patients with prurigo nodularis Kan apremilast reducere kløe hos patienter med prurigo nodularis?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003018-29,0,0,0 2016-003020-23,6,2019-04-01,2019-04-01,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shionogi Ltd.,"A Multicenter, Randomized, Double-blind, Parallelgroup, Clinical Study of S-649266 Compared with Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003020-23,0,0,0 2016-003020-23,6,2019-04-01,2019-04-01,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shionogi Europe,"A Multicenter, Randomized, Double-blind, Parallelgroup, Clinical Study of S-649266 Compared with Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003020-23,0,0,0 2016-003020-23,6,2019-04-01,2019-04-01,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Shionogi B.V.,"A Multicenter, Randomized, Double-blind, Parallelgroup, Clinical Study of S-649266 Compared with Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003020-23,0,0,0 2016-003023-30,2,2021-11-02,2021-11-02,1,0,0,1,0,1,1,0,0,2,0,0,0,0,1,"Ultragenyx Pharmaceutical, Inc.","A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Glucose-6-Phosphatase (G6Pase) in Adults with Glycogen Storage Disease...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003023-30,1,0,0 2016-003028-22,4,2018-05-18,2018-05-18,4,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Rigontec GmbH,"A Phase I/II, Multicenter, Open-label, Clinical Trial of Intratumoral/Intralesional Administration of RGT100 in Subjects with Advanced or Recurrent Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003028-22,0,0,0 2016-003029-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IOBA - University of Valladolid,Phase II safety assessment of intravitreal injection of mesenchymal stem cells for acute non arteritic anterior ischemic optic neuropathy (NAION) Estudio de Fase II de la seguridad de las células m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003029-40,0,0,0 2016-003030-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC),"“An open-label, randomized phase III study of Early switch maintenance vs DElayed second-line Nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003030-24,0,0,0 2016-003031-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC),Phase II randomized study of maintenance Regorafenib vs Placebo in no progression patients after first-line platinum and fluoropyrimidines based chemotherapy in HER2 negative locally advanced/metastat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003031-38,0,0,0 2016-003032-20,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC),Nivolumab plus Stereotactic Body Radiotherapy (SBRT) in II and III line of Patients With Metastatic Renal Cell Carcinoma (mRCC). Nivolumab plus Stereotactic Body Radiotherapy (SBRT) in II and III l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003032-20,0,0,0 2016-003036-20,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",A randomized trial of multifactorial primary prevention in high risk subjects candidate to a lung cancer early detection CT program Studio randomizzato di prevenzione primaria multifattoriale in so...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003036-20,0,0,0 2016-003038-26,7,2019-04-09,2019-06-07,7,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Argenx BVBA,"A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003038-26,0,0,0 2016-003046-87,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A multicenter, open Label study to assess the safety and efficacy of rIsankizuMab for MaInTenance in moderate to severe pLaquE type pSoriaSis (LIMMITLESS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003046-87,0,0,0 2016-003050-32,3,2021-07-07,2021-07-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo- Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination with Rituximab to Adult Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003050-32,0,0,0 2016-003050-32,3,2021-07-07,2021-07-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo- Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination with Rituximab to Adult Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003050-32,0,0,0 2016-003052-70,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Center of Amsterdam,Initial non-operative treatment strategy versus appendectomy treatment strategy for simple appendicitis in children aged 7-17 years old. APAC study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003052-70,0,0,0 2016-003059-31,7,2019-03-07,2019-03-07,6,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ContraFect Corporation,"A Multicenter, Double-Blind, Randomized, Comparative Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of CF-301 vs. Placebo in Addition to Standard-of-Care Antibacterial Therapy for t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003059-31,1,0,0 2016-003059-31,7,2019-03-07,2019-03-07,6,0,0,0,0,0,2,0,0,2,0,0,0,0,1,CONTRAFECT CORPORATION,"A Multicenter, Double-Blind, Randomized, Comparative Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of CF-301 vs. Placebo in Addition to Standard-of-Care Antibacterial Therapy for t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003059-31,1,0,0 2016-003060-40,1,2019-02-27,2019-02-27,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"University of Oxford, Clinical Trials and Research Governance",Targeting Iatrogenic Cushing’s Syndrome with 11β-hydroxysteroid dehydrogenase type 1 Inhibition,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003060-40,0,0,0 2016-003061-25,1,2019-01-30,2019-01-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University Salzburg",Pharmaco-EEG for Montelukast. Can we detect neural changes during medication with Montelukast in the EEG?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003061-25,0,0,0 2016-003064-38,2,2021-08-24,2021-08-24,1,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Adlai Nortye USA INC.,An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003064-38,1,0,0 2016-003064-38,2,2021-08-24,2021-08-24,1,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Adlai Nortye USA Inc,An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003064-38,1,0,0 2016-003066-10,1,2018-12-12,2018-12-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Gilead Sciences International Ltd.,"A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Subjects with Chronic HCV Infection and Chil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003066-10,0,0,0 2016-003069-25,8,2018-09-24,2018-09-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Daiichi Sankyo Europe GmbH,"A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003069-25,0,0,0 2016-003069-25,8,2018-09-24,2018-09-24,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,DAIICHI SANKYO EUROPE GMBH,"A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003069-25,0,0,0 2016-003074-40,3,2021-07-19,2021-07-19,1,1,0,1,0,0,1,0,0,2,1,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003074-40,1,0,0 2016-003078-41,1,2020-10-15,2020-10-15,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,MUCOS Pharma CZ s.r.o.,Reduction of post-traumatic systemic inflammatory response by Phlogenzym® using total hip replacement as a model. Snížení posttraumatické systémové zánětlivé odpovědi užitím Pholgenzymu® u pacient...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003078-41,0,0,0 2016-003082-26,2,2021-11-23,2021-11-23,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma - Master Protocol Revised version 06 dated 15-Nov-2018 - Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003082-26,1,0,0 2016-003082-26,2,2021-11-23,2021-11-23,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma - Master Protocol Revised version 06 dated 15-Nov-2018 - Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003082-26,1,0,0 2016-003083-39,4,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,Amgen Inc,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003083-39,0,1,0 2016-003083-39,4,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,AMGEN INC.,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003083-39,0,1,0 2016-003084-19,14,2018-05-31,2018-06-06,13,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A multi-center, randomized, double-blind, parallel-group dose-finding study to assess the effect of 3 doses of LIK066 compared to placebo or empagliflozin in type 2 diabetes mellitus patients with hea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003084-19,0,0,0 2016-003084-19,14,2018-05-31,2018-06-06,13,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS PHARMA AG,"A multi-center, randomized, double-blind, parallel-group dose-finding study to assess the effect of 3 doses of LIK066 compared to placebo or empagliflozin in type 2 diabetes mellitus patients with hea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003084-19,0,0,0 2016-003084-19,14,2018-05-31,2018-06-06,13,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,"A multi-center, randomized, double-blind, parallel-group dose-finding study to assess the effect of 3 doses of LIK066 compared to placebo or empagliflozin in type 2 diabetes mellitus patients with hea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003084-19,0,0,0 2016-003085-32,16,2018-04-11,2018-04-11,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multi-center, prospective, randomized, double-blind study to assess the impact of sacubitril/valsartan vs. enalapril on daily physical activity using a wrist worn actigraphy device in adult chronic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003085-32,0,0,0 2016-003085-32,16,2018-04-11,2018-04-11,14,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A multi-center, prospective, randomized, double-blind study to assess the impact of sacubitril/valsartan vs. enalapril on daily physical activity using a wrist worn actigraphy device in adult chronic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003085-32,0,0,0 2016-003086-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen,"More precise dosing of acenocoumarol in patients aged 80 and above, a pilot study Preciezer doseren van acenocoumarol in patiënten van 80 jaar en ouder: een pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003086-25,0,0,0 2016-003087-40,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,UHangers,Interest of intraveinous iron and tranexamic acid to reduce transfusion in hip fracture patients - HIFIT Study Intérêt du fer intraveineux et de l'acide tranexamique dans la réduction transfusionne...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003087-40,0,0,0 2016-003092-22,12,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffman-La Roche Ltd.,"A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003092-22,0,0,0 2016-003092-22,12,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003092-22,0,0,0 2016-003092-22,12,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Roche Farma S.A. (Soc. Unipersonal) que realiza el ensayo en España y que actúa como representante de F. Hoffmann-La R,"A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003092-22,0,0,0 2016-003092-22,12,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffman-La Roche GmbH,"A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003092-22,0,0,0 2016-003093-40,9,2020-01-31,2020-01-31,5,0,0,0,0,0,3,0,0,2,0,0,0,0,0,FONDAZIONE FADOI,Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end point (PROBE) study - the CARAVAGGIO study Apixaban zur behandlung von venö...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003093-40,1,0,0 2016-003093-40,9,2020-01-31,2020-01-31,5,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Fondazione FADOI,Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end point (PROBE) study - the CARAVAGGIO study Apixaban zur behandlung von venö...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003093-40,1,0,0 2016-003094-18,4,2019-07-26,2019-07-26,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Karyopharm Therapeutics Inc.,"A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients with Multiple Myeloma Previously Treated with Lenalidomide, Pomalidomide, Bortezomib, Carfi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003094-18,0,0,0 2016-003097-41,14,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination with Pomalidomide and Low-dose Dexamethasone versus Pomalidomide and Low-dose Dexamethasone in Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003097-41,0,0,0 2016-003097-41,14,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Sanofi-aventis recherche & développement,"A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination with Pomalidomide and Low-dose Dexamethasone versus Pomalidomide and Low-dose Dexamethasone in Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003097-41,0,0,0 2016-003098-17,1,2019-07-01,2019-07-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,SOLTI,CORALLEEN: A Phase 2 Clinical Trial of multi-agent Chemotherapy or letrozole plus Ribociclib (LEE001) as neoadjuvant treatment for postmenopausal patients with Luminal B/HER2-negative breast cancer. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003098-17,0,0,0 2016-003100-30,14,2020-10-26,2020-10-26,1,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Genzyme Corporation,"A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclerosis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003100-30,1,1,0 2016-003100-30,14,2020-10-26,2020-10-26,1,0,1,0,0,0,3,0,0,2,1,0,0,0,1,GENZYME CORPORATION,"A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients with Relapsing Remitting Multiple Sclerosis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003100-30,1,1,0 2016-003102-14,1,2020-08-27,2020-08-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Institut für Frauengesundheit GmbH,A PHASE II ONE-ARM OPEN-LABEL NEOADJUVANT STUDY OF PEMBROLIZUMAB IN COMBINATION WITH NAB-PACLITAXEL FOLLOWED BY PEMBROLIZUMAB IN COMBINATION WITH EPIRUBICIN AND CYCLOPHOSPHAMIDE IN PATIENTS WITH TRIPL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003102-14,0,0,0 2016-003103-56,1,2019-10-18,2019-10-18,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,LYSARC,A phase Ib - II study of Entospletinib (ENTO) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients with aaIPI ≥1 treated by R-CHOP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003103-56,0,0,0 2016-003105-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON,Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients TRATTAMENTO DI CARFILZOMIB E LENALIDOMIDE PER I PAZIENTI GIOVANI E PER I P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003105-33,0,0,0 2016-003107-65,1,2018-11-02,2018-11-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Opiant Pharmaceuticals Inc,"Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003107-65,0,0,0 2016-003109-32,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Oxford,An investigation of Levetiracetam in Alzheimer’s Disease (ILiAD): a proof of concept study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003109-32,0,0,0 2016-003110-27,1,2020-01-31,2020-01-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Bente Lomholt Langdahl, Dept. of Endocrinology and Internal Medicine, Aarhus University Hospital",Bone turnover markers as predictors of treatment break outcome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003110-27,0,0,0 2016-003111-35,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Southampton,CheckpOiNt blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003111-35,0,0,0 2016-003113-94,6,2018-07-30,2018-07-30,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,Phase 2 Single-Arm Open-Label Extension Study to Investigate Safety with Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study 1311.5,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003113-94,0,0,0 2016-003116-12,3,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,0,International Extranodal Lymphoma Study Group,RANDOMIZED PHASE II TRIAL ON FITNESS AND COMORBIDITY - TAILORED TREATMENT IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA (FIORELLA Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003116-12,0,0,0 2016-003116-12,3,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,0,International Extranodal Lymphoma Study Group - IELSG,RANDOMIZED PHASE II TRIAL ON FITNESS AND COMORBIDITY - TAILORED TREATMENT IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA (FIORELLA Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003116-12,0,0,0 2016-003116-12,3,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,0,IELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP,RANDOMIZED PHASE II TRIAL ON FITNESS AND COMORBIDITY - TAILORED TREATMENT IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA (FIORELLA Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003116-12,0,0,0 2016-003121-42,1,2019-08-09,2019-08-09,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Enceladus Pharmaceuticals BV,"A Phase I-IIa, Open label, Dose Escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous Pegylated Liposomal Dexamethasone Sodium Phosphate as Monotherapy in Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003121-42,0,0,0 2016-003122-16,7,2022-04-12,2022-04-12,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO EXPERIENCED PROGRESSION OF DISEASE ON HEDGEHOG PATHWAY INHIBITO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003122-16,1,0,0 2016-003122-16,7,2022-04-12,2022-04-12,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"REGENERON PHARMACEUTICALS, INC.","A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO EXPERIENCED PROGRESSION OF DISEASE ON HEDGEHOG PATHWAY INHIBITO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003122-16,1,0,0 2016-003123-32,21,2021-03-30,2021-05-14,20,1,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003123-32,1,0,0 2016-003123-32,21,2021-03-30,2021-05-14,20,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003123-32,1,0,0 2016-003126-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,"A PHASE II, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE CENTER STUDY OF THE EFFECT OF THE ACUTE ADMINISTRATION OF THE SGLT-2 INHIBITOR CANAGLIFLOZIN ON CONTERREGULATORY RESPONSE T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003126-16,0,0,0 2016-003128-22,1,2019-08-29,2019-08-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The University of Leeds,Intraoperative imaging of colon cancer using a fluorescent peptide (EMI-137) against the c-Met receptor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003128-22,0,0,0 2016-003129-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,"PHASE 4, MULTICENTER RANDOMISED STUDY, AIMED AT EVALUATING THE MAINTENANCE OF REMISSION AFTER 6, 12, 18 AND 24 MONTHS FROM SUSPENSION OF TNF-ALPHA THERAPIES (ADALIMUMAB, ETANERCEPT, INFLIXIMAB, CERTOL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003129-40,0,0,0 2016-003131-38,1,2017-10-17,2017-10-17,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"TARGID, KU Leuven","The effect of chlorpromazine (Largactil), a dopamine type 2-(D2-) receptor antagonist, on esophageal sensitivity in healthy volunteers: a randomized, double-blind, placebo-controlled study Het effe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003131-38,0,0,0 2016-003133-18,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,radboudumc,"Preoperative staging by combidex MRI in patients with resectable esophageal carcinoma, a feasibility study Pre-operatieve stadiering met combidex MRI bij patiënten met oesofaguscarcinoom",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003133-18,0,0,0 2016-003134-24,4,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients with Primary Hyperoxaluria Type 1",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003134-24,0,0,0 2016-003138-26,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,LUMC,Influenza vaccination in patients with Myasthenia Gravis Influenza vaccinatie in patienten met Myasthenia Gravis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003138-26,0,0,0 2016-003139-39,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Spherium Biomed,"Double-blind, randomized, placebo-controlled, Single-center, Exploratory Clinical Trial to Investigate Safety and Efficacy of COMBOPROFEN for treatment of muscular pain associated with DOMS Ensayo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003139-39,0,0,0 2016-003141-28,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,The Institute of Cancer Research,"ACE: Proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mCRPC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003141-28,0,0,0 2016-003143-11,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,CHU de Bordeaux,Effect of intra-venous ocytocine injection after fetal expulsion in management of third-stage of labor after second trimester medical pregnancy termination Analyse de la Délivrance Dirigée par Ocyt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003143-11,0,0,0 2016-003144-36,1,2018-10-29,2018-10-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Radboud University Medical Centre,Pilot study: postoperative pain reduction by pre emptive N-Acetylcysteine Pilot studie: postoperatieve pijn reductie door pre emptief N-Acetylcysteine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003144-36,0,0,0 2016-003153-15,9,2021-02-17,2021-02-17,7,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn¿s Disease Studio di fase II, in doppio ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003153-15,1,0,0 2016-003153-15,9,2021-02-17,2021-02-17,7,1,0,0,0,0,2,0,0,2,0,0,0,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn¿s Disease Studio di fase II, in doppio ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003153-15,1,0,0 2016-003154-32,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Leeds,SPAARK: Study of Peri-Articular Anaesthetic for Replacement of the Knee. The clinical and cost effectiveness of peri-articular liposomal bupivacaine compared with bupivacaine hydrochloride alone for p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003154-32,0,0,0 2016-003162-13,7,2021-07-27,2021-07-27,4,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"CLOVIS ONCOLOGY, INC","TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003162-13,1,0,0 2016-003162-13,7,2021-07-27,2021-07-27,4,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Clovis Oncology, Inc.","TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003162-13,1,0,0 2016-003163-20,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"CLOVIS ONCOLOGY, INC","TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homolog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003163-20,0,0,0 2016-003163-20,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Clovis Oncology, Inc.","TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homolog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003163-20,0,0,0 2016-003163-20,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Clovis Oncology Ireland Ltd,"TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homolog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003163-20,0,0,0 2016-003168-37,1,2021-11-18,2021-11-18,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,University Tuebingen,"Therapeutic Iloprost for the treatment of Acute Respiratory Distress Syndrome (ARDS) (the ThIlo-Trial): a prospective, randomized, multicenter phase II study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003168-37,0,0,0 2016-003171-21,8,2018-06-15,2018-06-15,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003171-21,0,0,0 2016-003172-43,8,2019-04-23,2019-06-11,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety and Efficacy of TEV-48125 for the Prevention of Cluster Headache",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003172-43,0,0,0 2016-003175-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Charite Universitätsmedizin Berlin,Two-arm randomized phase II trial to assess the feasibility and efficacy of a treatment with Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in combination with radiotherapy and a tr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003175-22,0,0,0 2016-003179-23,10,2020-07-20,2020-07-20,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn¿s Disease (SBCD) Studio di fase II, in doppio ci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003179-23,0,0,0 2016-003179-23,10,2020-07-20,2020-07-20,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn¿s Disease (SBCD) Studio di fase II, in doppio ci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003179-23,0,0,0 2016-003181-12,1,2018-07-22,2018-07-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Royal College of Surgeons in Ireland,Can sonographic assessment of pulmonary vascular reactivity following maternal hyperoxygenation therapy predict neonatal outcome in fetuses at risk of pulmonary hypertension?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003181-12,0,0,0 2016-003185-26,1,2017-07-20,2017-07-20,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Aarhus University Hospital,Qualification of 82Rb PET for measurement of tumor perfusion. Uptake in primary prostate cancer vs healthy prostate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003185-26,0,0,0 2016-003186-25,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase 3b, Controlled, Open-Label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline’s Meningococcal ACWY Conjugate Vaccine (Menveo), Administered to Health...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003186-25,0,1,1 2016-003189-16,3,2020-03-05,2020-03-10,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients with Heterozygous Familial Hypercholesterolemia or with Non-Familial Hype...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003189-16,0,0,0 2016-003190-17,21,2021-05-19,2021-05-19,20,1,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003190-17,1,0,0 2016-003190-17,21,2021-05-19,2021-05-19,20,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003190-17,1,0,0 2016-003191-50,23,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003191-50,0,0,0 2016-003191-50,23,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003191-50,0,0,0 2016-003192-22,1,2018-08-29,2018-08-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults with Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003192-22,0,0,0 2016-003197-41,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Dr. Reddy's Labaratories Ltd.,"A Multi-Center, Randomized, Double-Blind, Parallel-Group, Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003197-41,0,0,0 2016-003198-17,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Universitair Ziekenhuis Brussel Vrije Universiteit Brussel,A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003198-17,0,0,0 2016-003199-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","PHASE II TRIAL OF SUNITINIB IN PATIENTS WITH TYPE B3 THYMOMA OR THYMIC CARCINOMA IN SECOND AND FURTHER LINES Studio di fase 2 con Sunitinib in pazienti affetti da timoma B3 e carcinoma timico, reci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003199-27,0,0,0 2016-003201-34,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,F. Hoffmann-La Roche AG,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003201-34,0,1,1 2016-003202-14,11,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,Pharmacyclics LLC,"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003202-14,0,0,0 2016-003202-14,11,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,"PHARMACYCLICS, LLC","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003202-14,0,0,0 2016-003208-30,4,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,Legacy Healthcare (France) SAS,"Double-blind, vehicle-controlled, randomised, multi-centre study to evaluate the efficacy and safety of LH-8 cutaneous solution in children and adolescents with moderate to severe scalp alopecia areat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003208-30,0,0,0 2016-003210-27,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IIIA, randomized, single-blind, multi-centric study to evaluate the immunogenicity, reactogenicity and safety of three doses of Pediarix, Hiberix and Prevenar 13 when co-administered with two ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003210-27,0,1,1 2016-003213-98,1,2016-12-19,2016-12-19,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Dep. Anaesthesia and Intensive Care, Aarhus University Hospital",The lateral femoral cutaneous nerve – description of the sensory territory and a novel ultrasound guided nerve block technique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003213-98,0,0,0 2016-003214-27,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Irene Barrientos Ruiz,"Randomized, double-blind, 3-arm trial to evaluate the impact of blood loss following administration of three tranexamic acid regimens in patients undergoing bone or soft tissue sarcomas. Ensayo clí...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003214-27,0,0,0 2016-003215-35,1,,,0,1,0,0,0,0,2,0,1,1,1,1,0,1,1,Poxel,"A phase 2a, randomised, double-blind, placebo-controlled, cross-over, single and multiple dose study to assess the effects of imeglimin on nicotine-induced endothelial dysfunction in young non-smoker ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003215-35,0,0,0 2016-003223-30,1,,,0,1,0,0,0,1,3,0,0,0,0,0,0,0,0,University Hospital Tübingen,Prophylactic treatment of hemiplegic migraine with Lamotrigine Prophylaktische Therapie der hemiplegischen Migräne mit Lamotrigin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003223-30,0,0,0 2016-003225-41,7,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,Biogen Idec Research Limited,"An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Scler...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003225-41,0,0,0 2016-003225-41,7,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,BIOGEN IDEC RESEARCH LIMITED,"An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Scler...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003225-41,0,0,0 2016-003226-16,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Bellicum Pharmaceuticals, Inc.",Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003226-16,0,0,0 2016-003227-37,3,2018-03-05,2018-03-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 weeks of the Combination Regimen of MK-3682 + MK-8408 in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003227-37,0,0,0 2016-003228-22,4,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,0,University of Edinburgh,Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003228-22,0,0,0 2016-003228-22,4,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,0,NHS Lothian,Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003228-22,0,0,0 2016-003232-21,1,2020-01-22,2020-01-22,1,0,0,0,1,0,3,0,0,1,1,1,1,0,0,"Medizinische Universität Graz, Univers. Augenklinik",EffiCacy and safety of topical ketoroLac trOmethamine and sUbtenon triamcinolone acetonideand a “watch-and-wait” strategy for acute pseudophakic macular eDema: a randomized phase-3 trial Beurteilun...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003232-21,0,0,0 2016-003239-38,4,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,Philogen S.p.A.,A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003239-38,0,0,0 2016-003239-38,4,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,PHILOGEN S.P.A.,A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003239-38,0,0,0 2016-003240-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica Hospital Ramón y Cajal,"Prospective, multicenter, randomized study to assess the effect of rivaroxaban in the portal vein thrombosis recanalization and the survival in patients with cirrhosis and portal vein thrombosis Es...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003240-37,0,0,0 2016-003245-29,1,2020-11-06,2020-11-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Amsterdam AMC, locatie AMC",Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after Roux-en-Y gastric bypass and Sleeve Gastrectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003245-29,0,0,0 2016-003246-93,2,2018-12-17,2019-01-17,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Astrazeneca AB,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab following subcutaneous administration in Adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003246-93,0,0,0 2016-003248-34,1,,,0,1,1,0,0,0,1,1,0,4,0,0,0,0,0,NIAID and NICHD,A PHASE I TRIAL TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF RALTEGRAVIR IN HIV-1-EXPOSED NEONATES AT HIGH RISK OF ACQUIRING HIV-1 INFECTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003248-34,0,1,1 2016-003253-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Franciscus Gasthui,"MODULATION OF POSTPRANDIAL LIPEMIA, INFLAMMATION, AND VASCULAR FUNCTION BY PCSK9 INHIBITION IN DIABETES.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003253-15,0,0,0 2016-003255-30,3,2019-09-30,2019-09-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AMGEN INC.,A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-Cell Lymphoma Post-autologous Hematopoietic Stem-cell Transpla...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003255-30,0,0,0 2016-003255-30,3,2019-09-30,2019-09-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-Cell Lymphoma Post-autologous Hematopoietic Stem-cell Transpla...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003255-30,0,0,0 2016-003257-15,1,2019-09-17,2019-09-17,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Acceleron Pharma Inc.,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy Estudio de fase II, randomizado, doble ciego y controlado con placebo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003257-15,0,0,0 2016-003260-39,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,F. Hoffmann-La Roche AG,Intravenous Granisetron (Kytril) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003260-39,0,1,1 2016-003265-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Vienna,Pharmacokinetic/Pharmacodynamic effects of add-on antiplatelet therapy with parenteral cangrelor as compared to standard dual antiplatelet treatment in patients with ST-elevation myocardial infarction...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003265-26,0,0,0 2016-003273-18,1,2019-01-11,2019-01-11,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,University Hospital of Toulouse,"Effects of intranasal administrations of oxytocin on beahvioural troubles, hyperphagia and social skills in children with Prader-Willi syndrome aged from 3 to 12 years.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003273-18,0,0,0 2016-003275-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Uppsala County Council,Evaluation of the analgesic and sedative effects of dexmedetomidine for neonatal peripheral vein cannulation Sedering med dexmedetomidin vid perifer venkanylering av spädbarn,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003275-22,0,0,0 2016-003278-42,8,2019-04-23,2019-04-23,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003278-42,0,0,0 2016-003279-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboudumc,Phase 2 Study testing the COmbination of Vemurafenib With Cobimetinib in BRAF V600 mutated Melanoma Patients to Normalize LDH and Optimize immunotherapY with Nivolumab and Ipilimumab (COWBOY) Fase ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003279-23,0,0,0 2016-003281-84,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Academical Medical Centre, department of internal",The Effect of UrsodeoXyCholicacid (UDCA) and ezetimibe on total faecal steRol ExcreTion and plasma lipid lEvels,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003281-84,0,0,0 2016-003284-19,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,DEpletion of Serum amyloid P component In Alzheimer’s Disease: DESPIAD. Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer’s disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003284-19,0,0,0 2016-003286-26,7,2021-06-16,2021-07-12,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Pharmacyclics LLC,"A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003286-26,0,0,0 2016-003287-39,1,2019-12-31,2019-12-31,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,NuCana plc,A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003287-39,0,0,0 2016-003288-20,11,2019-05-22,2019-05-31,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003288-20,0,0,0 2016-003288-20,11,2019-05-22,2019-05-31,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003288-20,0,0,0 2016-003288-20,11,2019-05-22,2019-05-31,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche LTD","A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003288-20,0,0,0 2016-003291-47,1,2019-01-11,2019-01-11,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,University Hospital Southampton NHS Trust,A phase Ib/IIa clinical trial to combine the CSF1 receptor inhibitor pexidartinib with the androgen receptor antagonist enzalutamide in metastatic castration resistant prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003291-47,0,0,0 2016-003292-22,12,2021-09-23,2021-09-23,7,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of VAY736 in patients with primary Sjogren’s Syndrome Estudio de fase 2, mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003292-22,1,0,0 2016-003292-22,12,2021-09-23,2021-09-23,7,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of VAY736 in patients with primary Sjogren’s Syndrome Estudio de fase 2, mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003292-22,1,0,0 2016-003292-22,12,2021-09-23,2021-09-23,7,1,0,0,0,0,2,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of VAY736 in patients with primary Sjogren’s Syndrome Estudio de fase 2, mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003292-22,1,0,0 2016-003294-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",Phase II Study of Neoadjuvant Chemotherapy With Dose-Dense Paclitaxel In Association With Carboplatin followed by Radical Surgery for Locally Advanced Cervical Cancer (FIGO stage IB2- IIIA) Patients. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003294-18,0,0,0 2016-003300-31,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Hellenic Society for the Study of Bone Metabolism,"Evaluation of the efficacy of Denosumab in adult patients with Langerhans Cell Histiocytosis (LCH) : a multiple-site, single arm, open label Clinical Trial. ΑΞΙΟΛΟΓΗΣΗ ΤΗΣ ΕΠΙΔΡΑΣΗΣ ΤΗΣ ΔΕΝΟΣΟΥΜΑ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003300-31,0,0,0 2016-003301-34,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Cipla BioTec Pvt. Ltd.,"A Randomized, Double-blind, Multicentric, Parallel-group Study Comparing Efficacy, Safety and Immunogenicity of CBT124, a Candidate Biosimilar Bevacizumab in Combination with Carboplatin and Paclitaxe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003301-34,0,0,0 2016-003306-13,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,CCR 4557: Peri-operative Immuno-Chemotherapy in Operable oesophageal aNd gastrIc Cancer (ICONIC Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003306-13,0,0,0 2016-003307-62,2,2020-07-23,2020-07-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"REGENERON PHARMACEUTICALS, INC.","A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy, Following Repeat-Dose Administration of Evinacumab (anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003307-62,0,0,0 2016-003307-62,2,2020-07-23,2020-07-23,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy, Following Repeat-Dose Administration of Evinacumab (anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003307-62,0,0,0 2016-003315-35,8,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, OPEN LABEL STUDY OF LORLATINIB (PF 06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED ALK POSITIVE NON SMALL CELL LUNG CAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003315-35,0,0,0 2016-003315-35,8,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc,","A PHASE 3, RANDOMIZED, OPEN LABEL STUDY OF LORLATINIB (PF 06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED ALK POSITIVE NON SMALL CELL LUNG CAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003315-35,0,0,0 2016-003315-35,8,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,PFIZER INC,"A PHASE 3, RANDOMIZED, OPEN LABEL STUDY OF LORLATINIB (PF 06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED ALK POSITIVE NON SMALL CELL LUNG CAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003315-35,0,0,0 2016-003315-35,8,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Pfizer Inc.,"A PHASE 3, RANDOMIZED, OPEN LABEL STUDY OF LORLATINIB (PF 06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED ALK POSITIVE NON SMALL CELL LUNG CAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003315-35,0,0,0 2016-003320-23,7,2021-07-26,2021-07-26,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Actelion Pharmaceuticals Ltd,"Prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study assessing the efficacy and safety of macitentan in Fontan-palliated adult and adolescent subjects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003320-23,1,0,0 2016-003321-42,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Radboud University Medical Centre,Lengthening Adalimumab Dosing Interval in quiescent Crohn’s disease patients: the LADI study. Adalimumab interval verlenging voor de ziekte van Crohn,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003321-42,0,0,0 2016-003325-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,PREemptive Pharmacogenomic testing for Preventing Adverse drug REactions Präemptive pharmakogenetische Untersuchung zur Vermeidung von unerwünschten Arzneimittel-Nebenwirkungen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003325-41,0,0,0 2016-003328-22,4,2021-10-05,2021-10-05,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects with Low or Intermediate-1 Risk Myelodysplastic Sy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003328-22,0,0,0 2016-003328-22,4,2021-10-05,2021-10-05,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects with Low or Intermediate-1 Risk Myelodysplastic Sy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003328-22,0,0,0 2016-003331-38,7,2021-03-23,2021-03-23,7,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"Multicenter, Double-Blind, Randomized, Active- and Placebo Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients from 6 to Less than 18 Years of Age with Moderate-t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003331-38,0,0,0 2016-003331-38,7,2021-03-23,2021-03-23,7,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"Multicenter, Double-Blind, Randomized, Active- and Placebo Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients from 6 to Less than 18 Years of Age with Moderate-t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003331-38,0,0,0 2016-003332-21,1,2018-09-12,2018-09-12,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Clairance de l'Acétate et du gluconate au cours du Remplissage vasculaire des brûlés graves:CARE Clearance of Acetate during fluid REsuscitation in critically ill patients: The CARE trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003332-21,0,0,0 2016-003334-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Cologne,A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003334-25,0,0,0 2016-003339-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,JOSÉ MARÍA PALAZÓN AZORÍN,"A randomized, controlled and double-blind trial of intravenous azithromycin versus intravenous erythromycin as a single dose prior to endoscopy in upper gastrointestinal bleeding Ensayo clínico con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003339-39,0,0,0 2016-003340-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Technological University Dublin,Efficacy and Mechanisms of Low Dose Atropine in the Control of Myopia in Children Trial name: Myopia Outcome Study of Atropine in Children (MOSAIC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003340-37,0,0,0 2016-003341-28,1,2017-03-22,2017-03-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Paradigm Biopharmaceuticals,"A phase 2, randomised, double-blind, placebo-controlled, crossover study to evaluate the effects of a topical pentosan polysulphate sodium (PPS) formulation in subjects with seasonal allergic rhinitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003341-28,0,0,0 2016-003343-11,1,2020-10-06,2020-10-06,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,Psychiatric Centre Copenhagen,Does Glucagon-like Peptide 1 (GLP-1) receptor stimulation reduce alcohol intake in patients with alcohol dependence?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003343-11,0,0,0 2016-003345-29,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Kings College Hospital NHS Foundation Trust,Safety of tenofovir alafenamide (TAF) in patients with a history of tubulopathy on tenofovir disoproxil fumarate (TDF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003345-29,0,0,0 2016-003346-90,7,2022-02-17,2022-02-17,3,1,0,0,0,1,3,0,0,2,0,0,0,0,1,ASTRAZENECA AB,"A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Respon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003346-90,1,0,0 2016-003346-90,7,2022-02-17,2022-02-17,3,1,0,0,0,1,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Respon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003346-90,1,0,0 2016-003347-10,1,2018-10-10,2018-10-10,1,0,0,0,0,0,4,0,1,1,1,1,1,0,0,"Oulu University Hospital, Internal Medicine Research Unit",The effects of PXR activation on HDL-cholesterol PXR-aktivaation vaikutus HDL-kolesteroliin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003347-10,0,0,0 2016-003352-67,5,2021-05-17,2021-05-17,3,1,1,0,0,0,1,0,0,2,0,0,0,0,1,EISAI LIMITED,A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003352-67,1,0,0 2016-003352-67,5,2021-05-17,2021-05-17,3,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Eisai Ltd,A Phase 1/2 single-arm study evaluating the safety and efficacy of eribulin mesilate in combination with irinotecan in children with refractory or recurrent solid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003352-67,1,0,0 2016-003353-16,1,2019-02-21,2019-02-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc",A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003353-16,0,0,0 2016-003360-39,1,2021-02-15,2021-02-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Universitätsklinikum Freiburg,Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosis Sicherheit und Wirksamkeit von Abatacept bei Patienten mit behandlungsresistenter Sarkoidose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003360-39,0,0,0 2016-003361-25,9,2018-10-01,2018-10-01,6,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Shire Human Genetic Therapies, Inc.","A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003361-25,0,0,0 2016-003361-25,9,2018-10-01,2018-10-01,6,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"SHIRE HUMAN GENETIC THERAPIES, INC","A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003361-25,0,0,0 2016-003367-19,16,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,DR. FALK PHARMA GMBH,"Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003367-19,0,0,0 2016-003367-19,16,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003367-19,0,0,0 2016-003369-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Allergy Centre,Double-blind randomised controlled study to down regulate allergic responses in adults with allergic rhinoconjunctivitis by using three intralymphatic injections of grass and birch allergen or placebo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003369-24,0,0,0 2016-003370-40,4,2019-10-08,2019-10-08,4,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Global Blood Therapeutics, Inc.","A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003370-40,0,0,0 2016-003370-40,4,2019-10-08,2019-10-08,4,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"GLOBAL BLOOD THERAPEUTICS, INC","A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003370-40,0,0,0 2016-003373-18,3,2018-11-13,2018-11-13,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Akcea Therapeutics, Inc.","A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease (C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003373-18,0,0,0 2016-003373-18,3,2018-11-13,2018-11-13,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Ionis Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease (C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003373-18,0,0,0 2016-003374-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Tartu,The effects of augmented renal clearance on the pharmacokinetic/pharmacodynamic profile of piperacillin/tazobactam in children and young adults with malignant or non-malignant haematological or oncolo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003374-40,0,0,0 2016-003376-49,1,2018-10-08,2018-10-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,The Medicines Company,"An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and Efficacy of ALN-PCSSC in Subjects with Homozygous Familial Hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003376-49,0,0,0 2016-003392-22,2,2020-02-26,2020-02-26,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Biopharma SPRL,"A Phase 3, Multicenter, Randomized, Double-Blind Study with an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003392-22,0,0,0 2016-003394-18,1,2022-01-20,2022-01-20,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Michael Bau Mortensen,Treatment of peritoneal carcinomatosis with Pressurized IntraPeritoneal Aerosol Chemotherapy - PIPAC-2 trial -,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003394-18,0,0,0 2016-003403-66,13,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim bv,An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003403-66,0,0,0 2016-003403-66,13,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim B.V,An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003403-66,0,0,0 2016-003403-66,13,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim AB,An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003403-66,0,0,0 2016-003403-66,13,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim Fnland Ky,An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003403-66,0,0,0 2016-003403-66,13,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003403-66,0,0,0 2016-003403-66,13,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003403-66,0,0,0 2016-003403-66,13,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,SCS Boehringer Ingelheim Comm. V,An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003403-66,0,0,0 2016-003403-66,13,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co. KG,An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003403-66,0,0,0 2016-003403-66,13,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer-Ingelheim France,An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003403-66,0,0,0 2016-003403-66,13,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim Limited,An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003403-66,0,0,0 2016-003403-66,13,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.",An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003403-66,0,0,0 2016-003403-66,13,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,"Boehringer-Ingelheim España, S.A.",An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003403-66,0,0,0 2016-003403-66,13,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer-Ingelheim Pharma GmbH & Co. KG,An open-label extension trial to assess the long term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003403-66,0,0,0 2016-003406-14,1,2018-10-03,2018-10-03,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University Hospital of North Midlands NHS Trust,"The Metoclopramoide and selective oral decontamination for Avoiding Pneumonia after Stroke (MAPS-2) Trial: a 2x2 double-blind, randomized controlled trial of metoclopramide and selective oral decontam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003406-14,0,0,0 2016-003408-29,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Gilead Sciences, Inc.",A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003408-29,0,0,0 2016-003409-33,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Queen Silvias Childrens and Adolescents Hospital,Optimizing 6-mercaptopurine therapy in paediatric acute lymphoblastic leukemia by using allopurinol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003409-33,0,0,0 2016-003409-33,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Västra Götaland Regionen,Optimizing 6-mercaptopurine therapy in paediatric acute lymphoblastic leukemia by using allopurinol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003409-33,0,0,0 2016-003410-28,15,2019-10-24,2019-10-28,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, exercise capacity, symptoms and safety compared to individuali...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003410-28,0,0,0 2016-003410-28,15,2019-10-24,2019-10-28,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS PHARMA SERVICES AG,"A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, exercise capacity, symptoms and safety compared to individuali...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003410-28,0,0,0 2016-003410-28,15,2019-10-24,2019-10-28,13,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacética S.A.,"A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, exercise capacity, symptoms and safety compared to individuali...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003410-28,0,0,0 2016-003411-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,BSMO,"Precision 2: an open explorative phase II, open label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003411-34,0,0,0 2016-003413-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FIMABIS,MicroRNAs expression analysis in patients undergoing cardiac surgery treated with halogenated anesthetics. Identification of microRNAs related to the cardioprotective effect Análisis de la expresió...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003413-10,0,0,0 2016-003414-26,1,2019-12-06,2019-12-06,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Dr. John Lambert (Mater Misericordiae University Hospital),An open label study of the safety and efficacy of FDC Zepatier (elbasvir and grazoprevir +/- Ribavirin) administered in a community-based setting to HCV infected G1/4 treatment naïve patients on stab...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003414-26,0,0,0 2016-003417-95,2,2020-07-07,2020-07-07,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A multi-centre, randomized, double-blind (sponsor open), placebo controlled, repeat-dose, proof of mechanism study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and explore ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003417-95,0,0,0 2016-003418-28,1,2019-04-05,2019-04-05,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma AG,"A randomized, placebo-controlled, patient and investigator blinded, single dose, Proof of Concept study investigating the safety, tolerability and preliminary efficacy of intra-articular LNA043 in reg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003418-28,0,0,0 2016-003425-42,6,2019-12-13,2019-12-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Biopharma SRL,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003425-42,0,0,0 2016-003425-42,6,2019-12-13,2019-12-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Biopharma SPRL,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003425-42,0,0,0 2016-003426-16,3,2020-01-07,2020-01-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,UCB Biopharma SPRL,"A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study with an Initial Treatment Period Followed by a Randomized-Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003426-16,0,0,0 2016-003427-30,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,UCB Biopharma SRL,"A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003427-30,0,0,0 2016-003427-30,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,UCB Biopharma SPRL,"A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003427-30,0,0,0 2016-003428-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medical Centre,"Non-inferiority multicentre randomized controlled trial comparing short versus standard course postoperative antibiotic treatment for complex acute appendicitis Non-inferiority, multicenter gerando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003428-21,0,0,0 2016-003430-25,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,"Ultragenyx Pharmaceutical, Inc.","A Long-Term Follow-up Study to Evaluate the Safety, Tolerability, and Efficacy of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003430-25,0,0,0 2016-003433-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Anakinra versus placebo double blind Randomized controlled trial for the treatment of Acute Myocarditis Anakinra contre placebo:Etude randomisée,en double aveugle dans le traitement de la myocardit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003433-20,0,0,0 2016-003434-24,5,2019-06-25,2019-06-25,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ACADIA Pharmaceuticals Inc.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003434-24,0,0,0 2016-003435-38,9,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Acadia Pharmaceuticals Inc.,"A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003435-38,0,0,0 2016-003435-38,9,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,ACADIA Pharmaceuticals Inc.,"A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003435-38,0,0,0 2016-003435-38,9,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,ACADIA PHARMACEUTICALS INC.,"A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003435-38,0,0,0 2016-003436-20,5,2019-10-28,2019-10-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ACADIA Pharmaceuticals Inc.,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003436-20,0,0,0 2016-003437-18,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,ACADIA Pharmaceuticals Inc.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (Enhance-2) Eine randomisierte, doppe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003437-18,0,0,0 2016-003438-26,8,2021-01-15,2021-01-15,6,1,0,0,0,0,4,0,0,2,0,0,0,0,1,Baxalta US Inc.,"Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects with Primary Immunodeficiency Diseases",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003438-26,1,0,0 2016-003440-36,9,2018-10-02,2018-10-04,8,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Eli Lilly and Company,"A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer’s Disease Dementia (Extension of Study AZES, The AMARANTH Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003440-36,0,0,0 2016-003440-36,9,2018-10-02,2018-10-04,8,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Eli Lilly and Company Limited,"A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer’s Disease Dementia (Extension of Study AZES, The AMARANTH Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003440-36,0,0,0 2016-003440-36,9,2018-10-02,2018-10-04,8,1,0,0,0,0,3,0,0,1,1,0,1,0,2,Lilly S.A.,"A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer’s Disease Dementia (Extension of Study AZES, The AMARANTH Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003440-36,0,0,0 2016-003440-36,9,2018-10-02,2018-10-04,8,1,0,0,0,0,3,0,0,1,1,0,1,0,2,ELI LILLY COMPANY,"A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer’s Disease Dementia (Extension of Study AZES, The AMARANTH Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003440-36,0,0,0 2016-003444-37,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Sanofi,Bacillus clausii in the treatment of acute community–acquired diarrhea among Latin American children (cadiLAc),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003444-37,0,1,1 2016-003447-11,6,2018-12-27,2018-12-27,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Iovance Biotherapeutics, Inc.","A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003447-11,1,0,0 2016-003447-11,6,2018-12-27,2018-12-27,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"IOVANCE BIOTECHNOLOGIES, INC","A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003447-11,1,0,0 2016-003451-30,1,2019-02-28,2019-02-28,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),Subjects with subjective cognitive decline: 18F-Florbetaben Positrón Emission Tomography Study. Estudio de sujetos con deterioro cognitivo subjetivo: estudio con Tomografía por Emisión de Positrone...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003451-30,0,0,0 2016-003452-75,7,2018-03-26,2018-03-26,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Protagonist Therapeutics, Inc","A PHASE 2B RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL ADAPTIVE 2-STAGE, MULTI-CENTRE STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL PTG-100 INDUCTION IN SUBJECTS WITH MODERATE TO SEVERE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003452-75,0,0,0 2016-003456-70,5,2021-08-11,2021-08-11,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Sunovion Pharmaceuticals Inc.,"An Open-Label Randomized Crossover Trial, utilizing a Single-Blinded Rater to evaluate APL- 130277 compared to S.C. Apomorphine in Levodopa Responsive Subjects with Parkinson¿s Disease Complicated by ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003456-70,1,0,0 2016-003456-70,5,2021-08-11,2021-08-11,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,SUNOVION PHARMACEUTICALS INC,"An Open-Label Randomized Crossover Trial, utilizing a Single-Blinded Rater to evaluate APL- 130277 compared to S.C. Apomorphine in Levodopa Responsive Subjects with Parkinson¿s Disease Complicated by ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003456-70,1,0,0 2016-003457-15,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Icelandic Heart Association,"Intervention of carotid atherosclerotic plaque progression in individuals with low to intermediate coronary heart disease risk, the ICAPP study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003457-15,0,0,0 2016-003459-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Helse Bergen, Haukeland University Hospital",Treatment of patients with advanced breast cancer harboring TP53 mutations with dose-dense cyclophosphamide - the p53 trial Behandling av pasienter med metastatisk brystkreft med TP53 mutasjoner me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003459-31,0,0,0 2016-003460-38,1,,,0,1,1,0,0,1,4,0,0,4,0,0,0,0,1,"Horizon Therapeutics, LLC","An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003460-38,0,1,1 2016-003467-19,18,2019-10-30,2019-11-08,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003467-19,1,0,0 2016-003467-19,18,2019-10-30,2019-11-08,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003467-19,1,0,0 2016-003468-38,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Centre François baclesse,Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003468-38,0,0,0 2016-003469-24,1,2019-04-16,2019-04-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Spectrum Pharmaceuticals, Inc.","Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Doce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003469-24,0,0,0 2016-003472-52,13,2022-08-12,2022-08-22,9,0,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffman-La Roche Ltd.,"A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB FOR PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003472-52,1,0,0 2016-003472-52,13,2022-08-12,2022-08-22,9,0,0,0,0,0,3,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB FOR PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003472-52,1,0,0 2016-003472-52,13,2022-08-12,2022-08-22,9,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Roche Farma S.A.U que realiza el ensayo en España y que actúa como representante de F.Hoffmann-La Roche Ltd.,"A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB FOR PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003472-52,1,0,0 2016-003473-17,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Celgene Corporation,"A Phase 2, 24-Week Randomized, Double-blind, Placebo-Controlled Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiopath...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003473-17,0,0,0 2016-003475-21,4,,,0,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Genzyme Corporation,"An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of Avalglucosidase Alfa (NeoGAA, GZ402666) in Patients with Infantile-onset Pompe Disease Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003475-21,0,1,0 2016-003477-18,1,2019-12-04,2019-12-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Tuebingen,A double-blind randomized study to determine the effect of empagliflozin versus placebo on brain insulin sensitivity in patients with prediabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003477-18,0,0,0 2016-003479-22,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline Research and development Ltd,Clinical assessment of fluticasone propionate/ salmeterol xinafoate HFA MDI in 6-month to 4-year-old Japanese patients with bronchial asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003479-22,0,1,1 2016-003482-25,2,2020-01-13,2020-01-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A single-arm interventional Phase IV, post-authorisation study evaluating the safety of pediatric patients with transfusional hemosiderosis treated with deferasirox crushed film coated tablets",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003482-25,0,0,0 2016-003482-25,2,2020-01-13,2020-01-13,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,NOVARTIS PHARMA AG,"A single-arm interventional Phase IV, post-authorisation study evaluating the safety of pediatric patients with transfusional hemosiderosis treated with deferasirox crushed film coated tablets",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003482-25,0,0,0 2016-003485-11,16,2022-09-24,2022-10-15,6,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Esperion Therapeutics Inc.,","A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at high risk for, Cardiova...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003485-11,1,0,0 2016-003485-11,16,2022-09-24,2022-10-15,6,0,0,0,0,0,3,0,0,2,0,0,0,0,1,IQVIA RDS Ireland Ltd.,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at high risk for, Cardiova...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003485-11,1,0,0 2016-003486-26,2,2018-09-17,2018-09-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Esperion Therapeutics Inc.,","A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients with Hyperlipidemia at High Cardiovascular Risk Not Adequ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003486-26,0,0,0 2016-003489-25,2,2019-02-13,2019-02-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects with Genotype 1, 4, 5 and 6 Chronic HCV Infection Who are on Dialysis for End Stage Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003489-25,0,0,0 2016-003489-25,2,2019-02-13,2019-02-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects with Genotype 1, 4, 5 and 6 Chronic HCV Infection Who are on Dialysis for End Stage Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003489-25,0,0,0 2016-003491-41,3,2020-01-10,2020-01-10,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AnGes Inc.,A Long Term Follow-up Study of AMG0001 in Subjects with Critical Limb Ischemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003491-41,1,0,0 2016-003495-53,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Academic Medical Center - Cardiology,Prostacyclin receptor agonist Selexipag in patients with pulmonary arterial hypertension and congenital heart disease Prostacycline receptor agonist selexipag in patiënten met pulmonale arteriële h...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003495-53,0,0,0 2016-003497-40,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,SANTEN SAS,"A PHASE IV, PROSPECTIVE, OPEN-LABEL, MULTICENTRE, SINGLE ARM, 3-MONTH PROOF OF CONCEPT STUDY TO ASSESS THE EFFECT OF IKERVIS® 1MG/ML (CICLOSPORIN) EYE DROPS ADMINISTERED ONCE DAILY ON THE QUALITY OF V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003497-40,0,0,0 2016-003498-16,11,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,LOXO ONCOLOGY INCORPORATED,A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003498-16,0,0,0 2016-003498-16,11,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Bayer Consumer Care AG,A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003498-16,0,0,0 2016-003498-16,11,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Loxo Oncology Inc.,A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003498-16,0,0,0 2016-003501-33,1,2018-03-12,2018-03-12,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,AntibioTx ApS,"A prospective, single center, randomized, double-blind, placebo controlled study in two phases to evaluate the safety and efficacy of ATx201 as a topical antibiotic agent",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003501-33,0,0,0 2016-003502-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI,"A multicenter, randomized, open-label phase 3 study of two anti-angiogenic strategies in advanced hepatocellular carcinoma patients with cross-over at first-line failure: metronomic Capecitabine/Soraf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003502-13,0,0,0 2016-003503-64,21,2019-08-27,2019-11-20,18,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Abbvie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Placebo-Controlled Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003503-64,0,0,0 2016-003509-33,1,2019-02-28,2019-02-28,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Lungemedicinsk Forskningsenhed, Bispebjerg Hospital",The RECONSTRUCT study Reconstructing Disease Mechanisms in Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003509-33,0,0,0 2016-003517-95,15,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Oncopeptides AB,"A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/ Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003517-95,0,0,0 2016-003517-95,15,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,ONCOPEPTIDES AB,"A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/ Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003517-95,0,0,0 2016-003521-42,1,2021-05-12,2021-05-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Mitsubishi Tanabe Pharma GmbH,"SAICoDis – Safety of Argatroban Infusion in Conduction Disturbances. A prospective, open, multicenter safety study to investigate conduction disturbances in patients receiving argatroban therapy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003521-42,0,0,0 2016-003522-16,4,2018-03-23,2018-03-28,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Ra Pharmaceuticals, Inc.","A PHASE 2 MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RA101495 IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003522-16,0,0,0 2016-003523-34,4,2021-06-08,2021-10-26,3,1,0,0,0,1,2,0,0,2,1,0,0,0,1,"Ra Pharmaceuticals, Inc.","A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003523-34,1,0,0 2016-003525-42,2,2019-01-09,2019-01-09,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Achillion Pharmaceuticals, Inc.","A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients with Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003525-42,0,0,0 2016-003526-16,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Alexion Pharmaceuticals Inc.,A Phase 2 Open-label Study of ACH-0144471 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003526-16,0,0,0 2016-003526-16,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"ACHILLION PHARMACEUTICALS, INC.",A Phase 2 Open-label Study of ACH-0144471 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003526-16,0,0,0 2016-003529-41,1,2020-01-31,2020-01-31,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,University Medical Center Utrecht,CANGLIA: Endocannabinoid control of microglia activation as a new therapeutic target in the treatment of schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003529-41,0,0,0 2016-003535-38,8,2020-05-08,2020-06-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,0,EORTC AISBL/IVZW,Maintenance therapy with trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or metastatic soft tissue sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003535-38,0,0,0 2016-003535-38,8,2020-05-08,2020-06-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,0,European Organisation for Research and Treatment of Cancer,Maintenance therapy with trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or metastatic soft tissue sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003535-38,0,0,0 2016-003535-38,8,2020-05-08,2020-06-05,5,1,0,0,0,0,3,0,0,1,1,0,1,0,0,European Organisation for Research and Treatment of Cancer (EORTC),Maintenance therapy with trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or metastatic soft tissue sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003535-38,0,0,0 2016-003536-21,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC Studio di Fase III in ape...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003536-21,0,0,0 2016-003536-21,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC Studio di Fase III in ape...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003536-21,0,0,0 2016-003537-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Akershus University Hospital,The long-term effect of marine n-3 polyunsaturated fatty acid supplementation on glomerular filtration rate and development of fibrosis in the renal allograft: a randomized double blind placebo contro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003537-18,0,0,0 2016-003543-11,4,2022-04-28,2022-04-28,1,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Nektar Therapeutics,"A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients with Select Locally Advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003543-11,1,0,0 2016-003544-37,1,2018-08-31,2018-08-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Aneurin Bevan University Health Board,Perineural Local Anaesthetic Catheter aftEr Major lowEr limb amputatioN Trial (PLACEMENT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003544-37,0,0,0 2016-003546-84,1,2020-10-20,2020-10-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Dpt. of Growth and Reproduction,Denosumab and male infertility: a randomized double-blinded intervention study Denosumab og mandlig infertilitet: et randomiseret dobbelt-blindet interventionsstudie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003546-84,0,0,0 2016-003548-35,3,2018-12-12,2019-04-10,2,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Medical University of Vienna,Mesalamine for Colorectal Cancer Prevention Program in Lynch syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003548-35,0,0,0 2016-003551-30,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Universitätsklinikum Freiburg,Modeling of the impact of a PCSK9 inhibition on lipoproteins in patients with dyslipidemia Modelling der Auswirkung einer PCSK9 Inhibition auf die Lipoproteine bei Patienten mit Dyslipidämie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003551-30,0,0,0 2016-003552-75,8,2019-03-27,2019-03-27,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Novartis Pharma Services AG,"A multicenter phase II, open label, single arm study to evaluate the efficacy and safety of ruxolitinib in the treatment of anemic myelofibrosis patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003552-75,0,0,0 2016-003552-75,8,2019-03-27,2019-03-27,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,NOVARTIS PHARMA SERVICES AG,"A multicenter phase II, open label, single arm study to evaluate the efficacy and safety of ruxolitinib in the treatment of anemic myelofibrosis patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003552-75,0,0,0 2016-003552-75,8,2019-03-27,2019-03-27,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A multicenter phase II, open label, single arm study to evaluate the efficacy and safety of ruxolitinib in the treatment of anemic myelofibrosis patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003552-75,0,0,0 2016-003553-15,3,2020-03-05,2020-03-05,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Generon (Shanghai) Corporation Ltd.,"A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta Active-Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003553-15,0,0,0 2016-003554-33,11,2022-04-15,2022-04-15,7,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Amgen Inc,"A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the treatment of Patients With Relapsed or Refractory Multiple Myelom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003554-33,1,0,0 2016-003554-33,11,2022-04-15,2022-04-15,7,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Amgen Inc.,"A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the treatment of Patients With Relapsed or Refractory Multiple Myelom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003554-33,1,0,0 2016-003557-15,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Guy's and St Thomas NHS Foundation Trust,A Study to Investigate the Effect of β-Hydroxy-β-Methylbutyrate (HMB) on Skeletal Muscle Wasting in Early Critical Illness.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003557-15,0,0,0 2016-003558-34,3,2019-10-02,2019-10-02,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects with Active Sjogren’s Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003558-34,0,0,0 2016-003561-26,1,2021-06-30,2021-06-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bayer AG,"A randomized, parallel-group, double-blind and placebo-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids Randomizované, dvojitě zaslepe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003561-26,0,0,0 2016-003567-20,1,2022-01-28,2022-01-28,1,0,0,0,0,0,4,0,0,1,1,1,0,0,0,"Dept of Infectious Diseases, Aarhus University Hospital",A randomised controlled trial of a 12-dose rifapentine and isoniazid (RPT+INH) regimen using direct observed therapy (DOT) versus 6 months of daily isoniazid for latent tuberculosis infection (LTBI) i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003567-20,0,0,0 2016-003568-38,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Johann Wolfgang Goethe-University Frankfurt am Main,German Treatment Optimization Study for Children with De Novo and Relapsed Langerhans cell Histiocytosis (LCH) as Part of the International Study LCH-IV,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003568-38,0,0,0 2016-003570-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital (OUS),ALICE: A randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003570-40,0,0,0 2016-003575-21,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,MRC Clinical Trials Unit at UCL,"A multicentre, 48 week randomised controlled factorial trial of adding maraviroc and/or metformin for hepatic steatosis in HIV-1-infected adults on combination antiretroviral therapy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003575-21,0,0,0 2016-003578-42,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Antonio Pérez-Martínez,"Phase I / II Clinical Trial, multicenter, open, of infusion of activated NK cells for the treatment of children, adolescents and young adults with sarcomas. Ensayo Clínico Fase I/II, multicéntrico,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003578-42,0,0,0 2016-003579-22,7,2022-01-14,2022-01-14,6,0,0,0,0,0,2,0,0,1,0,0,0,0,1,F. Hoffmann-La Roche Ltd,A PHASE II STUDY EXPLORING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB ADMINISTERED IN COMBINATION WITH OBINUTUZUMAB OR RITUXIMAB ANTI-CD20 THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003579-22,0,0,0 2016-003579-22,7,2022-01-14,2022-01-14,6,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Roche Farma S.A. (Soc.unipersonal)que realiza el ensayo en España y que actúa como representante de F.Hoffmann- La Roche,A PHASE II STUDY EXPLORING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB ADMINISTERED IN COMBINATION WITH OBINUTUZUMAB OR RITUXIMAB ANTI-CD20 THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003579-22,0,0,0 2016-003579-22,7,2022-01-14,2022-01-14,6,0,0,0,0,0,2,0,0,1,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,A PHASE II STUDY EXPLORING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB ADMINISTERED IN COMBINATION WITH OBINUTUZUMAB OR RITUXIMAB ANTI-CD20 THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003579-22,0,0,0 2016-003582-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,"The added effect of oral ondansetron to care-as-usual on persisting vomiting in children aged 6 months to 6 years, presenting at primary care out of hours service with acute gastro-enteritis and conco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003582-25,0,0,0 2016-003585-11,2,2018-02-28,2018-02-28,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003585-11,0,0,0 2016-003586-26,2,2019-05-10,2019-05-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients with Heart Failure and Impaired S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003586-26,0,0,0 2016-003587-39,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Karolinska Institutet,"COMBAT-MS (COMparison Between All immunoTherapies for Multiple Sclerosis) A prospective long-term cohort study of safety, efficacy and patient’s satisfaction of MS disease modulatory treatments in re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003587-39,0,0,0 2016-003592-21,1,2016-12-07,2016-12-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharmaceuticals UK Limited,Evaluation of the eFfect of early Initiation of secukinumab in systemic treatment-naïve patients with moderate to severe plaque psoriasis Requiring Systemic Treatment (FIRST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003592-21,0,0,0 2016-003594-17,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AMC,Effects of a single denosumab injection on reduction of total contact cast treatment and consolidation of bonefractures caused by acute Charcotfoot in patients with diabetes mellitus (CHARCOT study...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003594-17,0,0,0 2016-003599-39,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Swiss Group for Clinical Cancer Research (SAKK),"PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients with Prostate Cancer after Prostatectomy Etude de phase II, randomisée, multicentrique de radiothé...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003599-39,0,0,0 2016-003599-39,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SAKK - SWISS GROUP FOR CLINICAL CANCER RESEARCH,"PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients with Prostate Cancer after Prostatectomy Etude de phase II, randomisée, multicentrique de radiothé...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003599-39,0,0,0 2016-003603-61,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,"Clinical trial on the administration of 3 doses of betamethasone (12 mg) in 18 hours apart in twin pregnancy patients with threatened preterm birth treated by Atosiban, rather than 2 doses of betameth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003603-61,0,0,0 2016-003604-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"José Luis Morales Rull, Institut de Recerca Biomédica Lleida IRB Hospital Arnau de Vilanova Servicio de Medicina Interna",Effects of intravenous iron therapy with ferric carboxymaltose compared with oral iron therapy in heart failure with preserved ejection fraction and iron deficiency. ( PREFER-HF) Efecto sobre la ca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003604-31,0,0,0 2016-003606-14,1,2019-04-17,2019-04-17,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Sheffield Children's NHS Foundation Trust,Do bisphosphonates alter the skeletal response to mechanical stimulation in children with osteogenesis imperfecta?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003606-14,0,0,0 2016-003607-59,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"DIPARTIMENTO AD ATTIVITà INTEGRATA CHIRURGICO, MEDICO, ODONTOIATRICO E DI SCIENZE MORFOLOGICHE",An Open-Label Study to Evaluate Long-Term Results With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) on ovarian function in fertile women With Genotype 1 and 4 Chron...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003607-59,0,0,0 2016-003608-30,3,2018-08-20,2018-08-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BerGenBio AS,"A Phase II, Multi Center Study of BGB324 in combination with Pembrolizumab in Patients with Previously Treated, Locally Advanced and Unresectable or Mestastic Triple Negative Breast Cancer (TNBC) or T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003608-30,0,0,0 2016-003608-30,3,2018-08-20,2018-08-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BerGenBio ASA,"A Phase II, Multi Center Study of BGB324 in combination with Pembrolizumab in Patients with Previously Treated, Locally Advanced and Unresectable or Mestastic Triple Negative Breast Cancer (TNBC) or T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003608-30,0,0,0 2016-003609-32,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BerGenBio AS,A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003609-32,0,0,0 2016-003609-32,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BerGenBio ASA,A Phase II Multi Center Study of BGB324 in Combination with Pembrolizumab in Patients with Previously Treated Advanced Adenocarcinoma of the Lung.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003609-32,0,0,0 2016-003611-35,5,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,"bluebird bio, Inc.","A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects with Transfusion-dependent β Thalassemia, who have a β0/β0 Genotype, by Transplantation of Autologous CD34+ St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003611-35,0,0,0 2016-003614-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI,Study on the effect of dapagliflozin on myocardial insulin sensitivity and perfusion (DapaHeart) Study on the effect of dapagliflozin on myocardial insulin sensitivity and perfusion (DapaHeart),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003614-27,0,0,0 2016-003616-13,10,,,0,0,1,0,0,1,0,0,0,3,0,0,0,0,1,"Turning Point Therapeutics, Inc.","A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003616-13,0,0,0 2016-003621-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital","Desferal administration to improve the impaired reaction to hypoxia in diabetes (DESIRED) A randomised, double-blind, placebo-controlled, cross-over study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003621-41,0,0,0 2016-003622-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,Targeting SPMS: Effect of teriflunomide treatment on microglial activation in an MS patient cohort at risk of progression. A [11C]PK11195 Brain PET study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003622-16,0,0,0 2016-003625-42,2,2018-10-17,2018-11-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic HCV Infection Who are on Dialysis for End Stage Renal Disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003625-42,0,0,0 2016-003627-29,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,OSPEDALE SANTA MARIA DELLA MISERICORDIA,PREvention of VENous Thromboembolism In Hemorrhagic Stroke patients PREvention of VENous Thromboembolism In Hemorrhagic Stroke patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003627-29,0,0,0 2016-003630-25,10,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Gilead Sciences, Inc.","A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003630-25,0,0,0 2016-003631-37,1,2018-09-14,2018-09-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Universitaire ziekenhuis Leuven,Therapeutic effect of ursodeoxycholic acid on duodenal permeability and meal related sensory motor function in functional dyspepsia patients Therapeutisch effect van ursodeoxycholzuur op duodenale ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003631-37,0,0,0 2016-003632-20,3,2020-01-30,2020-01-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects with Ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003632-20,0,0,0 2016-003632-20,3,2020-01-30,2020-01-30,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects with Ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003632-20,0,0,0 2016-003633-26,4,2018-06-29,2018-07-18,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Lycera Corp.,A MULTICENTER OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF LYC-30937-EC IN SUBJECTS WITH ACTIVE ULCERATIVE COLITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003633-26,0,0,0 2016-003636-21,5,2018-07-02,2018-07-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galapagos NV,"A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 12 weeks to subjects with active ankylosing spondylitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003636-21,0,0,0 2016-003637-14,5,2018-03-12,2018-03-12,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galapagos NV,"A randomized, double-blind, placebo-controlled, multicenter, Phase II study to assess the efficacy and safety of filgotinib administered for 16 weeks to subjects with moderately to severely active pso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003637-14,0,0,0 2016-003642-93,10,2022-04-18,2022-04-18,7,1,1,0,0,0,2,0,0,2,1,0,0,0,1,Janssen Sciences Ireland UC,"A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of J...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003642-93,1,0,0 2016-003642-93,10,2022-04-18,2022-04-18,7,1,1,0,0,0,2,0,0,2,1,0,0,0,1,Janssen Sciences Ireland Unlimited Company,"A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of J...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003642-93,1,0,0 2016-003643-10,1,,,0,0,0,1,0,1,1,0,0,4,0,0,0,0,0,UMC Utrecht,Modulating regulatory T cell function in JIA with Vitamin B3 (nicotinamide) treatment Beinvloeden van regulatoire Tcel functie in JIA met Vitamine B3 (nicotinamide) behandeling,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003643-10,0,0,0 2016-003644-37,2,2021-05-20,2021-05-20,2,1,0,0,0,0,2,0,0,1,1,0,1,0,0,Hellenic Cooperative Oncology Group (HeCOG),"Single-arm phase II study of panitumumab rechallenge in combination with oxaliplatin or irinotecan-based chemotherapy in patients with RAS wild type advanced colorectal cancer. Μελέτη ενός σκέλους,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003644-37,0,0,0 2016-003651-30,5,2020-01-20,2020-01-20,5,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Umecrine Cognition AB,"Safety, tolerability and pharmacokinetics (PKs) of multiple oral doses of GR3027 in healthy male volunteers and single and multiple doses in patients with cirrhosis. Preliminary efficacy in cirrhotic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003651-30,0,0,0 2016-003653-15,9,2021-03-12,2021-03-21,8,1,0,0,0,0,2,0,0,2,0,0,0,0,1,ACTELION Pharmaceuticals Ltd,"A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003653-15,1,0,0 2016-003654-33,1,2017-05-17,2017-05-17,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,BIOCODEX,"Effects of the probiotic Saccharomyces boulardii CNCM I-745 and the antibiotic Amoxicillin on the gut microbiota of healthy volunteers An open-label, randomized, parallel groups, monocentric study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003654-33,0,0,0 2016-003655-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,Acute appendicitis and microbiota- etiology and effects of the antimicrobial treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003655-29,0,0,0 2016-003657-15,1,2020-03-25,2020-03-25,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,NOXXON Pharma AG,"A Two-Part, Open-Label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy in M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003657-15,0,0,0 2016-003658-34,1,,,0,0,0,0,1,0,3,0,0,4,0,0,0,0,0,University Hospital of Montpellier,"Non-inferiority of intranasal fentanyl versus oral morphine sulfate in the treatment of pain in pediatric trauma : a controled randomized , single blind study Etude randomisée contrôlée en simple a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003658-34,0,0,0 2016-003661-26,3,2017-08-23,2017-08-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Haemostatix Ltd,"A controlled, randomized, multi-centre, double blind, phase II study to evaluate efficacy and safety of topical PeproStat in intraoperative surgical haemostasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003661-26,0,0,0 2016-003669-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,Amyloid PET imaging study for the diagnosis of Alzheimer's disease in the preclinical/predementia phase Studio della PET con tracciante per l’amiloide per la diagnosi della malattia di Alzheimer in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003669-24,0,0,0 2016-003670-40,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"Beatrix Children's Hospital, University Medical Center Groningen","Pediatric Ards Neuromuscular blockade (PAN) study: Life-threatening acute respiratory failure in children: to breathe or not to breathe spontaneously, that's the question. Pediatrisch Ards Neuromus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003670-40,0,0,0 2016-003672-47,1,2017-09-19,2017-09-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A single dose, randomised, double blind, double dummy, placebo controlled, 3-way crossover clinical study, comparing the onset of relief from methacholine-induced bronchoconstriction with CHF1535 100/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003672-47,0,0,0 2016-003673-18,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,UZ Brussel,"Can we with vitamin D3, improve the innate immune system? Kunnen we door middel van een behandeling met vitamine D3, het aangeboren immuunsysteem verbeteren? Peut-on au moyen d'un traitement ave...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003673-18,0,0,0 2016-003675-21,5,2018-10-05,2018-10-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003675-21,0,0,0 2016-003675-21,5,2018-10-05,2018-10-05,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003675-21,0,0,0 2016-003678-42,3,2020-01-14,2020-01-14,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"CTRG, University of Oxford","Immunological effects of an acellular pertussis booster vaccination in children, young adults and elderly with different immunisation background. An international study in Finland, the Netherlands and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003678-42,0,0,0 2016-003678-42,3,2020-01-14,2020-01-14,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,National Institute for Public Health and the Environment (RIVM),"Immunological effects of an acellular pertussis booster vaccination in children, young adults and elderly with different immunisation background. An international study in Finland, the Netherlands and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003678-42,0,0,0 2016-003678-42,3,2020-01-14,2020-01-14,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Turku,"Immunological effects of an acellular pertussis booster vaccination in children, young adults and elderly with different immunisation background. An international study in Finland, the Netherlands and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003678-42,0,0,0 2016-003678-42,3,2020-01-14,2020-01-14,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,RIVM,"Immunological effects of an acellular pertussis booster vaccination in children, young adults and elderly with different immunisation background. An international study in Finland, the Netherlands and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003678-42,0,0,0 2016-003678-42,3,2020-01-14,2020-01-14,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Clinical Trials and Research Governance,"Immunological effects of an acellular pertussis booster vaccination in children, young adults and elderly with different immunisation background. An international study in Finland, the Netherlands and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003678-42,0,0,0 2016-003678-42,3,2020-01-14,2020-01-14,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Turun Yliopisto,"Immunological effects of an acellular pertussis booster vaccination in children, young adults and elderly with different immunisation background. An international study in Finland, the Netherlands and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003678-42,0,0,0 2016-003679-23,4,2022-04-27,2022-04-27,3,0,1,0,0,0,3,0,0,2,0,0,0,0,1,DBV TECHNOLOGIES S.A.,"A double-blind, placebo-controlled, randomized phase III trial to assess the safety and efficacy of Viaskin® Peanut in peanut-allergic young children 1-3 years of age (EPITOPE study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003679-23,1,0,0 2016-003681-34,3,2018-03-29,2018-03-29,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Octapharma AG,"Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Patients with Severe Hemophilia A Badanie kliniczne w celu zbadania farmako...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003681-34,0,0,0 2016-003682-26,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Can-Fite BioPharma, Ltd.","A Phase 3, Randomized, Double-Blind, Active- and Placebo controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Art...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003682-26,0,0,0 2016-003684-19,1,2019-09-27,2019-09-27,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"RWTH Aachen, represented by the Rector, himself represented by the Dean of the Medical Faculty",Xenon-anesthesia on patients undergoing major liver-resection: randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003684-19,0,0,0 2016-003686-26,3,2019-03-01,2019-07-03,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,AbbVie Stemcentrx LLC,A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination with Nivolumab or Nivolumab and Ipilimumab for Adults with Extensive-Stage Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003686-26,0,0,0 2016-003686-26,3,2019-03-01,2019-07-03,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,ABBVIE STEMCENTRX LLC,A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination with Nivolumab or Nivolumab and Ipilimumab for Adults with Extensive-Stage Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003686-26,0,0,0 2016-003694-18,2,2019-07-22,2019-07-22,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Saniona A/S,"A double-blind, randomized, placebo-controlled, multiple-dose, multi-centre safety and efficacy study of co-administration of tesofensine/metoprolol in subjects with Prader-Willi syndrome (PWS) ""A 12 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003694-18,0,0,0 2016-003695-47,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffman-La Roche Ltd.,"A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003695-47,0,0,0 2016-003695-47,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003695-47,0,0,0 2016-003700-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oslo University Hospital,"Effects of nutrition therapy on growth, metabolism and inflammation in immature infants; a double-blind randomized, controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003700-31,0,0,0 2016-003703-62,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,A phase II study of metronomic chemotherapy in elderly non-fit patients (>65 years) with aggressive B-Cell lymphomas. Studio di fase II sull’uso della chemioterapia metronomica in pazienti anziani ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003703-62,0,0,0 2016-003704-31,1,2019-03-29,2019-03-29,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Uppsala University,Impact on the intestinal microbiota during antibiotic treatment Påverkan av tarmens normalflora i samband med antibiotikabehandling,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003704-31,0,0,0 2016-003705-34,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Universitätsklinikum Tübingen,PIGMENT – PDE6A gene therapy for retinitis pigmentosa PIGMENT – PDE6A Gentherapie für Retinitis Pigmentosa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003705-34,0,0,0 2016-003708-29,11,2021-05-10,2021-05-10,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects with Moderate to Severe Ul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003708-29,0,0,0 2016-003708-29,11,2021-05-10,2021-05-10,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER INC,"A Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects with Moderate to Severe Ul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003708-29,0,0,0 2016-003708-29,11,2021-05-10,2021-05-10,10,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects with Moderate to Severe Ul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003708-29,0,0,0 2016-003709-33,1,2022-03-08,2022-03-08,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,AIO-Studien-gGmbH,A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003709-33,0,0,0 2016-003712-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Södersjukhuset AB,Implementation project of AFL in clinical practice Implementationsprojekt om AFL i klinisk användning,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003712-12,0,0,0 2016-003716-12,4,2019-12-17,2019-12-17,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited",Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003716-12,0,0,0 2016-003716-12,4,2019-12-17,2019-12-17,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"MILLENNIUM PHARMACEUTICALS, INC.",Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003716-12,0,0,0 2016-003718-28,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Controlled, Multicenter, Open Label Study with Blinded Assessment of the Efficacy of the Humanized Anti-IL-23p19 Risankizumab Compared to FUMADERM® in Subjects with Moderate to Severe Pl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003718-28,0,0,0 2016-003719-37,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,NHS Greater Glasgow and Clyde,"StUdies of empaGliflozin and its cArdiovascular, Renal and metabolic effects in patients with Diabetes Mellitus (or prediabetes) and Heart Failure (SUGAR-DM-HF)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003719-37,0,0,0 2016-003719-37,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Glasgow,"StUdies of empaGliflozin and its cArdiovascular, Renal and metabolic effects in patients with Diabetes Mellitus (or prediabetes) and Heart Failure (SUGAR-DM-HF)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003719-37,0,0,0 2016-003721-41,1,2019-10-09,2019-10-09,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,"Department of Cardiology, Aarhus University Hospital, Skejby",Cangrelor versus Ticagrelor for Early Platelet Inhibition in ST-Elevation Myocardial Infarction. (The CanTi study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003721-41,0,0,0 2016-003722-16,2,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine when Administered Concomitantly with GSK Meningococcal MenACWY ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003722-16,0,1,0 2016-003722-16,2,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,1,GlaxoSmithKline Biologicals S.A.,"A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine when Administered Concomitantly with GSK Meningococcal MenACWY ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003722-16,0,1,0 2016-003724-23,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,"The George Institute for Global Health, University of New South Wales",Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial Triple therapie ter preventie van recidief herseninfarct of hersenbloeding na een intracerebrale bloeding,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003724-23,0,0,0 2016-003725-42,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Manchester,Does Interleukin-1 Receptor Antagonist Improve Outcome following aneurysmal Subarachnoid Haemorrhage (aSAH)? A Phase III trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003725-42,0,0,0 2016-003726-17,18,2020-02-12,2020-02-12,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003726-17,0,0,0 2016-003726-17,18,2020-02-12,2020-02-12,17,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003726-17,0,0,0 2016-003727-27,4,2019-04-26,2019-04-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MYOVANT SCIENCES GMBH,"LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co Administered with and without Low-Dose Estradiol and Norethindrone A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003727-27,0,0,0 2016-003727-27,4,2019-04-26,2019-04-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Myovant Sciences GmbH c/o Vischer AG,"LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co Administered with and without Low-Dose Estradiol and Norethindrone A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003727-27,0,0,0 2016-003727-27,4,2019-04-26,2019-04-29,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Myovant Sciences GmbH,"LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co Administered with and without Low-Dose Estradiol and Norethindrone A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003727-27,0,0,0 2016-003729-41,12,2021-02-02,2021-02-02,9,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003729-41,1,1,0 2016-003729-41,12,2021-02-02,2021-02-02,9,1,0,0,0,0,3,0,0,2,1,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003729-41,1,1,0 2016-003730-25,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Stealth Bio Therapeutics Inc,"A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington’s Disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003730-25,0,0,0 2016-003731-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"An Open-label, single-arm Phase II Safety Study of Nivolumab in Subjects with Advanced or metastatic non-small cell lung cancer who have progressed during or after receiving at least one prior systemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003731-37,0,0,0 2016-003732-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Cáncer de Pulmón,"NEO -ADJUVANT CHEMO/IMMUNOTHERAPY FOR THE TREATMENT OF RESECTABLE STAGE IIIA NON SMALL CELL LUNG CANCER (NSCLC): A PHASE II MULTICENTER EXPLORATORY STUD Ensayo clínico fase II, exploratorio y multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003732-20,0,0,0 2016-003733-23,1,2019-01-06,2019-01-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cassiopea S.p.A.,"A PHASE 2, MULTICENTER, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CB 03 01 (CORTEXOLONE 17α-PROPIONATE) SOLUTION FOR THE TRE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003733-23,0,0,0 2016-003736-21,1,,,0,1,0,1,0,1,1,0,0,3,0,0,0,0,1,Acerta Pharma BV,A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects with Relapsed/Refractory B-cell Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003736-21,0,0,0 2016-003737-15,2,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Acerta Pharma BV,A Phase 1/2 Proof-of-Concept Study Investigating AZD6738 monotherapy and Acalabrutinib in Combination with AZD6738 (ATR inhibitor) in Subjects with Relapsed or Refractory High-risk Chronic Lymphocytic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003737-15,0,0,0 2016-003738-25,1,2019-06-18,2019-06-18,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University Medical Center Hamburg-Eppendorf,"A 28-week, multi-center randomized, double-blind, placebo-controlled study to evaluate the potential of Dapagliflozin plus Exenatide in combination with high-dose intensive insulin therapy compared to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003738-25,0,0,0 2016-003739-40,1,2021-07-07,2021-07-07,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,AMC Amsterdam,The effect of Iberogast on heartburn in patients with dyspepsia Het effect van Iberogast op pyrosisklachten bij patiënten met dyspepsie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003739-40,0,0,0 2016-003740-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ICNAS Produção Lda.,Comparative study of 68Ga-PSMA-11 PET and 18F-Fluorocholine PET in the detection of Recurrence in Prostate Cancer Patients after Radical Treatment Estudo Comparativo entre 68Ga-PSMA-11 PET e 18F-Fl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003740-36,0,0,0 2016-003741-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,A.S.L. TO 2,MARAND-X Study: MARaviroc-based Treatment Switch in HIV-positive Patients with HAND: Consequences of Reducing Antiretroviral-associated NeurotoXicity Studio MARAND-X: Switch Basato su Maraviroc in ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003741-29,0,0,0 2016-003743-10,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Herlev og Gentofte Hospital,"Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function and Metabolism in Type 2 DM Patients at high cardiovascular risk: The SIMPle Randomized Clinical Trial Effekten af SGLT-2 hæmmere på hj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003743-10,0,0,0 2016-003749-27,1,2018-07-20,2018-07-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Octapharma AG,"Prospective, Randomised, Controlled Phase 2 Study Investigating the Haemostatic Efficacy and Safety of Fibrinogen Concentrate (Octafibrin) and Cryoprecipitate as Fibrinogen Supplementation Sources in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003749-27,0,0,0 2016-003752-79,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,Randomised Phase II clinical trial PIONEER- A Pre-operative wIndOw study of letrozole plus PR agonist (Megestrol Acetate) versus letrozole aloNE in post-menopausal patients with ER-positive breast can...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003752-79,0,0,0 2016-003753-14,1,2019-03-13,2019-03-13,1,0,0,0,1,0,3,0,0,1,0,0,1,0,0,Assistance Publique Hôpitaux de Marseille,CERVICAL PREPARATION UNDER PARACERVICAL BLOCK FOR THE ABORTION OF FIRST TRIMESTER: RANDOMIZED TRIAL PREPARATION CERVICALE DES IVG SOUS BLOC PARACERVICAL AU 1er TRIMESTRE: ESSAI CLINIQUE RANDOMISE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003753-14,0,0,0 2016-003755-29,1,2017-03-13,2017-03-13,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,LABORATOIRES SMB S.A,"A phase IV, randomised, parallel study to compare a monthly administration of vitamin D3 (D-CURE®) to a daily administration of vitamin D3 (VISTA-D3®).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003755-29,0,0,0 2016-003761-26,6,2020-11-09,2020-11-09,5,1,1,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS PHARMA AG,"A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis-re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003761-26,0,0,0 2016-003761-26,6,2020-11-09,2020-11-09,5,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis-re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003761-26,0,0,0 2016-003761-26,6,2020-11-09,2020-11-09,5,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A three-part randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic arthritis subtypes of psoriatic and enthesitis-re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003761-26,0,0,0 2016-003773-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,A prospective randomized open label study Intranasal dexmedetomidine versus inhaled nitrous oxide for children age 3 – 15 years for procedural sedation and analgesia in pediatric emergency department....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003773-17,0,0,0 2016-003774-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Oslo University Hospital,Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003774-40,0,0,0 2016-003775-22,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,AstraZeneca K.K.,"An Open-label, parallel-group, multi-centre, phase I / III study to assess the safety, pharmacokinetics, pharmacodynamics and efficacy of repeated once-daily oral administration of 961H 10 mg and D961...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003775-22,0,1,1 2016-003778-42,2,2020-12-16,2020-12-16,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Celgene Corporation,"A Phase 1/2 Open-label, Multicenter Study of Avadomide (CC-122) in Combination With R-CHOP-21 for Previously Untreated Poor-Risk (IPI ≥ 3) Diffuse Large B-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003778-42,0,0,0 2016-003784-19,2,2019-12-16,2019-12-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Laboratorio Reig Jofre, SA","Phase III, multicentre, randomised, double blind, parallel-group, clinical trial to evaluate the efficacy and safety of a new medicated nail lacquer for the treatment of toenail fungal infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003784-19,0,0,0 2016-003785-77,1,2020-11-05,2020-11-05,1,0,0,0,0,0,4,0,0,1,1,1,1,0,3,,Microdosing as a tool to individualize docetaxel dosing: development of a limited sampling model Het voorspellen van een therapeutische dosis van docetaxel per individu met behulp van een microdo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003785-77,0,0,0 2016-003789-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Hospital Universitari Vall d'Hebron - Institut de Recerca,Phase II trial for assessing different benznidazol regimens in the treatment of Chagas disease in adult patients on chronic phase . BERINECE project Ensayo clínico fase II para la evaluación de di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003789-21,0,0,0 2016-003790-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,The Netherlands Cancer Institute,Feasibility trial on combination of platinum doublets and hypofractionated radiotherapy for locally-advanced stage and / or inoperable non-small cell lung carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003790-18,0,0,0 2016-003795-49,1,2020-12-01,2020-12-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,IFCT,"A randomized multicenter, open label, controlled and non-comparative phase II study of anti–PDL1 ATEZOLIZUMAB (MPDL3280A) or chemotherapy as second-line therapy in patients with small cell lung cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003795-49,0,0,0 2016-003796-22,1,2021-02-18,2021-02-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,IFCT,Immunotherapy by Nivolumab after prior Chemotherapy for HIV+ patients with Advanced non-small cell lung cancer (NSCLC): IFCT-CHIVA2 phase IIa trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003796-22,0,0,0 2016-003797-40,2,2017-10-02,2017-10-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Arena Pharmaceuticals, Inc.","A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients with active Skin Extra-intestinal Manifestations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003797-40,0,0,0 2016-003798-16,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,CSL Behring LLC,"Comparison of 2 Infusion Devices with Respect to Pharmacokinetics, Safety, and Tolerability of Hizentra®: Investigational Wearable Infusor and the Crono S-PID-50 Infusion Pump",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003798-16,0,1,1 2016-003799-33,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,CSL Behring LLC,"An open-label multicenter study to evaluate the safety and tolerability of higher infusion parameters of immune globulin subcutaneous (human), 20% liquid (Hizentra®) in subjects with primary immunodef...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003799-33,0,1,1 2016-003801-32,7,2017-12-04,2017-12-04,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Celgene International II Sàrl,"Multicenter, Single-arm, Phase 2 Study to Determine the Efficacy for the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003801-32,0,0,0 2016-003801-32,7,2017-12-04,2017-12-04,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,CELGENE INTERNATIONAL II SàRL,"Multicenter, Single-arm, Phase 2 Study to Determine the Efficacy for the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003801-32,0,0,0 2016-003802-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Charité - Universitätsmedizin Berlin,Skin penetration of anti-inflammatory compounds in lesional compared to non-lesional skin of psoriasis patients Eindringen von entzündungshemmenden Wirkstoffen in erkrankter im Vergleich zu gesunde...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003802-14,0,0,0 2016-003812-10,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"DELCATH SYSTEMS, INCORPORATIONS","A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003812-10,0,0,0 2016-003812-10,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Delcath Systems Inc.,"A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003812-10,0,0,0 2016-003813-92,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,IBSA FARMACEUTICI ITALIA SRL,Open clinical trial to evaluate the efficacy of intravesical instillation of hyaluronate added to early instillation of mitomycin vs early instillation of mitomycin in patients suffering from low risk...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003813-92,0,0,0 2016-003815-37,3,2021-12-17,2021-12-17,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,The Medicines Company,"An open label, active comparator extension trial to assess the effect of long term dosing of inclisiran and evolocumab given as subcutaneous injections in subjects with high cardiovascular risk and el...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003815-37,1,0,0 2016-003815-37,3,2021-12-17,2021-12-17,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"An open label, active comparator extension trial to assess the effect of long term dosing of inclisiran and evolocumab given as subcutaneous injections in subjects with high cardiovascular risk and el...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003815-37,1,0,0 2016-003817-80,3,2018-10-31,2018-10-31,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Genfit SA,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Elafibranor at Doses of 80 mg and 120mg after 12 Weeks of Treatment in Patients With P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003817-80,0,0,0 2016-003818-26,9,2022-07-27,2022-07-27,7,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Kowa Research Institute, Inc.",Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN patiENts with diabeTes (PROMINENT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003818-26,1,0,0 2016-003819-36,1,2022-03-11,2022-03-11,1,0,0,0,0,0,2,0,0,1,1,1,0,0,0,VU Medical Centre,Combining SBRT and pembrolizumab in early stage non-small cellular lungcancer patients planned for surgery: exploring safety and immunological proof of principle. De combinatie van stereotactische...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003819-36,0,0,0 2016-003820-22,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Dutch Growth Research Foundation,"Intranasal administration of oxytocin in children with Prader-Willi Syndrome. A randomized, open-label, cross-over trial of different treatment regimens of oxytocin administration. Effects on eating b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003820-22,0,0,0 2016-003821-40,4,2019-06-19,2019-06-19,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Evaluation of safety following Immune Tolerance Induction treatment with turoctocog alfa in patients with haemophilia A following inhibitor development in NN7170-4213 trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003821-40,0,0,0 2016-003825-41,4,2018-05-15,2018-05-15,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Tricida, Inc.","A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects with Chronic Kidney Disease and Metabolic Acidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003825-41,0,0,0 2016-003826-18,1,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children with Achondroplasia, Age 0 to < 60 Months",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003826-18,0,0,0 2016-003827-45,3,2020-04-22,2020-04-22,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,CIBERES - Instituto Carlos III,"AN OPEN LABEL PHASE IV, MULTICENTER, INTERNATIONAL, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF DIET ON GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH IPF TREATED WITH PIRFENIDONE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003827-45,1,0,0 2016-003827-45,3,2020-04-22,2020-04-22,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,Institut d'Investigació Biomédica de Bellvitge (IDIBELL),"AN OPEN LABEL PHASE IV, MULTICENTER, INTERNATIONAL, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF DIET ON GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH IPF TREATED WITH PIRFENIDONE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003827-45,1,0,0 2016-003827-45,3,2020-04-22,2020-04-22,1,0,0,0,0,0,4,0,0,2,0,0,0,0,0,CIBER - Instituto Carlos III,"AN OPEN LABEL PHASE IV, MULTICENTER, INTERNATIONAL, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF DIET ON GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH IPF TREATED WITH PIRFENIDONE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003827-45,1,0,0 2016-003828-23,1,2019-04-10,2019-04-10,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin; Dpt. of Dermatology and Allergy,A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003828-23,0,0,0 2016-003830-26,1,2018-01-23,2018-01-23,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Exeltis France,"Single center, phase II, open label randomized clinical trial to evaluate the inhibition of ovulation of three prolonged release formulations containing a combination of Dienogest and Ethinyl Estradio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003830-26,0,0,0 2016-003831-39,2,2018-09-24,2018-09-24,2,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Exeltis France S.A.,"Multicentre, phase II, open label randomised clinical trial to assess the bleeding profile, tolerability and safety associated with the use of three prolonged release formulations containing a combina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003831-39,0,0,0 2016-003832-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Gemeinn. Salzburger Landeskliniken BetriebsGesmbH, University Hospital for Dermatology, EB-House Austria","A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis bullosa associated Locally Advanced/Metastatic Squamous Cell Carcinoma Offene ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003832-19,0,0,0 2016-003833-91,1,2019-07-31,2019-07-31,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,"Randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of intravenous neridronic acid in subjects with complex regional pain syndrome (CRPS) Ensayo aleatorizado, d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003833-91,0,0,0 2016-003835-39,1,2019-04-13,2019-04-13,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone Propionate/Salmeterol Multidose Dry ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003835-39,0,0,0 2016-003838-24,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD),A single arm Phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. Ensayo Clínico ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003838-24,0,0,0 2016-003839-38,7,2018-05-16,2018-05-16,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,"A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral partial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003839-38,0,0,0 2016-003839-38,7,2018-05-16,2018-05-16,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BAYER AG,"A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral partial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003839-38,0,0,0 2016-003841-27,1,2020-10-24,2020-10-24,1,0,0,0,0,1,2,0,0,1,0,0,1,0,1,Medicenna Therapeutics Inc.,"An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Recurrent or Progressive Glioblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003841-27,0,0,0 2016-003843-12,1,2019-08-30,2019-08-30,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,PILA PHARMA,"A Single-dose dose escalation trial in a randomised, single-blind, placebo-controlled group-comparison design to investigate the safety and tolerability of XEN-D0501 in 24 patients with diabetes melli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003843-12,0,0,0 2016-003846-97,1,2018-12-01,2018-12-01,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,"Section of Orofacial Pain and Jaw Function, Aarhus University",Phenotypic and genotypic characterization of a tension-type headache population,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003846-97,0,0,0 2016-003849-28,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Cutanea Life Sciences,"A randomized, double-blind, placebo-controlled study to assess the pharmacodynamics, safety, tolerability and efficacy of omiganan BID in patients with mild to moderate atopic dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003849-28,0,0,0 2016-003850-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,"RAMOS A randomized, multicenter open label phase II trial of Paclitaxel + Ramucirumab versus Paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003850-33,0,0,0 2016-003851-31,3,2019-10-31,2019-10-31,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, with Desmopressin Orally Disintegra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003851-31,0,0,0 2016-003852-60,1,,,0,1,0,1,0,1,1,0,0,3,0,0,0,0,1,NightstaRx Limited,"A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003852-60,0,0,0 2016-003856-59,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,MeiraGTX UK II Ltd,"Long-term follow-up study of participants following an open label, multi-centre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/8-hCARp.hCNGB3) for gene therapy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003856-59,0,0,0 2016-003858-33,8,2020-03-05,2020-03-05,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ARMO BioSciences Inc.,A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003858-33,0,0,0 2016-003858-33,8,2020-03-05,2020-03-05,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003858-33,0,0,0 2016-003858-33,8,2020-03-05,2020-03-05,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER",A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003858-33,0,0,0 2016-003866-14,13,2021-12-17,2022-02-11,9,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003866-14,1,0,0 2016-003866-14,13,2021-12-17,2022-02-11,9,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Pfizer Inc.,"A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003866-14,1,0,0 2016-003866-14,13,2021-12-17,2022-02-11,9,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States","A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003866-14,1,0,0 2016-003866-14,13,2021-12-17,2022-02-11,9,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003866-14,1,0,0 2016-003867-21,1,2019-05-02,2019-05-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,LEO Pharma A/S,A phase 4 trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate to severe plaque psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003867-21,0,0,0 2016-003870-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Universitario Príncipe de Asturias,Comparison of treatment of diabetic macular edema with Ozurdex® versus Ozurdex® plus laser in areas of peripheral non-perfusion Comparación del tratamiento del edema macular diabético con Ozurdex® ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003870-41,0,0,0 2016-003874-42,8,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,PRM|21097,"A phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly mod-4023 compared to daily genotropin® therapy in pre-pubertal children with growth hormone deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003874-42,0,0,0 2016-003874-42,8,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,OPKO Biologics Ltd.,"A phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly mod-4023 compared to daily genotropin® therapy in pre-pubertal children with growth hormone deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003874-42,0,0,0 2016-003875-22,1,2017-07-31,2017-07-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre Hospitalier Universitaire Brugmann,Randomized controlled prospective study on the injection of corticoids for the treatment of acute sprains of the proximal interphalangeal joints of the fingers (thumb excluded).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003875-22,0,0,0 2016-003876-29,6,2021-11-30,2022-01-18,3,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Orphalan,CHELATE STUDY: Trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003876-29,1,0,0 2016-003876-29,6,2021-11-30,2022-01-18,3,0,0,0,0,1,3,0,0,2,1,0,0,0,1,gmp-orphan SA,CHELATE STUDY: Trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003876-29,1,0,0 2016-003876-29,6,2021-11-30,2022-01-18,3,0,0,0,0,1,3,0,0,2,1,0,0,0,1,GMP ORPHAN SA,CHELATE STUDY: Trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003876-29,1,0,0 2016-003878-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,"SINGLE ARM, OPEN-LABEL, UNCONTROLLED PHASE II PILOT STUDY ON BRAIN PET WITH THE TRACER [18F]GE-180 (18FGEH120714) IN PATIENTS AFFECTED BY COGNITIVE DECLINE STUDIO PILOTA DI FASE II IN APERTO A BRAC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003878-41,0,0,0 2016-003881-14,13,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab or with Standard of Care Chemotherapy versus Standard of Care Chemotherapy in Participants with Previously Untreated Unres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003881-14,0,0,0 2016-003881-14,13,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab or with Standard of Care Chemotherapy versus Standard of Care Chemotherapy in Participants with Previously Untreated Unres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003881-14,0,0,0 2016-003883-38,3,2019-12-20,2019-12-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Adrenomed AG,"A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Proof of Concept and Dose-Finding Phase II Clinical Trial to Investigate the Safety, Tolerability and Efficacy of ADRECIZUMAB in Patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003883-38,0,0,0 2016-003884-20,6,,,0,0,1,0,1,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3 Randomized, Active-comparator-controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Subjects from Birth to less than 12 Years of Age ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003884-20,0,1,0 2016-003888-19,1,2020-04-30,2020-04-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,A. Carlsson Research AB,"Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of OSU6162 in the treatment of residual symptoms after stroke Dubbelblind, randomiserad, placebo-kontrollerad ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003888-19,0,0,0 2016-003893-42,2,2019-09-05,2019-09-05,2,1,0,1,0,1,1,0,0,1,1,1,0,0,1,Autolus Limited,"A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients with Relapsed or Refractory M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003893-42,0,0,0 2016-003896-24,6,2020-06-12,2020-09-28,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,AstraZeneca AB,A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003896-24,0,0,0 2016-003897-41,7,2019-07-17,2019-07-17,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003897-41,0,0,0 2016-003900-30,9,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients with Acute Myeloid Leukemia W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003900-30,0,0,0 2016-003902-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"RWTH Aachen University, represented by the Clinical Trial Center (CTC-A)",Intravenous Fish Oil based Lipid Emulsion as Pharmaconutrient Strategy in High-Risk Cardiac Surgery Patients: a Phase II Dosing Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003902-14,0,0,0 2016-003903-79,6,2018-11-16,2018-11-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sylentis SAU - PharmaMar Group,A double-masked study of SYL1001 in patients with moderate to severe dry eye disease (DED),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003903-79,0,0,0 2016-003903-79,6,2018-11-16,2018-11-16,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SYLENTIS S.A.U,A double-masked study of SYL1001 in patients with moderate to severe dry eye disease (DED),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003903-79,0,0,0 2016-003904-29,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,University of Birmingham,International phase I/II expansion trial of the MEK inhibitor selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult Acute Lymp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003904-29,0,0,0 2016-003906-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Begoña Quintana,FAST-TRACK IN ENDOVASCULAR AORTIC ANEURYSM REPAIR WITH DESFLURANE AND SEVOFLURANE: A RANDOMIZED CLINICAL TRIAL FAST-TRACK EN LA REPARACIÒN ENDOVASCULAR DEL ANEURISMA DE AORTA CON DESFLURANO Y SEVOF...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003906-16,0,0,0 2016-003912-11,2,2020-12-17,2020-12-17,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Symphogen A/S,"An Open-label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients with Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003912-11,0,0,0 2016-003917-83,1,2019-10-21,2019-10-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU de DIJON,Open and exploratory trial to investigate the pharmacokinetic of ceftobiprole medocaril in patients with CSF device,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003917-83,0,0,0 2016-003921-40,1,2018-05-02,2018-05-02,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,University Hospital of South Manchester NHS Foundation Trust,Open label study of the efficacy and safety of isavuconazole for the treatment of Chronic Pulmonary Aspergillosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003921-40,0,0,0 2016-003924-22,1,2019-09-26,2019-09-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROCHE SAS,"AN OPEN-LABEL, MULTICENTER, SINGLE-ARM, PHASE II STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALECTINIB IN PATIENTS WITH ALK-REARRANGED NON−SMALL CELL LUNG CANCER AFTER DISEASE PROGRESSION ON PRIOR ALK ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003924-22,0,0,0 2016-003926-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,"A phase II clinical trial of Pembrolizumab in combination with Carboplatin-Paclitaxel in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer: MITO28/MANGO O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003926-18,0,0,0 2016-003927-45,6,2019-10-15,2019-11-14,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Sensorion SA,"A multicentre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 2 dose regimens of orally administered SENS-111 (100mg and 200mg) given during 4 days in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003927-45,0,0,0 2016-003927-45,6,2019-10-15,2019-11-14,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Sensorion,"A multicentre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 2 dose regimens of orally administered SENS-111 (100mg and 200mg) given during 4 days in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003927-45,0,0,0 2016-003927-45,6,2019-10-15,2019-11-14,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,SENSORION,"A multicentre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 2 dose regimens of orally administered SENS-111 (100mg and 200mg) given during 4 days in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003927-45,0,0,0 2016-003928-23,7,2020-01-15,2020-01-15,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eisai Ltd.,"A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003928-23,0,0,0 2016-003930-26,7,2021-02-28,2021-03-03,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Daiichi Sankyo Inc.,Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation ¿ In Atrial Fibrillation. ENVISAGE TAVI-AF Edoxaban ris...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003930-26,1,0,0 2016-003930-26,7,2021-02-28,2021-03-03,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,DAIICHI SANKYO INC.,Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation ¿ In Atrial Fibrillation. ENVISAGE TAVI-AF Edoxaban ris...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003930-26,1,0,0 2016-003934-25,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp.,a subsidiary of Merck & Co.,Inc.",A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous ce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003934-25,0,0,0 2016-003934-25,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous ce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003934-25,0,0,0 2016-003934-25,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous ce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003934-25,0,0,0 2016-003936-19,2,2019-04-08,2019-04-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,SUN Pharmaceuticals Global FZE,"A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Subjects with Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003936-19,0,0,0 2016-003937-62,3,2019-09-24,2019-09-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SUN Pharma Global FZE,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects with Active Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003937-62,0,0,0 2016-003937-62,3,2019-09-24,2019-09-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SUN Pharmaceuticals Global FZE,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects with Active Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003937-62,0,0,0 2016-003939-38,1,2021-04-23,2021-04-23,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Short-term efficacy of a single ultrasound-guided intra-articular injection of botulinum toxin A associated with splinting for base-of-thumb osteoarthritis on pain at 3 months: A randomized placebo-co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003939-38,0,0,0 2016-003940-35,2,2018-05-02,2018-05-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Grünenthal GmbH,"Exploratory, randomized, double-blind, placebo-controlled evaluation of efficacy, tolerability, and safety of intravesical instillation of GRT6010 compared to placebo in subjects with bladder pain syn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003940-35,0,0,0 2016-003941-27,1,2019-03-22,2019-03-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Radboud University Medical Center,Bioequivalence study of CRUshed Sofosbuvir/velpAtasvir compareD to the wholE tablet (CRUSADE-1)/Hep-NED004,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003941-27,0,0,0 2016-003946-99,1,2021-07-27,2021-07-27,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,Grupo Español de Tumores Huérfanos e Infrecuentes (GETHI),"A multicenter phase 2 study of nivolumab combined with ipilimumab in patients with pediatric solid tumors presenting in adulthood Estudio multicéntrico, fase 2 de nivolumab en combinación con ipili...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003946-99,0,0,0 2016-003947-12,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Freistaat Bayern represented by University of Regensburg represented by Kaufmännischer Direktor,Treatment of steroid-resistant chronic graft-versus-host-disease with donor-derived regulatory T cells Therapie der Steroid-refraktären chronischen Graft-versus-Host-Erkrankung mit regulatorischen ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003947-12,0,0,0 2016-003948-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII,"Multicenter, national, prospective, open label, randomized, pilot, proof-of-concept study on the use of rilpivirine plus Darunavir/cobicistat as substitutive agents in virologic suppressed patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003948-36,0,0,0 2016-003949-28,1,,,0,0,0,0,0,0,3,1,0,0,0,0,0,0,0,PROF. ANTONELLA GIANNANTONI - CLINICA UROLOGICA - UNIVERSITà DI PERUGIA,Incobotulinumtoxin versus Onabotulinumtoxin in the treatment of patients with overactive bladder syndrome Incobotulinumtoxin A versus Onabotulinumtoxin A nel trattamento dei pazienti con sindrome d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003949-28,0,0,0 2016-003952-63,1,2019-12-12,2019-12-12,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Instituto de Investigación Sanitaria La Fe,Pilot study of vulval lichen sclerosus treatment by adipose tissue associated with autologous platelet-rich plasma Estudio piloto del tratamiento del liquen escleroso vulvar mediante tejido adiposo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003952-63,0,0,0 2016-003957-14,10,2022-05-12,2022-05-12,8,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"KARYOPHARM THERAPEUTICS, INC.","A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003957-14,1,0,0 2016-003957-14,10,2022-05-12,2022-05-12,8,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Karyopharm Therapeutics Inc.,"A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003957-14,1,0,0 2016-003959-29,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,"Helena Tinkanen, Tampereen yliopistollinen sairaala","Scientific title: A Protocol for a Randomized, Two-Parallel-group Study to Compare the Efficacy of Testing LH Surge at Home Versus Medically Triggered Ovulation with hCG (Pregnyl®) in the Naturally St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003959-29,0,0,0 2016-003961-25,6,2018-01-16,2018-01-16,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Biotie Therapies,"A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off”",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003961-25,0,0,0 2016-003961-25,6,2018-01-16,2018-01-16,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,BIOTIE THERAPIES INC.,"A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off”",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003961-25,0,0,0 2016-003962-24,1,2017-07-02,2017-07-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Medice Arzneimittel Pütter GmbH & Co. KG,"A multi-centre, randomized, placebo-controlled, double-blind, parallel-group study investigating safety and efficacy of a sore throat lozenge in the symptomatic treatment of patients with acute pharyn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003962-24,0,0,0 2016-003963-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AIO-Studien-gGmbH,Durvalumab (MEDI4736) in frail and elder patients with metastatic NSCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003963-20,0,0,0 2016-003964-38,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,The BAROCCO study (Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib): an Italian multicenter randomized phase II study of weekly paclitaxel vs. Cediranib-Olaparib with continuous sch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003964-38,0,0,0 2016-003967-21,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,MeiraGTx UK II Limited,"An open label, multi-centre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/5-hRKp.RPGR) for gene therapy of adults and children with X-linked Retinitis Pigmento...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003967-21,0,0,0 2016-003968-39,1,2019-01-09,2019-01-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee/NHS Tayside,Renal and Cardiovascular Effects of SGLT2 inhibition in combination with loop diuretics in diabetic patients with chronic heart failure.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003968-39,0,0,0 2016-003970-41,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,UNIVERSITÀ DEGLI STUDI MILANO BICOCCA,A PHASE 2 OPEN LABEL STUDY OF ORAL LORLATINIB (PF-06463922) IN PATIENTS WITH RELAPSED ALK POSITIVE LYMPHOMA PREVIOUSLY TREATED WITH ALK INHIBITORS STUDIO DI FASE 2 IN APERTO CON LORLATINIB (PF-0646...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003970-41,0,0,0 2016-003973-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,"Groningen International Study on Sentinel nodes in Vulvar cancer - III, a prospective phase 2 treatment trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003973-16,0,0,0 2016-003975-23,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Asherman Therapy S.L.U.,"Efficacy and safety of autologous, mobilized, non-expanded CD133+ cells to treat Asherman´s Syndrome: A prospective, multi-center, phase I/II clinical trial. Eficacia y seguridad de células CD133+ ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003975-23,0,0,0 2016-003978-41,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,"Pfizer, Inc.","A Phase 3, Multi-center, Open label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003978-41,0,1,1 2016-003980-21,11,2022-08-24,2022-08-24,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Rexgenero Limited,The Efficacy and Safety of Intra-Arterial Administration of REX-001 to Treat Ischaemic Ulcers in Subjects with Chronic Limb Threatening Ischaemia Rutherford Category 5 and Diabetes Mellitus: A Pivotal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003980-21,1,0,0 2016-003980-21,11,2022-08-24,2022-08-24,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Ixaka Limited,The Efficacy and Safety of Intra-Arterial Administration of REX-001 to Treat Ischaemic Ulcers in Subjects with Chronic Limb Threatening Ischaemia Rutherford Category 5 and Diabetes Mellitus: A Pivotal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003980-21,1,0,0 2016-003981-15,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"Merck & Co., Inc.","A Study in Healthy Neonates of Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured Using a Modified Process",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003981-15,0,1,1 2016-003982-24,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Asociación HHT España,"A phase IV-II, single-center, open, single arm treatment, low level of intervention, to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of he...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003982-24,0,0,0 2016-003984-20,6,2020-09-23,2020-09-23,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"LSK BioPartners, Inc","A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib plus Best Supportive Care (BS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003984-20,0,0,0 2016-003984-20,6,2020-09-23,2020-09-23,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"LSK BIOPARTNERS, INC.","A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib plus Best Supportive Care (BS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003984-20,0,0,0 2016-003984-20,6,2020-09-23,2020-09-23,4,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Elevar Therapeutics, Inc","A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib plus Best Supportive Care (BS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003984-20,0,0,0 2016-003986-25,1,2020-08-25,2020-08-25,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Instituto de Investigación Sanitaria INCLIVA,"Impact of self-measurement of blood pressure and self-adjustment of antihypertensive medication in the control of hypertension and adherence to treatment. A pragmatic, randomized, controlled clinical ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003986-25,0,0,0 2016-003989-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"CIRO, center of expertise in chronic organ failure",THE EFFECT OF TWICE DAILY ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE 340/12 MCG VS ONCE DAILY TIOTROPIUM RESPIMAT 5MCG ON STATIC AND DYNAMIC HYPERINFLATION IN PATIENTS WITH COPD DURING 24 HOURS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003989-12,0,0,0 2016-003990-17,5,2018-12-18,2018-12-18,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003990-17,0,0,0 2016-003990-17,5,2018-12-18,2018-12-18,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag Internacional NV,"A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003990-17,0,0,0 2016-003991-27,1,2019-11-04,2019-11-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca AB,"MAAST: A Double-blind, Randomized, Phase IV, Mechanistic, Placebo-controlled, Cross-over, Single-center Study to Evaluate the Effects of 5 Weeks Dapagliflozin Treatment on Insulin Sensitivity in Skele...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003991-27,0,0,0 2016-003992-23,7,2019-04-11,2019-04-11,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003992-23,0,0,0 2016-003993-42,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Prokrea BCN S.L.,"A multi-centre, randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of two concentrations of PKB171 against placebo in couples with asthenozoospermia who wish to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003993-42,0,0,0 2016-003996-23,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SAKK,ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents and non-progressive disease after subsequent treatmen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003996-23,0,0,0 2016-003997-41,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,CHU de Nantes,Controlled and double blind comparison of a traditional dressing versus a biologic dressing composed of fetal fibroblasts and keratinocytes in association with a collagen matrix on skin donor sites ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003997-41,0,0,0 2016-003998-17,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Grand Hôpital de Charleroi,A phase Ib/II study of Durvalumab (MEDI4736) combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003998-17,0,0,0 2016-004003-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE RICERCA TRASLAZIONALE (FORT),"SQUINT (Squamous Immunotherapy Nivolumab-Ipilimumab Trial): An open-label, randomized, phase II trial of Nivolumab plus Ipilimumab versus platinum-based chemotherapy in chemonaive metastatic or recurr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004003-31,0,0,0 2016-004004-60,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS ISTITUTO CLINICO HUMANITAS,Prospective study of anti-inflammatory therapy post interventional radiological treatment of HCC in the cirrhotic patient. Studio prospettico della terapia anti-infiammatoria dopo trattamenti di Ra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004004-60,0,0,0 2016-004008-71,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Erasmus MC Cancer Institute,The effect of curcumin and piperine on the pharmacokinetics of tamoxifen in patients with estrogen receptor positive breast cancer ‘the ELDORADO study’ Het effect van kurkuma en piperine op de farm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004008-71,0,0,0 2016-004009-15,5,2018-11-22,2018-11-22,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Visterra, Inc.","Phase 2b, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu®) Compared With Oseltamivir Alone in Hos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004009-15,0,0,0 2016-004010-10,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Liverpool,"PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004010-10,0,0,0 2016-004011-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SOGUG (Spanish Oncology Genitourinary Group),Phase II study to evaluate efficacy and safety of sunitinib therapy in patients with metastatic renal clear cell carcinoma who have progressed to first-line immunotherapy treatment (INMUNOSUN Study) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004011-12,0,0,0 2016-004012-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Graz,"Effect of albumin infusion on oxidative albumin modification, albumin binding capacity and plasma thiol status Effekt einer Albumininfusion auf die oxidative Albuminmodifikation, die Albuminbindung...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004012-35,0,0,0 2016-004015-13,2,2019-12-11,2019-12-11,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Ferrer Internacional, S.A.","A phase III, international, multicenter, randomized and open label study to evaluate the efficacy on LDLc and blood pressure reduction and safety of Trinomia® versus usual care in patients with very h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004015-13,0,0,0 2016-004017-27,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,European Uro-Oncology Group (EUOG),"""Neo-adjUvant veRsus AdjuvaNt chemotherapy in Upper Tract Urothelial Carcinoma: A feaSibility phase II randomized clinical trial (“URANUS”)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004017-27,0,0,0 2016-004019-11,7,2018-09-21,2022-01-13,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Prestige BioPharma Pte Ltd,"A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety and pharmacokinetics of HD201 to Herceptin® in patients with HER2+ early breast can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004019-11,1,0,0 2016-004019-11,7,2018-09-21,2022-01-13,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,PRESTIGE BIOPHARMA PTE LTD,"A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety and pharmacokinetics of HD201 to Herceptin® in patients with HER2+ early breast can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004019-11,1,0,0 2016-004019-11,7,2018-09-21,2022-01-13,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Cromos Pharma Ireland,"A randomised, double-blind, parallel group, equivalence, multicentre phase III trial to compare the efficacy, safety and pharmacokinetics of HD201 to Herceptin® in patients with HER2+ early breast can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004019-11,1,0,0 2016-004021-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS),Response to oral lansoprazole in inorganic pyrophosphate levels in patients with Grönblad-Stranberg disease (Pseudoxanthoma Elasticum) Respuesta al lansoprazol oral de los niveles del pirofosfato ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004021-16,0,0,0 2016-004023-24,1,2022-07-06,2022-07-06,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,"Copenhagen Affective Disorder research Center (CADIC), Psychiatric Centre Copenhagen, Rigshospitalet",Effect of erythropoietin (EPO) on cognitive function and frontal lobe activity in patients with bipolar disorder and unipolar depression in remission (PRETEC-EPO) Effekt af erythropoietin (EPO) på ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004023-24,0,0,0 2016-004024-29,9,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004024-29,0,0,0 2016-004024-29,9,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004024-29,0,0,0 2016-004031-20,1,,,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,Aarhus University Hospital,Determination of radiation dose for the bile acid tracer 11C-CSar in humans Bestemmelse af stråledosis for galdesyre sporstof 11C-CSar i mennesker,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004031-20,0,0,0 2016-004033-25,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Fundació Parc Taulí,Efect of nebulized bicarbonate on bacterial infections in patients with cystic fibrosis. Randomized clinical trial Efecto del bicarbonato nebulizado en vía aérea sobre las infecciones bacterianas e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004033-25,0,0,0 2016-004034-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,Randomized controlled phase IIb-III clinical trial to assess the effectiveness of different regimens with u-FSH in the infertile male Studio clinico randomizzato controllato di fase IIb-III per val...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004034-14,0,0,0 2016-004035-21,1,2018-05-29,2018-05-29,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"A multicenter, open-label, single-sequence cross-over study to assess safety, tolerability, and pharmacokinetics of intravenous selexipag in subjects with stable pulmonary arterial hypertension switch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004035-21,0,0,0 2016-004038-24,1,2018-11-14,2018-11-14,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Modern Biosciences plc,"A 12-Week, Double-Blind, Placebo-Controlled, Phase 2a Study to Investigate the Safety, Tolerability and Efficacy of MBS2320 in Patients with Active Rheumatoid Arthritis receiving Methotrexate",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004038-24,0,0,0 2016-004039-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Sarcomas (GEIS),Phase II multicenter trial of palbociclib in second line of advanced sarcomas with CDK4 overexpression. Ensayo fase II multicéntrico de palbociclib en segunda línea de sarcomas avanzados con sobree...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004039-19,0,0,0 2016-004040-10,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,GRUPO ESPAñOL DE INVESTIGACIóN EN SARCOMAS,Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas Ensayo fase I-II de sunitinib y nivolumab tras tratamiento estándar en sarcomas de pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004040-10,0,0,0 2016-004040-10,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Sarcomas (GEIS),Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas Ensayo fase I-II de sunitinib y nivolumab tras tratamiento estándar en sarcomas de pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004040-10,0,0,0 2016-004043-36,1,2022-01-14,2022-01-14,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Uppsala University,CD19-TARGETING 3RD GENERATION CAR T CELLS FOR REFRACTORY B CELL MALIGNANCY – A PHASE II TRIAL Behandling av terapiresistent B cells malignitet med CD19-specifika CAR T celler - en fas II studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004043-36,0,0,0 2016-004045-81,5,2019-10-10,2019-10-10,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Aurinia Pharmaceuticals, Inc.","A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004045-81,0,0,0 2016-004046-28,3,2021-10-07,2021-10-07,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Aurinia Pharmaceuticals, Inc.","A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis Es...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004046-28,1,0,0 2016-004051-78,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ITALIAN SARCOMA GROUP,Solitary fibrous tumor: phase II study on TRabectedin versus Adriamycin plus DAcarbazine in advanced patients (STRADA) Solitary fibrous tumor: phase II study on TRabectedin versus Adriamycin plus D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004051-78,0,0,0 2016-004052-30,3,2022-09-06,2022-09-06,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A randomized, placebo-controlled, patient and investigator blinded, Proof of Concept study investigating the safety, tolerability and preliminary efficacy of multiple intra-articular LNA043 injections...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004052-30,1,0,0 2016-004056-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Formación e Investigación Sanitaria,Clinical trial phase IV randomized controlled to study the influence of temperature control in patients with septic shock Ensayo clínico controlado aleatorizado en fase IV para estudiar el efecto e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004056-29,0,0,0 2016-004059-53,6,2020-10-04,2020-11-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ObsEva S.A.,"A Phase 3, multicentre, randomized, double-blind, placebo controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back therapy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004059-53,0,0,0 2016-004059-53,6,2020-10-04,2020-11-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ObsEva SA,"A Phase 3, multicentre, randomized, double-blind, placebo controlled study investigating the efficacy and safety of daily oral administration of OBE2109 alone and in combination with add-back therapy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004059-53,0,0,0 2016-004062-26,8,2018-06-20,2018-07-20,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,"A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral partial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004062-26,0,0,0 2016-004062-26,8,2018-06-20,2018-07-20,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BAYER AG,"A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral partial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004062-26,0,0,0 2016-004066-26,6,2022-02-28,2022-03-28,4,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AMGEN INC.,"A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004066-26,1,0,0 2016-004066-26,6,2022-02-28,2022-03-28,4,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Amgen Inc,"A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004066-26,1,0,0 2016-004072-22,1,2020-10-06,2020-10-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Norwegian University of Science and Technology (NTNU),"NTNU Intranasal Naloxone Trial Double blinded, double dummy, randomised controlled trial of intranasal naloxone for pre hospital use",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004072-22,0,0,0 2016-004076-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),"Randomised, multicentre, phase II pilot study to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed by ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004076-21,0,0,0 2016-004078-16,1,,,0,0,0,0,0,1,4,0,0,1,0,0,0,1,0,"Sahlgrenska University Hospital, Gothenburg","A dose-response study of markers of glucocorticoid action (DOSCORT)- A double-blind, randomized, two-period, two-dose, cross-over study in subjects with primary adrenal insufficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004078-16,0,0,0 2016-004080-39,1,2018-05-28,2018-05-28,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Medicinsk Forskning, Regionshospitalet Holstebro, Hospitalsenheden Vest",Determination of renal blood flow based on Rubidium-82 and PET-technology in healthy volunteers Renal blood flow bestemmelse hos raske forsøgsdeltagere baseret på rubidium-82 PET-teknologi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004080-39,0,0,0 2016-004082-39,4,2020-07-24,2020-07-31,3,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Linköping University,An Open-Label Phase II Study in anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES Eine offene Phase II Studie zur Evaluie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004082-39,0,0,0 2016-004084-39,4,2018-01-11,2018-01-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Esperion Therapeutics Inc.,","A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg/day as Add-on to Ezetimibe Therapy in Patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004084-39,0,0,0 2016-004086-87,9,2022-03-21,2022-03-31,5,1,1,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A randomized, double-blind, parallel group, multicenter, stratified, study evaluating the efficacy and safety of once daily fluticasone furoate/vilanterol inhalation powder compared to once daily flut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004086-87,1,1,0 2016-004087-19,8,2022-03-25,2022-03-25,3,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Genzyme Corporation,"ATLAS-PPX trial: an open-label, multinational, switching study to describe the efficacy and safety of fitusiran prophylaxis in hemophilia A and B patients previously receiving factor or bypassing agen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004087-19,1,1,0 2016-004087-19,8,2022-03-25,2022-03-25,3,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"ALNYLAM PHARMACEUTICALS, INC.","ATLAS-PPX trial: an open-label, multinational, switching study to describe the efficacy and safety of fitusiran prophylaxis in hemophilia A and B patients previously receiving factor or bypassing agen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004087-19,1,1,0 2016-004087-19,8,2022-03-25,2022-03-25,3,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","ATLAS-PPX trial: an open-label, multinational, switching study to describe the efficacy and safety of fitusiran prophylaxis in hemophilia A and B patients previously receiving factor or bypassing agen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004087-19,1,1,0 2016-004091-21,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004091-21,0,0,0 2016-004097-17,1,2017-12-28,2017-12-28,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Fakultni nemocnice Hradec Kralove,Evaluation of changes in concentrations of memantine in the cerebrospinal fluid of patients with Alzheimer´s disease. Sledování změn koncentrace memantinu v mozkomíšním moku pacientů S Alzheimerov...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004097-17,0,0,0 2016-004102-34,4,2022-09-12,2022-09-12,2,0,1,0,0,0,2,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co.KG,"An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects with Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004102-34,1,0,0 2016-004106-34,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Uppsala University Hospital,PERSISTENCE OF MAJOR MOLECULAR REMISSION IN CHRONIC MYELOID LEUKEMIA AFTER a second stop of TKI TREATMENT in patients who failed an initial stop attempt: A prospective multicenter study .,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004106-34,0,0,0 2016-004107-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS,Randomized clinical trial of concomitant chemoendocrine therapy versus chemotherapy followed by endocrine therapy as first line treatment of luminal B metastatic breast cancer. Studio clinico rando...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004107-31,0,0,0 2016-004108-73,2,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,ASTRAZENECA SPA,"A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004108-73,0,0,0 2016-004108-73,2,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,AstraZeneca,"A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced, Or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004108-73,0,0,0 2016-004109-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Medical University of Warsaw,"Evaluation of the safety and efficacy of the treatment of chronic wounds in diabetic foot syndrome with the use of autologous stem cells isolated from adipose tissue - within the project: ""Therapeutic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004109-15,0,0,0 2016-004110-10,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Medical University of Warsaw,Evaluation the safety and efficacy of the treatment of scars and cutis laxa syndrome with the use of autologous (fresh and stored) stem cells isolated from adipose tissue within the project: 'The ther...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004110-10,0,0,0 2016-004112-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,SOIBD (The Swedish Organisation for the study of Inflammatory Bowel Diseases),"Low-dose azathioprine and allopurinol- versus azathioprine monotherapy in patients with Inflammatory Bowel Disease: An investigator-initiated, open, multicentre, parallel-arm, randomized controlled tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004112-35,0,0,0 2016-004114-99,1,2018-09-03,2018-09-03,1,0,0,0,0,0,4,0,0,1,1,1,1,0,1,AB-BIOTICS,USE OF P.N680S POLYMORPHISM TO CHOOSE THE EXOGEN FSH DOSE IN CONTROLLED OVARIAN HYPERSTIMULATION: A PROSPECTIVE TRIAL USO DEL POLIMORFISMO p. N680S PARA ELEGIR LA DOSIS DE FSH EXÓGENA EN LA ESTIMUL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004114-99,0,0,0 2016-004115-12,4,2019-11-05,2019-11-05,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Esperion Therapeutics, Inc.",A Multicenter Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 mg,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004115-12,0,0,0 2016-004117-27,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,IBSAL (Instituto de Investigación Biomédica de,"CONTROLLED, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL FOR PROPHILAXIS OF POSOPERATIVE DELIRIUM IN HIGH RISK SURGICAL PATIENTS WITH QUETIAPINE. ENSAYO CLÍNICO CONTROLADO, DOBLE CIEGO Y ALEATORIZADO PA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004117-27,0,0,0 2016-004118-84,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,IRCCS ISTITUTO CLINICO HUMANITAS,"A multicenter, phase I-II trial of gemcitabine plus oxaliplatin and nbb-paclitaxel in subjects with advanced (unresectable or metastatic) biliary tract cancer (gallbladder cancer, cancer of the extrah...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004118-84,0,0,0 2016-004119-11,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,Study on half-dose Photodynamic therapy versus Eplerenone in chronic CenTRAl serous chorioretinopathy (SPECTRA trial) Studie naar halve dosis fotodynamische therapie versus eplerenon bij chronisch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004119-11,0,0,0 2016-004120-39,1,2022-06-22,2022-06-22,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Region Skåne,An experimental pilot study on immune and inflammatory biomarkers in patients with advanced prostatecancer treated with degarelix vs. GnRH agonist and with cardiovascular disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004120-39,0,0,0 2016-004121-16,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Edinburgh,Start or STop Anticoagulants Randomised Trial (SoSTART) after spontaneous intracranial haemorrhage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004121-16,0,0,0 2016-004122-41,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"Medical University Vienna, Dept. f. Transfusion Medicine","Plerixafor for stem cell mobilization in patients with multiple myeloma who mobilize moderate to optimize collection results - a randomized, placebo-controlled, double-blind study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004122-41,0,0,0 2016-004123-23,1,2021-03-19,2021-03-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Department of Infectious Diseases, Odense University Hospital","Immunization of immunosuppressed patients – Knowledge, practices and serological response Pneumokokvaccination af nyretransplanterede patienter i immunmodulerende behandling og end-stage nyresyge ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004123-23,0,0,0 2016-004124-26,1,2019-05-08,2019-05-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, subject- and investigator-blinded, placebo-controlled study to assess the safety, pharmacokinetics and efficacy of intravenous bimagrumab in overweight and obese patients with type 2 dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004124-26,0,0,0 2016-004126-42,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,F. Hoffman-La Roche Ltd,"A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004126-42,0,0,0 2016-004128-42,11,2020-01-14,2020-01-14,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eisai Ltd.,"A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease Studio di 24 mesi controllato verso placeb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004128-42,0,0,0 2016-004128-42,11,2020-01-14,2020-01-14,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,EISAI LIMITED,"A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease Studio di 24 mesi controllato verso placeb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004128-42,0,0,0 2016-004129-18,4,2020-06-22,2020-06-22,4,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Akari Therapeutics Plc,CONSERVE: Coversin Long Term Safety and Efficacy Surveillance Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004129-18,0,0,0 2016-004130-24,16,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3, Randomized, Double-Blind, Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004130-24,0,0,0 2016-004133-25,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Seqirus GmbH,"A Phase 3, Randomized, Multicenter, Observer-Blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Seqirus Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) with a ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004133-25,0,1,1 2016-004136-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA SENESE,"PROSPECTIC, RANDOMIZED, NATIONAL MULTICENTRIC STUDY, FINALIZED TO ASSESS THE STABILITY OF TSH LEVELS IN THYROIDECTOMISED PATIENTS IN THERAPY WITH TWO FORMULATIONS OF LEVOTYROXIN (TABLETS AND SOFT-GEL)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004136-38,0,0,0 2016-004138-12,9,2019-03-21,2019-03-23,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004138-12,0,0,0 2016-004140-10,4,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,AstraZeneca AB,"A randomised, double-blind, placebo- and active-controlled, parallel-arm, multicentre study to assess efficacy, pharmacokinetics, safety and tolerability of multiple dose levels of abediterol administ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004140-10,0,0,0 2016-004141-90,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Queen Mary University of London,"Stopping Perioperative Angiotensin II Converting Enzyme inhibitors and/or receptor blockers in major non-cardiac surgery (SPACE): a phase II, explanatory, randomised controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004141-90,0,0,0 2016-004143-36,7,2020-01-20,2020-01-20,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ILKOS THERAPEUTIQUE INC,"Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer. A 10-week randomized, double-blind, placebo-controlled, pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004143-36,0,0,0 2016-004143-36,7,2020-01-20,2020-01-20,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Ilkos Thérapeutique Inc.,"Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer. A 10-week randomized, double-blind, placebo-controlled, pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004143-36,0,0,0 2016-004143-36,7,2020-01-20,2020-01-20,6,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Ilkos Therapeutic Inc.,"Dose-response relationship study of S42909 on leg ulcer healing after oral repeated administration in patients with active venous leg ulcer. A 10-week randomized, double-blind, placebo-controlled, pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004143-36,0,0,0 2016-004147-37,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Center for Translational & Clinical Research Aachen (CTC-A),Intravenous iron in patients with heart failure and reduced ejection fraction (HFREF) plus iron deficiency: Effects upon phosphate and FGF23 metabolism Intravenöses Eisen in Patienten mit Herzinsuf...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004147-37,0,0,0 2016-004148-13,9,2019-04-29,2019-04-30,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004148-13,0,0,0 2016-004148-13,9,2019-04-29,2019-04-30,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004148-13,0,0,0 2016-004151-79,1,2019-03-28,2019-03-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Translational Research in Oncology (TRIO),A Presurgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide (ODM-201),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004151-79,0,0,0 2016-004152-30,9,2019-04-16,2019-04-16,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3, Randomized, Double-Blind, Study Comparing ABT-494 to Placebo in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004152-30,1,0,0 2016-004153-32,4,2020-12-03,2021-01-20,3,1,1,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004153-32,0,0,0 2016-004154-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,"A phase II, multicentric, open label, non-randomized, interventional study of Pembrolizumab in combination with Electrochemotherapy in patients with unresectable melanoma with superficial or superfici...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004154-15,0,0,0 2016-004155-67,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Greater Glasgow and Clyde,"PRIMUS 001 - An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker eval...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004155-67,0,0,0 2016-004156-29,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Greater Glasgow and Clyde,"PRIMUS 002: An umbrella phase II study examining two neo-adjuvant regimens (FOLFOX-A and AG) in resectable and borderline resectable Pancreatic Ductal Carcinoma (PDAC), focusing on biomarker and liqu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004156-29,0,0,0 2016-004157-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CENTRO CARDIOLOGICO SPA FONDAZIONE MONZINO,Effect of the administration of 75 mg of acetylsalicylic acid + 200mg of triglycerides of n-3 series fatty acids (omega 3 + ASA) on the biosynthesis of platelet thromboxane A2 in patients with cardiov...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004157-33,0,0,0 2016-004159-56,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II,"Efficacy and safety of mesalazine, rifaximin, alone or as extemporary combination, in the treatment of symptomatic uncomplicated diverticular disease of colon: multi-centre, randomised, double-blind, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004159-56,0,0,0 2016-004161-68,3,2020-07-02,2020-07-02,2,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"Oragenics, Inc.","A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004161-68,1,0,0 2016-004163-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ARCAGY-GINECO,"A randomized, open-label, multicentric phase II trial of PEMBROLIZUMAB (Ketruda®) with chemotherapy versus chemotherapy alone (standard of care) as neo adjuvant treatment of ovarian cancer not amenabl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004163-39,0,0,0 2016-004165-58,4,2018-04-25,2018-04-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Genentech, Inc","A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MOXR0916 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METAST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004165-58,0,0,0 2016-004169-18,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"Centro de Investigación Biomédica en Red, Enfermedades Neurodegenerativas (CIBERNED)","A multicenter, randomized, double-blind, placebo-controlled, 4-arm, 26 week parallel-group study to evaluate the safety, tolerability and anti-inflammatory effect of three oromucosal doses of Sativex®...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004169-18,0,0,0 2016-004176-22,1,2021-09-16,2021-09-16,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medizinische Universität Graz,IMProving Ultrafiltration and REmoval of uremic toxins by adapted automated peritoneal dialysis in a single center study (IMPURE-Study). Intensivierte Ultrafiltration und Clearance der urämischen T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004176-22,0,0,0 2016-004179-33,2,2018-03-28,2019-03-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,A Phase 2 Study of Once-Weekly LY3298176 Compared with Placebo and Dulaglutide in Patients with Type 2 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004179-33,0,0,0 2016-004182-60,6,2018-06-05,2018-06-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Open-Label, Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults with Chronic Hepatitis C Virus Genotype 1 – 6 Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004182-60,0,0,0 2016-004182-60,6,2018-06-05,2018-06-05,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Open-Label, Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults with Chronic Hepatitis C Virus Genotype 1 – 6 Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004182-60,0,0,0 2016-004184-39,7,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"AN OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS OF RISDIPLAM (RO7034067) IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004184-39,0,0,0 2016-004184-39,7,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"AN OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS OF RISDIPLAM (RO7034067) IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004184-39,0,0,0 2016-004186-83,5,2022-06-14,2022-06-14,2,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Rezolute, Inc.",An Open-Label Multiple-Dose Study of RZ358 in Patients with Congenital Hyperinsulinism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004186-83,1,0,0 2016-004188-38,1,2019-10-17,2019-10-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,LABORATOIRE INNOTECH INTERNATIONAL,"Contraceptive Efficacy, Tolerance and Acceptability of A Benzalkonium Chloride Spermicide Cream In Women Aged Over 40 Years of Age - PHASE IV, INTERNATIONAL, OPEN-LABEL, MULTICENTRE, PROSPECTIVE STUDY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004188-38,0,0,0 2016-004191-22,1,2021-12-07,2021-12-07,1,0,0,0,0,0,4,0,0,1,1,1,0,0,1,Palleos healthcare GmbH,"PRECYCLE: Multicenter, randomized phase IV intergroup trial to evaluate the impact of e Health-based patient reported outcome (PRO) assessment on quality of life in patients with hormone receptor posi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004191-22,0,0,0 2016-004193-18,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Semmelweis University, Heart and Vascular Center",Effect of repetitive levosimendan treatment on clinical outcomes of chronic heart failure patients: focus on optimal patient selection based on novel cardiac biomarkers. Ismételt levosimendan alkal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004193-18,0,0,0 2016-004194-40,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Instituto de Investigación Sanitaria INCLIVA,Changes in Myocardial Iron Content Following Administration of Intravenous Iron Cambios en el contenido de hierro miocárdico tras la administración intravenosa de hierro,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004194-40,0,0,0 2016-004198-41,6,2021-01-18,2021-01-18,5,0,0,0,0,0,3,0,0,2,0,0,0,0,0,University College Dublin,PROPHYLACTIC OROPHARYNGEAL SURFACTANT FOR PRETERM INFANTS: A RANDOMISED TRIAL (THE POPART TRIAL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004198-41,1,0,0 2016-004200-65,2,2019-10-10,2019-10-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharma A/S,"A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate to severe atopic dermatitis who are candidates f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004200-65,0,0,0 2016-004201-13,4,2019-08-14,2019-08-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharma A/S,"A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate to severe atopic dermatitis who are candidates f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004201-13,0,0,0 2016-004201-13,4,2019-08-14,2019-08-15,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO PHARMA A/S,"A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in subjects with moderate to severe atopic dermatitis who are candidates f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004201-13,0,0,0 2016-004209-15,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Global Blood Therapeutics, Inc.","A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants with Sickle Cell Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004209-15,0,0,0 2016-004210-10,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA,"A PILOT PHASE IV STUDY TO EVALUATE VARIATION IN BONE MINERAL DENSITY, LEAN AND FAT BODY MASS MEASURED BY DUAL-ENERGY X-RAY ABSORPTIOMETRY IN PATIENTS WITH PROSTATE CANCER WITHOUT BONE METASTASIS TREA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004210-10,0,0,0 2016-004213-28,1,2019-05-31,2019-05-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Neuroscience, NTNU",Botulinum toxin type A block of the otic ganglion in chronic cluster headache. Safety issues.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004213-28,0,0,0 2016-004214-96,1,2018-01-30,2018-01-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA,Bilastine and inflammation: an explorative study in subjects affected by Parietaria J.-induced Rhinoconjunctivitis – The Bi-FLO study BILASTINA E INFIAMMAZIONE: STUDIO ESPLORATIVO IN SOGGETTI AFFET...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004214-96,0,0,0 2016-004215-13,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Clatterbridge Cancer Centre NHS Foundation,Randomised Phase II Trial of Cediranib and Olaparib Maintenance in Advanced/Recurrent Cervical Cancer (COMICE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004215-13,0,0,0 2016-004216-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,I.R.C.C.S. POLICLINICO SAN DONATO,"Pilot, open-label, spontaneous, Phase II study on the efficacy of beclomethasone dipropionate (BDP) for treatment of Collagenous colitis (CC) Studio pilota, open-label, spontaneo, di fase II sull’...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004216-36,0,0,0 2016-004217-26,7,2019-08-30,2019-08-30,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,INDEX PHARMACEUTICALS AB,A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004217-26,0,0,0 2016-004217-26,7,2019-08-30,2019-08-30,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,InDex Pharmaceuticals AB,A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004217-26,0,0,0 2016-004222-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Hospitalier Régional Universitaire de Lille,"Validation of the efficiency of repurposed drugs on the basis of their cellular transcriptomic signature, antagonist to that of the influenza A infection. Validation de l’efficacité antigrippale d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004222-42,0,0,0 2016-004223-23,5,2020-05-19,2020-05-19,3,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Novimmune SA,"A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFNγ) monoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004223-23,1,0,0 2016-004223-23,5,2020-05-19,2020-05-19,3,1,1,0,0,1,2,0,0,2,0,0,0,0,1,Swedish Orphan Biovitrum AG,"A pilot, open-label, single arm, multicenter study to evaluate safety, tolerability, pharmacokinetics and efficacy of intravenous administrations of NI-0501, an anti-interferon gamma (anti-IFNγ) monoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004223-23,1,0,0 2016-004232-37,12,2019-12-13,2019-12-13,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004232-37,0,0,0 2016-004232-37,12,2019-12-13,2019-12-13,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA SPA,"A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004232-37,0,0,0 2016-004236-38,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Oxford,OPtimising Treatment for MIld Systolic hypertension in the Elderly: a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004236-38,0,0,0 2016-004247-37,1,2021-08-31,2021-08-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Grenoble,NA Impact de l’administration précoce de concentrés de complexe prothrombique chez les patients présentant une hémorragie post-traumatique grave,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004247-37,0,0,0 2016-004250-15,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospitals Birmingham,"A prospective, phase II, single centre, cross-sectional, randomised trial investigating Dehydroepiandrosterone and it's Pharmacokinetics in Trauma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004250-15,0,0,0 2016-004251-76,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University Hospitals of Leicester NHS Trust,"A pragmatic multi-centre randomised controlled non-inferiority, cost effectiveness trial comparing injections of collagenase into the cord to surgical correction in the treatment of moderate Dupuytren...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004251-76,0,0,0 2016-004255-70,5,2019-12-11,2019-12-11,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A randomised, double-blind, parallel group PhIII study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral nasal p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004255-70,0,0,0 2016-004258-14,1,2017-10-12,2017-10-12,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline Research & Development Limited,"A two part Phase IIa Study, to Evaluate the Safety and Tolerability, Pharmacokinetics, Proof of Mechanism and Potential for Efficacy of an Anti-IL-7 Receptor-α Monoclonal Antibody (GSK2618960) in the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004258-14,0,0,0 2016-004259-59,1,2017-06-12,2017-06-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Idorsia Pharmaceuticals Ltd,"Multi-center, single-arm, open-label study in patients with Insomnia Disorder to validate the Insomnia Daytime Symptoms and Impacts Questionnaire™ (IDSIQ™)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004259-59,0,0,0 2016-004261-10,8,2019-04-25,2019-04-25,7,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Aridis Pharmaceuticals, Inc.","Placebo-controlled, double-blind, randomized study of Aerucin® as adjunct therapy to antibiotics in the treatment of P. aeruginosa pneumonia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004261-10,0,0,0 2016-004261-10,8,2019-04-25,2019-04-25,7,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"ARIDIS PHARMACEUTICALS, INC.","Placebo-controlled, double-blind, randomized study of Aerucin® as adjunct therapy to antibiotics in the treatment of P. aeruginosa pneumonia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004261-10,0,0,0 2016-004262-26,2,2018-05-01,2018-05-01,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ReveraGen BioPharma Inc.,"A Phase IIa, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys with Duchenne Muscular Dys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004262-26,0,0,0 2016-004262-26,2,2018-05-01,2018-05-01,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"ReveraGen BioPharma, Inc.","A Phase IIa, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys with Duchenne Muscular Dys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004262-26,0,0,0 2016-004263-38,2,2018-09-15,2018-09-18,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"ReveraGen BioPharma, Inc.","A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004263-38,0,0,0 2016-004263-38,2,2018-09-15,2018-09-18,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ReveraGen BioPharma Inc.,"A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004263-38,0,0,0 2016-004264-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Uppsala County Council,Anesthesia with dexmedetomidine and fentanyl for neonatal surgery. A pilot study. Anestesi med dexmedetomidine och fentanyl för nyföddhetskirurgi. En pilotstudie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004264-19,0,0,0 2016-004266-25,9,2019-02-19,2019-02-19,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ObsEva S.A.,"A phase 3, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to improve pregnancy rates following IVF or ICSI in Day 3 a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004266-25,0,0,0 2016-004267-40,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Estetra SPRL,"A SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE OVARIAN FUNCTION INHIBITION OF A MONOPHASIC COMBINED ORAL CONTRACEPTIVE (COC) CONTAINING 15 MG ESTETROL (E4) AND 3 MG DROSPIRENON...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004267-40,0,0,0 2016-004268-21,1,2018-07-30,2018-07-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Profem GmbH,"A phase IIa randomized, active-controlled, double-blind, dose-escalation study in patients with vulvovaginal candidiasis to evaluate clinical efficacy, safety and tolerability and dose response relati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004268-21,0,0,0 2016-004269-14,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Hamlet Pharma AB,A Randomized Placebo controlled Phase I/II Study Evaluating the Safety and Efficacy of Alpha1H in adult patients with non-muscle invasive bladder cancer awaiting transurethral surgery Randomizovan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004269-14,0,0,0 2016-004271-52,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Francisco de la Gala/ Ignacio Garutti,IMPACTO DE LA ADMINISTRACIÓN DE LIDOCAINA INTRAVENOSA O PARAVERTEBRAL EN PERFUSIÓN CONTINUA DURANTE EL INTRAOPERATORIO DE LA CIRUGÍA DE RESECCIÓN PULMONAR SOBRE LA APARICIÓN DE COMPLICACIONES POSTOP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004271-52,0,0,0 2016-004275-40,1,2019-06-04,2019-06-04,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) In Combination with Low Dose Cytarabine in Subjects with Newly Diagnosed Acute Myeloid Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004275-40,0,0,0 2016-004276-21,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Lilly S.A.,"A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004276-21,0,0,0 2016-004276-21,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004276-21,0,0,0 2016-004277-41,1,2019-04-13,2019-04-13,1,0,0,0,0,1,2,0,1,1,0,0,1,0,0,St George's University of London,An observational study into the variety of electrocardiographic responses to an ajmaline Provocation in healthy subjects. What are the genetic and structural variations dictating this response ?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004277-41,0,0,0 2016-004282-31,1,2017-09-18,2017-09-18,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Vivolux AB,VLX1570 and Low-Dose Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma: A Clinical and Correlative Phase 1/2 Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004282-31,0,0,0 2016-004288-37,1,2021-07-22,2021-07-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Takeda Vaccines, Inc.","A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects who have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004288-37,0,0,0 2016-004289-25,2,2020-03-02,2020-03-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Incyte Corporation,"A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Soli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004289-25,0,0,0 2016-004290-41,2,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Medical Developments International Limited,"A randomised, double-blind, multicentre, placebo controlled study to evaluate the safety and efficacy of methoxyflurane (PENTHROX®) for the treatment of acute pain in children and adolescents from 6 t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004290-41,0,0,0 2016-004291-21,1,2021-10-28,2021-10-28,1,0,0,0,0,0,3,0,0,1,0,0,0,0,0,Insel Gruppe AG - Inselspital Universitätsklinik für Kardiologie,"Effect of phosphodiesterase-5 inhibition with Tadalafil on SystEmic Right VEntricular size and function – a multi-center, double-blind, randomized, placebo-controlled clinical trial – SERVE Trial W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004291-21,0,0,0 2016-004292-41,1,2018-04-30,2018-04-30,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,"Verisfield (UK) Ltd., Greek branch","Therapeutic Equivalence (non-inferiority), Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a Generic Formulation of Vaginal Ovule containi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004292-41,0,0,0 2016-004295-22,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Hagaziekenhuis,Treatment of thromBocytopenia with EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients with Immune ThrombocytoPenia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004295-22,0,0,0 2016-004298-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospital General Ciudad Real,Intrabdominal hyperthermic chemotherapy using gemcitabine to treat pancreatic carcinomatosis Quimioterapia intraabdominal hipertérmica mediante el uso de Gemcitabina para el tratamiento de la carci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004298-41,0,0,0 2016-004299-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC Kanker Instituut,Adjuvant hepatic arterial infusion pump chemotherapy after resection of colorectal liver metastases in patients with a low clinical risk score - a feasibility study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004299-24,0,0,0 2016-004300-65,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ghent University Hospital,Optimizing the Biologic Treatment Strategy in Rheumatoid Arthritis (RA) Patients that have failed a Tumor Necrosis Factor-alpha (TNFα) blocking Agent by immunoscintigraphy with Technetium-labeled Cimz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004300-65,0,0,0 2016-004302-33,1,,,0,1,0,0,1,0,3,0,0,1,0,0,0,1,0,INSTITUTO DE INVESTIGACIÓN SANITARIA LA FE,Clinical effect of follicular preparation with testosterone in poor ovarian response: a randomized controlled clinical trial (TESTOPRIM) Efecto clínico de la preparación folicular con testosterona ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004302-33,0,0,0 2016-004303-32,1,2021-03-18,2021-03-18,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,VU university medical center,ASsesment of Platelet function and Inhibition in patients Recovering from severe INfection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004303-32,0,0,0 2016-004307-30,3,2018-11-12,2018-11-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,IXALTIS,"A Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Phase II, Dose Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of oral Litoxetine 10mg, 20mg and 40mg Twice Daily (BID) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004307-30,0,0,0 2016-004307-30,3,2018-11-12,2018-11-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ixaltis SAS,"A Double-Blind, Randomised, Placebo-Controlled, Parallel Group, Phase II, Dose Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of oral Litoxetine 10mg, 20mg and 40mg Twice Daily (BID) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004307-30,0,0,0 2016-004309-15,6,2021-09-21,2021-09-21,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK 3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004309-15,1,0,0 2016-004311-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"ARCHIVEL FARMA, S.L.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TRIAL TO EVALUATE THE IMMUNOMODULATORY EFFECT OF RUTI® IN INDIVIDUALS WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) TREATED WITH INT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004311-12,0,0,0 2016-004315-13,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Novartis,"Multicentric, Open-label, Randomized, Parallel-group Study to Evaluate the Efficacy and Safety of Omalizumab in a 12-MonthPeriod, in Patients with Severe IgE-mediated Asthma Inadequately Controlled wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004315-13,0,1,1 2016-004317-27,1,,,0,1,0,0,1,0,3,0,0,4,0,0,0,0,1,Alcon China Ophthalmic,A Comparative Study of Olopatadine Hydrochloride Ophthalmic Solution 0.2% QD vs Olopatadine Hydrochloride Ophthalmic Solution 0.1% BID in the Treatment of Allergic Conjunctivitis in Chinese Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004317-27,0,1,1 2016-004318-82,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,Novartis Pharmaceuticals Corporation,Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004318-82,0,1,1 2016-004321-16,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Novartis Pharma AG,"A study of the effects of Coartem, Malarone and artesunate-mefloquine on auditory function in patients 12 years of age or older with acute uncomplicated P. falciparum malaria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004321-16,0,1,1 2016-004322-42,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Novartis Pharma Services AG,Efficacy and safety of long-term treatment with ICL670 in beta-thalassemia patients with transfusional hemosiderosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004322-42,0,1,1 2016-004323-23,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,Novartis,"An open-label, randomized, single dose, two period, crossover study to determine the bioequivalence between valsartan 160 mg pediatric final market image (FMI) formulation (solution) and clinical serv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004323-23,0,1,1 2016-004325-16,1,,,0,0,0,0,0,1,4,0,0,1,0,0,0,1,0,University Hospital of Toulouse,Long term evaluation of infants aged from 3 to 4 years old included in the OTBB2 study (repeated administrations of oxytocin in infants with PWS aged from 0 to 6 months) and comparison with not treate...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004325-16,0,0,0 2016-004328-43,6,2020-08-11,2020-08-11,5,1,1,0,0,0,1,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 1b, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed or Suspect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004328-43,1,1,0 2016-004334-17,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),"A phase 2 Randomized Open-Label Study of Oral ODM-201 vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate Cancer Estudio en fase II, aleatoriz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004334-17,0,0,0 2016-004334-17,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,EORTC AISBL/IVZW,"A phase 2 Randomized Open-Label Study of Oral ODM-201 vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate Cancer Estudio en fase II, aleatoriz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004334-17,0,0,0 2016-004339-19,4,2022-07-11,2022-07-11,1,0,0,0,0,2,0,0,0,2,1,0,0,0,1,"TG THERAPEUTICS, INC.","A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004339-19,1,0,0 2016-004339-19,4,2022-07-11,2022-07-11,1,0,0,0,0,2,0,0,0,2,1,0,0,0,1,TG Therapeutics,"A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004339-19,1,0,0 2016-004340-11,16,2019-08-21,2020-10-27,14,1,0,0,0,1,2,0,0,2,1,0,0,0,1,BAYER HEALTHCARE AG,"A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004340-11,1,0,0 2016-004340-11,16,2019-08-21,2020-10-27,14,1,0,0,0,1,2,0,0,2,1,0,0,0,1,Bayer AG,"A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004340-11,1,0,0 2016-004340-11,16,2019-08-21,2020-10-27,14,1,0,0,0,1,2,0,0,2,1,0,0,0,1,"Bayer AG, D-51368 Leverkusen, Germany","A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004340-11,1,0,0 2016-004342-28,1,2018-01-05,2018-01-05,1,0,0,0,0,1,3,0,1,1,0,0,1,0,1,Flamel Ireland Ltd trading under the business name Avadel Ireland,"A comparative, open label, randomized, 2 periods, 2 sequence crossover study to assess the relative bioavailability of sodium oxybate for extended release oral suspension (FT218) formulation (single d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004342-28,0,0,0 2016-004345-85,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HOSPITAL DE PALAMOS,RANDOMIZED CLINICAL TRIAL WITH TWO PATIENT AND PROFESSIONAL PARALLEL MASKS AND AN OPEN GROUP TO VALUE THE EFECTIVENESS AND EFFICIENCY OF HYPERBARIC OXYGENOTHERAPY WITH FOLLOW-UP TO A YEAR IN WOMEN WIT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004345-85,0,0,0 2016-004347-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Hospital,Femoralblock in endovenous laser LASKIMOVAJAATOIMINNAN POLIKLIINISEN LASERHOIDON KIVUNHALLINTA JA SEN VAIKUTUS POTILAAN TOIPUMISEEN (FEMINE RCT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004347-37,0,0,0 2016-004351-75,10,2017-12-14,2017-12-14,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004351-75,1,0,0 2016-004351-75,10,2017-12-14,2017-12-14,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004351-75,1,0,0 2016-004351-75,10,2017-12-14,2017-12-14,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Merck Sharp & Dohme Corp.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004351-75,1,0,0 2016-004352-30,3,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,ARACLON BIOTECH S.L.,"A Multi-center, Randomized, Doubleblind, Placebo-controlled, 24 months Study in Patients with amnestic Mild Cognitive Impairment or Very Mild Alzheimer’s Disease to Investigate the Safety, Tolerabilit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004352-30,0,0,0 2016-004352-30,3,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Araclon Biotech, S.L.","A Multi-center, Randomized, Doubleblind, Placebo-controlled, 24 months Study in Patients with amnestic Mild Cognitive Impairment or Very Mild Alzheimer’s Disease to Investigate the Safety, Tolerabilit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004352-30,0,0,0 2016-004353-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Spanish Lung Cancer Group (SLCG/GECP),"Survival, quality of life and self-reported outcomes of elderly patients with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (MK-3475) in the first line setting Ensayo clín...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004353-32,0,0,0 2016-004354-15,1,2020-12-05,2020-12-05,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Rigshospitalet,"Prevalence, pattern and disease course of arthritis and enthesitis in patients with psoriasis, and the effect of apremilast in subclinical US-defined psoriatic arthritis - A population-based study app...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004354-15,0,0,0 2016-004356-30,10,,,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,Pharmacyclics Switzerland GmbH,Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004356-30,0,0,0 2016-004356-30,10,,,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,"Pharmacyclics Switzerland GmbH, an AbbVie company",Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004356-30,0,0,0 2016-004356-30,10,,,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,PHARMACYCLICS SWITZERLAND GMBH,Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004356-30,0,0,0 2016-004358-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA,Bromfenac 0.09% versus dexamethasone 0.1% ophthalmic solutions to reduce inflammation after cataract surgery: the BVD Study. Comparazione di bromfenac 0.09% collirio versus desametasone 0.1% collir...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004358-14,0,0,0 2016-004359-57,9,2020-03-29,2020-03-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boston Biomedical, Inc.",A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004359-57,0,0,0 2016-004359-57,9,2020-03-29,2020-03-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Sumitomo Dainippon Pharma Oncology, Inc.",A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004359-57,0,0,0 2016-004359-57,9,2020-03-29,2020-03-29,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"BOSTON BIOMEDICAL, INC.",A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004359-57,0,0,0 2016-004360-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNICANCER,"Randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in estrog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004360-18,0,0,0 2016-004361-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fernando Sánchez,Oxidative stress and extracellular nucleosomes in critically ill patients with acute kidney failure treated with continuous renal replacement therapies. Effect of two anticoagulation strategies of the...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004361-12,0,0,0 2016-004362-26,16,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Ear...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004362-26,0,0,0 2016-004362-26,16,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Ear...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004362-26,0,0,0 2016-004362-26,16,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,Lilly S.A.,"A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Ear...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004362-26,0,0,0 2016-004363-39,8,2022-08-10,2022-08-10,4,0,1,0,0,0,3,0,0,2,1,0,0,0,1,ALK-Abelló A/S,A phase III trial evaluating the efficacy and safety of the house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet in children and adolescents (5-17 years) with HDM allergic asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004363-39,1,0,0 2016-004364-20,8,2022-09-07,2022-09-07,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004364-20,1,0,0 2016-004364-20,8,2022-09-07,2022-09-07,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp.,a subsidiary of Merck & Co.,Inc.","A Phase 3, Randomized, Double-Blind Study of Pembrolizumab plus Ipilimumab vs Pembrolizumab plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004364-20,1,0,0 2016-004365-16,5,2020-09-30,2020-10-09,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Reata Pharmaceuticals, Inc.",An extended Access Program to Assess Long-Term Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004365-16,0,0,0 2016-004366-25,13,2020-11-19,2020-11-19,9,1,0,0,0,1,3,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004366-25,1,0,0 2016-004366-25,13,2020-11-19,2020-11-19,9,1,0,0,0,1,3,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004366-25,1,0,0 2016-004366-25,13,2020-11-19,2020-11-19,9,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Roche Farma SA Soc Unipersonal que realiza el ensayo en España y que actúa como representante de F Hoffmann-La Roche Ltd,"A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004366-25,1,0,0 2016-004368-21,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ITALIAN SARCOMA GROUP,Phase II study on TSR-042 in advanced clear cells sarcoma Studio di fase II su TSR-042 nel sarcoma a cellule chiare avanzato,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004368-21,0,0,0 2016-004369-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Rennes,FLEGME (FLuoresceine dans l’Exérèse des GlioMEs) : Intérêt de la fluorescéine dans la résection fluoroguidée des glioblastomes : une étude randomisée FLEGME (FLuoresceine dans l’Exérèse des GlioMEs...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004369-15,0,0,0 2016-004371-51,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA USL DELLA VALLE D'AOSTA,68Ga-PSMA-PET/CT for detection of recurrent prostate cancer Utilizzo della PET/TC con 68Ga-PSMA nella rilevazione di recidiva in pazienti con neoplasia prostatica in progressione biochimica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004371-51,0,0,0 2016-004372-22,1,2017-08-02,2017-08-02,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,"Tioma Therapeutics, Inc.",A Phase 1-2 Study of Ti-061 Alone and in combination with other anti-cancer agents in Patients with Advanced Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004372-22,0,0,0 2016-004373-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center of the Johannes Gutenberg-University Mainz,"A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) progr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004373-40,0,0,0 2016-004374-18,9,2019-04-30,2019-06-12,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004374-18,0,0,0 2016-004374-18,9,2019-04-30,2019-06-12,8,1,0,0,0,0,0,0,0,1,1,0,1,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004374-18,0,0,0 2016-004376-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS,Investigation of 68GaPSMA PET/CT as an imaging biomarker in solid tumors BASKET GA-PSMA: ruolo della PET/TC con 68Ga-PSMA nello studio delle patologie oncologiche,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004376-21,0,0,0 2016-004377-41,1,2017-01-15,2017-01-15,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Dep. Anaesthesia and Intensive Care, Aarhus University Hospital",Regional anaesthesia of the cutaneus nerves of the hip - A randomized controlled trial of the transversalis fascia plane block,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004377-41,0,0,0 2016-004383-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,GORTEC,A Phase III randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in locally advanced squamous cell carcinoma of the head and neck Essai de phase III randomisé comparant l’as...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004383-19,0,0,0 2016-004384-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Austrian Breast & Colorectal Cancer Study Group (ABCSG),"A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive hom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004384-39,0,0,0 2016-004386-12,2,2018-12-06,2018-12-06,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Besins Healthcare Ireland Ltd.,Double-blind trial investigating the efficacy of different doses of Progesterone compared with Placebo for treatment of vasomotor symptoms Doppelblinde Studie zur Untersuchung der Wirksamkeit unter...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004386-12,0,0,0 2016-004387-18,10,2021-02-19,2021-02-19,7,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Roche Farma S.A (Soc.Unipersonal)que realiza el ensayo en España y que actúa como representante de FHoffman-La Roche Ltd,"A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004387-18,1,0,0 2016-004387-18,10,2021-02-19,2021-02-19,7,1,0,0,0,0,3,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004387-18,1,0,0 2016-004387-18,10,2021-02-19,2021-02-19,7,1,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffman-La Roche Ltd.,"A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004387-18,1,0,0 2016-004390-41,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Blueprint Medicines,"A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004390-41,0,0,0 2016-004390-41,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,F.Hoffmann-La Roche Ltd,"A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004390-41,0,0,0 2016-004392-41,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Study of the Comparative Bioavailability of Two Investigational Pediatric Oral Granule Formulations of Lamivudine and Tenofovir Compared to the Adult Marketed Formulations. Other PIP decision numbe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004392-41,0,1,1 2016-004394-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fondazione GONO,Randomized phase III study of triplet mFOLFOXIRI plus PANITUMUMAB versus mFOLFOX6 plus PANITUMUMAB as initial therapy for unresectable RAS and BRAF wild-type metastatic colorectal cancer patients S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004394-40,0,0,0 2016-004395-22,4,2020-10-30,2020-10-30,3,1,0,0,0,1,2,0,0,2,0,0,0,0,1,"Reata Pharmaceuticals, Inc.",A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004395-22,1,0,0 2016-004396-51,1,2021-11-29,2021-11-29,1,0,0,0,0,0,3,0,0,1,0,0,0,0,0,Friedrich Schiller University,Pentaerithrityl tetranitrate (PETN) for secondary prevention of intrauterine growth restriction (PETN Trial) Pentaeritrithyltetranitrat (PETN) zur Sekundärprophylaxe der intrauterinen Wachstumsret...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004396-51,0,0,0 2016-004398-41,2,2018-08-27,2018-08-27,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Institut Jules Bordet,"Multicentre, non-randomised, open-label, single agent phase II study to determine the clinical benefit of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer patients with brain me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004398-41,0,0,0 2016-004407-31,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A GLOBAL, RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD 1 ANTIBODY) VERSUS PLATINUM BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD L1 + NON-SMALL CE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004407-31,0,0,0 2016-004407-31,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Regeneron Pharmaneuticals, Inc.","A GLOBAL, RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD 1 ANTIBODY) VERSUS PLATINUM BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD L1 + NON-SMALL CE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004407-31,0,0,0 2016-004408-76,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004408-76,0,0,0 2016-004408-76,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004408-76,0,0,0 2016-004414-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"MS Centrum, Department of Neurology, Sshlgrenska University Hospital",Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily. Bestämning av koncentratio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004414-10,0,0,0 2016-004416-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Parc Taulí,"Efficacy and safety of three regimens based on tobramycin, dexamethasone and diclofenac for the prevention of pseudophakic macular edema. Randomized clinical trial Eficacia y seguridad de tres paut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004416-35,0,0,0 2016-004419-11,1,2020-04-02,2020-04-02,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Radboud university medical center,Safety and efficacy of interleukin-1 inhibitor anakinra for the amelioration of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004419-11,0,0,0 2016-004420-29,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase 2, Open-label, Controlled, Multi-Center Extension Study to Evaluate 4-Year Antibody Persistence and Booster Response Fol-lowing MenABCWY Vaccination in Healthy Adolescents and Young Adults who...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004420-29,0,1,1 2016-004421-17,3,2022-09-19,2022-09-19,2,0,1,0,0,0,1,0,1,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States","A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF BIVALENT rLP2086 WHEN ADMINISTERED AS A 2-DOSE REGIMEN AND A FIRST-IN-HUMAN S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004421-17,1,0,0 2016-004421-17,3,2022-09-19,2022-09-19,2,0,1,0,0,0,1,0,1,2,0,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF BIVALENT rLP2086 WHEN ADMINISTERED AS A 2-DOSE REGIMEN AND A FIRST-IN-HUMAN S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004421-17,1,0,0 2016-004422-42,8,,,0,0,1,0,0,0,2,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensive S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004422-42,0,1,0 2016-004424-38,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Queen Mary University of London,"A phase II study investigating preoperative combination strategies for immunotherapy in patients with untreated, operable ER+, HER2-negative primary breast cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004424-38,0,0,0 2016-004427-24,5,2018-10-30,2018-10-31,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Castle Creek Pharmaceuticals, LLC","An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004427-24,0,0,0 2016-004429-17,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PRE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004429-17,0,0,0 2016-004429-17,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PRE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004429-17,0,0,0 2016-004429-17,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Roche Farma S.A.(S.A.U.)que realiza el ensayo en España y que actúa como representante de F.Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PRE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004429-17,0,0,0 2016-004432-38,17,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogeneic stem cell trans...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004432-38,0,0,0 2016-004432-38,17,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.",A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogeneic stem cell trans...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004432-38,0,0,0 2016-004433-24,1,,,0,1,0,0,0,1,4,0,1,1,0,0,0,1,0,Leids Universitair Medisch Centrum,ACE inhibition in Fontan patients: its effect on body fluid regulation. ACE remmers bij Fontan patienten en het effect op vloeistof verplaatsingen binnen het lichaam.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004433-24,0,0,0 2016-004434-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AIO-Studien-gGmbH,Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer – The phase II AVETUX-CRC trial. Avelumab und Cetuximab in Kombination mit FOLFO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004434-26,0,0,0 2016-004435-20,1,2018-03-16,2018-03-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Research & Development Department, Hull & East Yorkshire Hospitals NHS Trust","The effect of empagliflozin versus metformin on hormonal, metabolic and cardiovascular risk factors in patients with polycystic ovary syndrome (PCOS) – a randomised open-label parallel study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004435-20,0,0,0 2016-004439-19,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Alfred Health,IV iron for Treatment of Anaemia before Cardiac Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004439-19,0,0,0 2016-004440-12,14,2021-07-09,2021-07-09,9,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of midostaurin (PKC412) in patients 18 years of age or older with newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004440-12,1,0,0 2016-004440-12,14,2021-07-09,2021-07-09,9,1,0,0,0,1,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of midostaurin (PKC412) in patients 18 years of age or older with newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004440-12,1,0,0 2016-004440-12,14,2021-07-09,2021-07-09,9,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of midostaurin (PKC412) in patients 18 years of age or older with newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004440-12,1,0,0 2016-004441-82,8,2022-01-17,2022-01-17,6,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004441-82,1,1,0 2016-004446-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University Hospital Wuerzburg, Institution under public law, represented by the Medical Director","Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004446-29,0,0,0 2016-004447-36,1,2021-06-28,2021-06-28,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Stichting Rotterdams Onderzoeksconsortium Kindergeneeskunde,"INTRAVENOUS-TO-ORAL ANTIBIOTIC SWITCH THERAPY FOR SUSPECTED NEONATAL BACTERIAL INFECTIONS: CLINICAL EFFICACY, SAFETY AND COST-EFFECTIVENESS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004447-36,0,0,0 2016-004448-12,5,,,0,0,0,0,0,1,0,0,0,3,0,0,0,0,1,Basilea Pharmaceutica International Ltd,A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma Studio pilota di ARQ in soggetti con colangiocarcinoma intraepatico ino...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004448-12,0,0,0 2016-004448-12,5,,,0,0,0,0,0,1,0,0,0,3,0,0,0,0,1,ARQULE INC,A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma Studio pilota di ARQ in soggetti con colangiocarcinoma intraepatico ino...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004448-12,0,0,0 2016-004450-15,1,2017-07-24,2017-07-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Verona Pharma plc,"A phase II, randomised, double blind, placebo controlled, three way crossover study to assess the bronchodilator effect of RPL554 administered in addition to open label tiotropium in patients with COP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004450-15,0,0,0 2016-004451-70,6,2020-11-21,2021-11-27,6,1,0,0,0,1,2,0,0,1,0,0,0,0,0,"Department of pediatrics, Aarhus University Hospital","NOR-GRASPALL 2016: SINGLE-ARM PHARMACOKINETIC/PHARMACODYNAMIC AND SAFETY STUDY OF ERYASPASE (GRASPA®) FOR PATIENTS WITH HYPERSENSITIVITY TO PEG-ASPARAGINASE, DIAGNOSED WITH PH(-) ACUTE LYMPHOBLASTIC L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004451-70,0,0,0 2016-004452-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS,"Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC) Studio randomiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004452-29,0,0,0 2016-004455-78,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Region Östergötland,Sedation with propofol and remifentanil during ventricular tachycardia treatment: patient-controlled versus nurse anesthetists controlled - a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004455-78,0,0,0 2016-004459-65,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Respira. Fundación Española del Pulmón (SEPAR),Reslizumab in patients with severe asthma who failed to respond to omalizumab: a pilot study Estudio piloto de reslizumab en pacientes con asma grave que no han respondido a omalizumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004459-65,0,0,0 2016-004460-19,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,G. Pohl-Boskamp GmbH & Co.KG,"A multi-centre, randomized, placebo-controlled, double-blind trial to assess the efficacy and safety of nitroglycerin sublingual powder on walking distance in a scheduled forced titration design in pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004460-19,0,0,0 2016-004461-47,1,2020-04-24,2020-04-24,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Dynavax Technologies Corporation,"A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004461-47,0,0,0 2016-004463-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Sahlgrenska University Hospital, Department of Internal Medicine/Respiratory Medicine and Allergology","Influence on cough and airway symptoms by oral capsaicin (capscium oleoresin ) – a phase II, randomised, placebo-controlled clinical study in patients with chronic idiopathic cough Inverkan på kron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004463-39,0,0,0 2016-004463-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Gothenburg,"Influence on cough and airway symptoms by oral capsaicin (capscium oleoresin ) – a phase II, randomised, placebo-controlled clinical study in patients with chronic idiopathic cough Inverkan på kron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004463-39,0,0,0 2016-004466-26,4,2020-02-28,2020-02-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,G1 Therapeutics,"Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004466-26,0,0,0 2016-004471-46,1,,,0,1,0,0,0,1,3,0,0,1,1,1,0,1,0,Sahlgrenska University Hospital,Drug level and Investigation of Novel Substances Indicated Downstream Effect in (INSIDE) glioblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004471-46,0,0,0 2016-004472-21,2,2019-03-20,2019-03-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pieris Pharmaceuticals GmbH,"Phase IIa study to evaluate the safety, pharmacokinetics, and pharmacodynamics of repeated administrations over 4 weeks of the hepcidin antagonist PRS-080#022-DP in anemic chronic kidney disease patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004472-21,0,0,0 2016-004472-21,2,2019-03-20,2019-03-20,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pieris Pharmaceuticals, GmbH","Phase IIa study to evaluate the safety, pharmacokinetics, and pharmacodynamics of repeated administrations over 4 weeks of the hepcidin antagonist PRS-080#022-DP in anemic chronic kidney disease patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004472-21,0,0,0 2016-004473-41,1,2019-11-26,2019-11-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Dundee and NHS Tayside,"INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation with Tiotropium and Olodaterol (INCOGNITO trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004473-41,0,0,0 2016-004477-40,4,2017-10-19,2017-10-19,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Galapagos NV,"A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate multiple doses of GLPG2222 in subjects with Cystic Fibrosis who are homozygous for the F508del mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004477-40,0,0,0 2016-004479-35,7,2018-12-21,2018-12-28,7,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Tezacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous or He...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004479-35,0,0,0 2016-004480-39,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Profil Institut für Stoffwechselforschung GmbH,DPP-4 inhibition with sitagliptin and the risk for hypoglycaemia in the fasting state in subjects with type 2 diabetes treated to fasting plasma glucose targets with insulin glargine and metformin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004480-39,0,0,0 2016-004482-89,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GBG Forschungs GmbH,"A RANDOMIZED, OPEN-LABEL, MULTI-CENTER PHASE IV STUDY EVALUATING PALBOCICLIB PLUS ENDOCRINE TREATMENT VERSUS A CHEMOTHERAPY-BASED TREATMENT STRATEGY IN PATIENTS WITH HORMONE RECEPTOR POSITIVE / HER2 N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004482-89,0,0,0 2016-004483-19,1,2020-02-26,2020-02-26,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospitals Birmingham NHS Foundation Trust,A randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004483-19,0,0,0 2016-004484-39,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Bayer AG,"An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004484-39,0,0,0 2016-004486-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Centre Utrecht,FOsfomycin Randomised controlled trial for E.coli Complicated urinary tract infections as Alternative Stepdown Treatment Gerandomiseerde gecontroleerde trial naar fosfomycine als alternatieve oral...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004486-37,0,0,0 2016-004488-38,1,2019-10-04,2019-10-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"J. W. Goethe University, represented by dean of the medical faculty",Iluvit – An investigator initiated monocentric pilot study to investigate inflammation parameters and growth factors in the vitreous during a cortisone long-term therapy with Iluvien® in patients with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004488-38,0,0,0 2016-004489-24,7,2022-05-20,2022-05-20,4,0,1,0,1,0,3,0,0,2,1,0,0,0,1,"Instituto Grifols, S.A","A Prospective, Randomised, Active-Controlled, Single-blind, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Haemostasis during...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004489-24,1,0,0 2016-004491-22,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Dept. Clinical Medicine, Aarhus Universit",Early detection of effects of chemotherapy in pancreatic cancer patients – a study using MR-hyperpolarization scanning based on hyperpolarized Pyruvate (13C) injection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004491-22,0,0,0 2016-004499-23,4,2018-03-12,2018-03-12,4,1,0,0,0,0,2,0,0,1,0,0,1,0,0,IDIBAPS,"Safety and tolerability of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis: a multicenter, double-blind, placebo controlled randomized clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004499-23,0,0,0 2016-004501-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"ZOLL, Inc.","COOL-AMI EU PIVOTAL TRIAL: A MULTICENTER, PROSPECTIVE, RANDOMIZED- CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFECTIVENESS OF COOLING AS AN ADJUNCTIVE THERAPY TO PERCUTANEOUS INTERVENTION INP A TIENTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004501-14,0,0,0 2016-004502-34,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004502-34,0,0,0 2016-004503-31,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,SOFAR S.P.A.,"Evaluation of the effect of Gerdoff administered in combination to a treatment with protonic pump inhibitors vs the only treatment with protonic pump inhibitors, administered for 6 weeks, on higher sy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004503-31,0,0,0 2016-004505-13,1,2021-06-17,2021-06-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Hospital Tuebingen,"Tocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study-TOFFIFE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004505-13,0,0,0 2016-004506-34,1,2021-10-29,2021-10-29,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Odense Universitetshospital,"The effect of myoinositol (MI) or metformin treatment on symptoms of polycystisk ovary syndrome (PCOS), including metabolism, menstrual pattern, quality of life and mental health. Effekten af myoin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004506-34,0,0,0 2016-004507-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Traitement de la néphropathie à IgA adapté à l'histologie rénale (TIGRE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004507-31,0,0,0 2016-004510-99,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,IRCCS ISTITUTO CLINICO HUMANITAS,PERFORMANCE OF BIORESORBABLE POLYMER-COATED EVEROLIMUS-ELUTING SYNERGY® STENT IN PATIENTS AT HIGH BLEEDING RISK UNDERGOING PERCUTANEOUS CORONARY REVASCULARIZATION FOLLOWED BY 1-MONTH DUAL ANTIPLATELET...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004510-99,0,0,0 2016-004513-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Medica Scientia Innovation Research (MedSIR),A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes Estudio de fase II de pembroliz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004513-27,0,0,0 2016-004514-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Raimo Tuuminen,Pre and post-operative corticosteroid and NSAID combination treatment in cataract surgery of diabetic patient,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004514-10,0,0,0 2016-004515-12,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Raimo Tuuminen,Comparison between peri- and post-operative anti-inflammatory medication in cataract surgery: a randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004515-12,0,0,0 2016-004521-17,1,2019-01-09,2019-01-09,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,BIT Pharma GmbH,"A Phase IIa: single ascending dose safety, tolerability and pharmacokinetic study of NicaPlant® in aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping Eine Phase IIa: ansteige...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004521-17,0,0,0 2016-004524-38,1,2021-03-29,2021-03-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Spanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón),A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors Estudio clínico de fase II de Durvalumab (MEDI4736) en pacientes VIH-1 (Virus de la Inmunodeficien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004524-38,0,0,0 2016-004526-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grand hôpital de Charleroi,A PHASE Ib/II STUDY TO EVALUATE SAFETY AND EFFICACY OF ATEZOLIZUMAB COMBINED WITH RADIO-CHEMOTHERAPY IN A PREOPERATIVE SETTING FOR PATIENTS WITH LOCALIZED RECTAL CANCER (R-IMMUNE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004526-41,0,0,0 2016-004527-23,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Center for Cancer Immune Therapy,Combination therapy with Nivolumab and PD-L1/IDO peptide vaccine with Montanide to patients with metastatic malignant melanoma Kombinationsbehandling med Nivolumab og PD-L1/IDO peptidvaccine med Mo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004527-23,0,0,0 2016-004529-17,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,F. Hoffman-La Roche Ltd,"A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED UNRESECTA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004529-17,0,0,0 2016-004537-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Léon Bérard,An Phase II trial aiming to evaluate the clinical interest of ABEMACICLIB monotherapy in patients with locally advanced/metastatic head and neck cancer after failure of platinum and cetuximab or anti-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004537-25,0,0,0 2016-004539-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Prolong Pharmaceuticals, LLC","A Phase 2, Open-Label, Multicenter, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of ANF–Rho™ in Patients with Chronic Neutropenia Étude de phase 2, en ouvert, multicentrique, portant s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004539-18,0,0,0 2016-004541-82,1,2017-01-22,2017-01-22,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"Dep. Anaesthesia and Intensive Care, Aarhus University Hospital",Regional anaesthesia of the cutaneous nerves of the hip - A novel ultrasound guided nerve block of the superior cluneal nerves,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004541-82,0,0,0 2016-004542-28,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Radboud University Medical Center,A randomized controlled pilot study comparing the efficacy of topical coal tar to topical corticosteroids in children aged 1 to < 16 years with moderate-severe atopic dermatitis. Een gerandomiseer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004542-28,0,0,0 2016-004544-10,3,2020-10-07,2020-10-07,2,1,0,0,0,0,2,0,0,2,0,0,0,0,2,Audion Therapeutics BV,A phase I/II multiple ascending dose open-label safety and efficacy study of the Notch Inhibitor LY3056480 in patients with mild to moderate sensorineural hearing loss.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004544-10,1,0,0 2016-004545-91,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"VU University Medical Center, department of reproductive Medicine",Continuous use of Oral contraceptives as an alternative for long term Pituitary down-regulation with GnRH agonist prior to IVF/ICSI in Endometriosis patients: a randomised controlled trial (COPIE tria...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004545-91,0,0,0 2016-004547-36,7,2020-05-05,2020-05-05,5,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Chiesi Farmaceutici S.p.A.,"A RANDOMIZED, OPEN, MULTINATIONAL, MULTICENTRE, 2-PART STUDY IN SPONTANEOUSLY BREATHING PRETERM NEONATES WITH MILD TO MODERATE RESPIRATORY DISTRESS SYNDROME TO INVESTIGATE THE SAFETY, TOLERABILITY AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004547-36,0,0,0 2016-004547-36,7,2020-05-05,2020-05-05,5,1,0,0,0,0,2,0,0,1,1,1,1,0,1,CHIESI FARMACEUTICI S.P.A.,"A RANDOMIZED, OPEN, MULTINATIONAL, MULTICENTRE, 2-PART STUDY IN SPONTANEOUSLY BREATHING PRETERM NEONATES WITH MILD TO MODERATE RESPIRATORY DISTRESS SYNDROME TO INVESTIGATE THE SAFETY, TOLERABILITY AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004547-36,0,0,0 2016-004548-12,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Replimune Inc.,"An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors [IGNYTE]",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004548-12,0,0,0 2016-004550-15,10,2018-11-05,2018-11-05,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design Dose-Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004550-15,0,0,0 2016-004550-15,10,2018-11-05,2018-11-05,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design Dose-Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004550-15,0,0,0 2016-004551-67,2,2020-02-11,2020-02-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sedana Medical AB,"A randomised, controlled, open-label study to confirm the efficacy and safety of sedation with isoflurane in invasively ventilated ICU patients using the AnaConDa administration system Eine randomi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004551-67,0,0,0 2016-004554-14,1,,,0,0,1,0,0,0,1,0,0,4,0,0,0,0,1,CTI BioPharma Corp.,"A Phase 1, Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients with Relapsed or Refractory Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004554-14,0,1,1 2016-004555-79,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,"RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty",Impact of preoperative midazolam on outcome of elderly patients: a multicenter randomised controlled trial Einfluss von präoperativem Midazolam auf den postoperativen Verlauf von älteren Patienten:...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004555-79,0,0,0 2016-004556-30,4,2021-03-04,2021-03-04,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-AVENTIS GROUPE,"A Multicenter, Randomized, Double-blind, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of a New Formulation of Zenon (Ezetimibe/Rosuvastatin Fixed Dose Combination) in Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004556-30,0,0,0 2016-004556-30,4,2021-03-04,2021-03-04,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Groupe,"A Multicenter, Randomized, Double-blind, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of a New Formulation of Zenon (Ezetimibe/Rosuvastatin Fixed Dose Combination) in Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004556-30,0,0,0 2016-004558-13,6,2022-03-15,2022-03-15,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ZAMBON SPA,"A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled Promixin® (colistimethate sodium) in the treatment of subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004558-13,1,0,0 2016-004558-13,6,2022-03-15,2022-03-15,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Zambon S.p.A.,"A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled Promixin® (colistimethate sodium) in the treatment of subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004558-13,1,0,0 2016-004566-26,12,2021-01-01,2021-03-09,10,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Tobira Therapeutics, a subsidiary of Allergan plc","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004566-26,1,0,0 2016-004566-26,12,2021-01-01,2021-03-09,10,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Tobira Therapeutics,Inc., a subsidiary of Allergan plc","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004566-26,1,0,0 2016-004566-26,12,2021-01-01,2021-03-09,10,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Tobira Therapeutics, Inc., a subsidiary of Allergan plc","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004566-26,1,0,0 2016-004566-26,12,2021-01-01,2021-03-09,10,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Tobira Therapeutics Inc., a subsidiary of Allergan plc","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004566-26,1,0,0 2016-004572-21,6,2020-09-16,2020-09-16,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Norway KS,Proof-of-concept study of BI 655130 add-on treatment in patients with mild-to-moderately active ulcerative colitis during TNF inhibitor therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004572-21,0,0,0 2016-004572-21,6,2020-09-16,2020-09-16,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim BV Netherlands,Proof-of-concept study of BI 655130 add-on treatment in patients with mild-to-moderately active ulcerative colitis during TNF inhibitor therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004572-21,0,0,0 2016-004572-21,6,2020-09-16,2020-09-16,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,Proof-of-concept study of BI 655130 add-on treatment in patients with mild-to-moderately active ulcerative colitis during TNF inhibitor therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004572-21,0,0,0 2016-004572-21,6,2020-09-16,2020-09-16,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Boehringer Ingelheim España, S.A.",Proof-of-concept study of BI 655130 add-on treatment in patients with mild-to-moderately active ulcerative colitis during TNF inhibitor therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004572-21,0,0,0 2016-004572-21,6,2020-09-16,2020-09-16,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Limited,Proof-of-concept study of BI 655130 add-on treatment in patients with mild-to-moderately active ulcerative colitis during TNF inhibitor therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004572-21,0,0,0 2016-004573-40,5,2018-11-14,2018-11-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"Multi-center, double-blind, randomised, placebo-controlled, phase IIa study to investigate efficacy, safety, tolerability, pharmacokinetics and pharmacogenomics of multiple intravenous doses of BI 655...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004573-40,0,0,0 2016-004573-40,5,2018-11-14,2018-11-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim AB,"Multi-center, double-blind, randomised, placebo-controlled, phase IIa study to investigate efficacy, safety, tolerability, pharmacokinetics and pharmacogenomics of multiple intravenous doses of BI 655...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004573-40,0,0,0 2016-004573-40,5,2018-11-14,2018-11-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Multi-center, double-blind, randomised, placebo-controlled, phase IIa study to investigate efficacy, safety, tolerability, pharmacokinetics and pharmacogenomics of multiple intravenous doses of BI 655...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004573-40,0,0,0 2016-004573-40,5,2018-11-14,2018-11-14,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","Multi-center, double-blind, randomised, placebo-controlled, phase IIa study to investigate efficacy, safety, tolerability, pharmacokinetics and pharmacogenomics of multiple intravenous doses of BI 655...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004573-40,0,0,0 2016-004574-17,5,2021-03-08,2021-08-03,3,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Celgene Corporation,"A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004574-17,1,0,0 2016-004575-49,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Federation Francophone de Cancerologie Digestive,MULTICENTER RANDOMIZED PHASE II STUDY COMPARING THE EFFECTIVENESS AND TOLERANCE OF AVELUMAB VERSUS STANDARD 2nd LINE TREATMENT CHEMOTHERAPY IN PATIENTS WITH COLORECTAL METASTATIC CANCER WITH MICROSATE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004575-49,0,0,0 2016-004576-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Catharina Hospital Eindhoven,"SAFETY, FEASIBILITY AND COST-ANALYSIS OF UGT1A1 GENOTYPE-GUIDED DOSING OF IRINOTECAN Geïndividualiseerd doseren van irinotecan door middel van genotyperen",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004576-22,0,0,0 2016-004578-16,1,2020-03-25,2020-03-25,1,1,0,1,0,1,1,0,0,1,1,1,0,0,1,"Valerion Therapeutics, LLC","A Three-month, Open-Label, Randomized, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VAL-1221 versus Myozyme®/Lumizyme® in Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004578-16,0,0,0 2016-004580-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AOU FEDERICO II,"Treatment of Growth Hormone Deficiency associated with Chronic Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Study TRATTAMENTO DEL DEFICIT DI GH ASSOCIATO AD INSUFFICIENZA CARDIACA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004580-39,0,0,0 2016-004585-25,13,2019-09-04,2019-09-04,12,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A 52-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis Who Are Biologic Disease-Mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004585-25,0,0,0 2016-004585-25,13,2019-09-04,2019-09-04,12,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Lilly S.A.,"A 52-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis Who Are Biologic Disease-Mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004585-25,0,0,0 2016-004586-67,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004586-67,0,0,0 2016-004586-67,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004586-67,0,0,0 2016-004586-67,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004586-67,0,0,0 2016-004591-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Medical University of Graz/Department of Internal Medicine/Division of Endocrinology and Diabetology,Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction (EMMY-Trial) – a phase III Study Einfluß von Empagliflozin auf die kardiale...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004591-22,0,0,0 2016-004594-41,1,2017-11-30,2017-11-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Jens Børglum,"Ultrasound-guided Transmuscular Quadratus Lumborum block for elective caesarean section. A double blind, randomized, placebo controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004594-41,0,0,0 2016-004599-23,6,2019-04-02,2019-04-08,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Genkyotex SA,"A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Oral GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004599-23,0,0,0 2016-004599-23,6,2019-04-02,2019-04-08,6,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GENKYOTEX SA,"A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Oral GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and with P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004599-23,0,0,0 2016-004600-53,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,WÖRWAG Pharma GmbH & Co. KG,"MACH 2 - Magnesium orotate in severe congestive heart failure - Part 2 Wirksamkeit von Magnesium-Orotat bei Patienten mit HFrEF in Bezug auf den Einfluss von NTproBNP - eine prospektive, monozentr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004600-53,0,0,0 2016-004601-14,4,2019-06-27,2019-06-27,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"PanOptica, Inc.","A Randomized, Double Masked, Uncontrolled, Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naïve Participants with Neovascular Age-Rela...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004601-14,0,0,0 2016-004603-31,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,PH Research,A pilot trial of PEGPH20 (pegylatedhyaluronidase) in combination with avelumab (anti-PD-L1 MSB0010718C) in chemotherapy resistant pancreatic cancer Estudio piloto de PEGPH20 (hialuronidasa pegilada...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004603-31,0,0,0 2016-004608-78,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Kepler University Hospital, Institute of Ophthalmology",The Effect of Intravitreal Aflibercept on Ocular Perfusion – a Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004608-78,0,0,0 2016-004610-95,6,2021-04-29,2021-04-29,3,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Biogen Idec Research Limited,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004610-95,1,0,0 2016-004610-95,6,2021-04-29,2021-04-29,3,1,0,0,0,0,2,0,0,2,0,0,0,0,1,BIOGEN IDEC RESEARCH LIMITED,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004610-95,1,0,0 2016-004611-13,4,2021-10-04,2021-10-04,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,G1 Therapeutics,Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy Fase 1b/2a studie naar de ve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004611-13,1,0,0 2016-004614-10,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,University Hospital Tübingen,An open label phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and nivolumab in patients with four and more symptomatic brain metastases of melanoma Eine offene ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004614-10,0,0,0 2016-004617-28,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The University of Manchester,A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy as Second-Line Therapy for Advanced/Metastatic Endometrial C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004617-28,0,0,0 2016-004618-93,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Manchester,Evaluation of the safety of CEdiranib in the prevention of Bowel perforation in platinum-resistant Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004618-93,0,0,0 2016-004623-23,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,AMO Pharma Ltd,"A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents with Congenital Myotonic Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004623-23,0,0,0 2016-004624-35,2,2019-10-25,2019-10-25,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Genentech, Inc.","A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT AND DOSE-RANGING STUDY OF GDC-0853 IN PATIENTS WITH REFRACTORY CHRONIC SPONTANEOUS URTICARIA (CSU)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004624-35,0,0,0 2016-004625-16,3,2020-09-04,2020-09-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Viro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004625-16,0,0,0 2016-004625-16,3,2020-09-04,2020-09-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Viro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004625-16,0,0,0 2016-004629-18,1,2021-09-06,2021-09-06,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Radboud University Nijmegen,The noradrenergic basis of Parkinson’s tremor: a systems-level fMRI approach De noradrenerge basis van Parkinson tremor: een fMRI studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004629-18,0,0,0 2016-004632-38,1,2019-05-13,2019-05-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Národný onkologický ústav,Phase II study of Avelumab in multiple relapsed/refractory testicular germ cell cancer. Klinické skúšanie fázy II: Avelumab u pacientov s relapsom germonatívneho tumoru.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004632-38,0,0,0 2016-004633-24,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,Cancer Research UK,A Cancer Research UK Phase I/IIa trial of BT1718 (a Bicycle drug conjugate) given intravenously in patients with advanced solid tumours,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004633-24,0,0,0 2016-004635-20,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,1,G. Pohl-Boskamp GmbH & Co. KG,"A monocentric, randomized, controlled, investigator-blind trial to evaluate the efficacy and safety of an investigational medical device (PB790) in subjects with head lice. Monozentrische, randomis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004635-20,0,0,0 2016-004638-99,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET",Phase II trial: uPAR PET/CT and FDG PET/CT for preoperative staging of gynecological cancers uPAR PET/CT og FDG PET/CT til præoperativ stadieinddeling af patienter med nydiagnosticeret Gynækologis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004638-99,0,0,0 2016-004646-29,1,2019-04-23,2019-04-23,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundación SEIMC-GESIDA,"A phase IV open- label, randomized and pilot clinical trial, designed to evaluate the potential neurotoxicity of dolutegravir/lamivudine/abacavir in neurosymptomatic HIV patients and their reversibil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004646-29,0,0,0 2016-004648-12,9,2018-12-10,2018-12-18,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Clearside Biomedical, Inc.","SAPPHIRE: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN CONJUNCTION WITH INTRAVITREAL AFLIBERCEPT IN SUBJECTS WITH RETINAL VEIN OCCLUSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004648-12,0,0,0 2016-004648-12,9,2018-12-10,2018-12-18,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"CLEARSIDE BIOMEDICAL, INC.","SAPPHIRE: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN CONJUNCTION WITH INTRAVITREAL AFLIBERCEPT IN SUBJECTS WITH RETINAL VEIN OCCLUSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004648-12,0,0,0 2016-004653-32,1,2020-03-30,2020-03-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Hospices Civils de Lyon,Etude préliminaire de l’efficacité d’un α1 bloquant (la prazosine) en prévention de la survenue d’un état de stress post-traumatique chez des patients présentant un état de stress aigu. Etude préli...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004653-32,0,0,0 2016-004655-75,2,2018-05-04,2018-05-04,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Glycopyrronium/Formoterol Fumarate fixed-dose combination relative to Umeclidinium/Vila...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004655-75,0,0,0 2016-004656-30,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Study of the Comparative Bioavailability of Two Second-Generation Investigational Pediatric Oral Granule Formulations of MK-1439 Compared to the Adult Formulation. Additional PIP decision number: ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004656-30,0,1,1 2016-004660-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Hospital Heidelberg,CDK4/6 inhibition in locally advanced/metastatic chordoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004660-19,0,0,0 2016-004661-23,8,2018-01-24,2018-02-22,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older with Severe Eosinophilic Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004661-23,0,0,0 2016-004662-25,1,2021-05-11,2021-05-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Krakowski Szpital Specjalistyczny im. Jana Pawła II,Regeneration of ischemic damages in cardiovascular system using Wharton’s jelly as an unlimited source of mesenchymal stem cells for regenerative medicine. Project of the National Centre for Research ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004662-25,0,0,0 2016-004664-18,6,2018-05-30,2018-09-12,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Prothena Therapeutics Limited,A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004664-18,0,0,0 2016-004664-18,6,2018-05-30,2018-09-12,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,PROTHENA THERAPEUTICS LIMITED,A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (PRONTO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004664-18,0,0,0 2016-004665-10,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"DIPARTIMENTO SCIENZE CHIRURGICHE, ONCOLOGICHE E GASTROENTEROLOGICHE (DISCOG) - UNIVERSITA' DI PADOVA",THE GIADA TRIAL. ENGAGING THE IMMUNE SYSTEM TO IMPROVE THE EFFICACY OF NEOADJUVANT CHEMO-ENDOCRINE THERAPY FOR PREMENOPAUSAL LUMINAL B BREAST CANCER PATIENTS. THE GIADA TRIAL. ENGAGING THE IMMUNE S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004665-10,0,0,0 2016-004672-21,9,2021-11-09,2021-11-09,3,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Kiadis Pharma Netherlands B.V.,"A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation deple...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004672-21,1,0,0 2016-004672-21,9,2021-11-09,2021-11-09,3,1,0,0,0,1,3,0,0,2,1,0,0,0,1,KIADIS PHARMA NETHERLANDS B.V.,"A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation deple...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004672-21,1,0,0 2016-004672-21,9,2021-11-09,2021-11-09,3,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Kiadis Pharma Netherlands BV,"A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation deple...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004672-21,1,0,0 2016-004674-17,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Prinses Maxima Centrum voor kinderoncologie,"A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lympfoblastic leukemia ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004674-17,0,0,0 2016-004674-17,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Princess Máxima Center for Pediatric Oncology,"A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lympfoblastic leukemia ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004674-17,0,0,0 2016-004675-52,5,2019-05-08,2019-05-08,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24 Week Study Followed by Long-Term Treatment for Evaluation of Efficacy and Safety of Baricitinib in Patients with Active Psoriatic Arthri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004675-52,1,0,0 2016-004675-52,5,2019-05-08,2019-05-08,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Eli Lilly and Company,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24 Week Study Followed by Long-Term Treatment for Evaluation of Efficacy and Safety of Baricitinib in Patients with Active Psoriatic Arthri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004675-52,1,0,0 2016-004675-52,5,2019-05-08,2019-05-08,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Lilly S.A.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24 Week Study Followed by Long-Term Treatment for Evaluation of Efficacy and Safety of Baricitinib in Patients with Active Psoriatic Arthri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004675-52,1,0,0 2016-004676-22,19,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004676-22,0,0,0 2016-004676-22,19,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004676-22,0,0,0 2016-004677-40,19,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004677-40,0,0,0 2016-004677-40,19,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004677-40,0,0,0 2016-004678-16,1,2018-10-25,2018-10-25,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Incyte Corporation,"A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors Estudio de f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004678-16,0,0,0 2016-004680-39,1,2020-05-18,2020-05-18,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Autolus Limited,"A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 in Paediatric and Adult Patients with Rela...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004680-39,0,0,0 2016-004682-11,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Autolus Limited,"A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 with Anti PD-1 Antibody in Patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004682-11,0,0,0 2016-004683-19,1,2021-03-10,2021-03-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Krakowski Szpital Specjalistyczny im. Jana Pawła II,Regeneration of ischemic damages in cardiovascular system using Wharton’s jelly as an unlimited source of mesenchymal stem cells for regenerative medicine. Project of the National Centre for Research...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004683-19,0,0,0 2016-004684-40,1,2021-09-28,2021-09-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Krakowski Szpital Specjalistyczny im. Jana Pawła II,Regeneration of ischemic damages in cardiovascular system using Wharton’s jelly as an unlimited source of mesenchymal stem cells for regenerative medicine. Project of the National Centre for Research ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004684-40,0,0,0 2016-004687-19,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Radboud University Medical Center,A randomized controlled trial evaluating the additional effect of topical coal tar to a topical corticosteroid regimen in patients aged >16 years of age with moderate-severe atopic dermatitis. Een...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004687-19,0,0,0 2016-004691-22,2,2019-12-17,2019-12-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Rechon Life Science AB,"A Randomised, Open, Parallel-group Phase III Biosimilarity Study to Assess the Long-term Safety, Focusing on Immunogenicity, of Rechon Insulin Human Soluble in Type 1 Diabetic Patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004691-22,0,0,0 2016-004692-53,1,2019-05-15,2019-05-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Zealand University Hospital Køge,Changes in bile acid homeostasis and stool habits after cholecystectomy Ændringer i galdesyrehomeostase og afføringsmønster efter cholecystektomi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004692-53,0,0,0 2016-004694-41,1,2018-11-30,2018-11-30,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Sophiris Bio Corp. 1258 Prospect Street La Jolla, CA 92037 USA","A Multi-Centre, Open Label, Phase IIb Study, Evaluating the Safety, Tolerability and Efficacy of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Si...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004694-41,0,0,0 2016-004698-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,MORphine use in the Fascia Iliaca Compartment block with UltraSound guidance.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004698-42,0,0,0 2016-004700-56,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,"Exploratory study of neo-adjuvant treatment with carboplatin, paclitaxel and pembrolizumab in primary stage IV serous ovarian cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004700-56,0,0,0 2016-004702-34,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,1,Cutanea Life Sciences,"A randomized, evaluator-blinded, vehicle-controlled study to explore the pharmacodynamic effects of omiganan and omiganan in combination with imiquimod in healthy volunteers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004702-34,0,0,0 2016-004706-33,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Finn Gustafsson,The Effect of Ivabradine Treatment on Exercise Capacity in Patients with Cardiac Allograft Vasculopathy after Heart Transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004706-33,0,0,0 2016-004707-32,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,"A Multi-Center, Open Label, Uncontrolled, Phase 2a Clinical Trial Evaluating the Safety and Efficacy of the Addition of Ibrutinib to Venetoclax through a MRD-guided Approach in Relapsed/Refractory Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004707-32,0,0,0 2016-004710-95,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Beroendecentrum Stockholm,Extended-release injectable suspension naltrexone (XR-NTX) as an adjunt pharmacotherapy for prevention of substance use in patients with SUD who are currently in treatment for ADHD: A multicenter rand...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004710-95,0,0,0 2016-004718-90,5,2022-07-04,2022-07-04,2,0,0,0,2,0,2,0,0,2,1,0,0,0,1,"TG THERAPEUTICS, INC.",A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgk...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004718-90,1,0,0 2016-004718-90,5,2022-07-04,2022-07-04,2,0,0,0,2,0,2,0,0,2,1,0,0,0,1,TG Therapeutics,A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgk...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004718-90,1,0,0 2016-004719-10,14,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Actelion Pharmaceuticals Ltd.,"Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004719-10,0,0,0 2016-004724-34,9,2020-07-02,2020-07-02,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Helsinn Healthcare SA,"A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients > o uguale a18 Years With Newly Diagnosed Acute Myeloid Leukemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004724-34,0,0,0 2016-004724-34,9,2020-07-02,2020-07-02,6,1,0,0,0,1,3,0,0,1,1,0,1,0,1,HELSINN HEALTHCARE SA,"A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients > o uguale a18 Years With Newly Diagnosed Acute Myeloid Leukemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004724-34,0,0,0 2016-004726-42,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,0,Birmingham Women's Hospital,Randomised controlled trial on the use of synthetic osmotic cervical dilator in induction of labour in comparison to dinoprostone vaginal insert,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004726-42,0,0,0 2016-004727-23,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,North Bristol NHS Trust Research & Innovation,A Trial of Intra-pleuraL OK-432 Therapy in mesothelioma (TILT): A feasibility study using the ‘trial within a cohort’ methodology,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004727-23,0,0,0 2016-004728-48,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc.",A Study to Evaluate the Comparative Bioavailability of the Investigational Oral Pediatric Minitablet Formulation of MK-1439 Compared to the Adult Formulation of MK-1439 in Healthy Adult Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004728-48,0,1,1 2016-004730-18,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,University Hospital Regensburg,The influence of Timolol Nasal Spray on Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Der Einfluss von Timolol Nasenspray auf Epistaxis bei Morbus Osler Patienten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004730-18,0,0,0 2016-004734-22,6,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,Roche Farma S.A.(Soc. Unipersonal)que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche LTD,A PHASE III RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NEOADJUVANT ANTHRACYCLINE/NAB-PACLITAXEL-BASED CHEMOTHERAPY COMPARED WITH ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004734-22,0,0,0 2016-004734-22,6,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffman-La Roche Ltd.,A PHASE III RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NEOADJUVANT ANTHRACYCLINE/NAB-PACLITAXEL-BASED CHEMOTHERAPY COMPARED WITH ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004734-22,0,0,0 2016-004734-22,6,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,A PHASE III RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NEOADJUVANT ANTHRACYCLINE/NAB-PACLITAXEL-BASED CHEMOTHERAPY COMPARED WITH ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004734-22,0,0,0 2016-004739-19,1,2019-09-13,2019-09-13,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Oslo University Hospital,"OSU6162 IN THE TREATMENT OF FATIGUE AND OTHER NEUROPSYCHOLOGICAL SEQUELAE AFTER ANEURYSMAL SUBARACHNOIDAL HEMORRHAGE - A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004739-19,0,0,0 2016-004740-11,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004740-11,0,0,0 2016-004740-11,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004740-11,0,0,0 2016-004742-28,10,2021-11-19,2021-11-26,7,1,0,0,0,1,2,0,0,2,0,0,0,0,1,"Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda","A Phase 2, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004742-28,1,0,0 2016-004742-28,10,2021-11-19,2021-11-26,7,1,0,0,0,1,2,0,0,2,0,0,0,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 2, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004742-28,1,0,0 2016-004743-37,5,2019-01-10,2019-01-10,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Genmab A/S,"A multi-center, open-label trial investigating the efficacy and safety of continued treatment with tisotumab vedotin in patients with solid tumors known to express tissue factor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004743-37,0,0,0 2016-004744-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Center,PDL-1 targeting in resectable oesophageal cancer: a phase IB feasibility study of Atezolizumab and chemoradiation (PERFECT) Haalbaarheidsonderzoek naar de behandeling van preoperatieve chemoradioth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004744-11,0,0,0 2016-004746-28,1,2020-12-23,2020-12-23,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI,Ticagrelor And PrEconditioning in patients with stable coronaRy artery diSease: a randomized pilot trial (TAPER-S trial) Ticagrelor e precondizionamento in pazienti con malattia coronarica stabile...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004746-28,0,0,0 2016-004749-10,3,2019-10-23,2019-10-23,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Adare Pharmaceutical,"FLUTicasone in Eosinophilic esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose ranging, and Maintenance Study of APT-1011 in Subjects with Eosinophilic Esophagitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004749-10,0,0,0 2016-004750-15,1,2022-08-12,2022-08-12,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,AIO-Studien-gGmbH,A randomized phase II study of Durvalumab (MEDI4736) and Tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma. Eine randomisierte Phase-II-Studie mit Dur...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004750-15,0,0,0 2016-004753-33,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Seqirus GmbH,"A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) with a US-licen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004753-33,0,1,1 2016-004754-15,7,2021-01-05,2021-04-21,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,TOBIRA THERAPEUTICS,Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004754-15,1,0,0 2016-004754-15,7,2021-01-05,2021-04-21,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Tobira Therapeutics, Inc., a subsidiary of Allergan plc",Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004754-15,1,0,0 2016-004755-75,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Clinique Juge,Intra articular injection of microfat and platelet-rich plasma in the treatment of knee osteoarthritis : a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004755-75,0,0,0 2016-004758-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Hamburg-Eppendorf,Multicenter randomized controlled study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy (IMSTAR HN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004758-13,0,0,0 2016-004763-40,1,2018-06-14,2018-06-14,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Sanofi Pasteur,Immunogenicity and Safety of Quadrivalent Influenza Vaccine (VaxigripTetra™) in Pregnant Women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004763-40,0,0,0 2016-004764-18,1,2021-09-18,2021-09-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,St Patrick’s Mental Health Services,Ketamine as an adjunctive therapy for Major Depression - a randomised controlled pilot trial: The KARMA-Dep Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004764-18,0,0,0 2016-004766-26,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Academic Medical Center,Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies (IMMEDIATE): a pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004766-26,0,0,0 2016-004768-20,1,2019-04-04,2019-04-04,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Copenhagen,The effect of liraglutide on pancreatic hormones and its size Effekten af liraglutid på bugspytkirtlens enzymer samt størrelse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004768-20,0,0,0 2016-004772-21,1,,,0,0,0,0,0,1,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA,"Dual-release hydrocortisone compared to immediate-release glucocorticoid replacement therapy in terms of glucose control, insulin sensitivity and glucose variability in patients with adrenal insuffici...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004772-21,0,0,0 2016-004774-17,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Pirkanmaan sairaanhoitopiiri,"Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy – lipid metabolism as a novel biomarker to predict prostate cancer progression – phase 3, double-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004774-17,0,0,0 2016-004774-17,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Tampereen yliopisto, Lääketieteen ja biotieteiden tiedekunta","Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy – lipid metabolism as a novel biomarker to predict prostate cancer progression – phase 3, double-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004774-17,0,0,0 2016-004777-40,2,2020-09-07,2020-09-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PsiOxus Therapeutics Ltd,A multicentre observational study for the long term follow up of subjects that have been treated with enadenotucirev during interventional clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004777-40,0,0,0 2016-004778-16,1,2020-06-30,2020-06-30,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,"Department of Medicine I, Ordensklinikum Linz, Elisabethinen Hospital Linz",Carfilzomib in combination with lenalidomide and dexamethasone – feasibility and efficacy of a new consolidation regimen in inducing and/or re-inducing minimal residual disease negativity in multiple ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004778-16,0,0,0 2016-004779-39,6,2021-07-19,2021-07-19,5,1,1,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche LTD.,"AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO ASCERTAIN THE OPTIMAL STARTING DOSE OF MIRCERA® GIVEN SUBCUTANEOUSLY FOR THE MAINTENANCE TREATMENT OF ANEMIA IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004779-39,0,0,0 2016-004779-39,6,2021-07-19,2021-07-19,5,1,1,0,0,0,2,0,0,1,0,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO ASCERTAIN THE OPTIMAL STARTING DOSE OF MIRCERA® GIVEN SUBCUTANEOUSLY FOR THE MAINTENANCE TREATMENT OF ANEMIA IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004779-39,0,0,0 2016-004779-39,6,2021-07-19,2021-07-19,5,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Roche Farma S.A(Soc unipersonal)que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche LTD.,"AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO ASCERTAIN THE OPTIMAL STARTING DOSE OF MIRCERA® GIVEN SUBCUTANEOUSLY FOR THE MAINTENANCE TREATMENT OF ANEMIA IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004779-39,0,0,0 2016-004782-11,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,1,Prometic Biotherapeutics Ltd,"A Phase 1/2A Prospective, Dose-Escalation, Open-Label Study of the Safety, Feasibility, and Initial Efficacy of Subcutaneous Plasminogen (Human) 10 for the Treatment of Diabetic Foot Ulcer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004782-11,0,0,0 2016-004784-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Raimo Tuuminen,Anti-inflammatory medication in cataract surgery of pseudoexfoliation eyes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004784-40,0,0,0 2016-004786-80,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,"Ruprecht-Karls-University Heidelberg, Medical Faculty","A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis. Phase IIa, ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004786-80,0,0,0 2016-004787-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Rheinische Friedrich-Wilhelms-Universität Bonn,"An Open Label, Randomized Phase 2 Clinical Trial of Nivolumab investigating Effiacy and safety of Nivolumab given once prior to, concurrent to the radiotherapy (RT) and as maintenance therapy over 12 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004787-20,0,0,0 2016-004789-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Ordensklinikum Linz, Krankenhaus der Elisabethinen Linz GmbH, III. Interne","The Effect of Phosphate Lowering using sucroferric oxyhydroxide (PA21) on Calcification Propensity of Serum – a randomized, controlled, open-label, cross-over trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004789-24,0,0,0 2016-004792-50,1,2021-03-25,2021-03-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Biologische Heilmittel Heel GmbH,"Multi-centre, Double-blind, Randomised, Active- and Placebo-Controlled, Confirmatory Trial to Demonstrate Efficacy and Safety of Traumed® Gel in Patients having Acute Ankle Sprain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004792-50,0,0,0 2016-004793-17,3,2018-05-16,2018-08-13,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Reata Pharmaceuticals, Inc.",A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients with Pulmonary Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004793-17,0,0,0 2016-004794-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Academical medical centre, dep of internal medicine",Arterial wall inflammation measured with 18F-FDG PET/CT in patients with statin intolerance before and after treatment with a PCSK-9 inhibitor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004794-41,0,0,0 2016-004797-18,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,3,Imperial College London,"Pilot study of the GLP-1 agonist, Liraglutide, on decreasing parenteral support requirements in short bowel patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004797-18,0,0,0 2016-004799-23,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE II, SINGLE ARM, MULTICENTER, PROOF OF MECHANISM STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BITOPERTIN (RO4917838) IN ADULTS WITH NON-TRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004799-23,0,0,0 2016-004800-71,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Bambino Gesù Children's Hospital,"Determination of intraoperative levels of Cefoxitin during cardiac surgery requiring cardiopulmonary bypass in neonates, infants, children below, and above 40 kg. Determinazione dei livelli plasmat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004800-71,0,0,0 2016-004803-30,1,2017-04-17,2017-04-17,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Hull and East Yorkshire Hospitals NHS Trust,"A multi-centre, randomised, placebo and active-controlled, double-blind, cross-over, phase IIa proof-of-concept trial to investigate the efficacy and safety of AX-8 Tablets 5 mg in patients with chron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004803-30,0,0,0 2016-004804-77,1,,,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,BAMBINO GESU' CHILDREN'S HOSPITAL,A prospective study to assess safety and efficacy of the use of bone-marrow derived MESenchymal stromal cells as immunomodulatory therapy for children and young adults with severe and difficult-to-tre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004804-77,0,0,0 2016-004806-32,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,"ITALIAN PULMONARY HYPERTENSION NETWORK, IPHNET",Right ventriculAr reverse reModeling and hemodynamic improvement after add-on combination therapy (ambriSentan/PDE-5i) in PAH patientS (RAMSES) Rimodellamento inverso del ventricolo destro e miglio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004806-32,0,0,0 2016-004808-60,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University Hospital Heidelberg,Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial Beha...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004808-60,0,0,0 2016-004819-12,1,,,0,0,0,0,1,0,4,0,0,1,1,1,0,1,0,OSPEDALE SAN RAFFAELE,Discontinuation of first-line disease modifying treatment (DMT) in long-term full responders MS patients: a multicentre randomized clinical trial. Sospensione del trattamento di prima linea in pazi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004819-12,0,0,0 2016-004820-41,3,2021-01-20,2021-01-20,3,1,1,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004820-41,0,0,0 2016-004822-41,3,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Bayer AG,"An open-label, parallel-group, randomized, multicenter study to assess the safety and efficacy of vilaprisan in subjects with uterine fibroids versus standard of care",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004822-41,0,0,0 2016-004823-21,1,2020-05-08,2020-05-08,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Prometic Biosciences Inc.,An Open-Label Rollover Study of PBI-4050 in Subjects with Alström Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004823-21,0,0,0 2016-004825-17,1,2020-05-31,2020-05-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Charité Universitätsmedizin Berlin,"A Proof-of-concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy Eine Proof-of-concept-Studie, um die Wirksamkeit ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004825-17,0,0,0 2016-004826-40,1,2017-08-24,2017-08-24,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Department of Psychology, Stockholm University",Effects of oxytocin on suggestibility and consciousness Effekter av oxytocin på suggererbarhet och medvetandetillstånd.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004826-40,0,0,0 2016-004827-22,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,Academic Medical Center,"A randomized, double-blind, placebo-controlled, double-dummy study to determine the safety/tolerability of a simultaneous subcutaneous treatment of BM41 and vitamin D 3 in patients with moderate to se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004827-22,0,0,0 2016-004829-16,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Fondazione Franco e Piera Cutino Onlus,Multicentric Randomized Clinical Trial of Deferiprone-Deferasirox Sequential Therapy versus Deferasirox or Deferiprone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004829-16,0,0,0 2016-004833-25,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar),"Synchronous effect of anesthetics on fMRI, EEG and clinical responses. Development of a more precise system for monitoring anesthetic effect. Efecto sincrónico de los anestésicos sobre la Resonanci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004833-25,0,0,0 2016-004834-11,5,2019-01-08,2019-01-08,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Rottapharm Biotech S.r.l.,"A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy, safety and pharmacokinetics of oral CR6086 administered at the doses of 30, 90 or 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004834-11,0,0,0 2016-004835-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Hospital Grenoble,"Dexamethasone in Herpes Simplex Virus Encephalitis Open label Randomized Controlled Trial with an Observer-blinded evaluation at 6 months Etude multicentrique, randomisée, contrôlée, en ouvert av...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004835-19,0,0,0 2016-004836-39,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Goethe Universität,An open label phase II study to evaluate the efficacy and safety of Inotuzumab Ozogamicin for Induction Therapy followed by a conventional chemotherapy based consolidation and maintenance therapy In p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004836-39,0,0,0 2016-004842-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Repha GmbH,Clinical Trial to investigate the efficacy and safety of ANGOCIN® Anti-Infekt N versus placebo in the prophylaxis of catheter associated urinary tract infections Klinische Prüfung zur Untersuchung ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004842-27,0,0,0 2016-004843-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHRU de Besançon,Infections urinaires masculines à entérobactéries productrices de bêta-lactamase à spectre étendue avec résistance associée aux fluoroquinolones et au cotrimoxazole : efficacité clinique de fosfomyci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004843-36,0,0,0 2016-004846-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,Efficacy of Sodium Oxybate to promote sleep in the ICU: A randomized controlled trial Behandeling van gestoorde nachtslaap op de intensive care met natriumoxybaat: een gerandomiseerd gecontroleerd ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004846-28,0,0,0 2016-004850-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Cancer de Ovario,"Multicentric Single Arm Phase II Clinical Trial, to Evaluate Safety and Efficacy of the Combination of Olaparib and PLD for Platinum Resistant Ovarian Primary Peritoneal Carcinoma, and Fallopian Tube ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004850-14,0,0,0 2016-004853-34,1,,,0,0,1,0,0,1,2,0,0,4,0,0,0,0,0,Dalhousie University,"A Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine Candidate in HIV-Infected Adults a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004853-34,0,1,1 2016-004857-33,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AIO-Studien-gGmbH,A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Transitional Cell Carcinoma Eine einarmige klinische Prüfung (Phase ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004857-33,0,0,0 2016-004867-38,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Autolus Limited,Long-term follow-up of patients previously treated with autologous T cells genetically modified with retroviral vectors. Langetermijn follow-up van patiënten die eerder zijn behandeld met autologe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004867-38,0,0,0 2016-004876-23,5,2018-08-13,2018-08-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland,"A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir(GLE)/Pibrentasvir(PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotypes 1 – 6 Inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004876-23,0,0,0 2016-004877-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACIÓN PETHEMA,"A phase II, open-label study to evaluate the effect of blinatumomab administered during consolidation to reduce the level of minimal residual disease (MRD) assessed through flow cytometry in adult pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004877-42,0,0,0 2016-004878-17,1,,,0,1,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Leicester,"The Effect of a SGLT2 inhibitor on Glucose flux, Lipolysis and Exercise in type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004878-17,0,0,0 2016-004879-46,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Birmingham,"AVAIL-T: A Phase 2a trial of Avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004879-46,0,0,0 2016-004883-20,1,2017-09-30,2017-09-30,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Ole Mathiesen,"Does perineural dexmedetomidine prolong the duration of an ulnar nerve block when controlling for possible systemic effects? - a randomized, blinded, placebo controlled, paired trial in healthy volun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004883-20,0,0,0 2016-004884-38,1,2019-06-18,2019-06-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Vall d'Hebron University Hospital,Prospective naturalistic clinical trail with loxapine in agitated patients with personality disorder Estudio naturalístico prospectivo con Loxapina en pacientes agitados con trastorno de personalid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004884-38,0,0,0 2016-004889-26,5,2019-10-25,2019-10-25,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis Recherche & Développement,"A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Moder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004889-26,0,0,0 2016-004889-26,5,2019-10-25,2019-10-25,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Moder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004889-26,0,0,0 2016-004889-26,5,2019-10-25,2019-10-25,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Moder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004889-26,0,0,0 2016-004904-74,13,2020-01-31,2020-01-31,10,1,1,0,0,0,3,0,1,2,0,0,0,0,1,Abbott Biologicals B.V.,"A Phase III, Observer-Blind, Randomized, Non-influenza Vaccine Comparator-Controlled, Parallel-Group, Multi-Country Study in Children Aged 6-35 Months to Assess the Safety and Efficacy of Abbott’s Can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004904-74,1,0,0 2016-004905-15,1,2019-08-28,2019-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Drugs for Neglected Diseases initiative (DNDi),"Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study to Evaluate Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients with Chronic Indeterminate Chagas Disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004905-15,0,0,0 2016-004906-32,5,2019-12-11,2019-12-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis Recherche & Développement,"A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Sever...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004906-32,0,0,0 2016-004906-32,5,2019-12-11,2019-12-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Sever...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004906-32,0,0,0 2016-004906-32,5,2019-12-11,2019-12-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Mellitus and Sever...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004906-32,0,0,0 2016-004907-30,8,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Agios Pharmaceuticals, Inc.","A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects = 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004907-30,0,0,0 2016-004907-30,8,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"AGIOS PHARMACEUTICALS, INC.","A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects = 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004907-30,0,0,0 2016-004928-39,3,2019-08-05,2019-08-05,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Ipsen Pharma,"A multicentre, randomised, dose-confirmation, factorial phase II study to evaluate the optimal dose of 68Ga-OPS202 as a PET imaging agent in subjects with gastroenteropancreatic neuroendocrine tumour ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004928-39,0,0,0 2016-004934-11,1,2017-05-29,2017-05-29,1,1,0,0,1,0,4,0,1,1,0,0,1,0,1,BIODRUG s.r.o.,"A single blind, randomized comparative and multicentre clinical trial of the immunogenicity and safety of booster immunisation with tetanus monovalent vaccines VACTETA 40 IU/0,5 ml (BIODRUG) and TETAV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004934-11,0,0,0 2016-004935-18,8,2018-09-18,2018-11-14,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GENEURO SA,"A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004935-18,0,0,0 2016-004935-18,8,2018-09-18,2018-11-14,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GeNeuro SA,"A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004935-18,0,0,0 2016-004936-39,1,2017-06-09,2017-06-09,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Department of Anesthesiology, Næstved Hospital","The influence of different doses of local anaesthetics on the sensory distribution of lateral femoral cutaneous nerve block - a randomised, blinded, paired trial in heathy volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004936-39,0,0,0 2016-004937-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación PETHEMA,"A multicenter, non-randomized, open label study to evaluate the efficacy and security of Ibrutinib followed by ofatumumab consolidation in previously untreated patients with Chronic Lymphocytic Leukem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004937-26,0,0,0 2016-004941-94,7,2019-05-31,2019-05-31,6,1,1,0,0,0,3,0,0,1,0,0,1,0,1,AIMMUNE THERAPEUTICS,PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW-ON STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004941-94,0,0,0 2016-004941-94,7,2019-05-31,2019-05-31,6,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Aimmune Therapeutics, Inc.",PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW-ON STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004941-94,0,0,0 2016-004942-27,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Centre Hospitalier de Versailles,A Phase 2 Study of Inotuzumab Ozogamicin (INO) Combined to Chemotherapy in Older Patients with Philadelphia Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004942-27,0,0,0 2016-004943-35,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Radboud University Medical Center,Stimulation of ADH independent urine concentration in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004943-35,0,0,0 2016-004944-12,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Eisai Inc.,"A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004944-12,0,1,1 2016-004945-10,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Eisai Co., ltd",An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004945-10,0,1,1 2016-004946-27,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Eisai Inc.,"A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004946-27,0,1,1 2016-004947-35,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Eisai Inc.,An Open-Label Study To Evaluate The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004947-35,0,1,1 2016-004948-11,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Eisai Inc.,"A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004948-11,0,1,1 2016-004949-92,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Eisai Inc.,"A 10-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride (Aricept) in the Treatment of the Cognitive Dysfunction Exhibited by Children with Down...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004949-92,0,1,1 2016-004950-14,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Eisai Inc.,An Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004950-14,0,1,1 2016-004951-55,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,Eisai Inc.,"A Multicenter, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004951-55,0,1,1 2016-004952-30,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,"Eisai Co, Ltd.","A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004952-30,0,1,1 2016-004953-34,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,"Eisai Co, Ltd.",A Long Term Extension Study of E2080 in Patients with Lennox-Gastaut Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004953-34,0,1,1 2016-004954-13,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,Eisai Taiwan Inc.,"A Multi-center, Randomized, Open-label, Parallel-group, Dose-titration, Add-on, Comparative Study in Evaluating the Efficacy and Safety of Zonisamide (Zonegran) and Lamotrigine (Lamictal) for Subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004954-13,0,1,1 2016-004955-64,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,1,Eisai Korea Inc.,A Multicenter Comparative Trial of Zonisamide and Topiramate as Monotherapy in Epilepsy Patients: Safety for cognitive function,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004955-64,0,1,1 2016-004956-32,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,1,Eisai Korea Inc.,A Multi-center Comparative Trial of Low and High Dose Zonisamide in Children with Newly Diagnosed Epilepsy as Monotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004956-32,0,1,1 2016-004957-33,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Eisai Korea Inc.,Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004957-33,0,1,1 2016-004958-14,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,1,Eisai Korea Inc.,"A Korean Open-label, Multi-center, Community-based Trial Assessing the Efficacy and Safety of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004958-14,0,1,1 2016-004959-80,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Special Account For Research Funds- National and Capodistrian University of Athens,"A randomized, pharmacodynamic comparison of ticagrelor 60mg bid vs prasugrel 5mg in patients with prior myocardial infarction Τυχαιοποιημένη, φαρμακοδυναμική συγκριτική μελέτη χορήγησης 60mg τικαγκ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004959-80,0,0,0 2016-004960-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region Östergötland,Local zoledronate for improved fixation of uncemented hip prostheses.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004960-20,0,0,0 2016-004963-38,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Netherlands Cancer Institute,"A randomized, open label, Phase IIB trial of Optimal Sequencing of Treatment Options for Poor Risk Metastasized Castration Resistant Prostate Cancer Previously Treated with Docetaxel (OSTRICh trial) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004963-38,0,0,0 2016-004965-22,11,2018-08-13,2018-08-13,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and safety of semaglutide 1.0 mg once-weekly versus liraglutide 1.2 mg once-daily as add-on to 1-3 oral anti-diabetic drugs (OADs) in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004965-22,0,0,0 2016-004965-22,11,2018-08-13,2018-08-13,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK. S.P.A.,Efficacy and safety of semaglutide 1.0 mg once-weekly versus liraglutide 1.2 mg once-daily as add-on to 1-3 oral anti-diabetic drugs (OADs) in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004965-22,0,0,0 2016-004967-38,10,2019-11-08,2019-11-08,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection and C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004967-38,0,0,0 2016-004970-16,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Medizinische Universität Wien,Imaging the functional and molecular impact of poly-unsaturated fatty acids on dopamine-dependent cognitive functions: a combined [11C]-(+)-PHNO PET/MRI study at different stages of cognitive impairme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004970-16,0,0,0 2016-004973-42,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,Boehringer Ingelheim Limited,"A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early interven...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004973-42,0,0,0 2016-004974-16,1,2020-09-08,2020-09-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge,DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED CLINICAL DOSE-RANGING STUDY TREATING MODERATE-SEVERE TRAUMATIC BRAIN INJURY PATIENTS WITH RECOMBINANT HUMAN INTERLEUKIN 1 RECEPTOR ANTAGONIST.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004974-16,0,0,0 2016-004977-42,4,2020-09-10,2020-09-10,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,COSMO TECHNOLOGIES LTD,"A Phase II, multicentre, randomised, double-blind, Placebo controlled, proof of concept study of efficacy and safety of Rifamycin SV-MMX® 600 mg tablets administered three or two times daily to patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004977-42,1,0,0 2016-004977-42,4,2020-09-10,2020-09-10,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Cosmo Technologies Ltd.,"A Phase II, multicentre, randomised, double-blind, Placebo controlled, proof of concept study of efficacy and safety of Rifamycin SV-MMX® 600 mg tablets administered three or two times daily to patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004977-42,1,0,0 2016-004978-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitari Bellvitge,"CLINICAL, RANDOMIZED, DOUBLE LIND CLINICAL TRIAL TO STUDY THE EFFECT OF PARENTERAL SUPPLEMENTATION WITH FISH OIL EMULSION IN THE NUTRITIONAL SUPPORT IN ESOPHAGECTOMIZED PATIENTS ENSAYO CLÍNICO PILO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004978-17,0,0,0 2016-004979-49,1,2019-02-05,2019-02-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NeRRe Therapeutics Ltd.,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF THREE DOSES OF ORVEPITANT IN SUBJECTS WITH CHRONIC REFRACTORY COUGH",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004979-49,0,0,0 2016-004981-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Henriette Svarre Nielsen,"Hydroxychloroquin (Plaquenil) treatment of recurrent pregnancy loss – a randomized, double blinded, placebo controlled study Hydroxychloroquin (Plaquenil) behandling af gentagne graviditetstab (ab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004981-24,0,0,0 2016-004986-18,5,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,Daiichi Sankyo Inc.,"A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Who are Resistant or Refractor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004986-18,0,0,0 2016-004986-18,5,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,DAIICHI SANKYO INC.,"A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Who are Resistant or Refractor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004986-18,0,0,0 2016-004987-21,1,2018-01-30,2018-01-30,1,1,0,1,0,1,1,0,0,1,1,1,0,0,1,"Ono Pharmaceutical Co., Ltd.","An open-label, multi-center, dose-escalation and expansion study to evaluate the safety and efficacy of ONO-7579 in patients with advanced solid tumors/ NTRK gene fusion positive advanced solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004987-21,0,0,0 2016-004989-25,2,2021-11-09,2021-11-09,1,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Incyte Biosciences International Sàrl,"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004989-25,1,0,0 2016-004990-42,1,2020-06-02,2020-06-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Rheumatologie","A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects with New-Onset Poly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004990-42,0,0,0 2016-004991-23,1,2019-10-31,2019-10-31,1,1,0,0,0,0,3,0,1,1,0,0,1,0,0,IBSAL (Instituto de Investigación Biomédica de Salamanca)-Fundación Instituto de Estudios de Ciencias de la Salud de,VACCINATION ADJUVED AGAINST HEPATITIS B IN SACYL WORKERS TYPED AS NO RESPONDERS TO CONVENTIONAL VACCINES VACUNACIÓN ADYUVADA FRENTE A HEPATITIS B EN TRABAJADORES DEL SACYL TIPIFICADOS COMO NO RESPO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004991-23,0,0,0 2016-004996-33,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,Vertex Pharmaceuticals Incoporated,"A Phase 4, Open-label Treatment, Randomized, Multicenter, 2-arm, Parallelgroup, Pilot Study of Adherence to Lumacaftor/Ivacaftor in CF Subjects Homozygous for the F508del-CFTR Mutation Estudio prel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004996-33,0,0,0 2016-004997-16,4,2019-09-09,2019-09-09,4,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of dupilumab administered concomitantly with topical corticosteroids in patients ≥6 years to <12 years of ag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-004997-16,0,0,0 2016-005000-26,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,"Sarepta Therapeutics, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Efficacy, Safety, Tolerability, and Pharmacokinetics Study of AVI-4658 (Eteplirsen), a Phosphorodiamidate Morpholino Oligomer, Administere...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005000-26,0,1,1 2016-005001-39,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,"Sarepta Therapeutics, Inc.","Open-Label, Multiple-Dose, Efficacy, Safety, and Tolerability Study of Eteplirsen in Subjects with Duchenne Muscular Dystrophy who Participated in Study 4658-us-201",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005001-39,0,1,1 2016-005002-19,1,,,0,1,1,0,0,1,3,0,0,4,0,0,0,0,1,"Sarepta Therapeutics, Inc.","An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005002-19,0,1,1 2016-005004-26,7,2019-02-15,2019-02-15,7,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Aimmune Therapeutics, Inc.",AR101 TRIAL IN EUROPE MEASURING ORAL IMMUNOTHERAPY SUCCESS IN PEANUT ALLERGIC CHILDREN (ARTEMIS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005004-26,0,0,0 2016-005004-26,7,2019-02-15,2019-02-15,7,1,1,0,0,0,3,0,0,1,0,0,1,0,1,AIMMUNE THERAPEUTICS,AR101 TRIAL IN EUROPE MEASURING ORAL IMMUNOTHERAPY SUCCESS IN PEANUT ALLERGIC CHILDREN (ARTEMIS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005004-26,0,0,0 2016-005008-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACIÓN PETHEMA,Carfilzomib and Dexamethasone in combination with Cyclophosphamide vs. Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: a phase II randomized controlled trial. C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005008-24,0,0,0 2016-005010-22,1,2020-08-24,2020-08-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Nanjing Luye Pharmaceutical Co., Ltd.","A Randomized, Open-Label, Cross-over Study to Assess the Relative Bioavailability of LY03004 and EU Risperdal® Consta® at 50 mg Following Multiple Intramuscular Injections in Stable Patients with Schi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005010-22,0,0,0 2016-005013-47,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Linköping University,Effects of the FAAH inhibitor PF-04457845 on fear extinction in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005013-47,0,0,0 2016-005014-21,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,University Medical Center Groningen,Pharmacokinetic evaluation and tolerability of dry powder tobramycin via the Cyclops® in children with cystic fibrosis Farmacokinetische evaluatie en verdraagzaamheid van droog poeder tobramycine v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005014-21,0,0,0 2016-005017-45,4,2018-05-17,2018-05-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NovImmune S.A.,"A Randomized, Placebo-Controlled, Double Blind, Multicenter Phase 2 Study to Explore Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Multiple Infusions of NI-0101,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005017-45,0,0,0 2016-005019-42,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Centre Léon Bérard,"A European, multicenter, randomized, open-label, Phase II trial aiming to assess the clinical and biological activity of an anti-PD-L1 (atezolizumab) in operable localized soft tissue sarcomas patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005019-42,0,0,0 2016-005020-29,8,2021-08-27,2021-08-27,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients with Pain Due to Osteoarthritis of the Knee or Hip",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005020-29,1,0,0 2016-005022-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Technische Universität München, Fakultät für Medizin",Improvement of synaptic plasticity and cognitive function in RAS pathway disorders Verbesserung der synaptischen Plastizität und kognitiven Funktionen bei Patienten mit Erkrankungen des RAS Signalw...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005022-10,0,0,0 2016-005023-92,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,"Sarepta Therapeutics, Inc.","An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005023-92,0,1,1 2016-005024-28,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,"Sarepta Therapeutics, Inc.","An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005024-28,0,1,1 2016-005025-37,3,2018-09-21,2018-09-21,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GALDERMA R&D, SNC","A randomized, double-blind, multi-center, parallel-group, placebo-controlled dose-ranging study to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005025-37,0,0,0 2016-005027-81,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Maria Siponen,Chlorhexidine and nystatin in the treatment of oral candidosis - a pilot study Klooriheksidiini ja nystatiini suun kandidoosin hoidossa -pilottitutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005027-81,0,0,0 2016-005029-36,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,NOGGO e.V.,"Comparison of QoL between Trabectedin / PLD and standard platinum-based therapy in patients with platinum sensitive recurrent ovarian, fallopian tube and peritoneal cancer - Intergroup-Study of NOGGO ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005029-36,0,0,0 2016-005031-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Pirkanmaan sairaanhoitopiiri,Metformin use to improve pregnancy outcome in women with type 1 diabetes. A double-blind placebo-controlled multicenter study. Kaksoissokkoutettu ja lumekontrolloitu monikeskustutkimus metformiinin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005031-32,0,0,0 2016-005032-14,3,2018-06-13,2018-06-13,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,INOTREM S.A.,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients with Septic Shock. A Randomised, Double-blind, Two-stage, Placebo Controlled Study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005032-14,0,0,0 2016-005035-33,4,2021-09-16,2021-09-16,1,1,0,0,0,1,2,0,0,2,0,0,0,0,1,"REGENERON PHARMACEUTICALS, INC.","A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of REGN2477 in patients with Fibrodysplasia Ossificans Progressiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005035-33,1,0,0 2016-005035-33,4,2021-09-16,2021-09-16,1,1,0,0,0,1,2,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of REGN2477 in patients with Fibrodysplasia Ossificans Progressiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005035-33,1,0,0 2016-005039-34,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Astex Pharmaceuticals, Inc.","Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005039-34,0,0,0 2016-005039-34,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,ASTEX PHARMACEUTICALS,"Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005039-34,0,0,0 2016-005042-37,2,2020-01-13,2020-01-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Boehringer Ingelheim France,"A phase II, open label, non-randomised study of afatinib in combination with pembrolizumab in patients with locally advanced or metastatic squamous cell carcinoma of the lung",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005042-37,0,0,0 2016-005042-37,2,2020-01-13,2020-01-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A phase II, open label, non-randomised study of afatinib in combination with pembrolizumab in patients with locally advanced or metastatic squamous cell carcinoma of the lung",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005042-37,0,0,0 2016-005043-16,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,KU Leuven - Drug Delivery and Disposition,Impact of stomach motility on the gastrointestinal behavior of fosamprenavir in healthy volunteers Impact van maagmotiliteit op het gastrointestinaal gedrag van fosamprenavir in gezonde vrijwillige...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005043-16,0,0,0 2016-005049-21,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"LLC Merz Pharma, Russia",Multi-center Open Comparative Randomized Trial of Clinical and Neurophysiological Efficacy and Safety of Xeomin (Botulinum Toxin Type A) vs. Botox (Complex of Botulinum Toxin Type A and Hemagglutinin)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005049-21,0,1,1 2016-005053-20,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Polish Myeloma Consortium,"A multicenter, single-arm, phase II study to evaluate a safety and efficacy of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed/refractory Waldenström Macroglobuline...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005053-20,0,0,0 2016-005057-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitario Sant Joan de Reus,"A prospective, randomized, parallel comparative clinical trial comparing the safety of perioperative analgesic efficacy of the PEC II block with BRILMA in breast surgery.Version 4, of May 16, 2017 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005057-21,0,0,0 2016-005061-31,1,2022-08-24,2022-08-24,1,0,0,0,0,1,2,0,0,1,0,0,0,0,0,LYSARC,"A PHASE II TRIAL EVALUATING COMBINATION OF ATEZOLIZUMAB, WITH VENETOCLAX AND OBINUTUZUMAB FOR RELAPSED/REFRACTORY LYMPHOMAS ETUDE DE PHASE II EVALUANT LA COMBINAISON ATEZOLIZUMAB, AVEC VENETOCLAX ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005061-31,0,0,0 2016-005062-61,1,2018-09-22,2018-09-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cliniques universitaires Saint-Luc,Effects of vitamin D supplementation during a non-surgical treatment of generalized chronic periodontitis: a randomized double-blinded placebo-controlled clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005062-61,0,0,0 2016-005063-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Repha GmbH,"Investigation of Efficacy, Safety, Acid Resistance and Mode of Action of Lipases in Nortase and Kreon with the Pancreo-Lip 13C breath test in Subjects with Severe Exocrine Pancreatic Insufficiency ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005063-13,0,0,0 2016-005065-31,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,University hospital of Montpellier,Comparison of preoperative hemoglobin after administration of epoetin alpha associated with oral martial supplementation vs intraveinous martial supplementation before craniosynostosis in children ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005065-31,0,0,0 2016-005068-33,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005068-33,0,0,0 2016-005068-33,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005068-33,0,0,0 2016-005069-30,1,2018-04-20,2018-04-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Pia Jæger,"Comparison of the analgesic effect of an adductor canal block using a new suture-method catheter vs a standard perineural catheter vs a single bolus: A randomized, blinded, controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005069-30,0,0,0 2016-005078-37,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,Hellenic Scientific Society for the Study of AIDS and Sexually Transmitted Diseases,Public health targeting of PrEP at HIV positives’ bridging networks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005078-37,0,0,0 2016-005081-60,1,2018-09-01,2018-09-01,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Jose Luis Calleja Panero,MULTICENTER CLINICAL TRIAL TO DETERMINE THE INFLUENCE OF TREATMENT WITH DIRECT ANTIVIRAL AGENTS IN THE GLOMERULAR AND TUBULAR FUNCTION OF PATIENTS WITH CHRONIC HCV HEPATITIS ENSAYO CLINICO MULTICEN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005081-60,0,0,0 2016-005082-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"MRI Research Unit, Radiology Department. Hospital del Mar.",Assessment of Tapentadol effects on patients with pain central sensitization using functional MRI Evaluación del efecto de tapentadol en pacientes con dolor por sensibilización central utilizando l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005082-31,0,0,0 2016-005083-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Conestat alfa as prophylactic treatment for idiopathic non-histaminergic acquired angioedema Conestat alfa (Ruconest®) behandeling voor het voorkómen van angio-oedeem aanvallen bij patiënten met a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005083-34,0,0,0 2016-005084-14,1,2017-08-21,2017-08-21,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Deoartment of Dermatology D92, Bispbjerg Hospital",PpIX in curetted and non-curetted skin after Metvix application,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005084-14,0,0,0 2016-005086-31,1,2021-06-24,2021-06-24,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,University Medical Center Utrecht (UMCU),Multicentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerine Patch Multicentrum gerandomiseerde klinische studie naar de behandeling met een nitroglycerine pleister...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005086-31,0,0,0 2016-005090-13,1,2020-05-15,2020-05-15,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Cancer Registry of Norway,Reducing painful colonoscopies in women participating in a colorectal cancer screening program: A randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005090-13,0,0,0 2016-005095-10,4,2022-04-11,2022-04-11,1,1,0,1,0,1,1,0,0,2,1,0,0,0,1,Wave Life Sciences UK Limited,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005095-10,1,0,0 2016-005095-10,4,2022-04-11,2022-04-11,1,1,0,1,0,1,1,0,0,2,1,0,0,0,1,Wave Life Science Ltd.,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005095-10,1,0,0 2016-005096-27,3,2020-11-12,2020-11-12,2,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Mereo BioPharma 3 Ltd.,"A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, incorporating an open label substudy, in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with setrusumab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005096-27,1,0,0 2016-005096-27,3,2020-11-12,2020-11-12,2,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Mereo Biopharma 3 Ltd.,"A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, incorporating an open label substudy, in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with setrusumab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005096-27,1,0,0 2016-005097-35,1,2020-01-09,2020-01-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of Birmingham,A randomised placebo-controlled trial of mifepristone and misoprostol versus misoprostol alone in the medical management of missed miscarriage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005097-35,0,0,0 2016-005100-26,1,2020-03-19,2020-03-19,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Hannover Medical School,"A pilot Study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency in patients with pulmonary hypertension and iron deficiency anemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005100-26,0,0,0 2016-005101-39,1,2019-11-29,2019-11-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Hannover Medical School,A phase IV study to explore the safety of ORal IrON supplementation with ferric maltol in treating iron deficiency in patients with heart failure carrying Left Ventricular Assist Devices (ORION-LVAD-1...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005101-39,0,0,0 2016-005104-25,1,2019-09-13,2019-09-13,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,Nova BioPharma Limited,"Relative bioavailability and comparative pharmacokinetics of 13-CRA oral liquid and extracted capsule formulations: a randomised, open label, multi-dose, cross-over clinical trial in patients requirin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005104-25,0,0,0 2016-005105-39,1,2022-02-08,2022-02-08,1,0,0,0,0,0,4,0,0,1,0,0,0,0,1,Cesra Arzneimittel GmbH & Co.KG,"Investigation of the effectiveness, tolerability and safety of ilon® Salbe classic in the treatment of acute inflammation of the hair follicle (folliculitis) - Prospective, open, evaluator-blinded, ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005105-39,0,0,0 2016-005110-22,1,,,0,0,0,1,0,1,1,0,0,1,1,1,0,1,1,Santhera Pharmaceuticals (Switzerland) Ltd,"Phase-Ib/IIa study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of orally inhaled multiple doses of POL6014 in patients with Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005110-22,0,0,0 2016-005111-40,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc","A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Flexible- Dosed Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005111-40,0,1,1 2016-005112-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,"Multicenter, randomized, phase II study of neoadjuvant chemotherapy associated or not with zoledronate and atorvastatin in triple negative breast cancers - YAPPETIZER Study Studio multicentrico, ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005112-17,0,0,0 2016-005113-50,4,2019-07-10,2019-07-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Myovant Sciences GmbH,"LIBERTY 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co Administered with and without Low-Dose Estradiol and Norethindrone A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005113-50,0,0,0 2016-005115-41,3,2020-11-02,2020-11-02,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Transgene S.A.,A phase II study evaluating the efficacy and the safety of first-line chemotherapy combined with TG4010 and nivolumab in patients with advanced non-squamous Non-Small-Cell Lung Cancer (NSCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005115-41,0,0,0 2016-005117-44,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of Novartis Meningococcal group B Vaccine When Administered Concomitantly with Novartis MenACWY Conjugate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005117-44,0,1,1 2016-005119-42,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT (INOPERABLE LOCALL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005119-42,0,0,0 2016-005119-42,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A. ( Soc.Unipersonal) que realiza el ensayo en España y que actua como representante de Hoffmann-La Roche.,"A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT (INOPERABLE LOCALL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005119-42,0,0,0 2016-005119-42,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF ATEZOLIZUMAB PLUS CHEMOTHERAPY FOR PATIENTS WITH EARLY RELAPSING RECURRENT (INOPERABLE LOCALL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005119-42,0,0,0 2016-005122-11,1,2019-08-29,2019-08-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Prof. Dr. Kristian Reich,"A multicenter, open label, single-arm pilot to evaluate the efficacy and safety of oral apremilast in patients with moderate to severe palmoplantar pustulosis (PPP) (APLANTUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005122-11,0,0,0 2016-005126-11,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,2,ASTRAZENECA AB,"A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma Studio Randomizzato, in Aperto, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005126-11,0,0,0 2016-005126-11,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,2,AstraZeneca AB,"A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma Studio Randomizzato, in Aperto, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005126-11,0,0,0 2016-005129-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA,"""Peptide Receptor Radionuclide Therapy (PRRT) with somatostatin analogs in tumors over-expressing somatostatin receptors"" ¿Terapia radiorecettoriale con analoghi radiomarcati della somatostatina in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005129-35,0,0,0 2016-005134-29,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Pfizer Inc,"A PHASE 4, RANDOMIZED, OPEN-LABEL TRIAL TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13- VALENT PNEUMOCOCCAL CONJUGATE VACCINE FORMULATED IN MULTIDOSE VIALS WHEN GIVEN WITH ROUTINE PEDI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005134-29,0,1,1 2016-005136-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CUB Erasme Hospital,Corticosteroids in patients with severe alcoholic hepatitis patients in early spontaneous improvement Traitement aux corticostéroïdes chez des patients ayant une hépatite alcoolique sévère et qui m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005136-16,0,0,0 2016-005140-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, PARALLEL-GROUP, SINGLE CENTER PILOT STUDY OF THE ACUTE AND CHRONIC EFFECTS OF DAPAGLIFLOZIN PLUS SAXAGLIPTIN IN ADDITION TO METFORMIN VERSUS SI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005140-41,0,0,0 2016-005141-23,13,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Retrophin, Inc.","A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005141-23,0,0,0 2016-005141-23,13,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"RETROPHIN, INC","A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005141-23,0,0,0 2016-005141-23,13,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Travere Therapeutics Inc.,"A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005141-23,0,0,0 2016-005141-23,13,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Travere Therapeutics,"A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005141-23,0,0,0 2016-005142-39,4,2021-05-10,2021-05-10,2,1,0,1,0,1,1,0,0,2,1,0,0,0,1,Wave Life Sciences UK Limited,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005142-39,1,0,0 2016-005142-39,4,2021-05-10,2021-05-10,2,1,0,1,0,1,1,0,0,2,1,0,0,0,1,WAVE Life Sciences Ltd,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005142-39,1,0,0 2016-005144-42,7,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,Novartis Pharma AG,"An open-label, multi-center, global, rollover study for patients who have previously received capmatinib (INC280) as monotherapy or in combination in a Novartis Sponsored trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005144-42,0,0,0 2016-005144-42,7,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","An open-label, multi-center, global, rollover study for patients who have previously received capmatinib (INC280) as monotherapy or in combination in a Novartis Sponsored trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005144-42,0,0,0 2016-005145-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,DIPARTIMENTO DI SCIENZE CHIRURGICHE - UNIVERSITà DEGLI STUDI DI TORINO,"Prospective randomized trial comparing corifollitropin alfa (CF-alfa) late start (day 4) vs. CF-alfa standard start (day2) in poor, normal and potential high-responders undergoing IVF/ICSI Trial ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005145-23,0,0,0 2016-005147-17,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,AIO-Studien-gGmbH,Second-line therapy with Nal-IRI/5-FU/FA after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy Zweitlinientherapie mit Nal-IRI/5-FU/FA nach...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005147-17,0,0,0 2016-005157-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Palleos healthcare GmbH,"A prospective, randomized, multicenter, open-label comparison of pre-surgical combination of trastuzumab and pertuzumab with concurrent taxane chemotherapy or endocrine therapy given for twelve weeks ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005157-21,0,0,0 2016-005159-25,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005159-25,0,1,1 2016-005160-34,1,2019-06-26,2019-06-26,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Universitetsklinikken for Nyresygdomme og Blodtryksforhøjelse, Regionshospitalet Holstebro, Hospitalsenheden Vest",18F-NaF PET/CT in combination with biomarkers for the classification of renal osteodystrophy in chronic kidney disease 18F-NaF PET/CT i kombination med biomarkører til klassificering af renal osteo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005160-34,0,0,0 2016-005161-31,2,2018-02-14,2018-02-14,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allecra Therapeutics SAS,"Randomized, Double-Blind, Multi-Center Study of Cefepime/AAI101 in Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005161-31,0,0,0 2016-005164-34,4,2018-08-02,2018-08-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, double dummy, active-controlled, 3-period complete cross-over study to assess the bronchodilator effect and safety of two doses of QVM149 compared to a fixed dose combinati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005164-34,0,0,0 2016-005165-31,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Sanofi Aventis Groupe,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Comparative Study to Assess the Efficacy and Safety of Spores of Enterogermina in Combination with Oral Rehydration Therapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005165-31,0,1,1 2016-005166-58,2,2017-11-28,2017-11-28,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Auris Medical Inc.,Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005166-58,0,0,0 2016-005181-57,1,2020-05-04,2020-05-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,GWT-TUD GmbH,"A randomized, placebo-controlled, double-blind study to scrutinize the efficacy of Secukinumab in patients with moderate to severe atopic dermatitis Randomisierte, Placebo-kontrollierte Doppelblin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005181-57,0,0,0 2016-005182-31,1,2018-09-12,2018-09-12,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Lund University,"""An exploratory study regarding the use of the biomarker DAT for image diagnosis of clear cell renal cell carcinoma"" ”En explorativ studie avseende användning av biomarkören DAT för bilddiagnostik ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005182-31,0,0,0 2016-005184-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MEDIOLANUM FARMACEUTICI S.P.A.,METRO STUDY - MESOGLYCAN VERSUS PLACEBO IN SECONDARY PREVENTION OF SURFACE VEIN THROMBOSIS STUDIO METRO - MESOGLICANO VERSUS PLACEBO NELLA PREVENZIONE SECONDARIA DELLA TROMBOSI VENOSA SUPERFICIALE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005184-13,0,0,0 2016-005186-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Department of Plastic Surgery, Breast and Burns Treatment","Fat Grafting with Ex-Vivo Expanded Adipose-Derived Stem Cells for Breast Reconstruction Following Mastectomy Rekonstruktion af brystet efter mastektomi, med fedt transplantation og ex-vivo opformer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005186-31,0,0,0 2016-005187-34,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,Stereotactic body radiotherapy with immunotherapy in early stage non-small cell lung cancer: tolerability and lung effects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005187-34,0,0,0 2016-005189-75,17,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"AN OPEN-LABEL, MULTICENTER EXTENSION AND LONG-TERM OBSERVATIONAL STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMANN LA ROCHE LTD-SPONSORED ATEZOLIZUMAB STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005189-75,0,0,0 2016-005189-75,17,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"AN OPEN-LABEL, MULTICENTER EXTENSION AND LONG-TERM OBSERVATIONAL STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMANN LA ROCHE LTD-SPONSORED ATEZOLIZUMAB STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005189-75,0,0,0 2016-005189-75,17,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Roche Farma S.A(Soc.Unipersonal) que realiza el ensayo en España y que actúa como representante de F.Hoffmann-La Roche,"AN OPEN-LABEL, MULTICENTER EXTENSION AND LONG-TERM OBSERVATIONAL STUDY IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMANN LA ROCHE LTD-SPONSORED ATEZOLIZUMAB STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005189-75,0,0,0 2016-005197-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland",A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005197-35,0,0,0 2016-005199-90,1,2019-08-19,2019-08-19,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,RedHill Biopharma Ltd.,An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects with Active Crohn’s Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study Otv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005199-90,0,0,0 2016-005202-19,1,2018-11-02,2018-11-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Chemische Fabrik Kreussler & Co. GmbH,"Multicenter, randomized, split-mouth study to evaluate the acceptance and preference of lidocaine gel compared to injection anesthesia after non surgical periodontal treatment Multizentrische, rand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005202-19,0,0,0 2016-005205-40,5,2018-02-15,2018-02-15,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Verona Pharma plc,"A Phase IIb, randomized, double blind, placebo controlled, dose ranging study to assess the effect of RPL554 in patients with moderate to severe COPD.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005205-40,0,0,0 2016-005206-19,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Fundación para la Formación e Investigación Sanitaria (FFIS),Randomised Controlled Trial with Pravastatin versus Placebo for Prevention of Preeclampsia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005206-19,0,0,0 2016-005207-30,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,HOSPITAL SON ESPASES,CLINICAL TRIAL FOR THE ADMINISTRATION OF PREOPERATIVE VITAMIN D AS PREVENTION IN TRANSITORY HYPOCALCEMIA IN POSTOPERATORY OF TOTAL THYROIDECTOMY ENSAYO CLÍNICO PARA LA ADMINISTRACIÓN DE VITAMINA D ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005207-30,0,0,0 2016-005208-24,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Prof. Harry Siristatidis,"A prospective, multicenter, double-blind, randomized, placebo-controlled, two-parallel groups Phase IIIb clinical study, to assess the efficacy and safety of adding low doses of hCG at a short IVF pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005208-24,0,0,0 2016-005210-22,1,2018-10-11,2018-10-11,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,BOOG Study Center,Explorative trial to identify the impact of denosumab on the systemic immunity and local immunologic microenvironment in postmenopausal patients with HER2 negative breast cancer. Exploratieve studi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005210-22,0,0,0 2016-005214-21,1,,,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,Grupo Español de Enfermedades Mieloproliferativas GEMFIN,Phase Ib/II clinical trial of ruxolitinib in combination with nilotinib and prednisona for myelofibrosis: RuNiC study Ensayo Clínico fase Ib/II de ruxolitinib en combinación con nilotinib y prednis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005214-21,0,0,0 2016-005215-41,1,,,0,0,0,0,1,3,4,0,0,0,0,0,0,0,0,Olli Leppänen,"DupuytrEn Treatment EffeCtiveness Trial (DETECT): a protocol for prospective, randomized, controlled, outcome assessor-blinded, three armed parallel 1:1:1, multicenter trial comparing efficacy and cos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005215-41,0,0,0 2016-005223-88,3,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10 to <18 years) with Type 2 Dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005223-88,0,1,0 2016-005225-37,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Sahlgrenska University Hospital,The ASTEROID trial - Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An open label randomized phase II trial with durvalumab following Stereotactic Body radiotherapy (SBRT) in patients ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005225-37,0,0,0 2016-005226-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI),"Phase 4 clinical trial, randomized to evaluate the effect on immune recovery of triple antiretroviral maintenance therapy (elvitegravir / cobicistat 150/150 mg + tenofovir + emtricitabine alapenamide ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005226-11,0,0,0 2016-005228-27,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust,INTERIM: a randomised phase II feasibility study of INTERmittent versus continuous dosing of oral targeted combination therapy In patients with BRAFV600 mutant stage 3 unresectable or metastatic Melan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005228-27,0,0,0 2016-005230-30,3,2019-06-19,2019-06-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"SPYRYX BIOSCIENCES, INC.","A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of SPX-101 Inhalation Solution in Subjects with Cystic Fibrosis (HOPE-1 STUDY: HYDRATION FOR OPTIMAL P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005230-30,0,0,0 2016-005230-30,3,2019-06-19,2019-06-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Spyryx Biosciences, Inc.","A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of SPX-101 Inhalation Solution in Subjects with Cystic Fibrosis (HOPE-1 STUDY: HYDRATION FOR OPTIMAL P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005230-30,0,0,0 2016-005238-31,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas Progressing after First-Line Platinum- based Therapy Studio di ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005238-31,0,0,0 2016-005241-23,1,2022-03-30,2022-03-30,1,1,0,0,0,0,2,0,0,1,0,0,0,0,0,Odense Universitetshospital,Lonsurf - RII Lonsurf (TAS-102) with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer. A randomized phase II study Lonsurf - RII Lonsurf (TAS-102) med eller u...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005241-23,0,0,0 2016-005244-42,2,,,0,0,0,0,0,2,2,0,0,2,1,0,0,0,0,Leiden University Medical Center,"An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Rich Tumors of Bone DENOEUROSARC-007 - Etude de phase 2 multicentrique, en ouvert du denosumab chez des patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005244-42,0,0,0 2016-005246-31,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Complexo Hospitalario Universitario de Pontevedra,"Analgesic effectiveness of ultrasound-guided bilateral Transversus Abdominis Plane (TAP) block technique for laparoscopic radical prostatectomy: a prospective, randomized, simple-blind study Efica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005246-31,0,0,0 2016-005248-41,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,KU Leuven - Drug Delivery and Disposition,Influence of gastrointestinal lipid digestion in the absorption of fenofibrate from a lipid-based formulation Invloed van gastrointestinale lipide digestie op de opname van fenofibraat uit een lipi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005248-41,0,0,0 2016-005251-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CONSORZIO ONCOTECH,"CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multi-center, pros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005251-25,0,0,0 2016-005252-21,1,2019-03-12,2019-03-12,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Netherlands Cancer Institute,Increasing pazopanib exposure by splitting intake moments Blootstelling aan pazopanib verhogen door het spreiden van inname momenten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005252-21,0,0,0 2016-005284-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"DIPARTIMENTO DI SCIENZE BIOMEDICHE SPERIMENTALI E CLINICHE, UNIVERSITà DI FIRENZE","A 2 arm, phase II controlled randomized trial comparing efficacy and safety of abiraterone and abiraterone associated with Ablative Radiation Therapy in patients with Oligometastatic castration resist...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-005284-13,0,0,0 2017-000039-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,"Paracetamol to enhance quality of life and daily function and to decrease care dependency in advanced dementia: A randomized, double-blind, placebo-controlled crossover trial in long-term care facilit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000039-16,0,0,0 2017-000040-17,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Inserm-ANRS,"Randomized, open-label and multicentric trial evaluating the non-inferiority of antiretroviral treatment taken 4 consecutive days per week versus continuous therapy 7/7 days per week in HIV-1 infected...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000040-17,0,0,0 2017-000042-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GAP MALLORCA,"Randomized, pragmátic, open-label clinical trial with blind evaluator, to evaluate the efficacy efficacy of continuing drug treatment in patients with advanced dementia. Ensayo clínico, pragmático,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000042-22,0,0,0 2017-000043-40,1,2018-09-30,2018-09-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Academic Medical Center,GLP-1 for bridging of hyperglycaemia during cardiac surgery: a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000043-40,0,0,0 2017-000044-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación PETHEMA,"Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab, 18 cyc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000044-18,0,0,0 2017-000047-41,3,2019-01-02,2019-01-02,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Faraday Pharmaceuticals, Inc.","A Phase 2A, Randomized, Double-Blind, Placebo- Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000047-41,0,0,0 2017-000048-17,8,2020-12-17,2020-12-17,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Novo Nordisk A/S,"A trial comparing the effect and safety of insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000048-17,1,0,0 2017-000048-17,8,2020-12-17,2020-12-17,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,NOVO NORDISK. S.P.A.,"A trial comparing the effect and safety of insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000048-17,1,0,0 2017-000050-18,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase II, Multicenter, Open-Label, Noncomparative Study of Raltegravir (MK-0518) in Two Oral Formulations in Combination with Other Antiretroviral Agents to Evaluate the Safety, Tolerability, and An...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000050-18,0,1,1 2017-000057-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,A prospective randomized double-blind study Intranasal dexmedetomidine versus intranasal S-ketamine for children age 1 – 3 years for procedural sedation and analgesia in pediatric emergency department...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000057-40,0,0,0 2017-000058-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin",Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial Perkutaner Verschluss des...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000058-21,0,0,0 2017-000062-30,2,2018-02-13,2018-02-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Zealand Pharma A/S,"A phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon And GlucaGen® Administered Subcutaneously in Patients with Type 1 Diabetes Mellitus (T1D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000062-30,0,0,0 2017-000064-15,1,2019-04-17,2019-04-17,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,"Akari Therapeutics Plc,","A Phase 2, single arm study of Safety and Efficacy of Coversin in adult aHUS subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000064-15,0,0,0 2017-000065-73,8,2020-08-31,2020-08-31,5,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Swedish Orphan Biovitrum AB (publ),"A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed with rFVIIIFc within a Timeframe of 60 Weeks in Severe Haemophilia A Patients with Inhibitors who have Failed P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000065-73,0,0,0 2017-000065-73,8,2020-08-31,2020-08-31,5,1,0,0,0,1,4,0,0,1,0,0,1,0,1,SWEDISH ORPHAN BIOVITRUM AB (PUBL),"A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed with rFVIIIFc within a Timeframe of 60 Weeks in Severe Haemophilia A Patients with Inhibitors who have Failed P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000065-73,0,0,0 2017-000066-29,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Galderma R&D,"Subject reported outcomes on satisfaction, efficacy and safety with Luxerm® in the field-directed treatment of thin or non-hyperkeratotic and non-pigmented Actinic Keratosis of the face or the scalp",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000066-29,0,0,0 2017-000068-14,1,2018-06-08,2018-06-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Institut for Klinisk Medicin, Aarhus Universitet",Postoperative analgesia after elective hip surgery - effect of obturator nerve blockade Postoperativ analgesi efter elektiv hoftekirurgi – effekt af nervus obturatorius-blokade,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000068-14,0,0,0 2017-000069-57,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BIOPROJET PHARMA,A Multisite Randomized Clinical Trial Evaluating BP1.3656 Versus Placebo For Alcohol Use Disorder Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000069-57,0,0,0 2017-000070-11,10,2022-05-12,2022-05-12,5,0,1,0,0,0,3,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK 6072, Human Monoclonal Antib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000070-11,1,1,0 2017-000070-11,10,2022-05-12,2022-05-12,5,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Merck Sharp & Dohme Corp.,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK 6072, Human Monoclonal Antib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000070-11,1,1,0 2017-000071-90,1,2018-01-27,2018-01-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Ghent University Hospital,Effect of sevoflurane and propofol on hepato-splanchnic pressure and flow during hepatobiliary surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000071-90,0,0,0 2017-000073-36,1,2020-03-05,2020-03-05,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,CHU de Nantes,"Effets de l’osmothérapie continue par sérum salé hypertonique sur le devenir des patients traumatisés crâniens - Etude multicentrique, prospective, contrôlée, randomisée, en simple aveugle avec évalua...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000073-36,0,0,0 2017-000075-85,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Karolinska Institutet,"A phase 3, randomised, double-blind, placebo-controlled, parallel-arm efficacy trial of Imatinib in acute ischaemic stroke",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000075-85,0,0,0 2017-000076-28,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) HARBORING A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000076-28,0,0,0 2017-000076-28,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) HARBORING A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000076-28,0,0,0 2017-000076-28,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Roche Farma S.A (Soc.Unipersonal) que realiza el ensayo,A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) HARBORING A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000076-28,0,0,0 2017-000082-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL),Study of the communication of the hypothalamus with the periphery: impact of metformin on leptin transport in the cerebrospinal fluid of obese patients. A monocentric prospective study Etude de la ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000082-72,0,0,0 2017-000084-32,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Centre for Human Drug Research,A study to characterize the humoral and cellular response following simultaneous immunization with a neo-antigen (KLH) and a recall antigen (tetanus) in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000084-32,0,0,0 2017-000086-74,5,2022-07-13,2022-07-13,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,European Organisation for Research and Treatment of Cancer,"A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck ""UPSTREAM""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000086-74,1,0,0 2017-000086-74,5,2022-07-13,2022-07-13,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),"A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck ""UPSTREAM""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000086-74,1,0,0 2017-000086-74,5,2022-07-13,2022-07-13,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,EORTC AISBL/IVZW,"A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck ""UPSTREAM""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000086-74,1,0,0 2017-000087-15,4,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015 (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON’S DISEASE WITH A 52 WEEK BLINDED ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000087-15,0,0,0 2017-000089-31,1,2021-12-21,2021-12-21,1,0,0,0,0,0,4,0,1,1,0,0,0,0,0,Leiden University Medical Center,Single dose rabies PRE-exposure Priming induces a rapid and effective anamnestic Antibody REsponse Inprenting van het immuungeheugen met een enkele dosis rabies vaccin zorgt voor een snelle en eff...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000089-31,0,0,0 2017-000091-28,4,2019-01-12,2019-01-12,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & développement,"Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Safety Extension P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000091-28,0,0,0 2017-000092-84,1,2021-03-08,2021-03-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & développement,"A 26-week, Randomized, Open-label, Parallel-group Comparison of SAR341402 Mix 70/30 to NovoMix®30 in Adult Patients with Diabetes Mellitus Using Pre-mix Insulin Analogs",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000092-84,0,0,0 2017-000093-11,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase 3b, Open Label, Controlled, Multi-Center, Extension Study to Athe Persistence of Bactericidal Activity at 4 to 7.5 Years After Two Dose Primary Series of GlaxoSmithKline Biologicals Meningococ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000093-11,0,1,1 2017-000094-36,1,,,0,0,0,0,0,1,2,0,1,0,0,0,0,0,0,Skåne University Hospital,The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders BioFINDER 2 studien - förbättrad diagnostik och ökad förståelse av sjukdomsmek...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000094-36,0,0,0 2017-000095-28,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Eli Lilly and Company,A Phase II Study of Pemetrexed in Children with Recurrent Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000095-28,0,1,1 2017-000098-35,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,SERVICIO DE ANESTESIOLOGÍA Y REANIMACIÓN HOSPITAL UNIVERSITARIO LA PAZ,"COMPARATIVE STUDY OF NAUTICS AND VOMITING IN THREE ANESTHETICAL REGIMENS: INTRAVENOUS, INHALATORY AND MIXED. ESTUDIO COMPARATIVO DE NÁUSEAS Y VÓMITOS EN TRES REGÍMENES ANESTÉSICOS: INTRAVENOSO, INH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000098-35,0,0,0 2017-000099-27,1,2020-01-06,2020-01-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,The Department of Urology,Toxicity of first-line abiraterone versus enzalutamide in men with metastatic castration-resistant prostate cancer: A randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000099-27,0,0,0 2017-000100-20,3,2019-10-24,2019-10-29,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,SCS Boehringer Ingelheim Comm. V,"Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment with BI 655130 in Patients with Active Ulcerative Colitis (UC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000100-20,0,0,0 2017-000100-20,3,2019-10-24,2019-10-29,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Limited,"Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment with BI 655130 in Patients with Active Ulcerative Colitis (UC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000100-20,0,0,0 2017-000100-20,3,2019-10-24,2019-10-29,3,1,0,0,0,0,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment with BI 655130 in Patients with Active Ulcerative Colitis (UC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000100-20,0,0,0 2017-000105-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AIO-Studien-gGmbH,Neoadjuvant anti PD-1 immunotherapy in resectable non-small cell lung cancer Neoadjuvante anti-PD-1 Immuntherapie bei operablem nichtkleinzelligen Lungenkrebs,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000105-20,0,0,0 2017-000106-38,8,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,CELGENE CORPORATION,"A Phase 2, Single-arm, Multi-cohort, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000106-38,0,0,0 2017-000106-38,8,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Celgene Corporation,"A Phase 2, Single-arm, Multi-cohort, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects with Aggressive B-Cell Non-Hodgkin Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000106-38,0,0,0 2017-000108-42,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,"Merck & Co., Inc.","A Phase IIa Randomized, Double-Blinded, Controlled With GARDASIL™ Clinical Trial to Study the Tolerability and Immunogenicity of V505 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like-Particle [...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000108-42,0,1,1 2017-000109-19,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,"Merck & Co., Inc.","A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging Study of Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000109-19,0,1,1 2017-000110-35,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Merck & Co., Inc.",Evaluation of Safety and Immunogenicity of GARDASIL™ in Healthy Females Between 9 and 26 Years of Age in SubSaharan Africa.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000110-35,0,1,1 2017-000111-16,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Merck & Co., Inc.","Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in healthy females 9 to 15 years of age in India.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000111-16,0,1,1 2017-000112-42,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,"Banyu Pharmaceutical Co., Ltd. a subsidiary of Merck & Co., Inc, Kenilworth, New Jersey",A Phase II Double-Blind Comparative Study of V501 in Females Aged 9 to 17 Years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000112-42,0,1,1 2017-000114-30,3,2019-11-12,2019-11-12,2,0,0,0,0,1,2,0,0,1,1,1,1,0,1,ASLAN Pharmaceuticals,"A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF VARLITINIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER AS SECON...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000114-30,0,0,0 2017-000114-30,3,2019-11-12,2019-11-12,2,0,0,0,0,1,2,0,0,1,1,1,1,0,1,ASLAN Pharmaceuticals Pte. Ltd.,"A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF VARLITINIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER AS SECON...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000114-30,0,0,0 2017-000116-42,1,2017-05-17,2017-05-17,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Ghent University Hospital,A clinical study of biomarkers of innate and adaptive immune activation associated with symptoms and immune responses after administration of a single dose of a quadrivalent inactivated split virus in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000116-42,0,0,0 2017-000123-28,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Jules Bordet,Multiorgan Metabolic imaging response assessment of Abemaciclib: the MiMe-A trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000123-28,0,0,0 2017-000124-95,1,2019-11-02,2019-11-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Oxford,Randomised Controlled Crossover Trial of Inhaled Furosemide for Dyspnoea Relief in Advanced Heart Failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000124-95,0,0,0 2017-000125-13,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc,"A Multi-center, Open-label, Non-controlled Study To Evaluate The Efficacy And Safety Of Lorazepam Intravenously Administered In Subjects With Status Epilepticus Or Repetitive Status Epilepticus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000125-13,0,1,1 2017-000128-81,2,2017-09-22,2017-10-24,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, New York","PHASE 2, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY AND TOLERABILITY OF PF-06649751 IN SUBJECTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000128-81,0,0,0 2017-000129-12,8,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,PHARMACYCLICS SWITZERLAND GMBH,Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000129-12,0,0,0 2017-000129-12,8,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,Pharmacyclics LLC,Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000129-12,0,0,0 2017-000131-13,1,2020-01-31,2020-01-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KU Leuven,Pharmacokinetics of Celebrex for the prevention/treatment of colorectal cancer: Systemic pharmacokinetics and elimination of Celebrex in healthy volunteers Farmacokinetiek van Celebrex in het kad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000131-13,0,0,0 2017-000133-31,1,2020-12-03,2020-12-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,UZ Gent,Combined hypofractionated stereotactic body radiotherapy with immunomodulating systemic therapy for inoperable recurrent head and neck cancer: detection of the maximum tolerated dose. Gecombineer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000133-31,0,0,0 2017-000135-14,5,2020-03-02,2020-03-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PREXTON THERAPEUTICS B.V.,"A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Red...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000135-14,0,0,0 2017-000135-14,5,2020-03-02,2020-03-02,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Prexton Therapeutics B.V.,"A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Red...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000135-14,0,0,0 2017-000136-34,6,2019-07-19,2019-08-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A multicenter, partially-blinded, randomized, 24-week, parallel-group, non-inferiority, open-label active controlled study to compare the efficacy and safety of QVM149 with a free triple combination o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000136-34,0,0,0 2017-000136-34,6,2019-07-19,2019-08-19,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A multicenter, partially-blinded, randomized, 24-week, parallel-group, non-inferiority, open-label active controlled study to compare the efficacy and safety of QVM149 with a free triple combination o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000136-34,0,0,0 2017-000137-31,1,2019-07-01,2019-07-01,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,VU University Medical Center,Pulmonary Hypertension REversal in Clusters of Patients With Identical Pathobiological Substrates. 6-Mercaptopurine Proof-of-Concept Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000137-31,0,0,0 2017-000141-52,1,2019-05-09,2019-05-09,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Asbjørn Mohr Drewes,"The effect of tapentadol on the human pain system: A study based on advanced neurophysiology and imaging techniques to illustrate the mechanism of tapentadol and oxycodone in the central, autonomic an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000141-52,0,0,0 2017-000142-22,1,2019-01-17,2019-01-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Helm AG,"Assessment of therapeutical equivalence of a newly developed vaginal tablet containing 10 μg of estradiol in comparison with a marketed reference product (Vagifem®) – a double-blind, double-dummy, mul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000142-22,0,0,0 2017-000144-18,2,2019-06-20,2019-06-20,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,TIZIANA LIFE SCIENCES PLC,Phase IIA Exploratory Study of Oral Milciclib Maleate in Patients with Unresectable or Metastatic Hepatocellular Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000144-18,0,0,0 2017-000144-18,2,2019-06-20,2019-06-20,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Tiziana Life Sciences Plc,Phase IIA Exploratory Study of Oral Milciclib Maleate in Patients with Unresectable or Metastatic Hepatocellular Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000144-18,0,0,0 2017-000145-40,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,montserrat zamora brito,Use of acupuncture for the reduction of hospital admissions in the induction of labor due to chronologically prolonged gestation. ACUPUNT STUDY Uso de acupuntura para la reducción de ingresos hosp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000145-40,0,0,0 2017-000146-21,4,2021-02-02,2021-02-02,1,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"Amicus Therapeutics UK, Ltd","AN OPEN-LABEL STUDY OF THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF 12-MONTH TREATMENT WITH MIGALASTAT IN PEDIATRIC SUBJECTS (AGED 12 TO <18 YEARS) WITH FABRY DISEASE AND AMENABLE G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000146-21,1,0,0 2017-000146-21,4,2021-02-02,2021-02-02,1,1,1,0,0,1,3,0,0,2,0,0,0,0,1,"Amicus Therapeutics, UK Ltd","AN OPEN-LABEL STUDY OF THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF 12-MONTH TREATMENT WITH MIGALASTAT IN PEDIATRIC SUBJECTS (AGED 12 TO <18 YEARS) WITH FABRY DISEASE AND AMENABLE G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000146-21,1,0,0 2017-000149-30,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospitals of Leicester NHS Trust,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000149-30,0,0,0 2017-000151-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Universitario La Paz,Antiretroviral therapy proviral genotype-guided: pilot-proof of concept clinical trial. Tratamiento antirretroviral guiado por genotipo proviral: ensayo clínico piloto de prueba de concepto.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000151-10,0,0,0 2017-000152-26,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,0,Technische Universität München Fakultät für Medizin,Intraoperative wound irrigation to prevent surgical site infection after laparotomy Intraoperative Wundspülung zur Prävention von postoperativen Wundinfektionen nach Laparatomie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000152-26,0,0,0 2017-000154-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,A phase II randomized trial comparing alpelisib and fulvestrant versus chemotherapy as maintenance therapy in patients with PIK3CA mutated advanced breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000154-19,0,0,0 2017-000155-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNICANCER,"An open label, randomized, phase III study, evaluating the efficacy of a Combination of Apalutamide with Radiotherapy and LHRH Agonist in high-risk postprostatectomy biochemically relapsed prostate ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000155-21,0,0,0 2017-000157-40,4,2018-01-23,2018-01-23,4,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Galderma R&D SNC,Efficacy comparison of Ivermectin 1% topical cream associated with Doxycycline 40 mg Modified release (MR) capsules versus Ivermectin 1% topical cream associated with Placebo in the treatment of seve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000157-40,0,0,0 2017-000158-21,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Karolinska Institutet,Ferroglycine Sulfate Absorption in patients with Heart Failure and Iron Deficency: an interventional before and after study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000158-21,0,0,0 2017-000159-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHRU TOURS,Targeted delivery of chemotherapy with ultrasound and microbubbles Délivrance ciblée de chimiothérapie par ultrasons et microbulles,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000159-15,0,0,0 2017-000160-15,13,2021-11-26,2021-11-26,10,0,0,0,0,0,3,0,0,2,0,0,0,0,1,MYOVANT SCIENCES GMBH,"HERO - MVT -601-3201: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer HERO - MVT -601-320...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000160-15,1,0,0 2017-000160-15,13,2021-11-26,2021-11-26,10,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Myovant Sciences GmbH,"HERO - MVT -601-3201: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer HERO - MVT -601-320...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000160-15,1,0,0 2017-000161-75,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University College London,An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer fo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000161-75,0,0,0 2017-000162-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Place de la scintigraphie au 99mTc-Leukoscan® dans la prise en charge diagnostique des suspicions d’endocardite infectieuse sur matériels Place de la scintigraphie au 99mTc-Leukoscan® dans la prise...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000162-30,0,0,0 2017-000166-30,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,A Multicenter Post Marketing Surveillance Study to Monitor the Safety of GSK Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subject...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000166-30,0,1,1 2017-000169-60,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU University Medical Center,A phase 2 study of nivolumab combined with daratumumab with or without low dose cyclophosphamide in relapsed/refractory multiple myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000169-60,0,0,0 2017-000174-11,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc",Safety and Efficacy of Aripiprazole in the Long-Term Maintenance Treatment of Pediatric Subjects with Irritability Associated with Autistic Disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000174-11,0,1,1 2017-000175-86,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization,","A 52-Week, Open-label, Multicenter Study of the Safety and Tolerability of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents with Autistic Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000175-86,0,1,1 2017-000177-37,1,2019-01-30,2019-01-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,King's College London,Low-dose IL-2 to expand endogenous regulatory T cells and achieve tolerance in liver transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000177-37,0,0,0 2017-000177-37,1,2019-01-30,2019-01-30,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,King's College Hospital,Low-dose IL-2 to expand endogenous regulatory T cells and achieve tolerance in liver transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000177-37,0,0,0 2017-000178-13,1,2018-11-19,2018-11-19,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust,How Effective are Topical NSAIDs in the Treatment of Hip Osteoarthritis: An In Vivo Study in Patients Undergoing Total Hip Arthroplasty,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000178-13,0,0,0 2017-000179-98,1,2018-03-19,2018-03-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.",An Open-Label Study to Evaluate the Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects who Participated in a Prior Gilead-Sponsored HCV Treatmen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000179-98,0,0,0 2017-000180-32,1,2018-02-12,2018-02-12,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Sint Maartenskliniek Nijmegen,"Pharmacokinetic Profile of Ropivacaine after Periarticular Local Infiltration Analgesia for Primary Total Knee Arthroplasty Without the use of a Tourniquet. Farmacokinetiek van ropivacaïne, gebruik...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000180-32,0,0,0 2017-000184-32,9,2019-12-30,2019-12-30,6,1,0,0,0,1,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000184-32,1,1,0 2017-000184-32,9,2019-12-30,2019-12-30,6,1,0,0,0,1,3,0,0,2,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000184-32,1,1,0 2017-000184-32,9,2019-12-30,2019-12-30,6,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"GlaxoSmithKline, S.A.","A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000184-32,1,1,0 2017-000186-76,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects with Perennial Allergic Rhinitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000186-76,0,1,1 2017-000187-15,2,2019-09-04,2019-09-04,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000187-15,0,0,0 2017-000188-33,3,2019-01-31,2019-01-31,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000188-33,0,0,0 2017-000189-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Pannon Reprodukciós Intézet B.1.2,Optimization and Safety Testing of Hormone Normalization Therapy in Advanced Maternal Age Infertile Women A Hormon Normalizációs Kezelés optimalizálása és biztonságosságának vizsgálata előrehaladod...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000189-31,0,0,0 2017-000192-86,1,2019-07-15,2019-07-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Medizinische Universität Innsbruck, Universitätsklinik für Neurologie","Nabilone for non-motor symptoms in Parkinson´s disease: A Randomized Placebo-controlled, double-blind, parallel-group, enriched enrollment randomized withdrawal Study Nabilon für nicht-motorische S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000192-86,0,0,0 2017-000197-11,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,0,Pfizer Inc.,Post Marketing Surveillance Study To Evaluate The Safety And Efficacy Of Vfend® IV,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000197-11,0,1,1 2017-000200-23,1,2020-09-16,2020-09-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,UZ Brussel,Phase II clinical trial on the combination of avelumab and axitinib for the treatment of patients with recurrent glioblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000200-23,0,0,0 2017-000202-37,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,AGO Research GmbH,Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer – a randomized Phase III trial Atezolizumab en combinación con Bevacizu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000202-37,0,0,0 2017-000204-15,1,2019-04-26,2019-04-26,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,"Professor, DMSc Tina Vilsbøll",Glimepiride monotherapy vs. combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes Glimepiridbehandling vs. kombinationsbehandling med glimepirid og linagliptin i patie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000204-15,0,0,0 2017-000205-21,4,2019-07-03,2019-07-08,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, subject- and investigator-blinded, placebo-controlled, multi-center, multiple dose study to assess the efficacy and safety of CJM112 in patients with inadequately controlled moderate to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000205-21,0,0,0 2017-000206-38,8,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Studio multicentrico, randomiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000206-38,0,0,0 2017-000206-38,8,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Studio multicentrico, randomiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000206-38,0,0,0 2017-000207-24,4,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A MULTICENTER, INTERNATIONAL, ROLLOVER STUDY OF ALECTINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE OR REARRANGED DURING TRANSFECTION (RET)-POSITIVE CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000207-24,0,0,0 2017-000207-24,4,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A MULTICENTER, INTERNATIONAL, ROLLOVER STUDY OF ALECTINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE OR REARRANGED DURING TRANSFECTION (RET)-POSITIVE CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000207-24,0,0,0 2017-000207-24,4,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A.U. que realiza el ensayo en España y que actúa como representante de F.Hoffmann-La Roche Ltd.,"A MULTICENTER, INTERNATIONAL, ROLLOVER STUDY OF ALECTINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE OR REARRANGED DURING TRANSFECTION (RET)-POSITIVE CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000207-24,0,0,0 2017-000211-16,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Eli Lilly and Company Limited,"F1J-MC-HMFN (a) An Open-Label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000211-16,0,1,1 2017-000212-41,2,2019-05-07,2019-05-07,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","An Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2586881 in Participants with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000212-41,0,0,0 2017-000212-41,2,2019-05-07,2019-05-07,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"An Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2586881 in Participants with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000212-41,0,0,0 2017-000213-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,ARNI-study: ARNI or ARB to arrest progression of nephropathy. ARNI-studie: ARNI of ARB ter voorkoming voortgang chronische nierschade.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000213-23,0,0,0 2017-000214-27,4,2022-04-28,2022-04-28,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Can-Fite BioPharma, Ltd.","A Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study of the efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally in Patients with Moderate-to-Severe Plaque Psoria...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000214-27,1,0,0 2017-000216-42,7,2020-02-10,2020-02-10,7,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"A multi-center, double-blind, placebo-controlled, Phase 3b study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patient’s self-r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000216-42,0,0,0 2017-000219-18,1,2020-04-17,2020-04-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Imperial College London,Psilocybin vs. escitalopram for major depressive disorder: comparative mechanisms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000219-18,0,0,0 2017-000220-10,2,2022-05-11,2022-05-11,1,0,0,0,0,0,2,0,0,2,0,0,0,0,0,Oslo University Hospital,A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with luminal B breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000220-10,1,0,0 2017-000222-35,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Medical University of Vienna,Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients – a randomized controlled trial Effekt von Etelcalcetide auf die kardiale Hypertrophie in Hämodialysepatienten - eine randomi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000222-35,0,0,0 2017-000225-12,2,2020-12-21,2020-12-21,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Janssen Biologics BV,"A Phase 1b Study to Evaluate SIMPONI® (golimumab) Therapy in Children, Adolescents and Young Adults with Pre-Symptomatic Type 1 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000225-12,0,0,0 2017-000227-27,1,2018-04-29,2018-04-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Eske Kvanner Aasvang,"Effect of high versus low dose intravenous dexamethason on complications in the immediate postoperative setting after mastectomy - a randomized, double-blind, controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000227-27,0,0,0 2017-000228-85,4,2018-01-31,2018-03-12,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,LEO PHARMA A/S,"Incidence of squamous cell carcinoma and other skin neoplasia in subjects with actinic keratosis treated with ingenol disoxate gel 0.018% or 0.037%, or vehicle A phase 3 trial to compare the incidenc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000228-85,0,0,0 2017-000228-85,4,2018-01-31,2018-03-12,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,LEO Pharma A/S,"Incidence of squamous cell carcinoma and other skin neoplasia in subjects with actinic keratosis treated with ingenol disoxate gel 0.018% or 0.037%, or vehicle A phase 3 trial to compare the incidenc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000228-85,0,0,0 2017-000230-62,1,,,0,1,0,0,1,0,3,0,0,4,0,0,0,0,1,Alfresa Pharma Corporation and Sanofi KK,A Phase III study of M071754 - A single-blind study in patients with infantile spasms.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000230-62,0,1,1 2017-000232-34,1,2020-04-30,2020-04-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Clínica Universidad de Navarra/Universidad de Navarra,"A multicenter, open-label, single-arm study of the safety and antitumoral efficacy of nivolumab in combination with selective internal radiation therapy (SIRT) using SIR-Spheres for the treatment of p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000232-34,0,0,0 2017-000233-31,1,2020-06-25,2020-06-25,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,RHEACELL GmbH & Co. KG,"An interventional, single arm, multicenter, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-CVU on wound healing of chronic venous ulcer (CVU).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000233-31,0,0,0 2017-000234-57,1,2020-06-29,2020-06-29,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,RHEACELL GmbH & Co. KG,"An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-DFU on wound healing of diabetic neuropathic ulcer (DFU).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000234-57,0,0,0 2017-000235-14,5,2020-05-15,2020-05-15,5,1,0,1,0,0,1,0,0,1,1,1,0,0,1,RHEACELL GmbH & Co. KG,"A RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND, INTERVENTIONAL, MULTICENTER, PHASE I/IIA CLINICAL TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF ALLO-APZ2-PAOD FOR THE TREATMENT OF PERIPHERAL ARTERIA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000235-14,0,0,0 2017-000236-34,6,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Inselspital (University Hospital) Bern,"Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): an international, multicentre, randomised-controlled, two-arm, assessor-bl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000236-34,0,0,0 2017-000236-34,6,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Insel Gruppe AG, Bern University Hospital, Department of Neurology","Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): an international, multicentre, randomised-controlled, two-arm, assessor-bl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000236-34,0,0,0 2017-000238-73,1,2021-12-20,2021-12-20,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000238-73,0,0,0 2017-000239-15,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Sanofi,"An open-label, uncontrolled 4-week study to assess the safety, efficacy and pharmacokinetics of Allegra® (dry syrup formulation) 15 mg or 30 mg twice daily in pediatric patients with perennial allergi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000239-15,0,1,1 2017-000240-17,1,2018-12-17,2018-12-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Bispebjerg University Hospital,Effect of SGLT2 inhibition on coronary microvascular function in type 2 diabetes Effekt af SGLT2 hæmmer på hjertets mikrovaskulære funktion hos patienter med diabetes type 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000240-17,0,0,0 2017-000241-49,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000241-49,0,0,0 2017-000241-49,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000241-49,0,0,0 2017-000241-49,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A.,"A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000241-49,0,0,0 2017-000242-22,3,2020-02-06,2020-02-06,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,STREKIN AG,"A Phase III multicenter, double-blind, placebo-controlled, study evaluating the safety, and efficacy of STR001 treatment in adults with Sudden Sensorineural Hearing Loss",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000242-22,0,0,0 2017-000244-18,12,2018-10-22,2018-10-22,11,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Bayer AG,"A randomized, placebo-controlled, double-blind, parallel-group, multi-center, exploratory dose-response study to assess the efficacy and safety of different oral doses of BAY 1128688 in women with sym...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000244-18,0,0,0 2017-000244-18,12,2018-10-22,2018-10-22,11,1,0,0,0,0,2,0,0,1,1,1,1,0,1,BAYER HEALTHCARE AG,"A randomized, placebo-controlled, double-blind, parallel-group, multi-center, exploratory dose-response study to assess the efficacy and safety of different oral doses of BAY 1128688 in women with sym...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000244-18,0,0,0 2017-000246-21,1,2018-08-08,2018-08-08,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,PledPharma AB,"A Randomised Open Label Exploratory, Safety and Tolerability Study with PP100-01 in Patients Treated with the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000246-21,0,0,0 2017-000250-19,1,2020-11-24,2020-11-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundació Hospital Universitari Vall d'Hebron - Institut de Recersa (VHIR),Effect of calcium dobesilate in early stages of diabetic retinopathy Efecto del dobesilato de calcio en estadios precoces de retinopatía diabética,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000250-19,0,0,0 2017-000251-74,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Sanofi,"An open-label, uncontrolled 4-week study to assess the safety, efficacy and pharmacokinetics of Allegra® (dry syrup formulation) 15 mg or 30 mg twice daily in pediatric patients with atopic dermatitis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000251-74,0,1,1 2017-000255-50,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, open-label, mono-centre, follow-up extension study to evaluate the persistence of immune response to GSK Biologicals’ HPV vaccine in healthy Chinese female subjects who received three dos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000255-50,0,1,1 2017-000257-39,1,2019-02-11,2019-02-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pharma Mar, S.A.","A Phase II, Open-label, Multicenter Study of PM060184 in Patients with Advanced Colorectal Cancer after Standard Treatment Estudio Fase II, Multicéntrico, Abierto de PM060184 en Pacientes con Cánce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000257-39,0,0,0 2017-000262-30,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,DR. REDDY’S LABORATORIES LIMITED,"Efficacy, Safety, Tolerability and Pharmacokinetics of EXN-32 and EXN-44 in patients with Parkinson¿s Disease experiencing motor fluctuations Efficacy, Safety, Tolerability and Pharmacokinetics of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000262-30,0,0,0 2017-000263-32,1,,,0,1,0,1,0,0,1,0,1,4,0,0,0,0,1,"Merck & Co., Inc.","A Double-Blind, Randomized, Placebo-Controlled, Safety and Tolerability Study of Live Pentavalent Human-Bovine Rotavirus Reassortant Vaccine in Chinese Healthy Adults, Children and Infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000263-32,0,1,1 2017-000264-15,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Banyu Pharmaceutical Co., Ltd. a subsidiary of Merck & Co.,Inc, Kenilworth, New Jersey, USA","A phase III randomized, placebo-controlled clinical trial to study the efficacy and safety of V260 in healthy infants in Japan",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000264-15,0,1,1 2017-000265-67,3,2019-07-15,2019-07-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Aprea Therapeutics AB,"PiSARRO-R: p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000265-67,0,0,0 2017-000266-29,7,2020-09-11,2020-09-11,3,1,1,0,0,1,3,0,0,2,1,0,0,0,1,"AveXis, Inc.","Phase 3, Open Label, Single Arm, Single Dose Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies Delivering AVXS 101 by Intravenous Inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000266-29,1,0,0 2017-000266-29,7,2020-09-11,2020-09-11,3,1,1,0,0,1,3,0,0,2,1,0,0,0,1,"AVEXIS, INC.","Phase 3, Open Label, Single Arm, Single Dose Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies Delivering AVXS 101 by Intravenous Inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000266-29,1,0,0 2017-000268-14,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"ASIH Stockholm Södra, Långbro Park","Vitamin D supplementation to palliative cancer patients - A double blind, randomised controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000268-14,0,0,0 2017-000277-37,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000277-37,0,1,1 2017-000278-13,1,,,0,1,0,1,0,0,1,0,1,1,0,0,0,1,1,BIOPROJET PHARMA,Palatability testing in children of a new paediatric formulation of Racecadotril as oral suspension strawberry-flavored administered via an oral graduated syringe compared to the current formulation (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000278-13,0,0,0 2017-000282-68,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"PROF.BRUNANGELO FALINI,DR.SSA MARIA PAOLA MARTELLI,UNIVERSITA' DI PERUGIA","A phase 2a study of the clinical activity and safety of actinomycin D in patients with NPM1-wild type AML (other than APL) aged = 70 years old and/or unfit for intensive chemotherapy, either newly dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000282-68,0,0,0 2017-000284-32,9,2022-05-19,2022-05-19,5,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Shire Human Genetic Therapies, Inc.","A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000284-32,1,0,0 2017-000285-30,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,0,Janssen Research and Development,"Continued access to darunavir/ritonavir (DRV/rtv) in HIV-1 infected adults, adolescents and children aged 3 years and above.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000285-30,0,1,1 2017-000290-37,2,2020-08-31,2020-08-31,1,1,0,0,0,0,4,0,0,2,0,0,0,0,1,Provepharm SAS,Open label clinical study to evaluate the safety and efficacy of ProvayBlueTM (methylene blue injection USP) for the treatment of acquired methemoglobinemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000290-37,1,0,0 2017-000292-83,1,2020-12-24,2020-12-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Servier Deutschland GmbH,"Prospective, Multicenter, Open-label Phase IV trial of Trifluridine/Tipiracil to Evaluate the Health-related Quality of Life in Patients with Metastatic Colorectal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000292-83,0,0,0 2017-000298-35,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Tilburg University,"Oxytocin, friendship and dealing with emotions",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000298-35,0,0,0 2017-000300-26,2,2022-07-25,2022-07-25,1,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Eisai Ltd.,"A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000300-26,1,0,0 2017-000302-37,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospital Southampton Foundation Trust,A phase IIa study of Rituximab and Varlilumab in relapsed or refractory B-cell malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000302-37,0,0,0 2017-000304-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Heinrich-Heine-University Düsseldorf,"Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma Phase II Studie zur Vakzinierung mit lysat-bela...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000304-14,0,0,0 2017-000305-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA,"Assessment of bone response after LHRH-A and Enzalutamide plus minus Zoledronic Acid in prostate cancer patients with hormone sensitive metastatic bone disease: a prospectic, phase II, randomized, mul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000305-21,0,0,0 2017-000307-24,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Pfizer Inc.,AN OPEN LABEL NON-RANDOMIZED STUDY TO CHARACTERIZE THE STEADY STATE PHARMACOKINETICS OF SULFASALAZINE DELAYED RELEASE TABLETS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000307-24,0,1,1 2017-000308-17,3,2021-02-10,2021-02-10,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Diso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000308-17,0,0,0 2017-000314-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Angiología y cirugía vascular. Hospital Universitario La Paz,RANDOMIZED STUDY TO CHECK THE EFFECTIVENESS OF TOPICAL TREATMENT WITH PLATELET- RICH PLASMA IN THE HEALING OF LOWER LIMBS' VENOUS CHRONIC ULCERS ESTUDIO ALEATORIZADO PARA COMPROBAR LA EFECTIVIDAD D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000314-29,0,0,0 2017-000317-22,1,2020-09-28,2020-09-28,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Linköping University,A pilot study of low dose acetylsalicylic acid (ASA) for reduction of breast density and inflammation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000317-22,0,0,0 2017-000318-40,6,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 3, Randomized, Controlled, Open-Label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000318-40,0,0,0 2017-000318-40,6,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Millennium Pharmaceuticals, Inc. (Takeda)","A Phase 3, Randomized, Controlled, Open-Label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000318-40,0,0,0 2017-000319-18,3,2022-04-05,2022-09-15,2,0,0,1,0,0,1,0,0,2,1,0,0,0,1,FIRST WAVE BIOPHARMA INCORPORATION,"A phase I/IIA, three-stage study to investigate the safety, the efficacy and the pharmacokinetics of niclosamide enemas in subjects with active ulcerative proctitis or ulcerative procto-sigmoiditis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000319-18,1,0,0 2017-000319-18,3,2022-04-05,2022-09-15,2,0,0,1,0,0,1,0,0,2,1,0,0,0,1,"First Wave BioPharma, Inc.","A phase I/IIA, three-stage study to investigate the safety, the efficacy and the pharmacokinetics of niclosamide enemas in subjects with active ulcerative proctitis or ulcerative procto-sigmoiditis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000319-18,1,0,0 2017-000320-10,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Hospira Inc,"A Phase III, Randomized, Double-Blind, Dose-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Dexmedetomidine in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000320-10,0,1,1 2017-000321-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ÁREA DE ATENCIÓN INTEGRADA DE ALBACETE,Effectiveness in preventing RAdial Spasm of different vasoDIlators and topic Local Anaesthesia during transradial cardiac catheterization: The E-RADIAL trial. Efectividad en la prevención del espas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000321-12,0,0,0 2017-000322-35,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Celgene Corporation,"A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With and Without...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000322-35,0,0,0 2017-000322-35,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,CELGENE CORPORATION,"A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With and Without...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000322-35,0,0,0 2017-000323-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,CuraVac Europe SA,"A Multi-center, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Myasthenia Gravis Active Targeted Immunotherapy CV-MG01 i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000323-27,0,0,0 2017-000327-27,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.","An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000327-27,0,1,1 2017-000328-85,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Helsinki University Hospital, Obstetrics and Gynecology","Randomized comparative trial between abrupt and tapered mode of discontinuation of longterm hormone therapy: Impact on endothelial function, recurrence of vasomotor symptoms and quality of life Va...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000328-85,0,0,0 2017-000329-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for elderly or frail elderly patients with metastatic colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000329-11,0,0,0 2017-000330-61,1,,,0,1,0,0,0,0,3,0,0,0,0,0,0,0,1,CHIESI ESPAÑA S.A.U.,Effect of Beclometasone dipropionate (BDP) on faecal Calprotectin levels in patients with clinically inactive Ulcerative Colitis at risk of relapse. BeCalCU study Efecto del dipropionato de beclome...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000330-61,0,0,0 2017-000332-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht",Topical or oral antibiotics for children with acute otitis media presenting with ear discharge? Lokaal (oordruppels) of oraal antibioticum voor kinderen met otitis media acuta en een loopoor?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000332-34,0,0,0 2017-000333-31,3,2018-04-05,2018-04-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergy Therapeutics (UK) Ltd.,"A multi-centre, randomised, double blind, placebo controlled study to determine the optimal effective and safe dose of Pollinex Quattro Grass 1.0 mL (Allergy Therapeutics, (UK) Ltd.) for the treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000333-31,0,0,0 2017-000338-70,1,2018-04-02,2018-04-02,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Mundipharma Pharmaceuticals, S.L.",A phase IIIb open randomized clinical trial to compare pain relief between methoxyflurane and standard of care for treating patients with trauma pain in Spanish emergency units. Ensayo clínico fase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000338-70,0,0,0 2017-000342-22,1,2018-08-01,2018-08-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Dr. Luis Fernández-Dr. Jesus Barrio,"A randomized, double-blind, placebo-controlled study of the usefulness of the probiotic 'Lactobacillus reuteri' in the therapy of quadruple eradication of Helicobacter pylori infection in usual clinic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000342-22,0,0,0 2017-000345-46,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CENTRO RICERCHE CLINICHE DI VERONA,"A Phase II Study of Liposomial IrinoTecan (nal-IRI) with 5-Fluorouracil, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer ¿nITRo trial"" Studio di fase II con Irinoteca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000345-46,0,0,0 2017-000347-41,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Modra Pharmaceuticals BV,Safety of extended use of the weekly oral docetaxel formulation ModraDoc006/r in patients with advanced solid tumours Veiligheid van voortgaand gebruik van de wekelijkse orale docetaxel formulerin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000347-41,0,0,0 2017-000348-17,6,2020-12-21,2020-12-21,3,1,0,0,0,1,3,0,0,2,1,0,0,0,1,CSL Behring LLC,"A Double-blind, Randomized-Withdrawal, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Human Plasma-Derived C1-esterase Inhibitor as Add-on to Standard of Care for the Treatment of Ref...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000348-17,1,0,0 2017-000349-30,1,2020-12-16,2020-12-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Academic Medical Center,"Effect of INtervention with DMR, GLP-1 and lifestyle intensification -in Subjects with insulin dePendent type 2 diabetes- on Insulin Requirement and mEtabolic parameters Effect van interventie met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000349-30,0,0,0 2017-000350-19,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"REGENERON PHARMACEUTICALS, INC.","An open-label, randomized, phase 3 clinical trial of REGN2810 versus investigator's choice of chemotherapy in recurrent or metastatic cervical carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000350-19,0,0,0 2017-000350-19,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","An open-label, randomized, phase 3 clinical trial of REGN2810 versus investigator's choice of chemotherapy in recurrent or metastatic cervical carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000350-19,0,0,0 2017-000351-95,4,2020-02-13,2020-02-13,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"REGENERON PHARMACEUTICALS, INC.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALIROCUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000351-95,0,0,0 2017-000351-95,4,2020-02-13,2020-02-13,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALIROCUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000351-95,0,0,0 2017-000353-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST,"The CONFRONT Phase I – II Trial: ACtivatiON oF immune RespONse in paTients with R-M Head and Neck Cancer. Multimodality immunotherapy with Avelumab, short course radiotherapy and Cyclophosphamide in H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000353-39,0,0,0 2017-000355-46,1,2018-04-23,2018-04-23,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Anika Therapeutics, Inc.","A Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal®) to Provide Symptom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000355-46,0,0,0 2017-000358-20,5,2020-10-29,2020-10-29,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,G1 Therapeutics,"Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000358-20,0,0,0 2017-000361-78,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,HOLOSTEM TERAPIE AVANZATE S.R.L.,"PROSPECTIVE, OPEN-LABEL, UNCONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF AUTOLOGOUS CULTURED ORAL MUCOSA GRAFTS FOR URETHRAL RECONSTRUCTION IN PATIENTS DUE TO HYPOSPADIAS TREATMENT FA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000361-78,0,0,0 2017-000364-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"VU University Medical Center, Department of Medical",A randomized phase II/III study of pulsatile high-dose sunitinib versus TAS-102 in patients with metastatic colorectal carcinoma (mCRC). Gerandomiseerde fase II-III studie tussen sunitinib versus T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000364-15,0,0,0 2017-000367-33,4,2020-07-02,2020-07-02,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined with Daratumumab in Participants with Advanced or Metastatic Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000367-33,0,0,0 2017-000367-33,4,2020-07-02,2020-07-02,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Bristol-Myers Squibb International Corporation,Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined with Daratumumab in Participants with Advanced or Metastatic Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000367-33,0,0,0 2017-000368-14,1,,,0,0,0,0,0,0,4,0,1,1,1,1,0,1,0,Sahlgrenska Univerisity Hospital Gothenburg,A head-to-head randomized clinical trial of methylphenidate and lisdexamphetamine treatment for executive functions and global functioning in adults with ADHD En jämförande randomiserad klinisk prö...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000368-14,0,0,0 2017-000369-54,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Intra-arterial Lutetium-177- dotatate for treatment of patients with neuroendocrine tumor liver metastases Gerichtere behandeling van levermetastasen bij patiënten met neuroendocriene tumoren: Intr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000369-54,0,0,0 2017-000370-10,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer: A phase III randomised study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000370-10,0,0,0 2017-000372-29,6,2020-09-23,2020-12-21,4,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Corbus pharmaceuticals Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000372-29,1,0,0 2017-000372-29,6,2020-09-23,2020-12-21,4,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Corbus Pharmaceuticals Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000372-29,1,0,0 2017-000372-29,6,2020-09-23,2020-12-21,4,1,0,0,0,1,3,0,0,2,1,0,0,0,1,"CORBUS PHARMACEUTICALS, INC","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000372-29,1,0,0 2017-000372-29,6,2020-09-23,2020-12-21,4,1,0,0,0,1,3,0,0,2,1,0,0,0,1,"Corbus pharmaceuticals, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000372-29,1,0,0 2017-000373-36,8,2021-02-15,2021-02-16,3,1,0,0,0,1,4,0,0,2,0,0,0,0,1,Bioverativ Therapeutics Inc.,"A Non-controlled, Open-Label, Multicenter, Study of Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects with Inhibitors Undergoing the First ITI Treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000373-36,1,1,0 2017-000373-36,8,2021-02-15,2021-02-16,3,1,0,0,0,1,4,0,0,2,0,0,0,0,1,BIOVERATIV THERAPEUTICS INC,"A Non-controlled, Open-Label, Multicenter, Study of Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects with Inhibitors Undergoing the First ITI Treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000373-36,1,1,0 2017-000376-28,1,2020-05-28,2020-05-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Limited,"A randomised, double-blind, placebo-controlled, mechanistic cardiac magnetic resonance study to investigate the effects of empagliflozin treatment on cardiac physiology and metabolism in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000376-28,0,0,0 2017-000379-96,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Karolinska University Hospital,Pharmacokinetic and pharmacodynamic aspects in children after intranasal administration of the opioid antagonist naloxone Farmakokinetisk och farmakodynamisk studie av opioidantagonisten naloxon h...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000379-96,0,0,0 2017-000381-29,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"SCYNEXIS, Inc.",Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients with Fungal Diseases that are Refractory to or Intolerant of Standard Antifungal Treatment (FURI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000381-29,0,0,0 2017-000384-32,2,2019-09-23,2019-09-23,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Merck KGaA,"A Phase IIb, Randomized, Double blind Study in Subjects with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Subjects with an Inadequate Response to Met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000384-32,0,0,0 2017-000386-77,1,2020-04-08,2020-04-08,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Effectiveness of Extended Release Methylphenidate in Reducing Cannabis Use in Young Cannabis-Dependent Patients with Attention Deficit Hyperactivity Disorder (ADHD) Efficacité du Méthylphénidate ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000386-77,0,0,0 2017-000387-14,6,2022-03-01,2022-03-01,3,0,1,0,0,1,2,0,0,2,0,0,0,0,1,"Rhythm Pharmaceuticals, Inc.",Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000387-14,1,0,0 2017-000390-37,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Centre Hospitalier Départemental Vendée de la Roche sur Yon,"Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, randomized, open-label, clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000390-37,0,0,0 2017-000391-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON,"A PHASE II, DOUBLE-BLIND, CONTROLLED, PARALLEL-ARM TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE INFUSION OF ALLOGENIC MESENCHYMAL STEM CELLS IN LUPUS NEPHRITIS (LN) ENSAYO CLÍNICO FASE II...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000391-28,0,0,0 2017-000393-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center utrecht,’Switching anticoagulant management from a VKA to a NOAC-based treatment strategy in frail elderly patients with atrial fibrillation (FRAIL-AF study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000393-11,0,0,0 2017-000394-36,1,2018-09-06,2018-09-06,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Hannover Medical School,Influences of angiotensin-neprilysin inhibition with Sacubitril/Valsartan (ENTRESTO®) on centrally generated sympathetic activity in heart failure patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000394-36,0,0,0 2017-000397-10,7,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,ITALFARMACO S.p.A.,"Open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in all DMD patients who have been previously treated in one of the GIVINOSTAT studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000397-10,0,0,0 2017-000401-21,13,2019-02-15,2019-02-15,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS PHARMA AG,"SKIPPAIN (Speed of onset of SecuKinumab-Induced relief from Pain in Patients with AxIal SpoNdyloarthritis) A 24-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the ef...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000401-21,0,0,0 2017-000401-21,13,2019-02-15,2019-02-15,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"SKIPPAIN (Speed of onset of SecuKinumab-Induced relief from Pain in Patients with AxIal SpoNdyloarthritis) A 24-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the ef...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000401-21,0,0,0 2017-000401-21,13,2019-02-15,2019-02-15,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","SKIPPAIN (Speed of onset of SecuKinumab-Induced relief from Pain in Patients with AxIal SpoNdyloarthritis) A 24-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the ef...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000401-21,0,0,0 2017-000402-38,9,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Gilead Sciences, Inc.","A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Inflammatory Bowel Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000402-38,0,0,0 2017-000402-38,9,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Galapagos NV,"A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Inflammatory Bowel Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000402-38,0,0,0 2017-000403-24,1,2019-02-18,2019-02-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Hannover Medical School,HepNet pilot trial: Multicenter trial for the treatment of chronic hepatitis E with sofosbuvir (SofE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000403-24,0,0,0 2017-000406-38,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,Hospira Inc,"A Phase II/III, Open-Label, Multicenter, Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Neonates Ages ≥ 28 Weeks to ≤ 44 Weeks Gestational Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000406-38,0,1,1 2017-000407-24,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,Hospira Inc,"A Phase II, Randomized, Open-Label, Single Center, Pharmacokinetic and Pharmacodynamic Study of Dexmedetomidine in Pediatric Subjects Aged 12 months through <24 months",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000407-24,0,1,1 2017-000408-71,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Hospira Inc,"A Phase II/Ill, Open-Label, Multicenter, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages 28 Weeks to < 36 Weeks Gestational Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000408-71,0,1,1 2017-000409-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,LYSARC,A phase II study of brentuximab vedotin in patients with relapsed or refractory peripheral T-cell lymphoma treated with gemcitabine followed by brentuximab vedotin maintenance Etude de phase II du ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000409-19,0,0,0 2017-000414-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University of Debrecen Faculty of Medicine, Department of","Administration of Preemptive Analgesia by Dexketoprofen to prevent Acute and Chronic Postcraniotomy Headache. A randomized Placebo Controlled, Single-center Study DEXKETOPROFEN ALKALMAZÁSA PREEMPTÍ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000414-35,0,0,0 2017-000416-42,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IIIb, double-blind, randomized, controlled, multicentre study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 AS04 vaccine administered intramuscularly acc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000416-42,0,1,1 2017-000419-17,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Alliance Foundation Trials (AFT),"A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000419-17,0,0,0 2017-000419-17,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Alliance Foundation Trials, LLC","A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000419-17,0,0,0 2017-000420-95,3,2018-07-18,2018-07-18,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Theracos Sub, LLC","A Phase 3, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effects of Bexagliflozin versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000420-95,0,0,0 2017-000421-13,6,2022-06-30,2022-06-30,1,0,0,0,0,1,0,0,0,2,1,0,0,0,0,ERASMUS MEDICAL CENTER,Newborns with Congenital Diaphragmatic hernia: inhaled Nitric Oxide versus intravenous Sildenafil: an international randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000421-13,1,0,0 2017-000421-13,6,2022-06-30,2022-06-30,1,0,0,0,0,1,0,0,0,2,1,0,0,0,0,Erasmus MC,Newborns with Congenital Diaphragmatic hernia: inhaled Nitric Oxide versus intravenous Sildenafil: an international randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000421-13,1,0,0 2017-000422-36,4,2019-12-09,2019-12-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Samsung Bioepis Co., Ltd.","A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB11 (proposed ranibizumab biosimilar) and Lucenti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000422-36,0,0,0 2017-000424-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,A Safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000424-10,0,0,0 2017-000426-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University of Vienna - Department of Neurology,"Efficacy of Rituximab at low doses in Multiple Sclerosis – A prospective, randomized, double-blind, active controlled, pilo trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000426-35,0,0,0 2017-000427-27,1,2019-04-17,2019-04-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Section for Transfusion Medicine, Capitol Region Blood Bank",Vasculopathic Injury and Plasma as Endothelial Rescue in septic shock (SHOCK) trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000427-27,0,0,0 2017-000429-10,2,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,CHU CAEN,FIVHeMA: Intraventricular fibrinolysis versus external ventricular drainage alone in aneurysmal subarachnoid hemorrhage: a randomized controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000429-10,0,0,0 2017-000431-14,14,2022-02-17,2022-02-17,11,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000431-14,1,0,0 2017-000432-34,1,2017-06-23,2017-06-23,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Fundación SEIMC-GESIDA,"A PHASE III, OPEN-LABEL, MULTICENTRIC CLINICAL TRIAL OF A SINGLE ARM OF 16 LENGTHS OF TIME TO EVALUATE RETENTION WITH ELBASVIR / GRAZOPREVIR PLUS SOFOSBUVIR AND RIBAVIRIN IN PATIENTS WITH HEPATITIS C ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000432-34,0,0,0 2017-000433-30,1,,,0,0,0,0,0,3,2,0,0,3,0,0,0,0,0,University College London,Phase II Trial of Pembrolizumab and Radiotherapy in Cutaneous T cell lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000433-30,0,0,0 2017-000435-13,1,2020-03-03,2020-03-03,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,"University Hospital Frankfurt for its Dermatology Department, Clinical Research","Exploratory study to evaluate changes in inflammatory pattern and analysis for serum biomarkers in patients with active, moderate-to-severe hidradenitis suppurativa after 2-week and 6-week treatment w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000435-13,0,0,0 2017-000437-32,2,2022-03-09,2022-03-09,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose- Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000437-32,1,0,0 2017-000438-79,2,2019-05-27,2019-09-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"Open label, prospective, exploratory study to investigate the effect of inhaled CHF5993 pMDI on central and peripheral airway dimensions in COPD patients by Functional Respiratory Imaging",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000438-79,0,0,0 2017-000439-14,3,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000439-14,0,0,0 2017-000440-18,1,2022-07-15,2022-07-15,1,0,0,1,0,1,1,0,0,1,1,1,0,0,1,Medigene AG,"A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial with Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR Modified T Cells, MDG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000440-18,0,0,0 2017-000442-21,1,2019-04-16,2019-04-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Nantes,"Effects of perioperative administration of dexamethasone on postoperative complications and mortality after non-cardiac major surgery : a randomized, multicentre, double blind, study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000442-21,0,0,0 2017-000445-51,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Henri Becquerel,Efficiency of an antibioprophylaxy (levofloxacin) in patient treated by azacitidine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000445-51,0,0,0 2017-000447-40,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,ASST SANTI PAOLO E CARLO,IMPACT ON BONE MINERAL DENSITY (BMD) OF TDF-SPARING ANTIRETROVIRAL REGIMENS IN HIV-POSITIVE MENOPAUSAL WOMEN AFFECTED BY OSTEOPENIA: THE TENOFOVIR SPARING STRATEGY (TESS) STUDY Impatto dei regimi a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000447-40,0,0,0 2017-000451-14,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"An open, single group, multi-centric, post marketing surveillance (PMS) to monitor the reactogenicity and safety of oral live attenuated human rotavirus (HRV) vaccine, Rotarix when administered accord...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000451-14,0,1,1 2017-000454-18,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase II randomized, observer blind, multicenter study of GlaxoSmithKline (GSK) Biologicals’ combined measles-mumps-rubella-varicella vaccine (MMRV) versus ProQuad, according to a one dose schedule,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000454-18,0,1,1 2017-000456-26,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Vejle Hospital,Predictive value of in-vitro testing anti-cancer therapy sensitivity on tumorspheres from patients with metastatic colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000456-26,0,0,0 2017-000457-39,1,,,0,1,1,0,0,1,3,0,0,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Randomized, Double-blind, Placebo controlled, Crossover Study to Evaluate the Efficacy of Ivacaftor in Subjects with Cystic Fibrosis Who are 6 Years of Age and Older and Have Either a 3849 + 10KB C-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000457-39,0,1,1 2017-000458-20,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A post-marketing surveillance (PMS) study to monitor the safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ human papillo-mavirus (HPV) vaccine (Cervarix) in 3,000 healthy female Filipino...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000458-20,0,1,1 2017-000469-62,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,"Pilot single‐arm clinical trial to evaluate the efficacy, PK interactions and safety of dolutegravir plus 2 NRTIs in HIV‐1‐infected solid organ transplant patients Ensayo clínico piloto de un brazo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000469-62,0,0,0 2017-000472-28,1,2019-01-04,2019-01-04,1,1,0,0,0,0,2,0,1,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2a, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of MK-7264 on Acute Cough in Participants with Induced Viral Upper Respiratory Tract Infecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000472-28,0,0,0 2017-000474-11,5,2022-09-08,2022-09-08,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Intercept Pharmaceuticals, Inc.","A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000474-11,1,0,0 2017-000475-90,9,2020-12-03,2021-12-03,5,1,1,0,0,0,3,0,0,2,0,0,0,0,1,DAIICHI SANKYO INC.,"AN OPEN-LABEL, RANDOMISED, PARALLEL-GROUP, MULTICENTRE, OBSERVATIONAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF EDOXABAN TOSYLATE IN CHILDREN FROM 38 WEEKS GESTATIONAL AGE TO LESS THAN 18 YEARS OF AGE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000475-90,1,0,0 2017-000475-90,9,2020-12-03,2021-12-03,5,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Daiichi Sankyo Inc,"AN OPEN-LABEL, RANDOMISED, PARALLEL-GROUP, MULTICENTRE, OBSERVATIONAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF EDOXABAN TOSYLATE IN CHILDREN FROM 38 WEEKS GESTATIONAL AGE TO LESS THAN 18 YEARS OF AGE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000475-90,1,0,0 2017-000485-29,1,2018-03-30,2018-03-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Dr,Prolonged ENoxapariN in primarY Percutaneous Coronary Intervention; a Pilot Pharmacodynamic study (PENNY PCI study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000485-29,0,0,0 2017-000486-72,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Biofrontera Bioscience GmbH,"A randomized, double-blind, intra-individual, multi-center phase III study to evaluate the safety and efficacy of BF 200 ALA (Ameluz®) versus placebo in the treatment of mild to severe actinic keratos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000486-72,0,0,0 2017-000487-15,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hamilton Health Sciences Corporation through its Population Health Research Institute,CLEAR SYNERGY (OASIS 9) A 2x2 factorial randomized controlled trial of CoLchicine and spironolactonE in patients with myocARdial infarction/SYNERGY Stent Registry – Organization to Assess Strategies...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000487-15,0,0,0 2017-000488-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UMBERTO I - POLICLINICO DI ROMA,"RIFAXIMIN BLUNTED HIGHER LEVELS OF ENDOTOXIN IN CIRRHOSIS PATIENTS: A RANDOMIZED, DOUBLE BLIND, SHORT TERM INTERVENTIONAL TRIAL. MODULAZIONE DEGLI ELEVATI LIVELLI DI ENDOTOSSINA NEI PAZIENTI CON CI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000488-34,0,0,0 2017-000490-36,1,2019-12-11,2019-12-11,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU de Bordeaux,"Etude monocentrique, exploratoire, comparant la TEP/TDM au 68Ga-RM2 à la TEP/TDM au 68Ga-PSMA-617 chez des patients atteints de cancers de la prostate de différents risques métastatiques, candidats à ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000490-36,0,0,0 2017-000494-36,2,2018-04-25,2018-04-25,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Actelion Pharmaceuticals Ltd,"A Phase 2a, multi-center, single-blind, within-subject, placebo-controlled study to assess the pharmacodynamics of ACT-709478 in subjects with photosensitive epilepsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000494-36,0,0,0 2017-000494-36,2,2018-04-25,2018-04-25,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Idorsia Pharmaceuticals Ltd,"A Phase 2a, multi-center, single-blind, within-subject, placebo-controlled study to assess the pharmacodynamics of ACT-709478 in subjects with photosensitive epilepsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000494-36,0,0,0 2017-000495-28,1,2019-06-30,2019-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Respiratory Research Unit, Bispebjerg University Hospital",SIGNATURE - the 6-gene signature as a predictor of response to treatment in severe asthma and ACOS Anvendelse af 6-gen signaturen til at forudsige behandlingseffekt ved svær astma og astma-KOL over...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000495-28,0,0,0 2017-000497-11,5,2021-12-01,2021-12-01,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Alkermes Inc,"A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000497-11,1,0,0 2017-000497-11,5,2021-12-01,2021-12-01,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ALKERMES,"A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000497-11,1,0,0 2017-000498-35,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000498-35,0,0,0 2017-000501-20,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,"Pfizer, Inc.","Voriconazole In High-Risk Patients With Invasive Fungal Infections In Slovakia. An Open, Prospective, Non-comparative Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000501-20,0,1,1 2017-000504-20,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,FONDAZIONE MELANOMA ONLUS,A phase II trial of vemurafenib plus cobimetinib in patients treated with prior first-line systemic immunotherapy for inoperable locally advanced or metastatic melanoma Uno studio clinico di fase I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000504-20,0,0,0 2017-000505-20,1,2018-11-24,2018-11-24,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Eske Kvanner Aasvang,"Effect of high versus low dose intravenous dexamethason on complications in the immediate postoperative setting after nephrectomy- a randomized, double-blind, controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000505-20,0,0,0 2017-000506-37,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Genethon,"CareCN: A phase I/II, open label, escalating dose study to evaluate safety and efficacy of an intravenous injection of GNT0003 (Adeno-associated Viral Vector expressing the UGT1A1 transgene) in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000506-37,0,0,0 2017-000506-37,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,GENETHON,"CareCN: A phase I/II, open label, escalating dose study to evaluate safety and efficacy of an intravenous injection of GNT0003 (Adeno-associated Viral Vector expressing the UGT1A1 transgene) in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000506-37,0,0,0 2017-000508-92,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Institute of Cancer Research,c-TRAK TN: A clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast can...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000508-92,0,0,0 2017-000514-35,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Tampere University Hospital,Prospective Randomised Open-label Trial to Evaluate risk faCTor management in patients with Unruptured intracranial aneurysms (PROTECT-U) Aivovaltimoaneurysmien vuodon ehkäisy lääkehoidon ja yksi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000514-35,0,0,0 2017-000514-35,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Ruprecht-Karls-University Heidelberg, Medical Faculty Mannheim",Prospective Randomised Open-label Trial to Evaluate risk faCTor management in patients with Unruptured intracranial aneurysms (PROTECT-U) Aivovaltimoaneurysmien vuodon ehkäisy lääkehoidon ja yksi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000514-35,0,0,0 2017-000516-42,1,2020-10-05,2020-10-05,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Cell Therapy Ltd (trading as Celixir),"A Phase IIB, Randomised, Double-Blinded, Placebo-Controlled Study of the Efficacy and Safety of Intramyocardial Injection of Allogeneic Human Immunomodulatory Progenitor (iMP) cells in Patients Underg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000516-42,0,0,0 2017-000519-18,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),PIMOC : Personalized targeted therapies in inflammatory complex multi organ disease Personnalisation des traitements de Pathologies Inflammatoires Multi Organes Complexes : PIMOC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000519-18,0,0,0 2017-000521-13,1,2021-03-01,2021-03-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dermapharm AG,"Double-blind, randomised clinical study comparing efficacy and safety of Clindamycin/Benzoyl Peroxide Gel (10 mg/g + 30 mg/g) (Test) vs. DUAC®10 mg/g + 30 mg/g Gel (Reference) vs. Vehicle in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000521-13,0,0,0 2017-000522-36,1,2021-06-02,2021-06-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dermapharm AG,"Double-blind, randomised clinical study comparing efficacy and safety of Clindamycin/Benzoyl Peroxide Gel (10 mg/g + 50 mg/g) (Test) vs. DUAC(R) Akne Gel (Reference) vs. Vehicle in patients with papul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000522-36,0,0,0 2017-000530-54,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Copenhagen,The effect of cannibinols in patients with pancreatic cancer in the palliative state Effekten af medicinsk cannabis på patienter med pancreas cancer i palliativ behandling,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000530-54,0,0,0 2017-000533-31,1,2020-09-10,2020-09-10,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Nottingham University Hospitals NHS Trust,TReatment of Irritable bowel syndrome using Titrated ONdansetron Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000533-31,0,0,0 2017-000537-31,7,2020-08-17,2020-08-17,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN027)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000537-31,0,0,0 2017-000538-78,11,2020-01-03,2020-07-13,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Incyte Corporation,"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft Versus-Host Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000538-78,0,0,0 2017-000538-78,11,2020-01-03,2020-07-13,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,INCYTE CORPORATION,"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft Versus-Host Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000538-78,0,0,0 2017-000540-18,2,2018-08-09,2018-08-09,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor (TEZ/IVA) in an Orkambi-experienced Population Who...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000540-18,0,0,0 2017-000544-17,1,2019-09-20,2019-09-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Eske Kvanner Aasvang,"Effect of high versus low dose intravenous dexamethason on complications in the immediate postoperative setting after periacetabular osteotomy- a randomized, double-blind, controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000544-17,0,0,0 2017-000545-52,4,2021-03-29,2021-06-30,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Galapagos Nv,"A multicenter, open-label, long-term extension safety and efficacy study of filgotinib treatment in subjects with moderately to severely active psoriatic arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000545-52,0,0,0 2017-000549-38,1,2018-08-09,2018-08-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Laboratorios Ojer Pharma S.L.,An open-label study to investigate the local tolerability and acceptability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) on patients with Recurrent Herpes Labialis Estud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000549-38,0,0,0 2017-000552-25,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Daiichi Sankyo Inc.,Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects with Intermediate-Risk (sub-massive) Acute Pulmonary Embolism (PE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000552-25,0,0,0 2017-000554-19,1,2021-02-11,2021-02-11,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,OSPEDALE SAN RAFFAELE,Implication for strategies of long term control of viral replication in patient with primary HIV infection (PHI) treated with multitarget antiviral therapy (MT-ART) Strategie di controllo a lungo t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000554-19,0,0,0 2017-000555-10,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,"Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000555-10,0,0,0 2017-000555-10,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON,"Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000555-10,0,0,0 2017-000556-26,6,2022-06-13,2022-06-13,3,0,0,1,0,0,1,0,0,2,1,0,0,0,1,Agenus Inc.,"A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000556-26,1,0,0 2017-000559-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA,A multicentric randomized PRAGmatic trial to compare the effectiveness of fingolimod versus dimethyl-fumarate on patient overall disease experience in relapsing remitting Multiple Sclerosis: novel da...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000559-26,0,0,0 2017-000560-15,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Intra-individual dose escalation of abiraterone acetate according to its plasma concentration in patients with progressive castration-resistant metastatic prostate cancer Escalade de dose intra-in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000560-15,0,0,0 2017-000562-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fondazione GONO,"A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with NIVolumab in Subjects with Recurrent or Metastatic Platinum-refrACTORy Squamous Cell Carcinoma of the Head and Neck (SCCHN) Stu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000562-30,0,0,0 2017-000565-76,5,2018-11-26,2018-11-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Merrimack Pharmaceuticals, Inc.","SHERBOC: A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000565-76,0,0,0 2017-000569-61,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Bordeaux,Comparison of therapeutic strategies with Cholinesterase Inhibitors: stop or still (SOS) trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000569-61,0,0,0 2017-000571-85,5,2018-03-26,2018-03-26,2,0,0,0,0,1,3,0,0,1,1,1,1,0,1,"ANTHERA Pharmaceuticals, Inc.","A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Cystic Fibrosis-Related Exocrine Pancreat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000571-85,0,0,0 2017-000572-28,9,2020-10-06,2020-10-06,9,1,1,0,0,0,3,0,0,1,1,0,1,0,1,"Shire Human Genetic Therapies, Inc.","A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (FIGARO UC 302)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000572-28,0,0,0 2017-000572-28,9,2020-10-06,2020-10-06,9,1,1,0,0,0,3,0,0,1,1,0,1,0,1,"Shire Human Genetic Therapies, Inc.","A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (FIGARO UC 302)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000572-28,0,0,0 2017-000573-37,19,2021-06-30,2021-07-01,18,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Shire Human Genetic Therapies, Inc.","A Phase 3 Randomized, Double-blind, Placebo controlled, Parallel group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000573-37,1,0,0 2017-000573-37,19,2021-06-30,2021-07-01,18,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"SHIRE HUMAN GENETIC THERAPIES, INC","A Phase 3 Randomized, Double-blind, Placebo controlled, Parallel group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000573-37,1,0,0 2017-000573-37,19,2021-06-30,2021-07-01,18,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Baxalta Innovations GmbH,"A Phase 3 Randomized, Double-blind, Placebo controlled, Parallel group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000573-37,1,0,0 2017-000574-11,19,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Shire Human Genetic Therapies, Inc.","A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis (AIDA) Estudio de fase 3, de extensión de seguridad a largo plazo de SHP647 en sujetos co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000574-11,0,0,0 2017-000574-11,19,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"SHIRE HUMAN GENETIC THERAPIES, INC","A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis (AIDA) Estudio de fase 3, de extensión de seguridad a largo plazo de SHP647 en sujetos co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000574-11,0,0,0 2017-000575-88,10,2020-10-08,2020-10-08,8,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"SHIRE HUMAN GENETIC THERAPIES, INC","A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 305)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000575-88,1,0,0 2017-000575-88,10,2020-10-08,2020-10-08,8,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Shire Human Genetic Therapies, Inc.","A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 305)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000575-88,1,0,0 2017-000576-29,9,2020-08-18,2020-08-18,9,1,1,0,0,0,3,0,0,1,1,0,1,0,1,"Shire Human Genetic Therapies, Inc.","A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 306)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000576-29,0,0,0 2017-000577-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospitals Leuven,"Durvalumab (MEDI4736) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000577-36,0,0,0 2017-000579-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","An open label, single-arm, phase 2 study of pembrolizumab and nanoparticle albumin-bound paclitaxel in patients with metastatic urothelial carcinoma after chemotherapy failure; the PEANUT study Stu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000579-10,0,0,0 2017-000580-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","Cabozantinib plus Ddurvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000580-32,0,0,0 2017-000583-15,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Leiden University Medical Center,Randomized controlled trial on the use of EPO to reduce top-up transfusions in neonates with red blood cell alloimmunization treated with intrauterine transfusions Gerandomiseerde gecontroleerde st...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000583-15,0,0,0 2017-000584-33,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,Belfast Health and Social Care Trust,"Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) trial: An open label dose escalation phase 1 trial followed by a randomised, double-blind, placebo-controlled pha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000584-33,0,0,0 2017-000585-30,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,CHU de Limoges,"Pilot study, single-blind, candesartan versus usual care of peripheral neuropathy development induced by vincristine (PNIV) in patients treated for lymphoma B.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000585-30,0,0,0 2017-000586-72,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Oslo University Hospital,KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000586-72,0,0,0 2017-000589-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SOCIETà CAMPANA DI IMMUNOTERAPIA ONCOLOGICA,multi stage phase II trial of Nivolumab (an anti –PD-1) in patients with platinum resistant Mismatch Repair deficient germinal cells tumours Studio di fase II multi step sul Nivolumab (un anti-PD-1...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000589-31,0,0,0 2017-000594-37,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) Estudio de fas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000594-37,0,0,0 2017-000596-87,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hellenic Institute for the Study of Sepsis,A RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT INFECTIONS OF THE ELDERLY: THE ACTIVATE TRIAL ΜΙΑ ΤΥΧΑΙΟΠΟIΗΜΕΝΗ ΚΛΙΝΙΚΗ ΜΕ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000596-87,0,0,0 2017-000597-11,8,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000597-11,0,0,0 2017-000599-27,9,2020-10-23,2020-10-23,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Shire Human Genetic Therapies, Inc.","A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (FIGARO UC 301)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000599-27,1,0,0 2017-000599-27,9,2020-10-23,2020-10-23,6,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"SHIRE HUMAN GENETIC THERAPIES, INC","A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (FIGARO UC 301)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000599-27,1,0,0 2017-000605-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Formación e Investigación Sanitarias de la Región de Murcia,PERIPHERAL TRANSCUTANEOUS NEUROMODULATION OF THE POST-TIBIAL NERVE (T-PTNS) FOR SOLIFENACIN 10mg. IN THE TREATMENT OF HYPERACTIVE BLADDER SYNDROME: NON-INFERIORITY PHASE IV RANDOMIZED CLINICAL TRIAL ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000605-20,0,0,0 2017-000606-37,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica Hospital Universitario La Paz,Safety and preliminary efficacy study of infusing mesenchymal stem cells derived from bone marrow for treating Recessive Dystrophic Epidermolysis Bullosa. Estudio de seguridad y eficacia preliminar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000606-37,0,0,0 2017-000607-25,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,2,Karyopharm Therapeutics Inc.,"A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000607-25,0,0,0 2017-000607-25,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,2,UZLEUVEN/BGOG,"A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000607-25,0,0,0 2017-000608-13,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A phase III multicentre, parallel-group, randomized, placebo-controlled, double-blind clinical trial to study the efficacy and safety of MK-4117 in Japanese subjects with chronic urticaria.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000608-13,0,1,1 2017-000609-18,1,2017-10-27,2017-10-27,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,Bayer AG,"Single-dose, open-label, randomized, 2-way crossover bioequivalence study of 20 mg granules for oral suspension rivaroxaban versus 20 mg tablets rivaroxaban under fed condition in healthy subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000609-18,0,0,0 2017-000610-26,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000610-26,0,1,1 2017-000611-17,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Alfresa Pharma Corporation and Sanofi KK,A Long term study of M071754 - A open-label study in patients with infantile spasms.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000611-17,0,1,1 2017-000613-22,1,2019-12-04,2019-12-04,1,1,0,0,1,0,2,0,1,1,0,0,1,0,1,Johnson & Johnson Consumer Inc,"A 16 Week, Single-center, Randomized, Placebo- and Active-controlled Proof of Principle Study to Assess the Efficacy and Safety of a 5% Minoxidil Topical Gel Formulation in Male subjects with Androgen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000613-22,0,0,0 2017-000614-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSLO UNIVERSITY HOSPITAL HF,Prevention of graft-versus-host disease in patients treated with allogeneic stem cell transplantation: Possible role of extracorporeal photophoresis Forebygging av transplantat-mot-vert-sykdom hos ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000614-39,0,0,0 2017-000617-23,19,2020-05-29,2021-09-13,17,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"SHIRE HUMAN GENETIC THERAPIES, INC","A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 307)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000617-23,1,0,0 2017-000617-23,19,2020-05-29,2021-09-13,17,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Shire Human Genetic Therapies, Inc.","A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 307)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000617-23,1,0,0 2017-000619-17,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,Common Services Agency (CSA),Phase II neoadjuvant study of Axitinib for reducing extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000619-17,0,0,0 2017-000621-12,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.","A Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000621-12,0,1,1 2017-000622-35,1,2019-01-07,2019-01-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Aalborg University Hospital,"Different dosis of corticosteroids in mandibular third molar surgery. A randomized, blinded clinical trial assessing pain, trismus, edema, and quality of life outcome measurements. En randomisered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000622-35,0,0,0 2017-000623-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundacion para la investigacion biomedica HUPA,"Role of autologous biological therapy in knee osteoarthritis. Intraosseous application of plasma rich in growth factors , improve of functional capacity and pain, compared to intraarticular applicati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000623-27,0,0,0 2017-000624-10,1,2022-03-05,2022-03-05,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,AIO-Studien-gGmbH,Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma - The randomized phase 2 INTEGA ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000624-10,0,0,0 2017-000625-12,3,2020-09-10,2020-09-10,2,1,0,1,0,0,1,0,0,1,1,1,0,0,1,"CytomX Therapeutics, Inc","A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Local...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000625-12,0,0,0 2017-000626-35,4,2019-06-14,2019-07-16,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000626-35,0,0,0 2017-000630-57,7,2019-02-04,2019-02-04,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amgen Inc.,A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000630-57,0,0,0 2017-000632-34,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Anaesthesia and Intensive Care Medicine, Aalborg University Hospital",Handling oxygenation targets in adults with acute hypoxaemic respiratory failure in the intensive care unit: A randomised clinical trial of a lower versus a higher oxygenation target,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000632-34,0,0,0 2017-000635-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Universität Leipzig,Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption Eskalationstherapie des MS-Schubs mit Methylprednisolon vs. Immunadsor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000635-13,0,0,0 2017-000638-75,3,2020-11-06,2020-11-06,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"TG Therapeutics, Inc.",Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000638-75,1,0,0 2017-000638-75,3,2020-11-06,2020-11-06,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,TG Therapeutics,Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000638-75,1,0,0 2017-000639-15,4,2020-11-12,2020-11-12,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,TG Therapeutics,Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000639-15,1,0,0 2017-000639-15,4,2020-11-12,2020-11-12,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"TG Therapeutics, Inc.",Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000639-15,1,0,0 2017-000640-18,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,NANT Operations Centre,"NANT 2015-02: PHASE 1 STUDY OF LORLATANIB (PF-06463922), AN ORAL SMALL MOLECULE INHIBITOR OF ALK/ROS1, FOR PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000640-18,0,0,0 2017-000641-44,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska intitutet,TailorDose®-II: Therapeutic dose monitoring of commonly used cytostatic drugs/regimes indicated for breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000641-44,0,0,0 2017-000642-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Jose Alberola-Rubio,Electromyographic study for the help and guidance of Botox administration in the treatment of chronic pelvic floor pain Estudio electromiográfico para la ayuda y guiado de administración de Botox ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000642-22,0,0,0 2017-000644-17,3,2018-02-24,2018-02-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, repeat dose cross-over study to assess the bronchodilator effects of once daily QVM149 following morning or evening dosing for 14 days compared to placebo in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000644-17,0,0,0 2017-000645-48,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Minna Laine,Open-label study to evaluate efficacy and safety of Cystadane for the treatment of aspartylglucosaminuria Cystadane aspartyyliglukosaminurian hoidossa: tehoa ja turvallisuutta koskeva tutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000645-48,0,0,0 2017-000645-48,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Prof. Ritva Tikkanen,Open-label study to evaluate efficacy and safety of Cystadane for the treatment of aspartylglucosaminuria Cystadane aspartyyliglukosaminurian hoidossa: tehoa ja turvallisuutta koskeva tutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000645-48,0,0,0 2017-000647-40,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,AnaptysBio Inc,Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients with Severe Eosinophilic Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000647-40,0,0,0 2017-000648-16,1,2017-10-27,2017-10-27,1,1,1,0,0,0,1,1,1,1,0,0,1,0,1,Bayer AG,"Single-dose, open-label, randomized, 2-way crossover bioequivalence study of 10 mg granules for oral suspension rivaroxaban versus 10 mg tablets rivaroxaban under fasted condition in healthy subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000648-16,0,0,0 2017-000653-39,1,,,0,1,0,0,0,1,2,0,0,3,0,0,0,0,1,"Imara, Inc","A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients with Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000653-39,0,0,0 2017-000656-26,6,2019-10-10,2019-10-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BAYER AG,"A randomized, double-blind, multicenter study to assess the efficacy and safety of a 6 month oral treatment with the chymase inhibitor BAY 1142524 at a dose of 25 mg BID in comparison to placebo on to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000656-26,0,0,0 2017-000656-26,6,2019-10-10,2019-10-10,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,"A randomized, double-blind, multicenter study to assess the efficacy and safety of a 6 month oral treatment with the chymase inhibitor BAY 1142524 at a dose of 25 mg BID in comparison to placebo on to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000656-26,0,0,0 2017-000657-39,8,2019-05-02,2019-05-02,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Develco Pharma Schweiz AG,"Randomised, double-blind, placebo-controlled, parallel-group, multi-centre, phase III trial to investigate the efficacy, safety and tolerability of Naloxone HCl PR Tablets in patients with opioid indu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000657-39,0,0,0 2017-000658-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Combinated systemic and intratympanic steroid therapy in idiopathic sudden sensorineural hearing loss Kombinált intratympanalis és szisztémás szteroid kezelés hirtelen halláscsökkenés esetén,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000658-20,0,0,0 2017-000659-23,1,2020-10-08,2020-10-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Aarhus University Hospital,A Safety and feasibility study of standard dosing day 1 carboplatin AUC 5 every 3rd weeks with daily Navelbine® 20/30mg (oral) during 4 cycles (12 weeks) for the treatment of advanced NSCLC; A feasibi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000659-23,0,0,0 2017-000662-29,2,,,0,0,0,1,0,1,1,0,0,2,0,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Residual FVIII Levels ≤ 1 IU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000662-29,0,0,0 2017-000663-33,1,,,0,1,0,0,0,1,2,0,0,3,0,0,0,0,1,"Achillion Pharmaceuticals, Inc.","A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000663-33,0,0,0 2017-000664-14,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Belfast Health and Social Care Trust,A 2x2 factorial randomised examiner blind open label trial to determine the CLinical and cost- Effectiveness of hypertonic saline (HTS 6%) and carbocisteine for Airway cleaRance versus usual care over...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000664-14,0,0,0 2017-000665-79,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"ACHILLION PHARMACEUTICALS, INC.",An Open-Label Study to Evaluate Efficacy and Safety of Long-term Treatment with ACH-0144471 in Patients with PNH who Completed Clinical Study ACH471-100,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000665-79,0,0,0 2017-000665-79,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Achillion Pharmaceuticals, Inc.",An Open-Label Study to Evaluate Efficacy and Safety of Long-term Treatment with ACH-0144471 in Patients with PNH who Completed Clinical Study ACH471-100,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000665-79,0,0,0 2017-000672-28,1,,,0,1,0,0,1,1,2,0,0,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, Single-Blind, Placebo-Controlled Study to Evaluate the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis, the G551D Mutation, and FEV1 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000672-28,0,1,1 2017-000673-37,1,,,0,1,0,0,0,1,2,0,0,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis, Residual CFTR Function, and FEV1 ≥40% Predicted",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000673-37,0,1,1 2017-000675-90,2,2017-05-29,2017-05-29,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Amgen Inc.,"A Phase 3b, Multicenter, Randomized, Double-blind, Parallel Group, Alendronate-Controlled Study in Postmenopausal Women with Osteoporosis Previously Treated with Romosozumab Followed by Alendronate Se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000675-90,0,0,0 2017-000676-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,BOOG Study Center,"Tailoring neoadjuvant therapy in hormone receptor positive, HER2 negative, luminal breast cancer. Neoadjuvante therapie op maat in hormoon receptor positieve, HER2 negatieve, luminale borstkanker.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000676-29,0,0,0 2017-000679-10,13,2021-11-18,2021-11-29,10,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to asses...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000679-10,1,0,0 2017-000679-10,13,2021-11-18,2021-11-29,10,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to asses...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000679-10,1,0,0 2017-000684-33,6,2021-04-15,2021-04-15,5,1,1,0,0,1,3,0,0,2,0,0,0,0,1,OxThera Intellectual Property AB,"A phase III double-blind, randomised study to evaluate the long-term efficacy and safety of Oxabact® in patients with primary hyperoxaluria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000684-33,1,0,0 2017-000685-29,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Eli Lilly and Company,"A Phase 3b, Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine Hydrochloride in Korean Pediatric Outpatients With Attention-Deficit/Hyperactivity Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000685-29,0,1,1 2017-000686-68,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Eli Lilly and Company,"Long-Term Extension, Open-Label Study of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000686-68,0,1,1 2017-000687-16,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,AOU FEDERICO II,Novel avenues for the rescue of intellectual disability in Down syndrome NUOVE STRATEGIE PER IL RECUPERO DELLA DISABILIT¿ INTELLETTIVA NELLA SINDROME DI DOWN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000687-16,0,0,0 2017-000688-34,1,,,0,0,0,0,1,0,4,0,0,3,0,0,0,0,0,University of Bristol,The Best Emollient for Eczema (BEE) trial: a randomised trial comparing the effectiveness of four commonly prescribed emollients for children with eczema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000688-34,0,0,0 2017-000689-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie",Expression/DNA methylation of cancer testis antigens may predict response to pembrolizumab in pretreated NSCLC patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000689-30,0,0,0 2017-000690-36,7,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamics Evaluation of Amcenestrant (SAR439859), Administered Orally as Monotherapy, then in Combination with Other AntiCancer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000690-36,0,0,0 2017-000690-36,7,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT,"A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamics Evaluation of Amcenestrant (SAR439859), Administered Orally as Monotherapy, then in Combination with Other AntiCancer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000690-36,0,0,0 2017-000692-92,5,2020-01-28,2020-01-28,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000692-92,0,0,0 2017-000693-11,6,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 4 Double-blinded, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000693-11,0,0,0 2017-000694-37,2,2018-12-14,2018-12-14,2,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University of New South Wales Sydney,"A phase IIIb, open-label, multicentre, international randomised controlled trial of simplified treatment monitoring for 8 weeks glecaprevir (300mg)/pibrentasvir (120mg) in chronic HCV treatment naïve ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000694-37,0,0,0 2017-000695-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitari Germans Trias i Pujol,Pilot study of Vitamin D biological effects in patients with resectable urinary tract urothelial carcinoma. Estudio piloto de los efectos biológicos de la vitamina D en pacientes con carcinoma uro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000695-28,0,0,0 2017-000697-11,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Charité Universitätsmedizin Berlin,"SPIRonolactone In the Treatment of Heart Failure - A double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate the efficacy and safety of spironolactone ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000697-11,0,0,0 2017-000701-21,1,2021-02-11,2021-02-11,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients with Achondroplasia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000701-21,0,0,0 2017-000702-38,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,AstraZeneca AB,"A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium to High-dose Inhaled Corticosteroid Plus Long-a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000702-38,0,1,1 2017-000703-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Vienna; Department of Surgery; Division of Transplantation,Treatment of anemia with intravenous iron in patients listed for orthotopic liver transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000703-24,0,0,0 2017-000704-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Influence of Endotracheal Intubation versus Endotracheal Intubation with Lidocaine on Intracranial Pressure assessed by Optic Nerve Sheath Diameter,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000704-26,0,0,0 2017-000705-20,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Università degli Studi Milano Bicocca,International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000705-20,0,0,0 2017-000706-37,1,2018-12-27,2018-12-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A Patient and Investigator-blinded, randomized, placebo controlled study of LLG783 in patients with peripheral artery disease (PAD) and intermittent claudication.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000706-37,0,0,0 2017-000708-10,6,2021-08-10,2021-08-10,4,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A prospective international multicenter phase II study to evaluate the efficacy, safety and quality of life of oral daily pazopanib in patients with advanced and/or metastatic renal cell carcinoma aft...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000708-10,1,0,0 2017-000708-10,6,2021-08-10,2021-08-10,4,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Farmacéuctica S.A.,"A prospective international multicenter phase II study to evaluate the efficacy, safety and quality of life of oral daily pazopanib in patients with advanced and/or metastatic renal cell carcinoma aft...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000708-10,1,0,0 2017-000708-10,6,2021-08-10,2021-08-10,4,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma Services AG,"A prospective international multicenter phase II study to evaluate the efficacy, safety and quality of life of oral daily pazopanib in patients with advanced and/or metastatic renal cell carcinoma aft...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000708-10,1,0,0 2017-000709-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Bernhoven,The effect of erector spinae block on postoperative pain and opioid use in patients undergoing breast cancer surgery with sentinel node dissection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000709-18,0,0,0 2017-000717-24,1,2018-08-01,2018-08-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Aarhus University Hospital,Concentration of piperacillin in plasma and subcutis in patients on crrt treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000717-24,0,0,0 2017-000718-52,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitario de Canarias,Efficacy of a new formulation of a daily lctp dose of tacrolimus (ENVARSUS®) to prevent diabetes post renal transplant in patients at risk: a controlled randomized open pilot study EFICACIA DE LA N...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000718-52,0,0,0 2017-000719-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,LYSARC,"A multicentre, phase II, open label, single arm study of pixantrone in patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma treated with rituximab, ifosfamide and etoposi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000719-17,0,0,0 2017-000720-98,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Redx Pharma plc,"A Modular, Multi-Arm, Phase 1/2a, Adaptive Design Study To Evaluate The Safety And Tolerability Of RXC004, Alone And In Combination With Anti-Cancer Treatments, In Patients With Advanced Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000720-98,0,0,0 2017-000722-35,1,2021-10-08,2021-10-08,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Ismail Gögenur,Perioperative metformin treatment for colon cancer - a randomized trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000722-35,0,0,0 2017-000724-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Center,Targeting esophageal cancer with HDL nanoparticles: an imaging study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000724-10,0,0,0 2017-000725-12,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"TiGenix, S.A.U.","A phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000725-12,0,0,0 2017-000725-12,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,TIGENIX S.A.U,"A phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000725-12,0,0,0 2017-000732-34,1,2019-05-22,2019-05-22,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,"Mech-Sense, Dept. Gastroenterology & Hepatology, Aalborg University Hospital",Oral Controlled Release Formulations to Patients with Gastrointestinal Dysfunction – Is the Release of Drug and the Absorption Impaired? Frigives og optages lægemidler i depotformuleringer tilstræk...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000732-34,0,0,0 2017-000735-14,1,2020-02-27,2020-02-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Lek-Am Sp. z o.o.,The efficacy and safety of new formulation of combination of fluticasone propionate / salmeterol (125μg / 25μg) in MDI HFA inhaler compared with the reference drug at a dose of 500μg / 50μg in DPI (d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000735-14,0,0,0 2017-000736-33,1,2019-11-12,2019-11-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A randomized, subject and investigator blinded, placebo-controlled, parallel group study to investigate whether AFQ056 reduces cocaine use in patients diagnosed with Cocaine Use Disorder (CUD). Est...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000736-33,0,0,0 2017-000737-31,12,2021-09-07,2021-10-01,7,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Chiasma, Inc.","A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotide capsules in patients who previously tolerated and demonstrated biochemical cont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000737-31,1,0,0 2017-000737-31,12,2021-09-07,2021-10-01,7,1,0,0,0,1,3,0,0,2,0,0,0,0,1,CHIASMA INC.,"A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of octreotide capsules in patients who previously tolerated and demonstrated biochemical cont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000737-31,1,0,0 2017-000739-15,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Eli Lilly and Company,A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000739-15,0,1,1 2017-000740-18,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Eli Lilly and Company,Evaluation of Academic Performance in Asian Children Aged 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Hydrochloride,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000740-18,0,1,1 2017-000742-21,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Gustave Roussy,Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with RA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000742-21,0,0,0 2017-000746-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Dermatology, Zealand University Hospital, Roskilde",Vascular changes in basal cell carcinoma undergoing either electrochemotherapy or conventional topical treatment assessed with optical coherence tomography Vaskulære ændringer i basalcellekræft und...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000746-22,0,0,0 2017-000748-16,7,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Minoryx Therapeutics S.L.,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL, MULTICENTER STUDY WITH OPEN-LABEL TREATMENT EXTENSION TO ASSESS THE EFFECT OF MIN-102 ON THE PROGRESSION OF ADRENOMYELONEUROPATHY IN MALE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000748-16,0,0,0 2017-000748-16,7,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,MINORYX THERAPEUTICS,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL, MULTICENTER STUDY WITH OPEN-LABEL TREATMENT EXTENSION TO ASSESS THE EFFECT OF MIN-102 ON THE PROGRESSION OF ADRENOMYELONEUROPATHY IN MALE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000748-16,0,0,0 2017-000754-19,3,2018-07-03,2018-07-03,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergopharma GmbH & Co. KG,"A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxide a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000754-19,0,0,0 2017-000755-97,1,,,0,0,0,0,1,0,2,0,0,4,0,0,0,0,0,"Defitech Chair in Brain-Machine Interface, EPFL",Brain-computer interface and neuromuscular stimulation for rehabilitation following chronic stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000755-97,0,1,1 2017-000758-20,9,2020-03-26,2020-03-27,8,1,0,0,0,1,2,0,0,1,0,0,1,0,1,UNITED THERAPEUTICS CORPORATION,"A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000758-20,0,0,0 2017-000758-20,9,2020-03-26,2020-03-27,8,1,0,0,0,1,2,0,0,1,0,0,1,0,1,United Therapeutics Corporation,"A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000758-20,0,0,0 2017-000759-20,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000759-20,0,0,0 2017-000759-20,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib or Nivolumab and Ipilimumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, Advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000759-20,0,0,0 2017-000760-15,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"IOVANCE BIOTECHNOLOGIES, INC","A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN 144) for Treatment of Patients with Metastatic Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000760-15,0,0,0 2017-000760-15,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Iovance Biotherapeutics, Inc.","A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN 144) for Treatment of Patients with Metastatic Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000760-15,0,0,0 2017-000762-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MDM S.P.A.,CHOLINA ALPHOSCERATE INJECTION VERSUS CITICOLINE INJECTION IN ELDERLY PATIENTS WITH COGNITIVE IMPAIRMENT RESULTING FROM CEREBROVASCULAR EVENT STUDIO DI CONFRONTO TRA UNA TERAPIA A BASE DI COLINA A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000762-29,0,0,0 2017-000763-33,1,,,0,0,0,1,0,1,1,0,0,1,0,0,0,1,1,"Amgen, Inc.","A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 592 in Adult Subjects with Steroid Refractory Chronic Graft versus Host Diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000763-33,0,0,0 2017-000764-15,3,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,0,Goethe Universität Frankfurt / Universitätsklinikum Frankfurt,"European Intergroup Trial on panobinostat maintenance after HSCT for high-risk AML and MDS - A randomized, multicenter phase III study to assess the efficacy of panobinostat maintenance therapy vs. st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000764-15,0,0,0 2017-000764-15,3,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,0,Universitätsklinikum Frankfurt,"European Intergroup Trial on panobinostat maintenance after HSCT for high-risk AML and MDS - A randomized, multicenter phase III study to assess the efficacy of panobinostat maintenance therapy vs. st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000764-15,0,0,0 2017-000765-78,1,2019-03-12,2019-03-12,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,"Medis, d.o.o.","Randomized, Double-blind, Placebo Controlled Clinical Study To Evaluate Analgesic Efficacy of Topically Administered Traditional Herbal Medicinal Product for Relief of Acute Muscular Pain. Randomiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000765-78,0,0,0 2017-000766-30,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,Blinatumomab added to prephase and consolidation therapy in precursor B-acute lymphoblastic leukemia in adults. A phase II trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000766-30,0,0,0 2017-000768-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Technische Universität Dresden,An open-label phase II multicenter study of vemurafenib (Zelboraf®) plus cobimetinib (Cotellic®) after radiosurgery in patients with active BRAF-V600-mutant melanoma brain metastases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000768-13,0,0,0 2017-000772-28,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Johan Styrke,Fosfomycin vs Ciprofloxacin for transrectal biopsy - a randomized controlled phaze II multicentre clinical trial Fosfomycin vs Ciprofloxacin vid transrektal prostatabiopsi - en randomiserad kontrol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000772-28,0,0,0 2017-000776-29,1,2020-08-18,2020-08-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Pharmacosmos A/S,"Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: a randomised, comparative, open-label trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000776-29,0,0,0 2017-000783-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Syros Pharmaceuticals Inc.,"A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000783-14,0,0,0 2017-000784-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,"Effect of Envarsus conversion on tacrolimus-associated tremor in renal transplant patients. An open-label, single centre, prospective pharmacodynamic/pharmacokinetic clinical study Efecto del cambi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000784-33,0,0,0 2017-000787-15,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Antonio Zebenzui Gimeno García,Phase IV clinical trial for evaluating the utility in clinical practice of a predictive system of incorrect colonic preparation in patients derived for ambulatory colonoscopy Ensayo clínico fase IV...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000787-15,0,0,0 2017-000788-34,2,2019-02-05,2019-02-05,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Interventional, randomized, double-blind, active-controlled study of the efficacy of Lu AF35700 in patients with early-in-disease or late-in-disease treatment-resistant schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000788-34,0,0,0 2017-000789-31,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Kuopio University Hospital Heart Center,"Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost-effective treatment of refractory angina. A phase II randomized, double-blinded, placebo-controlled stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000789-31,0,0,0 2017-000791-29,1,2018-10-01,2018-10-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Clínica Universidad de Navarra/Universidad de Navarra,"Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of cyclosporine mucoadhesive gel at two different concentrations in the topical treatment of lichen planus in the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000791-29,0,0,0 2017-000794-37,6,2020-06-25,2020-07-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffman-La Roche Ltd.,"A PHASE II, OPEN-LABEL, MULTICENTER, MULTI-COHORT STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH SOLID TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000794-37,0,0,0 2017-000797-11,2,2018-03-27,2018-03-27,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects with Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000797-11,0,0,0 2017-000800-59,5,2018-06-12,2018-06-12,1,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"Loxo Oncology, Inc.","A Phase 1 /2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000800-59,1,0,0 2017-000800-59,5,2018-06-12,2018-06-12,1,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company","A Phase 1 /2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000800-59,1,0,0 2017-000801-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER,"An interventional, open-label, Phase II study, to evaluate safety and efficacy of standard and high-dose chemotherapy associated with craniospinal irradiation in patients with metastatic medulloblasto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000801-19,0,0,0 2017-000803-25,2,2022-09-05,2022-09-05,1,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Allergan Ltd,"A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000803-25,0,0,0 2017-000803-25,2,2022-09-05,2022-09-05,1,0,0,0,0,0,3,0,0,1,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000803-25,0,0,0 2017-000806-39,4,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Bayer AG,"A phase 1/2 open-label safety and dose-finding study of BAY 2599023 (DTX201), an adeno-associated virus (AAV) hu37-mediated gene transfer of B-domain deleted human factor VIII, in adults with severe h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000806-39,0,0,0 2017-000808-22,2,2018-07-13,2018-07-13,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,An Open-label Trial Investigating the Association Between Nocturia and Sleep During 12 Weeks of Treatment with Desmopressin Orally Disintegrating Tablet (ODT) for Nocturia due to Nocturnal Polyuria in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000808-22,0,0,0 2017-000810-44,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Fundació Sant Joan de Déu,"Phase II clinical trial to evaluate the effectiveness and safety of acetazolamide in the treatment of cerebellar syndrome in patients with PMM2-CDG deficiency. Ensayo clínico fase II, para evaluar ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000810-44,0,0,0 2017-000813-22,1,2019-10-02,2019-10-02,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,ProQR Therapeutics,"An Open-Label, Single Arm, Multiple Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation (p....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000813-22,0,0,0 2017-000818-34,2,2021-02-11,2021-02-11,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Allergan Ltd.,"A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION OF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000818-34,0,0,0 2017-000820-83,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,0,University of Oulu,Otitis Media and Nasopharyngeal Microbiome in Children. The change of nasopharyngeal microbiome and its role as a risk factor of otitis media. Streptococcus salivarius K12 and the change of nasophar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000820-83,0,0,0 2017-000822-37,4,2020-02-25,2020-02-25,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Asarina Pharma,"A phase II, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study investigating efficacy and safety of Sepranolone (UC1010) in patients with PMDD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000822-37,0,0,0 2017-000826-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Efficacy and safety of immunoglobulin associated with rituximab versus rituximab alone in Childhood-Onset steroid-dependent nephrotic syndrome Evaluation de l'efficacité et de la tolérance de l'inj...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000826-36,0,0,0 2017-000830-68,8,2021-05-18,2021-05-18,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,F. Hoffman-La Roche Ltd.,"A PHASE IB/II STUDY OF COBIMETINIB ADMINISTERED AS SINGLE AGENT AND IN COMBINATION WITH VENETOCLAX, WITH OR WITHOUT ATEZOLIZUMAB, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000830-68,0,0,0 2017-000838-64,2,2019-11-12,2019-11-12,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Phase 2a, Randomised, Double-blind, Parallel Study to Assess the Efficacy, Safety and Tolerability of AZD9567 compared to Prednisolone 20 mg in patients with active Rheumatoid Arthritis (RA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000838-64,0,0,0 2017-000841-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VU University Medical Center,"Combined effects of SGLT2 inhibition and GLP-1 receptor agonism on food intake, body weight and central satiety and reward circuits in obese T2DM patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000841-28,0,0,0 2017-000842-23,1,2021-01-29,2021-01-29,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Medical University Innsbruck,Adjuvante Imiquimod Therapie zur Senkung der Rezidivrate nach operativer Therapie bei analen HPV-Läsionen Adjuvante Imiquimod Therapie zur Senkung der Rezidivrate nach operativer Therapie bei anal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000842-23,0,0,0 2017-000845-39,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,THE ROLE OF ANTI TNF ALPHA AGENTS IN BEH¿ET¿S DISEASE REFRACTORY TO STANDARD OF CARE THERAPIES: MULTICENTER RANDOMIZED CONTROLLED PROSPECTIVE PARALLEL GROUP SINGLE-BLIND TRIAL TO EVALUATE THE 6 MONTH ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000845-39,0,0,0 2017-000846-23,13,2021-02-24,2021-02-24,11,1,0,0,1,0,3,0,0,2,0,0,0,0,1,LABORATOIRES THEA,Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus Lumigan® 0.01% in ocular hypertensive or glaucomatous patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000846-23,1,0,0 2017-000846-23,13,2021-02-24,2021-02-24,11,1,0,0,1,0,3,0,0,2,0,0,0,0,1,Laboratoires THEA,Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus Lumigan® 0.01% in ocular hypertensive or glaucomatous patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000846-23,1,0,0 2017-000848-17,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,MedImmune,"A Phase 2, Open-Label, Single Arm Trial to Evaluate the Shedding and Safety of CAIV-T Administered to Children 6 to less than 60 Months of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000848-17,0,1,1 2017-000849-50,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,MedImmune,"A Phase I Randomized, Double-Blind Trial of the Safety and Immunogenicity of FluMist® A Live, Intranasal Influenza Virus Vaccine vs. Placebo in Immunocompromised Children Ages 5 Through 17 Years of Ag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000849-50,0,1,1 2017-000852-24,2,2020-10-20,2020-10-20,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,UNIVERSITY COLLEGE LONDON,"A Phase I/II, Open label, Multicentre, Ascending Single Dose, Safety Study of a Novel Adeno-associated Viral Vector (FLT180a) in Patients With Haemophilia B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000852-24,0,0,0 2017-000852-24,2,2020-10-20,2020-10-20,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,University College London (UCL),"A Phase I/II, Open label, Multicentre, Ascending Single Dose, Safety Study of a Novel Adeno-associated Viral Vector (FLT180a) in Patients With Haemophilia B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000852-24,0,0,0 2017-000858-18,8,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,Baxalta Innovations GmbH,"A phase 3, prospective, randomized, controlled, open-label, multicenter, 2-period crossover study with a single arm continuation evaluating the safety and efficacy of BAX 930 (rADAMTS13) in the prophy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000858-18,0,1,0 2017-000858-18,8,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,BAXALTA INNOVATIONS GMBH,"A phase 3, prospective, randomized, controlled, open-label, multicenter, 2-period crossover study with a single arm continuation evaluating the safety and efficacy of BAX 930 (rADAMTS13) in the prophy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000858-18,0,1,0 2017-000860-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Genera Research Ltd,"Patient and evaluator blinded non-inferiority study on safety, tolerability and lumbar fusion efficacy of a single administration of Osteogrow (rhBMP6 in autologous blood coagulum (ABC) carrier) in ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000860-14,0,0,0 2017-000861-58,2,2020-03-03,2020-03-03,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF IDASANUTLIN MONOTHERAPY IN PARTICIPANTS WITH HYDROXYUREA-RESISTANT/INTOLERANT POLYCY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000861-58,0,0,0 2017-000861-58,2,2020-03-03,2020-03-03,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF IDASANUTLIN MONOTHERAPY IN PARTICIPANTS WITH HYDROXYUREA-RESISTANT/INTOLERANT POLYCY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000861-58,0,0,0 2017-000862-31,1,2021-10-25,2021-10-25,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH),"A phase Ib/IIa pilot trial of the oral Hedgehog Signalling Inhibitor, Glasdegib, in Patients with sclerotic chronic graft-versus-host disease refractory to second-line treatment Ensayo clínico pilo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000862-31,0,0,0 2017-000863-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,,Curing chronic wounds with fibrin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000863-34,0,0,0 2017-000867-34,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,UMCG,‘Immune protective anesthesia during endoscopic colon surgery to improve long-term survival’,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000867-34,0,0,0 2017-000868-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical Center -University of Freiburg,Stereotactic Cisternal Lavage in Patients with Aneurysmal Subarachnoid Hemorrhage with Urokinase and Nimodipine for the Prevention of Secondary Brain Injury. A Randomized Controlled Trial. Stereota...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000868-15,0,0,0 2017-000870-12,5,2018-12-06,2019-01-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000870-12,0,0,0 2017-000870-12,5,2018-12-06,2019-01-04,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000870-12,0,0,0 2017-000871-10,4,2018-12-12,2018-12-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Patients with Moderate to Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000871-10,0,0,0 2017-000871-10,4,2018-12-12,2018-12-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Patients with Moderate to Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000871-10,0,0,0 2017-000873-35,8,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"Protocol I4V-MC-JAHN: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000873-35,0,0,0 2017-000873-35,8,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","Protocol I4V-MC-JAHN: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000873-35,0,0,0 2017-000873-35,8,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Lilly S.A.,"Protocol I4V-MC-JAHN: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000873-35,0,0,0 2017-000876-27,3,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,Audentes Therapeutics Inc.,"ASPIRO: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-Link...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000876-27,0,0,0 2017-000877-35,5,2019-05-28,2019-05-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BENEVOLENTAI BIO,Dose finding phase IIb study of Bavisant to evaluate its safety and effiCacy in treAtment of exceSsive daytime sleePiness (EDS) in PARkinson’s Disease (PD). CASPAR study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000877-35,0,0,0 2017-000877-35,5,2019-05-28,2019-05-28,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BenevolentAI Bio,Dose finding phase IIb study of Bavisant to evaluate its safety and effiCacy in treAtment of exceSsive daytime sleePiness (EDS) in PARkinson’s Disease (PD). CASPAR study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000877-35,0,0,0 2017-000878-11,3,2020-05-25,2020-05-25,3,1,0,1,0,0,1,0,0,1,1,0,0,0,1,OCTIMET Oncology NV,"A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanced,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000878-11,0,0,0 2017-000880-34,6,2020-06-12,2020-06-12,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine GSK3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000880-34,0,0,0 2017-000880-34,6,2020-06-12,2020-06-12,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine GSK3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000880-34,0,0,0 2017-000880-34,6,2020-06-12,2020-06-12,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline S.A.,"A Phase IIB, randomised, observer-blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, reactogenicity and immunogenicity of the GSK Biologicals’ investigational vaccine GSK3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000880-34,0,0,0 2017-000888-33,3,2022-02-28,2022-02-28,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"An open label, single arm, multiple dose study to assess efficacy, safety, pharmacokinetics and pharmacodynamics of LNP023 when administered in addition to Standard of Care (SoC) in patients with paro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000888-33,1,0,0 2017-000888-33,3,2022-02-28,2022-02-28,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"An open label, single arm, multiple dose study to assess efficacy, safety, pharmacokinetics and pharmacodynamics of LNP023 when administered in addition to Standard of Care (SoC) in patients with paro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000888-33,1,0,0 2017-000889-29,5,2021-04-23,2021-04-23,3,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"An open-label, non-randomized study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000889-29,1,0,0 2017-000889-29,5,2021-04-23,2021-04-23,3,1,0,0,0,1,2,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"An open-label, non-randomized study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000889-29,1,0,0 2017-000889-29,5,2021-04-23,2021-04-23,3,1,0,0,0,1,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","An open-label, non-randomized study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000889-29,1,0,0 2017-000891-27,11,2021-06-22,2021-06-22,7,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000891-27,1,0,0 2017-000892-10,4,2019-02-20,2019-02-21,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SPRL,"A Phase 2 Multicenter, Investigator-blind, Subject-blind, Placebo-controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects with Moderate to Severe Hidradenitis Suppura...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000892-10,0,0,0 2017-000893-12,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,0,The Newcastle Upon Tyne Hospitals NHS Foundation Trust,Nasal Airway Obstruction Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000893-12,0,0,0 2017-000895-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut de Recerca Hospital de la Santa Creu i Sant Pau,Can high-flow oxygen optimize the benefits of Pulmonary Rehabilitation in patients with Diffuse Interstitial LungDisease (ILD) with oxygen desaturation during effort? ¿Puede el oxígeno de alto fluj...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000895-27,0,0,0 2017-000896-99,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Edinburgh,A multicentre prospective randomised open-label blinded end-point controlled trial of high-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta blocker therapy to p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000896-99,0,0,0 2017-000896-99,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Lothian,A multicentre prospective randomised open-label blinded end-point controlled trial of high-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta blocker therapy to p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000896-99,0,0,0 2017-000899-28,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Albert Schweitzer Hospital,Dipeptidylpeptidase IV (CD26) on Philadelphia-positive leukemic stem cells (LSC) as marker and novel therapeutic target in chronic myeloid leukemia (CML). Dipeptidylpeptidase IV (CD26) op Philadelp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000899-28,0,0,0 2017-000900-38,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,FONDAZIONE TETTAMANTI M.DE MARCHI ONLUS,"Open label, single arm, multicenter, dose escalation Phase I-IIa, trial to determine the safety of Allogeneic (donor derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 Chim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000900-38,0,0,0 2017-000901-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR),Evaluation of the clinical and echographic response to Apremilast through clinical evaluation and through a joint-periarticular-nail echographic index in patients with active psoriatic arthritis. E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000901-19,0,0,0 2017-000903-26,3,,,0,0,1,0,0,2,3,0,0,3,0,0,0,0,1,"Global Blood Therapeutics, Inc.","A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease (HOPE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000903-26,0,0,0 2017-000903-26,3,,,0,0,1,0,0,2,3,0,0,3,0,0,0,0,1,"GLOBAL BLOOD THERAPEUTICS, INC.","A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease (HOPE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000903-26,0,0,0 2017-000905-19,4,2019-03-27,2019-03-27,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Recordati Industria Chimica e Farmaceutica S.p.A,"EFFECTS OF TWO DIFFERENT DOSES OF REC 0/0438 ADMINISTERED BY INTRA-VESICAL INSTILLATION IN PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD INJURY: A REPEATED DOSES, DOUBLE-BLIND, PL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000905-19,0,0,0 2017-000905-19,4,2019-03-27,2019-03-27,4,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Recordati S.p.A,"EFFECTS OF TWO DIFFERENT DOSES OF REC 0/0438 ADMINISTERED BY INTRA-VESICAL INSTILLATION IN PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD INJURY: A REPEATED DOSES, DOUBLE-BLIND, PL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000905-19,0,0,0 2017-000914-47,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Novo Nordisk A/S,"A long-term, multi-centre, randomised, controlled, double-blind, parallel-group trial, investigating the efficacy and safety of two doses of NN-220 in subjects with short stature born small for gestat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000914-47,0,1,1 2017-000918-36,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ALKERMES,"A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000918-36,0,0,0 2017-000918-36,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Alkermes Inc,"A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000918-36,0,0,0 2017-000920-81,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000920-81,0,0,0 2017-000922-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Graz,"Effects of continuous exercise on time spent in euglycemia and inflammation under the treatment of insulin degludec in patients with type 1 diabetes – a crossover, randomized trial (InflamEx)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000922-37,0,0,0 2017-000927-29,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Catharina Ziekenhuis,Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a multice...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000927-29,0,0,0 2017-000931-15,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Institute of Cancer Research,PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab For Patients Suffering from Metastatic Prostate Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000931-15,0,0,0 2017-000934-77,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University of Vienna,Target attainment of Cefazolin Continuous Infusion for Antibiotic Prophylaxis in patients undergoing CABG surgery Erreichen der Zielspiegel von Cefazolin als kontinuierliche Infusion zur antibioti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000934-77,0,0,0 2017-000937-30,7,2018-07-12,2019-02-04,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,ABIVAX,A Phase IIa study to evaluate the safety and efficacy of ABX464 50 mg once daily versus Placebo in subjects with Moderate to Severe Active Ulcerative Colitis who have failed or are intolerant to immun...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000937-30,0,0,0 2017-000940-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,,Phase IIa clinical study of 64 CuCl2: efficacy and safety of a new tracer for urologic tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000940-17,0,0,0 2017-000945-37,1,2018-02-23,2018-02-23,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,UMCG,Pharmacodynamic interactions between remifentanil and dexmedetomidine (PIRAD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000945-37,0,0,0 2017-000946-24,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,National Eye Institute,Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated with Age-Related Macular Degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000946-24,0,0,0 2017-000947-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Groupement des Hôpitaux de l’Institut Catholique de Lille,"ABATACEPT VERSUS TOCILIZUMAB BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TNF ALPHA INHIBITOR INADEQUATE RESPONDER PATIENTS: A RANDOMIZED, OPEN-LABELED, SUPERIORITY TRIA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000947-41,0,0,0 2017-000949-53,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Erasmus MC, Dept. Urology",REduce BlAdder CAncer REcurrence in patients treated for upper urinary tract urothelial carcinoma (REBACARE Trial) Verminder blaaskankerrecidief bij patiënten die worden behandeld voor urotheelcarc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000949-53,0,0,0 2017-000952-24,1,2018-02-28,2018-02-28,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Public Health England,Assessment of viral shedding in children previously in receipt of multiple doses of live attenuated influenza vaccine (LAIV) compared to influenza vaccine-naïve controls,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000952-24,0,0,0 2017-000953-38,4,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 1, Single- and Multiple-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate (MK-1986) in Inpatients Under 2 Years Old",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000953-38,0,1,0 2017-000955-25,1,2018-09-28,2018-09-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical University of Graz,"A single-centre, open-label, randomized controlled trial of efficacy, safety and usability of a basal insulin algorithm incorporated in the GlucoTab system compared to standard care for glycaemic mana...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000955-25,0,0,0 2017-000956-25,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Cook MyoSite, Incorporated","CELLEBRATE: An Adaptive, Two-Stage, Double-Blind, Stratified, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Female Subjects with Stress Urinary Incontinenc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000956-25,0,0,0 2017-000957-37,4,2020-05-25,2020-05-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SRL,"A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects with Active Ankylosin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000957-37,0,0,0 2017-000957-37,4,2020-05-25,2020-05-25,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SPRL,"A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects with Active Ankylosin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000957-37,0,0,0 2017-000958-19,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000958-19,0,0,0 2017-000960-14,5,2020-01-17,2020-01-20,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Futura Medical Developments Ltd.,"A Phase III, dose ranging, multi-centre, randomised, double blind, placebo controlled, home use, parallel group clinical trial of topically-applied glyceryl trinitrate (GTN) for the treatment of erect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000960-14,0,0,0 2017-000970-12,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,INCYTE CORPORATION,"A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor. Studio di f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000970-12,0,0,0 2017-000970-12,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Incyte Corporation,"A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor. Studio di f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000970-12,0,0,0 2017-000971-97,2,2018-05-29,2018-05-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ALK Abelló A/S,Safety and tolerability of shortened up-dosing with Alutard SQ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000971-97,0,0,0 2017-000975-10,1,2021-01-02,2021-01-02,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Fundación Investigación Biomédica Hospital Universitario Puerta de Hierro Majadahonda,Intrathecal administration of bone marrow adult autologous stem mesenchymal cells expanded in chronically established low injuries of the spinal cord Administración intratecal de células mesenquima...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000975-10,0,0,0 2017-000976-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC Cancer Institute,Biomarker discovery study to identify patients with advanced urothelial cancer benefitting from pembrolizumab treatment Een fase 2 onderzoek naar nieuwe biomarkers die voorspellen welke patiënten m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000976-27,0,0,0 2017-000977-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST,Randomized phase II study of FOLFOXIRI plus BEVACIZUMAB plus ATEZOLIZUMAB versus FOLFOXIRI plus BEVACIZUMAB as first-line treatment of unresectable metastatic colorectal cancer patients studio di f...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000977-35,0,0,0 2017-000980-33,4,2019-04-03,2022-04-27,4,1,0,0,0,0,2,0,0,1,0,0,0,0,1,Janssen-Cilag International NV,"A Multicenter, Double-Blind, Randomized, Parallel-Group, Active- and Placebo-Controlled Polysomnography Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Subjects with Insomn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000980-33,0,0,0 2017-000981-31,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE MICHELANGELO ONLUS PER L'AVANZAMENTO DELLO STUDIO E LA CURA DEI TUMORI,"Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced breast cancer Atezolizumab, Pertuzumab e Trastuzumab in com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000981-31,0,0,0 2017-000984-34,1,2018-09-19,2018-09-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Medice Arzneimittel Pütter GmbH & Co KG,"A multi-center, randomized, double-blind, phase II trial with intraindividual comparison to assess superiority of Soventol HydroCortisonACETAT 1 % Cremogel versus vehicle on lesional skin in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000984-34,0,0,0 2017-000985-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundació Clinic per a la Recerca Biomédica,"Phase 3b, single arm, single site simplification study with dual therapy including 3TC (300 mg QD) plus Raltegravir (1200 mg QD) in virologically suppressed HIV-1 infected atients experiencing inconve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000985-31,0,0,0 2017-000986-60,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundació Clinic per a la Recerca Biomédica,"Phase 3b, single arm, single site simplification study of HIV-1 infected patients with virological suppression under the combination of 3TC (150 mg BID) plus Raltegravir (400 mg BID) switching to 3TC ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000986-60,0,0,0 2017-000987-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA PER L'EMERGENZA CANNIZZARO,Phase II Study: Maintenance therapy with Trabectedin after combination therapy Liposomal Doxorubicin plus Trabectedin vs Liposomal Doxorubicin plus Trabectedin in patients affected by relapsed ovarian...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000987-14,0,0,0 2017-000988-32,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,VIRAMAL LIMITED,"A Comparative, Open-Label, Randomized, Parallel Group Study to determine Intraperitoneal fluids, tissue, and serum concentrations of VML-0501 following five days of daily vaginal applications of singl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000988-32,0,0,0 2017-000990-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA,EFFECTS OF ANTIDEPRESSANT TREATMENT WITH AGOMELATINE ON PATIENTS AFFECTED BY DEPRESSION AND EPILEPSY. A DOUBLE BLIND RANDOMIZED STUDY WITH ACTIVE CONTROL (ESCITALOPRAM) WITH PARALLEL GROUPS. EFFECT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000990-35,0,0,0 2017-000991-27,9,2021-04-12,2021-04-12,6,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Biogen Idec Research Limited,"A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Treating Pain Experienced by Subjects With C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000991-27,1,0,0 2017-000991-27,9,2021-04-12,2021-04-12,6,1,0,0,0,0,2,0,0,2,1,0,0,0,1,BIOGEN IDEC RESEARCH LIMITED,"A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Treating Pain Experienced by Subjects With C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000991-27,1,0,0 2017-000992-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitets klinik for nyresygdomme og Hypertension,"Prednisolone treatment in acute interstitial nephritis Prednisolon behandling ved akut interstitiel nefritis – et randomiseret, prospektivt studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000992-10,0,0,0 2017-000994-35,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Hospital General Universitario de Alicante,Study of tolerability of iron liposome compared to ferrous sulphate in pregnant women with iron deficiency anemia. Estudio de la tolerabilidad del hierro liposomado en comparación con sulfato ferr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000994-35,0,0,0 2017-000996-98,21,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,CSL Behring LLC,"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000996-98,0,0,0 2017-000996-98,21,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,CSL BEHRING GMBH,"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000996-98,0,0,0 2017-000997-13,1,2019-02-21,2019-02-21,1,1,0,1,0,0,1,1,1,1,0,0,0,0,0,"Center for Perioperative Optimization, Department of Surgery, Herlev Hospital","Pharmacokinetics of intravenous, rectal, intravesical, vaginal, and transdermal administration of exogenous melatonin in healthy female volunteers: a crossover study Farmakokinetik ved intravenøs,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-000997-13,0,0,0 2017-001002-15,5,2022-10-19,2022-10-19,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,UCB Biopharma SRL,"A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects with Ankylosing Spondylitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001002-15,1,0,0 2017-001002-15,5,2022-10-19,2022-10-19,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,UCB Biopharma SPRL,"A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects with Ankylosing Spondylitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001002-15,1,0,0 2017-001002-15,5,2022-10-19,2022-10-19,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,UCB BIOPHARMA SRL,"A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects with Ankylosing Spondylitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001002-15,1,0,0 2017-001003-74,3,2020-10-29,2020-10-29,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SRL,"A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects with Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001003-74,0,0,0 2017-001003-74,3,2020-10-29,2020-10-29,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SPRL,"A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects with Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001003-74,0,0,0 2017-001007-72,2,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,"Amsterdam UMC, location AMC",Atosiban versus placebo in the treatment of late threatened preterm birth (APOSTEL VIII).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001007-72,0,0,0 2017-001007-72,2,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Amsterdam UMC location AMC,Atosiban versus placebo in the treatment of late threatened preterm birth (APOSTEL VIII).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001007-72,0,0,0 2017-001011-36,1,2019-10-16,2019-10-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,INSTITUT DE CANCEROLOGIE DE L'OUEST,"Multicentric, comparative, randomized, open study comparing an early post-operative prophylactic non-invasive ventilation (NIV) to standard post-operative care in patients at high-risk of respirator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001011-36,0,0,0 2017-001012-11,1,2017-11-22,2017-11-22,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,Acerus Biopharma Inc.,"A multicenter, open label, variable dose, two arm pilot paediatric phase 1 PK study to evaluate testosterone nasal gel (4.5% w/w) in hypogonadal boys",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001012-11,0,0,0 2017-001013-89,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA ""BIANCHI-MELACRINO-MORELLI""",Double ASCT in MM: phase III study comparing between melphalan based regimen vs a new regimen consisting of melphalan and thiotepa Double ASCT in MM: phase III study comparing between melphalan ba...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001013-89,0,0,0 2017-001014-28,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,AZIENDA PROVINCIALE PER I SERVIZI SANITARI - PROVINCIA AUTONOMA DI TRENTO,"Effects of a reduced dose of tramadol intravenous, in association with paracetamol, in control of Postoperative Pain after tonsillectomy or adenotonsillectomy in Paediatric population:a clinical, cont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001014-28,0,0,0 2017-001016-11,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,0,SAKK,"Lurbinectedin Monotherapy in Patients with Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial Lurbinectedin Monotherapy in Patients with Progressive Malignant Pleu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001016-11,0,0,0 2017-001019-35,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Centre Hospitalier Sainte-Anne,Effect of vitamin D deficiency compensation in the treatment of drug-resistant epilepsy. Effet de la compensation du déficit en vitamine D dans le traitement de l'épilepsie pharmaco-résistante.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001019-35,0,0,0 2017-001022-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Breastcentre, Capio St Gorans Hospital",Vitamin D supplementation to breast cancer patients with adjuvant endocrine treatment – An observational clinical study where the patient is its own control.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001022-17,0,0,0 2017-001024-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"A.O.U. Università degli Studi della Campania ""Luigi Vanvitelli""",innovative model for the eradication of HCV in a population at high risk of irregular immigrants and low-income refugees modello innovativo per l'eradicazione dell'infezione da HCV in una popolazio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001024-21,0,0,0 2017-001025-41,2,,,0,0,0,0,0,1,3,0,2,0,0,0,0,0,0,"Amsterdam University Medical Center, location AMC",Prevention of relapse with Levamisole as adjuvant therapy to corticosteroids in children with first episode of idiopathic nephrotic syndrome Preventie van recidief na eerste episode van idiopathisc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001025-41,0,0,0 2017-001025-41,2,,,0,0,0,0,0,1,3,0,2,0,0,0,0,0,0,Academic Medical Center,Prevention of relapse with Levamisole as adjuvant therapy to corticosteroids in children with first episode of idiopathic nephrotic syndrome Preventie van recidief na eerste episode van idiopathisc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001025-41,0,0,0 2017-001028-23,2,2018-08-24,2018-08-24,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tools4Patient,Validation Study to Investigate the Effect of T4P1010 treatment in Patients with Osteoarthritic Pain of Knee or Hip. Etude de validation de l’effet du traitement T4P1010 chez des patients souffran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001028-23,0,0,0 2017-001031-39,1,2020-05-15,2020-05-15,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,Hospices Civils de Lyon,"BABH Study: Efficacy and safety of bevacizumab on severe bleedings associated with Hemorrhagic Hereditary Telangiectasia (HHT). A National, randomized multicenter phase III study. Etude BABH - Effi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001031-39,0,0,0 2017-001037-72,1,,,0,0,1,0,0,1,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,The efficacy of flEcainide Compared To metOprolol in reducing Premature ventrIcular Complexes. An open label cross-over study in pediatric patients. De effectiviteit van flecainide op de reductie ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001037-72,0,0,0 2017-001039-38,1,2020-10-28,2020-10-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Dundee/NHS Tayside,A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment – ADVANCE HCV Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001039-38,0,0,0 2017-001040-35,10,2020-10-21,2020-10-21,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Randomized, Double-blind, Parallel Group, Placebo controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001040-35,0,0,0 2017-001040-35,10,2020-10-21,2020-10-21,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA AB,"A Multicenter, Randomized, Double-blind, Parallel Group, Placebo controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001040-35,0,0,0 2017-001041-27,5,2021-07-29,2021-07-29,2,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"REGENERON PHARMACEUTICALS, INC.","A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001041-27,1,0,0 2017-001041-27,5,2021-07-29,2021-07-29,2,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001041-27,1,0,0 2017-001042-10,3,2018-11-08,2018-11-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,VERTEX PHARMACEUTICALS INCORPORATED,"A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001042-10,0,0,0 2017-001042-10,3,2018-11-08,2018-11-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001042-10,0,0,0 2017-001044-35,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine in Children Aged 6 months to 17 Years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001044-35,0,1,1 2017-001049-28,1,2017-12-20,2017-12-20,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,"University of Oxford, CTRG","A Phase I/II Study to assess the safety, immunogenicity and protective efficacy of novel malaria vaccine candidates ChAdOx1 LS2 and MVA LS2 in healthy UK adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001049-28,0,0,0 2017-001050-33,2,2022-02-02,2022-02-02,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,4SC AG,"An open-label Phase Ib/ II, multi-center study of 4SC-202 in Combination with Pembrolizumab in Patients with Unresectable Stage III/Metastatic Stage IV Cutaneous Melanoma primary refractory/non-respon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001050-33,1,0,0 2017-001051-32,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,"FORMA Therapeutics, Inc.","A Phase 1/2, Multicenter, Open-label Study of FT 2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an ID...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001051-32,0,0,0 2017-001051-32,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,"Forma Therapeutics, Inc.","A Phase 1/2, Multicenter, Open-label Study of FT 2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an ID...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001051-32,0,0,0 2017-001051-32,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,"FORMA THERAPEUTICS, INC.","A Phase 1/2, Multicenter, Open-label Study of FT 2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an ID...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001051-32,0,0,0 2017-001054-34,8,2021-10-08,2021-10-08,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ASTRAZENECA AB,"LUCY - Lynparza Breast Cancer Real World Utility, Clinical Effectiveness and Safety Study A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001054-34,1,0,0 2017-001054-34,8,2021-10-08,2021-10-08,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"LUCY - Lynparza Breast Cancer Real World Utility, Clinical Effectiveness and Safety Study A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001054-34,1,0,0 2017-001055-30,8,2022-04-05,2022-04-05,6,0,0,0,0,0,3,0,0,2,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001055-30,1,0,0 2017-001055-30,8,2022-04-05,2022-04-05,6,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001055-30,1,0,0 2017-001056-55,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL STUDY OF THE EFFICACY OF INTRAVENOUS CLARITHROMYCIN AS ADJUNCTIVE TREATMENT IN PATIENTS WITH SEPSIS AND RESPIRATORY AND MULTIPLE ORGAN DYSFUNCTI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001056-55,0,0,0 2017-001060-38,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Nordic Lymphoma Group,"Venetoclax, lenalidomide and rituximab in patients with relapsed/refractory mantle cell lymphoma.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001060-38,0,0,0 2017-001061-24,4,2018-07-09,2018-07-09,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,KeyBioscience AG,"A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of KBP-042 in Patients with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001061-24,0,0,0 2017-001065-24,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,"INSEL GRUPPE AG, BERN UNIVERSITY HOSPITAL, DEPARTMENT OF CARDIOLOGY",Facilitation through Aggrastat or cangrelor Bolus and infusion Over prasugreL: a muUlticenter randomized open-label trial in patientS with ST-elevation myocardial inFarction referred for primAry percu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001065-24,0,0,0 2017-001068-39,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,OMEQUI,"Changes in the bone morphology of the post-extraction socket, preserved with platelet-rich fibrin and leukocytes (L-PRF) versus Conventional treatment Cambios en la morfología ósea del alveolo pose...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001068-39,0,0,0 2017-001069-25,1,2018-10-08,2018-10-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,Randomized double blind (sponsor unblind) study evaluating the effect of 14 days of treatment with danirixin (GSK1325756) on neutrophil extracellular traps (NETs) formation in participants with stable...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001069-25,0,0,0 2017-001071-23,1,2019-07-09,2019-07-09,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Takeda Vaccines, Inc.","A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001071-23,0,0,0 2017-001074-42,8,2019-01-10,2019-01-10,6,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GlaxoSmithKline Research and Development Ltd.,"A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001074-42,0,0,0 2017-001074-42,8,2019-01-10,2019-01-10,6,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001074-42,0,0,0 2017-001074-42,8,2019-01-10,2019-01-10,6,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"GlaxoSmithKline, S.A.","A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001074-42,0,0,0 2017-001075-23,1,2019-06-10,2019-06-10,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,"University of Oxford, CTRG","A Phase I/IIa Sporozoite Challenge Study to assess the safety, immunogenicity and protective efficacy of intravenous boosting with malaria vaccine candidates ChAd63 and MVA encoding ME-TRAP",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001075-23,0,0,0 2017-001078-41,1,,,0,1,1,0,0,1,3,0,0,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001078-41,0,1,1 2017-001082-24,5,2018-09-12,2018-09-12,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Alnylam Pharmaceuticals, Inc.","A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients with Atypical Hemolytic Uremic Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001082-24,0,0,0 2017-001083-38,1,2022-02-12,2022-02-12,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Universitätsmedizin Greifswald,Combined treatment with Nivolumab and Trabectedin in patients with metastatic or inoperable soft tissue Sarcomas - The NiTraSarc Phase II Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001083-38,0,0,0 2017-001084-20,1,2019-11-06,2019-11-06,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Takeda Development Centre Europe Ltd.,"A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Subjects With...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001084-20,0,0,0 2017-001087-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Amiens-Picardie,CLArithromycin versus AZIthromycin in the treatment of Mycobacterium avium complex pulmonary infections: A randomized prospective controlled study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001087-38,0,0,0 2017-001090-16,1,2019-10-07,2019-10-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Medical Center Groningen,A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001090-16,0,0,0 2017-001094-16,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,South Tees NHS Foundation Trust,"Preventing cardiac damage in patients treated for breast cancer and lymphoma: a phase 3 Randomised, Open label, blinded endpoint, trial of enalapril to prevent Anthracycline-induced CardioToxicity (PR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001094-16,0,0,0 2017-001099-49,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,Clonal evolution in progressive CLL patients harboring subclonal TP53 aberrations treated with ibrutinib first-line Evoluzione clonale in pazienti con leucemia linfatica cronica in progressione por...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001099-49,0,0,0 2017-001100-30,1,2021-06-07,2021-06-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Fachingen Heil- und Mineralbrunnen GmbH,Investigation of efficacy and tolerability of the healing water Staatl. Fachingen STILL in patients for symptomatic treatment of heartburn in comparison to placebo Untersuchung zur Wirksamkeit und...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001100-30,0,0,0 2017-001103-77,1,2018-10-31,2018-10-31,1,1,0,0,1,0,2,0,1,1,0,0,1,0,1,Vaccitech Limited,A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed InaCTivated inflUenza vaccine in adultS aged 65 years and above,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001103-77,0,0,0 2017-001110-29,6,2020-08-13,2020-08-13,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen Sciences Ireland UC,"A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of 24 Weeks of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001110-29,0,0,0 2017-001110-29,6,2020-08-13,2020-08-13,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen Sciences Ireland Unlimited Company,"A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of 24 Weeks of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001110-29,0,0,0 2017-001111-36,10,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Cantargia AB,"An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001111-36,0,0,0 2017-001111-36,10,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Cantargia,"An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001111-36,0,0,0 2017-001117-86,1,,,0,0,0,0,1,1,4,0,0,3,0,0,0,0,0,University College London,"A phase IV, prospective, randomised single-blind UK multicentre non-inferiority trial of low-dose versus standard dose rituximab for prevention of relapses in acquired TTP",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001117-86,0,0,0 2017-001121-40,3,2020-05-05,2020-05-05,2,1,0,0,0,0,2,0,0,1,1,1,1,0,0,International CTEPH Association (ICA),"A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Prospective Study to Assess Efficacy of Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy With High Preo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001121-40,0,0,0 2017-001122-17,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,SILVIA GONZALEZ SANTOS,"""ANALGESIC EFFICACY OF INTRADURAL MORPHINE VERSUS INTERCOSTAL LEVOBUPIVACAINE IN THE POSTOPERATIVE PERIOD OF MAJOR PULMONARY RESECTION BY VIDEOTHORASCOCOPY"" “EFICACIA ANALGÉSICA DE LA MORFINA INTRA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001122-17,0,0,0 2017-001123-53,7,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001123-53,0,1,0 2017-001123-53,7,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc","An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001123-53,0,1,0 2017-001123-53,7,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,Merck Sharp & Dohme Corp.,"An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001123-53,0,1,0 2017-001132-19,1,2020-11-20,2020-11-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Aarhus University Hospital,Effects of Metformin on portal hypertension in patients with cirrhosis. Effekt af Metformin på portal hypertension og levererens gennemblødning hos patienter med levercirrose.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001132-19,0,0,0 2017-001139-38,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for StageIII-IVA Resectable Locoregionally Advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001139-38,0,0,0 2017-001142-10,5,2019-10-28,2020-03-03,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Galapagos NV,"A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with moder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001142-10,0,0,0 2017-001142-10,5,2019-10-28,2020-03-03,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Galapagos N.V.,"A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with moder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001142-10,0,0,0 2017-001143-12,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The National Eye Institute,A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Central Retinal Vein Occlusions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001143-12,0,0,0 2017-001144-36,1,2020-04-08,2020-04-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU de Bordeaux,"TRAnexamic Acid for Preventing postpartum hemorrhage following a Cesarean Delivery :a multicenter randomised, double blind placebo controlled trial (TRAAP2) L'acide tranéxamique en prévention de l'...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001144-36,0,0,0 2017-001148-37,1,2019-11-19,2019-11-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A randomized, double-blind (sponsor unblind), placebo-controlled, multi-centered phase IIa study to evaluate the safety and efficacy of 13 weeks of once daily oral dosing of the selective androgen rec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001148-37,0,0,0 2017-001149-28,3,2019-03-14,2019-03-14,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Phase IV, 12-week, randomised, double-blind, triple dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) with multiple inhaler therapy (bude...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001149-28,0,0,0 2017-001150-33,3,2019-03-18,2019-03-18,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Phase IV, 12-week, randomised, double-blind, triple dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) with multiple inhaler therapy (bude...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001150-33,0,0,0 2017-001156-55,1,2019-03-26,2019-03-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc. 235 East 42nd Street, New York, NY 10017","A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of PF-05221304 Administered Daily For 16-Weeks To Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001156-55,0,0,0 2017-001158-33,1,2019-12-19,2019-12-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,The Rotterdam Eye Hospital,A pilot study towards a therapy with prednisolone encapsulated liposomes for the treatment of Graves’ Orbitopathy with reduced systemic steroid exposure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001158-33,0,0,0 2017-001162-21,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Eli Lilly and Company,"An Open-Label, Randomized, Crossover Trial of CSII Reservoir In-use Comparing Insulin Lispro Formulation to Insulin Aspart in Patients with Type 1 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001162-21,0,1,1 2017-001163-20,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Biotest AG,"A randomized, active-controlled, multicenter, phase III study investigating efficacy and safety of intra-operative use of BT524 (human fibrinogen concentrate) in subjects undergoing major spinal or ab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001163-20,0,0,0 2017-001164-38,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661 in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001164-38,0,1,1 2017-001165-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,"A Multicentre, Randomised, Open-label, Phase 2 trial of mifamurtide combined with post-operative chemotherapy for newly diagnosed high risk osteosarcoma patients (metastatic osteosarcoma at diagnosis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001165-24,0,0,0 2017-001168-39,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,SyneuRx International (Taiwan) Corp,"An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo- Controlled, Multi-Center Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibitor, as an Add-on Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001168-39,0,0,0 2017-001169-26,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,SyneuRx International (Taiwan) Corp,"An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibitor, as an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001169-26,0,0,0 2017-001170-42,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,SyneuRx International (Taiwan) Corp,"An adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001170-42,0,0,0 2017-001171-23,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University Hospitals Bristol NHS Foundation Trust,A multicentre randomised trial of First Line treatment pathways for newly diagnosed Immune Thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001171-23,0,0,0 2017-001172-36,6,2019-03-28,2019-04-30,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Oculis ehf.,Efficacy and safety of dexamethasone nanoparticles eye drops in diabetic macular edema.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001172-36,0,0,0 2017-001176-31,12,2018-05-24,2018-05-24,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BAYER AG,BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001176-31,0,0,0 2017-001176-31,12,2018-05-24,2018-05-24,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Bayer AG,",BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001176-31,0,0,0 2017-001176-31,12,2018-05-24,2018-05-24,11,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bayer AG,BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001176-31,0,0,0 2017-001178-41,2,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,"Tolero Pharmaceuticals, Inc.","A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001178-41,0,0,0 2017-001179-21,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The National Eye Institute,A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Branch Retinal Vein Occlusions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001179-21,0,0,0 2017-001180-20,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Eisai Inc.,"Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generaliz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001180-20,0,1,1 2017-001185-20,1,2018-01-09,2018-01-09,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Proximagen Limited,"A Randomized, Double Dummy, Parallel Arm, Placebo and Active Controlled, Double Blind, Study of the Safety and Efficacy of PRX167700 as Monotherapy in Adults with Moderate to Severe Knee Pain Due to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001185-20,0,0,0 2017-001189-98,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aarhus Universitet,Neoadjuvant short-term Intensive Chemoresection versus Standard Adjuvant intravesical instillations in NMIBC - A study on effect and tolerability of neoadjuvant short-term intensive chemoresection an...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001189-98,0,0,0 2017-001190-16,1,2019-07-17,2019-07-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,"A Phase IV, 12 week, randomised, double-blind, double-dummy study to compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), with tiotropium monotherapy based ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001190-16,0,0,0 2017-001191-30,3,2018-12-18,2018-12-18,3,1,0,0,0,0,4,0,0,1,1,1,1,0,1,"Ironwood Pharmaceuticals, Inc.","A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared With...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001191-30,0,0,0 2017-001192-23,1,2021-06-21,2021-06-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"University Health Network, Toronto","A proof of concept, multi-centre, clinical trial of the combination cediranib-olaparib at the time of disease progression on PARP inhibitor in ovarian cancer. Ensayo clínico preliminar multicéntric...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001192-23,0,0,0 2017-001194-16,1,2020-01-31,2020-01-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KU Leuven,Pharmacokinetics of celecoxib for the prevention/treatment of colorectal cancer: optimization of intestinal sampling for celecoxib in healthy volunteers Farmacokinetiek van celecoxib in het kader v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001194-16,0,0,0 2017-001195-35,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001195-35,0,0,0 2017-001195-35,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001195-35,0,0,0 2017-001203-79,5,2021-10-18,2021-10-28,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb international Corporation,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001203-79,1,0,0 2017-001203-79,5,2021-10-18,2021-10-28,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001203-79,1,0,0 2017-001205-33,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001205-33,0,1,1 2017-001206-16,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Aarhus University hospital,"Treatment of primary minimal change nephropathy. A randomized, open-labeled, non-inferiotiry study on prednisolone and vitamin D Behandling af primær minimal change nefropati. Et randomiseret, ikke...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001206-16,0,0,0 2017-001207-68,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Martin-Luther-Universität Halle-Wittenberg,"A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors Multizentrische, ein...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001207-68,0,0,0 2017-001209-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FISEVI,"Phase III CLINICAL TRIAL, MULCHNTRIC, RANDOMIZED, BLIND DOUBLE IN TWO PARALLEL GROUPS TO COMPARE THE EFFECTIVENESS AND SAFETY OF THE SIMPLE CLOSURE OF THE CRYPTTOGLANDULAR ANAL FISTULA WITH OR WITHOUT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001209-34,0,0,0 2017-001215-37,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Birmingham,"A pivotal, international, randomised, double-blind, efficacy and safety trial of sodium valporate in paediatric and adult patients with Wolfram Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001215-37,0,0,0 2017-001216-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dra. A. Teresa Calderón Duque,Usefulness of botulinum toxin type A in the treatment of chronic anal fissure Utilidad de la toxina botulínica tipo A en el tratamiento de la fisura anal crónica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001216-11,0,0,0 2017-001219-35,10,2020-08-31,2020-08-31,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Cortendo AB,"A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001219-35,0,0,0 2017-001219-35,10,2020-08-31,2020-08-31,9,1,0,0,0,1,3,0,0,1,1,0,1,0,1,CORTENDO AB,"A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001219-35,0,0,0 2017-001220-22,2,2020-11-16,2020-11-16,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A Phase IIIB, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with Prevenar13 in a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001220-22,0,0,0 2017-001221-40,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Safety, tolerability and pharmacodynamics of single rising intravitreal and multiple rising intravitreal doses of BI 836880 in patients with wAMD (open label, non-randomized, uncontrolled).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001221-40,0,0,0 2017-001223-49,2,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"PTC Therapeutics, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001223-49,0,0,0 2017-001224-22,9,2020-12-23,2021-02-12,7,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Biogen Idec Research Limited,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001224-22,1,0,0 2017-001224-22,9,2020-12-23,2021-02-12,7,1,0,0,0,0,2,0,0,2,1,0,0,0,1,BIOGEN IDEC RESEARCH LIMITED,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001224-22,1,0,0 2017-001225-41,20,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo- Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Complet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001225-41,0,0,0 2017-001225-41,20,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Randomized, Double-Blind, Placebo- Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Complet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001225-41,0,0,0 2017-001226-18,21,2021-08-11,2021-08-18,18,1,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001226-18,1,0,0 2017-001226-18,21,2021-08-11,2021-08-18,18,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001226-18,1,0,0 2017-001227-45,1,2019-05-31,2019-05-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Portsmouth Hospitals NHS Trust,Comparison of ambulatory glucose profile prior to and during pancreatic enzyme replacement therapy in patients with diabetes and pancreatic exocrine insufficiency: a single-arm phase IV trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001227-45,0,0,0 2017-001236-19,4,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Celgene Corporation,"A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Mul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001236-19,0,0,0 2017-001237-65,1,,,0,1,0,0,0,0,4,0,1,3,0,0,0,0,0,"Queen Mary University of London, Joint Research Management Office",Helping Pregnant smokers quit: A multi-centre RCT of electronic cigarettes and nicotine patches,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001237-65,0,0,0 2017-001239-38,3,2018-06-12,2018-06-12,2,0,0,0,0,0,3,0,1,1,0,0,1,0,1,Medicago R&D Inc.,"A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64 Ye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001239-38,0,0,0 2017-001240-35,22,2022-01-13,2022-01-13,20,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001240-35,1,0,0 2017-001240-35,22,2022-01-13,2022-01-13,20,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001240-35,1,0,0 2017-001243-12,1,,,0,1,0,0,0,1,2,0,0,4,0,0,0,0,1,Eli Lilly and Company Limited,"An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001243-12,0,1,1 2017-001249-28,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Mutua Universal MUGENAT,"Phase III, Single-blinded, placebo-Controlled and randomized Clinical Trial with minimal intervention on the Treatment with Plasma Rich in Growth Factors (PRGF) of Work-site Acute Epicondylitis Resist...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001249-28,0,0,0 2017-001253-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZ Brussel,Does cerebral hypoperfusion play a role in reduced axonal metabolism and clinical disability in patients with multiple sclerosis ? Speelt cerebrale hypoperfusie een rol in het verminderd axonaal me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001253-13,0,0,0 2017-001255-31,4,2020-08-05,2020-08-05,3,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS OR INTRAVENOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001255-31,0,0,0 2017-001257-14,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Temocillin versus a carbapenem as initial intravenous treatment for extended-spectrum beta-lactamase related urinary tract infections, a non-inferiority study.TEMO-CARB Témocilline versus carbapénè...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001257-14,0,0,0 2017-001259-29,1,2020-02-18,2020-02-18,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,University of LIverpool,"A PHASE 1B/2A STUDY TO ASSESS THE TOLERABILITY AND ADVERSE EFFECT PROFILE OF CYSTEAMINE (CYSTAGON) IN ADULTS AND CHILDREN WITH HOMOZYGOUS ΔF508 CYSTIC FIBROSIS, IN PATIENTS TAKING EPIGALLOCATECHIN-3-G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001259-29,0,0,0 2017-001260-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Zuyderland Medical Center,PRODEO: PROfylactic Haloperidol in patients defined as high risk for DElirium with delirium risk mOdel,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001260-37,0,0,0 2017-001261-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AOU FEDERICO II,"PHARMACOLOGICAL, NO PROFIT, PROSPECTIVE RANDOMIZED, DOUBLE-BLIND PLACEBO, CONTROLLED STUDY TO EVALUATE THE EFFICACY OF LEVOTHYROXINE AND LIOTIRONINE (LT4+LT3) IN POST-SURGICAL HYPOTHYROIDISM PATIENTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001261-25,0,0,0 2017-001262-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Charité - Universitätsmedizin Berlin Klinik für Dermatologie und Allergologie,"A randomized, double-blind, placebo-controlled, proof-of-concept, multicenter, 16-week treatment study with a 16 week follow-up period to assess the exploratory efficacy and safety of Dupilumab (anti-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001262-25,0,0,0 2017-001263-20,2,2021-04-28,2021-04-28,2,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Ipsen Pharma SAS,"An International Multicentre, Open-Label First in Human Phase I/II study to evaluate the safety, tolerability, biodistribution and antitumour activity of 177Lu-3BP-227 for the treatment of subjects wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001263-20,0,0,0 2017-001264-38,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Masaryk Memorial Cancer Institute,Change in Metabolic Tumour Activity Seen at Sequential FDG-PET and Plasma/Tissue miRNA as a Biomarkers of Preoperative Treatment Strategy in Locally Advanced Oesophago-Gastric Cancer Zmena metaboli...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001264-38,0,0,0 2017-001264-38,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Masarykův onkologický ústav,Change in Metabolic Tumour Activity Seen at Sequential FDG-PET and Plasma/Tissue miRNA as a Biomarkers of Preoperative Treatment Strategy in Locally Advanced Oesophago-Gastric Cancer Zmena metaboli...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001264-38,0,0,0 2017-001265-24,1,2022-01-11,2022-01-11,1,0,0,1,0,1,1,0,0,1,1,1,0,0,1,"Checkpoint Therapeutics, Inc.","A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients with Advanced Solid Tumors Otwarte badanie fazy 1/2 mające na celu ocenę bezpiecze...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001265-24,0,0,0 2017-001267-21,3,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,F. Hoffman-La Roche Ltd.,"A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC NONSMALL CELL L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001267-21,0,0,0 2017-001270-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU NANCY,"Norepinephrine alone vs Norepinephrine and Dobutamine in cardiogenic shock : a randomised, opened, cross-over study. Heart SHOCK-NORDOB Study Etude noradrénaline seule ou en assiation avec la dobut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001270-41,0,0,0 2017-001271-23,7,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Pfizer Inc.,"AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, MULTI-CENTER, LEAD-IN STUDY TO EVALUATE PROSPECTIVE EFFICACY AND SELECTED SAFETY DATA OF CURRENT FACTOR IX (FIX) OR FACTOR VIII (FVIII) PROPHYLAXIS REPLACEM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001271-23,0,0,0 2017-001272-40,7,2019-07-01,2019-08-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001272-40,0,0,0 2017-001272-40,7,2019-07-01,2019-08-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS PHARMA AG,"A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001272-40,0,0,0 2017-001272-40,7,2019-07-01,2019-08-01,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001272-40,0,0,0 2017-001273-16,3,2019-07-30,2019-07-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001273-16,0,0,0 2017-001275-23,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Great Ormond Street Hospital for Children NHS Trust,Efficacy and safety of a cryopreserved formulation of autologous CD34+ haematopoietic stem cells transduced ex vivo with EFS lentiviral vector encoding for human ADA gene in subjects with Severe Combi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001275-23,0,0,0 2017-001276-27,1,2017-12-15,2017-12-15,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Global Blood Therapeutics Inc.,A Phase II open label study to evaluate the effect of GBT440 on hypoxemia in subjects with Idiopathic Pulmonary Fibrosis (IPF) who are using supplemental oxygen at rest (ZEPHYR),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001276-27,0,0,0 2017-001277-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Gustave Roussy,"Adjuvant immunotherapy after salvage surgery in head and neck squamous cell carcinoma : phase 2 trial evaluating the efficacy and the toxicity of nivolumab alone, and of the combination nivolumab and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001277-17,0,0,0 2017-001282-24,1,2017-10-31,2017-10-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,ReViral Ltd,"A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of RV521 Against Respiratory Syncytial Virus infection ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001282-24,0,0,0 2017-001284-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC Cancer Institute,The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) 'the BIO-GIO study' Het effect van protonpomp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001284-20,0,0,0 2017-001285-23,1,2019-02-28,2019-02-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Oslo University Hospital,A comparison of analgesic and respiratory effects from tapentadol versus oxycodone after laparoscopic hysterectomy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001285-23,0,0,0 2017-001290-17,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"F2G Ltd.,","An open-label single-arm Phase IIb study of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001290-17,0,0,0 2017-001290-17,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,F2G Biotech GmbH (FN 483749 x),"An open-label single-arm Phase IIb study of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001290-17,0,0,0 2017-001290-17,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,F2G Biotech GmbH,"An open-label single-arm Phase IIb study of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001290-17,0,0,0 2017-001292-23,7,2019-11-29,2019-11-29,5,0,0,1,0,0,1,0,0,2,1,0,0,0,1,"BioClin Therapeutics, Inc.","A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined with Pembrolizumab in Subjects with Locally Advanced or Metastatic Urothelial Carcinoma who have Progressed Foll...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001292-23,1,0,0 2017-001292-23,7,2019-11-29,2019-11-29,5,0,0,1,0,0,1,0,0,2,1,0,0,0,1,"Rainier Therapeutics, Inc.","A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined with Pembrolizumab in Subjects with Locally Advanced or Metastatic Urothelial Carcinoma who have Progressed Foll...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001292-23,1,0,0 2017-001294-16,2,2019-06-27,2019-06-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Alkermes, Inc.",A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001294-16,0,0,0 2017-001296-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Radboudumc,The efficacy of botulinum toxin A injection in pelvic floor muscles in chronic pelvic pain patients: a double-blinded randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001296-23,0,0,0 2017-001297-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oulu university hospital,Intranasal dexmedetomidine sedation and analgesia during minor procedures in the pediatric emergency room : Randomized double-blinded clinical trial Nenäsumutteena annosteltava deksmedetomidiini ki...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001297-41,0,0,0 2017-001300-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"UK für Anästhesieologie, Gemeinn. Sbg. Landeskliniken BetriebsgesmbH","Comparison of deep, intermediate and superficial cervical plexus block for carotid endarterectomies concerning paresis of the phrenic nerve, lung function and tissue distribution: a prospective, rando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001300-30,0,0,0 2017-001307-68,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI,"¿THE NOVEL 68Ga-PSMA THERANOSTIC PET/CT COMPOUND FOR FUNCTIONAL IMAGING OF GLIOMA¿ ""IMPIEGO DELL¿INNOVATIVO TRACCIANTE TERANOSTICO 68Ga-PSMA PER L¿IMAGING FUNZIONALE PET/TC DEL GLIOMA "" ¿THE NOVE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001307-68,0,0,0 2017-001308-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Polish Adult Leukaemia Group (PALG),"A Polish Adult Leukemia Group (PALG) prospective, multicenter clinical trial to compare the efficacy of two standard induction therapies (DA-90 vs DAC) and two standard salvage regimens (FLAG-IDA vs ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001308-31,0,0,0 2017-001309-34,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3b, Open-Label Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Cystic Fibrosis and Advanced Lung Disease, Homozygous for the F508del-CFTR Mut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001309-34,0,1,1 2017-001311-36,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Phase 3, Open-label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001311-36,0,0,0 2017-001313-93,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD,"AN OPEN-LABEL, SINGLE-ARM 4 YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS STUDIO IN APERTO, A SINGOLO BRACCIO, DELLA DURAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001313-93,0,0,0 2017-001313-93,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"AN OPEN-LABEL, SINGLE-ARM 4 YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS STUDIO IN APERTO, A SINGOLO BRACCIO, DELLA DURAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001313-93,0,0,0 2017-001313-93,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"AN OPEN-LABEL, SINGLE-ARM 4 YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS STUDIO IN APERTO, A SINGOLO BRACCIO, DELLA DURAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001313-93,0,0,0 2017-001319-36,4,2019-11-01,2019-11-01,4,0,0,1,0,0,1,0,0,1,1,0,0,0,1,"BioClin Therapeutics, Inc.","A Dose Escalation, Expansion Study of Vofatamab (B 701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects with Locally Advanced or Metastatic Urothelial Cell Carcinoma who have Relapsed After, or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001319-36,0,0,0 2017-001327-45,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,"A pilot study of Ceftobiprole diffusion in bone and joint, in patients with BIJ( bone and joint infection) undergoing hip or knee replacement. Etude pilote de dosage du Ceftobiprole dans les infect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001327-45,0,0,0 2017-001333-88,3,2018-11-12,2018-11-19,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Foresee Pharmaceuticals Co., Ltd.","An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects with Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001333-88,0,0,0 2017-001334-26,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Aimmune Therapeutics, Inc.","A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001334-26,0,0,0 2017-001334-26,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AIMMUNE THERAPEUTICS,"A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001334-26,0,0,0 2017-001338-24,9,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Incyte Corporation,"A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001338-24,0,0,0 2017-001338-24,9,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,INCYTE CORPORATION,"A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001338-24,0,0,0 2017-001339-38,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"AVANIR PHARMACEUTICALS, INC.","A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001339-38,0,0,0 2017-001339-38,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Avanir Pharmaceuticals Inc.,"A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001339-38,0,0,0 2017-001339-38,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001339-38,0,0,0 2017-001341-27,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Morten Schou,Empagliflozin in heart failure patients with reduced ejection fraction: A randomized clinical trial (Empire HF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001341-27,0,0,0 2017-001345-27,3,2020-04-21,2020-04-21,2,1,1,0,0,0,1,0,1,2,0,0,0,0,1,Janssen Vaccines & Prevention B.V.,"A Randomized, Double-blind, Phase 1/2a Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.preF in Adults 18 to 50 Years of Age and RSV-seropositive Toddlers 12 to 24 Months of A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001345-27,1,1,0 2017-001345-27,3,2020-04-21,2020-04-21,2,1,1,0,0,0,1,0,1,2,0,0,0,0,1,Janssen Vaccines and Prevention B.V.,"A Randomized, Double-blind, Phase 1/2a Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.preF in Adults 18 to 50 Years of Age and RSV-seropositive Toddlers 12 to 24 Months of A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001345-27,1,1,0 2017-001351-31,1,2019-05-12,2019-05-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Leeds,"A double-blind, randomized, placebo-controlled phase II pilot trial investigating efficacy, safety and feasibility of 11β-hydroxysteroid dehydrogenase type 1 inhibition by AZD4017 to improve skin func...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001351-31,0,0,0 2017-001355-31,4,2022-08-22,2022-08-22,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,Eberhard-Karls University Tübingen represented by University Hospital Tübingen and its Commercial Director,Penumbral Rescue by Normobaric O=O Administration in Patients with Ischemic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial Rescate de la zona de penumbra mediante la administ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001355-31,1,0,0 2017-001355-31,4,2022-08-22,2022-08-22,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,Universitätsklinikum (University Hospital) Tübingen,Penumbral Rescue by Normobaric O=O Administration in Patients with Ischemic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial Rescate de la zona de penumbra mediante la administ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001355-31,1,0,0 2017-001356-59,1,2022-03-08,2022-03-08,1,0,0,0,0,0,4,0,1,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IV, open-label, single-center study to evaluate long term immunogenicity up to 15 years after the first booster immunization with Encepur Adults (Polygeline-free Tick-borne Encephalitis vaccin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001356-59,0,0,0 2017-001357-14,1,2021-10-21,2021-10-21,1,0,0,0,0,0,2,0,0,1,1,1,0,0,0,Klinikum der Universität München - AöR verteten durch den Vorstand des Bereiches Humanmedizin,"Randomized, doubleblind, 4-arms, monocentric, interventinal Study for enhancing the efficacy of tDCS across from single intervention or Placebo by nicotinergic stimulation in schizophrenia. Random...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001357-14,0,0,0 2017-001362-25,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Helse Bergen HF, Haukeland University Hospital","Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001362-25,0,0,0 2017-001364-38,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER'S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001364-38,0,0,0 2017-001364-38,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER'S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001364-38,0,0,0 2017-001364-38,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A.(Soc. Unipersonal)que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche LTD,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER'S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001364-38,0,0,0 2017-001365-24,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001365-24,0,0,0 2017-001365-24,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Roche Farma S.A.(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F.Hoffmann-La Roche LTD,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001365-24,0,0,0 2017-001366-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,A long-term safety and efficacy follow-on study in participants with transfusion dependent β-thalassemia who have previously received GSK2696277 (autologous hematopoietic stem cells genetically modifi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001366-14,0,0,0 2017-001368-40,1,2020-04-02,2020-04-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Almirall S.A.,Open clinical study to assess long-term efficacy and safety of dimethyl fumarate in adults with moderate to severe chronic plaque psoriasis in real practice (DIMESKIN 1 Trial) Estudio clínico abie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001368-40,0,0,0 2017-001369-25,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,1,INFAI Institut für biomedizinische Analytik und NMR Imaging GmbH,The Sensitivity and Specificity of the Modified Helicobacter Test INFAI Using New Test Meal with 13C-Urea Breath Test in Helicobacter Pylori Positive and Negative Patients with Dyspepsia and GERD Taki...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001369-25,0,0,0 2017-001371-24,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Hôpitaux Universitaires de Strasbourg,"Prospective, randomised, placebo-controlled study of polyvalent intravenous immunoglobulins for the treatment of primary Sjögren's syndrome associated painful sensory neuropathies Etude prospectiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001371-24,0,0,0 2017-001373-16,1,2018-06-25,2018-06-25,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, subject- and investigator-blinded, placebo-controlled pharmacodynamic study of oral LIK066 in overweight and obese women with polycystic ovary syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001373-16,0,0,0 2017-001374-42,1,,,0,1,0,0,0,0,4,0,0,3,0,0,0,0,0,Guy's and St Thomas' NHS Foundation Trust,Study of the Golimumab Exposure-Response Relationship using Serum Trough Levels,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001374-42,0,0,0 2017-001375-22,4,2022-02-22,2022-02-22,4,0,0,0,0,0,2,0,0,1,0,0,0,0,0,European Organisation for the Research and Treatment of Cancer (EORTC),EORTC ILOC study: Phase II of immunotherapy plus local tumor ablation (RFA or stereotactic radiotherapy) in patients with colorectal cancer liver metastases EORTC ILOC-Studie: Eine Phase-II-Studie ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001375-22,0,0,0 2017-001376-28,2,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Radboud University Medical Center,"Multi-center, randomized non-inferiority trial of early treatment versus expectative management of patent ductus arteriosus in preterm infants. Multicenter, gerandomiseerde 'non-inferiority' studie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001376-28,0,0,0 2017-001379-21,3,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001379-21,0,0,0 2017-001382-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hagaziekenhuis,Read Dutch instructions Dosis Salbutamol (Ventolin) bij de reversibiliteitsmeting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001382-24,0,0,0 2017-001388-19,6,2020-03-17,2020-03-17,3,1,0,0,0,2,3,0,0,2,0,0,0,0,1,"REGENERON PHARMACEUTICALS, INC.","A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001388-19,1,0,0 2017-001388-19,6,2020-03-17,2020-03-17,3,1,0,0,0,2,3,0,0,2,0,0,0,0,1,Regeneron Pharmaceuticals Inc.,"A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001388-19,1,0,0 2017-001389-10,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust & University of Cambridge,A phase II randomised placebo controlled double blinded trial of Interleukin 1 blockade in Acute Severe Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001389-10,0,0,0 2017-001392-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Nantes,Randomized double-blind study on the benefit of spironolactone for treating acne of adult woman Etude randomisée en double-aveugle sur l'intérêt de la spironolactone dans le traitement de l'acné de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001392-22,0,0,0 2017-001394-16,3,,,0,1,0,1,0,0,1,0,0,3,0,0,0,0,1,Genmab B.V.,"First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001394-16,0,0,0 2017-001395-38,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA USL DELLA VALLE D'AOSTA,Treatment of Metastatic prostate cancer castration resistant (mCRPC) with 223RaCl2: response evaluation with a novel tracer 68Ga-PSMA PET molecular imaging Studio multicentrico di fase II di tratt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001395-38,0,0,0 2017-001397-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Antwerp University Hospital,A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients De rol van aspirine op de overleving van patiënten met dikkedarmkanker; e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001397-41,0,0,0 2017-001398-17,5,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001398-17,0,0,0 2017-001398-17,5,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001398-17,0,0,0 2017-001400-29,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Treatment of severe refractory systemic lupus erythematosus by injection of allogeneic mesenchymal stem cells derived from the umbilical cord - MSC SLE TRAITEMENT DU LUPUS ERYTHEMATEUX SYSTEMIQUE ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001400-29,0,0,0 2017-001405-32,1,2020-07-13,2020-07-13,1,0,0,0,0,1,4,0,0,1,0,0,1,0,0,Institut des Maladies Génétiques - Imagine,"A Monocentric Single-arm study to characterize the long-term safety, efficacy, and pharmacodynamic of GLP-2 analog (Revestive®) in the management of short bowel syndrome pediatric patients on home-par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001405-32,0,0,0 2017-001406-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per la Recerca Biomèdica,Adequate duration of antibiotic treatment in community acquired pneumonia categorized by pneumonia severity index (PSI) Duración adecuada del tratamiento antibiótico en la neumonía adquirida en la ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001406-15,0,0,0 2017-001409-34,10,2022-04-07,2022-04-07,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001409-34,1,0,0 2017-001409-34,10,2022-04-07,2022-04-07,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffman-La Roche Ltd.,"A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001409-34,1,0,0 2017-001409-34,10,2022-04-07,2022-04-07,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A.U. que realiza el ensayo en España y que actúa como representante de F.Hoffmann-La Roche Ltd.,"A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001409-34,1,0,0 2017-001415-36,2,2018-03-22,2018-03-22,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,"Gan & Lee Pharmaceuticals, USA","An Open-label, Randomized, Multicenter, Phase III Study to Compare the Immunogenicity, Efficacy, and Safety of Gan & Lee Pharmaceuticals Insulin Glargine Injection to Lantus® (Insulin Glargine Injecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001415-36,0,0,0 2017-001416-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR),Assessment of macular thickness after non-traumatic cataract surgery associated to intracamerular injection of Cefuroxima prepared at the hospital vs Prokam. Evaluación del grosor macular tras ciru...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001416-11,0,0,0 2017-001418-27,12,2022-07-12,2022-07-12,7,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Amgen Inc.,"A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF ABP 959 COMPARED WITH ECULIZUMAB IN ADULT SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001418-27,1,0,0 2017-001418-27,12,2022-07-12,2022-07-12,7,0,0,0,0,1,3,0,0,2,0,0,0,0,1,AMGEN INC.,"A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF ABP 959 COMPARED WITH ECULIZUMAB IN ADULT SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001418-27,1,0,0 2017-001420-21,2,2021-08-24,2021-08-24,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Pharma Two B Ltd,"A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to it...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001420-21,1,0,0 2017-001421-41,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Oxford,The TWO Study: Transplantation Without Over-immunosuppression. A Phase IIb Trial of Regulatory T Cells in Renal Transplantation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001421-41,0,0,0 2017-001426-17,1,2020-07-09,2020-07-09,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospitals Leuven (Gasthuisberg),Tranexamic Acid to reduce bleeding in patients treated with new oral anticoagulants undergoing dental extraction (EXTRACT-NOAC) Tranexaminezuur (Exacyl®) om het risico op bloeding na een tandextrac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001426-17,0,0,0 2017-001428-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,AssessinG Efficacy of carboplatin and ATezOlizumab in metastatic Lobular breast cancer: GELATO-trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001428-23,0,0,0 2017-001429-41,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA,“TOCIlizumab for difficult-to-treat RETroperitoneal fibrosis. TOCIRET Trial” “TOCilizumab come terapia per i casi di fibrosi RETroperitoneale idiopatica difficili da trattare. Studio TOCIRET”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001429-41,0,0,0 2017-001430-25,1,2019-07-28,2019-07-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Fundación Pública Andaluza Progreso y Salud,The effects of sufentanil or morphine added to hyperbaric bupivacaine in spinal anaesthesia for elective caesarean section. EFECTOS DEL SUFENTANILO O LA MORFINA JUNTO CON BUPIVACAINA HIPERBARICA EN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001430-25,0,0,0 2017-001431-39,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Phase 1/2 study to evaluate safety, pharmacokinetics and efficacy of isatuximab in combination with REGN2810 in patients with relapsed/refractory multiple myeloma I/II. fázisú vizsgálat a REGN281...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001431-39,0,0,0 2017-001431-39,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Sanofi-aventis recherche & developpement,"A Phase 1/2 study to evaluate safety, pharmacokinetics and efficacy of isatuximab in combination with REGN2810 in patients with relapsed/refractory multiple myeloma I/II. fázisú vizsgálat a REGN281...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001431-39,0,0,0 2017-001437-12,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University of Tartu,Effect of exenatide on cortisol secretion Eksenatiidi toime kortisooli sekretsioonile,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001437-12,0,0,0 2017-001438-25,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,VU University Medical Center,"A Study to Explore the Safety, Tolerability, Pharmacokinetic Profile, and Potential Efficacy of Guanabenz in Patients With Early Childhood Onset Vanishing White Matter (VWM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001438-25,0,0,0 2017-001439-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medical University of Vienna, Department of Anaesthesia, General Critical Care and Pain Management",The effect of pregabalin on the minimal alveolar concentration of sevoflurane Der Effekt von Pregabalin auf die minimale alveoläre Konzentration von Sevofluran,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001439-37,0,0,0 2017-001443-13,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made with an Alternati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001443-13,0,1,1 2017-001444-35,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly with M-M-R™ II",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001444-35,0,1,1 2017-001446-10,1,2019-01-15,2019-01-15,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),NA Induction et consolidation à base d'elotuzumab avant et après autogreffe de cellules souches périphériques chez des patients âgés atteints de myélome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001446-10,0,0,0 2017-001447-12,7,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Multicenter, Randomized, Double-blind, Placebo- and Active controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 years old) With Schizophreni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001447-12,0,0,0 2017-001447-12,7,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,"Otsuka Pharmaceutical Development and Commercialization, Inc","A Multicenter, Randomized, Double-blind, Placebo- and Active controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 years old) With Schizophreni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001447-12,0,0,0 2017-001450-34,3,2019-07-17,2019-07-17,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gan & Lee Pharmaceuticals, USA","An Open-label, Randomized, Multicenter, Phase III Study to Compare the Immunogenicity, Efficacy, and Safety of Gan & Lee Pharmaceuticals Insulin Glargine Injection to Lantus® (Insulin Glargine Injecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001450-34,0,0,0 2017-001451-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud university medical center,"Pharmacokinetics of a new paediatric formulation of valacyclovir used for prophylaxis and treatment of VZV and HSV infections in children, phase II (VALID II)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001451-30,0,0,0 2017-001452-55,2,,,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,GlaxoSmithKline Biologicals,"A first-time-in human (FTIH), Phase I/II, randomized, multi-centric, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GSK Biologica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001452-55,0,0,0 2017-001454-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dr. Albert Lecube Torello,"A randomized, non-blinded, 24-week pilot study to evaluate the effect of dapagliflozin (10 mg once daily) plus exenatide (2.0 mg once weekly) on type 2 diabetic patients awaiting for bariatric surgery...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001454-33,0,0,0 2017-001455-32,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Worldwide Innovative Network Association,A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to match ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001455-32,0,0,0 2017-001459-30,7,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,"Otsuka Pharmaceutical Development and Commercialization, Inc","A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001459-30,0,0,0 2017-001459-30,7,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc","A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001459-30,0,0,0 2017-001463-21,5,2017-09-25,2017-10-06,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the Combination Regimen of MK-3682B (Grazoprevir/Ruzasvir/Uprifosbuvir) in Participants with Chronic Hepatitis C Virus Genotype 3 Infect...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001463-21,0,0,0 2017-001465-24,10,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,CELGENE CORPORATION,Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells Protocollo di follow-up a lungo termine per i soggetti trattati con cellule T modificate geneticamente,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001465-24,0,0,0 2017-001465-24,10,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Celgene Corporation,Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells Protocollo di follow-up a lungo termine per i soggetti trattati con cellule T modificate geneticamente,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001465-24,0,0,0 2017-001466-21,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Erasmus MC University Medical Center,"Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands. The effect of periprocedural MEDication: heparin, antiplatelet agents, both or neither. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001466-21,0,0,0 2017-001467-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dept. of Oncology, Karolinska university hospital","Effects of Identifying and Treating Early, Subclinical Cardiotoxicity on the Long- Term Incidence of Clinical Cardiotoxicity in Women with Breast Cancer, a prospective randomised study: The Cardio-Onc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001467-20,0,0,0 2017-001468-39,7,2018-11-16,2018-11-16,4,1,1,0,0,0,1,0,0,1,1,1,1,0,1,"Gilead Sciences, Inc.",Phase 1b trial evaluating idelalisib in children and adolescents with relapsed or refractory diffuse large B-cell lymphoma or mediastinal B-cell lymphoma in combination with RICE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001468-39,0,0,0 2017-001469-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Spanish Oncology Genitourinary Group – SOGUG,Phase II trial evaluating olaparib maintenance in patients with MCRPC after docetaxel treatment reaching partial or stable response. Ensayo fase II para evaluar el tratamiento de mantenimiento con ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001469-26,0,0,0 2017-001470-42,1,2019-09-05,2019-09-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"BERG, LLC","A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously with Gemcitabine as 2nd/3rdline therapy in Advanced Pancreatic Cancer Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001470-42,0,0,0 2017-001471-23,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,UZ Brussel,"Phase I/IIa study to evaluate the safety, biodistribution, radiation dosimetry and tumor imaging potential of 68GaNOTA-Anti-MMR-VHH2, a new radiopharmaceutical for in vivo imaging of Tumour-Associated...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001471-23,0,0,0 2017-001474-41,1,2018-09-06,2018-09-06,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU CAEN,Bénéfices de la perfusion continue de lidocaïne intraveineuse en chirurgie bariatrique : une étude randomisée prospective contre placebo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001474-41,0,0,0 2017-001476-33,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Leeds,A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001476-33,0,0,0 2017-001479-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University Medical Center Hamburg-Eppendorf, Germany",Individualized perioperative hemodynamic goal-directed therapy in major abdominal surgery (iPEGASUS-trial) Terapia hemodinámica individualizada perioperatoria dirigida por objetivos en cirugía mayo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001479-22,0,0,0 2017-001481-23,1,2020-06-19,2020-06-19,1,0,0,0,0,1,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED CLINICAL TRIAL WITH RILUZOLE IN SPINOCEREBELLAR ATAXIA TYPE 2 Etude multicentrique, randomisée en double aveugle, contrôlée versus placebo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001481-23,0,0,0 2017-001483-38,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Bayer AG,"An international, multicenter, Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab as first-line treatment in cisplatin-ineligible patients with FGFR-positive locally advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001483-38,0,0,0 2017-001485-17,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Active Non-Infectious Uveitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001485-17,0,0,0 2017-001487-38,1,2020-08-28,2020-08-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"St George's, University of London",Babies born Early Antibody Response to Men B vaccination: BEAR Men B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001487-38,0,0,0 2017-001489-53,7,2020-11-05,2020-11-05,6,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001489-53,0,0,0 2017-001490-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Stockholms läns landsting,"Lisdexamphetamine treatment of Bulimia Nervosa with and without probable simultaneous Attention Deficit Hyperactivity Disorder (ADHD). A randomized , open, fase II-study with cross-over design. Lis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001490-16,0,0,0 2017-001491-35,3,,,0,0,0,1,0,2,1,0,0,2,1,0,0,0,1,Cellestia Biotech AG,"A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001491-35,0,0,0 2017-001499-43,4,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sahlgrenska University Hospital,Dual antiplatelet therapy with ticagrelor and acetylsalicylic acid (ASA) vs. ASA only after isolated coronary artery bypass grafting in patients with acute coronary syndrome (TACSI trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001499-43,0,0,0 2017-001502-15,2,2021-10-13,2021-10-13,2,1,0,0,0,0,3,0,0,1,0,0,0,0,0,"Insel Gruppe AG - Inselspital, Universitätsklinik für Kardiologie","Effects of the PCSK9 Antibody AliroCuMab on Coronary Atherosclerosis in PatieNts with Acute Myocardial Infarction. A Serial, Multivessel, Intravascular Ultrasound, Near-Infrared Spectroscopy And Optic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001502-15,0,0,0 2017-001502-15,2,2021-10-13,2021-10-13,2,1,0,0,0,0,3,0,0,1,0,0,0,0,0,Insel Gruppe AG - Inselspital,"Effects of the PCSK9 Antibody AliroCuMab on Coronary Atherosclerosis in PatieNts with Acute Myocardial Infarction. A Serial, Multivessel, Intravascular Ultrasound, Near-Infrared Spectroscopy And Optic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001502-15,0,0,0 2017-001507-76,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Region Örebro län,Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) A pragmatic clinical trial with partial registry-based follow-up,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001507-76,0,0,0 2017-001508-31,9,2020-12-14,2020-12-14,8,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients with Persistent Hypercholesterolemia Despite Maximally Tole...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001508-31,1,0,0 2017-001509-33,4,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Pfizer Inc.,A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001509-33,0,0,0 2017-001509-33,4,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001509-33,0,0,0 2017-001514-29,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,GlaxoSmithKline KK,"A multi-center, uncontrolled, open-label, evaluation of Lamotrigine monotherapy on newly diagnosed typical absence seizures in children and adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001514-29,0,1,1 2017-001515-36,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline K.K.,"Valproate dose reduction and its clinical evaluation by introducing lamotrigine in Japanese women with epilepsy – single arm, multicenter, and open-label study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001515-36,0,1,1 2017-001516-11,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"201832: A Randomised, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Adolescent and Adult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001516-11,0,1,1 2017-001521-41,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Liverpool,"A window of opportunity study to assess the biological effects of progesterone in premenopausal ER-positive, PgR-positive early breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001521-41,0,0,0 2017-001525-40,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Erasmus MC,Effectiveness of different strengths of topical steroids: providing evidence for a better treatment strategy in children with atopic dermatitis in general practice. Effectiviteit van verschillende ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001525-40,0,0,0 2017-001528-23,6,2020-07-02,2020-08-01,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Protalix Ltd.,"A Phase 3, Open Label, Switch Over Study to Assess the Safety, Efficacy and Pharmacokinetics of pegunigalsidase alfa (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks for 52 weeks i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001528-23,0,0,0 2017-001528-23,6,2020-07-02,2020-08-01,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,PROTALIX LTD,"A Phase 3, Open Label, Switch Over Study to Assess the Safety, Efficacy and Pharmacokinetics of pegunigalsidase alfa (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks for 52 weeks i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001528-23,0,0,0 2017-001529-41,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Pfizer Inc.,Prevenar Post-Licensure Safety Study in Russia: Frequency Of Fever Post Vaccination,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001529-41,0,1,1 2017-001531-40,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Octapharma AG,"Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Pediatric Patients with Severe Hemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001531-40,0,1,1 2017-001532-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,A randomised open-label study to compare the effectiveness of the fixed dose combination of FF/UMEC/VI (using the Connected Inhaler System) with the combination of FP/SAL plus tiotropium (without the ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001532-19,0,0,0 2017-001538-25,1,2022-03-15,2022-03-15,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,AIO-Studien-gGmbH,A randomized phase II trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with cholangio- and gallbladd...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001538-25,0,0,0 2017-001541-26,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,AbbVie Inc,A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001541-26,0,1,1 2017-001543-13,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Morten Tange Kristensen/Hvidovre Hospital,Preliminary effect and safety of physiotherapy with strength training and protein-dense nutritional supplement in combination with anabolic steroids in cross-continuum rehabilitation of patients with ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001543-13,0,0,0 2017-001547-12,1,2021-07-01,2021-07-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,VU University Medical Center,"A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, fol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001547-12,0,0,0 2017-001548-36,11,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001548-36,0,0,0 2017-001548-36,11,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A. (Soc.unipersonal)que realiza el ensayo en España y que actúa como representante de F.Hoffmann- La Roche,"A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001548-36,0,0,0 2017-001548-36,11,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATIC, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001548-36,0,0,0 2017-001550-34,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,FONDAZIONE TELETHON,Studio clinico pilota per valutare l’efficacia della terapia con fenilbutirrato in pazienti affetti da deficit di piruvato deidrogenasi Studio clinico pilota per valutare l’efficacia della terapia ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001550-34,0,0,0 2017-001551-31,9,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"BEIGENE USA, INC.","An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Ly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001551-31,0,0,0 2017-001551-31,9,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"BeiGene, Ltd.","An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Ly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001551-31,0,0,0 2017-001552-54,9,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"BEIGENE USA, INC.","An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001552-54,0,0,0 2017-001552-54,9,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,BeiGene Ltd.,"An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001552-54,0,0,0 2017-001553-14,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,"BeiGene USA, Inc.","A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001553-14,0,0,0 2017-001554-33,1,2021-03-17,2021-03-17,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"BeiGene USA, Inc.","A Phase 1b/2 study to assess the safety, tolerability and efficacy of BGB-290 in combination with radiation therapy and/or temozolomide in subjects with first-line or recurrent/refractory glioblastoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001554-33,0,0,0 2017-001555-32,7,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete res...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001555-32,0,0,0 2017-001555-32,7,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A,"A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete res...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001555-32,0,0,0 2017-001556-67,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UZ Brussel,The effect of emollients on pruritus in psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001556-67,0,0,0 2017-001559-30,1,2019-04-05,2019-04-05,1,0,0,0,0,0,4,0,0,1,1,1,1,0,1,Fresenius Kabi Deutschland GmbH,"Efficacy of long-term parenteral nutrition with SmofKabiven® E concomitant to chemo- and/or immunotherapy: A prospective, randomised, controlled, open, multicentre, two-stage, adaptive clinical trial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001559-30,0,0,0 2017-001565-25,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,MUNDIPHARMA PHARMACEUTICALS SRL,"Efficacy and safety of methoxyflurane vaporized (PENTHROX®) in the treatment of acute trauma pain in pre-hospital setting and in the emergency department in Italy: a multicentre, randomized, controlle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001565-25,0,0,0 2017-001566-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Ismail Gögenur,Effect of Low-dose Interferon-alfa2a on post-operative immune suppression - a randomized trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001566-21,0,0,0 2017-001567-20,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Assessment of Dual antiplatelet therapy versus Rivaroxaban In atrial Fibrillation patients Treated with left atrial appendage closure: The randomized ADRIFT Study Evaluation de la double antiagréga...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001567-20,0,0,0 2017-001570-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Hospital,Aggravated airway inflammation: research on genomics and optimal treatments (AirGOs),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001570-42,0,0,0 2017-001574-42,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A randomized, open-label, comparative study to evaluate an intermittent dosing regimen of fluticasone propionate 0·05% cream (twice per week) in reducing the risk of relapse when added to regular dail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001574-42,0,1,1 2017-001575-23,1,,,0,1,0,0,1,0,4,0,0,4,0,0,0,0,1,GlaxoSmithKline KK,Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese Subjects.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001575-23,0,1,1 2017-001579-22,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CHU DE POITIERS,Effectiveness of nebulization by high nasal flow during acute respiratory decompensations of chronic respiratory insufficiency.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001579-22,0,0,0 2017-001581-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE - ISMETT,THE ADDITION OF SIMVASTATIN ADMINISTRATION TO COLD STORAGE SOLUTION OF EXPLANTED WHOLE LIVER GRAFTS FOR FACING ISCHEMIA/REPERFUSION INJURY IN AN AREA WITH LOW RATE OF DECEASED DONATION. A MONOCENTRIC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001581-20,0,0,0 2017-001582-25,3,2020-04-08,2020-04-08,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A 12-week, randomized, single-blind, placebo-controlled, multi-centre, parallel group, phase IIa study to evaluate efficacy, safety and tolerability of oral AZD5718 after 4- and 12-weeks of treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001582-25,0,0,0 2017-001584-20,1,2020-09-15,2020-09-15,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase I/II, randomized, controlled, observer-blind, multi-center study to assess the reactogenicity, safety and immunogenicity of three GlaxoSmithKline (GSK) Biologicals’ investigational supra-seaso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001584-20,0,0,0 2017-001586-24,1,2020-10-09,2020-10-09,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Oxford,Delivering personalised care in the management of exacerbations of chronic obstructive pulmonary disease: A multi-centre randomised clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001586-24,0,0,0 2017-001587-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fédération Francophone de Cancérologie Digestive,"A phase II study evaluating FOLFOX + panitumumab according to a ""stop and go"" strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment, as the first line in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001587-38,0,0,0 2017-001588-19,8,2020-06-09,2021-04-08,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Myovant Sciences GmbH,"SPIRIT 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Aceta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001588-19,0,0,0 2017-001590-16,2,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,AbbVie Deutschland,An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001590-16,0,0,0 2017-001590-16,2,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001590-16,0,0,0 2017-001591-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA,"Multicenter, prospective, non-randomized, phase II trial designed to evaluate the activity of Cabazitaxel in patients with advanced Adreno-Cortical- Carcinoma progressing after previous chemotherapy l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001591-35,0,0,0 2017-001593-42,3,2019-01-22,2019-01-24,2,1,0,0,2,0,3,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A 24-week randomized, controlled, multicenter, open-label study to evaluate the effect of reminder notifications and motivational/adaptive messaging on treatment adherence of COPD subjects receiving U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001593-42,1,0,0 2017-001596-23,3,2019-09-27,2019-09-27,3,1,0,0,0,0,0,0,0,1,0,0,1,0,1,"Krka, d.d., Novo mesto",Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in newly diagnosed and uncontrol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001596-23,0,0,0 2017-001597-42,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,CHU CAEN,Évaluation des marqueurs d’instabilité de la plaque carotidienne en imagerie hybride TEP-IRM : Étude CAROTEP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001597-42,0,0,0 2017-001598-18,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Eli Lilly and Company Limited,"A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001598-18,0,1,1 2017-001599-46,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Eli Lilly and Company Limited,"A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001599-46,0,1,1 2017-001600-29,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"AROG PHARMACEUTICALS, INC.","Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects = 75 Years o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001600-29,0,0,0 2017-001600-29,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Arog Pharmaceuticals, Inc.","Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects = 75 Years o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001600-29,0,0,0 2017-001604-30,2,2020-04-09,2020-09-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité Berlin,"Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial Sicherheit, Verträglichkeit und Aktivität des ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001604-30,0,0,0 2017-001604-30,2,2020-04-09,2020-09-04,2,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical University of Vienna,"Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial Sicherheit, Verträglichkeit und Aktivität des ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001604-30,0,0,0 2017-001605-32,2,2019-03-31,2019-04-22,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Basilea Pharmaceutica International Ltd,"A randomized, double-blind, multicenter study to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001605-32,0,0,0 2017-001606-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Gustave Roussy,A study of patient preference between ODM-201 and Enzalutamide in men with metastatic castrate-resistant prostate cancer Etude de préférence des patients entre l’ODM-201 et l’Enzalutamide chez des ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001606-14,0,0,0 2017-001607-80,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,An open-label primary vaccination study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ Inactivated Poliomyelitis vaccine Poliorix administered as a three-dose primary vaccinat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001607-80,0,1,1 2017-001608-32,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,An open-label study to assess the safety and reactogenicity of GlaxoSmithKline Biologicals’ Inactivated Poliomyelitis Vaccine Poliorix administered as a booster dose at 18-24 months of age in healthy ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001608-32,0,1,1 2017-001611-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medical University Vienna, Gender Medicine Unit, Div. of Endocrinology, Dep of Medicine III",A 52 week prospective randomized controlled study to investigate the effect of intramuscular testosterone undecanoate supplementation vs placebo on intrahepatic fat content in overweight/obese men wit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001611-37,0,0,0 2017-001612-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Region Hovedstaden,A COMPARISON OF DEXMEDETOMIDINE VS PLACEBO AFFECT ON SLEEP-QUALLITY IN MECHANICAL VENTILATED CRITICAL ILL PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001612-11,0,0,0 2017-001613-83,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,Octreotide LAR in the induction of immunologic response in patient with neuroendocrine tumors: an interventional pharmacological study Valutazione del ruolo dell¿Octreotide LAR nell¿immunomodulazi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001613-83,0,0,0 2017-001615-36,1,2021-12-03,2021-12-03,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Affibody AB,"A phase II, randomized, parallel group, placebo-controlled, double-blinded, dose-finding study to evaluate efficacy, safety, tolerability, and pharmacokinetics of ABY-035 in subjects with moderate-to-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001615-36,0,0,0 2017-001616-11,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,University Hospital Wuerzburg,"Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subsequ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001616-11,0,0,0 2017-001618-27,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,2,STICHTING EUROPEAN MYELOMA NETWORK,A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001618-27,0,0,0 2017-001618-27,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,2,European Myeloma Network (EMN),A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001618-27,0,0,0 2017-001619-35,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,"Cliniques Universitaires Saint-lus, Université catholique de Louvain",Exploratory pathophysiological study in five patients suffering from new-onset lupus nephritis and treated with rituximab as first-line treatment Etude physiopathologique exploratoire chez cinq pat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001619-35,0,0,0 2017-001621-41,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO,A phase III randomized study of doxycycline and tauroursodeoxycholic acid (Doxy/TUDCA) plus standard supportive therapy versus standard supportive therapy alone in cardiac amyloidosis caused by transt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001621-41,0,0,0 2017-001623-44,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Ziekenhuis Oost Limburg (ZOL), Genk",Effect of Intravenous Ferric Carboxymaltose on reverse remodeling following Cardiac Resynchronization therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001623-44,0,0,0 2017-001624-22,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Incyte Corporation,"A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001624-22,0,0,0 2017-001624-22,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,INCYTE CORPORATION,"A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001624-22,0,0,0 2017-001625-40,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,GWT-TUD GmbH,"A MULTICENTER, PHASE I/II STUDY OF SEQUENTIAL EPIGENETIC AND IMMUNE TARGETING IN COMBINATION WITH NAB-PACLITAXEL/GEMCITABINE IN PATIENTS WITH ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001625-40,0,0,0 2017-001626-17,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001626-17,0,0,0 2017-001629-41,2,2021-03-19,2021-03-19,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ITALFARMACO S.P.A.,"A randomised, double-blind, placebo-controlled study to evaluate the micro-macroscopic effects on muscles, the safety and tolerability, and the efficacy of givinostat in patients with Becker Muscular ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001629-41,0,0,0 2017-001631-39,1,,,0,0,0,1,0,1,1,0,0,4,0,0,0,0,1,Audentes Therapeutics Inc.,"VALENS: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT342, an AAV8-Delivered Gene Transf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001631-39,0,0,0 2017-001632-19,6,2020-04-01,2021-05-31,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Myovant Sciences GmbH,"SPIRIT 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Aceta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001632-19,1,0,0 2017-001632-19,6,2020-04-01,2021-05-31,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,MYOVANT SCIENCES GMBH,"SPIRIT 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Aceta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001632-19,1,0,0 2017-001634-26,1,,,0,0,0,1,0,0,1,1,1,4,0,0,0,0,1,TRPHARM,"Phase I, Double Blind, Randomized, Parallel-Arm, Single-Dose, Pharmacokinetic and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator (Avastin®, Roche) in Healthy Male V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001634-26,0,1,1 2017-001636-19,1,2018-01-16,2018-01-16,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Heron Therapeutics, Inc.","A Phase 3, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Multicenter Study of HTX-011 via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001636-19,0,0,0 2017-001639-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD),A phase II trial to evaluate the efficacy and safety of FOLFIRI + panitumumab as first-line treatment in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good per...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001639-38,0,0,0 2017-001641-27,5,2021-11-17,2021-11-17,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Summit (Oxford) Limited,"A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001641-27,1,0,0 2017-001642-10,9,2021-11-19,2021-11-19,8,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Summit (Oxford) Limited,"A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001642-10,1,0,0 2017-001644-35,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Aarhus University Hospital,The effect of popliteal plexus block on pain after total knee replacement,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001644-35,0,0,0 2017-001646-10,1,2020-06-01,2020-06-01,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Uppsala University Hospital,Anesthesia Induced Hormonal Oliguria Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001646-10,0,0,0 2017-001647-12,2,2019-09-25,2019-09-25,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Arbutus Biopharma Corporation,"A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with PEG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001647-12,0,0,0 2017-001651-31,1,2020-04-02,2020-04-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,EMPOWER: EMesis in Pregnancy - Ondansetron With mEtoclopRamide.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001651-31,0,0,0 2017-001655-31,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Advenchen Laboratories LLC,"A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Studio di Fase III con AL38...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001655-31,0,0,0 2017-001655-31,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"ADVENCHEN LABORATORIES, LLC","A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Studio di Fase III con AL38...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001655-31,0,0,0 2017-001657-13,2,2020-01-27,2020-01-27,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Gan & Lee Pharmaceuticals USA Corporation,"AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE INSULIN LISPRO INJECTION TO HUMALOG® (INSULIN LISPRO INJECTION) IN ADULT SUBJECTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001657-13,0,0,0 2017-001660-38,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,FONDAZIONE TOSCANA GABRIELE MONASTERIO,"A prospective triple-arm, monocentric, phase-II explorative study on evaluation of diagnostic efficacy of the PET tracer (18F)-florbetaben (Neuraceq®) in patients with cardiac amyloidosis - FLORAMICAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001660-38,0,0,0 2017-001664-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC MILES 5 – A randomized phase 2 study comparing immunotherapy with chemo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001664-37,0,0,0 2017-001665-25,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Erasmus MC,"Formoterol-beclomethasone in patients with bronchiectasis: a randomized, double-blind, placebo-controlled trial (Forza study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001665-25,0,0,0 2017-001673-17,2,2018-05-25,2018-05-25,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Integrative Research Laboratories AB,"A randomized, double-blind, placebo-controlled, multi-centre phase IIa study evaluating the safety and tolerability of IRL752 in patients with Parkinson's Disease Dementia Satunnaistettu, kaksoisso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001673-17,0,0,0 2017-001677-16,2,2020-03-17,2020-03-17,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Galderma S.A.,"A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous T-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001677-16,0,0,0 2017-001677-16,2,2020-03-17,2020-03-17,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Galderma R&D SNC,"A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous T-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001677-16,0,0,0 2017-001678-40,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Novartis pharma AG,An extension study of safety of canakinumab in Japanese patients with periodic fever syndromes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001678-40,0,1,1 2017-001679-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Univeristy Medical Center Groningen,"Randomized, double blind, placebo controlled, multicenter pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure Gerandomiseerde, dubbel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001679-22,0,0,0 2017-001680-20,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Royal Marsden Hospital,"Phase II study of ROS1 targeting with crizotinib in advanced E-cadherin negative, ER positive lobular breast cancer or diffuse gastric cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001680-20,0,0,0 2017-001681-24,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Erasmus MC,Avoiding tacrolimus under- and overexposure by using a new dosing algorithm for pediatric renal transplant recipients Het voorkómen van onder- en overdosering van tacrolimus bij kinderen met een ni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001681-24,0,0,0 2017-001683-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fédération Francophone de Cancérologie Digestive,SecOnd-line Chemotherapy with RAmucirumab +/- pacliTaxel in Elderly advanced gastric or gastroesophageal junction cancer patients SecOnde ligne de Chimiothérapie avec RAmucirumab +/- pacliTaxel che...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001683-37,0,0,0 2017-001684-21,2,2019-12-09,2019-12-09,1,1,0,1,0,1,1,0,0,2,1,0,0,0,1,"NeuroVia, Inc.","Phase 1, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001684-21,1,0,0 2017-001684-21,2,2019-12-09,2019-12-09,1,1,0,1,0,1,1,0,0,2,1,0,0,0,1,Neurov Acquisition LLC,"Phase 1, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001684-21,1,0,0 2017-001688-20,2,2020-11-29,2020-11-29,2,1,0,1,0,0,1,0,0,1,0,0,0,0,0,Ghent University Hospital,INTRAPERITONEAL AEROSOLISATION OF ALBUMIN-STABILIZED PACLITAXEL NANOPARTICLES FOR PERITONEAL CARCINOMATOSIS – PHASE I/II STUDY PROTOCOL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001688-20,0,0,0 2017-001690-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Helse Bergen HF,Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to Temozolomide phase 1B/II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001690-16,0,0,0 2017-001691-39,14,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,0,University Hospital Münster,LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001691-39,0,0,0 2017-001691-39,14,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,0,Universitätsklinikum Münster,LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001691-39,0,0,0 2017-001695-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ISTITUTI FISIOTERAPICI OSPITALIERI,Monitoring the effectiveness and safety of biological drugs for treatment of psoriasis through evaluation of clinical and biological markers Monitoraggio dell'efficacia e sicurezza di farmaci biolo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001695-26,0,0,0 2017-001696-22,3,2018-10-16,2018-10-16,2,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Janssen-Cilag International NV,"A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001696-22,1,0,0 2017-001697-42,1,2018-12-14,2018-12-14,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Schülke & Mayr GmbH,"Randomized, placebo-controlled, parallel group, double-blind, multi-center Phase III study to assess the inhibition of plaque formation of 0.1% octenidine mouthwash vs placebo in subjects with a gingi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001697-42,0,0,0 2017-001698-18,2,2018-09-14,2018-09-14,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Schülke & Mayr GmbH,"Randomized, placebo-controlled, parallel group, double-blind, multi-center Phase III study to assess the inhibition of plaque formation of 0.1% octenidine mouthwash vs placebo in subjects with a gingi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001698-18,0,0,0 2017-001699-43,7,2022-03-11,2022-03-11,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Basilea Pharmaceutica International Ltd,"A randomized, double-blind, multi-center study to establish the efficacy and safety of ceftobiprole medocaril compared to daptomycin in the treatment of Staphylococcus aureus bacteremia, including inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001699-43,1,0,0 2017-001700-29,1,2019-07-25,2019-07-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Cambridge University Hospitals NHS Foundation Trust & The University of Cambridge,Targeted drug intervention to inhibit cancer progression in men on active surveillance for prostate cancer. Therapeutics in Active Prostate cancer Surveillance (TAPS01),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001700-29,0,0,0 2017-001701-33,1,2017-12-14,2017-12-14,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Department of Dermatology D92, Bispebjerg Hospital",Photodynamic therapy without curettage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001701-33,0,0,0 2017-001702-15,5,2020-11-02,2020-11-09,3,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo And NSAID-Controlled Study To Evaluate The Efficacy And Safety Of Fasinumab In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001702-15,1,0,0 2017-001708-31,1,2017-12-04,2017-12-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Aarhus University Hospital,The effect of the popliteal plexus block on postoperative pain after reconstruction of the anterior cruciate ligament Effekten af plexus popliteus blokade til postoperativ smertebehandling efter re...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001708-31,0,0,0 2017-001709-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Randomized, Double-blind, Placebo-controlled Trial on the Efficacy of the Botulinum Toxin for the Treatment of Lateral Epicondylitis Essai randomisé en double aveugle pour évaluer l’efficacité de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001709-33,0,0,0 2017-001710-28,1,2022-04-14,2022-04-14,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Incyte Corporation,"A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001710-28,0,0,0 2017-001714-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University hospital,Influence of epidural analgesia on opioid consumption and patients recovery after laparoskopic colorectal surgery. Epiduraalipuudutuksen vaikutus opiodikipulääkkeiden tarpeeseen ja potilaiden toipu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001714-29,0,0,0 2017-001715-36,4,2018-09-26,2018-09-26,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GALDERMA R&D, SNC",A study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001715-36,0,0,0 2017-001717-92,1,2020-11-30,2020-11-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Medical University of Vienna,"A randomised, double-blind, placebo-controlled Phase II study to target the type I IFN receptor by administrating Anifrolumab in RA patients with a high IFN signature (TarIFNiRA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001717-92,0,0,0 2017-001718-28,6,2019-03-07,2019-03-11,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001718-28,0,0,0 2017-001724-22,5,2019-03-11,2019-03-11,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001724-22,0,0,0 2017-001725-40,4,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001725-40,0,0,0 2017-001725-40,4,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 1b/2 Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001725-40,0,0,0 2017-001728-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Ghent University,"Efficacy of golimumab in early axial spondyloarthritis (axSpA) in relation to gut inflammation, an early remission induction study (GO GUT).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001728-23,0,0,0 2017-001730-26,1,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,1,Orchard Therapeutics (Europe) Ltd,"A single arm, open label, clinical study of cryopreserved autologous CD34+ cells transduced with lentiviral vector containing human ARSA cDNA OTL-200, for the treatment of early onset Metachromatic Le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001730-26,0,0,0 2017-001731-39,1,,,0,1,0,0,0,1,4,0,0,1,1,1,0,1,1,Orchard Therapeutics (Europe) Ltd,Methodology study to investigate the utility of retroviral insertion site analysis in samples from subjects treated with Strimvelis™ gene therapy Studio metodologico per valutare l’utilità dell’ana...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001731-39,0,0,0 2017-001735-39,8,2019-05-30,2019-05-30,6,1,1,0,0,1,2,0,0,1,1,0,1,0,1,"Chimerix, Inc","An Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir versus Standard of Care for Treatment of Aden...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001735-39,0,0,0 2017-001736-19,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Leeds,"A randomised phase II trial of Selinexor, cyclophosphamide and prednisolone vs cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma (RRMM) patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001736-19,0,0,0 2017-001737-85,1,2020-03-01,2020-03-01,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,academic medical centre,Efficacy of AlbenDazole to inDuce mUcosal healing in Patients with Crohn's disease on anti-TNF monotherapy Effectiviteit van albendazol voor het induceren van mucosale heling bij patiënten met de z...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001737-85,0,0,0 2017-001739-38,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,Takeda Development Centre Europe Ltd.,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001739-38,0,0,0 2017-001741-27,5,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001741-27,0,0,0 2017-001741-27,5,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Pfizer Inc.,"A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001741-27,0,0,0 2017-001743-12,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Incyte Corporation,"A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001743-12,0,0,0 2017-001746-10,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001746-10,0,0,0 2017-001746-10,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001746-10,0,0,0 2017-001746-10,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab versus placebo, with or without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001746-10,0,0,0 2017-001747-12,6,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"A phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Ped...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001747-12,0,0,0 2017-001747-12,6,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Ped...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001747-12,0,0,0 2017-001747-12,6,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Ped...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001747-12,0,0,0 2017-001748-36,9,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Genmab A/S,"A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001748-36,0,0,0 2017-001748-36,9,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,GENMAB A/S,"A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001748-36,0,0,0 2017-001750-34,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Incyte Corporation,An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non–Small Cell Lung Cancer Estudio abierto en fase I/II de INCB039110 en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001750-34,0,0,0 2017-001754-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA,Single versus Dual Antiplatelet Therapy in patients with Incomplete Revascularization after Coronary artery bypass graft surgery Studio prospettico randomizzato per valutare l’effetto della doppia ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001754-33,0,0,0 2017-001755-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Ruprecht-Karls-Universität Heidelberg, Medical Faculty",Randomized Phase-II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies Randomisier...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001755-31,0,0,0 2017-001758-32,6,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,1,AMGEN INC.,Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Follow-up sulla sicurezza a lungo termine dei pazienti con tumore a cellule giganti del...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001758-32,0,0,0 2017-001758-32,6,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,1,"Amgen, Inc.",Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Follow-up sulla sicurezza a lungo termine dei pazienti con tumore a cellule giganti del...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001758-32,0,0,0 2017-001760-38,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,Clinical study of the efficacy of liquid (drops) versus classic (tablets) formulations of levothyroxine in replacement therapy of adults with clinical hypothyroidism. Μελέτη της αποτελεσματικότητας...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001760-38,0,0,0 2017-001762-13,7,2021-07-09,2021-07-09,4,1,0,0,0,1,4,0,0,2,1,0,0,0,1,INTERCEPT PHARMACEUTICALS INC.,"A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients with Primary Biliary Cholangitis and Moderate to Severe Hepatic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001762-13,1,0,0 2017-001762-13,7,2021-07-09,2021-07-09,4,1,0,0,0,1,4,0,0,2,1,0,0,0,1,"Intercept Pharmaceuticals, Inc.","A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients with Primary Biliary Cholangitis and Moderate to Severe Hepatic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001762-13,1,0,0 2017-001764-37,4,2019-11-18,2019-11-18,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Genentech, Inc.","A PHASE II, OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA30044 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001764-37,0,0,0 2017-001764-37,4,2019-11-18,2019-11-18,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Roche Farma, S.A por delegación de Genentech, Inc.","A PHASE II, OPEN-LABEL EXTENSION STUDY OF PATIENTS PREVIOUSLY ENROLLED IN STUDY GA30044 TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001764-37,0,0,0 2017-001765-25,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Novartis,"An Investigation of the Safety and Efficacy of Elidel® 1% Cream in Atopic Disease Modification, Assessed in a 3-year Randomized Doubleblind Vehicle Controlled Phase to Evaluate Effects on Atopic Derma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001765-25,0,1,1 2017-001766-25,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,Novartis,"An open label, 52 week, multicenter study, of long term management to evaluate effectiveness, tolerability and safety of pimecrolimus cream 1% in pediatric patients with mild to moderate atopic dermat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001766-25,0,1,1 2017-001768-39,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA,"Randomized multicentre-controlled, placebo-controlled (1: 1) study to evaluate the efficacy and safety of Curosurf in patients under 12 months of age with moderate or severe acute respiratory distress...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001768-39,0,0,0 2017-001769-26,4,2021-01-14,2021-01-14,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,mAbxience Research SL,"STELLA – A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001769-26,0,0,0 2017-001770-42,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,A multicenter phase II non-randomised trial assessing the efficacy of Domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorecta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001770-42,0,0,0 2017-001772-28,6,2019-09-04,2020-03-16,2,1,0,0,0,1,0,0,0,2,0,0,0,0,1,CTI BioPharma Corp.,"An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001772-28,1,0,0 2017-001772-28,6,2019-09-04,2020-03-16,2,1,0,0,0,1,0,0,0,2,0,0,0,0,1,CTI BIOPHARMA CORP.,"An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001772-28,1,0,0 2017-001773-17,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"FibroGen, Inc.",A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (M...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001773-17,0,0,0 2017-001773-17,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,FIBROGEN,A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (M...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001773-17,0,0,0 2017-001774-41,5,2022-06-24,2022-06-24,2,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Amphera B.V.,"A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001774-41,1,0,0 2017-001774-41,5,2022-06-24,2022-06-24,2,0,0,0,0,1,2,0,0,2,0,0,0,0,1,AMPHERA BV,"A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001774-41,1,0,0 2017-001778-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leonor Cuadra Llopart,A Prospective Randomized Trial Comparing the Effect of 2 vitamin D supplementation regimens in elderly people after hip fracture surgery Ensayo clínico de bajo nivel de intervención comparando efec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001778-40,0,0,0 2017-001779-22,1,2019-12-19,2019-12-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Aarhus University Hospital, Department of Endocrinology",The Effect of Empagliflozin on Cardiac and Kidney Metabolism in Persons with Type 2 Diabetes Effekten af Empagliflozin på metabolismen i hjertet og nyrerne hos personer med type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001779-22,0,0,0 2017-001785-14,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospitals Birmingham NHS Foundation Trust,STRESS-L: STudy into the REversal of Septic Shock with Landiolol (Beta Blockade),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001785-14,0,0,0 2017-001788-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University Vienna,Metformin therapy to prohibit progression in patients with abdominal aortic aneurysm,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001788-19,0,0,0 2017-001790-16,1,2022-06-07,2022-06-07,1,0,0,1,0,1,1,0,0,1,1,1,0,0,1,RHEACELL GmbH & Co. KG,"AN INTERVENTIONAL, OPEN-LABEL, MULTICENTER PHASE I/IIA CLINICAL TRIAL TO INVESTIGATE THE SAFETY AND EFFICACY OF ASCENDING DOSES OF ALLOGENEIC ABCB5-POSITIVE LIMBAL STEM CELLS (LSC2) FOR THE TREATMENT ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001790-16,0,0,0 2017-001798-18,1,,,0,0,1,0,0,0,2,0,1,4,0,0,0,0,0,Inserm,Partnership for Research on Ebola VACcinations P/0307/2021 P/0334/2021 Partenariat de recherche sur les vaccins contre Ebola,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001798-18,0,1,1 2017-001799-41,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Novartis Pharmaceutical Corporation,"A 26-week randomized, double-blind, placebo-controlled, multi-center study to evaluate the effect of omalizumab on markers of asthma impairment in patients with persistent allergic asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001799-41,0,1,1 2017-001800-31,11,2020-12-15,2021-02-15,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Genentech Inc,"A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001800-31,0,0,0 2017-001800-31,11,2020-12-15,2021-02-15,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GENENTECH, INC.","A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001800-31,0,0,0 2017-001800-31,11,2020-12-15,2021-02-15,9,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Roche Farma, S.A por delegación de Genentech, Inc.","A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001800-31,0,0,0 2017-001803-57,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,Novartis Pharmaceuticals Corp,"A randomized, study in healthy subjects to determine the bioavailability of 200 mg LCZ696 mini-tablet compared to the 200 mg LCZ696 final market image tablet",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001803-57,0,1,1 2017-001804-31,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Novartis Pharma K.K,Ph3 trial of Glivec in CML-CP patients previously untreated with IFN-alfa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001804-31,0,1,1 2017-001805-34,1,,,0,1,0,0,0,1,2,0,0,4,0,0,0,0,1,Novartis Pharma K.K,Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001805-34,0,1,1 2017-001807-62,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Forschungsinstitut der Diabetes-Akademie Bad Mergentheim e.V.,"Evaluation of different algorithms for the calculation of the prandial insulin dose, considering the fat and protein content of the meal - Effects on postprandial glucose in type 1 diabetes patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001807-62,0,0,0 2017-001810-27,7,2020-10-16,2020-10-16,4,1,0,0,0,0,0,0,0,2,1,0,0,0,1,Incyte Corporation,A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Place...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001810-27,1,0,0 2017-001810-27,7,2020-10-16,2020-10-16,4,1,0,0,0,0,0,0,0,2,1,0,0,0,1,INCYTE CORPORATION,A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Place...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001810-27,1,0,0 2017-001819-36,2,2019-04-08,2019-04-08,2,0,0,0,0,0,3,0,1,1,0,0,1,0,1,VBI Vaccines Inc.,A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001819-36,0,0,0 2017-001820-22,4,2019-09-01,2019-10-01,4,0,0,0,0,0,3,0,1,1,0,0,1,0,1,VBI Vaccines INC.,A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001820-22,0,0,0 2017-001821-42,9,2021-10-27,2021-10-27,7,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"ChemoCentryx, Inc.","A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001821-42,1,0,0 2017-001823-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA,Efficacy and Safety of Intravenous Ferric Carboxymaltose in Patients Undergoing Cardiac Surgery A Randomized Controlled Study Efficacia e sicurezza della carbossimaltosio ferrico in pazienti che pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001823-26,0,0,0 2017-001824-23,1,2020-12-15,2020-12-15,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Fundación de Investigación Biomédica del Hospital Universitario Puerta de Hierro-Majadahonda (FIBM-HUPHM),Intrathecal administration of autologous adult bone marrow mesenchymal stem cells expanded in the diffuse axonal injury. ADMINISTRACION INTRATECAL DE CELULAS MESENQUIMALES TRONCALES ADULTAS AUTOLO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001824-23,0,0,0 2017-001826-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Narodowy Instytut Kardiologii Stefana kardynała Wyszyńskiego- Państwowy Instytut Badawczy,Optimal antiplatelet treatment to achieve Stroke Avoidance and Fall in Bleeding Events following Left Atrial Appendage Closure (SAFE-LAAC) Comparative Health Effectiveness Randomized Trial - PILOT ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001826-16,0,0,0 2017-001828-22,3,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Y-mAbs Therapeutics A/S,A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy using 131I-burtomab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001828-22,0,0,0 2017-001829-40,5,,,0,0,0,0,0,1,0,0,0,3,0,0,0,0,1,Y-mAbs Therapeutics A/S,A Phase 3 Trial of Antibody hu3F8 and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary or Secondary Refractory Osteomedullary Disease Ensay...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001829-40,0,0,0 2017-001830-24,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers Estudio de nivolumab en combinación con trametin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001830-24,0,0,0 2017-001830-24,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers Estudio de nivolumab en combinación con trametin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001830-24,0,0,0 2017-001831-38,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,Alexion Pharma GmbH,"A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Concurrent Control Study of the Safety, Efficacy, and Pharmacokinetics of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline Ph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001831-38,0,1,1 2017-001832-21,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001832-21,0,0,0 2017-001832-21,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001832-21,0,0,0 2017-001833-15,2,2019-01-31,2019-01-31,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,ASLAN Pharmaceuticals,"A Two-Part Phase 2/3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Of Varlitinib Plus mFOLFOX6 Versus Placebo Plus mFOLFOX6 in Subjects with HER1/ HER2 Co-Expressing Advanced or Meta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001833-15,0,0,0 2017-001834-25,5,2021-02-12,2021-05-31,3,0,0,0,0,0,4,0,0,2,0,0,0,0,0,ECRI-9,MAnagement of high bleeding risk patients post bioresorbable polymer coated STEnt implantation with an abbReviated versus prolonged DAPT regimen (MASTER-DAPT) Hantering av patienter med hög blödnin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001834-25,1,0,0 2017-001836-20,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"PROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA","STEP-WISE COMBINATION OF OBINUTUZUMAB, VEMURAFENIB AND COBIMETINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) PREVIOUSLY TREATED WITH PURINE ANALOGS OR UNFIT FOR CHEMOTHERAPY: A PHASE-2, SINGLE-ARMS, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001836-20,0,0,0 2017-001838-26,1,2017-10-31,2017-10-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,THEA,Comparison of NAABAK® efficacy versus FLUCON® in the treatment of moderate manifestations of allergic conjunctivitis to birch pollen in subjects exposed to birch in ALYATEC’s environmental exposure ch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001838-26,0,0,0 2017-001840-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU University Medical Center,"ERtugliflozin triAl in DIabetes with preserved or reduced ejeCtion FrAcTion mEchanistic evaluation in Heart Failure: ""ERADICATE-HF""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001840-37,0,0,0 2017-001841-28,6,2020-11-09,2020-11-09,4,1,0,0,0,0,0,0,0,2,0,0,0,0,1,Incyte Corporation,"A Phase 2, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001841-28,1,0,0 2017-001841-28,6,2020-11-09,2020-11-09,4,1,0,0,0,0,0,0,0,2,0,0,0,0,1,INCYTE CORPORATION,"A Phase 2, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) plus Epacadostat (INCB024360) Versus Pembrolizumab plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001841-28,1,0,0 2017-001842-82,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,PIERRE FABRE MEDICAMENT,"Phase I/II open label dose escalation and dose expansion study of intravenous infusion of W0101, an antibody-drug conjugate, in patients with advanced or metastatic solid tumors International, multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001842-82,0,0,0 2017-001846-90,5,2019-07-31,2019-07-31,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,The Medicines Company,"A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO EVALUATE THE EFFECT OF 300 MG OF INCLISIRAN SODIUM GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001846-90,0,0,0 2017-001848-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Juan Blanco Carrion,METRONIDAZOLE AS AN ADJUNCT OF NON-SURGICAL TREATMENT OF PERI-IMPLANTITIS: A 6-MONTHS PLACEBO-CONTROLLED CLINICAL TRIAL IN HUMANS. TRATAMIENTO NO QUIRÚRGICO DE PERIIMPLANTITIS CON O SIN METRONIDAZO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001848-35,0,0,0 2017-001851-29,1,2019-05-23,2019-05-23,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Bayer AG,"Randomized, multi-center, double-blind, placebo-controlled, group-comparison study to investigate safety, tolerability and pharmacodynamics of BAY2253651 after administration of a single nasal dose in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001851-29,0,0,0 2017-001853-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,An explorative study for halting inflammation in patients with emphysema by intravenous administration of autologous bone marrow derived mesenchymal stromal cells. Een exploratieve studie naar het ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001853-15,0,0,0 2017-001857-14,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,UNICANCER,A phase I/II basket trial evaluating a combination of Metronomic Oral Vinorelbine plus anti-PD-L1/anti-CTLA4 ImmunothErapy in patients with advanced solid tumours.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001857-14,0,0,0 2017-001861-25,4,2021-04-27,2021-04-27,4,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Diamyd Medical AB,"A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered into Lymph Nodes Combined with Oral Vitamin D to Investigate the Impact on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001861-25,0,0,0 2017-001862-56,10,2018-10-16,2018-10-16,9,1,1,0,0,0,2,0,0,2,1,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001862-56,1,0,0 2017-001862-56,10,2018-10-16,2018-10-16,9,1,1,0,0,0,2,0,0,2,1,0,0,0,1,Janssen-Cilag International NV,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001862-56,1,0,0 2017-001878-42,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,CONSORCIO HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA,Sildenafil Citrate effect on in vivo human trophoblast research. INVESTIGACIÓN SOBRE EL EFECTO DEL SILDENAFILO EN EL TROFOBLASTO HUMANO IN VIVO.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001878-42,0,0,0 2017-001899-32,1,2018-12-28,2018-12-28,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Dr. Abelardo Aguilera Peralta,Crossover and randomized clinical trial on the effect of Resincolestiramine in the intestinal absorption of new uremic toxins in patients in hemodialysis with chronic renal insufficiency Ensayo clí...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001899-32,0,0,0 2017-001902-14,1,2018-05-23,2018-05-23,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,"MedImmune LLC, a wholly owned subsidiary of AstraZeneca PLC","A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI4276 in Subjects with Select HER2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001902-14,0,0,0 2017-001903-60,16,2022-08-05,2022-08-05,10,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Sanofi-aventis recherche & développement,"A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Heterozygous Familial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001903-60,1,1,0 2017-001905-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundació Sant Joan de Déu,TREATMENT OF INTRAUTERINE GROWTH RESTRICTION WITH LOW MOLECULAR WEIGHT HEPARIN: RANDOMIZED CLINICAL TRIAL (TRACIP STUDY) TRATAMIENTO DEL CRECIMIENTO INTRAUTERINO RESTRINGIDO PRECOZ CON HEPARINA DE ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001905-33,0,0,0 2017-001909-32,1,2020-02-14,2020-02-14,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001909-32,0,0,0 2017-001910-27,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc","A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantly w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001910-27,0,1,1 2017-001912-13,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Kite Pharma, Inc.",A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) (ZUMA-5),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001912-13,0,0,0 2017-001914-27,1,2019-03-30,2019-03-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,St George's University Hospitals NHS Foundation Trust,Prostaglandin insert (Propess) versus tran-scervical balloon catheter for out-patient labour induction: A randomised controlled trial of feasibility (PROBIT-F),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001914-27,0,0,0 2017-001915-35,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Medical University of Graz,"GLUCOCORTICOID HIGH-DOSE VS. REPLACEMENT IN IMMUNE CHECKPOINT INHIBITOR ASSOCIATED HYPOPHYSITIS: AN OPEN, RANDOMIZED PILOT STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001915-35,0,0,0 2017-001929-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,"A prospective, randomized pilot study of the immunomodulatory effects of azithromycin in adults with pulmonary tuberculosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001929-40,0,0,0 2017-001939-38,2,2021-08-12,2021-08-12,2,0,0,0,0,0,2,0,0,1,0,0,1,0,0,LYSARC,"A prospective phase II study of nivolumab alone, or in combination with vinblastin in patients aged 61 years and older, with classical Hodgkin Lymphoma and coexisting medical conditions Etude de ph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001939-38,0,0,0 2017-001940-37,6,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,Sanofi-aventis recherche & développement,"Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001940-37,0,0,0 2017-001940-37,6,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001940-37,0,0,0 2017-001941-28,5,2020-05-08,2020-05-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6 Month Formulation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001941-28,0,0,0 2017-001941-28,5,2020-05-08,2020-05-08,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6 Month Formulation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001941-28,0,0,0 2017-001943-12,3,2019-05-02,2019-05-03,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Regeneron Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients with Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001943-12,0,0,0 2017-001944-36,3,2019-12-10,2020-05-13,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Amgen Inc,A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects with Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001944-36,0,0,0 2017-001945-29,1,2021-01-21,2021-01-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Linköping University, Department of clical and Experimental Medicine","Immediate post partum LNG-IUS insertion or standard insertion procedure after childbirth An open-label, randomized, multicenter study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001945-29,0,0,0 2017-001946-93,1,2019-10-16,2019-10-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,National Instute of Health and Welfare,"Double-blind, placebo-controlled randomised study on the efficacy of naloxone nasal spray for the treatment of gambling disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001946-93,0,0,0 2017-001950-33,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,UCL,Methylphenidate versus placebo for fatigue in advanced cancer (MePFAC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001950-33,0,0,0 2017-001954-32,1,2019-07-03,2019-07-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,LUMC,Near-infrared Fluorescence-Enhanced Identification of the Ureters using ZW800-1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001954-32,0,0,0 2017-001963-19,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen) Cabozantinib in pazienti affetti da neoplasia spinoce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001963-19,0,0,0 2017-001965-26,2,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Autolus Ltd,"A SINGLE ARM, OPEN-LABEL, MULTI-CENTRE, PHASE I/II STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF AUTO4, A CAR T CELL TREATMENT TARGETING TRBC1, IN PATIENTS WITH RELAPSED OR REFRACTORY TRBC1 POS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001965-26,0,0,0 2017-001970-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"MD, PhD Salome Kristensen","Dose reduction and discontinuation of biological therapy in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: Protocol for a 18 months randomised, open label, parall...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001970-41,0,0,0 2017-001972-46,3,2020-09-07,2020-09-07,3,1,0,0,1,0,4,0,0,1,1,1,1,0,1,Fresenius Kabi Deutschland GmbH,"Reaching Protein Target with SmofKabiven extra Nitrogen Versus Olimel N9E: A Prospective, Randomised, Active-controlled, Patient-blinded, Multicentre Clinical Trial During the Early Phase of Acute Cri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001972-46,0,0,0 2017-001976-48,12,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Bristol-Myers Squibb international Corporation,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS 986165 in Subjects with Moderate-to-Severe Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001976-48,0,0,0 2017-001976-48,12,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS 986165 in Subjects with Moderate-to-Severe Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001976-48,0,0,0 2017-001976-48,12,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS 986165 in Subjects with Moderate-to-Severe Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001976-48,0,0,0 2017-001977-18,1,2021-01-12,2021-01-12,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Medical Center Groningen,Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001977-18,0,0,0 2017-001979-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,"A randomized, open-label Phase II efficacy and safety study of Atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junct...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001979-23,0,0,0 2017-001980-19,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects with Metastatic or Locally Advanced Urothelial Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001980-19,0,0,0 2017-001980-19,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects with Metastatic or Locally Advanced Urothelial Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001980-19,0,0,0 2017-001982-26,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Hospital for Sick Children,"A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma (L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001982-26,0,0,0 2017-001983-39,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Medical Centre Utrecht,A placebo-controlled double blind randomized trial to investigate the efficacy and safety of the combination of Penicillin G / Hydrocortisone treatment in ALS patients (PHALS).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001983-39,0,0,0 2017-001987-39,7,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,Novartis Pharma AG,"An open label, multi-center roll-over study to assess long-term safety in patients who are ongoing or have completed a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001987-39,0,0,0 2017-001987-39,7,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","An open label, multi-center roll-over study to assess long-term safety in patients who are ongoing or have completed a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001987-39,0,0,0 2017-001992-22,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Oxford,Phase II open label randomised safety and efficacy study of the viral vectored ChAd-MVA 5T4 vaccine in combination with PD-1 checkpoint blockade in low- or intermediate-risk localized or locally advan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001992-22,0,0,0 2017-001993-40,1,2018-09-10,2018-09-10,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered as a Booster Dose in Children Vaccinated 3 Years Earlier as Toddlers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001993-40,0,0,0 2017-001994-18,7,2022-06-30,2022-06-30,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Synthon Biopharmaceuticals BV,"A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001994-18,1,0,0 2017-001994-18,7,2022-06-30,2022-06-30,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,SYNTHON BIOPHARMACEUTICAL BV,"A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001994-18,1,0,0 2017-001994-18,7,2022-06-30,2022-06-30,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Byondis BV,"A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001994-18,1,0,0 2017-001997-41,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Amgen Inc.,"A Phase 1/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination with Pomalidomide, with and without Dexamet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-001997-41,0,0,0 2017-002005-36,4,2020-09-25,2020-09-25,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Rhythm Pharmaceuticals, Inc.","An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset Leptin Receptor (LEPR) D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002005-36,0,0,0 2017-002007-97,1,2019-08-30,2019-08-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Cliniques universitaires Saint-Luc,Does LOW Dose DEXmedetomidine After Cardiopulmonary Bypass Separation Decrease the Incidence of DELirium: A Double-blind Randomized Placebocontrolled Study (LOWDEXDEL Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002007-97,0,0,0 2017-002008-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Region Skåne,A prospective open label study to evaluate treatment of chronic HCV infection with glecaprevir/pibrentasvir in PWID attending a needle exchange program,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002008-28,0,0,0 2017-002009-37,1,2018-08-15,2018-08-15,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Neuroanæstesiologisk Klinik, RH/Glostrup","""The effect of Betamethasone gel and NSAID gel lubricated on the laryngeal mask on pain in the throat, hoarseness and cough after anesthesia. "" “Effekten af Betamethason gel og NSAID gel smurt på L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002009-37,0,0,0 2017-002011-33,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Hellenic Institute for the Study of Sepsis,A RANDOMIZED PROSPECTIVE CLINICAL TRIAL TO ASSESS THE ROLE OF PROCALCITONIN-GUIDED ANTIMICROBIAL THERAPY TO REDUCE LONG-TERM INFECTIONS SEQUELAE ΜΙΑ ΠΡΟΟΠΤΙΚΗ ΤΥΧΑΙΟΠΟΙΗΜΕΝΗ ΚΛΙΝΙΚH ΜΕΛΕΤΗ ΓΙΑ ΤΗ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002011-33,0,0,0 2017-002012-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IRCCS ISTITUTO CLINICO HUMANITAS,EXPLORATIVE STUDY ON THE BIOLOGICAL MECHANISMS INVOLVED IN THE PATHOGENESIS OF PSORIASIS STUDIO ESPLORATIVO SUI MECCANISMI BIOLOGICI COINVOLTI NELLA PATOGENESI DELLA PSORIASI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002012-13,0,0,0 2017-002014-31,1,2018-07-05,2018-07-05,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novo Nordisk A/S,"A trial comparing the pharmacokinetic properties of fast-acting insulin aspart between children, adolescents and adults with type 1 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002014-31,0,0,0 2017-002018-29,8,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,PFIZER INC,"EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002018-29,0,0,0 2017-002018-29,8,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, New York, New York 10017","EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002018-29,0,0,0 2017-002018-29,8,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,Pfizer Inc.,"EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002018-29,0,0,0 2017-002022-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VU University Medical Center,The effect of inspiratory oxygen fraction on the ratio of partial arterial oxygen pressure and inspiratory oxygen fraction (PaO2/FiO2 ratio) in mechanically ventilated patients with and without mild t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002022-20,0,0,0 2017-002023-21,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (RCHP) VERSUS RITUXIMAB AND ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002023-21,0,0,0 2017-002023-21,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (RCHP) VERSUS RITUXIMAB AND ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002023-21,0,0,0 2017-002024-24,1,2020-06-11,2020-06-11,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,Aarhus Unversity Hospital,"Randomized, cohort study of standardized reduction of subcutaneous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy Randomiseret, kohorte studie om standa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002024-24,0,0,0 2017-002025-38,1,2018-01-23,2018-01-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MedImmune Limited, a wholly owned subsidiary of AstraZeneca","A Phase 2, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Different Doses of MEDI0382 in Overweight and Obese Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002025-38,0,0,0 2017-002026-20,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Carrick Therapeutics,"A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002026-20,0,0,0 2017-002028-26,1,2019-04-09,2019-04-09,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Ark Biosciences Pty Ltd.,"A Randomised, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002028-26,0,0,0 2017-002036-17,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Erasmus Medical Center,THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002036-17,0,0,0 2017-002037-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Antoine-LACASSAGNE,Study of the impact of DPD activity on the efficacy of capecitabine Etude de l’impact de l’activité DPD sur l’efficacité de la capécitabine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002037-31,0,0,0 2017-002038-21,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,F. Hoffman-La Roche Ltd.,"A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002038-21,0,0,0 2017-002046-71,1,2019-11-14,2019-11-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 12-week randomized, patient and investigator blinded, placebo-controlled, parallel group study to investigate the efficacy of LIK066 in obese patients with non-alcoholic steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002046-71,0,0,0 2017-002047-15,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,Novartis Pharma AG,"A multicenter, randomized, patient, investigator and sponsor blinded, placebo-controlled phase II study to evaluate the efficacy and safety of CSJ148 in pregnant women with primary HCMV infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002047-15,0,0,0 2017-002048-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Societe Francaise de Cardiologie,Effet pharmacométabolomique des statines : Etude METASTATINE Effet pharmacométabolomique des statines : Etude METASTATINE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002048-34,0,0,0 2017-002049-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Heart Center, Department of Cardiology, Rigshospitalet",Effect of Levosimedan or Placebo on Exercise Capatity and hemodynamics in Patients with Advanced Chronic Heart Failure (LOCO-CHF trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002049-31,0,0,0 2017-002050-36,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Personalised pharmacological approach to the tapering of corticosteroid doses in systemic lupus patients treated with prednisone Approche pharmacologique personnalisée de la Décroissance des doses ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002050-36,0,0,0 2017-002054-37,3,,,0,0,0,1,0,2,1,0,0,2,1,0,0,0,0,The Hospital for Sick Children,Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002054-37,0,0,0 2017-002054-37,3,,,0,0,0,1,0,2,1,0,0,2,1,0,0,0,0,Hospital for Sick Children,Pilot Study of Nivolumab in Pediatric Patients with Hypermutant Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002054-37,0,0,0 2017-002055-28,1,2019-04-05,2019-04-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Synektik Spółka Akcyjna,Safety and dose optimization for [11C] DMDPA as a PET imaging agent for evaluation of myocardial perfusion in subjects with known or suspected coronary artery disease (CAD).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002055-28,0,0,0 2017-002056-86,1,2021-11-20,2021-11-20,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,AIO-Studien-gGmbH,A multicenter open-label phase II trial to evaluate Nivolumab and Ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer Eine multizentrische offene Phase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002056-86,0,0,0 2017-002057-11,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Omeros Corporation,A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002057-11,0,0,0 2017-002060-40,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Single-Dose, Open-Label, Parallel Group Study to Characterize the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of Reslizumab Following Subcutaneous Administration in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002060-40,0,1,1 2017-002063-17,5,2021-03-31,2021-03-31,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,EUROPEAN THORACIC ONCOLOGY PLATFORM,A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002063-17,1,0,0 2017-002063-17,5,2021-03-31,2021-03-31,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,ETOP (European Thoracic Oncology Platform),A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002063-17,1,0,0 2017-002065-21,5,2019-09-26,2019-09-26,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharma A/S,"A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroid in subjects with moderate-to-severe atopic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002065-21,0,0,0 2017-002067-18,2,2020-09-14,2020-09-14,2,1,1,0,0,1,2,0,0,1,1,0,1,0,1,Advicenne,"A multicenter, randomised, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability and acceptability of repeated doses of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002067-18,0,0,0 2017-002068-42,2,2021-09-17,2021-09-17,2,0,1,0,0,1,0,0,0,1,1,0,1,0,1,Advicenne,"Open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and the acceptability of alkalising treatments at long-term in patients with cystinuria Etude multi-centriqu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002068-42,0,0,0 2017-002069-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CENTRE LEON BERARD,"BREASTIMMUNE02 - A multicenter, randomized, open-label, Phase II trial aiming to evaluate the impact of pegfilgrastim on trastuzumab anti-tumor effect and antibody-dependent cell-mediated cytotoxicity...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002069-22,0,0,0 2017-002078-38,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University Hospitals Bristol NHS Foundation Trust,"Effectiveness, cost effectiveness and safety of gabapentin versus placebo as an adjunct to multimodal pain regimens in surgical patients: A placebo controlled randomised controlled trial with blinding...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002078-38,0,0,0 2017-002079-24,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Academic Medical Center,Targeting the secondary bile acid glycodeoxycholic acid as therapeutic strategy in type 2 diabetes mellitus. Het aangrijpen van het secundaire galzout glycodeoxycholaat als therapeutische strategie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002079-24,0,0,0 2017-002080-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,Modified FOLFOX plus/minus Nivolumab and Ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction - A randomized phase 2 tri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002080-18,0,0,0 2017-002081-40,1,2018-03-28,2018-03-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Repha GmbH,"Investigation of the efficacy and safety of ANGOCIN® Anti-Infekt N versus placebo in adult patients with acute, uncomplicated rhinosinusits. A multi-center, randomized, double-blind, placebo-controlle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002081-40,0,0,0 2017-002088-16,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Bambino Gesù Children's Hospital,Phase I/II study of anti-CD19 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non Hodgkin Lymphoma Studio d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002088-16,0,0,0 2017-002089-37,3,2018-12-18,2018-12-18,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Clearside Biomedical, Inc.","TOPAZ: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN COMBINATION WITH AN INTRAVITREAL ANTI-VEGF AGENT IN SUBJECTS WITH RETINAL VEIN OCCLUSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002089-37,0,0,0 2017-002092-25,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital of Montpellier,"A phase 2/3 prospective, multicentre randomized, double-blind trial, comparing intra-discal allogeneic adult BM-MSC therapy and sham-treated controls in subjects with chronic low back pain due to lumb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002092-25,0,0,0 2017-002092-25,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CENTRE HOSPIITALIIER UNIIVERSIITAIIRE DE MONTPELLIIER,"A phase 2/3 prospective, multicentre randomized, double-blind trial, comparing intra-discal allogeneic adult BM-MSC therapy and sham-treated controls in subjects with chronic low back pain due to lumb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002092-25,0,0,0 2017-002093-40,1,2018-05-14,2018-05-14,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Radboudumc,"68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma or salivary duct carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002093-40,0,0,0 2017-002094-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA,Prospective evaluation of a continuation therapy with Midostaurin in adult patients with core-binding factor leukemia and integrated genetic analysis: a multi-center phase II study Valutazione pros...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002094-18,0,0,0 2017-002095-10,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,"Universitetsklinik for Nyresygdomme og Blodtryksforhøjelse, Regionshospitalet Holstebro; Hospitalsenheden Vest",Investigate the differences between treating Chronic Kidney Disease - Mineral and Bone Disorder with an iron-containing phosphate binder or a calcium-containing phosphate binder in Chronic Kidney Dise...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002095-10,0,0,0 2017-002096-26,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,"Universitetsklinik for Nyresygdomme og Blodtryksforhøjelse, Regionshospitalet Holstebro; Hospitalsenheden Vest",Investigate the differences between treating Chronic Kidney Disease - Mineral and Bone Disorder with an iron-containing phosphate binder or a calcium-containing phosphate binder in dialysis patients. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002096-26,0,0,0 2017-002097-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Centre Utrecht,"SAMe as an epigenetic treatment of depression in people with childhood trauma, a double blind placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002097-38,0,0,0 2017-002101-35,1,2021-06-12,2021-06-12,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Sten Madsbad,"THE ROLE OF HYPERGLYCEMIA, HYPERINSULINEMIA AND ELEVATED FREE FATTY ACIDS FOR CARDIAC FUNCTION IN PATIENTS WITH TYPE 2 DIABETES – THE HYPERCARD2 STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002101-35,0,0,0 2017-002106-13,2,2018-07-03,2018-07-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Athera Biotechnologies AB,"Double-blind, randomised, placebo-controlled, multicentre, Phase IIa study to investigate the effect of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002106-13,0,0,0 2017-002108-28,4,2021-01-07,2021-01-07,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Pfizer Inc, 235 East 42nd Street, New York, New York 10017","A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06687234 AS ADD-ON THERAPY TO INFLIXIMAB IN ACTIVE ULCERATIVE C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002108-28,0,0,0 2017-002108-28,4,2021-01-07,2021-01-07,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,PFIZER INC,"A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06687234 AS ADD-ON THERAPY TO INFLIXIMAB IN ACTIVE ULCERATIVE C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002108-28,0,0,0 2017-002110-32,3,2020-08-27,2020-08-27,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Regents of the University of Michigan,DMID Protocol Number: 10-0065 OVERCOME Trial: Randomized Controlled Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002110-32,1,0,0 2017-002110-32,3,2020-08-27,2020-08-27,1,0,0,0,0,0,3,0,0,2,0,0,0,0,0,THE REGENTS OF THE UNIVERSITY OF MICHIGAN,DMID Protocol Number: 10-0065 OVERCOME Trial: Randomized Controlled Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002110-32,1,0,0 2017-002113-64,1,2022-03-23,2022-03-23,1,0,0,0,0,0,4,0,0,1,0,0,0,0,1,Novartis Finland Oy,Controlled trial on the short-term effects of sacubitril/valsartan therapy on cardiac oxygen consumption and efficiency of cardiac work in patients with NYHA II-III heart failure and reduced systolic ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002113-64,0,0,0 2017-002115-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region Uppsala,A multicenter phase II/III-study of 68Ga-ABY-025 PET for non-invasive quantification of HER2-expression in advanced breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002115-34,0,0,0 2017-002116-14,11,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002116-14,0,0,0 2017-002116-14,11,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A",A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002116-14,0,0,0 2017-002119-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ZonMW,The PLUS study: Preventing LUmbar Disc Surgery PLUS studie: Het voorkomen van lumbale hernia operaties,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002119-33,0,0,0 2017-002120-24,3,2022-01-07,2022-02-02,3,0,0,0,0,0,2,0,0,1,1,0,0,0,1,Oncopeptides AB,An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination with either Bortezomib or Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002120-24,0,0,0 2017-002122-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dean of the Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg Prof. Dr. Jürgen Schüttler,Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma (IMPORTANCE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002122-20,0,0,0 2017-002124-24,1,,,0,1,0,0,0,1,2,0,0,3,0,0,0,0,0,Charité - Universitätsmedizin Berlin,Oral Propranolol for prevention of threshold retinopathy of prematurity Orales Propranolol zur Prävention einer höhergradigen Frühgeborenen-Retinopathie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002124-24,0,0,0 2017-002125-38,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,LM Diagnósticos S.L.,Effect of dapagliflozin on nighttime blood pressure in type 2 diabetes Efecto de la dapagliflozina en la presión arterial nocturna en pacientes con diabetes tipo 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002125-38,0,0,0 2017-002126-20,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Oxford,Interleukin-2 therapy of Autoimmunity in Diabetes: ITAD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002126-20,0,0,0 2017-002127-16,3,2018-10-19,2018-11-19,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Umecrine Cognition AB,"A phase IIa study of GR3027 in patients with idiopathic hypersomnia (IH) involving an open-label part to assess safety, tolerability and pharmacokinetics (PK) of a single oral GR3027 dose in female pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002127-16,0,0,0 2017-002129-39,1,2021-03-22,2021-03-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,XCELL Medical Solutions,Phase II Clinical Trial to Know the effectiviness and safety with a a treatment based in a therapy with serical autologous white cells versus the use of Platelet Rich Plasma in patients with rotulia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002129-39,0,0,0 2017-002130-23,1,2019-06-26,2019-06-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Zealand university hospital Roskilde,Ultrasoundguided Transmuscular Quadratus Lumborum(TQL) block for hand assisted laparoscopic nephrectomy - a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002130-23,0,0,0 2017-002134-23,5,2022-02-18,2022-02-18,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Sanofi-aventis groupe,"Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients with Moderate to Severe Asthma who Completed the TRAVERSE-LTS12551Clinical Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002134-23,1,1,0 2017-002134-23,5,2022-02-18,2022-02-18,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,sanofi-aventis groupe,"Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients with Moderate to Severe Asthma who Completed the TRAVERSE-LTS12551Clinical Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002134-23,1,1,0 2017-002136-16,4,2020-09-04,2020-09-04,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Allergan Ltd.,"A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002136-16,0,0,0 2017-002136-16,4,2020-09-04,2020-09-04,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,ALLERGAN LIMITED,"A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002136-16,0,0,0 2017-002137-32,1,2019-12-31,2019-12-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Hans-Gustaf Ljunggren,"Immunological responses after concomitant vaccination with the yellow fever-vaccine Stamaril and the TBE-vaccine FSME Immun, or JE-vaccine Ixiaro Immunologiskt svar efter samtidig vaccinering med ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002137-32,0,0,0 2017-002138-22,8,2022-02-16,2022-02-16,7,0,0,0,0,0,4,0,0,1,0,0,0,0,1,AOP Orphan Pharmaceuticals GmbH,"Phase IV, multicenter, prospective, randomized, open-label, controlled study on Landiolol in patients with septic shock resident in ICUs",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002138-22,0,0,0 2017-002138-22,8,2022-02-16,2022-02-16,7,0,0,0,0,0,4,0,0,1,0,0,0,0,1,AOP ORPHAN PHARMACEUTICALS AG,"Phase IV, multicenter, prospective, randomized, open-label, controlled study on Landiolol in patients with septic shock resident in ICUs",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002138-22,0,0,0 2017-002138-22,8,2022-02-16,2022-02-16,7,0,0,0,0,0,4,0,0,1,0,0,0,0,1,AOP Orphan Pharmaceuticals AG,"Phase IV, multicenter, prospective, randomized, open-label, controlled study on Landiolol in patients with septic shock resident in ICUs",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002138-22,0,0,0 2017-002139-41,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"REGENERON PHARMACEUTICALS, INC.","An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002139-41,0,0,0 2017-002139-41,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an anti CD20 x anti-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002139-41,0,0,0 2017-002143-15,11,2020-10-29,2020-10-30,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Allergan Ltd.,"A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002143-15,0,0,0 2017-002143-15,11,2020-10-29,2020-10-30,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ALLERGAN LIMITED,"A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002143-15,0,0,0 2017-002144-33,10,2020-11-05,2020-11-05,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Allergan Ltd.,"A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002144-33,0,0,0 2017-002144-33,10,2020-11-05,2020-11-05,9,1,0,0,0,0,3,0,0,1,1,0,1,0,1,ALLERGAN LIMITED,"A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002144-33,0,0,0 2017-002146-72,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,1,Celgene Corporation,"A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (REVLIMID®) in Pediatric Subjects from 1 to ≤ 18 Years of Age with Relapsed o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002146-72,0,1,1 2017-002153-11,4,2022-05-25,2022-05-25,2,0,0,0,0,2,0,0,0,2,0,0,0,0,1,GENSIGHT BIOLOGICS,Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials Follow-up a lungo termine di ND4 in soggetti affetti da neuropati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002153-11,1,0,0 2017-002154-36,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Novartis Pharma KK,"A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Adult and Adolescent Patients With Inadequately Controlled Se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002154-36,0,1,1 2017-002155-28,1,2022-06-17,2022-06-17,1,0,0,0,0,1,2,0,0,1,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation of allopurinol treatment for autistic disorders and epilepsy in adenylosuccinate lyase deficiency (ADSL) Evaluation d’un traitement à l’allopurinol sur les troubles autistiques et l’épil...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002155-28,0,0,0 2017-002156-84,17,2020-08-28,2020-08-28,15,1,1,0,0,0,3,0,0,2,1,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002156-84,1,1,0 2017-002156-84,17,2020-08-28,2020-08-28,15,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Janssen-Cilag International NV,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002156-84,1,1,0 2017-002158-35,4,2019-10-22,2019-10-22,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Inventiva S.A.,"A phase IIa study to investigate safety, Pharmacokinetics, and efficacy of odiparcil in patients 16 years and above with mucopolysaccharidosis (MPS) type VI.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002158-35,0,0,0 2017-002163-17,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,"RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty","A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICH´S ATAXIA (NICOFA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002163-17,0,0,0 2017-002163-17,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,RWTH Aachen University represented by the Center for Translational & Clinical Research Aachen (CTC-A),"A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICH´S ATAXIA (NICOFA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002163-17,0,0,0 2017-002163-17,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,"RWTH Aachen University, Center for Translational & Clinical Research Aachen (CTC-A)","A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICH´S ATAXIA (NICOFA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002163-17,0,0,0 2017-002164-41,1,,,0,0,0,0,1,1,4,0,0,0,0,0,0,0,0,Fundació Parc Taulí,Growth hormone therapy in adults with Prader-Willi syndrome: Effect on muscle tone assessed by functional magnetic resonance imaging (fMRI) and its relation to muscle strenght and body composition. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002164-41,0,0,0 2017-002165-21,8,2019-07-10,2019-07-10,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ionis Pharmaceuticals Inc.,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ISIS 416858 (IONIS-FXIRX an Antisense Inhibitor of Factor XI), ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002165-21,0,0,0 2017-002167-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Anna Meuronen,INTRANASAALINEN FENTANYYLI JA S-KETAMIINI AKUUTIN KIVUN HOIDOSSA PIENTRAUMAPOTILAILLA INTRANASAALINEN FENTANYYLI JA S-KETAMIINI AKUUTIN KIVUN HOIDOSSA PIENTRAUMAPOTILAILLA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002167-18,0,0,0 2017-002168-42,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Iciar Arteagoitia Calvo,Efficacy of clindamycin in preventing infection and failure after dental implant placement: a placebo-controlled randomized clinical trial. Eficacia de la clindamicina en la prevención de la infecc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002168-42,0,0,0 2017-002169-23,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Søren Rittig,The effect of clinical characterization of children with monosymptomatic nocturnal enuresis on the efficacy of desmopressin and alarm therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002169-23,0,0,0 2017-002169-23,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aarhus University Hospital,The effect of clinical characterization of children with monosymptomatic nocturnal enuresis on the efficacy of desmopressin and alarm therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002169-23,0,0,0 2017-002170-39,1,2019-03-01,2019-03-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Eksote,Combination of intrathecal morphine and local infiltration analgesia in treatment postoperative pain of total knee arthroplasty Intratekaalisen morfiinin ja LIA-puudutuksen yhdistelmähoito polven ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002170-39,0,0,0 2017-002171-26,1,2019-12-31,2019-12-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Hellenic Institute for the Study of Sepsis,A PERSONALIZED RANDOMIZED TRIAL OF VALIdATION AND RESTORATION OF IMMUNE DYSFUNCTION IN SEVERE INFECTIONS AND SEPSIS: THE PROVIDE TRIAL ΜΙΑ ΔΙΠΛΗ-ΤΥΦΛΗ ΤΥΧΑΙΟΠΟΙΗΜΕΝΗ ΜΕΛΕΤΗ ΑΞΙΟΛΟΓΗΣΗΣ ΚΑΙ ΑΠΟΚΑΤΑΣ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002171-26,0,0,0 2017-002175-25,1,2020-04-20,2020-04-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Profil Institut für Stoffwechselforschung GmbH,Effects on blood pressure and central sympathetic nerve traffic by SGLT2-inhibition with empagliflozin compared to hydrochlorothiazide in patients with type 2 diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002175-25,0,0,0 2017-002176-75,14,2020-08-06,2020-08-07,11,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A randomized, double blind, placebo controlled multicenter dose ranging study to assess the safety and efficacy of multiple oral ZPL389 doses in patients with moderate to severe Atopic Dermatitis (ZES...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002176-75,1,0,0 2017-002176-75,14,2020-08-06,2020-08-07,11,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, double blind, placebo controlled multicenter dose ranging study to assess the safety and efficacy of multiple oral ZPL389 doses in patients with moderate to severe Atopic Dermatitis (ZES...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002176-75,1,0,0 2017-002177-20,8,2020-07-16,2020-09-04,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Allergan Ltd.,"A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002177-20,0,0,0 2017-002179-24,1,2020-06-01,2020-06-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Center for Cancer Immune Therapy,"T-cell therapy in combination with checkpoint inhibitors for patients with advanced ovarian-, fallopian tube- and primary peritoneal cancer. T-celle terapi i kombination med checkpoint inhibitorer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002179-24,0,0,0 2017-002181-42,1,2018-04-10,2018-04-10,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Galapagos NV,"A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2737 in Orkambi-treated subjects with cystic fibrosis homozygous for the F508del mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002181-42,0,0,0 2017-002182-21,7,,,0,0,1,0,2,0,2,0,0,2,0,0,0,0,1,"Takeda Development Centre Europe, Ltd.","A Phase 2b, Extension Study to Determine the Long-term Safety of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease. (Long-term Safety With Vedolizumab IV in Pediatric Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002182-21,0,0,0 2017-002183-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UMCG,PET for Registration of Inflammation in the Vascular wall of Intracranial Aneurysms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002183-41,0,0,0 2017-002185-51,1,2022-07-11,2022-07-11,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Tampere University Hospital,Effect of perineural dexamethasone on the duration of popliteal nerve block for analgesia after ankle surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002185-51,0,0,0 2017-002187-40,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,GENSIGHT BIOLOGICS,"A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected with G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year ""Ensayo aleatorizado, con doble enmascaramiento y co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002187-40,0,0,0 2017-002189-39,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Oxford,A randomised placebo-controlled trial to assess the effect of melatonin on circadian sleep-wake disturbances in ocular disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002189-39,0,0,0 2017-002190-20,1,2019-01-22,2019-01-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Multicenter, Randomized, Double-blind Trial of Brexpiprazole versus Placebo for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002190-20,0,0,0 2017-002192-25,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Center of Expertise in Palliative Care, Maastricht University Medical Centre",Neurotoxic adverse effects of morphine and oxycodone in continuous subcutaneous infusion for treatment of pain in terminal patients with diminished renal function: a Randomized Controlled Trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002192-25,0,0,0 2017-002193-40,3,2019-12-20,2019-12-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Afyx Therapeutics A/S,"A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Study to Assess the Safety and Efficacy of Three Doses of Clobetasol Propionate when Administered Intra-orally Twice Daily in Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002193-40,0,0,0 2017-002194-18,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Medical Center - University of Freiburg,Phase 1/2 Trial to determine the Response Rate of Nivolumab in Acute Myeloid Leukemia (AML) relapse after Allogeneic Hematopoietic Cell Transplantation (allo-HCT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002194-18,0,0,0 2017-002195-13,15,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002195-13,0,0,0 2017-002195-13,15,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002195-13,0,0,0 2017-002196-26,1,2021-02-25,2021-02-25,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,SOTIO a.s.,"An open-label, single-group, multicenter phase II clinical trial evaluating the effect of maintenance DCVAC/OvCa after standard of care therapy in women with first relapse of platinum-sensitive epith...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002196-26,0,0,0 2017-002198-20,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,Dr. Franz Köhler Chemie GmbH,"A Prospective, randomized, single blind, multicentre Phase III study on organ preservation with Custodiol-N solution compared with Custodiol solution in organ transplantation (kidney, liver and pancre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002198-20,0,0,0 2017-002204-27,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,GENSIGHT-BIOLOGICS,"A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects with Retinitis Pigmentosa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002204-27,0,0,0 2017-002208-28,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1/PD-L1 Containing Therapy (HUDSON).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002208-28,0,0,0 2017-002210-31,2,2022-04-14,2022-04-14,1,0,0,0,0,1,2,0,0,2,1,0,0,0,0,FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO,A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy Randomisierte Phase II/III Stud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002210-31,1,0,0 2017-002210-31,2,2022-04-14,2022-04-14,1,0,0,0,0,1,2,0,0,2,1,0,0,0,0,Amyloid Center - Biotechnology Research Laboratories Policlinico San Matteo,A randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy Randomisierte Phase II/III Stud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002210-31,1,0,0 2017-002213-60,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Solid Biosciences Inc.,"A randomized, controlled, open-label, single-ascending dose, phase I/II study to investigate the safety and tolerability, and efficacy of intravenous SGT-001 in male adolescents and children with Duch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002213-60,0,0,0 2017-002214-31,5,2020-01-14,2020-01-14,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Xencor INC,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XmAb®5871 in Patients with IgG4-Related Disease (INDIGO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002214-31,0,0,0 2017-002214-31,5,2020-01-14,2020-01-14,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Xencor, Inc.","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XmAb®5871 in Patients with IgG4-Related Disease (INDIGO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002214-31,0,0,0 2017-002216-14,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Clinical Pharmacology, MUV",Investigation of Pharmacokinetic of Antiinfective Therapy in Healthy Subjects and Severely Burned Patients Admitted to the ICU Untersuchung der Pharmakokinetik von Antiinfektiva am gesunden Proband...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002216-14,0,0,0 2017-002217-59,17,2020-08-28,2020-08-28,15,1,1,0,0,0,3,0,0,1,1,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002217-59,0,0,0 2017-002217-59,17,2020-08-28,2020-08-28,15,1,1,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002217-59,0,0,0 2017-002219-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE GISCAD (GRUPPO ITALIANO PER LO STUDIO DEI CARCINOMI DELL'APPARATO DIGERENTE),"seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status seconD-line folfiri/aflIbercept in proSpe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002219-33,0,0,0 2017-002221-37,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO “PAOLO GIACCONE” DI PALERMO,Glecaprevir/ pibrentasvir plus fixed-dose combination for 6 weeks in patients with acute hepatitis C virus: a pilot study. Glecaprevir/ pibrentasvir in combinazione a dose fissa per 6 settimane in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002221-37,0,0,0 2017-002222-20,2,2019-01-02,2019-01-02,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Multicenter, Randomized, Double-blind Trial of Brexpiprazole versus Placebo for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002222-20,0,0,0 2017-002223-25,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Radboud University Medical Center,Pilot study on the effect of prophylactic versus therapeutic treatment with coal tar and vaseline lanette ointment on the skin barrier repair mechanisms in absence of a chronic inflammatory component....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002223-25,0,0,0 2017-002225-38,3,2019-07-31,2020-07-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects with Bipolar I Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002225-38,0,0,0 2017-002227-13,8,2019-09-09,2020-07-16,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,ACADIA Pharmaceuticals Inc.,"A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002227-13,1,0,0 2017-002227-13,8,2019-09-09,2020-07-16,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,ACADIA PHARMACEUTICALS INC.,"A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002227-13,1,0,0 2017-002231-41,7,2020-05-26,2020-05-26,7,1,1,0,0,0,2,0,0,1,0,0,1,0,1,"Takeda Development Centre Europe, Ltd.","A Phase 2, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Safety and Tolerability of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn’s Disease (A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002231-41,0,0,0 2017-002232-16,1,2018-02-01,2018-02-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects with Treatment-Resistant Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002232-16,0,0,0 2017-002236-17,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Guy's and St Thomas' NHS Foundation Trust,Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors: randomized placebo-controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002236-17,0,0,0 2017-002237-29,4,2019-10-31,2019-10-31,4,1,0,1,0,1,1,0,0,1,1,1,0,0,1,"BioLineRx, Ltd.","A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects with Acute...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002237-29,0,0,0 2017-002238-21,10,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,2,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination with Bortezomib (Velcade®), Lenalidomide (Revlimid®) and Dexamethasone versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002238-21,0,0,0 2017-002238-21,10,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,2,Sanofi-aventis recherche & développement,"A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination with Bortezomib (Velcade®), Lenalidomide (Revlimid®) and Dexamethasone versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002238-21,0,0,0 2017-002239-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,I.R.C.C.S. FONDAZIONE S.LUCIA,Effects of Safinamide therapy on reuroplasticity in patients with Parkinson's disease Effetti sulla neuroplasticit¿ indotti dalla terapia con Safinamide in pazienti affetti da malattia di Parkinson,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002239-41,0,0,0 2017-002241-30,5,2020-02-27,2020-02-27,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dr. Falk Pharma GmbH,"A phase IIa, double-blind, randomised, placebo-controlled, dose-finding study on the efficacy and tolerability of a 6-week treatment with ZED1227 capsules vs. placebo in subjects with well-controlled ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002241-30,0,0,0 2017-002243-15,1,,,0,1,0,1,0,0,1,0,0,3,0,0,0,0,1,Immunocore Ltd.,"A Phase I/II Open-Label, Multi-center Study of the Safety and Efficacy of IMCnyeso, an HLA-A* 0201-Restricted, NY-ESO-1 and LAGE-1A-specific soluble T Cell Receptor and Anti-CD3 Bi-specific Molecule, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002243-15,0,0,0 2017-002244-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Respiratory Research Unit Hvidovre, Department of Respiratory Medicine, Copenhagen University Hospital Hvidovre",Periostin-guided withdrawal of inhaled corticosteroids in patients with non-eosinophilic asthma Periostin-guidet udtrapning af inhalationssteroidbehandling hos patienter med non-eosinofil astma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002244-33,0,0,0 2017-002245-29,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Celgene Corporation,"A phase 2, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002245-29,0,0,0 2017-002245-29,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,CELGENE CORPORATION,"A phase 2, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002245-29,0,0,0 2017-002246-68,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación CRIS contra el cancer,The DUTRENEO Trial: A Prospective Study to Individualize the Approach with DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer patients. Ensayo DUTRENEO: Estudio prospectivo para i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002246-68,0,0,0 2017-002248-34,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King's College London,FInCH Study: A randomised feasibility study comparing fluoride interventions to prevent dental decay in older people in care homes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002248-34,0,0,0 2017-002254-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Tampere University Hospital,Quadratus Lumborum Block (QLB): An effect on postoperative pain therapy and recovery after laparoscopic nephrectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002254-37,0,0,0 2017-002257-11,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,AOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO,A phase I study of adoptive immunotherapy with Cytokine-Induced Killer (CIK) cells in relapsed and non-resectable sarcomas after multimodal treatment. Studio Clinico di Fase 1 sull’utilizzo di immu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002257-11,0,0,0 2017-002258-36,5,2020-08-05,2020-08-05,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,ALFASIGMA S.P.A.,"A Phase II, multicentre, double-blind, randomised, placebo-controlled study of Rifaximin delayed release 400 mg tablet: clinical efficacy and safety in the prevention of post-operative endoscopic Croh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002258-36,0,0,0 2017-002259-26,7,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Incyte Corporation,"A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Adv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002259-26,0,0,0 2017-002259-26,7,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,INCYTE CORPORATION,"A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Adv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002259-26,0,0,0 2017-002261-22,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Kite Pharma, Inc.","A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002261-22,0,0,0 2017-002263-17,1,2019-06-27,2019-06-27,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,BOIRON,"Efficacy and safety of Passiflora Compose in patients newly diagnosed with adjustment disorder with anxiety, as first-line treatment, compared to alprazolam Efficacité et tolérance de Passiflora co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002263-17,0,0,0 2017-002264-41,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude randomisée multicentrique évaluant l’efficacité et la tolérance de l’infliximab comparativement au Cyclophosphamide dans les formes sévères de maladie de Behçet "" Multicenter, randomized, prospe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002264-41,0,0,0 2017-002265-21,1,2018-10-08,2018-10-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A placebo-controlled, double-blind (sponsor open), randomised, crossover study to assess the efficacy, safety, and tolerability of GSK2798745 in participants with chronic cough",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002265-21,0,0,0 2017-002266-45,6,2018-08-03,2019-01-24,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"An open label, randomised, parallel group clinical study to evaluate the effect of the Connected Inhaler System (CIS) on adherence to Relvar/Breo ELLIPTA therapy, in asthmatic subjects with poor contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002266-45,0,0,0 2017-002266-45,6,2018-08-03,2019-01-24,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"An open label, randomised, parallel group clinical study to evaluate the effect of the Connected Inhaler System (CIS) on adherence to Relvar/Breo ELLIPTA therapy, in asthmatic subjects with poor contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002266-45,0,0,0 2017-002266-45,6,2018-08-03,2019-01-24,5,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","An open label, randomised, parallel group clinical study to evaluate the effect of the Connected Inhaler System (CIS) on adherence to Relvar/Breo ELLIPTA therapy, in asthmatic subjects with poor contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002266-45,0,0,0 2017-002267-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Sara Rafael Fernández,EFFICACY AND SAFETY OF THE CONCENTRATE OF AUTOMOTIVE RICH PLASMA IN GROWTH FACTORS IN THE TREATMENT OF THE FINE ENDOMETRY IN PATIENTS SUBMITTED TO TRANSFER OF CRIO-PRESERVED EMBRYOS: CLINICAL TRIAL II...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002267-18,0,0,0 2017-002268-42,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,GlaxoSmithKline Research & Development Ltd,"A randomized, repeat dose, open label, parallel group, multi-center study to evaluate the effect of daprodustat compared to darbepoetin alfa on forearm blood flow in participants with anemia of chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002268-42,0,0,0 2017-002269-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA,"PHARMACOKINETICS OF COLISTIN IN THE ELF AND THE PLASMA OF MDR-GNB OR XDR- GNB VAP OR VAT OR HCAP OR HAP PATIENTS WHO ARE MECHANICALLY VENTILATED: A RANDOMIZED CONTROLLED TRIAL STUDIO CONTROLLATO,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002269-23,0,0,0 2017-002270-39,5,2020-10-07,2020-10-07,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A 28-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center, study in recombinant human erythropoietin (rhEPO) naïve non-dialysis participants with anemia associated with chr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002270-39,1,0,0 2017-002270-39,5,2020-10-07,2020-10-07,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A 28-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center, study in recombinant human erythropoietin (rhEPO) naïve non-dialysis participants with anemia associated with chr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002270-39,1,0,0 2017-002270-39,5,2020-10-07,2020-10-07,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"GlaxoSmithKline, S.A.","A 28-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center, study in recombinant human erythropoietin (rhEPO) naïve non-dialysis participants with anemia associated with chr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002270-39,1,0,0 2017-002274-39,9,2022-03-18,2022-03-18,6,0,0,0,0,0,3,0,0,2,1,0,0,0,1,PFIZER INC,"A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002274-39,1,0,0 2017-002274-39,9,2022-03-18,2022-03-18,6,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, New York 10017","A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002274-39,1,0,0 2017-002274-39,9,2022-03-18,2022-03-18,6,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Pfizer Inc.,"A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002274-39,1,0,0 2017-002276-37,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,"Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET",Phase II trial: uPAR-PET/MR in patients with newly diagnosed prostate cancer; non-invasive characterization of tumor aggressiveness,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002276-37,0,0,0 2017-002280-18,1,2018-12-18,2018-12-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Nordsjællands Hospital Hillerød,"Catheter-based peripheral regional anaesthesia after orthopaedic surgery: Comparison of low dose, automated periodic infusions with conventional high dose, continuous infusion, and patient-initiated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002280-18,0,0,0 2017-002281-46,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,Novo Nordisk A/S,Safety of turoctocog alfa for prophylaxis and treatment of bleeding episodes in previously treated patients with moderate or severe Haemophilia A in India.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002281-46,0,1,1 2017-002283-41,1,2018-05-28,2018-05-28,1,1,0,0,1,0,4,0,1,1,0,0,1,0,1,HRA Pharma,"A prospective, randomized, parallel-group study to assess the effects on ovarian activity of ellaOne (ulipristal acetate 30 mg single dose) taken after three consecutive days of missed combined oral c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002283-41,0,0,0 2017-002284-18,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,"A randomized phase 2 study in patients with triple-negative, androgen receptor positive locally advanced (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine Etude d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002284-18,0,0,0 2017-002288-16,1,2019-06-25,2019-06-25,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Center for Man in Aviation,Effects of Modafinil and Caffeine during the circadian trough on vigilance in healthy RNLAF aircrew: a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002288-16,0,0,0 2017-002289-35,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Seattle Genetics, Inc.","Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002289-35,0,0,0 2017-002290-19,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Celgene Corporation,A Phase 3b randomized study of lenalidomide (CC-5013) plus rituximab maintenance therapy followed by lenalidomide single-agent maintenance versus rituximab maintenance in subjects with relapsed/refrac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002290-19,0,0,0 2017-002292-26,3,2018-10-03,2018-10-08,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma AG,"A randomized, controlled, evaluator-blinded, multicenter, study to evaluate LYS228 pharmacokinetics, clinical response, safety and tolerability in patients with complicated urinary tract infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002292-26,0,0,0 2017-002293-39,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ORIOL BESTARD,"MULTICENTER, RANDOMIZED STUDY, TO EVALUATE THE EFFECTIVENESS OF INDIVIDUALIZATION OF IMMUNOLOGICAL RISK BASED ON SELECTIVE BIOMARKERS (DISPARITY OF HLA EPLETS AND ELISPOT-γ) TO OPTIMIZE IMMUNOSUPPRESS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002293-39,0,0,0 2017-002297-39,10,2020-02-17,2020-02-17,6,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Sanofi-Aventis Recherche & Développement,An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Homozygous Familial Hypercholesterolemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002297-39,1,1,0 2017-002298-20,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Centre Hospitalier Départemental Vendée,Effets sur la douleur d’une infiltration par association acide hyaluronique et corticoïdes versus corticoïdes seuls dans la rhizarthrose.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002298-20,0,0,0 2017-002300-27,2,,,0,0,0,1,0,2,1,0,0,3,0,0,0,0,0,Cardiff University,Phase 1b/II Trial of Checkpoint Inhibitor (Pembrolizumab an Anti PD-1 Antibody) Plus Standard IMRT in HPV Induced Stage III Squamous Cell Carcinoma of Anus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002300-27,0,0,0 2017-002306-12,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,3,,"Determining the role of pre-existing factors, early diagnostic options and early treatment in the development of breast cancer related lymphedema. Bepaling van factoren, snelle diagnose en snelle b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002306-12,0,0,0 2017-002309-36,1,2019-04-18,2019-04-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT,"A randomized, double-blind, parallel-group, 2-treatment multiple dose study to assess the intestinal, metabolic and cardiovascular effects of an 8 weeks treatment with sotagliflozin QD as compared wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002309-36,0,0,0 2017-002310-31,8,2020-07-23,2020-07-23,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,INCYTE CORPORATION,"Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who ha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002310-31,1,0,0 2017-002310-31,8,2020-07-23,2020-07-23,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Incyte Corporation,"Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who ha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002310-31,1,0,0 2017-002310-31,8,2020-07-23,2020-07-23,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Incyte Biosciences Distribution B.V.,"Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who ha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002310-31,1,0,0 2017-002311-34,6,2020-08-04,2020-08-04,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Incyte Corporation,"A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB024360) or Placebo in Participants with Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002311-34,1,0,0 2017-002312-13,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,Rigshospitalet,PET/CT imaging of uPAR-expression in patients with neuroendocrine tumors using 68Ga-NOTA-AE105,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002312-13,0,0,0 2017-002314-31,1,2020-07-06,2020-07-06,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,Klinikum der Universität München,"Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of Allogeneic Donor Lymphocyte Infusions Combined with Blinatumomab in Patients with Treatment-Resistant Mixed Chimerism or Minimal Resid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002314-31,0,0,0 2017-002317-58,2,2019-04-09,2019-04-09,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Intra-Cellular Therapies, Inc. (ITI)","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients with Major Depressive Episodes As...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002317-58,0,0,0 2017-002320-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: A phase II randomized study by the UNICANCER with cooperation of AFSOS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002320-25,0,0,0 2017-002322-20,8,2022-07-11,2022-07-11,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB Biopharma SRL,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002322-20,1,0,0 2017-002322-20,8,2022-07-11,2022-07-11,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB Biopharma SPRL,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002322-20,1,0,0 2017-002323-25,1,2020-12-04,2020-12-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Center for cancer immune therapy,Adoptive cell therapy across cancer diagnoses,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002323-25,0,0,0 2017-002325-38,9,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,Albireo AB,An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002325-38,0,0,0 2017-002326-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación PETHEMA,"An Open-label, Multicenter, Phase 2 trial of selinexor (KPT-330), bortezomib and low-dose dexamethasone plus daratumumab (SELIBORDARA) for the treatment of patients with refractory or relapsed and ref...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002326-21,0,0,0 2017-002329-39,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University College London,Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage randomised controlled platform trial of adjuvant therapy in patients with rese...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002329-39,0,0,0 2017-002330-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University hospital of Montpellier,HEPATIC ARTERIAL INFUSION OF GEMCITABINE-OXALIPLATIN FOR SECOND-LINE THERAPY IN NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA: A MULTICENTRIC SINGLE-ARM PHASE II STUDY TRAITEMENT INT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002330-23,0,0,0 2017-002331-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Hamburg - Eppendorf,Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia with Identical GVHD Prophylaxis Passender unverwandter versus haploidenter Spende...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002331-41,0,0,0 2017-002333-40,4,2020-10-28,2020-10-28,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,argenx BVBA,"An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients with Mild to Moderate Pemphigus (Vulgar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002333-40,0,0,0 2017-002333-40,4,2020-10-28,2020-10-28,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ARGEN-X BVBA,"An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients with Mild to Moderate Pemphigus (Vulgar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002333-40,0,0,0 2017-002334-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dutch Breast Cancer Research Group (BOOG),Selecting the Optimal position of CDK4/6 Inhibitors in HR+ Advanced breast cancer: the SONIA trial Selecteren van de optimale plaats van CDK4/6-remmer bij de behandeling van uitgezaaide hormoonge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002334-23,0,0,0 2017-002336-17,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Clinical Sciences, Danderyd Hospital, Karolinska Intitutet",Randomized Evaluation of Decreased Usage of betablocCkErs after myocardial infarction in the SWEDEHEART registry REDUCe SWEDEHEART,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002336-17,0,0,0 2017-002338-21,9,2020-07-27,2020-07-28,8,1,1,0,0,1,3,0,0,1,0,0,1,0,1,ALBIREO AB,"A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002338-21,0,0,0 2017-002338-21,9,2020-07-27,2020-07-28,8,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Albireo AB,"A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002338-21,0,0,0 2017-002340-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE ARIANNA ANTICOAGULAZIONE,APIDULCIS: Extended anticoagulation with low-dose apixaban after a standard course anticoagulation in patients with a first venous thromboembolism who have positive d-dimer APIDULCIS: Terapia estes...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002340-32,0,0,0 2017-002341-30,1,2019-06-25,2019-06-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,INSTITUTO VALENCIANO DE INFERTILIDAD (IVI),Usefulness of medroxyprogesterone acetate in the follicular phase for ovarian donors to prevent premature luteinization Utilidad del acetato de medroxiprogesterona en fase folicular en donantes de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002341-30,0,0,0 2017-002343-14,3,2021-03-09,2021-03-09,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Ferrer Internacional, S.A.","A multicentre, randomised, open-label, parallel-group trial to study the safety and efficacy of a new therapeutic strategy (Trinomia®) versus usual care on LDLc and blood pressure levels in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002343-14,1,0,0 2017-002345-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Turku University Hospital,The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002345-29,0,0,0 2017-002349-30,1,2020-05-06,2020-05-06,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"TARGID, KU Leuven","Effect of codeine on pharyngeal and esophageal motility in healthy subjects: a double-blind, placebo-controlled, randomized, cross-over study Effect van codeine op motiliteit in farynx en slokdar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002349-30,0,0,0 2017-002350-36,9,2021-12-15,2021-12-15,6,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Genentech, Inc.","A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF UTTR1147A COMPARED WITH PLACEBO AND ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002350-36,1,0,0 2017-002350-36,9,2021-12-15,2021-12-15,6,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"GENENTECH, INC.","A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF UTTR1147A COMPARED WITH PLACEBO AND ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002350-36,1,0,0 2017-002350-36,9,2021-12-15,2021-12-15,6,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Roche Farma, S.A por delegación de Genentech, Inc.","A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF UTTR1147A COMPARED WITH PLACEBO AND ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002350-36,1,0,0 2017-002352-91,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Dra Antònia Dalmau i LLitjós del Servicio de Anestesia, Reanimación y Terapéutica del dolor del HUB -Idibell","Randomised, Double-blind Clinical Trial to Evaluate the Reduction of Pain in the Wounds Treatment Previously Applying Lidocaine Topical Solution vs Placebo in an outpatient. Ensayo clínico randomiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002352-91,0,0,0 2017-002355-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU of Pointe-A-Pitre,Impact of high dose of cholecalciferol in critically ill septic patients with vitamin D deficiency: the CaribDean study Impact of high dose of cholecalciferol in critically ill septic patients with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002355-28,0,0,0 2017-002359-27,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"A Multicentre, Open-label, Single-arm, Molecular Profiling Study of Patients with EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated with Osimertinib Estudio multicéntrico, abierto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002359-27,0,0,0 2017-002359-27,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Multicentre, Open-label, Single-arm, Molecular Profiling Study of Patients with EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated with Osimertinib Estudio multicéntrico, abierto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002359-27,0,0,0 2017-002361-22,11,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002361-22,0,0,0 2017-002361-22,11,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ASTRAZENECA AB,"A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002361-22,0,0,0 2017-002368-42,1,2019-02-15,2019-02-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Lument AB,"An open, randomized, controlled, single centre trial to evaluate CT image quality and diagnostic feasibility of Lumentin® 44, a new egg albumen based oral bowel filling agent, in comparison with dilut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002368-42,0,0,0 2017-002369-23,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Boehringer Ingelheim,"A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 28-week treatment period as adjunctive therap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002369-23,0,0,0 2017-002370-39,11,,,0,1,0,0,0,1,3,0,0,2,1,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Study of Ravulizumab Administered Subcutaneously Versus Intravenously in Adult Patients With Paroxysmal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002370-39,0,0,0 2017-002370-39,11,,,0,1,0,0,0,1,3,0,0,2,1,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 3, Randomized, Parallel-Group, Multicenter, Open-Label, Pharmacokinetic, Noninferiority Study of Ravulizumab Administered Subcutaneously Versus Intravenously in Adult Patients With Paroxysmal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002370-39,0,0,0 2017-002374-39,1,2018-09-04,2018-09-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"Protocol I8B-MC-ITSI A Prospective, Randomized, Double-Blind, Crossover Comparison Evaluating Compatibility and Safety of LY900014 and Insulin Lispro with an External Continuous Subcutaneous Insulin I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002374-39,0,0,0 2017-002377-19,1,2021-06-30,2021-06-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Abteilung für Hals-, Nasen- und Ohrenkrankheiten MUW, AKH Wien",Triamcinolone levels in cochlear perilymph Triamcinolon Spiegel in der cochleären Perilymphe,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002377-19,0,0,0 2017-002383-40,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,AIEOP- Associazione Italiana Ematologia Oncologia Pediatrica,Treatment study for children and adolescents with Acute Promyelocytic Leukemia Behandlingsstudie för barn och ungdomar med akut promyelocytleukemi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002383-40,0,0,0 2017-002385-49,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King's College Hospital NHS Foundation Trust,IN-UK-311-3956: A Feasibility Study of the Switch of Tenofovir disoproxil fumarate to Tenofovir alafenamide fumarate and the Effect on Glomerular Function in Chronic Hepatitis B and HIV co-infected in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002385-49,0,0,0 2017-002395-75,2,2021-10-26,2022-06-29,2,0,0,0,0,1,0,0,0,1,1,0,0,0,1,NightstaRx Ltd,"An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia with Bilateral, Sequential Administration of Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002395-75,0,0,0 2017-002397-39,9,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Amgen Inc.,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Epis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002397-39,0,0,0 2017-002397-39,9,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,AMGEN INC.,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Epis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002397-39,0,0,0 2017-002399-23,7,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,AMGEN INC.,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002399-23,0,0,0 2017-002399-23,7,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Amgen Inc.,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002399-23,0,0,0 2017-002400-26,5,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002400-26,0,0,0 2017-002402-13,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Manchester University NHS Foundation Trust,A Randomised controlled trial to Evaluate the effectiveness and cost benefit of prescribing high dose FLuoride toothpaste in preventing and treating dEntal Caries in high-risk older adulTs (REFLECT tr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002402-13,0,0,0 2017-002404-28,3,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondroplasia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002404-28,0,0,0 2017-002406-12,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,HAMLETT. Handling Antipsychotic Medication: Long-term Evaluation of Targeted Treatment. A pragmatic single blind RCT of continuation versus discontinuation/ dose reduction of antipsychotic medication ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002406-12,0,0,0 2017-002407-10,1,2020-06-11,2020-06-11,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University College London,"A double-blinded, randomised, placebo-controlled trial of liraglutide 3.0 mg in patients with poor weight-loss and a suboptimal glucagon-like peptide-1 response following bariatric surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002407-10,0,0,0 2017-002410-31,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Neurooncología (GEINO),"Phase Ib/II Multicentric Study Combining Glasdegib with temozolomide in patients with newly diagnosed Glioblastoma, safety and preliminary efficacy for the combination. Ensayo clínico fase Ib/II so...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002410-31,0,0,0 2017-002411-34,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,Amgen Inc.,"Phase 3, Randomized, Open-label, Controlled, Multiple-Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 days to < 18 Years of age With Second...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002411-34,0,1,1 2017-002419-32,1,2021-05-15,2021-05-15,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Research Maatschap Cardiologen Rijnmond Zuid,COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions’,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002419-32,0,0,0 2017-002421-38,5,2020-08-13,2020-08-13,3,1,1,0,0,1,3,0,0,1,1,0,1,0,1,AstraZeneca AB,"A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002421-38,0,0,0 2017-002421-38,5,2020-08-13,2020-08-13,3,1,1,0,0,1,3,0,0,1,1,0,1,0,1,ASTRAZENECA AB,"A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002421-38,0,0,0 2017-002423-19,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"BEIGENE USA, INC.","A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002423-19,0,0,0 2017-002423-19,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"BeiGene, Ltd. c/o BeiGene USA, Inc.","A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002423-19,0,0,0 2017-002423-19,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"BeiGene, Ltd.","A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002423-19,0,0,0 2017-002426-20,4,2021-05-03,2021-05-03,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Zambon SpA,"A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson's Disease (IPD) patients with motor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002426-20,0,0,0 2017-002426-20,4,2021-05-03,2021-05-03,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ZAMBON SPA,"A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of safinamide 100 mg once daily, as add-on therapy, in idiopathic Parkinson's Disease (IPD) patients with motor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002426-20,0,0,0 2017-002429-39,7,2021-12-31,2022-01-31,6,0,0,0,0,0,3,0,0,1,1,0,0,0,0,Medical University Innsbruck,REPETITIVE LEVOSIMENDAN INFUSIONS FOR PATIENTS WITH ADVANCED CHRONIC HEART FAILURE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002429-39,0,0,0 2017-002430-23,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,OSPEDALE SAN RAFFAELE,A phase I/II study evaluating safety and efficacy of autologous hematopoietic stem and progenitor cells genetically modified with IDUA lentiviral vector encoding for the human α-L-iduronidase gene for...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002430-23,0,0,0 2017-002432-17,13,2021-03-17,2021-05-31,10,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","ENVISION: A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002432-17,1,0,0 2017-002432-17,13,2021-03-17,2021-05-31,10,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"ALNYLAM PHARMACEUTICALS, INC.","ENVISION: A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002432-17,1,0,0 2017-002433-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU de BREST,"REduced dose versus full-dose of direct oral anticoagulant after uNprOvoked Venous thromboEmbolism. The RENOVE open-label, randomized, controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002433-31,0,0,0 2017-002435-42,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,DANTE: A randomised phase III trial to evaluate the Duration of ANti-PD1 monoclonal antibody Treatment in patients with metastatic mElanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002435-42,0,0,0 2017-002437-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CENTRO DI RIFERIMENTO ONCOLOGICO,Pilot study to evaluate the feasibility of an innovative approach to monitor patients with gastrointestinal stromal tumour treated with imatinib Studio pilota per valutare la fattibilità di un appr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002437-36,0,0,0 2017-002441-30,10,2019-05-22,2019-05-29,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC","A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migrai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002441-30,0,0,0 2017-002441-30,10,2019-05-22,2019-05-29,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migrai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002441-30,0,0,0 2017-002442-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GERCOR,RECIST 1.1 and iRECIST evaluation for patients with deficient MMR and/or MSI Metastatic Colorectal Cancer treated with nivolumab and ipilimumab. A GERCOR open-label phase II study NIPICOL C17-01,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002442-72,0,0,0 2017-002443-15,1,2020-04-01,2020-04-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,York Teaching Hospitals NHS Foundation Trust,"Improving cardiac function in high-risk surgical patients: exercise testing, biomarkers and beta-blockade",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002443-15,0,0,0 2017-002444-32,1,2020-07-23,2020-07-23,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,CHU CAEN,"Maintenance Brentuximab Vedotin (Bv) Following Allogeneic Stem Cell Transplantation for Hodgkin Lymphoma Patient: A Prospective, Multicenter, Phase II Study Maintenance Brentuximab Vedotin (Bv) Fol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002444-32,0,0,0 2017-002446-76,9,2022-05-11,2022-05-11,4,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Deciphera Pharmaceuticals, LLC","A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with AdvanCed Gastrointestinal Stromal TUmorS who have Received Treatment wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002446-76,1,0,0 2017-002446-76,9,2022-05-11,2022-05-11,4,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"DECIPHERA PHARMACEUTICALS, LLC","A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with AdvanCed Gastrointestinal Stromal TUmorS who have Received Treatment wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002446-76,1,0,0 2017-002447-15,5,2020-02-10,2020-02-10,4,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Stealth BioTherapeutics Inc.,"A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondrial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002447-15,0,0,0 2017-002449-31,2,2017-05-25,2018-05-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Zealand Pharma A/S,"A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002449-31,0,0,0 2017-002450-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI,Renal function evaluation through iohexol method in the elderly with sarcopenia and low serum creatinine Funzione renale nell'anziano sarcopenico a bassa creatinina. Valutazione del filtrato glomer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002450-37,0,0,0 2017-002452-87,5,2020-05-13,2020-05-25,5,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Pharmacosmos A/S,"A randomized, double-blinded, comparative trial comparing the incidence of hypophosphatemia in relation to repeated treatment courses of iron isomaltoside and ferric carboxymaltose in subjects with ir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002452-87,0,0,0 2017-002453-11,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Christie NHS Foundation Trust,"A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of nanoliposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002453-11,0,0,0 2017-002454-36,8,2021-06-01,2021-06-01,3,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"IDERA PHARMACEUTICALS, INC.",A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002454-36,1,0,0 2017-002454-36,8,2021-06-01,2021-06-01,3,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Idera Pharmaceuticals, Inc.",A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002454-36,1,0,0 2017-002455-29,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"AVANIR PHARMACEUTICALS, INC.","A Phase 3, Multicenter, Long-term, Extension Study of the Safety and Efficacy of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the Treatment of Agitation in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002455-29,0,0,0 2017-002455-29,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3, Multicenter, Long-term, Extension Study of the Safety and Efficacy of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the Treatment of Agitation in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002455-29,0,0,0 2017-002455-29,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Avanir Pharmaceuticals, Inc.","A Phase 3, Multicenter, Long-term, Extension Study of the Safety and Efficacy of AVP-786 (deuterated [d6] dextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the Treatment of Agitation in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002455-29,0,0,0 2017-002459-27,3,2020-06-08,2020-06-08,3,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Institut de Recherches Internationales Servier,"Phase I/II trial of S 81694 administered intravenously in combination with paclitaxel to evaluate the safety, pharmacokinetic and efficacy in metastatic breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002459-27,0,0,0 2017-002460-41,2,,,0,0,1,0,0,1,2,0,0,0,0,0,0,0,2,"University of Zurich, Tissue Biology Research Unit","A Phase IIb, prospective, intra-patient randomised controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for the t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002460-41,0,0,0 2017-002460-41,2,,,0,0,1,0,0,1,2,0,0,0,0,0,0,0,2,CUTISS AG,"A Phase IIb, prospective, intra-patient randomised controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for the t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002460-41,0,0,0 2017-002461-21,2,,,0,0,1,0,0,2,2,0,0,0,0,0,0,0,2,"University of Zurich, Tissue Biology Research Unit","A Phase IIb, prospective, intra-patient randomised controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for the t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002461-21,0,0,0 2017-002461-21,2,,,0,0,1,0,0,2,2,0,0,0,0,0,0,0,2,CUTISS AG,"A Phase IIb, prospective, intra-patient randomised controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for the t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002461-21,0,0,0 2017-002462-41,2,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,2,"University of Zurich, Tissue Biology Research Unit","A Phase II, prospective, intra-patient randomized controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for the tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002462-41,0,0,0 2017-002462-41,2,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,2,CUTISS AG,"A Phase II, prospective, intra-patient randomized controlled, multicentre study to evaluate the safety and efficacy of an autologous bio-engineered dermo-epidermal skin substitute (EHSG-KF) for the tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002462-41,0,0,0 2017-002464-40,10,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002464-40,0,0,0 2017-002464-40,10,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002464-40,0,0,0 2017-002465-22,16,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or intolerance to at Least O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002465-22,0,0,0 2017-002465-22,16,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or intolerance to at Least O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002465-22,0,0,0 2017-002468-41,1,2021-12-08,2021-12-08,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,University Medical Center of the Johannes Gutenberg- University Mainz,"A phase I/II multicenter, open-label Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and WNT signaling Alterations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002468-41,0,0,0 2017-002470-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC Cancer Institute,Observational study of the effects of probenecid on the pharmacokinetics and pharmacodynamics of sorafenib (PROSORA-study) Een observationele studie naar de effecten van probenecid op de farmacoki...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002470-40,0,0,0 2017-002471-25,2,2019-10-08,2019-10-08,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,F.Hoffmann La-Roche Ltd,"AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 (ISIS 443139) IN HUNTINGTON'S DISEASE PATIENTS WHO PARTICIPATED IN PRIOR INVESTIG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002471-25,0,0,0 2017-002472-30,5,2019-08-27,2019-08-27,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,The Medicines Company,"A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO EVALUATE THE EFFECT OF 300 MG OF INCLISIRAN SODIUM GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002472-30,0,0,0 2017-002473-19,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Cliniques Universitaires Saint-Luc,PREDICTIVE FACTORS AND MAGNITUDE OF RESPONSE TO OMALIZUMAB AND MEPOLIZUMAB IN ALLERGIC AND EOSINOPHILIC SEVERE ASTHMA: A MULTICENTER PRAGMATIC TRIAL IN BELGIUM,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002473-19,0,0,0 2017-002474-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Nykode Therapeutics AS,"An open-label first-in-human phase 1/2a study to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO or VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002474-39,0,0,0 2017-002475-26,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,IRCCS Ospedale Pediatrico Bambino Gesù,Phase I/II study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by High Risk and/or relapsed/refractory Neuroblastoma Studio di fase I/II di sicurezza ed ef...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002475-26,0,0,0 2017-002478-37,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,VU University Medical Center,"Right Dose, Right Now: Randomized Clinical Trial Meteen de juiste dosis: gerandomiseerde klinische trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002478-37,0,0,0 2017-002480-17,1,2019-05-08,2019-05-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Fundación Pública Andaluza Progreso y Salud,"Randomized, placebo-controlled, double-blind trial to evaluate the efficacy and safety of topical application of tranexamic acid for saving blood losses in patients subjected to prosthetic knee surge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002480-17,0,0,0 2017-002483-40,4,2019-09-30,2019-09-30,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase 2b Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for twelve weeks, compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002483-40,0,0,0 2017-002485-40,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III,TREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT) TREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002485-40,0,0,0 2017-002485-40,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (CNIC),TREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT) TREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002485-40,0,0,0 2017-002486-21,1,2019-11-21,2019-11-21,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"GLyPharma Therapeutic, Inc. (a wholly owned subsidiary of VectivBio Holding AG)","A once weekly, repeated dose, placebo controlled, double blind, randomised cross-over trial investigating safety, efficacy and pharmacodynamics of FE 203799 in patients with short bowel syndrome with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002486-21,0,0,0 2017-002487-41,1,2019-10-28,2019-10-28,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GLyPharma Therapeutic Inc. (a wholly owned subsidiary of VectivBio Holding AG),"A Phase Ib/IIa open-label, repeated dose, metabolic balance study of FE 203799 in patients with short bowel syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002487-41,0,0,0 2017-002490-19,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Universitätsklinikum Erlangen,Prospective single-centre randomized observer-blind placebo-controlled parallel-group phase IIa clinical trial to investigate the safety and efficacy of ripasudil 0.4% eye drops after descemetorhexis ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002490-19,0,0,0 2017-002491-10,5,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,1,"Takeda Development Center Americas, Inc.",Postauthorization Safety Study of the Long-Term Safety and Efficacy of Repeat Administration of Darvadstrocel in Patients With Crohn’s Disease and Complex Perianal Fistula,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002491-10,0,0,0 2017-002491-10,5,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,1,"Millennium Pharmaceuticals, Inc (MPI)",Postauthorization Safety Study of the Long-Term Safety and Efficacy of Repeat Administration of Darvadstrocel in Patients With Crohn’s Disease and Complex Perianal Fistula,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002491-10,0,0,0 2017-002494-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMC Utrecht,Dexamethasone for Cardiac Surgery trial: a novel 'Standard Practice Preference-Randomised Consent' Design. A PILOT STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002494-19,0,0,0 2017-002495-20,8,2021-03-29,2021-03-29,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Ferring Pharmaceuticals A/S,"A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receivi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002495-20,1,0,0 2017-002499-14,11,2020-07-02,2020-07-10,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined with Nivolumab versus Nivolumab in Participants with Metastatic or Unresectable Melanoma that is Previously Untreated",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002499-14,1,1,0 2017-002499-14,11,2020-07-02,2020-07-10,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined with Nivolumab versus Nivolumab in Participants with Metastatic or Unresectable Melanoma that is Previously Untreated",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002499-14,1,1,0 2017-002505-35,3,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Institut Català d'Oncologia (ICO),"BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002505-35,0,0,0 2017-002505-35,3,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,ABCSG (Austrian Breast & Colorectal Cancer Study Group),"BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002505-35,0,0,0 2017-002505-35,3,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Austrian Breast & Colorectal Cancer Study Group,"BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002505-35,0,0,0 2017-002508-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"MedUni Vienna, Dept of Anesthesia, Critical Care, Div. of Cardiothoracic and Vascular Anesthesia","Ceftaroline (Zinforo®) as antibiotic prophylaxis for CABG-surgery: An In-vivo microdialysis study Ceftarolin (Zinforo®), ein Cephalosporin der 5. Generation, als perioperative Antibiotikaprophylaxe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002508-29,0,0,0 2017-002511-34,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,"Academic Medical Centre, Amsterdam, NL",Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002511-34,0,0,0 2017-002511-34,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Academisch Medisch Centrum,Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002511-34,0,0,0 2017-002512-14,1,2021-12-13,2021-12-13,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Rigshospitalet,PET/CT imaging of angiogenesis in patients with neuroendocrine tumors using 68Ga-NODAGA-E[c(RGDyK)]2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002512-14,0,0,0 2017-002514-32,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"NeuroproteXeon, Inc.","XePOHCAS: Prospective, randomized, multicenter, interventional trial in adult subjects with out-of-hospital cardiac arrest (OHCA) comparing treatment with standard-of-care post-cardiac arrest intensiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002514-32,0,0,0 2017-002516-13,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,St. Olavs hospital,"“Follow the sutures“. An open multicenter, multinational pilot study to explore tolerability, safety and effect of a new procedure for injecting botulinum toxin in the head against chronic migraine.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002516-13,0,0,0 2017-002517-64,1,2018-05-16,2018-05-16,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,Biocompatibles UK Ltd,"An open label, single-arm, Phase I/II study of vandetanib-eluting radiopaque embolic beads (BTG-002814) in patients with hepatocellular carcinoma (HCC) without curative options",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002517-64,0,0,0 2017-002527-21,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Geneva,"Multicentre, Open-label, Randomised Study to Assess the Diagnostic Value of Amyloid PET Imaging in Patients with Subjective Cognitive Decline Plus, Mild Cognitive Impairment, or Dementia Where Alzheim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002527-21,0,0,0 2017-002529-39,1,2019-09-19,2019-09-19,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,CHU Angers,Intérêt de l’administration de charbon Activé pour les patients ayant un geste invasif reporté dû à un traitement Anticoagulant Oral Direct Intérêt de l’administration de charbon Activé pour les pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002529-39,0,0,0 2017-002530-23,11,2020-05-06,2020-05-06,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"MyoKardia, Inc.","A Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Studio clinico randomizzato, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002530-23,0,0,0 2017-002530-23,11,2020-05-06,2020-05-06,10,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"MYOKARDIA, INC.","A Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Studio clinico randomizzato, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002530-23,0,0,0 2017-002532-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Cliniques Universitaires Saint-Luc,Adjunctive systemic antimicrobial therapy in the surgical treatment of peri-implantitis. A prospective randomized clinical study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002532-16,0,0,0 2017-002533-32,10,2019-12-12,2019-12-12,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Insmed Incorporated,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety and Tolerability, and Pharmacokinetics of INS1007 Administered Once Daily for 24 Weeks...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002533-32,0,0,0 2017-002533-32,10,2019-12-12,2019-12-12,9,1,0,0,0,0,2,0,0,1,0,0,1,0,1,INSMED INCORPORATED,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety and Tolerability, and Pharmacokinetics of INS1007 Administered Once Daily for 24 Weeks...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002533-32,0,0,0 2017-002534-23,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Orion Corporation Orion Pharma,SAFETY AND PHARMACOKINETICS OF ODM-208 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002534-23,0,0,0 2017-002540-33,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,IFCT,A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with PDL1-positive stage IV Non-Small Cell...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002540-33,0,0,0 2017-002541-29,8,2022-09-07,2022-09-07,1,0,1,0,0,1,3,0,0,2,0,0,0,0,1,Clementia Pharmaceuticals Inc,"A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002541-29,1,1,0 2017-002541-29,8,2022-09-07,2022-09-07,1,0,1,0,0,1,3,0,0,2,0,0,0,0,1,Clementia Pharmaceuticals Inc.,"A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002541-29,1,1,0 2017-002541-29,8,2022-09-07,2022-09-07,1,0,1,0,0,1,3,0,0,2,0,0,0,0,1,CLEMENTIA PHARMACEUTICALS INC.,"A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002541-29,1,1,0 2017-002542-72,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Préparation colique et antibiotiques oraux avant chirurgie du cancer colique: un essai randomisé multicentrique en double aveugle,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002542-72,0,0,0 2017-002544-32,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,"A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002544-32,0,0,0 2017-002545-30,1,2020-11-29,2020-11-29,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Barts Health NHS Trust,Autologous Stem cell Transplantation In refractory Crohn's disease - Low Intensity Therapy Evaluation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002545-30,0,0,0 2017-002546-74,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Leipzig,Postoperative adjuvant radiochemotherapy (aRCH) with Cisplatin (C) versus aRCH with C and Pembrolizumab (P) in locally advanced head and neck squamous cell carcinoma (HNSCC); multicenter randomized Ph...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002546-74,0,0,0 2017-002553-11,1,2022-02-22,2022-02-22,1,0,0,0,0,0,2,0,1,1,0,0,0,0,0,"Bispebjerg Hospital, University of Copenhagen","Cardiovascular effects of high dose insulin therapy. A multi-arm, randomized, participant-and-investigator-blinded, crossover study investigating glucagon's effects on heart rate, blood pressure, and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002553-11,0,0,0 2017-002559-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Zaans Medisch Centrum,ED50 and ED90 of intrathecal 1% chloroprocaine in day-case knee arthroscopy ED50 en ED90 van intrathecaal 1% chloroprocaine bij knie artroscopieën via dagopname,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002559-27,0,0,0 2017-002560-41,1,2019-03-31,2019-03-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,University of Leicester,A Calcium channel or Angiotensin converting enzyme inhibitor/Angiotensin receptor blocker Regimen to reduce Blood pressure variability in acute ischaemic Stroke (CAARBS): A Feasibility Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002560-41,0,0,0 2017-002561-21,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,IFCT,Randomised Open Label Adaptive Phase III trial of addition of Belinostat to chemotherapy in patients with locally advanced potentially resectable Thymic Epithelial Tumors (TET),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002561-21,0,0,0 2017-002562-42,4,2019-02-22,2019-02-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Tricida, Inc.","A Blinded, Placebo-Controlled Extension to Study TRCA-301 to Evaluate the Long-term Safety and Durability of Effect of TRC101 in Subjects with Chronic Kidney Disease and Metabolic Acidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002562-42,0,0,0 2017-002563-18,1,2018-05-09,2018-05-09,1,1,0,0,1,0,2,0,1,1,0,0,1,0,1,Pulmocide Ltd,"A single-blind, placebo controlled, randomised study to evaluate antiviral activity and safety and pharmacokinetics of inhaled PC786 against respiratory syncytial virus (RSV) in healthy adult subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002563-18,0,0,0 2017-002565-22,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Lokon Pharma AB,Phase I/II Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002565-22,0,0,0 2017-002566-50,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.",A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenoca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002566-50,0,0,0 2017-002567-17,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Astellas Pharma Global Development, Inc. (APGD)","A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Posit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002567-17,0,0,0 2017-002567-17,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.","A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Posit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002567-17,0,0,0 2017-002571-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UZ Brussel,A comparison between corifollitropin alfa and recombinant FSH for follicular recruitment in women with polycystic ovaries who undergo IVM treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002571-25,0,0,0 2017-002574-39,1,,,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,GlaxoSmithKline Biologicals,"Ancillary study evaluating ChAd155-hIi-HBV shedding in a subset of chronic hepatitis B patients enrolled in the first-time-in-human, Phase I/II, randomised, multi-centric, single-blind study TH HBV VV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002574-39,0,0,0 2017-002577-18,1,2018-08-13,2018-08-13,1,1,0,1,0,1,1,0,0,1,1,1,0,0,1,APREA THERAPEUTICS AB,A phase I/IIa study to investigate the safety and clinical activity of APR-246 in combination with dabrafenib in patients with BRAF V600 mutant unresectable metastatic melanoma resistant to dabrafenib...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002577-18,0,0,0 2017-002579-25,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ObsEva SA,"A phase 2a, double-blind, parallel group, randomised, placebo controlled, proof of concept study to assess the efficacy, safety and pharmacokinetics of OBE022 added-on to atosiban, after oral administ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002579-25,0,0,0 2017-002581-51,1,2020-04-06,2020-04-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allakos Inc.,"An Open-Label, Pilot Study to Assess the Efficacy and Safety Of AK002 (Siglec-8) in Patients with Antihistamine-Resistant Chronic Urticaria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002581-51,0,0,0 2017-002588-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitätsklinikum Tübingen,"Safety and effects on visual function of 0.01% Atropin eye drops for myopia inhibition in children and adolescents Sicherheit und Auswirkungen auf die Sehfunktion von 0,01% Atropin-Augentropfen zur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002588-17,0,0,0 2017-002599-15,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Aarhus University,Effect of pyridostigmine (Mestinon®) on muscle strength in Myasthenia Gravis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002599-15,0,0,0 2017-002601-35,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,PrimeCell Advanced Therapy a.s.,"A Prospective, Randomized, Controlled, Multicenter, Phase II / III, Clinical Study to Evaluate the Effectiveness and Safety of NTC chondrograft® versus the Standard Procedure Arthroscopic Microfractur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002601-35,0,0,0 2017-002602-12,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Cardiff and Vale University Health Board,"Improving Transplant Opportunities for Patients who are Sensitised (ITOPS) – a feasibility, randomised, controlled phase III trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002602-12,0,0,0 2017-002604-27,1,2021-03-16,2021-03-16,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Clinical Physiology, Nuclear Medicin and PET",Phase II trial: RGD PET/MRI in sporadic Vestibular Schwannoma Kan tumorvækst forudsiges ved RGD-PET/MR af vestibularis schwannomer?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002604-27,0,0,0 2017-002605-35,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma. Een fase 2 studie naar de werkzaamheid van atez...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002605-35,0,0,0 2017-002608-29,1,2018-05-17,2018-05-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Entasis Therapeutics,"A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002608-29,0,0,0 2017-002611-34,4,2021-11-19,2021-11-19,2,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Janssen-Cilag International N.V.,"A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination with Daratumumab, Compared with Daratumumab Alone in Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002611-34,1,0,0 2017-002612-14,1,2021-02-08,2021-02-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME),"Preliminary efficacy and safety of Apremilast in the treatment of acne conglobata: A phase II, single centre, open label, proof of concept study for the treatment of acne conglobata with the PDE-4 inh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002612-14,0,0,0 2017-002616-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Maastricht Universitair Medisch Centrum,The effect of perioperative intravenous s-ketamine on acute and chronic postoperative craniotomy pain compared to placebo Het effect van perioperatieve intraveneuze s-ketamine op acute en chronisch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002616-13,0,0,0 2017-002626-20,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA,Efficacy study of gefitinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status Efficacy study of gefitinib in treatment-naïve patients with EGFR mutant NSCLC acc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002626-20,0,0,0 2017-002628-26,11,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc.","A Two-Part Study of ZX008 in Children and Adults with Lennox-Gastaut Syndrome (LGS); Part 1: A Randomized, Double-blind, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochlorid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002628-26,0,0,0 2017-002628-26,11,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Zogenix International Inc.,"A Two-Part Study of ZX008 in Children and Adults with Lennox-Gastaut Syndrome (LGS); Part 1: A Randomized, Double-blind, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochlorid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002628-26,0,0,0 2017-002628-26,11,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Zogenix International Limited,"A Two-Part Study of ZX008 in Children and Adults with Lennox-Gastaut Syndrome (LGS); Part 1: A Randomized, Double-blind, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochlorid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002628-26,0,0,0 2017-002630-22,1,2019-06-16,2019-06-16,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,University Hospital of Toulouse,Pain prevention during propofol infusion in pediatric: hypnoanalgesia of the hand versus lidocaine. Prévention de la douleur à l’injection du propofol en pédiatrie : Hypno-analgésie de la main ver...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002630-22,0,0,0 2017-002631-42,10,2021-09-30,2021-09-30,7,1,0,0,0,0,4,0,0,2,0,0,0,0,1,Merck KGaA,A 2-year prospective study to evaluate the onset of action of Mavenclad® in subjects with highly active relapsing multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002631-42,1,0,0 2017-002631-42,10,2021-09-30,2021-09-30,7,1,0,0,0,0,4,0,0,2,0,0,0,0,1,MERCK KGAA,A 2-year prospective study to evaluate the onset of action of Mavenclad® in subjects with highly active relapsing multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002631-42,1,0,0 2017-002632-17,16,2021-08-26,2021-08-26,11,1,0,0,0,0,4,0,0,2,0,0,0,0,1,Merck KGaA,A 2-year Prospective Study to Assess Health-related Quality of Life in Subjects with Highly-Active Relapsing Multiple Sclerosis Treated with Mavenclad®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002632-17,1,0,0 2017-002632-17,16,2021-08-26,2021-08-26,11,1,0,0,0,0,4,0,0,2,0,0,0,0,1,MERCK KGAA,A 2-year Prospective Study to Assess Health-related Quality of Life in Subjects with Highly-Active Relapsing Multiple Sclerosis Treated with Mavenclad®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002632-17,1,0,0 2017-002634-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Institutet,MultipleMS – Multiple-omics approach to accelerate personalised medicine in a prospective cohort of newly diagnosed MS and CIS patients. MultipleMS: En prospektiv studie för att validera ett flerdi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002634-24,0,0,0 2017-002635-41,1,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,0,Great Ormond Street Hospital,A paediatric phase I/II study of intermittent dosing of the MEK-1 inhibitor selumetinib in children with neurofibromatosis type-1 and inoperable plexiform neurofibroma and/or progressive optic pathway...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002635-41,0,0,0 2017-002636-16,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,VU University medical center Amsterdam,Cognitive impairment and functional reorganization in multiple sclerosis: The role of GABA and glutamate Cognitieve achteruitgang en functionele reorganisatie in multiple sclerose: de rol van GABA ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002636-16,0,0,0 2017-002637-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Kirurgisk Afdeling A, Odense Universitetshospital",Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in resected high risk colon cancer patients. - The PIPAC-OPC3 CC trial -,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002637-37,0,0,0 2017-002641-29,1,2019-01-08,2019-01-08,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Incyte Corporation,"A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002641-29,0,0,0 2017-002644-32,18,2020-03-19,2020-07-08,17,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002644-32,0,0,0 2017-002644-32,18,2020-03-19,2020-07-08,17,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002644-32,0,0,0 2017-002644-32,18,2020-03-19,2020-07-08,17,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-aventis Recherche & Développement,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Cardi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002644-32,0,0,0 2017-002651-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS,Multi-cohort investigational study to evaluate the impact of pelvic mp-3TMRI and whole-body 68Ga-PSMA PET/CT for diagnosis of clinically-significant prostate cancer and pre-surgical staging. Studio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002651-28,0,0,0 2017-002652-81,1,2020-08-28,2020-08-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Eske Kvanner Aasvang,"High dose steroids in liver resection – effects on complications and endothelial function in the immediate postoperative phase. A randomized, double-blind, controlled trial Høj dosis steroid før le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002652-81,0,0,0 2017-002659-28,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,Amgen Inc.,"An open-label, Randomized, Single-dose, 2-Period, ""-Treatment Crossover Study to Assess the Bioequivalence of Cinacalcet Capsule (Administered as Six of the 5 mg Cinacalcet Capsules) with 30 mg Commer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002659-28,0,1,1 2017-002660-41,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SANTEN SAS,"A Phase IIIb, prospective, interventional, multicentre, three-year study to explore the long-term evolution of sign and symptoms, and occurrence of complications in Dry Eye Disease patients with sever...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002660-41,0,0,0 2017-002666-47,1,2019-12-18,2019-12-18,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,"Dpt. of Ophthalmology, Rigshospitalet-Glostrup","Effect of drop-less surgery compared to topical NSAID alone and combination of steroid and NSAID on central macular thickness after cataract surgery, a randomized controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002666-47,0,0,0 2017-002667-17,5,2022-02-14,2022-02-14,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary fibr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002667-17,1,0,0 2017-002668-42,1,2018-02-14,2018-02-14,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Laboratoires SMB S.A.,"A randomised, interventional, double blind, crossover, controlled study to assess the effect of the administration of paracetamol on tramadol adverse events. Рандомизирано, интервенционално, двой...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002668-42,0,0,0 2017-002669-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospital General Universitari de Granollers,Prophylaxis of surgical wound infection with topical antibiotics Profilaxis de la infección de la herida quirúrgica con antibióticos tópicos.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002669-23,0,0,0 2017-002670-39,1,2020-02-21,2020-02-21,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Bispebjerg Hospital,"Hyperoxia and antioxidant intervention during major non-cardiac surgery and risk of cerebral and cardiovascular complications, a blinded 2x2 factorial randomized clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002670-39,0,0,0 2017-002671-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Isala,The effect of Opioids on P2Y12 Receptor Inhibition in patients with ST-Elevation Myocardial Infarction who are pre-treated with crushed Ticagrelor Het effect van opioïden op P2Y12 receptor remming ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002671-26,0,0,0 2017-002672-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002672-38,0,0,0 2017-002674-39,3,2021-02-26,2021-03-29,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Achillion Pharmaceuticals, Inc.",An Open-Label Phase 2 Proof-of-Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002674-39,0,0,0 2017-002674-39,3,2021-02-26,2021-03-29,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"ACHILLION PHARMACEUTICALS, INC.",An Open-Label Phase 2 Proof-of-Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002674-39,0,0,0 2017-002676-87,4,2019-10-14,2019-10-14,3,1,0,0,0,2,3,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Eligibl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002676-87,0,0,0 2017-002676-87,4,2019-10-14,2019-10-14,3,1,0,0,0,2,3,0,0,1,1,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Eligibl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002676-87,0,0,0 2017-002677-19,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Instituto Grifols S.A.,Pathogenesis of Acute on Chronic Liver Failure (ACLF) and Mechanisms of Action of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) in Decompensated Cirrhotic Subjects with Systemic Inflammation a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002677-19,0,0,0 2017-002677-19,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"INSTITUTO GRIFOLS, S.A.",Pathogenesis of Acute on Chronic Liver Failure (ACLF) and Mechanisms of Action of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) in Decompensated Cirrhotic Subjects with Systemic Inflammation a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002677-19,0,0,0 2017-002679-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,KU Leuven,Characterization of colonic motility patterns in different functional bowel disorders compared to health and their role in moving content Karakteriseren van colon motor patronen in verschillende f...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002679-25,0,0,0 2017-002686-21,5,2019-03-05,2019-03-05,4,1,0,1,0,1,1,0,0,1,0,0,0,0,1,WAVE LIFE SCIENCES USA INC,"A Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients with Duchenne Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002686-21,0,0,0 2017-002686-21,5,2019-03-05,2019-03-05,4,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Wave Life Sciences Ltd.,"A Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients with Duchenne Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002686-21,0,0,0 2017-002689-30,1,,,0,1,0,0,1,0,2,0,0,4,0,0,0,0,1,Alcon Research Ltd,Proof-of-Concept Study of a Single Application of an Investigational Otic Suspension in Treatment of Acute Otitis Media With Tympanostomy Tubes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002689-30,0,1,1 2017-002690-19,3,2021-06-30,2021-06-30,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A randomized, double-blind, placebo-controlled, multi-centre, sequential design, phase IIa study to evaluate safety and tolerability of epicardial injections of AZD8601 during coronary bypass graftin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002690-19,0,0,0 2017-002694-19,1,2020-01-23,2020-01-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Radboud University Medical Centre,Mifepristone and misoprostol versus misoprostol alone for uterine evacuation after early pregnancy failure: a randomized double blind placebo-controlled comparison (M&M trial). Mifepristone en miso...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002694-19,0,0,0 2017-002695-45,1,2020-10-29,2020-10-29,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"RWTH Aachen University represented by the Rector, himself, represented by the Dean of the Medical Faculty",Effect of Empagliflozin on Cardiac Output in Patients with Acute Heart Failure (EMPA Acute Heart Failure) Der Effekt von Empagliflozin auf das Herzzeitvolumen bei Patienten mit akuter Herzinsuffiz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002695-45,0,0,0 2017-002697-39,5,2020-11-26,2020-11-26,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,MaaT Pharma,Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disEase afteR AllogeneiC hematopoietic stem celL transplantation with fEcal microbiota transfer (HERACLES),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002697-39,1,0,0 2017-002697-39,5,2020-11-26,2020-11-26,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,MAAT PHARMA,Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disEase afteR AllogeneiC hematopoietic stem celL transplantation with fEcal microbiota transfer (HERACLES),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002697-39,1,0,0 2017-002698-20,5,2019-05-14,2019-05-14,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Opthea Ltd,"A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002698-20,0,0,0 2017-002698-20,5,2019-05-14,2019-05-14,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,OPTHEA LIMITED,"A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002698-20,0,0,0 2017-002698-20,5,2019-05-14,2019-05-14,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Opthea Limited,"A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002698-20,0,0,0 2017-002702-12,11,2019-01-30,2019-05-31,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd.,"A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION OF PHASE III STUDIES (BN29552/BN29553) OF CRENEZUMAB IN PATIENTS WITH ALZHEIMER¿S DISEASE ESTENSIONE A LUNGO TERMINE, MULTICENTRICA E IN APERTO DI STU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002702-12,0,0,0 2017-002702-12,11,2019-01-30,2019-05-31,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION OF PHASE III STUDIES (BN29552/BN29553) OF CRENEZUMAB IN PATIENTS WITH ALZHEIMER¿S DISEASE ESTENSIONE A LUNGO TERMINE, MULTICENTRICA E IN APERTO DI STU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002702-12,0,0,0 2017-002702-12,11,2019-01-30,2019-05-31,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Roche Farma S.A.(Soc. Unipersonal)que realiza el ensayo en España y que actúa como representante F.Hodmann-La Roche LTD,"A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION OF PHASE III STUDIES (BN29552/BN29553) OF CRENEZUMAB IN PATIENTS WITH ALZHEIMER¿S DISEASE ESTENSIONE A LUNGO TERMINE, MULTICENTRICA E IN APERTO DI STU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002702-12,0,0,0 2017-002704-27,7,2022-05-06,2022-05-06,4,0,1,0,0,1,2,0,0,2,0,0,0,0,1,"ReveraGen BioPharma, Inc.","A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002704-27,1,0,0 2017-002704-27,7,2022-05-06,2022-05-06,4,0,1,0,0,1,2,0,0,2,0,0,0,0,1,"ReveraGen BioPharma, Inc","A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002704-27,1,0,0 2017-002707-10,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Regional Dementia Research Centre, Dept of Neurology","Serum-monitoring of anti-dementia drugs, and the relevance to side-effects, clinical efficacy and compliance MONitorering af ANTI-demens lægemidler ved bestemmelse af serumkoncentrationer, betydnin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002707-10,0,0,0 2017-002708-28,9,2020-12-22,2020-12-22,5,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Alfasigma S.p.a,"Rifaximin delayed release (400 mg tablet) for the prevention of recurrent acute diverticulitis and diverticular complications. A phase II, multicenter, double-blind, placebo-controlled, randomized cli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002708-28,1,0,0 2017-002708-28,9,2020-12-22,2020-12-22,5,0,0,0,0,0,2,0,0,2,1,0,0,0,1,ALFASIGMA S.P.A.,"Rifaximin delayed release (400 mg tablet) for the prevention of recurrent acute diverticulitis and diverticular complications. A phase II, multicenter, double-blind, placebo-controlled, randomized cli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002708-28,1,0,0 2017-002709-36,1,2020-06-29,2020-06-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Rigshospitalet, Department of Physiology, Nuclear Medicine and PET",Phase II: 68Ga-NODAGA-E[c(RGDyK)]2 Angiogenese PET for imaging angiogenesis in ST-Elevation Myocardial Infarction(STEMI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002709-36,0,0,0 2017-002710-31,4,2018-12-15,2018-12-15,1,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Octapharma Pharmazeutika Produktionsges.m.b.H,"DOUBLE-BLIND, RANDOMIZED, PLACEBO- CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH DERMATOMYOSITIS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002710-31,0,0,0 2017-002712-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Rigshospitalet, Department of Physiology, Nuclear Medicine and PET",Phase II: 68Ga-NODAGA-E[c(RGDyK)]2 Angiogenese PET for imaging angiogenesis in ischaemic heart disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002712-14,0,0,0 2017-002713-58,2,2021-02-17,2021-02-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"HORIZON PHARMA USA, INC.","Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects with Thyroid Eye Disease Studio multicentrico di estensione in aperto, sulla sic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002713-58,0,0,0 2017-002713-58,2,2021-02-17,2021-02-17,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Horizon Therapeutics USA, Inc.","Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects with Thyroid Eye Disease Studio multicentrico di estensione in aperto, sulla sic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002713-58,0,0,0 2017-002715-34,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,ADIENNE SA,"A Phase I/II, open label, dose escalation study to investigate the pharmacokinetics, pharmacodynamics, safety and clinical activity of begelomab as an initial treatment of acute Graft-versus-Host Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002715-34,0,0,0 2017-002720-24,1,2018-05-16,2018-05-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,LEO Pharma A/S,Efficacy of twice daily application of LEO 124249 ointment 30 mg/g for 12 weeks on eyebrow alopecia areata. Exploratory Phase 2a,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002720-24,0,0,0 2017-002723-16,1,2018-12-12,2018-12-12,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Universitaetsklinikum Tuebingen,Evaluation of the potential anti-malarial effect of ivermectin: a controlled human malaria infection trial Evaluierung von Ivermectin als Wirkstoff gegen Malaria: eine kontrollierte Malariainfekti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002723-16,0,0,0 2017-002724-25,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Helle Holst,Intravenous and oral paracetamol in neonates: safety and ethanol-drug interactions – the PARASHUTE Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002724-25,0,0,0 2017-002726-20,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Alcon Research Ltd,Safety of PATANASE® Nasal Spray in Patients With Perennial Allergic Rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002726-20,0,1,1 2017-002727-24,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Alcon Research,An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002727-24,0,1,1 2017-002728-26,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Alcon Research,"A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of olopatadine hydrochloride (AL-4943A) Ophthalmic Solution 0.77% Administered Once Daily",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002728-26,0,1,1 2017-002729-39,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Alcon Research Ltd,An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in the USA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002729-39,0,1,1 2017-002730-23,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Alcon Research Ltd,An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in the USA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002730-23,0,1,1 2017-002732-17,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Alcon Research Ltd,An evaluation of Moxidex Ophthalmic Solution for the treatment of marginal corneal infiltrates.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002732-17,0,1,1 2017-002738-22,1,2021-03-27,2021-03-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Princess Máxima Center of Pediatric Oncology,Double blind placebo controlled randomized intervention study to validate the beneficial effect of hydrocortisone on dexamethasone-induced neurobehavioral side effects in pediatric acute lymphoblastic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002738-22,0,0,0 2017-002739-40,1,2021-06-21,2021-06-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Radboud university medical center,Beta cell imaging in type 1 diabetes with stable near-normal and unstable glucose control using PET Bètacel imaging bij type 1 diabetes met stabiele vrijwel normale en onstabiele glucoseregulatie m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002739-40,0,0,0 2017-002741-29,2,2018-07-25,2018-07-25,1,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A multicenter, randomized, open-label, active-controlled, dose-range finding study to assess the pharmacodynamic parameters, safety and tolerability of MAA868 and its effect on thrombogenesis biomarke...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002741-29,1,0,0 2017-002742-68,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Pfizer Inc.,"A Phase 3 Prospective, Randomized, Multicenter, Open-Label, Central Assessor-Blinded, Parallel Group, Comparative Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002742-68,0,0,0 2017-002742-68,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,PFIZER INC,"A Phase 3 Prospective, Randomized, Multicenter, Open-Label, Central Assessor-Blinded, Parallel Group, Comparative Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002742-68,0,0,0 2017-002751-28,8,2020-03-24,2020-10-30,5,1,1,0,0,1,2,0,0,2,1,0,0,0,1,Clementia Pharmaceuticals Inc.,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple Osteochondromas",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002751-28,1,1,0 2017-002751-28,8,2020-03-24,2020-10-30,5,1,1,0,0,1,2,0,0,2,1,0,0,0,1,CLEMENTIA PHARMACEUTICALS INC.,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple Osteochondromas",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002751-28,1,1,0 2017-002753-11,1,2020-05-14,2020-05-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Tampere University Hospital,The effect of tofacitinib on the activity of JAK-STAT pathways in patients with rheumatoid arthritis (RA) Tofasitinibin vaikutus JAK-STAT signaalinvälitysteiden aktiivisuuteen nivelreumapotilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002753-11,0,0,0 2017-002754-36,9,2020-06-25,2020-06-26,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Orion Corporation,Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002754-36,0,0,0 2017-002754-36,9,2020-06-25,2020-06-26,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ORION CORPORATION ORION PHARMA,Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002754-36,0,0,0 2017-002755-29,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Abl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002755-29,0,0,0 2017-002755-29,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Abl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002755-29,0,0,0 2017-002756-91,3,2021-09-16,2021-09-16,2,1,0,0,0,0,4,0,0,2,0,0,0,0,1,Sanofi Aventis Groupe,"A 12-week randomized, controlled trial to compare TOUJEO® and TRESIBA® in terms of glucose values in target range and variability during continuous glucose monitoring in patients with type 1 diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002756-91,1,0,0 2017-002758-35,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Insitut Jules Bordet,Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002758-35,0,0,0 2017-002760-41,1,2018-04-05,2018-04-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,institute de Recherches Internacionales Servier (promotor internacional),"Assessment of Active Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa) plasma kinetics in Patients at acute stage of Ischemic Stroke: Prospective, Multicentre, Open, Non-randomised, Biomarker Study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002760-41,0,0,0 2017-002762-44,3,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,0,University of Birmingham,A phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory cancers of Children and young adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002762-44,0,0,0 2017-002763-18,2,2020-10-06,2020-10-06,1,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"HORIZON PHARMA USA, INC.","A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects with Active Thyroid Eye Disease (OPTIC Trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002763-18,0,0,0 2017-002763-18,2,2020-10-06,2020-10-06,1,1,0,0,0,2,3,0,0,1,0,0,1,0,1,"Horizon Therapeutics USA, Inc.","A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects with Active Thyroid Eye Disease (OPTIC Trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002763-18,0,0,0 2017-002765-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Spanish Oncology Genitourinary Group - SOGUG,Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer Impacto de la combinacion d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002765-22,0,0,0 2017-002766-50,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,NextCell Pharma,"A DOUBLE-BLINDED, RANDOMIZED, PARALLEL, PLACEBO-CONTROLLED TRIAL OF WHARTON’S JELLY DERIVED ALLOGENEIC MESENCHYMAL STROMAL CELLS TO PRESERVE ENDOGENOUS INSULIN PRODUCTION IN ADULT PATIENTS DIAGNOSED W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002766-50,0,0,0 2017-002767-17,16,2022-03-10,2022-03-10,10,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ASTRAZENECA AB,"A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non-Germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Parti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002767-17,1,0,0 2017-002767-17,16,2022-03-10,2022-03-10,10,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non-Germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Parti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002767-17,1,0,0 2017-002771-25,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,2,NSABP Foundation Inc.,"A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002771-25,0,0,0 2017-002773-19,3,,,0,0,0,1,0,1,1,0,0,2,0,0,0,0,1,INCYTE CORPORATION,An Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002773-19,0,0,0 2017-002773-19,3,,,0,0,0,1,0,1,1,0,0,2,0,0,0,0,1,Incyte Corporation,An Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002773-19,0,0,0 2017-002774-39,2,2019-08-17,2019-08-17,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT,"An Exploratory, Randomized, Double-blind, Placebo-controlled, Parallel Arm Trial of the Safety and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients with Worsening Heart Fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002774-39,0,0,0 2017-002774-39,2,2019-08-17,2019-08-17,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"An Exploratory, Randomized, Double-blind, Placebo-controlled, Parallel Arm Trial of the Safety and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients with Worsening Heart Fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002774-39,0,0,0 2017-002776-83,1,2020-11-01,2020-11-01,1,0,0,0,1,0,4,0,0,1,1,1,1,0,0,Bispebjerg Hospital,Neuro-Ox-2018: Assessment of cerebral oxygenation under three clinically relevant conditions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002776-83,0,0,0 2017-002779-24,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Aberdeen,"A randomised, double-blind placebo controlled trial of the effectiveness of the beta-blocker bisoprolol in preventing exacerbations of chronic obstructive pulmonary disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002779-24,0,0,0 2017-002779-24,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,NHS Grampian,"A randomised, double-blind placebo controlled trial of the effectiveness of the beta-blocker bisoprolol in preventing exacerbations of chronic obstructive pulmonary disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002779-24,0,0,0 2017-002780-17,3,2018-10-15,2018-10-15,2,0,0,0,0,0,3,0,0,1,1,0,1,0,1,NEURODERM LTD.,"A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson¿s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND06...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002780-17,0,0,0 2017-002780-17,3,2018-10-15,2018-10-15,2,0,0,0,0,0,3,0,0,1,1,0,1,0,1,NeuroDerm Ltd.,"A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson¿s Disease to Assess the Relative Bioavailability of Levodopa Administered as ND06...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002780-17,0,0,0 2017-002781-48,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medica Scientia Innovation Research (MEDSIR),"INTERNATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CONTINUATION OF PALBOCICLIB IN COMBINATION WITH SECOND-LINE ENDOCRINE THERAPY IN HORM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002781-48,0,0,0 2017-002781-48,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medica Scientia Innovation Research (MedSIR),"INTERNATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF CONTINUATION OF PALBOCICLIB IN COMBINATION WITH SECOND-LINE ENDOCRINE THERAPY IN HORM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002781-48,0,0,0 2017-002783-40,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Ferring Pharmaceutical A/S,"A randomised, controlled, open label, parallel group, multicentre trial comparing the efficacy and safety of individualised FE 999049 (follitropin delta) dosing, using a long GnRH agonist protocol a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002783-40,0,0,0 2017-002783-40,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Ferring Pharmaceuticals A/S,"A randomised, controlled, open label, parallel group, multicentre trial comparing the efficacy and safety of individualised FE 999049 (follitropin delta) dosing, using a long GnRH agonist protocol a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002783-40,0,0,0 2017-002784-18,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Clinical Trials and Research Governance,Safety and efficacy of Tofacitinib in ameliorating ischaemia reperfusion injury and allograft pancreatitis in solid organ transplantation – a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002784-18,0,0,0 2017-002793-39,1,2022-09-16,2022-09-16,1,0,0,0,0,0,4,0,0,1,1,1,0,0,0,Universitätsklinikum Erlangen,Abatacept Bone Effects in Psoriatic Arthritis with Bone Biomarker – ABEPSA_BB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002793-39,0,0,0 2017-002798-21,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Oxford,"A multi-centre, blinded, randomised, placebo-controlled trial assessing the clinical and cost effectiveness of a 12 month course of oral alendronate (70mg weekly) in patients presenting with avascular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002798-21,0,0,0 2017-002799-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,José Alberto San Román Calvar,Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI) Beneficio del bloqueo del sistema renina-angioten...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002799-18,0,0,0 2017-002803-81,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IRCCS ISTITUTO GIANNINA GASLINI,Neurodevelopmental outcome after standard dose sevoflurane versus low-dose sevoflurane/dexmedetomidine/remifentanil anaesthesia in young children Sviluppo neurologico dopo con sevoflurano a dose st...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002803-81,0,0,0 2017-002804-29,5,2022-02-14,2022-02-14,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB Biopharma SRL,"A MULTICENTER, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002804-29,1,0,0 2017-002805-36,3,2021-11-30,2021-12-31,3,0,0,0,0,0,2,0,0,1,0,0,0,0,0,NSGO,NSGO-OV-UMB1; ENGOT OV30: A phase II umbrella trial in patients with relapsed ovarian cancer. Vaiheen II usean hoitohaaran tutkimus uusiutunutta munasarjasyöpää sairastavilla potilailla.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002805-36,0,0,0 2017-002806-10,2,2020-02-17,2020-02-17,2,0,0,1,0,1,1,0,0,1,1,1,0,0,1,Swedish Orphan Biovitrum AB (publ),"An open, non-controlled, parallel, ascending multiple-dose, multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SOBI003 in pediatric MPS IIIA patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002806-10,0,0,0 2017-002808-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Princess Margaret Cancer Centre,Olala Trial: A Retrospective/Prospective Analysis of Characterization of the Long-Term Responders on Olaparib in Solid Tumours Olala: Análisis retrospectivo/prospectivo de caracterización de pacien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002808-28,0,0,0 2017-002809-34,6,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,SLA Pharma UK Ltd,"Randomised, double-blind, placebo-controlled study of the, efficacy, safety and tolerability of EPA-FFA gastro-resistant capsules, in patients with familial adenomatous polyposis (FAP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002809-34,0,0,0 2017-002809-34,6,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,SLA Pharma (UK) Ltd,"Randomised, double-blind, placebo-controlled study of the, efficacy, safety and tolerability of EPA-FFA gastro-resistant capsules, in patients with familial adenomatous polyposis (FAP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002809-34,0,0,0 2017-002811-33,1,2021-04-20,2021-04-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,LAINCO S.A,"Unilateral, open and randomized phase IV study of 2 groups to assess the degree of comfort with simple Emuliquen® in patients undergoing proctological surgery Estudio de fase IV, unicéntrico, abier...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002811-33,0,0,0 2017-002815-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZ Groeninge,The dose response of Dexamethasone as perineural adjuvant in Brachial Plexus Block. Dosis effect relatie van perineuraal dexamethasone bij brachiaal plexus block.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002815-32,0,0,0 2017-002817-78,2,2018-12-06,2018-12-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MedImmune Limited, a wholly owned subsidiary of AstraZeneca","An Exploratory Phase 2a Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of MEDI0382 versus Placebo in Overweight/Obese Subjects with Type 2 Diabetes Mellitus Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002817-78,0,0,0 2017-002820-26,4,2022-08-25,2022-08-25,3,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Alexion Pharmaceuticals Incorporated,"A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002820-26,1,0,0 2017-002821-39,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Merus N.V.,Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002821-39,0,0,0 2017-002821-39,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Merus N.V,Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002821-39,0,0,0 2017-002822-19,10,,,0,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002822-19,0,0,0 2017-002822-19,10,,,0,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Pfizer Inc.,","A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002822-19,0,0,0 2017-002822-19,10,,,0,1,0,0,0,1,3,0,0,2,0,0,0,0,1,PFIZER INC,"A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002822-19,0,0,0 2017-002823-46,3,2020-02-12,2020-02-12,2,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Laboratoires THÉA; Research and Development Department,Efficacy and safety assessment of T4030 eye drops (unpreserved fixed combination of bimatoprost 0.01% and timolol 0.1% or 0.5%) versus Ganfort® UD (Unit Dose) in ocular hypertensive or glaucomatous pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002823-46,0,0,0 2017-002824-26,1,2019-10-31,2019-10-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Vall d' Hebron Institute of Oncology (VHIO),"Phase II trial of Pembrolizumab in combination with Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer (TOPIC) Ensayo clínico de fase II con Pembrolizumab combinado con Doxorrubici...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002824-26,0,0,0 2017-002835-40,1,2020-12-15,2020-12-15,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Akari Therapeutics Plc,Topical rVA576 for treatment of atopic keratoconjunctivitis: a randomised placebo double masked parallel trial (TRACKER) rVA576 tópico para el tratamiento de la queratoconjuntivitis atópica: un ens...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002835-40,0,0,0 2017-002836-18,2,2020-04-29,2020-04-29,2,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Akari Therapeutics Plc.,A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002836-18,0,0,0 2017-002837-48,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,HIV Eradication by combining Agents to reverse Latency in vivo (HEAL-1): a randomized controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002837-48,0,0,0 2017-002838-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oryzon Genomics S. A,"Randomized, double-blind, placebo-controlled, 3-arm, 36 weeks parallel-group study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002838-23,0,0,0 2017-002840-34,9,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002840-34,0,0,0 2017-002840-34,9,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Recordati AG,"An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002840-34,0,0,0 2017-002840-34,9,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002840-34,0,0,0 2017-002840-34,9,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A","An open-label, multi-center, roll-over study to assess long-term safety in patients with endogenous Cushing’s syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002840-34,0,0,0 2017-002841-31,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",Phase II study to test Pembrolizumab (MK-3475) in first line treatment of advanced NSCLC patients with PD-L1 low tumors (<50%)_ PEOPLE TRIAL (Pembrolizumab in Pd-L1 low Expressors) Studio di Fase I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002841-31,0,0,0 2017-002842-60,1,2021-07-31,2021-07-31,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,CHU Rennes,Randomised phase III study testing nivolumab and ipilimumab versus a carboplatin based doublet in first line treatment of PS 2 or elderly (more than 70 years old) patients with advanced non-small cell...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002842-60,0,0,0 2017-002843-14,1,2018-05-18,2018-05-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Bispebjerg Hospital,"Investigations of local skin reactions and safety after combined treatment of basal cell carcinoma using ablative fractional laser and ingenol mebutate - an exloratory, prospective, open-label phase 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002843-14,0,0,0 2017-002846-61,2,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Sanofi-aventis recherche & développement,"A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination with REGN2810 or Isatuximab alone, in Patients with Advanced ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002846-61,0,0,0 2017-002848-32,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Miltenyi Biomedicine GmbH,"A phase I/II safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19 positive B cell malignancies. Eine Phase-I/II-Studie mit MB-CART19.1 zur Beurteil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002848-32,0,0,0 2017-002849-30,1,,,0,1,1,0,0,1,1,0,0,4,0,0,0,0,0,University of Pennsylvania,A Phase I/IIA Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRzeta and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant Or Refractory CD19+ Leukemi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002849-30,0,1,1 2017-002850-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama),“LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES”. “ESTUDIO DE LARGO SEGUIMIENTO DE PACIENTES CON CÁNCER DE MAMA INCLUIDOS EN ESTUDIOS EN ESTADIOS PRECOCE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002850-35,0,0,0 2017-002853-13,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Goethe Universität Frankfurt,"Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and Blinat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002853-13,0,0,0 2017-002855-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITY HEALTH NETWORK,BonE health in ageING Women: Improvement or prevention of changes in Bone Mineral Density by Switching Antiretroviral Agents. Is there an optimal time to intervene? La salute delle ossa nell¿invecc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002855-27,0,0,0 2017-002857-12,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffman-La Roche Ltd.,"A PHASE III, DOUBLE-BLINDED, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002857-12,0,0,0 2017-002857-12,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, DOUBLE-BLINDED, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002857-12,0,0,0 2017-002857-12,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F.Hoffmann-La Roche Ltd.,"A PHASE III, DOUBLE-BLINDED, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002857-12,0,0,0 2017-002858-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FIMABIS Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina Y Salud,"STUDY OF THE EFFECTIVENESS AND CEREBRAL REORGANIZATION AFTER TREATMENT COMBINED WITH DONEPEZILO, INTENSIVE REHABILITATION AND TRANSCRANEAL DIRECT CURRENT STIMULATION IN POSTSTROKE CHRONIC AFASIA ES...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002858-36,0,0,0 2017-002860-42,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in patients with advanced (stage III B-C-IV) ovari...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002860-42,0,0,0 2017-002866-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE C. MONDINO,Pilot study for the evaluation of the efficacy of OnabotulinumtoxinA in high frequency migraine Studio pilota per la valutazione dell¿efficacia della tossina botulinica A nell¿emicrania ad alta fre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002866-38,0,0,0 2017-002871-24,1,2021-10-13,2021-10-13,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Intrexon T1D Partners, LLC (IT1D)","A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in patients with clinical recent-o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002871-24,0,0,0 2017-002875-25,1,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,0,SERMAS-FIBHULP,"An international multicentre randomized placebo-controlled, double blind three arm trial to investigate the efficacy of dobutamine with two different starting doses in the treatment of haemodynamic in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002875-25,0,0,0 2017-002876-26,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,South Tees Hospitals NHS Foundation Trust,"Telomerase ACTivator to reverse Immunosenescence in Acute Coronary Syndrome: a double-blind, phase II, pilot randomised controlled trial (TACTIC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002876-26,0,0,0 2017-002877-20,1,2021-10-11,2021-10-11,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Lytix Biopharma AS,An open-label phase II single-centre study investigating the safety and efficacy of LTX-315 and adoptive T-cell therapy in patients with advanced/metastatic soft tissue sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002877-20,0,0,0 2017-002878-38,1,2022-04-06,2022-04-06,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Leiden University Medical Center,Abatacept to Silence anti-Citrullinated protein Antibody-expressing B cells in Rheumatoid Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002878-38,0,0,0 2017-002887-42,9,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,0,European Organisation for Research and Treatment of Cancer,Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresectabl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002887-42,0,0,0 2017-002888-18,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CHU Dijon Bourgogne,Adjunction of daptomycin for the treatment of pneumococcal meningitis AddaMAP study Daptomycine en traitement adjuvant des méningites à pneumocoque. Etude ADDAMAP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002888-18,0,0,0 2017-002898-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Central Hospital,There is no English name for the trial. IndiviStat#1-tutkimus: Perinnöllisten ja muiden yksilötekijöiden vaikutus statiinilääkehoitoon,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002898-19,0,0,0 2017-002901-37,6,2021-05-17,2021-08-30,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Biogen Idec Research Limited,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects with Mild Cognitive Impairment due to Alzheimer’s Disease or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002901-37,1,0,0 2017-002904-29,2,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Incyte Corporation,"A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002904-29,0,0,0 2017-002906-10,2,2019-04-23,2019-04-23,1,1,0,0,0,0,3,0,1,1,1,0,1,0,1,"BHR Pharma, LLC","A Randomized, Double-blind, Placebo Controlled Trial of 4-Hydroxytamoxifen Gel for Reducing Breast Tissue Density in Women with BI-RADS Breast Density Categories C or D",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002906-10,0,0,0 2017-002910-29,1,2018-01-26,2018-01-26,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,PHARMATHEN,"Therapeutic Equivalence (non-inferiority), Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic Preservative-Free Formulation of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002910-29,0,0,0 2017-002911-33,5,2019-11-25,2019-11-25,2,0,0,0,0,0,3,0,0,1,1,1,1,0,1,ASIT biotech S.A.,"A multicentre, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of subcutaneous immunotherapy with gpASIT+™ in patients with grass poll...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002911-33,0,0,0 2017-002912-15,1,2020-10-23,2020-10-23,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,CHU de Bordeaux,Secondary Prophylaxis after CMV disease in Kidney transplant patients targeted by γδ T cells immunomonitoring. Prophylaxie secondaire après une infection à CMV chez les greffés rénaux ciblée par l’...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002912-15,0,0,0 2017-002914-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FIMABIS,LCZ696 in heart failure patients with reduced ejection fraction and high comorbidity: effect on left ventricular remodeling and fibrosis assessed by novel heart failure biomarkers and cardiac magnetic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002914-30,0,0,0 2017-002919-33,1,2022-05-27,2022-05-27,1,0,0,0,0,0,4,0,1,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"Phase IV, open-label, randomized study to enrol healthy adult volunteers, naïve to any previous meningococcal vaccination or meningococcal disease, aged 18-50 years, to be either vaccinated with GSK M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002919-33,0,0,0 2017-002921-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University hospital of Montpellier,Comparison of motor blockade duration in the context of scheduled caesarean section with spinal anaesthesia : hyperbaric Prilocaïne versus hyperbaric Bupivacaïne. Comparaison de la durée du bloc m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002921-39,0,0,0 2017-002925-39,4,2018-07-09,2018-07-09,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,NOVARTIS PHARMA AG,"A multicenter, randomized, open-label, blinded endpoint evaluation, active-controlled Phase 2 study to compare the efficacy and safety of s.c. MAA868 versus s.c. enoxaparin in adult patients undergoin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002925-39,0,0,0 2017-002925-39,4,2018-07-09,2018-07-09,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma AG,"A multicenter, randomized, open-label, blinded endpoint evaluation, active-controlled Phase 2 study to compare the efficacy and safety of s.c. MAA868 versus s.c. enoxaparin in adult patients undergoin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002925-39,0,0,0 2017-002925-39,4,2018-07-09,2018-07-09,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Novartis Farmacéutica, S.A.","A multicenter, randomized, open-label, blinded endpoint evaluation, active-controlled Phase 2 study to compare the efficacy and safety of s.c. MAA868 versus s.c. enoxaparin in adult patients undergoin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002925-39,0,0,0 2017-002926-19,1,2020-05-13,2020-05-13,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Novartis Pharma AG,"A first-in-human, two-part (open label, and randomized/double blind/placebo controlled), single- and repeat-dose study of CSJ137 in erythropoietin-treated chronic hemodialysis patients with functional...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002926-19,0,0,0 2017-002927-68,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,1,Prometic Biotherapeutics Ltd,"A Phase 1/2A, Dose Escalation, Randomized, Placebo Controlled Study of the Safety, Feasibility, and Efficacy of Subcutaneous Plasminogen (Human) 10 for the Treatment of Chronic Tympanic Membrane Perfo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002927-68,0,0,0 2017-002930-22,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,iOMEDICO AG,"A randomized, open-label, multicenter, two-arm, phase III study to evaluate efficacy and quality of life in patients with metastatic hormone receptor-positive HER2-negative breast cancer receiving rib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002930-22,0,0,0 2017-002932-18,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002932-18,0,0,0 2017-002932-18,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002932-18,0,0,0 2017-002935-40,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) gGmbH,International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002935-40,0,0,0 2017-002936-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Livio Falun,Treatment with intralipid in assisted fertilization,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002936-17,0,0,0 2017-002938-23,1,2021-09-26,2021-09-26,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Radboud University Medical Center,The effect of rectal swab culture-guided antimicrobial prophylaxis in men undergoing prostate biopsy on infectious complications and cost of care: A randomized controlled trial in the Netherlands. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002938-23,0,0,0 2017-002941-31,2,2020-06-03,2020-06-03,1,1,0,0,0,0,2,0,1,2,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase 2, randomised, observer-blind, multi-centre study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' GSK3277511A investigational vaccine when administered intramuscu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002941-31,1,0,0 2017-002946-62,4,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,VIIV HEALTHCARE UK LIMITED,"A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002946-62,0,0,0 2017-002946-62,4,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ViiV Healthcare UK Limited,"A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002946-62,0,0,0 2017-002946-62,4,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"ViiV Healthcare, S.L.","A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002946-62,0,0,0 2017-002949-30,7,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,Atara Biotherapeutics Inc.,"Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002949-30,0,0,0 2017-002949-30,7,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,"Atara Biotherapeutics, Inc.","Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002949-30,0,0,0 2017-002954-35,12,2020-12-10,2020-12-10,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,sanofi-aventis recherche & développement,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002954-35,0,0,0 2017-002954-35,12,2020-12-10,2020-12-10,11,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002954-35,0,0,0 2017-002956-10,2,2020-11-13,2020-11-17,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,sanofi-aventis recherche & développement,"A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients with Type 2 Dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002956-10,0,0,0 2017-002959-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud university medical center,Comparison of the beta cell mass during and shortly after the honeymoon phase of type 1 diabetes using Ga-68-exendin PET Vergelijking van de bètacel-massa tijdens en kort na de honeymoonfase van ty...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002959-29,0,0,0 2017-002960-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA,173/5000 Forse cercavi: Terapia radiometabolica recettoriale-mediata con [90Y-DOTA0-Tyr3]-octreotide (90Y-DOTATOC) nei tumori endocrini del tratto gastroenteropancreatico e bronchiale. (Yttrium-90-02...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002960-42,0,0,0 2017-002961-23,10,2021-03-22,2021-07-12,7,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Odonate Therapeutics, Inc.","A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002961-23,1,0,0 2017-002961-23,10,2021-03-22,2021-07-12,7,0,0,0,0,0,3,0,0,2,1,0,0,0,1,ODONATE THERAPEUTICS,"A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002961-23,1,0,0 2017-002961-23,10,2021-03-22,2021-07-12,7,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Odonate Therapeutics, Inc","A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002961-23,1,0,0 2017-002961-23,10,2021-03-22,2021-07-12,7,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Odonate Therapeutics, LLC","A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002961-23,1,0,0 2017-002961-23,10,2021-03-22,2021-07-12,7,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Odonate Therapeutics, INC.","A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002961-23,1,0,0 2017-002968-40,7,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002968-40,0,0,0 2017-002971-24,3,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Boehringer Ingelheim International GmbH,A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002971-24,0,0,0 2017-002971-24,3,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,BOEHRINGER INGELHEIM INTERNATIONAL GMBH,A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002971-24,0,0,0 2017-002972-15,1,2021-01-08,2021-01-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,Ferrous Acetyl-Aspartylated Casein Formulation Evaluation over Ferrous Sulfate in Iron Deficiency Anemia (Access): A Double-Dummy Randomized Clinical Trial Μία συγκριτική με double-dummy κλινική με...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002972-15,0,0,0 2017-002975-25,1,2018-07-18,2018-07-18,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Bispebjerg Hospital,Multimodal optical imaging for pretreatment evaluation for cutaneous microparticle delivery Forbehandlings betydning for applikation af guldmikropartikler vurderet ved multimodal optisk billeddanne...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002975-25,0,0,0 2017-002976-24,7,2019-08-30,2019-12-05,5,1,0,0,0,1,3,0,0,2,1,0,0,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Well-Controlled, Fixed-Dose Study of TEV 50717 (Deutetrabenazine) for the Treatment of Tics Associated with Tourette Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002976-24,1,0,0 2017-002978-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medizinische Universität Graz,Women's satisfaction with outpatient double-balloon catheter versus inpatient dinoprostone vaginal insert for induction of labour Zufriedenheit mit ambulanter Geburtseinleitung mittels Ballonkathet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002978-39,0,0,0 2017-002979-26,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non Muscle ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002979-26,0,0,0 2017-002985-28,2,2021-05-31,2021-05-31,2,1,1,0,0,1,1,0,0,1,0,0,1,0,1,Merck KGaA,"Open-label, Phase I/II study to evaluate pharmacokinetics, pharmacodynamics, safety, and anticancer activity of avelumab in pediatric subjects from birth to less than 18 years of age with refractory o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002985-28,0,0,0 2017-002988-18,16,2020-11-24,2020-11-24,9,1,0,0,0,2,3,0,0,2,1,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002988-18,1,0,0 2017-002988-18,16,2020-11-24,2020-11-24,9,1,0,0,0,2,3,0,0,2,1,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002988-18,1,0,0 2017-002989-42,10,2021-05-19,2021-05-19,6,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with polymyalgia rheumatica",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002989-42,1,0,0 2017-002989-42,10,2021-05-19,2021-05-19,6,1,0,0,0,0,3,0,0,2,1,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with polymyalgia rheumatica",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002989-42,1,0,0 2017-002992-25,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Amgen Inc.,A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of Ga...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002992-25,0,0,0 2017-002992-25,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AMGEN INC.,A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of Ga...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002992-25,0,0,0 2017-002997-38,2,2022-04-06,2022-04-06,2,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Bayer AG,"A randomized, parallel-group, double-blind and open-label, placebo-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids Dvojitě zaslepené ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002997-38,0,0,0 2017-002998-20,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Leicester,Effectiveness and cost of integrating a protocol with use of liraglutide 3.0mg into an obesity service (STRIVE Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-002998-20,0,0,0 2017-003003-22,1,2020-03-10,2020-03-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,2,"Aalborg University Hospital, Department of Orthopedics",postoperative effect of optimal multimodal pain management supplemented with systemic single dose of Dexamethason in the first week after UKA. Low dose (8mg) or mean dose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003003-22,0,0,0 2017-003003-22,1,2020-03-10,2020-03-10,1,1,0,0,0,0,4,0,0,1,1,1,1,0,2,Mogens Brouw Jørgensen,postoperative effect of optimal multimodal pain management supplemented with systemic single dose of Dexamethason in the first week after UKA. Low dose (8mg) or mean dose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003003-22,0,0,0 2017-003008-30,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,"A double-blind, randomised, placebo-controlled single-site study of high dose simvastatin treatment for secondary progressive multiple sclerosis: impact on vascular perfusion and oxidative damage",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003008-30,0,0,0 2017-003014-22,1,,,0,0,0,0,0,1,2,0,1,0,0,0,0,0,0,Medical University of Vienna,The role of leptin in regulating hepatic lipid metabolism in humans Die Rolle von Leptin in der Regulation des hepatischen Lipidstoffwechsels,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003014-22,0,0,0 2017-003017-25,5,2019-08-12,2019-08-13,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Provention Bio, Inc.","A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Oral PRV-6527 (JNJ-40346527), an Inhibitor of Colony Stimulating Factor-1 R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003017-25,0,0,0 2017-003019-21,4,2020-12-03,2020-12-03,2,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Immunomedics, Inc.","An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Rece...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003019-21,1,0,0 2017-003021-15,4,2020-02-19,2020-02-19,3,0,0,0,0,1,2,0,0,1,0,0,1,0,1,"CHEMOCENTRYX, INC.","A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003021-15,0,0,0 2017-003021-15,4,2020-02-19,2020-02-19,3,0,0,0,0,1,2,0,0,1,0,0,1,0,1,"ChemoCentryx, Inc.","A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003021-15,0,0,0 2017-003022-32,1,2020-06-24,2020-06-24,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,"ChemoCentryx, Inc.","An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003022-32,0,0,0 2017-003027-30,1,2019-03-20,2019-03-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Institut de Recerca Hospital de la Santa Creu i Sant Pau,Influence of albumin on the development of acute renal dysfunction associated with cardiac surgery under extracorporeal circulation Influencia de la Albúmina en el desarrollo de la disfunción renal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003027-30,0,0,0 2017-003028-59,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Radboud University Medical Centre,Treatment with Recombinant human Interleukin 1 receptor antagonist (Anakinra) in patients with Anaplastic Thyroid Cancer: a proof of concept study Behandeling met recombinant humaan Interleukine 1 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003028-59,0,0,0 2017-003029-14,1,2018-11-07,2018-11-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A phase 3b, multicenter, prospective, randomized, double blind, placebocontrolled study to reduce incidence of pre-dialysis hyperkalemia with Sodium Zirconium Cyclosilicate (DIALIZE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003029-14,0,0,0 2017-003036-37,1,2019-08-05,2019-08-05,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Tirol Kliniken GmbH,"A double-blind, placebo-controlled pilot trial to investigate the administration of von Willebrand factor concentrate (Willfact®, LFB France) in adult patients during extracorporeal membrane oxygenati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003036-37,0,0,0 2017-003037-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Efficacy of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease modifying anti-rheumatic drugs.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003037-28,0,0,0 2017-003038-98,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INTERGRUPPO MELANOMA ITALIANO,An evaluation of the efficacy beyond progression of vemurafenib combined with cobimetinib associated with local treatment compared to second-line treatment in patients with BRAFV600 mutation-positive ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003038-98,0,0,0 2017-003040-20,20,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003040-20,0,0,0 2017-003040-20,20,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003040-20,0,0,0 2017-003040-20,20,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Roche Farma S.A.(Soc. Unipersonal)que realiza el ensayo en España y que actúa como representante F.Hoffman-La Roche LTD,"A phase II, randomized, active-controlled, multi-center study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003040-20,0,0,0 2017-003044-20,1,2018-05-11,2018-05-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cassella-med GmbH & Co. KG,"A Randomised, Double-blind, Placebo-controlled, Multi-centre Clinical Study to Investigate the Efficacy and Safety of Three Doses of Cineole in Subjects with Severe Acute Bronchitis with or without As...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003044-20,0,0,0 2017-003051-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Rheinische Friedrich-Wilhelms-Universität Bonn,"Efficacy of BELImumab for therapy-resistant SKIN manifestations in patients with lupus erythematosus (LE): A phase III, multicenter, randomized, double-blind, placebo-controlled, 24-week trial (BELI-S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003051-35,0,0,0 2017-003053-42,6,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Subcutaneously Administered Guselkumab for the Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003053-42,0,0,0 2017-003053-42,6,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Subcutaneously Administered Guselkumab for the Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003053-42,0,0,0 2017-003054-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Wörwag Pharma GmbH & co. KG,"Randomized double-blind, placebo-controlled parallel group study over 12 months to assess the effects of treatment with benfotiamine on morphometric, neurophysiological, and clinical measures in type ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003054-16,0,0,0 2017-003055-30,5,2019-10-09,2019-10-09,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Gilead Sciences, Inc.",Immune Response to Influenza Vaccine in Subjects with B-cell Malignancies Treated with Idelalisib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003055-30,0,0,0 2017-003057-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Univeristy Hospital Tuebingen,Organ preservation in locally advanced rectal cancer by radiochemotherapy followed by consolidation chemotherapy. A prospective phase II pilot trial of the German Rectal Cancer Study Group Organerh...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003057-42,0,0,0 2017-003059-46,3,2018-04-19,2018-09-04,3,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Global, Open-label Study of Nivolumab in Combination with BMS-986205 vs Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003059-46,0,0,0 2017-003063-34,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Lofarma S.p.A.,"A double-blind, placebo-controlled dose-escalation study of carbamylated monomeric tree pollen drops in patients with a history of allergic rhinoconjunctivitis. Eine doppelblinde, placebo-kontrolli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003063-34,0,0,0 2017-003064-13,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB Biopharma SPRL,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003064-13,0,0,0 2017-003064-13,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB Biopharma SRL,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003064-13,0,0,0 2017-003065-95,9,2022-08-08,2022-08-08,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB Biopharma SRL,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003065-95,1,0,0 2017-003065-95,9,2022-08-08,2022-08-08,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB Biopharma SPRL,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003065-95,1,0,0 2017-003067-36,2,2020-04-14,2020-04-14,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Shire Human Genetic Therapies, Inc.",An Open-label Study Investigating the Safety and Efficacy of rhPTH(1-84) in Subjects with Hypoparathyroidism.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003067-36,0,0,0 2017-003072-31,1,2021-12-17,2021-12-17,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,VU University Medical Center,The effects of sex hormone administration on marrow and visceral adiposity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003072-31,0,0,0 2017-003074-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MYLAN INC.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr¿ IM versus Placebo IM as an Enhancer Adjunctive to Antide...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003074-14,0,0,0 2017-003076-31,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,VAXIMM GmbH,"An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment with or without second surgery.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003076-31,0,0,0 2017-003078-15,4,2020-11-12,2020-11-12,3,1,1,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003078-15,1,0,0 2017-003079-69,2,2020-09-25,2020-09-25,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicentre, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dep...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003079-69,0,0,0 2017-003081-27,4,2019-07-11,2019-07-11,4,1,0,1,0,0,1,0,0,1,1,0,0,0,0,INSERM-ANRS,A Phase I/II randomised therapeutic HIV vaccine trial in individuals who started antiretrovirals during primary or chronic infection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003081-27,0,0,0 2017-003081-27,4,2019-07-11,2019-07-11,4,1,0,1,0,0,1,0,0,1,1,0,0,0,0,Inserm-ANRS,A Phase I/II randomised therapeutic HIV vaccine trial in individuals who started antiretrovirals during primary or chronic infection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003081-27,0,0,0 2017-003083-13,3,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Safety and Efficacy of Intracerebroventricular AX 250 in Patients with Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003083-13,0,0,0 2017-003083-13,3,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Allievex Corporation,"A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Safety and Efficacy of Intracerebroventricular AX 250 in Patients with Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003083-13,0,0,0 2017-003084-34,1,2019-04-12,2019-04-12,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,University of Bristol,The pharmacological effects of granulocyte-colony stimulating factor (GCSF) on frataxin expression in patients with Friedreich Ataxia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003084-34,0,0,0 2017-003088-36,5,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,"Technische Universität München, Represented by the school of medicine",GPPAD-POInT (Global Platform of Autoimmune Diabetes – Primary Oral Insulin Trial) Oral Insulin Therapy for Prevention of Autoimmune Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003088-36,0,0,0 2017-003089-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Medical University of Vienna, Department of Biomedical Imaging and Image-guided Therapy",Measuring hallmarks of cancer for non-invasive characterization of breast lesions by simultaneous multiparametric 18F-ethylcholine PET- MRI – an exploratory study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003089-29,0,0,0 2017-003090-34,6,2022-07-04,2022-07-04,6,0,0,0,0,0,2,0,0,1,1,0,0,0,2,Boehringer Ingelheim Netherlands BV,Mechanism of Action and Clinical Effect of BI 655130 in Patients with fistulizing Crohn’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003090-34,0,0,0 2017-003090-34,6,2022-07-04,2022-07-04,6,0,0,0,0,0,2,0,0,1,1,0,0,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,Mechanism of Action and Clinical Effect of BI 655130 in Patients with fistulizing Crohn’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003090-34,0,0,0 2017-003090-34,6,2022-07-04,2022-07-04,6,0,0,0,0,0,2,0,0,1,1,0,0,0,2,Boehringer Ingelheim RCV GmbH & Co KG,Mechanism of Action and Clinical Effect of BI 655130 in Patients with fistulizing Crohn’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003090-34,0,0,0 2017-003090-34,6,2022-07-04,2022-07-04,6,0,0,0,0,0,2,0,0,1,1,0,0,0,2,SCS Boehringer Ingelheim Comm.V,Mechanism of Action and Clinical Effect of BI 655130 in Patients with fistulizing Crohn’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003090-34,0,0,0 2017-003090-34,6,2022-07-04,2022-07-04,6,0,0,0,0,0,2,0,0,1,1,0,0,0,2,Boehringer Ingelheim BV,Mechanism of Action and Clinical Effect of BI 655130 in Patients with fistulizing Crohn’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003090-34,0,0,0 2017-003092-55,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,The Medicines Company,A long term extension trial of the Phase III lipid-lowering trials to assess the effect of long term dosing of inclisiran given as subcutaneous injections in subjects with high cardiovascular risk and...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003092-55,0,0,0 2017-003092-55,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novartis Pharma AG,A long term extension trial of the Phase III lipid-lowering trials to assess the effect of long term dosing of inclisiran given as subcutaneous injections in subjects with high cardiovascular risk and...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003092-55,0,0,0 2017-003099-30,3,2019-10-17,2019-10-17,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, parallel group, Phase II, 24-week study investigating the efficacy, safety and tolerability of AIN457 in patients with active overuse tendinopathy refra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003099-30,0,0,0 2017-003101-17,9,2021-07-27,2021-07-27,5,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim France,An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment out...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003101-17,1,0,0 2017-003101-17,9,2021-07-27,2021-07-27,5,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment out...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003101-17,1,0,0 2017-003101-17,9,2021-07-27,2021-07-27,5,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.",An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment out...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003101-17,1,0,0 2017-003101-17,9,2021-07-27,2021-07-27,5,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment out...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003101-17,1,0,0 2017-003101-17,9,2021-07-27,2021-07-27,5,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim Limited,An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment out...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003101-17,1,0,0 2017-003101-17,9,2021-07-27,2021-07-27,5,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim BV,An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment out...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003101-17,1,0,0 2017-003101-17,9,2021-07-27,2021-07-27,5,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Boehringer Ingelheim España, S.A.",An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment out...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003101-17,1,0,0 2017-003101-17,9,2021-07-27,2021-07-27,5,1,0,0,0,0,2,0,0,2,1,0,0,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment out...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003101-17,1,0,0 2017-003102-40,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,NKI-AVL,Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003102-40,0,0,0 2017-003103-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",Advanced or Metastatic Collecting ducts renal cell carcinoma Cabozantinib nel carcinoma renale dei dotti collettori di Bellini.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003103-22,0,0,0 2017-003104-42,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,NightstaRx Ltd,A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Previously Treated with Adeno-Associated Viral Vector Encoding Rab Escort Protein...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003104-42,0,0,0 2017-003104-42,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,NightstaRx Ltd (A Biogen Company),A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Previously Treated with Adeno-Associated Viral Vector Encoding Rab Escort Protein...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003104-42,0,0,0 2017-003105-18,1,2019-05-08,2019-05-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Centre for Human Drug Research,"A randomized, placebo-controlled, evaluator-blinded, study to assess the anti-inflammatory effects of topical erythromycin and clindamycin in patients with inflammatory facial acne",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003105-18,0,0,0 2017-003106-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Maruho Co., Ltd.","A phase 2, randomized, vehicle and ketoconazole-controlled, evaluator-blinded, study to explore the efficacy, pharmacodynamics and safety of omiganan 1.75% topical gel BID in patients with mild to mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003106-41,0,0,0 2017-003108-27,1,2018-06-11,2018-06-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Axalbion SA,"A PILOT STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF AX-8 FOR THE TREATMENT OF REFRACTORY CHRONIC COUGH.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003108-27,0,0,0 2017-003112-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,National University of ireland Galway,A Randomised Double-Blinded Placebo-Controlled Trial to Assess the Efficacy and Safety of Scopolamine Compared to Placebo in Individuals with Bipolar Disorder who are Experiencing a Depressive Episode...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003112-39,0,0,0 2017-003113-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ROSA HERRERA CASTRO,"Hemodynamic safety of isobaric levobupivacaine versus isobaric bupivacaine for spinal anesthesia in patients over 65 years, underwent hip surgery. Seguridad hemodinámica de la levobupivacaína isobá...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003113-26,0,0,0 2017-003114-10,5,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,Swedish Orphan Biovitrum AG,"An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life, a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003114-10,0,0,0 2017-003114-10,5,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,Novimmune S.A.,"An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life, a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003114-10,0,0,0 2017-003115-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medical Center Rotterdam,Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: a prospective randomised multicenter double-blind placebo-controlled clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003115-20,0,0,0 2017-003117-25,1,2021-02-01,2021-02-01,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical University of Vienna,Longitudinal chemodenervation effects of botulinum toxin A after intramuscular application and the impact of physical activity Chemodenervierung nach intramuskulärer BoNT Applikation- Langzeiteffek...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003117-25,0,0,0 2017-003118-15,1,2019-07-01,2019-07-01,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,University Hospitals of Leicester NHS Trust,"A double blind, placebo controlled, randomised dose escalation trial to investigate the safety and efficacy of topical salbutamol in the improvement of scar appearance when applied to approximated wou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003118-15,0,0,0 2017-003119-21,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Medical University of Vienna,Effect of Omalizumab in patients with Aspirin-Exazerbated Respiratory Disease (AERD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003119-21,0,0,0 2017-003124-73,1,2019-11-11,2019-11-11,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Maastricht University,Carnitine supplementation as a therapy to improve insulin sensitivity in Type 2 diabetic patients with low carnitine status Carnitine supplementatie als therapy om insulin gevoeligheid te verbete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003124-73,0,0,0 2017-003127-29,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla. (FISEVI),Phase II clinical trial to evaluate an antibiotic regimen pharmacokinetic applicable to outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis Ensayo clínico Fa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003127-29,0,0,0 2017-003130-90,2,2018-10-03,2018-10-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma AG,"A randomized, controlled, evaluator-blinded, multi-center study to evaluate LYS228 pharmacokinetics, clinical response, safety, and tolerability in patients with complicated intra-abdominal infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003130-90,0,0,0 2017-003131-11,7,2022-04-26,2022-04-26,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"XENERA-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003131-11,1,0,0 2017-003131-11,7,2022-04-26,2022-04-26,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"XENERA-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003131-11,1,0,0 2017-003131-11,7,2022-04-26,2022-04-26,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,SCS Boehringer Ingelheim Comm.V,"XENERA-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003131-11,1,0,0 2017-003131-11,7,2022-04-26,2022-04-26,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim Limited,"XENERA-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003131-11,1,0,0 2017-003131-11,7,2022-04-26,2022-04-26,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Boehringer Ingelheim España, S.A.","XENERA-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003131-11,1,0,0 2017-003131-11,7,2022-04-26,2022-04-26,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.","XENERA-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003131-11,1,0,0 2017-003131-11,7,2022-04-26,2022-04-26,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim BV,"XENERA-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003131-11,1,0,0 2017-003133-28,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Universität zu Köln,"A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab), acalabrutinib (ACP-196) and ABT-199 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003133-28,0,0,0 2017-003134-85,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003134-85,0,0,0 2017-003134-85,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003134-85,0,0,0 2017-003144-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Board of Directors, Academic Medical Centre",Cost-effectiveness of perioperative vaginally administered oestrogen in postmenopausal women undergoing prolapse surgery. Kosteneffectiviteit van perioperatief gebruik van topicale oestrogenen bij ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003144-21,0,0,0 2017-003147-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Emilio Bouza Santiago,"Open, randomized clinical trial to evaluate the treatment of First Clostridium difficile infection episodes with bacteriotherapy Ensayo Clínico abierto para evaluar el tratamiento de Episodios Pri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003147-38,0,0,0 2017-003148-19,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,INCYTE CORPORATION,"A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor. Studio multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003148-19,0,0,0 2017-003148-19,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Incyte Corporation,"A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor. Studio multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003148-19,0,0,0 2017-003149-56,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Hospital Ulm,OBINUTUZUMAB in MARGINAL ZONE LYMPHOMA Obinutuzumab bei Marginalzonen-Lymphomen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003149-56,0,0,0 2017-003150-16,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Ulm,Copanlisib and Rituximab in Marginal Zone Lymphoma Patients Copanlisib and Rituximab bei Patiente mit Marginalzonenlymphom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003150-16,0,0,0 2017-003151-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Léon Bérard,"A multicenter, randomised, open-label Phase II study to evaluate the clinical benefit of a post-operative treatment associating radiotherapy + Nivolumab + Ipilimumab versus radiotherapy + Capecitabine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003151-34,0,0,0 2017-003153-42,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,Alexion Pharma GmbH,Extension Study of Protocol ENB-006-09 Evaluating the Long-Term Safety and Efficacy of Asfotase Alfa (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Children with Hypopho...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003153-42,0,1,1 2017-003158-18,10,2019-08-22,2019-11-14,8,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Biogen Idec Research Limited,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003158-18,0,0,0 2017-003158-18,10,2019-08-22,2019-11-14,8,1,0,0,0,1,2,0,0,1,1,0,1,0,1,BIOGEN IDEC RESEARCH LIMITED,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003158-18,0,0,0 2017-003159-44,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Spanish Oncology Genitourinary Group,Phase II trial of durvalumab (Medi4736) plus tremelimumab with concurrent radiotherapy in patients with localized muscle invasive bladder cancer treated with a selective bladder preservation approach ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003159-44,0,0,0 2017-003164-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Haga Teaching Hospital (Juliana Children's Hospital),Antibiotic prophylaxis for children with recurrent respiratory infections: towards evidence-based guidelines,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003164-13,0,0,0 2017-003169-82,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Trizell Ltd.,"A Phase III, Open Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003169-82,0,0,0 2017-003169-82,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Trizell Ltd,"A Phase III, Open Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003169-82,0,0,0 2017-003170-13,7,2021-04-15,2021-04-15,1,0,1,0,0,1,3,0,0,2,0,0,0,0,1,"REGENERON PHARMACEUTICALS, INC.",An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia STUDIO IN APERTO PER VALUTARE LA SICUREZZA E L’EFFICACIA A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003170-13,1,0,0 2017-003170-13,7,2021-04-15,2021-04-15,1,0,1,0,0,1,3,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.",An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia STUDIO IN APERTO PER VALUTARE LA SICUREZZA E L’EFFICACIA A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003170-13,1,0,0 2017-003171-64,3,2020-03-03,2020-03-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co.KG,Phase 3b Study for Management of Ocular Side Effects in Subjects with EGFR-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003171-64,0,0,0 2017-003172-32,2,2020-06-20,2020-06-30,2,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Imperial College London,Maraviroc Add-On Therapy for Steatohepatitis in HIV – The MASH Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003172-32,0,0,0 2017-003177-34,1,2019-08-20,2019-08-20,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Centre for Human Drug Research,A clinical study to assess the feasibility of measuring inhaled medication concentrations in exhaled breath condensate obtained from healthy volunteers and asthma patients and to assess the relationsh...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003177-34,0,0,0 2017-003180-35,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Manchester University NHS Foundation Trust,Feasibility study on the effects of postnatal enalapril on maternal cardiovascular function following preterm pre-eclampsia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003180-35,0,0,0 2017-003182-94,6,2020-02-04,2021-12-30,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"AN OPEN-LABEL, MULTICENTER, PHASE II STUDY TO EVALUATE THE THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003182-94,1,0,0 2017-003182-94,6,2020-02-04,2021-12-30,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Roche Farma S.A (Soc Unipersonal) que realiza el ensayo en España y actua como representante de F Hoffmann-La Roche LTD,"AN OPEN-LABEL, MULTICENTER, PHASE II STUDY TO EVALUATE THE THERAPEUTIC ACTIVITY OF RO6874281, AN IMMUNOCYTOKINE, CONSISTING OF INTERLEUKIN-2 VARIANT (IL-2V) TARGETING FIBROBLAST ACTIVATION PROTEIN-Α (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003182-94,1,0,0 2017-003183-13,1,2022-07-27,2022-07-27,1,0,0,0,0,0,2,0,0,1,1,1,0,0,0,GEICO - Grupo Español de Investigación en Cáncer de Ovario,Phase-II study of olaparib as maintenance therapy after response to trabectedinpegylated liposomal doxorubicin in recurrent ovarian carcinoma. Ensayo fase II de Olaparib de mantenimiento tras la re...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003183-13,0,0,0 2017-003185-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GERCOR,"A non-comparative randomized 2:1 phase II study of docetaxel, cisplatin, and 5-fluorouracil in combination or not with atezolizumab in patients with metastatic or unresectable locally advanced squamou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003185-27,0,0,0 2017-003188-36,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Lapland Central Hospital,"Keski-ikäisten pitkään tupakoineiden tupakasta vieroitus sähkötupakalla ( Efficacy and safety of e-cigarettes for smoking cessation in middle-aged heavy smokers, EFFECT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003188-36,0,0,0 2017-003189-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,L'Institut Mutualiste Montsouris,"A phase II/III multicentric randomized trial, compared abiraterone + dexamethasone versus standard abiraterone + prednisone in patients resistant-castration in metastatic prostate cancer Essai de p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003189-29,0,0,0 2017-003190-34,12,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Celgene Corporation,"A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Ris...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003190-34,0,0,0 2017-003190-34,12,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,CELGENE CORPORATION,"A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Ris...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003190-34,0,0,0 2017-003191-30,4,2022-03-09,2022-03-09,4,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Novartis Pharma AG,"A randomized, subject and investigator blinded, placebo-controlled, multi-center study in parallel groups to assess the efficacy and safety of LYS006 in patients with moderate to severe inflammatory a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003191-30,0,0,0 2017-003193-14,1,2021-09-18,2021-09-18,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Department of Ophthalmology, MUW","Disease-modification under treatment with aflibercept in advanced diabetic retinopathy - A pilot study Therapie mit Aflibercept bei proliferativer diabetischer Retinopathie - eine prospektive, klin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003193-14,0,0,0 2017-003194-33,1,2018-11-27,2018-11-27,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Janssen Vaccines and Prevention B.V.,"An Exploratory, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003194-33,0,0,0 2017-003197-13,1,2018-11-28,2018-11-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Ionis Pharmaceuticals, Inc.","A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ISIS 484137 (ISIS-DGAT2RX, an Antisense Inhibitor of Diacylglycerol Acyltrans...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003197-13,0,0,0 2017-003200-48,12,2020-01-30,2020-02-26,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SPRL,"A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug- Resist...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003200-48,0,0,0 2017-003200-48,12,2020-01-30,2020-02-26,11,1,0,0,0,0,2,0,0,1,0,0,1,0,1,UCB Biopharma SRL,"A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug- Resist...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003200-48,0,0,0 2017-003205-18,1,2018-08-08,2018-08-08,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Anika Therapeutics, Inc.","Extension Study to Cingal 16-02: Trial Extension to 39 Week Follow Up in the Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyalur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003205-18,0,0,0 2017-003206-41,1,2018-11-02,2018-11-02,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Millennium Pharmaceuticals, Inc.","A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Intole...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003206-41,0,0,0 2017-003212-39,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Lightpoint Medical Ltd,Evaluation of the LightPath Imaging System and the PET tracer 68Ga-RM2 in wide local excision (WLE) for breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003212-39,0,0,0 2017-003215-19,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Residu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003215-19,0,0,0 2017-003215-19,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,BIOMARIN PHARMACEUTICAL INC.,"A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Residu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003215-19,0,0,0 2017-003216-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Clinical utility of a next generation sequencing-based “oncochip” for therapeutic decision in metastatic breast cancer. Study SHARP Utilità clinica di una nuova generazione di sequenziamento basata...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003216-39,0,0,0 2017-003219-20,15,2021-02-22,2021-02-22,15,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Effect of semaglutide once-weekly versus insulin aspart three times daily, both as add on to metformin and optimised insulin glargine (U100) in subjects with type 2 diabetes A 52-week, multi-centre, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003219-20,0,0,0 2017-003220-78,1,2019-11-14,2019-11-14,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Eli Lilly and Company,"A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog in Children, Adolescents, and Adults with Type 1 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003220-78,0,0,0 2017-003221-15,1,2022-08-09,2022-08-09,1,1,0,0,0,0,3,0,0,1,1,1,0,0,0,Universität zu Köln,"PROSPEKTIV RANDOMISIERTE, MULTIZENTRISCHE STUDIE ZUM VERGLEICH DER EINER RADIKALEN HYSTEREKTOMIE NACH NEOADJUVANTER CHEMOTHERAPIE VERSUS EINER PRIMÄREN RADIOCHEMOTHERAPIE BEI PATIENTINNEN MIT EINEM ZE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003221-15,0,0,0 2017-003225-15,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI,Comparison between inhaled sedation with Sevoflurane vs endovenous sedation with Propofol in the Intensive Care Unit: a randomized prospective trial Confronto tra sedazione inalatoria con Sevoflura...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003225-15,0,0,0 2017-003226-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dean of the Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg Prof. Dr. Markus Neurath,First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell infiltration (CheckRad-CD8),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003226-33,0,0,0 2017-003228-54,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,PaloBiofarma S.L.,"A Phase IIa (proof of concept), randomized, double blind, placebo controlled, multicenter clinical trial to evaluate the safety and efficacy of oral treatment with PBF-677 in patients with mild to mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003228-54,0,0,0 2017-003229-14,14,2021-04-10,2021-04-10,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003229-14,1,0,0 2017-003229-14,14,2021-04-10,2021-04-10,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly Cork Limited,"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003229-14,1,0,0 2017-003229-14,14,2021-04-10,2021-04-10,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003229-14,1,0,0 2017-003230-93,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A randomized, placebo-controlled, patient and investigator blinded study investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of multiple doses of CFZ533 in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003230-93,0,0,0 2017-003232-36,1,,,0,0,0,0,1,0,2,0,0,3,0,0,0,0,0,NHS Greater Glasgow & Clyde,Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial with GOLD Imaging Theranostic (POST-IT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003232-36,0,0,0 2017-003232-36,1,,,0,0,0,0,1,0,2,0,0,3,0,0,0,0,0,University of Glasgow,Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial with GOLD Imaging Theranostic (POST-IT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003232-36,0,0,0 2017-003234-82,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Neurotech Pharmaceuticals,"A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia type 2",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003234-82,0,0,0 2017-003236-37,3,2021-01-21,2021-01-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003236-37,0,0,0 2017-003236-37,3,2021-01-21,2021-01-21,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AMGEN INC.,High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003236-37,0,0,0 2017-003238-96,15,2022-02-04,2022-02-04,10,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003238-96,1,0,0 2017-003238-96,15,2022-02-04,2022-02-04,10,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003238-96,1,0,0 2017-003238-96,15,2022-02-04,2022-02-04,10,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly Cork Limited,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003238-96,1,0,0 2017-003239-13,1,2019-04-10,2019-04-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Imperial College London JRC Office,Pharmacokinetics of Intramuscular Adrenaline in Food-Allergic Teenagers - does dose matter? The PIMAT study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003239-13,0,0,0 2017-003240-20,1,,,0,1,0,0,0,0,4,0,1,1,1,1,0,1,0,"RWTH Aachen, represented by the rector, himself represented by the dean of the Medical Faculty",Velphoro and impact on the oral cavity and gut microbiome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003240-20,0,0,0 2017-003241-26,21,2020-05-21,2020-12-11,16,1,0,0,0,0,2,0,0,2,1,0,0,0,1,UCB Biopharma SRL,"An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug-Resistant Epilepsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003241-26,1,0,0 2017-003241-26,21,2020-05-21,2020-12-11,16,1,0,0,0,0,2,0,0,2,1,0,0,0,1,UCB Biopharma SPRL,"An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug-Resistant Epilepsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003241-26,1,0,0 2017-003242-25,1,2020-07-30,2020-07-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,ASOCIACION GITuD,Analysis of 2nd line panitumumab + FOLFIRI efficacy in wild type RAS converted subjects from initially mutated RAS subjects with metastatic colorectal cancer treated in 1st line with standard FOLFOX +...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003242-25,0,0,0 2017-003243-37,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,"MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health",Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003243-37,0,0,0 2017-003249-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Cliniques Universitaires Saint-Luc,Study of the effects of TNF and IL23 blocking agents on Gene Expression pRofiles in the PsA Synovium (TIGERS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003249-18,0,0,0 2017-003250-16,1,2018-09-06,2018-09-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Menlo Therapeutics Inc.,"A Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy, Safety, And Tolerability Of Serlopitant For The Treatment Of Refractory Chronic Cough",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003250-16,0,0,0 2017-003252-24,5,2019-12-26,2019-12-26,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen Sciences Ireland UC,"A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ- 53718678 at Two Dose Level...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003252-24,0,0,0 2017-003253-41,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Polish Myeloma Consortium,PRE-emptive DAratumumab Therapy Of minimal Residual disease reappearance or biochemical relapse in multiple myeloma (PREDATOR). Prewencyjna terapia Daratumumabem nawrotu minimalnej choroby resztkow...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003253-41,0,0,0 2017-003254-17,1,2020-09-15,2020-09-15,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Institut de Recerca Hospital de la Santa Creu i Sant Pau,"A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Safinamide on Apathy in Patients With Parkinson's Disease Estudio de 24 se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003254-17,0,0,0 2017-003256-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Universitätsklinikum Münster,"Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) In Younger, High-Risk Patients with Diffuse Large B-Cell Lymphoma Ibrutinib und Standard-Immunochemotherapie (R-CHOEP-14) in jungen Hochrisi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003256-22,0,0,0 2017-003257-42,1,2018-10-05,2018-10-05,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,Achieve Life Sciences Inc,Repeat-Dose Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003257-42,0,0,0 2017-003258-18,1,2019-11-14,2019-11-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Leuven,A randomized controlled trial to evaluate the short-term efficacy and long-term health economic impact of a dietary intervention compared to pharmacotherapy with a musculotropic spasmolytic agent for ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003258-18,0,0,0 2017-003259-40,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Dra Beatriz Lozano-Hospital Universitario de Canarias,Periodontitis treatment in patients with reumatoid arthritis and high clinical activity in the. Randomized clinical trial. “Impacto del tratamiento de la Periodontitis avanzada en pacientes con al...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003259-40,0,0,0 2017-003260-12,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Neurotech Pharmaceuticals Inc.,"A Phase 3 Multicenter Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia type 2 Eine multizentrische randomerisierte, Scheineingriff-kontrol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003260-12,0,0,0 2017-003268-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC in patients with somatostatin receptor positive tumors (neuroendocrine tumors) Terapia radiorecettoriale con 90Y-DOTATOC nei tumori espriment...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003268-11,0,0,0 2017-003270-14,3,2021-03-30,2021-03-30,3,1,0,0,0,0,0,0,0,1,0,0,1,0,0,Radboud University Medical Center,"A phase IV, interventional, non-blinded, randomized, controlled, multicenter study of Posaconazole prophylaxis for the prevention of influenza-associated aspergillosis (IAA) in critically ill patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003270-14,0,0,0 2017-003270-14,3,2021-03-30,2021-03-30,3,1,0,0,0,0,0,0,0,1,0,0,1,0,0,UZ Leuven,"A phase IV, interventional, non-blinded, randomized, controlled, multicenter study of Posaconazole prophylaxis for the prevention of influenza-associated aspergillosis (IAA) in critically ill patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003270-14,0,0,0 2017-003271-61,1,2020-10-13,2020-10-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GREEN CROSS WellBeing,"Phase IIa (therapeutic exploratory), multicenter, randomized, double-blind, placebocontrolled, 2-stage, 4-arm study exploring the effect of BST204 on cancer-related cachexia in patients with gastroint...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003271-61,0,0,0 2017-003272-31,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,St. Antonius Ziekenhuis,Efficacy and safety of oral itraconazole in the reduction of epistaxis severity in hereditary hemorrhagic telangiectasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003272-31,0,0,0 2017-003277-34,1,2019-04-26,2019-04-26,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Laboratoires Théa,"Phase IV, open-label, randomized clinical trial to evaluate the effects of Fydrane® and standard topical mydriatics and anaesthetics protocol on ocular surface after cataract surgery. Ensayo clínic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003277-34,0,0,0 2017-003278-15,1,2021-01-09,2021-01-09,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Ghent University Hospital,"Hyperalgesia, Persistent Pain, and Fentanyl Dosing in On-Pump Coronary Artery Bypass Grafting",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003278-15,0,0,0 2017-003281-27,11,2022-04-27,2022-04-27,8,0,0,0,0,1,2,0,0,2,0,0,0,0,1,BIOCRYST PHARMACEUTICALS INC.,An Open-Label study to Evaluate the Long-Term Safety of Daily Oral BCX7353 in subjects with Type I and II Hereditary Angioedema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003281-27,1,0,0 2017-003281-27,11,2022-04-27,2022-04-27,8,0,0,0,0,1,2,0,0,2,0,0,0,0,1,BioCryst Pharmaceuticals Inc,An Open-Label study to Evaluate the Long-Term Safety of Daily Oral BCX7353 in subjects with Type I and II Hereditary Angioedema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003281-27,1,0,0 2017-003282-98,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Olatec Therapeutics LLC,"A Pilot, Open-Label, Phase 2, Single-Center, Repeat Dose, Proof-of-Concept Safety, Pharmacodynamics and Efficacy Study of Orally Administered Dapansutrile Capsules in Subjects with Schnitzler’s Syndro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003282-98,0,0,0 2017-003284-35,4,2022-08-15,2022-08-15,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ABIVAX,A follow-up Phase IIa study to evaluate the long-term safety and efficacy profile of ABX464 given at 50 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis Ensayo clínico de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003284-35,1,0,0 2017-003285-27,1,2018-11-28,2018-11-28,1,0,0,0,1,0,4,0,0,1,0,0,1,0,1,Laboratoires Thea,Clinical efficacy of topical hydrocortisone 0.335% (Softacort®) in patients with chronic dry eye disease and associated ocular surface inflammation Klinische Effektivität von Softacort® Augentropfe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003285-27,0,0,0 2017-003286-10,8,2020-05-08,2020-06-03,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003286-10,0,0,0 2017-003286-10,8,2020-05-08,2020-06-03,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003286-10,0,0,0 2017-003286-10,8,2020-05-08,2020-06-03,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003286-10,0,0,0 2017-003287-12,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Corcept Therapeutics Incorporated,"Phase 1/2a dose-escalation and expansion study to evaluate the safety, tolerability and pharmacokinetics of CORT125281 with enzalutamide in patients with metastatic castration-resistant prostate cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003287-12,0,0,0 2017-003288-36,8,2021-09-27,2021-10-27,6,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"COMPASS Pathfinder, Limited",The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression (P-TRD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003288-36,1,0,0 2017-003288-36,8,2021-09-27,2021-10-27,6,0,0,0,0,0,2,0,0,2,0,0,0,0,1,COMPASS Pathfinder Limited,The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression (P-TRD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003288-36,1,0,0 2017-003288-36,8,2021-09-27,2021-10-27,6,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"COMPASS Pathways, Ltd",The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression (P-TRD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003288-36,1,0,0 2017-003289-29,1,2019-08-07,2019-08-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & développement,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500 and the Coadministration of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003289-29,0,0,0 2017-003290-34,2,2020-02-21,2020-02-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Sanofi-aventis recherche & développement,"A randomized, double-blind, placebo-controlled, parallel-group, Proof-of-Concept (PoC) study to assess the efficacy, safety and tolerability of SAR440340, in patients with moderate-to-severe chronic o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003290-34,0,0,0 2017-003293-14,5,2019-02-04,2019-02-04,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Urovant Sciences GmbH,"An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overacti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003293-14,0,0,0 2017-003294-33,3,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Urovant Sciences GmbH,"An International Phase 3, Randomized, Double-Blind, Active (Tolterodine)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Patients with Symptoms of O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003294-33,0,0,0 2017-003295-31,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib With Enzalutamide In Metastatic Castration-resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003295-31,0,0,0 2017-003295-31,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Pfizer Inc.,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib With Enzalutamide In Metastatic Castration-resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003295-31,0,0,0 2017-003295-31,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Pfizer Inc.,","A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib With Enzalutamide In Metastatic Castration-resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003295-31,0,0,0 2017-003295-31,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,PFIZER INC,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib With Enzalutamide In Metastatic Castration-resistant Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003295-31,0,0,0 2017-003296-60,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GWT TUD GmbH,"Empagliflozin effect on glucose toxicity in type 2 diabetes patients - a randomized, open-label, controlled, parallel group, exploratory study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003296-60,0,0,0 2017-003298-32,2,2020-01-16,2020-01-16,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003298-32,0,0,0 2017-003299-30,8,2021-04-27,2022-02-21,5,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Eli Lilly and Company,"A Multicenter, Long-Term Extension to Evaluate the Long Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003299-30,1,0,0 2017-003299-30,8,2021-04-27,2022-02-21,5,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Multicenter, Long-Term Extension to Evaluate the Long Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003299-30,1,0,0 2017-003299-30,8,2021-04-27,2022-02-21,5,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Lilly S.A.,"A Multicenter, Long-Term Extension to Evaluate the Long Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003299-30,1,0,0 2017-003302-40,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH-RISK LOCALLY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003302-40,0,0,0 2017-003302-40,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffman-La Roche Ltd.,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH-RISK LOCALLY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003302-40,0,0,0 2017-003302-40,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Roche Farma S.A.(Soc.Unipersonal)que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY AFTER DEFINITIVE LOCAL THERAPY IN PATIENTS WITH HIGH-RISK LOCALLY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003302-40,0,0,0 2017-003304-43,1,2018-04-20,2018-04-20,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Incyte Corporation,"A Phase 3, Randomized, Global Trial of Nivolumab and Epacadostat with Platinum Doublet Chemotherapy versus Platinum Doublet Chemotherapy in First-line Treatment of Stage IV or Recurrent Non-Small Cell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003304-43,0,0,0 2017-003305-18,1,2018-04-20,2018-04-20,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Incyte Corporation,"A Randomized, Global, Phase 3 Trial of Nivolumab Plus Epacadostat in Combination with Chemotherapy (platinum + 5-fluorouracil) versus the EXTREME Regimen (cetuximab + platinum + 5-fluorouracil) in Fir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003305-18,0,0,0 2017-003306-40,1,2020-04-17,2020-04-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Ltd.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study with Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects with Irregular Sleep-Wake Rhythm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003306-40,0,0,0 2017-003309-16,11,2020-05-12,2020-05-12,10,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Jazz Pharmaceuticals Inc.,"A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pedia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003309-16,0,0,0 2017-003310-74,6,2021-03-27,2021-03-27,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,MYOVANT SCIENCES GMBH,"LIBERTY EXTENSION: An International Phase 3 Open-Label, Single-Arm, Long-Term Efficacy and Safety Extension Study to Evaluate Relugolix Co-Administered with Low-Dose Estradiol and Norethindrone Acetat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003310-74,1,0,0 2017-003310-74,6,2021-03-27,2021-03-27,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Myovant Sciences GmbH,"LIBERTY EXTENSION: An International Phase 3 Open-Label, Single-Arm, Long-Term Efficacy and Safety Extension Study to Evaluate Relugolix Co-Administered with Low-Dose Estradiol and Norethindrone Acetat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003310-74,1,0,0 2017-003311-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Medical Centre Hamburg-Eppendorf,Phase IIa proof-of-principle study for the induction treatment of autoimmune hepatitis using infliximab AIH-MAB Phase IIa proof-of-principle Studie zur Wirksamkeit von Infliximab in der Induktion...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003311-19,0,0,0 2017-003317-25,6,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Sanofi-aventis recherche & développement,One year study to evaluate the long-term safety and tolerability of dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003317-25,0,1,0 2017-003319-21,3,2019-12-23,2019-12-23,3,0,0,1,0,1,1,0,1,1,0,0,0,0,1,"Proteostasis Therapeutics, Inc.","A Phase 1 / 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Adults with Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003319-21,0,0,0 2017-003321-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Prevention of DElirium with MELatonine in intensive care unit : prospective, multicenter, randomized, double-blind, placebo, multi-arm, multi-stage trial. Prévention du DElirium en réanimation par ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003321-14,0,0,0 2017-003323-30,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,European Organisation for the Research and Treatment of Cancer (EORTC),"Open-label first line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003323-30,0,0,0 2017-003324-67,6,2019-10-15,2019-10-15,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,BAYER HEALTHCARE AG,Multiple escalating dose study of BAY 1093884 in adults with hemophilia A or B with or without inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003324-67,0,0,0 2017-003324-67,6,2019-10-15,2019-10-15,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Bayer AG,Multiple escalating dose study of BAY 1093884 in adults with hemophilia A or B with or without inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003324-67,0,0,0 2017-003328-56,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University College London Comprehensive Clinical Trials Unit,"A phase 3 randomised, double blind, clinical trial investigating the effectiveness of repurposed simvastatin compared to placebo, in secondary progressive multiple sclerosis, in slowing the progressio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003328-56,0,0,0 2017-003330-91,1,2018-09-30,2018-09-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratoires SMB S.A.,"A pharmacokinetic and pharmacodynamic, randomised, single dose, cross-over, partially blinded study to compare the systemic exposure and the efficacy of a fixed-dose combination of Budesonide-Salmeter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003330-91,0,0,0 2017-003331-10,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Leiden University,Acute effects of 40 mg cortisol on emotion and cognition. Acute effecten van 40 mg cortisol op emotie en cognitive.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003331-10,0,0,0 2017-003332-36,5,2018-09-18,2018-09-18,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Idorsia Pharmaceuticals Ltd.,"A multi-center, double-blind, randomized, placebo-controlled study to assess the pharmacodynamics, pharmacokinetics, tolerability, and safety of a single subcutaneous injection of ACT-246475 in adults...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003332-36,0,0,0 2017-003333-29,3,2021-02-15,2021-02-15,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Minerva Neurosciences, Inc.,","A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-Controlled, Monotherapy, 12-Week Study to Evaluate the Efficacy and Safety of 2 Fixed Doses of MIN-101 in Adult Patients with Negative ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003333-29,0,0,0 2017-003334-82,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Cologne,Abscopal Effect of Radiotherapy and Nivolumab in anti-PD1 Pretreated Relapsed or Refractory classical Hodgkin Lymphoma - An international multicenter Phase II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003334-82,0,0,0 2017-003336-37,1,2019-05-27,2019-05-27,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"SGHL – SOCIEDADE GESTORA DO HOSPITAL DE LOURES, S.A - Hospital Beatriz Ângelo",CA2209-9G7: Phase II multi-institutional proof of concept single-arm trial of Nivolumab in the treatment of patients with platinum-recurrent or platinum-refractory metastatic germ cell tumors CA220...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003336-37,0,0,0 2017-003338-94,4,2020-09-17,2020-12-17,3,1,1,0,0,0,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics, Safety and Efficacy of Daclatasvir (DCV) in Combination with Sofosbuvir (SOF) in Children from 3 to less than 18 Years of Age with GT-1 t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003338-94,1,1,0 2017-003342-25,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Long-term treatment of cancer associated VTE Optimal dose of apixaban API-CAT STUDY for APIxaban Cancer Associated Thrombosis Long-term treatment of cancer associated VTE Optimal dose of apixaban ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003342-25,0,0,0 2017-003343-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Combination of pembrolizumab with oral metronomic cyclophosphamide in patients with chest wall breast cancer (PERICLES): A phase II study. Combinazione di pembrolizumab con ciclofosfamide orale met...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003343-37,0,0,0 2017-003344-21,9,,,0,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"Astellas Pharma Global Development, Inc. (APGD)","An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003344-21,0,0,0 2017-003344-21,9,,,0,1,1,0,0,0,3,0,0,2,0,0,0,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.","An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003344-21,0,0,0 2017-003349-14,1,2021-06-20,2021-06-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,AIO-Studien-gGmbH,A randomized phase II study on the optimization of immunotherapy in squamous carcinoma of the head and neck (OPTIM) Eine randomisierte Phase-II-Studie zur Optimierung der Immuntherapie bei Plattene...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003349-14,0,0,0 2017-003351-38,3,2019-01-30,2019-01-30,1,0,0,1,0,1,1,0,0,2,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,A Phase 1/2 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects with Transfusion-Dependent β T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003351-38,1,0,0 2017-003351-38,3,2019-01-30,2019-01-30,1,0,0,1,0,1,1,0,0,2,0,0,0,0,1,CRISPR Therapeutics AG,A Phase 1/2 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects with Transfusion-Dependent β T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003351-38,1,0,0 2017-003353-41,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Leicester,Mesothelioma Stratified Therapy (MiST): A stratified multi-arm phase IIa clinical trial to enable accelerated evaluation of targeted therapies for relapsed malignant mesothelioma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003353-41,0,0,0 2017-003356-23,4,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,ABLYNX NV,"A randomized, double-blind, multicenter study to evaluate the efficacy and safety of ALX-0171 versus placebo, in addition to standard of care, in adults who have undergone hematopoietic stem cell tran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003356-23,0,0,0 2017-003356-23,4,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Ablynx NV,"A randomized, double-blind, multicenter study to evaluate the efficacy and safety of ALX-0171 versus placebo, in addition to standard of care, in adults who have undergone hematopoietic stem cell tran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003356-23,0,0,0 2017-003359-43,11,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF- 06700841 As Induction And Open Label Extension Treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003359-43,0,0,0 2017-003359-43,11,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Pfizer Inc.,"A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF- 06700841 As Induction And Open Label Extension Treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003359-43,0,0,0 2017-003359-43,11,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,PFIZER INC,"A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF- 06700841 As Induction And Open Label Extension Treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003359-43,0,0,0 2017-003362-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,OLVG,Ketanserin effects on Peripheral Temperature and Lactate De effecten van Ketanserine op de perifere temperatuur en lactaat,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003362-27,0,0,0 2017-003363-35,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,"APELLIS PHARMACEUTCIALS, INC.","An open label, prospective, study to assess the safety, tolerability, efficacy and pharmacokinetics of APL-2 in patients with Warm Antibody Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003363-35,0,0,0 2017-003364-12,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003364-12,0,0,0 2017-003364-12,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003364-12,0,0,0 2017-003365-99,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Maastricht University,"The effects of ceasing opioid, benzodiazepine, or Z-hypnotic drug use on measures of driving performance and postural balance. De effecten van het stoppen van opiaten, benzodiazepinen, of Z-hypnoti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003365-99,0,0,0 2017-003366-27,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Radboud University Nijmegen Medical Center,Efficacy of rituximab in comparison to continued corticosteroid treatment in idiopathic nephrotic syndrome unresponsive to 8 weeks of high dose prednisone.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003366-27,0,0,0 2017-003367-35,1,2020-07-20,2020-07-20,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Alvotech Swiss AG,"A Multicenter, Double-blind, Randomized, Parallel-group, Active Control Study to Compare the Efficacy, Safety, and Immunogenicity of AVT02 Versus Humira® in Patients with Moderate-to-Severe Chronic Pl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003367-35,0,0,0 2017-003369-85,8,2021-09-02,2021-09-02,5,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Idorsia Pharmaceuticals Ltd,"A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease Studio mul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003369-85,1,0,0 2017-003369-85,8,2021-09-02,2021-09-02,5,1,0,0,0,1,3,0,0,2,0,0,0,0,1,IDORSIA PHARMACEUTICALS LTD,"A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease Studio mul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003369-85,1,0,0 2017-003370-13,7,2020-07-19,2020-07-20,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-Aventis Groupe,A multi-center open-label parallel group randomized controlled trial to compare iGlarLixi versus premixed insulin in patients with type 2 diabetes who have failed to achieve glycemic control with basa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003370-13,0,0,0 2017-003372-31,4,2020-08-04,2020-08-04,2,1,0,0,0,1,2,0,0,2,0,0,0,0,1,La Jolla Pharmaceutical Company,"A Multi-center, Randomized, Open-Label, Parallel-Group Study with LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients with Transfusion-Dependent Beta Thalassemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003372-31,1,0,0 2017-003372-31,4,2020-08-04,2020-08-04,2,1,0,0,0,1,2,0,0,2,0,0,0,0,1,LA JOLLA PHARMACEUTICAL COMPANY,"A Multi-center, Randomized, Open-Label, Parallel-Group Study with LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients with Transfusion-Dependent Beta Thalassemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003372-31,1,0,0 2017-003374-14,1,2020-01-13,2020-01-13,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Savara ApS,"An Open-label, non-controlled, multicenter, Pilot clinical Trial of Inhaled Molgramostim in subjects with Antibiotic-resistant non-tuberculosis mycobacterial (NTM) infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003374-14,0,0,0 2017-003377-34,9,2021-11-30,2022-09-22,4,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Janssen-Cilag International N.V.,"An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age With Relapsed/Refractory Precursor B-cell or T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003377-34,1,1,0 2017-003380-35,16,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novo Nordisk A/S,SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003380-35,0,0,0 2017-003380-35,16,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novo Nordisk Hungária Kft.,SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003380-35,0,0,0 2017-003380-35,16,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,NOVO NORDISK. S.P.A.,SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003380-35,0,0,0 2017-003381-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CEA,Study in 18F-DPA714 PET to better locate preoperatively the epileptic focus to resect in drug-resistant partial epilepsy Etude en 18F-DPA714 TEP pour mieux localiser en préopératoire le foyer épile...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003381-27,0,0,0 2017-003382-10,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,GWT-TUD GmbH,"Quality of life in patients with non-adipocyte soft tissue sarcoma under palliative chemotherapy or pazopanib – a randomized, controlled trial- PazoQoL Lebensqualität bei Patienten mit nicht-adipoz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003382-10,0,0,0 2017-003386-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University of Vienna,"Effectiveness and safety of Dimethylfumarate in patients with Palmoplantar Pustulosis – a 24-week, open label, phase II trial Wirksamkeit und Sicherheit von Dimethylfumarat bei Patienten mit Palmop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003386-10,0,0,0 2017-003387-12,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University Hospital Tuebingen,"Dopamine action on metabolism depending on genetic heterogeneity – a randomized, placebo-controlled double blind study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003387-12,0,0,0 2017-003399-30,2,2018-10-30,2018-10-30,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Lilly S.A.,"A Prospective, Randomized, Double-Blind Comparison of LY900014 and Fiasp®, Both in Combination with Basal Insulin in Adults with Type 1 Diabetes, PRONTO-Compare",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003399-30,1,0,0 2017-003399-30,2,2018-10-30,2018-10-30,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Eli Lilly and Company,"A Prospective, Randomized, Double-Blind Comparison of LY900014 and Fiasp®, Both in Combination with Basal Insulin in Adults with Type 1 Diabetes, PRONTO-Compare",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003399-30,1,0,0 2017-003406-40,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,0,Université catholique de Louvain,Repetitive blood donations and endurance sport performance: does iron supplementation limit the negative effects on hematological parameters? Dons de sang répétés et performance en endurance: est-c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003406-40,0,0,0 2017-003410-20,5,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Ascendis Pharma Endocrinology Division A/S,"enliGHten: A Multicenter, Phase 3, Long-term, Open-label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children with Growth Hormone Deficiency (GHD) Who Have Comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003410-20,0,0,0 2017-003411-19,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,Fakultní nemocnice u sv. Anny v Brně,Compatibility of clopidogrel prepared for administration through nasogastric tube with enteral nutrition (CPU-003) Kompatibilita klopidogrelu připraveného pro podání do nasogastrické sondy s enterá...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003411-19,0,0,0 2017-003413-25,6,2022-08-02,2022-08-02,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Genmab A/S,"A single arm, multicenter, international trial of tisotumab vedotin (HuMax®-TF-ADC) in previously treated, recurrent or metastatic cervical cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003413-25,1,0,0 2017-003414-10,4,2020-05-01,2020-05-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity and type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003414-10,0,0,0 2017-003415-19,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Contera Pharma,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Combi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003415-19,0,0,0 2017-003416-38,3,2022-07-28,2022-07-28,2,0,0,0,0,0,3,0,0,2,0,0,0,0,0,Fraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME),"Randomised, open lable, active controlled clinical trial to demonstrate safety and efficacy of an i.v. administration of Polyglucoferron compared to i.v. Ferric Carboxymaltose and oral iron substituti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003416-38,1,0,0 2017-003422-32,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) gGmbH,"INTERNATIONAL MULTICENTER, OPEN-LABEL, PHASE 2 STUDY TO TREAT MOLECULAR RELAPSE OF PEDIATRIC ACUTE MYELOID LEUKEMIA WITH AZACITIDINE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003422-32,0,0,0 2017-003423-30,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Dutch Growth Research Foundation,"Randomized, double-blind, placebo-controlled oxytocin and dose-response trial in children with Prader-Willi syndrome. Effects on social behaviour.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003423-30,0,0,0 2017-003424-76,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Starpharma Pty Ltd,"A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CTX-SPL9111 (a cabazitaxel (CTX)-dendrimer conjugate) in patients with advanced sol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003424-76,0,0,0 2017-003425-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet","Patients with rheumatoid arthritis and synovitis treated with ultrasound guided intraarticular or intramuscular glucocorticoid injection - A randomised, double-blind, controlled study (Panguian) Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003425-15,0,0,0 2017-003426-32,5,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,DCprime bv,"AN INTERNATIONAL, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DIFFERENT VACCINATION REGIMENS OF IMMUNOTHERAPY WITH ALLOGENEIC DENDRITIC CELLS, DCP-001, IN PATIENTS WITH A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003426-32,0,0,0 2017-003426-32,5,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,DCrime bv,"AN INTERNATIONAL, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DIFFERENT VACCINATION REGIMENS OF IMMUNOTHERAPY WITH ALLOGENEIC DENDRITIC CELLS, DCP-001, IN PATIENTS WITH A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003426-32,0,0,0 2017-003426-32,5,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Mendus (former Immunicum),"AN INTERNATIONAL, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DIFFERENT VACCINATION REGIMENS OF IMMUNOTHERAPY WITH ALLOGENEIC DENDRITIC CELLS, DCP-001, IN PATIENTS WITH A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003426-32,0,0,0 2017-003428-61,5,2020-05-29,2020-05-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching from an Elvitegravir/ Cobicistat/ Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination Regimen or a Tenofovir Disoproxil Fumarate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003428-61,0,0,0 2017-003428-61,5,2020-05-29,2020-05-29,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching from an Elvitegravir/ Cobicistat/ Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination Regimen or a Tenofovir Disoproxil Fumarate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003428-61,0,0,0 2017-003430-85,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Helsinki University Hospital,"A randomized, open, parallel design study to evaluate the effect on liver fat, adipose tissue and metabolic parameters when switching a protease inhibitor or efavirenz to once daily raltegravir in HIV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003430-85,0,0,0 2017-003432-37,1,2019-07-05,2019-07-05,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Advanced Accelerator Applications International SA,Phase II study of preliminary diagnostic performance of [68Ga]-NeoBOMB1 in adult patients with malignancies known to overexpress Gastrin Releasing Peptide Receptor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003432-37,0,0,0 2017-003434-87,1,,,0,0,1,0,0,1,1,0,0,4,0,0,0,0,0,Cincinnati Children's Hospital Medical Center,"A Phase 1/Pilot Study of CPX-351 for Children, Adolescents and Young Adults with Recurrent or Refractory Hematologic Malignancies.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003434-87,0,1,1 2017-003435-11,2,2019-02-19,2019-02-19,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Vical Incorporated,A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Immunocompromised Adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003435-11,0,0,0 2017-003436-36,6,2020-04-19,2021-03-05,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Novo Nordisk A/S,Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003436-36,1,0,0 2017-003439-12,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fraunhofer Gesellschaft für sein Institut Fraunhofer für Molekulare Biologie und angewandte Ökologie (IME),Safety and efficacy of postoperative i.v. iron substitution with Polyglucoferron compared to Ferric Carboxymaltose and oral iron in patients with diagnosed iron deficiency anaemia pre- or postoperativ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003439-12,0,0,0 2017-003439-12,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fraunhofer Gesellschaft for its Institute Fraunhofer for Molecular Biology and Applied Ecology (IME),Safety and efficacy of postoperative i.v. iron substitution with Polyglucoferron compared to Ferric Carboxymaltose and oral iron in patients with diagnosed iron deficiency anaemia pre- or postoperativ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003439-12,0,0,0 2017-003444-20,1,,,0,0,1,0,0,1,1,0,0,4,0,0,0,0,0,Children's Oncology Group,"A Phase 1/2 Study of CPX-351 Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003444-20,0,1,1 2017-003450-16,9,2020-03-16,2020-03-16,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,OPEN-LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003450-16,0,0,0 2017-003455-35,7,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc","A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (ages 10 to 17 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003455-35,0,1,0 2017-003455-35,7,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (ages 10 to 17 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003455-35,0,1,0 2017-003456-23,5,2020-08-17,2020-08-17,3,1,0,0,0,0,2,0,1,2,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase 2b, randomized, controlled, observer-blind, multi-center study to evaluate safety and immunogenicity of different formulations of GSK Biologicals’ Meningococcal ACWY conjugate vaccine (GSK3536...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003456-23,1,1,0 2017-003456-23,5,2020-08-17,2020-08-17,3,1,0,0,0,0,2,0,1,2,0,0,0,0,1,GlaxoSmithKline S.A.,"A phase 2b, randomized, controlled, observer-blind, multi-center study to evaluate safety and immunogenicity of different formulations of GSK Biologicals’ Meningococcal ACWY conjugate vaccine (GSK3536...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003456-23,1,1,0 2017-003458-18,2,2019-06-12,2019-06-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Integrative Research Laboratories AB (IRLAB),"A randomised, double-blind, placebo-controlled, phase IIA study evaluating the efficacy and tolerability of IRL790 in Parkinson's disease dyskinesia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003458-18,0,0,0 2017-003460-13,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,NHS Greater Glasgow and Clyde,The effects of sacubitril/valsartan compared to valsartan on left ventricular remodelling in patients with asymptomatic left ventricular systolic dysfunction after myocardial infarction: a randomised...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003460-13,0,0,0 2017-003460-13,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Glasgow,The effects of sacubitril/valsartan compared to valsartan on left ventricular remodelling in patients with asymptomatic left ventricular systolic dysfunction after myocardial infarction: a randomised...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003460-13,0,0,0 2017-003461-96,1,2018-12-20,2018-12-20,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Ghent University Hospital,PSMA-PET/CT for prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003461-96,0,0,0 2017-003464-12,4,2021-01-28,2021-02-25,3,1,0,1,0,0,1,0,0,2,0,0,0,0,1,Array BioPharma Inc.,An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Previously Treated Microsatellite-stable (MSS) Metastatic Colorec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003464-12,1,0,0 2017-003466-28,3,2020-11-10,2020-11-10,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,DAIICHI SANKYO INC.,"A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201A IN SUBJECTS WITH HER2-EXPRESSING ADVANCED COLORECTAL CANCER [DESTINY-CRC01]",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003466-28,1,0,0 2017-003466-28,3,2020-11-10,2020-11-10,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Daiichi Sankyo Inc.,"A PHASE 2, MULTICENTER, OPEN-LABEL STUDY OF DS-8201A IN SUBJECTS WITH HER2-EXPRESSING ADVANCED COLORECTAL CANCER [DESTINY-CRC01]",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003466-28,1,0,0 2017-003467-34,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Terveyden ja hyvinvoinnin laitos (THL),Immune responses to influenza vaccinations and viruses among health care personnel Immuunivasteet influenssarokotteille ja -viruksille terveydenhoitohenkilökunnan keskuudessa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003467-34,0,0,0 2017-003470-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FIMABIS Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud,"Pilot clinical trial, multicenter, to compare the efficacy of RTG 1200 QD vs DRV-cb (800-150) QD both in combination with TAF/FTC in patients with HIV and CD4 infection <200 cells/microL. Ensayo cl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003470-14,0,0,0 2017-003470-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,APES Costa del Sol (Agencia Pública Empresarial Sanitaria Costa del Sol),"Pilot clinical trial, multicenter, to compare the efficacy of RTG 1200 QD vs DRV-cb (800-150) QD both in combination with TAF/FTC in patients with HIV and CD4 infection <200 cells/microL. Ensayo cl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003470-14,0,0,0 2017-003471-54,5,2021-01-12,2021-01-12,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose levels of TAK-831 in Adjunctive Treatment of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003471-54,0,0,0 2017-003471-54,5,2021-01-12,2021-01-12,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda","A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose levels of TAK-831 in Adjunctive Treatment of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003471-54,0,0,0 2017-003473-34,5,2020-03-20,2020-03-20,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity who have reached target dose during run-in period,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003473-34,0,0,0 2017-003479-78,4,2020-04-06,2020-04-06,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Seattle Genetics Inc.,"A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003479-78,1,0,0 2017-003479-78,4,2020-04-06,2020-04-06,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"SEATTLE GENETICS, INC.","A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003479-78,1,0,0 2017-003481-28,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospitals Birmingham NHS Foundation Trust,A pilot randomised controlled trial to examine the efficacy and optimal dose of Acetic Acid to treat colonised burns wounds.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003481-28,0,0,0 2017-003483-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Verein zur Förderung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und vaskulären Biologie (ATVB)",Pilot Study: The LIPL-PLATELET Study LIPid paneLs And PLATELET activity in coronary heart disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003483-12,0,0,0 2017-003484-36,2,2019-06-12,2019-06-12,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,MetrioPharm AG,"A Phase II, Multicenter, Double-blind, Placebo-controlled, Efficacy and Safety Study of Two Oral Doses (150 mg bid / 300 mg bid) of MP1032 in Male and Female Patients with Moderate-to-Severe Chronic P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003484-36,0,0,0 2017-003489-28,1,2020-12-31,2020-12-31,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,Medizinische Universität Graz,"Influence of high dose vitamin D3 intake on outcome in pancreatic cancer surgery: prospective, randomized, open, controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003489-28,0,0,0 2017-003490-33,8,2019-10-10,2019-10-10,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003490-33,0,0,0 2017-003490-33,8,2019-10-10,2019-10-10,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003490-33,0,0,0 2017-003490-33,8,2019-10-10,2019-10-10,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003490-33,0,0,0 2017-003493-13,6,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,BeiGene Ltd.,"A Phase 2, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based Fi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003493-13,0,0,0 2017-003493-13,6,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,"BeiGene, Ltd.","A Phase 2, Double-blind, Randomized Study of BGB-290 versus Placebo as Maintenance Therapy in Patients with Inoperable Locally Advanced or Metastatic Gastric Cancer that Responded to Platinum-based Fi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003493-13,0,0,0 2017-003495-31,1,2018-11-01,2018-11-01,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Novartis Pharma AG,"A randomized, Investigator-and patient-blind, placebo-controlled, parallel group first in human and proof of concept study to evaluate the safety, tolerability, and efficacy of CLL442 in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003495-31,0,0,0 2017-003496-54,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University Hospital, LMU Munich (Germany)",A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer (FOOTPATH) Eine randomisierte Multicenterstudie der Ph...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003496-54,0,0,0 2017-003497-14,11,2021-09-15,2021-09-15,10,1,0,0,0,2,3,0,0,2,0,0,0,0,1,Blueprint Medicines Corporation,"An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003497-14,1,0,0 2017-003497-14,11,2021-09-15,2021-09-15,10,1,0,0,0,2,3,0,0,2,0,0,0,0,1,BLUEPRINT MEDICINES CORPORATION,"An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003497-14,1,0,0 2017-003505-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,COSMO TECHNOLOGIES LTD,Colonic lesion staining and flagging efficacy of methylene blue administered as MMX® 25 mg modified release tablets to patients receiving a split dose regimen of bowel cleansing preparation for colono...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003505-17,0,0,0 2017-003507-22,9,2022-05-13,2022-05-13,4,0,0,0,0,0,0,0,0,2,1,0,0,0,1,"Five Prime Therapeutics, Inc.","A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 2 Preceded by Dos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003507-22,1,0,0 2017-003507-22,9,2022-05-13,2022-05-13,4,0,0,0,0,0,0,0,0,2,1,0,0,0,1,"FIVE PRIME THERAPEUTICS, INC.","A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 2 Preceded by Dos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003507-22,1,0,0 2017-003508-39,1,2020-06-24,2020-06-24,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Oncology Venture Aps,"Phase II, open label clinical study to investigate anti-tumour effect and tolerability of the PARP inhibitor 2X-121 in patients with metastatic breast cancer selected by the 2X-121 DRP®.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003508-39,0,0,0 2017-003509-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE RICERCA TRASLAZIONALE (FORT),Serum cytokine levels as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic Colo-Rectal Cancer patients (mCRC) Livelli sierici di citochine come predittori di effic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003509-16,0,0,0 2017-003510-16,21,2020-05-06,2020-06-05,20,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003510-16,0,0,0 2017-003510-16,21,2020-05-06,2020-06-05,20,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Sanofi-aventis Recherche & Développement,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003510-16,0,0,0 2017-003510-16,21,2020-05-06,2020-06-05,20,1,0,0,0,0,3,0,0,1,1,0,1,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003510-16,0,0,0 2017-003510-16,21,2020-05-06,2020-06-05,20,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Lexicon Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003510-16,0,0,0 2017-003510-16,21,2020-05-06,2020-06-05,20,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Lexicon Pharmaceuticals,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003510-16,0,0,0 2017-003511-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,Molecular imaging of zirconium-89-labeled atezolizumab in high-risk diffuse large B-cell lymphoma prior to atezolizumab treatment Moleculaire beeldvorming middels Zirkonium-89-gelabeled Atezolizuma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003511-20,0,0,0 2017-003512-40,2,2020-01-08,2020-01-08,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Amgen Inc.,"A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women With Osteoporosis to Evaluate the Noninferiority of Subject-administered Romosozumab via Autoinjector/Pen vs Healthc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003512-40,0,0,0 2017-003516-39,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,DR. FALK PHARMA GMBH,"Double-blind, randomized phase III trial in adult and adolescent patients with eosinophilic esophagitis to prove superiority compared to placebo of an episodic and/or a continuous 48-week treatment wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003516-39,0,0,0 2017-003516-39,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomized phase III trial in adult and adolescent patients with eosinophilic esophagitis to prove superiority compared to placebo of an episodic and/or a continuous 48-week treatment wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003516-39,0,0,0 2017-003523-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Hospital Grenoble,Vaccination after hematopoietic stem cell transplantation : a randomized study estimating the interest of an additional injection for patients not reponding at M3. Vaccination après allogreffe de c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003523-30,0,0,0 2017-003524-75,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,"Allogeneic Bone Marrow Derived Mesenchymal Stromal Cells for the Treatment of Refractory Proctitis in Ulcerative Colitis Allogene, uit het beenmerg afkomstige, mesenchymale stromale cellen voor de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003524-75,0,0,0 2017-003526-32,3,2018-10-27,2018-10-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FIDIA FARMACEUTICI S.P.A.,"Randomised, double blind, parallel-groups, non-inferiority versus Flector® and superiority versus Placebo, Phase III clinical trial with Diclofenac Sodium 140 mg medicated plaster in patients with imp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003526-32,0,0,0 2017-003526-32,3,2018-10-27,2018-10-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Fidia Farmaceutici S.p.A.,"Randomised, double blind, parallel-groups, non-inferiority versus Flector® and superiority versus Placebo, Phase III clinical trial with Diclofenac Sodium 140 mg medicated plaster in patients with imp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003526-32,0,0,0 2017-003528-62,6,2020-01-16,2020-01-16,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Enanta Pharmaceuticals, Inc.","A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Primary Biliary Cholangitis (P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003528-62,0,0,0 2017-003529-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Thomas Benfield,"Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacterermia: A randomized, non-blinded, non-inferiority interventional study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003529-13,0,0,0 2017-003530-85,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"GITMO GRUPPO ITALIANO PER IL TRAPIANTO DI MIDOLLO OSSEO, CELLULE STAMINALI EMOPOIETICHE E TERAPIA",Post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Cell Transplantation for Myeloid Malignancies ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003530-85,0,0,0 2017-003534-89,4,2019-11-19,2019-11-19,3,1,0,1,1,1,1,0,2,2,0,0,0,0,1,Dicerna Pharmaceuticals Inc,"A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi Center Study in Patients with Primary Hyperoxaluria to Evaluate the Safety, Tolerabili...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003534-89,1,0,0 2017-003535-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,The added value of the H2-antagonist ranitidine in premedication regimens during paclitaxel treatment Evaluatie van de meerwaarde van ranitidine als anti-allergiemiddel bij paclitaxel chemotherapie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003535-11,0,0,0 2017-003535-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Maasstad Hospital,The added value of the H2-antagonist ranitidine in premedication regimens during paclitaxel treatment Evaluatie van de meerwaarde van ranitidine als anti-allergiemiddel bij paclitaxel chemotherapie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003535-11,0,0,0 2017-003536-36,3,2022-05-06,2022-05-06,2,0,0,0,0,0,3,0,0,1,0,0,0,0,1,ACADIA Pharmaceuticals Inc.,"A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003536-36,0,0,0 2017-003538-10,8,2021-09-15,2021-09-15,5,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Bioverativ USA Inc.,"A PHASE 3, PIVOTAL, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WHO HAVE A RECENT HISTORY OF BLOOD TRANSFUSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003538-10,1,0,0 2017-003538-10,8,2021-09-15,2021-09-15,5,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Bioverativ a Sanofi Company Inc.,"A PHASE 3, PIVOTAL, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WHO HAVE A RECENT HISTORY OF BLOOD TRANSFUSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003538-10,1,0,0 2017-003538-10,8,2021-09-15,2021-09-15,5,1,0,0,0,1,3,0,0,2,0,0,0,0,1,BIOVERATIV THERAPEUTICS INC,"A PHASE 3, PIVOTAL, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WHO HAVE A RECENT HISTORY OF BLOOD TRANSFUSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003538-10,1,0,0 2017-003538-10,8,2021-09-15,2021-09-15,5,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Bioverativ USA, Inc.","A PHASE 3, PIVOTAL, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WHO HAVE A RECENT HISTORY OF BLOOD TRANSFUSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003538-10,1,0,0 2017-003539-12,8,2021-12-03,2021-12-03,3,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Bioverativ USA, Inc.","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WITHOUT A RECENT HISTORY OF BLOOD TRANSFUSIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003539-12,1,0,0 2017-003539-12,8,2021-12-03,2021-12-03,3,0,0,0,0,1,3,0,0,2,0,0,0,0,1,BIOVERATIV THERAPEUTICS INC,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WITHOUT A RECENT HISTORY OF BLOOD TRANSFUSIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003539-12,1,0,0 2017-003539-12,8,2021-12-03,2021-12-03,3,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Bioverativ USA Inc.,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WITHOUT A RECENT HISTORY OF BLOOD TRANSFUSIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003539-12,1,0,0 2017-003540-21,10,2019-09-24,2021-02-12,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A phase III, randomized, double-blind study of chemotherapy with daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation plus midostaurin (PKC412) o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003540-21,0,0,0 2017-003540-21,10,2019-09-24,2021-02-12,8,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.","A phase III, randomized, double-blind study of chemotherapy with daunorubicin or idarubicin and cytarabine for induction and intermediate dose cytarabine for consolidation plus midostaurin (PKC412) o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003540-21,0,0,0 2017-003541-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FIMABIS Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud,Neuropsiquiatric Evolution After Introduction of Raltegravir QD in substitution of dolutegravir: NEAR QD Study Sustitución de Dolutegravir por Raltegravir 1200 mg QD en pacientes infectados con VIH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003541-17,0,0,0 2017-003541-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,APES Costa del Sol (Agencia Pública Empresarial Sanitaria),Neuropsiquiatric Evolution After Introduction of Raltegravir QD in substitution of dolutegravir: NEAR QD Study Sustitución de Dolutegravir por Raltegravir 1200 mg QD en pacientes infectados con VIH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003541-17,0,0,0 2017-003544-20,3,2020-01-06,2020-01-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A double blind (sponsor open) placebo-controlled, stratified, parallel group study to evaluate the efficacy and safety of repeat doses of GSK3772847 in participants with moderate to severe asthma with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003544-20,0,0,0 2017-003547-38,2,2019-12-13,2019-12-13,2,0,0,0,0,1,2,0,0,1,0,0,1,0,1,"Allena Pharmaceuticals, Inc.",Pilot Study of ALLN-177 in Adult and Pediatric Subjects Aged 12 Years or Older with Enteric or Primary Hyperoxaluria and Hyperoxalemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003547-38,0,0,0 2017-003549-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Oncology Venture Aps,"Phase II study of Irofulven in AR-targeted and Docetaxel-Pretreated Metastatic Castration-Resistant Prostate Cancer Patients, who have a Drug Response Predictor (DRP™) indicating a high likelihood of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003549-72,0,0,0 2017-003551-32,1,2020-03-19,2020-03-19,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Hospital of South West Jutland,"Effects of GLP-1 receptor agonist treatment on pulmonary function and quality of life in obese patients with chronic obstructive pulmonary disease - A prospective, randomized, placebo-controlled, dou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003551-32,0,0,0 2017-003552-23,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003552-23,0,0,0 2017-003552-23,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003552-23,0,0,0 2017-003553-42,1,2021-12-10,2021-12-10,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,AIO-Studien-gGmbH,"A Phase II single-arm, open-label study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC) Eine offene, einarmig...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003553-42,0,0,0 2017-003555-35,1,2019-10-31,2019-10-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Fresenius Medical Care Nephrologica Deutschland GmbH,"A Multicentre, Randomised, Open-label, Parallel-Group Pilot Study to Evaluate the Efficacy of Patiromer in Optimising Mineralocorticoid Receptor Antagonist Therapy in Heart Failure Subjects with Hyper...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003555-35,0,0,0 2017-003556-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital of the Friedrich-Alexander University Erlangen-Nürnberg,"A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA4 Blockade Precondi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003556-23,0,0,0 2017-003558-17,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,TauRx Therapeutics Ltd,"Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of Hydromethylthionine Mesylate (LMTM) Monotherapy in Subjects with Alzheimer's Disease Followed by a 12-Mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003558-17,0,0,0 2017-003558-17,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,TAURX THERAPEUTICS LTD,"Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of Hydromethylthionine Mesylate (LMTM) Monotherapy in Subjects with Alzheimer's Disease Followed by a 12-Mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003558-17,0,0,0 2017-003559-49,7,2020-10-30,2020-10-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN030)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003559-49,0,0,0 2017-003559-49,7,2020-10-30,2020-10-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN030)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003559-49,0,0,0 2017-003560-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"On Target Laboratories, LLC","A Phase 2, Single dose, Open-Label, Exploratory Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003560-13,0,0,0 2017-003563-36,1,,,0,0,0,0,0,1,2,0,1,3,0,0,0,0,0,Cambridge University Hospital NHS Foundation Trust and University of Cambridge,ACQUIVAS - Acquired immunodeficiency in ANCA associated vasculitis (AAV),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003563-36,0,0,0 2017-003564-12,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,CHU Dijon Bourgogne,IMPACT D’UN FLASH PREOPERATOIRE DE CORTICOÏDES SUR LA MORBIDITE APRES RESECTION COLORECTALE : ETUDE PILOTE PROSPECTIVE MONOCENTRIQUE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003564-12,0,0,0 2017-003565-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Swiss Group for Clinical Cancer Research,"Neoadjuvant and adjuvant durvalumab in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer. A multicenter, single-arm phase II Trial. Neoadjuvante und adjuvante Ko...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003565-10,0,0,0 2017-003568-10,2,2020-04-30,2021-10-27,2,1,0,0,0,1,2,0,0,1,0,0,0,0,1,ReveraGen BioPharma Inc.,"A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003568-10,0,0,0 2017-003569-91,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hagaziekenhuis,The effect of body weight on trough concentrations of DOACs in patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003569-91,0,0,0 2017-003571-56,3,2020-03-31,2021-05-03,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Amplyx Pharmaceuticals, Inc.","An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Non-Neutropenic Patients with Candidemia, with or without Invasive Candidiasis, Inclusive of Patients with Suspected Resistance to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003571-56,0,0,0 2017-003573-34,5,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,BIOMARIN PHARMACEUTICAL INC.,"A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg in Hemophili...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003573-34,0,0,0 2017-003573-34,5,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII at a dose of 4E13 vg/kg in Hemophili...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003573-34,0,0,0 2017-003574-13,1,2021-06-01,2021-06-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Aalborg university hospital dept. of rheumatology,"The NordCAN study: Cannabis treatment in hand osteoarthritis and psoriatic arthritis. A randomized, double-blind placebo controlled study NordCAN studiet: Cannabis behandling ved hånd artrose og ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003574-13,0,0,0 2017-003581-27,5,2022-08-22,2022-08-22,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003581-27,1,0,0 2017-003581-27,5,2022-08-22,2022-08-22,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003581-27,1,0,0 2017-003582-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST,PHASE II STUDY OF PREOPERATIVE CHEMORADIOTHERAPY PLUS AVELUMAB IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER STUDIO DI FASE II DI CHEMIORADIOTERAPIA PREOPERATORIA IN ASSOCIAZIONE AD AVELUMAB IN P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003582-10,0,0,0 2017-003583-12,14,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003583-12,0,1,0 2017-003583-12,14,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003583-12,0,1,0 2017-003585-27,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,GENOSCIENCE PHARMA,"Phase 1/2a study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with primary or secondary liver cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003585-27,0,0,0 2017-003586-94,1,2021-08-20,2021-08-20,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Fakultní nemocnice Hradec Králové,"Monitoring of changes in donepezil concentrations, biomarkers of oxidative stress and activity of acetylchonesterase in the cerebrospinal fluid and plasma of patients with Alzheimer disease. Sledov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003586-94,0,0,0 2017-003590-33,1,2021-03-01,2021-03-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Bispebjerg University Hospital,Pharmacokinetics of prednisolone in children with airway disease -The POP child,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003590-33,0,0,0 2017-003592-64,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamous ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003592-64,0,0,0 2017-003593-13,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Leeds,UK CLL Long-term Follow-up Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003593-13,0,0,0 2017-003595-30,1,2021-12-31,2021-12-31,1,0,0,0,0,1,2,0,0,1,0,0,0,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,"Treat_CCM Clinical Trial. A multicenter randomized clinical trial on Propranolol in Cerebral Cavernous Malformation Studio multicentrico, randomizzato sul propranololo nella Malformazione Cavernosa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003595-30,0,0,0 2017-003598-33,2,2019-10-28,2019-10-28,2,1,0,0,2,1,2,0,0,1,0,0,1,0,1,La Jolla Pharmaceutical Company,"A Phase 2, Multi-center, Randomized, Placebo Controlled, Double-Blind Study with LJPC-401 for the Treatment of Iron Overload in Adult Patients with Hereditary Hemochromatosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003598-33,0,0,0 2017-003606-40,4,2020-09-24,2020-09-24,2,1,1,0,0,1,3,0,0,1,0,0,1,0,1,"Shire Human Genetic Therapies, Inc.","A Randomized, Open-label, 24-Week Safety, Efficacy, and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age with Short Bowel Syndrome Who are Dependent on Parenteral Support Origina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003606-40,0,0,0 2017-003607-22,15,2021-10-29,2021-10-29,13,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A 12 month, partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal anti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003607-22,1,0,0 2017-003607-22,15,2021-10-29,2021-10-29,13,0,0,0,0,0,2,0,0,2,1,0,0,0,1,NOVARTIS PHARMA AG,"A 12 month, partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal anti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003607-22,1,0,0 2017-003607-22,15,2021-10-29,2021-10-29,13,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A 12 month, partially-blinded, active-controlled, multicenter, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal anti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003607-22,1,0,0 2017-003612-39,1,2022-01-31,2022-01-31,1,0,0,0,0,0,4,0,0,1,1,1,0,0,0,Fundació Parc Taulí,Randomized clinical trial on the need for antibiotic to treat low-risk catheter bacteremia due to coagulase-negative staphylococci. Ensayo clínico randomizado sobre la necesidad de tratamiento anti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003612-39,0,0,0 2017-003616-39,3,2019-03-08,2019-03-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Seve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003616-39,0,0,0 2017-003619-20,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novo Nordisk A/S,Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003619-20,0,0,0 2017-003621-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA,A Phase II study of a Combination of Eribulin and capecitabiNe in second line Treatment after the failure of gemcitabine/abraxane first line in advanced pancreatic cancer Studio di Fase II di eribu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003621-15,0,0,0 2017-003622-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Gustave Roussy,Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer Etude de Phase II randomisée évaluant...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003622-33,0,0,0 2017-003623-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboudumc,MRI measurement of the effects of moderate versus deep neuromuscular blockade on the abdominal working space during laparoscopic surgery in a prospective cohort study. Het effect van standaard vers...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003623-29,0,0,0 2017-003625-15,1,2020-04-08,2020-04-08,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Zealand university hospital, Roskilde","Ultrasound-guided Transmuscular Quadratus Lumborum catheters for elective caesarean section. A double blind, randomised, placebo controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003625-15,0,0,0 2017-003626-32,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Medizinische Universität Wien, Univ. Klinik f. Dermatologie",Photodynamic therapy (pdt) for skin rejuvenation: A pilotstudy evaluating the effectiveness of two modalities of photodynamic therapy in the treatment of photodamaged skin Topische photodynamische ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003626-32,0,0,0 2017-003627-30,1,2021-02-22,2021-02-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Odense Research Center for Anaphylaxis (ORCA),Protection from food induced anaphylaxis by reducing serum level of specific IgE Beskyttelse mod fødevareinduceret anafylaksi ved reduktion af specifikt serum IgE overfor fødevaren.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003627-30,0,0,0 2017-003628-65,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,Intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with RAS/B-RAF wild-type metastatic colorectal cancer: a randomized phase 2 trial Intermittent or continuous...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003628-65,0,0,0 2017-003629-13,1,2019-10-17,2019-10-17,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,King's College London,"A Prospective, randomised placebo controlled feasibility trial of Faecal Microbiotica Transplantation in cirrhosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003629-13,0,0,0 2017-003629-13,1,2019-10-17,2019-10-17,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,King's College Hospital NHS Fundation Trust,"A Prospective, randomised placebo controlled feasibility trial of Faecal Microbiotica Transplantation in cirrhosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003629-13,0,0,0 2017-003631-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rear...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003631-12,0,0,0 2017-003633-28,3,2019-10-07,2019-10-07,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Institut de Recherches Internationales SERVIER (I.R.I.S.),"Clinical non-inferiority study between Micronized purified flavonoid fraction 1000 mg, one chewable tablet per day and Micronized Purified Flavonoid Fraction 500 mg, 2 tablets daily after eight weeks ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003633-28,0,0,0 2017-003634-93,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NewLink Genetics Corporation,A Phase 2/3 (Adaptive Design) Study of the Concomitant Administration of Indoximod or Placebo plus Pembrolizumab or Nivolumab in Adult Patients with Unresectable Stage III or Stage IV Malignant Melano...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003634-93,0,0,0 2017-003635-10,1,2019-10-31,2019-10-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University of Bristol,"Immediate oral, immediate topical or delayed oral antibiotics for acute otitis media with discharge (the Runny Ear STudy: REST)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003635-10,0,0,0 2017-003636-36,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous cell carcinoma of the head and neck,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003636-36,0,0,0 2017-003638-10,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,CHRU LILLE,INTRANASAL CLONIDINE PREDICTION IN PEDIATRIC SURGERY: RANDOMIZED STUDY AGAINST PLACEBO PREMEDICATION PAR CLONIDINE INTRANASALE EN CHIRURGIE PEDIATRIQUE : ETUDE RANDOMISEE CONTRE PLACEBO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003638-10,0,0,0 2017-003641-14,4,2019-05-07,2019-09-03,3,1,1,0,0,1,1,0,0,1,0,0,1,0,1,ASTRAZENECA AB,"A Multi-centre, Phase I, Open-label, Single-dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to less than 24 Months, with Sickle Cell Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003641-14,0,0,0 2017-003641-14,4,2019-05-07,2019-09-03,3,1,1,0,0,1,1,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multi-centre, Phase I, Open-label, Single-dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to less than 24 Months, with Sickle Cell Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003641-14,0,0,0 2017-003643-38,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,Fondation Lenval - Hôpitaux Pédiatriques de Nice CHU-LENVAL,INTRANASAL KETAMINE IN THE REDUCTION OF THE ISOLATED FRACTURES OF THE HIGHER MEMBER OF THE CHILD TO PEDIATRIC EMERGENCIES KETAMINE PAR VOIE INTRANASALE DANS LA REDUCTION DES FRACTURES ISOLEES DU ME...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003643-38,0,0,0 2017-003649-10,5,,,0,1,1,0,0,0,1,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE I, OPEN–LABEL, RANDOMIZED, PHARMACOKINETIC, PHARMACODYNAMIC, AND SAFETY STUDY OF ETROLIZUMAB FOLLOWED BY OPEN–LABEL EXTENSION AND SAFETY MONITORING IN PEDIATRIC PATIENTS FROM 4 YEARS TO LESS T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003649-10,0,0,0 2017-003649-10,5,,,0,1,1,0,0,0,1,0,0,2,0,0,0,0,1,Roche Farma S.A. (Soc unipersonal) que realiza el ensayo en España y que actúa como represntante de FHoffmann-La Roche,"A PHASE I, OPEN–LABEL, RANDOMIZED, PHARMACOKINETIC, PHARMACODYNAMIC, AND SAFETY STUDY OF ETROLIZUMAB FOLLOWED BY OPEN–LABEL EXTENSION AND SAFETY MONITORING IN PEDIATRIC PATIENTS FROM 4 YEARS TO LESS T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003649-10,0,0,0 2017-003651-29,5,2019-03-26,2019-03-26,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A phase 3 randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of PF-04965842 monotherapy in subjects aged 12 years and older, with mode...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003651-29,0,0,0 2017-003651-29,5,2019-03-26,2019-03-26,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A phase 3 randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of PF-04965842 monotherapy in subjects aged 12 years and older, with mode...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003651-29,0,0,0 2017-003652-22,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,INCYTE CORPORATION,"A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003652-22,0,0,0 2017-003652-22,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Incyte Coorporation,"A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003652-22,0,0,0 2017-003653-42,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,CENTRO DI RIFERIMENTO ONCOLOGICO,Phase II study to assess efficacy and safety of metronomic oral Idarubicin in patients with hepatocarcinoma at intermediate-advanced stage after failure or intolerance to Sorafenib and Regorafenib ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003653-42,0,0,0 2017-003659-52,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,António Robalo Nunes,"Impact of Iron Deficiency treatment with intravenous ferric carboxymaltose in patients with Chronic Obstructive Pulmonary Disease: an open-label, randomized, 2-arm, no treatment control, parallel stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003659-52,0,0,0 2017-003660-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Oscar Lambret,Phase II Randomized Study Measuring the Interest of Pursuing or Not the chemotherapy for Non-progressive Patients With Metastatic Esophageal Squamous-cell Cancer After 6 Weeks of LV5FU2-paclitaxel Giv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003660-13,0,0,0 2017-003662-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,An Open-Label Exploratory Phase 2/3 Study of Nivolumab with Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer Ensayo de fase 2/3 abierto...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003662-27,0,0,0 2017-003663-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Palobiofarma S.L,"A phase II, double-blind, randomized, parallel-group, placebocontrolled multi-center study to investigate the effect of the adenosine A1 receptor antagonist PBF-680 on forced expiratory volume in 1 se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003663-35,0,0,0 2017-003665-10,1,,,0,1,0,0,0,0,4,0,0,3,0,0,0,0,0,Royal Brompton and Harefield NHS Foundation Trust,A single-centre study of the relationship between eosinophil activation and the lung microbiome in severe eosinophilic asthma (SEA) and the effect of benralizumab on these factors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003665-10,0,0,0 2017-003667-35,1,2022-07-20,2022-07-20,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,GBG Forschungs GmbH,Anti-hormonal maintenance treatment with the CDK4/6 inhibitor Ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial Antihor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003667-35,0,0,0 2017-003668-11,6,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Eisai Ltd.,"An open-label, multi-center, roll-over study to assess long term safety of lenvatinib monotherapy or lenvatinib combination regimen or comparator treatment arm to cancer patients in Eisai sponsored le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003668-11,0,0,0 2017-003668-11,6,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,EISAI LIMITED,"An open-label, multi-center, roll-over study to assess long term safety of lenvatinib monotherapy or lenvatinib combination regimen or comparator treatment arm to cancer patients in Eisai sponsored le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003668-11,0,0,0 2017-003669-87,2,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Abbvie Deutschland GmbH & Co. KG,Phase 2 Study Comparing Efficacy and Safety of ABT-165 and FOLFIRI vs Bevacizumab and FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003669-87,0,0,0 2017-003670-14,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,University Hospital Limerick,The role of selective decontamination of the digestive tract in preventing surgical site infections in elective colorectal resections: a randomized controlled trial (SELDDEC Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003670-14,0,0,0 2017-003671-60,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA,"TOTAL NEOADJUVANT TREATMENT WITHOUT SURGERY FOR LOCALLY ADVANCED RECTAL CANCER: PROSPECTIVE CLINICAL TRIAL TO ASSESS TUMOR COMPLETE RESPONSE, CIRCULATING TUMOR GENETIC AND EPIGENETIC BIOMARKERS, AND S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003671-60,0,0,0 2017-003672-31,1,2019-05-23,2019-05-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,"KRKA, d.d., Novo mesto",Fixed-dose combination of rosuvastatin and valsartan for dual target achievement in patients with hypertension and hyperlipidaemia (UNIFY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003672-31,0,0,0 2017-003673-34,1,2020-06-22,2020-06-22,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Oslo University Hospital, Department of Endocrinologi, Morbid Obesity and Preventive Medicine",Identification of non-responders to levothyroxine-therapy: development of biomarkers reflecting T4 and T3 action at the tissue level,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003673-34,0,0,0 2017-003675-61,6,2020-07-31,2020-07-31,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients with Severe Nasal Polyposis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003675-61,0,0,0 2017-003676-31,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Georg-August-Universität Göttingen,Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003676-31,0,0,0 2017-003677-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,The Need for Titration or Monitoring of Direct Oral Anticoagulant Treatment: The MONDOAC and KIDOAC study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003677-33,0,0,0 2017-003679-75,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Synairgen Research Limited,"A randomised, double-blind, placebo-controlled study, in COPD patients with and without a confirmed respiratory virus infection assessing anti-viral biomarker responses and clinical effects of inhaled...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003679-75,0,0,0 2017-003680-35,6,2022-08-22,2022-08-22,3,0,0,0,0,1,2,0,0,2,0,0,0,0,0,EORTC AISBL/IVZW,Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IV mycosis fungoides/sezary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003680-35,1,0,0 2017-003680-35,6,2022-08-22,2022-08-22,3,0,0,0,0,1,2,0,0,2,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IV mycosis fungoides/sezary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003680-35,1,0,0 2017-003681-27,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Groupe Francophone des Myelodysplasies,A single-arm phase II multicenter study of IDH1 (AG 120) inhibitor in patients with IDH1 mutated myelodysplastic syndrome Studio multicentrico di fase II a singolo braccio dell'inibitore di IDH1 (A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003681-27,0,0,0 2017-003683-12,1,2019-08-21,2019-08-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,INSTITUTO DE INVESTIGACIÓN SANITARIA LA FE,Sentinel node in ovarian cáncer: tailoring clinical feasibility SENTOV: Ganglio centinela en cáncer de ovario en estadio inicial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003683-12,0,0,0 2017-003684-35,6,2021-10-27,2021-10-27,3,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti CTLA 4 Antibody) in the Second-Line Treatment of Patients with A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003684-35,1,0,0 2017-003685-27,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),NA Impact cognitif de l’utilisation des benzodiazépines dans les épilepsies de l’enfant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003685-27,0,0,0 2017-003687-12,1,2019-01-31,2019-01-31,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Region Ostergotland,"Infusion rate and volumekinetics for hyperoncotic albumin in healthy subjects (RAV), - A phase IV, randomized, open-labeled, cross-over study Infusionshastighetens påverkan på volymskinetik för 20...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003687-12,0,0,0 2017-003688-37,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Philipps-Universität Marburg,"Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension (PASSION), A randomized, placebo-controlled,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003688-37,0,0,0 2017-003689-28,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,GELTAMO (Grupo Español de Linfomas y trasplante autólogo de médula osea),"A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for Older Patients with Untreated Hodgkin Lymph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003689-28,0,0,0 2017-003691-31,6,2019-01-30,2021-08-25,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB COMPARED WITH SORAFENIB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003691-31,1,0,0 2017-003691-31,6,2019-01-30,2021-08-25,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A(Soc unipersonal)que realiza el ensayo en España y que actua como representante de F.Hoffmann-La Roche Lt,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB COMPARED WITH SORAFENIB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003691-31,1,0,0 2017-003691-31,6,2019-01-30,2021-08-25,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB IN COMBINATION WITH BEVACIZUMAB COMPARED WITH SORAFENIB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003691-31,1,0,0 2017-003692-61,4,2020-02-11,2020-02-11,3,1,0,0,2,0,2,0,1,1,0,0,1,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A phase 2b, randomized, controlled, observer-blind, multi-center, non-inferiority immunogenicity and safety study of two formulations of GSK Biologicals’ Meningococcal ACWY conjugate vaccine (GSK35368...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003692-61,0,0,0 2017-003692-61,4,2020-02-11,2020-02-11,3,1,0,0,2,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals,"A phase 2b, randomized, controlled, observer-blind, multi-center, non-inferiority immunogenicity and safety study of two formulations of GSK Biologicals’ Meningococcal ACWY conjugate vaccine (GSK35368...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003692-61,0,0,0 2017-003693-13,5,2020-04-28,2020-04-28,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Astellas Pharma Europe B.V.,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2a, Proof-of-Concept Study of ASP8302 in Subjects with Underactive Bladder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003693-13,0,0,0 2017-003694-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ziekenhuis Oost-Limburg,Onset and duration of Forearm nerve blockade performed with a single distal injection versus sequential injections at distal and proximal locations alongside the nerves: a blinded randomized controlle...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003694-34,0,0,0 2017-003695-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ziekenhuis Oost-Limburg,Fascia iliaca block for analgesia in unilateral direct anterior approach total hip arthroplasty Kwaliteit van pijnbestrijding met een zenuwblokkade bij spiersparende techniek voor totale heupprothe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003695-31,0,0,0 2017-003697-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aarhus University Hospital,"A randomised, double-blind, placebo-controlled, trial to evaluate the efficacy of brodalumab monotherapy on vascular and systemic inflammation by 18F-FDG-PET/CT in subjects with moderate-to-severe pl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003697-14,0,0,0 2017-003699-30,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"BeiGene, Ltd.","A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the anti-PD-1 Antibody BGB-A317 versus Chemotherapy as Second Line Treatment in Patients with Advanced Unresectable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003699-30,0,0,0 2017-003699-30,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"BeiGene, Ltd.c/o BeiGene USA, Inc.","A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the anti-PD-1 Antibody BGB-A317 versus Chemotherapy as Second Line Treatment in Patients with Advanced Unresectable...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003699-30,0,0,0 2017-003700-44,3,2021-04-21,2021-04-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BEIGENE USA, INC.","A Phase 2, Open-Label Study of BGB-A317 in Patients with Relapsed or Refractory Mature T- and NK-cell Neoplasms",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003700-44,0,0,0 2017-003700-44,3,2021-04-21,2021-04-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BeiGene, Ltd. c/o BeiGene USA, Inc.","A Phase 2, Open-Label Study of BGB-A317 in Patients with Relapsed or Refractory Mature T- and NK-cell Neoplasms",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003700-44,0,0,0 2017-003700-44,3,2021-04-21,2021-04-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"BeiGene, Ltd.","A Phase 2, Open-Label Study of BGB-A317 in Patients with Relapsed or Refractory Mature T- and NK-cell Neoplasms",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003700-44,0,0,0 2017-003702-41,6,2021-07-09,2021-07-09,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Soligenix UK Limited,"A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003702-41,1,0,0 2017-003703-22,8,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Immunic AG,"A phase 2, multicenter, randomized, double-blind, placebo controlled, dose-finding study to evaluate the efficacy and safety of IMU 838 for induction and maintenance therapy in moderate-to-severe ulce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003703-22,0,0,0 2017-003705-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,LUMC,Prevention of neuropsychiatric adverse effects caused by dexamethasone: translational insights from a placebo-controlled trial with hydrocortisone. De preventie van nadelige neuropsychiatrische ef...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003705-17,0,0,0 2017-003706-40,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",PAZOBONE: First line treatment with Pazopanib in untreated metastatic renal cell carcinoma patients with bone involvement PAZOBONE trial: Terapia di I linea con Pazopanib in pazienti affetti da car...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003706-40,0,0,0 2017-003710-58,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO “PAOLO GIACCONE” DI PALERMO,"Study to Investigate the Efficacy of elbasvir/grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Na¿ve, HCV-Infected Patients With non-severe Fibrosis, with or without glucose abnormali...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003710-58,0,0,0 2017-003712-39,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Gyroscope Therapeutics,"FOCUS: An open label first in human Phase I/II multicentre study to evaluate the safety, dose response and efficacy of GT005 administered as a single subretinal injection in subjects with Macular Atro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003712-39,0,0,0 2017-003714-68,1,2020-01-31,2020-01-31,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Medical University of Vienna,Effect of Supplemental Oxygen on Perioperative Brain Natriuretic Peptide Concentration in Cardiac Risk Patients - A prospective randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003714-68,0,0,0 2017-003722-33,2,2022-03-21,2022-03-21,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ALFASIGMA S.P.A.,"Safety and Efficacy of Rifaximin Delayed Release 400 mg Tablets in Patients with Moderate-to-Severe Papulopustular Rosacea and Positive Lactulose Breath Test. A Multicenter Double-Blind, Placebo-Contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003722-33,1,0,0 2017-003723-29,17,2020-06-17,2020-06-17,15,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Corbus Pharmaceuticals, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003723-29,0,0,0 2017-003723-29,17,2020-06-17,2020-06-17,15,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"CORBUS PHARMACEUTICALS, INC","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003723-29,0,0,0 2017-003724-79,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Imperial College London,IL-1 Signal Inhibition in Alcoholic Hepatitis (Isaiah),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003724-79,0,0,0 2017-003726-32,3,2021-03-23,2021-03-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVO NORDISK. S.P.A.,"Two-year effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity A heti egyszeri 2,4 mg szemaglutid két éves hatásosságának és biztonságosságának vizsgálata túlsú...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003726-32,0,0,0 2017-003726-32,3,2021-03-23,2021-03-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"Two-year effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity A heti egyszeri 2,4 mg szemaglutid két éves hatásosságának és biztonságosságának vizsgálata túlsú...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003726-32,0,0,0 2017-003728-64,4,2020-04-15,2020-04-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,EISAI LIMITED,"A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003728-64,0,0,0 2017-003728-64,4,2020-04-15,2020-04-20,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eisai Ltd,"A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003728-64,0,0,0 2017-003737-29,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomized, placebo-controlled, Phase II/III trial on the efficacy and tolerability of treatment with budesonide oral suspension vs. placebo in children and adolescents with eosinophilic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003737-29,0,0,0 2017-003739-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SOCIETà CAMPANA DI IMMUNOTERAPIA ONCOLOGICA,Preoperative Nivolumab in patients with locally advanced colon cancer (T3 or T4): a window-of-opportunity study Nivolumab preoperatorio in pazienti con cancro al colon localmente avanzato (T3 o T4)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003739-12,0,0,0 2017-003757-41,5,2020-04-17,2020-04-17,5,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Castle Creek Pharmaceuticals, LLC","An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003757-41,0,0,0 2017-003761-99,1,2021-10-07,2021-10-07,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"An Exploratory Phase 2, 2-part, Randomized, Double blind, Placebo controlled Study With a Long term, Open label Period to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003761-99,0,0,0 2017-003763-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,centre hospitalier universitaire de Lille,"Conservative Iron Chelation by Deferiprone as a disease-modifying Strategy for Amyotrophic Lateral Sclerosis using a Multicentre Parallel group, placebo controlled, Randomized clinical trial Chélat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003763-35,0,0,0 2017-003765-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",Immunotherapy Followed By EGFR Inhibitor In Locally Advanced Or Metastatic Squamous Cell Cancer Of The Skin: Tackling Primary And Secondary Resistance Immunoterapia seguita da inibitore delle EGFR ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003765-10,0,0,0 2017-003766-27,1,2022-06-28,2022-06-28,1,0,0,0,0,0,3,0,0,1,1,1,0,0,0,VU University Medical Centre,"The DREAMING study: Efficacy of low dose amitriptyline and mirtazapine for insomnia disorder: a double-blind, randomized, placebo-controlled trial in general practice",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003766-27,0,0,0 2017-003767-35,3,2018-07-12,2018-07-12,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mundipharma Research Limited,"A randomised, double-blind, parallel group study comparing patient controlled analgesia with Penthrox® (methoxyflurane) versus placebo during colonoscopy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003767-35,0,0,0 2017-003770-14,7,,,0,0,1,0,0,0,2,0,0,2,1,0,0,0,1,Allergan LTD,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Participants (Age 6 to 17 Years) with Irrit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003770-14,0,0,0 2017-003772-31,7,2019-12-14,2019-12-14,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Iterum Therapeutics International Limited,"A prospective, Phase 3, randomized, multi-center, double-blind, double dummy study of the efficacy, tolerability and safety of intravenous sulopenem followed by oral sulopenem-etzadroxil with probenec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003772-31,1,0,0 2017-003773-34,4,2019-10-02,2019-10-02,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Iterum Therapeutics International Limited,"A prospective Phase 3, double-blind, multicenter, randomized study of the efficacy and safety of sulopenem followed by sulopenem etzadroxil with probenecid versus ertapenem followed by ciprofloxacin a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003773-34,0,0,0 2017-003775-62,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Odense University Hospital,"FOLFIRINOX followed by local therapy (resection, RT and/or IRE) in patients with locally advanced pancreatic cancer (LAPC). A Nordic phase II study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003775-62,0,0,0 2017-003777-34,1,2021-04-12,2021-04-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,UMC Utrecht,"Proton pump inhibition for secondary hemochromatosis in hereditary anemia, a phase III placebo controlled randomized cross-over clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003777-34,0,0,0 2017-003778-15,1,,,0,1,0,1,0,1,1,0,0,4,0,0,0,0,1,Amgen Inc.,A Phase 1b/2 Study of Blinatumomab in Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Horai Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003778-15,0,1,1 2017-003779-75,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitario La Paz,Randomized clinical trial to assess the impact of treatment with empagliflozine on systemic inflammatory and renal parameters in patients with Diabetes Mellitus type 2 and ischemic heart disease. E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003779-75,0,0,0 2017-003780-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AIO-Studien-gGmbH,"Randomized phase II, open-label efficacy and safety study of second-line durvalumab plus tremelimumab versus platinum-based chemotherapy alone in patients with NSCLC and first-line checkpoint-inhibito...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003780-35,0,0,0 2017-003784-35,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB Biopharma SPRL,"A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoria...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003784-35,0,0,0 2017-003784-35,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB Biopharma SRL,"A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoria...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003784-35,0,0,0 2017-003788-36,13,2020-12-03,2020-12-03,11,1,0,0,0,1,3,0,0,2,0,0,0,0,1,NOVO NORDISK. S.P.A.,Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients with Severe Haemophilia A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003788-36,1,0,0 2017-003788-36,13,2020-12-03,2020-12-03,11,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Novo Nordisk A/S,Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients with Severe Haemophilia A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003788-36,1,0,0 2017-003790-34,1,2017-12-22,2017-12-22,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KU Leuven - Drug Delivery and Disposition,Drug disposition in the human colon: sampling optimization Geneesmiddelendispositie in het humane colon: optimalisering staalname,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003790-34,0,0,0 2017-003792-63,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,"Phase II trial of maintenance pembrolizumab following weekly paclitaxel for recurrent ovarian, fallopian tube or peritoneal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003792-63,0,0,0 2017-003793-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,centre hospitalier et universitaire de Lille,Arrêt précoce du traitement antifongique empirique en réanimation guidé par dosages sériques de biomarqueurs fongiques : Etude randomisée contrôlée Arrêt précoce du traitement a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003793-13,0,0,0 2017-003796-58,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,PPM SERVICES S.A.,AN OPEN LABEL CLINICAL STUDY TO EVALUATE THE LONG-TERM DERMAL SAFETY PROFILE OF 12-WEEKS TOPICAL ADMINISTRATION OF N-ACETYL-GED-0507-34-LEVO GEL 5% IN PATIENTS WITH FACIAL ACNE AN OPEN LABEL CLINIC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003796-58,0,0,0 2017-003803-22,7,2020-11-12,2020-11-12,5,1,0,0,0,1,3,0,0,1,1,0,1,0,1,"Agios Pharmaceuticals, Inc.",An Open-Label Study to Evaluate the Efficacy and Safety of AG-348 in Regularly Transfused Adult Subjects With Pyruvate Kinase (PK) Deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003803-22,0,0,0 2017-003809-17,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Follicum AB,"A randomised, double-blind, placebo-controlled phase 2 trial of FOL-005 to investigate efficacy on hair growth on scalp skin in healthy volunteers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003809-17,0,0,0 2017-003810-13,5,2021-09-13,2021-09-13,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Ferring Pharmaceuticals A/S,"A randomised, double-blind, placebo-controlled, parallel-group, dose-range trial to investigate the efficacy and safety of FE 999302 as add-on treatment to follitropin delta (REKOVELLE) in women under...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003810-13,1,0,0 2017-003813-24,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Charité-Universitätsmedizin Berlin,"A phase I/IIa, prospective, mono-center, randomized, open labeled, controlled study to assess the safety and efficacy of applying Iloprost locally in the fracture site to promote bone healing in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003813-24,0,0,0 2017-003818-11,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,ALMIRALL SPA,An open-label clinical study to evaluate the long-term efficacy and tolerability of treatment with dimethyl fumarate (DMF) in adults with chronic plaque psoriasis (Study DIMESKIN 2). Studio clinico...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003818-11,0,0,0 2017-003820-58,2,2019-03-18,2019-03-19,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,AstraZeneca AB,"A double-blind, randomized, parallel group, phase IV study to investigate the effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency and myocardial contractile work in type 2 diab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003820-58,0,0,0 2017-003823-31,9,2020-10-09,2020-10-09,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Agios Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003823-31,0,0,0 2017-003823-31,9,2020-10-09,2020-10-09,8,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"AGIOS PHARMACEUTICALS, INC.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003823-31,0,0,0 2017-003827-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INSTITUT DE CANCEROLOGIE DE L'OUEST,"Prostate cancer with OligometaSTatic relapse: Combining stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736), a randomized phase II trial Cancer prostatique en rechute oligométastatique: as...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003827-31,0,0,0 2017-003829-15,4,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ZEALAND UNIVERSITY HOSPITAL (ERLAND PEDERSEN),"Agents Intervening against Delirium in Intensive Care Unit (AID-ICU) A randomised, blinded, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003829-15,0,0,0 2017-003829-15,4,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Zealand University Hospital,"Agents Intervening against Delirium in Intensive Care Unit (AID-ICU) A randomised, blinded, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003829-15,0,0,0 2017-003830-97,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sahlgrenska University Hospital,Effects of an Opiod Sparing Care Pathway for Patients undergoing Obesity Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003830-97,0,0,0 2017-003832-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institute of Clinical Cancer Research (IKF) Krankenhaus Nordwest,Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction Type II/III adenocarcinoma – The phase III “PREVENT” trial ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003832-35,0,0,0 2017-003835-12,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,The University Of Edinburgh,A placebo controlled randomised trial of intravenous lidocaine in accelerating gastrointestinal recovery after colorectal surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003835-12,0,0,0 2017-003835-12,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,NHS Lothian,A placebo controlled randomised trial of intravenous lidocaine in accelerating gastrointestinal recovery after colorectal surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003835-12,0,0,0 2017-003836-35,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Population Health Research Institute,COlchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery COlchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003836-35,0,0,0 2017-003838-88,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Mye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003838-88,0,0,0 2017-003838-88,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Mye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003838-88,0,0,0 2017-003839-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS Ospedale PedT..trico Bambino Gesù,Belimumab for the treatment of frequently relapsing nephrotic syndrome open label phase II trial. BELNEPH STUDY BELNEPH: Studio prospettico aperto di fase II sull’uso del Belimumab per il trattamen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003839-11,0,0,0 2017-003841-39,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Alcon Research,Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Paediatric Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003841-39,0,1,1 2017-003843-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospital Universitario de Canarias- Dr. Francisco Bosa Ojeda,"Clinical trial, Phase III, randomized, prospective, unicentric, double-blind and placebo-controlled, to estimate the efficacy and safety of intravenous Levosimendan, in the first 24 hours after primar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003843-39,0,0,0 2017-003846-26,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Alcon Research Ltd,Safety Study of Olopatadine Nasal Spray,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003846-26,0,1,1 2017-003847-39,1,2020-09-03,2020-09-03,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Akari Therapeutics Plc.,"CAPSTONE: Phase III Confirmatory Assessment Protocol: rVA576 Safety and Efficacy in Three-Part, Two-Arm, Randomised Open Label Evaluation in patients with Paroxysmal Nocturnal Haemoglobinuria (PNH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003847-39,0,0,0 2017-003851-45,2,2019-02-27,2019-02-27,2,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"Aeglea Biotherapeutics, Inc.","A Phase 1/2 Open-label Study in Patients with Arginase 1 Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003851-45,0,0,0 2017-003854-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Antoni van Leeuwenhoek,"Neoadjuvant capecitabine, oxaliplatin, docetaxel and atezolizumab in non-metastatic, resectable gastric and GE-junction cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003854-17,0,0,0 2017-003855-47,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Apeptico Forschung und Entwicklung GmbH,"Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability oedema in patients with moderate-to-severe ARDS - a randomised, placebo-controlled, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003855-47,0,0,0 2017-003856-22,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Alcon Research Ltd,Safety and Efficacy of Olopatadine Hydrochloride Nasal Spray in 6-11 Year old Patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003856-22,0,1,1 2017-003859-36,7,2021-11-02,2021-11-02,4,1,1,0,0,0,1,0,1,2,1,0,0,0,1,Janssen Vaccines and Prevention B.V.,"A Randomized, Controlled, Observer-blind, Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers 12 to 24 Months of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003859-36,1,1,0 2017-003859-36,7,2021-11-02,2021-11-02,4,1,1,0,0,0,1,0,1,2,1,0,0,0,1,Janssen Vaccines & Prevention B.V.,"A Randomized, Controlled, Observer-blind, Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers 12 to 24 Months of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003859-36,1,1,0 2017-003860-11,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,VU University Medical Center,11C-erlotinib brain uptake in Diffuse Intrinsic Pontine Glioma imaged by PET,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003860-11,0,0,0 2017-003864-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,Hydrochlorothiazide and metformin cross-over study for attenuating aquaretic side-effects in ADPKD patients treated with tolvaptan Hydrochloorthiazide en metformine cross-over studie voor het vermi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003864-10,0,0,0 2017-003875-77,1,2019-03-26,2019-03-26,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospitals of North Midlands NHS Trust,"A Randomised, Controlled Double Blinded Non-inferiority Trial of intravenous Morphine compared with intravenous Paracetamol for pain relief in patients presenting to the Emergency Department with Susp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003875-77,0,0,0 2017-003897-15,6,2019-07-18,2019-07-18,6,1,0,0,1,0,2,0,0,1,0,0,1,0,1,Oxurion NV,"A Phase 2, randomised, single-masked, active-controlled, multicentre study to evaluate the efficacy and safety of intravitreal THR-317 administered in combination with ranibizumab, for the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003897-15,0,0,0 2017-003897-15,6,2019-07-18,2019-07-18,6,1,0,0,1,0,2,0,0,1,0,0,1,0,1,ThromboGenics NV,"A Phase 2, randomised, single-masked, active-controlled, multicentre study to evaluate the efficacy and safety of intravitreal THR-317 administered in combination with ranibizumab, for the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003897-15,0,0,0 2017-003899-31,3,,,0,0,0,0,2,0,3,0,0,2,0,0,0,0,2,DOBECURE S.L.,"International, multicenter, randomised, blind, sham-controlled, 2x2 cross over phase III clinical trial to assess the efficacy and security of an intravitreal injection of Etamsylate in the improveme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003899-31,0,0,0 2017-003899-31,3,,,0,0,0,0,2,0,3,0,0,2,0,0,0,0,2,"DOBECURE, S.L","International, multicenter, randomised, blind, sham-controlled, 2x2 cross over phase III clinical trial to assess the efficacy and security of an intravitreal injection of Etamsylate in the improveme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003899-31,0,0,0 2017-003900-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMC Utrecht,A Stratification trial to determine key immunological factors predicting Tofacitinib efficacy and drug free remission in Psoriatic Arthritis (PsA). TOFA-PREDICT TOFA-PREDICT: Onderzoek naar biomar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003900-28,0,0,0 2017-003902-42,1,,,0,1,0,0,0,1,4,0,0,1,1,1,0,1,0,Consorzio Futuro in Ricerca,"F9 Genotype and PK Hemophilia B International Study Relazioni fra genotipo del FIX e farmacocinetica del FIX ricombinante, Nonacog alfa, in pazienti affetti da emofilia B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003902-42,0,0,0 2017-003903-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Assessment of Beta blocker interruption after uncomplicated mYocardial infarction on Safety and Symptomatic cardiac events requiring hospitalization: The ABYSS Study Evaluation de l'arrêt de l'admi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003903-23,0,0,0 2017-003908-50,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,European Organisation for research and Treatment of cancer (EORTC),A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003908-50,0,0,0 2017-003909-17,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,LYSARC,Randomized Phase 3 Study evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) compared to Investigator’s Choice Therapy in Patient with Relapsed or Refractory Angioimmunoblastic T cell ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003909-17,0,0,0 2017-003909-17,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,LYSARC: THE LYMPHOMA ACADEMIC RESEARCH ORGANISATION,Randomized Phase 3 Study evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) compared to Investigator’s Choice Therapy in Patient with Relapsed or Refractory Angioimmunoblastic T cell ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003909-17,0,0,0 2017-003910-16,2,2019-12-20,2020-02-11,2,1,0,0,0,1,3,0,0,1,1,1,1,0,1,"CymaBay Therapeutics, Inc.",An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003910-16,0,0,0 2017-003911-21,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Oxford,Dapagliflozin during exercise for the prevention of hypoglycaemia in Type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003911-21,0,0,0 2017-003916-37,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Newcastle Upon Tyne Hospitals NHS Foundation Trust,"Multicentre, open label, prospective, single arm study of the safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003916-37,0,0,0 2017-003923-31,2,2018-10-18,2018-10-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,OPHTHOTECH CORPORATION,A Phase 2A Open-Label Trial to Assess the Safety of Zimura™ (Anti-C5) Administered in Combination With Lucentis® 0.5 mg in Treatment Naïve Subjects with Neovascular Age Related Macular Degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003923-31,0,0,0 2017-003925-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Rigshospitalet,"A phase II Open Label, two-armed Translational Study of Nivolumab in Combination with Bevacizumab for Recurrent Glioblastoma Behandling med nivolumab og bevacizumab til patienter med tilbagefald af...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003925-13,0,0,0 2017-003930-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Recherche et enseignement en douleur, anesthesie reanimation","KETAMINE'S EFFICIENCY IN THE TREATMENT OF CHRONIC PAIN WITH INFLAMMATORY COMPONENT: EXPLORING THE KYNURENIN PATHWAYS. A controlled, placebo-controlled, double-blind trial. EFFICACITÉ DE LA KÉTAMINE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003930-10,0,0,0 2017-003931-12,3,2019-07-09,2019-07-09,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,Baxter Healthcare Corporation,A Randomized Controlled Non-inferiority Study to Evaluate the Efficacy and Safety of Hemopatch Compared to TachoSil in Preventing or Reducing Postoperative Air Leaks After Pulmonary Resection Studi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003931-12,0,0,0 2017-003931-12,3,2019-07-09,2019-07-09,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,"BAXTER HEALTHCARE CORPORATION, ONE BAXTER PARKWAY, DEERFIELD, ILLINOIS 60015, USA",A Randomized Controlled Non-inferiority Study to Evaluate the Efficacy and Safety of Hemopatch Compared to TachoSil in Preventing or Reducing Postoperative Air Leaks After Pulmonary Resection Studi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003931-12,0,0,0 2017-003932-35,1,2021-01-20,2021-01-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Biophytis S.A.,"Safety and Efficacy of BIO-101 175 mg b.i.d. and 350 mg b.i.d. 26-week oral administration to patients suffering from age-related SARcopenia, including sarcopenic obesity, Aged ≥65 years and at risk o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003932-35,0,0,0 2017-003933-27,7,2019-07-17,2019-07-17,5,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Polyphor Ltd.,"A multicenter, open-label, randomized, active-controlled, parallel group, pivotal study to investigate the efficacy, safety and tolerability, and pharmacokinetics of murepavadin combined with one anti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003933-27,1,0,0 2017-003934-10,2,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Actelion Pharmaceuticals Ltd,"mUlticenter, single-arM, open-laBel, long-teRm safety study with macitEntan in patients with puLmonary arterial hypertension previousLy treated with mAcitentan in clinical studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003934-10,0,0,0 2017-003935-12,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge,"ATRiUM: A phase 1 trial to assess the safety, tolerability, pharmacokinetics and preliminary antitumor activity of ascending doses of combined therapy with ATR inhibitor AZD6738 and gemcitabine, Using...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003935-12,0,0,0 2017-003940-19,4,2022-06-01,2022-06-01,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo controlled, 2 Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003940-19,1,0,0 2017-003947-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Spanish Long Cancer Group (SLCG/GECP),A Phase II open-label multicenter exploratory study to assess efficacy of Pembrolizumab re-challange as second or further line in patients with advanced non - small cell lung cancer Ensayo clínico ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003947-39,0,0,0 2017-003950-18,2,2021-03-22,2021-03-22,1,1,0,0,0,1,2,0,0,2,0,0,0,0,0,Hellenic Society of Hematology,Efficacy of Daratumumab in Patients with Relapsed/Refractory Myeloma with Renal Impairment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003950-18,1,0,0 2017-003950-18,2,2021-03-22,2021-03-22,1,1,0,0,0,1,2,0,0,2,0,0,0,0,0,HELLENIC SOCIETY OF HEMATOLOGY,Efficacy of Daratumumab in Patients with Relapsed/Refractory Myeloma with Renal Impairment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003950-18,1,0,0 2017-003951-44,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,0,Hellenic Society of Hematology,"A Prospective, Multicenter, Non-comparative, Open-label, Phase II Study to Evaluate the Effects of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and /or Refractory Multiple Myel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003951-44,0,0,0 2017-003953-41,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Alcon Research Ltd,"An Open-label, Long-term Study, with AL-4943A Ophthalmic Solution, 0.2% in Patients with Allergic Conjunctivitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003953-41,0,1,1 2017-003955-50,2,2018-12-21,2018-12-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,ASTRAZENECA SPA,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ENERGIZE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003955-50,0,0,0 2017-003955-50,2,2018-12-21,2018-12-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"AstraZeneca, AB","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ENERGIZE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003955-50,0,0,0 2017-003956-22,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,"Gilead Sciences, Inc.",A Phase 1 Relative Bioavailability and Food Effect Study of a Pediatric Oral Granule Formulation of Ledipasvir/Sofosbuvir in Healthy Adult Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003956-22,0,1,1 2017-003958-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Academic Medical Center, University of Amsterdam",Effect of Reslizumab on small airways in asthma. RESSAPEA Effect van Reslizumab op de kleine luchtwegen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003958-16,0,0,0 2017-003960-11,11,2021-06-08,2021-06-08,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003960-11,0,0,0 2017-003966-29,14,2018-10-24,2022-04-06,7,1,0,0,0,1,3,0,0,2,1,0,0,0,1,BioCryst Pharmaceuticals Inc.,"A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003966-29,1,0,0 2017-003966-29,14,2018-10-24,2022-04-06,7,1,0,0,0,1,3,0,0,2,1,0,0,0,1,BIOCRYST PHARMACEUTICALS INC.,"A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003966-29,1,0,0 2017-003969-10,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Moleculin Biotech, Inc.",Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That Has Relapsed After Standard Induction Therapy. Badanie kliniczne fazy 1/2 liposomalnej an...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003969-10,0,0,0 2017-003970-16,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,Alcon Research Ltd,Safety and Pharmacokinetics of PATANASE in Paediatric Patients 2 to < 6 Years of Age with a history of allergic rhinitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003970-16,0,1,1 2017-003975-80,1,2019-10-22,2019-10-22,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Academic Medical Center,Shorter treatment of catheter related urinary tract infections Kortere behandeling van catheter gerelateerde urineweginfecties,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003975-80,0,0,0 2017-003977-32,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited","A Phase 2, Open-Label Study of Ixazomib + Daratumumab + Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003977-32,0,0,0 2017-003977-32,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited","A Phase 2, Open-Label Study of Ixazomib + Daratumumab + Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003977-32,0,0,0 2017-003977-32,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Millennium Pharmaceuticals, Inc","A Phase 2, Open-Label Study of Ixazomib + Daratumumab + Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003977-32,0,0,0 2017-003978-13,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003978-13,0,0,0 2017-003978-13,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003978-13,0,0,0 2017-003980-36,1,2018-04-19,2018-04-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Hull and East Yorkshire Hospitals NHS Trust,"A single-Centre, open-label, exploratory study of the effect of 20 mg ambroxol hydrochloride on cough reflex sensitivity in patients with acute cough.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003980-36,0,0,0 2017-003983-10,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"BEIGENE USA, INC.","A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients with Previously Treated Hepatocellular Unre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003983-10,0,0,0 2017-003983-10,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"BeiGene Ltd., c/o BeiGene USA, Inc.","A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients with Previously Treated Hepatocellular Unre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003983-10,0,0,0 2017-003984-37,2,2019-05-09,2019-05-09,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,"CHIMERIX, INC.","A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients with Adenovirus Viremia Estudio aleator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003984-37,0,0,0 2017-003984-37,2,2019-05-09,2019-05-09,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,"Chimerix, Inc","A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients with Adenovirus Viremia Estudio aleator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003984-37,0,0,0 2017-003989-27,6,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Promethera Therapeutics,HepaStem Long-Term Safety Registry : Registry for patients who have been administered HepaStem,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003989-27,0,0,0 2017-003989-27,6,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Promethera Biosciences,HepaStem Long-Term Safety Registry : Registry for patients who have been administered HepaStem,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003989-27,0,0,0 2017-003998-34,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Novartis Pharma AG,"A Randomized, Open-label, Phase III Study of single agent Nazartinib Versus Investigator’s choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients with locally advanced or metastatic Non-S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003998-34,0,0,0 2017-003999-31,1,,,0,0,0,0,1,0,3,0,0,1,1,1,0,1,0,CHU de Nantes,"Efficacité d’une Supplémentation anténatale maternelle en N-acétylcystéine dans les contextes de MAP (Menace d’Accouchement Prématuré) modérées ou sévères, sur la correction du déficit en glutathion d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-003999-31,0,0,0 2017-004003-46,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,DIPARTIMENTO DI BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE-UNIVERISITÀ DI TORINO,"A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004003-46,0,0,0 2017-004004-22,1,2020-02-17,2020-02-17,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University of Sussex,"A Multi-Centred, Open Label, Randomised Study Assessing the Cardiovascular Outcomes Following Treatment of White Coat Hypertension with Established Anti-Hypertensive Drugs versus Standard of Care in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004004-22,0,0,0 2017-004005-40,1,2018-11-20,2018-11-20,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Radboud university medical center,Controlled Human Malaria Infection study to assess gametocytaemia and mosquito transmissibility in participants challenged with Plasmodium falciparum by sporozoite challenge to establish a model for t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004005-40,0,0,0 2017-004006-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Pharmaceutical Technology and Biopharmacy, University of Groningen",Therapeutic effects of an inhaled levodopa dry powder formulation on the recovery from off periods in patients with Parkinson's disease Therapeutische effecten van een inhaleerbare levodopa droogpo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004006-18,0,0,0 2017-004009-42,4,2020-10-03,2020-10-03,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Eli Lilly and Company,A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004009-42,1,0,0 2017-004009-42,4,2020-10-03,2020-10-03,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Lilly S.A.,A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004009-42,1,0,0 2017-004009-42,4,2020-10-03,2020-10-03,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER",A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004009-42,1,0,0 2017-004010-26,1,2019-11-22,2019-11-22,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ThromboGenics NV,"A Phase 2, open-label, multi-centre study to assess the efficacy and safety of intravitreal THR-317 for the treatment of macular telangiectasia Type 1 (MacTel 1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004010-26,0,0,0 2017-004011-39,17,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UIC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004011-39,0,0,0 2017-004011-39,17,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UIC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004011-39,0,0,0 2017-004012-19,5,,,0,0,0,1,0,1,1,0,0,2,0,0,0,0,1,Principia Biopharma Inc.,"An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocyto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004012-19,0,0,0 2017-004012-19,5,,,0,0,0,1,0,1,1,0,0,2,0,0,0,0,1,"Principia Biopharma, a Sanofi Company","An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocyto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004012-19,0,0,0 2017-004018-25,1,,,0,1,0,0,0,1,3,0,0,1,0,0,0,1,1,CATALYST PHARMACEUTICALS INC.,"A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients with MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004018-25,0,0,0 2017-004021-33,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,AnaptysBio Inc.,A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004021-33,0,0,0 2017-004022-15,1,2021-04-23,2021-04-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AnaptysBio Inc,"A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects with Palmoplantar Pustulosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004022-15,0,0,0 2017-004024-30,1,2020-07-02,2020-07-02,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004024-30,0,0,0 2017-004026-15,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"AMAG Pharmaceuticals, Inc.","A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004026-15,0,0,0 2017-004028-31,2,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,FAES FARMA S.A,Effect of the administration of different Hidroferol® Soft Gelatine Capsules (calcifediol) and cholecalciferol (Dibase®) regimens on 25(OH)D levels and markers of bone remodelling in postmenopausal wo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004028-31,0,0,0 2017-004028-31,2,,,0,0,0,0,0,0,0,0,0,2,0,0,0,0,1,"FAES FARMA, S.A.",Effect of the administration of different Hidroferol® Soft Gelatine Capsules (calcifediol) and cholecalciferol (Dibase®) regimens on 25(OH)D levels and markers of bone remodelling in postmenopausal wo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004028-31,0,0,0 2017-004030-28,1,2019-05-30,2019-05-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Psychiatric Research Unit,Cognition and weight gain during antidepressant treatment.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004030-28,0,0,0 2017-004031-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of oncology, Odense University Hospital","A multicentre, single-arm, phase II study to investigate the safety and antiemetic efficacy of Akynzeo® (a fixed dose combination of palonosetron and netupitant) plus dexamethasone in patients receivi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004031-37,0,0,0 2017-004034-29,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Advanced Accelerator Applications International SA,"A Phase 1/2 open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients with p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004034-29,0,0,0 2017-004037-93,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet","TReat-to-tArget (T2T) with seCukinumab in axial spondyloarthritis. IdEntification of MRI and biochemical biomarkers for disease activity, treatment response and structural damage progression (the TRAC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004037-93,0,0,0 2017-004038-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitair Ziekenhuis Brussel,Comparative Prospective Randomized Study in Postoperative Cardiac Surgery Patients on Analgesia with Morphine Continuous Infusion or Sublingual Sufentanil (Zalviso®).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004038-28,0,0,0 2017-004040-38,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,NEAT ID Foundation,"AN OPEN-LABEL, MULTI-CENTRE, RANDOMISED, SWITCH STUDY TO EVALUATE THE VIROLOGICAL EFFICACY OVER 96 WEEKS OF 2-DRUG THERAPY WITH DTG/RPV FDC IN ANTIRETROVIRAL TREATMENT- EXPERIENCED HIV-1 INFECTED SUBJ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004040-38,0,0,0 2017-004040-38,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,European AIDS Treatment Network Infectious Disease Foundation (NEAT ID),"AN OPEN-LABEL, MULTI-CENTRE, RANDOMISED, SWITCH STUDY TO EVALUATE THE VIROLOGICAL EFFICACY OVER 96 WEEKS OF 2-DRUG THERAPY WITH DTG/RPV FDC IN ANTIRETROVIRAL TREATMENT- EXPERIENCED HIV-1 INFECTED SUBJ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004040-38,0,0,0 2017-004042-14,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,ObsEva SA,"An exploratory single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily for 12 weeks followed by 100 mg daily for 12 weeks in uterine adenomyosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004042-14,0,0,0 2017-004043-21,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,ObsEva SA,"An exploratory, single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily For 12 weeks followed by 100 mg daily for 12 weeks in rectovaginal endometriosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004043-21,0,0,0 2017-004044-37,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,"Gilead Sciences, Inc.",A Phase 1 Relative Bioavailability and Food Effect Study of a Pediatric Oral Granule Formulation of SOF/VEL in Healthy Adult Subjects.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004044-37,0,1,1 2017-004045-25,4,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,"GLOBAL BLOOD THERAPEUTICS, INC.",An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004045-25,0,0,0 2017-004045-25,4,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,"Global Blood Therapeutics, Inc.",An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004045-25,0,0,0 2017-004047-20,2,2019-12-27,2019-12-27,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A randomised, cross-over, open-label, multi-centre trial comparing the effect of insulin degludec and insulin glargine 100U/mL, with or without OADs in subjects with type 2 diabetes using flash glucos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004047-20,0,0,0 2017-004048-38,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,"A phase II study of Avelumab in combination with Axitinib in patients with advanced Thymic epithelial tumours (TET) Studio interventistico, multicentrico, in aperto, non randomizzato di fase II c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004048-38,0,0,0 2017-004049-26,1,2019-04-24,2019-04-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mestex,"Lopain (MTX-071 / resiniferatoxin) An open label, single dose phase Ib/IIa study to determine the safety and clinical effects of intra-articular injections of low doses of Lopain (MTX-071) in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004049-26,0,0,0 2017-004054-41,1,2022-07-01,2022-07-01,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,University Hospitals Leuven,"CareRA2020: Effectiveness of a combination of Methotrexate and a step down glucocorticoid regimen (COBRA-Slim) for remission induction in patients with early Rheumatoid Arthritis (RA), with or without...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004054-41,0,0,0 2017-004058-40,4,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,0,Katholieke Universiteit Leuven,"A multicentre, open-label, three-arm randomised Phase II trial assessing the safety and efficacy of the HSP90 inhibitor Ganetespib in combination with Carboplatin followed by maintenance treatment wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004058-40,0,0,0 2017-004058-40,4,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,0,UNIVERSITé CATHOLIQUE DE LOUVAIN,"A multicentre, open-label, three-arm randomised Phase II trial assessing the safety and efficacy of the HSP90 inhibitor Ganetespib in combination with Carboplatin followed by maintenance treatment wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004058-40,0,0,0 2017-004059-22,18,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,Institut de Recherches Internationales Servier,"An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004059-22,0,0,0 2017-004059-22,18,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004059-22,0,0,0 2017-004059-22,18,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,"SERVIER Portugal - Especialidades Farmacêuticas, Lda.","An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004059-22,0,0,0 2017-004059-22,18,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,Institute de Recherches Internationales Servier (promotor internacional),"An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004059-22,0,0,0 2017-004060-35,1,2019-02-05,2019-02-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ImmuPharma,An open-label study of the safety and tolerability of repeated administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004060-35,0,0,0 2017-004064-35,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Southern Health NHS Foundation Trust,Liraglutide and the management of overweight and obesity in people with schizophrenia: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004064-35,0,0,0 2017-004065-27,1,2018-06-01,2018-06-01,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,vTv THERAPEUTICS LLC,Open Label Extension Study For Continued Safety And Efficacy Evaluation Of Azeliragon In Patients With Mild Alzheimer's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004065-27,0,0,0 2017-004066-10,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Myovant Sciences GmbH,"SPIRIT EXTENSION: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered with Low-Dose Estradiol and Norethindrone Acetate in Women ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004066-10,0,0,0 2017-004066-10,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,MYOVANT SCIENCES GMBH,"SPIRIT EXTENSION: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered with Low-Dose Estradiol and Norethindrone Acetate in Women ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004066-10,0,0,0 2017-004069-29,1,2019-06-20,2019-06-20,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Sanofi Pasteur,"Persistence of Anti-HBs Antibodies at 6 to 7 Years of Age in Subjects Having Received a DTaP-IPV-HB-PRP~T Hexavalent Vaccine at 3, 5, and 11 to 12 Months of Age, and Evaluation of Their Immune Memory ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004069-29,0,0,0 2017-004070-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Urología. Hospital Universitario La Paz,"RANDOMIZED CLINICAL TRIAL, OPEN, TO EVALUATE THE BLADDER INSTILLATION OF NEOADYUVANT CHEMOTHERAPY TO THE TRANSURETHAL RESECTION OF BLADDER FOR THE PREVENTION OF RECURRENCE OF NONMUSCLE-INVASIVE UROTHE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004070-34,0,0,0 2017-004072-59,7,2019-10-09,2019-10-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Norway KS,"A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004072-59,0,0,0 2017-004072-59,7,2019-10-09,2019-10-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004072-59,0,0,0 2017-004072-59,7,2019-10-09,2019-10-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004072-59,0,0,0 2017-004072-59,7,2019-10-09,2019-10-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004072-59,0,0,0 2017-004072-59,7,2019-10-09,2019-10-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.","A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004072-59,0,0,0 2017-004072-59,7,2019-10-09,2019-10-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas A.E,"A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004072-59,0,0,0 2017-004072-59,7,2019-10-09,2019-10-09,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer-Ingelheim España, S.A.","A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004072-59,0,0,0 2017-004073-14,7,2019-09-18,2019-10-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.","A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004073-14,0,0,0 2017-004073-14,7,2019-09-18,2019-10-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Ellas A.E,"A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004073-14,0,0,0 2017-004073-14,7,2019-09-18,2019-10-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004073-14,0,0,0 2017-004073-14,7,2019-09-18,2019-10-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Norway KS,"A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004073-14,0,0,0 2017-004073-14,7,2019-09-18,2019-10-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004073-14,0,0,0 2017-004073-14,7,2019-09-18,2019-10-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004073-14,0,0,0 2017-004073-14,7,2019-09-18,2019-10-07,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer-Ingelheim España, S.A.","A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004073-14,0,0,0 2017-004078-32,7,2021-01-14,2021-01-14,4,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Savara ApS,"AN OPEN-LABEL, NON-CONTROLLED, MULTICENTRE CLINICAL TRIAL OF INHALED MOLGRAMOSTIM IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS PATIENTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004078-32,1,0,0 2017-004079-30,4,2021-01-09,2021-01-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Joint Research & Development Office (QMUL),"Stratification of Biologic Therapies for RA by Pathobiology (STRAP)-EU: A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004079-30,0,0,0 2017-004079-30,4,2021-01-09,2021-01-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA,"Stratification of Biologic Therapies for RA by Pathobiology (STRAP)-EU: A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004079-30,0,0,0 2017-004082-27,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,LLC Novartis Pharma,An extension study of eltrombopag in pediatric patients with chronic immune (idiopathic) thrombocytopenia purpura (ITP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004082-27,0,1,1 2017-004083-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,3,Assistance Publique Hôpitaux de Marseille,"A double-blind, randomized, multicenter study evaluating 200 mg versus 600 mg of Mifepristone on pain in voluntary abortion by drug prior to 7 SA. DoMy Study Etude multicentrique randomisée en d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004083-35,0,0,0 2017-004084-12,11,2021-08-03,2021-08-03,7,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Genzyme Corporation,"Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at risk of Rapidly Progres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004084-12,1,0,0 2017-004084-12,11,2021-08-03,2021-08-03,7,1,0,0,0,0,2,0,0,2,1,0,0,0,1,GENZYME CORPORATION,"Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at risk of Rapidly Progres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004084-12,1,0,0 2017-004087-35,5,2021-06-15,2021-06-15,1,1,0,0,0,1,3,0,0,2,1,0,0,0,1,"AveXis, Inc.","A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants with Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy with Multiple Copies of SMN2",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004087-35,1,0,0 2017-004087-35,5,2021-06-15,2021-06-15,1,1,0,0,0,1,3,0,0,2,1,0,0,0,1,"Novartis Gene Therapies, Inc.","A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants with Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy with Multiple Copies of SMN2",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004087-35,1,0,0 2017-004092-31,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Eli Lilly and Company,"A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Studio d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004092-31,0,0,0 2017-004092-31,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Lilly S.A.,"A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Studio d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004092-31,0,0,0 2017-004092-31,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Studio d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004092-31,0,0,0 2017-004098-15,2,2018-08-28,2022-05-22,2,1,0,0,0,0,2,0,0,1,1,1,0,0,1,DS Biopharma,"A Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of Orally Administered DS107 in a once daily dose of 2g in Haemodialysis Patients with Moderate to Sever...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004098-15,0,0,0 2017-004099-71,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","Randomized Phase II study on Decitabine plus Carboplatin versus physician’s choice chemotherapy in recurrent, platinum-resistant ovarian cancer Studio randomizzato di Fase II su Decitabina più Car...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004099-71,0,0,0 2017-004100-22,3,2018-12-03,2018-12-03,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Osmotica Pharmaceutical US LLC,"A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients with Multi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004100-22,0,0,0 2017-004101-40,3,2020-01-27,2020-01-27,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Osmotica Pharmaceutical US LLC,An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity (Study OS440-3005).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004101-40,0,0,0 2017-004108-23,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Belfast Health and Social Care Trust,Low-dose atropine eye drops to reduce progression of myopia in children: a multi-centre placebo controlled randomised trial in the United Kingdom (CHAMP UK),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004108-23,0,0,0 2017-004110-25,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Technische Universität Dresden,MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004110-25,0,0,0 2017-004112-19,2,2020-03-24,2020-03-24,1,1,0,1,0,1,1,0,0,1,1,1,0,0,1,POLARIS GROUP,Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004112-19,0,0,0 2017-004112-19,2,2020-03-24,2020-03-24,1,1,0,1,0,1,1,0,0,1,1,1,0,0,1,"Polaris Pharmaceuticals, Inc.",Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004112-19,0,0,0 2017-004115-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology",Subacute Effect of Tolvaptan on Total Kidney Volumen in Adult Patients with Autosomal Dominant Polycystic Kidney Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004115-39,0,0,0 2017-004116-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital,"The AP-GELP Study: A randomized, placebo-controlled clinical trial on the effects of phosphodiesterase 4-inhibitor apremilast in female genital erosive lichen planus AP-GELP-studien: Behandling m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004116-19,0,0,0 2017-004122-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Hospital of Montpellier,"A randomized, double-blind, placebo-controlled trial comparing the efficacy and tolerance of sodium oxybate in patients affected with idiopathic hypersomnia. Etude bi-centrique contrôlée randomisée...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004122-15,0,0,0 2017-004123-67,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Hospitalier Régional Universitaire de Nancy,CHOCMSC Study Effects of mesenchymal stem cells administration on organ failure during septic shock: Phase II randomized placebo-controlled study Etude CHOCMSC Effets de l’administration de cellule...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004123-67,0,0,0 2017-004125-32,2,2020-03-02,2020-03-02,2,0,0,0,0,0,2,0,0,1,1,0,1,0,1,Apodemus Aktiebolag,"A randomised, double blind, placebo controlled trial to evaluate the safety, efficacy and pharmakokinetics of Pleconaril as an add on to AchEI/memantine for treatment of patients with Alzheimer’s dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004125-32,0,0,0 2017-004127-79,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,UZ Leuven,Comparison of treatment with preservative-free versus preserved dexamethasone 0.1% and diclofenac 0.1% eye drops after cataract surgery.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004127-79,0,0,0 2017-004128-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fakultní nemocnice Plzeň,Imaging of the prostate tumors using PET/CT and PET/MRI with the ligand of the prostatic specific membrane antigene 68Ga-PSMA-11 Zobrazení nádorů prostaty pomocí PET/CT a PET/MRI s využitím ligand...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004128-32,0,0,0 2017-004129-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Friedrich-Alexander-Universtiy Erlangen-Nürnberg, Medical Faculty","Randomized, double-blind, placebo controlled, parallel-group, prospective clinical study to analyse the effect of evolocumab on vascular function. Randomisierte, doppel-blinde, Plazebo kontrolliert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004129-33,0,0,0 2017-004130-28,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Universitätsklinikum Bonn,Occurence of Oronasal Fistulas (ONF) using a fibrin sealant patch in primary palatoplasty Untersuchung zum Auftreten oronasaler Fisteln bei LKG-Spalten unter Verwendung eines Fibrinkollagenschwamme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004130-28,0,0,0 2017-004132-11,6,2019-02-05,2019-02-05,5,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004132-11,1,0,0 2017-004133-82,4,2018-10-08,2018-10-08,4,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004133-82,0,0,0 2017-004134-29,6,2020-09-09,2020-09-09,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004134-29,0,0,0 2017-004135-36,13,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Alexion Pharmaceuticals, Inc","A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004135-36,0,0,0 2017-004135-36,13,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Wilson Therapeutics AB,"A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004135-36,0,0,0 2017-004135-36,13,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004135-36,0,0,0 2017-004137-91,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundacion SEIMC-GESIDA,"A single-arm, open-label, multicenter phase IV trial to evaluate the efficacy and safety of elvitegravir / cobicistat / emtricitabine / tenofovir alfa-namide as first-line treatment in naïve patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004137-91,0,0,0 2017-004139-35,3,2019-12-19,2019-12-19,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,MALLINCKRODT ARD INC.,"A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Subjects 4 to 8 Years of Age With Duchenne Muscul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004139-35,0,0,0 2017-004139-35,3,2019-12-19,2019-12-19,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Mallinckrodt ARD Inc.,"A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Subjects 4 to 8 Years of Age With Duchenne Muscul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004139-35,0,0,0 2017-004140-38,1,2021-08-18,2021-08-18,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),A phase II study from the POLA national network of nivolumab for recurrent IDH mutated High-Grade Gliomas Nivolumab dans les gliomes de haut-grade avec mutation IDH en rechute: une étude de phase ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004140-38,0,0,0 2017-004141-24,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Brighton and Sussex University Hospitals NHS Trus,"A phase IV, open-label pilot study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004141-24,0,0,0 2017-004143-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Bioinova, a.s.","Efficacy of autologous bone marrow-derived mesenchymal stem cells seeded on a 3D scaffold in treatment of knee cartilage defects. A randomized, controlled, open-label, multi-centre clinical trial. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004143-21,0,0,0 2017-004148-39,1,,,0,1,0,1,0,1,1,0,0,1,1,1,0,1,1,Sanofi-Aventis Recherche & Développement,"An open-label, first-in-human, dose escalation study of SAR440234 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004148-39,0,0,0 2017-004149-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Charité Universitätsmedizin Berlin,Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction Effekt von Metformin und Empagliflozin bei insulinresistenten Patienten mit Her...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004149-26,0,0,0 2017-004153-17,1,2020-08-24,2020-08-24,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Copenhagen Neuromuscular Center,"Evaluation of the effect of Triheptanoin on fatty acid oxidation and exercise tolerance in patients with debrancher deficiency, glycogenin-1 deficiency and phosphofructokinase deficiency at rest and d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004153-17,0,0,0 2017-004154-41,5,2022-09-30,2022-09-30,4,0,0,0,0,0,3,0,0,1,1,1,0,0,1,Isofol Medical AB,"A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5 fluorouracil, oxaliplatin, and bevacizumab in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004154-41,0,0,0 2017-004157-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE RICERCA TRASLAZIONALE (FORT),Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation Studio di fase II a singolo braccio con cabozantinib in pazienti con carcinoma polmonare non...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004157-16,0,0,0 2017-004158-40,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),A Prospective study evaluating the effect of ocrelizumab on brain innate immune Microglial cells Activation in Multiple Sclerosis using PET-MRI with 18F-DPA714 Une étude prospective évaluant l'effe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004158-40,0,0,0 2017-004160-35,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Immune System Regulation AB (ISR),"A prospective, randomised, controlled, parallel arm, open phase IIa study on the efficacy and safety of the GnRH analogue triptorelin for HIV-1 reservoir reduction in HIV-1 infected male adult patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004160-35,0,0,0 2017-004162-99,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,RAMTAS A Phase III study of RAMucirumab in combination with TAS102 vs. TAS102 monotherapy in chemotherapy refractory metastatic colorectal cancer patients RAMTAS Ramucirumab in Kombination mit TAS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004162-99,0,0,0 2017-004163-12,1,2019-01-16,2019-01-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ReposPharma,A phase 2a TDM-guided clinical study on the safety and efficacy of mebendazole in patients with advanced gastrointestinal cancer or cancer of unknown origin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004163-12,0,0,0 2017-004166-10,5,2020-01-15,2020-01-15,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"CLOVIS ONCOLOGY, INC","A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004166-10,0,0,0 2017-004166-10,5,2020-01-15,2020-01-15,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Clovis Oncology, Inc.","A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004166-10,0,0,0 2017-004168-36,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,A phase II study of pembrolizumab in patients with advanced gynaecological clear cell cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004168-36,0,0,0 2017-004169-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,I.R.C.C.S. FONDAZIONE S.LUCIA,Augmentation versus switch: comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression Studio di efficacia comparata in pazienti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004169-28,0,0,0 2017-004174-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Targid, KU Leuven",A placebo-controlled trial with citalopram for the treatment of typical reflux symptoms in patients with reflux hypersensitivity or functional heartburn with incomplete proton pump inhibitor response ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004174-34,0,0,0 2017-004175-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"TARGID, KU Leuven",A placebo-controlled trial with prucalopride for the treatment of typical reflux symptoms in patients with gastro-esophageal reflux disease with incomplete proton pump inhibitor response Een placeb...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004175-31,0,0,0 2017-004176-62,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NOVARTIS FARMA S.P.A.,"A phase IIIb, open-label, local, multicenter study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004176-62,0,0,0 2017-004181-10,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety of Sanofi Pasteur’s DTaP IPV HB PRP~T Combined Vaccine Given as a Three-Dose Primary Series at 2, 3, 4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004181-10,0,1,1 2017-004187-35,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,Falun Hospital,"The FACE (Facial nerve palsy And Cortisone Evaluation) study in children: a randomised double-blind, placebo-controlled, multicenter trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004187-35,0,0,0 2017-004188-11,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004188-11,0,0,0 2017-004188-11,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004188-11,0,0,0 2017-004190-13,2,2021-01-19,2021-01-19,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Tanvex Biologics Corp.,"A randomized, double-blind, parallel group, Phase III trial to compare the efficacy, safety, and immunogenicity of TX05 with Herceptin® in subjects with HER2 positive early breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004190-13,0,0,0 2017-004195-58,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"A.O.U. Università degli Studi della Campania ""Luigi Vanvitelli""",CAVE (Cetuximab-AVElumab) lung: A single arm phase II clinical study of the combination of avelumab plus cetuximab in the second line treatment of metastatic non small cell lung cancer (NSCLC) patient...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004195-58,0,0,0 2017-004200-21,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Sahlgrenska University Hospital,A phase Ib/II randomized double-blind placebo controlled trial evaluating the effect of nivolumab for patients with in-transit melanoma metastases treated with isolated limb perfusion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004200-21,0,0,0 2017-004202-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Interhospitalaria para la Investigación Cardiovascular,CRioablation vs Antiarrhythmic Drugs for Persistent Atrial Fibrillation Trial (CRAFT) Crioablación de venas pulmonares vs fármacos antiarrítmicos en fibrilación auricular persistente (CRAFT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004202-18,0,0,0 2017-004203-41,4,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Janssen-Cilag International N.V.,A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004203-41,0,0,0 2017-004206-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Not done Comparaison des effets rénaux des solutés de remplissage vasculaire PlASmalyte Viaflo et NaCl 0,9 % au cours de la réanimation de patients TRAUmatisés graves.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004206-17,0,0,0 2017-004207-52,5,2021-01-05,2021-02-03,5,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A multicenter, randomized, double-blind, placebo-controlled phase 2b dose-finding study to investigate the efficacy and safety of ligelizumab (QGE031) in adolescent patients with Chronic Spontaneous U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004207-52,0,0,0 2017-004207-52,5,2021-01-05,2021-02-03,5,1,1,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A multicenter, randomized, double-blind, placebo-controlled phase 2b dose-finding study to investigate the efficacy and safety of ligelizumab (QGE031) in adolescent patients with Chronic Spontaneous U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004207-52,0,0,0 2017-004208-24,9,2020-10-15,2020-10-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized, double-blind, multicenter study to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004208-24,0,0,0 2017-004208-24,9,2020-10-15,2020-10-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVARTIS PHARMA AG,"A randomized, double-blind, multicenter study to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004208-24,0,0,0 2017-004208-24,9,2020-10-15,2020-10-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,"A randomized, double-blind, multicenter study to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoho...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004208-24,0,0,0 2017-004209-41,10,2021-05-21,2021-05-21,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Naïve Subjects with Moderatel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004209-41,1,0,0 2017-004209-41,10,2021-05-21,2021-05-21,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Naïve Subjects with Moderatel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004209-41,1,0,0 2017-004209-41,10,2021-05-21,2021-05-21,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Naïve Subjects with Moderatel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004209-41,1,0,0 2017-004210-25,3,2020-02-06,2020-02-06,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Menlo Therapeutics Inc.,"A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004210-25,0,0,0 2017-004211-40,3,2020-04-08,2020-04-08,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Menlo Therapeutics Inc.,An Open-Label Long-Term Safety Study of Serlopitant for the Treatment of Pruritus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004211-40,0,0,0 2017-004213-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,"A RANDOMIZED TRIAL OF DURVALUMAB AND TREMELIMUMAB ¿ PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK, METASTATIC (STAGE IV) SQUAMOUS OR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) A RANDO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004213-24,0,0,0 2017-004219-37,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Universitätsklinikum Freiburg, Leitender Ärztlicher Direktor","A randomized, prospective, multicenter, controlled and double-blinded Phase II Clinical Trial to evaluate the influence of inhaled Aviptadil on Cough and Quality of Life in Sarcoidosis patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004219-37,0,0,0 2017-004219-37,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Universitätsklinikum Freiburg, Kaufmännische Direktorin","A randomized, prospective, multicenter, controlled and double-blinded Phase II Clinical Trial to evaluate the influence of inhaled Aviptadil on Cough and Quality of Life in Sarcoidosis patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004219-37,0,0,0 2017-004220-30,2,2021-09-08,2021-09-08,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"RADIUS HEALTH, INC","A Randomized, Double blind, Placebo controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide SC for the Treatment of Men with Osteoporosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004220-30,0,0,0 2017-004220-30,2,2021-09-08,2021-09-08,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Radius Health, Inc.","A Randomized, Double blind, Placebo controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide SC for the Treatment of Men with Osteoporosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004220-30,0,0,0 2017-004221-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,Department of Anesthesia Reanimation of University of Liege,Mechanism of action of the quadratus lumborum block,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004221-32,0,0,0 2017-004226-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,King Christian 10th Hospital for Rheumatology,"CAN-ART The efficacy and safety of using cannabis derivatives cannabidiol (CBD) and tetrahydrocannabinol (THC) for the treatment of pain in patients with inflammatory arthritis (RA, AS). A randomi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004226-15,0,0,0 2017-004227-75,2,2018-11-18,2018-11-21,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Alkahest, Inc.",A Single Arm Open-Label Study to Evaluate the Therapeutic Effects and Safety of a 6-Week Treatment Regimen of ALK4290 in Patients with Newly Diagnosed Wet Age-Related Macular Degeneration (wAMD). E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004227-75,0,0,0 2017-004228-31,2,2018-11-29,2018-11-29,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Alkahest, Inc.",A Single Arm Open-Label Study to Evaluate the Therapeutic Effects and Safety of a 6-Week Treatment Regimen of ALK4290 in Patients with Refractory Wet Age-Related Macular Degeneration (wAMD) Egykaro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004228-31,0,0,0 2017-004230-28,11,2020-02-04,2020-05-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim International GmbH,"A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 (SPESOLIMAB) Induction Therapy in patients with moderate-to-severely act...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004230-28,0,0,0 2017-004230-28,11,2020-02-04,2020-05-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 (SPESOLIMAB) Induction Therapy in patients with moderate-to-severely act...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004230-28,0,0,0 2017-004230-28,11,2020-02-04,2020-05-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim bv,"A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 (SPESOLIMAB) Induction Therapy in patients with moderate-to-severely act...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004230-28,0,0,0 2017-004230-28,11,2020-02-04,2020-05-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Boehringer Ingelheim España, S.A.","A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 (SPESOLIMAB) Induction Therapy in patients with moderate-to-severely act...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004230-28,0,0,0 2017-004230-28,11,2020-02-04,2020-05-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 (SPESOLIMAB) Induction Therapy in patients with moderate-to-severely act...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004230-28,0,0,0 2017-004230-28,11,2020-02-04,2020-05-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 (SPESOLIMAB) Induction Therapy in patients with moderate-to-severely act...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004230-28,0,0,0 2017-004230-28,11,2020-02-04,2020-05-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Denmark A/S,"A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 (SPESOLIMAB) Induction Therapy in patients with moderate-to-severely act...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004230-28,0,0,0 2017-004230-28,11,2020-02-04,2020-05-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Limited,"A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 (SPESOLIMAB) Induction Therapy in patients with moderate-to-severely act...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004230-28,0,0,0 2017-004230-28,11,2020-02-04,2020-05-18,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm. V,"A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 (SPESOLIMAB) Induction Therapy in patients with moderate-to-severely act...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004230-28,0,0,0 2017-004231-37,2,2021-01-05,2021-01-05,2,1,0,0,0,1,2,0,0,1,0,0,1,0,2,,"Effisayil™ 1:Multi-center, double-blind, randomised, placebo-controlled, Phase II study to evaluate efficacy, safety and tolerability of BI 655130 in patients with Generalized Pustular Psoriasis (GPP)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004231-37,0,0,0 2017-004231-37,2,2021-01-05,2021-01-05,2,1,0,0,0,1,2,0,0,1,0,0,1,0,2,Boehringer Ingelheim France,"Effisayil™ 1:Multi-center, double-blind, randomised, placebo-controlled, Phase II study to evaluate efficacy, safety and tolerability of BI 655130 in patients with Generalized Pustular Psoriasis (GPP)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004231-37,0,0,0 2017-004232-11,1,2020-06-18,2020-06-18,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2, Open-Label, Multicenter, Dose-Escalation and Expansion Study of Venetoclax in combination with Pomalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma Es...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004232-11,0,0,0 2017-004233-86,2,2021-08-04,2021-08-04,2,1,0,0,0,0,2,0,1,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegalovirus [...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004233-86,0,0,0 2017-004235-36,1,2020-09-02,2020-09-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Ewopharma AG,"A phase 4, randomized, open label multi-centre clinical study to evaluate efficacy of Isoprinosine® in female subjects with low-grade cervical dysplasia caused by HrHPV. Randomizovaná, multicentric...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004235-36,0,0,0 2017-004239-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Antoine Lacassagne,"Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Patients with Oligometastatic Sarcomas Etude de phase II rand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004239-35,0,0,0 2017-004244-37,2,2019-08-01,2019-08-01,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Grünenthal GmbH,Placebo-controlled efficacy and safety trial of intravenous neridronic acid in subjects with complex regional pain syndrome (CRPS) Placebem kontrolované klinické hodnocení účinnosti a bezpečnosti i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004244-37,0,0,0 2017-004246-20,8,,,0,0,0,1,0,1,1,0,0,2,0,0,0,0,1,Bayer Consumer Care AG,A Phase 1 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers Formerly: A Phase 1/2 Study of the TRK Inhibitor Selitrect...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004246-20,0,0,0 2017-004246-20,8,,,0,0,0,1,0,1,1,0,0,2,0,0,0,0,1,"Loxo Oncology, Inc",A Phase 1 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers Formerly: A Phase 1/2 Study of the TRK Inhibitor Selitrect...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004246-20,0,0,0 2017-004248-39,1,2020-09-22,2020-09-22,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"TARGID, KU Leuven",Effect of Proton Pump Inhibitors on the duodenal microbiome in healthy volunteers Effect van Proton Pomp Inhibitoren op het duodenale microbioom in gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004248-39,0,0,0 2017-004250-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Västmanland County Council,"Does NSAID protect against Post-ERCP Pancreatitis? A parallel-group, open, randomised, multicentre study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004250-42,0,0,0 2017-004251-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,National Treatment Program with Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Philadelphia Chromosome-Negative B-Cell Programma terapeutico ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004251-23,0,0,0 2017-004253-16,1,2020-01-31,2020-01-31,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"Medizinische Universität Innsbruck, Universitätsklinik für Neurologie",Nabilone for non-motor symptoms in Parkinson’s disease: An open-label study to evaluate long-term safety and efficacy Nabilon für nicht-motorische Symptome bei der Parkinsonkrankheit: eine offene ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004253-16,0,0,0 2017-004259-22,6,2021-04-02,2021-04-02,5,0,0,0,0,1,2,0,0,1,1,0,1,0,1,"Ionis Pharmaceuticals, Inc.","A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor) Administered On...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004259-22,0,0,0 2017-004260-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Associació Per a la Recerca Oncològica (APRO),"Phase II multicentre, randomized, open-label study to evaluate the safety and efficacy of avelumab with gemcitabine/carboplatin versus gemcitabine/carboplatin alone in patients with unresectable or me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004260-36,0,0,0 2017-004261-26,6,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,"Ipsen Bioscience, Inc","RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based Fi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004261-26,0,0,0 2017-004261-26,6,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,"IPSEN BIOSCIENCE, Inc.","RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based Fi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004261-26,0,0,0 2017-004262-95,10,,,0,0,0,0,2,0,3,0,0,2,0,0,0,0,1,Santen SAS,"Phase III, Multinational, Multicenter, Investigator-Masked, Randomised, Active-Controlled Trial, comparing the efficacy and safety of DE-130A with Xalatan® in Patients with Open-Angle Glaucoma or Ocul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004262-95,0,0,0 2017-004262-95,10,,,0,0,0,0,2,0,3,0,0,2,0,0,0,0,1,SANTEN SAS,"Phase III, Multinational, Multicenter, Investigator-Masked, Randomised, Active-Controlled Trial, comparing the efficacy and safety of DE-130A with Xalatan® in Patients with Open-Angle Glaucoma or Ocul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004262-95,0,0,0 2017-004268-36,7,2020-08-13,2020-08-13,6,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Apellis Pharmaceuticals, Inc.","A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Een fas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004268-36,0,0,0 2017-004279-30,9,2020-10-05,2020-10-05,7,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Santhera Pharmaceuticals (Switzerland) Limited,A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004279-30,1,0,0 2017-004279-30,9,2020-10-05,2020-10-05,7,1,0,0,0,1,3,0,0,2,1,0,0,0,1,SANTHERA PHARMACEUTICALS,A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004279-30,1,0,0 2017-004281-10,1,2020-06-30,2020-06-30,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,"Department of Pediatric oncology, Aarhus University hospital",Pharmacokinetics and pharmacodynamics of Piperacillin-Tazobactam (PT) in pediatric oncology patients with fever and neutropenia Farmakokinetiske og farmakodynamiske studier af Piperacillin-Tazobact...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004281-10,0,0,0 2017-004288-11,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,ADC THERAPEUTICS SA,A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004288-11,0,0,0 2017-004288-11,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,ADC Therapeutics SA,A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004288-11,0,0,0 2017-004292-31,14,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Celgene International II Sàrl,"Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004292-31,0,0,0 2017-004292-31,14,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,CELGENE INTERNATIONAL II SàRL,"Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004292-31,0,0,0 2017-004293-33,15,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Celgene International II Sàrl,"Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn¿s Disease Estudo de Ind...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004293-33,0,0,0 2017-004294-14,24,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Celgene International II Sàrl,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn¿s Disease Estudo de fase 3, multicêntrico,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004294-14,0,0,0 2017-004294-14,24,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,CELGENE INTERNATIONAL II SàRL,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn¿s Disease Estudo de fase 3, multicêntrico,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004294-14,0,0,0 2017-004295-55,24,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Celgene International II Sàrl,"A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004295-55,0,0,0 2017-004295-55,24,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,CELGENE INTERNATIONAL II SàRL,"A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004295-55,0,0,0 2017-004297-34,1,2019-10-31,2019-10-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Aston University,A placebo controlled double blind randomised controlled proof of concept study of zolpidem for the treatment of motor and cognitive deficits in late-stage Parkinson’s,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004297-34,0,0,0 2017-004298-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IVI Alicante,"A Phase III multicentre, randomized, unblinded clinical trial to test the effect of treatment with recombinant LH prior to controlled ovarian stimulation in poor ovarian responder women with an adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004298-15,0,0,0 2017-004299-69,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Hipercolesterolemia Familiar,"Low interventional, open and multicentric clinical trial to evaluate the effect of alirocumab on volume, architecture and composition of atheroma plaque in patients with familial hypercholesterolemia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004299-69,0,0,0 2017-004301-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS,FURosemide Stress Test to predict need of Renal Replacement THERapy in Ischemic Acute Tubular Necrosis in Intensive Care Units Intérêt du Furosémide Stress Test pour prédire le besoin d’épuration ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004301-41,0,0,0 2017-004301-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Assistance Publique-Hopitaux de Paris(AP-HP),FURosemide Stress Test to predict need of Renal Replacement THERapy in Ischemic Acute Tubular Necrosis in Intensive Care Units Intérêt du Furosémide Stress Test pour prédire le besoin d’épuration ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004301-41,0,0,0 2017-004302-18,7,2020-08-14,2020-08-14,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galapagos NV,"A Phase II randomized, double-blind, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004302-18,0,0,0 2017-004305-40,8,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,uniQure biopharma B.V.,"Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004305-40,0,0,0 2017-004305-40,8,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,UNIQURE BIOPHARMA B.V.,"Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene (AA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004305-40,0,0,0 2017-004307-51,1,2021-08-16,2021-08-16,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,University Medical Center Utrecht,Complement C5 Antibodies for decreasing brain injury after aneurysmal Subarachnoid Hemorrhage: safety and proof-of-concept. Complement C5 antilichamen om hersenschade na een aneurysmatische subarac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004307-51,0,0,0 2017-004309-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fédération francophone de cancérologie digestive,"Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed by two months of gemcitabine+Nab-paclitaxel, in metastatic pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004309-41,0,0,0 2017-004310-25,6,2022-08-02,2022-08-02,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Array BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.),"A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients with Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004310-25,1,0,0 2017-004310-25,6,2022-08-02,2022-08-02,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Array BioPharma Inc.,"A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients with Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004310-25,1,0,0 2017-004310-25,6,2022-08-02,2022-08-02,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,ARRAY BIOPHARMA INC.,"A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients with Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004310-25,1,0,0 2017-004311-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Academic Medical Center,Tranexamic Acid to Prevent Operation in Chronic Subdural Hematoma Tranexaminezuur ter Voorkoming van een Operatie voor Chronisch Subduraal Hematoom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004311-40,0,0,0 2017-004316-18,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Jazz Pharmaceuticals,Defibrotide for Patients with Hepatic Veno-occlusive Disease (VOD): A Treatment IND Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004316-18,0,1,1 2017-004318-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU University Medical Center,Early high-dose vitamin C in post-cardiac arrest syndrome. Vroege hoge dosis intraveneuze vitamine C na reanimatie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004318-25,0,0,0 2017-004319-37,1,,,0,0,0,0,1,0,2,0,1,0,0,0,0,0,0,"Medical University of Vienna, Department of Surgery","A prospective, randomised, single-blind explorative study to investigate the efficacy and safety of fat graft enrichment with autologous platelet lysate in female breast augmentation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004319-37,0,0,0 2017-004322-15,1,2020-06-24,2020-06-24,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,UZ Leuven,"An Open-label phase III study to investigate the safety, tolerability and immunogenicity of a nine-valent human papillomavirus (HPV) vaccine (Gardasil®9) in solid organ transplant recipients and HIV-i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004322-15,0,0,0 2017-004323-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medica Scientia Innovation Research (MedSIR),"Multicenter, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Niraparib plus Aromatase Inhibitors for Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004323-72,0,0,0 2017-004324-30,1,2021-03-31,2021-03-31,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Medica Scientia Innovation Research (MEDSIR),"A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally- recurrent or metastatic breast cancer patients after progressi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004324-30,0,0,0 2017-004326-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"UNIVERSITÀ DEGLI STUDI ""G. D'ANNUNZIO"" CHIETI-PESCARA",EXenatide onCe weekly or sitAgliptin as add on to basaL Insulin: effects on novel markers of endothelial fnction/dysfunction and on metaBolic control in T2DM sUbjects tRial: the EXCALIBUR Trial Exe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004326-15,0,0,0 2017-004331-37,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS = ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004331-37,0,0,0 2017-004331-37,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS = ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004331-37,0,0,0 2017-004331-37,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A.(Soc.Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS = ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004331-37,0,0,0 2017-004332-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SPARKLE SRL,"Use of 64CuCl2 PET/CT Imaging in the selection of patients with prostate cancer in biochemical relapse after prostatectomy, to be successfully treated with salvage radiotherapy on the prostatic bed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004332-11,0,0,0 2017-004335-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Anavex Life Sciences Corp.,"A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004335-36,0,0,0 2017-004339-35,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Aridis Pharmaceuticals, Inc.",A Randomized double-blind placebo-controlled multicenter Phase 3 study of efficacy and safety of AR-301 as adjunct therapy to antibiotics in the treatment of Ventilator-Associated Pneumonia (VAP) caus...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004339-35,0,0,0 2017-004341-24,3,2021-12-21,2022-01-21,3,0,0,0,0,0,0,0,0,1,0,0,0,0,1,"Krka, d.d., Novo Mesto","Efficacy of pregabalin and duloxetine in patients with painful diabetic peripheral neuropathy (PDPN): the effect of pain on cognitive function, sleep and quality of life (BLOSSOM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004341-24,0,0,0 2017-004341-24,3,2021-12-21,2022-01-21,3,0,0,0,0,0,0,0,0,1,0,0,0,0,1,"Krka, d.d., Novo mesto","Efficacy of pregabalin and duloxetine in patients with painful diabetic peripheral neuropathy (PDPN): the effect of pain on cognitive function, sleep and quality of life (BLOSSOM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004341-24,0,0,0 2017-004341-24,3,2021-12-21,2022-01-21,3,0,0,0,0,0,0,0,0,1,0,0,0,0,1,"KRKA, d.d., Novo mesto","Efficacy of pregabalin and duloxetine in patients with painful diabetic peripheral neuropathy (PDPN): the effect of pain on cognitive function, sleep and quality of life (BLOSSOM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004341-24,0,0,0 2017-004345-24,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Pfizer Inc.,"A PHASE 2, OPEN LABEL STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF AVELUMAB (BAVENCIO) IN COMBINATION WITH AXITINIB (INLYTA) IN PATIENTS WITH ADVANCED OR METASTATIC PREVIOUSLY TREATED NON-SMALL C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004345-24,0,0,0 2017-004345-24,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, New York,NY 10017","A PHASE 2, OPEN LABEL STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF AVELUMAB (BAVENCIO) IN COMBINATION WITH AXITINIB (INLYTA) IN PATIENTS WITH ADVANCED OR METASTATIC PREVIOUSLY TREATED NON-SMALL C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004345-24,0,0,0 2017-004348-39,1,2020-05-28,2020-05-28,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU Saint-Etienne,Association between methotrexate erythrocyte polyglutamate concentration and clinical response in rheumatoid arthritis patients treated with subcutaneous injectable methotrexate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004348-39,0,0,0 2017-004350-42,11,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Sierra Oncology, Inc.",Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004350-42,0,0,0 2017-004350-42,11,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Gilead Sciences, Inc.",Extended Access of Momelotinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004350-42,0,0,0 2017-004351-23,4,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD-1 Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004351-23,0,0,0 2017-004351-23,4,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD-1 Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004351-23,0,0,0 2017-004352-33,4,2019-10-28,2019-10-28,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,ALLENA PHARMACEUTICALS INCORPORATED,"Evaluate the Safety and Efficacy of ALLN-177 in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004352-33,0,0,0 2017-004352-33,4,2019-10-28,2019-10-28,3,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Allena Pharmaceuticals, Inc.","Evaluate the Safety and Efficacy of ALLN-177 in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004352-33,0,0,0 2017-004355-23,1,2020-09-22,2020-09-22,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"TARGID, KU Leuven",Effect of Proton Pump Inhibitors on the duodenal microbiome in Functional Dyspepsia patients Effect van Proton Pomp Inhibitoren in Functionele Dyspepsie patiënten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004355-23,0,0,0 2017-004358-40,2,2021-09-10,2021-09-10,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Mylan Inc,"A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects with Diabetic Macular Edema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004358-40,0,0,0 2017-004362-95,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Hospital Ulm,"Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004362-95,0,0,0 2017-004364-35,1,,,0,0,1,0,0,0,2,0,0,4,0,0,0,0,0,"National Heart, Lung, and Blood",Eltrombopag added to standard immunosuppression in treatment-naïve severe aplastic anemia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004364-35,0,1,1 2017-004365-27,2,2019-07-10,2019-07-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Enanta Pharmaceuticals Inc.,"A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Non-Alcoholic Steatohepati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004365-27,0,0,0 2017-004366-10,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Leicester,A Phase 2 Placebo-controlled Double Blinded Study to Assess the Efficacy and Safety of Belimumab in Subjects with Immunoglobulin A Nephropathy (IgAN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004366-10,0,0,0 2017-004367-12,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Fundación CRIS de investigación para vencer el cáncer,A phase I-II study to evaluate the efficacy and safety of niraparib in combination with cabozantinib (XL184) in patients with advanced urothelial cancer after failure to first-line platinum-based chem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004367-12,0,0,0 2017-004369-29,4,2019-10-08,2019-10-10,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Limited,The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGYTM ELLIPTATM) when Compared with Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Pat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004369-29,0,0,0 2017-004369-29,4,2019-10-08,2019-10-10,4,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.",The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGYTM ELLIPTATM) when Compared with Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Pat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004369-29,0,0,0 2017-004370-34,2,2018-09-03,2018-09-03,1,1,0,0,0,1,4,0,0,1,1,1,1,0,1,"Amicus Therapeutics, Inc.",A Prospective Study in Subjects with Late-onset Pompe Disease who are Currently Being Treated with Enzyme Replacement Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004370-34,0,0,0 2017-004372-56,6,2020-06-19,2020-06-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase 3 randomized, double-blind, active-controlled, parallel-group, multi-center study in hemodialysis participants with anemia of chronic kidney disease to evaluate the efficacy, safety and pharma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004372-56,0,0,0 2017-004372-56,6,2020-06-19,2020-06-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A Phase 3 randomized, double-blind, active-controlled, parallel-group, multi-center study in hemodialysis participants with anemia of chronic kidney disease to evaluate the efficacy, safety and pharma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004372-56,0,0,0 2017-004372-56,6,2020-06-19,2020-06-19,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"GlaxoSmithKline, S.A.","A Phase 3 randomized, double-blind, active-controlled, parallel-group, multi-center study in hemodialysis participants with anemia of chronic kidney disease to evaluate the efficacy, safety and pharma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004372-56,0,0,0 2017-004376-64,1,,,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,Eurocine Vaccines AB,"A Phase I/II, randomised, multicentre, placebo-controlled, partially-blinded, parallel-group study to assess the safety, tolerability and immune response following vaccination with ImmunoseTM FLU in o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004376-64,0,0,0 2017-004377-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SOGUG (Spanish Genitourinary Oncologic Group),"A multi-arm, multi-stage, randomized phase II/III trial of immunotherapy strategies in metastatic hormone-sensitive prostate cancer. Ensayo clínico aleatorizado, fase II/III, con múlt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004377-13,0,0,0 2017-004378-32,4,2020-07-01,2020-07-06,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A phase III, randomized, double-blind, placebo-controlled, efficacy, and safety study of Balovaptan in adults with Autism Spectrum Disorder with a 2 year open-label extension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004378-32,0,0,0 2017-004378-32,4,2020-07-01,2020-07-06,3,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD,"A phase III, randomized, double-blind, placebo-controlled, efficacy, and safety study of Balovaptan in adults with Autism Spectrum Disorder with a 2 year open-label extension.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004378-32,0,0,0 2017-004385-94,8,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004385-94,0,0,0 2017-004385-94,8,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004385-94,0,0,0 2017-004385-94,8,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004385-94,0,0,0 2017-004387-35,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Eisai Ltd,"A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with Adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004387-35,0,0,0 2017-004387-35,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,EISAI LIMITED,"A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with Adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004387-35,0,0,0 2017-004388-11,4,2019-05-23,2019-07-23,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,EIP Pharma Inc,"A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects with Mild Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004388-11,0,0,0 2017-004392-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"A.O.U. Università degli Studi della Campania ""Luigi Vanvitelli""",CAVE (Cetuximab-AVElumab) mCRC: A single arm phase IIclinical study of the combination of avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients. CAVE (Cetuximab...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004392-32,0,0,0 2017-004393-33,13,2022-04-25,2022-04-25,9,0,0,0,2,0,3,0,0,2,0,0,0,0,1,Idorsia Pharmaceuticals Ltd,"Multi-center, blinded, randomized, parallel-group, Phase 3 study with aprocitentan in subjects with Resistant Hypertension (RHT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004393-33,1,0,0 2017-004393-33,13,2022-04-25,2022-04-25,9,0,0,0,2,0,3,0,0,2,0,0,0,0,1,IDORSIA PHARMACEUTICALS LTD,"Multi-center, blinded, randomized, parallel-group, Phase 3 study with aprocitentan in subjects with Resistant Hypertension (RHT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004393-33,1,0,0 2017-004394-14,8,2022-07-26,2022-07-26,5,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Zealand Pharma A/S,"A Phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide in patients with short bowel syndrome (SBS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004394-14,1,0,0 2017-004397-34,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently with Platinum-based Chemoradiation Therapy in Patients with Locally Advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004397-34,0,0,0 2017-004399-68,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Allergan Ltd.,"A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A (AGN 151607) Injections into the Epicardial Fat ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004399-68,0,0,0 2017-004399-68,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ALLERGAN LIMITED,"A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A (AGN 151607) Injections into the Epicardial Fat ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004399-68,0,0,0 2017-004401-40,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Birmingham,"STELLAR: A phase II, randomiSed study of CHOP-R in combination with acalabruTinib comparEd to CHOP-R in patients with newLy diagnosed Richter’s Syndrome (RS) and a pLAtfoRm for initial investigations ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004401-40,0,0,0 2017-004405-41,6,2019-03-06,2019-03-06,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CHIESI FARMACEUTICI S.P.A.,"A phase II, multicentre, randomised, double-blind, double-dummy, active-controlled, 3-way cross-over study to evaluate the efficacy of CHF 5993 administered via Dry Powder Inhaler (DPI) versus CHF 599...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004405-41,0,0,0 2017-004405-41,6,2019-03-06,2019-03-06,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A phase II, multicentre, randomised, double-blind, double-dummy, active-controlled, 3-way cross-over study to evaluate the efficacy of CHF 5993 administered via Dry Powder Inhaler (DPI) versus CHF 599...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004405-41,0,0,0 2017-004406-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IRCC INRCA,Geriatric outcomes among older Type 2 diabetic patients treated with DPP4 inhibitors or glinides: focus on pro-inflammatory and oxidative stress markers (GOOD-WP1) Outcomes geriatrici in pazienti a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004406-18,0,0,0 2017-004409-42,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Lupin Limited (Biotechnology Division),"A Global, Phase III, Double Blind, Randomized Controlled Study to Compare the Efficacy, Safety & Immunogenicity of LUBT010 with Lucentis® in Patients with Neovascular Age-Related Macular Degeneration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004409-42,0,0,0 2017-004413-98,1,2020-04-06,2020-04-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Fundación CRIS,"“Phase II clinical trial of doxycycline 50 mg or 100 mg daily for the prevention of skin toxicity in patients with metastatic colorectal cancer treated with panitumumab and chemotherapy"" ""Estudio d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004413-98,0,0,0 2017-004415-39,3,2019-04-15,2019-04-15,1,0,0,1,0,0,1,0,0,2,1,0,0,0,1,"Taiho Oncology, Inc.","A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF TAS0728, AN ORAL COVALENT BINDING INHIBITOR OF HER2, IN SUBJECTS WITH ADVANCED SOLID TUMORS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004415-39,1,0,0 2017-004416-19,1,2020-01-18,2020-01-18,1,0,0,0,0,1,3,0,0,1,1,1,1,0,0,CHU Angers,Hydroxychloroquine versus placebo : Impact sur les récidives thrombotiques dans le syndrome primaire des antiphospholipides – PAPIRUS Hydroxychloroquine versus placebo : Impact sur les récidives th...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004416-19,0,0,0 2017-004417-42,18,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004417-42,0,0,0 2017-004417-42,18,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004417-42,0,0,0 2017-004419-38,12,2021-09-13,2021-09-13,8,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Institut de Recherches Internationales Servier,"Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004419-38,1,0,0 2017-004419-38,12,2021-09-13,2021-09-13,8,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"SERVIER Portugal – Especialidades Farmacêuticas, LDA.","Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004419-38,1,0,0 2017-004419-38,12,2021-09-13,2021-09-13,8,1,1,0,0,0,3,0,0,2,1,0,0,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004419-38,1,0,0 2017-004420-30,11,2021-08-18,2021-10-26,6,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Institut de Recherches Internationales Servier,"Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo controlled multice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004420-30,1,0,0 2017-004420-30,11,2021-08-18,2021-10-26,6,1,1,0,0,0,3,0,0,2,1,0,0,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo controlled multice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004420-30,1,0,0 2017-004420-30,11,2021-08-18,2021-10-26,6,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"SERVIER Portugal – Especialidades Farmacêuticas, LDA.","Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo controlled multice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004420-30,1,0,0 2017-004423-78,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,OSPEDALE SAN RAFFAELE,A phase II trial of allogeneic peripheral blood stem cell transplantation from family haploidentical donors in patients with myelodisplastic syndrome and acute leukemia under primary antifungal prophy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004423-78,0,0,0 2017-004424-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Center,Pharmacogenetics Use For Further treatment Improvement in childreN (PUFFIN) trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004424-29,0,0,0 2017-004429-34,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,UZ Brussel,Histological and Transcriptional Changes caused by Endometrial Flushing with Lipiodol: A Cross Over Study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004429-34,0,0,0 2017-004433-93,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"Nicholas Stephen Macklon, Professor, MD, PhD",RIOT C: REDUCING THE IMPACT OF OVARIAN STIMULATION. NOVEL APPROACHES TO LUTEAL SUPPORT IN IVF. STUDY 2. RIOT C: OPTIMERING AF OVARIESTIMULATION MHP. AT REDUCERE BEHOVET FOR LUTEALSTØTTE VED IVF. ST...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004433-93,0,0,0 2017-004439-36,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ACADIA Pharmaceuticals Inc.,"A 52-Week Open-Label Extension Study of Pimavanserin in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease 52-седмично, открито разширено изпитване на pi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004439-36,0,0,0 2017-004443-20,2,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Herantis Pharma Plc,"A Phase II, double-blind, placebo-controlled, randomized study to assess the efficacy, safety and tolerability of Lymfactin® (AdAptVEGF-C Adenoviral Vector) in combination with a surgical lymph node t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004443-20,0,0,0 2017-004444-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Krankenhaus Nordwest gGmbH,Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detect...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004444-38,0,0,0 2017-004450-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut,"PHASE IV, OPEN, UNICENTRIC AND PILOT CLINICAL TRIAL TO EVALUATE THE INFLUENCE ON THE BIODISPONIBILITY AND PHARMACOKINETIC CHARACTERISTICS OF ENVARSUS® COMPARED WITH ADVAGRAF® OF FAST OR INGESTION IN S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004450-41,0,0,0 2017-004451-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per a la Reserca Biomèdica,"Phase IV, unicentric, open-label, randomized clinical trial to evaluate clinic and non-invasive response to clobetasol cream versus betamethasone dipropionate and calcipotriol foam treatments in plaqu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004451-24,0,0,0 2017-004454-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Vall d'Hebron Research Institute,English A pilot interventional study to arrest the progression of cognitive decline in diabetic patients at high risk of developing Alzheimer's disease by reducing hypoglycemic events. Estudio pilo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004454-42,0,0,0 2017-004456-30,8,2021-12-22,2021-12-22,6,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Pfizer Inc.,"A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH TH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004456-30,1,0,0 2017-004456-30,8,2021-12-22,2021-12-22,6,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH TH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004456-30,1,0,0 2017-004456-30,8,2021-12-22,2021-12-22,6,0,0,0,0,0,3,0,0,2,1,0,0,0,1,PFIZER INC,"A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH TH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004456-30,1,0,0 2017-004458-41,1,2021-07-07,2021-07-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Charité - Universitätsmedizin Berlin Klinik für Dermatologie und Allergologie,"A multicenter, randomized, double-blind, placebo-controlled, phase 2, 16-week treatment study with a 16 week follow-up period to assess the efficacy and safety of Dupilumab (anti-IL4Ra) in adult patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004458-41,0,0,0 2017-004459-21,1,2021-11-03,2021-11-03,1,0,0,0,0,1,2,0,0,1,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA,"Colchicine for Amyotrophic Lateral Sclerosis: a phase II, randomized, double blind, placebo controlled, multicenter clinical trial Trattamento con colchicina per la Sclerosi Laterale Amiotrofica: u...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004459-21,0,0,0 2017-004465-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC Cancer Institute,The effects of the proton pump inhibitor esomeprazole alone or in combination with Coca-Cola on the absorption of Capecitabine in patients with colorectal cancer or other solid tumours ' the COCA stud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004465-27,0,0,0 2017-004467-13,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Barts Health NHS Trust,A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004467-13,0,0,0 2017-004469-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,MUNDIPHARMA,"Multicentre, randomised, double-blind study assessing the efficacy and safety of Penthrox® combined with a standard analgesia (SoC) in comparison to a placebo combined with a standard analgesia (SoC) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004469-28,0,0,0 2017-004471-31,10,,,0,0,1,0,0,2,3,0,0,3,0,0,0,0,1,Eli Lilly and Company,A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients from 1 Year to <18 Years of Age with Juvenile Idiopathic Arthritis (JIA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004471-31,0,0,0 2017-004471-31,10,,,0,0,1,0,0,2,3,0,0,3,0,0,0,0,1,Lilly S.A.,A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients from 1 Year to <18 Years of Age with Juvenile Idiopathic Arthritis (JIA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004471-31,0,0,0 2017-004471-31,10,,,0,0,1,0,0,2,3,0,0,3,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER",A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients from 1 Year to <18 Years of Age with Juvenile Idiopathic Arthritis (JIA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004471-31,0,0,0 2017-004475-31,2,2019-12-18,2019-12-18,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Theranexus S.A.,"Randomised, double-blind, placebo-controlled, complete 3-way cross-over phase IIa trial to investigate safety and efficacy of two THN102 doses in subjects with excessive daytime sleepiness associated...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004475-31,0,0,0 2017-004478-32,1,2020-11-15,2020-11-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Aarhus University Hospital,"The effect of metoprolol on myocardial function, hemodynamics and heart failure symptoms in patients with hypertrophic obstructive cardiomyopathy Effekten af metoprolol på myokardiefunktion, hæmody...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004478-32,0,0,0 2017-004480-12,1,2018-07-02,2018-07-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,Restrictive vs. Liberal Oxygen Therapy for Trauma patients. PILOT: The TRAUMOX Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004480-12,0,0,0 2017-004486-27,1,2021-04-15,2021-04-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Associació Per a la Recerca Oncològica(APRO),Phase II Study of Paclitaxel and TAK-228 in metastatic urothelial carcinoma (UC) and the impact of PI3K-mTOR pathway genomic alterations Estudio fase II de paclitaxel y TAK-228 en el carcinoma urot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004486-27,0,0,0 2017-004489-88,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,CHU Toulouse,Evaluation of perioperative eltrombopag for the management of elective surgery and invasive acts in patients with inherited thrombocytopenia Evaluation de l’ELtrombopag en Peri-Opératoire lors de c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004489-88,0,0,0 2017-004493-34,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Cliniques universitaires Saint-Luc,Evaluation of multiple subgingival irrigations with 10% povidone iodine after scaling and root planing : a randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004493-34,0,0,0 2017-004494-13,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",IMPROVING TREATMENT STRATEGIES IN THYMIC EPITHELIAL TUMORS: A TYME COLLABORATIVE EFFORT Miglioramento delle strategie di trattamento nei tumori epiteliali del timo: un impegno congiunto del TYME.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004494-13,0,0,0 2017-004495-60,10,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less Than 18 Years Old with Systemic Juvenile Idiopathic Arthritis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004495-60,0,0,0 2017-004495-60,10,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Lilly S.A,"A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less Than 18 Years Old with Systemic Juvenile Idiopathic Arthritis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004495-60,0,0,0 2017-004495-60,10,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less Than 18 Years Old with Systemic Juvenile Idiopathic Arthritis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004495-60,0,0,0 2017-004496-31,6,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,Janssen Biologics B.V.,"A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Part...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004496-31,0,0,0 2017-004496-31,6,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,Janssen Biologics BV,"A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Part...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004496-31,0,0,0 2017-004497-33,1,2021-04-18,2021-04-18,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Copenhagen University Hospital at Hvidovre,Measuring effects on pain and quality of life after Dysport® injection in children with cerebral palsy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004497-33,0,0,0 2017-004500-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC),Phase II multicentre trial of perioperative chemotherapy in operable patients with gastric cancer (PERISCOPE trial) PERISCOPE: studio di fase II multicentrico di chemioterapia perioperatoria nel ca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004500-22,0,0,0 2017-004501-40,6,2019-11-14,2020-02-14,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,InflaRx GmbH,"A randomized, double-blind, placebo-controlled, multicenter Phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004501-40,0,0,0 2017-004506-18,1,2022-08-08,2022-08-08,1,0,0,0,0,1,2,0,0,1,0,0,0,0,1,Nordic Nanovector ASA,A phase 2 open-label study of Betalutin in combination with rituximab in patients with relapsed/refractory follicular lymphoma (Archer-1),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004506-18,0,0,0 2017-004508-23,1,2018-06-11,2018-06-11,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,LEO Pharma A/S,Capture of LEO 90100 medication usage with digital tracker and evaluation of efficacy in patients with psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004508-23,0,0,0 2017-004509-42,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Celleron Therapeutics Ltd,"A Phase Ib/ II Trial to Assess the Safety and Efficacy of CXD101 in Combination with the PD-1 Inhibitor Nivolumab in Patients with Metastatic, Previously-Treated, Microsatellite-Stable Colorectal Carc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004509-42,0,0,0 2017-004512-19,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Unicancer,"An open label, randomized, phase III trial, evaluating efficacy of Atezolizumab in addition to one year BCG (Bacillus CaLmette-Guerin) bladder instillation in BCG-naive patients with high-risk non-mus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004512-19,0,0,0 2017-004512-19,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNICANCER,"An open label, randomized, phase III trial, evaluating efficacy of Atezolizumab in addition to one year BCG (Bacillus CaLmette-Guerin) bladder instillation in BCG-naive patients with high-risk non-mus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004512-19,0,0,0 2017-004514-25,1,2019-12-27,2019-12-27,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Nutrición Medica S.L.,EFFICACY AND SAFETY OF THE ADMINISTRATION OF THE PASSIFLORA EXTRACT FOR BENZODIAZEPINE WITHDRAWAL IN INSTITUTIONALIZED OLDER ADULTS : CLINICAL TRIAL PHASE III. EFICACIA Y SEGURIDAD DE LA ADMINIST...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004514-25,0,0,0 2017-004515-39,6,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A randomized, open-label, multicenter trial to assess the efficacy of subcutaneous secukinumab after twelve weeks of treatment, and to assess the long-term safety, tolerability and efficacy in subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004515-39,0,0,0 2017-004515-39,6,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, open-label, multicenter trial to assess the efficacy of subcutaneous secukinumab after twelve weeks of treatment, and to assess the long-term safety, tolerability and efficacy in subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004515-39,0,0,0 2017-004518-24,10,2022-01-26,2022-01-26,6,1,1,0,0,2,3,0,0,2,0,0,0,0,1,Lilly S.A.,"A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Juvenile Idiopathic Arthritis (JIA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004518-24,1,0,0 2017-004518-24,10,2022-01-26,2022-01-26,6,1,1,0,0,2,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Juvenile Idiopathic Arthritis (JIA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004518-24,1,0,0 2017-004518-24,10,2022-01-26,2022-01-26,6,1,1,0,0,2,3,0,0,2,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Juvenile Idiopathic Arthritis (JIA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004518-24,1,0,0 2017-004519-38,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD,Randomized phase II study to evaluate the efficacy of second-line FOLFIRI + panitumumab in subjects with wild type RAS metastatic colorectal cancer who have received FOLFOX + panitumumab in first-line...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004519-38,0,0,0 2017-004520-30,1,,,0,0,1,0,0,0,3,0,1,3,0,0,0,0,1,Sanofi Pasteur,Immunogenicity and safety study of an investigational quadrivalent meningococcal conjugate vaccine in infants and toddlers when administered using a 1+1 schedule in a National Immunization Schedule ha...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004520-30,0,0,0 2017-004521-32,7,2021-01-18,2021-01-18,6,1,0,0,1,0,2,0,0,2,0,0,0,0,1,"MedImmune, LLC, a wholly owned subsidiary of AstraZeneca PLC","A Randomized, Placebo-controlled Phase 2b Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004521-32,1,0,0 2017-004521-32,7,2021-01-18,2021-01-18,6,1,0,0,1,0,2,0,0,2,0,0,0,0,1,"MedImmune LLC, a wholly owned subsidiary of AstraZeneca PLC","A Randomized, Placebo-controlled Phase 2b Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004521-32,1,0,0 2017-004522-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centro Ricerche Cliniche di Verona,A phase II trial of the FGFR inhibitor INCB054828 in patients with advanced esophageal-gastric junction (EGJ)/Gastric cancer Trastuzumab Resistant: the FiGhTeR trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004522-14,0,0,0 2017-004524-29,1,,,0,1,0,0,1,0,3,0,0,1,0,0,0,1,1,PHARMATHEN,"Therapeutic Equivalence (non-inferiority), Randomized, Observer-blind, two Parallel Group, Clinical Trial for Comparing the Efficacy and Tolerability of a new Generic Preservative-Free Formulation of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004524-29,0,0,0 2017-004527-67,2,2019-06-27,2019-06-27,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,DermaTools Biotech GmbH,"A Randomised Dose Finding Study Comparing The Safety And Efficacy Of three blinded doses of Diperoxochloric Acid (DPOCl, DermaPro®) and A Standard Moist Wound Dressing In Patients With Non-Healing Dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004527-67,0,0,0 2017-004530-29,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,1,WinMedica SA,"A Randomized, Multicentre, Double-blind, two Parallel Group, Clinical Phase III Trial for Comparing the Efficacy and Tolerability of a combination IM product of Thiocolchicoside and Diclofenac vs. Dic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004530-29,0,0,0 2017-004531-36,1,2021-03-31,2021-03-31,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Ardeypharm GmbH,Escherichia coli strain Nissle 1917 - Suspension for treatment of patients with Clostridium difficile associated diarrhoea Escherichia coli Stamm Nissle 1917-Suspension zur Behandlung von Patiente...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004531-36,0,0,0 2017-004532-10,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,Effects of immunomodulatory therapy on gonadal function in women with autoimmune premature ovarian insufficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004532-10,0,0,0 2017-004534-28,7,2022-02-02,2022-02-02,6,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Dr. August Wolff GmbH & Co. KG Arzneimittel,"Combined Randomized, Double-Blind, Dose-Confirming Phase 3a Study in Parallel Design to Assess the Efficacy and Safety of Topical 4-Week Treatment With 1% GPB Cream vs Placebo and Open-Label Phase 3b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004534-28,1,0,0 2017-004539-36,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Great Ormond Street Hospital for Children NHS Foundation Trust,Study of Montelukast In Children with Sickle Cell Disease (SMILES),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004539-36,0,0,0 2017-004540-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SANT'ANDREA,The effects of sequential Mitomycin and Bacillus Calmette-Guérin treatment versus Bacillus Calmette-Guérin monotherapy in patients with High risk Non-Muscle Invasive Bladder Cancer Effetti della co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004540-37,0,0,0 2017-004542-24,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Oxford,Clinical effectiveness of standard step up care (methotrexate) compared to early combination DMARD therapy with standard step up care compared to early use of TNF inhibitors with standard step up care...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004542-24,0,0,0 2017-004543-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,EFFECTS OF ABATACEPT ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM (PALABA). EFECTOS DE ABATACEPT EN LA PROGRESIÓN DE LA ARTRITIS REUMATOIDE EN PACIENTES CON R...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004543-20,0,0,0 2017-004544-38,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Pfizer Inc.,"A PROSPECTIVE, RANDOMIZED, OPEN-LABEL, COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) AND BEST AVAILABLE THERAPY FOR THE TREATMENT OF SERIOUS INFECT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004544-38,0,0,0 2017-004545-24,2,2022-03-07,2022-03-07,1,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Zealand Pharma A/S,"A Randomized Trial in 2 Parts: Double-Blind, Placebo-Controlled, Crossover Part 1 and Open-label Part 2, Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenita...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004545-24,1,0,0 2017-004546-15,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Zealand Pharma A/S,An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004546-15,0,0,0 2017-004547-21,2,2020-10-05,2020-10-05,1,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Zealand Pharma A/S,"A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004547-21,1,0,0 2017-004554-42,6,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,0,"University of Basel Children's Hospital, Division of Neuropediatrics","Tamoxifen in Duchenne muscular dystrophy - TAMDMD A multicentre, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial Le tamoxifène dans la dystrophie musculaire ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004554-42,0,0,0 2017-004556-27,1,2020-10-15,2020-10-15,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Cisplatin-Ineli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004556-27,0,0,0 2017-004557-17,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"CLOVIS ONCOLOGY, INC","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004557-17,0,0,0 2017-004557-17,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Clovis Oncology, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004557-17,0,0,0 2017-004558-41,7,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"PHARMACYCLICS, LLC","Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004558-41,0,0,0 2017-004558-41,7,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Pharmacyclics LLC,"Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004558-41,0,0,0 2017-004558-41,7,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Pharmacyclics LLC (An AbbVie Company),"Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004558-41,0,0,0 2017-004564-35,4,2018-12-06,2018-12-06,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"GlaxoSmithKline, S.A.","A Phase IIa Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study to Investigate the Clinical Efficacy, Safety, and Tolerability of Nemiralisib (GSK2269557) in Symptomatic COPD Participant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004564-35,0,0,0 2017-004564-35,4,2018-12-06,2018-12-06,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,GlaxoSmithKline Research and Development Ltd.,"A Phase IIa Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study to Investigate the Clinical Efficacy, Safety, and Tolerability of Nemiralisib (GSK2269557) in Symptomatic COPD Participant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004564-35,0,0,0 2017-004565-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACIÓN TEÓFILO HERNANDO,"Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 mg on Treatment Free-Remission Rate in Patients with Phil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004565-27,0,0,0 2017-004566-99,2,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC COLORECTAL CANCE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004566-99,0,0,0 2017-004568-37,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Nova Laboratories Limited,"A prospective open label, pharmacokinetic study of an oral hydroxyurea solution in children with sickle cell anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004568-37,0,0,0 2017-004570-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Medical Center - University of Freiburg,"Phase II, Open-label, Study in Patients with anaplastic (ATC) or poorly differentiated thyroid carcinomas (PDTC) to investigate the Clinical Efficacy and Safety of the Combination Therapy of Lenvatini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004570-34,0,0,0 2017-004572-62,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Norwegian University of Science and Technology, Department of Clinical and molecular medicine",A randomized phase II study comparing atezolizumab after concurrent chemo-radiotherapy with chemo-radiotherapy alone in limited disease small-cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004572-62,0,0,0 2017-004574-34,9,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004574-34,0,0,0 2017-004574-34,9,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004574-34,0,0,0 2017-004574-34,9,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Lilly S.A.,"A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004574-34,0,0,0 2017-004576-57,7,2022-10-03,2022-10-03,4,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Dr. Falk Pharma GmbH,"Randomised, double-blind, double-dummy, active-controlled, phase III clinical trial on the efficacy and safety of an 8-week add-on treatment with budesonide 9 mg capsules vs. budesonide 6 mg capsules ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004576-57,1,0,0 2017-004577-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Ústav hematologie a krevní transfuze,Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults. Jeden cyklus blinatumomabu následovaný vysokodávkova...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004577-14,0,0,0 2017-004578-33,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Athenex, Inc.",A Safety Study of Oraxol (HM30181 + oral paclitaxel) in Cancer Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004578-33,0,0,0 2017-004579-29,1,2018-09-01,2018-09-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KU Leuven Drug Delivery & Disposition,Gastrointestinal behavior of atazanavir in healthy volunteers Gastrointestinaal gedrag van atazanavir in gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004579-29,0,0,0 2017-004580-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Instituto de investigación del sueño,Treatment of Restless Legs Syndrome with the Hypocretin Antagonist Suvorexant Tratamiento del Síndrome de Piernas Inquietas con el antagonista de las hipocretinas suvorexant: Un estudio piloto”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004580-12,0,0,0 2017-004581-10,5,2020-07-14,2020-07-14,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Institut de Recherches Internationales Servier,"Efficacy and safety of 3 doses of S201086/GLPG1972 administered orally once daily in patients with knee osteoarthritis. A 52-week international, multi-regional, multi-center, randomized, double-blind,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004581-10,0,0,0 2017-004582-27,1,2019-09-30,2019-09-30,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Bavarian Nordic A/S,"A Phase 2a Randomized, Double-blinded, Placebo-controlled Trial to assess the Safety, Immunogenicity, and Efficacy of the recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infection i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004582-27,0,0,0 2017-004588-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Maastricht University Medical Centre,Control Crohn Safe Trial: Long term efficacy and safety of periodic treatment with adalimumab versus standard step-care for newly diagnosed Crohn's disease. Veilige controle van de ziekte van Crohn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004588-11,0,0,0 2017-004592-31,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Health Research Institute Hospital La Fe,Venous Thromboembolism Prophylaxis with Apixaban in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma Receiving Induction Therapy with an Immunomodulatory-Based Regimen Profilaxis ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004592-31,0,0,0 2017-004593-34,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Zealand University Hospital Roskilde,"Ultrasound-guided Transmuscular Quadratus Lumborum block for Laparoscopic Hysterectomy. A double blind, randomized, placebo controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004593-34,0,0,0 2017-004596-31,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,UMC Utrecht,CeRebrUm and CardIac protection with Allopurinol in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass Cerebrale en cardiale protectie met allopur...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004596-31,0,0,0 2017-004600-22,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,CATALYST PHARMACEUTICALS INC.,"A Randomized, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Amifampridine Phosphate in Ambulatory Patients with Spinal Muscular Atrophy (SMA) Type 3 Studio clinico rand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004600-22,0,0,0 2017-004601-40,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,MUNDIPHARMA RESEARCH LIMITED,"Efficacy and safety of methoxyflurane in helicopter emergency medical system and hostile environment: a prospective, multicentre clinical trial Studio clinico prospettico, multicentrico di valutazi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004601-40,0,0,0 2017-004602-17,1,2019-05-21,2019-05-21,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Otsuka Pharmaceutical,"A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System with Healthcare Professionals and Adult Subjects with Schizophre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004602-17,0,0,0 2017-004603-52,9,2021-10-04,2021-10-04,5,1,0,0,0,1,2,0,0,2,1,0,0,0,1,"Astex Pharmaceuticals, Inc.","An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004603-52,1,0,0 2017-004603-52,9,2021-10-04,2021-10-04,5,1,0,0,0,1,2,0,0,2,1,0,0,0,1,ASTEX PHARMACEUTICALS,"An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004603-52,1,0,0 2017-004605-41,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Travere Therapeutics Inc.,"A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004605-41,0,0,0 2017-004605-41,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Retrophin, Inc.","A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004605-41,0,0,0 2017-004605-41,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"RETROPHIN, INC","A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004605-41,0,0,0 2017-004606-18,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA,Terapia di disassuefazione con metilprednisolone e diazepam ev in pazienti affetti da cefalea cronica con uso eccessivo di sintomatici Terapia di disassuefazione con metilprednisolone e diazepam ev...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004606-18,0,0,0 2017-004608-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Nice,"Open, prospective, single-center study evaluating the efficacy and safety of 0.05% ingénol mebutate (Picato® 500) in the treatment of basal cell carcinoma Study ""PICABAS"" Etude ouverte, prospective...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004608-22,0,0,0 2017-004609-42,1,,,0,0,0,0,0,0,4,0,1,3,0,0,0,0,0,"Clinical Trials and Research Governance (CTRG), University of Oxford",Evaluating the effect of immunisation with group B meningococcal vaccines on meningococcal carriage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004609-42,0,0,0 2017-004610-26,1,,,0,1,0,0,0,1,2,0,1,3,0,0,0,0,0,"Clinical Trials and Research Governance (CTRG), University of Oxford",Evaluating the Long Term Immunogenicity of adenoviral and MVA vectored Ebola vaccine schedules and response to late boosting with AD26.ZEBOV vaccine: an open-label clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004610-26,0,0,0 2017-004611-38,3,2020-03-26,2020-03-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bond Avillion 2 Development LP,"A phase 2b randomized, double-blind, placebo controlled, multi-center 12-week study with an additional 40-week follow-up assessment of efficacy, safety and tolerability of M1095 in subjects with moder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004611-38,0,0,0 2017-004612-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut de Recerca Hospital de la Santa Creu i Sant Pau,EFFICACY OF THE SUPRAESCAPULAR NERVE APPROACH WITH CORTICOIDS ADMINISTRATION VERSUS PULSED RADIOFREQUENCY IN CHRONIC SHOULDER PAIN. DOUBLE BLIND RANDOMIZED CLINICAL TRIAL EFICACIA DEL ABORDAJE DEL ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004612-19,0,0,0 2017-004614-25,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Helsinki Eye Hospital,Adenoviruksen aiheuttaman silmätulehduksen hoito Adenoviruksen aiheuttaman silmätulehduksen hoito,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004614-25,0,0,0 2017-004616-19,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,ASIT biotech S.A.,A dose-ranging clinical study to determine the range of grass pollen allergen (gpCPT+) concentrations to be used in a conjunctival provocation test to grade moderate to severe grass pollen allergic rh...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004616-19,0,0,0 2017-004618-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IRCCS ISTITUTO CLINICO HUMANITAS,Evaluation of CardioprOtection by the use of betablocker Nebivolol in paTients with bReast cancer Or diffuse Large B cell lymphoma undergoing chemotherapy with anthracyclines: a randomized controlled ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004618-24,0,0,0 2017-004624-30,1,2019-11-05,2019-11-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Linköping University,Modulating proinflammatory processes using tocilizumab in major depressive disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004624-30,0,0,0 2017-004625-32,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Sarepta Therapeutics, Inc.","Long-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004625-32,0,0,0 2017-004625-32,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"SAREPTA THERAPEUTICS, INC.","Long-term, Open-label Extension Study for Patients with Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004625-32,0,0,0 2017-004628-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione Italiana Linfomi ONLUS,"Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL) Rituximab, bendamustina e citarabina seguiti da venetoclax (V-RB...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004628-31,0,0,0 2017-004630-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,"A phase II, open label, multicenter trial of Venetoclax (ABT-199/GDC-0199) as single agent in patients with relapsed/refractory BCL-2 positive peripheral T cell lymphoma not otherwise specified (PTCL-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004630-29,0,0,0 2017-004632-11,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004632-11,0,0,0 2017-004632-11,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004632-11,0,0,0 2017-004634-28,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN CISPLATIN-INELIGIBLE PATIENTS WITH LOCALL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004634-28,0,0,0 2017-004637-85,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,The George Institute for Global Health,A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients Een fase III gerandomiseerde gecontroleerde studi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004637-85,0,0,0 2017-004641-25,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITY MEDICAL CENTER GRONINGEN,Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-3) ROTAZIONE DI DIVERSI FARMACI PER LA VALUTAZIONE DEL FARMACO OTTIMALE PER LA RIDUZIONE DELL`ALBUMINURIA (ROTATE 3),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004641-25,0,0,0 2017-004641-25,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen,Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-3) ROTAZIONE DI DIVERSI FARMACI PER LA VALUTAZIONE DEL FARMACO OTTIMALE PER LA RIDUZIONE DELL`ALBUMINURIA (ROTATE 3),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004641-25,0,0,0 2017-004642-20,4,2020-02-25,2020-02-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Idorsia Pharmaceuticals Ltd,"Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography study to assess the efficacy and safety of ACT-541468 in adult and elderly subjects with insomnia disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004642-20,0,0,0 2017-004642-20,4,2020-02-25,2020-02-25,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,IDORSIA PHARMACEUTICALS LTD,"Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography study to assess the efficacy and safety of ACT-541468 in adult and elderly subjects with insomnia disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004642-20,0,0,0 2017-004643-20,8,2020-05-14,2020-05-14,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Idorsia Pharmaceuticals Ltd,"Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography study to assess the efficacy and safety of ACT-541468 in adult and elderly subjects with insomnia disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004643-20,0,0,0 2017-004644-38,11,2021-02-22,2021-02-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Idorsia Pharmaceuticals Ltd,"Multi-center, double-blind, parallel-group, randomized, placebo-controlled, three doses, 40-week extension to studies ID-078A301 and ID-078A302 to assess the long term safety and tolerability of ACT-5...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004644-38,0,0,0 2017-004644-38,11,2021-02-22,2021-02-22,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,IDORSIA PHARMACEUTICALS LTD,"Multi-center, double-blind, parallel-group, randomized, placebo-controlled, three doses, 40-week extension to studies ID-078A301 and ID-078A302 to assess the long term safety and tolerability of ACT-5...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004644-38,0,0,0 2017-004645-24,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge,"A randomized, double blind, controlled mechanistic study of rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004645-24,0,0,0 2017-004647-20,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Cortendo AB,"An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004647-20,0,0,0 2017-004651-23,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Institut Jules Bordet,A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Bre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004651-23,0,0,0 2017-004652-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CONSORZIO ONCOTECH,Second line ERIbulin followed by CApecitabine or the reverse sequence in HER2-negative Metastatic Breast Cancer (MBC) patients: a randomized phase II study – ERICA trial ERIbulina in seconda linea ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004652-35,0,0,0 2017-004655-23,2,2019-07-02,2019-07-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Rottapharm Biotech s.r.l.,"A randomized, double-blind, active- and placebo-controlled, parallel group, single dose, multicentre study to assess the analgesic effect of CR4056 in postoperative dental pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004655-23,0,0,0 2017-004655-23,2,2019-07-02,2019-07-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ROTTAPHARM BIOTECH S.R.L.,"A randomized, double-blind, active- and placebo-controlled, parallel group, single dose, multicentre study to assess the analgesic effect of CR4056 in postoperative dental pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004655-23,0,0,0 2017-004656-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Instituto de Investigación en Ciencias de la Salud Germans Trias i Pujol (IGTP),EVOlocumab in stable Heart Failure with reduced ejection fraction of ischemic etiology: EVO-HF Pilot Evolocumab en insuficiencia cardíaca estable con fracción de eyección reducida de etiología isqu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004656-30,0,0,0 2017-004663-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"A.O.U. Università degli Studi della Campania ""Luigi Vanvitelli""",Geriatric outcomes among older Type 2 diabetic patients treated with DPP4 inhibitors or glinides: focus on cognitive functioning (GOOD-WP3) Outcomes geriatrici in pazienti anziani affetti da diabet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004663-12,0,0,0 2017-004664-36,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,1,Evestra GmbH,"Characterization of ovulation inhibition of a new vaginal delivery system containing trimegestone - an open-label, single-centre study in healthy females of childbearing potential",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004664-36,0,0,0 2017-004667-13,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King's College London,Effect of Iron (III) Isomaltoside 1000 on Cardiac Energetics in Anaemic and Non-anaemic Patients with Symptomatic Chronic Heart Failure and Iron Deficiency: The Ferric Iron in Heart Failure (FERRIC-HF...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004667-13,0,0,0 2017-004667-13,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King’s College Hospital NHS Foundation Trust,Effect of Iron (III) Isomaltoside 1000 on Cardiac Energetics in Anaemic and Non-anaemic Patients with Symptomatic Chronic Heart Failure and Iron Deficiency: The Ferric Iron in Heart Failure (FERRIC-HF...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004667-13,0,0,0 2017-004669-28,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,CENTRO GINECOLOGICO GINFER,A clinical tryal of the utility of ozone in patients with implantation failures Ensayo clínico para investigar la utilidad del ozono en pacientes con fallos de implantación,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004669-28,0,0,0 2017-004675-31,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Center,A randomized Phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on first l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004675-31,0,0,0 2017-004675-31,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ACADEMIC MEDICAL CENTRE AMSTERDAM,A randomized Phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on first l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004675-31,0,0,0 2017-004677-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Dose IndividualizAtion of Beta-lactam and fluOroquinoLone AntiBiotics in ICU patients: to TDM or not to TDM and the effects on Outcome (DIABOLO-study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004677-14,0,0,0 2017-004679-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Immunotherapy in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporation in curative intent: French multicenter phase 2 therapeutic trial Immunothérapie en traitem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004679-29,0,0,0 2017-004684-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Lady Cilento Children's Hospital,Nitric Oxide during Cardio Pulmonary Bypass during surgery for congenital heart defects: A Randomised Controlled Trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004684-12,0,0,0 2017-004686-28,1,2020-04-08,2020-04-08,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Belfast Health and Social Care Trust (BHSCT),"A randomised, double-blind, placebo-controlled trial to evaluate the effect of Epstein-Barr virus suppression in chronic obstructive pulmonary disease (EViSCO trial).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004686-28,0,0,0 2017-004689-93,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004689-93,0,0,0 2017-004690-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,"RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL (REPRAB study – MITO 36) RECHALLENGE CON DOXORUBICINA LIPOSOMALE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004690-14,0,0,0 2017-004692-31,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy with Nivolumab or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004692-31,0,0,0 2017-004692-31,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy with Nivolumab or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004692-31,0,0,0 2017-004699-77,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004699-77,0,0,0 2017-004700-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU SAINT-Etienne,Rotation or Change of Biotherapy After TNF blocker treatment failure for axial Spondyloarthritis: The ROC-SpA study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004700-22,0,0,0 2017-004701-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,"A PILOT, PHASE II STUDY WITH A PROSPECTIVE, RANDOMIZED, CROSS-OVER, PLACEBO-CONTROLLED, DOUBLE-BLIND DESIGN TO ASSESS THE SHORT-TERM EFFECTS OF TOLVAPTAN PLUS PLACEBO VS TOLVAPTAN PLUS OCTREOTIDE LAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004701-40,0,0,0 2017-004702-17,9,2020-05-05,2020-05-05,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma AG,A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004702-17,0,0,0 2017-004702-17,9,2020-05-05,2020-05-05,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS PHARMA AG,A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004702-17,0,0,0 2017-004702-17,9,2020-05-05,2020-05-05,7,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A.",A 12 week randomized open label parallel group multicenter study to evaluate bioequivalence of 20 mg subcutaneous ofatumumab injected by pre-filled syringe or autoinjector in adult RMS patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004702-17,0,0,0 2017-004703-51,18,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novartis Pharma AG,"An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004703-51,0,0,0 2017-004703-51,18,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A","An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004703-51,0,0,0 2017-004707-43,6,2020-08-31,2020-08-31,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,PLEDPHARMA AB,"A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in the a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004707-43,1,0,0 2017-004707-43,6,2020-08-31,2020-08-31,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,PledPharma AB,"A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in the a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004707-43,1,0,0 2017-004709-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Martini Hospital,"An open-label randomised cross-over study to evaluate the albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes Een open-label gerandomiseer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004709-42,0,0,0 2017-004711-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Merja Kokki,Tramadol-paracetamol in spine surgery Tramadoli-parasetamoli-yhdistelmävalmiste selkärankaleikkauspotilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004711-39,0,0,0 2017-004714-25,1,2020-06-02,2020-06-02,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,Fundación PETHEMA,"Phase I-II trial, open and nonrandomized, to assess the role of Idelalisib in patients with acute lymphoblastic leukemia (ALL) relapsed or refractory to other treatments, and in elderly patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004714-25,0,0,0 2017-004715-40,1,2019-02-15,2019-02-15,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Fundació Hospital Universitari Vall d’Hebron-Institut de Recerca (VHIR),An effectiveness and safety study of Varenicline for smoking cessation in hospitalized patients with psychiatric disorders. Estudio de eficacia y seguridad de vareniclina para dejar de fumar en pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004715-40,0,0,0 2017-004729-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Medical Center- Universtíty of Freiburg Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics","Effects of transdermal estrogen on Bone Mass in adolescent female patients with Anorexia nervosa (AN) – a placebo-controlled, double-blind, randomized, interventional study „Wirkung von transdermal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004729-34,0,0,0 2017-004730-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,fédération francophone de cancérologie digestive,Nal-IRI/LV5-FU VERSUS PACLITAXEL AS SECOND-LINE THERAPY IN PATIENTS WITH METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA Nal-IRI/LV5FU VERSUS PACLITAXEL EN DEUXIEME LIGNE DE TRAITEMENT CHEZ LES PAT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004730-28,0,0,0 2017-004731-36,7,,,0,0,1,0,0,0,3,0,1,2,0,0,0,0,1,Sanofi Pasteur Inc.,Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers in Eu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004731-36,0,0,0 2017-004732-11,1,2020-09-28,2020-09-28,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Oxford,Preventing meningitis in young people after infant immunisation: effect of a single meningococcal 4CMenB vaccine booster over 10 years of age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004732-11,0,0,0 2017-004734-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,"Patients on osimertinib with EGFR mutation exon 20, non-T790M in lung cancer. The position-20 trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004734-28,0,0,0 2017-004735-37,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Erasmus University Rotterdam,Can Acetaminophen Ease the Heartbreak of Social Rejection?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004735-37,0,0,0 2017-004737-85,1,2020-09-10,2020-09-10,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Amsterdam UMC, location VUmc",Alkaline Phosphatase to prevent ischemia reperfusion injury in living kidney transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004737-85,0,0,0 2017-004738-27,3,2019-08-19,2022-03-09,2,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Acceleron Pharma Inc.,"A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004738-27,0,0,0 2017-004742-23,6,2021-10-18,2021-10-18,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A Two-Year, Three-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004742-23,1,0,0 2017-004742-23,6,2021-10-18,2021-10-18,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A Two-Year, Three-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004742-23,1,0,0 2017-004742-23,6,2021-10-18,2021-10-18,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A Two-Year, Three-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004742-23,1,0,0 2017-004744-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Tays Sydänkeskus Oy,New truncal nerve blocks for upper torso. Part 1. Serratus anterior plane block (SAPB): Effect on pain and recovery after thoracoskopic lung surgery. Part 2. Subpectoral interfacial plane block (SIP)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004744-38,0,0,0 2017-004745-24,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Merus N.V.,Phase 1/2 dose escalation and cohort expansion study evaluating single-agent MCLA-158 in metastatic colorectal cancer and other advanced solid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004745-24,0,0,0 2017-004746-17,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,"Joint Research Compliance Office, Imperial College London and Imperial College Healthcare NHS Trust",Pain relief with disease modification by Capsaicin 8% patch: a clinical study in Diabetic Peripheral Neuropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004746-17,0,0,0 2017-004750-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FUNDACIÓ LLUITA CONTRA LA SIDA,EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004750-42,0,0,0 2017-004751-23,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,AMC,A Phase 1b-2 study of Mitomycin-C / Capecitabine chemoradiotherapy combined with Ipilumimab and Nivolumab or Nivolumab monotherapy as bladder sparing curative treatment for muscle Invasive bladder Ca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004751-23,0,0,0 2017-004752-34,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Amsterdam University Medical Centers location AMC,Study of pembrolizumab combined with ataluren in Patients with metastatic pMMR and dMMR colorectal cancer adenocarcinomas or metastatic dMMR endometrial carcinoma: the ATAPEMBRO study. Haalbaarheid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004752-34,0,0,0 2017-004753-16,1,2018-07-17,2018-07-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Surgery, Herlev Hospital","Intraperitoneal administration of fosfomycin, metronidazole and molgramostim versus intravenous conventional antibiotics for perforated appendicitis – a pivotal quasi-randomized controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004753-16,0,0,0 2017-004754-42,7,2020-08-31,2020-08-31,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,PLEDPHARMA AB,"A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5 FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004754-42,1,0,0 2017-004754-42,7,2020-08-31,2020-08-31,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,PledPharma AB,"A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5 FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004754-42,1,0,0 2017-004758-40,7,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Genmab A/S,A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004758-40,0,0,0 2017-004758-40,7,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,GENMAB A/S,A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) Monotherapy and in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004758-40,0,0,0 2017-004761-28,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Sarcomas,"A multicenter, phase Ib/II trial of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) Ensayo fase Ib/II multicéntrico de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004761-28,0,0,0 2017-004767-13,1,2019-12-19,2019-12-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Desitin Arzneimittel GmbH,"A randomized, placebo-controlled, multiple dose, double blind, phase IIb, dose guiding trial to explore safety and tolerability of four weeks treatment with sulthiame in patients with moderate to seve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004767-13,0,0,0 2017-004768-37,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"Ruprecht-Karls-University Heidelberg, Medical Faculity, represented by University Hospital Heidelberg",A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) induction and lenalidomide maintenance in patients with newly diagno...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004768-37,0,0,0 2017-004772-65,1,2022-01-10,2022-01-10,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,ParaTech A/S,Probiotic Treatment of Ulcerative Colitis with Trichuris suis ova (TSO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004772-65,0,0,0 2017-004773-13,1,2022-01-21,2022-01-21,1,1,0,0,0,0,2,0,0,1,0,0,0,0,0,Research Center for Emergency Medicine Department of Clinical Medicine Aarhus University,"Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest – A Randomized, Double-Blind, Placebo-Controlled Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004773-13,0,0,0 2017-004775-30,1,,,0,0,0,0,1,1,4,0,0,0,0,0,0,0,0,Kirsi Mikkonen/Helsinki University Hospital,PREDICTION AND PREVENTION OF INFANTILE SPASMS IN HIGH RISK CHILDREN INFANTIILISPASMIOIREYHTYMÄN ENNAKOIMINEN JA ESTÄMINEN RISKILAPSILLA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004775-30,0,0,0 2017-004776-56,1,2018-10-29,2018-10-29,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Arctic Therapeutics ehf,"Phase IIa Biomarker Study to Evaluate the Efficacy, Safety and Tolerability of AT-1 in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) - the AT1-HCCAA study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004776-56,0,0,0 2017-004777-14,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,1,CATALYST PHARMACEUTICALS INC.,Long term safety study of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis patients Studio sulla sicurezza a lungo termine dell’amifampri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004777-14,0,0,0 2017-004780-13,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Greater Glasgow & Clyde,"An open-label, randomised, phase II trial of ruCaparib combined with Nivolumab +/- Ipilimumab to augment response in homologous repair deficient patients with relapsed Ovarian, primary peritoneal and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004780-13,0,0,0 2017-004780-13,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Glasgow,"An open-label, randomised, phase II trial of ruCaparib combined with Nivolumab +/- Ipilimumab to augment response in homologous repair deficient patients with relapsed Ovarian, primary peritoneal and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004780-13,0,0,0 2017-004781-94,2,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,1,"DAIICHI SANKYO, INC.","A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004781-94,0,0,0 2017-004783-35,5,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,OPHTHOTECH CORPORATION,"A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004783-35,0,0,0 2017-004783-35,5,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,IVERIC bio,"A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004783-35,0,0,0 2017-004783-35,5,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"IVERIC bio, Inc.","A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004783-35,0,0,0 2017-004784-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hellenic Cooperative Oncology Group (HeCOG),Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer (SCLC) ΧΡΟΝΙΣΜΕΝΗ ΧΟΡΗΓΗΣΗ AVELUMAB ΣΕ ΣΥΝΔΥΑΣΜΟ ΜΕ ΧΗΜΕΙΟΘΕΡΑΠΕΙΑ ΩΣ ΘΕΡΑΠΕΙΑ Π...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004784-12,0,0,0 2017-004785-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Landspitali University Hospital,Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple myeloma (MM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004785-10,0,0,0 2017-004792-30,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Hellenic Cooperative Oncology Group (HeCOG),Phase Ib-II study of Ramucirumab combined with standard Nab-paclitaxel and Gemcitabine as first-line treatment in patients with advanced pancreatic adenocarcinoma Μελέτη φάσης IΒ-II του συνδυασμού ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004792-30,0,0,0 2017-004793-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),68Ga-DOTATATE PET-CTA imaging for the early detection of progressing coronary atherosclerosis Détection précoce d'une athérosclérose coronaire évolutive avec la TEP avec injection de 68Ga-DOTATATE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004793-34,0,0,0 2017-004794-13,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, 2-part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004794-13,0,1,1 2017-004797-33,1,2019-08-02,2019-08-02,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU Tivoli,The efficacy of continuous ropivacaine wound infusion after cesarean delivery in pain management. L'efficacité analgésique de la ropivacaïne en perfusion continue dans la plaie de césarienne.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004797-33,0,0,0 2017-004800-23,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Birmingham,A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in compl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004800-23,0,0,0 2017-004804-23,1,2019-09-06,2019-09-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Krka, d.d., Novo mesto",The efficacy and safety of a single dose Flebavena® (Diosmin) of 1000 mg per day in patients with chronic venous disease (LIGHTEN-UP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004804-23,0,0,0 2017-004805-42,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Sangamo Therapeutics, Inc.","A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy via Zinc Finger Nuclease (ZFN) mediated targeted integration of SB-FIX in Subjects wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004805-42,0,0,0 2017-004806-17,5,,,0,1,0,1,0,1,1,0,0,2,1,0,0,0,1,Wings Therapeutics Inc.,"A first in human, double-blind, randomized, intra-subject placebo-controlled, multiple dose study of QR-313 evaluating safety, proof of mechanism, preliminary efficacy and systemic exposure in subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004806-17,0,0,0 2017-004806-17,5,,,0,1,0,1,0,1,1,0,0,2,1,0,0,0,1,ProQR Theraputics,"A first in human, double-blind, randomized, intra-subject placebo-controlled, multiple dose study of QR-313 evaluating safety, proof of mechanism, preliminary efficacy and systemic exposure in subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004806-17,0,0,0 2017-004806-17,5,,,0,1,0,1,0,1,1,0,0,2,1,0,0,0,1,ProQR Therapeutics,"A first in human, double-blind, randomized, intra-subject placebo-controlled, multiple dose study of QR-313 evaluating safety, proof of mechanism, preliminary efficacy and systemic exposure in subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004806-17,0,0,0 2017-004807-31,3,2021-12-14,2022-05-04,3,0,0,1,0,1,1,0,0,1,1,0,0,0,1,UCB Biopharma SPRL,"A 2-Stage, Multicenter, Randomized, Placebo-Controlled Study to Evaluate Safety/Tolerability, Pharmacokinetics, and Efficacy of UCB7858 in Adult Kidney Transplant Recipients With Chronic Allograft Inj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004807-31,0,0,0 2017-004807-31,3,2021-12-14,2022-05-04,3,0,0,1,0,1,1,0,0,1,1,0,0,0,1,UCB Biopharma SRL,"A 2-Stage, Multicenter, Randomized, Placebo-Controlled Study to Evaluate Safety/Tolerability, Pharmacokinetics, and Efficacy of UCB7858 in Adult Kidney Transplant Recipients With Chronic Allograft Inj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004807-31,0,0,0 2017-004810-25,4,2021-11-26,2021-11-26,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants with Multiple Myeloma Who Had 3 or More ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004810-25,1,0,0 2017-004810-25,4,2021-11-26,2021-11-26,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants with Multiple Myeloma Who Had 3 or More ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004810-25,1,0,0 2017-004810-25,4,2021-11-26,2021-11-26,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"GlaxoSmithKline, S.A.","A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants with Multiple Myeloma Who Had 3 or More ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004810-25,1,0,0 2017-004814-24,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,INSTITUT CLAUDIUS REGAUD,Pharmacologic interaction between Ifosfamide and Aprepitant in treated patients with soft tissue sarcoma. Interaction Pharmacologique entre Ifosfamide et APrépitant chez les patients traités pour u...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004814-24,0,0,0 2017-004822-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Spanish Lung Cancer Group (SLCG/GECP),"An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer with HRAS mutations Estudio Fase II, abierto para el tratamiento de Tipifarnib en el cáncer de pulmón avan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004822-13,0,0,0 2017-004823-66,1,2021-07-09,2021-07-09,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,Radboudumc,"Early-life stress, the endocannabinoid system, and fear memory extinction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004823-66,0,0,0 2017-004825-34,8,2021-05-13,2021-05-19,8,0,0,0,0,0,3,0,0,1,1,0,1,0,1,"Chengdu Kanghong Biotechnology Co., Ltd.","A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age related Macular Degeneration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004825-34,0,0,0 2017-004826-14,7,2021-05-19,2021-05-19,5,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"CHENGDU KANGHONG BIOTECHNOLOGY CO., LTD.","A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age related Macular Degeneration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004826-14,1,0,0 2017-004826-14,7,2021-05-19,2021-05-19,5,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Chengdu Kanghong Biotechnology Co., Ltd.","A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age related Macular Degeneration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004826-14,1,0,0 2017-004828-29,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,IBSA INSTITUT BIOCHIMIQUE SA,"A pilot, double-blind, randomized, placebo-controlled, dose finding, proof of concept study to evaluate efficacy, safety and tolerability of self- administered subcutaneous diclofenac sodium 25-50-75m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004828-29,0,0,0 2017-004829-33,4,2020-02-21,2020-02-21,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Interventional, open-label, flexible-dose study of vortioxetine on emotional functioning in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004829-33,0,0,0 2017-004829-33,4,2020-02-21,2020-02-21,3,1,0,0,0,0,4,0,0,1,0,0,1,0,1,H. LUNDBECK A/S,"Interventional, open-label, flexible-dose study of vortioxetine on emotional functioning in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004829-33,0,0,0 2017-004830-28,6,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A Phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-conso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004830-28,0,0,0 2017-004830-28,6,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"A Phase II, open-label, single arm study to evaluate the safety, efficacy, and pharmacokinetics of twice daily midostaurin (PKC412) combined with standard chemotherapy and as a single agent post-conso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004830-28,0,0,0 2017-004831-35,1,2021-12-17,2021-12-17,1,0,0,0,0,0,2,0,1,1,0,0,0,0,0,"Dept of Psychiatry, Umeå University Hospital",TACT –Thiamine in Anorexia Clinical Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004831-35,0,0,0 2017-004833-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica,Clinical trial ramdomized for treatment of perineal pain and dyspareunia portpartum through local anesthetic infiltrations vs anesthetic and corticoids Ensayo clínico aleatorizado del tratamiento d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004833-10,0,0,0 2017-004834-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Albert Schweitzer hospital,Influence of dose interval on the pharmacokinetics of both unbound and total fractions of clozapine and norclozapine in psychiatric patients in the Netherlands Wat is de invloed van de doseerfrequ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004834-26,0,0,0 2017-004836-13,7,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Blueprint Medicines Corporation,"An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Masto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004836-13,0,0,0 2017-004836-13,7,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,BLUEPRINT MEDICINES CORPORATION,"An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Masto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004836-13,0,0,0 2017-004846-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University medical centre Maribor,Impact of vitamin D supplementation in patients with multiple sclerosis Vpliv nadomeščanja vitamina D pri bolnikih z multiplo sklerozo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004846-31,0,0,0 2017-004847-19,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Hospices Civils de Lyon,"Bev-IP : Essai de phase II évaluant la tolérance et l’efficacité de l’administration de bevacizumab en périopératoire pour les patients traités pour une carcinose péritonéale d’origine colorectale, pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004847-19,0,0,0 2017-004850-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"VU Medical Center, department of Rheumatology",[18F]Fluoride PET-CT imaging for detection and monitoring of bone formation in spondyloarthritis [18F]Fluoride PET-CT beeldvorming voor het aantonen en monitoren van botformatie bij spondylartriti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004850-40,0,0,0 2017-004851-22,17,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A phase 3 multi-center, long-term extension study investigating the efficacy and safety of Abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004851-22,0,0,0 2017-004851-22,17,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Pfizer Inc.,"A phase 3 multi-center, long-term extension study investigating the efficacy and safety of Abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004851-22,0,0,0 2017-004851-22,17,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,PFIZER INC,"A phase 3 multi-center, long-term extension study investigating the efficacy and safety of Abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004851-22,0,0,0 2017-004851-22,17,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY, 10017.","A phase 3 multi-center, long-term extension study investigating the efficacy and safety of Abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004851-22,0,0,0 2017-004851-22,17,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc, 235 East 42nd Street, New York, NY, 10017","A phase 3 multi-center, long-term extension study investigating the efficacy and safety of Abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004851-22,0,0,0 2017-004852-52,1,2018-11-27,2018-11-27,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Medical University of Vienna, Department of Clinical Pharmacology",The effect of Tetrahydrocannabinol on ocular hemodynamics in healthy subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004852-52,0,0,0 2017-004854-41,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Biogen Idec Research Limited,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004854-41,0,0,0 2017-004854-41,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BIOGEN IDEC RESEARCH LIMITED,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004854-41,0,0,0 2017-004856-41,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,"Regeneration in Cervical Degenerative Myelopathy - a multi-centre, double-blind, randomised, placebo controlled trial assessing the efficacy of Ibudilast as an adjuvant treatment to decompressive surg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004856-41,0,0,0 2017-004859-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital of Monptellier,Treatment of hepatocellular carcinoma on child cirrhosis A/B7 by intra-arterial injection of a Lipiodol and Idarubicin emulsion : a multicentric single-arm phase II study Traitement des carcinomes ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004859-22,0,0,0 2017-004861-29,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,"FOU, Nevroklinikken, Oslo University Hospital -Ullevål","BackToBasic: The effect of Infliximab in patients with chronic low back pain and Modic changes. A randomized, double blind, placebo-controlled, multicenter trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004861-29,0,0,0 2017-004864-37,2,2018-09-21,2018-09-21,1,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Aspen Global Incorporated,"A Multinational, Phase 3, Double-blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of Ovestin in the Treatment of Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004864-37,0,0,0 2017-004865-28,7,2021-11-24,2021-11-24,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A","A phase II open-label, randomized, three-arm, multicenter study of LAG525 given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or seco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004865-28,1,0,0 2017-004865-28,7,2021-11-24,2021-11-24,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A phase II open-label, randomized, three-arm, multicenter study of LAG525 given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or seco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004865-28,1,0,0 2017-004865-28,7,2021-11-24,2021-11-24,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A phase II open-label, randomized, three-arm, multicenter study of LAG525 given in combination with spartalizumab (PDR001), or with spartalizumab and carboplatin, or with carboplatin, as first or seco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004865-28,1,0,0 2017-004866-86,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation of the benefit of adjuvant treatment with hydroxychloroquine to usual medical care for uncomplicated term pregnancy in patients with primary obstetrical antiphospholipid syndrome: randomize...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004866-86,0,0,0 2017-004868-35,8,2019-11-26,2019-11-26,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allecra Therapeutics SAS,"A Phase 3, Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Cefepime- AAI101 Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004868-35,0,0,0 2017-004869-27,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004869-27,0,0,0 2017-004872-76,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medizinische Universtitätsklinik, Kantonsspital Baselland","Reduction of corticosteroid use in outpatient treatment of exacerbated COPD – a randomized, double-blind, non-inferiority study (The “RECUT”-Trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004872-76,0,0,0 2017-004877-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Antwerp University Hospital, Department Thoracic Oncology",Randomised phase II trial of definitive radiotherapy with or without metformin in patients with inoperable stage III non-small cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004877-15,0,0,0 2017-004878-34,2,2020-06-23,2020-06-23,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,"Millendo Therapeutics US, Inc.",A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia Ensayo multicéntrico sin enmascaramiento de ajuste de la dosis ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004878-34,0,0,0 2017-004878-34,2,2020-06-23,2020-06-23,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,"Millendo Therapeutics, Inc.",A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia Ensayo multicéntrico sin enmascaramiento de ajuste de la dosis ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004878-34,0,0,0 2017-004880-11,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Barts Health NHS Trust,"A single site, placebo controlled, double blind randomised clinical trial evaluating the effectiveness of metformin to prevent post-transplant diabetes in a cohort of patients undergoing renal transpl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004880-11,0,0,0 2017-004881-85,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SANT'ANDREA,PET-CT with 68Ga-PSMA as a marker of neoangiogenesis in lung adenocarcinoma La PET-TC con 68Ga-PSMA come marker di neoangiogenesi nell’adenocarcinoma del polmone,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004881-85,0,0,0 2017-004883-37,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,University of Cologne,Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients (NB2015-LR),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004883-37,0,0,0 2017-004886-29,19,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004886-29,0,0,0 2017-004886-29,19,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004886-29,0,0,0 2017-004886-29,19,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Roche Farma SA (Soc unipersonal) que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd,"A SINGLE ARM, OPEN LABEL MULTICENTRE EXTENSION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS PREVIOUSLY ENROLLED IN A F. HOFFMANN-LA ROCHE SPONSORED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004886-29,0,0,0 2017-004889-10,1,2021-11-30,2021-11-30,1,1,0,0,0,0,4,0,0,1,1,1,0,0,0,University Hospital Tuebingen,"Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study Einflu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004889-10,0,0,0 2017-004890-15,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Eustralis Pharmaceuticals Ltd.,"A double-blind placebo-controlled study with an open-label pilot phase, assessing the efficacy, tolerability and safety of EU-C-001 in patients with moderate to severe traumatic brain injury",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004890-15,0,0,0 2017-004893-32,3,2020-08-28,2020-08-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Oryzon Genomics S.A.,"A multicentre, multinational, randomised, double-blind, placebo-controlled, 3-arm, 24-week parallel-group study to evaluate the safety, tolerability and preliminary efficacy of ORY-2001 in patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004893-32,0,0,0 2017-004896-30,6,2018-10-02,2018-10-02,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Active-Controlled, Blinded, Phase III Clinical Trial of BMS- 986213 (Fixed Dose Combination of Relatlimab [anti-LAG-3] and Nivolumab) in Combination with Chemotherapy versus Placebo in C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004896-30,1,0,0 2017-004897-32,7,2019-02-07,2019-02-07,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A phase III, randomized, multicenter, open-label, two-arm study to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous administration of the fixed-dose combination of pertuzumab and tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004897-32,1,0,0 2017-004897-32,7,2019-02-07,2019-02-07,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,"A phase III, randomized, multicenter, open-label, two-arm study to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous administration of the fixed-dose combination of pertuzumab and tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004897-32,1,0,0 2017-004897-32,7,2019-02-07,2019-02-07,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A. (Soc Unip.) que realiza el ensayo en España y que actúa como responsable de F.Hoffmann-La Roche Ltd.,"A phase III, randomized, multicenter, open-label, two-arm study to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous administration of the fixed-dose combination of pertuzumab and tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004897-32,1,0,0 2017-004898-14,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,Sahlgrenska University Hospital,See down below. Maternella serum koncentrationen av magnesium under 24 timmar efter en bolusdos (6g) av magnesiumsulfat vid hotande förtidsbörd,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004898-14,0,0,0 2017-004901-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital District of Southwestern Finland,"A Phase IV Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Elective...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004901-41,0,0,0 2017-004902-16,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,CALLIDITAS THERAPEUTICS AB,"A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004902-16,0,0,0 2017-004902-16,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Calliditas Therapeutics AB,"A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004902-16,0,0,0 2017-004903-33,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Orphazyme A/S,"Phase 2/3 Study of Arimoclomol in Inclusion Body Myositis (IBM) A Randomized, Double-blind, Placebo-Controlled Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004903-33,0,0,0 2017-004909-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Akershus University Hospital Trust (HF),"PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy: A Randomized, Placebo-controlled, Multicenter Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004909-41,0,0,0 2017-004915-38,1,2020-07-02,2020-07-02,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Mont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004915-38,0,0,0 2017-004916-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska Institute,Early intervention and recovery of sexual function in men and women after treatment of rectal cancer–a randomized controlled study with tadalafil compared to standard care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004916-21,0,0,0 2017-004919-39,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Nitto Denko Corporation,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004919-39,0,0,0 2017-004921-33,2,2021-01-07,2021-01-07,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients with Pain Due to Osteoarthritis of the Hip or Knee",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004921-33,1,0,0 2017-004923-63,1,2019-04-22,2019-04-22,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Vicore Pharma AB,"A phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of C21 in patients with Idiop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004923-63,0,0,0 2017-004927-56,1,2019-02-11,2019-02-11,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,"Sierra Oncology, Inc.","A Phase 1b/2, Open-label, Multicenter Dose-ranging Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SRA737 in Combination With Niraparib in Subjects Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004927-56,0,0,0 2017-004929-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"KH Hietzing, Department of Ophthalmology",Effect of Ciclosporin eyedrops on ocular symptoms and optical image quality in patients with primary or secondary Sjögren syndrome Effekt von Ciclosporin Augentropfen auf okuläre Symptomatik und op...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004929-33,0,0,0 2017-004930-27,1,2021-12-16,2021-12-16,1,1,0,0,0,0,2,0,0,1,1,1,0,0,0,Medical University of Vienna,Systems medicine analysis of sarcoidosis by targeting mTOR in a pilot study of sirolimus as treatment in patients with sarcoidosis Eine Pilotstudie zur Untersuchung der Wirksamkeit und Sicherheit v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004930-27,0,0,0 2017-004932-12,6,2020-01-07,2020-07-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are Cand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004932-12,0,0,0 2017-004932-12,6,2020-01-07,2020-07-08,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are Cand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004932-12,0,0,0 2017-004936-13,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,GORTEC,A phase III randomized trial of post-operative adjuvant nivolumab and concomitant chemo-radiotherapy in high-risk patients with resected squamous cell carcinoma of head and neck (SCCHN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004936-13,0,0,0 2017-004944-39,4,2020-02-17,2020-02-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"neopharma Japan Co., Ltd","A 24 Week, Phase IIa, Double blind, Randomized, Parallel Group, Placebo-controlled, Proof of Concept Study to Assess the Efficacy and Safety of Two Doses of 5 Aminolevulinic Acid Co-administered with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004944-39,0,0,0 2017-004958-42,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Momenta Pharmaceuticals, Inc.","A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004958-42,0,0,0 2017-004959-23,2,2020-03-11,2020-03-11,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"neopharma Japan Co., Ltd","A 24-week, Phase IIa, Double blind, Randomized, Parallel Group, Placebo controlled, Exploratory Study to Evaluate the Efficacy and Safety of 5 Aminolevulinic Acid Co-administered with Sodium Ferrous C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004959-23,0,0,0 2017-004963-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Haga Teaching Hospital,Oral Fosfomycin versus Ciprofloxacin for Febrile Urinary Tract Infection in Men: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004963-11,0,0,0 2017-004967-11,1,,,0,0,0,0,0,1,3,0,1,0,0,0,0,0,0,CHU Nantes,Poca,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004967-11,0,0,0 2017-004969-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,A multicenter randomized open-label trial comparing the efficacy and safety of Infliximab versus Cyclophosphamide in Subjects with Idiopathic Refractory Scleritis CIRIS: Cyclophosphamide vs. Inflixim...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004969-27,0,0,0 2017-004971-30,1,2019-03-06,2019-03-06,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"FluGen, Inc","A Phase 2a Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Bris10 M2SR (H3N2 A/Brisbane/10/2007) Vaccine Administered as a Single Intranasal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004971-30,0,0,0 2017-004972-74,5,,,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,AMGEN INC.,"An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004972-74,0,0,0 2017-004972-74,5,,,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,Amgen Inc.,"An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004972-74,0,0,0 2017-004973-15,1,2018-08-23,2018-08-23,1,0,0,0,0,0,4,0,1,1,1,1,1,0,0,Leiden University Medical Center,Reversal through TRH of opioid-induced respiratory depression (OIRD) in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004973-15,0,0,0 2017-004977-15,1,,,0,0,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc,Safety and Immunogenicity of a 3-Dose Schedule of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004977-15,0,1,1 2017-004978-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Clermont-ferrand,Efficacy of Testosterone gel to restore normal serum values of testosterone during the acute phase of critical illness in adult ICU patients. An open-label parallel randomized controlled pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004978-34,0,0,0 2017-004981-85,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Cidara Therapeutics, Inc.","A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Un...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004981-85,0,0,0 2017-004981-85,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Cidara Therapeutics Inc.,"A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Un...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004981-85,0,0,0 2017-004981-85,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"CIDARA THERAPEUTICS, INC","A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Un...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004981-85,0,0,0 2017-004982-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la Formación e Investigación Sanitarias de la Región de Murcia,"Phase IIb prospective, unicentric, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the intravenous infusion of prostaglandins as therapy in patients with non-arteriti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004982-28,0,0,0 2017-004983-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación para la Formación e Investigación Sanitarias de la Región de Murcia,"Multicenter, randomized, prospective study to establish the clinical efficacy and the mechanisms of tolerance following immunosuppression withdrawal in liver transplantation Estudio multicéntrico, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004983-37,0,0,0 2017-004984-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"""Study of maintenance of the efficacy and adverse effects of pharmacological treatments in sex offenders with paraphilia"" ESPARA "" Etude de maintien de l'efficacité et des effets indésirables des t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004984-11,0,0,0 2017-004986-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Medizinische Universität Graz, Klin. Abteilung für Orale Chirurgie und Kieferorthopädie","Effect of systemic antibiotic therapy on postoperative complications in patients undergoing wisdom teeth removal surgery. A double-blind, randomised, placebo-controlled Trial Auswirkung einer syste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004986-28,0,0,0 2017-004997-32,7,2022-07-12,2022-07-12,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Roche Farma, S.A por delegación de Genentech, Inc.",A PHASE II OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF UTTR1147A IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS OR CROHN'S DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004997-32,1,0,0 2017-004997-32,7,2022-07-12,2022-07-12,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Genentech, Inc.",A PHASE II OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF UTTR1147A IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS OR CROHN'S DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004997-32,1,0,0 2017-004997-32,7,2022-07-12,2022-07-12,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"GENENTECH, INC.",A PHASE II OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF UTTR1147A IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS OR CROHN'S DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004997-32,1,0,0 2017-004998-13,7,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,1,LEO PHARMA A/S,Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and =120 kg body weight Regime di dosaggio di brod...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004998-13,0,0,0 2017-004998-13,7,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,1,LEO Pharma A/S,Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and =120 kg body weight Regime di dosaggio di brod...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-004998-13,0,0,0 2017-005005-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UZ Brussel,"Initiation of ovarian stimulation with recombinant-human FSH (Bemfola®) in the late follicular phase, a randomised controlled study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005005-12,0,0,0 2017-005006-35,7,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"Rhythm Pharmaceuticals, Inc.",Long Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 receptor i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005006-35,0,0,0 2017-005008-88,1,2019-03-11,2019-03-11,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Medicinsk Forskning, Regionshospitalet Holstebro, Hospitalsenheden Vest",Test of reliability of PET-rubidium82-scan in determination of renal blood flow in healthy subjects Test af pålidelighed af PET-rubidium-82-scanning til bestemmelse af renal blod flow hos raske fo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005008-88,0,0,0 2017-005010-59,1,2019-05-20,2019-05-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Theragnostics Ltd,"A Phase II, Open-label Study to Assess Safety and Clinical Utility of 68Ga-THP-PSMA PET/CT in Patients with High Risk Primary Prostate Cancer or Biochemical Recurrence after Radical treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005010-59,0,0,0 2017-005011-14,4,2022-05-05,2022-05-05,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GE Healthcare Ltd. and its Affiliates,"A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (F 18) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005011-14,1,0,0 2017-005015-13,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Clatterbridge Cancer Centre NHS Foundation Trust,NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005015-13,0,0,0 2017-005017-31,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST,DENOSUMAB IN EBV RELATED NASOPHARYNGEAL CARCINOMA (NPC) AS A MODEL FOR RANK-MEDIATED IMMUNOLOGIC MODULATION OF VIRUS-RELATED TUMOURS – DERN STUDY DENOSUMAB NEL CARCINOMA NASOFARINGEO (NPC) ASSOCIAT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005017-31,0,0,0 2017-005018-76,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Hospitals Leuven,"An open-label, single arm, prospective, multi-center, tandem two stage designed, phase II study to evaluate the efficacy of Fulvestrant in women with recurrent/metastatic estrogen receptor positive gy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005018-76,0,0,0 2017-005019-15,10,2021-05-30,2021-05-30,1,0,1,0,0,0,2,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005019-15,1,0,0 2017-005019-15,10,2021-05-30,2021-05-30,1,0,1,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005019-15,1,0,0 2017-005019-15,10,2021-05-30,2021-05-30,1,0,1,0,0,0,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005019-15,1,0,0 2017-005021-21,1,2019-11-29,2019-11-29,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University of Edinburgh,A feasibility study investigating pravastatin for the prevention of preterm birth in women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005021-21,0,0,0 2017-005021-21,1,2019-11-29,2019-11-29,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,NHS Lothian,A feasibility study investigating pravastatin for the prevention of preterm birth in women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005021-21,0,0,0 2017-005022-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,Oxytocin in mr guided focused ultrasound treatment (MRI-HIFU),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005022-38,0,0,0 2017-005025-20,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"UCB Biosciences, Inc.","An open-label, multicenter study to assess the safety of certolizumab pegol in children and adolescents with active Crohn's Disease who completed C87035 or who were terminated from C87035 when the stu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005025-20,0,1,1 2017-005026-37,8,2021-11-01,2021-11-01,7,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005026-37,1,0,0 2017-005027-25,3,2021-10-20,2021-10-20,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005027-25,1,0,0 2017-005027-25,3,2021-10-20,2021-10-20,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005027-25,1,0,0 2017-005028-11,13,2022-04-01,2022-04-01,9,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005028-11,1,0,0 2017-005028-11,13,2022-04-01,2022-04-01,9,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Eli Lilly and Company,"A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005028-11,1,0,0 2017-005029-19,13,2022-03-31,2022-03-31,10,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarctio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005029-19,1,0,0 2017-005029-19,13,2022-03-31,2022-03-31,10,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarctio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005029-19,1,0,0 2017-005031-17,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Bayer HealthCare LLC,"A Double-Blind, Randomized, Crossover Study to Assess Menstrual Cramp Pain Associated with Primary Dysmenorrhea",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005031-17,0,1,1 2017-005032-42,1,2020-12-15,2020-12-15,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty",Effect of Liraglutide on the Metabolic Profile in Patients with Type 2 Diabetes and Cardiovascular Disease Effekt von Liraglutid auf das Stoffwechselprofil in Patienten mit Typ 2 Diabetes und kardi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005032-42,0,0,0 2017-005033-22,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Liverpool,"In patients taking Protease Inhibitors does switching to a Bictegravir, Tenofovir Alafenamide and Emtricitabine combination, reduce cardiovascular risk: An open-label, randomised, serial CT pilot stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005033-22,0,0,0 2017-005034-36,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,IRCCS ISTITUTO CLINICO HUMANITAS,An Italian database-based randomized controlled trial with Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) Studio randomizzato controllato con rituximab ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005034-36,0,0,0 2017-005038-53,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina Y Salud (FIMABIS),"Randomized double-blind, placebo-controlled study evaluate the efficacy and mechanisms involved in immunotherapy Sublingual specifies with Pru p 3 (Pru p 3-ITSL) in patients with allergy to nsLTP with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005038-53,0,0,0 2017-005047-32,7,2022-06-22,2022-06-22,6,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Hookipa Biotech GmbH,"A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Seropos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005047-32,0,0,0 2017-005047-32,7,2022-06-22,2022-06-22,6,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Hookipa Biotech AG,"A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Seropos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005047-32,0,0,0 2017-005049-67,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Bayer HealthCare LLC,"A Randomized, Double-Blind, Placebo-Controlled Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005049-67,0,1,1 2017-005050-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,A.O. OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI,"Effects of Selenium and cholecalciferol on hyperthyroidism due to Graves' disease treated with methimazole: a randomized, clinical, open label, pilot trial Studio clinico randomizzato pilota in ape...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005050-11,0,0,0 2017-005053-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,José Luis Morales Rull. Institut de Recerca Biomèdica de Lleida (IRBLleida),Effect on the functional capacity of treatment with intravenous iron carboxymaltose or oral iron sucrosomial in patients with heart failure with depressed left ventricular ejection fraction and iron d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005053-37,0,0,0 2017-005057-36,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,GLG Pharma S.A.,"A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability and Recommended Phase II Dose (RP2D) of GLG-801 in patients with Advanced Solid Tumors (Phase I); and safety, tolerability and antica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005057-36,0,0,0 2017-005059-10,1,2021-03-03,2021-03-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Ghent University Hospital,"Multicentric, double-blind, placebo controlled clinical trial with 5-hydroxytryptophan (5-HTP) in patients with inflammatory bowel disease in clinical and biologic remission: effect on fatigue scores",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005059-10,0,0,0 2017-005060-18,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,Manchester University NHS Foundation Trust,"The Role of Uric Acid Metabolism in Pathogenesis of Anaphylaxis: the Effect of Allopurinol on Experimentally-induced Allergic Reaction to Peanut in Peanut Allergic Adults- a randomised, double-blind p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005060-18,0,0,0 2017-005062-21,1,,,0,0,0,1,0,0,1,0,1,1,1,1,0,1,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK 1654 in Pre-Term and Full-Term Infants Estudio de dosis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005062-21,0,0,0 2017-005065-47,1,2019-08-21,2019-08-21,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,TikoMed AB,"A single-centre, open single-arm study where the safety, tolerability and efficacy of subcutaneously administered ILB will be evaluated in patients with Amyotrophic Lateral Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005065-47,0,0,0 2017-005066-22,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,2,University of Oxford,HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005066-22,0,0,0 2017-005066-22,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,2,The Medicines Company,HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005066-22,0,0,0 2017-005067-40,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ETOP IBCSG Partners Foundation,"Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for postmenopau...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005067-40,0,0,0 2017-005067-40,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INTERNATIONAL BREAST CANCER STUDY GROUP,"Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for postmenopau...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005067-40,0,0,0 2017-005068-16,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,University Hospital of Aarhus,Measurement of Acetylsalicylic acid Concentration and Effect - MACE Måling af Acetylsalicylsyres Koncentration og Effekt - MAKE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005068-16,0,0,0 2017-005074-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasme Hospital,Minimal optimal dose of Sugammadex during ambulatory surgery in dentistry Dose minimale optimale de sugammadex lors d’une chirurgie ambulatoire de stomatologie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005074-19,0,0,0 2017-005075-91,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Copenhagen University Hospital Rigshospitalet,"LOW DOSE THROMBOLYSIS, ULTRASOUND ASSISTED THROMBOLYSIS OR HEPARIN FOR INTERMEDIATE HIGH RISK PULMONARY EMBOLISM LAV-DOSIS TROMBOLYSE, KATETERBASERET TROMBOLYSE ELLER HEPARIN TIL INTERMEDIÆR-HØJ RI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005075-91,0,0,0 2017-005076-26,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Seattle Genetics, Inc.",Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005076-26,0,0,0 2017-005076-26,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Seagen, Inc.",Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005076-26,0,0,0 2017-005077-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Instituto de Investigación Sanitaria INCLIVA,Betablockers Withdrawal in Patients with Heart Failure with Preserved Ejection Fraction and Chronotropic Incompetence: Effect on Functional Capacity and life quality Retirada del Tratamiento Betabl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005077-39,0,0,0 2017-005079-21,1,2020-02-28,2020-02-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lofarma S.p.A.,"A Prospective, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Phase-II Study for the Efficacy and Safety of LAIS® House Dust Mites Sublingual Tablets in Patients with Mite-Induced Allergi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005079-21,0,0,0 2017-005080-40,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Freeline Therapeutics Limited,"An Open-Label, Multicentre, Long-Term Follow-Up Study to Investigate the Safety and Durability of Response Following Dosing of a Novel Adeno-Associated Viral Vector (FLT180a) in Patients with Haemophi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005080-40,0,0,0 2017-005081-22,2,2021-04-14,2021-04-14,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"MedImmune Limited, a wholly owned subsidiary of AstraZeneca","An Exploratory Phase 2, Randomised, Double-blind, Placebo-controlled, and Open-label Active Comparator Study to Evaluate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005081-22,1,0,0 2017-005082-47,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Sydän- ja keuhkokeskus, HUS",Repolarization study in LQTS patients Repolarisaatiotutkimus LQTS potilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005082-47,0,0,0 2017-005091-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Skåne University Hospital,Clonidine for analgesia to preterm infants during neonatal intensive care – a prospective pharmacokinetic/pharmacodynamic/pharmacogenetic observational study. Cohort 2 in The SANNI project.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005091-26,0,0,0 2017-005093-19,4,2019-04-29,2019-04-29,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Akros Pharma Inc.,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JTT-251 Administered for 24 Weeks to Participants with Heart Failure with Reduced Ejec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005093-19,0,0,0 2017-005097-19,4,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Oslo University Hospital,Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005097-19,0,0,0 2017-005100-99,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University and University Hospital,Pharmacoepidemiology and pharmacogenetics of antidepressant treatment for depressive disorders (PEGAD) Masennuslääkehoidon farmakoepidemiologia ja -genetiikka (PEGAD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005100-99,0,0,0 2017-005103-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA DI PADOVA,A PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CLENBUTEROL IN PATIENTS WITH SPINAL AND BULBAR MUSCULAR ATROPHY (SBMA) TRIAL CLINICO CONTROLLATO CON PLACEBO PER VALUTARE EFFICACIA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005103-27,0,0,0 2017-005104-10,7,2021-09-03,2021-09-03,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A (Soc Uni) que realiza el ensayo en España y que actúa como representante de F.Hoffmann La-Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB (RO6867461) IN PATIENTS WITH DIABETIC MACULAR EDEMA (YOSEMITE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005104-10,1,0,0 2017-005104-10,7,2021-09-03,2021-09-03,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F.Hoffmann La-Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB (RO6867461) IN PATIENTS WITH DIABETIC MACULAR EDEMA (YOSEMITE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005104-10,1,0,0 2017-005104-10,7,2021-09-03,2021-09-03,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB (RO6867461) IN PATIENTS WITH DIABETIC MACULAR EDEMA (YOSEMITE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005104-10,1,0,0 2017-005105-12,8,2021-08-23,2021-08-23,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A(Soc uni.) que realiza el ensayo en España y que actua como representante de F.Hoffmann La-Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB (RO6867461) IN PATIENTS WITH DIABETIC MACULAR EDEMA (RHINE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005105-12,1,0,0 2017-005105-12,8,2021-08-23,2021-08-23,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F.Hoffmann La-Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB (RO6867461) IN PATIENTS WITH DIABETIC MACULAR EDEMA (RHINE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005105-12,1,0,0 2017-005105-12,8,2021-08-23,2021-08-23,1,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB (RO6867461) IN PATIENTS WITH DIABETIC MACULAR EDEMA (RHINE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005105-12,1,0,0 2017-005106-35,1,2022-01-13,2022-01-13,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Clínica Universidad de Navarra/Universidad de Navarra,PHASE I - II STUDY OF INTRATUMORAL URELUMAB COMBINED WITH NIVOLUMAB IN PATIENTS WITH SOLID TUMORS ESTUDIO FASE I - II DE URELUMAB INTRATUMORAL COMBINADO CON NIVOLUMAB EN PACIENTES CON TUMORES SÓLID...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005106-35,0,0,0 2017-005108-89,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,VALL D'HEBRON INSTITUTE OF ONCOLOGY (VHIO),"Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumors.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005108-89,0,0,0 2017-005108-89,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Vall d’Hebron Institute of Oncology (VHIO),"Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumors.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005108-89,0,0,0 2017-005109-11,2,2021-06-01,2021-06-01,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Incyte Corporation,An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005109-11,0,0,0 2017-005110-58,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Medical Centre Leeuwarden,Efficacy of a predefined vitamin D dosing regimen in vitamin D-insufficient multiple myeloma patients. Effectiviteit van een vooraf gedefinieerd vitamine D-doseringsschema bij patiënten met vitamin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005110-58,0,0,0 2017-005111-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Kepler Universitätsklinikum, Medcampus III, Klinik für Interne 2","First-line Treatment of Helicobacter pylori with the Probiotic Lactobacillus casei rhamnosus LCR35 Alone or in Combination with a Levofloxacin-based Sequential Therapy: A Randomized, Placebo-controlle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005111-14,0,0,0 2017-005115-13,4,2018-06-05,2018-07-11,2,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Ionis Pharmaceuticals, Inc.",A Non-Interventional Study to Monitor the Survival Status of Patients that Discontinued from ISIS 420915-CS2 or ISIS 420915-CS3,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005115-13,1,0,0 2017-005117-31,5,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Wockhardt Bio AG,"A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem followed by Optional Oral Therapy in the Treatment of Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005117-31,0,0,0 2017-005118-74,2,2021-05-05,2021-05-05,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, MULTICENTER, RANDOMIZED STUDY TO COMPARE THE EFFICACY OF VENETOCLAX PLUS FULVESTRANT VERSUS FULVESTRANT IN WOMEN WITH ESTROGEN RECEPTOR−POSITIVE, HER2−NEGATIVE LOCALLY ADVANCED OR METASTAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005118-74,1,0,0 2017-005120-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Amsterdam UMC, Location VUmc",Ulipristal versus standard surgical treatment in symptomatic uterine fibroids Ulipristal versus standaard chirurgie in de behandeling van symptomatische uterine myomen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005120-16,0,0,0 2017-005121-21,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Universitätsklinikum Essen,Exploring the theragnostic value of osimertinib in EGFR-mutated lung cancer (THEROS) - A multicentric phase II study in patients with TKI-resistant EGFR-mutated lung cancer exhibiting early metabolic ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005121-21,0,0,0 2017-005124-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC Cancer Institute,Therapeutic Drug Monitoring guided tamoxifen dosing: a feasibility study in patients with hormone positive breast cancer Therapeutic Drug Monitoring gestuurde tamoxifen dosering: een haalbaarheidss...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005124-24,0,0,0 2017-005125-20,10,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005125-20,0,0,0 2017-005125-20,10,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005125-20,0,0,0 2017-005126-37,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005126-37,0,0,0 2017-005126-37,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005126-37,0,0,0 2017-005128-12,1,2019-07-05,2019-07-05,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,GlaxoSmithKline Biologicals SA,"A Phase II, Randomized, Open-label, Multicenter Study to Assess the Immunogenicity and Safety of GSK Meningococcal MenABCWY Vaccine, and of GSK Meningococcal Group B and MenACWY Conjugate Vaccines Adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005128-12,0,0,0 2017-005129-18,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Università degli Studi Aldo Moro,"Multi-centre, randomised, open label pragmatic trial to compare the effectiveness and safety of interferon beta-1a (IFN-beta-1a) weekly i.m. and glatiramer-acetate (GA) in paediatric patients affected...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005129-18,0,0,0 2017-005130-27,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,Low-dose interleukin-2 for the reduction of vascular inflammation in Acute Coronary Syndromes (IVORY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005130-27,0,0,0 2017-005136-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina Y Salud (FIMABIS),SGLT-2 Inhibition and Cardiovascular Disease. Metabolomics Study of Potential Factors Involved in Cardioprotection Inhibición de SGLT-2 y Enfermedad Cardiovascular. Estudio Metabolómico de Potencia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005136-41,0,0,0 2017-005137-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with Activated-B-Cell (A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005137-23,0,0,0 2017-005140-16,2,2019-10-22,2019-10-22,1,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Apellis Pharmaceuticals,"A Phase IIa, Open Label, Multiple Dose Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005140-16,0,0,0 2017-005142-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNICANCER,PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer Immunothérapies et Irradiation concomitante sur des sites tumoraux variés dans les cancer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005142-29,0,0,0 2017-005143-33,6,2021-03-16,2021-03-16,5,1,1,0,0,0,3,0,0,2,0,0,0,0,1,LEO Pharma A/S,"A randomised, double-blind, placebo-controlled, parallel-group, multi-centre trial to evaluate the efficacy, safety, and tolerability of tralokinumab monotherapy in adolescent subjects with moderate-t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005143-33,1,0,0 2017-005144-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Forteza Gil,Comparative study of two types of cardioplegia during cardiac surgery in the adult patient Estudio comparativo de dos tipos de cardioplejia durante la cirugía cardiaca en el paciente adulto,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005144-14,0,0,0 2017-005146-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sahlgrenska universitetssjukhuset,See below PREMEDICINERINGSSTUDIEN Blodkoncentrationen av per os tillfört Oxykodon mäts hos 20 kvinnor som sövs och opereras på en dagkirurgisk enhet. Dessutom mäts smärtan efter operationen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005146-30,0,0,0 2017-005149-64,3,2019-11-21,2019-12-13,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Minerva Neurosciences, Inc","A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (5.0 mg or 2.5 mg) of MIN-117 in Adult Patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005149-64,0,0,0 2017-005151-83,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Charité Universitätsmedizin Berlin,INDUCTION AND MAINTENANCE OF MUCOSAL HEALING IN CROHN’S DISEASE WITH USTEKINUMAB IN CLINICAL PRACTICE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005151-83,0,0,0 2017-005153-37,6,,,0,0,1,0,0,0,2,0,0,2,1,0,0,0,1,La Jolla Pharmaceutical Company,"A Randomised, Placebo-controlled, Double-blind, Multicentre Efficacy and Safety Study of LJPC-501 in Paediatric Patients > 2 to 17 Years of Age with Catecholamine-Resistant Hypotension Associated with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005153-37,0,0,0 2017-005154-11,1,2022-03-31,2022-03-31,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Spanish Lung Cancer Group (SLCG/GECP),Phase II non-randomized study of Atezolizumab (MPDL3280A) in combination with Carboplatin Plus Pemetrexed in patients who are chemotherapy-naïve and have stage IV non-squamous non-small cell lung canc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005154-11,0,0,0 2017-005158-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Ruprecht-Karls-University Heidelberg Medical Faculty, University Hospital",TEAM-Trial: Targeting Epigenetic therapy resistance in AML with Bortezomib: A multi-centre matched threshold crossing phase II approach TEAM-Studie: Überwindung der epigenetischen Chemotherapie-Res...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005158-12,0,0,0 2017-005160-18,3,2019-11-18,2019-11-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Redwood Pharma AB,"A Phase II, multicentre, randomised, placebo-controlled, double-masked trial of RP101 ophthalmic formulation versus vehicle in post-menopausal women with moderate to severe dry eye syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005160-18,0,0,0 2017-005162-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHRU de Nancy,A multi-center randomized phase II study comparing corticosteroids alone versus corticosteroids and extracorporal photopheresis (ECP) as first-line treatment of standard risk Grade II acute graft-vers...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005162-22,0,0,0 2017-005165-49,4,2022-08-02,2022-08-02,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Pluristem Ltd.,"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005165-49,1,0,0 2017-005166-22,1,2019-08-08,2019-08-08,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,UK für Anästhesiologie und allgemeine Intensivmedizin,Effect of acetazolamide on the incidence of high altitude pulmonary edema at 4559 m Effekt von Acetazolamid auf die Inzidenz des Höhenlungenödems in 4559 m Höhe,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005166-22,0,0,0 2017-005169-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU DE POITIERS,"An open label, multicenter, randomized trial of 2% chlorhexidine-70% isopropanol vs 5% povidone iodine-69% ethanol for skin antisepsis in reducing surgical-site infection after cardiac surgery",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005169-33,0,0,0 2017-005170-19,2,,,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,Renishaw Neuro Solutions Ltd.,A Long-Term Follow-up Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Implanted with the DDS and/or Who Received Treatment in the Main Study and/or Extension Study Långtidsuppföl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005170-19,0,0,0 2017-005175-78,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Prestige BioPharma Limited,"A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005175-78,0,0,0 2017-005175-78,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Prestige BioPharma Pte Ltd,"A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005175-78,0,0,0 2017-005179-21,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,"Department of infectious Diseases, Odense University Hospital","Four weeks treatment for chronic hepatitis C in patients under 50 years of age with no significant liver fibrosis Fire ugers behandling af kronisk leverbetændelse type C hos personer under 50 år, u...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005179-21,0,0,0 2017-005180-40,1,2018-08-23,2018-08-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Aarhus University Hospital,"The effect of the popliteal plexus block on postoperative pain after total knee arthroplasty - a randomized, controlled, double-blinded study Effekten af plexus popliteus blokade på postoperative s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005180-40,0,0,0 2017-005197-19,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO,"Inhibitor development in previously untreated patients with severe haemophilia A, first treated with plasma-derived factor VIII and then switched to recombinant product: an international, multicentre,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005197-19,0,0,0 2017-005198-38,1,2021-05-03,2021-05-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Odense University Hospital,"Tetra-hydro-cannabinol, cannabidiol and their combination for the treatment of peripheral neuropathic pain. A randomised placebo-controlled trial. Tetra-hydro-cannabinol, cannabidiol og deres kombi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005198-38,0,0,0 2017-005200-96,1,2021-01-03,2021-01-03,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Associate Professor, Consultant Jens Børglum","Improving perioperative pain management for laparoscopic surgery due to colon cancer using the ultrasound-guided Transmuscular Quadratus Lumborum block. A double blind, randomized, placebo controlled ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2017-005200-96,0,0,0 2018-000001-23,3,2021-03-30,2021-03-30,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bionorica SE,"A phase III, multi-centre, randomised, double-blind, placebo-controlled, parallel-group clinical trial to investigate the efficacy and safety of BX-1 for the symptomatic relief of spasticity in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000001-23,0,0,0 2018-000003-16,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King's College London,Prevention of Gestational Diabetes in Obese Pregnant Women; a Proof of Principle Study Targeting Early Pregnancy Intervention to Women at Risk,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000003-16,0,0,0 2018-000003-16,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Guy's and St Thomas' NHS Foundation Trust,Prevention of Gestational Diabetes in Obese Pregnant Women; a Proof of Principle Study Targeting Early Pregnancy Intervention to Women at Risk,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000003-16,0,0,0 2018-000004-42,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Clatterbridge Cancer Centre NHS Foundation Trust,TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE/TAE for patients with intermediate stage HCC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000004-42,0,0,0 2018-000005-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Twente,Ghrelin treatment of comatose patients after cardiac arrest: A clinical trial to promote cerebral recovery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000005-23,0,0,0 2018-000010-38,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,Department of Clinical Pharmacology/Medical University of Vienna,Development of intravascular microdialysis as a tool for therapeutic drug monitoring in children.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000010-38,0,0,0 2018-000011-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Avoiding tacrolimus under- and overexposure by using a new dosing algorithm for renal transplant recipients Het voorkomen van onder- en overdosering van tacrolimus met een nieuw doseer algoritme,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000011-25,0,0,0 2018-000013-20,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,KU Leuven,Placebo-controlled crossover study of the ability of Naloxegol to reverse opioid effect on colonic motor patterns in healthy volunteers Placebo-gecontrolleerde crossover studie over de mogelijkheid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000013-20,0,0,0 2018-000014-38,1,2019-07-29,2019-07-29,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Therapix Biosciences Ltd.,"A Randomized, Double-Blind, Placebo Controlled Proof of Concept Study to Evaluate the Safety, Tolerability and Efficacy of Daily Oral THX-110 in Treating Adults with Tourette Syndrome (“ENTOURAGE”)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000014-38,0,0,0 2018-000016-19,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Universitair ziekenhuis Brussel,Randomized comparative double blind prospective study with hyperbaric prilocaine 2 % and 3 different doses of sufentanil for elective caesarean section.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000016-19,0,0,0 2018-000017-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitäts-Herzzentrum Freiburg • Bad Krozingen,Antiplatelet effect of acetylsalicylic acid in patients after cardiac surgery: Impact of dipyrone (metamizole) Postoperativer thrombozytenhemmender Effekt von Acetylsalicylsäure bei herzchirurgis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000017-20,0,0,0 2018-000019-26,1,2019-02-04,2019-02-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MedImmune Limited, a wholly owned subsidiary of AstraZeneca","A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Subjects with Type 2 Diabetes Mellitus and Renal Impairment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000019-26,0,0,0 2018-000022-66,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Hansa Medical AB,"A Randomized, Open-Label, Multi-Centre, Active Control Study Investigating the Efficacy and Safety of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibody-M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000022-66,0,0,0 2018-000022-66,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Hansa Biopharma,"A Randomized, Open-Label, Multi-Centre, Active Control Study Investigating the Efficacy and Safety of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibody-M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000022-66,0,0,0 2018-000023-13,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Dova Pharmaceuticals,"A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000023-13,0,0,0 2018-000023-13,2,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Sobi, Inc","A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000023-13,0,0,0 2018-000026-54,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medicinkliniken, Sjukhuset Lidköping","A comparison of sedatives used during gastroscopy, alfentanil vs midazolam En jämförelse mellan lugnande läkemedel vid gastroskopi, alfenatnil vs midazolam",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000026-54,0,0,0 2018-000027-14,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Imperial College London,"A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment Chronic Active Antibody Mediated Rejection in Renal Transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000027-14,0,0,0 2018-000028-33,1,2019-08-09,2019-08-09,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Ipsen Pharma,"A non-randomised, phase II study to evaluate the optimal uptake time of 68Ga-OPS202 as a sstr2 positive PET imaging agent in subjects with newly diagnosed breast cancer. (Sub-study of Master Protocol ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000028-33,0,0,0 2018-000029-29,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,VU University Medical Center,Extra energy for hearts with a genetic defect: ENERGY trial Extra energie voor harten met een genetische afwijking: ENERGY trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000029-29,0,0,0 2018-000031-28,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A randomized, active-controlled, patient and investigator-masked, multiple dose proof-of-concept study of intravitreal LKA651 in patients with diabetic macular edema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000031-28,0,0,0 2018-000031-28,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, active-controlled, patient and investigator-masked, multiple dose proof-of-concept study of intravitreal LKA651 in patients with diabetic macular edema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000031-28,0,0,0 2018-000034-36,1,2019-10-30,2019-10-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cutanea Life Sciences,"A phase 2, randomized, double blind, vehicle controlled, parallel group study to explore the efficacy, pharmacodynamics and safety of topical ionic contra-viral therapy (ICVT), comprised of digoxin an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000034-36,0,0,0 2018-000036-96,5,,,0,0,0,0,1,0,2,0,0,3,0,0,0,0,1,"Ablative Solutions, Inc.","A Phase 2, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects with Hypertension, in the Absence of Antihypertensive Medications",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000036-96,0,0,0 2018-000037-13,1,2019-07-24,2019-07-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Paratek Pharma, LLC, a wholly-owned subsidiary of Paratek Pharmaceuticals, Inc.","A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of IV or IV/PO Omadacycline and IV/PO Levofloxacin in the Treatment of Adults with Acute Pyelonephritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000037-13,0,0,0 2018-000039-28,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,TRANSGENE S.A.,A Phase I/IIa study of TG6002 (VV TK-RR-FCU1) administered by intravenous (IV) infusions in combination with oral flucytosine (5-FC) in patients with advanced gastro-intestinal (GI) tumors Estudio ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000039-28,0,0,0 2018-000040-26,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator's Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000040-26,0,0,0 2018-000040-26,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator's Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000040-26,0,0,0 2018-000045-40,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Universitair ziekenhuis Brussel,The effects of nitrous oxide on human vision,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000045-40,0,0,0 2018-000046-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud University Medical Center,18F-PSMA PET/CT for visualization of glioblastoma multiforme 18F-PSMA PET/CT voor visualisatie van glioblastoma multiforme,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000046-19,0,0,0 2018-000047-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) adult AML and high risk myelodysplasia (M...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000047-31,0,0,0 2018-000048-24,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Sahlgrenska University Hospital/VGR,"A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER TRIAL ON THE EFFICACY OF VARENICLINE AND BUPROPION, IN COMBINATION AND ALONE, FOR THE TREATMENT OF ALCOHOL USE DISORDER En randomiserad dubb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000048-24,0,0,0 2018-000050-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Skåne University Hospital, Department of Oncology",Irinotecan-based triplet (FOLFOXIRI) as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000050-22,0,0,0 2018-000053-53,2,2020-11-16,2020-11-16,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,European Organisation for Research and Treatment of Cancer,Phase II trial in inoperable œsophageal cancer evaluating the feasibility of the combination of definitive chemoradiation with the immune checkpoint blockers Nivolumab +/- Ipilimumab (CRUCIAL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000053-53,0,0,0 2018-000058-22,3,,,0,0,0,1,0,2,1,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000058-22,0,0,0 2018-000058-22,3,,,0,0,0,1,0,2,1,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000058-22,0,0,0 2018-000059-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU DE TOULOUSE,Comparison of short infusion versus prolonged infusion of ceftolozane-tazobactam among patients with ventilator associated-pneumonia to Pseudomonas aeruginosa in intensive care units Comparaison de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000059-42,0,0,0 2018-000060-29,3,2019-06-20,2019-06-20,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Allergan Ltd.,"A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Monotherapy in Patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000060-29,0,0,0 2018-000062-11,3,2020-06-25,2020-06-25,2,1,0,1,0,1,1,0,0,1,1,0,0,0,1,Incyte Corporation,"An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000062-11,0,0,0 2018-000063-88,2,2019-06-20,2019-06-20,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Allergan Ltd.,"A Randomized, Double-blind, Placebo- and Active- controlled, Multicenter Study of Rapastinel as Monotherapy in Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000063-88,1,0,0 2018-000064-28,5,2019-06-20,2019-06-20,5,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Allergan Ltd.,"A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel in the Prevention of Relapse in Patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000064-28,0,0,0 2018-000065-37,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Oxford,Randomised controlled trial of nasal decongestants versus placebo to prolong treatment free periods from continuous positive airway pressure therapy in mild to moderate obstructive sleep apnoea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000065-37,0,0,0 2018-000066-11,4,2021-11-04,2021-11-11,4,1,0,0,0,0,3,0,0,1,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized, Double-blind, Active Comparator-controlled, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Recipients of Allogeneic Hematopoietic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000066-11,0,0,0 2018-000070-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Aarhus University Hospital,IMPROVE Intervention Trial: Implementing non-invasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer IMPROVE IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000070-30,0,0,0 2018-000075-33,14,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Omeros Corporation,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000075-33,0,0,0 2018-000075-33,14,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,OMEROS CORPORATION,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000075-33,0,0,0 2018-000080-85,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU CAEN,Pilot study of the pharmacokinetic profile of paracetamol subcutaneously versus intravenously in patients receiving palliative care Etude pilote du profil pharmacocinétique du paracétamol par voie ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000080-85,0,0,0 2018-000089-12,1,2018-06-10,2018-06-10,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Institut for Klinisk Medicin, Aarhus Universitet",Effect and safety of the iliopsoas plane block in healthy volunteers Effekt og sikkerhed af iliopsoas plane blok hos raske forsøgspersoner,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000089-12,0,0,0 2018-000094-76,2,2022-01-17,2022-01-17,2,0,0,0,0,0,2,0,0,1,1,0,0,0,1,"InCarda Therapeutics, Inc.","A prospective, randomized, multicenter study of flecainide acetate oral inhalation solution in single and repeat dose regimens for acute conversion to sinus rhythm (SR) in subjects with recent onset o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000094-76,0,0,0 2018-000095-15,1,,,0,0,0,0,0,3,2,0,0,3,0,0,0,0,0,University of Oxford,"A Phase II, Open Label, Randomised Study of Ipilimumab With Temozolomide Versus Temozolomide Alone after Surgery and Chemoradiotherapy in Patients with Recently Diagnosed Glioblastoma (IPI-GLIO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000095-15,0,0,0 2018-000096-32,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,Centre Oscar Lambret,Metro-PD1: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors or lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000096-32,0,0,0 2018-000097-30,1,2021-04-20,2021-04-20,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Herlev and Gentofte Hospital,"Efficacy of brodalumab in patients with psoriasis with failure of other anti-IL-17 treatments Effekt af brodalumab hos patienter, som har haft svigt af anti-IL-17A-behandling",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000097-30,0,0,0 2018-000098-61,1,2018-07-13,2018-07-13,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Galapagos NV,"A Phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered combination of GLPG3067, GLPG222...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000098-61,0,0,0 2018-000100-41,1,2020-01-14,2020-01-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Abide Therapeutics, Inc.","A Randomized, Placebo-Controlled Study of ABX-1431 in Adult Patients with Tourette Syndrome or Chronic Motor Tic Disorder Estudio aleatorizado y controlado con placebo de ABX-1431 en pacientes adul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000100-41,0,0,0 2018-000102-33,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Hospices Civils de Lyon,Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in children: a multicenter European randomized controlled trial Efficacité des immunoglobulines humaines normales (IGH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000102-33,0,0,0 2018-000103-16,3,2020-04-23,2020-04-23,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,SUNOVION PHARMACEUTICALS INC.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SEP-4199 for the Treatment of Major Depressive Episode Associated with Bipolar I Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000103-16,0,0,0 2018-000105-23,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,UZ Brussel,"Oral dydrogesterone (OD) versus micronized vaginal progesterone (MVP) for luteal phase support (LPS) in IVF/ICSI: pharmacokinetics and the impact on the endometrium, the microbiota of the genital trac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000105-23,0,0,0 2018-000106-32,1,2021-01-21,2021-01-21,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,"Windtree Therapeutics, Inc.","A Multinational, Multicenter, Masked, Randomized, Parallel Group, Controlled Study to Assess the Safety and Efficacy of Lucinactant for Inhalation versus nCPAP alone in Preterm Neonates 26 to 32 Weeks...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000106-32,0,0,0 2018-000108-41,3,2020-06-23,2020-06-23,2,1,0,1,0,0,1,0,0,1,1,1,0,0,1,"Sunesis Pharmaceuticals, Inc.","A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS 062, in Patients With B-Lymphoid Malignancies Studio di fase 1b/2, di ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000108-41,0,0,0 2018-000109-22,1,2018-12-02,2018-12-02,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Fakultní nemocnice Hradec Králové,Monitoring of efficacy of antibiotic prophylaxis in thoracic surgery Monitorace účinnosti antibiotické profylaxe u hrudní chirurgie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000109-22,0,0,0 2018-000112-21,1,2020-01-17,2020-01-17,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"Ruprecht-Karls-Universität Heidelberg, Medizinische Fakultät, vertreten durch das Universitätsklinikum Heidelberg",Prospective Window of opportunity trial 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000112-21,0,0,0 2018-000120-33,3,2022-07-15,2022-07-15,1,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"Agenus Inc.,","A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination with AGEN2034 in Subjects with Metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000120-33,1,0,0 2018-000121-32,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,Janssen-Cilag International NV,"A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000121-32,0,0,0 2018-000124-34,1,2021-02-02,2021-02-02,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Pfizer Inc, 253 East 42nd Street, New York, NY 10017","A Phase 1b/2, study to evaluate safety and clinical activity of avelumab in combination with binimetinib with or without talazoparib in patients with locally advanced or metastatic RAS-Mutant Solid Tu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000124-34,0,0,0 2018-000125-30,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Peloton Therapeutics, Inc., a Wholly-Owned Subsidiary of Merck & Co., Inc.",An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000125-30,0,0,0 2018-000125-30,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,PELOTON THERAPEUTICS INC,An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000125-30,0,0,0 2018-000125-30,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Peloton Therapeutics, Inc.",An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000125-30,0,0,0 2018-000126-55,1,2019-05-03,2019-05-03,1,1,0,1,0,1,1,0,1,1,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,A Phase 1/2 Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000126-55,0,0,0 2018-000127-14,5,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,Heidelberg University Hospital,INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000127-14,0,0,0 2018-000128-33,2,2019-08-01,2019-08-01,2,1,0,0,1,0,2,0,1,1,0,0,1,0,1,Bayer AG,"Multi-center, randomized, comparator-controlled, single-blind, parallel-group study to investigate the pharmacodynamics, pharmacokinetics and safety of an intrauterine system (BAY 987443) with three d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000128-33,0,0,0 2018-000131-27,1,,,0,1,0,0,1,0,3,0,0,3,0,0,0,0,2,University of Edinburgh,Heme arginate in transplantation - a multi-centre blinded parallel-group randomised trial of heme arginate versus placebo to reduce delayed graft function in kidney transplant recipients. (The HOT 2 T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000131-27,0,0,0 2018-000131-27,1,,,0,1,0,0,1,0,3,0,0,3,0,0,0,0,2,NHS Lothian,Heme arginate in transplantation - a multi-centre blinded parallel-group randomised trial of heme arginate versus placebo to reduce delayed graft function in kidney transplant recipients. (The HOT 2 T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000131-27,0,0,0 2018-000133-12,3,2020-06-06,2020-06-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Angelini S.p.A.,"Efficacy and safety of Fixed-Dose Combination (FDC) products containing trazodone and gabapentin in patients affected by painful diabetic neuropathy: randomized, controlled, dose finding study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000133-12,0,0,0 2018-000137-13,8,2020-12-18,2020-12-21,5,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Orphazyme A/S,"A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotrophic Lateral Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000137-13,1,0,0 2018-000137-13,8,2020-12-18,2020-12-21,5,0,0,0,0,1,3,0,0,2,0,0,0,0,1,ORPHAZYME APS,"A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotrophic Lateral Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000137-13,1,0,0 2018-000138-37,1,2019-02-06,2019-02-06,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Laboratorios Farmalíder S.A.,PHASE III CLINICAL TRIAL FOR THE EVALUATION OF THE EFFICACY AND SAFETY OF A PARACETAMOL + IBUPROFEN COMBINATION IN PATIENTS WITH PRIMARY DYSMENORRHOEA Ensayo clínico en fase III para evaluar la efi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000138-37,0,0,0 2018-000139-28,4,2022-04-12,2022-04-12,1,0,0,1,0,0,1,0,0,2,0,0,0,0,1,IO Biotech Aps,"An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination with Pembrolizumab, with or without Chemotherapy, as First-line Treatment for Patients with M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000139-28,1,0,0 2018-000141-39,1,2020-02-07,2020-02-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Merete Hædersdal,Tolerabililty of laser-assisted cisplatin+5-fluorouracil― an exploratory proof of concept study of topical combination chemotherapy for basal cell carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000141-39,0,0,0 2018-000142-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,Feasibility and pharmacodynamics of subcutaneously given combination of dexmedetomidine and ketamine infusion in ALS patients receiving palliative care Ihonalaisesti annostellun deksmedetomidiini-k...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000142-18,0,0,0 2018-000144-25,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King's College Hospital NHS Foundation Trust,"Multicentre prospective double blinded randomised controlled trial of the effect of intravenous iron supplementation and exercise training in Iron deficient, but not anaemic, patients with Chronic Kid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000144-25,0,0,0 2018-000145-39,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Actelion Pharmaceuticals Ltd,"A prospective, multicenter, open-label, single-arm, Phase 2 study to investigate the safety, tolerability and pharmacokinetics of selexipag in children with pulmonary arterial hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000145-39,0,1,0 2018-000148-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Norwegian University of Science and Technology,Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimer’s disease: the ExPlas Study Trent plasma som behandling for tidlig Alzheimers sykdom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000148-24,0,0,0 2018-000150-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Turku University Hospital,Intravesical instillation therapy with bacillus Calmette-Guérin (BCG) and sequential BCG and electromotive Mitomycin-C (EMDA-MCC) in patients with high risk non-muscle-invasive bladder carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000150-22,0,0,0 2018-000151-40,3,,,0,0,0,0,2,0,3,0,0,0,0,0,0,0,1,Surgimab,"Multicenter, semi-blinded, randomized, controlled, parallel arms clinical study on the performance of SGM-101, a fluorochrome-labeled anti- carcino-embryonic antigen (CEA) monoclonal antibody, for the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000151-40,0,0,0 2018-000151-40,3,,,0,0,0,0,2,0,3,0,0,0,0,0,0,0,1,SURGIMAB,"Multicenter, semi-blinded, randomized, controlled, parallel arms clinical study on the performance of SGM-101, a fluorochrome-labeled anti- carcino-embryonic antigen (CEA) monoclonal antibody, for the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000151-40,0,0,0 2018-000155-41,1,,,0,0,0,0,0,1,2,0,1,0,0,0,0,0,0,"Department of Medical and Clinical Genetics, University of Helsinki",The effect of vitamin C on the gene methylation load in patients with TET2 mutations C-vitamiinin vaikutus geenien metylaatiokuormaan TET2 geenimutaation kantajilla.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000155-41,0,0,0 2018-000156-18,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Ultragenyx Pharmaceutical, Inc.",A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Late-O...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000156-18,0,0,0 2018-000157-41,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The University of Liverpool,NEO21-RS: A phase II randomised study of the cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with oestrogen suppression therapy versus oestrogen suppression therapy alone as neoadjuva...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000157-41,0,0,0 2018-000160-28,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,1,CATALYST PHARMACEUTICALS INC.,Long term safety study of amifampridine phosphate in ambulatory patients with Spinal Muscular Atrophy (SMA) type 3 Long term safety study of amifampridine phosphate in ambulatory patients with Spin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000160-28,0,0,0 2018-000163-89,1,2020-11-10,2020-11-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Cognition Therapeutics, Inc.",A Pilot Study to Evaluate the Effect of CT1812 Treatment on Aβ Oligomer Displacement into CSF in Subjects with Mild to Moderate Alzheimer's Disease Followed by a Six-Month Open Label Extension of a Si...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000163-89,0,0,0 2018-000168-27,13,2021-09-16,2021-09-16,10,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"COMBI-APlus: Open-label, phase IIIb study of dabrafenib in COMBInation with trametinib in the Adjuvant treatment of stage III BRAF V600 mutation-positive melanoma after complete resection to evaluate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000168-27,1,0,0 2018-000168-27,13,2021-09-16,2021-09-16,10,1,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"COMBI-APlus: Open-label, phase IIIb study of dabrafenib in COMBInation with trametinib in the Adjuvant treatment of stage III BRAF V600 mutation-positive melanoma after complete resection to evaluate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000168-27,1,0,0 2018-000170-30,8,2022-03-23,2022-03-24,4,0,0,0,0,2,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000170-30,1,0,0 2018-000170-30,8,2022-03-23,2022-03-24,4,0,0,0,0,2,3,0,0,2,0,0,0,0,1,ASTRAZENECA AB,"A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients with Severe Eosinophilic Asthma on H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000170-30,1,0,0 2018-000174-29,6,2020-04-02,2020-04-02,5,1,0,0,1,0,3,0,0,1,1,0,1,0,1,PAION UK LIMITED,Phase III confirmatory efficacy and safety trial of remimazolam (CNS7056) compared with propofol for intravenous anaesthesia during elective surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000174-29,0,0,0 2018-000174-29,6,2020-04-02,2020-04-02,5,1,0,0,1,0,3,0,0,1,1,0,1,0,1,PAION UK Limited,Phase III confirmatory efficacy and safety trial of remimazolam (CNS7056) compared with propofol for intravenous anaesthesia during elective surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000174-29,0,0,0 2018-000175-33,5,2020-05-22,2020-05-22,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AstraZeneca AB,"A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy with Sodium Zirconium Cyc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000175-33,0,0,0 2018-000176-15,1,2020-02-04,2020-02-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Izana Bioscience Limited,"A phase 2a proof of concept, randomised, double-blind, placebo-controlled study to evaluate the safety/tolerability and efficacy of 4 subcutaneous injections of namilumab (150 mg) given over 10 weeks ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000176-15,0,0,0 2018-000177-72,7,2022-09-09,2022-09-09,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ViiV Healthcare UK Limited,"A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infecte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000177-72,1,0,0 2018-000177-72,7,2022-09-09,2022-09-09,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,VIIV HEALTHCARE UK LIMITED,"A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infecte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000177-72,1,0,0 2018-000178-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación e Innovación Biosanitaria de Asturias (FINBA),Metabolic Dysfunctions Associated with Pharmacological Treatment of Schizophrenia Alteraciones metabólicas asociadas al tratamiento farmacológico de la esquizofrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000178-31,0,0,0 2018-000183-28,10,2019-04-24,2019-04-24,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,VERTEX PHARMACEUTICALS INCORPORATED,"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000183-28,0,0,0 2018-000183-28,10,2019-04-24,2019-04-24,9,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000183-28,0,0,0 2018-000184-89,3,2018-12-12,2018-12-28,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000184-89,0,0,0 2018-000185-11,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000185-11,0,0,0 2018-000185-11,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,VERTEX PHARMACEUTICALS INCORPORATED,"A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000185-11,0,0,0 2018-000186-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut Bergonié,Phase III trial investigating the potential benefit of intensified peri-operative Chemotherapy in patients with in high-risk CINSARC patients with resectable soft-tissue SARComas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000186-36,0,0,0 2018-000187-28,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Hospital Ulm,Pembrolizumab in Marginal Zone Lymphoma - a multicenter open label single-arm phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000187-28,0,0,0 2018-000187-28,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Universitätsklinikum Ulm,Pembrolizumab in Marginal Zone Lymphoma - a multicenter open label single-arm phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000187-28,0,0,0 2018-000189-12,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Bispebjerg Hospital,"Treatment of photodamaged skin of the décolleté with fractional laser, radio-frequency microneedling, and photodynamic therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000189-12,0,0,0 2018-000191-15,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,IRICYS- Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal,Effectiveness and Safety on Cardiac Frecuency Control With Ivabradine on the Cardiogenic Shock. (ES-FISH) Eficacia y seguridad del control de frecuencia cardíaca mediante Ivabradina en el shock car...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000191-15,0,0,0 2018-000192-33,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Sangamo Therapeutics, Inc.","A Phase 1/2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects with Mucopolysaccharidosis II (MPS II)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000192-33,0,0,0 2018-000195-15,4,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Lysogene SA,"An Open-Label, Single-Arm, Multicenter Study of Intracerebral Administration of Adeno-Associated Viral Vectors Serotype rh10 Carrying the Human N-sulfoglucosamine sulfohydrolase (SGSH) cDNA for the Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000195-15,0,0,0 2018-000196-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HU DE GIRONA DR JOSEP TRUETA,"PILOT STUDY ON THE USE OF HYDROCORTISONE, VITAMIN C AND THYAMINE IN PATIENT WITH SEPSIS AND SEPTIC SHOCK. ESTUDIO PILOTO SOBRE EL USO DE HIDROCORTISONA, VITAMINA C Y TIAMINA EN PACIENTE CON SEPSIS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000196-32,0,0,0 2018-000197-30,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The University of Liverpool,Sodium Valproate for Epigenetic Reprogramming in the Management of High Risk Oral Epithelial Dysplasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000197-30,0,0,0 2018-000201-24,1,2020-11-30,2020-11-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Bernardino Clavo - Hospital Dr. Negrín,"Effectiveness and cost-effectiveness of Ozone therapy in patients with ischemic heart disease refractory to medical and surgical treatment: Randomized, triple-blind clinical trial. Efectividad y co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000201-24,0,0,0 2018-000202-37,3,2022-04-07,2022-04-07,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Kyowa Kirin Pharmaceutical Development Limited,"A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000202-37,1,0,0 2018-000202-37,3,2022-04-07,2022-04-07,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Kyowa Kirin Pharmaceutical Development Ltd,"A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000202-37,1,0,0 2018-000203-16,1,2019-08-22,2019-08-22,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,SOM Biotech,"Phase IIa, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3335 in Huntington`s disease (HD) patients with chorea movements. Estudio de fase IIa, doble ciego, al...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000203-16,0,0,0 2018-000205-22,1,2021-02-01,2021-02-01,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Celyad Onclogy SA,"An open-label, Phase I/II study to assess the safety and clinical activity of NKR-2 treatment administration after a non-myeloablative preconditioning chemotherapy in relapse/refractory acute myeloid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000205-22,0,0,0 2018-000206-28,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Sangamo Therapeutics, Inc.","A Phase 1/2, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects with Mucopolysaccharidosis I (MPS I)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000206-28,0,0,0 2018-000211-25,1,2019-11-16,2019-11-16,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Themis Bioscience GmbH,"Observer blinded, randomised study to investigate safety, tolerability and long-term immunogenicity of different dose regimens and formulations of MV-CHIK in healthy volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000211-25,0,0,0 2018-000212-25,10,2019-12-16,2020-02-06,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A 52-week, multicenter, randomized, double-blind, double-dummy, parallel-group, placebo-controlled study of fevipiprant once daily plus standard-of-care (SoC) for reduction of systemic corticosteroids...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000212-25,0,0,0 2018-000212-25,10,2019-12-16,2020-02-06,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Novartis Farmacéutica S.A.,"A 52-week, multicenter, randomized, double-blind, double-dummy, parallel-group, placebo-controlled study of fevipiprant once daily plus standard-of-care (SoC) for reduction of systemic corticosteroids...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000212-25,0,0,0 2018-000215-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundacion SEIMC-GESIDA,"A single-arm, open-label and multicentre phase IV trial to evaluate the immunogenicity of the nonavalent vaccine against human papillomavirus in HIV-infected men who have sex with men. GESIDA 10017 St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000215-24,0,0,0 2018-000217-21,1,2019-11-29,2019-11-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Aarhus University Hospital,Do use of torniquete reduce the impact of the antibiotic treatment during orthopedic treatment? Kan brug af blodtomhed mindske effekten af antibiotika-behandlingen ved ortopædkirurgiske operationer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000217-21,0,0,0 2018-000220-33,1,2021-05-25,2021-05-25,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Novartis Pharma GmbH,"A randomized, double-blind, active-controlled study to assess the effect of sacubitril/valsartan compared with enalapril to improve erectile function in patients with heart failure with reduced ejecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000220-33,0,0,0 2018-000221-31,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Daiichi Sankyo Inc.,"A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER2-positive, unresectable and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000221-31,0,0,0 2018-000222-61,6,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,Daiichi Sankyo Inc.,"A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000222-61,0,0,0 2018-000222-61,6,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,DAIICHI SANKYO INC.,"A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000222-61,0,0,0 2018-000224-34,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000224-34,0,0,0 2018-000224-34,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase III, Randomized, Double-blind Trial Comparing Trastuzumab Plus Chemotherapy and Pembrolizumab With Trastuzumab Plus Chemotherapy and Placebo as First-line Treatment in Participants With HER2 P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000224-34,0,0,0 2018-000226-58,8,2020-08-20,2020-08-20,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A Phase 3, Randomized, Double Blind, Placebo Controlled, Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000226-58,0,0,0 2018-000226-58,8,2020-08-20,2020-08-20,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Pfizer Inc.,"A Phase 3, Randomized, Double Blind, Placebo Controlled, Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (AS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000226-58,0,0,0 2018-000228-33,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,CHU Saint-Pierre,"Prospective longitudinal study on immunogenicity, induction of cellular immune responses and safety of vaccination against HPV with the 9valent vaccine in HIV-positive women Etude longitudinale et ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000228-33,0,0,0 2018-000230-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS,"Phase II study on the combination of trabectedin and olaparib for advanced, platinum-resistant ovarian/tubes and primary of peritoneum cancer. - TROOPS trial (TRabectedin plus Olaparib in advanced Ova...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000230-35,0,0,0 2018-000231-27,14,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,Novo Nordisk A/S,A trial comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® in children with growth hormone deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000231-27,0,0,0 2018-000231-27,14,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,NOVO NORDISK. S.P.A.,A trial comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® in children with growth hormone deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000231-27,0,0,0 2018-000232-10,12,2020-03-05,2020-03-05,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,NOVO NORDISK. S.P.A.,A dose-finding trial evaluating the effect and safety of once-weekly treatment of somapacitan compared to daily Norditropin® in children with short stature born small for gestational age with no catch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000232-10,1,0,0 2018-000232-10,12,2020-03-05,2020-03-05,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Novo Nordisk A/S,A dose-finding trial evaluating the effect and safety of once-weekly treatment of somapacitan compared to daily Norditropin® in children with short stature born small for gestational age with no catch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000232-10,1,0,0 2018-000236-97,2,2021-12-25,2021-12-25,1,1,0,0,0,0,3,0,0,1,1,0,0,0,1,Tanvex Biologics Corp.,A double-blinded extension study to provide adjuvant treatment with single agent Herceptin® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer fo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000236-97,0,0,0 2018-000237-12,4,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Be...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000237-12,0,0,0 2018-000240-26,1,2020-06-01,2020-06-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Pulmocide Ltd,"An open-label, pilot study to assess safety, tolerability, pharmacokinetics and effects of inhaled PC945 in the pre-emptive treatment of Aspergillus fumigatus colonisation in lung transplant recipient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000240-26,0,0,0 2018-000241-39,12,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,Idorsia Pharmaceuticals Ltd,"A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical deterioration due to de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000241-39,0,0,0 2018-000241-39,12,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,IDORSIA PHARMACEUTICALS LTD,"A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical deterioration due to de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000241-39,0,0,0 2018-000242-19,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University Hospitals Southampton NHS Trust,Change in nutritional state and postoperative outcome following preoperative introduction of nutritional supplements and pancreatic enzymes in patients undergoing Whipple’s procedure for pancreatic ca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000242-19,0,0,0 2018-000243-87,1,2020-06-01,2020-06-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Pulmocide Ltd,"An open-label study to assess the safety, pharmacokinetics and pharmacodynamics of inhaled PC945 in adult Cystic Fibrosis (CF) patients with persistent pulmonary Aspergillus fumigatus infection.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000243-87,0,0,0 2018-000244-26,1,2020-06-01,2020-06-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Pulmocide Ltd,"A double-blind, placebo-controlled study to assess the effects of inhaled PC945 in the treatment of culture-positive Aspergillus or Candida fungal bronchitis in subjects with moderate to severe asthma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000244-26,0,0,0 2018-000245-39,4,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"BeiGene Ltd., c/o BeiGene USA Inc.","A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti−PD1 Antibody) Compared with Docetaxel in Patients with Non−Small Cell Lung Cancer Who Have...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000245-39,0,0,0 2018-000246-19,2,2019-05-16,2019-05-16,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Asahi Kasei Pharma America Corporation,"SCARLET-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Sepsis and Coagulopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000246-19,0,0,0 2018-000249-38,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Manchester,Phase II trial of interleukin-1 receptor antagonist in intracerebral haemorrhage: BLOcking the Cytokine IL-1 in ICH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000249-38,0,0,0 2018-000254-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Essen,Window of opportunity study of preoperative immunotherapy with atezolizumab (Tecentriq®) or FAP-interleukin 2v (IL2v) (RO6874281) in local squamous cell carcinoma of the head and neck (the PIONEER tri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000254-21,0,0,0 2018-000257-45,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University Hospital Essen,"A phase Ib/II single-arm study evaluating the safety and efficacy of combined immunotherapy with mFOLFOX6, bevacizumab and atezolizumab in advanced-stage biliary cancer Eine einarmige Phase Ib/II S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000257-45,0,0,0 2018-000261-36,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,HOLOSTEM TERAPIE AVANZATE S.R.L.,"MULTICENTRE, OPEN-LABEL, UNCONTROLLED, PIVOTAL CLINICAL TRIAL TO CONFIRM THE EFFICACY AND SAFETY OF AUTOLOGOUS FIBRIN-CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED FOR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000261-36,0,0,0 2018-000263-92,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU CAEN,"Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: a multicenter randomized, double-blind study Spironolactone et fibrillation atriale survenant après chir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000263-92,0,0,0 2018-000264-28,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Celgene Corporation,"A Phase 2, Multi-Cohort, Open-Label, Multi-center Study to Evaluate the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000264-28,0,0,0 2018-000264-28,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,CELGENE CORPORATION,"A Phase 2, Multi-Cohort, Open-Label, Multi-center Study to Evaluate the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000264-28,0,0,0 2018-000265-37,1,2020-09-08,2020-09-08,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"BeiGene, Ltd.","Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-PD-L1 Monoclonal Antibody BGB-A333 Alone and in Combination with Anti-PD-1 Monoclonal An...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000265-37,0,0,0 2018-000268-26,6,2021-09-30,2021-09-30,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,AbbVie Deutschland,An Extension Study of ABBV-8E12 in Early Alzheimer's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000268-26,1,0,0 2018-000268-26,6,2021-09-30,2021-09-30,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,An Extension Study of ABBV-8E12 in Early Alzheimer's Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000268-26,1,0,0 2018-000269-36,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,JORGE ORDUÑA VALLS,"Randomized clinical trial to evaluate the efficacy of two techniques against chronic hip pain: cooled radiofrequency over sensitive nerves of the hip, compared to intraarticular injection of steroids ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000269-36,0,0,0 2018-000271-32,7,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Pierre Fabre Médicament,"Phase II, open-label, single arm, multicenter study of encorafenib, binimetinib plus cetuximab in subjects with previously untreated BRAF V600E -mutant Metastatic Colorectal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000271-32,0,0,0 2018-000279-34,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,"Research, Enterprise & Development (RED), University of Bristol",Mistletoe And Breast Cancer (MAB): A pilot study for a randomized double-blind controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000279-34,0,0,0 2018-000280-81,3,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Genentech, Inc","A PHASE II, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY OF MTIG7192A, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB IN CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000280-81,0,0,0 2018-000280-81,3,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Roche Farma, S.A por delegación de Genentech, Inc.","A PHASE II, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY OF MTIG7192A, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB IN CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000280-81,0,0,0 2018-000282-37,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,DIPARTIMENTO DI NEUROSCIENZE SALUTE MENTALE E ORGANI DI SENSO - NESMOS - SAPIENZA UNIVERSITÀ DI ROMA,"Riluzole (Glentek) in patients with SpinoCerebellar Ataxia type 7: a randomized, double-blind, placebo-controlled pilot trial with a lead in phase Studio pilota randomizzato, doppio cieco, controll...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000282-37,0,0,0 2018-000283-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Potential effect of proton-pump inhibitor on angiogenic markers in preeclampsia: a pilot study Effect van protonpompremmers op angiogene markers in preeclampsie: een pilot studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000283-28,0,0,0 2018-000284-93,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Mapi Pharma Ltd.,"A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing forms of Multiple Sclerosis (RMS) to assess the efficacy, safety ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000284-93,0,0,0 2018-000285-10,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,CellCentric Ltd,"An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination, in patients with advanced solid/metastatic tumours.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000285-10,0,0,0 2018-000286-36,2,2018-12-19,2018-12-19,2,1,0,0,2,0,3,0,0,1,0,0,1,0,1,NTC s.r.l.,"An international, multicenter, randomized, blinded-assessor, parallel-group clinical study comparing eye drops of combined LEvofloxAcin + DExamethasone foR 7 days followed by dexamethasone alone for a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000286-36,0,0,0 2018-000286-36,2,2018-12-19,2018-12-19,2,1,0,0,2,0,3,0,0,1,0,0,1,0,1,NTC SRL,"An international, multicenter, randomized, blinded-assessor, parallel-group clinical study comparing eye drops of combined LEvofloxAcin + DExamethasone foR 7 days followed by dexamethasone alone for a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000286-36,0,0,0 2018-000287-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Karolinska Institutet,"Immediate versus delayed insertion of intrauterine contraception at the time of medical abortion An open-label, randomized, multicenter study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000287-29,0,0,0 2018-000294-78,1,2021-02-12,2021-02-12,1,1,0,0,1,0,2,0,0,1,1,1,1,0,1,Nektr Technologies,"A Randomized, Single-Blinded, Comparative Study of Mycosinate and Curanail in the Treatment of Fungal Nail Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000294-78,0,0,0 2018-000298-65,9,2019-11-01,2019-11-04,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,"A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve phYsical functioning in activitie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000298-65,0,0,0 2018-000298-65,9,2019-11-01,2019-11-04,8,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BAYER AG,"A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve phYsical functioning in activitie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000298-65,0,0,0 2018-000299-13,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Novadip Biosciences,A prospective multicentre single-arm study in adults to evaluate the safety and preliminary efficacy of the autologous 3D osteogenic implant NVD-003 for bone reconstruction for the treatment of recalc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000299-13,0,0,0 2018-000302-39,1,2018-09-25,2018-09-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Fundació Lluita contra la SIDA,Bictegravir concentrations and antiviral activity in cerebrospinal fluid in HIV-1 Infected individuals Concentraciones de bictegravir y actividad antiviral en el líquido cefalorraquídeo en personas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000302-39,0,0,0 2018-000305-23,3,2020-11-26,2020-11-26,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Boston Pharmaceuticals, Inc.",A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000305-23,0,0,0 2018-000307-17,1,2019-12-04,2019-12-04,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Hospices Civils de Lyon,Microcirculatory and Macrocirculatory Effects of Landiolol on Postoperative Atrial Fibrillation: a Randomized Study. MMELPOAF study. Effets Microcirculatoires et Macrocirculatoires du Landiolol da...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000307-17,0,0,0 2018-000308-41,5,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Milestone Pharmaceuticals Inc.,"Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000308-41,0,0,0 2018-000309-21,1,2019-07-16,2019-07-16,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,"Inovio Pharmaceuticals, Inc.","An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination with Atezolizumab in Subjects with Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma Ensayo abierto ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000309-21,0,0,0 2018-000312-24,6,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"BeiGene, Ltd","A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) plus Platinum and Fluoropyrimidine Versus Placebo plus Platinum and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000312-24,0,0,0 2018-000312-24,6,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"BEIGENE USA, INC.","A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) plus Platinum and Fluoropyrimidine Versus Placebo plus Platinum and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000312-24,0,0,0 2018-000314-38,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,CHRU de NANCY,"Efficiency of IV dexamethasone compared to placebo, administrated after a lower limb blockade is done, on the post operative pain in children : a controled, randomised, double blind study. Efficaci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000314-38,0,0,0 2018-000318-39,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Birmingham,A phase II trial assessing nivolumab in strong class II expressing microsatellite stable colorectal cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000318-39,0,0,0 2018-000322-63,4,2020-01-17,2020-01-17,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"An investigational trial comparing the efficacy and safety of once weekly NNC0148-0287 C (insulin 287) versus once daily insulin glargine, both in combination with metformin, with or without DPP-4 inh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000322-63,0,0,0 2018-000326-58,7,2018-11-23,2018-11-23,4,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Aimmune Therapeutics, Inc.","Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adolescents: Real-World, Open-Label, Quality of Life Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000326-58,1,0,0 2018-000329-29,4,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,CSL BEHRING GMBH,"A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft-versus-host disease in patients rec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000329-29,0,0,0 2018-000329-29,4,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,CSL Behring LLC,"A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft-versus-host disease in patients rec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000329-29,0,0,0 2018-000331-27,4,2019-12-03,2019-12-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"AnaptysBio, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects with Moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000331-27,0,0,0 2018-000331-27,4,2019-12-03,2019-12-03,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AnaptysBio Inc,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects with Moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000331-27,0,0,0 2018-000334-35,10,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim RCV GmbH&Co. KG,"An open label, long term safety trial of BI 655130 (Spesolimab) treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000334-35,0,0,0 2018-000334-35,10,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An open label, long term safety trial of BI 655130 (Spesolimab) treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000334-35,0,0,0 2018-000334-35,10,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim bv Netherlands,"An open label, long term safety trial of BI 655130 (Spesolimab) treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000334-35,0,0,0 2018-000334-35,10,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,SCS Boehringer Ingelheim Comm. V,"An open label, long term safety trial of BI 655130 (Spesolimab) treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000334-35,0,0,0 2018-000334-35,10,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"An open label, long term safety trial of BI 655130 (Spesolimab) treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000334-35,0,0,0 2018-000334-35,10,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim Norway KS,"An open label, long term safety trial of BI 655130 (Spesolimab) treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000334-35,0,0,0 2018-000334-35,10,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim LImited,"An open label, long term safety trial of BI 655130 (Spesolimab) treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000334-35,0,0,0 2018-000334-35,10,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Boehringer Ingelheim España, S.A.","An open label, long term safety trial of BI 655130 (Spesolimab) treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000334-35,0,0,0 2018-000335-27,1,2022-08-11,2022-08-11,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Universitätsklinikum Erlangen,Early PsA on treatment strategy Strategie zur Frühbehandlung einer Psoriasis Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000335-27,0,0,0 2018-000338-36,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ERYDEL S.P.A.,"Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000338-36,0,0,0 2018-000338-36,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,EryDel S.p.A.,"Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000338-36,0,0,0 2018-000339-28,5,2020-06-02,2020-06-02,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination with Nivolumab (BMS-936558) with and without chemotherapy in Patients with Advanced Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000339-28,1,0,0 2018-000339-28,5,2020-06-02,2020-06-02,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination with Nivolumab (BMS-936558) with and without chemotherapy in Patients with Advanced Pancreatic Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000339-28,1,0,0 2018-000340-26,6,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000340-26,0,0,0 2018-000340-26,6,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000340-26,0,0,0 2018-000342-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Otto-von-Guericke-Universität Magdeburg, Medizinische Fakultät","Prospective, randomized, double-blind clinical trial phase II for the anti-inflammatory effects of Curazink (zinc histidine) for 8 weeks in elderly patients with mild cognitive impairment in Alzheimer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000342-19,0,0,0 2018-000344-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU CAEN,"Essai, randomisé, contrôlé, ouvert, de deux schémas standardisés de décroissance, respectivement rapide (nord-américain) et lent (européen), de cortisone dans l’artérite à cellules géantes. Essai, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000344-25,0,0,0 2018-000345-39,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Pfizer Inc.,A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000345-39,0,0,0 2018-000345-39,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000345-39,0,0,0 2018-000345-39,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,PFIZER INC,A Phase 2 Study to Evaluate Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib In Patients with BRCA or ATM Mutant Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000345-39,0,0,0 2018-000346-19,2,2020-08-31,2020-08-31,2,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Herantis Pharma Plc,"A Randomised, Double-Blind, Multi-centre, Active Treatment, Extension and Safety Study for Patients with Idiopathic Parkinson’s Disease (PD) Who Previously Completed the CDNF/DDS Main Study HP-CD-CL-2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000346-19,0,0,0 2018-000347-60,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Grupo de Tratamiento de los Tumores Digestivos,Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000347-60,0,0,0 2018-000347-60,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000347-60,0,0,0 2018-000348-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Otorhinolaryngology, Head and Neck Surgery",Mesenchymal stem cells for radiation-induced hyposalivation and xerostomia in previous oropharyngeal head and neck cancer patients (MESRIX-II) Mesenkymale stamceller til behandling af stråleinducer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000348-24,0,0,0 2018-000349-38,8,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Eli Lilly and Company,"I4V-MC-JAIP A Phase 3, Multicenter, Randomized, Double blind, Placebo controlled, Parallel group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000349-38,0,0,0 2018-000349-38,8,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Lilly S.A.,"I4V-MC-JAIP A Phase 3, Multicenter, Randomized, Double blind, Placebo controlled, Parallel group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000349-38,0,0,0 2018-000353-50,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,CHIESI FARMACEUTICI S.p.A,Comparison of two formulations of beclometasone/formoterol pMDI on respiratory system impedance using impulse oscillometry in asthmatic patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000353-50,0,0,0 2018-000356-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center utrecht,Individualized dosing of fludarabine during innate allo SCT: A randomized phase II study (TARGET Study) ‘Per patiënt op maat’ doseren van fludarabine tijdens de voorbereidende behandeling van een ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000356-18,0,0,0 2018-000358-23,1,,,0,1,0,0,0,1,3,0,0,1,1,1,0,1,1,CATALYST PHARMACEUTICALS INC.,"A phase 3, multicenter, double-blind, placebo-controlled, randomized, outpatient two-period two-treatment crossover study to evaluate the efficacy and safety of amifampridine phosphate (3,4 diaminopyr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000358-23,0,0,0 2018-000359-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,Geriatric outcomes among older Type 2 diabetic patients treated with DPP4 inhibitors or glinides: focus on sarcopenia markers of muscle and physical performance status (GOOD-WP2) Outcome geriatrici...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000359-42,0,0,0 2018-000363-91,4,,,0,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Calithera Biosciences Inc,"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000363-91,0,0,0 2018-000365-37,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Lipopharma Therapeutics,"A randomized, double-blind, placebo-controlled adjuvant trial in newly diagnosed primary glioblastoma subjects to assess the efficacy and safety of 2-hydroxyoleic acid (2-OHOA) in combination with rad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000365-37,0,0,0 2018-000365-37,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Laminar Pharmaceuticals,"A randomized, double-blind, placebo-controlled adjuvant trial in newly diagnosed primary glioblastoma subjects to assess the efficacy and safety of 2-hydroxyoleic acid (2-OHOA) in combination with rad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000365-37,0,0,0 2018-000366-11,5,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Cáncer de Ovario (GEICO),"A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovari...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000366-11,0,0,0 2018-000367-83,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Cáncer de Ovario (GEICO),"A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persiste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000367-83,0,0,0 2018-000368-27,1,,,0,0,0,0,0,1,4,0,0,1,0,0,0,1,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,ND CHANGE IN PLASMA LYSO GL3 AND RELIEF OF GASTRO INTESTINAL SYMPTOMS IN PATIENTS SWITCHED FROM AGALSIDASE ALFA TO AGALSIDASE BETA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000368-27,0,0,0 2018-000373-80,1,2018-12-03,2018-12-03,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,"Dermecular Therapeutics, Inc.","A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Safety and Efficacy of LX3305, a Sphingosine-1-Phosphate Lyase Inhibitor, for Treatment of Darier’s Disease or Hail...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000373-80,0,0,0 2018-000377-68,2,2021-07-30,2021-07-30,2,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"SynCore Biotechnology Co., Ltd.","A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000377-68,0,0,0 2018-000378-30,5,2022-02-15,2022-02-15,3,0,0,0,0,1,2,0,0,2,1,0,0,0,1,AlgiPharma AS,"A randomised, double-blind, dose finding study of inhaled alginate oligosaccharide (OligoG) vs placebo in patients with Cystic Fibrosis (CF).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000378-30,1,0,0 2018-000381-11,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A subject and investigator blinded, randomized, placebo-controlled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with chronic pulmonary sarcoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000381-11,0,0,0 2018-000383-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Essen,Perioperative chemotherapy vs. immunotherapy vs. chemo-immunotherapy stratified by early response evaluation in patients with advanced gastric cancer (GC) and adenocarcinoma of the esophago-gastric ju...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000383-28,0,0,0 2018-000386-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA SENESE,A Pilot study on the efficacy of Daratumumab in Multiple Myeloma (MM) patients in >VGPR/MRD-positive by next generation flow (NGF) STUDIO PILOTA SULL’EFFICACIA DI DARATUMUMAB IN PAZIENTI AFFETTI DA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000386-36,0,0,0 2018-000388-10,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Daniel Sanabria,"Clinical trial on the effects of the tramadol and paracetamol on physical, cognitive and brain performance during cycling Efecto del tramadol y el paracetamol sobre el rendimiento físico, cognitivo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000388-10,0,0,0 2018-000390-67,6,2022-05-11,2022-05-11,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with atezolizumab or isatuximab alone in patients with advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000390-67,1,0,0 2018-000390-67,6,2022-05-11,2022-05-11,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Sanofi-aventis recherche & développement,"A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with atezolizumab or isatuximab alone in patients with advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000390-67,1,0,0 2018-000391-15,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia,"Multicentric, open-label, prospective study of subcutaneous tocilizumab in adult patients with refractory myositis Studio multicentrico prospettico in aperto per valutare l’efficacia e la sicurezz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000391-15,0,0,0 2018-000392-33,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,"A Safety Run-in and phase II, open-label, multicentre, study investigating safety, tolerability and effectiveness of Venetoclax add in combination at Fludarabine, Cytarabine and Idarubicine in induct...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000392-33,0,0,0 2018-000393-29,1,2021-02-03,2021-02-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Hospices Civils de Lyon,Dulaglutide And Insulin MicrosecretiON in type I Diabetes - DIAMOND,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000393-29,0,0,0 2018-000397-30,9,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,"Millenium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda pharmaceutical Company Limited)","A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000397-30,0,0,0 2018-000397-30,9,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,"Takeda Development Center Americas, Inc.","A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000397-30,0,0,0 2018-000397-30,9,,,0,0,0,0,0,2,3,0,0,2,0,0,0,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000397-30,0,0,0 2018-000398-64,1,2019-12-02,2019-12-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Vall d' Hebron Institute of Oncology (VHIO),Patterns of uptake of 18F-FDG and 68Ga-DOTA PET in advanced neuroendoctrine tumors Identificación de los diferentes patrones de captación mediante PET con 18F-FDG y 68Ga-DOTA-péptidos en los tumor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000398-64,0,0,0 2018-000399-13,1,2022-10-14,2022-10-14,1,0,0,0,0,1,2,0,0,1,1,1,0,0,0,University of Cologne,A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced NSCLC harbouring FGFR genetic alterations after relapse of standard therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000399-13,0,0,0 2018-000404-42,6,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet",Effects of restricting intravenous fluids vs. standard care fluid therapy in patients with septic shock The Conservative vs. Liberal Approach to fluid therapy of Septic Shock in Intensive Care (CLASSI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000404-42,0,0,0 2018-000404-42,6,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Dept. of Intensive Care, Copenhagen Univeristy Hospital Rigshospitalet",Effects of restricting intravenous fluids vs. standard care fluid therapy in patients with septic shock The Conservative vs. Liberal Approach to fluid therapy of Septic Shock in Intensive Care (CLASSI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000404-42,0,0,0 2018-000405-23,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Juha Rinne / PET Centre,In vivo PET imaging of neuroinflammation in Parkinson’s disease using the purinergic P2X7 receptor ligand [11C]SMW139 (PRI-PD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000405-23,0,0,0 2018-000406-36,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VES...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000406-36,0,0,0 2018-000407-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Amiens-Picardie,Prospective multicenter randomized double-blind study comparing caspofungin to placebo for the treatment of ICU yeast intra-abdominal infection Essai prospectif randomisé multicentrique en double a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000407-16,0,0,0 2018-000411-24,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,CHRU de Brest,Reduction of bleeding during abdominal plastids with Exacyl® RESPA : Réduction grâce à l’Exacyl® du saignement au cours des plasties abdominales.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000411-24,0,0,0 2018-000413-20,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"TESARO, Inc.","A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Non-mucino...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000413-20,0,0,0 2018-000413-20,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"TESARO, INCORPORATED","A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Non-mucino...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000413-20,0,0,0 2018-000415-25,1,2021-07-09,2021-07-09,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,University Hospital Heidelberg,"PANCREATIC RESECTION WITH PERIOPERATIVE OFF-LABEL STUDY OF PROPRANOLOL AND ETODOLAC – A PHASE II RANDOMIZED TRIAL PROSPER Studie – Randomisierte, doppelt verblindete, Placebo-kontrollierte, Phase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000415-25,0,0,0 2018-000416-21,6,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000416-21,0,0,0 2018-000416-21,6,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000416-21,0,0,0 2018-000421-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Ordensklinikum Linz GmbH, ELISABETHINEN, Interne 3",A study to investigate the influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000421-31,0,0,0 2018-000422-55,9,,,0,0,1,0,0,0,1,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A Phase I/II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric patients with grade II-IV acute graft vs. host disease after allogeneic hematopoietic stem ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000422-55,0,0,0 2018-000422-55,9,,,0,0,1,0,0,0,1,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase I/II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric patients with grade II-IV acute graft vs. host disease after allogeneic hematopoietic stem ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000422-55,0,0,0 2018-000425-31,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,MeiraGTx UK II Ltd,"Long term follow-up study of participants following an open label, multicentre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/5-hRKp.RPGR) for gene therapy of a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000425-31,0,0,0 2018-000431-27,6,2021-11-16,2021-11-16,3,1,0,1,0,0,1,0,1,2,0,0,0,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A Phase 1/2, randomized, observer-blind, controlled, multi-center study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals' respiratory syncytial virus (RSV) investigational vacc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000431-27,1,0,0 2018-000431-27,6,2021-11-16,2021-11-16,3,1,0,1,0,0,1,0,1,2,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase 1/2, randomized, observer-blind, controlled, multi-center study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals' respiratory syncytial virus (RSV) investigational vacc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000431-27,1,0,0 2018-000431-27,6,2021-11-16,2021-11-16,3,1,0,1,0,0,1,0,1,2,0,0,0,0,1,"GlaxoSmithKline S.A,","A Phase 1/2, randomized, observer-blind, controlled, multi-center study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals' respiratory syncytial virus (RSV) investigational vacc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000431-27,1,0,0 2018-000434-34,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Sealantium Medical Ltd.,"A Phase I/II, randomized, prospective, controlled, multi-center, open-label, two arm study evaluating the safety and preliminary efficacy of sFilm-FS in controlling parenchymal bleeding during electiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000434-34,0,0,0 2018-000439-29,2,2019-02-14,2019-02-14,1,1,0,1,0,1,1,0,0,2,0,0,0,0,1,"Castle Creek Pharmaceuticals, LLC","A Multi-center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein after Maximum Use, Topical Administration of CCP-020 (Diacerein 1% ointment) to Patients with E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000439-29,1,0,0 2018-000444-26,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,BioInvent International AB,"Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000444-26,0,0,0 2018-000445-39,3,2021-03-12,2021-03-12,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,AC Immune SA,"A Phase II Double-Blind, Randomized, Placebo-Controlled, Adaptive Design Study to Assess the Safety, Tolerability, Immunogenicity and Target Engagement of ACI-24 Formulations in Patients with Mild Alz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000445-39,1,0,0 2018-000446-19,4,2020-06-16,2020-06-16,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Revance Therapeutics Inc,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000446-19,1,0,0 2018-000446-19,4,2020-06-16,2020-06-16,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Revance Therapeutics, Inc","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000446-19,1,0,0 2018-000447-11,3,2021-05-25,2021-05-25,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Revance Therapeutics Inc,"A Phase 3, Open-Label, Multi-Center Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia (ASPEN-OLS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000447-11,1,0,0 2018-000447-11,3,2021-05-25,2021-05-25,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Revance Therapeutics, Inc","A Phase 3, Open-Label, Multi-Center Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia (ASPEN-OLS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000447-11,1,0,0 2018-000450-21,2,2019-07-31,2019-07-31,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,FUNDACIÓN PARA INVESTIGACIÓN BIOMÉDICA DEL HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL,"Prospective, Randomized, Open, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of the MON4STRAT Approach for Optimizing Meropenem Therapy in Intubated and Mechanically-Ventilated, Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000450-21,0,0,0 2018-000450-21,2,2019-07-31,2019-07-31,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Fundación Investigación Biomédica Hospital Ramón y Cajal,"Prospective, Randomized, Open, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of the MON4STRAT Approach for Optimizing Meropenem Therapy in Intubated and Mechanically-Ventilated, Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000450-21,0,0,0 2018-000451-41,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,HOVON Foundation,"A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000451-41,0,0,0 2018-000452-18,5,2022-10-03,2022-10-03,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids (TAP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000452-18,1,0,0 2018-000452-18,5,2022-10-03,2022-10-03,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids (TAP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000452-18,1,0,0 2018-000452-18,5,2022-10-03,2022-10-03,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids (TAP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000452-18,1,0,0 2018-000453-41,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,University Hospital Tuebingen,Effects of closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) on outcome of extremely preterm infants – a randomized controlled parallel group multicenter trial for safety an...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000453-41,0,0,0 2018-000454-22,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,A translational phase II study of single agent Olaparib in the treatment of advanced oesophagogastric cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000454-22,0,0,0 2018-000459-41,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Endocyte, Inc., A Novartis Company","VISION: An international, prospective, open label, multicenter, randomized Phase 3 study of 177LU-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000459-41,0,0,0 2018-000459-41,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Endocyte, Inc.","VISION: An international, prospective, open label, multicenter, randomized Phase 3 study of 177LU-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000459-41,0,0,0 2018-000459-41,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Endocyte, Inc., a Novartis company","VISION: An international, prospective, open label, multicenter, randomized Phase 3 study of 177LU-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000459-41,0,0,0 2018-000462-11,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000462-11,0,0,0 2018-000462-11,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naive Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000462-11,0,0,0 2018-000464-29,3,2020-09-22,2020-09-22,3,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Catabasis Pharmaceuticals, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, GLOBAL PHASE 3 STUDY OF EDASALONEXENT IN PEDIATRIC PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000464-29,0,0,0 2018-000468-27,5,2020-07-02,2020-07-02,5,1,0,0,0,0,3,0,1,1,0,0,1,0,1,BiondVax Pharmaceuticals Ltd.,"A pivotal, multicentre, randomized, modified double-blind, placebo-controlled phase 3 trial to assess the safety and clinical efficacy of M-001, an influenza vaccine administered intramuscularly twice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000468-27,0,0,0 2018-000469-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Oryzon Genomics S. A.,"A pilot study to assess the safety, tolerability, dose finding and efficacy ORY-1001 in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cell l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000469-35,0,0,0 2018-000477-77,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI","Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi-centre, 2 parallel arms randomized controlled trial Metformin versusTo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000477-77,0,0,0 2018-000478-31,3,2021-12-22,2021-12-22,3,1,0,0,0,1,2,0,0,1,1,1,0,0,1,Oncopeptides AB,A Study of the Pharmacokinetics of Melphalan During Treatment with Melflufen and Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma and Impaired Renal Function,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000478-31,0,0,0 2018-000480-87,4,2020-02-19,2020-02-19,3,1,1,0,0,0,2,0,0,1,0,0,1,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed Dose Combination in Adolescents and Childre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000480-87,0,0,0 2018-000480-87,4,2020-02-19,2020-02-19,3,1,1,0,0,0,2,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.","A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed Dose Combination in Adolescents and Childre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000480-87,0,0,0 2018-000482-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Oryzon Genomics S. A.,"A pilot study to assess the safety, tolerability, dose finding and efficacy of ORY-1001 in combination with azacitidine in older patients with AML in first line therapy. Estudio piloto para evaluar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000482-36,0,0,0 2018-000484-86,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Rigshospitalet,DAN-WAR-D Danish Warfarin-Dialysis Study Safety and efficacy of warfarin in patients with atrial fibrillation on dialysis - A nationwide parallel-group open randomized clinical trial DAN-WAR-D Dan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000484-86,0,0,0 2018-000486-37,2,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Heart Initiative,"STRONG-HF: Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies STRONG-HF: Sigurnost, podnošljivost i učinkovitost brze optimizacije t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000486-37,0,0,0 2018-000487-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,Intravenous amino acid therapy for kidney protection in cardiac surgery: a multi-centre randomised blinded placebo controlled clinical trial Intravenous amino acid therapy for kidney protection in ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000487-28,0,0,0 2018-000488-98,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,Proton pump inhibitors (PPI) as a new strategy for therapy in sepsis: clinical trial to reduce severity of organ failure and in vitro experiments to search specific hallmarks in monocytes from septic ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000488-98,0,0,0 2018-000492-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Charité-Universitätsmedizin Berlin,"Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections Einfluss von Antibiotikatherapien auf Mikrobiota, pulmonale Immunantwort und Inzide...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000492-32,0,0,0 2018-000495-15,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,IRCCS ISTITUTO CLINICO HUMANITAS,"n.a. Studio multicentrico, randomizzato, a gruppi paralleli di fase IV, per confrontare efficacia, sicurezza e tollerabilità di PLENVU® (preparazione per pulizia intestinale 1 L a base PEG+ASC) ris...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000495-15,0,0,0 2018-000497-30,1,2021-07-29,2021-07-29,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI),Phase II clinical trial to evaluate the safety and efficacy of Vedolizumab combined with antiretroviral treatment to achieve functional healing in people infected with HIV-1 without previous antiretro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000497-30,0,0,0 2018-000501-23,10,2020-10-07,2020-10-07,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A phase 3 randomized withdrawal, double-blind, placebo-controlled, multi-center study investigating the efficacy and safety of PF-04965842 in subjects aged 12 years and over, with moderate to severe ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000501-23,0,0,0 2018-000501-23,10,2020-10-07,2020-10-07,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A phase 3 randomized withdrawal, double-blind, placebo-controlled, multi-center study investigating the efficacy and safety of PF-04965842 in subjects aged 12 years and over, with moderate to severe ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000501-23,0,0,0 2018-000503-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Assistance Publique- Hôpiaux de Paris,"Randomized, double-blind, single-centre, randomized study evaluating the efficacy of CLORazepate dipotassium in the treatment of migraine crisis in the emergency department. Étude monocentrique ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000503-16,0,0,0 2018-000504-42,1,2022-02-08,2022-02-08,1,1,0,1,0,1,1,0,0,1,1,1,0,0,1,Abeona Therapeutics Inc,"A Phase I/II Open Label, Single-dose, Gene Transfer Study of scAAV9.U1a.hSGSH (ABO-102) in Patients with Middle and Advanced Phases of MPS IIIA Disease Ensayo Fase I/II abierto, dosis única de tran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000504-42,0,0,0 2018-000506-34,1,2021-06-30,2021-06-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,NBMI Science Ltd.,"EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000506-34,0,0,0 2018-000508-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Pharma Patent Kft.,"Controlled randomized open label clinical study to compare the efficacy and the safety of the loading dose schedules of Vitamin D3 (colecalciferol) 30,000 IU product in deficient patients Kontrollá...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000508-40,0,0,0 2018-000515-24,11,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,0,University of Birmingham,An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Uno studio globale su bambini e adulti con RabdoMioSarcoma frontline e recidivante,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000515-24,0,0,0 2018-000515-24,11,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,0,UNIVERSITY OF BIRMINGHAM,An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Uno studio globale su bambini e adulti con RabdoMioSarcoma frontline e recidivante,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000515-24,0,0,0 2018-000515-24,11,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,0,Oslo universitetssykehus,An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Uno studio globale su bambini e adulti con RabdoMioSarcoma frontline e recidivante,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000515-24,0,0,0 2018-000516-22,3,2022-07-21,2022-07-21,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Biogen Idec Research Limited,"A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3- Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000516-22,1,0,0 2018-000518-39,4,2020-08-05,2020-08-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"Multicenter, rAndomized, double-blind, placebo-conTrolled, 52-week stUdy to demonstRatE the efficacy, safety and tolerability of subcutaneous secukinumab injections with 2 mL auto-injectors (300 mg) i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000518-39,0,0,0 2018-000518-39,4,2020-08-05,2020-08-05,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","Multicenter, rAndomized, double-blind, placebo-conTrolled, 52-week stUdy to demonstRatE the efficacy, safety and tolerability of subcutaneous secukinumab injections with 2 mL auto-injectors (300 mg) i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000518-39,0,0,0 2018-000519-26,9,2021-10-14,2021-10-14,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Astellas Pharma Global Development, Inc. (APGD)","A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLDN) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000519-26,1,0,0 2018-000523-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universidad Miguel Hernandez,Transplantation of autologous mesenchymal stem cells of adipose origin for the treatment of corneal diseases Trasplante de Células Madre Mesenquimales Autólogas de origen adiposo para el tratamient...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000523-14,0,0,0 2018-000525-32,5,2022-08-30,2022-08-30,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000525-32,1,0,0 2018-000525-32,5,2022-08-30,2022-08-30,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim Limited,An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000525-32,1,0,0 2018-000525-32,5,2022-08-30,2022-08-30,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,SCS Boehringer Ingelheim Comm.V,An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000525-32,1,0,0 2018-000525-32,5,2022-08-30,2022-08-30,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000525-32,1,0,0 2018-000525-32,5,2022-08-30,2022-08-30,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Boehringer Ingelheim España, S.A.",An open-label extension trial of the long term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000525-32,1,0,0 2018-000528-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar),Tranexamic acid use to reduce de blood transfusion in femur fracture patients. Clinical randomized trial with placebo control Utilidad del ácido tranexámico para disminuir las necesidades transfus...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000528-32,0,0,0 2018-000532-94,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO,"Optimal duration of dual antiplatelet therapy in patients treated by endovascular revascularization of the superficial femoral artery (Dual Antiplatelet Therapy-Superficial Femoral Artery, DAPT-SFA) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000532-94,0,0,0 2018-000533-13,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Gesellschaft für Pädiatrische Onkologie und Hämatologie gGmbH,"Randomized multi-centre open-label non-inferiority phase 3 clinical trial for patients with a stage IV childhood renal tumour comparing upfront Vincristine, Actinomycin-D and Doxorubicin (VAD, standar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000533-13,0,0,0 2018-000533-13,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE,"Randomized multi-centre open-label non-inferiority phase 3 clinical trial for patients with a stage IV childhood renal tumour comparing upfront Vincristine, Actinomycin-D and Doxorubicin (VAD, standar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000533-13,0,0,0 2018-000536-10,1,2020-07-13,2020-07-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Promore Pharma AB,"A Study in Patients with Hard-to-Heal Venous Leg Ulcers to Measure Efficacy and Safety of Locally Administered LL-37; A Phase IIb, Double-blind, Randomised, Placebo-controlled, Multi-centre Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000536-10,0,0,0 2018-000537-12,1,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,0,CHU de Rennes,International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones Etude rand...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000537-12,0,0,0 2018-000539-29,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hamilton Health Sciences Corporation,PeriOperative ISchemic Evaluation – 3 Trial (POISE-3). Valutazione dell’ischemia perioperatoria - 3 (POISE-3),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000539-29,0,0,0 2018-000540-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,Carfilzomib (K) plus Lenalidomide (R) and Dexamethasone (D) for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomas: a phase II study Carfilzomib (K) in combinazione con Lenalido...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000540-25,0,0,0 2018-000542-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNICANCER,Randomized phase III study of oral cyclophosphamide vs doxorubicin in 65 years or older patients with advanced or metastatic soft tissue sarcoma: a UNICANCER/GERICO multicenter program,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000542-20,0,0,0 2018-000545-39,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,ASL 1 AVEZZANO-SULMONA-L'AQUILA,"A randomized half-side comparative study of Methyl aminolevulinate (MAL, Metvix®) Daylight photodynamic therapy (DL-PDT) with or without pre-treatment with calcitriol (Silkis®) for Actinic Keratosis (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000545-39,0,0,0 2018-000548-25,3,2019-06-25,2019-07-22,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Allergopharma GmbH & Co. KG,"A multicentre, randomized, open label clinical trial for safety evaluation of an accelerated high dose escalation schedule with one strength for an allergen immunotherapy with an aluminium hydroxide a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000548-25,0,0,0 2018-000550-21,10,2022-03-16,2022-03-28,7,1,1,0,0,1,3,0,0,2,1,0,0,0,1,Amgen Inc,"Multicenter, Single-arm Open-label Extension Study to Assess Long term Safety and Efficacy of Current or Prior Treatment with Denosumab in Children/Young Adults with Osteogenesis Imperfecta",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000550-21,1,0,0 2018-000550-21,10,2022-03-16,2022-03-28,7,1,1,0,0,1,3,0,0,2,1,0,0,0,1,AMGEN INC.,"Multicenter, Single-arm Open-label Extension Study to Assess Long term Safety and Efficacy of Current or Prior Treatment with Denosumab in Children/Young Adults with Osteogenesis Imperfecta",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000550-21,1,0,0 2018-000552-18,1,2022-05-31,2022-05-31,1,0,0,0,0,0,3,0,0,1,0,0,0,0,0,Medical University of Vienna,Denosumab in the prevention of immobilization-induced bone loss in Intensive Care Unit patients Denosumab in der Prävention des Knochenabbaus immobilisierter Patienten auf einer Intensivstation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000552-18,0,0,0 2018-000564-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut de Recerca H. de la Santa Creu i Sant Pau - IIB Sant Pau,Genetic characterization of drug-induced Long QT Syndrome Caracterización Genética del Síndrome del QT Largo Asociado a Fármacos,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000564-28,0,0,0 2018-000565-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Oulu,Paracetamol and ibuprofen/indomethacin in closing persistent ductus arteriosus Parasetamolin ja ibuprofeenin/indometasiinin yhteisvaikutus pienen keskosen avoimen duktuksen hoidossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000565-36,0,0,0 2018-000566-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Oulu,Extremely low gestational age infants' PARAcetamol Study Hyvin pienten keskosten parasetamolitutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000566-11,0,0,0 2018-000572-15,9,2022-01-18,2022-01-18,5,0,0,0,0,1,3,0,0,2,1,0,0,0,1,ERYTECH PHARMA S.A.,"A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma Studio randomizzato di fase ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000572-15,1,0,0 2018-000572-15,9,2022-01-18,2022-01-18,5,0,0,0,0,1,3,0,0,2,1,0,0,0,1,ERYTECH Pharma,"A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma Studio randomizzato di fase ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000572-15,1,0,0 2018-000573-72,1,2019-04-18,2019-04-18,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Atossa Genetics Inc,"Karma CREME-1: A double-blind, placebo-controlled, three-armed, pilot study of the effects, safety and tolerability of topical endoxifen in women within the Karma Cohort",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000573-72,0,0,0 2018-000575-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Isabel Maria Ruiz,Results of the injection of botulinum toxin vs platelet rich plasma for the treatment of plantar fasciitis Resultados de la infiltración de toxina botulínica vs plasma rico en plaquetas en el trata...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000575-32,0,0,0 2018-000578-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medicine Rostock,Impact of benralizumab treatment on circulating dendritic cells in patients with eosinophilic asthma Einfluss einer Benralizumab-Behandlung auf zirkulierende dendritische Zellen von Patienten mit e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000578-31,0,0,0 2018-000579-34,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Constellation Pharmaceuticals, Inc.","A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000579-34,0,0,0 2018-000580-90,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA,Multicenter randomized open-label phase III trial of Adjuvant Chemotherapy vs. observation or mitotane after primary surgical resection of localized Multicenter randomized open-label phase III tri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000580-90,0,0,0 2018-000582-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOint INhibiTor (anti PD1/PDL1) Studio di fase 2 in aperto ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000582-36,0,0,0 2018-000584-85,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Rigshospitalet,Effect of insulin sensitization on insulin like growth factor-1 responses to growth hormone treatment in children born small for gestational age Effekt af øget insulin følsomhed på insulin-ligne...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000584-85,0,0,0 2018-000586-37,3,2019-03-07,2019-03-07,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Cytokinetics, Inc.","A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability Of CK-2127107 In Patients with Amyotrophic Lateral Sclerosi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000586-37,0,0,0 2018-000587-28,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"BeiGene, Ltd.","A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with Chemotherapy as First-Line Treatment in Patients with Un...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000587-28,0,0,0 2018-000587-28,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,BeiGene Ltd.,"A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with Chemotherapy as First-Line Treatment in Patients with Un...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000587-28,0,0,0 2018-000587-28,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"BeiGene, Ltd., c/o BeiGene USA, Inc.","A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination with Chemotherapy as First-Line Treatment in Patients with Un...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000587-28,0,0,0 2018-000588-99,9,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Blueprint Medicines Corporation,"A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000588-99,0,0,0 2018-000588-99,9,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,BLUEPRINT MEDICINES CORPORATION,"A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000588-99,0,0,0 2018-000590-75,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oslo University Hospital,BEta-Blocker Treatment after Acute Myocardial Infarction in revascularized patients with preserved left ventricular systolic function (BETAMI trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000590-75,0,0,0 2018-000595-15,10,2020-08-25,2020-08-25,6,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A randomized, double blind, multicenter extension to CZPL389A2203 dose-ranging study to assess the short-term and long-term safety and efficacy of oral ZPL389 with concomitant or intermittent use of T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000595-15,1,0,0 2018-000600-42,9,2019-09-19,2019-09-19,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults with Treatment-Resistant Migraine - The CONQUER Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000600-42,0,0,0 2018-000600-42,9,2019-09-19,2019-09-19,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Lilly S.A.,"A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults with Treatment-Resistant Migraine - The CONQUER Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000600-42,0,0,0 2018-000601-22,2,2022-07-13,2022-07-13,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000601-22,1,0,0 2018-000603-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Antoni van leeuwenhoek,PERICLES (PEnile cancer Radio- and Immunotherapy CLinical Exploration Study) – a Phase 2 study of atezolizumab with or without radiotherapy in penile cancer PERICLES (PEniskanker Radio en Immunot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000603-17,0,0,0 2018-000605-24,1,2021-10-15,2021-10-15,1,1,0,0,0,1,2,0,0,1,0,0,0,0,1,CSL Behring LLC,"A multicenter, randomized, placebo-controlled, parallel-arm study to investigate the efficacy, pharmacokinetics, and safety of CSL312 in subjects with hereditary angioedema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000605-24,0,0,0 2018-000608-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI,Aspirin versus Aspirin plus Clopidogrel in Patients Undergoing Transcatheter Aortic Valve Replacement: a Randomized Multicenter Study Confronto Randomizzato tra Acido Acetil Salicilico versus Acido...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000608-40,0,0,0 2018-000610-38,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000610-38,0,0,0 2018-000610-38,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000610-38,0,0,0 2018-000610-38,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000610-38,0,0,0 2018-000613-21,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Medical Ethics UK Ltd,"An open, randomised, parallel group controlled, single centre safety study to assess the safety and efficacy of Tri-Solfen in providing anaesthesia prior to surgical debridement of leg ulcers and post...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000613-21,0,0,0 2018-000614-37,1,,,0,0,0,0,1,1,2,0,0,0,0,0,0,0,0,Region Örebro Län,Kort-SGS: Does a series of intralesional steroid injections after endoscopic treatments for subglottic stenosis prolong interval between between surgical interbentions? A prospective single blinded ra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000614-37,0,0,0 2018-000615-25,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Alcon Research Ltd,Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Acute Otitis Externa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000615-25,0,1,1 2018-000616-25,1,2020-01-01,2020-01-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,3,,Pharmacokinetics of fosfomycin: a study in patients with prolonged treatment for urinary tract infection Pharmacokinetiek van fosfomycine: een studie in patiënten met langdurige behandeling voor ur...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000616-25,0,0,0 2018-000617-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The MITO 31 transalational study. Studio clinico di fase 2 di Olaparib ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000617-20,0,0,0 2018-000618-39,2,,,0,0,0,0,0,2,2,0,0,1,1,1,0,1,1,SYMPHOGEN A/S,"A Phase 2, Randomized, Open-Label, Multicenter, Three-Arm Trial of Sym004 versus each of its Component Monoclonal Antibodies, Futuximab and Modotuximab, in Patients with Chemotherapy-Refractory Metast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000618-39,0,0,0 2018-000618-39,2,,,0,0,0,0,0,2,2,0,0,1,1,1,0,1,1,Symphogen A/S,"A Phase 2, Randomized, Open-Label, Multicenter, Three-Arm Trial of Sym004 versus each of its Component Monoclonal Antibodies, Futuximab and Modotuximab, in Patients with Chemotherapy-Refractory Metast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000618-39,0,0,0 2018-000620-34,2,,,0,0,0,0,2,0,2,0,0,0,0,0,0,0,0,"Department of Clinical Neuroscience, Karolinska Institutet","Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000620-34,0,0,0 2018-000624-33,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HOVON Foundation,"A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000624-33,0,0,0 2018-000626-60,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,"A multicenter, randomized, open label, phase II study evaluating the feasibility and tolerance of nivolumab neoadjuvant immunotherapy in high risk HPV driven Oropharynx Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000626-60,0,0,0 2018-000627-13,2,2021-02-10,2021-02-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,GAMAMABS Pharma,"OPEN, NON CONTROLLED, PARALLEL COHORTS, MULTICENTER, PHASE 2A STUDY FOR EVALUATION OF THE ANTITUMOR ACTIVITY OF GM102/MURLENTAMAB SINGLE AGENT AND IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH LOC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000627-13,0,0,0 2018-000634-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Althaia Xarxa Assistencial Universitària de Manresa. Fundació Privada.,HIGH-FLOW NASAL CANNULA THERAPY AS AN ADJUVANT IN THE TREATMENT OF SEVERE SEPSIS. A Multicenter parallel-group randomized clinical trial. LA OXIGENOTERAPIA DE ALTO FLUJO COMO ADYUVANTE EN EL TRATAM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000634-35,0,0,0 2018-000635-27,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"ARIAD Pharmaceuticals, Inc.(a wholly-owned subsidiary of Takeda Pharmaceutical Ltd.)","Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000635-27,0,0,0 2018-000635-27,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"ARIAD PHARMACEUTICALS, INC.","Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000635-27,0,0,0 2018-000637-12,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Efficacy and safety of rituximab in the treatment of good prognosis microscopic polyangiitis Efficacité et tolérance du rituximab dans le traitement de la polyangéite microscopique de bon pronosti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000637-12,0,0,0 2018-000640-26,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Alcon Research Ltd,Safety and Efficacy Evaluation of Topical Moxidex Otic Solution Compared to Moxifloxacin Solution in the Treatment of Acute Otitis Media with Otorrhea through Tympanostomy Tubes (AOMT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000640-26,0,1,1 2018-000641-39,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Alcon Research Ltd,Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Acute Otitis Externa (AOE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000641-39,0,1,1 2018-000642-19,1,,,0,1,0,0,1,0,2,0,0,4,0,0,0,0,1,Alcon Research Ltd,Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Peri-Operative Tube Otorrhea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000642-19,0,1,1 2018-000643-37,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Alcon Research Ltd,Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Acute Otitis Media with Otorrhea in Tympanostomy Tubes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000643-37,0,1,1 2018-000644-26,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Southampton,Aspirin To Target Arterial events in Chronic Kidney Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000644-26,0,0,0 2018-000648-25,3,,,0,1,1,0,0,1,3,0,0,2,1,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Phase 3b, Open-Label, Single Arm, Multi-Centre Study to Assess the Safety and Efficacy of Pegvaliase (BMN 165) Treatment in adults With Phenylketonuria Not Controlled With Current Management",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000648-25,0,0,0 2018-000650-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universidad Autónoma de Madrid,CLINICAL TRIAL FOR EVALUATION OF THE ADIPOQUINAS: NEW PHARMACOLOGICAL TARGETS TO PREVENT VASCULAR AGING ENSAYO CLÍNICO PARA EVALUACIÓN DE LAS ADIPOQUINAS: NUEVAS DIANAS FARMACOLÓGICAS PARA PREVENIR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000650-21,0,0,0 2018-000652-18,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Imperial College London,Study to compare once-daily Extended Release Tacrolimus Versus twice-daily Immediate Release Tacrolimus following renal allograft failure to Reduce the risk of Allosensitisation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000652-18,0,0,0 2018-000653-45,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,"Department of Clinical Pharmacology, Medical University of Vienna",Pharmacokinetics of a novel extended infusion regimen of fosfomycin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000653-45,0,0,0 2018-000655-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",ADJUVANT CAPECITABINE IN HIGH RISK PSEUDOMYXOMA PERITONEI PATIENTS TREATED WITH CYTOREDUCTIVE SURGERY (CRS) AND HYPERTERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) CAPECITABINA ADIUVANTE NEI PAZIENTI ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000655-40,0,0,0 2018-000656-18,2,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,SINTETICA SA,"Randomized, multi-center, double-blind, two-armed, parallel active groups, prospective trial, to evaluate, in pediatric population undergoing 'Calcaneo stop' surgery or Inguinal hernia repair, the eff...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000656-18,0,0,0 2018-000659-42,3,2022-10-13,2022-10-13,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,TrialNet Coordinating Center,HYDROXYCHLOROQUINE FOR PREVENTION OF ABNORMAL GLUCOSE TOLERANCE AND DIABETES IN INDIVIDUALS AT-RISK FOR TYPE 1 DIABETES MELLITUS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000659-42,1,0,0 2018-000662-11,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Ono Pharmaceutical Co., Ltd.","ONO-7436 Phase III Study – A multicenter, open-label, uncontrolled study for the prevention of chemotherapy-induced nausea and vomiting",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000662-11,0,1,1 2018-000663-80,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Ono Pharmaceutical Co., Ltd.","ONO-7847 Japanese Clinical Study in Pediatric Patients Multicenter, open-label, uncontrolled study for the prevention of CINV",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000663-80,0,1,1 2018-000665-36,12,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Amgen Inc,"A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000665-36,0,0,0 2018-000666-10,4,2020-03-26,2020-03-26,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination with Upadacitinib (ABBV-599 Combination) with a Background of Conventional Synthetic DMARDs in Subjects...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000666-10,0,0,0 2018-000668-28,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Birmingham,A Phase II pilot safety and tolerability study of ILB in patients with Motor Neurone Disease (MND)/Amyotrophic Lateral Sclerosis (ALS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000668-28,0,0,0 2018-000669-35,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000669-35,0,0,0 2018-000669-35,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000669-35,0,0,0 2018-000670-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CONSORZIO ONCOTECH,Avelumab as single agent in metastatic or locally advanced urothelial cancer in patients unfit for cisplatin. The ARIES Study Avelumab in monoterapia nel carcinoma uroteliale metastatico o localmen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000670-29,0,0,0 2018-000673-68,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,Great Ormond Street Hospital for Children NHS Trust,Phase I/II study of lentiviral gene transfer for SCID-X1 with low dose targeted busulfan,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000673-68,0,0,0 2018-000677-77,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Hospital Leuven,Novel strategies in weight loss in women with polycystic ovary syndrome: does the gut microbiome play a role?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000677-77,0,0,0 2018-000680-93,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IRCCS ISTITUTO CLINICO HUMANITAS,Postoperative effects of high-dose esmolol during mitral valve surgery for mitral regurgitation. ESMOLOLO IN CHIRURGIA MITRALICA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000680-93,0,0,0 2018-000681-10,8,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Eli Lilly and Company,"Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab with Adalimumab Reference Arm, in Children with Juvenile Idiopathic Arthritis Subtypes of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000681-10,0,0,0 2018-000681-10,8,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab with Adalimumab Reference Arm, in Children with Juvenile Idiopathic Arthritis Subtypes of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000681-10,0,0,0 2018-000682-36,1,2019-11-05,2019-11-05,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,Radboud university medical center,"The efficacy of cabozantinib in advanced salivary gland cancer patients, a phase II clinical trial de effectiviteit van cabozantinib in gevorderd speekselkliercarcinoom, een fase 2 studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000682-36,0,0,0 2018-000684-82,1,2019-05-14,2019-05-14,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Radboud university medical center,The effect of lactate administration on cerebral blood flow during hypoglycemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000684-82,0,0,0 2018-000685-12,3,2020-05-27,2020-12-11,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Drug Delivery Solutions Ltd (part of MC2 Therapeutics),"A Multicentre, Open-label, Single-group Maximal Use Trial, Evaluating the Safety and Pharmacokinetic Profile of the Active Ingredients and their Metabolites after application of MC2-01 Cream in Adoles...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000685-12,0,0,0 2018-000685-12,3,2020-05-27,2020-12-11,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MC2 Therapeutics Ltd.,"A Multicentre, Open-label, Single-group Maximal Use Trial, Evaluating the Safety and Pharmacokinetic Profile of the Active Ingredients and their Metabolites after application of MC2-01 Cream in Adoles...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000685-12,0,0,0 2018-000685-12,3,2020-05-27,2020-12-11,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,MC2 Therapeutics Ltd,"A Multicentre, Open-label, Single-group Maximal Use Trial, Evaluating the Safety and Pharmacokinetic Profile of the Active Ingredients and their Metabolites after application of MC2-01 Cream in Adoles...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000685-12,0,0,0 2018-000686-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden univerisity medical centre,(Methyl)prednisolone and diazoxide in type 1 diabetes at onset (Methyl)prednisolon en diazoxide bij recent vastgestelde type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000686-37,0,0,0 2018-000689-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University hospital Brussel,Clinical pregnancy rate for frozen embryo transfer with HRT: a pilot study comparing 1 versus 2 weeks of treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000689-13,0,0,0 2018-000690-78,3,2020-05-26,2020-05-26,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Bayer AG,LowEr Administered Dose with highEr Relaxivity: Gadovist vs Dotarem,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000690-78,0,0,0 2018-000690-78,3,2020-05-26,2020-05-26,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,BAYER AG,LowEr Administered Dose with highEr Relaxivity: Gadovist vs Dotarem,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000690-78,0,0,0 2018-000692-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA,"EFFICACY OF METFORMIN ON MOTILITY AND STRENGTH IN MYOTONIC DYSTROPHY TYPE 1. A randomized, double blind, placebo-controlled, multicenter clinical trial. EFFICACIA DELLA METFORMINA SULLA MOTILITA’ ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000692-32,0,0,0 2018-000693-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ENTE OSPEDALIERO OSPEDALI GALLIERA,"EXemestane in Progesterone and/or Estrogen receptor positive epithelial ovarian cancer. A Randomized phase III Trial, EXPERT. EXemestane in Progesterone and/or Estrogen receptor positive epithelial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000693-30,0,0,0 2018-000695-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hôpitaux Universitaires de Strasbourg,Intravenous Immunoglobulins for Prevention of BKV Viremia in Kidney Transplant Recipients According to BKV genotype-specific Neutralizing Antibody Titers at the day of transplantation: A Multicenter S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000695-15,0,0,0 2018-000708-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,Association of Radiochemotherapy and Immunotherapy for the treatment of unresectable Oesophageal caNcer: a comparative randomized phase II trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000708-40,0,0,0 2018-000712-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Andrew Lindford,Prospective Randomised Non-inferiority Nordic Frostbite Treatment Study comparing tPA and iloprost therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000712-15,0,0,0 2018-000714-37,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000714-37,0,0,0 2018-000715-25,3,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"An Open-Label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects with Polyarticular Course Juvenile Idiopathic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000715-25,0,0,0 2018-000715-25,3,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"An Open-Label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects with Polyarticular Course Juvenile Idiopathic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000715-25,0,0,0 2018-000717-20,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Medigene AG,"Long-Term Follow-Up Clinical Trial of Subjects Treated with PRAME TCR modified T cells, MDG1011",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000717-20,0,0,0 2018-000721-31,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,"Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital",RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MS A randomized trial of long-term dosage of rituximab in multiple sclerosis The RIDOSE-MS trial is a multi-centre trial of long-term tre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000721-31,0,0,0 2018-000724-34,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oslo University Hospital HF,"Norwegian Nucleoside Analogue Stop Study (Nuc-STOP) - A randomized open-label trial in HBeAg negative chronic hepatitis B, aiming at achieving a functional Cure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000724-34,0,0,0 2018-000726-63,1,2021-04-30,2021-04-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Department of Clinical Physiology and Nuclear Medicine, Herlev and Gentofte Hospital",Pre- and Postoperative Imaging and Monitoring of Patients with Primary Hyperparathyroidism: Preoperative imaging in primary hyperparathyroidism using dual-isotope subtraction scintigraphy (SPECT/CT) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000726-63,0,0,0 2018-000727-13,6,2020-12-01,2020-12-01,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,miRagen Therapeutics Inc.,"SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000727-13,0,0,0 2018-000727-13,6,2020-12-01,2020-12-01,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"miRagen Therapeutics, Inc.","SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000727-13,0,0,0 2018-000731-27,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc.,"A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Of The Safety And Efficacy Of AN2728 Topical Ointment, 2% In Children, Adolescents, And Adults (Ages 2 Years And Older) With Atopic De...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000731-27,0,1,1 2018-000734-35,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Single-Dose, Open-Label Study to Characterize the Pharmacokinetics, Safety and Tolerability of Subcutaneous administration of Fremanezumab in Pediatric Migraine Patients (6 to 11 Years of Age Incl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000734-35,0,1,1 2018-000737-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST,"The CARACAS Study. Randomized phase 2 trial of cetuximab and avelumab or avelumab alone for unresectable, locally advanced or metastatic squamous cell anal carcinoma (SCCAC) progressed after at least ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000737-12,0,0,0 2018-000739-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA,Comparison of 1-year treatment with inhaled long acting bronchodilators (LABD) plus inhaled glucocorticosteroids (ICS) versus LABD without ICS on re-hospitalizations and/or death in elderly patients w...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000739-28,0,0,0 2018-000740-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI,"“TRANSARTERIAL EMBOLIZATION ALONE VERSUS DRUG-ELUTING BEADS CHEMOEMBOLIZATION FOR HEPATOCELLULAR CARCINOMA. A RANDOMIZED CONTROLLED TRIAL” ""EMBOLIZZAZIONE TRANSARTERIOSA VERSUS CHEMIOEMBOLIZZAZIONE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000740-25,0,0,0 2018-000741-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hôpitaux Universitaires de Strasbourg,"EFFECT OF AZITHROMYCIN ON THE PROPORTION OF FAILURES OF SEVERE PERIODONTITIS NON-SURGICAL TREATMENTS : A RANDOMIZED, DOUBLE-BLIND VERSUS PLACEBO STUDY EFFET DE L'AZITHROMYCINE SUR LA PROPORTION D'E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000741-39,0,0,0 2018-000746-19,7,2022-06-27,2022-06-27,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,LEO PHARMA A/S,"An open-label, single-arm, multi-centre, long-term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with atopic dermatitis who participated in previous tralokinumab clin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000746-19,1,0,0 2018-000746-19,7,2022-06-27,2022-06-27,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,LEO Pharma A/S,"An open-label, single-arm, multi-centre, long-term extension trial to evaluate the safety and efficacy of tralokinumab in subjects with atopic dermatitis who participated in previous tralokinumab clin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000746-19,1,0,0 2018-000747-76,6,2020-06-24,2020-09-28,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,LEO Pharma A/S,"A randomised, double-blind, placebo-controlled, parallel-group, multi-centre, phase 3 trial investigating the efficacy, safety, and tolerability of tralokinumab administered in combination with topica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000747-76,0,0,0 2018-000748-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VUmc,Partial neuromuscular blockade to facilitate lung and diaphragm protective mechanical ventilation in ICU patients. A randomized controlled pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000748-24,0,0,0 2018-000750-22,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Novo Nordisk A/S,A trial investigating the long-term efficacy and safety of two doses of NN-220 (somatropin [genetical recombination]) in short stature due to Noonan syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000750-22,0,1,1 2018-000752-18,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,UMC Utrecht,Ajmaline provocation in asymptomatic PLN and PKP2 mutation carriers for early detection of Arrhythmogenic Cardiomyopathy Ajmaline provocatie in asymptomatische mutatie dragers van PLN and PKP2 mut...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000752-18,0,0,0 2018-000753-45,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,NAVARRBIOMED-FUNDACION MIGUEL SERVET,"Vitreretinal surgery with and without oral anticoagulants: surgical complications, visual results and perioperative thromboembolic events. Cirugía vitreorretiniana con y sin anticoagulantes orales:...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000753-45,0,0,0 2018-000754-22,7,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Infant Bacterial Therapeutics AB (IBT),"A randomized, double blind, parallel-group, placebo controlled study to evaluate the efficacy and safety of IBP-9414 in premature infants 500-1500g birth weight in the prevention of necrotizing entero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000754-22,0,0,0 2018-000755-40,14,2020-12-15,2020-12-15,10,1,0,0,0,1,3,0,0,2,1,0,0,0,1,"Amicus Therapeutics, Inc.",A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Alglucosi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000755-40,1,0,0 2018-000755-40,14,2020-12-15,2020-12-15,10,1,0,0,0,1,3,0,0,2,1,0,0,0,1,"AMICUS THERAPEUTICS, INC.",A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Alglucosi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000755-40,1,0,0 2018-000756-17,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,KU Leuven,Impact of Tight blood Glucose Control within normal fasting ranges with insulin titration prescribed by the Leuven algorithm in adult critically ill patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000756-17,0,0,0 2018-000757-49,6,2021-03-30,2021-04-04,4,1,0,0,0,2,3,0,0,2,1,0,0,0,1,"Quark Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for Acut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000757-49,1,0,0 2018-000759-41,5,,,0,1,0,0,0,0,2,0,0,2,1,0,0,0,1,F. Hoffman-La Roche Ltd.,A PHASE II TWO COHORT STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB PLUS ATEZOLIZUMAB IN BRAFV600 WILD-TYPE MELANOMA WITH CENTRAL NERVOUS SYSTEM METASTASES AND COBIMETINIB PLUS ATEZOLIZUMAB ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000759-41,0,0,0 2018-000759-41,5,,,0,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD,A PHASE II TWO COHORT STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB PLUS ATEZOLIZUMAB IN BRAFV600 WILD-TYPE MELANOMA WITH CENTRAL NERVOUS SYSTEM METASTASES AND COBIMETINIB PLUS ATEZOLIZUMAB ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000759-41,0,0,0 2018-000759-41,5,,,0,1,0,0,0,0,2,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,A PHASE II TWO COHORT STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB PLUS ATEZOLIZUMAB IN BRAFV600 WILD-TYPE MELANOMA WITH CENTRAL NERVOUS SYSTEM METASTASES AND COBIMETINIB PLUS ATEZOLIZUMAB ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000759-41,0,0,0 2018-000761-37,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,"Pfizer, Inc.","A Twelve-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study With Follow-up Evaluating The Safety And Efficacy Of Varenicline For Smoking Cessation In Healthy Adoles...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000761-37,0,1,1 2018-000764-29,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000764-29,0,0,0 2018-000765-36,1,2018-11-10,2018-11-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Idorsia Pharmaceuticals Ltd,"A multi-center, open-label, randomized, study to assess the onset of platelet aggregation inhibition after a single subcutaneous injection of ACT-246475 in adults with acute myocardial infarction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000765-36,0,0,0 2018-000767-91,1,2020-03-16,2020-03-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University of Oxford / Clinical Trials and Research Governance,INtravenous Iron to Treat Anaemia in CriTical Care Survivors (INTACT): a feasibility study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000767-91,0,0,0 2018-000768-27,10,2021-06-08,2021-06-08,7,1,0,0,0,1,2,0,0,2,1,0,0,0,1,InflaRx GmbH,"A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED, MULTICENTER, 2-PART PHASE II STUDY ON REPLACEMENT OF STEROIDS BY IFX-1 IN ACTIVE GRANULOMATOSIS WITH POLYANGIITIS (GPA) AND MICROSCOPIC POL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000768-27,1,0,0 2018-000769-35,1,2021-08-30,2021-08-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,"University Hospital, KU Leuven",In search for an innovative neural marker and intervention for socio-communicative difficulties in children with and without autism spectrum disorders,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000769-35,0,0,0 2018-000770-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,The Rotunda Hospital,Investigating the role of early low-dose aspirin in diabetes: A phase III multicentre double-blinded placebo-controlled randomised trial of low-dose aspirin initiated in the first trimester of diabete...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000770-29,0,0,0 2018-000774-30,1,2020-03-09,2020-03-09,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,Prolonged ENoxapariN in primarY percutaneous coronary intervention compared WIth Standard-of-carE therapy: Feasibility study (PENNYWISE Feasibility),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000774-30,0,0,0 2018-000775-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Vall d'Hebron Institut de Recerca,"Phase IV, randomized, open, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in febrile neutropenic Oncohematological Paediatric patients. Estudio de fase IV, al...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000775-32,0,0,0 2018-000777-80,1,2018-11-23,2018-11-23,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Sensorion,"A randomized, cross-over, placebo controlled, and meclizine calibrated study to assess the safety and pharmacodynamic effects of SENS-111 (100 mg and 200 mg) single dose in healthy subjects exposed to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000777-80,0,0,0 2018-000779-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud University Medical Center,Effect of a reduced dose on cognitive side effects of enzalutamide in frail mCRPC patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000779-33,0,0,0 2018-000780-91,1,2021-02-15,2021-02-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,ROCHE,"AN OPEN-LABEL, SINGLE-ARM PHASE IV STUDY TO ASSESS OCRELIZUMAB EFFICACY, SAFETY AND IMPACT ON PATIENT REPORTED OUTCOMES (PROS) IN PATIENTS WITH ACTIVE RELAPSING MULTIPLE SCLEROSIS (PRO-MSACTIVE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000780-91,0,0,0 2018-000781-10,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,"EFFICACY AND TOLERABILITY OF LOW VS. STANDARD DAILY DOSES OF ANTIEPILEPTIC DRUGS IN NEWLY DIAGNOSED, PREVIOUSLY UNTREATED EPILEPSY (STANDLOW). A MULTICENTER, RANDOMIZED, SINGLE-BLIND, PARALLEL GROUP T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000781-10,0,0,0 2018-000783-29,2,2021-08-03,2021-08-03,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Inchos Sciences SA (renamed from Glenmark Pharmaceuticals SA),"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 in Adult Subjects with Moderate to Severe Atopic Dermatitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000783-29,0,0,0 2018-000783-29,2,2021-08-03,2021-08-03,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Ichnos Sciences SA,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 in Adult Subjects with Moderate to Severe Atopic Dermatitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000783-29,0,0,0 2018-000788-95,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",Exploiting metformin plus/minus cyclic FAsting Mimicking diet (FMD) to improve the Efficacy of platinum-pemetrexed chemotherapy in advanced LKB1-mutated lung adenocarcinoma: the FAME trial Combinaz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000788-95,0,0,0 2018-000789-13,9,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,ISA Therapeutics B.V.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Oropharyngeal Cancer (OPC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000789-13,0,0,0 2018-000790-79,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Academic Medical Centre Amsterdam,IMPROVING OUTCOME IN SUBARACHNOID HEMORRHAGE WITH NADROPARINE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000790-79,0,0,0 2018-000802-46,7,2022-03-27,2022-03-27,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000802-46,1,0,0 2018-000805-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Neuroplast BV,"A multi-center, double-blind, randomized, placebo-controlled, delayed- start phase II/III study to assess the efficacy and safety of Neuro-Cells in (sub)acute spinal cord injury patients Estudio mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000805-22,0,0,0 2018-000811-26,1,2022-01-06,2022-01-06,1,0,0,0,0,0,3,0,0,1,0,0,0,0,0,Vall D'Hebron Institut de Recerca (VHIR),"A phase III, multicentric, Randomized, open-label, parallel-group clinical trial to detect false positives from first-trimester preeclampsia screening (StopPRE) at the second-trimester of pregnancy. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000811-26,0,0,0 2018-000812-47,5,2022-01-12,2022-01-12,4,0,0,0,0,1,2,0,0,2,0,0,0,0,1,SENSORION SA,"A two- part, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of SENS-401 in subjects with severe or profound sudden sensorineural hearing loss",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000812-47,1,0,0 2018-000813-19,2,2021-06-18,2021-06-18,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,MOLMED S.P.A,A Phase I-IIa trial to assess the safety and antitumor activity of autologous CD44v6 CAR T-cells in acute myeloid leukemia and multiple myeloma expressing CD44v6. Klinická studie fáze I-IIa k posou...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000813-19,0,0,0 2018-000813-19,2,2021-06-18,2021-06-18,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,MolMed S.p.A.,A Phase I-IIa trial to assess the safety and antitumor activity of autologous CD44v6 CAR T-cells in acute myeloid leukemia and multiple myeloma expressing CD44v6. Klinická studie fáze I-IIa k posou...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000813-19,0,0,0 2018-000816-96,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AP-HP/ DRCI,A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism Intravenöse thrombolytische Behandlung in reduzierter Dosis für Patienten mit akuter Lunge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000816-96,0,0,0 2018-000816-96,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS,A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism Intravenöse thrombolytische Behandlung in reduzierter Dosis für Patienten mit akuter Lunge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000816-96,0,0,0 2018-000816-96,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Assistance Publique – Hôpitaux de Paris, Clinical Research and Innovation Delegation (DRCI)",A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism Intravenöse thrombolytische Behandlung in reduzierter Dosis für Patienten mit akuter Lunge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000816-96,0,0,0 2018-000818-37,2,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Mestex AG,"A randomized, double-blind, placebo-controlled, single dose phase IIb exploratory study to document the clinical effects and safety of intra-articular injections of Lopain (MTX-071) in patients with c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000818-37,0,0,0 2018-000819-25,5,2019-10-07,2019-10-07,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Afimmune,"A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients with Severe Acute Decompensated Alcoholic Hepatitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000819-25,0,0,0 2018-000821-29,8,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,Shire Development LLC,"A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-label ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000821-29,0,0,0 2018-000821-29,8,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,"Takeda Development Center Americas, Inc.","A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-label ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000821-29,0,0,0 2018-000823-15,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Oslo University Hospital,Glucose metabolism in South Asian women with impaired glucose tolerance or impaired fasting glucose. DIAbetes in South Asians – DIASA 3 A 12-week intervention trial with oral antidiabetic medication ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000823-15,0,0,0 2018-000824-32,2,2018-10-22,2018-10-22,2,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Immune Design Corp.,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Subjects Followin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000824-32,0,0,0 2018-000827-15,1,2019-08-13,2019-08-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Incyte Corporation,"A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000827-15,0,0,0 2018-000832-82,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE TOSCANA GABRIELE MONASTERIO,GLYcemic Control with EMpagliflozin vs standard of care in patients with type 2 dIAbetes and Heart failure: effects on cardiac remodeling and neurohormonal activation EFFETTI DI EMPAGLIFLOZIN SU RI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000832-82,0,0,0 2018-000839-28,12,2022-06-14,2022-06-14,11,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000839-28,1,0,0 2018-000839-28,12,2022-06-14,2022-06-14,11,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A","A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000839-28,1,0,0 2018-000840-24,13,2022-06-14,2022-06-14,7,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000840-24,1,0,0 2018-000840-24,13,2022-06-14,2022-06-14,7,0,1,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000840-24,1,0,0 2018-000840-24,13,2022-06-14,2022-06-14,7,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000840-24,1,0,0 2018-000843-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GEICO (Grupo Español de Investigación en Cáncer de Ovario),"A phase II multicenter, open-label, single arm trial of avelumab in combination with pegylated liposomal doxorubicin in recurrent/metastatic endometrial cancer Ensayo abierto, multicéntrico, de un ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000843-14,0,0,0 2018-000844-25,9,2022-06-07,2022-06-07,4,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (EoE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000844-25,1,0,0 2018-000849-38,1,2021-02-23,2021-02-23,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase I/II, randomized, placebo-controlled, observer-blind, multicenter study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ investigational respiratory syncytial viru...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000849-38,0,0,0 2018-000851-42,2,2020-12-01,2020-12-01,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Idorsia Pharmaceuticals Ltd,"A randomized, double-blind, placebo-controlled, 12-week treatment study to evaluate the effect of ACT-774312 in subjects with bilateral nasal polyposis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000851-42,0,0,0 2018-000853-29,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Klinikum der Universität München,"Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, multicentre clinical trial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000853-29,0,0,0 2018-000853-29,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,KLINIKUM DER UNIVERSITAET MUENCHEN,"Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, multicentre clinical trial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000853-29,0,0,0 2018-000859-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UMBERTO I - POLICLINICO DI ROMA,"A randomized, double blind placebo controlled clinical trial to assess the efficacy and safety of sitagliptin on bone measures in women affected by type 2 diabetes. A gender-oriented approach to addre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000859-40,0,0,0 2018-000863-98,1,2018-10-30,2018-10-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical University of Graz,"A single-centre, open-label, non-controlled trial of acceptance, usability, safety and efficacy of a tablet based workflow and decision support system with incorporated basal-insulin algorithm for gly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000863-98,0,0,0 2018-000867-10,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Sma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000867-10,0,0,0 2018-000867-10,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Sma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000867-10,0,0,0 2018-000868-29,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,DBV Technologies S.A.,"Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Phase I Safety Study in Adult and Pediatric Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000868-29,0,1,1 2018-000873-59,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Cologne,Consolidation Therapy with Brentuximab Vedotin after Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma Konsolidierungstherapie mit Brentuximab Vedotin nach allogener ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000873-59,0,0,0 2018-000874-31,1,2019-02-01,2019-02-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mimer Medical AB,Iron deficinency and heart failure Järnbrist och hjärtsvikt,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000874-31,0,0,0 2018-000875-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,National Center for Cancer Immune Therapy,Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000875-34,0,0,0 2018-000876-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"University Hospital Frankfurt, Goethe University","ACO/ARO/AIO-18.1: Short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000876-14,0,0,0 2018-000877-61,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,Activity and safety of front-line venetoclax and rituximab association (VeRiTAs) in young and fit patients with chronic lymphocytic leukemia (CLL) and unmutated IGHV and/or disrupted TP53. A phase 2 m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000877-61,0,0,0 2018-000886-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Enrique Gomez-Barrena,"Evaluation of safety, feasibility and preliminary efficacy of MSCs from third party donors in the treatment of patients with osteonecrosis of the femoral head after allogeneic Stem Cell Transplantatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000886-35,0,0,0 2018-000889-11,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Medical Sciences, Akademiska sjukhuset",Randomized Evaluation of Beta Blocker and ACE-Inhibitor/Angiotensin Receptor Blocker Treatment in MINOCA patients - MINOCA-BAT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000889-11,0,0,0 2018-000889-11,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Medical Sciences, Uppsala Universitet",Randomized Evaluation of Beta Blocker and ACE-Inhibitor/Angiotensin Receptor Blocker Treatment in MINOCA patients - MINOCA-BAT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000889-11,0,0,0 2018-000892-33,2,2019-06-28,2019-06-28,2,1,1,0,0,0,3,0,0,1,0,0,1,0,1,Zealand Pharma A/S,"A phase 3, randomized, double-blind, placebo- and active-controlled, parallel-arm trial to assess the efficacy, safety, and pharmacokinetics of dasiglucagon relative to placebo and GlucaGen® when admi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000892-33,0,0,0 2018-000899-15,3,2020-07-17,2020-07-17,2,1,0,0,0,0,3,0,0,1,1,1,1,0,0,European Organisation for Research and Treatment of Cancer (EORTC),Radiotherapy and 6-month androgen deprivation therapy with or without apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a phase III study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000899-15,0,0,0 2018-000900-40,1,2020-04-20,2020-04-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LEO Pharma A/S,"A phase 2b, double-blind, randomised, 5-arm, vehicle-controlled, dose-ranging trial to evaluate the efficacy and safety of twice daily topical application of delgocitinib cream 1, 3, 8, and 20 mg/g fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000900-40,0,0,0 2018-000904-40,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc.,"A Multicenter, Open-Label Study Of The Long-Term Safety Of AN2728 Topical Ointment, 2% In The Treatment Of Children, Adolescents, And Adults (Ages 2 Years And Older) With Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000904-40,0,1,1 2018-000910-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA UDINE,Efficacy of tranexamic acid in reducing post-operative bleeding in oncologic-reconstructive breast surgery Efficacia dell’acido tranexamico topico nel ridurre i sanguinamenti post-operatori in chir...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000910-39,0,0,0 2018-000911-25,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Banc de Sang i Teixits,"A prospective multicenter open, not controlled phase Ib-II clinical trial to assess the safety and immunologic efficacy of virus-specific T lymphocytes from the best donor in receptors of hematopoieti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000911-25,0,0,0 2018-000913-19,1,2018-06-30,2018-06-30,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,"FAES FARMA, S.A.","Phase IV, single centre, randomised, open-label, two-period, two-way crossover clinical trial to assess the efficacy of Bilastine 20mg in the suppression of wheal and flare induced by intradermal hist...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000913-19,0,0,0 2018-000915-26,3,2021-07-18,2021-07-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ferring Pharmaceuticals A/S,"A randomised, double-blind, placebo-controlled, proof-of-mechanism phase 2 trial investigating the effect of quinagolide extended-release vaginal ring on reduction of lesions assessed by high-resoluti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000915-26,0,0,0 2018-000915-26,3,2021-07-18,2021-07-18,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ferring Pharmaceutical A/S,"A randomised, double-blind, placebo-controlled, proof-of-mechanism phase 2 trial investigating the effect of quinagolide extended-release vaginal ring on reduction of lesions assessed by high-resoluti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000915-26,0,0,0 2018-000916-75,6,2021-02-25,2021-02-25,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,RECARDIO Inc.,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000916-75,0,0,0 2018-000918-38,4,2020-08-27,2020-08-28,3,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Pfizer Inc.,"A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL, CROSSOVER STUDY ASSESSING SUBJECT PERCEPTION OF TREATMENT BURDEN WITH USE OF WEEKLY GROWTH HORMONE (SOMATROGON) VERSUS DAILY GROWTH HORMONE (GENOTROPIN®...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000918-38,1,0,0 2018-000919-24,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Leicester,A randomised placebo-controlled trial of anti-ST2 in COPD (COPD-ST2OP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000919-24,0,0,0 2018-000921-29,8,2022-05-19,2022-05-19,4,1,0,0,0,0,3,0,0,2,1,0,0,0,1,ALLENA PHARMACEUTICALS INCORPORATED,"Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000921-29,1,0,0 2018-000921-29,8,2022-05-19,2022-05-19,4,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Allena Pharmaceuticals, Inc.","Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000921-29,1,0,0 2018-000923-15,1,,,0,0,1,0,0,0,1,0,0,4,0,0,0,0,1,Amgen,"A Phase I, Randomized, Open-label, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000923-15,0,1,1 2018-000924-32,4,2021-02-15,2021-02-15,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,AGMT gGmbH,"Denosumab for high risk SMM and SLiM CRAB positive, early myeloma patient- a randomised, placebo controlled, phase II trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000924-32,1,0,0 2018-000924-32,4,2021-02-15,2021-02-15,1,0,0,0,0,0,2,0,0,2,1,0,0,0,0,Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH,"Denosumab for high risk SMM and SLiM CRAB positive, early myeloma patient- a randomised, placebo controlled, phase II trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000924-32,1,0,0 2018-000926-79,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide versus Dolutegravir + Emtricitabine/Tenofovir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000926-79,0,0,0 2018-000929-32,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Celgene Corporation,"A global randomized multicenter Phase 3 trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000929-32,0,0,0 2018-000929-32,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,CELGENE CORPORATION,"A global randomized multicenter Phase 3 trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000929-32,0,0,0 2018-000930-37,7,2021-08-27,2022-01-10,5,0,0,0,0,0,2,0,0,2,1,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of ABBV-323 in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000930-37,1,0,0 2018-000930-37,7,2021-08-27,2022-01-10,5,0,0,0,0,0,2,0,0,2,1,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of ABBV-323 in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000930-37,1,0,0 2018-000942-21,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Celso Arango,"A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000942-21,0,0,0 2018-000943-15,1,2020-07-29,2020-07-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"Randomized, double-blind, multicenter head-to-head study of erenumab against topiramate - migraine study to assess tolerability and efficacy in a patient-centered setting (HER-MES)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000943-15,0,0,0 2018-000964-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Institutet,Medical termination of pregnancy from day 85 to day 153 of gestation: A randomized comparison between administration of the initial dose of misoprostol at home or in the clinic,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000964-27,0,0,0 2018-000966-12,1,2022-04-05,2022-04-05,1,0,0,0,0,1,2,0,0,1,0,0,0,0,1,Eloxx Pharmaceuticals Inc,"A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients with Cystic Fibrosis wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000966-12,0,0,0 2018-000967-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Toulouse,Autologous transplantation of Adipose tissue derived mesenchymal Stroma/stem Cells (ASC) in patients with critical limb ischemia: a phase II study (ACellDream 2).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000967-10,0,0,0 2018-000970-31,1,2020-01-09,2020-01-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Double-Blind, Placebo-Controlled, Cross-over Phase 2 Study of Continuous 8 Hour Intravenous Infusions of BMS-986231 in Patients with Heart Failure and Impaired Systolic Function Given a ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000970-31,0,0,0 2018-000972-14,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,CHU DE POITIERS,Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole alone in non- or mildly- immunocompromised patients with Chronic Pulmo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000972-14,0,0,0 2018-000975-34,5,2020-01-20,2020-01-20,3,1,0,1,0,2,1,0,0,2,1,0,0,0,1,Wave Life Sciences Ltd.,"A Multicenter, Open-Label Extension Study of WVE-210201 in Patients Previously Enrolled in WVE-DMDX51-001",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000975-34,1,0,0 2018-000975-34,5,2020-01-20,2020-01-20,3,1,0,1,0,2,1,0,0,2,1,0,0,0,1,WAVE LIFE SCIENCES USA INC,"A Multicenter, Open-Label Extension Study of WVE-210201 in Patients Previously Enrolled in WVE-DMDX51-001",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000975-34,1,0,0 2018-000977-62,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Queen Mary University London,"A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer Eine randomisierte, of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000977-62,0,0,0 2018-000977-62,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Queen Mary University of London,"A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer Eine randomisierte, of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000977-62,0,0,0 2018-000981-12,1,2020-04-03,2020-04-03,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Medical University of Graz,"A PILOT STUDY INVESTIGATING THE EFFECTS OF LIPID-THERAPY INTENSIFICATION WITH ALIROCUMAB ON ENDOTHELIAL FUNCTION, CAROTID ARTERIES, LIPOPROTEIN PARTICLE SUBFRACTIONS, INFLAMMATION AND POST-PRANDIAL LI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000981-12,0,0,0 2018-000985-12,1,2019-04-12,2019-04-12,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Leiden University Medical Center,Near-infrared fluorescence imaging in kidney transplantations using ZW800-1 for perfusion assessment: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000985-12,0,0,0 2018-000991-13,1,,,0,0,0,0,0,0,2,0,1,4,0,0,0,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,"The MAGIC trial (Melatonin for Anxiety prior to General anaesthesia In Children): A Multicentre, Parallel Randomised Controlled Trial of Melatonin Versus Midazolam in the Premedication of Anxious Chil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000991-13,0,0,0 2018-000992-34,3,2019-08-28,2019-08-28,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,H. Lundbeck A/S,"Interventional, randomized, double-blind, placebo-controlled study of the efficacy and safety of initial administration of 25 mg vortioxetine intravenously with 10 mg/day vortioxetine orally in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000992-34,0,0,0 2018-000993-31,10,2021-04-15,2021-04-15,7,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A multicenter, randomized, double-blind, placebo- controlled phase 2b dose-finding study to investigate the efficacy, safety and tolerability of LOU064 in adult chronic spontaneous urticaria patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000993-31,1,0,0 2018-000993-31,10,2021-04-15,2021-04-15,7,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Farmacéutica,"A multicenter, randomized, double-blind, placebo- controlled phase 2b dose-finding study to investigate the efficacy, safety and tolerability of LOU064 in adult chronic spontaneous urticaria patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000993-31,1,0,0 2018-000995-14,3,,,0,0,0,1,0,1,1,0,0,2,0,0,0,0,1,Medivir AB,"A Phase 1/2a Study in 3 Parts (Phase 1a and Phase 1b - Dose Escalations and Phase 2a Expansion Cohorts) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000995-14,0,0,0 2018-000998-72,1,2020-11-12,2020-11-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Kyowa Kirin Co., Ltd.","A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects with Moderate to Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-000998-72,0,0,0 2018-001003-36,9,2020-11-12,2020-12-11,7,1,0,0,0,1,2,0,0,2,0,0,0,0,1,"Kiniksa Pharmaceuticals, Ltd. (Hamilton, Bermuda) c/o Kiniksa Pharmaceuticals Corp.","A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL-301 in giant cell arteritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001003-36,1,0,0 2018-001005-85,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Achilles Therapeutics UK Limited,"An open label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with advanced non-small cell lung cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001005-85,0,0,0 2018-001005-85,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Achilles Therapeutics Limited,"An open label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with advanced non-small cell lung cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001005-85,0,0,0 2018-001006-28,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Amgen Inc.,PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001006-28,0,0,0 2018-001008-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS,A SUPAR GUIDED DOUBLE BLIND RANDOMIZED CLINICAL TRIAL OF INITIATION OF ANTIBIOTICS FOR PRESUMED INFECTION AT THE EMERGENCY DEPARTMENT: THE SUPERIOR TRIAL ΜΙΑ ΔΙΠΛΗ-ΤΥΦΛΗ ΤΥΧΑΙΟΠΟΙΗΜΕΝΗ ΚΛΙΝΙΚΗ ΜΕΛΕ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001008-13,0,0,0 2018-001009-98,5,2021-11-26,2021-11-26,2,1,0,1,0,1,1,0,0,2,1,0,0,0,1,RHEACELL GmbH & Co. KG,"An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001009-98,1,0,0 2018-001010-15,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,ReViral Ltd.,"A Phase 2a Open-Label Study in Infants with REspiratory Syncytial VIRus Lower RespirAtory Tract Infection, Followed by a DoubLe-blind, Placebo controlled Part, to Evaluate the Safety, Tolerability, Ph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001010-15,0,0,0 2018-001012-30,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,University of Birmingham,"A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects with Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Main...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001012-30,0,0,0 2018-001013-32,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,HOSPITAL CLÍNIC BARCELONA,ANTITHROMBOTIC THERAPY AFTER LEFT ATRIAL APPENDAGE OCCLUSION: DOUBLE ANTIPLATELET THERAPY VS. APIXABAN TRATAMIENTO ANTITROMBÓTICO POSTERIOR AL CIERRE PERCUTÁNEO DE OREJUELA IZQUIERDA: APIXABAN VERS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001013-32,0,0,0 2018-001014-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,university hospital leuven,Frozen-thawed embryo transfer in a natural versus artificial cycle: a randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001014-15,0,0,0 2018-001016-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Nuclear Medicine, Medical University Innsbruck","PROSPECTIVE STUDY OF 68GA-NODAGA-RGD-PET FOR THE NON-INVASIVE DETERMINAITON OF THE INTEGRIN αvβ3 EXPRESSION IN PATIENTS WITH UNTREATED OR RECURRENT BREAST CANCER, COLORECTAL CANCER, NON-SMALL CELL LUN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001016-30,0,0,0 2018-001018-14,1,2019-12-05,2019-12-05,1,0,0,1,0,1,1,0,0,1,1,1,0,0,1,CELLECTIS SA,"Phase I, open label dose-escalation study to evaluate the safety, expansion, persistence and clinical activity of multiple infusions of UCART123 (allogeneic engineered T-cells expressing anti-CD123 ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001018-14,0,0,0 2018-001020-19,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Ghent University Hospital,Nifedipine induced pain relief during hysteroscopy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001020-19,0,0,0 2018-001021-10,1,2020-06-18,2020-06-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Sahlgrenska University Hospital,"Brodalumab in a randomised, open, phase IV study evaluating clinical efficacy in psoriasis patients switching from TNF-alpha inhibitor treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001021-10,0,0,0 2018-001023-38,9,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Celgene Corporation,"A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001023-38,0,0,0 2018-001024-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier Départemental Vendée,Glucose disorders Induced by Tacrolimus on pre Transplantation End-stage renal disease patients Evaluation de l'effet du tacrolimus sur le métabolisme glucidique chez les patients dialysés en pré...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001024-19,0,0,0 2018-001025-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Anestesiología y Reanimación del Hospital Universitario La Paz,COMPARISON OF POSTOPERATIVE ANALGESIA OF INTRAPERITONEAL NEBULIZED ROPIVACAIN BEFORE AND AFTER LAPAROSCOPIC GASTRIC BY-PASS IN OBESITY SURGERY COMPARACIÓN DE LA ANALGESIA POSTOPERATORIA DE LA ROPIV...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001025-20,0,0,0 2018-001027-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Paoli-Calmettes,ERIBRAIN - A phase II study of Eribulin in brain metastases from HER2-negative breast cancer pre-treated with anthracyclines and taxanes ERIBRAIN - Etude de phase 2 de l’Eribuline chez des patien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001027-40,0,0,0 2018-001028-21,2,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"MedImmune, LLC","A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001028-21,0,0,0 2018-001029-14,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after partially HLA compatible allogeneic hematopoietic st...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001029-14,0,0,0 2018-001030-17,3,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001030-17,0,0,0 2018-001030-17,3,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001030-17,0,0,0 2018-001032-22,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Agalimmune Ltd.,"A phase I/IIa, multicentre, open label study designed to evaluate the safety and tolerability of escalating doses of AGI-134 in unresectable/metastatic solid tumours.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001032-22,0,0,0 2018-001034-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,Phase II monocentric study to evaluate a novel approach for staging prostate cancer patients by using a fully integrated hybrid PET/MRI Studio monocentrico di Fase II per valutare un approccio inno...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001034-18,0,0,0 2018-001036-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,Phase II monocentric study on prostate cancer restaging using PET/MR with innovative radiotracers Studio monocentrico di fase II sulla ristadiazione del carcinoma prostatico mediante utilizzo della...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001036-21,0,0,0 2018-001037-41,1,2018-11-13,2018-11-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Verona Pharma plc,"A PHASE II, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, THREE WAY CROSSOVER STUDY TO ASSESS THE BRONCHODILATOR EFFECT OF RPL554 ADMINISTERED IN ADDITION TO OPEN LABEL TIOTROPIUM/OLODATEROL IN PATIEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001037-41,0,0,0 2018-001038-17,5,2019-07-08,2022-03-16,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir (LET) prophylaxis when extended from 100 days to 200 days post transplant in cyt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001038-17,1,0,0 2018-001038-17,5,2019-07-08,2022-03-16,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir (LET) prophylaxis when extended from 100 days to 200 days post transplant in cyt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001038-17,1,0,0 2018-001039-29,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, CONTROLLED STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH CHOP OR CHP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001039-29,0,0,0 2018-001042-33,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,IRCCS Istituto Giannina Gaslini,Efficacy of humanized anti-CD20 antibodies (Ofatumumab) in the treatment of childhood steroid-dependent nephrotic syndrome and development of cell biomarkers predicting outcome. Efficacia dell’ant...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001042-33,0,0,0 2018-001043-31,6,2020-10-15,2020-12-11,4,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3B/4, MULTICENTER, RANDOMIZED, ASSESSOR BLINDED, VEHICLE AND ACTIVE (TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR) CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY, SAFETY, AND LOCAL TOLER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001043-31,1,0,0 2018-001043-31,6,2020-10-15,2020-12-11,4,1,1,0,0,0,3,0,0,2,1,0,0,0,1,PFIZER INC,"A PHASE 3B/4, MULTICENTER, RANDOMIZED, ASSESSOR BLINDED, VEHICLE AND ACTIVE (TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR) CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY, SAFETY, AND LOCAL TOLER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001043-31,1,0,0 2018-001043-31,6,2020-10-15,2020-12-11,4,1,1,0,0,0,3,0,0,2,1,0,0,0,1,Pfizer Inc.,"A PHASE 3B/4, MULTICENTER, RANDOMIZED, ASSESSOR BLINDED, VEHICLE AND ACTIVE (TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR) CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY, SAFETY, AND LOCAL TOLER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001043-31,1,0,0 2018-001044-54,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,St Olavs Hospital -Trondheim University Hospital,A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM DIAGNOSIS: A RANDOMIZED PROSPECTIVE TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001044-54,0,0,0 2018-001048-70,1,2020-01-28,2020-01-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 16-week randomized, open-label, multicenter study to assess the superiority of secukinumab over guselkumab in the complete treatment of ustekinumab-resistant psoriatic plaques – ARROW",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001048-70,0,0,0 2018-001049-15,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,"ANOVA (Andrologi, Sexualmedicin, Transmedicin) Karolinska Universitetssjukhuset och Umeå Universitet",Pharmacological treatment of hypersexual disorder; an open pilot study to evaluate the feasibility and effectiveness of treatment with Naltrexone Farmakologisk behandling av hypersexualitet; en öpp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001049-15,0,0,0 2018-001051-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Saint-Etienne,VEDO - PREDIRESPUC project - Value of pharmacokinetic assays (Vedolizumab and anti-vedolizumab antibody) in the prediction of induction and maintenance therapeutic response in Ulcerative Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001051-12,0,0,0 2018-001054-96,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bone Therapeutics S.A.,"Phase IIb, Placebo-Controlled, Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB) Single Implantation in Tibial Fracture",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001054-96,0,0,0 2018-001057-26,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,Management of the patient with heart failure and diabetes: may insulin be a problem? A pilot randomized clinical study (Insulin-HF). Trattamento del paziente con insufficienza cardiaca e diabete: l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001057-26,0,0,0 2018-001059-12,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Hansa Biopharma AB,"An open-label, single arm, multi-centre, phase II study investigating safety, tolerability, efficacy, pharmacodynamics and pharmacokinetics of imlifidase (IdeS) in patients with Guillain-Barré Syndrom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001059-12,0,0,0 2018-001060-35,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Sun Pharma Global FZE,A Long-Term Extension Study to Demonstrate Safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001060-35,0,0,0 2018-001060-35,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Sun Pharmaceutical Industries Limited (SPIL),A Long-Term Extension Study to Demonstrate Safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001060-35,0,0,0 2018-001061-16,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AstraZeneca AB,"A Phase III, randomized, double-blind, placebo-controlled, multicenter, international study of Osimertinib as maintenance therapy in patients with locally advanced, unresectable EGFR mutation-positive...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001061-16,0,0,0 2018-001063-23,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,"Queen Mary Innovation Centre, Queen Mary University of London",PHASE II STUDY ASSESSING THE COMBINED USE OF AUTOLOGOUS BONE MARROW DERIVED MONONUCLEAR CELLS AND G-CSF WITH PERCUTANEOUS CIRCULATORY ASSISTANCE IN THE TREATMENT OF DILATED CARDIOMYOPATHY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001063-23,0,0,0 2018-001064-30,1,2019-09-26,2019-09-26,1,1,1,0,0,0,1,0,0,1,0,0,1,0,1,ACADIA Pharmaceuticals Inc.,"A Phase 1, Open Label, Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Pimavanserin in Adolescents with Psychiatric Disorders",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001064-30,0,0,0 2018-001066-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Spanish Group of Neuroendocrine Tumors (GETNE),"A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma - The DUTHY trial Estudio de fase II de durvalumab ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001066-42,0,0,0 2018-001067-23,1,2018-08-13,2018-08-13,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Zealand University Hospital,Pasireotide in the treatment of hypoglycemia following gastric bypass surgery Pasireotid i behandlingen af hypoglykæmi efter gastric bypass,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001067-23,0,0,0 2018-001069-18,9,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG- 3) and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001069-18,0,0,0 2018-001069-18,9,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG- 3) and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001069-18,0,0,0 2018-001070-20,1,2019-05-16,2019-05-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Active-Controlled, Open-Label, Phase 2 Clinical Trial of BMS-986213, in Combination with Various Standard-of-Care Therapeutic Regimens, in Participants with Recurrent, Locally Advanced, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001070-20,0,0,0 2018-001071-20,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Pharmatrophix Inc,"A 10-day prospective, single-center, double-blind, placebo-controlled, randomized study to evaluate safety, tolerability and pharmacokinetics of 600 mg b.i.d. oral doses of LM11A-31-BHS in healthy eld...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001071-20,0,0,0 2018-001072-37,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,2,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,AtTEnd: Atezolizumab Trial in Endometrial cancer - Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001072-37,0,0,0 2018-001072-37,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,2,IRCCS - Istituto di Ricerche Farmacologiche Mario Negri,AtTEnd: Atezolizumab Trial in Endometrial cancer - Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001072-37,0,0,0 2018-001075-20,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ISTITUTO ONCOLOGICO VENETO - IRCCS,"The METROPHOLYS Study - Metronomic cyclophosphamide vs doxorubicin in elderly patients with advanced soft tissue sarcomas. Randomized, controlled open label clinical trial The METROPHOLYS Study - M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001075-20,0,0,0 2018-001076-38,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"GlycoMimetics, Inc.","A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001076-38,0,0,0 2018-001077-24,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Nevakar Inc.,"CHAMP: A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children with Myopia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001077-24,0,0,0 2018-001082-17,13,2020-09-15,2020-10-28,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MENARINI RICERCHE S.p.A.,"A randomized, observer-blinded, active-controlled, Phase IIIb study to compare IV / Oral delafloxacin fixed-dose monotherapy with best available treatments in a microbiologically enriched population w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001082-17,0,0,0 2018-001082-17,13,2020-09-15,2020-10-28,10,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MENARINI RICERCHE SPA,"A randomized, observer-blinded, active-controlled, Phase IIIb study to compare IV / Oral delafloxacin fixed-dose monotherapy with best available treatments in a microbiologically enriched population w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001082-17,0,0,0 2018-001085-42,1,,,0,1,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Oxford,Clinical effectiveness of symptomatic therapy compared to standard step up care for the treatment of low impact psoriatic oligoarthritis: a 2 arm parallel group feasibility study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001085-42,0,0,0 2018-001094-25,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA,Phenylbutyrate Therapy in Mitochondrial Disease with lactic acidosis: an opel label clinical trial in MELAS and PHD deficiency patients Phemi: Terapia con Fenilbutirrato nelle malattie mitocondrial...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001094-25,0,0,0 2018-001096-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Cliniques universitaires Saint-Luc,"Avelumab combined with cetuximab and irinotecan for treatment refractory metastatic colorectal microsatellite stable cancer – A proof of concept, open label non-randomized Phase IIa study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001096-20,0,0,0 2018-001098-26,2,2020-06-30,2020-06-30,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001098-26,0,0,0 2018-001099-39,1,2020-06-07,2020-06-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Naestved Hospital,Dexamethasone twice for pain treatment of total knee arthroplasty (DEX-2-TKA) A randomized blinded placebo-controlled clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001099-39,0,0,0 2018-001100-11,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University College London,Defining best Management in Adult Chronic RhinOsinusitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001100-11,0,0,0 2018-001105-85,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Hospitalier Annecy Genevois,A multicenter phase II study evaluating denosumab (XGEVA®) in combination with nivolumab (OPDIVO®) as second-line therapy for patients with stage IV non-small–cell lung cancer (squamous and non-squamo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001105-85,0,0,0 2018-001109-99,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Cardiff University,"A randomised, placebo controlled trial of azithromycin for the prevention of chronic lung disease of prematurity in preterm infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001109-99,0,0,0 2018-001114-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"VU Medical Center, department of Rheumatology",Positron emission tomography with macrophage targeting to select individuals at risk for rheumatoid arthritis. Positron emissie tomografie met een macrofagen tracer voor het selecteren van individ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001114-15,0,0,0 2018-001115-73,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Uppsala University Hospital,"A Phase I/II, 2-Arm, Open Label, Single Centre Study to Investigate the Safety and Effect of Oral GABA Therapy on β-cell Regeneration in Type 1-diabetes Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001115-73,0,0,0 2018-001120-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Stichting Pediatrisch Onderzoek Enschede,The protective effect of azelastine/fluticasone propionate (Dymista) on exercise-induced airway obstruction Het beschermende effect van azelastine/fluticason propionaat (Dymista) op inspanningsgeïn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001120-18,0,0,0 2018-001124-20,1,2020-06-25,2020-06-25,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest,"Efficacy of Olaratumab and Rechallenge with Doxorubicin in anthracycline pretreated, advanced soft tissue sarcoma patients. An exploratory phase-II study - The OlaReDo Phase II Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001124-20,0,0,0 2018-001125-15,1,2019-10-18,2019-10-18,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Atox Bio,"Phase III, randomized, double-blind, placebo controlled, parallel-group, study of AB103 as compared to placebo in patients with necrotizing soft tissue infections (NSTI) Etude de phase III, random...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001125-15,0,0,0 2018-001127-40,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,A PHASE I/II TRIAL OF MOSUNETUZUMAB (BTCT4465A) AS CONSOLIDATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING FIRST-LINE IMMUNOCHEMOTHERAPY AND AS THERAPY IN PATIENTS WITH PREVIOUS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001127-40,0,0,0 2018-001129-15,1,2020-11-03,2020-11-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A.,The ELTION study – A multicenter open-label interventional study of Eltrombopag in patients with poor graft function after allogeneic hematopoietic stem cell transplantation ELTION- Estudio multicé...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001129-15,0,0,0 2018-001132-22,7,2019-06-17,2019-06-26,6,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Celgene Corporation,"A Phase 3, Randomized, Blinded, Placebo-controlled Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects with Locally Adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001132-22,1,0,0 2018-001132-22,7,2019-06-17,2019-06-26,6,0,0,0,0,0,3,0,0,2,1,0,0,0,1,CELGENE CORPORATION,"A Phase 3, Randomized, Blinded, Placebo-controlled Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects with Locally Adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001132-22,1,0,0 2018-001133-40,1,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"Amicus Therapeutics, Inc.",An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Fabry Subjects with Amenable GLA Variants and Severe Renal Impairment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001133-40,0,0,0 2018-001136-21,7,2019-08-13,2019-08-13,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of PF-04965842 Monotherapy in Subjects Aged 12 Years and Older, with Mode...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001136-21,0,0,0 2018-001136-21,7,2019-08-13,2019-08-13,7,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of PF-04965842 Monotherapy in Subjects Aged 12 Years and Older, with Mode...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001136-21,0,0,0 2018-001137-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hvidovre Hospital. Dep of Respiratory Medicine,"Use of Omalizumab will increase the pregnancy rate, proof of concept study, where women with asthma and infertility will be treated three times with weight and IgE balanced dosis at the sixth day of t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001137-41,0,0,0 2018-001141-13,2,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"AN OPEN-LABEL, MULTICENTER, PHASE Ib/II TRIAL EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN PATIENTS WITH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001141-13,0,0,0 2018-001143-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"Ioulia and Irene Tseti Pharmaceutical Laboratories S.A., d.t. ""Intermed S.A.""",Efficacy of a new ibuprofen formulation for vaginal application Αποτελεσματικότητα μίας νέας φαρμακοτεχνικής μορφής ιβουπροφαίνης για κολπική εφαρμογή,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001143-32,0,0,0 2018-001145-14,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"bluebird bio, Inc.",A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects inferior or equal to 17 Years of Age With Cerebral Adrenoleukodystrophy (CALD) St...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001145-14,0,0,0 2018-001145-14,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"BLUEBIRD BIO, INC.",A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects inferior or equal to 17 Years of Age With Cerebral Adrenoleukodystrophy (CALD) St...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001145-14,0,0,0 2018-001148-67,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,PROTALIX LTD,Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102) in Patients With Fabry Disease Otevřené pokračovací klinické hodnocení posuzující dlouhodo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001148-67,0,0,0 2018-001148-67,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Protalix Ltd.,Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102) in Patients With Fabry Disease Otevřené pokračovací klinické hodnocení posuzující dlouhodo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001148-67,0,0,0 2018-001149-15,1,2018-12-06,2018-12-06,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,NTC SRL,"Aqueous humour concentrations after topical apPlication of combinEd levofloxacin dexamethasone eye dRops and of its single components: a randoMized, assEssor-blinded, parallel-group study in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001149-15,0,0,0 2018-001152-35,2,2020-11-05,2020-11-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children with Sickle Cell Disease (PNEU–SICKLE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001152-35,0,0,0 2018-001152-35,2,2020-11-05,2020-11-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children with Sickle Cell Disease (PNEU–SICKLE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001152-35,0,0,0 2018-001153-27,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Guy's and St Thomas' NHS Foundation Trust,A feasibility study of a prospective randomised controlled trial comparing the use of open label pentoxifylline and tocopherol versus current standard of care for the prevention of fibrosis related ou...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001153-27,0,0,0 2018-001155-13,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,GBG Forschungs GmbH,"A Phase III, Randomized, Open-Label Study Investigating the Addition of Durvalumab to an Anthracycline-Taxane based Chemotherapy in Early-Stage Triple-Negative Breast Cancer Eine randomisierte, of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001155-13,0,0,0 2018-001157-27,1,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,CHRU of Lille,"Reversing poor graft function with eltrombopag after allogeneIc hematopoietic cell transplantation : a prospective, phase II study by the SFGM-TC. Étude multicentrique, prospective, de phase II éva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001157-27,0,0,0 2018-001158-82,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación SEIMC-GESIDA,"Phase IV, Open Label, Randomized, Clinical Trial to Evaluate the Reversibility of abacavir/lamivudine/dolutegravir CNS-Related Neurotoxicity After Switching to tenofovir alafenamide/emtricitabine/daru...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001158-82,0,0,0 2018-001159-11,4,2019-07-17,2019-07-17,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Polyphor Ltd.,"A multicenter, open-label, sponsor-blinded, randomized, active-controlled, parallel group, pivotal study to evaluate the efficacy, safety, and tolerability of murepavadin given with ertapenem versus a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001159-11,0,0,0 2018-001159-11,4,2019-07-17,2019-07-17,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Polyphor Deutschland GmbH,"A multicenter, open-label, sponsor-blinded, randomized, active-controlled, parallel group, pivotal study to evaluate the efficacy, safety, and tolerability of murepavadin given with ertapenem versus a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001159-11,0,0,0 2018-001162-42,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO,A phase 2 open-label study to evaluate the efficacy of allogeneic human cord blood-derived mesenchymal stromal cells in maintaining remission after immunosuppressive therapy withdrawal in pediatric pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001162-42,0,0,0 2018-001165-16,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of infectious Diseases, Aarhus University Hospital","Combining a TLR9 agonist with broadly neutralizing antibodies for reservoir reduction and immunological control of HIV infection: An investigator-initiated randomized, placebo-controlled, phase IIa tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001165-16,0,0,0 2018-001166-42,2,,,0,0,1,0,2,0,2,0,0,1,1,1,0,1,1,AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.,"A multi-centre, randomized, parallel-group, single blind Phase II trial to evaluate the pharmacokinetics and PKPD relationship of trazodone after single and repeated oral doses in children from 2 to ≤...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001166-42,0,0,0 2018-001166-42,2,,,0,0,1,0,2,0,2,0,0,1,1,1,0,1,1,Aziende Chimiche Riunite Angelini Francesco ACRAF S.p.A (Angelini S.p.A.),"A multi-centre, randomized, parallel-group, single blind Phase II trial to evaluate the pharmacokinetics and PKPD relationship of trazodone after single and repeated oral doses in children from 2 to ≤...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001166-42,0,0,0 2018-001167-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Immunomedics, Inc.","A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy Étude de phase II en ouvert de l’IMMU 132 da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001167-23,0,0,0 2018-001169-18,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Of Liverpool,The efficacy and mechanism of surfactant therapy for critically ill infants with bronchiolitis: The Bronchiolitis Endotracheal Surfactant Study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001169-18,0,0,0 2018-001171-20,11,2019-12-20,2019-12-20,8,1,0,0,0,1,3,0,0,2,1,0,0,0,1,"CymaBay Therapeutics, Inc.","A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intoleran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001171-20,1,0,0 2018-001176-38,4,2020-05-22,2020-05-22,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001176-38,0,0,0 2018-001180-23,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Marinus Pharmaceuticals, Inc.","A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001180-23,0,0,0 2018-001187-33,13,,,0,0,0,0,0,2,3,0,0,2,1,0,0,0,1,United Therapeutics Corporation,A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001187-33,0,0,0 2018-001187-33,13,,,0,0,0,0,0,2,3,0,0,2,1,0,0,0,1,"Arena Pharmaceuticals, Inc.",A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001187-33,0,0,0 2018-001189-40,14,,,0,0,0,0,0,2,3,0,0,2,1,0,0,0,1,United Therapeutic Corporation,A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001189-40,0,0,0 2018-001189-40,14,,,0,0,0,0,0,2,3,0,0,2,1,0,0,0,1,United Therapeutics Corporation,A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001189-40,0,0,0 2018-001189-40,14,,,0,0,0,0,0,2,3,0,0,2,1,0,0,0,1,"Arena Pharmaceuticals, Inc.",A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001189-40,0,0,0 2018-001191-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,"Levobupivacaine versus Liposomal Bupivacaine (Exparel®) for Treatment of Pain and Disability in Lateral Epicondylitis – Off-Label, Investigator Initiated Randomized, Controlled, Double-Blind Cross-Ove...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001191-38,0,0,0 2018-001201-93,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación ONCOSUR,Phase II study for the evaluation of neoadjuvant treatment with cabozantinib prior to cytoreductive nephrectomy in patients with locally advanced or metastatic renal cell carcinoma Estudio de fase ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001201-93,0,0,0 2018-001203-36,3,2020-05-15,2020-05-15,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,4D Pharma Plc,"A Phase 2 Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix™ in Adult Subjects with Irritable Bowel ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001203-36,0,0,0 2018-001207-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Miquel Pujol i Rojo ( Servicio de Enfermedades Infecciosas del Hospital Universitari de Bellvitge,"Phase IV-III Clinical Trial, randomized, controlled, open and multicentric, with parallel groups, to evaluate the efficacy of Cloxacillin and fosfomycin combination versus Cloxacillin monotherapy in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001207-37,0,0,0 2018-001209-95,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,INTEC PHARMA LTD,An open-label Phase 2 study to assess the pharmacokinetics of Accordion Pill¿ Carbidopa-Levodopa compared to immediate release carbidopa-levodopa in patients with Parkinson¿s disease Studio di fas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001209-95,0,0,0 2018-001210-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Masarykův onkologický ústav,Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR) Racion...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001210-15,0,0,0 2018-001212-30,1,2019-10-22,2019-10-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Central Institute of Mental Health, represented by commercial and administrative Director",A trial to study effects of a single dose Citalopram on emotion processing in female patients with Borderline Personality Disorder and the associated modulation of fMRI BOLD signals,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001212-30,0,0,0 2018-001213-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medica Scientia Innovation Research (MedSIR),Effectiveness of olaparib plus trastuzumab in HER2-positive BRCA-mutated or Homologous Recombination Deficiency (HRD) advanced breast cancer patients – The OPHELIA Study – Eficacia de olaparib en c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001213-32,0,0,0 2018-001216-29,1,2019-07-08,2019-07-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PRCL Research Inc.,"A Phase 2a Study to Evaluate Safety, Tolerability, and Efficacy of PRCL-02 in Patients with Moderate to Severe Chronic Plaque Psoriasis Štúdia fázy 2a na hodnotenie bezpečnosti, znášanlivosti a úči...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001216-29,0,0,0 2018-001219-53,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Trevi Therapeutics, Inc.","A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study in Prurigo Nodularis with Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001219-53,0,0,0 2018-001220-19,1,2019-12-22,2019-12-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MedImmune Limited, a wholly owned subsidiary of AstraZeneca","An Exploratory Phase 2a, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001220-19,0,0,0 2018-001221-98,1,2018-10-16,2018-10-16,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Medical University of Vienna, Department of Clinical Pharmacology","DEXAMETHASONE AS ADJUVANT FOR PERIPHERAL NERVE BLOCKADE: A RANDOMIZED, TRIPLE-BLINDED AND CROSSOVER STUDY IN VOLUNTEERS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001221-98,0,0,0 2018-001224-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Lekárska fakulta Univerzity Komenského v Bratislave,Non-invasive in-vivo prediction of therapeutic response to inhibitors of angiogenesis using gallium (68Ga) NODAGA-RGD PET/CT Neinvazívna in-vivo predikcia odpovede na terapiu inhibítormi angiogenéz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001224-19,0,0,0 2018-001227-39,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University of Bergen, Faculty of Medicin, Department of Clinical Dentistry",A randomized controlled clinical trial to assess the efficacy of a combination of autologous mesenchymal stem cells and biomaterial in jaw bone regeneration prior to dental implant placement in compar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001227-39,0,0,0 2018-001228-20,11,2022-09-30,2022-09-30,6,0,0,0,0,0,4,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A 12-month prospective, randomized, interventional, global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs. oral prophylactics) in adult e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001228-20,1,0,0 2018-001228-20,11,2022-09-30,2022-09-30,6,0,0,0,0,0,4,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A 12-month prospective, randomized, interventional, global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs. oral prophylactics) in adult e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001228-20,1,0,0 2018-001229-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,Idelalisib (I) in combination with Obinutuzumab (G) for the treatment of patients with relapsed / refractory follicular lymphoma: multicentric phase II single arm study. Idelalisib (I) in combinazi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001229-18,0,0,0 2018-001230-18,1,2019-03-28,2019-03-28,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Hellenic Genito-Urinary Cancer Group (HGUCG),"Long-term thromboprophylaxis with tinzaparin in high-risk prostate or breast cancer patients. A prospective, randomised, international multicentre, open-label, blinded-endpoint Phase III study. PROBE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001230-18,0,0,0 2018-001231-48,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU DE POITIERS,Effectiveness of oral corticosteroids in unilateral recurrent laryngeal nerve palsy after thyroidectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001231-48,0,0,0 2018-001233-40,6,2021-11-29,2021-11-29,5,0,0,0,0,0,3,0,0,1,0,0,0,0,1,AMGEN INC.,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction and Decr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001233-40,0,0,0 2018-001233-40,6,2021-11-29,2021-11-29,5,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Amgen Inc,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction and Decr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001233-40,0,0,0 2018-001233-40,6,2021-11-29,2021-11-29,5,0,0,0,0,0,3,0,0,1,0,0,0,0,1,"Cytokinetics, Inc","A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects with Heart Failure with Reduced Ejection Fraction and Decr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001233-40,0,0,0 2018-001234-18,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Imperial College NHS Trust,Effect of EVOlocumab on CARotid plaque composition in asymptomatic carotid artery stenosis (EVOCAR-1),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001234-18,0,0,0 2018-001238-16,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patients with Moderate-to-Severe Plaque-Type Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001238-16,0,0,0 2018-001238-16,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patients with Moderate-to-Severe Plaque-Type Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001238-16,0,0,0 2018-001240-61,2,2021-03-26,2021-03-26,2,1,0,1,0,0,1,0,0,1,1,1,0,0,1,RHEACELL GmbH & Co. KG,"An interventional, single arm, multicenter, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-ACLF for the treatment of acute-on-chronic liver failure (ACLF)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001240-61,0,0,0 2018-001246-34,6,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,Celgene Corporation,"A Phase 1b/2, open-label, single arm, multicohort, multicenter trial to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory (r/r) B-cell acute lymphoblastic leuk...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001246-34,0,0,0 2018-001252-35,1,2021-08-13,2021-08-13,1,0,0,0,1,0,4,0,1,1,1,1,1,0,0,Kirsten Møller,Neuroplasticity induced by general anaesthesia Anæstetikainduceret neuroplasticitet,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001252-35,0,0,0 2018-001257-27,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,KU Leuven,Cognitive brain circuits and the spread of tau in vivo in humans Cognitieve hersencircuits en de verspreiding van tau in de hersenen in vivo bij de mens,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001257-27,0,0,0 2018-001261-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ÖNH-kliniken Sunderby Sjukhus,"Betamethasone (Betapred®) as premedication for reducing postoperative vomiting and pain after tonsillectomy – a randomized, double-blind, placebo-controlled trial Betamethasone (Betapred®) som p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001261-16,0,0,0 2018-001265-17,1,2020-09-17,2020-09-17,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Turku University Central Hospital,Relationship of edoxaban plasma concentration and blood coagulation in healthy volunteers using standard laboratory tests and viscoelastic analysis (EdoRot). Edoksabaanin veripitoisuuden ja yksittä...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001265-17,0,0,0 2018-001267-22,1,2022-03-01,2022-03-01,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Radboud University Medical Center,"F18-PSMA-1007 PET for early biochemical recurrence of prostate cancer, comparison with 18F-Fluciclovine. F18-PSMA-1007 PET voor vroege detectie van een biochemisch recidief van prostaatkanker, verg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001267-22,0,0,0 2018-001268-40,1,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,0,Guy's and St. Thomas' NHS Foundation Trust,"Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001268-40,0,0,0 2018-001269-18,3,2020-10-19,2020-10-19,3,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Mycovia Pharmaceuticals, Inc","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects with Recurrent Vulvovaginal Candidiasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001269-18,0,0,0 2018-001270-26,3,2020-10-09,2020-10-09,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Mycovia Pharmaceuticals, Inc","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects with Recurrent Vulvovaginal Candidiasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001270-26,0,0,0 2018-001271-20,4,2021-02-05,2021-03-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PFIZER INC,"A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001271-20,0,0,0 2018-001271-20,4,2021-02-05,2021-03-05,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Pfizer Inc 235 East 42nd Street, New York, NY10017 US","A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001271-20,0,0,0 2018-001272-37,11,2021-11-16,2021-12-31,4,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Theravance Biopharma Ireland Limited,"A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy with 2 Doses of TD-1473 in Subjects with Moderately-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001272-37,1,0,0 2018-001272-37,11,2021-11-16,2021-12-31,4,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Theravance Biopharma US, Inc.","A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy with 2 Doses of TD-1473 in Subjects with Moderately-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001272-37,1,0,0 2018-001272-37,11,2021-11-16,2021-12-31,4,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Theravance Biopharma UC Inc.,"A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Induction Therapy with 2 Doses of TD-1473 in Subjects with Moderately-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001272-37,1,0,0 2018-001275-21,3,2021-06-14,2021-06-14,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine Rec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001275-21,0,0,0 2018-001275-21,3,2021-06-14,2021-06-14,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine Rec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001275-21,0,0,0 2018-001275-21,3,2021-06-14,2021-06-14,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited)","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine Rec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001275-21,0,0,0 2018-001277-24,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,VU University Medical Center (VUmc),"Microvascular Recovery in Acute MI, a single center, prospective, randomized, single blind parallel-group comparison of sonothrombolysis versus standard of care performed after (post) coronary reperfu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001277-24,0,0,0 2018-001279-19,2,2019-12-29,2019-12-29,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"BURL Concepts, Inc.",Evaluation of the SONAS® ultrasound device for the assessment of bilateral cerebral perfusion in subjects with acute stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001279-19,0,0,0 2018-001280-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Merja Kokki,"- NENÄSUMUTTEENA ANNETUN FENTANYYLIN KÄYTTÖN SYDÄNLEIKKAUKSEN JÄLKEISEN KIVUN HOIDOSSA - TEHO, IMEYTYMINEN JA TURVALLISUUS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001280-22,0,0,0 2018-001282-17,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,Eisai Inc.,"A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001282-17,0,1,1 2018-001284-24,3,,,0,0,0,0,0,2,2,0,0,3,0,0,0,0,1,"BEIGENE USA, INC.","A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001284-24,0,0,0 2018-001284-24,3,,,0,0,0,0,0,2,2,0,0,3,0,0,0,0,1,"BeiGene, Ltd.","A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001284-24,0,0,0 2018-001285-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,NEAT ID Foundation,A PHASE 3 STUDY EVALUATING THE EFFECT OF PITAVASTATIN TO PREVENT CARDIOVASCULAR EVENTS IN HIV-1 INFECTED INDIVIDUALS Estudio en fase III para evaluar el efecto de la pitavastatina para prevenir los...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001285-41,0,0,0 2018-001286-16,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Rigshospitalet,Low-dose Atropine for the Prevention of Childhood Myopia Progression in Danish Children (APP-study) Lav-dosis atropin til at forebygge udviklingen af nærsynethed hos danske børn (APP-study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001286-16,0,0,0 2018-001290-24,1,2021-09-16,2021-09-16,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical University of Graz,NFAT-regulated gene expression after tacrolimus NFAT-regulierte Genexpression nach Lebertransplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001290-24,0,0,0 2018-001291-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud University Medical Center,In vivo efficacy of Salbutamol Sandoz versus salbutamol Ventolin GSK in children with asthma in vivo effectiviteit van Salbutamol Sandoz versus Salbutamol Ventolin GSK in kinderen met astma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001291-38,0,0,0 2018-001292-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Rennes,Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001292-21,0,0,0 2018-001294-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO,Regional Hypo-perfusion as metabolic raiser of ventilator-induced lung injury (VILI): pilot clinica trial L’IPOPERFUSIONE POLMONARE REGIONALE COME MOLTIPLICATORE DEL DANNO POLMONARE INDOTTO DALLA V...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001294-25,0,0,0 2018-001295-37,1,2021-02-10,2021-02-10,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,CUB HOPITAL ERASME,CILOSTAZOL AS IMATINIB SYNERGISER IN PATIENTS WITH UNRESECTABLE OR METASTATIC GIST TREATED BY GLIVEC®,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001295-37,0,0,0 2018-001301-90,5,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Sanifit Therapeutics S.A,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001301-90,0,0,0 2018-001301-90,5,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,SANIFIT THERAPEUTICS S.A.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001301-90,0,0,0 2018-001301-90,5,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Sanifit Therapeutics S.A.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001301-90,0,0,0 2018-001303-36,13,2022-05-19,2022-09-27,6,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Tricida Inc.,"A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001303-36,1,0,0 2018-001303-36,13,2022-05-19,2022-09-27,6,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Tricida, Inc.","A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001303-36,1,0,0 2018-001305-82,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Laura Perelló Moreno,Study on the advantages of local post-operative infiltration in forefoot surgery. Estudio sobre las ventajas de la infiltración local postoperatoria en la cirugía de antepié,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001305-82,0,0,0 2018-001309-95,6,2022-05-20,2022-05-20,4,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Mereo BioPharma 4 Ltd,"A Phase 2, proof-of-concept, multicentre, double-blind, randomised, dose-ascending, sequential group, placebo-controlled study to evaluate the mechanistic effect, safety, and tolerability of 12 weeks ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001309-95,1,0,0 2018-001311-79,8,2020-12-18,2020-12-18,6,1,0,0,0,0,3,0,0,2,1,0,0,0,1,JAZZ PHARMACEUTICALS INC,"A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) with an Open-label Safety Extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001311-79,1,0,0 2018-001311-79,8,2020-12-18,2020-12-18,6,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Jazz Pharmaceuticals,"A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) with an Open-label Safety Extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001311-79,1,0,0 2018-001311-79,8,2020-12-18,2020-12-18,6,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Jazz Pharmaceuticals Inc,"A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) with an Open-label Safety Extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001311-79,1,0,0 2018-001312-30,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Common Services Agency,SPRING - Seizure PRophylaxis IN Glioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001312-30,0,0,0 2018-001316-29,7,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,GlaxoSmithKline Research and Development Ltd.,"A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001316-29,0,0,0 2018-001316-29,7,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001316-29,0,0,0 2018-001317-33,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,"A Phase II, open-label, ophthalmological external investigator-blinded, single-center, randomized, superiority, no profit, pilot clinical trial to evaluate the effects of atorvastatin on Graves' Orbit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001317-33,0,0,0 2018-001320-19,4,,,0,0,0,1,0,1,1,0,0,2,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Ce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001320-19,0,0,0 2018-001320-19,4,,,0,0,0,1,0,1,1,0,0,2,0,0,0,0,1,VERTEX PHARMACEUTICALS INCORPORATED,A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Ce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001320-19,0,0,0 2018-001321-68,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,"Pfizer, Inc.",Gemtuzumab Ozogamicin (mylotarg (registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/refractory Acute Myelogenous Leukemia Who May Benefit From Treatment...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001321-68,0,1,1 2018-001324-19,1,2019-04-05,2019-04-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Marinomed Biotech AG,Demonstration of therapeutic equivalence/non-inferiority as well as early onset of action of the novel water-soluble budesonide nasal spray (Budesolv) compared with marketed Rhinocort® aqua 64 in pati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001324-19,0,0,0 2018-001326-25,5,,,0,0,1,0,0,0,2,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase 2b open-label, single-arm study to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in pediatric participants from birth to less than 18 years of age at risk of devel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001326-25,0,1,0 2018-001326-25,5,,,0,0,1,0,0,0,2,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc","A Phase 2b open-label, single-arm study to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in pediatric participants from birth to less than 18 years of age at risk of devel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001326-25,0,1,0 2018-001327-39,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Imperial College London,"A Phase II, Two-Stage, Trial of Pembrolizumab in Cancer of unknown primary - CUPem",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001327-39,0,0,0 2018-001328-21,1,2022-02-28,2022-02-28,1,0,0,0,0,0,4,0,0,1,1,1,0,0,0,Leiden University Medical Center,Chronotherapy with aspirin for reduction of cardiovascular disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001328-21,0,0,0 2018-001331-48,3,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase 3, Dose-Escalating Study in Children With Hyperkalaemia Between Birth and <18 Years of Age to Evaluate Increasing Doses of Sodium Zirconium Cyclosilicate (SZC) Given Three Times Daily for the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001331-48,0,0,0 2018-001334-18,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,Associazione Italiana Pazienti Leucemia Mieloide Cronica (AIPLMC),Cardiovascular assessment of Ponatinib as treatment option in chronic phase chronic myeloid leukemia after failure of Imatinib and Bosutinib (CarPAs) Valutazione cardiovascolare di Ponatinib come o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001334-18,0,0,0 2018-001337-41,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"SK Life Science, Inc.","A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001337-41,0,0,0 2018-001339-33,1,2019-07-15,2019-07-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Academisch medisch centrum Amsterdam,"A randomized, double-blind, placebo-controlled, study to determine the added value of vitamin D3 to treatment with subcutaneous immunotherapy in patients with moderate to severe allergic rhinitis/ rhi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001339-33,0,0,0 2018-001340-62,2,2019-09-06,2019-09-06,2,1,0,1,0,0,1,0,1,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"A study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ investigational unadjuvanted RSV maternal vaccine compared to placebo when administered to healthy non-pregnant wo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001340-62,0,0,0 2018-001343-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU-Hôpitaux de Rouen,Double regional anesthesia in video assisted thoracoscopy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001343-31,0,0,0 2018-001344-57,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"GITMO GRUPPO ITALIANO PER IL TRAPIANTO DI MIDOLLO OSSEO, CELLULE STAMINALI EMOPOIETICHE E TERAPIA",Pentaglobin as early adjuvant treatment for febrile neutropenia in acute leukemia or allogeneic hematopoietic stem cell transplant patients colonized by carbapenem-resistant Enterobacteriaceae or Pseu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001344-57,0,0,0 2018-001345-14,1,2022-04-27,2022-04-27,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Ziekenhuis Oost-Limburg Autonome Verzorgingsinstelling,"A multi-center, randomized, double-blind, phase IV clinical trial on the diuretic effects of Acetazolamide (Diamox ®) in patients with Decompensated heart failure and Volume OveRload.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001345-14,0,0,0 2018-001346-34,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Immodulon Therapeutics Ltd,A Study of the Safety and Efficacy of IMM-101 in Combination with Checkpoint Inhibitor Therapy in Patients with Advanced Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001346-34,0,0,0 2018-001347-31,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,IRCCS ISTITUTO CLINICO HUMANITAS,Anti-nerve reactivity as predictor of response to immune therapy in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A proof of concept study with rituximab in patients...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001347-31,0,0,0 2018-001355-12,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,SANOFI-AVENTIS GROUPE,"Phase IV, randomized, double-blind, multicenter, placebo-controlled clinical trial to evaluate the efficacy and the safety of enterogermina (Bacillus clausii) in treating patients with small intestina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001355-12,0,0,0 2018-001356-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University of Heidelberg,ACO/ARO/AIO-18.2 Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized phase III trial of the...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001356-35,0,0,0 2018-001358-84,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Saint Etienne,"Bone, Inflammation, Gut and Renal Biomarkers in Antiretroviral Naïve HIV-1 positive subjects commencing Antiretroviral Therapy Les biomarqueurs osseux, inflammatoires, intestinaux et rénaux chez de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001358-84,0,0,0 2018-001359-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHRU TOURS,"0.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001359-11,0,0,0 2018-001360-39,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,SARC,"A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity Studio co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001360-39,0,0,0 2018-001362-41,1,2020-06-05,2020-06-05,1,1,0,1,0,1,1,0,1,1,0,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single-ascending and Multiple-dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-AAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001362-41,0,0,0 2018-001364-27,4,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,"Zeno Alpha, Inc.,","A PHASE 1/2 OPEN LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF ZN-C5 ALONE AND IN COMBINATION WITH PALBOCICLIB IN SUBJECTS WITH ESTROGEN-REC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001364-27,0,0,0 2018-001366-42,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BeiGene Ltd.,"A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001366-42,0,0,0 2018-001366-42,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"BeiGene, Ltd.","A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001366-42,0,0,0 2018-001366-42,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"BeiGene, Ltd. c/o BeiGene USA, Inc.,","A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001366-42,0,0,0 2018-001368-43,4,2021-10-20,2021-10-20,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Myovant Sciences GmbH,"An International Phase 3 Double-Blind, Placebo-controlled, Randomized Withdrawal Study of Relugolix Co-administered with Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Asso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001368-43,1,0,0 2018-001368-43,4,2021-10-20,2021-10-20,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,MYOVANT SCIENCES GMBH,"An International Phase 3 Double-Blind, Placebo-controlled, Randomized Withdrawal Study of Relugolix Co-administered with Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Asso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001368-43,1,0,0 2018-001371-20,1,2019-03-07,2019-03-07,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,CHU de Nice,Study of the role of local treatments on the modulation of the microbiome in psoriatic skin Etude du rôle des traitements locaux sur la modulation du microbiome dans la peau psoriasique,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001371-20,0,0,0 2018-001375-21,2,2019-09-25,2019-09-25,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients with PD-L1-High Expression...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001375-21,1,0,0 2018-001376-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,María Dolores Sousa Regueiro,"Antimicrobials Local Administration for Intraabdominal Abscesses Treatment: Controlled, Randomized, Open, Parallel Groups, Clinical Trial Administración Local de Antimicrobianos para el Tratamiento...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001376-38,0,0,0 2018-001377-24,1,2019-10-29,2019-10-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Chong Kun Dang Pharmaceutical Corporation (CKD),"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of CKD-506 Administered to Adult Subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001377-24,0,0,0 2018-001379-20,1,2019-01-11,2019-01-11,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Myovant Sciences GmbH,"A Phase 2a Randomized, Double-Blind, Placebo and Active Comparator-Controlled, Parallel Group, Dose-Range Finding Study of MVT-602 in Healthy Premenopausal Women Undergoing Controlled Ovarian Stimulat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001379-20,0,0,0 2018-001380-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Franciscus Gasthuis en Vlietland,The effect of tamsulosin on the spontaneous passage of bile stones Het effect van tamsulosine voor de spontane expulsie van galstenen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001380-23,0,0,0 2018-001381-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,IMMULAB – A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001381-42,0,0,0 2018-001382-17,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Alimentiv Inc,"Stopping Aminosalicylate Therapy in Inactive Crohn’s Disease (STATIC) Study: A Randomized, Open-label, Non-inferiority Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001382-17,0,0,0 2018-001383-28,16,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001383-28,0,0,0 2018-001386-16,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Technische Universität Dresden,Investigation of the efficacy of acamprosate and calcium in comparison to placebo as validation of a behavioural test for alcohol dependence (TEMACA) Untersuchung der Wirksamkeit von Acamprosat und...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001386-16,0,0,0 2018-001387-39,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Thoraxklinik-Heidelberg gGmbH,"A prospective, randomized, controlled trial to assess the effect of long-term oxygen therapy on 6-minute walking distance, clinical parameters and hemodynamics in patients with pulmonary arterial hype...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001387-39,0,0,0 2018-001392-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,A randomized trial to investigate the reset of humoral autoimmunity by combining belimumab with rituximab in severe systemic lupus erythematosus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001392-21,0,0,0 2018-001393-16,11,,,0,0,1,0,0,2,2,0,0,2,1,0,0,0,1,Premacure AB,"A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001393-16,0,0,0 2018-001393-16,11,,,0,0,1,0,0,2,2,0,0,2,1,0,0,0,1,"PREMACURE AB, A MEMBER OF SHIRE GROUP OF COMPANIES","A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001393-16,0,0,0 2018-001393-16,11,,,0,0,1,0,0,2,2,0,0,2,1,0,0,0,1,"Premacure AB, A Member of the Shire Group of Companies","A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001393-16,0,0,0 2018-001393-16,11,,,0,0,1,0,0,2,2,0,0,2,1,0,0,0,1,Oak Hill Bio,"A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001393-16,0,0,0 2018-001395-37,1,2020-12-10,2020-12-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Repha GmbH,"Investigation of the efficacy and safety of ANGOCIN® Anti-Infekt N versus placebo in adult patients with acute bronchitis. A multicenter, randomized, double-blind, placebo-controlled, parallel-group p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001395-37,0,0,0 2018-001400-11,8,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Amgen Inc.,"A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001400-11,0,0,0 2018-001402-28,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Hospital Universitario La Paz,PROTOCOL FOR THE OPTIMIZATION OF THE PREPARATION FOR THE COLONOSCOPY IN PATIENTS WITH INTESTINAL INFLAMMATORY DISEASE PROTOCOLO PARA LA OPTIMIZACIÓN DE LA PREPARACIÓN PARA LA COLONOSCOPIA EN PACIEN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001402-28,0,0,0 2018-001404-11,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,GENENTA SCIENCE SRL,A phase I/IIa dose escalation study evaluating the safety and efficacy of autologous CD34+-enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001404-11,0,0,0 2018-001405-87,7,2021-02-10,2021-04-12,5,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Galapagos NV,"A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001405-87,1,0,0 2018-001406-29,5,2021-02-10,2021-02-10,2,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Galapagos NV,"A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001406-29,0,0,0 2018-001406-29,5,2021-02-10,2021-02-10,2,1,0,0,0,1,3,0,0,1,1,1,1,0,1,GALAPAGOS NV,"A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001406-29,0,0,0 2018-001411-71,2,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,"Regeneron Pharmaceuticals, Inc.",Study to Evaluate Synovial Fluid in the Phase 3 Fasinumab Program for Osteoarthritis of the Knee and Hip,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001411-71,0,0,0 2018-001412-30,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Laboratorios Farmalíder S.A.,"Double blind, randomized, pilot clinical trial controlled with placebo to evaluate the comparative efficacy of ibuprofen combined with different doses of tramadol and tramadol 100 mg by intravenous ro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001412-30,0,0,0 2018-001415-75,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de TOULOUSE,"Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase III, multicenter, parallel-group randomized, controlled tri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001415-75,0,0,0 2018-001416-30,11,2020-03-16,2020-04-16,11,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL IN COMBINATION WITH STANDARD-OF-CARE NEURAMINIDASE INHIBITOR IN HO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001416-30,0,0,0 2018-001417-32,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CHU-Hôpitaux de Rouen,"Long-term Follow-up of patients participants with pemphigus From Study RITUXIMAB3. Immunological, clinical and medicoeconomic evaluation Suivi clinique et immunologique à long terme des patients at...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001417-32,0,0,0 2018-001418-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UMBERTO I - POLICLINICO DI ROMA,Assessment of clinical efficacy of Sildenafil 75 mg orodispersable film vs Sildenafil 100 mg tablet in patients with erectile dysfunction Valutazione dell’efficacia clinica del sildenafil 75mg film...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001418-14,0,0,0 2018-001420-19,10,2020-09-07,2020-09-07,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Novartis Pharma AG,"A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adult p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001420-19,0,0,0 2018-001420-19,10,2020-09-07,2020-09-07,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,NOVARTIS PHARMA AG,"A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adult p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001420-19,0,0,0 2018-001420-19,10,2020-09-07,2020-09-07,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Novartis Farmacéutica, S.A","A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adult p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001420-19,0,0,0 2018-001423-40,13,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001423-40,0,0,0 2018-001423-40,13,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001423-40,0,0,0 2018-001429-26,8,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Zealand Pharma A/S,A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients with Short Bowel Syndrome (SBS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001429-26,0,0,0 2018-001430-18,1,2021-02-22,2021-02-22,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Kuopio University Hospital,Does postoperative intravenous corticosteroid and intravenous beta blocker management prevent atrial fibrillation after cardiac surgery? Estääkö postoperatiivisesti suonensisäisesti annettava korti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001430-18,0,0,0 2018-001431-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Kuopio University Hospital,Does postoperative corticosteroid management prevent atrial fibrillation after mitral valve surgery? Estääkö postoperatiivisesti annettu kortikosteroidi hiippaläppäleikkauksen jälkeisen eteisvärinä...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001431-40,0,0,0 2018-001433-41,1,2021-06-28,2021-06-28,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,University Hospital Tuebingen,Phase II Studie zur Verminderung der Peritonealkarzinose-Inzidenz nach kurativer Gastrektomie eines Magenkarzinoms oder Adenokarzinoms des gastroösophagealen Übergangs durch hypertherme intraperitonea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001433-41,0,0,0 2018-001435-52,5,2022-06-28,2022-06-28,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Apellis Pharmaceuticals Inc.,"A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy with Sham Injections in Patients with Geographic Atro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001435-52,1,0,0 2018-001435-52,5,2022-06-28,2022-06-28,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"APELLIS PHARMACEUTCIALS, INC.","A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy with Sham Injections in Patients with Geographic Atro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001435-52,1,0,0 2018-001436-22,5,2022-06-20,2022-06-20,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"APELLIS PHARMACEUTCIALS, INC.","A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy with Sham Injections in Patients with Geographic Atro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001436-22,1,0,0 2018-001436-22,5,2022-06-20,2022-06-20,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Apellis Pharmaceuticals Inc.,"A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy with Sham Injections in Patients with Geographic Atro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001436-22,1,0,0 2018-001437-40,9,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,1,KURA ONCOLOGY INC,"The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001437-40,0,0,0 2018-001437-40,9,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,1,"Kura Oncology, Inc.","The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001437-40,0,0,0 2018-001440-53,5,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001440-53,0,0,0 2018-001440-53,5,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001440-53,0,0,0 2018-001441-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IFOM - Istituto FIRC di Oncologia Molecolare - Milano,PEMBROLIZUMAB IN MMR-PROFICIENT METASTATIC COLORECTAL CANCER PHARMACOLOGICALLY PRIMED TO TRIGGER DYNAMIC HYPERMUTATION STATUS PEMBROLIZUMAB IN PAZIENTI CON CANCRO DEL COLON RETTO METASTATICO CON SI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001441-14,0,0,0 2018-001443-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,DOAC Levels prior to Incision study: DALI study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001443-31,0,0,0 2018-001444-66,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA,"ASSESSING TOLERABILITY AND EFFICACY OF VORTIOXETINE VERSUS SSRIs IN ELDERLY PATIENTS WITH DEPRESSION: A PRAGMATIC, MULTICENTER, OPEN-LABEL, PARALLEL-GROUP, SUPERIORITY, RANDOMIZED TRIAL Valutare la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001444-66,0,0,0 2018-001447-31,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Gustave Roussy,"Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolida...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001447-31,0,0,0 2018-001448-78,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Vita Green Europa S.A.,"Single-site, open, randomized clinical trial to assess the non-inferiority of Cysticlean® versus Fosfomicina in the treatment of cystitis in women in Spain. Ensayo clínico unicéntrico, abierto y co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001448-78,0,0,0 2018-001451-13,6,2021-12-14,2021-12-14,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"VenatoRx Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-blind, Active-controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults with Complicated Urinary Tract Infections,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001451-13,1,0,0 2018-001456-34,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,"CytomX Therapeutics, Inc.","A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001456-34,0,0,0 2018-001457-28,1,,,0,0,0,0,1,0,3,0,0,4,0,0,0,0,0,CHU Amiens-Picardie,Analgesic contribution of the suprazygomatic maxillary nerve block after cleft palate surgery in children Apport du bloc du nerf maxillaire par voie suprazygomatique dans l’analgésie après chirurgi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001457-28,0,0,0 2018-001461-16,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001461-16,0,0,0 2018-001461-16,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001461-16,0,0,0 2018-001462-42,8,2020-12-28,2020-12-28,5,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"PellePharm, Inc.","A Multicenter, Randomized, Double blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001462-42,1,0,0 2018-001464-35,4,2020-12-22,2020-12-22,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Otonomy, Inc.","A prospective, randomized, double blind, placebo-controlled, multicenter, Phase 3 efficacy and safety study of OTO-104 given as a single intratympanic injection in subjects with unilateral Meniere's d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001464-35,1,0,0 2018-001464-35,4,2020-12-22,2020-12-22,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"OTONOMY, INC.","A prospective, randomized, double blind, placebo-controlled, multicenter, Phase 3 efficacy and safety study of OTO-104 given as a single intratympanic injection in subjects with unilateral Meniere's d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001464-35,1,0,0 2018-001466-42,1,2021-11-16,2021-11-16,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Fondation Lenval - Hôpitaux Pédiatriques de Nice CHULENVAL,EFFECTIVENESS OF INTRANASAL DEXMEDETOMIDINE FOR SEDATED AUDITORY BRAINSTEM RESPONSE TESTING EFFICACITE DE LA DEXMEDETOMIDINE PAR VOIE INTRANASALE DANS LA SEDATION POUR LA REALISATION DE POTENTIELS ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001466-42,0,0,0 2018-001467-23,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,CHU de Toulouse,"Dexamethasone plus salvage chemotherapy versus salvage chemotherapy alone in patients with first relapsed or refractory acute myeloid leukemia: a randomized, controlled, open-label, multicenter, phase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001467-23,0,0,0 2018-001468-48,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur,"Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Aged 10 to 55 Years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001468-48,0,1,1 2018-001469-18,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Dipartimento di Scienze della Vita e Biotecnologie dell'Università degli Studi di Ferrara,Treatment of beta-thalassemia patients with rapamycin (sirolimus): from pre-clinical research to a clinical trial Trattamento di pazienti con beta-talassemia con Rapamicina (sirolimus): dalla ricer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001469-18,0,0,0 2018-001470-18,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc.,Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001470-18,0,1,1 2018-001471-20,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc.,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001471-20,0,1,1 2018-001472-38,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc.,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Other Pediatric Vaccines in Healthy Toddlers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001472-38,0,1,1 2018-001473-24,1,,,0,0,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc,Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001473-24,0,1,1 2018-001475-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FILO,"Preemptive therapy with Venetoclax for high risk CLL stage A patients, a phase II trial of the FILO PREVENE (PREemptive Venetoclax) trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001475-20,0,0,0 2018-001476-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dra. Carlota Gudiol González. Servicio de Enfermedades Infecciosas. Hospital Universitari de Bellvitge.,Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in hematologic patients (BEATLE study). Eficacia de la infusión extendida de los antibióticos β-lactám...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001476-37,0,0,0 2018-001480-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,"IMMUNIB - An open-label, single-arm phase II study of immunotherapy with nivolumab in combination with lenvatinib for advanced stage hepatocellular carcinoma (HCC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001480-23,0,0,0 2018-001481-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ITF RESEARCH PHARMA S.L.U.,"Prospective, multicentre, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of a 0.005% estriol vaginal gel in the prevention of recurrent urinary tract infections i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001481-42,0,0,0 2018-001485-42,2,2021-06-03,2021-06-03,1,0,0,0,1,0,4,0,0,2,0,0,0,0,0,Radboudumc,RECOVER study: the effect of low- versus normal pressure pneumoperitoneum during laparoscopic colorectal surgery on the early quality of recovery with perioperative care according to the enhanced reco...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001485-42,1,0,0 2018-001488-21,1,2019-07-01,2019-07-01,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Sergio Aleman,EFFECT OF VITAMIN D SUPPLEMENTATION ON THE VENTRICULAR DEFORMATION RATE (STRAIN RATE) IN PATIENTS WITH HEART FAILURE WITH PRESERVED OR MODERATELY REDUCED EYECTION FRACTION EFECTO DE LA SUPLEMENTACI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001488-21,0,0,0 2018-001489-41,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset,Radiation- and alkylator-free hematopoietic cell transplantation for bone marrow failure due to dyskeratosis congenita / telomere disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001489-41,0,0,0 2018-001494-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET",In vivo molecular imaging of angiogenesis after VEGF-D gene therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001494-24,0,0,0 2018-001495-38,3,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,"Xynomic Pharmaceuticals, Inc.","A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Estudio de fase 3, aleato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001495-38,0,0,0 2018-001496-20,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Katairo GmbH,"A multi-national, multi-centre, double-masked, placebo-controlled proof of concept trial to evaluate the safety and efficacy of oral soraprazan in Stargardt Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001496-20,0,0,0 2018-001502-28,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Imperial College London,Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001502-28,0,0,0 2018-001505-90,1,2020-03-10,2020-03-10,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU de Saint Etienne,Decolonization of patients carrying S. aureus before cardiac surgery: study of the risk factors associated with failure Décolonisation des patients porteurs de Staphylococcus aureus en chirurgie ca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001505-90,0,0,0 2018-001508-12,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A placebo-controlled, patient and investigator blinded, randomized parallel cohort study to assess pharmacodynamics, pharmacokinetics, safety, tolerability and preliminary clinical efficacy of VAY736 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001508-12,0,0,0 2018-001508-12,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A placebo-controlled, patient and investigator blinded, randomized parallel cohort study to assess pharmacodynamics, pharmacokinetics, safety, tolerability and preliminary clinical efficacy of VAY736 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001508-12,0,0,0 2018-001510-15,2,2021-08-25,2021-11-15,2,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Goli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001510-15,0,0,0 2018-001511-73,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001511-73,0,0,0 2018-001511-73,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001511-73,0,0,0 2018-001514-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Bezirkskliniken Schwaben,Effects of early clozapine treatment on remission rates in acute schizophrenia (EARLY) Effekte der frühzeitigen Applikation von Clozapin auf die Remissionsrate bei akuter Schizophrenie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001514-15,0,0,0 2018-001516-30,3,2020-08-10,2020-08-10,2,1,1,0,0,0,2,0,0,2,0,0,0,0,1,GUERBET,"Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, P03277, in pediatric patients from 2 to 17 years of age undergoing central nervous system contrast-enhanced MRI.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001516-30,1,0,0 2018-001517-32,6,2021-02-18,2021-05-07,2,0,0,0,0,0,0,0,0,2,1,0,0,0,1,MERCK KGAA,"A Phase II, Multicenter, Randomized, Open- Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001517-32,1,0,0 2018-001517-32,6,2021-02-18,2021-05-07,2,0,0,0,0,0,0,0,0,2,1,0,0,0,1,Merck KGaA,"A Phase II, Multicenter, Randomized, Open- Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001517-32,1,0,0 2018-001517-32,6,2021-02-18,2021-05-07,2,0,0,0,0,0,0,0,0,2,1,0,0,0,1,Merck Healthcare KGaA,"A Phase II, Multicenter, Randomized, Open- Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001517-32,1,0,0 2018-001518-13,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Maatschap Cardiologie Zwolle,Comparison between treatment with catheter ablation or anti-arrhythmic drugs (sotalol or combination of verapamil and flecainide) of patients with benign ventricular premature beats and ventricular ta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001518-13,0,0,0 2018-001521-97,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis,Phase II single arm study of afatinib in combination with cetuximab in EGFR exon 20 insertion positive non-small-cell lung cancer Fase II één-armige studie met afatinib in combinatie met cetuximab ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001521-97,0,0,0 2018-001522-25,6,,,0,0,1,0,0,1,2,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001522-25,0,0,0 2018-001522-25,6,,,0,0,1,0,0,1,2,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001522-25,0,0,0 2018-001522-25,6,,,0,0,1,0,0,1,2,0,0,2,1,0,0,0,1,Recordati AG,"A phase II, multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing’s disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001522-25,0,0,0 2018-001527-39,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SEAGEN INC.,A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001527-39,0,0,0 2018-001527-39,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Seagen Inc.,A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001527-39,0,0,0 2018-001529-24,2,2021-05-27,2021-05-27,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Merck KGaA,"A Phase IIa, single-arm, multi center study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in participants with advanced squam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001529-24,1,0,0 2018-001534-17,3,2019-11-06,2019-11-06,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Merck KGaA,"A Phase II, Randomized, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination with Avelumab and Carboplatin in Comparison to Standard of Care Th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001534-17,0,0,0 2018-001534-17,3,2019-11-06,2019-11-06,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,MERCK KGAA,"A Phase II, Randomized, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination with Avelumab and Carboplatin in Comparison to Standard of Care Th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001534-17,0,0,0 2018-001539-39,1,2022-04-14,2022-04-14,1,0,0,0,0,0,3,0,0,1,0,0,0,0,0,Národní ústav duševního zdraví,Clinical and neurobiological predictors of response to ketamine: towards personalized treatment of depression Klinické a neurobiologické prediktory odpovědi na ketamin jako podklad pro personalizov...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001539-39,0,0,0 2018-001540-56,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A multi-center, randomized, double-blind, parallel-group, placebo controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and charac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001540-56,0,0,0 2018-001543-30,4,2020-02-12,2020-07-28,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2A STUDY TO ASSESS THE EFFICACY AND SAFETY OF REGN3500 MONOTHERAPY AND COMBINATION OF REGN3500 PLUS DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001543-30,0,0,0 2018-001544-64,4,2020-02-12,2020-07-24,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY INVESTIGATING THE EFFICACY, SAFETY, AND PHARMACOKINETIC PROFILES OF REGN3500 ADMINISTERED TO ADULT PATIENTS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001544-64,0,0,0 2018-001545-13,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001545-13,0,0,0 2018-001546-33,1,2020-02-20,2020-02-20,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Southampton Hospital NHS Foundation Trust,IBD Biosimilar to Biosimilar Infliximab Switching Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001546-33,0,0,0 2018-001547-32,17,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001547-32,0,0,0 2018-001547-32,17,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001547-32,0,0,0 2018-001552-36,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,INSTITUT CLAUDIUS REGAUD,The use of FES-PET imaging as a tool to detect a possible reversion of Estrogen Receptor (ER)-α status in patients with metastatic breast cancer HER2 + and ERα neg treated with trastuzumab + pertuzuma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001552-36,0,0,0 2018-001557-27,4,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001557-27,0,0,0 2018-001569-17,1,2019-12-20,2019-12-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Radboud university medical center,Effect of the SGLT-2 inhibitor dapagliflozin on impaired awareness of hypoglycemia in type 1 diabetes Effect van de SGLT-2 remmer dapagliflozine op verminderde hypoglykemie symptoomgewaarwording (a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001569-17,0,0,0 2018-001571-21,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,0,Leiden University,Training immune functions through pharmacotherapeutic conditioning in juvenile idiopathic arthritis Training van immuunfuncties door middel van farmacotherapeutisch conditioneren in juveniele idiop...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001571-21,0,0,0 2018-001573-24,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,0,Antwerp University Hospital,Functional Respiratory Imaging (FRI) to assess the short-term effect of the product ORKAMBI (lumacaftor/ ivacaftor) on lung function in ORKAMBI-naive patients with Cystic Fibrosis Homozygous for Phe50...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001573-24,0,0,0 2018-001581-42,6,2020-08-05,2020-09-03,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,H. Lundbeck A/S,"Interventional, randomized, double-blind, parallel-group, placebo-controlled, fixed-flexible-dose study of Lu AF11167 for the treatment of persistent prominent negative symptoms in patients with schiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001581-42,0,0,0 2018-001581-42,6,2020-08-05,2020-09-03,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,H. Lunbeck A/S,"Interventional, randomized, double-blind, parallel-group, placebo-controlled, fixed-flexible-dose study of Lu AF11167 for the treatment of persistent prominent negative symptoms in patients with schiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001581-42,0,0,0 2018-001582-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO,"Efficacy of Albumin Replacement and Balanced Crystalloid Solutions in Septic Shock (the ALBIOSS-BALANCED trial): a 2-by-2 factorial, investigator-initiated, open-label, multicenter, randomized, contro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001582-16,0,0,0 2018-001584-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital of Montpellier,"""Microglial Activation in Narcolepsy Type 1: Positron Emission Tomography (PET) Study in [18F] DPA-714"" ""Activation microgliale dans la Narcolepsie de type 1: Etude en tomographie par émission de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001584-23,0,0,0 2018-001585-42,5,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001585-42,0,0,0 2018-001585-42,5,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001585-42,0,0,0 2018-001587-32,5,2022-01-12,2022-01-12,2,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Rafael Pharmaceuticals Inc,A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenoc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001587-32,1,0,0 2018-001587-32,5,2022-01-12,2022-01-12,2,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Rafael Pharmaceuticals, Inc",A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenoc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001587-32,1,0,0 2018-001588-22,6,2021-10-25,2021-10-28,3,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Rafael Pharmaceuticals Inc,Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitox...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001588-22,1,0,0 2018-001588-22,6,2021-10-25,2021-10-28,3,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Rafael Pharmaceuticals, Inc.",Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitox...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001588-22,1,0,0 2018-001590-24,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,2,University of Dundee,"A Trial of the Safety, Tolerability and Efficacy of 2 doses of Cayston (Aztreonam Lysine) compared to placebo in participants with bronchiectasis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001590-24,0,0,0 2018-001590-24,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,2,NHS Tayside,"A Trial of the Safety, Tolerability and Efficacy of 2 doses of Cayston (Aztreonam Lysine) compared to placebo in participants with bronchiectasis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001590-24,0,0,0 2018-001594-24,9,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001594-24,0,0,0 2018-001594-24,9,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001594-24,0,0,0 2018-001596-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Helixor Heilmittel GmbH,Influence of a Helixor® P infusion therapy on the Cancer-related Fatigue (CrF) of female patients with advanced breast cancer or female or male patients with NSCLC during oncological standard therapy ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001596-20,0,0,0 2018-001597-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sitnikova Victoria,Efficacy of botulinum toxin in treating temporomandibular disorders Kliininen tutkimus botuliinihoidon tehokkuudesta potilailla joilla on diagnosoitu purentaelimistön toimintahäiriöitila,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001597-16,0,0,0 2018-001600-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Dipartimento di Medicina di Precisione - Università degli studi della Campania ""L. Vanvitelli""",Phase II randomized study evaluating the efficacy of panitumumab (VEctibix) and Trifluridine-Tipiracil (LOnsurf) in pretreated RAS wild type metastatic colorectal cancer patients: the VELO trial St...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001600-12,0,0,0 2018-001601-82,1,2020-06-29,2020-06-29,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Mundipharma Pharmaceuticals B.V.,Open randomized clinical trial to compare pain relief between low-dose methoxyflurane and standard of care for the treatment of patients with trauma pain in emergency medical services in the Netherlan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001601-82,0,0,0 2018-001603-37,6,2021-10-12,2021-10-12,6,1,0,0,0,0,2,0,0,1,1,1,0,0,1,ACTELION Pharmaceuticals Ltd,"A long-term, multicenter, single-arm, open-label extension of the SERENADE study, to assess the safety and efficacy of macitentan in subjects with heart failure with preserved ejection fraction and pu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001603-37,0,0,0 2018-001604-10,1,2018-11-29,2018-11-29,1,1,0,0,1,0,4,0,1,1,0,0,1,0,1,BIODRUG s.r.o.,"A single blind, randomized comparative and multicentre clinical trial of the immunogenicity and safety of booster immunisation with bivalent vaccine against tetanus and diphtheria VACDITE (BIODRUG) an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001604-10,0,0,0 2018-001605-93,11,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,AstraZeneca AB,"A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001605-93,0,0,0 2018-001605-93,11,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,ALLERGAN LIMITED,"A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001605-93,0,0,0 2018-001605-93,11,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Allergan Ltd.,"A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001605-93,0,0,0 2018-001606-29,11,2022-05-16,2022-05-16,1,0,0,0,0,1,3,0,0,2,1,0,0,0,1,INCYTE CORPORATION,A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001606-29,1,0,0 2018-001606-29,11,2022-05-16,2022-05-16,1,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Incyte Corporation,A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001606-29,1,0,0 2018-001608-12,5,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Iovance Biotherapeutics, Inc.","A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001608-12,0,0,0 2018-001613-33,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA,"Efficacy and safety of adjunctive IgM-enriched immunoglobulin therapy with a personalized dose based on serum IgM-titers vs. standard dose in patients with septic shock. A multicenter, interventional,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001613-33,0,0,0 2018-001615-78,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,3,,Effect of Duloxetine 30/60 mg Once Daily Versus Placebo in Adolescents With Juvenile Primary Fibromyalgia Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001615-78,0,1,1 2018-001616-30,7,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,CORCEPT THERAPEUTICS,An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001616-30,0,0,0 2018-001616-30,7,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Corcept Therapeutics Incorporated,An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001616-30,0,0,0 2018-001618-13,2,2020-10-27,2020-10-27,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Regeneron Pharmaceuticals, Inc.",Study to Evaluate Arthroplasty Specimens in the Phase 3 Fasinumab Program for Osteoarthritis of the Knee and Hip,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001618-13,0,0,0 2018-001619-65,1,2020-12-03,2020-12-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001619-65,0,0,0 2018-001622-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,FIDIA FARMACEUTICI S.P.A.,"A randomized, double-blind, placebo-controlled, multicenter clinical trial to assess safety and effectiveness of Liposom in enhance and speed up response to antidepressant therapy with citalopram in e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001622-26,0,0,0 2018-001623-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Verein zur Förderung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und vaskulären Biologie (ATVB)",Assessment of body composition changes after Levosimendan treatment in patients with advanced heart failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001623-39,0,0,0 2018-001625-96,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,UZ Leuven,"The effect of hydroxychloroquine sulphate on hedonic food intake, appetite-related sensations and gastrointestinal hormone release in overweight female subject",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001625-96,0,0,0 2018-001626-26,3,2020-04-08,2020-04-08,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,OMEICOS Therapeutics GmbH,"A Placebo-controlled, double-blind, Randomized, dose finding phase II study on OMT-28 in MaIntenance of Sinus rhythm after Electrical cardioversion in patients with persistent Atrial Fibrillation (PRO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001626-26,0,0,0 2018-001627-39,8,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Incyte Corporation,A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001627-39,0,0,0 2018-001627-39,8,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,INCYTE CORPORATION,A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001627-39,0,0,0 2018-001631-46,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus University Medical Center,Implementation of pharmacokinetic-guided dosing of DDAVP and VWF-containing concentrates in von Willebrand disease Implementatie van farmacokinetisch gestuurd doseren van DDAVP en VWF-bevattende s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001631-46,0,0,0 2018-001633-41,1,2021-06-08,2021-06-08,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Dermapharm AG,"Double-blind, randomised clinical study comparing efficacy and safety of Ciclopirox Olamine Cream 10 mg/g (Test) vs. Batrafen® Cream (Reference) vs. Vehicle in patients with skin mycoses Doppelblin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001633-41,0,0,0 2018-001639-35,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Merz Pharmaceuticals GmbH,"Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity caused by stroke or traumatic br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001639-35,0,0,0 2018-001644-61,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CHU Besançon,"Efficacité en 1ère ligne de traitement d’une polychimiothérapie (méthotrexate, L-asparaginase, idarubicine et dexamethasone) dans la leucémie à cellules dendritiques plasmacytoïdes (LpDC) de l’adulte.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001644-61,0,0,0 2018-001645-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Spanish HIV/AIDS Research Networkº,"An open randomized multicenter study comparing TAF/FTC/DRV/cobi vs. ABC/3TC/DTG in HIV-infected antiretroviral naïve patients. (The Symtri study) Estudio SYMTRI: Ensayo clínico abierto, aleatorizad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001645-14,0,0,0 2018-001646-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU CAEN,A MULTICENTRE OPEN-LABEL PHASE II STUDY OF IXAZOMIB -DARATUMUMAB WITHOUT DEXAMETHASONE (IDARA) IN ELDERLY RELAPSE REFRACTORY MULTIPLE MYELOMA.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001646-34,0,0,0 2018-001650-98,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Edinburgh and NHS Lothian,"Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): A randomised, parallel-group, allocation concealed, controlled, open, phase 3 pragmatic clinical and cost- e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001650-98,0,0,0 2018-001650-98,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,NHS Lothian,"Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): A randomised, parallel-group, allocation concealed, controlled, open, phase 3 pragmatic clinical and cost- e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001650-98,0,0,0 2018-001653-27,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Aposcience AG,"A randomized, placebo-controlled, double-blind study to evaluate safety and dose dependent clinical efficacy of APO-2 at three different doses in patients with diabetic foot ulcer (MARSYAS II) Eine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001653-27,0,0,0 2018-001656-35,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,"Dept.Dermotology , Aarhus University",Metabolic imaging of patients with mycosis fungoides using hyperpolarized 13C-Pyruvate magnetic resonance imaging – A feasibility study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001656-35,0,0,0 2018-001657-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,,Comparison of ultrasound guided Serratus Anterior Plane Block (SAPB) with continuous local anesthetic infusion and epidural analgesia in the treatment of multiple rib fracture analgesia: a prospective...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001657-27,0,0,0 2018-001659-11,1,2019-05-22,2019-05-22,1,0,0,0,0,0,3,0,1,1,0,0,1,0,0,COSMETIC SURGERY BCN SLP,A pilot study to evaluate the safety and efficacy of the application of Belkyra™ in the fat located in the hypogastric zone. Estudio piloto para evaluar la seguridad y la eficacia de la aplicación ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001659-11,0,0,0 2018-001660-29,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,FAB: Functional Analysis of BRCAness,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001660-29,0,0,0 2018-001661-17,9,2021-05-18,2021-07-08,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001661-17,1,0,0 2018-001661-17,9,2021-05-18,2021-07-08,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Lilly S.A.,Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001661-17,1,0,0 2018-001661-17,9,2021-05-18,2021-07-08,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER",Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001661-17,1,0,0 2018-001661-17,9,2021-05-18,2021-07-08,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly Cork Limited,Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001661-17,1,0,0 2018-001663-22,1,2020-11-06,2020-11-06,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Maastricht University,Effects of ciprofibrate on myocardial insulin sensitivity in pre-diabetes Effect van ciprofibraat op insuline gevoeligheid van het hart in pre-diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001663-22,0,0,0 2018-001664-38,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Hospital Schleswig-Holstein (UKSH),A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome) Konzeptnachweis und Bewertung der Maximalwirkun...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001664-38,0,0,0 2018-001667-24,1,2019-05-01,2019-05-01,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Pulmocide Ltd,"A double blind, placebo-controlled study to assess the anti-viral effect, safety and tolerability of inhaled PC786 for the treatment of acute respiratory syncytial virus (RSV) infection in adult hemat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001667-24,0,0,0 2018-001669-17,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Nottingham University Hospitals NHS Trust,ICaRAS (IV Iron for Cancer Related Anaemia Symptoms) – A Feasibility Study of Intravenous Iron Therapy for Anaemia in Palliative Cancer Care.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001669-17,0,0,0 2018-001671-21,11,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Kartos Therapeutics, Inc.","A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001671-21,0,0,0 2018-001671-21,11,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Kartos Therapeutics, Inc","A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001671-21,0,0,0 2018-001672-38,4,2022-02-11,2022-02-11,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Kartos Therapeutics, Inc.","A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemia V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001672-38,1,0,0 2018-001678-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,VU Medical Center,Tofacitinib: salvage therapy for patients with RCDII - a pilot study Tofacitinib: laatste redmiddel voor patiënten met RCDII - een pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001678-10,0,0,0 2018-001680-24,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Medical University of Vienna - Abteilung für Thoraxchirurgie,Combined low-dose everolimus and low-dose tacrolimus after alemtuzumab induction therapy: a randomized prospective trial in lung transplantation Ein Protokoll mit niedrig dosierte Immunosuppressio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001680-24,0,0,0 2018-001683-37,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Rigshospitalet,"The RIME-IVF study Investigation of RIsk factors in out-of-hospital-cardiac-arrest patients, and MEdical treatment in Idiopathic Ventricular Fibrillation patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001683-37,0,0,0 2018-001684-22,1,2019-05-08,2019-05-08,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,University of Antwerp,"A Phase 2, partial blind, randomized, placebo-controlled, multicenter study to evaluate the safety and immunogenicity of two novel live attenuated serotype 2 oral poliovirus vaccines candidates, in he...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001684-22,0,0,0 2018-001686-17,1,,,0,0,0,1,0,1,1,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Essai Bayésien de phase I/II évaluant l’efficacité et la tolérance du danazol chez les patients ayant une atteinte hématologique ou pulmonaire sévère liée à une téloméropathie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001686-17,0,0,0 2018-001690-25,4,2020-04-23,2020-04-23,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Celltrion, Inc","A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P17 with Humira when Co-administered with Methotrexate in Patients with Moderate to Severe Active Rheu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001690-25,0,0,0 2018-001693-25,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Groupe Francophone des Myelodysplasies,A single-arm phase II multicenter study of IDH2 (AG 221) inhibitor in patients with IDH2 mutated myelodysplastic syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001693-25,0,0,0 2018-001695-38,2,2020-08-07,2020-08-07,2,1,1,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-445/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001695-38,0,0,0 2018-001696-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Erasmus MC Kanker Instituut,Adjuvant hepatic arterial infusion pump chemotherapy after resection of colorectal liver metastases in patients with a low clinical risk score - a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001696-21,0,0,0 2018-001698-25,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,IDIBAPS,"Efficacy of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis to prevent ACLF development: a multicenter, double-blind, placebo controlled randomized clinical tria...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001698-25,0,0,0 2018-001698-25,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,0,IDIBAPS (CONSORCIO INSTITUTO DE INVESTIGACIONES BIOMèDICAS AUGUST PI I SUNYER),"Efficacy of the combination of simvastatin plus rifaximin in patients with decompensated cirrhosis to prevent ACLF development: a multicenter, double-blind, placebo controlled randomized clinical tria...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001698-25,0,0,0 2018-001701-82,3,2019-12-03,2019-12-03,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Xynomic Pharmaceuticals, Inc.","Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients with Relapsed or Refractory Follicular Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001701-82,0,0,0 2018-001702-28,1,2020-10-29,2020-10-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medica Scientia Innovation Research (MEDSIR),"Neoadjuvant Letrozole and Palbociclib in patients with Stage II-IIIb breast cancer, HR (+) / HER2 (-) phenotype and Intermediate (18-25) or High (>25) Recurrence-Score by Oncotype-DX; analysis of RS a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001702-28,0,0,0 2018-001703-37,1,2019-11-08,2019-11-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Ipsen Innovation SAS,"A double-blind, randomised, placebo controlled, proof-of-concept study in subjects with abdominal or thoracic chronic scar pain to assess the analgesic properties of intradermal doses of Dysport®",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001703-37,0,0,0 2018-001704-10,2,2019-11-12,2019-11-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomized, Double-blind, Two Treatment, Two Period, Chronic dosing (4 weeks), Crossover, Multi-center Pilot study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate and Glycop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001704-10,0,0,0 2018-001705-91,1,2021-01-13,2021-01-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Center for Perioperative Optimization, Department of Surgery, Herlev Hospital","MELADERM-trial: Melatonin cream against acute radiation dermatitis in patients with early breast cancer: a pivotal phase 2, double-blind, randomized, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001705-91,0,0,0 2018-001708-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Alcedis GmbH,"A single arm phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in combination with cetuximab in subjects with unresectable stage III or stage IV cutan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001708-12,0,0,0 2018-001709-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),I-MICRO: Ilomedine in the treatment of septic shock with persistence of microperfusion disorders: Multicenter randomized and controlled double-blind study. I-MICRO : Ilomedine dans le traitement du...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001709-10,0,0,0 2018-001711-67,1,,,0,1,1,0,0,1,3,0,0,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-659/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001711-67,0,1,1 2018-001714-14,6,2021-06-24,2021-06-24,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Pfizer Inc.,"A PHASE 2B/3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001714-14,1,0,0 2018-001714-14,6,2021-06-24,2021-06-24,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, New York, New York 10017","A PHASE 2B/3 RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, DOSE RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001714-14,1,0,0 2018-001715-79,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,BioLineRx Ltd.,"A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as compared to Placebo an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001715-79,0,0,0 2018-001715-79,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,BiolineRx Ltd.,"A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-CSF as compared to Placebo an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001715-79,0,0,0 2018-001718-13,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,MAPS Europe B.V.,"An Open- Label, Phase 2, Multicenter Feasibility Study if Manualized MDMA-Assisted Psychotherapy with an fMRI sub-study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Disord...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001718-13,0,0,0 2018-001719-65,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,University Medial Center Groningen,CALCification as an early marker of vasculopathy and organ involvement in Systemic Sclerosis CALC-SSc study Calcificatie als vroege marker van vaat-en orgaanschade bij systemische sclerose (SSc)̓,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001719-65,0,0,0 2018-001720-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut de Terapia Regenerativa Tissular S.L. (ITRT),"Phase II clinical trial to evaluate the effect and safety of MSV * in Xerostomia * adult autologous bone marrow mesenchymal stem cells, expanded under GMP of IBGM Ensayo clínico fase II para evalu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001720-19,0,0,0 2018-001722-25,2,2019-08-07,2019-08-07,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Phase IIa, Randomised, Multi-centre, Double-blind, Placebo and Active-controlled, 3 Periods, Crossover Study to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Inhaled AZD8871...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001722-25,0,0,0 2018-001724-19,1,2021-01-07,2021-01-07,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Chiesi Farmaceutici S.p.A.,"A randomised, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CHF6467 after single and repeated ascending doses in subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001724-19,0,0,0 2018-001725-75,1,2020-05-05,2020-05-05,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,"FirstString Research, Inc.","A Phase 3, Randomized, Double-blind, Parallel-group, Vehicle controlled, Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001725-75,0,0,0 2018-001726-26,5,2019-08-22,2019-08-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001726-26,0,0,0 2018-001726-26,5,2019-08-22,2019-08-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001726-26,0,0,0 2018-001726-26,5,2019-08-22,2019-08-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001726-26,0,0,0 2018-001727-39,1,2020-03-13,2020-03-13,1,1,0,0,1,0,3,0,0,1,0,0,1,0,1,Polpharma S.A.,"A PHASE III, MULTICENTRE, RANDOMISED, INVESTIGATOR-MASKED, CROSSOVER, COMPARATIVE, NON-INFERIORITY TRIAL EVALUATING THE EFFICACY AND TOLERABILITY OF GENERIC LATANOPROST 0.05 MG/ML EYE DROPS SOLUTION (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001727-39,0,0,0 2018-001728-20,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Ruprecht-Karls-Universität Heidelberg,"- RACE - Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) A randomized phase III join...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001728-20,0,0,0 2018-001730-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación Hospital Vall d'Hebron- Institut de Recerca,"Phase III, random, one-site, pilot, open, parallell group trial for evaluating the eficacy and safety of electrocoagulation vs topic sinecatechins vs topic cidofovir in the High-grade anal intraepithe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001730-18,0,0,0 2018-001735-49,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,"Rivaroxaban versus warfarin for stroke patients with antiphospholipid syndrome, with or without SLE (RISAPS): a randomised, controlled, open-label, phase II/III, non-inferiority trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001735-49,0,0,0 2018-001741-14,1,,,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,OSPEDALE SAN RAFFAELE,A phase I/II dose escalation study evaluating safety and activity of autologous CD34+-enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human inter...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001741-14,0,0,0 2018-001743-31,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Dermapharm AG,"Double-blind, randomised clinical study comparing efficacy and safety of Methylprednisolone Aceponate 0.1% Cutaneous emulsion (Test) vs. Advantan Milk 0.1% Cutaneous emulsion (Reference) vs. Vehicle i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001743-31,0,0,0 2018-001744-62,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Gustave Roussy,"A multicenter, open label, phase II basket trial exploring the efficacy and safety of the combination of rucaparib (PARP inhibitor) and atezolizumab (anti-PD-L1 antibody) in patients with DNA repair-d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001744-62,0,0,0 2018-001746-34,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001746-34,0,0,0 2018-001746-34,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001746-34,0,0,0 2018-001747-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Tranplant (LTx) recipients with bronchiolitis obliterans sydrome (BOS) grade 1-2 Essai multicentrique, randomisé contre placebo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001747-31,0,0,0 2018-001749-15,4,2022-07-05,2022-07-05,3,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Aimmune Therapeutics, Inc.",Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001749-15,1,0,0 2018-001749-15,4,2022-07-05,2022-07-05,3,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Aimmune Therapeutics , Inc.",Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001749-15,1,0,0 2018-001751-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,uz brussels,Vitamin D Supplementation to increase free testosterone in Type 2 Diabetes Mellitus men: a Placebo-controlled Randomized Clinical Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001751-12,0,0,0 2018-001755-12,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Imperial College,"A pilot double-blind, randomised, placebo-controlled, cross-over study of metformin to reduce airway glucose in stable COPD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001755-12,0,0,0 2018-001756-35,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,"University of California, San Francisco","A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Optic N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001756-35,0,0,0 2018-001757-27,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001757-27,0,0,0 2018-001757-27,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc.","A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001757-27,0,0,0 2018-001757-27,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001757-27,0,0,0 2018-001758-89,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Medical University Graz; Department of Rheumatology and Immunology,Validation of the PsASon ULtrasound scores in patients with psoriatic arthritis undergoing TReatment with Apremilast,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001758-89,0,0,0 2018-001762-42,14,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,"Sarepta Therapeutics, Inc.","A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of a High Dose of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients with Duchenne Muscular Dys...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001762-42,0,0,0 2018-001763-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Reinier van Arkel,Treatment of headaches post-ECT with oxygen therapy; a proof of concept study Behandeling van hoofdpijnklachten post-ECT middels zuurstoftherapie; een proof of concept studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001763-23,0,0,0 2018-001767-23,1,,,0,0,0,0,0,3,2,0,0,3,0,0,0,0,0,University College London,A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström’s macroglobulinaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001767-23,0,0,0 2018-001770-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Complejo Asistencial Universitario de León,Analysis of the effectiveness of Non-painful Endovenous Management (MENA) in the administration of Propofol Análisis de la efectividad del manejo endovenoso no doloroso (MENA) en la administración ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001770-15,0,0,0 2018-001771-21,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Exelixis, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Target...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001771-21,0,0,0 2018-001771-21,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"EXELIXIS, INC.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Target...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001771-21,0,0,0 2018-001772-38,11,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001772-38,0,0,0 2018-001772-38,11,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001772-38,0,0,0 2018-001773-24,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Genentech Inc.,"A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001773-24,0,0,0 2018-001774-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Tampere university hospital,"Clinical Drug Trial: Efficacy, safety and pharmacokinetics of tinzaparin during Slow Low Efficient Daily Dialysis in Intensive Care Patients Tintsapariinin teho, turvallisuus ja farmakokinetiikka t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001774-23,0,0,0 2018-001775-20,1,,,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,Centre for Human Drug Research,Immunomonitoring of tacrolimus in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001775-20,0,0,0 2018-001778-12,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Fundació Institut de Recerca en Ciències de la Salut Germans Trias i Pujol,USE OF A FIBRINE ADHESIVE TO REDUCE THE DEHISCENCE OF ESOFAGOYEYUNAL ANASTOMOSIS IN TOTAL GASTRECTOMIES BY CANCER: RANDOMIZED AND MULTICENTRIC STUDY. UTILIZACIÓN DE UN ADHESIVO DE FIBRINA PARA DISM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001778-12,0,0,0 2018-001780-23,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001780-23,0,0,0 2018-001781-41,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Nederlandse Vereniging van Artsen voor longziekten en Tuberculose,"Evaluation of safety and tolerability of pirfenidone in asbestosis, a multicenter study Evaluatie van de veiligheid en tolerantie van Pirfenidone bij asbestose, een multicenter studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001781-41,0,0,0 2018-001788-21,9,2021-07-26,2021-07-26,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Pharma AG,"An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multi center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001788-21,1,0,0 2018-001788-21,9,2021-07-26,2021-07-26,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Farmacéutica S.A.,"An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multi center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001788-21,1,0,0 2018-001789-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Léon Bérard,"Trial Of Imatinib After Ponatinib Induction (Tipi) - A multicentre, open label phase II trial evaluating the safety and efficacy of ponatinib induction followed by imatinib maintenance in adult patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001789-41,0,0,0 2018-001795-38,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Karolinska University Hospital,ALLTogether1¿ A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001795-38,0,0,0 2018-001796-21,3,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"FORMA Therapeutics, Inc.",A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001796-21,0,0,0 2018-001796-21,3,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"Forma Therapeutics, Inc.",A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001796-21,0,0,0 2018-001801-98,8,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001801-98,0,0,0 2018-001802-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Wuerzburg,"A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma. Eine multizentrische, offene Phase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001802-27,0,0,0 2018-001803-35,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Deciphera Pharmaceuticals, LLC","A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001803-35,0,0,0 2018-001803-35,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"DECIPHERA PHARMACEUTICALS, LLC","A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001803-35,0,0,0 2018-001807-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,Phase II study of maintenance anti-PD-L1 treatment with atezolizumab after chemo-radiotherapy for muscle-infiltrating bladder cancer patients not eligible for radical cystectomy: Bladder Sparing,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001807-35,0,0,0 2018-001808-11,10,2022-08-22,2022-08-22,5,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Idorsia Pharmaceuticals Ltd,"A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001808-11,1,0,0 2018-001808-11,10,2022-08-22,2022-08-22,5,0,0,0,0,0,2,0,0,2,0,0,0,0,1,IDORSIA PHARMACEUTICALS LTD,"A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe systemic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001808-11,1,0,0 2018-001811-59,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001811-59,0,0,0 2018-001811-59,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001811-59,0,0,0 2018-001817-33,4,2020-06-22,2020-06-22,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,GALAPAGOS NV,"A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001817-33,0,0,0 2018-001817-33,4,2020-06-22,2020-06-22,3,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Galapagos NV,"A Phase 2a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of orally administered GLPG1690 for 24 weeks in subjects with systemic sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001817-33,0,0,0 2018-001823-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Technische Universität München, Fakultät für Medizin vertreten durch den Dekan","A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001823-38,0,0,0 2018-001829-11,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Liverpool,"The Carboprost or Oxytocin Postpartum haemorrhage Effectiveness Study. Carboprost vs Oxytocin as the First Line Treatment of Primary Postpartum Haemorrhage; A phase IV, double-blind, double-dummy, ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001829-11,0,0,0 2018-001833-42,7,2020-08-11,2020-08-11,6,0,0,0,0,1,2,0,0,1,0,0,1,0,1,"Crinetics Pharmaceuticals, Inc.","A double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly that are responders to octreotide LAR or l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001833-42,0,0,0 2018-001836-24,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A 12-month, open-label, multicenter, randomized, safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) study of two regimens of anti-CD40 monoclonal antibody, CFZ533 vs. standard of care con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001836-24,0,0,0 2018-001836-24,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"A 12-month, open-label, multicenter, randomized, safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) study of two regimens of anti-CD40 monoclonal antibody, CFZ533 vs. standard of care con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001836-24,0,0,0 2018-001836-24,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A 12-month, open-label, multicenter, randomized, safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) study of two regimens of anti-CD40 monoclonal antibody, CFZ533 vs. standard of care con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001836-24,0,0,0 2018-001842-33,7,2021-07-26,2021-07-26,4,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multi center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001842-33,1,0,0 2018-001842-33,7,2021-07-26,2021-07-26,4,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Pharma AG,"An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multi center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001842-33,1,0,0 2018-001843-29,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Greater Glasgow and Clyde,TASTER- TArgeting STEm cell Resistance An umbrella adaptive randomised multi–arm screening phase II trial for patients with 2nd/3rd generation TKI resistant chronic myeloid leukaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001843-29,0,0,0 2018-001843-29,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Glasgow,TASTER- TArgeting STEm cell Resistance An umbrella adaptive randomised multi–arm screening phase II trial for patients with 2nd/3rd generation TKI resistant chronic myeloid leukaemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001843-29,0,0,0 2018-001845-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Academic medical centre, department of internal medicine",EvaluaTion of Clinical and laboratory outcomes of Rivaroxaban in short Bowel syndrome patients dEpending on Long term parenteral nutrition: a prospective cohort study (TINCRBEL study) Evaluatie va...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001845-15,0,0,0 2018-001846-32,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"VO Barnmedicin, Skånes University Hospital","Treatment of NF1-related plexiform neurofibroma with trametinib; a single arm, open-label trial with the goals of volumetric partial remission and pain relief Behandling av NF1-relaterade plexiform...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001846-32,0,0,0 2018-001850-80,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Nordic Lymphoma Group,Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001850-80,0,0,0 2018-001850-80,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Skåne University Hospital,Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001850-80,0,0,0 2018-001853-28,2,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Eli Lilly and Company,"An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability when Receiving Abemaciclib for Patients with Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001853-28,0,0,0 2018-001853-28,2,,,0,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Lilly S.A.,"An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability when Receiving Abemaciclib for Patients with Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001853-28,0,0,0 2018-001855-10,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Department of Ophtalmology, Rigshospitalet-Glostrup",Steroids and Non-steroidal Anti-inflammatory drugs in the Postoperative regime after trabeculectomy. An investigator-initiated randomized study (The SNAP study) Steroid eller Non-steroid Anti-infla...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001855-10,0,0,0 2018-001856-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,A RANDOMIZED PHASE 2 CLINICAL TRIAL TO EVALUATE THE ACTIVITY OF ATRA IN COMBINATION WITH ANASTROZOLE IN PRE-OPERATIVE PHASE OF OPERABLE HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER EBC ATRA TRIAL ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001856-36,0,0,0 2018-001857-29,7,,,0,0,1,0,0,0,3,0,1,2,0,0,0,0,1,Seqirus UK Limited,"A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001857-29,0,1,0 2018-001860-45,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Plató,Impact of topical antibiotic prophylaxis with Gentamicin on SSI rate on elective incisional hernia surgery: a randomised clinical trial. Impacto de la profilaxis antibiótica tópica con Gentamicina ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001860-45,0,0,0 2018-001863-21,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Vestre Viken Hospital Trust,"First-line treatment with osimertinib in EGFR-mutated non-small cell lung cancer, coupled to extensive translational studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001863-21,0,0,0 2018-001867-22,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Banc de Sang i teixits,"TRANSFUSION OF RED BLOOD CELLS, TRANEXAMIC ACID AND FIBRINOGEN CONCENTRATE FOR SEVERE TRAUMA HEMORRHAGE AT PRE-HOSPITAL PHASE OF CARE. A PILOT TRIAL. Estudio PILOTO sobre los efectos de la transfus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001867-22,0,0,0 2018-001868-36,5,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Spectrum Pharmaceuticals, Inc.","A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001868-36,0,0,0 2018-001868-36,5,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,SPECTRUM PHARMACEUTICALS,"A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001868-36,0,0,0 2018-001874-89,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Friedrich-Schiller-Universität Jena,Randomised controlled multicentre study of albumin replacement therapy in septic shock Randomisierte kontrollierte multizentrische Studie zur Albuminersatztherapie im septischen Schock,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001874-89,0,0,0 2018-001878-21,1,2019-10-18,2019-10-18,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,"ENANTA Pharmaceuticals, Inc","A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Pharmacokinetics And Antiviral Activity Of Multiple Doses Of Orally Administered EDP-938 Against Respiratory Sync...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001878-21,0,0,0 2018-001879-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grenoble Alps University Hospital,Radiotherapy of multiple brain metastases using AGuIX® gadolinium-chelated polysiloxane based nanoparticles: a prospective randomized phase II clinical trial. Traitement de métastases cérébrales mu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001879-20,0,0,0 2018-001880-22,1,2019-12-19,2019-12-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PILA PHARMA AB,"A randomised, double-blind, placebo-controlled, parallel-group trial investigating the effect of 4 weeks bi-daily dosing of XEN-D0501 on blood glucose reduction as add-on to metformin in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001880-22,0,0,0 2018-001881-40,5,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Atezolizumab or placebo in combination with neoadjuvant doxorubicin + cyclophosphamide f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001881-40,0,0,0 2018-001881-40,5,,,0,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Atezolizumab or placebo in combination with neoadjuvant doxorubicin + cyclophosphamide f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001881-40,0,0,0 2018-001883-48,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Astrazeneca AB,"Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001883-48,0,0,0 2018-001883-48,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001883-48,0,0,0 2018-001884-21,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Cambridgeshire and Peterborough NHS Foundation Trust and University of Cambridge,"A randomised, placebo-controlled, double-blind trial of the antidepressant efficacy of a novel CNS-penetrant P2X7 receptor antagonist, JNJ-54175446, in people with major depressive disorder, an incomp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001884-21,0,0,0 2018-001887-46,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,"A Phase II, Placebo Controlled, Double Blind, Randomised Clinical Trial to assess the safety and tolerability Of 30mg/kg daily Ursodeoxycholic Acid (UDCA) in Patients with Parkinson’s Disease (PD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001887-46,0,0,0 2018-001891-39,1,2021-12-01,2021-12-01,1,1,0,0,0,0,2,0,0,1,0,0,0,0,0,XiCoCo study group,"Rifaximin-treatment of Collagenous colitis: A prospective, double-blind, placebo-controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001891-39,0,0,0 2018-001894-26,2,2019-06-19,2019-06-25,2,0,0,0,0,0,3,0,1,1,0,0,1,0,1,Medicago R&D Inc.,"A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001894-26,0,0,0 2018-001895-39,5,2022-06-24,2022-06-24,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Immunic AG,"A phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding trial to evaluate the efficacy and safety of IMU-838 for treatment of patients with active Crohn’s disease with an op...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001895-39,1,0,0 2018-001896-19,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Immunic AG,"Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by magnetic resonance imaging (MRI), as well as safety and tole...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001896-19,0,0,0 2018-001904-12,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,University of Nottingham,Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001904-12,0,0,0 2018-001906-27,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Nottingham University Hospitals NHS Trust,Feasibility Studies to Investigate the Role of Ursodeoxycholic acid in the prevention of Recurrence of C.difficile Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001906-27,0,0,0 2018-001908-11,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,UNIVERSITY OF BIRMINGHAM,"A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha as first line ThErapyfor high risk polycythemia vera",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001908-11,0,0,0 2018-001912-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITY MEDICAL CENTRE LJUBLJANA,Treatment of headache attributed to temporomandibular disorder with a flat plane occlusal splint and injections of botulinum toxin Zdravljenje glavobola v zvezi s temporomandibularno motnjo z Michi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001912-31,0,0,0 2018-001914-13,1,2019-03-26,2019-03-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Salsarulo Pharma,Clinical Trial to Evaluate the Efficacy and Safety of MACRORANGE® in Patients Suffering from Functional Constipation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001914-13,0,0,0 2018-001915-63,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Oxford / Clinical Trials and Research Governance,A randomised controlled pilot trial of the use of GnRH-antagonist pituitary suppression during medicated frozen-thawed embryo transfer (FET) cycles,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001915-63,0,0,0 2018-001917-34,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona,Cardiac complications associated to perioperative hyperoxia in elective colorectal surgery Complicaciones cardíacas asociadas a la aplicación de hiperoxia perioperatoria en pacientes programados de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001917-34,0,0,0 2018-001923-38,4,,,0,0,0,1,0,1,1,0,0,2,1,0,0,0,1,KITE PHARMA INC.,Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia Estudio multicéntrico de fase 1/2 para evaluar la s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001923-38,0,0,0 2018-001923-38,4,,,0,0,0,1,0,1,1,0,0,2,1,0,0,0,1,"Kite Pharma, Inc",Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia Estudio multicéntrico de fase 1/2 para evaluar la s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001923-38,0,0,0 2018-001925-24,7,2020-11-30,2020-11-30,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001925-24,1,0,0 2018-001925-24,7,2020-11-30,2020-11-30,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001925-24,1,0,0 2018-001925-24,7,2020-11-30,2020-11-30,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb Company,"A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001925-24,1,0,0 2018-001926-25,5,2020-09-02,2020-09-02,4,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001926-25,1,0,0 2018-001926-25,5,2020-09-02,2020-09-02,4,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Bristol-Myers Squibb Company,"A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001926-25,1,0,0 2018-001930-17,3,2020-03-31,2020-03-31,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Cara Therapeutics INC,"A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS CR845 IN HEMODIALYSIS PATIENTS WITH MODERATE-TO-SEVERE PRURITUS, WITH A 52-WEEK ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001930-17,0,0,0 2018-001931-27,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,IRCCS Istituto Giannina Gaslini,Comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS Confronto di strategie terapeutiche step-up e step-down nell'artrite idiopatica giovanile,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001931-27,0,0,0 2018-001934-16,2,2019-07-09,2019-07-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Amzell BV,"A placebo-controlled, double-blind, randomized, trial of Diclofenac Gel AMZ001 3.06 % for the treatment of knee osteoarthritis symptoms",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001934-16,0,0,0 2018-001936-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dr. Adolfo Fontenla Cerezuela,"A multicenter, randomized, open-label, phase III clinical trial to compare the efficacy and safety of Ivabradine versus Digoxine in the chronic control of heart rate in patients with permanent atrial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001936-23,0,0,0 2018-001942-33,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Rare Partners s.r.l. Impresa Sociale,A personalized medicine approach for beta-thalassemia transfusion dependent patients: testing SIROLIMUS in a first pilot clinical trial. Approccio di medicina personalizzata in pazienti con beta-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001942-33,0,0,0 2018-001945-14,4,2021-03-25,2021-03-25,3,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Novo Nordisk A/S,Investigation of safety and efficacy of NNC0174-0833 for weight management – a dose finding trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001945-14,1,0,0 2018-001946-32,2,,,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,ARRAY BIOPHARMA INC.,"A Multicenter, Open-label Phase Ib Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma P/071/2018 Multicentrická...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001946-32,0,0,0 2018-001946-32,2,,,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,Array BioPharma Inc.,"A Multicenter, Open-label Phase Ib Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma P/071/2018 Multicentrická...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001946-32,0,0,0 2018-001947-30,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Protalix Ltd.,Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001947-30,0,0,0 2018-001947-30,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,PROTALIX LTD,Open Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegunigalsidase Alfa (PRX-102) 2 mg/kg Administered by Intravenous Infusion Every 4 Weeks in Patients with Fabry Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001947-30,0,0,0 2018-001949-13,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,KU Leuven,"The effect of liraglutide on MMC activity, gastrointestinal hormones, hunger ratings and ad libitum food intake in healthy volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001949-13,0,0,0 2018-001953-28,11,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Sanofi-aventis Recherche & Développement,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstruct...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001953-28,0,0,0 2018-001953-28,11,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstruct...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001953-28,0,0,0 2018-001954-91,16,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Sanofi-aventis Recherche & Développement,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients with Moderate-to-severe Chronic Obstruct...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001954-91,0,0,0 2018-001957-29,9,2022-05-09,2022-05-09,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Takeda Development Center Americas, Inc. (TDCA)",A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive on–Small-Cell Lung Cancer Patients Who Have Progressed o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001957-29,1,0,0 2018-001957-29,9,2022-05-09,2022-05-09,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"ARIAD Pharmaceuticals, Inc.(a wholly-owned subsidiary of Takeda Pharmaceutical Ltd.)",A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive on–Small-Cell Lung Cancer Patients Who Have Progressed o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001957-29,1,0,0 2018-001957-29,9,2022-05-09,2022-05-09,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"ARIAD PHARMACEUTICALS, INC.",A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive on–Small-Cell Lung Cancer Patients Who Have Progressed o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001957-29,1,0,0 2018-001958-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Abteilung für Hals-, Nasen- und Ohrenkrankheiten MUW, AKH Wien","Dexamethasone 21-dihydrogenphosphat and Triamcinolone acetonide in the treatment of Menière´s disease: a randomized, multicentric efficacy trial Dexamethasone 21-dihydrogenphosphat und Triamcinolon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001958-10,0,0,0 2018-001963-22,1,2020-04-24,2020-04-24,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Celon Pharma SA,"A multicentre, double-blind, randomised, placebo - controlled phase II study to assess efficacy, safety and pharmacokinetics of inhaled Esketamine in subject with treatment-resistant depression in the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001963-22,0,0,0 2018-001967-22,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-ri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001967-22,0,0,0 2018-001968-33,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Étude ouverte de phase 1/2 évaluant la sécurité et l’efficacité de l’injection de cellules CD34 + autologues transduites ex vivo par le vecteur lentiviral GLOBE1 qui exprime le gène de la globine ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001968-33,0,0,0 2018-001970-66,1,2019-10-02,2019-10-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,MC2 Therapeutics Ltd.,"A Randomised, Multicentre, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to Vehicle and Active Comparator in Subjects with Mild-to-Moderate Psor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001970-66,0,0,0 2018-001973-25,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Merck Sharp & Dohme Corp.,"A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA non-mutated Advanced Epith...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001973-25,0,0,0 2018-001973-25,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA non-mutated Advanced Epith...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001973-25,0,0,0 2018-001974-76,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001974-76,0,0,0 2018-001974-76,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001974-76,0,0,0 2018-001974-76,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001974-76,0,0,0 2018-001976-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GORTEC,A phase II trial of radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck Essai de phase II évaluant l’association radiothérapie-durvalumab ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001976-39,0,0,0 2018-001978-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CHU de LIMOGES,Injections of Sodium Thiosulfate for ectopic calcifications or ossifications. A pilot study. Injections de thiosulfate de sodium dans le traitement de calcifications ou d’ossifications ectopiques. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001978-22,0,0,0 2018-001981-40,4,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study with an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults with Primary Hyperoxal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001981-40,0,0,0 2018-001983-49,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,Ultragenyx Pharmaceutical Inc,"An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children from 1 to 4 Years Old with X-linked Hypophosphatemia (XLH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001983-49,0,1,1 2018-001984-21,3,2020-03-31,2020-03-31,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Protagonist Therapeutics, Inc.",Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) ß-Thalassemia Subjects with Chronic Anemia Studio di fase 2 di PTG-300 in soggetti affetti da beta-talasse...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001984-21,0,0,0 2018-001986-18,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, observer-blind, randomized, multi-country study to assess the reactogenicity and safety of the Porcine circovirus (PCV) free liquid formulation of GSK’s oral live attenuated human rotavir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001986-18,0,1,1 2018-001988-23,2,2020-01-24,2020-01-24,2,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Aeterna Zentaris GmbH,"Open label, group comparison, dose escalation trial to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of macimorelin acetate after single oral dosing of 0.25 mg/kg, 0.5 mg/kg,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001988-23,0,0,0 2018-001989-42,4,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,1,AETERNA ZENTARIS GMBH,"Multicenter, open label trial to investigate the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as growth hormone stimulation test (GHST) in pediatric patients with suspect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001989-42,0,0,0 2018-001989-42,4,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,1,Aeterna Zentaris GmbH,"Multicenter, open label trial to investigate the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as growth hormone stimulation test (GHST) in pediatric patients with suspect...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001989-42,0,0,0 2018-001991-39,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"SpringWorks Subsidiary 2, PBC","A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF) Sperimentazione random...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001991-39,0,0,0 2018-001991-39,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,SpringWorks Therapeutics,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF) Sperimentazione random...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001991-39,0,0,0 2018-001994-25,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Immutep S.A.S.,"TACTI-002 (Two ACTive Immunotherapeutics): A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurrent P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001994-25,0,0,0 2018-001997-52,8,2020-12-22,2020-12-22,7,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Amgen Inc,"A Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tezepelumab Alone or Combined with Topical Corticosteroids in Moderate-to-Severe Atopic Dermatitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001997-52,1,0,0 2018-002000-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University hospital Brussel,Effect of recombinant FSH dosing following corifollitropin alfa in patients undergoing IVF/ICSI in a GnRH antagonist protocol: a randomized controlled dose-finding study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002000-13,0,0,0 2018-002001-65,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,University of Birmingham,"A Phase Ib/IIb, Randomised, Double Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability and Clinical Activity of Humanised Antibody GSK1070806 in the Treatment of Patients with Mode...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002001-65,0,0,0 2018-002003-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,FIDIA FARMACEUTICI S.P.A.,"A double blind, double dummy, multicenter, randomized, placebo- and active-controlled clinical trial to evaluate effectiveness of Tricortin 1000 in patients affected by chronic low back pain Studio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002003-33,0,0,0 2018-002008-15,1,2019-07-22,2019-07-22,1,1,0,0,0,1,4,0,0,1,0,0,1,0,0,University Medical Center Utrecht,Optimal cerebral perfusion after an extracranial-intracranial bypass: should we increase blood pressure or cardiac output? Optimale cerebrale perfusie na een extracraniële-intracraniële bypass: moe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002008-15,0,0,0 2018-002010-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Klinikum der Ludwig-Maximilians-Universität München - Klinikum Großhadern (vertreten durch den kaufmännischen Direktor),Avelumab added to FOLFIRI plus Cetuximab followed by Avelumab maintenance in patients with previously untreated RAS/BRAF wild-type metastatic colorectal cancer - The phase II FIRE-6-Avelumab study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002010-12,0,0,0 2018-002011-10,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002011-10,0,0,0 2018-002011-10,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002011-10,0,0,0 2018-002012-27,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Leicester,"A Single Centre, Open-label, Single-group Exploratory Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients with Immunoglobulin A Nephropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002012-27,0,0,0 2018-002013-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU University Medical Center,"FES (16α-[18F]-fluoro-17β-estradiol)-PET: Towards a new standard to stage clinical stage II/III and recurrent, estrogen receptor positive (ER+) breast cancer? Pilot study to compare [18F]FES-PET and [...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002013-35,0,0,0 2018-002014-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fédération Francophone de Cancérologie Digestive,A randomized phase II study evaluating FOLFIRI + durvalumab vs FOLFIRI + durvalumab and tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002014-13,0,0,0 2018-002016-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOSPICES CIVILS DE LYON,Diagnostic par TEP-IRM de la pseudoprogression tumorale chez des patients porteurs d’un glioblastome traités par radiochimiothérapie concomitante et adjuvante avec du temozolomide TIGRE (TepIrmGliobl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002016-27,0,0,0 2018-002042-36,1,2019-06-21,2019-06-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Assembly Biosciences,"A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 + Entecavir vs Entecavir Alone for the Treatment of Viremic, HBeAg-positive Patients with Chronic Hepatitis B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002042-36,0,0,0 2018-002062-39,16,2022-07-19,2022-07-19,12,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002062-39,1,0,0 2018-002062-39,16,2022-07-19,2022-07-19,12,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002062-39,1,0,0 2018-002062-39,16,2022-07-19,2022-07-19,12,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002062-39,1,0,0 2018-002063-26,14,2022-07-26,2022-07-26,8,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002063-26,1,0,0 2018-002063-26,14,2022-07-26,2022-07-26,8,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002063-26,1,0,0 2018-002063-26,14,2022-07-26,2022-07-26,8,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002063-26,1,0,0 2018-002064-15,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Academic Medical Center,Treatment of Perianal FIstulas in Crohn’s Disease: Surgical closure vs Anti-TNF,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002064-15,0,0,0 2018-002068-15,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,FO.NE.SA.Onlus,CARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE (KRd) versus LENALIDOMIDE - DEXAMETHASONE (Rd) IN NEWLY DIAGNOSED MYELOMA PATIENTS NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A RANDOMIZED PHASE ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002068-15,0,0,0 2018-002069-21,3,2020-11-16,2020-11-16,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled Cort...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002069-21,1,0,0 2018-002070-51,7,2021-11-10,2021-11-10,4,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Incyte Corporation,A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002070-51,1,0,0 2018-002073-22,5,2020-06-11,2020-06-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of fevipiprant once daily plus standard-of-care (SoC) for assessment of the efficacy in reduction of nasal polyps size...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002073-22,0,0,0 2018-002073-22,5,2020-06-11,2020-06-11,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,NOVARTIS PHARMA AG,"A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of fevipiprant once daily plus standard-of-care (SoC) for assessment of the efficacy in reduction of nasal polyps size...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002073-22,0,0,0 2018-002076-41,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Leicester,"A RANDOMISED CONTROLLED TRIAL OF PRE-SURGERY SODIUM VALPROATE, FOR THE PREVENTION OF ORGAN INJURY IN CARDIAC SURGERY: Val-CARD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002076-41,0,0,0 2018-002077-21,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Institute of Cancer Research,PHOENIX Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemothera...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002077-21,0,0,0 2018-002078-27,1,2020-06-10,2020-06-10,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"American Regent, Inc.","A Multicenter, Multinational, Randomized, Active-Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency Anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002078-27,0,0,0 2018-002079-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INSTITUT DE CANCEROLOGIE DE L'OUEST,Evaluation of the 64Cu-ATSM PET-CT as a predictor of the response to neo-adjuvant treatment in locally advanced rectal cancers Evaluation de la TEP-TDM au 64Cu-ATSM comme facteur prédictif de la ré...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002079-17,0,0,0 2018-002080-25,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Skåne University Hospital,A TRANSLATIONAL RANDOMIZED PHASE III STUDY EXPLORING THE EFFECT OF THE ADDITION OF CAPECITABINE TO CARBOPLATINUM BASED CHEMOTHERAPY IN EARLY “TRIPLE NEGATIVE” BREAST CANCER.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002080-25,0,0,0 2018-002081-39,3,2021-06-03,2021-07-01,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Abiogen Pharma S.p.A.,"A randomised, double-blind, parallel-group, multicenter, placebo-controlled, dose-ranging study, to evaluate the efficacy and safety of clodronate ampoules at different dosages, after intra-articular ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002081-39,0,0,0 2018-002081-39,3,2021-06-03,2021-07-01,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,ABIOGEN PHARMA S.P.A.,"A randomised, double-blind, parallel-group, multicenter, placebo-controlled, dose-ranging study, to evaluate the efficacy and safety of clodronate ampoules at different dosages, after intra-articular ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002081-39,0,0,0 2018-002087-12,3,,,0,0,1,0,0,1,2,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002087-12,0,0,0 2018-002087-12,3,,,0,0,1,0,0,1,2,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002087-12,0,0,0 2018-002088-25,2,2021-01-20,2021-01-20,2,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Noorik Biopharmaceuticals AG,"A Phase II, Single-arm, Open-Label Study to Characterise the Effect on Portal Pressure, the Effect on Renal Function and the Pharmacokinetic Profile of N-003 in Patients with Decompensated Cirrhosis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002088-25,0,0,0 2018-002089-37,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,EUROPEAN MYELOMA NETWORK,"A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE II STUDY COMPARING DARATUMUMAB combined with BORTEZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE (Dara-VCd) VERSUS THE ASSOCIATION OF BORTEZOMIB-THALIDOMIDE-DEXAMETHA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002089-37,0,0,0 2018-002089-37,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,EUROPEAN MYELOMA NETWORK (EMN),"A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE II STUDY COMPARING DARATUMUMAB combined with BORTEZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE (Dara-VCd) VERSUS THE ASSOCIATION OF BORTEZOMIB-THALIDOMIDE-DEXAMETHA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002089-37,0,0,0 2018-002090-21,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Fondazione EMN Italy Onlus,"Daratumumab, pomalidomide and dexamethasone for del(17p) positive relapsed and relapsed/refractory multiple myeloma patients [DEDALO] Daratumumab, pomalidomide e desametasone per pazienti affetti d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002090-21,0,0,0 2018-002093-42,4,2021-10-30,2021-10-30,3,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Shire (Shire is now part of Takeda),"SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002093-42,1,1,0 2018-002093-42,4,2021-10-30,2021-10-30,3,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Shire,"SPRING STUDY: An Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Lanadelumab for Prevention Against Acute Attacks of Hereditary Angioedema (HAE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002093-42,1,1,0 2018-002094-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación de investigación de HM Hospitales,A Phase II Trial to Assess the Evolution of KRAS Mutation Load by Liquid Biopsy in Patients with Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant NALIRINOX Ensayo fase II para e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002094-22,0,0,0 2018-002095-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación de investigación de HM Hospitales,"Phase II, multicenter, open-label, non-randomized study of neoadjuvant chemotherapy NALIRINOX (5-FU/LV + oxaliplatin + nal-IRI) followed by chemoradiotherapy in patients with rectal c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002095-40,0,0,0 2018-002096-17,5,2020-09-30,2021-03-25,3,1,0,0,0,1,2,0,0,2,1,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),"Reduced dose-density of denosumab for maintenance therapy of unresectable giant cell tumor of bone: a multicenter phase II study ""REDUCE""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002096-17,1,0,0 2018-002097-51,4,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Freeline Therapeutics Ltd,"A Phase 1/2, Baseline-controlled, Non-randomised, Open-label, Single-ascending Dose Study of a Novel Adeno-associated Viral Vector (FLT190) in Patients With Fabry disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002097-51,0,0,0 2018-002097-51,4,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Freeline Therapeutics Limited,"A Phase 1/2, Baseline-controlled, Non-randomised, Open-label, Single-ascending Dose Study of a Novel Adeno-associated Viral Vector (FLT190) in Patients With Fabry disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002097-51,0,0,0 2018-002098-23,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002098-23,0,0,0 2018-002098-23,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"ALNYLAM PHARMACEUTICALS, INC.","HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002098-23,0,0,0 2018-002100-13,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Hellenic GenitoUrinaty Cancer Group (HGUCG),"Intravesical administration of Durvalumab (MEDI4736) to patients with high-risk, non-muscle-invasive bladder cancer (NMIBC). A phase II study with correlative biomarker studies. Ενδοκυστική χορήγησ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002100-13,0,0,0 2018-002101-65,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Ángel Lanas Arbeloa-Instituto de Investigación Sanitaria Aragón,Assessment of direct biomarkers of aspirin action to develop a precision chemoprevention therapy of colorectal cancer Evaluación de biomarcadores de acción directa del ácido acetilsalicílico para e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002101-65,0,0,0 2018-002102-31,4,2019-07-30,2019-07-30,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,BIOGEN IDEC RESEARCH LIMITED,"A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Blind, Controlled Study of Aducanumab (BIIB037) in Subjects With Mild Cognitive Impairment due to Alzheimer’s Disease or With Mild Alzheimer’...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002102-31,0,0,0 2018-002102-31,4,2019-07-30,2019-07-30,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Biogen Idec Research Limited,"A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Blind, Controlled Study of Aducanumab (BIIB037) in Subjects With Mild Cognitive Impairment due to Alzheimer’s Disease or With Mild Alzheimer’...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002102-31,0,0,0 2018-002103-33,4,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZ Sint-Jan Brugge-Oostende AV,Pulmonary vein isolation with versus without continued antiarrhythmic drug treatment in subjects with persistent atrial fibrillation: a prospective multi-centre randomized controlled clinical study (P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002103-33,0,0,0 2018-002108-15,2,2020-12-29,2020-12-29,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Bristol-Myers Squibb International Corporation,Phase 1/2 Study of BMS-986310 Administered Alone and in Combination with Nivolumab in Participants with Advanced Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002108-15,0,0,0 2018-002108-15,2,2020-12-29,2020-12-29,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,Phase 1/2 Study of BMS-986310 Administered Alone and in Combination with Nivolumab in Participants with Advanced Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002108-15,0,0,0 2018-002109-70,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"EA Pharma Co., Ltd.",Early phase 2 clinical trial of E6011 in patients with active Crohn’s disease Az E6011 korai 2. fázisú klinikai vizsgálata aktív Crohn-betegségben szenvedő betegeknél,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002109-70,0,0,0 2018-002114-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Efficacy of Colchicine to prevent skin relapses in adult's IgA vasculitis Efficacité de la colchicine pour prévenir les rechutes cutanées au cours de la vascularite à IgA de l'adulte,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002114-13,0,0,0 2018-002115-96,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Klinikum Stuttgart, Landeshauptstadt Stuttgart gKAöR",Optimizing MATRix as remission induction in PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III trial Optimierung der Induktionstherapie mit ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002115-96,0,0,0 2018-002117-36,3,2020-07-06,2020-07-06,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cristal Therapeutics,A Phase IIa Exploratory 2-stage Design Study of CriPec® docetaxel Monotherapy in Subjects with Platinum Resistant Ovarian Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002117-36,0,0,0 2018-002119-81,1,2020-09-01,2020-09-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Erasmus MC,Carriage of S. aureus and interaction with the nasal microbiome Dragerschap van S. aureus en interactie met het nasale microbioom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002119-81,0,0,0 2018-002125-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AELIX Therapeutics,"A Phase IIa, randomized, double-blind, placebo-controlled, study of HIV-1 Vaccines MVA.HTI and ChAdOx1.HTI with TLR7 agonist vesatolimod (GS-9620), in early treated HIV-1 infection Estudio de fase ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002125-30,0,0,0 2018-002130-20,1,,,0,0,0,0,1,0,3,0,0,3,0,0,0,0,0,Norfolk and Norwich University Hospitals NHS Foundation Trust,Research on Efficacy of Teriparatide use in the Return of recruits to Normal duty.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002130-20,0,0,0 2018-002132-25,8,2020-04-06,2020-04-06,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,argenx BVBA,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis Having Generalized Muscle Wea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002132-25,0,0,0 2018-002132-25,8,2020-04-06,2020-04-06,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,ARGEN-X BVBA,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis Having Generalized Muscle Wea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002132-25,0,0,0 2018-002132-25,8,2020-04-06,2020-04-06,7,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Argenx BVBA,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis Having Generalized Muscle Wea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002132-25,0,0,0 2018-002133-37,7,2022-06-30,2022-06-30,6,0,0,0,0,1,3,0,0,2,0,0,0,0,1,ARGEN-X BVBA,"A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002133-37,1,0,0 2018-002133-37,7,2022-06-30,2022-06-30,6,0,0,0,0,1,3,0,0,2,0,0,0,0,1,argenx BVBA,"A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized Mu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002133-37,1,0,0 2018-002134-20,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002134-20,0,0,0 2018-002134-20,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002134-20,0,0,0 2018-002135-19,11,2021-09-01,2021-09-01,8,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Theravance Biopharma Ireland Limited,"A 3-Year, Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects with Ulcerative Colitis (UC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002135-19,1,0,0 2018-002136-24,11,2021-09-01,2021-09-01,8,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Theravance Biopharma Ireland Limited,"A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with TD-1473...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002136-24,1,0,0 2018-002140-88,1,2019-10-22,2019-10-22,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Oryzon Genomics S.A.,"An unicenter, open-label, 1-arm, 8-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in adult population with Alzheimer’s Disease (AD), Lewy Body Dementia (LBD), ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002140-88,0,0,0 2018-002141-11,14,2022-05-09,2022-05-09,9,0,1,0,0,1,3,0,0,2,0,0,0,0,1,"Millennium Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease in Subjects Underg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002141-11,1,1,0 2018-002141-11,14,2022-05-09,2022-05-09,9,0,1,0,0,1,3,0,0,2,0,0,0,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease in Subjects Underg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002141-11,1,1,0 2018-002141-11,14,2022-05-09,2022-05-09,9,0,1,0,0,1,3,0,0,2,0,0,0,0,1,"Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease in Subjects Underg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002141-11,1,1,0 2018-002144-85,7,2022-08-17,2022-08-17,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland,"A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002144-85,1,0,0 2018-002144-85,7,2022-08-17,2022-08-17,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002144-85,1,0,0 2018-002145-11,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Biogen Idec Research Limited,"A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With Relapsi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002145-11,0,0,0 2018-002145-11,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,BIOGEN IDEC RESEARCH LIMITED,"A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With Relapsi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002145-11,0,0,0 2018-002146-37,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Incyte Corporation,A Phase 2 Dose-Escalation Study of the Safety and Tolerability of INCB050465 in Participants With Pemphigus Vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002146-37,0,0,0 2018-002146-37,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,INCYTE CORPORATION,A Phase 2 Dose-Escalation Study of the Safety and Tolerability of INCB050465 in Participants With Pemphigus Vulgaris,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002146-37,0,0,0 2018-002147-28,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"CELLTRION, Inc.","A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non Sq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002147-28,0,0,0 2018-002152-32,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F.Hoffmann La-Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002152-32,0,0,0 2018-002152-32,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A.(Soc. Unipersonal)que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche LTD,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002152-32,0,0,0 2018-002152-32,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002152-32,0,0,0 2018-002153-30,4,2022-10-12,2022-10-12,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,"A randomized, multicenter, open-label cross-over study to evaluate patient preference and satisfaction of subcutaneous administration of the fixed-dose combination of pertuzumab and trastuzumab in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002153-30,1,0,0 2018-002153-30,4,2022-10-12,2022-10-12,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Roche Farma S.A.(Soc Uni) que realiza el ensayo en España y que actúa como representante de F. Hoffmann-La Roche Ltd.,"A randomized, multicenter, open-label cross-over study to evaluate patient preference and satisfaction of subcutaneous administration of the fixed-dose combination of pertuzumab and trastuzumab in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002153-30,1,0,0 2018-002154-70,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BALOXAVIR MARBOXIL IN OTHERWISE HEALTHY PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 1 YEAR WITH INFLU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002154-70,0,0,0 2018-002154-70,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann,"A MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BALOXAVIR MARBOXIL IN OTHERWISE HEALTHY PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 1 YEAR WITH INFLU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002154-70,0,0,0 2018-002155-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Cáncer de Ovario (GEICO),"A randomized, open label, phase II trial of Anti-PD1, TSR-042, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation Ensayo aleatorizado, fase II...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002155-15,0,0,0 2018-002158-59,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Södersjukhuset,A prospective study of the safety of peripherally administered norepinephrine during surgery En prospektiv studie av säkerheten av noradrenalininfusion i perifer venkateter under kirurgi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002158-59,0,0,0 2018-002161-19,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Kralovske Vinohrady,Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002161-19,0,0,0 2018-002161-19,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fakultní nemocnice Královské Vinohrady,Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002161-19,0,0,0 2018-002163-26,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Hôpitaux Universitaires de Strasbourg,Pilot study on doxorubicin kinetic distribution during arterial chemoembolization Etude pilote de la cinétique de distribution de la Doxorubicine lors de la chimio-embolisation artérielle,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002163-26,0,0,0 2018-002165-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University Vienna,"Neo-BCC trial: Neoadjuvant treatment of difficult to resect, locally advanced basal cell carcinoma (BCC) with Talimogene laherparepvec (T-VEC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002165-19,0,0,0 2018-002168-14,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,Radboudumc,Validation of USPIO-enhanced MRI for detection of lymph node metastases in head and neck carcinoma: a pilot study. Validatie van nano-MRI voor detectie van lymfekliermetastasen in hoofd-halskanker:...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002168-14,0,0,0 2018-002169-21,2,2019-04-03,2019-08-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Roche Farma SA que realiza un el ensayo en España y que actúa como representante de F. Hoffmann-La Roche Ltd,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE (OSELTAMIVIR)-CONTROLLED STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BALOXAVIR MARBOXIL IN OTHERWISE HEALTHY PEDIATRIC PATIENTS 1 TO <...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002169-21,0,0,0 2018-002169-21,2,2019-04-03,2019-08-27,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,F. Hoffmann-La Roche Ltd,"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE (OSELTAMIVIR)-CONTROLLED STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF BALOXAVIR MARBOXIL IN OTHERWISE HEALTHY PEDIATRIC PATIENTS 1 TO <...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002169-21,0,0,0 2018-002170-52,1,2021-11-22,2021-11-22,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,VU University Medical Center (VUmc),TrimetaziDine as a Performance-enhancING drug in Heart Failure with Preserved Ejection Fraction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002170-52,0,0,0 2018-002172-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,Primary Ipilimumab and Nivolumab combo-immunotherapy followed by adjuvant Nivolumab in locally advanced or limited metastatic melanoma. Combo-Immunoterapia primaria con Ipilimumab e Nivolumab segui...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002172-40,0,0,0 2018-002173-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Anti-inflammatory effects of tiotropium in patients with stable COPD Anti-inflammatoire effecten van tiotropium bij patiënten met stabiel COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002173-22,0,0,0 2018-002176-41,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,"Imperial College of Science, Technology and Medicine",PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002176-41,0,0,0 2018-002176-41,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Imperial College London,PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002176-41,0,0,0 2018-002176-41,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Imperial College of Science Technology and Medicine,PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002176-41,0,0,0 2018-002179-17,6,2021-11-04,2021-11-04,5,0,0,0,0,1,2,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Prospective, Open-Label, Single Arm, Phase 2, Multi-Center Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects with T-cell Prolymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002179-17,1,0,0 2018-002179-17,6,2021-11-04,2021-11-04,5,0,0,0,0,1,2,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Prospective, Open-Label, Single Arm, Phase 2, Multi-Center Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects with T-cell Prolymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002179-17,1,0,0 2018-002180-25,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,European Thoracic Oncology Platform (ETOP),A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002180-25,0,0,0 2018-002180-25,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,EUROPEAN THORACIC ONCOLOGY PLATFORM,A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002180-25,0,0,0 2018-002190-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione per la Medicina Personalizzata,The ROME trial from histology to target: the road to personalize target therapy and immunotherapy Studio ROME dall’istologia al target: la via per personalizzare la terapia a bersaglio molecolare e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002190-21,0,0,0 2018-002191-41,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,Uppsala University,Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002191-41,0,0,0 2018-002192-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,KU Leuven,Characterization of nerve-modulated macrophage population in the gastrointestinal tract,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002192-18,0,0,0 2018-002195-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,CHemical OptImization of Cerebral Embolectomy in patients with acute stroke treated with mechanical thrombectomy Optimización química de la embolectomía cerebral en pacientes con un ictus agudo tra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002195-40,0,0,0 2018-002202-31,1,2021-01-05,2021-01-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Bio-Thera Solutions, Ltd.","A Randomized, Double-Blind, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002202-31,0,0,0 2018-002207-34,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Anja Bisgaard Pinborg,Preparing and timing of the endometrium in modified natural cycle frozen-thawed embryo transfers (mNC-FET) - a randomized controlled multicenter trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002207-34,0,0,0 2018-002208-15,3,2020-02-06,2020-02-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,VIIV HEALTHCARE UK LIMITED,"A Randomized, Double-Blind (Sponsor-unblinded), Placebo-Controlled, Adaptive Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK3640254 in HIV-1 Infected Treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002208-15,0,0,0 2018-002208-15,3,2020-02-06,2020-02-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ViiV Healthcare, S.L.","A Randomized, Double-Blind (Sponsor-unblinded), Placebo-Controlled, Adaptive Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK3640254 in HIV-1 Infected Treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002208-15,0,0,0 2018-002208-15,3,2020-02-06,2020-02-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ViiV Healthcare UK Limited,"A Randomized, Double-Blind (Sponsor-unblinded), Placebo-Controlled, Adaptive Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK3640254 in HIV-1 Infected Treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002208-15,0,0,0 2018-002210-12,8,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,IDORSIA PHARMACEUTICALS LTD,"A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002210-12,0,0,0 2018-002210-12,8,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Idorsia Pharmaceuticals Ltd,"A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002210-12,0,0,0 2018-002211-10,3,2022-03-31,2022-03-31,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ERYTECH Pharma,A Randomized Phase 2/3 Study of Eryaspase in Combination with Gemcitabine and Carboplatin Chemotherapy versus Chemotherapy Alone As First-Line Treatment in Patients with Metastatic or Locally Recurren...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002211-10,1,0,0 2018-002217-35,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Agios Pharmaceuticals, Inc.","A Phase 2, Open-Label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-Transfusion-Dependent Thalassemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002217-35,0,0,0 2018-002220-16,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002220-16,0,0,0 2018-002220-16,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002220-16,0,0,0 2018-002222-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,APHP,"Cobimetinib for BRAF-wild-type histiocytoses : a randomized, placebo-controlled, double blind study Cobimetinib pour le traitement des histiocytoses sans mutation BRAFV600E : Une étude randomisée, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002222-23,0,0,0 2018-002224-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Leids Universitair Medisch Centrum,GON-injection for a sooner and better treatment of cluster headache: a double-blind randomized controlled trial GON-injectie voor een snellere en betere behandeling van clusterhoofdpijn: een dubbel...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002224-17,0,0,0 2018-002225-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL UNIVERSITARIO FUNDACION ALCORCON,EVALUATION OF THE COFACTORS IN THE MAINTENANCE PHASE REACTIONS AFTER MILK AND EGG ORAL IMMUNOTHERAPY EVALUACIÓN DEL PAPEL DE LOS COFACTORES EN LAS REACCIONES DE FASE DE MANTENIMIENTO TRAS LA DESENS...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002225-26,0,0,0 2018-002226-22,1,2020-06-17,2020-06-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical University of Vienna,The Impact of Target Temperature Management on Drug Metabolism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002226-22,0,0,0 2018-002227-42,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,Avelumab in the frontline treatment of advanced classical Hodgkin lymphoma - a window study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002227-42,0,0,0 2018-002230-20,8,2020-08-31,2020-08-31,7,0,0,0,0,1,2,0,0,1,0,0,1,0,1,"Crinetics Pharmaceuticals, Inc.","An open label exploratory study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly treated with somatostatin analogue based treatment regimens (ACROBAT EDGE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002230-20,0,0,0 2018-002231-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut régional du Cancer de Montpellier,"A randomized phase III trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failure of standard therapies, according to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002231-24,0,0,0 2018-002233-37,5,2021-06-15,2021-06-15,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Impax Laboratories, LLC",A randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson's disease patients with motor fluctuations.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002233-37,1,0,0 2018-002234-21,6,2022-03-21,2022-03-21,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Impax Laboratories, LLC",AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON’S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002234-21,1,0,0 2018-002235-15,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Oslo,"The effect of methenamine hippurate to reduce antibiotic prescribing due to new episodes of urinary tract infections (UTI) in elderly women with recurrent UTI – a triple-blinded,randomized placebo-con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002235-15,0,0,0 2018-002239-11,5,2019-10-24,2019-10-24,4,0,0,1,0,0,1,0,0,2,0,0,0,0,1,MyoKardia Inc.,"Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002239-11,1,0,0 2018-002242-36,6,2020-08-18,2020-08-18,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GB001, Inc.","A Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 as maintenance therapy in adult subjects with moderate to severe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002242-36,0,0,0 2018-002245-11,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,UMC Utrecht,Assessing penetration of high dose Nicotinamide (Vitamin B3) in synovial fluid Beoordelen van de penetratie van hoge dosering nicotinamide (vitamine B3) in synoviaal vocht,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002245-11,0,0,0 2018-002247-28,5,2020-06-25,2020-06-25,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Momenta Pharmaceuticals, Inc.","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults with Gen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002247-28,0,0,0 2018-002247-28,5,2020-06-25,2020-06-25,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"MOMENTA PHARMACEUTICALS, Inc","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults with Gen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002247-28,0,0,0 2018-002248-95,4,2019-12-09,2019-12-19,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,FAES FARMA S.A.,"Multi-centre, randomised, double blind, placebo-controlled, parallel, phase III study to assess the safety, tolerability and efficacy of bilastine ophthalmic solution 0.6% in adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002248-95,0,0,0 2018-002249-13,4,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,ORION CORPORATION ORION PHARMA,"SAFETY AND PHARMACOKINETICS OF ODM-209 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002249-13,0,0,0 2018-002249-13,4,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,Orion Corporation Orion Pharma,"SAFETY AND PHARMACOKINETICS OF ODM-209 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002249-13,0,0,0 2018-002250-79,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Royal Marsden NHS Foundation Trust,iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002250-79,0,0,0 2018-002251-14,1,2020-11-30,2020-11-30,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Kings College Hospital NHS Foundation Trust,Localized on site testing and treatment of hepatitis C in homeless persons in London: a pilot non-randomised phase 4 interventional clinical trial of grazoprevir and elbasvir ± ribavirin in participan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002251-14,0,0,0 2018-002253-30,5,2020-02-20,2020-02-20,2,1,1,0,0,1,1,0,0,1,1,1,1,0,1,INCYTE CORPORATION,"An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Pe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002253-30,0,0,0 2018-002253-30,5,2020-02-20,2020-02-20,2,1,1,0,0,1,1,0,0,1,1,1,1,0,1,Incyte Corporation,"An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Pe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002253-30,0,0,0 2018-002255-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Hospital,No official English language name DPDIMP#1-tutkimus: DPYD-geenitestin vaikutus fluoropyrimidiinilääkityksen turvallisuuteen ja tehoon,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002255-15,0,0,0 2018-002256-33,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Friedrich-Schiller-Universität Jena,Frontline Asciminib combination in chronic phase CML,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002256-33,0,0,0 2018-002258-56,1,2020-10-10,2020-10-10,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,University Hospitals Leuven,"The use of xenon and dexmedetomidine for the prevention of postoperative emergence delirium after anaesthesia for pediatric cardiac catheterization: A randomized, controlled, observer-blinded pilot tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002258-56,0,0,0 2018-002261-19,8,2021-12-17,2021-12-17,5,1,0,0,0,2,3,0,0,2,1,0,0,0,1,Principia Biopharma,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002261-19,1,0,0 2018-002261-19,8,2021-12-17,2021-12-17,5,1,0,0,0,2,3,0,0,2,1,0,0,0,1,Principia Biopharma Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002261-19,1,0,0 2018-002262-39,3,2022-05-31,2022-05-31,3,0,0,0,0,1,2,0,0,1,0,0,0,0,1,TELIX International Pty Ltd,"A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I-IP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002262-39,0,0,0 2018-002263-26,6,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS,Optimizing response to Li treatment through personalized evaluation of individuals with bipolar I disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002263-26,0,0,0 2018-002263-26,6,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,DRCI APHP,Optimizing response to Li treatment through personalized evaluation of individuals with bipolar I disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002263-26,0,0,0 2018-002263-26,6,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Assistance Publique - Hopitaux de Paris,Optimizing response to Li treatment through personalized evaluation of individuals with bipolar I disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002263-26,0,0,0 2018-002264-57,10,2020-12-09,2020-12-09,9,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatiti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002264-57,1,0,0 2018-002264-57,10,2020-12-09,2020-12-09,9,1,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatiti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002264-57,1,0,0 2018-002267-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fakultní nemocnice Brno,SAFETY AND EFFICACY OF OLANZAPINE TREATMENT IN PSYCHOSIS: EFFECT OF GENETIC AND EPIGENETIC FACTORS – COVARIATES OF TREATMENT RESPONSE BEZPEČNOST A ÚČINNOST TERAPIE OLANZAPINEM U PSYCHÓZ: VLIV GENET...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002267-25,0,0,0 2018-002270-48,1,2020-05-18,2020-05-18,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Randomized, Placebo-controlled Trial to Evaluate the Long-term (ie, Maintenance) Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects with Tourette’s Disorder Randomizált, placeb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002270-48,0,0,0 2018-002275-18,5,2021-04-12,2021-04-12,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Merck KGaA,"A multicenter study with an open-label Phase Ib part followed by a randomized, placebo-controlled, double-blind, Phase II part to evaluate efficacy, safety, tolerability, and pharmacokinetics of the D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002275-18,1,0,0 2018-002275-18,5,2021-04-12,2021-04-12,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,MERCK KGAA,"A multicenter study with an open-label Phase Ib part followed by a randomized, placebo-controlled, double-blind, Phase II part to evaluate efficacy, safety, tolerability, and pharmacokinetics of the D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002275-18,1,0,0 2018-002277-22,3,2022-07-06,2022-07-06,1,0,0,0,0,0,4,0,1,2,0,0,0,0,0,Stichting VUmc,"AMYPAD Prognostic and Natural History Study (PNHS), an open label, prospective, multicentre, cohort study in individuals without dementia to evaluate the additional value of quantitative amyloid imagi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002277-22,1,0,0 2018-002278-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Department of Clinical Pharmacology/Medical University of Vienna,Pharmacokinetics of antibiotics in cerebrospinal fluid of children with external ventricular drain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002278-33,0,0,0 2018-002279-16,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Enterome,"A MulticenteR, Open-Label, First-in-Human, PhaSe Ib/IIa Trial of EO2401, a Novel Multipeptide Therapeutic VAccine, with and without PD-1 Check Point Inhibitor, FoLlowing Standard Treatment in PatIents...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002279-16,0,0,0 2018-002282-19,1,2022-05-31,2022-05-31,1,0,0,0,0,1,2,0,0,1,0,0,0,0,0,Hellenic Society of Hematology,"A Phase 2, Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Ixazomib and Dexamethasone as Second Line Therapy in Multiple Myeloma Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002282-19,0,0,0 2018-002285-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Department of Gynaecology and Obstetrics Nordsjællands Hospital,Validating the Effect of Ondansetron and Mirtazapine In Treating Hyperemesis Gravidarum. A Double-blind Randomized Placebo-Controlled Multicentre Trial. Validering af effekten af ondansetron og m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002285-39,0,0,0 2018-002291-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Gelderse Vallei Hospital,The effect of administering VITamin K preprocedural on the vitamin K dependent coagulation factors and the INR in patients anticoagulated with ACEnocoumarol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002291-41,0,0,0 2018-002292-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital of Montpellier,CT air-trapping characterization for the early identification of Benralizumab responders among eosinophilic asthma patients Identification précoce d’une réponse au Benralizumab par caractérisation...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002292-18,0,0,0 2018-002293-44,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,VIFOR FRANCE,A Pragmatic randomized study to evaluate the comparative effectiveness of Akynzeo® and Standard of care (including Emend®) for the prevention of nausea and vomiting (CINV) in cancer patients receiving...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002293-44,0,0,0 2018-002294-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab as Consolidation Therapy in Patients with Locally Advanced, Unresectable, Non-Small Cell Lung Cancer (Stage I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002294-22,0,0,0 2018-002295-40,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Copenhagen Neuromuscular Center,Pharmacokinetics and safety of treatment with paracetamol in children and adults with spinal muscular atrophy and cerebral palsy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002295-40,0,0,0 2018-002299-41,3,2020-10-08,2020-10-08,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Kymab Limited,"A Phase IIa, Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002299-41,0,0,0 2018-002301-61,4,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,"Astellas Pharma Global Development, Inc. (APGD)","A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002301-61,0,0,0 2018-002301-61,4,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.","A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002301-61,0,0,0 2018-002303-33,20,2020-09-28,2020-09-28,17,1,0,0,0,0,3,0,0,1,1,0,1,0,1,UCB Biopharma SRL,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002303-33,0,0,0 2018-002303-33,20,2020-09-28,2020-09-28,17,1,0,0,0,0,3,0,0,1,1,0,1,0,1,UCB Biopharma SPRL,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002303-33,0,0,0 2018-002306-31,4,2020-09-03,2020-09-09,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial with ABBV-105 Given A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002306-31,0,0,0 2018-002308-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),COrticosteroids in acUte uRticAria in emerGency dEpartment Corticothérapie dans l’urticaire aiguë aux urgences,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002308-15,0,0,0 2018-002310-12,1,2019-12-03,2019-12-03,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Fundació Lluita contra la SIDA,Bictegravir concentrations and antiviral activity in genital fluids and rectal compartment in HIV-1 infected individuals (“BIGER Study”). Concentraciones de bictegravir y actividad antiviral en flu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002310-12,0,0,0 2018-002311-10,2,2021-10-18,2021-10-18,2,1,0,0,0,0,3,0,0,1,0,0,0,0,1,Swiss Cardio Technologies AG,"A multi-center, open label, single group, observational study to investigate the effects of training on the administration of Cardioplexol (TM) Eine multizentrische, offene Beobachtungsstudie mit ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002311-10,0,0,0 2018-002315-98,1,2022-03-01,2022-03-01,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Aarhus Universitetshospital,The effect of medical cannabis on neuropathic pain and spasticity in patients with Multiple Sclerosis and in patients with spinal cord injury. A multicenter national placebo-controlled trial Effekt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002315-98,0,0,0 2018-002318-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Zealand University Hospital,The effect of low-dose salicylate treatment on platelet function in patients with renal failure treated with darbopoietin alfa (EPOASA study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002318-11,0,0,0 2018-002319-86,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,Dominantly Inherited Alzheimer Network - DIAN Red de Alzheimer heredado de forma autosómica dominante (DIAN - Dominantly Inherited Alzheimer Network) - Barcelona,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002319-86,0,0,0 2018-002324-17,1,2020-10-27,2020-10-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Aarhus University Hospital,Thiamin against robust IBD fatigue - The effect of oral thiamin supplement in 4 weeks to patients with inflammatory bowel disease (IBD) in remission and chronic fatigue. A randomised placebo controlle...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002324-17,0,0,0 2018-002328-18,5,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,F. Hoffman-La Roche Ltd.,"A RANDOMIZED, MULTICENTER, PHASE Ib/III STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTANEOUS COMPARED WITH ATEZOLIZUMAB INTRAVENOUS IN PATIENTS WITH PREVIOUSLY ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002328-18,0,0,0 2018-002328-18,5,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A RANDOMIZED, MULTICENTER, PHASE Ib/III STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTANEOUS COMPARED WITH ATEZOLIZUMAB INTRAVENOUS IN PATIENTS WITH PREVIOUSLY ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002328-18,0,0,0 2018-002338-19,1,2021-12-16,2021-12-16,1,0,0,0,0,0,3,0,1,1,0,0,0,0,0,Oslo University Hospital,BUSCLAB - A DOUBLE BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL INVESTIGATING THE EFFECT OF INTRAVENOUS BUTYLSCOPOLAMINE BROMIDE TO TREAT SLOW PROGRESS IN LABOR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002338-19,0,0,0 2018-002339-23,1,2021-09-23,2021-09-23,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medical University Graz, Department of Ophtalmology",Prospective intraindividual comparison of the mydriasis of a standardized intracameral anaesthetics with the topical preoperative drop application in the uncomplicated cataract surgery Prospektiver...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002339-23,0,0,0 2018-002342-36,3,2019-04-15,2019-04-15,2,0,0,0,0,0,3,0,0,1,1,0,1,0,1,JHL Biotech (Hong Kong) Limited,"A Multinational, Randomized, Double-blind, Positive-controlled, Parallel Group Clinical Study to Compare the Efficacy and Safety of the JHL1101 in Combination with CHOP (J-CHOP) versus Rituximab in Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002342-36,0,0,0 2018-002342-36,3,2019-04-15,2019-04-15,2,0,0,0,0,0,3,0,0,1,1,0,1,0,1,JHL Biotech Inc.,"A Multinational, Randomized, Double-blind, Positive-controlled, Parallel Group Clinical Study to Compare the Efficacy and Safety of the JHL1101 in Combination with CHOP (J-CHOP) versus Rituximab in Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002342-36,0,0,0 2018-002343-29,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Service of Neurology, CHU Liege","Synaptic modifications in subjective cognitive decline. A study using [18F]UCB-H, a synaptic vesicle 2A radiotracer. Modifications synaptiques lors du déclin cognitive subjectif. Une étude avec le ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002343-29,0,0,0 2018-002344-81,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Boehringer Ingelheim Limited,"An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD-(L)1 naïve and PD-(L)1 pretreated patient populations with advan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002344-81,0,0,0 2018-002345-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Etude multi-centrique, en double aveugle, randomisée, contrôlée contre placebo, en groupes parallèles pour évaluer l'efficacité de la toxine botulinique A dans le phénomène de Raynaud secondaire à une...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002345-12,0,0,0 2018-002350-78,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Karolinska Institute,ProBio : an outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002350-78,0,0,0 2018-002350-78,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Karolinska Institutet,ProBio : an outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002350-78,0,0,0 2018-002355-15,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Novartis pharma AG,"An open label, single-arm, active-treatment, efficacy and safety study of canakinumab (ACZ885) administered for at least 48 weeks in Japanese patients with Systemic Juvenile Idiopathic Arthritis (SJIA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002355-15,0,1,1 2018-002359-14,1,2019-03-05,2019-03-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Fresenius Kabi Deutschland GmbH,Blood Glucose Response After Oral Intake of Lactulose (Laevolac®) in Mildly Constipated Patients with Diabetes Mellitus Type 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002359-14,0,0,0 2018-002362-39,1,2021-06-30,2021-06-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,St Maartenskliniek,Comparing Methotrexate monotherapy with methotrexate Plus LEflunomide combination ThErapy in Psoriatic Arthritis: A pragmatic randomized placebo-controlled double-blind clinical trial. Vergelij...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002362-39,0,0,0 2018-002364-44,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,IELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP,MALIBU trial - Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002364-44,0,0,0 2018-002365-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Line Velling Magnussen,"Muscle strength and -mass after bariatric surgery - a possible effect of testosterone replacement therapy? Randomized, placebo-controlled and double-blinded study Effekten af testosteron på krops...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002365-19,0,0,0 2018-002366-39,1,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,0,University of Oxford / Clinical Trials and Research Governance,A pilot trial of intravenous iron for the treatment of iron deficiency in adult patients with cystic fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002366-39,0,0,0 2018-002367-26,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Litaphar Laboratorios,"A randomized, double-blind, three-arm, parallel-group, multicentre superiority study assessing the efficacy and safety of mifepristone (2.5 mg and 5 mg) vs. placebo for the treatment of endometriosis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002367-26,0,0,0 2018-002368-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR),"Phase IV, open, low-level intervention, clinical trial to compare the immunogenicity in immunosuppressed patients of an adjuvanted anti-hepatitis B vaccine with an anti-hepatitis B vaccine with increa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002368-18,0,0,0 2018-002371-18,9,2021-07-02,2021-07-02,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog with an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type 1 Diabetes PRONTO-PEDS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002371-18,1,0,0 2018-002371-18,9,2021-07-02,2021-07-02,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog with an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type 1 Diabetes PRONTO-PEDS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002371-18,1,0,0 2018-002371-18,9,2021-07-02,2021-07-02,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Lilly S.A.,"A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog with an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type 1 Diabetes PRONTO-PEDS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002371-18,1,0,0 2018-002374-46,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,A randomised phase II trial assessing REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002374-46,0,0,0 2018-002376-41,1,2021-02-27,2021-02-27,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Zealand University Hospital, Gynecological department",Modulating the Vaginal Microbiome after Implantation Failure - A randomized placebo controlled study of lactobacilli supplements Modulering af den vaginale bakterieflora efter manglende implantatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002376-41,0,0,0 2018-002378-30,10,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Pfizer Inc.,"OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002378-30,0,0,0 2018-002378-30,10,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,PFIZER INC,"OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002378-30,0,0,0 2018-002380-26,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,SOCIETÀ ITALO BRITANNICA L. MANETTI - H. ROBERTS & C. PER AZIONI,"Single-group, open study on the systemic bioavailability, safety and local tolerability of a new gel formulation of Somatoline¿ in 30 healthy women. Single-group, open study on the systemic bioavai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002380-26,0,0,0 2018-002382-19,5,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,PDC*line Pharma SAS,"An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002382-19,0,0,0 2018-002383-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Oulu,Premedication for less invasive surfactant administration Esilääkitys vähemmän kajoavassa surfaktantin annossa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002383-38,0,0,0 2018-002385-39,1,2020-06-26,2020-06-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,County Council of Västerbotten,Infusion of hypertonic solutions: A risk factor for delirium after cardiac surgery? A randomised double blinded controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002385-39,0,0,0 2018-002387-86,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Pascoe pharmazeutische Präparate GmbH,"A DOUBLE-BLIND, PLACEBO-CONTROLLED, 4-ARM PILOT STUDY ON THE USE OF PASCORBIN® AS ADD-ON THERAPY IN PATIENTS WITH ACUTE HERPES ZOSTER Eine doppelblinde, Placebo-kontrollierte, 4armige Pilotstudie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002387-86,0,0,0 2018-002401-56,6,2019-12-06,2020-02-27,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Eli Lilly & Company,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects with Moderate-to-Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002401-56,0,0,0 2018-002401-56,6,2019-12-06,2020-02-27,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects with Moderate-to-Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002401-56,0,0,0 2018-002401-56,6,2019-12-06,2020-02-27,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Lilly S.A.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects with Moderate-to-Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002401-56,0,0,0 2018-002405-64,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,1,CATALYST PHARMACEUTICALS INC.,Long term safety study of amifampridine phosphate in patients with Congenital Myasthenic Syndromes (CMS) Studio sulla sicurezza a lungo termine dell’amifampridina fosfato nei pazienti con Sindromi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002405-64,0,0,0 2018-002406-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut de Cancérologie Lucien Neuwirth,HOMEORAD : Randomized Phase III Trial Evaluating Homeopathic Radium Bromatum® Impact on the Prevention and Treatment of Radiodermites in Breast Cancer Patients HOMEORAD : Essai de phase III randomi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002406-32,0,0,0 2018-002425-34,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Turku University Hospital,LIRAGLUTIDE IN THE PREVENTION OF T2DM AFTER GESTATIONAL DIABETES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002425-34,0,0,0 2018-002430-21,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,GWT-TUD GmbH,Primary comparison of Liposomal Anthracycline based treatment versus conventional care strategies prior to allogeneic stem cell transplantation in patients with higher risk MDS and oligoblastic AML,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002430-21,0,0,0 2018-002431-18,5,2022-03-28,2022-03-28,4,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Novo Nordisk A/S,Effect and safety of semaglutide 2.4 mg once weekly on weight management in adolescents with overweight or obesity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002431-18,1,0,0 2018-002433-38,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,ProQR Therapeutics,A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002433-38,0,0,0 2018-002442-37,4,2021-04-01,2021-04-01,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab in combination with other anti-cancer therapies in participants with lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002442-37,1,0,0 2018-002442-37,4,2021-04-01,2021-04-01,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Sanofi-aventis recherche & developpement,"A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab in combination with other anti-cancer therapies in participants with lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002442-37,1,0,0 2018-002443-28,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ACERTA PHARMA BV,"A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002443-28,0,0,0 2018-002443-28,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Acerta Pharma B.V.,"A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002443-28,0,0,0 2018-002446-36,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,F. Hoffmann-La Roche Ltd,AN OPEN LABEL PHASE 2A TRIAL ASSESSING THE CLINICAL EFFICACY AND SAFETY OF RO5459072 IN MODERATE TO SEVERE PSORIASIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002446-36,0,0,0 2018-002447-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medizinische Universität Wien, klinische Abteilung für Nephrologie und Dialyse",THE ENTERAL RESUSCITATION IN INTENSIVE CARE STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002447-29,0,0,0 2018-002448-10,6,2021-10-20,2021-10-20,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Bial - Portela & Ca, S.A.","An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002448-10,1,0,0 2018-002448-10,6,2021-10-20,2021-10-20,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"BIAL-Portela & Ca, S.A.","An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002448-10,1,0,0 2018-002448-10,6,2021-10-20,2021-10-20,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Bial - Portela & Ca, S.A","An open-label, multicentre study to evaluate pharmacokinetics, safety and efficacy of zamicastat as adjunctive therapy in pulmonary arterial hypertension (PAH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002448-10,1,0,0 2018-002463-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Antoni van Leeuwenhoek,Neoadjuvant treatment in rectal cancer with radiotherapy followed by atezolizumab and bevacizumab (TARZAN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002463-25,0,0,0 2018-002465-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,Efficacy and tolerance of 4 weeks of tedizolid in prosthetic joint infections treated with implant removal Eficacia y tolerancia de 4 semanas de tedizolid en infecciones articulares protésicas trat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002465-18,0,0,0 2018-002466-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Morphine or Fentanyl for Refractory dyspnea in COPD Morfine of fentanyl voor refractaire dyspnoe bij COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002466-39,0,0,0 2018-002470-42,1,2019-04-01,2019-04-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Imperial College London JRC Office,Assessment of viral shedding week following administration of live attenuated influenza vaccine in children: FluSHED-2 study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002470-42,0,0,0 2018-002471-18,1,,,0,1,0,0,0,0,4,0,0,3,0,0,0,0,0,Imperial College London,The clinical effectiveness and cost effectiveness of clozapine for inpatients with borderline personality disorder: randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002471-18,0,0,0 2018-002473-21,7,2022-06-10,2022-06-10,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Aspen Global Incorporated,"An Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002473-21,1,0,0 2018-002474-52,7,2022-03-28,2022-03-28,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Auris Medical AG,Multicenter randomized controlled phase 2 trial to evaluate AM-125 in the treatment of acute peripheral vertigo following neurosurgery (TRAVERS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002474-52,1,0,0 2018-002474-52,7,2022-03-28,2022-03-28,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Auris Medical Ltd,Multicenter randomized controlled phase 2 trial to evaluate AM-125 in the treatment of acute peripheral vertigo following neurosurgery (TRAVERS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002474-52,1,0,0 2018-002476-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Nice,Personalized Medicine for Membranous Nephropathy PMMN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002476-40,0,0,0 2018-002477-22,1,2020-04-06,2020-04-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Regeneron Pharmaceuticals, Inc.","A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY IN CAT-ALLERGIC PATIENTS WITH ASTHMA TO EVALUATE THE EFFICACY OF A SINGLE DOSE OF REGN1908-1909 TO REDUCE BRONCHOCONSTRICT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002477-22,0,0,0 2018-002480-26,11,2021-12-20,2021-12-20,7,1,0,0,0,0,3,0,0,1,1,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002480-26,0,0,0 2018-002480-26,11,2021-12-20,2021-12-20,7,1,0,0,0,0,3,0,0,1,1,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002480-26,0,0,0 2018-002480-26,11,2021-12-20,2021-12-20,7,1,0,0,0,0,3,0,0,1,1,0,0,0,1,Novartis Farmacéutica S.A.,"A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002480-26,0,0,0 2018-002482-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Besancon,"Détermination de la Concentration Minimale Efficace pour 90% de Ropivacaïne (MEC90) des blocs du plexus brachial au creux axillaire, avec et sans ajout de Dexamethasone intraveineuse Détermination ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002482-18,0,0,0 2018-002483-11,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Imperial College London,CHOlesterol Reduction with Evolocumab and coronAry microvascuLar function: The CHORAL Flow Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002483-11,0,0,0 2018-002484-25,2,2020-06-09,2020-06-09,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Takeda Development Center Americas, Inc.","A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-935 (OV935) AS AN ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS WITH DEV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002484-25,0,0,0 2018-002485-39,4,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,"Takeda Development Center Americas, Inc.","A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH DEVELOPMENTAL ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002485-39,0,1,0 2018-002485-39,4,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,"Ovid Therapeutics, Inc.","A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH DEVELOPMENTAL ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002485-39,0,1,0 2018-002491-40,1,2021-05-03,2021-05-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A randomized patient-and-physician blinded, placebo-controlled, 24-week study to assess the safety, tolerability and efficacy of LMB763 in patients with diabetic nephropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002491-40,0,0,0 2018-002492-17,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Universität zu Köln,"A prospective, open-label, multicentre Phase-II-Trial to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK Inhibitor, plus tislelizumab (BGB-A317), a PD-1 Inhibitor, for treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002492-17,0,0,0 2018-002496-18,4,2019-12-10,2019-12-10,3,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002496-18,1,0,0 2018-002498-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO “PAOLO GIACCONE” DI PALERMO,The Role of Benralizumab on airway Remodeling Assessed by HRCT in severe asthma (BREATH Study) Il ruolo del Benralizumab sul rimodellamento delle vie aeree nell'asma grave valutato tramite HRCT (St...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002498-23,0,0,0 2018-002499-42,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Cliniques Universitaires Saint-Luc,Evaluation of the effect of repeated injections of high doses of botulinum toxin into the lower limb of spastic brain lesions on functional and biomechanical parameters of walking Évaluation de l’e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002499-42,0,0,0 2018-002501-53,4,2022-05-18,2022-05-18,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Sever...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002501-53,1,0,0 2018-002502-31,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Rocket Pharmaceuticals, Inc.",A Phase II Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene (Orphan Drug) in Patients with Fanconi Anemia S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002502-31,0,0,0 2018-002509-78,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Kings College Hospital NHS Foundation Trust,"Beta-blockers Or Placebo for Primary Prophylaxis of oesophageal varices (BOPPP Trial). A blinded, UK multi-centre, clinical effectiveness and cost-effectiveness randomised controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002509-78,0,0,0 2018-002510-13,1,,,0,0,0,0,1,0,4,0,0,1,0,0,0,1,0,Antoni Sabaté Pes (Servicio de Anestesiología y Reanimación) del Hospital Universitari de Bellvitge,"Impact of two thrombelastography-guided strategies of fibrinogen correction on blood product requirements in liver transplantation: a multicenter, randomized trial. TROMBOFIB trial Impacto de dos ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002510-13,0,0,0 2018-002513-36,4,2020-03-18,2020-03-18,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Rakuten Medical, Inc.","A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician’s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002513-36,1,0,0 2018-002513-36,4,2020-03-18,2020-03-18,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Rakuten Aspyrian, Inc.","A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician’s Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002513-36,1,0,0 2018-002514-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE SANDRO PITIGLIANI PER LA LOTTA CONTRO I TUMORI - ONLUS,"Phase II, multicenter, single arm trial to assess the feasibility of first line ribociclib in combination with a non steroidal aromatase inhibitor in elderly patients with hormone receptor positive/HE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002514-12,0,0,0 2018-002518-10,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Multicenter, Open-label, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) in Participants with Advanced Melanoma Previously E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002518-10,0,0,0 2018-002520-16,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002520-16,0,0,0 2018-002520-16,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002520-16,0,0,0 2018-002521-30,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"An extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability up to 4 years in patients with Juvenile Idiopathic Arthritis subtypes of Juvenile Psoriatic A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002521-30,0,0,0 2018-002521-30,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novartis Pharma AG,"An extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability up to 4 years in patients with Juvenile Idiopathic Arthritis subtypes of Juvenile Psoriatic A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002521-30,0,0,0 2018-002521-30,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","An extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability up to 4 years in patients with Juvenile Idiopathic Arthritis subtypes of Juvenile Psoriatic A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002521-30,0,0,0 2018-002522-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Inmunotek S.L.,"A prospective, randomized, double-blind placebo-controlled dose-finding study of different regimens of mannan-conjugated allergoids of birch pollen allergens administered subcutaneously to patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002522-23,0,0,0 2018-002523-42,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,AstraZeneca AB,"A randomised, double-blind, placebo-controlled, dose-response study of the efficacy and safety of MEDI7352 in subjects with painful diabetic neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002523-42,0,0,0 2018-002523-42,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,AstraZenecaAB,"A randomised, double-blind, placebo-controlled, dose-response study of the efficacy and safety of MEDI7352 in subjects with painful diabetic neuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002523-42,0,0,0 2018-002525-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA,Conservative vs conventional oxygen administration in critically ill patients: effects on ICU mortality. A multicentre randomized open label clinical trial. Somministrazione di ossigeno conservativ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002525-35,0,0,0 2018-002526-23,3,2021-07-26,2021-07-26,2,1,0,0,1,0,3,0,0,2,0,0,0,0,1,Entasis Therapeutics,"A Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter baumannii-calcoaceticus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002526-23,1,0,0 2018-002529-48,1,2020-12-14,2020-12-14,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Center for Aktiv Sundhed, Rigshospitalet",Urine concentrations of vilanterol after inhaled administration of vilanterol/fluticasone furoate: Defining a urine threshold and decision limit for vilanterol in doping control analysis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002529-48,0,0,0 2018-002530-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español Multidisciplinar de Melanoma,Multicentric phase II clinical trial to evaluate the activity of encorafenib and binimetinib before local treatment in patients with BRAF mutated melanoma with metastasis to the brain. Ensayo clíni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002530-20,0,0,0 2018-002531-18,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,"Topical Everolimus versus placebo for the treatment of facial angiofibromas in patients with tuberous sclerosis complex. A phase II/III, multicentre, randomized, double-blind, placebo-controlled study...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002531-18,0,0,0 2018-002532-24,1,2019-11-04,2019-11-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,HELM AG,"A phase III, multicentre, randomised, double-blind, parallel-group trial to evaluate the efficacy and safety of a generic gel (calcipotriol + betamethasone 50 μg/g + 0.5 mg/g gel) compared to originat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002532-24,0,0,0 2018-002541-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Prevention of post-operative Atrial Fibrillation by BOTulinum toxin injections into epicardial fat pads around pulmonary veins in patients undergoing cardiac surgery Prévention de la Fibrillation ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002541-11,0,0,0 2018-002543-28,2,2021-12-31,2021-12-31,2,0,0,0,0,0,2,0,0,1,1,1,0,0,1,MEGAINPHARM GmbH,"A multi-center, randomized, placebo-controlled, double-blind, dose-finding clinical trial investigating the short-term relief of symptoms of acute pharyngitis such as throat soreness pain and difficul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002543-28,0,0,0 2018-002546-36,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Oslo University Hospital,"TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS): A PROSPECTIVE, RANDOMIZED-CONTROLLED, DOUBLE-DUMMY, DOUBLE-BLIND PHASE 3 MULTI-CENTRE TRIAL OF TNK 0.25 MG/KG + PLACEBO VS. ASA + PL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002546-36,0,0,0 2018-002547-29,3,2019-10-21,2019-10-21,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Atox Bio,"Phase 2 randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of Reltecimod as compared to placebo in addition to standard of care in patients with sep...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002547-29,0,0,0 2018-002548-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,PET/MRI study of amyloid burden in patients with Cerebral Amyloid Angiopathy-related inflammation Studio PET/MRI del carico di amiloide in pazienti con angiopatia amiloide cerebrale infiammatoria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002548-10,0,0,0 2018-002550-71,1,2020-12-30,2020-12-30,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,Santhera Pharmaceuticals (Switzerland) Ltd,"Phase-Ib/IIa study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of orally inhaled multiple doses of POL6014 in patients with Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002550-71,0,0,0 2018-002551-15,3,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.","A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002551-15,0,0,0 2018-002551-15,3,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,"Astellas Pharma Global Development, Inc. (APGD)","A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002551-15,0,0,0 2018-002553-30,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,EORTC AISBL/IVZW,A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cance (APPALACHES),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002553-30,0,0,0 2018-002553-30,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,European Organisation for research and treatment of Cancer,A Phase II study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS with high-risk ER+/HER2- early breast cance (APPALACHES),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002553-30,0,0,0 2018-002556-32,9,2021-01-21,2021-01-21,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ADC THERAPEUTICS SA,"A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002556-32,1,0,0 2018-002556-32,9,2021-01-21,2021-01-21,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ADC Therapeutics SA,"A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002556-32,1,0,0 2018-002562-40,1,2020-08-05,2020-08-05,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1,Portola Pharma UK Ltd,"A phase 1, open-label, single dose, non-randomized study to evaluate pharmacokinetics, pharmacodynamics, and safety of Betrixaban in pediatric patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002562-40,0,0,0 2018-002563-25,1,2021-10-04,2021-10-04,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,IDIAP Jordi Gol,"Effectiveness of antitussive, anticholinergic and honey therapy versus usual practice in adults with uncomplicated acute bronchitis [AB4T study] Efectividad del tratamiento antitusígeno, anticoliné...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002563-25,0,0,0 2018-002564-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Universitair Medisch Centrum Groningen,"Short-term safety, efficacy and mode of action of apremilast in mild to moderate cutaneous pemphigoid: a phase IIa open label single arm study. Korte termijn veiligheid, werkzaamheid en werkingsmec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002564-10,0,0,0 2018-002565-18,3,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"SCYNEXIS, Inc.","A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Coadministration of SCY-078 with Voriconazole in Patients with Invasive Pulmonary Aspergillosis (SCYNERGIA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002565-18,0,0,0 2018-002571-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,EFFECT OF FERRIC CARBOXYMALTOSE ON EXERCISE CAPACITY AFTER KIDNEY TRANSPLANTATION: A MULTICENTER RANDOMIZED CONTROLLED TRIAL Het effect van ferric carboxymaltose op inspanningstolerantie na niertr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002571-18,0,0,0 2018-002572-41,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002572-41,0,0,0 2018-002572-41,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002572-41,0,0,0 2018-002573-21,10,2020-01-15,2020-03-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002573-21,0,0,0 2018-002573-21,10,2020-01-15,2020-03-06,9,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER INC,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002573-21,0,0,0 2018-002574-52,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Allergan Ltd.,A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002574-52,0,0,0 2018-002574-52,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ALLERGAN LIMITED,A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002574-52,0,0,0 2018-002575-17,13,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"Intercept Pharmaceuticals, Inc.","A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Bi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002575-17,0,0,0 2018-002577-22,1,2021-10-13,2021-10-13,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,"COMPASS Pathfinder, Limited",The safety and efficacy of psilocybin as an adjunctive therapy in participants with treatment-resistant depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002577-22,0,0,0 2018-002578-37,1,,,0,0,0,0,1,0,2,0,1,0,0,0,0,0,0,"Medical University of Vienna, Department of Clinical Pharmacology",The effect of antibiotic eye drops on the nasal microbiome in healthy subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002578-37,0,0,0 2018-002579-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Karolinska University Hospital, Stockholm CF center",Evaluation of the possible use of analysis of posaconazole in exhaled breath as a surrogate marker for the lung to monitor adequate dosages of posaconazole in CF patients treated for Aspergillus spp. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002579-16,0,0,0 2018-002583-11,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Maastricht University Medical Centre,Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer Fase II-studie naar de activiteit van L19-IL2-immunot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002583-11,0,0,0 2018-002583-11,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Maastricht University,Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer Fase II-studie naar de activiteit van L19-IL2-immunot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002583-11,0,0,0 2018-002584-25,1,2021-11-08,2021-11-08,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,HOSPICES CIVILS DE LYON,A phase II study of olaparib in recurrent IDH mutated high grade gliomas OLAGLI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002584-25,0,0,0 2018-002587-28,2,2020-08-06,2020-09-02,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"BeiGene, Ltd.","A Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002587-28,0,0,0 2018-002588-24,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Pfizer Inc.,"A PHASE 4, OPEN-LABEL, SINGLE-ARM TRIAL TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF TRUMENBA® WHEN ADMINISTERED TO IMMUNOCOMPROMISED PARTICIPANTS ≥10 YEARS OF AGE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002588-24,0,0,0 2018-002589-38,2,2021-10-27,2021-10-27,1,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Novo Nordisk A/S,PIONEER 12 China multi-regional clinical trial: Efficacy and safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes mellitus treated with metformin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002589-38,0,0,0 2018-002590-22,1,2021-10-27,2021-10-27,1,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Novo Nordisk A/S,"China multi-regional clinical trial: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only PIONEER 11 Kína, több régió...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002590-22,0,0,0 2018-002591-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS,Evaluation of bronchial remodeling during mepolizumab treatment in severe eosinophilic asthma Evaluation du remodelage bronchique lors d’un traitement par mépolizumab dans l’asthme sévère éosinophi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002591-40,0,0,0 2018-002595-41,1,2020-09-29,2020-09-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Herlev and Gentofte Hospital,CHECKPOINT INHIBITOR INDUCED COLITIS AND ARTHRITIS – IMMUNOMODULATION WITH IL-6 BLOCKADE AND EXPLORATION OF DISEASE MECHANISMS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002595-41,0,0,0 2018-002596-18,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,LOFARMA S.P.A.,Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS Birch tablets for patients with tree pollen-induced allergic rhinoconjunctivitis with or without mild controlled asthma Efficacy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002596-18,0,0,0 2018-002597-41,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,Adamed Pharma S.A.,A multi-centre clinical trial evaluating patients’ ability to independently and safely use the medicinal product indicated in the treatment of erectile dysfunction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002597-41,0,0,0 2018-002598-22,2,2021-11-05,2021-11-05,2,0,0,0,0,0,2,0,0,1,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined with Chemotherapy as a First-line Treatment for Non-Small Cell Lung Cancer (KEYNOTE-782) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002598-22,0,0,0 2018-002601-57,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First-line Therapy in Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-913))",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002601-57,0,0,0 2018-002601-57,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First-line Therapy in Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-913))",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002601-57,0,0,0 2018-002605-62,1,2020-05-20,2020-05-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Herlev and Gentofte Hospital,Phase IIa trial with PD-L1 IO103 vaccination with montanide in patients with basal cell carcinoma. Vaccination mod PD-L1 IO103 til patienter med basal celle kræft,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002605-62,0,0,0 2018-002606-31,1,2020-04-21,2020-04-21,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial","Sublingual versus intravenous Fentanyl in patients with acute trauma - a randomized, double-blind, double-dummy study to demonstrate non-inferiority TraumaPACT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002606-31,0,0,0 2018-002607-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC),"Phase II, open-label study of atezolizumab in a CoHort of pretreated, Advanced Non-small cell lung cancer (NSCLC) patients with rare histologiCal subtypEs – CHANCE trial Studio di fase II, in apert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002607-34,0,0,0 2018-002608-15,3,2022-02-09,2022-02-09,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Celgene Corporation,"A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate to Severe Genital Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002608-15,1,0,0 2018-002608-15,3,2022-02-09,2022-02-09,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Amgen Inc.,"A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate to Severe Genital Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002608-15,1,0,0 2018-002608-15,3,2022-02-09,2022-02-09,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,CELGENE CORPORATION,"A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate to Severe Genital Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002608-15,1,0,0 2018-002610-12,1,2021-06-08,2021-06-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase 2 trial to investigate the safety and efficacy of secukinumab (AIN457) in patients with giant cell arteritis (TitAIN)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002610-12,0,0,0 2018-002611-99,19,2021-02-12,2021-02-12,16,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Bayer AG,"Open-label, randomized, two–arm, controlled study to assess the efficacy, safety, and tolerability of intravitreal (IVT) aflibercept compared to laser photocoagulation in patients with retinopathy of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002611-99,1,0,0 2018-002613-35,1,2021-03-21,2021-03-21,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Radboud university medical centre,"Fluconazole pharmacokinetics, including bioavailability, in Obese subjects after an Intravenous and oral Administration (FOLIA).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002613-35,0,0,0 2018-002614-12,1,2022-01-31,2022-01-31,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Instituto de Investigación Sanitaria INCLIVA,Short-term Effects of Dapagliflozin on Peak VO2 in Patients with Heart Failure with Reduced Ejection Fraction and Type 2 Diabetes Efectos a corto plazo de la dapagliflozina en el consumo pico de ox...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002614-12,0,0,0 2018-002617-35,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomised, placebo-controlled, phase IIa trial on the efficacy and tolerability of an 8-week treatment with two different doses of budesonide orodispersible tablets vs. placebo for prev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002617-35,0,0,0 2018-002618-11,4,2021-04-22,2021-04-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002618-11,0,0,0 2018-002618-11,4,2021-04-22,2021-04-22,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002618-11,0,0,0 2018-002619-89,5,2021-04-27,2021-07-22,4,1,0,0,0,1,4,0,0,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG™) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002619-89,1,0,0 2018-002619-89,5,2021-04-27,2021-07-22,4,1,0,0,0,1,4,0,0,2,0,0,0,0,1,Pfizer Inc.,"A SINGLE ARM, OPEN-LABEL, PHASE 4 STUDY EVALUATING QT INTERVAL, PHARMACOKINETICS, AND SAFETY OF GEMTUZUMAB OZOGAMICIN (MYLOTARG™) AS A SINGLE-AGENT REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY CD33...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002619-89,1,0,0 2018-002620-17,16,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,1,"Portola Pharmaceuticals, LLC.",A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR Ensayo clínico aleatorio de f...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002620-17,0,0,0 2018-002620-17,16,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,1,"Portola Pharmaceuticals, LLC",A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR Ensayo clínico aleatorio de f...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002620-17,0,0,0 2018-002620-17,16,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,1,"Portola Pharmaceuticals, Inc",A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR Ensayo clínico aleatorio de f...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002620-17,0,0,0 2018-002620-17,16,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,1,"Alexion Pharmaceuticals, Inc",A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR Ensayo clínico aleatorio de f...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002620-17,0,0,0 2018-002620-17,16,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,1,PORTOLA PHARMACEUTICALS INC,A PHASE 4 RANDOMIZED CLINICAL TRIAL OF ANDEXANET ALFA [ANDEXANET ALFA FOR INJECTION] IN ACUTE INTRACRANIAL HEMORRHAGE IN PATIENTS RECEIVING AN ORAL FACTOR XA INHIBITOR Ensayo clínico aleatorio de f...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002620-17,0,0,0 2018-002623-42,1,2021-11-27,2021-11-27,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Academic Medical Center,Vasospastic angina treatment by Endothelin Receptor Antagonism; a proof of concept study Vasospastische angina-behandeling door endotheline Receptorantagonisme; een proof of concept-studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002623-42,0,0,0 2018-002624-16,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,ASSISTANC-PUBLIQUE-HOPITAUX DE PARIS (AP-HP),Validation of respiratory epithelial functional assessment to predict clinical efficacy of Orkambi®. Pathway to personalized therapy in Cystic Fibrosis PREDICT-CF Validation de l'exploration fo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002624-16,0,0,0 2018-002625-38,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,ADC Therapeutics SA,A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002625-38,0,0,0 2018-002625-38,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,ADC THERAPEUTICS SA,A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002625-38,0,0,0 2018-002629-51,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn’s ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002629-51,0,0,0 2018-002629-51,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn’s ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002629-51,0,0,0 2018-002629-51,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn’s ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002629-51,0,0,0 2018-002630-21,6,2021-10-07,2021-10-07,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Cidara Therapeutics Inc.,"A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection versus Intravenous Caspofungin Followed by Optional Oral Fluconazole Step-down in the Trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002630-21,1,0,0 2018-002630-21,6,2021-10-07,2021-10-07,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"CIDARA THERAPEUTICS, INC","A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection versus Intravenous Caspofungin Followed by Optional Oral Fluconazole Step-down in the Trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002630-21,1,0,0 2018-002631-15,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,1,RESPIRENT Pharmaceuticals,"A phase III, randomized, multicenter, parallel-group clinical trial for examining the therapeutic equivalence between Fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder/Respirent P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002631-15,0,0,0 2018-002632-24,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Therapeutic plasma exchange, rituximab and intravenous immunoglobulins (IVIg) for severe acute exacerbation of idiopathic pulmonary fibrosis admitted in ICU: an open, randomized, controlled trial L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002632-24,0,0,0 2018-002633-38,2,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,The Newcastle upon Tyne Hospitals NHS Foundation Trust,An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002633-38,0,0,0 2018-002633-38,2,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,ISTITUTO ORTOPEDICO RIZZOLI,An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002633-38,0,0,0 2018-002634-20,1,2022-02-01,2022-02-01,1,1,0,0,0,0,4,0,0,1,0,0,0,0,0,"Anaesthesia Department, Hvidovre Hospital, Capital Region of Denmark","Highdose steroid for total knee arthroplasty - A randomized doubleblindet controlled trial. Højdosis steroid til Total KnæAlloplastik - Et randomiseret, dobbeltblindet kontrolleret forsøg.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002634-20,0,0,0 2018-002635-23,1,2021-03-01,2021-03-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Anaesthesia Department, Hvidovre Hospital, Capital Region of Denmark.",Highdose steroids in High Pain Responders undergoing total knee-arthroplasty - A randomized doubleblindet controlled trial. Højdosis steroid til High Pain Responders der opereres med Total Knæallop...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002635-23,0,0,0 2018-002636-25,1,2021-03-01,2021-03-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Anaesthesia Department, Hvidovre Hospital, Capital Region of Denmark.",Highdose Steroid for High Pain Responders undergoing Total Hip-arthroplasty - A randomized doubleblindet controlled trial. Højdosis steroid til High Pain Responders der opereres med Total Hofteallo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002636-25,0,0,0 2018-002637-37,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Leiden University,Manipulating NMDA-dependent learning to alter nocebo effects: A pharmacological fMRI study on pain and itch.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002637-37,0,0,0 2018-002640-82,1,2022-01-06,2022-01-06,1,0,0,0,0,0,4,0,0,1,1,1,0,0,0,Nordsjællands Hospital,"A randomized, controlled, multicentre trial regarding the safety and feasibility of treatment with empagliflozin compared with NPH insulin treatment in patients with newly onset diabetes following ini...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002640-82,0,0,0 2018-002641-11,1,2020-08-19,2020-08-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Sint Maartenskliniek,The BRIDGE-PMR study: B-cell depletion with Rituximab for Dose reduction of Glucocorticoids: Efficacy in PolyMyalgia Rheumatica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002641-11,0,0,0 2018-002643-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Amsterdam UMC, location VUmc","Safety and tolerability of neoadjuvant nivolumab for locally advanced resectable oral cancer, combined with [18F]BMS-986192 / [18F]-FDG PET imaging and immunomonitoring for response prediction. Ve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002643-28,0,0,0 2018-002644-91,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,"A phase II, open label, multicenter trial of Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP) in patients with relapsed/refractory CD38 positive peripheral T-cell lymph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002644-91,0,0,0 2018-002646-36,1,2020-03-24,2020-03-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Medical University of Graz,Pilot study to evaluate glycemic control with GlucoTab using an ultra-long acting insulin analogue in non-critically ill patients with type 2 diabetes at the genaral ward Pilotstudie zur Bestimmung...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002646-36,0,0,0 2018-002647-29,7,2022-05-06,2022-05-06,7,1,0,0,0,1,2,0,0,1,1,0,0,0,1,PCI Biotech AS,"A Multi-Centre, Randomised, Open-Label, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine/Cis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002647-29,0,0,0 2018-002650-67,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Ibermutuamur (Mutua Colaboradora con la Seguridad Social nº 274),"Comparison of the efficacy of autologous platelet rich plasma injections, and extracorporeal shock wave therapy, in the treatment of work –related lateral epicondylitis. Comparación de la eficacia ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002650-67,0,0,0 2018-002652-33,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,University Hospital of Regensburg,A phase 2 trial to assess haploidentical Alpha/ß T-depleted stem cell transplantation in patients with sickle cell disease with no available sibling donor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002652-33,0,0,0 2018-002653-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE,"Multicenter, randomized, dose-finding, parallel, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of intramuscular administration of allogeneic mesenchymal cells deriv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002653-29,0,0,0 2018-002654-79,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"TEMOTRAD 01 : First-line chemotherapy with temozolomide alone for non-enhancing adult brainstem gliomas, with a diffuse subtype and showing clinical and/or radiological infiltrative pattern of progre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002654-79,0,0,0 2018-002655-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,CHRU BREST,BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica (BACHELOR study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002655-14,0,0,0 2018-002661-19,2,2019-05-10,2019-05-10,2,0,0,0,1,0,3,0,0,1,0,0,1,0,1,"Xeris Pharmaceuticals, Inc","G-PEN (GLUCAGON INJECTION) COMPARED TO GLUCAGEN® HYPOKIT® (GLUCAGON) FOR INDUCED HYPOGLYCEMIA RESCUE IN ADULTS WITH T1D: A PHASE 3 MULTI-CENTER, RANDOMIZED, CONTROLLED, SINGLE BLIND, 2-WAY CROSSOVER S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002661-19,0,0,0 2018-002664-73,7,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Galecto Biotech AB,"GALACTIC-1- A randomized, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002664-73,0,0,0 2018-002669-20,1,2021-02-19,2021-02-19,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Celon Pharma SA,"A multicentre, double-blind, randomised, placebo - controlled phase II study to assess efficacy, safety and pharmacokinetics of inhaled Esketamine in subjects with treatment-resistant bipolar depressi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002669-20,0,0,0 2018-002673-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Rennes,EFFICACI : EFFicacy of intravenous Infliximab versus vedolizumab after failure of subCutaneous Anti-TNF in patients with UlCerative colitis : A double blinded Randomized Clinical Trial. EFFICACI : ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002673-21,0,0,0 2018-002675-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Ruprecht-Karls-University of Heidelberg Medical Faculty represented in law by Heidelberg University Hospital,Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002675-17,0,0,0 2018-002676-40,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002676-40,0,0,0 2018-002676-40,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002676-40,0,0,0 2018-002677-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,Doppler sonography of skin and nodal metastases as a predictor of clinical response to Talimogene Laherparepvec (T-VEC) in melanoma patients (T-VEC – US Doppler) Ecografía Doppler de piel y metásta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002677-22,0,0,0 2018-002678-34,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,University Hospital Ulm,Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics - AMLSG 30-18 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002678-34,0,0,0 2018-002680-26,1,,,0,0,0,1,0,1,1,0,0,1,1,1,0,1,1,"Rocket Pharmaceuticals, Inc.",Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Lentivir...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002680-26,0,0,0 2018-002686-19,1,2020-08-31,2020-08-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Department of Cardiology, Copenhagen University Hospital Rigshospitalet",Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response after Out-of-Hospital Cardiac Arrest Interleukin-6 receptorantistoffer til hæmning af det systemiske inflammatori...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002686-19,0,0,0 2018-002687-65,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,The NUVOLA TRIAL: Neoadjuvant chemoteraphy in Unresectable oVarian cancer with OLAparib and weekly carboplatin plus paclitaxel. A phase II open-label multi-centre study. Studio NUVOLA: Studio di fa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002687-65,0,0,0 2018-002688-24,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Gustave Roussy,Phase I-II study of nivolumab in combination with temozolomide and radiotherapy in children and adolescents with newly diagnosed high-grade glioma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002688-24,0,0,0 2018-002697-45,13,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,Sanofi-aventis recherche & developpement,"Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002697-45,0,1,0 2018-002697-45,13,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002697-45,0,1,0 2018-002699-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Bispebjerg Frederiksberg Hospital,Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002699-42,0,0,0 2018-002700-14,1,2020-01-27,2020-01-27,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Navad Life Sciences Pte Ltd,"Single-center, open-label, adaptive design study to evaluate the influence on hormonal and ovarian function and vaginal bleeding pattern of different dosages of levonorgestrel administered once daily ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002700-14,0,0,0 2018-002701-59,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut de Recerca Hospital de la Santa Creu i Sant Pau,"Randomized, open and multi-center clinical trial to compare the efficacy and safety of Buckberg vs Del Nido cardioplegia in isolated aortic valve replacement Ensayo clínico aleatorizado, abierto y ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002701-59,0,0,0 2018-002708-15,5,2020-08-14,2020-09-14,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,H. Lundbeck A/S,"Interventional, open-label, flexible-dose, long-term safety extension study of Lu AF11167 in patients with schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002708-15,0,0,0 2018-002715-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Elisabet Leiva Badosa. Phamacy Department. Hospital Universitari de Bellvitge,"RANDOMIZED, DOUBLE-BLIND, PILOT CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF FISH OIL-BASED INTRAVENOUS LIPID EMULSIONS IN HOSPITALIZED ADULT PATIENTS TREATED WITH TOTAL PARENTERAL NUTRITION W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002715-10,0,0,0 2018-002716-27,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Alnylam Pharmaceuticals Inc,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002716-27,0,0,0 2018-002717-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP),Non inferiority multicenter phase III randomized trial comparing preoperative chemotherapy only to chemoradiotherapy for locally advanced resectable rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002717-35,0,0,0 2018-002719-87,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Kiniksa Pharmaceuticals, Ltd","Phase 3, double-blind, placebo-controlled, randomized withdrawal study with open-label extension, to assess the efficacy and safety of Rilonacept treatment in subjects with recurrent pericarditis – ri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002719-87,0,0,0 2018-002721-29,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Newcastle upon Tyne Hospitals NHS Foundation Trust,"Randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in patients with Mitochondrial Myopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002721-29,0,0,0 2018-002722-22,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Humanitas Mirasole SpA,Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002722-22,0,0,0 2018-002722-22,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,IRCCS ISTITUTO CLINICO HUMANITAS,Safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002722-22,0,0,0 2018-002732-24,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Faron Pharmaceuticals Ltd,"A Phase I/II Open–Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002732-24,0,0,0 2018-002734-20,5,2021-06-10,2021-06-10,1,1,0,0,0,1,2,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","An Open Label, Single Arm Study to Evaluate the Efficacy and Safety of REGN3918 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Naive or Have Not Recently Recei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002734-20,1,0,0 2018-002734-20,5,2021-06-10,2021-06-10,1,1,0,0,0,1,2,0,0,2,0,0,0,0,1,"REGENERON PHARMACEUTICALS, INC.","An Open Label, Single Arm Study to Evaluate the Efficacy and Safety of REGN3918 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Naive or Have Not Recently Recei...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002734-20,1,0,0 2018-002735-26,7,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,1,Celgene Corporation,"A PHASE 4, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN SUBJECTS WITH EARLY, OLIGOARTICULAR PSORIATIC ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002735-26,0,0,0 2018-002735-26,7,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,1,CELGENE CORPORATION,"A PHASE 4, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN SUBJECTS WITH EARLY, OLIGOARTICULAR PSORIATIC ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002735-26,0,0,0 2018-002735-26,7,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,1,Amgen Inc.,"A PHASE 4, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN SUBJECTS WITH EARLY, OLIGOARTICULAR PSORIATIC ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002735-26,0,0,0 2018-002740-82,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Boehringer Ingelheim Limited,"A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 week t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002740-82,0,0,0 2018-002742-37,1,2021-06-07,2021-06-07,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,University Medical Center Utrecht,Effect of intranasal administration of palivizumab on respiratory syncytial virus-associated infection – a randomized controlled trial Effect van intranasale toediening van palivizumab op respirato...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002742-37,0,0,0 2018-002747-29,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"BIAL-Portela & Ca, S.A.",Prevention of epilepsy in stroke patients at high risk of developing unprovoked seizures: anti-epileptogenic effects of eslicarbazepine acetate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002747-29,0,0,0 2018-002747-29,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Bial - Portela & Ca, S.A.",Prevention of epilepsy in stroke patients at high risk of developing unprovoked seizures: anti-epileptogenic effects of eslicarbazepine acetate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002747-29,0,0,0 2018-002747-29,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Bial - Portela & Ca, S.A",Prevention of epilepsy in stroke patients at high risk of developing unprovoked seizures: anti-epileptogenic effects of eslicarbazepine acetate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002747-29,0,0,0 2018-002748-10,7,2022-05-11,2022-05-11,4,0,0,0,0,0,4,0,0,2,0,0,0,0,1,Amgen Inc.,"A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects with Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002748-10,1,0,0 2018-002748-10,7,2022-05-11,2022-05-11,4,0,0,0,0,0,4,0,0,2,0,0,0,0,1,CELGENE CORPORATION,"A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects with Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002748-10,1,0,0 2018-002748-10,7,2022-05-11,2022-05-11,4,0,0,0,0,0,4,0,0,2,0,0,0,0,1,Celgene Corporation,"A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects with Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002748-10,1,0,0 2018-002749-12,1,2020-07-02,2020-07-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Intra-Cellular Therapies, Inc. (ITI)","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients with Major Depr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002749-12,0,0,0 2018-002751-15,1,2020-04-15,2020-04-15,1,0,0,0,0,1,3,0,0,1,1,1,1,0,1,Hope Pharmaceuticals Ltd,"A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002751-15,0,0,0 2018-002752-33,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,VU University Medical Center,"A phase I/II trial towards the safety and efficacy of preemptive vaccination with PD-L silenced, minor histocompatibility antigen UTA2-1 peptide-loaded Dendritic Cells after Allogeneic Stem Cell Trans...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002752-33,0,0,0 2018-002757-30,7,2019-12-30,2019-12-30,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A randomized, subject and investigator blinded, placebo controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002757-30,1,0,0 2018-002757-30,7,2019-12-30,2019-12-30,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, subject and investigator blinded, placebo controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002757-30,1,0,0 2018-002761-19,7,2021-12-11,2022-01-11,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Oncopeptides AB,"An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002761-19,1,0,0 2018-002761-19,7,2021-12-11,2022-01-11,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,ONCOPEPTIDES AB,"An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002761-19,1,0,0 2018-002763-26,1,2019-11-21,2019-11-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"NeRRe Therapeutics Ltd,","A DOUBLE-BLIND, RANDOMISED, PLACEBO CONTROLLED, ADAPTIVE DESIGN STUDY OF THE EFFICACY, SAFETY AND PHARMACOKINETICS OF NT-814 IN FEMALE SUBJECTS WITH MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002763-26,0,0,0 2018-002764-94,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,"Adjuvant vaccination against HPV in surgical treatment of CIN lesions, a Randomised Controlled Trial Vaccinatie tegen HPV bij behandeling van CIN afwijkingen. Een RCT. (VACCIN studie)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002764-94,0,0,0 2018-002767-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Center,"Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX) Liposomaal iRInotecan, Carboplatin of o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002767-26,0,0,0 2018-002773-21,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,TELIX International Pty Ltd,"A confirmatory, prospective, open-label, multi-centre phase 3 study to evaluate diagnostic performance of 89Zirconium-labelled girentuximab(89Zr-TLX250) to non-invasively detect clear cell renal cell ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002773-21,0,0,0 2018-002776-40,1,2022-02-18,2022-02-18,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Octapharma AG,Phase 1/2 study to assess the safety and pharmacokinetic of subcutaneous injection of OCTA101 in previously treated adult patients with severe hemophilia A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002776-40,0,0,0 2018-002778-35,1,2019-08-28,2019-08-28,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU de Limoges,"Description of the evolution of plasma and urinary concentrations of iohexol in a cirrhotic patient population. ""Pilot study on 9 patients"" Description de l’évolution des concentrations plasmatique...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002778-35,0,0,0 2018-002782-19,4,2021-09-30,2021-09-30,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Allergan Ltd.,"A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS AN ADJUNCT TO ANTIDEPRESSANTS IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER WHO HAVE HAD AN INADEQUATE RESPONSE TO ANTIDEPRESSA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002782-19,1,0,0 2018-002783-88,4,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A 12-week, Multicenter, Active-treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer’...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002783-88,0,0,0 2018-002790-22,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO,"Tocilizumab in Graves’ Orbitopathy (TOGO). Multicenter, randomized, observer-blind, controlled study of the anti-IL-6 receptor antibody tocilizumab (TCZ) or methylprednisolone (MP) treatment in patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002790-22,0,0,0 2018-002793-47,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Nerviano Medical Sciences S.r.l.,"A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML Studio di fase I/II con NMS-03592088, un inibitore di FLT3, KIT e CSF1R, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002793-47,0,0,0 2018-002793-47,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,NERVIANO MEDICAL SCIENCES SRL,"A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML Studio di fase I/II con NMS-03592088, un inibitore di FLT3, KIT e CSF1R, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002793-47,0,0,0 2018-002794-21,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Guy's & St Thomas NHS Foundation Trust,"Investigation of the Faecal loss of Vedolizumab and its role in influencing serum drug levels, Outcomes and Response in ulcerative colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002794-21,0,0,0 2018-002796-18,5,2022-02-17,2022-02-17,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"BIAL-Portela & Ca, S.A.","An open-label, multicentre study to evaluate the safety and efficacy of zamicastat as adjunctive therapy in long-term treatment of pulmonary arterial hypertension (PAH) disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002796-18,1,0,0 2018-002796-18,5,2022-02-17,2022-02-17,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Bial - Portela & Ca, S.A","An open-label, multicentre study to evaluate the safety and efficacy of zamicastat as adjunctive therapy in long-term treatment of pulmonary arterial hypertension (PAH) disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002796-18,1,0,0 2018-002796-18,5,2022-02-17,2022-02-17,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Bial - Portela & Ca, S.A.","An open-label, multicentre study to evaluate the safety and efficacy of zamicastat as adjunctive therapy in long-term treatment of pulmonary arterial hypertension (PAH) disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002796-18,1,0,0 2018-002800-16,5,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,PFIZER INC,"A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME AND AVIBACTAM IN NEONATES AND INFANTS F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002800-16,0,0,0 2018-002800-16,5,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, New York, New York 10017","A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME AND AVIBACTAM IN NEONATES AND INFANTS F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002800-16,0,0,0 2018-002800-16,5,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,Pfizer Inc.,"A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF CEFTAZIDIME AND AVIBACTAM IN NEONATES AND INFANTS F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002800-16,0,0,0 2018-002806-30,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,"Pulmotect, Inc.","A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Study of PUL-042 Inhalation Solution in Rhinovirus-induced Symptoms in Current Smokers with Gold Stage 0 Chronic Obstructive Pulmonary Disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002806-30,0,0,0 2018-002810-11,2,2020-04-08,2020-04-08,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Regeneron Pharmaceuticals, Inc.",Long Term Safety Study of PRALUENT in Patients with Heterozygous Familial Hypercholesterolemia or with Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enroll...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002810-11,0,0,0 2018-002813-37,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Department of Clinical Pharmacology, Medical University of Vienna",Pharmacokinetics of different antibiotics in cerebrospinal fluid in children with malignant brain tumors – a pilot study Pharmakokinetik verschiedener Antibiotika im Liquor von Kindern mit malignen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002813-37,0,0,0 2018-002816-29,2,2022-07-18,2022-07-18,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"GlaxoSmithKline, S.A.",A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Multiple Myeloma (DRE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002816-29,1,0,0 2018-002816-29,2,2022-07-18,2022-07-18,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Multiple Myeloma (DRE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002816-29,1,0,0 2018-002820-18,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Ipsen Pharma,"A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002820-18,0,0,0 2018-002821-45,6,2022-01-18,2022-01-18,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Actelion Pharmaceuticals Ltd,"AC-055H302, RUBATO OL, Prospective, multi-center, single-arm, open-label long-term study assessing the safety, tolerability, and effectiveness of macitentan in Fontan-palliated adult and adolescent su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002821-45,1,0,0 2018-002822-22,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Sint Maartenskliniek,US-guided Percutaneous needle tenotomy in Patients with Lateral Elbow Tendinopathy: A multicenter Randomized Controlled Trial Echografisch-geleide percutane naald tenotomie bij patiënten met latera...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002822-22,0,0,0 2018-002823-41,11,2022-06-07,2022-06-07,7,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Actelion Pharmaceuticals Ltd,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipag a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002823-41,1,0,0 2018-002823-41,11,2022-06-07,2022-06-07,7,0,0,0,0,1,3,0,0,2,1,0,0,0,1,ACTELION PHARMACEUTICALS LTD,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipag a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002823-41,1,0,0 2018-002824-17,1,2021-04-24,2021-04-24,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,University Medical Centre Hamburg-Eppendorf,"Placebo-controlled, double-blind, randomized trial to assess the efficacy and safety of Adrecizumab in subjects with cardiogenic shock Eine placebokontrollierte, doppelblinde, randomisierte Studie ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002824-17,0,0,0 2018-002826-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Dijon Bourgogne,"MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial Méthotrexate versus tocilizumab pour le traitement de l’artérite à cellules géante...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002826-22,0,0,0 2018-002829-33,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,TNO,Memory reconsolidation: a new treatment approach towards nicotine addiction. Geheugen reconsolidatie: een nieuwe methode voor de behandeling van nicotineverslaving.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002829-33,0,0,0 2018-002830-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Toulouse University Hospital,"A randomized, double blind placebo-controlled multicenter study of the efficacy and safety of dupilumab in patients with moderate to severe hand eczema refractory to highly potent topical corticostero...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002830-19,0,0,0 2018-002831-65,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Belgian Group of Digestive Oncology (BGDO),BALLAD BELGIUM: A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002831-65,0,0,0 2018-002833-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU DE BORDEAUX,A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as pre-operative treatment for locally recurrent rectal cancer (GRECCAR – PRODIGE – FR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002833-39,0,0,0 2018-002835-76,8,2020-06-12,2020-06-12,6,1,0,0,0,1,3,0,0,2,0,0,0,0,1,VERTEX PHARMACEUTICALS INCORPORATED,"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002835-76,1,0,0 2018-002835-76,8,2020-06-12,2020-06-12,6,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002835-76,1,0,0 2018-002841-12,6,2021-05-07,2021-09-26,3,1,1,0,0,0,1,0,0,2,1,0,0,0,1,PFIZER INC,"A Phase 1, Open-Label, Single-Dose Study To Assess The Pharmacokinetics, Safety And Tolerability Of Ceftazidime-Avibactam (Caz-Avi) In Children From 3 Months To Less Than 18 Years Of Age Who Are Hospi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002841-12,1,0,0 2018-002841-12,6,2021-05-07,2021-09-26,3,1,1,0,0,0,1,0,0,2,1,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, New York, New York 10017","A Phase 1, Open-Label, Single-Dose Study To Assess The Pharmacokinetics, Safety And Tolerability Of Ceftazidime-Avibactam (Caz-Avi) In Children From 3 Months To Less Than 18 Years Of Age Who Are Hospi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002841-12,1,0,0 2018-002841-12,6,2021-05-07,2021-09-26,3,1,1,0,0,0,1,0,0,2,1,0,0,0,1,Pfizer Inc.,"A Phase 1, Open-Label, Single-Dose Study To Assess The Pharmacokinetics, Safety And Tolerability Of Ceftazidime-Avibactam (Caz-Avi) In Children From 3 Months To Less Than 18 Years Of Age Who Are Hospi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002841-12,1,0,0 2018-002842-35,1,2019-11-07,2019-11-07,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,CMC Ambroise Paré,Interest of parasternal block to prevent hypertensive and tachycardia episodes during sternotomy in patients undergoing coronary artery bypass graft Intérêt d’un bloc parasternal en injection uniqu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002842-35,0,0,0 2018-002844-10,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Scancell Ltd,"A Phase 2, Multicenter, Open-Label Study of SCIB1 in Patients with Advanced Unresectable Melanoma Receiving Pembrolizumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002844-10,0,0,0 2018-002849-11,1,2021-06-16,2021-06-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Klinikum der Universität München, Ludwig-Maximilians-Universität München, represented by the managing medical director",Optimal anti-EGFR Treatment of mCRC Patients with Low-Frequency RAS Mutation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002849-11,0,0,0 2018-002850-58,4,2021-11-04,2021-11-04,1,1,0,0,0,0,4,0,0,2,0,0,0,0,1,Celgene International II SARL,"A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT OF APREMILAST (CC-10004) ON QUALITY OF LIFE, EFFICACY, AND SAFETY IN SUBJECTS WITH MANIFESTATIONS OF PLAQUE PS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002850-58,1,0,0 2018-002850-58,4,2021-11-04,2021-11-04,1,1,0,0,0,0,4,0,0,2,0,0,0,0,1,Amgen Inc.,"A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT OF APREMILAST (CC-10004) ON QUALITY OF LIFE, EFFICACY, AND SAFETY IN SUBJECTS WITH MANIFESTATIONS OF PLAQUE PS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002850-58,1,0,0 2018-002850-58,4,2021-11-04,2021-11-04,1,1,0,0,0,0,4,0,0,2,0,0,0,0,1,CELGENE INTERNATIONAL II SàRL,"A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT OF APREMILAST (CC-10004) ON QUALITY OF LIFE, EFFICACY, AND SAFETY IN SUBJECTS WITH MANIFESTATIONS OF PLAQUE PS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002850-58,1,0,0 2018-002851-14,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACIÓN PETHEMA,A 2:1 randomized phase II trial to compare the efficacy and safety of standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in adult patients with newly diagnosed FLT3 wild-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002851-14,0,0,0 2018-002852-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZLeuven,Progression-free Survival after Minimally Invasive Surgical Microwave Ablation plus Durvalumab (MEDI4736) and Tremelimumab for Unresectable Non-metastatic Locally Advanced Pancreatic Cancer. MIMIPAC t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002852-34,0,0,0 2018-002856-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Foundation for Liver research,Modifying tacrolimus related toxicity after liver transplantation. A randomized controlled trial comparing Envarsus® and Advagraf® in de novo liver transplant recipients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002856-34,0,0,0 2018-002857-31,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Samsung Bioepis Co., Ltd.","A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB12 (proposed eculizumab biosimilar) and Soliris® in Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002857-31,0,0,0 2018-002863-24,4,,,0,0,0,0,2,1,3,0,0,3,0,0,0,0,0,Erasmus MC,Intralesional steroid injections to prevent refractory strictures in patinets with esophageal atresia - a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002863-24,0,0,0 2018-002863-24,4,,,0,0,0,0,2,1,3,0,0,3,0,0,0,0,0,Erasmus Universitu Medical Center - Sophia Children's Hospital,Intralesional steroid injections to prevent refractory strictures in patinets with esophageal atresia - a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002863-24,0,0,0 2018-002869-18,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust","A randomised, double-blind, placebo controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002869-18,0,0,0 2018-002870-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Dept. of Plastic Surgery and Burns Treatment, Copenhagen University Hospital Rigshospitalet",Adipose-derived Stem Cells in the treatment of Acute Burns (ASCAB),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002870-27,0,0,0 2018-002872-42,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002872-42,0,0,0 2018-002876-41,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,CHU Grenoble-Alpes,Assesment of Propofol sedation during intra tracheal surfactant administration by the LISA method (Less Invasive Surfactant Administration) Evaluation de la sédation au Propofol lors de l’administr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002876-41,0,0,0 2018-002877-23,1,2021-11-15,2021-11-15,1,0,0,0,0,0,2,0,1,1,1,1,0,0,0,Abteilung für Neurologie der Medizinischen Universität Innsbruck,"Oxytocin and social attention in healthy controls and patients with Parkinson's disease. A randomised, double-blind, placebo-controlled, crossover eye tracking study. Oxytocin und soziale Aufmerksa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002877-23,0,0,0 2018-002878-50,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novo Nordisk A/S,Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002878-50,0,0,0 2018-002878-50,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,NOVO NORDISK. S.P.A.,Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002878-50,0,0,0 2018-002879-17,3,2022-04-21,2022-04-21,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Amgen Inc,"A Phase 1b/2 Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002879-17,0,0,0 2018-002880-25,10,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,Genzyme Corporation,"ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002880-25,0,1,0 2018-002880-25,10,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,GENZYME CORPORATION,"ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002880-25,0,1,0 2018-002882-20,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Imperial College London,A multicentre randomised controlled trial to assess the safety and efficacy of adding rituximab to standard of care in treating acute antibody-mediated rejection in kidney transplantation (Transplant ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002882-20,0,0,0 2018-002885-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Stichting Het Nederlands Kanker Instituut-Antoni van Leuewenhoek Ziekenhuis,Trastuzumab-emtansine and osimertinib combination treatment to target HER2 bypass track resistance in EGFR mutation positive NSCLC Trastuzumab-emtasine en osimertinib combinatie behandeling bij HER...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002885-38,0,0,0 2018-002886-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNICANCER,A Phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in Metastatic Pancreatic Ductal Adenocarcinoma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002886-21,0,0,0 2018-002893-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC),Phase II Study on NIVolumab in combination with FOLFOXIRI/Bevacizumab in first line chemotherapy of Advanced COloRectal cancer RASm/BRAFm patients Studio di fase II con Nivolumab in combinazione co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002893-38,0,0,0 2018-002894-23,11,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Incyte Corporation,"A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002894-23,0,0,0 2018-002894-23,11,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,INCYTE CORPORATION,"A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002894-23,0,0,0 2018-002895-42,4,2020-05-07,2020-06-02,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,AstraZeneca AB,"A randomized, double blind, placebo-controlled, parallel group, multicentre, phase 2a study to assess target engagement, safety and tolerability of AZD4831 in patients with Heart Failure with preserve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002895-42,0,0,0 2018-002896-17,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"MEI Pharma, Inc.","A Multicenter, Open-Label, Single-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies Studio multicentrico, in aperto, a braccio ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002896-17,0,0,0 2018-002896-17,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,MEI Pharma Inc,"A Multicenter, Open-Label, Single-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies Studio multicentrico, in aperto, a braccio ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002896-17,0,0,0 2018-002897-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"IBSA, Institut Biochimique, S.A.","A proof of concept, randomized, controlled clinical trial to assess the efficacy of subcutaneous progesterone (Prolutex) versus vaginal proges-terone (Progeffik) for endometrial preparation in women u...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002897-27,0,0,0 2018-002898-21,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,NOVARTIS FARMA S.P.A.,"A phase II, single-arm, multicenter study of full treatment-free remission in patients with chronic myeloid leukemia in chronic phase treated with nilotinib in first-line therapy who have achieved a s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002898-21,0,0,0 2018-002904-14,1,2022-08-03,2022-08-03,1,0,0,0,0,0,2,0,0,1,1,1,0,0,1,Pharming Technologies B.V.,"A Phase I/II, Open Label, Proof of Concept Study to investigate Tolerability and Safety of Treatment with Recombinant Human C1 Inhibitor in Patients with Preeclampsia. Een fase 1/2 open label, be...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002904-14,0,0,0 2018-002910-11,4,2020-11-19,2020-11-19,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,ObsEva SA,"A phase 3, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of a single oral administration of nolasiban to increase ongoing pregnancy rate following fresh single b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002910-11,1,0,0 2018-002911-80,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO ""PAOLO GIACCONE"" DI PALERMO","Open-label study to evaluate the safety, tolerability, and efficacy of LOmitapide for the treatment of patients with Familial CHylomicroNEmia Syndrome Studio in aperto per valutare sicurezza, tolle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002911-80,0,0,0 2018-002913-37,1,,,0,1,0,0,0,0,4,0,1,1,0,0,0,1,1,Antibiotic-Razgrad AD,"Multicenter, prospective, randomized, double-blind, two-armed phase IV clinical study for efficacy and safety assessment of two 2% mupirocin containing nasal ointments (MupiroNasal 20mg/g, nasal ointm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002913-37,0,0,0 2018-002914-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC Cancer Institute,FUnctional selection of advanced breast cancer patients for Talazoparib treatment Using the REpair Capacity (RECAP) test: The FUTURE trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002914-10,0,0,0 2018-002915-93,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,CELGENE CORPORATION,"A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002915-93,0,0,0 2018-002915-93,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Celgene Corporation,"A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other Luspatercept (ACE-536) clinical trials.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002915-93,0,0,0 2018-002917-36,1,,,0,0,1,0,0,0,4,0,0,4,0,0,0,0,1,Jubilant DraxImage Inc.,"A phase IV, monocentric, open-label, single-arm, dosimetry study of Rubidium (82Rb) chloride injection, administered as tracer for Positron Emission Tomography (PET) in paediatric patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002917-36,0,1,1 2018-002918-12,6,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,CELGENE CORPORATION,"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Apremilast (CC-10004) in Pediatric Subjects from 6 through 17 Years of Age with Moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002918-12,0,0,0 2018-002918-12,6,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Celgene Corporation,"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Apremilast (CC-10004) in Pediatric Subjects from 6 through 17 Years of Age with Moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002918-12,0,0,0 2018-002918-12,6,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Amgen Inc.,"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Apremilast (CC-10004) in Pediatric Subjects from 6 through 17 Years of Age with Moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002918-12,0,0,0 2018-002924-18,1,,,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,"Astellas Pharma Global Development, Inc. (APGD)",A Phase 1 Crossover Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet and Pediatric Azo Dye free Mini-tablet (Solid and Suspension) Co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002924-18,0,0,0 2018-002925-47,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Fundación de Investigación Biomédica del Hospital Universitario de La Princesa,Identification of predictive biomarkers for response to biologic therapies in inflammatory bowel disease by proteomic and mass cytometry approaches IDENTIFICACIÓN DE BIOMARCADORES DE RESPUESTA AL T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002925-47,0,0,0 2018-002926-22,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Helsinn Healthcare SA,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss and Anorexia in A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002926-22,0,0,0 2018-002926-22,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,HELSINN HEALTHCARE SA,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCL for the Treatment of Malignancy Associated Weight Loss and Anorexia in A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002926-22,0,0,0 2018-002927-40,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Helsinn Healthcare SA,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002927-40,0,0,0 2018-002929-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dra. Virginia Raquel Céspedes Nava,COMPARATIVE STUDY OF THE EFFICACY OF THE TREATMENT OF PLANTAR FASCITIS WITH INFILTRATION OF CORTICOIDS VS BOTULINIC TOXIN. ECOGRAPHIC FINDINGS ESTUDIO COMPARATIVO DE LA EFICACIA DEL TRATAMIENTO DE ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002929-36,0,0,0 2018-002930-19,10,2021-11-11,2021-11-11,9,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Xbrane Biopharma,"A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002930-19,1,0,0 2018-002931-35,5,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"MEDIMMUNE, LLC","A Phase 2, Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Ce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002931-35,0,0,0 2018-002931-35,5,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"MedImmune, LLC, a wholly owned subsidiary of AstraZeneca PLC","A Phase 2, Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Ce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002931-35,0,0,0 2018-002932-26,4,2021-01-13,2021-01-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MedImmune, LLC, a wholly owned subsidiary of AstraZeneca PLC","A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable, Early-stage (I [> 2 cm] to IIIA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002932-26,0,0,0 2018-002932-26,4,2021-01-13,2021-01-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"MEDIMMUNE, LLC","A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable, Early-stage (I [> 2 cm] to IIIA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002932-26,0,0,0 2018-002935-88,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,VERTEX PHARMACEUTICALS INCORPORATED,A Long-term Follow-up Study of Subjects With ß-thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001) Studio di follow-up a lungo termine ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002935-88,0,0,0 2018-002935-88,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,A Long-term Follow-up Study of Subjects With ß-thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001) Studio di follow-up a lungo termine ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002935-88,0,0,0 2018-002936-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"RWTH Aachen University repr. by the Rector, himself repr. by the Dean of Medical faculty",Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a second line therapy in patients with Cholangiocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002936-26,0,0,0 2018-002938-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Charite - Universitätsmedizin Berlin,Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002938-20,0,0,0 2018-002939-21,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Klinikum der Universität München,An Open-Label Phase II Study of Relatlimab (BMS-986016) with Nivolumab (BMS- 936558) in Combination with 5-Azacytidine for the Treatment of Patients with Refractory/Relapsed Acute Myeloid Leukemia and...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002939-21,0,0,0 2018-002941-12,6,2022-06-28,2022-06-28,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Incyte Corporation,A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002941-12,1,0,0 2018-002941-12,6,2022-06-28,2022-06-28,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,INCYTE CORPORATION,A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002941-12,1,0,0 2018-002942-35,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University College London Comprehensive Clinical Trials Unit,A Randomised Controlled Trial of Escitalopram and Nortriptyline compared with placebo and standard psychological care for depression in Parkinson’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002942-35,0,0,0 2018-002944-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Memorial Sloan Kettering Cancer Center,Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002944-10,0,0,0 2018-002947-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Charité – Universitätsmedizin Berlin,"Simvastatin add-on to Escitalopram in patients with comorbid obesity and major depression: A multicenter, randomized, double-blind, placebo-controlled trial Simvastatin als Zusatztherapie zur anti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002947-27,0,0,0 2018-002948-88,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ALMA MATER STUDIORUM UNIVERSITà DI BOLOGNA,"Phase II study to evaluate the activity and safety of Cabozantinib in pretreated, advanced RET-reArranged non-small cell lung cancer patients: CRETA trial Studio di fase II per valutare l’attività ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002948-88,0,0,0 2018-002949-11,2,2020-07-15,2020-07-15,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Pulmatrix, Inc.","A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PUR19...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002949-11,0,0,0 2018-002952-34,6,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,Novo Nordisk A/S,Efficacy and safety of oral semaglutide versus placebo both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002952-34,0,0,0 2018-002961-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UZ Leuven,The effect of deep neuromuscular block and reversal with sugammadex on surgical conditions and perioperative morbidity in shoulder surgery using a deltopectoral approach,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002961-21,0,0,0 2018-002964-25,3,2020-09-10,2020-09-10,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F. Hoffmann-La Roche Ltd,"A PHASE IB/II STUDY, EVALUATING THE SAFETY AND EFFICACY OF IDASANUTLIN IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN PATIENTS NEWLY DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) AND THE SAFETY AND ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002964-25,0,0,0 2018-002964-25,3,2020-09-10,2020-09-10,1,1,0,0,0,0,2,0,0,1,1,0,1,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE IB/II STUDY, EVALUATING THE SAFETY AND EFFICACY OF IDASANUTLIN IN COMBINATION WITH CYTARABINE AND DAUNORUBICIN IN PATIENTS NEWLY DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) AND THE SAFETY AND ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002964-25,0,0,0 2018-002965-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"SOLEDAD CARREGUI, NATIVIDAD BANEGAS, SARA CRUZ","A randomized, open, 2 treatment arms clinical trial to evaluate the efficacy and safety of cervical ripening with Foley catheter vs cervical ripening with intravaginal synthetic analogue of prostaglan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002965-20,0,0,0 2018-002966-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Belgian Society of Medical Oncology,Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002966-37,0,0,0 2018-002969-19,1,2020-03-24,2020-03-24,1,1,0,1,0,1,1,0,0,1,1,1,0,0,1,Reneo Pharma Ltd.,"An open-label study to evaluate the safety and tolerability of 12 weeks treatment with oral REN001 in patients with primary mitochondrial myopathy (PMM), with an optional extension of treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002969-19,0,0,0 2018-002975-16,1,2021-03-19,2021-03-19,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ABX GmbH,Phase III study of F-18-PSMA-1007 vs F-18-Fluorocholine PET to compare the detection rate of prostate cancer lesions in patients with biochemical recurrence after previous definitive treatment for loc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002975-16,0,0,0 2018-002976-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,RIVM,‘Premature infants and maternal pertussis immunization. Is second trimester vaccination beneficial?’ te vroeg geboren kinderen en maternale kinkhoestvaccinatie; is vaccinatie in het tweede trimeste...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002976-41,0,0,0 2018-002977-24,4,2021-08-13,2021-08-13,3,1,0,0,0,0,2,0,1,2,0,0,0,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A Phase IIA, open-label study to evaluate the immunogenicity and safety of sequential use of GSK's investigational vaccine GSK3277511A when administered to healthy smokers and ex-smokers aged 50 to 80...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002977-24,1,0,0 2018-002977-24,4,2021-08-13,2021-08-13,3,1,0,0,0,0,2,0,1,2,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase IIA, open-label study to evaluate the immunogenicity and safety of sequential use of GSK's investigational vaccine GSK3277511A when administered to healthy smokers and ex-smokers aged 50 to 80...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002977-24,1,0,0 2018-002977-24,4,2021-08-13,2021-08-13,3,1,0,0,0,0,2,0,1,2,0,0,0,0,1,GlaxoSmithKline S.A.,"A Phase IIA, open-label study to evaluate the immunogenicity and safety of sequential use of GSK's investigational vaccine GSK3277511A when administered to healthy smokers and ex-smokers aged 50 to 80...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002977-24,1,0,0 2018-002978-52,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitair Medisch Centrum Groningen,"Guselkumab for hidradenitis suppurativa, a mode of action study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002978-52,0,0,0 2018-002979-17,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Ruprecht-Karls University Heidelberg Medical Faculty, University Hospital",Use of doxapram as a new antiarrhythmic drug for a specific therapy of atrial fibrillation Einsatz von Doxapram als neues Antiarrhythmikum für eine spezifische Vorhofflimmertherapie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002979-17,0,0,0 2018-002980-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSP.DEGLI INFERMI DI BIELLA,"Randomized, multicenter, open-label study on PREvention of respiratory SEquelae of RSV bronchiolitis in preterm babies (PRESERV) Studio randomizzato, multicentrico, in aperto, sulla prevenzione del...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002980-25,0,0,0 2018-002981-37,3,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"SK Life Science, Inc.",A Multicenter Open-label Extension Study to Evaluate the Long-term Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generalized Tonic-Clonic Seizures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002981-37,0,0,0 2018-002982-20,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Royal Liverpool University Hospital,A Pilot Study to assess the efficacy and safety of reduced dose oral iron in the treatment of iron deficiency anaemia in inflammatory bowel disease patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002982-20,0,0,0 2018-002983-26,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK- 7902) in Combination with Pembrolizumab (MK-3475) Versus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002983-26,0,0,0 2018-002983-26,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK- 7902) in Combination with Pembrolizumab (MK-3475) Versus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002983-26,0,0,0 2018-002984-24,5,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Recordati Rare Diseases,"Open-label, Single-arm, Multicenter Study to Assess the Safety of Cystadrops® in Pediatric Cystinosis Patients from 6 Months to Less Than 2 Years Old [SCOB2 Study]",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002984-24,0,0,0 2018-002984-24,5,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,RECORDATI Rare Diseases SARL,"Open-label, Single-arm, Multicenter Study to Assess the Safety of Cystadrops® in Pediatric Cystinosis Patients from 6 Months to Less Than 2 Years Old [SCOB2 Study]",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002984-24,0,0,0 2018-002987-14,6,2022-03-23,2022-03-24,4,0,0,0,0,1,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002987-14,1,0,0 2018-002987-14,6,2022-03-23,2022-03-24,4,0,0,0,0,1,3,0,0,2,0,0,0,0,1,F.Hoffmann La-Roche Ltd,"A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002987-14,1,0,0 2018-002988-25,3,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Gesellschaft für Pädiatrische Onkologie & Hämatologie (GPOH gGmbH),Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002988-25,0,0,0 2018-002990-24,11,2021-04-15,2021-04-15,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Radius Pharmaceuticals Inc.,"Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002990-24,1,0,0 2018-002990-24,11,2021-04-15,2021-04-15,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"RADIUS HEALTH, INC","Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002990-24,1,0,0 2018-002992-16,11,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,2,STICHTING EUROPEAN MYELOMA NETWORK,"A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple My...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002992-16,0,0,0 2018-002992-16,11,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,2,European Myeloma Network (EMN),"A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple My...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002992-16,0,0,0 2018-002997-29,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002997-29,0,0,0 2018-002997-29,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002997-29,0,0,0 2018-002998-21,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002998-21,0,0,0 2018-002998-21,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002998-21,0,0,0 2018-002998-21,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novartis Farmacéutica S.A.,"A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-002998-21,0,0,0 2018-003000-39,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,St George’s University of London,"A Multi-centre, Multiple-dose, Open-label Study to Investigate the Safety, Tolerability, Pharmacodynamics, and Efficacy of Erythrocyte Encapsulated Thymidine Phosphorylase (EE-TP) in Patients with Mit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003000-39,0,0,0 2018-003001-26,1,2021-10-04,2021-10-04,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Medizinische Universität Innsbruck, Universitätsklinik für Anästhesie und Allgemeine Intensivmedizin","Ropivacain 0,2% plus Dexamethason versus Ropivacain 0,2% plus Placebo in modified pectoral block - A randomized, double-blind, prospective trial Prospektiv randomisierter doppel-blind Vergleich von...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003001-26,0,0,0 2018-003002-12,1,2020-03-23,2020-03-23,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Novartis Farmacéutica, S.A.","A multi-center, randomized, subject and investigator-blinded, placebo-controlled, active comparator, parallel-group proof of concept study to evaluate the efficacy, safety, tolerability, and pharmacok...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003002-12,0,0,0 2018-003006-32,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,"""A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hematopoi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003006-32,0,0,0 2018-003007-19,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003007-19,0,0,0 2018-003007-19,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003007-19,0,0,0 2018-003008-38,12,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Biogen Idec Research Limited,"An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003008-38,0,0,0 2018-003008-38,12,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,BIOGEN IDEC RESEARCH LIMITED,"An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003008-38,0,0,0 2018-003009-24,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003009-24,0,0,0 2018-003009-24,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003009-24,0,0,0 2018-003011-22,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ETOP IBCSG Partners Foundation,"A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the primary ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003011-22,0,0,0 2018-003011-22,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,EUROPEAN THORACIC ONCOLOGY PLATFORM,"A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the primary ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003011-22,0,0,0 2018-003011-22,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ETOP (European Thoracic Oncology Platform),"A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the primary ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003011-22,0,0,0 2018-003012-51,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer who have ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003012-51,0,0,0 2018-003012-51,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase II, Single Arm Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer who have ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003012-51,0,0,0 2018-003022-89,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS,"GUT-DERIVED INCRETIN HORMONES IN THE PATHOPHYSIOLOGY OF TYPE 1 DIABETES MELLITUS; EFFECT OF METFORMIN TREATMENT (THE INCREDIBLE-ME TRIAL) Ο ΡΟΛΟΣ ΤΩΝ ΟΡΜΟΝΩΝ ΤΟΥ ΕΝΤΕΡΟΥ, ΤΩΝ ΙΝΚΡΕΤΙΝΩΝ, ΣΤΗΝ ΠΑΘΟΦ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003022-89,0,0,0 2018-003025-28,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Technische Universität Dresden,Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax Phase-I/II Studie für Patienten mit rezidivierter oder refraktärer Akuter Myeloisch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003025-28,0,0,0 2018-003027-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CONSORZIO ONCOTECH,"A prospective, multi-center, open-label, single-arm, two- step phase II study of DURvalumab (MEDI4736) in patients WIth poor performance status as first-liNe treatment for advanced urothelial cancer: ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003027-11,0,0,0 2018-003028-35,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University College London Comprehensive Clinical Trial Unit,"A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003028-35,0,0,0 2018-003041-41,1,2020-01-29,2020-01-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Queen Mary University of London,A pragmatic pilot randomised controlled trial of Prothrombin Complex Concentrate (PCC) versus Fresh Frozen Plasma (FFP) in adult patients who are undergoing Heart Surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003041-41,0,0,0 2018-003042-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut de Recerca H. de la Santa Creu i Sant Pau,Randomized clinical trial to evaluate the efficacy of fibrin membrane graft with eye drops concentrated in autologous growth factors in primary pterygium surgery comparing it with amniotic membrane gr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003042-16,0,0,0 2018-003047-32,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,CardioPulmonary resuscitation with Argon (CPAr) trial Rianimazione CardioPolmonare con Argon – Studio CPAr,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003047-32,0,0,0 2018-003048-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universität zu Köln,A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal ad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003048-22,0,0,0 2018-003050-24,6,2020-05-07,2020-05-07,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 CREAM APPLIED ONCE OR TWIC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003050-24,0,0,0 2018-003051-38,6,2020-04-20,2021-04-20,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE-CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY TO ASSESS EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 TOPICAL CREAM APPLIED ONCE OR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003051-38,0,0,0 2018-003053-21,1,2020-08-26,2020-08-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AbbVie Deutschland GmbH & Co. KG,"Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Subjects with Moderate to Severe Rheumatoid Arthrit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003053-21,0,0,0 2018-003054-24,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc.,"A Phase 3, Multicenter, Single-arm, Open-label Study To Assess The Safety, Tolerability, And Immunogenicity Of A Single Dose Of 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003054-24,0,1,1 2018-003056-21,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge,Window-of-opportunity clinical trials platform for evaluation of novel treatment strategies in renal cell cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003056-21,0,0,0 2018-003062-13,6,2020-05-25,2020-05-25,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Millendo Therapeutics SAS,"A Phase 2b/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003062-13,0,0,0 2018-003063-64,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Orion Corporation, Orion Pharma","Open clinical trial to evaluate safety, tolerability, and efficacy of Dexdor for sedation in paediatric patients in intensive care settings. Multi-centre trial in Russia for marketing registration of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003063-64,0,1,1 2018-003068-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Evaluation of immunological response following a revaccination with PPS23 boosted or not by PCV13 in splenectomised patients (SPLENEVAC-2) Évaluation de la réponse immunologique à la suite d’une ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003068-29,0,0,0 2018-003069-33,8,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Daiichi Sankyo Inc.,"A phase 3, multicenter, randomized, open-label, active-controlled trial of trastuzumab deruxtecan (DS-8201a), an anti-HER2-antibody drug conjugate (ADC), versus treatment of physician’s choice for HER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003069-33,0,0,0 2018-003072-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,rigshospitalet,Radiation Therapy Planning by Multi-parametric PET/MRI Imaging in patients with cervical cancer Anvendelse af multiparametrisk PET/MR til planlægning af strålebehandling hos patienter med livmoderh...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003072-12,0,0,0 2018-003074-27,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,WntResearch,"A Randomized, Multicentre, Open-Label Controlled Phase II Trial of Foxy-5 as Neo-Adjuvant Therapy in Subjects with Wnt-5a Low Colon Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003074-27,0,0,0 2018-003076-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Instituto Português de Oncologia de Lisboa Francisco Gentil,Effect of topical mesalazine on the formation of adenomas in rectal stumps or ileal pouches of familial adenomatous polyposis or MUTYH associated polyposis patients after colectomy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003076-13,0,0,0 2018-003078-28,6,2021-07-21,2021-07-28,5,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003078-28,1,0,0 2018-003078-28,6,2021-07-21,2021-07-28,5,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim Limited,"Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003078-28,1,0,0 2018-003078-28,6,2021-07-21,2021-07-28,5,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co. KG,"Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003078-28,1,0,0 2018-003078-28,6,2021-07-21,2021-07-28,5,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003078-28,1,0,0 2018-003078-28,6,2021-07-21,2021-07-28,5,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim France,"Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003078-28,1,0,0 2018-003078-28,6,2021-07-21,2021-07-28,5,1,0,0,0,1,2,0,0,2,0,0,0,0,1,SCS Boehringer Ingelheim Comm.V,"Multi-center, double-blind, randomised, placebo-controlled, phase IIb dose-finding study to evaluate efficacy and safety of different subcutaneous doses of BI 655130 in patients with moderate to sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003078-28,1,0,0 2018-003080-56,5,,,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,Boehringer Ingelheim España S.A.,"An open-label, long term extension study to assess the safety and efficacy of BI 655130 treatment in patients with Generalized Pustular Psoriasis (GPP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003080-56,0,0,0 2018-003080-56,5,,,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"An open-label, long term extension study to assess the safety and efficacy of BI 655130 treatment in patients with Generalized Pustular Psoriasis (GPP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003080-56,0,0,0 2018-003080-56,5,,,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,Boehringer Ingelheim France,"An open-label, long term extension study to assess the safety and efficacy of BI 655130 treatment in patients with Generalized Pustular Psoriasis (GPP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003080-56,0,0,0 2018-003080-56,5,,,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,SCS Boehringer Ingelheim Comm. V,"An open-label, long term extension study to assess the safety and efficacy of BI 655130 treatment in patients with Generalized Pustular Psoriasis (GPP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003080-56,0,0,0 2018-003080-56,5,,,0,0,0,0,0,1,0,0,0,2,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An open-label, long term extension study to assess the safety and efficacy of BI 655130 treatment in patients with Generalized Pustular Psoriasis (GPP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003080-56,0,0,0 2018-003081-14,11,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (Spesolimab) compared to placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003081-14,0,0,0 2018-003081-14,11,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (Spesolimab) compared to placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003081-14,0,0,0 2018-003081-14,11,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim France,"Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (Spesolimab) compared to placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003081-14,0,0,0 2018-003081-14,11,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim BV,"Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (Spesolimab) compared to placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003081-14,0,0,0 2018-003081-14,11,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim Netherlands BV,"Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (Spesolimab) compared to placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003081-14,0,0,0 2018-003081-14,11,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,"Boehringer Ingelheim España, S.A.","Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (Spesolimab) compared to placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003081-14,0,0,0 2018-003081-14,11,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (Spesolimab) compared to placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003081-14,0,0,0 2018-003081-14,11,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,SCS Boehringer Ingelheim Comm. V,"Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (Spesolimab) compared to placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003081-14,0,0,0 2018-003081-14,11,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Effisayil™ 2: Multi-center, randomized, parallel group, double blind, placebo controlled, Phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (Spesolimab) compared to placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003081-14,0,0,0 2018-003083-30,1,2020-10-22,2020-10-22,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,UZ Leuven,"The effect of hydroxychloroquine sulphate on hedonic food intake, appetite-related sensations and gastrointestinal hormone release in healthy female subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003083-30,0,0,0 2018-003086-33,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Pfizer Inc.,"Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003086-33,0,0,0 2018-003086-33,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003086-33,0,0,0 2018-003089-14,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust and University of Cambridge,Azathioprine Immunosuppression and Disease Modification in Parkinson’s Disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003089-14,0,0,0 2018-003090-95,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Helse Bergen HF,The Norwegian Tenecteplase Stroke Trial 2 ( NOR-TEST 2 ) Tenecteplase in Acute Stroke 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003090-95,0,0,0 2018-003093-27,1,,,0,1,0,1,0,1,1,0,0,3,0,0,0,0,1,"GB002, Inc.","A Phase 1b, Randomized, Subject- and Investigator-Blinded, Placebo-Controlled, Multi-Center Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biomarkers of Inhaled GB002 i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003093-27,0,0,0 2018-003094-10,3,2019-10-17,2019-10-17,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Centrexion Therapeutics Corp,"An Open-label, 8 Week Study to Compare the Comfort and Ease of Use of Five Different Treatment Regimens for CNTX 4975-05 Intra-articular Injection in Subjects with Chronic, Moderate-to-Severe Osteoart...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003094-10,0,0,0 2018-003095-12,1,,,0,1,0,0,1,0,2,0,0,1,0,0,0,1,1,PROGE FARM SRL,"An investigator-blinded, active controlled, randomized, two parallel group, multi-dose clinical trial to prove the non-inferior efficacy of Lactobacillus plantarum P 17630 100.000.000 CFU soft vaginal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003095-12,0,0,0 2018-003096-35,8,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Corcept Therapeutics Incorporated,"Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003096-35,0,0,0 2018-003096-35,8,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,CORCEPT THERAPEUTICS,"Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003096-35,0,0,0 2018-003098-91,8,2021-06-21,2021-06-29,5,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Dicerna Pharmaceuticals Inc,"A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003098-91,1,0,0 2018-003098-91,8,2021-06-21,2021-06-29,5,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Dicerna Pharmaceuticals Inc.,"A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003098-91,1,0,0 2018-003099-10,8,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Dicerna Pharmaceuticals Inc,An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003099-10,0,0,0 2018-003099-10,8,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Dicerna Pharmaceuticals Inc.,An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003099-10,0,0,0 2018-003106-29,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,CHI Créteil,"Feasibility and efficacy of a new ovarian stimulation regimen with RANDom start, use of corifollitropin alpha and progestin protocol for Oocyte donorS Faisabilité et efficacité d’un protocole de st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003106-29,0,0,0 2018-003107-19,3,2019-09-20,2019-09-30,3,1,0,1,0,1,1,0,0,1,1,1,0,0,1,Novartis Pharma AG,A phase I/II multi-center study of HDM201 added to chemotherapy in adult subjects with relapsed/refractory (R/R) or newly diagnosed acute myeloid leukemia (AML),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003107-19,0,0,0 2018-003107-19,3,2019-09-20,2019-09-30,3,1,0,1,0,1,1,0,0,1,1,1,0,0,1,NOVARTIS PHARMA AG,A phase I/II multi-center study of HDM201 added to chemotherapy in adult subjects with relapsed/refractory (R/R) or newly diagnosed acute myeloid leukemia (AML),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003107-19,0,0,0 2018-003110-40,1,2022-06-03,2022-06-03,1,0,0,0,0,0,2,0,0,1,1,1,0,0,0,Aarhus University,"The effect of lacosamide in peripheral neuropathic pain: a randomized, double-blind, placebo-controlled, phenotype-stratified study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003110-40,0,0,0 2018-003112-53,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Vejle Hospital,Predictive value of in-vitro testing anti-cancer therapy sensitivity on tumoroids from patients with metastatic pancreatic cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003112-53,0,0,0 2018-003113-17,1,2019-08-06,2019-08-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,The Medicines Evaluation Unit (MEU) Ltd. (Investigator led study),"A randomised, open label 2-way cross-over study to compare the effects of inhaled Beclometasone/Formoterol/Glycopyrronium (TRIMBOW) pMDI to Beclometasone/Formoterol (FOSTAIR) pMDI on hyperinflation an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003113-17,0,0,0 2018-003115-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Gustave Roussy,A phase II whole exoMe sequencing-bAsed baskeT trIal for combination therapy with durvaLumab (anti-PDL1) (MEDI4736) anD tremelimumAb (anti-CTLA4) in patients with metastatic solid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003115-21,0,0,0 2018-003117-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dr. Jordi Carratalà Fernández (Servicio de Enfermedades Infecciosas) del Hospital Universitario de Bellvitge,"A phase III randomized, controlled, open label multicenter clinical trial, with two parallel groups, to evaluate the efficacy of albumin administration in patients hospitalized with community-acquired...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003117-18,0,0,0 2018-003118-42,4,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003118-42,0,0,0 2018-003118-42,4,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,AstraZeneca AB,"Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003118-42,0,0,0 2018-003119-22,3,2021-07-06,2021-07-06,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ENYO Pharma SA,"A Phase 2a, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003119-22,1,0,0 2018-003120-36,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Immunocore Limited,A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A*0201-positive Patients with Advanced MAGE-A4-positive Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003120-36,0,0,0 2018-003122-88,4,2019-11-14,2019-11-14,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Tetherex Pharmaceuticals Corporation,"A Phase 2, Randomized, Active Comparator-Controlled, Open-Label, Adaptive Design Study to Assess the Safety and Efficacy of Intravenously-Administered SelK2 in Patients Undergoing Total Knee Arthropla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003122-88,0,0,0 2018-003135-30,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Urovant Sciences GmbH,"A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men with Overactive Bladder (OAB) Symptoms on Pharmacologica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003135-30,0,0,0 2018-003139-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU GRENOBLE ALPES,"Efficacy and safety of levocetirizine alone or in combination with tranexamic acid in the treatment of spontaneous chronic urticaria. Multicentric controlled randomized study in cross-over, double-bli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003139-31,0,0,0 2018-003141-42,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novo Nordisk A/S,Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003141-42,0,0,0 2018-003141-42,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,NOVO NORDISK. S.P.A.,Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003141-42,0,0,0 2018-003142-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University of Vienna,A prospective controlled trial to evaluate safety and efficacy of in vitro expanded recipient regulatory T cell therapy and tocilizumab together with donor bone marrow infusion in HLA-mismatched livin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003142-16,0,0,0 2018-003144-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Liège,Treating severe brain-injured patients with apomorphine : a behavioural and neuroimaging study Traitement des patients cérébro-lésés avec l'apomorphine : une étude pilote comportementale et en neur...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003144-23,0,0,0 2018-003146-17,5,2021-07-08,2021-07-08,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Quantum Genomics,"A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventric...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003146-17,1,0,0 2018-003148-21,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,NTNU- Norwegian University of Science and Technology,BASIC - Botulinum toxin type A blockade of the sphenopalatine ganglion in treatment-refractory chronic cluster headache,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003148-21,0,0,0 2018-003148-21,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Norwegian University of Science and Technology,BASIC - Botulinum toxin type A blockade of the sphenopalatine ganglion in treatment-refractory chronic cluster headache,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003148-21,0,0,0 2018-003149-41,4,2022-05-17,2022-05-17,2,0,0,0,0,1,2,0,0,2,0,0,0,0,1,CSL Behring GmbH,"A Multicenter, Randomized, Open-label, Crossover, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of IgPro20 (subcutaneous immunoglobulin, Hizentra®) and IgPro10 (intravenous immunoglobuli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003149-41,1,0,0 2018-003149-41,4,2022-05-17,2022-05-17,2,0,0,0,0,1,2,0,0,2,0,0,0,0,1,CSL BEHRING GMBH,"A Multicenter, Randomized, Open-label, Crossover, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of IgPro20 (subcutaneous immunoglobulin, Hizentra®) and IgPro10 (intravenous immunoglobuli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003149-41,1,0,0 2018-003151-38,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003151-38,0,0,0 2018-003155-38,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Janssen-Cilag International NV,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects with Active Lupus Nephritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003155-38,0,0,0 2018-003156-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CRG UZ Brussel,Natural cycle versus hormone replacement therapy cycle for a frozen-thawed embryo transfer in PGT patients: a randomised trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003156-20,0,0,0 2018-003162-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA,A Study to investigate Bone turnover Markers in patients planned to receive tofacitinib Uno studio per indagare marcatori di turnover osseo in pazienti in procinto di avviare la terapia con tofacit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003162-13,0,0,0 2018-003163-67,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Aeglea Biotherapeutics, Inc.","An Open-label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AEB1102 in Patients with Arginase I Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003163-67,0,0,0 2018-003164-31,4,2021-09-06,2021-09-06,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd.,"A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS AN ADJUNCT TO ANTIDEPRESSANTS IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER WHO HAVE HAD AN INADEQUATE RESPONSE TO ANTIDEPRESSA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003164-31,0,0,0 2018-003167-54,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"EIGER BIOPHARMACEUTICALS, INC.","A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003167-54,0,0,0 2018-003167-54,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Eiger BioPharmaceuticals, Inc.","A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003167-54,0,0,0 2018-003168-29,1,2020-09-02,2020-09-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Ghent University Hospital,[18F]PSMA-11 PET/CT for prostate cancer – phase 3 clinical trial [18F]PSMA-11 PET/CT voor prostaatkanker – fase 3 klinische studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003168-29,0,0,0 2018-003171-35,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,CSL BEHRING GMBH,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) Étude destinée à évaluer l'efficacité, la séc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003171-35,0,0,0 2018-003171-35,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,CSL Behring LLC,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) Étude destinée à évaluer l'efficacité, la séc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003171-35,0,0,0 2018-003172-12,3,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Kymab Limited,"A Phase 1/2, open-label, multi-center study of the safety and efficacy of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003172-12,0,0,0 2018-003172-12,3,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Kymab Ltd,"A Phase 1/2, open-label, multi-center study of the safety and efficacy of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003172-12,0,0,0 2018-003176-13,1,2020-03-26,2020-03-26,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Maastricht University,Lowering Branched-Chain Amino Acids as a New Strategy to Treat Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003176-13,0,0,0 2018-003180-54,18,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,Bayer AG,An extension study to evaluate the long-term outcomes of patients who received treatment for retinopathy of prematurity in study 20090 Допълнително изпитване за дългосрочна оценка на изхода от лече...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003180-54,0,0,0 2018-003182-34,1,2020-12-02,2020-12-02,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,CHR d'ORLEANS,"Randomized, double-blind, controlled clinical trial for comparison of continuous phenylephrine versus norepinephrine infusion for maintenance of hemodynamic stability during cesarean section under sp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003182-34,0,0,0 2018-003184-65,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Vifor Pharma,POREIIL - Postoperative replacement of intraoperative iron losses POREIIL - Postoperativer Ersatz von intraoperativen Eisenverlusten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003184-65,0,0,0 2018-003188-78,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.",PHASE 1/2 FIH STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA ESTUDIO DE FASE 1/2 FIH DE REGN5458 (ANTI-BCMA X ANTICUERPO BIESP...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003188-78,0,0,0 2018-003189-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospitals Leuven,STRAUSS: responSe To ustekinumab foR Anti-tnf IndUced pSoriasiform Skin lesions STRAUSS: antwoord van anti-TNF geïnduceerde psoriasiforme huidletsels aan ustekinumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003189-15,0,0,0 2018-003190-96,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Jiangsu Hengrui Medicine Co., Ltd.","One multicenter, randomized, open, phase III clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of metastatic hormone-sensitive ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003190-96,0,0,0 2018-003194-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMCG,OPen label multicenter randomized Trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003194-10,0,0,0 2018-003197-28,12,2022-02-01,2022-02-01,10,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A 24-week multi-center, double-blind, placebo controlled dose range finding study to investigate the efficacy and safety of oral QBW251 in COPD patients on triple inhaled therapy (LABA/LAMA/ICS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003197-28,1,0,0 2018-003197-28,12,2022-02-01,2022-02-01,10,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A.,"A 24-week multi-center, double-blind, placebo controlled dose range finding study to investigate the efficacy and safety of oral QBW251 in COPD patients on triple inhaled therapy (LABA/LAMA/ICS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003197-28,1,0,0 2018-003199-10,1,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,1,AB2 Bio Ltd.,Open-label extension study with Tadekinig alfa (r-hIL-18BP) to monitor safety and tolerability in patients with IL-18 driven monogenic autoinflammatory conditions: NLRC4 mutation and XIAP deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003199-10,0,0,0 2018-003200-39,2,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 1/2 Study to Compare Bempegaldesleukin Combined with Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI alone in Participants with Previously Untreated Advanced or Metastatic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003200-39,0,0,0 2018-003202-82,2,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","Multi-national Phase 3, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Pipera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003202-82,0,0,0 2018-003204-39,4,,,0,0,0,0,2,1,3,0,0,3,0,0,0,0,1,BREATH Therapeutics Inc.,"A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003204-39,0,0,0 2018-003205-25,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,BREATH Therapeutics Inc.,"A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003205-25,0,0,0 2018-003205-25,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Zambon SpA,"A Phase III, Prospective, Multicenter, Randomized, Controlled Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003205-25,0,0,0 2018-003206-58,5,2021-11-30,2021-11-30,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003206-58,1,0,0 2018-003206-58,5,2021-11-30,2021-11-30,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003206-58,1,0,0 2018-003210-40,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"IMMUNOGEN, INC.","A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients with CD123- positive Acute Myeloid Leukemia and Other CD123 positive Hematologic Malignancies ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003210-40,0,0,0 2018-003214-41,10,2020-11-11,2020-11-11,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Janssen-Cilag International N.V.,"Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthritis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003214-41,0,0,0 2018-003214-41,10,2020-11-11,2020-11-11,8,1,0,0,0,0,3,0,0,1,1,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,"Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthritis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003214-41,0,0,0 2018-003218-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Nantes,Phase 2 study evaluating MEchanisms of resistance on tumor tissue and Liquid biopsy in patients with EGFR mutated nonpretreated advanced Lung cancer Receiving OSimErtinib until and beyond radiological...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003218-42,0,0,0 2018-003219-23,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Bristol,CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson’s Disease): A phase 3 randomised double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003219-23,0,0,0 2018-003221-29,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Xenon Pharmaceuticals Inc.,"A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-label Extens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003221-29,0,0,0 2018-003221-29,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Xenon Pharmaceuticals Inc,"A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-label Extens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003221-29,0,0,0 2018-003222-92,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Erasmus MC,Dendritic cells loaded with allogeneic tumor cell lysate (PheraLys™) in surgically resected pancreatic cancer patients (REACtiVe Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003222-92,0,0,0 2018-003231-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Aránzazu Vázquez Doce,EFFECTIVENESS OF THE REPEATED INFILTRATIONS OF BOTULINUM TOXIN A IN THE GAIT AND QUALITY OF LIFE IN ADULTS WITH SPASTIC PARAPARESIA SECONDARY TO MULTIPLE SCLEROSIS EFECTIVIDAD DE LAS INFILTRACIONES...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003231-30,0,0,0 2018-003232-80,1,2021-02-04,2021-02-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE,"RENACTIF: Reduction of the Thrombotic Phenotype in Renal Insufficiency With N-AcetylCysteine : A Randomized, Double-blind, Placebo-controlled, Cross-over Trial RENACTIF : Réduction par la N-AcétylC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003232-80,0,0,0 2018-003233-14,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,CHU de Saint Etienne,Evaluation of the neonatal autonomic stress during intubations under Propofol in a population of premature infants under 33 w’GA Evaluation autonomique du stress lors de l’intubation en séquence ra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003233-14,0,0,0 2018-003242-16,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,4D pharma plc,"A first in human, double-blind, placebo-controlled, multicentre Phase I/II study to evaluate the safety, tolerability and immune modulatory effects of MRx-4DP0004, (a lyophilised formulation of Bifido...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003242-16,0,0,0 2018-003243-39,10,,,0,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Alexion Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003243-39,0,0,0 2018-003243-39,10,,,0,1,0,0,0,1,3,0,0,2,0,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003243-39,0,0,0 2018-003249-41,3,2020-11-09,2020-11-09,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Modra Pharmaceuticals B.V.,"A multicentre phase IIa study to evaluate the efficacy and tolerability of ModraDoc006/r in patients with recurrent or metastatic HER-2 negative breast cancer, suitable for treatment with a taxane",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003249-41,1,0,0 2018-003251-37,4,2020-05-29,2020-05-29,4,1,0,0,0,0,3,0,0,1,1,1,1,0,1,ACADIA Pharmaceuticals Inc,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Resp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003251-37,0,0,0 2018-003252-20,4,2021-02-22,2021-02-28,2,1,0,0,0,0,3,0,0,2,1,0,0,0,1,ACADIA Pharmaceuticals Inc,A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003252-20,1,0,0 2018-003252-20,4,2021-02-22,2021-02-28,2,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Acadia Pharmaceuticals Inc,A 52-Week Open-Label Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003252-20,1,0,0 2018-003253-24,3,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"Reata Pharmaceuticals, Inc.",An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients with Chronic Kidney Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003253-24,0,0,0 2018-003254-24,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University Hospitals Birmingham NHS Foundation Trust,AGe-adapted benefits of Envarsus versus twice-daily tacrolimus ImmunosuppressioN druGs after kidney transplantation (AGEING) – a feasibility study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003254-24,0,0,0 2018-003255-38,2,,,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF GAZYVA SHORT DURATION INFUSION (SDI) IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003255-38,0,0,0 2018-003257-16,1,2019-12-17,2019-12-17,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Goodwill Pharma Kft.,"Efficacy, Safety and Tolerability of CitraFleet, a New Bowel Cleansing Agent – a Prospective, Single-Center, Single-Group Phase IV Study Az újonnan forgalomba került CitraFleet béltisztító készítmé...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003257-16,0,0,0 2018-003258-25,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Odense University Hospital,Bone Study Bone Healing During Ninlaro Exposure. An open label phase 2 single centre clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003258-25,0,0,0 2018-003265-34,6,2021-09-15,2021-09-15,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Merck KGaA,"A Multicenter, Double Blind, Randomized, Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003265-34,1,0,0 2018-003270-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Universität zu Köln B.1.2,"A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine fol-lowed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and ve-neto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003270-27,0,0,0 2018-003271-35,1,2019-12-18,2019-12-18,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University of Copenhagen,STUDY OF ATTENTION AND IMPULSIVITY IN HEALTHY HUMAN VOLUNTEERS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003271-35,0,0,0 2018-003272-12,4,2021-07-30,2021-09-02,3,1,1,0,0,0,2,0,0,2,1,0,0,0,1,Mayne Pharma,"A Phase 2 Randomized, Multi-center, Double-blind, Vehicle-controlled, 12-Week, Safety, Efficacy, and Systemic Exposure Study followed by a 12-Week Open-label Extension of Trifarotene (CD5789) Cream HE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003272-12,1,0,0 2018-003272-12,4,2021-07-30,2021-09-02,3,1,1,0,0,0,2,0,0,2,1,0,0,0,1,Mayne Pharma LLC,"A Phase 2 Randomized, Multi-center, Double-blind, Vehicle-controlled, 12-Week, Safety, Efficacy, and Systemic Exposure Study followed by a 12-Week Open-label Extension of Trifarotene (CD5789) Cream HE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003272-12,1,0,0 2018-003273-10,8,2021-10-05,2021-10-05,6,1,0,0,0,1,3,0,0,2,1,0,0,0,1,"CORBUS PHARMACEUTICALS, INC","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003273-10,1,0,0 2018-003273-10,8,2021-10-05,2021-10-05,6,1,0,0,0,1,3,0,0,2,1,0,0,0,1,"Corbus Pharmaceuticals, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003273-10,1,0,0 2018-003278-28,8,2021-05-17,2021-05-17,6,1,0,0,0,0,2,0,0,2,1,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A multicentre randomized, double-blind (sponsor open), placebo-controlled Phase 2 study to evaluate the safety, tolerability, efficacy, dose-response, pharmacokinetics and pharmacodynamics of repeat d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003278-28,1,0,0 2018-003281-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación CRIS contra el Cáncer,"Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in Molecular Response (ResToP) Estudio fase II, exploratorio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003281-14,0,0,0 2018-003283-31,1,2021-07-07,2021-07-07,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,"School of Nutrition and Translational research in Metabolism (NUTRIM), Maastricht University","MaasFlex: A Double-Blind, Randomized, Phase IV, Mechanistic, Placebo-Controlled, Cross-Over, Single-Center Study to Evaluate the Effects of 2 Weeks Dapagliflozin Treatment on Nocturnal Substrate Oxida...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003283-31,0,0,0 2018-003284-62,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Queen Mary University London,"A randomised, blinded, placebo controlled, Phase 2a study to evaluate the safety and efficacy of administering Regadenoson to patients with critical injury and signs of haemorrhagic shock",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003284-62,0,0,0 2018-003286-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Bordeaux,In vivo involvement of the cholinergic and dopaminergic systems in the pathophysiology of apathy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003286-34,0,0,0 2018-003287-31,1,2019-08-21,2019-08-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2, Multicenter, Single Arm, Open Label Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003287-31,0,0,0 2018-003289-15,11,2021-07-21,2021-07-21,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Theravance Biopharma Ireland Limited,"A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autono...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003289-15,1,0,0 2018-003289-15,11,2021-07-21,2021-07-21,8,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"THERAVANCE BIOPHARMA ANTIBIOTICS, INC.","A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autono...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003289-15,1,0,0 2018-003291-12,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Shire Human Genetic Therapies, Inc.","A Global, Multicenter, Open-label, Matched Historical Control Study of Intrathecal SHP611 in Subjects with Late Infantile Metachromatic Leukodystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003291-12,0,0,0 2018-003291-12,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"SHIRE HUMAN GENETIC THERAPIES, INC","A Global, Multicenter, Open-label, Matched Historical Control Study of Intrathecal SHP611 in Subjects with Late Infantile Metachromatic Leukodystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003291-12,0,0,0 2018-003296-35,6,,,0,0,1,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A Phase II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003296-35,0,0,0 2018-003296-35,6,,,0,0,1,0,0,0,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase II open-label, single-arm, multi-center study of ruxolitinib added to corticosteroids in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003296-35,0,0,0 2018-003297-27,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,AB2 Bio Ltd.,"Multicenter, double-blind, placebo-controlled, randomized withdrawal trial with Tadekinig alfa (r-hIL-18BP) in patients with IL-18 driven monogenic autoinflammatory conditions: NLRC4 mutation and XIAP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003297-27,0,0,0 2018-003298-90,1,2020-06-11,2020-06-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Opthea Ltd,Phase 1b/2a study of OPT-302 in combination with aflibercept for persistent central-involved diabetic macular edema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003298-90,0,0,0 2018-003299-11,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,East and North Hertfordshire NHS Trust,Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy (DAPT) improve thrombotic status in acute coronary syndrome (ACS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003299-11,0,0,0 2018-003300-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica de Córdoba,Clinical trial of efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis in lung transplant recipients. Ensayo clínico de eficacia y seguridad ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003300-39,0,0,0 2018-003303-19,1,2021-12-09,2021-12-09,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Reistone Biopharma Company Limited,"A Phase II randomized, placebo controlled, double-blind, 4 arms dose-ranging study to evaluate the efficacy and safety of SHR0302 compared to placebo in patients with moderate to severe active Crohn’s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003303-19,0,0,0 2018-003304-39,1,2022-04-10,2022-04-10,1,0,0,0,1,0,4,0,0,1,0,0,0,0,0,Morten Rasmussen,"Efficacy of a novel 1l PEG plus ascorbate (Plenvu) bowel preparation vs. 2l PEG plus ascorbate (Moviprep), a randomized controlled multicenter trial Effektivitet af lav-volumen udtømningsmiddel sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003304-39,0,0,0 2018-003307-19,3,2020-05-13,2020-05-13,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,PPM SERVICES S.A.,"A double-blind, randomized, vehicle-controlled clinical multi-center study to evaluate the efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel, 2 and 5%, applied once daily for 12 weeks in patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003307-19,0,0,0 2018-003308-38,2,2021-03-26,2021-03-26,2,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants (PNEU - LINK)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003308-38,0,0,0 2018-003313-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA SENESE,Efficacy of vitamin D supplementation in patients with depressive disorder or bipolar disorder: randomized controlled clinical trial Efficacia della supplementazione con vitamina d in pazienti con ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003313-17,0,0,0 2018-003318-42,2,2022-06-06,2022-06-06,2,0,0,0,0,0,2,0,0,1,0,0,0,0,1,"Millennium Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003318-42,0,0,0 2018-003318-42,2,2022-06-06,2022-06-06,2,0,0,0,0,0,2,0,0,1,0,0,0,0,1,"Takeda Development Center Americas, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003318-42,0,0,0 2018-003321-29,1,2020-07-01,2020-07-01,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty",Clinical relevance of the antimicrobial resistance testing in the treatment of chronic wounds with antiseptics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003321-29,0,0,0 2018-003323-10,5,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,DBV TECHNOLOGIES S.A.,EPITOPE OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM CLINICAL BENEFIT AND SAFETY OF DBV712 IN PEANUT-ALLERGIC CHILDREN (EPOPEX),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003323-10,0,0,0 2018-003329-26,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Oscotec Inc.,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703, SYK Inhibitor, in Patients with Persistent and Chronic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003329-26,0,0,0 2018-003330-32,1,2020-10-13,2020-10-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Oscotec Inc.,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703 in Patients With Active Rheumatoid Arthritis Despite Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003330-32,0,0,0 2018-003335-29,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"German Pediatric Oncology Group, GPOH gGmbH",An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including A randomized phase III study evaluating the non-inferiority of three courses of high-d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003335-29,0,0,0 2018-003337-15,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sun Pharma Advanced Research Company (SPARC) Limited,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson’s Disease Estudio en fase II, aleatorizado, doble ciego y controlado con placebo de K0706 en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003337-15,0,0,0 2018-003340-24,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,LOXO ONCOLOGY INCORPORATED,A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003340-24,0,0,0 2018-003340-24,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Loxo Oncology, Inc.",A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003340-24,0,0,0 2018-003342-16,8,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,1,Amgen Inc,"A Phase 4, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Chronic Migraine and Medication Overuse Headache Studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003342-16,0,0,0 2018-003342-16,8,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,1,AMGEN INC.,"A Phase 4, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Chronic Migraine and Medication Overuse Headache Studi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003342-16,0,0,0 2018-003346-17,5,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,0,NKI-AVL,Phase III Randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy: OVHIPEC-2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003346-17,0,0,0 2018-003346-17,5,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,0,THE NETHERLANDS CANCER INSTITUTE,Phase III Randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy: OVHIPEC-2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003346-17,0,0,0 2018-003346-17,5,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,0,Institut du Cancer de Montpellier,Phase III Randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy: OVHIPEC-2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003346-17,0,0,0 2018-003347-28,1,,,0,1,0,0,0,0,2,0,1,3,0,0,0,0,1,Merck Sharp & Dohme Corp,"A Phase 2a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Participants Inoculated with Experimental Respiratory Syncytial Virus.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003347-28,0,0,0 2018-003349-41,8,2021-04-13,2021-04-13,6,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Sublimity Therapeutics (Hold Co) Ltd.,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects with Moderately to Severely Active Ulcerative Coli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003349-41,1,0,0 2018-003349-41,8,2021-04-13,2021-04-13,6,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Sublimity Therapeutics HoldCo Limited,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects with Moderately to Severely Active Ulcerative Coli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003349-41,1,0,0 2018-003350-25,4,,,0,0,0,0,0,2,2,0,0,3,0,0,0,0,0,Cardiff University,"An open label, 3-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib in combination with either Chemotherapy or Blinatumomab with Imatinib plus Chemotherapy as front-line th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003350-25,0,0,0 2018-003351-37,14,2020-01-18,2020-01-18,1,0,0,0,0,0,4,0,0,2,1,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Randomized, Active Controlled, Parallel Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis Μια ανοικτή, τυχαιοποιημένη, ελεγχόμενη δοκιμή με δραστικό παράγοντα σύγκριση...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003351-37,1,0,0 2018-003351-37,14,2020-01-18,2020-01-18,1,0,0,0,0,0,4,0,0,2,1,0,0,0,1,Eli Lilly and Company,"A Randomized, Active Controlled, Parallel Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis Μια ανοικτή, τυχαιοποιημένη, ελεγχόμενη δοκιμή με δραστικό παράγοντα σύγκριση...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003351-37,1,0,0 2018-003351-37,14,2020-01-18,2020-01-18,1,0,0,0,0,0,4,0,0,2,1,0,0,0,1,Lilly S.A,"A Randomized, Active Controlled, Parallel Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis Μια ανοικτή, τυχαιοποιημένη, ελεγχόμενη δοκιμή με δραστικό παράγοντα σύγκριση...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003351-37,1,0,0 2018-003352-20,15,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003352-20,0,0,0 2018-003352-20,15,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003352-20,0,0,0 2018-003354-24,11,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Exelixis, Inc.","A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Syste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003354-24,0,0,0 2018-003354-24,11,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"EXELIXIS, INC.","A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Syste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003354-24,0,0,0 2018-003355-38,5,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003355-38,0,0,0 2018-003359-40,1,2020-02-26,2020-02-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Akros Pharma Inc.,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of JTE-451 Administered for 16 Weeks in Subjects with Moderate to Severe Plaque Ps...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003359-40,0,0,0 2018-003364-31,1,2021-02-03,2021-02-03,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Reistone Biopharma Company Limited,"A Phase II randomized, placebo controlled, double-blind, 4 arms dose-ranging study to evaluate the efficacy and safety of SHR0302 compared to placebo in patients with moderate to severe active Ulcerat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003364-31,0,0,0 2018-003365-34,2,2019-09-26,2019-09-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Primary Biliary Cholangitis Who Have an Inadequat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003365-34,0,0,0 2018-003365-34,2,2019-09-26,2019-09-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Primary Biliary Cholangitis Who Have an Inadequat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003365-34,0,0,0 2018-003367-58,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,SOLTI,"Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer, who have progressed on or after CDK 4/6 inhibitor t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003367-58,0,0,0 2018-003370-27,2,,,0,1,1,0,0,1,3,0,0,2,1,0,0,0,1,GW Research Ltd,"A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-P; CBD-OS) in patients with Rett syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003370-27,0,0,0 2018-003370-27,2,,,0,1,1,0,0,1,3,0,0,2,1,0,0,0,1,GW RESEARCH LTD.,"A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-P; CBD-OS) in patients with Rett syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003370-27,0,0,0 2018-003377-97,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Swedish CLL-group,Long term effect on immune response after pneumococcal vaccination in patients with chronic lymphocytic leukemia and evaluation of the effect of revaccination.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003377-97,0,0,0 2018-003379-37,3,2020-10-02,2020-10-02,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Valneva Austria GmbH,"IMMUNOGENICITY AND SAFETY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003379-37,0,0,0 2018-003381-14,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Umeå University Hospital,"Budesonide versus Prednisolone as Primary Treatment for Autoimmune Hepatitis: An Open-label, Randomized, Prospective Multicenter 12-month Clinical Trial Evaluating Effect and Side-Effects.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003381-14,0,0,0 2018-003382-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NeuroPharm,Prophylactic effects of psilocybin on chronic cluster headache: an open-label clinical trial and neuroimaging study. Forebyggende effekter af psilocybin på Hortons hovedpine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003382-34,0,0,0 2018-003385-14,9,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,ARROWHEAD PHARMACEUTICALS,"A Placebo-Controlled, Multi-dose, Phase 2/3 Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003385-14,0,0,0 2018-003385-14,9,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"Arrowhead Pharmaceuticals, Inc.","A Placebo-Controlled, Multi-dose, Phase 2/3 Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003385-14,0,0,0 2018-003391-13,3,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003391-13,0,0,0 2018-003393-27,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Dijklander Ziekenhuis, lawfully represented by mw. Y.S. Fokma, MSc, member board of directors","ACTION-1: ACT Guided Heparinization During Open Abdominal Aortic Aneurysm Repair, a Randomised Trial. ACTION-1: ACT geleide heparinisatie bij open abdominale aneurysma aorta operaties: een gerando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003393-27,0,0,0 2018-003395-12,6,,,0,0,0,0,0,1,3,2,0,3,0,0,0,0,1,ASTEX PHARMACEUTICALS,"A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003395-12,0,0,0 2018-003395-12,6,,,0,0,0,0,0,1,3,2,0,3,0,0,0,0,1,"Astex Pharmaceuticals, Inc.","A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003395-12,0,0,0 2018-003398-87,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,1,"Roche Farma, S.A por delegación de Genentech, Inc.","A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH MODERATE ALZHEIMER’S DISEASE ESTUDIO EN FASE II, MULT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003398-87,0,0,0 2018-003402-63,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Genmab A/S,"First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors Emberen történő első alkalmazást értékelő („first-in-h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003402-63,0,0,0 2018-003402-63,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,GENMAB A/S,"First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors Emberen történő első alkalmazást értékelő („first-in-h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003402-63,0,0,0 2018-003406-11,6,2020-01-17,2020-01-17,6,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A trial comparing NNC0148-0287 C (insulin 287) versus insulin glargine U100, both in combination with metformin, with or without DPP4 inhibitors and with or without SGLT2 inhibitors, in insulin-naïve ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003406-11,0,0,0 2018-003407-18,3,2020-01-27,2020-01-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novo Nordisk A/S,"A trial comparing NNC0148-0287 C (insulin 287) versus insulin glargine U100, both in combination with metformin, with or without DPP4 inhibitors and with or without SGLT2 inhibitors, in basal insulin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003407-18,0,0,0 2018-003407-18,3,2020-01-27,2020-01-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,NOVO NORDISK. S.P.A.,"A trial comparing NNC0148-0287 C (insulin 287) versus insulin glargine U100, both in combination with metformin, with or without DPP4 inhibitors and with or without SGLT2 inhibitors, in basal insulin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003407-18,0,0,0 2018-003409-25,1,2021-06-16,2021-06-16,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,KU Leuven,Dose-dependent effects of propranolol on extinction learning and return of fear,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003409-25,0,0,0 2018-003411-21,10,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Impact Biomedicines, Inc, a wholly owned subsidiary of Celgene Corporation","A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS - intermediate or high-risk primary mye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003411-21,0,0,0 2018-003411-21,10,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Impact Biomedicines, Inc., a Wholly Owned Subsidiary of Celgene Corporation","A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS - intermediate or high-risk primary mye...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003411-21,0,0,0 2018-003414-40,2,2021-05-12,2021-05-12,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Liquidia Technologies, Inc.","A Two Part, Phase 2 Open-label, Multi-Centre, Dose Escalation Hemodynamic Study to Evaluate Dose-Response and Safety of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003414-40,0,0,0 2018-003415-22,2,2022-06-30,2022-06-30,1,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Aurealis Oy,"A Phase 1/2A clinical study to evaluate the safety, tolerability and efficacy of single and repeated doses of AUP1602-C as topical treatment of diabetic foot ulcers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003415-22,1,0,0 2018-003416-50,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Odense University Hospital,Prevention of breast cancer-related lymphedema with tacrolimus Tacrolimus til forebyggelse af lymfødem efter brystkræft,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003416-50,0,0,0 2018-003418-41,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Navidea Biopharmaceuticals Ltd,A Comparison of Tc 99m Tilmanocept Quantitative Imaging with Immunohistochemical (IHC) Analysis of CD206 Expression in Synovial Tissue from Subjects Clinically Diagnosed with Rheumatoid Arthritis (RA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003418-41,0,0,0 2018-003421-28,1,2021-07-15,2021-07-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,St Patrick's Mental Health Services,"Ketamine interleaved with electroconvulsive therapy for depression, a pragmatic randomised controlled pilot trial (KITE-Dep)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003421-28,0,0,0 2018-003422-84,7,2021-01-04,2021-04-01,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 versus Titrated Insulin Degludec on Glycemic Control in Patients with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003422-84,0,0,0 2018-003422-84,7,2021-01-04,2021-04-01,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 versus Titrated Insulin Degludec on Glycemic Control in Patients with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003422-84,0,0,0 2018-003422-84,7,2021-01-04,2021-04-01,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A,"A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 versus Titrated Insulin Degludec on Glycemic Control in Patients with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003422-84,0,0,0 2018-003426-89,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"Eisai Co., Ltd. (Japan)","A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003426-89,0,1,1 2018-003427-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Probelte Pharma S.L.U.,Efficacy and safety assessment of a subcutaneous immunotherapy (Beltavac®) with polymerized allergenic extract from house dust mites in patients with allergic rhinitis/rhinoconjuntivitis Evaluación...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003427-11,0,0,0 2018-003428-35,8,2022-02-24,2022-04-26,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Kodiak Sciences Inc.,"A Phase 2, Prospective, Randomised, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003428-35,1,0,0 2018-003429-27,1,2020-03-11,2020-03-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Genentech Inc.,"A PHASE II, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF MSTT1041A IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003429-27,0,0,0 2018-003430-33,1,,,0,0,0,0,0,1,4,0,0,4,0,0,0,0,1,CSL Behring,Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003430-33,0,1,1 2018-003431-29,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,MeiraGTx UK II Limited,"An open label, multi-centre, Phase I/II dose escalation trial of an adeno-associated virus vector (AAV2/8-hG1.7p.coCNGA3) for gene therapy of children with achromatopsia owing to defects in CNGA3",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003431-29,0,0,0 2018-003432-72,1,2021-06-17,2021-06-17,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Sint Maartenskliniek,Randomised controlled trial of dose reduction and withdrawal strategies of TNF inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis. “Dose REduction Strategy Study of TNF inhibitors in Psoria...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003432-72,0,0,0 2018-003436-74,2,2019-08-14,2019-08-14,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Intas Pharmaceuticals Ltd,"A Randomized, Double-Blind, Placebo-controlled, Three-arm, Parallel Assignment, Multi-Centre, Therapeutic Equivalence Study of Two Fluorouracil 5% Topical Cream Formulations in Adult Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003436-74,0,0,0 2018-003437-15,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS,Rituximab from the FIRst Episode of Idiopathic Nephrotic Syndrome Rituximab dès le premier épisode de Syndrome Néphrotique à Lésions Glomérulaires Minimes de l’adulte,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003437-15,0,0,0 2018-003441-42,5,2020-07-09,2020-07-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003441-42,0,0,0 2018-003441-42,5,2020-07-09,2020-07-09,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ASTRAZENECA AB,"An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003441-42,0,0,0 2018-003442-16,2,2020-03-07,2020-03-07,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003442-16,0,0,0 2018-003443-31,13,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomised, placebo-controlled, phase IIb trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003443-31,0,0,0 2018-003446-16,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Achilles Therapeutics UK Limited,"An open-label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with metastatic or recurrent melanoma. Estudio en fase I/IIa si...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003446-16,0,0,0 2018-003447-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hellenic Genitourinary Cancer Group (HGUCG),"Nivolumab plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC) not undergoing cystectomy: a phase II, randomized study Το nivolumab σε συνδυασμό με χημειοακτινοθεραπεία σε ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003447-34,0,0,0 2018-003451-38,1,,,0,1,0,0,0,0,4,0,1,3,0,0,0,0,0,Clinical Trials and Research Governance (CTRG),Immunogenicity and reactogenicity of concomitantly administered hexavalent and Group B meningococcal vaccines in infancy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003451-38,0,0,0 2018-003453-16,7,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Baxalta Innovations GmbH,"A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONGTERM SAFETY AND EFFICACY OF rVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003453-16,0,0,0 2018-003453-16,7,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,BAXALTA INNOVATIONS GMBH,"A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONGTERM SAFETY AND EFFICACY OF rVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003453-16,0,0,0 2018-003456-20,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,"Division of Allergy, Immunology, and Transplantation; National Institute of Allergy and Infectious Disease",Grass Pollen Sublingual Tablet Immunotherapy plus Dupilumab for Induction of Tolerance in Adults with Moderate to Severe Seasonal Allergic Rhinitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003456-20,0,0,0 2018-003459-39,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Agios Pharmaceuticals, Inc.","An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects with Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003459-39,0,0,0 2018-003459-39,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"AGIOS PHARMACEUTICALS, INC.","An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects with Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003459-39,0,0,0 2018-003460-30,5,2022-06-03,2022-06-03,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003460-30,1,0,0 2018-003461-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Oncology, Herlev & Gentofte Hospital","Randomised phase 2 trial of stereotactic body radiation therapy, SBRT of a soft tissue metastasis in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003461-34,0,0,0 2018-003464-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Effect of mirtazapine on seizure frequency in medically refractory epileptic patients with vagal nerve stimulation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003464-32,0,0,0 2018-003465-33,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Polish Lymphoma Research Group - PLRG,Acalabrutinib in CLL and MCL patients subjected to allogeneic hematopoietic stem cell transplantation (alloSCT). Zastosowanie akalabrutynibu u chorych z przewlekłą białaczką limfocytową lub chłonia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003465-33,0,0,0 2018-003467-64,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,Astra Zeneca AB,"A 24-week Randomised Exploratory Open-Label Study aiming to characterise changes in airway inflammation, symptoms, lung function, and reliever use in asthma patients using SABA (Salbutamol) or AntiInf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003467-64,0,0,0 2018-003471-35,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003471-35,0,0,0 2018-003474-27,1,2021-06-08,2021-06-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Hannover Medical School,Multicenter trial for the treatment of acute Hepatitis C for 8 weeks with Sofosbuvir/Velpatasvir fix dose combination - The HepNet Acute HCV-V study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003474-27,0,0,0 2018-003476-12,1,2021-10-07,2021-10-07,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,University Medical Center Utrecht,"A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the effects of evolocumab added to standard lipid-lowering therapy on fasting and post fat load lipids in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003476-12,0,0,0 2018-003481-13,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,NEAT ID Foundation,"An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease. The Late Presenter Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003481-13,0,0,0 2018-003483-32,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,FILO,BLINAtumomab after R-CHOP debulking therapy for patients with Richter Transformation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003483-32,0,0,0 2018-003484-56,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Miguel Caballero Campo,Efficacy of corifolitropin alfa in double ovarian stimulation compared with two conventional ovarian stimulation cycles for embryo accmulation in low responder patients. Multicenter randomized control...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003484-56,0,0,0 2018-003487-31,1,2021-07-27,2021-07-27,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Phase II long-term extension study to assess the safety, tolerability, and efficacy of BI 730357 in patients with moderate-to-severe plaque psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003487-31,0,0,0 2018-003490-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GETAID,An open-label randomized trial COmparing staNdard of care versus Treat to target with telemonitoRing and patient education in patients with ulcerative cOlitis initiating adalimumab : The CONTROL trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003490-10,0,0,0 2018-003496-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Dosage optimization of piperacillin/tazobactam in ICU patients based on therapeutic drug monitoring of amikacin - OPTIMA Optimisation du dosage de pipéracilline tazobactam en fonction du monitoring...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003496-36,0,0,0 2018-003498-82,7,2022-06-23,2022-06-23,4,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Acucela Inc.,"A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride with Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003498-82,1,0,0 2018-003500-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ProQR Therapeutics,"An Open-Label Extension Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to the C.2991+1655a>G Mutation (P.C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003500-40,0,0,0 2018-003501-25,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,PROQR THERAPEUTICS N.V.,"A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety, Tolerability and Systemic Exposure of QR-110 in Subjects with Leber's Congenital Amaurosis (LCA) due to c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003501-25,0,0,0 2018-003501-25,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,ProQR Therapeutics,"A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety, Tolerability and Systemic Exposure of QR-110 in Subjects with Leber's Congenital Amaurosis (LCA) due to c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003501-25,0,0,0 2018-003505-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ABIOGEN PHARMA S.P.A.,"Randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of treatment with Neridronate 100 mg (4 infusions over a period of 10 days) in patients with transi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003505-26,0,0,0 2018-003507-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA USL TOSCANA NORD OVEST,"“Phase III, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy of pre-surgical HPV 9-valent vaccination in women treated with electrosurgical excision with diather...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003507-19,0,0,0 2018-003510-41,1,2019-01-23,2019-01-23,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Centre for Human Drug Research,Investigating anti-inflammatory effects of topical antibiotics in an LPS skin challenge model,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003510-41,0,0,0 2018-003515-22,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Leiden University Medical Center,Respiratory effects of tapentadol and oxycodone assessed by pharmacokinetic-pharmacodynamic and response surface modeling in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003515-22,0,0,0 2018-003517-17,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,Asparaginase Activity Monitoring (AAM) in adult patients with Acute Lymphoblastic Leukemia (ALL). Monitoraggio dell’Attività dell’Asparaginasi (AAM) in pazienti adulti con Leucemia Linfoblastica Ac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003517-17,0,0,0 2018-003518-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboudumc,Efficacy of Diltiazem to improve coronary microvascular dysfunction: A randomized clinical trial De effectiviteit van Diltiazem om coronaire microvasculaire dysfunctie te verbeteren: een gerandomis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003518-41,0,0,0 2018-003519-24,6,2020-10-20,2020-10-20,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Alnylam Pharmaceuticals, Inc.","An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Disease Progression ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003519-24,0,0,0 2018-003519-24,6,2020-10-20,2020-10-20,5,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"ALNYLAM PHARMACEUTICALS, INC.","An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Disease Progression ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003519-24,0,0,0 2018-003520-37,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Birmingham,A multi-stage randomised trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003520-37,0,0,0 2018-003521-28,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Hôpitaux Universitaires de Strasbourg,Cryotherapy under interventional radiology combined with in situ ipilimumab and a flat dose of Nivolumab in stage IIIB/C melanoma. Prospective proof of concept study. Destruction ciblée des métasta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003521-28,0,0,0 2018-003522-86,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,Imaging tumor angiogenesis using 18F-Fluciclatide PET/CT in patients with colorectal and pancreatic cancer. Tumor angiogenese beeldvorming door middel van 18F-Fluciclatide PET/CT in patienten met c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003522-86,0,0,0 2018-003523-11,3,2022-04-22,2022-04-22,1,0,0,1,0,0,1,1,0,2,0,0,0,0,1,Hexal AG,"A randomized, double-blind, multicenter integrated phase I/III study in postmenopausal women with osteoporosis to compare the pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003523-11,1,0,0 2018-003524-36,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMC Amsterdam location AMC,"Randomized, Multicenter Study to Investigate the Efficacy of Dashboard Driven Individualized Dosing of Infliximab Compared To Standard Dosing During the Induction in Patients with Acute Severe Ulcerat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003524-36,0,0,0 2018-003526-88,4,,,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,University Hospital Ulm,Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia Efficacia e sicurezza di Carfilzomib in combinazione con Ibrutininb versus Ib...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003526-88,0,0,0 2018-003526-88,4,,,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,UNIVERSITäTSKLINIK ULM,Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia Efficacia e sicurezza di Carfilzomib in combinazione con Ibrutininb versus Ib...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003526-88,0,0,0 2018-003528-35,4,2021-07-02,2021-08-11,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Astellas Pharma Global Development, Inc.","A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women Suffering fro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003528-35,1,0,0 2018-003529-27,4,2021-04-23,2021-04-23,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Astellas Pharma Global Development, Inc.","A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, followed by a Non- Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women Suffering fr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003529-27,1,0,0 2018-003531-30,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,"Electrochemotherapy versus narrow excision margins for high-risk, primary cutaneous melanoma Elettrochemioterapia versus escissione chirurgica con margini stretti nel melanoma cutaneo primario ad a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003531-30,0,0,0 2018-003532-71,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MukoCell GmbH,Efficacy and safety of a tissue-engineered oral mucosa (MukoCell®) vs. native oral mucosa graft urethroplasty in male patients with urethral stricture,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003532-71,0,0,0 2018-003533-15,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Department of Cardiology, Aarhus University Hospital",Clinical and pathophysiological aspects of visualization of metabolic flux in the failing human heart using hyperpolarized [1-13C]-pyruvate cardiac magnetic resonance,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003533-15,0,0,0 2018-003534-32,6,2021-06-08,2021-06-08,5,1,0,1,0,1,1,0,1,1,1,0,0,0,1,"MOMENTA PHARMACEUTICALS, Inc","A 4-part Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 in healthy volunteers and in patients with immune thrombocytopenic purpura",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003534-32,0,0,0 2018-003534-32,6,2021-06-08,2021-06-08,5,1,0,1,0,1,1,0,1,1,1,0,0,0,1,"Momenta Pharmaceuticals, Inc.","A 4-part Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 in healthy volunteers and in patients with immune thrombocytopenic purpura",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003534-32,0,0,0 2018-003535-30,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,CHU de Lille,A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects with Previously Untreated Multiple Myeloma who are In...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003535-30,0,0,0 2018-003535-30,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,CHRU de Lille,A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects with Previously Untreated Multiple Myeloma who are In...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003535-30,0,0,0 2018-003537-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University Vienna,"Different dosing of Tranexamic Acid in patients undergoing elective total hip or knee arthroplasty. A randomized, controlled, double-blinded clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003537-15,0,0,0 2018-003539-31,10,2021-12-29,2021-12-29,8,1,0,0,0,1,3,0,0,2,1,0,0,0,0,European Organisation for Research and Treatment of Cancer,IDH mutated 1p/19q intact lower grade glioma following resection: Wait Or Treat? IWOT – A phase III study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003539-31,1,0,0 2018-003541-42,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Institut régional du Cancer de Montpellier,"Safety, tolerability and efficacy of regorafenib in combination with FOLFIRINOX in patients with RAS-mutated metastatic colorectal cancer: a dose-escalation, phase I/II trial - FOLFIRINOX-R",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003541-42,0,0,0 2018-003542-17,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE ETS,Early and low dose Deferasirox (3.5 mg/kg FCT) to suppress NTBI and LPI as early intervention to prevent tissue iron overload in lower risk MDS Dose bassa e precoce di Deferasirox ( 3.5 mg/kg FCT) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003542-17,0,0,0 2018-003546-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Debiopharm International SA,"SMARTPLUS-106: Debio 1143 a SMAC Mimetic In Combination With Nivolumab In Patients Failing Prior PD-1/PD-L1 Treatment: A Basket Trial A dose-optimization, exploratory phase Ib/II study to assess safe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003546-16,0,0,0 2018-003548-22,8,2021-02-01,2021-02-01,6,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Chiesi Farmaceutici S.p.A.,"A 52 week, randomised, double blind, multinational, multicentre, 4-arm parallel group trial to assess the efficacy and safety of 3 doses of CHF 6532 (10, 25 or 50 mg BID) compared to placebo on top of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003548-22,1,0,0 2018-003548-22,8,2021-02-01,2021-02-01,6,1,0,0,0,0,3,0,0,2,1,0,0,0,1,CHIESI FARMACEUTICI S.P.A.,"A 52 week, randomised, double blind, multinational, multicentre, 4-arm parallel group trial to assess the efficacy and safety of 3 doses of CHF 6532 (10, 25 or 50 mg BID) compared to placebo on top of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003548-22,1,0,0 2018-003553-19,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,International Breat Cancer Study Group (IBCSG),"A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003553-19,0,0,0 2018-003553-19,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,International Breast Cancer Study Group (IBCSG),"A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003553-19,0,0,0 2018-003553-19,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,INTERNATIONAL BREAST CANCER STUDY GROUP,"A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-ne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003553-19,0,0,0 2018-003555-38,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"MacroGenics, Inc.","A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti–B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti–PD-1 Antibody) in Patients with Advanced Solid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003555-38,0,0,0 2018-003556-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"INSTITUTO VALENCIANO DE INFERTILIDADE - CLÍNICA DE REPRODUÇÃO ASSISTIDA, LDA",How do different ovarian stimulation protocols affect endometrial receptivity during a fresh in vitro fertilization attempt? Avaliação do efeito de diferentes protocolos de estimulação ovárica na ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003556-20,0,0,0 2018-003557-21,1,2020-06-29,2020-06-29,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University Hospital Tuebingen,Effect of insulin glargine and lixisenatide versus insulin glargine on brain insulin sensitivity in patients with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003557-21,0,0,0 2018-003558-26,10,2021-04-16,2021-04-16,7,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ABIVAX,"A randomized, double blind, placebo controlled, parallel group, multiple dose, induction study to evaluate the safety, tolerability and optimal dose of ABX464 compared with placebo in patients with mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003558-26,1,0,0 2018-003558-26,10,2021-04-16,2021-04-16,7,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Abivax,"A randomized, double blind, placebo controlled, parallel group, multiple dose, induction study to evaluate the safety, tolerability and optimal dose of ABX464 compared with placebo in patients with mo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003558-26,1,0,0 2018-003560-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitätsklinikum Münster,A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003560-31,0,0,0 2018-003564-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aarhus University Hospital,Low dose catheter directed thrombolysis for acute intermediary-high risk pulmonary embolism. Lokal blodpropsopløsende medicin hos patienter med akutte blodpropper i lungerne.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003564-31,0,0,0 2018-003565-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,. Intérêt de la corticothérapie préopératoire sur la cicatrisation après ostéosynthèse des fractures du membre inférieur,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003565-33,0,0,0 2018-003566-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud university medical center,iPAVE – imaging Pituitary ActiVation by Exendin iPAVE - beeldvorming van hypofyse activatie door exendin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003566-13,0,0,0 2018-003567-66,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"FUJIFILM Toyama Chemical Co., Ltd.","A Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T 817MA in patients with mild cognitive impairment due to Alzheimer’s ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003567-66,0,0,0 2018-003570-26,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,"Humacyte, Inc.",A Phase 2 Assessment of Humacyte’s Human Acellular Vessel in Patients Needing Vascular Access for Dialysis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003570-26,0,0,0 2018-003573-97,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,King's College London,"A randomised, placebo controlled trial of psilocybin in treatment resistant depression: A feasibility study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003573-97,0,0,0 2018-003573-97,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,South London & Maudsley NHS Foundation Trust,"A randomised, placebo controlled trial of psilocybin in treatment resistant depression: A feasibility study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003573-97,0,0,0 2018-003574-28,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Rafael Correa Rocha,"Phase I / II clinical trial, randomized, exploratory and prospective to evaluate the safety and efficacy of the transfusion of autologous TREG cells obtained from thymic tissue in the prevention of re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003574-28,0,0,0 2018-003575-34,1,2021-02-01,2021-02-01,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,"Professor, Ph.d. MD. Filip Krag Knop",Treatment of bile acid malabsorption with liraglutid Behandling af galdesyremalabsorption med liraglutid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003575-34,0,0,0 2018-003576-12,4,2021-07-14,2021-07-14,3,1,1,0,0,1,3,0,0,2,1,0,0,0,1,OxThera Intellectual Property AB,An open-label single-arm treatment extension study to evaluate the long- term efficacy and safety of Oxabact® for patients with primary hyperoxaluria who completed study OC5-DB-02,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003576-12,1,0,0 2018-003584-53,13,2022-01-04,2022-01-04,7,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Debiopharm International SA,"A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003584-53,1,0,0 2018-003585-14,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Ipsen Bioscience, Inc.","An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003585-14,0,0,0 2018-003585-14,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"IPSEN BIOSCIENCE, Inc.","An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003585-14,0,0,0 2018-003588-69,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,The ENDURRANCE-1 Study. Exploring durable remission with rituximab in ANCA associated vasculitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003588-69,0,0,0 2018-003589-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx: a randomized controlled trial Elettrochemioterapia come trattamento di prima li...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003589-15,0,0,0 2018-003590-10,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Leeds,"Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003590-10,0,0,0 2018-003592-34,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Aarhus University Hospital,"Subcutaneous immunoglobulin in de-novo CIDP (Randomized, parallel study of subcutaneous versus intravenous immunoglobulin in treatment-naïve patients with chronic inflammatory demyelinating polyneurop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003592-34,0,0,0 2018-003594-95,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amsterdam UMC location AMC,Methotrexate to suppress immunogenicity to anti-tumor necrosis factor therapy in IBD patients with loss of response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003594-95,0,0,0 2018-003595-13,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,"Research and Innovation, Nottingham University Hospital","Pilot dose conversion study of extended release tacrolimus, Envarsus from standard twice daily tacrolimus in paediatric renal transplant recipients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003595-13,0,0,0 2018-003596-36,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Biotherapy Services Ltd.,"A single centre, open label Randomised Controlled Trial of the RAPID™* PRP (Platelet Rich Plasma) Haematogel Wound Care Treatment in addition to Usual and Customary Care, (UCC); compared to Usual and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003596-36,0,0,0 2018-003597-26,7,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,ALLERGAN LIMITED,An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003597-26,0,0,0 2018-003597-26,7,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Allergan Ltd.,An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003597-26,0,0,0 2018-003608-38,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients >= 16...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003608-38,0,0,0 2018-003608-38,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients >= 16...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003608-38,0,0,0 2018-003609-24,1,2020-04-27,2020-04-27,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma AG,"A randomized, subject- and investigator-blinded, placebo controlled study to assess the efficacy and safety of LOU064 in patients with inadequately controlled asthma Randomizowane, zaślepione dla p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003609-24,0,0,0 2018-003612-45,2,2020-10-16,2020-12-14,2,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Pfizer Inc.,TREATMENT RESISTANCE FOLLOWING ANTI-CANCER THERAPIES (TRANSLATE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003612-45,0,0,0 2018-003614-40,1,2020-09-13,2020-09-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bracco Imaging Spa,MOLECULAR FLUORESCENCE-GUIDED SURGERY USING BEVA800 FOR THE ASSESSMENT OF TUMOR MARGINS DURING BREAST CONSERVING SURGERY OF PATIENTS WITH PRIMARY BREAST CANCER (MARGIN-II) Molekulare fluoreszenz-g...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003614-40,0,0,0 2018-003615-22,3,2020-05-07,2020-05-07,3,1,0,0,0,1,2,0,0,1,1,1,1,0,1,LEO Pharma A/S,"Efficacy and safety of twice-daily application of delgocitinib cream 20 mg/g for 6 weeks in subjects with active discoid lupus erythematosus. A phase 2a exploratory, randomised, double-blind, vehicle-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003615-22,0,0,0 2018-003616-49,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Finnish Melanoma Group,The effect of seasonal prophylactic influenza vaccination and factors influencing the patients' immune-competence during anti-PD-1 treatment of patients with melanoma Kausittaisen influenssarokotte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003616-49,0,0,0 2018-003617-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Antwerp University Hospital (UZA),"Efficacy, patient acceptability and safety of topical treatment versus systemic treatment: a randomized, multicenter, comparative pragmatic trial in adult patients suffering from diverse localized neu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003617-17,0,0,0 2018-003618-41,6,2020-12-09,2020-12-09,4,1,0,0,0,1,2,0,0,2,1,0,0,0,1,"Momenta Pharmaceuticals, Inc.","An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients with Generalized Myasthenia Gravis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003618-41,1,0,0 2018-003618-41,6,2020-12-09,2020-12-09,4,1,0,0,0,1,2,0,0,2,1,0,0,0,1,"MOMENTA PHARMACEUTICALS, Inc","An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients with Generalized Myasthenia Gravis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003618-41,1,0,0 2018-003619-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,MEDICE Arzneimittel Pütter GmbH & Co. KG,"EFFICACY AND SAFETY OF A PARENTERALLY ADMINISTERED FIXED VITAMIN COMBINATION (VITAMIN B6, B12 AND FOLIC ACID) ON VITAMIN B12 STATUS AND METHYLATION CAPACITY IN COBALAMIN DEFICIENCY COMPARED TO ORAL VI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003619-23,0,0,0 2018-003620-37,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,"NEPTUNE: Enhancement of immuNothEraPy combining avelumab and repeaT doses of radiUm-223 in ER+ve, HER2-ve metastatic breast caNcEr.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003620-37,0,0,0 2018-003621-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IUCPQ,Short-Term Anticoagulation versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES study. Anticoagulación versus terapia antiplaquetaria a co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003621-28,0,0,0 2018-003626-91,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI,CAFFEINE TREATMENT IN DELIVERY ROOM FOR VERY PRETERM INFANTS : A FEASIBILITY STUDY TRATTAMENTO DEL NEONATO MOLTO PRETERMINE CON CAFFEINA IN SALA PARTO: STUDIO DI FATTIBILITA’,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003626-91,0,0,0 2018-003630-33,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Southampton,Spironolactone for Adult Female Acne: A pragmatic multicentre double-blind randomised superiority trial to investigate the clinical and cost-effectiveness of spironolactone for moderate or severe pers...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003630-33,0,0,0 2018-003635-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP),NA Induction des lymphocytes T régulateur par l’interleukine 2 à faible dose chez des femmes ayant des fausses couches spontanées précoces répétées inexpliquées (FCRI).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003635-30,0,0,0 2018-003636-79,13,2022-04-19,2022-06-30,9,0,0,0,0,0,2,0,0,2,1,0,0,0,1,NEKTAR THERAPEUTICS,"A Phase 2, single-arm study of bempegaldesleukin (NKTR-214) in combination with nivolumab in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003636-79,1,0,0 2018-003636-79,13,2022-04-19,2022-06-30,9,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Nektar Therapeutics,"A Phase 2, single-arm study of bempegaldesleukin (NKTR-214) in combination with nivolumab in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003636-79,1,0,0 2018-003637-14,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Ghent University Hospital,Local injection of collagenase clostridium histolyticum (XiapexR) for refractory gastrointestinal strictures: an open-label pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003637-14,0,0,0 2018-003640-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE - ISMETT,"USE OF HEPATITIS C+ DONORS FOR SOLID ORGAN TRANSPLANTATION IN A GEOGRAPHICAL AREA WITH HCV+ ENDEMIC INFECTION AND WITH A LOW-RATE CADAVERIC ORGAN DONOR AVAILABILITY. A PHASE II OPEN, MONOCENTRIC CLINI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003640-23,0,0,0 2018-003642-17,1,2021-10-28,2021-10-28,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Medical University Graz,AN EXPLORATORY STUDY TO INVESTIGATE THE BIOAVAILABILITY AND PHARMACODYNAMICS OF DUPILUMAB IN DERMAL INTERSTITIAL FLUID OF ATOPIC DER-MATITIS PATIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003642-17,0,0,0 2018-003645-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE RICERCA TRASLAZIONALE,Phase II trial evaluating the efficacy of durvalumab (MEDI4736) as second-line therapy in Non- Small-Cell Lung Cancer patients receiving concomitant steroids Studio di fase II che mira a valutare l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003645-41,0,0,0 2018-003648-22,2,2021-04-15,2021-04-15,2,1,0,0,0,0,3,0,0,1,1,0,1,0,0,SAKK,"Ribociclib-endocrine combination therapy versus chemotherapy as 1st line treatment in patients with visceral metastatic breast cancer. A multicenter, randomized phase III trial. Ribociclib-endokri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003648-22,0,0,0 2018-003650-24,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bayer AG,"A single arm, open-label, multicenter Phase 2 study of regorafenib in participants who have been treated in a previous Bayer-sponsored regorafenib study (monotherapy or combination treatment) that has...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003650-24,0,0,0 2018-003650-24,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BAYER AG,"A single arm, open-label, multicenter Phase 2 study of regorafenib in participants who have been treated in a previous Bayer-sponsored regorafenib study (monotherapy or combination treatment) that has...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003650-24,0,0,0 2018-003652-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE CLASSIFICATO EQUIPARATO SACRO CUORE DON CALABRIA - PRESIDIO OSPEDALIERO ACCREDITATO,"Interventional two arms open-label study for evaluating the diagnostic performance of PET PSMA in patients affected by biochemical recurrent prostate cancer. Studio interventistico a due braccia, i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003652-21,0,0,0 2018-003653-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,UZ Leuven,Abatacept in patients with Birdshot HLA A29 uveitis: A Phase II Prospective 0pen Label Interventional Proof-of-Concept Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003653-16,0,0,0 2018-003655-37,6,2022-08-26,2022-08-26,4,0,0,0,0,0,4,0,0,2,0,0,0,0,1,Bayer Consumer Care AG,Post-marketing investigation (PMI) to assess safety and efficacy of Jivi® (BAY 94-9027) treatment in patients with hemophilia A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003655-37,1,0,0 2018-003660-31,8,2021-09-10,2021-09-10,1,0,1,0,0,1,3,0,0,2,1,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017",An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A or B Patients With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003660-31,1,0,0 2018-003660-31,8,2021-09-10,2021-09-10,1,0,1,0,0,1,3,0,0,2,1,0,0,0,1,Pfizer Inc.,An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A or B Patients With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003660-31,1,0,0 2018-003660-31,8,2021-09-10,2021-09-10,1,0,1,0,0,1,3,0,0,2,1,0,0,0,1,PFIZER INC,An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A or B Patients With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003660-31,1,0,0 2018-003662-14,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,NHS Greater Glasgow and Clyde,"Patiromer-facilitated, dose-escalation of mineralocorticoid antagonists for the management of worsening congestion in people with heart failure and hyperkalaemia. A Phase IV, registry-based, randomi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003662-14,0,0,0 2018-003662-14,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Glasgow,"Patiromer-facilitated, dose-escalation of mineralocorticoid antagonists for the management of worsening congestion in people with heart failure and hyperkalaemia. A Phase IV, registry-based, randomi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003662-14,0,0,0 2018-003665-34,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,InnoUP Farma SL,"A multicenter double-blind, randomized, placebo-controlled phase I/II study to determine the safety, tolerability, potential efficacy and dose finding of INP20, an oral formulation for treatment of im...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003665-34,0,0,0 2018-003666-13,3,,,0,0,0,0,0,2,3,0,1,0,0,0,0,0,1,Janssen Vaccines & Prevention B.V.,"A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 In...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003666-13,0,0,0 2018-003669-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST,GRANISETRON TRANSDERMAL SYSTEM (GTDS) IN PREVENTING NAUSEA AND VOMITING INDUCED BY CISPLATIN-BASED CHEMOTHERAPY AND CONCURRENT RADIOTHERAPY FOR HEAD AND NECK CANCER GRANISTERON CEROTTO TRANSDERMICO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003669-32,0,0,0 2018-003671-35,6,2020-05-27,2020-05-27,6,1,0,0,0,0,3,0,0,1,0,0,1,0,2,"Spero Therapeutics, Inc.","A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003671-35,0,0,0 2018-003672-12,1,2020-10-16,2020-10-16,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Saniona A/S,"A 24-week phase 2, double-blind, randomized, placebo-controlled, single-centre safety and efficacy study to evaluate overall safety and tolerability of co-administration of tesofensine and metoprolol ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003672-12,0,0,0 2018-003673-10,6,2022-02-07,2022-02-07,3,1,1,0,0,0,3,0,0,2,0,0,0,0,1,Bond Avillion 2 Development LP,"A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in Symp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003673-10,1,0,0 2018-003674-27,3,2021-07-20,2021-07-20,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Bond Avillion 2 Development LP,"A 12-week, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT008 and PT007 Administered QID in Adults...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003674-27,0,0,0 2018-003675-35,4,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Institutet,Efficacy of Very Early Medical Abortion - a randomized controlled noninferiority trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003675-35,0,0,0 2018-003675-35,4,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Gynmed Clinic Vienna,Efficacy of Very Early Medical Abortion - a randomized controlled noninferiority trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003675-35,0,0,0 2018-003676-12,3,2021-03-12,2021-06-24,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Athera Biotechnologies AB,"A phase IIa, placebo-controlled, double blind, randomised multicentre pilot study to investigate the efficacy, safety and tolerability of the monoclonal antibody ATH3G10 in patients with ST-elevation ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003676-12,0,0,0 2018-003680-62,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Oscar Lambret,Phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer considering two different settings: Primary Debulking Surgery (PDS) and Interval Debu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003680-62,0,0,0 2018-003682-34,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,CSL Behring LLC,A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003682-34,0,0,0 2018-003682-34,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Vitaeris Inc.,A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003682-34,0,0,0 2018-003687-31,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Ghent University Hospital,"Influence of continuous administration of phenylephrine versus dobutamine on spinal oxygen saturation, measured with near-infrared spectroscopy (NIRS).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003687-31,0,0,0 2018-003688-73,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination with either Cytotoxic Chemothe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003688-73,0,0,0 2018-003690-10,1,2019-10-14,2019-10-14,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Idera Pharmaceuticals, Inc.",Study of Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors Estudio de Tilsotomod en combinación con Nivolumab e Ipilimumab para el tratamiento de tumores s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003690-10,0,0,0 2018-003691-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Technische Universität Dresden,Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) AIO-KRK-0217 Evaluierung der adjuvanten Therapie beim Dickdarmkrebs im Stadium II nach ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003691-12,0,0,0 2018-003692-35,1,2021-06-29,2021-06-29,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Friedrich Schiller University Jena,Effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure Auswirkungen von Empagliflozin auf Diurese und Nierenfunktion bei Patienten mit akuter dek...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003692-35,0,0,0 2018-003693-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,Intraoperative near-infrared fluorescence imaging of endometriosis with OTL38: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003693-27,0,0,0 2018-003697-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO,Effect of inhalatory sedation on cerebral perfusion in subarchnoid hemorrhage Effetto della sedazione inalatoria sulla perfusione cerebrale nella emorragia subaracnoidea,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003697-27,0,0,0 2018-003699-11,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,NHS Greater Glasgow and Clyde,Asthma Exacerbation Profile in patients on open label treatment with Benralizumab for severe eosinophilic asthma - an exploratory cohort study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003699-11,0,0,0 2018-003701-26,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,MedImmune LLC,A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003701-26,0,1,1 2018-003703-19,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,"RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty",The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Randomized Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003703-19,0,0,0 2018-003704-39,5,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Bayer Consumer Care AG,"An open-label, multicenter, Phase 1/2 study of radium-223 dichloride in combination with pembrolizumab in participants with stage IV non-small cell lung cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003704-39,0,0,0 2018-003706-88,2,2020-12-09,2020-12-09,2,1,1,0,0,0,3,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch -up Vaccination Regimens of V114 in Healthy Infant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003706-88,0,0,0 2018-003707-19,5,2022-01-02,2022-10-19,2,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Merck KGaA,"A Phase II, Multicenter, Open label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolerant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003707-19,1,0,0 2018-003707-19,5,2022-01-02,2022-10-19,2,0,0,0,0,1,2,0,0,2,0,0,0,0,1,MERCK KGAA,"A Phase II, Multicenter, Open label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolerant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003707-19,1,0,0 2018-003709-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospital Son Llatzer,Value of ultrasound-guided treatment with Platelet Rich Plasma or high volume injection in the rotator cuff tendon: Prospective randomized clinical trial. EudraCT number 2018-003709-25 Valor del tr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003709-25,0,0,0 2018-003711-21,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Merck KGaA,"An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003711-21,0,0,0 2018-003711-21,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK KGAA,"An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003711-21,0,0,0 2018-003712-45,5,2020-12-01,2020-12-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,INCYTE CORPORATION,"A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long Term Safety Extension Period in Adolescents and Adults With Atopic Der...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003712-45,0,0,0 2018-003712-45,5,2020-12-01,2020-12-01,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Incyte Corporation,"A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long Term Safety Extension Period in Adolescents and Adults With Atopic Der...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003712-45,0,0,0 2018-003713-18,5,2020-11-09,2020-11-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Incyte Corporation,"A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long Term Safety Extension Period in Adolescents and Adults With Atopic Der...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003713-18,0,0,0 2018-003714-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Servicio de Angiología y Cirugía Vascular del Hospital Universitario Cruces,IMPACT OF INTRAVENOUS IRON TREATMENT OF PREOPERATIVE ANEMIA IN PATIENTS WITH LOWER EXTREMITY PERIPHERAL ARTERY DISEASE IMPACTO DEL HIERRO INTRAVENOSO EN EL TRATAMIENTO PREOPERATORIO DE LA ANEMIA EN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003714-40,0,0,0 2018-003715-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Inmunotek, S.L.","Prospective, randomized, placebo-controlled, multi-center trial comparing the efficacy and safety of subcutaneous immunotherapy with a mixture of grasses and mites at adequate doses versus monotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003715-22,0,0,0 2018-003716-47,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Genmab A/S,"A first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1042 in subjects with malignant solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003716-47,0,0,0 2018-003719-23,2,2020-04-14,2020-04-14,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 2 Multi-Center Randomized Trial to Assess Early Intervention with Adjuvant Nivolumab in Non- Small Cell Lung Cancer Participants with ctDNA detected Minimal Residual Disease after Surgical Res...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003719-23,1,0,0 2018-003724-36,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Ole Lander Svendsen,"The DENOCHARCOT trial Efficacy of treatment with DENOsumab of an acute CHARCOT foot in patients with diabetes. A multicenter, double-blind, randomized, placebo-controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003724-36,0,0,0 2018-003726-93,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS,Heparin Anticoagulation to improve Outcomes in septic shock : The HALO International phase II RCT. ΜΙΑ ΠΡΟΟΠΤΙΚΗ ΤΥΧΑΙΟΠΟΙΗΜΕΝΗ ΚΛΙΝΙΚΗ ΜΕΛΕΤΗ ΓΙΑ ΤΗΝ ΑΝΤΙΠΗΚΤΙΚΗ ΑΓΩΓΗ ΜΕ ΗΠΑΡΙΝΗ ΣΕ ΑΣΘΕΝΕΙΣ ΜΕ ΣΗ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003726-93,0,0,0 2018-003727-10,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) VERSUS R-GEMO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003727-10,0,0,0 2018-003727-10,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F.Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) VERSUS R-GEMO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003727-10,0,0,0 2018-003727-10,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE SAFETY AND EFFICACY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB PLUS GEMCITABINE PLUS OXALIPLATIN (R-GEMOX) VERSUS R-GEMO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003727-10,0,0,0 2018-003734-32,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,"BioXcel Therapeutics, Inc","A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1 (PD-1) Monoclonal Antibody Pembrolizumab (PE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003734-32,0,0,0 2018-003736-77,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,"A MULTICENTER, OPEN-LABEL PHASE II TRIAL OF A NEW CUSTOMIZED DOSING (RATIONAL ADJUSTMENT OF DOSE TO REDUCE ADVERSE REACTIONS “RADAR” DOSING) OF NIRAPARIB AS MAINTENANCE THERAPY IN PLATINUM SENSITIVE O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003736-77,0,0,0 2018-003736-77,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Istituto di Ricerche Farmacologiche Mario Negri IRCCS,"A MULTICENTER, OPEN-LABEL PHASE II TRIAL OF A NEW CUSTOMIZED DOSING (RATIONAL ADJUSTMENT OF DOSE TO REDUCE ADVERSE REACTIONS “RADAR” DOSING) OF NIRAPARIB AS MAINTENANCE THERAPY IN PLATINUM SENSITIVE O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003736-77,0,0,0 2018-003739-32,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Actuate Therapeutics Inc,"Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignancie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003739-32,0,0,0 2018-003741-42,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 2, Open-label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Subjects Undergoin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003741-42,0,1,1 2018-003742-17,5,2022-07-21,2022-07-21,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003742-17,1,0,0 2018-003742-17,5,2022-07-21,2022-07-21,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC","A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003742-17,1,0,0 2018-003747-37,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003747-37,0,0,0 2018-003747-37,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003747-37,0,0,0 2018-003748-22,6,2020-07-27,2020-07-27,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"miRagen Therapeutics, Inc.","PRISM: An Open-label, Multi-Center Extension Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) Following Systemic Treatment in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003748-22,0,0,0 2018-003752-21,7,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003752-21,0,0,0 2018-003752-21,7,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003752-21,0,0,0 2018-003753-13,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS,"Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis Essai prospectif, multicentrique, randomisé c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003753-13,0,0,0 2018-003756-20,1,2019-10-10,2019-10-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Nordic Society of Gynaecological Oncology-Clinical Trial Unit,A randomized double-blind placebo-controlled phase II trial of Rucaparib maintenance therapy for patients with locally advanced cervical cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003756-20,0,0,0 2018-003768-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,"Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC in pancreatic neuroendocrine tumors Terapia radiorecettoriale (PRRT) con Y-90-DOTATOC a scopo neoadiuvante, nei tumori neur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003768-30,0,0,0 2018-003775-35,4,2021-08-05,2021-08-05,1,1,0,0,0,1,2,0,0,2,0,0,0,0,1,BAXALTA INNOVATIONS GMBH,"A Phase 2, multicenter, randomized, placebo-controlled, double-blind study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) to evaluate the pharmacokinetics, safety, and efficacy o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003775-35,1,0,0 2018-003775-35,4,2021-08-05,2021-08-05,1,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Baxalta Innovations GmbH,"A Phase 2, multicenter, randomized, placebo-controlled, double-blind study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) to evaluate the pharmacokinetics, safety, and efficacy o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003775-35,1,0,0 2018-003775-35,4,2021-08-05,2021-08-05,1,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Baxalta Innovation GmbH,"A Phase 2, multicenter, randomized, placebo-controlled, double-blind study in patients with acquired thrombotic thrombocytopenic purpura (aTTP) to evaluate the pharmacokinetics, safety, and efficacy o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003775-35,1,0,0 2018-003778-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Istituto Nazionale Tumori G. Pascale,Phase II study on the use of the FOLFIRI + Cetuximab association in the first-line treatment of patients with advanced colorectal carcinoma with wild type RAS and FcYRIIIA-V / V Studio di fase II s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003778-29,0,0,0 2018-003779-36,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Institute of Cancer Research,ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003779-36,0,0,0 2018-003787-31,7,2021-08-05,2021-08-05,7,1,1,0,0,0,3,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Active -comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (PNEU-PED-EU-1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003787-31,0,0,0 2018-003787-31,7,2021-08-05,2021-08-05,7,1,1,0,0,0,3,0,1,1,0,0,1,0,1,Merck Sharp & Dohme Corp.,"A Phase 3, Multicenter, Randomized, Double-blind, Active -comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (PNEU-PED-EU-1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003787-31,0,0,0 2018-003788-70,5,2021-10-29,2021-11-02,5,1,0,0,0,0,3,0,1,1,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Active-comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003788-70,0,0,0 2018-003788-70,5,2021-10-29,2021-11-02,5,1,0,0,0,0,3,0,1,1,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Multicenter, Randomized, Double-blind, Active-comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003788-70,0,0,0 2018-003789-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Cardiology, Hartcentrum, University Medical Center Groningen",Digoxin Evaluation in Chronic heart failure: Investigational Study In Outpatients in the Netherlands Digoxine behandeling voor patiënten met chronisch hartfalen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003789-15,0,0,0 2018-003790-10,3,2020-10-14,2020-10-14,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix® or NeisVac-C® in Healthy Toddlers 12 to 23 Months of Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003790-10,0,0,0 2018-003791-12,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003791-12,0,0,0 2018-003791-12,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab (MK-3475) in combination with lenvatinib (E7080/MK-7902) versus docetaxel in previously treated...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003791-12,0,0,0 2018-003794-98,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003794-98,0,0,0 2018-003794-98,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003794-98,0,0,0 2018-003804-37,7,2020-04-08,2020-04-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTI CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF 04965842 CO ADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003804-37,0,0,0 2018-003804-37,7,2020-04-08,2020-04-08,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PFIZER INC,"A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTI CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF 04965842 CO ADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003804-37,0,0,0 2018-003806-23,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Karolinska University Hospital,Postoperative pain and recovery after robot assisted laparoscopic prostatectomy - a single-blinded randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003806-23,0,0,0 2018-003808-39,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-Eligible Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003808-39,0,0,0 2018-003808-39,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized Double Blind Study to Evaluate Peri-operative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-Eligible Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003808-39,0,0,0 2018-003809-26,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscleinvasive Bladder Cancer (KEYNOTE-905),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003809-26,0,0,0 2018-003809-26,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscleinvasive Bladder Cancer (KEYNOTE-905),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003809-26,0,0,0 2018-003811-23,3,2022-07-05,2022-07-05,1,0,0,0,0,2,2,0,0,2,0,0,0,0,1,Imago BioSciences Inc.,"A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients with Myelofibrosis Studio multicentrico in aperto per valutare la s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003811-23,1,0,0 2018-003811-23,3,2022-07-05,2022-07-05,1,0,0,0,0,2,2,0,0,2,0,0,0,0,1,"Imago BioSciences, Inc.","A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients with Myelofibrosis Studio multicentrico in aperto per valutare la s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003811-23,1,0,0 2018-003816-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU DE NIMES,Add-on buprenorphine at analgesic doses for the treatment of severe suicidal ideas during a major depressive episode Traitement des idées suicidaires sévères durant un épisode dépressif caractérisé...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003816-38,0,0,0 2018-003817-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Kinarus AG,"A 52 weeks double blind, randomized and placebo controlled trial evaluating the effect of oral KIN001 150 mg plus pioglitazone 10 mg daily on injection frequency of Standard of Care in patients with d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003817-16,0,0,0 2018-003819-22,4,2019-12-18,2019-12-18,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Idorsia Pharmaceuticals Ltd,"Multi-center, blinded, randomized study with aprocitentan in subjects with uncontrolled blood pressure and chronic kidney disease stage 3 or 4.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003819-22,0,0,0 2018-003824-35,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003824-35,0,0,0 2018-003825-27,2,2022-04-07,2022-04-07,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Biogen Idec Research Limited,"A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003825-27,1,0,0 2018-003831-31,3,2021-06-03,2021-06-03,1,0,0,0,0,2,2,0,0,1,1,0,1,0,1,AzurRx SAS,"A multicenter, open-label Phase 2 study with escalating doses of MS1819-SD on top of a stable dose of PPEs, to investigate the efficacy and safety of this combination for the compensation of severe ex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003831-31,0,0,0 2018-003831-31,3,2021-06-03,2021-06-03,1,0,0,0,0,2,2,0,0,1,1,0,1,0,1,AzurRx,"A multicenter, open-label Phase 2 study with escalating doses of MS1819-SD on top of a stable dose of PPEs, to investigate the efficacy and safety of this combination for the compensation of severe ex...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003831-31,0,0,0 2018-003832-57,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,"DOLAF- An international multicenter phase II trial of Durvalumab (MEDI4736) plus OLAparib plus Fulvestrant in metastatic or locally advanced ER-positive, HER2-negative breast cancer patients selected ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003832-57,0,0,0 2018-003833-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC),A Phase IV study on impact of Edoxaban treatment in Italian cancer patients with venous thromboembolism (EDOI Cancer Study) during antineoplastic therapy Studio di fase IV sull’impatto del trattame...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003833-14,0,0,0 2018-003834-34,1,2019-07-29,2019-07-29,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Zealand Pharma A/S,"A phase 3b, randomized, double-blind, crossover trial to compare the efficacy and safety of 2 different batches of subcutaneous dasiglucagon in patients with type 1 diabetes mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003834-34,0,0,0 2018-003837-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Centro Hospitalar e Universitário de Coimbra, E.P.E.",Rosuvastatin effect on atherosclerotic plaque metabolism ¿ a subclinical atherosclerosis imaging study with 18F-NaF PET-CT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003837-13,0,0,0 2018-003838-32,1,,,0,1,0,1,0,0,1,0,1,4,0,0,0,0,1,Sanofi Pasteur,"Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (SP0173) in Healthy Adolescents, Adults, and Older Adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003838-32,0,1,1 2018-003842-18,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Orchard Therapeutics Ltd.,"A Single Arm, Open Label Clinical Study of Haematopoietic Stem Cell Gene Therapy with Cryopreserved Autologous CD34+ Cells Transduced with Lentiviral Vector encoding WAS cDNA in Subjects with Wiskott-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003842-18,0,0,0 2018-003845-40,1,2019-12-30,2019-12-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Mayne Pharma LLC,"An open label evaluation of the adrenal suppression potential and pharmacokinetic properties of twice daily halobetasol propionate foam, 0.05% in subjects 12 to less than 18 years of age with plaque p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003845-40,0,0,0 2018-003850-25,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,PaxVax Inc,"A Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (Cholera Vaccine, Live, Oral) in Children 2 to <18 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003850-25,0,1,1 2018-003852-19,1,2020-07-15,2020-07-15,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,King's College London,"An Open Label, Non-Randomised, Phase IV Clinical Trial to Determine the Transfer of Apixaban and Rivaroxaban in Breast Milk Following Oral Administration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003852-19,0,0,0 2018-003852-19,1,2020-07-15,2020-07-15,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,King's College Hospital NHS Foundation Trust,"An Open Label, Non-Randomised, Phase IV Clinical Trial to Determine the Transfer of Apixaban and Rivaroxaban in Breast Milk Following Oral Administration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003852-19,0,0,0 2018-003856-19,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Department of Otorhinolaryngology, Head and Neck Surgery and Audiology. Rigshospitalet, University Hospital of Cph, DK",A Phase I Open Label Study Evaluating the Safety and Feasibility of Allogeneic Mesenchymal stem cells for radiation-induced hyposalivation and xerostomia in previous oropharyngeal patients Et open...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003856-19,0,0,0 2018-003857-73,1,,,0,1,0,1,0,0,1,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refract...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003857-73,0,0,0 2018-003858-24,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BIOGEN IDEC RESEARCH LIMITED,"A Multicenter, Double-Blind, Multidose, Placebo-Controlled, Randomized, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 for Patients with Brain Contusion Es...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003858-24,0,0,0 2018-003858-24,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Biogen Idec Research Limited,"A Multicenter, Double-Blind, Multidose, Placebo-Controlled, Randomized, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 for Patients with Brain Contusion Es...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003858-24,0,0,0 2018-003863-67,1,,,0,0,0,0,1,1,3,0,0,4,0,0,0,0,0,Fondation Ophtalmologique Adolphe de Rothschild,Multicenter randomized controlled trial on the interest of intravitreal injections of anti-VEGF as initial and adjuvant treatment in Coats disease Étude contrôlée randomisée multicentrique sur l’in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003863-67,0,0,0 2018-003864-30,2,2022-08-02,2022-08-02,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Apexigen, Inc.","A Phase II Multicenter, Open label Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M With or Without Stereotactic Body Radiation Therapy in Adults with Unresectable or M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003864-30,1,0,0 2018-003865-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Alejandro Rodriguez Oviedo ‐ Critical Care Department – Hospital Universitario de Tarragona Joan XXIII,"Efficacy, safety and pharmacokinetics profile of nebulized Aztreonam Lysine (AZLI) for prevention of Gram negative pneumonia in heavily colonized mechanically ventilated patients: AZLIS Perfil de e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003865-32,0,0,0 2018-003866-14,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Apexigen, Inc.",A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic M...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003866-14,0,0,0 2018-003867-79,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,"Astellas Pharma Global Development, Inc.",Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003867-79,0,1,1 2018-003868-32,1,2021-05-17,2021-05-17,1,1,0,0,1,0,4,0,0,1,1,1,1,0,0,Göteborgs universitet,See below Natriumkloridinjektioner som profylaktisk behandling av kronisk migrän - en randomiserad kontrollerad studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003868-32,0,0,0 2018-003869-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus University Medical Center,Implementation of pharmacokinetic-guided dosing of prophylaxis in hemophilia patients. Implementatie van farmacokinetisch gestuurd doseren van profylaxe bij hemofilie patienten.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003869-33,0,0,0 2018-003877-91,1,2022-06-28,2022-06-28,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Universitätsklinikum Erlangen,Sequential B cell/T cell therapy to re-induce humoral immune tolerance in ACPA-positive Rheumatoid Arthritis (TOLERA): a prospective randomized controlled open-label single-centre clinical trial in ad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003877-91,0,0,0 2018-003880-79,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI""",Efficacy and safety of the switch from Efavirenz / emtricitabine / tenofovir difumarate taken once daily or alternate days to Bictegravir / emtricitabine / tenofovir alafenamide in HIV + virologically...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003880-79,0,0,0 2018-003882-32,2,2022-09-22,2022-09-22,2,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Novartis Pharma GmbH,"A randomized, open label multicenter trial to investigate the efficacy of a treat-to-target treatment strategy with secukinumab (AIN457) as a first-line biologic compared to a standard-of-care treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003882-32,0,0,0 2018-003888-56,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Nephrology, Herlev & Gentofte Hospital, Herlev Hospital",Treatment of adynamic bone disorder with parathyroid hormone in patients with chronic kidney disease Diagnostik og behandling af knoglesygdom hos patienter med nedsat nyrefunktion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003888-56,0,0,0 2018-003889-14,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Skåne University Hospital, Department of Oncology","R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, >= 80 years, or frail >= 75 years – an open label randomize...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003889-14,0,0,0 2018-003889-14,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Skane University Hospital, Department of Oncology","R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, >= 80 years, or frail >= 75 years – an open label randomize...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003889-14,0,0,0 2018-003890-91,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Medical University of Warsaw,The development of innovative advanced therapy medicinal product (biological dressing of the human race) in the treatment of Epidermolysis Bullosa (EB) and other chronic wounds. Opracowanie innowa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003890-91,0,0,0 2018-003891-11,1,,,0,1,0,0,0,0,2,0,1,3,0,0,0,0,1,Life Molecular Imaging SA,"An Open Label, Single Center Study, to evaluate the Safety and Imaging Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau deposition in the brains of subjects with amnestic mild cognit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003891-11,0,0,0 2018-003893-29,1,2020-09-23,2020-09-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,King's College London,"Randomised factorial design controlled trial comparing carbamazepine, levetiracetam or active monitoring combined with or without sleep behaviour intervention in treatment naive children with rolandic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003893-29,0,0,0 2018-003893-29,1,2020-09-23,2020-09-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,King's College Hospital NHS Foundation Trust,"Randomised factorial design controlled trial comparing carbamazepine, levetiracetam or active monitoring combined with or without sleep behaviour intervention in treatment naive children with rolandic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003893-29,0,0,0 2018-003896-37,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,"Odonate Therapeutics, Inc.","A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003896-37,0,0,0 2018-003898-94,5,2022-03-30,2022-03-30,2,0,0,0,0,1,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON’S DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003898-94,1,0,0 2018-003898-94,5,2022-03-30,2022-03-30,2,0,0,0,0,1,3,0,0,2,0,0,0,0,1,F.Hoffmann La-Roche Ltd,AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON’S DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003898-94,1,0,0 2018-003898-94,5,2022-03-30,2022-03-30,2,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD,AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON’S DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003898-94,1,0,0 2018-003899-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,The effect of IntraDialytic Parenteral Nutrition on nutritional status and quality of life in hemodialysis patients Het effect van intradialytische parenterale voeding op de voedingstoestand en kwa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003899-13,0,0,0 2018-003902-14,1,2020-01-27,2020-01-27,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,European Organisation for Research and Treatment of Cancer,DKN-01/atezolizumab as second line treatment of biliarY tract cancer and in combiNAtion or not with paclitaxel as second line treatMent of esophagogastrIC cancer: a multi-center Phase II Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003902-14,0,0,0 2018-003903-21,1,2019-07-29,2019-07-29,1,1,0,0,1,1,2,0,0,1,1,1,1,0,1,Insmed Incorporated,"A Randomized, Single-Blind Study to Evaluate the Pharmacokinetics (PK), and Pharmacodynamics (PD) of INS1007 Administered for 12 Weeks in Subjects with Granulomatosis with Polyangiitis (GPA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003903-21,0,0,0 2018-003905-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,H.A.C. Pharma,Evaluation of efficacy and tolerance of fludrocortisone (Flucortac) in the treatment of neurogenic orthostatic hypotension Evaluation de l'efficacité et de la tolérance de la fludrocortisone (Fluco...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003905-25,0,0,0 2018-003906-26,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Zenith Epigenetics Ltd.,A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003906-26,0,0,0 2018-003907-20,1,2020-09-18,2020-09-18,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1,"Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limit","Open-Label Phase 1 Study to Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously to Pediatric Patients Aged 0 to <18 Years With Relapsed or Refractory...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003907-20,0,0,0 2018-003915-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundacio Lluita contra la SIDA,Doravirine concentrations and antiviral activity in Cerebrospinal fluid in HIV-1 Infected individuals Concentraciones de doravirina y actividad antiviral en líquido cefalorraquídeo en individuos in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003915-24,0,0,0 2018-003916-38,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,CRISPR Therapeutics AG,A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9–Engineered T Cells (CTX110) in Subjects with Relapsed or Refractory B-Cell Malignancies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003916-38,0,0,0 2018-003920-35,1,2019-12-16,2019-12-16,1,1,1,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Farmacéutica,"A multicenter, open-label, 8 day treatment study to assess the pharmacokinetics, safety and tolerability of fevipiprant delivered via a once daily chewable tablet in children aged 6 to <12 years with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003920-35,0,0,0 2018-003921-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Lluita contra la SIDA Foundation,Doravirine concentrations and antiviral activity in genital fluids in HIV-1 infected individuals. Concentraciones de doravirina y actividad antiviral en fluidos genitales en individuos infectados c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003921-27,0,0,0 2018-003924-35,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Leicester,A Randomised Controlled Trial of Mepolizumab Initiated During Admission to Hospital for a Severe Exacerbation of Eosinophilic COPD,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003924-35,0,0,0 2018-003925-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,Prospective phase IIb study to evaluate the efficacy of laparoscopic electrochemotherapy in the treatment of locally advanced pancreatic cancer Studio prospettico di fase IIb per valutare l’efficac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003925-27,0,0,0 2018-003926-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Bordeaux,Prospective comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the initial work-up of Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003926-10,0,0,0 2018-003927-12,5,2020-01-02,2020-01-20,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Genzyme Corporation,"A Phase 2b dose-finding study for SAR442168, a Bruton's tyrosine kinase inhibitor, in participants with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003927-12,0,0,0 2018-003933-14,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Galapagos NV,"A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males with active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003933-14,0,0,0 2018-003936-62,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL UNIVERSITARI DE BELLVITGE-IDIBELL,RENINE ANGIOTENSINE SYSTEM BLOCKADE (RAAS) IN RENAL TRANSPLANT RECIPIENTS WITH RENAL PROGENITOR CELLS (PEC's) IN URINE: RANDOMIZED CLINICAL TRIAL BLOQUEO DEL SISTEMA RENINA ANGIOTENSINA (SRAA) EN P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003936-62,0,0,0 2018-003939-30,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,Oslo University Hospital,"Determination of analgesic equipotent doses of inhaled metoxyflurane vs. intravenous fentanyl using cold pressor test (CPT) in volunteers: A randomized, double blind, placebo-controlled crossover stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003939-30,0,0,0 2018-003940-21,1,2019-07-18,2019-07-18,1,1,0,0,1,0,4,0,0,1,0,0,1,0,1,"FAES FARMA, S.A.","A pilot, multicentre, single-blind, randomized, placebo-controlled, parallel-group clinical trial, to assess the safety of Bilastine treatment regarding psychomotor performance using a virtual reality...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003940-21,0,0,0 2018-003941-41,10,2021-10-31,2021-11-10,6,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Theravance Biopharma Ireland Limited,"A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003941-41,1,0,0 2018-003942-18,6,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,"Astex Pharmaceuticals, Inc.","An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) Estudio de extensión abierto y multicéntrico para pacientes que partic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003942-18,0,0,0 2018-003943-46,1,2019-12-06,2019-12-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Danish Headache Center,An open label study to evaluate the efficacy and tolerability of erenumab in the prophylactic treatment of persistent headache attributed to mild traumatic injury to the head ET ÅBENT EKSPLORATIVT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003943-46,0,0,0 2018-003945-40,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Maastricht University,"EFFECTS OF VAPORISED CANNABIS, WITH AND WITHOUT CBD, ON DRIVING AND COGNITION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003945-40,0,0,0 2018-003946-18,6,2020-12-09,2020-12-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GUERBET,Efficacy and safety of gadopiclenol for body magnetic resonance imaging (MRI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003946-18,0,0,0 2018-003949-42,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003949-42,0,0,0 2018-003949-42,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"GlaxoSmithKline, S.A.","A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003949-42,0,0,0 2018-003951-39,3,2020-01-06,2020-01-06,1,1,0,0,0,0,3,0,0,2,1,0,0,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003951-39,1,0,0 2018-003951-39,3,2020-01-06,2020-01-06,1,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003951-39,1,0,0 2018-003953-46,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Amiens Picardie,Influence des dermocorticoïdes sur la densité minérale osseuse chez les patients atteints de pemphigoïde bulleuse Influence des dermocorticoïdes sur la densité minérale osseuse chez les patients a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003953-46,0,0,0 2018-003954-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC Cancer Institute,CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy Op basis van CYP3A4*22 genotype doseren van tyrosine-kinase remmers bij patiënten met kanker: een nieu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003954-26,0,0,0 2018-003956-19,1,,,0,1,0,0,0,1,3,0,0,1,1,1,0,1,1,"Ra Pharmaceuticals, Inc.","Phase 3, Multicenter, Open-Label, Single-Arm Study to Confirm the Safety and Efficacy of Zilucoplan in Treatment-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003956-19,0,0,0 2018-003958-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla,Screening for cancer with PET / CT in patients with unprovoked venous thromboembolic disease with a high risk of developing cancer. Open randomized clinical trial. Detección del cáncer con PET/TAC ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003958-25,0,0,0 2018-003959-37,4,2022-06-30,2022-06-30,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"NanoCarrier Co, Ltd.",Phase IIa/IIb Clinical Trial of NC-6004 in Combination with Pembrolizumab in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed Platinum or a Platinum-c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003959-37,1,0,0 2018-003959-37,4,2022-06-30,2022-06-30,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Nano Carrier Co, Ltd.",Phase IIa/IIb Clinical Trial of NC-6004 in Combination with Pembrolizumab in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed Platinum or a Platinum-c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003959-37,1,0,0 2018-003960-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,Improving cesarean section practices - focus on bleeding and infection complications,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003960-29,0,0,0 2018-003964-30,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Replimune, Inc.","A Randomized, Controlled, Open-label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003964-30,0,0,0 2018-003969-33,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Innate Pharma SA,"TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003969-33,0,0,0 2018-003969-33,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,INNATE PHARMA,"TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003969-33,0,0,0 2018-003970-28,4,2020-08-20,2020-08-20,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003970-28,0,0,0 2018-003971-37,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Greater Glasgow and Clyde Health Board,PRIMUS 004: A multi-arm non-comparative signal seeking phase II platform trial of biomarker-directed novel second-line treatments in metastatic pancreatic cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003971-37,0,0,0 2018-003971-37,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Glasgow,PRIMUS 004: A multi-arm non-comparative signal seeking phase II platform trial of biomarker-directed novel second-line treatments in metastatic pancreatic cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003971-37,0,0,0 2018-003973-82,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE RICERCA TRASLAZIONALE (FORT),Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-small-cell lung cancer patients Studio randomizzato di fase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003973-82,0,0,0 2018-003974-29,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progressed on First-Line Osimertinib Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003974-29,0,0,0 2018-003975-36,5,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,"Astellas Pharma Global Development, Inc.","A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003975-36,0,1,0 2018-003977-93,1,2021-10-06,2021-10-06,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,RevImmune,"International, multicenter, randomized, double-blinded, placebo-controlled study of Recombinant Interleukin-7 (CYT107) to restore absolute lymphocyte counts (ALC) in patients with Sepsis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003977-93,0,0,0 2018-003978-28,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,"Takeda Vaccines, Inc.","A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003978-28,0,1,1 2018-003979-34,1,,,0,0,1,0,0,0,3,0,1,4,0,0,0,0,1,"Takeda Vaccines, Inc.","Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Childr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003979-34,0,1,1 2018-003980-77,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,"Takeda Vaccines, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003980-77,0,1,1 2018-003983-30,1,2020-12-22,2020-12-22,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Croma-Pharma GmbH,Randomized double blind Phase 3 study to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo followed by an open label extension study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003983-30,0,0,0 2018-003985-15,19,2022-02-16,2022-02-16,15,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Arena Pharmaceuticals Inc.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003985-15,1,0,0 2018-003985-15,19,2022-02-16,2022-02-16,15,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"ARENA PHARMACEUTICALS, INC.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003985-15,1,0,0 2018-003986-33,20,2021-12-07,2022-02-01,16,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"ARENA PHARMACEUTICALS, INC.","A Phase 3, Randomized, Double Blind, Placebo Controlled, 12 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003986-33,1,0,0 2018-003986-33,20,2021-12-07,2022-02-01,16,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Arena Pharmaceuticals, Inc.","A Phase 3, Randomized, Double Blind, Placebo Controlled, 12 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003986-33,1,0,0 2018-003986-33,20,2021-12-07,2022-02-01,16,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Arena Pharmaceuticals Inc.,"A Phase 3, Randomized, Double Blind, Placebo Controlled, 12 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003986-33,1,0,0 2018-003987-29,19,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Arena Pharmaceuticals Inc.,An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003987-29,0,0,0 2018-003987-29,19,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"ARENA PHARMACEUTICALS, INC.",An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003987-29,0,0,0 2018-003988-54,6,2020-09-11,2020-09-11,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Guerbet,Efficacy and Safety of gadoPIClenol for CenTral NervoUs System (CNS) Magnetic REsonance Imaging (MRI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003988-54,0,0,0 2018-003988-54,6,2020-09-11,2020-09-11,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,GUERBET,Efficacy and Safety of gadoPIClenol for CenTral NervoUs System (CNS) Magnetic REsonance Imaging (MRI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003988-54,0,0,0 2018-003990-93,1,2021-03-10,2021-03-10,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,"Department of Hematology, Herlev and Gentofte University Hospital",Phase IIa trial of PD-L1 peptide vaccination as monotherapy in high risk smoldering multiple myeloma Fase IIa studie af vaccination med PD-L1 peptid til patienter med høj-risiko asymptomatisk myel...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003990-93,0,0,0 2018-003993-29,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"GlaxoSmithKline, S.A.","DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003993-29,0,0,0 2018-003993-29,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003993-29,0,0,0 2018-003993-29,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003993-29,0,0,0 2018-003994-80,1,2021-02-22,2021-02-22,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Centre Léon Bérard,A Phase II study evaluating AGuIX® nanoparticles in combination with Stereotactic Radiation for oligo brain metastases Etude de phase II évaluant les nanoparticules AGUIX® en combinaison avec la ra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003994-80,0,0,0 2018-003996-37,1,2022-05-31,2022-05-31,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Westdeutsche Studiengruppe GmbH (WSG),"A prospective, multicenter, open label, neoadjuvant phase II single arm study with pembrolizumab in combination with dual anti-HER2 blockade with trastuzumab and pertuzumab in early breast cancer pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003996-37,0,0,0 2018-003998-96,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Maria Sklodowska-Curie National Research Institute of Oncology (MSCNRIO),"A Phase II, single arm Study of avelumab In combination with Axitinib in Patients With unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003998-96,0,0,0 2018-003998-96,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Centrum Onkologii – Instytut im. Marii Skłodowskiej - Curie,"A Phase II, single arm Study of avelumab In combination with Axitinib in Patients With unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-003998-96,0,0,0 2018-004002-25,14,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004002-25,0,0,0 2018-004002-25,14,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004002-25,0,0,0 2018-004003-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZ Brussel,A stratified dual-arm open-label two-stage phase 2 trial of trametinib in patients with advanced pretreated BRAFV600 wild-type melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004003-39,0,0,0 2018-004004-19,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"QED Therapeutics, Inc.","A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004004-19,0,0,0 2018-004004-19,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,QED Therapeutics Inc.,"A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004004-19,0,0,0 2018-004005-81,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Instituto Grifols, S.A.","A prospective, multicenter, open-label, single-arm study to evaluate the efficacy and safety of human plasma-derived fibrinogen concentrate (FIB Grifols) in subjects with congenital afibrinogenaemia a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004005-81,0,0,0 2018-004006-26,2,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Allergan Ltd,"A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004006-26,0,0,0 2018-004009-22,9,2019-12-16,2020-01-09,4,1,0,0,0,1,2,0,0,2,1,0,0,0,1,Wave Life Sciences UK Limited,"A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 in Ambulatory Patients with Duchenne Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004009-22,1,0,0 2018-004010-18,3,2021-06-24,2021-06-24,2,1,0,0,0,0,4,0,0,2,0,0,0,0,1,Almirall Ltd,"An Open Label, Multi-Center, 24 Week, Exploratory Study to Assess the Efficacy and Safety of Skilarence® (Dimethyl Fumarate) in Patients with Moderate Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004010-18,1,0,0 2018-004010-18,3,2021-06-24,2021-06-24,2,1,0,0,0,0,4,0,0,2,0,0,0,0,1,Almirall Ltd.,"An Open Label, Multi-Center, 24 Week, Exploratory Study to Assess the Efficacy and Safety of Skilarence® (Dimethyl Fumarate) in Patients with Moderate Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004010-18,1,0,0 2018-004011-44,3,,,0,0,0,0,0,1,0,0,0,3,0,0,0,0,0,The University of Adelaide,"A randomised trial of URsodeoxycholic acid versus RIFampicin in severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC study, comparing their effectiveness in the reduction of pruritis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004011-44,0,0,0 2018-004011-44,3,,,0,0,0,0,0,1,0,0,0,3,0,0,0,0,0,The University Of Adelaide,"A randomised trial of URsodeoxycholic acid versus RIFampicin in severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC study, comparing their effectiveness in the reduction of pruritis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004011-44,0,0,0 2018-004012-22,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Madrigal Pharmaceuticals, Inc.","A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Prog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004012-22,0,0,0 2018-004013-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC,Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004013-41,0,0,0 2018-004014-17,3,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children with Primary Hyperoxaluria Type 1",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004014-17,0,0,0 2018-004015-49,1,2020-04-07,2020-04-07,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Vaccitech Ltd,Efficacy of MVA-NP+M1 in the influenza H3N2 Human Challenge model,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004015-49,0,0,0 2018-004016-22,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,1,ApoPharma Inc.,Safety and acceptability of deferiprone delayed release tablets in patients with systemic iron overload Ασφάλεια και επίπεδο αποδοχής των δισκίων δεφεριπρόνης καθυστερημένης αποδέσμευσης από ασθεν...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004016-22,0,0,0 2018-004019-34,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,Assembly Biosciences,"A Multi-center, Open-label, Long-term Extension Study of ABI-H0731 + Nucleos(t)ide as Finite Treatment for Chronic Hepatitis B Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004019-34,0,0,0 2018-004024-11,5,2021-01-27,2021-07-15,5,1,0,1,0,1,1,0,0,1,1,1,0,0,1,Baxalta Innovations GmbH,"An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004024-11,0,0,0 2018-004031-68,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Polish Myeloma Consortium,"A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004031-68,0,0,0 2018-004032-29,1,2021-05-10,2021-05-10,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital,Effect of the moderate CYP3A4-inhibitor erythromycin on the pharmacokinetics of palbociclib Effect van de matige CYP3A4-remmer erythromycine op de farmacokinetiek van palbociclib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004032-29,0,0,0 2018-004038-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Klinikum der Universität München,A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination with Obinutuzumab in Patients w...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004038-13,0,0,0 2018-004039-64,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"MYOKARDIA, INC.",A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004039-64,0,0,0 2018-004039-64,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"MyoKardia, Inc.",A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004039-64,0,0,0 2018-004040-28,1,2022-06-13,2022-06-13,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Merck KGaA,"A Phase Ib/II, Open-Label Study of M7824 in Combination with Chemotherapy in Participants with Stage IV Non-small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004040-28,0,0,0 2018-004042-42,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F.Hoffmann La-Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004042-42,0,0,0 2018-004042-42,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004042-42,0,0,0 2018-004042-42,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S.A.(Soc. Unipersonal)que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche LTD,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004042-42,0,0,0 2018-004043-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Schleswig-Holstein (UKSH),Cognitive function after liver transplantation comparing Tacrolimus formulations Kognitive Funktion nach Lebertransplantation im Vergleich verschiedener Tacrolimus Formulierungen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004043-23,0,0,0 2018-004045-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Léon Bérard,"REGOSTA – A randomized, placebo-controlled, double-blinded, multicentre study evaluating the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bone ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004045-16,0,0,0 2018-004046-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University of Bergen,",A multicentre clinical trial; Alveolar bone augmentation using Mesenchymal Stem Cells and biphasic calcium phosphate granules prior to dental implants Ensayo clínico multicéntrico; Aumento de hueso...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004046-41,0,0,0 2018-004047-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Bergen,Evaluation of safety and feasibility of autologous MSCs combined to biomaterial to enhance bone healing in patients with delayed consolidation after long bone defects requiring graft apposition or alt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004047-23,0,0,0 2018-004048-50,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Aberdeen,Double blind randomised controlled trial of exogenous administration of melatonin in chronic pain (DREAM-CP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004048-50,0,0,0 2018-004048-50,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Grampian,Double blind randomised controlled trial of exogenous administration of melatonin in chronic pain (DREAM-CP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004048-50,0,0,0 2018-004050-16,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University Hospital Karolinska,HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A phase I/II multicenter study to assess the tolerability and efficacy of the addition of hydroxyurea to standard ara-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004050-16,0,0,0 2018-004055-20,1,2021-07-01,2021-07-01,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety of a Purified Vero Rabies Vaccine – Serum Free in Comparison with Verorab® and Imovax® Rabies, in a Simulated Rabies Post-exposure Regimen in Healthy Adults in France",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004055-20,0,0,0 2018-004056-37,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE IIIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL EFFICACY STUDY OF BALOXAVIR MARBOXIL FOR THE REDUCTION OF DIRECT TRANSMISSION OF INFLUENZA FROM OTHERWISE HEALTHY PATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004056-37,0,0,0 2018-004056-37,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE IIIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL EFFICACY STUDY OF BALOXAVIR MARBOXIL FOR THE REDUCTION OF DIRECT TRANSMISSION OF INFLUENZA FROM OTHERWISE HEALTHY PATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004056-37,0,0,0 2018-004057-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IRCCS MATERNO INFANTILE BURLO GAROFOLO,Oral Ibuprofene versus oral kethorolac for children with musculoskeletal injury: a double blind randomized controlled study. Ibuprofene versus Ketorolac per bocca nel trattamento del dolore acuto d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004057-25,0,0,0 2018-004058-11,3,2021-03-08,2021-03-08,2,1,0,0,0,1,3,0,0,2,0,0,0,0,1,"Rhythm Pharmaceuticals, Inc.","A Phase 3 trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and AlstrC6m syndrome (AS) Patients with Moderate to Severe Obesity Ensayo de fas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004058-11,1,0,0 2018-004059-18,8,2021-05-21,2021-05-21,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bayer AG,"A Multicenter, Randomized, Parallel Group, Double Blind, Active and Placebo Controlled Study of BAY 1753011, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients with Congestive Heart Failure: A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004059-18,0,0,0 2018-004063-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS),"Mechanisms of cardio and nephroprotection in patients who are going on cardiac surgery with right ventricular dysfunction, with preoperative treatment of levosimendan compared with placebo. (PRELEVD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004063-31,0,0,0 2018-004064-62,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,NOXXON Pharma AG,"Single-arm, Dose-Escalation, Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination with Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients with Unmethylated MGMT Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004064-62,0,0,0 2018-004067-31,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,"Bioinova, s.r.o.",Autologous bone marrow-derived mesenchymal stem cells seeded on a 3D scaffold in treatment of knee cartilage defects. Prospective open-label study to assess safety and feasibility. Autologní mezen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004067-31,0,0,0 2018-004068-74,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,I.R.C.C.S. POLICLINICO SAN DONATO,ZEro_PLASma Trial in small infants undergoing cardiac surgery Studio randomizzato controllato Plasma vs. Concentrati di fattori della coagulazione in cardiochirurgia pediatrica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004068-74,0,0,0 2018-004072-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Nice,Study of the value of early treatment with an endothelin inhibitor (Bosentan) in patients with sudden blindness secondary to giant cell arteritis Etude de l’intérêt d’un traitement précoce par un...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004072-35,0,0,0 2018-004073-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ARCI (trade name LYON RECHERCHE CLINIQUE : LyREC),Dupilumab impact on skin resident memory T cells,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004073-27,0,0,0 2018-004076-35,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Incyte Corporation,"A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma Estudio F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004076-35,0,0,0 2018-004079-11,6,2021-11-22,2021-11-22,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricaemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004079-11,1,0,0 2018-004079-11,6,2021-11-22,2021-11-22,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ASTRAZENECA AB,"A Phase 2b, Multicentre, Randomised, Double-blind, Placebo-controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricaemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004079-11,1,0,0 2018-004081-34,1,2021-01-29,2021-01-29,1,1,0,0,0,0,4,0,1,1,0,0,1,0,3,,The effect of oxytocin on patient-physician relationships: a placebo controlled study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004081-34,0,0,0 2018-004083-62,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Semmelweis University, Oro-Maxillofacial Surgery and Stomatology","Effect of preoperative intramasseteric methylprednisolone injection on the post-operative sequelae of lower third molar surgery: a placebo controlled, randomized, double-blinded study Preoperatívan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004083-62,0,0,0 2018-004084-31,2,,,0,0,1,0,0,0,2,0,0,4,0,0,0,0,1,"Esperion Therapeutics, Inc.","AN OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF BEMPEDOIC ACID IN PEDIATRIC PATIENTS (6 TO 17 YEARS OF AGE) WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004084-31,0,0,0 2018-004089-33,6,2022-06-22,2022-07-08,3,0,0,1,0,1,1,0,0,2,1,0,0,0,1,Dynacure SAS,"A Phase 1/2 trial on the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of DYN101 in patients ≥ 16 years of age with centronuclear myopathies caused by mutations in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004089-33,1,0,0 2018-004089-33,6,2022-06-22,2022-07-08,3,0,0,1,0,1,1,0,0,2,1,0,0,0,1,Dynacure,"A Phase 1/2 trial on the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of DYN101 in patients ≥ 16 years of age with centronuclear myopathies caused by mutations in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004089-33,1,0,0 2018-004091-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Erasmus University Medical Center,Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004091-35,0,0,0 2018-004096-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,LUMC,Open-label randomized controlled trial for the effects of continuous ethinylestradiol/levonorgestrel (30/150 μg/day) compared with vitamin E (400 IU/day) in the treatment of menstrually-related migrai...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004096-12,0,0,0 2018-004103-39,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,TRANSGENE S.A.,A dose escalation and phase IIa study of TG6002 plus flucytosine in patients with unresectable colorectal cancer with liver metastases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004103-39,0,0,0 2018-004104-19,4,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,Philogen S.p.A.,A randomized study to investigate the efficacy and safety of the tumor-targeting human antibody-cytokine fusion protein L19TNF in previously treated patients with advanced stage or metastatic soft-tis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004104-19,0,0,0 2018-004104-19,4,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,PHILOGEN S.P.A.,A randomized study to investigate the efficacy and safety of the tumor-targeting human antibody-cytokine fusion protein L19TNF in previously treated patients with advanced stage or metastatic soft-tis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004104-19,0,0,0 2018-004105-85,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004105-85,0,0,0 2018-004105-85,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004105-85,0,0,0 2018-004109-21,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants (PNEU-PED)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004109-21,0,1,1 2018-004114-17,8,2019-07-23,2019-07-23,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Inovio Pharmaceuticals, Inc.","REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-16 a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004114-17,1,0,0 2018-004114-17,8,2019-07-23,2019-07-23,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"INOVIO PHARMACEUTICALS, INC.","REVEAL 2: A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation with CELLECTRA™ 5PSP for the Treatment of HPV-16 a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004114-17,1,0,0 2018-004116-22,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Cas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004116-22,0,0,0 2018-004116-22,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Cas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004116-22,0,0,0 2018-004117-40,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004117-40,0,0,0 2018-004117-40,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004117-40,0,0,0 2018-004117-40,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Merck Sharp & Dohme Corp.,"A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004117-40,0,0,0 2018-004118-16,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc","A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004118-16,0,0,0 2018-004118-16,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC) W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004118-16,0,0,0 2018-004119-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital,"Altered tumor oxygenation by Metformin, a potential step in overcoming radiotherapy resistance in locally advanced cervical cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004119-36,0,0,0 2018-004120-11,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,NHS Greater Glasgow and Clyde,"Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide and Dapagliflozin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004120-11,0,0,0 2018-004120-11,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Glasgow,"Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide and Dapagliflozin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004120-11,0,0,0 2018-004121-80,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Christie Hospital NHS Foundation Trust,"A proof of concept, window trial of the IMmunological effects of AveLumab and Aspirin in Triple-Negative Breast Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004121-80,0,0,0 2018-004124-10,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004124-10,0,0,0 2018-004135-77,1,2022-02-21,2022-02-21,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,MUMC,Randomized controlled trial on the effect of vitamin C supplementation in autologous stem cell transplantations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004135-77,0,0,0 2018-004136-30,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Charité - Universitätsmedizin Berlin Klinik für Dermatologie und Allergologie,"An Open-Label, Pilot Study to assess the effect of Lanadelumab on the clinical signs and symptoms of Hereditary angioedema with normal C1-inhibitor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004136-30,0,0,0 2018-004138-13,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,THE ROYAL MARSDEN NHS FOUNDATION,A multicentre phase II non-randomised trial assessing the efficacy of DKN-01 plus atezolizumab in patients with advanced mismatch repair proficient oesophagogastric cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004138-13,0,0,0 2018-004139-66,1,2020-10-23,2020-10-23,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Ghent University Hospital,Effect of norepinephrine infusion on hepatic blood flow during goal-directed hemodynamic therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004139-66,0,0,0 2018-004140-28,1,2020-06-02,2020-06-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP),NA « Administration de méthionine par voie orale ou entérale chez les patients atteints de protéinose alvéolaire primitive par mutations du gène MARS»,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004140-28,0,0,0 2018-004141-17,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Children's Oncology Group,A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004141-17,0,0,0 2018-004142-42,7,2021-09-17,2021-09-17,4,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004142-42,1,0,0 2018-004142-42,7,2021-09-17,2021-09-17,4,1,0,0,0,1,2,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004142-42,1,0,0 2018-004145-16,2,2021-01-05,2021-01-05,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,ZAMBON SPA,"A 12-weeks, multicentre, randomized, double-blind, placebo-controlled, exploratory, pilot study to evaluate the safety and efficacy of safinamide 200 mg once daily, as add-on therapy, in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004145-16,0,0,0 2018-004145-16,2,2021-01-05,2021-01-05,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Zambon SpA,"A 12-weeks, multicentre, randomized, double-blind, placebo-controlled, exploratory, pilot study to evaluate the safety and efficacy of safinamide 200 mg once daily, as add-on therapy, in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004145-16,0,0,0 2018-004146-41,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,CHU Angers,"First-BLINDOS - Evaluation d’une stratégie de dépistage systématique de la carence en vitamine D et du traitement en cas de déficit, sur l’amélioration de la distance maximale de marche chez les patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004146-41,0,0,0 2018-004147-24,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,DIPARTIMENTO DI ONCOLOGIA-UNIVERSITA' DEGLI STUDI DI TORINO,"A Phase II, Randomized, Trial of Niraparib Versus Best Supportive Care as Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004147-24,0,0,0 2018-004148-53,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,NKI-AVL,"ICRA (Improve Checkpoint-blockade Response in Advanced urothelial cancer), an adaptive clinical study to determine efficacy of combining weekly paclitaxel with tremelimumab +/- durvalumab (MEDI4736)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004148-53,0,0,0 2018-004149-17,1,,,0,0,0,1,1,0,1,0,0,3,0,0,0,0,0,University of Oxford / Clinical Trials and Research Governance,"A randomised, placebo-controlled, single-blind study to characterise the biomarker effects of the CSF-1 receptor antagonist JNJ-40346527 in participants with mild cognitive impairment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004149-17,0,0,0 2018-004150-13,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Zealand University hospital,Combination Therapy with Interferon-Alpha2a and Ruxolitinib in Newly Diagnosed Patients with Polycythemia Vera. A Danish Safety and Efficacy Study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004150-13,0,0,0 2018-004153-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amsterdam UMC - location Vrije Universiteit Amsterdam,Tubal flushing with oil-based contrast during HSG in subfertile women: Is early flushing effective and cost-effective as compared to delayed flushing? Is het verrichten van een HSG met olie contras...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004153-24,0,0,0 2018-004154-25,12,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,A multicenter study to evaluate long-term safety and tolerability of open label sacubitril/valsartan in pediatric patients with heart failure due to systemic left ventricle systolic dysfunction who ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004154-25,0,0,0 2018-004154-25,12,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,A multicenter study to evaluate long-term safety and tolerability of open label sacubitril/valsartan in pediatric patients with heart failure due to systemic left ventricle systolic dysfunction who ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004154-25,0,0,0 2018-004154-25,12,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.",A multicenter study to evaluate long-term safety and tolerability of open label sacubitril/valsartan in pediatric patients with heart failure due to systemic left ventricle systolic dysfunction who ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004154-25,0,0,0 2018-004156-37,11,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,NeuroDerm Ltd.,"A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004156-37,0,0,0 2018-004156-37,11,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,NEURODERM LTD.,"A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004156-37,0,0,0 2018-004158-11,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,NextCell Pharma,"AN OPEN LABEL, PARALLEL SINGLE CENTRE TRIAL OF WHARTON’S JELLY DERIVED ALLOGENEIC MESENCHYMAL STROMAL CELLS REPEATED TREATMENT TO PRESERVE ENDOGENOUS INSULIN PRODUCTION IN ADULT PATIENTS DIAGNOSED WIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004158-11,0,0,0 2018-004159-19,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,University Hospital Basel,Use of Copeptin Measurement after Arginine Infusion for the Diagnosis of Diabetes Insipidus - the CARGOx Study Copeptin Messung nach Arginininfusion zur Diagnose des Diabetes insipidus (die CARGOx...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004159-19,0,0,0 2018-004164-60,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,CLINUVEL (UK) LTD,"A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Variegate Porphyria (VP)-related skin disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004164-60,0,0,0 2018-004165-13,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Jules Bordet,"Neo-adjuvant chemotherapy combined with SBRT to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab in luminal B breast cancer: a phase ll randomized trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004165-13,0,0,0 2018-004166-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,ORGAN SPARING FOR LOCALLY ADVANCED RECTAL CANCER AFTER NEOADJUVANT TREATMENT FOLLOWED BY ELECTROCHEMOTHERAPY ORGAN SPARING FOR LOCALLY ADVANCED RECTAL CANCER AFTER NEOADJUVANT TREATMENT FOLLOWED BY...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004166-33,0,0,0 2018-004171-12,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Polski Bank Komórek Macierzystych JSC (PBKM),The evaluation of the effect of Wharton’s Jelly Mesenchymal Stem Cells (WJMSCs) on the immune system of patients with Amyotrophic Lateral Sclerosis (ALS) Ocena wpływu komórek macierzystych galarety...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004171-12,0,0,0 2018-004175-12,11,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Pfizer Inc.,"A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004175-12,0,0,0 2018-004175-12,11,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,PFIZER INC,"A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004175-12,0,0,0 2018-004176-35,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,Aristea Therapeutics Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004176-35,0,0,0 2018-004179-11,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Radboudumc,"Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, SAIPAN-trial: a multicentre, randomized, open-label, parallel-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004179-11,0,0,0 2018-004179-11,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,RADBOUD UNIVERSITY MEDICAL CENTER,"Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, SAIPAN-trial: a multicentre, randomized, open-label, parallel-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004179-11,0,0,0 2018-004180-31,10,2020-11-18,2020-11-18,7,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Orion Corporation,Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label extension for patients completing study 3119002,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004180-31,1,0,0 2018-004180-31,10,2020-11-18,2020-11-18,7,1,0,0,0,1,3,0,0,2,1,0,0,0,1,ORION CORPORATION ORION PHARMA,Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS: open label extension for patients completing study 3119002,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004180-31,1,0,0 2018-004185-34,9,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Janssen-Cilag International N.V.,A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004185-34,0,0,0 2018-004185-34,9,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004185-34,0,0,0 2018-004186-14,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Corcept Therapeutics Incorporated,"A Phase 2, Randomized, Open-label, 3-arm Study of Relacorilant in Combination with Nab-Paclitaxel for Patients with Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004186-14,0,0,0 2018-004188-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,Pre-operative phase II trial for breast cancer with nivolumab in combination with novel IO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004188-30,0,0,0 2018-004191-35,1,,,0,0,1,0,0,0,4,0,0,0,0,0,0,0,0,Cliniques universitaires Saint-Luc,Evaluation of the safety and efficacy of administration of Empagliflozin in a new treatment for neutropenia in patients with Glycogen Storage Disease type 1b (GSD1b) and G6PC3 deficiency. Évaluati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004191-35,0,0,0 2018-004192-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Amsterdam UMC, location VU medical Center",Oil- based versus water-based contrast media for hysterosalpingography (HSG) in infertile women with unevaluated indications: a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004192-12,0,0,0 2018-004201-33,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Immunomedics, Inc.",Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negativ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004201-33,0,0,0 2018-004201-33,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"IMMUNOMEDICS, INC.",Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negativ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004201-33,0,0,0 2018-004202-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Luis Nombela Franco,Usefulness of amiodarone for the Prevention of new onset Atrial Fibrillation after transcatheter aortic valve implantation: a randomized controlled trial Utilidad de la amiodarona en la prevención ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004202-25,0,0,0 2018-004207-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AGO Research GmbH,"A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy. supported by: DIAGNOSTIC PRO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004207-39,0,0,0 2018-004208-20,1,2021-11-06,2021-11-06,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,Gh Research Limited,A phase 1/2 study of GH001 in patients with treatment-resistant depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004208-20,0,0,0 2018-004211-42,6,2021-08-04,2021-08-04,3,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Polyphor Ltd.,"An International, Phase 3, Multicenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004211-42,1,0,0 2018-004212-21,5,2020-07-02,2020-08-13,4,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"AMAG Pharmaceuticals, Inc.","A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects with Severe Preecla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004212-21,1,0,0 2018-004213-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Ghent,Effect of intravenous replenishment of iron in the preoperative management of anemia in patients with colon cancer: RIPAC-trial Het effect van intraveneuze ijzertoediening in de preoperatieve behan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004213-41,0,0,0 2018-004215-50,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Soleno Therapeutics UK Ltd.,"A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients with Prader-Willi Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004215-50,0,0,0 2018-004216-22,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Soleno Therapeutics UK Ltd.,"An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients with Prader-Willi Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004216-22,0,0,0 2018-004220-11,1,2021-06-23,2021-06-23,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,"Apellis Pharmaceuticals, Inc.","A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Randomizowane, wieloośrodkow...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004220-11,0,0,0 2018-004222-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Malmö University,Efficacy of topical treatment with clobetasol in symptomatic oral lichen planus. A multicenter placebo-controlled randomized clinical trial. Effekten av lokalbehandling med klobetasol vid symptomgi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004222-28,0,0,0 2018-004223-36,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Dr. Reddy’s Laboratories S.A.,"A Randomised, Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) with MabThera® in Subjects with Previously Unt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004223-36,0,0,0 2018-004223-36,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Dr. Reddy's Laboratories S.A.,"A Randomised, Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) with MabThera® in Subjects with Previously Unt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004223-36,0,0,0 2018-004229-10,1,2019-09-26,2019-09-26,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,McNeil AB,"DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF PHARMACODYNAMIC EFFECTS OF 4 MG NICOTINE GUM. A STUDY IN HEALTHY SMOKERS WILLING TO QUIT Podwójnie zaślepione, z kontrolą placebo, badanie efektów farmakod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004229-10,0,0,0 2018-004231-72,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS),Randomized study of the detection of RAS / BRAF mutations by BEAMing technology in advance of the radiological diagnosis of progression in patients with metastatic colorectal cancer RAS / BRAF WT and ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004231-72,0,0,0 2018-004234-15,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004234-15,0,0,0 2018-004237-32,9,2021-04-06,2021-04-06,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Janssen-Cilag International NV,"A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004237-32,0,0,0 2018-004237-32,9,2021-04-06,2021-04-06,8,1,0,0,0,0,2,0,0,1,1,0,1,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in Sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004237-32,0,0,0 2018-004239-63,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC,Botulinum toxin (BOTOX®) to prevent post-operative pancreatic fistula in patients who undergo distal pancreatectomy. PROFIT study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004239-63,0,0,0 2018-004241-16,7,2021-01-15,2021-01-15,7,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PF-06700841 TO EVALUATE THE EFFICACY AT 16 WEEKS AND TO EVALUATE THE SAFETY AND EFFICACY UP TO 1 YEAR IN SUBJECTS WITH ACTIVE PSORIATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004241-16,0,0,0 2018-004242-42,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Lilly S.A.,"A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004242-42,0,0,0 2018-004242-42,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004242-42,0,0,0 2018-004242-42,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004242-42,0,0,0 2018-004243-23,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with relapsed, Recurrent, or Refractory Synovial Sarcoma. Studio di Fase 1/2, Randomizzato, in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004243-23,0,0,0 2018-004243-23,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Lilly S.A.,"A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with relapsed, Recurrent, or Refractory Synovial Sarcoma. Studio di Fase 1/2, Randomizzato, in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004243-23,0,0,0 2018-004243-23,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with relapsed, Recurrent, or Refractory Synovial Sarcoma. Studio di Fase 1/2, Randomizzato, in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004243-23,0,0,0 2018-004244-33,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,"aTyr Pharma, Inc.","A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients with Pulmonary Sarcoidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004244-33,0,0,0 2018-004245-16,1,2021-04-23,2021-04-23,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Maastricht University,Targeting the beta-2 adrenergic pathway to improve skeletal muscle glucose uptake in healthy humans Activatie van het beta-2 adrenerge pathway in gezonde mensen om de glucose opname door de spier t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004245-16,0,0,0 2018-004247-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,[89Zr]trastuzumab PET/CT imaging of HER2 positive breast cancer for predicting pathologic complete response after neoadjuvant chemotherapy; A multicentre study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004247-23,0,0,0 2018-004248-49,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Leiden University Medical Center,Phase 1b/2 Study Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced Uveal Melanoma (CHOPIN) Fase 1b/2 studie naar de combinatie van leverperfusie met ipilimumab en ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004248-49,0,0,0 2018-004250-17,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,University of Birmingham,An International Prospective Trial on High-Risk Medulloblastoma in Patients Older than 3 Years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004250-17,0,0,0 2018-004250-17,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,UNIVERSITY OF BIRMINGHAM,An International Prospective Trial on High-Risk Medulloblastoma in Patients Older than 3 Years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004250-17,0,0,0 2018-004252-38,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004252-38,0,0,0 2018-004252-38,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004252-38,0,0,0 2018-004253-24,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,"An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004253-24,0,0,0 2018-004253-24,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004253-24,0,0,0 2018-004254-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Charite University,"Efficacy of Tofacitinib in Reduction of Inflammation Detected on MRI in Patients with Psoriatic ArthritiS PresenTing with Axial InvOlvement - a Randomized, Double-Blind, Placebo-Controlled, Multicen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004254-22,0,0,0 2018-004255-20,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,"On Target Laboratories, LLC","A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004255-20,0,0,0 2018-004258-77,1,2019-10-21,2019-10-21,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,ChemomAb Ltd.,"A Phase 2, Open Label, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of CM-101 Administered for 12 Weeks in Adult Subjects with Primary Sclerosing Cholangitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004258-77,0,0,0 2018-004261-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Vestre Viken Trust,MUscle Side-Effects of atorvastatin in coronary patients (MUSE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004261-14,0,0,0 2018-004262-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Inmunotek, S.L.","Randomized, placebo-controlled, prospective clinical trial of efficacy and safety for the treatment of rhinitis/rhinoconjunctivitis and asthma against a mixture of Dermatophagoides pteronyssinus and D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004262-34,0,0,0 2018-004266-33,3,2020-07-03,2020-07-03,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004266-33,0,0,0 2018-004266-33,3,2020-07-03,2020-07-03,3,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004266-33,0,0,0 2018-004267-32,4,2019-12-16,2020-01-16,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Novartis Farmaceutica, S.A.","A multi-center, proof-of-mechanism study of multiple, oral doses of fevipiprant (QAW039) in COPD patients with eosinophilia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004267-32,0,0,0 2018-004267-32,4,2019-12-16,2020-01-16,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Novartis Pharma AG,"A multi-center, proof-of-mechanism study of multiple, oral doses of fevipiprant (QAW039) in COPD patients with eosinophilia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004267-32,0,0,0 2018-004269-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Belgian IBD research and development,Loss of RESponse to Ustekinumab treated by dose Escalation Verlies van respons op ustekinumab behandeld via dosis escalatie Perte de réponse à l’ustékinumab traitée par augmentation de la dose.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004269-14,0,0,0 2018-004273-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"PRESURGY, S.",Multicenter clinical trial with medical device associated with a drug in an authorised therapeutic use for the treatment of CVNMI evaluating the efficacy and tolerability of the adyuvant treatment wit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004273-27,0,0,0 2018-004278-91,1,2020-02-12,2020-02-12,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS ?65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004278-91,0,0,0 2018-004279-11,1,2019-12-09,2019-12-09,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE–NAÏVE ADULTS 18 YEARS OF AGE AND OLDER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004279-11,0,0,0 2018-004280-32,11,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Eidos Therapeutics, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004280-32,0,0,0 2018-004280-32,11,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Eidos Therapeutics, Inc","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004280-32,0,0,0 2018-004283-65,2,2020-12-07,2020-12-07,1,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 1/2, Randomized Study Evaluating Multiple Nivolumab Combination Therapies in Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) after Failure of Platinum-Based Chemotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004283-65,1,0,0 2018-004284-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Asklepios Klink Sankt Augustin,Effectiveness of Canakinumab for first line steroid free treatment in systemic onset juvenile idiopathic arthritis / juvenile Still’s disease Effektivität von Canakinumab zur steroidfreien Erstbeha...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004284-30,0,0,0 2018-004285-34,1,,,0,0,0,0,0,0,4,0,1,3,0,0,0,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,The impact of aspirin dose modification on the innate immune response - WILL lOWer dose aspirin Therapy ReducE the response to Endotoxin? – (WILLOW TREE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004285-34,0,0,0 2018-004287-56,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,Randomized placebo-controlled trial comparing Methotrexate vs. Methotrexate/Metformin association in rheumatoid arthritis patients: METorMET² study Essai clinique randomisé multicentrique en double...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004287-56,0,0,0 2018-004289-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Surgical Sciences, Uppsala University",Metformin for Abdominal Aortic Aneurysm Inhibition. A randomized controlled trial MAAAGI trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004289-33,0,0,0 2018-004290-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Pharmacokinetic boosting of osimertinib in patients with non-small cell lung cancer. Farmacokinetische boosting van osimertinib in patiënten met niet kleincelling longcarcinoom.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004290-28,0,0,0 2018-004293-10,6,2021-01-27,2021-01-27,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects with Active Psoriatic Arthritis (PsA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004293-10,0,0,0 2018-004293-10,6,2021-01-27,2021-01-27,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects with Active Psoriatic Arthritis (PsA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004293-10,0,0,0 2018-004299-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","NIVOLUMAB plus IPILIMUMAB and TEMOZOLOMIDE in combination in microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC): the MAYA study. Trattamento di combinazione con NIVOLUMA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004299-37,0,0,0 2018-004300-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU DE NICE,Target-controled infusion with propofol in the Emergency Department : a prospective study on 50 adult patients Sédation Intraveineuse à Objectif de Concentration (SIVOC) au propofol à l’accueil des...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004300-19,0,0,0 2018-004301-32,5,,,0,0,1,0,0,0,2,0,0,2,0,0,0,0,1,Janssen Sciences Ireland UC,"A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004301-32,0,1,0 2018-004301-32,5,,,0,0,1,0,0,0,2,0,0,2,0,0,0,0,1,Janssen Sciences Ireland Unlimited Company,"A Phase 2, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004301-32,0,1,0 2018-004304-19,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"AMAG Pharmaceuticals, Inc.","A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004304-19,0,0,0 2018-004305-11,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospitals of Derby & Burton NHS Foundation Trust,"Salbutamol for analgesia in renal colic: A prospective, randomised, placebo controlled Phase II trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004305-11,0,0,0 2018-004310-18,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Saving Patients' Lives Medical B.V.,"A confirmatory, prospective, open-label, single-arm, reader-blinded multi-centre phase 3 study to assess the diagnostic accuracy of Ferumoxtran-10-enhanced Magnetic Resonance Imaging (MRI) and unenhan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004310-18,0,0,0 2018-004314-17,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Christie NHS Foundation Trust,The CAPER study: A Phase Ib clinical trial of Cyclophosphamide And PEmbrolizumab in metastatic Renal cell carcinoma (CAPER Trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004314-17,0,0,0 2018-004316-22,1,2020-07-02,2020-07-02,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004316-22,0,0,0 2018-004318-16,4,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,"Ansun Biopharma, Inc.",A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004318-16,0,0,0 2018-004320-11,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004320-11,0,0,0 2018-004320-11,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004320-11,0,0,0 2018-004321-86,3,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,BioNTech SE,"First-in-human, dose titration and expansion trial to evaluate safety, immunogenicity and preliminary efficacy of W_pro1 (BNT112) monotherapy and in combination with cemiplimab in patients with prosta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004321-86,0,0,0 2018-004323-37,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Academic Medical Centre,Prevention of hepatic Encephalopathy by Administration of Rifaximin and Lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt: a multi-cent...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004323-37,0,0,0 2018-004325-88,1,2021-10-02,2021-10-02,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Monash University - Eastern Health Clinical School,"A multicentre, randomised controlled Trial of Exenatide versus standard care in Acute Ischemic Stroke (TEXAIS) Randomoitu kontrolloitu monikeskustutkimus eksenatidista tavanomaiseen hoitoon verratt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004325-88,0,0,0 2018-004329-10,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel","A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy Randomisi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004329-10,0,0,0 2018-004330-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Assistance Publique - Hôpitaux de Paris (AP-HP),"A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethasone for relapsed multiple myeloma Étude de phase III rando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004330-15,0,0,0 2018-004331-71,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,IntraBio Ltd,"Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C: A multinational, multicenter, open-label, rater-blinded Phase II study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004331-71,0,0,0 2018-004332-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Léon Bérard,"LENVAGIST - A multicentre, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imatinib...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004332-30,0,0,0 2018-004333-33,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,European Myeloma Network,Phase 2 study of daratumumab monotherapy in previously untreated patients with stage 3B light chain (AL) amyloidosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004333-33,0,0,0 2018-004337-32,8,2022-01-20,2022-01-20,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ALLERGAN LIMITED,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE (PROGR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004337-32,1,0,0 2018-004337-32,8,2022-01-20,2022-01-20,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Allergan Limited,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ATOGEPANT FOR THE PREVENTION OF CHRONIC MIGRAINE (PROGR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004337-32,1,0,0 2018-004338-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Dermatology, Erasmus University Medical Center",Short term clinical efficacy of topical treatment with clindamycin-benzoyl peroxide gel compared with clindamycin lotion in mild to moderate Hidradenitis Suppurativa Effectiviteit van lokale behand...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004338-13,0,0,0 2018-004346-42,13,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Allergan Ltd.,"A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004346-42,0,0,0 2018-004346-42,13,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,AstraZeneca AB,"A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004346-42,0,0,0 2018-004346-42,13,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,ALLERGAN LIMITED,"A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004346-42,0,0,0 2018-004348-47,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Oncología Genitourinaria (SOGUG),EFFICACY OF ATEZOLIZUMAB CONCURRENT WITH RADIOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER EFICACIA DEL ATEZOLIZUMAB CON RADIOTERAPIA CONCOMITANTE EN PACIENTES CON CÁNCER DE VEJIGA MÚSCU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004348-47,0,0,0 2018-004351-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aarhus University Hospital,"Intraoperative methadone in same-day hysterectomy: a prospective, double-blind, randomised controlled trial Intraoperativt metadon til sammedags hysterektomi: et prospektivt, dobbelt blindet random...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004351-20,0,0,0 2018-004352-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Centraal Ziekenfonds (CZ) health insurance company,Local Application of Pilocarpine for Relieving Dry Mouth Complaints: A randomized controlled pilot trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004352-38,0,0,0 2018-004353-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación PETHEMA,"A phase II, multicentre, open label clinical trial to assess the efficacy and toxicity of induction and consolidation with CPX-351 for patients aged 60 to 75 years with secondary or high-risk acute my...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004353-24,0,0,0 2018-004354-21,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004354-21,0,0,0 2018-004354-21,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004354-21,0,0,0 2018-004355-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HUS,"Mechanical bowel preparation and oral antibiotics versus mechanical bowel preparation only prior rectal surgery - a prospective, randomized controlled trial Suolen valmistelu suun kautta otettavall...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004355-20,0,0,0 2018-004356-38,8,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004356-38,0,0,0 2018-004362-34,13,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004362-34,0,0,0 2018-004362-34,13,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004362-34,0,0,0 2018-004364-66,1,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,BioMarin Pharmaceutical Inc.,A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondroplasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004364-66,0,0,0 2018-004365-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GZA vzw,"A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-adrogen therapy (A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004365-13,0,0,0 2018-004370-96,1,2021-03-15,2021-03-15,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Jacob Pontoppidan Thyssen,The effects of topical corticosteroid use on insulin sensitivity and bone turnover Effekten af binyrebarkhormon lokalbehandling på udvikling af diabetes og knogleskørhed,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004370-96,0,0,0 2018-004372-36,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,BioLineRx Ltd.,"A phase IIa, multicenter, Open-Label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients with Metastatic Pancreatic Cancer, the COMBAT study Estudio ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004372-36,0,0,0 2018-004378-92,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Clínic per la Recerca Biomèdica,Effect of cannabinoids (THC / CBD) on hyperalgesia in patients with deep endometriosis Efecto de los cannabinoides (THC/CBD) sobre la hiperalgesia en pacientes con endometriosis profunda,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004378-92,0,0,0 2018-004381-33,5,2019-12-16,2020-10-26,5,1,0,0,0,0,2,0,2,1,1,0,1,0,1,Novartis Pharma AG,"Randomized, subject and investigator blinded, placebo-controlled study to demonstrate the anti-inflammatory effect of fevipiprant (QAW039) in moderate-severe asthma patients with high sputum and blood...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004381-33,0,0,0 2018-004381-33,5,2019-12-16,2020-10-26,5,1,0,0,0,0,2,0,2,1,1,0,1,0,1,"Novartis Farmacéutica, S.A","Randomized, subject and investigator blinded, placebo-controlled study to demonstrate the anti-inflammatory effect of fevipiprant (QAW039) in moderate-severe asthma patients with high sputum and blood...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004381-33,0,0,0 2018-004382-13,1,2020-11-05,2020-11-05,1,1,0,0,0,1,2,0,0,1,1,1,1,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF CEMDISIRAN (ALN-CC5) FOLLOWING WITHDRAWAL OF CHRONIC ECULIZUMAB THERAPY IN PATIENTS WITH ATYPICA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004382-13,0,0,0 2018-004383-65,4,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Scholar Rock, Inc.",Phase 2 Active Treatment Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with Later-Onset Spinal Muscular Atrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004383-65,0,0,0 2018-004384-31,1,2021-01-25,2021-01-25,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Allergan Ltd.,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004384-31,0,0,0 2018-004385-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,"Neoadjuvant Aspirin and/or Metformin during preoperative induction chemotherapy and chemoradiotherapy for locally-advanced rectal cancer. A multi-arm, multi-stage, intergroup (STAR-04/SICO-CR01/GISCAD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004385-34,0,0,0 2018-004387-54,7,2022-04-26,2022-04-27,4,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Novartis Pharma AG,"An adaptive Phase 2 randomized double-blind, placebo-controlled multi-center study to evaluate the safety and efficacy of multiple LOU064 doses in patients with moderate to severe Sjögren’s Syndrome (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004387-54,1,0,0 2018-004387-54,7,2022-04-26,2022-04-27,4,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","An adaptive Phase 2 randomized double-blind, placebo-controlled multi-center study to evaluate the safety and efficacy of multiple LOU064 doses in patients with moderate to severe Sjögren’s Syndrome (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004387-54,1,0,0 2018-004389-33,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Olli Lahtinen,Contrast enhanced ultrasound a novel technique in lymphatic imaging – A Prospective study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004389-33,0,0,0 2018-004391-34,1,,,0,1,0,0,0,0,2,0,1,3,0,0,0,0,0,University of Oxford,"A Phase I/IIa Sporozoite Challenge Study to assess the safety, immunogenicity and protective efficacy of adjuvanted R21, administered in different dose schedules in healthy UK volunteers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004391-34,0,0,0 2018-004392-12,7,2021-11-10,2021-11-10,4,1,0,0,0,1,2,0,0,2,0,0,0,0,1,UCB Biopharma SPRL,"An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004392-12,1,0,0 2018-004392-12,7,2021-11-10,2021-11-10,4,1,0,0,0,1,2,0,0,2,0,0,0,0,1,UCB Biopharma SRL,"An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004392-12,1,0,0 2018-004393-10,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Greater Glasgow & Clyde,"A randomised, double-blind, placebo-controlled, cross-over trial of zibotentan in microvascular angina",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004393-10,0,0,0 2018-004393-10,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Glasgow,"A randomised, double-blind, placebo-controlled, cross-over trial of zibotentan in microvascular angina",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004393-10,0,0,0 2018-004397-96,1,2019-08-07,2019-08-07,1,1,0,0,1,0,2,0,1,1,0,0,1,0,0,Merete Hædersdal,Impact of thermo-mechanical intervention on Protoporphyrin IX accumulation and biodistribution in normal skin following topical 5-aminolevulinic acid at high and low vehicle viscosity Effekten af t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004397-96,0,0,0 2018-004400-19,1,2021-12-31,2021-12-31,1,1,0,0,0,0,3,0,0,1,1,1,0,0,0,IVIRMA MADRID,Study of the effects of telomerase reactivation with Danazol on ovarian function. A Pilot Study. Estudio de los efectos de la reactivación de la telomerasa con Danazol en la función ovárica. Estudi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004400-19,0,0,0 2018-004401-79,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,"University of Oxford, Clinical Trials and Research Governance","The use of Benralizumab, an interleukin-5 receptor-α monoclonal antibody as treatment of acute exacerbations of airways disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004401-79,0,0,0 2018-004405-64,4,2020-09-09,2020-09-14,4,1,0,0,0,1,2,0,0,1,0,0,1,0,1,"Minoryx Therapeutics BE, SA","A Double-Blind, Placebo-Controlled Study on the Effects of MIN-102 on Biochemical, Imaging, Neurophysiological, and Clinical Markers in Patients with Friedreich’s Ataxia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004405-64,0,0,0 2018-004406-25,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,IntraBio Ltd,"Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A multinational, multicenter, open-label, rater-blinded Phase II study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004406-25,0,0,0 2018-004407-39,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,IntraBio Ltd.,"Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A multinational, multicenter, open-label, rater-blinded Phase II study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004407-39,0,0,0 2018-004407-39,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,IntraBio Ltd,"Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A multinational, multicenter, open-label, rater-blinded Phase II study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004407-39,0,0,0 2018-004409-17,2,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"An Open-label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects with Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004409-17,0,0,0 2018-004411-49,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,". Essai de non-infériorité comparant le switch vers un biosimilaire de l’infliximab (Inflectra®) à la poursuite du médicament princeps, chez les patients atteints de maladie inflammatoire chronique...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004411-49,0,0,0 2018-004418-16,1,,,0,0,0,0,0,1,3,0,0,1,1,1,0,1,1,Advicenne SA,A Phase 3b Open-Label Extension of Study B23CS (ARENA 2) Evaluating the Continued Safety and Efficacy of ADV7103 in Subjects With Primary Distal Renal Tubular Acidosis (ARENA 2 Open-label Extension S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004418-16,0,0,0 2018-004419-32,1,2021-12-22,2021-12-22,1,1,0,0,0,1,2,0,0,1,0,0,0,0,1,Pharmascience Inc.,"A Phase IIa, Proof of Concept, Randomized, Double-Blind, Dose-Finding, Cross-Over Study of the Efficacy, Safety and Tolerability of a New Enteric-Coated Cholestyramine Capsule in Adult Short Bowel Syn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004419-32,0,0,0 2018-004422-29,1,,,0,1,0,0,0,0,3,0,0,3,0,0,0,0,1,Eli Lilly and Company,"A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients with Type 2 Diabetes (SURPASS-2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004422-29,0,0,0 2018-004423-36,3,2020-04-06,2020-04-06,2,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Protagonist Therapeutics, Inc.",An Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) ß-thalassemia Subjects Studio di estensione in aperto su PTG-300 in soggetti affetti da be...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004423-36,0,0,0 2018-004427-37,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,0,Odense Research Centre for Anaphylaxis (ORCA),Treatment with Omalizumab in food allergic children Behandling af børn med førevareallergi med Omalizumab (Xolair),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004427-37,0,0,0 2018-004429-94,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"VU Medical Center, department of Rheumatology",[18F]PEG-folate PET-CT imaging for monitoring of therapy response in rheumatoid arthritis patients [18F]PEG-folaat PET-CT beeldvorming voor de monitoring van response op therapie bij reumatoïde art...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004429-94,0,0,0 2018-004431-79,4,2021-09-28,2021-09-28,1,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Celgene Corporation,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSEFINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND LIVER F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004431-79,1,0,0 2018-004438-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Västra Götalandsregionen,See below The Sahlgrenska anti-VEGF (SAHLVE) study – en prospektiv randomiserad dubbelblind jämförelse mellan bevacizumab och aflibercept hos patienter med våt åldersrelaterad makuladegeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004438-14,0,0,0 2018-004445-17,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Acesion Pharma ApS,"A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study of AP30663 Given Intravenously for Cardioversion in Patients with Atrial Fibrillation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004445-17,0,0,0 2018-004446-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SANITARIA OSPEDALIERA S.CROCE E CARLE CUNEO,Maintenance Of aNtiplatElet Therapy in patients with coronary stenting undergoing surgery Mantenimento della terapia antiaggregante nei pazienti portatori di stent coronarico candidati a chirurgia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004446-42,0,0,0 2018-004447-23,6,2020-05-29,2020-05-29,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Respivant Sciences, GmbH","Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004447-23,0,0,0 2018-004447-23,6,2020-05-29,2020-05-29,5,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Respivant Sciences GmbH,"Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004447-23,0,0,0 2018-004449-18,6,2020-08-31,2020-08-31,5,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Promethera Biosciences,"Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in patients with cirrhotic and pre-cirrhotic non-alcoholic steato-hepatitis (NASH).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004449-18,1,0,0 2018-004450-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Tergooi Hospital, dep of internal medicine",A pharmacokinetic study of edoxaban in patients with breast cancer using the P-glycoprotein inhibitor tamoxifen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004450-24,0,0,0 2018-004451-20,1,2021-07-20,2021-07-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Rheinische Friedrich-Wilhelms-Universität Bonn,"A multicenter, open label, single-arm pilot study to evaluate the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP) Multizentrische, offe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004451-20,0,0,0 2018-004456-38,6,,,0,0,1,0,0,0,2,0,0,2,1,0,0,0,1,Eisai Limited,An Open-Label Study with Extension Phase to Evaluate the Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Subjects (Age 1 Month to Less Than 18 Years) With Childhoo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004456-38,0,0,0 2018-004457-24,1,2021-08-01,2021-08-01,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Karolinska University Hospital,PREDIX II HER2. Improving pre-operative systemic therapy for human epidermal growth factor receptor 2 (HER2) amplified breast cancer Part of a platform of translational phase 2 trials based on molecul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004457-24,0,0,0 2018-004458-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,Phase III clinical trial Oligometastatic and Oligorecurrent PROstate Cancer: enhancing patients’ selection by new ImagiNG biomarkers Studio clinico di fase III sul carcinoma prostatico oligometasta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004458-14,0,0,0 2018-004459-19,8,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,1,Novartis Pharma AG,"An open label, multi-center roll-over study to assess long-term effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004459-19,0,0,0 2018-004459-19,8,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,1,Novartis Farmacéutica S.A.,"An open label, multi-center roll-over study to assess long-term effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004459-19,0,0,0 2018-004460-63,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,South London and Maudsley NHS Foundation Trust,Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO): An Open Label Randomised Controlled Trial of Injectable Depot Maintenance Buprenorphine versus Standard-Of-Care Oral Maintenance Opioid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004460-63,0,0,0 2018-004460-63,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,King's College London,Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO): An Open Label Randomised Controlled Trial of Injectable Depot Maintenance Buprenorphine versus Standard-Of-Care Oral Maintenance Opioid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004460-63,0,0,0 2018-004464-57,4,2021-08-11,2021-08-11,2,0,0,0,0,0,4,0,0,2,0,0,0,0,0,"Klinik für Neurologie, Inselspital, Universitätsspital Bern",Solitaire™ With the Intention For Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaire™ Stent-retriever Thrombectomy in Acute Anterior Circulation Stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004464-57,1,0,0 2018-004464-57,4,2021-08-11,2021-08-11,2,0,0,0,0,0,4,0,0,2,0,0,0,0,0,Universtiy Hospital Bern,Solitaire™ With the Intention For Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaire™ Stent-retriever Thrombectomy in Acute Anterior Circulation Stroke,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004464-57,1,0,0 2018-004466-34,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Amsterdam UMC VUmc,Tau PET imaging in cognitively normal elderly subjects: A twin approach Tau PET-beeldvorming bij cognitief normale oudere proefpersonen: een tweeling benadering,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004466-34,0,0,0 2018-004467-31,1,2021-03-01,2021-03-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,3,,An exploratory study: Dendritic cells for immunotherapy of metastatic endometrial cancer patients Immunotherapie met dendritische cellen bij patiënten met een uitgezaaide baarmoederkanker.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004467-31,0,0,0 2018-004472-35,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Lofarma S.p.A.,"A single arm, open label, dose-escalation study of carbamylated monomeric grass pollen drops in patients with a history of allergic rhinoconjunctivitis Studio in aperto, singolo braccio, di increme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004472-35,0,0,0 2018-004473-27,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Ultragenyx Pharmaceutical Inc.,A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Glucose-6-Phosphatase (G6Pase) in Adults with Glycogen Stora...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004473-27,0,0,0 2018-004476-35,12,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A 48-week, 6-arm, randomized, double-blind, placebo-controlled multicenter trial to assess the safety and efficacy of multiple CFZ533 doses administered subcutaneously in two distinct populations of p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004476-35,0,0,0 2018-004479-11,10,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled phase II multi-center study of intravenous MBG453 added to hypomethylating agents in adult subjects with intermediate, high or very high risk myelodyspla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004479-11,0,0,0 2018-004479-11,10,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo-controlled phase II multi-center study of intravenous MBG453 added to hypomethylating agents in adult subjects with intermediate, high or very high risk myelodyspla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004479-11,0,0,0 2018-004480-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Národní ústav duševního zdraví,Psilocybin versus ketamine – fast acting antidepressant strategies in treatment-resistant depression Psilocybin versus ketamin – strategie rychlé antidepresivní odpovědi u deprese rezistentní k léč...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004480-31,0,0,0 2018-004482-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP),Tocolysis in the management of preterm premature rupture of membranes before 34 weeks of gestation: a double-blinded randomized controlled trial Tocolyse en cas de rupture prématurée des membranes...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004482-14,0,0,0 2018-004484-31,4,2021-06-10,2021-06-10,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Novo Nordisk A/S,Investigation of efficacy and safety of semaglutide s.c. once-weekly versus placebo in subjects with non-alcoholic steatohepatitis and compensated liver cirrhosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004484-31,1,0,0 2018-004486-13,7,2022-06-10,2022-06-10,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Qilu Pharmaceutical Co., Ltd.","A Randomized, Phase 3, Double-masked, Parallel-group, Multicenter Study to Compare Efficacy and Safety of QL1205 Versus Lucentis® in Subjects With Neovascular Age-related Macular Degeneration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004486-13,1,0,0 2018-004489-32,7,2020-12-08,2020-12-08,5,1,0,0,0,1,2,0,0,2,0,0,0,0,1,KalVista Pharmaceuticals Ltd,"A randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, an oral plasma kallikrein inhibitor, in the on-demand treatment of ang...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004489-32,1,0,0 2018-004489-32,7,2020-12-08,2020-12-08,5,1,0,0,0,1,2,0,0,2,0,0,0,0,1,KalVista Pharmaceuticals Ltd.,"A randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, an oral plasma kallikrein inhibitor, in the on-demand treatment of ang...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004489-32,1,0,0 2018-004490-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INSTITUT CLAUDIUS REGAUD,"A multicentric Phase II, open-label study evaluating the efficacy of the combination of hypofractionated stereotactic radiation therapy with the anti-PDL1 immune checkpoint inhibitor Durvalumab in NSC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004490-27,0,0,0 2018-004491-35,2,2019-11-13,2019-11-13,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Incyte Corporation,"A Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004491-35,0,0,0 2018-004492-12,1,2020-02-07,2020-02-07,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"SCYNEXIS, Inc.","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects with Acute Vulvovaginal Candidias...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004492-12,0,0,0 2018-004494-27,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,Landeskrankenhaus Salzburg,pilotstudy- efficacy of infectoscab 5% creme in patients with scabies Pilotstudie- Untersuchung zur Wirksamkeit von Infectoscab 5%® Creme bei Patienten mit Skabies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004494-27,0,0,0 2018-004496-12,6,2020-06-26,2022-06-20,2,0,0,0,0,2,0,0,0,2,1,0,0,0,1,"Marinus Pharmaceuticals, Inc.","A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)- related epilepsy followed by long-term open-label treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004496-12,1,0,0 2018-004496-12,6,2020-06-26,2022-06-20,2,0,0,0,0,2,0,0,0,2,1,0,0,0,1,"Marinus Pharmaceuticals, Inc","A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)- related epilepsy followed by long-term open-label treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004496-12,1,0,0 2018-004497-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ITALIAN SARCOMA GROUP,"Phase 2 randomized trial of trabectedin + olaparib vs. trabectedin in advanced, metastatic or unresectable soft tissue sarcoma after failure of standard treatments Studio randomizzato di fase II pe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004497-10,0,0,0 2018-004499-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona,"Study to assess bone health with bone mineral density, bone microarchitecture and bone tissue quality after switching from a TDF regimen to Bictegravir-TAF-FTC Estudio para evaluar la salud ósea co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004499-36,0,0,0 2018-004502-26,1,,,0,1,0,0,0,0,2,0,1,1,0,0,0,1,1,Przedsiębiorstwo Produkcji Farmaceutycznej (P.P.F.)HASCO-LEK S.A.,"""Randomized, double-blind, cross-over efficacy and safety study based on the pharmacodynamic model of topical use of the new combination gel containing diphenhydramine hydrochloride 20 mg/g and lidoca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004502-26,0,0,0 2018-004505-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,A phase 2a study on the anti-tumoral effect of cannabis oil (THC 10% / CBD 5%) in patients with advanced untreatable hepatocellular carcinoma Een fase 2a studie naar het anti-tumorigene effect van...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004505-34,0,0,0 2018-004512-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasme University Hospital,Effect of dexmedetomidine vs 0.9% sodium chloride on Nol-Index guided remifentanil analgesia: a double-blinded bicenter randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004512-22,0,0,0 2018-004515-45,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación GECP,A randomized phase II study of neo-adjuvant chemo/immunotherapy versus chemotherapy alone for the treatment of locally advanced and potentially resectable non-small cell lung cancer (NSCLC) patients ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004515-45,0,0,0 2018-004519-31,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Sanofi,"Randomized, placebo-controlled, clinical trial to evaluate the efficacy of probiotic Bacillus clausii in the treatment of pediatric patients with irritable bowel syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004519-31,0,1,1 2018-004520-10,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,0,National Cancer Institute (NCI),"2018-004520-10 A Phase II Study of Sunitinib (NSC# 736511, IND# 74019) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004520-10,0,1,1 2018-004522-29,1,,,0,0,0,1,0,3,1,0,0,3,0,0,0,0,0,University College London,Phase Ib/II trial of Histone Deacetylase Inhibitor CXD101 in combination with Programmed Cell Death Protein-1 Inhibitor Pembrolizumab for relapsed or refractory Diffuse Large B-cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004522-29,0,0,0 2018-004523-36,1,2021-08-16,2021-08-16,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,University Clinics Tübingen,Safety and protective efficacy of a simplified Plasmodium falciparum sporozoite Chemoprophylaxis Vaccine (PfSPZ-CVac) regimen in healthy malaria-naïve adults in Germany Sicherheit und Wirksamkeit ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004523-36,0,0,0 2018-004529-96,5,2020-11-09,2020-11-09,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novo Nordisk A/S,Efficacy and safety of semaglutide 2.0 mg s.c. once-weekly compared to semaglutide 1.0 mg s.c. once-weekly in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004529-96,0,0,0 2018-004530-14,14,2022-05-24,2022-05-24,8,0,1,0,0,2,3,0,0,2,0,0,0,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004530-14,1,0,0 2018-004530-14,14,2022-05-24,2022-05-24,8,0,1,0,0,2,3,0,0,2,0,0,0,0,1,: Boehringer Ingelheim RCV GmbH & Co KG,"A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004530-14,1,0,0 2018-004530-14,14,2022-05-24,2022-05-24,8,0,1,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim France,"A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004530-14,1,0,0 2018-004530-14,14,2022-05-24,2022-05-24,8,0,1,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim Finland Ky,"A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004530-14,1,0,0 2018-004530-14,14,2022-05-24,2022-05-24,8,0,1,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim Limited,"A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004530-14,1,0,0 2018-004530-14,14,2022-05-24,2022-05-24,8,0,1,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004530-14,1,0,0 2018-004530-14,14,2022-05-24,2022-05-24,8,0,1,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim BV,"A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004530-14,1,0,0 2018-004530-14,14,2022-05-24,2022-05-24,8,0,1,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim Norway KS,"A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004530-14,1,0,0 2018-004530-14,14,2022-05-24,2022-05-24,8,0,1,0,0,2,3,0,0,2,0,0,0,0,1,SCS Boehringer Ingelheim Comm.V,"A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004530-14,1,0,0 2018-004530-14,14,2022-05-24,2022-05-24,8,0,1,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004530-14,1,0,0 2018-004530-14,14,2022-05-24,2022-05-24,8,0,1,0,0,2,3,0,0,2,0,0,0,0,1,,"A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004530-14,1,0,0 2018-004530-14,14,2022-05-24,2022-05-24,8,0,1,0,0,2,3,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co. KG,"A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004530-14,1,0,0 2018-004530-14,14,2022-05-24,2022-05-24,8,0,1,0,0,2,3,0,0,2,0,0,0,0,1,"Boehringer Ingelheim España, S.A.","A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004530-14,1,0,0 2018-004530-14,14,2022-05-24,2022-05-24,8,0,1,0,0,2,3,0,0,2,0,0,0,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda","A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with ninted...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004530-14,1,0,0 2018-004532-30,2,2022-04-27,2022-04-27,2,0,0,0,0,0,3,0,0,1,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"Single-arm, Open-label Extension to a Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004532-30,0,0,0 2018-004532-30,2,2022-04-27,2022-04-27,2,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Janssen-Cilag International NV,"Single-arm, Open-label Extension to a Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004532-30,0,0,0 2018-004534-15,1,2020-05-04,2020-05-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lateral Pharma Pty Ltd,A Phase IIa study of the efficacy and safety of oral LAT8881 in neuropathic pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004534-15,0,0,0 2018-004536-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,Efficacy and tolerance of the association of MTX and phototherapy versus phototherapy in adults with progressive vitiligo : a randomized double blind prospective study (METVI) Efficacité et toléran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004536-29,0,0,0 2018-004539-54,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fraunhofer Fraunhofer Gesellschaft for its Fraunhofer Institute for Molecular Biology and Applied Ecology IME,Capability of Tofacitinib or Etanercept to accelerate clinical relevant tapering of non-steroidal anti-inflammatory drugs and treat-to-target guided de-escalation of corticosteroids in patients with a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004539-54,0,0,0 2018-004543-24,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Provincia Religiosa di S.Pietro Ordine Ospedaliero San Giovanni di Dio Fatebenefratelli,Intestinal preparation with new 1 L Peg + Asc solution or with gold standard 4 L Peg in split dose. Multicenter randomized controlled trial (OVER). Preparazione intestinale con la nuova soluzione 1...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004543-24,0,0,0 2018-004553-25,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"Investigator- and subject-blinded, randomized, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and efficacy of CFZ533 in pediatric and young adults with new onset type 1 di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004553-25,0,0,0 2018-004553-25,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"Investigator- and subject-blinded, randomized, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and efficacy of CFZ533 in pediatric and young adults with new onset type 1 di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004553-25,0,0,0 2018-004555-21,3,2022-01-27,2022-01-27,1,0,0,0,0,0,2,0,0,1,1,0,0,0,1,ARRAY BIOPHARMA INC.,"A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004555-21,0,0,0 2018-004555-21,3,2022-01-27,2022-01-27,1,0,0,0,0,0,2,0,0,1,1,0,0,0,1,Array BioPharma Inc.,"A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004555-21,0,0,0 2018-004557-24,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,"Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel",Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004557-24,0,0,0 2018-004558-30,4,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz,"A 3-arm, randomized, open-label, parallel active controlled, multicenter international study to compare the response of ultrasound-assessed synovitis to baricitinib, alone and combined with methotrexa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004558-30,0,0,0 2018-004562-33,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"University Heidelberg, Med. Fac. repr. by University Hospital and its Commercial Managing Director","A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or ref...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004562-33,0,0,0 2018-004563-31,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Reims,Cell therapy in Critical Limb Ischemia by implantation of allogeneic umbilical cord-derived mesenchymal stem cells Thérapie cellulaire allogénique de l’ischémie critique des membres inférieurs par ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004563-31,0,0,0 2018-004564-59,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Heidelberg University,WITH PONATINIB ON THE TRACK FOR TREATMENT-FREE-REMISSION IN CHRONIC MYELOID LEUKEMIA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004564-59,0,0,0 2018-004565-14,19,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AMGEN INC.,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004565-14,0,0,0 2018-004565-14,19,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Amgen Inc.,"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004565-14,0,0,0 2018-004567-31,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"EXELIXIS, INC.","A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Meta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004567-31,0,0,0 2018-004567-31,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Exelixis, Inc.","A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Meta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004567-31,0,0,0 2018-004568-72,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Astex Pharmaceuticals, Inc.","A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects with Advanced Solid Tumors Estudio en fase I/II de la seguridad, la farmacocinética y la actividad de ASTX029 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004568-72,0,0,0 2018-004571-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ITALIAN SARCOMA GROUP,"ERibulin in Advanced Solitary fibrous tumor, an ItaliaN sarcoma Group phase II study (ERASING) Tumore Fibroso solitario: studio di fase II su eribulina in pazienti con malattia avanzata",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004571-12,0,0,0 2018-004572-35,4,2020-03-06,2020-03-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Cara Therapeutics, Inc.","An Open-Label, Multicenter Study to Evaluate the Safety and Effectiveness of Intravenous CR845 in Hemodialysis Patients with Moderate-to-Severe Pruritus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004572-35,0,0,0 2018-004572-35,4,2020-03-06,2020-03-06,4,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Cara Therapeutics INC,"An Open-Label, Multicenter Study to Evaluate the Safety and Effectiveness of Intravenous CR845 in Hemodialysis Patients with Moderate-to-Severe Pruritus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004572-35,0,0,0 2018-004575-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,"DOMEC - phase II trial of Durvalumab (MEDI4736) and Olaparib in Metastatic/recurrent Endometrial Cancer, a DGOG trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004575-12,0,0,0 2018-004579-11,4,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE I/II, MULTICENTER, OPEN-LABEL, MULTI-ARM STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF IDASANUTLIN IN COMBINATION WITH EITHER CHEMOTHERAPY OR VENETO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004579-11,0,0,0 2018-004580-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Oslo University Hospital,Comparative effectiveness of intestinal microbiota versus vancomycin for primary Clostridium difficile infection – randomized trials.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004580-31,0,0,0 2018-004581-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Instituto Hispalense de Pediatría,"An open-label Phase IV trial to evaluate the immunogenicity and safety of Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004581-34,0,0,0 2018-004587-61,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medical Center,Deep profiling of lipid changes in patients with active ulcerative colitis treated with either tofacitinib or infliximab Profileren van lipidenveranderingen in patienten met actieve colitis ulceros...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004587-61,0,0,0 2018-004588-30,1,2020-06-05,2020-06-05,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Multicenter, Randomized, Open-label, Parallel group, Functionality, and Performance Study of an Accessorized Pre-filled Syringe and Autoinjector with Home-administered Subcutaneous Tezepelumab in A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004588-30,0,0,0 2018-004590-27,5,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Gedeon Richter Plc,"2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004590-27,0,0,0 2018-004591-35,1,,,0,1,1,0,0,1,1,0,0,4,0,0,0,0,0,National Cancer Institute Cancer Therapy Evaluation Program (NCI/CTEP),"A PHASE 1 STUDY OF XL184 (CABOZANTINIB, IND# 116059) IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004591-35,0,1,1 2018-004593-98,7,2022-08-16,2022-08-16,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT,"An Open Label Randomized Phase 2 Trial of SAR439859, Versus Endocrine Monotherapy as per Physician’s Choice in Patients with Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004593-98,1,0,0 2018-004593-98,7,2022-08-16,2022-08-16,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"An Open Label Randomized Phase 2 Trial of SAR439859, Versus Endocrine Monotherapy as per Physician’s Choice in Patients with Estrogen Receptor-positive, HER2-Negative Locally Advanced or Metastatic Br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004593-98,1,0,0 2018-004604-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ghent University Hospital,Myo-inositol versus clomiphene citrate as first line treatment for ovulation induction in PCOS Myo-inositol versus clomifeencitraat als eerstelijnsbehandeling voor ovulatie-inductie bij PCOS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004604-20,0,0,0 2018-004605-57,1,,,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,Reade,"Concentration-guided dose reduction versus standard dosing in tocilizumab-treated rheumatoid arthritis patients: a randomised, multicenter, non-inferiority trial (TODORA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004605-57,0,0,0 2018-004608-21,11,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,AMGEN INC.,"Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents > = 2 to < 18 Years of age With Secondary Hyperpa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004608-21,0,0,0 2018-004608-21,11,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,Amgen Inc.,"Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents > = 2 to < 18 Years of age With Secondary Hyperpa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004608-21,0,0,0 2018-004611-50,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust,"A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of rituximab in treating de novo or relapsing NS in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004611-50,0,0,0 2018-004614-18,16,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Eli Lilly and Company,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004614-18,0,0,0 2018-004614-18,16,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Lilly S.A.,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004614-18,0,0,0 2018-004614-18,16,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004614-18,0,0,0 2018-004618-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region Örebro län,Rituximab - Immunotherapy for Schizophrenia spectrum disorder in adults. An open pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004618-17,0,0,0 2018-004619-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region Örebro län,Rituximab - Immunotherapy for Obsessive-Compulsive Disorder. An open pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004619-28,0,0,0 2018-004621-89,2,2021-02-04,2021-02-04,1,0,0,0,1,0,2,0,0,1,1,0,1,0,1,"Lyra Therapeutics, Inc.","A Phase II, Randomized, Blinded, Sham Procedure-Controlled, Parallel-Group Trial to Evaluate the Efficacy, Safety and Tolerability of LYR-210 in Adult Subjects with Chronic Sinusitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004621-89,0,0,0 2018-004622-28,5,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine – the REBUILD-2 Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004622-28,0,0,0 2018-004622-28,5,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine – the REBUILD-2 Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004622-28,0,0,0 2018-004623-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Uppsala University Hospital,"A MolEcularly Guided Anti-Cancer Drug Off-Label Trial – a multicenter, basket and umbrella explorative trial on the efficacy and safety of molecular profile selected commercially available targeted a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004623-36,0,0,0 2018-004624-11,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Region Östergötland,A non-randomized experimental study to optically study pharmacodynamic responses in the delivery of vasoactive substances to the skin through iontophoresis in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004624-11,0,0,0 2018-004626-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,SymbioPharm GmbH,"Randomized, double-blind, placebo-controlled, multi-centre trial to evaluate the efficacy, safety and tolerability of oral treatment with living bacteria of E. coli DSM 17252 (Symbioflor®2) in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004626-28,0,0,0 2018-004641-16,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Birmingham,"Letrozole or Clomifene, with or without metformin, for ovulation induction in women with polycystic ovary syndrome: a 2x2 factorial design randomised trial (The LOCI trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004641-16,0,0,0 2018-004645-16,3,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004645-16,0,0,0 2018-004645-16,3,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,"GlaxoSmithKline, S.A.","A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004645-16,0,0,0 2018-004648-44,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medica Scientia Innovation Research S.L (MEDSIR),"A multicentre, Open-Label, Non-comparative, three-arm, phase IIa trial of Ipatasertib (GDC-0068) in Combination with non-Taxane chemotherapy agents for taxane-pretre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004648-44,0,0,0 2018-004651-20,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Reata Pharmaceuticals, Inc.",A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004651-20,0,0,0 2018-004651-20,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"REATA PHARMACEUTICALS, INC.",A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004651-20,0,0,0 2018-004652-38,5,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004652-38,0,0,0 2018-004653-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Odense Universitets Hospital,Impact of an Angiotensin Receptor Blocker in Aortic Stenosis – A Randomized Controlled Trial Betydning af angiotensin receptor blocker i aortastenose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004653-24,0,0,0 2018-004654-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación GECP,A phase II open-label study of Atezolizumab in combination with bevacizumab as first line treatment for locally advanced or metastatic high-intermediate tumour mutation burden (TMB) selected non-squam...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004654-17,0,0,0 2018-004655-20,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS,CLINICAL EFFICACY OF INHIBITION OF ORGAN DYSFUNCTION THROUGH BERMEKIMAB IN SYSTEMIC SCLEROSIS: A PROOF-OF-CONCEPT DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL (THE LIGHT TRIAL) Η ΚΛΙΝΙΚΗ ΑΠΟΤΕΛΕΣΜΑΤΙΚΟΤΗ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004655-20,0,0,0 2018-004662-33,3,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Imperial College London,NOVEL: Nonavalent HPV vaccine after local conservative treatment for cervical pre-invasive disease - a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004662-33,0,0,0 2018-004667-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ENTE OSPEDALIERO OSPEDALI GALLIERA,Diagnostic and clinical value of 64CuCl2 in HGG/DIPG Ruolo diagnostico e aspetti dosimetrici del 64CuCl2 nei Gliomi infiltranti ad alto grado dell’età pediatrica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004667-30,0,0,0 2018-004669-16,1,2020-11-26,2020-11-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc,"A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004669-16,0,0,0 2018-004670-10,7,2021-01-14,2021-01-14,4,0,1,0,0,1,3,0,0,2,1,0,0,0,1,"Eidos Therapeutics, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004670-10,1,0,0 2018-004670-10,7,2021-01-14,2021-01-14,4,0,1,0,0,1,3,0,0,2,1,0,0,0,1,"Eidos Therapeutics, Inc","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004670-10,1,0,0 2018-004672-35,1,2022-07-16,2022-07-16,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,"Institution for Clinical Science, Karolinska Institutet",Open heart surgery – does it have to hurt that much? PACS – Parasternal After Cardiac Surgery. A prospective randomised study to assess the analgesic effect of a continuous bilateral parasternal block...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004672-35,0,0,0 2018-004674-94,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Riga Stradiņš University,Open-label Phase IV Study to Investigate Broad-and Cross-neutralizing Antibodies after Primary Vaccination with Two Different TBE Vaccines,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004674-94,0,0,0 2018-004675-13,3,2022-04-23,2022-04-23,2,0,0,0,0,2,3,0,0,1,0,0,0,0,1,Octapharma AG,CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF WILATE DURING PROPHYLAXIS IN PREVIOUSLY TREATED PATIENTS WITH VON WILLEBRAND DISEASE (VWD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004675-13,0,0,0 2018-004676-35,3,2021-03-09,2021-03-09,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Immunovant Sciences GmbH,"A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients with Active, Moderate to Severe Graves’ Ophthalmopathy Estudio en fase IIb, ale...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004676-35,0,0,0 2018-004677-27,2,2021-04-27,2021-04-27,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Abivax,"Phase IIa randomized, double blind, placebo controlled, parallel group, multiple dose study on ABX464 in combination with methotrexate (MTX), in patients with moderate to severe active Rheumatoid Arth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004677-27,0,0,0 2018-004679-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Division of Thoracic and Hyperbaric Surgery, Medical University Graz",Hyperbaric Oxygenation (HBO) in traumatic spinal cord injury - prospective study with 100 patients. Hyperbare Sauerstofftherapie bei traumatischen Rückenmarksverletzungen - prospektive Studie mit 1...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004679-11,0,0,0 2018-004680-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Lene Ringholm,A randomised controlled trial comparing the effect of the faster-acting insulin analog - insulin Fiasp® – versus insulin Novorapid® in the treatment of women with type 1 or type 2 diabetes during preg...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004680-31,0,0,0 2018-004685-33,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,azM,Surgical excision versus photodynamic therapy and topical 5-fluorouracil in treatment of Bowen’s disease: a multicenter randomized controlled trial (Kosten)effectiviteit van chirurgische excisie v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004685-33,0,0,0 2018-004686-13,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Octapharma Pharmazeutika Produktionsges.m.b.H.,"An Open-label, Multicenter, Post-Marketing Requirement (PMR) Study to Investigate the Safety, Tolerability and Efficacy of Octaplas in the Management of Pediatric Patients Who Require Replacement of M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004686-13,0,1,1 2018-004687-64,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004687-64,0,0,0 2018-004688-30,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine Plus Cisplatin Versus Placebo in Combination with Gemcitabine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004688-30,0,0,0 2018-004688-30,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine Plus Cisplatin Versus Placebo in Combination with Gemcitabine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004688-30,0,0,0 2018-004689-32,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Shire Human Genetic Therapies, Inc.","A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects with Fabry Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004689-32,0,0,0 2018-004694-27,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004694-27,0,0,0 2018-004694-27,8,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004694-27,0,0,0 2018-004695-35,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004695-35,0,0,0 2018-004695-35,8,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004695-35,0,0,0 2018-004696-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA,"Clinical, Instrumental and Histological evaluation of the combined use of Onabotulinumtoxin A and hyaluronic acid fillers in patients with facial paralysis Valutazione Clinica, Strumentale ed Istol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004696-12,0,0,0 2018-004700-19,1,2020-02-18,2020-02-18,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Merck Healthcare KGaA,"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with an Interferon Beta 1a (Avonex®), in Participants with Relapsing M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004700-19,0,0,0 2018-004701-11,1,2020-02-18,2020-02-18,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Merck Healthcare KGaA,"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with an Interferon Beta 1a (Avonex®), in Participants with Relapsing M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004701-11,0,0,0 2018-004704-19,4,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc","A Phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosoco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004704-19,0,1,0 2018-004705-26,4,2021-10-06,2021-10-06,2,1,0,0,0,0,4,0,0,2,0,0,0,0,1,SANOFI-AVENTIS GROUPE,A randomized double blind placebo controlled study evaluating the effect of dupilumab on sleep in adult patients with moderate to severe atopic dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004705-26,1,0,0 2018-004705-26,4,2021-10-06,2021-10-06,2,1,0,0,0,0,4,0,0,2,0,0,0,0,1,Sanofi Aventis Groupe,A randomized double blind placebo controlled study evaluating the effect of dupilumab on sleep in adult patients with moderate to severe atopic dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004705-26,1,0,0 2018-004707-40,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Sanofi Pasteur SA,"Verorab® immunogenicity and safety after a one week, 4-site, intradermal (ID) post-exposure prophylaxis regimen (4-4-4-0-0) followed by a one visit, 4-site, ID booster at five years.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004707-40,0,1,1 2018-004708-21,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Given as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and in HIV-Exposed Uninfected Infan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004708-21,0,1,1 2018-004712-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GERCOR,"Peri-operative association of immunotherapy (pre-operative association of nivolumab and ipilimumab, post-operative nivolumab alone) in localized microsatellite instability (MSI) and/or deficient misma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004712-22,0,0,0 2018-004715-41,5,2021-06-23,2021-06-23,4,0,0,0,0,0,2,0,0,1,1,1,1,0,1,"Odonate Therapeutics, Inc.","A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004715-41,0,0,0 2018-004720-11,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004720-11,0,0,0 2018-004720-11,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,",A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004720-11,0,0,0 2018-004721-88,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Met...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004721-88,0,0,0 2018-004723-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU de Brest,TEP/TDM pulmonaire de ventilation-perfusion au Gallium68 pour le diagnostic de l'embolie pulmonaire : une étude diagnostique versus angioscanner thoracique. TEP/TDM pulmonaire de ventilation-perfu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004723-36,0,0,0 2018-004724-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medical Center,"Clinical effectiveness of 2 treat to target strategies, mimicking standard care compared to early secukinumab for the treatment of Moderate to Severe Psoriatic Arthritis: a parallel group randomised c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004724-11,0,0,0 2018-004725-86,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,UCB Biopharma SRL,"A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004725-86,0,0,0 2018-004727-37,5,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Advanced Accelerator Applications International SA,"A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004727-37,0,0,0 2018-004729-97,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Dutch Growth Research Foundation,"Randomized, controlled growth hormone study in children and adolescents with a Prader-Willi-like phenotype, followed by a two year open-label growth hormone study - effects on body composition, growth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004729-97,0,0,0 2018-004730-15,4,2020-10-19,2020-10-29,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN5069 in Patients with Pain due to Osteoarthritis of the Knee",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004730-15,0,0,0 2018-004731-76,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Genzyme Corporation,Long-term extension safety and efficacy study of SAR442168 in participants with relapsing multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004731-76,0,0,0 2018-004732-30,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Sussex,"A Phase IV, Randomised, Open-Label Pilot Study to Evaluate Switching from Protease-Inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in Integrase Inhibit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004732-30,0,0,0 2018-004734-15,1,2022-03-29,2022-03-29,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Universitätsklinikum Erlangen,EBIO – Enthesitis biopsy study EBIO - Enthesitis Biopsie Studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004734-15,0,0,0 2018-004738-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Red Andaluza de Diseño y Traslación de Terapias Avanzadas - Fundación Pública Andaluza Progreso y Salud,PHASE II CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICACY OF A TISSUE ENGINEERED AUTOLOGOUS SKIN SUBSTITUTE RECONSTRUCTIVE SURGERY FOR BASAL CELL CARCINOMA. ENSAYO CLINICO FASE II PARA EVALUAR LA ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004738-14,0,0,0 2018-004739-58,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,EISAI LIMITED,"A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease Studio di ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004739-58,0,0,0 2018-004739-58,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Eisai Limited,"A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease Studio di ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004739-58,0,0,0 2018-004740-36,3,2021-01-15,2021-01-15,2,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"PTC Therapeutics, Inc.",A MULTICENTER RANDOMIZED PLACEBO-CONTROLLED PHASE 3 STUDY ON THE SAFETY AND EFFICACY OF DEFLAZACORT (EMFLAZA®) IN SUBJECTS WITH LIMB-GIRDLE MUSCULAR DYSTROPHY 2I (LGMD2I,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004740-36,0,0,0 2018-004742-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IFCT,"A phase II single-arm trial evaluating safety and efficacy of Durvalumab in ECOG Performance Status 2-3, treatment-naive, patients with stage IV Non-Small Cell Lung Cancer (NSCLC) and high PD-L1 tumo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004742-42,0,0,0 2018-004744-31,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Trevi Therapeutics, Inc.","A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis With Nalbuphine ER Tablets for the Treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004744-31,0,0,0 2018-004745-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,Detection of Early Esophageal Cancer by Near-Infrared Fluorescence molecular Endoscopy using Bevacizumab-800CW,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004745-17,0,0,0 2018-004750-21,1,2020-10-28,2020-10-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda","A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Adult Subjects With Chronic Complex Regional Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004750-21,0,0,0 2018-004751-20,2,2021-08-23,2021-08-23,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Polpharma Biologics S.A.,Antelope: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004751-20,0,0,0 2018-004756-38,1,2022-07-11,2022-07-11,1,0,0,0,1,0,2,0,0,1,0,0,0,0,0,Institut de Cancérologie Lucien Neuwirth,Study of thromboelastography during tranexamic acid treatment in preventing bleeding in patients with haematological malignancies presenting severe thrombocytopenia (TTRAP-bleeding) Evolution du th...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004756-38,0,0,0 2018-004758-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA,A PHASE II STUDY OF CAPECITABINE PLUS CONCOMITANT RADIATION THERAPY FOLLOWED BY DURVALUMAB (MEDI4736) AS PREOPERATIVE TREATMENT IN RECTAL CANCER STUDIO DI FASE II DEL TRATTAMENTO PREOPERATORIO CON...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004758-39,0,0,0 2018-004762-33,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,InfectoPharm Arzneimittel und Consilium GmbH,"Prospektive, randomisierte, Nicht-Behandlungs-kontrollierte, Untersucher-verblindete, Multizenter-Studie zur Prophylaxe von frühkindlichen Symptomen der Atopischen Dermatitis bei Hochrisiko-Kindern du...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004762-33,0,0,0 2018-004767-31,6,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Celgene Corporation,"A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004767-31,0,0,0 2018-004767-31,6,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,CELGENE CORPORATION,"A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination with Standard Treatments in Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004767-31,0,0,0 2018-004768-69,4,2022-03-29,2022-03-29,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Incyte Corporation,"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004768-69,1,0,0 2018-004768-69,4,2022-03-29,2022-03-29,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,INCYTE CORPORATION,"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004768-69,1,0,0 2018-004774-97,12,2022-04-11,2022-04-11,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Rigel Pharmaceuticals, Inc.","A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004774-97,1,0,0 2018-004774-97,12,2022-04-11,2022-04-11,7,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"RIGEL PHARMACEUTICALS, INC.","A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004774-97,1,0,0 2018-004775-13,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Sydnexis, Inc.","A Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the Treatment of Myopia in Children",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004775-13,0,0,0 2018-004778-81,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IKF Klinische Krebsforschung GmbH,"A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004778-81,0,0,0 2018-004785-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Allergan Pharmaceuticals International Limited,"A 12-month, Prospective, Open-label, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Treatment Naïve Patients (according to standard clinical prac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004785-33,0,0,0 2018-004788-30,6,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,4SC AG,"A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004788-30,0,0,0 2018-004791-36,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,JSC BIOCAD,International Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial Evaluating Efficacy and Safety Of BCD-100 in combination with Pemetrexed+Cisplatin/Carboplatin Compared to Placebo i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004791-36,0,0,0 2018-004792-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Neurofix S.L.,"A randomized, double-blind, placebo controlled, parallel group, multicentric, phase IIa clinical trial to evaluate the safety, tolerability and therapeutic efficacy of daily oral treatment with NFX88...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004792-13,0,0,0 2018-004793-95,1,2020-01-14,2020-01-14,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Aarhus University Hospital,Analgesic efficacy of repetitive nerve blockade after major ankle and hindfoot surgery - A feasibility study Analgetisk effekt af repetitiv nerveblokade efter stor ankelkirurgi - et feasibility stu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004793-95,0,0,0 2018-004798-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis,Track and treat in NSCLC (TATIN) – ctDNA guided treatment of early resistance to targeted treatment in patients with EGFR positive NSCLC Monitoren en behandelen van vroege resistentie tijdens osime...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004798-29,0,0,0 2018-004800-20,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Rad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004800-20,0,0,0 2018-004800-20,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Rad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004800-20,0,0,0 2018-004800-20,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Rad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004800-20,0,0,0 2018-004802-24,1,2020-06-14,2020-06-14,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Radboud University Nijmegen Medical Centre,Optimizing timing of glucocorticoid treatment in children with congenital adrenal hyperplasia Vermijden van over en onderbehandeling door optimalisatie van de timing van cortisol behandeling bij ki...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004802-24,0,0,0 2018-004804-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,"A Randomized, Double-blind, Placebo-controlled Trial on the Prevention of Chronic Postoperative Pain after Inguinal Hernia and Knee Surgery by Postoperative Treatment with Tapentadol.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004804-21,0,0,0 2018-004809-58,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Institute for study, research, education and therapy of vascular, heart, brain and kidney nosologies (I.N.A.K.E.N)",Comparative study of eplerenone-based treatment strategy versus irbesartan-based blood pressure lowering in obese hypertensive patients (HEBRO Study) Συγκριτική μελέτη της θεραπευτικής στρατηγικής ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004809-58,0,0,0 2018-004813-42,7,2022-08-15,2022-08-29,5,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A randomized, open-label, phase II study of canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in subjects with resectable non-small cell lung cancer (CANOPY-N)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004813-42,1,0,0 2018-004813-42,7,2022-08-15,2022-08-29,5,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, open-label, phase II study of canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in subjects with resectable non-small cell lung cancer (CANOPY-N)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004813-42,1,0,0 2018-004815-33,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Ascendis Pharma Bone Diseases A/S,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administere...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004815-33,0,0,0 2018-004815-33,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Ascendis Pharma Bone Disease A/S,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administere...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004815-33,0,0,0 2018-004826-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Oncology, Herlev & Gentofte Hospital","A Single Center, Randomized, Phase II Study of the combination of Cisplatin and Gemcitabine with or without Tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004826-27,0,0,0 2018-004827-36,6,2022-05-09,2022-05-09,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,INOTREM S.A.,"Efficacy, Safety and Tolerability of Nangibotide in Patients with Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection Study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004827-36,1,0,0 2018-004828-11,1,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,0,University Hospital of Montpellier,"Phosphodiesterase-type 5 inhibitors in adult and adolescent patients with univentricular heart disease: a multi-center, randomized, double blind phase III study Intérêt des inhibiteurs de la Phosph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004828-11,0,0,0 2018-004829-82,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Linköping University,Effects of the appetite-inducing hormone ghrelin on decision making in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004829-82,0,0,0 2018-004835-56,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo español mutidisciplinar en cáncer digestivo (GEMCAD),Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer Estudio en fase II de Durvalumab (MEDI4736) más terapia total neoadyuvante en el cánc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004835-56,0,0,0 2018-004837-34,5,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"Aeglea Biotherapeutics, Inc.","PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004837-34,0,0,0 2018-004837-34,5,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"Aeglea Biotherapeutics, Inc","PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004837-34,0,0,0 2018-004840-51,1,2020-10-15,2020-10-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"EIP Pharma, Inc.","A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004840-51,0,0,0 2018-004841-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE MELANOMA ONLUS,"A phase II randomized non-comparative study, with neoadjuvant plus adjuvant therapy with combination or sequence of vemurafenib, cobImetinib, and atezolizuMab in patients with high-risk, surgically re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004841-17,0,0,0 2018-004842-40,5,2021-10-04,2021-10-04,3,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Kaleido Biosciences,"A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004842-40,1,0,0 2018-004843-22,7,2020-06-24,2020-06-24,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc",A Phase 3 Study of Pembrolizumab in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Partici...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004843-22,0,0,0 2018-004843-22,7,2020-06-24,2020-06-24,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Merck Sharp & Dohme Corp.,A Phase 3 Study of Pembrolizumab in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Partici...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004843-22,0,0,0 2018-004843-22,7,2020-06-24,2020-06-24,4,1,0,0,0,0,3,0,0,1,1,0,1,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase 3 Study of Pembrolizumab in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Partici...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004843-22,0,0,0 2018-004844-43,6,2021-02-11,2021-02-11,4,1,0,0,0,0,4,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 4, Open-label, Single Arm Study to Evaluate the Safety and Tolerability of a Three-day Fosaprepitant Regimen Administered for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004844-43,1,0,0 2018-004845-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Lene Bæksgaard Jensen,LON-GAS TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without Bevacizumab in patients with platinum-refractory esophago-gastric adenocarcinoma. A randomized phase III study LON-GAS Et randomiseret fase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004845-18,0,0,0 2018-004852-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Dijon Bourgogne,"Benefit of a flash dose of corticosteroids in digestive surgical oncology: a randomized, double blind, placebo-controlled trial Intérêt d'une dose flash de corticoïdes dans la chirurgie des cancers...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004852-39,0,0,0 2018-004853-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Turku University Hospital,The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in treatment naive metastatic prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004853-26,0,0,0 2018-004854-12,1,2021-10-21,2021-10-21,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis,"An Open-label Single-arm Pharmacokinetic Trial, Investigating the Effect of CYP3A4 inhibitor Ritonavir on the Pharmacokinetics of Erlotinib Een open-label, eenarmige studie waarbij er wordt gekeke...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004854-12,0,0,0 2018-004869-14,1,2021-03-08,2021-03-08,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Dept. of hematology, Herlev Hospital",Peptide vaccination with PD-L1 and PD-L2 peptides in untreated chronic lymphatic leukemia. Peptidvaccination med PD-L1 og PD-L2 peptider til patienter med ubehandlet kronisk lymfatisk leukæmi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004869-14,0,0,0 2018-004871-11,1,2022-09-26,2022-09-26,1,0,0,0,0,0,2,0,0,1,1,1,0,0,1,Cardiorentis AG,"RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE ESCALATION STUDY OF ULARITIDE FOLLOWED BY A 42-HOUR INFUSION FOR THE TREATMENT OF ACUTE KIDNEY INJURY (AKI) IN PATIENTS POST CARDIAC SURGERY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004871-11,0,0,0 2018-004875-11,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,NOVARTIS FARMA S.P.A.,"A RandomizEd, double-blind, cross-over Study to assess Erenumab effecT on BRAIN networks function and structure in comparison to placebo in episodic migraine patients (RESET BRAIN) Studio randomizz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004875-11,0,0,0 2018-004878-99,8,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Incyte Biosciences International Sàrl,"An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004878-99,0,0,0 2018-004878-99,8,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,INCYTE BIOSCIENCES INTERNATIONAL SàRL,"An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004878-99,0,0,0 2018-004880-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Jordi Carratalà Fernández (Servicio de Enfermedades Infecciosas) del Hospital Universitario de Bellvitge,"Phase IV randomized, controlled, open and multicentre clinical trial with two parallel groups, to assess the impact of integral molecular tests in the antimicrobial use in community-acquired pneumonia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004880-29,0,0,0 2018-004885-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA SENESE,THE EFFECTS OF SWITCHING FROM DOLUTEGRAVIR/LAMIVUDINE/ABACAVIR (D/L/A) TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (B/F/TAF) IN PATIENTS WITH SUPPRESSED VIRAL LOAD ON NEUROPSYCHIATRIC SIDE EFFE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004885-32,0,0,0 2018-004886-15,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,IBSA INSTITUT BIOCHIMIQUE SA,"Evaluation of Treatment Satisfaction, Effectiveness and Tolerability in Subjects treated with Low-dose Diclofenac Epolamine Soft Capsules for Acute, Mild or Moderate Musculoskeletal Pain Valutazion...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004886-15,0,0,0 2018-004887-74,8,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Actelion Pharmaceuticals Ltd,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004887-74,0,0,0 2018-004887-74,8,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,ACTELION PHARMACEUTICALS LTD,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004887-74,0,0,0 2018-004888-31,4,,,0,0,0,0,0,1,0,0,0,3,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"Long Term Follow-Up of Participants Exposed to GSK3377794 (NYESO- 1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004888-31,0,0,0 2018-004888-31,4,,,0,0,0,0,0,1,0,0,0,3,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"Long Term Follow-Up of Participants Exposed to GSK3377794 (NYESO- 1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004888-31,0,0,0 2018-004888-31,4,,,0,0,0,0,0,1,0,0,0,3,0,0,0,0,1,GlaxoSmithKline research & development Ltd.,"Long Term Follow-Up of Participants Exposed to GSK3377794 (NYESO- 1c259 T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004888-31,0,0,0 2018-004889-34,14,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Novo Nordisk A/S,Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004889-34,0,0,0 2018-004889-34,14,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,NOVO NORDISK. S.P.A.,Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004889-34,0,0,0 2018-004890-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA,(A)nalysis of immunological (VA)riables in ex vivo (T)ofacitinib-treated human biopsies from (A)ctive ulcerative colitis patients to predict clinical (R)esponse (the AVATAR study). Analisi delle va...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004890-28,0,0,0 2018-004891-36,15,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,NOVO NORDISK. S.P.A.,Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004891-36,0,0,0 2018-004891-36,15,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Novo Nordisk A/S,Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004891-36,0,0,0 2018-004892-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE SANTA MARIA DELLA MISERICORDIA,"A randomized, double-blind, placebo controlled, multicentre study to evaluate the effect of safinamide on freezing of gait (FOG) in mid- to late-stage fluctuating PD patients Studio multicentrico r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004892-11,0,0,0 2018-004893-84,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Mental Health Center Glostrup,Cannabidiol for treatment of non-affective psychosis with comorbid cannabis use,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004893-84,0,0,0 2018-004926-26,8,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Provention Bio, Inc.","A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, anti-CD3 Monoclonal Antibody, in Chi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004926-26,0,0,0 2018-004946-41,2,,,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA OSPEDALI RIUNITI DI ANCONA,Personalized Versus Standardized Parenteral Nutrition for Preterm Infants With a Birth Weight Greater Than 1250 Grams: a Multicenter Randomized Phase IV Clinical Trial Nutrizione parenterale person...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004946-41,0,0,0 2018-004946-41,2,,,0,0,0,0,2,0,4,0,0,0,0,0,0,0,0,"Dr. Virgilio P. Carnielli,",Personalized Versus Standardized Parenteral Nutrition for Preterm Infants With a Birth Weight Greater Than 1250 Grams: a Multicenter Randomized Phase IV Clinical Trial Nutrizione parenterale person...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004946-41,0,0,0 2018-004967-30,1,,,0,0,0,0,1,0,4,0,0,3,0,0,0,0,0,University Hospital Southampton NHS Foundation Trust,IBD Reference and Biosimilar adalimumab CroSS over Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004967-30,0,0,0 2018-004986-15,1,2019-04-07,2019-04-07,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Aarhus University Hospital,Ultrasound-guided nerve block of the anterior femoral cutaneous nerves in healthy volunteers Ultralydsvejledt nerveblokade af de anteriore kutane grene fra n. femoralis hos raske forsøgspersoner,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-004986-15,0,0,0 2018-005006-62,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Albert Schweitzer hospital,Pharmacokinetics of Paracetamol before and after Roux-en-Y gastric bypass Farmacokinetiek van paracetamol voor en na Roux-en-Y gastric bypass,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-005006-62,0,0,0 2018-005026-39,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc,Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 months to 17 Years of Age,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-005026-39,0,1,1 2018-005027-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Ruprecht-Karls University Heidelberg Medical Faculty, represented by Heidelberg University Hospital",Improvement of functional Outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial IMPROVE CODEL: Verbesserung des funktionellen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-005027-16,0,0,0 2018-005028-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA,"A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-005028-40,0,0,0 2018-005030-38,10,2021-09-02,2021-09-02,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Relypsa, Inc., a Vifor Company","A Multicenter, Double-blind, Placebo controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin Angiotensin Aldosterone System ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-005030-38,1,0,0 2018-005030-38,10,2021-09-02,2021-09-02,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Vifor Pharma, Inc.","A Multicenter, Double-blind, Placebo controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin Angiotensin Aldosterone System ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-005030-38,1,0,0 2018-005030-38,10,2021-09-02,2021-09-02,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Relypsa Inc,"A Multicenter, Double-blind, Placebo controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin Angiotensin Aldosterone System ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-005030-38,1,0,0 2018-005030-38,10,2021-09-02,2021-09-02,6,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Relypsa, Inc.","A Multicenter, Double-blind, Placebo controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin Angiotensin Aldosterone System ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-005030-38,1,0,0 2018-005038-39,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Queen Mary University of London,"ChariotMS – A national (UK), multi-centre, randomised, double-blind, placebo-controlled (1:1) phase IIb efficacy trial with cost-utility analysis of cladribine tablets (3.5mg/kg over two years) in peo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-005038-39,0,0,0 2018-005046-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Radboud university medical center,Anakinra: Efficacy of interleukin-1 pathway inhibitor anakinra for the management of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-005046-10,0,0,0 2018-005086-39,4,2021-06-17,2021-09-27,3,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Landos Biopharma Inc.,"A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-005086-39,0,0,0 2019-000058-77,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Essen,Prospective Phase-II Trial of induction chemotherapy and chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed by surgery or definitive chemoradiation boost and consolidation durvalumab ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000058-77,0,0,0 2019-000060-20,2,2021-04-20,2021-04-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,HEXAL AG,"Efficacy and safety of acetylcysteine for the treatment of acute uncomplicated rhinosinusitis: a prospective, randomized, double-blind, placebo-controlled trial Wirksamkeit und Sicherheit von Acety...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000060-20,0,0,0 2019-000060-20,2,2021-04-20,2021-04-20,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Hexal AG,"Efficacy and safety of acetylcysteine for the treatment of acute uncomplicated rhinosinusitis: a prospective, randomized, double-blind, placebo-controlled trial Wirksamkeit und Sicherheit von Acety...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000060-20,0,0,0 2019-000061-20,4,2022-05-18,2022-05-18,2,0,0,0,0,1,2,0,0,2,1,0,0,0,1,BAYER AG,"An open-label, multicenter rollover study to provide continued treatment with anetumab ravtansine for participants with solid tumors who were enrolled in previous Bayer-sponsored studies.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000061-20,1,0,0 2019-000061-20,4,2022-05-18,2022-05-18,2,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Bayer AG,"An open-label, multicenter rollover study to provide continued treatment with anetumab ravtansine for participants with solid tumors who were enrolled in previous Bayer-sponsored studies.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000061-20,1,0,0 2019-000063-24,2,2021-12-02,2021-12-02,2,1,0,0,0,0,3,0,0,1,0,0,0,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000063-24,0,0,0 2019-000064-21,3,2020-07-24,2020-07-24,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Sanofi Aventis Groupe (SAG),"A randomized, open-label, active comparator, 2-arm, prospective study to assess the glycosphingolipid clearance and clinical benefits of agalsidase beta (Fabrazyme®) in male patients with classic Fabr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000064-21,0,0,0 2019-000065-20,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,1,Sanofi Aventis Groupe (SAG),"A randomized, open-label, active comparator, 2-arm, prospective study to assess the glycosphingolipid clearance and clinical effects of switching to agalsidase beta (Fabrazyme®) versus continuing on m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000065-20,0,0,0 2019-000068-86,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Arrowhead Pharmaceuticals, Inc.","A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000068-86,0,0,0 2019-000069-19,13,2021-02-27,2022-01-27,12,1,0,0,0,0,4,0,0,2,0,0,0,0,1,Merck KGaA,Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Par...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000069-19,1,0,0 2019-000069-19,13,2021-02-27,2022-01-27,12,1,0,0,0,0,4,0,0,2,0,0,0,0,1,MERCK KGAA,Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Par...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000069-19,1,0,0 2019-000069-19,13,2021-02-27,2022-01-27,12,1,0,0,0,0,4,0,0,2,0,0,0,0,1,"Merck, S.L.",Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment with Cladribine Tablets for Multiple Sclerosis: An Exploratory Phase IV Ambispective Study of Patients Who Previously Par...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000069-19,1,0,0 2019-000099-41,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Edinburgh,Motor Neurone Disease Systematic Multi-arm Adaptive Randomised Trial (MND-SMART),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000099-41,0,0,0 2019-000099-41,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Lothian,Motor Neurone Disease Systematic Multi-arm Adaptive Randomised Trial (MND-SMART),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000099-41,0,0,0 2019-000104-15,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,CellCentric Ltd,An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies. Estudio abierto de fase I/IIa para evaluar la se...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000104-15,0,0,0 2019-000105-73,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","Efficacy of metfOrmin in PrevenTIng glucocorticoid-induced diabetes in Melanoma, breAst or Lung cancer patients with brain metastases: the phase II OPTIMAL study Studio OPTIMAL: Studio di fase II d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000105-73,0,0,0 2019-000111-84,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,ACERTA PHARMA BV,"An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma Studio di fase 1b/2, in aperto di acalabrutinib in monoterapia o in ass...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000111-84,0,0,0 2019-000114-11,15,,,0,0,1,0,0,0,3,0,1,3,0,0,0,0,1,"MEDIMMUNE, LLC","A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000114-11,0,0,0 2019-000114-11,15,,,0,0,1,0,0,0,3,0,1,3,0,0,0,0,1,"MedImmune, LLC","A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000114-11,0,0,0 2019-000119-10,4,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","An Open-label, Active-Controlled, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000119-10,0,0,0 2019-000119-10,4,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Eli Lilly and Company,"An Open-label, Active-Controlled, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chron...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000119-10,0,0,0 2019-000122-21,4,2021-02-25,2021-08-02,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000122-21,0,0,0 2019-000130-20,5,2022-04-07,2022-04-07,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"REGENERON PHARMACEUTICALS, INC.","An open-label extension study to evaluate the long-term safety, tolerability, and efficacy of REGN3918 in patients with paroxysmal nocturnal hemoglobinuria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000130-20,1,0,0 2019-000130-20,5,2022-04-07,2022-04-07,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","An open-label extension study to evaluate the long-term safety, tolerability, and efficacy of REGN3918 in patients with paroxysmal nocturnal hemoglobinuria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000130-20,1,0,0 2019-000131-51,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Zealand University Hospital,Preoperative endoscopic treatment with fosfomycin and metronidazole in patients with right-sided colon cancer and colon adenoma: a clinical proof-of-concept intervention study MEFO trial Præoperati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000131-51,0,0,0 2019-000132-25,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Mel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000132-25,0,0,0 2019-000133-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Center,A proof-of-concept study to evaluate 99mTechnetium radiolabeled Fucoidan as a diagnostic modality for thrombosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000133-39,0,0,0 2019-000134-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University of Antwerp,"Metformin as RenoProtector in Non-Diabetic Patients with Progressive Chronic Kidney Disease (CKD stages 2, 3A and 3B): a multi-centre, practice-oriented, repurposing, double-blind, placebo-controlle...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000134-18,0,0,0 2019-000136-26,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Friedrich-Schiller-Universität Jena,Midostaurin in MRD positive acute myeloid leukemia after allogeneic stem cell transplantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000136-26,0,0,0 2019-000138-20,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Alector Inc.,"A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of Fr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000138-20,0,0,0 2019-000159-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,"Prospective study on the incidence of hepatitis B virus reactivation in untreated patients with diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive treated with Rituximab, Chemother...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000159-14,0,0,0 2019-000169-19,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Queen Mary University London,Clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in saliva of patients with Multiple Sclerosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000169-19,0,0,0 2019-000171-16,1,,,0,0,0,0,1,0,4,0,0,3,0,0,0,0,0,King's College Hospital NHS Foundation Trust,Comparison between Propofol and Inhalational Anaesthetic Agents on Cardiovascular Outcomes following Cardiac Surgery - a Randomised Controlled Feasibility Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000171-16,0,0,0 2019-000175-16,1,2019-11-15,2019-11-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Avexxin AS,"A Phase IIa, Randomized, Vehicle- and Comparator-Controlled, Double-Blind for the IMPs, Observer-Blind for the Comparator Trial to Evaluate the Safety and Antipsoriatic Efficacy of AVX001 in a Psorias...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000175-16,0,0,0 2019-000176-41,4,2020-04-30,2020-04-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Otsuka Pharmaceutical Development and Commercialization, Inc","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Trial to Assess the Efficacy and Safety of Orally Administered OPS-2071 for 12 Weeks in Subjects With Crohn’s Dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000176-41,0,0,0 2019-000176-41,4,2020-04-30,2020-04-30,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Trial to Assess the Efficacy and Safety of Orally Administered OPS-2071 for 12 Weeks in Subjects With Crohn’s Dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000176-41,0,0,0 2019-000177-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"IMMUNOTHERAPY WITH INTRAVENOUS IMMUNOGLOBULINS, CYCLOPHOSPHAMIDE AND METHYLPREDNISOLONE IN PATIENTS WITH PARANOPLASTIC SENSITIVE NEURONOPATHIES WITH ANTI-HU ANTIBODIES IMMUNOTHERAPIE PRECOCE PAR IM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000177-23,0,0,0 2019-000178-50,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Medical University of Graz,Perioperative off-label application (from admission up to 72 hours postoperatively) of Fentanyl TTS as part of a pain management in comparison to a certified pain medication management in adult patien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000178-50,0,0,0 2019-000199-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación SEIMC-GESIDA,"A phase IV, multicenter, open and randomized study to evaluate the impact of the change of antiretroviral treatment from dual therapy to triple therapy on inflammation in patients with type 1 HIV infe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000199-41,0,0,0 2019-000201-69,16,,,0,0,1,0,0,0,2,0,1,2,0,0,0,0,1,"MedImmune, LLC","A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-ris...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000201-69,0,0,0 2019-000201-69,16,,,0,0,1,0,0,0,2,0,1,2,0,0,0,0,1,"MEDIMMUNE, LLC","A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-ris...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000201-69,0,0,0 2019-000202-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Centro Clínico Académico - Braga, Associação (2CA-Braga)","Single-center, double-blind, placebo-controlled study evaluating the efficacy of pre-incisional local analgesia with ropivacaine and dexamethasone for pain management after tonsillectomy Estudo uni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000202-29,0,0,0 2019-000203-33,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Klinisk Farmakologisk Afdeling,Paracetamol Discontinuation in the Elderly after long-term consumption (PARADISE) Ophør af paracetamol anvendt som langtidsbehandling hos patienter på 65 år og derover.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000203-33,0,0,0 2019-000204-14,8,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Gilead Sciences, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000204-14,0,0,0 2019-000204-14,8,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000204-14,0,0,0 2019-000205-77,1,2020-08-06,2020-08-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Grünenthal GmbH,"Open-label investigation of the pharmacokinetic profile, safety, tolerability, and efficacy of multiple administrations of tapentadol oral solution used for treatment of acute pain in children aged 2 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000205-77,0,0,0 2019-000208-13,3,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,CELGENE CORPORATION,A phase 2a study to evaluate the safety and pharmacokinetics of Luspatercept (ACE-536) in paediatric subjects who require regular red blood cell transfusions due to beta (β) thalassemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000208-13,0,0,0 2019-000208-13,3,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Celgene Corporation,A phase 2a study to evaluate the safety and pharmacokinetics of Luspatercept (ACE-536) in paediatric subjects who require regular red blood cell transfusions due to beta (β) thalassemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000208-13,0,0,0 2019-000210-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fraunhofer Gesellschaft for its Fraunhofer Institute for Molecular Biology and Applied Ecology IME,Prevention of Paclitaxel-induced neuropathic pain by Telmisartan in patients with planned Paclitaxel chemotherapy due to ovarian or breast cancer (PrevTel) Prävention von Paclitaxel-induzierten neu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000210-11,0,0,0 2019-000211-80,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Child and adolescent Psychiatry, South Jutland",Melatonin – production and release in children and adolescents with ADHD and chronic sleep problems,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000211-80,0,0,0 2019-000212-28,5,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,"Loxo Oncology, Inc.",A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000212-28,0,0,0 2019-000212-28,5,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,"Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company",A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000212-28,0,0,0 2019-000212-28,5,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,"Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company",A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000212-28,0,0,0 2019-000212-28,5,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,LOXO ONCOLOGY INCORPORATED,A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000212-28,0,0,0 2019-000215-92,1,2020-08-03,2020-08-03,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,Bay Pharma GmbH,"Prospective, randomized, double blinded, placebo controlled, multicentre study for the evaluation of efficacy and safety of a Tacrolimus-containing solution (TACRO-Skin) in subjects with mild to sever...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000215-92,0,0,0 2019-000216-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC,Safety and efficacy of the addition of IMM-101 Heat-Killed Whole Cell Mycobacterium obuense to standard stereotactic radiotherapy in locally advanced pancreatic cancer patients (LAPC-2 trial).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000216-29,0,0,0 2019-000218-12,4,2021-07-07,2021-07-07,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pfizer Inc.,"A 16-WEEK, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF-06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES MEL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000218-12,0,0,0 2019-000220-18,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Jiangsu Hengrui Medicine Co., Ltd.","A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib (Rivoceranib) Mesylate Versus Sorafenib as First-Line Therapy in Subjects with Adv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000220-18,0,0,0 2019-000221-45,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CONSORZIO ONCOTECH,Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000221-45,0,0,0 2019-000222-21,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Amicus Therapeutics, UK Limited","A LONG-TERM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACODYNAMICS, AND EFFICACY OF MIGALASTAT IN SUBJECTS > 12 YEARS OF AGE WITH FABRY DISEASE AND AMENABLE GLA VARIANTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000222-21,0,0,0 2019-000239-21,1,2021-05-06,2021-05-06,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,"Birte Nygaard, Dept of Endocrinology, Herelv Hosptial, University og Copenhagen,",Characterization of L-T4 treated patients with persistent hypothyroid symptoms - Effect of Synthetic LT4/L-T3 combination therapy versus desiccated animal thyroid extract? Effekt af udtræk fra dy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000239-21,0,0,0 2019-000243-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Odense University Hospital,"The effect of bupropion in peripheral neuropathic pain. A randomized, double-blind, placebo-controlled study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000243-27,0,0,0 2019-000244-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Region Uppsala,Influence of antibiotic treatment on the normal flora and the presence of resistance genes in known carriers of ESBL and VRE Påverkan av antibiotikabehandling avseende normalflora och förekomst av ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000244-10,0,0,0 2019-000245-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Repha GmbH,Controlled clinical trial to evaluate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type irrit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000245-12,0,0,0 2019-000247-27,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,ZIONEXA,Non-inferiority study of the molecular imaging of dopamine transporters using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to distinguish between Parkinson’s Disease and Essential Tremor. Etude de non...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000247-27,0,0,0 2019-000252-34,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000252-34,0,0,0 2019-000252-34,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000252-34,0,0,0 2019-000256-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Uppsala University Hospital,"A randomized, double-blinded, placebo-controlled study of Rituximab in patients with Psychosis and/or Obsessive Compulsive Disorder, with an indication of immune system involvement",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000256-33,0,0,0 2019-000258-76,1,,,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,Proveca Ltd.,"A single-dose, open-label, randomised, three-way crossover study to assess the comparative bioavailability of Captopril oral solution 5 mg/mL relative to captopril tablets and to investigate the effec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000258-76,0,0,0 2019-000260-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNICANCER,"Open-label, randomized, multicenter, phase III study, comparing standard chemotherapy to standard combination of endocrine therapy with Abemaciclib as initial Metastatic treatment among patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000260-14,0,0,0 2019-000261-21,7,2020-04-28,2020-04-28,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Boehringer Ingelheim, S.A.","A randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler as add-on therapy to s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000261-21,0,0,0 2019-000261-21,7,2020-04-28,2020-04-28,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Boehringer Ingelheim Limited,"A randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler as add-on therapy to s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000261-21,0,0,0 2019-000261-21,7,2020-04-28,2020-04-28,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,SCS Boehringer Ingelheim Comm.V,"A randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler as add-on therapy to s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000261-21,0,0,0 2019-000261-21,7,2020-04-28,2020-04-28,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Boehringer Ingelheim France,"A randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler as add-on therapy to s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000261-21,0,0,0 2019-000261-21,7,2020-04-28,2020-04-28,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Boehringer Ingelheim,"A randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler as add-on therapy to s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000261-21,0,0,0 2019-000261-21,7,2020-04-28,2020-04-28,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, placebo-controlled and parallel group trial to evaluate efficacy and safety of twice daily inhaled doses of BI 1265162 delivered by Respimat® inhaler as add-on therapy to s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000261-21,0,0,0 2019-000262-38,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000262-38,0,0,0 2019-000266-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal,Randomized clinical trial to evaluate the efficacy and safety of the treatment with supplementary oxygen in patients with Intermediate-Risk pulmonary embolism (PE) Ensayo clínico aleatorizado para ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000266-37,0,0,0 2019-000267-25,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,Characterisation of a novel regimen of very low-dose aspirin combined with rivaroxaban in patients with chronic coronary syndromes: WILL lOWer dose aspirin be better with rivaroxaban in patients with ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000267-25,0,0,0 2019-000270-29,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Rigshopitalet/Copenhagen University Hospital,"Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000270-29,0,0,0 2019-000274-36,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,Centre François Baclesse,Phase III trial comparing 2 diagnostic strategies for the preoperative localization of parathyroid adenoma in primary hyperparathyroidism: TEMP / CT with Tc99m-sestaMIBI or PET / CT with F18-choline i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000274-36,0,0,0 2019-000275-16,6,2022-01-04,2022-01-04,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Astellas Pharma Global Development, Inc.","A Randomized, Placebo-controlled, Double-blind Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women Suffering from Vasomotor Symptoms (Hot Flashes) Associated with Menop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000275-16,1,0,0 2019-000276-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Study on the effects of an OCT2/MATE1 substrate (metformin) and inhibitor (cimetidine) on the exposure of trifluridine/tipiracil (Lonsurf®) in patients with metastatic colorectal cancer (mCRC). Stu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000276-41,0,0,0 2019-000281-37,3,2021-09-23,2021-09-23,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Emalex Biosciences, Inc.","A Multicenter, Placebo-Controlled, Double-Blind, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette’s ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000281-37,1,0,0 2019-000282-20,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Emalex Biosciences, Inc.","A Multicenter, Open-Label, Extension Study Intended to Evaluate the Long-term Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette’s Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000282-20,0,0,0 2019-000283-26,8,2022-06-28,2022-06-28,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ObsEva S.A.,"A Phase 3 multicenter, randomized, double-blind, placebo-controlled, clinical study to assess the efficacy and safety of linzagolix in subjects with moderate to severe endometriosis-associated pain.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000283-26,1,0,0 2019-000284-24,2,2021-06-22,2021-06-22,2,1,0,0,0,0,0,0,0,1,0,0,1,0,1,Pfizer Inc,A RANDOMIZED COMPARATIVE STUDY ASSESSING THE INTERCHANGEABILITY OF PF-06410293 AND HUMIRA® IN COMBINATION WITH METHOTREXATE IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000284-24,0,0,0 2019-000285-38,1,2020-10-14,2020-10-14,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,London School of Hygiene and Tropical Medicine,"Pharmacokinetics of Tranexamic Acid after oral, intramuscular or intravenous administration: a prospective, randomised, cross-over trial in healthy volunteers. Pharmacocinétique de l'acide tranexam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000285-38,0,0,0 2019-000300-16,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS,NA Evaluation de l’efficacité du traitement hormonal chez les adolescents souffrant de dysphorie de genre,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000300-16,0,0,0 2019-000302-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Clinic per a la Recerca Biomèdica,ALBUMIN FOR MANAGEMENT OF HYPERVOLEMIC HYPONATREMIA IN PATIENTS WITH DECOMPENSATED CIRRHOSIS. A PROOF OF CONCEPT STUDY ALBUMINA PARA EL MANEJO DE LA HIPONATREMIA HIPERVOLEMICA EN PACIENTES CON CIRR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000302-29,0,0,0 2019-000305-79,1,2019-09-17,2019-09-17,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Acceleron Pharma Inc.,An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy (FSHD) Previously Enrolled in Study A083-02 and in Patients with Char...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000305-79,0,0,0 2019-000307-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Repha GmbH,Clinical trial for examination of efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhea-dominant irritable bowel syndrom (IBS-D) Kontrollierte klinische Prüfung zur Unte...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000307-32,0,0,0 2019-000308-13,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab versus Durvalumab plus Radiotherapy followed by Adjuvant Tremelimumab and D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000308-13,0,0,0 2019-000309-64,3,2022-07-15,2022-07-15,2,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Ayala Pharmaceuticals, Inc.","A Phase 2, Open-Label, Multi-Center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000309-64,1,0,0 2019-000312-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,APHP / DRCI,Extending time without diabetes after bariatric surgery: a randomized controlled trial comparing the metformin addition or not to standard care Prolonger la rémission du diabète après chirurgie de ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000312-28,0,0,0 2019-000315-91,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Birmingham,The pAToMiUM Trial: pilot trial of Antioxidant Therapy of Men in Unexplained Miscarriage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000315-91,0,0,0 2019-000316-29,1,,,0,0,0,1,0,0,1,0,0,4,0,0,0,0,0,King's College Hospital NHS Foundation Trust,Hepatocytes co-encapsulated with mesenchymal stromal cells in alginate microbeads for the treatment of acute liver failure in paediatric patients: HELP study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000316-29,0,0,0 2019-000318-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,MITO CERV 3:Phase II study on Carboplatin-Paclitaxel-Pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer MITO CERV 3: Studio di Fase II su Carboplatino-Paclitaxel-Pembrolizum...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000318-12,0,0,0 2019-000324-17,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Leeds,Amitriptyline at Low-dose and Titrated for Irritable Bowel Syndrome as Second-line Treatment (The ATLANTIS study): A Double-blind Placebo-controlled Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000324-17,0,0,0 2019-000325-49,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A randomized, subjects and investigator blinded, placebo controlled parallel group study to assess the mode of action of QBW251 in patients with Chronic Obstructive Pulmonary Disease (COPD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000325-49,0,0,0 2019-000326-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,The role of Contrast-Enhanced Spectral Mammography (CESM) in the diagnostic process of breast cancer: can it improve specificity of first-line examinations and therefore reduce the suspicious lesions ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000326-22,0,0,0 2019-000328-16,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Amgen Inc,A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000328-16,0,0,0 2019-000328-16,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AMGEN INC.,A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000328-16,0,0,0 2019-000330-19,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000330-19,0,0,0 2019-000331-63,4,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,"bluebird bio, Inc.",A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000331-63,0,0,0 2019-000331-63,4,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,"BLUEBIRD BIO, INC.",A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000331-63,0,0,0 2019-000333-39,7,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,"MILLENNIUM PHARMACEUTICALS, INC.",A Follow-up of a Phase 3 Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects With Crohn’s Disease Who Have Participated in ADM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000333-39,0,0,0 2019-000333-39,7,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,"Millennium Pharmaceuticals, Inc (MPI)",A Follow-up of a Phase 3 Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects With Crohn’s Disease Who Have Participated in ADM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000333-39,0,0,0 2019-000333-39,7,,,0,0,0,0,0,1,4,0,0,2,0,0,0,0,1,"Takeda Development Center Americas, Inc",A Follow-up of a Phase 3 Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel in the Treatment of Complex Perianal Fistula in Subjects With Crohn’s Disease Who Have Participated in ADM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000333-39,0,0,0 2019-000337-39,4,2022-08-31,2022-08-31,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"SAREPTA THERAPEUTICS, INC.","An Open-Label Safety, Tolerability, and Efficacy Study of Eteplirsen in Patients with Duchenne Muscular Dystrophy Who Have Completed Study 4658-102",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000337-39,1,0,0 2019-000337-39,4,2022-08-31,2022-08-31,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"Sarepta Therapeutics, Inc","An Open-Label Safety, Tolerability, and Efficacy Study of Eteplirsen in Patients with Duchenne Muscular Dystrophy Who Have Completed Study 4658-102",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000337-39,1,0,0 2019-000338-20,7,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2/3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000338-20,0,1,0 2019-000341-12,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight We...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000341-12,0,1,1 2019-000359-15,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Basilea Pharmaceutica International AG,"An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02) Un estudio Fase 1b/2, abi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000359-15,0,0,0 2019-000359-15,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Basilea Pharmaceutica International Ltd.,"An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer expressing activating molecular FGFR aberrations (FIDES-02) Un estudio Fase 1b/2, abi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000359-15,0,0,0 2019-000361-21,1,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,Argenx BVBA,"A Multicenter, Open-Label, Phase 2 Trial to Evaluate the Safety and Activity of Efgartigimod (ARGX-113) in Adult Patients with Primary Immune Thrombocytopenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000361-21,0,0,0 2019-000364-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA,"Randomized open label multicentric phase II trial of Adjuvant RadioChemotherapy, Concurrent versus Sequential, in resected non-small cell lung cancer (NSCLC) patients with mediastinal involvement (pN2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000364-24,0,0,0 2019-000367-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO,"Acute effect of parenteral rehydration solution commonly used in children with acute gastroenteritis on acid-base balance, free-fatty acids metabolism and glucose homeostasis Effetto acuto delle so...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000367-25,0,0,0 2019-000368-12,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"OptiNose US, Inc.","A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (BID)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000368-12,0,0,0 2019-000370-27,3,2021-10-15,2021-10-15,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Cortexyme, Inc.","A Randomized, Double-Blind, Placebo Controlled Study of COR388 HCl in Subjects with Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000370-27,1,0,0 2019-000373-23,9,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A randomized, open-label, phase I/II open platform study evaluating safety and efficacy of novel ruxolitinib combinations in myelofibrosis patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000373-23,0,0,0 2019-000373-23,9,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A","A randomized, open-label, phase I/II open platform study evaluating safety and efficacy of novel ruxolitinib combinations in myelofibrosis patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000373-23,0,0,0 2019-000374-39,8,2020-07-02,2021-07-02,5,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Orphazyme A/S,"Open-label, Non-randomised Extension Trial to Assess the Long-Term Safety and Efficacy of 1200 mg/day Arimoclomol 400 mg Three Times a Day (t.i.d.) in Subjects with Amyotrophic Lateral Sclerosis (ALS)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000374-39,1,0,0 2019-000374-39,8,2020-07-02,2021-07-02,5,0,0,0,0,1,3,0,0,2,0,0,0,0,1,ORPHAZYME APS,"Open-label, Non-randomised Extension Trial to Assess the Long-Term Safety and Efficacy of 1200 mg/day Arimoclomol 400 mg Three Times a Day (t.i.d.) in Subjects with Amyotrophic Lateral Sclerosis (ALS)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000374-39,1,0,0 2019-000375-16,1,2020-04-20,2020-04-20,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Bellus Health Inc.,"A Randomized, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000375-16,0,0,0 2019-000376-41,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Fundación de Investigación del Hospital Universitario La Paz (FIBHULP),Randomized and multicenter clinical trial to evaluate the effectiveness and efficiency of a voriconazole preemptive genotyping strategy in patients with risk of aspergillosis. Ensayo clínico aleato...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000376-41,0,0,0 2019-000398-21,1,2021-01-29,2021-01-29,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Neuraly, Inc.","A Phase 2a Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NLY01, a PEGylated Exenatide, when Administered as a Single Dose in Subjects with Type 2 Diab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000398-21,0,0,0 2019-000399-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,NOGGO e. V.,Rucaparib MAintenance after Bevacizumab Maintenance following Carboplatin based first line chemotherapy in Ovarian Cancer patients Rucaparib Erhaltungstherapie nach Bevacizumab-Therapie und Carbop...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000399-41,0,0,0 2019-000401-76,1,2022-06-15,2022-06-15,1,0,0,0,1,0,3,0,0,1,0,0,0,0,0,University hospital of Montpellier,"Transfusion savings in heart surgery: impact of individual strategy, optimized by erythropoietin (EPO) and metabolic adjustment (ScvO2) Epargne transfusionnelle en chirurgie cardiaque : impact d’u...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000401-76,0,0,0 2019-000402-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Viktoria Lindberg-Larsen,"The effect of perioperative dexamethasone administration on postoperative pain in patients undergoing periacetabular osteotomy: A randomised double-blind, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000402-30,0,0,0 2019-000403-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Roessingh Research and Development,The effect of lidocaïne injections in the m. vastus intermedius and the m. rectus femoris on the gait pattern in patients walking with stiff knee gait after a stroke. Het effect van lidocaïne injec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000403-32,0,0,0 2019-000404-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Thomas Benfield,Shortened Antibiotic Treatment in Community-Acquired Pneumonia: A Nationwide Danish Randomized Controlled Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000404-15,0,0,0 2019-000406-30,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,1,Allergan Limited,Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000406-30,0,0,0 2019-000412-29,1,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,0,"F.I. Proctor Foundation, University of California San Francisco",Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial (ADJUST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000412-29,0,0,0 2019-000413-36,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"BeiGene, Ltd.","A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000413-36,0,0,0 2019-000413-36,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BeiGene Ltd.,"A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000413-36,0,0,0 2019-000415-87,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000415-87,0,0,0 2019-000415-87,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000415-87,0,0,0 2019-000415-87,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"GlaxoSmithKline, S.A.","Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000415-87,0,0,0 2019-000415-87,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,GlaxoSmithKline BV,"Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000415-87,0,0,0 2019-000417-37,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ARRAY BIOPHARMA INC.,"A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAF V600E-mutant Non-small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000417-37,0,0,0 2019-000417-37,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Array BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.),"A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAF V600E-mutant Non-small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000417-37,0,0,0 2019-000417-37,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Array BioPharma Inc.,"A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAF V600E-mutant Non-small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000417-37,0,0,0 2019-000419-98,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,1,Eli Lilly and Company,Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tasks P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000419-98,0,1,1 2019-000439-14,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"A phase II multi-center, single arm, safety and efficacy study of MBG453 in combination with azacitidine and venetoclax for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit for ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000439-14,0,0,0 2019-000439-14,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A phase II multi-center, single arm, safety and efficacy study of MBG453 in combination with azacitidine and venetoclax for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit for ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000439-14,0,0,0 2019-000440-10,1,2022-01-06,2022-01-06,1,0,0,0,0,0,2,0,0,1,1,1,0,0,1,Novartis Pharma AG,"NASH EXploratory Single and COmbination Treatment (NEXSCOT): An open label, multicenter, platform study to evaluate the safety, tolerability, pharmacokinetics and efficacy of various single and combin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000440-10,0,0,0 2019-000443-28,3,,,0,1,0,0,0,0,3,0,0,1,1,0,0,1,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Maintenance Treatment and Flare Reduction with Crisaborole Ointment, 2%, Once Daily Over 52 Weeks i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000443-28,0,0,0 2019-000447-26,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,1,"Spark Therapeutics, Inc","An Open-label, Non-investigational Product, Multi-center, Lead-in Study to Evaluate Prospective Bleeding and Infusion Data of Current FVIII Replacement Therapy in Adult Males with Hemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000447-26,0,0,0 2019-000460-21,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,KU Leuven Drug Delivery & Disposition,Gastrointestinal behavior of dasatinib in healthy volunteers Gastrointestinaal gedrag van dasatinib in gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000460-21,0,0,0 2019-000465-20,7,,,0,0,0,1,0,1,1,0,1,2,0,0,0,0,1,Novo Nordisk A/S,"Safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple subcutaneous doses of NNC0365-3769 (Mim8) in healthy subjects and in subjects with haemophilia A with or without fact...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000465-20,0,0,0 2019-000465-20,7,,,0,0,0,1,0,1,1,0,1,2,0,0,0,0,1,NOVO NORDISK. S.P.A.,"Safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple subcutaneous doses of NNC0365-3769 (Mim8) in healthy subjects and in subjects with haemophilia A with or without fact...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000465-20,0,0,0 2019-000469-19,6,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,Kyowa Kirin Pharmaceutical Development Ltd.,"A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients from Birth to Less than 1 Year of Age w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000469-19,0,0,0 2019-000469-19,6,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,Kyowa Kirin Pharmaceutical Development Limited,"A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients from Birth to Less than 1 Year of Age w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000469-19,0,0,0 2019-000470-36,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,Sunovion Pharmaceuticals Inc.,"A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000470-36,0,0,0 2019-000473-23,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000473-23,0,0,0 2019-000473-23,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Janssen-Cilag International N.V.,A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000473-23,0,0,0 2019-000476-42,10,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,Bayer Consumer Care AG,"A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000476-42,0,0,0 2019-000502-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,German Cancer Research Center (DKFZ),Personalized Vitamin D Supplementation for Reducing or Preventing Fatigue and Enhancing Quality of Life of Patients with Colorectal Tumor: Randomized Intervention Trial Personalisierte Vitamin-D-S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000502-30,0,0,0 2019-000505-72,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Transparency in Healthcare,Pragmatic trial baricitinib versus First biological in “Tight Control” Patients suffering from Rheumatoid Arthritis (PERFECT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000505-72,0,0,0 2019-000510-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITÀ DEGLI STUDI MILANO BICOCCA,"A Phase 2, open label, multicenter, single arm trial evaluating the activity and safety of Abemaciclib + Aromatase Inhibitors (AIs) after 1st-line treatment with High-Dose Fulvestrant in Hormone-Recep...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000510-11,0,0,0 2019-000514-11,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Swiss Group for Clinical Cancer Research (SAKK),"Reduced intensity radio-chemotherapy for stage IIA/B seminoma. A multicenter, open label phase II trial with two cohorts Radio-Chemotherapie mit reduzierter Intensität bei Patienten mit einem Semin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000514-11,0,0,0 2019-000515-84,1,2021-12-03,2021-12-03,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Ghent University Hospital,Comparison of pain and comfort in patients following cardiac surgery: opioid-morphine managed vs multimodal pain-management.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000515-84,0,0,0 2019-000538-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISABEL ANDIA ORTIZ,PAINFUL SYNDROME OF THE MAJOR TROCANTER: Randomized clinical trial with masked evaluation of parallel groups to evaluate the efficacy and safety of the sub-fascial infiltration of PRP compared with we...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000538-21,0,0,0 2019-000558-68,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,Národný onkologický ústav,Phase II study of disulfiram and cisplatin in refractory testicular germ cell cancer. Klinické skúšanie fázy II: Cisplatina + disulfiram u pacientov s relapsom germinatívneho tumoru.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000558-68,0,0,0 2019-000560-22,7,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,ALK-Abelló A/S,A one-year placebo-controlled phase III trial evaluating the efficacy and safety of the house dust mite (HDM) SLIT-tablet in children (5-11 years of age) with HDM allergic rhinitis/rhinoconjunctivitis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000560-22,0,0,0 2019-000561-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Tampere University Hospital,Monitoring of neuromuscular blockade during general anaesthesia after reversal with neostigmine Yleisanestesiaan liittyvän hermo-lihasliitoksen salpauksen käyttäytyminen neostigmiinilla kumotun sal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000561-20,0,0,0 2019-000566-38,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000566-38,0,0,0 2019-000566-38,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"REGENERON PHARMACEUTICALS, INC.","A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000566-38,0,0,0 2019-000569-19,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemother...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000569-19,0,0,0 2019-000570-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE ARIANNA ANTICOAGULAZIONE,The Jason study: Sulodexide (VESSEL®) for the prevention of recurrent venous thromboembolism in elderly patients after a first episode of venous thrombembolism (VTE) Studio Giasone Prevenzione sec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000570-33,0,0,0 2019-000572-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Cliniques Universitaires Saint-Luc,An open label phase II study combining anti-PD-1 or PD-L1 and Celecoxib in patients with advanced « cold » solid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000572-41,0,0,0 2019-000579-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Gilead Sciences, Inc.",A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors Estudio abierto de fase II de sacituzumab govitecan (IMMU-132) en pacientes con tumores sólid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000579-18,0,0,0 2019-000580-24,1,2020-05-01,2020-05-01,1,1,0,0,0,0,2,0,1,1,1,1,1,0,0,Hull & East Yorkshire Hospitals NHS trust,"A single arm, open-label clinical trial of azithromycin in pulmonary sarcoidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000580-24,0,0,0 2019-000581-38,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University College London Comprehensive Clinical Trials Unit,ASEPTIC: Primary Antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000581-38,0,0,0 2019-000582-21,3,2021-11-29,2021-11-29,3,1,0,0,0,0,2,0,0,1,0,0,0,0,1,Modra Pharmaceuticals,"A multicentre Phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic Castration Resistant Prostate Cancer (mCRPC), suitable for treatment with a taxane.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000582-21,0,0,0 2019-000582-21,3,2021-11-29,2021-11-29,3,1,0,0,0,0,2,0,0,1,0,0,0,0,1,Modra Pharmaceuticals B.V.,"A multicentre Phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic Castration Resistant Prostate Cancer (mCRPC), suitable for treatment with a taxane.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000582-21,0,0,0 2019-000583-18,12,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Sierra Oncology, Inc.","A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000583-18,0,0,0 2019-000585-38,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospitals Coventry and Warwickshire NHS Trust,Chronic Endometritis and Recurrent Miscarriage - The CERM trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000585-38,0,0,0 2019-000586-20,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc","A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretrovi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000586-20,0,0,0 2019-000586-20,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretrovi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000586-20,0,0,0 2019-000587-23,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc","A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000587-23,0,0,0 2019-000587-23,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000587-23,0,0,0 2019-000588-26,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc","A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000588-26,0,0,0 2019-000588-26,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000588-26,0,0,0 2019-000589-39,3,,,0,0,0,0,0,2,2,0,0,3,0,0,0,0,1,Adaptimmune LLC,A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000589-39,0,0,0 2019-000590-23,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000590-23,0,0,0 2019-000590-23,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc","A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000590-23,0,0,0 2019-000591-42,4,2022-07-07,2022-07-07,3,0,0,0,0,1,2,0,0,1,1,0,0,0,1,"Ionis Pharmaceuticals, Inc.","An Open-Label Extension Trial of IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor Administered Monthly Subcutaneously to Patients with Acromegaly Being Treated with Long-Acting Som...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000591-42,0,0,0 2019-000593-32,1,2020-04-06,2020-04-06,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novalon S.A.,"Phase III, open-label, multi-center study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 10.8 mg goserelin subcutaneous implant (Novalon) in male subjects with prostat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000593-32,0,0,0 2019-000595-42,1,2022-04-19,2022-04-19,1,1,0,0,0,0,4,0,0,1,1,1,0,0,0,Steno Diabetes Center Copenhagen,"A randomized, double-blind, placebo controlled, parallel, multicentre study of the effects of 12-weeks of sodium zirconium cyclosilicate (Lokelma) on albuminuria (UACR) in patients with diabetes and h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000595-42,0,0,0 2019-000596-16,1,2021-08-14,2021-08-14,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospitals Leuven,"Erector spinae plane block for minimal invasive direct coronary artery bypass surgery. A double blind, prospective randomized placebo-controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000596-16,0,0,0 2019-000597-34,1,,,0,1,0,0,0,1,2,0,0,1,0,0,0,1,1,CLINUVEL EUROPE LIMITED,"A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum (XP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000597-34,0,0,0 2019-000598-22,1,2022-06-08,2022-06-08,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,"University Hospital Schleswig Holstein, Represented by the Board of Directors which is represented by the chairman",Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki) Effekte einer Tralokinumab-Behandlung auf die Hautbarrierefunktion bei Patienten mit moderater bis schwerer ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000598-22,0,0,0 2019-000599-40,4,2022-05-24,2022-05-24,3,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Khondrion B.V.,"A Phase IIb double-blind, randomised, placebo-controlled, multi-centre, confirmative three-way cross-over study on cognitive function with two doses of KH176 in subjects with a genetically confirmed m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000599-40,1,0,0 2019-000601-77,6,,,0,0,0,0,0,2,2,0,0,2,1,0,0,0,1,"Sarepta Therapeutics, Inc.","A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, then Dose Expansion, in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000601-77,0,0,0 2019-000602-30,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Kamada Ltd.,"A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of “Kamada-AAT for Inhalation” 80 mg per day in Adult Patients with Congenital Alpha-1 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000602-30,0,0,0 2019-000604-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"UNIVERSITÀ DEGLI STUDI ""G. D'ANNUNZIO"" CHIETI-PESCARA","Multicentre, randomized, double-blind, placebo-controlled, parallel-group Phase II study aimed at evaluating the efficacy and safety of “Zinco Solfato” in Mild Cognitive Impairment due to Alzheimer’s ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000604-15,0,0,0 2019-000607-33,4,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK's paediatric Herpes Zoster subunit candidate vaccine (PED-HZ/su) when administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000607-33,0,0,0 2019-000607-33,4,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,GlaxoSmithKline S.A.,"A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK's paediatric Herpes Zoster subunit candidate vaccine (PED-HZ/su) when administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000607-33,0,0,0 2019-000607-33,4,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK's paediatric Herpes Zoster subunit candidate vaccine (PED-HZ/su) when administered ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000607-33,0,0,0 2019-000608-14,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,Tartu University Hospital,Prospective validation of individualized Bayesian dose optimization tool DosOpt for Vancomycin treatment in neonates. Bayesi indiviidipõhise vankomütsiini doosi optimeerimise tarkvara DosOpt’i pros...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000608-14,0,0,0 2019-000610-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,"Effects of low-dose Rivaroxaban combined with low-dose Aspirin versus low-dose aspirin alone on in vivo platelet Activation, endothelial function and inflammation in type 2 diabetic patients with stab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000610-10,0,0,0 2019-000612-29,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000612-29,0,0,0 2019-000616-28,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AGMT gGmbH,"Multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of Dronabinol in the Improvement of ChemOthErapy-induced and tumor-Related sy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000616-28,0,0,0 2019-000617-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rijnstate ziekenhuis,StudY of effect of Nimodipine and Acetaminophen on Postictal Symptoms after ECT Onderzoek naar de invloed van paracetamol en nimodipine op de verschijnselen na een behandeling met elektroconvulsiet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000617-37,0,0,0 2019-000618-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Vejle Hospital,Bevacizumab and tocotrienol in recurrent ovarian cancer. A marker based phase II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000618-13,0,0,0 2019-000620-17,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Dilafor AB,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Proof of Concept Study (section A) with a conditional dose finding follow up (Section B) to Evaluate the Efficacy on Cervical ripening, S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000620-17,0,0,0 2019-000622-22,7,2022-04-24,2022-04-26,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Janssen Sciences Ireland UC,"A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000622-22,1,0,0 2019-000622-22,7,2022-04-24,2022-04-26,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Janssen Sciences Ireland Unlimited Company,"A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000622-22,1,0,0 2019-000623-40,6,2020-09-08,2020-09-08,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,JSC BIOCAD,An International Randomized Double-blind Clinical Trial of BCD-100 Plus Platinum-based Chemotherapy with and without Bevacizumab versus Placebo Plus Platinum-based Chemotherapy with and without Bevaci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000623-40,1,0,0 2019-000638-20,6,2022-07-14,2022-07-14,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000638-20,1,0,0 2019-000638-20,6,2022-07-14,2022-07-14,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000638-20,1,0,0 2019-000640-10,1,2020-06-18,2020-06-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,LABORATOIRES SMB S.A.,"A phase II, randomised, double-blind, and parallel study to estimate the dose-response of vitamin D supplementation in chronic kidney disease patients with secondary hyperparathyroidism and vitamin D ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000640-10,0,0,0 2019-000642-35,2,2021-04-19,2021-04-19,2,0,0,0,0,0,2,0,0,1,1,0,1,0,1,"HANLIM PHARM CO., LTD","A phase IIa randomized, double-blind, multicentre study to evaluate safety and efficacy of HL217 topical ophthalmologic solution in the treatment of exudative Age-Related Macular Degeneration (AMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000642-35,0,0,0 2019-000643-27,1,,,0,1,0,0,0,0,2,0,1,3,0,0,0,0,0,University of Oxford / Clinical Trials and Research Governance,A Phase IIa challenge study to assess efficacy of the Plasmodium vivax malaria vaccine candidates ChAd63 PvDBP and MVA PvDBP in healthy adults living in the UK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000643-27,0,0,0 2019-000645-12,1,2020-07-14,2020-07-14,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,GENFIT SA,"A Double-Blind, Placebo-Controlled, Cross-over Phase II Study to Evaluate the Effect of a 6-week Elafibranor (120mg) treatment administered once daily on hepatic lipid composition in subjects with Non...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000645-12,0,0,0 2019-000647-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Dicofarm S.p.A.,Evaluation of efficacy and bioavailability of a new pediatric formulation based on ibuprofen lysinate vs ibuprofen in the management of pain in children Valutazione dell'efficacia e della biodispon...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000647-27,0,0,0 2019-000648-86,6,2022-05-04,2022-05-04,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"OptiNose US, Inc.","A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 μg of OPN-375 Twice a Day (BID)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000648-86,1,0,0 2019-000650-61,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000650-61,0,0,0 2019-000654-59,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Minoryx Therapeutics S.L.,"An exploratory, open-label, multicenter study in male pediatric patients with cerebral X-linked Adrenoleukodystrophie (cALD) to assess the effect of MIN-102 treatment on the progression of cerebral le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000654-59,0,0,0 2019-000655-14,5,2020-06-05,2020-06-05,4,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Sanofi Pasteur,Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine Administered by the Intramuscular Route in Subjects 60 Years of Age and Older,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000655-14,0,0,0 2019-000655-14,5,2020-06-05,2020-06-05,4,1,0,0,0,0,3,0,1,1,0,0,1,0,1,SANOFI PASTEUR,Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine Administered by the Intramuscular Route in Subjects 60 Years of Age and Older,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000655-14,0,0,0 2019-000657-31,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Erasmus MC Cancer Institute,Adoptive therapy with TCR gene-engineered T cells to treat patients with MAGE-C2-positive melanoma and head and neck cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000657-31,0,0,0 2019-000660-25,1,2020-06-25,2020-06-25,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"CELLTRION, Inc.","A Phase III, Open-label, Single-arm, Multiple-dose Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients with Moderate to Severe Active Rheumatoid Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000660-25,0,0,0 2019-000661-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Vilnius University Hospital Santaros klinikos,Ivabradine to prevent anthracycline-induced cardiotoxicity: a prospective randomized open label clinical trial. Ivabradino įtaka kardiotoksinės chemoterapijos indukuotos ankstyvosios miokardo pažai...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000661-20,0,0,0 2019-000667-24,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Sangamo Therapeutics, Inc.","A Phase I/II, Multicenter, Open-Label, SingleDose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects with Fabry Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000667-24,0,0,0 2019-000668-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Marta Maia Boscá Watts,Pilot Project for the Treatment of Perianal Disease through the Local Injection of Remsima Guided by Ultrasound. Number of cases. Proyecto Piloto del Tratamiento de la Enfermedad Perianal Mediante ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000668-27,0,0,0 2019-000670-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud University Medical Center,Imaging tumor-infiltrating CD8+ T-cells in non-small cell lung cancer upon neo-adjuvant treatment with Durvalumab (MEDI4736). Afbeelden van tumor-infiltrerende CD8+ T-cellen in niet-kleincellig lon...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000670-37,0,0,0 2019-000674-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Dipartimento di Medicina di Precisione - Università degli studi della Campania ""L. Vanvitelli""",A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC). Studio di fase II per valutare l'attività di cabozantinib in pazienti pret...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000674-28,0,0,0 2019-000676-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Center Hospital of Guadeloupe,Efficacy of metformin versus sitagliptin on benign thyroid nodules size in type 2 diabetes: a 2-years prospective multicentric study Etude multicentrique d’efficacité de la metformine versus la sit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000676-42,0,0,0 2019-000678-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Léon Bérard,CABRAMET - A phase 2 study of cabozantinib in renal cell carcinoma (mRCC) with brain metastases CABRAMET - Etude de phase 2 évaluant le cabozantinib dans le traitement du carcinome à cellules rénal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000678-41,0,0,0 2019-000679-18,3,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Genzyme Corporation,"ATLAS-PEDS: An open-label, multinational study of fitusiran prophylaxis in male pediatric subjects aged 1 to less than 12 years with hemophilia A or B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000679-18,0,1,0 2019-000679-18,3,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,GENZYME CORPORATION,"ATLAS-PEDS: An open-label, multinational study of fitusiran prophylaxis in male pediatric subjects aged 1 to less than 12 years with hemophilia A or B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000679-18,0,1,0 2019-000690-22,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Janssen Vaccines & Prevention B.V.,"A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000690-22,0,1,1 2019-000691-42,1,,,0,1,1,0,0,1,3,0,1,4,0,0,0,0,1,Janssen Vaccines & Prevention B.V.,"A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000691-42,0,1,1 2019-000694-24,1,2020-09-07,2020-09-07,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Meda Pharma GmbH & Co. KG (A Mylan company),Evaluation of the antiseptic activity of 4 different modes of application of a 5% alcoholic povidone-iodine product (Bétadine® Alcoolique 5%) EVALUATION DE L'ACTIVITE ANTISEPTIQUE D'UN PRODUIT ALCO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000694-24,0,0,0 2019-000695-41,1,2020-05-06,2020-05-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Janssen-Cilag International NV,"A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ-67953964 in Subjects with Major...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000695-41,0,0,0 2019-000696-16,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Sunovion Pharmaceuticals Inc.,An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000696-16,0,0,0 2019-000697-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Sunovion Pharmaceuticals Inc.,"A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000697-37,0,0,0 2019-000698-22,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc","A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000698-22,0,0,0 2019-000698-22,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000698-22,0,0,0 2019-000700-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University Graz,"Pilot-Study comparing analgosedation concepts during placement of regional anaesthesia with either fentanyl, remifentanil, clonidine, EMLA-Patch or placebo in regard of patient's wellbeing, pain and s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000700-14,0,0,0 2019-000702-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Odense University Hospital,Fibromyalgia and Naltrexone: The FINAL study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000702-30,0,0,0 2019-000709-55,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitair Ziekenhuis Brussel,Sugammadex dose-finding study for reversal of deep rocuronium-induced neuromuscular block,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000709-55,0,0,0 2019-000710-11,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SOLTI,Targeting EGFR/ERBB2 with Neratinib in Hormone Receptor (HR)-positive/HER2-negative HER2-enriched advanced/metastatic breast cancer (NEREA trial) Terapia con Neratinib dirigida a los receptores EGF...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000710-11,0,0,0 2019-000716-28,9,2022-09-09,2022-09-09,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000716-28,1,0,0 2019-000716-28,9,2022-09-09,2022-09-09,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000716-28,1,0,0 2019-000717-37,1,2020-06-08,2020-06-08,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Fundación Publica Andaluza para la Gestión de Salud en Sevilla (FISEVI),"LOSS OF RESPONSE OF THE ADALIMUMAB BIOSIMILAR COMPARED WITH THE LOSS OF RESPONSE OF THE ADALIMUMAB ORIGINAL: CONTROLLED, RANDOMIZED, NON-INFERIORITY OPEN STUDY. ""ADA-SWITCH Study"" PÉRDIDA DE RESPUE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000717-37,0,0,0 2019-000718-13,3,2022-06-16,2022-06-16,1,0,0,0,1,1,2,0,0,2,0,0,0,0,1,BREATH Therapeutics Inc.,"A Phase IIa Multi-Center, Randomized, Single-Blind Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000718-13,1,0,0 2019-000718-13,3,2022-06-16,2022-06-16,1,0,0,0,1,1,2,0,0,2,0,0,0,0,1,Breath Therapeutics Inc.,"A Phase IIa Multi-Center, Randomized, Single-Blind Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000718-13,1,0,0 2019-000720-17,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"MOMENTA PHARMACEUTICALS, Inc","Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000720-17,0,0,0 2019-000720-17,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000720-17,0,0,0 2019-000720-17,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Momenta Pharmaceuticals, Inc.","Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000720-17,0,0,0 2019-000721-50,12,2021-04-18,2021-04-23,10,1,0,0,2,0,2,0,0,2,1,0,0,0,1,INCYTE CORPORATION,"A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000721-50,1,0,0 2019-000721-50,12,2021-04-18,2021-04-23,10,1,0,0,2,0,2,0,0,2,1,0,0,0,1,Incyte Corporation,"A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000721-50,1,0,0 2019-000727-41,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Centre François Baclesse,"A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000727-41,0,0,0 2019-000730-19,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Amsterdam Univeristy Medical Center - Vu Univeristy Medical Center,"A phase 4, monocenter, prospective, randomized, placebo-controlled, double-blind, cross-over mechanistic intervention trial to assess effect of 4-week Ertugliflozin (SGLT-2 inhibitor) therapy on renal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000730-19,0,0,0 2019-000732-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Stockholm Health Care Services,Effect of Exenatide on disease progression in early Parkinson's disease. Effekt av Exenatid på sjukdomsprogression vid tidig Parkinsons sjukdom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000732-26,0,0,0 2019-000733-39,11,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,ABIVAX,"A phase 2b, open-label, efficacy and safety study of ABX464 as maintenance therapy in patients with moderate to severe Ulcerative Colitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000733-39,0,0,0 2019-000733-39,11,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Abivax,"A phase 2b, open-label, efficacy and safety study of ABX464 as maintenance therapy in patients with moderate to severe Ulcerative Colitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000733-39,0,0,0 2019-000735-61,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Dutch Growth Research Foundation,"N- acetylcysteine treatment for skin picking in children and young adults with PWS: a randomized, controlled, cross-over trial. Behandeling met N-acetylcysteïne voor skin picking gedrag in kindere...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000735-61,0,0,0 2019-000736-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universidad Complutense de Madrid,Efficacy of Non-Steroidal Anti-Inflammatory (Ibuprofen) Chronotherapy in Healing After Mandibular Third Molar Surgical Extraction – A Randomized Clinical Trial Eficacia de la posología de un anti-I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000736-25,0,0,0 2019-000737-39,7,2022-03-18,2022-03-18,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Adial Pharmaceuticals Inc.,"A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Tolerability of AD04 (Ondansetron) in Adults with Alco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000737-39,1,0,0 2019-000740-10,1,2020-04-21,2020-04-21,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,NUI As,Hyperbaric oxygen therapy after cerebral infarction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000740-10,0,0,0 2019-000742-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA,PROTOCOL FOR THE DIAGNOSIS AND THERAPY OF INTRAOCULAR RETINOBLASTOMA PROTOCOLLO DIAGNOSTICO E TERAPEUTICO DEL RETINOBLASTOMA INTRAOCULARE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000742-35,0,0,0 2019-000744-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SPARKLE SRL,"Higher diagnostic accuracy of 64Cu PET/CT compared to standard 18F-choline PET/CT in the detection rate of metastasis from prostate cancer. Phase III multicenter, sponsored, interventional ""open-label...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000744-10,0,0,0 2019-000747-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SOCIETÀ INDUSTRIA FARMACEUTICA ITALIANA (SIFI) SPA,"A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase II Study to evaluate the Safety and Efficacy of Pro-ocular™ 0.5% and 1% in Patients with Dry Eye Syndrome Studio di fase II multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000747-27,0,0,0 2019-000749-11,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Orphazyme A/S,"An open-label, non-randomized trial to investigate the efficacy and safety of early versus delayed start of arimoclomol in patients with sporadic inclusion body myositis who have completed the IBM4809...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000749-11,0,0,0 2019-000750-63,7,2022-05-06,2022-06-10,3,0,0,0,0,1,2,0,0,2,1,0,0,0,1,AbbVie Deutschland,A Phase 2 Study of ABBV-3067 Alone and in Combination with ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000750-63,1,0,0 2019-000750-63,7,2022-05-06,2022-06-10,3,0,0,0,0,1,2,0,0,2,1,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 2 Study of ABBV-3067 Alone and in Combination with ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000750-63,1,0,0 2019-000751-13,1,2020-10-30,2020-10-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Fundacja “Centrum Rozwoju Medycyny”,"Efficacy and safety of Concor 5mg plus amlodipine 5mg in hypertensive patients whose blood pressure cannot be controlled under 5mg of amlodipine monotherapy, a phase III multicentre, randomised, doubl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000751-13,0,0,0 2019-000752-34,3,2022-07-12,2022-07-12,3,0,0,0,0,1,2,0,0,1,0,0,0,0,1,DSLP,"A Phase 2/3, multi-center, double-blind, placebo-controlled, randomized, parallel-group, dose-response comparison of the efficacy and safety of a topical rapamycin cream for the treatment of facial an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000752-34,0,0,0 2019-000752-34,3,2022-07-12,2022-07-12,3,0,0,0,0,1,2,0,0,1,0,0,0,0,1,Dermatology Specialities Limited Partnership (DSLP),"A Phase 2/3, multi-center, double-blind, placebo-controlled, randomized, parallel-group, dose-response comparison of the efficacy and safety of a topical rapamycin cream for the treatment of facial an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000752-34,0,0,0 2019-000753-31,1,2021-04-22,2021-04-22,1,1,0,0,1,0,3,0,0,1,0,0,1,0,0,CHU Nantes,Evaluation of REMIFENTANIL as an alternative to curare for rapid sequence anesthetic induction in patients at risk of gastric fluid inhalation Évaluation du REMIFENTANIL en remplacement du curare p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000753-31,0,0,0 2019-000755-14,2,2022-06-30,2022-06-30,1,0,0,0,0,0,2,0,1,2,0,0,0,0,0,"Sapienza University of Rome, Department of Human Neurosciences","A randomized, double blind, placebo-controlled, cross-over, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000755-14,1,0,0 2019-000755-14,2,2022-06-30,2022-06-30,1,0,0,0,0,0,2,0,1,2,0,0,0,0,0,UMBERTO I - POLICLINICO DI ROMA,"A randomized, double blind, placebo-controlled, cross-over, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000755-14,1,0,0 2019-000756-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Region Jönköping County,The SANT - study A randomized controlled clinical trial of Streptococcus group A-negative acute tonsillitis in primary health care - a comparison of phenoxymethylpenicillin and no antibiotic treatment...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000756-34,0,0,0 2019-000757-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,South-east health region of Noway,Effect of zoledronic acid on osteoarthritis of the hip Effekten av zoledronsyre på hofteartrose,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000757-31,0,0,0 2019-000780-24,6,2022-08-02,2022-08-02,3,0,0,1,0,0,1,0,0,2,0,0,0,0,1,MorphoSys AG,"A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000780-24,1,0,0 2019-000781-38,1,2022-04-04,2022-04-04,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Aarhus University Hospital,Effect of Empagliflozin and Semaglutide on Cardio-Renal Target Organ Damage in patients with type 2 diabetes – A randomized Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000781-38,0,0,0 2019-000782-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Vall d' Hebron Institute of Oncology (VHIO),Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC) – MONEO Study Estudio fase I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000782-21,0,0,0 2019-000783-15,1,2019-08-09,2019-08-09,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,"Genentech, Inc.","A RANDOMIZED, OPEN-LABEL, TWO PART STUDY TO EXPLORE THE PERFORMANCE OF ENTRECTINIB PROTOTYPE MINI-TABLET FORMULATIONS AND THE EFFECT OF DRUG SUBSTANCE PARTICLE SIZE ON ENTRECTINIB BIOAVAILABILITY IN H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000783-15,0,0,0 2019-000788-26,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Enrique de Madaria,Effect of early weight-based aggressive versus non-aggressive goal-directed fluid resuscitation in the early phase of acute pancreatitis: an open-label multicenter randomized-controlled trial Efect...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000788-26,0,0,0 2019-000790-23,4,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,"Adlai Nortye USA Inc.,","The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000790-23,0,0,0 2019-000790-23,4,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,Adlai Nortye USA Inc.,"The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000790-23,0,0,0 2019-000793-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS,"A phase II study on adjuvant Vaccination with dendritic cells loaded with autologous tumor homogenate in resected stage IV rare cancers: Head&Neck (H&N), neuroendocrine Tumors (NET) and soft tissue sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000793-27,0,0,0 2019-000794-23,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,CHU ANGERS,AntiCoagulants et COGnition (essai ACCOG) : Essai contrôlé randomisé en simple aveugle comparant les effets neurocognitifs du rivaroxaban par rapport à un antagoniste de la vitamine K AntiCoagulant...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000794-23,0,0,0 2019-000795-41,2,2022-05-19,2022-05-19,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Genentech Inc.,"A PHASE IIa, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF MTPS9579A IN PATIENTS WITH ASTHMA REQUIRING INHALED CORTICOSTEROI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000795-41,1,0,0 2019-000796-16,5,2021-12-09,2021-12-09,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Bone Therapeutics SA,"A Multicenter, Randomized, Double-blind, Placebo- and Active-Controlled Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000796-16,1,0,0 2019-000797-39,8,2022-08-16,2022-08-16,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study comparing GSK3196165 with placebo and with tofacitinib, in combination with methotrexate in participants with moder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000797-39,1,0,0 2019-000797-39,8,2022-08-16,2022-08-16,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study comparing GSK3196165 with placebo and with tofacitinib, in combination with methotrexate in participants with moder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000797-39,1,0,0 2019-000800-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI),"Effectiveness of a dual therapy based on dolutegravir plus lamivudine on reduction of the viral reservoir, immune recovery and immune activation compared with a triple antiretroviral therapy based on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000800-14,0,0,0 2019-000801-61,1,,,0,0,0,0,0,0,3,0,1,1,0,0,0,1,0,Institute of Tropical Medicine Antwerp,Toward an optimal accelerated Tick-Borne Encephalitis (TBE) vaccination schedule for the last-minute traveler,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000801-61,0,0,0 2019-000804-14,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Medical University of Vienna, Department of Clinical Pharmacology",The effect of hyperoxia and hypoxia on fluorescence lifetime imaging ophthalmoscopy in healthy subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000804-14,0,0,0 2019-000809-71,1,2020-12-18,2020-12-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark","Direct comparison of intra-articular saline injections with an education plus exercise program for treatment of knee osteoarthritis symptoms: A randomised, open label, controlled, evidence based trial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000809-71,0,0,0 2019-000810-12,15,2020-09-17,2020-09-17,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000810-12,1,0,0 2019-000810-12,15,2020-09-17,2020-09-17,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000810-12,1,0,0 2019-000810-12,15,2020-09-17,2020-09-17,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000810-12,1,0,0 2019-000812-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IMEA,"Initiation of first-line antiretroviral treatment with TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the first clinical contact in France: Trial IMEA 055 – FAST Instauration immédiate, dès...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000812-27,0,0,0 2019-000817-35,3,2022-02-16,2022-02-16,1,0,0,0,0,0,4,0,0,2,0,0,0,0,1,Almirall,"An open-label, randomized, Phase IV study, to assess the efficacy and safety of tildrakizumab in patients with moderate to severe chronic plaque psoriasis who are non-responders to dimethyl fumarate t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000817-35,1,0,0 2019-000818-11,2,2021-07-02,2021-07-02,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,Almirall,Clinical study to evaluate the efficacy and safety of a combination therapy with dimethyl fumarate (DMF) and NB-UVB phototherapy (versus DMF monotherapy) in adults with moderate-to-severe chronic plaq...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000818-11,0,0,0 2019-000818-11,2,2021-07-02,2021-07-02,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,"Almirall, S.A.",Clinical study to evaluate the efficacy and safety of a combination therapy with dimethyl fumarate (DMF) and NB-UVB phototherapy (versus DMF monotherapy) in adults with moderate-to-severe chronic plaq...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000818-11,0,0,0 2019-000821-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Bernardino Clavo - Hospital Universitario de G. C. Dr. Negrín,"Effectiveness and cost-effectiveness of Ozone therapy in patients with pain secondary to chemotherapy-induced peripheral neuropathy. Randomized, triple-blind clinical trial. Efectividad y coste-efe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000821-37,0,0,0 2019-000824-17,4,2022-02-10,2022-02-10,4,0,0,0,0,0,2,0,0,1,1,0,0,0,1,Landos Biopharma Inc.,"A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000824-17,0,0,0 2019-000826-22,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to characterize safety, tolerability and brain microglia response, as measured by TSPO binding, following mult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000826-22,0,0,0 2019-000833-37,9,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,VERTEX PHARMACEUTICALS INCORPORATED,"A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000833-37,0,0,0 2019-000833-37,9,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000833-37,0,0,0 2019-000836-24,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,National Institute of Health and the Environment,Immune responses to influenza and pneumococcal conjugate vaccines in older adults compared to middle-aged adults and adults.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000836-24,0,0,0 2019-000839-21,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Centre Hospitalier Intercommunal de Créteil,"Evaluation of the efficacy and safety of aprepitant in the management of vaso-occlusive crisis in sickle cell children: randomized, single-center, randomized, phase IIb/III prospective study Evalua...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000839-21,0,0,0 2019-000842-36,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Clatterbridge Cancer Centre NHS Foundation Trust,A Polatuzumab Vedotin Containing Chemo-Immunotherapeutic Regimen in Patients with Diffuse Large B-Cell Lymphoma Unsuitable for Full Dose R-CHOP Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000842-36,0,0,0 2019-000843-29,1,,,0,1,0,0,0,1,2,0,0,4,0,0,0,0,1,Ipsen Pharma,"Recombinant Human Growth Hormone (rhGH) and Recombinant Human Insulin-like Growth Factor-1 (rhIGF-1) Combination Therapy in Children with Short Stature Associated with IGF-1 Deficiency: A Six-year, Ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000843-29,0,1,1 2019-000844-81,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Ipsen Pharma,"RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF CHILDREN AND ADOLESCENTS WITH GROWTH FAILURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: AN OPEN-LABEL, MULTI-CENTER, EXTENSION STUD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000844-81,0,1,1 2019-000845-12,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,Canisius Wilhelmina Ziekenhuis,The effectiveness of vitamin D suppletion on improving symptoms of fatigue in children between 12 and 18 years old Het effect van de behandeling van vermoeidheidsklachten met vitamine D suppletie b...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000845-12,0,0,0 2019-000846-37,6,2021-10-20,2021-10-21,6,1,0,0,0,0,3,0,0,1,0,0,0,0,1,Incyte Corporation,"A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000846-37,0,0,0 2019-000846-37,6,2021-10-20,2021-10-21,6,1,0,0,0,0,3,0,0,1,0,0,0,0,1,INCYTE CORPORATION,"A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000846-37,0,0,0 2019-000847-28,6,2021-10-01,2021-10-01,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,INCYTE CORPORATION,"A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000847-28,0,0,0 2019-000847-28,6,2021-10-01,2021-10-01,5,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Incyte Corporation,"A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000847-28,0,0,0 2019-000848-95,1,2021-09-13,2021-09-13,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,"Dansk Hovedpine Center, Neurologisk Klinik, Rigshospitalet - Glostrup","A Placebo-Controlled, Double-Blind, Randomized, Proof-of-Concept Study to Evaluate the Efficacy and Tolerability of Erenumab in Patients with Trigeminal Neuralgia Et randomiseret, dobbelt-blindet, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000848-95,0,0,0 2019-000851-15,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,NKI-AVL,Treatment of metastatic vulvar carcinoma in a neoadjuvant setting with Carboplatin and Paclitaxel chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000851-15,0,0,0 2019-000852-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ErasmusMC,A preliminary study of Low Dose Naltrexone for the induction of remission in patients with mild to moderate Crohn’s Disease that failed conventional treatment: The LDN Crohn study. Een preliminair...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000852-32,0,0,0 2019-000853-30,1,2021-06-10,2021-06-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Druggability Technologies Holdings Ltd,"A Randomized, Double-Blind, Adaptive Trial with an Open-Label Treatment Extension to Determine the Efficacy and Safety of Topical DRGT-119 0.1% and 0.2% Gels in Patients with Chronic Anal Fissure ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000853-30,0,0,0 2019-000854-69,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"INFINITY PHARMACEUTICALS, INC.","A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination with IPI 549 Compared to Nivolumab Monotherapy in th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000854-69,0,0,0 2019-000854-69,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Infinity Pharmaceuticals, Inc.","A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination with IPI 549 Compared to Nivolumab Monotherapy in th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000854-69,0,0,0 2019-000857-29,1,2022-06-30,2022-06-30,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Rigshospitalet - University Hospital of Copenhagen,Hyperbaric oxygen treatment in humans with Gram Positive Cocci endocarditis Hyperbar Iltbehandling til patienter med gram positiv endokarditis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000857-29,0,0,0 2019-000860-99,5,2021-01-13,2021-01-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Eli Lilly and Company,"A Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide versus Placebo in Patients with Type 2 Diabetes Inadequately Controlled on Insulin Glargine with or withou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000860-99,0,0,0 2019-000860-99,5,2021-01-13,2021-01-13,5,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Lilly S.A.,"A Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide versus Placebo in Patients with Type 2 Diabetes Inadequately Controlled on Insulin Glargine with or withou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000860-99,0,0,0 2019-000867-26,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in parti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000867-26,0,0,0 2019-000868-18,9,2022-02-01,2022-02-01,6,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in partic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000868-18,1,0,0 2019-000868-18,9,2022-02-01,2022-02-01,6,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A 24-week, phase 3, multicentre, randomised, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in partic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000868-18,1,0,0 2019-000878-30,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,A multi-centre long-term extension study to assess the safety and efficacy of GSK3196165 in the treatment of rheumatoid arthritis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000878-30,0,0,0 2019-000880-26,1,2021-08-25,2021-08-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Heidelberg ImmunoTherapeutics GmbH,"A Randomized, Double-Blind, Double-Dummy Phase II Study of Single Dose HDIT101 versus Standard of Care Valaciclovir in Patients with Chronic Recurrent Anogenital HSV-2 Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000880-26,0,0,0 2019-000881-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Besançon,A phase II study evaluating the interest to combine UCPVax a CD4 TH1-inducer cancer vaccine and atezolizumab for the treatment of HPV positive cancers Etude de phase II évaluant l’intérêt d’associe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000881-39,0,0,0 2019-000882-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Efficacy of add-on PEramPanel in focal motor Status epilepticus Efficacité du PEramPanel (PER) dans le traitement de l'état de mal épileptique focal moteur,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000882-19,0,0,0 2019-000883-40,8,2022-04-14,2022-04-14,3,0,0,0,0,1,3,0,0,2,1,0,0,0,1,UCB Biopharma SRL,"An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000883-40,1,0,0 2019-000884-26,14,2022-04-14,2022-04-27,11,0,0,0,0,1,3,0,0,2,1,0,0,0,1,UCB Biopharma SRL,"A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000884-26,1,0,0 2019-000885-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Universitätsmedizin Göttingen,Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000885-39,0,0,0 2019-000886-19,5,2022-08-25,2022-08-26,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Millennium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited)","A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn’s Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000886-19,1,0,0 2019-000886-19,5,2022-08-25,2022-08-26,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Millennium Pharmaceuticals, Inc (a wholly owned subsidiary","A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn’s Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000886-19,1,0,0 2019-000886-19,5,2022-08-25,2022-08-26,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Millennium Pharmaceuticals, Inc (A wholly owned subsidiary of Takeda Pharmaceutical Company Limited)","A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn’s Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000886-19,1,0,0 2019-000889-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oslo University Hospital,Strategies towards personalised treatment in Juvenile Idiopathic Arthritis (JIA): An open randomised multicentre blinded-assessor trial assessing the effectiveness of intra-articular glucocorticoid ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000889-38,0,0,0 2019-000890-21,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Pfizer Inc,"A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CHILDREN 6 TO 17 YEARS OF AGE IN INDIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000890-21,0,1,1 2019-000894-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Department of Stem Cell Transplantation - University Medical Center Hamburg-Eppendorf,Phase II multicenter study of extracorporeal photopheresis with UvadexTM plus standard steroid treatment for high risk acute Graft-versus-Host Disease Multizentrische Phase II Studie zur Behandlung...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000894-22,0,0,0 2019-000895-40,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Aarhus University Hospital,Beta-agonist Efficacy and Tolerability as Adjuvant therapy in Myasthenia Gravis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000895-40,0,0,0 2019-000896-17,1,2020-07-16,2020-07-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Spring Bank Pharmaceuticals, Inc.","A PHASE 2, EXPLORATORY STUDY EVALUATING THE SAFETY AND ANTIVIRAL EFFICACY OF INARIGIVIR SOPROXIL IN NON-CIRRHOTIC, HEPATITIS B e ANTIGEN NEGATIVE SUBJECTS INFECTED WITH CHRONIC HEPATITIS B VIRUS AND R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000896-17,0,0,0 2019-000898-23,1,2020-02-12,2020-02-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,London School of Hygiene and Tropical Medicine,Pharmacokinetics of intramuscular tranexamic acid in trauma patients: a clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000898-23,0,0,0 2019-000902-31,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,OMEQUI,Healing efficacy after impacted mandibular third molar surgery with the use of autologous platelet-rich fibrin: a randomized controlled clinical study Eficacia en la cicatrización tras el uso de L-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000902-31,0,0,0 2019-000904-14,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie,"A Phase 3b, multicenter, interventional, open-label study of adult subjects with moderate to severe plaque psoriasis who have a suboptimal response to secukinumab or ixekizumab and are switched to ris...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000904-14,0,0,0 2019-000904-14,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co.KG,"A Phase 3b, multicenter, interventional, open-label study of adult subjects with moderate to severe plaque psoriasis who have a suboptimal response to secukinumab or ixekizumab and are switched to ris...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000904-14,0,0,0 2019-000904-14,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 3b, multicenter, interventional, open-label study of adult subjects with moderate to severe plaque psoriasis who have a suboptimal response to secukinumab or ixekizumab and are switched to ris...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000904-14,0,0,0 2019-000905-57,1,2020-10-01,2020-10-01,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,"The Department of Hepatology and Gastroenterology, Aarhus University Hospital",Efficacy of zinc on human gut copper uptake depending on zinc type and dose regimen quantified with 64CuCl2 PET/CT-scan Effekten af zink på kobberoptag i tarmen afhængig af zinktype og dosisregime...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000905-57,0,0,0 2019-000906-31,7,2020-09-15,2020-09-15,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,CSL BEHRING GMBH,"A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro10 (Intravenous Immunoglobulin, Privigen®) for the Treatment of Adults with Syste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000906-31,0,0,0 2019-000906-31,7,2020-09-15,2020-09-15,6,1,0,0,0,1,2,0,0,1,1,0,1,0,1,CSL Behring GmbH,"A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro10 (Intravenous Immunoglobulin, Privigen®) for the Treatment of Adults with Syste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000906-31,0,0,0 2019-000907-34,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Hookipa Biotech GmbH,A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000907-34,0,0,0 2019-000908-15,2,2022-08-08,2022-08-08,1,0,0,0,0,0,2,0,1,2,0,0,0,0,0,Aarhus University,"A randomized, double-blind, placebo-controlled, cross-over trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing observed by fu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000908-15,1,0,0 2019-000910-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Helperby Therapeutics Ireland Limited,"A Double-blinded, Parallel-group, Randomized, Active-controlled Phase 2 Clinical Trial to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous HY-001 Versus Standard Colistin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000910-12,0,0,0 2019-000913-35,1,,,0,0,0,0,1,0,3,0,0,1,0,0,0,1,1,BECRO (Cyprus) Ltd,"A Randomized, Observer-blind, two Parallel Group, Multi-center, Clinical Trial for Comparing the Efficacy and Tolerability of Dorzo-Vision® sine Preservative-Free Eye Drops vs. Trusopt® Preservative-F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000913-35,0,0,0 2019-000914-12,1,2022-03-17,2022-03-17,1,1,0,0,0,0,2,0,0,1,1,1,0,0,0,University of Cologne,"Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors Gazyvaro (Obinutuzumab) als zielgerichtete Therapie gegen Tumorwachstum fördernde, regulatorische B-Zellen bei soliden Tumoren",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000914-12,0,0,0 2019-000916-27,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,University of Birmingham,Investigation into the combination of PLX2853 with ruxolitinib in patients with intermediate-2 or high risk myelofibrosis not receiving an adequate response with ruxolitinib alone.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000916-27,0,0,0 2019-000919-85,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,DAMIAN Pharma AG,"DP13 – A Phase II Study in Patients with Primary Aldosteronism to Evaluate the Efficacy, Safety and Tolerability of the Aldosterone Synthase Inhibitor, DP13, over an 8-week Treatment Period",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000919-85,0,0,0 2019-000921-39,2,2021-04-12,2021-04-12,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,PHARMATHEN SA,"A prospective, phase III, multicenter, randomized, investigator-masked, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety and of a generic fixed combination of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000921-39,0,0,0 2019-000922-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Goethe-Universität Frankfurt,Transarterial chemoembolization (TACE) with Irinotecan and Mitomycin C versus TACE with Doxorubicin in patients with Hepatocellular carcinoma not amenable to curative treatment - IRITACE- a randomized...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000922-23,0,0,0 2019-000924-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS,"Multicenter, randomized, phase III, trial assessing the immunogenicity and safety of three meningococal B vaccine strategies among patients with asplenia Essai multicentrique, randomisé de phase I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000924-17,0,0,0 2019-000925-27,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Profem GmbH,"A phase IIb/III, parallel-arm, randomized, active-controlled, double-blind, double-dummy, multicenter, non-inferiority study in patients with recurrent vulvovaginal candidosis to compare the clinical ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000925-27,0,0,0 2019-000932-25,2,2020-09-03,2020-09-03,2,1,0,0,0,0,2,0,0,1,1,1,1,0,1,DS Biopharma Ltd.,"A Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Orally Administered DS107 in Adult Patients with Moderate to Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000932-25,0,0,0 2019-000935-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire (CHU) de Dijon,CIRCULATE- CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II CIRCULATE - Décision de traitement adjuvant des cancers coliques de stade II basée sur l’analyse de l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000935-15,0,0,0 2019-000936-24,2,2021-11-12,2021-12-11,2,0,0,0,0,0,2,0,0,1,0,0,0,0,0,"Section for Transfusion Medicine, Capital Region Blood Bank, Copenhagen University Hospital","Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in trauma patients with haemorrhagic shock induced endotheliopathy – a multicentre randomized, placebo-controlled, blinded, invest...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000936-24,0,0,0 2019-000938-20,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Radboudumc,Pharmacokinetic study of minocycline in patients with pulmonary nontuberculous mycobacterial disease Farmacokinetisch onderzoek naar minocycline in patienten met pulmonale nontuberculeuze mycobact...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000938-20,0,0,0 2019-000941-10,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,MENARINI RICERCHE SPA,A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000941-10,0,0,0 2019-000941-10,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Menarini Ricerche S.p.A,A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000941-10,0,0,0 2019-000942-36,3,2022-05-25,2022-05-25,3,0,0,0,0,0,2,0,1,1,1,0,0,0,0,Aarhus University,"A randomized, double-blind, placebo-controlled, cross-over, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000942-36,0,0,0 2019-000942-36,3,2022-05-25,2022-05-25,3,0,0,0,0,0,2,0,1,1,1,0,0,0,0,UMBERTO I - POLICLINICO DI ROMA,"A randomized, double-blind, placebo-controlled, cross-over, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000942-36,0,0,0 2019-000944-82,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000944-82,0,0,0 2019-000944-82,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000944-82,0,0,0 2019-000946-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Assistance Publique-Hôpitaux de Marseille,Molecular imaging exploration of ocular angiogenic activity and evaluation of its relevance in the therapeutic follow-up of AMD patients. Exploration par imagerie moléculaire de l’activité angiogé...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000946-37,0,0,0 2019-000949-13,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"OncXerna Therapeutics, Inc.","A Phase 2, multicenter open-label, non-randomized study of bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer who have progressed on or after at least one prio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000949-13,0,0,0 2019-000950-78,1,2021-05-11,2021-05-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Cassiopea S.p.A.,"A Phase 2, multicenter, prospective, randomized, double-blind, Minoxidil and vehicle controlled, dose-ranging study to evaluate the efficacy and safety of CB-03-01 (Cortexolone 17α-propionate) solutio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000950-78,0,0,0 2019-000951-14,6,2022-06-02,2022-06-02,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,RhoVac ApS,"A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000951-14,1,0,0 2019-000953-30,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Uppsala University Hospital,"Effects of phenoximetylpenicillin, amoxicillin and amoxicillin-clavulanic acid on the gut microbiota of healthy volunteers: a randomized clinical trail Fenoximetylpenicillin, amoxicillin och amoxi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000953-30,0,0,0 2019-000954-67,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Amicus Therapeutics, Inc.",A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000954-67,0,0,0 2019-000954-67,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"AMICUS THERAPEUTICS, INC.",A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000954-67,0,0,0 2019-000955-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Vienna,"Pulmonary pharmacokinetics of piperacillin/tazobactam and levofloxacin in patients with chronic obstructive pulmonary disease or cystic fibrosis: Comparison of epithelial lining fluid, in-vivo microdi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000955-16,0,0,0 2019-000959-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU de Brest,The NIPA study: A randomized double-blind control clinical trial Naloxegol administration to prevent opioids induced gastrointestinal motility disturbance in brain Injured PAtients. Etude NIPA : Es...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000959-14,0,0,0 2019-000968-18,9,2021-10-26,2021-10-26,6,0,0,0,0,1,3,0,0,2,0,0,0,0,1,UCB Biopharma SRL,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000968-18,1,0,0 2019-000968-18,9,2021-10-26,2021-10-26,6,0,0,0,0,1,3,0,0,2,0,0,0,0,1,UCB Biopharma SPRL,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000968-18,1,0,0 2019-000969-21,9,2021-09-01,2021-09-01,5,1,0,0,0,1,3,0,0,2,0,0,0,0,1,UCB Biopharma SRL,"A Randomized, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000969-21,1,0,0 2019-000969-21,9,2021-09-01,2021-09-01,5,1,0,0,0,1,3,0,0,2,0,0,0,0,1,UCB Biopharma SPRL,"A Randomized, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000969-21,1,0,0 2019-000971-17,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,UZ Brussel,Double trigger and ovum retrieval vs. conventional antagonist ovarian stimulation protocol in poor prognosis women undergoing IVF/ICSI: A pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000971-17,0,0,0 2019-000972-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Universitätsklinikum Freiburg,Safety and Efficacy of abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiency Sicherheit und Wirksamkeit von Abatacept (s.c.) in Patienten mit CTLA4 Insuffizi-enz oder LRBA Defizi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000972-40,0,0,0 2019-000973-22,1,,,0,0,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,"Immunogenicity and Safety of a Purified Vero Rabies Vaccine – Serum Free in Comparison with Verorab® and Imovax® Rabies, in a Pre-exposure Regimen in Both Pediatric and Adult Populations and Single Bo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000973-22,0,1,1 2019-000974-44,1,2022-03-11,2022-03-11,1,0,0,1,0,0,1,0,0,1,1,1,0,0,1,AstraZeneca AB,"A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000974-44,0,0,0 2019-000979-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Guillem Cuatrecasas - CPEN S.L.,Dapagliflozin effect in the reduction of different abdominal fat layers in type 2 diabetic patients. Efecto de dapagliflozina en la reducción de diferentes capas de grasa abdominal en pacientes dia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000979-16,0,0,0 2019-000982-19,1,2021-01-31,2021-01-31,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Instituto de Oftalmobiología Aplicada (IOBA),A Phase IV Open-Label Clinical Trial to Evaluate the Efficacy of Ikervis® on Clinical Parameters and Molecular/Cellular Biomarkers in Dry Eye Patients with Severe Keratitis who have not improved despi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000982-19,0,0,0 2019-000987-80,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Centre Léon Bérard,COTESARC - A multicentre Phase I-II study evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advanced and/or metastatic soft tissue sarcoma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000987-80,0,0,0 2019-000989-38,1,2020-05-06,2020-05-06,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE Ib, MULTICENTER, OPEN-LABEL, 6-WEEK STUDY WITH A 48 WEEK EXTENSION TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF BALOVAPTAN IN CHILDREN AGES 2-4 YEARS WITH AUTISM SPECTRUM D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000989-38,0,0,0 2019-000990-22,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,GARDP FOUNDATION,"A MULTI-CENTER, RANDOMIZED, OPEN-LABEL, NON INFERIORITY TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A SINGLE, ORAL DOSE OF ZOLIFLODACIN COMPARED TO A COMBINATION OF A SINGLE INTRAMUSCULAR DOSE OF CE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000990-22,0,0,0 2019-000991-41,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,STICHTING EUROPEAN MYELOMA NETWORK,"Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000991-41,0,0,0 2019-000991-41,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,Stichting European Myeloma Network,"Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000991-41,0,0,0 2019-000993-44,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000993-44,0,1,1 2019-000994-22,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000994-22,0,1,1 2019-000996-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Thomas Møller Jensen,Risk of post-polypectomy bleeding in patients on uninterrupted Clopidogrel therapy before polypectomy of sessile polyps; a double-blinded randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000996-17,0,0,0 2019-000998-23,1,2021-03-19,2021-03-19,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Institut de Recherches Internationales Servier,"A Phase I/II, open label, non-randomized study to evaluate safety, tolerability, pharmacokinetics and clinical activity of S64315 in patients with locally advanced or metastatic breast cancer in combi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000998-23,0,0,0 2019-000999-42,3,2020-05-21,2020-05-21,3,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"CytomX Therapeutics, Inc","A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody™ Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors (PROCLAIM-CX-072-002)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-000999-42,0,0,0 2019-001002-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospital Universitari Germans Trias i Pujol,"Pathophysiological mechanisms in the development of anal fistula. Oral antibiotics after anal abscess drainage to diminish perianal Fistula Formation: a multicenter, randomized, observer-blind, placeb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001002-18,0,0,0 2019-001003-20,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Affimed GmbH,A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (RE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001003-20,0,0,0 2019-001004-37,2,2021-03-24,2021-03-24,2,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma AG,"A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab every 4 weeks versus Aflibercept every 4 weeks in Adult Patients with Visual...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001004-37,0,0,0 2019-001005-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Hospital,Preoperative intravenous iron therapy in patients with gastric cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001005-25,0,0,0 2019-001009-26,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,KU Leuven - Drug Delivery and Disposition,Gastrointestinal behaviour of mesalazine in healthy volunteers Gastrointestinaal gedrag van mesalazine in gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001009-26,0,0,0 2019-001010-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Dermapharm AG,"Double-blind, randomised clinical study comparing efficacy and safety of Miconazole 2%_Fluprednidene 0.1% Cream (Test) vs. Vobaderm® Cream (Reference) vs. Vehicle in patients with moderate to severely...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001010-42,0,0,0 2019-001013-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU DIJON,FOLFIRINOX VERSUS PLATINUM - ETOPOSIDE AS FIRST LINE CHEMOTHERAPY FOR METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF GASTRO ENTERO PANCREATIC AND UNKNOWN PRIMARY ASSOCIATED WITH ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001013-16,0,0,0 2019-001015-23,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxychol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001015-23,0,0,0 2019-001016-35,1,2021-12-08,2021-12-08,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,"Associate Professor, Consultant Jens Børglum","The ultrasound-guided multiple-injection costotransverse block for mastectomy and primary reconstructive surgery. A double blind, randomised, placebo controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001016-35,0,0,0 2019-001020-36,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Ipsen Pharma,"RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF PREPUBERTAL CHILDREN WITH GROWTH FAILURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A PHASE 3, RANDOMIZED, OPEN LABEL, OBSERVATION-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001020-36,0,1,1 2019-001023-13,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Oxford / Clinical Trials and Research Governance,PAX-D: Randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001023-13,0,0,0 2019-001025-28,6,2022-03-02,2022-03-02,3,0,0,0,0,1,3,0,0,2,1,0,0,0,1,NuCana plc,"A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Trac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001025-28,1,0,0 2019-001027-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Poitiers,Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001027-12,0,0,0 2019-001030-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Egis Pharmaceuticals PLC,"A Prospective Open-label, Multicentric, Phase IV Trial to Compare the Efficacy of 10-Week Therapy of Ramipril and Indapamide SR Tablets Given Concomitantly with that of the Monotherapy of Ramipril or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001030-34,0,0,0 2019-001031-31,1,2021-02-22,2021-02-22,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Novartis Pharma GmbH,"A comperative BouBle Masked, Two-Arm, Randomized, MUlticenter, Phase IIb Study analyZing the Efficacy and Safety of BroluciZumab versus Aflibercept in Paients with Visual ImpaiRment due to Diabetic Ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001031-31,0,0,0 2019-001032-54,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Saint Etienne,Impact of anti-cytomegalovirus (valganciclovir) treatment in the management of relapsing ulcerative colitis (UC) requiring vedolizumab therapy: a randomized clinical trial comparing a strategy with or...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001032-54,0,0,0 2019-001037-13,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Boehringer Ingelheim International GmbH,"A streamlined, multicentre, randomised, parallel group, double-blind placebo-controlled superiority trial to evaluate the effect of EMPAgliflozin on hospitalisation for heart failure and mortality in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001037-13,0,0,0 2019-001038-32,1,2020-03-19,2020-03-19,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Lead Chemical Company Ltd,"Randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety of a Loxoprofen sodium 60 mg tape medicated plaster vs. placebo in the local symptomatic and short-term tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001038-32,0,0,0 2019-001042-18,6,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER",A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001042-18,0,0,0 2019-001042-18,6,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Eli Lilly and Company,A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001042-18,0,0,0 2019-001042-18,6,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Lilly SA,A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001042-18,0,0,0 2019-001043-41,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Mirati Therapeutics, Inc.",A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001043-41,0,0,0 2019-001043-41,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MIRATI THERAPEUTICS INCORPORATED,A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001043-41,0,0,0 2019-001044-22,1,,,0,1,0,0,0,1,2,0,0,3,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.","A Randomized, Double Blind, Placebo Controlled, Phase 2a Study to Assess the Clinical Efficacy of ISIS 721744, a Second Generation Ligand Conjugated Antisense Inhibitor of Prekallikrein, in Patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001044-22,0,0,0 2019-001045-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Grupo Español Multidisciplinar de Melanoma,"Phase II, Open-Label Study of preliminary efficacy of Durvalumab (MEDI4736) in Combination with Cediranib in Patients with Metastatic Uveal Melanoma Estudio abierto de fase II para evaluar la efica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001045-40,0,0,0 2019-001046-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Uppsala University,"A multicentre, register-based, randomized, controlled trial comparing dapagliflozin with metformin treatment in early stage type 2 diabetes patients by assessing mortality and macro- and microvascular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001046-17,0,0,0 2019-001059-37,2,2021-04-14,2021-04-15,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Alkahest, Inc.","Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001059-37,0,0,0 2019-001061-32,1,2020-08-18,2020-08-18,1,1,0,1,0,1,1,0,0,1,1,1,0,0,1,"ModernaTX, Inc.","A Global, Phase 1/2, Open Label, Dose Escalation Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3704 in Patients with Isolated Methylmalonic Acidemia Due to Methylmalonyl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001061-32,0,0,0 2019-001066-15,1,2020-03-27,2020-03-27,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Merete Hædersdal,"Treatment of hypertrophic scars using needle-free jet-injection of triamcinolone and 5-Fluorouracile: a prospective, controlled, randomized, single-blinded split-lesion trial. Behandling af hypert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001066-15,0,0,0 2019-001068-31,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Gustave Roussy,High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001068-31,0,0,0 2019-001068-31,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Goustave Roussy,High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001068-31,0,0,0 2019-001068-31,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,,High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001068-31,0,0,0 2019-001068-31,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,GUSTAVE ROUSSY,High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001068-31,0,0,0 2019-001071-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Cliniques Universitaires Saint-Luc,"Open label, phase II, Proof of Concept study of neoadjuvant celecoxib in newly diagnosed patients with endometrial carcinoma Acronym: Celebrido",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001071-37,0,0,0 2019-001072-11,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,A PHASE IB/III STUDY OF IPATASERTIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE LOCALLY ADVANCED UNRESECTABLE OR MET...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001072-11,0,0,0 2019-001073-86,3,2021-04-14,2021-04-14,2,1,0,0,0,1,2,0,0,2,1,0,0,0,1,"Molecular Templates, Inc.","Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory DLBCL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001073-86,1,0,0 2019-001074-29,6,2022-09-09,2022-09-09,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"An open-label, multicenter, extension study to evaluate the long-term safety and tolerability of LOU064 in eligible subjects with CSU who have participated in CLOU064A2201",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001074-29,1,0,0 2019-001075-36,1,2022-04-12,2022-04-12,1,0,0,0,0,0,2,0,0,1,1,1,0,0,0,Universitätsmedizin Mainz,"A phase II study to evaluate the safety, tolerability and efficacy of Cabozantinib in patients with hepatocellular carcinoma (HCC) and impaired liver function (Child-Pugh score B7-8) - CABOCHILD - ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001075-36,0,0,0 2019-001076-11,14,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001076-11,0,0,0 2019-001077-87,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut Jules Bordet,Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced head and neck cancer patients trea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001077-87,0,0,0 2019-001078-27,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Bayer AG,"Safety and efficacy of inhaled pegylated adrenomedullin (PEG-ADM) in patients suffering from Acute Respiratory Distress Syndrome (ARDS): a double-blind, randomized, placebo-controlled, multicenter Pha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001078-27,0,0,0 2019-001078-27,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,BAYER AG,"Safety and efficacy of inhaled pegylated adrenomedullin (PEG-ADM) in patients suffering from Acute Respiratory Distress Syndrome (ARDS): a double-blind, randomized, placebo-controlled, multicenter Pha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001078-27,0,0,0 2019-001079-35,1,2021-04-21,2021-04-21,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Cliniques universitaires Saint-Luc,A prospective randomized study in ambulatory patients undergoing upper limb bone surgery under single shot axillary plexus block.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001079-35,0,0,0 2019-001081-15,2,2021-04-06,2021-04-06,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Asarina Pharma ApS,"An exploratory phase II, randomised, double-blind, placebo-controlled, parallel-group study investigating the efficacy and safety of Sepranolone in women with menstrual migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001081-15,0,0,0 2019-001083-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska Institutet,A multicenter randomized double-blinded controlled phase 2 study evaluating the efficacy of valganciclovir as add-on therapy in glioblastoma patients En multicenter randomiserad dubbel-blind ko...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001083-30,0,0,0 2019-001084-71,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Pfizer Inc. 235 East 42nd Street, New York, New York","A PHASE 3 OPEN LABEL, MULTI CENTER, LONG TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001084-71,0,0,0 2019-001084-71,6,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Pfizer Inc.,"A PHASE 3 OPEN LABEL, MULTI CENTER, LONG TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001084-71,0,0,0 2019-001085-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,LABO’LIFE Belgium sprl,"Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infections. Étude randomisée, contrôlée contre placebo, en double ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001085-15,0,0,0 2019-001086-32,1,2022-10-06,2022-10-06,1,0,0,0,0,0,3,0,0,1,1,1,0,0,0,"RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty",ADVANCE-CSX Pilot – Antioxidant Treatment with Vitamin C in Cardiac Surgery Patients – a Clinical Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001086-32,0,0,0 2019-001087-30,13,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Celltrion, Inc","A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001087-30,0,0,0 2019-001087-30,13,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,CELLTRION INC.,"A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001087-30,0,0,0 2019-001088-58,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,SEntinel Lymph node in EarLY ovarian cancer: the SELLY protocol Accuratezza del Linfonodo Sentinella nel Carcinoma Ovarico Iniziale: il protocollo SELLY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001088-58,0,0,0 2019-001095-11,1,,,0,1,0,0,0,1,2,0,0,4,0,0,0,0,1,Ipsen Pharma,"RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF SHORT STATURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A MULTICENTER, OPEN-LABEL, CONCENTRATION-CONTROLLED TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001095-11,0,1,1 2019-001100-38,5,2022-06-30,2022-06-30,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Biohaven Pharmaceuticals, Inc.","Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001100-38,1,0,0 2019-001100-38,5,2022-06-30,2022-06-30,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Biohaven Pharmaceuticals, Inc","Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001100-38,1,0,0 2019-001106-23,6,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Apellis Pharmaceuticals, Inc.","An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). EINE OFFENE, NICHT ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001106-23,0,0,0 2019-001118-40,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Department of Pulmonology,Response to pneumococcal polysaccharide vaccination in healthy adults De respons op pneumokokken polysaccharide vaccinatie bij gezonde volwassenen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001118-40,0,0,0 2019-001123-13,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Verastem, INC","A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001123-13,0,0,0 2019-001123-13,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Verastem, Inc.","A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001123-13,0,0,0 2019-001125-27,1,2021-12-06,2021-12-06,1,1,0,0,0,0,4,0,0,1,0,0,0,0,0,University Hospitals Leuven,"Erector Spinae plane block for minimal invasive mitral valve surgery. A double blind, prospective randomized placebo-controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001125-27,0,0,0 2019-001131-31,1,2022-06-28,2022-06-28,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,"Section for transfusion Medicines, Capital Region Blood Bank, Copenhagen University Hospital","“Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in patients with septic shock induced endotheliopathy – a multicentre randomized, placebo-controlled, blinded, investigator-initi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001131-31,0,0,0 2019-001134-33,1,2021-05-19,2021-05-19,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Aarhus University Hospital,Does repeated administration of cefuroxime after orthopedic surgery provide a better prophylactic profile regarding postoperativ infection than a single administration of preoperative antimicrobial ?...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001134-33,0,0,0 2019-001138-32,6,,,0,0,0,0,0,2,2,0,0,3,0,0,0,0,1,"GlaxoSmithKline, S.A.","A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001138-32,0,0,0 2019-001138-32,6,,,0,0,0,0,0,2,2,0,0,3,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001138-32,0,0,0 2019-001139-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F. Hoffman-La Roche Ltd.,"A SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY STUDY OF RO7049389 IN: (1) SINGLE- (WITH OR WITHOUT FOOD) AND MULTIPLE- (WITH MIDAZOLAM) ASCENDING DOSES IN HEALTHY VOLUNTEERS; (2) PATIENTS CHRO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001139-30,0,0,0 2019-001142-18,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Hospices Civils de Lyon,Étude de tolérance au Cabozantinib dans le carcinome hépatocellulaire CLERANCE HCC (Cabozantinib toLERANCE study in HepatoCellular Carcinoma),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001142-18,0,0,0 2019-001143-43,1,2019-10-11,2019-10-11,1,0,0,0,0,0,4,0,1,1,1,1,1,0,1,Gedeon Richter Plc.,"An Open-label, Multi-center, Pharmacokinetic/Pharmacodynamic Study to Evaluate the Effect of a Single Dose of Levonorgestrel 1.5 mg Tablet on Ovulation Inhibition during Mid-follicular Phase in Underw...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001143-43,0,0,0 2019-001144-22,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Hinova Pharmaceuticals (USA), Inc.","PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-Inferiority, Efficacy and Safety Study of Oral HC-1119 versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001144-22,0,0,0 2019-001144-22,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Hinova Pharmaceuticals (USA) Inc.,"PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-Inferiority, Efficacy and Safety Study of Oral HC-1119 versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001144-22,0,0,0 2019-001146-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ROCHE SPA,"A PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) IN COMBINATION WITH CARBOPLATIN PLUS ETOPOSIDE TO INVESTIGATE SAFETY AND EFFICACY IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001146-17,0,0,0 2019-001147-51,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Västra götalandsregionen,Congenital myopathy intervention study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001147-51,0,0,0 2019-001151-40,1,2020-03-31,2020-03-31,1,1,0,0,1,0,2,0,1,1,1,1,1,0,1,RIEMSER Pharma GmbH,"Phase II pilot study: To determine an effective and tolerable dose of Hylase® ""Dessau"" (bovine hyaluronidase) in the treatment of hyaluronic acid filler overshoots by injection into defined areas of h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001151-40,0,0,0 2019-001153-10,10,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,X4 Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001153-10,0,0,0 2019-001153-10,10,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"X4 PHARMACEUTICALS, INC.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001153-10,0,0,0 2019-001154-26,1,,,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,Fundación de Investigación Biomédica Hospital Niño Jesús,Feasibility clinical trial of the combination of AloCelyvir with chemotherapy and radiotherapy for the treatment of children and adolescents with relapsed or refractory extracranial solid tumors. E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001154-26,0,0,0 2019-001155-39,5,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN PEDIATRICS AND YOUNG ADULTS WITH NO CURATIVE FIRST-LINE TREATMENT OPTION OR RECURRENT/REFRACTORY SOLID TUMORS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001155-39,0,0,0 2019-001155-39,5,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN PEDIATRICS AND YOUNG ADULTS WITH NO CURATIVE FIRST-LINE TREATMENT OPTION OR RECURRENT/REFRACTORY SOLID TUMORS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001155-39,0,0,0 2019-001160-29,1,2020-08-20,2020-08-20,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,LABORATOIRES SMB S.A,"A single blind, placebo controlled, three period, chronic dosing (6 weeks), multicentre, exploratory study to evaluate the effects of Nacystelyn (20 mg BID and 40 mg BID) on Functional Respiratory Ima...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001160-29,0,0,0 2019-001164-30,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Taiho Oncology, Inc.",A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001164-30,0,0,0 2019-001164-30,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,TAIHO ONCOLOGY INC.,A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001164-30,0,0,0 2019-001167-75,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,BTI I MAS D,"Randomized Clinical Trial, conventional treatment-controlled, studying the efficacy of Plasma Rich in Growth Factor (PRGF®) in alveolar ridge preservation after simple exodontia in the anterior region...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001167-75,0,0,0 2019-001169-34,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,Amgen Inc.,"An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone (KPd)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001169-34,0,0,0 2019-001169-34,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,AMGEN INC.,"An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone (KPd)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001169-34,0,0,0 2019-001169-34,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,,"An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma with Carfilzomib, Pomalidomide, and Dexamethasone (KPd)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001169-34,0,0,0 2019-001172-11,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,Medica Scientia Innovation Research (MedSIR),"A Multicenter, Open-Label, Single-ARm, PHase II Clinical Trial to Evaluate the Efficacy and Safety of INCMGA00012 in Advanced Penile SquamoUS Cell Carcinoma. ORPHEUS Phase II Study of the Efficacy of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001172-11,0,0,0 2019-001172-11,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,2,"MEDICA SCIENTIA INNOVATION RESEARCH, ARO","A Multicenter, Open-Label, Single-ARm, PHase II Clinical Trial to Evaluate the Efficacy and Safety of INCMGA00012 in Advanced Penile SquamoUS Cell Carcinoma. ORPHEUS Phase II Study of the Efficacy of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001172-11,0,0,0 2019-001176-11,2,2022-05-17,2022-05-17,2,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, parallel group, phase III multicenter study of intravenous secukinumab to compare efficacy at 16 weeks with placebo and to assess safety and tolerabilit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001176-11,0,0,0 2019-001177-90,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, parallel group, phase III multicenter study of intravenous secukinumab to compare efficacy at 16 weeks with placebo and to assess safety and tolerabilit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001177-90,0,0,0 2019-001181-15,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Fulcrum Therapeutics, Inc.","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 24-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001181-15,0,0,0 2019-001185-15,4,2021-11-16,2021-11-16,4,0,0,0,0,0,2,0,0,1,0,0,0,0,1,SynAct Pharma ApS,"A double-blind, multi-center, two-part, randomized, placebo-controlled study of the safety, tolerability, and efficacy of 4 weeks of treatment with AP1189 in early rheumatoid arthritis (RA) patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001185-15,0,0,0 2019-001186-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FISABIO,"Clinical trial, phase IV, randomized, double-blind, controlled, in children aged 12 to 35 months, of the vaccine against seasonal influenza to estimate efficacy against influenza and other respiratory...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001186-33,0,0,0 2019-001189-14,1,2020-03-16,2020-03-16,1,1,0,0,1,0,2,0,0,1,0,0,1,0,1,PIQUR Therapeutics AG,Exploratory study of the efficacy and safety of topical bimiralisib in an inflammatory and hyperproliferative skin condition,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001189-14,0,0,0 2019-001191-11,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Camurus AB,"A Phase 3, randomized, double-blind, placebo-controlled, multi-center trial to assess efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001191-11,0,0,0 2019-001197-28,1,2022-05-01,2022-05-01,1,1,0,0,0,0,2,0,0,1,1,1,0,0,0,University Medical Center Groningen,Can 89Zr-atezolizumab PET scan identify patients with metastatic invasive lobular breast cancer who will respond to chemotherapy-immune checkpoint inhibition?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001197-28,0,0,0 2019-001198-10,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Takeda,"A Phase 3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Inductio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001198-10,0,1,1 2019-001199-12,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Takeda,"Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001199-12,0,1,1 2019-001200-38,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset,"Octreotide treatment to improve nutritional recovery after surgery for patients with esophageal or gastric cancer, a prospective randomized open label phase II study - OTIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001200-38,0,0,0 2019-001201-24,7,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,"Kartos Therapeutics, Inc.","An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001201-24,0,0,0 2019-001201-24,7,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,"Kartos Therapeutics, Inc","An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001201-24,0,0,0 2019-001202-14,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Amsterdam UMC,CiPA Trial: Effect of Citalopram on chest pain in patients with achalasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001202-14,0,0,0 2019-001204-37,2,2022-06-30,2022-06-30,2,0,0,0,0,0,2,0,1,1,1,0,0,0,0,UMBERTO I - POLICLINICO DI ROMA,"A randomized, double-blind, placebo-controlled, cross-over, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001204-37,0,0,0 2019-001204-37,2,2022-06-30,2022-06-30,2,0,0,0,0,0,2,0,1,1,1,0,0,0,0,"Institute of Neuroscience (IoNS), Université catholique de Louvain","A randomized, double-blind, placebo-controlled, cross-over, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin and tapentadol on biomarkers of pain processing ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001204-37,0,0,0 2019-001209-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,INSTITUT DE CANCEROLOGIE DE L'OUEST,"Multicentre, randomized, controlled, open-label, multi-centre medico-economic study evaluating the efficacy of adding zoledronic acid to Stereotaxic radiotherapy in the treatment of vertebral metastas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001209-26,0,0,0 2019-001211-22,8,2022-09-01,2022-09-01,3,0,1,0,0,1,3,0,0,2,0,0,0,0,1,Mirum Pharmaceuticals Inc.,MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PF...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001211-22,1,0,0 2019-001212-29,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Aarhus University Hospital, Henrik Birn",Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001212-29,0,0,0 2019-001213-17,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,MYR GmbH,"""A Multicenter, Open-label, Randomized Phase 3 Clinical Study to Assess Efficacy and Safety of Bulevirtide in Patients with Chronic Hepatitis Delta"" ""Studio multicentrico, randomizzato, in aperto, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001213-17,0,0,0 2019-001216-38,1,2020-08-31,2020-08-31,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,"Hvidovre Hospital, Region Hovedstaden",Measurement of systemic pH and lactate in labouring women after intake of bicarbonate. Måling af systemisk pH og laktat hos fødende kvinder efter indtag af bikarbonat.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001216-38,0,0,0 2019-001219-22,4,2022-02-08,2022-02-08,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Seattle Genetics, Inc.",Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001219-22,1,0,0 2019-001219-22,4,2022-02-08,2022-02-08,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Seagen, Inc.",Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001219-22,1,0,0 2019-001219-22,4,2022-02-08,2022-02-08,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"SEATTLE GENETICS, INC.",Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001219-22,1,0,0 2019-001220-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CHU de Toulouse,A randomized double-blinded pilot study of the efficacy and safety of dupilumab versus placebo in patients with Netherton syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001220-35,0,0,0 2019-001222-98,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001222-98,0,0,0 2019-001222-98,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001222-98,0,0,0 2019-001226-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,PHASE II PROSPECTIVE STUDY OF NIRAPARIB IN THE SALVAGE TREATMENT OF PATIENTS WITH METASTATIC/RECURRENT/PERSISTENT UTERINE CERVICAL CARCINOMA: PROOF OF CONCEPT (Translational substudy: Evaluation of ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001226-10,0,0,0 2019-001227-12,10,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3b, open label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who successfully completed treatment in the M16-046 study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001227-12,0,0,0 2019-001227-12,10,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 3b, open label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who successfully completed treatment in the M16-046 study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001227-12,0,0,0 2019-001230-34,17,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and nivoluMAb clin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001230-34,0,1,0 2019-001230-34,17,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K: CHECKpoint pathway and nivoluMAb clin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001230-34,0,1,0 2019-001232-59,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Ghent University Hospital,Safety and Efficacy of Patient Controlled Analgesia using the Sublingual Sufentanil Tablet System (SSTS) in a fast track rehabilitation program after Total Knee Arthroplasty.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001232-59,0,0,0 2019-001234-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HUS Syöpäkeskus,Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Women with Breast Cancer Taking an Aromatase Inhibitor. Paikallisestrogeenin ja aromataasinestäjän yhteiskäytön aikaiset ver...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001234-34,0,0,0 2019-001235-31,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Charité – Universitätsmedizin Berlin,Factor XII-associated cold autoinflammatory syndrome (FACAS) linked to kallikrein-kinin pathology: Proof of concept treatment with Lanadelumab (DX-2930),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001235-31,0,0,0 2019-001237-14,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Dr. Jesús María Villar del Moral and Dr. José Luis Muñoz de Nova,"Randomized clinical trial, blinded for the researcher and multicenter, to evaluate the efficacy and safety of preoperative preparation with Lugol solution in euthyroid patients with Graves-Basedow dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001237-14,0,0,0 2019-001238-32,1,,,0,0,1,0,0,1,2,0,0,4,0,0,0,0,0,National Cancer Institute Cancer Therapy Evaluation,"Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001238-32,0,1,1 2019-001240-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Amsterdam UMC, location AMC","Exposure to orally administered antibiotics during the initial phase of infection in non-critically ill, febrile patients Blootstelling aan orale antibiotica tijdens de initiële fase van infectie b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001240-21,0,0,0 2019-001258-25,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Leeds,Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transpla...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001258-25,0,0,0 2019-001259-37,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,AstraZeneca AB,"An Open-Label, Multi-Centre, Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of 2-Week Treatment with Inhaled AZD7594 in Adolescents (12 to 17 years) with Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001259-37,0,1,1 2019-001260-29,1,2020-05-25,2020-05-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,CCH Pharmaceuticals,Proof of concept study for evaluation of the effect of ketamine intranasal spray in treatment of chronic Cluster Headache (CCH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001260-29,0,0,0 2019-001261-33,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,"Randomised phase II/III study of Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as initial therapy for Waldenström's macroglobulinaemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001261-33,0,0,0 2019-001262-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University Innsbruck,Comparison of Biphozyl® and Phoxilium® as a replacement fluid during Continuous Veno-Venous Hemofiltration (CVVH) with Regional Citrate Anticoagulation (RCA) for Acute Kidney Injury (AKI) in adults an...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001262-15,0,0,0 2019-001263-70,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Institut de Recerca H. de la Santa Creu i Sant Pau,"Immunotherapy with differential, adult, autologous, peripheral blood cells, expanded and transduced (genetically modified) using a lentiviral vector to express a chimeric receptor with anti-CD30 speci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001263-70,0,0,0 2019-001264-30,3,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Universitätsklinikum Würzburg,"A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001264-30,0,0,0 2019-001273-81,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001273-81,0,0,0 2019-001273-81,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,sanofi-aventis recherche & développement,"Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001273-81,0,0,0 2019-001277-93,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"""Príncipe de Asturias"" University Hospital",Usefulness of strengthering the bowel-cleansing preparation with Macrogol 3350 in patients with weak previous colonoscopy preparation Utilidad de intensificar la preparación de la colonoscopia con ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001277-93,0,0,0 2019-001279-34,5,2021-02-10,2021-04-13,3,1,0,0,0,1,2,0,0,2,1,0,0,0,1,Galapagos NV,"A multicenter, open-label extension study to evaluate the long-term safety, tolerability and efficacy of orally administered GLPG1690 in subjects with systemic sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001279-34,1,0,0 2019-001279-34,5,2021-02-10,2021-04-13,3,1,0,0,0,1,2,0,0,2,1,0,0,0,1,GALAPAGOS NV,"A multicenter, open-label extension study to evaluate the long-term safety, tolerability and efficacy of orally administered GLPG1690 in subjects with systemic sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001279-34,1,0,0 2019-001281-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Graz,A trial investigating the effect on blood glucose after the injection of fast-acting insulin aspart (Fiasp®) in comparison to insulin aspart (NovoRapid®) around exercise in participants with type 1 di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001281-14,0,0,0 2019-001283-30,4,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Spark Therapeutics,"Phase 1/2, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of SPK-3006 in adults with late-onset Pompe disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001283-30,0,0,0 2019-001285-15,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,University Medical Centre Ljubljana,Platelet inhibition with cangrelor in comatose survivors of out-of-hospital cardiac arrest undergoing primary percutaneous coronary intervention Inhibicija trombocitov s kangrelorjem pri komatoznih...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001285-15,0,0,0 2019-001289-14,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Estetra SPRL,A Randomized Double-blind Placebo Controlled Phase 3 Trial to evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001289-14,0,0,0 2019-001289-14,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Estetra SRL,A Randomized Double-blind Placebo Controlled Phase 3 Trial to evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001289-14,0,0,0 2019-001298-96,1,,,0,0,1,0,0,1,2,0,0,4,0,0,0,0,1,Eli Lilly and Company Limited,"Protocol I6T-MC-AMBU A Mulitcenter, Open-Label PK Study of Mirikizumab in Pediatric Patients with Moderately to Severely Active Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001298-96,0,1,1 2019-001301-24,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,National Institute for Public Health and the Environment (RIVM),‘Primary and booster meningococcal vaccination in Dutch elderly: study to investigate the immune response and determine functional antibodies after the tetravalent MenACWY-TT conjugate vaccine in the ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001301-24,0,0,0 2019-001302-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,BIOKOSMOS S.A.,Phase III study of Positron/Computerized Tomography (PETCT) with F-18-PSMA-1007 versus F-18-Fluorocholine to compare the detection rate of prostate cancer lesions in patients with biochemical recurren...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001302-15,0,0,0 2019-001306-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Amsterdam UMC, location VUmc",Reversal Of Arterial Disease by modulating Magnesium and Phosphate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001306-23,0,0,0 2019-001310-42,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospital Southampton NHS Foundation Trust,A RANDOMIZED PHASE II TRIAL ASSESSING TRIMODALITY THERAPY WITH OR WITHOUT ADJUVANT DURVALUMAB (MEDI4736) TO TREAT PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001310-42,0,0,0 2019-001310-42,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Canadian Cancer Trials Group (CCTG),A RANDOMIZED PHASE II TRIAL ASSESSING TRIMODALITY THERAPY WITH OR WITHOUT ADJUVANT DURVALUMAB (MEDI4736) TO TREAT PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001310-42,0,0,0 2019-001314-41,1,2020-07-01,2020-07-01,1,0,0,0,0,1,4,0,0,1,1,1,1,0,3,,Kinetics of ivacaftor at Switch Orkambi Symkevi study Kinetiek van ivacaftor op het moment van Switch Orkambi Symkevi onderzoek,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001314-41,0,0,0 2019-001316-38,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Department of Oncology, Herlev University Hospital",A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma Et fase II studie af en individualiseret behandlingsstrategi til patienter med m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001316-38,0,0,0 2019-001317-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ErasmusMC,The TRAIN study: TRAmetinib In Neurofibromatosis type 1 related symptomatic plexiform neurofibromas De TRAIN studie: TRAmetinib voor Neurofibromatose type 1 gerelateerde pleximorme neurofibromen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001317-16,0,0,0 2019-001318-40,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Starpharma Pty Ltd,"A phase 1/2 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SN38-SPL9111 (DEP®-SN38), a SN38 dendrimer conjugate, in patients with advanced sol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001318-40,0,0,0 2019-001323-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación PETHEMA,"A randomized phase III, multicentre, open label clinical trial comparing azacitidine plus pevonedistat versus azacitidine in Older/Unfit patients with newly diagnosed acute myeloid leukemia who are in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001323-12,0,0,0 2019-001324-35,1,2022-07-19,2022-07-19,1,0,0,0,1,0,4,0,0,1,0,0,0,0,0,Friedrich-Schiller-University Jena,Randomized single-blind study on the adherence to treatment with topical methylprednisolone aceponate (Advantan®) in different vehicles (AD-HERE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001324-35,0,0,0 2019-001325-27,2,2021-03-09,2021-03-09,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,H. Lundbeck A/S,"Interventional, open-label effectiveness study of flexible doses of vortioxetine on depressive symptoms in patients with major depressive disorder comorbid with generalized anxiety disorder Estudio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001325-27,0,0,0 2019-001325-27,2,2021-03-09,2021-03-09,1,1,0,0,0,0,4,0,0,1,1,0,1,0,1,H. LUNDBECK A/S,"Interventional, open-label effectiveness study of flexible doses of vortioxetine on depressive symptoms in patients with major depressive disorder comorbid with generalized anxiety disorder Estudio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001325-27,0,0,0 2019-001326-10,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,H. LUNDBECK A/S,"Interventional, open-label study of flexible doses of vortioxetine on depressive symptoms in patients with major depressive disorder and early dementia Estudio intervencionista sin enmascaramiento ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001326-10,0,0,0 2019-001326-10,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,H. Lundbeck A/S,"Interventional, open-label study of flexible doses of vortioxetine on depressive symptoms in patients with major depressive disorder and early dementia Estudio intervencionista sin enmascaramiento ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001326-10,0,0,0 2019-001328-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UMBERTO I - POLICLINICO DI ROMA,Multicenter prospective single-arm study investigating the efficacy and safety of second-line cetuximab plus chemotherapy treatment in initially RAS-mt mCRC patients who converted to RAS-wt at the tim...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001328-36,0,0,0 2019-001331-31,10,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Zogenix International Limited,An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients with Rare Seizure Disorders Such as E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001331-31,0,0,0 2019-001334-34,4,2021-05-07,2021-07-27,3,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"Randomized, Non-comparative Neoadjuvant Phase II Study in Patients with ER+/HER2- Breast Cancer >= 2 cm with Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001334-34,1,0,0 2019-001336-62,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Population Health Research Institute,Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001336-62,0,0,0 2019-001336-62,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hamilton Health Sciences Corporation,Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001336-62,0,0,0 2019-001337-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GETAID,USTekinumab in fistulising Perianal Crohn’s Disease: The USTAP CD study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001337-13,0,0,0 2019-001340-22,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Universtitätsklinikum St.Pölten,"A prospective, randomized, multicenter trial to compare a Taurolock™ based lock solution to a Citrate and Citrate/Urokinase based lock solution in tunneled hemodialysis catheters for the prevention of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001340-22,0,0,0 2019-001341-40,14,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes (PRO) in patients with relapsing multiple sclerosis (RMS) transiti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001341-40,0,0,0 2019-001341-40,14,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Farmacéutica S.A.,"A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes (PRO) in patients with relapsing multiple sclerosis (RMS) transiti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001341-40,0,0,0 2019-001342-18,1,2022-04-02,2022-04-02,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Instituto Bernabeu,CONVENTIONAL STIMULATION IN FOLICULAR PHASE VS. STIMULATION IN LUTEA PHASE IN PATIENTS WITH SUBOPTIMA RESPONSE. RANDOMIZED CLINICAL TRIAL. SUBLUTEAL STUDY ESTIMULACIÓN CONVENCIONAL EN FASE FOLICULA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001342-18,0,0,0 2019-001343-44,1,2021-05-08,2021-05-08,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Instituto Bernabeu,Conventional ovarian stimulation vs. stimulation with single injection of Corifollitropin alfa in oocyte donors. Randomized clinical trial. Tail Studio Estimulación ovárica convencional vs. estimul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001343-44,0,0,0 2019-001346-17,7,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,"ALNYLAM PHARMACEUTICALS, INC.","ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001346-17,0,1,0 2019-001346-17,7,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001346-17,0,1,0 2019-001358-24,4,2020-09-29,2020-09-29,2,1,0,1,0,0,1,0,0,1,1,0,0,0,1,Pfizer Inc.,A Phase 1b/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination with Bempegaldesleukin (NKTR-214) with or without Talazoparib or Enzalutamide in Participants with Locally Advanc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001358-24,0,0,0 2019-001361-33,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Cynata Therapeutics Limited,"A Randomised, Double-blind, Placebo-controlled Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of CYP-002 in Adults with Critical Limb Ischaemia who are Unsuitable for Revascularisa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001361-33,0,0,0 2019-001362-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital of Montpellier,Hepatocellular carcinoma less than 3 cm treated with percutaneous tumour destruction: multicentric phase 2 trial assessing the impact of idarubicin-lipiodol intra-arterial chemotherapy on hepatic recu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001362-15,0,0,0 2019-001363-67,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstructi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001363-67,0,0,0 2019-001364-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Assistance Publique- Hôpitaux de Paris,Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for FOLFIRINOX,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001364-30,0,0,0 2019-001365-32,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Imperial Joint Research Compliance Office,IP4- CHRONOS: Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001365-32,0,0,0 2019-001381-14,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Verastem, Inc.","A Phase 2, Randomized, Open-label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non-Hodgkin Lymphoma (iNHL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001381-14,0,0,0 2019-001381-14,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Verastem, INC","A Phase 2, Randomized, Open-label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non-Hodgkin Lymphoma (iNHL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001381-14,0,0,0 2019-001382-32,1,,,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,Beckley Canopy Therapeutics Ltd.,"A Double-Blind, Randomized Phase 1/2 Study to Assess the Efficacy and Safety of BCT-521 Versus Placebo for Pain Associated With Cancer in Patients Already Receiving Standard of Care Treatment With Opi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001382-32,0,0,0 2019-001384-68,1,2020-03-06,2020-03-06,1,1,1,0,0,0,1,0,0,1,0,0,1,0,1,Janssen Sciences Ireland UC,A Study to Assess the Acceptability of Scored Film-coated darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) Fixed-dose Combination (FDC) Tablets in HIV-1 Infected Pediatric Particip...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001384-68,0,0,0 2019-001385-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Clinic for Medicine and rehabilitation, Nord-Trondelag Trust (HNT)","Botulinum toxin A in frequent and chronic tension-type headache. A double blind, randomized, placebo-controlled cross-over trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001385-16,0,0,0 2019-001386-33,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,1,"Amplyx Pharmaceuticals, Inc.","A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients with Invasive Mold Infections Caused by Aspergillus Species or Rare Molds",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001386-33,0,0,0 2019-001388-55,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CONSORZIO ONCOTECH,A Phase II Trial of atezolizumab plus carboplatin plus paclitaxel as first-line therapy in metastatic Triple-negative PD-L1 positive breast cancer patients Studio Clinico di fase II con atezolizuma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001388-55,0,0,0 2019-001399-13,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,"MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable NRAS Melanoma: A Phase Ib/II Trial of Trametinib plus Hydroxychloroquine in Patients with NRAS Melanoma. CHLORO TRAM MEL E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001399-13,0,0,0 2019-001401-25,1,2022-04-01,2022-04-01,1,0,0,0,0,0,3,0,1,1,1,1,0,0,1,Sanofi Pasteur Inc.,Relative Effectiveness of a High-Dose Quadrivalent Influenza Vaccine versus a Standard-Dose Quadrivalent Influenza Vaccine in Subjects 65 Years of Age and Older,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001401-25,0,0,0 2019-001402-20,11,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,1,AstraZeneca AB,"An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001402-20,0,0,0 2019-001402-20,11,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,1,ASTRAZENECA AB,"An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001402-20,0,0,0 2019-001408-39,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Cardiff University,Treating Anxiety to PrevEnt Relapse in Psychosis (TAPERS): a feasibility trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001408-39,0,0,0 2019-001409-26,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,OncoSec Medical Incorporated,"A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melano...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001409-26,0,0,0 2019-001413-16,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001413-16,0,0,0 2019-001413-16,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001413-16,0,0,0 2019-001416-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Heinrich-Heine-University Düsseldorf represented by the Coordinating Investigator,IDH2-Post-Allo-Trial: Enasidenib as consolidation or salvage therapy for patients with IDH2 mutated AML or MDS following allogeneic blood stem cell transplantation IDH2-Post-Allo-Trial: Enasideni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001416-30,0,0,0 2019-001419-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de Nantes,Optimization of skin preparation to reduce Cutibacterium acnes colonization in superficial and deep samples during prosthetic shoulder surgery in male patients Optimisation de la préparation cutané...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001419-21,0,0,0 2019-001425-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Thoraxcentrum Erasmus MC,Rotterdam Edoxaban Leaflet Evaluation in Patients after Transcatheter Aortic Valve Implantation Rotterdam Edoxaban Klepblad evaluatie bij patienten na een percutane aortaklep vervanging,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001425-26,0,0,0 2019-001430-33,7,2021-12-14,2021-12-14,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001430-33,1,0,0 2019-001430-33,7,2021-12-14,2021-12-14,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001430-33,1,0,0 2019-001431-31,1,2020-03-18,2020-03-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Atea Pharmaceuticals, Inc.",A Phase 2 Study Assessing the Safety and Efficacy of AT-527 in Combination with Daclatasvir in Subjects with Chronic HCV Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001431-31,0,0,0 2019-001434-34,1,2022-02-28,2022-02-28,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,"Department of haematology, Zealand university hospital",Dual Vaccine Trial in Myeloproliferative Neoplasms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001434-34,0,0,0 2019-001435-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,ITF Research Pharma S.L.U.,Prospective and open clinical trial to evaluate the rapidity of action of a 0.005% estriol vaginal gel on the signs and symptoms of vaginal atrophy in postmenopausal women. BLISSET Study. Ensayo cl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001435-31,0,0,0 2019-001436-54,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Oryzon Genomics S. A.,"A single-center, open-label, single-arm, 13-week study to evaluate the efficacy, safety and tolerability of ORY-2001 in aggression in Alzheimer’s Disease (AD) – REIMAGINE-AD Estudio abierto, unicé...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001436-54,0,0,0 2019-001437-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Associazione Chirurghi Ospedalieri Italiani,Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in colorectal carcinoma at high risk of peritoneal carcinomatosis. Short and long-term outcomes....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001437-14,0,0,0 2019-001440-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Skåne University Hospital,"Phase 2, multicenter, randomized, open-label, controlled, 2-arm cross-over study to evaluate the clinical efficacy and safety of a renin inhibitor, aliskiren, compared to an angiotensin converting enz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001440-22,0,0,0 2019-001441-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,SciClone Pharmaceuticals Limited Ltd,A phase II trial to assess the activity and tolerability of Thymosin alpha 1 in Cystic Fibrosis Patients. Studio di Fase II per determinare l’attività e la tollerabilità di Timosina alfa 1 in pazi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001441-40,0,0,0 2019-001443-52,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,LABO'LIFE Belgium sprl,Randomized study to evaluate 2LVERU® JUNIOR and 2LVERU® efficacy on the treatment of warts. Protocol EVAsION Etude randomisée pour évaluer l’efficacité du 2LVERU® JUNIOR et du 2LVERU® sur le traite...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001443-52,0,0,0 2019-001447-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ENTE OSPEDALIERO OSPEDALI GALLIERA,Pilot Study of Daily Exemestane in Women with Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer Studio pilota con exemestane gi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001447-40,0,0,0 2019-001450-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Institute for Public Health and Caring Sciences, Uppsala University",Can the experience of a diminished effect of local anesthetics be verified by an objective test?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001450-26,0,0,0 2019-001453-10,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,Roche Farma S. A. U. que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche Ltd,"A MULTICENTER, LOW-INTERVENTIONAL STUDY DOCUMENTING THE EFFICACY, HEALTH-RELATED QUALITY OF LIFE, AND SAFETY OF STANDARD-OF-CARE TREATMENT WITH ECULIZUMAB OR TREATMENT WITH RAVULIZUMAB IN PATIENTS WIT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001453-10,0,0,0 2019-001458-24,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (AT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001458-24,0,0,0 2019-001458-24,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"ALNYLAM PHARMACEUTICALS, INC.","APOLLO-B: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (AT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001458-24,0,0,0 2019-001459-38,1,2020-12-01,2020-12-01,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Karus Therapeutics Limited,A Phase II study of selective HDAC6 inhibition with KA2507 in advanced biliary tract cancer previously treated with standard of care chemotherapy (ABC-11),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001459-38,0,0,0 2019-001461-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IrsiCaixa AIDS Research Institute,Immune Therapy and Analytical Treatment Interruption in HIV+ participants who received an allogeneic stem cell transplantation (ITATI) Terapia Inmune e Interrupción Analítica del Tratamiento en pac...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001461-32,0,0,0 2019-001462-15,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,medac Gesellschaft für klinische Spezialpräparate mbH,"A Randomised, Open label, Multicentre, Phase 3 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid refractor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001462-15,0,0,0 2019-001463-75,1,2021-07-21,2021-07-21,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,INSTITUT DE CANCEROLOGIE DE L'OUEST,Pilot Feasibility Study: Inflammation and presence of M2 macrophages explorations with[18F]-DPA-714 PET/CT in Triple Negative breast cancers Étude Pilote de faisabilité : Exploration par TEP/TDM a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001463-75,0,0,0 2019-001469-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE MELANOMA ONLUS,"A phase II, single arm study investigating neoadjuvant plus adjuvant treatment with Cemiplimab in high risk, surgically resectable, stage III Cutaneaous Squamous Cell Carcinoma Studio di fase II, a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001469-34,0,0,0 2019-001471-36,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Greater Glasgow and Clyde,Priming the Tumour MicroEnvironment for Effective Treatment with Immunotherapy in Locally Advanced Rectal Cancer: A Phase II trial of Durvulamab in Combination with Extended Neoadjuvant Regimens in R...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001471-36,0,0,0 2019-001471-36,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The University of Glasgow,Priming the Tumour MicroEnvironment for Effective Treatment with Immunotherapy in Locally Advanced Rectal Cancer: A Phase II trial of Durvulamab in Combination with Extended Neoadjuvant Regimens in R...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001471-36,0,0,0 2019-001476-11,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Alector Inc.,"A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AL002 IN PARTICIPANTS WITH EARLY ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001476-11,0,0,0 2019-001478-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Associazione Chirurghi Ospedalieri Italiani,Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in gastric carcinoma at high risk of peritoneal carcinomatosis. Short and long-term outcomes. A ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001478-27,0,0,0 2019-001483-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Reponex Pharmaceuticals A/S,"Effect of topical rhGM-CSF on the healing of venous leg ulcers: a randomized, placebo-controlled, double-blind, clinical phase II study Effekten af lokal behandling med rhGM-CSF på heling af venøse...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001483-30,0,0,0 2019-001485-15,2,2022-09-23,2022-09-23,1,0,0,0,0,1,2,0,0,2,0,0,0,0,1,MYR GmbH,"A Multicenter, Open-label, Randomized Phase 2b Clinical Study to Assess Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon alfa-2a in Patients with Chronic Hepatitis Delta",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001485-15,1,0,0 2019-001488-60,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Westdeutsche Studiengruppe GmbH,"A randomized, controlled, open-label, phase-III trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001488-60,0,0,0 2019-001491-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IRCCS SAN RAFFAELE PISANA GESTITO DA SAN RAFFAELE ROMA SRL,Phase IV study for efficacy and safety of Evolocumab added to Ezetimibe (Standard of Care) in high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia. Studio di ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001491-11,0,0,0 2019-001492-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital,Zoledronic acid as adjuvant therapy in neovascular Age-related Macular Degeneration (The Z-AMD study): a randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001492-37,0,0,0 2019-001493-28,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Medizinische Universität Graz, Univ.-Augenklinik",Raxone® treatment for patients with dominant optic atrophy due to OPA1 gene mutation Raxone® Behandlung bei OPA1 bedingter dominanter Optikusatrophie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001493-28,0,0,0 2019-001494-88,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Léon Bérard,"MegaMOST - A multicenter, open-label, biology driven, Phase II study evaluating the activity of anti-cancer treatments targeting tumor molecular alterations/characteristics in advanced / metastatic tu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001494-88,0,0,0 2019-001496-36,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,KU Leuven,The intestinal disposition of sulindac in healthy volunteers De intestinale dispositie van sulindac in gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001496-36,0,0,0 2019-001497-29,2,2021-06-14,2021-06-14,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Ra Pharmaceuticals, Inc.","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Immune-Mediated Necrotizing Myopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001497-29,0,0,0 2019-001500-38,9,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,ALLERGAN LIMITED,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of Linaclotide Administered Orally to Children, Ages 6 to 17 Years, With Functional Cons...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001500-38,0,0,0 2019-001500-38,9,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Allergan Ltd,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of Linaclotide Administered Orally to Children, Ages 6 to 17 Years, With Functional Cons...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001500-38,0,0,0 2019-001501-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST,"PHASE II STUDY OF AVELUMAB AND CETUXIMAB AND MODIFIED FOLFOXIRI AS INITIAL THERAPY FOR RAS WILD-TYPE UNRESECTABLE METASTATIC COLORECTAL CANCER PATIENTS Studio di fase II di FOLFOXIRI modificato, CE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001501-24,0,0,0 2019-001502-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rafael Uña,"Randomized, open and controlled clinical trial to evaluate pain after elective open surgery of the liver and pancreas in patients treated with spinal anesthesia with morphine chloride. On-Q incisional...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001502-23,0,0,0 2019-001503-20,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,"MEDICA SCIENTIA INNOVATION RESEARCH, ARO",PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FIRST LINE ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NEGATIVE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001503-20,0,0,0 2019-001503-20,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,Medica Scientia Innovation Research (MedSIR),PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FIRST LINE ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NEGATIVE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001503-20,0,0,0 2019-001505-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Department of Neurology, Division of Clinical Neuroscience, Oslo University Hospital",Norwegian study of Oral cladribine versus Rituximab in Multiple Sclerosis (NOR-MS). A prospective randomized open-label blinded endpoint (PROBE) multicenter non-inferiority study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001505-24,0,0,0 2019-001506-17,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,OXURION NV,"A Phase 2, randomised, multicentre study to assess the dose level of multiple THR-149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic mac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001506-17,0,0,0 2019-001506-17,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Oxurion NV,"A Phase 2, randomised, multicentre study to assess the dose level of multiple THR-149 injections and to evaluate the efficacy and safety of THR-149 versus aflibercept for the treatment of diabetic mac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001506-17,0,0,0 2019-001509-25,2,2021-05-15,2021-05-15,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Janssen Sciences Ireland UC,"A Two-Part Study With a Birth Cohort (Observational Stage) for Early Diagnosis of Respiratory Syncytial Virus (RSV), Followed by an Optional Phase 2a, Randomized, Double-blind, Placebo-controlled Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001509-25,1,0,0 2019-001512-34,3,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,1,Daiichi Sankyo Inc.,"A PHASE 2, OPEN-LABEL, SINGLE-ARM TRIAL OF TRASTUZUMAB DERUXTECAN (DS-8201A) IN HER2-POSITIVE, UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA SUBJECTS WHO HAVE PR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001512-34,0,0,0 2019-001512-34,3,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,1,DAIICHI SANKYO INC.,"A PHASE 2, OPEN-LABEL, SINGLE-ARM TRIAL OF TRASTUZUMAB DERUXTECAN (DS-8201A) IN HER2-POSITIVE, UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA SUBJECTS WHO HAVE PR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001512-34,0,0,0 2019-001515-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Régional du Cancer de Montpellier,Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma Etu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001515-23,0,0,0 2019-001517-16,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Allergy Therapeutics (UK) Ltd.,"A randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001517-16,0,0,0 2019-001518-40,1,2022-08-12,2022-08-12,1,0,0,0,0,0,4,0,0,1,1,1,0,0,0,VU Medical Center,"Netherlands study of Optimal, PERsonalized Antidepressant use (OPERA-DISCONTINUATION) Nederlandse studie naar Optimaal gePERsonaliseerd Antidepressiva gebruik (OPERA-AFBOUW)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001518-40,0,0,0 2019-001520-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospital Gelderse Vallei,Efficacy of low dose amitriptyline vs. cognitive behavioural therapy for chronic insomnia and medical comorbidity: a randomized controlled non inferiority trial. Effectiviteit van een lage doserin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001520-35,0,0,0 2019-001521-27,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Adare Pharmaceuticals US, LP","Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001521-27,0,0,0 2019-001528-37,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,1,Cbusinez,Long-term safety study of personalized magistral prepared cholic acid capsules in patients with bile acid synthesis defects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001528-37,0,0,0 2019-001529-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Reims,Efficacité et tolérance de l’ustekinumab dans la pemphigoïde bulleuse Efficacité et tolérance de l’ustekinumab dans la pemphigoïde bulleuse,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001529-28,0,0,0 2019-001530-33,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,CHRU TOURS,TOPical sirolimus in linGUal microkystic lymphatic malformation-TOPGUN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001530-33,0,0,0 2019-001531-32,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Imperial College Healthcare NHS Trust,"OBADIAH-2: A randomised, double-blind, placebo-controlled trial of two doses of obeticholic acid and placebo in patients with primary bile acid diarrhoea",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001531-32,0,0,0 2019-001532-65,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,1,LOFARMA S.P.A.,"A prospective, multicenter, double-blind, placebo-controlled randomized study to assess efficacy and safety of LAIS® Grass pollen tablets in patients with seasonal grass pollen-induced allergic rhinoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001532-65,0,0,0 2019-001534-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Odense University Hospital,Propofol and thiopental for intravenous induction in neonates: a dose finding study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001534-34,0,0,0 2019-001538-33,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Merck Healthcare KGaA,"A Phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and havin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001538-33,0,0,0 2019-001538-33,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK HEALTHCARE KGaA,"A Phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and havin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001538-33,0,0,0 2019-001539-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"The Fertility Clinic, Skive Regional Hospital",Optimizing serum progesterone level during luteal phase in hormone replacement therapy frozen embryo transfer (HRT-FET) cycle – interventional and observational trial Optimering af progesteronnivea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001539-29,0,0,0 2019-001540-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Abteilung für Hals- Nasen- Ohrenkrankheiten MUW, AKH Wien",Assessment of vertigo control rate following common treatments in Menière´s disease Schwindelkontrolle bei Morbus Menière,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001540-22,0,0,0 2019-001542-17,1,,,0,0,0,0,1,0,2,0,0,3,0,0,0,0,0,Timo Laitio,"Effect of xenon on brain injury, neurological outcome and survival in patients after aneurysmal subarachnoid hemorrhage Ksenonin vaikutus lukinkalvonalainen verenvuoto -potilaiden aivovaurioon, neu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001542-17,0,0,0 2019-001545-41,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,KURA ONCOLOGY INC,A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia Studio di fase 1/2A condotto per la prima volta sull’uomo d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001545-41,0,0,0 2019-001546-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE),"A phase II study of Platinum-doublet chemotherapy in combination with nivolumab as first-line treatment, in subjects with unresectable, locally advanced or metastatic G3 Neuroendocrine Neoplasms (NENs...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001546-18,0,0,0 2019-001548-23,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Guy's & St Thomas' NHS Foundation Trust,Does subarachnoid administration of hyperbaric prilocaine produce an improved recovery from anaesthesia when compared with hyperbaric bupivacaine when used to facilitate cervical cerclage in pregnant ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001548-23,0,0,0 2019-001549-42,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Sheffield Teaching Hospitals,"A multicentre, randomised controlled trial to evaluate the efficacy of autologous haematopoietic stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001549-42,0,0,0 2019-001550-26,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001550-26,0,0,0 2019-001550-26,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Lilly S.A,"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001550-26,0,0,0 2019-001550-26,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001550-26,0,0,0 2019-001551-39,8,2021-12-22,2022-02-04,5,0,1,0,0,0,2,0,0,2,1,0,0,0,1,Janssen Sciences Ireland Unlimited Company,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-5371867...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001551-39,1,0,0 2019-001551-39,8,2021-12-22,2022-02-04,5,0,1,0,0,0,2,0,0,2,1,0,0,0,1,Janssen Sciences Ireland UC,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-5371867...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001551-39,1,0,0 2019-001552-18,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,"Pfizer, Inc.","A LOCAL, SINGLE-CENTRE, EXTENSION, OPEN LABEL ACCESS STUDY, TO PROVIDE SILDENAFIL THERAPY FOR SUBJECTS WHO COMPLETED A1481156 STUDY AND ARE JUDGED BY THE INVESTIGATOR TO DERIVE CLINICAL BENEFIT FROM C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001552-18,0,1,1 2019-001553-12,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Fundacion ONCOSUR,"Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Base...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001553-12,0,0,0 2019-001554-25,1,,,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,Reade,Adalimumab dose optimization in rheumatoid arthritis using therapeutic drug monitoring (ADDORA): multi-center open label randomized controlled trail,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001554-25,0,0,0 2019-001555-40,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001555-40,0,0,0 2019-001559-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama),"A Randomized Phase II Study to Evaluate the Incidence of Discontinuations due to Diarrhoea at 3 Cycles in patients with Early-stage HER2-positive (HER2+), Hormone Receptor-positive (HR+) Breast Cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001559-38,0,0,0 2019-001560-30,2,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,Bayer AG,"Multicenter, single-blind, adaptive dose finding study of single intravenous injections of BAY 1747846 with corresponding blinded read in adult participants with known or highly suspected CNS lesions ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001560-30,0,0,0 2019-001561-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,"Dupilumab in adults with severe chronic hand eczema with an inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled proof of concept efficacy study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001561-32,0,0,0 2019-001562-15,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Advanced Accelerator Applications SA,"This is a multicenter, stratified, randomized, open-label comparator-controlled, Phase III study in patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs, diag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001562-15,0,0,0 2019-001563-74,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU de Nancy,Effect of early use of levosimendan versus placebo on top of a conventional strategy of inotrope use on a combined morbidity-mortality endpoint in patients with cardiogenic shock. LevoHeartShock Study...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001563-74,0,0,0 2019-001564-30,4,2021-12-30,2021-12-30,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Ra Pharmaceuticals, Inc.","A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001564-30,1,0,0 2019-001565-33,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Ra Pharmaceuticals, Inc. (now part of UCB)","A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001565-33,0,0,0 2019-001565-33,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Ra Pharmaceuticals, Inc.","A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001565-33,0,0,0 2019-001566-15,1,2020-07-14,2020-07-14,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,EIP Pharma Inc,"A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of the Oral P38 Alpha Kinase Inhibitor Neflamapimod in Dementia with Lewy Bodies (DLB) Een dubbelblind, placebogecontroleer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001566-15,0,0,0 2019-001572-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,LABO’LIFE Belgium sprl,"Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent genital herpes infections. Étude randomisée, contrôlée contre placebo, en double av...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001572-11,0,0,0 2019-001573-89,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001573-89,0,0,0 2019-001573-89,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001573-89,0,0,0 2019-001575-37,2,2020-09-07,2020-09-07,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,AMGEN INC.,Long-term Follow-up of Adult Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia Relapsed Refractory Patients Enrolled in Study 00103311,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001575-37,0,0,0 2019-001575-37,2,2020-09-07,2020-09-07,1,1,0,0,0,1,4,0,0,1,0,0,1,0,1,Amgen Inc.,Long-term Follow-up of Adult Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia Relapsed Refractory Patients Enrolled in Study 00103311,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001575-37,0,0,0 2019-001576-11,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"TESARO, Inc.","A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced En...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001576-11,0,0,0 2019-001576-11,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"TESARO, INCORPORATED","A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced En...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001576-11,0,0,0 2019-001578-27,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Abivax,"A follow-up Phase 2a open-label study to evaluate the one-year safety and efficacy profile of ABX464 in patients with moderate to severe active Rheumatoid Arthritis. II.a fázisú, nyílt utánkövetési...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001578-27,0,0,0 2019-001579-35,2,2020-08-05,2020-08-05,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"KBP BioSciences Co., Ltd.","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Pharmacokinetics of KBP-5074 in Patients with Moderate-to-Severe Chronic Kidney Disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001579-35,0,0,0 2019-001585-15,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire Vaudois,Genetically stratified randomized double-blinded allocation event-driven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia Etude d’allocation génétique de la prophyl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001585-15,0,0,0 2019-001587-30,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Queen Mary University London,AZD1656 in Transplantation with Diabetes tO PromoTe Immune TOleraNce,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001587-30,0,0,0 2019-001588-63,3,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neonate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001588-63,0,0,0 2019-001598-10,7,2021-12-22,2021-12-22,7,0,0,0,0,1,2,0,0,1,1,1,0,0,1,"PhaseBio Pharmaceuticals, Inc.","A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous Injections of a Sustained-Release VIP Analogue, PB1046, in Adult ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001598-10,0,0,0 2019-001599-12,4,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Ascelia Pharma AB,"A Multicenter, Open-label Study to Evaluate the Safety and Diagnostic Efficacy of Mangoral in Patients with Known or Suspected Focal Liver Lesions and Severe Renal Impairment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001599-12,0,0,0 2019-001605-24,3,2021-03-24,2021-03-24,1,1,1,0,0,1,3,0,0,2,1,0,0,0,1,GW RESEARCH LTD.,"An open-label extension trial to investigate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in patients with Rett Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001605-24,1,0,0 2019-001605-24,3,2021-03-24,2021-03-24,1,1,1,0,0,1,3,0,0,2,1,0,0,0,1,GW Research Ltd,"An open-label extension trial to investigate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in patients with Rett Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001605-24,1,0,0 2019-001618-41,1,,,0,0,0,0,1,0,2,0,0,3,0,0,0,0,0,Guy's and St Thomas NHS Foundation Trust,"FERARO: A prospective, randomised placebo controlled feasibility trial of Faecal microbiota Transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001618-41,0,0,0 2019-001619-21,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,HOSPITAL UNIVERSITARI DE BELLVITGE- IDIBELL,PILOT STUDY FOR THE OPTIMITZATION OF THE MAINTENANCE DOSE OF ECULIZUMAB ACCORDING TO THE WEIGHT IN ADULT PATIENTS WITH ATYPIC HEMOLYTIC UREMIC SYNDROME ESTUDIO PILOTO PARA LA OPTIMITZACIÓN DE LA DO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001619-21,0,0,0 2019-001621-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,A pilot study on oral s-ketamine for depression and demoralization in patients with advanced cancer receiving palliative care Pilotstudie naar het effect van orale Esketamine op depressie en demora...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001621-27,0,0,0 2019-001623-12,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,RANDOMIZED PHASE III MULTICENTRE STUDY INVESTIGATING THE ROLE OF LETROZOLE IN HEAVILY PRETREATED RECURRENT OVARIAN CANCER Studio randomizzato di fase 3 sulla somministrazione del letrozolo in pazie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001623-12,0,0,0 2019-001629-28,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,1,ENYO Pharma SA,"A Phase 2a, randomized, double-blind, placebo-controlled study of oral FXR modulator EYP001a combined with nucleos(t)ide analogues (NA) in virologically suppressed chronic hepatitis B patients to impr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001629-28,0,0,0 2019-001631-31,1,2021-03-19,2021-03-19,1,0,0,0,1,0,4,0,0,1,0,0,1,0,0,Steno Diabetes Center Copenhagen,Dual-Hormone Closed-Loop Glucose Control in Type 1 Diabetes Automatisk regulering af blodsukkeret med insulin og glukagon hos patienter med type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001631-31,0,0,0 2019-001633-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA","A single-centre, open-label pilot study to assess the efficacy and safety of CBD oral solution as an adjunctive treatment for pediatric subjects with Developmental and Epileptic Encephalopathy Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001633-14,0,0,0 2019-001636-60,1,2021-06-09,2021-06-09,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"University clinic of Nephrology and Hypertension, Regional Hospital Holstebro",The effect of spironolactone on renal hemodynamics in patients with essential hypertension Effekten af spironolakton på renal hæmodynamik hos essentielle hypertonikere,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001636-60,0,0,0 2019-001639-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Spanish Oncology Genitourinary Group - SOGUG,"Pilot study of cabozantinib efficacy, safety and tolerability in metastatic renal carcinoma in aged fragile patients: CABOMAYOR study Estudio piloto para evaluar eficacia, seguridad y tolerabilidad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001639-30,0,0,0 2019-001641-40,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTI FISIOTERAPICI OSPITALIERI,Induction Durvalumab (MEDI4736) & Radiotherapy (RT) for Locally Advanced but Resectable Head and Neck Squamous Cell Carcinomas: A Pilot Study Studio pilota di induzione con Durvalumab (MEDI4736) e ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001641-40,0,0,0 2019-001642-18,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,"Department of Ophthalmology, Rigshospitalet-Glostrup",Effect on the ocular surface when treating glaucoma with eye drops: an investigation of the conjunctival goblet cells Påvirkningen af øjets overflade ved behandling af glaukom: en undersøgelse af d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001642-18,0,0,0 2019-001645-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Memorial Sloan Kettering Cancer center,"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001645-41,0,0,0 2019-001647-46,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut de Recerca H. de la Santa Creu i Sant Pau,Evaluation of the regenerative efficacy of Endoret® (PRGF-Plasm Rich in Growth Factors) on the ocular surface of glaucoma patients treated chronically with ocular hypotensive drugs Evaluación de la...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001647-46,0,0,0 2019-001650-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital South West Jutland,Zoledronic acid for prevention of bone loss after bariatric surgery Zoledronsyre til forebyggelse af knogletab efter operation for overvægt,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001650-26,0,0,0 2019-001653-99,7,2021-04-16,2021-04-16,7,1,0,0,0,0,3,0,0,1,1,0,1,0,1,Eli Lilly and Company,"A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active- Controlled Treat-Through Study of Mirikizumab and Vedolizumab in Participants with Moderately to Severely Active Ulcerative Col...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001653-99,0,0,0 2019-001655-39,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Seagen Inc.,"A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin Versus Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer Ensayo en fase III, aleatoriz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001655-39,0,0,0 2019-001655-39,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Genmab A/S,"A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin Versus Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer Ensayo en fase III, aleatoriz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001655-39,0,0,0 2019-001655-39,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SEAGEN INC.,"A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin Versus Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer Ensayo en fase III, aleatoriz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001655-39,0,0,0 2019-001656-19,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Rocket Pharmaceuticals, Inc.",Gene Therapy for Pyruvate Kinase Deficiency (PKD): A Phase I Clinical Trial to Evaluate the Safety of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the Codon Opti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001656-19,0,0,0 2019-001657-42,2,2021-03-10,2021-03-10,2,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Alkahest, Inc.","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson's Disease on Stable Dopaminergic Treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001657-42,0,0,0 2019-001660-30,3,2021-03-09,2021-03-09,2,1,0,0,2,0,3,0,0,1,0,0,1,0,1,Sintetica S.A.,"A prospective, observer-masked, randomized clinical trial to investigate and compare the clinical efficacy of chloroprocaine 3% gel and tetracaine 0.5% eye drop as topical anesthetics in phacoemulsifi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001660-30,0,0,0 2019-001660-30,3,2021-03-09,2021-03-09,2,1,0,0,2,0,3,0,0,1,0,0,1,0,1,SINTETICA S.A.,"A prospective, observer-masked, randomized clinical trial to investigate and compare the clinical efficacy of chloroprocaine 3% gel and tetracaine 0.5% eye drop as topical anesthetics in phacoemulsifi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001660-30,0,0,0 2019-001666-15,4,2022-09-13,2022-09-13,1,0,0,0,0,0,3,0,1,2,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK's meningococcal Group B and combined ABCWY vaccines when administered to health...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001666-15,1,1,0 2019-001673-93,6,2022-09-23,2022-09-23,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim BV,"An open label, long term safety trial of spesolimab treatment in patients with fistulising Crohn’s disease who have completed previous spesolimab trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001673-93,1,0,0 2019-001673-93,6,2022-09-23,2022-09-23,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim S.A.,"An open label, long term safety trial of spesolimab treatment in patients with fistulising Crohn’s disease who have completed previous spesolimab trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001673-93,1,0,0 2019-001673-93,6,2022-09-23,2022-09-23,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An open label, long term safety trial of spesolimab treatment in patients with fistulising Crohn’s disease who have completed previous spesolimab trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001673-93,1,0,0 2019-001673-93,6,2022-09-23,2022-09-23,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim,"An open label, long term safety trial of spesolimab treatment in patients with fistulising Crohn’s disease who have completed previous spesolimab trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001673-93,1,0,0 2019-001673-93,6,2022-09-23,2022-09-23,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"An open label, long term safety trial of spesolimab treatment in patients with fistulising Crohn’s disease who have completed previous spesolimab trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001673-93,1,0,0 2019-001677-81,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Akershus Universitetssykehus,"Remifentanil tapering and post-adenotonsillectomy pain in children: a randomised, placebo controlled, double blind study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001677-81,0,0,0 2019-001678-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de NIMES,Erectus nerve block for lumbar spine surgery : a prospective randomized study Efficacité analgésique du bloc des érecteurs du rachis pour arthrodèse rachidienne lombaire : étude comparative contre ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001678-26,0,0,0 2019-001679-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Aarhus University,Treatment Of Metastic Bladder cancer at the time Of biochemical reLApse following radical cystectomy Behandling af metastatisk blærekræft ved biokemisk recidiv efter radikal cystektomi,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001679-36,0,0,0 2019-001680-69,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Athersys, Inc.",MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001680-69,0,0,0 2019-001682-33,1,2020-08-05,2020-08-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"GB001, Inc.","A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study to evaluate the effect of GB001 in patients with chronic rhinosinusitis with or without nasal polyps Multicentrická rand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001682-33,0,0,0 2019-001683-29,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-61393215 as Adjunctive Treatment in Adults with Major Depressive Disorder with Anxious ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001683-29,0,0,0 2019-001684-77,1,2021-08-18,2021-08-18,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A 12-weeks Phase II, randomized, double-blind, placebocontrolled, parallel-group, proof-of-concept trial of BI 730357 in patients with active ankylosing spondylitis A BI 730357 vizsgálati gyógyszer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001684-77,0,0,0 2019-001687-30,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,European Thoracic Oncology Platform (ETOP),"A randomised non-comparative open label phase II trial of atezolizumab plus bevacizumab, with carboplatin-paclitaxel or pemetrexed, in EGFR mutant non-small cell lung carcinoma with acquired resistanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001687-30,0,0,0 2019-001688-66,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Warwick,Sugar or Salt (SOS) trial: Hyperosmolar therapy in traumatic brain injury,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001688-66,0,0,0 2019-001688-66,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University Hospitals Birmingham NHS Foundation Trust,Sugar or Salt (SOS) trial: Hyperosmolar therapy in traumatic brain injury,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001688-66,0,0,0 2019-001691-11,1,,,0,1,0,0,0,1,2,0,0,4,0,0,0,0,1,"PTC Therapeutics, Inc.","Phase 2, Non-Interventional, Clinical Study to Assess Dystrophin Levels in Subjects With Nonsense Mutation Duchenne Muscular Dystrophy Who Have Been Treated With Ataluren for ≥9 Months",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001691-11,0,1,1 2019-001692-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Tuebingen,"Pharmacologic treatment augmentation in chronic depression randomized, controlled, double blinded, phase II study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001692-37,0,0,0 2019-001693-28,1,2021-02-17,2021-02-17,1,1,0,0,0,1,2,0,0,1,0,0,1,0,1,Octapharma Pharmazeutika Produktionsges.m.b.H.,"Prospective, open-label, single arm, multicenter, pharmacokinetic, and safety study of a single dose intravenous human plasma-derived C1 Esterase Inhibitor (C1-INH) concentrate in patients with congen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001693-28,0,0,0 2019-001696-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,Study of efficacy of low-dose recombinant human interleukin-2 in immunological changes associated with depression (IL2REG) Studio di efficacia dell’interleuchina-2 ricombinante umana a basso dosagg...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001696-36,0,0,0 2019-001698-10,9,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Ionis Pharmaceuticals, Inc.","A Phase 3 Global, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001698-10,0,0,0 2019-001699-12,1,2019-12-17,2019-12-17,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,GlaxoSmithKline Research and Development Ltd,"An open-label, randomized three period cross-over relative bioavailability study to compare the pharmacokinetic parameters of a lower dose formulation of ambrisentan (GSK1325760) with marketed ambrise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001699-12,0,0,0 2019-001703-20,6,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,"Dyax Corporation, a Takeda company","A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001703-20,0,0,0 2019-001703-20,6,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,DYAX CORP.,"A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001703-20,0,0,0 2019-001706-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,BOOG Study Center,"A phase 2 study of trifluridine/tipiracil in patients with ER-positive, HER2-negative advanced breast cancer that previously received chemotherapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001706-15,0,0,0 2019-001707-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AIO-Studien-gGmbH,Single-Arm Phase II-Study in Patients with extensive stage small-cell lung cancer (ES-SCLC) with Poor Performance Status receiving Atezolizumab-Carboplatin-Etoposide Eine einarmige Phase-II-Studie ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001707-21,0,0,0 2019-001709-25,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The Institute of Cancer Research,Randomised phase II trial testing efficacy of intra-tumoural hydrogen peroxide as a radiation sensitiser in patients with locally advanced/recurrent breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001709-25,0,0,0 2019-001711-23,1,2021-07-01,2021-07-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Centre Léon Bérard,CICA-RT – Phase III randomized multicenter study evaluating Cicaderma® ointment efficacy versus the current practice of each center for the radiation dermatitis prevention in patients with non-metasta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001711-23,0,0,0 2019-001717-17,1,2020-03-30,2020-03-30,1,0,0,0,0,0,4,0,0,1,0,0,1,0,1,Pohl-Boskamp GmbH & Co. KG,"A multi-centre, randomised, placebo-controlled, double-blind parallel-group trial to assess the efficacy and safety of SIA capsules in subjects with acute rhinosinusitis. Wirksamkeit und Verträglic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001717-17,0,0,0 2019-001719-21,1,2020-09-29,2020-09-29,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomized, double blind, placebo-controlled, multi-center, parallel group study to compare the efficacy of inhaled tiotropium + olodaterol, fixed dose combination (5μg/5μg) vs. placebo delivered by...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001719-21,0,0,0 2019-001720-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Besançon,Evaluation de l’intérêt d’une polychimiothérapie par XELOXIRI-3 chez les patients âgés ou fragiles atteints d’un adénocarcinome pancréatique métastatique Evaluation de l’intérêt d’une polychimiothé...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001720-35,0,0,0 2019-001723-12,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Universitätsspital Zürich, Klinik für Angiologie",Aspirin® plus rivaroxaban versus rivaroxaban alone for the prevention of venous stent thrombosis in patients with post-thrombotic syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001723-12,0,0,0 2019-001724-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Universitario de La Paz (FIBHULP),AMASCIS-02. ALOGENIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN ISCHEMIC STROKE. A PHASE IIB MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED CLINICAL TRIAL. AMASCIS-02. ADMINISTRACIÓN INTRAVENOSA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001724-35,0,0,0 2019-001725-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Martin-Luther-Universität Halle-Wittenberg,"A randomized, open, three-arm comparative study of modern methods of postoperative pain therapy in patients with knee endoprostheses. Eine randomisierte, offene dreiarmige Vergleichsstudie bestehen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001725-27,0,0,0 2019-001726-99,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier de Versailles,Comparison of corticosteroids versus placebo on duration of ventilatory support during severe acute exacerbations of COPD patients in the intensive care unit: a multicentre randomized controlled trial...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001726-99,0,0,0 2019-001727-12,1,,,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,Topas Therapeutics GmbH,"A multi-centre, open-label, phase 1 study, Part A single ascending dose and Part B multiple dose, to evaluate the safety, tolerability and pharmacokinetics, and to explore early signs of effectiveness...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001727-12,0,0,0 2019-001730-34,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Sangamo Therapeutics France SAS,"A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001730-34,0,0,0 2019-001731-31,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Aarhus University Hospital,Cytotoxicity of Yellow Fever specific CD8 T cells Following YF-17D Vaccination Immunrespons efter gul feber (YF-17D) vaccination,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001731-31,0,0,0 2019-001734-34,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, treatment open-label, dose-blinded, parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001734-34,0,0,0 2019-001734-34,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A randomized, treatment open-label, dose-blinded, parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001734-34,0,0,0 2019-001735-31,2,2020-07-24,2020-07-24,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3b, Randomized, Double blind, Controlled Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001735-31,0,0,0 2019-001739-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medica Scientia Innovation Research S.L. (MEDSIR),"A Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan (DS-8201a) in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001739-29,0,0,0 2019-001745-40,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001745-40,0,0,0 2019-001745-40,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001745-40,0,0,0 2019-001748-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Leiden University Medical Center,"Multicenter, open-label, controlled, parallel arms clinical study on the performance of SGM-101, a fluorochrome-labeled anti-carcino-embryonic antigen (CEA) monoclonal antibody, for locally advanced o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001748-23,0,0,0 2019-001754-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Reade,Using adalimumab serum concentration to choose a subsequent biological treatment in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): an open label randomized superiority tra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001754-25,0,0,0 2019-001755-39,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Acerta Pharma B.V. (A Member of the AstraZeneca Group),"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects <= 65 Year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001755-39,0,0,0 2019-001755-39,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ACERTA PHARMA BV,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects <= 65 Year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001755-39,0,0,0 2019-001755-39,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Acerta Pharma B.V.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects <= 65 Year...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001755-39,0,0,0 2019-001756-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,María de los Ángeles Tena Pajuelo (Investigador independiente),"MULTI-CENTER, DOUBLE-BLIND, CONTROLLED, PARALLEL AND RANDOMIZED STUDY TO COMPARE THE EFFECTIVENESS OF 0.1 ΜG / KG / MIN OF LEVOSIMENDAN VERSUS PLACEBO IN THE POSTOPERATIVE OF CARDIAC PROGRAMMED SURGER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001756-19,0,0,0 2019-001757-54,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Apollomics, Inc.","Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001757-54,0,0,0 2019-001757-54,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Apollomics Inc.,"Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001757-54,0,0,0 2019-001759-38,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Ruprecht-Karls University Heidelberg Medical Faculty, University Hospital represented in law by its commercial director","Pharmacokinetics of a microdosed cocktail containing rivaroxaban, apixaban and edoxaban in children with congenital heart defects Pharmakokinetik eines mikrodosierten Cocktails bestehend aus Rivaro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001759-38,0,0,0 2019-001760-30,2,2020-01-09,2020-01-09,2,1,0,0,0,1,2,0,0,1,1,1,1,0,1,CymaBay Therapeutics,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients with Primary ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001760-30,0,0,0 2019-001762-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen,"Evaluation of the anti-inflammatory effects of glycopyrronium added to indacaterol/mometasone on the allergen-induced late asthmatic response Een gerandomiseerd, dubbelblind, cross-over onderzoek n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001762-14,0,0,0 2019-001764-29,8,2022-08-18,2022-08-18,5,0,0,0,0,2,3,0,0,2,0,0,0,0,1,Regeneron Pharmaceuticals. Inc.,"Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients with Retinopathy of Prematurity",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001764-29,1,0,0 2019-001767-67,1,,,0,1,0,0,0,1,2,0,0,4,0,0,0,0,1,"PTC Therapeutics, Inc.",Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment with Ataluren,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001767-67,0,1,1 2019-001770-29,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Philipps-Universität Marburg,"Viral load guided Immunosuppression after Lung Transplantation An open-label, randomized, controlled, parallel-group, multicenter trial (VIGILung) Viruslast gesteuerte Immunsuppression nach Lunge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001770-29,0,0,0 2019-001771-36,1,2020-09-30,2020-09-30,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,Centre for Human Drug Research,Assessment of Neublastin-Induced Skin and Sensory Alterations and Headache in Healthy Subjects and Migraine Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001771-36,0,0,0 2019-001772-10,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Assistance Publique-Hôpitaux de Marseille,Phase I study of oral metronomic NAVELBINE® and HEMANGIOL®combination for children and teenagers with refractory/relapsing solid tumors Etude de phase I d’une combinaison orale de propranolol et d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001772-10,0,0,0 2019-001773-90,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA SANT'ANDREA,"Metagenomic analysis of the gut microbiota in patients with psoriatic arthritis upon treatment with the jak-stat inhibitor tofacitinib: correlations with immunological, clinical and imaging markers ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001773-90,0,0,0 2019-001775-37,2,2022-02-28,2022-02-28,2,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Medicines Development for Global Health Limited,"A Phase II, randomized, double-blind, parallel group dose finding study of single oral doses of moxidectin in adults with scabies Eine randomisierte, doppelblinde, Parallelgruppenstudie der Phase-I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001775-37,0,0,0 2019-001775-37,2,2022-02-28,2022-02-28,2,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Medicines Development Limited (trading as Medicines Development for Global Health),"A Phase II, randomized, double-blind, parallel group dose finding study of single oral doses of moxidectin in adults with scabies Eine randomisierte, doppelblinde, Parallelgruppenstudie der Phase-I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001775-37,0,0,0 2019-001789-13,1,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,0,"Clinical Trials and Research Governance (CTRG), University of Oxford","A randomised, open label study, exploring the differences in immunogenicity and reactogenicity of infants after immunisation with either an acellular (aP) or whole cell pertussis (wP) vaccine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001789-13,0,0,0 2019-001792-37,17,2022-09-01,2022-09-01,9,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A multi-center, double-blinded and open-label extension study to evaluate the efficacy and safety of ligelizumab as retreatment, self-administered therapy and monotherapy in Chronic Spontaneous Urtica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001792-37,1,0,0 2019-001792-37,17,2022-09-01,2022-09-01,9,0,1,0,0,0,3,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A multi-center, double-blinded and open-label extension study to evaluate the efficacy and safety of ligelizumab as retreatment, self-administered therapy and monotherapy in Chronic Spontaneous Urtica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001792-37,1,0,0 2019-001793-28,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Reade,"Adalimumab dose reduction aiming low serum concentration with control of disease activity (ADDORA-LOW) : a single blind, non-inferiority, randomised clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001793-28,0,0,0 2019-001800-39,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001800-39,0,0,0 2019-001800-39,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001800-39,0,0,0 2019-001801-26,1,2020-12-30,2020-12-30,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomized, Open-Label, Two Period Crossover, Chronic Dosing, 1-Week, Pilot Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Inhalation Aerosol Administered with a Space...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001801-26,0,0,0 2019-001804-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación PETHEMA,Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression Estudio fase III aleatorizado para i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001804-39,0,0,0 2019-001806-40,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"Afsnit 360, Gastroenheden","Statins for prevention of disease progression and hospitalization in Liver Cirrhosis: A multi-center, randomized, double blind, placebo-controlled trial. The STATLiver Trial. Atorvastatin til behan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001806-40,0,0,0 2019-001807-19,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC","An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001807-19,0,0,0 2019-001807-19,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001807-19,0,0,0 2019-001815-21,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase IIIB, open label, long term follow-up study to assess persistence of immune responses to GSK’s HZ/su vaccine 4-7 years after primary vaccination; and immunogenicity and safety assessment of re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001815-21,0,0,0 2019-001820-36,1,2019-10-21,2019-10-21,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,"Novartis Farmacéutica, S.A.","A 12-month prospective, phase IIIb, multicenter, open-label clinical trial to assess health-related quality of life (HRQoL) in patients with chronic or high-frequency episodic migraine treated with er...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001820-36,0,0,0 2019-001825-28,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,The University of Manchester,"Mesoangioblast-mediated exon 51 skipping for genetic correction of dystrophin, based upon a single injection in individual skeletal muscles of five non ambulant patients affected by Duchenne Muscular ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001825-28,0,0,0 2019-001827-11,2,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445/TEZ/IVA Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001827-11,0,0,0 2019-001828-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001828-36,0,0,0 2019-001829-26,3,,,0,0,1,0,0,1,2,0,0,0,0,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients with Relapsing Neuromyelitis Optica Spectrum Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001829-26,0,0,0 2019-001829-26,3,,,0,0,1,0,0,1,2,0,0,0,0,0,0,0,1,Alexion Pharmaceuticals Inc.,"A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients with Relapsing Neuromyelitis Optica Spectrum Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001829-26,0,0,0 2019-001830-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Hospital Toulouse,Phase III Trial to assess impact of ultra-long versus long down-regulation protocol on IVF/ICSI outcomes in infertile women presenting with adenomyosis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001830-32,0,0,0 2019-001832-77,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab compared to Mepolizumab in the treatment of Eosinophilic Gr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001832-77,0,0,0 2019-001832-77,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"A Randomized, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab compared to Mepolizumab in the treatment of Eosinophilic Gr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001832-77,0,0,0 2019-001833-14,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,EAU Research Foundation,"Open-label, single-arm, Phase II study, evaluating safety and efficacy of INCB054828 (Pemigatinib) as adjuvant therapy for molecularly-selected, high-risk patients with urothelial carcinoma who have r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001833-14,0,0,0 2019-001834-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,LABORATORIO FARMACEUTICO CT SRL,Efficacy and safety of Sodium Oxybate in reducing alcohol consumption and maintaining abstinence in alcohol-dependent subjects with high and very high drinking risk level. “OXYLIFE Study“ Effica...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001834-33,0,0,0 2019-001835-29,1,2022-07-01,2022-07-01,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,University Medical Center Groningen,Canagliflozin REnal Distribution Intervention Trial (CREDIT); A feasibility study for the use of 18F-canagliflozin to quantify individual differences in target-site exposure in diabetes patients. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001835-29,0,0,0 2019-001836-69,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University of Vienna,Effects of Vortioxetine in Mild Cognitive Impairment measured by Functional Magnetic Resonance Imaging Effekte von Vortioxetin bei PatientInnen mit leichter kognitiver Störung gemessen mit funktion...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001836-69,0,0,0 2019-001837-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de NIMES,"Apport de l'optimisation posologique individualisée d'amikacine guidée par un logiciel de modélisation pharmacocinétique chez les patients en choc septique : Essai clinique randomisé, contrôlé, en ou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001837-15,0,0,0 2019-001838-34,1,,,0,1,0,0,0,1,2,0,0,3,0,0,0,0,1,"Global Blood Therapeutics, Inc.","A Phase 2, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor in Patients with Sickle Cell Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001838-34,0,0,0 2019-001843-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud University Medical Center,Imaging of tumour microenvironment in patients with oropharyngeal head and neck squamous cell carcinoma using RGD PET/CT imaging.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001843-37,0,0,0 2019-001845-42,10,2022-05-24,2022-05-24,1,0,0,0,0,2,3,0,0,2,0,0,0,0,1,"Millennium Pharmaceuticals, Inc. Millennium Pharmaceuticals is a wholly owned subsidiary of Takeda Pharmaceutical",A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Ex...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001845-42,1,0,0 2019-001845-42,10,2022-05-24,2022-05-24,1,0,0,0,0,2,3,0,0,2,0,0,0,0,1,"MILLENNIUM PHARMACEUTICALS, INC.",A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Ex...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001845-42,1,0,0 2019-001845-42,10,2022-05-24,2022-05-24,1,0,0,0,0,2,3,0,0,2,0,0,0,0,1,"Millennium Pharmaceuticals, Inc.",A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Ex...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001845-42,1,0,0 2019-001848-21,4,2022-08-30,2022-08-30,1,0,0,1,0,0,1,0,0,2,1,0,0,0,1,"Aileron Therapeutics, Inc.","A Phase 1b/2 Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression Studio di fase 1b/2 del duplice inibitore di MDMX/MDM2, ALRN-6924, per la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001848-21,1,0,0 2019-001849-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Efficacité de l’éverolimuS pour le traitement des TrAnsplantés Rénaux présentant un Rejet secondaire à l’activation des NK par le « missing-self » - STARR Efficacité de l’éverolimuS pour le traitem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001849-41,0,0,0 2019-001853-25,1,2021-09-17,2021-09-17,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Medical University of Vienna,"THE USE OF ADV6209 FOR PREMEDICATION IN PAEDIATRIC ANAESTHESIA: A CONTROLLED, RANDOMIZED, DOUBLE BLINDED STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001853-25,0,0,0 2019-001854-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medical Center,Long-term outcomes in immunologically low-risk kidney transplant recipients using tacrolimus. Extension study of: Tacrolimus monotherapy in immunologically low-risk kidney transplant recipients: a pil...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001854-24,0,0,0 2019-001857-13,12,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Milestone Pharmaceuticals Inc.,"Multi-Centre, Multi-National, Open Label, Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001857-13,0,0,0 2019-001857-13,12,,,0,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Milestone Pharmaceutiques Inc.,"Multi-Centre, Multi-National, Open Label, Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001857-13,0,0,0 2019-001859-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Franciscus Gasthuis & Vlietland,PEROPERATIVE TRANEXAMIC ACID IN BARIATRIC FAST TRACK SURGERY TO REDUCE HEMORRAGE RATES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001859-40,0,0,0 2019-001861-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,Cannabis-opioid interaction in the treatment of fibromyalgia pain – an open label proof-of-concept study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001861-33,0,0,0 2019-001862-13,11,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,ABScience,"A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001862-13,0,0,0 2019-001862-13,11,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,AB SCIENCE,"A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001862-13,0,0,0 2019-001862-13,11,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,AB Science,"A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001862-13,0,0,0 2019-001863-60,1,2021-11-08,2021-11-08,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,"Abteilung für Hals-, Nasen- und Ohrenkrankheiten MUW, AKH Wien",Cerebrospinal fluid levels of triamcinolone acetonide Triamcinolonacetonid-Spiegel im Liquor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001863-60,0,0,0 2019-001866-14,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE) Studio di estensione a lungo termine in aperto volto a esami...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001866-14,0,0,0 2019-001866-14,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Allergan Limited,"An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE) Studio di estensione a lungo termine in aperto volto a esami...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001866-14,0,0,0 2019-001866-14,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE) Studio di estensione a lungo termine in aperto volto a esami...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001866-14,0,0,0 2019-001868-30,6,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,LEO Pharma A/S,"A phase 3, randomised, double-blind, multi-centre trial to evaluate the efficacy, safety, and tolerability of brodalumab treatment compared to placebo (blinded) and ustekinumab (open-label) in adolesc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001868-30,0,0,0 2019-001868-30,6,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,LEO PHARMA A/S,"A phase 3, randomised, double-blind, multi-centre trial to evaluate the efficacy, safety, and tolerability of brodalumab treatment compared to placebo (blinded) and ustekinumab (open-label) in adolesc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001868-30,0,0,0 2019-001869-32,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Radboudumc,Nano-MRI to visualize pancreatic inflammation in individuals with recent-onset type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001869-32,0,0,0 2019-001872-12,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,Dr. Franz Köhler Chemie GmbH,"A Prospective, randomized, single blind, multicenter Phase III study on organ preservation with Custodiol-N solution compared with Custodiol solution in liver transplantation Un estudio prospectivo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001872-12,0,0,0 2019-001873-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS,"ANTIBIOTIC THERAPY IN RESPIRATORY TRACT INFECTIONS: AIR. A controlled randomized, open label, multicenter, non-inferiority trial evaluating an individualized antibiotic duration treatment strategy bas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001873-10,0,0,0 2019-001876-12,6,2022-05-26,2022-05-26,4,0,1,0,0,0,3,0,2,2,0,0,0,0,1,Chemo Research S.L.,"A multicentre, uncontrolled trial on the contraceptive efficacy, safety, tolerability and pharmacokinetics of LPRI-424 (dienogest 2 mg / ethinyl estradiol 0.02 mg) during 13 cycles",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001876-12,1,0,0 2019-001877-97,5,2022-03-22,2022-03-22,3,0,0,0,0,0,3,0,1,2,0,0,0,0,1,Chemo Research S.L.,"A multicentre, double-blind, double-dummy, randomised trial on the contraceptive efficacy, tolerability and safety of LPRI-424 (dienogest 2 mg / ethinyl estradiol 0.02 mg) during nine cycles in compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001877-97,1,0,0 2019-001878-28,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Phase 1/2 Open-Label, Dose Escalation Study to Determine the Safety and Efficacy of BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Phenylalanine Hydroxylase in Subjects wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001878-28,0,0,0 2019-001879-37,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,"GB006, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc.","A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination with an Anti-PD-1 Antibody in Patients with Specified Advanced Solid Tumors or in Combination wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001879-37,0,0,0 2019-001881-14,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"Department of Endocrinology and Internal Medicine, Aarhus University Hospital","Endocrine, cardiovascular, pharmacologic and physiologic aspects of sex hormone treatment in Turner syndrome - project part 1 Endokrinologiske, kardiovaskulære, farmakologiske og fysiologiske aspe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001881-14,0,0,0 2019-001882-34,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Rigel Pharmaceuticals, Inc.",A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001882-34,0,0,0 2019-001882-34,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"RIGEL PHARMACEUTICALS, INC.",A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001882-34,0,0,0 2019-001883-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU Univesity Medical Center (VUmc),Microvascular Recovery using contrast Ultrasound in ST-elevation Myocardial Infarction in the ambulance (MRUSMI-Ambulance),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001883-31,0,0,0 2019-001885-14,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,"National Research, Development and Innovation Office",The prognostic value of Biomarkers and the Effect of Tolperisone in Acute low back pain and sciatic pain – BETA A Phase 3 investigator initiated study Biomarkerek prognosztikus Értéke és az izomre...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001885-14,0,0,0 2019-001887-31,8,2022-08-11,2022-08-11,5,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Galderma S.A.,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001887-31,1,0,0 2019-001888-75,6,2022-09-26,2022-09-26,1,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Galderma SA,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001888-75,1,0,0 2019-001888-75,6,2022-09-26,2022-09-26,1,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Galderma S.A.,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001888-75,1,0,0 2019-001889-15,14,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Galderma S.A.,"A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001889-15,0,0,0 2019-001889-15,14,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Galderma SA,"A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001889-15,0,0,0 2019-001890-98,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Vaccitech Ltd.,"A Phase 1b/2 Randomised, Placebo-controlled, Dose-ranging Study to Evaluate Safety, Tolerability and Immunogenicity of a Chimpanzee Adenovirus (ChAdOx1)-vectored Multigenotype High Risk Human Papillom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001890-98,0,0,0 2019-001892-35,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc","An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001892-35,0,0,0 2019-001896-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Puma Biotechnology, Inc","An Open-Label Phase 2 Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib Estudo aberto de fase 2, para caracterizar a patologia do cólon em d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001896-35,0,0,0 2019-001897-27,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Genentech Inc,"A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF BFKB8488A COMPARED WITH PLACEBO IN PATIENTS WITH N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001897-27,0,0,0 2019-001898-87,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA,Pilot study on sleep pathologies treatments in patients with Vegetative or Minimally conscious state diagnosis for improving Consciounsess level. STRIVE Project. Studio pilota sui trattamenti delle...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001898-87,0,0,0 2019-001899-11,1,2020-08-06,2020-08-06,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,"Cyclerion Therapeutics, Inc.","A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001899-11,0,0,0 2019-001906-61,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,AMGEN INC.,Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001906-61,0,0,0 2019-001906-61,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Amgen Inc.,Phase 2 Study of Talimogene Laherparepvec in Combination With Pembrolizumab in Subjects With Unresectable/Metastatic Stage IIIB-IVM1d Melanoma Who Have Progressed on Prior Anti PD-1 Based Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001906-61,0,0,0 2019-001907-19,1,2021-03-18,2021-03-18,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Region Skåne,Pramipexole augmentation to target anhedonia in depression - a pilot study Tilläggsbehandling med Pramipexol mot anhedonisymptom vid depression - en pilotstudie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001907-19,0,0,0 2019-001910-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud University,Combining emotion recognition training with oxytocin administration: A psychobiological approach,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001910-40,0,0,0 2019-001911-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Antoni van Leeuwenhoek Ziekenhuis,Neo-adjuvant T-VEC + NivolumabAnti-PD-1 combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001911-22,0,0,0 2019-001912-50,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Cardiology, Aarhus University Hospital, Denmark","Influence of Intensive Lipid-lowering with statin and ezetimbe prescription on Computed Tomography Derived Fractional Flow Reserve in Patients With Stable Chest Pain: The ""FLOW-PROMOTE"" study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001912-50,0,0,0 2019-001914-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Slovensko Združenje za gastroenterologijo in hepatologijo,Prospective randomised trial of first and second line treatments of Helicobacter pylori infection in Slovenia Primerjava različnih shem zdravljenja Helicobacter pylori okužbe prvega in drugega reda...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001914-41,0,0,0 2019-001915-22,1,2020-02-26,2020-02-26,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Center for Clinical Metabolic Research at Herlev-Gentofte Hospital,Dasiglucagon in the treatment of postprandial hypoglycaemia after Roux-en-Y gastric bypass Behandling med dasiglucagon ved postprandial hypoglykæmi efter Roux-en-Y gastrisk bypass,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001915-22,0,0,0 2019-001916-44,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Medical University Innsbruck, Department of Visceral, Transplant und Thoracic Surgery","A multicenter, randomized, double blind placebo controlled trial of Micronized purified Flavonoid- Fraction (MPFF) in the management of radiation proctitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001916-44,0,0,0 2019-001920-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de NIMES,"Phase II a study to evaluate the safety, tolerability, distribution and dose effect of neoadjuvant doxorubicin arterial embolization in patients with prostate cancer at high risk of recurrence before ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001920-36,0,0,0 2019-001923-11,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,BioInvent International AB,"Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD1 or Anti-PDL1 A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001923-11,0,0,0 2019-001924-37,4,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,AstraZeneca AB,"SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001924-37,0,0,0 2019-001924-37,4,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001924-37,0,0,0 2019-001925-28,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"FibroGen, Inc.","A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancrea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001925-28,0,0,0 2019-001925-28,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,FIBROGEN,"A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancrea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001925-28,0,0,0 2019-001929-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Radboud University Medical Centre,Infusion of ex vivo-generated allogeneic natural killer cells in combination with subcutaneous IL-2 in patients with acute myeloid leukemia: a phase I/IIa study’,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001929-27,0,0,0 2019-001931-30,2,,,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Three-Part, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Evinacumab in Pediatric Patients with Homozygous Familial Hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001931-30,0,0,0 2019-001937-16,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Autolus Limited,"An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating The Safety and Efficacy Of AUTO1, A CAR T Cell Treatment Targeting CD19, In Adult Patients With Relapsed Or Refractory B Cell Acute Lymphoblas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001937-16,0,0,0 2019-001941-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IRCCS MATERNO INFANTILE BURLO GAROFOLO,Shortened antibiotic therapy for febrile urinary tract infections (UTI) in childhood: a multicentre randomized controlled trial Terapia antibiotica breve nelle infezioni delle vie urinarie (IVU) fe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001941-41,0,0,0 2019-001946-17,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"SEATTLE GENETICS, INC.",Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001946-17,0,0,0 2019-001946-17,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Seattle Genetics, Inc.",Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001946-17,0,0,0 2019-001947-28,1,,,0,1,1,0,0,1,1,0,0,4,0,0,0,0,0,Therapeutic Advances in Childhood Leukemia Consortium (TACL),A TACL Phase 1/2 Study of PO Ixazomib in Combination with Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001947-28,0,1,1 2019-001948-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE,Double-blind randomised placebo controlled study evaluating local co-administration of autologous ADIpose derived stromal vascular fraction with microfat for refractory perianal CROHN’s fistulas.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001948-21,0,0,0 2019-001955-38,2,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Allergan Ltd,"A Phase 3, Open-label, Long-term Safety Study of Oral Linaclotide Administered to Pediatric Participants with Functional Constipation (FC) or Irritable Bowel Syndrome with Constipation (IBS-C)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001955-38,0,0,0 2019-001957-16,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,0,Národný onkologický ústav,"Phase II study of Vinorelbine, cisplatin, disulfiram and copper in CTC_EMT positive refractory metastatic breast cancer. Klinické skúšanie fázy II: Vinorelbín+ Cisplatina + disulfiram a meď u pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001957-16,0,0,0 2019-001960-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku PET centre,Effect of cladribine treatment on microglial activation in the CNS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001960-31,0,0,0 2019-001961-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,INSERM ANRS,"ANRS 173 ALTAR A randomized, open-label, phase III trial comparing a dual nucleoside analogues strategy preceded by an induction period with an integrase inhibitor based triple therapy to an immediate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001961-34,0,0,0 2019-001962-13,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO,"A multi-center open label phase II study of daratumumab and pomalidomide in previously treated patients with AL amyloidosis Studio di fase II, multicentrico, in aperto, volto a valutare l’associazi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001962-13,0,0,0 2019-001966-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU CLERMONT FERRAND - DRCI,"Using INDOcyanine green to analyse ovarian vascularization after ovarian laparoscopic CYStectomy, Diagnostic study of feasibility. Étude de la vascularisation ovarienne après traitement coelioscop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001966-14,0,0,0 2019-001967-58,2,,,0,0,0,0,0,0,2,0,0,1,1,0,0,1,1,Biogen Idec Research Limited,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Reference (Ocrelizumab), Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous Dapirolizumab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001967-58,0,0,0 2019-001969-33,3,2022-03-24,2022-03-24,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Akaza Bioscience Limited,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Proof-of-Concept, Phase 2a Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-242 in Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001969-33,1,0,0 2019-001972-12,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Department of Oncology, Herlev & Gentofte Hospital","A phase 1b/2 open-label, dose-escalating study of safety and efficacy of disulfiram, copper and vinorelbine in advanced solid tumors and advanced breast cancer Et fase 1b/2 åbent, dosis eskalering...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001972-12,0,0,0 2019-001974-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire Vaudois (CHUV),Reducing the Burden of Influenza after Solid-Organ Transplantation: the STOP-FLU trial [Swiss Trial in solid Organ transplantation on Prevention of inFLUenza] Reducción de la carga de enfermedad po...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001974-27,0,0,0 2019-001976-12,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Fundación Pethema,"A multicenter, prospective, non-randomized, Phase I-II trial to assess the efficacy and safety of the combination of oral quizartinib and the FLAG-IDA chemotherapy regimen in first relapsed/refractory...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001976-12,0,0,0 2019-001978-28,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001978-28,0,0,0 2019-001978-28,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Eli Lilly and Company,"A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001978-28,0,0,0 2019-001978-28,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Lilly S.A.,"A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001978-28,0,0,0 2019-001979-36,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Eli Lilly and Company,"A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Platinum-Pemetrexed Chemotherapy Plus Investigator’s Choice of Pembrolizumab in Patients with Advanced, Treatment-Naïve RET F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001979-36,0,0,0 2019-001979-36,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Platinum-Pemetrexed Chemotherapy Plus Investigator’s Choice of Pembrolizumab in Patients with Advanced, Treatment-Naïve RET F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001979-36,0,0,0 2019-001979-36,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Lilly S.A.,"A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Platinum-Pemetrexed Chemotherapy Plus Investigator’s Choice of Pembrolizumab in Patients with Advanced, Treatment-Naïve RET F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001979-36,0,0,0 2019-001982-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Pirkanmaan sairaanhoitopiiri,Measuring Oncogical Value of Exercise and Statin Syöpäpotilaan ennusteen parantaminen muuttamalla syövän mikroympäristöä ja me-taboliaa liikunnalla ja lääkkeellisesti,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001982-34,0,0,0 2019-001983-31,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Galectin Therapeutics Inc.,"A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esoph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001983-31,0,0,0 2019-001986-34,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University of Turku,Exploring the impact of pertussis immunization during pregnancy on the differences in immune response of infants after primary immunization with an acellular pertussis containing vaccine: an open lab...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001986-34,0,0,0 2019-001987-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Deutsche Diabetes Forschungsgesellschaft e.V.,COMBined Active Treatment in Type 2 Diabetes with NASH Kombinierte aktive Behandlung bei NASH und Typ 2 Diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001987-31,0,0,0 2019-001988-75,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTI FISIOTERAPICI OSPITALIERI,REPURPOSING THE ANTIPSYCHOTIC DRUG CLORPROMAZINE AS A THERAPEUTIC AGENT IN THE COMBINED TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME Riposizionamento dell’antipsicotico clorpromazina come a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001988-75,0,0,0 2019-001989-15,7,2022-08-31,2022-08-31,4,0,0,0,0,0,4,0,0,2,0,0,0,0,1,"TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Mi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001989-15,1,0,0 2019-001989-15,7,2022-08-31,2022-08-31,4,0,0,0,0,0,4,0,0,2,0,0,0,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Mi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001989-15,1,0,0 2019-001991-12,4,2021-05-14,2021-05-14,3,1,0,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase II, randomised, observer-blind, placebo controlled multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of GSK Biologicals’ investigationa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001991-12,1,0,0 2019-001991-12,4,2021-05-14,2021-05-14,3,1,0,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline S.A.,"A Phase II, randomised, observer-blind, placebo controlled multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of GSK Biologicals’ investigationa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001991-12,1,0,0 2019-001992-35,5,,,0,1,0,0,0,1,2,0,0,1,1,0,0,1,1,Merck Healthcare KGaA,"A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp alfa (M7824) as First-line Treatment of Biliary Tract Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001992-35,0,0,0 2019-001992-35,5,,,0,1,0,0,0,1,2,0,0,1,1,0,0,1,1,MERCK HEALTHCARE KGaA,"A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp alfa (M7824) as First-line Treatment of Biliary Tract Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001992-35,0,0,0 2019-001995-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CENTRO CARDIOLOGICO SPA FONDAZIONE MONZINO,Cardiac Arrhythmia catheter ablation procedures guided by x-Ray imaging: N-Acetylcysteine Protection Against radiation induced Cellular damagE (CARAPACE Study). Procedure di ablazione transcatetere...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001995-12,0,0,0 2019-001996-35,11,2021-05-11,2021-05-11,8,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Gilead Sciences Inc.,"A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Are Naïve to Biologic DMA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001996-35,1,0,0 2019-001996-35,11,2021-05-11,2021-05-11,8,1,0,0,0,0,3,0,0,2,1,0,0,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Are Naïve to Biologic DMA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001996-35,1,0,0 2019-001997-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut klinické a experimentální medicíny,Rationalisation of ATB therapy in diabetic foot infection and its impact on the intestinal microbiota Racionalizace ATB terapie infekce u syndromu diabetické nohy a její vztah ke střevnímu mikrobio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001997-27,0,0,0 2019-001998-90,2,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"Alkermes, Inc.",A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors- ARTISTRY-1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001998-90,0,0,0 2019-002000-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS,Experimental study to evaluate the impact of 18F-PSMA PET / CT in the management of patients with prostate cancer. Studio sperimentale per valutare l'impatto della PET / TC 18F-PSMA nella gestione ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002000-41,0,0,0 2019-002001-21,4,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,University College Dublin,"BETTER-B: BETter TreatmEnts for Refractory Breathlessness. An International, Multicentre, Randomised Controlled Pragmatic Trial of Mirtazapine to alleviate Breathlessness in Palliative and End of Life...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002001-21,0,0,0 2019-002001-21,4,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,King's College London,"BETTER-B: BETter TreatmEnts for Refractory Breathlessness. An International, Multicentre, Randomised Controlled Pragmatic Trial of Mirtazapine to alleviate Breathlessness in Palliative and End of Life...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002001-21,0,0,0 2019-002002-43,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Instituto de Investigación Sanitaria Aragón,"Phase IV, unicentric, randomized and open study to confirm the decrease of the incidence of the surgical site infection after elective right hemicolectomy with anterographic mechanical preparation ass...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002002-43,0,0,0 2019-002006-51,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc","A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002006-51,0,0,0 2019-002006-51,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002006-51,0,0,0 2019-002008-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI,Effect of metyrapone on cardiovascular risk factors in patients with adrenal incidentalomas and subclinical/mild Cushing's syndrome Effetto della terapia con Metirapone sul rischio cardiovascolare ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002008-41,0,0,0 2019-002012-12,1,,,0,0,0,1,0,0,1,1,1,0,0,0,0,0,1,InfectoPharm Arzneimittel und Consilium GmbH,"A randomised, two-period two-stage cross-over study on the relative bioavailability of two different liquid formulations of single noscapine doses (phase I/IV, open-label) in healthy volunteers (faste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002012-12,0,0,0 2019-002013-20,5,2021-02-23,2021-02-23,1,0,0,1,0,0,1,0,0,2,1,0,0,0,1,"Alkermes, Inc.",A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (ARTISTRY-2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002013-20,1,0,0 2019-002014-39,3,2019-11-15,2019-11-15,3,0,0,0,0,0,3,0,1,1,1,1,1,0,1,"resTORbio, Inc.","A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002014-39,0,0,0 2019-002015-26,4,2021-05-28,2021-05-28,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT,"Phase 2 window study of two dose levels of SAR439859 (SERD) versus letrozole in newly diagnosed preoperative post-menopausal patients with ER positive, HER2 negative primary breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002015-26,0,0,0 2019-002015-26,4,2021-05-28,2021-05-28,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"Phase 2 window study of two dose levels of SAR439859 (SERD) versus letrozole in newly diagnosed preoperative post-menopausal patients with ER positive, HER2 negative primary breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002015-26,0,0,0 2019-002020-33,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Erasmus University Medical Center,Pentoxifylline dose optimization in neonatal sepsis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002020-33,0,0,0 2019-002021-29,8,2021-03-18,2021-05-11,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Gilead Sciences Inc.,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002021-29,1,0,0 2019-002021-29,8,2021-03-18,2021-05-11,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002021-29,1,0,0 2019-002023-15,11,2022-02-03,2022-02-03,7,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Bioverativ Therapeutics Inc.,"Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002023-15,1,1,0 2019-002023-15,11,2022-02-03,2022-02-03,7,1,1,0,0,1,3,0,0,2,0,0,0,0,1,Bioverativ Therapeutics Inc. (a Sanofi company),"Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002023-15,1,1,0 2019-002023-15,11,2022-02-03,2022-02-03,7,1,1,0,0,1,3,0,0,2,0,0,0,0,1,BIOVERATIV THERAPEUTICS INC,"Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTEN; ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002023-15,1,1,0 2019-002026-75,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Ultimovacs ASA,"A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002026-75,0,0,0 2019-002027-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU DE NIMES,Etude de la pharmacocinétique plasmatique et pulmonaire du ceftobiprole administré à haute dose en perfusion continue dans la pneumonie aiguë communautaire grave sous ventilation mécanique.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002027-15,0,0,0 2019-002030-36,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men With Advanced Castration-resitant Prostate Cancer Studio di Fase 3, randomizzato, in doppio ci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002030-36,0,0,0 2019-002030-36,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men With Advanced Castration-resitant Prostate Cancer Studio di Fase 3, randomizzato, in doppio ci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002030-36,0,0,0 2019-002032-84,1,2022-07-04,2022-07-04,1,1,0,0,0,0,2,0,0,1,1,1,0,0,1,Disphar International B.V,"Evaluating the Use of a Progesterone Receptor Modulator for Cervical Ripening at Full Term Pregnancy – a Randomized, Double-blind , placebo controlled Study (LUCYNA) Hodnocení použití modulátoru pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002032-84,0,0,0 2019-002034-36,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc","A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants with Advanced/Metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002034-36,0,0,0 2019-002034-36,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants with Advanced/Metastat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002034-36,0,0,0 2019-002036-90,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Cologne,"A randomized, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of subcutaneous Dupilumab in localized scleroderma Randomisierte, Placebo kontrollierte klinische Phase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002036-90,0,0,0 2019-002037-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital,Intravenous Iron supplement for Iron deficiency in patients with Severe Aortic Stenosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002037-11,0,0,0 2019-002038-35,1,2021-11-26,2021-11-26,1,1,0,0,0,0,4,0,0,1,0,0,0,0,0,UZ Leuven,A prospective study investigating ustekinumab concentrations through dried blood spot sampling in Crohn’s disease patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002038-35,0,0,0 2019-002039-27,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hyp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002039-27,0,0,0 2019-002039-27,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-week Phase 3 Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hyp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002039-27,0,0,0 2019-002040-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dextra fertility clinic,Iron defiency as an ignored cause of infertility Rautavaje hedelmättömyyden osatekijänä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002040-24,0,0,0 2019-002040-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Annika Tulenheimo-Silfvast,Iron defiency as an ignored cause of infertility Rautavaje hedelmättömyyden osatekijänä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002040-24,0,0,0 2019-002041-38,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,AZ Maria Middelares,Evaluation of the Safety and Effectiveness of switching from Originator (Humira®) to Biosimilar (Imraldi®) adalimumab in Flanders (SafE-OrBi),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002041-38,0,0,0 2019-002045-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,"AN OPEN-LABEL, EXPLORATORY STUDY ASSESSING THE FEASIBILITY OF SGM-101, A FLUOROCHROME-LABELED ANTI-CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY FOR THE INTRAOPERATIVE DETECTION OF LUNG METASTASIS IN C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002045-38,0,0,0 2019-002046-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Innovación en Biomedicina-FIBMED,Effects of SGLT2 inhibition on the mechanisms of cardiac damage in the diabetic patient with HFpEF.-CARDIA-STIFF. Efectos de la inhibición del cotransportador sodio-glucosa-2 sobre los mecanismos d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002046-20,0,0,0 2019-002051-42,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,University of Manchester,"A phase I-II, study of autologous CD34+ haematopoietic stem cells transduced ex vivo with CD11b lentiviral vector encoding for human SGSH in patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002051-42,0,0,0 2019-002053-33,5,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002053-33,0,0,0 2019-002053-33,5,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,"TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002053-33,0,0,0 2019-002055-42,5,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002055-42,0,0,0 2019-002055-42,5,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002055-42,0,0,0 2019-002056-16,5,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002056-16,0,0,0 2019-002056-16,5,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,"TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC","A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002056-16,0,0,0 2019-002057-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación de Investigación Biomédica Hospital Puerta de Hierro,"A RANDOMISED, DOUBLE-BLIND CONTROLLED TRIAL TO EVALUATE THE EFFICACY OF INTRACAVERNOSAL INFUSION OF PLATELET RICH PLASMA (PRP) AGAINST PLATELET POOR PLASMA (PPP) IN THE TREATMENT OF VASCULOGENIC ERECT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002057-34,0,0,0 2019-002063-95,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA,"A Phase 3, Open, Randomized controlled trial on Completion Rate of daily Rifapentine/Isoniazid for One Month Compared with Daily Rifampicin/Isoniazid for Three Months for the Treatment of Latent Tuber...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002063-95,0,0,0 2019-002067-10,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A randomized, double-masked, 48-week parallel-group, placebo-controlled, proof-of-concept study to investigate the efficacy and safety of RG7774 in patients with Diabetes Mellitus Type 1 or Type 2 wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002067-10,0,0,0 2019-002068-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klinische Abteilung für Nephrologie",Influence of once vs twice daily corticosteroid administration on glycemia assessed by continuous glucose monitoring in patients with ANCA vasculitis Auswirkung einer einmal vs zweimal täglichen K...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002068-29,0,0,0 2019-002070-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Copenhagen University Hospital Hvidovre,Adherence of a 1.600 mg single tablet 5-ASA treatment of Ulcerative colitis (EASI-trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002070-31,0,0,0 2019-002071-34,1,2020-04-02,2020-04-02,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Vejle Hospital,Allocation of patients with pre-treated solid tumors to anti-cancer therapy based on gene expression drug response prediction - a phase II basket trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002071-34,0,0,0 2019-002073-56,4,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Galmed Research and Development, Ltd.","A Phase 3, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) The ARMOR St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002073-56,0,0,0 2019-002074-32,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IFOM - Istituto FIRC di Oncologia Molecolare,POST-SURGICAL LIQUID BIOPSY-GUIDED TREATMENT OF STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS TRATAMIENTO POSTQUIRÚRGICO GUIADO POR BIOPSIA LÍQUIDA DE PACIENTES CON CÁNCER DE COLON EN ESTA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002074-32,0,0,0 2019-002074-32,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IFOM - Istituto FIRC di Oncologia Molecolare - Milano,POST-SURGICAL LIQUID BIOPSY-GUIDED TREATMENT OF STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS TRATAMIENTO POSTQUIRÚRGICO GUIADO POR BIOPSIA LÍQUIDA DE PACIENTES CON CÁNCER DE COLON EN ESTA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002074-32,0,0,0 2019-002075-33,11,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,0,"Hamilton Health Sciences, through its Population Health Research Institute",Edoxaban for intracranial hemorrhage survivors with atrial fibrillation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002075-33,0,0,0 2019-002075-33,11,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,0,"Hamilton Health Sciences Corporation, through its Population Health Research Institute",Edoxaban for intracranial hemorrhage survivors with atrial fibrillation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002075-33,0,0,0 2019-002075-33,11,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,0,"Hamilton Health Sciences, through its Population Health Research Institute",Edoxaban for intracranial hemorrhage survivors with atrial fibrillation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002075-33,0,0,0 2019-002075-33,11,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,0,Population Health Research Institute,Edoxaban for intracranial hemorrhage survivors with atrial fibrillation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002075-33,0,0,0 2019-002076-13,7,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"NS Pharma, Inc.","A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002076-13,0,0,0 2019-002076-13,7,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"NS Pharma, Inc","A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002076-13,0,0,0 2019-002078-30,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Erasmus MC,"Autoimmune epilepsy Modulated by IVIg – effects on Cortical Excitability, the AMICE study Auto-immuun epilepsie gemoduleerd door IVIg - effect op corticale exciteerbaarheid, de AMICE studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002078-30,0,0,0 2019-002081-12,1,2020-03-04,2020-03-04,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Amryt Research Ltd.,"An exploratory randomized, intra-individual controlled trial of the cutaneous healing properties of Petrolatum versus the vehicle for Oleogel-S10 versus no treatment when applied topically to mechanic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002081-12,0,0,0 2019-002085-13,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Athenex, Inc",A Pilot Study of Oraxol in Subjects with Cutaneous Angiosarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002085-13,0,0,0 2019-002086-35,4,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, RANDOMISED, ADAPTIVE, OPEN-LABEL PLATFORM TRIAL TO EVALUATE EFFICACY AND SAFETY OF MULTIPLE COMBINATION THERAPIES IN PARTICIPANTS WITH CHRONIC HEPATITIS B",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002086-35,0,0,0 2019-002089-11,13,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplasti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002089-11,0,0,0 2019-002089-11,13,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplasti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002089-11,0,0,0 2019-002093-32,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Lument AB,"Randomised, open, non-inferiority within patient-controlled trial evaluating the diagnostic usefulness of Lumentin® 44 when used as contrast agent in CT-enterography as compared to MRI- enterography i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002093-32,0,0,0 2019-002094-55,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Universitair Ziekenhuis Brussel, Belgium",Safety and feasibility of S-Caine patch use in children under the age of three Veiligheid en haalbaarheid van S-Caine patch gebruik bij kinderen onder de leeftijd van drie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002094-55,0,0,0 2019-002098-68,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Blueberry Therapeutics Ltd,"A Multi-Centre, International, Randomised, Vehicle Controlled, Parallel-Group, Double-Blinded Phase 2 Trial of BB2603 Topical Treatment in Subjects with Distal Subungual Onychomycosis (DSO) of the To...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002098-68,0,0,0 2019-002100-41,11,2022-02-03,2022-02-09,7,0,0,0,0,1,3,0,0,2,0,0,0,0,1,argenx BVBA,"A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002100-41,1,0,0 2019-002100-41,11,2022-02-03,2022-02-09,7,0,0,0,0,1,3,0,0,2,0,0,0,0,1,ARGENX BV,"A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002100-41,1,0,0 2019-002101-21,12,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,argenx BV,"A Phase 3, Multicenter, Open-Label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia Sperim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002101-21,0,0,0 2019-002101-21,12,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,argenx BVBA,"A Phase 3, Multicenter, Open-Label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia Sperim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002101-21,0,0,0 2019-002101-21,12,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,ARGENX BV,"A Phase 3, Multicenter, Open-Label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia Sperim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002101-21,0,0,0 2019-002104-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centro Nacional de Investigaciones Oncológicas (CNIO),"A phase II, open-label, biomarker-guided study of Carboplatin efficacy in pretreated metastatic castration-resistant Prostate Cancer (mCRPC)-BioChiP Estudio de fase II, abierto, guiado por biomarca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002104-40,0,0,0 2019-002105-22,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,BeiGene Ltd.,"A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002105-22,0,0,0 2019-002105-22,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,LYSARC,"A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002105-22,0,0,0 2019-002106-52,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,King's College London,CANnabidiol for Behavioural Symptoms in Alzheimer’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002106-52,0,0,0 2019-002106-52,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,South London and Maudsley NHS Foundation Trust,CANnabidiol for Behavioural Symptoms in Alzheimer’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002106-52,0,0,0 2019-002108-41,2,2021-10-07,2021-10-07,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Mitsubishi Tanabe Development America Inc.,"A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002108-41,1,0,0 2019-002108-41,2,2021-10-07,2021-10-07,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Mitsubishi Tanabe Pharma Development America, Inc.","A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002108-41,1,0,0 2019-002109-24,1,2021-01-21,2021-01-21,1,0,0,0,0,1,2,0,0,1,0,0,1,0,0,Tampere University Hospital,Oral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002109-24,0,0,0 2019-002113-19,10,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002113-19,0,1,0 2019-002113-19,10,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002113-19,0,1,0 2019-002114-38,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,DOMPé FARMACEUTICI S.P.A.,"Randomized, single dose, placebo-controlled, double-blind, parallel group study to evaluate the onset of pain response after administration of ketoprofen lysine salt 40 mg, in male and female subjects...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002114-38,0,0,0 2019-002115-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Hospitalier Franco-Britanique,Cetuximab as salvage therapy in patients with neo wild-type RAS/RAF metastatic colorectal cancer. A Proof-of-concept study Cetuximab chez des patients atteints d'un cancer colorectal métastatique p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002115-26,0,0,0 2019-002116-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,AB-Biotics S.A.,Interventional post-marketing study to evaluate i3.1 efficacy on SIBO (Small Intestinal Bacterial Overgrowth)reduction in IBS (Irritable bowel syndrom) patients Estudio intervencional aleatorizado ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002116-10,0,0,0 2019-002118-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Rafael Blancas-Gómez Casero,"MULTICENTER, DOUBLE BLIND CLINICAL TRIAL TO EVALUATE THE ANTIHEMORRAGIC EFFECT OF THE TOPICAL TRANEXAMIC ACID DURING PACEMAKER IN ANTICOAGULATED PATIENTS ENSAYO CLÍNICO MULTICÉNTRICO, DOBLE CIEGO P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002118-37,0,0,0 2019-002120-32,3,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,Shionogi B.V.,"A Single Arm, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Paediatric Subjects 3 Months to < 18 Years of Age wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002120-32,0,0,0 2019-002121-30,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Shionogi B.V.,"An Open-label Study with a Nonrandomized Single-dose Phase in Subjects with Suspected or Confirmed Aerobic Gram-negative Bacterial Infections followed by a Randomized, Multiple-dose, Active-controlled...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002121-30,0,0,0 2019-002123-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama),"Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative high/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002123-15,0,0,0 2019-002124-32,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Chiesi Farmaceutici S.p.A.,"READY 1: A Phase 3, Randomized, Double-Blind, Active and Placebo-Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002124-32,0,0,0 2019-002126-75,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,Allergan,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Sequential, Ascending, Multidose Study to Evaluate the Safety and Efficacy of Linaclotide in Pediatric Participants (Age 2 to 5 Years) with Fun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002126-75,0,1,1 2019-002129-31,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Imperial College London,The RIO Trial: A randomised placebo controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo in treated Primary HIV Infection on viral con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002129-31,0,0,0 2019-002138-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amsterdam University Medical Centers - location AMC,Heavy menstrual bleeding in premenopausal women treated with direct oral anticoagulants - the MEDEA study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002138-35,0,0,0 2019-002147-20,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,University of Birmingham,"A randomised, open-label, multicentre,phase III trial of in vivo purging with anti-CD38 (Daratumumab) to enhance myeloma autografting",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002147-20,0,0,0 2019-002161-36,9,2022-02-07,2022-02-07,7,0,0,0,0,1,3,0,0,1,1,0,0,0,1,Oncopeptides AB,"A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in combination with Daratumumab Compared with Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002161-36,0,0,0 2019-002178-30,4,2021-03-29,2021-04-28,3,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Wave Life Sciences UK Limited,"A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002178-30,0,0,0 2019-002179-32,6,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y actúa como representante F. Hoffmann-La Roche Ltd,"A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB IN PATIENTS WITH MILD OR MODERATE HEMOPHILIA A WITHOUT FVIII INHIBITORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002179-32,0,0,0 2019-002179-32,6,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB IN PATIENTS WITH MILD OR MODERATE HEMOPHILIA A WITHOUT FVIII INHIBITORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002179-32,0,0,0 2019-002181-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTI FISIOTERAPICI OSPITALIERI,EXPLORING OPTIMAL SEQUENCE TREATMENT IN HER2+ PERTUZUMAB PRE- TREATED ADVANCED BREAST CANCER PATIENTS. THE STEP TRIAL. VALUTAZIONE DELLA SEQUENZA OTTIMALE DI TRATTAMENTO NELLE PAZIENTI AFFETTE DA C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002181-12,0,0,0 2019-002182-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,KU Leuven - TARGID,"The effect of oral buspirone hydrochloride on esophageal motility, bolus transit and symptoms of dysphagia, in patients with poor esophageal motility: A randomized, double-blind, placebo controlled, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002182-35,0,0,0 2019-002184-97,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Centre François Baclesse,A phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure Etude de phase II évaluant l’efficacité et la tolérance...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002184-97,0,0,0 2019-002185-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,KU Leuven - TARGID,"A Randomized, Double Blind, Placebo Controlled, Crossover Trial of Clebopride vs Placebo in the Treatment of Clinically Suspected Rumination. Een gerandomiseerde, dubbel-blinde, placebo-gecontrolee...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002185-13,0,0,0 2019-002186-36,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Uppsala University Hospital,"A multicenter, open-label, randomized, phase I/II clinical trial comparing safety and durable overall response rate (DOR) at 56 days in patients with steroid resistant severe acute GvHD after allogene...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002186-36,0,0,0 2019-002187-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,KU Leuven - TARGID,A Prospective evaluation of the effect of a single dose of neostigmine in patients with patients with weak or absent esophageal peristalsis Prospectieve evaluatie naar het effect van een enkelvoudi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002187-26,0,0,0 2019-002189-11,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, Randomized, Placebo-Controlled, Double-blind Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects Aged 12 Years and Older With Cystic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002189-11,0,1,1 2019-002190-66,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Camurus AB,"A Phase 3, open-label, single-arm, multi-center trial to assess the long term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002190-66,0,0,0 2019-002192-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IKF Klinische Krebsforschung GmbH,Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy- Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002192-33,0,0,0 2019-002193-31,4,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"Crinetics Pharmaceuticals, Inc.","AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CRN00808 IN SUBJECTS WITH ACROMEGALY (ACROBAT ADVANCE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002193-31,0,0,0 2019-002195-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University Hospital ""Príncipe de Asturias""",Randomized clinical trial to assess the monocitary functionality and their relationship with the administration of intravenous iron in patient in hemodialysis according to practice guidelines or accor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002195-14,0,0,0 2019-002196-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE Followed by Surgery for resectable Pancreatic Neuroendocrine Tumors (Neo.Lu.Pa.NET) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002196-34,0,0,0 2019-002197-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Universitätsmedizin Mainz, Interdisziplinäres Zentrum klinische Studien","AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compared to osimertinib in patients with EGFRmutated/T790M Mutation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002197-31,0,0,0 2019-002200-40,1,2021-04-29,2021-04-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,"Anæstesiologisk afdeling, Sjællands Universitetshospital, Roskilde",The minimal effective volume (MEV90) of ropivacaine 0.75 % for ultrasound-guided transmuscular quadratus lumborum block for unilateral percutaneous nephrolitotomy – A dose finding study. Det minima...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002200-40,0,0,0 2019-002201-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Novartis Pharma GmbH,Assessment of Prolonged safety and tOLerability of erenumab in migraine patients in a Long-term OpeN-label study (APOLLON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002201-22,0,0,0 2019-002202-43,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AOU FEDERICO II,Effects of empagliflozin on cardiac remodeling and myocardial sympathetic nervous system in diabetic patients affected by chronic heart failure Effetti di empagliflozin sul rimodellamento cardiaco ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002202-43,0,0,0 2019-002205-22,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"""A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects with Active Systemic Lupus Erythematosus or Primary Sjögren’...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002205-22,0,0,0 2019-002207-17,2,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,PolyPid Ltd.,"A Phase III, Prospective, Multinational, Multicenter, Randomized, Parallel Controlled, Two arms, Single Blind, Study to Assess the Efficacy and Safety of D-PLEX Administered Concomitantly with the Sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002207-17,0,0,0 2019-002209-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Bausch Health Americas, Inc.(affiliate of Bausch Health US ,formerly known as Dow Pharmaceutical Sciences)","A Phase 4 (Phase 2 in European Union), Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-122 Lotion in P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002209-23,0,0,0 2019-002213-19,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of British Columbia,"A 6-Week Randomised, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy of Lurasidone Adjunctive Therapy in Improving Cognitive Functioning in Euthymic Bipolar Disorder Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002213-19,0,0,0 2019-002217-19,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"Randomized, Double-blind, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remissio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002217-19,0,0,0 2019-002217-19,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"Randomized, Double-blind, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remissio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002217-19,0,0,0 2019-002218-38,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Safety of a Quadrivalent Influenza Vaccine (VaxigripTetraTM) in Subjects Aged 6 Months and Older in Vietnam,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002218-38,0,1,1 2019-002221-29,2,2021-11-03,2021-11-03,1,1,0,0,0,2,2,0,0,2,0,0,0,0,1,VIFOR (INTERNATIONAL) INC.,"A Phase 2a, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Study on Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Doses of VI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002221-29,1,0,0 2019-002221-29,2,2021-11-03,2021-11-03,1,1,0,0,0,2,2,0,0,2,0,0,0,0,1,Vifor (International) Inc.,"A Phase 2a, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Study on Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Doses of VI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002221-29,1,0,0 2019-002224-32,1,2021-12-03,2021-12-03,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Fundació Hospital Universitari Vall d' Hebrón - Institut de Recerca (VHIR),"Sense, rhYhm & Networks: the study of how erenumab modulates CHROnic migraine Sentidos, ritmo y conexiones: un estudio de cómo Erenumab® modula la migraña crónica. Estudio SYNCHRO.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002224-32,0,0,0 2019-002225-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Impact of low protein diet supplemented with ketoanalogues on uremic toxins production and glucose metabolism in chronic kidney disease_KETO GUT study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002225-30,0,0,0 2019-002226-79,2,,,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,Region Skåne,"A 30-day, randomized, evalUator-blind, controlled, multi-centre, parallel Group, phase III study to evaluate the Effect of a Low Maintenance Dose TicAgrelor Regimen versus Standard Dose Clopidogrel on...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002226-79,0,0,0 2019-002230-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IFCT,"A phase II non-randomized, single group assignment, open-label, multicenter study of efficacy and safety of lORlatinib (PF-06463922) monotherapy after failure of first-line second-generation ALK kinas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002230-37,0,0,0 2019-002232-82,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Institutet,Downstream targets of SSRI effect in treatment of Major Depressive Disorder,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002232-82,0,0,0 2019-002233-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. José González Costello.Unidad de Insuficiencia cardíaca avanzada y Trasplante cardíaco. Hospital Univ. Bellvitge,"The proposed study is a phase IV, randomized, controlled, multicenter and open clinical trial, with two parallel groups, to evaluate the effectiveness of a preventive strategy against CMV infection in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002233-11,0,0,0 2019-002236-91,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Nîmes,Place des inhibiteurs de la transcriptase inverse dans le traitement du psoriasis : Essai « preuve de concept biologique » Place des inhibiteurs de la transcriptase inverse dans le traitement du ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002236-91,0,0,0 2019-002238-35,1,2021-02-04,2021-02-04,1,1,1,0,0,0,2,0,0,1,0,0,1,0,1,Chiesi Farmaceutici S.p.A.,"A SINGLE-DOSE, UNCONTROLLED, OPEN LABEL, NON-RANDOMIZED, CLINICAL PHARMACOLOGY STUDY OF CHF 5993 100/6/12.5 μg PMDI (FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002238-35,0,0,0 2019-002239-27,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Clinica Dental AndreuDental,Study on the relationship between periodontal disease and serum levels of ultrasensitive Reactive C-Protein and fibrinogen ESTUDIO SOBRE LA RELACIÓN ENTRE LA ENFERMEDAD PERIODONTAL Y LOS NIVELES SÉ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002239-27,0,0,0 2019-002240-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut klinické a experimentální medicíny,The evolution of advanced microangiopathic diabetic complications before and after simultaneous pancreas and kidney transplantation evaluated with progressive non-invasive methods VÝVOJ ORGÁNOVÝCH...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002240-24,0,0,0 2019-002245-37,1,,,0,1,1,0,0,0,1,1,1,1,1,1,0,1,1,Janssen Sciences Ireland UC,"A Single-Dose, Open-Label, Randomized, Replicate Crossover Pivotal Bioequivalence Study in Healthy Subjects to Assess the Bioequivalence of Darunavir 675 mg, Emtricitabine 200 mg, and Tenofovir Alafen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002245-37,0,0,0 2019-002247-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,Single arm phase II study on Pembrolizumab in preneoplastic high grade HPV-related vulvar and cervical lesions Studio di Fase II a singolo braccio su Pembrolizumab nel trattamento neoadiuvante dell...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002247-23,0,0,0 2019-002251-42,1,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,3,,"An open-label, single-center study on the safety and efficacy of avalglucosidase alpha in late-onset Pompe patients ≥5 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002251-42,0,0,0 2019-002254-23,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 1, Randomized, Open-label Study to Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Lumacaftor in Combination With Ivacaftor in Healthy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002254-23,0,1,1 2019-002256-16,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Fraunhofer Society,"Acute and two-week effects of Spiolto® Respimat® (Tiotropium/Olodaterol) on cardiac function, the autonomic nervous system and small airway function in hyperinflated COPD subjects Akute und zweiwö...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002256-16,0,0,0 2019-002258-22,1,2021-11-22,2021-11-22,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"Phase II randomized, observer-blind, placebo-controlled, multi-country study in healthy non-pregnant women 18-45 years of age to evaluate the safety, reactogenicity and immunogenicity of a 1st intramu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002258-22,0,0,0 2019-002259-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Sunovion Pharmaceuticals Inc.,"A Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002259-40,0,0,0 2019-002261-35,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Dr.Antonio Calles Blanco,"“Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Pembrolizumab in Patients with Relapsed Small Cell Lung Cancer (the LUPER study)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002261-35,0,0,0 2019-002262-12,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Hospital Universitari Germans Trias i Pujol,"""Effect of dapagliflozin on glomerular hyperfiltration in nondiabetic obese patients with or without treatment with ACEIs"". Pilot clinical trial of efficacy, low level of intervention, unicentric, ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002262-12,0,0,0 2019-002263-99,15,2021-04-12,2021-04-12,1,1,0,0,0,0,2,0,0,2,1,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002263-99,1,0,0 2019-002263-99,15,2021-04-12,2021-04-12,1,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"GlaxoSmithKline, S.A.","A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002263-99,1,0,0 2019-002263-99,15,2021-04-12,2021-04-12,1,1,0,0,0,0,2,0,0,2,1,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002263-99,1,0,0 2019-002264-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Swiss GO Trial Group,MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO) including LOGOS (Lo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002264-27,0,0,0 2019-002267-10,5,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole (POS, MK-5592) in Pediatric Participants Aged 2 to <18 Years With Invasive Aspergillosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002267-10,0,1,0 2019-002267-10,5,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole (POS, MK-5592) in Pediatric Participants Aged 2 to <18 Years With Invasive Aspergillosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002267-10,0,1,0 2019-002267-10,5,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.","A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole (POS, MK-5592) in Pediatric Participants Aged 2 to <18 Years With Invasive Aspergillosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002267-10,0,1,0 2019-002268-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Hepatology and Gastroenterology, Aarhus University Hospital","Single-center, randomized, double-blind, placebo-controlled clinical trial for the safety, tolerability and efficacy of ularitide in cirrhosis patients with refractory ascites. Behandling af refrak...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002268-28,0,0,0 2019-002271-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ARCAGY-GINECO,"A multicenter, pilot study evaluating immune impact and safety of nivolumab in combination with ipilimumab (immune combination) before initial RT-CT treatment for cervix cancer. COLIBRI Study Etude...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002271-34,0,0,0 2019-002274-31,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Signe Sørensen Torekov,Young adults with early-onset obesity treated with liraglutide,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002274-31,0,0,0 2019-002276-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"University Hospital Essen, Department of Dermatology","Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratification",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002276-13,0,0,0 2019-002278-30,2,,,0,0,1,0,0,2,3,0,0,0,0,0,0,0,1,Amryt Pharmaceuticals DAC,"Phase III, single-arm, open-label, international, multi-centre study to evaluate the efficacy and safety of lomitapide in paediatric patients with Homozygous Familial Hypercholesterolaemia (HoFH) on s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002278-30,0,0,0 2019-002280-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,St. Olav's University Hospital,Effects of intranasal oxytocin in the treatment of benzodiazepine withdrawal: A pilot randomized parallel group placebo-controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002280-10,0,0,0 2019-002281-12,5,2021-02-11,2021-04-07,3,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Sojournix, Inc","A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of SJX-653 in Postmenopausal Women with Moderate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002281-12,1,0,0 2019-002281-12,5,2021-02-11,2021-04-07,3,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Sojournix, Inc.","A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of SJX-653 in Postmenopausal Women with Moderate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002281-12,1,0,0 2019-002282-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,Nerve growth factor in pediatric severe traumatic brain injury : translational and clinical studies on a candidate biomarker and therapeutic drug Fattore di crescita neuronale nel trauma cranico gr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002282-35,0,0,0 2019-002283-27,3,2020-12-28,2020-12-28,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Shionogi B.V.,"A phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose selection study of S-600918 in patients with refractory chronic cough",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002283-27,1,0,0 2019-002284-10,1,2019-10-08,2019-10-08,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,Novo Nordisk A/S,A TRIAL TO COMPARE THE INJECTION SITE EXPERIENCE OF 0.25 MG SEMAGLUTIDE SC ADMINISTERED BY 2 DIFFERENT PRODUCTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002284-10,0,0,0 2019-002285-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"LABORATORIO OJER PHARMA, S.L.","An exploratory, multicenter, randomized, open-label with blind evaluation, active-controlled study to evaluate the safety and efficacy of Keramod (imiquimod 50 mg/g, Gel) compared with Aldara (imiqui...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002285-12,0,0,0 2019-002288-84,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"RenovoRx, Inc.",Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable Loca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002288-84,0,0,0 2019-002290-63,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Catharina Ziekenhuis,Bidirectional treatment consisting of repetitive laparoscopic electrostatic pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) and systemic intravenous chemotherapy for isol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002290-63,0,0,0 2019-002291-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Kite Pharma, Inc",A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-12),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002291-13,0,0,0 2019-002302-46,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la Formación e Investigación Sanitarias de la Región de Murcia,Phase II clinical trial of intramuscular infusion of autologous bone marrow stem cells in patients with amyotrophic lateral sclerosis Ensayo clínico en fase II de infusión intramuscular de células ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002302-46,0,0,0 2019-002304-40,1,2022-07-24,2022-07-24,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,University Hospitals Leuven,"Transmuscular Quadratus lumborum block (TQL) for laparoscopic colorectal surgery: A multi-center, double blind, prospective randomized placebo-controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002304-40,0,0,0 2019-002308-42,4,2021-11-03,2021-11-03,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc","A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Adult Participants with Recent Onset Chronic Cough",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002308-42,1,0,0 2019-002310-39,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,"Norrtälje Sjukhus, Tiohundra AB",VAsopressin and STeroids in addition to Adrenaline in cardiac arrest - a randomized clinical trial Vasopressin och steroider i tillägg till adrenalin vid hjärtstopp- en randomiserad klinisk studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002310-39,0,0,0 2019-002311-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IDIVAL,PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION IN haploidentical PROGENITORS HEMATOPOIETIC TRANSPLANTATIONWITH ADOPTIVE CELL IMMUNOTHERAPY. PROFILAXIS DE LA INFECCIÓN POR CITOMEGALOVIRUS EN EL TRASPLAN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002311-26,0,0,0 2019-002317-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Martin-Luther-Universität Halle-Wittenberg,Prophylactic nimodipine treatment for hearing preservation after vestibular schwannoma surgery: a randomized multi-center phase III trial Prophylaktische Nimodipin-Therapie zum Erhalt der Hörfunkti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002317-19,0,0,0 2019-002318-37,1,2020-07-14,2020-07-14,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,Eli Lilly and Company Limited,"A Study to Assess the Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900027 in Patients with Type 1 Diabetes Mellitus on Continuous Subcutaneous Insulin Infusion Therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002318-37,0,0,0 2019-002319-25,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,LOXO ONCOLOGY INCORPORATED,A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201) Progr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002319-25,0,0,0 2019-002321-29,3,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc","A Phase 3b Randomized Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Women with Chronic Cough and Stress Urinary Incontinence",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002321-29,0,0,0 2019-002323-15,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Helsinki University Hospital,"Pre- vs. postoperative thromboprophylaxis for liver resection – a prospective, multicenter, randomized controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002323-15,0,0,0 2019-002324-32,7,2022-07-15,2022-07-15,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor (LJN452) & licogliflozin (LIK066) combination therapy and each monotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002324-32,1,0,0 2019-002324-32,7,2022-07-15,2022-07-15,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor (LJN452) & licogliflozin (LIK066) combination therapy and each monotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002324-32,1,0,0 2019-002324-32,7,2022-07-15,2022-07-15,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor (LJN452) & licogliflozin (LIK066) combination therapy and each monotherapy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002324-32,1,0,0 2019-002325-30,1,2020-08-11,2020-08-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Dr. August Wolff GmbH & Co. KG Arzneimittel,"Prospective, open-label, monocenter, trial to investigate the efficacy and tolerability of Vagisan® a lactic acid containing vaginal suppository, in a panel of post-menopausal women suffering from vu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002325-30,0,0,0 2019-002328-33,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,VACCIBODY A.S.,"A Multi-Centre, Open-label Phase 2a Trial of the Combination of VB10.16 and Atezolizumab in Patients with Advanced or Recurrent, Non-resectable HPV16-Positive Cervical Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002328-33,0,0,0 2019-002328-33,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Nykode Therapeutics A.S.,"A Multi-Centre, Open-label Phase 2a Trial of the Combination of VB10.16 and Atezolizumab in Patients with Advanced or Recurrent, Non-resectable HPV16-Positive Cervical Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002328-33,0,0,0 2019-002331-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Amgen Inc.,"Biomarker and Genetic Predictors of Erenumab Treatment Response, a Phase 4 Investigational Open-label Study (INTERROGATE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002331-28,0,0,0 2019-002332-81,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Institut Bergonié,CombinatiOn of NivolumAb plus Relatlimab in patients with Advanced or metastatic soft-tissue Sarcoma: a proof-of-concept randomized phase II study Association du nivolumab et du relatlimab chez les...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002332-81,0,0,0 2019-002341-38,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"NGM Biopharmaceuticals, Inc.","Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects with Compensated Cirrhosis Due to Non...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002341-38,0,0,0 2019-002343-14,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Leiden University Medical Center,PHASE I/II CLINICAL TRIAL OF AUTOLOGOUS HEMATOPOIETIC STEM CELL GENE THERAPY FOR RAG1-DEFICIENT SEVERE COMBINED IMMUNODEFICIENCY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002343-14,0,0,0 2019-002345-37,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002345-37,0,0,0 2019-002345-37,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002345-37,0,0,0 2019-002348-26,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Hospital,Role of delay and antibiotics on PERForation rate while waiting appendECTomy – Randomized non-inferiority trial (PERFECT) Viiveen ja antibioottihoidon merkitys umpilisäkkeen puhkeamiselle leikkaust...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002348-26,0,0,0 2019-002350-22,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Chemo Research S.L.,"Multi-center, phase 2, open-label, randomized clinical trial to evaluate the inhibition of ovulation of 3 dosing strengths of levonorgestrel (LNG) vaginal delivery system (VDS), releasing during 28 da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002350-22,0,0,0 2019-002351-42,1,2021-04-01,2021-04-01,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"Viela Bio, Inc.","An Observational, Follow-on Study to the MEDI4920 (D5100C00002) Study to Evaluate the Duration of Clinical and Pharmacodynamic Efficacy of 12 weeks of Treatment with VIB4920 in Subjects with Moderate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002351-42,0,0,0 2019-002353-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOSPITAL UNIVERSITARI DE BELLVITGE- IDIBELL,"PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY OF APIXABAN IN PATIENTS IN HEMODAFILTRATION FARMACOCINÉTICA, FARMACODINAMIA Y SEGURIDAD DE APIXABÁN EN PACIENTES EN HEMODIAFILTRACIÓN",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002353-29,0,0,0 2019-002361-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,region Skåne,"Intavenous Lidocain and postoperative recovery after liver surgery- a randomized double blinded trial Intravenöst Lidokain och postoperativ återhämtning efter leverkirurgi, en randomiserad dubbelbl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002361-35,0,0,0 2019-002364-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ABCSG (Austrian Breast & Colorectal Cancer Study Group),"An open-label, two-arm, randomized, single-stage phase II study of ATezolizumab in combination with dual HER2 blockade plus epirubicin as NEoadjuvant therapy for HER2-positive early breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002364-27,0,0,0 2019-002365-35,11,2021-10-08,2021-10-08,9,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Bayer AG,"Multicenter, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 study to compare the safety of the oral FXIa inhibitor BAY 2433334 to apixaban i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002365-35,1,0,0 2019-002366-12,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Johns Hopkins University,ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE)Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002366-12,0,0,0 2019-002369-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación GECP,Clinical Utility of Liquid Biopsy as a tool to assess the evolution of brigatinib treated patients with non-small cell lung cancer with EML4-ALK translocation: an exploratory study Utilidad clínica...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002369-36,0,0,0 2019-002370-31,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Immatics US InC,Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002370-31,0,0,0 2019-002373-59,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center of the Johannes Gutenberg University Mainz,"A prospective, multicenter randomized phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with or without Tafasitamab (MOR208) for patients with relapsed/refractory Aggressive Lymphoma (GOA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002373-59,0,0,0 2019-002375-34,7,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,GENZYME CORPORATION,"A multicenter, multinational, randomized, double-blind, placebo-controlled study to assess the efficacy, pharmacodynamics, pharmacokinetics, safety, and tolerability of venglustat in late-onset GM2 ga...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002375-34,0,0,0 2019-002375-34,7,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Genzyme Corporation,"A multicenter, multinational, randomized, double-blind, placebo-controlled study to assess the efficacy, pharmacodynamics, pharmacokinetics, safety, and tolerability of venglustat in late-onset GM2 ga...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002375-34,0,0,0 2019-002383-27,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Centre for Human Drug Research,"An exploratory, single-center, double-blinded, healthy volunteer controlled study to characterize psoriasis patients and explore novel biomarkers for the treatment response of psoriasis with a multi-m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002383-27,0,0,0 2019-002385-12,5,2022-03-14,2022-03-14,3,0,0,0,0,1,3,0,0,2,1,0,0,0,0,University Hospital of Toulouse,"OXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME: A STUDY OF THE SAFETY AND EFFICACY ON ORAL AND SOCIAL SKILLS AND, FEEDING BEHAVIOR OF INTRANASAL ADMINIST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002385-12,1,0,0 2019-002385-12,5,2022-03-14,2022-03-14,3,0,0,0,0,1,3,0,0,2,1,0,0,0,0,University Hospital Toulouse,"OXYTOCIN TREATMENT IN NEONATES AND INFANTS AGED FROM 0 TO 3 MONTHS WITH PRADER-WILLI SYNDROME: A STUDY OF THE SAFETY AND EFFICACY ON ORAL AND SOCIAL SKILLS AND, FEEDING BEHAVIOR OF INTRANASAL ADMINIST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002385-12,1,0,0 2019-002390-60,6,2021-11-04,2021-11-05,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim Limited,"A Phase II, randomized, parallel group, dose-finding study of subcutaneously administered BI 456906 for 16 weeks, compared with placebo and open-label semaglutide in patients with type 2 diabetes mell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002390-60,1,0,0 2019-002390-60,6,2021-11-04,2021-11-05,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Phase II, randomized, parallel group, dose-finding study of subcutaneously administered BI 456906 for 16 weeks, compared with placebo and open-label semaglutide in patients with type 2 diabetes mell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002390-60,1,0,0 2019-002390-60,6,2021-11-04,2021-11-05,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Boehringer Ingelheim España, S.A.","A Phase II, randomized, parallel group, dose-finding study of subcutaneously administered BI 456906 for 16 weeks, compared with placebo and open-label semaglutide in patients with type 2 diabetes mell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002390-60,1,0,0 2019-002390-60,6,2021-11-04,2021-11-05,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A Phase II, randomized, parallel group, dose-finding study of subcutaneously administered BI 456906 for 16 weeks, compared with placebo and open-label semaglutide in patients with type 2 diabetes mell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002390-60,1,0,0 2019-002390-60,6,2021-11-04,2021-11-05,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase II, randomized, parallel group, dose-finding study of subcutaneously administered BI 456906 for 16 weeks, compared with placebo and open-label semaglutide in patients with type 2 diabetes mell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002390-60,1,0,0 2019-002391-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AOU FEDERICO II,Platelet inhibition with Ticagrelor 60 mg versus Ticagrelor 90 mg twice daily in elderly patients with acute coronary syndrome (ACS). Inibizione dell'aggregazione piastrinica con Ticagrelor 60 mg v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002391-13,0,0,0 2019-002393-31,1,2021-05-18,2021-05-18,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,OnTarget Laboratories,"A phase 1a/1b/2a study to assess the safety, tolerability and pharmacokinetics of OTL78, a PSMA-targeted fluorescent agent, for the intraoperative imaging of prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002393-31,0,0,0 2019-002394-59,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"The Parker Institute, Bispebjerg and Frederiksberg Hospital","Medical Cannabis for fibromyalgia - The CANNFIB trial Protocol for a randomized, double-blind, placebo-controlled, parallelgroup, single-center trial Medicinsk Cannbis for fibromyalgi - CANNFIB stu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002394-59,0,0,0 2019-002396-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP),Antibioprophylaxis for excision-graft surgery in burn patient: a multicenter randomized double-blind study Antibioprophylaxie pour la chirurgie d'excision-greffe chez le patient brûlé : Etude multi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002396-34,0,0,0 2019-002400-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fédération Francophone de Cancérologie Digestive,"A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF SELECTIVE INTERNAL RADIATION THERAPY PLUS XELOX, BEVACIZUMAB AND ATEZOLIZUMAB (IMMUNE CHEKPOINT INHIBITOR) IN ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002400-40,0,0,0 2019-002404-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,PD Dr. med. Mira Katan,Midregional proatrial natriuretic peptide to guide secondary stroke prevention: The MOSES-study Δευτερογενής πρόληψη εγκεφαλικού επεισοδίου καθοδηγούμενη από τον δείκτη MRproANP: Η μελέτη MOSES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002404-41,0,0,0 2019-002406-43,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Bausch Health Americas, Inc.(affiliate of Bausch Health US , LLC, formerly known as Dow Pharmaceutical Sciences)","A Phase 4 (Phase 2 in European Union), Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion in P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002406-43,0,0,0 2019-002407-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Federation Francophone de Cancerologie Digestive,FFCD 1703 -POCHI PEMBROLIZUMAB IN COMBINATION WITH XELOX BEVACIZUMAB IN PATIENTS WITH MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE: A PROOF OF CONCEPT STUDY P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002407-18,0,0,0 2019-002408-42,7,2022-06-28,2022-06-28,4,0,0,0,0,1,3,0,0,2,1,0,0,0,1,LABORATOIRES SMB S.A.,"A Phase 3, Double Blind, Multicentric, Randomised, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Itraconazole Dry Powder for Inhalation for the Prevention of Invasive Mou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002408-42,1,0,0 2019-002408-42,7,2022-06-28,2022-06-28,4,0,0,0,0,1,3,0,0,2,1,0,0,0,1,LABORATOIRES SMB S.A,"A Phase 3, Double Blind, Multicentric, Randomised, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Itraconazole Dry Powder for Inhalation for the Prevention of Invasive Mou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002408-42,1,0,0 2019-002409-23,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Cullinan Pearl Corp.,"A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002409-23,0,0,0 2019-002410-39,8,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,ObsEva S.A.,A double-blind randomized extension study to assess the long-term efficacy and safety of linzagolix in subjects with endometriosis-associated pain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002410-39,0,0,0 2019-002410-39,8,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Kissei Pharmaceutical Co., Ltd.",A double-blind randomized extension study to assess the long-term efficacy and safety of linzagolix in subjects with endometriosis-associated pain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002410-39,0,0,0 2019-002413-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Sint Maartenskliniek,The efficacy of Methotrexate for glucocorticoid dose reduction in recently diagnosed polymyalgia rheumatica patients: a double-blind randomized placebo controlled clinical trial. De effectiviteit ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002413-18,0,0,0 2019-002414-40,1,2020-08-12,2020-08-12,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,Complexa Inc.,"A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects with Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002414-40,0,0,0 2019-002419-24,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,The University of Birmingham,A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophospham...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002419-24,0,0,0 2019-002425-30,12,2021-11-12,2021-11-12,8,0,0,0,0,2,3,0,0,2,1,0,0,0,1,Theravance Biopharma Ireland Limited,"A Phase 3, 182-week, Open-Label, Extension Study to Investigate the Safety and Tolerability of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (symptomatic nOH) in Subjects with Pri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002425-30,1,0,0 2019-002428-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL CLINICO SAN CARLOS,"ONE CENTRE, DOUBLE BLIND, ONE CENTRE, RANDOMIZED CLINICAL TRIAL, IN TWO PARALLEL GROUPS TO EVALUATE THE EFICACY IN THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING OF DEXAMETHASONE VERSUS METHILPRE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002428-34,0,0,0 2019-002430-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Klinikum der Ludwig-Maximilians-Universität München -,"A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002430-36,0,0,0 2019-002438-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboudumc,"Multiple doses versus single dose of cefazolin to prevent periprosthetic joint infection after revision arthroplasty: a multicenter open-label, randomized clinical trial. Verlengde profylaxe versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002438-35,0,0,0 2019-002438-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sint Maartenskliniek,"Multiple doses versus single dose of cefazolin to prevent periprosthetic joint infection after revision arthroplasty: a multicenter open-label, randomized clinical trial. Verlengde profylaxe versu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002438-35,0,0,0 2019-002444-24,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Camurus AB,"An Exploratory Trial Assessing Vascular Digital Perfusion, Pharmacokinetics, Safety and Tolerability Following a Single Dose of CAM2043 (Treprostinil Subcutaneous Depot) in Patients with Raynaud’s Phe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002444-24,0,0,0 2019-002446-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IBSAL (Instituto de Investigación Biomédica de Salamanca),"Phase III, multicentre, randomized, open clinical trial comparing treatment with allogenic mesenchymal cells against autologous mesenchymal cells and against active control with hyaluronic acid in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002446-21,0,0,0 2019-002449-39,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasiv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002449-39,0,0,0 2019-002449-39,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasiv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002449-39,0,0,0 2019-002450-23,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Tine Nygaard Gregersen,Dosimetry based PRRT versus standard dose PRRT with Lu-177-DOTATOC in NEN patients- a randomized study; a step towards tailored PRRT. Dosimetribaseret PRRT versus standard PRRT med Lu-177-DOTATOC t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002450-23,0,0,0 2019-002451-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IRCCS ISTITUTO CLINICO HUMANITAS,nd Valutazione dell’outcome clinico tra la terapia sub-linguale PCA con sufentanil e la terapia per os associata a single shot peri-femorale nel percorso Fast Track della chirurgia protesica tota...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002451-42,0,0,0 2019-002452-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UMC Utrecht,Inhibition of Mast cell Activation in AtheroScleroTic lesions using an Anti-IgE antibody approach (MAST-trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002452-16,0,0,0 2019-002455-42,9,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002455-42,0,0,0 2019-002455-42,9,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002455-42,0,0,0 2019-002461-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Heidelberg,"Monocenter, randomized, controlled, open-label, phase-II clinical trial of PREoperative endoscopic injection of BOTulinum toxin in the sphincter of Oddi to reduce postoperative pancreatic fistula afte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002461-35,0,0,0 2019-002462-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden Universitair Medisch Centrum,Imaging tumor angiogenesis using [18F]-PSMA-1007 PET/CT in patients with colon and gastric cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002462-12,0,0,0 2019-002463-10,12,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,BLUEPRINT MEDICINES CORPORATION,"A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR FIRST-LINE TREATMENT OF RET FUSION-POSITIVE, METASTATIC NON-SMALL CELL LUNG CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002463-10,0,0,0 2019-002463-10,12,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Blueprint Medicines Corporation,"A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR FIRST-LINE TREATMENT OF RET FUSION-POSITIVE, METASTATIC NON-SMALL CELL LUNG CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002463-10,0,0,0 2019-002463-10,12,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR FIRST-LINE TREATMENT OF RET FUSION-POSITIVE, METASTATIC NON-SMALL CELL LUNG CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002463-10,0,0,0 2019-002466-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH,Nivolumab with chemotherapy in pleural mesothelioma after surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002466-13,0,0,0 2019-002469-37,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002469-37,0,0,0 2019-002469-37,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002469-37,0,0,0 2019-002470-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSITANCE PUBLIQUE DES HOPITAUX DE PARIS,NEw Clinical End-points in patients with primary Sjögren's Syndrome (pSS): an Interventional Trial based on stratifYing patients Nuovi end-points clinici in pazienti con sindrome di Sjögren primari...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002470-32,0,0,0 2019-002474-30,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,PERSONALIZED MOLECULAR DRIVEN SURGERY ACCORDING TO BRCA MUTATIONAL STATUS IN ADVANCED EPITHELIAL OVARIAN CANCER PATIENTS WITH HIGH TUMOR LOAD Approccio chirurgico personalizzato basato sullo stato ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002474-30,0,0,0 2019-002475-34,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Recordati Rare Diseases,"Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002475-34,0,0,0 2019-002477-56,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"IMMUNOGEN, INC.",A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002477-56,0,0,0 2019-002477-56,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"ImmunoGen, Inc.",A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002477-56,0,0,0 2019-002478-29,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Essen,Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002478-29,0,0,0 2019-002479-33,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Hull University Teaching Hospitals NHS Trust,"A parallel group, double-blind, randomised, placebo-controlled trial comparing the effectiveness and cost effectiveness of low dose oral modified release morphine versus placebo on patient-reported wo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002479-33,0,0,0 2019-002480-94,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Assessment of cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in first or secondary platinum-resistant recurrent ovarian epithelial cancer. HIPOVA-01 HIPOVA-01: Evalu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002480-94,0,0,0 2019-002481-13,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"AGIOS PHARMACEUTICALS, INC.","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002481-13,0,0,0 2019-002481-13,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Agios Pharmaceuticals, Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002481-13,0,0,0 2019-002485-12,5,,,0,0,0,0,2,0,4,0,0,3,0,0,0,0,1,Alimentiv Inc.,"VERDICT: In actiVE ulcerative colitis, a RanDomIzed Controlled Trial for determination of the optimal treatment target",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002485-12,0,0,0 2019-002485-12,5,,,0,0,0,0,2,0,4,0,0,3,0,0,0,0,1,Alimentiv,"VERDICT: In actiVE ulcerative colitis, a RanDomIzed Controlled Trial for determination of the optimal treatment target",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002485-12,0,0,0 2019-002485-12,5,,,0,0,0,0,2,0,4,0,0,3,0,0,0,0,1,ALIMENTIV INC.,"VERDICT: In actiVE ulcerative colitis, a RanDomIzed Controlled Trial for determination of the optimal treatment target",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002485-12,0,0,0 2019-002485-12,5,,,0,0,0,0,2,0,4,0,0,3,0,0,0,0,1,Alimentiv Inc. (formerly Robarts Clinical Trials),"VERDICT: In actiVE ulcerative colitis, a RanDomIzed Controlled Trial for determination of the optimal treatment target",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002485-12,0,0,0 2019-002488-91,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"AN OPEN-LABEL, PHASE IIIB, SINGLE ARM, MULTICENTER SAFETY STUDY OF ATEZOLIZUMAB (TECENTRIQ) PLUS NABPACLITAXEL OR PACLITAXEL IN THE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002488-91,0,0,0 2019-002488-91,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"AN OPEN-LABEL, PHASE IIIB, SINGLE ARM, MULTICENTER SAFETY STUDY OF ATEZOLIZUMAB (TECENTRIQ) PLUS NABPACLITAXEL OR PACLITAXEL IN THE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002488-91,0,0,0 2019-002491-14,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002491-14,0,0,0 2019-002491-14,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002491-14,0,0,0 2019-002491-14,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002491-14,0,0,0 2019-002495-13,1,2020-11-24,2020-11-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Eli Lilly & Company,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults with Chronic Spontaneous Urticaria Inadequately Controll...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002495-13,0,0,0 2019-002496-33,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Helsingin ja Uudenmaan sairaanhoitopiiri,TROMBOOSIPROFYLAKSIA JA HYYTYMISAKTIVAATIO HAIMASYÖVÄN NEOADJUVANTTIHOIDON AIKANA – YHTEYS ENNUSTEESEEN JA TAUDIN UUSIUTUMISEEN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002496-33,0,0,0 2019-002496-33,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Helsingin yliopisto,TROMBOOSIPROFYLAKSIA JA HYYTYMISAKTIVAATIO HAIMASYÖVÄN NEOADJUVANTTIHOIDON AIKANA – YHTEYS ENNUSTEESEEN JA TAUDIN UUSIUTUMISEEN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002496-33,0,0,0 2019-002498-80,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Mikkel Brabrand,Will titrated oxygen flow to a peripheral oxygen saturation of 88-92% compared with oxygen flow to a saturation >94% reduce mortality in Chronic Obstructive Pulmonary Disease patients with acute exace...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002498-80,0,0,0 2019-002499-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU Amiens-Picardie,RELYAGE (Relapse LYmphoma AGEd) : Assessment of survival and autonomy with Rituximab-Lenalidomide and Rituximab-Chemotherapy for elderly patients with relapsed diffuse large-B cell lymphoma : a random...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002499-14,0,0,0 2019-002501-22,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,pH Pharma Inc.,"A Multi-Center, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Tolerability of the Neutrophil Elastase Inhibitor PHP-303 in Adults with Alpha-1 Antitrypsin Deficien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002501-22,0,0,0 2019-002503-17,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Amgen Inc,"A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002503-17,0,0,0 2019-002503-17,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AMGEN INC.,"A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002503-17,0,0,0 2019-002504-41,3,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,Pfizer Inc.,Single-Arm Study of Lorlatinib in Participants with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002504-41,0,0,0 2019-002504-41,3,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,PFIZER INC,Single-Arm Study of Lorlatinib in Participants with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002504-41,0,0,0 2019-002507-18,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Gustave Roussy,Efficacy and feasibility of pasireotide to reduce clinically relevant digestive leakage after complete cytoreductive surgery (CRS) plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for peritonea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002507-18,0,0,0 2019-002508-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Aarhus University Hospital,"A randomized, multicenter, double-blind, placebo-controlled comparison of standard (neo)adjuvant therapy plus placebo versus standard (neo)adjuvant therapy plus atorvastatin in patients with early bre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002508-42,0,0,0 2019-002509-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,Impact of totally transdermal sedation in the weaning from remifentanil infusion among critically ill patients undergoing mechanical ventilation: a pilot randomized-controlled Study IMPATTO DI UN P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002509-22,0,0,0 2019-002511-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Rigshospitalet,Repeated Injection Therapy of Allogeneic Stem Cells in Ischemic No-option Patients - A Multi-Centre Study (SCIENCE REPEAT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002511-26,0,0,0 2019-002514-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI""",Phase II study on the safety and efficacy of cysteamine in association with standard tuberculosis therapy for the treatment of patients with pulmonary tuberculosis: a new therapy for tuberculosis dire...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002514-40,0,0,0 2019-002521-30,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"HUYABIO International, LLC","A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002521-30,0,0,0 2019-002528-34,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in complete remission and/or with detectable bone marrow minim...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002528-34,0,0,0 2019-002529-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oslo University Hospital,SAFETY AND EFFICACY OF SHINGRIX VACCINATION IN VARICELLA NAÏVE RENAL TRANSPLANT RECIPIENTS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002529-31,0,0,0 2019-002531-29,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Visterra, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002531-29,0,0,0 2019-002533-11,14,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,ACTELION Pharmacteuticals Ltd.,"A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerabi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002533-11,0,0,0 2019-002533-11,14,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,ACTELION PHARMACEUTICALS LTD,"A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerabi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002533-11,0,0,0 2019-002534-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ENTE OSPEDALIERO OSPEDALI GALLIERA,Diagnostic and predictive role of 64CuCl2 PET / CT in bladder cancer patients eligible for chemotherapy Ruolo diagnostico e predittivo della 64CuCl2 PET/CT nei pazienti affetti da tumore della vesc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002534-37,0,0,0 2019-002535-28,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,Hôpitaux Universitaires de Strasbourg,Braking effect on myopia with atropine eye drops at 0.01%. Effet freinateur sur la myopie par l’atropine collyre à 0.01%,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002535-28,0,0,0 2019-002537-11,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital,Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002537-11,0,0,0 2019-002541-37,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Region Örebro län,Primary TBE vaccination for the elderly Primär TBE vaccination till äldre,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002541-37,0,0,0 2019-002542-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU de TOURS,Efficacité de la vaccination anti-pneumococcique en prime-boost chez les patients atteints de lymphome diffus à grandes cellules B traités par Rituximab en 1ère ligne Efficacité de la vaccination ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002542-20,0,0,0 2019-002544-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS,NA « EVALUATION DE L’EFFICACITE DU CHLORURE DE POTASSIUM DANS LA PRISE EN CHARGE DES ARRETS CARDIAQUES EXTRA-HOSPITALIERS PAR FIBRILLATION VENTRICULAIRE REFRACTAIRE»,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002544-24,0,0,0 2019-002545-38,1,2021-12-30,2021-12-30,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,"Bispebjerg Hospital, Department of Dermatology",Biodistribution of ablative fractional laser-assisted topical delivery of Vismodegib in basal cell carcinomas.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002545-38,0,0,0 2019-002548-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Royal College of Surgeons in Irlenad,"Can Pentoxifylline improve long-term outcomes in preterm infants with late-onset sepsis or necrotizing enterocolitis? A pragmatic, randomised, placebo controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002548-26,0,0,0 2019-002549-39,7,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,"Takeda Development Center Americas, Inc.","A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphobla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002549-39,0,0,0 2019-002549-39,7,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,TAKEDA DEVELOPMENT CENTER AMERICAS INC.,"A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphobla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002549-39,0,0,0 2019-002550-23,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,UCB Biopharma SRL,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002550-23,0,0,0 2019-002551-42,8,2022-09-28,2022-09-28,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,UCB Biopharma SRL,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002551-42,1,0,0 2019-002553-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,1Globe Health Institute,"A Phase II/III Randomized, Open-Label Clinical Study of Napabucasin in Combination with Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic Pancreatic Cancer Following Chemotherapy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002553-35,0,0,0 2019-002554-23,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"BeiGene, Ltd.","An Open-Label, Multicenter, Long-term Extension Study of Tislelizumab-Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002554-23,0,0,0 2019-002554-23,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,BeiGene Ltd.,"An Open-Label, Multicenter, Long-term Extension Study of Tislelizumab-Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002554-23,0,0,0 2019-002558-21,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Applied Therapeutics Inc.,"Aldose Reductase Inhibition for Stabilization of Exercise capacity in Heart Failure (ARISE-HF): A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-001 in Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002558-21,0,0,0 2019-002560-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients. Pembrolizumab en lenvatinib behandeling bij een eerder behandeld maligne mesothelioom.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002560-28,0,0,0 2019-002562-12,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,HOSPITAL GENERAL DE CATALUNYA,"PRAGMATIC, COMPARATIVE AND RANDOMIZED CLINICAL TRIAL OF THE NEW SOLUTION OF 1 LITER POLYETHYLENE GLYCOL VERSUS SODIUM PICOSULFATE WITH MAGNESIUM CITRATE IN THE EFFECTIVENESS OF SCREENING AND SURVEILL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002562-12,0,0,0 2019-002566-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amsterdam University Medical Center,Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002566-13,0,0,0 2019-002567-96,9,2021-05-28,2021-06-23,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A phase 3, randomized, double-blind trial of nivolumab in combination with intravesical BCG versus standard of care BCG alone in participants with high-risk non-muscle invasive bladder cancer that is ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002567-96,1,0,0 2019-002567-96,9,2021-05-28,2021-06-23,2,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A phase 3, randomized, double-blind trial of nivolumab in combination with intravesical BCG versus standard of care BCG alone in participants with high-risk non-muscle invasive bladder cancer that is ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002567-96,1,0,0 2019-002571-33,1,2020-03-06,2020-03-06,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,CHU Angers,Transcutaneous measurement of oxygen during transient hyperoxia Mesure transcutanée de l’oxygène au cours de l’hyperoxie transitoire,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002571-33,0,0,0 2019-002575-34,7,2022-01-21,2022-01-21,5,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bayer AG,"A randomised, placebo-controlled, double-blind, parallel-group, multi-centre, proof-of-concept study to assess the efficacy and safety of BAY 1817080 in patients with overactive bladder (OAB) over a 1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002575-34,1,0,0 2019-002578-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboudumc,Functional Improvement of non-infarcT relaTed coronary artery stenosis by Extensive LDL-C Reduction with a PCSK9 Antibody. Functionele verbetering van de niet-infarct gerelateerde coronairarterieve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002578-29,0,0,0 2019-002579-33,5,2021-08-24,2021-08-24,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Phathom Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind, Two-Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophagiti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002579-33,1,0,0 2019-002585-12,2,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,1,Sanofi Pasteur,"Immunogenicity and Safety of DTaP-IPV-HB-PRP~T Combined Vaccine Given at 3, 5, and 12 Monhs of Age Concomitantly or Sequentially 4CMenB Vaccine in Italian Infants Immunogenicità e sicurezza del vac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002585-12,0,0,0 2019-002585-12,2,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,1,SANOFI PASTEUR,"Immunogenicity and Safety of DTaP-IPV-HB-PRP~T Combined Vaccine Given at 3, 5, and 12 Monhs of Age Concomitantly or Sequentially 4CMenB Vaccine in Italian Infants Immunogenicità e sicurezza del vac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002585-12,0,0,0 2019-002587-28,1,2022-01-07,2022-01-07,1,0,0,0,0,1,4,0,1,1,0,0,0,0,0,Radboudumc,ABSORB 2:An exploratie study determining the oral antibiotic drug absorption in patients with short bowel syndrome. ABSROB 2: onderzoek naar orale antibiotica opname bij patienten met short bowel s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002587-28,0,0,0 2019-002591-14,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Belfast Health & Social Care Trust,The Fenofibrate And Microvascular Events in Type 1 diabetes Eye (FAME 1 Eye): A randomised trial to evaluate the efficacy on retinopathy and safety of fenofibrate in adults with type 1 diabetes. A mu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002591-14,0,0,0 2019-002592-34,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University College London,Research to Improve the Detection and Treatment of Latent Tuberculosis Infection: Diagnostics (RID-TB:Dx) A randomised controlled trial to evaluate the effectiveness of using the RD-1 based C Tb skin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002592-34,0,0,0 2019-002593-31,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,"Efficacy of Nintedanib per os as a treatment for epistaxis in HHT disease A national, randomized, multicenter phase II study EPICURE EPICURE : Efficacité du Nintedanib par voie orale pour le trai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002593-31,0,0,0 2019-002597-32,1,2021-01-05,2021-01-05,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Ghent,Dynamics and tracer distribution of Tilmanocept using combined subareolar and peritumoral injection technique for scintigraphic sentinel lymph node detection in early stage breast cancer. Vergelijk...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002597-32,0,0,0 2019-002598-78,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,UCB Biopharma SRL,"A Phase 1/2 Open-Label, Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002598-78,0,0,0 2019-002600-40,2,2021-11-29,2021-11-29,2,1,0,0,0,0,3,0,0,1,0,0,0,0,1,"SCYNEXIS, Inc.","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects with Recurrent Vulvovagin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002600-40,0,0,0 2019-002603-17,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,Eli Lilly and Company,"A Phase 1, Open-Label, Single-Dose Pharmacokinetic Study of Lasmiditan in Pediatric Patients With Migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002603-17,0,1,1 2019-002605-22,2,2022-04-06,2022-04-06,2,0,0,0,0,1,2,0,0,1,0,0,0,0,1,"Kezar Life Sciences, Inc.","A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients with Active Polymyositis or Dermatomyosi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002605-22,0,0,0 2019-002607-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Hospital Tuebingen,"Randomized, controlled interventional trial to investigate the efficacy of amiloride for the treatment of edema in human nephrotic syndrome Randomisierte, kontrollierte Interventionsstudie zur Unte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002607-18,0,0,0 2019-002611-26,5,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"AveXis, Inc.",A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002611-26,0,0,0 2019-002611-26,5,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Novartis Gene Therapies, Inc.",A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002611-26,0,0,0 2019-002611-26,5,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"AVEXIS, INC.",A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002611-26,0,0,0 2019-002615-25,4,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,GE Healthcare Ltd.,"An Open-label, Single-dose, Safety and Pharmacokinetic Study of Regadenoson in Paediatric Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002615-25,0,0,0 2019-002615-25,4,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,GE HEALTHCARE,"An Open-label, Single-dose, Safety and Pharmacokinetic Study of Regadenoson in Paediatric Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002615-25,0,0,0 2019-002618-38,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"ASSOCIAZIONE ""LA NOSTRA FAMIGLIA"" - SEZIONE SCIENTIFICA I.R.C.C.S. ""E.MEDEA""",Clinical trial - phase II - to test safety and efficay of Etravirine's treatment in Friedreich Ataxia's patients Studio clinico di fase II per testare sicurezza ed efficacia del trattamento con Etr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002618-38,0,0,0 2019-002619-24,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Allergic Bronchopulmonary Aspergillosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002619-24,0,0,0 2019-002621-30,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002621-30,0,0,0 2019-002621-30,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002621-30,0,0,0 2019-002623-14,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,GW Pharma Ltd,"A Double-blind, Randomized, Placebo-controlled, Parallel-group Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray as Add-on Therapy in Patients with Spasticity Due to Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002623-14,0,0,0 2019-002625-29,3,2022-05-10,2022-05-10,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GW Pharma Limited,"A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Patients with Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002625-29,1,0,0 2019-002626-67,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut Català d'Oncologia,"EFFICACY AND SAFETY OF THE COMBINATION OF BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS EVALUACIÓN DE LA EFICACIA Y SEGURIDAD DE LA COMBINACIÓN DE BORTEZOM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002626-67,0,0,0 2019-002627-16,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Integrative Research Laboratories Sweden AB (IRLAB),"A randomised, placebo-controlled, multicentre phase IIb study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinson’s disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002627-16,0,0,0 2019-002629-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Léon Bérard,"REGOMAIN – A randomized, placebo-controlled, double-blinded, multicentre, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients with high grade bone sarcomas (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002629-31,0,0,0 2019-002631-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,MRSA Knowlege center,A randomized placebo-controlled double-blinded trial of the treatment of MRSA throat carriage with either standard decolonization therapy or standard decolonization therapy combined with oral clindamy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002631-29,0,0,0 2019-002632-90,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"""Olainfarm"" AS","A prospective, double-blind, randomised, placebo-controlled trial on the efficacy and safety of Neiromidin 20 mg tablets in the treatment of patients with lumbosacral radiculopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002632-90,0,0,0 2019-002635-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Utrecht,The effect of hyperbaric oxygen therapy on breast cancer patients with late radiation toxicity Het effect van hyperbare zuurstoftherapie bij borstkankerpatiënten met late radiatieschade,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002635-28,0,0,0 2019-002636-82,1,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,1,Orchard Therapeutics (Europe) Limited,"An open label, non-randomised trial to evaluate the safety and efficacy of a single infusion of OTL-200 in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002636-82,0,0,0 2019-002637-11,14,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novartis Pharma AG,"EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002637-11,0,0,0 2019-002638-36,1,,,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,"Bispebjerg Hospital, University of Copenhagen","Glucagon Dose-response Relationship for Cardiovascular Activity A Randomized, participant-blinded, Crossover Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002638-36,0,0,0 2019-002640-25,3,2020-04-06,2020-04-06,2,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Sage Therapeutics, Inc.","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF SAGE-217 WITH FIXED, REPEATED TREATMENT REGIMEN ON RELAPSE PREVENTION IN ADULTS WITH MAJOR DEPRESSIVE DISORD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002640-25,0,0,0 2019-002641-37,2,2020-03-26,2020-03-26,2,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Novo Nordisk A/S,"Efficacy and safety of once-weekly subcutaneous administration of concizumab prophylaxis in patients with haemophilia A and B, with or without inhibitors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002641-37,0,0,0 2019-002643-23,1,,,0,0,0,0,1,0,2,0,0,3,0,0,0,0,0,Sheffield Teaching Hospitals NHS Foundation Trust,Validation of a novel composite of skin biomarkers as a primary outcome measure for evaluating the safety of treatments for atopic dermatitis: a randomized controlled trial (phase 2) comparing the eff...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002643-23,0,0,0 2019-002644-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Diater, Laboratorio de Diagnóstico y Aplicaciones Terapéuticas S.A.","Biological standarization of allergic extracts of will grasses: Phleum pratense, Lolium perenne, Poa pratensis y Dactylis glomerata and its mixture to determinate their biological activity, the In Hou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002644-24,0,0,0 2019-002658-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Pharma GmbH,"A Phase II, randomized (1:1) open-label study to assess the efficacy and safety of eltrombopag in combination with dexamethasone compared to dexamethasone, as first-line treatment in adult patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002658-21,0,0,0 2019-002660-27,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally advance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002660-27,0,0,0 2019-002660-27,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally advance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002660-27,0,0,0 2019-002660-27,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A","A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally advance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002660-27,0,0,0 2019-002661-35,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King's College London,Effect of Iron Isomaltoside on Perioperative Myocardial Injury in Patients Undergoing Coronary Artery Bypass Graft ± Valve Surgery: The Ferric Iron in Coronary Artery Bypass Grafting (FERRIC-CABG) Tri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002661-35,0,0,0 2019-002661-35,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King's College Hospital NHS Foundation Trust,Effect of Iron Isomaltoside on Perioperative Myocardial Injury in Patients Undergoing Coronary Artery Bypass Graft ± Valve Surgery: The Ferric Iron in Coronary Artery Bypass Grafting (FERRIC-CABG) Tri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002661-35,0,0,0 2019-002662-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ARCAGY-GINECO,A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002662-12,0,0,0 2019-002663-10,11,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Biogen Idec Research Limited,"Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002663-10,0,0,0 2019-002663-10,11,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,BIOGEN IDEC RESEARCH LIMITED,"Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002663-10,0,0,0 2019-002665-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Mikkel Holm Vendelbo,16α-18F-fluor-17β-estradiol PET/CT for detection of estrogen receptor positive liver metastases in breast cancer 16α-18F-fluor-17β-østradiol PET/CT til detektion af østrogenreceptor-positive lever...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002665-35,0,0,0 2019-002666-12,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A phase I/Ib open-label, multi-center dose escalation study of JBH492 in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Non Hodgkin’s Lymphoma (NHL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002666-12,0,0,0 2019-002668-28,5,2021-03-15,2021-03-15,4,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Phathom Pharmaceuticals, Inc.",A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy with Oral Vonoprazan 20 mg or Double-Blind Triple Therapy with Oral Vonoprazan 20 mg Compared to D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002668-28,1,0,0 2019-002669-37,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"GB002, Inc.","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002669-37,0,0,0 2019-002672-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ALMA MATER STUDIORUM UNIVERSITà DI BOLOGNA,CPAP Reduces Hypoxemia After Cardiac Surgery (CRHACS Trial). A randomized controlled trial La CPAP riduce l’ipossiemia dopo chirurgia cardiaca (CRHACS trial): studio randomizzato e controllato,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002672-13,0,0,0 2019-002674-31,6,2022-06-09,2022-06-09,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Janssen Sciences Ireland UC,"A Randomized, Double blind, Placebo-controlled Phase 2b Study to Evaluate Efficacy, Pharmacokinetics, and Safety of 48-week Study Intervention With JNJ-73763989+JNJ-56136379+Nucleos(t)ide Analog (NA) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002674-31,1,0,0 2019-002674-31,6,2022-06-09,2022-06-09,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Janssen Sciences Ireland Unlimited Company,"A Randomized, Double blind, Placebo-controlled Phase 2b Study to Evaluate Efficacy, Pharmacokinetics, and Safety of 48-week Study Intervention With JNJ-73763989+JNJ-56136379+Nucleos(t)ide Analog (NA) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002674-31,1,0,0 2019-002676-14,5,2022-02-07,2022-02-07,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Pfizer Inc.,"A 24-WEEK RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, ACTIVE COMPARATOR, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF PF 06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PART...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002676-14,1,0,0 2019-002677-57,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dra. Julia Origüen Sabater,"A phase III, multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of oral vancomycin versus placebo in preventing relapse of Clostridioides difficile infection in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002677-57,0,0,0 2019-002678-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Anavex Life Sciences Corp.,Open Label Extension Study for Patients with Parkinson’s Disease with Dementia Previously Enrolled in ANAVEX2-73-PDD-001 Study for Continued Safety Assessment Estudio abierto de extensión para paci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002678-29,0,0,0 2019-002686-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Dermapharm AG,"Double-blind, randomised clinical study comparing efficacy and safety of Methylprednisolone Aceponate 0.1% Ointment (Test) vs. Advantan 0.1% Ointment (Reference) vs. Vehicle in patients with mild to m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002686-35,0,0,0 2019-002687-27,13,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Eli Lilly and Company,"A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002687-27,0,0,0 2019-002687-27,13,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002687-27,0,0,0 2019-002688-89,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Histocell S.L.,"Phase 1/2 clinical study to assess the feasibility, safety, tolerability and preliminary efficacy of the administration of HCR040, a drug whose active substance is HC016, allogeneic adipose-derived ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002688-89,0,0,0 2019-002691-14,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,"IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA","VISCOUS BUDESONIDE IN PATIENTS AFFECTED BY EOSINOPHILIC ESOPHAGITIS, OPERATED FOR ESOPHAGEAL ATRESIA BUDESONIDE VISCOSA NEI PAZIENTI AFFETTI DA ESOFAGITE EOSINOFILA, OPERATI DI ATRESIA ESOFAGEA St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002691-14,0,0,0 2019-002692-34,2,2022-05-05,2022-05-05,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,"NTNU, Dept of Clinical and Molecular Medicine, Gastrosenteret","A pilot study on safety, feasibility and insulin-promotion by intra-inguinal lymph node injections of glutamic acid decarboxylase (GAD) in patients with LADA type of diabetes.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002692-34,0,0,0 2019-002694-63,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,INSERM,« Mécanismes de résilience neuronale dans la maladie d'Alzheimer et ses variantes focales: une étude TEP/IRM »,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002694-63,0,0,0 2019-002698-74,11,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Pfizer Inc,"A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PF-06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002698-74,0,0,0 2019-002698-74,11,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,PFIZER INC,"A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PF-06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002698-74,0,0,0 2019-002704-41,7,2022-02-07,2022-02-07,6,0,0,0,0,0,4,0,0,1,0,0,0,0,1,H. Lundbeck A/S,"A randomised, double-blind, parallel-group, active controlled study evaluating the efficacy of vortioxetine versus desvenlafaxine in adult patients suffering from major depressive disorder with partia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002704-41,0,0,0 2019-002706-46,1,2021-06-14,2021-06-14,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Vakzine Projekt Management GmbH,"A Phase II/III, Multicenter, Randomized, Observer-blinded, Active Controlled Clinical Study to Assess the Safety and Immunogenicity of the Tetanus, Diphtheria and Acellular Pertussis Vaccine SIIPL Tda...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002706-46,0,0,0 2019-002709-23,5,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Pliant Therapeutics Inc.,"A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN 74809 in participants with idiopathic pulmonary fibrosis (IPF) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002709-23,0,0,0 2019-002713-19,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Viela Bio, Inc.","A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects with Sjögren's Syndrome (SS) Studio proof of concept di fas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002713-19,0,0,0 2019-002713-19,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,VIELABIO Inc.,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in Subjects with Sjögren's Syndrome (SS) Studio proof of concept di fas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002713-19,0,0,0 2019-002716-43,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU DE NANCY,Pilot Study evaluating somatostatin receptor's PET imaging to detect inflammatory phases of myocarditis Etude pilote d'évaluation de l'imagerie TEP des récépteurs de la somatostatine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002716-43,0,0,0 2019-002721-30,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Oslo University Hospital,Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002721-30,0,0,0 2019-002729-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación y la Innovación Biosanitaria del Principado de Asturias (FINBA),18F-fluorocholine PET/CT in primary hyperparathyroidism with negative preoperative localization PET/TC con 18F-Fluorocolina en el hiperparatiroidismo primario con localización prequirúrgica negativ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002729-31,0,0,0 2019-002730-36,1,2022-06-29,2022-06-29,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,"Department of Dermatology, Bispebjerg Hospital",Calcium electroporation for basal cell carcinomas – a ’Proof of concept’ study Calcium elektroporation til behandling af basalcellekarcinomer – ’Proof of concept’ studium,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002730-36,0,0,0 2019-002733-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FUNDACIÓ LLUITA CONTRA LA SIDA,"Exploratory, open-label, randomized clinical trial to assess the efficacy of first-line dual vs. triple antiretroviral therapy (art) in hiv-1 reservoir and in peripheral compartments in hiv-infected p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002733-10,0,0,0 2019-002734-37,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University of Cologne,"Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irinotecan Combined with Oxaliplatin and 5-Fluorouracil/Folinic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002734-37,0,0,0 2019-002735-28,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Eli Lilly and Company,The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002735-28,0,0,0 2019-002735-28,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER",The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002735-28,0,0,0 2019-002735-28,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Lilly S.A.,The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002735-28,0,0,0 2019-002738-36,2,2021-09-16,2021-09-16,2,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Alkahest, Inc.","A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 with Loading Doses of Aflibercept in Patients with Newly Diagnosed Neovascular Age-Related Macular Deg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002738-36,0,0,0 2019-002741-37,13,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002741-37,0,0,0 2019-002741-37,13,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002741-37,0,0,0 2019-002741-37,13,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002741-37,0,0,0 2019-002742-20,2,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,Regeneron Pharmaceuticals Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Patients with Moderate-to-Severe Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002742-20,0,0,0 2019-002743-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Paulien van Deutekom Foundation,Pembrolizumab alone versus pembrolizumab-chemotherapy in first line NSCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002743-26,0,0,0 2019-002744-24,1,,,0,1,0,0,0,0,4,0,0,3,0,0,0,0,1,Chiesi Farmaceutici S.p.A.,"A phase IV, open label, multicentre, randomised, 2-way cross-over exploratory clinical trial comparing a fixed combination of beclometasone dipropionate plus formoterol fumarate plus glycopyrronium ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002744-24,0,0,0 2019-002745-38,5,2021-03-10,2021-03-10,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Galera Therapeutics, Inc.",An Open Label Multi-Center Study of the Effects of Superoxide Dismutase Mimetic GC4419 when Administered to Reduce the Incidence and Severity of Severe Oral Mucositis (SOM) Associated with Chemoradiot...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002745-38,1,0,0 2019-002746-21,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español de linfomas y trasplante autologo de medula osea (GELTAMO),"A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin’s Lymphoma, Followed by Brentuxima...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002746-21,0,0,0 2019-002746-21,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación GELTAMO,"A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin’s Lymphoma, Followed by Brentuxima...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002746-21,0,0,0 2019-002747-14,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"""Olainfarm"" AS","A multi-center, randomized, double-blind, double-dummy, parallel-group, active drug controlled, adaptive, Phase III study to investigate efficacy, safety and tolerability of Furamag (Furaginum solubil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002747-14,0,0,0 2019-002748-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Oncology, Odense Universitetshospital",Repurposing disulfiram as treatment for metastatic colorectal cancer An investigator initiated clinical phase II trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002748-25,0,0,0 2019-002749-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA,Intervertebral Disc REgeneration mediated by Autologous Mesenchymal stem/stromal cells intradiscal injection: a phase IIB randomized clinical trial. Rigenerazione del disco intervertebrale mediante...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002749-40,0,0,0 2019-002752-16,4,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Genmab Holding B.V.,"Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma – A First-in-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002752-16,0,0,0 2019-002754-22,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Ascendis Pharma Growth Disorders A/S,"ACcomplisH: A Phase 2, multicenter, double-blind, randomized, placebo-controlled, dose escalation trial evaluating safety, efficacy, and pharmacokinetics of subcutaneous doses of TransCon CNP administ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002754-22,0,0,0 2019-002755-42,5,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Mirum Pharmaceuticals Inc.,"MRX-800: A Long-Term Safety Study of Maralixibat, an Apical Sodium Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002755-42,0,0,0 2019-002758-21,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Innovative Diabetes Treatments Studies LLC,PILOT STUDY FOR EVALUATION OF THE IMPACT OF PULSATILE INSULIN INFUSION THERAPY ON VASCULAR FUNCTION IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS Pilotstudie zur Bewertung der Auswirkungen e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002758-21,0,0,0 2019-002768-28,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Wockhardt Bio AG,"A Phase 3, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-zidebactam vs. Meropenem in the Treatment of Complicated Urinary Tract Infection or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002768-28,0,0,0 2019-002769-37,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,CHRU DE TOURS,Cerebrovascular reaction to nitrous oxide in Resistant Depression: Pilot study (PROTO-BRAIN) Réactivité Cérébrovasculaire au Protoxyde d’Azote dans la Dépression Résistante : Etude pilote (PROTO-BR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002769-37,0,0,0 2019-002771-33,3,2020-10-22,2020-10-22,3,1,0,0,0,0,2,0,0,1,1,0,1,0,1,UNION therapeutics A/S,"A Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults with Mild to Moderate Atopic Derma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002771-33,0,0,0 2019-002776-14,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,CAPRI-Universiteit Antwerpen,"Inflammation-based stratification for adjunctive double immunotargeting in psychosis: an open-label, randomised, single-blind, parallel-group clinical trial of adjunctive celecoxib and minocycline for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002776-14,0,0,0 2019-002778-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA","Efficacy and safety of memantine as antimanic and mood-stabilizing medication for adolescents with Bipolar Disorder: a multi-center, randomized, double-blind, placebo-controlled clinical trial Effi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002778-30,0,0,0 2019-002779-32,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,BERTA CASTELLANO PAULIS,“Pre-emptive analgesia with Ibuprofen in outpatient laparoscopic cholecystectomy. Recovery Quality ” “Analgesia pre-emptive con Ibuprofeno en colecistectomía laparoscópica ambulatoria. Calidad d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002779-32,0,0,0 2019-002781-12,1,2022-07-05,2022-07-05,1,0,0,0,1,0,3,0,1,1,0,0,0,0,0,"University of Southern Denmark, Bandim Health Project",Using BCG vaccine to strengthen the immune system in the elderly and improve the response to influenza vaccine. A randomized clinical trial. Immunforsvar mod influenza,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002781-12,0,0,0 2019-002782-35,1,2022-01-14,2022-01-14,1,1,0,0,0,0,3,0,0,1,0,0,0,0,1,Aprea Therapeutics AB,"A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002782-35,0,0,0 2019-002783-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Amsterdam University Medical Center,"A 12-month, open-label, parallel-cohort study to evaluate the efficacy, safety and tolerability of Canakinumab in Kawasaki disease Een 12 maanden durende, open-label, parallel-cohort studie naar de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002783-27,0,0,0 2019-002784-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Roche Farma S.A. (Soc. Unipersonal),"A PHASE IIIb, SINGLE ARM STUDY OF CARBOPLATIN OR CISPLATIN PLUS ETOPOSIDE WITH ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER ESTUDIO FASE IIIb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002784-10,0,0,0 2019-002785-12,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"CYTOKINETICS, INC.","A multi-center, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-3773274 in adults with symptomatic h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002785-12,0,0,0 2019-002785-12,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Cytokinetics, Inc.","A multi-center, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-3773274 in adults with symptomatic h...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002785-12,0,0,0 2019-002786-35,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,Charlotte Uggerhøj Andersen,Pharmacokinetics and side effects for tetrahydrocannabinol and cannabidiol (Sativex) among patients with chronic kidney disease and patients on dialysis. Farmakokinetik og bivirkninger for tetrahyd...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002786-35,0,0,0 2019-002787-27,4,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Amgen Inc.,"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002787-27,0,0,0 2019-002787-27,4,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,AMGEN INC.,"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002787-27,0,0,0 2019-002788-88,9,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Amgen Inc.,"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002788-88,0,0,0 2019-002788-88,9,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,AMGEN INC.,"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002788-88,0,0,0 2019-002790-58,5,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination with Trans-arterial ChemoEmbolization (TACE) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002790-58,0,0,0 2019-002790-58,5,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination with Trans-arterial ChemoEmbolization (TACE) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002790-58,0,0,0 2019-002795-13,1,,,0,0,1,0,0,0,4,0,0,0,0,0,0,0,0,Fundación de Investigación Hospital Universitario La Paz,"Identification of ""omic"" biomarkers and their inter and intra-individual variability that allow improvement in the individualization of tacrolimus: uncontrolled clinical trial in pediatric patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002795-13,0,0,0 2019-002799-15,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,ALMA MATER STUDIORUM UNIVERSITà DI BOLOGNA,Efficacy of a very low-volume Polyethylene Glycole (PEG 1L) bowel preparation vs. low-volume (2L) and high-volume (4L) PEG-based preparations. A randomized controlled study. Efficacia di una prepar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002799-15,0,0,0 2019-002801-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Jessa Hospital,"Evaluation of the added value of Metamizole to standard post-operative treatment after ambulant surgery: a double-blind, randomized controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002801-23,0,0,0 2019-002804-42,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Almirall S.A.,"An international, multicentre, open label, interventional phase IV clinical study to investigate the efficacy and safety of tildrakizumab 100 mg in patients with moderate-to-severe chronic plaque psor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002804-42,0,0,0 2019-002804-42,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Almirall SA,"An international, multicentre, open label, interventional phase IV clinical study to investigate the efficacy and safety of tildrakizumab 100 mg in patients with moderate-to-severe chronic plaque psor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002804-42,0,0,0 2019-002805-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IFCT,"A Phase II, multi-centre study, to evaluate the efficacy and safety of osimertinib treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC) with Brain or Leptomeningeal metastases",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002805-23,0,0,0 2019-002806-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SOLTI,TARGETING THE PAM50 HER2-ENRICHED PHENOTYPE WITH ENZALUTAMIDE IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER Ensayo con enzalutamida dirigido al subtipo Her2-enriquecido por PA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002806-28,0,0,0 2019-002810-37,5,2022-04-20,2022-04-20,5,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Dr. Reddy’s Laboratories S.A.,"A Randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002810-37,0,0,0 2019-002813-20,2,2020-08-19,2021-06-27,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults With Borderline Personality Disorder Eine multizentrische, randomisierte, do...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002813-20,0,0,0 2019-002817-21,13,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,ACTELION PHARMACEUTICALS LTD,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel- Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002817-21,0,0,0 2019-002817-21,13,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Actelion Pharmaceuticals Ltd.,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel- Group, Event-Driven, Group-Sequential Study with Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002817-21,0,0,0 2019-002818-40,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Inserm-ANRS,"A Phase II randomised, placebo-controlled trial of vedolizumab with or without therapeutic HIV MVA vaccine in individuals who started antiretrovirals during primary or chronic infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002818-40,0,0,0 2019-002818-40,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,INSERM-ANRS,"A Phase II randomised, placebo-controlled trial of vedolizumab with or without therapeutic HIV MVA vaccine in individuals who started antiretrovirals during primary or chronic infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002818-40,0,0,0 2019-002819-25,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Leeds Teaching Hospital NHS Trust,"Dequalinium versus usual care antibiotics for the treatment of bacterial vaginosis (DEVA): a multicentre, randomised, open label, non-inferiority trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002819-25,0,0,0 2019-002821-31,1,2020-04-27,2020-04-27,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Alkahest, Inc",The Effect of AKST4290 on Choroidal Blood Flow in Patients with Neovascular Age-Related Macular Degeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002821-31,0,0,0 2019-002824-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Clermont-Ferrand,". Taux résiduel sanguin d’amoxicilline chez les patients traités par forte dose, pendant la première semaine de traitement : variabilité intra- et interindividuelle, facteurs associés au surdosage ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002824-34,0,0,0 2019-002826-58,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Rijnstate Hospital, Arnhem",The effects of enoximone in acute exacerbation COPD: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002826-58,0,0,0 2019-002827-14,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,IRCCS Fondazione Stella Maris,Phase 2 pharmacological experimental study to test the safety of miglustat in subjects with hereditary spastic paraplegia type 11 Studio sperimentale farmacologico di fase 2 per valutare la sicurez...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002827-14,0,0,0 2019-002829-29,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,INSERM ANRS,Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex with Men using oral TDF/FTC for HIV Pre-Exposure Prophylaxis (PrEP) Prévention combinée des infections sexuellement...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002829-29,0,0,0 2019-002833-12,1,2022-04-07,2022-04-07,1,0,0,0,0,3,3,0,0,1,1,1,0,0,0,University Medical Centre Hamburg-Eppendorf,"Investigator-initiated, placebo-controlled, randomized trial to assess the efficacy and safety of platelet inhibition and/ or lipid lowering in non-ACS-patients with elevated high-sensitivity troponin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002833-12,0,0,0 2019-002834-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST,Randomized phase II study of PAnitumumab REchallenge followed by REgorafenib versus the reverse sequence in RAS and BRAF WILD-TYPE chemorefractory metastatic colorectal cancer patients. STUDIO RAND...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002834-35,0,0,0 2019-002835-27,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"IONIS PHARMACEUTICALS, INC.","A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002835-27,0,0,0 2019-002835-27,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.","A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002835-27,0,0,0 2019-002836-10,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Pfizer Inc.,"A Phase 4, Multicenter, Open Label Safety Study Of Crisaborole Ointment 2% In Children Aged 3 Months To Less Than 24 Months With Mild To Moderate Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002836-10,0,1,1 2019-002840-26,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A randomized, subject- and investigator-blinded, placebo-controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of QBW251 in patients with bronchiec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002840-26,0,0,0 2019-002843-81,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IMEA,"Switch to Tenofovir Alafenamide (TAF), Emtricitabine (FTC), Bictegravir (BIC)(Biktarvy®) in HIV-1-infected patients over 65 years old at risk of polymedication",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002843-81,0,0,0 2019-002844-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Daniel Hägi-Pedersen,"Effect of Combinations of Paracetamol, Ibuprofen, and Dexamethasone on Patient-Controlled Morphine Consumption in the First 24 Hours After Total Hip Arthroplasty. The RECIPE Randomized Clinical Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002844-25,0,0,0 2019-002845-39,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Aalborg University Hospital,Partial oral antibiotic treatment for bacterial brain abscess: An open-label randomised non-inferiority trial (ORAL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002845-39,0,0,0 2019-002847-62,1,2021-04-22,2021-04-22,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Marinomed Biotech AG,Clinical evaluation of two different dosage groups of Tacrosolv over 8 days with once daily administration in a placebo controlled cross-over design to evaluate safety and efficacy in patients sufferi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002847-62,0,0,0 2019-002848-24,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"GIGA-Consciousness Thematic Unit, Anesthesia and Intensive Care Laboratory, Liege University",Brain functional signature of connected consciousness under general anesthesia using the isolated forearm technique Signature fonctionnelle cérébrale de la conscience connectée à l’environnement au...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002848-24,0,0,0 2019-002849-38,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Aquilon Pharmaceuticals,"A prospective, active-controlled, randomized, open label, single-center, multiple dose, two-period crossover clinical trial to assess the safety, pharmacodynamics, pharmacokinetics, and preliminary ef...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002849-38,0,0,0 2019-002851-40,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,ANTIBIOTICE SA,"A Randomized, Parallel Design, Multiple-Site Study to Evaluate the non-inferiority of generic Clotrimazole 10mg/g cream (Antibiotice SA) compared to Canesten® 10mg/g cream in Patients with Tinea Pedis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002851-40,0,0,0 2019-002852-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Marta Cobo Marcos,Efficacy and Safety of Intravenous Furosemide administered with Hypertonic Saline Solution at the Heart Failure Day Hospital. SSH-IC study Eficacia y Seguridad de la Furosemida Intravenosa administ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002852-17,0,0,0 2019-002854-22,1,,,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,Aryogen Pharmed,"A RANDOMIZED, MULTICENTER, DOUBLE BLIND CLINICAL TRIAL COMPARING PHARMACODYNAMIC, PHARMACOKINETIC AND SAFETY OF A BIOSIMILAR EPTACOG ALFA (ARYOSEVEN) AND NOVOSEVEN®, IN PATIENTS WITH HAEMOPHILIA A OR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002854-22,0,0,0 2019-002855-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Helse Fonna,"A phase IIa multicentre randomized controlled double blind clinical trial to demonstrate clinical efficacy on cognitive, neuropsychiatric and functional outcomes of Ambroxol in New and Early patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002855-41,0,0,0 2019-002856-18,3,2021-07-15,2021-07-16,2,0,0,0,1,0,2,0,0,2,0,0,0,0,1,NTC SRL,Efficacy and Safety of mAnniTol in bowel preparation: assessment of adequacy and presence of Intestinal levelS of hydrogen and methane during elective colonoscopy aFter mAnnitol or standard split 2-li...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002856-18,1,0,0 2019-002856-18,3,2021-07-15,2021-07-16,2,0,0,0,1,0,2,0,0,2,0,0,0,0,1,NTC s.r.l.,Efficacy and Safety of mAnniTol in bowel preparation: assessment of adequacy and presence of Intestinal levelS of hydrogen and methane during elective colonoscopy aFter mAnnitol or standard split 2-li...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002856-18,1,0,0 2019-002859-42,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Opiant Pharmaceuticals Inc,"Randomised, double-blind, placebo-controlled trial evaluating the effects of naltrexone hydrochloride nasal spray on alcohol consumption in Alcohol Use Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002859-42,0,0,0 2019-002860-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS ISTITUTO CLINICO HUMANITAS,Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A Phase II study (Immunocabo). Studi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002860-29,0,0,0 2019-002869-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE RICERCA TRASLAZIONALE (FORT),"A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002869-35,0,0,0 2019-002871-32,7,2022-10-25,2022-10-25,1,0,0,0,0,1,3,0,0,2,1,0,0,0,2,AstraZeneca AB,"A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002871-32,1,0,0 2019-002871-32,7,2022-10-25,2022-10-25,1,0,0,0,0,1,3,0,0,2,1,0,0,0,2,ASTRAZENECA AB,"A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis (MESSINA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002871-32,1,0,0 2019-002872-14,1,,,0,1,0,1,0,0,1,0,1,3,0,0,0,0,0,University of Oxford / Clinical Trials and Research Governance,"A Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium vivax malaria vaccine candidate PvDBPII in Matrix M1 in healthy adults living in the UK",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002872-14,0,0,0 2019-002873-80,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE,"Unicentre, open, uncontrolled clinical trial to assess the morphological, biochemical and functional effects of Diflunisal treatment in patients with transthyretin cardiac amyloidosis Ensayo clínic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002873-80,0,0,0 2019-002880-82,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,King's College London,Randomised controlled trial of Gestational treatment with Ursodeoxycholic Acid compared to Metformin to Reduce effects of Diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002880-82,0,0,0 2019-002880-82,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Guy’s and St Thomas NHS Foundation Trust,Randomised controlled trial of Gestational treatment with Ursodeoxycholic Acid compared to Metformin to Reduce effects of Diabetes mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002880-82,0,0,0 2019-002888-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Byondis BV,"A single-arm phase II trial to evaluate the safety and efficacy of the antibody-drug conjugate SYD985 in patients with HER2-expressing recurrent, advanced or metastatic endometrial carcinoma who previ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002888-10,0,0,0 2019-002895-14,13,2020-07-30,2021-03-23,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Arena Pharmaceuticals Inc.,"A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects with Moderately to Seve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002895-14,0,0,0 2019-002895-14,13,2020-07-30,2021-03-23,5,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"ARENA PHARMACEUTICALS, INC.","A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects with Moderately to Seve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002895-14,0,0,0 2019-002897-30,1,,,0,1,0,0,0,0,3,0,0,0,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc","A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder Ensayo multicéntrico en abierto para...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002897-30,0,0,0 2019-002907-17,1,2020-11-02,2020-11-02,1,0,0,0,0,1,3,0,0,1,0,0,1,0,1,Ovid Therapeutics Inc.,"A MulticeNter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in PediaTric IndividUals With AngelmaN SyndromE (NEPTUNE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002907-17,0,0,0 2019-002910-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Study on the pharmacokinetic interaction between green tea and tamoxifen in patients with breast cancer. “the TEA study” Studie naar de farmacokinetische interactie tussen groene thee en tamoxifen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002910-37,0,0,0 2019-002911-25,1,2021-11-16,2021-11-16,1,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Alvotech Swiss AG,"Multicenter, Double-blind, Randomized, Parallel-group, Study Evaluating Pharmacokinetic, Efficacy, Safety, and Immunogenicity Between Patients with Moderate to Severe Chronic Plaque Psoriasis Receivin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002911-25,0,0,0 2019-002912-25,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"American Regent, Inc.","A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002912-25,0,0,0 2019-002915-24,1,2020-08-28,2020-08-28,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Theravance Biopharma Ireland Limited,"A Randomized, Double-blind, Placebo-controlled, 3-period Crossover Study to Evaluate the Effects of Repeated Doses of Inhaled TD-8236 and Impact on Airway Responses Following Allergen Challenge in Pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002915-24,0,0,0 2019-002921-31,5,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,PFIZER INC,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002921-31,0,0,0 2019-002921-31,5,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Pfizer Inc.,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-06939926 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002921-31,0,0,0 2019-002923-13,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA OSPEDALI RIUNITI DI ANCONA,Indication for the exougenous surfactant administration to treat neonatal respiratory distress syndrome in the preterm infant: a single-center randomized phase 4 trial based on the comparison of two l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002923-13,0,0,0 2019-002925-31,8,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002925-31,0,0,0 2019-002925-31,8,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY, IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002925-31,0,0,0 2019-002930-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Univeristy of Cologne,Phase II trial of TisaGenlecleucel in Elderly Patients with First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002930-35,0,0,0 2019-002931-27,3,,,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER",A Phase 1b Dose Escalation Study of Abemaciclib in Combination with Temozolomide and Irinotecan (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002931-27,0,0,0 2019-002931-27,3,,,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,Eli Lilly and Company,A Phase 1b Dose Escalation Study of Abemaciclib in Combination with Temozolomide and Irinotecan (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002931-27,0,0,0 2019-002932-10,6,2022-05-03,2022-05-03,6,1,1,0,0,0,3,0,0,1,0,0,0,0,1,"Dermira, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002932-10,0,0,0 2019-002932-10,6,2022-05-03,2022-05-03,6,1,1,0,0,0,3,0,0,1,0,0,0,0,1,"Dermira, a wholly owned subsidiary of Eli Lilly and Company","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002932-10,0,0,0 2019-002933-12,3,2022-04-28,2022-04-28,1,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Dermira, Inc","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002933-12,1,0,0 2019-002933-12,3,2022-04-28,2022-04-28,1,1,1,0,0,0,3,0,0,2,1,0,0,0,1,"Dermira, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002933-12,1,0,0 2019-002934-35,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,Children's Oncology Group,"A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078) a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Sol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002934-35,0,1,1 2019-002935-27,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,National Cancer Institute,"A Feasibility Trial of MLN4924 (Pevonedistat,TAK924) Given in Combination With Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute My...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002935-27,0,1,1 2019-002936-97,2,2022-04-07,2022-04-07,1,0,0,1,0,1,1,0,0,2,1,0,0,0,1,Abeona Therapeutics Europe SL.,A Long-term Follow-up Study of Patients with MPS IIIB from Gene Therapy Clinical Trials Involving the Administration of ABO-101 (rAAV9.CMV.hNAGLU),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002936-97,1,0,0 2019-002939-28,1,2020-09-07,2020-09-07,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,OSIVAX,"A phase 2a, single center, randomized, observer blind, controlled study to evaluate the immunogenicity and the safety of one dose of OVX836 influenza vaccine at two dose levels (90 µg and 180 μg), in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002939-28,0,0,0 2019-002942-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Region Örebro län,NORDTREAT The Nordic IBD treatment strategy trial – a randomized controlled trial of access to a protein profile,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002942-19,0,0,0 2019-002943-85,3,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002943-85,0,0,0 2019-002944-26,1,,,0,1,0,0,0,0,4,0,1,1,1,1,0,1,0,KU Leuven Drug Delivery & Disposition,Exploring the gastrointestinal behavior of dasatinib in healthy volunteers Verkennen van het gastrointestinaal gedrag van dasatinib in gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002944-26,0,0,0 2019-002945-39,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,ChemomAb Ltd,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects with Primary Sclerosing Cholangitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002945-39,0,0,0 2019-002946-19,9,2021-06-02,2021-06-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002946-19,0,0,0 2019-002946-19,9,2021-06-02,2021-06-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim RCV GmgH & Co KG,"A multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002946-19,0,0,0 2019-002946-19,9,2021-06-02,2021-06-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Boehringer Ingelheim España, S.A.","A multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002946-19,0,0,0 2019-002946-19,9,2021-06-02,2021-06-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim B. V.,"A multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002946-19,0,0,0 2019-002946-19,9,2021-06-02,2021-06-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim,"A multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002946-19,0,0,0 2019-002946-19,9,2021-06-02,2021-06-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002946-19,0,0,0 2019-002946-19,9,2021-06-02,2021-06-02,8,1,0,0,0,0,3,0,0,1,0,0,1,0,1,SCS Boehringer Ingelheim Comm.V,"A multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002946-19,0,0,0 2019-002947-41,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Netherlands Cancer Institute- Antoni van Leeuwenhoek,"Neoadjuvant trial on the efficacy of propranolol monotherapy in angiosarcoma (PROPANGIO). Neo-adjuvante ""window of opportunity"" studie naar de effectiviteit van propranolol monotherapie in patiënte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002947-41,0,0,0 2019-002949-38,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Cerevel Therapeutics, LLC","A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON'S DISEASE (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002949-38,0,0,0 2019-002949-38,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Cerevel Therapeutics LLC,"A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON'S DISEASE (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002949-38,0,0,0 2019-002950-22,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Cerevel Therapeutics, LLC","A Phase 3, Double-Blind, Randomized, Placebo Controlled, Parallel Group, Flexible-Dose, 27 Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002950-22,0,0,0 2019-002950-22,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Cerevel Therapeutics LLC,"A Phase 3, Double-Blind, Randomized, Placebo Controlled, Parallel Group, Flexible-Dose, 27 Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002950-22,0,0,0 2019-002951-40,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Cerevel Therapeutics, LLC","A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002951-40,0,0,0 2019-002951-40,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Cerevel Therapeutics LLC,"A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002951-40,0,0,0 2019-002952-17,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Cerevel Therapeutics, LLC",58-Week Open-label Trial of Tavapadon in Parkinson's Disease (TEMPO-4 Trial) Sperimentazione in aperto della durata di 58 settimane su tavapadon nella malattia di Parkinson (Sperimentazione TEMPO-4...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002952-17,0,0,0 2019-002952-17,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Cerevel Therapeutics LLC,58-Week Open-label Trial of Tavapadon in Parkinson's Disease (TEMPO-4 Trial) Sperimentazione in aperto della durata di 58 settimane su tavapadon nella malattia di Parkinson (Sperimentazione TEMPO-4...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002952-17,0,0,0 2019-002954-21,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"QED Therapeutics, Inc.","Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL 2",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002954-21,0,0,0 2019-002956-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Zymeworks Inc.,Phase 2a Study of ZW25 in Combination with Palbociclib Plus Fulvestrant Estudio de fase 2a de ZW25 en combinación con palbociclib más fulvestrant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002956-18,0,0,0 2019-002957-46,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002957-46,0,0,0 2019-002957-46,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002957-46,0,0,0 2019-002959-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Groupement de Coopération Sanitaire Ramsay Générale de Santé pour l’Enseignement et la Recherche,Optimization of the use of anti-TNF antibodies in Verneuil's disease: Interest of a systematic initial prescription of methotrexate Optimisation de l’utilisation des anticorps anti-TNF dans la mal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002959-42,0,0,0 2019-002960-29,1,2021-09-09,2021-09-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Merete Haedersdal [Bispebjerg Hospital],"Assessing the efficacy of image-guided laser-assisted Enstilar® delivery for treatment of psoriatic nails - a proof-of-concept, single-center, prospective, open-label, randomized, clinical trial with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002960-29,0,0,0 2019-002962-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,GWT-TUD GmbH,"An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etopos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002962-10,0,0,0 2019-002963-92,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A randomized, placebo-controlled, subject and Investigator blinded study investigating the safety, tolerability and preliminary efficacy of 8-week treatment with intra-articular LRX712 to egenerate a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002963-92,0,0,0 2019-002968-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre François Baclesse,Multicentric phase III trial comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration (3.7 GBq I131 after rhTSH) versus decision of r...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002968-27,0,0,0 2019-002971-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut Regional du Cancer de Montpellier,A Double blind randomized phase III study of pravastatin vs placebo as primary prevention of severe subcutaneous breast fibrosis in hyper-radiosensitive identified patients with breast cancer Etude...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002971-32,0,0,0 2019-002973-77,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Service de Neurologie, CHU Liège",Multimodal quantification of cortical microstructure and synaptic density in MS patients Quantification multimodale de la microstructure et de la densité synaptique corticale chez des patients souf...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002973-77,0,0,0 2019-002974-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación de investigación de HM Hospitales,A phase II single arm trial evaluating the preliminary efficacy of the combination of 177Lu-DOTATATE and nivolumab in Grade 3 well-differentiated neuroendocrine tumours (NET) or poorly differentiated ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002974-29,0,0,0 2019-002977-69,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"A.O.U. Università degli Studi della Campania ""Luigi Vanvitelli""",Durability of combination of insulin and GLP-1 receptor agonist or SGLT-2 inhibitors versus basal bolus insulin regimen in type 2 diabetes: a randomized controlled trial Durability della terapia di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002977-69,0,0,0 2019-002979-34,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Abeona Therapeutics Inc,A Long-term Follow-up Study of Patients with MPS IIIA from Gene Therapy Clinical Trials Involving the Administration of ABO-102 (scAAV9.U1a.hSGSH) Estudio de seguimiento a largo plazo de pacientes ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002979-34,0,0,0 2019-002980-81,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Clovis Oncology, Inc.","LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002980-81,0,0,0 2019-002980-81,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"CLOVIS ONCOLOGY, INC","LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002980-81,0,0,0 2019-002986-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI,"A randomized, run-in, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1 Studio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002986-36,0,0,0 2019-002987-29,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"BREATH Therapeutics, Inc.","A Phase III, Multicenter, Open-Label, Extension Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A (L-CsA) Inhalation Solution Delivered via the PARI Investigationa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002987-29,0,0,0 2019-002988-10,2,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A phase IV, single-blind, randomised, controlled, multi-country study to evaluate the immunogenicity and safety of GSK's Infanrix hexa (DTPa-HBV-IPV/Hib) versus MCM Vaccine BV's Vaxelis (DTaP5-HBV-IPV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002988-10,0,0,0 2019-002988-10,2,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,1,GlaxoSmithKline Biologicals SA,"A phase IV, single-blind, randomised, controlled, multi-country study to evaluate the immunogenicity and safety of GSK's Infanrix hexa (DTPa-HBV-IPV/Hib) versus MCM Vaccine BV's Vaxelis (DTaP5-HBV-IPV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002988-10,0,0,0 2019-002989-12,6,2022-04-06,2022-04-06,3,1,0,0,0,1,2,0,0,2,1,0,0,0,1,"IMARA, Inc.",A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002989-12,1,0,0 2019-002989-12,6,2022-04-06,2022-04-06,3,1,0,0,0,1,2,0,0,2,1,0,0,0,1,IMARA Inc.,A Phase 2 Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002989-12,1,0,0 2019-002991-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SOLTI,HER2-PREDICT: Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302 HER2-PREDICT: Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002991-15,0,0,0 2019-002992-33,13,2022-07-15,2022-07-15,12,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared With Q...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002992-33,1,0,0 2019-002999-13,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,Octapharma,"CLINICAL PHASE 3 STUDY TO MONITOR THE SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (CUTAQUIG®) ADMINISTERED AT MODIFIED DOSING REGIMENS IN PATIENTS WITH PRIMARY IMMUNODEFICI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-002999-13,0,1,1 2019-003001-94,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Lekárska fakulta UK Bratislava,Use of GLP-1 analogs in the treatment of multiple sclerosis Použitie GLP-1 analógov v terapii sklerózy multiplex,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003001-94,0,0,0 2019-003002-27,5,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Estetra SRL,"A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety, Compliance and Pharmacokinetics associated with the use of a Combined Oral Contraceptive Containing 15 mg Estetrol monohydrate and 3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003002-27,0,0,0 2019-003002-27,5,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Estetra SPRL,"A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety, Compliance and Pharmacokinetics associated with the use of a Combined Oral Contraceptive Containing 15 mg Estetrol monohydrate and 3...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003002-27,0,0,0 2019-003003-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de LILLE,THE IMMUNOTHERAPY PLEURAL 5-ALA PDT “IMPALA” trial: Intrapleural Photodynamic Therapy by Video-Assisted Thoracoscopy followed by Anti-PD-1 NIVOLUMAB in Patients with Malignant Pleural Mesothelioma- a ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003003-35,0,0,0 2019-003007-35,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.",A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003007-35,0,0,0 2019-003008-11,4,2022-02-04,2022-02-04,1,1,1,0,0,0,0,0,0,2,0,0,0,0,1,JAZZ PHARMACEUTICALS INC,"A Phase 1, Open-Label, Single Ascending Dose Study to Evaluate the Pharmacokinetics and Safety of Solriamfetol in Pediatric Subjects with Narcolepsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003008-11,1,0,0 2019-003008-11,4,2022-02-04,2022-02-04,1,1,1,0,0,0,0,0,0,2,0,0,0,0,1,"Jazz Pharmaceuticals, Inc.","A Phase 1, Open-Label, Single Ascending Dose Study to Evaluate the Pharmacokinetics and Safety of Solriamfetol in Pediatric Subjects with Narcolepsy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003008-11,1,0,0 2019-003011-55,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome Mesalamin til forebyggelse af kolorectalcancer ved Lynch Syndrom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003011-55,0,0,0 2019-003013-34,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Leicester,Beyond Allergic Th2 Severe Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003013-34,0,0,0 2019-003014-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,INSTITUT CLAUDIUS REGAUD,Interest of peri operative CHemotherapy In patients with CINSARC high-risk localized grade 1 or 2 Soft Tissue Sarcoma. Intérêt de la chimiothérapie péri-opératoire chez les patients porteurs de sar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003014-13,0,0,0 2019-003016-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Assistance Publique – Hôpitaux de Paris,Impact of aminoglycosides-based antibiotics combination and protective isolation on outcomes in critically-ill neutropenic patients with sepsis:A randomized 2 by 2 factorial design randomized pragmati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003016-32,0,0,0 2019-003022-24,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,NKI-AVL,INFLUENCE (INtra-operative evaluation of a novel FLUorescENt C-mEt tracer in penile and tongue cancer),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003022-24,0,0,0 2019-003024-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,FAES FARMA SA,"Multicenter, double-blind, randomized clinical trial to evaluate and compare the efficacy and safety of Hemorrane® Plus (Hemorrane® + benzocaine) with Hemorrane® and with placebo in patients with grad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003024-20,0,0,0 2019-003025-22,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Great Ormond Street Hospital for Children NHS Foundation Trust,PlasmaLyte Usage and assessment of kidney Transplant Outcomes in children: the PLUTO trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003025-22,0,0,0 2019-003028-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA","Clinical-instrumental definition of the phenotypic spectrum, response to treatment and natural history in Pearson and Kearns-Sayre syndrome Definizione clinico-strumentale dello spettro fenotipico,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003028-19,0,0,0 2019-003029-83,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Service de Neurologie, CHU Liège",Assessment of changes in regional brain synaptic density in patients with Obstructive Sleep Apnea (OSA) measured by positron emission tomography and 18F-UCB-H.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003029-83,0,0,0 2019-003032-23,1,,,0,1,1,0,0,1,1,0,0,4,0,0,0,0,0,National Taiwan University Hospital,A Phase I/II Clinical Trial for Treatment of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003032-23,0,1,1 2019-003033-42,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,INSTITUTO DE INVESTIGACIÓN SANITARIA LA FE,The impact of deep versus standard muscle relaxation on intra-operative safety during laparoscopic surgery: a multicenter strategy study – EURO RELAX STUDY Impacto de una estrategia de bloqueo neur...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003033-42,0,0,0 2019-003034-16,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Grupo Español de Investigación en Sarcomas (GEIS),Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas Ensayo fase I/II aleatorizado de LB-100 ms doxorrubicina vs. doxorrubicin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003034-16,0,0,0 2019-003036-23,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Imperial College London,Mechanisms of adverse effects of long-acting beta-agonists in asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003036-23,0,0,0 2019-003047-30,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"GlaxoSmithKline, S.A.","A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone in P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003047-30,0,0,0 2019-003047-30,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone in P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003047-30,0,0,0 2019-003048-63,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003048-63,0,0,0 2019-003048-63,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003048-63,0,0,0 2019-003051-11,14,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,Promethera Therapeutics,"Randomized, placebo-controlled, double blind, multi-centre Phase IIb study to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) - DHELIVER Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003051-11,0,0,0 2019-003051-11,14,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,Promethera Biosciences SA,"Randomized, placebo-controlled, double blind, multi-centre Phase IIb study to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) - DHELIVER Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003051-11,0,0,0 2019-003051-11,14,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,Promethera Therapeutics SA,"Randomized, placebo-controlled, double blind, multi-centre Phase IIb study to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) - DHELIVER Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003051-11,0,0,0 2019-003051-11,14,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,Promethera Biosciences,"Randomized, placebo-controlled, double blind, multi-centre Phase IIb study to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) - DHELIVER Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003051-11,0,0,0 2019-003052-36,1,,,0,0,0,0,0,1,2,0,1,3,0,0,0,0,0,The University of Nottingham,Triple Modality Functional Magnetic Resonance Lung Imaging in Cystic Fibrosis and Non-CF Bronchiectasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003052-36,0,0,0 2019-003058-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"VÝCHODOSLOVENSKÝ ONKOLOGICKÝ ÚSTAV, a.s.","Prospective, multicentre phase II study of de-escalation of primary chemoradiotherapy of squamous cell carcinoma of oropharynx (OPC) associated with human papilloma virus (HPV) Prospektívna multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003058-10,0,0,0 2019-003060-42,4,2022-09-30,2022-09-30,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc","A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination with IV Pembrolizumab vs IV Pembrolizumab Mono...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003060-42,1,0,0 2019-003063-21,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Shanghai Henlius Biotech, Inc.","A Randomized, Double-Blind, Multicenter, Phase III Study to Compare Clinical Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003063-21,0,0,0 2019-003064-50,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Shanghai Henlius Biotech, Inc.","A Randomized, Double-Blind, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection) + Chemotherapy (Carboplatin-Nanoparticle Albumin-Bound (nab)-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003064-50,0,0,0 2019-003068-39,1,2020-11-18,2020-11-18,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,UMC Utrecht,Withdrawal of Infliximab in patients with inflammatory bowel disease in remission guided by pharmacokinetics: WINK study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003068-39,0,0,0 2019-003072-39,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,0,National Taiwan University Hospital,A Clinical Trial for Treatment of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC - An Expansion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003072-39,0,1,1 2019-003073-25,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,Adamed Pharma S.A.,A multi-centre clinical trial evaluating safety and patients' ability to independently use the medicinal product indicated in the treatment of erectile dysfunction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003073-25,0,0,0 2019-003076-39,13,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,argenx BVBA,"A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003076-39,0,0,0 2019-003076-39,13,,,0,0,0,0,0,2,2,0,0,2,0,0,0,0,1,ARGENX BV,"A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003076-39,0,0,0 2019-003078-24,1,,,0,0,1,0,0,0,3,0,0,4,0,0,0,0,1,Regeneron Pharmaceuticals,"A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003078-24,0,1,1 2019-003082-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Orion Corporation Orion Pharma,EFFECT OF ELECTRONIC MONITORING AND FEEDBACK ON ADHERENCE TO EASYHALER CONTROLLER MEDICATION IN PATIENTS WITH ASTHMA Wirkung elektronischer Überwachung und Rückmeldungen zur Einhaltung von Easyhale...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003082-17,0,0,0 2019-003084-21,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"PROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA","A phase-II academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab or nivolumab in relapsed or refractory classical Hodgkin l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003084-21,0,0,0 2019-003087-43,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,Synektik Spółka Akcyjna,"A Phase I/II Seamless Adaptive, Open label study to assess Safety, Tolerability, Radiation Dosimetry, Biodistribution, and diagnostic ability of a Novel 18F-labelled Tracer, SYN2, for Positron Emissio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003087-43,0,0,0 2019-003088-22,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Hand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003088-22,0,0,0 2019-003089-42,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Medical University of Vienna, Department of Clinical Pharmacology",The effect of Tetrahydrocannabinol on ocular hemodynamics in patients with primary open angle glaucoma- A Phase II Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003089-42,0,0,0 2019-003093-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",Targeting triple negative BREAst cancer metabolism with a combination of chemotherapy and a diet mimicking FASTing plus/minus metformin in the preoperative setting: the BREAKFAST trial Dieta Mima D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003093-13,0,0,0 2019-003096-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medica Scientia Innovation Research S.L. (MEDSIR),A randomized phase II trial to evaluate the antitumor activity of Enzalutamide and Talazoparib (PF-06944076) for the treatment of metastatic hormone-naïve prostate cancer Ensayo de fase II randomiz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003096-20,0,0,0 2019-003097-11,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"A double-blind, placebo controlled, randomized, phase II study evaluating the efficacy and safety of capmatinib (INC280) and spartalizumab (PDR001) combination therapy versus capmatinib and placebo as...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003097-11,0,0,0 2019-003097-11,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A double-blind, placebo controlled, randomized, phase II study evaluating the efficacy and safety of capmatinib (INC280) and spartalizumab (PDR001) combination therapy versus capmatinib and placebo as...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003097-11,0,0,0 2019-003098-24,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003098-24,0,0,0 2019-003098-24,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardiomyo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003098-24,0,0,0 2019-003100-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Martin-Luther-Universität Halle-Wittenberg,Pharmacokinetics of edoxaban in patients with advanced chronic kidney disease (CKD) treated for stroke prevention Pharmakokinetik von Edoxaban zur Schlaganfallprävention bei Patienten mit fortgesch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003100-13,0,0,0 2019-003101-97,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE,"An unicentric, open, randomized and crossover clinical trial to evaluate vitamin D supplementation effect of colecalciferol versus calcidiol in mineral metabolism in hemodialisis patients. Ensayo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003101-97,0,0,0 2019-003102-26,1,,,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,"Therapeutic vaccination: A Phase I/II Randomized, Placebo-Controlled Trial of ChAdOx1.tHIVconsvX prime-MVA.tHIVconsvX Boost Vaccination Regimen in Early-treated durably-controlling HIV-1 positive Adul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003102-26,0,0,0 2019-003104-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,NKI-AVL,Treatment of locally advanced VULvar CArcinoma in a Neoadjuvant setting with Carboplatin and Paclitaxel chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003104-12,0,0,0 2019-003105-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Wound Infections following Implant Removal below the level of the knee; the influence of 2g of prophylactic Cefazolin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003105-10,0,0,0 2019-003106-28,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,"Janssen Research & Development, LLC","A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients with EGFR Mutation Positive Advanced Non-Small Cell Lu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003106-28,0,0,0 2019-003106-28,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Yuhan Corporation,"A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients with EGFR Mutation Positive Advanced Non-Small Cell Lu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003106-28,0,0,0 2019-003107-35,12,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,argenx BVBA,"Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003107-35,0,0,0 2019-003107-35,12,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,ARGENX BV,"Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003107-35,0,0,0 2019-003108-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Clinic per a la Recerca Biomèdica,The GOING Study: Regorafenib followed by Nivolumab in patients with Hepatocellular Carcinoma progressing under sorafenib Estudio GOING: Regorafenib seguido del Nivolumab en pacientes con progresión...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003108-10,0,0,0 2019-003109-92,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Trinity College Dublin,Ketamine as an adjunctive therapy for Major Depression (2) - a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003109-92,0,0,0 2019-003112-31,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Rollover Study to Evaluate the Safety of Long-term Treatment With Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003112-31,0,1,1 2019-003113-34,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A randomized, multi-center, subject and investigator blinded, placebo controlled, parallel group study to assess the efficacy, safety and tolerability of LYS006 in patients with mild to moderate ulcer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003113-34,0,0,0 2019-003114-13,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie","Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: A multicenter, single arm study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003114-13,0,0,0 2019-003117-33,3,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,"Takeda Development Center Americas, Inc.","A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003117-33,0,0,0 2019-003117-33,3,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003117-33,0,0,0 2019-003117-33,3,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,"Millennium Pharmaceuticals, Inc.","A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003117-33,0,0,0 2019-003119-77,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Leiden University Medical Center,Near-infrared fluorescence imaging with IndoCyanine Green for the intraoperative identification of Gastrointestinal stromal cell tumours: a pilot study Nabij-infrarood fluorescentie en indocyanine ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003119-77,0,0,0 2019-003125-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),EFFECT OF INTRAVENOUS IRON SUPPLEMENTATION ON CELIAC DISEASE REMISSION IN PATIENTS WITH IRON DEFICIENCY AND INTESTINAL VILLOUS ATROPHY: A RANDOMIZED TRIAL Effet de la supplémentation en fer par vo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003125-21,0,0,0 2019-003126-25,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Dizal (Jiangsu) Pharmaceutical Co., Ltd","A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003126-25,0,0,0 2019-003126-25,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"DIZAL (JIANGSU) PHARMACEUTICAL CO.,LTD","A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003126-25,0,0,0 2019-003127-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VUmc Neurology Department,"Efficacy of add-on high dose simvastatin on markers for disease progression in MS patients treated with ocrelizumab and natalizumab (SIMSON), a phase II clinical trial. Effectiviteit van add-on hog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003127-38,0,0,0 2019-003128-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Psykiatrisk Center Glostrup,Biomarkers in Clozapine-responding Schizophrenia Biomarkører i Clozapin responderende Skizofreni,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003128-19,0,0,0 2019-003131-31,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2a, Double-Blind, Randomized, Placebo-Controlled Study of Ravagalimab in Subjects with Moderately to Severely Active Primary Sjogren’s Syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003131-31,0,0,0 2019-003133-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medical University of Vienna, Department of Ophthalmology and Optometry","Personalized treatment aided by automated analysis of fluid in active neovascular age-related macular degeneration (nAMD) in a prospective, multicenter, randomized study Personalisiertes Behandlung...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003133-42,0,0,0 2019-003135-36,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003135-36,0,1,1 2019-003136-23,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially with Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003136-23,0,1,1 2019-003137-42,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie",Exploring P-glycoprotein-mediated efflux transport at the blood-brain barrier as a biomarker of drug-resistance in focal epilepsy Erforschung des P-Glykoprotein-vermittelten Effluxtransports an der...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003137-42,0,0,0 2019-003138-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Cliniques universitaires Saint-Luc,"A 24 weeks proof of concept study to evaluate the clinical, MRI and synovial tissue benefit of Sarilumab in active RA patients despite TNF agents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003138-17,0,0,0 2019-003139-47,12,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smolde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003139-47,0,0,0 2019-003139-47,12,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smolde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003139-47,0,0,0 2019-003140-71,2,,,0,0,1,0,0,0,3,0,0,1,1,0,0,1,1,"Rockwell Medical, Inc.",Hemoglobin maintenance in pediatric ESRD patients by ferric pyrophosphate citrate (FPC) Hämoglobinerhalt bei pädiatrischen ESRD-Patienten durch Eisenpyrophosphatcitrat (FPC).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003140-71,0,0,0 2019-003141-15,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Amsterdam University Medical Center - location VU Medical Center,"A phase 4, monocenter, randomized, double-blind, placebo-controlled, 4-armed cross-over mechanistic intervention study to assess the renal hemodynamic effect of mono- and combination therapy with empa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003141-15,0,0,0 2019-003142-32,3,2020-09-28,2020-09-28,2,0,0,0,0,1,2,0,0,1,1,0,1,0,1,"Tiburio Therapeutics, Inc.","A One Year, Randomized, Double-Blind, Placebo-Controlled Study of TBR-760 in Adult Patients with Non-Functioning Pituitary Adenomas",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003142-32,0,0,0 2019-003144-76,1,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Global Blood Therapeutics, Inc.",An Open-Label Extension Study of Voxelotor Administered Orally to Pediatric Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003144-76,0,0,0 2019-003150-86,1,,,0,0,0,0,1,0,3,0,0,3,0,0,0,0,0,Royal Cornwall Hospitals NHS Trust,A Study to Investigate the Effect of Different Durations of Ameluz Application on Response to Treatment of Acral Actinic Keratoses,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003150-86,0,0,0 2019-003151-11,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,UZ Leuven,Stelara fOr ChRonic AntibioTic rEfractory pouchitiS (SOCRATES): A Belgian open label multicenter pilot-study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003151-11,0,0,0 2019-003152-37,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc","A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003152-37,0,0,0 2019-003152-37,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003152-37,0,0,0 2019-003153-28,16,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003153-28,0,0,0 2019-003153-28,16,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"ALNYLAM PHARMACEUTICALS, INC.","HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003153-28,0,0,0 2019-003158-10,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants with Primary Biliary Cholangitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003158-10,0,0,0 2019-003158-10,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants with Primary Biliary Cholangitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003158-10,0,0,0 2019-003159-12,2,,,0,0,0,1,0,2,1,0,0,0,0,0,0,0,1,"Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company",A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of PR006A in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003159-12,0,0,0 2019-003162-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Technische Universität München, Fakultät für Medizin","An investigator-initiated, multi-center, randomized, double-blind, placebo controlled study of Dupilumab to demonstrate efficacy in subjects with nummular eczema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003162-41,0,0,0 2019-003168-37,1,2021-07-23,2021-07-23,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Novartis Pharma GmbH,"A randomized, double-blind, multicenter, 24-week study of subcutaneous secukinumab to assess anti-interleukin-17A treatment in plaque psoriasis patients with coexisting non-alcoholic fatty liver disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003168-37,0,0,0 2019-003172-40,1,,,0,0,0,0,0,0,4,0,1,3,0,0,0,0,0,University Hospitals Plymouth NHS Trust,High Dose Loperamide in Patients with Intestinal Failure (IF): Plasma Concentration and Electrocardiogram(ECG) Changes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003172-40,0,0,0 2019-003175-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Steno Diabetes Center Copenhagen,"Renal effects of treatment with Empagliflozin alone or in combination with Semaglutide in patients with type 2 diabetes and albuminuria - A double blinded, randomised, placebo controlled, parallel, si...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003175-19,0,0,0 2019-003177-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UMCG,Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy Androgeendeprivatietherapie voor Oligo-recidiverende prostaatkanker in aanvulling op radiotherapie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003177-26,0,0,0 2019-003178-25,1,2022-03-14,2022-03-14,1,0,0,0,0,1,2,0,0,1,0,0,0,0,1,"Synspira Therapeutics, Inc.","A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Effect of Inhaled SNSP113 in Adult Subjects with Cystic Fibrosis Fázis II/a, randomizált, kettős...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003178-25,0,0,0 2019-003179-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Meander Medical Centre,‘A pilot study to assess the safety and feasibility of fluorescent sentinel lymph node identification in colon carcinoma using Indocyanine green’ Een pilot studie om de veiligheid en haalbaarheid v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003179-20,0,0,0 2019-003182-17,5,2021-07-14,2021-07-14,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Phase II, randomised, double-blind, placebo-controlled, parallel-group, dose-ranging, proof-of-concept trial of BI 730357 given for 12 weeks in patients with active psoriatic arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003182-17,1,0,0 2019-003182-17,5,2021-07-14,2021-07-14,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim Limited,"A Phase II, randomised, double-blind, placebo-controlled, parallel-group, dose-ranging, proof-of-concept trial of BI 730357 given for 12 weeks in patients with active psoriatic arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003182-17,1,0,0 2019-003186-18,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,"EFICACY AND TOLERABILITY OF TWO REDUCED VOLUME PRODUCTS FOR COLORRECTAL CANCER SCREENING COLONOSCOPY: A COMPARATIVE, PARALLEL RANDOMIZED CLINICAL TRIAL. LOWOL STUDY. EFICACIA Y TOLERABILIDAD DE DOS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003186-18,0,0,0 2019-003190-26,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Julius-Maximilian University of Würzburg,An investigator-sponsored Phase 3b Open-label Study of Anti-FGF23 Antibody Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH) in GERmany - BurGER Eine Prüfarzt-initiierte offe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003190-26,0,0,0 2019-003192-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,German Cancer Research Center,Continuous ReAssessment with Flexible ExTension in Rare Malignancies – CRAFT: The NCT PMO-1602 Phase II Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003192-18,0,0,0 2019-003197-24,1,2020-07-09,2020-07-09,1,0,0,0,0,0,2,0,1,1,1,1,1,0,1,"Palatin Technologies, Inc.","A Phase 2, Randomized, 3-Arm Parallel Group, Placebo and Active-Controlled Study of the Effect of PL8177 Administered via Subcutaneous Injection in Healthy Male Volunteers on Inflammatory Onset and Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003197-24,0,0,0 2019-003202-27,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Laboratoire Innotech Internationnal,"Assessment of the eFficacy, the onset-of-Action and the Safety of Tot'héma ® in adults with moderate iron deficiency anaemia Évaluation de la l'efficacité, du délai d'action, et de la tolérance de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003202-27,0,0,0 2019-003203-35,1,,,0,1,0,0,0,1,2,0,0,3,0,0,0,0,1,Vicore Pharma AB,"A Phase 2, single-center, randomised, double-blind, placebo-controlled, cross-over, cold challenge study investigating the effect of C21 on cold-induced vasoconstriction in subjects with Raynaud’s Phe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003203-35,0,0,0 2019-003204-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Consorcio PSMAR,"Multicentre, randomised, double-blind, parallel-group, Phase III study to evaluate the genetic polymorphisms influence in the response to Ranibizumab and Bevacizumab treatment in patients with Age-Ass...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003204-12,0,0,0 2019-003208-11,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Chelsea and Westminster Hospital NHS Foundation Trust,Efficacy of BIC/F/TAF versus standard of care in the treatment of new HIV infection diagnoses in the context of 'test and treat',https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003208-11,0,0,0 2019-003209-89,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Graz,A trial investigating ultra-long-acting basal insulins’ flexibility around multiple spontaneous exercise sessions in people with type 1 diabetes: a head to head comparison of 2nd generation insulin Gl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003209-89,0,0,0 2019-003211-57,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003211-57,0,0,0 2019-003211-57,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003211-57,0,0,0 2019-003211-57,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novartis Farmacéutica S.A.,"A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003211-57,0,0,0 2019-003213-34,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Active or Prior Inhibitors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003213-34,0,0,0 2019-003213-34,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,BIOMARIN PHARMACEUTICAL INC.,"A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients with Active or Prior Inhibitors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003213-34,0,0,0 2019-003215-63,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Hospices Civils de Lyon - Direction de la Recherche Clinique et de l'Innovation,Cultured Autologous Oral Mucosa Epithelial sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency - FEMJA for « Feuillet Epithélial de Muqueuse Jugale Autologue » Culture d’un Feuillet E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003215-63,0,0,0 2019-003218-15,1,2020-07-31,2020-07-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Almirall S.A.,A phase IV interventional study to assess the disease-modifying effect of long-term treatment with tildrakizumab in adult patients with moderate-to-severe plaque psoriasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003218-15,0,0,0 2019-003220-21,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Leeds,"Management of diarrhoea in ulcerative colitis: multi-arm multi-stage trial of low FODMAP diet, amitriptyline, ondansetron, or loperamide: MODULATE.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003220-21,0,0,0 2019-003229-12,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003229-12,0,0,0 2019-003229-12,7,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult Subjects with Axial Spondyloarthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003229-12,0,0,0 2019-003230-17,14,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003230-17,0,0,0 2019-003230-17,14,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,NOVARTIS PHARMA AG,"A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003230-17,0,0,0 2019-003230-17,14,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Farmacéutica S.A.,"A Multicenter, Double-blind, Randomized Withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003230-17,0,0,0 2019-003234-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,InfectoPharm Arzneimittel und Consilium GmbH,"Prospektive, offene, multizentrische, initial 1-armige und bei Therapieversagen 3-armig randomisierte klinische Prüfung der Phase III/IV zur eskalierenden Therapie der Skabies mit INFECTOSCAB 5% (Perm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003234-16,0,0,0 2019-003236-23,6,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Viruslike P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003236-23,0,0,0 2019-003236-23,6,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Viruslike P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003236-23,0,0,0 2019-003236-23,6,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,1,Merck Sharp & Dohme Corp.,"A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Viruslike P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003236-23,0,0,0 2019-003237-41,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Dur...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003237-41,0,0,0 2019-003237-41,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Dur...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003237-41,0,0,0 2019-003244-79,11,2022-02-10,2022-02-21,8,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bayer AG,"Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003244-79,1,0,0 2019-003244-79,11,2022-02-10,2022-02-21,8,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BAYER AG,"Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003244-79,1,0,0 2019-003247-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Use of the NMF biomarker as predictive diagnostic for effective use of cyclosporine in the treatment of atopic dermatitis. De NMF biomarker als hulpmiddel bij het voorspellen van de effectiviteit v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003247-30,0,0,0 2019-003248-63,10,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,QED Therapeutics Inc.,"Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Altera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003248-63,0,0,0 2019-003248-63,10,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"QED Therapeutics, Inc.","Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Altera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003248-63,0,0,0 2019-003254-91,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Ghent University Hospital,Characterisation and intervention study in patients with long-term use of nasal decongestants. Karakterisatie- en interventiestudie bij patiënten met langdurig gebruik van nasale decongestiva.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003254-91,0,0,0 2019-003257-29,2,2021-06-30,2021-08-31,2,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Angelini S.p.A.,"Phase IV study comparing the efficacy and safety of Benzydamine hydrochloride 0,3% oromucosal spray and Benzydamine hydrochloride 3 mg lozenges in patients with acute sore throat. 4-es fázisú vizsg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003257-29,0,0,0 2019-003261-18,1,2022-03-03,2022-03-03,1,0,0,0,0,0,4,0,0,1,0,0,0,0,3,,The effects of allergen immunotherapy on anti-viral immunity in patients with allergic asthma Effekten af allergen immunoterapi på anti-viral immunitet hos patienter med allergisk astma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003261-18,0,0,0 2019-003265-17,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Universitair Ziekenhuis Leuven/endocrinologie,"Phase II, dose ranging, efficacy study of anti-thymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes (T1D)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003265-17,0,0,0 2019-003265-17,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Universitair Ziekenhuis Leuven (UZ Leuven),"Phase II, dose ranging, efficacy study of anti-thymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes (T1D)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003265-17,0,0,0 2019-003265-17,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,"Universitair Ziekenhuis Leuven, Belgium","Phase II, dose ranging, efficacy study of anti-thymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes (T1D)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003265-17,0,0,0 2019-003268-33,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Ipsen Innovation,"A Phase Ib/II, Multicentre, Double-blind, Randomised, Placebo-controlled Dose-escalation and Dose-finding study to Evaluate the Safety and Efficacy of IPN59011 in improving appearance of Moderate to S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003268-33,0,0,0 2019-003269-16,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 1, Single-Dose, Cross-Over Study Evaluating the Relative Bioavailability of a Pediatric Oral Granule Formulation of Tenofovir Alafenamide in Healthy Adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003269-16,0,1,1 2019-003271-19,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,KU Leuven,Intestinal disposition of budesonide in healthy volunteers intestinale dispositie van budesonide in gezonde vrijwilligers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003271-19,0,0,0 2019-003276-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VALL HEBRON UNIVERSITY HOSPITAL,Liver impairment recovery related to parenteral nutrition with omega-3 fatty acids: randomized clinical trial. Recuperación de daño hepático relacionado con nutrición parenteral con ácidos omega-3 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003276-39,0,0,0 2019-003280-22,2,2022-06-27,2022-06-27,2,0,0,0,0,0,2,0,0,1,0,0,0,0,1,"Kowa Research Institute, Inc.","A Double-Masked, Randomised, Placebo-Controlled, Parallel-Group, 12-Week, Phase 2 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Patients with Fuc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003280-22,0,0,0 2019-003281-40,4,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,ASTEX PHARMACEUTICALS,"A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003281-40,0,0,0 2019-003281-40,4,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Astex Pharmaceuticals, Inc.","A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003281-40,0,0,0 2019-003282-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Thomas Benfield,"Short course antibiotic treatment of Gram-negative bacteremia: A multicenter, randomized, non-blinded, non-inferiority interventional study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003282-17,0,0,0 2019-003284-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboudumc,Radio guided lymph node dissection in oligo metastatic prostate cancer patients; a feasibility study Radioligand gestuurde lymfeklier dissecties bij prostaatkanker patienten met oligo-gemetastaseer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003284-21,0,0,0 2019-003290-26,1,,,0,0,0,0,1,0,4,0,0,4,0,0,0,0,0,APHP,na Analgésie par le MEOPA (Mélange Equimolaire d’Oxygène et de Protoxyde d’Azote lors de la pose des sondes nasogastriques chez les enfants âgés de 3 mois à 3ans.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003290-26,0,0,0 2019-003296-19,3,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Affimed GmbH,"A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AFM24 in Patients with Advanced Solid Cancers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003296-19,0,0,0 2019-003297-53,11,2022-04-05,2022-04-05,10,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Bayer AG,"A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of individually titrated oral doses of runcaciguat in subjects with clinical diagnosis of chronic k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003297-53,0,0,0 2019-003298-24,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.",A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003298-24,0,0,0 2019-003299-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,"A randomized double blind, multicenter trial to assess time-interval between cytoreductive surgery and adjuvant chemotherapy after administration of local anesthetic intraperitoneally/perioperatively ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003299-38,0,0,0 2019-003300-12,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Lokon Pharma AB,A Phase I/II Trial Investigating LOAd703 in Combination with Atezolizumab in Malignant Melanoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003300-12,0,0,0 2019-003301-97,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-ST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003301-97,0,0,0 2019-003301-97,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F.Hoffman-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-ST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003301-97,0,0,0 2019-003301-97,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-ST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003301-97,0,0,0 2019-003302-27,3,2022-06-28,2022-06-28,2,0,0,0,0,0,2,0,2,2,0,0,0,0,1,ANAVEX Life Sciences Corp.,"A Phase 2b/3, Double-Blind, Randomised, Placebo-Controlled 48 week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer’s Disease (AD).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003302-27,1,0,0 2019-003302-27,3,2022-06-28,2022-06-28,2,0,0,0,0,0,2,0,2,2,0,0,0,0,1,Anavex Germany GmbH,"A Phase 2b/3, Double-Blind, Randomised, Placebo-Controlled 48 week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer’s Disease (AD).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003302-27,1,0,0 2019-003304-12,2,2022-08-11,2022-08-11,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003304-12,1,0,0 2019-003306-27,10,2022-04-22,2022-04-22,4,0,1,0,0,0,3,0,1,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN AS A SERIES OF 2 INFANT DOSES AND 1 TODDLER DOSE IN HEALTHY INFA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003306-27,1,0,0 2019-003306-27,10,2022-04-22,2022-04-22,4,0,1,0,0,0,3,0,1,2,0,0,0,0,1,Pfizer Inc,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN AS A SERIES OF 2 INFANT DOSES AND 1 TODDLER DOSE IN HEALTHY INFA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003306-27,1,0,0 2019-003306-27,10,2022-04-22,2022-04-22,4,0,1,0,0,0,3,0,1,2,0,0,0,0,1,Pfizer Inc.,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN AS A SERIES OF 2 INFANT DOSES AND 1 TODDLER DOSE IN HEALTHY INFA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003306-27,1,0,0 2019-003306-27,10,2022-04-22,2022-04-22,4,0,1,0,0,0,3,0,1,2,0,0,0,0,1,PFIZER INC,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN AS A SERIES OF 2 INFANT DOSES AND 1 TODDLER DOSE IN HEALTHY INFA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003306-27,1,0,0 2019-003307-35,5,2022-08-31,2022-08-31,3,0,1,0,0,0,3,0,1,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003307-35,1,0,0 2019-003307-35,5,2022-08-31,2022-08-31,3,0,1,0,0,0,3,0,1,2,0,0,0,0,1,Pfizer Inc,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003307-35,1,0,0 2019-003308-11,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Pfizer Inc.,"A PHASE 3, SINGLE-ARM TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY CHILDREN 15 MONTHS THROUGH 17 YEARS OF AGE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003308-11,0,1,1 2019-003309-88,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,United Therapeutics Corporation,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World Healt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003309-88,0,0,0 2019-003309-88,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,UNITED THERAPEUTICS CORPORATION,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World Healt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003309-88,0,0,0 2019-003310-14,1,2021-10-11,2021-10-11,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,"Department of Dermatology, Bispebjerg Hospital",Laser immunotherapy with and without topical anti-PD1 in basal cell carcinomas Laser immunterapi med og uden topikal anti-PD1 til behandling af basal celle karcinomer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003310-14,0,0,0 2019-003315-60,1,,,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,Criceto IKM B.V.,"A phase 1/2 study investigating the pharmacokinetics, safety and efficacy of a highly concentrated buccal formulation of apomorphine (APORON®) in subjects with Parkinson's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003315-60,0,0,0 2019-003317-33,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Cytovation AS,"A first-in-human, open-label, dose escalation followed by dose expansion phase I/IIa trial to evaluate the safety, preliminary efficacy and pharmacokinetics of intratumoral CyPep-1 monotherapy and in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003317-33,0,0,0 2019-003319-76,1,2021-06-30,2021-06-30,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Univerity Hospitals Leuven,"High volume PCEA versus PIEB for labor analgesia: a randomized, double-blind multicenter non-inferiority study in nulliparous women.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003319-76,0,0,0 2019-003321-14,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,1,Tesla Medical s.r.o.,"12-weeks, Open-label, Randomized, Multicenter, Post Marketing Clinical Follow-up Study to Evaluate Safety, Tolerability and Efficacy of the Home-Based electrical Transcutaneous NeuroModulation (eTNM)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003321-14,0,0,0 2019-003323-38,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Eli Lilly & Company,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults with Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003323-38,0,0,0 2019-003324-20,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,VU University Medical Center,"Saracatinib trial TO Prevent FOP Een onderzoek ter beoordeling van de veiligheid, verdraagbaarheid en effecten op abnormale botvorming van het onderzoeksgeneesmiddel AZD0530 (saracatinib) bij patië...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003324-20,0,0,0 2019-003327-37,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF VENETOCLAX AND OBINUTUZUMAB VERSUS FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003327-37,0,0,0 2019-003327-37,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF VENETOCLAX AND OBINUTUZUMAB VERSUS FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003327-37,0,0,0 2019-003333-42,5,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Epizyme, Inc.","A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refract...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003333-42,0,0,0 2019-003333-42,5,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"EPIZYME, INC.","A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refract...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003333-42,0,0,0 2019-003334-16,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Dr. Falk Pharma GmbH,"Randomised, double-blind, placebo-controlled, multicentre study to compare the efficacy and safety of novel 4 mg budesonide suppository in combination with oral mesalazine versus oral mesalazine monot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003334-16,0,0,0 2019-003335-37,2,2021-11-03,2021-12-14,2,0,0,0,0,0,2,0,0,1,1,1,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Platform Study Evaluating the Efficacy and Safety of Interventions in Participants with Moderately to Severely Active Crohn’s Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003335-37,0,0,0 2019-003335-37,2,2021-11-03,2021-12-14,2,0,0,0,0,0,2,0,0,1,1,1,0,0,1,Janssen-Cilag International NV,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Platform Study Evaluating the Efficacy and Safety of Interventions in Participants with Moderately to Severely Active Crohn’s Dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003335-37,0,0,0 2019-003337-41,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"CStone Pharmaceuticals (Suzhou) Co., Ltd.","A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib as First-Li...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003337-41,0,0,0 2019-003339-53,2,2021-10-01,2021-10-08,2,1,0,0,0,0,2,0,0,1,0,0,0,0,1,Eli Lilly and Company,"A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003339-53,0,0,0 2019-003341-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación para la Formación e Investigación Sanitarias de la Región de Murcia (FFIS),"Aspirin versus placebo in twin pregnancies for preeclampsia prevention: A multicentre, randomised, double-blind, placebo-controlled trial. Aspirina versus Placebo para la Prevención de Preclampsia ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003341-15,0,0,0 2019-003343-29,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ACADIA Pharmaceuticals Inc.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE 2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003343-29,0,0,0 2019-003343-29,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ACADIA PHARMACEUTICALS INC.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE 2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003343-29,0,0,0 2019-003346-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Léon Bérard,PREFAcE : Interest of PET-PSMA imaging potentiated by androgen blockade in patients with biological relapse or persistent biological disease of a localized prostatic adenocarcinoma after initial treat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003346-32,0,0,0 2019-003350-80,1,2022-01-24,2022-01-24,1,0,0,0,0,0,3,0,0,1,0,0,0,0,0,Université de Sherbrooke,Lessening Organ Dysfunction with VITamin C (LOVIT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003350-80,0,0,0 2019-003351-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GPRI,Triple therapy effectiveness in COPD patients with characteristics of asthma: A pragmatic Primary Care trial - The TRACkER trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003351-11,0,0,0 2019-003352-37,8,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003352-37,0,0,0 2019-003352-37,8,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003352-37,0,0,0 2019-003354-92,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"Arcutis Biotherapeutics, Inc.","A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Adolescents and Adults with Scalp and Body Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003354-92,0,0,0 2019-003357-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Régional du Cancer de Montpellier (ICM),Intensive intraperitoneal therapy in advanced ovarian cancer combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) and postoperative intraperitoneal chemotherapy (IPC)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003357-29,0,0,0 2019-003358-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Carmen Olmos Blanco,Short-course antibiotic regimen compared to conventional antibiotic treatment for gram-positive cocci infective endocarditis: randomized clinical trial Terapia antibiótica corta comparada con el tr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003358-10,0,0,0 2019-003360-45,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Grenoble,Effect of impact of PCSK9 inhibitor on coronary microvascular dysfunction in patients with atherosclerotic cardiovascular disease proved by myocardial ischemia and needing coronarography. Évaluati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003360-45,0,0,0 2019-003362-41,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO,Phase I/IIa clinical trial on the safety and preliminary efficacy of donor-derived anti-leukemia cytotoxic T lymphocytes for the prevention of leukemia relapse in children given haploidentical hematop...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003362-41,0,0,0 2019-003369-16,2,2022-03-02,2022-03-02,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,GW Research Ltd.,"A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants with Schizophrenia Experiencing Inadequate Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003369-16,1,0,0 2019-003370-35,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Rare Thyroid Therapeutics International,Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003370-35,0,0,0 2019-003370-35,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Rare Thyroid Therapeutics International AB,Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003370-35,0,0,0 2019-003372-39,3,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Incyte Corporation,"A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non–Small Cell Lung Cancer (POD1UM-304)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003372-39,0,0,0 2019-003374-91,4,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,1,"Sarepta Therapeutics, Inc.","A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003374-91,0,0,0 2019-003375-19,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Pfizer Inc.,"A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an Anti-PD-1 antibody, in Combination With Bacillus Calmette- Guerin (BCG Induction With or Without BCG Maint...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003375-19,0,0,0 2019-003375-19,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,PFIZER INC,"A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an Anti-PD-1 antibody, in Combination With Bacillus Calmette- Guerin (BCG Induction With or Without BCG Maint...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003375-19,0,0,0 2019-003381-40,3,2022-02-18,2022-02-18,3,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Blue Earth Diagnostics Ireland Ltd.,"A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with newly diagnosed prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003381-40,0,0,0 2019-003382-18,2,2021-10-12,2021-10-12,2,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Blue Earth Diagnostics Ireland Ltd.,"A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with suspected prostate cancer recurrence base...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003382-18,0,0,0 2019-003383-47,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis Studio di fase 2, randomizzato, controllato ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003383-47,0,0,0 2019-003386-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Neurology and Clinical Neurophysiology, St Olavs Hospital, Trondheim University hospital","CandMig III study Candesartan for migraine prevention: A multicentre, binational, triple blind, placebo controlled, parallel group study of two doses of candesartan (8 and 16 mg)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003386-18,0,0,0 2019-003387-46,1,2021-04-16,2021-04-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Research Center for Emergency Medicine Department of Clinical Medicine Aarhus University,"Calcium for Out-of-Hospital Cardiac Arrest – A Randomized, Double-Blind, Placebo-Controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003387-46,0,0,0 2019-003395-39,8,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Mirum Pharmaceuticals Inc.,MRX-503: An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003395-39,0,0,0 2019-003396-19,5,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,ENTEROME,"A phase 1/2 trial of EO2401, a novel microbial-derived peptide therapeutic vaccine, in combination with PD-1 check point blockade, for treatment of patients with locally advanced or metastatic adrenoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003396-19,0,0,0 2019-003396-19,5,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Enterome,"A phase 1/2 trial of EO2401, a novel microbial-derived peptide therapeutic vaccine, in combination with PD-1 check point blockade, for treatment of patients with locally advanced or metastatic adrenoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003396-19,0,0,0 2019-003399-38,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novo Nordisk A/S,Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003399-38,0,0,0 2019-003400-12,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,GENFIT,"An Open Label, Randomized, Multicenter Study to Assess the Pharmacokinetic and Pharmacodynamic Profile and the Safety and Tolerability of Two Dose Levels of Elafibranor (80 mg and 120 mg) in Children ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003400-12,0,1,1 2019-003405-94,4,2022-04-20,2022-04-20,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Affibody AB,"A multicenter, randomized, double-blind, placebo-controlled, dose-finding clinical trial inpatients with active psoriatic arthritis to investigate efficacy, tolerability, safety, pharmacokinetics and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003405-94,1,0,0 2019-003406-27,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,UCB Biopharma SRL,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Sy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003406-27,0,0,0 2019-003407-35,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,UCB Biopharma SRL,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Sy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003407-35,0,0,0 2019-003409-83,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,UCB Biopharma SRL,"A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003409-83,0,0,0 2019-003416-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus University Medical Center,Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Real-time Fluorescence Imaging Geleid door licht: Tumor-gerichte fluorescente stoffen helpen bij het volledig wegsnijden van e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003416-30,0,0,0 2019-003419-68,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Center (AMC),"From fungus to virus, a phase 2a clinical trial investigating the safety and efficacy of terbinafine in chronic hepatitis B patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003419-68,0,0,0 2019-003421-22,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Gyroscope Therapeutics,"EXPLORE: A phase 2, outcomes assessor-masked, multicentre, randomised study to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003421-22,0,0,0 2019-003426-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IRCCS FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA ONLUS,24-hour efficacy and tolerability of the tafluprost-timolol fixed association without preservatives in glaucomatous or ocular hypertensive patients already treated with latanoprost preserved with BAK....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003426-24,0,0,0 2019-003427-38,5,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,HZRM – Hämophilie-Zentrum Rhein Main GmbH,MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – An International Low-Interventional Pragmatic Investigator Initiated Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003427-38,0,0,0 2019-003430-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial - SCLERITA Etude SCLERITA - Tolérance et efficacité de l’itacitinib dans la sclérodermi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003430-16,0,0,0 2019-003431-33,15,2022-02-17,2022-02-18,11,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BAYER AG,"Multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic is...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003431-33,1,0,0 2019-003431-33,15,2022-02-17,2022-02-18,11,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bayer AG,"Multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic is...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003431-33,1,0,0 2019-003437-42,1,2021-06-16,2021-06-16,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Lars Arendt-Nielsen,A Mechanism Based Proof of Concept Study of the Effects of Duloxetine in the Treatment of Patients with Osteoarthritic Knee Pain,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003437-42,0,0,0 2019-003438-18,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Julius Clinical,Evaluation of safety and efficacy in mitapivat sulfate in adult patients with sickle cell disease Evaluatie van de veiligheid en werkzaamheid van mitapivat sulfaat in volwassen patiënten met sikkel...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003438-18,0,0,0 2019-003440-74,1,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,1,Alexion Pharmaceuticals Inc.,"Phase 4, Single-Arm Study of Ravulizumab in Adult Participants with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with High-Dose Eculizumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003440-74,0,0,0 2019-003444-72,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc","An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD- 1/L1 and VEGF-Targeted Therapies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003444-72,0,0,0 2019-003444-72,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD- 1/L1 and VEGF-Targeted Therapies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003444-72,0,0,0 2019-003444-72,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD- 1/L1 and VEGF-Targeted Therapies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003444-72,0,0,0 2019-003448-58,7,2022-08-04,2022-08-04,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ALLERGAN LIMITED,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prophylaxis of Migraine in Parti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003448-58,1,0,0 2019-003448-58,7,2022-08-04,2022-08-04,5,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Allergan Limited,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prophylaxis of Migraine in Parti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003448-58,1,0,0 2019-003449-14,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Genentech Inc.,"A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE FOLLOWING ADJUVANT PLATINUM-DOUBLET CHEMOTHERAP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003449-14,0,0,0 2019-003451-11,13,2022-04-14,2022-05-05,7,0,0,0,0,1,3,0,0,2,1,0,0,0,1,UCB Biopharma SRL,"A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003451-11,1,0,0 2019-003454-83,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Amsterdam UMC, VU University Medical Center",Ipilimumab plus Nivolumab and ChemoRadiotherapy followed by Surgery in patients with resectable and borderline resectable T3-4N0-1 NSCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003454-83,0,0,0 2019-003455-11,3,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003455-11,0,0,0 2019-003456-36,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Institut de Recherches Internationales Servier,"A first in human Phase 1/2 open-label, multicenter, dose escalation and expansion study of PRS-344/S095012 in patients with solid tumors Estudio de primera administración en humanos de fase I/II, a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003456-36,0,0,0 2019-003459-12,1,,,0,0,0,1,1,1,1,0,1,3,0,0,0,0,1,"Rallybio, IPA, LLC","A Single-blind, Placebo-controlled, Single-center Study Investigating the Dose of Human Anti-Human Platelet Antigen (HPA)-1a Immune Globulin (NAITgam) Needed to Eliminate HPA-1a Positive Platelets Tra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003459-12,0,0,0 2019-003460-50,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,KU Leuven Drug Delivery and Disposition,The influence of gastrointestinal lipid digestion on the intraluminal behavior of abiraterone acetate in healthy volunteers De invloed van gastro-intestinale vetvertering op het intraluminaal gedra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003460-50,0,0,0 2019-003461-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Amsterdam UMC, location VUmc",Pathophysiological relevance of IRON deficiency and related mitochondrial dysfunction in Heart Failure with Preserved Ejection Fraction (IRON-HFpEF) De pathofysiologische relevantie van ijzer defic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003461-17,0,0,0 2019-003462-40,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,Great Ormond Street Hospital for Children NHS Trust,"Phase 1 , open label study of CRISPR-CAR genome edited T cells (TT52CAR19) in relapsed /refractory B Cell Acute Lymphoblastic Leukaemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003462-40,0,0,0 2019-003463-22,4,2021-10-19,2021-10-19,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Laboratorios Salvat, S.A.","A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of Clotrimazole 1% Otic Solution Compared to Placebo for the Treatment of Fungal Otitis Externa (Oto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003463-22,1,0,0 2019-003465-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Breast Cancer Trials,A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in “window” or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in earl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003465-18,0,0,0 2019-003466-41,1,,,0,1,0,0,0,0,2,0,1,1,1,1,0,1,0,"Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET",In vivo molecular imaging of angiogenesis in type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003466-41,0,0,0 2019-003468-27,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Homerton University Hospital NHS Trust,A Randomised Controlled trial investigating the effects of Progesterone for luteal phase support in Natural Cycles for unexplained infertility,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003468-27,0,0,0 2019-003474-35,3,2022-07-05,2022-07-05,3,0,0,1,0,0,1,0,0,1,1,0,0,0,1,NEKTAR THERAPEUTICS,"A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab with or without Chemotherapy in Patients with L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003474-35,0,0,0 2019-003474-35,3,2022-07-05,2022-07-05,3,0,0,1,0,0,1,0,0,1,1,0,0,0,1,Nektar Therapeutics,"A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab with or without Chemotherapy in Patients with L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003474-35,0,0,0 2019-003481-41,1,2021-02-01,2021-02-01,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Croma-Pharma GmbH,"A Double-Blinded Randomized Controlled Study to Compare the Efficacy, Time to Onset, and Duration of Effect of Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003481-41,0,0,0 2019-003483-43,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo de Investigación en Tumores Uro-oncológicos,Phase II Safety and Efficacy of personalized lymphadenectomy or guided by Indocyanine Green (IGC) vs extended pelvic lymph node dissection in patients diagnosed with Prostate Cancer subsidiaries of Ra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003483-43,0,0,0 2019-003485-40,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,The Institute of Cancer Research,ACTION: Phase I/II Trial of Abiraterone Acetate in Combination with Tildrakizumab (anti-IL23 targeting monoclonal antibody) in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003485-40,0,0,0 2019-003486-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CARMEN HIDALGO TENORIO,Immunogenicity and safety of a 9-valent human papillomavirus vaccine in HIV-positive women Ensayo Clínico en fase IV sobre la seguridad e inmunogenicidad de la vacuna Gardasil-9 en mujeres infectad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003486-17,0,0,0 2019-003489-41,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,A first-in-patient Phase I/II clinical study to investigate the safety and efficacy of genome-edited hematopoietic stem and progenitor cells in subjects with severe complications of sickle cell diseas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003489-41,0,0,0 2019-003497-13,5,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Amgen Inc.,"A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003497-13,0,0,0 2019-003497-13,5,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,CELGENE CORPORATION,"A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003497-13,0,0,0 2019-003497-13,5,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Celgene Corporation,"A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003497-13,0,0,0 2019-003501-10,3,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Västra Götalandsregionen,"Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003501-10,0,0,0 2019-003501-10,3,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"Vãstre Gõtalandsregionen, Sweden","Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003501-10,0,0,0 2019-003502-28,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Algiax Pharmaceuticals GmbH,"A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of AP-325 in Subjects with Peripheral Post-surgical Neuropathic Pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003502-28,0,0,0 2019-003503-35,1,2021-11-30,2021-11-30,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Region Östergötland,"A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Effect of Botulinum Toxin A on Patients with Atypical Odontalgia/Persistent Dentoalveolar Pain.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003503-35,0,0,0 2019-003505-96,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.","A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Patients with Non-Transfusi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003505-96,0,0,0 2019-003506-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitari Son Espases,Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy Determinación de la función paratiroidea mediante fluorescencia con verde de indocianina...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003506-26,0,0,0 2019-003509-80,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"IMMUNOGEN, INC.","MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003509-80,0,0,0 2019-003509-80,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"ImmunoGen, Inc.","MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003509-80,0,0,0 2019-003513-33,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Bayer HealthCare LLC,"A Randomized, Double-Blind, Single-Dose, Parallel, Placebo-Controlled Trial to Determine the Dose of Caffeine in a Fixed Dose Combination Tablet of Naproxen Sodium and Caffeine to Effectively Alleviat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003513-33,0,1,1 2019-003514-14,7,2020-07-15,2020-07-15,5,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Institut de Recherches Internationales Servier,"A Multicentre, Randomized, Double-blind, Placebo-controlled Dose-finding Study of S62798 in Patients with Intermediate-High Risk Acute Pulmonary Embolism on heparin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003514-14,1,0,0 2019-003514-14,7,2020-07-15,2020-07-15,5,1,0,0,0,0,2,0,0,2,1,0,0,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"A Multicentre, Randomized, Double-blind, Placebo-controlled Dose-finding Study of S62798 in Patients with Intermediate-High Risk Acute Pulmonary Embolism on heparin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003514-14,1,0,0 2019-003514-14,7,2020-07-15,2020-07-15,5,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Servier Portugal - Especialidades Farmaceuticas, Lda.","A Multicentre, Randomized, Double-blind, Placebo-controlled Dose-finding Study of S62798 in Patients with Intermediate-High Risk Acute Pulmonary Embolism on heparin",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003514-14,1,0,0 2019-003518-15,2,2021-10-21,2022-01-18,2,1,0,0,0,0,4,0,0,1,0,0,0,0,1,"Celltrion, Inc.",A Follow-Up Study of Long-Term Efficacy of Patients with HER2-Positive Early Breast Cancer Who Had Been Enrolled in Study CT-P6 3.2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003518-15,0,0,0 2019-003520-20,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003520-20,0,0,0 2019-003521-21,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,GALAPAGOS NV,"An exploratory, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered GLPG2737 for 52 weeks, in sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003521-21,0,0,0 2019-003521-21,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Galapagos NV,"An exploratory, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of orally administered GLPG2737 for 52 weeks, in sub...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003521-21,0,0,0 2019-003522-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AP-HP,Ostéomyélite aiguë non sévère de l’enfant - Stratégie de prise en charge ambulatoire avec antibiothérapie orale comparée à une stratégie standard avec hospitalisation conventionnelle et antibiothérapi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003522-25,0,0,0 2019-003524-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A phase II multicenter, randomized, double-blind, 12-week treatment, 3-arm, parallel-group, placebo-controlled study to investigate the efficacy, safety and tolerability of RO7017773 in participants a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003524-20,0,0,0 2019-003529-36,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"ModernaTX, Inc","A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants with Propionic Acidemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003529-36,0,0,0 2019-003532-23,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Vivoryon Therapeutics AG,"A Phase 2b Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of PQ912 in Subjects with Mild Cognitive Impairment and Mild ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003532-23,0,0,0 2019-003532-23,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Vivoryon Therapeutics N.V.,"A Phase 2b Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Dose Finding, Safety, Tolerability and Efficacy Study of PQ912 in Subjects with Mild Cognitive Impairment and Mild ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003532-23,0,0,0 2019-003541-15,1,2021-11-19,2021-11-19,1,1,0,0,0,0,4,0,0,1,1,1,0,0,0,Aarhus University,"Adjunct effect of fluconazole in the treatment of Candida-associated refractory severe periodontitis – A single-center, placebo-controlled, triple blind, randomized clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003541-15,0,0,0 2019-003542-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. José Manuel Porcel Pérez,Randomised clinical trial: saline washouts versus standard treatment in complicated parapneumonic pleural effusion or empyema. SCOPE study. Ensayo clínico randomizado: lavados con suero salino vs t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003542-32,0,0,0 2019-003543-30,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,European Organisation for Research and Treatment of Cancer,A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003543-30,0,0,0 2019-003543-30,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,EORTC AISBL/IVZW,A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003543-30,0,0,0 2019-003549-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"MediciNova, Inc.","A PHASE 2B/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 MONTH CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MN-166 (IBUDILAST) FOLLOWED BY AN OPEN-LABEL EXTENSION IN SUBJE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003549-14,0,0,0 2019-003550-88,1,2020-11-13,2020-11-13,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Themis Bioscience GmbH,"Full title of the trial: A Phase I/II open-label, dose-escalation, safety, clinical activity, pharmacokinetic and pharmacodynamic study of intra-tumoral application of TMV-018 in combination with 5-Fl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003550-88,0,0,0 2019-003551-11,3,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,Sun Pharma Global FZE,"A Multicenter, Randomized, Placebo and Active Comparator-Controlled Clinical trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects from 6 to <18 Years of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003551-11,0,0,0 2019-003551-11,3,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,Sun Pharma Advanced Research Company Ltd.,"A Multicenter, Randomized, Placebo and Active Comparator-Controlled Clinical trial to Study the Efficacy, Safety and Pharmacokinetics (PK) of Tildrakizumab in Pediatric Subjects from 6 to <18 Years of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003551-11,0,0,0 2019-003552-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Cognition Therapeutics, Inc.",A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects With Mild to Moderate Alzheimer’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003552-36,0,0,0 2019-003554-86,5,2021-05-17,2021-05-17,4,1,0,0,0,1,3,0,0,2,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3b, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 6 Through 11 Years of Age Who Are Heterozygous for t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003554-86,1,0,0 2019-003555-11,1,,,0,0,0,1,0,0,1,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE-HOPÏTAUX DE PARIS,"A Phase 1/2 Open Label non randomized Study, multicentric, single arm evaluating the Safety and Efficacy of Gene Therapy of the severe combined immunodeficiency (SCID) caused by mutations in the human...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003555-11,0,0,0 2019-003558-98,1,2022-06-03,2022-06-03,1,0,0,0,0,1,2,0,1,1,0,0,0,0,0,Centre for Human Drug Research,"Randomized, double-blind, placebo-controlled, two way crossover, single centre study evaluating the acute and chronic effect of clonazepam on cognitive tests and patient-reported outcome measures in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003558-98,0,0,0 2019-003559-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA,"Prospective, open-label, non-randomized, single-arm, dose titration study to investigate the efficacy and safety of IncobotulinumtoxinA in children deemed to require a total body dose up to 22U/kg (ma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003559-12,0,0,0 2019-003561-17,6,2022-01-18,2022-01-18,3,1,0,0,0,0,2,0,0,2,1,0,0,0,1,"Toray Industries, Inc.","A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TRK-750 in Colorectal Cancer Patients with Chemotherapy-induced Peripheral Neuropathy Following Oxaliplatin-contai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003561-17,1,0,0 2019-003563-22,4,2020-10-27,2020-11-26,4,1,0,0,0,1,3,0,0,1,1,1,1,0,1,Catabasis Pharmaceuticals Inc.,An Open-Label Extension Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003563-22,0,0,0 2019-003567-21,1,2021-09-07,2021-09-07,1,0,0,0,0,0,2,0,1,1,0,0,1,0,0,Centre for Human Drug Research,"A randomized, evaluator-blind, vehicle controlled, parallel group study to explore the effects of the anti-inflammatory drug prednisolone in a TLR4 and TLR7 challenge model in healthy volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003567-21,0,0,0 2019-003570-11,1,2022-03-09,2022-03-09,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Ghent University Hospital,The use of buffered soluble alendronate 70 mg (Steovess/Binosto) after denosumab discontinuation to prevent increase in bone turnover.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003570-11,0,0,0 2019-003571-19,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Royal Brompton and Harefield NHS Foundation Trust,"PAciFy Cough: A multicentre, double blind, placebo controlled, crossover trial of morphine sulfate for the treatment of PulmonAry Fibrosis Cough",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003571-19,0,0,0 2019-003573-26,1,,,0,0,1,0,0,0,2,0,0,4,0,0,0,0,0,Cliniques universitaires Saint-Luc,Monocentric pilot trial evaluating efficacy of Trametinib in Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003573-26,0,0,0 2019-003575-19,3,2021-10-26,2021-10-26,2,1,0,0,0,1,2,0,0,1,1,1,0,0,1,4SC AG,"A phase II, open label, multicenter study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with treatment-naïve metastatic Merkel Cell Carcinoma - the ME...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003575-19,0,0,0 2019-003576-40,5,2022-05-05,2022-05-05,3,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 2, Randomized, Open-label Study of Cusatuzumab in Combination with Azacitidine Compared with Azacitidine Alone in Patients with Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003576-40,1,0,0 2019-003576-40,5,2022-05-05,2022-05-05,3,1,0,0,0,0,2,0,0,2,1,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 2, Randomized, Open-label Study of Cusatuzumab in Combination with Azacitidine Compared with Azacitidine Alone in Patients with Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003576-40,1,0,0 2019-003577-25,5,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,Shionogi B.V.,"A Phase 1/2, Multicentre, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Naldemedine in Paediatric Patients Who Are Receiving or Who Are About to Receive Treatment with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003577-25,0,0,0 2019-003581-41,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Eli Lilly and Company,EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003581-41,0,0,0 2019-003582-18,14,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Amgen, Inc.","A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003582-18,0,0,0 2019-003582-18,14,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Amgen Inc.,"A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003582-18,0,0,0 2019-003582-18,14,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AMGEN INC.,"A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003582-18,0,0,0 2019-003583-40,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Merck Healthcare KGaA,"A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-Containin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003583-40,0,0,0 2019-003585-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,St. Antonius Hospital,"An uncontrolled, open label pilot-study assessing the efficacy in reducing bleeding severity, and the safety of oral tacrolimus in patients with hereditary hemorrhagic telangiectasia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003585-40,0,0,0 2019-003588-24,2,2022-05-03,2022-05-03,2,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Novartis Pharma AG,"A proof of concept study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg over 32 weeks in adult patients with biopsy-proven forms of lichen planus not adequately controlled wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003588-24,0,0,0 2019-003589-41,3,2021-09-22,2021-10-01,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Mul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003589-41,1,0,0 2019-003589-41,3,2021-09-22,2021-10-01,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Lilly S.A.,"A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Mul...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003589-41,1,0,0 2019-003590-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,a Randomized controlled trial for epidural Analgesia for Pain relief after lumbar Interlaminar Decompressive spine surgery - RAPID,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003590-25,0,0,0 2019-003591-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin und Schmerztherapie","Efficacy of Cannabidiol in Treatment of Pain due to symptomatic Osteoarthritis of the Knee: A randomized, double-blind, placebo-controlled",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003591-40,0,0,0 2019-003593-17,3,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,BioNTech SE,"Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003593-17,0,0,0 2019-003593-17,3,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,BioNTech Small Molecules GmbH,"Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003593-17,0,0,0 2019-003595-38,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Audentes Therapeutics, Inc.","FORTIS: A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients with Late Onset Pompe Disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003595-38,0,0,0 2019-003596-19,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Cristcot HCA LLC,"A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90 mg Suppository For...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003596-19,0,0,0 2019-003597-10,2,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc","A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine/Islatravir in Adolescents with HIV-1 Infection who are Virologically Suppressed, are >=12 to <18 Years of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003597-10,0,1,0 2019-003597-10,2,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine/Islatravir in Adolescents with HIV-1 Infection who are Virologically Suppressed, are >=12 to <18 Years of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003597-10,0,1,0 2019-003601-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amsterdam University Medical Centers,Treatment of Skin Severity in Ichthyosis with Hyperbaric Oxygen Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003601-10,0,0,0 2019-003602-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Nantes,Comparison of pharmacokinetic (PK) levels before and after conversion from twice-daily tacrolimus to once-daily extended-release tacrolimus (LCPT) in diabetic transplant recipients Comparaison de l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003602-27,0,0,0 2019-003604-12,1,2021-03-31,2021-03-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Institute of Tropical Medicine,Evaluation of a chlorhexidine mouthwash for the eradication of asymptomatic pharyngeal Neisseria gonorrhoeae infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003604-12,0,0,0 2019-003606-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UZ/KU Leuven,WP3-Influence of cromones on EVH-test in young elite athletes who tested positive for EIB.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003606-27,0,0,0 2019-003607-35,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,PFIZER INC,"A PHASE 2, 12-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FOC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003607-35,0,0,0 2019-003607-35,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Pfizer Inc.,"A PHASE 2, 12-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FOC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003607-35,0,0,0 2019-003609-84,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc",A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003609-84,0,0,0 2019-003610-13,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003610-13,0,0,0 2019-003611-62,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"LIB Therapeutics, LLC","Randomized, Open-Label, Cross-Over, Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 with Evolocumab in Homozygous Familial Hypercholesterolemia Patients on Stable Lipid-Lowering Therapy.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003611-62,0,0,0 2019-003614-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI""","Feasibility, efficacy and safety of rapid (within 7 days from HIV diagnosis) antiretroviral initiation strategy based on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-infected naïve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003614-14,0,0,0 2019-003616-31,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-733...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003616-31,0,0,0 2019-003616-31,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-733...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003616-31,0,0,0 2019-003618-15,18,2021-06-14,2021-06-14,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Bayer Consumer Care AG,"An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003618-15,1,0,0 2019-003620-20,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Tolerogenic dendritic cell therapy for rheumatoid arthritis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003620-20,0,0,0 2019-003622-25,1,2020-10-02,2020-10-02,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Rhizen Pharmaceuticals SA,"A Phase 2, Open label Study to Assess the Efficacy and Safety of Tenalisib (RP6530), a Novel PI3K Dual δ/γ Inhibitor, in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003622-25,0,0,0 2019-003623-37,1,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,King's College London,CANnabidiol for Parkinson’s Disease Psychosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003623-37,0,0,0 2019-003623-37,1,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,South London and Maudsley NHS Foundation Trust,CANnabidiol for Parkinson’s Disease Psychosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003623-37,0,0,0 2019-003625-16,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"TG Therapeutics, Inc.",An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003625-16,0,0,0 2019-003626-24,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,MyoKardia Inc.,"An Open-Label, Exploratory Study of the Safety and Preliminary Efficacy of Danicamtiv in Stable Ambulatory Patients with Primary Dilated Cardiomyopathy due to either MYH7 or TTN Variants.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003626-24,0,0,0 2019-003627-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Georges-François Leclerc,18F-Fluorocholine (FCH) versus 18F-Fluorodesoxyglucose (FDG) PET/CT for the detection of lesions in patients with multiple myeloma 18F-Fluorocholine (FCH) versus 18F-Fluorodesoxyglucose (FDG) PET/C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003627-38,0,0,0 2019-003629-78,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ASTRAZENECA AB,A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Horm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003629-78,0,0,0 2019-003629-78,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Horm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003629-78,0,0,0 2019-003632-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Curie,LOC-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 with a newly diagnosed Pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003632-23,0,0,0 2019-003633-41,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003633-41,0,0,0 2019-003633-41,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003633-41,0,0,0 2019-003633-41,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003633-41,0,0,0 2019-003637-42,4,2021-03-29,2021-05-04,3,1,0,0,0,1,2,0,0,1,1,1,1,0,1,Wave Life Sciences UK Limited,"A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003637-42,0,0,0 2019-003638-18,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,SANTEN INCORPORATED,"LUMINA: A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 µg DE-109 for the Treatment of Active, Non-Infec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003638-18,0,0,0 2019-003643-30,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients with Diabetic Macular Edema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003643-30,0,0,0 2019-003644-68,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003644-68,0,1,1 2019-003645-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hopital Foch,Benefit of the GnRH agonist before frozen embryo transfer in patients with endometriosis and / or adenomyosis: randomized prospective study Bénéfice de l’agoniste de la GnRH avant un transfert d’em...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003645-16,0,0,0 2019-003646-33,7,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"Amgen, Inc.","Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003646-33,0,0,0 2019-003646-33,7,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,AMGEN INC.,"Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003646-33,0,0,0 2019-003647-29,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Solstice Neurosciences, LLC, USA, a wholly-owned subsidiary of US WorldMeds, LLC, USA","A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity Followed by an Open-Label...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003647-29,0,0,0 2019-003647-29,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Solstice Neurosciences a wholly-owned subsidiary of US WorldMeds, LLC","A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity Followed by an Open-Label...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003647-29,0,0,0 2019-003648-55,4,,,0,0,0,1,0,1,1,0,0,2,0,0,0,0,1,"Epizyme, Inc.","A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003648-55,0,0,0 2019-003649-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Epizyme, Inc.",A PHASE 1B/2 OPEN-LABEL STUDY EVALUATING TAZEMETOSTAT IN COMBINATION WITH ENZALUTAMIDE OR ABIRATERONE/PREDNISONE IN CHEMOTHERAPY NAIVE SUBJECTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003649-14,0,0,0 2019-003650-92,4,2020-11-14,2020-11-14,4,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003650-92,0,0,0 2019-003653-29,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Bicycle Tx Limited,"Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003653-29,0,0,0 2019-003654-83,1,2020-01-04,2020-01-04,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Novo Nordisk A/S,A TRIAL TO COMPARE THE INJECTION SITE PAIN EXPERIENCE OF 0.25 MG SEMAGLUTIDE B AND SEMAGLUTIDE D ADMINISTERED SC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003654-83,0,0,0 2019-003656-37,6,2022-05-04,2022-05-04,4,0,0,0,0,0,4,0,0,1,0,0,0,0,1,Menarini International Operations Luxembourg SA,"A randomized, double-blind, placebo-controlled, parallel arm group study to evaluate the analgesic efficacy and safety of dexketoprofen trometamol and tramadol hydrochloride oral fixed dose combinatio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003656-37,0,0,0 2019-003659-13,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Imago BioSciences, Inc","A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003659-13,0,0,0 2019-003659-13,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Imago BioSciences Inc.,"A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003659-13,0,0,0 2019-003662-40,1,2022-03-07,2022-03-07,1,0,0,0,0,0,4,0,0,1,1,1,0,0,0,Universitätsklinikum Erlangen,"Prospective, open-label, single-arm, single-center phase IV clinical trial to evaluate efficacy and safety of the adalimumab biosimilar Amgevita in subjects with moderate to severe active chronic infl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003662-40,0,0,0 2019-003666-41,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Erasmus MC University Medical Center,"Doxapram versus placebo in preterm newborns: an international double blinded multicenter randomized controlled trial. Doxapram versus placebo in premature neonaten: een internationaal, multicenter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003666-41,0,0,0 2019-003668-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UZ Brussel,A randomized phase II clinical trial of SBRT and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/ CD141 (BDCA-3)+ myeloid dendritic cells in NSCLC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003668-32,0,0,0 2019-003671-19,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Stichting Epilepsie Instellingen Nederland,Efficacy and safety of hydralazine in combination with valproate to treat hypocretin deficiency in recent onset narcolepsy: a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003671-19,0,0,0 2019-003676-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,,Effects of sodium lactate infusion in patients with glucose transporter 1 deficiency syndrome (GLUT1DS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003676-39,0,0,0 2019-003678-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Infectopharm Arzneimittel GmbH,"Prospektive, dreiarmige, randomisierte Doppelblind-Studie gemäß MPG und AMG zur Wirksamkeit und Sicherheit der Behandlung der leichten bis moderaten aktinischen Keratose mit einer 5%-igen Kaliumhydrox...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003678-16,0,0,0 2019-003679-20,1,2021-12-31,2021-12-31,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Radboudumc,DUAL pathway inhibition (low-dose rivaroxaban and aspirin) as compared to aspirin only to improve endothelial function in peripheral artery disease (PAD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003679-20,0,0,0 2019-003685-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Groupe Francophone des Myélodysplasies (GFM),A PHASE II PROSPECTIVE STUDY “GFM-DACORAL-DLI” ASTX727 AND DONOR LYMPHOCYTE INFUSIONS (DLI) AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO SCT) IN VERY HIGH RISK MDS OR AML PATIENTS Étude prospe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003685-40,0,0,0 2019-003686-17,4,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Glycostem Therapeutics BV,"A prospective Phase I/IIa, open-label, multicenter trial to evaluate the safety and efficacy of oNKord®, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation, in subjects with acute myelo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003686-17,0,0,0 2019-003688-23,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Amgen Inc.,"A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of AMG 890 (a GalNAc-conjugated Small Interfering RNA [siRNA]) in Subjects with Elevated Lip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003688-23,0,0,0 2019-003696-19,12,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,Eisai Ltd,"A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003696-19,0,0,0 2019-003696-19,12,,,0,0,1,0,0,1,2,0,0,2,0,0,0,0,1,EISAI LIMITED,"A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003696-19,0,0,0 2019-003697-70,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,"Viela Bio, Inc.","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients with Rheumatoid Arthritis (RA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003697-70,0,0,0 2019-003698-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Amsterdam UMC, location VUmc",Patient preference-based phosphate binder therapy in haemodialysis patients: a feasibility study on patient satisfaction Haalbaarheid van een behandelstrategie gebaseerd op voorkeuren van de patien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003698-24,0,0,0 2019-003699-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,DETECTION RATE AND CLASSIFICATION OF BREAST LESIONS WITH DIGITAL MAMMOGRAPHY WITH CONTRAST MEDIUM (CEDM) ALONE AND IN COMBINATION WITH TOMOSYNTHESIS COMPARED TO MR IMAGING WITH GADOLINIUM IN DYNAMICS ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003699-38,0,0,0 2019-003700-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Saint-Etienne,Association between methotrexate erythrocyte polyglutamate concentration and biological drug concentration and clinical response in rheumatoid arthritis patients treated with subcutaneous injectable m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003700-12,0,0,0 2019-003703-35,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 1/2 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003703-35,0,0,0 2019-003703-35,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 1/2 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003703-35,0,0,0 2019-003706-27,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,AstraZeneca AB,"SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Brea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003706-27,0,0,0 2019-003706-27,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Brea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003706-27,0,0,0 2019-003710-13,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,University Hospital Essen,"A multi-center interventional study to assess pharmacokinetics, effectiveness and tolerability of prolonged-release Tacrolimus after Paediatric Kidney Transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003710-13,0,0,0 2019-003711-60,6,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"Alexion Pharmaceuticals, Inc","A Phase 2, single-arm, pathologist-blinded study using liver biopsy specimens to assess copper concentration and histopathologic changes in patients with Wilson disease who are treated with ALXN1840 f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003711-60,0,0,0 2019-003713-33,1,2021-08-02,2021-08-02,1,1,0,0,0,1,2,0,0,1,0,0,1,0,0,Princess Máxima Center for pediatric oncology,Diagnostic accuracy of neuroblastoma patient imaging with [18F]-mFBG PET-CT compared to [123]I-mIBG scanning Diagnostische nauwkeurigheid van beeldvorming van neuroblastoompatiënten met [18F]mFBG ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003713-33,0,0,0 2019-003714-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,TheraOp gGmbH,"Modulation of the FOLFIRI-based standard 1st-line therapy with cetuximab, controlled by monitoring the RAS mutation load by liquid biopsy in RAS-mutated mCRC patients Anpassung einer FOLFIRI-Erstli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003714-14,0,0,0 2019-003717-34,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003717-34,0,0,0 2019-003717-34,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and le...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003717-34,0,0,0 2019-003720-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Zagreb School of Medicine,Varenicline Versus Cytisine for Smoking Cessation in the Primary Care Setting in Croatia and Slovenia - a Randomized Controlled Trial Usporedba učinkovitosti Vareniklina i Citizina u odvikavanju od...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003720-20,0,0,0 2019-003721-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region Östergötland,Randomized prospective phase II clinical trial investigating pharmacokinetics and safety aspects of higher doses of rifampicin and pyrazinamide in an shortened tuberculosis treatment compared to stand...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003721-25,0,0,0 2019-003722-25,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Cincinnati,Recombinant Factor VIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003722-25,0,0,0 2019-003723-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut klinické a experimentální medicíny (IKEM),"rATG versus rATG combined with IVIG induction immunosuppression in HLA incompatible transplantation Randomizovaná, otevřená studie fáze III.b prokazující non-inferioritu indukční imunosuprese pomoc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003723-37,0,0,0 2019-003727-38,4,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,MENARINI RICERCHE SPA,"OPEN-LABEL, MULTICENTRE, PHASE IB/II STUDY OF MEN1611, A PI3K INHIBITOR, AND CETUXIMAB IN PATIENTS WITH PIK3CA MUTATED METASTATIC COLORECTAL CANCER FAILING IRINOTECAN, OXALIPLATIN, 5-FU AND ANTI-EGFR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003727-38,0,0,0 2019-003727-38,4,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Menarini Ricerche S.p.A.,"OPEN-LABEL, MULTICENTRE, PHASE IB/II STUDY OF MEN1611, A PI3K INHIBITOR, AND CETUXIMAB IN PATIENTS WITH PIK3CA MUTATED METASTATIC COLORECTAL CANCER FAILING IRINOTECAN, OXALIPLATIN, 5-FU AND ANTI-EGFR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003727-38,0,0,0 2019-003733-41,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ITALIAN SARCOMA GROUP,Phase II study on Trabectedin in advanced rearranged Mesenchymal chondrosarcoma (MCS) Studio di fase II con trabectedina per il trattamento di giovani adulti e adulti affetti da condrosarcoma mesen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003733-41,0,0,0 2019-003734-17,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,"Eisai Co., Ltd. (Japan)","A Multicenter, Uncontrolled, Open-label Study and Extension Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Patients with Partial Onset Seizures (Including Second...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003734-17,0,1,1 2019-003735-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Helse Bergen HF, Department of Medicine","The role of sonoporation-enhanced treatment with Gemcitabine, Nab-Paclitaxel and FOLFIRINOX in patients with inoperable pancreatic cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003735-28,0,0,0 2019-003736-22,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,AbbVie Inc.,Bioavailability and Food Effect of Experimental Glecaprevir + Pibrentasvir Pediatric Formulation in Healthy Adult Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003736-22,0,1,1 2019-003740-77,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amsterdam UMC location VUmc,Personalized prediction and regulation of 5-FU exposure Gepersonaliseerd voorspelling en regulatie van 5-FU blootstelling,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003740-77,0,0,0 2019-003742-32,1,,,0,0,0,0,1,0,4,0,0,3,0,0,0,0,0,University Hospitals Plymouth NHS Trust,"The Soft Tissue Injection of Corticosteroid And Local anaesthetic Study - A Single site, non-inferiority randomised control trial evaluating pain after soft tissue corticosteroid injections with and w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003742-32,0,0,0 2019-003746-33,2,2021-12-07,2021-12-07,2,0,0,0,0,0,2,0,0,1,1,1,0,0,1,ReViral Ltd.,"Randomized, double-blind, placebo-controlled trial of the safety, tolerability, and efficacy of RV521 in the treatment of adult subjects who have undergone hematopoietic cell transplantation (HCT) wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003746-33,0,0,0 2019-003749-14,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,Braintree Laboratories,"Efficacy, Safety and Tolerability of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003749-14,0,1,1 2019-003751-10,2,2021-01-13,2021-01-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,Sanofi-Aventis Recherche & Developpement,"A randomized, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy, safety, and tolerability of SAR440340 (anti-IL-33 mAb) in patients with moderate-to-severe asthma Estudio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003751-10,0,0,0 2019-003751-10,2,2021-01-13,2021-01-13,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A randomized, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy, safety, and tolerability of SAR440340 (anti-IL-33 mAb) in patients with moderate-to-severe asthma Estudio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003751-10,0,0,0 2019-003752-36,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury Estudio de prueba de concepto, a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003752-36,0,0,0 2019-003753-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke Estudio de prueba de concepto, aleatorizado, doble cie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003753-29,0,0,0 2019-003756-37,4,2021-03-12,2021-03-12,4,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Anthos Therapeutics,"A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Active-Controlled, Dose-Ranging Study to Compare the Efficacy and Safety of i.v. MAA868 and s.c. Enoxaparin in Adult Patients Underg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003756-37,0,0,0 2019-003757-28,1,,,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,Lupin Europe GmbH,"An Open-label, non-Comparative Study to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of Mexiletine in Adolescents and Children with Myotonic Disorders Étude ouverte non comparat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003757-28,0,0,0 2019-003758-97,1,,,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,Lupin Europe GmbH,Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Mexiletine in Paediatric Patients with Myotonic Disorders Who Have Completed MEX-NM-301 and MEX-NM-302 Studies Étude de p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003758-97,0,0,0 2019-003759-13,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Department of Oncology, Herlev & Gentofte",Phase 1/2 study in locally advanced or metastatic pancreatic cancer to assess safety and potential efficacy of dual checkpoint inhibition in combination with gemcitabine and nab-paclitaxel followed by...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003759-13,0,0,0 2019-003760-47,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Assistance Publique Hôpitaux de Marseille,"Evaluation of 68Ga-PSMA PET-CT in the initial extension assessment of advanced renal cell carcinoma a prospective, multicenter, open study Evaluation de la TEP-TDM au 68Ga-PSMA dans le bilan d'exte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003760-47,0,0,0 2019-003761-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,"A RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone or enzalutamide) as first-line of therapy in mCRPC patients with adverse prognostic fac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003761-17,0,0,0 2019-003763-22,1,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,0,Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside,A Pragmatic Proof of Concept Study to Evaluate the Effect of Benralizumab on Mannitol Challenge in Severe Eosinophilic Asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003763-22,0,0,0 2019-003764-45,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Leicester,"Multicentre, open-label, randomised controlled trial of early surfactant therapy versus expectant management in late preterm and early term infants with respiratory distress.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003764-45,0,0,0 2019-003765-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"DIPARTIMENTO AD ATTIVITà INTEGRATA CHIRURGICO, MEDICO, ODONTOIATRICO E DI SCIENZE MORFOLOGICHE",Gender-related response to Tyrosine Kinase-Inhibitor drugs in hepatocellular carcinoma Risposta genere-correlata a farmaci inibitori dei recettori tirosin kinasici (TKI) nel carcinoma epatocellular...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003765-18,0,0,0 2019-003766-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Amsterdam UMC-AMC,The effect of Voxelotor on Cerebral Perfusion and Oxygenation (Coverage Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003766-41,0,0,0 2019-003768-31,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Lungemedicinsk Forskningsenhed,Effects of azithromycin treatment on anti-viral immunity in patients with asthma and COPD. Effekten af Azithromycin behandling på Immunsystemet hos patienter med astma og KOL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003768-31,0,0,0 2019-003770-85,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,German Cancer Research Center (DKFZ),Effect of low-dose acetylsalicylic acid on early detection of advanced colorectal neoplasms Mit ASS Darmtumore früher erkennen 2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003770-85,0,0,0 2019-003771-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aarhus Universitetshospital,The effect of improved insulin sensitivity on bone turnover markers and bone biomechanical properties in persons with type 2 diabetes mellitus Effekten af øget insulinfølsomhed på knoglemarkører og...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003771-19,0,0,0 2019-003772-39,1,,,0,1,0,0,0,0,4,0,0,0,0,0,0,0,0,Umeå University,"Diet, physical exercise, and metabolic control intervention to reduce the incidence of major neurocognitive disorders among individuals with type 2 diabetes combined with mild neurocognitive impairmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003772-39,0,0,0 2019-003774-41,2,2022-02-03,2022-02-03,1,0,0,0,0,0,3,0,0,1,1,0,0,0,1,Sanofi-aventis Recherche & Développement,"A randomized, double blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003774-41,0,0,0 2019-003775-19,6,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Sanofi-aventis Recherche & Développement,"Master protocol of three randomized, double-blind, placebo-controlled, multi center, parallel-group studies of dupilumab in patients with chronic spontaneous urticaria (CSU) who remain symptomatic des...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003775-19,0,1,0 2019-003775-19,6,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"Master protocol of three randomized, double-blind, placebo-controlled, multi center, parallel-group studies of dupilumab in patients with chronic spontaneous urticaria (CSU) who remain symptomatic des...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003775-19,0,1,0 2019-003777-26,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003777-26,0,0,0 2019-003777-26,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ASTRAZENECA AB,Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003777-26,0,0,0 2019-003779-20,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Scandion Oncology A/S,"An open-label phase II prospective clinical trial to investigate safety, tolerability, maximum tolerated dose and anti-tumor effect for SCO-101 in combination with FOLFIRI as a safe and efficient trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003779-20,0,0,0 2019-003780-21,2,2021-12-02,2021-12-02,2,0,0,0,0,0,4,0,0,1,0,0,0,0,1,Alimentiv Inc.,Pharmacokinetics and Pharmacodynamic Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis (PROPHETIC Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003780-21,0,0,0 2019-003787-48,3,,,0,0,0,1,0,2,1,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"AN OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7248824 IN PARTICIPANTS WITH ANGELMAN SYNDROME",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003787-48,0,0,0 2019-003787-48,3,,,0,0,0,1,0,2,1,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche,"AN OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7248824 IN PARTICIPANTS WITH ANGELMAN SYNDROME",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003787-48,0,0,0 2019-003791-39,6,2021-01-19,2021-01-19,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,ASTRAZENECA AB,"A Phase II Randomised, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer, who hav...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003791-39,1,0,0 2019-003791-39,6,2021-01-19,2021-01-19,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,AstraZeneca AB,"A Phase II Randomised, Multi-Centre Study to Investigate the Efficacy and Tolerability of a Second Maintenance Treatment in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer, who hav...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003791-39,1,0,0 2019-003795-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,"Premedication with intranasal dexmedetomidine in sedation of patients undergoing total knee arthroplasty (TKADEX) - a prospective, double blinded randomized controlled trial Nenän kautta annostelta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003795-39,0,0,0 2019-003797-10,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Apellis Pharmaceuticals, Inc.","A Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003797-10,0,0,0 2019-003797-10,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"APELLIS PHARMACEUTCIALS, INC.","A Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003797-10,0,0,0 2019-003798-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC),"A phase II, single arm study of CarbopLatin plus Etoposide with Bevacizumab and Atezolizumab in patients with exTEnded-disease small-cell lung cancer (SCLC) – CeLEBrATE trial Studio di fase II, a b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003798-25,0,0,0 2019-003801-90,6,2021-11-22,2021-11-22,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Sanofi-aventis Recherche & Développement,"A randomized, double blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003801-90,1,0,0 2019-003801-90,6,2021-11-22,2021-11-22,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A randomized, double blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003801-90,1,0,0 2019-003805-82,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Besançon,UCPVax plus Nivolumab versus standard chemotherapy as second line therapy in advanced non-small cell lung cancer : a randomized non-comparative phase II trial UCPVax plus Nivolumab versus chimiothé...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003805-82,0,0,0 2019-003807-37,8,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Albireo AB,"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy (BOLD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003807-37,0,0,0 2019-003807-37,8,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,ALBIREO AB,"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy (BOLD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003807-37,0,0,0 2019-003812-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC,Primovist CT: proof of concept Primovist contrastmiddel: bruikbaar ook voor CT?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003812-30,0,0,0 2019-003814-16,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Gilead Sciences, Inc.",A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003814-16,0,0,0 2019-003814-16,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,GILEAD SCIENCES INCORPORATED,A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003814-16,0,0,0 2019-003816-29,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,ASSISTANCE PUBLIQUE -HOPITAUX DE PARIS (AP-HP),Fecal microbiota transplantation in Crohn’s disease as relay after anti-TNF withdrawal Transplantation de microbiote fécal dans la maladie de Crohn comme relais après arrêt des anti-TNF,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003816-29,0,0,0 2019-003819-56,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre for Surgical Science,Effects of intravenous administered iron in non-anemic iron deficient patients with colorectal cancer. A double blinded clinical randomized trial. Effekterne af intravenøs jern hos ikke anæmiske...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003819-56,0,0,0 2019-003821-70,1,2020-06-30,2020-06-30,1,0,0,0,0,0,3,0,0,1,0,0,1,0,1,"American Regent, Inc.",Evaluating the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency Anemia and an Unsatisfactory Response to Oral Iron under Study Protocol 1VIT17044,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003821-70,0,0,0 2019-003825-56,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,"An exploratory prospective, open-label, unicentric study with cross-over design, comparing Lymphoseek® vs. albumin nanocolloid for Image-Guided Sentinel Lymph Node Mapping in Head and Neck, Melanoma a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003825-56,0,0,0 2019-003826-25,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"G1 Therapeutics, Inc.","PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003826-25,0,0,0 2019-003826-25,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,G1 Therapeutics Inc.,"PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003826-25,0,0,0 2019-003828-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,St Antonius Hospital,Identification of sentinel lymph nodes in breast cancer patients through non-invasively and percutaneously fluorescent imaging using indocyanine green Identificatie van de schildwachtklier bij bors...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003828-21,0,0,0 2019-003829-18,7,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular H...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003829-18,0,0,0 2019-003829-18,7,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Alexion Pharmaceuticals Inc.,A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular H...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003829-18,0,0,0 2019-003830-17,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Alexion Pharmaceuticals Inc.,"A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003830-17,0,0,0 2019-003830-17,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Achillion Pharmaceuticals, Inc., a wholly owned subsidiary of Alexion Pharmaceuticals Inc.","A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003830-17,0,0,0 2019-003836-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HUS Helsinki University Hospital,"TWO-STAGE, TWO-ARM, OPEN-LABEL PHASE II STUDY OF VENETOCLAX IN COMBINATION WITH AZACYTIDINE IN ACUTE MYELOID LEUKEMIA PATIENTS SELECTED USING EX VIVO DRUG SENSITIVITY SCREENING Vaiheen II kaksiosai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003836-22,0,0,0 2019-003839-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,Phase II basket trial evaluating the efficacy of a combination of pembrolizumab and vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003839-33,0,0,0 2019-003842-34,4,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formulati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003842-34,0,1,0 2019-003844-57,1,2020-02-26,2020-02-26,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Novo Nordisk A/S,A TRIAL TO COMPARE THE INJECTION SITE PAIN EXPERIENCE OF SEMAGLUTIDE 0.25 MG AND DULAGLUTIDE 0.75 MG ADMINISTERED SC,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003844-57,0,0,0 2019-003847-31,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"ImCheck Therapeutics, Inc.","A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003847-31,0,0,0 2019-003847-31,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,ImCheck Therapeutics,"A first-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an immune checkpoint inhibit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003847-31,0,0,0 2019-003849-15,9,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Celltrion, Inc.","A Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003849-15,0,0,0 2019-003849-15,9,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,CELLTRION INC.,"A Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003849-15,0,0,0 2019-003850-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Hospital Pharmacy Funen, Research Department, Odense University Hospital",Oral laxatives after hip fracture surgery: A randomised controlled trial. Oral laksantia efter hoftenære frakturer: Et randomiseret kontrolleret studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003850-10,0,0,0 2019-003851-12,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bayer AG,"Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003851-12,0,0,0 2019-003851-12,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BAYER AG,"Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003851-12,0,0,0 2019-003854-99,8,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,0,University of Cologne,"A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003854-99,0,0,0 2019-003855-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación Instituto de Investigación Sanitaria Aragón,"Phase III Clinical Trial, single-center, randomized, double-blind, to demonstrate a lower incidence of acute diaphragmatic paralysis of the brachial plexus block with interscalene approach in arthrosc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003855-12,0,0,0 2019-003856-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University of Cologne,Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA) Daratumumab als Primärtherapie bei nichttransplantat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003856-35,0,0,0 2019-003857-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Radboudumc,"177Lu-PSMA Radioligand Therapy for advanced salivary gland cancer, a phase II pilot study. 177Lu-PSMA radioligand therapie voor gevorderde speekselklierkanker, een fase II pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003857-27,0,0,0 2019-003858-85,1,2021-12-14,2021-12-14,1,1,0,0,0,0,4,0,0,1,1,1,0,0,0,Medical University Innsbruck,Randomized double-blind explorative controlled clinical trial analyzing the effects of ferric carboxymaltose in patients with iron deficiency and chronic heart failure Randomisierte doppel-blinde e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003858-85,0,0,0 2019-003859-11,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F.Hoffmann-La Roche Ltd,"RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE III STUDY OF ENTRECTINIB VERSUS CRIZOTINIB IN PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBORING ROS1 GENE REARRANGEMENTS WITH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003859-11,0,0,0 2019-003859-11,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE III STUDY OF ENTRECTINIB VERSUS CRIZOTINIB IN PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBORING ROS1 GENE REARRANGEMENTS WITH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003859-11,0,0,0 2019-003859-11,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"RANDOMIZED, OPEN LABEL, MULTICENTER, PHASE III STUDY OF ENTRECTINIB VERSUS CRIZOTINIB IN PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER HARBORING ROS1 GENE REARRANGEMENTS WITH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003859-11,0,0,0 2019-003862-41,3,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,EORTC AISBL/IVZW,Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003862-41,0,0,0 2019-003862-41,3,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,0,European Organisation for Research and Treatment of Cancer,Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003862-41,0,0,0 2019-003863-23,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Technische Universität Dresden,Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia Midostaurin in Kombination mit Gemtuzumab Ozogamicin als Erstlinientherapie für Patienten m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003863-23,0,0,0 2019-003864-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HUS / Mika Mäkelä,Effect of inhalation formulation on uncontrolled asthma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003864-27,0,0,0 2019-003865-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medizinische Universität Wien,"Neoadjuvant CHemoradiotherapy with sequential Ipilimumab and NivOlumab in RECtal cancer (CHINOREC): a prospective randomized, open-label, multicenter, phase II clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003865-17,0,0,0 2019-003868-42,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University of Manchester,"A randomised, phase IIa treatment delayed-start trial of the oral JAK 1/2 inhibitor, baricitinib, in the treatment of adult idiopathic inflammatory myopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003868-42,0,0,0 2019-003871-20,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,"Phase III study to assess the impact of gemtuzumab ozogamicin, in combination with standard chemotherapy, on the levels of minimal residual disease, and the role of glasdegib as a post-transplant main...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003871-20,0,0,0 2019-003872-37,1,2022-07-13,2022-07-13,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,University Hospitals Leuven,18F-MFBG PET imaging of the norepinephrine transporter in neural crest and neuroendocrine tumors: a phase I PET/CT study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003872-37,0,0,0 2019-003876-38,2,2021-10-05,2021-10-05,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Enanta Pharmaceuticals Inc.,"A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects with Liver-Biopsy Proven Non-Alcoholic Steatohepatitis (NASH) (ARGON-2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003876-38,1,0,0 2019-003883-28,4,2022-03-16,2022-03-16,4,0,0,0,0,0,3,0,0,1,0,0,0,0,1,"Samsung Bioepis Co., Ltd.","A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB15 (proposed aflibercept biosimilar) and Eylea®...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003883-28,0,0,0 2019-003884-23,3,2022-07-20,2022-07-20,3,0,0,0,0,0,3,0,0,1,1,1,0,0,1,Vascular Biogenics Ltd.,"The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003884-23,0,0,0 2019-003887-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Cliniques universitaires Saint-Luc,Molecular effects of Apremilast (Otezal) in synovial biopsies of patients with psoriatic arthisis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003887-39,0,0,0 2019-003888-22,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Zagreb School of Medicine,"A multicENter, randomized, open-label, parallel group, pilot study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients Multicentrično, randomizirano, otvoreno pilot-istraživa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003888-22,0,0,0 2019-003888-22,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University of Zagreb, School of Medicine","A multicENter, randomized, open-label, parallel group, pilot study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients Multicentrično, randomizirano, otvoreno pilot-istraživa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003888-22,0,0,0 2019-003897-24,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,The Institute of Cancer Research,PreOperative Endocrine Therapy for Individualised Care with Abemaciclib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003897-24,0,0,0 2019-003898-26,1,2020-02-03,2020-02-03,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,"Mirati Therapeutics, Inc.","A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO ASSESS THE MASS BALANCE, ROUTE OF ELIMINATION, AND METABOLIC PROFILE OF [14C] LABELED MGCD516 MALATE SALT IN HEALTHY MALE SUBJECTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003898-26,0,0,0 2019-003900-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Cliniques universitaires Saint-Luc,Pharmacokinetics of intravenous meropenem administered over 12 hours at 2g 3x/d every 6 hours,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003900-10,0,0,0 2019-003901-93,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA","Monocentric, indipendent, phase II clinical trial, randomized in open to three different lZ delivery sequences in pediatric patients aged 1 and 12, in intensive care and mechanically ventilated. Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003901-93,0,0,0 2019-003902-29,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA",Early Administration of Ivabradine in Children with Heart Failure. “Somministrazione precoce di ivabradina nei bambini ospedalizzati per scompenso cardiaco-EArly adminiStration of Ivabradine in CHI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003902-29,0,0,0 2019-003903-36,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","An Open-Label, Multicenter, Single-arm Study to Evaluate the Immunogenicity of VARIVAX™ in Healthy Russian Individuals 12 Months of Age and Older",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003903-36,0,1,1 2019-003906-28,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CHU de Toulouse,Subcutaneous injections of autologous cultured adipose-derived stroma/stem cells to heal refractory ischemic digital ulcers in patients with scleroderma : a phase II study Injection de cellules ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003906-28,0,0,0 2019-003907-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Università Campus Bio-Medico,"The effects of vitamin D on bone, muscle and adipose tissue: a phase IV randomized double-blind study. Gli effetti della vitamina D sull’osso, muscolo e tessuto adiposo: uno studio di fase IV rando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003907-37,0,0,0 2019-003913-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Ruprecht-Karls-University of Heidelberg Medical Faculty represented in law by Heidelberg University Hospital,Randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare intensive postremission therapy double blinded with or without gla...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003913-32,0,0,0 2019-003914-15,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi-aventis recherche & développement,"Open-label, single-arm trial to evaluate antitumor activity, safety, and pharmacokinetics of SAR408701 used in combination with ramucirumab in metastatic, non-squamous, non–small-cell lung cancer (NSQ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003914-15,0,0,0 2019-003914-15,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi-Aventis Research and Development,"Open-label, single-arm trial to evaluate antitumor activity, safety, and pharmacokinetics of SAR408701 used in combination with ramucirumab in metastatic, non-squamous, non–small-cell lung cancer (NSQ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003914-15,0,0,0 2019-003916-29,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,"- TREASURE- Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease: a randomized, open-label, multicenter phase II study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003916-29,0,0,0 2019-003919-53,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PROGR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003919-53,0,0,0 2019-003919-53,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PROGR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003919-53,0,0,0 2019-003921-99,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,CSL Behring K.K.,"An open-label, single-arm, non-randomized phase 3 study to evaluate clinical efficacy, safety, and pharmacokinetics of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003921-99,0,1,1 2019-003923-39,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,BIOEQ GMBH,"A Phase 3 Randomized, Double-masked, Multicenter Study to Compare the Efficacy and Safety of the Proposed Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients with Neovascular Age Related...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003923-39,0,0,0 2019-003923-39,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Bioeq GmbH,"A Phase 3 Randomized, Double-masked, Multicenter Study to Compare the Efficacy and Safety of the Proposed Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients with Neovascular Age Related...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003923-39,0,0,0 2019-003924-19,5,2021-10-12,2021-10-12,4,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Immunovant Sciences GmbH,"A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003924-19,1,0,0 2019-003927-39,6,2022-05-12,2022-05-12,5,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bayer AG,"Factor XI LICA to Reduce Thrombotic Events in End-Stage Renal Disease Patients on Hemodialysis: A Phase 2, Randomized, Double-Blind, Placebo- Controlled Study of the Safety, Pharmacokinetics, and Phar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003927-39,1,0,0 2019-003932-22,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic Ste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003932-22,0,0,0 2019-003932-22,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic Ste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003932-22,0,0,0 2019-003933-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Haaglanden Medisch Centrum,Prediction of Flucloxacillin Absorption and %time/MIC using the Flucloxacillin absorption test Voorspelbaarheid van de absorptie van flucloxacilline en %tijd/MIC van de flucloxacilline absorptietes...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003933-40,0,0,0 2019-003936-21,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,"A Phase 3, prospective, randomized multi-center intervention trial of early intensification in AML patients bearing FLT3 mutations based on peripheral blast clearance. A MYNERVA-GIMEMA study. AMELIOR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003936-21,0,0,0 2019-003940-61,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Uppsala county council,"Metformin Intervention in children and adolescents with obesity. A parallel, three arms, randomized, 6 months, multi-center study with metformin extended release (XR) plus lifestyle or metformin immed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003940-61,0,0,0 2019-003948-71,5,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Ipsen Innovation,"AN INTEGRATED PHASE I/II, MULTICENTRE, DOUBLE-BLIND, RANDOMISED, DYSPORT AND PLACEBO-CONTROLLED, DOSE ESCALATION AND DOSE-FINDING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IPN59011 IN THE TREATMENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003948-71,0,0,0 2019-003948-71,5,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,IPSEN INNOVATION,"AN INTEGRATED PHASE I/II, MULTICENTRE, DOUBLE-BLIND, RANDOMISED, DYSPORT AND PLACEBO-CONTROLLED, DOSE ESCALATION AND DOSE-FINDING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IPN59011 IN THE TREATMENT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003948-71,0,0,0 2019-003955-13,1,,,0,0,1,0,0,0,2,0,0,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine in Participants With HIV-1 Aged 4 Weeks to <12 Years of Age and Weighing <35 kg",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003955-13,0,1,1 2019-003956-35,3,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003956-35,0,0,0 2019-003956-35,3,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc",A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02A,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003956-35,0,0,0 2019-003957-27,11,2022-05-30,2022-06-30,9,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Bayer AG,"A randomized, double-blind, parallel group, placebo-controlled, multi-center study to assess the safety and tolerability of monthly subcutaneous administrations of a low and high dose cohort of osocim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003957-27,1,0,0 2019-003957-27,11,2022-05-30,2022-06-30,9,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BAYER AG,"A randomized, double-blind, parallel group, placebo-controlled, multi-center study to assess the safety and tolerability of monthly subcutaneous administrations of a low and high dose cohort of osocim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003957-27,1,0,0 2019-003958-86,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Gilead Sciences, Inc.",Study of Females Exposed to Eleclazine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003958-86,0,0,0 2019-003962-41,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,Trial of Ondansetron as a Parkinson’s HAllucinations Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003962-41,0,0,0 2019-003964-30,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust,"Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory primary non-ANCA associated vasculit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003964-30,0,0,0 2019-003966-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC,Adjuvant hepatic arterial infusion pump chemotherapy after repeat hepatectomy for patients with recurrent colorectal liver metastases without a history of extrahepatic disease – a phase II study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003966-42,0,0,0 2019-003969-18,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients with EGF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003969-18,0,0,0 2019-003969-18,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients with EGF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003969-18,0,0,0 2019-003971-20,1,2021-05-11,2021-05-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Rigshospitalet Glostrup,An open label study to evaluate the efficacy and tolerability of erenumab in the management of persistent redness and flushing in rosacea Et åbent eksplorativt studie med henblik på at vurdere effe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003971-20,0,0,0 2019-003972-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Arnau de Vilanova - Lliria,Comparative study of cloroprocaine versus prilocaine intrathecal anestesia in major ambulatory surgery Estudio comparativo de cloroprocaína versus prilocaína en anestesia intratecal en cirugía mayo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003972-37,0,0,0 2019-003976-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP),EFFECT OF STW5 (Iberogast ®) AND STW5-II (Iberogast N®) ON TRANSIT AND TOLERANCE OF INTESTINAL GAS EFECTO DE STW5 (Iberogast®) Y STW5-II (Iberogast® N) EN EL TRANSITO Y TOLERANCIA DE GAS INTESTINAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003976-38,0,0,0 2019-003977-24,3,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc",A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003977-24,0,0,0 2019-003977-24,3,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003977-24,0,0,0 2019-003978-22,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02C ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003978-22,0,0,0 2019-003981-42,11,2021-04-13,2021-04-13,1,1,0,0,0,0,2,0,0,2,1,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003981-42,1,0,0 2019-003981-42,11,2021-04-13,2021-04-13,1,1,0,0,0,0,2,0,0,2,1,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003981-42,1,0,0 2019-003982-17,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,"SEATTLE GENETICS, INC.",A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003982-17,0,0,0 2019-003983-28,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,SEAGEN INC.,"A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classic Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma (P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003983-28,0,0,0 2019-003984-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Central Institute of Mental Health,"A phase II randomized, double-blind, active placebo-controlled parallel group trial to examine the efficacy and safety of psilocybin in treatment-resistant major depression Eine randomisierte, dopp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003984-24,0,0,0 2019-003987-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University Medical Centre Ljubljana, Department of gastroenterology",Exposure-response of golimumab during maintenance in ulcerative colitis: An exploratory Pharmacokinetics/Pharmacodynamics comparison of different dose regimens Primerjava farmakokinetike in farmako...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003987-37,0,0,0 2019-003992-21,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003992-21,0,0,0 2019-003992-21,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003992-21,0,0,0 2019-003997-25,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,"Prospective randomized study on the feasibility of allogeneic stem cell transplantation in higher-risk-myelodysplastic syndromes, performed upfront or preceded by azacitidine or conventional chemother...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003997-25,0,0,0 2019-003998-26,2,2021-10-18,2021-10-18,1,1,0,1,0,0,1,0,0,2,1,0,0,0,1,Genmab A/S,"First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1044 in subjects with malignant solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003998-26,1,0,0 2019-003999-39,1,2020-09-24,2020-09-24,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN OPEN LABEL EXTENSION TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVERE U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-003999-39,0,0,0 2019-004003-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Jessa Hospital,Implementation of pre-emptive geno- and phenotyping in 5-FU- or capecitabine-treated patients with the aim of reducing toxicity Implementatie van preemptieve geno- en fenotypering bij behandeling m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004003-12,0,0,0 2019-004007-12,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Sussex,Brain connectivity and patient reported outcomes in people with HIV (PWH) with symptoms of insomnia switching integrase inhibitor-based ART; a randomised controlled study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004007-12,0,0,0 2019-004010-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Narodowy Instytut Onkologii im. M. Skłodowskiej-Curie – Państwowy Instytut Badawczy, Oddział w Gliwicach",Assessment of tolerance and spread of the whole body at myeloablative doses in association with cladribine before allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004010-34,0,0,0 2019-004013-13,11,2021-07-13,2021-07-23,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,Pfizer Inc.,"A PHASE 3B RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED MULTI-CENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004013-13,1,0,0 2019-004013-13,11,2021-07-13,2021-07-23,5,1,0,0,0,0,3,0,0,2,1,0,0,0,1,PFIZER INC,"A PHASE 3B RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED MULTI-CENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004013-13,1,0,0 2019-004016-58,1,,,0,0,0,1,0,1,1,0,0,4,0,0,0,0,1,WPD Pharmaceuticals Sp. z o.o.,"A Phase 1, Multicenter, Open-label, Dose Escalation Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin® in Pediatric Patients with Progressive, Refractory, or Recurrent High G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004016-58,0,0,0 2019-004018-33,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Department of Psychiatry and Psychotherapy, Medical University of Vienna",Prefrontal circuits for cognitive flexibility in an extradimensional set-shifting task for humans.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004018-33,0,0,0 2019-004019-29,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Dipartimento di Medicina-DIMED, università di Padova",Medical combination therapy with retinoic acid and cabergoline in ACTH-secreting pituitary adenoma: a prospective and randomized study. Studio prospettico randomizzato multicentrico sull’efficacia ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004019-29,0,0,0 2019-004021-25,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Afimetoran in Participants with Active Systemic Lupus Erythematosus.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004021-25,0,0,0 2019-004023-20,14,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Parti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004023-20,0,0,0 2019-004023-20,14,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Parti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004023-20,0,0,0 2019-004023-20,14,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Parti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004023-20,0,0,0 2019-004025-24,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,BRIDGE trial: Phase II trial of durvalumaB and chemotheRapy Induction followed by Durvalumab and radiotherapy in larGe volumE stage III NSCLC Essai BRIDGE : Essai de phase II sur le Durvalumab et l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004025-24,0,0,0 2019-004025-24,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS - ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,BRIDGE trial: Phase II trial of durvalumaB and chemotheRapy Induction followed by Durvalumab and radiotherapy in larGe volumE stage III NSCLC Essai BRIDGE : Essai de phase II sur le Durvalumab et l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004025-24,0,0,0 2019-004034-42,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 2003 CLASS III OR IV LUPUS NEPHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004034-42,0,0,0 2019-004034-42,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 2003 CLASS III OR IV LUPUS NEPHRITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004034-42,0,0,0 2019-004039-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St Antonius Hospital,"Efficacy of Pectoral Nerve (PECS II) Block for Breast Conserving Surgery: A Prospective Randomized Controlled Trial Effectiviteit van PECSII blok voor borstsparende chirurgie: een prospectief, gera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004039-21,0,0,0 2019-004041-32,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Leicester,"The effect of Canagliflozin 300mg, in subjects without diabetes after bariatric surgery, on glucose homeostasis (The CONTROL Study): A proof-of-concept, randomised, open-label, two period crossover st...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004041-32,0,0,0 2019-004045-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Catharina Hospital Eindhoven,PredicTive value of FluoR-18 PSMA-1007 PET/CT and anti-3-[18F] FACBC PET/CT before PLND for lymph nodE staging in primary pRostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004045-33,0,0,0 2019-004046-16,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Immunocore Ltd.,A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004046-16,0,0,0 2019-004050-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,"A phase II study to determine the efficacy and safety of Vvax001, a therapeutic Semliki Forest Virus based cancer vaccine, in patients with HPV-16 induced grade 3 cervical intraepithelial neoplasia. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004050-29,0,0,0 2019-004052-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,"A phase II trial assessing Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in a pre-operative setting for resectable and untreated head and neck squamous cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004052-11,0,0,0 2019-004053-91,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Leeds,Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004053-91,0,0,0 2019-004054-28,1,,,0,0,0,0,1,0,2,0,0,3,0,0,0,0,0,Imperial College London,Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004054-28,0,0,0 2019-004055-37,1,2020-05-28,2020-05-28,1,1,0,0,0,1,2,0,0,1,1,1,1,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study of ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia Estudio en fase II, aleatorizado, doble ciego, controlado con placebo, d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004055-37,0,0,0 2019-004062-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Nekkar Lab srl,"OPEN, COMPARATIVE STUDY TO EVALUATE THE PERFORMANCE AND SAFETY OF THE MEDICAL DEVICE MARIAL® IN ASSOCIATION WITH PROTON-PUMP INHIBITORS VERSUS PPI ALONE IN PATIENTS AFFECTED BY GASTROESOPHAGEAL REFLUX...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004062-17,0,0,0 2019-004063-49,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,1,Octapharma,Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients with Chronic Immune Thrombocytopenia (ITP),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004063-49,0,1,1 2019-004066-18,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Alector Inc.,"A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004066-18,0,0,0 2019-004070-26,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,FONDAZIONE RICERCA TRASLAZIONALE (FORT),"A Phase 1/2 Study Exploring Safety, Tolerability and Efficacy of BRIgatinib in Combination With CEtuximab in Subjects With Advanced EGFR mutated or ALK or ROS1 positive Non-Small Cell Lung Cancer and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004070-26,0,0,0 2019-004073-76,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Advanced Accelerator Applications International SA,"A multicenter, open-label post authorization safety study to evaluate the effect of LysaKare® infusion on serum potassium levels in GEP-NET patients eligible for Lutathera® treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004073-76,0,0,0 2019-004073-76,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Advanced Accelerator Applications SA,"A multicenter, open-label post authorization safety study to evaluate the effect of LysaKare® infusion on serum potassium levels in GEP-NET patients eligible for Lutathera® treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004073-76,0,0,0 2019-004074-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,"A Phase II Open-Label Randomized COntrolled Pre-Surgical Feasibility Study of Antibiotic COmbinations in Early Breast Cancer Studio di Fase II, randomizzato, in aperto, controllato, pre-chirurgico ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004074-25,0,0,0 2019-004078-24,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,IDIVAL,Effect of Sarilumab on atherosclerotic disease measured by PET/CT (Positron Emission Tomography/Computed Tomography) in Rheumatoid Arthritis Efecto de Sarilumab sobre la enfermedad aterosclerótica ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004078-24,0,0,0 2019-004080-43,2,,,0,0,0,0,0,0,4,0,0,2,0,0,0,0,1,sanofi-aventis Private Co. Ltd.,Suliqua® (iGlarLixi) in Participants uncontrolled on basal insulin to Evaluate the change of time in target Range By using Continuous Glucose Monitoring Suliqua® (iGlarLixi) alkalmazása bázisinzuli...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004080-43,0,0,0 2019-004081-18,7,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Celgene Corporation,"A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004081-18,0,0,0 2019-004081-18,7,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,CELGENE CORPORATION,"A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004081-18,0,0,0 2019-004084-49,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,TAIHO ONCOLOGY INC.,A PHASE 2 STUDY OF FUTIBATINIB IN PATIENTS WITH SPECIFIC FGFR ABERRATIONS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004084-49,0,0,0 2019-004084-49,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Taiho Oncology Inc.,A PHASE 2 STUDY OF FUTIBATINIB IN PATIENTS WITH SPECIFIC FGFR ABERRATIONS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004084-49,0,0,0 2019-004085-17,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Imperial College London,Treating severe paediatric asthma; a randomised controlled trial of mepolizumab and omalizumab (TREAT trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004085-17,0,0,0 2019-004089-16,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Consorci Sanitari Integral,Comparison between mid-axillary ultrasound-guided transversus abdominis plane (TAP) block and local wound infiltration for postoperative analgesia in laparoscopic radical prostatectomy. Impact on earl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004089-16,0,0,0 2019-004090-50,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,ONCOSTELLAE S.L.,"A Phase Ib/IIa, randomized, double blind, placebo controlled, multicenter clinical trial to evaluate the safety, pharmacokinetics and efficacy of oral treatment with OST-122 in patients with moderate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004090-50,0,0,0 2019-004092-39,2,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE PHARMACOKINETICS, EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PEDIATRIC PATIENTS WITH AQP4 ANTIBODY POS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004092-39,0,0,0 2019-004095-19,1,2020-10-21,2020-10-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Laboratoires SMB S.A.,"A pharmacodynamic, randomised, single dose, cross-over study to compare the bronchodilator effect of a new formulation of Tiotropium DPI versus Spiriva® 18 μg Handihaler®",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004095-19,0,0,0 2019-004098-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CONSORZIO ONCOTECH,Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study). Studio di fase II sull’uso in prima linea di avelumab in ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004098-23,0,0,0 2019-004099-20,10,,,0,0,0,0,1,0,4,0,0,2,1,0,0,0,1,LEO Pharma A/S,Efficacy and safety comparison of brodalumab versus guselkumab in adult subjects with moderate-to-severe plaque psoriasis and inadequate response to ustekinumab.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004099-20,0,0,0 2019-004099-20,10,,,0,0,0,0,1,0,4,0,0,2,1,0,0,0,1,LEO PHARMA A/S,Efficacy and safety comparison of brodalumab versus guselkumab in adult subjects with moderate-to-severe plaque psoriasis and inadequate response to ustekinumab.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004099-20,0,0,0 2019-004100-35,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,GBG Forschungs GmbH,"Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004100-35,0,0,0 2019-004101-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sint Maartenskliniek,"INDIGO: Comparing pharmacokinetic parameters of golimumab 50 mg and golimumab 100 mg with a prolonged dose interval in patients with a rheumatic disease, a within-subject controlled study’ Het besc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004101-27,0,0,0 2019-004103-12,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Takeda Development Center Americas, Inc. (Takeda)","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Persistent/Chronic Primary Immune Thrombocytopenia Estudio de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004103-12,0,0,0 2019-004103-12,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"MILLENNIUM PHARMACEUTICALS, INC.","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Persistent/Chronic Primary Immune Thrombocytopenia Estudio de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004103-12,0,0,0 2019-004103-12,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Millennium Pharmaceuticals, Inc. (Takeda)","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Persistent/Chronic Primary Immune Thrombocytopenia Estudio de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004103-12,0,0,0 2019-004108-37,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Celgene Corporation,"A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects with Active Ankylosing Spondylitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004108-37,0,0,0 2019-004109-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Daniel Podzamczer Palter,HIV-1 RNA decay in semen and rectum and changes in HIV reservoir in rectal tissue in ART-naïve HIV+ men treated with dolutegravir plus lamivudine compared to Bictegravir/FTC/TAF (“DOLLARS study”) D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004109-28,0,0,0 2019-004112-60,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004112-60,0,0,0 2019-004113-13,1,2022-07-08,2022-07-08,1,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Merz Pharmaceuticals GmbH,"A prospective, randomized, double-blind, placebo-controlled, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the simultaneous treatment of upp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004113-13,0,0,0 2019-004118-33,1,2022-03-25,2022-03-25,1,0,0,0,0,0,3,0,0,1,0,0,0,0,0,Universität Witten/Herdecke,"A multi-centre randomised, double-blind, placebo-controlled trial of pre-hospital treatment with tranexamic acid for severely injured patients at risk of acute traumatic coagulopathy. Eine multizen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004118-33,0,0,0 2019-004119-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Instituto Palacios,EVALUATION OF THE ACCEPTABILITY AND EFFICACY OF 10 MICROGRAMS OF ESTRADIOL VAGINAL TABLETS VS PROMESTRIENE VAGINAL CREAM Evaluación de la aceptabilidad y eficacia de 10 microgramos de estradiol tab...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004119-30,0,0,0 2019-004121-25,1,2020-12-10,2020-12-10,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,A single-blinded multicenter randomized study comparing intubating conditions after either rocuronium 0.6 mg/kg or remifentanil 2 µg/kg in elderly patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004121-25,0,0,0 2019-004125-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UMCG,Reduced Anticoagulation Targets in Extracorporeal life support,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004125-24,0,0,0 2019-004126-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Leipzig,Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 inhibitors Cabozantinib-Behandlung in einer Phase-II-Studie für Patienten mit hepatoze...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004126-13,0,0,0 2019-004127-21,3,2022-01-10,2022-01-10,2,0,0,0,0,1,2,0,0,1,1,0,0,0,1,Oncopeptides AB,"A randomized, two-period, cross-over, Phase 2 study, comparing the pharmacokinetics, and assessing safety and tolerability of peripheral and central intravenous administration of melflufen in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004127-21,0,0,0 2019-004131-24,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,ACTELION Pharmaceuticals Ltd.,"A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in inoper...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004131-24,0,0,0 2019-004131-24,9,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,ACTELION PHARMACEUTICALS LTD,"A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in inoper...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004131-24,0,0,0 2019-004132-37,6,2022-09-08,2022-09-08,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,SamChunDang Pharm. Co. Ltd.,"A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity between SCD411 and Eylea® in Subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004132-37,1,0,0 2019-004132-37,6,2022-09-08,2022-09-08,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Sam Chun Dang Pharm. Co. Ltd,"A Phase III Randomized, Double-Masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity between SCD411 and Eylea® in Subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004132-37,1,0,0 2019-004134-42,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Sellas Life Sciences,"A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004134-42,0,0,0 2019-004134-42,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Sellas Life Sciences Group, Inc","A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004134-42,0,0,0 2019-004134-42,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Sellas Life Sciences Group Inc,"A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004134-42,0,0,0 2019-004138-41,1,2020-11-20,2020-11-20,1,1,0,0,0,0,4,0,0,1,1,1,1,0,1,Sanofi-Aventis Groupe,"A phase IV randomized, double-blind, 3-treatment, 3-period, 6-sequence crossover clinical trial to assess the efficacy and safety of hyoscine butylbromide co-administered with ibuprofen compared to pl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004138-41,0,0,0 2019-004139-21,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University College London,A randomised prospective open label pilot trial comparing mycophenolate mofetil (MMF) with no immunosuppression in adults with limited cutaneous systemic sclerosis MINIMISE-Pilot (Mycophenolate in lim...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004139-21,0,0,0 2019-004141-32,3,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Active-Controlled, Efficacy Assessor-Blinded Study to Evaluate Pharmacokinetics, Safety and Efficacy of Risankizumab in Patients from 6 to Less than 18 Years of Age with Moderate to Seve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004141-32,0,1,0 2019-004144-29,1,2022-03-18,2022-03-18,1,0,0,0,0,0,4,0,1,1,0,0,0,0,0,Oslo University Hospital,"Methoxyflurane and fentanyl in hypovolemia induced by lower body negative pressure in healthy volunteers; A randomized, placebo-controlled crossover study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004144-29,0,0,0 2019-004145-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma S.A.S,"A one-year, single-arm, open-label, multicenter study assessing the effect of brolucizumab on disease control in adult patients with suboptimal anatomically controlled neovascular age-related macular ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004145-33,0,0,0 2019-004148-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medisch Centrum Dept. of Pulmonology,The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004148-31,0,0,0 2019-004152-10,1,2021-09-03,2021-09-03,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,Evaluating the Short-Term Renal and Systemic Effects of SGLT2 Inhibition in Non-Diabetic Patients at Risk of Accelerated GFR Decline Because of Glomerular Hyperfiltration: a sequential OFF-ON-OFF Stud...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004152-10,0,0,0 2019-004153-93,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,German Paediatric Oncology Group,INTERNATIONAL EURO EWING TRIAL FOR TREATMENT OPTIMISATION IN PATIENTS WITH EWING SARCOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004153-93,0,0,0 2019-004154-28,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Sanofi-Aventis Recherche & Développement,"A Phase 1b/2 study to evaluate the safety, pharmacokinetics, and preliminary efficacy of isatuximab (SAR650984) in patients awaiting kidney transplantation Estudio de fase 1b/2 para evaluar la segu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004154-28,0,0,0 2019-004155-37,3,2021-08-23,2021-08-23,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Aptabio Therapeutics, Inc","A randomized, Placebo-controlled, Double-blinded, Multi-centre, Phase 2 Study to Assess Safety, Tolerability and Renal Effects of APX-115 in Subjects with Type 2 Diabetes and Nephropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004155-37,1,0,0 2019-004163-47,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,UCB Biopharma SRL,"A Multicenter, Open-Label Extension Study to Asses the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004163-47,0,0,0 2019-004167-45,12,2020-10-15,2021-10-15,8,1,0,0,0,1,2,0,0,2,1,0,0,0,2,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004167-45,1,0,0 2019-004167-45,12,2020-10-15,2021-10-15,8,1,0,0,0,1,2,0,0,2,1,0,0,0,2,,"A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004167-45,1,0,0 2019-004167-45,12,2020-10-15,2021-10-15,8,1,0,0,0,1,2,0,0,2,1,0,0,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004167-45,1,0,0 2019-004167-45,12,2020-10-15,2021-10-15,8,1,0,0,0,1,2,0,0,2,1,0,0,0,2,Boehringer Ingelheim Finland Ky,"A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004167-45,1,0,0 2019-004167-45,12,2020-10-15,2021-10-15,8,1,0,0,0,1,2,0,0,2,1,0,0,0,2,Boehringer Ingelheim B.V.,"A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004167-45,1,0,0 2019-004167-45,12,2020-10-15,2021-10-15,8,1,0,0,0,1,2,0,0,2,1,0,0,0,2,Boehringer Ingelheim Limited,"A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004167-45,1,0,0 2019-004167-45,12,2020-10-15,2021-10-15,8,1,0,0,0,1,2,0,0,2,1,0,0,0,2,Boehringer Ingelheim,"A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004167-45,1,0,0 2019-004167-45,12,2020-10-15,2021-10-15,8,1,0,0,0,1,2,0,0,2,1,0,0,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004167-45,1,0,0 2019-004169-42,10,2021-07-23,2021-07-23,8,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Bayer AG,"Randomized, double-blind, parallel group, Phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004169-42,1,0,0 2019-004171-39,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Incyte Corporation,"An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004171-39,0,0,0 2019-004177-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospitals Leuven,Investigating the role of JAK inhibition in achieving and maintaining disease remission in early psoriatic arthritis (PsA).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004177-35,0,0,0 2019-004178-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amphia,Defining long-term macrolide maintenance therapy in COPD: a single center randomized controlled trial: Het nader definieren van langdurig macrolide onderhoudstherapie bij COPD door middel van een g...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004178-24,0,0,0 2019-004179-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Västra Götalandsregionen,Effects of tofacitinib vs methotrexate on clinical and molecular disease activity markers in joints and lungs in early rheumatoid arthritis Effekter av tofacitinib jämfört med metotrexate på klinis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004179-38,0,0,0 2019-004183-21,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Iperboreal Pharma Srl,"A Study to Evaluate the EffIcacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004183-21,0,0,0 2019-004186-40,4,2021-07-19,2021-07-19,3,1,0,0,0,0,2,0,2,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Double-Blinded, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of BMS-986259 in Stabilized Patients Hospitalized for Acute Decompensated Heart Failure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004186-40,1,0,0 2019-004188-35,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,CENTRO CARDIOLOGICO SPA FONDAZIONE MONZINO,Time-dependent activity of N-acetylcysteine on plasma antioxidant capacity in subjects with redox unbalance-Studio CAPITAL Effetto tempo-dipendente dell’N-acetilcisteina sulla capacità antiossidant...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004188-35,0,0,0 2019-004190-46,1,2020-06-18,2020-06-18,1,0,0,0,0,1,3,0,0,1,1,1,1,0,1,AstraZeneca AB,"A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Number of Vaso-Occlusive Crises in Paediatric Patients Aged...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004190-46,0,0,0 2019-004194-95,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Celgene Corporation,"A Phase 2, multicenter, open-label, multi-cohort study to assess safety and efficacy of CC-90011 in combination with nivolumab in subjects with advanced cancers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004194-95,0,0,0 2019-004194-95,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,CELGENE CORPORATION,"A Phase 2, multicenter, open-label, multi-cohort study to assess safety and efficacy of CC-90011 in combination with nivolumab in subjects with advanced cancers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004194-95,0,0,0 2019-004195-19,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre de Recherche et d’Etudes sur la Pathologie Tropicale et le Sida (CREPATS),A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma viremia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004195-19,0,0,0 2019-004195-19,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre de Recherche et d’Etudes sur la Pathologie Tropical et le Sida (CREPATS),A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma viremia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004195-19,0,0,0 2019-004196-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,"A randomized, phase II study comparing the sequences of regorafenib and trifluridine/tipiracil, after failure of standard therapies in patients with metastatic colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004196-39,0,0,0 2019-004200-35,1,,,0,1,0,1,0,0,1,0,0,1,1,1,0,1,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE Ib/II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF VENETOCLAX IN COMBINATION WITH TRASTUZUMAB EMTANSI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004200-35,0,0,0 2019-004207-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Vejle Hospital,Tocotrienol and Bevacizumab in metastatic colorectal cancer. A randomized phase II marker trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004207-13,0,0,0 2019-004208-37,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,UZ Leuven,Drug repurposing - Statins as microbiota modulating agents in ulcerative colitis Hergebruik van geneesmiddelen - Statines als microbiota-modulerende middelen bij colitis ulcerosa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004208-37,0,0,0 2019-004210-33,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Sigilon Therapeutics, Inc.","A Phase 1/2 Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of SIG-001 in Adult Patients with Severe or Moderately-Severe Haemophilia A Without Inhibitors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004210-33,0,0,0 2019-004212-64,4,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Immunocore Ltd,"An Open-label Study Evaluating the Safety, Antiviral Activity, and Pharmacokinetics of IMC-I109V in HLA-A*02:01 Positive Patients with Chronic HBV who are Non-Cirrhotic, Hepatitis B e Antigen-negativ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004212-64,0,0,0 2019-004213-13,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Sapience Therapeutics, Inc.",A phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004213-13,0,0,0 2019-004219-29,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Amsterdam UMC,"“Personalized AZithromycin/metronidAZole, in combination with standard induction therapy, to achieve a fecal microbiome community structure and metagenome changes associated with sustained remission i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004219-29,0,0,0 2019-004222-22,1,2021-09-02,2021-09-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Radboud University Medical Center,Adjustment of insulin Degludec to Reduce post-Exercise (nocturnal) hypoglycaeMia in people with diabetes – the ADREM study Aanpassing van insuline Degludec om (nachtelijke) hypoglykemie na inspanni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004222-22,0,0,0 2019-004223-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Charité Universitätsmedizin Berlin,"Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004223-20,0,0,0 2019-004224-38,6,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in Pe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004224-38,0,1,0 2019-004225-24,6,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004225-24,0,1,0 2019-004226-16,6,2022-07-26,2022-07-27,3,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Mitsubishi Tanabe Development America Inc.,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X-L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004226-16,1,0,0 2019-004226-16,6,2022-07-26,2022-07-27,3,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Mitsubishi Tanabe Pharma Development America (MTDA), Inc.","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X-L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004226-16,1,0,0 2019-004230-42,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboudumc,"Dose reduction of the new generation biologics (IL17 and IL23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio study Dosis reductie van de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004230-42,0,0,0 2019-004231-23,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Queen Mary University of London,Phase IIb randomised clinical trial repurposing ATRA as a stromal targeting agent in a novel drug combination for pancreatic cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004231-23,0,0,0 2019-004233-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Graz,INDUCING REMISSION IN MELANOMA PATIENTS WITH CHECKPOINT INHIBITOR THERAPY USING FECAL MICROBIOTA TRANSPLANTATION.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004233-16,0,0,0 2019-004234-42,3,2020-06-24,2020-06-24,3,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Novo Nordisk A/S,Effect and safety of two different dose-escalation regimens for once-weekly semaglutide s.c. in subjects with type 2 diabetes mellitus previously treated with GLP-1 RAs,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004234-42,0,0,0 2019-004235-23,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Abbvie Deutschland GmbH & Co. KG,An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004235-23,0,0,0 2019-004235-23,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004235-23,0,0,0 2019-004240-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FUNDACIÓN PARA LA INVESTIGACION BIOMEDICA HU PUERTA DE HIERRO MAJADAHONDA,"Phase IV, unicentric, multiple dose, clinical trial, with a single treatment arm to evaluate bronchopulmonary penetration of isavuconazole in pulmonary transplant recipients (PBISA01) ENSAYO CLÍNIC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004240-30,0,0,0 2019-004241-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI,Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression Effica...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004241-32,0,0,0 2019-004246-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma GmbH,"A 28-week, randomized, double-blind, active-controlled, multicenter study to evaluate the efficacy of subcutaneously administered secukinumab compared to ustekinumab in adult patients with psoriatic a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004246-15,0,0,0 2019-004250-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IRCCS ISTITUTO CLINICO HUMANITAS,EXPLORING THE EFFECTS OF IL-23 INHIBITION BY RISANKIZUMAB ON PSORIASIS AUTOIMMUNITY. ESPLORARE GLI EFFETTI DELL'INIBIZIONE IL-23 DI RISANKIZUMAB SULL'AUTOMUNITÀ DELLA PSORIASI.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004250-28,0,0,0 2019-004254-28,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscras...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004254-28,0,0,0 2019-004254-28,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Caelum Biosciences, Inc.","A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscras...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004254-28,0,0,0 2019-004255-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset,"Cesar - an open, randomized controlled phase II study, comparing Naltrexon and Fluoxetin treating Compulsive Sexual Behavior Disorder. Cesar - en öppen randomiserad kontrollerad fas II-studie som j...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004255-36,0,0,0 2019-004256-11,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Mitsubishi Tanabe Development America Inc.,"A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004256-11,0,0,0 2019-004256-11,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)","A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004256-11,0,0,0 2019-004259-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Rigshospitalet,Ebastine in combination with docetaxel as a treatment for castration-resistant metastatic prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004259-35,0,0,0 2019-004264-21,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase II, 6-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial with a quetiapine arm to evaluate the efficacy, tolerability and safety of oral BI 135...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004264-21,0,0,0 2019-004264-21,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A Phase II, 6-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial with a quetiapine arm to evaluate the efficacy, tolerability and safety of oral BI 135...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004264-21,0,0,0 2019-004266-18,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"bluebird bio, Inc.",Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004266-18,0,0,0 2019-004281-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Odense University Hospital,Clonidine for Tourniquet-related Pain in Children (CLOTCH) -Study: A Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004281-18,0,0,0 2019-004282-41,1,2020-11-04,2020-11-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"CeleCor Therapeutics, Inc.",A Phase-2 open label study to assess the pharmacodynamic and pharmacokinetic properties of a single subcutaneous injection of RUC-4 in patients with ST-elevation myocardial infarction presenting to ca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004282-41,0,0,0 2019-004284-51,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"Amsterdam UMC, VU University Medical Center",An exploratory study of durvalumab (MEDI4736) uptake during concurrent chemoradiotherapy in stage III NSCLC patients using 89Zr-labeled durvalumab PET,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004284-51,0,0,0 2019-004290-84,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,BarcelonaBeta Brain Research Center,Characterization of cerebral tau aggregates with 18F-RO6958948 PET in the ALFA population. Caracterización en la población ALFA de agregados cerebrales tau con PET 18F-RO6958948,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004290-84,0,0,0 2019-004292-40,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Anesthesia and Intensive Care Medicine, Nordsjællands hospital","Goal directed fluid removal with furosemide in intensive care patients with fluid overload - A randomised, blinded, placebo-controlled trial (GODIF).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004292-40,0,0,0 2019-004293-25,8,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Galderma S.A.,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004293-25,0,0,0 2019-004293-25,8,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Galderma SA,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004293-25,0,0,0 2019-004294-13,11,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Galderma SA,"A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004294-13,0,0,0 2019-004294-13,11,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Galderma S.A.,"A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004294-13,0,0,0 2019-004295-18,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,Aarhus University Hospital,Fibrinogen and platelets in patients with acute myeloid leukaemia and thrombocytopenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004295-18,0,0,0 2019-004297-26,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Institut National de la Santé et de la Recherche Médicale (INSERM),Prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004297-26,0,0,0 2019-004297-26,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,INSERM-ANRS,Prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004297-26,0,0,0 2019-004297-26,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,INSERM The Institut national de la santé et de la recherche médicale,Prophylactic treatment of the ductus arteriosus in preterm infants by acetaminophen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004297-26,0,0,0 2019-004300-34,1,2021-09-16,2021-09-16,1,1,1,0,0,0,3,0,0,1,0,0,1,0,1,"Dermira, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB WHEN USED IN COMBINATION WITH TOPICAL CORTICOSTEROID TREATMENT IN PATIENTS WITH MODERATE-TO-SEV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004300-34,0,0,0 2019-004301-28,1,2022-06-22,2022-06-22,1,0,1,0,0,0,3,0,0,1,0,0,0,0,1,Dermira Inc.,"AN OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADOLESCENT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004301-28,0,0,0 2019-004302-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Västra Götalandsregionen, Sahlgrenska University hospital",A randomized controlled open-label multi-center study to assess the efficacy of Tocilizumab in treatment of chronic active antibody-mediated rejection in kidney transplant recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004302-10,0,0,0 2019-004303-12,1,2022-07-08,2022-07-08,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,"University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro","The effects of SGLT2-inhibition in patients with type 2 diabetes and preserved kidney function on renal hemodynamics, kidney function and vasoactive hormones Effekten af SGLT2-hæmning hos patienter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004303-12,0,0,0 2019-004305-26,1,2021-01-28,2021-01-28,1,0,0,0,0,0,2,0,1,1,0,0,1,0,1,Follicum AB,"A randomized, double-blind, vehicle-controlled, dose-finding, multi-center, phase 2a trial of FOL-005 topical formulations to investigate hair growth potential and safety in healthy male volunteers wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004305-26,0,0,0 2019-004308-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut National de la Santé et de la Recherche Médicale (INSERM),Penetration of the innovative antibiotic gepotidacin into prostate and tonsillar tissue. Pénétration de l'antibiotique innovant gépotidacine dans le tissu prostatique et amygdalien,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004308-37,0,0,0 2019-004309-28,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,The Medicines Evaluation Unit (MEU) Ltd. (Investigator led study),"Application of Chronotherapy to Asthma: Towards the Personalisation of Asthma Management. A randomised, mechanistic study of 400mcg Clenil® Modulite® (Beclometasone dipropionate) in the morning ver...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004309-28,0,0,0 2019-004310-33,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Dr. Antonio Pérez Martínez,"A Phase I Trial of Memory T Cells Expressing an ANTI-NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults with Advanced Sarcoma Ensayo fase I de células T de memoria que expre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004310-33,0,0,0 2019-004313-13,4,2022-07-24,2022-07-24,3,0,0,0,0,0,3,0,1,2,0,0,0,0,1,Pfizer Inc.,"A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY PARTICIPANTS ≥10 TO <26 YEARS OF AGE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004313-13,1,0,0 2019-004314-34,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Julie Gehl,PHASE II INVESTIGATION OF CALCIUM ELECTROPORATION AS A TREATMENT FOR CUTANEOUS AND SUBCUTANEOUS MALIGNANT TUMOURS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004314-34,0,0,0 2019-004315-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Julie Gehl,PHASE II INVESTIGATION OF THE HISTOPATHOLOGIC EFFECT OF CALCIUM ELECTROPORATION ON CANCER IN THE SKIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004315-31,0,0,0 2019-004323-20,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,BioNTech Cell & Gene Therapies GmbH,"Phase 1/2a, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-pos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004323-20,0,0,0 2019-004326-19,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Pragmatic management of progressive disease in idiopathic pulmonary fibrosis: a randomized trial Prise en charge pragmatique de la fibrose pulmonaire idiopathique en progression : essai randomis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004326-19,0,0,0 2019-004328-39,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica_FCRB,"Hemodynamic profile of terlipressin and octreotide in patients with cirrhosis and portal hypertension. A randomised, single blinded clinical trial. Perfil hemodinámico de la terlipresina y el octre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004328-39,0,0,0 2019-004332-36,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Starpharma Pty Ltd,"A Phase 1/2 Modular, Multi-Arm Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of DTX-SPL8783 (DEP docetaxel/DEP-DTX) in Combination with Anti-Cancer Treatments, in Patients with A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004332-36,0,0,0 2019-004336-31,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004336-31,0,0,0 2019-004336-31,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004336-31,0,0,0 2019-004337-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOVON Foundation,"REtreatment with VEnetoclax and Acalabrutinib after venetoclax Limited duration (REVEAL) A prospective, multicenter, phase-II trial of venetoclax plus acalabrutinib in patients who have relapsed afte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004337-17,0,0,0 2019-004340-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004340-30,0,0,0 2019-004343-76,1,2021-05-18,2021-05-18,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Rigshospitalet,"A single-blinded multicenter randomized interventional study of rocuronium 0.3 mg/kg, and 0.9 mg/kg comparing onset time, duration of action and effect on intubating conditions in elderly patients (≥ ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004343-76,0,0,0 2019-004345-32,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Anavex Germany GmbH,"A Double-Blind, Randomised, Placebo-Controlled, Safety and Efficacy Study of ANAVEX2-73 in Patients with Rett Syndrome",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004345-32,0,0,0 2019-004349-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska University Hospital,Early mental response to hormonal treatment in transgender men Snabba mentala effekter av könskonträr hormonbehandling hos transmän,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004349-34,0,0,0 2019-004357-86,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC),A Phase II open-label multicentreTrial of first-line Oxaliplatin-based chemotherapy combined with ABP 980 (Biosimilar Trastuzumab) in patients with advanced Gastric or gastro-Esophageal juncTion (GEJ)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004357-86,0,0,0 2019-004359-35,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,Induction of Cure in Early Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004359-35,0,0,0 2019-004360-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (Ciberned),MULTI-TECHNICAL TEST ON THE USE OF COMBINED THERAPY OF THEMIN AND BIOTINE IN PATIENTS WITH HUNTINGTON'S DISEASE ENSAYO MULTICÉNTRICO SOBRE EL USO DE TERAPIA COMBINADA DE TIAMINA Y BIOTINA EN PACIEN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004360-22,0,0,0 2019-004361-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU de la Réunion,Apport du TEP-scanner pour l’évaluation préopératoire des lésions d’endométriose symptomatique.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004361-40,0,0,0 2019-004364-21,1,2022-03-21,2022-03-21,1,0,0,0,0,0,3,0,0,1,0,0,0,0,1,bioeq GmbH,"A Randomised, Double-blind, Parallel-group, Phase 3 Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara in Patients with Moderate-to-Seve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004364-21,0,0,0 2019-004365-41,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,"MITO27: Prospective, non randomized, Phase II study on MK-3475 in recurrent, platinum-resistant, CPS >1 positive ovarian, Fallopian tube and primary peritoneal cancer patients MITO27: Studio di fas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004365-41,0,0,0 2019-004366-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GERCOR,MAZEPPA: Phase II PRODIGE-GERCOR study to evaluate MAintenance therapy with olaparib or selumetinib plus durvalumab according to BRCAness and KRAS somatic status Personalized in metastatic Pancreatic ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004366-18,0,0,0 2019-004368-22,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Biogen Idec Research Limited,"Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004368-22,0,0,0 2019-004368-22,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BIOGEN IDEC RESEARCH LIMITED,"Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 2...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004368-22,0,0,0 2019-004369-42,6,2021-02-12,2022-06-06,5,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Fresenius Kabi SwissBioSim GmbH,"A Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Two-Arm Study to Evaluate the Efficacy, Safety and Immunogenicity of MSB11456 Compared to European Union approved RoActemra® in Patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004369-42,1,0,0 2019-004370-26,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Hull University Teaching Hospitals NHS Trust,"Exploratory single centre prospective 12-week comparative double blinded randomised trial of the impact of high-dose iron isomaltoside vs iron carboxymaltose on measures of FGF23, bone metabolism and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004370-26,0,0,0 2019-004374-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA UDINE,Thoracic duct identification with Indocyanine green fluorescence during minimally invasive esophagectomy with patient in prone position Identificazione del dotto toracico mediante l'utilizzo del ve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004374-25,0,0,0 2019-004375-40,4,2021-12-06,2021-12-06,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Octapharma Pharmazeutika Produktionsges.m.b.H.,"Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia (""PRO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004375-40,1,0,0 2019-004375-40,4,2021-12-06,2021-12-06,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H.,"Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia (""PRO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004375-40,1,0,0 2019-004378-24,7,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","Pediatric Options for Migraine Relief: A randomized, double-blind, placebo-controlled study of lasmiditan for acute treatment of migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004378-24,0,0,0 2019-004378-24,7,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Eli Lilly and Company,"Pediatric Options for Migraine Relief: A randomized, double-blind, placebo-controlled study of lasmiditan for acute treatment of migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004378-24,0,0,0 2019-004379-38,7,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Eli Lilly and Company,"A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004379-38,0,0,0 2019-004379-38,7,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004379-38,0,0,0 2019-004380-40,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination with Subcutaneous Nivolumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004380-40,0,0,0 2019-004380-40,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,A Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab Monotherapy and in Combination with Subcutaneous Nivolumab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004380-40,0,0,0 2019-004388-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-based Chemotherapy in Pleural and Malignant Peritoneal MESOthelioma Patie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004388-37,0,0,0 2019-004391-19,1,2022-08-05,2022-08-05,1,0,0,0,0,1,2,0,0,1,0,0,0,0,1,Allakos Inc.,"A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AK002 in Adult and Adolescent Patients with Active Eosinophilic Esophagitis Een ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004391-19,0,0,0 2019-004394-10,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Genzyme Corporation,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004394-10,0,0,0 2019-004396-38,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,IELSG - International Extranodal Lymphoma Study Group,Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004396-38,0,0,0 2019-004396-38,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,IELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP,Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004396-38,0,0,0 2019-004397-26,1,2021-09-06,2021-09-06,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,"Department of Oncology, Herlev & Gentofte Hospital",FOLFOX + Immunotherapy with intrahepatic administration of oxaliplatin for patients with multiple non-resectable liver metastasis from colorectal cancer. FOLFOX + Immunterapi med oxaliplatin intrah...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004397-26,0,0,0 2019-004400-35,1,2022-06-27,2022-06-27,1,0,0,0,0,1,2,0,0,1,0,0,0,0,0,Oslo University Hospital,The ReSScue trial. Aiming to Reduce disease-related gastro-intestinal symptoms in patients with Systemic Sclerosis by repeat intestinal infusions of Anaerobic Cultivated Human Intestinal Microbiome (A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004400-35,0,0,0 2019-004401-27,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Oslo University Hospital, Department of Hematology",The REMNANT (RElapse from Mrd Negativity As iNdication for Treatment) study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004401-27,0,0,0 2019-004402-10,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Fecal transplantation to Eradicate Colonizing Emergent Superbugs,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004402-10,0,0,0 2019-004403-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS,Phase II multicenter study of talimogene laherparepvec in classic or endemic Kaposi sarcoma Kapvec Study Essai clinique de phase II multicentrique évaluant le talimogene laherparepvec dans la mala...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004403-12,0,0,0 2019-004417-13,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,CHU de Bordeaux,PROSPECTIVE RANDOMIZED CLINICAL TRIAL OF EARLY OXYBUTININ TREATMENT FOR BOYS WITH POSTERIOR URETHRAL VALVES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004417-13,0,0,0 2019-004418-32,4,2022-01-28,2022-02-03,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,DAIICHI SANKYO INC.,"A MULTI-CENTER, OPEN-LABEL, PHASE 2 STUDY TO EVALUATE SAFETY AND EFFICACY OF U3-1402 IN SUBJECTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER (CRC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004418-32,1,0,0 2019-004418-32,4,2022-01-28,2022-02-03,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"DAIICHI SANKYO, INC","A MULTI-CENTER, OPEN-LABEL, PHASE 2 STUDY TO EVALUATE SAFETY AND EFFICACY OF U3-1402 IN SUBJECTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER (CRC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004418-32,1,0,0 2019-004426-24,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA,Deflazacort TREATment in LMNA related congenital muscular dystrophy: study of clinical effectiveness and search for reliable biomarkers. Deflazacort TRATTAMENTO nella distrofia muscolare congenita ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004426-24,0,0,0 2019-004427-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Luis Puente Maestu,"PHASE IV, SINGLE-CENTER, DOUBLE BLIND, RANDOMIZED, CROSSOVER, PLACEBO-CONTROLLED STUDY, TO INVESTIGATE THE EFFECT OF DUAL BRONCHODILATION WITH UMECLIDINIUM VILANTEROL ON PATIENTS WITH COPD, HYPERINFLA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004427-20,0,0,0 2019-004429-26,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,PRZEDSIEBIORSTWO FARMACEUTYCZNE LEK-AM SPÓŁKA Z OGRANICZONA ODPOWIEDZIALNOSCIA,"A multicentre, randomized, open-label, cross-over equivalence study to compare the pharmacodynamic properties, safety, and tolerability of a new combination dry powder of fluticasone propionate and sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004429-26,0,0,0 2019-004430-42,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,GWT-TUD GmbH,"Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004430-42,0,0,0 2019-004431-23,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"AN OPEN-LABEL, MULTI-CENTER, ROLL-OVER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004431-23,0,0,0 2019-004431-23,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"AN OPEN-LABEL, MULTI-CENTER, ROLL-OVER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004431-23,0,0,0 2019-004431-23,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F Hoffmann-La Roche Ltd,"AN OPEN-LABEL, MULTI-CENTER, ROLL-OVER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004431-23,0,0,0 2019-004433-17,11,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,MRC Clinical Trials Unit at UCL,"Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004433-17,0,0,0 2019-004433-17,11,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,UNIVERSITY COLLEGE LONDON,"Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004433-17,0,0,0 2019-004433-17,11,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,MRC CTU at UCL,"Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004433-17,0,0,0 2019-004433-17,11,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,Medical Research Council Clinical Trials Unit at University College London,"Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004433-17,0,0,0 2019-004433-17,11,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,0,MRC Clinical Trials Unit at University College London (UCL),"Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004433-17,0,0,0 2019-004434-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Flemming Pociot,"Fenofibrate as an Early Treatment Option in Type 1 Diabetes: A randomized, double-blind, placebo-controlled, trial to evaluate antidiabetic effects of Fenofibrate in patient with newly onset type 1 di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004434-41,0,0,0 2019-004435-23,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,VIIV HEALTHCARE UK LIMITED,"A Phase IIb, randomized, partially blind, active controlled, dose-range finding study of GSK3640254 compared to a reference arm of dolutegravir, each in combination with nucleoside reverse transcripta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004435-23,0,0,0 2019-004435-23,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ViiV Healthcare UK Limited,"A Phase IIb, randomized, partially blind, active controlled, dose-range finding study of GSK3640254 compared to a reference arm of dolutegravir, each in combination with nucleoside reverse transcripta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004435-23,0,0,0 2019-004438-40,1,2021-11-17,2021-11-17,1,1,0,0,0,0,2,0,0,1,1,1,0,0,0,"Department of Oncology, Herlev & Gentofte Hospital","Phase 2 study in pretreated patients with advanced pancreatic cancer to assess efficacy of ipilimumab, nivolumab and tocilizumab in combination with radiation. Behandling med ipilimumab, nivolumab ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004438-40,0,0,0 2019-004440-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Intra-Cellular Therapies, Inc. (ITI)","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients with Major Depressive Episodes As...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004440-29,0,0,0 2019-004441-33,8,,,0,0,1,0,0,0,2,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004441-33,0,1,0 2019-004441-33,8,,,0,0,1,0,0,0,2,0,0,2,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004441-33,0,1,0 2019-004441-33,8,,,0,0,1,0,0,0,2,0,0,2,0,0,0,0,1,Merck Sharp & Dohme Corp.,"An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004441-33,0,1,0 2019-004447-80,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro","The effects of SGLT2-inhibition in patients with type 2 diabetes and chronic kidney disease on renal hemodynamics, kidney function and vasoactive hormones Effekten af SGLT2-hæmning hos patienter me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004447-80,0,0,0 2019-004451-37,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004451-37,0,0,0 2019-004451-37,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,PFIZER INC,"Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004451-37,0,0,0 2019-004452-11,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novo Nordisk A/S,Effect of semaglutide 2.4 mg once weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004452-11,0,0,0 2019-004455-36,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,CHU DE POITIERS,Evaluation of the effect of Atomoxetine on impulsive state of High impulsive Tourette’s patients.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004455-36,0,0,0 2019-004457-92,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,PhaseBio Pharmaceuticals Inc.,"A Phase 3, Multicenter, Open-Label, Single-Arm Study of PB2452 in Ticagrelor-Treated Patients with Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004457-92,0,0,0 2019-004457-92,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"PhaseBio Pharmaceuticals Inc., together w/its operational rep. SFJ Pharmaceuticals X, Ltd. c/o SFJ Pharmaceuticals, Inc.","A Phase 3, Multicenter, Open-Label, Single-Arm Study of PB2452 in Ticagrelor-Treated Patients with Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004457-92,0,0,0 2019-004458-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rigshospitalet,Optimizing the fertility potential of bilateral cryptorchidism by treatment with adjuvant kryptocur. Optimering af fertilitetspotentialet ved bilateral kryptorkisme med supplerende kryptocur behand...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004458-27,0,0,0 2019-004459-35,1,,,0,0,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc,A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004459-35,0,1,1 2019-004460-22,1,,,0,0,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc,Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004460-22,0,1,1 2019-004461-41,1,,,0,1,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc,Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004461-41,0,1,1 2019-004462-18,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Uppsala University Hospital,MESENCHYMAL STROMAL CELL THERAPY FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME Validation of Mechanistic Pathways and Clinical Efficacy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004462-18,0,0,0 2019-004463-44,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Saint Pierre,Intratympanic injection of N-acetylcysteine for prevention of Cisplatine-induced ototoxicity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004463-44,0,0,0 2019-004467-50,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University Clinic of Nephrology and Hypertension, Regional Hospital Holstebro","The effects of SGLT2-inhibition in patients with non-diabetic chronic kidney disease on renal hemodynamics, kidney function and vasoactive hormones Effekten af SGLT2-hæmning hos patienter med non-d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004467-50,0,0,0 2019-004468-23,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,"St George's, University of London",Comparison of abatacept with tumor necrosis factor inhibitors in the treatment of rheumatoid arthritis pain: A phase IV trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004468-23,0,0,0 2019-004469-41,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Protagonist Therapeutics, Inc.","A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Oral PN-943 in Subjects with Moderate to Severe Active Ulcerative Coli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004469-41,0,0,0 2019-004469-41,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Protagonist Therapeutics, Inc","A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Oral PN-943 in Subjects with Moderate to Severe Active Ulcerative Coli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004469-41,0,0,0 2019-004471-39,4,2022-04-06,2022-04-06,2,1,0,0,0,1,2,0,0,2,1,0,0,0,1,IMARA Inc.,A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004471-39,1,0,0 2019-004471-39,4,2022-04-06,2022-04-06,2,1,0,0,0,1,2,0,0,2,1,0,0,0,1,"IMARA, Inc.",A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004471-39,1,0,0 2019-004474-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,"Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL). A randomized, open label, phase III stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004474-26,0,0,0 2019-004475-39,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen Sciences Ireland Unlimited Company,"A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004475-39,0,0,0 2019-004476-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA,Autologous mesenchymal stem/stromal Cells for the Treatment of workers affected by chronic low back pain due to multilevel InterVErtebral disc degeneration: a phase IIB randomized clinical trial - ACT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004476-19,0,0,0 2019-004478-24,2,2021-06-04,2021-06-04,2,1,0,0,0,1,3,0,0,1,0,0,1,0,1,Ovid Therapeutics Inc.,"An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals with Angelman Syndrome (ELARA)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004478-24,0,0,0 2019-004480-48,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Bayer AG,"A prospective, lead-in study to collect bleeding episodes, Factor VIII (FVIII) infusions, and patient-reported outcomes in patients with hemophilia A",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004480-48,0,0,0 2019-004483-22,4,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004483-22,0,0,0 2019-004483-22,4,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004483-22,0,0,0 2019-004488-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Niels Bang,Botox injektion in the hip joint for pain relief and diagnosis of pain lokalisation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004488-33,0,0,0 2019-004489-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Medizinische Universität Wien, Universitätsklinik für Psychiatrie und Psychotherapie",Ketamine for the treatment of depressive and negative symptoms in patients with schizophrenia: a randomized controlled cross-over pilot study. Ketamin zur Behandlung von depressiven und Negativ-Sym...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004489-16,0,0,0 2019-004491-19,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Universitätsklinikum Frankfurt,"A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of ponatinib (Iclusig®) in adult patients with minimal residual disease (MRD) in Philadelphia-Chromosome p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004491-19,0,0,0 2019-004493-26,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) versus Investigator's Choice Chemotherapy in HER2- Low, Hormone Receptor Positive Breast Cancer Patients whose D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004493-26,0,0,0 2019-004493-26,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) versus Investigator's Choice Chemotherapy in HER2- Low, Hormone Receptor Positive Breast Cancer Patients whose D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004493-26,0,0,0 2019-004496-39,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,REGENXBIO Inc.,A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501 Studio di follow-up a lungo termine per valutare la sicurezza e l'efficacia di RGX-501,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004496-39,0,0,0 2019-004497-25,11,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,H. LUNDBECK A/S,"Interventional, randomized, double-blind, parallel-group, placebo-controlled study with an extension period to evaluate the efficacy and safety of eptinezumab for the prevention of migraine in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004497-25,0,0,0 2019-004497-25,11,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,H. Lundbeck A/S,"Interventional, randomized, double-blind, parallel-group, placebo-controlled study with an extension period to evaluate the efficacy and safety of eptinezumab for the prevention of migraine in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004497-25,0,0,0 2019-004498-18,1,,,0,0,1,0,0,1,2,0,0,0,0,0,0,0,0,Dr. Jordi Gascón / Dra. Lola Ledesma,EFFICACY AND SAFETY CLINICAL TRIAL WITH EFAVIRENZ IN PATIENTS DIAGNOSED WITH ADULT NIEMANN-PICK TYPE C WITH COGNITIVE IMPAIRMENT ENSAYO CLÍNICO DE EFICACIA Y SEGURIDAD DE EFAVIRENZ EN PACIENTES DIA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004498-18,0,0,0 2019-004501-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Vienna,Perioperative analgesia in children undergoing ophthalmic surgery Perioperatives Schmerzmanagement in der Augenchirurgie bei Kindern,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004501-27,0,0,0 2019-004503-12,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,Astellas Pharma Global Development Inc.,"A Phase 1, Randomized, Single Dose, Blinded, Dose-Escalation Study to Assess Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Compariso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004503-12,0,1,1 2019-004505-27,5,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"Basilea Pharmaceutica International Ltd, Allschwil","A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aber...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004505-27,0,0,0 2019-004505-27,5,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Basilea Pharmaceutica International Ltd.,"A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aber...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004505-27,0,0,0 2019-004505-27,5,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,Basilea Pharmaceutica International AG,"A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aber...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004505-27,0,0,0 2019-004506-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004506-10,0,0,0 2019-004509-29,7,2022-09-20,2022-09-20,4,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Quantum Genomics,"A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004509-29,1,0,0 2019-004511-31,9,2022-02-21,2022-02-21,6,0,0,0,0,2,2,0,0,2,1,0,0,0,0,"IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA",Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004511-31,1,0,0 2019-004511-31,9,2022-02-21,2022-02-21,6,0,0,0,0,2,2,0,0,2,1,0,0,0,0,Bambino Gesù Children's Hospital,Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004511-31,1,0,0 2019-004511-31,9,2022-02-21,2022-02-21,6,0,0,0,0,2,2,0,0,2,1,0,0,0,0,Bambino Gesù Children´s Hospital,Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004511-31,1,0,0 2019-004512-58,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,"Technische Universität München, Fakultät für Medizin",Comparison of Fluorescein-INtra-VItal microscopy Versus conventional frozen section diagnosis for intraOperative histopathological evaluation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004512-58,0,0,0 2019-004515-31,1,2021-10-07,2021-10-07,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Nordic Bioscience Clinical Development A/S,A Phase 2b Trial of SB-061 for the Treatment of Symptomatic Osteoarthritis of the Knee,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004515-31,0,0,0 2019-004523-21,2,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,DBV Technologies S.A.,"A Phase 2 Study To Evaluate The Sensitivity, Specificity And Safety Of DBV1605, A Ready To Use Atopy Patch Test For The Diagnosis Of Non-Immunoglobulin E Mediated Cow’s Milk Allergy In Children Stu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004523-21,0,0,0 2019-004531-22,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004531-22,0,0,0 2019-004531-22,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004531-22,0,0,0 2019-004536-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leipzig University,Treatment of MDS/AML patients with an impending hematological relapse with azacitidine alone or in combination with pevonedistat - a randomized phase 2 trial Behandlung von MDS und AML Patienten mi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004536-37,0,0,0 2019-004537-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHRU de Brest,Comparison of an inhaled sedation strategy to an intravenous sedation strategy in ICU patients treated with invasive mechanical ventilation Comparaison d’une stratégie de sédation inhalée à une str...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004537-16,0,0,0 2019-004538-40,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Ghent University Hospital,A multicentric randomised controlled clinical trial to study the impact of bedside model-informed precision dosing of vancomycin in critically ill children.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004538-40,0,0,0 2019-004540-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Ústav hematologie a krevní transfuze,Ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph-positive acute lymphoblastic leukemia Ponatinib v kombinaci s redukovanou chemoterapií v první li...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004540-29,0,0,0 2019-004541-33,1,,,0,0,0,0,0,0,4,0,1,4,0,0,0,0,0,Västra Götalandsregionen,A clinical study to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer. Klinisk studie för undersökning av cellulär och ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004541-33,0,0,0 2019-004542-15,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Seattle Genetics, Inc.","An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004542-15,0,0,0 2019-004542-15,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"SEATTLE GENETICS, INC.","An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004542-15,0,0,0 2019-004542-15,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Seagen Inc.,"An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004542-15,0,0,0 2019-004545-32,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,1,Empros Pharma AB,"Lean Efficacy Phase IIa Proof of concept trial (LEAAP). A multi-centre, double-blind, placebo controlled, randomised study in overweight and obese patients during twenty-six weeks, investigating the e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004545-32,0,0,0 2019-004547-77,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,ReNeuron Ltd,"First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Subjects with Retinitis Pigmentosa (RP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004547-77,0,0,0 2019-004548-31,1,2022-06-29,2022-06-29,1,1,0,0,0,0,2,0,0,1,1,1,0,0,0,Cinto Segalàs,"A RANDOMIZED, CONTROLLED, OPEN AND UNICENTRIC PHASE II CLINICAL TRIAL, WITH TWO PARALLEL GROUPS, TO EVALUATE THE ANTIDEPRESSANT EFFICACY OF PSYCHOTHERAPY AND CITALOPRAM IN WOMEN DIAGNOSED WITH BREAST ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004548-31,0,0,0 2019-004554-29,6,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,"Kartos Therapeutics, Inc.","An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004554-29,0,0,0 2019-004554-29,6,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,"Kartos Therapeutics, Inc","An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), Or Po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004554-29,0,0,0 2019-004557-92,1,2021-01-31,2021-01-31,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Steno Diabetes Center Copenhagen,Acute effects of Sodium-glucose coTRansporter-2 inhibition on renal OxygeNation and AUTonomic function in type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004557-92,0,0,0 2019-004561-41,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,The Functional Gut Clinic,The use of Antacids and Alginates during Pre-Investigation Proton Pump Inhibitor Washout: Impact on Compliance and Symptom Burden,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004561-41,0,0,0 2019-004566-17,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,European Organisation for Research and Treatment of Cancer,"Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004566-17,0,0,0 2019-004566-17,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,EORTC AISBL/IVZW,"Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004566-17,0,0,0 2019-004578-25,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,BioGaia Pharma AB,A randomised placebo-controlled safety study of Lactobacillus reuteri BGP-014 in patients with active mild to moderate ulcerative colitis Randomiserad placebokontrollerad säkerhetsstudie av Lactoba...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004578-25,0,0,0 2019-004581-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Lone Nikolajsen,"Clinical effectiveness and safety of intraoperative methadone in patients undergoing cystectomy: a randomised, double-blind trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004581-18,0,0,0 2019-004582-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Amsterdam UMC-Location AMC-dept. Internal Medicin,TIming of start of systemIc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a randomized controlled multicenter trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004582-40,0,0,0 2019-004586-41,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Leicester,Impact of exercise training in combination with dapagliflozin on physical function in adults with type 2 diabetes mellitus: A Randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004586-41,0,0,0 2019-004594-44,15,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novo Nordisk A/S,The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004594-44,0,0,0 2019-004594-44,15,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NOVO NORDISK. S.P.A.,The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004594-44,0,0,0 2019-004597-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design - IMMUWIN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004597-26,0,0,0 2019-004600-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Hepatology and Gastroenterology, Aarhus University Hospital","Fat-reduced diet vs. bile acid binder as a treatment for bile acid malabsorption in patients with chronic diarrhoea as a late side effect after cancer treatment in the pelvic region - a randomised, co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004600-35,0,0,0 2019-004602-94,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Biophytis,"A 3-part, Randomized, Double Blind, Adaptive Seamless Phase 1-3 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of BIO101 in Non-Ambulatory Patients with a Genetically C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004602-94,0,0,0 2019-004604-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VU University Medical Center,A phase 2 study of CC220 (iberdomide) combined with low-dose cyclophosphamide and dexamethasone in relapsed/refractory multiple myeloma (IberCd): ICON study Een fase 2 studie van iberdomide gecom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004604-35,0,0,0 2019-004605-27,1,2021-03-30,2021-03-30,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects with Advanced Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004605-27,0,0,0 2019-004610-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Rigshospitalet,"An investigation of postoperative pain, why still in hospital and days alive and out of hospital following transoral robotic surgery for squamous cell carcinoma of unknown primary Optimering af sm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004610-34,0,0,0 2019-004613-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,POLISH ADULT LEUKEMIA GROUP,"A prospective, multicenter, phase II trial to assess the efficacy and safety of MRD-driven treatment with VEnetoclax and RItuximab combination in previously unTreated pAtients with chronic lymphocytic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004613-14,0,0,0 2019-004619-30,10,2021-08-16,2021-10-17,5,1,0,0,0,1,3,0,0,2,1,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004619-30,1,0,0 2019-004619-30,10,2021-08-16,2021-10-17,5,1,0,0,0,1,3,0,0,2,1,0,0,0,1,Alexion Pharmaceuticals,"A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004619-30,1,0,0 2019-004620-38,1,2020-09-14,2020-09-14,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Fundació Lluita contra la SIDA,Study to assess the effect of a Darunavir/Cobicistat-based regimen on weight and body composition in HIV-infected subjects who present weight gain during a dolutegravir-based regimen. Estudio para ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004620-38,0,0,0 2019-004621-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IFCT,A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004621-24,0,0,0 2019-004624-38,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Bioncotech Therapeutics, S.L",Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal j...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004624-38,0,0,0 2019-004624-38,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Highlight Therapeutics, S.L",Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal j...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004624-38,0,0,0 2019-004625-24,8,2022-08-18,2022-08-18,5,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AM-Pharma B.V.,"A Randomized, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group, Multi-Center Phase 3 Pivotal Trial to Investigate the Efficacy and Safety of Recombinant Human Alkaline Phosphatase for Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004625-24,1,0,0 2019-004628-39,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Queen Mary University of London,A phase II study of neoadjuvant immune checkpoint inhibitors in urothelial cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004628-39,0,0,0 2019-004630-42,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,TAIHO ONCOLOGY INC.,"A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangement...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004630-42,0,0,0 2019-004630-42,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Taiho Oncology, Inc.","A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangement...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004630-42,0,0,0 2019-004630-42,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Taiho Oncology Inc,"A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangement...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004630-42,0,0,0 2019-004634-41,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Institut de Recerca HSCSP,Study of the positron emission tomography (PET) tracer for tau 18F-PI-2620 in individuals with Down syndrome Estudio del trazador de tomografía por emisión de positrones (PET) para tau 18F-PI-2620 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004634-41,0,0,0 2019-004637-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE,"Pilot, single-center, non-comparative clinical trial to assess the safety and preliminary efficacy of the administration of adipose tissue-derived MSCs (MSCs-TA) injected at the edges of the ulcer and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004637-16,0,0,0 2019-004638-40,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,AstraZenenca AB,An Open-label Study to Evaluate the Pharmacokinetics and Pharmacodynamics and Long-term Safety of Benralizumab Administered Subcutaneously in Children with Severe Eosinophilic Asthma.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004638-40,0,1,1 2019-004645-32,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Freeline Therapeutics Ltd,"A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT190) in Subjects with Fabry Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004645-32,0,0,0 2019-004647-74,9,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,Sanofi-Aventis Groupe,"Randomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004647-74,0,0,0 2019-004647-74,9,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,SANOFI-AVENTIS GROUPE,"Randomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004647-74,0,0,0 2019-004651-36,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Academic Medical Center Amsterdam,Glibenclamide Treatment for Cantú syndrome Glibenclamide behandeling voor Cantú syndroom,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004651-36,0,0,0 2019-004652-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"RANDOMIZED, OPEN-LABEL PHASE 3B STUDY OF ETROLIZUMAB BASED INDUCTION THERAPY COMBINATIONS FOLLOWED BY ETROLIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS Randomiz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004652-11,0,0,0 2019-004657-89,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Ethicon Inc,"A Prospective Study Evaluating the Safety and Effectiveness of EVARREST® Fibrin Sealant Patch in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open, Abdominal, Retrope...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004657-89,0,0,0 2019-004664-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Kuopio University Hospital,Stable Isotope Labeling Kinetics in Normal Pressure Hydrocephalus: implications for neurodegeneration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004664-22,0,0,0 2019-004665-40,6,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A randomized, multicenter, active-comparator controlled, open-label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult patients with PNH and residual anemia, despite treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004665-40,0,0,0 2019-004665-40,6,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, multicenter, active-comparator controlled, open-label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult patients with PNH and residual anemia, despite treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004665-40,0,0,0 2019-004669-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University of Birmingham,STAR-TREC: Can we Save the rectum by watchful waiting or TransAnal microsurgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004669-41,0,0,0 2019-004671-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitair Ziekenhuis Brussel (UZ Brussel),The effect of handheld-multimedia versus midazolam premedication on the level of perioperative anxiety in pediatric day-care. A randomized controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004671-39,0,0,0 2019-004676-18,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,University Medical Center Utrecht,Differences in effect of treatment with mepolizumab and benralizumab on resident and inflammatory eosinophils Het verschil in effect van behandeling met mepolizumab en benralizumab op residente en ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004676-18,0,0,0 2019-004677-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"UNIVERSITA' DEGLI STUDI DI MODENA E REGGIO EMILIA - DIPARTIMENTO DI SCIENZE BIOMEDICHE, METABOLICHE E NEUROSCIENZE",Pharmacodynamics and safety of human recombinant luteinising hormone in hypogonadotropic hypogonadal men. Farmacodinamica e Sicurezza dell’ormone luteinizzante umano in maschi con ipogonadismo ipog...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004677-12,0,0,0 2019-004680-51,2,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,GlaxoSmithKline Biologicals SA,"A phase 3, randomized, open-label, multi-country study to evaluate the immunogenicity, safety, reactogenicity and persistence of a single dose of the RSVPreF3 OA investigational vaccine and different ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004680-51,0,0,0 2019-004680-51,2,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase 3, randomized, open-label, multi-country study to evaluate the immunogenicity, safety, reactogenicity and persistence of a single dose of the RSVPreF3 OA investigational vaccine and different ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004680-51,0,0,0 2019-004682-40,9,2022-05-09,2022-05-09,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004682-40,1,0,0 2019-004682-40,9,2022-05-09,2022-05-09,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmaceutica, S.A.","EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004682-40,1,0,0 2019-004682-40,9,2022-05-09,2022-05-09,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004682-40,1,0,0 2019-004683-22,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Ostfold Hospital Trust,Daratumumab as a treatment for adult immune thrombocytopenia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004683-22,0,0,0 2019-004685-18,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA,Evaluation of diagnostic accuracy of [68Ga]Ga-PSMA-11 PET/CT in primary staging of Intermediate and High Risk Prostatic Cancer in men newly diagnosed Valutazione della accuratezza diagnostica della...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004685-18,0,0,0 2019-004686-41,5,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,Helsinn Healthcare SA,MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004686-41,0,0,0 2019-004696-40,1,2020-09-03,2020-09-03,1,1,0,0,0,0,4,0,1,1,0,0,1,0,1,Vifor (International) Inc.,"A phase IV, randomized, double blind cross-over study to evaluate palatability of Patiromer compared to Sodium Polystyrene Sulfonate in healthy subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004696-40,0,0,0 2019-004697-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,The Rotunda Hospital,"The Home Induction trial: A randomised open-label trial to assess efficacy of inpatient vs outpatient induction of labour, and compare efficacy of Propess vs Dilapan-S® for induction of labour at 39 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004697-25,0,0,0 2019-004699-21,4,2021-12-20,2021-12-20,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"MacroGenics, Inc.","A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004699-21,1,0,0 2019-004699-21,4,2021-12-20,2021-12-20,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"MACROGENICS, INC.","A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004699-21,1,0,0 2019-004704-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region Örebro,Masseter myofascial pain relief following an intra-muscular injection with botulinum toxin type A. A randomized double-blind controlled multicenter pilot study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004704-35,0,0,0 2019-004706-10,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Dragonfly Therapeutics, Inc.","A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004706-10,0,0,0 2019-004718-32,2,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,UMC Utrecht,"Upfront autologous hematopoietic stem cell transplantation versus immunosuppressive medication in early diffuse cutaneous systemic sclerosis: an international multicentre, open-label, randomized contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004718-32,0,0,0 2019-004718-32,2,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,UNIVERSITY MEDICAL CENTER UTRECHT,"Upfront autologous hematopoietic stem cell transplantation versus immunosuppressive medication in early diffuse cutaneous systemic sclerosis: an international multicentre, open-label, randomized contr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004718-32,0,0,0 2019-004720-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,Effects of late surfactant treatment delivered after a recruitment maneuver on respiratory outcomes in extremely low gestational age newborns: a randomized controlled trial – LATE-REC-SURF Trial. E...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004720-38,0,0,0 2019-004721-24,1,,,0,0,1,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc.,"Efficacy, Immunogenicity, and Safety of High-Dose Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months through 35 Months of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004721-24,0,1,1 2019-004728-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,"A Phase II, non-randomized, single arm, translational study of CAbozantinib for Patients with HepatocellUlaR CarcinOma (HCC) Refractory to LenvAtinib Treatment Eine nicht randomisierte, einarmige P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004728-39,0,0,0 2019-004730-42,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,IQVIA RDS FRANCE SAS,Prospective evaluation of potential effects of repeated gadolinium-based contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004730-42,0,0,0 2019-004733-17,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Aurora Pujol Onofre,"Effect of plasma exchange by albumin replacement in Adrenomyeloneuropathy: unicentric, single arm, proof of concept trial Efecto del recambio plasmático con albúmina en pacientes con Adrenomieloneu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004733-17,0,0,0 2019-004739-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Rheinische Friedrich-Wilhelms-Universität Bonn,"Efficacy of ruxolitinib cream in Prurigo nodularis patients: A randomized, placebo-controlled pilot study (PRUX) Wirksamkeit von topischer Ruxolitinib-Creme bei Prurigo nodularis Patienten: Eine r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004739-22,0,0,0 2019-004740-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Hospitalier Le Vinatier,Cannabidiol for reducing drinking in alcohol use disorder and modifying the effects of alcohol on the brain and the liver: a phase 2 clinical trial. Le cannabidiol dans la réduction de la consommat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004740-30,0,0,0 2019-004749-33,13,2020-10-19,2020-11-19,12,1,0,0,0,1,2,0,0,1,1,0,1,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004749-33,0,0,0 2019-004749-33,13,2020-10-19,2020-11-19,12,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim,"An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004749-33,0,0,0 2019-004749-33,13,2020-10-19,2020-11-19,12,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004749-33,0,0,0 2019-004749-33,13,2020-10-19,2020-11-19,12,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004749-33,0,0,0 2019-004749-33,13,2020-10-19,2020-11-19,12,1,0,0,0,1,2,0,0,1,1,0,1,0,1,"Unilfarma - União Internacional de Lab. Farmacêuticos, Lda","An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004749-33,0,0,0 2019-004749-33,13,2020-10-19,2020-11-19,12,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Finland Ky,"An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004749-33,0,0,0 2019-004749-33,13,2020-10-19,2020-11-19,12,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Norway KS,"An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004749-33,0,0,0 2019-004749-33,13,2020-10-19,2020-11-19,12,1,0,0,0,1,2,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm. V,"An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004749-33,0,0,0 2019-004749-33,13,2020-10-19,2020-11-19,12,1,0,0,0,1,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Limited,"An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004749-33,0,0,0 2019-004750-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitair Ziekenhuis Brussel,Electrocardiographic And Clinical Effects Of Target-Controlled Infusion Of Propofol In Adults With Brugada Syndrome. A Pilot Study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004750-28,0,0,0 2019-004753-87,1,2021-05-05,2021-05-05,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,"Sumitomo Dainippon Pharma Oncology, Inc.","A Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Sumitomo Dainippon Pharma Oncology, Inc. sponsored Napabucasin Protocols",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004753-87,0,0,0 2019-004756-11,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,UCB Pharma SA,"A multi-center, open-label, uncontrolled, long-term, extension study to evaluate the safety and efficacy of Lacosamide as adjunctive therapy in Japanese and Chinese adults with partial-onset seizures ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004756-11,0,1,1 2019-004757-88,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Goethe-Universität, vertreten durch den Präsidenten, dieser vertreten durch den LKP (bevollmächtigt durch den Sponsor)",Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line treatment Zusätzliche Chemotherapie für Patienten mit EGFR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004757-88,0,0,0 2019-004758-27,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Gillberg Neuropsychiatry Centre,Intravenous immunoglobulin (IVIG) treatment in children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS): an open-label trial in South-western Sweden,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004758-27,0,0,0 2019-004760-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE MELANOMA ONLUS,"Dabrafenib and trametinib in circulating free DNA BRAFV600 mutated metastatic melanoma patients: a prospective phase II, open label, multicentre study – (Bioliquid TAILOR study – BIO-TAILOR) Dabraf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004760-21,0,0,0 2019-004764-22,7,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Spruce Biosciences, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004764-22,0,0,0 2019-004764-22,7,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Spruce Biosciences Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004764-22,0,0,0 2019-004765-40,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Spruce Biosciences, Inc.","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Conge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004765-40,0,0,0 2019-004766-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Region Västerbotten,"The Fragility Fracture Trial (FFT): A randomized, double-blind, placebo-controlled trial to investigate whether zoledronic acid prevents new fractures in older adults with a recent non-hip, non-verteb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004766-17,0,0,0 2019-004767-53,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Novartis Pharma GmbH,"A 52-week, two arm, randomized, open-label, multicenter study assessing the efficacy and safety of two different brolucizumab 6 mg dosing regimens for patients with suboptimal anatomically controlled ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004767-53,0,0,0 2019-004769-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hôpitaux Universitaires de Strasbourg,Prospective randomized versus placebo study evaluating the feasibility of plasma therapy in septic shock induced coagulopathy Étude prospective randomisée versus placebo évaluant la faisabilité d'u...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004769-41,0,0,0 2019-004770-25,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Participants with Recurrent or Metastatic Squamous Cell Carcinoma of the Head a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004770-25,0,0,0 2019-004770-25,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Participants with Recurrent or Metastatic Squamous Cell Carcinoma of the Head a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004770-25,0,0,0 2019-004771-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Rigshospitalet,ProTarget A Danish Nationwide Clinical Trial on Targeted Anti-Cancer Treatment based on Genomic Profiling,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004771-40,0,0,0 2019-004772-19,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Steno Diabetes Center Copenhagen,Platelet aggregation and aspirin low response in type one diabetes and the association with vascular damage and diabetic nephropathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004772-19,0,0,0 2019-004773-29,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004773-29,0,0,0 2019-004773-29,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004773-29,0,0,0 2019-004775-39,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Pfizer Inc.,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004775-39,0,0,0 2019-004775-39,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004775-39,0,0,0 2019-004778-25,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,UCB Biopharma SRL,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Gliom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004778-25,0,0,0 2019-004780-52,3,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Amgen,"A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of adults with Relapsed or Refractory B cell Pre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004780-52,0,0,0 2019-004782-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,"An open label, single-arm, phase 2 study of neoadjuvant PEMbrolizumab before radical PROstatectomy (PEM-PRO) in high-risk prostate cancer patients Studio di fase 2, open-lable, a braccio singolo su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004782-40,0,0,0 2019-004783-22,3,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,1,ACTELION Pharmaceuticals Ltd.,"A Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004783-22,0,0,0 2019-004789-17,4,2022-03-30,2022-03-30,4,0,1,0,0,0,3,0,0,1,0,0,0,0,1,Galderma S.A.,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004789-17,0,0,0 2019-004791-19,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Aeglea Biotherapeutics, Inc.","A Phase 1/2 Multiple Ascending-Dose Study in Subjects With Homocystinuria Due to Cystathionine β-Synthase (CBS) Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of ACN00177",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004791-19,0,0,0 2019-004793-26,2,,,0,0,0,1,0,0,1,0,0,2,0,0,0,0,1,"Harpoon Therapeutics, Inc.","A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004793-26,0,0,0 2019-004796-40,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CHU de Lille,"Multicenter Phase II study with dose-light escalation, intraoperative glioblastoma photodynamic therapy Etude de Phase II multicentrique avec escalade de dose-lumière, de la thérapie photodynamique...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004796-40,0,0,0 2019-004805-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St. Antonius Hospital,What is the optimal antithrombotic strategy in patients presenting with acute coronary syndrome having atrial fibrillation with indication for anticoagulants? Wat is de optimale antitrombotische s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004805-28,0,0,0 2019-004807-11,3,2021-10-11,2021-11-11,2,0,0,0,0,0,3,0,0,1,1,0,0,0,1,Radius Health Inc.,"A Randomized, Non-Inferiority, Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women with Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004807-11,0,0,0 2019-004812-73,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University,The influence of pharmacological conditioning with S-ketamine on centralized pain in patients with Fibromyalgia Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004812-73,0,0,0 2019-004813-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZ Turnhout,Serum concentrations of ropivacaine after unilateral pectoral nerve block type II (Pecs II) in breast cancer surgery Serumconcentraties van ropivacaine na unilaterale Pecs II block in borstkankerch...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004813-15,0,0,0 2019-004814-32,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Yuhan Corporation,"A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib versus Gefitinib as the First-line Treatment in Patients with Epidermal Growth Factor Receptor Sensitizing M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004814-32,0,0,0 2019-004817-15,1,2022-05-06,2022-05-06,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,GZA vzw,"A prospective, biomarker-based, clinical trial in patients with metastatic castration resistant prostate cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004817-15,0,0,0 2019-004818-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Cancer Trials Ireland,"DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004818-34,0,0,0 2019-004819-31,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,IN3BIO,"A Phase I/II, multi-centre, open-label, adaptive design, umbrella study assessing the safety, tolerability, immunogenicity and efficacy of IN01 in combination with small-molecule inhibitors in two coh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004819-31,0,0,0 2019-004822-15,1,2022-01-24,2022-01-24,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,GeNeuro Innovation SAS,"A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients with Relap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004822-15,0,0,0 2019-004823-20,6,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Takeda Development Center Americas (TDCA),An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema with Normal C1-Inhibitor (C1-INH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004823-20,0,0,0 2019-004823-20,6,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,TAKEDA DEVELOPMENT CENTER AMERICAS INC.,An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema with Normal C1-Inhibitor (C1-INH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004823-20,0,0,0 2019-004826-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Association of Dutch Burn Centres,Safety and preliminary efficacy of Alkaline Phosphatase in severely burned patients Veiligheid en preliminaire werkzaamheid van Alkalische Fosfatase bij ernstige brandwondenpatiënten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004826-12,0,0,0 2019-004831-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital,10 to 12 year extended follow-up of the SCHEDULE study (SCANDINAVIAN HEART TRANSPLANT EVEROLIMUS DE NOVO STUDY WITH EARLY CNI AVOIDANCE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004831-21,0,0,0 2019-004833-18,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Merck Healthcare KGaA,"A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with HMGA2-expressing Triple Negative Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004833-18,0,0,0 2019-004834-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospitals Leuven,"Do peri-operative high doses of intravenous glucocorticoids improve short-term functional outcome after direct anterior total hip arthroplasty? A randomized, single surgeon, placebo controlled, double...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004834-40,0,0,0 2019-004838-41,9,,,0,0,0,0,0,0,3,2,0,0,0,0,0,0,1,Hexal AG,"A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea®, administered intravitreally, in patients with neovascular a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004838-41,0,0,0 2019-004840-30,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Policlinico di Bari-UO Gastroenterologia,Comparison of low-volume versus high-volume polyethylene glycol based bowel preparation for colonoscopy in people receiving hemodialysis: a randomized non-inferiority trial. Confronto tra preparazi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004840-30,0,0,0 2019-004841-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Mika Harju,Selective laser trabeculoplasty versus eye drops for first line treatment of exfoliation ocular hypertension or glaucoma: a randomised clinical trial Selektiivinen lasertrabekuloplastia verrattuna ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004841-34,0,0,0 2019-004844-32,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,European Myeloma Network – EMN,Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004844-32,0,0,0 2019-004844-32,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,STICHTING EUROPEAN MYELOMA NETWORK,Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004844-32,0,0,0 2019-004844-32,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,European Myeloma Network by EMN,Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004844-32,0,0,0 2019-004848-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Rigshospitalet,"A Danish, single centre, double-blind, randomized study evaluating allogeneic adipose tissue derived mesenchymal stromal cell therapy to reduce primary graft dysfunction after lung transplantation. A ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004848-30,0,0,0 2019-004851-36,4,2022-06-21,2022-06-22,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Otsuka Pharmaceutical Development and Commercialization, Inc","Phase 3b, Randomized, Open-label, Active-controlled Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004851-36,1,0,0 2019-004851-36,4,2022-06-21,2022-06-22,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Otsuka Pharmaceutical (OPDC),"Phase 3b, Randomized, Open-label, Active-controlled Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004851-36,1,0,0 2019-004854-27,1,2020-10-24,2020-10-24,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Erasmus MC Cancer Institute,The influence of UGT inhibition on endoxifen exposure in cancer patients treated with tamoxifen: A proof of concept study. “The PROTAM study” De invloed van UGT remming op endoxifen blootstelling ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004854-27,0,0,0 2019-004857-10,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004857-10,0,0,0 2019-004857-10,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004857-10,0,0,0 2019-004857-10,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Genentech, Inc","A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004857-10,0,0,0 2019-004860-23,1,2022-02-28,2022-02-28,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Andres Iñiguez Romo,REACTIC-TAVI TRIAL: Platelet REACtivity according to TICagrelor dose after Trancathter Aortic Valve Implantation. A pilot study. Ensayo REACTIC-TAVI: REACtividad de plaquetas según la dosis de TICa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004860-23,0,0,0 2019-004862-16,5,2022-04-29,2022-04-29,5,0,0,0,0,0,2,0,0,1,0,0,0,0,1,AstraZeneca AB,"A Phase 2, MulticEntre, Double-Blind, THree-Arm, Placebo and Active Control Efficacy and SafetY STudy to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved Ejection Fraction ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004862-16,0,0,0 2019-004868-22,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Gilead Sciences Inc,Open-label Rollover Study to Evaluate Long-Term Safety in Subjects with Metastatic Solid Tumors that are Benefiting from Continuation of Therapy with Sacituzumab Govitecan.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004868-22,0,0,0 2019-004868-22,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Immunomedics, Inc.",Open-label Rollover Study to Evaluate Long-Term Safety in Subjects with Metastatic Solid Tumors that are Benefiting from Continuation of Therapy with Sacituzumab Govitecan.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004868-22,0,0,0 2019-004871-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE,"Phase IV, single-center, open study to assess the benefits of the start of immediate treatment without immunovirological data (“Same Day Treatment”) compared to conventional treatment with BIC / FTC /...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004871-38,0,0,0 2019-004873-17,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Neurocrine Biosciences, Inc.","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Lab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004873-17,0,0,0 2019-004875-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione GONO,The induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) Trattamento di induzione e mantenimento con inibitore di ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004875-38,0,0,0 2019-004878-26,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004878-26,0,0,0 2019-004879-39,2,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of BMS-986165 in Adolescent Subjects with Moderate to Severe Plaque Psori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004879-39,0,0,0 2019-004881-16,4,2021-05-04,2021-05-04,3,1,0,0,0,1,2,0,0,2,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-864 in PiZZ Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004881-16,1,0,0 2019-004883-23,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,APHP,A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB) transplantation in adult ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004883-23,0,0,0 2019-004884-32,1,,,0,0,0,0,1,0,3,0,1,0,0,0,0,0,0,CHU CAEN Normandie,COMPARAISON DU PROFIL PHARMACOCINETIQUE ET DE LA SECURITE DE LA DAPTOMYCINE ADMINISTREE PAR VOIE SOUS-CUTANEE PAR RAPPORT A LA VOIE INTRAVEINEUSE : ETUDE EN CROSS-OVER COMPARAISON DU PROFIL PHARMAC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004884-32,0,0,0 2019-004889-18,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Medical University of Vienna,Effect of Dupilumab in patients with aspirin-exacerbated respiratory disease (AERD) -A single-center prospective pilot study Wirksamkeit von Dupilumab auf den Krankheitsverlauf bei Patienten mit AE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004889-18,0,0,0 2019-004890-21,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Academic Hospital Maastricht (azM),Effectiveness of Periocular drug Injection in CATaract surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004890-21,0,0,0 2019-004891-20,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,European Organisation for Research and Treatment of Cancer,Study to determine the aetiology of chlormethine gel induced-skin drug reaction in early stage mycosis fungoides cutaneous T cell lymphoma (MF-CTCL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004891-20,0,0,0 2019-004891-20,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,EORTC,Study to determine the aetiology of chlormethine gel induced-skin drug reaction in early stage mycosis fungoides cutaneous T cell lymphoma (MF-CTCL),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004891-20,0,0,0 2019-004895-21,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE II, SAFETY, AND EFFICACY STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY IN PATIENTS WITH METASTATIC AND/OR RECURRENT PD-L1-POSITIVE CERVICAL CANCER. STUDIO DI FASE II V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004895-21,0,0,0 2019-004895-21,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, SAFETY, AND EFFICACY STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY IN PATIENTS WITH METASTATIC AND/OR RECURRENT PD-L1-POSITIVE CERVICAL CANCER. STUDIO DI FASE II V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004895-21,0,0,0 2019-004896-38,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Institut de Recherches Internationales Servier,"Phase I/II, international, multicentre, open-label, non-randomised, non-comparative study evaluating the safety, tolerability and clinical activity of intravenously administered S64315, a selective Mc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004896-38,0,0,0 2019-004898-63,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,Copanlisib in combination with Rituximab-Bendamustine in patients with Relapsed-Refractory Diffuse Large B-cell Lymphoma: a multicentric Phase II trial Copanlisib in combinazione con Rituximab e Be...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004898-63,0,0,0 2019-004899-19,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,UNICANCER,"Adjuvant PalbOciclib + LetrOzole combination for hormone receptor positive / HER2-negative, Intermediate Risk breast cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004899-19,0,0,0 2019-004901-28,3,2021-11-10,2021-11-10,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Evelo Biosciences Inc.,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Cohort, Dose-Ranging Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004901-28,1,0,0 2019-004902-85,1,,,0,0,0,0,1,0,2,0,0,3,0,0,0,0,1,Assembly Biosciences,"A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004902-85,0,0,0 2019-004905-29,11,2022-09-06,2022-09-06,6,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A 12-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled study to assess the efficacy and safety of CSJ117, when added to existing asthma therapy in patients =18 years of age...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004905-29,1,0,0 2019-004905-29,11,2022-09-06,2022-09-06,6,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Novartis Farmacéutica S.A.,"A 12-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled study to assess the efficacy and safety of CSJ117, when added to existing asthma therapy in patients =18 years of age...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004905-29,1,0,0 2019-004905-29,11,2022-09-06,2022-09-06,6,0,0,0,0,0,2,0,0,2,1,0,0,0,1,NOVARTIS PHARMA AG,"A 12-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled study to assess the efficacy and safety of CSJ117, when added to existing asthma therapy in patients =18 years of age...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004905-29,1,0,0 2019-004906-88,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen,Placebo-controlled double-blind randomized controlled trial investigating vitamin K supplementation on vascular calcification propensity in vitamin K deficient renal transplant recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004906-88,0,0,0 2019-004909-27,2,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Denali Therapeutics Inc.,"A PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DNL310 IN PEDIATRIC SUBJECTS WITH HUNTER SYNDROME",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004909-27,0,0,0 2019-004914-32,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University Medical Center Utrecht,Sentinel lymph node (SLN) detection in early oral cancer using Gallium-68-Tilmanocept PET-CT Detectie van schildwachtklieren bij vroeg-stadium mondholtekanker met behulp van Gallium-68-Tilmanocept ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004914-32,0,0,0 2019-004916-76,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,A phase II study of nivolumab combined with metformin in pre-treated metastatic renal cell carcinoma (mRCC) patients. Studio di fase II di nivolumab in combinazione con metformina in pazienti con c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004916-76,0,0,0 2019-004917-15,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,ISTITUTO AUXOLOGICO ITALIANO,"Crossover, Double-blind, Phase 2 Study of a Fixed Dose Combination of Reboxetine\Oxybutynin (AD128) Versus Placebo in Obstructive Sleep Apnea (RebOx) Studio di Fase 2, in doppio cieco, cross-over, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004917-15,0,0,0 2019-004921-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amsterdam UMC,Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteremia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004921-25,0,0,0 2019-004930-41,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,"Astellas Pharma Global Development, Inc.","A Phase 1, Open-Label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004930-41,0,1,1 2019-004931-21,13,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,F. Hoffman-La Roche Ltd.,"A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN ADULT AND ADOLESCENT PATIENTS WITH PAROXYSMAL NOCTURNAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004931-21,0,0,0 2019-004931-21,13,,,0,0,1,0,0,1,3,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN ADULT AND ADOLESCENT PATIENTS WITH PAROXYSMAL NOCTURNAL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004931-21,0,0,0 2019-004934-40,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"Department of Endocrinology and Internal Medicine, Aarhus University Hospital","Endocrine, cardiovascular, pharmacologic and physiologic aspects of sex hormone treatment in Turner syndrome - project part B Endokrinologiske, kardiovaskulære, farmakologiske og fysiologiske aspek...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004934-40,0,0,0 2019-004935-22,1,2021-06-30,2021-06-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,NewAmsterdam Pharma BV,"A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination with Ezetimibe in Participants with Mild Dyslipidemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004935-22,0,0,0 2019-004936-52,1,2020-12-04,2020-12-04,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,Cassella-med GmbH & Co KG,"Prospective, controlled, randomized double-blind study to determine the sensory perception of two nasal sprays using the model of treatment of post-operative complaints after surgery on the nasal muco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004936-52,0,0,0 2019-004939-24,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,Cell and Gene Therapy Catapult,"Phase I/II open-label study to assess the safety, tolerability and efficacy of a novel tissue engineered airway product, consisting of expanded autologous bone marrow (BM) derived Mesenchymal Stromal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004939-24,0,0,0 2019-004940-31,1,,,0,1,0,0,0,1,4,0,0,1,1,1,0,1,0,Terese Katzenstein,Effect of timing of enzyme replacement therapy (Creon®) at meals on fat malabsorption in adult patients with cystic fibrosis - a cross-over trial Effekt af timing af enzymtilskud (Creon®) til målti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004940-31,0,0,0 2019-004941-34,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,GENFIT,"A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadeq...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004941-34,0,0,0 2019-004942-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Jules Bordet,Neoadjuvant study of targeting ROS1 in combination with endocrine therapy in invAsive Lobular carcINoma of the breast,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004942-14,0,0,0 2019-004943-54,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Stayble Therapeutics AB,"A multi-country, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of STA363 at two concentrations (60 mg/mL and 120 mg/mL) compared to placebo in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004943-54,0,0,0 2019-004946-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Univeristy Hospital Tuebingen,Conversion to extended-release MeltDose® tacrolimus after kidney transplantation - impact on glucose metabolism and lipid profile,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004946-13,0,0,0 2019-004947-65,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Santiago Grau Cerrato,IMPACT ON THE CLINICAL OUTCOMES AND COST-EFFECTIVENESS OF THE ANTIMICROBIAL THERAPEUTIC MONITORING PROGRAM IN CRITICAL PATIENTS IMPACTO EN LOS RESULTADOS CLÍNICOS Y EN EL COSTE-EFECTIVIDAD DEL PROG...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004947-65,0,0,0 2019-004948-30,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,INCYTE CORPORATION,"A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004948-30,0,0,0 2019-004948-30,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Incyte Corporation,"A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004948-30,0,0,0 2019-004949-32,1,,,0,0,0,1,0,1,1,0,0,4,0,0,0,0,1,Lysogene,An open-label adaptive-design study of intracisternal administration of adeno-associated viral vector serotype rh.10 carrying the human β-galactosidase cDNA for the treatment of GM1 gangliosidosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004949-32,0,0,0 2019-004952-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Ghent,Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004952-13,0,0,0 2019-004953-96,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Jounce Therapeutics, Inc.","Phase 2 Study of PD-1 Inhibitor JTX-4014 Alone and in Combination with Vopratelimab, an ICOS Agonist, in Biomarker-selected Subjects with Metastatic NSCLC After One Prior Platinum-containing Regimen",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004953-96,0,0,0 2019-004956-12,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,CORCEPT THERAPEUTICS,"Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-Con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004956-12,0,0,0 2019-004956-12,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Corcept Therapeutics Incorporated,"Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia (GRADIENT): A Phase 3, Randomized, Double-Blind, Placebo-Con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004956-12,0,0,0 2019-004958-29,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,EFFECT OF POLYETHYLENE GLYCOL TREATMENT ON INTESTINAL INFLAMMATION ASSOCIATED WITH CYSTIC FIBROSIS IN CHILDREN EFFET D’UN TRAITEMENT PAR POLYETHYLENE GLYCOL SUR L’INFLAMMATION INTESTINALE ASSOCIEE ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004958-29,0,0,0 2019-004959-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ZonMw,A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment (MCI). Fase 2 studie met de PDE4 inhibitor roflumilast in patiënten met milde cogni...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004959-36,0,0,0 2019-004961-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Ghent University Hospital,SPondyloArthritis: inducing drug-free Remission by early TNF-Alpha bloCkade Under guidance of Single cell RNA sequencing and epigenetic profiling SPondyloArtritis: het bekomen van medicatie-vrije R...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004961-42,0,0,0 2019-004972-20,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK HEALTHCARE KGaA,"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004972-20,0,0,0 2019-004972-20,10,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Merck Healthcare KGaA,"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004972-20,0,0,0 2019-004975-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hamilton Health Sciences through the Population Health Research Institute,Low INR to Minimize bleeding with mechanical valves Trial INR bajo para minimizar el sangrado con válvulas mecánicas.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004975-37,0,0,0 2019-004978-26,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2, randomized, open-label, multicenter study to evaluate efficacy, pharmacokinetics, safety, and tolerability of response-guided treatment with JNJ-73763989 + JNJ-56136379 + nucleos(t)ide anal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004978-26,0,0,0 2019-004979-39,1,2020-11-09,2020-11-09,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,Milestone Pharmaceuticals Inc.,"An open-label, mass balance study to investigate the absorption, distribution, metabolism and excretion of [14C]-etripamil nasal spray after a single dose to healthy male subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004979-39,0,0,0 2019-004980-36,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Merck Healthcare KGaA,"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004980-36,0,0,0 2019-004980-36,12,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,MERCK HEALTHCARE KGaA,"A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004980-36,0,0,0 2019-004981-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Editas Medicine, Inc.","Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants with Leber Congenital Amaurosis Type 10 (LCA10), with Centro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004981-16,0,0,0 2019-004982-42,1,,,0,0,0,0,0,0,3,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologics SA (GSK),"A phase IIIB, randomized, controlled, observer-blind study to evaluate safety and immunogenicity of GSK’s meningococcal ABCWY vaccine when administered in healthy adolescents and adults, previously pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004982-42,0,1,1 2019-004983-23,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University Medical Center Groningen,Bioequivalence study of prednisolone and dexamethasone: corticosteroids revisited Bio-equivalentie studie naar de effecten van prednisolon en dexamethason: corticosteroïden opnieuw onder de loep,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004983-23,0,0,0 2019-004984-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU TOURS,"Nitrous Oxide in Resistant Depression in Elderly Subjects: A Randomized, Double-blind, Comparator Trial Protoxyde d’Azote dans la Dépression Résistante du Sujet Âgé: un essai randomisé en double a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004984-31,0,0,0 2019-004987-23,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,UMC Utrecht,"A Dose-Escalating Phase I/II Study in Patients with RAS-Mutated Metastatic Colorectal Cancer to Investigate Safety and Clinical Activity of the Triple Combination of: MEK-inhibitor binimetinib, Pan-EG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004987-23,0,0,0 2019-004991-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Clinic per a la Recerca Biomèdica,A phase II triAl of Cabozantinib for hepaTocellular carcInoma patients intOlerant to sorafenib treatment or first line treatment different to sorafeNib. (ACTION trial) Ensayo en fase II de Cabozant...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004991-20,0,0,0 2019-004997-24,1,2022-01-07,2022-01-07,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,"Atea Pharmaceuticals, Inc.",A Phase I/IIa Study Assessing AT-777 in Healthy Subjects and AT-777 in Combination with AT-527 in HCV-Infected Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004997-24,0,0,0 2019-004998-34,1,2020-09-14,2020-09-14,1,1,0,0,0,0,2,0,0,1,1,1,1,0,1,"Blade Therapeutics, Inc.","A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004998-34,0,0,0 2019-004999-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of infectious diseases, Hvidovre Hospital","Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamuvidine compared to continued treatment with dolutegravir/abacavir/lamuvidine for virologically suppressed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-004999-19,0,0,0 2019-005000-17,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Jagiellonian University,"A Randomized, Double Blind, Two Arms, Controlled Phase I/II Safety and Efficacy Study on MesoCellA-Ortho Tissue Engineered Product Intraarticularly Administrated in Adult Patients with Osteoarthrosis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-005000-17,0,0,0 2019-005005-43,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona,Ferinject in Addition to pulmonary rehabilitation in patients with COPD and iron deficiency to improve Exercise tolerance (FACE II study) Deficiencia de hierro en pacientes con EPOC: “Impacto de la...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-005005-43,0,0,0 2019-005007-40,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,University Hospitals Leuven,Natural history study in adult patients with SMA types 2-3-4 and Role of neurodegenerative and neuro-inflammatory biomarkers in SMA adults treated with nusinersen.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-005007-40,0,0,0 2019-005008-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Hamburg-Eppendorf,"Stop of proton-pump inhibitor treatment in patients with liver cirrhosis – a double-blind, placebo-controlled trial Absetzen einer Therapie mit Protonenpumpeninhibitoren bei Patienten mit Leberzirr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-005008-16,0,0,0 2019-005010-19,1,2021-04-30,2021-04-30,1,1,0,0,1,0,4,0,0,1,0,0,1,0,0,Hospital Clínic de Barcelona,Ultrasound-guided Genicular Nerve Block an Analgesic Alternative to LIA for Total Knee Arthroplasty. Randomized clinical trial. Comparación del bloqueo de los nervios geniculares con ayuda de la ec...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-005010-19,0,0,0 2019-005011-73,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Amiens-Picardie,Determination of a trough serum concentration of ofloxacin associated to increase in side effects frequency in elderly treated for bone and joint infection Relations concentration-toxicité de l’ofl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-005011-73,0,0,0 2019-005017-39,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Seattle Genetics, Inc.","Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-005017-39,0,0,0 2019-005017-39,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Seagen Inc.,"Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-005017-39,0,0,0 2019-005017-39,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"SEATTLE GENETICS, INC.","Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-005017-39,0,0,0 2019-005021-79,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amsterdam UMC - location Academic Medical Centre (AMC),Revised dosing recommendations of ciprofloxacin for patients with impaired renal function: a bioequivalence study. Vernieuwde aanbevolen doseringen van ciprofloxacine voor patiënten met een vermind...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-005021-79,0,0,0 2019-005039-94,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Curie,RETINO 2018 : Ocular conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome. RETINO 2018 :Traitements conservateurs du rétinoblastome: efficacité de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-005039-94,0,0,0 2020-000033-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aalborg University Hospital,Aciclovir for HSV-2 meningitis: A double-blind randomised controlled trial (AMEN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000033-41,0,0,0 2020-000035-50,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi aventis recherche & développement,"Randomized, open-label, Phase 2 study of SAR408701 combined with pembrolizumab and pembrolizumab alone in patients with CEACAM5 and PD-L1 positive advanced/metastatic non-squamous non–small-cell lung ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000035-50,0,0,0 2020-000041-14,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Norfolk and Norwich University Hospitals NHS Foundation Trust,The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): a randomised placebo-controlled multi-centre clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000041-14,0,0,0 2020-000043-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Groupe Hospitalier Paris Saint-Joseph,Efficacy and tolerance of Liraglutide for weight loss in obese type 2 diabetic hemodialysis patients Efficacité et tolérance du Liraglutide sur la perte de poids chez les patients hémodialysés dia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000043-31,0,0,0 2020-000047-31,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Applied Molecular Transport Inc.,"A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000047-31,0,0,0 2020-000048-73,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Applied Molecular Transport Inc.,"A Combined Phase 2/3 12-week, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of AMT-101 in Subjects with Chronic Antibiotic-resistant Pouchitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000048-73,0,0,0 2020-000050-10,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,University of Queensland,Finding the Optimal Regimen for Mycobacterium abscessus Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000050-10,0,0,0 2020-000053-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UMC Utrecht,The MEtformin-LIfestyle in Antipsychotic users trial (MELIA): optimizing the use of metformin in the management of antipsychotic-induced weight gain.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000053-27,0,0,0 2020-000057-27,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,Leiden University Medical Center,Recovery of carotid body function after full recovery neuromuscular block,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000057-27,0,0,0 2020-000058-89,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000058-89,0,0,0 2020-000058-89,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000058-89,0,0,0 2020-000065-16,2,2022-05-03,2022-05-03,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Afimmune Ltd.,"A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients with Hypertriglyceridemia and Type 2 Diabete...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000065-16,1,0,0 2020-000065-16,2,2022-05-03,2022-05-03,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Afimmune,"A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients with Hypertriglyceridemia and Type 2 Diabete...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000065-16,1,0,0 2020-000067-23,2,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Polyneuron Pharmaceuticals AG,"First in Human Study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of PPSGG in anti-MAG neuropathy patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000067-23,0,0,0 2020-000073-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Cancer Trials Ireland,"Paricalcitol Trial: Phase II, Open label clinical trial of Paricalcitol in combination with Gemcitabine/ Nab-Paclitaxel therapy in advanced pancreatic cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000073-24,0,0,0 2020-000077-25,2,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,Eli Lilly and Company,"Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000077-25,0,0,0 2020-000078-12,10,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim BV,"A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 1358894 once daily over 12 week treatment period in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000078-12,0,0,0 2020-000078-12,10,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim France,"A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 1358894 once daily over 12 week treatment period in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000078-12,0,0,0 2020-000078-12,10,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 1358894 once daily over 12 week treatment period in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000078-12,0,0,0 2020-000078-12,10,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim,"A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 1358894 once daily over 12 week treatment period in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000078-12,0,0,0 2020-000078-12,10,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 1358894 once daily over 12 week treatment period in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000078-12,0,0,0 2020-000078-12,10,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 1358894 once daily over 12 week treatment period in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000078-12,0,0,0 2020-000078-12,10,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,SCS Boehringer Ingelheim Comm. V,"A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 1358894 once daily over 12 week treatment period in patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000078-12,0,0,0 2020-000079-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Pharmathen S.A.,"A phase III, multicentre, prospective, randomized, assessor-blinded, two-arm, parallel group, therapeutic non-inferiority 3-month clinical trial to compare the efficacy and safety of a generic fixed c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000079-18,0,0,0 2020-000082-16,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,EsoCap AG,"A randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000082-16,0,0,0 2020-000085-42,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,1,LABO'LIFE Belgium sprl,"Randomized, placebo-controlled, double blind study to evaluate the efficacy of 2LEBV® and 2LXFS® on asthenia in patients with an EBV infection. EBVAST Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000085-42,0,0,0 2020-000086-17,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Akari Therapeutics Plc,Multicentre Study of nomacopan in Paediatric Haematopoietic Stem-Cell Transplant Associated Thrombotic Microangiopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000086-17,0,0,0 2020-000087-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CMC AMBROISE PARE,Time to transit Recovery After treatment with Naloxegol in cardiac Surgery Intensive care Trial Intérêt du Naloxégol dans la reprise du transit en postopératoire de chirurgie cardiaque,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000087-26,0,0,0 2020-000089-41,1,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,1,Foundation Consumer Healthcare (FCH),"Randomized, Open-Label, Multicenter Proof-of-Principle Study to Assess the Effect of Single Doses of 1.5 mg and 3.0 mg Levonorgestrel During the Mid-Follicular Phase on the Inhibition of Ovulation in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000089-41,0,0,0 2020-000090-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"TiumBio Co., Ltd.","A Phase IIa, Multicenter, Randomized, Double-Blind, Parallel- Group, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of Orally Administered TU2670 in Subjects with Moder...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000090-25,0,0,0 2020-000094-24,4,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000094-24,0,0,0 2020-000095-38,1,,,0,1,1,0,0,1,3,0,0,4,0,0,0,0,1,"AveXis, Inc.","Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000095-38,0,1,1 2020-000096-21,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NX Development Corp.,A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients with Newly Diagnosed or Recurrent Meningiomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000096-21,0,0,0 2020-000097-15,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000097-15,0,0,0 2020-000097-15,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000097-15,0,0,0 2020-000100-11,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffman-La Roche Ltd.,"A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS DOCETAXEL MONO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000100-11,0,0,0 2020-000100-11,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS DOCETAXEL MONO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000100-11,0,0,0 2020-000102-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Mental Healt Center Copenhagen,Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration in glycaemic control in prediabetic or diabetic patients with schizophrenia spectrum disorder treated with the antip...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000102-28,0,0,0 2020-000105-92,6,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study with Open-Label Extension to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LMI070/branaplam when A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000105-92,0,0,0 2020-000105-92,6,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,NOVARTIS PHARMA AG,"A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study with Open-Label Extension to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LMI070/branaplam when A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000105-92,0,0,0 2020-000105-92,6,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Novartis Farmacéutica S.A.,"A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study with Open-Label Extension to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LMI070/branaplam when A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000105-92,0,0,0 2020-000107-36,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Vertanical GmbH,"Proof of efficacy, maintenance of efficacy, long-term safety and investigation of the potential for dependence and abuse and the effect of abrupt drug withdrawal of VER-01 in a multicenter study in th...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000107-36,0,0,0 2020-000109-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,DIPARTIMENTO DI ONCOLOGIA-UNIVERSITA' DEGLI STUDI DI TORINO,"A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000109-10,0,0,0 2020-000110-15,4,2022-08-31,2022-08-31,1,0,0,0,0,0,0,0,0,2,0,0,0,0,1,ALFASIGMA S.P.A.,"Multicentre, multinational, randomised, double blind, placebo-controlled study on Sulodexide for the management of leg symptoms in patients with chronic venous disease VEINS (VEnous INvestigation wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000110-15,1,0,0 2020-000110-15,4,2022-08-31,2022-08-31,1,0,0,0,0,0,0,0,0,2,0,0,0,0,1,Alfasigma S.p.A.,"Multicentre, multinational, randomised, double blind, placebo-controlled study on Sulodexide for the management of leg symptoms in patients with chronic venous disease VEINS (VEnous INvestigation wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000110-15,1,0,0 2020-000111-69,6,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,CTI BioPharma Corp.,"PACIFICA Phase 3: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000111-69,0,0,0 2020-000111-69,6,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,CTI BIOPHARMA CORP.,"PACIFICA Phase 3: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000111-69,0,0,0 2020-000112-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,[18F]fluoro-PEG-folate PET/CT imaging in patients with epithelial ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000112-29,0,0,0 2020-000116-30,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000116-30,0,0,0 2020-000119-66,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000119-66,0,0,0 2020-000119-66,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000119-66,0,0,0 2020-000120-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Cliniques universitaires Saint-Luc,Activity and safety of peptide-based immunotherapy in an umbrella window pre-operative opportunity phase II study in patients with squamous cell carcinoma of the head and neck.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000120-19,0,0,0 2020-000121-37,3,2021-10-12,2021-10-12,3,0,0,0,0,0,3,0,0,1,0,0,0,0,1,CYCLOPHARMA,A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000121-37,0,0,0 2020-000121-37,3,2021-10-12,2021-10-12,3,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Curium PET France,A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000121-37,0,0,0 2020-000122-26,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,University College London (UCL),"A Phase IIa, open label, single-site, 48 week randomised controlled trial evaluating the safety and efficacy of Exenatide once-weekly in the treatment of patients with Multiple System Atrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000122-26,0,0,0 2020-000123-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Investigación Biomédica Hospital Ramón y Cajal,"Phase II clinical trial, randomized, double blind, masked, controlled with physiological serum about the efficacy of intravenous administration of vitamin C during the anhepatic phase of liver transpl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000123-39,0,0,0 2020-000126-26,1,2021-03-08,2021-03-08,1,1,0,0,0,0,3,0,1,1,0,0,1,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc",A Hepatitis B Vaccine Challenge Study to Demonstrate the Durability of Protection Against Hepatitis B Virus Infection in Healthy Children Vaccinated Approximately 9 Years Previously With a 2- or 3-Dos...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000126-26,0,0,0 2020-000130-18,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Fundación para la Inv. Biomédica Hospital Clínico San Carlos,"Co-THEIA (Combination THerapy with mEthotrexate and adalImumAb for uveitis): Efficacy, safety and cost-effectiveness of methotrexate, adalimumab, or their combination in non infectious non anterior uv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000130-18,0,0,0 2020-000134-17,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Diffuse Cutaneous Systemic Scleros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000134-17,0,0,0 2020-000134-17,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Mitsubishi Tanabe Development America Inc.,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Diffuse Cutaneous Systemic Scleros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000134-17,0,0,0 2020-000134-17,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Mitsubishi Tanabe Pharma Development America (MTDA), Inc.","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Diffuse Cutaneous Systemic Scleros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000134-17,0,0,0 2020-000135-47,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitario Fundación Alcorcón,"Analgesic efficacy of erector spinae plane block in lumbar spine surgery: a prospective, randomized and double blind study. ANALGESIA POSTOPERATORIA MEDIANTE EL BLOQUEO BILATERAL DEL PLANO DEL MÚSC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000135-47,0,0,0 2020-000138-16,4,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,ASTRAZENECA AB,"A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma (ADAGIO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000138-16,0,0,0 2020-000138-16,4,,,0,0,0,0,0,1,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma (ADAGIO)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000138-16,0,0,0 2020-000140-58,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,Complement Inhibition: Attacking the Overshooting Inflammation @fter Traumatic Brain Injury - A phase II trial on the safety and efficacy of C1 esterase inhibitor Cinryze for the acute management of s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000140-58,0,0,0 2020-000142-34,5,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,0,Princess Máxima Center for pediatric oncology,"A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML, ITCC-092",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000142-34,0,0,0 2020-000144-61,7,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000144-61,0,0,0 2020-000144-61,7,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000144-61,0,0,0 2020-000146-33,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,"Randomized phase III trial on NIraparib-Dostarlimab) vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000146-33,0,0,0 2020-000148-76,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Stockholm Health Care Services,Effects of Montelukast on neuroinflammation in Parkinson's Disease. An open-label single-center trial. Effekt av Montelukast på neuroinflammation vid Parkinsons sjukdom.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000148-76,0,0,0 2020-000149-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Karolinska University Hospital,NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000149-15,0,0,0 2020-000154-10,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Warwick,Paramedic Analgesia Comparing Ketamine and MorphiNe in trauma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000154-10,0,0,0 2020-000155-12,1,,,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,InBrain Pharma SAS,A new concept of continuous dopaminergic stimulation by cerebroventricular administration of A-dopamine (dopamine stored in anaerobia) for severe motor fluctuations in Parkinson’s disease? Evaluati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000155-12,0,0,0 2020-000156-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000156-35,0,0,0 2020-000157-27,3,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Incyte Corporation,A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor–Naïve With Selected Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000157-27,0,0,0 2020-000158-88,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Hutchison MediPharma Limited,"A Global, Multi Center, Randomized, Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000158-88,0,0,0 2020-000160-28,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Medical University of Vienna,Investigation of SSRI induced neuroplastic changes in musicians using functional magnetic resonance imaging Untersuchung von SSRI induzierten neuroplastischen Veränderungen bei Musikern mittels fun...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000160-28,0,0,0 2020-000165-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amsterdam University Medical Center - location VU Medical Center,"A single-center, prospective, placebo-controlled, double-blind, randomized, cross-over mechanistic intervention study to investigate the effect of empagliflozin on kidney function in people with eithe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000165-16,0,0,0 2020-000168-53,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Ellipses Pharma Limited,"A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000168-53,0,0,0 2020-000169-17,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase 2b Multinational, Randomized, Double-blind, Parallel Group, 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Chronic Spontaneous ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000169-17,0,0,0 2020-000172-38,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,NETRIS PHARMA,"A randomised, multicentre, open label, Phase I/II study to evaluate the safety (Phase I - safety run in), clinical and biological activity (Phase II) of a humanized monoclonal antibody targeting Netri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000172-38,0,0,0 2020-000177-25,5,,,0,0,1,0,0,1,2,0,0,0,0,0,0,0,1,Atara Biotherapeutics Inc.,"An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus associated Diseases Studio di Fase 2, multi-coorte, a br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000177-25,0,0,0 2020-000177-25,5,,,0,0,1,0,0,1,2,0,0,0,0,0,0,0,1,"Atara Biotherapeutics, Inc.","An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus associated Diseases Studio di Fase 2, multi-coorte, a br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000177-25,0,0,0 2020-000179-19,5,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"IMMUNOGEN, INC.","SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000179-19,0,0,0 2020-000179-19,5,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"ImmunoGen, Inc.","SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000179-19,0,0,0 2020-000185-42,2,2022-01-25,2022-01-25,1,0,0,0,0,1,2,0,0,2,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000185-42,1,0,0 2020-000189-41,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An open-label, single arm, long term trial of Spesolimab treatment in patients with Palmoplantar Pustulosis (PPP) who have completed previous BI Spesolimab trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000189-41,0,0,0 2020-000189-41,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Boehringer Ingelheim France,"An open-label, single arm, long term trial of Spesolimab treatment in patients with Palmoplantar Pustulosis (PPP) who have completed previous BI Spesolimab trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000189-41,0,0,0 2020-000189-41,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"An open-label, single arm, long term trial of Spesolimab treatment in patients with Palmoplantar Pustulosis (PPP) who have completed previous BI Spesolimab trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000189-41,0,0,0 2020-000189-41,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,SCS Boehringer Ingelheim Comm. V,"An open-label, single arm, long term trial of Spesolimab treatment in patients with Palmoplantar Pustulosis (PPP) who have completed previous BI Spesolimab trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000189-41,0,0,0 2020-000189-41,7,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Boehringer Ingelheim Limited,"An open-label, single arm, long term trial of Spesolimab treatment in patients with Palmoplantar Pustulosis (PPP) who have completed previous BI Spesolimab trials",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000189-41,0,0,0 2020-000192-20,3,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,1,"DAIICHI SANKYO, INC.","A Phase 4, multicenter study to evaluate the discontinuation and re treatment in subjects with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000192-20,0,0,0 2020-000192-20,3,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,1,DAIICHI SANKYO INC.,"A Phase 4, multicenter study to evaluate the discontinuation and re treatment in subjects with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000192-20,0,0,0 2020-000195-38,6,2021-03-12,2021-03-12,6,1,0,0,0,0,3,0,0,1,1,1,1,0,1,AstraZeneca AB,"A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab for the Prevention of Recurrence of Nasal Polyps Following Surgical Remova...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000195-38,0,0,0 2020-000197-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.",An Open-Label Extension Study of ISIS 721744 in Patients with Hereditary Angioedema,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000197-14,0,0,0 2020-000201-84,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Das Kinderwunsch Institut Schenk GmbH,Oral and intravenous iron substitution for the treatment of iron deficiency symptoms in the context of fertility treatment - an exploratory pilot study Orale und intravenöse Eisensubstitution zur B...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000201-84,0,0,0 2020-000204-11,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novo Nordisk A/S,Effect of subcutaneous semaglutide 2.4 mg once-weekly compared to placebo in subjects with obesity and knee osteoarthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000204-11,0,0,0 2020-000205-89,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Infectious Diseases, Hvidovre Hospital","Changes in weight, body composition and metabolic parameters after switch to either dolutegravir/lamivudine or doravirine/tenofovir/lamivudine compared to continued treatment with dolutegravir/tenofov...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000205-89,0,0,0 2020-000209-10,6,2022-08-08,2022-08-08,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ASTRAZENECA AB,"A Phase II, Open-label Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination with Durvalumab and in Combination with Cabazitaxel and Durvalumab in Patients Who Have Progress...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000209-10,1,0,0 2020-000209-10,6,2022-08-08,2022-08-08,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase II, Open-label Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination with Durvalumab and in Combination with Cabazitaxel and Durvalumab in Patients Who Have Progress...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000209-10,1,0,0 2020-000210-15,6,2021-04-27,2021-04-27,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Ionis Pharmaceuticals, Inc.","A Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Patients with Mild to Moderate COPD with Chronic Bronchitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000210-15,1,0,0 2020-000210-15,6,2021-04-27,2021-04-27,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"IONIS PHARMACEUTICALS, INC.","A Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Patients with Mild to Moderate COPD with Chronic Bronchitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000210-15,1,0,0 2020-000213-33,1,2021-02-23,2021-02-23,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Department of Dentistry and Oral Health,Fluoride in saliva during and after use of high-fluoride toothpaste Fluorid i saliva under og efter anvendelse af højfluorid tandpasta,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000213-33,0,0,0 2020-000220-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Verein zur Förderung von Wissenschaft und Forschung an der 1. Med. Abteilung der Krankenanstalt Rudolfstiftung,Comparing effects of weight loss by Liraglutide 3.0 mg with conventional liver fasting in non-alcoholic fatty liver disease before bariatric surgery Liraglutide 3.0 mg im Vergleich zu konventionel...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000220-19,0,0,0 2020-000226-26,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Shire,"A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients with Status Epilepticus (Convulsive) in the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000226-26,0,1,1 2020-000228-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Graz,Probiotic dietary Intervention in Polycystic Ovary Syndrome – A Randomized Controlled Trial Probiotische Interventionsstudie bei Polyzystischem Ovarsyndrom (PCOS) - eine randomisiert kontrollierte ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000228-20,0,0,0 2020-000229-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Galderma S.A.,An Open-label Drug-Drug Interaction Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Subjects with Moderate-to-Severe Atopic Dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000229-24,0,0,0 2020-000233-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sahlgrenska University Hospital,Labour induction in an outpatient setting - a multicenter randomized controlled trial. OPTION - OutPatienT InductiON,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000233-41,0,0,0 2020-000235-51,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Nottingham University Hospitals NHS Trust,"BCG+MM Trial Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: a randomised phase 3 trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000235-51,0,0,0 2020-000236-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Chronic Obstructive Pulmonary Disease Trial Network (COP:TRIN),COPD EXacerbation and Pulmonary hypertension Trial - The effect of Sildenafil treatment to patients with COPD exacerbation and pulmonary hypertension Klinisk forsøg vedrørende behandling med Silden...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000236-22,0,0,0 2020-000238-16,2,2022-08-23,2022-08-23,1,0,0,0,0,0,2,0,0,1,1,1,0,0,1,"Arena Pharmaceuticals, Inc.","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Effect on Microvascular Obstruction of Temanogrel in Subjects Undergoing Percutaneous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000238-16,0,0,0 2020-000241-14,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,ADC Therapeutics SA,A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000241-14,0,0,0 2020-000241-14,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,ADC THERAPEUTICS SA,A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000241-14,0,0,0 2020-000249-14,1,2021-04-16,2021-04-16,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AKL Research and Development Ltd,"A placebo-controlled, double-blinded, randomized, trial using a combination of apocynin and paeonol (APPA) for the treatment of knee osteoarthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000249-14,0,0,0 2020-000250-94,1,,,0,1,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO AUXOLOGICO ITALIANO,Mutation-specific therapy for the long QT syndrome Terapia mutazione-specifica per la sindrome del QT lungo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000250-94,0,0,0 2020-000252-35,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Lone Skov,The risk of an elevated intraocular pressure after treatment with topical corticosteroids in the periocular region Risikoen for intraokulær trykstigning efter behandling med topikale kortikosteroid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000252-35,0,0,0 2020-000253-27,7,2021-06-08,2021-07-19,5,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"PellePharm, Inc.","A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects with Gorlin Syndrome (Basal Cell Nevus Syndrome)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000253-27,1,0,0 2020-000255-12,2,2022-03-08,2022-03-08,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase 2b, Multicentre, Randomised, Double-blind, Placebo controlled, and Open-label Comparator Study of Cotadutide in Participants Who Have Chronic Kidney Disease with Type 2 Diabetes Mellitus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000255-12,1,0,0 2020-000256-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Aalborg University Hospital,Does intravenous immunoglobulin and prednisolone treatment improve success rate in women with recurrent pregnancy loss after assisted reproductive technology treatment? Kan IVIG og prednisolon beha...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000256-35,0,0,0 2020-000273-24,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Birmingham,Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: A Molecularly Guided Phase 2 Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000273-24,0,0,0 2020-000276-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Álvaro Ruibal Morell,Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response Estudios de heterogeneidad tumoral mediante PET dedicado de ma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000276-38,0,0,0 2020-000282-16,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust and The University of Cambridge,Pharmacological management of seizures post traumatic brain injury (MAST),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000282-16,0,0,0 2020-000284-23,6,2022-11-01,2022-11-01,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly versus Insulin Lispro (U100) Three Times Daily in Participants with Type 2 Diabetes Inadequately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000284-23,1,0,0 2020-000284-23,6,2022-11-01,2022-11-01,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ELI LILLY ITALIA,"A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly versus Insulin Lispro (U100) Three Times Daily in Participants with Type 2 Diabetes Inadequately...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000284-23,1,0,0 2020-000285-42,4,2022-09-13,2022-09-13,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,AstraZeneca AB,"A Phase 2 Multinational, Randomized, Double-blind, Parallel-group, 16-week Placebo-controlled Study with a 36–week Extension to Investigate the Use of Benralizumab for Patients with Moderate to Severe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000285-42,1,0,0 2020-000287-32,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000287-32,0,0,0 2020-000287-32,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000287-32,0,0,0 2020-000290-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Eli Lilly and Company,CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated with a Novel Hormonal Agent and Taxane-based Chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000290-24,0,0,0 2020-000294-24,1,2023-03-20,2023-03-20,1,0,0,0,0,0,4,0,0,1,1,1,0,0,0,Aarhus University Hospital,Analgesic efficacy of repetitive nerve blockade after major ankle and hindfoot surgery - A feasibility study Analgetisk effekt af repetitiv nerveblokade efter stor ankelkirurgi - et feasibility stu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000294-24,0,0,0 2020-000295-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA,"Phase II trial, open label, single-arm, of Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions Studio di fase II, in aperto, a braccio singolo su inibitore del checkpoint immunitario...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000295-38,0,0,0 2020-000296-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP),Rapid rEcognition of COrticosteroid Resistant or sentive Sepsis RECORDS A Multicentre Concealed‐Allocation Multi-arms Blinded Randomized Controlled Trial to Identify the Best Sepsis Population for Cor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000296-21,0,0,0 2020-000297-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,IMMUNOGAST: An umbrella phase 2 trial to assess personalized targeted IMMUNOtherapy-based regimens in recurrent advanced/metastatic GASTric adenocarcinoma patients IMMUNOGAST: essai « parapluie » d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000297-17,0,0,0 2020-000299-39,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novo Nordisk A/S,Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in subjects with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000299-39,0,0,0 2020-000301-87,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Repare Therapeutics,"Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination with Talazoparib in Advanced Solid Tumors with ATR inhibitor Sen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000301-87,0,0,0 2020-000302-28,1,,,0,0,0,0,0,0,4,0,0,1,1,1,0,1,1,Mundipharma Pharmaceuticals S.L.,Open randomized low interventional clinical trial to compare efficiency in symptom control between fluticasone propionate/formoterol k-haler at medium strength versus an high strength ICS/LABA for the...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000302-28,0,0,0 2020-000306-29,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bayer AG,"A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000306-29,0,0,0 2020-000306-29,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BAYER AG,"A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000306-29,0,0,0 2020-000308-12,1,,,0,0,0,0,0,1,2,0,1,0,0,0,0,0,0,ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS,« Mesenchymal stromal cells treatment in Lyell syndrome: A pilot phase 1-2 open trial” Cellules stromales mésenchymateuses dans le traitement du syndrome du Lyell : une étude de phase pilote I-II e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000308-12,0,0,0 2020-000310-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Christoffer Laustsen,MRI WITH HYPERPOLARISED PYRUVATE IN GLIOBLASTOMA – A PHASE II STUDY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000310-15,0,0,0 2020-000311-71,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,AP-HP/DRCD,Pilot study of a new technique of Oral Fecal Transplantation using frozen stool capsules for the maintenance treatment of UC with pediatric onset Etude pilote d’une nouvelle technique de Transplan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000311-71,0,0,0 2020-000313-33,2,2021-06-18,2021-06-18,1,0,0,0,0,0,4,0,0,2,1,0,0,0,0,UMC Utrecht,"‘Bronchodilators for wheeze in young children presenting to primary care: a randomised, placebo-controlled, multicentre, parallel group trial’",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000313-33,1,0,0 2020-000314-15,1,,,0,1,0,0,0,0,4,0,1,4,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,Open label exploratory study to evaluate the effect of dupilumab on skin barrier function in patients with moderate to severe atopic dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000314-15,0,1,1 2020-000315-76,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,"Centro Hospitalar Universitário de Lisboa Central, EPE",Low molecular weight heparin in the treatment of early fetal growth restriction Heparina de baixo peso molecular no tratamento da restrição de crescimento fetal precoce,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000315-76,0,0,0 2020-000337-40,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000337-40,0,0,0 2020-000338-16,4,2022-07-14,2022-07-14,3,0,0,0,0,0,3,0,0,1,1,0,0,0,1,Janssen-Cilag International NV,"A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000338-16,0,0,0 2020-000341-14,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000341-14,0,0,0 2020-000344-67,4,2021-09-07,2021-09-07,1,1,1,0,0,1,1,0,0,2,0,0,0,0,1,"Dicerna Pharmaceuticals, Inc.","A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients with Primary Hyperox...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000344-67,1,0,0 2020-000346-33,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000346-33,0,0,0 2020-000348-77,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Exelixis, Inc.","A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000348-77,0,0,0 2020-000348-77,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"EXELIXIS, INC.","A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000348-77,0,0,0 2020-000349-14,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"A phase II, open label, randomized, parallel arm study of NIS793 (with and without spartalizumab) in combination with SOC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alone ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000349-14,0,0,0 2020-000349-14,6,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A phase II, open label, randomized, parallel arm study of NIS793 (with and without spartalizumab) in combination with SOC chemotherapy gemcitabine/nab-paclitaxel, and gemcitabine/nab-paclitaxel alone ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000349-14,0,0,0 2020-000350-96,6,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment with Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults with Early, Seropositive Rheumatoid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000350-96,0,0,0 2020-000350-96,6,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment with Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults with Early, Seropositive Rheumatoid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000350-96,0,0,0 2020-000352-36,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Christoffer Laustsen,MRI of neurometabolic impairment in ALS and TIA using hyperpolarized pyruvate,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000352-36,0,0,0 2020-000353-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Bern University Hospital,Clinical Surveillance vs. Anticoagulation for Low-risk Patients with Isolated Subsegmental Pulmonary Embolism: A Multicenter Randomized Placebo-Controlled Non-Inferiority Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000353-26,0,0,0 2020-000354-10,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Celgene Corporation,"A PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY TO ASSESS SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF CC-220, ALONE AND IN COMBINATION WITH AN ANTI-CD20 MONOCLONAL ANTIBODY (MAB) IN SUBJECTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000354-10,0,0,0 2020-000362-42,7,2022-05-16,2022-06-29,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,OXURION NV,"A Phase 2, randomised, multicentre study to assess the dose level of multiple THR-687 injections and to evaluate the efficacy and safety of THR-687 versus aflibercept for the treatment of diabetic mac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000362-42,1,0,0 2020-000362-42,7,2022-05-16,2022-06-29,3,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Oxurion NV,"A Phase 2, randomised, multicentre study to assess the dose level of multiple THR-687 injections and to evaluate the efficacy and safety of THR-687 versus aflibercept for the treatment of diabetic mac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000362-42,1,0,0 2020-000374-21,2,2022-01-25,2022-01-25,2,0,0,0,0,0,2,0,0,1,0,0,0,0,1,"Portola Pharmaceuticals, INC.","PROSPECTIVE, OPEN-LABEL STUDY OF ANDEXANET ALFA IN PATIENTS RECEIVING A FACTOR XA INHIBITOR WHO REQUIRE URGENT SURGERY (ANNEXA-S)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000374-21,0,0,0 2020-000374-21,2,2022-01-25,2022-01-25,2,0,0,0,0,0,2,0,0,1,0,0,0,0,1,"Portola Pharmaceuticals, Inc.","PROSPECTIVE, OPEN-LABEL STUDY OF ANDEXANET ALFA IN PATIENTS RECEIVING A FACTOR XA INHIBITOR WHO REQUIRE URGENT SURGERY (ANNEXA-S)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000374-21,0,0,0 2020-000376-38,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Mitsubishi Tanabe Development America Inc.,"A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered over 96 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000376-38,0,0,0 2020-000376-38,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Mitsubishi Tanabe Pharma Development America, Inc.","A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered over 96 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000376-38,0,0,0 2020-000377-25,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,DEBIOPHARM INTERNATIONAL S.A.,"A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000377-25,0,0,0 2020-000377-25,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Debiopharm International S.A.,"A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000377-25,0,0,0 2020-000377-25,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Healthcare KGaA, an affiliate of Merck KGaA, Darmstadt, Germany","A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000377-25,0,0,0 2020-000382-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical Center - University of Freiburg,"Efficacy of daratumumab (Dara) retreatment using a histone deacetylase-inhibitor (HDACi: panobinostat) as a Dara-longevity-inducing, epigenetic agent in combination with bortezomib-dexamethasone as ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000382-16,0,0,0 2020-000384-23,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A multicenter, randomized, double-blind, parallel group, placebo controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000384-23,0,0,0 2020-000384-23,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim Limited,"A multicenter, randomized, double-blind, parallel group, placebo controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000384-23,0,0,0 2020-000384-23,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim España S.A.,"A multicenter, randomized, double-blind, parallel group, placebo controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000384-23,0,0,0 2020-000388-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Ruprecht-Karls University Heidelberg, Medical Faculty, repr. by HD University Hospital and its Commercial Managing Dir.","Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB (T3N2 only) non-squamous Non-Small Cell Lun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000388-21,0,0,0 2020-000393-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,DIP. MEDICINA DEI SISTEMI UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA,USE OF SULFUR HEXAFLUORIDE MICROBUBBLES IN INTRAOPERATIVE SURGICAL EVALUATION OF AXILLARY LYMPH NODES IN LOCO-REGIONAL ANESTHESIA BREAST SURGERY: COMPARISON WITH THE TRADITIONAL METHODICAL. PRELIMINAR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000393-20,0,0,0 2020-000396-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Mech-Sense, Aalborg University Hospital","Opium tincture against chronic diarrhea - Patients: An investigator initiated, randomized placebo-controlled, clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000396-20,0,0,0 2020-000397-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,MEDICA SCIENTIA INNOVATION RESEARCH S.L.,"A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic CArcinoma PaTIents. PECATI Studio ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000397-18,0,0,0 2020-000402-29,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F.Hoffmann La-Roche Ltd,"A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000402-29,0,0,0 2020-000402-29,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F.Hoffmann-La Roche Ltd,"A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000402-29,0,0,0 2020-000402-29,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000402-29,0,0,0 2020-000404-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,FIGO 2018 stage IB2 (≥2cm - <4 cm) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000404-11,0,0,0 2020-000405-83,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Vanda Pharmaceuticals Inc.,"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of iloperidone for 4 weeks in the treatment of patients with acute manic episodes associated with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000405-83,0,0,0 2020-000408-13,1,2021-10-28,2021-10-28,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Allergy Therapeutics (UK) Ltd.,"A randomised, double-blind, placebo-controlled exploratory study to explore the efficacy and safety of PQ Grass 27600 SU in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000408-13,0,0,0 2020-000409-94,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,"An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in combination with Bortezomib and Dexamethasone in patients with Relapsed or Refractory Plasmablastic lymphoma (DALYA trial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000409-94,0,0,0 2020-000412-30,2,,,0,0,0,0,0,0,0,0,1,4,0,0,0,0,1,Chemo Research S.L.,"A multicenter, open-label, controlled study to investigate the effect of LF111 on bone mineral density (BMD) in adolescent and adult women in comparison with non-users of hormonal contraceptive method...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000412-30,0,0,0 2020-000417-33,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,VIELABIO Inc.,"A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4 Related Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000417-33,0,0,0 2020-000417-33,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Viela Bio, Inc.","A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4 Related Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000417-33,0,0,0 2020-000419-56,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ITB-MED AB,"A 12-month, randomized, controlled, open-label, dose escalation study evaluating safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of an anti-CD2 monoclonal antibody, TCD601 (sipli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000419-56,0,0,0 2020-000421-76,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Hospital,Aggravated airway inflammation: research on biological treatment (Mepolizumab) AirGOs-biologics,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000421-76,0,0,0 2020-000424-19,4,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Viiv Healthcare UK Limited,"A Phase IIIb, open-label, hybrid type III trial evaluating implementation strategies for long-acting cabotegravir plus long-acting rilpivirine every two months in HIV-1 infected, virologically suppres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000424-19,0,0,0 2020-000428-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"DIPARTIMENTO DI SCIENZE BIOMEDICHE SPERIMENTALI E CLINICHE, UNIVERSITà DI FIRENZE",ExclUsive endocRine therapy Or Partial breast irradiation for women aged =70 years with luminal A-like early stage breast cancer (EUROPA): a randomized phase 3 non-inferiority trial. Terapia endocr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000428-21,0,0,0 2020-000429-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University of Oslo, Faculty of Medicine, Institute of Health and Society",BASIC - Better treatment for acute sinusitis in primary care: a randomized controlled trial testing topical treatment with chloramphenicol eye drops,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000429-17,0,0,0 2020-000431-49,14,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,Celgene Corporation,"A Phase 3, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000431-49,0,0,0 2020-000431-49,14,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,CELGENE CORPORATION,"A Phase 3, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000431-49,0,0,0 2020-000433-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus University Medical Centre Rotterdam,Treatment of vascular stiffness in patients with autosomal dominant polycystic kidney disease Behandeling van vaatstijfheid bij patiënten met autosomaal dominante polycysteuze nierziekte,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000433-40,0,0,0 2020-000435-45,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University of Graz,"A randomised, double-blind, placebo controlled, parallel group, multi-centre trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of Verapamil SR on preservat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000435-45,0,0,0 2020-000437-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,NEWRON PHARMACEUTICALS SPA,"A pilot, open-label, rater-blinded, randomized, parallel-group, multi-center study to evaluate the safety, tolerability and preliminary efficacy of three add-on fixed doses of Evenamide in patients wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000437-41,0,0,0 2020-000439-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,NEWRON PHARMACEUTICALS SPA,"An open-label, multi-center, extension study to evaluate the long-term safety, tolerability and preliminary efficacy of Evenamide as add-on treatment in patients with treatment-resistant schizophrenia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000439-32,0,0,0 2020-000440-63,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F.Hoffmann La-Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000440-63,0,0,0 2020-000440-63,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000440-63,0,0,0 2020-000441-13,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL OR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000441-13,0,0,0 2020-000441-13,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F.Hoffmann La-Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL OR ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000441-13,0,0,0 2020-000442-34,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,NOVO NORDISK. S.P.A.,"A 78-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with non-insulin anti-diabetic treatment, in insulin naï...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000442-34,0,0,0 2020-000442-34,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novo Nordisk A/S,"A 78-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with non-insulin anti-diabetic treatment, in insulin naï...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000442-34,0,0,0 2020-000444-58,1,2022-02-24,2022-02-24,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Adocia,A Phase 2 Trial to Assess the Efficacy and Safety of M1 Pram P037 prandial insulin in T1DM subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000444-58,0,0,0 2020-000446-34,3,2021-04-24,2021-04-24,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,ALK-Abelló A/S,"A 28-day, single-armed, open-label trial to evaluate safety of the house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet in adolescent subjects (12-17 years of age) with HDM allergic rh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000446-34,0,0,0 2020-000449-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Amsterdam University Medical Centers, location AMC",Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000449-15,0,0,0 2020-000451-12,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BioNTech SE,"A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000451-12,0,0,0 2020-000454-10,3,2022-03-01,2022-03-01,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novo Nordisk A/S,"A 26-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin degludec, both with or without non-insulin anti-diabetic drugs, in subjects with type 2 diabetes tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000454-10,1,0,0 2020-000455-12,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ALK-Abelló A/S,"A randomised, parallel-group, double-blind, placebo-controlled phase III trial assessing the efficacy and safety of 5-grass mix SLIT-drops in adults with grass pollen-induced rhinoconjunctivitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000455-12,0,0,0 2020-000459-11,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Zymeworks Inc.,"A Phase 2b, open-label, single-arm study of ZW25 monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers Studio di fase 2b, in aperto, a braccio singolo, su ZW25 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000459-11,0,0,0 2020-000462-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Västerbotten county,"Efficacy, tolerability and preferences of peroral or subcutaneous methotrexate in patients with early rheumatoid arthritis – a randomized register based multicenter study Effektivitet, tolerabilite...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000462-41,0,0,0 2020-000464-27,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Artelo Biosciences Limited,A Phase 1/2 Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000464-27,0,0,0 2020-000465-17,1,2020-12-03,2020-12-03,1,1,0,0,0,0,2,0,1,1,0,0,1,0,1,Sintetica S.A.,"A Phase II/III, Randomized, Double-Masked, Vehicle-Controlled, Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in healthy volunteers Eine randomisierte, doppelt maskierte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000465-17,0,0,0 2020-000469-18,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Initiator Pharma,"A Randomised, Double-Blind, Placebo-Controlled, Crossover Trial Studying the Efficacy and Safety of IP2018 in Depressed, Erectile Dysfunction (ED) Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000469-18,0,0,0 2020-000471-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CH Tourcoing,"Rifabutin versus rifampicin for treatment of staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy): a multicenter randomized, open-label...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000471-20,0,0,0 2020-000472-37,4,2022-06-23,2022-06-23,4,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Novo Nordisk A/S,"A 26-week double blinded, multiregional, trial comparing the effect and safety of once weekly insulin icodec and once daily insulin degludec 100 units/mL, both in combination with non-insulin anti-dia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000472-37,0,0,0 2020-000473-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grand Hôpital de Charleroi,ESKETamine for FIBromyalgia treatment Perfusions intraveineuses de S-KETAMINE dans les syndromes fibromyalgiques : une étude exploratoire,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000473-25,0,0,0 2020-000474-16,3,2022-06-16,2022-06-16,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVO NORDISK. S.P.A.,"A 26-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with bolus insulin with or without non-insulin anti-diab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000474-16,1,0,0 2020-000474-16,3,2022-06-16,2022-06-16,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novo Nordisk A/S,"A 26-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with bolus insulin with or without non-insulin anti-diab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000474-16,1,0,0 2020-000475-21,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Actelion Pharmaceuticals Ltd,"A Multicenter, Single-arm, Open-label, Long-term Follow-up Safety Study of Selexipag in Participants who Participated in a Previous Selexipag Study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000475-21,0,0,0 2020-000476-38,4,2022-08-29,2022-08-29,3,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novo Nordisk A/S,Effectiveness and safety of once weekly insulin icodec used with DoseGuide versus once daily basal insulin analogues in an insulin naïve type 2 diabetes population in a clinical practice setting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000476-38,1,0,0 2020-000483-27,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,"St. Joseph’s Healthcare, McMaster University",Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis in ICU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000483-27,0,0,0 2020-000489-40,1,2020-10-13,2020-10-13,1,0,0,0,0,1,2,0,0,1,1,1,1,0,1,Inflazome (Australia) Pty Ltd.,"A Multi-Centre, Randomised, Open-Label, Phase IIb Study to Evaluate the Safety, Tolerability and Efficacy of IZD174 in Patients with Cryopyrin Associated Periodic Syndromes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000489-40,0,0,0 2020-000493-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Radboud University Medical Center,Dose tapering and Early Discontinuation to InCreAse cosT-effectIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000493-15,0,0,0 2020-000496-20,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,INCYTE CORPORATION,An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherap...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000496-20,0,0,0 2020-000496-20,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Incyte Corporation,An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherap...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000496-20,0,0,0 2020-000501-93,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,BioCryst Pharmaceuticals Inc,"A Phase 2, Open-Label Study to Evaluate the Long-term Safety of Oral BCX9930 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH) Uno studio di fase 2, in aperto, per valutare la sicurezza a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000501-93,0,0,0 2020-000501-93,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,BIOCRYST PHARMACEUTICALS INC.,"A Phase 2, Open-Label Study to Evaluate the Long-term Safety of Oral BCX9930 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH) Uno studio di fase 2, in aperto, per valutare la sicurezza a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000501-93,0,0,0 2020-000502-29,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffman-La Roche Ltd.,"A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000502-29,0,0,0 2020-000502-29,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000502-29,0,0,0 2020-000504-11,7,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Novo Nordisk A/S,"Open-label study investigating efficacy, safety and pharmacokinetics of concizumab prophylaxis in children below 12 years with haemophilia A or B with or without inhibitors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000504-11,0,0,0 2020-000504-11,7,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,NOVO NORDISK. S.P.A.,"Open-label study investigating efficacy, safety and pharmacokinetics of concizumab prophylaxis in children below 12 years with haemophilia A or B with or without inhibitors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000504-11,0,0,0 2020-000505-80,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,TRANSGENE,"A phase I/IIa study of intra-tumoral BT-001 (TG6030) administered alone and in combination with pembrolizumab in patients with cutaneous or, subcutaneous lesions or easily injectable lymph nodes of me...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000505-80,0,0,0 2020-000508-13,3,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Princess Máxima Center for Pediatric Oncology,"An open-label, randomized clinical trial on teicoplanin infection prophylaxis in pediatric patients with acute myeloid leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000508-13,0,0,0 2020-000509-96,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Princess Maxima Center for pediatric oncology,"Near-infrared fluorescence imaging using indocyanine green as an adjunct to improve standard-of-care sentinel lymph node procedure in pediatric patients with melanoma or sarcoma of head/neck/trunk, pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000509-96,0,0,0 2020-000511-77,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, double-blind, placebo-controlled, parallel-group study of the safety, tolerability, pharmacokinetics, and therapeutic efficacy of SAR441344 in adult patients with primary Sjögren’s synd...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000511-77,0,0,0 2020-000517-33,1,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,"Rocket Pharmaceuticals, Inc.",Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I):A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Lentiv...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000517-33,0,0,0 2020-000520-19,1,2021-11-11,2021-11-11,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Bayer AG,"Proof-of-concept, multi-center, randomized, double-blind, placebo-controlled, two-way crossover study to investigate the effect strength of BAY 2586116 on the apnea-hypopnea-index after repetitive nas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000520-19,0,0,0 2020-000529-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Technische Universität Dresden,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSS-OVER STUDY FOR EVALUATION OF THE EFFICIENCY AND SAFETY OF TIOTROPIUM INHALATION SOLUTION (5 µG) VIA RESPIMAT® INHALER once a day for 24 weeks for c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000529-19,0,0,0 2020-000532-22,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,Pearl Therapeutics Inc.,"A Randomized, Double-Blind, Parallel Group, Multi-Center 24 Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persisten...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000532-22,0,1,1 2020-000533-40,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Innovent Biologics (Suzhou) Co., Ltd.","A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000533-40,0,0,0 2020-000535-45,5,2022-10-18,2022-10-18,1,0,1,0,0,1,2,0,0,2,0,0,0,0,1,ProQR Therapeutics,"An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects <8 Years of Age with Leber Congenital Amauros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000535-45,1,0,0 2020-000535-45,5,2022-10-18,2022-10-18,1,0,1,0,0,1,2,0,0,2,0,0,0,0,1,PROQR THERAPEUTICS N.V.,"An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects <8 Years of Age with Leber Congenital Amauros...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000535-45,1,0,0 2020-000540-60,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"SEATTLE GENETICS, INC.","MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000540-60,0,0,0 2020-000540-60,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Seattle Genetics, Inc.","MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000540-60,0,0,0 2020-000543-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Antev Ltd.,"An Adaptive Phase 2, Open-Label, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix Trifluoroacetate, a Gonadotropin-releasing Hormone (GnRH) Anta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000543-31,0,0,0 2020-000546-34,3,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Novo Nordisk A/S,"Effect and safety of liraglutide 3.0 mg on weight management in children with obesity aged 6 to <12 years: 56-week, double-blind, randomised, placebo-controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000546-34,0,0,0 2020-000547-31,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"BeiGene, Ltd.","An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B cell Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000547-31,0,0,0 2020-000547-31,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BeiGene Ltd.,"An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B cell Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000547-31,0,0,0 2020-000548-71,1,2021-02-04,2021-02-04,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Nederlandse Obesitas Kliniek,Liraglutide for low-responders after bariatric surgery Liraglutide voor patiënten die na bariatrische chirurgie minder afvallen dan verwacht.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000548-71,0,0,0 2020-000549-15,1,2022-06-13,2022-06-13,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,University Hospitals Leuven,Al18F-NOTA-octreotide PET imaging of the somatostatin receptor in neuroendocrine tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000549-15,0,0,0 2020-000551-12,1,2021-01-04,2021-01-04,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Steno Diabetes Center Copenhagen,Low-Dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People with Type 1 Diabetes Lav-dosis dasiglucagon til forebyggelse af insulin-induceret hypoglykæmi hos personer med type 1 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000551-12,0,0,0 2020-000553-27,2,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000553-27,0,0,0 2020-000554-97,2,,,0,0,1,0,0,0,1,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase I, Open-Label Study to Evaluate the Pharmacokinetics of Tezepelumab in Children ≥ 5 to 11 Years of Age with Mild, Moderate, or Severe Asthma (TRAILHEAD) I. fázisú, nyílt vizsgálat a tezepel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000554-97,0,0,0 2020-000556-35,14,2022-06-14,2022-06-14,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000556-35,1,0,0 2020-000556-35,14,2022-06-14,2022-06-14,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,ASTRAZENECA AB,"A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Sta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000556-35,1,0,0 2020-000557-27,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000557-27,0,0,0 2020-000557-27,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000557-27,0,0,0 2020-000560-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO ONCOLOGICO VENETO - IRCCS,"Pressurized intraperitoneal aerosol chemotherapy in patients with peritoneal carcinomatosis. PIPAC-IOV study. Single-center, single-arm open-label phase II clinical trial Chemioterapia intraperiton...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000560-37,0,0,0 2020-000561-16,5,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,"EPIK-P2 - A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000561-16,0,0,0 2020-000561-16,5,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"EPIK-P2 - A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000561-16,0,0,0 2020-000569-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital of Montpellier,NEOADUVANT ATEZOLIZUMAB AND ADJUVANT ATEZOLIZUMAB + BEVACIZUMAB IN COMBINATION WITH PERCUTANEOUS RADIOFREQUENCY ABLATION OF SMALL HCC: A MULTICENTER RANDOMIZED PHASE II TRIAL ATEZOLIZUMAB NEOADJUVA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000569-18,0,0,0 2020-000570-25,4,2022-06-07,2022-06-07,3,0,0,0,0,1,3,0,0,2,0,0,0,0,1,CSL BEHRING GMBH,"A multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000570-25,1,0,0 2020-000570-25,4,2022-06-07,2022-06-07,3,0,0,0,0,1,3,0,0,2,0,0,0,0,1,CSL Behring LLC,"A multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in the prophylactic treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000570-25,1,0,0 2020-000571-20,7,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000571-20,0,0,0 2020-000573-25,1,2021-08-23,2021-08-23,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Aarhus University Hospital,Evaluation of patients after cardiac surgery: Novel ultrasound parameters for quantification of renal perfusion & analysis of phenylephrines’ effect on invasive haemodynamics and echocardiographic mea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000573-25,0,0,0 2020-000578-31,3,,,0,0,1,0,0,0,3,0,0,4,0,0,0,0,1,Sedana Medical AB,A Randomised Active-controlled Study to Compare Efficacy and Safety of Inhaled Isoflurane Delivered by the AnaConDa-S (Anaesthetic Conserving Device) to Intravenous Midazolam for Sedation in Mechanica...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000578-31,0,0,0 2020-000579-19,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Stichting TRICALS Foundation,"A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000579-19,0,0,0 2020-000585-41,1,2022-01-12,2022-01-12,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,T-Balance Therapeutics GmbH,Effects of tregalizumab on allergen-induced airway responses and airway inflammation in asthmatic patients Effekte von Tregalizumab auf allergen-induzierte Atemwegsreaktionen und Atemwegsentzündung...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000585-41,0,0,0 2020-000595-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fakultní nemocnice v Motole,Pharmacokinetics and pharmacodynamics of levobupivacaine during continuous caudal epidural analgesia in newborns Farmakokinetika a farmakodynamika levobupivakainu u novorozenců během kontinuální ka...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000595-37,0,0,0 2020-000597-26,12,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,F.Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN ADULT AND ADOLESCENT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000597-26,0,0,0 2020-000597-26,12,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN ADULT AND ADOLESCENT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000597-26,0,0,0 2020-000599-38,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,NANTES CHU,"A phase I/II study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of FR104, a novel antagonist pegylated anti-CD28 Fab’ antibody fragment in de novo renal transpla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000599-38,0,0,0 2020-000604-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",Phase II study of adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the prevention of peritoneal metastases after curative-intent surgery for high-risk colorectal cancer. Studio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000604-11,0,0,0 2020-000605-84,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"KARYOPHARM THERAPEUTICS, INC.","A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000605-84,0,0,0 2020-000605-84,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Karyopharm Therapeutics Inc.,"A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000605-84,0,0,0 2020-000607-36,8,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Celgene Corporation,"A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON CONCOMITA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000607-36,0,0,0 2020-000607-36,8,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,CELGENE CORPORATION,"A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON CONCOMITA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000607-36,0,0,0 2020-000609-10,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Center for Surgical Science,"A combined treatment with GM-CSF, fosfomycin and metronidazole for pouchitis in ulcerative colitis patients after restorative ileal pouch anal anastomosis surgery A clinical safety and proof-of-concep...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000609-10,0,0,0 2020-000612-30,11,2022-05-25,2022-05-25,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000612-30,1,0,0 2020-000612-30,11,2022-05-25,2022-05-25,1,0,0,0,0,0,3,0,0,2,1,0,0,0,1,ASTRAZENECA AB,"A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000612-30,1,0,0 2020-000619-58,2,2022-05-02,2022-05-02,1,0,0,0,0,0,3,0,0,2,1,0,0,0,0,The University of Calgary,A pilot study assessing the feasibility of a randomized controlled trial evaluating aspirin in postpartum women at risk of developing venous thromboembolism Pilot PARTUM Trial: Postpartum Aspirin to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000619-58,1,0,0 2020-000619-58,2,2022-05-02,2022-05-02,1,0,0,0,0,0,3,0,0,2,1,0,0,0,0,CHU SAINT-ETIENNE,A pilot study assessing the feasibility of a randomized controlled trial evaluating aspirin in postpartum women at risk of developing venous thromboembolism Pilot PARTUM Trial: Postpartum Aspirin to...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000619-58,1,0,0 2020-000620-18,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Nantes University Hospital,"Human recombinant interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a double-blind, international phase 2, randomized, placebo-controlled trial - the PR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000620-18,0,0,0 2020-000622-26,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Participants with New-Onset or Relapsing Giant Cell Arteritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000622-26,0,0,0 2020-000622-26,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Participants with New-Onset or Relapsing Giant Cell Arteritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000622-26,0,0,0 2020-000624-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Leipzig University,Core decompression versus core decompression followed by infusion of Iloprost in the treatment of idiopathic non-traumatic avascular necrosis of the femoral head,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000624-20,0,0,0 2020-000627-40,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Erasmus MC,Azole-echinocandin combination therapy for invasive aspergillosis. A randomized pragmatic superiority trial (IA-DUET),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000627-40,0,0,0 2020-000630-17,10,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Mersana Therapeutics, Inc.","A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000630-17,0,0,0 2020-000633-40,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000633-40,0,0,0 2020-000633-40,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins-mutated Locally Advanced or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000633-40,0,0,0 2020-000637-41,11,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Genzyme Corporation,"A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000637-41,0,0,0 2020-000637-41,11,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,GENZYME CORPORATION,"A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000637-41,0,0,0 2020-000638-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oslo University Hospital,ZOLEDRONATE EARLY TO HIP FRACTURE PATIENTS – SAFE AND EFFECTIVE? A DOUBLE-BLINDED RANDOMIZED CONTROLLED TREATMENT STRATEGY TRIAL ON ZOLEDRONATE IN HIP FRACTURE PATIENTS THE ZEBRA TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000638-17,0,0,0 2020-000640-64,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Masarykův onkologický ústav,11C-METHIONIN IN DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH AGGRESSIVE GLIOBLASTOM SHOWING A TIME POST-OPERATING PROGRESS BEFORE INITIATING ADJUVANT ONCOLOGICAL TREATMENT 11C-METHIONIN V DIAGNOSTICE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000640-64,0,0,0 2020-000641-13,2,2022-05-31,2022-05-31,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"89bio, Inc.","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects with Severe Hypertriglyceridemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000641-13,1,0,0 2020-000644-55,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Genzyme Corporation,"A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000644-55,0,0,0 2020-000645-14,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Genzyme Corporation,"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000645-14,0,0,0 2020-000645-14,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,GENZYME CORPORATION,"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000645-14,0,0,0 2020-000647-30,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Genzyme Corporation,"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000647-30,0,0,0 2020-000647-30,15,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,GENZYME CORPORATION,"A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000647-30,0,0,0 2020-000649-16,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Provention Bio, Inc.","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients with Non-Responsive Celiac Disease as an Adjunct to a Gl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000649-16,0,0,0 2020-000650-10,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Octapharma,"An open-label, multicenter, Post-Marketing Requirement study to investigate the safety and tolerability of octaplas™ in the management of pediatric patients who require therapeutic plasma exchange.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000650-10,0,1,1 2020-000656-35,1,2021-10-11,2021-10-11,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Radboud University Medical Centre,The inflammatory response of monocytes and neutrophils to Crystals after Low dose colchicine in patients with coronary artery disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000656-35,0,0,0 2020-000657-27,3,2022-02-23,2022-02-23,1,0,0,1,0,0,1,0,1,2,1,0,0,0,1,Janssen Vaccines & Prevention B.V.,"A Randomized, Observer-blind, First-in-Human Phase 1/2a Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000657-27,1,0,0 2020-000658-83,1,2021-04-07,2021-04-07,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galapagos NV,"A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, efficacy and pharmacokinetics of GLPG3970, administered orally for 6 weeks in adult subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000658-83,0,0,0 2020-000659-11,1,2021-05-31,2021-05-31,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Galapagos NV,"A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of GLPG3970, administered orally for 6 weeks in adult subjects wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000659-11,0,0,0 2020-000661-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rigshospitalet Glostrup,The effect of anti-calcitonin gene-related peptide (CGRP) receptor antibodies on the headache inducing properties of CGRP and cilostazol in migraine patients Virkningen af anti-calcitonin gene-rela...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000661-16,0,0,0 2020-000664-31,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Astra Zeneca AB,"A Registry-based, Randomized, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Heart Failure or Cardiovascular Death in Patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000664-31,0,0,0 2020-000670-22,2,,,0,0,0,1,0,1,1,0,0,2,1,0,0,0,1,Y-mAbs Therapeutics Inc.,A Phase I/II Dose-escalation and Expansion Cohort Trial of Intracerebroventricular Radioimmunotherapy Using 177Lu-DTPA-omburtamab in Pediatric and Adolescent Patients with Recurrent or Refractory Medu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000670-22,0,0,0 2020-000670-22,2,,,0,0,0,1,0,1,1,0,0,2,1,0,0,0,1,"Y-mAbs Therapeutics, Inc.",A Phase I/II Dose-escalation and Expansion Cohort Trial of Intracerebroventricular Radioimmunotherapy Using 177Lu-DTPA-omburtamab in Pediatric and Adolescent Patients with Recurrent or Refractory Medu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000670-22,0,0,0 2020-000675-20,6,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"IONIS PHARMACEUTICALS, INC.","An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherapy i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000675-20,0,0,0 2020-000675-20,6,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"Ionis Pharmaceuticals, Inc.","An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherapy i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000675-20,0,0,0 2020-000676-38,12,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"IVERIC bio, Inc.","A Phase 3 Multicenter, Randomized, Double Masked, Sham-Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with G...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000676-38,0,0,0 2020-000681-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University of Leipzig,Long-term need of ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due to central retinal vein occlusion Langzeitbedarf von Ran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000681-42,0,0,0 2020-000685-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ghent University Hospital,Virological and immunological assessment in HIV positive participants on 2DR versus 3DR in a prospective randomized controlled switch trial. Virologische en immunologische oppuntstelling bij HIV po...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000685-42,0,0,0 2020-000686-16,1,2020-11-05,2020-11-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Centre for Human Drug Research,"Randomized, double-blind, placebo-controlled crossover study to validate finger tapping tasks for the quantification of levodopa/carbidopa effects in Parkinson’s Disease patients.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000686-16,0,0,0 2020-000688-22,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Dr. Willmar Schwabe GmbH & Co. KG,"Multi-centre, double-blind, placebo- and reference-controlled, randomised trial to prove the efficacy and safety of Silexan (WS®1265) in patients with a major depressive episode of mild to moderate se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000688-22,0,0,0 2020-000689-40,1,,,0,1,1,0,0,1,1,0,1,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Relative Bioavailability of a Granule Formulation of Tezacaftor and Ivacaftor Compared to a Fixed-dose Combination Tablet in Healthy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000689-40,0,1,1 2020-000692-21,1,2021-10-25,2021-10-25,1,1,0,0,0,0,2,0,1,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase 2b, open-label, multi-center, extension study to evaluate the safety and immunogenicity of a revaccination dose of the RSVPreF3 older adults (OA) investigational vaccine administered intramusc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000692-21,0,0,0 2020-000693-18,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Hospital Regensburg,"Breaking the big Five Barriers of Brain Metastasis (Break B5-BM NSCLC Trial): A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab and bevacizumab together with 2 c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000693-18,0,0,0 2020-000695-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset,"Healthy diet rich in potassium containing fruits, vegetables and nuts to chronic kidney disease patients thought the use of sodium zirconium cyclosilicate: A Feasibility Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000695-38,0,0,0 2020-000696-20,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,"Shionogi & Co., Ltd.","A phase 3 randomized, double-blind, placebo-controlled study to confirm the efficacy of a single dose of baloxavir marboxil in the prevention of influenza virus infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000696-20,0,1,1 2020-000697-22,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,FIBROGEN,"Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000697-22,0,0,0 2020-000697-22,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"FibroGen, Inc.","Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000697-22,0,0,0 2020-000698-26,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"FibroGen, Inc.","A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination with Systemic Corticosteroids in Subjects with Non-ambulatory Duchenne Muscular Dystrophy (DMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000698-26,0,0,0 2020-000698-26,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,FIBROGEN,"A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination with Systemic Corticosteroids in Subjects with Non-ambulatory Duchenne Muscular Dystrophy (DMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000698-26,0,0,0 2020-000699-39,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,FIBROGEN,"A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination with Systemic Corticosteroids in Ambulatory Subjects with Duchenne Muscular Dystrophy (DMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000699-39,0,0,0 2020-000699-39,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"FibroGen, Inc.","A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination with Systemic Corticosteroids in Ambulatory Subjects with Duchenne Muscular Dystrophy (DMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000699-39,0,0,0 2020-000702-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IDIBELL (Institut d’Investigació Biomédica de Bellvitge),Phase-II randomized clinical trial to evaluate the effect of Loratadine associated with Rapamune on Lymphagioleiomyomatosis (LAM). Ensayo Clínco randomizado Fase-II para evaluar el efecto de Lorata...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000702-29,0,0,0 2020-000705-86,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VALL HEBRON UNIVERSITY HOSPITAL,Control of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2: randomized clinical trial COVID-19 Co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000705-86,0,0,0 2020-000711-76,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Alexander Egeberg,"Efficacy of roflumilast in the treatment of psoriasis – a randomised controlled trial Effekten af roflumilast ved behandling af psoriasis – et randomiseret, kontrolleret studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000711-76,0,0,0 2020-000712-30,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Radboudumc,Targeted glucocorticoid administration to improve safety learning in PTSD patients with HPA axis dysregulation Doelgerichte behandeling met glucocorticoïden bij PTSS patiënten met stress-as ontreg...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000712-30,0,0,0 2020-000713-32,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscras...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000713-32,0,0,0 2020-000713-32,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Caelum Biosciences, Inc.","A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscras...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000713-32,0,0,0 2020-000714-15,1,,,0,0,0,0,0,0,4,0,1,4,0,0,0,0,0,ULB ERASME,Phentolamines and their role in everyday dentistry Les phentolamines et leur impact dans la dentisterie au quotidien.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000714-15,0,0,0 2020-000715-71,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jagiellonian University Medical College,"The assessment of cysteinyl leukotriene receptor antagonist role in inhibition of atherosclerosis, proliferation and its influence on endothelial function in patients undergoing endovascular treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000715-71,0,0,0 2020-000716-30,5,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,1,Gedeon Richter Plc.,"A randomized, double-blind, placebo-controlled, multicenter, proof-of-concept study to evaluate a combined oral contraceptive (COC) containing 30 µg ethinylestradiol and 150 µg levonorgestrel plus 50 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000716-30,0,0,0 2020-000720-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,IDI FARMACEUTICI SRL,"A prospective, randomized, multicenter, open- label, two-arm and parallel-group Study to evaluate the efficacy and safety of Nicotinamide DS compared to Ciclopirox olamine cream at 1% in patients affe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000720-19,0,0,0 2020-000721-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centre hospitalier de PAU,Management of Anticoagulant Therapy monitored by an implantable device with telecardiology in patients with Acute Coronary Syndrome associated with de novo atrial Fibrillation Arrhythmia (SCA-FA): A p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000721-11,0,0,0 2020-000722-26,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"AlloVir, Inc.","Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transpla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000722-26,0,0,0 2020-000725-27,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,"Center for Surgical Science, Department of Surgery, Zealand University Hospital",Intratumoral Influenza Vaccine for Early Colorectal Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000725-27,0,0,0 2020-000727-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Biogen Idec Research Limited,"A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacute ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000727-40,0,0,0 2020-000730-17,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"DAIICHI SANKYO, INC",HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (N...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000730-17,0,0,0 2020-000730-17,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,DAIICHI SANKYO INC.,HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects with Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (N...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000730-17,0,0,0 2020-000732-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Pablo Rama Maceiras,Effectiveness comparative study of oblique subcostal transversus abdominis plane block (OSTAP block) versus laparoscopic ports infiltration in patients undergoing elective cholecystectomy. Estudio ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000732-22,0,0,0 2020-000736-21,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,1,Shanghai Henlius Biotech Inc.,"A Phase 3 Multi-Centre, Randomised, Double-Blind, Parallel-Arm Study to Evaluate the Efficacy and Safety of HLX01 Versus Rituximab (Mabthera®) as First Line Treatment in Patients With Low Tumour Burde...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000736-21,0,0,0 2020-000739-28,2,,,0,0,0,1,0,1,1,0,0,2,1,0,0,0,1,uniQure biopharma B.V.,A Phase I/IIb extension study assessing the long-term safety and efficacy of an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) previously administered to a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000739-28,0,0,0 2020-000741-13,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ITALIAN SARCOMA GROUP,A Randomized & Observational phase II trial assessing the activity of TrabectedIn vs gemCitabine in patients with metastatic or locally advanced LEiomyosarcoma pretreated with conventional chemotherap...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000741-13,0,0,0 2020-000743-31,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR Mutated Locally Advanced or Metastatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000743-31,0,0,0 2020-000743-31,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR Mutated Locally Advanced or Metastatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000743-31,0,0,0 2020-000744-55,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie,"A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000744-55,0,0,0 2020-000744-55,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000744-55,0,0,0 2020-000744-55,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000744-55,0,0,0 2020-000749-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Academisch ziekenhuis Maastricht,Resolution Enhancement by a Supplemental Open-Label Venoactive drug for Eight weeks in Deep Vein Thrombosis Verbetering van trombusresolutie met een aanvullend open-label venoactief medicijn voor a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000749-15,0,0,0 2020-000753-28,6,,,0,0,0,0,0,0,3,0,1,2,1,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose and annual revaccination doses of GSK’s RSVPreF3 OA investigational vaccine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000753-28,0,0,0 2020-000753-28,6,,,0,0,0,0,0,0,3,0,1,2,1,0,0,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose and annual revaccination doses of GSK’s RSVPreF3 OA investigational vaccine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000753-28,0,0,0 2020-000754-97,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University Hospitals Bristol and Weston NHS Foundation Trust,"Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness: a randomized controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000754-97,0,0,0 2020-000755-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Poitiers,"ESTIMATION OF THE INCIDENCE OF COLONIZATION OF PERIPHERAL VENOUS CATHETERS AFTER SKIN DISINFECTION WITH 0.5% SODIUM HYPOCHLORITE, PRECEDED OR NOT BY AN APPLICATION OF 70% ETHANOL: PILOT, MONOCENTRIC, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000755-13,0,0,0 2020-000758-81,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska Institutet,Chlorhexidine gluconate as treatment and prophylaxis of vulvovaginal Candidiasis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000758-81,0,0,0 2020-000761-16,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000761-16,0,0,0 2020-000761-16,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000761-16,0,0,0 2020-000763-23,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Anji Pharma (US) LLC,"A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo- and Comparator-Controlled Study to Compare the Glycemic Effects, Safety, and Tolerability of Metformin Hydrochloride Delayed-Release T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000763-23,0,0,0 2020-000766-42,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF LONG-TERM GANTENERUMAB ADMINISTRATION IN PARTICIPANTS WITH ALZHEIMER'S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000766-42,0,0,0 2020-000766-42,13,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF LONG-TERM GANTENERUMAB ADMINISTRATION IN PARTICIPANTS WITH ALZHEIMER'S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000766-42,0,0,0 2020-000767-23,2,2021-07-20,2021-07-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,AstraZeneca AB,"A Randomized, Parallel, Double-blind, Placebo-controlled, Dose-ranging, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD8233 Treatment in Participants With Dyslipidemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000767-23,0,0,0 2020-000769-18,10,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,Bioverativ Therapeutics Inc.,"A Phase 3 open-label, multicenter study of the safety, efficacy, and pharmacokinetics of intravenous recombinant coagulation Factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000769-18,0,1,0 2020-000769-18,10,,,0,0,1,0,0,1,3,0,0,2,0,0,0,0,1,BIOVERATIV THERAPEUTICS INC,"A Phase 3 open-label, multicenter study of the safety, efficacy, and pharmacokinetics of intravenous recombinant coagulation Factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000769-18,0,1,0 2020-000770-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GORTEC,"A phase II randomized trial, non comparative, evaluating chemotherapy associated cisplatin, 5-fluorouracil and docetaxel at adapted doses in patients with locally advanced squamous cell carcinoma E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000770-21,0,0,0 2020-000775-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,"A phase II study evaluating reduced starting dose and dose escalation of Cabozantinib as second-line therapy for advanced HCC in patients with preserved liver function Eine Phase II Studie, in der ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000775-20,0,0,0 2020-000777-24,6,2021-10-05,2021-11-05,4,0,0,0,0,1,2,0,0,1,1,0,0,0,1,"Takeda Development Center Americas, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000777-24,0,0,0 2020-000777-24,6,2021-10-05,2021-11-05,4,0,0,0,0,1,2,0,0,1,1,0,0,0,1,TAKEDA DEVELOPMENT CENTER AMERICAS INC.,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000777-24,0,0,0 2020-000784-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Philipps-Universität Marburg,The effects of esketamine and treatment expectation in acute major depressive disorder: a pharmacological fMRI-study (Expect) Die Effekte von Behandlungserwartung an Esketamin vs. Placebo bei akut...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000784-23,0,0,0 2020-000789-40,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase II, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MEDI3506 in Adult Participants with Uncontrolled Moderate-to-severe Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000789-40,0,0,0 2020-000790-24,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Universität Salzburg,BECONTRA - Effects of combined oral contraceptives on brain and behavior BECONTRA - Einfluss kombinierter oraler Kontrazeptiva auf Gehirn und Verhalten,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000790-24,0,0,0 2020-000791-38,12,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000791-38,0,0,0 2020-000791-38,12,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000791-38,0,0,0 2020-000796-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Regensburg,"Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® compared with Advagraf® in de novo liver transplant recipients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000796-20,0,0,0 2020-000798-26,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Avanir Pharmaceuticals, Inc.","A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000798-26,0,0,0 2020-000798-26,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000798-26,0,0,0 2020-000799-39,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Avanir Pharmaceuticals, Inc.","A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000799-39,0,0,0 2020-000819-67,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Maidstone and Tunbridge Wells NHS Trust,SENTINUS: Technical feasibility and diagnostic accuracy of intradermal microbubbles and contrast enhanced ultrasound to identify sentinel lymph node metastases in breast cancer patients following trai...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000819-67,0,0,0 2020-000820-20,1,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,NovalGen Ltd,"AN OPEN-LABEL, PHASE 1/2, FIRST IN HUMAN STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF NVG-111 IN SUBJECTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000820-20,0,0,0 2020-000821-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Karyopharm Therapeutics Inc.,"A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients with Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethason...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000821-22,0,0,0 2020-000822-24,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Vicore Pharma AB,"A Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy and Pharmacokinetics of C21 in Subjects with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000822-24,0,0,0 2020-000823-38,1,2021-11-10,2021-11-10,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Erasmus MC Cancer Institute,Study on the pharmacokinetic interaction between cabazitaxel and darolutamide in metastatic castration-resistant prostate cancer (mCRPC) patients. Studie naar de farmacokinetische interactie tussen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000823-38,0,0,0 2020-000824-21,2,2021-11-24,2021-11-24,2,1,0,0,0,0,2,0,0,1,0,0,0,0,0,Institut Jules Bordet,An open label phase II study to evaluate neratinib for treatment and prevention of subsequent CNS event(s) in patients with brain metastasis of advanced HER2 positive breast cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000824-21,0,0,0 2020-000825-18,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Gustave Roussy,"An open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNATM, a DNA repair inhibitor, administered intravenously in addition to Niraparib in patients with relapsed plat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000825-18,0,0,0 2020-000826-24,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Incyte Corporation,"A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcino...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000826-24,0,0,0 2020-000826-24,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,INCYTE CORPORATION,"A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcino...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000826-24,0,0,0 2020-000828-19,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novo Nordisk A/S,REMODEL - Renal mode of action of semaglutide in patients with type 2 diabetes and chronic kidney disease Studio clinico REMODEL– Meccanismo di azione a livello renale di semaglutide in pazienti co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000828-19,0,0,0 2020-000828-19,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NOVO NORDISK. S.P.A.,REMODEL - Renal mode of action of semaglutide in patients with type 2 diabetes and chronic kidney disease Studio clinico REMODEL– Meccanismo di azione a livello renale di semaglutide in pazienti co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000828-19,0,0,0 2020-000829-55,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Psychiatric Centre Copenhagen,"Can a one-off administration of psilocybin reduce alcohol intake in patients with alcohol use disorder? A randomized, double-blinded, placebo-controlled clinical trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000829-55,0,0,0 2020-000831-34,1,,,0,0,0,0,1,0,2,0,1,0,0,0,0,0,0,Medical University of Vienna,InvestiGating the rOle of Growth Hormone in hepatic lipid metabolism in humans,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000831-34,0,0,0 2020-000832-23,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Khondrion B.V.,"A Phase IIb open-label, multi-centre, extension study to explore the long-term safety and efficacy of KH176 in subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000832-23,0,0,0 2020-000835-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Zealand University Hospital,Neoadjuvant electrochemotherapy for colorectal cancer – a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000835-33,0,0,0 2020-000836-23,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA,Continous fentanyl infusion in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia: pharmacokinetics study Fentanile in infusione continua in neonati con encefalopati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000836-23,0,0,0 2020-000840-75,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase IIB, Randomized, Double blinded, Placebo controlled, Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction, Persistent Inflamm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000840-75,0,0,0 2020-000840-75,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase IIB, Randomized, Double blinded, Placebo controlled, Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction, Persistent Inflamm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000840-75,0,0,0 2020-000841-15,7,2020-06-30,2020-06-30,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.",A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000841-15,0,0,0 2020-000842-32,7,2020-06-26,2020-06-26,6,1,0,0,0,0,3,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.",A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000842-32,0,0,0 2020-000845-15,9,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Genmab A/S,"A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000845-15,0,0,0 2020-000845-15,9,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,GENMAB A/S,"A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000845-15,0,0,0 2020-000848-57,4,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Genmab A/S,"A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000848-57,0,0,0 2020-000849-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,Monalizumab and trastuzumab In Metastatic HER2-pOStive breAst cancer: MIMOSA-trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000849-14,0,0,0 2020-000851-11,2,2022-01-31,2022-01-31,2,0,0,0,1,0,4,0,0,1,0,0,0,0,1,Pierre Fabre Dermatologie,"Frequency and Intensity of local reactions in patients treated with 4% 5-FU vs 4% 5-FU associated with an emollient cream: a randomised, controlled clinical trial Fréquence et Intensité des réactio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000851-11,0,0,0 2020-000854-85,5,2022-06-22,2022-06-22,2,0,1,0,0,1,1,0,0,2,1,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000854-85,1,1,0 2020-000854-85,5,2022-06-22,2022-06-22,2,0,1,0,0,1,1,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000854-85,1,1,0 2020-000855-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Cardiology, Copenhagen University Hospital Rigshospitalet",STEROID TREATMENT AS ANTI-INFLAMMATORY AND NEUROPROTECTIVE AGENT FOLLOWING OUT-OF-HOSPITAL CARDIAC ARREST. A RANDOMIZED TRIAL. STEROIDBEHANDLING SOM ANTI-INFLAMMATORISK OG NEUROPROTEKTIV AGENT EFTE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000855-11,0,0,0 2020-000860-51,1,2021-05-19,2021-05-19,1,0,0,0,0,0,4,0,1,1,0,0,1,0,1,Cassella-med GmbH & Co. KG,The effect of early administered cineole on the course of a common cold,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000860-51,0,0,0 2020-000863-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Thomas Benfield,"Safety and immunogenicity following meningococcal and pneumococcal immunization among adult people living with HIV A single center, non-blinded, randomized clinical trial Sikkerhed og immunrespons...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000863-22,0,0,0 2020-000864-42,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,InflaRx GmbH,"OPEN LABEL, MULTICENTER PHASE II STUDY OF THE C5A-ANTIBODY IFX-1 ALONE OR IFX-1 + PEMBROLIZUMAB IN PATIENTS WITH PD-1- OR PD-L1-RESISTANT/REFRACTORY LOCALLY ADVANCED OR METASTATIC CUTANEOUS SQUAMOUS C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000864-42,0,0,0 2020-000866-41,1,,,0,0,0,0,0,0,2,0,1,4,0,0,0,0,0,Women on Web International Foundation,Combined Phase II/ III Multicentre Single-arm Trial of a Mifepristone 50 mg as a weekly Contraceptive,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000866-41,0,1,1 2020-000867-21,2,,,0,0,0,0,0,2,3,0,0,4,0,0,0,0,1,Octapharma Pharmazeutika Produktionsges.m.b.H.,A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000867-21,0,1,0 2020-000869-17,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"A phase Ib/II, open label study of sabatolimab as a treatment for patients with acute myeloid leukemia and presence of measurable residual disease after allogenic stem cell transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000869-17,0,0,0 2020-000869-17,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A phase Ib/II, open label study of sabatolimab as a treatment for patients with acute myeloid leukemia and presence of measurable residual disease after allogenic stem cell transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000869-17,0,0,0 2020-000873-26,9,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV600 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000873-26,0,0,0 2020-000873-26,9,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV600 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000873-26,0,0,0 2020-000874-92,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Lumos Pharma, Inc.","A Multicenter, 6-Month, Randomized, Open-Label, Active Control, Parallel Arm, Phase 2b Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children with Growth Hormone Deficiency (GHD) W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000874-92,0,0,0 2020-000875-20,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Pfizer Inc.,"A Phase 2b, Multi Center, Randomized, Double-Blind, Vehicle-Controlled, Intra-Participant Study, to Evaluate Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Pediatric and Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000875-20,0,1,1 2020-000876-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Jules Bordet,"A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN intermediate-risk, stage II-III rectAl cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000876-40,0,0,0 2020-000877-25,1,2022-01-06,2022-01-06,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Odense University Hospital,Tacrolimus as Treatment of Breast Cancer-Related Lymphedema Tacrolimus som behandling af brystkræft-relateret lymfødem,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000877-25,0,0,0 2020-000878-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Sentinel node Navigation surgery in early esophageal Adenocarcinoma Patients with lymph node involvement: SNAP-IV study Schildwachtklierprocedure bij patiënten met een vroeg slokdarmadenocarcinoom ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000878-15,0,0,0 2020-000885-40,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Windtree Therapeutics, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000885-40,0,0,0 2020-000886-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,"SUBGLOTTIC INSTILLATION OF FLURBIPROFENE TO PREVENT LARYNGEAL INFLAMMATION FOLLOWING ENDOTRACHEAL INTUBATION: PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED PILOT STUDY INSTILLAZIONE SOT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000886-17,0,0,0 2020-000890-25,1,,,0,1,0,0,0,0,3,0,0,0,0,0,0,0,0,Fondation Méditerranée Infection (FMI) - IHU Méditerranée Infection,Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000890-25,0,0,0 2020-000893-69,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000893-69,0,0,0 2020-000893-69,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000893-69,0,0,0 2020-000894-26,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000894-26,0,0,0 2020-000894-26,9,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000894-26,0,0,0 2020-000913-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of gothenburg,Semaglutide and dapagliflozin in diabetic patients with different pathophysiology,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000913-33,0,0,0 2020-000915-53,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Radiology, Rigshospitalet, Denmark",Randomized double-blind placebo-controlled trial on the efficiency of a single dose dexamethasone in reducing the postembolization syndrome in men undergoing prostatic artery embolization for benign p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000915-53,0,0,0 2020-000917-34,11,2022-09-19,2022-10-19,6,0,1,0,0,0,3,0,0,2,1,0,0,0,1,Nektar Therapeutics,"A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000917-34,1,0,0 2020-000917-34,11,2022-09-19,2022-10-19,6,0,1,0,0,0,3,0,0,2,1,0,0,0,1,NEKTAR THERAPEUTICS,"A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000917-34,1,0,0 2020-000919-69,1,2021-03-17,2021-03-17,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,University Medical Center,"Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Guérin vaccination, a randomized controlled trial (COVID-19).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000919-69,0,0,0 2020-000923-37,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST,A phase 1/2 study exploring the safety and activity of Trifluridine/tipiracil in combination with capecitabine and bevacizumab in metastatic colorectal cancer patients. Studio di fase 1/2 su toller...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000923-37,0,0,0 2020-000926-24,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Heidelberg ImmunoTherapeutics,"A Randomised, Double-Blind Phase II Trial of Topical HDIT101 versus Placebo in Patients with Chronic Recurrent HSV-1 Infection and Orolabial Lesion",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000926-24,0,0,0 2020-000927-38,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,AIGO - Associazione Italiana Gastroenterologi ed Endoscopisti DIgestivi Ospedalieri,"Bowel preparation with either novel 1L PEG+Asc or 2L PEG+Asc solution: a multicenter, randomized study in elderly outpatients: the PLATONE Study. Preparazione intestinale per colonscopia con una nu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000927-38,0,0,0 2020-000929-42,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Ascendis Pharma Endocrinology Division A/S,"foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-controlled (open-label) trial to compare the efficacy and safety of once-weekly lonapegsomatropin wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000929-42,0,0,0 2020-000931-35,1,2021-06-09,2021-06-09,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"AstraZeneca AB, 151 85 Södertälje, Sweden","A Phase 2a Randomised, Double Blind, Multi-centre Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults with Type 2 Diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000931-35,0,0,0 2020-000934-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,TNO,Reconsolidation: a new intervention towards combat-related PTSD.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000934-16,0,0,0 2020-000936-23,11,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,INSERM,"Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000936-23,0,0,0 2020-000936-23,11,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Inserm,"Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000936-23,0,0,0 2020-000942-32,1,2020-10-07,2020-10-07,1,0,0,0,0,0,2,0,0,1,1,1,1,0,1,Inflazome Ireland Ltd.,"A 12-week, multi-center, double-blinded, parallel-group, randomized, placebo-controlled phase IIb study to evaluate the safety, tolerability and efficacy of IZD334 to reduce CRP in cardiovascular high...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000942-32,0,0,0 2020-000946-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Cancer Trials Ireland,"Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000946-32,0,0,0 2020-000948-60,2,2022-09-15,2022-09-15,2,0,0,0,0,0,2,0,1,1,1,1,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2b, OPEN-LABEL TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY INFANTS 2 AND 6 MONTHS OF AGE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000948-60,0,0,0 2020-000949-14,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,VIELABIO Inc.,"A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 STUDY WITH OPEN-LABEL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF INEBILIZUMAB IN ADULTS WITH MYASTHENIA GRAVIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000949-14,0,0,0 2020-000949-14,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Viela Bio, Inc.","A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 STUDY WITH OPEN-LABEL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF INEBILIZUMAB IN ADULTS WITH MYASTHENIA GRAVIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000949-14,0,0,0 2020-000951-11,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Jiangsu Hengrui Medicine Co., Ltd.","A Phase 3, Randomized , Open-Label, Multicenter Study of the Efficacy and Safety of Pyrotinib versus Docetaxel in Patients with Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000951-11,0,0,0 2020-000952-36,4,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"CELLTRION, Inc.","A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000952-36,0,0,0 2020-000954-86,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Daehwa Pharmaceutical Co., Ltd.","A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients with R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000954-86,0,0,0 2020-000955-11,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Sun Pharma Global FZE,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000955-11,0,0,0 2020-000956-37,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Sun Pharma Global FZE,"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Subjects with Active Psoriatic Arthritis II (INSPIRE 2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000956-37,0,0,0 2020-000958-98,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Régional de lutte contre le Cancer Eugène Marquis,A phase II trial evaluating conformational intensity modulated radiotherapy with concomitant nivolumab followeb by nivolumab for patients with locally advanced non-small cell lung cancer Essai de p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000958-98,0,0,0 2020-000960-52,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Daehwa Pharmaceutical Co., Ltd.","A Multi-national, Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®, Oral Paclitaxel) Compared to IV Paclitaxel in Patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000960-52,0,0,0 2020-000963-22,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Vivet Therapeutics SAS,"A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients with Wilson's Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000963-22,0,0,0 2020-000970-10,1,2022-01-11,2022-01-11,1,1,0,0,0,0,3,0,0,1,1,1,0,0,1,Sanofi Aventis Groupe,"Phase III, randomized, double blind, parallel groups, clinical trial to evaluate the efficacy and safety of Bacillus clausii versus placebo in the prevention of antibiotic associated diarrhea (AAD) in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000970-10,0,0,0 2020-000971-18,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,SynAct Pharma ApS,"An exploratory, randomized, double-blind, multicenter, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and efficacy of AP1189 daily doses versus placebo administered for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000971-18,0,0,0 2020-000974-22,4,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Mirum Pharmaceuticals Inc.,"Randomized, Double-blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Biliary Atresia after Hepatoportoenterostomy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000974-22,0,0,0 2020-000976-40,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"IONIS PHARMACEUTICALS, INC.","A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexander ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000976-40,0,0,0 2020-000976-40,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Ionis Pharmaceuticals,"A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexander ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000976-40,0,0,0 2020-000976-40,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Ionis Pharmaceuticals, Inc","A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexander ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000976-40,0,0,0 2020-000980-21,1,,,0,0,1,0,0,1,2,0,0,4,0,0,0,0,1,"PTC Therapeutics, Inc.",An Open-Label Study Evaluating the Safety and Pharmacokinetics of Ataluren in Children From ≥6 Months to <2 Years of Age with Nonsense Mutation Duchenne Muscular Dystrophy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000980-21,0,1,1 2020-000981-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Med. Univ. Wien, Klinik f. Innere Mdizin I, Onkologie",Phase II Study of Trastuzumab-Deruxtecan (T-DX; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000981-41,0,0,0 2020-000982-18,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Karolinska University hospital,The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000982-18,0,0,0 2020-000982-18,2,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Oslo University Hospital,The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19).,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000982-18,0,0,0 2020-000983-41,15,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Idorsia Pharmaceuticals Ltd,"Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000983-41,0,0,0 2020-000983-41,15,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,IDORSIA PHARMACEUTICALS LTD,"Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000983-41,0,0,0 2020-000986-17,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Alzheon Inc.,"A Phase 2, Single Arm, Study of the Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer’s Disease Who Are Carriers of the ε4 Variant of the Apolipoprotein E Gene (APOE4/4 or APOE3/4) Een ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000986-17,0,0,0 2020-000987-53,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Incyte Corporation,"A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000987-53,0,0,0 2020-000993-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHRU NANCY,AGATA: Value of contrast-enhanced ultrasound in adnexal torsion AGATA: Apport diagnostic de l’échoGraphie de contrAste dans la Torsion Annexielle,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000993-27,0,0,0 2020-000994-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska Institutet,"An open, randomised, controlled phase II trial of CellProtect in combination with Isatuximab antibody versus Isatuximab antibody alone as maintenance treatment in patients with Multiple Myeloma underg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000994-26,0,0,0 2020-000996-19,6,2021-11-11,2021-11-15,3,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Catalyst Biosciences, Inc.","Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptacog Alfa (Activated) For On-Demand Treatment and Control of Bleeding Episodes in Subjects with Haemophilia A or Haemophilia B,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000996-19,1,0,0 2020-001000-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Vienna,"The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, vitamin D, the immune system and related diseases such as depression and osteoporosis Der Zusammenhang von choleste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001000-42,0,0,0 2020-001001-22,3,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001001-22,0,0,0 2020-001002-26,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,NERVIANO MEDICAL SCIENCES SRL,Phase I/II study on safety and efficacy of NMS-01940153E in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy. Studio di fase I/II sulla sicur...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001002-26,0,0,0 2020-001007-16,3,2021-11-24,2021-11-24,3,0,0,0,0,0,2,0,0,1,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM, PHASE II, NEOADJUVANT STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF GDC-9545 PLUS PALBOCICLIB COMPARED WITH ANASTROZOLE PLUS PALBOCICLI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001007-16,0,0,0 2020-001009-22,2,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,H. Lundbeck A/S,"Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of IV eptinezumab in adolescents (12-17 years) for the preventive treatment of ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001009-22,0,0,0 2020-001010-38,1,2020-05-20,2020-05-20,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Akershus University Hospital,NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTIO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001010-38,0,0,0 2020-001014-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,Pharmacogenetics of hypertension: randomized monocentric study in patients with essential hypertension and treated with Spironolactone or Torasemide Farmacogenetica dell’ipertensione: studio monoce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001014-37,0,0,0 2020-001019-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"University Medical Center Groningen, Department of Rheumatology and Clinical Immunology",[18F]fluor-PEG-folate PET/CT imaging in Giant Cell Arteritis. [18F]fluor-PEG-folaat PET/CT beeldvorming in reuscelarteriitis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001019-26,0,0,0 2020-001021-31,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF GLOFITAMAB IN COMBINATION WITH GEMCITABINE PLUS OXALIPLATIN VERSUS RITUXIMAB IN COMBINATION WITH GEMCITABIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001021-31,0,0,0 2020-001022-57,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,Wojciech Zbigniew Pawlak,"The effect of Qutenza application in patients with post-operative neuropathic pain: A double-blind, randomized, controlled pilot study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001022-57,0,0,0 2020-001023-14,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Synairgen Research Limited,A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNβ-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001023-14,0,0,0 2020-001024-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,Oral antimicrobial treatment vs. outpatient parenteral for infective endocarditis. Tratamiento antimicrobiano oral vs. parenteral ambulatorio para la endocarditis infecciosa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001024-34,0,0,0 2020-001025-31,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,CHRU Nancy,HIGHLIGHTING THE BENEFITS OF THERAPEUTIC GARDENS IN ALZHEIMER'S DISEASE with 18F-FDG Cerebral PET / CT MISE EN EVIDENCE DES BENEFICES DES JARDINS THERAPEUTIQUES DANS LA MALADIE D’ALZHEIMER par un...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001025-31,0,0,0 2020-001026-62,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,University Hospital Dr Josep Trueta,"Benefits of inhalation of 7% hypertonic saline solution prior to ELTGOL physiotherapy, in patients with bronchiectasis. A randomized controlled trial. Beneficios de la inhalación de una solución sa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001026-62,0,0,0 2020-001027-13,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Tetherex Pharmaceuticals Corporation,"A Two Part, Randomised, Double-blind, Placebo-controlled, Phase 2 Parallel Group Study to Evaluate the Safety and Efficacy of Intravenously-Administered SelK2 on Airway Responses Following Allergen Ch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001027-13,0,0,0 2020-001028-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU DE NIMES,"Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, hi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001028-32,0,0,0 2020-001029-30,1,,,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,Fondazione Penta ONLUS,"A multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in HIV-1 infected chil...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001029-30,0,0,0 2020-001031-27,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,"FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA",Treatment of non-severe confirmed cases of COVID-19 and chemoprophylaxis of their contacts as prevention strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study) Tratamiento de casos confir...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001031-27,0,0,0 2020-001032-99,1,2021-05-04,2021-05-04,1,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Drossapharm AG,"Randomized, controlled, double-blind, multi-center trial to evaluate the efficacy and safety of “Lixim 70 mg wirkstoffhaltiges Pflaster” (etofenamate 70 mg medicated plaster) applied once daily (every...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001032-99,0,0,0 2020-001033-12,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Niels Eske Bruun,PROPHYLACTIC ANTIBIOTIC TREATMENT IN END-STAGE KIDNEY DISEASE AND CENTRAL VENOUS CATHETER AS HEMODIALYSIS VASCULAR ACCESS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001033-12,0,0,0 2020-001034-35,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,University of Birmingham,Accelerating the Development and implementation of Personalised Treatments of DNA Damage Response agents and radiotherapy +/- immunotherapy for head and neck squamous cell cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001034-35,0,0,0 2020-001038-36,1,2022-04-13,2022-04-13,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,BioNTech SE,"A multi-site, Phase I/II, 2-part, dose escalation trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-19 using different dosing regimens in hea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001038-36,0,0,0 2020-001039-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS,EFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH: THE ESCAPE CLINICAL TRIAL ΠΡΟΣΩΠΟΠΟΙΗ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001039-29,0,0,0 2020-001044-26,1,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,1,mAbxience Research S.L.,"A Double-Blind, Randomised, Placebo-Controlled Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated with Respiratory Syncytial Virus (RSV)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001044-26,0,0,0 2020-001045-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Celltrion, Inc","A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients with Moderate to Severe Plaque Psoriasis Randomiseeritud aktiivkontr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001045-39,0,0,0 2020-001046-19,1,2022-07-01,2022-07-01,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Oramed Ltd.,An Open-Label Multi-Center Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001046-19,0,0,0 2020-001048-24,12,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Novo Nordisk A/S,"A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001048-24,0,0,0 2020-001048-24,12,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,NOVO NORDISK. S.P.A.,"A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001048-24,0,0,0 2020-001049-38,13,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001049-38,0,0,0 2020-001049-38,13,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001049-38,0,0,0 2020-001050-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Universitätsmedizin Mainz, Interdisziplinäres Zentrum klinische Studien",A Phase II randomized Study to evaluate the efficacy and safety of Cisplatin / Etoposide and concomitant Radiotherapy combined with Durvalumab followed by Maintenance Therapy with Durvalumab versus Ci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001050-22,0,0,0 2020-001052-18,5,2020-07-30,2020-09-10,4,1,0,0,0,0,3,0,0,1,0,0,1,0,0,Regents of the University of Minnesota,"A Multicenter, Adaptive, Randomised Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Version for European Unio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001052-18,0,0,0 2020-001053-44,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Rigshospitalet, Department of Vascular Surgery",Stabilization of vulnerable atherosclerotic carotid plaques by Rivaroxaban as evaluated by 3D contrast enhanced ultrasound (CEUS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001053-44,0,0,0 2020-001054-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Claus Anders Bertelsen,Laparoscopic vs Ultrasound-Guided Transversus Abdominis Plane Block in Minimally Invasive Colon Surgery: A Randomized Controlled Multicentre Clinical Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001054-22,0,0,0 2020-001055-40,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,BioMarin Pharmaceutical Inc.,"A randomized, controlled, open-label clinical trial with an open-label extension to investigate the safety of BMN 111 in infants and young children with achondroplasia at risk of requiring cervicomedu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001055-40,0,0,0 2020-001056-17,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Kings's College London,A randomised feasibility trial investigating Sativex® for the treatment of the Agitation & Aggression (A/A) in Alzheimer’s Dementia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001056-17,0,0,0 2020-001056-17,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,South London and Maudsley NHS Foundation Trust,A randomised feasibility trial investigating Sativex® for the treatment of the Agitation & Aggression (A/A) in Alzheimer’s Dementia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001056-17,0,0,0 2020-001060-28,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Aarhus Universitet,"Documentation of efficacy and dose finding for intralymphatic allergen immunotherapy in a phase II/III randomized, parallel group, double blind placebo-controlled multisite field trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001060-28,0,0,0 2020-001061-37,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Kodiak Sciences Inc.,"A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Afli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001061-37,0,0,0 2020-001062-11,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Kodiak Sciences Inc.,"A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Afli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001062-11,0,0,0 2020-001063-82,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Kodiak Sciences Inc.,"A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Afli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001063-82,0,0,0 2020-001064-29,5,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,Kodiak Sciences Inc.,"A Prospective, Randomized, Double-masked, Sham-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants with Moderately Severe to Se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001064-29,0,0,0 2020-001066-10,1,,,0,0,1,0,0,0,3,0,0,4,0,0,0,0,1,UCB Biopharma SRL,"A Multicenter, Open-Label, Randomized, Active Comparator Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001066-10,0,1,1 2020-001068-27,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,"PAmidronate for Pain in Sternocostoclavicular Hyperostosis: the PAPS-study, a double-blind randomized placebo-controlled trial PAmidronate voor Pijn in Sternocostoclaviculaire hyperostose: de PAPS-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001068-27,0,0,0 2020-001069-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau – IIB Sant Pau,Impact of Exercise and Mediterranean diet vs Aspirin on live-birth rate and cardiovascular programming in In Vitro Fertilization (MEDITATE-IVF): a Randomized Study. Impacto del Ejercicio y Dieta Me...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001069-35,0,0,0 2020-001071-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BirrBeheerBV,Role of the intestine on osteoarthritis of the hand and the effect of Sustained Release Calcium Butyrate. De rol van de darm bij het ontstaan van artrose van de hand,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001071-33,0,0,0 2020-001072-15,1,,,0,0,0,0,1,0,2,0,1,3,0,0,0,0,0,University of Oxford,"A phase I/II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001072-15,0,0,0 2020-001074-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Netherlands cancer institute (NKI) Antioni van Leeuwenhoek (AvL),Neo-adjuvant nivolumab or nivolumab with ipilimumab in advanced cutaneous squamous cell carcinoma patients prior to standard of care surgery; the MATISSE trial Neo-adjuvante therapie met nivolumab...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001074-30,0,0,0 2020-001075-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH,"RE-ExPEL A pilot study of ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001075-32,0,0,0 2020-001076-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Oulu University Hospital, Oulu, Finland",Efficacy of Streptococcus salivarius K12 oral probiotic products in preventing acute otitis media: A randomized placebo-controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001076-14,0,0,0 2020-001079-33,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Randomised, Open-Label, Parallel-Group, Pre surgical Study to Investigate the Biological Effects of AZD9833 in Women with ER-positive, HER2-negative Primary Breast Cancer (SERENA-3)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001079-33,0,0,0 2020-001083-29,5,2022-03-18,2022-03-18,2,0,0,0,2,0,2,0,0,2,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis B Virus (B-Clear)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001083-29,1,0,0 2020-001083-29,5,2022-03-18,2022-03-18,2,0,0,0,2,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis B Virus (B-Clear)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001083-29,1,0,0 2020-001084-83,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Grenoble-Alpes,Urea treatment of hyponatremia during subarachnoid hemorrhage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001084-83,0,0,0 2020-001085-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CUB ULB Hôpital Erasme,"Pre-operative evaluation by [18F]-JK PSMA-7 PET/CT in intermediate and high-risk prostate cancer patients, candidates for radical prostatectomy with curative intent: a pilot study L’évaluation préo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001085-11,0,0,0 2020-001087-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU Toulouse,Anti-IL6 receptor antibodies to reduce allo-sensitization post allograft nephrectomy ; a pilot phase II study Réduire le risque d'allo-immunisation post ablation du greffon rénal par utilisation d'...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001087-28,0,0,0 2020-001097-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Amsterdam UMC, VU University Medical Center","Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients, a proof-of-concept study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001097-29,0,0,0 2020-001098-55,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,"Mind Medicine, Inc.","Safety and efficacy of repeated low dose D-lysergic acid diethylamide (LSD) D-Tartrate (MM-120) as treatment for ADHD in adults: a multi-center, randomized, double- blind, placebo-controlled Phase 2a ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001098-55,0,0,0 2020-001099-14,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,FAES FARMA S.A.,"Randomised, double-blind, double-dummy, multicentre trial to evaluate the efficacy and safety of three different weekly dosages of calcifediol versus placebo in subjects with either vitamin D deficien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001099-14,0,0,0 2020-001099-14,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"FAES FARMA, S.A.","Randomised, double-blind, double-dummy, multicentre trial to evaluate the efficacy and safety of three different weekly dosages of calcifediol versus placebo in subjects with either vitamin D deficien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001099-14,0,0,0 2020-001101-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amsterdam UMC,Study to evaluate the efficacy and side effects of Envarsus in patients who had a kidney transplantation Onderzoek bij patiënten met een niertransplantatie naar werking en bijwerkingen van Envarsus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001101-22,0,0,0 2020-001102-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Department of Internal Medicine Vejle Hospital,Venetoclax and Dexamethasone in translocation (11;14) positive relapsed and refractory multiple myeloma (VICTORIA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001102-29,0,0,0 2020-001103-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Cliniques universitaires Saint-Luc,"Gut microbiota, pharmacogenetics and Integrase Strand Transfer Inhibitors response",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001103-17,0,0,0 2020-001104-41,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 2, open-label study to assess copper and molybdenum balance in participants with Wilson disease treated with ALXN1840",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001104-41,0,0,0 2020-001105-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre François Baclesse,TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma: A single-arm Phase 2 trial TALazoparib et Avelumab en tant que traitement...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001105-24,0,0,0 2020-001108-40,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001108-40,0,0,0 2020-001108-40,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001108-40,0,0,0 2020-001108-40,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc","A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001108-40,0,0,0 2020-001109-22,1,,,0,0,0,1,0,1,1,0,0,4,0,0,0,0,1,"Passage Bio, Inc.","A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001109-22,0,0,0 2020-001110-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE ""G. PASCALE""",Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia Multicenter study on the efficacy and tolerability of tocilizumab in the treat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001110-38,0,0,0 2020-001113-21,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Oxford,Randomised Evaluation of COVID-19 Therapy (RECOVERY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001113-21,0,0,0 2020-001135-27,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Oxford / Clinical Trials and Research Governance,Pre-operative 5-Aminolevulinic acid to activate haem oxygenase to improve outcomes in cardiac surgery: A dose finding study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001135-27,0,0,0 2020-001154-22,7,2020-07-28,2020-07-28,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001154-22,1,0,0 2020-001154-22,7,2020-07-28,2020-07-28,5,1,0,0,0,0,3,0,0,2,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001154-22,1,0,0 2020-001155-40,1,2022-05-12,2022-05-12,1,0,0,0,0,0,4,0,1,1,0,0,0,0,0,Steno Diabetes Center Copenhagen,"Kidney Fat in Type 2 Diabetes & Diabetic Kidney Disease and the Effects of Ezetimibe: A Cross-Sectional Study and Randomized, Placebo-Controlled Trial Nyrefedt ved type 2 diabetes & diabetisk nyres...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001155-40,0,0,0 2020-001156-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación para la investigación Biomedica Hospital Universitario La Paz,Randomized clinical trial to evaluate the efficacy of different treatments in patients with COVID-19 who require hospitalization Ensayo clínico aleatorizado para evaluar la eficacia de diferentes t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001156-18,0,0,0 2020-001157-48,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,0,Imperial College London,Identifying a safe and tolerated dose of Imatinib for patients with Pulmonary Arterial Hypertension (PAH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001157-48,0,0,0 2020-001160-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medica Scientia Innovation Research S.L. (MEDSIR),"A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined with Pembrolizumab (MK-3475) in Patients with Coronavirus Disease 2019 (COVID-19)-Pneum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001160-28,0,0,0 2020-001162-12,4,2020-09-02,2020-09-02,3,1,0,0,0,0,3,0,0,1,0,0,1,0,1,Sanofi-aventis Recherche et Développement,"An adaptive phase 2/3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID-19 Estudio adaptativo de fase 2/3, aleator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001162-12,0,0,0 2020-001165-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dipartimento di Medicina Sperimentale e Clinica- Università di Firenze,"A Phase 2, Monocentric, Pilot Study to evaluate safety and efficacy of CC 486 (Oral Azacitidine) Plus Best Supportive Care as maintenance of response to sc azacitidine in IPSS higher risk elderly MDS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001165-36,0,0,0 2020-001167-93,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,SWEDISH ORPHAN BIOVITRUM AB (PUBL),"A phase 2/3, randomized, open-label, parallel group, 3-arm, multicenter study investigating the efficacy and safety of intravenous administrations of emapalumab, an anti-interferon gamma (anti-IFN¿) m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001167-93,0,0,0 2020-001168-28,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001168-28,0,0,0 2020-001168-28,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001168-28,0,0,0 2020-001169-34,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Region Stockholm,Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001169-34,0,0,0 2020-001172-15,4,2020-12-26,2020-12-26,3,1,0,0,0,0,2,0,0,2,0,0,0,0,1,APEIRON Biologics AG,Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 Rekombinantes humanes Angiotensin-konvertierendes Enzym 2 (rhACE2) als Behandlung für Patienten...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001172-15,1,0,0 2020-001173-69,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Pernille Ravn,Impact of LTBI treatment on glucose tolerance and chronic inflammation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001173-69,0,0,0 2020-001174-30,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F.Hoffman-La Roche Ltd.,"AN EXPLORATORY, PROSPECTIVE, MULTI-CENTER, OPEN-LABEL, SINGLE-ARM, INTERVENTIONAL, PHASE IIB STUDY TO INVESTIGATE AQUEOUS HUMOR AND MULTIMODAL IMAGING BIOMARKERS IN TREATMENT-NAÏVE PATIENTS WITH DIABE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001174-30,0,0,0 2020-001174-30,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"AN EXPLORATORY, PROSPECTIVE, MULTI-CENTER, OPEN-LABEL, SINGLE-ARM, INTERVENTIONAL, PHASE IIB STUDY TO INVESTIGATE AQUEOUS HUMOR AND MULTIMODAL IMAGING BIOMARKERS IN TREATMENT-NAÏVE PATIENTS WITH DIABE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001174-30,0,0,0 2020-001175-32,3,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,"Bial - Portela & Ca, S.A.","Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated pain.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001175-32,0,0,0 2020-001175-32,3,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,"BIAL-Portela & Ca, S.A.","Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated pain.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001175-32,0,0,0 2020-001176-15,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"Bial - Portela & Ca, S.A.","Open-label, single-arm, pilot study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated sleep disorders.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001176-15,0,0,0 2020-001177-78,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,University of Utah,Certolizumab to Prevent Pregnancy Complications in High-Risk Patients with APS or SLE Certolizumab en prévention de complications de la grossesse chez les patientes à haut risque atteintes d’un Sy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001177-78,0,0,0 2020-001178-31,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CEL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001178-31,0,0,0 2020-001178-31,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CEL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001178-31,0,0,0 2020-001185-11,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO,"A proof-of concept study of the use of Janus Kinase 1 and 2 Inhibitor, Baricitinib, in the treatment of COVID-19-related pneumonia: a two-step phase II clinical trial Baricitinib per la polmonite d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001185-11,0,0,0 2020-001188-96,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,CHU de Saint Etienne,Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers: a randomized double-blind placebo-controlled clinical trial Essai de chimioprophylaxie de l’infection à SARS-CoV-2...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001188-96,0,0,0 2020-001189-13,4,,,0,0,0,0,2,1,2,0,0,3,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001189-13,0,0,0 2020-001189-13,4,,,0,0,0,0,2,1,2,0,0,3,0,0,0,0,1,PFIZER INC,"A PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001189-13,0,0,0 2020-001189-13,4,,,0,0,0,0,2,1,2,0,0,3,0,0,0,0,1,Pfizer Inc.,"A PHASE 2 MULTIPLE DOSE, RANDOMIZED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001189-13,0,0,0 2020-001191-14,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Merck Sharp & Dohme LLC,A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001191-14,0,0,0 2020-001191-14,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001191-14,0,0,0 2020-001191-14,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001191-14,0,0,0 2020-001194-69,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Félix Gutiérrez Rodero,Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the SARS-CoV-2 coronavirus (COVID-19) Estudio piloto para evaluar la eficacia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001194-69,0,0,0 2020-001194-69,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Mar Masiá Canuto,Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the SARS-CoV-2 coronavirus (COVID-19) Estudio piloto para evaluar la eficacia...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001194-69,0,0,0 2020-001198-55,1,2022-01-16,2022-01-16,1,1,0,0,0,0,2,0,0,1,1,1,0,0,0,Chronic Obstructive Pulmonary Disease Trial Network (COP:TRIN),Proactive Prophylaxis with Azithromycin and Hydroxychloroquine Patients Hospitalized with COVID Pro-aktiv Beskyttelse af Indlagte Patienter med COVID,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001198-55,0,0,0 2020-001200-42,1,2021-09-06,2021-09-06,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"Department of Infecitous Diseases, Aarhus University Hospital","The Impact of Camostat Mesilate on COVID-19 Infection: An investigator-initiated randomized, placebo-controlled, phase IIa trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001200-42,0,0,0 2020-001202-32,10,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,VectivBio AG,"A multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of apraglutide in adult subjects with short bowel syndrome and intestinal failure (SBS-IF)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001202-32,0,0,0 2020-001203-16,1,,,0,1,0,0,1,0,4,0,0,3,0,0,0,0,0,Guy's and St Thomas' NHS Foundation Trust,"Lipid ibuprofen versus standard of care for acute hypoxaemic respiratory failure due to COVID-19: a multicentre, randomised, controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001203-16,0,0,0 2020-001203-16,1,,,0,1,0,0,1,0,4,0,0,3,0,0,0,0,0,King's College London,"Lipid ibuprofen versus standard of care for acute hypoxaemic respiratory failure due to COVID-19: a multicentre, randomised, controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001203-16,0,0,0 2020-001205-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Helse Bergen HF, Haukeland University Hospital",Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001205-23,0,0,0 2020-001206-35,2,2021-12-31,2021-12-31,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Medizinische Universität Innsbruck,"Stopping ACE-inhibitors in COVID-19 - a randomized, controlled clinical trial Stopp von ACE-Hemmern bei Patienten mit COVID 19 - eine randomisierte, kontrollierte klinische Prüfung",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001206-35,0,0,0 2020-001209-22,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Oxford / Clinical Trials and Research Governance,Platform Randomised trial of INterventions against COVID-19 In older peoPLE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001209-22,0,0,0 2020-001211-24,8,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Dermira Inc. a wholly-owned subsidiary of Eli Lilly and Company,A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001211-24,0,0,0 2020-001211-24,8,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company",A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001211-24,0,0,0 2020-001211-24,8,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Dermira Inc. a wholly-owned subsidiary of Eli Lilly and Company,A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001211-24,0,0,0 2020-001215-24,1,2021-06-18,2021-06-18,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Aarhus University Hospital,"The effect of subpectineal obturator nerve block on opioid consumption and pain after hip arthroscopy A double-blind randomized, controlled trial Effekten af subpectineal obturatorius nervebloka...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001215-24,0,0,0 2020-001217-20,5,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,Sanofi Aventis Recherche & Developpement,"A phase 4, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of the effect of dupilumab on sleep disturbance in patients with uncontrolled persistent asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001217-20,0,0,0 2020-001217-20,5,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A phase 4, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of the effect of dupilumab on sleep disturbance in patients with uncontrolled persistent asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001217-20,0,0,0 2020-001218-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"fertility clinic, Herlev university hospital","Estradiol levels in early pregnancy after natural, estradiol + progesterone or gonadotrophin stimulated frozen embryo transfer (FET) cycle Østradiol-niveauer i tidlig graviditet efter naturlig, ø...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001218-39,0,0,0 2020-001218-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fertilti clinic Hvidovre University hospital,"Estradiol levels in early pregnancy after natural, estradiol + progesterone or gonadotrophin stimulated frozen embryo transfer (FET) cycle Østradiol-niveauer i tidlig graviditet efter naturlig, ø...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001218-39,0,0,0 2020-001219-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,tichting Het Nederlands Kanker Instituut_Antoni van Leeuwenhoek,Prostatic Artery Injection vs Intra-Venous Injection of 18F-DCFPyL to evaluate treatment strategy in Prostate Cancer Toediening via de prostaatslagaders vs intra-veneuze toediening van f 18F-DCFPyL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001219-26,0,0,0 2020-001223-14,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur SA,"Imovax® Rabies and VERORAB® Immunogenicity and Safety after One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Intradermal or Intramuscular...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001223-14,0,1,1 2020-001224-33,1,2021-02-26,2021-02-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Universitätsklinikum Tübingen,Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001224-33,0,0,0 2020-001228-32,1,,,0,0,0,0,1,0,2,0,1,3,0,0,0,0,0,CTRG,"A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001228-32,0,0,0 2020-001235-27,1,,,0,1,1,0,0,1,1,0,0,4,0,0,0,0,1,"AveXis, Inc.",Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001235-27,0,1,1 2020-001236-10,2,2021-02-01,2021-02-01,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Amsterdam UMC,"COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in Covid19 – a randomized, double --blind, placebo controlled, clinical trial in patients with severe Covid19 disease’ Effecten van ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001236-10,0,0,0 2020-001239-29,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"REGENERON PHARMACEUTICALS, INC.","A PHASE 2 STUDY OF CEMIPLIMAB, AN ANTI-PD-1 MONOCLONAL ANTIBODY, AND ISA101B VACCINE IN PATIENTS WITH RECURRENT/METASTATIC HPV16 CERVICAL CANCER WHO HAVE EXPERIENCED DISEASE PROGRESSION AFTER FIRST LI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001239-29,0,0,0 2020-001239-29,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A PHASE 2 STUDY OF CEMIPLIMAB, AN ANTI-PD-1 MONOCLONAL ANTIBODY, AND ISA101B VACCINE IN PATIENTS WITH RECURRENT/METASTATIC HPV16 CERVICAL CANCER WHO HAVE EXPERIENCED DISEASE PROGRESSION AFTER FIRST LI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001239-29,0,0,0 2020-001240-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboudumc,Phase 2 INSPIRE trial: Ipilimumab with Nivolumab in molecular-selected patients with castration-resistant prostate cancer Fase II studie INSPIRE: Ipilimumab met Nivolumab in moleculair geselecteerd...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001240-25,0,0,0 2020-001243-15,1,2020-06-10,2020-06-10,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,UZLeuven,"Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001243-15,0,0,0 2020-001244-26,1,2021-08-23,2021-08-23,1,0,0,0,0,1,2,0,0,1,1,1,1,0,0,"Department of Clinical Pharmacology, Medical University of Vienna, Vienna Austria",COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial. COVID-19: Wirksamkeit von Solnatide zur Behandlu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001244-26,0,0,0 2020-001246-18,1,2020-11-26,2020-11-26,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Assistance Publique - Hôpitaux de Paris,Cohort Multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001246-18,0,0,0 2020-001247-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,"An Open Label, Phase IV, Mechanistic, Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin treatment in Type 2 Diabetes Mellitus Patients with Impaired Renal Function",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001247-12,0,0,0 2020-001249-37,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ-73763989 + Nucleos(t)ide Anal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001249-37,0,0,0 2020-001249-37,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ-73763989 + Nucleos(t)ide Anal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001249-37,0,0,0 2020-001250-21,1,2021-06-10,2021-06-10,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,GUSTAVE ROUSSY,COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001250-21,0,0,0 2020-001251-41,1,2021-01-29,2021-01-29,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,CH de Versailles,A PROOF OF CONCEPT STUDY TESTING THE VALUE OF IMATINIB IN PREVENTION OF COVID-19 IN AGED PATIENTS. ETUDE DE PREUVE DE CONCEPT TESTANT L’INTERET DE L’IMATINIB MESYLATE DANS LA PREVENTION DE COVID-19...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001251-41,0,0,0 2020-001254-22,1,2021-02-26,2021-02-26,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,University Hospital Ghent,"A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine®) in improving oxygenation and short- and long-term outcome of COVID-19 patients with a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001254-22,0,0,0 2020-001255-40,1,2020-11-10,2020-11-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Clínica Universidad de Navarra/Universidad de Navarra,Sarilumab Treatment In cytoKinE storm caused by infection with COVID-19. Tratamiento con sarilumab para síndrome de liberación de citoquinas causado por infección con COVID-19.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001255-40,0,0,0 2020-001257-51,1,2020-12-16,2020-12-16,1,0,0,0,0,1,3,0,0,1,1,1,1,0,0,Rigshospitalet,The Danish Pre-HCQ Dialysis Study: Hydroxychloroquine for prevention of COVID-19 in dialysis-treated patients with end-stage renal disease - A multicenter parallel-group open randomized clinical tria...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001257-51,0,0,0 2020-001258-23,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA,COLCHICINE TO COUNTERACT INFLAMMATORY RESPONSE IN COVID-19 PNEUMONIA COLCHICINA PER CONTRASTARE LA RISPOSTA INFIAMMATORIA IN CORSO DI POLMONITE DA COVID 19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001258-23,0,0,0 2020-001262-11,1,2021-04-29,2021-04-29,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Instituto de Investigación Sanitaria Fundación Jiménez Díaz,"Randomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001262-11,0,0,0 2020-001263-85,9,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Savara ApS,"A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP) Studio cl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001263-85,0,0,0 2020-001263-85,9,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,SAVARA APS,"A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP) Studio cl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001263-85,0,0,0 2020-001264-28,5,2021-02-23,2021-02-23,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Immunic AG,"A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Care ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001264-28,0,0,0 2020-001265-36,1,2020-07-23,2020-07-23,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,University College Dublin,"A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001265-36,0,0,0 2020-001266-11,1,2020-11-11,2020-11-11,1,0,0,0,1,0,2,0,0,1,1,1,1,0,0,Fundación Instituto de Investigación Sanitaria Fundación Jiménez Diaz,"Two-center, randomized, controlled clinical trial with two treatment arms to evaluate the safety and efficacy of intravenous administration of expanded allogeneic adipose tissue adult mesenchymal cell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001266-11,0,0,0 2020-001270-29,5,2020-06-22,2020-06-25,4,1,0,0,0,0,2,0,0,1,1,1,1,0,1,sanofi-aventis recherche & développement,"An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001270-29,0,0,0 2020-001271-33,1,,,0,1,0,0,0,0,3,0,0,1,0,0,0,1,0,CHU Angers,HYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19 à risque d’aggravation secondaire : étude prospective multicentrique randomisée en double aveugle HYCOVID ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001271-33,0,0,0 2020-001273-73,1,2020-06-18,2020-06-18,1,0,0,0,0,0,3,0,1,1,1,1,1,0,0,Assistance Publique Hôpitaux de Paris,COVID-19+ Etude multicentrique randomisée évaluant l’efficacité de l’azithromycine et de l’hydroxychloroquine dans la prévention de l’infection par le SARS-CoV-2 au sein de la population hospitalière...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001273-73,0,0,0 2020-001275-32,1,2020-10-09,2020-10-09,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,"The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark",Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients with Severe SARS-CoV-2 Pneumonia: An Open-Label Multicenter Sequential Randomized Controlled Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001275-32,0,0,0 2020-001276-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Amiens-Picardie,Does high-dose vitamin B3 supplementation prevent major adverse kidney events during septic shock? A multicenter randomized controlled study. La supplémentation à forte dose en vitamine B3 permet-e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001276-15,0,0,0 2020-001278-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES),"A comparative, randomised controlled trial for evaluating the efficacy of dexamethasone administration in the treatment of patients affected by COVID-19 with Acute Respiratory Distress Syndrome Ens...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001278-31,0,0,0 2020-001281-11,1,2020-04-28,2020-04-28,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,CHU de Saint Etienne,Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit. Évaluation de la relation concentration effet Virologique de l’HYdrO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001281-11,0,0,0 2020-001285-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,"A Randomized, open label, Non-inferiority trial on the efficacy of Lacosamide versus Duloxetine in Patients with Chemotherapy-induced Polyneuropathy – A strategy trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001285-11,0,0,0 2020-001287-28,1,2021-10-26,2021-10-26,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Assitance Publique-Hôpitaux de Paris,NA Thérapie cellulaire par cellules stromales mésenchymateuses issues de cordon ombilical dans le syndrome de détresse respiratoire aiguë (SDRA) associé au SARS-CoV-2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001287-28,0,0,0 2020-001288-99,14,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Pfizer Inc.,"AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001288-99,0,0,0 2020-001288-99,14,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001288-99,0,0,0 2020-001288-99,14,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,PFIZER INC,"AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001288-99,0,0,0 2020-001290-74,1,2021-05-05,2021-05-05,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Consorci Parc de Salut Mar (PSMAR),Efficacy and safety of sarilumab in the early treament of hospitalized patients with mild-moderate neumonia and COVID19 infection versus standard of care Eficacia y seguridad de Sarilumab en el tra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001290-74,0,0,0 2020-001296-33,1,2021-04-26,2021-04-26,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,"Section for Transfusion Medicine, Capital Region Blood bank, Copenhagen University Hospital","Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in patients with COVID-19 induced respiratory failure – a multicentre randomized, placebo-controlled, blinded, investigator-initia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001296-33,0,0,0 2020-001301-23,1,2022-02-03,2022-02-03,1,0,0,0,0,0,3,0,0,1,1,1,0,0,0,Assistance Publique - Hôpitaux de Paris,Efficacy of Addition of Naproxen in the Treatment of critically ill Patients Hospitalized for COVID-19 Infection / Enacovid Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001301-23,0,0,0 2020-001302-30,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Medical University of Vienna,"A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001302-30,0,0,0 2020-001303-16,1,2021-06-02,2021-06-02,1,0,0,0,1,0,3,0,0,1,1,1,1,0,0,Hôpitaux Universitaires de Strasbourg,"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multi-Centre, Adaptive, Blinded Study Efficacité de l’Hydrox...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001303-16,0,0,0 2020-001304-42,1,,,0,0,0,0,1,0,2,0,0,3,0,0,0,0,0,University of Nottingham,Efficacy of Nitric Oxide in Stroke -2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001304-42,0,0,0 2020-001305-23,5,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,AMGEN INC.,A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001305-23,0,0,0 2020-001305-23,5,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,Amgen,A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001305-23,0,0,0 2020-001306-35,1,2021-04-26,2021-04-26,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,DRCI APHP,Protective role of inhaled steroids for COVID-19 infection Rôle protecteur des stéroïdes inhalés pour l'infection par COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001306-35,0,0,0 2020-001307-16,1,2020-06-03,2020-06-03,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Fundación para la Investigación Biomédica Hospital Ramón y Cajal,Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to COVID-19. Eficacia y seguridad de los corticoides en pacientes con síndrome de distrés res...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001307-16,0,0,0 2020-001308-40,1,2021-05-26,2021-05-26,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,ALMA MATER STUDIORUM UNIVERSITà DI BOLOGNA,"Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19 Intermediate dose enoxaparin in hospitalized patients with mode...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001308-40,0,0,0 2020-001309-22,1,,,0,1,0,0,0,0,4,0,0,1,0,0,0,1,1,IQVIA Commercial GmbH & Co. OHG,"Evaluation of immunological effects of the hedgehog inhibitors on basal cell carcinoma - An open label, prospective, observational biomarker study of the DeCOG. Bewertung der immunologischen Wirkun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001309-22,0,0,0 2020-001310-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,DRK-Bluspendedienst Baden-Württemberg - Hessen gGmbH,"A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19 Randomisierte, prospektive, offene klinische...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001310-38,0,0,0 2020-001313-20,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffman-La Roche Ltd,"A PHASE IIIb, GLOBAL, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001313-20,0,0,0 2020-001313-20,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE IIIb, GLOBAL, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001313-20,0,0,0 2020-001313-20,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE IIIb, GLOBAL, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001313-20,0,0,0 2020-001314-37,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Dr. Falk Pharma GmbH,"Double-blind, double-dummy, randomized, parallel-group, non-inferiority phase III trial on the efficacy and tolerability of 2 mg once daily vs. 1 mg twice daily budesonide orodispersible tablets for i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001314-37,0,0,0 2020-001317-20,5,2017-08-15,2017-08-15,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Imcyse SA,"A Phase IIa, randomized, double-blind, dose comparison, placebo-controlled, multi-centre clinical trial to evaluate the immune signature of the treatment with the Imotope™ IMCY-0098 and its effect on...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001317-20,1,0,0 2020-001318-39,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Prof. Dr. Martina Kerscher, University of Hamburg",Skin perception after intradermal application of IncobotulinumtoxinA within upper and midface (Interventional Phase II),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001318-39,0,0,0 2020-001319-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Instituto de Investigación Sanitaria Fundación Jiménez Díaz,"Multicenter, randomized, controlled, open-label clinical trial to assess the prognostic implications of rosuvastatin treatment in patients discharged after hospitalization for COVID-19 Positive. En...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001319-26,0,0,0 2020-001320-34,2,2021-05-25,2021-05-25,1,1,0,0,0,0,4,0,0,2,1,0,0,0,0,Radboudumc,"A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease Een dubb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001320-34,1,0,0 2020-001321-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospital Universitario de Fuenlabrada,"Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001321-31,0,0,0 2020-001322-54,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University Hospitals Bristol and Weston NHS Foundation Trust,Carbon Dioxide Insufflation and Brain Protection During Open Heart Surgery: A Randomised Controlled Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001322-54,0,0,0 2020-001324-33,1,2021-02-02,2021-02-02,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (APHP),"Use of a respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in patients with severe confirmed COVID-19 pneumonia : a multicenter, parallel-group, open-label, randomized controll...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001324-33,0,0,0 2020-001325-31,1,2021-01-21,2021-01-21,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Radboud University Medical Center,[68Ga]Ga-DOTA-(RGD)2 PET/CT imaging of activated endothelium in lung parenchyma of COVID-19 patients. [68Ga]Ga-DOTA-(RGD)2 PET/CT beeldvorming van geactiveerd endotheel in longparenchym van COVID-1...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001325-31,0,0,0 2020-001327-13,1,2021-06-14,2021-06-14,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,Med. Univ. Wien,"A SINGLE-BLINDED RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PROPHYLACTIC TREATMENT WITH ORAL AZITHROMYCIN VERSUS PLACEBO IN CANCER PATIENTS UNDERGOING ANTINEOPLASTIC TREATMENT DURING THE COVID-1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001327-13,0,0,0 2020-001329-30,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Massachussetts General Hospital,Inhaled Nitric Oxide Gas Therapy in Mechanically Ventilated Patients with Severe Acute Respiratory Syndrome in COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001329-30,0,0,0 2020-001331-26,1,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust,ChemoPROphyLaxIs For covId-19 infeCtious disease (the PROLIFIC trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001331-26,0,0,0 2020-001333-13,1,2020-08-07,2020-08-07,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Groupe Hospitalier Paris Saint-Joseph,Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial Dexaméthasone associée à l'hy...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001333-13,0,0,0 2020-001335-28,4,2021-12-01,2021-12-01,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,InflaRx GmbH,"A pragmatic adaptive randomized controlled Phase II/III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - ""PANAMO""",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001335-28,1,0,0 2020-001336-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Centre Hamburg-Eppendorf,"Multicenter, randomized, double-blind, biomarker-guided, phase II trial with Adrecizumab (HAM 8101) to improve proGNosis and outcomES in patients with moderate to severe covid-19 - Adrecizumab (HAM810...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001336-10,0,0,0 2020-001340-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Utrecht,"Enrichment randomized double-blind, placebo-controlled cross-over trial with PHEnytoin cream in patients with painful chronic idiopathic axonal polyNEuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001340-25,0,0,0 2020-001342-19,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Asieris MediTech Co., Ltd.","A double blind, prospective, randomized, placebo controlled, multi-center phase 3 study to evaluate efficacy and safety of Cevira® in patients with cervical histologic high-grade squamous intraepithel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001342-19,0,0,0 2020-001345-38,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,1,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,"CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS SARS-CoV-2 (COVID-19): THE HOPE OPEN-LABEL, NON-RANDOMIZED CLINICAL TRIAL Η ΦΩΣΦΟΡΙΚΗ ΧΛΩΡΟΚΙΝΗ ΓΙΑ ΛΟΙΜΩΞΕΙΣ ΑΠΟ ΤΟ ΝΕΟ ΚΟΡΟΝΟΪΟ SA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001345-38,0,0,0 2020-001348-25,5,2022-07-11,2022-07-11,4,0,0,0,0,0,2,0,0,1,0,0,0,0,1,"COMPASS Pathfinder, Ltd",A multicentre study to assess safety and efficacy of COMP360 in patients with treatment-resistant depression following completion of COMP 001 and COMP 003 trials (P-TRD LTFU),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001348-25,0,0,0 2020-001348-25,5,2022-07-11,2022-07-11,4,0,0,0,0,0,2,0,0,1,0,0,0,0,1,"COMPASS Pathways, Ltd",A multicentre study to assess safety and efficacy of COMP360 in patients with treatment-resistant depression following completion of COMP 001 and COMP 003 trials (P-TRD LTFU),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001348-25,0,0,0 2020-001349-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska Institutet,"A Randomized, Controlled, Open Label, Multicentre Clinical Trial to explore Safety and Efficacy of Hyperbaric Oxygen for preventing ICU admission, Morbidity and Mortality in Adult Patients With COVID...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001349-37,0,0,0 2020-001350-21,2,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,"Apellis Pharmaceuticals, Inc.","An Open-Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Biologic Activity of Pegcetacoplan in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001350-21,0,0,0 2020-001354-22,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,Cambridge University Hospitals NHS Foundation Trust,Multiarm Therapeutic study in pre-ICU patients admitted with COVID-19 - Repurposed Drugs (TACTIC-R),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001354-22,0,0,0 2020-001355-40,5,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase III, randomized, double-blind, placebo-controlled multi-country study to demonstrate efficacy of a single dose of unadjuvanted RSV Maternal vaccine, administered IM to pregnant women 18 to 49 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001355-40,0,0,0 2020-001355-40,5,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A Phase III, randomized, double-blind, placebo-controlled multi-country study to demonstrate efficacy of a single dose of unadjuvanted RSV Maternal vaccine, administered IM to pregnant women 18 to 49 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001355-40,0,0,0 2020-001355-40,5,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,1,GlaxoSmithKline S.A.,"A Phase III, randomized, double-blind, placebo-controlled multi-country study to demonstrate efficacy of a single dose of unadjuvanted RSV Maternal vaccine, administered IM to pregnant women 18 to 49 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001355-40,0,0,0 2020-001357-52,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IDIVAL,"Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001357-52,0,0,0 2020-001363-85,1,,,0,1,0,0,0,0,3,0,1,1,1,1,0,1,0,Odense University Hospital,"COVID-19 Prophylaxis with hydroxychloroquine, Vitamin D, and Zinc supplementation in Danish nursing home residents – a randomized controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001363-85,0,0,0 2020-001364-29,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Red Andaluza de Diseño y Traslación de Terapias Avanzadas-Fundación Progreso y Salud,Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia Ensayo clínico Fase I/II...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001364-29,0,0,0 2020-001365-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,NU-hospital Group,A randomized double-blind clinical trial comparing Hypochlorous Acid and Polyhexamethylene biguanide in treating diabetic foot ulcers En randomiserad dubbelblind klinisk prövning jämförande Hypokl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001365-36,0,0,0 2020-001366-11,8,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,FIB-HCSC,An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001366-11,0,0,0 2020-001366-11,8,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,WHO (World Health Organization),An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001366-11,0,0,0 2020-001366-11,8,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,World Health Organization,An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001366-11,0,0,0 2020-001366-11,8,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Ministry of Health of the Republic of Latvia,An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001366-11,0,0,0 2020-001366-11,8,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Ministry of Health,An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001366-11,0,0,0 2020-001366-11,8,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,World Health Organisation,An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001366-11,0,0,0 2020-001366-11,8,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Department of Health,An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001366-11,0,0,0 2020-001366-11,8,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Ministerstvo Zdravotníctva Slovenskej republiky,An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001366-11,0,0,0 2020-001366-11,8,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,AICIB,An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001366-11,0,0,0 2020-001366-11,8,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA,An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001366-11,0,0,0 2020-001366-11,8,,,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,Vilnius University Hospital Santaros Klinikos,An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001366-11,0,0,0 2020-001367-88,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,Department of Infectious diseases,"Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial pla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001367-88,0,0,0 2020-001370-30,6,2020-12-22,2020-12-22,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001370-30,1,0,0 2020-001370-30,6,2020-12-22,2020-12-22,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001370-30,1,0,0 2020-001370-30,6,2020-12-22,2020-12-22,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Farmacéutica S.A.,"Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001370-30,1,0,0 2020-001373-70,1,2021-07-06,2021-07-06,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Centre Léon Bérard,"IMMUNONCOVID-20 : A prospective, controlled, randomized, multicenter study to compare the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001373-70,0,0,0 2020-001375-32,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,UMCG,"Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001375-32,0,0,0 2020-001376-15,1,2020-09-03,2020-09-03,1,1,0,0,0,0,3,0,1,1,1,1,1,0,1,Vakzine Projekt Management GmbH,"A phase III, double-blind, randomized, placebo-controlled multicentre clinical trial to assess the efficacy and safety of VPM1002 in reducing healthcare professionals’ absenteeism in the SARS-CoV-2 pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001376-15,0,0,0 2020-001379-34,1,2021-03-31,2021-03-31,1,1,0,0,0,0,4,0,0,1,1,1,1,0,0,Instituto de Investigación Sanitaria INCLIVA,Sedation with sevoflurane versus propofol in patients with Acute Respiratory Distress Syndrome caused by COVID-19 infection Sedación con sevoflurano versus propofol en pacientes con Síndrome De Dis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001379-34,0,0,0 2020-001381-11,1,2020-11-28,2020-11-28,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),COVID-19 - ACE inhibitors or ARBs discontinuation for Clinical Outcome Risk reduction in patients hospitalized for the Endemic Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection: the...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001381-11,0,0,0 2020-001384-87,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE PHARMACODYNAMIC EFFECTS OF ONCE WEEKLY ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH EARLY (PRODOMAL TO MILD) ALZHEIMER'S DI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001384-87,0,0,0 2020-001384-87,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE II, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE PHARMACODYNAMIC EFFECTS OF ONCE WEEKLY ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS WITH EARLY (PRODOMAL TO MILD) ALZHEIMER'S DI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001384-87,0,0,0 2020-001385-11,1,2021-07-11,2021-07-11,1,0,0,0,0,0,3,0,1,1,0,0,1,0,0,Plan Nacional Sobre SIDA,Prevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial controlled with p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001385-11,0,0,0 2020-001386-37,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia,Uno studio randomizzato multicentrico in aperto per valutare l’efficacia della somministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID-19. Uno studio randomizzato m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001386-37,0,0,0 2020-001387-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud University Medical Center,18F-PSMA-1007 PET to detect primary prostate cancer: a comparative study with mpMRI and correlation to histopathology.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001387-28,0,0,0 2020-001389-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aarhus University Hospital,"The Postoperative Iron in Cardiac Surgery (PICS-) trial: A randomised clinical trial comparing the efficacy of single-, high-dose intravenous iron and oral iron for the treatment of anaemia following ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001389-12,0,0,0 2020-001390-76,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI""","A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001390-76,0,0,0 2020-001391-15,1,2021-04-12,2021-04-12,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Royal College of Surgeons Ireland,"A randomized double-blind placebo-controlled, pilot trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001391-15,0,0,0 2020-001392-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SolasCure Ltd,"An adaptive open label, multiple ascending dose study of the safety, tolerability and bio-effect of Aurase for wound debridement in patients with venous leg ulcers and diabetic foot ulcers (CLEANVLU/D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001392-32,0,0,0 2020-001395-15,1,2021-06-12,2021-06-12,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,"Deparment of Intensive Care, Rigshospitalet",Low dose hydrocortisone in patients with COVID-19 and severe hypoxia – the COVID STEROID trial Lavdosis hydrokortison til patienter med COVID-19 sygdom og svær hypoxi – COVID STEROID forsøget,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001395-15,0,0,0 2020-001396-33,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,SLA Pharma (UK) Ltd,"A randomised, double-blind, placebo-controlled study of eicosapentaenoic acid (EPA-FFA) gastro-resistant capsules to treat hospitalised subjects with confirmed SARS-CoV-2",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001396-33,0,0,0 2020-001396-33,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,KD Swiss GmbH,"A randomised, double-blind, placebo-controlled study of eicosapentaenoic acid (EPA-FFA) gastro-resistant capsules to treat hospitalised subjects with confirmed SARS-CoV-2",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001396-33,0,0,0 2020-001397-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Ruprecht-Karls-University Heidelberg, Medical Faculty rep. by University hospital and Commercial Managing Director",APOS study- Antibiotic Prophylaxis for preventing infectious complications in Orthognathic Surgery Antibiotische Prophylaxe zur Vorbeugung von Infektionen nach Orthognather Umstellungsosteotomie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001397-30,0,0,0 2020-001398-59,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,OSE Immunotherapeutics,"Randomized, double-blind, Phase 2 study to evaluate the efficacy and the safety of OSE-127 versus placebo in subjects with moderate to severe active ulcerative colitis who have failed or are intoleran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001398-59,0,0,0 2020-001400-41,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BioNTech SE,"An open label Phase II randomized trial of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy as a first line therapy in patients with unresectable recurrent, or metastatic Head...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001400-41,0,0,0 2020-001402-38,1,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,0,University College London,"An international, Bayesian platform adaptive, randomized, placebo-controlled trial assessing the effectiveness of candidate interventions in preventing COVID-19 disease in healthcare workers.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001402-38,0,0,0 2020-001404-42,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,A Phase 3b Open label Study Evaluating the Long term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects Ages 6 Years and Older Who Are Heterozygous...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001404-42,0,0,0 2020-001405-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación de Investigación HM Hospitales,Randomized phase II clinical trial of ruxolitinib plus simvastatin in the prevention and treatment of respiratory failure of COVID-19.Ruxo-Sim-20 clinical trial. Ensayo fase II randomizado de ruxol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001405-23,0,0,0 2020-001406-27,1,2020-06-08,2020-06-08,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University Hospital of Montpellier,"Randomized open label trial assessing efficacy and safety of hydroxychloroquine plus azithromycin versus hydroxychloroquine for hospitalized patients with COVID-19 Etude multicentrique, randomisée...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001406-27,0,0,0 2020-001408-41,1,2020-08-31,2020-08-31,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Universitätsklinikum Freiburg,"A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001408-41,0,0,0 2020-001409-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FFIS,"A prospective, multicenter, randomized, parallel, double-blind, placebo-controlled phase IIb clinical trial to evaluate intravenous infusion of Defibrotide in the prevention and treatment of respirato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001409-21,0,0,0 2020-001411-25,6,2021-01-13,2021-01-13,3,1,0,0,1,0,2,0,0,2,1,0,0,0,1,Karyopharm Therapeutics Inc.,A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001411-25,1,0,0 2020-001413-20,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Fundació Clínic per a la Recerca Biomèdica,"Phase 2, randomized, open-label study to compare the efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID19 pneumonia Estudio fase 2, aleatorizado, abierto para...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001413-20,0,0,0 2020-001416-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH,Pharmacokinetics of Ceftazidime-Avibactam in Bile Fluid – an in-vivo Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001416-15,0,0,0 2020-001417-21,1,2020-06-26,2020-06-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Institute of Tropical Medicine,An open label single center randomized controlled trial to evaluate the effect of hydroxychloroquine on viral shedding in mild COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001417-21,0,0,0 2020-001419-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Jagiellonian University Medical College,Preoperative intraperitoneal chemotherapy in adjuvant hyperthermia adjunctive therapy in advanced gastric cancer with high-risk of peritoneal recurrence - a multicentre randomized trial Przedopera...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001419-25,0,0,0 2020-001420-34,1,2021-01-25,2021-01-25,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Aarhus University,"Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial BEHANDLING MED SENICAPOC TIL COVID-19 POSITIVE PATIENTER INDLAGT PÅ INTENSIV",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001420-34,0,0,0 2020-001421-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sociedad Española de Farmacia Hospitalaria,"Clinical trial randomized, unblinded and controled for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001421-31,0,0,0 2020-001424-34,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Sage Therapeutics, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF SAGE-217 IN THE TREATMENT OF ADULTS WITH SEVERE POSTPARTUM DEPRESSION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001424-34,0,0,0 2020-001428-33,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Pliant Therapeutics, Inc","A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with primary sclerosing cholangitis (PS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001428-33,0,0,0 2020-001429-30,14,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001429-30,0,0,0 2020-001429-30,14,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001429-30,0,0,0 2020-001430-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Rennes,Evaluation of the hemodynamic effects of fludrocortisone on the pressive response to norepinephrine in patients in septic shock Evaluation des effets hémodynamiques de la fludrocortisone sur la rép...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001430-35,0,0,0 2020-001431-27,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,Klinikum St. Georg gGmbH,"Treatment of Sars-CoV2 infections (Covid-19) in patients without or with chronic kidney disease (CKD) with valsartan vs placebo, a three-armed randomized, partly blinded trial Dreiarmige randomisie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001431-27,0,0,0 2020-001434-35,1,2020-05-06,2020-05-06,1,0,0,0,0,0,4,0,0,1,0,0,1,0,0,Cliniques universitaires Saint-Luc,Monocentric Population Pharmacokinetic study of Hydroxychloroquine in COVID-19 Patients to inform its dosing optimization. Etude pharmacocinétique de population de l’hydroxychloroquine chez les pat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001434-35,0,0,0 2020-001435-27,1,2021-10-22,2021-10-22,1,0,0,0,0,0,3,0,0,1,0,0,0,0,0,"CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, ETABLISSEMENT PUBLIC","Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety of several experimental treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001435-27,0,0,0 2020-001437-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR),"Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs ENSAYO CLÍNICO ALEATORIZADO, CONTROLADO, ABIERTO, UNICÉNTRICO,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001437-12,0,0,0 2020-001440-26,1,2020-04-08,2020-04-08,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI),"Pilot, double-blind clinical trial to evaluate the efficacy and safety of pre-exposure use of hydroxychloroquine versus placebo in the prevention of SARS-CoV-2 (COVID-19) infection in healthcare perso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001440-26,0,0,0 2020-001441-39,2,,,0,1,0,0,0,0,3,0,1,2,1,0,0,0,0,UNIVERSITY OF OXFORD,"Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001441-39,0,0,0 2020-001441-39,2,,,0,1,0,0,0,0,3,0,1,2,1,0,0,0,0,University of Oxford,"Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001441-39,0,0,0 2020-001442-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INSTITUT DE RECERCA H. SANTA CREU I SANT PAU,"Pilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19) Ensayo clínico pi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001442-19,0,0,0 2020-001445-39,1,2020-06-29,2020-06-29,1,0,0,0,0,0,2,0,0,1,1,1,1,0,0,Dr. Xavier Solanich Moreno. Servei Medicina Interna. Hospital de Bellvitge,"PRAGMATIC, CONTROLLED, OPEN, SINGLE CENTER, RANDOMIZED, PHASE II CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001445-39,0,0,0 2020-001448-24,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Birmingham,Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001448-24,0,0,0 2020-001449-38,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Chelsea and Westminster Hospital NHS Foundation Trust,A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19: Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001449-38,0,0,0 2020-001450-22,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,0,Fundación de Investigación del Hospital Infantil Universitario Niño Jesús,Phase II Clinical Trial to explore the efficacy of allogeneic mesenchymal cells from umbilical cord tissue in patients with severe pulmonary involvement by COVID-19. Ensayo Clínico Fase II para exp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001450-22,0,0,0 2020-001453-49,1,2020-09-23,2020-09-23,1,1,0,0,0,0,4,0,0,1,0,0,1,0,1,"Gilead Sciences, Inc.",Expanded Access Treatment Protocol: Remdesivir (RDV;GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection- COVID-19 Protocolo del tratamiento de acceso expandido: Remdesivir (RDV;GS-5734) para el...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001453-49,0,0,0 2020-001455-40,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Hellenic Society of Rhythmology,The Greek study in the Effects of Colchicine in Covid-19 complications prevention ΧΟΡΗΓΗΣΗ ΚΟΛΧΙΚΙΝΗΣ ΣΕ ΑΣΘΕΝΕΙΣ ΜΕ CORONAVIRUS DISEASE-19 (COVID-19) ΓΙΑ ΤΗΝ ΠΡΟΛΗΨΗ ΕΞΕΛΙΞΗΣ ΚΑΙ ΤΩΝ ΕΠΙΠΛΟΚΩΝ ΤΗΣ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001455-40,0,0,0 2020-001456-18,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,3,Nadační fond Donatio intensivistam,"Azithromycin added to Hydrochloroquine in Patients Admitted to Intensive Care due to Coronavirus Disease 2019 (COVID-19) - Randomised Controlled Trial, phase III Azitromycin přidaný k hydrochloroch...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001456-18,0,0,0 2020-001457-43,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,APHP,Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia Dexamethasone et stratégies d’oxygénation des patients hospitalisés en réanimation atteints de pneumonies à Covid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001457-43,0,0,0 2020-001459-42,1,2022-02-17,2022-02-17,1,0,0,0,0,0,2,0,0,1,1,1,0,0,0,Zealand University Hospital,Ruxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001459-42,0,0,0 2020-001461-36,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,uniQure biopharma B.V.,"A Phase Ib/II Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001461-36,0,0,0 2020-001466-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hellenic Institute for the Study of Sepsis,"suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19: THE SAVE OPEN-LABEL, NON-RANDOMIZED SINGLE-ARM TRIAL ΑΞΙΟΛΟΓΗΣΗ ΤΟΥ ΚΙΝΔΥΝ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001466-11,0,0,0 2020-001467-82,1,2022-07-27,2022-07-27,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Leiden University Medical Center,An Open-Label Study Evaluating Anti-Viral Effects of Voclosporin in SARS-CoV-2 Positive Kidney Transplant Recipients – the VOCOVID Study (COVID-19),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001467-82,0,0,0 2020-001469-35,1,2020-12-31,2020-12-31,1,1,0,0,0,0,4,0,0,1,0,0,1,0,0,Wroclaw Medical University,"A multicenter, open, randomized, non-commercial study to evaluate the efficacy and safety of chloroquine phosphate in the outpatient treatment of COVID-19 in combination with telemedicine care for pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001469-35,0,0,0 2020-001472-14,1,2022-05-16,2022-05-16,1,1,0,0,0,0,2,0,0,1,1,1,0,0,0,Istituto Nazionale per le Malattie Infettive “Lazzaro Spallanzani”,"AN OPEN-LABEL, RANDOMIZED, PARALLEL-ARM STUDY INVESTIGATING THE EFFICACY AND SAFETY OF INTRAVENOUS ADMINISTRATION OF PAMREVLUMAB VERSUS STANDARD OF CARE IN PATIENTS WITH SARS-COV-2 INFECTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001472-14,0,0,0 2020-001473-79,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,"Saint Luke’s Hospital of Kansas City, Kansas City, Missouri, USA","An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients with COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001473-79,0,0,0 2020-001474-29,1,2020-12-10,2020-12-10,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Clínica Universidad de Navarra/Universidad de Navarra,Pilot study to evaluate the potential of ivermectin to reduce COVID-19 transmission Estudio piloto para evaluar el potencial de la ivermectina para disminuir la transmisión del COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001474-29,0,0,0 2020-001475-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"DIPARTIMENTO DI MEDICINA, UNIVERSITà DI PERUGIA",Treatment with COLchicine of patients affected by COVID-19: a Pilot Study Treatment with COLchicine of patients affected by COVID-19: a Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001475-33,0,0,0 2020-001478-30,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,UCB Biopharma SRL,"A Multicenter, Open-Label, Follow-Up Study to Assess the Long-Term Use of Oral Lacosamide in Study Participants Who Completed EP0034 or SP848 and Received Lacosamide Treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001478-30,0,0,0 2020-001479-34,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Samsung Bioepis Co., Ltd.","A Phase III, Randomised, Double-blind, Multicentre Clinical Study to Compare the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity between SB16 (proposed denosumab biosimilar) a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001479-34,0,0,0 2020-001481-11,1,2021-06-30,2021-06-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Friedrich-Schiller-Universität Jena,Front line treatment with Ruxolitinib in stage II/III Covid-19 patients with defined Hyperinflammation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001481-11,0,0,0 2020-001482-37,1,2021-01-07,2021-01-07,1,1,0,0,0,0,3,0,0,1,1,1,1,0,0,University Hopsital Tuebingen,Randomized controlled trial of hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of elderly COVID-19 Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001482-37,0,0,0 2020-001483-28,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,Janssen Vaccines & Prevention B.V.,"A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001483-28,0,0,0 2020-001488-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Assistance Publique Hopitaux de Paris,Multisite open-label randomized phase II clinical trial in newly diagnosed glioblastoma treated by concurrent TemoRadiation and adjuvant temozolomide +/- ultrasound-induced blood brain barrier opening...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001488-10,0,0,0 2020-001490-68,1,2021-04-15,2021-04-15,1,1,0,0,1,0,2,0,0,1,0,0,1,0,0,Stockholm County Council; Danderyd Hospital,Inhaled Nitric Oxide Gas Therapy in Mechanically Ventilated Patients with Severe Acute Respiratory Syndrome in COVID-19 Behandling med inhalerad kväveoxid hos patienter med COVID-19 infektion och r...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001490-68,0,0,0 2020-001492-33,1,2021-12-15,2021-12-15,1,0,0,0,0,0,3,0,0,1,0,0,0,0,0,Hôpital Fondation Adolphe de Rothschild,Interest in the administration of Dornase alpha aerosol in ARDS secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19 Intérêt de l'administration de Dornase alpha en aérosol da...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001492-33,0,0,0 2020-001493-29,1,2022-01-06,2022-01-06,1,0,0,0,0,0,2,0,0,1,1,1,0,0,0,Charité - Universitaetsmedizin Berlin,Charité trial of Cenicriviroc (CVC) treatment for COVID-19 patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001493-29,0,0,0 2020-001496-32,4,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,KEDRION S.P.A,"A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety, and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001496-32,0,0,0 2020-001497-30,5,2021-09-01,2021-09-01,2,1,0,0,0,0,3,0,0,2,1,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001497-30,1,0,0 2020-001497-30,5,2021-09-01,2021-09-01,2,1,0,0,0,0,3,0,0,2,1,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pne...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001497-30,1,0,0 2020-001498-63,3,2022-06-06,2022-06-06,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Biophytis S.A.,"Adaptive design phase 2 to 3, randomized, double- blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deteriorati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001498-63,1,0,0 2020-001500-41,1,2021-05-21,2021-05-21,1,1,0,0,0,0,3,0,0,1,0,0,1,0,0,University Hospital Ghent,"A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001500-41,0,0,0 2020-001501-24,1,,,0,0,0,0,0,0,2,0,1,1,1,1,0,1,0,ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS,PROTECT: A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19). PROTECT: studio randomizzato con idrossic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001501-24,0,0,0 2020-001502-38,1,2020-10-13,2020-10-13,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Vicore Pharma AB,"A randomised, double blind, placebo controlled, Phase 2 trial investigating the safety and efficacy of C21 in hospitalised subjects with COVID-19 infection not requiring mechanical ventilation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001502-38,0,0,0 2020-001504-42,3,2022-05-20,2022-05-20,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,INOTREM S.A.,"Efficacy and Safety Study Exploring Nangibotide Treatment in COVID-19 pAtients with ventiLatory support (ESSENTIAL). A randomized, double-blind, placebo-controlled study with adaptive features Estu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001504-42,1,0,0 2020-001505-22,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Banc de Sang i Teixits,"Double-blind, randomized, parallel, placebo-controlled pilot clinical trial, nested in a prospective cohort observational study, for the evaluation of the efficacy and safetyof two doses of WJ-MSC in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001505-22,0,0,0 2020-001509-21,1,,,0,1,0,0,0,0,2,0,0,0,0,0,0,0,1,Pfizer Inc.,"A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE SAFETY OF RITLECITINIB (PF 06651600) IN ADULT PARTICIPANTS WITH ALOPECIA AREATA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001509-21,0,0,0 2020-001511-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FFIS,"Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19 Estudio aleatorizado, abierto y controlado para valorar el beneficio de Colchicina en pacientes c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001511-25,0,0,0 2020-001512-26,1,2020-10-12,2020-10-12,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Universitätsklinikum Tübingen,Hydroxychloroquine for the treatment of mild COVID-19 disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001512-26,0,0,0 2020-001513-20,1,,,0,1,0,0,0,0,2,0,0,1,0,0,0,1,0,OSPEDALE SAN RAFFAELE,Use of Defibrotide to reduce progression of acute respiratory failure rate in patients with COVID-19 pneumonia Uso di Defibrotide in infusione intravenosa per ridurre la progressione dell'insuffici...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001513-20,0,0,0 2020-001517-21,4,2021-06-10,2021-06-10,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Lilly S.A.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients with COVID-19 Infection Studio di fase 3 randomizzato, in doppio cieco, controllato con place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001517-21,1,0,0 2020-001517-21,4,2021-06-10,2021-06-10,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients with COVID-19 Infection Studio di fase 3 randomizzato, in doppio cieco, controllato con place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001517-21,1,0,0 2020-001517-21,4,2021-06-10,2021-06-10,2,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients with COVID-19 Infection Studio di fase 3 randomizzato, in doppio cieco, controllato con place...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001517-21,1,0,0 2020-001518-40,1,,,0,0,0,0,0,0,4,0,1,3,0,0,0,0,1,Sanofi Aventis Recherche & Developpement,Open-label exploratory study to evaluate the effect of dupilumab on skin barrier function in pediatric patients with moderate to severe atopic dermatitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001518-40,0,0,0 2020-001520-34,7,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Meter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001520-34,0,0,0 2020-001520-34,7,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,ASTRAZENECA AB,"A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Meter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001520-34,0,0,0 2020-001521-31,4,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Meter...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001521-31,0,0,0 2020-001526-59,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Institut de Recherches Internationales Servier,"A phase IIa efficacy and safety trial with intravenous S95011 in primary Sjögren’s Syndrome patients. An international, multicentre, randomised, double-blind, placebo-controlled study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001526-59,0,0,0 2020-001527-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,COVID-19: addition of azithromycin to chloroquine treatment COVID-19: toevoegen van azitromycine aan behandeling met chloroquine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001527-14,0,0,0 2020-001528-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI""",Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals Studio randomizzato adattivo per la terapia della malattia da Corona virus 2019 a casa con antivirali...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001528-32,0,0,0 2020-001529-30,3,2022-01-04,2022-01-04,3,0,0,0,0,0,2,0,0,1,0,0,0,0,1,"Enanta Pharmaceuticals, Inc.","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection with Respiratory Syncytial Virus in Ambulator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001529-30,0,0,0 2020-001530-35,1,2020-12-29,2020-12-29,1,1,0,0,0,0,4,0,1,1,1,1,1,0,0,Fundación para la Investigación Biomédica del Hospital La Paz (FIBHULP),Randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts. COVID-19 Ensayo clínico multicéntrico aleatorizado para...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001530-35,0,0,0 2020-001531-27,1,2021-04-06,2021-04-06,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Fundación para la Investigación Biomédica de Córdoba,Clinical trial of Sarilumab in adults hospitalized with COVID-19 presenting cytokine release syndrome Ensayo clínico de Sarilumab en adultos hospitalizados con COVID-19 que presentan síndrome de li...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001531-27,0,0,0 2020-001536-98,1,2020-04-27,2020-04-27,1,0,0,0,0,0,3,0,1,1,1,1,1,0,0,HOSPITAL UNIVERSITARI MÚTUA TERRASSA,Prophylaxis of COVID-19 infection with hydroxychloroquine in healthcare personnel with high risk of infection. Profilaxis de la infección por COVID-19 con hidroxicloroquina en personal sanitario co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001536-98,0,0,0 2020-001537-13,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001537-13,0,0,0 2020-001537-13,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001537-13,0,0,0 2020-001538-37,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Clovis Oncology, Inc.",CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy with Rucaparib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001538-37,0,0,0 2020-001538-37,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"CLOVIS ONCOLOGY, INC",CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy with Rucaparib,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001538-37,0,0,0 2020-001541-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica de Córdoba,Pilot study of single-dose bevacizumab as a treatment for acute respiratory distress syndrome in patients with COVID-19 Estudio piloto de bevacizumab dosis única como tratamiento del síndrome de di...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001541-39,0,0,0 2020-001542-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU NICE,"A 12-Week Multicentre, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Placebo in Patients > 6 years of age with EB simplex generalized severe",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001542-19,0,0,0 2020-001543-94,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,Tagraxofusp in Patients with CD123+ or with Blastic Plasmacytoid Dendritic Cell Neoplasm Immunophenotype-like Acute Myeloid Leukemia. Tagraxofusp nei pazienti affetti da Leucemia Mieloide Acuta CD1...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001543-94,0,0,0 2020-001544-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Center for Clinical Metabolic Research, Gentofte Hospital",Effects of discontinuing renin-angiotensin system inhibitors in patients with COVID-19 Effekten af seponering af hæmmere af renin-angiotensin systemet hos patienter med COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001544-26,0,0,0 2020-001546-19,1,2020-10-26,2020-10-26,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,argenx BV,"A First-in-Human Study in Adult Subjects Hospitalized with Covid-19 to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Efficacy of ARGX-117",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001546-19,0,0,0 2020-001548-24,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Fundación de Investigación HM Hospitales,"A randomized, single-blind study with a parallel control group on the efficacy and safety of bemiparin at therapeutic dose vs. prophylactic dose in patients hospitalized for COVID-19 Estudio aleato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001548-24,0,0,0 2020-001549-38,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Gesundheit Nord gGmbH,An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care - WHO-SOLIDARITY-GERMANY,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001549-38,0,0,0 2020-001550-22,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,Amyndas Pharmaceuticals S.A.,"A Phase 2 Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor, AMY-101, in patients with Acute Respiratory Distress Syndrome (ARDS) due to Covid-19.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001550-22,0,0,0 2020-001553-48,1,2020-08-18,2020-08-18,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Hospices Civils de Lyon,Corticoïdes au cours de la pneumonie virale Covid-19 liée à l’infection par le SARS-Cov-2 Corticoïdes au cours de la pneumonie virale Covid-19 liée à l’infection par le SARS-Cov-2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001553-48,0,0,0 2020-001558-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASUR (Azienda Sanitaria Unica Regionale) Marche,Hydroxychloroquine sulfate early administration in symptomatic out of hospital COVID-19 positive patients. Hydro-Stop-COVID19 Trial Utilizzo precoce a domicilio di Idrossiclorochina solfato in pazi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001558-23,0,0,0 2020-001565-37,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,ISGlobal,"PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE FOR HIGH-RISK HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (PrEP_COVID): A UNICENTRIC, DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL. PROFILÁXIS PRE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001565-37,0,0,0 2020-001570-30,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,GHU PARIS PSYCHIATRIE ET NEUROSCIENCES,Interest of early treatment with polyvalent immunoglobulins in the management of respiratory distress syndrome associated with SARS-CoV-2 infections_COVID-19 Intérêt d’un traitement précoce par imm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001570-30,0,0,0 2020-001571-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Assistance Publique Hôpitaux de Paris,Low dose of IL-2 In Acute respiratory DistrEss syndrome related to COVID-19 LILIADE-COVID,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001571-32,0,0,0 2020-001573-78,1,2022-03-24,2022-03-24,1,0,0,0,0,0,2,0,0,1,1,1,0,0,1,RevImmune,Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001573-78,0,0,0 2020-001574-29,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001574-29,0,0,0 2020-001574-29,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001574-29,0,0,0 2020-001575-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Universitätsklinikum Freiburg,Low-dose AtropIne for Myopia control in children Niedrig dosiertes Atropin zur Myopie-Kontrolle bei Kindern,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001575-33,0,0,0 2020-001576-15,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase II Open-Label, Single-arm Clinical Trial to Study the Safety, Efficacy and Pharmacokinetics of MK-3009 (Daptomycin) in Japanese Pediatric Participants Aged 1 to 17 Years with Complicated Skin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001576-15,0,1,1 2020-001577-70,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA,Allogeneic Mesenchymal Stromal Cell (MSC) Therapy for SARS-CoV-2 Pneumonia: A Prospective Randomized Multicentre Phase I/IIa Open Label Study Studio prospettico randomizzato multicentrico di fase I...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001577-70,0,0,0 2020-001578-31,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"A phase III, randomized, controlled, open-label, multicenter, global study of capmatinib versus SoC docetaxel chemotherapy in previously treated patients with EGFR wt, ALK negative, locally advanced o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001578-31,0,0,0 2020-001578-31,9,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A phase III, randomized, controlled, open-label, multicenter, global study of capmatinib versus SoC docetaxel chemotherapy in previously treated patients with EGFR wt, ALK negative, locally advanced o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001578-31,0,0,0 2020-001587-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Barcelona Institute for Global Health (ISGlobal),Hydroxychloroquine efficacy in preventing SARS-CoV-2 infection and CoVid-19 disease severity during pregnancy Eficacia de la hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y la ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001587-29,0,0,0 2020-001588-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS-A.O.U. SAN MARTINO-IST,"A randomized, phase IIb study of adjuvant durvalumab (MEDI4736) plus regorafenib vs untreated control in stage IV colorectal cancer patients with no evidence of disease (NED): VIVA trial Studio r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001588-10,0,0,0 2020-001590-68,1,,,0,1,1,0,0,1,1,0,0,4,0,0,0,0,1,Y-mAbs Therapeutics Inc.,Phase I Study Of Intrathecal Radioimmunotherapy Using 131I-Omburtamab for Central Nervous System/Leptomeningeal Neoplasms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001590-68,0,1,1 2020-001591-15,1,2021-09-22,2021-09-22,1,1,0,0,1,0,4,0,1,1,0,0,1,0,0,Radboudumc,"Reducing hospital admission of elderly in SARS-CoV-2 pandemic via the induction of trained immunity by bacillus Calmette-Guérin vaccination, a randomized controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001591-15,0,0,0 2020-001592-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Rigshospitalet,Maternal Mental Health (MAMA) Study. Short time estrogen as a candidate strategy to prevent postpartum depression in a high-risk group,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001592-33,0,0,0 2020-001595-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Henrik Birn,The Measures to Optimize RAAS-blockade in Patients with Hyperkalemia and Chronic Kidney Disease Undersøgelse af den nyrebeskyttende effekt ved optimeret blokade af Renin-Angiotensin-Aldosteron-Syst...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001595-15,0,0,0 2020-001597-30,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,1,4D pharma plc,"A pilot, multiple dose study to evaluate the efficacy and safety of MRx-4DP0004 in hospitalised patients with symptoms of COVID-19 (SARS-CoV-2 infection)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001597-30,0,0,0 2020-001598-66,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Centre Hospitalier de Versailles,Preliminary randomized controlled trial of poractant alfa (Curosurf®) by fiberoptic bronchoscopy-directed endobronchial administration in acute respiratory distress syndrome (ARDS) due to COVID-19 vir...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001598-66,0,0,0 2020-001599-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospital Vall Hebron,Tenecteplase Compared to Alteplase for Large Vesel Oclusion patients before Thrombectomy Tenecteplasa en comparación con Alteplasa para pacientes con oclusión de gran vaso antes de la trombectomía.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001599-13,0,0,0 2020-001601-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospitals of Leuven,Pharmacokinetics of apixaban in patients with short bowel syndrome requiring long term parenteral nutrition,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001601-23,0,0,0 2020-001602-34,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,0,CHU Angers,COvid-19 and Vitamin D supplementation: a multicenter randomized controlled Trial of high dose versus standard dose vitamin D3 in high-risk COVID-19 patients CoVitTrial- Supplémentation en vitamine...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001602-34,0,0,0 2020-001603-16,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,IDIVAL,"A RANDOMIZATION, MULTICENTRIC, OPEN-LABEL, CONTROLLED, CLINICAL TRIAL TO INVESTIGATE THE EFFECTIVENESS OF EARLY CHOLCHICINE ADMINISTRATION IN PATIENTS OVER 70 YEARS OF AGE WITH HIGH RISK OF DEVELOPING...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001603-16,0,0,0 2020-001605-23,1,2020-10-05,2020-10-05,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,Basque Health Service,Effectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir/ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infection Efectividad de ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001605-23,0,0,0 2020-001606-33,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,Instituto Investigación Sanitario Biocruces Bizkaia,Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection. Ensayo clínico aleatorizado para la evaluación de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001606-33,0,0,0 2020-001608-40,1,2021-02-15,2021-02-15,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Zhejiang Hisun Pharmaceutical Co. Ltd.,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients with COVID-19-Moderate Type",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001608-40,0,0,0 2020-001610-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Slagelse Sygehus,Irbesartan and Oseltamivir treatment of COVID-19 infection. Irbesartan og Oseltamivir til behandling af COVID-19 infektion.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001610-38,0,0,0 2020-001611-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma GmbH,"A two-year multi-center Phase 3 study to investigate the efficacy and safety of secukinumab in adult patients with active, moderate to severe thyroid eye disease (ORBIT), with a randomized, parallel-g...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001611-24,0,0,0 2020-001614-38,1,2021-03-15,2021-03-15,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,UZLeuven,"Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001614-38,0,0,0 2020-001616-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clinic per a la Recerca Biomèdica,Treatment with inhaled corticoids in patients with COVID-19 admitted to hospital with pneumonia Tratamiento con corticoides inhalados en enfermos COVID-19 ingresados por neumonía,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001616-18,0,0,0 2020-001617-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aarhus University Hospital,"The Effect of Trimetazidine on Mitochondrial Function, Myocardial Performance, and Invasive Hemodynamics in Patients Diagnosed with Wild-Type Transthyretin Cardiac Amyloidosis. Effekten af Trimetaz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001617-21,0,0,0 2020-001618-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Oryzon Genomics S. A.,"A Phase II, randomized, open–label study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with standard of care treatment to prevent Acute Respiratory Distress Sy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001618-39,0,0,0 2020-001620-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE-PUBLIQUE HOPITAUX DE PARIS (AP-HP),HYdrocortisone and VAsopressin in Post-RESuscitation Syndrome Hydrocortisone et vasopressine dans l’état de choc post-ressuscitation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001620-33,0,0,0 2020-001622-64,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dra Ana Pueyo Bastida,OUTPATIENT TREATMENT OF COVID-19 WITH EARLY PULMONARY CORTICOSTEROIDS AS AN OPPORTUNITY TO MODIFY THE COURSE OF THE DISEASE TRATAMIENTO AMBULATORIO DE COVID-19 CON CORTICOIDES EN FASE DE NEUMONÍA ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001622-64,0,0,0 2020-001623-13,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,Triiodothyronine for the treatment of critically ill patients with COVID-19 infection (Thy-Support Study) Η τριϊωδοθυρονίνη για την θεραπεία των σοβαρά νοσούντων ασθενών με λοίμωξη από COVID-19 (με...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001623-13,0,0,0 2020-001626-56,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001626-56,0,0,0 2020-001626-56,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001626-56,0,0,0 2020-001627-14,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001627-14,0,0,0 2020-001627-14,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001627-14,0,0,0 2020-001629-29,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Previously...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001629-29,0,0,0 2020-001629-29,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Previously...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001629-29,0,0,0 2020-001632-10,1,2022-04-05,2022-04-05,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,"Ruprecht-Karls-Universität Heidelberg, Medical Faculty, University Hospital Heidelberg -",A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Dise...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001632-10,0,0,0 2020-001634-36,1,2020-12-04,2020-12-04,1,1,0,0,0,0,2,0,0,1,0,0,1,0,0,Rosario García de Vicuña,Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection. Estudio piloto abierto aleatorizado para evaluar la eficacia de s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001634-36,0,0,0 2020-001635-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AB Science,"A Randomized, Double-blind, Placebo-controlled Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib combined with Isoquercetin, and Best Supportive Care in Hospitalized Patients wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001635-27,0,0,0 2020-001636-95,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Manchester,Subcutaneous and Intravenous anakinra in COVID-19 Infection - Feasibility & Pharmacokinetics/ Pharmacodynamics study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001636-95,0,0,0 2020-001638-37,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Semmelweis Egyetem Fogorvostudományi Kar Arc- Állcsont- Szájsebészeti és Fogászati Klinika, Budapest","Comparison of the preventive painkiller effect of etoricoxib and celecoxib after M3M surgery: A randomized, double-masked clinical trial Az etoricoxib és a celecoxib preventív fájdalomcsillapító ha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001638-37,0,0,0 2020-001640-26,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,"A pilot, open label, phase II clinical trial of nebulised recombinant tissue-Plasminogen Activator (rtPA)in patients with COVID-19 ARDS: The Plasminogen Activator COVID-19 ARDS (PACA) trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001640-26,0,0,0 2020-001642-18,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations with Anti-cancer Agents in Patients with Advanced Haematological Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001642-18,0,0,0 2020-001643-13,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Dundee,A randomised double-blind placebo-controlled trial of Brensocatib (INS1007) in patients with severe COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001643-13,0,0,0 2020-001644-25,5,2020-11-15,2020-11-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,ACERTA PHARMA BV,A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 Étude de phase 2 randomisée évalu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001644-25,0,0,0 2020-001644-25,5,2020-11-15,2020-11-17,3,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Acerta Pharma B.V.,A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib with Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized with COVID-19 Étude de phase 2 randomisée évalu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001644-25,0,0,0 2020-001645-40,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,DOMPé FARMACEUTICI S.P.A.,"Adaptive phase 2/3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia Studio adattativo di fase 2/3,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001645-40,0,0,0 2020-001648-24,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,MEDICA SCIENTIA INNOVATION RESEARCH S.L.,"A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as fi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001648-24,0,0,0 2020-001648-24,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,Medica Scientia Innovation Research (MEDSIR),"A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as fi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001648-24,0,0,0 2020-001649-38,2,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,H. Lundbeck A/S,"Long-term, open-label (dose-blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001649-38,0,0,0 2020-001651-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,palleos healthcare GmbH,An adaptive randomized neoadjuvant two arm trial in triple-negative breast cancer comparing a mono Atezolizumab window followed by a Atezolizumab - CTX therapy with Atezolizumab – CTX therapy (neoMono...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001651-40,0,0,0 2020-001654-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Justus-Liebig-University Gießen,Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia Granulozyten-Monozyten-Kolonie-stimulierende Faktor (GM-CSF) Inhalation zur Verhinderun...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001654-21,0,0,0 2020-001655-41,1,,,0,0,0,0,1,0,2,0,1,0,0,0,0,0,0,CHU de Rennes,P-glypoprotein inhibition effect on the pharmacokinetics of two tacrolimus formulations: prolonged and extended-release Effet De l’inhibition de la glycoprotéine P sur la pharmacocinétique de deux...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001655-41,0,0,0 2020-001656-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital,Inhaled Nitric Oxide As A Bridge To Mechanical Ventilation In Patients With Suspected Covid-19 Respiratory Failure,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001656-18,0,0,0 2020-001659-42,1,2021-01-15,2021-01-15,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Fundación para la Investigación Biomédica de Córdoba,Pilot study of antithrombin as prophylaxis of acute respiratory distress syndrome in patients with COVID-19 Estudio piloto de antitrombina como profilaxis del síndrome de distres respiratorio agudo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001659-42,0,0,0 2020-001662-11,5,2020-10-17,2020-10-17,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001662-11,1,0,0 2020-001662-11,5,2020-10-17,2020-10-17,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,Novartis Pharma AG,"Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001662-11,1,0,0 2020-001662-11,5,2020-10-17,2020-10-17,3,1,0,0,0,0,3,0,0,2,0,0,0,0,1,NOVARTIS PHARMA AG,"Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001662-11,1,0,0 2020-001663-90,2,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Rhizen Pharmaceuticals SA,"An Open label, Compassionate Use Study of Tenalisib (RP6530) in Patients currently receiving treatment on Tenalisib trials in Hematological Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001663-90,0,0,0 2020-001665-37,2,2022-05-11,2022-05-11,1,0,0,0,0,0,3,0,1,2,0,0,0,0,1,SANOFI PASTEUR,"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix®, and When Administered Alone or Concomitantly with 9vHPV and Tdap-IPV Vaccines in Healthy Adolescents...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001665-37,1,0,0 2020-001665-37,2,2022-05-11,2022-05-11,1,0,0,0,0,0,3,0,1,2,0,0,0,0,1,Sanofi Pasteur,"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix®, and When Administered Alone or Concomitantly with 9vHPV and Tdap-IPV Vaccines in Healthy Adolescents...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001665-37,1,0,0 2020-001667-85,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hôpital Fondation Adolphe de Rothschild,A randomized controlled trial evaluating the efficacy of local budesonide therapy in the management of hyposmia in COVID-19 patients without signs of severity Essai randomisé contrôlé évaluant l’ef...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001667-85,0,0,0 2020-001671-32,1,2021-12-25,2021-12-25,1,0,0,0,0,0,2,0,0,1,1,1,0,0,1,"Staidson (Beijing) Biopharmaceutical Co., Ltd. and Beijing Defengrui Biological Technology Co., Ltd.","A multi-center, open-label, randomized parallel controlled evaluation on the efficacy and safety of BDB-001 injection in the treatment of progressive severe COVID-19 in phase II Evaluación de fase ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001671-32,0,0,0 2020-001673-75,6,2021-03-16,2021-04-16,3,1,0,0,0,0,2,0,0,2,1,0,0,0,1,ABIVAX,"A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001673-75,1,0,0 2020-001673-75,6,2021-03-16,2021-04-16,3,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Abivax,"A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failure ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001673-75,1,0,0 2020-001675-33,1,2021-10-12,2021-10-12,1,1,0,0,0,0,3,0,1,1,0,0,0,0,1,Vakzine Projekt Management GmbH,"A phase III, randomized, double-blind, placebo-controlled, multicentre, clinical trial to assess the efficacy and safety of VPM1002 in reducing hospital admissions and/or severe respiratory infectious...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001675-33,0,0,0 2020-001678-31,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Assistance Publique Hopitaux de Paris,Randomized controlled trial evaluating the efficacy of vaccination with Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 via the strengthening of innate immunity in Health Care Workers...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001678-31,0,0,0 2020-001682-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CITOSPIN S.L.,"Double-blind, placebo-controlled phase I/II clinical trial to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSV®-allo) in acute respiratory failure in patients with COVID-19 p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001682-36,0,0,0 2020-001684-89,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University of Birmingham,CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001684-89,0,0,0 2020-001685-11,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,INSTITUT DE CANCEROLOGIE DE L'OUEST,RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine Récidive en loge prostatique déjà irradiée : une étude phase I/II...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001685-11,0,0,0 2020-001686-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE,"A double-blind, randomized study versus placebo of avdoralimab (IPH5401), an anti-C5aR antibody, in patients with COVID-19 induced pneumonia Etude clinique en double aveugle, randomisée versus pla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001686-36,0,0,0 2020-001689-12,4,2020-12-18,2021-01-19,2,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Montreal Health Innovations Coordinating Centre,COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19) ENSAYO DE COLCHICINA EN EL SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001689-12,1,0,0 2020-001689-12,4,2020-12-18,2021-01-19,2,0,0,0,0,0,3,0,0,2,1,0,0,0,0,Montreal Heart Institute Coordinating Centre,COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19) ENSAYO DE COLCHICINA EN EL SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001689-12,1,0,0 2020-001689-12,4,2020-12-18,2021-01-19,2,0,0,0,0,0,3,0,0,2,1,0,0,0,0,MONTREAL HEART INSTITUTE,COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19) ENSAYO DE COLCHICINA EN EL SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001689-12,1,0,0 2020-001690-72,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Who H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001690-72,0,0,0 2020-001690-72,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Who H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001690-72,0,0,0 2020-001696-32,1,2021-03-03,2021-03-03,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Instituto Grifols, S.A","A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alone ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001696-32,0,0,0 2020-001697-30,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,NAVARRABIOMED - FUNDACIÓN MIGUEL SERVET,PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19. (COVIDNA) PROFILAXIS PRE-EXPOSICIÓN CON HIDROXICLOROQUINA EN SANITARIOS ALTAMENTE EXPUESTOS A COVID-19. (C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001697-30,0,0,0 2020-001700-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),Efficacy of captopril nebulization in Covid-19 patients suffering of SARS-CoV-2 pneumonia. A randomized phase II study Etude d’efficacité de l’administration d’aérosols de captopril pour les patie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001700-42,0,0,0 2020-001704-42,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,IDIVAL Instituto de Investigación Sanitaria Valdecilla,Controlled and randomised trial to assess the safety and efficacy of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in hospital healthcare personnel (Sanitarios sin COVID-19 -SANsinCOVID-1...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001704-42,0,0,0 2020-001707-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IIS BIODONOSTIA,"PHASE III RANDOMIZED, UNICENTRIC, OPEN, CONTROLLED CLINICAL TRIAL TO DEMONSTRATE THE EFFECTIVENESS OF TOCILIZUMAB AGAINST SYSTEMIC CORTICOTHERAPY IN PATIENTS ENTERED BY COVID-19 WITH BILATERAL PNEUMON...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001707-16,0,0,0 2020-001708-41,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA,Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: comparison of 40 mg o.d. versus 40 mg b.i.d. A randomized Clinical Trial Enoxaparina per la tromboprofilassi di pazienti ospedal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001708-41,0,0,0 2020-001709-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHRU de Nancy,"Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001709-21,0,0,0 2020-001710-37,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Academisch Medisch Centrum,Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial. Intraveneuze immunoglobulines als aanvullende behandeling bij pas ge...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001710-37,0,0,0 2020-001714-38,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Red Cross Hospital Beverwijk,Alkaline phosphatase for reducing systemic inflammatory response syndrome (SIRS) in patients with Sars-CoV-2 infection and acute respiratory insufficiency (COVID 19),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001714-38,0,0,0 2020-001714-38,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jessa Hospital,Alkaline phosphatase for reducing systemic inflammatory response syndrome (SIRS) in patients with Sars-CoV-2 infection and acute respiratory insufficiency (COVID 19),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001714-38,0,0,0 2020-001717-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica de Córdoba,Prevention and treatment with Calcifediol of Coronavirus COVID-19-induced acute respiratory syndrome (SARS) Prevención y tratamiento con Calcifediol del síndrome respiratorio agudo (SARS) inducido ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001717-20,0,0,0 2020-001720-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UNIVERSITÀ CAMPUS BIO-MEDICO DI ROMA,Cyclosporine 0.1% Eye Drops as Prophylactic Treatment in Post Surgical Ocular Surface System Failure Within The Age Ciclosporina 0.1% topica come trattamento profilattico dello scompenso della supe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001720-33,0,0,0 2020-001721-31,1,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,Hampshire Hospitals NHS TRust,Can a sinus rinse and mouth wash reduce viral load in COVID-19 positive individuals?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001721-31,0,0,0 2020-001722-66,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Clínic per a la recerca Biomèdica,Plasma turnover in patients with COVID-19 disease and invasive mechanical ventilation: a randomized study Recambio plasmático en pacientes con enfermedad COVID-19 y ventilación mecánica invasiva: e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001722-66,0,0,0 2020-001723-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,GROUPE HOSPITALIER PARIS SAINT-JOSEPH,A randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001723-13,0,0,0 2020-001724-34,2,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,UCB Biopharma SRL,"A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001724-34,0,0,0 2020-001728-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Region Skåne,Adjuvant instillations in intermediate risk NMIBC: A Study comparIng Gemcitabine and MitomYciN (SIGYN-trial) Adjuvant instillation med gemcitabin eller mitomycin efter TURB för intermediärrisk ick...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001728-33,0,0,0 2020-001732-10,1,2021-07-30,2021-07-30,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Philipps-Universität Marburg,"Ruxolitinib for treatment of Covid-19 induced lung injury ARDS (RuXoCoil) A single-arm, open-label, proof of concept study Ruxolitinib zur Behandlung von Covid-19 induziertem Lungenversagen ARDS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001732-10,0,0,0 2020-001733-12,6,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE IIIb, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUS EMICIZUMAB IN PATIENTS FROM BIRTH TO 12 MONTHS OF AGE W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001733-12,0,0,0 2020-001733-12,6,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE IIIb, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SUBCUTANEOUS EMICIZUMAB IN PATIENTS FROM BIRTH TO 12 MONTHS OF AGE W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001733-12,0,0,0 2020-001734-36,1,,,0,1,0,0,0,0,3,0,0,1,1,1,0,1,0,CHRU de TOURS,Efficacy and safety of ANAkinra during Adult « COVID-19 » with Aggravating respiratory symptoms: a multicenter open-label controlled randomized trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001734-36,0,0,0 2020-001736-95,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospital Southampton NHS Foundation Trust,"ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001736-95,0,0,0 2020-001739-28,1,2021-05-04,2021-05-04,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,UZLeuven,"A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001739-28,0,0,0 2020-001740-26,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,"University of Oxford, Clinical Trials and Research Governance",A multi-centre open-label two-arm randomised superiority clinical trial of Azithromycin versus usual care In Ambulatory COVID-19 (ATOMIC2),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001740-26,0,0,0 2020-001743-10,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATINGTHE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH ADVANCED LIVER CANCERS (MORP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001743-10,0,0,0 2020-001745-40,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,ASST FATEBENEFRATELLI SACCO,PILOT STUDY ON THE USE OF SARILUMAB IN PATIENTS WITH COVID-19 INFECTION PILOT STUDY ON THE USE OF SARILUMAB IN PATIENTS WITH COVID-19 INFECTION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001745-40,0,0,0 2020-001747-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Instituto de Saúde Pública Universidade Porto,Impact of Montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): an investigator-initiated open labelled randomized controlled pragmatic trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001747-21,0,0,0 2020-001748-24,1,2021-05-17,2021-05-17,1,0,0,0,0,0,2,0,0,1,0,0,1,0,0,Karolinska University Hospital,"A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treatmen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001748-24,0,0,0 2020-001749-38,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Azienda Ospedaliero-Universitaria S. Andrea,PET/CT with 68Ga-IL2 for imaging IL2R+ cells in COVID-19+ patients La PET/TC con 68Ga-IL2 per l’imaging delle cellule IL2R+ in pazienti affetti da COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001749-38,0,0,0 2020-001750-22,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Joint Research Compliance Office,"MATIS: Phase 2/3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001750-22,0,0,0 2020-001752-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Amiens Picardie,Proactive Management of Outpatient Covid-19 Patients : a randomised controlled trial Prise en charge proactive des Patients Covid-19 en Ambulatoire Un essai randomisé ouvert,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001752-17,0,0,0 2020-001754-21,1,2021-07-09,2021-07-09,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Assistance Publique Hôpitaux de Marseille,An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease Etude prospective randomisée évalua...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001754-21,0,0,0 2020-001755-41,4,2022-07-06,2022-07-06,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Green Valley (Shanghai) Pharmaceuticals Co., Ltd.","A Phase 3, multi-center, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy and safety of sodium oligomannate (GV-971) in treatment of mild to moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001755-41,1,0,0 2020-001755-41,4,2022-07-06,2022-07-06,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Shanghai Green Valley Pharmaceutical Co., Ltd.","A Phase 3, multi-center, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy and safety of sodium oligomannate (GV-971) in treatment of mild to moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001755-41,1,0,0 2020-001757-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Pfizer Inc.,"PHASE 1/2a DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF 06873600 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001757-40,0,0,0 2020-001759-42,6,2021-08-16,2021-08-16,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001759-42,1,0,0 2020-001759-42,6,2021-08-16,2021-08-16,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001759-42,1,0,0 2020-001759-42,6,2021-08-16,2021-08-16,5,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"GlaxoSmithKline, S.A.","A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001759-42,1,0,0 2020-001760-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Sociedad Española de Farmacia Hospitalaria,Phase II clinical trial to evaluate the efficacy and safety of inhaled ethanol in the treatment of early-stage COVID-19. Ensayo clínico fase II para evaluar la eficacia y seguridad de etanol inhala...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001760-29,0,0,0 2020-001762-11,5,2020-10-06,2020-10-21,5,0,0,0,0,1,2,0,0,1,1,0,1,0,1,"Corbus Pharmaceuticals, Inc.",An Observational Long-Term Safety Surveillance Study of Participants from Corbus Sponsored Lenabasum Pivotal Clinical Trials Eine Beobachtungsstudie zur Langzeit-Sicherheitsüberwachung von Teilnehm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001762-11,0,0,0 2020-001765-37,1,2020-06-26,2020-06-26,1,1,0,0,0,0,2,0,0,1,1,1,1,0,0,Institut Català d’Oncologia,Pragmatic clinical trial to evaluate the efficacy of hydroxychloroquine in the treatment of COVID-19 infection in two cohorts: patients with oncohaematological disease and SARS-CoV-2 positive without ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001765-37,0,0,0 2020-001766-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE,Losartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit Intérêt du traitement par losartan et de la spironolactone sur la régulation du sys...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001766-11,0,0,0 2020-001767-86,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University College Dublin,"An open-label, multi-centre, randomised trial comparing different doses of single-dose tocilizumab in adults with severe, non-critical, PCR-confirmed COVID-19 infection with evidence of progressive de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001767-86,0,0,0 2020-001768-27,1,2021-11-05,2021-11-05,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,CH Versailles,"""STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE"" GERONIMO 19 « ETUDE DE L’EFFICACITE DES IMMUNOGLO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001768-27,0,0,0 2020-001769-35,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,Oulu University Hopsital,Preventing urinary tract infections in infants and young children with probiotic E. coli Nissle: FinNiss- trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001769-35,0,0,0 2020-001770-30,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,CHU AMBROISE PARE,COVID 19: Experimental use of tocilizumab (Roactemra®) in severe SARS-CoV-2 related pneumonia.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001770-30,0,0,0 2020-001776-15,5,2021-11-25,2022-01-19,2,1,0,0,0,0,2,0,0,2,1,0,0,0,1,MERCK HEALTHCARE KGaA,A Phase II single-arm study to investigate tepotinib combined with cetuximab in RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) patients having acquired resistance to anti-EGFR antib...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001776-15,1,0,0 2020-001776-15,5,2021-11-25,2022-01-19,2,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Merck Healthcare KGaA,A Phase II single-arm study to investigate tepotinib combined with cetuximab in RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) patients having acquired resistance to anti-EGFR antib...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001776-15,1,0,0 2020-001777-71,1,,,0,1,0,0,0,0,4,0,0,3,0,0,0,0,0,Guy’s and St Thomas' NHS Foundation Trust,Ruxolitinib therapy to Avoid Ventilation and improve outcome for deteriorating COVID-19 patiENts - RAVEN,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001777-71,0,0,0 2020-001782-37,1,2021-03-05,2021-03-05,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"NPO Petrovax Pharm, LLC","A multi-centre, adaptive, randomized, double-blind, placebo-controlled comparative clinical trial of the safety and efficacy of 12 mg Polyoxidonium®, lyophilizate solution for injections (NPO Petrovax...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001782-37,0,0,0 2020-001783-28,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,National Korányi Institute of Pulmonology,REDUCING ABSENCE FROM WORK OF HEALTHCARE WORKERS DUE TO COVID-19 INFECTION BY BCG (BACILLUS CALMETTE-GUÉRIN) VACCINATION,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001783-28,0,0,0 2020-001784-88,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University of Helsinki,WHO SOLIDARITY Finland: The multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001784-88,0,0,0 2020-001786-36,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,RevImmune SAS France,Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection “ILIAD 7 trial”,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001786-36,0,0,0 2020-001793-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Copenhagen University Hospital of Bispebjerg,Preventing Disease Aggravation in COVID-19 by high dose Vitamin D: a randomized trial (COVIT-D),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001793-30,0,0,0 2020-001794-77,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INSTITUT CATALÀ D'ONCOLOGIA GIRONA - HOSPITAL JOSEP TRUETA,Phase II Clinical Trial to evaluate the efficacy of silibinin supplementation in the prevention of the progression of the respiratory failure in patients with onco-hematological diseases and infection...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001794-77,0,0,0 2020-001795-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,"A randomized, double blind, placebo-COntrolled trial of MavrilimumaB for Acute respiratory failure due To COVID-19 pneumonia with hyperinflammation: the COMBAT-19 trial Studio in doppio cieco rando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001795-15,0,0,0 2020-001803-17,2,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,Gilead Sciences Inc.,"A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001803-17,0,0,0 2020-001803-17,2,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,GILEAD SCIENCES INCORPORATED,"A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants from Birth to < 18 Years of Age with COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001803-17,0,0,0 2020-001805-21,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospital Coventry & Warwickshire,"Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001805-21,0,0,0 2020-001806-42,1,2022-01-18,2022-01-18,1,1,0,0,0,0,3,0,0,1,1,1,0,0,0,SOCIETA' ITALIANA DI REUMATOLOGIA - SIR,- ColcHicine in patients with COVID-19: a home CarE study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001806-42,0,0,0 2020-001807-18,3,2021-04-20,2021-04-21,2,1,0,0,0,0,2,0,0,2,0,0,0,0,1,Theravance Biopharma Ireland Limited,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated with CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001807-18,1,0,0 2020-001808-42,1,2021-02-06,2021-02-06,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Pharmamel S.L.,"PHASE II CLINICAL TRIAL, SINGLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TO EXPLORE THE EFFECTIVENESS AND SAFETY OF MELATONIN I.V. IN PATIENTS WITH COVID-19 ENTERED INTO THE ICU (MELCOVID STUDY) ENSAY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001808-42,0,0,0 2020-001811-26,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001811-26,0,0,0 2020-001817-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"St. Antonius Hospital Nieuwegein, The Netherlands",Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001817-20,0,0,0 2020-001818-38,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Sanofi-Aventis Recherche & Developpement,"Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001818-38,0,0,0 2020-001818-38,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001818-38,0,0,0 2020-001819-24,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Sanofi-Aventis Recherche & Developpement,"Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001819-24,0,0,0 2020-001823-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Saint Etienne,Evaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study Évaluation de la relation concentration effet de l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001823-15,0,0,0 2020-001824-33,11,2022-08-16,2022-08-16,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, multicenter, double-blind phase 3 study of amcenestrant SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001824-33,1,0,0 2020-001824-33,11,2022-08-16,2022-08-16,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A randomized, multicenter, double-blind phase 3 study of amcenestrant SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001824-33,1,0,0 2020-001825-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NAVARRABIOMED - FUNDACIÓN MIGUEL SERVET,CLINICAL TRIAL OF THE USE OF ANAKINRA (ANTI IL-1) IN CYTOKINE STORM SYNDROME (CSS) SECONDARY TO COVID-19 ENSAYO CLÍNICO DEL USO DE ANAKINRA (ANTI IL-1) EN EL SÍNDROME DE TORMENTA DE CITOQUINA (CSS)...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001825-29,0,0,0 2020-001827-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,NAVARRABIOMED - FUNDACIÓN MIGUEL SERVET,EARLY TREATMENT OF PNEUMONIA COVID-19 WITH GLUCOCORTICOIDS. RANDOMIZED CONTROLLED CLINICAL TRIAL TRATAMIENTO PRECOZ DE LA NEUMONÍA COVID-19 CON GLUCOCORTICOIDES. ENSAYO CLÍNICO CONTROLADO ALEATORIZ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001827-15,0,0,0 2020-001841-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Sociedad Española de Cardiología,Colchicine for the Treatment of Hyperinflammation associated with Pneumonia due to COVID-19 Colchicina para el Tratamiento de la Hiperinflamación asociada a la Neumonía por COVID-19.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001841-38,0,0,0 2020-001847-16,8,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001847-16,0,0,0 2020-001847-16,8,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,TUMOR-AGNOSTIC PRECISION IMMUNOONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001847-16,0,0,0 2020-001849-39,1,2022-08-31,2022-08-31,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Region Skåne,"Aerosolized DNase I for the treatment of severe respiratory failure in COVID-19 - a phase 2, randomized controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001849-39,0,0,0 2020-001852-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Maxima MC,Effect of Iodine treatment in patiënts with COVID-19 disease Effect van Jodium behandeling bij patiënten met COVID-19 ziekte,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001852-16,0,0,0 2020-001854-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI,"Cumulative adaptive, multiarm, multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID-19 Trial randomizzato cumulativo, adattivo, multibraccio, e multifase dell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001854-23,0,0,0 2020-001856-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rennes University Hospital,Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumor VOLUME in Patients Treated for Conventional HODgkin's Lymphoma Evaluation de la RElation entre exposition aux anti-PD-1 et VOLUme...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001856-16,0,0,0 2020-001857-31,2,2022-06-15,2022-06-15,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Pluristem Ltd.,"A Randomized, Controlled, Multicenter, Parallel-Group Phase IIa Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX-PAD for the Treatment of severe COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001857-31,1,0,0 2020-001860-27,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,0,University of Liverpool,AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001860-27,0,0,0 2020-001862-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"University Hospitals Leuven, Clinical Trial Centre","Early administration of Vitamin C in patients with sepsis or septic shock in emergency departments: a multicentre, double blinded, randomized controlled trial: the C-EASIE trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001862-12,0,0,0 2020-001863-10,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001863-10,0,0,0 2020-001863-10,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001863-10,0,0,0 2020-001867-94,1,2021-03-22,2021-03-22,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,CHU CAEN Normandie,Effet du tenofovir/emtricitabine en cure courte sur la clairance virale chez des patients infectés par le SARS-CoV2 (COVID-19) non hospitalisés Effet du tenofovir/emtricitabine en cure courte sur l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001867-94,0,0,0 2020-001868-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,LYSARC,"Phase 2, Open-Label Study evaluating Axi-Cel as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible to Autologous Stem Cell Transplantation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001868-28,0,0,0 2020-001870-32,5,2020-12-24,2020-12-24,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Farmacéutica S.A,"Phase 2, randomized, controlled, open label multi-center study to assess efficacy and safety of DFV890 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respirator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001870-32,0,0,0 2020-001870-32,5,2020-12-24,2020-12-24,5,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Novartis Pharma AG,"Phase 2, randomized, controlled, open label multi-center study to assess efficacy and safety of DFV890 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respirator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001870-32,0,0,0 2020-001872-13,4,2022-07-21,2022-07-21,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"PTC Therapeutics, Inc.",Evaluation of the efficacy and safety of PTC299 in hospitalized subjects with COVID-19 (FITE19),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001872-13,1,0,0 2020-001878-29,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,Rennes University Hospital,The efficacy of traumatic memory modification using a memory reconsolidation procedure under propranolol among adolescents with post-traumatic stress disorder (PROPRADO) Impact d’une procédure de r...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001878-29,0,0,0 2020-001879-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2) Studio sull’efficacia di Osimertinib in prima linea nei pazienti con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001879-33,0,0,0 2020-001882-36,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Hellenic Institute for the Study of Sepsis,ANTI-INFLAMMATORY CLARITHROMYCIN TO IMPROVE SARS-CoV-2 (COVID-19) INFECTION EARLY: THE ACHIEVE OPEN-LABEL NON-RANDOMIZED CLINICAL TRIAL ΑΞΙΟΛΟΓΗΣΗ ΤΗΣ ΑΝΤΙΦΛΕΓΜΟΝΩΔΟΥΣ ΔΡΑΣΗΣ ΤΗΣ ΚΛΑΡΙΘΡΟΜΥΚΙΝΗΣ ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001882-36,0,0,0 2020-001886-35,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University Hospital Southampton NHS Foundation Trust,A clinical trial of nebulized surfactant for the Treatment of moderate to severe COVID-19 in adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001886-35,0,0,0 2020-001888-90,1,2021-07-31,2021-07-31,1,1,0,0,1,0,3,0,1,1,0,0,1,0,0,University of Southern Denmark,Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic. A randomised controlled multi-center trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001888-90,0,0,0 2020-001889-10,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,"University of Oxford, Clinical Trials and Research Governance",Use of inhaled corticosteroids as treatment of early COVID-19 infection to prevent clinical deterioration and hospitalisation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001889-10,0,0,0 2020-001890-56,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universidad Católica de Murcia (UCAM),Double-blind randomized placebo-controlled clinical trial to evaluate the efficacy and safety of the use of intravenous gammaglobulins in the treatment of patients with COVID-19 Ensayo clínico alea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001890-56,0,0,0 2020-001891-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Neumosur,"Impact of the use of low molecular weight heparins (LMWH), at prophylactic versus intermediate doses, on SARS-CoV2 infection (COVID-19) Impacto del uso de heparinas de bajo peso molecular (HBPM), a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001891-14,0,0,0 2020-001892-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU Amiens-Picardie,"Treatment of COVID-19 by Nebulization of Inteferon Beta 1b added to lopinavir/ritonavir: Feasibility, Efficiency and Safety Study Traitement du COVID-19 : Etude de faisabilité, d’efficacité et de s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001892-34,0,0,0 2020-001898-78,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,"A Phase II Single Arm Interventional Trial Evaluating the Activity and Safety of combination between Cabozantinib and Temozolomide in Lung and GEP-NENs progressive after SSAr, everolimus, sunitinib or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001898-78,0,0,0 2020-001899-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Universitätsklinikum Erlangen,"A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001899-14,0,0,0 2020-001903-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,HOSPITAL UNIVERISTARIO DE MOSTOLES,A randomized clinical trial (IIIb) of eficacy of a single dose of Tocilizumab or a combination of Tocilizumab plus Vitamin D (single i.m. dose) for the treatment of the COVID-19 hyperimmune complicati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001903-17,0,0,0 2020-001904-41,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,NHS Greater Glasgow and Clyde,Glasgow Early Treatment Arm FavIpiravir : A randomized controlled study of favipiravir as an early treatment arm in COVID-19 patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001904-41,0,0,0 2020-001904-41,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,The University of Glasgow,Glasgow Early Treatment Arm FavIpiravir : A randomized controlled study of favipiravir as an early treatment arm in COVID-19 patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001904-41,0,0,0 2020-001907-18,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001907-18,0,0,0 2020-001908-42,5,2021-11-08,2021-11-08,1,0,0,1,0,0,1,0,0,2,1,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001908-42,1,0,0 2020-001908-42,5,2021-11-08,2021-11-08,1,0,0,1,0,0,1,0,0,2,1,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc",A Phase 1b/2 Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001908-42,1,0,0 2020-001909-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),EFFICACY OF INTRAVENOUS ALMITRINE IN REDUCING THE NEED FOR MECHANICAL VENTILATION IN PATIENTS WITH HYPOXEMIC ACUTE RESPIRATORY FAILURE DUE TO COVID-19-RELATED PNEUMONIA: A RANDOMIZED CONTROLLED DOUBL...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001909-22,0,0,0 2020-001911-26,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Part...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001911-26,0,0,0 2020-001911-26,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Part...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001911-26,0,0,0 2020-001921-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA,"Steroids and unfractionated heparin in critically-ill patients with pneumonia from COVID-19 infection. A multicenter, interventional, randomized, three arms study design. Steroidi e eparina non fra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001921-30,0,0,0 2020-001926-71,4,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,DOMPé FARMACEUTICI S.P.A.,"A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001926-71,0,0,0 2020-001926-71,4,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Dompe farmaceutici s.p.a.,"A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001926-71,0,0,0 2020-001927-15,3,2022-01-17,2022-01-17,3,0,0,0,0,0,2,0,0,1,1,0,0,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults with T2-low/non-T2 Severe Uncontrolled Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001927-15,0,0,0 2020-001928-34,1,2022-04-01,2022-04-01,1,0,0,0,0,0,2,0,0,1,1,1,0,0,0,Capio S:t Görans Sjukhus,Inhalation of Ciclesonide for patients with Covid-19: A randomised open treatment study (HALT Covid-19). HALT Covid-19-studien: Inhalation av Ciklesonid mot SARS-coronavirus-2 orsakad lunginflammat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001928-34,0,0,0 2020-001929-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Investigación Biomédica Hospital Ramón y Cajal,"Controlled, randomized, non-blind trial on the usefulness of pioglitazone treatment in patients with type 2 diabetes mellitus and COVID-19. Ensayo controlado, aleatorizado, no ciego, sobre la utili...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001929-31,0,0,0 2020-001933-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Leflunomide and Hydroxychloroquine combination therapy for primary Sjögren’s Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001933-11,0,0,0 2020-001934-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IDIVAL Instituto de Investigación Sanitaria Valdecilla,USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION (GLUCOCOVID). Pragmatic trial inserted in real practice during a pandemic COVID-19 USO DE CORTICOIDES EN PACIENTES CON INFECC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001934-37,0,0,0 2020-001936-86,1,2021-11-15,2021-11-15,1,0,0,0,0,0,2,0,0,1,1,1,0,0,0,Hannover Medical School,"A prospective, randomized, open label Phase 2 clinical trial to evaluate superiority of anti-SARS-CoV-2 convalescent plasma versus standard-of-care in hospitalized patients with mild COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001936-86,0,0,0 2020-001937-11,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,University College London,"A single-site, randomised, controlled, parallel design, open-label investigation of an approved nebulised recombinant human DNase enzyme (dornase alfa) to reduce hyperinflammation in hospitalised part...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001937-11,0,0,0 2020-001938-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut für Frauengesundheit GmbH,AIRE: – ASSESSING IMMUNORESPONSE POST ERIBULIN: ERIBULIN AND IMMUNOGENICITY IN ADVANCED BREAST CANCER – A PROSPECTIVELY RANDOMIZED PHASE IV STUDY AIRE: Ermittlung der Immunantwort nach Eribulin: ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001938-35,0,0,0 2020-001939-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medizinische Universität Graz, Universitätsklinik für Zahn-, Mund- und Kieferheilkunde",The effect of systemic antibiotics on post-surgical complications and patient-centered outcomes in patients undergoing implant surgery with guided bone regeneration and simultaneous sinus floor elevat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001939-27,0,0,0 2020-001940-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Institut für Frauengesundheit GmbH,A PHASE II OPEN-LABEL STUDY FOR THE COMPREHENSIVE ANALYSIS OF PREDICTORS OF THE TREATMENT WITH PEMBROLIZUMAB AND OLAPARIB IN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2 NEGATIVE BREAST CANCER AND A ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001940-25,0,0,0 2020-001942-20,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,A TWINSS extension trial to evaluate the safety and tolerability of CFZ533 (iscalimab) at two dose levels administered subcutaneously in patients with Sjögren’s Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001942-20,0,0,0 2020-001942-20,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,A TWINSS extension trial to evaluate the safety and tolerability of CFZ533 (iscalimab) at two dose levels administered subcutaneously in patients with Sjögren’s Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001942-20,0,0,0 2020-001943-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Institut für Frauengesundheit GmbH,"NeoOn – Neoadjuvant treatment of Ontruzant® (SB3) in patients with HER2-positive early breast cancer: An open-label, multicenter, phase IV study NeoOn – Neoadjuvante Behandlung von Patientinnen mit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001943-21,0,0,0 2020-001951-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Uniwersytet Mikołaja Kopernika w Toruniu,Amiodarone or Verapamil in COVID-19 hospitalized patients with symptoms: Randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001951-42,0,0,0 2020-001952-16,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Amsterdam UMC, location VUmc",Progesterone for Breast Development in Trans Women; Assessment of effects and safety -a pilot trial-,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001952-16,0,0,0 2020-001953-36,1,2021-06-11,2021-06-11,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,"Instituto Grifols, S.A","A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin® plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001953-36,0,0,0 2020-001957-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Eija Kalso,"Sleep and neuropathic pain: Sleep structure in neuropathic pain patients, psychological factors, brain connectivity, and the effects of pregabalin on sleep and pain Uni ja hermovauriokipu: Unen rak...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001957-31,0,0,0 2020-001960-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Investigation Institute Bioaraba,Efficacy of vitamin D treatment in patients diagnosed with pneumonia who require hospital admission and have vitamin D deficiency and a positive diagnosis for SARS-Cov-2 (COVID-19) Eficacia del tra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001960-28,0,0,0 2020-001961-34,8,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,DR. FALK PHARMA GMBH,"Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of RhuDex granules with placebo in the treatment of primary biliary cholangitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001961-34,0,0,0 2020-001961-34,8,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of RhuDex granules with placebo in the treatment of primary biliary cholangitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001961-34,0,0,0 2020-001963-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Centre Hospitalier Intercommunal de Toulon La Seyne-sur-mer,"Interleukin-1 (IL-1) and Interferon gamma (IFNg) inhibition during COVID 19 inflammation: Randomized, controlled study assessing efficacy and safety of Anakinra and Ruxolitinib Etude de l’inhibiti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001963-10,0,0,0 2020-001966-13,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Enanta Pharmaceuticals, Inc.","A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TO EVALUATE EDP-938 REGIMENS IN SUBJECTS AGED 28 DAYS TO 24 MONTHS INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001966-13,0,0,0 2020-001968-28,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,H. Lundbeck A/S,"Interventional, open-label, fixed-dose multiple administration study to evaluate long-term treatment with eptinezumab in patients with chronic cluster headache",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001968-28,0,0,0 2020-001968-28,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,H. LUNDBECK A/S,"Interventional, open-label, fixed-dose multiple administration study to evaluate long-term treatment with eptinezumab in patients with chronic cluster headache",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001968-28,0,0,0 2020-001969-37,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,H. LUNDBECK A/S,"Interventional, randomized, double-blind, parallel-group, placebo-controlled delayed-start study to evaluate the efficacy and safety of eptinezumab in patients with episodic Cluster Headache",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001969-37,0,0,0 2020-001969-37,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,H. Lundbeck A/S,"Interventional, randomized, double-blind, parallel-group, placebo-controlled delayed-start study to evaluate the efficacy and safety of eptinezumab in patients with episodic Cluster Headache",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001969-37,0,0,0 2020-001971-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Carmen Hidalgo,"Pragmatic study ""CORIVER"": Ivermectin as antiviral treatment for patients infected by SARS-COV2 (COVID-19) PRUEBA DE CONCEPTO “CORIVER”: IVERMECTINA COMO TRATAMIENTO ANTIVÍRICO EN PACIENTES INFECTA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001971-33,0,0,0 2020-001972-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA,Randomised controlled trial comparing efficacy and safety of high versus low low-molecular weight heparin dosages in hospitalised patients with severe COVID-19 pneumonia and coagulopathy not requiring...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001972-13,0,0,0 2020-001973-66,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ROCHE SPA,"A PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) IN COMBINATION WITH BEVACIZUMAB TO INVESTIGATE SAFETY AND EFFICACY IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA NOT PR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001973-66,0,0,0 2020-001976-14,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,"An open-label, randomised, phase III study comparing trifluridine/tipiracil in combination with bevacizumab to trifluridine/tipiracil monotherapy in patients with refractory metastatic colorectal canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001976-14,0,0,0 2020-001976-14,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Institut de Recherches Internationales Servier,"An open-label, randomised, phase III study comparing trifluridine/tipiracil in combination with bevacizumab to trifluridine/tipiracil monotherapy in patients with refractory metastatic colorectal canc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001976-14,0,0,0 2020-001979-33,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Ayala Pharmaceuticals, Inc.","A Phase 2, Multicenter, Open-label, Single-arm Study of AL101 Monotherapy in Patients with Notch-activated Triple Negative Breast Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001979-33,0,0,0 2020-001981-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Incyte Corporation,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001981-13,0,0,0 2020-001982-36,1,2022-01-24,2022-01-24,1,0,0,0,0,0,3,0,0,1,1,1,0,0,0,Fakultní nemocnice u sv. Anny,Alteplase compared to tenecteplase in patients with acute ischemic stroke: Registry-based pragmatic randomized controlled trial Porovnání alteplasy s tenecteplasou u pacientů s akutní ischemií mozk...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001982-36,0,0,0 2020-001984-10,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMPARED WITH PHYSICIAN'S CHOICE OF ENDOCRINE MONOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED ESTRO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001984-10,0,0,0 2020-001985-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,LYSARC,"A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas after CAR T-cells therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001985-12,0,0,0 2020-001987-28,1,,,0,0,0,0,1,0,3,0,1,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,PRECOV: a randomized controlled clinical trial on the effects of hydroxychloroquine in the prevention of COVID-19 in healthcare workers at risk PRECOV: studio clinico controllato e randomizzato sug...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001987-28,0,0,0 2020-001989-10,9,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Constellation Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001989-10,0,0,0 2020-001990-53,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Interv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001990-53,0,0,0 2020-001990-53,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Interv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001990-53,0,0,0 2020-001992-34,1,2021-04-16,2021-04-16,1,1,0,0,0,1,3,0,0,1,0,0,1,0,1,GALDERMA Research & Development LLC,Clinical Trial Exit Interview Study in Cutaneous T-cell Lymphoma (CTCL) to Capture Meaningful Treatment Benefit from a Patient’s Perspective Befragungsstudie nach Behandlungsabschluss bei kutanem ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001992-34,0,0,0 2020-001994-66,1,2020-12-31,2020-12-31,1,0,0,0,0,0,3,0,0,1,1,1,1,0,0,Fundació Assistencial Mútua Terrassa,Ramdomised clinical trial of ivermectin for treatment and prophylaxis of COVID-19 ENSAYO CLINICO CON IVERMECTINA PARA EL TRATAMIENTO Y LA PROFILAXIS DEL COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001994-66,0,0,0 2020-001995-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación SEIMC-GESIDA,"A multicentre, open-label clinical trial to evaluate the effectiveness and safety of intravenous tocilizumab for treating patients with COVID-19 pneumonia: the BREATH-19 Study Ensayo clínico abiert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001995-13,0,0,0 2020-001996-33,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"CytoDyn, Inc.","A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001996-33,0,0,0 2020-002000-39,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"B-Fine: An open label, single arm study to mechanistically interrogate the therapeutic effect of GSK3228836 in patients with Chronic Hepatitis B via intrahepatic immunophenotyping",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-002000-39,0,0,0 2020-002004-39,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Bio-Thera Solutions, Ltd.","A Multicenter, Double-blind, Randomized, Parallel-group Study to Compare the Efficacy and Safety of BAT2506 Versus Simponi® in Participants with Active Psoriatic Arthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-002004-39,0,0,0 2020-002009-25,1,2022-09-01,2022-09-01,1,0,0,0,0,0,2,0,0,1,1,1,0,0,0,Fakultní nemocnice Plzeň,The efficacy and safety of Eftilagimod Alpha Treatment by immune modulation in COVID-19 disease (EAT COVID trial) Účinnost a bezpečnost léčby Eftilagimodem alfa imunitní modulací u onemocnění COVID...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-002009-25,0,0,0 2020-002010-41,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Integrative Research Laboratories Sweden AB,"A randomized, double-blind, placebo-controlled phase IIB study evaluating the efficacy of mesdopetam on DAILY on-time without troublesome dyskinesia in patients with Parkinson's disease Studio di f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-002010-41,0,0,0 2020-002010-41,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Integrative Research Laboratories Sweden AB (IRLAB),"A randomized, double-blind, placebo-controlled phase IIB study evaluating the efficacy of mesdopetam on DAILY on-time without troublesome dyskinesia in patients with Parkinson's disease Studio di f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-002010-41,0,0,0 2020-002011-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta Leonor y Sureste (FIIB),"Bicentric, phase 2, randomized, open-label study to evaluate the efficacy and safety of maraviroc associated with standard treatment in hospitalized patients with pulmonary SARS-CoV-2 infection (COVID...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-002011-21,0,0,0 2020-002017-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU DE POITIERS,Clinical trial assessing the immunogenicity of an anti-pneumococcal combined vaccination strategy in adult patients treated for an acute leukemia or a lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-002017-18,0,0,0 2020-002021-28,1,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Plexxikon Inc.,"A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-002021-28,0,0,0 2020-002023-11,11,2022-03-18,2022-04-18,9,1,1,0,0,0,3,0,0,1,1,0,0,0,1,Janssen-Cilag International NV,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir in Infants and Children (>or=28 Days to or=28 Days to = 32) Utilidad del uso de N-Acetilcisteína asociado ala trat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004549-35,0,0,0 2020-004552-15,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Centre Jean Perrin,Phase I/II study of AGuIX nanoparticles with radiotherapy plus concomitant Temozolomide in the treatment of newly diagnosed glioblastoma Etude de phase I/II testant l’association de nanoparticules ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004552-15,0,0,0 2020-004553-72,9,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Loxo Oncology, Inc.","A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004553-72,0,0,0 2020-004553-72,9,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,LOXO ONCOLOGY INCORPORATED,"A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004553-72,0,0,0 2020-004553-72,9,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company","A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004553-72,0,0,0 2020-004554-30,8,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Loxo Oncology Inc,"A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Sma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004554-30,0,0,0 2020-004554-30,8,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,LOXO ONCOLOGY INCORPORATED,"A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Sma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004554-30,0,0,0 2020-004556-15,7,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Wave Life Sciences UK Limited,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004556-15,0,0,0 2020-004559-34,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,DAIICHI SANKYO INC.,"A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects with HER2 Positive Metastatic and/or Unresectable Gastric or Gastro Esophageal Junction (GEJ) Adenocarc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004559-34,0,0,0 2020-004559-34,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Daiichi Sankyo, Inc.","A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects with HER2 Positive Metastatic and/or Unresectable Gastric or Gastro Esophageal Junction (GEJ) Adenocarc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004559-34,0,0,0 2020-004561-39,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,LEO Pharma A/S,A phase 2 trial to evaluate the efficacy and safety of orally administered LEO 152020 tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe atopic der...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004561-39,0,0,0 2020-004564-26,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Karolinska Institute,Role of antibiotics in conjunction with oral bone augmentation procedures (BAS20),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004564-26,0,0,0 2020-004567-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Zealand University Hospital,Effect of Low-dose Interferon-alfa2a on peri operative immune suppression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004567-11,0,0,0 2020-004568-25,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,DIPARTIMENTO DI SCIENZE CLINICHE E BIOLOGICHE (UNITO),"Open-label, prospective, phase II descriptive pilot trial of belimumab therapy for refractory and/or non-criteria manifestations of Antiphospholipid Syndrome. Studio pilota in aperto, prospettico, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004568-25,0,0,0 2020-004569-37,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Anaveon AG,"ANV419 Single Agent (Parts A-C) or Combination (Part D) First in Human Study Phase 1/2: Open-label, Dose Escalation and Expansion Study in Patients with Relapsed/Refractory Advanced Solid Tumors AN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004569-37,0,0,0 2020-004570-21,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,"Pfizer, Inc.","A SINGLE COUNTRY, MULTICENTER, OPEN-LABEL AND NON-RANDOMIZED CLINICAL TRIAL WITH MOROCTOCOG ALFA (AF-CC) PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES IN PREVIOUSLY TREATED PATIENTS WITH MODERATE AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004570-21,0,1,1 2020-004571-41,3,2021-08-10,2021-08-10,2,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Cyxone AB,"A Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety and Efficacy of Rabeximod Compared to Standard of Care in Patients With Moderate Coronavirus Disease (COVID-19)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004571-41,0,0,0 2020-004583-26,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,LAVA Therapeutics B.V.,"A Phase 1 and 2a open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity of LAVA-051 in patients with relapsed or refractory CD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004583-26,0,0,0 2020-004583-26,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,LAVA Therapeutics NV,"A Phase 1 and 2a open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity of LAVA-051 in patients with relapsed or refractory CD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004583-26,0,0,0 2020-004583-26,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,LAVA Therapeutics N.V.,"A Phase 1 and 2a open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity of LAVA-051 in patients with relapsed or refractory CD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004583-26,0,0,0 2020-004584-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Maxima MC,Optimal postoperative Pain management After Lung surgery (OPtriAL): multi-centre randomised trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004584-11,0,0,0 2020-004589-21,8,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004589-21,0,0,0 2020-004589-21,8,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Novartis Farmacéutica S.A.,"A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004589-21,0,0,0 2020-004589-21,8,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004589-21,0,0,0 2020-004590-51,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,BIOGEN IDEC RESEARCH LIMITED,"A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004590-51,0,0,0 2020-004590-51,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Biogen Idec Research Limited,"A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004590-51,0,0,0 2020-004591-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Mikrobiomik Healthcare Company S.L.,"A randomised, controlled, open-label phase III clinical trial in patients with recurrent Clostridioides difficile (CD) infection, to evaluate the efficacy and safety of capsules of lyophilised faecal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004591-17,0,0,0 2020-004592-40,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,University of Edinburgh,An open label exploratory study to assess the safety of using 100mg of methotrexate as a standard dose treatment for women with unruptured tubal ectopic pregnancy (OSPREY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004592-40,0,0,0 2020-004592-40,1,,,0,0,0,0,0,0,4,0,0,3,0,0,0,0,0,NHS Lothian,An open label exploratory study to assess the safety of using 100mg of methotrexate as a standard dose treatment for women with unruptured tubal ectopic pregnancy (OSPREY),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004592-40,0,0,0 2020-004594-43,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,CECS/I-Stem,"AUDIOWOLF: A phase II, open-label, efficacy study of daily administration of sodium valproate in patients clinically affected by Wolfram syndrome due to monogenic mutation AUDIOWOLF: Etude de phase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004594-43,0,0,0 2020-004602-59,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU DE POITIERS,Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly diagnosed Non Frail transplant Ineligible Multiple Myeloma elde...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004602-59,0,0,0 2020-004604-33,4,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,1,"Univar Solutions, B.V.","Open label, Multicenter, Prospective Study to Characterize the Pharmacokinetics and Pharmacodynamics of Cufence (Trientine Dihydrochloride) and to Investigate the Efficacy and Safety in Wilson’s Disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004604-33,0,0,0 2020-004606-60,8,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004606-60,0,0,0 2020-004606-60,8,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS WITH...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004606-60,0,0,0 2020-004608-32,1,,,0,0,0,1,0,1,1,0,0,4,0,0,0,0,1,Dynacure,"A Phase 1/2, multicenter, open-label, dose-confirmation trial to evaluate the safety and preliminary efficacy of DYN101 in subjects 2 to 17 years of age with centronuclear myopathy caused by mutations...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004608-32,0,0,0 2020-004610-35,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Allarity Therapeutics,"Phase II, open label, single arm study to investigate anti-tumor effect of ixabepilone in patients with locally recurrent metastatic breast cancer (mBC) selected by the ixabepilone Drug Response Predi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004610-35,0,0,0 2020-004610-35,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Allarity Therapeutics Europe Aps,"Phase II, open label, single arm study to investigate anti-tumor effect of ixabepilone in patients with locally recurrent metastatic breast cancer (mBC) selected by the ixabepilone Drug Response Predi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004610-35,0,0,0 2020-004612-97,8,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,DR. FALK PHARMA GMBH,"A phase IIb, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004612-97,0,0,0 2020-004612-97,8,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Dr. Falk Pharma GmbH,"A phase IIb, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004612-97,0,0,0 2020-004614-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Ismail Gögenur,Treatment with SGLT-2 inhibitor for postoperative hyperglycemia in acute abdominal surgery – a randomized trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004614-35,0,0,0 2020-004623-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Zealand University Hospital,"Irreversible electroporation in combination with immune checkpoint inhibi-tion , in patients with metastatic pancreatic cancer - A prospective, phase 2 study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004623-17,0,0,0 2020-004624-41,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Zealand University Hospital,Calcium Electroporation for Malignant GI Bleeding – a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004624-41,0,0,0 2020-004627-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Hospital,Clinical Validation of Quantitative Flutemetamol PET/CT in Cardiac Amyloidosis Sydämen transtyretiini-amyloidoosin kvantitatiivien isotooppikuvantaminen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004627-16,0,0,0 2020-004628-40,3,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Mirum Pharmaceuticals Inc,"Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants with Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004628-40,0,0,0 2020-004630-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region Jämtland/Härjedalen,"Sclerotherapy for hydro and spermatoceles with 99.5% Ethanol, an open clinical multicenter dose escalation study, phase 2 Etanol 99,5% som sklerosering vid vatten- eller spermiebråck, en öppen klin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004630-38,0,0,0 2020-004636-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GERCOR,A phase II study to evaluate the rate of cardiovascular events during trifluridine/tipiracil +/-oxaliplatin treatment in colorectal/oesogastric adenocarcinoma patients that have experienced a past e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004636-25,0,0,0 2020-004637-20,4,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,AstraZeneca AB,A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004637-20,0,0,0 2020-004639-26,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Lexicon Pharmaceuticals, Inc.","A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX9211 in the Treatment of Postherpetic Neuralgia (RELIEF-PHN1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004639-26,0,0,0 2020-004643-80,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Daiichi Sankyo, Inc.",Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer without Actionable Genomic Alterations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004643-80,0,0,0 2020-004643-80,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,DAIICHI SANKYO INC.,Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer without Actionable Genomic Alterations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004643-80,0,0,0 2020-004645-36,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Fraunhofer Gesellschaft for its Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP),Impact of different silymarin dosages to decrease drug-induced elevated liver enzymes compared to placebo in a prospective controlled dose finding Phase IIb trial (SILVER),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004645-36,0,0,0 2020-004649-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione GONO,"Pembrolizumab and olaparib in recurrent/metastatic, platinum resistant nasopharyngeal cancer Pembrolizumab e Olaparib nel cancro nasofaringeo recidivante/metastatico, resistente al platino",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004649-35,0,0,0 2020-004653-69,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Biohaven Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder Een gerandomiseerd, dubbelblind, placebogecontroleerd onderzoek naar troriluzole als ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004653-69,0,0,0 2020-004653-69,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Biohaven Pharmaceuticals, Inc","A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder Een gerandomiseerd, dubbelblind, placebogecontroleerd onderzoek naar troriluzole als ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004653-69,0,0,0 2020-004654-30,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Biohaven Pharmaceuticals, Inc","A Multicenter, 48-week Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder Een multicentrische, open-label veiligheidsstudie van 48 weken aanvullende be...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004654-30,0,0,0 2020-004656-14,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,BeiGene Ltd.,"A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGBA1217) Plus Tislelizumab (BGB-A317) Versus Durvalumab in Patients With Locally Advanced, Unresectable, PD L1 Selected Non- Small Cell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004656-14,0,0,0 2020-004656-14,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"BeiGene, Ltd.","A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGBA1217) Plus Tislelizumab (BGB-A317) Versus Durvalumab in Patients With Locally Advanced, Unresectable, PD L1 Selected Non- Small Cell...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004656-14,0,0,0 2020-004657-77,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"BeiGene, Ltd.",Phase 2 Study Investigating Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody BGB-A1217 in Patients With Previously T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004657-77,0,0,0 2020-004657-77,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"BeiGene, Ltd. c/o BeiGene USA, Inc.",Phase 2 Study Investigating Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody BGB-A1217 in Patients With Previously T...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004657-77,0,0,0 2020-004658-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"BeiGene, Ltd.","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody BGB-A121...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004658-32,0,0,0 2020-004662-19,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ALX Oncology Inc.,A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB AND CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (ASPEN-04),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004662-19,0,0,0 2020-004682-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Thomayerova nemocnice,"Pilot, open-label, monocentric study evaluating safety and clinical effect of application of NORMOSANG® in patients with COVID-19 disease Pilotní, otevřená, monocentrická studie hodnotící bezpečnos...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004682-39,0,0,0 2020-004686-39,5,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of avalglucosidase alfa in Treatment naïve Pediatric Participants ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004686-39,0,1,0 2020-004686-39,5,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of avalglucosidase alfa in Treatment naïve Pediatric Participants ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004686-39,0,1,0 2020-004692-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Dilafor AB,"An Exploratory, Open label, Randomized, Parallel-Group, Pilot Study to evaluate Safety, Tolerability and Efficacy of daily, subcutaneous tafoxiparin treatment from the time of diagnosis for up to 4 we...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004692-40,0,0,0 2020-004694-46,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Opthea,"A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004694-46,0,0,0 2020-004694-46,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Opthea Limited,"A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004694-46,0,0,0 2020-004694-46,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,OPTHEA LIMITED,"A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004694-46,0,0,0 2020-004695-18,1,2021-10-29,2021-10-29,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Heinrich-Heine-University Düsseldorf,Reconvalescent plasma/Camostat mesylate early in Sars-CoV-2 Q-PCR positive high risk individuals Rekonvaleszenten Plasma / Camostat mesylat bei Sars-CoV-2 Q-PCR-positiven Personen mit hohem Risiko ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004695-18,0,0,0 2020-004699-16,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Kartos Therapeutics, Inc","An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004699-16,0,0,0 2020-004699-16,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Kartos Therapeutics, Inc.","An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004699-16,0,0,0 2020-004703-14,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A randomized, double-blind, placebo controlled, proof of concept study assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004703-14,0,0,0 2020-004703-14,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, double-blind, placebo controlled, proof of concept study assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004703-14,0,0,0 2020-004704-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,"Recovery from deep neuromuscular blockade using different sugammadex doses in elderly patients undergoing laparoscopic robot-assisted prostatectomy: a prospective, randomized, double-blind clinical tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004704-34,0,0,0 2020-004705-31,1,2021-07-20,2021-07-20,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,RhoVac ApS,Long-term follow-up study of immune response to vaccinations with RV001 in patients enrolled in RhoVac-001 study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004705-31,0,0,0 2020-004708-32,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Biogen Idec Research Limited,A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With Nusinersen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004708-32,0,0,0 2020-004715-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Nocion Therapeutics, Inc.","A Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetic Profiles of Inhaled Doses of NOC-100 in Adult Participants wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004715-27,0,0,0 2020-004718-36,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Chiesi Farmaceutici S.p.A,"A Double Blind, Multicentre, Randomised, Placebo-Controlled, 3-Way Cross-Over Study To Evaluate The Effect Of A Triple Combination Of Beclometasone Dipropionate And Formoterol Fumarate Plus Glycopyrro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004718-36,0,0,0 2020-004719-28,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004719-28,0,0,0 2020-004721-23,4,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Amgen Inc.,"A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004721-23,0,0,0 2020-004721-23,4,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,AMGEN INC.,"A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004721-23,0,0,0 2020-004725-23,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Γενικό Νοσοκομείο Θεσσαλονίκης ""Γεώργιος Παπανικολάου""","Administration of rapidly generated multipathogen-specific T-Lymphocytes for the Treatment of AdV, CMV, EBV, BKV and Aspergillus fumigatus infections post Allogeneic Stem Cell Transplant Χορήγηση...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004725-23,0,0,0 2020-004734-37,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Octapharma Pharmazeutika Prod.Ges.m.b.H,"Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with prim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004734-37,0,0,0 2020-004736-24,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Opthea Limited,"A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004736-24,0,0,0 2020-004736-24,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,OPTHEA LIMITED,"A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004736-24,0,0,0 2020-004738-39,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Nordic Society of Gynaecological Oncology - Clinical Trial Unit,"ENGOT-OV56-NSGO-CTU-DOVACC. A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004738-39,0,0,0 2020-004741-37,5,,,0,0,0,1,0,0,1,0,1,3,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase I/II, observer-blind, randomised, controlled study to assess the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine when administered to healthy adults (Phase I)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004741-37,0,1,0 2020-004742-11,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexametha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004742-11,0,0,0 2020-004742-11,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexametha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004742-11,0,0,0 2020-004743-83,9,2022-02-10,2022-02-10,6,0,0,0,0,0,3,0,0,2,0,0,0,0,1,Synairgen Research Limited,"A randomised, double-blind, placebo-controlled, Phase III trial to determine the efficacy and safety of inhaled SNG001 for the treatment of patients hospitalised due to moderate COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004743-83,1,0,0 2020-004746-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,The Florey Institute of Neuroscience and Mental Health,STOP-MSU – Stopping haemorrhage with Tranexamic acid for hyperacute Onset Presentation including Mobile Stroke Units STOP-MSU –tutkimus traneksaamihapon käytöstä aivoverenvuodon kasvun estämisessä,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004746-10,0,0,0 2020-004748-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,LMU University Hospital Munich,Escalated single platelet inhibition for one month plus direct oral anticoagulation in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004748-27,0,0,0 2020-004749-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,A phase 2 immunoPET imaging study with ZED88082A/CED88004S in patients with Large B-cell lymphoma before and after CD19-directed CAR T-cell therapy Een fase 2 immunoPET-beeldvormingsonderzoek met Z...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004749-35,0,0,0 2020-004752-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF RO6889450 (RALMITARONT) IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AND NEGATIVE SYMPTOMS ESTUDIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004752-16,0,0,0 2020-004753-68,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Red Andaluza de Diseño y Traslación de Terapias Avanzadas-Fundación Progreso y Salud,"Phase II, Single-Center, Randomized, Double-blind, Placebo-controlled Clinical Trial to determine the safety and efficacy of the use of allogeneic adipose tissue adult stem mesenchymal cells in the tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004753-68,0,0,0 2020-004767-77,3,2022-08-22,2022-08-24,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients with Moderate to Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004767-77,1,0,0 2020-004768-24,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,CELLECTIS SA,"Open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004768-24,0,0,0 2020-004770-22,5,2022-08-03,2022-08-03,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Taiho Oncology, Inc.",A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004770-22,1,0,0 2020-004770-22,5,2022-08-03,2022-08-03,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,TAIHO ONCOLOGY INC.,A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating Mutations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004770-22,1,0,0 2020-004772-18,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Astex Pharmaceuticals, Inc.","A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia Estudio abierto de un solo grupo de la f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004772-18,0,0,0 2020-004774-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Herlev Gentofte Hospital,The separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004774-22,0,0,0 2020-004775-40,14,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Arena Pharmaceuticals Inc.,"A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004775-40,0,0,0 2020-004775-40,14,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"ARENA PHARMACEUTICALS, INC.","A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004775-40,0,0,0 2020-004777-49,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Hansa Biopharma,"A prospective, observational long-term follow-up trial of kidney transplant patients treated with imlifidase or plasma exchange after an active/chronic active Antibody-Mediated Rejection episode",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004777-49,0,0,0 2020-004780-71,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,Karolinska University Hospital,A phase III Randomized Double-Blinded Placebo-Controlled Study of Use of GnRHa during Chemotherapy for Fertility Protection of Young Women and Teenagers with Cancer - ProFertil En fas III Randomis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004780-71,0,0,0 2020-004782-39,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Daiichi Sankyo Inc.,"A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Subjects with HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004782-39,0,0,0 2020-004782-39,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,DAIICHI SANKYO INC.,"A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Subjects with HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004782-39,0,0,0 2020-004785-19,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi-Aventis Recherche et Développement,"A Phase 2, double-blind, randomized, placebo-controlled study assessing efficacy and safety of SAR441344, a CD40L-antagonist monoclonal antibody, in participants with relapsing multiple sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004785-19,0,0,0 2020-004802-70,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Assistance Publique – Hôpitaux de Paris,Impact of post-ARDS COVID sedation on late neuroinflammation Impact de la sédation post-SDRA COVID sur la neuroinflammation tardive,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004802-70,0,0,0 2020-004805-30,7,,,0,0,0,0,0,1,3,0,0,2,1,0,0,0,1,Pharnext SA,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004805-30,0,0,0 2020-004809-31,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg administered subcutaneously versus placebo, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004809-31,0,0,0 2020-004809-31,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg administered subcutaneously versus placebo, in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004809-31,0,0,0 2020-004812-81,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE,Ketamine Low dOse Evaluation on morphine consumption in traumatic patient : a prospective randomized controlled double-blind study Impact de la kétamine à faible dose sur l’épargne morphinique chez...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004812-81,0,0,0 2020-004815-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Cardiorentis AG,"Open-label, dose escalation study of ularitide for the investigation of hemodynamic effects in patients with pulmonary arterial hypertension (UPAH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004815-29,0,0,0 2020-004826-47,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Lone Nikolajsen,"Intraoperative methadone for postoperative pain management in spinal fusion surgery: a prospective, double-blind, randomised controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004826-47,0,0,0 2020-004828-42,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Atossa Therapeutics Inc.,"A Phase 2, Randomized, Double-blinded, Placebo - controlled, Dose Response Study of Oral (Z)-endoxifen in Premenopausal Women with Measurable Breast Density",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004828-42,0,0,0 2020-004832-48,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,NHS Greater Glasgow and Clyde,"DAPA-RESIST - Sodium glucose cotransporter-2 inhibitor DAPAgliflozin versus thiazide diuretic in patients with heart failure and diuretic RESISTance: a multi-centre, open-label, randomised controlled ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004832-48,0,0,0 2020-004832-48,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,University of Glasgow,"DAPA-RESIST - Sodium glucose cotransporter-2 inhibitor DAPAgliflozin versus thiazide diuretic in patients with heart failure and diuretic RESISTance: a multi-centre, open-label, randomised controlled ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004832-48,0,0,0 2020-004835-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS-A.O.U. SAN MARTINO-IST,"Single-center, randomized, controlled study to evaluate the effects of a six-month treatment with renal glucose transport inhibitor (SGLT2i) drugs on markers of senescence, inflammation and tubulointe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004835-26,0,0,0 2020-004836-93,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SANTEN INCORPORATED,"An Exploratory Study to Assess the 24-hour Intraocular Pressure (IOP) Lowering Characteristics, Duration of Action and Safety of DE-126 ophthalmic solution 0.002% versus Latanoprost ophthalmic solutio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004836-93,0,0,0 2020-004838-37,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Fundación de Investigación Biomédica Hospital Niño Jesús,"Phase IB clinical trial to assess the safety, tolerability, and preliminary efficacy of AloCELYVIR (Mesenchymal allogenic cells + ICOVIR-5) in children, adolescent and young adults with newly diagnose...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004838-37,0,0,0 2020-004839-25,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,F.Hoffmann-La Roche Ltd,"A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004839-25,0,0,0 2020-004839-25,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004839-25,0,0,0 2020-004839-25,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004839-25,0,0,0 2020-004840-27,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE IB RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISODES ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004840-27,0,0,0 2020-004840-27,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE IB RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISODES ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004840-27,0,0,0 2020-004840-27,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,F.Hoffmann-La Roche Ltd,"A PHASE IB RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO-OCCLUSIVE EPISODES ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004840-27,0,0,0 2020-004844-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,"SURE-01_An open label, single-arm, phase 2 study of neoadjuvant sacituzumab govitecan, before radical cystectomy, for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004844-27,0,0,0 2020-004848-29,19,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novo Nordisk A/S,A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004848-29,0,0,0 2020-004848-29,19,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NOVO NORDISK. S.P.A.,A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004848-29,0,0,0 2020-004850-31,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Pfizer Inc.,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004850-31,0,0,0 2020-004850-31,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,PFIZER INC,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004850-31,0,0,0 2020-004851-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,INSIGHTEC,Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy Valutazione della sicurezza e del...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004851-34,0,0,0 2020-004853-59,15,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Novo Nordisk A/S,"ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004853-59,0,0,0 2020-004853-59,15,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,NOVO NORDISK. S.P.A.,"ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004853-59,0,0,0 2020-004855-34,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Bayer Consumer Care AG,"A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004855-34,0,0,0 2020-004859-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo de Tratamiento de los Tumores Digestivos (TTD),Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations Olaparib y durvalumab (MEDI4736) en pacientes con cáncer de páncreas metastá...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004859-32,0,0,0 2020-004863-14,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novo Nordisk A/S,Investigation of the safety and efficacy of semaglutide s.c. in combination with NNC0480-0389 in participants with type 2 diabetes – a dose finding study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004863-14,0,0,0 2020-004864-25,18,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novo Nordisk A/S,A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004864-25,0,0,0 2020-004864-25,18,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NOVO NORDISK. S.P.A.,A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004864-25,0,0,0 2020-004870-22,4,2022-04-20,2022-04-20,3,0,0,0,0,1,2,0,0,2,0,0,0,0,1,"AmMax Bio., Inc.","A Phase 2, Adaptive, Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Intravenous AMB-05X in Subjects with Tenosynovial Giant Ce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004870-22,1,0,0 2020-004872-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,INSTITUT CURIE,A Double-blind Randomized non-inferiority Trial of erector spinae block (ESP) versus paravertebral block (PVB) before Breast Cancer Surgery: Effects on acute Postoperative Pain Essai clinique rando...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004872-17,0,0,0 2020-004873-29,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Seagen Inc.,"A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004873-29,0,0,0 2020-004873-29,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SEAGEN INC.,"A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004873-29,0,0,0 2020-004875-41,1,2022-06-05,2022-06-05,1,1,0,0,0,0,4,0,1,1,0,0,0,0,0,"Mech-Sense, Aalborg University Hospital","Opium tincture against chronic diarrhea - Healthy: An investigator initiated, randomized placebo-controlled, double-blinded, cross-over, clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004875-41,0,0,0 2020-004876-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,"SURE-02_An open label, single-arm, phase 2 study of perioperative pembrolizumab plus sacituzumab govitecan for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004876-16,0,0,0 2020-004877-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Uniwersytet Jagielloński - Collegium Medicum,Ivabradine for PREVENTion of Myocardial Injury after Noncardiac Surgery (MINS) - PREVENT-MINS Trial Iwabradyna w prewencji okołozabiegowego uszkodzenia mięśnia sercowego po zabiegach niekardiochir...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004877-38,0,0,0 2020-004878-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS,Pharmacokinetic and Placental Transfer of Levetiracetam Etude de la pharmacocinétique maternelle et du passage transplacentaire du Lévétiracétam,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004878-22,0,0,0 2020-004881-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA USL TOSCANA SUD EST Sezione di Arezzo,Comparison of norepinephrine and dobutamine in patients in cardiogenic shock Confronto fra Noradrenalina e Dobutamina nei pazienti in shock cardiogeno,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004881-20,0,0,0 2020-004883-25,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Deciphera Pharmaceuticals, LLC","A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004883-25,0,0,0 2020-004883-25,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"DECIPHERA PHARMACEUTICALS, LLC","A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004883-25,0,0,0 2020-004885-21,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004885-21,0,0,0 2020-004887-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Marcin Gruchała Medical University of Gdańsk,Dual Antithrombotic Therapy with Dabigatran and Ticagrelor in Patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004887-24,0,0,0 2020-004891-16,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Servier Portugal - Especialidades Farmaceuticas, Lda.",Evaluation of the clinical efficacy and safety of perindopril 10 mg/indapamide 2.5 mg/amlodipine 5 or 10 mg/bisoprolol 5 mg in single-pill combination after 8 weeks of treatment versus the free combin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004891-16,0,0,0 2020-004891-16,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Institut de Recherches Internationales Servier,Evaluation of the clinical efficacy and safety of perindopril 10 mg/indapamide 2.5 mg/amlodipine 5 or 10 mg/bisoprolol 5 mg in single-pill combination after 8 weeks of treatment versus the free combin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004891-16,0,0,0 2020-004891-16,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,INSTITUT DE RECHERCHES INTERNATIONALES SERVIER,Evaluation of the clinical efficacy and safety of perindopril 10 mg/indapamide 2.5 mg/amlodipine 5 or 10 mg/bisoprolol 5 mg in single-pill combination after 8 weeks of treatment versus the free combin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004891-16,0,0,0 2020-004892-41,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Vera Therapeutics, Inc.","A Phase IIb Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004892-41,0,0,0 2020-004894-29,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,1,Institut de Recherches Internationales Servier,"A multicentre, Phase II Randomized study, Open-label, with 2-arm Parallel Group, comparing the pharmacokinetics of the Liquid and the Lyophilized Formulations of pegaspargase (S95014) in Treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004894-29,0,1,1 2020-004895-17,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,1,Institut de Recherches Internationales Servier,"A multicentre, roll-over study to provide continued treatment with lyophilized pegaspargase (S95014) in Pediatric Patients with Acute Lymphoblastic Leukemia (ALL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004895-17,0,1,1 2020-004897-22,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Novartis Pharma AG,"A 5-year, randomized, double-blind, placebo-controlled, multi-center study assessing the efficacy, safety, and tolerability of intra-articular regimens of LNA043 versus placebo in patients with sympto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004897-22,0,0,0 2020-004897-22,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A 5-year, randomized, double-blind, placebo-controlled, multi-center study assessing the efficacy, safety, and tolerability of intra-articular regimens of LNA043 versus placebo in patients with sympto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004897-22,0,0,0 2020-004898-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,MEDICAL UNIVERSITY OF GDAŃSK,"A multicentre, parallel group, randomised, double blind, placebo-controlled, phase II study evaluating the efficacy and safety of reperfusion thrombolytic therapy with intravenous recombinant tissue p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004898-41,0,0,0 2020-004899-18,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,GWT-TUD GmbH,"A phase IIIb, open-label, single arm study to evaluate the efficacy and safety of luspatercept in patients with lower-risk MDS and ring-sideroblastic phenotype (MDS-RS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004899-18,0,0,0 2020-004901-29,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Medical University of Gdańsk,"The efficacy and safety of Metoprolol as add-on treatment to standard of care in preventing cardiomyopathy in patients with Duchenne Muscular Dystrophy aged 8-16 years. A randomized, double-blind, pla...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004901-29,0,0,0 2020-004902-67,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación GECP,A phase II single arm clinical trial assessing the efficacy and safety of BIntrafusp alfa (M7824) in previously treated advanced malignant pleural MESothelioma (BIMES). Ensayo clínico de fase II de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004902-67,0,0,0 2020-004903-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Alabama at Birmingham,Denosumab (DMAB) Discontinuation and Switching Study in Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study Studio pilota sulla sospensione di denosumab e il passaggio ad altro trattamento ne...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004903-15,0,0,0 2020-004906-79,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg","An international multicenter, open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004906-79,0,0,0 2020-004908-33,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Bayer Consumer Care AG,"A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 26 weeks in postmenopausal women",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004908-33,0,0,0 2020-004909-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Department of Oncology,Can Eribulin enhance the effect of subsequent endocrine therapy?- a phase 2 study for patients with ER positive HER2 normal metastatic breast cancer Kan Eribulin øge effekten af efterfølgende antih...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004909-32,0,0,0 2020-004910-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,LYSARC,A randomized phase II trial evaluating Ibrutinib plus CD20 Ab and Ibrutinib-Venetoclax plus CD20 Ab in patients with untreated mantle cell lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004910-37,0,0,0 2020-004913-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboudumc,genotype-guided strategy for antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease’ De toegevoegde waarde van genetisch onderzoek bij het voorschrijven van...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004913-11,0,0,0 2020-004918-35,4,2022-07-07,2022-07-07,4,0,0,0,0,0,2,0,0,1,1,1,0,0,1,"MacroGenics, Inc.",A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination with Retifanlimab or Tebotelimab in the First-Line Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004918-35,0,0,0 2020-004928-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium,Open-label study to assess the safety of REMdesivir-HU as Eligible Novel therapY for moderate and severe Covid-19 patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004928-42,0,0,0 2020-004929-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Individual albuminuria lowering response to dapagliflozin in a decentralized clinical trial in patients with type 2 diabetes mellitus and elevated albuminuria Individuele albuminurie verlagende eff...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004929-23,0,0,0 2020-004930-39,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"G1 Therapeutics, Inc.","A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004930-39,0,0,0 2020-004931-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,Intranasal dexmedetomidine pharmacokinetics on patients under general anesthesia Nenän kautta annosteltavan deksmedetomidiinin farmakokinetiikka nukutetuilla potilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004931-25,0,0,0 2020-004933-19,1,,,0,0,0,0,1,1,3,0,0,4,0,0,0,0,0,"Region Västra Götaland, Sahlgrenska Universitetssjukhuset","A Randomized Intervention, Multi-Center Study to Determine the Role of Dexamethasone eye drops against proliferative retinopathy of prematurity En randomiserad, multicenter interventionsstudie i s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004933-19,0,0,0 2020-004935-26,1,2022-08-30,2022-08-30,1,0,0,0,0,1,2,0,0,1,0,0,0,0,0,Aarhus University Hospital,"PBC induced fatigue treated with thiamine - The effect of oral thiamine supplement in 4 weeks to patients with primary biliary cholangitis (PBC) and chronic fatigue. A randomised, double-blinded, plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004935-26,0,0,0 2020-004936-72,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE II, OPEN-LABEL, MULTICENTER, PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF BIOMARKER-DRIVEN THERAPIES IN PATIENTS WITH PERSISTENT OR RECURRENT RARE EPITHELIAL OVARIAN TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004936-72,0,0,0 2020-004936-72,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, OPEN-LABEL, MULTICENTER, PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF BIOMARKER-DRIVEN THERAPIES IN PATIENTS WITH PERSISTENT OR RECURRENT RARE EPITHELIAL OVARIAN TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004936-72,0,0,0 2020-004937-19,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A multi-center, randomized, participant- and investigator- blinded, placebo-controlled, parallel group basket study to evaluate the safety, tolerability and efficacy of MHV370 in participants with Sjö...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004937-19,0,0,0 2020-004937-19,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A multi-center, randomized, participant- and investigator- blinded, placebo-controlled, parallel group basket study to evaluate the safety, tolerability and efficacy of MHV370 in participants with Sjö...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004937-19,0,0,0 2020-004938-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,"ADVANCE: A phase II single-arm, open-label study of Atezolizumab and Derazantinib for patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements ADVANCE: Eine einarmig...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004938-38,0,0,0 2020-004940-27,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,AiCuris Anti-infective Cures AG,"A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in imm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004940-27,0,0,0 2020-004940-27,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,AiCuris Anti-infective Cures GmbH,"A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in imm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004940-27,0,0,0 2020-004942-12,1,2020-12-13,2020-12-13,1,1,0,0,0,0,4,0,1,1,0,0,1,0,0,Aarhus University Hospital,Selective ultrasound-guided nerve block of the medial femoral cutaneous nerve in healthy volunteers Selektiv ultralydvejledt nerveblokade af den mediale kutane gren fra n. femoralis hos raske forsø...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004942-12,0,0,0 2020-004944-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo Universtity Hospital,NORMOTHERMIC INTRAPERITONEAL CHEMOTHERAPY IN PERITONEAL METASTASES FROM COLORECTAL CANCER – FEASIBILITY STUDY (NIPEC-OXA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004944-27,0,0,0 2020-004951-34,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Thirty Respiratory Limited,"Community participants with COPD or bronchiectasis and at risk of Respiratory Viral Infections including SARS-CoV-2: An open-label, multicentre feasibility study of an inhaled nitric oxide generating ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004951-34,0,0,0 2020-004952-14,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Constellation Pharmaceuticals, Inc.",A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004952-14,0,0,0 2020-004954-31,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"DAIICHI SANKYO, INC.","Single-Arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004954-31,0,0,0 2020-004954-31,3,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,DAIICHI SANKYO INC.,"Single-Arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004954-31,0,0,0 2020-004960-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,RHEACELL GmbH & Co. KG,"A randomized, placebo-controlled, double-blind, dose-ranging, multicenter, phase IIb clinical trial to investigate the efficacy and safety of allo-APZ2-CVU on wound healing of therapy-resistant chroni...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004960-24,0,0,0 2020-004961-38,1,2022-07-11,2022-07-11,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,LEO Pharma A/S,Phase 2a trial to assess the efficacy and safety of LEO 152020 in adult patients with cholinergic urticaria Phase 2a Studie zur Beurteilung der Wirksamkeit und Sicherheit von LEO 152020 bei erwachs...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004961-38,0,0,0 2020-004962-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Wojskowy Instytut Medyczny,"""MetCool ACS”- Metformin “Cooling” Effect on metformin-naive Patients Treated with PCI because of Acute Coronary Syndrome “MetCool ACS”- stabilizujacy wpływ metforminy u pacjentów do tej pory jej n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004962-21,0,0,0 2020-004964-25,3,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Affibody AB,"A phase 2 trial of the efficacy and safety of the interleukin-17A inhibitor ABY-035 in the treatment and prevention of relapse/recurrence of non-infectious intermediate, posterior or pan-uveitis, incl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004964-25,0,0,0 2020-004966-20,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud University Medical Center,A GLP-1 receptor PET imaging add-on study within the Ver-A-T1D trial investigating the effects of Verapamil or placebo on beta cell mass (ImageVer-A-T1D) GLP-1 Rezeptor PET Bildgebungsstudie im Ra...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004966-20,0,0,0 2020-004971-42,9,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Altavant Sciences GmbH,"A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004971-42,0,0,0 2020-004972-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AGMT gGmbH,Isatuximab in combination with Lenalidomide-Dexamethasone compared to Lenalidomide-Dexamethasone in elderly patients (aged ≥70 years) with newly diagnosed myeloma: a randomized phase II study (SGZ-201...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004972-17,0,0,0 2020-004978-22,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Medical University of Vienna, Department of Clinical Pharmacology",Detection of acetylsalicylic acid and omega-3 fatty acids in Schirmers’ test strips using mass spectrometry in healthy adults: an open-label pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004978-22,0,0,0 2020-004980-24,1,,,0,0,0,1,0,1,1,0,0,4,0,0,0,0,1,"ModernaTX, Inc.","A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA-3705 in Participants with Isolated Methylmalonic Acidemia ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004980-24,0,0,0 2020-004981-20,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004981-20,0,0,0 2020-004981-20,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004981-20,0,0,0 2020-004982-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,MEDICAL UNIVERSITY OF GDAŃSK,Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrome Wczesne leczenie rituximabem dzieci z idiopatycznym zes...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004982-37,0,0,0 2020-004985-21,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,BeiGene Ltd.,"A Phase 3, Randomized, Double-Blind Study of BGB A1217, an Anti TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD L1 Selected, and Lo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004985-21,0,0,0 2020-004985-21,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"BeiGene, Ltd.,c/o BeiGene USA, Inc.","A Phase 3, Randomized, Double-Blind Study of BGB A1217, an Anti TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD L1 Selected, and Lo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004985-21,0,0,0 2020-004985-21,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"BeiGene, Ltd.","A Phase 3, Randomized, Double-Blind Study of BGB A1217, an Anti TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD L1 Selected, and Lo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004985-21,0,0,0 2020-004986-38,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Inventiva S.A.,"A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004986-38,0,0,0 2020-004986-38,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,INVENTIVA S.A.,"A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004986-38,0,0,0 2020-004994-27,1,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Ashford and St Peter's Hospitals NHS Foundation Trust,Clinical Efficacy of Nitric Oxide Nasal Spray (NONS) for the Treatment of Mild COVID-19 Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004994-27,0,0,0 2020-004995-17,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AMsterdam UMC-AMC,Low dose iron chelation as TReatment of Oxidative stress in Sickle cell disease; TROS study Lage dosis ijzer chelatie therapie als behandeling van oxidatieve stress bij patienten met sikkel cel zie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004995-17,0,0,0 2020-004997-23,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004997-23,0,0,0 2020-004997-23,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004997-23,0,0,0 2020-004997-23,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-004997-23,0,0,0 2020-005005-17,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Open-label, Two-arm Study to Evaluate the Safety, Efficacy, and Pharmacodynamic Effects of Pozelimab and Cemdisiran Combination Treatment in Patients with Paroxysmal Nocturnal Hemoglobin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005005-17,0,0,0 2020-005007-40,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005007-40,0,0,0 2020-005011-52,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"BIAL – Portela & Cª, S.A.","A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005011-52,0,0,0 2020-005011-52,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"BIAL-Portela & Ca, S.A.","A Phase III, Double-Blind, Randomized, Placebo-Controlled and Parallel Group Study to Evaluate the Efficacy and Safety of Opicapone, as Add on to Stable Levodopa (L-DOPA) Plus a Dopa Decarboxylase Inh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005011-52,0,0,0 2020-005015-40,1,2021-06-21,2021-06-21,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,Chemo Research S.L.,"A multicentre, phase III, double-blind, randomised, parallel, placebo-controlled trial to assess efficacy and safety of early administration of Ivermectin during 3 consecutive days to prevent SARS CoV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005015-40,0,0,0 2020-005016-21,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Famewave Ltd.,"A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in combination with nivolumab in adults with advanced solid tumours Estudio de fase I/I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005016-21,0,0,0 2020-005017-41,1,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,0,Medical University of Silesia,AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia. A randomized phase III study conducted in agreement with the AIEOP-BFM study gr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005017-41,0,0,0 2020-005018-17,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,The University of Queensland,Targeting metabolic flexibility in ALS (MetFlex); Safety and tolerability of Trimetazidine for the treatment of ALS Aangrijpen op de metabole flexibiliteit in patiënten met amyotrofische laterale s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005018-17,0,0,0 2020-005019-29,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,Medical University of Lodz,Single-arm interventional study with ruxolitinib and AIOEP-BFM2017 chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway. Jednoramienne badanie int...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005019-29,0,0,0 2020-005020-11,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Políclinica Nuestra Señora del Rosario,Randomized multicenter single-blind controlled trial on ozonated blood in COVID-19 severe pneumonia Ensayo clínico controlado simple-ciego multicentrico con sangre ozonizada en neumonia grave por C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005020-11,0,0,0 2020-005025-85,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE TETTAMANTI M.DE MARCHI ONLUS,"Measurable residual disease driven strategy for one or two infusions of non-viral, transposon-manipulated CARCIK-CD19 cells. A Phase II study in pediatric and adult patients with relapsed/refractory B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005025-85,0,0,0 2020-005027-37,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (K...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005027-37,0,0,0 2020-005027-37,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (K...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005027-37,0,0,0 2020-005027-37,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (K...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005027-37,0,0,0 2020-005028-13,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005028-13,0,0,0 2020-005028-13,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005028-13,0,0,0 2020-005028-13,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005028-13,0,0,0 2020-005030-15,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Pfizer Inc.,"AN EXPLORATORY, MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY OF CLINICAL OUTCOMES, TOLERABILITY, AND SAFETY OF 2 DOSES OF ORAL PANTOPRAZOLE IN PEDIATRIC PARTICIPANTS AGED 1 TO 11 YEARS AND 12 TO 17 YEA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005030-15,0,0,0 2020-005034-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HOSPITAL DR JOSEP TRUETA,EFFECT OF DEXAMETASONE ON LOWER LIMB EDEMA IN PATIENTS UNDERTAKEN FOR TOTAL HIP ARTHROPLASTY EFECTO DE LA DEXAMETASONA EN EL EDEMA DE LA EXTREMIDAD INFERIOR EN PACIENTES INTERVENIDOS DE ARTROPLASTI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005034-15,0,0,0 2020-005037-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Národní ústav duševního zdraví,"Psilocybin - a strategy of rapid antidepressant response in depression comorbid with cancer, a randomized double-blind study with the possibility of entering open extension. Psilocybin – strategie ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005037-32,0,0,0 2020-005039-59,1,,,0,1,0,0,0,0,2,0,1,4,0,0,0,0,1,"Pfizer, Inc.","A PHASE 2, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN WITH, OR SEPARATELY FROM, 13-VALENT PNEUMOCOCCAL CONJUGATE VACCI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005039-59,0,1,1 2020-005040-35,1,2022-08-24,2022-08-24,1,0,0,0,0,0,4,0,1,1,0,0,0,0,0,Aarhus University Hospital,The effect of effervescent and buffered alendronate on bone turnover compared to conventional alendronate: A randomized non-inferiority trial Effekten af Binosto® på knogleomsætningen –et non-infer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005040-35,0,0,0 2020-005042-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,IASON GmbH,"Prospective study of added value of florastamin (18F) PET/CT in localisation of clinically significant prostate cancer in patients with PI-RADS≤3 report of multi-parametric MRI, elevated serum PSA lev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005042-42,0,0,0 2020-005045-17,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,AMC,Resuscitation for repair of endothelial permeability in endotoxemia Resuscitatie voor herstel van endotheel permeabiliteit in endotoxemie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005045-17,0,0,0 2020-005048-46,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005048-46,0,0,0 2020-005048-46,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Br...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005048-46,0,0,0 2020-005050-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,"An open label, single-arm, phase 2 study od neoadjuvant nivolumab and nab-paclitaxel before cystectomy for patients with muscle-invasive bladder cancer Studio di Fase II, in aperto, a singolo bracc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005050-20,0,0,0 2020-005051-20,1,,,0,0,0,0,0,1,4,0,0,4,0,0,0,0,0,Institute of Mother and Child,Determination Of Molecular Status And Benefit Of Use Fludeoxyglucose (18F-FDG) In PET/CT imagining In Juvenile Patients With Histiocytosis Oszacowanie profilu molekularnego oraz przydatności i bezp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005051-20,0,0,0 2020-005052-37,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Institute of Mother and Child,Optymalizacja czasu leczenia i dawkowania wemurafenibu u małoletnich pacjentów z opornymi na konwencjonalną terapię rozrostami z komórek histiocytarnych z obecnością mutacji w genie BRAF. Optimaliz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005052-37,0,0,0 2020-005053-25,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,Institute of Mother and Child,Optimalization Of The Time And Dosage Of Trametinib In BRAF Negative Juvenile Patients With Refractory Histiocytosis Or After Failure Of Vemurafenib Treatment. Optymalizacja czasu leczenia i dawkow...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005053-25,0,0,0 2020-005054-19,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,MorphoSys AG,"A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy - IGNAZ",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005054-19,0,0,0 2020-005055-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"An open-label, non-randomized, biopsy-based mechanistic study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome Etude mécani...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005055-20,0,0,0 2020-005059-19,2,2022-09-09,2022-09-09,1,0,0,0,0,0,3,0,1,2,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3B, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF NIMENRIX® IN HEALTHY INFANTS, GIVEN AT 3 AND 12 MONTHS OF AGE BADANIE FAZY 3B PROWADZONE METODĄ OTWARTEJ PRÓBY OCENIAJĄC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005059-19,1,0,0 2020-005061-13,12,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Acceleron Pharma Inc.,An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005061-13,0,0,0 2020-005061-13,12,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,ACCELERON PHARMA INC.,An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005061-13,0,0,0 2020-005068-70,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),NA Etude de la réponse clinique et biologique à l’administration répétée d’interleukine-2 à faible dose chez des patients présentant un diabète de type 1 ayant gardé une sécrétion résiduelle d’insu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005068-70,0,0,0 2020-005069-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Stichting TRICALS Foundation,RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 TRIAL OF TRIUMEQ IN AMYOTROPHIC LATERAL SCLEROSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005069-15,0,0,0 2020-005072-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Vifor (International) Inc.,"A phase 2a, double-blind, randomized, placebo-controlled, ascending dose and maintenance dose, efficacy, and safety study of multiple doses of VIT-2763 in subjects with sickle cell disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005072-34,0,0,0 2020-005073-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universidad Rey Juan Carlos,"Double-blind, randomized, crossover design for evaluation of efficacy and safety of methylphenidate in cognition in patients with Parkinson's disease using electrophysiological measures Ensayo clín...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005073-28,0,0,0 2020-005078-82,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA,Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS mutated in LIquid BIopsy to compare in first-line therapy FOLFIRI plus CetuximAb or BevacizumAb Studio di fase III in pazient...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005078-82,0,0,0 2020-005079-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Hospitalier Universitaire de Bordeaux,"Efficacy and tolerance of the association of baricitinib (4mg) and phototherapy versus phototherapy in adults with progressive vitiligo: a randomized double blind, non comparative phase II study. E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005079-12,0,0,0 2020-005081-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Medical University of Vienna,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of Baricitinib as a Remission-Induction and Glucocorticoid-Sparing Reg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005081-34,0,0,0 2020-005087-66,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Deventer Hospital,The Effect of Enzalutamide on Oxycodone Metabolism in Men with Prostate Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005087-66,0,0,0 2020-005088-30,1,,,0,0,0,0,0,1,2,0,1,0,0,0,0,0,0,Kirsten Grønbæk,STOP-LEUKEMIA: Repurposing metformin as a leukemia-preventive drug in CCUS and LR-MDS STOP-LEUKEMIA: Genanvendelse af metformin som et leukæmi-forbyggende lægemiddel i CCUS og lav-risiko MDS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005088-30,0,0,0 2020-005090-26,1,2022-09-26,2022-09-26,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,LimmaTech Biologics AG,Safety and immunogenicity of a Klebsiella pneumoniae tetravalent bioconjugate vaccine (Kleb4V) administered to healthy adults: A FTIH phase I/II randomized and controlled study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005090-26,0,0,0 2020-005091-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Stichting Catharina Hospital,Signal TrAnsduction Pathway activity analysis for OVarian cancER treatment. STAPOVER study Signaaltransductie pad activiteit analyse voor de behandeling van eierstokkanker. STAPOVER studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005091-36,0,0,0 2020-005092-13,5,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A MULTICENTER, OPEN-LABEL PHASE IV STUDY TO EVALUATE OVERALL HEALTH, PHYSICAL ACTIVITY, AND JOINT OUTCOMES, IN PARTICIPANTS AGED = 13 AND < 70 YEARS WITH SEVERE OR MODERATE HEMOPHILIA A WITHOUT FVIII ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005092-13,0,0,0 2020-005092-13,5,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A MULTICENTER, OPEN-LABEL PHASE IV STUDY TO EVALUATE OVERALL HEALTH, PHYSICAL ACTIVITY, AND JOINT OUTCOMES, IN PARTICIPANTS AGED = 13 AND < 70 YEARS WITH SEVERE OR MODERATE HEMOPHILIA A WITHOUT FVIII ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005092-13,0,0,0 2020-005092-13,5,,,0,0,0,0,0,1,4,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A MULTICENTER, OPEN-LABEL PHASE IV STUDY TO EVALUATE OVERALL HEALTH, PHYSICAL ACTIVITY, AND JOINT OUTCOMES, IN PARTICIPANTS AGED = 13 AND < 70 YEARS WITH SEVERE OR MODERATE HEMOPHILIA A WITHOUT FVIII ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005092-13,0,0,0 2020-005096-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset,"Utvärdering av två kortison behandlingsstrategier hos patienter med nydiagnostiserad, tidigare obehandlad reumatoid artrit: en randomiserad, öppen, non-inferiority klinisk studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005096-12,0,0,0 2020-005097-10,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Naïve to Biologic Disease-m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005097-10,0,0,0 2020-005097-10,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Naïve to Biologic Disease-m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005097-10,0,0,0 2020-005098-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II,"Novel therapeutic strategies to reduce coronary microvascular obstruction and to OPTImize non-culprit stenoses revascularization in ST-Elevation acute Myocardial Infarction Randomized, no-profit, ope...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005098-29,0,0,0 2020-005099-36,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"POETYK PsA-2 (055) - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Participants with Active Psoriatic Arthritis (PsA) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005099-36,0,0,0 2020-005099-36,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"POETYK PsA-2 (055) - A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Participants with Active Psoriatic Arthritis (PsA) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005099-36,0,0,0 2020-005100-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Dijon Bourgogne,Evaluation Médicoéconomique de l’iMplant d’Acétonide de fluocinolone versus l’implant de dexaméthasone dans l’œdème maculaire diabétique résistant,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005100-18,0,0,0 2020-005101-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AGO Research GmbH,"Window-of-opportunity proof-of-concept, non-randomized, open-label phase II trial of Olaparib given alone (cohort A) or in combination with Durvalumab (cohort B) prior to primary debulking surgery in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005101-12,0,0,0 2020-005103-39,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Avalyn Pharma, Inc.","Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005103-39,0,0,0 2020-005104-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Noorik Biopharmaceuticals AG,"A randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of ambrisentan in patients with severe COVID-19 Randomizované, dvojito zaslepené, placebom kontrolované klin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005104-20,0,0,0 2020-005106-25,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced Ha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005106-25,0,0,0 2020-005106-25,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced Ha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005106-25,0,0,0 2020-005107-40,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Syndax Pharmaceuticals, Inc.","AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005107-40,0,0,0 2020-005107-40,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"SYNDAX PHARMACEUTICALS, INC.","AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005107-40,0,0,0 2020-005108-21,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Dong-A ST Co. Ltd.,"A Randomized, Double-Blind, Multicentric, Parallel Group Therapeutic Equivalence Study Comparing Efficacy, Safety and Immunogenicity of Subcutaneous DMB-3115 and EU Sourced Stelara® in Patients with M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005108-21,0,0,0 2020-005110-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA,Pharmacodynamic and pleiotropic effects of Rivaroxaban in Coronary Artery Disease and Atrial Fibrillation Effetti farmacodinamici e pleiotropici di Rivaroxaban in pazienti con coronaropatia e fibri...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005110-17,0,0,0 2020-005111-51,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,Amgen Inc.,"A Multicenter, Open-label, Single-arm, Study to Evaluate Safety and Tolerability of Repatha in Patients with Homozygous Familial Hypercholesterolemia (HoFH) in India",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005111-51,0,1,1 2020-005114-18,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2, Multicenter, Multi Arm, Study to Evaluate Pembrolizumab (MK- 3475) or MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) in Participants with Microsatellite Instability-High (MSI-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005114-18,0,0,0 2020-005114-18,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 2, Multicenter, Multi Arm, Study to Evaluate Pembrolizumab (MK- 3475) or MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) in Participants with Microsatellite Instability-High (MSI-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005114-18,0,0,0 2020-005116-21,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Certa Therapeutics Pty Ltd,"A phase II, randomised, double blind, placebo-controlled study of the pharmacokinetics, pharmacodynamic effects, and safety, of oral FT011 in participants with diffuse systemic sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005116-21,0,0,0 2020-005117-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"InnoCare Pharma, Inc.","A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005117-41,0,0,0 2020-005122-28,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,AB Science,"A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous of AB8939 in patients with Relapsed/Refractory Acute Myeloid Leukemia Estudio de fase I/II para evaluar ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005122-28,0,0,0 2020-005123-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Oslo University Hospital,"A randomized, double-blind, parallel-group non-inferiority phase III withdrawal trial of paracetamol versus placebo in conjunction with opioids for moderate to severe cancer-related pain",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005123-36,0,0,0 2020-005126-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Liège,Comparison of ultrasound-guided PENG block and supra-inguinal fascia iliaca compartment block for postoperative pain and early motor recovery after total hip arthroplasty: a randomized controlled non-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005126-28,0,0,0 2020-005128-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Vilnius University Hospital Santaros klinikos,An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia − An open-label randomized controlled study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005128-12,0,0,0 2020-005129-99,1,,,0,0,0,0,0,1,2,0,0,1,1,1,0,1,1,VectivBio AG,"A multicenter, open-label, metabolic balance study to evaluate the effects of apraglutide on intestinal absorption in adult subjects with short bowel syndrome, intestinal failure (SBS-IF), and colon-i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005129-99,0,0,0 2020-005130-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Nicolaus Copernicus University in Torun,"Evaluation of safety and efficacy of two ticagrelor-based de-escalation antiplatelet strategies in acute coronary syndrome: the randomized, multicentre, double-blind ELECTRA RCT study. Ocena bezp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005130-15,0,0,0 2020-005131-74,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER,"Phase II, single-arm, open-label interventional clinical trial to evaluate the role of anthracycline infusion after radiotherapy (RT) in pediatric and young adult patients with glioblastoma (pGBM) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005131-74,0,0,0 2020-005134-15,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,University Medical Center Utrecht,The bilateral sentinel node detection rate of fluorescent indocyanine green compared to 99mTc and blue dye in the sentinel node procedure in stage I-IIA cervical cancer De bilaterale schildwachtkli...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005134-15,0,0,0 2020-005135-73,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Biohorm, S.L.","A Randomised, Double-blind, Two-arm, Parallel Groups, Multicentre Study to evaluate the efficacy and safety of a Fixed Dose Combination of Rupatadine and Montelukast vs. Rupatadine in adult patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005135-73,0,0,0 2020-005136-30,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005136-30,0,0,0 2020-005136-30,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005136-30,0,0,0 2020-005136-30,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005136-30,0,0,0 2020-005141-16,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Erasmus MC,Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005141-16,0,0,0 2020-005149-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University of Vienna,"Preclinical antiplatelet treatment with Cangrelor in patients presenting with ST-Elevation myocardial infarction: a randomized, double-blind, placebo-controlled pilot trial Präklinische thrombozyt...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005149-18,0,0,0 2020-005156-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA,AlteRnative antIthrombotic pathwayS in acutE myocardial infarction: a randomized pilot trial Meccanismi antitrombotici alternativi nell'infarto miocardico acuto - uno studio pilota randomizzato,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005156-38,0,0,0 2020-005157-24,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,UMC Utrecht,[18F]mFBG PET-CT imaging of pheochromocytoma [18F]mFBG PET-CT feochromocytoom beeldvorming,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005157-24,0,0,0 2020-005165-14,1,2021-11-06,2021-11-06,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Teikoku Seiyaku Co Ltd.,"Randomized, controlled, double-blind, multi-center trial to evaluate the Randomisierte, kontrollierte, doppelblinde, multizentrische Studie zur Bewertung der Wirksamkeit und Sicherheit eines Esfl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005165-14,0,0,0 2020-005169-15,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"GB002, Inc.",An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005169-15,0,0,0 2020-005170-10,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE RICERCA TRASLAZIONALE (FORT),"A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-line therapy in metastatic non-small-cell lung cancer progress...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005170-10,0,0,0 2020-005173-28,11,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Blueprint Medicines Corporation,"A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005173-28,0,0,0 2020-005173-28,11,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,BLUEPRINT MEDICINES CORPORATION,"A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005173-28,0,0,0 2020-005174-94,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.","A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geograph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005174-94,0,0,0 2020-005177-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Bispebjerg Hospital,Preoperative Viscous Lidocaine for Upper Gastrointestinal Endoscopy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005177-27,0,0,0 2020-005182-14,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Alligator Bioscience AB,An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma Étude de phase Ib/II en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005182-14,0,0,0 2020-005186-13,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005186-13,0,0,0 2020-005187-63,2,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Future Medicine Co., Ltd.","A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults with Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005187-63,0,0,0 2020-005189-32,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,CHRU de Brest,Contribution of indocyanine green angiography in the detection of parathyroids and the prevention of hypoparathyroidism post total thyroidectomy Apport de l’angiographie au vert d’indocyanine dans ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005189-32,0,0,0 2020-005191-35,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER",LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005191-35,0,0,0 2020-005191-35,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Eli Lilly and Company,LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005191-35,0,0,0 2020-005191-35,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Lilly SA,LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005191-35,0,0,0 2020-005193-94,5,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Wave Life Sciences UK Limited,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontote...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005193-94,0,0,0 2020-005194-27,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Zealand Pharma A/S,"A Single-Center Phase 3b Trial Investigating the Long-term Effect on Intestinal Absorption, Nutritional Status and Long-Term Safety of treatment with Glepaglutide in Patients with Short Bowel Syndrome...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005194-27,0,0,0 2020-005197-10,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Viracta Therapeutics, Inc.","An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005197-10,0,0,0 2020-005198-29,8,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"CymaBay Therapeutics, Inc.",ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005198-29,0,0,0 2020-005205-42,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Amgen, Inc.","A Multicenter, Randomized, Double-blinded Study Evaluating the Pharmacokinetics, Efficacy and Safety of Multiple Switches Between Ustekinumab and ABP 654 Compared With Continued Use of Ustekinumab in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005205-42,0,0,0 2020-005210-18,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Uppsala University,"EFFIPEC – Efficacy of Hyperthermic Intraperitoneal Chemotherapy Single-arm Phase I study, followed by an open-label, randomized, controlled registry-based Phase III trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005210-18,0,0,0 2020-005212-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Celgene International II Sàrl,"A Phase 2, Multicenter, Global, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Cendakimab (CC-93538) in Adult Subjects with Moderate to Sever...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005212-22,0,0,0 2020-005213-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SPECTRUM PHARMACEUTICALS,An Open-Label Extension Study to Allow Continued Dosing and/or Follow-up of Patients who have had Previous Exposure to Poziotinib Studio di estensione in aperto per consentire la prosecuzione del t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005213-40,0,0,0 2020-005214-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Vilnius University Hospital Santaros klinikos,An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients without Pneumonia − An open-label randomized controlled study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005214-18,0,0,0 2020-005215-46,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Department of Neurosurgery, Medical University of Vienna",Intraoperative application of nimodipine to the facial and cochlear nerves during vestibular schwannoma resection to avoid spasm-related postoperative facial paralysis and deafness - a prospective ran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005215-46,0,0,0 2020-005217-41,1,2022-08-15,2022-08-15,1,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Lead Chemical Company Ltd,"Randomized, controlled, multi-center trial to evaluate the efficacy and safety of a Flurbiprofen 40 mg cutaneous hydrogel medicated plaster vs. placebo and vs. a marketed active comparator in the loca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005217-41,0,0,0 2020-005224-12,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Haga Teaching Hospital,"Elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis using tacrolimus, a drug - drug interaction study Elexacaftor/tezacaftor/ivacaftor in patienten met cystic fibrosis die tacrolimus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005224-12,0,0,0 2020-005225-81,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,LYSARC,A PHASE II OPEN-LABEL STUDY EVALUATING VALEMETOSTAT TOSYLATE AS A SINGLE AGENT IN PATIENTS WITH RELAPSE/REFRACTORY B-CELL LYMPHOMA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005225-81,0,0,0 2020-005226-28,3,2021-03-12,2021-03-12,1,0,0,0,0,0,3,0,1,1,1,0,1,0,1,ASTRAZENECA AB,"A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005226-28,0,0,0 2020-005226-28,3,2021-03-12,2021-03-12,1,0,0,0,0,0,3,0,1,1,1,0,1,0,1,AstraZeneca AB,"A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005226-28,0,0,0 2020-005227-37,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Olatec Therapeutics LLC,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Ear...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005227-37,0,0,0 2020-005229-95,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Passage Bio, Inc.","A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of PBKR03 Administered to Pediatric Subjects with Early Infantile Krabbe Diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005229-95,0,0,0 2020-005230-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación GECP,"A Phase II study of pembrolizumab, lenvatinib and chemotherapy combination in first line extensive-stage small cell lung cancer (ES-SCLC) Ensayo clínico Fase II de combinación de pembrolizumab, len...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005230-15,0,0,0 2020-005231-78,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005231-78,0,0,0 2020-005231-78,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005231-78,0,0,0 2020-005232-30,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Salix Pharmaceuticals Inc.,"A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects with Mild to Moderate Ulcerative Colitis (UC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005232-30,0,0,0 2020-005232-30,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Salix Pharmaceuticals, Inc.","A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects with Mild to Moderate Ulcerative Colitis (UC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005232-30,0,0,0 2020-005234-15,3,,,0,0,1,0,0,2,1,0,0,3,0,0,0,0,1,Blueprint Medicines Corporation,"A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005234-15,0,0,0 2020-005234-15,3,,,0,0,1,0,0,2,1,0,0,3,0,0,0,0,1,BLUEPRINT MEDICINES CORPORATION,"A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005234-15,0,0,0 2020-005239-53,4,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,F. Hoffman-La Roche Ltd.,"PHASE III RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005239-53,0,0,0 2020-005239-53,4,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"PHASE III RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005239-53,0,0,0 2020-005239-53,4,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"PHASE III RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005239-53,0,0,0 2020-005241-16,1,2022-06-12,2022-06-12,1,0,0,0,0,0,2,0,1,1,0,0,0,0,0,Center for Clinical Metabolic Research at Herlev-Gentofte Hospital,Ready-to-use dasiglucagon for the treatment of postprandial hypoglycaemia in Roux-en-Y gastric bypass operated patients RTU-behandling med dasiglucagon ved postprandial hypoglykæmi efter Roux-en-Y ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005241-16,0,0,0 2020-005242-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA USL DI BOLOGNA,FIBRINOGEN REPLACEMENT TO PREVENT INTRACRANIAL HAEMORRHAGE IN ISCHEMIC STROKE PATIENTS AFTER THROMBOLYSIS: A PILOT PROBE RANDOMIZED CONTROLLED TRIAL SOMMINISTRAZIONE DI FIBRINOGENO PER LA PREVENZIO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005242-41,0,0,0 2020-005246-42,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,INTAS PHARMACEUTICALS LIMITED,"A Multicenter, Three- arm, Double- blind, Double dummy, Parallel-group, placebo controlled Study for efficacy and safety evaluation of prolonged release formulation of Betahistine PR 48 mg once daily ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005246-42,0,0,0 2020-005263-31,3,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,NTC SRL,"Assessment of the effects and tolerability of RD03/2016 (Levofloxacin; Ketorolac Trometamol 0.5+0.5% w/v eye drops solution) for the treatment of bacterial conjunctivitis in adults: a multicentre, ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005263-31,0,0,0 2020-005263-31,3,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,NTC s.r.l.,"Assessment of the effects and tolerability of RD03/2016 (Levofloxacin; Ketorolac Trometamol 0.5+0.5% w/v eye drops solution) for the treatment of bacterial conjunctivitis in adults: a multicentre, ran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005263-31,0,0,0 2020-005265-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Gilead Sciences, Inc.",A Phase 2 Multi-Arm Study of Magrolimab in Patients with Solid Tumors Estudio de fase 2 de multiples brazos de Magrolimab en pacientes con tumores solidos,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005265-14,0,0,0 2020-005266-34,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Ultragenyx Pharmaceutical Inc.,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Seamless, Adaptive, Safety, Dose-finding, and Phase 3 Clinical Study of UX701 AAV-mediated Gene Transfer for the Treatment of Wilson Diseas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005266-34,0,0,0 2020-005269-15,9,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR TREATMENT OF RET-MUTATED MEDULLARY THYROID CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005269-15,0,0,0 2020-005269-15,9,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR TREATMENT OF RET-MUTATED MEDULLARY THYROID CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005269-15,0,0,0 2020-005270-10,1,2022-09-01,2022-09-01,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,LABORATOIRES SMB S.A,"A randomized, partially blinded, parallel study to evaluate the effects of nacystelyn in combination with isotretinoin in the treatment of recalcitrant acne vulgaris.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005270-10,0,0,0 2020-005271-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Erasmus MC, Department of Dermatology",Rediscovery of metformin for the chronic disabling auto-inflammatory disease hidradenitis suppurativa Herontdekking van metformine als behandeling voor de chronische huidziekte hidradenitis suppura...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005271-12,0,0,0 2020-005273-27,4,,,0,0,0,0,0,0,3,0,2,0,0,0,0,0,1,Janssen Vaccines & Prevention B.V,"Randomized, Double-Blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Path...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005273-27,0,0,0 2020-005278-86,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.,Efficacy and safety of the combination of ibuprofen and paracetamol versus ibuprofen in monotherapy in acute Low Back Pain (LBP) Efficacia e sicurezza della combinazione di ibuprofene e paracetamol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005278-86,0,0,0 2020-005279-11,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Amgen, Inc.","A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (INN Sotorasib) for the Treatment of Subjects in Selected European Countries with Previously Treated Locally Advanced and Unr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005279-11,0,0,0 2020-005279-11,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AMGEN INC.,"A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (INN Sotorasib) for the Treatment of Subjects in Selected European Countries with Previously Treated Locally Advanced and Unr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005279-11,0,0,0 2020-005280-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Eurecat,"Phase IV, single-center, randomized and open-label study to evaluate the impact of early treatment with a combination of an inhaled corticosteroid and a long-acting β2 adrenergic agonist (budesonide /...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005280-31,0,0,0 2020-005281-34,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novo Nordisk A/S,"A 52 week study comparing the efficacy and safety of once weekly IcoSema and once weekly insulin icodec, both treatment arms with or without oral anti diabetic drugs, in participants with type 2 diabe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005281-34,0,0,0 2020-005286-13,3,,,0,0,0,0,0,1,0,0,0,3,0,0,0,0,1,"Global Blood Therapeutics, Inc.","A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005286-13,0,0,0 2020-005286-13,3,,,0,0,0,0,0,1,0,0,0,3,0,0,0,0,1,"GLOBAL BLOOD THERAPEUTICS, INC.","A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005286-13,0,0,0 2020-005287-60,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"GLOBAL BLOOD THERAPEUTICS, INC.","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso occlusive Crises",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005287-60,0,0,0 2020-005287-60,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Global Blood Therapeutics, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso occlusive Crises",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005287-60,0,0,0 2020-005288-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Rouen,"Efficacy of a personalized caplacizumab regimen based on ADAMTS-13 activity monitoring in adult acquired thrombotic thrombocytopenic purpura: A phase II, multicenter non-inferiority single-arm study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005288-30,0,0,0 2020-005289-32,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Global Blood Therapeutics, Inc.",An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005289-32,0,0,0 2020-005289-32,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"GLOBAL BLOOD THERAPEUTICS, INC.",An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005289-32,0,0,0 2020-005291-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AOU POLICLINICO DI MODENA,A multicenter randomized trial to evaluate the efficacy of tocilizumab in patients with severe Coronavirus Disease 2019 (Covid-19) pneumonia failing glucocorticoids. Studio multicentrico randomizza...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005291-35,0,0,0 2020-005297-10,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Cellectar Biosciences, Inc.","An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005297-10,0,0,0 2020-005298-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St. Antonius Hospital,Monitoring the effect of oral anticoagulants during percutaneous coronary intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005298-29,0,0,0 2020-005299-36,4,2022-03-18,2022-03-18,3,0,0,1,0,0,1,0,0,1,1,1,0,0,1,ExeVir Bio BV,"A 2-part Clinical Study Including a First-in-Human, Open-label, Single Ascending Dose Part (Phase 1) Followed by a Randomised, Double-blind, Placebo-controlled Part (Phase 2) to Evaluate the Efficacy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005299-36,0,0,0 2020-005299-36,4,2022-03-18,2022-03-18,3,0,0,1,0,0,1,0,0,1,1,1,0,0,1,ExeVir Bio,"A 2-part Clinical Study Including a First-in-Human, Open-label, Single Ascending Dose Part (Phase 1) Followed by a Randomised, Double-blind, Placebo-controlled Part (Phase 2) to Evaluate the Efficacy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005299-36,0,0,0 2020-005300-19,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Medical University Vienna,Intracochlear application versus round window instillation of Triamcinolone acetonide in patients with sudden sensorineural hearing loss-a comparative study Intracochleäre Applikation versus Rundf...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005300-19,0,0,0 2020-005303-39,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to Bio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005303-39,0,0,0 2020-005303-39,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to Bio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005303-39,0,0,0 2020-005305-54,1,2021-07-15,2021-07-15,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,"Corvus Pharmaceuticals, Inc.","Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalize...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005305-54,0,0,0 2020-005306-25,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,PIrfenidone to prevent fibrOsis in ARDS. A RaNdomizEd controllEd tRial (PIONEER) GR-2019-12371063 PIrfenidone to prevent fibrOsis in ARDS. A RaNdomizEd controllEd tRial (PIONEER) GR-2019-12371063,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005306-25,0,0,0 2020-005308-21,4,,,0,0,0,0,0,0,3,0,2,0,0,0,0,0,1,Novo Nordisk A/S,"A 52 week study comparing the efficacy and safety of once weekly IcoSema and once weekly semaglutide, both treatment arms with or without oral anti diabetic drugs, in participants with type 2 diabetes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005308-21,0,0,0 2020-005309-18,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novo Nordisk A/S,"A 52 week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units/mL combined with insulin aspart, both treatment arms with or without oral anti diabetic dr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005309-18,0,0,0 2020-005309-18,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NOVO NORDISK. S.P.A.,"A 52 week study comparing the efficacy and safety of once weekly IcoSema and daily insulin glargine 100 units/mL combined with insulin aspart, both treatment arms with or without oral anti diabetic dr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005309-18,0,0,0 2020-005315-44,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005315-44,0,0,0 2020-005315-44,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005315-44,0,0,0 2020-005317-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Odense University Hospital - Department of Cardiology,Empagliflozin to elderly and obese patients with cardiovascular disease (EMPIRE II): A randomized controlled trial Effekten af Empagliflozin hos patienter med hjertekarsygdom og risiko for at udvik...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005317-40,0,0,0 2020-005319-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación Cínic per a la Reserca Biomèdica,EFFICACY AND SAFETY OF THE INTRATRACHEAL ADMINISTRATION OF BUDESONIDE WITH SURFACTANT IN VERY PRETERM INFANTS TO PREVENT BRONCHOPULMONARY DYSPLASIA: RANDOMIZED CLINICAL TRIAL EFICACIA Y SEGURIDAD D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005319-33,0,0,0 2020-005328-13,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005328-13,0,0,0 2020-005328-13,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005328-13,0,0,0 2020-005330-14,1,,,0,1,0,0,0,0,2,0,1,1,1,1,0,1,1,Janssen Vaccines & Prevention B.V.,"An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants. Estudio en fase II, abierto para evaluar la seguridad, la re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005330-14,0,0,0 2020-005331-78,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A Phase 2 non-randomized, open-label, multi-cohort, multi center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005331-78,0,0,0 2020-005331-78,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Phase 2 non-randomized, open-label, multi-cohort, multi center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005331-78,0,0,0 2020-005332-30,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Phase 1/2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR- 707) combined with cemiplimab for the treatment of participants with advance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005332-30,0,0,0 2020-005337-33,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,University Medical Center Utrecht,EXtended use of FOsfomycin for the treatment of CYstitis in primary care,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005337-33,0,0,0 2020-005339-56,6,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A 52 week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005339-56,0,0,0 2020-005339-56,6,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"A 52 week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005339-56,0,0,0 2020-005339-56,6,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A 52 week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005339-56,0,0,0 2020-005340-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospitals Leuven,Duodenal neuro-immune interactions and effects of proton pump inhibitors in functional dyspepsia Duodenale neuro-immuun interacties en effect van proton pomp inhibitoren in functionele dyspepsie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005340-39,0,0,0 2020-005343-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IRCCS ISTITUTO ORTOPEDICO GALEAZZI S.P.A,Effect of the antiresorptive treatment with alendronate versus no treatment after denosumab and aromatase inhibitors discontinuation in low fracture risk osteopenic postmenopausal women with non metas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005343-23,0,0,0 2020-005344-27,4,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"SK Life Science, Inc.",Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-onset (Focal) Seizures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005344-27,0,0,0 2020-005364-57,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Shanghai Henlius Biotech. Inc.,"A Phase 3, Two-part (Open-label Followed by Randomized Double-masked Active Controlled) Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection with Ranibizumab in S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005364-57,0,0,0 2020-005366-34,6,2021-10-13,2021-10-13,6,1,0,0,0,0,2,0,0,1,0,0,0,0,1,F. Hoffmann La Roche Ltd.,"A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, PHARMACOKINETICS, AND EFFICACY OF RO7496998 (AT-527) IN NON-HOSPITALIZED ADULT PATIENTS WITH ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005366-34,0,0,0 2020-005382-14,1,2021-11-28,2021-11-28,1,0,0,0,0,0,4,0,1,1,0,0,0,0,0,"Associate Professor, Consultant Jens Børglum",Does administration of the Transmuscular Quadratus lumborum block cause quadriceps muscle weakness? A randomised double-blinded volunteer study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005382-14,0,0,0 2020-005384-31,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Rigshospitalet,A single blinded multicenter randomized study comparing intubating conditions during rapid sequence induction with either suxamethonium 1.0 mg/kg or rocuronium 1.0 mg/kg in elderly patients (≥ 80 year...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005384-31,0,0,0 2020-005386-13,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Arcus Biosciences Inc,"A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer Estudio de plataforma en f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005386-13,0,0,0 2020-005386-13,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Arcus Biosciences, Inc.","A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer Estudio de plataforma en f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005386-13,0,0,0 2020-005393-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO EUROPEO DI ONCOLOGIA,An Italian multicenter phase II trial of Metronomic Temozolomide in unfit patients with advanced neuroendocrine neoplasms (NENs): MeTe study Studio italiano multicentrico di fase II con Temozolomid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005393-10,0,0,0 2020-005395-35,1,,,0,1,0,0,0,0,2,0,0,3,0,0,0,0,0,Bill & Melinda Gates Medical Research Institute,"A randomized, controlled, Phase 2b study to evaluate safety and efficacy of rivaroxaban (Xarelto®) for high risk people with mild COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005395-35,0,0,0 2020-005407-38,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005407-38,0,0,0 2020-005407-38,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005407-38,0,0,0 2020-005409-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Copenhagen University Hospital, Rigshospitalet",The PREVENT AGITATION trial II – children ≤1 year,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005409-26,0,0,0 2020-005410-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie Samodzielny Publiczny Zakład Opieki Zdrowotnej,"Multicentre, randomized, double-blind, placebo-controlled, non-commercial clinical trial to evaluate the efficacy and safety of specific anti-SARS-CoV-2 immunoglobulin in the treatment of COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005410-18,0,0,0 2020-005412-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Ghent University Hospital,Effect of dobutamine on hepatic blood flow during goal-directed hemodynamic therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005412-21,0,0,0 2020-005416-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Gilead Sciences Inc.,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005416-22,0,0,0 2020-005423-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Raincy Montfermeil intercommunal hospital group,Impact évaluation of an ivermectin single dose administration in the early phase of COVID-19 to negative viral load in SARS-CoV-2 determined by RT-PCR_ IVERCoV. Évaluation de l'impact de l'adminis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005423-37,0,0,0 2020-005427-36,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Erasmus MC Cancer Center,"A multicenter, open label non-randomized phase I/II dose escalation study with extension cohort to determine the safety, tolerability and immune modulating effects of the therapeutic LRPAP1 synthetic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005427-36,0,0,0 2020-005429-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,European Organisation for Research and Treatment of Cancer EORTC,Romiplostim for thrombocytopenia induced by lomustine at first progression of MGMT promoter-methylated glioblastoma: a randomized phase II open label multicenter study Romiplostim para tratar la t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005429-10,0,0,0 2020-005431-70,7,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Crinetics Pharmaceuticals, Inc.","A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Treated with Long-acting Somatostatin Receptor Ligands",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005431-70,0,0,0 2020-005435-75,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novo Nordisk A/S,Protocol Title: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005435-75,0,0,0 2020-005437-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005437-32,0,0,0 2020-005438-14,4,,,0,0,1,0,0,0,2,0,0,4,0,0,0,0,1,Takeda,"A Phase 2, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten-Fr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005438-14,0,1,0 2020-005438-14,4,,,0,0,1,0,0,0,2,0,0,4,0,0,0,0,1,TAKEDA,"A Phase 2, Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-062 for the Treatment of Active Celiac Disease in Subjects Attempting a Gluten-Fr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005438-14,0,1,0 2020-005442-42,2,,,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,BioNTech SE,"A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBOCONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A SARS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005442-42,0,0,0 2020-005443-23,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Hospital Sant Joan de Reus,Comparative study between two ultrasound-guided peripheral blocks for postoperative analgesia of primary total knee arthroplasty Estudio comparativo entre dos bloqueos periféricos ecoguiados para a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005443-23,0,0,0 2020-005444-35,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,BioNTech SE,"A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEALTHY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005444-35,0,0,0 2020-005445-16,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,"Erasmus MC, University Medical Center Rotterdam","Fasting before live kidney donation, effect on donor wellbeing and postoperative recovery Preoperatief vasten voor levende nierdonatie, effect op donor welzijn en postoperatief herstel.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005445-16,0,0,0 2020-005447-23,1,2022-03-21,2022-03-21,1,0,0,0,0,0,2,0,0,1,1,1,0,0,0,"Amsterdam Universitair Medische Centra, location VUmc","A randomised, double-blind, placebo-controlled study to investigate the safety and efficacy of intravenous imatinib mesilate (Impentri®) in subjects with Acute Respiratory Distress Syndrome induced by...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005447-23,0,0,0 2020-005448-48,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE III, NON-INFERIORITY, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND RADIOLOGICAL AND CLINICAL EFFECTS OF SUBCUTANE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005448-48,0,0,0 2020-005448-48,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, NON-INFERIORITY, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND RADIOLOGICAL AND CLINICAL EFFECTS OF SUBCUTANE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005448-48,0,0,0 2020-005448-48,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, NON-INFERIORITY, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP, MULTICENTER STUDY TO INVESTIGATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND RADIOLOGICAL AND CLINICAL EFFECTS OF SUBCUTANE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005448-48,0,0,0 2020-005449-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hôpital Fondation A. de Rothschild / Service de recherche clinique,Spontaneous retinal artery pulses as a prognostic determinant of central retinal vein occlusions in patients with and without intravitreal aflibercept injections. Pulsations artérielles rétinienne...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005449-18,0,0,0 2020-005450-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,SPACe 2 STAR : Safety and pharmacokinetics of antipsychotics in children 2. Studying TDM in An RCT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005450-18,0,0,0 2020-005452-38,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005452-38,0,0,0 2020-005452-38,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005452-38,0,0,0 2020-005457-25,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Perception Neuroscience, Inc","A randomized, placebo-controlled, double-blind study to assess the safety and efficacy of intravenous PCN-101 in treatment-resistant depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005457-25,0,0,0 2020-005457-25,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Perception Neuroscience,"A randomized, placebo-controlled, double-blind study to assess the safety and efficacy of intravenous PCN-101 in treatment-resistant depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005457-25,0,0,0 2020-005458-97,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Janssen Vaccines & Prevention B.V.,"A Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of Lower Respiratory Tract Disease Caused by RSV in Adults Aged 60 Years and O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005458-97,0,0,0 2020-005461-14,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Righospitalet,PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE INTENSITY VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA INCLUDING COMPREHENSIVE EXPLORATORY AML PROFILING AND EVALUATION OF EX VIVO DRUG...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005461-14,0,0,0 2020-005461-14,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Rigshospitalet,PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE INTENSITY VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA INCLUDING COMPREHENSIVE EXPLORATORY AML PROFILING AND EVALUATION OF EX VIVO DRUG...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005461-14,0,0,0 2020-005462-34,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Thoraxklinik Heidelberg gGmbH,"An open-label, prospective, single centre study of the effects of Riociguat on RIght VEntricular size and function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005462-34,0,0,0 2020-005465-13,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Radboudumc,Cemiplimab treatment in patients with locally advanced and metastatic secondary angiosarcomas Cemiplimab in de behandeling van lokaal vergevorderde en gemetastaseerde secundaire angiosarcomen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005465-13,0,0,0 2020-005483-66,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,UNIVERSITÀ DEGLI STUDI MILANO BICOCCA,ERAS versus ERAS plus arTificiAl nutrition in open pancreatoduodenectomy (The RASTA trial) ERAS versus ERAS più nutrizione artificiale nella duodenocefalopancreasectomia laparoscopica (Lo studio RA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005483-66,0,0,0 2020-005484-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU CAEN Normandie,SPironolactONe for the maintenance of Sinus Rhythm in hypertensive patients with atrial fibrillation and preserved left ventricular ejection fraction: a Prospective Randomized Open Blinded End-point (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005484-31,0,0,0 2020-005486-14,1,2022-01-04,2022-01-04,1,0,0,0,0,0,4,0,1,1,1,1,0,0,0,Wroclaw Medical University,Using of convalescent plasma in the treatment of COVID-19 patients with metabolomic and laboratory evaluation of the progress of plasma therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005486-14,0,0,0 2020-005492-12,5,2022-09-02,2022-09-02,1,0,0,1,0,0,1,0,0,2,1,0,0,0,1,"Black Diamond Therapeutics, Inc.","MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005492-12,1,0,0 2020-005492-12,5,2022-09-02,2022-09-02,1,0,0,1,0,0,1,0,0,2,1,0,0,0,1,"Black Diamond Therapeutics, Inc","MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005492-12,1,0,0 2020-005493-10,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Moleculin Biotech, Inc.",Phase 1/2 Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML) that is Refractory to or Relapsed after Induction Therapy.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005493-10,0,0,0 2020-005496-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Modern Biosciences Ltd.,"A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2b Study to Investigate the Efficacy and Safety of MBS2320 With Background Methotrexate (MTX) in Participants With Moderate to Severe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005496-13,0,0,0 2020-005502-25,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Zealand Pharma A/S,"A 104-Week, Multicenter, Single-Arm, Long-Term, Phase 3 Extension Trial Investigating the Safety and Efficacy of Glepaglutide in Adult Patients with Short Bowel Syndrome (SBS) Completing the EASE SBS ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005502-25,0,0,0 2020-005503-40,1,,,0,0,1,0,0,1,3,0,0,4,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab in Pediatric Participants With Active Juvenile...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005503-40,0,1,1 2020-005506-26,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Antti Väänänen,Spinal fentanyl or epidural analgesia in the early first phase of induced labor Spinaalinen fentanyyli tai epiduraalipuudutus alkuvaiheen synnytyskivunlievityksessä synnytyksen käynnistyksen yhteyd...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005506-26,0,0,0 2020-005512-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3b Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Apremilast for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005512-21,0,0,0 2020-005513-41,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,VectivBio AG,An open-label extension trial to evaluate the long-term safety of apraglutide in short bowel syndrome Estudio de prolongación sin enmascaramiento para evaluar la seguridad a largo plazo de apraglut...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005513-41,0,0,0 2020-005515-51,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University Medical Center Groningen,An explorative and feasibility study of Venetoclax combined with Tamoxifen in patients with relapsed/refractory Diffuse Large B-cell Lymphoma Een verkennend en haalbaarheidsonderzoek van Venetoclax...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005515-51,0,0,0 2020-005518-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Universitätsklinikum Erlangen,U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005518-16,0,0,0 2020-005521-84,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,Long-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel Estudio de seguimiento a largo plazo de participantes tratados previamente con ciltacabtagén autoleucel,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005521-84,0,0,0 2020-005522-28,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.","A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients with Fused in Sarcoma Mutations...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005522-28,0,0,0 2020-005522-28,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"IONIS PHARMACEUTICALS, INC.","A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients with Fused in Sarcoma Mutations...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005522-28,0,0,0 2020-005523-37,1,2022-02-14,2022-02-14,1,0,0,0,0,0,2,0,0,1,1,1,0,0,1,URSAPHARM Arzneimittel GmbH,A prospective controlled proof-of-concept trial to demonstrate anti-viral effects of oral bromelaine in COVID-19 positive patients Eine prospektive kontrollierte Proof-of-Concept-Studie zum Nachwei...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005523-37,0,0,0 2020-005524-11,1,2021-06-02,2021-06-02,1,0,0,0,0,0,4,0,1,1,0,0,1,0,0,Fakultní nemocnice Ostrava,"Pilot, monocentre, phase-IV clnical trial assessing the clinical effect of per oral immunomodulation treatment using the IMUNOR® preparation in the prevention of COVID-19 disease Pilotní monocentri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005524-11,0,0,0 2020-005526-29,1,2021-08-04,2021-08-04,1,0,0,0,0,0,3,0,0,1,1,1,1,0,1,Vanda Pharmaceuticals Inc.,"ODYSSEY: A randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in treating inflammatory lung injury and improving clinical outcomes associated with severe COV...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005526-29,0,0,0 2020-005528-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Viela Bio, Inc.","A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus Estudio de fase II, aleator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005528-12,0,0,0 2020-005530-15,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Farmalíder S.A.,"Randomized, double blind, placebo-controlled, active treatment clinical trial to assess the analgesic efficacy and the safety of an oral ibuprofen (arginine)-tramadol HCI combination administered to p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005530-15,0,0,0 2020-005532-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Toscana Life Sciences Sviluppo,"Randomized, placebo-controlled, double-blind, multicenter, seamless adaptive phase II-III clinical trial to select the dose and evaluate safety and efficacy of MAD0004J08 monoclonal antibody in adult ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005532-29,0,0,0 2020-005534-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Proveca Pharma LTD,"Double-blind, placebo-controlled, randomized clinical trial comparing the efficacy and safety of Sialanar plus oral rehabilitation against placebo plus oral rehabilitation for children and adolescents...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005534-15,0,0,0 2020-005537-32,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination with Platinum and Etoposide for the First Line Treatment of Patients with Extensive-stage Small Cell Lung Cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005537-32,0,0,0 2020-005537-32,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination with Platinum and Etoposide for the First Line Treatment of Patients with Extensive-stage Small Cell Lung Cance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005537-32,0,0,0 2020-005539-62,1,2022-01-20,2022-01-20,1,0,0,0,0,0,2,0,0,1,1,1,0,0,1,Mitochon Technologies Kft.,"Phase II/III, multi-centre, double-blind, parallel assignment, randomized, placebo-controlled study to evaluate the preventive effect of BGP-15 on the hospitalisation of newly diagnosed COVID-19 patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005539-62,0,0,0 2020-005541-16,1,2022-09-26,2022-09-26,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,LEO Pharma A/S,"A phase 2a, randomised, double-blind, placebo-controlled, multi-site, proof of concept trial to evaluate the efficacy and safety of LEO 138559 in adult subjects with moderate to severe atopic dermatit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005541-16,0,0,0 2020-005542-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region Västerbotten,Intrathecal contrast-enhanced MRI for investigation of cerebrospinal fluid transportation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005542-42,0,0,0 2020-005544-34,1,2021-06-30,2021-06-30,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,URSAPHARM Arzneimittel GmbH,"Double-blind placebo-controlled proof-of-concept trial to demonstrate the anti-viral efficacy of different doses of azelastine in COVID-19 positive patients. Doppelblinde, Placebo-kontrollierte Pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005544-34,0,0,0 2020-005546-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundacio Clinic per a la Recerca Biomedica,Sentinel lymph node assessment in ovarian cancer. Lymphatic mapping with two tracers and intraoperative lymphoscintigraphy. Evaluación del ganglio centinela en el cáncer de ovario. Estudio del mapa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005546-42,0,0,0 2020-005548-48,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Teva Branded Pharmaceutical Products R&D, Inc.","A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (PROLIA®) in Patients with Postmenopausal Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005548-48,0,0,0 2020-005549-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI,Role of [68Ga]Ga-FAPI PET/CT in oncological patients with doubtful or inconclusive findings at [18F]F-FDG PET/CT Ruolo della PET/TC con 68Ga-FAPI nei pazienti in cui la PET/TC con 18F-FDG sia risul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005549-17,0,0,0 2020-005552-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Västragötalandsregionen, Sahlgrenska Universitetssjukhuset","Vaginal progesterone as luteal support for improvement of live birth in frozen/thawed in-vitro fertilization natural cycles; a multicenter, open, randomized trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005552-38,0,0,0 2020-005553-24,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC","A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Followed by an Open-Label...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005553-24,0,0,0 2020-005554-23,13,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,2,Boehringer Ingelheim Norway KS,A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005554-23,0,0,0 2020-005554-23,13,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,2,BOEHRINGER-INGELHEIM ITALIA S.P.A.,A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005554-23,0,0,0 2020-005554-23,13,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,2,Boehringer Ingelheim Finland Ky,A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005554-23,0,0,0 2020-005554-23,13,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005554-23,0,0,0 2020-005554-23,13,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,2,,A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005554-23,0,0,0 2020-005554-23,13,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,2,"Boehringer Ingelheim Portugal, Lda",A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005554-23,0,0,0 2020-005554-23,13,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,2,SCS Boehringer Ingelheim Comm. V,A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005554-23,0,0,0 2020-005554-23,13,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,2,Boehringer Ingelheim bv Netherlands,A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005554-23,0,0,0 2020-005554-23,13,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,2,Boehringer Ingelheim RCV GmbH & Co KG,A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005554-23,0,0,0 2020-005554-23,13,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,2,"Boehringer Ingelheim España, S.A.",A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005554-23,0,0,0 2020-005554-23,13,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,2,Boehringer Ingelheim RCV GmbH & Co KG,A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005554-23,0,0,0 2020-005554-23,13,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,2,Boehringer Ingelheim BV,A study to evaluate long-term safety of nintedanib in children and adolescents with interstitial lung disease (InPedILD®-ON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005554-23,0,0,0 2020-005557-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospices Civils de Lyon - Direction de la Recherche Clinique et de l'Innovation,Étude pilote visant à évaluer l’efficacité d’un mélange de kétamine/lidocaïne administré par mésothérapie dans la prise en charge des douleurs neuropathiques du Syndrome Douloureux Régional Complexe d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005557-24,0,0,0 2020-005559-19,3,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ADAMED Pharma S.A.,"FRUTI - a phase III, randomized, multicenter, double-blind, active control study to evaluate the efficacy and safety of Furazidin prolonged-release tablets, 200 mg compared with Nitrofurantoin prolong...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005559-19,0,0,0 2020-005561-14,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic He...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005561-14,0,0,0 2020-005561-14,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"An International, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic He...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005561-14,0,0,0 2020-005565-13,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005565-13,0,0,0 2020-005565-13,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Sc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005565-13,0,0,0 2020-005566-33,3,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Sanofi Pasteur,Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to Stamaril® in Adults,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005566-33,0,0,0 2020-005568-79,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Nipocalimab in Adult Participants with Active Lupus Nephritis Um estudo de fase 2, multicêntrico, aleatorizado, de dupl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005568-79,0,0,0 2020-005569-14,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005569-14,0,0,0 2020-005575-12,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Byondis B.V.,"A multicenter, randomized, double-blind, placebo-controlled trial with a single arm run-in period to evaluate the safety and efficacy of sodium thiosulfate (BYON5667) eye drops to reduce ocular toxici...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005575-12,0,0,0 2020-005576-35,1,,,0,0,0,0,0,0,3,0,1,1,1,1,0,1,1,Medicago R&D Inc.,"A Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005576-35,0,0,0 2020-005580-32,1,2022-05-30,2022-05-30,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Medical University of Vienna,Pilot study on silibinin as a possible therapeutic agent for mildly ill COVID-19 patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005580-32,0,0,0 2020-005582-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,Prospective pilot study evaluating a therapeutic synergy between the infusion of CMV-specific immunoglobulins and the level before transplantation of negative gamma delta Vdelta 2 T lymphocytes expres...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005582-13,0,0,0 2020-005587-55,9,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Boehringer Ingelheim España, S.A.","An open-label, long-term extension trial of spesolimab treatment in adult patients with Hidradenitis Suppurativa (HS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005587-55,0,0,0 2020-005587-55,9,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,SCS Boehringer Ingelheim Comm. V,"An open-label, long-term extension trial of spesolimab treatment in adult patients with Hidradenitis Suppurativa (HS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005587-55,0,0,0 2020-005587-55,9,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim,"An open-label, long-term extension trial of spesolimab treatment in adult patients with Hidradenitis Suppurativa (HS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005587-55,0,0,0 2020-005587-55,9,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"An open-label, long-term extension trial of spesolimab treatment in adult patients with Hidradenitis Suppurativa (HS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005587-55,0,0,0 2020-005587-55,9,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"An open-label, long-term extension trial of spesolimab treatment in adult patients with Hidradenitis Suppurativa (HS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005587-55,0,0,0 2020-005587-55,9,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim Norway KS,"An open-label, long-term extension trial of spesolimab treatment in adult patients with Hidradenitis Suppurativa (HS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005587-55,0,0,0 2020-005587-55,9,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"An open-label, long-term extension trial of spesolimab treatment in adult patients with Hidradenitis Suppurativa (HS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005587-55,0,0,0 2020-005587-55,9,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Boehringer Ingelheim France,"An open-label, long-term extension trial of spesolimab treatment in adult patients with Hidradenitis Suppurativa (HS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005587-55,0,0,0 2020-005588-29,6,2021-06-25,2021-10-04,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Boehringer Ingelheim España, S.A.","A Phase II/III seamless, randomised, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for the treatment of symptomati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005588-29,0,0,0 2020-005588-29,6,2021-06-25,2021-10-04,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"A Phase II/III seamless, randomised, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for the treatment of symptomati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005588-29,0,0,0 2020-005588-29,6,2021-06-25,2021-10-04,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,"Boehringer Ingelheim Portugal, Lda","A Phase II/III seamless, randomised, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for the treatment of symptomati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005588-29,0,0,0 2020-005588-29,6,2021-06-25,2021-10-04,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,SCS Boehringer Ingelheim Comm. V,"A Phase II/III seamless, randomised, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for the treatment of symptomati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005588-29,0,0,0 2020-005588-29,6,2021-06-25,2021-10-04,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim,"A Phase II/III seamless, randomised, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for the treatment of symptomati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005588-29,0,0,0 2020-005588-29,6,2021-06-25,2021-10-04,4,1,0,0,0,0,2,0,0,1,1,0,1,0,1,Boehringer Ingelheim B.V.,"A Phase II/III seamless, randomised, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for the treatment of symptomati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005588-29,0,0,0 2020-005591-35,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,Incyte Corporation,"A Phase 1b/2a Basket Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Combination Therapy With the Anti-CD19 Monoclonal Antibody Tafasitamab and the PI3K delta Inhibitor P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005591-35,0,0,0 2020-005591-35,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,INCYTE CORPORATION,"A Phase 1b/2a Basket Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Combination Therapy With the Anti-CD19 Monoclonal Antibody Tafasitamab and the PI3K delta Inhibitor P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005591-35,0,0,0 2020-005595-35,1,2021-04-16,2021-04-16,1,1,0,0,0,0,2,0,1,1,0,0,1,0,0,Centre for Human Drug Research,A dermal inflammatory challenge study to evaluate complement activation in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005595-35,0,0,0 2020-005598-28,5,2022-04-15,2022-04-15,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Adagio Therapeutics Inc,"A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005598-28,1,0,0 2020-005600-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS,LEvOsimendaN vs. Placebo Before Tricuspid VAlve Surgery in Patients with Right Ventricular Dysfunction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005600-19,0,0,0 2020-005602-26,2,2021-11-23,2021-11-23,2,1,0,0,0,0,2,0,0,1,1,1,0,0,1,Flame Biosciences,"A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients with Surgically Resectable Non-Small Cell Lung Cancer Een Twee-cohorten, Fase 2 Onderzoek naar FL-101 als neoadjuvante behan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005602-26,0,0,0 2020-005605-93,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.P.A.,"Efficacy and safety of Silycus® in Cushing’s disease: a multicenter, single arm, open label, dose titration, proof of concept study (Silycus®-21) Efficacia e sicurezza di Silycus® nella malattia di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005605-93,0,0,0 2020-005607-39,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Multicentre, International Study with a Parallel, Randomised, Double blind, Placebo controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005607-39,0,0,0 2020-005607-39,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase III, Multicentre, International Study with a Parallel, Randomised, Double blind, Placebo controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NF...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005607-39,0,0,0 2020-005608-20,4,,,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase I/II, Single-Arm, Open label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged = 1 to < 7 Years with Neurofibroma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005608-20,0,0,0 2020-005608-20,4,,,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase I/II, Single-Arm, Open label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged = 1 to < 7 Years with Neurofibroma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005608-20,0,0,0 2020-005609-20,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase 2 Study of Pembrolizumab (MK-3475) every 6 weeks (Q6W) in Participants with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-ce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005609-20,0,0,0 2020-005609-20,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 2 Study of Pembrolizumab (MK-3475) every 6 weeks (Q6W) in Participants with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-ce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005609-20,0,0,0 2020-005609-20,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Merck Sharp & Dohme Corp.,A Phase 2 Study of Pembrolizumab (MK-3475) every 6 weeks (Q6W) in Participants with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-ce...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005609-20,0,0,0 2020-005611-46,4,2022-10-20,2022-10-20,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Tavanta Therapeutics, Inc.",Phase 3 study investigating the efficacy and safety of TAVT-45 (abiraterone acetate) Granules for Oral Suspension (a novel abiraterone acetate formulation) relative to a reference abiraterone acetate ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005611-46,1,0,0 2020-005618-16,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CuraTeQ Biologics Private Limited,"A Multicenter, Randomised, Double blind, Parallel, Phase III Global Study to Assess the Efficacy and Safety of BP01 (Bevacizumab) when compared to Avastin®-EU in Combination with Carboplatin and Pacli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005618-16,0,0,0 2020-005619-35,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,SINGLE-CELL DEEP PHENOTYPING OF B LYMPHOCYTES TO PERSONALIZE IMMUNOTHERAPY IN PATIENTS WITH MYASTHENIA GRAVIS: CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF RITXUXIMAB IN GENERALIZED ACHR-ANTI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005619-35,0,0,0 2020-005620-12,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator’s Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005620-12,0,0,0 2020-005620-12,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator’s Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005620-12,0,0,0 2020-005624-10,1,2022-02-17,2022-02-17,1,0,0,0,0,0,3,0,0,1,1,1,0,0,0,University Hospital Zurich,ENOXAPARIN FOR PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY PATIENTS WITH CORONAVIRUS: THE MULTICENTER RANDOMIZED CONTROLLED OVID TRIAL Wirksamkeit und Sicherheit eines Blutverdünners (Clexane®) zur V...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005624-10,0,0,0 2020-005626-29,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,A phase II study on trabectedin in combination with PPARg agonist pioglitazone in patients with round cell myxoid liposarcomas or dedifferentiated G1 and G2 liposarcomas with stable disease after a mo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005626-29,0,0,0 2020-005628-12,4,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1/L1- refractory Extensive-Stage Small Cell...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005628-12,0,0,0 2020-005628-12,4,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1/L1- refractory Extensive-Stage Small Cell...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005628-12,0,0,0 2020-005633-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005633-33,0,0,0 2020-005639-65,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama),A randomized phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced BrEasT cancer. “ALPHABET Stu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005639-65,0,0,0 2020-005641-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Medical University of Bialystok,Non-commercial clinical trial of statins CAncer preventive and Pleiotropic TherApy IN smokers with chronic obstructive pulmonary disease (COPD) Clinical part: Atorvastatin effect on reduction of COPD ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005641-17,0,0,0 2020-005642-42,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Kartos Therapeutics, Inc.","An Open-Label, Multicenter, Phase 2 Study Assessing the Safety and Efficacy of KRT-232 or TL-895 in Janus-associated Kinase Inhibitor Treatment-Naïve Myelofibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005642-42,0,0,0 2020-005643-22,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Eidos Therapeutics, Inc.",An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005643-22,0,0,0 2020-005643-22,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Eidos Therapeutics, Inc",An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301) ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005643-22,0,0,0 2020-005647-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Melanoma Institute Australia,"A phase II, open label, randomised trial of ipilimumab and nivolumab with concurrent intracranial stereotactic radiotherapy versus ipilimumab and nivolumab alone in patients with melanoma brain metast...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005647-24,0,0,0 2020-005648-52,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase I, Single-Arm, Sequential Study to Evaluate the Effect of Food on the Gastrointestinal Toxicity and Pharmacokinetics of Selumetinib after Multiple Doses in Adolescent Children with Neurofibrom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005648-52,0,0,0 2020-005649-17,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005649-17,0,0,0 2020-005649-17,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005649-17,0,0,0 2020-005651-21,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Oncorena AB,"A phase I/II, open label, single arm study on safety, tolerability and anti -tumour efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal cell carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005651-21,0,0,0 2020-005653-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Clínica Integral del pie-Ana Sans,Effectiveness of botulinum toxin infiltration in spasticity of the 1st toe in patients with neurological pathology Efectividad de la infiltración con toxina botulínica en la espasticidad del 1º ded...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005653-24,0,0,0 2020-005661-14,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren's syndrome (NEPTUNUS-1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005661-14,0,0,0 2020-005661-14,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren's syndrome (NEPTUNUS-1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005661-14,0,0,0 2020-005682-13,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Radboudumc,Exploratory study into age-related immunological differences related to immunogenicity in influenza vaccination and herpes zoster vaccination Exploratief onderzoek naar leeftijdsgebonden immunolo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005682-13,0,0,0 2020-005708-20,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Gilead Sciences, Inc.",A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005708-20,0,0,0 2020-005712-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Gedeon Richter Ibérica,"Prospective, randomized, multicenter study to compare the efficacy at 52 weeks (1 year) of biosimilar teriparatide and alendronate in the prevention of new morphometric vertebral fractures and / or ag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005712-22,0,0,0 2020-005717-40,1,,,0,0,0,0,0,1,2,0,1,0,0,0,0,0,0,IVI Foundation,Umbilical cord plasma for treating endometrial pathologies (thin endometrium / Ash erman’s syndrome/ endometria atrophy) Plasma rico en plaquetas procedente de cordón umbilical para el tratamiento ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005717-40,0,0,0 2020-005720-11,1,,,0,0,1,0,0,0,2,0,1,4,0,0,0,0,1,Janssen Vaccines & Prevention B.V.,"A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Dose Levels of Ad26.COV2.S Administered as a Two-dose Regimen Fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005720-11,0,1,1 2020-005721-82,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VieCuri,The Gout TrEatment STrategy Project (GO TEST) Overture trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005721-82,0,0,0 2020-005726-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University Innsbruck,An open label signal detection study to evaluate the effects of cariprazine on cognitive functioning in patients with schizophrenia in need of adjustment of oral antipsychotic treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005726-29,0,0,0 2020-005730-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sint Maartenskliniek,"GOut TrEatment STrategy (GO TEST) FINALE study, a multicentre pragmatic randomized superiority trial of continuation versus cessation of urate lowering therapies in gout in remission. Het vergelijk...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005730-15,0,0,0 2020-005731-67,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Haaglanden Medisch Centrum,Complement Inhibition: Attacking the Overshooting Inflammation @fter Subarachnoid Hemorrhage - A phase II trial on the safety and efficacy of C1 esterase inhibitor for the acute management of subarach...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005731-67,0,0,0 2020-005732-29,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Janssen-Cilag International N.V.,"Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005732-29,0,0,0 2020-005732-29,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005732-29,0,0,0 2020-005735-79,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UNICANCER,Treatment with Tucatinib in addition to Pertuzumab and Trastuzumab in patients with HER2-positive metastatic breast cancer after local therapy of isolated brain progression TRAITEMENT PAR TUCATINIB...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005735-79,0,0,0 2020-005738-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Region Skåne,Pivmecillinam with Amoxicillin/clavulanic acid for Step Down Oral Therapy in Febrile UTIs Caused by ESBL-producing Enterobacterales.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005738-13,0,0,0 2020-005740-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu,"Effect of Intravenous FERRic carboxymaltose on mortality and cardiovascular morbidity, and quality of life in iron deficient patients with recent myocardial infarction Wpływ dożylnego leczenia kar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005740-27,0,0,0 2020-005741-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Amsterdam University Medical Centers, location AMC",Hyperbaric OXygen therapy for ACute Acoustic Trauma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005741-17,0,0,0 2020-005745-16,1,2022-01-27,2022-01-27,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Steno Diabetes Center Copenhagen,"Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People with Type 1 Diabetes: A Randomized, Open-Label, Two-Period Crossover Outpatient Study To-ugers afprøv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005745-16,0,0,0 2020-005747-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Nemocnice Agel Ostrava-Vítkovice a.s.,"Use of mucolytic solution before gastroscopy, double-blind, randomized study Použití mukolytického roztoku před gastroskopií, dvojitě zaslepená, randomizovaná studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005747-23,0,0,0 2020-005751-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Blueprint Medicines,Open-Label Extension Study to Evaluate the Safety of Long-Term Treatment with Avapritinib for Patients Previously Involved in an Avapritinib Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005751-21,0,0,0 2020-005752-38,1,2022-08-15,2022-08-15,1,0,0,0,0,0,4,0,0,1,0,0,0,0,1,Novartis Pharma GmbH,An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants with secondary progressive multiple sclerosis treated with Mayzent (siponimod) (AMA-VACC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005752-38,0,0,0 2020-005754-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA,"Stereotactic body radiation therapy on Prostate with or without Androgen deprivation therapy, a phase III randomized controlled trial (SPA Trial) RADIOTERAPIA STEREOTASSICA PROSTATICA CON O SENZA T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005754-23,0,0,0 2020-005755-20,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Alzheon, Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer's Disease and APOE4/4 Genotype",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005755-20,0,0,0 2020-005756-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Gestión de la,Double blind randomized clinical trial comparing noradrenaline plus placebo versus noradrenaline plus terlipressin in septic shock Ensayo clínico aleatorizado doble ciego comparando noradrenalina m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005756-37,0,0,0 2020-005759-18,7,2021-12-02,2021-12-07,6,1,1,0,0,0,3,0,0,1,1,0,0,0,1,F. Hoffmann La Roche Ltd.,"A MULTICENTER, PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OUTPATIENT STUDY TO EVALUATE THE EFFICACY, SAFETY, AND ANTIVIRAL ACTIVITY OF RO7496998 (AT-527) IN PATIENTS WITH MILD OR MODERATE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005759-18,0,0,0 2020-005759-18,7,2021-12-02,2021-12-07,6,1,1,0,0,0,3,0,0,1,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A MULTICENTER, PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OUTPATIENT STUDY TO EVALUATE THE EFFICACY, SAFETY, AND ANTIVIRAL ACTIVITY OF RO7496998 (AT-527) IN PATIENTS WITH MILD OR MODERATE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005759-18,0,0,0 2020-005760-57,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005760-57,0,0,0 2020-005760-57,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005760-57,0,0,0 2020-005760-57,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005760-57,0,0,0 2020-005762-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Medical University of Lublin,A phase 2 clinical trial assessing the efficacy and safety of adding cladribine for treatment modifying course of seropositive myasthenia gravis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005762-34,0,0,0 2020-005763-31,2,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,INTERVENTIONAL CARDIOVASC. RESEARCH & CLINICAL TRIALS AT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,FREEDOM COVID Anticoagulation Strategy Randomized Trial Strategia di cura anticoagulante per i malati Covid-19. Studio clinico randomizzato.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005763-31,0,0,0 2020-005763-31,2,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,0,Icahn School of Medicine at Mount Sinai,FREEDOM COVID Anticoagulation Strategy Randomized Trial Strategia di cura anticoagulante per i malati Covid-19. Studio clinico randomizzato.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005763-31,0,0,0 2020-005764-62,8,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,HORIZON THERAPEUTICS IRELAND DAC,"A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005764-62,0,0,0 2020-005764-62,8,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Horizon Therapeutics Ireland DAC,"A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005764-62,0,0,0 2020-005766-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Assembly Biosciences, Inc.","A Randomized Phase 2a, Multicenter, Open-Label, Multiple-Cohort Study Evaluating Regimens Containing Vebicorvir in Subjects with Chronic Hepatitis B Virus Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005766-34,0,0,0 2020-005767-31,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 1b/2, Randomized, Controlled, Open-Label Study Evaluating the Safety and Efficacy of ABBV-927 Administered in Combination with Modified FOLFIRINOX (mFFX) With or Without Budigalimab compared t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005767-31,0,0,0 2020-005768-74,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hellenic Institute for the Study of Sepsis,"PERSONALIZED IMMUNOTHERAPY IN SEPSIS: A MULTICENTRE AND MULTINATIONAL, DOUBLE-BLIND, DOUBLE-DUMMY RANDOMIZED CLINICAL TRIAL (THE IMMUNOSEP TRIAL) ΕΞΑΤΟΜΙΚΕΥΜΕΝΗ ΑΝΟΣΟΘΕΡΑΠΕΙΑ ΣΤΗ ΣΗΨΗ: ΜΙΑ ΠΟΛΥΚΕΝΤ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005768-74,0,0,0 2020-005770-99,8,2022-05-13,2022-05-31,6,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim,"Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab (BI 655130) efficacy in patients with fibrostenotic Crohn's Disease Studio di fase IIa, multicentr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005770-99,1,0,0 2020-005770-99,8,2022-05-13,2022-05-31,6,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim AB,"Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab (BI 655130) efficacy in patients with fibrostenotic Crohn's Disease Studio di fase IIa, multicentr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005770-99,1,0,0 2020-005770-99,8,2022-05-13,2022-05-31,6,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim France,"Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab (BI 655130) efficacy in patients with fibrostenotic Crohn's Disease Studio di fase IIa, multicentr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005770-99,1,0,0 2020-005770-99,8,2022-05-13,2022-05-31,6,0,0,0,0,0,2,0,0,2,1,0,0,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab (BI 655130) efficacy in patients with fibrostenotic Crohn's Disease Studio di fase IIa, multicentr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005770-99,1,0,0 2020-005770-99,8,2022-05-13,2022-05-31,6,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim Norway KS,"Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab (BI 655130) efficacy in patients with fibrostenotic Crohn's Disease Studio di fase IIa, multicentr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005770-99,1,0,0 2020-005770-99,8,2022-05-13,2022-05-31,6,0,0,0,0,0,2,0,0,2,1,0,0,0,1,"Boehringer Ingelheim Portugal, Lda","Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab (BI 655130) efficacy in patients with fibrostenotic Crohn's Disease Studio di fase IIa, multicentr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005770-99,1,0,0 2020-005770-99,8,2022-05-13,2022-05-31,6,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim B.V,"Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab (BI 655130) efficacy in patients with fibrostenotic Crohn's Disease Studio di fase IIa, multicentr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005770-99,1,0,0 2020-005770-99,8,2022-05-13,2022-05-31,6,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Boehringer Ingelheim Ltd,"Multi-center, double-blind, randomized, placebo-controlled, phase IIa trial to evaluate spesolimab (BI 655130) efficacy in patients with fibrostenotic Crohn's Disease Studio di fase IIa, multicentr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005770-99,1,0,0 2020-005771-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AIO-Studien-gGmbH,"Neoadjuvant encorafenib, binimetinib and cetuximab for patients with BRAF V600E mutated/pMMR localized colorectal cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005771-12,0,0,0 2020-005772-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UCLouvain,Study on linezolid use and adverse drug reactions in clinical practice: Follow-up of patients treated in Belgian Hospitals,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005772-35,0,0,0 2020-005773-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP),"BARIcitinib Cognitive Emotional and Neural signaTuRE BARICENTRE BARIcitinib signaTuRE Cognitive, Emotionnelle et Neuronale BARICENTRE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005773-27,0,0,0 2020-005775-12,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Biogen Idec Research Limited,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Backg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005775-12,0,0,0 2020-005776-35,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Biogen Idec Research Limited,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Backg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005776-35,0,0,0 2020-005776-35,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,BIOGEN IDEC RESEARCH LIMITED,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Backg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005776-35,0,0,0 2020-005777-27,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie,"A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents with Acute Hepatitis C Virus (HCV) Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005777-27,0,0,0 2020-005777-27,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents with Acute Hepatitis C Virus (HCV) Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005777-27,0,0,0 2020-005777-27,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co.KG,"A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents with Acute Hepatitis C Virus (HCV) Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005777-27,0,0,0 2020-005777-27,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents with Acute Hepatitis C Virus (HCV) Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005777-27,0,0,0 2020-005781-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC Cancer Institute,"A nationwide multicentre, open-label study of six months avelumab maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after at least ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005781-34,0,0,0 2020-005787-58,1,2022-07-04,2022-07-04,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Michael Patrick,Endoscopic assisted Calcium electroporation in esophageal cancer – a safety study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005787-58,0,0,0 2020-005791-35,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Shire,"A 24-week Safety, Efficacy, Pharmacodynamic, and Pharmacokinetic Study of Teduglutide in Japanese Pediatric Subjects, Aged 4 Months Through 15 Years, With Short Bowel Syndrome Who Are Dependent on Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005791-35,0,1,1 2020-005792-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC),Pilot ‘Window of Opportunity’ Neoadjuvant Study of Abemaciclib in Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC) Studio Pilota...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005792-12,0,0,0 2020-005793-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Jakob Benedict Seidelin,Open label Randomized Controlled clinical Trial of vedolizumab versus conventional treatment for Checkpoint Inhibitor induced Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005793-10,0,0,0 2020-005801-14,2,,,0,0,0,0,0,0,3,0,1,2,0,0,0,0,1,Janssen Vaccines & Prevention B.V.,"A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005801-14,0,0,0 2020-005802-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Adaptimmune LLC,A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects with Advanced Esophageal or Esophagogastric Junction Cancers Ensayo clínico en fase II y sin enmascaramiento de ADP-A2M4CD8 en pacient...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005802-24,0,0,0 2020-005805-25,3,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Subjects with Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005805-25,0,0,0 2020-005807-37,2,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,Aurinia Pharmaceuticals Inc.,"A Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Efficacy, Safety and Pharmacokinetics of Voclosporin in Adolescents with Lupus Nephritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005807-37,0,0,0 2020-005822-27,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Blueprint Medicines Corporation,A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005822-27,0,0,0 2020-005823-35,1,2022-02-28,2022-02-28,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Aarhus Universitet,"ILIT.FT – Dose finding for intralymphatic allergen immunotherapy in a randomized, parallel group, double blind placebo-controlled field trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005823-35,0,0,0 2020-005826-27,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Hellenic Society of Hematology (EAE),"A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of Belantamab Mafodotin administered in combination with Lenalidomide and Dexamethasone in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005826-27,0,0,0 2020-005827-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital of Toulouse,"SARS-CoV-2 neurotropism, micRoglial ActivatioN and cytokine dySregulaTiOn in COVID-19 patients with delirium Neurotropisme viral, activation microgliale et dysfonction cytokinique chez les patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005827-35,0,0,0 2020-005828-11,2,2021-06-28,2021-06-28,1,0,0,0,0,0,3,0,0,1,0,0,1,0,0,Hellenic Institute for the Study of Sepsis,"suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19: THE SAVE-MORE DOUBLE-BLIND, RANDOMIZED, PHASE III CONFIRMATORY TRIAL Ο ΒΙΟ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005828-11,0,0,0 2020-005829-88,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,UCB Biopharma SRL,"A PATIENT- AND INVESTIGATOR-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BEPRANEMAB (UCB0107) IN STUDY PARTICIPANTS WITH PRODROMAL TO MILD ALZHEIMER’S DISEASE ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005829-88,0,0,0 2020-005830-14,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, parallel group, placebo-controlled, multicenter Phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005830-14,0,0,0 2020-005830-14,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, parallel group, placebo-controlled, multicenter Phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005830-14,0,0,0 2020-005832-31,1,2022-07-04,2022-07-04,1,0,0,0,0,1,2,0,1,1,0,0,0,0,1,Alexion Pharmaceuticals Inc.,Efficacy of ALXN1840 on human hepatic copper uptake quantified with 64CuCl2 PET/CT-scan. Effekten af ALXN1840 på kobberoptag i leveren målt ved 64CuCl2 PET/CT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005832-31,0,0,0 2020-005833-34,6,,,0,0,0,0,0,2,2,0,0,3,0,0,0,0,1,"Ayala Pharmaceuticals, Inc.","RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005833-34,0,0,0 2020-005835-60,1,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,0,Assistance Publique – Hôpitaux de Paris (AP-HP),Induction therapy for lupus nephritis with no added oral corticosteroids : An open label randomised multicentre controlled trial comparing oral corticosteroids plus mycophenolate mofetil (MMF) versus...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005835-60,0,0,0 2020-005836-31,1,2022-05-31,2022-05-31,1,1,0,0,1,0,4,0,0,1,1,1,0,0,0,Steno Diabetes Center Copenhagen,Dual-Hormone Closed-Loop Glucose Control in Adolescents with Type 1 Diabetes Afprøvning af en kunstig bugspytkirtel med insulin og glukagon til unge med type 1 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005836-31,0,0,0 2020-005838-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aarhus University Hospiotal,"The effect of iliopsoas plane block on opioid consumption and pain after hip arthroscopy A double-blind randomized, controlled trial Effekten af iliopsoas plane blokade på opioidforbrug og smert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005838-15,0,0,0 2020-005839-76,1,2022-01-10,2022-01-10,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,"University hospital Bispebjerg and Frederiksberg, Department of Clinical Pharmacology","Effects of single dose tadalafil on urethral and anal closure function and on urinary flow in healthy females: A randomised, controlled, double-blinded, two-period cross-over study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005839-76,0,0,0 2020-005841-18,9,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,argenx BV,"Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005841-18,0,1,0 2020-005841-18,9,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,ARGENX BV,"Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005841-18,0,1,0 2020-005842-41,1,2021-02-23,2021-02-23,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,"KRKA, d.d., Novo mesto","COMPARATIVE, RANDOMISED, SINGLE-DOSE, CROSSOVER, 3-WAY BIOAVAILABILITY STUDY OF DAPAGLIFLOZIN 10 mg FORMULATIONS IN HEALTHY VOLUNTEERS UNDER FED CONDITIONS PRIMERJALNA, RANDOMIZIRANA, NAVZKRIŽNA T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005842-41,0,0,0 2020-005843-21,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Kite Pharma, Inc.",Long-term Follow-up Study for Participants of Kite Sponsored Interventional Studies Treated With Gene-Modified Cells,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005843-21,0,0,0 2020-005843-21,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,KITE PHARMA INC.,Long-term Follow-up Study for Participants of Kite Sponsored Interventional Studies Treated With Gene-Modified Cells,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005843-21,0,0,0 2020-005844-47,8,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants with H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005844-47,0,0,0 2020-005845-18,7,2022-07-14,2022-07-14,5,0,0,0,0,0,2,0,0,2,0,0,0,0,1,AstraZeneca AB,"A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants with Hyperlipidaemia Randomizált, párhuz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005845-18,1,0,0 2020-005849-16,2,2022-10-31,2022-10-31,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Kinarus AG,"An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005849-16,1,0,0 2020-005854-90,1,2022-06-08,2022-06-08,1,0,0,0,0,1,2,0,0,1,0,0,0,0,1,"Annexon, Inc.","A Phase 2, Single-Center, Open-Label, Repeat-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Intravenous ANX005 in Participants with Primary Co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005854-90,0,0,0 2020-005855-19,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,BIOCRYST PHARMACEUTICALS INC.,"An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005855-19,0,0,0 2020-005855-19,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,BioCryst Pharmaceuticals Inc,"An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005855-19,0,0,0 2020-005858-21,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel",PHASE III STUDY COMPARING TRABECTEDIN (T) VERSUS T PLUS tTF-NGR TO ENTRAP T INSIDE THE TUMOR IN PATIENTS WITH METASTATIC AND/OR REFRACTORY SOFT TISSUE SARCOMA (STS) PHASE III STUDIE MIT TRABECTEDIN...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005858-21,0,0,0 2020-005863-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASST FATEBENEFRATELLI SACCO,"Nebulised heparin in COVID-19-related ARDS patients undergoing non-invasive ventilation with helmet cPAP: a prospective, randomised, double blind, placebo-controlled, multicentre study Ruolo dell’e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005863-29,0,0,0 2020-005865-14,1,,,0,1,0,0,0,0,4,0,0,1,1,1,0,1,0,Rigshospitalet,Pain relief of methoxyflurane in patients with burns,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005865-14,0,0,0 2020-005875-10,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Regeneron Pharmaceuticals. Inc.,An Extension Study to Evaluate the Long-Term Outcomes of Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005875-10,0,0,0 2020-005878-10,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Ionis Pharmaceuticals,"A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Study assessing the Safety, Tolerability and Efficacy of IONIS-AGT-LRX, an Antisense Inhibitor of Angiotensinogen Production, Admin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005878-10,0,0,0 2020-005882-15,1,2022-09-19,2022-09-19,1,0,0,0,0,0,2,0,0,1,1,1,0,0,1,Novartis Pharma AG,"Open-label, multicenter, pilot-trial evaluating the safety and utility of a hybrid decentralized clinical trial (DCT) approach using a TELEmedicine platform in patients with HR-positive/HER2-negative ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005882-15,0,0,0 2020-005884-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,UNIVERSITà DEGLI STUDI DI PERUGIA,EFFICACY AND SAFETY OF HEPARIN THROMBOPROPHYLAXIS IN PATIENTS WITH COVID-19 AND RESPIRATORY FAILURE: AN OPEN LABEL RANDOMIZED STUDY. The RESPECT-COVID (RESPiratory failure and hEparin Clinical Trial i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005884-29,0,0,0 2020-005886-15,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University Medical Center Groningen,Evaluation of pharmacokinetic and –dynamic characteristics of norepinephrine for the augmentation of arterial blood pressure in healthy volunteers prior to and during general anesthesia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005886-15,0,0,0 2020-005887-70,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fakultní nemocnice Brno,"Effect of dexamethasone in patients with ARDS and COVID-19 – prospective, multi-centre, open-label, parallel-group, randomized controlled trial Účinek dexamethasonu u pacientů s ARDS a COVID-19 – ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005887-70,0,0,0 2020-005890-29,1,,,0,0,0,0,0,0,3,0,0,1,1,1,0,1,0,FONDAZIONE RICERCA TRASLAZIONALE (FORT),Comparative efficacy of therapeutic strategies for at home early treatment of mild or moderate COVID-19 patients on the reduction of the risk of disease worsening: A multi-stage multi-arm adaptive ran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005890-29,0,0,0 2020-005893-93,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Uniwersytet Medyczny w Białymstoku,"A randomized, double-blind, placebo-controlled study evaluating levosimendan re-infusions in patients with severe heart failure with reduced left ventricular ejection fraction. Randomizowane, podwo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005893-93,0,0,0 2020-005895-37,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,1,Aspire Pharma Limited,"An open label one-treatment, one-period, one-sequence, single oral dose bioavailability study for Melatonin in healthy, adult, human subjects under fasting conditions. Otvoreno kliničko ispitivanje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005895-37,0,0,0 2020-005896-12,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Novartis Farmacéutica S.A.,EPIK-P3: A phase II study to evaluate the long-term safety and efficacy of alpelisib in patients with PIK3CA-Related Overgrowth Spectrum (PROS) who previously participated in Study CBYL719F12002 (EPIK...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005896-12,0,0,0 2020-005896-12,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,EPIK-P3: A phase II study to evaluate the long-term safety and efficacy of alpelisib in patients with PIK3CA-Related Overgrowth Spectrum (PROS) who previously participated in Study CBYL719F12002 (EPIK...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005896-12,0,0,0 2020-005899-36,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib 100 mg b.i.d. versus teriflunomide 14 mg q.d. in participants with relapsing multiple ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005899-36,0,0,0 2020-005899-36,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Farmacéutica S.A.,"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib 100 mg b.i.d. versus teriflunomide 14 mg q.d. in participants with relapsing multiple ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005899-36,0,0,0 2020-005899-36,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib 100 mg b.i.d. versus teriflunomide 14 mg q.d. in participants with relapsing multiple ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005899-36,0,0,0 2020-005900-21,1,2022-03-09,2022-03-09,1,0,0,0,0,0,2,0,0,1,1,1,0,0,1,Janssen-Cilag International NV,"A Phase 2a, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Interventional Study to Assess the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Multiple IV doses of Bermekimab for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005900-21,0,0,0 2020-005902-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS ISTITUTO CLINICO HUMANITAS,"Phase II Clinical Trial to optimize the dose of an anti-NKG2A monoclonal antibody (humZ270 mAb, IPH2201) for patients with acute myeloid leukemia or myelodysplastic syndrome undergoing haploidentical ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005902-24,0,0,0 2020-005910-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Martin-Luther-Universität Halle-Wittenberg,Phase 2 multicenter study investigating the tolerability and efficacy of UV1 vaccine in patients with recurrent or metastatic PD-L1 positive (CPS≥1) head and neck squamous cell carcinoma planned for f...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005910-17,0,0,0 2020-005911-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,KU Leuven,The DAWN camostat trial: the efficacy of camostat for COVID-19 infections presenting to ambulatory care: a randomized controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005911-27,0,0,0 2020-005914-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitair Ziekenhuis Brussel,COmbining Interventions of fertility preservation to Mitigate fertility loss after BReAst cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005914-16,0,0,0 2020-005915-39,1,,,0,0,0,0,0,0,2,0,1,1,0,0,0,1,1,REITHERA SRL,"COVID-19 A Phase II/III, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GRAd-COV2 Vaccine in Adults Aged 18 Years and Older ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005915-39,0,0,0 2020-005916-23,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,"Genentech, Inc.","A Phase IV, Multicenter, Single-Arm, Open-Label Study of Emicizumab Prophylaxis in Patients With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005916-23,0,1,1 2020-005919-51,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,DOMPé FARMACEUTICI S.P.A.,"A phase 3, double-blind, randomized, placebo-controlled, multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with severe COVID-19 pneumonia. Studio m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005919-51,0,0,0 2020-005923-35,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Ryvu Therapeutics S.A.,"An Open-label, Single Agent, Phase I/II Trial Investigating the Safety and Efficacy of RVU120 (SEL120) in Patients with Relapsed / Refractory Metastatic or Advanced Solid Tumors Badanie fazy I/II z...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005923-35,0,0,0 2020-005924-12,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,H. Lundbeck A/S,"Interventional, randomised, double-blind, parallel-group, placebo-controlled study of Lu AG09222 for the prevention of migraine in patients with unsuccessful prior preventive treatments Intervenční...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005924-12,0,0,0 2020-005929-89,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib 100 mg b.i.d. versus teriflunomide 14 mg q.d. in participants with relapsing multiple ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005929-89,0,0,0 2020-005929-89,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib 100 mg b.i.d. versus teriflunomide 14 mg q.d. in participants with relapsing multiple ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005929-89,0,0,0 2020-005929-89,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Farmacéutica S.A.,"A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib 100 mg b.i.d. versus teriflunomide 14 mg q.d. in participants with relapsing multiple ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005929-89,0,0,0 2020-005931-58,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),ACTIVE : ACid tranexamic or Terlipressin for Initial emergency treatment of mild to seVere hEmoptysis ACTIVE : Evaluation de l'acide tranexamique et de la terlipressine pour le traitement initial d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005931-58,0,0,0 2020-005933-34,4,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Sorin CRM SAS,Evaluation of a modified Anti-Platelet Therapy associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy Bewertung ein...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005933-34,0,0,0 2020-005933-34,4,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Sorin CRM SAS (Microport CRM),Evaluation of a modified Anti-Platelet Therapy associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy Bewertung ein...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005933-34,0,0,0 2020-005936-31,1,,,0,1,0,0,0,0,2,0,0,1,1,1,0,1,1,Sermonix Pharmaceuticals,"An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005936-31,0,0,0 2020-005938-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital,Health risks and treatment of anabolic-androgenic steroid (AAS) induced hypogonadism among men – a pilot study exploring off-label use of clomiphene citrate to reduce symptoms of androgen deficiency a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005938-15,0,0,0 2020-005941-18,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005941-18,0,0,0 2020-005941-18,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005941-18,0,0,0 2020-005941-18,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005941-18,0,0,0 2020-005942-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC),"A multicenter phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maintenance in patients with metastatic pulmonary large-cell neur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005942-41,0,0,0 2020-005947-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA,Effect of siponimod on relevant imaging and immunological hallmarks of progressive multiple sclerosis Effetto del siponimod su variabili di neuroimmagine e immunologiche in pazienti con sclerosi mu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005947-22,0,0,0 2020-005948-33,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"An open-label, single arm phase II study of DFV890 to assess the safety, tolerability and efficacy in participants with familial cold auto-inflammatory syndrome (FCAS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005948-33,0,0,0 2020-005948-33,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"An open-label, single arm phase II study of DFV890 to assess the safety, tolerability and efficacy in participants with familial cold auto-inflammatory syndrome (FCAS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005948-33,0,0,0 2020-005949-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,A GnRH Agonist IN pre-menopausal women STudy to treat severe Polycystic Liver Disease Een GnRH Agonist IN pre-menopauzale vrouwen Studie om ernstige Polycysteuze Leverziekte te behandelen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005949-16,0,0,0 2020-005951-19,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Pharma Mar, S.A.","A Phase 3, Multicentre, Randomised, Controlled Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Versus Control in Adult Patients Requiring Hospitalisation for Management of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005951-19,0,0,0 2020-005952-39,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,CORAT Therapeutics GmbH,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, FIRST-IN-HUMAN, PHASE IB/II STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY, AND E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005952-39,0,0,0 2020-005956-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Toulouse,Treatment of pediatric Post-traumatic Stress Disorder with memory reactivation under the influence of propranolol: A randomized placebo-controlled trial Traitement du Trouble Stress Post-Traumatiq...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005956-39,0,0,0 2020-005960-68,1,,,0,0,0,0,0,0,3,0,0,1,0,0,0,1,1,Astrazeneca AB,"A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants with BRCA Wild Type Advanced (FIGO Stage III-IV) High Grade Serous or Endometrioid O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005960-68,0,0,0 2020-005961-16,1,2022-02-10,2022-02-10,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Lars Jørgen Østergaard,Coenzyme Q10 as treatment for Long Term COVID-19 (The QVID study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005961-16,0,0,0 2020-005963-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University of Melbourne,Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial Australasian COVID-19 Forsøg (ASCOT) ADAptiv Platform Forsøg,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005963-29,0,0,0 2020-005969-13,4,2022-07-06,2022-07-06,2,0,0,0,0,0,2,0,0,1,1,0,0,0,1,AXCELLA HEALTH INC,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EMMPO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005969-13,0,0,0 2020-005969-13,4,2022-07-06,2022-07-06,2,0,0,0,0,0,2,0,0,1,1,0,0,0,1,"Axcella Health, Inc.","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EMMPO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005969-13,0,0,0 2020-005971-11,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"AL-S Pharma, AG","A Phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in patients with familial amyotrop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005971-11,0,0,0 2020-005974-91,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Celltrion, Inc","A Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women with Osteoporo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005974-91,0,0,0 2020-005979-12,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,XENOTHERA,"An international, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy and safety of 150 mg XAV-19 infusion, in patients with moderate COVID-19: the EUROXAV study М...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005979-12,0,0,0 2020-005980-30,7,2022-03-31,2022-04-14,5,0,0,0,0,0,2,0,0,2,1,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir (JNJ-53718678) in Adult Outpatients with Respiratory Syncytial Virus (RSV) Infection wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005980-30,1,0,0 2020-005980-30,7,2022-03-31,2022-04-14,5,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Janssen-Cilag International NV,"A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir (JNJ-53718678) in Adult Outpatients with Respiratory Syncytial Virus (RSV) Infection wh...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005980-30,1,0,0 2020-005984-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud University Medical Center,[89Zr]Df-IAB22M2C anti-CD8 minibody PET/CT imaging to assess the in vivo distribution of CD8+ T-cells in COVID-19 patients PET/CT beeldvorming met [89Zr]Df-IAB22M2C anti-CD8 minibody voor het beoor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005984-29,0,0,0 2020-005985-33,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,"Pacira Pharmaceuticals, Inc.",A Multicenter Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postsurgical Analgesia in Pediatric Subjects Aged 6 to Less Than 17 Years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005985-33,0,1,1 2020-005987-67,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Akari Therapeutics Plc,"A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pemphi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005987-67,0,0,0 2020-005990-29,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,0,Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU),An Early Phase Randomised Trial of APX005M and radiation therapy in combination with chemotherapy in BRCAwt Patients with Recurrent Ovarian Cancer. ENGOT-OV64/NSGO-CTU-SOLERO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005990-29,0,0,0 2020-005991-36,1,,,0,0,1,0,0,1,3,0,0,4,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 12 weeks of Age with Autosomal Recessive Polycystic Kidney D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005991-36,0,0,0 2020-005992-10,1,,,0,0,1,0,0,1,3,0,0,4,0,0,0,0,1,"Otsuka Pharmaceutical Development & Commercialization, Inc.","A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 18 years of Age with Autosomal Recessive Polycystic Kidney D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005992-10,0,0,0 2020-005995-37,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A Phase IIIb, open-label, single-arm, single-dose, multicenter study to evaluate the safety, tolerability and efficacy of gene replacement therapy with intravenous OAV101 (AVXS-101) in pediatric patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005995-37,0,0,0 2020-005995-37,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"A Phase IIIb, open-label, single-arm, single-dose, multicenter study to evaluate the safety, tolerability and efficacy of gene replacement therapy with intravenous OAV101 (AVXS-101) in pediatric patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005995-37,0,0,0 2020-005996-11,9,,,0,0,1,0,0,0,3,0,1,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005996-11,0,1,0 2020-005996-11,9,,,0,0,1,0,0,0,3,0,1,3,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005996-11,0,1,0 2020-005997-82,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,UMCG,Anti-COVID19 AKS-452 Phase I/II VaccinaTion Study (ACT-study) Anti-COVID19 AKS-452 fase I/II VaccinaTie Studie (ACT-Studie),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005997-82,0,0,0 2020-005998-27,1,2022-09-30,2022-09-30,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,University of Southern Denmark,Interleukin-6 inhibitors and drug-drug interactions in patients with Rheumatoid Arthritis.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005998-27,0,0,0 2020-005999-36,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Horizon Therapeutics U.S.A., Inc.","A Phase 3b/4, Double-masked, Randomized, International, Parallel- assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005999-36,0,0,0 2020-005999-36,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"HORIZON THERAPEUTICS USA, INC.","A Phase 3b/4, Double-masked, Randomized, International, Parallel- assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-005999-36,0,0,0 2020-006001-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Heidelberg,Randomized controlled trial of PREoperative injection of BOTulinum toxin into the sphincter of Oddi to reduce bile leakage after hepatic resection PREBOT-II Randomisiert-kontrollierte Studie zur ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006001-35,0,0,0 2020-006003-42,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,CHIP - Rigshospitalet - University of Copenhagen,National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006003-42,0,0,0 2020-006004-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Celon Pharma S.A.,"Phase II, Double blind, Randomized, Placebo controlled, Parallel group, Trial to Explore the Potential Anti-dyskinetic Properties of CPL500036 (PDE10A inhibitor) in Patients with Parkinson's Disease S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006004-16,0,0,0 2020-006009-43,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,PROgnostic value of precision medicine in patients with Myocardial Infarction and non-obStructive coronary artEries: the PROMISE study. Valore prognostico della medicina di precisione nei pazienti ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006009-43,0,0,0 2020-006011-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Petra Pietarinen,Laryngeaalisen leukoplakian mikrobilääkehoito -tutkimusprojekti Laryngeaalisen leukoplakian mikrobilääkehoito -tutkimusprojekti,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006011-23,0,0,0 2020-006012-24,1,2022-06-13,2022-06-13,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Neurocrine Biosciences,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of NBI-827104 in Subjects with Essential Tremor",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006012-24,0,0,0 2020-006017-38,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Chemical Works of Gedeon Richter Plc.,"A Randomised, Double-blind, Multicentre Phase III Study to Assess the Efficacy and Safety of RGB-14-P Compared to Prolia® in Women with Postmenopausal Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006017-38,0,0,0 2020-006017-38,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Gedeon Richter Plc.,"A Randomised, Double-blind, Multicentre Phase III Study to Assess the Efficacy and Safety of RGB-14-P Compared to Prolia® in Women with Postmenopausal Osteoporosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006017-38,0,0,0 2020-006023-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut d’Investigacions Biomèdiques August Pi i Sunyer,"Efficacy of simvastatin reducing liver fibrosis in patients with advanced fibrosis due to alcohol: a randomized, double-blind, placebo-controlled clinical trial. Eficacia de la simvastatina para r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006023-33,0,0,0 2020-006042-39,1,2021-12-08,2021-12-08,1,0,0,0,0,0,2,0,0,1,1,1,0,0,0,Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium,"A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of Favipiravir-HU compared to placebo as add-on therapy to standard of care in asymptomatic to mild severity COVI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006042-39,0,0,0 2020-006044-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Edesa Biotech Research Inc.,"A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of EB05 + SOC vs. placebo + SOC in adult hospitalized patients with COVID19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006044-14,0,0,0 2020-006048-15,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Sequential Treatment with Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy a...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006048-15,0,0,0 2020-006050-51,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Galderma S.A.,Evaluation of the risk of atrophic acne scar formation during treatment of acne vulgaris subjects with trifarotene 50 µg/g cream versus vehicle cream over 24 weeks Évaluation du risque de formation...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006050-51,0,0,0 2020-006051-17,7,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,1,"ModernaTX, Inc.","A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006051-17,0,0,0 2020-006051-17,7,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,1,Moderna Italy srl,"A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006051-17,0,0,0 2020-006053-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Neurolixis SAS,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 versus Placebo in Levodopa-induced Dyskinesia in Parkinson’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006053-22,0,0,0 2020-006054-43,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Università degli Studi di Trieste,Randomized controlled trial of methylprednisolone versus dexamethasone in COVID-19 pneumonia Metilprednisolone versus Desametasone nelle polmoniti COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006054-43,0,0,0 2020-006057-21,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006057-21,0,0,0 2020-006057-21,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"A phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006057-21,0,0,0 2020-006057-21,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Novartis Farmacéutica S.A.,"A phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006057-21,0,0,0 2020-006060-89,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Odense University Hospital,Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients (SABLe): An Investigator Sponsored Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006060-89,0,0,0 2020-006062-36,8,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,Newron Pharmaceuticals S.p.A.,"A PHASE II/III, PROSPECTIVE, MULTI-CENTER, RANDOMIZED, 4-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, DESIGNED TO DETERMINE THE SAFETY, TOLERABILITY, EEG EFFECTS AND EFFICACY OF ORAL DOSES OF 30 MG B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006062-36,0,0,0 2020-006062-36,8,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,Newron Pharmaceuticals S.p.A,"A PHASE II/III, PROSPECTIVE, MULTI-CENTER, RANDOMIZED, 4-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, DESIGNED TO DETERMINE THE SAFETY, TOLERABILITY, EEG EFFECTS AND EFFICACY OF ORAL DOSES OF 30 MG B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006062-36,0,0,0 2020-006062-36,8,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,NEWRON PHARMACEUTICALS SPA,"A PHASE II/III, PROSPECTIVE, MULTI-CENTER, RANDOMIZED, 4-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, DESIGNED TO DETERMINE THE SAFETY, TOLERABILITY, EEG EFFECTS AND EFFICACY OF ORAL DOSES OF 30 MG B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006062-36,0,0,0 2020-006063-28,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Jiangsu Hengrui Medicine Co., Ltd","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line Treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006063-28,0,0,0 2020-006063-28,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Jiangsu Hengrui Pharmaceutical Co., Ltd","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line Treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006063-28,0,0,0 2020-006067-28,1,2022-07-18,2022-07-18,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,"CuraSen Therapeutics, Inc.","A Phase II, Randomized, Placebo-Controlled, Double-Blind, Crossover, Study of the Pharmacodynamic Effects of CST-103 co-administered with CST-107 on the Central Nervous System in Subjects with Neurode...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006067-28,0,0,0 2020-006068-99,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"Narodowe Centrum Badań Jądrowych, Ośrodek Radioizotopów POLATOM","Tandem therapy LutaPol/ItraPol (177Lu / 90Y-DOTATATE) as an effective method in the treatment of neuroendocrine neoplasms, Acronym: DuoNen, 2019 / ABM / 01/00077 Zastosowanie terapii tandemowej Lut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006068-99,0,0,0 2020-006072-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Heliodor Święcicki Clinical Hospital of the Poznań University of Medical Sciences,Pulmonary REsistance modification under treatment with Sacubitil/valsartaN in paTients with HeartFailure with reduced ejection fraction Sakubitryl/walsartan w leczeniu nadciśnienia płucnego wtórne...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006072-32,0,0,0 2020-006075-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Amsterdam UMC,"Convalescent Antibody-Mediated Treatment of COVID-19 Infections in Patients with B-cell dysfunction, a Randomized Trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006075-15,0,0,0 2020-006081-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FILO,STop and restart Acalabrutinib In fRail patients with previously untreated CLL (STAIR) Arrêt et reprise de l’Acalabrutinib chez les patients fragiles présentant une leucémie lymphoîde chronique no...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006081-36,0,0,0 2020-006082-11,6,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Adagio Therapeutics Inc.,"A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants with Mild or Moderate COVID-19 (STAMP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006082-11,0,0,0 2020-006102-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,Study of a novel combination of immunovirologic and genetic parameters in early-treated HIV-1 patients undergone to antiretroviral therapy interruption (ATI) aimed at defining an algorithm predictive ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006102-23,0,0,0 2020-006104-17,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Farmacéutica S.A.,"A randomized, two-arm, placebo-controlled, participant and investigator-blinded study investigating the efficacy, safety and tolerability of DFV890 in patients with symptomatic knee osteoarthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006104-17,0,0,0 2020-006104-17,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A randomized, two-arm, placebo-controlled, participant and investigator-blinded study investigating the efficacy, safety and tolerability of DFV890 in patients with symptomatic knee osteoarthritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006104-17,0,0,0 2020-006110-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Vejle Sygehus, Ortopædkirurgisk afdeling, Forskningsenheden (COFU)",Repeat dose steroid to prevent pain relapse after Total Knee Arthroplasty in patients with high pain response - A randomized blinded placebo-controlled trial Højdosis Steroid før og efter total knæ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006110-20,0,0,0 2020-006114-20,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,"A Phase 2, prospective, multi-center intervention trial in patients with acute myeloid leukemia secondary to myeloproliferative neoplasms unfit for intensive chemotherapy investigating a treatment com...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006114-20,0,0,0 2020-006115-19,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Samsung Bioepis Co., Ltd","A Phase III, Randomised, Double-blind, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SB17 (proposed ustekinumab biosimilar) Compare...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006115-19,0,0,0 2020-006118-19,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Hutchison MediPharma Limited,An Open-Label Phase 2 Study of Surufatinib in Patients with Neuroendocrine Tumours in Europe,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006118-19,0,0,0 2020-006121-65,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Odense University Hospital,"STUDY PROTOCOL: A multi-centre, randomized, double-blinded, placebo controlled 1-year study to compare the effect of hydrocortisone and palcebo in patients with partial adrenal insufficiency after ces...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006121-65,0,0,0 2020-006127-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Verein zur Förderung der Wissenschaft und Forschung an der 1.Med. Abteilung der Krankenanstalt Rudolfstiftung,Empagliflozin as potential treatment option for postprandial hyperinsulinemic hypoglycaemia after bariatric surgery – a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006127-34,0,0,0 2020-006130-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA,"Multicenter randomized, double-blind, placebo-controlled, clinical trial of Acetylsalicylic acid in the prevention of severe COVID-19 pneumonia in hospitalised patients (Asperum) Studio multicentri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006130-12,0,0,0 2020-006131-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Arena Pharmaceuticals, Inc.","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of APD418 in Subjects with Heart Failure with R...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006131-10,0,0,0 2020-006141-19,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,University Medical Center Groningen,Fluorescence guided surgery for intra-operative detection of meningioma using Bevacizumab-IRDye800CW Fluorescentie gestuurde chirurgie voor intra-operatieve detectie van meningeoom bij gebruik van ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006141-19,0,0,0 2020-006142-39,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Facultad de Odontología. Universidad Complutense de Madrid,INFLUENCE OF THE ANTIBIOTIC GUIDELINE ON IMPLANT SURVIVAL INFLUENCIA DE LA PAUTA ANTIBIÓTICA EN LA SUPERVIVENCIA DE LOS IMPLANTES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006142-39,0,0,0 2020-006143-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Śląski Uniwersytet Medyczny w Katowicach,"A Single center, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of neoadjuvant and adjuvant Pembrolizumab on top of standard Chemo-Radiotherapy (Stupp protocol) in Treatment of Patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006143-26,0,0,0 2020-006144-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Charité Universitätsmedizin Berlin,"Post-resection/ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418) Prospective, randomized, open, multicenter Phase III trial to investigate the effica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006144-18,0,0,0 2020-006161-11,1,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,0,Toulouse University Hospital,LONG -TERM INTERVENTIONAL FOLLOW-UP STUDY UP TO 4 YEARS OF AGE OF CHILDREN WITH PRADER-WILLI SYNDROME INCLUDED IN THE OTBB3 CLINICAL TRIAL AND COMPARISON WITH AN UNTREATED COHORT OF CHILDREN WITH PRAD...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006161-11,0,0,0 2020-006165-11,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006165-11,0,0,0 2020-006165-11,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-006165-11,0,0,0 2021-000001-25,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Oxolife S.L.,"A phase II, randomised, double-blind, parallel-group, placebo-controlled trial to assess the ongoing pregnancy rate with OXO-001 (200 mg, 300 mg) or placebo at 10 weeks following fresh single blastocy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000001-25,0,0,0 2021-000003-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aarhus University Hospital,"AN INVESTIGATOR INITIATED, PHASE 4, OPEN-LABEL, SINGLE-ARM, SINGLE-CENTER STUDY INVESTIGATING THE RESIDUAL DISEASE MEMORY IN PSORIASIS SKIN DURING ENSTILAR® AND NARROW-BAND ULTRAVIOLET B THERAPY. THE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000003-20,0,0,0 2021-000006-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of subcutaneous belimumab or placebo in addition to rituximab in adult patients with persistent or chronic immu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000006-16,0,0,0 2021-000007-21,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A two-part, randomized, placebo controlled, double blind, multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000007-21,0,0,0 2021-000007-21,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A two-part, randomized, placebo controlled, double blind, multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000007-21,0,0,0 2021-000009-25,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,CHU SAINT-ETIENNE,Rituximab therapy in anti-MAG patients with characteristics of good responders: THERAMAG study Traitement par Rituximab de patients avec neuropathie anti-MAG et facteurs de bonne réponse: l’étude ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000009-25,0,0,0 2021-000010-41,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A multi-cohort, randomized, Phase 2, open-label study to assess the preliminary efficacy, safety, and pharmacokinetics of BIVV020 for prevention and treatment of antibody-mediated rejection in adult k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000010-41,0,0,0 2021-000010-41,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A multi-cohort, randomized, Phase 2, open-label study to assess the preliminary efficacy, safety, and pharmacokinetics of BIVV020 for prevention and treatment of antibody-mediated rejection in adult k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000010-41,0,0,0 2021-000014-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Aquilon Pharmaceuticals,"A randomized, double-blind, placebo-controlled, parallel, trial to determine the safety and efficacy of inhaled AQ001S in the management of acute COVID-19 symptoms Étude clinique interventionnelle ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000014-42,0,0,0 2021-000016-28,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,VIIV HEALTHCARE UK LIMITED,"A Phase IIb, randomized, double-blind, parallel-group study to assess the efficacy, safety, tolerability, and resistance profile of GSK3640254 in combination with dolutegravir compared to dolutegravir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000016-28,0,0,0 2021-000016-28,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ViiV Healthcare UK Limited,"A Phase IIb, randomized, double-blind, parallel-group study to assess the efficacy, safety, tolerability, and resistance profile of GSK3640254 in combination with dolutegravir compared to dolutegravir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000016-28,0,0,0 2021-000021-27,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,K-Group Beta,"A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination with Gemcitabine in Adult and Pediatric Subjects with Relapsed or Refractory Osteosarcoma Estudio de fase I/II, de Escal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000021-27,0,0,0 2021-000028-36,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Immunic AG,"A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000028-36,0,0,0 2021-000036-57,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000036-57,0,0,0 2021-000037-14,10,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Prothena Biosciences Limited,"A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Lig...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000037-14,0,0,0 2021-000038-33,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Dragonfly Therapeutics, Inc.","A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monothera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000038-33,0,0,0 2021-000039-29,4,,,0,0,0,0,2,0,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 2 Randomized Double-blind Study of BMS-986207 in Combination with Nivolumab and Ipilimumab as First-line Treatment for Participants with Stage IV Non-Small Cell Lung Cancer Estudio en fase ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000039-29,0,0,0 2021-000041-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Maastricht University,A study to investigate the effects of repeated low doses of psilocybin and ketamine on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000041-40,0,0,0 2021-000042-17,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Netherlands Cancer Institute,Sarcomas and DDR-Inhibition; a neoadjuvant phase I combined modality study – SADDRIN-1 Sarcomen in combinatie met remmers van DNA schade: een fase I studie met een gecombineerde behandeling van rem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000042-17,0,0,0 2021-000043-49,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,LOXO ONCOLOGY INCORPORATED,"A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000043-49,0,0,0 2021-000043-49,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Loxo Oncology Inc,"A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000043-49,0,0,0 2021-000044-22,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Pfizer Inc.,"AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000044-22,0,0,0 2021-000044-22,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,PFIZER INC,"AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000044-22,0,0,0 2021-000045-41,1,2022-01-07,2022-01-07,1,0,0,0,0,0,2,0,0,1,0,0,0,0,0,Institut Pasteur de Lille,"Adaptive, Ambulatory, Randomised, Placebo-Controlled, Double-Blind, Phase 2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of TEE001DP in Patients at the Early Stage of Symptomatic COVID-1...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000045-41,0,0,0 2021-000048-23,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Immunic AG,"Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000048-23,0,0,0 2021-000049-42,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Zealand University Hospital (Universitetshospital Sjælland),"Orismilast for the treatment of mild to severe hidradenitis suppurativa; A phase 2, open-label, proof of concept trial comparing the response to an oral tablet formulation of orismilast in adult patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000049-42,0,0,0 2021-000050-26,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"AVEO Pharmaceuticals, Inc.","TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000050-26,0,0,0 2021-000050-26,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"AVEO PHARMACEUTICALS, INC.","TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000050-26,0,0,0 2021-000055-39,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Immutep S.A.S.,"TACTI-003 (Two ACTive Immunotherapeutics): A multicenter, open label, randomized, Phase II trial to investigate a soluble LAG-3 fusion protein, eftilagimod alpha (efti; IMP321) in combination with pem...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000055-39,0,0,0 2021-000058-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC Cancer Institute,Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis. Toediening van immune checkpoint inhibitors via een elastomeer pomp. Een ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000058-24,0,0,0 2021-000059-38,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Bayer Consumer Care AG,"A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 52 weeks in postmenopausal women.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000059-38,0,0,0 2021-000062-14,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE IV MULTICENTER, OPEN-LABEL STUDY EVALUATING B CELL LEVELS IN INFANTS POTENTIALLY EXPOSED TO OCRELIZUMAB DURING PREGNANCY – THE MINORE STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000062-14,0,0,0 2021-000063-79,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE IV MULTICENTER, OPEN-LABEL STUDY EVALUATING B CELL LEVELS IN INFANTS OF LACTATING WOMEN WITH CIS OR MS RECEIVING OCRELIZUMAB – THE SOPRANINO STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000063-79,0,0,0 2021-000066-16,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,CHU Dijon Bourgogne,"ÉVALUATION D’UNE ANESTHÉSIE GÉNÉRALE BALANCÉE NON OPIOÏDE EN CHIRURGIE CARDIAQUE AVEC CIRCULATION EXTRA-CORPORELLE : ESSAI CLINIQUE RANDOMISÉ, CONTRÔLE, MULTICENTRIQUE DE SUPÉRIORITÉ",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000066-16,0,0,0 2021-000067-68,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.,Efficacy and safety of different dosage regimens of the combination methocarbamol/paracetamol in acute Low Back Pain (LBP): MioPain study Efficacia e sicurezza di diversi regimi di dosaggio della c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000067-68,0,0,0 2021-000068-30,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Ectin Research AB,"An open-label, multi-center, phase I/II study of MFA-370 in patients with metastatic urothelial cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000068-30,0,0,0 2021-000069-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Mech-Sense, Aalborg University Hospital","Effects of a peripherally acting μ-opioid receptor antagonist on recurrent acute pancreatitis: An investigator-initiated, randomized, placebo-controlled, double-blind clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000069-34,0,0,0 2021-000070-29,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,VU University Medical Center,A Proof-of-Concept Study to Explore the Potential Efficacy of Deferiprone in Patients With Pelizaeus-Merzbacher disease (PMD),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000070-29,0,0,0 2021-000079-35,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Lilly, S.A.","EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive, HER2 Negati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000079-35,0,0,0 2021-000079-35,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Eli Lilly and Company,"EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive, HER2 Negati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000079-35,0,0,0 2021-000081-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose- Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Non-Segmental Vitiligo",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000081-15,0,0,0 2021-000083-29,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Leiden University Medical Center,Influence of ∆9-tetrahydrocannabinol (THC) on oxycodone induced ventilatory depression in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000083-29,0,0,0 2021-000085-14,6,2021-07-08,2021-07-08,1,0,1,0,0,1,3,0,0,2,1,0,0,0,1,AstraZeneca AB,"A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate the Efficacy and Safety of Benralizumab in Patients with Eosinophilic Gastritis and/or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000085-14,1,0,0 2021-000085-14,6,2021-07-08,2021-07-08,1,0,1,0,0,1,3,0,0,2,1,0,0,0,1,ASTRAZENECA AB,"A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate the Efficacy and Safety of Benralizumab in Patients with Eosinophilic Gastritis and/or ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000085-14,1,0,0 2021-000091-11,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Prometheus Biosciences, Inc.","A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy with PRA023 in Subjects with Moderately to Severely Active U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000091-11,0,0,0 2021-000091-11,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Prometheus Biosciences Inc.,"A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy with PRA023 in Subjects with Moderately to Severely Active U...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000091-11,0,0,0 2021-000092-37,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Prometheus Biosciences, Inc.","A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects with Moderately to Severely Active Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000092-37,0,0,0 2021-000094-91,1,,,0,0,1,0,0,1,3,0,0,4,0,0,0,0,0,Toulouse University Hospital,EFFECT OF INTRANASAL OXYTOCIN ON DYSPHAGIA RELATED TO OROPHARYNGO-OESOPHAGEAL DYSMOTILITY TRANSIT IN CHILDREN AND ADOLESCENTS WITH PRADER-WILLI SYNDROME: A PHASE 3 STUDY (DYSMOT) EFFETS DE L’ADMINI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000094-91,0,0,0 2021-000095-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospices Civils de Lyon,Evaluation of the long-term efficacy of the injection of botulinum toxin A into the salivary glands versus scopolamine patches in the treatment of drooling in children over 4 years old with cerebral p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000095-10,0,0,0 2021-000096-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Dermatology and Copenhagen Wound Healing Center, Bispebjerg Hospital","The effect of subcutaneous injection of Botulinum Toxin A on chronic wound pain in lower extremities, a prospective exploratory study Effekt af subkutan injektion af Botulinum toxine (Botox) på kro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000096-36,0,0,0 2021-000097-29,4,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF OBINUTUZUMAB IN ADOLESCENT PATIENTS WITH ACTIVE CLASS III OR IV LU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000097-29,0,0,0 2021-000097-29,4,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,F. Hoffman-La Roche Ltd.,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF OBINUTUZUMAB IN ADOLESCENT PATIENTS WITH ACTIVE CLASS III OR IV LU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000097-29,0,0,0 2021-000097-29,4,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF OBINUTUZUMAB IN ADOLESCENT PATIENTS WITH ACTIVE CLASS III OR IV LU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000097-29,0,0,0 2021-000099-12,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS,Dose-adjustment of enoxaparin by a bayesian pharmacological approach in pediatric renal transplant recipients Ajustement de dose de l’énoxaparine par une approche pharmacologique bayésienne chez l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000099-12,0,0,0 2021-000100-37,1,2022-09-28,2022-09-28,1,0,0,0,0,0,2,0,1,1,0,0,0,0,1,"Bausch Health Americas, Inc.","A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Clinical Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel (0.3% adapalene/2.5% BPO), in the Treatment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000100-37,0,0,0 2021-000102-25,1,,,0,0,0,0,0,1,2,0,0,1,0,0,0,1,0,Aarhus University Hospital,Efficacy of ALXN1840 on human biliary copper excretion quantified with 64CuCl2 PET/MR-scan Effekten af ALXN1840 på kobberudskillelse i galden målt ved 64CuCl2 PET/MR-scan,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000102-25,0,0,0 2021-000103-20,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,"An explorative randomized, placebo-controlled and double-blind intervention crossover study: Transvamix (100mg/mL THC / 50mg/mL CBD) to treat chronic pain in Epidermolysis Bullosa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000103-20,0,0,0 2021-000104-38,4,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Sanofi Pasteur,"A Phase IIIb, Open-label, Multi-center Study to Evaluate the Immunogenicity and Safety of a Booster Dose and Describe the Immune Persistence of MenACYW Conjugate Vaccine with 5- and/or 10-year Booster...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000104-38,0,0,0 2021-000122-10,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"NS Pharma, Inc.","A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000122-10,0,0,0 2021-000122-10,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"NS Pharma, Inc","A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000122-10,0,0,0 2021-000123-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Odense University Hospital,PRISMA-PET - Primary Staging of Prostate Cancer: A Randomized Controlled Trial Comparing 18F-PSMA-1007 PET/CT to Conventional Imaging,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000123-12,0,0,0 2021-000125-27,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,European Organisation for Research and Treatment of Cancer (EORTC),TOLERANCE: a 3 arm randomized study on healTh-related quality Of Life of EldeRly pAtients with advaNced soft tissue sarComa undergoing doxorubicin every three weeks or doxorubicin weekly or cyclophosp...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000125-27,0,0,0 2021-000127-12,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Saniona A/S,"A Phase 2b, Double-blind, Randomized, Placebo-controlled, Multi center, 16-week Dose finding, Safety and Efficacy Study with Open-label Extension Period of Tesomet in Adult and Adolescent Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000127-12,0,0,0 2021-000129-28,16,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000129-28,0,0,0 2021-000129-28,16,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000129-28,0,0,0 2021-000133-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitätsmedizin Göttingen,Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder Verstärkung der Expositionstherapie bei Patienten mit Binge-Eating-Störung mittels Glucocorticoiden,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000133-13,0,0,0 2021-000135-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region Östergötland,The Effect of tinzaparin on Biomarkers in FIGO Stage III-IV Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy – A randomized pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000135-31,0,0,0 2021-000136-59,5,2022-09-30,2022-09-30,2,0,0,0,0,1,2,0,0,2,1,0,0,0,1,KalVista Pharmaceuticals Ltd,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of Three Dose Levels of KVD824, an Oral Plasma Kallikrein Inhibitor, for Long-Term Prophylactic Treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000136-59,1,0,0 2021-000136-59,5,2022-09-30,2022-09-30,2,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Kalvista Pharmaceuticals Ltd,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of Three Dose Levels of KVD824, an Oral Plasma Kallikrein Inhibitor, for Long-Term Prophylactic Treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000136-59,1,0,0 2021-000137-14,1,2022-05-13,2022-05-13,1,0,1,0,0,0,2,0,0,1,0,0,0,0,1,Cessatech A/S,Pharmacokinetic study of intranasal CT001 in children 1-17 years of age undergoing elective surgical procedures,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000137-14,0,0,0 2021-000138-33,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.",A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients with Familial Partial Lipodystrophy Estudio aleator...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000138-33,0,0,0 2021-000144-21,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Diurnal Limited,"A Double-Blind, Double-Dummy, Two-Way Cross-Over, Randomised, Phase II Study of Efficacy, Safety and Tolerability of Modified-Release Hydrocortisones: Chronocort® Versus Plenadren®, in Adrenal Insuffi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000144-21,0,0,0 2021-000146-18,1,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Saniona A/S,"A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose finding, Multi-center, 36-week Safety and Efficacy Study with Open-label Extension Period of Tesomet in Subjects with Hypothalamic Obesit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000146-18,0,0,0 2021-000147-45,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,YONSUNG GMBH,"A non-inferiority, randomized, investigator - masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost (YSLT) versus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000147-45,0,0,0 2021-000148-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Essen,68Ga-FAPI-46 PET for imaging of FAP expressing cancer: A single-center prospective interventional single-arm clinical Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000148-23,0,0,0 2021-000149-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Synermore Biologics Co., Ltd","A Phase 3, Randomized, Double-blind, Parallel group, Active Controlled Study to Compare the Efficacy and Safety of SYN008 to Xolair® in Adult Patients with Chronic Spontaneous Urticaria and Inadequate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000149-42,0,0,0 2021-000150-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,"Phase IIA trial of short-term chemotherapy and pembrolizumab, followed by Pembrolizumab and Olaparib as firstline therapy in Her-2 negative gastric/gastroesophageal-junction (GEJ) Adenocarcinoma – POL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000150-26,0,0,0 2021-000152-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER)",Control strategies and pharmacogenetic study for the personalized treatment of fatty liver associated with metabolic dysfunction in patients with prediabetes. Estrategias de control y estudio farma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000152-19,0,0,0 2021-000166-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Meditop Gyógyszeripari Kft,"A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ivermectin in asymptomatic and mild severity COVID-19 patients Randomizált, kettős-vak, placebo-kontrollos ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000166-15,0,0,0 2021-000167-69,1,2022-05-06,2022-05-06,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,AiCuris Anti-Infective Cures GmbH,"A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AIC649 in the treatment of otherwise healthy subjects with asymptomatic or mildly symptomatic SARS-CoV-2 inf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000167-69,0,0,0 2021-000169-34,4,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000169-34,0,0,0 2021-000170-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Eli Lilly and Company,"Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000170-29,0,0,0 2021-000171-36,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,INSERM,PHASE I-II EFFICACY-TOXICITY OF ARTESUNATE IN FRIEDREICH ATAXIA Evaluation de l’Effet de l’Artésunate dans l’Ataxie de Friedreich (AF) Etude de Tolérance et d’Efficacité de Phase I/II,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000171-36,0,0,0 2021-000175-37,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Karolinska Universitetssjukhuset,"Immunological Responses after Vaccination for COVID-19 with the mRNA Vaccine Comirnaty in Immunosuppressed and Immunocompetent Individuals. An open, non-randomized , phase IV multicenter study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000175-37,0,0,0 2021-000176-11,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Hanmi Pharm. Co., Ltd.","A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 in Adult Subjects with Short Bowel Syndrome-associated Intestinal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000176-11,0,0,0 2021-000176-11,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Hanmi Pharmaceutical Co., Ltd.","A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 in Adult Subjects with Short Bowel Syndrome-associated Intestinal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000176-11,0,0,0 2021-000177-80,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Deciphera Pharmaceuticals, LLC","A Phase 1b/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ripretinib in Combination with Binimetinib in Patients with Gastrointestinal Stroma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000177-80,0,0,0 2021-000179-36,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Merck Healthcare KGaA,"An Open-label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Bintrafusp alfa (M7824) Clinical Studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000179-36,0,0,0 2021-000179-36,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Merck KGaA,"An Open-label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Bintrafusp alfa (M7824) Clinical Studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000179-36,0,0,0 2021-000179-36,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,MERCK KGAA,"An Open-label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Bintrafusp alfa (M7824) Clinical Studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000179-36,0,0,0 2021-000180-70,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Beacon Hospital,Knee osteoarthritis Injection Therapy (KNiT) trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000180-70,0,0,0 2021-000182-33,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Radboudumc,Effect of Bacillus Calmette-Guérin vaccination on the immunogenicity of the mRNA BNT162b2 COVID-19 vaccine in health care workers Effect van Bacillus Calmette-Guérin vaccinatie op de immunogenicite...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000182-33,0,0,0 2021-000183-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Eberhard-Karls University Tübingen, Med. Fac. rep. by University Hospital and its Commercial Director",Early Reperfusion Therapy with Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION) - A double-blind randomized placebo-controlled phase II proof-of-concep...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000183-29,0,0,0 2021-000184-78,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Odense University Hospital,Recurrent and Metastatic Prostate Cancer: Impact of 18F-PSMA-1007 PET/CT on clinical decision making and response monitoring,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000184-78,0,0,0 2021-000186-32,3,2022-02-02,2022-02-02,2,0,0,0,0,0,2,0,0,1,1,1,0,0,1,"G1 Therapeutics, Inc.","A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rd Line Setting (PRES...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000186-32,0,0,0 2021-000186-32,3,2022-02-02,2022-02-02,2,0,0,0,0,0,2,0,0,1,1,1,0,0,1,G1 Therapeutics Inc.,"A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib versus Placebo in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated with Docetaxel in the 2nd/3rd Line Setting (PRES...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000186-32,0,0,0 2021-000190-81,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Goethe-University Frankfurt,A prospective multicenter placebo-controlled trial to study the efficacy and safety of Tiotropium in preventing severe asthma exacerbations in partial and uncontrolled preschool asthma. TIPP-Study ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000190-81,0,0,0 2021-000192-37,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Hôpital Foch,Oxidative Phosphorylation Targeting In Malignant glioma Using Metformin plus radiotherapy temozolomide La metformine en association avec radiothérapie-témozolomide comme thérapie ciblée métabolique...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000192-37,0,0,0 2021-000194-93,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud University Medical Center,Exendin PET/CT for imaging of paragangliomas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000194-93,0,0,0 2021-000199-12,12,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Acceleron Pharma Inc.,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000199-12,0,0,0 2021-000199-12,12,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,ACCELERON PHARMA INC.,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000199-12,0,0,0 2021-000200-38,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"University Clinic of Dentistry, Medical University of Vienna",THE IMPACT OF VITAMIN D3 HIGH DOSES SUPPLEMENTATTION ON EARLY BONE HEALING AFTER MANDIBULAR THIRD MOLAR (M3) REMOVAL: A PILOT STUDY Einfluss von hochdosiertem Vitamin D3 auf die anfängliche Knochen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000200-38,0,0,0 2021-000202-22,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pom...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000202-22,0,0,0 2021-000203-20,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,MERUS N.V.,"Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000203-20,0,0,0 2021-000203-20,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Merus N.V.,"Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000203-20,0,0,0 2021-000205-24,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"G1 Therapeutics, Inc.","A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Metasta...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000205-24,0,0,0 2021-000206-17,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Karolinska University Hospital,"Studies of ongoing and completed SARS-CoV-2 infection (which causes COVID-19) within the healthcare in Stockholm County, with regard to vaccinations. Studier av pågående och genomgången SARS-CoV-2 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000206-17,0,0,0 2021-000211-23,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Agios Pharmaceuticals, Inc.","A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000211-23,0,0,0 2021-000211-23,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"AGIOS PHARMACEUTICALS, INC.","A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000211-23,0,0,0 2021-000212-34,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Agios Pharmaceuticals, Inc.","A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000212-34,0,0,0 2021-000212-34,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"AGIOS PHARMACEUTICALS, INC.","A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000212-34,0,0,0 2021-000213-16,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Princess Máxima Center for Pediatric Oncology,International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000213-16,0,0,0 2021-000214-42,6,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,InMed Pharmaceuticals Inc.,"A Randomised, Double-Blind, Vehicle-Controlled Phase 2 Study of Topically Applied INM-755 (cannabinol) Cream in Patients with Epidermolysis Bullosa.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000214-42,0,0,0 2021-000224-35,1,2022-03-18,2022-03-18,1,1,0,0,0,0,2,0,0,1,0,0,0,0,0,Marie Kristine Jessen,"Restrictive Fluid Administration vs. Standard of Care in Emergency Department Sepsis Patients - a Multicenter, Randomized Clinical Feasibility Trial Restriktiv vs. vanlig væskebehandling til sepsi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000224-35,0,0,0 2021-000225-27,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Kodiak Sciences Inc.,"A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Afli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000225-27,0,0,0 2021-000227-13,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Pharvaris Netherlands BV,"A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema At...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000227-13,0,0,0 2021-000230-33,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,UMBERTO I - POLICLINICO DI ROMA,"A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED, ADD-ON TRIAL EVALUATING EFFICACY AND SAFETY OF HYDROXYCHLOROQUINE IN EARLY SYSTEMIC SCLEROSIS (SSc)- HYDROXYSSc STUDIO CLINICO IN DOPPIO CIECO, RANDO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000230-33,0,0,0 2021-000235-30,1,2021-04-23,2021-04-23,1,0,0,0,0,0,4,0,0,1,1,1,1,0,0,General Practitioners Research Institute,COVID-19 Primary care Platform for Early treatment and Recovery (COPPER) Study: an open-label adaptive platform randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000235-30,0,0,0 2021-000239-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BIOGAIA PHARMA,A randomized placebo-controlled study to assess safety and preliminary efficacy of BGP345A in patients with constipation due to the use of opioid-based medications for the management of chronic non ca...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000239-29,0,0,0 2021-000242-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Region Hospital Silkeborg,"The effect of the popliteal plexus block on postoperative opioid consumption, pain, muscle strength and mobilization after total knee arthroplasty - a randomized, controlled, blinded study Effekte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000242-17,0,0,0 2021-000243-50,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI""",Understanding the Impact of HIV-DNA resistance mutations detected by NGS in Simplification strategies to 2-Drug Regimens for patients virologically suppressed with previous failures and/or previous re...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000243-50,0,0,0 2021-000244-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,"MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer. Mito 35a -...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000244-21,0,0,0 2021-000245-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,"Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. The phase III randomized, open label MITO 35b study: a project...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000245-41,0,0,0 2021-000248-23,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Pfizer Inc.,"TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000248-23,0,0,0 2021-000248-23,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,PFIZER INC,"TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000248-23,0,0,0 2021-000250-26,8,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,AMYLYX PHARMACEUTICALS Inc.,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Late...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000250-26,0,0,0 2021-000250-26,8,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Amylyx Pharmaceuticals Inc.,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Late...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000250-26,0,0,0 2021-000251-39,5,2021-10-05,2021-11-05,4,0,0,0,0,1,2,0,0,1,1,0,0,0,1,"Takeda Development Center Americas, Inc.","A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000251-39,0,0,0 2021-000251-39,5,2021-10-05,2021-11-05,4,0,0,0,0,1,2,0,0,1,1,0,0,0,1,TAKEDA DEVELOPMENT CENTER AMERICAS INC.,"A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000251-39,0,0,0 2021-000264-29,1,2022-04-25,2022-04-25,1,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Vicore Pharma AB,"A randomized, double-blind, placebo-controlled, parallel group, phase 3, multicenter trial investigating the efficacy and safety of C21 as add on to standard of care in adult subjects with COVID-19. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000264-29,0,0,0 2021-000265-33,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,The Rotterdam Eye Hospital,Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000265-33,0,0,0 2021-000266-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,"Effect of proton pump inhibitors on the structural integrity of endoscopic sleeve gastroplasty: a single-centre open-label, randomized, controlled pilot clinical trial Effetto degli inibitori di po...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000266-15,0,0,0 2021-000267-72,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (OR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000267-72,0,0,0 2021-000267-72,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (OR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000267-72,0,0,0 2021-000269-34,1,2022-01-17,2022-01-17,1,0,0,0,0,0,3,0,0,1,1,1,0,0,1,Grifols Therapeutics LLC,"A Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of Anti-COVID-19 Immune Globulin (Human) 20% (C19-IG 20%) versus Placebo in Asymptomatic Ambulatory Ou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000269-34,0,0,0 2021-000270-28,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,Selective Indocyanine Green Injection of a Segmental Hepatic Artery Followed by Near-Infrared Fluorescence Guided Anatomical Liver Resection: A Feasibility Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000270-28,0,0,0 2021-000271-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Philipps University Marburg,"Guselkumab in Patients with Oral Lichen Planus - An open label, parallel, randomized, multi- center, phase II trial Guselkumab in Patienten mit oralem Lichen-Planus – Eine offene, parallele, rando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000271-36,0,0,0 2021-000275-36,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Sahlgrenska University Hospital,"Prevention of Glucocorticoid induced impairment of bone metabolism – A Randomized, Placebo-Controlled, Single Centre Clinical Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000275-36,0,0,0 2021-000290-84,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Seimc-Gesida Foundation,Virologic Outcomes of Lamivudine/Dolutegravir in Virologically suppressed subjects with Expected or confirmed Resistance to Lamivudine (VOLVER study). Eficacia virológica de dolutegravir/lamivudina...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000290-84,0,0,0 2021-000291-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Medical University of Vienna,Characterization of immune responsiveness after SARS-CoV-2 Vaccination in patients with Immunodeficiency or immunosuppressive therapy (COVID-19),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000291-11,0,0,0 2021-000293-28,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Aravive, Inc.","A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB S6 500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer 3. fáze,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000293-28,0,0,0 2021-000296-36,8,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Zymeworks Inc.,"A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000296-36,0,0,0 2021-000300-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Antwerp University Hospital,"Vaccination against cOvid-19 In CancER patients under active treatment (Belgium, B-VOICE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000300-38,0,0,0 2021-000304-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU de Poitiers,Tumescent anesthesia efficiency in pain management during a dynamic phototherapy session in vertex actinic keratosis treatment: a single-center prospective randomized study.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000304-38,0,0,0 2021-000305-24,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,"Anebulo pharmaceuticals, Inc.","A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of CB1 antagonist ANEB-001 in healthy occasional can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000305-24,0,0,0 2021-000307-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Novartis Pharma Vertriebs GmbH,Tracking the immune response to SARS-CoV-2 modRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab s.c. (KYRIOS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000307-20,0,0,0 2021-000311-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,Fixed-duration therapy with ibrutinib and obinutuzumab (GA-101) in treatment-naïve patients with CLL Terapia a durata fissa con ibrutinib e obinutuzumab (GA-101) in pazienti con leucemia linfatica ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000311-23,0,0,0 2021-000316-31,1,2021-08-30,2021-08-30,1,1,0,0,0,0,3,0,0,1,1,1,1,0,1,FAES FARMA S.A.,"Multicenter, double-blind, randomized clinical trial to evaluate the efficacy of calcifediol soft capsules versus placebo in reducing hospital admissions in patients with a positive diagnostic test fo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000316-31,0,0,0 2021-000317-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación para la Gestión de la Investigación Biomédica de Cádiz-INIBICA,Survival analysis after neoadjuvant therapy in patients with resectable pancreatic cancer and risk factors ANÁLISIS DE SUPERVIVENCIA TRAS NEOADYUVANCIA EN CÁNCER DE PÁNCREAS RESECABLE CON FACTORES ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000317-17,0,0,0 2021-000319-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Charité – Universitätsmedizin Berlin,Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000319-21,0,0,0 2021-000320-35,1,2021-05-28,2021-05-28,1,0,0,0,0,0,2,0,0,1,0,0,1,0,1,Oxygen Biotech s.r.o.,"Open label, monocentric pilot study to evaluate safety and efficacy of Bazedoxifene in addition to Standard of Care in hospitalized COVID-19 patients suffering from moderate to severe Pneumonia Ote...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000320-35,0,0,0 2021-000324-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboudumc,Anakinra in Cerebral haemorrhage to Target secondary Injury resulting from Neuroinflammation - a phase II clinical trial Het gebruik van Anakinra om hersenschade door inflammatie na een intracerebr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000324-36,0,0,0 2021-000325-26,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Annexon Biosciences,"Phase 2a Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Intravenous ANX005 in Subjects with Amyotrophic Lateral Sclerosis Étude de phase 2a sur l'innocuité, la tolérance, la ph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000325-26,0,0,0 2021-000333-13,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,APHP DRCI,Efficacy of the nonavalent HPV vaccine in the treatment of difficult-to-treat palmo-plantar warts Efficacité du vaccin HPV nonavalent dans le traitement des verrues palmo-plantaires difficiles à tr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000333-13,0,0,0 2021-000336-55,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Open Label, Randomised, 3 Arm, Multi Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET Driven, Unresectable and Locally Adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000336-55,0,0,0 2021-000336-55,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase III, Open Label, Randomised, 3 Arm, Multi Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Durvalumab Monotherapy in Participants with MET Driven, Unresectable and Locally Adva...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000336-55,0,0,0 2021-000343-53,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Xenikos B.V.,"A Phase 3, Randomized, Open-Label, Multicenter Study, to Compare T-Guard to Ruxolitinib for the Treatment of Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000343-53,0,0,0 2021-000344-21,5,2022-07-28,2022-07-28,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,MetrioPharm AG,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PROOF-OF-CONCEPT, PHASE IIA STUDY OF MP1032 PLUS STANDARD OF CARE VS STANDARD OF CARE IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH MODERA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000344-21,1,0,0 2021-000346-18,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Banc de Sang i Teixits,"A phase I/II, randomized, double-blind, placebo-controlled, parallel, 2-arms clinical trial to assess the safety and efficacy of intrathecal administration of WJ-MSC in chronic traumatic cervical inco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000346-18,0,0,0 2021-000348-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Keros Therapeutics, Inc.","A Phase 2, Open-label, Dose Escalation and Dose Expansion Study of KER-047 for the Treatment of IRIDA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000348-22,0,0,0 2021-000349-42,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,3,"Sahlgrenska Academy, University of Gothenburg",Evaluation of the Durability of Immune Responses to SARS-CoV-2 Using Novel Rapid Spike Interferon-Gamma Release and Activation-Induced Marker Assays and Anti-Spike IgG Following COVID-19 Vaccination,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000349-42,0,0,0 2021-000350-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Oryzon Genomics, S.A.","A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000350-26,0,0,0 2021-000352-19,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,UCB Biopharma SRL,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants Wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000352-19,0,0,0 2021-000354-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FINBA,A multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients: efficacy and microbiologic safety. Un ensayo aleatorizado multicéntrico de fosfomi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000354-25,0,0,0 2021-000355-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest,SOLARIS – A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refractory to atezolizumab and bevacizumab/ IO-based therapy S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000355-40,0,0,0 2021-000357-26,2,2022-06-06,2022-06-06,1,0,0,0,0,0,3,0,1,2,0,0,0,0,1,GlaxoSmithKline S.A.,"A Phase III, observer-blind, randomized, multi-country study to evaluate the lot-to-lot consistency of GSK’s investigational RSV maternal vaccine and the immune response, safety and reactogenicity of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000357-26,1,0,0 2021-000357-26,2,2022-06-06,2022-06-06,1,0,0,0,0,0,3,0,1,2,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase III, observer-blind, randomized, multi-country study to evaluate the lot-to-lot consistency of GSK’s investigational RSV maternal vaccine and the immune response, safety and reactogenicity of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000357-26,1,0,0 2021-000360-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Hospital,Determination of serum paracetamol concentration with an electrochemical measurement tool from blood and saliva samples in patients using also other medication.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000360-30,0,0,0 2021-000362-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg and its Commercial",Early Stage Follicular Lymphoma and Radiotherapy PLUS anti-CD20 Antibody Therapie des nodalen Follikulären Lymphoms im frühen Stadium: Radiotherapie plus anti-CD20 Antikörper,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000362-15,0,0,0 2021-000364-30,1,,,0,1,0,1,0,0,1,0,0,4,0,0,0,0,1,Eli Lilly and Company,"A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000364-30,0,1,1 2021-000365-33,1,2021-08-20,2021-08-20,1,1,0,0,0,0,2,0,0,1,0,0,1,0,1,Molecular Partners AG,"A Phase 2a open label, non-comparative, single dose escalation study to evaluate the dynamics of viral clearance, pharmacokinetics and tolerability of ensovibep in patients with symptomatic COVID-19 d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000365-33,0,0,0 2021-000382-32,2,2022-09-09,2022-09-09,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,DOMPé FARMACEUTICI S.P.A.,"A multicenter, randomized, double-blind, placebo-controlled phase 2 study to assess the efficacy and safety of oral reparixin in cancer related fatigue in patients with locally advanced or metastatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000382-32,1,0,0 2021-000382-32,2,2022-09-09,2022-09-09,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Dompé farmaceutici s.p.a.,"A multicenter, randomized, double-blind, placebo-controlled phase 2 study to assess the efficacy and safety of oral reparixin in cancer related fatigue in patients with locally advanced or metastatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000382-32,1,0,0 2021-000386-32,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,F2G Ltd.,"A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000386-32,0,0,0 2021-000387-30,2,2022-06-28,2022-06-28,1,0,0,0,0,0,3,0,0,2,0,0,0,0,1,"Concert Pharmaceuticals, Inc.","A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CTP-543 IN ADULT PATIENTS WITH MODERATE TO SEVERE ALOPECIA AREATA ESTUDIO DOBLE CIEGO, ALEATORIZADO Y CON...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000387-30,1,0,0 2021-000392-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Oslo University Hospital,A double-blind randomized placebo-controlled four-arm trial to assess the efficacy of oral bicarbonate and intravenous butylscopolamine bromide to facilitate spontaneous (non-operative) delivery in pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000392-37,0,0,0 2021-000398-10,5,2022-10-13,2022-10-13,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, multicenter, double-blind, Phase 3 study of amcenestrant (SAR439859) versus tamoxifen for the treatment of patients with hormone receptor-positive, human epidermal growth factor 2-negati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000398-10,1,0,0 2021-000398-10,5,2022-10-13,2022-10-13,3,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Sanofi-aventis recherche & développement,"A randomized, multicenter, double-blind, Phase 3 study of amcenestrant (SAR439859) versus tamoxifen for the treatment of patients with hormone receptor-positive, human epidermal growth factor 2-negati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000398-10,1,0,0 2021-000399-12,2,2022-01-07,2022-01-07,2,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Grand Medical Pty Ltd,"A Randomized, Open-Label, Multi-Centre, Phase 2a Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects with Severe COVID-19 Pneumonia Een gerandomizeerde, open-label, m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000399-12,0,0,0 2021-000401-24,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Sciensano,Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection (PICOV) A Non-commercial multicentre academic prospective cohort study in nursing hom...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000401-24,0,0,0 2021-000403-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Anna-Kaisa Tuomaala,Glycemic outcomes and safety with Minimed 780G system in children with type 1 diabetes aged 2-6 years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000403-21,0,0,0 2021-000404-37,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,LEO Pharma A/S,"A phase 1 open-label, multi-centre, single-arm trial to evaluate the safety and pharmacokinetics (including MUsT) of twice daily topical application of delgocitinib cream for 8 weeks in adults, adoles...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000404-37,0,1,1 2021-000407-20,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE HOPITAUX DE PARIS,Treatment of nonsevere sporadic Hemophagocytosis Lymphohistiocytosis (HLHs) with ITACITINIB: a phase II prospective trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000407-20,0,0,0 2021-000408-39,1,,,0,1,0,0,0,0,3,0,1,1,1,1,0,1,1,SCS Boehringer Ingelheim Comm. V,"A Phase III randomized, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for post-exposure prevention of SARS-CoV-2 i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000408-39,0,0,0 2021-000412-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Hopital Erasme, Université Libre de Bruxelles",COVID-19: Sars-Cov2 vaccination in kidney transplant patient: a phase IV study of the immunogenicity and its determinants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000412-28,0,0,0 2021-000413-17,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Region Skåne - Kliniska Studier Sverige, Forum Söder","COVERS (COVID-Vaccination Efficiency Risk and Safety Study) - an open trial for follow-up of efficacy, risk and safety in persons who have been vaccinated against SARS-CoV-2 in Region Skåne with vacci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000413-17,0,0,0 2021-000414-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut régional du Cancer de Montpellier,Multicentric Phase II-III study evaluating the tailored management of locally-advanced rectal carcinoma after a favorable response to Induction chemotherapy Essai phase II-III multicentrique évalua...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000414-41,0,0,0 2021-000415-23,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Pharma Mar, S.A.","Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM14 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors Estudio clínico y farmacoci...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000415-23,0,0,0 2021-000417-16,1,2022-08-03,2022-08-03,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,University of Cologne,A Phase I / randomized Phase II trial to analyse safety and efficacy of human SARS-CoV 2 specific T lymphocyte transfer in patients with COVID-19 in need of treatment or at risk of severe COVID-19 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000417-16,0,0,0 2021-000421-27,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Bayer AG,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000421-27,0,0,0 2021-000421-27,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,BAYER AG,"A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of k...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000421-27,0,0,0 2021-000424-35,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urtica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000424-35,0,0,0 2021-000425-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación GECP,Nivolumab plus Ipilimumab plus two cycles of platinum-based chemotherapy as first line treatment for stage IV/recurrent non-small cell lung cancer (NSCLC) patients with synchronous Brain metastases ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000425-27,0,0,0 2021-000428-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Zealand University Hospital, Department of Anaesthesiology","Oral dexamethasone as an adjunct to a brachial plexus block in patients undergoing orthopaedic surgery of the forearm and hand. A randomised, blinded, placebo-controlled, parallel, triple-arm clinical...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000428-36,0,0,0 2021-000429-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Zealand University Hospital, Department of Anaesthesiology","Combined intravenous dexamethasone and dexmedetomidine as adjuncts to popliteal and saphenous nerve blocks in patients undergoing orthopaedic surgery of the foot and ankle. A randomised, blinded, plac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000429-28,0,0,0 2021-000437-13,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients with Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000437-13,0,0,0 2021-000440-22,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Universiteit Antwerpen,Vaccination against COVID-19 in Pregnant and Lactating Women in Belgium,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000440-22,0,0,0 2021-000441-41,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Numab Therapeutics AG,A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients with Advanced Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000441-41,0,0,0 2021-000442-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,National Institute of Cardiology,Strategy To Optimize PeriproCeduraL AnticOagulation in Structural Transseptal Interventions (STOP CLOT Trial) Optymalna śródzabiegowa strategia antykoagulacji u chorych poddawanych procedurom kardi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000442-18,0,0,0 2021-000444-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC,Differences in coagulation between fresh frozen plasma and Solventdetergent plasma in pediatric congenital heart surgery,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000444-22,0,0,0 2021-000448-23,4,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,Galderma S.A.,"A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000448-23,0,0,0 2021-000452-19,5,,,0,0,0,0,0,0,3,0,0,2,0,0,0,0,1,ObsEva S.A.,"A long-term follow-up study to assess bone mineral density in subjects with uterine fibroids completing the Phase 3 studies of linzagolix, PRIMROSE 1 or PRIMROSE 2",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000452-19,0,0,0 2021-000454-26,1,2022-08-03,2022-08-03,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,Leiden University Medical Center,"Establishing the safety, tolerability and immunogenicity of intradermal delivery of mRNA SARS-CoV-2 vaccine in healthy adults Veiligheid en immunogeniciteit van intradermale injectie van mRNA SARS-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000454-26,0,0,0 2021-000455-39,1,2022-08-22,2022-08-22,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Pharma Holdings AS,"A double-blind, placebo-controlled, interventional parallel group study to evaluate the antiviral effect of a single nasal application of LTX-109 3% gel, in comparison to placebo gel, in subjects with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000455-39,0,0,0 2021-000456-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Ghent,Use of 18F-PSMA-11 PET for detection of lesions in iodine refractory thyroid cancers Gebruik van 18F-PSMA PET voor detectie van letsels bij iodiumrefractaire schildkliertumoren.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000456-19,0,0,0 2021-000458-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE,Pilot study on electrochemotherapy in metastatic breast cancer (BREAST ECT) Studio pilota su elettrochemioterapia nel cancro della mammella metastatico (BREAST ECT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000458-24,0,0,0 2021-000461-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Hopital Erasme, Université Libre de Bruxelles",Covid-19: Sars-Cov2 vaccination in hemodialysis patient: a phase IV study of the immunogenicity and its determinants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000461-33,0,0,0 2021-000465-32,7,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000465-32,0,0,0 2021-000465-32,7,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000465-32,0,0,0 2021-000468-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Kooperativní lymfomová skupina, z.s.","A phase II, open-label, study of polatuzumab-vedotin in combination with bendamustine and rituximab for patients with mantle cell lymphoma, who relapse after previous therapy with Bruton tyrosine kina...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000468-32,0,0,0 2021-000469-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Amsterdam UMC location AMC,"A Prospective Multicenter Randomized Controlled, Open-label Study to Compare the Efficacy of Subcutaneous Infliximab Monotherapy with Subcutaneous Infliximab and Concomitant Immunosuppression in the T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000469-33,0,0,0 2021-000471-37,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urtica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000471-37,0,0,0 2021-000471-37,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Farmacéutica S.A.,"A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urtica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000471-37,0,0,0 2021-000471-37,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urtica...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000471-37,0,0,0 2021-000472-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BIOPROJET PHARMA,"A double-blind, placebo-controlled pilot trial of BP1.4979 for the treatment of binge eating disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000472-11,0,0,0 2021-000473-83,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació ACE-Institut Català de Neurociències Aplicades,PET imaging study of the brain tau deposit in individuals with subjective cognitive decline and mild cognitive impairment: FACEHBI cohort. Estudio de imagen PET del depósito cerebral de tau en indi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000473-83,0,0,0 2021-000474-29,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"PTC Therapeutics, Inc.",A Phase 3 Study of PTC923 in Subjects with Phenylketonuria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000474-29,0,0,0 2021-000482-32,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3B, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants with Active Psoriatic Arthritis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000482-32,0,0,0 2021-000486-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Turku University Hospital,"99mTc-MIP-1404 SPECT/CT for primary PROstate cancer STAging: comparative prospective, randomized trial to present guideline imaging",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000486-33,0,0,0 2021-000491-10,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000491-10,0,0,0 2021-000492-36,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,UCLouvain,Home and Outpatients Precocious Eradication of COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000492-36,0,0,0 2021-000493-29,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants with Recurrent or Refractory Classical H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000493-29,0,0,0 2021-000497-28,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"PTC Therapeutics, Inc.",Phase 3 Open-Label Extension Study of PTC923 in Phenylketonuria,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000497-28,0,0,0 2021-000507-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Instituto de Investigación Sanitaria INCLIVA,"Phase II randomized trial to assess the effect of intensive vs standard adjuvant chemotherapy in localised colon cancer with circulating tumor DNA Ensayo clínico aleatorizado, fase II, para evaluar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000507-20,0,0,0 2021-000508-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Hanmi Pharm. Co., Ltd.","A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000508-39,0,0,0 2021-000509-26,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Inserm-ANRS,A phase II trial assessing immunogenicity and safety of COVID-19 mRNA Vaccine BNT162b2 in adult volunteers with no history of SARS CoV-2 infection administered with two doses of vaccine (D1-D29) and i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000509-26,0,0,0 2021-000510-42,2,2022-08-10,2022-08-10,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Janssen-Cilag International NV,"A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Proof-of-concept Study Evaluating the Efficacy and Safety of Nipocalimab Administered Intravenously in Participants with Ac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000510-42,1,0,0 2021-000515-24,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,Erasmus University Medical Center,Vaccination Against Covid in Primary Immune Deficiencies Covid-19 vaccinatie in primaire immuundeficienties,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000515-24,0,0,0 2021-000516-37,1,2022-01-21,2022-01-21,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,TurnSole Biologics Llc,"A Phase I/II open-label study for Azacitidine, initiated with a lead-in dose escalation pharmacokinetic Phase I/b part in the 20–50 mg/m2 range to evaluate safety in Hospitalized COVID-19 Patients in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000516-37,0,0,0 2021-000518-40,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Leiden University Medical Center,"RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials - The MMRD-GREEN trial -",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000518-40,0,0,0 2021-000520-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA,Multiparametric assessment of bone response in mCRPC patients treated with Cabozantinib upon progression to chemotherapy and next generation hormonal agents: a phase II study VALUTAZIONE MULTIPARAM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000520-35,0,0,0 2021-000541-41,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Oslo University Hospital,European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000541-41,0,0,0 2021-000541-41,11,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,OSLO UNIVERSITETSSYKEHUS HF,European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000541-41,0,0,0 2021-000542-18,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Amgen Inc.,"A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Multiple Switches Between Humira® (adalimumab [US]) and ABP 501 Compared With Con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000542-18,0,0,0 2021-000545-40,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University of Vienna,"Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection – A Phase 2 Pilot Trial Sicherheit, Verträglichkeit und Effektivität de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000545-40,0,0,0 2021-000546-17,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"SERENA-6: A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000546-17,0,0,0 2021-000546-17,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"SERENA-6: A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000546-17,0,0,0 2021-000548-23,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,University Medical Center Hamburg-Eppendorf,"A multi-center, phase Ib trial to assess the safety, tolerability and immunogenicity of the candidate vaccine MVA-SARS-2-ST in adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000548-23,0,0,0 2021-000549-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Oslo University Hospital,PreMeFen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000549-42,0,0,0 2021-000553-40,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer thera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000553-40,0,0,0 2021-000553-40,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer thera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000553-40,0,0,0 2021-000553-40,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer thera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000553-40,0,0,0 2021-000554-26,6,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Sustained Virologic Response in Chronic Hepatitis B Participants With and Without Nucleos(t)ide Therapy Who Have Received...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000554-26,0,0,0 2021-000554-26,6,,,0,0,0,0,0,0,2,0,0,2,1,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Sustained Virologic Response in Chronic Hepatitis B Participants With and Without Nucleos(t)ide Therapy Who Have Received...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000554-26,0,0,0 2021-000556-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Rigshospitalet, Department of Anaesthesia, Centre of Head and Orthopaedics",Comparing Restrictive vs. Liberal Oxygen Strategies for Trauma Patients: The TRAUMOX2 Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000556-19,0,0,0 2021-000559-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Herlev and Gentofte University Hospital, Department of Obstetrics and Gynecology","The effect of intravesical Lidocaine solution versus placebo as anesthesia prior to intravesical injection of onabotulinum toxin A. A randomized, double-blind, placebo controlled cross-over study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000559-38,0,0,0 2021-000563-69,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Ilya Pharma AB,"A Randomized, Double-Blind, Placebo-controlled, Parallel, Exploratory Phase 2a Study to Evaluate Safety and Biological Effect on Wound Healing of ILP100 in Subjects with Diabetic Foot Ulcers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000563-69,0,0,0 2021-000566-14,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Masarykova univerzita,Post-authorization Phase IV effectiveness and safety multicentric study of COVID-19 vaccines – CoVigi Poregistrační multicentrická studie fáze IV sledující účinnost a bezpečnost vakcín proti COVID-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000566-14,0,0,0 2021-000567-77,4,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,"A Short-term Exploratory Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000567-77,0,1,0 2021-000567-77,4,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Short-term Exploratory Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000567-77,0,1,0 2021-000570-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Tampere University Hospital,"Accelerated infliximab infusions in inflammatory bowel disease, Phase IV trial Nopeutetut infliksimabi-infuusiot tulehduksellisissa suolisairauksissa, Faasi IV-tutkimus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000570-28,0,0,0 2021-000573-80,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,APHP DRCI,"Acute Myocardial infarction Upbound to percutaneous coronary intervention, immediately (STEMI) or in the Next three Days (NSTEMI), and randomized to Subcutaneous Evolocumab or Normal strategies to rea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000573-80,0,0,0 2021-000574-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FUNDACIÓ CLÍNIC PER A LA RECERCA BIOMÈDICA,Erector Spinae Plane block in robotic cardiac surgery Bloqueo en el Plano del Erector Espinal en cirugía cardiaca robótica,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000574-29,0,0,0 2021-000580-78,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,The Children’s Memorial Health Institute,"""The assessment of effectiveness and safeness of utilizing empagliflozin in the treatment of neutropenia of patients suffering from glycogenolysis type Ib"" „Ocena skuteczności i bezpieczeństwa emp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000580-78,0,0,0 2021-000583-30,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Suzhou Connect Biopharmaceuticals Ltd.,"A Multi-center, Randomized, Double-blind, Parallel Group, Placebo-controlled, Efficacy and Safety Study of CBP-201 in Patients with Moderate to Severe Persistent Asthma with Type 2 Inflammation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000583-30,0,0,0 2021-000585-15,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Suzhou Connect Biopharmaceuticals Ltd.,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate CBP-201 in Adult Patients with Chronic Rhinosinusitis with Nasal Polyps",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000585-15,0,0,0 2021-000591-10,9,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000591-10,0,0,0 2021-000591-10,9,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000591-10,0,0,0 2021-000591-10,9,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000591-10,0,0,0 2021-000593-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CHU DE BORDEAUX,A Prospective Pilot Study to assess the efficacy of BOTOX-A in patients with Low Anterior Resection syndrome (LARS>20) and refractory medical treatment after rectal resection Etude pilote prospecti...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000593-29,0,0,0 2021-000598-95,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Camurus AB,"A Phase 2, randomized, double-blind, placebo-controlled, multi-center trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acute respiratory distress syn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000598-95,0,0,0 2021-000602-17,8,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Novartis Farmacéutica S.A.,"An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit fro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000602-17,0,0,0 2021-000602-17,8,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit fro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000602-17,0,0,0 2021-000602-17,8,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit fro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000602-17,0,0,0 2021-000603-21,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Canc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000603-21,0,0,0 2021-000603-21,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Canc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000603-21,0,0,0 2021-000605-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IDIAP Jordi Gol,"Double-blind Randomized Clinical Trial, Placebo-controlled to Assess the Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID: E-SPERANZA COVID PROJECT Ensayo c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000605-24,0,0,0 2021-000608-39,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Idogen AB,"An open-label, multi-center, first in human, phase 1/2a trial to evaluate the safety and preliminary efficacy of autologous tolerogenic dendritic cells ex vivo loaded with recombinant Factor VIII (FVI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000608-39,0,0,0 2021-000610-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Amsterdam UMC - location VUmc,Dynamic and test-retest whole body [18F]FES PET imaging in patients with metastatic ER+ breast cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000610-42,0,0,0 2021-000613-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Charité – Universitätsmedizin Berlin,"CCR1 antagonist treatment in patients hospitalized with COVID-19 A multi-centric, randomized, double-blind, and placebo-controlled clinical phase II trial CCR1 Antagonist Behandlung zur Therapie vo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000613-16,0,0,0 2021-000617-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Karyopharm Therapeutics Inc.,"Open-Label, Phase 1/2 Study Evaluating the Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics and the Tolera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000617-16,0,0,0 2021-000621-27,7,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,"TRAVERE THERAPEUTICS, INC","A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000621-27,0,0,0 2021-000621-27,7,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,"Travere Therapeutics, Inc.","A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000621-27,0,0,0 2021-000623-13,3,,,0,0,1,0,0,0,3,0,0,2,0,0,0,0,1,"Vir Biotechnology, Inc.","A Phase 3 randomized, multi-center, open label study to assess the efficacy, safety, and tolerability of monoclonal antibody VIR-7831 (sotrovimab) given intramuscularly versus intravenously for the tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000623-13,0,0,0 2021-000625-27,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Oulu Functional NeuroImaging, MRC/MIPT, Oulu University Hospital",Augmenting glymphatic function with electroacoustic treatment. Glymfaattisen toiminnan tehostaminen elektroakustisella hoidolla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000625-27,0,0,0 2021-000627-12,6,2022-03-16,2022-03-16,4,1,0,0,2,0,3,0,0,2,1,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A MULTICENTER, OBSERVATIONAL, 6 MONTH FOLLOW-UP STUDY OF PATIENTS WITH COVID 19 PREVIOUSLY ENROLLED IN A RO7496998 (AT-527) STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000627-12,1,0,0 2021-000627-12,6,2022-03-16,2022-03-16,4,1,0,0,2,0,3,0,0,2,1,0,0,0,1,F. Hoffmann La Roche Ltd.,"A MULTICENTER, OBSERVATIONAL, 6 MONTH FOLLOW-UP STUDY OF PATIENTS WITH COVID 19 PREVIOUSLY ENROLLED IN A RO7496998 (AT-527) STUDY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000627-12,1,0,0 2021-000630-34,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,"Takeda Development Center Americas, Inc.",A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Intravenous in Pediatric Patients With Ulcerative Colitis or Crohn’s Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000630-34,0,0,0 2021-000633-14,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Státní zdravotní ústav,DYNAMICS OF POSTVACCINATION ANTI- SARS-COV-2 ANTIBODY RESPONSE IN EMPLOYES OF THE NATIONAL INSTITUTE OF PUBLIC HEALTH AND VOLUNTARIES 1-2021 STUDIE DYNAMIKY POSTVAKCINAČNÍCH PROTILÁTEK ANTI- SARS-C...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000633-14,0,0,0 2021-000634-33,8,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harbori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000634-33,0,0,0 2021-000634-33,8,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harbori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000634-33,0,0,0 2021-000637-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AZIENDA USL TOSCANA CENTRO,Cardiac and renal protective effect of colchicine early on-admission administered in patient with acute coronaric syndrome in treatment with atorvastatin Effetto cardio- e nefro-protettivo della co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000637-13,0,0,0 2021-000639-30,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AB Science,"A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000639-30,0,0,0 2021-000640-21,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"Center for Pain Medicine, Erasmus MC",Long-term pain modulation by intravenous esketamine in Complex Regional Pain Syndrome: a non-inferiority study Lange-termijn pijnmodulatie met intraveneuze esketamine bij Complex Regionaal Pijnsynd...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000640-21,0,0,0 2021-000641-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Helse Bergen HF, Haukeland University Hospital",PROSPECTIVE COMPARISON OF SIROLIMUS AGAINST CORTICOSTEROIDS IN TREATMENT OF PATIENTS WITH ACTIVE THYROID EYE DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000641-41,0,0,0 2021-000648-23,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000648-23,0,0,0 2021-000648-23,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000648-23,0,0,0 2021-000665-32,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) Studio multicentrico, randomizzato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000665-32,0,0,0 2021-000665-32,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) Studio multicentrico, randomizzato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000665-32,0,0,0 2021-000667-74,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Medisch Centrum Leeuwarden BV,The effect of bile acid binding with colesevelam on postprandial glucose concentrations in patients after RYGB and cholecystectomy : a meal test study Het effect van galzuurbinding met Colesevelam ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000667-74,0,0,0 2021-000670-28,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A randomized, participant- and investigator-blinded, placebo-controlled study to investigate efficacy, safety and tolerability of LTP001 in participants with pulmonary arterial hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000670-28,0,0,0 2021-000670-28,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, participant- and investigator-blinded, placebo-controlled study to investigate efficacy, safety and tolerability of LTP001 in participants with pulmonary arterial hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000670-28,0,0,0 2021-000672-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000672-11,0,0,0 2021-000673-83,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Liège,Impact of the immune system on response to COVID-19 vaccine in allogeneic stem cell recipients Impact du système immunitaire sur la réponse au vaccin COVID-19 chez les patients ayant reçu une allog...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000673-83,0,0,0 2021-000678-27,14,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000678-27,0,0,0 2021-000678-27,14,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000678-27,0,0,0 2021-000678-27,14,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Novartis Farmacéutica S.A.,"A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000678-27,0,0,0 2021-000679-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP),"SATELITE “Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis” SATELITE ""Traitement de sauvetage pour les patients ayant une répons...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000679-35,0,0,0 2021-000680-74,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Laboratorios Viñas, S.A.","Multicenter, randomized, double-blind, comparative clinical trial to assess the efficacy of Zinc Acexamate (ACZ) versus placebo in the prevention of events in patients with compensated liver cirrhosis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000680-74,0,0,0 2021-000682-32,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Prestige Biopharma Limited,"A First in human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients with Advanced/Metastatic Pancreatic Cancer Pri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000682-32,0,0,0 2021-000683-30,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,Umeå university,"CoVacc - Immune response to vaccination against Covid-19, an open multicenter phase IV study CoVacc - Immunsvar vid vaccination mot Covid-19, en öppen multicenter fas IV studie",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000683-30,0,0,0 2021-000685-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Axcella Health, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of AXA1125 in Subjects With Non Cirrhotic, Non Alcoholic Steatohepatitis and Fibro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000685-15,0,0,0 2021-000687-30,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Arrowhead Pharmaceuticals, Inc.","A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Severe Hypertriglyceridemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000687-30,0,0,0 2021-000688-57,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Arrowhead Pharmaceuticals, Inc.","A Double-blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Mixed Dyslipidemia Kettős vak, placebo kontrollált IIb. fázisú vizsgálat az ARO APO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000688-57,0,0,0 2021-000689-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Helsinki University Hospital,The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile Yksilöllistä syövänho...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000689-14,0,0,0 2021-000691-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Rigshospitalet,Comparison of the effect of xylometazoline and cocaine on epistaxis when administered as local vasoconstrictors prior to nasal intubation Sammenligning af effekten af xylometazolin og kokain på mæn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000691-11,0,0,0 2021-000692-36,3,2022-09-15,2022-09-15,2,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A 12-week, randomized, participant-and investigator-blinded, placebo-controlled, parallel group study to explore the efficacy, pharmacodynamics, safety, and pharmacokinetics of two doses of inhaled CS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000692-36,1,0,0 2021-000694-85,12,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000694-85,0,0,0 2021-000694-85,12,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,VERTEX PHARMACEUTICALS INCORPORATED,"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000694-85,0,0,0 2021-000700-38,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,GENENTA SCIENCE SRL,A follow-up study evaluating the long term safety of autologous CD34+-enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human interferon-a2 gene pr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000700-38,0,0,0 2021-000701-24,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Erasmus MC,Switching of COVID-19 Vaccines: a solution for the problems?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000701-24,0,0,0 2021-000705-25,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ALX Oncology Inc.,A PHASE 1/2 STUDY OF ALX148 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) (ASPEN-02),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000705-25,0,0,0 2021-000706-21,1,2021-12-09,2021-12-09,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,"Amicus Therapeutics, Inc.",LONG-TERM FOLLOW-UP OF AT-GTX-501 SCAAV9 GENE TRANSFER IN SUBJECTS WITH CLN6 BATTEN DISEASE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000706-21,0,0,0 2021-000707-20,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Affimed GmbH,"A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination with Atezolizumab in Patients with Selected Advanced/Metastatic EG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000707-20,0,0,0 2021-000708-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Rheinische Friedrich-Wilhelms-Universität Bonn,Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy Phase I/II Studie zur Anwendung von Meclofenamate bei Glioblastom-Rezidiv mit m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000708-39,0,0,0 2021-000709-26,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Rigshospitalet, Centre of Head and Orthopaedics",Drug test detection 24 hours after nasal administration of cocaine as a local vasoconstrictor prior to nasal intubation Lægemiddeloptagelse 24 timer efter nasal administration af kokain som lokal v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000709-26,0,0,0 2021-000710-42,1,2022-02-16,2022-02-16,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,Sint Maartenskliniek,"The RTX-COVAC study: humoral response to COVID-19 vaccination after rituximab, and relation with dose and vaccination timing. A prospective cohort study. De RTX-COVAC studie: humorale response door...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000710-42,0,0,0 2021-000712-31,7,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000712-31,0,0,0 2021-000713-17,4,,,0,0,1,0,0,1,3,0,0,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000713-17,0,0,0 2021-000715-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE ITALIANA LINFOMI ONLUS,Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy: a phase II study in BTKi-treated (or BTKi intolerant) Relapsed/Refractory (R/R) Mantle Cell Lymphoma (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000715-23,0,0,0 2021-000720-36,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Academisch Medisch Centrum,oral PHA-022121 for the acute treatment and prophylaxis Of angioedema attacks in Patients with Acquired C1-Inhibitor Deficiency Oraal PHA-022121 voor de acute behandeling en profylaxe van angio-oed...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000720-36,0,0,0 2021-000722-96,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,Lymph Node Microenvironment Modifications in Patients with CLL Treated with Venetoclax-based regimens Modificazioni del microambiente linfonodali in pazienti con leucemia linfatica cronica CLL in t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000722-96,0,0,0 2021-000724-35,2,2022-04-06,2022-04-06,2,1,0,0,0,0,2,0,0,1,0,0,0,0,1,"Vir Biotechnology, Inc.","A Multicenter, Randomized, Double-Blind, Parallel Group Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Second Generation VIR-7831 Material in Non-Hospitalized Participan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000724-35,0,0,0 2021-000725-28,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Kymab Ltd, a Sanofi Company","A Phase IIb, Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000725-28,0,0,0 2021-000725-28,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Kymab Limited,"A Phase IIb, Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000725-28,0,0,0 2021-000726-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,Evaluating the short-term renal and systemic effects of Dapagliflozin in non-diabetic patients with stage IV CKD at risk of ESKD because of severe renal insufficiency and persistent proteinuria: A pro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000726-10,0,0,0 2021-000727-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital of Toulouse,Quality Assessment of Tracheal intubation without neuromuscular blocking drugs (Propofol+ Remifentanil) in obese patients: Pilot Study Évaluation de la qualité d’intubation sans curare (propofol...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000727-12,0,0,0 2021-000728-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Tampere University Hospital,Laparoskooppisen paksusuoliresektion leikkauksen jälkeisten kivunhoitomenetelmien vertailu nykytiedon valossa Laparoskooppisen paksusuoliresektion leikkauksen jälkeisten kivunhoitomenetelmien verta...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000728-36,0,0,0 2021-000730-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE TOSCANA GABRIELE MONASTERIO,"HeAd-to-head compaRison of single versus dual antiplatelet treatMent strategY after percutaneous left atrial appenDAge closure: A MULticenter, randomizEd sTudy the ARMYDA-AMULET study Confronto tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000730-34,0,0,0 2021-000731-31,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Maastricht University,Targeting the beta-2 adrenergic pathway to improve skeletal muscle glucose uptake in obese humans Activatie van het beta-2 adrenerge pathway in obese mensen om de glucose opname door de spier te ve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000731-31,0,0,0 2021-000732-54,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Rheinische Friedrich-Wilhelms-Universität Bonn,FINISHER - Fight Inflammation to Improve outcome after aneurysmal Subarachnoid Hemorrhage,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000732-54,0,0,0 2021-000733-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University of Vienna,"SGLT2 INHIBITION (DAPAGLIFLOZIN) IN DIABETIC AND NON-DIABETIC HEMODIALYSIS PATIENTS WITH AND WITHOUT RESIDUAL URINE VOLUME: A PROSPECTIVE RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PHASE II TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000733-14,0,0,0 2021-000738-32,2,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,Janssen-Cilag International NV,A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children Aged ≥3 Years and Weighing ≥15 ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000738-32,0,1,0 2021-000740-21,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Octapharma AG,"Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) therapy with factor Xa inhibitor.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000740-21,0,0,0 2021-000740-21,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,OCTAPHARMA AG,"Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) therapy with factor Xa inhibitor.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000740-21,0,0,0 2021-000743-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,PIERRE FABRE MéDICAMENT,Adjuvant encorafenib & binimetinib vs. placebo in resected stage II BRAF V600E/K mutated melanoma: a randomized triple-blind Phase III Study in collaboration with the EORTC Melanoma Group. Encorafe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000743-41,0,0,0 2021-000745-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA,Interventional clinical trial to assess efficacy and safety of the extemporaneous combination of Zofenopril calcium and amlodipine in grade 1-2 hypertensive patients versus each monotherapy Sperime...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000745-40,0,0,0 2021-000748-24,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Techfields Inc.,"A Phase 2, Multicenter, Randomized, Double-blind (Within Dose), Placebo-controlled, Parallel-group, and Dose-range-finding Study to Evaluate the Efficacy and Safety of TF0023 Versus Placebo in Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000748-24,0,0,0 2021-000761-33,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Kronos Bio, Inc.","A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000761-33,0,0,0 2021-000761-33,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Kronos Bio Inc.,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000761-33,0,0,0 2021-000764-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,"Hyperbaric Oxygen for Treatment of Long COVID syndrome; A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000764-30,0,0,0 2021-000781-15,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Amsterdam UMC VUmc,Neuroinflammation and post-infectious fatigue in individuals with and without Covid-19 Chronische vermoeidheidsklachten en neuro-inflammatie na een covid-19 infectie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000781-15,0,0,0 2021-000801-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IRCCS MATERNO INFANTILE BURLO GAROFOLO,Intranasal dexmedetomidine: pilot pharmacokinetics / pharmacodynamics (PK/PD) study in a preterm population undergoing percutaneous central venous catheter placement Dexmedetomidina intranasale: st...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000801-25,0,0,0 2021-000805-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Østfold Hospital Trust,"An Open-Label, Phase 2, Feasibility Study of Manualized MDMA-Assisted Psychotherapy in Subjects with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000805-26,0,0,0 2021-000824-36,5,,,0,0,0,1,0,1,1,0,2,3,0,0,0,0,1,Unicyte AG,"An open-label, controlled, multi-site, Phase I clinical trial to assess the ureagenesis capacity in newborns and infants up to the age of 12 months with neonatal and infantile onset of urea cycle diso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000824-36,0,0,0 2021-000826-89,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Rennes,Etude pharmacocinétique de l’apomorphine en perfusion sous-cutanée continue diurne chez le patient parkinsonien équilibré sous traitement Etude pharmacocinétique de l’apomorphine en perfusion sous-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000826-89,0,0,0 2021-000827-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Turku University Hospital,Clinical use of USPIO contrast media in the assessment of pelvic lymph node metastasis in rectal cancer. USPIO-varjoaineen kliininen käyttö peräsuolisyövän lantion imusolmukemetastasoinnin arvioinn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000827-11,0,0,0 2021-000829-27,10,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Sanofi-aventis Recherche & Développement,"A randomized, double-blind, head-to-head comparison of dupilumab versus omalizumab in severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and comorbid asthma patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000829-27,0,0,0 2021-000829-27,10,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A randomized, double-blind, head-to-head comparison of dupilumab versus omalizumab in severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and comorbid asthma patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000829-27,0,0,0 2021-000830-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA,Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial. PIPAC_VEROne La...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000830-33,0,0,0 2021-000835-30,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,"RESCUE THERAPY WITH THE HUMAN ANTI-CD38 ANTIBODY MOR202 (FELZARTAMAB) IN PATIENTS WITH MEMBRANOUS NEPHROPATHY WHO FAILED ANTI-CD20 TARGETED THERAPY: A PILOT, PROOF-OF-CONCEPT STUDY “Rescue therap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000835-30,0,0,0 2021-000842-16,1,,,0,0,0,0,0,0,4,0,1,1,0,0,0,1,0,Kristina Jakobsson,Does PFAS-exposure modify the risk of COVID-19 infection or the immunological response after vaccination against SARS-CoV-2? Modifierar PFAS-exponering risk för COVID-19 eller immunologiskt svar ef...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000842-16,0,0,0 2021-000843-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hellenic Institute for the Study of Sepsis,Fenofibrate as a Metabolic Intervention for Coronavirus Disease 2019 (COVID-19): A randomized controlled trial (FERMIN trial) Η ΦΑΙΝΟΦΙΜΠΡΑΤΗ ΩΣ ΜΕΤΑΒΟΛΙΚΗ ΠΑΡΕΜΒΑΣΗ ΓΙΑ ΤΗΝ ΝΟΣΟ COVID-19: ΜΙΑ ΤΥΧ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000843-33,0,0,0 2021-000845-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,CCGCRO,"Impact of time of alpelisib administration, concomitant fasting and low carbohydrate diet on alpelisib toxicity and efficacy; a pilot randomized controlled phase IIb trial - ITACA UTJECAJ VREMENA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000845-42,0,0,0 2021-000849-40,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Camurus AB,"A randomized, multi-center, open-label, active-controlled Phase 3 trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) versus octreotide LAR or lanreotide ATG in patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000849-40,0,0,0 2021-000850-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Jesús Rodríguez Requena,A study on the effect of an Echinacea formulation on the clinical manifestations and evolution of Covid-19. Estudio sobre el efecto de un preparado de Equinácea sobre las manifestaciones clínicas y...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000850-24,0,0,0 2021-000850-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,José Luis Pérez Albiac,A study on the effect of an Echinacea formulation on the clinical manifestations and evolution of Covid-19. Estudio sobre el efecto de un preparado de Equinácea sobre las manifestaciones clínicas y...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000850-24,0,0,0 2021-000853-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,DKMS gemeinnuetzige GmbH,Graft vs Host Disease Prophylaxis in unrelated donor transplantation: a randomized clinical trial comparing PTCY vs ATG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000853-17,0,0,0 2021-000854-24,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ALFASIGMA S.P.A.,"Velusetrag for the treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A multicenter double-blind, placebo-controlled, cross-over, multiple (n=1) trial. Velusetrag para el tratamiento de la ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000854-24,0,0,0 2021-000857-23,4,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti TIGIT/Anti-PD-1 Bispecific Antibody in Parti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000857-23,0,0,0 2021-000859-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Eupraxia Pharmaceuticals Inc.,"A Phase 2, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety, Efficacy and Pharmacokinetics of Single Dose EP-104IAR for 24 Weeks in Patients with Osteoarthritis of the Knee",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000859-39,0,0,0 2021-000862-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Copenhagen Affective Disorder research Center (CADIC),",Effects of low dose Aspirin in bipolar disorder – a randomized controlled trial (the A-Bipolar RCT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000862-14,0,0,0 2021-000863-56,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Aarhus University, The MR Research Center",Early detection of hepatocellular carcinoma by Hyperpolarized [1-13C]pyruvate MRI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000863-56,0,0,0 2021-000864-32,1,2022-04-04,2022-04-04,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,Erasmus MC,A Phase I-II study of virus neutralizing antibodies against SARS-CoV-2. A focus on convalescent plasma and hyperimmune anti-SARS-CoV2 immunoglobulines Een fase I-II studie over virus neutraliserend...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000864-32,0,0,0 2021-000865-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,INSTITUTO DE INVESTIGACIÓN SANITARIA BIOARABA,"Randomized, parallel controlled study with routine clinical practice to evaluate the efficacy and tolerability of PRFC ENDORET® in the treatment of frontal fibrosing alopecia Estudio aleatorizado, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000865-33,0,0,0 2021-000867-65,1,2021-10-30,2021-10-30,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Luye Pharma Switzerland AG,"Comparative, randomized, open, crossover clinical trial to investigate adhesiveness of a newly developed rotigotine-containing transdermal patch in patients with Parkinson's disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000867-65,0,0,0 2021-000868-30,1,2022-03-23,2022-03-23,1,0,0,0,0,0,4,0,1,1,0,0,0,0,0,RECOVAC consortium,"The immune-response and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant De immuun respons en veiligheid van COVID-19 vaccinat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000868-30,0,0,0 2021-000870-27,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000870-27,0,0,0 2021-000872-13,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University Medical Center Groningen,Vaccination against cOvid In CancEr,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000872-13,0,0,0 2021-000874-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Gyn.Dept, Aabenraa Hospital, Sygehus Sønderjylland","Effect of 24 mg dexamethasone preoperatively on surgical stress, pain and recovery in robotic-assisted laparoscopic hysterectomy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000874-28,0,0,0 2021-000877-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Bispebjerg Hospital, Department of Dermatology",Longevity of microwave thermolysis and botulinum toxin A for treatment of axillary hyperhidrosis: a randomized intra-individual trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000877-10,0,0,0 2021-000880-63,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Skåne University Hospital, department of rheumatology in Lud and Malmö","COVID-19 vaccine in patients with inflammatory rheumatic diseases: The impact of immunomodulating treatments on the antibody response, T cells response and protection against infection (COVID19-REUMA)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000880-63,0,0,0 2021-000890-10,2,2022-04-28,2022-04-28,1,0,0,0,0,0,2,0,0,1,1,1,0,0,1,Molecular Partners AG,"A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000890-10,0,0,0 2021-000891-12,1,,,0,0,0,1,0,0,1,0,1,4,0,0,0,0,1,GlaxoSmithKline Biologicals,"A staged Phase I/II observer-blind, randomised, controlled, multi-country study to evaluate the safety, reactogenicity, and immune responses to the GVGH altSonflex1-2-3 vaccine against S. sonnei and S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000891-12,0,0,0 2021-000893-27,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,AZ Sint-Jan Brugge-Oostende AV,COVID-19: study to detect transfer of SARS-Cov-2 antibodies in breastmilk,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000893-27,0,0,0 2021-000894-94,1,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,Vifor Fresenius Medical Care Renal Pharma Ltd.,"An Open-label, Single Arm Study to Evaluate the Pharmacokinetics of a Single Dose of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis Studio in aperto, a braccio singol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000894-94,0,0,0 2021-000898-83,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ADIENNE SA,"A phase II, randomized, double-blind, placebo-controlled, two-period, crossover trial to assess the efficacy and safety of begelomab in combination with standard steroid and/or immunosuppressant thera...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000898-83,0,0,0 2021-000903-19,3,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Ultragenyx Pharmaceutical Inc.,"A Phase 1/2 First-in-human, 2-part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part 1: Open-label) and Repeat Doses (Part 2: Randomized, Double-blind, P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000903-19,0,0,0 2021-000903-19,3,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,ULTRAGENYX PHARMACEUTICAL INC.,"A Phase 1/2 First-in-human, 2-part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part 1: Open-label) and Repeat Doses (Part 2: Randomized, Double-blind, P...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000903-19,0,0,0 2021-000904-39,4,,,0,0,0,0,0,0,3,0,1,2,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000904-39,0,0,0 2021-000905-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Oncology, Uppsala University Hospita",Immune response to Covid-19 vaccination in patients with immune modulatory treatment for cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000905-26,0,0,0 2021-000930-32,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,AZ Sint-Jan Brugge-Oostende AV,COVID-19: Documentation of humoral and cellular immune response of hemodialysis patients after vaccination against SARS-CoV-2 COVID-19: Documentatie van humorale en cellulaire immuunrespons van hem...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000930-32,0,0,0 2021-000932-70,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,ASSISTANCE PUBLIQUE -HOPITAUX DE PARIS,Randomized prospective trial evaluating the efficacy of the antiCD38 monoclonal antibody isatuximab in the treatment of PCRA by major ABO mismatch after allogeneic hematopoietic stem cell transplantat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000932-70,0,0,0 2021-000933-15,2,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A 52-week, open-label, single arm study to investigate the efficacy and safety of mepolizumab SC in participants aged 6 to 17 years with hypereosinophilic syndrome. Estudio abierto, de un solo grup...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000933-15,0,0,0 2021-000934-32,1,2022-03-11,2022-03-11,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,Coegin Pharma AB,"A single-center, randomized double-blind, vehicle-controlled, dose-ranging decentralised clinical trial to evaluate the safety and efficacy of daily field-directed topical applications of AVX001 sili...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000934-32,0,0,0 2021-000937-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,UMCG,A phase II non-inferiority design study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/refractory Non-Hodgkin Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000937-15,0,0,0 2021-000938-34,2,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Antwerp University Hospital,Single blind randomized controlled trial to assess the safety and efficacy of high dose pulse intravenous corticosteroid therapy to treat patients with complicated/fulminant acute myocarditis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000938-34,0,0,0 2021-000938-34,2,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA,Single blind randomized controlled trial to assess the safety and efficacy of high dose pulse intravenous corticosteroid therapy to treat patients with complicated/fulminant acute myocarditis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000938-34,0,0,0 2021-000941-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundacion Santiago Dexeus Font,The impact of the intensity of ovarian stimulation on embryo quality in predicted suboptimal responders. A randomized controlled trial. El impacto de la intensidad de la estimulación ovárica en la ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000941-42,0,0,0 2021-000943-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SOGUG (Spanish Genitourinary Oncologic Group),Randomized phase II study evaluating the clinical utility of switching from prednisone to dexamethasone after initial biochemical progression in patients with hormone-sensitive metastatic prostate can...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000943-30,0,0,0 2021-000962-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Charité - Universitätsmedizin Berlin,"A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000962-14,0,0,0 2021-000963-54,2,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Adamed Pharma S.A.,"Effectiveness and pharmacokinetic /pharmacodynamic study of Furazidin, prolonged- release tablets, 200 mg in the treatment of patients with uncomplicated lower urinary tract infections (acute or recur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000963-54,0,0,0 2021-000981-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach,Skuteczność leczenia amantadyną chorych na COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000981-13,0,0,0 2021-000982-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación y la Innovación Biosanitaria de Asturias,CROSS-OVER ANALYSIS OF THE CONTROL OF RISK FACTORS AND ANTIAGGREGATION WITH POLIPILL (POLICROSS TRIAL) ANALISIS CROSS-OVER DEL CONTROL DE FACTORES DE RIESGO Y ANTIAGREGACIÓN CON POLIPÍLDORA (ENSAYO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000982-33,0,0,0 2021-000986-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center of the Johannes Gutenberg-University Mainz,"A phase II, open-label, multicenter trial to investigate the clinical activity and safety of Cabozantinib in combination with avelumab in patients refractory to standard chemotherapy with advanced neu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000986-34,0,0,0 2021-000988-68,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Region Stockholm,Immune response after covid-19 vaccination in patients with renal failure stadium 4 or 5 . Immunologiskt svar vid vaccination mot covid- 19 av patienter med njursvikt stadium 4 eller 5.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000988-68,0,0,0 2021-000994-96,3,,,0,0,1,0,0,0,3,0,1,3,0,0,0,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A Phase III, double-blind, randomized, placebo-controlled study to evaluate the safety, reactogenicity and immune response of a single intramuscular dose of unadjuvanted RSV Maternal vaccine, in high ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000994-96,0,0,0 2021-000994-96,3,,,0,0,1,0,0,0,3,0,1,3,0,0,0,0,1,GlaxoSmithKline S.A.,"A Phase III, double-blind, randomized, placebo-controlled study to evaluate the safety, reactogenicity and immune response of a single intramuscular dose of unadjuvanted RSV Maternal vaccine, in high ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000994-96,0,0,0 2021-000994-96,3,,,0,0,1,0,0,0,3,0,1,3,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase III, double-blind, randomized, placebo-controlled study to evaluate the safety, reactogenicity and immune response of a single intramuscular dose of unadjuvanted RSV Maternal vaccine, in high ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000994-96,0,0,0 2021-000995-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Cardiology, Herlev and Gentofte hospital","A 6-Month, Randomized, Double-Blind Study to Evaluate the Effect of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000995-13,0,0,0 2021-000996-36,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,ALBIREO AB,An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients with Alagille Syndrome (ASSERT-EXT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000996-36,0,0,0 2021-000996-36,6,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Albireo AB,An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients with Alagille Syndrome (ASSERT-EXT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000996-36,0,0,0 2021-000999-11,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Monopar Therapeutics Inc.,"A Phase 2b/3, multicenter, randomized, double-blind, placebocontrolled study comparing the efficacy and safety of clonidine mucoadhesive buccal tablet to placebo to prevent chemoradiotherapy-induced s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-000999-11,0,0,0 2021-001003-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Antwerp University Hospital,Controlled Interruption of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Infections Gecontroleerd staken van antivirale behandelingen in chronische hepatitis B infecties,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001003-32,0,0,0 2021-001004-15,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,ACCELERON PHARMA INC.,"A Phase 1b/2 Open-Label, Multiple-Ascending Dose Study Followed by a Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic Effects, and Efficacy ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001004-15,0,0,0 2021-001005-67,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Hamburg-Eppendorf,Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy) Allogene Stam...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001005-67,0,0,0 2021-001008-14,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ALX Oncology Inc.,A Phase 2/3 Study of ALX148 in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma Uno studio di Fase 2/3 su ALX148 in pazienti con adenocarcinoma gastrico o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001008-14,0,0,0 2021-001008-14,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ALX ONCOLOGY INC,A Phase 2/3 Study of ALX148 in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma Uno studio di Fase 2/3 su ALX148 in pazienti con adenocarcinoma gastrico o...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001008-14,0,0,0 2021-001009-56,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001009-56,0,0,0 2021-001009-56,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Multicenter, Open-label, Phase 2 Basket Study of MK-7684A, a Coformation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants with Selec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001009-56,0,0,0 2021-001010-10,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Cogent Biosciences, Inc.","A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001010-10,0,0,0 2021-001015-82,3,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A multicenter, randomized, controlled, open-label, rater-blinded study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of ALXN1840 versus standard of care in pediatric participant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001015-82,0,0,0 2021-001018-13,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,BioCryst Pharmaceuticals Inc,"A Phase 3, Randomized, Open Label, Active-controlled Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of IV Peramivir Compared to Oral Oseltamivir in Pediatric Subjects With Acute Unco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001018-13,0,1,1 2021-001019-95,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,Pharmacokinetic/pharmacodynamic aspects of colistin intravenous administration in critically ill patients suffering from hospital infections caused by multi-antibiotic-resistant germs and receiving co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001019-95,0,0,0 2021-001022-22,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Γενικό Νοσοκομείο Θεσσαλονίκης ""Γεώργιος Παπανικολάου""",Generation of SARS-CoV-2-specific T lymphocytes from recovered donors and administration to high-risk COVID-19 patients Παραγωγή Τ λεμφοκυττάρων ειδικών κατά του SARS-CoV-2 από αναρρώσαντες ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001022-22,0,0,0 2021-001026-22,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,"Shionogi & Co., Ltd.","An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Baloxavir Marboxil 2% Granules after Administration of a Single Dose to Otherwise Healthy Pediatric Patients w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001026-22,0,1,1 2021-001028-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación e Innovación Biomédica (FIIB) del Hospital Universitario Infanta Leonor y Hospital Unive,DEXamethasone EARLY administration in hospitalized patients with Covid-19 pneumonia and high risk of developing acute respiratory distress syndrome Administración precoz de dexametasona en paciente...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001028-16,0,0,0 2021-001029-32,3,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Pyramid Biosciences,A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001029-32,0,0,0 2021-001029-32,3,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Pyramid Biosciences, Inc.",A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001029-32,0,0,0 2021-001030-19,1,2022-01-28,2022-01-28,1,1,0,1,0,0,1,0,0,1,1,1,0,0,1,Faron Pharmaceuticals Ltd,"A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001030-19,0,0,0 2021-001031-72,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Aarhus University, The MR Research Center",Metabolic MRI with hyperpolarized pyruvate in long-term COVID19 patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001031-72,0,0,0 2021-001033-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Vir Biotechnology, Inc.","A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001033-39,0,0,0 2021-001036-25,1,2021-12-10,2021-12-10,1,0,0,0,0,0,2,0,0,1,1,1,0,0,1,UNION therapeutics A/S,A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UNI91103 INTRANASAL ADMINISTRATION IN ADULTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC COVID-19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001036-25,0,0,0 2021-001037-39,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients with Recurring Chronic Lymphocytic Leukemia Estudio multicéntrico, ab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001037-39,0,0,0 2021-001037-39,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Venetoclax-Obinutuzumab Retreatment in Patients with Recurring Chronic Lymphocytic Leukemia Estudio multicéntrico, ab...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001037-39,0,0,0 2021-001040-10,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Medical University of Graz,Humoral and cellular immune response to COVID-19 vaccines in immunocompromised and healthy individuals – The CoVVac study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001040-10,0,0,0 2021-001045-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Asarina Pharma ApS,"A randomized, open-label, multicenter, phase 2 clinical trial to explore the safety and efficacy of sepranolone in pediatric and adult patients with Tourette Syndrome.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001045-12,0,0,0 2021-001054-57,1,,,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,OLVG,SARS-CoV-2 vaccination response in people living with HIV SARS-CoV-2 vaccinatie respons in mensen die leven met HIV,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001054-57,0,0,0 2021-001057-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Glostrup Hospital, Danish Headache Center","A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine (ATOM).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001057-31,0,0,0 2021-001058-73,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fakultní nemocnice Královské Vinohrady,Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation - Prospective Randomised Study Brolucizumab vs. aflibercept pro retinální angiomatózní proliferaci – prospektivní randomizovaná st...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001058-73,0,0,0 2021-001059-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Fysiologiska Kliniken, Linköping US",The value of 99mTc-MIP-1404 SPECT/CT Veriton CZT for staging of prostate cancer and before primary therapy and in biochemical recurrence after radical prostatectomy. Fase II study. Titel: Rollen av...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001059-15,0,0,0 2021-001060-23,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,F. Hoffman-La Roche Ltd,"A PHASE Ib/II OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF MOSUNETUZUMAB IN COMBINATION WITH TIRAGOLUMAB WITH OR WITHOUT ATEZOLIZUMAB IN PATIENTS WITH RELAPSE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001060-23,0,0,0 2021-001069-20,1,,,0,0,1,0,0,0,4,0,0,0,0,0,0,0,0,Vall d'Hebron Hospital Universitari,Tolerability and acceptance of two oral hydrocortisone compounding formulation for pediatrics Estudio de tolerabilidad y aceptación de dos fórmulas magistrales de hidrocortisona oral para pediatría,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001069-20,0,0,0 2021-001070-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Tuebingen,B-pVAC-SARS-CoV-2: Phase I/II multi-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults with B-cell/antibody deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001070-38,0,0,0 2021-001072-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amsterdam UMC location VUmc,"COBRA-KAI study: COVID-19 vaccination in patients with reduced B-cell and T-cell immunity: response after vaccination of a kaleidoscopic group hematological patients, what’s the impact? COBRA-KAI s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001072-41,0,0,0 2021-001073-23,1,,,0,0,0,1,0,0,1,0,0,4,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 1b, Open-label study to Evaluate the PK, Safety and Efficacy of B/F/TAF in HIV-1 infected, Virologically Suppressed, Pregnant Women in their Second and Third Trimesters",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001073-23,0,1,1 2021-001075-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"BeiGene, Ltd.","AdvanTIG-205: A Phase 2, Randomized, Double-blind Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Sensitizing...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001075-17,0,0,0 2021-001079-18,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Freeline Therapeutics Ltd,A dose confirmation study of FLT180a (adeno-associated viral vector containing the Padua variant of a codon-optimized human Factor IX gene) in adult subjects with hemophilia B. Dosisbestätigungsstu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001079-18,0,0,0 2021-001080-24,1,2022-01-11,2022-01-11,1,1,0,0,0,0,4,0,1,1,1,1,0,0,0,Maastricht University,The effect of plant stanol ester consumption on the vaccination response to a COVID-19 vaccine Het effect van het consumeren van plantenstanolen op de vaccinatierespons van een COVID-19 vaccin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001080-24,0,0,0 2021-001081-38,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Arcturus Therapeutics, Inc.","Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Par...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001081-38,0,0,0 2021-001083-16,4,,,0,0,1,0,0,1,2,0,0,0,0,0,0,0,1,Dicerna Pharmaceuticals Inc,"A Phase 2 Open-Label Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Nedosiran in Pediatric Patients from Birth to 11 Years of Age with Primary Hyperoxaluria and Relative...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001083-16,0,0,0 2021-001083-16,4,,,0,0,1,0,0,1,2,0,0,0,0,0,0,0,1,Dicerna Pharmaceuticals Inc.,"A Phase 2 Open-Label Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Nedosiran in Pediatric Patients from Birth to 11 Years of Age with Primary Hyperoxaluria and Relative...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001083-16,0,0,0 2021-001086-20,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,ITM Solucin GmbH,"A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient- reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001086-20,0,0,0 2021-001086-20,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,ITM SOLUCIN GMBH,"A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient- reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001086-20,0,0,0 2021-001087-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Danish Headache Center,"A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine (ATOM).",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001087-24,0,0,0 2021-001088-26,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH SATRALIZUMAB AS AN INTERVENTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001088-26,0,0,0 2021-001088-26,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH SATRALIZUMAB AS AN INTERVENTION",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001088-26,0,0,0 2021-001103-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Graz,The HEPCOViVac Registry - Immunological response in patients with liver disease vaccinated against COVID-19 Das HEPCOViVac Register - Immunantwort bei Patienten mit Leberkrankheit die gegen Covid-1...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001103-32,0,0,0 2021-001107-33,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,MUMC,SARS-CoV-2 vaccination response in patients with haematological disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001107-33,0,0,0 2021-001123-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Amsterdam UMC, VU University Medical Center","18F-fluciclovine PET/CT and 18F-DCFPyL PET/CT in patients with biochemical recurrence of disease after radical prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial 18...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001123-40,0,0,0 2021-001126-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Division of Thoracic and Hyperbaric Surgery, Medical University Graz",Hyperbaric Oxygenation for patients with post-COVID-19 sequelae. Pilot study. Hyperbare Sauerstofftherapie bei Patienten mit post-COVID-19 Symptomen. Pilotstudie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001126-21,0,0,0 2021-001144-98,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie,The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus Zastosowanie amantadyny w zapobieganiu progresji i leczeniu ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001144-98,0,0,0 2021-001165-21,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"A phase Ib/II open label dose confirmation, proof of concept study of siremadlin in combination with venetoclax plus azacitidine in unfit adult AML participants who responded sub-optimally to first-li...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001165-21,0,0,0 2021-001165-21,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A phase Ib/II open label dose confirmation, proof of concept study of siremadlin in combination with venetoclax plus azacitidine in unfit adult AML participants who responded sub-optimally to first-li...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001165-21,0,0,0 2021-001167-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,SID - Società Italiana di Diabetologia e Malattie del Metabolismo,"Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial. Confronto in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001167-24,0,0,0 2021-001172-41,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Intra-Cellular Therapies, Inc.","An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001172-41,0,0,0 2021-001174-29,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Amsterdam UMC,Effectiveness of methylphenidate in adults with phenylketonuria and attention-deficit/hyperactivity disorder: An N-of-1 series Effectiviteit van methylfenidaat bij volwassenen met fenylketonurie en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001174-29,0,0,0 2021-001176-42,6,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,KalVista Pharmaceuticals Ltd,"An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with Hered...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001176-42,0,0,0 2021-001177-22,1,2022-04-28,2022-04-28,1,0,0,0,0,0,3,0,0,1,0,0,0,0,0,"Copenhagen University Hospital, Hvidovre , Capital Region","Amantadine for COVID-19: A randomized, placebo controlled, double-blinded, clinical trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001177-22,0,0,0 2021-001181-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Academic Medical Center,"Anti-PD-1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiCiOus-dMMR): a proof-of-principle study Anti-PD-1, Capecitabine en Oxaliplatin voor de eer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001181-38,0,0,0 2021-001182-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"University Hospital Puerta de Hierro Majadahonda, Madrid, Spain","RANDOMIZED, UNICENTRIC, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL TO ASSESS THE EFFICACY OF PARACERVICAL ANESTHESIA FOR PAIN CONTROL DURING AN OFFICE HYSTEROSCOPY ENSAYO CLÍNICO, UNICÉNTRICO, RANDOMIZ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001182-21,0,0,0 2021-001184-25,3,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GANTENERUMAB IN PARTICIPANTS AT RISK FOR OR AT THE EARLIEST STAGES O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001184-25,0,0,0 2021-001184-25,3,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE III, MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GANTENERUMAB IN PARTICIPANTS AT RISK FOR OR AT THE EARLIEST STAGES O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001184-25,0,0,0 2021-001184-25,3,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GANTENERUMAB IN PARTICIPANTS AT RISK FOR OR AT THE EARLIEST STAGES O...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001184-25,0,0,0 2021-001186-20,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,GRUPO ESPAÑOL DE INVESTIGACIÓN EN SARCOMAS,Phase Ib/II multicohort trial of different schemes of PM14 in monotherapy and in combination with radiotherapy in soft tissue sarcomas and other solid tumors Ensayo multicohorte fase Ib/II de difer...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001186-20,0,0,0 2021-001188-26,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab in Participants with Advanced Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001188-26,0,0,0 2021-001192-17,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Intra-Cellular Therapies, Inc.","A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001192-17,0,0,0 2021-001194-24,1,2022-06-03,2022-06-03,1,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Veru Inc.,"Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Resp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001194-24,0,0,0 2021-001198-22,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) A danik...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001198-22,0,0,0 2021-001198-22,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) A danik...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001198-22,0,0,0 2021-001200-15,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001200-15,0,0,0 2021-001200-15,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001200-15,0,0,0 2021-001202-30,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Diakonessenhuis,SARS-CoV-2 immune response,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001202-30,0,0,0 2021-001203-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO,"An open-label, multi-center, phase 2 study of chemo-immunotherapy followed by reduced-dose hypo-fractionated RT and maintenance immunotherapy for stage III unresectable Non –small-cell lung carcinoma ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001203-32,0,0,0 2021-001205-73,4,2022-04-20,2022-04-20,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,"IMPACT Therapeutics, Inc.","A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib Maintenance in mCRPC Patients with Homologous Recombination Repair Gene Alterations after Docetaxel ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001205-73,1,0,0 2021-001205-73,4,2022-04-20,2022-04-20,1,1,0,0,0,0,2,0,0,2,0,0,0,0,1,IMPACT Therapeutics Inc.,"A Randomized, Double-Blinded, Placebo-Controlled, Multicenter, Phase II Study to Evaluate Senaparib Maintenance in mCRPC Patients with Homologous Recombination Repair Gene Alterations after Docetaxel ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001205-73,1,0,0 2021-001206-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fondazione GONO,ShorTrip study - Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoadjuvant therapy for locally advanced rectal cancer. ShorT...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001206-29,0,0,0 2021-001211-90,2,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 2, Multiple Ascending Dose, Randomized, Double-Blind, Placebo- Controlled Study of ALXN1830 Administered Subcutaneously in Patients with Warm Autoimmune Hemolytic Anemia (WAIHA) Studio di f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001211-90,0,0,0 2021-001211-90,2,,,0,1,0,0,0,1,2,0,0,1,1,1,0,1,1,"Alexion Pharmaceuticals, Inc.","A Phase 2, Multiple Ascending Dose, Randomized, Double-Blind, Placebo- Controlled Study of ALXN1830 Administered Subcutaneously in Patients with Warm Autoimmune Hemolytic Anemia (WAIHA) Studio di f...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001211-90,0,0,0 2021-001212-29,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Intra-Cellular Therapies, Inc.","A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001212-29,0,0,0 2021-001213-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Isarna Therapeutics GmbH,TGF-BETa 2 antisense ISTH0036 for the Treatment of diabetic macular Edema (DME) and neovascular age-related maculaR degeneration (nAMD) The “BETTER” Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001213-36,0,0,0 2021-001225-43,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Instituto Bernabeu,Dual Stim comparison of triggers for the second egg collection: Is there any advantage using 3 different methods of trigger for the second egg collection in Dual Stim cycles in predicted low responder...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001225-43,0,0,0 2021-001226-21,7,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,KalVista Pharmaceuticals Ltd,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001226-21,0,0,0 2021-001227-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, M.P. (CSIC)","A Randomized, Open-label, Standard-of-care comparative, Repositioning Clinical Trial to Evaluate the Efficacy and Safety of FDA-135 in combination with standard of care in the Treatment of Infection C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001227-41,0,0,0 2021-001228-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, M.P. (CSIC)","A Randomized, double-blind, Repositioning Clinical Trial, placebo controlled, to Evaluate the Efficacy and Safety of FDA-277 in combination with standard of care in the Treatment of Infection Caused b...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001228-17,0,0,0 2021-001229-26,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Alexion Pharmaceuticals,"A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis Estudio de fase 2,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001229-26,0,0,0 2021-001229-26,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthenia Gravis Estudio de fase 2,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001229-26,0,0,0 2021-001234-20,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Loxo Oncology Inc,"A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-313)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001234-20,0,0,0 2021-001234-20,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,LOXO ONCOLOGY INCORPORATED,"A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-313)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001234-20,0,0,0 2021-001234-20,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Loxo Oncology Inc.,"A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-313)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001234-20,0,0,0 2021-001235-12,1,2022-07-04,2022-07-04,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,Galecto Biotech AB,"GULLIVER-2 - a single (open-label) and repeat dose (randomised, placebo-controlled) trial to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in participants with hepat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001235-12,0,0,0 2021-001238-21,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Institute of Health and Biomedical Research of Alicante,Gender biases in pain medicine: from omics to healthcare. Sesgos de género en la medicina del dolor: de las ómicas a la atención sanitaria.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001238-21,0,0,0 2021-001242-35,11,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA ve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001242-35,0,0,0 2021-001243-27,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboudumc,Effect of oral magnesium supplementation on insulin sensitivity in people with type 2 diabetes Effect van orale magnesium suppletie op de insulinegevoeligheid bij mensen met type 2 diabetes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001243-27,0,0,0 2021-001244-95,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001244-95,0,0,0 2021-001244-95,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.",Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001244-95,0,0,0 2021-001244-95,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001244-95,0,0,0 2021-001245-13,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,4Living Biotech SAS,"A randomized, double-blind, placebo-controlled, two parallel groups, international multicenter trial to evaluate the effect of Plerixafor in acute respiratory failure related to COVID-19 (LEONARDO) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001245-13,0,0,0 2021-001246-36,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Ambrx, Inc.","A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001246-36,0,0,0 2021-001247-27,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen,SeMaglutide and Albuminuria Reduction Trial in obese individuals without diabetes Ensayo para la redución de la albuminuria con Semaglutida en pacientes obsesos sin diabetes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001247-27,0,0,0 2021-001248-82,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients with Mild-to-Moderate Hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001248-82,0,0,0 2021-001249-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset,"PARACHUTES: Pedophilia At Risk – Acute Treatment – E-therapy vs SSRI PARACHUTES: Pedophilia At Risk – Acute Treatment – E-therapy vs SSRI En öppen, randomiserad kontrollerad studie som jämför eff...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001249-11,0,0,0 2021-001253-32,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Horizon Therapeutics Ireland DAC,"A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001253-32,0,0,0 2021-001253-32,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,HORIZON THERAPEUTICS IRELAND DAC,"A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001253-32,0,0,0 2021-001256-34,5,2022-08-23,2022-08-23,4,0,0,0,0,0,3,0,0,2,1,0,0,0,1,Novartis Pharma AG,"A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase III study to investigate the efficacy and safety of secukinumab (Cosentyx) 300 mg administered subcutaneously in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001256-34,1,0,0 2021-001256-34,5,2022-08-23,2022-08-23,4,0,0,0,0,0,3,0,0,2,1,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase III study to investigate the efficacy and safety of secukinumab (Cosentyx) 300 mg administered subcutaneously in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001256-34,1,0,0 2021-001256-34,5,2022-08-23,2022-08-23,4,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase III study to investigate the efficacy and safety of secukinumab (Cosentyx) 300 mg administered subcutaneously in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001256-34,1,0,0 2021-001257-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Pharmaceutical Biosciences, Uppsala University","An open, single center two-step trial (A+B), comparing the safety and tolerability of idarubicin 10 mg and 15 mg after separate single hepatic intra-arterial injections of a drug formulation based on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001257-31,0,0,0 2021-001266-38,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc,"A PHASE 3, MULTICENTER, OPEN-LABEL STUDY OF THE LONG-TERM SAFETY OF CRISABOROLE OINTMENT, 2% IN JAPANESE PEDIATRIC AND ADULT PARTICIPANTS WITH MILD TO MODERATE ATOPIC DERMATITIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001266-38,0,1,1 2021-001267-24,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Arthroscopic Surgery Unit,Pilot study to evaluate intra-articular infiltrations of allogeneic Platelet Rich Plasma (PRP) for the treatment of knee osteoarthritis. Estudio piloto para evaluar las infiltraciones intraarticula...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001267-24,0,0,0 2021-001268-58,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Semmelweis University, STIA-POC-2020",Investigation of cellbiological effects of cariprazine in patients with mitochondrial schizophrenia A cariprazine sejtbiológiai hatásának vizsgálata mitochondriális dysfunkcióval asszociált schizop...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001268-58,0,0,0 2021-001270-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud University Medical Centre,Enhancement of immune response by combining immune checkpoint blockade and radiation in patients with recurrent / refractory malignant lymphoma (re-directing the immune system). Verbetering van de ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001270-34,0,0,0 2021-001271-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AGO Research GmbH,Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001271-16,0,0,0 2021-001273-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MEDESIS PHARMA SA,"A prospective, multicenter, with a first part randomized, placebo-controlled, parallel-group, double-blind period followed by an open-label trial period trial to evaluate the clinical safety and effic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001273-23,0,0,0 2021-001277-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,argenx BV,"A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001277-23,0,0,0 2021-001278-44,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Fundación Hospital Provincial de Castellón,Comparative analysis of the effectiveness of clozapine in resistant schizophrenia and schizoafective disorder. Análisis comparativo de la efectividad de la clozapina en esquizofrenia resistente y t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001278-44,0,0,0 2021-001279-18,1,,,0,0,0,0,1,0,4,0,1,4,0,0,0,0,0,King’s College London,Overall Study Name: NHS CHECK - Health & Experiences of staff working at NHS Trusts and Nightingale Hospitals. Embedded RCT Full Title: Effectiveness of a smartphone app-based intervention in improvi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001279-18,0,1,1 2021-001280-24,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Vedanta Biosciences, Inc.","Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001280-24,0,0,0 2021-001285-38,9,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of two doses (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 24 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001285-38,0,0,0 2021-001285-38,9,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,"Boehringer Ingelheim Portugal, Lda","Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of two doses (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 24 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001285-38,0,0,0 2021-001285-38,9,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,Boehringer Ingelheim Pharma GmbH & Co. KG,"Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of two doses (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 24 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001285-38,0,0,0 2021-001285-38,9,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,Boehringer-Ingelheim RCV GmbH & Co KG,"Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of two doses (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 24 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001285-38,0,0,0 2021-001285-38,9,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of two doses (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 24 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001285-38,0,0,0 2021-001285-38,9,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,SCS Boehringer Ingelheim Comm. V,"Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of two doses (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 24 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001285-38,0,0,0 2021-001285-38,9,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,Boehringer Ingelheim bv Netherlands,"Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of two doses (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 24 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001285-38,0,0,0 2021-001285-38,9,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,"Boehringer Ingelheim España, S.A.","Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of two doses (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 24 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001285-38,0,0,0 2021-001285-38,9,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,Boehringer Ingelheim B. V.,"Randomised, double-blind, placebo-controlled and parallel group trial to investigate the effects of two doses (up-titration to a fixed dose regimen) of oral BI 685509 on portal hypertension after 24 w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001285-38,0,0,0 2021-001286-20,6,,,0,0,1,0,0,2,1,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001286-20,0,0,0 2021-001286-20,6,,,0,0,1,0,0,2,1,0,0,3,0,0,0,0,1,NOVARTIS PHARMA AG,"A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001286-20,0,0,0 2021-001288-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IDIBAPS,"Safety, tolerance and antiretroviral activity of dasatinib: a pilot clinical trial in patients with recent HIV-1 infection Seguridad, tolerancia y actividad antirretroviral de dasatinib: estudio cl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001288-26,0,0,0 2021-001289-39,1,,,0,0,1,0,0,0,3,0,1,4,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001289-39,0,1,1 2021-001290-23,1,,,0,0,1,0,0,0,2,0,0,4,0,0,0,0,1,BioNTech SE,"A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VACCINE CANDIDATE BNT162b2 IN IMMUNOCOMPROMISED PARTICIPANTS ≥2 YEARS OF AGE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001290-23,0,0,0 2021-001291-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitätsklinikum Freiburg,Radiotherapy in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer Behandlung von Patienten mit einem persi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001291-42,0,0,0 2021-001294-23,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Biogen Idec Research Limited,A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001294-23,0,0,0 2021-001294-23,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,BIOGEN IDEC RESEARCH LIMITED,A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001294-23,0,0,0 2021-001304-15,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,vzw az groeninge,COVID-19:Immuneresponse after vaccination against SARS-COV-2 COVID-19: Studie van de immuunrespons na vaccinatie tegen SARS-CoV-2,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001304-15,0,0,0 2021-001306-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut Régional du Cancer de Montpellier,A prospective randomized phase II study to assess the schemas of retreatment with Lutathera® ([177Lu]Lu-DOTA-TATE) in patients with new progression of intestinal well-differentiated neuroendocrine tum...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001306-30,0,0,0 2021-001309-60,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer Klinické hod...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001309-60,0,0,0 2021-001309-60,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer Klinické hod...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001309-60,0,0,0 2021-001309-60,5,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Merck Sharp & Dohme Corp.,A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer Klinické hod...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001309-60,0,0,0 2021-001324-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,A Study to Assess the Effects of the Endothelin Receptor Antagonist Zibotentan and the SGLT2 Inhibitor Dapagliflozin in Patients with Type 2 Diabetes and elevated Albuminuria: a Randomized Double Blin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001324-18,0,0,0 2021-001327-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la formación e investigación sanitarias de la Región de Murcia,Withdrawal of pharmacological treatment in patients responding to cardiac resynchronization therapy: Open and randomized study Retirada de tratamiento farmacologico en pacientes respondedores a ter...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001327-41,0,0,0 2021-001328-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la formación e investigación sanitarias de la Región de Murcia,Histological and clinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1. Efectos clínicos e histológicos de la Imipramina en el tratamiento de pacientes con...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001328-17,0,0,0 2021-001329-29,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,iTeos Belgium SA,"A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participants with advanced solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001329-29,0,0,0 2021-001332-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,IDIAP Jordi Gol,Clinical effectiveness and bacteriological eradication of 3 short-course antibiotic regimens and single-dose of fosfomicyn trometamol for lower urinary tract infections in adult women [SCOUT study]. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001332-26,0,0,0 2021-001333-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI),Cognitive effects of adjuntive Vortioxetine in early Schizophrenia Efectos cognitivos de vortioxetina adyuvante en la esquizofrenia temprana,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001333-38,0,0,0 2021-001335-24,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Aarhus University,"Thromboprophylaxis in Oesophageal Cancer Patients – A Randomized, Controlled Trial Forebyggelse af blodpropper efter operation for kræft i spiserøret",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001335-24,0,0,0 2021-001337-40,1,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,"BioXcel Therapeutics, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER ESTUDIO ALEATORIZADO, DOBL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001337-40,0,0,0 2021-001338-21,2,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,Eli Lilly and Company,"A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients from 1 Year to Less Than 18 Years Old Hospitalized with COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001338-21,0,0,0 2021-001338-21,2,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,Lilly S.A.,"A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients from 1 Year to Less Than 18 Years Old Hospitalized with COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001338-21,0,0,0 2021-001342-34,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Steno Diabetes Center Copenhagen,Low-dose glucagon for Prevention of Exercise-Induced Hypoglycemia in People with Type 1 Diabetes Lav-dosis glucagon til forebyggelse af motionsinduceret hypoglykæmi hos personer med type 1 diabet...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001342-34,0,0,0 2021-001351-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Assistance Publique des Hôpitaux de Paris(AP-HP),"Interest of famotidine in reducing endothelial expression of P-selectin in children with sickle cell disease: pilot study, single-center, prospective, non-comparative Intérêt de la famotidine pour ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001351-13,0,0,0 2021-001352-33,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Avanir Pharmaceuticals, Inc.","A multicenter, randomized, double-blind, placebo-controlled, parallel-arm study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001352-33,0,0,0 2021-001353-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut régional du Cancer de Montpellier,RANDOMIZED PHASE II MULTICENTRIC TRIAL EVALUATING THE EFFECTIVENESS OF A SEQUENTIAL GEMCITABINE PLUS NABPACLITAXEL (GEMBRAX) TREATMENT FOLLOWED BY FOLFIRINOX VERSUS FOLFIRINOX IN PATIENTS TREATED FOR ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001353-31,0,0,0 2021-001357-31,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,National Institute of Health and the Environment,Immune Responses Induced by Vaccination Against COVID-19 in Dutch healthy subjects Immuun responsen opgewekt door vaccinatie tegen COVID-19 in Nederlandse gezonde proefpersonen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001357-31,0,0,0 2021-001360-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO,"MINECRAFT Study: MINEralcorticoid receptor antagonism with CanRenone As eFfective Treatment in moderate to severe ARDS in COVID-19, a phase 2 clinical trial. Studio MINECRAFT: antagonismo del rece...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001360-20,0,0,0 2021-001367-24,5,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase II, randomized, partially blinded study to assess the safety, tolerability and immunogenicity of meningococcal combined ABCWY vaccine when administered to healthy infants.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001367-24,0,0,0 2021-001367-24,5,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A Phase II, randomized, partially blinded study to assess the safety, tolerability and immunogenicity of meningococcal combined ABCWY vaccine when administered to healthy infants.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001367-24,0,0,0 2021-001367-24,5,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,1,GlaxoSmithKline SA,"A Phase II, randomized, partially blinded study to assess the safety, tolerability and immunogenicity of meningococcal combined ABCWY vaccine when administered to healthy infants.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001367-24,0,0,0 2021-001369-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Multicenter, Open-label, Phase 2, Extension Trial to Study the Long-term Safety in Participants With PROS or Proteus Syndrome Who Are Currently Being Treated with Miransertib in Other Studies Spe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001369-19,0,0,0 2021-001375-16,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,The Children's Memorial Health Institute,"DIPGEN – Multicenter, open label study using molecularly determined targeted therapies in children 3-18 years of age with DIPG (diffuse intrinsic pontine glioma- DIPG) Zastosowanie terapii celowane...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001375-16,0,0,0 2021-001376-42,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Innovacell AG,"Skeletal muscle-derived cell implantation for the treatment of fecal incontinence: a phase III, randomized, controlled, double blind, two armed clinical study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001376-42,0,0,0 2021-001381-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Plastikkirurgisk og brystkirurgisk afdeling, Region Sjælland","Topical use of tranexamic acid for optimisation of wound healing in a novel, acute wound model Topisk brug af tranexamsyre til optimering af sårheling i en ny, akut human sårmodel",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001381-38,0,0,0 2021-001384-25,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,"Goethe-Universität, vertreten durch den Präsidenten, dieser vertreten durch die LKP (bevollmächtigt durch den Sponsor)","An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL) Eine off...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001384-25,0,0,0 2021-001385-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","RANDOMIZED STUDY TO PROTECT FROM RADIATION IATROGENIC HYPOTHYROIDISM PATIENTS WITH MEDULLOBLASTOMA (ANY AGE, STAGE AND ANY BIOLOGICAL RISK) AND PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA AND NON-HODGKIN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001385-38,0,0,0 2021-001387-20,3,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Electra Therapeutics, Inc.","A Phase 1b, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Doses of ELA026 in Adults and Adolescents with Secondary Hemophagocytic Lymphohi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001387-20,0,0,0 2021-001389-39,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Mirum Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (VANTAGE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001389-39,0,0,0 2021-001391-42,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Medical University of Graz,Characterisation of the effects of Spermidine on the immune response to Covid-19 vaccine in older people - a feasibility study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001391-42,0,0,0 2021-001392-17,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bayer AG,"A randomized, double-blind, cross-over, placebo-controlled, multi-center, Phase 2a study to assess the safety and efficacy of BAY 2395840 in patients with diabetic neuropathic pain.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001392-17,0,0,0 2021-001393-31,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Bavarian Nordic A/S,"An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of the ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects. Offene Phase 2 Studie zur Best...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001393-31,0,0,0 2021-001394-23,5,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Rain Therapeuthic Inc,A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001394-23,0,0,0 2021-001394-23,5,,,0,0,0,0,0,1,3,0,0,2,0,0,0,0,1,"Rain Therapeutics, Inc.",A Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001394-23,0,0,0 2021-001398-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SOLTI,"Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutations or RAD51-foci low test: RADIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001398-22,0,0,0 2021-001400-16,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,Riga Stradins university,Investigation of pain syndrome and clinical-biochemical parameters in 7 to 18 years old children with acute uncomplicated appendicitis who received non-surgical treatment. Sāpju sindroma un klīnisk...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001400-16,0,0,0 2021-001404-14,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Quantum Genomics,"A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-to-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001404-14,0,0,0 2021-001404-14,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,QUANTUM GENOMICS,"A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-to-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001404-14,0,0,0 2021-001406-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Eli Lilly and Company,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Two Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 to Treat Adults with At Least Moderately A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001406-30,0,0,0 2021-001409-64,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Averitas Pharma, Inc.","An interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial evaluating the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001409-64,0,0,0 2021-001411-82,1,,,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,"LABORATORIOS HIPRA, S.A.",A phase I/IIa study to evaluate safety and immunogenicity of recombinant protein RBD fusion dimer candidate vaccine against SARS-CoV-2 in adult healthy volunteers. Estudio de fase I/IIa para evalua...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001411-82,0,0,0 2021-001414-10,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University Medical Center Groningen,Vaccine response against SARS-CoV-2 in patients with primary Sjögren’s syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001414-10,0,0,0 2021-001416-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación para la Investigación e Innovación Biomédica (FIIB) del Hospital Universitario Infanta Leonor y Hospital Unive,EARLY TREATMENT STRATEGY WITH HIGH-DOSE VERSUS STANDARD-DOSE DEXAMETHASONE IN PATIENTS WITH SARS-COV-2 PNEUMONIA (COVID-19). ESTRATEGIA DE TRATAMIENTO PRECOZ CON DEXAMETASONA A DOSIS ALTAS FRENTE ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001416-29,0,0,0 2021-001417-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOSPITAL CLINICO UNIVERSITARIO,CLINICAL TRIAL PHASE IIB ON THE TREATMENT WITH PIPAC (PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY) IN PATIENTS WITH NON-RESECTABLE PERITONEAL CARCINOMATOSIS ENSAYO CLÍNICO FASE IIB SOBRE EL TR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001417-36,0,0,0 2021-001418-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Florida,Tailoring P2Y12 Inhibiting Therapy in Patients requiring Oral Anticoagulation after undergoing Percutaneous Coronary Intervention: The Switching Anti-Platelet and Anti-Coagulant Therapy – 2 Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001418-12,0,0,0 2021-001419-10,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,CLINUVEL EUROPE LIMITED,"A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum C and V (XPC and XPV)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001419-10,0,0,0 2021-001424-17,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Chemo Research S. L.,"A multicentre, phase III, double-blind, randomised clinical trial to assess the efficacy and safety of LPRI-CF113 in the treatment of endometriosis versus placebo after 3 medication cycles followed by...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001424-17,0,0,0 2021-001425-48,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,"Division of Anaesthesiology - Department of Acute Medicine - Geneva Children's Hospital, University Hospitals of Geneva",Dexamethasone and postoperative bleeding following tonsillectomy in children,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001425-48,0,0,0 2021-001426-22,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001426-22,0,0,0 2021-001426-22,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ALEXION PHARMACEUTICALS INCORPORATED,"A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001426-22,0,0,0 2021-001427-40,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"IONIS PHARMACEUTICALS, INC.","An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001427-40,0,0,0 2021-001427-40,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.","An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001427-40,0,0,0 2021-001429-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Hospital Mutua de Terrassa,"Utility of inhaled extrafine triple therapy with glycopyrronium bromide, formoterol fumarate dihydrate and beclometasone dipropionate to improve expiratory flow limitation in severe COPD exacerbations...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001429-34,0,0,0 2021-001431-56,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of norucholic acid tablets with placebo in the treatment of primary biliary cholangitis in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001431-56,0,0,0 2021-001433-39,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Neurocrine Biosciences, Inc.","A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of NBI-921352 as Adjunctive Therapy in Adult Subjects wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001433-39,0,0,0 2021-001434-19,12,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim B.V,"Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empaglifl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001434-19,0,0,0 2021-001434-19,12,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim RCV GmbH & Co KG,"Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empaglifl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001434-19,0,0,0 2021-001434-19,12,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim Norway KS,"Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empaglifl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001434-19,0,0,0 2021-001434-19,12,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim AB,"Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empaglifl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001434-19,0,0,0 2021-001434-19,12,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empaglifl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001434-19,0,0,0 2021-001434-19,12,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim,"Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empaglifl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001434-19,0,0,0 2021-001434-19,12,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim España S.A.,"Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empaglifl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001434-19,0,0,0 2021-001434-19,12,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Boehringer Ingelheim Portugal, Lda","Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empaglifl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001434-19,0,0,0 2021-001438-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA,Randomized controlled trial on daily Rifampicin for Four Months Compared with daily Rifampicin/Isoniazid for Three Months for the Treatment of Tuberculosis Infection among migrants: Completion Rate an...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001438-20,0,0,0 2021-001440-99,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AnaptysBio Inc.,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects with Hidradenitis Suppurativa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001440-99,0,0,0 2021-001442-35,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTI FISIOTERAPICI OSPITALIERI,A PHASE 2 MONOCENTRIC PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PIOGLITAZONE IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO STUDIO PILOTA DI FASE 2 PER LA VALUTAZIONE DELL’EFFICACI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001442-35,0,0,0 2021-001443-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,"Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer. (CA209-6E8, CNN-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001443-27,0,0,0 2021-001445-12,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Gilead Sciences, Inc.","A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001445-12,0,0,0 2021-001447-27,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AnaptysBio Inc.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001447-27,0,0,0 2021-001448-90,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AnaptysBio Inc.,"A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001448-90,0,0,0 2021-001449-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,CHIESI FARMACEUTICI S.P.A.,"An exploratory, double-blind, randomised, multicenter, psychopharmacological study in adult patients with moderate to severe asthma to compare two pressurised Metered-Dose Inhalers (pMDIs) on patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001449-11,0,0,0 2021-001453-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Copenhagen University Hospital Rigshospitalet,"Automated pupillometry and NIRS-EEG to detect signatures of consciousness in acute brain injury after apomorphine and methylphenidate stimulation: A placebo-controlled, randomized, cross-over study ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001453-31,0,0,0 2021-001456-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University of Vienna,A prospective randomized pilot trial on safety and feasibility of Argatroban as anticoagulant in patients with extracorporeal membrane oxygenation (ECMO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001456-34,0,0,0 2021-001459-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Graz,Immune response to COVID-19 Vaccination in people with Diabetes Mellitus - COVAC-DM study Immunantwort auf COVID-19 Impfung bei Personen mit Diabetes-Mellitus - COVAC-DM-Studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001459-15,0,0,0 2021-001465-20,1,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Laboratorios Farmalíder S.A.,"A double-blind, multicenter, randomized clinical trial to assess the efficacy and safety of Montelukast in patients with erosive / inflammatory arthrosis of the hands Ensayo clínico aleatorizado, m...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001465-20,0,0,0 2021-001466-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Västra Götalandsregionen, Sahlgrenska University Hospital",Adenosine’s effect on STunning resolution in Acute Myocardial Infarction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001466-37,0,0,0 2021-001486-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Helsinki/CLUE working Group,A Multicentre Randomised Control Trial Assessing the Efficacy of Antimicrobial Prophylaxis for Extracorporeal Shock Wave Lithotripsy on reducing Urinary Tract Infections,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001486-21,0,0,0 2021-001488-25,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Foghorn Therapeutics Inc.,"A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered FHD-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001488-25,0,0,0 2021-001492-16,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,Stichting Het Nederlands Kanker Instituut – Antoni van Leeuwenhoek Ziekenhuis,Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma – NADINA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001492-16,0,0,0 2021-001492-16,2,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,NKI-AVL,Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant nivolumab in macroscopic stage III melanoma – NADINA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001492-16,0,0,0 2021-001498-21,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Acceleron Pharma Inc.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) Worl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001498-21,0,0,0 2021-001498-21,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,ACCELERON PHARMA INC.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) Worl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001498-21,0,0,0 2021-001501-69,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novo Nordisk A/S,Investigation of Clinical Comparability of Semaglutide Drug Products Based on the Proposed and the Approved Drug Substance Manufacturing Processes in Participants with Type 2 Diabetes Klinické skúš...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001501-69,0,0,0 2021-001508-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Johann Wolfgang Goethe-Universität Frankfurt,"Randomized, controlled, double-blind trial to investigate the effect of colchicin on the endothelial function in patients with CHIP mutations and chronic heart failure with reduced left ventricular fu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001508-13,0,0,0 2021-001509-66,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud University Medical Center,rEaL-world pharmacokinetics of Immune Checkpoint InhibiTors (ELICIT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001509-66,0,0,0 2021-001512-28,1,2021-12-30,2021-12-30,1,0,0,0,0,0,4,0,1,1,0,0,0,0,0,Charité - Universitätsmedizin Berlin,Immunogenicity of COVID-19 vaccines in medical staff and special risk populations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001512-28,0,0,0 2021-001519-10,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"ALNYLAM PHARMACEUTICALS, INC.","A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients with Recurrent Calcium Oxalate Kidney Stone Disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001519-10,0,0,0 2021-001519-10,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients with Recurrent Calcium Oxalate Kidney Stone Disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001519-10,0,0,0 2021-001520-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,RECOVAC consortium,"Long term efficacy and safety of SARS-CoV-2 vaccination in Dutch patients with chronic kidney disease stage G4-G5, on dialysis or after kidney transplantation Lange termijn effectiviteit en veili...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001520-18,0,0,0 2021-001528-16,3,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,Insmed Incorporated,"A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in participants with Pulm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001528-16,0,0,0 2021-001530-19,3,2022-08-26,2022-08-26,2,0,0,0,0,0,2,0,0,2,0,0,0,0,1,"Kartos Therapeutics, Inc.","An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects with Relapsed or Refractory Small Cell Lung Cancer (SCLC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001530-19,1,0,0 2021-001534-19,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AP-HP/DRCI,Direct oral Anticoagulants for Prevention of lEft ventRIcular Thrombus after anterior acute myocardial InFarction Impact de la prescription d’un traitement anticoagulant oral direct chez les patie...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001534-19,0,0,0 2021-001535-99,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Novartis Pharmaceuticals Corporation,"A phase II, open label, multi-center trial to determine the efficacy and safety of tisagenlecleucel re-infusion in Pediatric and Adolescent Young Adult (AYA) patients with acute lymphoblastic leukemia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001535-99,0,1,1 2021-001541-13,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Scandinavian Biopharma Holding AB,"A Phase 2 immunological bridging study assessing the non-inferiority of a new formulation of ETVAX®. A prospective double-blind, randomized study in healthy volunteers",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001541-13,0,0,0 2021-001554-61,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Oslo University Hospital,Anti-Coagulation versus AcetylSalicylic Acid after Transcatheter Aortic Valve Implantation (ACASA-TAVI),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001554-61,0,0,0 2021-001557-31,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ALKERMES,"A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001557-31,0,0,0 2021-001557-31,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Alkermes, Inc.","A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001557-31,0,0,0 2021-001560-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE,"Single-center, open-label, uncontrolled clinical trial to evaluate the association between the expression of the JAK / STAT pathway and the response to tofacitinib in patients with refractory rheumato...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001560-14,0,0,0 2021-001564-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE TOSCANA GABRIELE MONASTERIO,Evaluation of the cardioprotective metabolic effect of trimetazidine in patients with myocardial ischaemia Valutazione dell’effetto metabolico cardioprotettivo della Trimetazidina in pazienti con i...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001564-26,0,0,0 2021-001567-25,4,2022-04-07,2022-04-07,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,Sanofi-Aventis Recherche et Développement,"Efficacy and safety of SAR441344 in the treatment of Systemic Lupus Erythematosus: A randomized, double blind, placebo-controlled, Phase 2, proof of concept study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001567-25,1,0,0 2021-001567-25,4,2022-04-07,2022-04-07,1,0,0,0,0,0,2,0,0,2,1,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"Efficacy and safety of SAR441344 in the treatment of Systemic Lupus Erythematosus: A randomized, double blind, placebo-controlled, Phase 2, proof of concept study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001567-25,1,0,0 2021-001568-10,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Eisai Limited,"An Open-Label, Multicenter, Phase 1b/2 Study of E7386 in Combination With Pembrolizumab in Previously Treated Subjects With Selected Solid Tumors Estudio abierto, multicéntrico, de fase 1b/2 con E7...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001568-10,0,0,0 2021-001572-42,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Shanghai Fosun Pharmaceutical Industrial Development Co.,Ltd.","A multi-center, open-label, single-arm Phase I dose-escalation and Phase II dose-expansion study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of FCN-159 in adult an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001572-42,0,0,0 2021-001573-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Orion Corporation,Use of Buventol Easyhaler and Bufomix Easyhaler as Relievers in Methacholine Challenge Testing and Inspiratory Flow Profiles during Induced Bronchoconstriction in Adult Subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001573-22,0,0,0 2021-001575-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Centre Régional de lutte contre le Cancer Eugène Marquis,A multicenter open-label randomized controlled prospective phase II study evaluating the efficacy of Selective Internal Radiation Therapy (Yttrium-90 glass microspheres) combined with Capecitabine in ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001575-16,0,0,0 2021-001577-24,9,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Swedish Orphan Biovitrum AG (Sobi AG),"A Two-cohort, Open-label, Single arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001577-24,0,0,0 2021-001577-24,9,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Swedish Orphan Biovitrum AG,"A Two-cohort, Open-label, Single arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Emapalumab in Children and Adults with Macrophage Activa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001577-24,0,0,0 2021-001586-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Bispebjerg Hospital, Department of Dermatology",Does 4% 5-fluorouracil pre-treatment improve the efficacy of daylight photodynamic therapy for actinic keratoses – a randomized controlled study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001586-21,0,0,0 2021-001624-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Karolinska University Hospital,Safety of oral micronized progesterone versus norethisterone acetate in continuous combination with oral estrogen as menopausal hormone therapy – a double-blind randomized study- PROBES study (Progest...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001624-17,0,0,0 2021-001626-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Vall d'Hebron Institute of Research,"A Multicentre Controlled Open Randomized Clinical Trial to evaluate the efficacy and safety profile of an anti-TB drug combination based on High Dose Rifampicin, High Dose Moxifloxacin and Linezolid d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001626-22,0,0,0 2021-001627-40,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"InCarda Therapeutics, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001627-40,0,0,0 2021-001628-16,2,2022-07-26,2022-07-26,1,0,0,0,0,1,3,0,0,2,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,A Phase 3b Open-label Study Evaluating the Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cough and Physical Activity in Cystic Fibrosis Subjects 12 Years of Age and Older Who Are Heterozygous for the...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001628-16,1,0,0 2021-001629-38,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Dompè Farmaceutici S.p.A.,"A phase 2, multicenter, randomized, double blind, active controlled, parallel group study assessing the analgesic effect and safety of two doses of DFL24412 in patients with chronic low back pain comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001629-38,0,0,0 2021-001629-38,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,DOMPé FARMACEUTICI S.P.A.,"A phase 2, multicenter, randomized, double blind, active controlled, parallel group study assessing the analgesic effect and safety of two doses of DFL24412 in patients with chronic low back pain comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001629-38,0,0,0 2021-001633-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Thoraxklinik Heidelberg gGmbH,"Efficacy and safety of riociguat (MK-4836) in incipient pulmonary vascular disease as an indicator for early pulmonary arterial Hypertension Doubleblind, randomized, multicentre, multinational, placeb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001633-40,0,0,0 2021-001634-18,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,Merz Pharmaceuticals GmbH,"A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lower...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001634-18,0,0,0 2021-001637-39,1,,,0,0,0,1,0,0,1,0,0,4,0,0,0,0,1,Repare Therapeutics,"Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001637-39,0,0,0 2021-001639-23,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Vifor (International) Inc.,"A Phase 2b, double-blind, randomised, placebo-controlled, multicentre study to assess the efficacy and safety of VIT-2763 multiple doses in adults with transfusion-dependent ß-thalassaemia Studio d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001639-23,0,0,0 2021-001639-23,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,VIFOR (INTERNATIONAL) INC.,"A Phase 2b, double-blind, randomised, placebo-controlled, multicentre study to assess the efficacy and safety of VIT-2763 multiple doses in adults with transfusion-dependent ß-thalassaemia Studio d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001639-23,0,0,0 2021-001641-13,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001641-13,0,1,0 2021-001641-13,12,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001641-13,0,1,0 2021-001644-10,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001644-10,0,0,0 2021-001644-10,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001644-10,0,0,0 2021-001645-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Oslo University Hospital,Alpha 2 adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): randomised controlled trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001645-12,0,0,0 2021-001647-28,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F.Hoffmann-La Roche Ltd,"A PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF GLOFITAMAB IN COMBINATION WITH RITUXIMAB (R) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN CIRCULATING TUMOR (ct)DNA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001647-28,0,0,0 2021-001647-28,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Roche Farma S.A que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF GLOFITAMAB IN COMBINATION WITH RITUXIMAB (R) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN CIRCULATING TUMOR (ct)DNA ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001647-28,0,0,0 2021-001648-91,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Norwegian University of Science and Technology,Randomized phase III trial investigating the survival benefit of adding thoracic radiotherapy to durvalumab (MEDI4736) immunotherapy plus chemotherapy in extensive stage small-cell lung cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001648-91,0,0,0 2021-001654-65,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi-Aventis Recherche & Developpement,"A Phase 2a, open label, two-part study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) on airway inflammation in patients with chronic obstructive pulmonary disease (COPD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001654-65,0,0,0 2021-001655-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboudumc,SARS-CoV2 vaccination and activation of the coagulation system,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001655-13,0,0,0 2021-001661-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Herlev and Gentofte Hospital,Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - A Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001661-21,0,0,0 2021-001663-24,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Regents of the University of Minnesota,"An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001663-24,0,0,0 2021-001663-24,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Office of Sponsored Projects,University of Minnesota","An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Tr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001663-24,0,0,0 2021-001665-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Semmelweis University Department of Oralbiology,"Prospective, randomized, controlled, double-blinded study on the efficacy of nebulized 4.2% sodium-bicarbonate in COVID-19 pneumonia Prospektív, kontrollált, randomizált kettős vak vizsgálat 4,2 %-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001665-20,0,0,0 2021-001670-33,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase IIb, Randomized, Observer-Blind study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001670-33,0,0,0 2021-001671-16,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A multicenter, open-label, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001671-16,0,0,0 2021-001671-16,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi aventis recherche et developpement,"A multicenter, open-label, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001671-16,0,0,0 2021-001672-42,1,,,0,0,1,0,0,0,1,1,0,4,0,0,0,0,1,Intas Pharmaceuticals Ltd,"A Multicentre, Open Label, Balanced, Randomized, Single-Dose, Two-Stage, Two-Treatment, Two-Period, Two-Sequence, Two-Way, Cross-Over Study To Evaluate Comparative Bioavailability Of Temozolomide Powd...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001672-42,0,1,1 2021-001674-34,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Agios Pharmaceuticals, Inc.","A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001674-34,0,0,0 2021-001674-34,4,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"AGIOS PHARMACEUTICALS, INC.","A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001674-34,0,0,0 2021-001680-24,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ITB-MED AB,"A 60 month, single-arm, proof-of-concept study to induce allogeneic tolerance in deceased donor liver transplant recipients using siplizumab, an anti-CD2 antibody in combination with cyclophosphamide ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001680-24,0,0,0 2021-001685-38,11,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Astellas Pharma Global Development, Inc.","A Phase 3b, Randomized, Double-blind, Placebo-controlled, 24-week Study to Assess the Efficacy and Safety of Fezolinetant in Menopausal Women Suffering from Moderate to Severe Vasomotor Symptoms (Hot ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001685-38,0,0,0 2021-001685-38,11,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.","A Phase 3b, Randomized, Double-blind, Placebo-controlled, 24-week Study to Assess the Efficacy and Safety of Fezolinetant in Menopausal Women Suffering from Moderate to Severe Vasomotor Symptoms (Hot ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001685-38,0,0,0 2021-001691-41,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,European Myeloma Network,"A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001691-41,0,0,0 2021-001691-41,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,STICHTING EUROPEAN MYELOMA NETWORK,"A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001691-41,0,0,0 2021-001693-33,2,,,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,"Intellia Therapeutics, Inc.","Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001693-33,0,0,0 2021-001695-42,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Cantargia AB,"A Phase 1/2 study of CAN04, a fully humanised monoclonal antibody against IL1RAP, in combination with different chemotherapy regimens in subjects with advanced solid tumours Estudio de fase 1/2 de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001695-42,0,0,0 2021-001696-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Vestre Viken Health Trust,Sotorasib in advanced KRASG12C-mutated non-small cell lung cancer patients with comorbidities,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001696-16,0,0,0 2021-001700-15,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK- 7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematologic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001700-15,0,0,0 2021-001700-15,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK- 7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematologic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001700-15,0,0,0 2021-001703-32,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Crinetics Pharmaceuticals, Inc.","A Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Non-pharmacologically Treated Acromegaly",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001703-32,0,0,0 2021-001704-15,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi aventis recherche et developpement,"A Phase 2, randomized, double-blind, placebo-controlled, multicenter proof-of-concept study evaluating efficacy and safety of rilzabrutinib in adult patients with moderate-to-severe atopic dermatitis ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001704-15,0,0,0 2021-001707-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medical Center Rotterdam,Nivolumab dose optimization during nivolumab therapy in melanoma patients after achieving a complete or partial response (NIVOPTIMIZE-trial) Optimalisatie van de nivolumab dosering tijdens de behan...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001707-32,0,0,0 2021-001708-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Region Östergötland,Antibiotic Impregnated Bone Graft to reduce infection in revision hip replacement. The ABOGRAFT trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001708-14,0,0,0 2021-001711-85,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,PentixaPharm GmbH,"A prospective, international, multi-centre, open-label,single-arm phase II study investigating the predictive value of [68Ga]Ga-PentixaFor PET imaging in primary and isolated secondary CNS lymphoma p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001711-85,0,0,0 2021-001713-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE RICERCA TRASLAZIONALE (FORT),"Phase II, two-cohorts, randomized trial comparing standard of care versus immune-based combination in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durval...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001713-37,0,0,0 2021-001716-29,5,2022-09-20,2022-09-20,2,0,1,0,0,1,3,0,0,2,1,0,0,0,1,SynOx Therapeutics Ltd,"A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001716-29,1,0,0 2021-001721-40,2,2022-10-14,2022-10-14,1,0,0,0,0,0,3,0,1,2,0,0,0,0,1,Seqirus UK Limited,"A Phase 3, Randomized, Observer-blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine in Compari...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001721-40,1,0,0 2021-001722-21,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"MONETTE: A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001722-21,0,0,0 2021-001722-21,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"MONETTE: A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001722-21,0,0,0 2021-001729-38,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,Arnis Eņģelis,Clinical and economical efficiency and safety and inflammation parameter correlations study of concervative treatment of non-complicated acute appendicitis in 7 to 18 years old children. Konservatī...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001729-38,0,0,0 2021-001730-19,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,Medical Univerity of Vienna,Hormones and Muscle – Unravelling the metabolic pathways of endocrine myopathies A translational magnetic resonance spectroscopy and imaging pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001730-19,0,0,0 2021-001732-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Palobiofarma, S.L","A phase IIa, randomized, double blind, placebo-controlled study to assess the effect of PBF-680 in patients with moderate to severe COPD on top of standard medication. Ensayo de fase IIa, doble cie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001732-25,0,0,0 2021-001735-10,1,2021-08-25,2021-08-25,1,1,0,0,0,0,3,0,1,1,1,1,1,0,1,Bayer AG,"COVID-19: A Phase 3, open-label, parallel group, multicenter clinical study to evaluate the safety, reactogenicity, and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in particip...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001735-10,0,0,0 2021-001768-95,1,,,0,0,1,0,0,0,1,1,1,4,0,0,0,0,1,Intas Pharmaceuticals Ltd.,"AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWOSEQUENCE, SINGLE ORAL DOSE, CROSSOVER, COMPARATIVE BIOAVAILABILITY STUDY OF IMATINIB ORAL SOLUTION 800 MG/10 ML (AT A DOSE OF 05 ML) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001768-95,0,1,1 2021-001769-19,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,GUVAX (Gothenburg University Vaccine Research Institute),"Immune response to SARS-CoV-2 in health care workers, previously infected subjects, and immunocompromised subjects, before and after Covid-19 vaccination: a phase IV trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001769-19,0,0,0 2021-001785-38,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,Ferring Pharmaceuticals A/S,"A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the ovarian response of a starting dose of 15 µg follitropin delta (REKOVELLE) to a starting dose ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001785-38,0,0,0 2021-001789-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,LAVA Therapeutics N.V.,"A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of LAVA-1207, a PSMA-targeting bispecific γδ-T cell e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001789-39,0,0,0 2021-001790-23,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Genmab A/S,"First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1047 in subjects with malignant solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001790-23,0,0,0 2021-001796-17,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Teva Pharmaceuticals, Inc.","A Multinational, Multicenter, Randomized, Double Blind Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of TEV 45779 Compared to Omalizumab ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001796-17,0,0,0 2021-001796-17,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Teva Pharmaceuticals Development, Inc.","A Multinational, Multicenter, Randomized, Double Blind Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of TEV 45779 Compared to Omalizumab ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001796-17,0,0,0 2021-001798-21,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Gilead Sciences, Inc.",A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma Víceramenná studie fáze 2 hodnotící kombinace magrolimabu u pacientů s relabujícím/refrakt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001798-21,0,0,0 2021-001801-56,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Gynial GmbH,Efficacy and Safety of a hyaluronic and lactic acid containing vaginal gel “HydroSanta® Vaginalgel” for the treatment of vaginal dryness symptoms – a multicenter randomized two-arm study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001801-56,0,0,0 2021-001802-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fraunhofer Institut für Translationale Medizin und Pharmakologie (ITMP),Efficacy of belimumab to improve subclinical cardiovascular abnormalities using imaging endpoints with cardiac magnetic resonance in patients with systemic lupus erythematosus (BeCarma),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001802-30,0,0,0 2021-001805-63,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,EVELO Biosciences Inc,"A phase 2, multicenter, double-blind, placebo-controlled, multiple-cohort study investigating the effect of EDP1815 in participants for the treatment of mild, moderate and severe atopic dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001805-63,0,0,0 2021-001810-13,8,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Calliditas Therapeutics Suisse SA,"TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001810-13,0,0,0 2021-001810-13,8,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Genkyotex Suisse SA,"TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevate...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001810-13,0,0,0 2021-001811-94,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001811-94,0,0,0 2021-001811-94,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advance...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001811-94,0,0,0 2021-001817-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud University Medical Center,Suboxone (buprenorphine/naloxone) versus methadone opioid rotation in patients with escalated opioid use and chronic pain: a randomized trial. Suboxone (buprenorfine/naloxon) versus methadon opioïd...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001817-35,0,0,0 2021-001825-33,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001825-33,0,0,0 2021-001825-33,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001825-33,0,0,0 2021-001827-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Amiens-Picardie,Evaluation of the early use of norepinephrine in major abdominal surgery on postoperative organ dysfunction Évaluation de l’utilisation préventive de la noradrénaline en chirurgie abdominale majeur...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001827-41,0,0,0 2021-001831-17,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Mitsubishi Tanabe Pharma Development America (MTDA), Inc.","A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Prot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001831-17,0,0,0 2021-001831-17,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"Mitsubishi Tanabe Pharma Development America, Inc.","A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Prot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001831-17,0,0,0 2021-001831-17,5,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Mitsubishi Tanabe Development America Inc.,"A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Prot...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001831-17,0,0,0 2021-001838-19,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Keros Therapeutics, Inc.","A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Estudio de fase II, abierto, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001838-19,0,0,0 2021-001839-77,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,IRCCS MATERNO INFANTILE BURLO GAROFOLO,"A Multicentric, Drug-Repositioning, Self Controlled Case Series (SCCS) Clinical Trial to Evaluate the Efficacy and Safety of Perampanel in Improving Behavioral Symptoms and Increasing the Quality of L...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001839-77,0,0,0 2021-001840-83,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Short-course aminoglycosides as adjunctive treatment in adults with sepsis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001840-83,0,0,0 2021-001841-11,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MaaT Pharma,"Evaluation of the efficacy of MaaT013 as salvage therapy in acute GVHD patients with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001841-11,0,0,0 2021-001855-15,2,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,"QED Therapeutics, Inc.","Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL OLE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001855-15,0,0,0 2021-001866-39,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Noema Pharma,"A Phase II/III, multicentre, 8-week run-in phase followed by a 12- week, prospective, parallel-group, double-blind, randomized withdrawal, placebo-controlled study, with a 52 week open label extensio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001866-39,0,0,0 2021-001905-66,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Spanish Cardiology Society,Randomized clinical trial assessing the value of Beta-Blockers and Antiplatelet Agents in patients with Spontaneous Coronary Artery Dissection Ensayo clínico aleatorizado para evaluar el efecto de ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001905-66,0,0,0 2021-001907-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Biocompatibles UK Ltd, a wholly owned indirect subsidiary of Boston Scientific Corporation","An Open-Label, Prospective, Multi-Center, Randomized Clinical Trial To Evaluate The Efficacy and Safety Of TheraSphere™ followed by Durvalumab (Imfinzi®) With Tremelimumab, Versus TheraSphere™ Alone F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001907-33,0,0,0 2021-001909-77,2,2022-08-12,2022-08-12,1,0,0,0,0,0,3,0,1,2,0,0,0,0,1,Janssen Vaccines & Prevention B.V.,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59Years, Including Those at High-risk for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001909-77,1,0,0 2021-001910-13,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Aerovate Therapeutics, Inc.","IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hyper...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001910-13,0,0,0 2021-001911-96,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants with C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001911-96,0,0,0 2021-001911-96,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase 3, International, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants with C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001911-96,0,0,0 2021-001917-35,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Noxopharm Limited,A Phase 1b/2a Multicenter Study of NOX66 and External Beam Radiotherapy in Patients with Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors Fázis 1b/2a multicentrikus klinikai ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001917-35,0,0,0 2021-001921-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospital Ghent,GRACE-trial: A randomized active-controlled trial for vulvovaginal atrophy in breast cancer patients on endocrine therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001921-31,0,0,0 2021-001924-16,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Faraday Pharmaceuticals, Inc.","IOCYTE AMI-3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous FDY-5301 in Patients with an Anterior ST-Elevation Myocardial Infarction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001924-16,0,0,0 2021-001928-17,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Genmab A/S,"A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer Af...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001928-17,0,0,0 2021-001928-17,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,GENMAB A/S,"A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer Af...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001928-17,0,0,0 2021-001930-20,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH ATEZOLIZUMAB AS MAINTENANCE THERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL-CE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001930-20,0,0,0 2021-001930-20,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F.Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH ATEZOLIZUMAB AS MAINTENANCE THERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL-CE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001930-20,0,0,0 2021-001930-20,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH ATEZOLIZUMAB AS MAINTENANCE THERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL-CE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001930-20,0,0,0 2021-001933-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"OncXerna Therapeutics, Inc.","A Phase 3 Multicenter, Open-Label, Randomized Study of Navicixizumab Plus Paclitaxel and Navicixizumab Monotherapy in Comparison to Paclitaxel Monotherapy in Patients with Platinum-Resistant Epithelia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001933-38,0,0,0 2021-001938-19,1,2022-10-12,2022-10-12,1,0,0,0,0,0,2,0,1,1,0,0,0,0,1,MedinCell S.A.,"A multicentre randomised, Double-Blind, Placebo-controlled, Study to evaluate the efficAcy and safety of oral IVErmectin tablets in the prevention of COVID-19 (the SAIVE Trial) Многоцентрово, рандо...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001938-19,0,0,0 2021-001940-86,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Reistone Biopharma Company Limited,"A Phase 3 Study to Evaluate the Efficacy and Long-term Safety of SHR0302 for Induction, Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001940-86,0,0,0 2021-001941-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Rijnstate hospital,Ultrasound-guided radiofrequency ablation versus radioactive iodine as treatment for hyperthyroidism caused by solitary autonomous thyroid nodules. Echogeleide radiofrequentie ablatie versus radioa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001941-11,0,0,0 2021-001953-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Verein zur Förderung der Wissenschaft und Forschung an der 1. Med. Abteilung der Klinik Landstraße,Alternate day dosing compared to consecutive day dosing of oral iron supplements in bariatric patients with iron-deficiency Alternative Eisen-Ersatztherapie bei Patienten mit Eisenmangel nach Gewic...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001953-30,0,0,0 2021-001954-76,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Ratiopharm GmbH Teva EU Medical Affairs,"A Randomized Open Label, Parallel Group Study to Evaluate the Hemodynamic Effects of Cafedrine/Theodrenaline vs Norepinephrine in the Treatment of Intraoperative Arterial Hypotension in Adults after I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001954-76,0,0,0 2021-001957-30,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Celgene Corporation,"A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib And Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib And Dexamethasone (PVd) In Subjects With Relaps...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001957-30,0,0,0 2021-001959-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,Adjunctive cannabidiol therapy in patients with CDKL5 deficiency disorder. Interventional drug study on efficacy and safety with focus on seizure effects Terapia con cannabidiolo in add-on nei paz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001959-13,0,0,0 2021-001965-19,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,chu de NANTES,Étude prospective interventionnelle thérapeutique de phase 3 monocentrique randomisée contrôlée en double insu évaluant l’efficacité de la noradrénaline en prévention de l’hypotension liée à l’intubat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001965-19,0,0,0 2021-001966-39,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001966-39,0,0,0 2021-001966-39,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Farmacéutica S.A.,"EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001966-39,0,0,0 2021-001966-39,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001966-39,0,0,0 2021-001967-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi aventis recherche & développement,Open-label study of tusamitamab ravtansine (SAR408701) in combination with ramucirumab in participants previously treated for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma with CE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001967-26,0,0,0 2021-001970-41,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Intas Pharmaceuticals Ltd.,"A Double Masked, Parallel Group, Randomized, Multicenter, Clinical Study to Compare Efficacy and Safety of Intas Ranibizumab with Lucentis® in Patients with Neovascular (Wet) Age-Related Macular Degen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001970-41,0,0,0 2021-001972-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Helsinki University Hospital, Otorhinolaryngology and Head and Neck Surgery",Treatment of Warthin's tumor: schlerotherapy and its natural course Warthinin tuumorin hoito: skleroterapia ja taudin luonnollinen kulku,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001972-41,0,0,0 2021-001973-21,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,GeNeuro Innovation SAS,A long-term extension of Study GNC-401 with temelimab in patients with Relapsing forms of Multiple Sclerosis (RMS) under treatment with rituximab,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001973-21,0,0,0 2021-001975-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Queen Mary University of London,A randomised phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer Estudio de fase II aleatorizado para comparar 3 y 6 ci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001975-17,0,0,0 2021-001976-40,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,National Institute for Public Health and the Environment,Monitoring immunogenicity of SARS-Cov-2 vaccination in Dutch middle-aged and older individuals (participating in the Doetinchem Cohort Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001976-40,0,0,0 2021-001978-37,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Instituto de Salud Carlos III. ISCIII,"A Phase 2, Comparative, Randomised, Adaptive Trial to Evaluate the safety and immunogenicity of one dose of COMIRNATY in subjects that had received one dose of VAXZEVRIA. Ensayo clínico de Fase II,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001978-37,0,0,0 2021-001979-16,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects with Episodic Migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001979-16,0,0,0 2021-001979-16,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AbbVie,"Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects with Episodic Migraine",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001979-16,0,0,0 2021-001989-38,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia,"IMPACT OF THE COMBINED TREATMENT OF THE LIPOSOMATED POLYPHENOLS CÚRCULA AND RESVERATROL® WITH DUTASTERIDE, IN THE CLINICAL IMPROVEMENT OF PATIENTS WITH ALS TREATED WITH RILUZOLE IMPACTO DEL TRATAMI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001989-38,0,0,0 2021-001990-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hellenic Society of Haematology (HSH),"An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination with Da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001990-22,0,0,0 2021-001993-52,1,,,0,0,0,0,1,0,4,0,1,0,0,0,0,0,0,University of Antwerp,"Assessment of the immunogenicity and safety of marketed vaccines for COVID-19 after regular schedule and adapted vaccine schedules and routes: BNT162b2 (Comirnaty®; Pfizer-BioNTech), mRNA-1273 Vaccine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-001993-52,0,0,0 2021-002006-27,17,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002006-27,0,0,0 2021-002006-27,17,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (V...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002006-27,0,0,0 2021-002008-11,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Immunocore Limited,"An open-label dose-escalation study evaluating the safety, pharmacokinetics and antiviral activity of IMC-M113V in HLA-A*02:01 positive subjects with chronic HIV infection who are virologically suppre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002008-11,0,0,0 2021-002009-85,1,2022-01-06,2022-01-06,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,"Can-Fite BioPharma, Ltd.","Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Pilot Trial Пиклиденозон за лечение на COVID-19 – Рандомизирано, двойно-заслепено, плацебо-контролирано пилот...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002009-85,0,0,0 2021-002011-61,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Academisch ziekenhuis Maastricht,The glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11.2 deletion syndrome De glutamaat/GABA balans als nieuw therapeutisch target voor psychotische en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002011-61,0,0,0 2021-002012-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2a, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab and Golimumab Combination Therapy in Participants with Active Psori...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002012-31,0,0,0 2021-002014-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fakultní nemocnice Hradec Králové,Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients with...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002014-14,0,0,0 2021-002024-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fakultní nemocnice u sv. Anny v Brně,"Randomized placebo controlled clinical trial evaluating the safety and efficacy of ivermectin in hospitalized patients with Covid-19 disease Randomizované, placebem kontrolované klinické hodnocení ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002024-21,0,0,0 2021-002026-24,3,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Randomized, Double-Blind, Parallel Group, Multicenter 24 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002026-24,0,0,0 2021-002026-24,3,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,ASTRAZENECA AB,"A Randomized, Double-Blind, Parallel Group, Multicenter 24 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002026-24,0,0,0 2021-002027-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,SOLTI,"A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer - HARMONIA trial Estudio de fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002027-38,0,0,0 2021-002030-16,1,2021-12-31,2021-12-31,1,0,0,0,0,0,4,0,1,1,0,0,0,0,0,"Medizinische Universität Innsbruck, Institut für Virologie",Immune response and breakthrough infections following an in-label vaccination with Comirnaty against SARS-CoV-2 in the district of Schwaz Immunantwort und Infektion nach Impfdurchbrüchen nach zulas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002030-16,0,0,0 2021-002037-42,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Seagen Inc.,"An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002037-42,0,0,0 2021-002039-40,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","An open-label, multi-center, phase 2 basket study to assess efficacy, safety and pharmacokinetics of iptacopan (LNP023) in participants with autoimmune benign hematological disorders",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002039-40,0,0,0 2021-002039-40,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"An open-label, multi-center, phase 2 basket study to assess efficacy, safety and pharmacokinetics of iptacopan (LNP023) in participants with autoimmune benign hematological disorders",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002039-40,0,0,0 2021-002039-40,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"An open-label, multi-center, phase 2 basket study to assess efficacy, safety and pharmacokinetics of iptacopan (LNP023) in participants with autoimmune benign hematological disorders",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002039-40,0,0,0 2021-002040-78,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002040-78,0,0,0 2021-002045-15,9,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,"Genentech, Inc.","A PHASE IIb, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002045-15,0,0,0 2021-002046-33,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Farmacéutica S.A.,"An adaptive, randomized, double-blind, dose exploration, parallel group, placebo-controlled, multicenter phase 2 trial to evaluate the efficacy, safety and tolerability of LNP023 in combination with s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002046-33,0,0,0 2021-002046-33,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"An adaptive, randomized, double-blind, dose exploration, parallel group, placebo-controlled, multicenter phase 2 trial to evaluate the efficacy, safety and tolerability of LNP023 in combination with s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002046-33,0,0,0 2021-002047-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Amiens Picardie,Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled trial Comparaison de l’azathioprine au méthotrexate en co...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002047-29,0,0,0 2021-002051-10,1,,,0,0,1,0,0,0,3,0,0,4,0,0,0,0,0,"Takeda Development Center, Americas (TDC Americas)","A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients with Status Epilepticus (Convulsive) in Community Settings",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002051-10,0,1,1 2021-002055-12,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Canisius Wilhelmina Hospital,Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002055-12,0,0,0 2021-002058-96,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Lek Pharmaceuticals d.d.,"Efficacy and safety of the combination of acetylcysteine, paracetamol and phenylephrine for the treatment of common cold: a prospective, randomized, double-blind, controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002058-96,0,0,0 2021-002062-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud university medical center,Pharmacokinetic study with a loading dose of clofazimine in adult patients with nontuberculous mycobacterial disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002062-40,0,0,0 2021-002068-30,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Intra-Cellular Therapies, Inc.","A Randomized, Double-blind, Placebo-controlled, Parallel- group Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002068-30,0,0,0 2021-002071-19,17,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Bayer AG,"A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight adjusted oral finerenone regimen, in addition to an ACEI ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002071-19,0,1,0 2021-002071-19,17,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,BAYER AG,"A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age-and body weight adjusted oral finerenone regimen, in addition to an ACEI ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002071-19,0,1,0 2021-002073-26,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Medical Center - University of Freiburg,Phase 1/2 Trial to determine the safety and efficacy of Extracorporeal photopheresis as treatment for steroid-refractory immune related adverse events after immune checkpoint inhibitor therapy Phas...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002073-26,0,0,0 2021-002076-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BALOVAPTAN IN PATIENTS WITH ACUTE ISCHEMIC STROKE AT HIGH RISK OF DEVELOPING MALIGNAN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002076-39,0,0,0 2021-002087-47,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,"Aimmune Therapeutics, Inc.",Oral Desensitization to Peanut in Peanut-Allergic Children and Adults using Characterized Peanut Allergen (CPNA) Oral Immunotherapy (OIT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002087-47,0,1,1 2021-002089-42,4,,,0,0,0,0,0,0,3,0,0,2,1,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients with Allergic Rhinitis Who Live with a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies during Natural Cat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002089-42,0,0,0 2021-002093-34,1,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,NEWRON PHARMACEUTICALS SPA,"A Phase II/III, multi-center, open-label, extension study to determine the long-term safety, tolerability, and efficacy of evenamide in patients with psychiatric disorders who participated in a previo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002093-34,0,0,0 2021-002094-26,1,,,0,0,1,0,0,1,4,0,0,4,0,0,0,0,0,Les Hôpitaux Universitaires de Strasbourg,Optimization of the management of drepanocytosis patients treated with hydroxyurea: Interest of the pharmacological therapeutic follow-up Optimisation de la prise en charge des patients drépanocyt...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002094-26,0,0,0 2021-002098-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Friedrich-Schiller-Universität Jena,"A randomized, controlled, multicenter, open label phase II clinical study to evaluate infliximab in the treatment of patients with severe COVID-19 disease (INFLIXCOVID) Eine randomisierte, kontro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002098-25,0,0,0 2021-002104-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Faron Pharmaceuticals Ltd.,"A Phase I/II Open-Label, Two-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody Bexmarilimab in C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002104-12,0,0,0 2021-002105-99,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002105-99,0,0,0 2021-002105-99,5,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002105-99,0,0,0 2021-002108-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Sunovion Pharmaceuticals Inc.,"A 12-Month Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Effectiveness of SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002108-11,0,0,0 2021-002124-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ARCAGY-GINECO,Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting: DOMENICA STUDY (GINECO-EN105b/ENGOT-e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002124-21,0,0,0 2021-002125-15,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Fundación Pethema,"An open label, multicenter, phase I/II study of belantamab mafodotin in combination with Kd for the treatment of relapsed myeloma patients, refractory to lenalidomide Estudio de fase I/II, abierto ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002125-15,0,0,0 2021-002126-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Sunovion Pharmaceuticals Inc.,"A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002126-24,0,0,0 2021-002146-33,1,,,0,0,0,0,0,0,2,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc.,Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Toddlers and Infants,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002146-33,0,1,1 2021-002147-29,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH MELANOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002147-29,0,0,0 2021-002147-29,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH MELANOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002147-29,0,0,0 2021-002147-29,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TREATMENT COMBINATIONS IN PATIENTS WITH MELANOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002147-29,0,0,0 2021-002148-56,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,ACTICOR BIOTECH,"A RANDOMIZED, DOUBLE BLIND, MULTICENTER, MULTINATIONAL, PLACEBO CONTROLLED, PARALLEL GROUP, SINGLE DOSE, ADAPTIVE EFFICACY AND SAFETY STUDY OF GLENZOCIMAB USED AS AN ADD-ON THERAPY ON TOP OF STANDARD ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002148-56,0,0,0 2021-002150-91,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"Phase 2 non-randomized, open-label, multi-cohort, multicenter study assessing the clinical benefit of SAR444245 (THOR-707) with or without other anticancer therapies for the treatment of adults and ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002150-91,0,0,0 2021-002150-91,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"Phase 2 non-randomized, open-label, multi-cohort, multicenter study assessing the clinical benefit of SAR444245 (THOR-707) with or without other anticancer therapies for the treatment of adults and ad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002150-91,0,0,0 2021-002161-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GERMAN ONCOLOGY CENTER,Diagnostic ability comparison between [18F]- SiF Alin - TATE and [18F] - FDOPA for Neuro-Endocrine Tumor (NET) patients Σύγκριση διαγνωστικής ικανότητας του [18F]- SiF Alin - TATE με το [18F] - FDO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002161-17,0,0,0 2021-002162-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Haaglanden Medisch Centrum,"IBIS: A single-centre, phase II study to evaluate the safety, tolerability and pharmacokinetics of 2-IminoBiotin in acute Ischemic Stroke due to large vessel occlusion",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002162-40,0,0,0 2021-002163-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Nanobiotix SA,A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for platinum-based Chemotherapy-ineligible Elderly Pati...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002163-22,0,0,0 2021-002166-40,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Galderma S.A.,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis with Inadequate Response to or for Whom Cycl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002166-40,0,0,0 2021-002166-40,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Galderma SA,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis with Inadequate Response to or for Whom Cycl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002166-40,0,0,0 2021-002170-72,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Groningen,T&T trial: adding Testosterone to Tamoxifen in male breast cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002170-72,0,0,0 2021-002171-19,1,,,0,0,0,0,1,0,2,0,1,0,0,0,0,0,0,"Medizinische Universität Innsbruck, Institut für Virologie","Heterologous vaccination with a Vaxzervia (ChAdOx1-S) prime and a Comirnaty (BNT162b2) boost Heterologe Impfung mit Vaxzervia (ChAdOxl-S, AstraZeneca) gefolgt von Comirnaty (BNT162b2, Pfizer)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002171-19,0,0,0 2021-002172-39,2,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent ß-Thalassemia Studio di fase 3 per valutare la sicurezza e l'efficaci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002172-39,0,0,0 2021-002172-39,2,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,1,VERTEX PHARMACEUTICALS INCORPORATED,A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent ß-Thalassemia Studio di fase 3 per valutare la sicurezza e l'efficaci...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002172-39,0,0,0 2021-002173-26,2,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,1,VERTEX PHARMACEUTICALS INCORPORATED,A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002173-26,0,0,0 2021-002173-26,2,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002173-26,0,0,0 2021-002174-52,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Assistance Publique -Hopitaux de Paris,Essai multicentrique randomisé en ouvert comparant l’efficacité immunologique d’un schéma vaccinal combinant deux vaccins ARNm Covid19 (Pfizer-BioNTech et Moderna) à celle d’une vaccination homologue ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002174-52,0,0,0 2021-002176-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Veru Inc.,ARTEST - A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with Andr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002176-39,0,0,0 2021-002177-25,2,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,NEKTAR THERAPEUTICS,"A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 in Combination with Cetuximab as a Salvage Regimen for Solid Tumors Estudio de fase 1b/2, abierto, multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002177-25,0,0,0 2021-002177-25,2,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,Nektar Therapeutics,"A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 in Combination with Cetuximab as a Salvage Regimen for Solid Tumors Estudio de fase 1b/2, abierto, multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002177-25,0,0,0 2021-002178-17,4,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Chemo Research S.L.,"A multicentre, phase III, double-blind, randomised clinical trial to assess the efficacy and safety of LPRI-424 (dienogest 2.00 mg / ethinyl estradiol 0.02 mg) in the treatment of polycystic ovary syn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002178-17,0,0,0 2021-002179-21,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AB Science,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib as add-on therapy in patients with mild to moderate Alzheimer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002179-21,0,0,0 2021-002179-21,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ABScience,"A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib as add-on therapy in patients with mild to moderate Alzheimer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002179-21,0,0,0 2021-002181-41,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Sanofi-Aventis Recherche & Developpement,"A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002181-41,0,0,0 2021-002181-41,4,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002181-41,0,0,0 2021-002184-22,1,2021-09-01,2021-09-01,1,0,0,0,1,0,2,0,0,1,0,0,1,0,0,Athens Medical Society,"A phase II randomized, single-blind dose study to evaluate the safety and efficacy of exosomes overexpressing CD24 in 10^9 dose versus 10^10 dose, for the prevention of clinical deterioration in patie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002184-22,0,0,0 2021-002186-17,1,2021-11-26,2021-11-26,1,0,0,0,0,0,4,0,1,1,0,0,0,0,0,RadboudUMC,Timing and sequence of vaccination against COVID-19 and Influenza Timing en volgorde van vaccinatie tegen COVID-19 en Influenza,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002186-17,0,0,0 2021-002187-49,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Eden Biologics, Inc., Taiwan","A Multinational, Randomized, Double-Blind, Active-Controlled Phase 3 Study to Compare the Clinical Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EB1001 Biosimilar With EU-Licensed Prolia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002187-49,0,0,0 2021-002188-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Bispebjerg Hospital,Association between variations in CYP pheno- and genotypes and plasma concentration of chlordiazepoxide in the treatment of alcohol withdrawal symptoms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002188-23,0,0,0 2021-002190-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundacion PETHEMA,"Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment regimens in transplant ineligible newly diagnosed patients...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002190-25,0,0,0 2021-002192-19,9,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002192-19,0,0,0 2021-002193-63,1,2021-10-22,2021-10-22,1,1,0,0,0,0,3,0,0,1,1,1,0,0,1,"Agenus, Inc.",A Phase 3 Trial of Balstilimab versus Investigator Choice Chemotherapy in Patients with Recurrent Cervical Cancer after Platinum-Based Chemotherapy 3 fazės balstilimabo palyginimo su tyrėjo pasirin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002193-63,0,0,0 2021-002197-78,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Assistance Publique - Hôpitaux de Paris,Antimicrobial Stewardship For Ventilator Associated Pneumonia in Intensive Care Acronym: ASPIC Optimisation de l'antibiothérapie pour les pneumonies précoces survenant chez les patients ventilés en...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002197-78,0,0,0 2021-002200-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,MUMC AZm,"A multiple dosing study to demonstrate the safety, tolerability, pharmacokinetics and efficacy potential of intravenously administered ANXV (a recombinant human Annexin A5) in patients with confirmed ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002200-12,0,0,0 2021-002203-34,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,AbbVie Deutschland,"A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002203-34,0,1,1 2021-002207-36,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,INCYTE CORPORATION,"An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002207-36,0,0,0 2021-002207-36,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Incyte Corporation,"An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002207-36,0,0,0 2021-002210-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"The department of cardiac, thoracic and vascular surgery - Odense University Hospital",Post-Operative Atrial Fibrillation after Surgical Aortic Valve Replacement and the influence of HMG-CoA reductase inhibitors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002210-13,0,0,0 2021-002211-65,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Fundación Española de Gastroenterología,"EFFECT OF TOFACITINIB ON COAGULATION AND PLATELET FUNCTION, AND ITS ROLE IN THROMBOEMBOLIC EVENTS EFECTO DE TOFACITINIB SOBRE LA COAGULACIÓN Y FUNCIÓN PLAQUETARIA, Y SU PAPEL EN LOS EVENTOS TROMBOE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002211-65,0,0,0 2021-002212-31,1,,,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,MIMETECH SRL,NEurotrophins Mimetic compound for the treatment of diabetic foot UlcerS Composto mimetico delle neurotrofine per il trattamento delle ulcere del piede diabetico,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002212-31,0,0,0 2021-002217-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI,Tuscany project to investigate on efficacy and safety of Cannabis phytotherapic preparations for the treatment of Aromatase iNhibitor-induced chronic resistaNt pAin in Breast cancer patIents: a prospe...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002217-34,0,0,0 2021-002218-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Region Skåne,"Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors - An open-label, multicenter, randomized controlled trial comparing safety and efficacy of personalized vs non-personalized radionuclid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002218-15,0,0,0 2021-002225-18,1,2022-06-30,2022-06-30,1,0,0,0,0,0,3,0,1,1,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase 3, randomized, double-blind, multi-country study to evaluate consistency, safety, and reactogenicity of 3 lots of RSVPreF3 OA investigational vaccine administrated as a single dose in adults a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002225-18,0,0,0 2021-002244-70,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,IPSEN PHARMA SAS,"Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged >=14 Years with Fibrodysplasia Ossifi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002244-70,0,0,0 2021-002244-70,4,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Ipsen Pharma SAS,"Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged >=14 Years with Fibrodysplasia Ossifi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002244-70,0,0,0 2021-002245-15,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Charité - Universitätsmedizin Berlin,A low-interventional study to investigate the efficacy and safety of SARS-CoV-2 vaccines in patients with rheumatic diseases. Niedrig-interventionelle Studie zur Untersuchung der Effektivität und S...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002245-15,0,0,0 2021-002247-30,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,CHU TOULOUSE,Evaluation of Amoxicillin diffusion in breast milk according to a population pharmacokinetic approach.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002247-30,0,0,0 2021-002251-11,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Transposon Therapeutics, Inc",A Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD (Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002251-11,0,0,0 2021-002252-36,1,2022-06-13,2022-06-13,1,0,0,0,0,0,3,0,0,1,0,0,0,0,1,Inmunotek S.L.,"A prospective, randomized, double-blind placebo-controlled multicentre study with 10 000 mTU/mL mannan-conjugated birch pollen allergoids administered subcutaneously to patients with birch pollen-indu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002252-36,0,0,0 2021-002253-29,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of ZED1227 capsules with placebo in the treatment of non-alcoholic fatty liver disease (NAFLD) with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002253-29,0,0,0 2021-002254-86,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Dr. Falk Pharma GmbH,"Double-blind, randomised, placebo-controlled, dose-finding phase IIb trial to evaluate the efficacy, safety, and tolerability of a 12-week-treatment with Naronapride in adult participants with at leas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002254-86,0,0,0 2021-002257-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA UDINE,Randomised controlled trial to evaluate the efficacy of local anaesthetic application in spray for the repair of 1st- 2nd perineal lacerations following vaginal delivery Trial controllato randomizz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002257-28,0,0,0 2021-002264-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"ImmunoGen, Inc.","A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936-0901 (Anti-ADAM9 Antibody Drug Conjugate) in Patients with Advanced Solid Tumors Un estudio de fase 1/2, prim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002264-41,0,0,0 2021-002284-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Helse-Bergen HF, Haukeland University Hospital",Hyperbaric oxygen treatment added to standard care for acute idiopathic sudden sensorineural hearing loss - a multicentre randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002284-22,0,0,0 2021-002286-17,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Incyte Corporation,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002286-17,0,0,0 2021-002288-24,1,2022-04-22,2022-04-22,1,1,0,0,0,0,4,0,0,1,1,1,0,0,0,Amsterdam UMC,Effect of citalopram on chest pain in patients with functional chest pain Het effect van citalopram op klachten van pijn op de borst bij patiënten met functionele retrosternale pijn.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002288-24,0,0,0 2021-002297-11,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Actelion Pharmaceuticals Ltd,"A Prospective, Open-label, Platform Study for Long-term Follow-up of Participants Using Study Intervention in Pulmonary Hypertension Parent Studies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002297-11,0,0,0 2021-002298-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP),"A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge Ensayo multicéntrico, a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002298-25,0,0,0 2021-002300-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Friedrich Schiller University,Epirubicin for the Treatment of Sepsis & Septic Shock Epirubicin für die Behandlung von Sepsis und septischen Schock,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002300-12,0,0,0 2021-002301-10,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Eli Lilly and Company,"postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002301-10,0,0,0 2021-002301-10,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"ELI LILLY & COMPANY, LILLY CORPORATE CENTER","postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002301-10,0,0,0 2021-002301-10,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Lilly S.A.,"postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002301-10,0,0,0 2021-002308-11,2,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,Celgene International II Sàrl,"A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral ozanimod (RPC1063) in pediatric subjects with moderately to sev...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002308-11,0,0,0 2021-002311-64,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ALFASIGMA CZECH s.r.o.,Efficacy and safety of sulodexide in the treatment of chronic primary venous disease of the lower extremities: randomized double-blind placebo-controlled clinical trial Účinnost a bezpečnost sulode...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002311-64,0,0,0 2021-002317-34,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Allergopharma GmbH & Co. KG,"A multicenter, randomized, open label clinical trial for safety evaluation of an allergen immunotherapy with an accelerated dose escalation schedule using one strength of an aluminium hydroxide adsorb...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002317-34,0,0,0 2021-002318-15,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,"Copenhagen University Hospital, Amager and Hvidovre, Department of Clinical Research",A pharmacological trial with Sativex® and gentamicin for optimized pharmacological treatment of older patients with a focus on appetite stimulation and renal risk drugs Farmakologisk forsøg med Sat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002318-15,0,0,0 2021-002320-20,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,sanofi-aventis recherche et développement,"A randomized, open-label, parallel-group, 18-month Phase 3 study to evaluate the effect of venglustat compared with usual standard of care on left ventricular mass index in participants with Fabry dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002320-20,0,0,0 2021-002320-20,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A randomized, open-label, parallel-group, 18-month Phase 3 study to evaluate the effect of venglustat compared with usual standard of care on left ventricular mass index in participants with Fabry dis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002320-20,0,0,0 2021-002321-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University of Liège,Complexity-enhancing drugs to treat disorders of consciousness (DoC): a ketamine study Agents pharmacologiques augmentant la complexité cérébrale pour traiter les troubles de la conscience après un...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002321-23,0,0,0 2021-002322-24,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,SOLTI,Neoadjuvant and adjuvant RIBOciclib and endocrine therapy for cLinicAlly high-RISk estrogen receptor-positive (ER+) and HER2-negative (HER2-) breast cancer (RIBOLARIS) Ribociclib y terapia endocrin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002322-24,0,0,0 2021-002323-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,German Breast Group,"A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002323-38,0,0,0 2021-002325-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""",Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsatellite stable locally Advanced RecTal Cancer: the CATARTIC t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002325-18,0,0,0 2021-002326-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Alkermes, Inc.","A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002326-24,0,0,0 2021-002327-38,1,2022-02-28,2022-02-28,1,0,0,0,0,0,4,0,1,1,1,1,0,0,0,Academic Medical Center,PREGCOVAC-19: the follow up of pregnant women who received COVID-19 vaccination in the Dutch national vaccination program,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002327-38,0,0,0 2021-002329-56,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC)",Exploratory study to evaluate the efficacy and safety of nutritionally administering 1.5 g protein/kg/day vs. 1.0 g protein/kg/day in the catabolic phase of the critically ill patient on mechanical ve...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002329-56,0,0,0 2021-002335-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Philipps University Marburg,"Inhaled ColiFin® in adult bronchiectasis patients with early asymptomatic Pseudomonas aeruginosa infection– an open-label, proof of concept - randomized controlled trial Inhaliertes ColiFin® in er...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002335-33,0,0,0 2021-002339-44,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"IGM Biosciences, Inc.","A Phase 1/2 Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas Estudio de fase I/II ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002339-44,0,0,0 2021-002343-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Unity Health Toronto, at its St. Michael’s site",A randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery (NEWTON-CABG),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002343-30,0,0,0 2021-002344-73,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi-aventis recherche & développement,"A long-term extension study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in adult participants with moderate to severe atopic dermatitis who participated in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002344-73,0,0,0 2021-002346-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE IIIB, MULTINATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PATIENT PREFERENCE FOR HOME ADMINISTRATION OF FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002346-33,0,0,0 2021-002348-57,1,2021-11-08,2021-11-08,1,0,0,0,1,0,2,0,0,1,0,0,0,0,0,Medical University of Vienna,"A Randomized, Parallel Group, Single-Blind, Phase 2 Study to Evaluate the immune response of two classes of SARS-CoV-2 Vaccines (COVID-19) employed as Second Boost in Patients under current Rituximab ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002348-57,0,0,0 2021-002350-90,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A randomized, double-blind, placebo-controlled, 12 month Phase 3 study to evaluate the effect of venglustat on neuropathic and abdominal pain in male and female adults with Fabry disease who are treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002350-90,0,0,0 2021-002350-90,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A randomized, double-blind, placebo-controlled, 12 month Phase 3 study to evaluate the effect of venglustat on neuropathic and abdominal pain in male and female adults with Fabry disease who are treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002350-90,0,0,0 2021-002352-36,1,2022-05-17,2022-05-17,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,F. Hoffmann La Roche Ltd.,"A PHASE II, OPEN-LABEL, SINGLE-ARM DECENTRALIZED HOME-BASED APPROACH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALECTINIB IN LOCALLY ADVANCED OR METASTATIC ALK-POSITIVE SOLID TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002352-36,0,0,0 2021-002356-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Clinic per a la Recerca Biomèdica (FCRB),Study about the response to the administration of a third dose of mRNA-1273 vaccine (COVID19 vaccine Moderna) in renal transplants with immunological failure initial to vaccination ESTUDIO SOBRE LA...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002356-37,0,0,0 2021-002360-51,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Antoni van Leeuwenhoek ziekenhuis,"Prospective, randomized, neoadjuvant phase II study with combination immuno-oncology in primary clear cell renal cell cancer at risk for recurrence or distant metastases (NESCIO-trial; M21NSC; CA209-6...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002360-51,0,0,0 2021-002361-17,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS,A multicentric phase 2 study of venetoclax and azacitidine for the management of the molecular relapse/progression in adult NPM1- mutaded acute myeloid leukemia. Studio multicentrico di fase II su ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002361-17,0,0,0 2021-002363-22,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,National Institute for Public Health and the Environment,Vaccination of older persons against Sars-Cov-2 and cellular immunogenicity for long term protection (participating in the Doetinchem Cohort Study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002363-22,0,0,0 2021-002365-18,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Concert Pharmaceuticals, Inc.","A MULTICENTER, OPEN-LABEL, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF CTP-543 IN ADULT PATIENTS WITH MODERATE TO SEVERE ALOPECIA AREATA EINE MULTIZENTRISCHE, OFFENE VERLÄNGERUNG...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002365-18,0,0,0 2021-002366-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA,"Phase II, multicenter, randomized, open-label study with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcoma Studio di fase II, multicentrico, randomizzato, in aper...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002366-41,0,0,0 2021-002367-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska Universitetssjukhuset,"Fettvävsheterogenitet och dess koppling till typ 2 diabetes : En randomiserad öppen behandlingsstudie som jämför Empagliflozin, Pioglitazon och Semaglutide",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002367-21,0,0,0 2021-002369-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,GETAID,"Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial, the POMEROL trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002369-17,0,0,0 2021-002387-50,1,2022-09-16,2022-09-16,1,0,0,0,0,0,2,0,1,1,0,0,0,0,1,BioNTech SE,"A Phase II, open-label, rollover trial to evaluate the safety and immunogenicity of one or two boosting doses of Comirnaty or one dose of BNT162b2s01 in BNT162-01 trial subjects, or two boosting doses...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002387-50,0,0,0 2021-002389-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002389-41,0,0,0 2021-002390-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Fab'entech,"A two-stage randomized, placebo-controlled, double-blind, phase 2a study to characterize the safety and pharmacokinetics of FBR-002 in patients hospitalized with COVID-19 need of supplemental oxygen a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002390-25,0,0,0 2021-002391-39,11,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Chiesi Farmaceutici S.p.A.,"A 26 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002391-39,0,0,0 2021-002391-39,11,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,CHIESI FARMACEUTICI S.P.A.,"A 26 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF BECL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002391-39,0,0,0 2021-002392-20,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim International GmbH,"Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002392-20,0,0,0 2021-002392-20,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim B.V.,"Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002392-20,0,0,0 2021-002392-20,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim B.V,"Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002392-20,0,0,0 2021-002392-20,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim bv Netherlands,"Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002392-20,0,0,0 2021-002392-20,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG,"Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002392-20,0,0,0 2021-002392-20,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim Norway KS,"Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002392-20,0,0,0 2021-002392-20,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002392-20,0,0,0 2021-002392-20,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Boehringer Ingelheim España, S.A.","Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002392-20,0,0,0 2021-002392-20,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim,"Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002392-20,0,0,0 2021-002392-20,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim AB,"Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002392-20,0,0,0 2021-002392-20,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SCS Boehringer Ingelheim Comm. V,"Brightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002392-20,0,0,0 2021-002395-39,4,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER BASKET STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH ANTI-N-MET...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002395-39,0,0,0 2021-002395-39,4,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER BASKET STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PATIENTS WITH ANTI-N-MET...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002395-39,0,0,0 2021-002445-15,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,InfectoPharm Arzneimittel und Consilium GmbH,Placebo-kontrollierte randomisierte doppel-blinde Phase III Studie zur Wirksamkeit und Sicherheit von Ivermectin Tabletten (Driponin®) für die Prophylaxe der COVID-19 Erkrankung bei im Haushalt lebend...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002445-15,0,0,0 2021-002449-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospitals Leuven (UZ Leuven),Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002449-13,0,0,0 2021-002450-81,2,2021-12-29,2021-12-29,2,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2, Open-label, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, Nucleos(t)ide Analogs, and Pegylated Interferon Alpha-2a in Pati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002450-81,0,0,0 2021-002452-37,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Imago BioSciences, Inc","A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients with Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Cli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002452-37,0,0,0 2021-002452-37,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Imago BioSciences Inc.,"A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients with Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Cli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002452-37,0,0,0 2021-002453-28,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,0,AZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA,"First line Immunotherapy-chemotherapy versus Immunotherapy-chemotherapy Combined With Stereotactic Body Radiation for Metastatic NSCLC patients: A Phase II Randomized, Open Label Clinical Trial. I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002453-28,0,0,0 2021-002457-29,6,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,Pfizer Inc.,AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER SPONSORED AVELUMAB CLINICAL STUDIES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002457-29,0,0,0 2021-002457-29,6,,,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,PFIZER INC,AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER SPONSORED AVELUMAB CLINICAL STUDIES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002457-29,0,0,0 2021-002460-46,8,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,argenx BV,"A Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX-113-2006 to Evaluate Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis Speri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002460-46,0,0,0 2021-002460-46,8,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,ARGENX BV,"A Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX-113-2006 to Evaluate Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis Speri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002460-46,0,0,0 2021-002461-18,8,2022-04-15,2022-04-22,5,1,0,0,0,0,2,0,0,2,1,0,0,0,1,Nektar Therapeutics,"A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined with Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002461-18,1,0,0 2021-002461-18,8,2022-04-15,2022-04-22,5,1,0,0,0,0,2,0,0,2,1,0,0,0,1,NEKTAR THERAPEUTICS,"A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined with Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002461-18,1,0,0 2021-002467-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundacion Santiago Dexeus Font,Dual Trigger vs. GnRH-a Trigger for Elective Fertility Preservation. A randomized controlled trial. Doble descarga versus descarga con agonista de la GnRH para preservación de la fertilidad social....,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002467-22,0,0,0 2021-002470-42,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Univeristy Medical Center Utrecht,Sentinel lymph node detection in thyroid carcinoma using [68Ga]Ga-tilmanocept PET/CT: A proof of concept study Detectie van schildwachtklieren bij schildklier carcinoom met behulp van [68Ga]Ga-tilm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002470-42,0,0,0 2021-002474-99,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Grupo Español Multidisciplinar de Melanoma (GEM),"Phase II, Open-Label Study of preliminary efficacy of Sitravatinib in Combination with Tislelizumab in Patients with Metastatic Uveal Melanoma with liver metastases. Estudio fase II, abierto de la ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002474-99,0,0,0 2021-002476-39,1,,,0,0,0,0,0,0,4,0,1,1,1,1,0,1,1,DOMPé FARMACEUTICI S.P.A.,Prospective study to evaluate the effects of Raloxifene therapy on SARS-CoV-2 immunity after COVID-19 vaccination Prospective study to evaluate the effects of Raloxifene therapy on SARS-CoV-2 immun...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002476-39,0,0,0 2021-002477-26,3,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,1,"Nuvalent, Inc.",A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002477-26,0,0,0 2021-002478-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA,IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY PSORIATIC ARTHRITIS: THE PRECISE STUDY. IDENTIFICATION OF SYNOVIAL BIOMARKERS OF RESPONSE TO IXEKIZUMAB IN REFRACTORY P...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002478-20,0,0,0 2021-002479-20,2,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Janssen-Cilag Invernational N.V.,"An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to less than 18 years with Generalized Myasthenia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002479-20,0,1,0 2021-002480-22,9,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,1,"Takeda Development Center Americas, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002480-22,0,0,0 2021-002480-22,9,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,1,TAKEDA DEVELOPMENT CENTER AMERICAS INC.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002480-22,0,0,0 2021-002481-40,9,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"Takeda Development Center Americas, Inc.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002481-40,0,0,0 2021-002481-40,9,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,TAKEDA DEVELOPMENT CENTER AMERICAS INC.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subject...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002481-40,0,0,0 2021-002482-17,10,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"Takeda Development Center Americas, Inc","A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Len...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002482-17,0,1,0 2021-002482-17,10,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,TAKEDA DEVELOPMENT CENTER AMERICAS INC.,"A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Len...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002482-17,0,1,0 2021-002485-41,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Sanofi-aventis recherche & developpement,"A randomized, Phase 3, open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed and/o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002485-41,0,0,0 2021-002490-26,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi aventis recherche et developpement,"A randomized, double-blind, placebo-controlled, parallel-group, 12 week Proof-of-Concept (PoC) study to assess the efficacy, safety, and tolerability of rilzabrutinib in participants with moderate-to-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002490-26,0,0,0 2021-002491-39,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Seagen Inc.,"A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002491-39,0,0,0 2021-002491-39,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SEAGEN INC.,"A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002491-39,0,0,0 2021-002504-12,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,argenx BV,"A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002504-12,0,0,0 2021-002504-12,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,ARGENX BV,"A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasth...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002504-12,0,0,0 2021-002505-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Amsterdam University Medical Centre,Rescue Alkaline Phosphatase In Defense against all cause Acute Kidney Injury (RAPID-AKI) Rescue alkalisch fosfatase als behandeling van acute nierinsufficiëntie onafhankelijk van oorzaak (RAPID-AKI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002505-10,0,0,0 2021-002528-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Copenhagen University Hospital Rigshospitalet,"RESCUE - Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insufficiency; A multicentre, randomised, double blinded, placebo-controlled clinical trial on health-relat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002528-18,0,0,0 2021-002530-17,1,2022-08-02,2022-08-02,1,0,0,0,0,0,2,0,1,1,0,0,0,0,1,AstraZeneca AB,"A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Both Previously Vaccinated and Unvaccinated Adults to Determine the Safety and Immunogenicity of AZD2816,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002530-17,0,0,0 2021-002531-27,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,2,European Myeloma Network (EMN),Phase 3 Study of Teclistamab in Combination with Lenalidomide versus Lenalidomide Alone in Participants with Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Tran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002531-27,0,0,0 2021-002531-27,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,2,STICHTING EUROPEAN MYELOMA NETWORK,Phase 3 Study of Teclistamab in Combination with Lenalidomide versus Lenalidomide Alone in Participants with Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Tran...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002531-27,0,0,0 2021-002532-23,4,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,2,EspeRare Foundation,"A prospective, open-label, genotype-match controlled, multicenter clinical trial to investigate the efficacy and safety of intra-amniotic ER004 as a prenatal treatment for male subjects with X-linked ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002532-23,0,0,0 2021-002532-23,4,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,2,Pierre Fabre Médicament,"A prospective, open-label, genotype-match controlled, multicenter clinical trial to investigate the efficacy and safety of intra-amniotic ER004 as a prenatal treatment for male subjects with X-linked ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002532-23,0,0,0 2021-002532-23,4,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,2,ESPERARE FOUNDATION,"A prospective, open-label, genotype-match controlled, multicenter clinical trial to investigate the efficacy and safety of intra-amniotic ER004 as a prenatal treatment for male subjects with X-linked ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002532-23,0,0,0 2021-002533-42,1,,,0,1,1,0,0,0,2,0,0,4,0,0,0,0,1,"Aimmune Therapeutics, Inc.",Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen (CPNA) Peanut Oral Immunotherapy (OIT) Safety Follow-On Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002533-42,0,1,1 2021-002534-16,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundació Sant Joan de Déu,"12-month randomized, double-blind, placebo-controlled, pharmacological clinical trial to evaluate the effectiveness, cost-utility and neurobiological effects of low-dose Naltrexone in patients with fi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002534-16,0,0,0 2021-002535-39,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Osivax,"Phase 2a, single center, randomized, double-blind, controlled study to evaluate the immunogenicity and the safety of one single administration of OVX836 influenza vaccine at two dose levels (300µg and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002535-39,0,0,0 2021-002537-41,12,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Amgen Inc.,"A Phase 2, Dose-Finding, Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002537-41,0,0,0 2021-002537-41,12,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AMGEN INC.,"A Phase 2, Dose-Finding, Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002537-41,0,0,0 2021-002539-51,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,"Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy and systemic Nabpaclitaxel-Gemcitabine chemotherapy for pancreatic cancer peritoneal metastases. A single-arm, open-label, phase...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002539-51,0,0,0 2021-002540-67,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,Centre Oscar Lambret,Phase 2 trial evaluating metronomic chemotherapy in patients with relapsed or refractory Wilms tumor Etude de phase II évaluant la chimiothérapie métronomique chez des patients avec une tumeur WILM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002540-67,0,0,0 2021-002542-33,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Zynerba Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome - RECONNECT",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002542-33,0,0,0 2021-002549-13,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,InDex Pharmaceuticals,A Randomised Double-Blind Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Cobitolimod as an Induction and Maintenance Therapy in Participants with Moderate to Sev...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002549-13,0,0,0 2021-002549-13,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,InDex Pharmaceuticals AB,A Randomised Double-Blind Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Cobitolimod as an Induction and Maintenance Therapy in Participants with Moderate to Sev...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002549-13,0,0,0 2021-002549-13,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,INDEX PHARMACEUTICALS AB,A Randomised Double-Blind Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Cobitolimod as an Induction and Maintenance Therapy in Participants with Moderate to Sev...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002549-13,0,0,0 2021-002551-11,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Aarhus University,Chronic kidney disease – imaging the metabolic derangements with ultra-sensitive MRI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002551-11,0,0,0 2021-002555-10,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Daiichi Sankyo, Inc.","A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002555-10,0,0,0 2021-002557-29,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Synektik Spółka Akcyjna,A Phase III Study of [11C]-DMDPA Tracer for Positron Emission Tomography PET-CT Myocardial Perfusion Imaging (MPI). Badanie III fazy dotyczące znacznika [11C]-DMDPA stosowanego do obrazowania perfu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002557-29,0,0,0 2021-002561-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama),Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2-positive non-resectable locally advanced or metastatic brea...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002561-18,0,0,0 2021-002565-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,"Multi-center study to evaluate virological efficacy, safety tolerability, drug exposure and patients’ reported outcomes over 48 weeks following randomization to 2-drug therapy with DTG/3TC FDC or cont...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002565-17,0,0,0 2021-002566-40,9,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AMGEN INC.,"A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 757 in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002566-40,0,0,0 2021-002566-40,9,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Amgen Inc.,"A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 757 in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002566-40,0,0,0 2021-002567-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IFCT,"A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002567-22,0,0,0 2021-002569-16,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Eli Lilly and Company,"A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared with Insulin Degludec in Participants with Type 2 Diabetes Currently Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002569-16,0,0,0 2021-002569-16,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Lilly S.A.,"A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared with Insulin Degludec in Participants with Type 2 Diabetes Currently Tre...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002569-16,0,0,0 2021-002570-54,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Modular Phase II, Open-label, Multicentre Study to Assess AZD4573 Efficacy and Safety as Monotherapy or in Combination with Anti-cancer Agents in Patients with Relapsed/Refractory Peripheral T-cell ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002570-54,0,0,0 2021-002571-19,9,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.","A Phase 3 Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ISIS 721744 in Patients with Hereditary Angioedema (HAE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002571-19,0,0,0 2021-002571-19,9,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"IONIS PHARMACEUTICALS, INC.","A Phase 3 Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ISIS 721744 in Patients with Hereditary Angioedema (HAE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002571-19,0,0,0 2021-002590-26,1,,,0,0,0,0,0,1,4,0,0,4,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,A French multicenter Phase 4 open label extension study of long term safety and efficacy in patients with Pompe disease who previously participated in avalglucosidase development studies in France,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002590-26,0,0,0 2021-002604-12,1,,,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,Medical University of Vienna,"Unraveling the aesthetic mind in anhedonia, insights from pharmacological imaging of the human brain: A single-blind, randomized, placebo-controlled cross-over study Einfluss von Ketamin auf ästhet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002604-12,0,0,0 2021-002605-10,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002605-10,0,0,0 2021-002605-10,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002605-10,0,0,0 2021-002609-93,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,Sanofi aventis recherche et developpement,"A randomized, double-blind, placebo-controlled, multicenter, dose-ranging Phase 2 study of rilzabrutinib followed by an open-label extension phase in patients with moderate-to-severe chronic spontaneo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002609-93,0,0,0 2021-002609-93,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A randomized, double-blind, placebo-controlled, multicenter, dose-ranging Phase 2 study of rilzabrutinib followed by an open-label extension phase in patients with moderate-to-severe chronic spontaneo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002609-93,0,0,0 2021-002609-93,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,,"A randomized, double-blind, placebo-controlled, multicenter, dose-ranging Phase 2 study of rilzabrutinib followed by an open-label extension phase in patients with moderate-to-severe chronic spontaneo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002609-93,0,0,0 2021-002610-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Aarhus University Hospital, Department of Neurology","Mestinon and Salbutamol Tolerability and Efficacy as therapy for Post-COVID-19 Myopathy - A randomized, placebo-controlled, rater and subject-blinded, 2x2 crossover study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002610-14,0,0,0 2021-002612-31,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA,"Adaptive, randomized, placebo-controlled trial to evaluate the efficacy of monoclonal antibodies in outpatients with mild or moderate COVID-19 (MANTICO) Studio clinico adattativo, randoMizzato, con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002612-31,0,0,0 2021-002613-34,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University Medical Center Utrecht,Prospective monitoring of antibody response following COVID-19 vaccination in patients with Down Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002613-34,0,0,0 2021-002614-13,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI,Electrochemotherapy with Carboplatinum plus Bleomycin versus Bleomycin alone in vulvar cancer: the ElechtraPlatinum Study. A Randomized Controlled Trial Elettrochemioterapia a base di carboplatino ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002614-13,0,0,0 2021-002617-33,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Versantis AG,"A Phase 2a, open-label, randomized, controlled, multi-center, proof of concept study, to assess the efficacy, safety and tolerability of VS-01 on top of standard of care, compared to standard of care ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002617-33,0,0,0 2021-002622-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma GmbH,"A randomized, parallel-group, double-blind, placebo-controlled, multicenter trial to investigate the efficacy and safety of subcutaneously administered secukinumab in patients with new-onset of giant ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002622-24,0,0,0 2021-002625-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Hospitals Leuven,"Intrathecal morphine administration for minimally invasive pancreatic surgery: A double blind, prospective randomized placebo-controlled trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002625-20,0,0,0 2021-002629-95,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Surgical department, Lillebaelt Hospital",Cefuroxime and Piperacillin Concentrations in the Biliary System,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002629-95,0,0,0 2021-002630-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical Unicersity of Gdansk,"Treatment of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and Dexamethasone (BGD) with autologous bone marrow transplantation in lymphoma patients Hodgkin resistant to treatment o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002630-17,0,0,0 2021-002632-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTI FISIOTERAPICI OSPITALIERI,"A proof-of-concept, biomarker-driven, phase-II clinical trial to explore the activity of decitabine repurposing against advanced, refractory, KRAS-dependent pancreatic ductal adenocarcinoma (PDAC): T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002632-23,0,0,0 2021-002634-16,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiation in sarcopenic patients with head and neck squamous cell carcinoma Wekelijks lage-dosis versus drie-w...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002634-16,0,0,0 2021-002635-35,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Inhibrx, Inc.","A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002635-35,0,0,0 2021-002635-35,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Inhibrx, INC","A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002635-35,0,0,0 2021-002637-42,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,UCB Biopharma SRL,"An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002637-42,0,0,0 2021-002638-18,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,AMGEN INC.,"A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002638-18,0,0,0 2021-002638-18,8,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Amgen Inc.,"A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC Whose Tumors Harbor a KRASG12C Mutation in Need of First-line Treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002638-18,0,0,0 2021-002639-48,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Janssen-Cilag International N.V.,"A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002639-48,0,0,0 2021-002639-48,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002639-48,0,0,0 2021-002640-70,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Hansa Biopharma AB,"A controlled, open-label post-authorisation efficacy and safety study in imlifidase desensitised kidney transplant patients with positive crossmatch against a deceased donor prior to imlifidase treatm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002640-70,0,0,0 2021-002641-15,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Point BioPharma Inc.,SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002641-15,0,0,0 2021-002669-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Genentech Inc.,"A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT AND DOSE-RANGING STUDY OF MTPS9579A IN PARTICIPANTS WITH REFRACTORY CHRONIC SPONTANEOUS URTICARIA ESTUDIO DE FASE II, MU...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002669-16,0,0,0 2021-002672-40,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Seagen Inc.,An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subje...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002672-40,0,0,0 2021-002686-18,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,UCB Biopharma SRL,"A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002686-18,0,0,0 2021-002687-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,NewAmsterdam Pharma BV,"A Phase 2a, Proof-of-Concept, Open-Label Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Obicetrapib in Patients with Early Alzheimer’s Disease (Hetero/Homozygote APOE4 Carrier...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002687-41,0,0,0 2021-002691-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Assistance Publique-Hôpitaux de Paris,"INTERVENTIONAL RESEARCH PROTOCOL INVOLVING HUMAN PARTICIPANTS CONCERNING A MEDICINAL PRODUCT FOR HUMAN USE Essai multicentrique, randomisé, ouvert, de phase III évaluant l'immunogénicité et la tolé...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002691-39,0,0,0 2021-002693-10,1,,,0,0,0,0,1,0,2,0,1,0,0,0,0,0,0,"Medical University of Vienna, Department for Internal Medicine III, Division of Rheumatology",A Phase II Study to Evaluate Safety and Efficacy to a Third Vaccination in Immunocompromised Patients with Inadequate Humoral Response after Primary mRNA SARS-CoV-2 (Covid-19) Vaccination Eine rand...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002693-10,0,0,0 2021-002695-40,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F. Hoffmann La-Roche Ltd,"A PHASE II, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER PLATINUM-BASED CONCURRENT CHEMORADIATION...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002695-40,0,0,0 2021-002695-40,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE II, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER PLATINUM-BASED CONCURRENT CHEMORADIATION...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002695-40,0,0,0 2021-002701-94,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Fundación para la Gestión de la Investigación Biomédica de Cádiz,Pirfenidone for the reduction of pulmonary inflammatory and fibrogenic activity in patients with silicosis due to artificial stone and progressive massive fibrosis. Pirfenidona para la reducción de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002701-94,0,0,0 2021-002712-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD,"PHASE III, RANDOMISED, DOUBLE-BLIND, CLINICAL TRIAL TO DETERMINE THE ROLE OF MAGNESIUM SULPHATE IN ADDUCTOR CANAL BLOCK IN ARTHROSCOPIC KNEE SURGERY ENSAYO CLÍNICO FASE III, ALEATORIZADO, DOBLE CIE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002712-30,0,0,0 2021-002713-34,11,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,2,Princess Maxima Center for Pediatric Oncology in The Netherlands,"A Phase I/II study of Brigatinib in pediatric and young adult patients with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or other solid tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002713-34,0,0,0 2021-002725-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Pública Andaluza Progreso y Salud,ULTRASOUND-GUIDED ERECTOR SPINAE BLOCKADE AS PART OF MULTIMODAL ANALGESIA IN LUMBOSACRAL SURGERY: A PROSPECTIVE RANDOMISED STUDY. BLOQUEO ECOGUIADO DEL ERECTOR ESPINAL COMO PARTE DE LA ANALGESIA MU...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002725-23,0,0,0 2021-002728-19,5,2022-08-02,2022-08-02,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,ProQR Therapeutics IV B.V.,"A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002728-19,1,0,0 2021-002729-74,5,2022-10-12,2022-10-12,2,0,0,0,0,1,2,0,0,2,1,0,0,0,1,ProQR Therapeutics IV B.V.,"A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002729-74,1,0,0 2021-002730-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,GeneOne Life Science Inc.,"Safety, Tolerability, Efficacy and Dose Response of GLS-1027 in the Prevention of Severe Pneumonitis caused by SARS-CoV-2 Infection",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002730-16,0,0,0 2021-002731-32,8,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Diamyd Medical AB,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults with Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002731-32,0,0,0 2021-002744-74,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Sociedad Española de Ozonoterapia - SEOT,"Effect of rectal ozone therapy on the clinical progress of hospitalized patients with mild-moderate covid19 infection: A triple- blind, randomized controlled trial. Evaluación del efecto del ozono ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002744-74,0,0,0 2021-002744-74,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Cátedra de Ozonoterapia y Dolor Crónico de la Universidad Católica San Antonio de Murcia - UCAM,"Effect of rectal ozone therapy on the clinical progress of hospitalized patients with mild-moderate covid19 infection: A triple- blind, randomized controlled trial. Evaluación del efecto del ozono ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002744-74,0,0,0 2021-002784-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Västra Götalandsregionen,"Botulinum toxin type A as treatment for chronic myogenous orofacial pain - a radomized controlled, double-blind clinical trial Botulinumtoxin A som behandling vid långvarig orofacial smärta – en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002784-21,0,0,0 2021-002789-42,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Medizinische Universität Innsbruck,"Analysis and characterization of the immune response after influenza, SARS-CoV-2 and pneumococcal vaccinations (IMMUNE Study) Analyse und Charakterisierung des Immunresponse nach Influenza-, SARS-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002789-42,0,0,0 2021-002795-39,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A randomized, two-arm, placebo-controlled, participant, investigator and sponsor-blinded, proof-of-concept study investigating the efficacy, safety and tolerability of QUC398 in patients with symptoma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002795-39,0,0,0 2021-002795-39,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Farmacéutica S.A.,"A randomized, two-arm, placebo-controlled, participant, investigator and sponsor-blinded, proof-of-concept study investigating the efficacy, safety and tolerability of QUC398 in patients with symptoma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002795-39,0,0,0 2021-002803-37,1,,,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,"XyloCor Therapeutics, Inc.","A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human Vascular Endothelial Growth Factor, to the Ischemic Myo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002803-37,0,0,0 2021-002805-88,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Eli Lilly and Company,A Phase 2 Study of Once-Daily LY3502970 Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002805-88,0,0,0 2021-002806-29,3,2022-09-29,2022-09-29,1,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Eli Lilly and Company,A Phase 2 Study of Once-Daily LY3502970 Compared with Placebo and Once-Weekly Dulaglutide in Participants with Type 2 Diabetes Mellitus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002806-29,1,0,0 2021-002819-60,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitario de Burgos,Treatment of chronic anal fissure with ultrasound-guided intersphincteric infiltration of botulinum toxin A. Tratamiento de la fisura anal crónica con infiltraciones interesfinterianas ecoguiadas d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002819-60,0,0,0 2021-002821-32,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"Neurologia Aplicada, SLP",The FENDEEP Study: Fenfluramine for the treatment of different types of developmental and epileptic encephalopathies: a pilot trial exploring epileptic and non-epileptic outcomes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002821-32,0,0,0 2021-002823-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Nouscom S.r.l.,"A Phase I/IIa, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors Estudio abierto, multicéntrico de fase I/IIa de la vacuna genética...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002823-40,0,0,0 2021-002824-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Liège,Study of the hypnotic and anti-nociceptive components of Magnesium using Electroencephalogram Spectral Entropy and pupillometry during total intravenous general anesthesia : a randomized double-blind ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002824-19,0,0,0 2021-002844-66,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Incyte Corporation,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic Anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002844-66,0,0,0 2021-002844-66,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,INCYTE CORPORATION,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic Anemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002844-66,0,0,0 2021-002846-33,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Abliva AB,"An interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose, adaptive study of the efficacy of KL1333 in adult patients with primary mitochondrial disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002846-33,0,0,0 2021-002855-12,5,,,0,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Rhythm Pharmaceuticals Inc.,"A 2-Stage (Open-Label Run-in followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled, Phase 2 study of Setmelanotide in Patients with Specific Gene Defects in the Melanocortin-4 Receptor ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002855-12,0,0,0 2021-002857-28,5,2022-07-25,2022-07-25,4,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Pfizer Inc.,"AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002857-28,1,0,0 2021-002860-31,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Aclaris Therapeutics, Inc.","A Phase 2b, Randomized, Multicenter, Double-blind, Parallel Group, Placebo Controlled, Dose Ranging Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002860-31,0,0,0 2021-002862-42,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca,A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002862-42,0,0,0 2021-002862-42,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,AstraZeneca AB,A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002862-42,0,0,0 2021-002864-36,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Priothera S.A.S.,"A prospective randomized, double-blind, placebo-controlled, multi-center phase IIb study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult in acute ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002864-36,0,0,0 2021-002869-18,9,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD): AIM-CD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002869-18,0,0,0 2021-002869-18,9,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD): AIM-CD",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002869-18,0,0,0 2021-002871-20,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"LIB Therapeutics, LLC","Randomized, Open Label, Phase 3 Study to Evaluate the Efficacy and Safety of Lerodalcibep (LIB003) compared to Inclisiran in Patients With Cardiovascular Disease, or at High Risk for Cardiovascular D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002871-20,0,0,0 2021-002873-24,5,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,Rhythm Pharmaceuticals Inc.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melanocor...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002873-24,0,0,0 2021-002894-24,3,2022-04-12,2022-04-12,3,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Pfizer Inc.,"A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF-07321332/RITONAVIR IN PREVENTING SYMPTOMATIC S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002894-24,0,0,0 2021-002895-38,4,2022-04-22,2022-04-22,3,0,0,0,0,0,2,0,0,2,0,0,0,0,1,Pfizer Inc.,"AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIP...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002895-38,1,0,0 2021-002897-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Pfizer Inc.,"AN INTERVENTIONAL PHASE 2, OPEN-LABEL, ONE-ARM, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA BEAVA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002897-19,0,0,0 2021-002905-89,6,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Bayer AG,"An 18-month, open-label, single-arm safety extension study of an age-and bodyweight-adjusted oral finerenone regimen, in addition to an ACEI or ARB, for the treatment of children and young adults from...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002905-89,0,0,0 2021-002909-10,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Maastricht University,THE IMPACT OF PSILOCYBIN ON PAIN IN FIBROMYALGIA PATIENTS AND HEALTHY VOLUNTEERS: A MULTICENTER TRIAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002909-10,0,0,0 2021-002911-72,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Laboratorios ERN, S.A.","A randomized, double blind, double dummy, parallel group, multicenter clinical trial to evaluate the safety and clinical and microbiologic efficacy of oral fosfomycin calcium in adult women with uUTI....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002911-72,0,0,0 2021-002924-18,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Cyclacel Pharmaceuticals,"A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002924-18,0,0,0 2021-002926-26,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Desitin Arzneimittel GmbH,"Efficacy, Safety and Tolerability of 3 doses of Sulthiame in Patients with Obstructive Sleep Apnea. A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002926-26,0,0,0 2021-002927-39,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Medical University of Vienna,Preventive strategies against SARS-CoV-2 in kidney transplant recipients: Intervention A – vaccination: Single blinded randomized controlled trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or ChAd...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002927-39,0,0,0 2021-002947-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Celon Pharma SA,"A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety and Pharmacokinetics after 2-weeks Administration of CPL207280 (GPR40 agonist) in Subjects Wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002947-32,0,0,0 2021-002966-41,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Assistance Publique – Hôpitaux de Paris / DRCI,Anti-Covid-19 vaccine protection in immunocompromised children (1-15 years) with acute leukemia and their siblings (≥ 12 years). Phase I-II trial evaluating safety and post-vaccination humoral and cel...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002966-41,0,0,0 2021-002967-23,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Almirall SA,"A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients Wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002967-23,0,0,0 2021-002967-23,8,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Almirall, S.A.","A Randomised, Double-Blind, Placebo-Controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adult and Adolescent Patients Wit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002967-23,0,0,0 2021-002968-49,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PATIENTS WITH GUILLAIN-BARRÉ SYND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002968-49,0,0,0 2021-002984-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Graz,Retrospective quantification of anti-SARS-CoV-2 antibody response after mRNA COVID-19 vaccine in patients treated with peritoneal dialysis Retrospektive Quantifizierung anti-SARS-CoV2 Antikörper A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-002984-23,0,0,0 2021-003005-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Region Örebro län,Klonidin as pain relief in eye examination of premature infants - cloROP Klonidin som smärtlindring vid ögonundersökning av prematurfödda barn - cloROP,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003005-21,0,0,0 2021-003008-42,2,,,0,0,0,1,0,2,1,0,0,0,0,0,0,0,1,Zentalis Pharmaceuticals,"A Single Arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis Studio di fase 1/2, a braccio singolo, in aperto, su ZN-d5 per il trattam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003008-42,0,0,0 2021-003008-42,2,,,0,0,0,1,0,2,1,0,0,0,0,0,0,0,1,"K-Group Alpha, Inc","A Single Arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis Studio di fase 1/2, a braccio singolo, in aperto, su ZN-d5 per il trattam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003008-42,0,0,0 2021-003011-26,3,2022-04-21,2022-04-21,2,0,0,0,0,0,3,0,0,2,0,0,0,0,1,FAES FARMA S.A.,"A multicentre, open-label clinical trial to assess plasma levels and safety of bilastine in children from 2 to 5 years of age with seasonal and/or perennial allergic rhinoconjunctivitis or urticaria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003011-26,1,0,0 2021-003014-39,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Inmunotek, S.L.","Prospective, randomised, double-blind, double-dummy, placebo-controlled multicenter clinical trial of efficacy and safety with immunotherapy in patients with controlled mild to moderate allergic asthm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003014-39,0,0,0 2021-003015-26,3,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Amzell B.V.,"A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of AMZ002, Compared to Vigabatrin, in the Treatment of Infantile Spasms",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003015-26,0,0,0 2021-003019-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Effectiveness of analgesic ear drops as add-on treatment to oral analgesics in children with acute otitis media: a pragmatic randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003019-24,0,0,0 2021-003020-32,4,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,Acceleron Pharma Inc.,"Phase 2, Double-blind, Randomized, Placebo controlled Study to Evaluate the Effects of Sotatercept versus Placebo-Controlled for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hype...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003020-32,0,0,0 2021-003020-32,4,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,ACCELERON PHARMA INC.,"Phase 2, Double-blind, Randomized, Placebo controlled Study to Evaluate the Effects of Sotatercept versus Placebo-Controlled for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hype...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003020-32,0,0,0 2021-003023-14,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,InDex Pharmaceuticals AB,Pharmacokinetics of Cobitolimod Enemas in Participants with active Ulcerative Colitis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003023-14,0,0,0 2021-003026-69,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,IO Biotech ApS,"A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Can...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003026-69,0,0,0 2021-003028-34,3,,,0,0,0,1,0,0,1,0,0,2,1,0,0,0,1,"Jacobio Pharmaceuticals Co., Ltd.","A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-21822 Monotherapy and Combination Therapy in A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003028-34,0,0,0 2021-003029-31,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Aristea Therapeutics Inc.,"A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003029-31,0,0,0 2021-003031-29,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003031-29,0,0,0 2021-003031-29,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003031-29,0,0,0 2021-003035-28,1,,,0,0,0,1,0,1,1,0,0,4,0,0,0,0,0,Assistance Publique - Hôpitaux de Paris,""" Combination of an Anti-PD1 antibody with Tisagenlecleucel Reinfusion in children, adolescents and young adults with Acute Lymphoblastic Leukemia after loss of persistence "" CAPTiRALL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003035-28,0,0,0 2021-003037-11,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bayer AG,"A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003037-11,0,0,0 2021-003037-11,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BAYER AG,"A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003037-11,0,0,0 2021-003049-40,5,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,H. Lundbeck A/S,"Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief educational intervention for the preventive treatment of migraine in patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003049-40,0,0,0 2021-003050-23,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Oppilan Pharma limited,"A Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcerati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003050-23,0,0,0 2021-003050-23,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Oppilan Pharma Ltd.,"A Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcerati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003050-23,0,0,0 2021-003050-23,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Oppilan Pharma Ltd., wholy owned subsidiary of Ventyx Biosciences Inc.","A Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcerati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003050-23,0,0,0 2021-003052-16,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Brainvectis,"An Open-Label Phase I/II Dose Finding Study to evaluate the Safety, Tolerability, and Preliminary Efficacy of Striatal Administration of BV-101 in Adult Subjects with Early Manifest Huntington's Disea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003052-16,0,0,0 2021-003053-37,2,2021-12-31,2021-12-31,2,0,0,0,0,0,2,0,0,1,0,0,0,0,1,Bayer AG,A non-blinded retrospective biomarker add-on study to FIGARO-DKD for Bioprofiling the pharMacodynamic response to finerenone in FIGARO-DKD subjects (FIGARO-BM) Estudio de biomarcadores complementar...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003053-37,0,0,0 2021-003059-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo-controlled, multicenter trial assessing the reduction of the rate of lipoprotein apheresis after treatment with pelacarsen (TQJ230) compared to placebo in patients ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003059-41,0,0,0 2021-003062-12,6,2022-06-02,2022-06-22,4,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Palladio Biosciences Inc.,","A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003062-12,1,0,0 2021-003062-12,6,2022-06-02,2022-06-22,4,0,0,0,0,1,3,0,0,2,1,0,0,0,1,"Palladio Biosciences, Inc.","A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003062-12,1,0,0 2021-003064-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Philogen S.p.A.,"An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003064-27,0,0,0 2021-003068-28,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Sentinel lymph node detection of cervical occult lymph node metastases in patients with parotid gland carcinoma by means of sentinel node biopsy using 68-galium-tilmanocept PET-CT. Detectie van occ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003068-28,0,0,0 2021-003070-31,1,,,0,0,1,0,0,0,1,0,1,4,0,0,0,0,1,Sanofi Pasteur Inc.,"Safety and Immunogenicity of an Investigational Multicomponent Meningococcal Group B Vaccine in Adults, Adolescents, Toddlers, and Infants",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003070-31,0,1,1 2021-003076-14,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Anthos Therapeutics,"A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003076-14,0,0,0 2021-003076-14,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Anthos Therapeutics Inc,"A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003076-14,0,0,0 2021-003076-14,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Anthos Therapeutics, Inc","A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003076-14,0,0,0 2021-003085-12,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Anthos Therapeutics, Inc","A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003085-12,0,0,0 2021-003085-12,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Anthos Therapeutics,"A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003085-12,0,0,0 2021-003087-27,7,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,argenx BV,"A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003087-27,0,0,0 2021-003088-87,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Westfälische Wilhelms-Universität Münster,Biomarker-guided implementation of angiotensin-II (AT-II) to reduce the occurrence of kidney damage after cardiac surgery Biomarker-gesteuerter Einsatz von Angiotensin II zur Verringerung des Auft...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003088-87,0,0,0 2021-003089-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC),"Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients: a Spanish Multicenter, Randomized, Controlled Parallel-group Trial: The TRAINING Study Tratamiento de las...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003089-11,0,0,0 2021-003091-14,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AnHeart Therapeutics Inc,"A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003091-14,0,0,0 2021-003149-39,5,,,0,0,0,0,0,2,2,0,0,3,0,0,0,0,1,Pfizer Inc.,"A PHASE 2 OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003149-39,0,0,0 2021-003149-39,5,,,0,0,0,0,0,2,2,0,0,3,0,0,0,0,1,PFIZER INC,"A PHASE 2 OPEN LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF RECIFERCEPT IN CHILDREN WITH ACHONDROPLASIA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003149-39,0,0,0 2021-003151-41,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Institut de Recherches Internationales Servier,"A randomised, open-label, multi-centre, two-arm Phase 3 study comparing futuximab/modotuximab in combination with trifluridine/tipiracil to trifluridine/tipiracil single agent with a Safety Lead-In pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003151-41,0,0,0 2021-003154-23,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim AB,"A Phase II, 8-week-treatment, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, tolerability and safety of orally administered BI 1358894 in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003154-23,0,0,0 2021-003154-23,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim RCV GmBH & Co KG,"A Phase II, 8-week-treatment, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, tolerability and safety of orally administered BI 1358894 in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003154-23,0,0,0 2021-003154-23,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim,"A Phase II, 8-week-treatment, multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, tolerability and safety of orally administered BI 1358894 in pat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003154-23,0,0,0 2021-003157-27,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Swedish Orphan Biovitrum AB,"An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (TA-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003157-27,0,0,0 2021-003157-27,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,SWEDISH ORPHAN BIOVITRUM AB (PUBL),"An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (TA-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003157-27,0,0,0 2021-003160-27,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Swedish Orphan Biovitrum AB,"A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CAD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003160-27,0,0,0 2021-003162-12,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,CSL Behring LLC,"A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects with Idiopathic Pulmonary Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003162-12,0,0,0 2021-003164-27,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Treeway TW001AD B.V.,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003164-27,0,0,0 2021-003166-12,1,,,0,0,0,0,0,0,2,0,0,1,1,1,0,1,1,Frame Pharmaceuticals B.V.,A Phase II Trial of Personalized Tumor Neoantigen Based Vaccine FRAME-001 for Advanced Non-Small Cell Lung Cancer Een Fase II studie naar gepersonaliseerd tumor neoantigeen gebaseerd vaccin FRAME-0...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003166-12,0,0,0 2021-003168-28,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Academic Medical Center (AMC), department of Internal Medicine",Impact of Triglyceride-Lowering on Inflammatory Activity in Patients with Hypertriglyceridemia Effect van triglyceride verlaging op inflammatoire activiteit in patienten met hypertriglyceridemie.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003168-28,0,0,0 2021-003170-31,1,2021-11-25,2021-11-25,1,0,0,0,0,0,2,0,1,1,0,0,0,0,0,"Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Herlev and Gentofte Hospital",Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003170-31,0,0,0 2021-003172-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amsterdam UMC,The renal and metabolic outcomes after sodium-glucose cotransporter 2 inhibitor in cardiac surgery – an open-label phase IV randomized controlled trial De perioperatieve renale en metabole uitkomst...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003172-13,0,0,0 2021-003175-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Oslo University Hospital,DAPARHT: DAPAgliflozin for Renal protection in Heart Transplant recipients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003175-34,0,0,0 2021-003176-14,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Sanofi-Aventis Groupe,"An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients with Non-Hodgkin’s ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003176-14,0,1,1 2021-003177-58,5,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Sant Joan de Déu (FSJD),"A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIOMET...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003177-58,0,0,0 2021-003177-58,5,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,Fundació Privada per a la Recerca y la Docencia Sant Joan de Déu,"A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIOMET...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003177-58,0,0,0 2021-003179-33,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,OM Pharma SA,"A Randomised, Double-Blind, Placebo-controlled, 32-week, Phase IIa trial to investigate the efficacy of OM-85 versus matched placebo in reducing disease severity in children aged 3 to 24 months with e...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003179-33,0,0,0 2021-003185-12,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003185-12,0,0,0 2021-003185-12,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LCC,"A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003185-12,0,0,0 2021-003185-12,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003185-12,0,0,0 2021-003185-12,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003185-12,0,0,0 2021-003185-12,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.","A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003185-12,0,0,0 2021-003188-90,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,CHIP - Rigshospitalet - University of Copenhagen,A Phase IV Vaccine Study under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE PLUS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003188-90,0,0,0 2021-003191-14,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,CHU SAINT-ETIENNE,Cohort assessing the immunogenicity and the safety of the COVID-19 Vaccine Janssen in healthy volunteers based on 3 age groups: 65 years or older - 55 to 65 years - 18 to 45 years - Covicompare-Jansse...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003191-14,0,0,0 2021-003192-34,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003192-34,0,0,0 2021-003192-34,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003192-34,0,0,0 2021-003200-40,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,Octapharma,"Multicenter, Prospective, Parallel Group, Open-label, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Poly...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003200-40,0,1,1 2021-003206-41,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Loxo Oncology, Inc.","A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314) Estudio de fase III, abi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003206-41,0,0,0 2021-003208-42,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Open Label, Randomized, Non-Inferiority Pharmacokinetic Study of Nivolumab Administered Subcutaneously (Nivo SC) Versus Intravenous Administration of Nivolumab in Participants with Stage II...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003208-42,0,0,0 2021-003209-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,UNION therapeutics A/S,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults with Moderate-to-Severe Plaque-Type Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003209-22,0,0,0 2021-003210-39,4,,,0,0,0,1,0,1,1,0,0,3,0,0,0,0,2,Sixera Pharma,"A phase I/II, multicenter, randomized, double-blind, placebo within-patient controlled, first-in-human (FIH) Proof of Concept (PoC) study to evaluate the safety and efficacy of topically applied SXR10...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003210-39,0,0,0 2021-003212-11,9,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,0,Princess Máxima Center,A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003212-11,0,0,0 2021-003212-11,9,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,0,Princess Maxima Center,A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003212-11,0,0,0 2021-003212-11,9,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,0,Princess Máxima Center for Paediatric Oncology,A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003212-11,0,0,0 2021-003214-40,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,1,MinervaX Aps,"A multicentre, multinational, parallel group, observer-blind, randomised, placebo-controlled study on the Group B Streptococcus vaccine (GBS-NN/NN2), investigating the immunogenicity and safety of fou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003214-40,0,0,0 2021-003218-38,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,Aalborg University Hospital,Pain after thoracoscopic lung surgery – the effect of intercostal nerve blockades with standard bupivacaine and liposomal bupivacaine – a randomised controlled feasibility trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003218-38,0,0,0 2021-003220-32,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,IRCCS MATERNO INFANTILE BURLO GAROFOLO,Impact of early proactive therapeutic drug monitoring on the durability and efficacy of infliximab therapy in pediatric inflammatory bowel disease: a multicenter open-label randomized-control trial. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003220-32,0,0,0 2021-003221-30,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,AstraZeneca AB,"A Phase 2, Open-label, Uncontrolled, Single-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Occurrence of Antidrug Antibody for Nirsevimab in Immunocompromised Children ≤ 24 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003221-30,0,0,0 2021-003222-76,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Zogenix International Limited,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EXAMINE THE EFFICACY AND SAFETY OF ZX008 IN SUBJECTS WITH CDKL5 DEFICIENCY DISORDER FOLLOWED BY AN OPEN-LABEL E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003222-76,0,0,0 2021-003226-71,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffman-La Roche Ltd,"A PHASE IIIB, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFECTIVENESS AND SAFETY OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB VS AFLIBERCEPT TREAT & EXT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003226-71,0,0,0 2021-003226-71,10,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE IIIB, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED STUDY OF THE EFFECTIVENESS AND SAFETY OF A 36-WEEK REFILL REGIMEN FOR THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB VS AFLIBERCEPT TREAT & EXT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003226-71,0,0,0 2021-003227-15,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Keros Therapeutics, Inc.","A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination with Ruxolitinib in Participants with Myelofibrosis Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003227-15,0,0,0 2021-003234-37,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003234-37,0,0,0 2021-003237-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fraunhofer Gesellschaft for its Institute for translationale Medicine and Pharmacology ITMP,Effect of Bronchipret on antiviral immune response in patients with mild COVID-19 (BroVID),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003237-11,0,0,0 2021-003238-35,1,2022-06-14,2022-06-14,1,0,0,0,0,0,4,0,1,1,0,0,0,0,0,Oslo University Hospital,"Effects of supplemental oxygen on systemic and cerebral hemodynamics in experimental hypovolemia: A randomized, phase IV, crossover study to study the effect of supplemental oxygen vs. room air on cer...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003238-35,0,0,0 2021-003243-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Exelixis, Inc.",A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer Estudio en fase III aleatorizado y sin enmascaramiento de XL092 + Atezoliz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003243-21,0,0,0 2021-003245-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Unai Ortega Mera,Randomized clinical trial to compare the efficacy of opioid-free versus traditional balanced anesthesia in laparoscopic colorectal surgery Ensayo clínico aleatorizado para comparar la eficacia de l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003245-38,0,0,0 2021-003246-20,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Enlivex Therapeutics R&D, Ltd.","A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients with Severe or Critical COVID-19 with Associated Acute Respirat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003246-20,0,0,0 2021-003250-23,1,,,0,0,1,0,0,1,3,0,0,4,0,0,0,0,0,Amsterdam UMC,"Cannabidiol (Epidyolex) for behavioural problems in patients with Tuberous Sclerosis Complex, Sanfilippo and Fragile X Syndrome: an N-of-1 series Cannabidiol (Epidyolex) voor gedragsproblemen bij p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003250-23,0,0,0 2021-003253-36,1,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,1,"Belite Bio, Inc","Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003253-36,0,0,0 2021-003254-23,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Revolution Medicines, Inc.","A Phase 2, Open-Label, Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRASG12CMutation After Failure of Prior Standard Therapies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003254-23,0,0,0 2021-003258-21,1,,,0,0,1,0,0,0,2,0,1,0,0,0,0,0,1,Cessatech A/S,"Analgesic Efficacy and Pharmacokinetic-pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001 after Impacted Mandibular Third Molar Extraction",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003258-21,0,0,0 2021-003265-36,5,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"Agios Pharmaceuticals, Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Regularly Tran...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003265-36,0,0,0 2021-003266-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital,A PHASE 2 RANDOMISED OPEN TWO-ARM STUDY TO ASSESS THE TOLERABILITY AND EFFICACY OF IMMUNOTHERAPY COMBINED WITH EXTENSIVE RADIATIOTHERAPY FOR THE TREATMENT OF STAGE IV NON-SMALL CELL LUNG CANCER,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003266-13,0,0,0 2021-003272-13,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,CellPoint B.V.,"A phase I/II, multicenter study evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003272-13,0,0,0 2021-003273-66,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Enlivex Therapeutics R&D Ltd.,"A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Fai...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003273-66,0,0,0 2021-003275-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,IRCCS-A.O.U. SAN MARTINO-IST,TEMOZOLOMIDE + ULTRA-HYPER-FRACTIONATED RADIOTHERAPY VS TEMOZOLOMIDE ALONE FOR THE MAINTENANCE TREATMENT OF GLIOBLASTOMA PATIENTS - PILOT STUDY Temozolomide + radioterapia ultra-iper-frazionata ris...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003275-34,0,0,0 2021-003277-55,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medical University of Innsbruck, University Clinic for Pediatrics III",COVID-19 Antibody Responses in Cystic Fibrosis: CAR-CF,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003277-55,0,0,0 2021-003280-95,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.",An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003280-95,0,0,0 2021-003282-36,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,Västra Götalands Regionen,"A Randomized, Multi-Center Phase III Trial comparing two conditioning regimens (CloFluBu and BuCyMel) in children with Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003282-36,0,0,0 2021-003284-10,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,European Myeloma Network (EMN),"A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003284-10,0,0,0 2021-003285-12,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"BeiGene, Ltd.","A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003285-12,0,0,0 2021-003294-66,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Insmed Incorporated,"A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertensio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003294-66,0,0,0 2021-003296-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd.,OPEN-LABEL MULTICENTER STUDY TO DETERMINE THE EFFECT OF OCRELIZUMAB ON LEPTOMENINGEAL INFLAMMATION IN MULTIPLE SCLEROSIS (LEGATO),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003296-33,0,0,0 2021-003299-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica del Hospital La Paz,"A double blinded, phase II, placebo controlled, single center randomized clinical trial to evaluate metformin compared with placebo for reversal of accelerated biological aging in persons living with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003299-15,0,0,0 2021-003301-22,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Archivel Farma S.L.,A phase IIB study to explore the efficacy and safety of the concomitant administration of RUTI® immunotherapy with the standard treatment in patients with TB (CONSTAN) Ensayo clínico Fase IIb para...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003301-22,0,0,0 2021-003302-50,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,argenx BV,"A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel- Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy,Pharmacokinetics, Pharmacodynamics, and Immunogenicity o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003302-50,0,0,0 2021-003302-50,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,ARGENX BV,"A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel- Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy,Pharmacokinetics, Pharmacodynamics, and Immunogenicity o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003302-50,0,0,0 2021-003304-41,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,Boehringer Ingelheim RCV GmbH & Co KG,"A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003304-41,0,0,0 2021-003304-41,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,"Boehringer Ingelheim Portugal, Lda","A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003304-41,0,0,0 2021-003304-41,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,Boehringer Ingelheim BV,"A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003304-41,0,0,0 2021-003304-41,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003304-41,0,0,0 2021-003304-41,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,Boehringer Ingelheim España S.A.,"A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003304-41,0,0,0 2021-003304-41,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,Boehringer Ingelheim bv Netherlands,"A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003304-41,0,0,0 2021-003304-41,11,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,2,Boehringer Ingelheim B.V.,"A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003304-41,0,0,0 2021-003305-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC),First-line Osimertinib plus Consolidation Radiotherapy compared with Osimertinib alone in oligometastatic NSCLC EGFR mutated patients: the randomized phase II OCRa trial GOIRC-06-2019 Studio random...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003305-21,0,0,0 2021-003306-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Novo Nordisk A/S,SELECT-LIFE (SELECT follow-up study to evaluate Longterm Impact oF anti-obEsity medication),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003306-42,0,0,0 2021-003307-18,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University of Antwerp,"Immunogenicity, molecular profiling and safety of a marketed quadrivalent influenza vaccine (Vaxigrip Tetra®) administered by the intramuscular route in participants 60 years of age and older",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003307-18,0,0,0 2021-003311-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Prinses Máxima Centrum,DAVINCY trial: optimal Duration of (fos)aprepitant prophylaxis for nausea and Vomiting INduced by ChemotherapY in children: a double-blind placebo-controlled crossover randomized phase III trial’ D...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003311-26,0,0,0 2021-003313-18,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003313-18,0,0,0 2021-003313-18,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003313-18,0,0,0 2021-003314-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003314-39,0,0,0 2021-003315-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,3,ASSISTANCE PUBLIQUE – HÔPITAUX DE PARIS - Direction de la Recherche Clinique et de l’Innovation,Botulinum toxin and degenerative rotator cuff tendinopathies: a randomized trial »DEROTOX (DEgenerative ROtator cuff disease and botulinum TOXin) Toxine botulique et tendinopathies dégénératives d...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003315-25,0,0,0 2021-003327-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC,"An open-label, 8-week, proof of concept trial on thymosin-α1 (thymalfasin) in the treatment of primary antibody deficiency (PAD) associated mood disorders (TIDAM18). Een open-label 8-weken proof-of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003327-15,0,0,0 2021-003331-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Felix Gutierrez Rodero,"Randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of the COMIRNATY vaccine (COVID-19 mRNA vaccine, Pfizer-BioNTech) in people with long COVID Ensayo cl...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003331-28,0,0,0 2021-003333-11,3,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"Agios Pharmaceuticals, Inc.","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Not Regularly ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003333-11,0,0,0 2021-003338-35,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase 2, Randomised, Double-Blind, Placebo and Active Comparator-Controlled Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD5718 Given Orally Once Daily for Twelve Weeks in Adults ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003338-35,0,0,0 2021-003346-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,DOMPé FARMACEUTICI S.P.A.,"A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution versus vehicle, in patients with sever...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003346-21,0,0,0 2021-003369-37,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase II Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIA) Non-small Cell Lung Cancer (NeoCOAST-2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003369-37,0,0,0 2021-003373-64,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,NOEMI GUEMES VILLAHOZ,"POST-MARKETING PARALLEL CLINICAL TRIAL TO DETERMINE THE EFFECTIVENESS AND TOLERABILITY OF DIMS LENSES IN THE CONTROL OF MYOPIA IN PEDIATRIC POPULATION ENSAYO CLÍNICO PARALELO POSTCOMERCIALIZACIÓN, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003373-64,0,0,0 2021-003374-30,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA,A pilot study to Evaluate the Safety and Feasibility of Sonodynamic Therapy Using the ExAblate MRI-Guided Focused Ultrasound in the Treatment of Cerebral Glioblastomas. Studio Pilota per valutare l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003374-30,0,0,0 2021-003376-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Mariano Artes Caselles,"Efficacy of amoxicillin/clavulanic acid after surgical drainage of perianal abscess in the prevention of the development of anal fistula. A randomized, double-blind clinical trial. Ensayo clínico r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003376-14,0,0,0 2021-003380-95,2,,,0,0,0,1,0,0,1,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003380-95,0,0,0 2021-003386-35,2,,,0,0,0,0,0,0,4,0,0,2,1,0,0,0,0,Regents of the University of Minesota,SARS-CoV-2 vaccination strategies in previous hospitalised and recovered COVID-19 patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003386-35,0,0,0 2021-003387-27,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,1,Pharmaceutical Works Polpharma S.A. (Polpharma S. A.),"A PHASE III, MULTICENTRE, RANDOMISED, INVESTIGATOR-MASKED, CROSS-OVER, COMPARATIVE, NON-INFERIORITY TRIAL OF GENERIC LATANOPROST + TIMOLOL (50μG + 5MG)/ML EYE DROPS, SOLUTION (POLPHARMA S.A.) COMPARED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003387-27,0,0,0 2021-003388-90,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Princess Máxima Center for Pediatric Oncology,Prospective monitoring of immune response following COVID-19 vaccination in children with cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003388-90,0,0,0 2021-003392-34,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Odense Universitetshospital,"“FAST ACUTE SEDATION AT INTENSIVE CARE VS. HIGH-DOSE I.V. ANTI-SEIZURE MEDICATION FOR TREATMENT OF NON-CONVULSIVE STATUS EPILEPTICUS - A RANDOMIZED, MULTICENTER TRIAL (FAST TRIAL)” ”HURTIG SEDATION...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003392-34,0,0,0 2021-003395-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bioventus LLC,"A Multiple Arm, Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 2 Study of Intra-Articular Administration of an Allogeneic Human Placental Tissue Particulat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003395-13,0,0,0 2021-003397-32,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Merck Sharp & Dohme Corp.,A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003397-32,0,0,0 2021-003397-32,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003397-32,0,0,0 2021-003397-32,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003397-32,0,0,0 2021-003397-32,7,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme LLC., a subsidiary of Merck & Co.,Inc.",A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003397-32,0,0,0 2021-003402-46,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Cantargia AB,A randomized non-comparative open-label phase 1b/2 study of nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. “TRIFOUR study”. Es...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003402-46,0,0,0 2021-003407-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Clinic of Nephrology and Hypertension,"Combined effects of potassium, nitrate and sodium on blood pressure in patients with hypertension Kombinerede effekter af kalium, nitrat og salt på blodtrykket hos patienter med hypertension",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003407-17,0,0,0 2021-003410-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Modular Phase I/II, Open-label, Dose Escalation and Expansion, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0466 as Monotherapy or in Combin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003410-39,0,0,0 2021-003415-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Oncology, Rigshospitalet",HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first line treatment for HER2 positive esophageal squamous cell carcinoma patients HERES: Trastuzumab og standardbeh...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003415-26,0,0,0 2021-003417-19,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,F.Hoffmann-La Roche Ltd,"A TWO-PART, SEAMLESS, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7204239 IN COMBINAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003417-19,0,0,0 2021-003417-19,5,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A TWO-PART, SEAMLESS, MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7204239 IN COMBINAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003417-19,0,0,0 2021-003420-33,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first line therapy: a Randomized trial (TAILOR study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003420-33,0,0,0 2021-003425-30,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Epygenix Therapeutics, Inc.","A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole HCl) as Adjunctive Therapy in Patients with Dravet Syndrome (ARGUS trial) Ensayo multicéntrico, aleat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003425-30,0,0,0 2021-003427-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Akershus University Hospital,A randomized controlled trial of subcutaneous versus intravenous morphine when switching from oral to parenteral route in palliative cancer patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003427-14,0,0,0 2021-003434-36,7,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Gilead Sciences Inc,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previou...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003434-36,0,0,0 2021-003436-92,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003436-92,0,0,0 2021-003436-92,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc","A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003436-92,0,0,0 2021-003436-92,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Merck Sharp & Dohme Corp.,"A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003436-92,0,0,0 2021-003436-92,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003436-92,0,0,0 2021-003436-92,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatme...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003436-92,0,0,0 2021-003441-38,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Marinus Pharmaceuticals Inc.,"A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003441-38,0,0,0 2021-003444-25,11,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,Pfizer Inc.,PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE® ) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE AND/OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR RE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003444-25,0,0,0 2021-003445-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Aghia Sophia Children’s Hospital,A Phase 2 Study of the Efficacy and Safety of a Dose of Donor-Derived CD19-targeted CAR T cells for children and young adults (up to 39 years old) with recurrent or persistent CD19 (+) Acute Leukemia ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003445-37,0,0,0 2021-003450-22,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"AlloVir, Inc.","Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, with Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003450-22,0,0,0 2021-003451-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Dept. of Growth and Reproduction,"FITMI - First In Treating Male Infertility FITMI - First In Treating Male Infertility, Et randomiseret dobbelt-blindet interventionsforsøg",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003451-42,0,0,0 2021-003453-28,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,SOM Innovation Biotech S.A.,"Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington's Disease with choreic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003453-28,0,0,0 2021-003453-28,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,SOM Innovation Biotech SA (SOM Biotech),"Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington's Disease with choreic ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003453-28,0,0,0 2021-003460-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboudumc,CXCR4-directed [68Ga]Ga-PentixaFor PET vs AVS performance in a diagnoStic randomized Trial Ultimately comparing hypertenSion outcome in primary aldosteronism CXCR4-gerichte [68Ga]Ga-PentixaFor PET...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003460-27,0,0,0 2021-003461-35,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AMGEN INC.,"A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003461-35,0,0,0 2021-003461-35,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Amgen Inc.,"A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003461-35,0,0,0 2021-003463-97,1,2022-04-06,2022-04-06,1,0,0,0,0,0,2,0,1,1,0,0,0,0,1,"Revelation Biosciences, Inc.",A Phase IIb Study Assessing Prophylactic Efficacy of Intranasal REVTx-99 in an H3N2 Influenza Challenge Model in Healthy Subjects.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003463-97,0,0,0 2021-003466-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,MCM Klosterfrau Vertriebsgesellschaft mbH,"A double-blind, randomised, multi-centre, controlled clinical trial to compare D-mannose versus antibiotic in the treatment of acute uncomplicated lower urinary tract infections in female patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003466-12,0,0,0 2021-003467-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,HUS Naistenklinikka,Infections after hysterectomy - a placebo-controlled study comparing the profylactic use of azithromycin and cefuroxime with single cefuroxime Kohdunpoistoleikkauksen jälkeinen infektio: vertailev...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003467-10,0,0,0 2021-003469-36,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,1,"Laboratorios Théa, S.A.","“Prospective evaluation of the efficacy and safety of topical hydrocortisone treatment on clinical signs and symptoms of dry eye disease associated with moderate meibomian gland dysfunction” ""Evalu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003469-36,0,0,0 2021-003471-34,5,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Reneo Pharma Ltd.,"AN OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF REN001 IN SUBJECTS WITH PRIMARY MITOCHONDRIAL MYOPATHY (PMM)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003471-34,0,0,0 2021-003472-14,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Artios Pharma Limited,"A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003472-14,0,0,0 2021-003474-31,1,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,1,Novartis Pharma AG,"A randomized, sham-controlled, double-blind study to evaluate the efficacy and safety of intrathecal (IT) OAV101 in patients with later onset Type 2 spinal muscular atrophy (SMA) who are ≥ 2 to < 18 y...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003474-31,0,0,0 2021-003477-61,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Amgen Inc.,A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003477-61,0,0,0 2021-003514-39,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,Gillberg Neuropsychiatry Centre,"Testing E/I imbalance in autism with Bumetanide – a parallel group randomized waitlist-control trial in adolescents and adults Randomiserad, väntelist-kontrollerad behandlingsstudie med bumetanid i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003514-39,0,0,0 2021-003523-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universität des Saarlandes,A feasibility trial investigating inductive Apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003523-16,0,0,0 2021-003525-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Aarhus University Hospital, Steno Diabetes Center Aarhus",Effect of colchicine on cardiovascular target organ damage in patients with type 2 diabetes - A randomized plecebo-controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003525-30,0,0,0 2021-003526-80,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Kooperativní lymfomová skupina, z.s.","A Phase II Open Label Study of Brentuximab Vedotin in combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas. Otevřená klinická studie, fáze 2 zkoum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003526-80,0,0,0 2021-003527-14,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,AstraZeneca AB,"An Open-Label, Randomised, Phase 4 Study of Continuing Sodium Zirconium Cyclosilicate (SZC) after Discharge in Participants with Chronic Kidney Disease treated for Hyperkalaemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003527-14,0,0,0 2021-003527-14,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"An Open-Label, Randomised, Phase 4 Study of Continuing Sodium Zirconium Cyclosilicate (SZC) after Discharge in Participants with Chronic Kidney Disease treated for Hyperkalaemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003527-14,0,0,0 2021-003528-33,2,,,0,0,1,0,0,1,2,0,0,0,0,0,0,0,1,Horizon Therapeutics Ireland DAC,"An Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects with Neuromyelitis Optica Spectrum Disorder",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003528-33,0,0,0 2021-003536-92,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Cytokinetics, Inc.","A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricula...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003536-92,0,0,0 2021-003543-16,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,LEO Pharma A/S,"A 24 week, randomised, assessor blinded, active-controlled, parallel group, phase 3, 2 arm trial to compare the efficacy and safety of delgocitinib cream 20 mg/g twice-daily with alitretinoin capsules...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003543-16,0,0,0 2021-003543-16,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,LEO PHARMA A/S,"A 24 week, randomised, assessor blinded, active-controlled, parallel group, phase 3, 2 arm trial to compare the efficacy and safety of delgocitinib cream 20 mg/g twice-daily with alitretinoin capsules...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003543-16,0,0,0 2021-003547-24,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,CHU de Saint Etienne,Factors influencing the COVID-19 vaccine immune response (reactogenicity and immunogenicity) according to age and presence or not of a past history of COVID-19. COVIMMUNAGE study Etude des facteurs...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003547-24,0,0,0 2021-003554-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Utrecht,Sentinel lymph node detection in early-stage ORal Cavity squamous cell carcinoma using Magnetic Resonance (MR) lymphogrAphy Detectie van schildwachtklieren bij vroeg-stadium mondholtekanker met beh...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003554-23,0,0,0 2021-003567-10,5,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,GLAXOSMITHKLINE BIOLOGICALS,"A phase 2, single-blinded, randomised, controlled multi-country study to evaluate the safety, reactogenicity, efficacy and immune response following sequential treatment with an anti-sense oligonucleo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003567-10,0,0,0 2021-003567-10,5,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase 2, single-blinded, randomised, controlled multi-country study to evaluate the safety, reactogenicity, efficacy and immune response following sequential treatment with an anti-sense oligonucleo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003567-10,0,0,0 2021-003567-10,5,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,GlaxoSmithKline SA,"A phase 2, single-blinded, randomised, controlled multi-country study to evaluate the safety, reactogenicity, efficacy and immune response following sequential treatment with an anti-sense oligonucleo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003567-10,0,0,0 2021-003569-36,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with Rela...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003569-36,0,0,0 2021-003569-36,3,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"AstraZeneca AB,","A Phase I/II Open-label, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Patients with Rela...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003569-36,0,0,0 2021-003570-31,1,,,0,0,1,0,0,1,2,0,0,4,0,0,0,0,0,St. Jude Children's Research Hospital,A Randomized Phase I/II Study of Onivyde in Combination with Talazoparib or Temozolomide in Children and Young Adults with Recurrent Solid Malignancies and Ewing Sarcoma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003570-31,0,1,1 2021-003573-58,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Antwerp University Hospital,Vaccination against cOvid-19 In CancEr: booster shot BNT161b2 vaccine after full vaccination with ChAdOx1-S vaccine (Tri-VOICE plus),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003573-58,0,0,0 2021-003574-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University of Copenhagen,Treatment of whiplash by pramipexole - a dopamine agonist Behandling af whiplash med pramipexol – en dopamin agonist,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003574-31,0,0,0 2021-003574-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,jens astrup,Treatment of whiplash by pramipexole - a dopamine agonist Behandling af whiplash med pramipexol – en dopamin agonist,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003574-31,0,0,0 2021-003578-30,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,GILEAD SCIENCES INCORPORATED,"Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003578-30,0,0,0 2021-003578-30,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Gilead Sciences, Inc.","Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003578-30,0,0,0 2021-003586-35,4,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,GlaxoSmithKline Biologicals,"A Phase I/II, observer-blind, randomised, placebo controlled, multi-country study to evaluate reactogenicity, safety, immune response, and efficacy of an HSV vaccine in healthy participants aged 18-40...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003586-35,0,0,0 2021-003586-35,4,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,"GlaxoSmithKline, S.A.","A Phase I/II, observer-blind, randomised, placebo controlled, multi-country study to evaluate reactogenicity, safety, immune response, and efficacy of an HSV vaccine in healthy participants aged 18-40...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003586-35,0,0,0 2021-003588-85,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UCLouvain,"Individualized care with antipsychotics in patients suffering from schizophrenia spectrum disorders- How to conciliate plasma concentrations, clinical response and genetic factors ?",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003588-85,0,0,0 2021-003592-34,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"ImmunoGen, Inc.","PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Recepto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003592-34,0,0,0 2021-003592-34,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"IMMUNOGEN, INC.","PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Recepto...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003592-34,0,0,0 2021-003596-34,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A phase Ib/II, open label study of siremadlin monotherapy and in combination with donor lymphocyte infusion as a treatment for patients with acute myeloid leukemia post-allogeneic stem cell transplant...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003596-34,0,0,0 2021-003601-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Zionexa,"Impact of 18F-FES TEP on therapeutical management in patients with metastatic breast cancer, ER positive and HER2 negative, in relapse after a first line of treatment combining hormonal therapy Imp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003601-21,0,0,0 2021-003602-41,2,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,HUTCHMED Limited,"AN OPEN-LABEL, MULTICENTER PHASE 1/2 STUDY OF SURUFATINIB IN COMBINATION WITH GEMCITABINE IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003602-41,0,0,0 2021-003603-18,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,BioMarin Pharmaceutical Inc.,"A Phase 1/2, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of BMN 331, an Adeno-Associated Virus (AAV) Vector-Mediated Gene Transfer of Human SERPING1, in Subje...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003603-18,0,0,0 2021-003606-53,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 1/2, Safety Confirmation and Double-blind, Placebo-controlled, Randomized Study of Relatlimab in Combination with Nivolumab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellula...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003606-53,0,0,0 2021-003608-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Galderma S.A.,Evaluation of acne-induced hyperpigmentation during treatment of acne vulgaris subjects with trifarotene 50 µg/g cream versus vehicle cream over 24 weeks. Evaluación de la hiperpigmentación inducid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003608-41,0,0,0 2021-003609-24,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,mAbxience Research S.L.,"A randomised, double-blind, parallel, multicentre, multinational study to compare the efficacy, pharmacokinetics, pharmacodynamics, safety and immunogenicity of MB09 (proposed denosumab biosimilar) ve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003609-24,0,0,0 2021-003616-10,1,,,0,0,0,0,0,0,4,0,0,1,0,0,0,1,0,Institute of Tropical Medicine,An open label randomized controlled trial comparing the effect of ceftriaxone plus azithromycin versus ceftriaxone for the treatment of Neisseria gonorrhoeae on the resistome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003616-10,0,0,0 2021-003618-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oslo University Hospital,REVACCINATION OF IMMUNOSUPPRESSED PATIENTS WITH POOR/NO SARS-COV-2 VACCINE RESPONSE.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003618-37,0,0,0 2021-003635-29,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Ionis Pharmaceuticals, Inc.",An Open-Label Safety Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) Previously Treated with Volanesorsen (ISIS 304801),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003635-29,0,0,0 2021-003636-88,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,KBP BioSciences PTE. Ltd.,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of KBP-5074, a Mineralocorticoid Receptor Antagonist, in Subjects with Uncontrolled Hyperte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003636-88,0,0,0 2021-003642-20,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,CLINUVEL EUROPE LTD,"A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum (XP) Eine „Proof of Concept“, Ph...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003642-20,0,0,0 2021-003650-23,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Martin-Luther-Universität Halle-Wittenberg,"Fedratinib in Combination with CC-486, a Hypomethylating Agent, in Patients with Accelerated Phase Myelofibrosis Fedratinib in Kombination mit CC-486, einem Hypomethylierungsmittel, bei Patient*inn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003650-23,0,0,0 2021-003651-42,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Alvotech Swiss AG,"A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT06 Compared with EU-Eylea® in Subjects with Neovascular (wet) Age related Macular Dege...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003651-42,0,0,0 2021-003658-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Xencor, Inc.","A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of XmAb®13676 (Plamotamab) Combined with Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003658-22,0,0,0 2021-003659-40,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"CNS Pharmaceuticals, Inc.","A Multicenter, Open-Label Study with a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003659-40,0,0,0 2021-003664-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medical University of Vienna, Department of Anaesthesia, Critical Care and Pain Medicine",The Effect of Pregabalin on the Cp50 of Propofol Der Effekt von Pregabalin auf die Cp50 von Propofol,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003664-28,0,0,0 2021-003665-35,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Eiger BioPharmaceuticals, Inc.","A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003665-35,0,0,0 2021-003665-35,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"EIGER BIOPHARMACEUTICALS, INC.","A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003665-35,0,0,0 2021-003667-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AbbVie,"A Phase 3, Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003667-10,0,0,0 2021-003669-36,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Merck Healthcare KGaA,"A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Loca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003669-36,0,0,0 2021-003676-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University of Vienna,"A prospective randomized, double blind, controlled, safety and non-inferiority study of esketamine plus propofol compared to methohexital anesthesia for electroconvulsive therapy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003676-13,0,0,0 2021-003677-66,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Amsterdam University Medical Center,Clemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosis Clemastine fumaraat als remyeliniserende therapie in internucleaire oftalmoplegie en multiple...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003677-66,0,0,0 2021-003679-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sint Maartenskliniek,"Erector spinae plane block for reduction of early postoperative pain scores and opioid use in lumbar spinal fusion surgery, a prospective double-blinded randomized placebo controlled trial Erector ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003679-32,0,0,0 2021-003680-10,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Arrowhead Pharmaceuticals, Inc.",A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003680-10,0,0,0 2021-003683-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SelectImmune Pharma AB,"Kineret for the treatment of Bladder Pain Syndrome (BPS). Randomized, double-blind, cross-over, phase II trial.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003683-28,0,0,0 2021-003690-65,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,St Antonius Hospital,Peppermint Oil for the treatment of Irritable Bowel Syndrome or Functional Abdominal Pain in Children: the MINT study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003690-65,0,0,0 2021-003693-31,2,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003693-31,0,0,0 2021-003700-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2b Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis Estudio en fa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003700-41,0,0,0 2021-003702-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Pfizer Inc.,"AN INTERVENTIONAL PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY AND SAFETY OF RITLECITINIB (PF-06651600) IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003702-42,0,0,0 2021-003710-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,INSTITUT JULES BORDET,COVID-19: Immune response in patients with cancer undergoing mRNA vaccination against SARS-CoV-2. I-SPARC study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003710-39,0,0,0 2021-003712-27,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Immunovaccine Technologies Inc. (IMV Inc.),"A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, with and without Intermittent LowDose Cyclophosphamid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003712-27,0,0,0 2021-003712-27,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,IMV Inc.,"A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, with and without Intermittent LowDose Cyclophosphamid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003712-27,0,0,0 2021-003715-26,10,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Pfizer Inc.,"A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI-H/DMMR METASTATIC CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003715-26,0,0,0 2021-003717-18,1,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"An open-label, non-comparator, multicenter study to describe the pharmacokinetics (PK), pharmacodynamics (PD; viral load) and safety following a single intravenous or intramuscular dose of sotrovimab ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003717-18,0,0,0 2021-003747-22,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase 2 study of PHE885, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003747-22,0,0,0 2021-003747-22,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"A Phase 2 study of PHE885, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003747-22,0,0,0 2021-003747-22,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A Phase 2 study of PHE885, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003747-22,0,0,0 2021-003749-39,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,DOMPé FARMACEUTICI S.P.A.,"A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL ophthalmic solution versus vehicle, in patients with seve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003749-39,0,0,0 2021-003751-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,IRCCS ISTITUTO CLINICO HUMANITAS,Randomized phase III clinical trial of Neo-Adjuvant Intravesical mitomycin C (MMC) treatment in patients with primary treatment-naïve vesical neoplasms. Studio clinico randomizzato di fase III sull...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003751-42,0,0,0 2021-003756-16,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE MASKED, ACTIVE COMPARATORCONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003756-16,0,0,0 2021-003756-16,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE MASKED, ACTIVE COMPARATORCONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003756-16,0,0,0 2021-003759-40,5,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Novartis Pharma AG,"Efficacy, safety, tolerability and quality of life of ongoing individually optimized  lipid-lowering therapy with or without inclisiran (KJX839) – a randomized, placebo-controlled, double-blind multic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003759-40,0,0,0 2021-003760-27,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Université Libre de Bruxelles,"INCENTIVE-QIV-3-EU: Immunogenicity, molecular profiling of a marketed quadrivalent influenza vaccine (Vaxigrip Tetra®) administered by the intramuscular route in participants aged 6 to 7 months",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003760-27,0,0,0 2021-003762-13,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie – Państwowy Instytut Badawczy (NIO-PIB),PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (L-ANNAMYCIN) IN PATIENTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS WITH PULMONARY METASTASES (ANNA-SARC),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003762-13,0,0,0 2021-003764-27,3,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,Camurus AB,"A randomized, placebo-controlled, double-blind, multi-center Phase 2/3 trial to assess efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with symptomatic polycystic liver dise...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003764-27,0,0,0 2021-003767-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD),Phase II trial of Pembrolizumab and Olaparib in homologous-recombination deficient (HRD) advanced colorectal cancer (CRC). Ensayo de fase II de Pembrolizumab y Olaparib en cáncer colorrectal avanza...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003767-10,0,0,0 2021-003768-29,2,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,DOT Therapeutics-1 Inc. (Day One),"A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003768-29,0,0,0 2021-003771-34,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003771-34,0,0,0 2021-003771-34,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003771-34,0,0,0 2021-003772-14,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE EFFICACY OF FENEBRUTINIB IN RELAPSING MULTIPLE SCLEROSIS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003772-14,0,0,0 2021-003774-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,DIPARTIMENTO BIOMEDICINA E PREVENZIONE UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA,"Enhancing Treatment in Persistent Glioblastoma through AGuIX Nanoparticles for Precision Radiotherapy (NanoGBM-Precision): A Phase II, monocenter, open-label, single-arm, no-profit clinical trial. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003774-32,0,0,0 2021-003776-13,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Alnylam Pharmaceuticals, Inc.","A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003776-13,0,0,0 2021-003777-63,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,University Medical Center Groningen,Tetrahydrobiopterin (BH4) treatment in Phenylketonuria - comparing different practices of dosing regimen Tetrahydrobiopterine (BH4) behandeling bij Phenylketonurie - vergelijking van verschillende ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003777-63,0,0,0 2021-003778-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Drossapharm AG,"Randomized, controlled, multi-center trial to evaluate the efficacy and safety of Lixim 70 mg wirkstoffhaltiges Pflaster (etofenamate 70 mg medicated plaster) vs. placebo in the local symptomatic and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003778-30,0,0,0 2021-003779-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud University Medical Center,HYPo-fractionated Radiotherapy of Lymph Node Metastases guided by NanO-MRI in Prostate Cancer Patients: A Pilot Study (HYPNO-study). MRI-gestuurde radiotherapie van lymfekliermetastasen van prostaa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003779-32,0,0,0 2021-003784-94,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"Rigshospitalet, department of Neurology",Treatment of Myotonia - Lamotrigine versus Namuscla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003784-94,0,0,0 2021-003788-82,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Department of Oncology, Herlev & Gentofte Hospital",An open label phase 2 study on propranolol and pembrolizumab in advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma – a Scandinavian Sarcoma Group collaboration,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003788-82,0,0,0 2021-003790-65,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Dermapharm AG,"Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Ointment (Test) vs. Lotricomb® Ointment (Reference) vs. Vehicle in patients with moderate to severely inflamed candi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003790-65,0,0,0 2021-003791-13,4,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,F. Hoffmann La-Roche Ltd,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF 52 WEEKS OF TREATMENT WITH BASMISANIL IN CHILDREN WITH DUP15Q S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003791-13,0,0,0 2021-003791-13,4,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF 52 WEEKS OF TREATMENT WITH BASMISANIL IN CHILDREN WITH DUP15Q S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003791-13,0,0,0 2021-003791-13,4,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF 52 WEEKS OF TREATMENT WITH BASMISANIL IN CHILDREN WITH DUP15Q S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003791-13,0,0,0 2021-003797-30,9,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003797-30,0,0,0 2021-003799-15,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Ascelia Pharma AB,"A Randomized, Double-blind Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of ASC-201 Plus Trifluridine/Tipiracil Compared With Trifluridine/Tipiracil in Patients With Advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003799-15,0,0,0 2021-003804-42,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Helse Bergen HF,"Immunogenicity, molecular profiling and safety of a marketed quadrivalent influenza vaccine (Vaxigrip Tetra) administered by the intramuscular route in children 3-11 years old",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003804-42,0,0,0 2021-003805-23,1,,,0,1,1,0,0,0,1,0,1,4,0,0,0,0,1,"Pfizer, Inc.","A PHASE 1, OPEN LABEL, CROSSOVER STUDY TO EVALUATE PALATABILITY AND RELATIVE BIOAVAILABILITY OF TWO PEDIATRIC MICROSPHERE FORMULATIONS OF CRIZOTINIB IN HEALTHY PARTICIPANTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003805-23,0,1,1 2021-003809-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Karolinska University Hospital,A phase II multicenter single-armed study using subject-specific minimal residual disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myelodysplastic syndro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003809-22,0,0,0 2021-003814-37,1,2022-06-21,2022-06-21,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,Odense University Hosipital,The effect of dicloxacillin on oral absorption of drugs Dicloxacillins effekt på optagelsen af lægemidler fra tarmen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003814-37,0,0,0 2021-003815-25,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,CellPoint B.V.,"A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003815-25,0,0,0 2021-003816-20,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO,IMPACT OF STRUCTURAL AND MYELIN ABNORMALITIES ON COGNITIVE IMPAIRMENTS IN RECENT-ONSET SCHIZOPHRENIA – before and after lurasidone treatment IMPATTO DELLE ANOMALIE STRUTTURALI E MIELINICHE SUI DEFI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003816-20,0,0,0 2021-003821-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Region Jönköping, Sweden",Patient-controlled Sedation in Port Implantation (PACSPI 2)- a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003821-31,0,0,0 2021-003821-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Region Östergötland, Sweden",Patient-controlled Sedation in Port Implantation (PACSPI 2)- a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003821-31,0,0,0 2021-003822-54,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003822-54,0,0,0 2021-003823-14,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,Amsterdam UMC,Pharmacokinetic cross-over study of compounded chenodeoxycholic acid.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003823-14,0,0,0 2021-003825-31,3,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,Guerbet,"Gadopiclenol Pharmacokinetics, Safety and Efficacy in Pediatric Patients < 2 Years of Age Undergoing Contrast-enhanced MRI P/0145/2019",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003825-31,0,0,0 2021-003829-30,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Ribon Therapeutics, Inc","A Phase 1b/2, multicenter, single arm study of RBN-2397 in combination with pembrolizumab in patients with Squamous Cell Carcinoma of the Lung (SCCL) Estudio de Fase 1b/2, multicéntrico, de un solo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003829-30,0,0,0 2021-003832-96,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Jagiellonian University Medical College,Immunotherapy with dinutuximab beta in combination with chemotherapy for the treatment of patients with primary neuroblastoma refractory to standard therapy and with relapsed or progressive disease ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003832-96,0,0,0 2021-003847-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI),"Efficacy and safety of 7 versus 14 days of antibiotic treatment for Pseudomonas aeruginosa bacteraemia: a multicentre, randomized clinical trial (SHORTEN-2) with a DOOR/RADAR analysis Eficacia y se...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003847-10,0,0,0 2021-003850-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Amsterdam UMC, location VUmc",Precision psychiatry: Anti-inflammatory medication in Immuno-metabolic depression Precieze psychiatrie: Anti-inflammatoire medicatie bij immune-metabole depressie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003850-21,0,0,0 2021-003851-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Gillberg Neuropsychiatry Centre,A Randomized Waitlist-Control Trial with Bumetanide in Children with Autism En Väntelist-kontrollerad Behandlingsstudie med Bumetanide till Barn med Autism,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003851-41,0,0,0 2021-003852-18,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"PTC Therapeutics, INC","A PHASE 2A, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PTC518 IN SUBJECTS WITH HUNTINGTON'S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003852-18,0,0,0 2021-003855-40,4,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,MORPHOSYS AG,"A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refrac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003855-40,0,0,0 2021-003855-40,4,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,MorphoSys AG,"A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refrac...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003855-40,0,0,0 2021-003867-87,1,,,0,0,1,0,0,0,2,0,0,4,0,0,0,0,1,Idorsia Pharmaceuticals Ltd,"Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administratio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003867-87,0,0,0 2021-003871-32,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"ADVENCHEN LABORATORIES, LLC","A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects wi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003871-32,0,0,0 2021-003874-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI).,"RANDOMIZED MULTI-CENTER CLINICAL TRIAL TO ASSESS THE EFFECTIVENESS AND SAFETY OF TIROFIBAN VERSUS INTRAVENOUS ASPIRIN IN PATIENTS WITH ACUTE ISCHEMIC STROKE SECONDARY TO TANDEM INJURY, SUBJECT TO RECA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003874-30,0,0,0 2021-003875-32,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,InFlectis BioScience,"A double-blind, placebo-controlled, exploratory randomised clinical trial to assess the safety and efficacy of IFB-088 plus riluzole 100 mg vs placebo plus riluzole 100 mg in patients with bulbar-on...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003875-32,0,0,0 2021-003880-88,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,CHU Dijon Bourgogne,TOLEDDO: Effet d’un traitement par agoniste GLP1 hebdomadaire dans le « diabète double »,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003880-88,0,0,0 2021-003889-12,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,"Consorcio Centro de Investigacion Biomedica en Red, M.P. (CIBER)","Prospective, multicenter and open study to evaluate the efficacy of esmolol in the early identification of cardiovascular disorders induced by cirrhosis, diabetes mellitus and cardiotoxic treatments. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003889-12,0,0,0 2021-003891-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI),Ramdomized non-inferiority clinical trial to evaluate the safety and efficacy of short duration therapy for non complicated enterococcal bacteremia. Ensayo clínico aleatorizado de no inferioridad p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003891-15,0,0,0 2021-003895-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Bispebjerg Hospital, Department of Dermatology and Venereology",Impact of human papillomavirus (HPV) vaccination on burden of disease in patients with actinic keratosis ― a double-blind randomized controlled trial Humant papillomvirus (HPV) vaccination til beh...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003895-15,0,0,0 2021-003897-30,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Jagiellonian University Medical College,Long-term aspirin therapy as a predictor of decreased susceptibility to SARS-CoV-2 infection in aspirin-exacerbated respiratory disease Przewlekłe stosowanie aspiryny jako czynnik prognostyczny obn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003897-30,0,0,0 2021-003898-59,4,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of tolebrutinib (SAR442168) in adults with generalized myasthenia gravis (MG)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003898-59,0,0,0 2021-003898-59,4,,,0,0,0,0,0,2,3,0,0,0,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of tolebrutinib (SAR442168) in adults with generalized myasthenia gravis (MG)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003898-59,0,0,0 2021-003900-42,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Mitsubishi Tanabe Development America Inc.,"A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003900-42,0,0,0 2021-003900-42,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)","A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Stud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003900-42,0,0,0 2021-003901-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Kowa Research Institute, Inc","A Phase 2, Multicenter, Placebo-Controlled, Randomized, Double-Blind, 48-Week Study to Evaluate the Efficacy and Safety of Combination Therapy of K-877-ER and CSG452 in Patients with Noncirrhotic Nona...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003901-23,0,0,0 2021-003903-16,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Sanofi-aventis Recherche & Développement,"A Randomized, Double-Blind, Placebo controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients with Uncontrolled Moderate to Severe Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003903-16,0,0,0 2021-003907-16,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Stealth BioTherapeutics Inc.,"A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondrial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003907-16,0,0,0 2021-003907-16,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,STEALTH BIOTHERAPEUTICS,"A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondrial...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003907-16,0,0,0 2021-003913-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amsterdam UMC,"A Prospective, Open-label Pilot Study to Evaluate Effector mechanisms of Hyperbaric Oxygen Therapy in Patients with Moderate-to-Severe Ulcerative Colitis: The PARADOX study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003913-21,0,0,0 2021-003914-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fundación Pública Andaluza para la Gestión de la Investigación,Efficacy and safety of different antimicrobial DURATions for the treatment of infections associated with Osteosynthesis Material implanted after long bone fractures (DURATIOM). Phase 4 pragmatic multi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003914-38,0,0,0 2021-003927-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Biomédica Galicia Sur,Single antiplatelet therapy with Ticagrelor vs Aspirin after Transcatheter Aortic Valve Implantation: multicenter randomized clinical trial. REAC TAVI 2 Tratamiento antiplaquetario único con ticagr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003927-13,0,0,0 2021-003928-32,5,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Galderma S.A.,"A Double-Blind, Placebo-Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects with Prurigo Nodularis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003928-32,0,0,0 2021-003929-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Ligalli BV,INFLUENCE OF OXYBUTYNIN - MEDRING LIGALLI ON OVERACTIVE BLADDER SYMPTOMS IN WOMEN De invloed van oxybutynine-MedRing Ligalli op symptomen van overactieve blaas in vrouwen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003929-30,0,0,0 2021-003931-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Oncology, Herlev & Gentofte Hospital","Nivolumab, ipilimumab and radiation in combination with influenza vaccine in patients with pancreatic cancer.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003931-27,0,0,0 2021-003936-10,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"MAJIC: A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003936-10,0,0,0 2021-003953-43,2,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Janssen Vaccines & Prevention B.V.,"A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003953-43,0,0,0 2021-003955-40,1,2022-09-28,2022-09-28,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,Janssen-Cilag International NV,"A Single-dose, Open-label, Randomized, Crossover Pivotal Bioequivalence Study in Healthy Participants to Assess the Bioequivalence of Darunavir 600 mg in the Presence of Cobicistat 90 mg When Administ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003955-40,0,0,0 2021-003989-12,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Neurocrine Biosciences, Inc.","A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Adjunctive NBI-1065845 in Adult Subjects With Major Depressive Disorder (MDD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003989-12,0,0,0 2021-003990-74,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer Ensa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003990-74,0,0,0 2021-003993-30,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,IDP Discovery Pharma S.L.,"A phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies Estudio fase 1/2 multicéntrico, abierto, de escalado de dosis de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003993-30,0,0,0 2021-003994-72,4,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"Akebia Therapeutics, Inc.","A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ONCE DAILY ORAL VADADUSTAT FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE NAÏVE TO ERYTHROPOIESIS-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-003994-72,0,0,0 2021-004002-21,1,2021-12-21,2021-12-21,1,0,0,0,0,0,2,0,0,1,0,0,0,0,1,AOP Orphan Pharmaceuticals GmbH,"A single center, open-label, two-period, non-randomized, paired-design study to compare steady-state plasma levels following switch from a 10 mg/ml treprostinil formulation to a 20 mg/ml treprostinil ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004002-21,0,0,0 2021-004003-41,1,,,0,0,1,0,0,0,3,0,1,1,1,1,0,1,1,"GlaxoSmithKline, S.A.","A Phase III, randomized, open-label, active vaccine-controlled crossover study to evaluate the reactogenicity, safety and immune response of unadjuvanted RSV maternal vaccine in healthy non-pregnant g...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004003-41,0,0,0 2021-004008-16,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AMGEN INC.,"A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004008-16,0,0,0 2021-004008-16,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Amgen, Inc.","A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004008-16,0,0,0 2021-004009-37,2,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,Prothya Biosolutions BV,A Phase 1/2 study of the dose-response in pharmacodynamics and safety of prothrombin complex concentrate Cofact in healthy subjects under vitamin K antagonist anticoagulation,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004009-37,0,0,0 2021-004015-11,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,Erasmus MC,"Investigator led, double-masked, multicenter, randomized clinical trial for the comparison of Atropine 0.5% versus Atropine 0.05% eye drops for the prevention of myopia progression in Dutch children. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004015-11,0,0,0 2021-004016-26,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Meilahti Vaccine Research Center - Helsinki University Hospital,"Substudy ""Responses to Covid-19 vaccines"" in research ""Clinical picture, immunology, genetics and pathogenesis of COVID-19 infection"" ""COVID-19 infektion taudinkuva, immuunivaste, genetiikka ja pa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004016-26,0,0,0 2021-004021-71,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Center Utrecht,COrticosteroids for COVID-19 induced loss of Smell – COCOS trial Corticosteroiden voor COVID-19 geinduceerd reukverlies - de COCOS studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004021-71,0,0,0 2021-004022-30,3,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"Akebia Therapeutics, Inc.","A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ONCE DAILY ORAL VADADUSTAT FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH ANEMIA OF CHRONIC KIDNEY DISEASE AFTER CONVERSION FROM AN...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004022-30,0,0,0 2021-004026-30,1,2022-03-22,2022-03-22,1,1,0,0,0,0,3,0,0,1,1,1,0,0,1,Chiesi Farmaceutici S.p.A.,"READY 2: A PHASE 3, OPEN LABEL, SINGLE ARM STUDY ON THE USE OF CUSA-081 FOR DYSFUNCTIONAL CENTRAL VENOUS ACCESS DEVICES (CVADs)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004026-30,0,0,0 2021-004031-86,1,,,0,0,0,0,1,1,4,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO,"“A randomized, two-armed, single-blind, parallel, active controlled, and non-inferiority clinical trial to Compare Efficacy and Safety of anti TNF-alfa biosimilar molecules to the originators in child...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004031-86,0,0,0 2021-004032-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud University Medical Center,"Pharmacokinetic boosting of olaparib to improve exposure, tolerance and cost-effectiveness (PROACTIVE-study) Farmacokinetisch boosten van olaparib om blootstelling, tolerantie en kosten-effectivite...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004032-28,0,0,0 2021-004034-11,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,Genera Research Ltd,"A randomized, evaluator-blinded, dose-ranging, proof of concept study of efficacy, safety and tolerability of rhBMP6 (delivered in autologous blood coagulum [ABC] supplemented with synthetic ceramics ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004034-11,0,0,0 2021-004035-88,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE,"A randomized, open-label, active controlled, parallel group, multicenter phase 3 study to evaluate the efficacy and tolerability of Bamlanivimab and Etesevimab, Casirivimab and Imdevimab, and Sotrovim...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004035-88,0,0,0 2021-004039-10,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,UMC Utrecht - Van Creveldkliniek,Pharmacokinetic-guided dosing of emicizumab in congenital haemophilia A patients – The DosEmi study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004039-10,0,0,0 2021-004040-19,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Guard Therapeutics International AB,"A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Adaptive, Parallel Group Clinical Study to Evaluate the Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Followi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004040-19,0,0,0 2021-004047-25,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,"Sanofi(China) Investment Co Ltd, Shanghai Branch","A Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients with Infantile-Onset Pompe Disease with One Year Alglucosidase Alfa Treatment",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004047-25,0,1,1 2021-004050-31,3,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,Lek Pharmaceuticals d.d.,"A multicenter, randomized, double-blind, placebo and active controlled parallel-group trial to assess the efficacy and safety of the fixed combination medicinal product Mometasone furoate + Azelastine...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004050-31,0,0,0 2021-004053-23,3,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 4, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Vaxelis™ in Healthy Children Previously Vaccinated With a 2-Dose Primary Infant Series of Either Va...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004053-23,0,0,0 2021-004053-23,3,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase 4, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Vaxelis™ in Healthy Children Previously Vaccinated With a 2-Dose Primary Infant Series of Either Va...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004053-23,0,0,0 2021-004057-23,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Radboudumc,Ethanol submandibular duct ligation for drooling in children with neurodisabilities,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004057-23,0,0,0 2021-004061-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,VHIO Vall d’Hebron Institute of Oncology,Single cell characterization of persistent cells upon treatment with durvalumab (MEDI4736) with or without tremelimumab in MSS and MSI colorectal and endometrial tumors Estudio transcriptómico de c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004061-13,0,0,0 2021-004067-28,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PARTICIPANT AND HEALTHCARE PROFESSIONAL REPORTED PREFERENCE FOR SUBCUTANEOUS ATEZOLIZUMAB COMPARED WITH INTRAVENOUS ATEZOLIZUMAB FORM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004067-28,0,0,0 2021-004067-28,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PARTICIPANT AND HEALTHCARE PROFESSIONAL REPORTED PREFERENCE FOR SUBCUTANEOUS ATEZOLIZUMAB COMPARED WITH INTRAVENOUS ATEZOLIZUMAB FORM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004067-28,0,0,0 2021-004067-28,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PARTICIPANT AND HEALTHCARE PROFESSIONAL REPORTED PREFERENCE FOR SUBCUTANEOUS ATEZOLIZUMAB COMPARED WITH INTRAVENOUS ATEZOLIZUMAB FORM...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004067-28,0,0,0 2021-004073-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,Treating microalbuminuria over 24 weeks in subjects with or without type 2 diabetes or hypertension,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004073-31,0,0,0 2021-004108-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University Vienna,Host factors predicting target site concentration of antibiotics in critically ill patients: An explorative pharmacokinetic biomarker study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004108-16,0,0,0 2021-004110-20,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Leiden University Medical Center,"Improving symptomatic treatment with pyridostigmine and amifampridine: a randomized double-blinded, placebo controlled crossover trial in patients with myasthenia gravis (IMPACT-MG) Verbeteren van ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004110-20,0,0,0 2021-004130-11,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,FUNDACION PETHEMA,GEM21menos65. A Phase III trial for NDMM patients who are candidates for ASCT comparing Extended VRD plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D Ensayo de fase III...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004130-11,0,0,0 2021-004131-84,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medical Center,Chronotherapy in Inflammatory Arthritis (ChronIA trial): a crossover randomized controlled trial comparing the effectiveness of morning and evening dosing of tofacitinib extended-release Chronoth...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004131-84,0,0,0 2021-004135-89,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,ASTRAZENECA AB,"Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004135-89,0,0,0 2021-004135-89,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004135-89,0,0,0 2021-004137-36,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,iTeos Belgium SA,"Study of EOS884448 alone, and in combination with iberdomide with or without dexamethasone, in participants with relapsed or refractory multiple myeloma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004137-36,0,0,0 2021-004138-12,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Takeda Development Center Americas, Inc.","A Phase 3, Prospective, Randomized, Open-label, Adaptive Group Sequential, Multicenter Trial with Blinded Endpoint Assessment to Evaluate the Efficacy and Safety of PROTHROMPLEX TOTAL for the Reversal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004138-12,0,0,0 2021-004143-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hospital Universitario Niño Jesus,"A Phase III, Multicenter, Randomized, Controlled, Open-label, Non-inferiority to Evaluate the Safety and Efficacy of Amoxicillin Ambulatory Short Treatment in Children with Acute Streptococcal Pharyng...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004143-24,0,0,0 2021-004149-19,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffmann La Roche Ltd.,"A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004149-19,0,0,0 2021-004149-19,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS, WITH LOCALLY ADVANCED, UNRESECTABLE, STAGE III ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004149-19,0,0,0 2021-004151-16,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,GlaxoSmithKline Research & Development Ltd,"A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004151-16,0,0,0 2021-004151-16,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004151-16,0,0,0 2021-004151-16,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"GlaxoSmithKline, S.A.","A Phase 2, Randomized, Parallel, Open-Label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-Agent Belantamab Mafodotin (GSK2857916) in Participants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004151-16,0,0,0 2021-004156-42,6,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,Sanofi-aventis recherche & développement,"A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an ope...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004156-42,0,0,0 2021-004156-42,6,,,0,0,0,0,0,2,2,0,0,0,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"A Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR443820 in adult participants with amyotrophic lateral sclerosis, followed by an ope...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004156-42,0,0,0 2021-004160-94,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,HOSPICES CIVILS DE LYON,"Etude de preuve de concept de phase IIB, multicentrique, en double aveugle, randomisée, contrôlée versus placebo, évaluant le diltiazem en association avec le traitement standard dans la prise en cha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004160-94,0,0,0 2021-004167-27,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Rhythm Pharmaceuticals Limited,"A Phase 3 Multi-Center, One-Year, Open-Label study of Setmelanotide in Pediatric Patients Aged 2 to <6 years of age with Rare Genetic Causes of Obesity",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004167-27,0,0,0 2021-004174-64,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Dimerix Bioscience Pty Ltd,"A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004174-64,0,0,0 2021-004188-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI""","A Phase III Randomized, Open-label, Multicenter Study to Determine the Safety and Efficacy of different MONoclonal Antibodies (MoAbs) to SARS-CoV-2 for the Early Treatment of COVID-19 in Non-hospitali...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004188-28,0,0,0 2021-004189-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,OSPEDALE SAN RAFFAELE,Role of Hydroxychloroquine in therapeutic strategy of Head and Neck cancer and Non-small cell lung cancer Il ruolo dell'idrossiclorochina nella strategia dei tumori del distretto Testa e Collo e ne...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004189-37,0,0,0 2021-004191-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,BOOG Study Center,"SEQUence of Endocrine therapy in advanced Luminal Breast cancer (SEQUEL-Breast): A phase 2 study on fulvestrant beyond progression in combination with alpelisib for PIK3CA-mutated, hormone-receptor p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004191-33,0,0,0 2021-004192-13,2,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"River 3 Renal, Corporation","A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004192-13,0,0,0 2021-004193-64,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Reviva Pharmaceuticals Holdings Inc.,"Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia, F...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004193-64,0,0,0 2021-004226-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Oramed Ltd.,"A Double-Blinded, Placebo-controlled, Multi-center Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004226-30,0,0,0 2021-004248-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Akershus University Hospital,Antibiotic THErapy iN vIral Airway iNfections (ATHENIAN): An open labelled randomized controlled pragmatic trial to evaluate the efficacy and safety of discontinuing antibiotic therapy in adult patien...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004248-11,0,0,0 2021-004253-22,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Alexion Pharmaceuticals Inc.,A Long-term Extension (LTE) Study to Characterize the Safety and Efficacy of Danicopan as an Add-on Therapy to a Complement Component 5 Inhibitor (C5i) in Patients with Paroxysmal Nocturnal Hemoglobin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004253-22,0,0,0 2021-004254-37,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Ferring Pharmaceuticals A/S,"A randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of FE 999049 for treatment of men with idiopathic infertility",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004254-37,0,0,0 2021-004257-24,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Uniwersytet Medyczny w Białymstoku,Multicentre Evaluation of Clinical Applications of Innovative PET/MRI with a 68Ga-PSMA-11 Radiotracer when Planning a Personalised Therapy in Prostate Cancer Patients Wieloośrodkowa ocena przydatn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004257-24,0,0,0 2021-004259-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,OBCTCD-24 Ltd,"A Phase IIb Randomized, Quadruple-blinded Multicenter, Multinational, Placebo-controlled Study to Evaluate the safety and efficacy of exosomes overexpressing CD24 to prevent clinical deterioration in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004259-17,0,0,0 2021-004262-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Gedeon Richter Plc.,"A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome Estudio en fase II, aleatoriza...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004262-35,0,0,0 2021-004265-12,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Neurocrine Biosciences, Inc.","Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects with Focal Onset Seizures (FOS) Estudio de ext...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004265-12,0,0,0 2021-004266-35,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA,"A phase 3, multicentre, single-blinded, randomized controlled study to compare the efficacy and safety of Casirivimab and Imdevimab or Bamlanivimab and Etesevimab or Sotrovimab in COVID-19 home patien...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004266-35,0,0,0 2021-004271-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Aarhus University Hospital, department of Cardiology",Effect of Dapagliflozin on myocardial and renal function following aortic valve stenosis intervention,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004271-14,0,0,0 2021-004276-33,1,,,0,0,0,1,0,1,1,0,0,4,0,0,0,0,1,Atamyo Therapeutics,"A phase 1-2 multicenter study (2 stages) to evaluate the safety and efficacy of intravenous GNT0006, adeno-associated viral vector carrying the FKRP gene, in patients with FKRP-related limb-girdle mus...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004276-33,0,0,0 2021-004277-31,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,eTheRNA immunotherapies NV,"A phase I/IIa open label study to assess the safety, tolerability, immunogenicity and clinical activity of EI-201 mRNA immunotherapy given intravenously in subjects with recurrent or metastatic HPV16 ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004277-31,0,0,0 2021-004278-76,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ARCAGY-GINECO,A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Ad...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004278-76,0,0,0 2021-004279-15,4,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"Takeda Development Center Americas, Inc.","A Phase 3, Open-label, Single-arm, Repeated-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infecti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004279-15,0,1,0 2021-004280-27,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Gilead Sciences, Inc.","An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non−Small-Cell Lung Cancer (NSCLC) Without Actionable Ge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004280-27,0,0,0 2021-004284-27,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION,"A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors Primer ensayo en seres humanos, fase 1/2 de BMS-986288 en monoterapia y en combin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004284-27,0,0,0 2021-004284-27,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors Primer ensayo en seres humanos, fase 1/2 de BMS-986288 en monoterapia y en combin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004284-27,0,0,0 2021-004285-35,6,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,"A Phase 3, Randomized, Open-label (Sponsor Blinded) Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of M...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004285-35,0,0,0 2021-004287-98,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Sanofi-Aventis Recherche & Developpement,"An open-label, first-in-human, dose-escalation study of SAR443579 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004287-98,0,0,0 2021-004307-40,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Octapharma AG,"A multicentre, prospective, open-label, uncontrolled Phase 3 study to assess the efficacy, safety and pharmacokinetics of Atenativ in patients with congenital antithrombin deficiency undergoing surger...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004307-40,0,0,0 2021-004307-40,6,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,OCTAPHARMA AG,"A multicentre, prospective, open-label, uncontrolled Phase 3 study to assess the efficacy, safety and pharmacokinetics of Atenativ in patients with congenital antithrombin deficiency undergoing surger...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004307-40,0,0,0 2021-004310-19,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Pierre Fabre Médicament,Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004310-19,0,0,0 2021-004313-39,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Ascendis Pharma Endocrinology Division A/S,"A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults with Growth Hormone Deficiency Μια Πολυκεντρική, ανοικτής επισήμανσης, μελέτη ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004313-39,0,0,0 2021-004315-76,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Sanofi-aventis Recherche & Développement,"Master protocol of two randomized, double blind, placebo-controlled, multi-center, parallel group studies to evaluate the efficacy and safety of dupilumab in adult patients with chronic pruritus of un...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004315-76,0,0,0 2021-004315-76,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"Master protocol of two randomized, double blind, placebo-controlled, multi-center, parallel group studies to evaluate the efficacy and safety of dupilumab in adult patients with chronic pruritus of un...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004315-76,0,0,0 2021-004320-16,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004320-16,0,0,0 2021-004323-33,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,AudioCure Pharma GmbH,"Phase II, Multi-Center, Randomized, Blinded Study Evaluating the Efficacy, Safety and Tolerability of a Single Intratympanic Dose of AC102 Compared to Oral Steroids for the Treatment of Idiopathic Sud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004323-33,0,0,0 2021-004325-80,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Anavex Germany GmbH,Open Label Extension Study for Patients with Early Alzheimer’s Disease (AD) Enrolled in Study ANAVEX2-73-AD-004,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004325-80,0,0,0 2021-004327-32,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomized, Doubleblind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Nonsm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004327-32,0,0,0 2021-004328-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital Tübingen,Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitor therapy by investigation of the CD8+ immune infiltrate using [89Zr]Zr-Df-IAB22M2C-PET,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004328-13,0,0,0 2021-004346-37,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004346-37,0,0,0 2021-004349-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"Almirall, S.A.","A Phase 4, Multi-centre, Randomized, Evaluatorblinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004349-18,0,0,0 2021-004389-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,FluoGuide A/S,"An open-label, non-randomized, single dose, exploratory Phase II trial of FG001 (an imaging agent) for localization of biopsy-proven primary non-small cell lung cancer (NSCLC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004389-37,0,0,0 2021-004390-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE MASKED, ACTIVE COMPARATORCONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 IN COMBINAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004390-31,0,0,0 2021-004392-13,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novo Nordisk A/S,Efficacy and safety of once-weekly semaglutide s.c. 2.0 mg as add-on to dose reduced insulin glargine vs titrated insulin glargine in participants with type 2 diabetes and overweight,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004392-13,0,0,0 2021-004392-13,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NOVO NORDISK. S.P.A.,Efficacy and safety of once-weekly semaglutide s.c. 2.0 mg as add-on to dose reduced insulin glargine vs titrated insulin glargine in participants with type 2 diabetes and overweight,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004392-13,0,0,0 2021-004393-62,8,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Neurocrine Biosciences, Inc.","A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects with SCN8A Developmental and Epileptic Encephal...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004393-62,0,0,0 2021-004395-34,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Pfizer Inc.,ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES HOOFDPROTOCOL ENCORAFENIB/BINIMETINIB: EEN OPEN-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004395-34,0,0,0 2021-004398-30,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,ABIVAX,A follow-up Phase II open-label study to evaluate the long-term safety and efficacy profile of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis A napi ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004398-30,0,0,0 2021-004398-30,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Abivax,A follow-up Phase II open-label study to evaluate the long-term safety and efficacy profile of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis A napi ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004398-30,0,0,0 2021-004404-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO,The impact of aripiprazole long-acting on myelin and cognition in the onset of schizophrenia Impatto della terapia con aripiprazolo long-acting sulle anomalie strutturali e mieliniche e sui deficit...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004404-18,0,0,0 2021-004417-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helse Bergen HF,The effect of pregabalin in the treatment of acute post-operative peripheral neuropathic pain – a pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004417-40,0,0,0 2021-004419-14,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Turku University Hospital,COVID-19 infections in hospital personnel COVID-19 -infektiot sairaalahenkilökunnalla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004419-14,0,0,0 2021-004420-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,A Phase 2 clinical study to assess efficacy of Induction ipilimumab/nivolumab to spare the Bladder in urothelial bladder cancer (Indi-Blade) Een fase 2 klinische studie naar de effectiviteit van in...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004420-15,0,0,0 2021-004422-30,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","An open-label, multicenter, roll-over study for patients who have completed a prior Novartis-sponsored sabatolimab (MBG453) study and are judged by the investigator to benefit from continued treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004422-30,0,0,0 2021-004423-32,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi Aventis Recherche & Développement,"Open-label, Phase 2 study, evaluating the efficacy and safety of tusamitamab ravtansine in non-squamous non-small-cell lung cancer (NSQ NSCLC) participants with negative or moderate CEACAM5 expression...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004423-32,0,0,0 2021-004423-32,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT,"Open-label, Phase 2 study, evaluating the efficacy and safety of tusamitamab ravtansine in non-squamous non-small-cell lung cancer (NSQ NSCLC) participants with negative or moderate CEACAM5 expression...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004423-32,0,0,0 2021-004449-19,1,,,0,0,0,0,0,0,2,0,0,1,0,0,0,1,1,Novartis Pharma AG,"A randomized, placebo-controlled, participant-and investigator-blinded, sponsor open-label study to evaluate the safety, tolerability, and efficacy with different dosing regimens of subcutaneously adm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004449-19,0,0,0 2021-004450-36,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004450-36,0,0,0 2021-004450-36,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004450-36,0,0,0 2021-004450-36,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc","A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants with Aggressive and Indolent B-cell Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004450-36,0,0,0 2021-004453-23,9,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004453-23,0,0,0 2021-004456-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hôpital Universitaire Des Enfants Reine Fabiola,"Prospective, randomized, double-blind, double-dummy, active-controlled, phase 3 clinical trial comparing the safety and efficacy of intranasal dexmedetomidine to oral midazolam as premedication for pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004456-42,0,0,0 2021-004467-26,1,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,1,Diurnal Limited,A Phase 3 Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Chronocort in the Treatment of Participants Aged 16 Years and Over with Congenital Adrenal Hyperplasia,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004467-26,0,0,0 2021-004469-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,PHERECYDES PHARMA,"A Pilot, Multicenter, Randomized, Non Comparative, Double-Blind Study of Phage Therapy in Patients with Hip or Knee Prosthetic Joint Infection due to Staphylococcus aureus Treated with DAIR and Antibi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004469-11,0,0,0 2021-004471-13,4,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Pharma Mar, S.A.","A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relapsed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004471-13,0,0,0 2021-004506-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitario Fundación Alcorcón,ERECTOR SPINAE PLANE CATHETERS IN SCOLIOSIS SURGERY Bloqueo en el plano del erector espinal en cirugía de escoliosis (BEE trial),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004506-21,0,0,0 2021-004526-29,4,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,University of Cologne,"A MULTINATIONAL, PHASE 2, RANDOMISED, ADAPTIVE PROTOCOL TO EVALUATE IMMUNOGENICITY AND REACTOGENICITY OF DIFFERENT COVID-19 VACCINES ADMINISTRATION IN OLDER ADULTS (≥75) ALREADY VACCINATED AGAINST SAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004526-29,0,0,0 2021-004529-57,4,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,"Equillium, Inc.","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination with Corticosteroids for the Initial Treatment of Acute Graft Versus Host Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004529-57,0,0,0 2021-004530-11,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Altos Biologics Inc.,"A Randomized, Phase 3, Double Masked, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of ALT L9 Versus Eylea® in Patients With Neovascular Age Related Macular Degeneration (ALTERA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004530-11,0,0,0 2021-004536-28,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Uppsala University, Department of Women's and Children´s Health","Vaginal administration of selective estrogen receptor modulator (Tamoxifen) treatment to improve sexual function for women with breast cancer. A randomized, double-blinded, placebo controlled longitud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004536-28,0,0,0 2021-004550-33,1,,,0,0,0,0,1,0,3,0,1,0,0,0,0,0,0,Assistance publique Hopitaux de Paris/ DRCI,Immunogenicity and reactogenicity following a booster dose of COVID-19 mRNA vaccine (Pfizer-BioNtech) and two adjuvanted sub-unit vaccines (SP/GSK) administered in adults who received 2 doses of Pfize...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004550-33,0,0,0 2021-004554-32,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Pulmocide Ltd,"A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004554-32,0,0,0 2021-004555-16,4,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004555-16,0,0,0 2021-004555-16,4,,,0,0,1,0,0,1,1,0,0,3,0,0,0,0,1,ABBVIE DEUTSCHLAND GMBH & CO. KG,"A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004555-16,0,0,0 2021-004558-44,1,2022-03-12,2022-03-12,1,0,0,0,0,0,4,0,0,1,0,0,0,0,0,UMCG,Optimal Booster Strategy for SARS-CoV-2 Vaccination in Kidney Transplant patients Optimale booster strategie voor SARS-CoV-2 vaccinatie in niertransplantatie patiënten.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004558-44,0,0,0 2021-004564-94,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Randomized, Double-Blind, Phase 3 Study of MK-7684A Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004564-94,0,0,0 2021-004564-94,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Double-Blind, Phase 3 Study of MK-7684A Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004564-94,0,0,0 2021-004565-13,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA,"Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease. A multicenter, randomized, double-blind, placebo-controlled, phase 2 trial. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004565-13,0,0,0 2021-004573-32,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Centre Hospitalier Annecy Genevois,"Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) versus Standard-Dose (QIV-SD), in subjects 65 years of age and older on innate immunity, including gene expression. Effet d’un vaccin ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004573-32,0,0,0 2021-004576-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación GECP,Phase II clinical trial of AMG510 (Sotorasib) in stage III unresectable NSCLC KRAS p.G12C patients and medically ineligible for concurrent chemo-radiotherapy_(MERIT-lung) Ensayo clínico de fase II ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004576-34,0,0,0 2021-004577-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FUNDACION INVESTIGACION BIOMEDICA HOSPITAL PUERTA DE HIERRO MAJADAHONDA,EARLY treatment with Candesartan vs Placebo in asymptomatic GENEtic carriers of Dilated Cardiomyopathy (EARLY-GENE trial) Inicio temprano de tratamiento con Candesartan vs Placebo en portadores gen...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004577-30,0,0,0 2021-004579-16,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Adamed Pharma S.A.,"A Phase II, Randomized, Parallel design, Open label, Dose ranging Study to evaluate the efficacy and safety of Furazidin vaginal tablets in women with bacterial vaginosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004579-16,0,0,0 2021-004588-29,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,VectivBio AG,"A randomized, double-blind trial to evaluate the safety and efficacy of apraglutide in subjects with Grade II to IV (MAGIC) steroid refractory gastrointestinal (GI) acute graft versus host disease on ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004588-29,0,0,0 2021-004590-30,1,,,0,0,1,0,0,0,2,0,0,4,0,0,0,0,1,Regeneron Pharmaceuticals Inc.,"A Phase 2a, Open-Label Study Assessing Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Single-Dose Subcutaneous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab and Imdevimab)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004590-30,0,1,1 2021-004593-56,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE,A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients Studio clinico di ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004593-56,0,0,0 2021-004594-32,8,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,IO Biotech ApS,"An open-label, randomized, Phase 3 clinical trial of IO102-IO103 in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic (advanc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004594-32,0,0,0 2021-004597-65,2,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,1,"Rhythm Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) with a Crossover to Open-Label Once Weekly Setmelanotide in Patients with Specific Gene Defects in the...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004597-65,0,0,0 2021-004600-17,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,Royal College of Surgeons in Ireland,The use of Sildenafil in Neonates with Down Syndrome to Reduce Pulmonary Vascular Resistance.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004600-17,0,0,0 2021-004601-47,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,"A multi-center, randomized, double-blind, placebo controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004601-47,0,0,0 2021-004601-47,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A multi-center, randomized, double-blind, placebo controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004601-47,0,0,0 2021-004601-47,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A multi-center, randomized, double-blind, placebo controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed to...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004601-47,0,0,0 2021-004606-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-bas...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004606-21,0,0,0 2021-004627-33,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Calliditas Therapeutics Suisse SA,"A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability, and Effects on Tumour Biomarkers of the NOX1/4 Inhibitor Setanaxib, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004627-33,0,0,0 2021-004627-33,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Genkyotex Suisse SA,"A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability, and Effects on Tumour Biomarkers of the NOX1/4 Inhibitor Setanaxib, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004627-33,0,0,0 2021-004628-14,1,,,0,0,0,0,0,3,3,0,0,0,0,0,0,0,0,Oulu University Hospital,Lomake täytetään suomeksi Laparoscopic-Guided Transversus Abdominis Plane Block versus epidural analgesia in a colorectal laparoscopic surgery -effects to hospital stay and postoperative opioid use...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004628-14,0,0,0 2021-004631-92,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,"Westfälische Wilhelms-Universität Münster, C/o Universitätsklinikum Münster Geschäftsbereich Recht u. Drittmittel",Phase I/II dose escalation trial of radiodynamic therapy (RDT) with 5-Aminolevulinic acid in patients with first recurrence of glioblastoma Eine Phase I/II-Dosis-Eskalations-Studie zur Radiodynamis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004631-92,0,0,0 2021-004648-27,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Merck Healthcare KGaA,"A Phase II, Randomized, Double-Blind, Placebo Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lup...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004648-27,0,0,0 2021-004727-33,3,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,1,Cytokinetics Inc,"A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004727-33,0,0,0 2021-004730-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University of Vienna,"A prospective, controlled, single-arm pilot study on treosulfan, fludarabine, and cyclophosphamide (TreoFC) as conditioning treatment before haploidentical hematopoietic stem cell transplantation for ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004730-11,0,0,0 2021-004732-29,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Protagonist Therapeutics, Inc.",A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004732-29,0,0,0 2021-004734-11,2,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Eli Lilly and Company,"A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Relapsed or Refractory Ewing's Sarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004734-11,0,0,0 2021-004734-11,2,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Lilly S.A.,"A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Relapsed or Refractory Ewing's Sarcoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004734-11,0,0,0 2021-004740-24,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,INCYTE CORPORATION,"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004740-24,0,0,0 2021-004740-24,4,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Incyte Corporation,"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004740-24,0,0,0 2021-004748-62,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,1,"Q-Med AB, part of the Galderma Group","A Phase IV, Randomized, Interventional, Study to Assess Subject Treatment Session Perception and Investigator Treatment Experience of Alluzience and Vacuum-Dried Botulinum Neurotoxin Type A for Aes...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004748-62,0,0,0 2021-004750-39,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Herlev Gentofte Hospital - Department of Dermatology and Allergy,The role of Interleukin-1B targeted therapy for patients suffering with allergic contact dermatitis: A randomized controlled trial with Anakinra vs. Placebo.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004750-39,0,0,0 2021-004756-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Diakonhjemmet sykehus,The NOR-CACTUS Trial: A NORwegian trial CompAring treatment strategies for Carpal TUnnel Syndrome,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004756-42,0,0,0 2021-004762-35,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease Estudio...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004762-35,0,0,0 2021-004766-35,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Galderma S.A.,"A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects with Chronic Kidney Disease with Associated Moderate to Severe Pruritus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004766-35,0,0,0 2021-004787-10,4,2022-08-10,2022-08-10,1,0,0,0,0,1,2,0,0,2,1,0,0,0,1,Pfizer Inc.,"AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO ADULT PARTICIPANTS ≥18 AND ≤80 WITH ACTIVE DERMATOMYOSITIS.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004787-10,1,0,0 2021-004788-29,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Finnish Institute for Health and Welfare,COVID-19 vaccine immunological studies in Finland Koronavirusrokotteiden immuunivasteet Suomessa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004788-29,0,0,0 2021-004789-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universität Heidelberg,"Randomized, controlled trial of the use of intranasal midazolam for the treatment of terminal agitation in palliative care patients Randomisierte, kontrollierte Studie zur Anwendung von intranasale...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004789-36,0,0,0 2021-004790-31,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Stratified, Double-blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004790-31,0,0,0 2021-004791-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,VU medical center,"Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis: a randomized controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004791-34,0,0,0 2021-004792-14,1,,,0,0,1,0,0,0,3,0,0,4,0,0,0,0,1,Intas Pharmaceuticals Ltd.,"A Randomized, Active-Controlled, Multicenter, Open label, Two Arm Study to Assess Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics with Pegfilgrastim PFS of Intas Pharmaceutical Limited Compar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004792-14,0,1,1 2021-004794-31,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Kinevant Sciences GmbH,"A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004794-31,0,0,0 2021-004795-34,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Eledon Pharmaceuticals, Inc","A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients with IgA Nephropathy Estudio en fase IIa, multicéntrico y abierto para evaluar la seguridad y la...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004795-34,0,0,0 2021-004809-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"GemVax &KAEL Co., Ltd.","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004809-40,0,0,0 2021-004811-26,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Alkem Laboratories Limited,"A Phase 3, Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics and Immunogenicity of Enzene Denosumab (ENZ215) and Pro...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004811-26,0,0,0 2021-004813-37,1,,,0,1,1,0,0,0,2,0,1,4,0,0,0,0,1,Seqirus Inc. formerly Novartis Vaccines and Diagnostics Inc.,"A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Differ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004813-37,0,1,1 2021-004814-21,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,CHU de Besançon,Intraoperative indocyanine green fluorescence angiography in colorectal surgery to prevent anastomotic leakage: a single-blind phase III multicenter randomized controlled trial (intergroup FRENCH-GREC...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004814-21,0,0,0 2021-004849-20,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Biogen Idec Research Limited,"A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004849-20,0,0,0 2021-004858-30,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Bayer Consumer Care AG,"A phase 3, single group treatment, open-label, study to evaluate the safety of BAY 94-9027 infusions for prophylaxis and treatment of bleeding in previously treated children aged 7 to <12 years with s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004858-30,0,0,0 2021-004864-81,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI,"Proposta di studio per valutare l’efficacia di Obinutuzumab, un anticorpo anti-CD20, in pazienti con nefropatia membranosa intolleranti, resistenti o dipendenti alla terapia con Rituximab (studio ORIO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004864-81,0,0,0 2021-004865-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Win Medica Pharmaceuticals S.A.,"Comparison of the effectiveness of IntraVenous FLECainide plus oral ranolazine versus intravenous flecainide alone in the cardioversion of recent onset atrial fibrillation – a randomized, prospective,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004865-11,0,0,0 2021-004868-95,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Inv. Biomédica Hospital Clínico San Carlos,"AMANTADINE AND TRANSCRANIAL MAGNETIC STIMULATION FOR TREATING FATIGUE IN MULTIPLE SCLEROSIS: PHASE III STUDY, CONTROLLED, RANDOMIZED, CROSSED OVER AND DOUBLE BLIND AMANTADINA Y ESTIMULACIÓN MAGNÉTI...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004868-95,0,0,0 2021-004870-78,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,University Medical Centre Groningen,Detecting mitochondrial oxygen tension (mitoPO2) as a measure of local tissue oxygenation in patients with various stages of PAD with the Cellular Oxygen Metabolism (COMET) measurement system of Photo...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004870-78,0,0,0 2021-004884-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Pharma Stulln GmbH,"A Randomized, Double-Blind, Placebo-Controlled Dose Finding Study of 0.05%, 0.025%, 0.01% and 0.005% Atropine Eye Drops to inhibit myopia progression in children in a European population Eine rando...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004884-29,0,0,0 2021-004889-35,4,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,University College Dublin,"An International Multicentre, Phase 2, Randomised, Adaptive Protocol to determine the need for, optimal timing of and immunogenicity of administering a 4th homologous mRNA vaccination dose against SAR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004889-35,0,0,0 2021-004891-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turku University Hospital,COVID-19 vaccine induced immune response in patients with primary antibody deficiency COVID-19 rokotuksen synnyttämät immuunivasteet primaarista vasta-ainepuutosta sairastavilla potilailla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004891-33,0,0,0 2021-004895-32,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Hellenic Society of Hematology (EAE),"A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide maintenance in Newly Diagnosed Patients with Multiple Myeloma a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004895-32,0,0,0 2021-004897-77,1,,,0,0,1,0,0,0,1,0,0,4,0,0,0,0,1,Intas Pharmaceuticals Ltd.,"A multicentric, open label, balanced, randomized, two-stage, two-treatment, two-period, two-sequence, crossover, multiple oral dose, comparative bioavailability study of cyclophosphamide powder for or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004897-77,0,1,1 2021-004917-38,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Hellenic Society of Hematology (EAE),A Phase 2 Study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM Patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004917-38,0,0,0 2021-004919-11,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,"Donders Institute for Brain, Cognition and Behaviour, Radboud University",The effect of colchicine on Food-reLAted effort-based decision making in brain and behavIouR in overweight and obesity: the FLAIR-i study. Het effect van colchicine op voedselgerelateerd inspanning...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004919-11,0,0,0 2021-004923-34,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Bavarian Nordic A/S,"A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN®-RSV Vaccine in Adults ≥60 Years of Age Randomisierte, doppel-blinde Pha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004923-34,0,0,0 2021-004924-14,1,2022-09-15,2022-09-15,1,0,0,0,0,0,4,0,0,1,1,1,0,0,0,Leiden University Medical Center,New treatment strategy for patients with multiple recurrent Clostridioides difficile infection with bezlotoxumab as first option Nieuwe behandelstrategie voor patiënten met multipel recurrente Clos...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004924-14,0,0,0 2021-004927-34,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Ketabon GmbH,"A multicentre, double-blind, randomised, placebo-controlled phase II trial with a 3 week treatment period to assess the efficacy, safety and tolerability of add-on treatment with Ketamine hydrochlorid...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004927-34,0,0,0 2021-004928-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Celgene Corporation,"A Phase 2, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) for the Treatment of Anemia in Adults with Alpha (α...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004928-15,0,0,0 2021-004934-12,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,INCYTE CORPORATION,"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced Non– Small Cell Lung Cancer With an FGFR Alteration Who Progressed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004934-12,0,0,0 2021-004934-12,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Incyte Corporation,"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced Non– Small Cell Lung Cancer With an FGFR Alteration Who Progressed...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004934-12,0,0,0 2021-004938-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Clínico Universitario de Valladolid,Prevention of cardiac surgery-associated acute kidney injury through the use of sodium-glucose cotransporter 2 inhibitors Prevención del fracaso renal agudo asociado a cirugía cardiaca mediante el ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004938-11,0,0,0 2021-004972-32,4,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,Novartis Pharma AG,"A Phase II, double-blind, randomized, multiple dose, cross over, three-treatment, three-period, six sequence placebo controlled trial to evaluate efficacy, pharmacokinetics (PK), pharmacodynamics (PD)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004972-32,0,0,0 2021-004972-32,4,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A Phase II, double-blind, randomized, multiple dose, cross over, three-treatment, three-period, six sequence placebo controlled trial to evaluate efficacy, pharmacokinetics (PK), pharmacodynamics (PD)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004972-32,0,0,0 2021-004979-14,6,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,"Aridis Pharmaceuticals, Inc.","A Phase 3, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Efficacy and Safety of Suvratoxumab in Mechanically Ventilated Adults and Adolescents for the Prevention of N...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004979-14,0,0,0 2021-004981-37,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helse Bergen HF,Benzodiazepine maintenance treatment for patients with benzodiazepine dependence undergoing opioid agonist therapy (BMX-BAR),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004981-37,0,0,0 2021-004993-68,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Steno Diabetes Center Copenhagen,The HYPO-AVOID STUDY: Low-dose Glucagon and Advanced Hybrid Closed-loop System for Prevention of Exercise-Induced Hypoglycaemia in People with Type 1 Diabetes Lav-dosis glukagon og avanceret hybrid...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004993-68,0,0,0 2021-004994-30,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,Roessingh,Pulmonary function and sleep related disorders during cervical admission of intrathecal baclofen in spinal cord injury; a safety study Longfunctie en slaapgerelateerde stoornissen tijdens cervicaa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004994-30,0,0,0 2021-004998-32,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,argenx BV,"A Long-Term Extension of the ARGX-117-2002 Trial to Evaluate the Long-term Safety and Tolerabillity, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults with Multifo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-004998-32,0,0,0 2021-005000-36,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"VasaraGen, Inc.","A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005000-36,0,0,0 2021-005001-26,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,UMC Utrecht,Influencing Progression of Airway Disease in Primary Antibody Deficiency,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005001-26,0,0,0 2021-005013-14,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,NERVIANO MEDICAL SCIENCES SRL,"A Phase I/II Combination Study of NMS-03592088 And Azacitidine for the Treatment of Patients With FLT3-Mutated AML with Relapsed /Refractory Disease or Who Are Unfit For Intensive Chemotherapy, or of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005013-14,0,0,0 2021-005020-38,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Grünenthal GmbH,"A randomized, double-blind, placebo-controlled, Phase III trial to evaluate the efficacy and safety of a single intra-articular injection of RTX-GRT7039 in adult subjects with pain associated with ost...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005020-38,0,0,0 2021-005022-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Icahn School of Medicine at Mount Sinai,Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG Antikoagulation bei neu auftretendem postoperativem Vorhofflimmern nach CABG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005022-18,0,0,0 2021-005024-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,Evaluation of [18F]MC225 to measure P-glycoprotein function in neurodegenerative disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005024-37,0,0,0 2021-005026-20,4,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,"ModernaTX, Inc.","A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults ≥ 60 Years of...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005026-20,0,0,0 2021-005029-26,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Grünenthal GmbH,"A randomized, double-blind, placebo-controlled, Phase III trial to evaluate the efficacy and safety of intra-articular injections of RTX-GRT7039 in adult subjects with pain associated with osteoarthri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005029-26,0,0,0 2021-005032-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Attgeno AB,"An open-label, multicenter study to evaluate the DOSE, efficacy, safety and tolerability of PDNO (Nitrosooxypropanol) infusion in patients with pulmonary hypertension after cardiopulmonary bypass (CPB...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005032-30,0,0,0 2021-005033-16,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Astex Pharmaceuticals, Inc.","Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects with Wild-Type TP53 Advanced Solid Tumors Estudio abierto en fase I/II de la seguridad, l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005033-16,0,0,0 2021-005034-42,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc","A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizuma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005034-42,0,0,0 2021-005034-42,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizuma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005034-42,0,0,0 2021-005034-42,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LCC,"A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizuma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005034-42,0,0,0 2021-005034-42,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizuma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005034-42,0,0,0 2021-005034-42,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,"A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizuma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005034-42,0,0,0 2021-005034-42,12,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc","A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizuma...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005034-42,0,0,0 2021-005037-16,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A randomised, double-blind, parallel group Phase III study to assess the efficacy and safety of 100 mg SC depemokimab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) – ANCHOR-1 (dep...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005037-16,0,0,0 2021-005043-71,4,,,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,University Medical Center Utrecht,"A Phase 2, Comparative Randomised Trial to Evaluate the impact of reduced COVID-19 mRNA vaccination regimen on immunological responses and reactogenicity in paediatric subjects withprior SARS-CoV-2 im...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005043-71,0,0,0 2021-005046-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Grünenthal GmbH,"A single-arm, open-label, Phase III trial to evaluate the safety and tolerability of intra-articular injections of RTX-GRT7039 in subjects with moderate to severe pain associated with osteoarthritis o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005046-15,0,0,0 2021-005051-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Amsterdam University Medical Centre,The Dutch neutralizing monoclonal antibody cohort against COVID-19: a cohort study for the evaluation of the use of neutralizing monoclonal SARS-CoV-2 antibodies Het nederlandse neutraliserende an...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005051-37,0,0,0 2021-005055-36,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A randomised, double-blind, parallel group Phase III study to assess the efficacy and safety of 100 mg SC depemokimab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) – ANCHOR-2 (de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005055-36,0,0,0 2021-005055-36,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT,"A randomised, double-blind, parallel group Phase III study to assess the efficacy and safety of 100 mg SC depemokimab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) – ANCHOR-2 (de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005055-36,0,0,0 2021-005055-36,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"GlaxoSmithKline, S.A.","A randomised, double-blind, parallel group Phase III study to assess the efficacy and safety of 100 mg SC depemokimab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) – ANCHOR-2 (de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005055-36,0,0,0 2021-005058-27,1,,,0,0,1,0,0,1,3,0,0,4,0,0,0,0,1,BioMarin Pharmaceutical Inc.,A Phase 3 Multi-Center Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase in Adolescent Subjects (Ages 12-17) with Phenylketonuria Featuring an Open-Label Randomized Tw...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005058-27,0,0,0 2021-005059-35,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F4Pharma GmbH i.G.,"Potential of FX06 to prevent disease progression in hospitalised non-intubated COVID-19 patients (Ixion) Potenzial von FX06 eine Verschlechterung von COVID-19 bei hospitalisierten, nicht intubierte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005059-35,0,0,0 2021-005059-35,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F4 PHARMA Gmbh,"Potential of FX06 to prevent disease progression in hospitalised non-intubated COVID-19 patients (Ixion) Potenzial von FX06 eine Verschlechterung von COVID-19 bei hospitalisierten, nicht intubierte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005059-35,0,0,0 2021-005059-35,5,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,F4Pharma GmbH,"Potential of FX06 to prevent disease progression in hospitalised non-intubated COVID-19 patients (Ixion) Potenzial von FX06 eine Verschlechterung von COVID-19 bei hospitalisierten, nicht intubierte...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005059-35,0,0,0 2021-005064-22,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NewAmsterdam Pharma B.V.,"Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROOKLYN): A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participan...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005064-22,0,0,0 2021-005065-40,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NewAmsterdam Pharma BV,"Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY): A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants W...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005065-40,0,0,0 2021-005067-52,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Aalborg University Hospital, Department of Oncology",A randomized phase II study of gemcitabine versus reduced-dose combination chemotherapy in fragile patients with non-resectable pancreatic cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005067-52,0,0,0 2021-005071-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Alvotech Swiss AG,"A Randomized, Double-Blind, Parallel Design, Repeat Dose, 2-arm, Multicenter Study Comparing the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profiles of AVT03 and US-Prolia® in Postmenopausa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005071-40,0,0,0 2021-005078-25,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,CHU de Bordeaux,"Phase III randomized, multicenter open label study to evaluate the efficacy of immunomodulatory therapy in case of psychiatric disorders with proven dysimmunity.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005078-25,0,0,0 2021-005092-39,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NewAmsterdam Pharma BV,"Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double- Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005092-39,0,0,0 2021-005092-39,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,NewAmsterdam Pharma B.V.,"Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double- Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular D...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005092-39,0,0,0 2021-005094-28,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"Medical University of Vienna, Department for Internal Medicine III, Division of Rheumatology","Population-based prospective, clinical study on efficacy and safety of a booster COVID-19 vaccination Eine Populations-basierte prospektive klinische Studie zur Effektivität und Sicherheit der Covi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005094-28,0,0,0 2021-005097-25,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,Universitätskinderspital beider Basel (UKBB),A randomised placebo-controlled multi-centre effectiveness trial of adjunct betamethasone therapy in hospitalised children with community acquired pneumonia (CAP) Eine randomisierte kontrollierte ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005097-25,0,0,0 2021-005105-27,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"AlloVir, Inc.","Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005105-27,0,0,0 2021-005110-34,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"ImCheck Therapeutics, Inc.","A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advanced s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005110-34,0,0,0 2021-005115-32,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"GlaxoSmithKline, S.A.","A Phase 2, Randomized, Open-label Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated Locally Advanced/Metastatic Programm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005115-32,0,0,0 2021-005115-32,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A Phase 2, Randomized, Open-label Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated Locally Advanced/Metastatic Programm...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005115-32,0,0,0 2021-005116-64,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Aarhus University Hospital, Department of Anesthesiology","Low-dose ketamine as an adjunct to morphine for acute pain in the ED: a randomized, double-blinded, superiority trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005116-64,0,0,0 2021-005121-24,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novo Nordisk A/S,Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants withoverweight or obesityand type 2 diabetes A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005121-24,0,0,0 2021-005124-38,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,DARYD,Conditioned Autologous Serum Therapy (Orthokine) on the dorsal root ganglion in patients with chronic radiculalgia (RADISAC) Terapia con Suero Autólogo Condicionado (Orthokine) sobre el ganglio de ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005124-38,0,0,0 2021-005132-33,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,JANSSEN CILAG INTERNATIONAL NV,"A Phase 2 Open-label Trial to Evaluate Safety, Efficacy, Tolerability, and Pharmacodynamics of a Combination of JNJ-73763989, Nucleos(t)ide Analogs, and a PD-1 inhibitor in Chronic Hepatitis B Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005132-33,0,0,0 2021-005132-33,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2 Open-label Trial to Evaluate Safety, Efficacy, Tolerability, and Pharmacodynamics of a Combination of JNJ-73763989, Nucleos(t)ide Analogs, and a PD-1 inhibitor in Chronic Hepatitis B Patient...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005132-33,0,0,0 2021-005135-23,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.",Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy follow...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005135-23,0,0,0 2021-005135-23,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LLC,Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy follow...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005135-23,0,0,0 2021-005135-23,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.,Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy follow...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005135-23,0,0,0 2021-005135-23,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy follow...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005135-23,0,0,0 2021-005167-51,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Celgene Corporation,"An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005167-51,0,0,0 2021-005170-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Genetic S.p.A.,PHASE III MULTICENTER RANDOMIZED TRIAL OF PRESERVATIVE FREE LATANOPROST 50µG/ML VS XALATAN IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION Studio multicentrico randomizzato di confronto...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005170-25,0,0,0 2021-005171-40,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Boehringer Ingelheim España, S.A.","Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005171-40,0,0,0 2021-005171-40,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer-Ingelheim RCV GmbH & Co KG,"Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005171-40,0,0,0 2021-005171-40,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BOEHRINGER-INGELHEIM ITALIA S.P.A.,"Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005171-40,0,0,0 2021-005171-40,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim bv Netherlands,"Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005171-40,0,0,0 2021-005171-40,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim Pharma GmbH & Co. KG - Clinical Research Germany,"Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005171-40,0,0,0 2021-005171-40,6,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Boehringer Ingelheim B. V.,"Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005171-40,0,0,0 2021-005173-95,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Oculis SA,"A Phase 2/3 Double-Masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005173-95,0,0,0 2021-005178-25,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,GlaxoSmithKline Biologicals SA,"A Phase 1/2a, observer-blind, randomized, controlled, two-stage, multi-country study to evaluate the safety, reactogenicity, and immune response of the trivalent vaccine against invasive nontyphoidal ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005178-25,0,0,0 2021-005184-42,4,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,NOVARTIS PHARMA AG,A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005184-42,0,0,0 2021-005184-42,4,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Novartis Pharma AG,A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005184-42,0,0,0 2021-005184-42,4,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.",A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005184-42,0,0,0 2021-005185-18,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Hepion Pharmaceuticals, Inc.","ASCEND-NASH: A PHASE 2B, RANDOMIZED, MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRV431 IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS AND ADVANCED...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005185-18,0,0,0 2021-005192-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Groningen,Programmed death ligand 1 (PD-L1) PET imaging in patients with (Diffuse) Large B-cell lymphoma who are treated with CD19-directed CAR T-cell therapy Programmed death ligand (PD-L1) PET-beeldvorming...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005192-39,0,0,0 2021-005194-77,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,University of Antwerp,The optimal timing of vaccination in pregnancy: a multi-dimensional mechanistic approach to measure immune responses in pregnant women,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005194-77,0,0,0 2021-005197-25,1,,,0,0,1,0,1,0,3,0,1,0,0,0,0,0,1,BioNTech SE,A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162b2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162b2 Ein Phase-III-Gesamtprüfplan zur Beurteilung einer zusätzlichen Dosis...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005197-25,0,0,0 2021-005200-35,7,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,Denali Therapeutics Inc.,"A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysacc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005200-35,0,0,0 2021-005201-27,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005201-27,0,0,0 2021-005202-98,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Nipocalimab in Participants with Active Idiopathic Inflammatory Myopat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005202-98,0,0,0 2021-005206-10,6,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Prometheus Biosciences, Inc.","A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005206-10,0,0,0 2021-005217-14,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Dicerna Pharmaceuticals, Inc.",A Phase 2 Open-Label Extension Study to Evaluate the Safety and Pharmacodynamics of Belcesiran in Patients with PiZZ Alpha-1 Antitrypsin Deficiency Associated Liver Disease Estudio de prolongación ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005217-14,0,0,0 2021-005221-24,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005221-24,0,0,0 2021-005223-21,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-l...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005223-21,0,0,0 2021-005226-26,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,HIPRA SCIENTIFIC,"A Phase IIb, double-blind, randomized, active controlled, multi-centre, non-inferiority trial followed by a Phase III, single arm, open label trial, to assess immunogenicity and safety of a booster va...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005226-26,0,0,0 2021-005229-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Miguel Angel Pavón Ribas,"A Non-Randomized, Open-Label Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV16/18-Positive Women Before and After Vaccination with 9vHPV, a Multiv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005229-26,0,0,0 2021-005231-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients with BRCA Mutations and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005231-22,0,0,0 2021-005238-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"EQRx, Inc.",A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants with Advanced Breast Cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005238-40,0,0,0 2021-005239-22,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Biohaven Pharmaceuticals Holding Company Limited,"A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention with Multiple Dosing Regimens",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005239-22,0,0,0 2021-005246-15,2,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,1,Biohaven Pharmaceuticals Holding Company Limited,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 years of age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005246-15,0,0,0 2021-005247-78,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Oxygen Biotech s.r.o.,"A 2-Part, Open-label, Non-randomized (Part A) and Randomized, Double-blinded, Placebo-controlled (Part B) multicentric, international study with adaptive design to evaluate safety and tolerability of ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005247-78,0,0,0 2021-005273-47,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Eli Lilly and Company,Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease using M...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005273-47,0,0,0 2021-005314-34,5,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"Scholar Rock, Inc.","Phase 3, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Apitegromab (SRK-015) in Patients with Later-Onset Spinal Muscular Atrophy Receiving Background Nusinersen or Ris...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005314-34,0,0,0 2021-005319-30,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,GlaxoSmithKline Biologicals,"A phase 3b, open-label, multi-country, multi-centre, long-term follow-up study of ZOSTER-049 (follow-up of ZOSTER-006/022 studies) to assess the prophylactic efficacy, safety and persistence of immune...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005319-30,0,0,0 2021-005320-38,12,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3 Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of ELX/TEZ/IVA in Cystic Fibrosis Subjects 6 Years of Age and Older With a Non-F508del ELX/TEZ/IVA-respo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005320-38,0,0,0 2021-005320-38,12,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,VERTEX PHARMACEUTICALS INCORPORATED,"A Phase 3 Double-blind, Randomized, Placebo-controlled Study Evaluating the Efficacy and Safety of ELX/TEZ/IVA in Cystic Fibrosis Subjects 6 Years of Age and Older With a Non-F508del ELX/TEZ/IVA-respo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005320-38,0,0,0 2021-005327-20,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Rigshospitalet,TEMPLE - Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005327-20,0,0,0 2021-005331-23,2,,,0,0,0,0,0,1,2,0,0,2,1,0,0,0,1,"Radius Pharmaceuticals, Inc.","A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients with Prader-Willi Syndrome En randomiserad, dubbelblind, placebo-...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005331-23,0,0,0 2021-005332-27,5,,,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A PHASE Ib, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB IN PEDIATRIC PATIENTS HOSPITALIZED WITH COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005332-27,0,0,0 2021-005332-27,5,,,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A PHASE Ib, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF TOCILIZUMAB IN PEDIATRIC PATIENTS HOSPITALIZED WITH COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005332-27,0,0,0 2021-005339-22,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,Instytut Matki i Dziecka,To evaluate the efficacy and safety of regorafenib in patients with refractory primary bone tumors. Ocena skuteczności i bezpieczeństwa zastosowania regorafenibu u pacjentów z opornymi na leczenie ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005339-22,0,0,0 2021-005344-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Amsterdam UMC, location VUmc",TETRA-pilot: Testosterone in transgender women after vaginoplasty: a dose-finding and feasibility pilot study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005344-30,0,0,0 2021-005347-79,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud University Medical Center,"The influence of having bariatric surgery on the pharmacokinetics, safety and efficacy of the novel non-nucleoside reverse transcriptase inhibitor doravirine (LABRADOR) De invloed van bariatrische...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005347-79,0,0,0 2021-005353-82,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Sanofi-Aventis S.A,Prospective study to assess with Continuous Glucose Monitoring (CGM) the efficacy and safety of switching to insulin glargine 300 U/ml from insulin glargine 100 U/ml in Type 2 Diabetes (T2DM) patients...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005353-82,0,0,0 2021-005356-10,4,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,IntraBio Ltd,"Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005356-10,0,0,0 2021-005358-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Pontificia Universidad Católica de Chile,"Hemodynamic Phenotype-Based, Capillary Refill Time-Targeted Resuscitation In Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial (A2) Reanimación del Shock Séptico precoz basada en ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005358-28,0,0,0 2021-005362-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hannover Medical School,Hepatitis B immunoglobulins to induce HBsAg clearance in patients with chronic hepatitis B,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005362-18,0,0,0 2021-005364-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Spanish Oncology Genitourinary Group (SOGUG),Phase II non randomized clinical trial of NIVOLUMAB/IPILIMUMAB maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer. Ensayo clínico de fase...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005364-22,0,0,0 2021-005366-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Uniwersytet Medyczny w Białymstoku,Evaluation of metformin effect on the fertility of women treated with 131I for thyroid cancer Ocena wpływu metforminy na płodność pacjentek leczonych 131lz powodu raka brodawkowego tarczycy 2020/AB...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005366-17,0,0,0 2021-005373-51,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Leiden University Medical Center,Reversal of opioid-induced respiratory depression with opioid antagonists - a study in opioid naïve individuals and chronic opioid users under real-life conditions,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005373-51,0,0,0 2021-005374-26,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,OMEQUI coordinator,Efficacy of platelet- and leukocyte-rich fibrin (L-PRF) in reducing healing time in sinus lift combined with deproteinized bovine mineralized bone (DBBM): randomized clinical trial. Eficacia de la ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005374-26,0,0,0 2021-005382-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Dr. Reddy's Laboratories Ltd.,"A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005382-40,0,0,0 2021-005387-22,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Acadia Pharmaceuticals Inc.,"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder Estudio ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005387-22,0,0,0 2021-005388-32,3,,,0,0,0,0,0,0,2,0,0,3,0,0,0,0,1,Acadia Pharmaceuticals Inc.,"A 52-Week Open-Label Extension Study of Pimavanserin in Children and Adolescents with Irritability Associated with Autism Spectrum Disorder (ASD) A pimavanszerin 52 hetes, nyílt, kiterjesztett vizs...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005388-32,0,0,0 2021-005392-39,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,GlaxoSmithKline Research and Development Ltd.,OPAL Master Protocol: A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of Treatments in Participants with Ovarian Cancer (OPAL) (PR-3...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005392-39,0,0,0 2021-005392-39,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"GlaxoSmithKline, S.A.",OPAL Master Protocol: A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments and/or Combinations of Treatments in Participants with Ovarian Cancer (OPAL) (PR-3...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005392-39,0,0,0 2021-005394-66,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AZIENDA OSPEDALIERA UNIVERSITARIA SENESE,Effects of Dapagliflozin on cardiac deformation and clinical outcomes in heart failure with reduced and mildly reduced ejection fraction Effetti del Dapagliflozin sulla deformazione cardiaca e sugl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005394-66,0,0,0 2021-005399-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Innovacell AG,"Skeletal muscle-derived cell implantation for the treatment of fecal incontinence: a single arm, open label, interventional, follow-up study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005399-21,0,0,0 2021-005401-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Hospital of Clermont-Ferrand,Effects of the combination of magnesium bisphosphonates versus bisphosphonates alone on bone remodeling: Randomized pilot clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005401-28,0,0,0 2021-005402-10,3,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Sanofi-aventis recherche & développement,"A phase 3, multicenter, multinational, randomized, double-blind, double-dummy, active-comparator study to evaluate the efficacy and safety of venglustat in adult and pediatric patients with Gaucher di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005402-10,0,0,0 2021-005404-36,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Shire,"A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Japanese Pediatric Subjects with Short Bowel Syndrome Who Completed SHP633-302",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005404-36,0,1,1 2021-005406-96,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,AB Science,"A 24-week, multicenter, randomized, double blind, placebo-controlled, dose-range finding phase II study to compare efficacy and safety of oral masitinib to placebo in treatment of patients with severe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005406-96,0,0,0 2021-005427-20,6,,,0,0,0,0,1,0,3,0,1,2,1,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY, AND LOT CONSISTENCY OF A 6 VALENT OspA-BASED LYME DISEASE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005427-20,0,0,0 2021-005427-20,6,,,0,0,0,0,1,0,3,0,1,2,1,0,0,0,1,Pfizer Inc.,"A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY, AND LOT CONSISTENCY OF A 6 VALENT OspA-BASED LYME DISEASE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005427-20,0,0,0 2021-005429-26,1,2022-03-25,2022-03-25,1,0,0,0,0,0,2,0,1,1,0,0,0,0,0,Centre for Human Drug Research,Immunological characterization of TLR-7 mediated inflammation and complement activation after prolonged Imiquimod exposure in healthy volunteers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005429-26,0,0,0 2021-005431-23,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MiNA Alpha Limited,"AN OPEN LABEL, RANDOMISED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MTL-CEBPA ADMINISTERED IN COMBINATION WITH SORAFENIB OR SORAFENIB ALONE, IN TKI NAÏVE PARTICIPANTS WITH PREVIOUSLY TREAT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005431-23,0,0,0 2021-005441-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Linköping University,"DIAGNODE-B, A Phase I/II Open Label Pilot Study to evaluate the safety and feasibility of an additional intralymphatic booster administration of GAD-alum (Diamyd®) in individuals with Type 1 diabetes",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005441-32,0,0,0 2021-005446-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Groningen,A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Severe Chronic Kidney Disease Een placebo gecontroleerde studie om...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005446-15,0,0,0 2021-005452-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medizinische Universität Innsbruck,Influence of the PECS II block on postoperative pain and opioid demand in patients undergoing minimal invasive cardiac surgery Einfluss des PECS II Blocks auf postoperative Schmerzen und den postop...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005452-11,0,0,0 2021-005455-37,2,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,Astellas Pharma Global Development Inc.,"A Phase 3, Open Label, Multicenter, Baseline-Controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron Prol...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005455-37,0,0,0 2021-005457-85,5,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Multicentre, Single-arm, Phase 3b Efficacy and Safety Study of Tezepelumab 210 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Participants with Severe Asthma on High-dose ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005457-85,0,0,0 2021-005458-27,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.","A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005458-27,0,0,0 2021-005458-27,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.","A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005458-27,0,0,0 2021-005473-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Hellenic Institute for the Study of Sepsis,BEZLOTOXUMAB YIELDED OUTCOMES BY ADDRESSING PERSONALIZED NEEDS IN CLOSTRIDIOIDES DIFFICILE INFECTION: THE BEYOND DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL Η ΑΠΟΤΕΛΕΣΜΑΤΙΚΟΤΗΤΑ ΤΗΣ ΜΠΕΖΛΟΤΟΞΟΥΜΑΜΠΗΣ ΣΤ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005473-10,0,0,0 2021-005478-24,1,,,0,0,0,1,0,1,1,0,0,4,0,0,0,0,1,"Dyne Therapeutics, Inc","A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participants ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005478-24,0,0,0 2021-005481-18,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,BioNTech SE,"First-in-human, open-label, multicenter, Phase I/IIa, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005481-18,0,0,0 2021-005483-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Akershus University Hospital,Chiropractic spinal manipulative therapy for acute neck pain: a 4-armed clinical placebo randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005483-21,0,0,0 2021-005484-53,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase IIb/III Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis with Fibrosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005484-53,0,0,0 2021-005486-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE,Phase IIa multicenter clinical trial to determine the feasibility and safety of the use of adipose-derived mesenchymal stem cells (ASC) in the treatment of patients with cicatricial conjunctivitis ass...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005486-40,0,0,0 2021-005487-22,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,iTeos Belgium SA,"A randomized, double-blind, placebo-controlled, Phase 2 study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with nonsquamous non-small cell lun...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005487-22,0,0,0 2021-005490-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hospital Universitario Son Llàtzer,EFFECTIVENESS OF TREATMENT WITH ANTISEPTICS VERSUS TOPICAL ANTIBIOTICS IN MILD IMPETIGO IN PEDIATRIC PATIENTS EFECTIVIDAD DEL TRATAMIENTO CON ANTISÉPTICOS FRENTE A ANTIBIÓTICOS TÓPICOS EN EL IMPÉTI...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005490-30,0,0,0 2021-005493-25,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,Fakultní nemocnice Brno,Effect of Prophylactic Fibrinogen Concentrate In Scoliosis Surgery: A randomized pilot study (EFISS trial) Vliv profylaktického podání fibrinogenu u operací skoliózy: Randomizovaná pilotní studie (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005493-25,0,0,0 2021-005495-19,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,University Hospital Schleswig-Holstein,A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005495-19,0,0,0 2021-005499-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Research Maatschap Cardiologen Rotterdam Zuid,COMPARE STEMI ONE- Comparison Of reduced DAPT followed by P2Y12 inhibitor Monotherapy with Prasugrel vs stAndard Regimen in STEMI patients treated with OCT-guided vs aNgio-guided completE revasculari...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005499-20,0,0,0 2021-005501-27,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Rigshospitalet,64Cu-DOTATATE PET/CT-skanning to diagnose macrophage infiltation in the heart valves of patients with infectiv endocarditis. 64Cu-DOTATATE PET/CT-skanning til diagnostik af makrofag infiltration af...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005501-27,0,0,0 2021-005504-36,2,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Bavarian Nordic A/S,"Covid-19: Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts—Randomized...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005504-36,0,0,0 2021-005509-28,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Akston Biosciences Corporation,Anti-COVID19 VaccinaTion AKS-452X BOOSTER Study (ACT-BOOSTER study) Anti-COVID19 VaccinaTie AKS-452X BOOSTER Studie (ACT-BOOSTER studie),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005509-28,0,0,0 2021-005511-32,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Xeolas Pharmaceuticals Ltd.,"A Randomized Control Trial Phase (IIIa) Unicentric, Placebo Controlled, Double-Blinded Study to confirm the Efficacy and Safety of “Effects of topical Alendronic Acid on alveolar bone remodeling after...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005511-32,0,0,0 2021-005528-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkum...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005528-39,0,0,0 2021-005529-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"ASAC Pharmaceutical Inmunology, S.A.",In vivo Biological Standardization of Gramineae Allergenic Extracts Estandarización Biológica “in vivo” de Extracto Alergénico Gramíneas,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005529-25,0,0,0 2021-005530-42,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Institute of Molecular Medicine and Biomedical Research (IMBE),The impact of Thromboprophylaxis on Progression Free Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer & Tinzaparin Prospective (imPaCT-PRO) study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005530-42,0,0,0 2021-005546-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Gileas Science,"Simplified model of linkage & retention to care, using a mobile unit and a same-day test & treat approach among excluded population. The SIMPLIFIED Study Modelo simplificado de acceso y retención a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005546-15,0,0,0 2021-005550-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amsterdam UMC,Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005550-28,0,0,0 2021-005551-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock from Acute Myocardial Infarction: A Multicenter Randomized Tr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005551-36,0,0,0 2021-005552-11,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Genzyme Corporation,A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005552-11,0,1,1 2021-005564-21,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Leiden University Medical Center,Five-year boostability after single-visit single-dose intramuscular rabies pre-exposure prophylaxis. Anamnestische antistofrespons vijf jaar na een enkele rabiesvaccinatie als pre-exposure profylax...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005564-21,0,0,0 2021-005568-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Bethesda Diabetes Research Center,Bouncing Metformin Intervention (BMI) Study: a long term randomized controlled trial to cure early type 2 diabetes. Bouncing Metformine Interventie (BMI) Studie: gerandomiseerd en gecontro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005568-23,0,0,0 2021-005569-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Pfizer Inc.,"LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005569-42,0,0,0 2021-005571-39,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,"Inselspital, Bern University Hospital",High Dose Steroids in Children with Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial Hochdosierte Steroide bei Kindern mit Schlaganfall und einseitiger fokaler A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005571-39,0,0,0 2021-005571-39,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,0,"Inselspital, Children's University Hosptial, Dicision of Pediatric Neurology, Development and Rehabilitation",High Dose Steroids in Children with Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial Hochdosierte Steroide bei Kindern mit Schlaganfall und einseitiger fokaler A...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005571-39,0,0,0 2021-005573-12,2,,,0,0,1,0,2,0,2,0,0,0,0,0,0,0,1,LEO Pharma A/S,"A single (assessor) blinded, randomised, parallel-group, monotherapy trial to evaluate the pharmacokinetic and safety of tralokinumab in children (age 2 to <12 years) with moderate-to-severe atopic de...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005573-12,0,0,0 2021-005578-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR),Therapheutic optimization of omalizumab in allergic severe asthma patients by dose and frequency of administration adjustment Optimización terapéutica de omalizumab en pacientes con asma alérgica g...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005578-24,0,0,0 2021-005579-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Aarhus University Hospital, Department of Endocrinology","Cabergoline as a Preventive Treatment for Chronic Migraine: an Investigator-Initiated, Randomized Clinical Trial Cabergolin som forebyggende behandling af kronisk migræne: et investigator-initieret...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005579-38,0,0,0 2021-005586-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Radboudumc,Colchicine and Inflammation in Aortic Stenosis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005586-40,0,0,0 2021-005596-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MAPS Europe B.V.,Long-Term Safety and Persistence of Effectiveness of Manualized MDMA Assisted Therapy for the Treatment of Posttraumatic Stress Disorder Dlouhodobé sledování bezpečnosti a persistence MDMA-asistova...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005596-39,0,0,0 2021-005602-10,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Verein zur Förderung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und vaskulären Biologie (ATVB)",POESIA Study: Pleiotropic effects of PCSK 9 inhibition and bempedoic acid - Changes in Platelet Function and Inflammation Markers,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005602-10,0,0,0 2021-005604-35,1,,,0,0,1,0,0,0,2,0,0,4,0,0,0,0,0,National Cancer Institute (NCI),NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005604-35,0,1,1 2021-005607-13,10,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Novo Nordisk A/S,A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with sho...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005607-13,0,0,0 2021-005609-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Dr. Alfons Segarra Medrano,A PILOT PROOF-OF–CONCEPT STUDY TO ASSESS THE EFFICACY AND SAFETY OF A 6 MONTHS RAVULIZUMAB TREATMENT IN PATIENTS WITH FLARES OF CORTICOSTEROID-RESISTANT IDIOPATHIC IgA NEPHROPATHY ESTUDIO PILOTO DE...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005609-28,0,0,0 2021-005610-33,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"ImaginAb, Inc.","iPREDICT Trial: A Phase IIB, Open Label, Study of 89Zr-Df-Crefmirlimab PET/CT in Subjects with Selected Advanced or Metastatic Malignancies including Melanoma, Merkel Cell, Renal Cell and Non-Small Ce...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005610-33,0,0,0 2021-005611-31,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Corcept Therapeutics Incorporated,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients with Amyotrophic Lateral Sclerosis (DAZALS)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005611-31,0,0,0 2021-005614-34,1,,,0,0,0,1,0,0,1,0,0,4,0,0,0,0,1,Helsinn Healthcare SA,"A Phase 1b/2, Multicenter, Open-Label Study of Oral Infigratinib in Pediatric Subjects with Advanced Solid and Central Nervous System (CNS) Tumors (Phase 1b) and in Subjects with Recurrent or progress...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005614-34,0,0,0 2021-005617-14,2,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,Novartis Pharma AG,Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005617-14,0,0,0 2021-005617-14,2,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,"Novartis Farmacéutica, S.A.",Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005617-14,0,0,0 2021-005627-21,1,,,0,0,1,0,0,0,3,0,0,0,0,0,0,0,0,APHP,3-day intravenous antibiotic treatment versus 3-day intravenous followed by 7-day oral antibiotic treatment for acute pyelonephritis in children 1 month to 3 years old: a non-inferiority open randomiz...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005627-21,0,0,0 2021-005646-15,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,BioInvent International AB,"Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors - CONTRAS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005646-15,0,0,0 2021-005648-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Turun Yliopistollinen keskussairaala,Vastasyntyneen aivojen kontrastiultraääni- ja elastografiatutkimus Vastasyntyneen aivojen kontrastiultraääni- ja elastografiatutkimus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005648-31,0,0,0 2021-005687-22,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren’s syndrome (NEPTUNUS-2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005687-22,0,0,0 2021-005687-22,7,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren’s syndrome (NEPTUNUS-2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005687-22,0,0,0 2021-005688-36,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Amsterdam UMC,"Quinidine versus verapamil in short-coupled idiopathic ventricular fibrillation: An open label, randomized crossover pilot trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005688-36,0,0,0 2021-005692-39,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults with Hypereosinophilic Syndrome (HES) Un estudio aleatorizado, doble ciego y con...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005692-39,0,0,0 2021-005713-13,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"ACELYRIN, Inc.",A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005713-13,0,0,0 2021-005713-13,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"ACELYRIN, INC.",A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005713-13,0,0,0 2021-005719-29,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Ipsen Pharma SAS,"An open-label, multicentre, single arm study to assess the efficacy and safety of triptorelin 6-month formulation administered subcutaneously in participants with locally advanced and/or metastatic pr...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005719-29,0,0,0 2021-005724-38,2,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Telios Pharma, Inc.","An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with Ruxolitinib in Janus associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005724-38,0,0,0 2021-005725-24,4,,,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005725-24,0,0,0 2021-005726-15,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,GlaxoSmithKline Research & Development Limited,"A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with re...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005726-15,0,0,0 2021-005729-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Vestre Viken Health Trust,"A Randomized Phase II, Open-label, Multicenter Study Investigating Efficacy and Safety of Pembrolizumab +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic n...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005729-25,0,0,0 2021-005731-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis,"Pembrolizumab for locally advanced, irresectable, non-metastatic dMMR colorectal cancers. The PUMA study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005731-23,0,0,0 2021-005733-16,1,,,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,Denali Therapeutics Inc.,"A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Hea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005733-16,0,0,0 2021-005741-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,UCLouvain,Plasma pharmacokinetics of temocillin in urinary tract infection patients with variable degrees of renal impairment,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005741-32,0,0,0 2021-005742-14,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Gilead Sciences, Inc.","A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inop...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005742-14,0,0,0 2021-005743-79,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Gilead Sciences, Inc.","A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negativ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005743-79,0,0,0 2021-005744-29,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Genmab A/S,"A RANDOMIZED, OPEN-LABEL, MULTICENTER, GLOBAL, PHASE 2 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF EPCORITAMAB (GEN3013; DUOBODY®-CD3×CD20) AS MONOTHERAPY OR IN COMBINATION WITH LENALIDOMIDE AS FIRST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005744-29,0,0,0 2021-005746-15,15,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005746-15,0,0,0 2021-005746-15,15,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,F. HOFFMANN - LA ROCHE LTD.,"A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005746-15,0,0,0 2021-005746-15,15,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005746-15,0,0,0 2021-005772-19,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A three-year, open-label extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability in patients with active lupus nephritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005772-19,0,0,0 2021-005772-19,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A three-year, open-label extension study of subcutaneous secukinumab to evaluate the long-term efficacy, safety and tolerability in patients with active lupus nephritis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005772-19,0,0,0 2021-005774-25,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SOTIO Biotech AG,"A phase 2, open-label, single-arm, multicenter study of SOT101 in combination with pembrolizumab to evaluate the efficacy and safety in patients with selected advanced/refractory solid tumors II....",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005774-25,0,0,0 2021-005775-39,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Incyte Biosciences International Sarl,"A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TIM-3) as First-Line Treatment in Participants With PD-L1–Posi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005775-39,0,0,0 2021-005788-34,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,St. Antonius Hospital,Platelet inhibition versus direct oral anticoagulation in patients undergoing percutaneous closure of patent foramen ovale or atrial septal defect Plaatjes inhibitie versus directe orale anticoagul...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005788-34,0,0,0 2021-005790-60,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Panbela Therapeutics, Inc","A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With Or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma Estud...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005790-60,0,0,0 2021-005850-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital,An open label phase II trial in hormone receptor positive breast cancer patients randomized to neoadjuvant chamotherapy with or without bevacizumab (if ViRP signature positive) followed by endocrine t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005850-27,0,0,0 2021-005856-12,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Helsinki University Central Hospital,Monoclonal gammopathies of renal significance (MGRS) in Finland,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005856-12,0,0,0 2021-005861-41,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc","A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination with R-CHP in Participants with DLBCL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005861-41,0,0,0 2021-005873-25,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,SOTIO Biotech a.s.,A multicentric phase 1/2 trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care treatment in patients with gastric and pancreatic adenocarcinoma ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005873-25,0,0,0 2021-005874-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Juan Enrique Domínguez Muñoz,"Open label randomized, multicentre, controlled trial of pancreatic enzyme replacement therapy (PERT) for pancreatic exocrine insufficiency (PEI) in patients with unresectable pancreatic cancer Ensa...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005874-24,0,0,0 2021-005876-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,"Department of Cardiology, Copenhagen University Hospital, Rigshospitalet",The Danish Out-of-Hospital Cardiac Arrest study (DANOHCA) Det danske studie af hjertestop uden for hospital (DANOHCA),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005876-21,0,0,0 2021-005878-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Lilly, S.A.","A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults with Type 2 Diabet...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005878-25,0,0,0 2021-005879-40,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Daiichi Sankyo, Inc.","HERTHENA–Lung02: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005879-40,0,0,0 2021-005881-17,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,UNITED THERAPEUTICS CORPORATION,"A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis (TETON-2)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005881-17,0,0,0 2021-005886-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Aarhus University Hospital,Efficacy of Perioperative Long-acting Anesthesia by Local Infiltration Following Median Sternotomy - The PAIN Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005886-41,0,0,0 2021-005888-52,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Nimbus Lakshmi, Inc.","A Phase 2b, Randomized, Multi-center, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects with Active Psoriatic Arthritis...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005888-52,0,0,0 2021-005891-21,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Eli Lilly and Company,"A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults with Ty...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005891-21,0,0,0 2021-005892-38,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Eli Lilly and Company,"A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared with Insulin Degludec in Participants with Typ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005892-38,0,0,0 2021-005903-11,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,BioNTech SE,"A Phase 3, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of The Vaccine Candidate BNT162b2 Against COVID-19 in H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005903-11,0,1,1 2021-005906-83,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Lyra Therapeutics, Inc.","ENLIGHTEN 1: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults ENLIGHT...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005906-83,0,0,0 2021-005914-33,11,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,A Phase 3 Open-label Study Evaluating the Longterm Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects With Non-F508del CFTR Genotypes,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005914-33,0,0,0 2021-005919-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet",Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients with Neuroendocrine Neoplasms,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005919-30,0,0,0 2021-005922-82,1,,,0,0,0,0,1,0,2,0,0,3,0,0,0,0,0,"Prehospital Emergency Medical Services, Central Denmark Region",Intravenous vs. Intraosseous Vascular Access During Out-of-Hospital Cardiac Arrest - A Randomized Clinical Trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005922-82,0,0,0 2021-005927-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación SEIMC-GESIDA,"Phase IV, randomized, multicenter, double-blind clinical trial designed to evaluate the safety and convenience of switching from Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir alafenam...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005927-19,0,0,0 2021-005928-38,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,MoonLake Immunotherapeutics AG,"Phase 2, randomized, parallel-group, double-blind, placebo-controlled study of sonelokimab in patients with active moderate to severe hidradenitis suppurativa",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005928-38,0,0,0 2021-005930-40,1,,,0,0,1,0,0,1,3,0,0,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,"A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005930-40,0,0,0 2021-005932-50,3,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"BioCryst Pharmaceuticals, Inc.",A PHASE 3 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF BEROTRALSTAT PROPHYLAXIS IN CHILDREN WITH HEREDITARY ANGIOEDEMA WHO ARE 2 TO < 12 YEARS OF AGE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005932-50,0,0,0 2021-005948-29,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,2,UroGen Pharma Ltd.,"A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005948-29,0,0,0 2021-005949-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University of Cologne,"Prospective, single-arm trial of neoadjuvant nivolumab plus ipilimumab in patients with localized renal cell carcinoma who are at a high risk of relapse after radical nephrectomy (NEONIRenCa)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005949-33,0,0,0 2021-005987-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005987-23,0,0,0 2021-005992-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy, safety, tolerability, and pharmacokinetics of single subcutaneous MIJ821 injection in addition to standar...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005992-38,0,0,0 2021-005996-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Zealand University Hospital,Gene and protein expression profiles after treatment of actinic keratosis Gen- og proteinekspessionsprofiler efter behandling af aktiniske keratoser,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005996-37,0,0,0 2021-005999-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Instituto de Investigación Sanitaria Aragón,Effect of obesity on COX1 and 2 acetylation by aspirin as a biomarker of its efficacy in colon cancer chemoprevention and therapy. Efecto de la obesidad en la acetilación de la COX1 y 2 por aspirin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-005999-18,0,0,0 2021-006003-15,1,,,0,1,0,0,0,0,4,0,0,4,0,0,0,0,1,Eisai Korea Inc.,Post-Marketing Surveillance of Fycompa in Korean Patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006003-15,0,1,1 2021-006005-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Apogenix AG,"A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy of Asunercept for the Treatment of Hospitalized Patients with Moderate to Severe COVID-19 Disease ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006005-30,0,0,0 2021-006007-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center (LUMC),Januse kinase Inhibition with Filgotinib to Silence Autoreactive B cells in Rheumatoid Arthritis Het remmen van Janus kinases door filgotinib om B cellen gericht tegen gecitrullineerde eiwitten bij...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006007-15,0,0,0 2021-006013-11,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,"Erasmus MC, department of dermatology",Hyperbaric Oxygen Therapy for Pyoderma gangrenosum As a New Treatment Strategy Hyperbare Zuurstoftherapie voor pyoderma gangrenosum als nieuwe behandel mogelijkheid,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006013-11,0,0,0 2021-006015-29,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Mylan Pharmaceuticals Inc., a Viatris Company","A Multicenter, Open-Label, Randomized, Parallel Group, Interchangeability Study in Moderate to Severe Chronic Plaque Psoriasis evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity Between...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006015-29,0,0,0 2021-006028-41,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,Pomorski Uniwersytet Medyczny w Szczecinie,Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas- BERUBICIN Ocena bezpieczeństwa i skuteczności berubicyny w leczeniu chłoniaków ośrodkowego u...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006028-41,0,0,0 2021-006030-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Med. Univ. Wien, Klinik f. Innere Med I, Onkologie","EFFICACY OF POLATUZUMAB, BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MANTLE CELL LYMPHOMA – A SINGLE CENTER PHASE II TRIAL",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006030-40,0,0,0 2021-006031-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Charité - Universitätsmedizin Berlin,Treatment of patients with Lichen planus with the JAK-Inhibitor Upadacitinib (Rinvoq®) – a mono-centered double-blinded placebo controlled randomized pilot study (investigator-initiated trial) Beh...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006031-25,0,0,0 2021-006038-37,3,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Takeda Development Center Americas, Inc.","A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refract...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006038-37,0,0,0 2021-006040-27,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Cardior Pharmaceuticals GmbH,"Phase 2, Multicenter, Randomized, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction (≤ 45%) After Myocardia...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006040-27,0,0,0 2021-006042-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MEDITOP Gyógyszeripari Kft.,A randomized double blind placebo controlled multicenter study to assess the efficacy and tolerability of tolperisone as add on treatment with standardized NSAID of acute non specific low back pain. ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006042-13,0,0,0 2021-006044-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,IFCT,A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) after 6 months of platinum-based doublet chemotherapy plus pembr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006044-27,0,0,0 2021-006048-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AOU MATERDOMINI,"BotulInum toxin type A for peripheral Neuropathic pain in subjEcts with Carpal Tunnel syndrome: a multicenter, randomized, double-blind, placebo-controlled study Studio multicentrico, randomizzato,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006048-29,0,0,0 2021-006049-36,5,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Incyte Corporation,"A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006049-36,0,0,0 2021-006050-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oulun yliopisto,Vieritestauksen perusteella suunnattu kortisonihoito pienten lasten uloshengitysvaikeudessa,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006050-31,0,0,0 2021-006052-14,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Pfizer Inc.,"A randomized, 2-arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after undergoing autolog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006052-14,0,0,0 2021-006052-14,11,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,PFIZER INC,"A randomized, 2-arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after undergoing autolog...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006052-14,0,0,0 2021-006056-13,2,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,AstraZeneca AB,"Covid-19: Open-Label, Uncontrolled, Single dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of AZD7442 in Pediatric Participants Aged ≥ 29 weeks Gestational Age to < 18 years",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006056-13,0,0,0 2021-006068-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE,CLINICAL TRIAL PHASE IIa TO EVALUATE THE SAFETY AND EFFECTIVENESS OF TREATMENT WITH FAT-DERIVED MESENCHYMAL ALLOGENIC MESENCHYMAL TRONCAL CELLS IN PATIENTS WITH SINGLE INFLAMMATORY STENOSIS IN THE CON...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006068-26,0,0,0 2021-006069-39,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A Randomized, Double-Blind, Parallel-Group Clinical Trial to Assess the Efficacy of Essentiale on Hepatic Steatosis Added to Standard of Care Versus Placebo Added to Standard of Care, in Non-Alcoholic...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006069-39,0,0,0 2021-006072-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Amsterdam University Medical Center (AUMC),Dual-AntiPlatelet Therapy strategies FOR elective PCI in a REAL-world setting Dubbele antiplaatjes therapie strategieën voor electieve percutane coronair interventies,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006072-16,0,0,0 2021-006075-42,2,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,"Alexion Pharmaceuticals, Inc.","A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With A...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006075-42,0,0,0 2021-006108-34,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,AmsterdamUMC (location VUmc),Trial Examining Methods for Antidepressant Discontinuation Methoden om antidepressiva te stoppen vergeleken. De TEMPO-studie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006108-34,0,0,0 2021-006127-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Narodowy Instytut Kardiologii Stefana kardynała Wyszyńskiego- Państwowy Instytut Badawczy,Optimal Antiplatelet Treatment to Achieve Stroke Avoidance and Fall in Bleeding Events following Left Atrial Appendage Closure – Chronic Kidney Disease (SAFE LAAC CKD). Comparative Health Effectivenes...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006127-17,0,0,0 2021-006168-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Aarhus University Hospital, Department of Anesthesia(Bedøvelse og operation)",IMpact of Phenylephrine vs. norAdrenaline on systemic hemodynamics and Cerebral Tissue circulation and oxygenation in anesthetized brain tumor patients (IMPACT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006168-26,0,0,0 2021-006172-16,1,2022-10-04,2022-10-04,1,0,0,0,0,0,4,0,1,1,1,1,0,0,0,Medical University of Graz,Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies after COVID-19 Booster Vaccines – The CoVVacBoost Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006172-16,0,0,0 2021-006176-16,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Charité - Universitätsmedizin Berlin,Definition of neuroimaging and laboratory biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine (PREDICT),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006176-16,0,0,0 2021-006184-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Sparrow Pharmaceuticals, Inc.",SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome SPI-62 като лечение за адренокортикотропен хормон-зависим синдром на Кушинг,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006184-19,0,0,0 2021-006189-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboudumc,Trained immunity by dual-pathway inhibition (low-dose rivaroxaban and acetylsalicylic acid) in coronary artery disease,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006189-19,0,0,0 2021-006196-42,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","KontRASt-03: A Phase Ib/II, multicenter, open-label platform study of JDQ443 with select combinations in patients with advanced solid tumors harboring the KRAS G12C mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006196-42,0,0,0 2021-006196-42,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Novartis Pharma AG,"KontRASt-03: A Phase Ib/II, multicenter, open-label platform study of JDQ443 with select combinations in patients with advanced solid tumors harboring the KRAS G12C mutation",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006196-42,0,0,0 2021-006200-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Clairvoyant Therapeutics Inc.,"A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults with Alco...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006200-33,0,0,0 2021-006215-29,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,GlaxoSmithKline Biologicals SA,"A Phase I/II, observer-blind, randomised, placebo-controlled study to assess safety, immunogenicity and efficacy of GSK S. aureus candidate vaccine when administered to healthy adults (dose-escalation...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006215-29,0,0,0 2021-006219-28,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Medical University Innsbruck,"MR-Spectroscopy: Investigating neurochemical changes in brain metabolism in migraineurs before and after CGRPAntibody treatment – a randomized, controlled, open-label trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006219-28,0,0,0 2021-006220-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Hvidovre Hospital, Department of Gynecology",Double-blinded randomized placebo-controlled trial on tacrolimus in women with an euploid pregnancy loss and PCOS and/or thyroid autoimmunity Behandling med tacrolimus af kvinder med et euploidt gr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006220-40,0,0,0 2021-006223-18,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Poxel S.A.,A randomized open-label Phase 2a study to assess the pharmacokinetics and pharmacodynamic parameters of PXL770 after 12 weeks of treatment in male subjects with adrenomyeloneuropathy (AMN),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006223-18,0,0,0 2021-006226-49,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Novo Nordisk A/S,Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy (ATTR CM),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006226-49,0,0,0 2021-006227-17,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and i...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006227-17,0,0,0 2021-006229-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"FONDAZIONE IRCCS ""ISTITUTO NAZIONALE DEI TUMORI""","Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas. Studio pilota di fase II di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006229-23,0,0,0 2021-006255-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,F.Hoffmann-La Roche Ltd,"A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE PHARMACODYNAMICS, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF RO7204239 IN PARTICIPANTS WITH FAC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006255-34,0,0,0 2021-006276-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Cancer Trials Ireland,PaTcH Trial: A phase 2 study to explore primary and emerging resistance mechanisms in patients with metastatic refractory pancreatic cancer treated with trametinib and hydroxychloroquine.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006276-16,0,0,0 2021-006295-17,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,MedTrace Pharma,"A Phase 3, Multicenter, Open Label Study to Confirm the Diagnostic Potential of Intravenously Administered 15O- H2O to Identify Coronary Artery Disease During Pharmacological Stress and Resting Condit...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006295-17,0,0,0 2021-006326-48,3,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,F.Hoffmann-La Roche Ltd,"A PHASE I/II, OPEN-LABEL, SINGLE-ARM, TWO-PART TRIAL TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF GLOFITAMAB IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN PEDIATRIC AND Y...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006326-48,0,0,0 2021-006326-48,3,,,0,0,1,0,0,0,1,0,0,3,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE I/II, OPEN-LABEL, SINGLE-ARM, TWO-PART TRIAL TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF GLOFITAMAB IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN PEDIATRIC AND Y...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006326-48,0,0,0 2021-006329-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Incyte Corporation,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis Estudio en fase II, aleatorizado, doble c...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006329-23,0,0,0 2021-006333-19,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Amsterdam UMC,EMECLO: the Electroconvulsive therapy vs. MEdication in patients with CLOzapine-refractory symptoms trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006333-19,0,0,0 2021-006334-39,1,2022-06-10,2022-06-10,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,Trevena Inc,"Protocol title should be: A randomised, double-blind, placebo-controlled, dose-ranging partial-block crossover study to investigate the effect of intravenous oliceridine on CNS functioning and nocice...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006334-39,0,0,0 2021-006335-26,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Aarhus University,Hyperpolarized xenon lung MRI in long-term COVID19,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006335-26,0,0,0 2021-006336-94,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia. ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006336-94,0,0,0 2021-006337-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING DOSES OF REGN5381, AN NPR1 AGONIST, I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006337-19,0,0,0 2021-006340-27,4,,,0,0,1,0,0,0,3,0,0,3,0,0,0,0,1,LEO Pharma A/S,A phase 3 clinical trial to evaluate efficacy and safety of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle for a 16-week treatment period in adolescents 12-17 years...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006340-27,0,0,0 2021-006371-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Hanna-Reeta Viljamaa,Lasten vesikoureteraalisen refluksin diagnosointi isotooppimiktiokystografia- ja kontrastiaine UÄ-tutkimuksilla Lasten vesikoureteraalisen refluksin diagnosointi isotooppimiktiokystografia- ja ko...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006371-42,0,0,0 2021-006372-17,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Muehlenkreiskliniken AoeR,Evaluation of clinical and immunological effects of PD-1 inhibition on actinic keratoses in patients with advanced or metastatic cutaneous squamous cell carcinoma in combination with a pronounced fiel...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006372-17,0,0,0 2021-006374-24,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplifie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006374-24,0,0,0 2021-006378-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Biogen Idec Research Limited,"A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 in Adult Participants with Active Systemic Lupus Erythematosus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006378-22,0,0,0 2021-006386-38,6,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Amgen, Inc.","A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE 301)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006386-38,0,0,0 2021-006390-37,1,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,1,Vertex Pharmaceuticals Incorporated,A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects with Transfusion-Dependent...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006390-37,0,0,0 2021-006398-41,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,1,"Eisai Co., Ltd.",A Post-marketing Observational Study of Tazemetostat on Safety in Patients With Relapsed or Refractory Follicular Lymphoma With EZH2 Gene Mutation in Japan,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006398-41,0,1,1 2021-006410-36,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Clínica Universidad Navarra,Phase Ib/II open-label clinical study of intratumoral administration of BO-112 in combination with radiotherapy and nivolumab in patients with metastatic PD-1/PDL-1 refractory non-small cell lung canc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006410-36,0,0,0 2021-006413-11,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Celldex Therapeutics,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Assess the Efficacy and Safety of CDX-0159 in Patients with Chronic Spontaneous Urticaria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006413-11,0,0,0 2021-006426-43,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Kepler Universitätsklinikum Linz Neuromed Campus,"An open label, single arm monocentric phase II study to evaluate safety, tolerability, and preliminary efficacy of carrier-added 4-L- [131I]iodophenylalanine (131I-IPA), administered as sequential inj...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006426-43,0,0,0 2021-006427-18,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Anna Coquard Rafales,M-POC-O2: high flow nasal cannula oxygen versus conventional oxygen therapy in exacerbated chronic obstructive pulmonary disease (COPD) patients without respiratory acidosis. Pilot Study. M-POC-O2:...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006427-18,0,0,0 2021-006447-95,4,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Celldex Therapeutics,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX-0159 in Patients with Chronic Inducible Urticaria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006447-95,0,0,0 2021-006474-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,BTI I MAS D S.L.,"Randomized, treatment-controlled clinical trial Conventional efficacy of Plasma Rich in Factors of Growth (PRGF®) in the treatment of atrophic vulvar lichen sclerosus Ensayo clínico, aleatorizado, ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006474-23,0,0,0 2021-006475-42,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,InnoCare Pharma Inc.,"A Phase I/II, Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006475-42,0,0,0 2021-006481-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus MC - Sophia Kinderziekenhuis,Personalized tacrolimus treatment for pediatric kidney transplant recipients by using a dosing algorithm and a once-daily tacrolimus formulation Gepersonaliseerde tacrolimus dosering door gebruik t...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006481-21,0,0,0 2021-006493-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Nimes University Hospital,Evaluation of the patient postoperative experience of two modes of WALANT-type anesthesia (lidocaine alone or combined with ropivacaine) used in ambulatory upper-extremity surgery Evaluation de l’...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006493-23,0,0,0 2021-006495-16,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI""",Immunogenicity and safety of Sotrovimab (Vir 7831) IV as primary prophylaxis in anti-SARS-CoV-2 vaccine non responders Immunogenicità e sicurezza di Sotrovimab (Vir 7831) IV come profilassi primari...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006495-16,0,0,0 2021-006497-23,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Hospital,Corticosteroid in treatment of acute laryngitis among vocal professionals Kortisonilääkitys akuutin kurkunpäätulehduksen hoidossa ääniammattilaisilla,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006497-23,0,0,0 2021-006498-49,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"ACELYRIN, Inc.","A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006498-49,0,0,0 2021-006510-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboudumc,Exploring the Pharmacomicrobiomics of Depression Verkennen van de farmacomicrobiomics van depressie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006510-36,0,0,0 2021-006511-29,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"PTC Therapeutics, Inc.","A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OF PTC857 IN ADULT SUBJECTS WITH AMYOTROPHIC LATERAL SCL...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006511-29,0,0,0 2021-006512-87,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Institut für Klinische Krebsforschung IKF GmbH,"Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma - A phase II trial of the AIO study group – PHERFLOT – ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006512-87,0,0,0 2021-006538-38,1,,,0,1,0,0,0,0,3,0,0,4,0,0,0,0,1,Pfizer Inc.,"A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF CRISABOROLE OINTMENT, 2% IN CHINESE AND JAPANESE PEDIATRIC AND ADULT SUBJECTS (AGES 2 YEARS AND...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006538-38,0,1,1 2021-006540-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Levicept Ltd.,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of LEVI-04 in Patients with Osteoarthritis of the Knee",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006540-28,0,0,0 2021-006545-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Biocon Biologics UK Limited,"A Randomized, Double-blind, Multicenter, Parallel-arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia in Postmenopausal Women with Oste...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006545-36,0,0,0 2021-006550-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,SPANISH SOCIETY OF CARDIOLOGY,Efficacy and Security of BempeDoic acid in Acute Coronary Syndrome Eficacia y seguridad del ácido bempedoico en el síndrome coronario agudo,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006550-31,0,0,0 2021-006556-14,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,Rigshospitalet,CLIC-1901 CAR T-cells for treatment of patients with relapsed/refractory CD19-positive ALL and NHL (DAN-CART 1901),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006556-14,0,0,0 2021-006562-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Universitätsklinikum Erlangen,JAK Inhibition in PReclinical Arthritis Hemmung der Januskinasen im Vorstadium der rheumatoiden Arthritis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006562-20,0,0,0 2021-006570-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI,The Role Of The New Promising Oncological Pet/Ct Tracer [68Ga] Ga-Fapi For Staging Lung Cancer: A Preliminary Study Il ruolo del nuovo promettente radiofarmaco oncologico PET/TC [68Ga]-FAPI nella s...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006570-23,0,0,0 2021-006574-23,3,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"Aytu BioPharma, Inc.","A multicenter, randomized, double-blind, placebo-controlled study of enzastaurin for the prevention of arterial events in patients with vascular Ehlers-Danlos Syndrome (vEDS) confirmed with COL3A1 mut...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006574-23,0,0,0 2021-006575-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aarhus University Hospital,The effect of subpectineal obturator nerve block on opioid consumption and pain after hip arthroscopy A double blind randomized controlled trial Effekten af subpectineal obturatorius nerveblokade p...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006575-42,0,0,0 2021-006577-30,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Da...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006577-30,0,0,0 2021-006579-41,3,2022-06-29,2022-06-29,2,0,0,0,0,1,2,0,0,1,1,1,0,0,1,Angion Biomedica Corp.,"A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of Safety and Efficacy Of ANG-3070 in Patients with Primary Glomerular Disease and Persistent Proteinuria",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006579-41,0,0,0 2021-006581-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud univeristy medical centre,"A patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: a prospective, multi-centre, non-randomised non-inferiority study.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006581-20,0,0,0 2021-006597-23,3,,,0,0,1,0,0,1,2,0,0,4,0,0,0,0,1,Ultragenyx Pharmaceutical Inc.,"A Randomized, Double-Blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006597-23,0,0,0 2021-006611-29,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,University Medical Centre Utrecht Department of Vascular Surgery,A randomized placebo-controlled double-blind trial studying the effect of antiplatelet monotherapy (clopidogrel) versus dual antiplatelet therapy (clopidogrel + aspirin) on the occurrence of atherothr...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006611-29,0,0,0 2021-006614-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Carina Blomström Lundqvist,First-line cryoablation for early treatment of Persistent Atrial Fibrillation – a randomized study comparing early trigger isolation using the Cryoballoon versus antiarrhythmic medication. Kryoabla...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006614-37,0,0,0 2021-006617-11,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Region Nordjylland,A Randomised controlled trial to compare efficacy and tolerability of Plenvu® and Picoprep® as cleansing agents before colonoscopy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006617-11,0,0,0 2021-006621-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,DRK-Blutspendedienst Baden-Württemberg - Hessen gGmbH,"A Randomised Open-Label Trial of Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19 as model of early treatment in a pandemia with a new pathoge...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006621-22,0,0,0 2021-006624-41,3,,,0,0,1,0,0,0,3,0,1,0,0,0,0,0,1,"Pfizer Inc., 235 East 42nd Street, New York, NY 10017","A PHASE 3, RANDOMIZED, PARTIALLY DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY TODDLERS 12 THROUGH 23 MONTHS OF AGE WITH 2 PRIOR I...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006624-41,0,0,0 2021-006629-23,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006629-23,0,0,0 2021-006632-67,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,0,CHU de Bordeaux,Alkalinization of adrenalized lidocaine in extending epidural analgesia for extremely urgent cesarean section during labor: a randomized controlled trial. Alcalinisation de la lidocaïne adrénalinée...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006632-67,0,0,0 2021-006633-19,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"TFF Pharmaceuticals, Inc.","A Phase 2, Open-Label, Randomized, Safety, Pharmacokinetic, and Efficacy Study of Voriconazole Inhalation Powder Compared to Oral Voriconazole Tablets in Subjects with Acute Invasive Pulmonary Aspergi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006633-19,0,0,0 2021-006638-38,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,GUSTAVE ROUSSY,A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors - VAPOR (GETUG T06),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006638-38,0,0,0 2021-006647-99,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Medical University of Bialystok,Safety Outcomes Post kidney Biopsy – randomized Clinical Evaluation of Efficacy of Desmopressin,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006647-99,0,0,0 2021-006665-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Cyxone AB,"APPRAIS - A 24-week multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy, safety and tolerability of orally administered Rabeximod in patients with...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006665-38,0,0,0 2021-006668-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Biocon Biologics UK Limited,"A Randomized, Double-Blind, Parallel Group, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Bmab 1200 and Stelara® in Patients with Moderate to Severe Chronic Plaque Psoriasis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006668-25,0,0,0 2021-006677-26,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Maastricht University,Metabolic effects of ketohexokinase inhibition in individuals with non-alcoholic fatty liver disease Metabole effecten van een ketohexokinase remmer in personen met niet-alcoholische leververvettin...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006677-26,0,0,0 2021-006679-41,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-Experienced Adults 50 Years of Age or Older Estudio clínico de fase 3 para evaluar ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006679-41,0,0,0 2021-006686-37,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur,Immunogenicity and Safety of a DTwP-HepB-Hib-IPV (SHAN6™) Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers in Thailand,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006686-37,0,1,1 2021-006687-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Leiden University Medical Centre,Repeated corticosteroid injections around the Greater Occipital Nerve (GON) as prophylactic treatment in chronic cluster headache,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006687-25,0,0,0 2021-006689-18,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,The Children's Memorial Health Institute,An open randomized phase II clinical trial evaluating the safety and efficacy of rapamycin in the treatment of gliomas high-grade malignant gliomas in children as part of the establishment management ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006689-18,0,0,0 2021-006692-42,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Genmab B.V.,"First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate the safety of GEN1053 as monotherapy and in combination with an immunomodulator in subjects with malignant solid tu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006692-42,0,0,0 2021-006694-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Lantmännen Medical AB,"An open-label, historical cohort control study to evaluate the safety and tolerability of AF-16 in patients with cerebral oedema caused by traumatic brain injury (TBI)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006694-39,0,0,0 2021-006700-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Meander Medical Centre,A pilot study to assess the safety and feasibility of fluorescent sentinel lymph node identification in colon carcinoma using submucosal bevacizumab-800CW. Een pilot studie om de veiligheid en haa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006700-32,0,0,0 2021-006706-69,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Psychiatry – Aalborg University Hospital, Unit for Psychiatric Research","Lithium versus cariprazine in the acute phase treatment of bipolar depression: a pragmatic head-to-head open, randomized multicenter study. The 9th study of the Danish University Antidepressant Group ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006706-69,0,0,0 2021-006707-15,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,UNION therapeutics A/S,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults With Moderate to Severe Atopic Dermatitis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006707-15,0,0,0 2021-006709-31,2,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","Phase IIIb, open-label, single-arm, multi-center study to evaluate the safety, tolerability and efficacy of OAV101 administered intrathecally (1.2 x 1014 vector genomes) to participants 2 to 12 years ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006709-31,0,0,0 2021-006709-31,2,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"Phase IIIb, open-label, single-arm, multi-center study to evaluate the safety, tolerability and efficacy of OAV101 administered intrathecally (1.2 x 1014 vector genomes) to participants 2 to 12 years ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006709-31,0,0,0 2021-006711-29,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Anaveon AG,A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti PD-1 or Anti-CTLA-4 Antibody Following Anti PD 1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutane...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006711-29,0,0,0 2021-006712-93,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LLC,A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006712-93,0,0,0 2021-006752-14,1,,,0,0,0,0,0,1,4,0,0,0,0,0,0,0,0,"Rigshospitalet, Neurologisk afdeling",Glucagone Like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as treatment of Idiopathic Intracranial Hypertension Glukagonlignende peptid-receptor (GLP-1R) agonist-assiste...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006752-14,0,0,0 2021-006754-31,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,Leiden University Medical Center,Establishing immunogenicity and safety of needle-free intradermal delivery by nanoporous ceramic skin patch of mRNA SARS-CoV-2 vaccine as a revaccination strategy in healthy volunteers Onderzoeken ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006754-31,0,0,0 2021-006765-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oxular Ltd.,"A Multi-Center, Open-label, 24-week Clinical Investigation to Evaluate Safety and Tolerability of Treatment with the Oxulumis®, Suprachoroidal Drug Administration Device, Delivering 2.4mg Triamcinolo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006765-38,0,0,0 2021-006766-21,1,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,0,Hospital de Girona Dr. Josep Trueta,"Towards a treatment for accelerated maturation in girls testing spiomet in a randomised placebo controlled, multicentre study. Efectos del tratamiento con spiomet a mitad de dosis en niñas con pube...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006766-21,0,0,0 2021-006767-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Amsterdam UMC,Alkaline Phosphatase as treatment of Ischemia Reperfusion Injury to prevent delayed graft function Alkalische fosfatase als behandeling van ischemie-reperfusieletsel om vertraagde transplantaatfunc...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006767-14,0,0,0 2021-006779-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA","HIV-1 RNA suppression and drug concentrations in semen, cervicovaginal fluid and rectum in HIV-1 infected individuals receiving intramuscular long-acting cabotegravir plus rilpivirine (“CAR-GR Study)...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006779-41,0,0,0 2021-006787-25,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Rigshospitalet The Heart Center,Effects of DAPAgliflozin on cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial Hypertension: A double blind randomized trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006787-25,0,0,0 2021-006788-11,3,,,0,0,0,0,0,1,2,0,0,3,0,0,0,0,1,"Neurocrine Biosciences, Inc.","Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pediatric Subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep Estudio d...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006788-11,0,0,0 2021-006792-42,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Hellenic Society of Hematology (EAE),"A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of Belantamab Mafodotin administered in combination with Daratumumab, Lenalidomide and Dexamethasone in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006792-42,0,0,0 2021-006796-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Meander Medical Centre,A pilot study to assess the safety and feasibility of fluorescent sentinel lymph node identification in colon carcinoma using intravenous bevacizumab-800CW Een pilot studie om de veiligheid en haal...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006796-41,0,0,0 2021-006800-34,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO,The Role of Negr1 In modulating Neuroplasticity in major depression Il ruolo di Negr1 nella modulazione della neuroplasticità nella Depressione Maggiore,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006800-34,0,0,0 2021-006801-31,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Barbara Burgos-Blasco,RANDOMIZED PARALLEL CLINICAL TRIAL TO DETERMINE THE EFFECTIVENESS AND SAFETY OF TOPICAL INSULIN IN THE TREATMENT OF DRY EYE IN PATIENTS WITH DRY EYE ENSAYO CLÍNICO ALEATORIZADO PARALELO PARA DETERM...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006801-31,0,0,0 2021-006804-34,2,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Cytovation ASA,"A Phase 1b/2a, Open-Label, Multi-Center Study of CyPep-1 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety of CyPep-1 in Patients With Advanced or Metastatic Head and Neck Squamous...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006804-34,0,0,0 2021-006809-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NKI-AVL,Body surface area-based vs concentration-based dosing of cisplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) in women with advanced ovarian cancer,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006809-29,0,0,0 2021-006816-10,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd,"A PHASE I/II, OPEN-LABEL, MULTI-COHORT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CEVOSTAMAB IN PRIOR B CELL MATURATION ANTIGEN-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ESTUDIO ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006816-10,0,0,0 2021-006832-24,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Ziekenhuis Oost-Limburg A.V.,"Heterogeneity, durability and efficacy of the humoral immune response against SARS-CoV-2 (Covid-19) after hospital-wide vaccination",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006832-24,0,0,0 2021-006860-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Noordwest Ziekenhuisgroep,Pharmacokinetic and pharmacodynamic target attainment of cefuroxime in adult patients on general wards with different degrees of renal function: a prospective observational cohort study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006860-26,0,0,0 2021-006861-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,GH Research Ireland Limited,A Phase 2 Clinical Trial of GH001 in Patients with Bipolar II Disorder and a Current Major Depressive Episode (GH001-BD-202),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006861-39,0,0,0 2021-006868-24,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud university medical centre,Pharmacokinetics of fluconazole given orally or intravenously as prophylaxis or therapy to children and adolescents with invasive fungal infections (FOCUS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006868-24,0,0,0 2021-006879-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,GH Research Ireland Limited,A phase 2 clinical trial of GH001 in patients with postpartum depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006879-42,0,0,0 2021-006883-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Bispebjerg hospital, Dermato-Venerologisk afdeling, Jacob Pontoppidan Thyssen",The Pathogenic Role Of Staphylococcus Aureus And The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis Danish title: Den patogene rolle af staphylococcus aureus og hudmikrobiomet un...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006883-25,0,0,0 2021-006884-67,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,"Arcutis Biotherapeutics, Inc.","A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis Badanie fazy 3, 4-tygo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006884-67,0,0,0 2021-006885-19,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,"Arcutis Biotherapeutics, Inc.","A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis Badanie przedłużone, fazy 3, wieloośrodk...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006885-19,0,0,0 2021-006902-61,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,"Arcutis Biotherapeutics, Inc.","A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis Badanie fazy 3, 4-tygo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006902-61,0,0,0 2021-006903-14,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,"Arcutis Biotherapeutics, Inc.","A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis Badanie fazy 3, 4-tygo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006903-14,0,0,0 2021-006904-34,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Centre Hospitalier Départemental Vendée,Evaluation of the interest of perianal infiltration during thermodestruction of haemorrhoidal disease by Radiofrequency (RAFAELO® procedure) Evaluation de l’intérêt de l’infiltration périanale au ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006904-34,0,0,0 2021-006906-58,3,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Pharvaris Netherlands BV,"A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006906-58,0,0,0 2021-006908-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Sonia Luque Pardos,Intrapulmonary penetration of ceftolozane / tazobactam and ceftazidime / avibactam administered in continuous infusion in critically ill patients with nosocomial pneumonia PENETRACIÓN INTRAPULMONAR...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006908-32,0,0,0 2021-006911-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Lyra Therapeutics, Inc.","ENLIGHTEN 2: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults ENLIGHTEN ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006911-27,0,0,0 2021-006931-25,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Bispebjerg and Frederiksberg Hospital, University of Copenhagen",Efficacy and safety of oral roflumilast in the treatment of palmoplantar pustulosis – a randomised controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006931-25,0,0,0 2021-006950-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A one month, investigator and participant blinded study to investigate the efficacy and safety of remibrutinib (LOU064) at multiple dose levels in adult participants with peanut allergy Estudio dob...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006950-30,0,0,0 2021-006951-32,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,DOMPé FARMACEUTICI S.P.A.,Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006951-32,0,0,0 2021-006951-32,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Dompé farmaceutici s.p.a.,Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinatio...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006951-32,0,0,0 2021-006953-77,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Aarhus University Hospital,Treatment effects of Bisoprolol and Verapamil in symptomatic patients with non-obstructive hypertrophic cardiomyopathy Effekten af Bisoprolol og Verapamil hos symptomatiske patienter med hypertrof...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006953-77,0,0,0 2021-006970-22,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,FISEVI,"A multicentre, randomized, open-label study of romiplostim plus dexamethasone vs dexamethasone in patients with newly diagnosed primary immune thrombocytopenia Estudio multicéntrico, aleatorizado y...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006970-22,0,0,0 2021-006975-41,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,GICOR,Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy: a multicentre phase III randomised c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2021-006975-41,0,0,0 2022-000034-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Aarhus University Hospital - Psychiatry, Department of Affective Disorders",The Estimated 12-Hour Serum Lithium Level Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000034-42,0,0,0 2022-000035-23,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Valneva Austria GmbH,"OPEN-LABEL PHASE 2/3 CLINICAL STUDY TO INVESTIGATE SAFETY AND IMMUNOGENICITY OF A SINGLE VLA2001 BOOSTER VACCINATION IN ADULT VOLUNTEERS, AFTER RECEIPT OF NATIONALLY ROLLED OUT MRNA COVID-19 VACCINES...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000035-23,0,0,0 2022-000049-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,Sanofi-aventis recherche & développement,"A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open label long-te...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000049-34,0,0,0 2022-000064-21,1,,,0,0,1,0,0,1,2,0,0,4,0,0,0,0,1,"Transposon Therapeutics, Inc",A Phase 2a Study of TPN-101 in Patients with Aicardi-Goutières Syndrome (AGS),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000064-21,0,0,0 2022-000065-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Sanofi-aventis recherche & développement,"A randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to assess the efficacy, safety, and tolerability of subcutaneous amlitelimab in adult participants with moderate to-s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000065-41,0,0,0 2022-000073-12,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"PTC Therapeutics, Inc.","A PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF UNESBULIN IN UNRESECTABLE OR METASTATIC, RELAPSED OR REFRACTORY LEIOMYOSARCOMA",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000073-12,0,0,0 2022-000074-25,2,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,HIPRA SCIENTIFIC,"A PHASE III, OPEN LABEL TRIAL, SINGLE ARM, MULTI-CENTER, TRIAL TO ASSESS THE SAFETY AND IMMUNOGENICITY OF A BOOSTER VACCINATION WITH A RECOMBINANT PROTEIN RBD FUSION HETERODIMER CANDIDATE (PHH-1V) AGA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000074-25,0,0,0 2022-000074-25,2,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,HIPRA SCIENTIFIC S.L.U,"A PHASE III, OPEN LABEL TRIAL, SINGLE ARM, MULTI-CENTER, TRIAL TO ASSESS THE SAFETY AND IMMUNOGENICITY OF A BOOSTER VACCINATION WITH A RECOMBINANT PROTEIN RBD FUSION HETERODIMER CANDIDATE (PHH-1V) AGA...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000074-25,0,0,0 2022-000075-39,2,,,0,0,1,0,0,0,2,0,0,3,0,0,0,0,1,Pfizer Inc.,"A PHASE 2/3, INTERVENTIONAL SAFETY, PHARMACOKINETICS, AND EFFICACY, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332 (NIRMATRELVIR)/RITONAVIR IN NONHOSPITALIZE...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000075-39,0,0,0 2022-000077-57,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Rigshospitalet,"Methadone versus fentanil and oxycodone for post-operative pain reduction in patients undergoing coronary artery bypass grafting and/or valve surgery – a placebo-controlled, double-blind, randomized ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000077-57,0,0,0 2022-000080-43,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,reMYND,"A randomized, placebo-controlled, double-blind, parallel-group Phase 2a exploratory study with placebo run-in to investigate PK/PD effects, safety, tolerability and pharmacokinetics of REM0046127 oral...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000080-43,0,0,0 2022-000082-41,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Fundación para la Investigación en Urología,Impact of pitavastatin use in prostate cancer patients treated with new generation androgen therapy: multicenter clinical trial Impacto del uso de pitavastatina en pacientes con cáncer de próstata...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000082-41,0,0,0 2022-000093-25,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Aarhus University Hospital,The effect of lateral pectoral nerve block in combination with interscalene nerve block on opioid consumption and pain on awake shoulder arthroscopy patients - A feasibility study Effekten af lat...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000093-25,0,0,0 2022-000095-18,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Bayer Consumer Care AG,"A double-blind, randomized, placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms caused by adjuvant endocrine therapy, over 5...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000095-18,0,0,0 2022-000099-20,2,,,0,0,0,0,0,0,3,0,1,3,0,0,0,0,1,Sanofi Pasteur,A Phase IIIb randomized open-label study of nirsevimab (versus no intervention) in preventing hospitalizations due to respiratory syncytial virus in infants (HARMONIE),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000099-20,0,0,0 2022-000122-21,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,"Nuvalent, Inc.",A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1) Estudio en fase I/II del inhibidor selectivo ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000122-21,0,0,0 2022-000123-20,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,University Medical Centre Groningen,"Prospective, single-centre, feasibility study to evaluate the use of 18F-PSMA PET/CT in patients with biochemically active medullary thyroid cancer. Prospectieve, single-centre studie om de waarde ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000123-20,0,0,0 2022-000135-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BioAtla Inc.,A Phase 2 Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression On or Are Intolera...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000135-23,0,0,0 2022-000137-17,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,BioAtla,A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors Estudio de fase 1/2 de aumento y ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000137-17,0,0,0 2022-000144-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación Instituto de Investigación Sanitaria de Santiago de Compostela,"SePkLin Study: Pragmatic, Multicenter, Randomized, Controlled Clinical Trial in Patients with Sepsis to Evaluate the Safety and Efficacy of Personalized Pk/Pd Dosing Versus Standard Dosing of LINezoli...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000144-30,0,0,0 2022-000152-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,AstraZeneca AB,BURAN: Effects of Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma using Functional Respiratory Imaging Parameters BURAN: Efecto del Benralizumab sobre la dinámica de la vía aérea en e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000152-11,0,0,0 2022-000156-11,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,0,KU Leuven,Oxytocin and the development of attachment: Looking beyond the expected? Oxytocine en de ontwikkeling van gehechtheid: een blik voorbij de verwachting?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000156-11,0,0,0 2022-000157-87,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hvidovre Hospital,HypoBar I: Delaying intestinal glucose absorption to ameliorate post-bariatric hypoglycaemia. A randomized cross-over clinical trial. HypoBarI: Reduceret risiko for lave blodsukre efter fedmekirurg...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000157-87,0,0,0 2022-000161-40,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medical University of Vienna, Division of Endocrinology",Investigating cardiometabolic risk factors and changes in chronobiology patterns in patients with autonomous adrenal cortisol secretion,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000161-40,0,0,0 2022-000168-22,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,1,Addmedica,"An open-label, non-comparative, multicentre study to evaluate the acceptability of a new paediatric formulation of hydroxycarbamide in children with sickle cell disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000168-22,0,0,0 2022-000169-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Kiniksa Pharmaceuticals, Ltd.","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects with Moderate to Severe, Active Rheumatoid Arthri...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000169-42,0,0,0 2022-000179-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Bispebjerg Hospital,"Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomized double-blind, placebo-controlled trial of tezepelumab",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000179-38,0,0,0 2022-000186-40,6,,,0,0,1,0,0,1,2,0,0,3,0,0,0,0,1,Pfizer Inc.,"A PROSPECTIVE, RANDOMIZED, OPEN-LABEL PHASE 2 STUDY TO EVALUATE THE SUPERIORITY OF INOTUZUMAB OZOGAMICIN MONOTHERAPY VERSUS ALLR3 FOR INDUCTION TREATMENT OF CHILDHOOD HIGH RISK FIRST RELAPSE B-CELL PR...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000186-40,0,0,0 2022-000193-25,3,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,"Biohaven Pharmaceuticals, Inc.","A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants with Spinal Muscular Atrophy with Open-Labe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000193-25,0,0,0 2022-000193-25,3,,,0,0,0,0,0,2,3,0,0,3,0,0,0,0,1,"Biohaven Pharmaceuticals, Inc","A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants with Spinal Muscular Atrophy with Open-Labe...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000193-25,0,0,0 2022-000199-20,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Genentech, Inc.","A PHASE III RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH EXEMESTANE PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR-POS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000199-20,0,0,0 2022-000214-34,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SYLENTIS S.A.U,"A Randomized, Double masked, Parallel group, Dose-finding study to evaluate SYL1801 in patients with neovascular AMD Randomizovaná, dvojitě maskovaná studie s paralelními skupinami k určení dávky S...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000214-34,0,0,0 2022-000215-31,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,UZ Leuven,A monocentric academic trial comparing the diagnostic value of history taking and nasal lysine aspirin provocation test in the diagnosis of AERD in CRSwNP patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000215-31,0,0,0 2022-000222-24,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Cyclacel Pharmaceuticals,"A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CYC140, AN ORAL PLK1 INHIBITOR, IN SUBJECTS WITH ADVANCED SOLID TUMORS AND LYMPHOMA Estudio en...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000222-24,0,0,0 2022-000234-42,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Medical University of Vienna, Div. of Gastroenterology & Hepatology",Fecal Microbiota Transplant (FMT) combined with Atezolizumab plus Bevacizumab in Patients with HepatoCellular Carcinoma who failed to respond to prior Immunotherapy – the FAB-HCC Trial Fäkale Mikro...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000234-42,0,0,0 2022-000240-30,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"Center for Experimental and Molecular Medicine, G2 (AMC)",The chemopreventive effect of Lithium on adenoma development in patients with familial adenomatous polyposis (FAP); a pilot study Het preventieve effect van Lithium op adenoomvorming in patienten m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000240-30,0,0,0 2022-000241-32,1,,,0,0,1,0,0,1,3,0,0,0,0,0,0,0,0,Amsterdam UMC,Effectiveness of L-serine dietary supplementation in children with a GRIN2B loss-of-function mutation: n-of-1 series,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000241-32,0,0,0 2022-000243-80,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hospital Universitario Rio Hortega,"PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF MESENCHYMAL CELLS (MSV-allo®) IN THE TREATMENT OF LUPUS NEPHRITIS. ENSAYO CLÍNICO FASE II, DOBLE CIEGO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000243-80,0,0,0 2022-000245-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Medical University of Lublin,To evaluate the effect of low-dose naltrexone (LDN) on pain perception and quality of life in women Ocena wpływu niskich dawek Naltreksonu (LDN) na odczuwanie bólu i jakość życia kobiet z wulwodyn...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000245-33,0,0,0 2022-000253-92,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Emerald Health Pharmaceuticals Inc.,"A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients with Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 Ensayo ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000253-92,0,0,0 2022-000258-27,2,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000258-27,0,0,0 2022-000265-41,4,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000265-41,0,0,0 2022-000269-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Randers Regional Hospital, Department of Gynecology and Obstetrics",Improving diagnostics in cervical dysplasia Bedre diagnostik af celleforandringer på livmoderhalsen,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000269-42,0,0,0 2022-000271-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Adeptio Pharmaceuticals Ltd,"Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD) Otvoreno kliničko ispitivanje faze 2 titriranja doze lijeka (+)-α-DHTBZ za ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000271-39,0,0,0 2022-000279-38,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,FUNDACION INVESTIGACION BIOMEDICA HOSPITAL PUERTA DE HIERRO MAJADAHONDA,"AN OPEN LABEL, RANDOMISED, CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY OF ENDOBRONCHIAL ADMINISTRATION OF ALLOGENEIC MESENCHYMAL STROMAL CELLS IN PATIENTS WITH LUNG TRANSPLANT CHRONIC REJECTION: St...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000279-38,0,0,0 2022-000281-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Haukeland University Hospital, Dept. of Oncology and Medical Physics",A pilot study using subcutaneous injections of the anti-CD38 antibody daratumumab in six patients with moderate to severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Resetting the humoral immu...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000281-18,0,0,0 2022-000284-48,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,EVELO Biosciences Inc,A Long-Term Extension Trial in participants with Atopic Dermatitis who participated in previous Phase 2 and 3 EDP1815 trials,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000284-48,0,0,0 2022-000291-19,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fakultní nemocnice u sv. Anny v Brně,Pharmacokinetics of colistin in critically ill patients with extracorporeal membrane oxygenation Farmakokinetika colistinu u kriticky nemocných pacientů s extrakorporální membránovou oxygenací,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000291-19,0,0,0 2022-000294-67,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Bristol-Myers Squibb International Corporation,A Phase II Study of Adjuvant Nivolumab Switch from Intravenous (IV) to Subcutaneous (SC) Use in Participants with Resected Stage III or Stage IV Melanoma or High Risk Invasive Urothelial Carcinoma Ori...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000294-67,0,0,0 2022-000297-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Assistance Publique – Hôpitaux de Paris (AP-HP),lNA Comparaison d’une faible dose à une dose standard d’insulinothérapie dans l’acidocétose diabétique de l’adulte en réanimation et unité de surveillance continue pour diminuer les complications m...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000297-26,0,0,0 2022-000299-20,1,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,"Sparrow Pharmaceuticals, Inc.",A trial of prednisolone in combination with SPI-62 or placebo in subjects with polymyalgia rheumatica (PMR),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000299-20,0,0,0 2022-000302-10,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Institute of hematology and blood transfusion,Significance of T cell response to vaccination against SARS-CoV2 for leukemic patients with weakend immune system Význam specifické T buněčné odpovědi po vakcinaci proti SARS-CoV2 pro leukemické pa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000302-10,0,0,0 2022-000317-14,1,,,0,0,0,1,0,1,1,0,0,4,0,0,0,0,1,"GRIN Therapeutics, Inc.","A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Multiple Individually Titrated Doses of Radiprodil in Children with GRIN-rel...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000317-14,0,0,0 2022-000319-30,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Institut Klinické a Experimentální Medicíny,"Assessment of association between 3rd dose of mRNA vaccine and risk of SARS-CoV-2 infection in kidney transplant recipients, safety and immunogenicity assessment. Aspekty imunitní odpovědi a efekti...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000319-30,0,0,0 2022-000336-28,2,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Takeda Development Center Americas, Inc.","A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple Sy...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000336-28,0,0,0 2022-000338-41,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Stichting Radboud universitair medisch centrum,Pred Forte® in chronic central serous chorioretinopathy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000338-41,0,0,0 2022-000339-21,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,"Salubris Biotherapeutics, Inc.","A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients with Unresectable Locally Advanced or Metastatic Ca...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000339-21,0,0,0 2022-000355-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC Cancer Institute,Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000355-37,0,0,0 2022-000358-26,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Institut d’Investigacions Biomèdiques August Pi i Sunyer,"Safety, tolerability, and efficacy of a dose reduction strategy based on bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV-infected adults. Seguridad, tolerabilidad y ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000358-26,0,0,0 2022-000364-21,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000364-21,0,0,0 2022-000371-39,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000371-39,0,0,0 2022-000382-41,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Reproducción Bilbao. Ginegorama S.L.,Protection of the luteal phase by means of progesterone in assisted reproduction procedures. Comparison of different routes of administration and study of predictive parameters of reproductive success...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000382-41,0,0,0 2022-000389-16,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Fulcrum Therapeutics,"A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, 48-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Patients with Facioscapulohumeral Muscular Dystrophy",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000389-16,0,0,0 2022-000391-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,"AZIENDA OSPEDALIERA ""S. MARIA""","A Single Arm Phase II Study of CAbozantinib in relapsing IDH-1wt, MET amplified Glioblastoma: (“CAT” Study) Sperimentazione clinica di fase 2 a singolo braccio con CAbozantinib nel glioblastoma rec...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000391-19,0,0,0 2022-000404-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"AMC, Cardiovascular Sciences",Does the hematopoietic stem cell govern residual inflammatory cardiovascular risk in type 2 diabetes?,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000404-35,0,0,0 2022-000408-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,ZonMw,OMAMA-study – prevention of opioid-induced constipation in patients with metastatic cancer OMAMA-studie - voorkomen van opioïde-geïnduceerde obstipatie in patiënten met uitgezaaide kanker,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000408-36,0,0,0 2022-000415-32,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,Allergan,Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months With Suspected or Confirmed Bacterial Infection,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000415-32,0,1,1 2022-000422-16,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Umecrine Cognition AB,"A randomised, double-blind, placebo-controlled, two-part study to evaluate the pharmacokinetics, safety and tolerability, and preliminary efficacy of two dose levels of golexanolone in subjects with p...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000422-16,0,0,0 2022-000427-20,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Inreda Diabetic,A stable glucagon analog administered by a bihormonal closed loop system; a feasibility study Een stabiele glucagon analoog toegediend door een bihormonaal gesloten loop systeem; een haalbaarheidss...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000427-20,0,0,0 2022-000434-42,3,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG,"A Phase 3b/4 Randomized, Double-blind, Dose-Flexibility Study of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis (Flex-Up)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000434-42,0,0,0 2022-000435-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AlgoTherapeutix,"A multicenter, randomized, double-blind, parallel group, placebo controlled, Phase 2 study to assess the efficacy and safety of ATX01 (topical amitriptyline hydrochloride 10% and 15% w/w) in compariso...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000435-23,0,0,0 2022-000460-21,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Alexion Pharmaceuticals, Inc","A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. Estudio de fase 3,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000460-21,0,0,0 2022-000474-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Radboudumc,Pancreatitis and early omega-3-fatty acid infusion for reduction of organ failure and mortality: a multicenter randomized controlled trial (PLANCTON),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000474-26,0,0,0 2022-000476-18,2,,,0,0,0,0,0,1,3,0,0,3,0,0,0,0,1,"EnBiotix, Inc.",Tolerability and Safety of Inhaled Colistimethate Sodium Administered Once Daily Compared to Twice Daily Dosing in Adult and Adolescent Subjects with Cystic Fibrosis and Chronic Pseudomonas Aeruginosa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000476-18,0,0,0 2022-000491-18,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Applied Therapeutics Inc.,"A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Pharmacodynamic Efficacy and Clinical Benefit of AT 007 in Patients with Sorbitol Dehydrogenase (SORD) Deficiency Rand...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000491-18,0,0,0 2022-000492-39,1,,,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,Xintela AB,"A single-centre, randomised, single-blind Phase I/IIa study to evaluate the safety, tolerability and efficacy of a single topical dose of allogeneic integrin α10β1-selected mesenchymal stem cells (XST...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000492-39,0,0,0 2022-000493-26,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Al...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000493-26,0,0,0 2022-000498-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Redx Pharma Plc,"A Multi-Cohort, Randomised, Placebo-Controlled Phase 2a Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Ascending Doses of RXC007 in Patients with Idiopathic Pu...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000498-15,0,0,0 2022-000503-13,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Daiichi Sankyo, Inc.","A Phase 2, Multicenter, Randomized, Open-label Study of DS-7300a, a B7-H3 Antibody Drug Conjugate (ADC), in Subjects with Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000503-13,0,0,0 2022-000506-10,1,,,0,0,0,0,0,0,2,0,0,4,0,0,0,0,0,Assistance Publique des Hôpitaux de Paris,Bariticinib in the treatment of new-onset juvenile dermatomyositis :a phase II trial Baricitinib dans le traitement de la dermatomyosite juvénile d’apparition récente: un essai de phase II.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000506-10,0,0,0 2022-000514-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Erasmus MC,CHemotherapy And Sequential ImmunoTherapy for locally advanced urothelial cancer: the CHASIT study CHemotherapie en sequentiële immunotherapie voor lokaal gevorderde urotheelkanker: de CHASIT-studi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000514-33,0,0,0 2022-000525-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000525-25,0,0,0 2022-000535-23,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Barcelona Institute for Global Health (ISGlobal),Efficacy of low dose acetylsalicylic acid in preventing adverse maternal and perinatal outcomes in SARS-CoV-2 infected pregnant women Evaluación de la eficacia del ácido acetilsalicílico a dosis ba...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000535-23,0,0,0 2022-000556-11,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Medical University of Vienna, Department of Anesthesia, Intensive Care Medicine and Pain Medicine",The effect of desflurane versus Sevoflurane on postoperative recovery in patients undergoing minor- to moderate-risk noncardiac surgery - a prospective double-blinded randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000556-11,0,0,0 2022-000559-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,None,COMPLICATIONS AND DEGREE OF TOLERANCE OF THE ADMINISTRATION OF LOCAL ANESTHESIA IN DIAGNOSTIC / THERAPEUTIC THORACOCENTESIS PROCEDURES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000559-35,0,0,0 2022-000565-40,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Glycomine, Inc","A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000565-40,0,0,0 2022-000576-19,3,,,0,0,1,0,0,0,3,0,1,3,0,0,0,0,1,Sanofi Pasteur Inc,Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine Compared with Egg-Based Standard-Dose Quadrivalent Influenza Vaccine in Children 3 to 8 Years of Age.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000576-19,0,0,0 2022-000577-11,2,,,0,0,1,0,0,0,3,0,1,0,0,0,0,0,1,Sanofi Pasteur Inc,Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000577-11,0,0,0 2022-000578-25,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Gilead Sciences, Inc.","A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000578-25,0,0,0 2022-000581-17,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Cerevel Therapeutics, LLC","A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 in Participants With Schizophrenia E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000581-17,0,0,0 2022-000602-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Oxford University Hospitals NHS Foundation Trust,Short or Long Antibiotic Regimes in Orthopaedics (SOLARIO): A Randomised Open Label Multi-Centre Clinical Trial Regímenes antibióticos cortos o largos en ortopedia (SOLARIO): Un ensayo clínico ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000602-10,0,0,0 2022-000603-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud University,Oxytocin and reactivity to infant signals in mothers with postpartum depression,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000603-12,0,0,0 2022-000609-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Centre Groningen,"ANIfrolumab treatment for 24 weeks in patients with primary Sjögren’s syndrome – Efficacy and safety assessment in a randomized, double-blind, placebo-controlled phase-IIa proof-of-concept trial (ANIS...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000609-28,0,0,0 2022-000615-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Diater Laboratorio de Diagnósticos y Aplicaciones Terapéuticas,"Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial in parallel groups which evaluates the clinical efficacy and safety of immunotherapy with the purified major allergen...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000615-31,0,0,0 2022-000617-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR),"A prospective, randomized, controlled trial assessing the effect of conversion from Tacrolimus-antimetabolite to Tacrolimus-mTor-inhibitors based immunosuppression to booster SARS-CoV-2-specific seroc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000617-13,0,0,0 2022-000623-21,3,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,GlaxoSmithKline Biologicals SA,"A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety and reactogenicity of an RSVPreF3 OA investigational vaccine when co-administered with FLU ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000623-21,0,0,0 2022-000623-21,3,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,"GlaxoSmithKline, S.A.","A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety and reactogenicity of an RSVPreF3 OA investigational vaccine when co-administered with FLU ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000623-21,0,0,0 2022-000624-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Laboratorios Salvat, S.A.","A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in t...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000624-37,0,0,0 2022-000632-27,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Radboud University Medical Center,Pragmatic trial on the safety and tolerability of an optimized dose of rifampicin in tuberculosis patients,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000632-27,0,0,0 2022-000636-40,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Pacific Pediatric Neuro-Oncology Consortium (PNOC),PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000636-40,0,0,0 2022-000641-33,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,"Fundació FLS de Lluita contra la Sida, les Malalties Infeccioses i la Promoció de la Salut i La Ciència","Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study Recambio plasmático como tratamiento para pacientes con Síndrome post-COVID-19: Estudio piloto aleatoriz...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000641-33,0,0,0 2022-000642-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hellenic Institute for the Study of Sepsis,"Hydrogen sulfate guided therapy with STS for COVID-19 patients in need of critical care: The H4COVID open-label, randomized, triple-arm trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000642-16,0,0,0 2022-000652-11,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Spago Nanomedical AB,"A Phase IIa, single centre, open label, proof of concept study concerning efficacy of the novel intravenous contrast agent SN132D in patients with suspected endometriosis.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000652-11,0,0,0 2022-000660-22,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,0,Landeskrankenhaus Salzburg,Investigation to assess the efficacy of topical benzyl benzoate 10/25% emulsion versus permethrin 5% creme for scabies treatment Untersuchung zur Wirksamkeit von Benzylbenzoat 25% Emulsion vs. Perm...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000660-22,0,0,0 2022-000676-19,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Clinical Director, Daiichi Sankyo, Inc.","A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of DS-1211b in Individuals with Pseudoxanthoma Elasticum",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000676-19,0,0,0 2022-000691-19,1,,,0,0,1,0,0,1,2,0,0,0,0,0,0,0,1,F. Hoffmann-La Roche Ltd,"A two-part, open-label systemic gene delivery study to evaluate the safety and expression of RO7494222 (SRP-9001) in subjects under the age of four with Duchenne muscular dystrophy Estudio abierto,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000691-19,0,0,0 2022-000693-26,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,ISTITUTO AUXOLOGICO ITALIANO,"Crossover, Double-blind, Phase 2 Study of a Fixed Dose Combination of Atomoxetine and Acetazolamide Versus Placebo in Obesity Hypoventilation Syndrome Crossover, doppio cieco, studio di fase 2 di u...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000693-26,0,0,0 2022-000695-19,2,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,"Samsung Bioepis Co., Ltd","A Phase IV, Randomised, Double-blind, Parallel-group, Multiple-dose, Active Comparator, Multicentre Clinical Study to Evaluate the Pharmacokonetics, Efficacy, Safety, and Immunogenicity of SB5 Versus ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000695-19,0,0,0 2022-000706-10,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center of the Johannes Gutenberg- University Mainz,Pilot study on Administration of Tildrakizumab in patients with Hidradenitis Suppurativa. Pilotstudie zur Anwendung von Tildrakizumab bei Patienten mit Akne inversa.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000706-10,0,0,0 2022-000715-31,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,NEAT ID,"Clinical Trials targeting macro-, micro-immuno-thrombosis, vascular hyperinflammation, and hypercoagulability and renin-angiotensin-aldosterone system (RAAS) in hospitalized patients with COVID-19 (AC...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000715-31,0,0,0 2022-000719-30,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Galapagos NV,"A randomized, double-blind, controlled, multi-center study to evaluate the efficacy and safety of dose de-escalation of orally administered filgotinib in subjects with ulcerative colitis in clinical r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000719-30,0,0,0 2022-000736-37,3,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Biotest AG,"A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with moderate or severe COVID-19",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000736-37,0,0,0 2022-000740-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Department of Renal Medicine, Aarhus University Hospital",Sodium glucose cotransporter 2 inhibitors or Mineralocorticoid receptor antagonists for the treatment of Albuminuric Chronic Kidney Disease - A randomized controlled trial Sodium-glucose Cotranspor...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000740-29,0,0,0 2022-000747-77,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Biogen Idec Research Limited,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122/DNL151 in Participants with Parkinson’s Disease and Pathogenic LRRK2 Variants...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000747-77,0,0,0 2022-000753-80,3,,,0,0,0,0,1,0,2,0,0,0,0,0,0,0,1,Ferring Pharmaceuticals A/S,"A randomised, assessor-blind, active-controlled, parallel-group, dose-finding trial to investigate the efficacy and safety of FE 999302 for triggering of final follicular maturation in women undergoin...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000753-80,0,0,0 2022-000757-93,7,,,0,0,1,0,0,1,3,0,0,3,0,0,0,0,1,"IONIS PHARMACEUTICALS, INC.","An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000757-93,0,0,0 2022-000763-45,1,,,0,0,0,0,0,1,4,0,0,4,0,0,0,0,1,"AlloVir, Inc.",Global Registry for Long-Term Follow-up of Patients Participating in Clinical Trials with Posoleucel (ALVR105) Registro mundial para el seguimiento a largo plazo de pacientes que participan en ensa...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000763-45,0,0,0 2022-000776-19,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000776-19,0,0,0 2022-000785-18,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,HIPRA SCIENTIFIC,"A Phase III, open label, single arm, multi-center, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000785-18,0,0,0 2022-000795-19,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,HIPRA SCIENTIFIC,"A PHASE IIB, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED, MULTI-CENTER, NON-INFERIORITY TRIAL TO ASSESS IMMUNOGENICITY AND SAFETY OF A BOOSTER VACCINATION WITH A RECOMBINANT PROTEIN RBD FUSION DIMER C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000795-19,0,0,0 2022-000800-37,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,St. Olav's University Hospital,"An open, controlled investigation of the effect of micro-doses of glucagon on the performance of continuous glucose monitoring in patients with diabetes mellitus type 1.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000800-37,0,0,0 2022-000842-14,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Dra.Margarita Ramirez&Dra.Ifara Sánchez,Trial study to evaluate the effectiveness of botulinum toxin A (incobotulinumtoxin) injection in reducing the pain and size of painful scars (including hypertrophic and keloid scars) Estudio para e...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000842-14,0,0,0 2022-000845-34,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,1,Pfizer Inc.,A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHILDREN AGED 5 MONTHS TO ≤60 MONTHS AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000845-34,0,1,1 2022-000847-62,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Aclaris Therapeutics, Inc.","A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zunsemetinib vs Placebo in Patients with Mod...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000847-62,0,0,0 2022-000849-32,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Helsinki University Hospital,The effect of tenofovir disoproxil fumarate (TDF) versus tenofovir alafenamide (TAF) on proximal small intestine – a potential mechanism to explain opposing effects on body weight,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000849-32,0,0,0 2022-000855-35,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Horizon Therapeutics Ireland DAC,An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Daxdilimab (HZN-7734) in Subjects with Systemic Lupus Erythematosus,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000855-35,0,0,0 2022-000857-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Liège,Isobaric versus hyperbaric intrathecal bupivacaine: influence of baricity on blood pression variation during elective total knee arthroplasty: a randomized clinical trial.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000857-10,0,0,0 2022-000880-40,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,"Regeneron Pharmaceuticals, Inc.","Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients with Fibrodysplasia Ossificans Progressiva Estudio en fase III, aleatorizado y co...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000880-40,0,0,0 2022-000882-41,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novo Nordisk A/S,Investigation of once-weekly semaglutide s.c. dose-response in patients with type 2 diabetes and overweight – a participant- and investigator-blinded and sponsor open-label study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000882-41,0,0,0 2022-000886-42,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,OM Pharma SA,"A Randomised, Placebo-Controlled, 3-Arm, Double-Blind, Multicentre, Phase 4 Study to Assess the Efficacy of OM-85 (Broncho Vaxom) Short- and Long-Term Treatment vs. Placebo in the Prevention of Respir...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000886-42,0,0,0 2022-000887-23,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A multicenter, participant and investigator-blinded, randomized, placebo-controlled Phase 2a study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of TIN816 in the treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000887-23,0,0,0 2022-000887-23,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.","A multicenter, participant and investigator-blinded, randomized, placebo-controlled Phase 2a study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of TIN816 in the treat...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000887-23,0,0,0 2022-000894-16,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,Predicting Response to Iron Supplementation in Patients with Inflammatory Bowel Disease during Induction Therapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000894-16,0,0,0 2022-000897-24,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"VCN Biosciences, S.L.","A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer Estudio aleatorizado, sin enmascaramiento de fase IIb de ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000897-24,0,0,0 2022-000902-82,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Alzecure Pharma AB,"A Phase 2a, randomised, double-blind, placebo-controlled crossover study to explore the effects of ACD440 in patients with peripheral neuropathic pain with sensory hypersensitivity",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000902-82,0,0,0 2022-000904-36,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Instituto de Investigación Biomédica de Salamanca,Randomized clinical trial to evaluate the dose and administration time of indocyanine green in near-infrared fluorescent cholangiography during laparoscopic cholecystectomy. Ensayo clínico aleatori...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000904-36,0,0,0 2022-000905-29,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE ""LAZZARO SPALLANZANI""",Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies Cinetica tempoRale de...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000905-29,0,0,0 2022-000909-28,4,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Di...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000909-28,0,0,0 2022-000933-18,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,1,Unicyte AG,"An Open-label, Non-controlled, Multi-center, Phase 2 Study to Assess the Efficacy and Safety of Allogeneic Human Liver Stem Cells (HLSCs) in the Treatment of Pediatric Patients with Early-onset Urea C...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000933-18,0,0,0 2022-000995-21,2,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Novartis Pharma AG,"A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelo...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-000995-21,0,0,0 2022-001005-43,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,1,Biocodex,Etude de l’intérêt de l’association du stiripentol (Diacomit®) et de la carbamazépine dans le traitement des patients atteints d’épilepsies focales pharmacorésistantes.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001005-43,0,0,0 2022-001012-26,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"aTyr Pharma, Inc.","A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous efzofitimod in patients with pulmonary sarcoidosis",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001012-26,0,0,0 2022-001013-39,1,,,0,1,0,0,0,1,2,0,0,4,0,0,0,0,1,"PTC Therapeutics, Inc","A Phase 2, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001013-39,0,1,1 2022-001015-14,1,,,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,Janssen Vaccines & Prevention B.V.,"A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older Estudio en...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001015-14,0,0,0 2022-001066-36,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"CELLTRION, Inc.","A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of Two Intravenous Infusion Formulations of Tocilizumab (CT-P47 and RoActemra) when Co-administered with Met...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001066-36,0,0,0 2022-001088-29,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Novartis Pharma AG,KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001088-29,0,0,0 2022-001088-29,2,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Novartis Farmacéutica, S.A.",KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001088-29,0,0,0 2022-001091-34,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Boehringer Ingelheim España S.A.,"A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) Ensayo doble ciego,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001091-34,0,0,0 2022-001093-55,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Erasmus Medical center,COATS study: genetic Clopidogrel response testing to finetune the antithrombotic regimen in (D)OAC Treated patients undergoing PCI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001093-55,0,0,0 2022-001097-64,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,UAB Švenčionių vaistažolės,"An open-label, randomized, parallel-controlled, phase II-III clinical trial to evaluate the tolerability, efficacy and safety of Aesculus Hippocastanum L seed extract in COVID-19 patients with mild pn...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001097-64,0,0,0 2022-001107-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundación para la Formación e Investigación Sanitarias de la Región de Murcia (FFIS),Combined treatment of intraperitoneal chemotherapy after optimal interval surgery in advanced ovarian cancer Esquema combinado de quimioterapia intraperitoneal tras cirugía de intervalo óptimo en c...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001107-41,0,0,0 2022-001134-11,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Boehringer Ingelheim Norway KS,"A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001134-11,0,0,0 2022-001134-11,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Boehringer Ingelheim España S.A.,"A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001134-11,0,0,0 2022-001135-85,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Arrowhead Pharmaceuticals, Inc.","A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia 2. fázisú, nyílt, kiterjesztett vizsgálat az ARO-APOC3 hosszútávú biztons...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001135-85,0,0,0 2022-001139-98,1,,,0,0,0,0,1,0,3,0,0,0,0,0,0,0,0,Institut Curie,Opioid-Free versus Opioid-Based Anaesthesia for secondary free-flap reconstruction surgery of the breast: A phase III multicentric randomized controlled study Anesthésie sans morphinique versus Ane...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001139-98,0,0,0 2022-001146-38,1,,,0,1,0,0,0,0,3,0,1,4,0,0,0,0,0,Pfizer Inc.,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY UNBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY JAPANESE INFANTS",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001146-38,0,1,1 2022-001151-16,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Cerevel Therapeutics, LLC","A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 in Adult Participants With Schizophrenia 52-hetes, II. fázisú, nyílt vizsgálat a CVL-231 hosszú táv...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001151-16,0,0,0 2022-001177-31,3,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first line therapeutic plasma exchange in adults with immune-medi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001177-31,0,0,0 2022-001184-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Oslo University Hospital,"Perioperative Propranolol in Robotic Assisted Laparoscopic Prostatectomy - A Pilot Study A parallel-group, phase 2, double-blind, 2-arm study to assess the feasibility of conducting a formal larger r...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001184-28,0,0,0 2022-001237-37,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,University Medical Center Utrecht,SENtinel lymph node mapping with GAllium-68-tilmanocept PET/CT in high/high-intermediate risk endometrial cancer: a pilot study Schildwachtklierprocedure met gallium-68-tilmanocept PET/CT in hoog/h...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001237-37,0,0,0 2022-001252-41,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU de Liège,Preventing postoperative anaemia in total knee arthroplasty and impact of intravenous iron supplementation on postoperative functional recovery : a randomized clinical trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001252-41,0,0,0 2022-001262-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"The Brigham and Women's Hospital, Inc.","A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients Who Have Been Stabi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001262-35,0,0,0 2022-001282-12,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,Novadip Biosciences,"A proof-of-concept study with NVD-003, an autologous osteogenic bone graft, in the treatment of congenital pseudarthrosis of the tibia in pediatric patients",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001282-12,0,0,0 2022-001283-10,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud University Medical Center,The effects of medication induced blood pressure reduction on cerebral hemodynamics in hypertensive frail elderly,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001283-10,0,0,0 2022-001294-31,3,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,1,AstraZeneca AB,"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001294-31,0,0,0 2022-001298-30,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,St. Antonius Hospital,What is the optimal antithrombotic strategy in patients with atrial fibrillation having acute coronary syndrome or undergoing percutaneous coronary intervention? Wat is de optimale antitrombotische...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001298-30,0,0,0 2022-001315-44,1,,,0,1,1,0,0,1,2,0,0,4,0,0,0,0,1,"Takeda Development Center America, Inc.","A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Patients With 15Q Duplication Syndrome or CDKL5 Deficiency Disorder (ARCADE Study)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001315-44,0,1,1 2022-001361-12,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,FluoGuide A/S,"An open-label, non-randomized, single center, single dose, exploratory phase II trial of FG001 (an imaging agent) for localization of oral and oropharyngeal squamous cell carcinoma Et åbent, ikke- ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001361-12,0,0,0 2022-001362-35,3,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Pfizer Inc.,"AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE NIRMATRELVIR/RITONAVIR IN NONHOSPITALIZED PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH SYMPTOMATIC CO...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001362-35,0,0,0 2022-001373-31,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Inreda Diabetic B.V.,Fully Automated glycemic control with ultrarapid insulin in a bihormonal closed loop System in patients with Type 1 diabetes Volledig automatische glucoseregeling met ultrasnelle insuline in een bi...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001373-31,0,0,0 2022-001374-60,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,BCN Peptides,"A randomized, double blinded, placebo controlled clinical trial to evaluate the antipruritic efficacy of the topical application of PARENTIDE cream in histamine-induced itch in healthy volunteers E...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001374-60,0,0,0 2022-001410-20,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Radboud university medical center,Determining the clinical relevance of the interaction between enzalutamide and the opioid morphine and the DOAC edoxaban to improve rational pharmacological care of patients with prostate cancer V...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001410-20,0,0,0 2022-001441-21,1,,,0,0,0,0,0,0,3,0,1,4,0,0,0,0,1,Sanofi Pasteur,Immunogenicity and Safety of the Quadrivalent Inactivated Split-Virion Influenza Vaccine in Participants 6 Months of age and Older in India,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001441-21,0,1,1 2022-001442-38,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,1,Janssen-Cilag International NV,"A Phase 3 Study Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma who have Received at least 4 Prior Therapies Including an Immunomodulatory Drug,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001442-38,0,0,0 2022-001476-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AstraZeneca AB,"A Randomized, Double-Blind, 12-Week (with an Extension to 52 weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) De...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001476-33,0,0,0 2022-001478-78,1,,,0,0,0,0,0,1,3,0,0,4,0,0,0,0,1,Rare Thyroid Therapeutics International AB,"Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): A Double blind, Randomized, Placebo controlled Study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001478-78,0,0,0 2022-001485-35,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,1,Sanofi-Aventis Recherche & Développement,"A 24-Week, Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001485-35,0,0,0 2022-001504-17,1,,,0,1,1,0,0,0,3,0,0,4,0,0,0,0,1,Bayer AG,"Prospective, historically controlled study to evaluate the efficacy and safety of a new pediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas’ disease",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001504-17,0,1,1 2022-001514-18,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Medical Center Ljubljana,Cytomegalovirus Prophylaxis with Letermovir in Heart Transplant Recipients: A Non-randomized Cohort Pilot Study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001514-18,0,0,0 2022-001516-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Novartis Pharma GmbH,"A randomized, double-blind, placebo-controlled, parallel group, multicenter, 24-week study investigating the efficacy and safety of secukinumab compared to placebo in adult patients with moderate to s...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001516-26,0,0,0 2022-001522-30,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación Hospital Nacional de Parapléjicos,Effects of a CB1 receptor reverse antagonist/agonist (Rimonabant) on wandering ability in patients with incomplete spinal cord injuries Efectos de un antagonista/agonista inverso del receptor CB1 (...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001522-30,0,0,0 2022-001527-32,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SOTIO Biotech AG,"A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy and safety of SOT101 in combination with cetuximab in patients with RAS wild-type colorectal cancer (AURELIO-05) Estudi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001527-32,0,0,0 2022-001534-11,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Grupo Gallego de Investigación en Tumores Digestivos (GITuD),Prophylaxis of venous thromboembolic disease with LMWH (TINzaparin) in patients with metastatic colorectal cancer who start the first line of treatment. Profilaxis de la enfermedad tromboembólica v...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001534-11,0,0,0 2022-001563-26,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Region Skåne,Pramipexole for Anhedonic Depression (PRIME-PRAXOL) Tilläggsbehandling med Pramipexol mot Anhedonisymptom vid Depression - PRIME-PRAXOL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001563-26,0,0,0 2022-001585-36,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,Amsterdam UMC,"EffectS of L-glutaMIne on oxIdative stress, sickLE erythrocyte viability, inflammation and endothelial activity in sickle cell disease (SMILE trial)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001585-36,0,0,0 2022-001590-31,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Norwegian Institute of Public Health,"A parallel group, prevention, phase iv, unblinded 2-arm study to investigate hospital admission and deaths due to COVID-19, after receiving an invitation to take a second booster COVID-19 vaccine comp...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001590-31,0,0,0 2022-001591-33,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Fundació Clinic per a la Recerca Biomèdica,"Open-label, single-arm, unicenter and Pilot Study of a Switch strategy from Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance Estudio abiert...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001591-33,0,0,0 2022-001603-40,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Leiden University Medical Center,"Combined effect of Pregabalin and Oxycodone, and Lacosamide and Oxycodone, on breathing: an exploratory study in healthy volunteers the POLO study",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001603-40,0,0,0 2022-001624-14,2,,,0,0,1,0,0,1,3,0,0,4,0,0,0,0,1,Pharming Technologies B.V.,"An Open-Label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 4 to 11 Years) With APDS (Activated Phosphoinositide 3-Kinase ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001624-14,0,0,0 2022-001635-91,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,DexTech Medical AB,A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001635-91,0,0,0 2022-001638-12,3,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,"ModernaTX, Inc.","A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older.",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001638-12,0,0,0 2022-001662-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,BTI I MAS D S.L.,"Randomized, double-blind, parallel group clinical trial to evaluate the efficacy and safety of PRGF eye drops as a treatment for dry eye disease in patients with glaucoma Ensayo clínico aleatorizad...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001662-35,0,0,0 2022-001679-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,Pfizer Inc.,"PHASE 1/2A DOSE ESCALATION, FINDING AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07104091 AS A SINGLE AGENT AND IN COMBINATION ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001679-15,0,0,0 2022-001695-34,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,1,"Lumos Pharma, Inc.","An Open-Label, Multicenter, Phase 2 Study to Evaluate Growth and Safety of LUM-201 Following 12 Months of Daily rhGH Treatment in Children with Idiopathic Growth Hormone Deficiency who have Previously...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001695-34,0,0,0 2022-001750-29,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,AUVA Trauma Center Vienna,"Influence of zoledronic acid on healing after arthroscopic repair of chronic rotator cuff lesions - A prospective, randomized, placebo-controlled phase II trial Einfluss von Zoledronsäure auf die...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001750-29,0,0,0 2022-001759-17,2,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Laboratoire français du Fractionnement et des Biotechnologies (LFB BIOTECHNOLOGIES),"A multicenter, randomized, double-blind, placebo-controlled, parallel, phase 3 study to assess the efficacy and safety of fibrinogen concentrate (FGTW) in the management of bleeding in patients underg...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001759-17,0,0,0 2022-001770-59,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Bio-Thera Solutions, Ltd.","A Multicenter, Randomized, Double-Blind, Parallel-Arm, Phase 3 Study to Compare Efficacy and Safety of BAT2306 with Cosentyx® in Patients with Moderate to Severe Plaque Psoriasis Multicentrikus, ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001770-59,0,0,0 2022-001785-35,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,Merck Sharp & Dohme LLC,"A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age o...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001785-35,0,0,0 2022-001802-23,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Fundación para la Investigación Biomédica Hospital Ramón y Cajal,Exploratory clinical trial of safety and efficacy of daily application of topical dutasteride in emulsion in men with androgenic alopecia. Ensayo Clínico exploratorio de seguridad y eficacia de la ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001802-23,0,0,0 2022-001810-21,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Aarhus University Hospital, Department of Anaesthesiology","Intraoperative clonidine for postoperative pain management in patients undergoing surgical treatment for endometriosis: a prospective, double-blind, randomized controlled trial",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001810-21,0,0,0 2022-001811-16,1,,,0,0,0,0,0,1,2,0,0,4,0,0,0,0,0,Princess Maxima Center for pediatric oncology,"68Ga-SATO in pediatric neuroblastoma patient; exploratory, safety, non-randomized, open label, comparative study 68Ga-SATO in pediatrische neuroblastoom patiënten; een verkennende, veiligheid, nie...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001811-16,0,0,0 2022-001824-13,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Leiden University Medical Center,Influence of oxycodone on individuals taking an SSRI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001824-13,0,0,0 2022-001828-15,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,SynAct Pharma ApS,"A double-blind, multi-center, randomized, placebo-controlled study of the safety and efficacy of 12 weeks extended treatment with AP1189 in early rheumatoid arthritis (RA) patients naïve to DMARD trea...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001828-15,0,0,0 2022-001832-27,1,,,0,0,1,0,0,0,2,0,0,0,0,0,0,0,1,Allecra Therapeutics SAS,"A Single Group Treatment, Phase 2 study to investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam administered by intra-venous infusion over 2 hours in Male or Female Partici...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001832-27,0,0,0 2022-001837-35,1,,,0,0,1,0,0,0,3,0,0,4,0,0,0,0,1,"Basilea Pharmaceutica International Ltd, Allschwil","A multicenter, open-label, single-arm, multiple-dose study to evaluate the safety, pharmacokinetics, and efficacy of ceftobiprole medocaril in term and preterm neonates and infants up to 3 months of a...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001837-35,0,1,1 2022-001852-41,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Radboud university medical center,BetaFIT study: Beta cell imaging after Faecal mIcrobiota Transplantation BetaFIT studie: beeldvorming van bètacellen na fecale microbiota transplantatie,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001852-41,0,0,0 2022-001857-22,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"Sygehus Sønderjylland, Orthopedic department",Perioperative Methadone for ameliorating postoperative pain and reduction in postoperative opioid consumption in hip fracture patients – Dosage adjusting pilot-study,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001857-22,0,0,0 2022-001873-29,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Baxalta US Inc.,"A Phase 3, Open-label, Non-controlled, Multi-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Efficacy of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Jap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001873-29,0,1,1 2022-001873-29,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Baxalta Innovations GmbH,"A Phase 3, Open-label, Non-controlled, Multi-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Efficacy of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Jap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001873-29,0,1,1 2022-001873-29,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Takeda Pharmaceutical Company Limited,"A Phase 3, Open-label, Non-controlled, Multi-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Efficacy of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Jap...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001873-29,0,1,1 2022-001908-17,1,,,0,0,0,0,0,1,2,0,0,0,0,0,0,0,0,Leiden University Medical Center,Neo- and adjuvant targeted therapy in BRAF-mutated anaplastic cancer of the thyroid (NEO-ATACT study),https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001908-17,0,0,0 2022-001909-53,1,,,0,0,1,0,0,0,3,0,0,4,0,0,0,0,1,MediWound Ltd.,"Long Term (>30 months following wound closure) assessments of cosmesis, function and quality of life in pediatric subjects following participation in study MW2012-01-01 evaluating the efficacy and saf...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001909-53,0,0,0 2022-001938-11,1,,,0,0,0,0,0,0,2,0,1,0,0,0,0,0,1,Pharma Holdings AS,"A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 compared to Placebo for nasal decolonisation of Staphylococcus aureus",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001938-11,0,0,0 2022-001941-19,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Hellenic Society of Hematology (EAE),"A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of Belantamab Mafodotin administered in combination with Daratumumab, Pomalidomide and Dexamethasone in ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001941-19,0,0,0 2022-001942-39,1,,,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,Hellenic Society of Hematology (EAE),"A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in combination with lenalidomide, dexamethasone and nirogacestat in...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001942-39,0,0,0 2022-001958-36,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Corporativo de Servicios Médicos Especializados S.A de C.V V (Centro Médico del Noroeste),"Endothelial protection in convalecent COVID-19 patients. The effect of Sulodexide on serum levels of biomarkers for endothelial dysfunction. A prospective, randomized, placebo-controlled, investigator...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001958-36,0,0,0 2022-001975-15,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,3,,The effect of extra hydration on kidney function during carboplatinpemetrexed-pembrolizumab in patients with advanced non-small cell lung cancer.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001975-15,0,0,0 2022-001981-36,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,1,"GlaxoSmithKline, S.A.","A Phase 3, observer-blind, randomized, placebo controlled study to evaluate the non inferiority of the immune response and safety of the RSVPreF3 OA investigational vaccine in adults 50-59 years of ag...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-001981-36,0,0,0 2022-002012-23,7,,,0,0,0,0,0,0,3,0,0,3,0,0,0,0,1,STALLERGENES,"A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-induc...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002012-23,0,0,0 2022-002134-14,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Catharina Hospital Eindhoven,Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases – a phase II study Intraperitoneale irinotecan met gelijktijdig FO...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002134-14,0,0,0 2022-002137-34,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Hospital of South West Jutland,Rapid infusion of Ringer's lactate solution at different temperatures and the effects on circulation and perfusion in healthy volunteers – a randomized crossover trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002137-34,0,0,0 2022-002179-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,Matilde Zaballos,Determination of the effective dose 50 of intrathecal hyperbaric prilocaine required for the transrectal ultrasound guidance fusion-targeted prostate biopsy in ambulatory surgery Determinación de l...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002179-12,0,0,0 2022-002189-34,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"Shanghai Henlius Biotech, Inc.","A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Pertuzumab Biosimilar HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of H...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002189-34,0,0,0 2022-002190-28,1,,,0,1,0,0,0,0,2,0,0,4,0,0,0,0,1,Institut de Recherches Internationales Servier (IRIS),"A Phase 2 Clinical Study of SHP674 in Patients with Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002190-28,0,1,1 2022-002191-36,1,,,0,1,1,0,0,0,1,1,1,4,0,0,0,0,1,Shire,"A Phase 1, Open-label, Randomized, Crossover, Bioavailability, Dose Proportionality, and Food Effect Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Su...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002191-36,0,1,1 2022-002266-33,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,BETH ISRAEL DEACONESS MEDICAL CENTER,STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTS (SATURN) USO DE ESTATINAS EN PACIENTES CON HEMORRAGIA INTRACEREBRAL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002266-33,0,0,0 2022-002267-29,1,,,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,Wave Life Sciences UK Limited,"A Multicenter, Open-label Extension (OLE) Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-004 in Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002267-29,0,0,0 2022-002269-14,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,"AMC, Cardiovascular Sciences",Dotatate to locate coronary plaques at high-risk of myocardial infarction,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002269-14,0,0,0 2022-002311-39,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,University Of Cyprus,Phase II trial for the use of ketotifen to enhance therapy in patients with sarcoma receiving standard chemotherapy,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002311-39,0,0,0 2022-002316-23,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,Novartis Pharma AG,"An open-label, single arm, multicenter extension study to evaluate long-term safety and tolerability of inclisiran in participants with heterozygous or homozygous familial hypercholesterolemia who ha...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002316-23,0,0,0 2022-002326-27,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,1,"Cognition Therapeutics, Inc.","A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CT1812 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002326-27,0,0,0 2022-002330-13,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Fakultní nemocnice v Motole,"The randomized, double blind study phase III.b of the Comprehensive assessment of the musculoskeletal health in children with cystic fibrosis – on the search for means of improvement Randomizovaná,...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002330-13,0,0,0 2022-002336-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"CELLTRION, Inc","A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 with Humira in Patients with Moderate to Severe Chronic Plaque Psoriasis Ra...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002336-31,0,0,0 2022-002350-68,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,1,"Astellas Pharma China, Inc.","A Multicenter, Open-label, Non-comparative Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric Allograft Liver and Kidney T...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002350-68,0,1,1 2022-002351-19,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,1,"Astellas Pharma China, Inc.","A Long-term, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipi...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002351-19,0,1,1 2022-002352-39,1,,,0,0,0,0,0,1,4,0,1,0,0,0,0,0,0,Assistance Publique – Hôpitaux de Paris (AP-HP),Follow-up of Contact Persons at Risk of Monkeypox infection: prospective cohort study (MONKEY VAX) Suivi des Personnes Contacts à Risque d’infection Monkeypox : étude de cohorte prospective (MONKEY...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002352-39,0,0,0 2022-002367-29,1,,,0,0,0,0,0,0,3,0,1,0,0,0,0,0,0,Instituut van Tropische Geneeskunde Antwerpen,A two-centre open-label non-inferiority trial to assess the immunogenicity and safety of an intradermal and an intramuscular single-visit dosing regimen of purified chick-embryo cell-culture rabies va...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002367-29,0,0,0 2022-002375-11,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,Sanofi-aventis recherche & développement,"A Randomized, Double Blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Persistent Asthma",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002375-11,0,1,1 2022-002384-30,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,Erasmus MC - Sophia,Reduction of blood loss in pediatric osteotomies around the hip - A randomized placebo-controlled trial with tranexamic acid –,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002384-30,0,0,0 2022-002385-32,1,,,0,0,0,0,0,1,3,0,0,0,0,0,0,0,0,Assistance Publique – Hôpitaux de Paris (AP-HP),Immediate versus delayed treatment with azathioprine or rituximab in anti-myelin oligodendrocytes glycoprotein (anti-MOG) antibodies associated acute demyelinating syndromes in children: a randomized ...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002385-32,0,0,0 2022-002390-28,1,,,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,Hellenic Institute for the Study of Sepsis,"IMMUNOTHERAPY NAVIGATED BY SERUM PRESEPSIN FOR INFECTIONS OF THE RESPIRATORY TRACT: THE INSPIRE DOUBLE-BLIND, RANDOMIZED, PHASE IIa EXPLORATORY TRIAL ΑΝΟΣΟΘΕΡΑΠΕΙΑ ΠΛΟΗΓΟΥΜΕΝΗ ΑΠΟ ΤΗΝ ΠΡΕΣΗΨΙΝΗ ΤΟΥ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002390-28,0,0,0 2022-002451-19,1,,,0,0,0,0,1,0,4,0,0,0,0,0,0,0,0,Radboudumc,Deep versus moderate neuromuscular blockade during total HIP replacement surgery to improve POstoperative quality of recovery and immune function: a randomized controlled study Diepe versus gematig...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002451-19,0,0,0 2022-002471-11,1,,,0,0,0,0,0,1,4,0,0,4,0,0,0,0,1,"Takeda (China) International Trading Co., Ltd.","An Open Label, Multicenter, Single-arm and Prospective Study to Assess the Efficacy and Safety of Leuprorelin 3M in the Treatment of Central Precocious Puberty (CPP)",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002471-11,0,1,1 2022-002482-15,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,AbbVie Deutschland GmbH & Co. KG (AbbVie),"A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects with Moderate to Severe Atopic Dermati...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002482-15,0,0,0 2022-002496-11,1,,,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,Aarhus University Hospital,METATONS - Intraoperative methadone for postoperative pain in patients undergoing tonsillectomy - a randomized controlled trial,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002496-11,0,0,0 2022-002499-35,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,Jadran - galenski laboratorij d.d. (JGL),"Multicentre, randomized, double-blind, parallel design clinical trial of efficacy, safety and tolerability of Xylometazoline + Sodium Hyaluronate nasal spray, compared to Xylometazoline, Sodium Hyalur...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002499-35,0,0,0 2022-002514-16,1,,,0,0,0,0,0,1,4,0,0,4,0,0,0,0,1,"Actelion Pharmaceuticals Trading (Shanghai) Co., Ltd",A single-arm uncontrolled 12-month Clinical Study to evaluate the Safety and Efficacy of miglustat (Zavesca®) for the Treatment of Niemann-Pick Disease Type C (NPC) in Chinese subjects,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002514-16,0,1,1 2022-002520-13,1,,,0,1,0,0,0,1,4,0,0,4,0,0,0,0,1,Baxalta Innovations GmbH,"Phase IV Multi-center, Prospective, Interventional, Post-marketing Study in Hemophilia B Patients in India receiving RIXUBIS as On-demand or Prophylaxis Under Standard Clinical Practice",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002520-13,0,1,1 2022-002523-36,1,,,0,1,1,0,0,0,1,0,0,4,0,0,0,0,1,UCB Biopharma SRL,"A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, TOLERABILITY, AND SAFETY OF A SINGLE DOSE OF STACCATO ALPRAZOLAM IN ADOLESCENT STUDY PARTICIPANTS WITH EPILEPSY",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002523-36,0,1,1 2022-002560-73,1,,,0,0,0,0,0,0,4,0,1,0,0,0,0,0,0,Erasmus MC,SWITCH ON: Analysing the immunogenicity of additional booster vaccinations in healthcare workers.,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002560-73,0,0,0 2022-002621-98,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Takeda,"A Phase 3 Multi-center, Open-label Study to Evaluate the Efficacy and Safety of Lanadelumab (SHP643) in Japanese Subjects with Hereditary Angioedema",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002621-98,0,1,1 2022-002627-35,1,,,0,1,0,0,0,1,3,0,0,4,0,0,0,0,1,Takeda Pharmaceutical Company Limited,"A Multicenter, Open-Label, Non-randomized Phase 3 Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneous Administration of Icatibant (TAK-667) in Japanese Children and Adolescents w...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002627-35,0,1,1 2022-002636-31,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,Assistance Publique Hôpitaux de Paris/DRCI,Piperacillin-tazobactam and temocillin as carbapenem-alternatives for the treatment of severe infections due to extended-spectrum beta-lactamase–producing Gram-negative Enterobacteriaceae in the inten...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002636-31,0,0,0 2022-002697-80,1,,,0,0,0,0,0,0,4,0,1,4,0,0,0,0,0,Université Libre de Bruxelles,Maternal determinants of infant immunity to pertussis,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002697-80,0,0,0 2022-002777-29,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,AbbVie Inc,"A Phase 3 Randomized, Multicenter, Double-Blind Study to Evaluate the Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects in Japan with Moderate to Seve...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002777-29,0,1,1 2022-002860-59,1,,,0,0,0,0,0,0,3,0,0,0,0,0,0,0,1,"IVERIC bio, Inc.",An Open-label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of avacincaptad pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy Who Previously Compl...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002860-59,0,0,0 2022-002892-12,1,,,0,0,0,0,0,0,4,0,0,0,0,0,0,0,0,CHU Brugmann,Comparison of the efficacy of ephedrine versus norepinephrine in the treatment of hypotension occurring after induction of general anesthesia in patients with chronic renal failure: randomized double-...,https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-002892-12,0,0,0 2022-003265-38,1,,,0,0,1,0,0,1,2,0,0,4,0,0,0,0,1,"PTC Therapeutics, Inc.","An Open-Label Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Vatiquinone in Children With Friedreich Ataxia Younger Than 7 Years of Age",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-003265-38,0,1,1 2022-003274-22,1,,,0,0,0,0,0,0,3,0,0,4,0,0,0,0,1,Bayer HealthCare LLC,"A Randomized, Double-Blind, Single-Dose, Parallel, Placebo-Controlled Pivotal Trial to Confirm the Efficacy of a Fixed Dose Combination Tablet of Naproxen Sodium and Caffeine to Effectively Alleviate ...",https://www.clinicaltrialsregister.eu/ctr-search/search?query=2022-003274-22,0,1,1